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Gefördert durch die 
Medical-Data-Models.Org  
A collection of freely available forms (September 2016) 
 
MDM-Portal (Medical Data-Models) is a meta-data repository for creating, analysing, sharing and 
reusing medical forms, developed by the Institute of Medical Informatics, University of Muenster in 
Germany. 
Electronic forms for documentation of patient data are an integral part within the workflow of 
physicians. A huge amount of data is collected either through routine documentation forms (EHRs) 
for electronic health records or as case report forms (CRFs) for clinical trials. This raises major 
scientific challenges for health care, since different health information systems are not necessarily 
compatible with each other and thus information exchange of structured data is hampered. 
Software vendors provide a variety of individual documentation forms according to their standard 
contracts, which function as isolated applications. Furthermore, free availability of those forms is 
rarely the case. Currently less than 5 % of medical forms are freely accessible. 
Based on this lack of transparency harmonization of data models in health care is extremely 
cumbersome, thus work and know-how of completed clinical trials and routine documentation in 
hospitals are hard to be re-used. 
The MDM-Portal serves as an infrastructure for academic (non-commercial) medical research to 
contribute a solution to this problem. It already contains more than 8,000 system-independent forms 
(CDISC ODM Format, www.cdisc.org, Operational Data Model) with more than 580,000 data-
elements. This enables researchers to view, discuss, download and export forms in most common 
technical formats such as PDF, CSV, REDCap, FHIR, R, etc. A growing user community will lead to a 
growing database of medical forms. In this matter, we would like to encourage all medical 
researchers to register and add forms and discuss existing forms. 
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team@medical-data-models.org 
Institut für Medizinische Informatik 
WWU Münster 
Albert-Schweitzer-Campus 1, Geb. A11 
48149 Münster 
HIS Hospitalist Progress Note
Form from OpenVistA
All rights reserved. Please visit https://medical-data-
models.org/forms/105
HIS
Hospitalist-Progress Note
Progress Note*
CUMULATIVE V/S*
Yes
No
VITALS*
LABS
CBC*
Hematocrit - finding*
Hemoglobin*
PATIENT CURRENT LABS(14DAY)*
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HIS HIS Reconciliation Nursing
Form from HIS OpenVistA
All rights reserved. Please visit https://medical-data-
models.org/forms/108
HIS
MEDICATION RECONCILIATION
NURSING
Hypersensitivity*
Home Medications*
Inpatient Medications*
The patient/family has provided a list of current
home medications.*
Yes
No
NOTIFY MD*
Yes
No
A current list of home medications is not available
at this time.*
Yes
No
The patient/family cannot provide a list of current
home medications because of the patient's
medical condition.*
Yes
No
The patient does not have any home
medications.*
Yes
No
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Eligibility NCT00403832 Cataract
ODM derived from
http://clinicaltrials.gov/ct2/show/record/NCT00403832
All rights reserved. Please visit https://medical-data-
models.org/forms/109
Eligibility
Inclusion Criteria
non infectious uveitis *
Yes
No
no active inflammation *
Yes
No
significant visual disturbance related to lens
opacification*
Yes
No
Age at least 18 years*
Yes
No
Exclusion Criteria
vitreous opacification *
Yes
No
ocular hypertension/glaucoma*
Yes
No
Medical concepts
Diagnosis*
Cataract*
Uveitis*
Inflammation *
Visual disturbance*
Age*
Vitreous opacities*
Glaucoma*
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HIS Social History
From from OpenVista
All rights reserved. Please visit https://medical-data-
models.org/forms/111
HIS
Habits
Alcohol  in the past year*
Yes
No
Amount of Alcohol per day*
Alcohol abuse or Alcohol program*
Tobacco (lifelong Non-user, Ex-tobacco user,
Current user)*
Tobacco packs per day*
Other drugs (never used, past user, present
user)*
Other drugs (additional text)*
Marital/Domestic Status
Living arrangements*
Marital status (married, widowed, divorced,
single, other)*
Marital status (comment)*
Other (Education, Occupation, Travel history,
Exercise habits etc.)*
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Eligibility NCT00156338 Fluid Management
ODM derived from
http://clinicaltrials.gov/ct2/show/record/NCT00156338
All rights reserved. Please visit https://medical-data-
models.org/forms/115
Eligibility
Inclusion Criteria
18 Years to 90 Years*
Yes
No
epidural anesthesia
*
Yes
No
ASA I-III*
Yes
No
Exclusion Criteria
metastasized cancer*
Yes
No
pregnancy*
Yes
No
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Eligibility NCT01428297 Atopic Dermatitis
ODM derived from
http://clinicaltrials.gov/ct2/show/record/NCT01428297
All rights reserved. Please visit https://medical-data-
models.org/forms/116
Eligibility
Inclusion Criteria Healthy volunteers
Healthy male and female subjects of non
childbearing potential, 18 to 65 years of age
inclusive and in good health*
Yes
No
Inclusion Criteria Patients with atopic
dermatitis
Male and female subjects, 18 to 65 years of age
inclusive and having passed screening
examinations*
Yes
No
Presence of atopic dermatitis confirmed by Itchy
skin condition in the past 12 months (must have)
Plus three or more of the following:
1. History of involvement of the skin creases
2. Personal history of asthma or hay fever
3. History of generally dry skin in the past year
4. Onset before age of 2 years
5. Visible flexural dermatitis*
Yes
No
Diagnosis of at least moderate atopic dermatitis
by the IGA and a minimum target area (right or
left) situated on the forearm including the
antecubital fossa with a corresponding baseline
total lesional sign score (TLSS)*
Yes
No
Inclusion Criteria Patients with Netherton
Syndrome
Patients with Netherton syndrome, male and
female subjects, 18 to 65 years of age inclusive
and having passed screening examinations*
Yes
No
Confirmed diagnosis of Netherton syndrome
(SPINK5 mutation or LEKTI deficiency in the
skin)*
Yes
No
Minimum total lesional sign score NS (TLSS-NS)
of 5-9 for two selected target areas at baseline.
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The TLSS-NS values need to be similar between
the two areas at baseline*
Yes
No
Exclusion Criteria Healthy volunteers
History of hypersensitivity to any of the study
drugs or to drugs of similar chemical classes or
history of serious allergic reaction.*
Yes
No
Use of any prescription drugs, herbal
supplements, within four (4) weeks prior to initial
dosing, and/or over-the-counter (OTC)
medication, dietary supplements (vitamins
included) within two (2) weeks prior to initial
dosing*
Yes
No
Exclusion Criteria Patients with atopic
dermatitis
History of hypersensitivity to any of the study
drugs or to drugs of similar chemical classes or
history of serious allergic reaction.*
Yes
No
History of abnormal skin reactivity to UV light.
Unusual exposure to UV light in the previous 3
weeks to study start (screening), including
tanning and sun beds*
Yes
No
Pregnant or nursing (lactating) women*
Yes
No
Women of child-bearing potential must use highly
effective contraception (as further defined in
study protocol)*
Yes
No
Use of topical prescription treatment for eczema
within 1 week prior to initial dosing of topical
corticosteroids (TCS).*
Yes
No
Recent previous treatment with systemic
treatment including phototherapy. A washout
period will be required for such patients to be
eligible to participate in the trial.*
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Eligibility NCT01428297 Atopic Dermatitis
Yes
No
Exclusion Criteria Patients with Netherton
Syndrome
History of hypersensitivity to any of the study
drugs or to drugs of similar chemical classes or
history of serious allergic reaction*
Yes
No
History of abnormal skin reactivity to UV light.
Unusual exposure to UV light in the previous 3
weeks to study start (screening), including
tanning and sun beds*
Yes
No
Pregnant or nursing (lactating) women*
Yes
No
Women of child-bearing potential must use highly
effective contraception (as further defined in
study protocol)*
Yes
No
Use of topical prescription treatment within 2
week prior to initial dosing of study drug*
Yes
No
Recent previous treatment with systemic
treatment. A washout period will be required for
such patients to be eligible to participate in the
trial.*
Yes
No
Medical Concepts
Age*
Healthy Subject*
Diagnosis*
Dermatitis, Atopic*
Pruritus*
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Eligibility NCT01428297 Atopic Dermatitis
Skin crease*
Asthma*
Hay fever (Seasonal Allergy)*
Dry skin*
Onset*
Flexural eczema*
Allergic reaction, due to correct medicinal
substance properly administered*
Medication*
Dietary Supplements*
Ultraviolet Rays*
pregnant*
Breast feeding, Nursing*
Contraception*
Topical Corticosteroid*
Phototherapy*
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Eligibility NCT01428297 Atopic Dermatitis
Eligibility NCT00185393 Lymphoma, Non-
Hodgkin
ODM derived from
http://clinicaltrials.gov/show/NCT00185393
All rights reserved. Please visit https://medical-data-
models.org/forms/129
Eligibility
Inclusion Criteria
18 Years and older*
Yes
No
Non Hodgkin Lymphoma stage III or IV at
timepoint of diagnosis*
Yes
No
Patients who have achieved a remission after first
line chemotherapy*
Yes
No
No less than 6 weeks and no more than 12
weeks since last dose of chemotherapy*
Yes
No
written informed consent*
Yes
No
Exclusion Criteria
Any other anticancer treatment for NHL except
the preceding first line chemotherapy*
Yes
No
Prior radiation therapy*
Yes
No
Patients who have not recovered from the toxic
effects of the first line chemotherapy*
Yes
No
Any other cancer or history of cancer less than
10 years ago*
Yes
No
Patients with known HIV positivity*
Yes
No
patients with pleural effusion or ascites*
Yes
No
female patients who are pregnant or breast
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feeding (women of childbearing potential must
have a negative serum pregnancy test at study
entry)*
Yes
No
Adults not employing an effective method of birth
control during study treatment and 12 months
thereafter*
Yes
No
Patients unable or unwilling to comply with
protocol*
Yes
No
Medical concepts
Age*
Diagnosis*
Lymphoma, Non-Hodgkin (Non-Hodgkins
lymphoma)*
Diagnostic Neoplasm Staging*
Disease remission*
Medication*
Chemotherapy*
Informed Consent*
First-Line Treatment (primary treatment)*
Radiotherapy*
Recovery - healing process*
Malignant Neoplasms*
HIV negative*
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Eligibility NCT00185393 Lymphoma, Non-Hodgkin
Pleural effusion disorder*
Ascites*
pregnant*
Breast feeding, Nursing*
Serum pregnancy test (B-HCG)*
Contraception*
Compliance*
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Eligibility NCT00185393 Lymphoma, Non-Hodgkin
Eligibility NCT00204321 Renal
Transplantation
ODM derived from
http://clinicaltrials.gov/show/NCT00204321
All rights reserved. Please visit https://medical-data-
models.org/forms/131
Eligibility
Inclusion Criteria
18 Years to 75 Years*
Yes
No
renal transplantation stable function*
Yes
No
Exclusion Criteria
acute rejection*
Yes
No
Medical Concepts
Age*
Therapeutic procedure*
Diagnosis*
Renal transplant*
Functional status of graft*
Acute rejection of renal transplant*
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Eligibility NCT00195507 Psoriasis
ODM derived from
http://clinicaltrials.gov/show/NCT00195507
All rights reserved. Please visit https://medical-data-
models.org/forms/132
Eligibility
Inclusion Criteria
18 Years and older*
Yes
No
Stable, active plaque psoriasis*
Yes
No
Failure to respond to the following systemic
therapies: Methotrexate, Cyclosporine, PUVA or
Fumarate*
Yes
No
Exclusion Criteria
Evidence of skin conditions other than psoriasis
that would interfere with evaluations of the effect
of the study*
Yes
No
Systemic psoriasis therapy within 28 days prior*
Yes
No
Medical concepts
Age*
Diagnosis*
Psoriasis*
Nummular psoriasis (Plaque psoriasis, Discoid
psoriasis)*
Medication*
Methotrexate*
Ciclosporin*
PUVA*
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Fumarate*
Dermatosis (Skin disorder, Dermatological
disease)*
Systemic Therapy*
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Eligibility NCT00195507 Psoriasis
HIS Family Hx
Form from HIS OpenVistA
All rights reserved. Please visit https://medical-data-
models.org/forms/162
HIS
Maternal Family History
Mutter lebt*
Ja
Nein
Hypertonie*
Ja
Nein
Diabetes mellitus*
Ja
Nein
Schlaganfall*
Ja
Nein
Herzinfarkt*
Ja
Nein
Early Coronary Vascular Disease*
Ja
Nein
Brustkrebs*
Ja
Nein
Darmkrebs*
Ja
Nein
Other*
FH: Age at death*
Todesursache (Mutter)*
Kommentar*
Paternal Family History
Vater lebt*
Ja
Nein
Hypertonie*
Ja
Nein
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Diabetes mellitus*
Ja
Nein
Schlaganfall*
Ja
Nein
Herzinfarkt*
Ja
Nein
Early Coronary Vascular Disease*
Ja
Nein
Prostatakrebs*
Ja
Nein
Darmkrebs*
Ja
Nein
Other*
FH: Age at death*
Todesursache (Vater)*
Kommentar*
Siblings Family History
Geschwister ohne signifikante Erkrankung*
Geschwister mit signifikanter Erkrankung*
Ja
Nein
Hypertonie*
Ja
Nein
Schlaganfall*
Ja
Nein
Herzinfarkt*
Ja
Nein
Diabetes mellitus*
Ja
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HIS Family Hx
Nein
Early Coronary Vascular Disease*
Ja
Nein
Darmkrebs*
Ja
Nein
Other*
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HIS Family Hx
HIS DISCHARGE INSTRUCTIONS
Form from HIS OpenVistA
All rights reserved. Please visit https://medical-data-
models.org/forms/167
HIS
DISCHARGE INSTRUCTIONS
DISCHARGE TO*
DISCHARGE STATUS*
Ja
Nein
CALL IN EMERGENCY*
ACTIVITY: no restrictions, printed instructions
given for*
ACTIVITY ON DISCHARGE*
SMOKING CESSATION COUNSELING
PROVIDED*
Ja
Nein
WEIGHT MANAGEMENT INFORMATION
PROVIDED*
Ja
Nein
Home Medications*
ACTIVE MEDICATIONS*
Additional Discharge Medications
(NAME/ROUTE/FREQUENCY/PURPOSE)*
Diet: Regular diet, low fat/low cholesterol diet,
diabetic diet, other*
DIET Instructions*
CARDIAC Instructions*
DISCHARGE INSTRUCTIONS PROVIDED*
WARFARIN EDUCATION PROVIDED*
Ja
Nein
REFER TO OUTPATIENT CARDIAC
Rehabilitation*
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Ja
Nein
Discharge Medications*
ASS*
OR Aspirin CONTRAINDICATIONS*
PLAVIX(CLOPIDOGREL)*
Beta-Blocker*
OR Beta Blocker CONTRAINDICATIONS: *
ACE INHIBITOR*
OR ACE Inhibitor CONTRAINDICATION*
Angiotensin Receptor Blocker (ARB)*
OR ARB CONTRAINDICATION*
LIPID LOWERING AGENT*
OR Lipid lowering agent CONTRAINDICATIONS:
*
APPOINTMENT*
INSTRUCT PATIENT TO FOLLOW UP WITH*
MD PHONE NUMBER:*
TO BE SEEN IN*
DATE*
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HIS DISCHARGE INSTRUCTIONS
HIS DISCHARGE NOTE BRIEF ORIGINAL
Form from HIS OpenVistA
All rights reserved. Please visit https://medical-data-
models.org/forms/169
HIS
DISCHARGE Note
PATIENT PHONE*
PERSON/PHONE NUMBER TO CONTACT IN
CASE OF EMERGENCY*
Primary NEXT OF KIN information*
DISCHARGE STATUS (stable, improved,
unchanged)*
Discharge comment*
Discharge Medication
None*
Ja
Nein
Darvocet N-100mg*
Ja
Nein
Tylenol #3*
Ja
Nein
Lortab 5/500mg*
Ja
Nein
Lortab 7.5/500mg*
Ja
Nein
Lortab 10/500mg*
Ja
Nein
Number of tabs PO*
Q*
Hours PRN Pain*
Discharge Medications*
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Diet
DISCHARGE DIET*
Ja
Nein
Cardiac*
Ja
Nein
Clear Liquid*
Ja
Nein
Diabetic*
Ja
Nein
Renal*
Ja
Nein
As Tolerated*
Ja
Nein
Advance as tolerated*
Ja
Nein
Activity
As tolerated*
Ja
Nein
Ad lib*
Ja
Nein
As much as possible*
Ja
Nein
Avoid lifting over 10 lbs*
Ja
Nein
Limited*
Ja
Nein
Restricted*
Ja
Nein
Körperliche Aktivität*
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HIS DISCHARGE NOTE BRIEF ORIGINAL
DISCHARGE INSTRUCTIONS
DISCHARGE INSTRUCTIONS*
Return to office (physician, nurse, none)*
appointment*
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HIS DISCHARGE NOTE BRIEF ORIGINAL
HIS Discharge Summary
Form from HIS OpenVistA
All rights reserved. Please visit https://medical-data-
models.org/forms/172
HIS
DISCHARGE SUMMARY
Final Diagnosis*
ACTIVE PROBLEM LIST*
HOSPITALIZATION SUMMARY*
OPERATIONS / PROCEDURES*
Lab Findings*
NARRATIVE*
Transfusions/tissue transplants*
CONDITION AT DISCHARGE (stable, improved,
unchanged)*
Condition at discharge comment*
Ja
Nein
DISCHARGE INSTRUCTIONS*
MEDICATIONS
Inpatient Medications*
Home Medications*
Discharge Medications*
Nutrition and Care
NUTRITION STATUS*
DISCHARGE DIET*
HOME CARE*
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DISCHARGE RETURN INSTRUCTIONS
RETURN TO SEE NURSE*
Ja
Nein
RETURN TO SEE MD*
Ja
Nein
Next appointment*
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HIS Discharge Summary
HIS ENDOSCOPY PROCEDURE OTHER
Form from HIS OpenVistA
All rights reserved. Please visit https://medical-data-
models.org/forms/181
HIS
General Info
DATE & TIME OF ARRIVAL*
Behandelnder Arzt*
ASSISTED BY*
ROOM#*
Diagnose*
SCOPE INSTRUMENT USED
COLONOSCOPE*
EGD SCOPE*
FLEX SIGMOID SCOPE*
ERCP SCOPE*
ENTEROSCOPE*
DB CHANNEL SCORE*
VIDEO CAMERA*
Procedure Info
ENDOSCOPY START*
PROCEDURE*
PROCEDURE START*
PROCEDURE STOP*
PROCEDURE COMMENTS*
Electrosurgical Unit (ESU)*
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SETTINGS*
GROUNDING PAD*
Diagnose*
ERCP CONTRAST MEDIUM USED [ml]*
FLUOROSCOPY TIME [minutes]*
TIME OF DEPARTURE*
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HIS ENDOSCOPY PROCEDURE OTHER
Eligibility NCT00247390 Chronic Insomnia
ODM derived from
http://clinicaltrials.gov/show/NCT00247390
All rights reserved. Please visit https://medical-data-
models.org/forms/185
Eligibility
Einschlusskriterien
Alter 18 Jahre und älter*
Ja
Nein
Females of childbearing potential who are
sexually active must agree to use adequate
contraception*
Ja
Nein
Females of childbearing potential can neither be
pregnant nor lactating from Screening throughout
the duration of the study*
Ja
Nein
Body mass index between 18 and 34, inclusive*
Ja
Nein
Based on sleep history, has had chronic insomnia
for at least 3 months*
Ja
Nein
Based on sleep history, reports a subjective sleep
latency greater than or equal to 45 min*
Ja
Nein
Based on sleep history, reports a subjective total
sleep time less than or equal to 6.5 hours*
Ja
Nein
Based on sleep history, habitual bedtime is
between 10:00 PM and 1:00 AM*
Ja
Nein
Mean latency to persistent sleep of greater than
20 minutes on two consecutive screening nights
with neither night less than 15 minutes*
Ja
Nein
A mean of 60 minutes of wake time during the
480 minutes in bed across two nights with no
night less than 45 minutes*
Ja
Nein
Based on sleep history, normally uses
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pharmacological assistance to sleep 0 to 4 times
per week in the last 3 months*
Ja
Nein
Ausschlusskriterien
Known hypersensitivity to ramelteon or related
compounds, including melatonin, and melatonin
related compounds*
Ja
Nein
Participated in any other investigational study
and/or taken any investigational drug within 30
days or five half-lives prior to the first dose of
single-blind study medication, whichever is
longer*
Ja
Nein
Sleep schedule changes required by employment
(eg, shift worker) within three months prior to the
administration of single-blind study medication*
Ja
Nein
Flown across greater than three time zones
within 7 days prior to or during screening*
Ja
Nein
Participated in a weight loss program or has
substantially altered their exercise routine within
30 days prior to the administration of single-blind
study medication*
Ja
Nein
Has ever had a history of seizures, sleep apnea,
restless leg syndrome, periodic leg movement
syndrome, chronic obstructive pulmonary disease
or fibromyalgia*
Ja
Nein
History of psychiatric disorder within the past 6
months*
Ja
Nein
History of alcohol abuse within the past 12
months, as defined in Diagnostic & Statistical
Manual of Mental Disorders, 4th Edition Revised,
or regularly consumes more than 14 alcoholic
drinks per week, or consumed any alcoholic
drinks within 24 hours of any polysomnogram
visits*
Ja
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Eligibility NCT00247390 Chronic Insomnia
Nein
History of drug abuse within the past 12 months,
as defined in Diagnostic & Statistical Manual of
Mental Disorders, 4th Edition Revised*
Ja
Nein
Current significant hepatic, renal, endocrine,
cardiovascular, gastrointestinal, pulmonary,
hematologic, neurological, or metabolic disease,
unless currently controlled and stable with
protocol-allowed medication, within 30 days prior
to the first night of single-blind study medication*
Ja
Nein
Apnea hypopnea index (per hour of sleep)
greater than 10 as seen on the first
polysomnogram screening night*
Ja
Nein
Periodic Leg Movement Syndrome with arousal
index (per hour of sleep) greater than 10 as seen
on the first polysomnogram screening night*
Ja
Nein
Positive urine drug screen at Screening Visit 1 or
any of the polysomnogram assessment visits*
Ja
Nein
Positive breathalyzer test on any of the
polysomnogram assessment visits*
Ja
Nein
Uses tobacco products (including nicotine gum
and patch) or any other products that may
interfere with the sleep wake cycle during nightly
awakenings*
Ja
Nein
Used any central nervous system medication or
other drugs or supplements known to affect
sleep/wake function within 1 week (or 5 half lives
of the drug, whichever is longer) prior to the
administration of single-blind study medication.
These medications must not have been used to
treat psychiatric disorders.*
Ja
Nein
Intends to continue taking any disallowed
medication or any prescription medication or over
the counter medication that is known to affect the
sleep/wake function or otherwise interfere with
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evaluation of the study medication. The subject
must report all prescription and over the counter
medications taken in the three weeks prior to
screening*
Ja
Nein
Is required to take or continues taking any
disallowed medication, prescription medication,
herbal treatment or over-the counter medication
that may interfere with evaluation of the study
medication, including:*
Ja
Nein
Anxiolytics*
Ja
Nein
Sedatives*
Ja
Nein
Hypnotics*
Ja
Nein
CNS active drugs (including herbal)*
Ja
Nein
Antidepressants*
Ja
Nein
Narcotic analgesics*
Ja
Nein
Anticonvulsants*
Ja
Nein
Beta blockers*
Ja
Nein
Sedating H1 antihistamines*
Ja
Nein
St. John's Wort*
Ja
Nein
Systemic steroids*
Ja
Nein
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Kava-kava*
Ja
Nein
Respiratory stimulants*
Ja
Nein
Ginkgo-biloba*
Ja
Nein
Decongestants*
Ja
Nein
Over-the-counter and prescription stimulants*
Ja
Nein
Antipsychotics*
Ja
Nein
Over-the-counter and prescription diet aids*
Ja
Nein
Muscle Relaxants*
Ja
Nein
Melatonin and all other drugs or supplements
known to affect sleep/wake function*
Ja
Nein
Any additional condition(s) that in the
Investigator's opinion would affect sleep/wake
function, prohibit the subject from completing  the
study, indicate that continuation in the study
would not be in the best interests of the subject*
Ja
Nein
History of hepatitis B or hepatitis C*
Ja
Nein
Medizinische Konzepte
Alter*
Diagnose*
Kontrazeption*
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Eligibility NCT00247390 Chronic Insomnia
Stillzeit*
schwanger*
BMI*
Chronic Insomnia*
Reduced sleep latency*
Bedtime*
Allergic reaction to substance*
Ramelteon (substance)*
Melatonin (substance)*
Blind study*
Medikation*
Time zone*
Screening*
Weight loss advised*
Convulsion*
SAS - Sleep apnea syndrome *
Restless legs syndrome*
Periodic leg movements of sleep*
COPD*
Fibromyalgia*
Psychiatric disorder*
Alkohol-Abusus*
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Drug abuse*
Liver diseases*
Kidney Diseases*
Endocrine system diseases*
Disease affecting entire cardiovascular system*
Disorder of gastrointestinal tract*
Lungenerkrankung*
Diseases of blood and bloodforming organs*
Neurological disorder*
MD - metabolic disorders*
Periodic limb movement disorder (PLMD)*
Urine drug screen positive*
Polysomnogram*
Breathalyzer test*
positive*
Use of tobacco products at least daily*
Nicotine chewing gum*
Nicotine m/r transdermal patch*
Organic disorder of sleep wake cycle*
Central nervous system agents*
Single-blind study*
Misuse of over-the-counter medications*
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Herbal drugs*
Anxiolytic Agents*
Sedative (substance)*
Hypnotic agent*
Antidepressive Agents*
Narcotic analgesic product*
Anticonvulsant (substance)*
Beta-Blocker*
H1 antihistamine (substance)*
St. John's Wort*
Long term (current) use of systemic steroids*
Kava kava*
Respiratory stimulant (substance)*
Ginkgo biloba extract*
Decongestant preparation*
Stimulant (substance)*
Prescription (procedure)*
Antipsychotic agent (substance)*
Diet Aid*
Muscle relaxants*
Type B viral hepatitis*
Viral hepatitis C*
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Eligibility NCT00247390 Chronic Insomnia
HIS NUTRITION CARE PLAN
Form from HIS OpenVistA
All rights reserved. Please visit https://medical-data-
models.org/forms/186
HIS
INTAKE
Hypermetabolism (Increased energy needs)*
Ja
Nein
Hypometabolism (Decreased energy needs)*
Ja
Nein
Inadequate energy intake*
Ja
Nein
Excessive energy intake*
Ja
Nein
Inadequate oral food/beverage intake*
Ja
Nein
Excessive oral food/beverage intake*
Ja
Nein
Inadequate intake form enteral/parenteral
nutrition*
Ja
Nein
Excessive intake from enteral/parenteral
nutrition*
Ja
Nein
Inadequate infusion of enteral/parenteral
nutrition*
Ja
Nein
Inadequate fluid intake*
Ja
Nein
Excessive fluid intake*
Ja
Nein
Inadequate bioactive substance abuse*
Ja
Nein
Excessive bioactive substance intake*
Ja
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Nein
Excessive alcohol intake*
Ja
Nein
Increased nutrient needs-(specify)*
Ja
Nein
Evident protein energy malnutrition*
Ja
Nein
Inadequate protein-energy intake*
Ja
Nein
Decreased nutrient needs-(specify)*
Ja
Nein
Imbalance of nutrients*
Ja
Nein
Inadequate fat intake*
Ja
Nein
Excessive fat intake*
Ja
Nein
Inappropriate intake of food fats-(specify)*
Ja
Nein
Inadequate protein intake*
Ja
Nein
Excessive protein intake*
Ja
Nein
Inappropriate intake of amino acids-(specify)*
Ja
Nein
Inadequate carbohydrate intake*
Ja
Nein
Excessive carbohydrate intake*
Ja
Nein
Inappropriate intake of types of carbohydrates*
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Ja
Nein
Inconsistant carbohydrate intake*
Ja
Nein
Inadequate fiber intake*
Ja
Nein
Excessive fiber intake*
Ja
Nein
Inadequate vitamin intake-(specify)*
Ja
Nein
Excessive vitamin intake of:*
Ja
Nein
A*
Ja
Nein
Thiamin*
Ja
Nein
Riboflavin*
Ja
Nein
Niacin*
Ja
Nein
Folate*
Ja
Nein
C*
Ja
Nein
D*
Ja
Nein
E*
Ja
Nein
K*
Ja
Nein
Other:*
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HIS NUTRITION CARE PLAN
Inadequate mineral intake of:*
Ja
Nein
Calcium*
Ja
Nein
Potassium*
Ja
Nein
Iron*
Ja
Nein
Zinc*
Ja
Nein
Other:*
Excessive mineral intake of:*
Ja
Nein
Calcium*
Ja
Nein
Potassium*
Ja
Nein
Iron*
Ja
Nein
Zinc*
Ja
Nein
Other:*
CLINICAL
Swallowing difficulty*
Ja
Nein
Chewing (masticatory) difficulty*
Ja
Nein
Breastfeeding difficulty*
Ja
Nein
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Altered GI function*
Ja
Nein
Impaired nutrient utilization*
Ja
Nein
Altered nutrition-related laboratory values*
Ja
Nein
Food-medication interaction*
Ja
Nein
Underweight*
Ja
Nein
Involuntary weight loss*
Ja
Nein
Overweight/obesity*
Ja
Nein
Involuntary weight gain*
Ja
Nein
BEHAVIORAL-ENVIROMENTAL
Food- and nutrition-related knowledge deficit*
Ja
Nein
Harmful beliefs/attitudes about food-or*
Ja
Nein
nutrition related topics(use with caution)*
Ja
Nein
Not ready for diet/lifestyle change*
Ja
Nein
Self-monitoring deficit*
Ja
Nein
Disordered eating pattern*
Ja
Nein
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Limited adherance to nutrition related
recommendations*
Ja
Nein
Undesirable food choices*
Ja
Nein
Physical inactivity*
Ja
Nein
Excessive exercise*
Ja
Nein
Inability or lack of desire to manage self-care*
Ja
Nein
Impaired ability to prepare foods/meals*
Ja
Nein
Poor nutrition quality of life*
Ja
Nein
Self-feeding difficulty*
Ja
Nein
Intake of unsafe food*
Ja
Nein
Limited access to food*
Ja
Nein
Nutritional Status
Nutritional Status (1= Normal, 2= Mildly
compromised, 3= Moderately compromised, 4=
Severely compromised, Comfort measures only -
follow as needed)*
Goals*
FOOD AND/OR NUTRIENT DELIVERY
General/healthful diet*
Ja
Nein
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HIS NUTRITION CARE PLAN
Modify distributions, type, or amount of food and
nutrients within meals or at specified time*
Ja
Nein
Specific foods/beverage or groups*
Ja
Nein
Initiate enteral or parenteral nutrition*
Ja
Nein
Modify rate, concentration, composition or
schedule*
Ja
Nein
Discontinue enteral or parenteral nutrition*
Ja
Nein
Insert enteral feeding tube*
Ja
Nein
Site Care*
Ja
Nein
Other-(specify)*
SUPPLEMENTS
Commercial beverage*
Ja
Nein
Commercial food*
Ja
Nein
Modified beverage*
Ja
Nein
Modified food*
Ja
Nein
Multivitamin / mineral*
Ja
Nein
Vitamin*
Ja
Nein
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HIS NUTRITION CARE PLAN
Thiamin*
Ja
Nein
Riboflavin*
Ja
Nein
Niacin*
Ja
Nein
A*
Ja
Nein
C*
Ja
Nein
D*
Ja
Nein
E*
Ja
Nein
K*
Ja
Nein
Folate*
Ja
Nein
Multivitamin*
Ja
Nein
Other-(specify)*
Mineral*
Ja
Nein
Calcium*
Ja
Nein
Potassium*
Ja
Nein
Iron*
Ja
Nein
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HIS NUTRITION CARE PLAN
Zinc*
Ja
Nein
Phosphorus*
Ja
Nein
Magnesium*
Ja
Nein
Multi-trace elements*
Ja
Nein
Other-(specify)*
Nutrition interventions
Initiate*
Ja
Nein
Dose change*
Ja
Nein
Form change*
Ja
Nein
Route change*
Ja
Nein
Administration schedule*
Ja
Nein
Discontinue-(specify)*
Adaptive equipment*
Ja
Nein
Feeding position*
Ja
Nein
Meal set-up*
Ja
Nein
Mouth Care*
Ja
Nein
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HIS NUTRITION CARE PLAN
Other-(specify)*
Lighting*
Ja
Nein
Odors*
Ja
Nein
Distraction*
Ja
Nein
Table height*
Ja
Nein
Table service / setup*
Ja
Nein
Room temperature*
Ja
Nein
Other-(specify)*
NUTRITION EDUCATION
Purpose of the nutrition education*
Priority information*
Survival information*
Other-(specify)*
Recommended modifications*
Advanced or related topics*
Result interpretation*
Other-(specify)*
NUTRITION COUNSELING
Theory or approach*
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HIS NUTRITION CARE PLAN
Behavior modification*
Ja
Nein
Cognitive-behavioral theory*
Ja
Nein
Social learning theory*
Ja
Nein
Transtheoretical*
Ja
Nein
Other-(specify)*
Strategies*
Ja
Nein
Cognitive restructuring*
Ja
Nein
Goal setting*
Ja
Nein
Motivational interviewing*
Ja
Nein
Problem solving*
Ja
Nein
Rewards/reinforcement*
Ja
Nein
Self-monitoring*
Ja
Nein
Social support*
Ja
Nein
Stimulates control / contingency management*
Ja
Nein
Stress management*
Ja
Nein
Other-(specify)*
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HIS NUTRITION CARE PLAN
Phase*
Ja
Nein
Involving*
Ja
Nein
Exploring*
Ja
Nein
Resolving*
Ja
Nein
Closing*
Ja
Nein
COORDINATION OF NUTRITION CARE
Collaboration/referral to other providers*
Referral to community agencies/programs*
Team meeting*
Ja
Nein
Referral to RD with different expertise*
Ja
Nein
Collaboration/referral to other providers*
Ja
Nein
Referral to community agencies /  program*
Ja
Nein
(specify)-*
PES STATEMENTS
PROBLEM*
ETIOLOGY*
SIGNS/SYMPTOMS*
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HIS NUTRITION CARE PLAN
MONITOR & EVALUATION
MONITOR & EVALUATION*
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HIS NUTRITION CARE PLAN
HIS SHORT STAY RECORD-ORTHO
SURGICARE
Form from HIS OpenVistA
All rights reserved. Please visit https://medical-data-
models.org/forms/191
HIS
Medical History
Hauptbeschwerden*
Anamnese der aktuellen Erkrankung*
Anamnese*
Frühere Operationen*
Allergie*
aktuelle Medikation*
Anamnese der Organsysteme*
Familienanamnese*
Sozialanamnese*
Impfung*
Physical Examination
Allgemeinzustand*
Head, Ears, Eyes, Nose and Throat (HEENT)*
Hals*
Thorax*
Brust*
Herz*
Abdomen*
Lymphknoten*
Genitalia/Rectal (default: deferred)*
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Extremitäten*
Haut*
NEUROLOGICAL: intact*
Ja
Nein
Neurologische Untersuchung*
Diagnosis and Plan
Aufnahmediagnose*
Planung*
ASA Status*
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HIS SHORT STAY RECORD-ORTHO SURGICARE
Eligibility NCT00251966 Gastroesophageal
Reflux
ODM derived from
http://clinicaltrials.gov/show/NCT00251966
All rights reserved. Please visit https://medical-data-
models.org/forms/193
Eligibility
Einschlusskriterien
Alter 60 Jahre und älter*
Ja
Nein
A clinical diagnosis of a condition (cardiovascular
and/or cerebrovascular protection or other
reasons) that requires daily intake of low-dose
ASA, 75-325 mg, and is expected to continue for
the duration of the study (daily is defined as at
least 5 days per week)*
Ja
Nein
No gastric and/or duodenal ulcer at the baseline
endoscopy*
Ja
Nein
H. pylori negative by serology test at screening*
Ja
Nein
Ausschlusskriterien
Upper GI symptoms*
Ja
Nein
Erosive oesophagitis*
Ja
Nein
Malignancy*
Ja
Nein
Medizinische Konzepte
Alter*
Diagnose*
ASS*
Magenulkus*
Duodenalulkus*
1 / 2
Endoskopie*
Helicobacter pylori*
negativ*
Serologischer Test*
Screening*
oberer Gastrointestinaltrakt*
Erosive Oesophagitis*
Krebs*
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Eligibility NCT00251966 Gastroesophageal Reflux
BRADEN  SCALE
Form from HIS OpenVista
All rights reserved. Please visit https://medical-data-
models.org/forms/198
BRADEN  SCALE
BRADEN SCALE Data
SENSORY PERCEPTION: Ability to respond
meaningfully to pressure.*
COMPLETELY LIMITED Unresponsive
to painful stimuli, due to diminished level
of consciousness or sedation, OR
Limited ability to feel pain over most of
body surface (SCORE=1) (1)
VERY LIMITED Responds only to painful
stimuli, cannot communicate discomfort
except by moaning or restlessness OR
Has a sensory impairment, which limits
the ability to feel pain or discomfort over
1/2 the body (SCORE=2) (2)
SLIGHTLY LIMITED Responds to verbal
commands but cannot always
communicate discomfort or need to be
turned, OR Has some sensory
impairment, which limits ability to feel
pain or discomfort in 1 or 2 extremities.
(SCORE=3) (3)
NO IMPAIRMENT Responds to verbal
command. Has no sensory deficit which
would limit ability to feel or voice pain or
discomfort. (SCORE=4) (4)
MOISTURE: The degree to which skin is exposed
to moisture.*
CONSTANTLY MOIST Perspiration,
urine, etc. keeps skin moist almost
constantly. Dampness is detected every
time a patient is moved or turned.
(SCORE=1) (1)
MOIST Skin is often but not always
moist. Linen must be changed at least
once a shift. (SCORE=2) (2)
OCCASIONALLY MOIST Skin is
occasionally moist requiring an extra
linen change approximately once a day.
(SCORE=3) (3)
RARELY MOIST Skin is usually dry;
linen requires changing only at routine
intervals. (SCORE=4) (4)
ACTIVITY: Degree of physical activity.*
BEDFAST Confined to bed (SCORE=1)
(1)
CHAIR FAST Ability to walk is severly
limited or nonexistant. Cannot bear
weight and/or must be assisted into a
chair or wheelchair. (SCORE=2) (2)
WALKS OCCASIONALLY Walks
occasionally during the day but for very
short distances, with or without
assistance. Spends majority of each shift
1 / 3
in a bed or a chair.(SCORE=3) (3)
WALKS FREQUENTLY Walks outside
the room at least twice a day and inside
the room at least once every 2 hours
during waking hours. (SCORE=4) (4)
MOBILITY: The ability to change and control
position.*
COMPLETELY IMMOBILE Does not
make even slight changes in body or
extremity position without assistance.
(SCORE=1) (1)
VERY LIMITED Makes occasional slight
changes in body or extremity position but
unable to make frequent or significant
changes independently. (SCORE=2) (2)
SLIGHTLY LIMITED Makes frequent
though slight changes in body or
extremity position independently.
(SCORE=3) (3)
NO LIMITATIONS Makes major and
frequent changes in position without
assistance. (SCORE=4) (4)
NUTRITION: Usual food intake pattern*
VERY POOR Never eats a complete
meal. Rarely eats more than 1/3 of any
food offered. Eats 2 servings or less of
protein (meat or dairy products) per day.
Takes fluids poorly. Does not take a
liquid dietary supplement, OR Is NPO
and/or maintained on clear liquids or IV
for more than 5 days. (SCORE=1) (1)
PROBABLY INADEQUATE: Rarely eats
a complete meal and generally eats only
about 1/2 of any food offered. Protein
intake includes only 3 servings of meat
or dairy products per day. Occasionally
will take a dietary supplement, OR
Receives less than optimal amount of
liquid diet or tube feeding.  (SCORE=2)
(2)
ADEQUATE Eats over 1/2 of most meals.
Eats a total of 4 servings of protein
(meat, dairy products) each day.
Occasionally will refuse a meal, but will
usually take a supplement if offered, OR
Is on a tube feeding or TPN regimen,
which probably meets most of nutritional
needs. (SCORE=3) (3)
EXCELLENT Eats most of every meal.
Never refuses a meal. Usually eats a
total of 4 or more servings of meat and
dairy products. Occasionally eats
between meals. Does not require
supplementation. (SCORE=4) (4)
FRICTION AND SHEAR:*
PROBLEM Requires moderate to
maximum assistance in moving.
2 / 3
BRADEN  SCALE
Complete lifting without sliding against
sheets is impossible. Frequently slides
down in bed or chair, requiring frequent
repositioning with maximum assistance.
Spasticity, contractures, or agitation
leads to almost constant friction.
(SCORE=1) (1)
POTENTIAL PROBLEM Moves feebly or
requires minimum assistance. During a
move, skin probably slides to some
extent against sheets, chair, restraints, or
other devices. Maintains relatively good
position in chair or bed most of the time,
but occasionally slides down.
(SCORE=2) (2)
NO APPARENT PROBLEM Moves in
bed and in chair independently and has
sufficient muscle strength to lift up
completely during a move. Maintains
good position in bed or chair at all times.
(SCORE=3) (3)
TOTAL SCORE= *
PRESSURE ULCER PREVENTION
GUIDELINES:
THE SCORE IS 18 OR LESS IMPLEMENT THE
PRESSURE ULCER PREVENTION
PROTOCOL, AND REFER TO SPECIALTY BED
PROTOCOL AND CHECKLIST TO DETERMINE
WHICH PRESSURE REDUCING SURFACE IS
INDICATED.
1. The*
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BRADEN  SCALE
Eligibility NCT00255281 Atrial Fibrillation
ODM derived from
http://clinicaltrials.gov/show/NCT00255281
All rights reserved. Please visit https://medical-data-
models.org/forms/205
Eligibility
Einschlusskriterien
Alter 18 Jahre bis 80 Jahre*
Ja
Nein
Clinical indication for cardioversion of Atrial
Fibrillation. Effective oral anticoagulation
according to local routines or a TEE without any
finding of intracardial thrombus or signs of
thrombogenecity*
Ja
Nein
Ausschlusskriterien
Clinically significant sinus and/or AV node
dysfunction. Serum or plasma potassium <3.8
mmol/L or >5.0 mmol/L. QTc(Bazett) >450 ms.
Any QRS duration >150 ms*
Ja
Nein
Medizinische Konzepte
Alter*
Diagnose*
Cardioversion*
Vorhofflimmern*
Use of anticoagulation*
transösophageale Echokardiographie*
Thrombus*
Coronary sinus rhythm disorder*
Atrioventricular nodal disease*
Serumkalium abnormal*
Plasmakalium abnormal*
1 / 1
HIS RESP THERAPY O2 PROTOCOL
DOCUMENTATION INTERDISCIPLINARY
Form from HIS OpenVistA
All rights reserved. Please visit https://medical-data-
models.org/forms/211
HIS
Oxygen Therapy Protocol
1.Evaluate patient on receipt of physician order
for Respiratory Therapy Consult.*
Ja
Nein
2.Determine if the patient meets the criteria for
the oxygen therapy protocol.*
Ja
Nein
3 If the patient meets the criteria for the oxygen
therapy protocol, insure that no contraindications
are met.*
Ja
Nein
4.Obtain a room air Sp02 (Sp02 is saturation
offered by Pulse Oximetry).*
Ja
Nein
5.The Sp02 threshold of 90% has been
established .(above or equal to 95% on Cardiac
patients)*
Ja
Nein
6.If the Sp02 is < 90% on room air, determine the
need for a low flow or high flow system.*
Ja
Nein
7.If low flow system, place the patient on a NC @
2 l/m.  Titrate the Fi02 by 1 l/m to Room Air to
maintain and Sp02 above or equal to 90%.*
Ja
Nein
8.If high flow system, notify the physician.  Titrate
the Fi02 to maintain Spo2 above or equal 90%.
Once the Fi02 reaches 40%,convert the patient
to NC @ 6 l/m and titrate the Fio2 by 1 l/m until
on room air to maintain Spo2 above or equal to
90%.*
Ja
Nein
9.If the Sp02 decreases to < 90% while on room
air, place the patient back on the   previous flow
for re-evaluation.*
Ja
Nein
10.Once the patient is weaned to room air,
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evaluation will continue for the next 24 hours
before protocols are discontinued.*
Ja
Nein
11.Sp02 checks will be done PRN and
QShift.Continuous pulse oximetry will be done on
patients with Fi02 above or equal to 40%.*
Ja
Nein
12.Oxygen will remain in the room for PRN
purposes only for patients that are being
monitored for chest pain or cardiac disease.
Oxygen will not be discontinued on patients that
use oxygen at home.*
Ja
Nein
13.Patients will be discontinued from oxygen
when the room air Sp02 is above or equal to 90%
and oxygen is not needed for exercise or
ambulation.*
Ja
Nein
14.The physician and nurse will be notified if the
Sp02 < 85% or if the oxygen requirements
increase by 2 l/m or 10% above baseline.*
Ja
Nein
Settings and O2 findings
Herzfrequenz*
Respiratory equipment*
L FLOW/%OXYGEN*
Patient activity checklist*
Oximetrie*
Delivered oxygen flow rate*
periphere O2-Sättigung*
COMMENT*
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HIS RESP THERAPY O2 PROTOCOL DOCUMENTATION
INTERDISCIPLINARY
HIS PATIENT FAMILY EDUCATION
RECORD INTERDISCIPLINARY NOTE
Form from HIS OpenVistA
All rights reserved. Please visit https://medical-data-
models.org/forms/213
HIS
Anticipated discharge planning on
admission
Assisted Living, Residential Care*
Ja
Nein
Home (lives alone)*
Ja
Nein
Home with parent(s)*
Ja
Nein
Home w/Significant Other*
Ja
Nein
Home w/Spouse*
Ja
Nein
Home w/Family (children)*
Ja
Nein
Home w/Friend (caretaker)*
Ja
Nein
Dependent in ADLs*
Ja
Nein
Independent in ADLs*
Ja
Nein
Pflegeheim*
Ja
Nein
Rehabilitation*
Ja
Nein
Retirement Center/Assisted Living Facility*
Ja
Nein
Requires Assistance with ADLs*
Ja
Nein
Other*
1 / 2
Educational learning assessment
Did You participate in any pre-hospital
education?*
Do You have any religious or cultural practices
that may alter your care or education?*
Is patient sensory impaired (hearing, visual,
speech)?*
Is the patient/family motivated to learn?*
Ja
Nein
Do You have any emotional/family/home
concerns that need to be addressed during your
hospitalization?*
Ja
Nein
Do You have any physical or cognitive limitation
that may alter care or limit your learning ability?*
Ja
Nein
Reading preference (English| Spanish| Unable to
read| other)*
Spoken Language*
Collaborative Patient/Family Education
record
Patient Family Education record*
Maternal/Child Patient and Family teaching
(Labor and Delivery| Post Partum| Nursery)*
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HIS PATIENT FAMILY EDUCATION RECORD INTERDISCIPLINARY
NOTE
HIS SHORT STAY RECORD-PAIN
MANAGEMENT
Form from HIS OpenVistA
All rights reserved. Please visit https://medical-data-
models.org/forms/214
HIS
SHORT STAY RECORD-PAIN
MANAGEMENT
Hauptbeschwerden*
Anamnese der aktuellen Erkrankung*
Anamnese*
Frühere Operationen*
Allergie*
aktuelle Medikation*
Anamnese der Organsysteme*
Familienanamnese*
Sozialanamnese*
Physical Exam
Allgemeinzustand*
Head, Ears, Eyes, Nose and Throat*
Hals*
Thorax*
Brust*
Herz*
Abdomen*
Lymphknoten*
GENITALIA/RECTAL*
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Extremitäten*
Haut*
Nervensystem*
Aufnahmediagnose*
PLAN: Surgery*
Ja
Nein
ASA Status*
2 / 2
HIS SHORT STAY RECORD-PAIN MANAGEMENT
BRADEN  SCALE
Formular aus dem KIS OpenVistA
All rights reserved. Please visit https://medical-data-
models.org/forms/222
BRADEN  SCALE
BRADEN SCALE Data
SENSORY PERCEPTION: Ability to respond
meaningfully to pressure.*
COMPLETELY LIMITED Unresponsive
to painful stimuli, due to diminished level
of consciousness or sedation, OR
Limited ability to feel pain over most of
body surface (SCORE=1) (1)
VERY LIMITED Responds only to painful
stimuli, cannot communicate discomfort
except by moaning or restlessness OR
Has a sensory impairment, which limits
the ability to feel pain or discomfort over
1/2 the body (SCORE=2) (2)
SLIGHTLY LIMITED Responds to verbal
commands but cannot always
communicate discomfort or need to be
turned, OR Has some sensory
impairment, which limits ability to feel
pain or discomfort in 1 or 2 extremities.
(SCORE=3) (3)
NO IMPAIRMENT Responds to verbal
command. Has no sensory deficit which
would limit ability to feel or voice pain or
discomfort. (SCORE=4) (4)
MOISTURE: The degree to which skin is exposed
to moisture.*
CONSTANTLY MOIST Perspiration,
urine, etc. keeps skin moist almost
constantly. Dampness is detected every
time a patient is moved or turned.
(SCORE=1) (1)
MOIST Skin is often but not always
moist. Linen must be changed at least
once a shift. (SCORE=2) (2)
OCCASIONALLY MOIST Skin is
occasionally moist requiring an extra
linen change approximately once a day.
(SCORE=3) (3)
RARELY MOIST Skin is usually dry;
linen requires changing only at routine
intervals. (SCORE=4) (4)
ACTIVITY: Degree of physical activity.*
BEDFAST Confined to bed (SCORE=1)
(1)
CHAIR FAST Ability to walk is severly
limited or nonexistant. Cannot bear
weight and/or must be assisted into a
chair or wheelchair. (SCORE=2) (2)
WALKS OCCASIONALLY Walks
occasionally during the day but for very
short distances, with or without
assistance. Spends majority of each shift
1 / 3
in a bed or a chair.(SCORE=3) (3)
WALKS FREQUENTLY Walks outside
the room at least twice a day and inside
the room at least once every 2 hours
during waking hours. (SCORE=4) (4)
MOBILITY: The ability to change and control
position.*
COMPLETELY IMMOBILE Does not
make even slight changes in body or
extremity position without assistance.
(SCORE=1) (1)
VERY LIMITED Makes occasional slight
changes in body or extremity position but
unable to make frequent or significant
changes independently. (SCORE=2) (2)
SLIGHTLY LIMITED Makes frequent
though slight changes in body or
extremity position independently.
(SCORE=3) (3)
NO LIMITATIONS Makes major and
frequent changes in position without
assistance. (SCORE=4) (4)
NUTRITION: Usual food intake pattern*
VERY POOR Never eats a complete
meal. Rarely eats more than 1/3 of any
food offered. Eats 2 servings or less of
protein (meat or dairy products) per day.
Takes fluids poorly. Does not take a
liquid dietary supplement, OR Is NPO
and/or maintained on clear liquids or IV
for more than 5 days. (SCORE=1) (1)
PROBABLY INADEQUATE: Rarely eats
a complete meal and generally eats only
about 1/2 of any food offered. Protein
intake includes only 3 servings of meat
or dairy products per day. Occasionally
will take a dietary supplement, OR
Receives less than optimal amount of
liquid diet or tube feeding.  (SCORE=2)
(2)
ADEQUATE Eats over 1/2 of most meals.
Eats a total of 4 servings of protein
(meat, dairy products) each day.
Occasionally will refuse a meal, but will
usually take a supplement if offered, OR
Is on a tube feeding or TPN regimen,
which probably meets most of nutritional
needs. (SCORE=3) (3)
EXCELLENT Eats most of every meal.
Never refuses a meal. Usually eats a
total of 4 or more servings of meat and
dairy products. Occasionally eats
between meals. Does not require
supplementation. (SCORE=4) (4)
FRICTION AND SHEAR:*
PROBLEM Requires moderate to
maximum assistance in moving.
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BRADEN  SCALE
Complete lifting without sliding against
sheets is impossible. Frequently slides
down in bed or chair, requiring frequent
repositioning with maximum assistance.
Spasticity, contractures, or agitation
leads to almost constant friction.
(SCORE=1) (1)
POTENTIAL PROBLEM Moves feebly or
requires minimum assistance. During a
move, skin probably slides to some
extent against sheets, chair, restraints, or
other devices. Maintains relatively good
position in chair or bed most of the time,
but occasionally slides down.
(SCORE=2) (2)
NO APPARENT PROBLEM Moves in
bed and in chair independently and has
sufficient muscle strength to lift up
completely during a move. Maintains
good position in bed or chair at all times.
(SCORE=3) (3)
Total Score (if 18 OR LESS IMPLEMENT THE
PRESSURE ULCER PREVENTION
PROTOCOL, AND REFER TO SPECIALTY BED
PROTOCOL AND CHECKLIST TO DETERMINE
WHICH PRESSURE REDUCING SURFACE IS
INDICATED)
THE SCORE IS 18 OR LESS IMPLEMENT THE
PRESSURE ULCER PREVENTION
PROTOCOL, AND REFER TO SPECIALTY BED
PROTOCOL AND CHECKLIST TO DETERMINE
WHICH PRESSURE REDUCING SURFACE IS
INDICATED.
*
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BRADEN  SCALE
HIS SPEECH THERAPY PROGRESS
NOTE
Form from HIS OpenVista
All rights reserved. Please visit https://medical-data-
models.org/forms/225
HIS
subjektiv
Patient tolerated treatment well with no
complaints of pain.*
Ja
Nein
Behandlung nicht gut toleriert*
Ja
Nein
Other*
objektiv
Bericht*
Untersuchung
Beschreibung*
Planung
Continue Plan Of Care*
Ja
Nein
Modify Goals*
Ja
Nein
Received D/C ST Order*
Ja
Nein
Other*
Charge Time [minutes]*
Reassessment*
Oral Motor Exercise*
Ja
Nein
Slow Speech Training*
Ja
Nein
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Follow One-Step Directions*
Ja
Nein
Vocal Intensity Training*
Ja
Nein
Respiratory Support Exercise*
Ja
Nein
Gedächtnistraining*
Ja
Nein
Entspannung*
Ja
Nein
Bericht*
ID Function of Objects*
Ja
Nein
Word Retrieval*
Ja
Nein
Improve Sentence Complexity*
Ja
Nein
Speaking Valve*
Ja
Nein
Orientation Training*
Ja
Nein
Confrontational Naming*
Ja
Nein
Yes/No Questions*
Ja
Nein
Assistive Communication*
Ja
Nein
Patient/Family Education*
Ja
Nein
Bericht*
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HIS SPEECH THERAPY PROGRESS NOTE
HIS SPEECH THERAPY EVALUATION
Form from HIS OpenVista
All rights reserved. Please visit https://medical-data-
models.org/forms/226
HIS
General Info
Medical Diagnosis*
Treatment Diagnosis*
Grund für Überweisung*
Prior level of function/ Previous Speech Therapy
treatments*
SPEECH-LANGUAGE TESTING
Assessment Protocol*
AUDITORY COMPREHENSION *
READING COMPREHENSION *
VERBAL EXPRESSION *
WRITTEN EXPRESSION *
PRAGMATICS*
Kognition*
summary, conclusion*
Severity Rating Scale*
normal (1)
mild (2)
moderat (3)
schwer (4)
Pflegeplanung
Pflegeplanung*
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Eligibility NCT00275379 Cystitis, Interstitial
ODM derived from
http://clinicaltrials.gov/show/NCT00275379
All rights reserved. Please visit https://medical-data-
models.org/forms/231
Eligibility
Einschlusskriterien
Alter 18 Jahre und älter*
Ja
Nein
Subjects seeking medical treatment for
symptoms consistent with IC that have been
ongoing for > 9 months or seeking medical
treatment for a previous documented diagnosis of
IC*
Ja
Nein
Subjects who are not surgically sterile or
postmenopausal (amenorrheic > 12 months)
must agree and commit to the use of a medically
acceptable, highly-effective (i.e. double-barrier or
IUD), non-hormonal form of birth control during
the study and for 30 days after the last dose of
test*
Ja
Nein
Ausschlusskriterien
Use of herbal supplements (except for a daily
multivitamin/mineral supplement not containing
herbal components)*
Ja
Nein
History of cancer (other than resected cutaneous
basal or squamous cell carcinoma or in situ
cervical cancer) with less than 5 years
documentation of a disease-free state*
Ja
Nein
Vaginitis or vaginal infection within 1 month
before randomization*
Ja
Nein
Medizinische Konzepte
Alter*
Diagnose*
medical treatment approach*
1 / 2
Interstitial Cystitis*
Contraceptive method: female sterilization*
Postmenopause*
Absence of menstruation*
Einverständniserklärung*
Kontrazeption*
Barrier contraception method*
Intrauterine contraceptive device*
Herbal supplement*
Krebs*
Basalzellenkarzinom*
Squamous cell carcinoma*
Carcinoma of cervix*
Inflammation of vagina*
Vaginal infection*
Random Allocation*
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Eligibility NCT00275379 Cystitis, Interstitial
HIS NURSING ASSESSMENT (adult)
Form from HIS OpenVista
All rights reserved. Please visit https://medical-data-
models.org/forms/237
HIS
Adult Nursing Assessment
see initial Admission Assessment*
Ja
Nein
DONE ON *
ADMISSION TEXT*
POST OP DAY*
Neuro / Psychosocial
Normal Baseline: Alert, responsive to stimuli,
sensation intact, speech clear and appropriate,
PERRLA, hand grips equal, can follow directions,
oriented X4, cooperative with treatment plan,
hygiene and grooming adequate, maintains eye
contact, poses no danger to self or to others,
normal affect.*
Ja
Nein
Narrative: Abnormal Findings*
GLASGOW COMA SCALE ADULT
EYES OPEN*
None (1)
To pain (2)
To speech (3)
Spontaneously (4)
BEST VERBAL RESPONSE*
None (1)
Incomprehensible words (2)
Inappropriate words (3)
Confused (4)
Oriented (5)
BEST MOTOR RESPONSE*
None (1)
Extension to pain (2)
Flexion to pain (3)
Withdraws (4)
Localize to pain (5)
Obeys command (6)
GLASCOW COMA SCALE SCORE ADULT*
1 / 25
Pupillen
Right Size [mm]*
Right Reaction*
Left Size [mm]*
Left Reaction*
ORIENTATION
Orientierung*
HX OF SEIZURE ACTIVITY*
Affekt*
Sprache*
NUMBNESS OR TINGLING PRESENT*
Kardiovaskuläres System
NORMAL BASELINE: Regular rate and rhythm,
no edema, capillary refill less than 3 seconds,
rate: 60-100 per minute, BP normotensive.*
Ja
Nein
Narrative: Abnormal Findings*
TEDS ON*
Ja
Nein
SCDS ON*
Ja
Nein
Herztöne*
Radial pulse (L/R)*
Pedal pulse (L/R)*
Tibialis posterior-Puls (L/R)*
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Popliteal-Puls (L/R)*
Brachialis-Puls (L/R)*
Karotis-Puls (L/R)*
AV SHUNT/GRAFT*
BRUIT*
SHUNT/GRAFT BRUITS*
THRILL PALPATED*
CAPILLARY REFILL*
NAIL BED COLOR*
Ödem*
Heart RHYTHM*
OTHER HR*
(künstlicher) Herzschrittmacher*
Ja
Nein
Eyes Ear Nose & Throat
Normal Baseline EYES: Without drainage, sclera
white. *
Ja
Nein
Normal Baseline EARS: No complaint of pain.*
Ja
Nein
Normal Baseline NOSE: No drainage or
congestion. *
Ja
Nein
Normal Baseline THROAT: No complaint of pain.*
Ja
Nein
NARRATIVE: Abnormal Findings*
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Augen
Pupil Right Size [mm]*
Pupil Right Reaction*
Pupil Left Size [mm]*
Pupil Left Reaction*
Eye Complains*
Right Sclera*
Left Sclera*
Drainage*
Ja
Nein
Drainage Color*
Ohren
EARS(EXTERNAL CANAL)*
C/O Pain*
Ja
Nein
Trommelfell*
Tubes*
Hard of Hearing*
Ja
Nein
Hearing Loss*
Ja
Nein
Deafness*
Ja
Nein
Hearing Aids*
RT (1)
LT (2)
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bilateral (3)
Patent*
Ja
Nein
Schwindel*
Ja
Nein
Tinnitus*
Ja
Nein
Drainage*
Ja
Nein
Color of Ear Drainage*
Nase
Nares patent*
Ja
Nein
Nares Drainage*
Ja
Nein
Nasenseptum*
Pharynx
Sore throat, Pain in throat, Pharyngeal pain*
Ja
Nein
Mouth Sores*
Ja
Nein
Appearance of Throat*
Mucous Membranes*
Respiratory
Normal Baseline: Regular, unlabored,
symmetrical, no accessory muscles used, no
abnormal breathsounds, rate 12-20 per minute.*
Ja
Nein
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NARRATIVE: Abnormal Findings*
Atemgeräusch*
RESPIRATORY EFFORT*
CHEST EXPANSION*
symmetrical (1)
non-symmetrical (2)
INCENTIVE SPIROMETRY DONE*
Ja
Nein
OXYGEN DELIVERY METHOD*
Pulse Oximeter present with alarms set*
Ja
Nein
Cardio-Respriratory Monitor present with alarms
set*
Ja
Nein
Husten*
Sputum*
CHEST TUBE PRESENT*
Ja
Nein
CHEST TUBE LOCATION*
Ja
Nein
Chest Tube Suction Setting*
Air Leak*
none (1)
small (2)
moderate (3)
large (4)
Gastrointestinal
Normal Baseline GI: Abdomen soft, non-
distended, bowel tones present X4, continent,
stool soft, brown and formed, states regular
bowel movements.*
Ja
Nein
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Last Bowel Movement*
NARRATIVE: Abnormal Findings*
Abdomen*
Darmgeräusche*
FLATUS*
Ja
Nein
GASTRIC SYMPTOMS*
NARES*
Nasogastric Tube Type*
NG placement checked*
Ja
Nein
Suction Setting*
Gastric Content Color*
NGT irrigated (with # ML's of #)*
OSTOMY TYPE*
RECTAL BAG PRESENT*
Ja
Nein
Urogenitales System
Normal Baseline Genitourinary: Voids without
pain, burning, or hesitation, urine clear, no strong
odor, no distention, continent.*
Ja
Nein
NARRATIVE: Abnormal Findings*
Geschlecht*
Male (1)
Female (2)
INCONTINENT*
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Ja
Nein
VOIDS SUFFICIENT QUANITY*
Ja
Nein
IS PATIENT RECEIVING DIALYSIS*
Ja
Nein
ODOR PRESENT*
Ja
Nein
URINE COLOR*
Katheter*
Ja
Nein
Katheter-Größe*
Date of insertion*
Urine color*
URINARY SYMPTOMS*
SEXUALLY ACTIVE*
Ja
Nein
CURRENTLY ON MENSES*
Ja
Nein
Ausfluss*
Ja
Nein
Discharge color*
Discharge odor*
Discharge consistency*
ABNORMAL GENITALIA DESCRIPTION*
Muskuloskeletales System
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Normal Baseline Musculoskeletal: Full ROM, no
muscle weakness, long bones intact, gait steady.*
Ja
Nein
NARRATIVE: Abnormal Findings*
GENERALIZED WEAKNESS*
Ja
Nein
LIMITED ROM*
Ja
Nein
LIMITED MOBILITY*
Ja
Nein
CONTRACTURES*
Ja
Nein
FRACTURE(S) LOCATION*
FINGER DIGITS*
TOE DIGITS*
PARALYSIS TYPE*
Hemiplegia Side*
left (1)
right (2)
LEFT UPPER EXTREMITIES*
RIGHT UPPER EXTREMITIES*
GRIPS EQUAL*
Ja
Nein
LEFT LOWER EXTREMITIES*
RIGHT LOWER EXTREMITIES*
UNSTEADY GAIT*
Ja
Nein
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Haut
NORMAL BASELINE: Warm, dry, turgor elastic,
pink undertone to skin or mucosa, no lesions,
skin smooth and intact, moist mucous
membranes.*
Ja
Nein
NARRATIVE: Abnormal Findings*
SKIN COLOR*
Temperatur*
MOIST*
Ja
Nein
SKIN TURGOR*
RASH LOCATION*
RASH DESCRIPTION*
TATTOO'S/PIERCINGS *
SKIN TEARS, LOCATION/ Description*
PRESSURE ULCER ASSESSMENT
Bony Prominences Assessed*
Ja
Nein
At risk for skin breakdown*
Ja
Nein
Braden Score 18 or less*
Ja
Nein
Pressure ulcer(s) present*
Ja
Nein
ULCER #*
Ulcer LOCATION*
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ULCER STAGE*
Ulcer Length*
Ulcer Width*
Ulcer Depth*
Wunde
Wunde*
Wound healed*
Ja
Nein
Wound Location*
Length (cm, mm)*
Width (cm, mm)*
Depth (cm, mm)*
Undermining*
Ja
Nein
Tunneling*
Ja
Nein
Surrounding Skin*
Wound Base*
Exsudat*
Exudate Color*
Sensation*
Odor: Before Cleaning *
Ja
Nein
Odor: After Cleaning *
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Ja
Nein
Cleansed with/irrigated with*
Hemostasis Achieved with*
Wound Medication Applied*
Wound Filled with*
Wound covered with*
Wound secured with*
Wound Pressure Relief*
Comments*
Photograph Date*
Inzision
Inzision*
MID WOUND#*
Site*
Closure Type*
Incision Appearance*
Dressing Changed*
Ja
Nein
Date Dressing Changed*
Dressing Type*
Dressing Appearance*
Drainage*
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Nutrition
Diät*
Ernährung über Sonde*
Ja
Nein
Feeding Tube Type*
Formula:  # strength @ # cc's/hour via kangaroo
pump*
RESIDUALS CHECKED:   AMOUNT # CC*
NPO*
Ja
Nein
BREAKFAST*
Breakfast: Amount taken*
Breakfast: Patient fed by*
LUNCH*
Lunch: Amount taken*
Lunch: Patient fed by*
SUPPER*
Supper: Amount taken*
Supper: Patient fed by*
Supper: Amount taken*
intravenöse Therapie
NARRATIVE: IV Therapy*
IV HEPLOCKED*
Ja
Nein
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IV Site APPEARANCE*
IV DISCONTINUED*
Ja
Nein
CATHETER INTACT*
Ja
Nein
IV Catheter Size*
IV Site Location*
Zentralvenöser Katheter (ZVK)*
Infusion*
Left to count: *
IV Fluid Rate: @  ml/hr*
TPN/LIPIDS: TPN @ ml/hr and Lipids @ ml/hr*
PCA PUMP:  at @ cc's/hr*
IV Site APPEARANCE*
INSERTION DATE*
DRESSING CHANGE DUE*
SITE CHANGE DUE*
PLACED ON IMED*
Ja
Nein
Patientensicherheit
SIDE RAILS UP*
Ja
Nein
IN LOW POSTION*
Ja
Nein
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BED/CRIB*
CALL BELL WITHIN REACH*
Ja
Nein
ALLERGY BAND ON*
Ja
Nein
NAME BAND ON*
Ja
Nein
BLOOD BAND ON*
Ja
Nein
BED SAFETY*
Hendrich II Fall Risk Assessment
Unable to assess fall risk status at this time due
to patient is:*
Confusion/Disorientation/Impulsivity   +4*
Ja
Nein
Symptomatic Depression  +2*
Ja
Nein
Altered Elimination  +1*
Ja
Nein
Dizziness/Vertigo   +1*
Ja
Nein
Gender (male)  +1*
Ja
Nein
Any Administered Antiepileptics (Anticonvulsants)
+2 *
Ja
Nein
Any Administered Benzodiazepines  +1 *
Ja
Nein
GET UP AND GO TEST: RISING FROM A
CHAIR*
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Ability to rise in single movement-No loss
of balance with steps   +0 (Ability to rise
in single movement-No loss of balance
with steps   +0)
Multiple attempts but successful  +3
(Multiple attempts but successful  +3)
Pushes up, successful in one attempt
+1 (Pushes up, successful in one
attempt   +1)
Unable to rise without assistance during
test (OR if a medical order states the
same and/or complete bed rest is
ordered)  +4 (Unable to rise without
assistance during test (OR if a medical
order states the same and/or complete
bed rest is ordered)  +4)
FINAL Hendrich II RISK SCORE*
INTERVENTIONS
Assist with Ambulation*
Ja
Nein
Reorient Q2H or Less*
Ja
Nein
Gait Belt*
Ja
Nein
ID Patient at Risk*
Ja
Nein
Restraints (see policy)*
Ja
Nein
Multi-personnel Transfer*
Ja
Nein
Close Observation*
Ja
Nein
Non-slip Footwear*
Ja
Nein
Bed in lowest position*
Ja
Nein
Lock wheels of vehicles of conveyance during
transfer*
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Ja
Nein
Upper siderails raised*
Ja
Nein
Call light in reach*
Ja
Nein
Assist with ambulation*
Ja
Nein
Offer toileting at least every 2 hours*
Ja
Nein
Offer fluid/nutrition every 2 hours*
Ja
Nein
Place frequently used objects within reach*
Ja
Nein
Provide adequate lighting*
Ja
Nein
Provide sensory impairment/orientation devices
(clocks,etc)*
Ja
Nein
Provide adequate rest periods*
Ja
Nein
Use age appropriate distractions for
confusion/disorientation*
Ja
Nein
Remove harmful hazards*
Ja
Nein
Provide appropriate and least restrictive patient
supervision/surveillance*
Ja
Nein
Communicate information about fall risk to
caregivers*
Ja
Nein
Encourage family/support system to participate in
care*
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Ja
Nein
Teach/educate family/support system Fall
Prevention information*
Ja
Nein
Implement Fall Prevention Protocol for Hendrich II
Score>5*
Ja
Nein
IMPAIRED MOBILITY RISK
Implement Universal Fall Prevention Intervention*
Ja
Nein
Monitor transfers to/from bed/chair(etc.)*
Ja
Nein
Use appropriate assistance for transfers to/from
bed/chair*
Ja
Nein
Use chairs with armrests and of proper height for
transfers*
Ja
Nein
Implement progressive ambulation(unless
contraindicated by condition/orders)*
Ja
Nein
Encourage/Provide self-care assistance*
Ja
Nein
Remain in attendance during toileting/ADL's*
Ja
Nein
Provide assistive devices for ambulation
(canes/walkers/etc.)*
Ja
Nein
Gait Belt during transport/ambulation*
Ja
Nein
Teach patient/family to call for help and WAIT for
help before*
Ja
18 / 25
HIS NURSING ASSESSMENT (adult)
Nein
attempting any transfer/ambulation*
Ja
Nein
ALTERED ELIMINATION
Implement Universal Fall Prevention
Interventions*
Ja
Nein
Remain in attendance during toileting/ADL's*
Ja
Nein
Assist with post-elimination hygiene*
Ja
Nein
Remove non-essential clothing*
Ja
Nein
Instruct patient on importance of toileting when
offered by staff*
Ja
Nein
Monitor for 'patient's normal' bladder/bowel
habits*
Ja
Nein
Monitor for causes of incontinence
(diuretics,cathartics,etc.)*
Ja
Nein
Monitor skin integrity*
Ja
Nein
HIGH RISK FALL MEDICATIONS
(ANTIEPILEPTICS &
BENZODIAZEPINES)
Implement Universal Fall Prevention
Interventions*
Ja
Nein
Monitor drug dosages*
Ja
Nein
Evaluate sensory functions*
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Ja
Nein
Monitor/Assess for drug overdose*
Ja
Nein
Monitor response to exercise*
Ja
Nein
Educate patient/support system about drug
classification, side effects,precautions, toxic
symptoms of overdose.*
Ja
Nein
INTERVENTIONS (FOR ONCOLOGY
USE ONLY)
UNIVERSAL FALL PRECAUTIONS*
Ja
Nein
Neutropenic Precautions taken.*
Ja
Nein
Date of last chemotherapy cycle *
Chemotherapy Agent/Dosage*
day  of chemotherapy*
Chemotherapy ADVERSE EFFECTS *
Radiation Safety Precautions taken.*
Ja
Nein
RADIATION INTERNAL*
Radiation External: Location of Markings *
Radiation: Number of Fractions prescribed*
Remaining Radiations*
Radiation Adverse Effects*
ONN Unit specific
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AFFECTED SITE*
CIRCULATORY STATUS*
SKIN COLOR*
Sensation*
MOVEMENT*
Temperatur*
Hautzustand*
PULSE(s) SITE(s)*
RESPONSE*
POSITION OF LIMB*
ORTHOPEDIC DEVICE IN USE*
CONTINUOUS PASSIVE MOTION*
POUNDS*
CERVICAL COLLARS*
AFO BRACE:  Foot/Feet (LEFT-RIGHT-
BILATERAL)*
SWELLING*
PIN SITES*
CLEANED WITH*
NARRATIVE*
Antepartum specific
Gravida*
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Para*
EDC*
Weeks gestation*
Fetal movement*
Ja
Nein
FHR*
Vision*
Kopfschmerzen*
Ja
Nein
Abdominal Cramps*
Ja
Nein
Uterine Contraction*
Ja
Nein
Epigastric Pain*
Ja
Nein
Vaginal Discharge*
Ja
Nein
Additional Findings*
Fundal Height*
NARRATIVE: Antepartum*
Post partum specific
Fundal Location*
LOCHIA*
Perineum*
Brust*
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Mamillen*
Mother/Baby Relationship*
BONDING*
Feedings*
Hämorrhoiden*
NARRATIVE: Post partum*
Post Surgical
Patient activity*
Vaginal Packing*
Equipment/Devices*
EQUIPMENT/DEVICES*
ADOLESCENT INTERACTION
Prepared for treatment/procedure as soon as
possible.*
Definitely Yes (1)
Yes (2)
No (3)
not applicable (4)
Provided detailed information about
events/procedures/treatments.*
Definitely Yes (1)
Yes (2)
No (3)
NA (4)
Allowed contact with peer group.*
Definitely Yes (1)
Yes (2)
No (3)
NA (4)
NARRATIVE*
GERIATRIC INTERVENTION (65+)
Involved in decision process regarding pain
control/medication/care decisions*
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Def. Yes (1)
Yes (2)
No (3)
NA (4)
Encouraged family/S.O.to visit                  *
Def. Yes (1)
Yes (2)
No (3)
NA (4)
Independence promoted.                          *
Def. Yes (1)
Yes (2)
No (3)
NA (4)
NARRATIVE*
Hendrich Fall Risk
Confusion/Disorientation +3*
Ja
Nein
Depression +4*
Ja
Nein
Altered Elimination (incontinence, nocturia) +3*
Ja
Nein
Non-Adaptive Mobility/Generalized Weakness
+2*
Ja
Nein
Dizziness/Vertigo  +3*
Ja
Nein
Primary Cancer Diagnosis  +3*
Ja
Nein
RECENT HISTORY of FALLS  +7*
Ja
Nein
FINAL Hendrich Fall RISK SCORE*
SUGGESTED INTERVENTIONS
Assist with Ambulation      *
Definitely Yes (1)
Yes (2)
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No (3)
NA (4)
Toileting Q2H               *
Definitely Yes (1)
Yes (2)
No (3)
NA (4)
Sensory Impairment Device   *
Definitely Yes (1)
Yes (2)
No (3)
NA (4)
Reorient Q2H or Less        *
Definitely Yes (1)
Yes (2)
No (3)
NA (4)
Gait Belt                   *
Definitely Yes (1)
Yes (2)
No (3)
NA (4)
ID Patient at Risk          *
Definitely Yes (1)
Yes (2)
No (3)
NA (4)
Restraints (see policy)*
Definitely Yes (1)
Yes (2)
No (3)
NA (4)
Multi-personnel Transfer    *
Definitely Yes (1)
Yes (2)
No (3)
NA (4)
Close Observation           *
Definitely Yes (1)
Yes (2)
No (3)
NA (4)
Non-slip Footwear           *
Definitely Yes (1)
Yes (2)
No (3)
NA (4)
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HIS NURSING ASSESSMENT (pedi)
Form from HIS OpenVista
All rights reserved. Please visit https://medical-data-
models.org/forms/238
HIS
Child Nursing Assessment
see initial Admission Assessment*
Ja
Nein
DONE ON *
ADMISSION TEXT*
POST OP DAY*
Neuro / Psychosocial
Normal Baseline: Alert, appropriate verbalization,
response appropriate for age, pupils equal and
reactive, sensation intact.*
Ja
Nein
Narrative: Abnormal Findings*
GLASGOW COMA SCALE ADULT
EYES OPEN*
None (1)
To pain (2)
To speech (3)
Spontaneously (4)
BEST VERBAL RESPONSE*
None (1)
Incomprehensible words (2)
Inappropriate words (3)
Confused (4)
Oriented (5)
BEST MOTOR RESPONSE*
None (1)
Extension to pain (2)
Flexion to pain (3)
Withdraws (4)
Localize to pain (5)
Obeys command (6)
GLASCOW COMA SCALE SCORE ADULT*
Pupillen
Right Size [mm]*
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Right Reaction*
Left Size [mm]*
Left Reaction*
GLASGOW COMA SCALE CHILD
EYES OPEN*
None (1)
To pain (2)
To speech (3)
Spontaneously (4)
BEST VERBAL RESPONSE
BEST MOTOR RESPONSE*
None (1)
Extension in response to pain (2)
Flexion in response to pain (3)
Withdraws in response to pain (4)
Localizes painful stimuli (5)
Obeys command (6)
GLASCOW COMA SCALE SCORE CHILD*
GLASGOW COMA SCALE INFANT
EYES OPEN*
None (1)
To pain (2)
To speech (3)
Spontaneously (4)
BEST VERBAL RESPONSE*
None (1)
Moans in response to pain (2)
Cries in response to pain (3)
Irritable, cries (4)
Coos and babbles (5)
BEST MOTOR RESPONSE*
None (1)
Decerebrate posturing (abnormal
extension) in response to pain (2)
Decorticate posturing (abnormal flexion)
in response to pain (3)
Withdraws in response to pain (4)
Withdraws in response to touch (5)
Moves spontaneously and purposely (6)
GLASCOW COMA SCALE SCORE INFANT*
ORIENTATION
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Orientierung*
HX OF SEIZURE ACTIVITY*
Affekt*
Sprache*
NUMBNESS OR TINGLING PRESENT*
Kardiovaskuläres System
Normal Baseline: Regular rate and rhythm, no
edema, capillary refill less than 2 seconds, pink
nailbeds, warm extemities, peripheral pulses
strong and regular.*
Ja
Nein
Narrative: Abnormal Findings*
TEDS ON*
Ja
Nein
SCDS ON*
Ja
Nein
Herztöne*
Radial pulse (L/R)*
Pedal pulse (L/R)*
Tibialis posterior-Puls (L/R)*
Popliteal-Puls (L/R)*
Brachialis-Puls (L/R)*
Karotis-Puls (L/R)*
AV SHUNT/GRAFT*
SHUNT/GRAFT LOCATION*
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BRUIT*
SHUNT/GRAFT BRUITS*
THRILL PALPATED*
CAPILLARY REFILL*
NAIL BED COLOR*
Ödem*
Heart RHYTHM*
OTHER HR*
(künstlicher) Herzschrittmacher*
Ja
Nein
Eyes Ear Nose & Throat
Normal Baseline EYES: Without drainage, sclera
white. *
Ja
Nein
Normal Baseline EARS: No complaint of pain.*
Ja
Nein
Normal Baseline NOSE: No drainage or
congestion. *
Ja
Nein
Normal Baseline THROAT: No complaint of pain.*
Ja
Nein
NARRATIVE: Abnormal Findings*
Augen
Pupil Right Size [mm]*
Pupil Right Reaction*
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Pupil Left Size [mm]*
Pupil Left Reaction*
Eye Complains*
Right Sclera*
Left Sclera*
Drainage*
Ja
Nein
Drainage Color*
Ohren
EARS(EXTERNAL CANAL)*
C/O Pain*
Ja
Nein
Trommelfell*
Tubes*
Hard of Hearing*
Ja
Nein
Hearing Loss*
Ja
Nein
Deafness*
Ja
Nein
Hearing Aids*
RT (1)
LT (2)
bilateral (3)
Patent*
Ja
Nein
Schwindel*
Ja
Nein
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Tinnitus*
Ja
Nein
Drainage*
Ja
Nein
Color of Ear Drainage*
Nase
Nares patent*
Ja
Nein
Nares Drainage*
Ja
Nein
Nasenseptum*
Pharynx
Sore throat, Pain in throat, Pharyngeal pain*
Ja
Nein
Mouth Sores*
Ja
Nein
Appearance of Throat*
Mucous Membranes*
Respiratory
Normal Baseline Respiratory: Unlabored
respirations, BBS clear, chest rise symmetrical,
pink mucous membranes.*
Ja
Nein
NARRATIVE: Abnormal Findings*
Atemgeräusch*
RESPIRATORY EFFORT*
CHEST EXPANSION*
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symmetrical (1)
non-symmetrical (2)
INCENTIVE SPIROMETRY DONE*
Ja
Nein
OXYGEN DELIVERY METHOD*
Pulse Oximeter present with alarms set*
Ja
Nein
Cardio-Respriratory Monitor present with alarms
set*
Ja
Nein
Husten*
Sputum*
CHEST TUBE PRESENT*
Ja
Nein
CHEST TUBE LOCATION*
Ja
Nein
Chest Tube Suction Setting*
Air Leak*
none (1)
small (2)
moderate (3)
large (4)
Gastrointestinal
Normal Baseline GI: Abdomen soft,
nondistended, bowel sounds normoactive in all
quadrants.*
Ja
Nein
Last Bowel Movement*
NARRATIVE: Abnormal Findings*
Abdomen*
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Darmgeräusche*
FLATUS*
Ja
Nein
Inkontinenz*
Ja
Nein
GASTRIC SYMPTOMS*
NARES*
Nasogastric Tube Type*
NG placement checked*
Ja
Nein
Suction Setting*
Gastric Content Color*
NGT irrigated (with # ML's of #)*
Ernährung über Sonde*
Ja
Nein
Feeding Tube Type*
Formula (# strength @ # ml's/hour via kangaroo
pump)*
OSTOMY TYPE*
RECTAL BAG PRESENT*
Ja
Nein
Urogenitales System
Normal Baseline Genitourinary: Voids without
pain or hesitation, no suprapubic distention.*
Ja
Nein
NARRATIVE: Abnormal Findings*
Geschlecht*
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Male (1)
Female (2)
INCONTINENT*
Ja
Nein
VOIDS SUFFICIENT QUANITY*
Ja
Nein
IS PATIENT RECEIVING DIALYSIS*
Ja
Nein
ODOR PRESENT*
Ja
Nein
Katheter*
Ja
Nein
Katheter-Größe*
Date of insertion*
Urine color*
URINARY SYMPTOMS*
SEXUALLY ACTIVE*
Ja
Nein
CURRENTLY ON MENSES*
Ja
Nein
Ausfluss*
Ja
Nein
Discharge color*
Discharge odor*
Discharge consistency*
ABNORMAL GENITALIA DESCRIPTION*
Muskuloskeletales System
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Normal Baseline Musculoskeletal: Full ROM, no
muscle weakness, bones intact, gait steady or
age appropriate.*
Ja
Nein
NARRATIVE: Abnormal Findings*
GENERALIZED WEAKNESS*
Ja
Nein
LIMITED ROM*
Ja
Nein
LIMITED MOBILITY*
Ja
Nein
PARALYSIS TYPE*
Hemiplegia Side*
left (1)
right (2)
FRACTURE(S) LOCATION*
FINGER DIGITS*
TOE DIGITS*
LEFT UPPER EXTREMITIES*
RIGHT UPPER EXTREMITIES*
GRIPS EQUAL*
Ja
Nein
LEFT LOWER EXTREMITIES*
RIGHT LOWER EXTREMITIES*
UNSTEADY GAIT*
Ja
Nein
Haut
Normal Baseline Skin: Warm, pink, dry, elastic,
intact, moist mucous membranes.*
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Ja
Nein
NARRATIVE: Abnormal Findings*
Temperatur*
SKIN COLOR*
MOIST*
Ja
Nein
SKIN TURGOR*
Inzision
Inzision*
MID WOUND#*
Site*
Closure Type*
Incision Appearance*
Dressing Changed*
Ja
Nein
Date Dressing Changed*
Dressing Type*
Dressing Appearance*
Drainage*
Wunde
Wunde*
MID WOUND#*
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Wound Location*
Length (cm, mm)*
Width (cm, mm)*
Depth (cm, mm)*
Undermining*
Ja
Nein
Tunneling*
Ja
Nein
Surrounding Skin*
Wound Base*
Exsudat*
Exudate Color*
Sensation*
Odor: Before Cleaning *
Ja
Nein
Odor: After Cleaning *
Ja
Nein
Cleansed with/irrigated with*
Wound Medication Applied*
Wound Filled with*
Wound covered with*
Wound secured with*
Wound Pressure Relief*
Comments*
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Photograph Date*
RASH LOCATION*
RASH DESCRIPTION*
TATTOO'S/PIERCINGS *
SKIN TEARS, LOCATION/ Description*
SPECIALTY BEDS*
Nutrition
Diät*
NPO*
Ja
Nein
Ernährung über Sonde*
Ja
Nein
Feeding Tube Type*
Formula:  # strength @ # cc's/hour via kangaroo
pump*
RESIDUALS CHECKED:   AMOUNT # CC*
BREAKFAST*
Breakfast: Amount taken*
Breakfast: Patient fed by*
LUNCH*
Lunch: Amount taken*
Lunch: Patient fed by*
SUPPER*
13 / 22
HIS NURSING ASSESSMENT (pedi)
Supper: Amount taken*
Supper: Patient fed by*
Supper: Amount taken*
intravenöse Therapie
NARRATIVE: IV Therapy*
IV HEPLOCKED*
Ja
Nein
IV Site APPEARANCE*
IV DISCONTINUED*
Ja
Nein
CATHETER INTACT*
Ja
Nein
IV Catheter Size*
IV Site Location*
Zentralvenöser Katheter (ZVK)*
Infusion*
Left to count: *
IV Fluid Rate: @  ml/hr*
TPN/LIPIDS: TPN @ ml/hr and Lipids @ ml/hr*
PCA PUMP:  at @ cc's/hr*
IV Site APPEARANCE*
INSERTION DATE*
DRESSING CHANGE DUE*
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HIS NURSING ASSESSMENT (pedi)
SITE CHANGE DUE*
PLACED ON IMED*
Ja
Nein
Patientensicherheit
SIDE RAILS UP*
Ja
Nein
IN LOW POSTION*
Ja
Nein
BED/CRIB*
CALL BELL WITHIN REACH*
Ja
Nein
ALLERGY BAND ON*
Ja
Nein
NAME BAND ON*
Ja
Nein
BLOOD BAND ON*
Ja
Nein
FALL BAND ON*
Ja
Nein
BED SAFETY*
Pediatric Fall Risk Assessment
Unable to assess fall risk status at this time due
to patient is:*
Geschlecht*
Bewusstseinslage*
Awake/Alert                                         (0)
Drowsy/Medicated for pain/Seizures (1)
Lethargic/Confused (2)
Seizures/Previous history of falls*
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HIS NURSING ASSESSMENT (pedi)
No significant medical history of falls/ (0)
No difficulty in ambulation, Generalized
weakness/Dizziness/Syncope/ (1)
PT or OT Services, Altered mental
status/Developmental Delay/ (2)
MEDICATION/EQUIPMENT*
No prescribed medication that has been
known to alter LOC.  No IV or other
equipment (IV, Pulse Oximeter)
prescribed for the patient (0)
Prescribed pain medication (oral),
seizure medication (oral), continuous IV
therapy requiring infusion device (1)
Prescribed IV/IM pain medication,
seizure medication/PCA pump, crutches,
CR monitor (2)
Verweildauer*
Admission as inpatient 0-3 Days (0)
Admission as inpatient 4-7 Days (1)
Admission as inpatient greater than 7
Days (2)
ELIMINATION*
Takes care of elimination needs
independently with no assist/Infant in
diapers (0)
Independent with frequent trips to
bathroom (1)
Needs assist with toilet (2)
GET UP AND GO TEST: "RISING FROM A
CHAIR" *
Ability to rise in single movement-No loss
of balance with steps (0)
Pushes up, successful in one attempt (1)
Multiple attempts but successful (3)
Unable to rise without assistance during
test (OR if a medical order states the
same and/or complete bed rest is
ordered) (4)
FINAL RISK SCORE (Pediatric Fall Risk
Assessment)*
INTERVENTIONS
Assist with Ambulation*
Ja
Nein
Reorient Q2H or Less*
Ja
Nein
Gait Belt*
Ja
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HIS NURSING ASSESSMENT (pedi)
Nein
ID Patient at Risk*
Ja
Nein
Restraints (see policy)*
Ja
Nein
Multi-personnel Transfer*
Ja
Nein
Close Observation*
Ja
Nein
Non-slip Footwear*
Ja
Nein
Bed in lowest position*
Ja
Nein
Lock wheels of vehicles of conveyance during
transfer*
Ja
Nein
Upper siderails raised*
Ja
Nein
Call light in reach*
Ja
Nein
Offer toileting at least every 2 hours*
Ja
Nein
Offer fluid/nutrition every 2 hours*
Ja
Nein
Place frequently used objects within reach*
Ja
Nein
Provide adequate lighting*
Ja
Nein
Provide sensory impairment/orientation devices
(clocks,etc)*
Ja
Nein
Provide adequate rest periods*
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HIS NURSING ASSESSMENT (pedi)
Ja
Nein
Use age appropriate distractions for
confusion/disorientation*
Ja
Nein
Remove harmful hazards*
Ja
Nein
Provide appropriate and least restrictive patient
supervision/surveillance*
Ja
Nein
Communicate information about fall risk to
caregivers*
Ja
Nein
Encourage family/support system to participate in
care*
Ja
Nein
Teach/educate family/support system Fall
Prevention information*
Ja
Nein
Implement Fall Prevention Protocol for Hendrich II
Score>5*
Ja
Nein
IMPAIRED MOBILITY RISK
Implement Universal Fall Prevention Intervention*
Ja
Nein
Monitor transfers to/from bed/chair(etc.)*
Ja
Nein
Use appropriate assistance for transfers to/from
bed/chair*
Ja
Nein
Use chairs with armrests and of proper height for
transfers*
Ja
Nein
Implement progressive ambulation(unless
contraindicated by condition/orders)*
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HIS NURSING ASSESSMENT (pedi)
Ja
Nein
Encourage/Provide self-care assistance*
Ja
Nein
Remain in attendance during toileting/ADL's*
Ja
Nein
Provide assistive devices for ambulation
(canes/walkers/etc.)*
Ja
Nein
Gait Belt during transport/ambulation*
Ja
Nein
Teach patient/family to call for help and WAIT for
help before*
Ja
Nein
attempting any transfer/ambulation*
Ja
Nein
ALTERED ELIMINATION
Implement Universal Fall Prevention
Interventions*
Ja
Nein
Remain in attendance during toileting/ADL's*
Ja
Nein
Assist with post-elimination hygiene*
Ja
Nein
Remove non-essential clothing*
Ja
Nein
Instruct patient on importance of toileting when
offered by staff*
Ja
Nein
Monitor for 'patient's normal' bladder/bowel
habits*
Ja
Nein
Monitor for causes of incontinence
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HIS NURSING ASSESSMENT (pedi)
(diuretics,cathartics,etc.)*
Ja
Nein
Monitor skin integrity*
Ja
Nein
HIGH RISK FALL MEDICATIONS
(ANTIEPILEPTICS &
BENZODIAZEPINES)
Implement Universal Fall Prevention
Interventions*
Ja
Nein
Monitor drug dosages*
Ja
Nein
Evaluate sensory functions*
Ja
Nein
Monitor/Assess for drug overdose*
Ja
Nein
Monitor response to exercise*
Ja
Nein
Educate patient/support system about drug
classification, side effects,*
Ja
Nein
precautions, toxic symptoms of overdose.*
Ja
Nein
Hendrich II Fall Risk Assessment
Unable to assess fall risk status at this time due
to patient is:*
HENDRICH CALCULATION*
ONN Unit specific
AFFECTED SITE*
CIRCULATORY STATUS*
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HIS NURSING ASSESSMENT (pedi)
SKIN COLOR*
SENSATION*
MOVEMENT*
Temperatur*
Hautzustand*
PULSE(s) SITE(s)*
RESPONSE*
POSITION OF LIMB*
ORTHOPEDIC DEVICE IN USE*
CONTINUOUS PASSIVE MOTION*
POUNDS*
CERVICAL COLLARS*
AFO BRACE:  Foot/Feet (LEFT-RIGHT-
BILATERAL)*
SWELLING*
PIN SITES*
CLEANED WITH*
NARRATIVE*
Post Surgical
Patient activity*
Vaginal Packing*
Equipment/Devices*
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HIS NURSING ASSESSMENT (pedi)
EQUIPMENT/DEVICES*
ADOLESCENT INTERACTION
Prepared for treatment/procedure as soon as
possible.*
Definitely Yes (1)
Yes (2)
No (3)
not applicable (4)
Provided detailed information about
events/procedures/treatments.*
Definitely Yes (1)
Yes (2)
No (3)
NA (4)
Allowed contact with peer group.*
Definitely Yes (1)
Yes (2)
No (3)
NA (4)
NARRATIVE*
GERIATRIC INTERVENTION (65+)
Involved in decision process regarding pain
control/medication/care decisions*
Def. Yes (1)
Yes (2)
No (3)
NA (4)
Encouraged family/S.O.to visit                  *
Def. Yes (1)
Yes (2)
No (3)
NA (4)
Independence promoted.                          *
Def. Yes (1)
Yes (2)
No (3)
NA (4)
NARRATIVE*
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HIS NURSING ASSESSMENT (pedi)
HIS SOCIAL SERVICES PSYCHOSOCIAL
ASSESSMENT NOTE
Form from HIS OpenVista
All rights reserved. Please visit https://medical-data-
models.org/forms/240
HIS
Psychosocial Assessment
INFORMANT*
Family (1)
Nurse (2)
Patient (3)
Physician (4)
Therapist (5)
Other (6)
PRIMARY
CONTACT/RELATIONSHIP/TELEPHONE*
LANGUAGE/COMMUNICATION BARRIER*
Ja
Nein
Spoken Language*
PHYSICIAN*
Diagnose*
Anamnese*
DISCUSSED ADVANCE DIRECTIVE WITH
PATIENT*
Ja
Nein
PATIENT HAS EXECUTED AN ADVANCE
DIRECTIVE*
Ja
Nein
IS ADVANCE DIRECTIVE FORM IN THE
ELECTRONIC RECORD? *
Ja
Nein
NOTES regarding Advance Directive*
Therapien
HBO*
Ja
Nein
Occupational Therapy*
Ja
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Nein
Physical Therapy*
Ja
Nein
Phototherapy*
Ja
Nein
Radiation / Chemotherapy*
Ja
Nein
Atemtherapie*
Ja
Nein
Speech Therapy*
Ja
Nein
Wound Care*
Ja
Nein
None*
Ja
Nein
Time of Patient's condition
THE FOLLOWING ASSESSMENT REFLECTS
THE PATIENTS' CONDITION*
Prior to hospitalization (1)
At current level (2)
Patient Status
Alert*
Ja
Nein
Disoriented*
Ja
Nein
Comatose*
Ja
Nein
Speech impairment*
Ja
Nein
Vision impairment*
Ja
Nein
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HIS SOCIAL SERVICES PSYCHOSOCIAL ASSESSMENT NOTE
Hearing impairment*
Ja
Nein
Notes*
Living Situation
Lives with family*
Ja
Nein
Lives with spouse*
Ja
Nein
Pflegeheim*
Ja
Nein
Foster home*
Ja
Nein
Home alone*
Ja
Nein
Notes*
FINANCIAL INFORMATION
employed*
Ja
Nein
unemployed*
Ja
Nein
commercial insurance*
Ja
Nein
MEDICAID*
Ja
Nein
MEDICARE*
Ja
Nein
SS*
Ja
Nein
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HIS SOCIAL SERVICES PSYCHOSOCIAL ASSESSMENT NOTE
SSD*
Ja
Nein
SSI*
Ja
Nein
AFDC*
Ja
Nein
CSHCN*
Ja
Nein
CHIP*
Ja
Nein
MCHD*
Ja
Nein
VA*
Ja
Nein
No Income*
Ja
Nein
Notes*
SUPPORT SYSTEM
Spouse/Family*
Ja
Nein
Church*
Ja
Nein
Agency*
Ja
Nein
None*
Ja
Nein
Notes*
CAREGIVER
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HIS SOCIAL SERVICES PSYCHOSOCIAL ASSESSMENT NOTE
Self*
Ja
Nein
Spouse/Family*
Ja
Nein
Friend*
Ja
Nein
Agency personnel*
Ja
Nein
Community Clinic*
Ja
Nein
Notes*
SKILLED NEEDS
intravenöse Therapie*
Ja
Nein
Foley Catheter Care*
Ja
Nein
Ostomy Care*
Ja
Nein
Wound Care*
Ja
Nein
Feeding Tube Care*
Ja
Nein
Dialysis*
Ja
Nein
Drain Care*
Ja
Nein
Ventilator*
Ja
Nein
None*
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HIS SOCIAL SERVICES PSYCHOSOCIAL ASSESSMENT NOTE
Ja
Nein
Notes*
CURRENT ASSISTIVE DEVICES
EQUIPMENT NEEDS
Wheelchair*
Ja
Nein
Crutches*
Ja
Nein
Walker*
Ja
Nein
Cane*
Ja
Nein
Hospital Bed/Rails*
Ja
Nein
Hoyer lift/Trapeze*
Ja
Nein
Oxygen*
Ja
Nein
Apnea Monitor*
Ja
Nein
Carseat*
Ja
Nein
Crib*
Ja
Nein
None*
Ja
Nein
Notes*
DAILY LIVING ACTIVITY
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HIS SOCIAL SERVICES PSYCHOSOCIAL ASSESSMENT NOTE
Wheelchair*
Ja
Nein
Bedbound*
Ja
Nein
Inkontinenz*
Ja
Nein
Hygiene preparation*
Ja
Nein
Meal preparation*
Ja
Nein
Ernährung über Sonde*
Ja
Nein
Grooming / Dressing*
Ja
Nein
Shopping*
Ja
Nein
Laundry*
Ja
Nein
Cleaning*
Ja
Nein
Total independence*
Ja
Nein
Mobility impaired*
Ja
Nein
No assistance required*
Ja
Nein
Notes*
PSYCHOSOCIAL ASSESSMENT
PATIENT'S/FAMILY'S PERCEPTION OF
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HIS SOCIAL SERVICES PSYCHOSOCIAL ASSESSMENT NOTE
ILLNESS/ADMISSION*
COPING STRENGTHS*
Coping WEAKNESSES*
NOTED
COGNITIVE/BEHAVIORAL/BONDING/FUNCTIO
NAL PROBLEMS*
EXPLANATION OF FAMILY DYNAMICS/PATIENT
INVOLVEMENT/PEDI/SPOUSE/BOYFRIEND
INVOLVEMENT*
RELIGIOUS/CULTURAL PREFERENCE
RELIGIOUS/CULTURAL PREFERENCE*
POSSIBLE NEEDS
No Needs evident*
Ja
Nein
Adoption*
Ja
Nein
Adult protective Services*
Ja
Nein
Assistance ADL's*
Ja
Nein
Child protective Services*
Ja
Nein
Counseling / Therapy*
Ja
Nein
Ausbildung*
Ja
Nein
Equipment*
Ja
Nein
Financial Resources*
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HIS SOCIAL SERVICES PSYCHOSOCIAL ASSESSMENT NOTE
Ja
Nein
Food / Clothing*
Ja
Nein
Home health*
Ja
Nein
Hospice*
Ja
Nein
Housing*
Ja
Nein
Lifeline / ERS*
Ja
Nein
LTAC*
Ja
Nein
Medication / Supplies*
Ja
Nein
PBCCMHMR*
Ja
Nein
Meals on Wheels*
Ja
Nein
Nursing facility placement*
Ja
Nein
Other hospital*
Ja
Nein
Rehabilitation*
Ja
Nein
Safe Place*
Ja
Nein
Skilled Nursing Facility*
Ja
Nein
Substance abuse treatment*
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HIS SOCIAL SERVICES PSYCHOSOCIAL ASSESSMENT NOTE
Ja
Nein
Support Group*
Ja
Nein
Transportation*
Ja
Nein
WIC*
Ja
Nein
Other*
Ja
Nein
INITIAL ASSESSMENT NOTE*
AT THIS TIME CONTINUED INTERVENTION IS*
indicated (1)
not indicated (2)
PLANNED DISPOSITION*
ANTICIPATED DATE OF PLANNED
DISPOSITION*
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HIS SOCIAL SERVICES PSYCHOSOCIAL ASSESSMENT NOTE
Eligibility NCT00351910 Major Depressive
Disorder
ODM derived from
http://clinicaltrials.gov/show/NCT00351910
All rights reserved. Please visit https://medical-data-
models.org/forms/241
Eligibility
Einschlusskriterien
18 bis 65 Jahre*
Ja
Nein
A documented diagnosis of major depressive
disorder*
Ja
Nein
Ausschlusskriterien
Patients with a DSM IV Axis I disorder other than
MDD within 6 months of enrolment*
Ja
Nein
Patients with a diagnosis of DSM IV Axis II
disorder which has a major impact on the
patient's current psychiatric status*
Ja
Nein
Patients whose current episode of depression
exceeds 12 months or is less than 4 weeks prior
to enrolment*
Ja
Nein
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Eligibility NCT00303589 Soft Tissue
Infections
ODM derived from
http://clinicaltrials.gov/show/NCT00303589
All rights reserved. Please visit https://medical-data-
models.org/forms/246
Eligibility
Einschlusskriterien
Alter >=18 Jahre*
Ja
Nein
skin or skin structure infection requiring
hospitalization*
Ja
Nein
clinical diagnosis of a skin or skin structure
infection caused by bacteria known or suspected
to be susceptible to the randomized study
treatment*
Ja
Nein
material from site of infection is clinically purulent
or seropurulent*
Ja
Nein
Ausschlusskriterien
presenting with sustained shock (SBP<90mm Hg
for > 2 hours, despite adequate fluid
resuscitation)*
Ja
Nein
known or suspected concomitant bacterial
infection requiring antibiotic treatment*
Ja
Nein
skin infection or chronic non-healing ulcer of > 2
weeks duration*
Ja
Nein
patients in whom surgery is the primary
treatment*
Ja
Nein
Medizinische Konzepte
Alter*
Diagnose*
1 / 2
Erkrankung im Erwachsenenalter*
Skin Infection*
Inpatient care (regime/therapy)*
klinische Diagnose*
Haut*
Bakterium*
Randomized Clinical Trial*
purulent*
SKIN LESION, SEROPURULENT*
Circulatory collapse*
Sustained (qualifier value)*
Systolic Blood Pressure*
Reanimation*
Body Fluid or Substance*
bakterielle Infektion*
Concomitant*
Antibiotikatherapie*
non-healing ulcer of skin*
chronisch*
operative procedures*
First-Line Therapy*
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Eligibility NCT00303589 Soft Tissue Infections
Anal Cancer NCT00550589 - Lab - AMC-046 HIV
T-Cell Laboratory Values (F24) 2933199_v1_0
AMC-046 HIV T-Cell Laboratory Values (F24)
Cidofovir in Treating HIV-Infected Patients With High-Grade
Squamous Intraepithelial Lesions of the Skin Near the Anus
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=71583731-
B241-1194-E040-BB89AD437269
All rights reserved. Please visit https://medical-data-
models.org/forms/325
AMC-046 HIV T-Cell Laboratory
Values (F24)
Hauptmodul
Fallnummer
Laufende Nummer
Datum der Auswertung
Datum der Auswertung (mm / tt / jjjj)
T-Zell- Laborwerte
T-Helferzellen CD4+ %
T-Helferzellen CD4 + absolute Anzahl
T-Suppressor CD8+ %
T-Suppressor CD8+ absolute Anzahl
Andere, angeben
Prozent an positiven Lymphozyten
Absolute Anzahl
Kommentare
Kommentare
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Lymphoma NCT01190449 - Response - CALGB
50901 Response Assessment Form 3210253_v1_0
CALGB 50901 Response Assessment Form
Ofatumumab in Treating Patients With Previously Untreated
Stage II, Stage III, or Stage IV Follicular Non-Hodgkin
Lymphoma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=9F3EEDEF-
C25E-2960-E040-BB89AD433C2A
All rights reserved. Please visit https://medical-data-
models.org/forms/329
CALGB 50901 Response
Assessment Form
Wirkungs-Bewertung
Objective-Status bei dieser Evaluierung
Vollständige Wirkung (complete
response)
Teilweise Wirkung (partial response)
Progressive Erkrankung (progressive
disease)
Stabile Erkrankung (stable disease)
Datum: Progressive Erkrankung zuerst
beobachtet (PD)
Modifizierter Ann Arbor Stage (Zeitpunkt des
Rezidivs mit einem X markieren)
I (I)
IE (IE)
II (II)
IIE (IIE)
III (III)
IIIE (IIIE)
IIIE+S (IIIE+S)
IIIS (IIIS)
IV (IV)
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Anal Cancer NCT00324415 Lab - AMC-045
Chemistries, LFT's (F23) - 2720598v1.0
Anal Cancer NCT00324415 Lab - AMC-045 Chemistries,
LFT's (F23) - 2720598v1.0
All rights reserved. Please visit https://medical-data-
models.org/forms/500
AMC-045 Chemistries, LFT's (F23)
Header Module
Visit number
Sequence number
Date of evaluation (mm/dd/yyyy)
Reporting Period (select one)
Baseline (Baseline)
On Treatment (On treatment)
Post-therapy (Post therapy)
Ccrr Module For Chemistries, Lft's - Rf23
Sodium (mEq/L)
Potassium (mEq/L)
Chloride (mEq/L)
Magnesium
Bicarbonate (mEq/L)
Alkaline Phosphatase (mU/ml)
SGOT (AST) (mU/ml)
SGPT (ALT) (mU/ml)
BUN (mg/dl)
Creatinine (mg/dl)
Total Bilirubin (mg/dl)
Indirect Bilirubin (mg/dl)
Albumin (g/dl)
Other, specify test
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Other specify value
Units (other, specify test)
Comments Module
Comments
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Anal Cancer NCT00324415 Lab - AMC-045 Chemistries, LFT's (F23) -
2720598v1.0
Anal Cancer NCT00550589 Off Treatment - AMC-
046 Off-Study Summary Form (F50) - 2989536v1.0
Anal Cancer NCT00550589 Off Treatment - AMC-046 Off-
Study Summary Form (F50) - 2989536v1.0
All rights reserved. Please visit https://medical-data-
models.org/forms/504
AMC-046 Off-Study Summary Form
(F50)
Ccrr Module For Off Study Summary -
Rf50
Off Study Date (mm/dd/yyyy)
Off Study Reason (select the primary reason)
Adverse Event/side Effects/complications
(Adverse Event/Side
Effects/Complications)
Death (Death)
Other (Other)
Lost To Follow-up (Patient lost to follow-
up)
Patient Refused Follow-up (Patient
refused follow-up)
Protocol-defined Follow-up Completed
(Protocol-defined follow-up completed)
Other, specify
Comments
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Anal Cancer NCT00550589 On-Study - AMC-046 Perianal
Exam and Disease Evaluation Form (PAE) - 2743327v1.0
Anal Cancer NCT00550589 On-Study - AMC-046 Perianal
Exam and Disease Evaluation Form (PAE) - 2743327v1.0
All rights reserved. Please visit https://medical-data-
models.org/forms/521
AMC-046 Perianal Exam and
Disease Evaluation Form (PAE)
Header Module
Visit number
Disease Evaluation
Anal Pap smear performed (at this visit)
No (No)
Yes (Yes)
Cervical Pap smear performed (at this visit)
Not Available (N/A)
No (No)
Yes (Yes)
Vaginal and Vulvar colposcopy performed (at this
visit)
Not Available (N/A)
No (No)
Yes (Yes)
High-resolution anoscopy performed (at this visit)
No (No)
Yes (Yes)
Lesion
Lesion Number (NOTE: Each perianal lesion
must be designated by the same letter A-J on this
form for subsequent evaluations)
Site of Involvement
Anus (Anus)
Perianus (Perianus)
Vulva (Vulva)
Lesion Location
Anterior (Anterior)
Left Anterior (Left anterior)
Left Lateral (Left lateral)
Left Posterior (Left posterior)
Posterior (Posterior)
Right Anterior (Right anterior)
Right Lateral (Right lateral)
Right Posterior (Right posterior)
Lesion Type
Diffuse Similar (Diffuse Similar)
Multiple Similar (Multiple Similar)
Noncountable (Noncountable)
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Single (Single)
Dimension 1 (mm)
Dimension 2 (mm)
Product of Diameters
Sum of Products of Greatest Diameters
Is lesion confluent with other lesions
No (No)
Yes (Yes)
Is lesion thick or thin
Thick (Thick)
Thin (Thin)
Is lesion pigmented
No (No)
Yes (Yes)
Is lesion verrucous
No (No)
Yes (Yes)
Was biopsy performed
No (No)
Yes (Yes)
Comments
Comments
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Anal Cancer NCT00550589 On-Study - AMC-046 Perianal Exam and
Disease Evaluation Form (PAE) - 2743327v1.0
Anal Cancer NCT00324415 Off Treatment - AMC-
045 Off Study Summary Form (F50) - 2936969v1.0
Anal Cancer NCT00324415 Off Treatment - AMC-045 Off
Study Summary Form (F50) - 2936969v1.0
All rights reserved. Please visit https://medical-data-
models.org/forms/527
AMC-045 Off Study Summary Form
(F50)
Ccrr Module For Off Study Summary -
Rf50
Off Study Date (mm/dd/yyyy)
Off Study Reason (select the primary reason)
Adverse Event/side Effects/complications
(Adverse Event/Side
Effects/Complications)
Death (Death)
Other (Other)
Lost To Follow-up (Patient lost to follow-
up)
Patient Refused Follow-up (Patient
refused follow-up)
Protocol-defined Follow-up Completed
(Protocol-defined follow-up completed)
Other, specify
Comments
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Anal Cancer NCT00550589 Response - AMC-
046 Perianal Response Form - 2742877v1.0
Anal Cancer NCT00550589 Response - AMC-046 Perianal
Response Form - 2742877v1.0
All rights reserved. Please visit https://medical-data-
models.org/forms/600
AMC-046 Perianal Response Form
Extra Nodal Involvement Evaluation
Evaluable for response
No (No)
Yes (Yes)
Specify (if no,)
Date of Last Clinical Assessment (mm/dd/yyyy)
Method of Evaluation
Biopsy (Biopsy)
Physical Exam (Physical exam)
Extra Nodal Involvement Evaluation
Complete response first observed (CR)
No (No)
Yes (Yes)
Complete Response (CR) First Observed Date (If
yes)
Extra Nodal Involvement Evaluation
Partial response first observed (PR)
No (No)
Yes (Yes)
Partial Response (PR) First Observed Date
(mm/dd/yyyy)
Stable Disease
Stable disease first observed
No (No)
Yes (Yes)
Stable Disease First Observed Date
(mm/dd/yyyy)
Extra Nodal Involvement Evaluation
Has the patient been diagnosed with a new
progression? (If Yes, continue. Otherwise, stop)
No (No)
Yes (Yes)
Progressive Disease First Observed Date (PD
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mm/dd/yyyy)
Please indicate the site of progression (check
one)
New Site Only (New site only)
New Site Plus Original Site (New site
plus original site)
Original Site Only (Original site only)
Comments
Comments
2 / 2
Anal Cancer NCT00550589 Response - AMC-046 Perianal Response
Form - 2742877v1.0
Anal Cancer NCT01164722 Lab - AMC-076 HIV T-
Cell Laboratory Values Form (F24) - 3253279v1.0
Anal Cancer NCT01164722 Lab - AMC-076 HIV T-Cell
Laboratory Values Form (F24) - 3253279v1.0
All rights reserved. Please visit https://medical-data-
models.org/forms/604
AMC-076 HIV T-Cell Laboratory
Values Form (F24)
Unnamed1
Visit number
Sequence number
Unnamed2
Date of Evaluation (mm/dd/yyyy)
T-cell Laboratory Values
T-Helper CD4+ %
T-Helper CD4+ absolute count
T-Suppressor CD8+ %
T-Suppressor CD8+ absolute count
Other, specify
Percent Positive Lymphocytes
Absolute Count
Comments
Comments
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Breast Cancer Follow-Up - IBCSG Long Term Follow-
Up Death Form (18-LTF-Death) - 3108545v1.0
Breast Cancer Follow-Up - IBCSG Long Term Follow-Up
Death Form (18-LTF-Death) - 3108545v1.0
All rights reserved. Please visit https://medical-data-
models.org/forms/682
IBCSG Long Term Follow-Up Death
Form (18-LTF-Death)
Header Module
Visit number
IBCSG Patient ID
IBCSG Study No.
Randomization No.
Institution Code Number
Institution Name
Long Term Follow-up Death
Date of Death (day month year)
Disease status at time of death (or last known
report)
Distant Metastasis (Distant metastases)
Local Recurrence (Local recurrence)
No Recurrence Or Second Non-breast
Primary Malignancy (No recurrence or
second non-breast primary malignancy)
Regional Recurrence (Regional
recurrence)
Primary cause of death (use codes below)
Cause Unknown (Cause unknown)
Endometrial Cancer (Endometrial
cancer)
Myocardial Infarction (Myocardial
infarction)
Other Cause (Other cause)
Progression Of Underlying Breast
Cancer (Progression of underlying breast
cancer)
Second Non-breast Primary Malignancy
(Second non-breast primary malignancy)
Stroke (Stroke)
Thromboembolic Event
(Thromboembolic event)
Other cause, specify
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Footer Module
Investigator/Designee Signature
Date (day month year)
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Breast Cancer Follow-Up - IBCSG Long Term Follow-Up Death Form (18-
LTF-Death) - 3108545v1.0
Brain and Central Nervous System Tumors NCT00890747 Lab
- AMC-061 Pharmacokinetics Form (P61) - 2913656v1.0
Brain and Central Nervous System Tumors NCT00890747
Lab - AMC-061 Pharmacokinetics Form (P61) -
2913656v1.0
All rights reserved. Please visit https://medical-data-
models.org/forms/683
AMC-061 Pharmacokinetics Form
(P61)
Header Module
Visit number
Pharmacodynamics
Date PK Performed (mm/dd/yyyy)
Collection period
Baseline (Baseline)
Day 15 (Day 15)
Day 2 (Day 2)
Day 22 (Day 22)
Day 29 (Day 29)
Day 30 (Day 30)
Day 32 (Day 32)
Day 35 (Day 35)
Day 38 (Day 38)
Day 42 (Day 42)
Day 8 (Day 8)
Hour 1 (Hour 1)
Hour 2 (Hour 2)
Hour 3 (Hour 3)
Hour 4 (Hour 4)
Hour 5 (Hour 5)
Hour 6 (Hour 6)
Hour 7 (Hour 7)
Hour 8 (Hour 8)
Pre-baseline (Pre-Baseline)
Time Specimen Collected (hh:mm)
Comments
Comments
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Breast Cancer Follow-Up - IBCSG Long Term Follow-
Up Medication Form (18-LTF-M) - 3108532v1.0
Breast Cancer Follow-Up - IBCSG Long Term Follow-Up
Medication Form (18-LTF-M) - 3108532v1.0
All rights reserved. Please visit https://medical-data-
models.org/forms/693
IBCSG Long Term Follow-Up
Medication Form (18-LTF-M)
Header Module
Visit number
IBCSG Patient ID
IBCSG Study No.
Randomization No.
Institution Code Number
Institution Name
Long Term Follow-up Medication
Did the patient receive bone active medication
other than calcium or vitamin D during this follow-
up period (e.g., bisphosphonates)
Continuing (Continuing)
No (No)
Yes (Yes)
If yes or continuing
Biphosphonate Therapy (Biphosphonate)
Other (Other)
Specify
Did the patient receive glucocorticosteroids
during this follow-up period
Continuing (Continuing)
No (No)
Yes (Yes)
Specify (If yes or continuing, medication)
Did the patient receive continuous, non-steroidal,
anti-inflammatory drug during this follow-up
period (e.g., COX-2 inhibitors, aspirin, Ibuprofen)
Continuing (Continuing)
No (No)
Yes (Yes)
Specify (If yes or continuing, medication)
1 / 2
Did patient receive extended adjuvant endocrine
therapy for primary breast cancer during this
follow-up period (If treatment was given for breast
cancer recurrence, do not record)
Continuing (Continuing)
No (No)
Yes (Yes)
Begin date (If yes or continuing day month year)
End date (day month year)
Adjuvant Hormonal Therapy Administered Type
(Extended)
Anastrozole (Anastrozole)
Exemestane (Exemestane)
Letrozole (Letrozole)
Other (Other)
Tamoxifen (Tamoxifen)
Other, specify
Reason Stopped (If extended treatment stopped,
what was the reason)
Adverse Event (Adverse Event)
Completed Treatment (completed
treatment)
Other (Other)
Physician Decision (Physician decision)
Progression Of Disease/second
Malignancy (Progression of
disease/second malignancy)
Other specify
Footer Module
Investigator/Designee Signature
Date (day month year)
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Breast Cancer Follow-Up - IBCSG Long Term Follow-Up Medication
Form (18-LTF-M) - 3108532v1.0
Brain and Central Nervous System Tumors NCT00890747 On-
Study - AMC-061 Protocol Deviation Form (DEV) - 3099397v1.0
Brain and Central Nervous System Tumors NCT00890747
On-Study - AMC-061 Protocol Deviation Form (DEV) -
3099397v1.0
All rights reserved. Please visit https://medical-data-
models.org/forms/696
AMC-061 Protocol Deviation Form
(DEV)
Header Module
AMC Protocol Number
Date Protocol Deviation Occurred (mm/dd/yyyy)
Specify deviation
Protocol Deviation Information
Protocol Deviation Description (Reason for
deviation from the protocol)
Action Taken (What steps were taken to resolve
this deviation)
Is the protocol deviation associated with a
particular participant
No (no)
Yes (yes)
Participant ID
Did the protocol deviation result in an adverse
event
No (no)
Yes (yes)
Is the participant still being followed (will the
participant continue in the study)
No (no)
Yes (yes)
Participating Investigator or Physician Name
(printed investigator name)
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Brain and Central Nervous System Tumors NCT00890747
On-Study - AMC-061 Missed Visit Form (F35) - 2935003v1.0
Brain and Central Nervous System Tumors NCT00890747
On-Study - AMC-061 Missed Visit Form (F35) -
2935003v1.0
All rights reserved. Please visit https://medical-data-
models.org/forms/702
AMC-061 Missed Visit Form (F35)
Unnamed1
Visit number
Unnamed2
Missed Visit Date (mm/dd/yyyy)
Reason patient missed visit
Health Reasons (Health reasons)
Other (Other)
Patient Could Not Get Off Work (Patient
could not get off work)
Patient Decided To Discontinue Study
(Patient decided to discontinue study)
Patient Experienced An Adverse Event
(Patient experienced an Adverse Event)
Patient Forgot (Patient forgot)
Patient Had Transportation Problems
(Patient had transportation problems)
Patient Unable To Obtain Dependent
Care (Patient unable to obtain dependent
care)
Patient Unhappy With Frequency Of
Visits (Patient unhappy with frequency of
visits)
Scheduling Difficulties (Scheduling
difficulties)
Other, specify
Next visit scheduled (Items missed will be made
up at the new visit.)
No (No)
Yes (Yes)
Comments
Comments
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Breast Cancer Follow-Up - IBCSG Long Term Follow-
Up Recurrence Form (18-LTF-RC) - 3108571v1.0
Breast Cancer Follow-Up - IBCSG Long Term Follow-Up
Recurrence Form (18-LTF-RC) - 3108571v1.0
All rights reserved. Please visit https://medical-data-
models.org/forms/712
IBCSG Long Term Follow-Up
Recurrence Form (18-LTF-RC)
Header Module
Visit number
IBCSG Patient ID
IBCSG Study No.
Randomization No.
Institution Code Number
Institution Name
Proven Recurrence/metastasis Or
Contralateral Invasive Breast Cancer
Site (Sites of Recurrence Local Regional Distant)
Breast Scar / Skin (Breast scar / skin)
Breast Tissue (Breast tissue)
Chest Wall (Chest wall)
Chest Wall / Outside Breast (Chest wall /
outside breast)
Ipsi Axilla (Ipsi axilla)
Ipsi Axillary Nodes (Ipsi axillary nodes)
Ipsi Infraclavicular Nodes (Ipsi
infraclavicular nodes)
Ipsi Internal Mammary Nodes (Ipsi
internal mammary nodes)
Ipsi Supraclavicular Nodes (Ipsi
supraclavicular nodes)
Scar (Scar)
Specify Site (Specify site)
Specify
Date of diagnosis of recurrent/metastatic disease
(day month year)
Hormone Receptor Analysis
Was Hormone Receptor Analysis performed (on
a recurrence reported during this follow-up
period)
No (No)
1 / 2
Yes (Yes)
Specify
Date Specimen collected (day month year)
ER % Positive (Results of immunohistochemistry
IHC: Percent of positive cells use 0-100)
PR % Positive (g Results of
immunohistochemistry IHC: Percent of positive
cells use 0-100)
ER Status (select one)
Negative (Negative)
Positive (Positive)
Unknown (Unknown)
PgR Status (select one)
Negative (Negative)
Positive (Positive)
Unknown (Unknown)
Footer Module
Investigator/Designee Signature
Date (day month year)
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Breast Cancer Follow-Up - IBCSG Long Term Follow-Up Recurrence
Form (18-LTF-RC) - 3108571v1.0
Breast Cancer Follow-Up - IBCSG Long Term Follow-Up
Second Non-Breast Malignancy (18-LTF-SM) - 3108558v1.0
Breast Cancer Follow-Up - IBCSG Long Term Follow-Up
Second Non-Breast Malignancy (18-LTF-SM) -
3108558v1.0
All rights reserved. Please visit https://medical-data-
models.org/forms/725
IBCSG Long Term Follow-Up
Second Non-Breast Malignancy (18-
LTF-SM)
Header Module
Visit number
IBCSG Patient ID
IBCSG Study No.
Randomization No.
Institution Code Number
Institution Name
Second Non-breast Malignancy
Specify site (non-breast)
Specify type (non-breast)
Date of Diagnosis of Second Primary Cancer
(non-breast day month year)
Second Non-breast Malignancy
Specify site (non-breast)
Specify type (non-breast)
Date of Diagnosis of Second Primary Cancer
(non-breast day month year)
Footer Module
Investigator/Designee Signature
Date (day month year)
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Brain and Central Nervous System Tumors NCT00890747
Lab - AMC-061 HIV Viral Load Form (F40) - 2933381v1.0
Brain and Central Nervous System Tumors NCT00890747
Lab - AMC-061 HIV Viral Load Form (F40) - 2933381v1.0
All rights reserved. Please visit https://medical-data-
models.org/forms/726
AMC-061 HIV Viral Load Form (F40)
Unnamed1
Visit number
Unnamed2
Date Specimen Obtained (mm/dd/yyyy)
Results of HIV viral load assay  (Enter results
from right to left.)
Equal To (Equal to (=))
Greater Than (>) (Greater than (>))
Less Than (Less than (<))
Undetectable (Undetectable)
HIV viral load value
Method of detection
Abbott Realtime Hiv-1 Assay (Abbott
RealTime HIV-1 assay)
Cobas Ampliprep/taqman Hiv-1 Assay
(COBAS AmpliPrep/TAQMAN HIV-1
assay)
Other (Other)
Roche Amplicor Monitor Assay (Roche
Amplicor Monitor Assay)
Versant Hiv-1 Rna Assay By Branched
Dna (Versant HIV-1 RNA assay by
branched DNA)
Other, specify
HIV viral load assay type
Standard (Standard)
Ultra (Ultra)
Limits of detection (Copies/mL)
Lab Facility Name (Testing Laboratory
information)
Comments
Comments
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Brain and Central Nervous System Tumors NCT00890747 Response -
AMC-061 Response Evaluation Form (R61) - 2934625v1.0
Brain and Central Nervous System Tumors NCT00890747
Response - AMC-061 Response Evaluation Form (R61) -
2934625v1.0
All rights reserved. Please visit https://medical-data-
models.org/forms/731
AMC-061 Response Evaluation
Form (R61)
Header Module
Date of Last Clinical Assessment (mm/dd/yyyy)
Extra Nodal Involvement Evaluation
Complete response first observed (CR)
No (No)
Yes (Yes)
Complete Response (CR) First Observed Date
(mm/dd/yyyy)
Complete response confirmed (CR)
No (No)
Yes (Yes)
Complete Response Confirmed Date (CR
mm/dd/yyyy)
Method of Evaluation
Biopsy (Biopsy)
Aspirate, Bone Marrow (Bone Marrow
Aspirate)
Bone Marrow Biopsy (Bone Marrow
Biopsy)
Bone Scan (Bone scan)
Ct Scan (CT scan)
Gallium Scan (Gallium scan)
Intravenous Pyelogram (IVP)
Lymphangiogram (Lymphangiogram)
Mri Scan (MRI scan)
Other (Other)
Palpation (Palpation)
Peripheral Blood Counts (Peripheral
Blood Counts)
Pet Scan (PET scan)
Pet/ct Scan (PET/CT scan)
Ultrasound (Ultrasound)
X-ray (X-ray)
Other Specify
Morphologic Complete Remission
Morphologic Complete Remission (CR) First
Observed
No (No)
1 / 5
Yes (Yes)
Morphologic Complete Remission (CR) First
Observed Date (mm/dd/yyyy)
Morphologic Complete Remission (CR)
Confirmed
No (No)
Yes (Yes)
Morphologic Complete Remission (CR)
Confirmed Date (mm/dd/yyyy)
Method of Evaluation
Biopsy (Biopsy)
Aspirate, Bone Marrow (Bone Marrow
Aspirate)
Bone Marrow Biopsy (Bone Marrow
Biopsy)
Bone Scan (Bone scan)
Ct Scan (CT scan)
Gallium Scan (Gallium scan)
Intravenous Pyelogram (IVP)
Lymphangiogram (Lymphangiogram)
Mri Scan (MRI scan)
Other (Other)
Palpation (Palpation)
Peripheral Blood Counts (Peripheral
Blood Counts)
Pet Scan (PET scan)
Pet/ct Scan (PET/CT scan)
Ultrasound (Ultrasound)
X-ray (X-ray)
Other Specify
Complete Response, Unconfirmed
Complete Response, Unconfirmed (CRu) First
Observed
No (No)
Yes (Yes)
Complete Response, Unconfirmed (CRu) First
Observed Date (mm/dd/yyyy)
Complete Response, Unconfirmed (CRu)
Confirmed
No (No)
Yes (Yes)
Complete Response, Unconfirmed (CRu)
Confirmed Date (mm/dd/yyyy)
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Brain and Central Nervous System Tumors NCT00890747 Response -
AMC-061 Response Evaluation Form (R61) - 2934625v1.0
Method of Evaluation
Biopsy (Biopsy)
Aspirate, Bone Marrow (Bone Marrow
Aspirate)
Bone Marrow Biopsy (Bone Marrow
Biopsy)
Bone Scan (Bone scan)
Ct Scan (CT scan)
Gallium Scan (Gallium scan)
Intravenous Pyelogram (IVP)
Lymphangiogram (Lymphangiogram)
Mri Scan (MRI scan)
Other (Other)
Palpation (Palpation)
Peripheral Blood Counts (Peripheral
Blood Counts)
Pet Scan (PET scan)
Pet/ct Scan (PET/CT scan)
Ultrasound (Ultrasound)
X-ray (X-ray)
Other Specify
Morphologic Complete Remission With
Incomplete Blood Count Recovery
Morphologic Complete Remission With
Incomplete Blood Count Recovery (CRi) First
Observed
No (No)
Yes (Yes)
Morphologic Complete Remission With
Incomplete Blood Count Recovery (CRi) First
Observed Date (mm/dd/yyyy)
Morphologic Complete Remission With
Incomplete Blood Count Recovery (CRi)
Confirmed
No (No)
Yes (Yes)
Morphologic Complete Remission With
Incomplete Blood Count Recovery (CRi)
Confirmed Date (mm/dd/yyyy)
Method of Evaluation
Biopsy (Biopsy)
Aspirate, Bone Marrow (Bone Marrow
Aspirate)
Bone Marrow Biopsy (Bone Marrow
Biopsy)
Bone Scan (Bone scan)
Ct Scan (CT scan)
Gallium Scan (Gallium scan)
Intravenous Pyelogram (IVP)
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Brain and Central Nervous System Tumors NCT00890747 Response -
AMC-061 Response Evaluation Form (R61) - 2934625v1.0
Lymphangiogram (Lymphangiogram)
Mri Scan (MRI scan)
Other (Other)
Palpation (Palpation)
Peripheral Blood Counts (Peripheral
Blood Counts)
Pet Scan (PET scan)
Pet/ct Scan (PET/CT scan)
Ultrasound (Ultrasound)
X-ray (X-ray)
Other Specify
Extra Nodal Involvement Evaluation
Partial response first observed (PR)
No (No)
Yes (Yes)
Partial Response (PR) First Observed Date
(mm/dd/yyyy)
Partial response confirmed
No (no)
Yes (yes)
Partial Response Confirmed Date (mm/dd/yyyy)
Method of Evaluation
Biopsy (Biopsy)
Aspirate, Bone Marrow (Bone Marrow
Aspirate)
Bone Marrow Biopsy (Bone Marrow
Biopsy)
Bone Scan (Bone scan)
Ct Scan (CT scan)
Gallium Scan (Gallium scan)
Intravenous Pyelogram (IVP)
Lymphangiogram (Lymphangiogram)
Mri Scan (MRI scan)
Other (Other)
Palpation (Palpation)
Peripheral Blood Counts (Peripheral
Blood Counts)
Pet Scan (PET scan)
Pet/ct Scan (PET/CT scan)
Ultrasound (Ultrasound)
X-ray (X-ray)
Other Specify
Partial Remission
Partial Remission (PR) First Observed
No (No)
Yes (Yes)
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Brain and Central Nervous System Tumors NCT00890747 Response -
AMC-061 Response Evaluation Form (R61) - 2934625v1.0
Partial Remission (PR) First Observed Date
(mm/dd/yyyy)
Partial Remission (PR) Confirmed
No (No)
Yes (Yes)
Partial Remission (PR) Confirmed Date
(mm/dd/yyyy)
Method of Evaluation
Biopsy (Biopsy)
Aspirate, Bone Marrow (Bone Marrow
Aspirate)
Bone Marrow Biopsy (Bone Marrow
Biopsy)
Bone Scan (Bone scan)
Ct Scan (CT scan)
Gallium Scan (Gallium scan)
Intravenous Pyelogram (IVP)
Lymphangiogram (Lymphangiogram)
Mri Scan (MRI scan)
Other (Other)
Palpation (Palpation)
Peripheral Blood Counts (Peripheral
Blood Counts)
Pet Scan (PET scan)
Pet/ct Scan (PET/CT scan)
Ultrasound (Ultrasound)
X-ray (X-ray)
Other Specify
Extra Nodal Involvement Evaluation
Has the patient been diagnosed with
relapsed/recurrent or progressive disease (If Yes,
continue. Otherwise, stop)
No (No)
Yes (Yes)
Progression/relapsed disease first observed date
(mm/dd/yyyy)
Please indicate site of progression/relapse
New Site Only (New site only)
New Site Plus Original Site (New site
plus original site)
Original Site Only (Original site only)
Comments
Comments
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Brain and Central Nervous System Tumors NCT00890747 Response -
AMC-061 Response Evaluation Form (R61) - 2934625v1.0
Brain and Central Nervous System Tumors NCT00890747 Off
Treatment - AMC-061 Off Study Summary Form (F50) - 2934990v1.0
Brain and Central Nervous System Tumors NCT00890747
Off Treatment - AMC-061 Off Study Summary Form (F50) -
2934990v1.0
All rights reserved. Please visit https://medical-data-
models.org/forms/744
AMC-061 Off Study Summary Form
(F50)
Ccrr Module For Off Study Summary -
Rf50
Off Study Date (mm/dd/yyyy)
Off Study Reason (select the primary reason)
Adverse Event/side Effects/complications
(Adverse Event/Side
Effects/Complications)
Death (Death)
Other (Other)
Lost To Follow-up (Patient lost to follow-
up)
Patient Refused Follow-up (Patient
refused follow-up)
Protocol-defined Follow-up Completed
(Protocol-defined follow-up completed)
Other, specify
Comments
1 / 1
Breast Cancer NCT00068601 Pre-Study - Southwest
Oncology Group PreStudy (S0230) - 2170510v3.0
Breast Cancer NCT00068601 Pre-Study - Southwest
Oncology Group PreStudy (S0230) - 2170510v3.0
All rights reserved. Please visit https://medical-data-
models.org/forms/766
Southwest Oncology Group
PreStudy (S0230)
Disease Description
Date of Initial Diagnosis of Primary Tumor
Stage
T1*, N0, M0 (I)
Ii, According To Current Ajcc Guidelines
(II)
T0, N2, M0 Or T1*, N2, M0 Or T2, N2,
M0 Or T3, N1, M0 Or T3, N2, M0 (IIIA)
Date of last menses (Please fill in the following
values if the Patient has not had regular menses
within the past 6 weeks)
Laboratory Tests
FSH level: (IU/L)
Laboratory lower limit for post menopausal FSH
(IU/L)
Estradiol level (pg/mL)
Laboratory upper limit for post menopausal
estradiol (pg/mL)
Planned Chemotherapy regimen (select one)
Ac (AC)
Ac Followed By A Taxane (AC followed
by a Taxane)
Caf (CAF)
Cef (CEF)
Tac (TAC)
Other anthracycline-based regimen, specify
chemotherapy agents and duration (months or
cycles)
Cmf (CMF)
Other Anthracycline-based Regimen,
Specify Chemotherapy Agents And
Duration (Other anthracycline-based
regimen, specify chemotherapy agents
and duration)
Other anthracycline-based regimen, specify
chemotherapy agents and duration (months or
cycles)
Cmf (CMF)
Other Anthracycline-based Regimen,
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Specify Chemotherapy Agents And
Duration (Other anthracycline-based
regimen, specify chemotherapy agents
and duration)
Ccrr Module For Southwest Oncology
Group Prestudy (s0230)
SWOG Patient ID (L, F, M)
Insitution/Affiliate
Physician
Group Name
Study No.
Pt. ID
Patient Characteristics
Patient Characteristics
Performance Status
0 (0)
1 (1)
2 (2)
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Breast Cancer NCT00068601 Pre-Study - Southwest Oncology Group
PreStudy (S0230) - 2170510v3.0
Breast Cancer NCT01101438 Lab - NCIC MA.32
Correlative Studies Report - 3027424v1.0
Breast Cancer NCT01101438 Lab - NCIC MA.32
Correlative Studies Report - 3027424v1.0
All rights reserved. Please visit https://medical-data-
models.org/forms/1177
NCIC MA.32 Correlative Studies
Report
Archival Tumour Tissue Submission
Reviewing Pathologist
Specimen ID Number
Specimen Collection Date
Name of the contact person responsible for
sample submission
Pathology Institution Name
Dept/Building
Person Completing Form, First Name
Person Completing Form, Last Name
Phone
E-mail
Correlative Studies - Question
Did the patient consent to the OPTIONAL whole
blood, serum and plasma banking and correlative
studies
No (no)
Yes (yes)
Correlative Studies
Specimen Type
Time of blood specimen collection
Was a blood specimen collected?
No (No)
Yes (Yes)
Specimen Collection Date
1 / 2
Reason
Institution Error (Institution error)
Intercurrent Illness (Intercurrent illness)
Other (Other)
Patient Did Not Keep Appointment
(Patient did not keep appointment)
Patient Request (Patient request)
Statutory Holiday (Statutory holiday)
Unsuccessful Blood Draw (Unsuccessful
blood draw)
Other, specify
Date Specimen Shipped
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Breast Cancer NCT01101438 Lab - NCIC MA.32 Correlative Studies
Report - 3027424v1.0
Cervical Cancer NCT00064077 Treatment -
GOG Treatment Completion Form - 2059221v3.0
Cervical Cancer NCT00064077 Treatment - GOG
Treatment Completion Form - 2059221v3.0
All rights reserved. Please visit https://medical-data-
models.org/forms/1199
GOG Treatment Completion Form
Header Module
Date form originally completed (m d y)
Date form amended (m d y)
Person amending form, last name
Patient Name, Last
Patient Name, First
Patient Study ID
Person Completing Form, Last Name
Treatment Schedule
Total number of cycles given
Last date (any modality of) protocol therapy was
given (m d y)
Off-treatment Reason
Reason treatment ended (check only one)
Death Of Patient Occurred After The
Patient Began Protocol Therapy (Death
after beginning protocol therapy)
Disease Progression, Relapse During
Active Treatment (Disease progression,
relapse during active treatment)
Other (Other)
Patient Off-treatment For Other
Complicating Disease (Patient off-
treatment for other complicating disease)
Patient Withdrawal Or Refusal For
Reason Other Than Toxicity (Patient
withdrawal or refusal for reason other
than toxicity)
Routine Completion Of Planned Protocol
Treatment (Routine completion of
planned protocol treatment)
Toxicity/side Effects/complications
(Toxicity/side effects/complications)
Specify toxicity (unnamed)
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Specify reason (unnamed)
Specify disease (unnamed)
Other, specify (Off Treatment Reason)
Will patient receive further treatment?
No (No)
Yes (Yes)
Specify further treatment (unnamed)
Comments
COMMENTS
Footer Module
Participating Group Code
Participating Group Protocol Number
Participating Patient Study ID
Ccrr Module For Gog Treatment
Completion Form
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Cervical Cancer NCT00064077 Treatment - GOG Treatment Completion
Form - 2059221v3.0
Cervical Cancer NCT00064077 On-Study - GOG Recurrent
Gynecologic Cancer - On Study Form - 2058732v3.0
Cervical Cancer NCT00064077 On-Study - GOG Recurrent
Gynecologic Cancer - On Study Form - 2058732v3.0
All rights reserved. Please visit https://medical-data-
models.org/forms/1201
GOG Recurrent Gynecologic Cancer
- On Study Form
Header Module
Date form originally completed (m d y)
Date form amended (m d y)
Person amending form, last name
Patient Name, Last
Patient Name, First
Patient Study ID
Person Completing Form, Last Name
Disease Description - Prior History
Date of definitive histologic diagnosis of primary
tumor (m d y  Note: Word ?tumor? obstructed by
graphic)
Stage (at diagnosis FIGO)
Refer To Figo Staging For Specific
Gynecologic Cancer (I)
Refer To Figo Staging For Specific
Gynecologic Cancer (II)
Refer To Figo Staging For Specific
Gynecologic Cancer (III)
Refer To Figo Staging For Specific
Gynecologic Cancer (IV)
Primary surgery date (m d y)
Primary surgery type (check all that apply)
Bilateral Salpingo-oophorectomy
(Bilateral Salpingo-Oophorectomy)
Cervical Conization (Cervical conization)
Omentectomy (Omenectomy)
Other, Specify (Other, specify)
Para-aortic Node Sampling/dissection
(Para-aortic node sampling/dissection)
Partial Hysterectomy (Partial
hysterectomy)
Pelvic Node Sampling/dissection (Pelvic
node sampling/dissection)
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Radical Hysterectomy (Radical
hysterectomy)
Radical Trachelectomy (Radical
Trachelectomy)
Total Hysterectomy (Total hysterectomy)
Unilateral Salpingo-oophorectomy
(Unilateral Salpingo-Oophorectomy)
Other (Primary Surgery Type), specify
Disease Description - Current History
Current status of disease
Primary Gyn Disease Continues To Be
Present Following Initial Treatment
(Persistent)
Primary Tumor (Primary (advanced
stage))
Progression Of Gyn Disease Per Recist
Criteria (Progression)
Recurrence Of Same Gyn Disease
Previously Treated Successfully
(Recurrence)
Date of first recurrence or progression (m d y)
What was the method used to determine
progression? (recurrence or check all that apply)
Clinical Examination (Clinical)
Histology (Histologic)
Radiographic (Radiographic)
Site(s) of disease (at study entry check all that
apply)
Ascites (Ascites)
Bladder (Bladder)
Bone (Bone)
Cervix (Cervix)
Cns/brain (CNS/Brain)
Colon (Colon)
Endometrium (Endometrium)
Liver (Liver)
Lung (Lung)
Lymph Nodes, Specify (Lymph nodes)
Other, Specify (Other, specify)
Ovary (Ovary)
Parametrial Involvement (Parametrial
involvement)
Peritoneum (Peritoneum)
Pleura (Pleura)
Pleural Effusion (Pleural effusion)
Skin (Skin)
Uterus (Uterus)
Other (Sites of Disease), specify
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Cervical Cancer NCT00064077 On-Study - GOG Recurrent Gynecologic
Cancer - On Study Form - 2058732v3.0
Prior Treatment For Gynecologic Cancer
Prior systemic chemotherapy?
No (No)
Yes (Yes)
Date prior chemotherapy started (m d y)
Date prior chemotherapy ended
Chemotherapy regimen
First Line Agent (First line, specify
agent(s))
Other, Specify (Other, specify agent(s))
Second Line Agent (Second line, specify
agent(s))
First line, specify agent(s)
First line, specify agent(s)
Other, specify agent(s)
No. of courses
Prior hormonal therapy?
No (No)
Yes (Yes, specify)
Yes (Prior Hormonal), specify
Non-protocol biologic response modifier?
No (No)
Yes (Yes, specify)
Yes, (Non-protocol BRM) specify
Prior radiation therapy?
No (No)
Yes (Yes, specify)
Yes, (Prior RT) specify
Is the site of recurrence within the field previously
treated by radiation therapy?
No (No)
Yes (Yes)
Comments
COMMENTS
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Cervical Cancer NCT00064077 On-Study - GOG Recurrent Gynecologic
Cancer - On Study Form - 2058732v3.0
Footer Module
Participating Group Code
Participating Group Protocol Number
Participating Patient Study ID
Ccrr Module For Gog Recurrent
Gynecologic Cancer - On Study Form
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Cervical Cancer NCT00064077 On-Study - GOG Recurrent Gynecologic
Cancer - On Study Form - 2058732v3.0
Cervical Cancer NCT00064077 Response - GOG
Solid Tumor Evaluation Form - 2059416v3.0
Cervical Cancer NCT00064077 Response - GOG Solid
Tumor Evaluation Form - 2059416v3.0
All rights reserved. Please visit https://medical-data-
models.org/forms/1211
GOG Solid Tumor Evaluation Form
Header Module
Date form originally completed (m d y)
Date form amended (m d y)
Person amending form, last name
Patient Name, Last
Patient Name, First
Patient Study ID
Person Completing Form, Last Name
Target Lesion(s) Evaluation
Lesion Number (unnamed)
1 (1)
10 (10)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
7 (7)
8 (8)
9 (9)
Site of Lesion
Date of Evaluation (m d y)
Method of Evaluation (* Methods of Evaluation: 1
= Clinical examination, 2 = Chest X-ray, 3 = CT
Scan, 4 = Spiral CT Scan, 5 = MRI NMR, 6 =
Ultrasound, 9 = Other coded values)
Chest X-ray (Chest X-ray)
Clinical Examination (Clinical
examination)
Ct Scan (CT Scan)
Mri (MRI (NMR))
Other (Other)
Spiral Ct Scan (Spiral CT Scan)
Ultrasound (Ultrasound)
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If Other, specify (Method of Eval)
Longest Diameter of Lesion(s) (cm)
Sum of longest diameters of all target lesions
Non-target Lesion(s) Evaluation
Are there any nontarget lesions?
No (No)
Yes (Yes)
Lesion Number (unnamed)
1 (1)
10 (10)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
7 (7)
8 (8)
9 (9)
Site of Lesion
Date of Evaluation (m d y)
Method of Evaluation (* Methods of Evaluation: 1
= Clinical examination, 2 = Chest X-ray, 3 = CT
Scan, 4 = Spiral CT Scan, 5 = MRI NMR, 6 =
Ultrasound, 9 = Other coded values)
Chest X-ray (Chest X-ray)
Clinical Examination (Clinical
examination)
Ct Scan (CT Scan)
Mri (MRI (NMR))
Other (Other)
Spiral Ct Scan (Spiral CT Scan)
Ultrasound (Ultrasound)
If Other, specify (Method of Eval)
Follow-Up Status of Lesion(s)
Absent (Absent)
Complete Response (CR)
Progressive Disease (PD)
Present (Present)
Stable Disease Or Unchanged (Stable)
Unequivocal Progression (Unequivocal
Progression)
New Target Lesion(s) At Follow-up
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Cervical Cancer NCT00064077 Response - GOG Solid Tumor Evaluation
Form - 2059416v3.0
Evaluation
Was the appearance of any new lesions
documented since the baseline evaluation?
No (No)
Yes (Yes)
Lesion Number (unnamed)
1 (1)
10 (10)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
7 (7)
8 (8)
9 (9)
Site of Lesion
Date of Evaluation (m d y)
Method of Evaluation (* Methods of Evaluation: 1
= Clinical examination, 2 = Chest X-ray, 3 = CT
Scan, 4 = Spiral CT Scan, 5 = MRI NMR, 6 =
Ultrasound, 9 = Other coded values)
Chest X-ray (Chest X-ray)
Clinical Examination (Clinical
examination)
Ct Scan (CT Scan)
Mri (MRI (NMR))
Other (Other)
Spiral Ct Scan (Spiral CT Scan)
Ultrasound (Ultrasound)
If Other, specify (Method of Eval)
Overall Response
Overall response status at this assessment
(check one)
Complete Response (CR)
Null (Insufficient evaluation to determine
response status)
Progressive Disease (PD)
Partial Response (PR)
Stable Disease (SD)
Response confirmed date (m d y)
Comments
COMMENTS
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Footer Module
Participating Group Code
Participating Group Protocol Number
Participating Patient Study ID
Ccrr Module For Gog Solid Tumor
Evaluation Form
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Cervical Cancer NCT00064077 Follow-Up -
GOG Follow-Up Form - 2059334v3.0
Cervical Cancer NCT00064077 Follow-Up - GOG Follow-
Up Form - 2059334v3.0
All rights reserved. Please visit https://medical-data-
models.org/forms/1228
GOG Follow-Up Form
Header Module
Date form originally completed (m d y)
Date form amended (m d y)
Person amending form, last name
Patient Name, Last
Patient Name, First
Patient Study ID
Person Completing Form, Last Name
Vital Status
Patient's vital status
Alive (Alive)
Dead (Dead)
Primary cause of death
Due To Other Cause (Due to other
cause)
Due To Protocol Treatment (Due to
protocol treatment)
Due To This Disease (Due to this
disease)
Unknown (Unknown)
Death due to protocol treatment (specify)
Death due to protocol treatment (specify)
Death date / last contact date (m d y)
Was patient unable to be contacted for current
scheduled follow-up?
No (No)
Yes (Yes)
Notice Of Progression
Has the patient been diagnosed with a new
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progression?
No (No)
Yes (Yes)
Date of progression (recurrence m d y)
Site(s) of progression
What was the method used to determine
progression?
Histology (Histologic)
Physical Exam (Physical exam)
Radiographic (Radiologic)
Tumor Markers (Tumor marker)
Ca125 And Other Biomarkers
Marker 1 (Marker names & values)
Marker 1 (Marker names & values)
Marker 1 Value
Marker 1 Value
Date of CA125 (s or other biomarkers Please
provide dates of the measurements
corresponding to the values given. m d y)
Notice Of New Primary
Has a new primary cancer or MDS been
diagnosed that has not been previously reported?
(myelodysplastic syndrome)
No (No)
Yes (Yes)
Date of diagnosis (m d y)
Site(s) of new primary
Late Adverse Event
Has the patient experienced (prior to diagnosis of
recurrence or second primary) any severe (Grade
>/= 3), long term toxicity that has not been
previously reported?
No (No)
Yes (Yes)
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Adverse event term
Late adverse event grade
Late Adverse Event Onset Date (m d y)
CTC adverse event attribution (*Adverse Event
Attribution Codes 1=Unrelated, 2=Unlikely,
3=Possibly, 4=Probably, 5=Definitely)
Definitely (Definitely)
Possibly (Possibly)
Probably (Probably)
Unlikely (Unlikely)
Unrelated (Unrelated)
Non-protocol Therapy
Is the patient receiving any non-protocol cancer
therapy not previously reported?
No (No)
Yes (Yes)
Name of other non-protocol therapy
Date of first non-protocol therapy (m d y)
Additional therapy reason
Comments
COMMENTS
Footer Module
Participating Group Code
Participating Group Protocol Number
Participating Patient Study ID
Ccrr Module For Gog Follow-up Form
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Cervical Cancer NCT00064077 Pathology -
GOG Pathology Form - 2059039v3.0
Cervical Cancer NCT00064077 Pathology - GOG
Pathology Form - 2059039v3.0
All rights reserved. Please visit https://medical-data-
models.org/forms/1231
GOG Pathology Form
Header Module
Date form originally completed (m d y)
Date form amended (m d y)
Person amending form, last name
Patient Name, Last
Patient Name, First
Patient Study ID
Person Completing Form, Last Name
Primary Disease Assessment
Primary site
Cervix (Cervix)
Endometrium (Endometrium)
Fallopian Tube (Fallopian tube)
Gestational Trophoblastic Disease (GTD)
Other, Specify (Other, specify)
Ovary (Ovary)
Peritoneum (Peritoneum)
Uterine Sarcoma (Uterine sarcoma)
Vagina (Vagina)
Vulva (Vulva)
Other (Primary Site), specify
Histologic type (check one)
Adenocarcinoma With Squamous
Differentiation (Adenocarcinoma with
squamous differentiation)
Adenocarcinoma, Unspecified
(Adenocarcinoma, type unspecified)
Adenosquamous (Adenosquamous
carcinoma)
Benign (Benign NOS)
Carcinosarcoma/mesodermal (mullerian)
Mixed Tumor (Carcinosarcoma,
heterologous)
Carcinosarcoma, homolgous
(Carcinosarcoma, homolgous)
Clear Cell Carcinoma (Clear cell
carcinoma)
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Dysgerminoma (Dysgerminoma)
Endodermal Sinus Tumor (yolk Sac
Tumor) (Endodermal sinus tumor)
Endometrial Stromal Sarcoma
(Endometrial stromal sarcoma, high
grade)
Endometrioid Adenocarcinoma
(Endometrioid adenocarcinoma)
Fibroma (Fibroma)
Germ Cell Tumor, Mixed (Germ cell
tumor, mixed)
Granulosa Cell Tumor (Granulosa cell
tumor)
Leiomyosarcoma (Leiomyosarcoma)
Mixed Epithelial Carcinoma, Specify
Components (Mixed epithelial tumor)
Mixed serous/mucinous LMP (Mixed
serous/mucinous LMP)
Mucinous Adenocarcinoma (Mucinous
adenocarcinoma)
Mucinous Cystadenoma (benign)
(Mucinous cystadenoma)
Mucinous Tumor Of Low Malignant
Potential (Mucinous tumor of low
malignant potential)
Normal Tissue (Normal tissue)
Other, Specify (Other, specify)
Serous Adenocarcinoma (Serous
adenocarcinoma)
Serous Cystadenoma (benign) (Serous
cystadenoma)
Serous Tumor Of Low Malignant
Potential (Serous tumor of low malignant
potential)
Sex-cord/stromal, Unclassified (Sex cord
stomal tumor, unclassified)
Small Cell Carcinoma (Small cell
carcinoma)
Squamous Cell Carcinoma (Squamous
cell carcinoma, invasive)
Teratoma, Immature, Specify
Components (Teratoma, immature)
Teratoma, Mature (Teratoma, mature
cystic)
Transitional Cell Carcinoma, Including
Brenner Tumor (Transitional cell
carcinoma)
Undifferentiated Carcinoma
(Undifferentiated carcinoma)
Villoglandular Carcinoma (Villoglandular
carcinoma)
Other (Histologic Type), specify
Histologic grade (Differentiation)
Grade 1-well Differentiated (1)
Grade 2-moderately Differentiated (2)
Grade 3-poorly Differentiated (3)
Indeterminate (Indeterminate)
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Not Applicable (Not applicable)
Grade Unknown (Unknown)
Method of evaluation
Biopsy (Biopsy)
Cytology (Cytology)
Primary Surgery (Primary surgery)
Staging surgery (Staging surgery)
Surgery (Surgery)
Date of evaluation (m d y)
ID # of the blocks/slides
Specimen site
Bladder Peritoneum (Bladder
peritoneum)
Bowel Peritoneum/serosa (Bowel
peritoneum/serosa)
Cervix (Cervix)
Corpus (Corpus)
Cul-de-sac (Cul-de-sac)
Diaphragm (Diaphragm)
Endometrium (Endometrium)
Fallopian Tube (Fallopian tube)
Lymph Node(s) (Lymph node(s), specify)
Metastatic Site (Metastatic site, specify)
Omentum (Omentum)
Other (Other, specify)
Ovary (Ovary)
Paracolic Gutter Left (Paracolic gutter
left)
Paracolic Gutter Right (Paracolic gutter
right)
Pelvic Wall Left (Pelvic wall left)
Pelvic Wall Right (Pelvic wall right)
Peritoneum/uterine Serosa
(Peritoneum/uterine serosa)
Lymph node(s), specify (Specimen Site)
Metastatic site, specify (Specimen Site)
Other (Specimen Site), specify
Secondary Disease Assessment
Method of evaluation
Biopsy (Biopsy)
Cytology (Cytology)
Other, Specify (Other, Specify)
Primary Gyn Disease Continues To Be
Present Following Initial Treatment
(Persistence)
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Recurrence Of Same Gyn Disease
Previously Treated Successfully
(Recurrence)
Second look (Second look)
Surgery (Surgery)
Date of evaluation (m d y)
ID # of the blocks/slides
Specimen site
Bladder Peritoneum (Bladder
peritoneum)
Bowel Peritoneum/serosa (Bowel
peritoneum/serosa)
Cervix (Cervix)
Corpus (Corpus)
Cul-de-sac (Cul-de-sac)
Diaphragm (Diaphragm)
Endometrium (Endometrium)
Fallopian Tube (Fallopian tube)
Lymph Node(s) (Lymph node(s), specify)
Metastatic Site (Metastatic site, specify)
Omentum (Omentum)
Other (Other, specify)
Ovary (Ovary)
Paracolic Gutter Left (Paracolic gutter
left)
Paracolic Gutter Right (Paracolic gutter
right)
Pelvic Wall Left (Pelvic wall left)
Pelvic Wall Right (Pelvic wall right)
Peritoneum/uterine Serosa
(Peritoneum/uterine serosa)
Lymph node(s), specify (Specimen Site)
Metastatic site, specify (Specimen Site)
Other (Specimen Site), specify
Footer Module
Participating Group Code
Participating Group Protocol Number
Participating Patient Study ID
Ccrr Module For Gog Pathology Form
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Cervical Cancer NCT00064077 Registration
- GOG Registration Form - 2058698v3.0
Cervical Cancer NCT00064077 Registration - GOG
Registration Form - 2058698v3.0
All rights reserved. Please visit https://medical-data-
models.org/forms/1232
GOG Registration Form
Header Module
Date form originally completed (m d y)
Date form amended (m d y)
Person amending form, last name
Patient Name, Last
Patient Name, First
Patient Study ID
Person Completing Form, Last Name
Tracking Information
Institution name (affiliate)
Treating physician
Patient medical record number
Patient's date of birth
Patient social security number
Patient's zip code (USA)
Country of residence (if not USA)
Demographic Information
Patient race (mark all that apply)
Native_american_cdus (American Indian
or Alaska Native)
Asian_cdus (Asian)
Black_cdus (Black or African)
Pacific_islander_cdus (Native Hawaiian
or other Pacific Islander)
Unknown (Unknown)
White_cdus (White)
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Patient ethnicity (check one)
Hispanic_or_latino (Hispanic or Latino)
Non_hispanic (Non-Hispanic)
Unknown (Unknown)
Method of payment
Medicaid (Medicaid)
Medicaid And Medicare (Medicaid &
Medicare)
Medicare (Medicare)
Medicare And Private Insurance
(Medicare/Private)
Military Or Veterans Sponsored Nos
(Military or Veterans Sponsored NOS)
Military Sponsored (including Champus
& Tricare) (Military Sponsored (including
CHAMPUS or TRICARE))
No Means Of Payment (no Insurance)
(No means of payment (no insurance))
Other (Other, specify)
Private Insurance (Private)
Self Pay (no Insurance) (Self pay (no
insurance))
Unknown (Unknown)
Veterans Sponsored (Veterans
Sponsored)
Other (Payment Method), specify
Patient height (cm)
Patient weight (kg)
Performance status (Zubrod)
0 (0 = Fully active, able to carry on all
pre-disease performance without
restriction (Kamofsky 90-100))
1 (1 = Restricted in physically strenuous
activity, but ambulatory (K 70-80))
2 (2 = Ambulatory and capable of all
selfcare but unable to carry out any work
activities (K 50-60))
3 (3 = Capable of only limited selfcare,
confined to bed or chair for more than
50% of waking hours (K 30-40))
4 (4 = Completely disabled (K 10-20))
Has the patient had any prior cancer diagnosed?
No (No)
Yes (Yes)
Prior cancer type
Prior cancer diagnosis date
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Comments
COMMENTS
Footer Module
Participating Group Code
Participating Group Protocol Number
Participating Patient Study ID
Ccrr Module For Gog Registration Form
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Cervical Cancer NCT00980954 Quality of Life -
RTOG 0724 FACT-Cx (Version 4) - 2820310v1.0
Cervical Cancer NCT00980954 Quality of Life - RTOG
0724 FACT-Cx (Version 4) - 2820310v1.0
All rights reserved. Please visit https://medical-data-
models.org/forms/1251
RTOG 0724 FACT-Cx (Version 4)
Physical Well-being
I have a lack of energy
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have nausea
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
Because of my physical condition, I have trouble
meeting the needs of my family
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have pain
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am bothered by side effects of treatment
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I feel ill
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am forced to spend time in bed
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
Social/family Well-being
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I feel close to my friends
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I get emotional support from my family
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I get support from my friends
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
My family has accepted my illness
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am satisfied with family communication about
my illness
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I feel close to my partner (or the person who is
my main support)
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am satisfied with my sex life
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
Emotional Well-being
I feel sad
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
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I am satisfied with how I am coping with my
illness
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am losing hope in the fight against my illness
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I feel nervous
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I worry about dying
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I worry that my condition will get worse
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
Functional Well-being
I am able to work (include work at home)
2 (A little bit)
1 (Not at all)
4 (Quite a bit)
3 (Somewhat)
5 (Very much)
My work is fulfilling (include work at home)
2 (A little bit)
1 (Not at all)
4 (Quite a bit)
3 (Somewhat)
5 (Very much)
I am able to enjoy life
2 (A little bit)
1 (Not at all)
4 (Quite a bit)
3 (Somewhat)
5 (Very much)
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I have accepted my illness
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am sleeping well
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am enjoying the things I usually do for fun
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am content with the quality of my life right now
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
Additional Concerns
I am bothered by discharge or bleeding from my
vagina
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am bothered by odor coming from my vagina
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am afraid to have sex
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I feel sexually attractive.
2 (A little bit)
1 (Not at all)
4 (Quite a bit)
3 (Somewhat)
5 (Very much)
My vagina feels too narrow or short
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A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have concerns about my ability to have children
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am afraid the treatment may harm my body
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am interested in sex
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I like the appearance of my body
2 (A little bit)
1 (Not at all)
4 (Quite a bit)
3 (Somewhat)
5 (Very much)
I am bothered by constipation
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have a good appetite
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have trouble controlling my urine
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
It burns when I urinate
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
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Very Much (Very much)
I have discomfort when I urinate
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am able to eat the foods that I like
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
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Cervical Cancer NCT01101451 Lab - Gynecologic Oncology
Group Specimen Form (Form SP) - 2759412v1.0
Cervical Cancer NCT01101451 Lab - Gynecologic
Oncology Group Specimen Form (Form SP) - 2759412v1.0
All rights reserved. Please visit https://medical-data-
models.org/forms/1258
Gynecologic Oncology Group
Specimen Form (Form SP)
Header Module
Date form originally completed
Date form amended
Person amending form, last name
Patient Study ID
GOG Bank ID #
Person Completing Form, Last Name
Site Contact Information
Phone number
Email address
General Specimen Information
Specimen Code
Time point
Collected
Not Submitted (No)
Submitted (Yes)
Specify
Collection date
Collection time (when required by the protocol)
Specimen type
Buffy Coat (Buffy coat)
Cells (Cells)
Fixed Tissue (Fixed tissue)
Frozen Tissue (Frozen tissue)
Other (Other)
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Plasma (Plasma)
Serum (Serum)
Urine (Urine)
Whole Blood (Whole blood)
Other, specify
Other, specify
Items shipped
Block (Block)
Oct-mold (OCT-mold)
Other (Other)
Piece (Piece)
Slide (Slide)
Tube/vial (Tube/Vial)
Quantity of items shipped
Processing time
<1 Hour (<1 hour)
>4 Hours (>4 hours)
1-2 Hours (1-2 hours)
2-4 Hours (2-4 hours)
N/a (NA)
Storage type
Other (Other)
Refrigerator (Refrigerator)
Room Temperature (Room temperature)
Standard Non-cycling Freezer (Standard
non-cycling freezer)
Ultracold Freezer/liquid N2/dry Ice
(Ultracold freezer/liquid N2/dry ice)
Other specify
Date shipped
Courier tracking number
Comments
Blood/fluid Products
Type of blood collection tube
Acid Citrate Dextrose (acd) (ACD)
Citrate (Citrate)
Edta (EDTA)
Heparin (Heparin)
Other (Other)
Red Top (Red top)
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Serum Separator (Serum separator)
Other specify
Platelet count required?
No (No)
Yes (Yes)
Platelet count
Platelet Date
Preservative
No (No)
Yes (Yes)
Yes, specify below
Urine collection method
24-hour (24-hour)
Clean Catch (Clean catch)
Other (Other)
Other, specify
Tissue/cells
Tissue type
Metastatic Tumor (Metastatic tumor)
Normal (Normal)
Other (Other)
Pre-malignant (Pre-malignant)
Primary Tumor (Primary tumor)
Recurrent/persistent Tumor
(Recurrent/persistent tumor)
Other specify
Processing method
Ethanol-fixed (Ethanol-fixed)
Fixed & Paraffin-embedded (Fixed &
paraffin-embedded)
Formalin-fixed (Formalin-fixed)
Oct-frozen (OCT-frozen)
Other (Other)
Snap-frozen (Snap-frozen)
Other, specify
Cell type
Buccal (Buccal)
Cervical (Cervical)
Other (Other)
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Other, specify
Gog Tissue Bank/laboratory Information
Receiving institution
Gog Tissue Bank (GOG Tissue Bank)
Laboratory (Laboratory)
Specimen received date (m d y)
Phone number
Total volume/weight
Email address
Units
Additional processing required
No (No)
Yes (Yes)
Specify
Condition of received specimens
Satisfactory (Satisfactory)
Unsatisfactory (Unsatisfactory)
Unsatisfactory, specify
Staff name
Lab name
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All rights reserved. Please visit https://medical-data-
models.org/forms/1265
RTOG 0724 FACT/GOG-Ntx (Version
4)
Physical Well-being
I have a lack of energy
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have nausea
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
Because of my physical condition, I have trouble
meeting the needs of my family
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have pain
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am bothered by side effects of treatment
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I feel ill
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am forced to spend time in bed
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
Social/family Well-being
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I feel close to my friends
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I get emotional support from my family
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I get support from my friends
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
My family has accepted my illness
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am satisfied with family communication about
my illness
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I feel close to my partner (or the person who is
my main support)
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am satisfied with my sex life
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
Emotional Well-being
I feel sad
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
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I am satisfied with how I am coping with my
illness
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am losing hope in the fight against my illness
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I feel nervous
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I worry about dying
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I worry that my condition will get worse
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
Functional Well-being
I am able to work (include work at home)
2 (A little bit)
1 (Not at all)
4 (Quite a bit)
3 (Somewhat)
5 (Very much)
My work is fulfilling (include work at home)
2 (A little bit)
1 (Not at all)
4 (Quite a bit)
3 (Somewhat)
5 (Very much)
I am able to enjoy life
2 (A little bit)
1 (Not at all)
4 (Quite a bit)
3 (Somewhat)
5 (Very much)
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I have accepted my illness
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am sleeping well
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am enjoying the things I usually do for fun
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am content with the quality of my life right now
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
Ntx4 Subscale
I have numbness or tingling in my hands
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have numbness or tingling in my feet
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I feel discomfort in my hands
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I feel discomfort in my feet
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have joint pain or muscle cramps
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A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I feel weak all over
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have trouble hearing
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I get a ringing or buzzing in my ears
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have trouble buttoning buttons
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have trouble feeling the shape of small objects
when they are in my hand
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have trouble walking
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
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Chimerism
Chimerism
Visit Date
Date of Transplant
Course #
Day in Course (Cycle)
Date of Test
Time of Test
Days Post Transplant
Specimen (Select a specimen from the pick list.)
Pheresis Cell (Apheresis Cells)
Bone Marrow (Bone Marrow)
Cd14/cd15 Myeloid Cells (CD14/CD15
Myeloid Cells)
Cd3 Lymphoid Cells (CD3 Lymphoid
Cells)
Cd33 Myeloid Cells (CD33 Myeloid
Cells)
Cerebrospinal Fluid (Cerebrospinal Fluid
(CSF))
Peripheral Blood Mononuclear Cell
(Peripheral Blood Mononuclear Cells
(PBMC))
Saliva (Saliva)
Serum (Serum)
Tumor Tissue (Tumor Tissue)
Urine (Urine)
Whole Blood (Whole Blood)
Result
Comments
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N107C Randomization (Step 2)
Form and Eligibility Checklist
Pre-treatment Requirements
Planning MRI confirmed zero, one, two, or three
unresected lesions. Each unresected lesion must
measure <3.0 cm in maximal extent on the
contrasted planning MRI brain scan (NOTE: The
pre-registration brain scan may be used for the
planning scan if obtained <=14 days prior to
randomization)
No (No)
Yes (Yes)
Planning MRI confirms resection cavity measures
<5.0 cm in maximal extent (NOTE: The pre-
registration brain scan may be used for the
planning scan if obtained <=14 days prior to
randomization)
No (No)
Yes (Yes)
Negative urine or serum pregnancy test done
<=7 days prior to randomization, for women of
childbearing potential only (If not a woman of
childbearing potential or male check NA)
N/a (N/A)
No (No)
Yes (Yes)
Negative urine or serum pregnancy test date (If a
woman of childbearing potential mm/dd/yyyy)
Registration Check
Treatment on this protocol must commence at the
accruing membership under the supervision of a
CTSU or NCCTG member physician
No (No)
Yes (Yes)
Treatment cannot begin prior to randomization
and must begin <=21 days after randomization
No (No)
Yes (Yes)
Tests/procedures must be completed after pre-
registration, but  prior to randomization (see
Section 4.0 for further details Note: Quality of
Life; Functional independence; and
Neurocognitive evaluation completed after
informed consent and prior to randomization)
No (No)
Yes (Yes)
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Date Informed Consent Signed (from pre-
registration checklist mm/dd/yyyy)
Earliest test/procedure date (mm/dd/yyyy NOTE:
These dates are for the Quality of Life; Functional
independence; and Neurocognitive test only. The
negative serum or urine pregnancy test date is
collected in the Inclusion Criteria above)
Latest test/procedure date (mm/dd/yyyy NOTE:
These dates are for the Quality of Life; Functional
independence; and Neurocognitive test only. The
negative serum or urine pregnancy test date is
collected in the Inclusion Criteria above)
Stratification Factors
Age (years)
<60 Years Of Age (<60)
>=60 Years Of Age (>=60)
Number of Preoperative Brain Metastases
1 (1)
2 To 4 Metastases (2 to 4)
Resection cavity maximal diameter
Resection Cavity Maximal Diameter <=3
Cm (<=3 cm)
Resection Cavity Maximal Diameter >3
Cm (>3 cm)
Extracranial disease controlled (months)
Extracranial Disease Controlled <=3
Months (<=3)
Extracranial Disease Controlled >3
Months (>3)
Histology
Lung (Lung)
Other (Other)
Radioresistant (Radioresistant)
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CALGB: 80203 DERMATOLOGY
SPECIFIC QUALITY-OF-LIFE
QUESTIONNAIRE (DSQL)
Cetuximab Skin Toxicities
Mark with an X if there are none
Completed by
If ongoing mark with an X
Adverse event end date
Adverse event onset date
Cetuximab Dose Modification
Dose held (Dose held)
Dose reduced (Dose reduced)
Drug discontinued (Drug discontinued)
Adverse event grade
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
Other, specify
Adverse event term
Dry skin (Dry skin)
Erithema multiforme (Erithema
multiforme)
Nail changes (Nail changes)
Other, specify (Other, specify)
Pruritus (Pruritus)
Rash/desquamation
(Rash/desquamation)
MedDRA
Date form originally completed
Ccrr Module For Calgb: 80203
Dermatology Specific Quality-of-life
Questionnaire (dsql)
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Patient Initials
To
From
CALGB Patient ID
CALGB Study No.
Participating Group Patient ID
Participating Group Protocol No.
Participating Group
Institution/Affiliate
Patient Hospital No.
Are data amended
Yes (Yes)
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CALGB: CES-D (SHORT FORM)
Ccrr Module For Calgb: Ces-d (short
Form)
Patient Initials
Have you had 2 years or more in your life when
you felt depressed or sad most days, even if you
felt okay sometimes? (mark one with an X)
No (No)
Yes (Yes)
In the past year, have you had 2 weeks or more
during which you felt sad, blue, or depressed, or
lost pleasure in things that you usually cared
about or enjoyed?
No (No)
Yes (Yes)
You felt that people disliked you
Most or all of the time (Most or all of the
time)
Occasinally or a moderate amount of
time (Occasinally or a moderate amount
of time)
Rarely or none of the time (Rarely or
none of the time)
Some or a little of the time (Some or a
little of the time)
You felt sad
Most or all of the time (Most or all of the
time)
Occasinally or a moderate amount of
time (Occasinally or a moderate amount
of time)
Rarely or none of the time (Rarely or
none of the time)
Some or a little of the time (Some or a
little of the time)
You had bad crying spells
Most or all of the time (Most or all of the
time)
Occasinally or a moderate amount of
time (Occasinally or a moderate amount
of time)
Rarely or none of the time (Rarely or
none of the time)
Some or a little of the time (Some or a
little of the time)
You enjoyed life
Most or all of the time (Most or all of the
time)
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Occasinally or a moderate amount of
time (Occasinally or a moderate amount
of time)
Rarely or none of the time (Rarely or
none of the time)
Some or a little of the time (Some or a
little of the time)
Your sleep was restless
Most or all of the time (Most or all of the
time)
Occasinally or a moderate amount of
time (Occasinally or a moderate amount
of time)
Rarely or none of the time (Rarely or
none of the time)
Some or a little of the time (Some or a
little of the time)
You felt depressed (blue or down) (You
felt depressed (blue or down))
You felt depressed
Most or all of the time (Most or all of the
time)
Occasinally or a moderate amount of
time (Occasinally or a moderate amount
of time)
Rarely or none of the time (Rarely or
none of the time)
Some or a little of the time (Some or a
little of the time)
Assessment Number
Interviewer or CRA
Participating Group Patient ID
Participating Group Protocol No.
Participating Group
Institution/Affiliate
Patient Hospital No.
If yes, have you felt depressed or sad much of the
time in the past year?
No (No)
Yes (Yes)
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CALGB: FACT/GOG
NEUROTOXICITY SUBSCALE
Ccrr Module For Calgb: Fact/gog
Neurotoxicity Subscale
Patient Initials
I have trouble feeling the shape of small objects
when they are in my hand.
A little bit (A little bit)
Not at all (Not at all)
Quite a bit (Quite a bit)
Somewhat (Somewhat)
Very much (Very much)
I have trouble buttoning buttons
A little bit (A little bit)
Not at all (Not at all)
Quite a bit (Quite a bit)
Somewhat (Somewhat)
Very much (Very much)
I get ringing or buzzing in my ears
A little bit (A little bit)
Not at all (Not at all)
Quite a bit (Quite a bit)
Somewhat (Somewhat)
Very much (Very much)
I have trouble hearing
A little bit (A little bit)
Not at all (Not at all)
Quite a bit (Quite a bit)
Somewhat (Somewhat)
Very much (Very much)
I feel weak all over
A little bit (A little bit)
Not at all (Not at all)
Quite a bit (Quite a bit)
Somewhat (Somewhat)
Very much (Very much)
I have joint pain or muscles cramps
A little bit (A little bit)
Not at all (Not at all)
Quite a bit (Quite a bit)
Somewhat (Somewhat)
Very much (Very much)
I have discomfort in my feet
A little bit (A little bit)
Not at all (Not at all)
Quite a bit (Quite a bit)
Somewhat (Somewhat)
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Very much (Very much)
I feel discomfort in my hands
A little bit (A little bit)
Not at all (Not at all)
Quite a bit (Quite a bit)
Somewhat (Somewhat)
Very much (Very much)
I have numbness or tingling in my feet
A little bit (A little bit)
Not at all (Not at all)
Quite a bit (Quite a bit)
Somewhat (Somewhat)
Very much (Very much)
I have numbness or tingling in my hands
A little bit (A little bit)
Not at all (Not at all)
Quite a bit (Quite a bit)
Somewhat (Somewhat)
Very much (Very much)
Assessment Number
30 Day (30 Day)
7 Day (7 Day)
Interviewer or CRA
Participating Group Patient ID
Participating Group Protocol No.
Participating Group
Institution/Affiliate
Patient Hospital No.
I have trouble walking.
A little bit (A little bit)
Not at all (Not at all)
Quite a bit (Quite a bit)
Somewhat (Somewhat)
Very much (Very much)
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CALGB: 80203 CHANGES IN
FUNCTION FORM-Rev
Ccrr Module For Calgb: 80203 Changes In
Function Form-rev
Patient Initials
First (First)
Last (Last)
Middle (Middle)
Has your ability to enjoy social life gotten
A little better (A little better)
A little worse (A little worse)
About the same (About the same)
Moderatly better (Moderatly better)
Moderatly worse (Moderatly worse)
Very much better (Very much better)
Very much worse (Very much worse)
Has your emotional state gotten
A little better (A little better)
A little worse (A little worse)
About the same (About the same)
Moderatly better (Moderatly better)
Moderatly worse (Moderatly worse)
Very much better (Very much better)
Very much worse (Very much worse)
Has your physical condition gotten
A little better (A little better)
A little worse (A little worse)
About the same (About the same)
Moderatly better (Moderatly better)
Moderatly worse (Moderatly worse)
Very much better (Very much better)
Very much worse (Very much worse)
Assessment Number
30 Day (30 Day)
7 Day (7 Day)
Interviewer or CRA
Participating Group Patient ID
Participating Group Protocol No.
Participating Group
Institution/Affiliate
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Patient Hospital No.
Has your overall quality of life gotten
A little better (A little better)
A little worse (A little worse)
About the same (About the same)
Moderatly better (Moderatly better)
Moderatly worse (Moderatly worse)
Very much better (Very much better)
Very much worse (Very much worse)
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CALGB: HOSPITALIZATION FORM
Ccrr Module For Calgb: Hospitalization
Form
Patient Initials
Completed by
Other, specify
Reason for hospitalization
Non-study indication (Non-study
indication)
Other, specify (Other, specify)
Treatment of complications related to
protocol therapy (Treatment of
complications related to protocol therapy)
Treatment of disease related
complications (Treatment of disease
related complications)
Hospital discharge date
Hospital admit date
CALGB Patient ID
CALGB Study No.
Participating Group Patient ID
Participating Group Protocol No.
Participating Group
Institution/Affiliate
Patient Hospital No.
Date from originally completed
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Physical Exam - Screening
Physcial Exam - Screening
Visit Date (Enter the date the physical
examination took place.)
PE Done? (Indicate whether the physical
examination was performed:)
No (No)
Yes, All (Yes)
Date of Examination (Enter the date the physical
examination took place. )
Finding Result (Indicate whether the finding
results for the particular body system.)
Abnormal (A)
Normal (N)
Not Examined (X)
Comments (Give a brief description for all
abnormal finding results.)
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NCI Standard Physical Examination
Template
Mandatory Physical Examination
Questions
Evaluation Date (Enter the date the physical
examination is performed.)
Conditional Physical Examination
Questions
Body System (Enter the body system)
Abdomen (ABDOMEN)
Allergy Or Drug Sensitivity History
(Allergy/Drug Sensitivity)
Appearance (Appearance)
Body As A Whole (Body as a Whole)
Breasts (BREASTS)
Cardiovascular (CARDIOVASCULAR)
Central Nervous System (Central
Nervous System)
Chest (Chest)
Constitutional (Constitutional)
Dermatologic (DERMATOLOGIC)
Endocrine System (Endocrine)
Endocrine/metabolic
(ENDOCRINE/METABOLIC)
Extremities (Extremities)
Gastrointestinal (GASTROINTESTINAL)
Genitalia (GENITALIA)
Genitourinary (Genitourinary)
H/e/e/n/t (H/E/E/N/T)
Hematologic (HEMATOLOGIC)
Hematopoietic/lymph
(HEMATOPOIETIC/LYMPH)
Hepatic (Hepatic)
Immune (IMMUNE)
Integumentary/hair (Integumentary/Hair)
Musculoskeletal (MUSCULOSKELETAL)
Neck (NECK)
Neurologic (NEUROLOGIC)
Other (OTHER)
Pelvis (PELVIS)
Peripheral Vascular System (Peripheral
Vascular)
Psychiatric (Psychiatric)
Psychologic (PSYCHOLOGIC)
Pulmonary (Pulmonary)
Rectal (Rectal)
Renal (Renal)
Reproductive History (Reproductive
History)
Respiratory (RESPIRATORY)
Spleen (Spleen)
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Substance Abuse/dependency
(Substance abuse/Dependency)
Transfusion History (Transfusion History)
Urinary (URINARY)
Specify Other Body System/Site (Enter
description of other body system/site.)
Finding Description (Enter the physical exam
description or relevant findings for the body
system. Required if the Finding Result is
Abnormal.)
Finding Result (Enter the result of the
assessment for a particular body system.)
Abnormal (Abnormal)
Normal (Normal)
None Examined (Not Examined)
Overall Physical Exam Performed (Enter whether
the overall physical exam is performed.  If yes,
report all abnormal findings on Medical History
CRF.)
No (No)
Yes (Yes)
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Eligibility Checklist
Eligibility Checklist
Visit Date (Enter the date the form was
completed i.e. the date information was
gathered.)
Checklist Number (Note: This field cannot be
modified by the user.)
Effective Date (Note: This field cannot be
modified by the user.)
Waiver Number
Criterion Response (Select the patient's status
relative to the eligibility inclusion criterion.)
No (N)
Not Applicable (X)
Yes, All (Y)
Sequence
Eligibility Waiver Reason
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Deviations Template - 2750875v1.0
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NCI Standard Protocol Deviations
Template
Conditional Protocol Deviations Questions
Protocol Deviation Notification Date (Enter the
date the local study team and/or site PI became
aware of the deviation.)
Optional Protocol Deviations Questions
Protocol Deviation Occurrence Date (Enter the
date on which the protocol deviation occurred.)
Protocol Deviation Description (Enter a
description of the protocol deviation including
reasons and contributing factors.)
Protocol Deviation Severity Type (Select
categorization to indicate a level of severity for
the deviation.)
Will Affect Major Endpoint Data Integrity
Or Will Have A Major Impact On
Participant Safety Or Ethical Concerns
(Major)
No Meaningful Effect On Data Integrity
And No Meaningful Risk To Participant
Safety (Minor)
Potential To Affect Data Integrity Or
Jeopardize Participant Safety (Moderate)
Protocol Deviation Other Category Descriptive
Text (Enter Other protocol category.  Enter only
when Deviation Category choice list "Other" was
selected.)
Treating Physician Or Participating Investigator
Name (Enter the participating investigator or
treating physician name.)
Protocol Deviation Category (Select the category
to classify the deviation.)
Concomitant Medications: Prohibited
Concomitant Medication Was Taken Or
Administered (Concomitant Medications)
Validity And Accuracy Of The Study Data
Is Compromised By Either Mishandling,
Omitting, Or Falsifying Collected Data.
(Data Integrity Compromised)
Participant Eligibility Criteria Was Not
Fully Verified Before Starting
Intervention. (Eligibility not checked)
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Participant Was Granted A Waiver For
Violated Eligibility Criteria Before Or
During Trial Intervention. (Eligibility
waiver)
Informed Consent: Not Collected Or
Mishandled (Informed Consent)
Other, Specify: Deviation Does Not Fit
Into Types Listed (Other, specify)
Study Procedures: Other Study
Procedures, Such As Labs, Images,
Missed Or Out Of The Window From
That Described In The Protocol (Study
Procedures)
Treatment: Study Drug
Agent/intervention Not Given As Directed
In The Protocol (Treatment)
Protocol Deviation Action Text (Describe the
actions initiated by the site to prevent the
reoccurrence of the protocol deviation.)
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NCI Standard Demography Template
Mandatory Demography Question
Gender
Female Gender (Female)
Male Gender (Male)
Unknown (Unknown)
Unspecified (Unspecified)
Race
A Person Having Origins In Any Of The
Original Peoples Of North And South
America (including Central America),
And Who Maintains Tribal Affiliation Or
Community Attachment. (American
Indian or Alaska Native)
A Person Having Origins In Any Of The
Original Peoples Of The Far East,
Southeast Asia, Or The Indian
Subcontinent Including, For Example,
Cambodia, China, India, Japan, Korea,
Malaysia, Pakistan, The Philippine
Islands, Thailand, And Vietnam. (Asian)
A Person Having Origins In Any Of The
Black Racial Groups Of Africa. Terms
Such As "haitian" Or "negro" Can Be
Used In Addition To "black Or African
American." (Black or African American)
A Person Having Origins In Any Of The
Original Peoples Of Hawaii, Guam,
Samoa, Or Other Pacific Islands. (Native
Hawaiian or other Pacific Islander)
Not Provided Or Available (Not
Reported)
Could Not Be Determined Or Unsure
(Unknown)
A Person Having Origins In Any Of The
Original Peoples Of Europe, The Middle
East, Or North Africa. (White)
Patient's Date of Birth
Ethnicity
A Person Of Mexican, Puerto Rican,
Cuban, Central Or South American Or
Other Spanish Culture Or Origin,
Regardless Of Race. (Hispanic or Latino)
A Person Not Meeting The Definition For
Hispanic Or Latino. (Not Hispanic or
Latino)
Not Provided Or Available (Not reported)
Could Not Be Determined Or Unsure
(Unknown)
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Conditional Demography Question
ZIP Code
Payment Method
Managed Care/medicare (Managed
Care/Medicare)
Medicaid (Medicaid)
Medicare And Medicaid (Medicaid and
Medicare)
Medicare (Medicare)
Medicare And Private Insurance
(Medicare and Private Insurance)
Military Or Veterans Sponsored
Insurance, Not Otherwise Specified
(Military or Veterans Sponsored, NOS)
Military Insurance (Military Sponsored
(Including CHAMPUS & TriCare))
No Insurance (No Means of Payment
(No Insurance))
Other (Other)
Private Insurance (Private Insurance)
Self Payment (Self-Pay (No Insurance))
State Supplemental Health Insurance
(State Supplemental Health Insurance)
Unknown (Unknown)
Veterans Administration Sponsor
Insurance (Veterans Sponsored)
Country of Residence
Date Completed
CDC Race Code
CDC Ethnicity Code
Optional Demography Quesitons
Highest Education Level
Bachelor's Degree (Bachelor's Degree)
Professional Doctorate Or Doctorate
Degree (Doctoral degree or professional
degree)
Grade School (Grade School)
Graduation Or Professional Degree
(Graduate or professional degree)
High School Completion Or General
Equivalency Diploma (ged) Completion
(High school graduate (including
equivalency))
Master's Degree (Master's Degree)
No Formal Schooling (No formal
education)
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Not High School Graduate (Not high
school graduate)
Some College Or Associates Degree
(Some college or associate degree)
Country of Birth
Other Country (Other country)
Other Country, Specify (Other country,
specify)
Usa (USA)
Usa, Specify The 2 Letter State Code,
Eg Ny (USA, specify the 2 letter State
code, eg NY)
Highest Education Level
10th Grade (10th Grade)
11th Grade (11th Grade)
12th Grade (12th Grade No Diploma)
1st Grade (1st Grade)
2nd Grade (2nd Grade)
3rd Grade (3rd Grade)
4th Grade (4th Grade)
5th Grade (5th Grade)
6th Grade (6th Grade)
7th Grade (7th Grade)
8th Grade (8th Grade)
9th Grade (9th Grade)
Academic Doctorate Degree Completion
(Academic Doctorate Degree)
Associate Degree (Associate Degree)
Bachelor's Degree Completion (Bachelor
Degree)
Does Not Know (Don't Know)
General Equivalency Diploma (General
Equivalency Diploma)
High School Graduate (High School
Graduate)
Kindergarten Completion (Kindergarten)
Master's Degree Completion (Master's
Degree)
Never Attended (No Formal Schooling)
Preschool Completion (Preschool)
Professional Doctorate Degree
Completion (Professional Doctorate
Degree)
Refuse (Refused)
Some College (Some College, No
Degree)
Vocational Degree (VoTech Program)
Census Tract Code at Enrollment
Marital Status
Divorced: C51776 (Divorced)
Domestic Partner (Domestic Partnership)
Married: C51773 (Married)
Never Married (Never Married)
Separated (Separated)
Widowed (Widowed)
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Longitudinal Follow-Up of
Restorations - Clinical Data
Collection Form
Long Name
Definition
Context
Protocol Long Name
Workflow
Type
Public ID
Version
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FACT-En (Version 4), GOG-0209
Physical Well-being
I have a lack of energy
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have nausea
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
Because of my physical condition, I have trouble
meeting the needs of my family
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have pain
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am bothered by side effects of treatment
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I feel ill
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am forced to spend time in bed
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
Functional Well-being
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I am able to work (include work at home)
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
My work (include work at home) is fulfilling
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am able to enjoy life
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have accepted my illness
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am sleeping well
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am enjoying the things I usually do for fun
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am content with the quality of my life right now
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
Additional Concerns
I have swelling in my stomach area
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
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I have cramps in my stomach area
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have discomfort or pain in my stomach area
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have vaginal bleeding or spotting
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have vaginal discharge
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am unhappy about a change in my appearance
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have hot flashes
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have cold sweats
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have night sweats
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I feel fatigued
A Little Bit (A little bit)
Not At All (Not at all)
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Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have pain or discomfort with intercourse
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have trouble digesting food
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have been short of breath
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am bothered by constipation
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I urinate more frequently than usual
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have discomfort or pain in my pelvic area
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have numbness or tingling in my hands
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have numbness or tingling in my feet
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
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I feel discomfort in my hands
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I feel discomfort in my feet
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
Ccrr Module For Fact-en (version 4), Gog-
0209
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NCI Standard Medical History
Template
Mandatory Medical History Questions
Medical History Date (Enter the date that the
medical history is collected.)
Optional
Ongoing (Enter whether the medical history
condition is ongoing at the time of collection.)
Not Applicable (N/A)
No (No)
Yes (Yes)
Description (Enter description of medical history
at the time of collection.)
Finding (Enter the result of the assessment for a
particular body system.)
Abnormal (Abnormal)
Normal (Normal)
No Assessment (Not Assessed)
Medical History System (Enter the body system.)
Abdomen (Abdomen)
Breast (Breasts)
Cardiovascular System (Cardiovascular)
Dermatologic (Dermatologic)
Endocrine System (Endocrine/Metabolic)
Gastrointestinal System
(Gastrointestinal)
Genitourinary System (Genitourinary)
Head, Ears, Eyes, Nose And Throat
(HEENT)
Hematopoietic And Lymphatic System
(Hematopoietic/Lymph Nodes(s))
Immune System (Immune)
Musculoskeletal System
(Musculoskeletal)
Neck (Neck)
Neurologic Examination (Neurologic)
Other (Other)
Pelvic Examination (Pelvis)
Psychological (Psychologic)
Respiratory System (Respiratory)
Other (Body) System/Site Text (Enter description
of other body system/site.)
Medical History Assessment Indicator (Enter
whether the medical history was
assessed/gathered.)
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GOG-0249 Quality of  Life (QOL)
Form
Physical Well-being
I have a lack of energy.
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have nausea.
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
Because of my physical condition, I have trouble
meeting the needs of my family.
2 (A little bit)
1 (Not at all)
4 (Quite a bit)
3 (Somewhat)
5 (Very much)
I have pain.
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am bothered by side effects of treatment.
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I feel ill
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am forced to spend time in bed
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
Functional Wellbeing
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I am able to work (include work at home)
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
My work (include work at home) is fulfilling
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am able to enjoy life.
2 (A little bit)
1 (Not at all)
4 (Quite a bit)
3 (Somewhat)
5 (Very much)
I have accepted my illness
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am sleeping well
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am enjoying the things I usually do for fun
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am content with the quality of my life right now
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
Additional Concerns
I have swelling in my stomach area
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
2 / 8
Endometrial Cancer NCT00807768 Quality of Life - GOG-0249 Quality of
Life (QOL) Form - 2786253v1.0
I have cramps in my stomach area
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have discomfort or pain in my stomach area
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have vaginal bleeding or spotting
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have vaginal discharge
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am unhappy about a change in my appearance
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have hot flashes
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have cold sweats
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have night sweats
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I feel fatigued
A Little Bit (A little bit)
Not At All (Not at all)
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Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have pain or discomfort with intercourse
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have trouble digesting food
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have been short of breath
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am bothered by constipation
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I urinate more frequently than usual
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have discomfort or pain in my pelvic area
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
My vagina feels too narrow or short
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have control of my bowels
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
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I have diarrhea
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
Ntx4 Subscale
I have numbness or tingling in my hands
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have numbness or tingling in my feet
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I feel discomfort in my hands
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I feel discomfort in my feet
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
Additional Concerns
I feel tired
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I feel weak all over
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I feel listless ("washed out")
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
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I have trouble starting things because I am tired
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have trouble finishing things because I am tired
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have energy
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am able to do my usual activities
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I need to sleep during the day
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am too tired to eat
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I feel fatigued
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I need help doing my usual activities
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am frustrated by being too tired to do the things
I want to do
A Little Bit (A little bit)
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Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have to limit my social activity because I am
tired
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
Promis Fatigue Short Form 1
I feel tired
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
How often did you experience extreme
exhaustion
Always (Always)
Never (Never)
Often (Often)
Rarely (Rarely)
Sometimes (Sometimes)
How often did you run out of energy
Always (Always)
Never (Never)
Often (Often)
Rarely (Rarely)
Sometimes (Sometimes)
How often did your fatigue limit you at work
(include work at home)
Always (Always)
Never (Never)
Often (Often)
Rarely (Rarely)
Sometimes (Sometimes)
How often were you too tired to think clearly
Always (Always)
Never (Never)
Often (Often)
Rarely (Rarely)
Sometimes (Sometimes)
How often were you too tired to take a bath or
shower
Always (Always)
Never (Never)
Often (Often)
Rarely (Rarely)
Sometimes (Sometimes)
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How often did you have enough energy to
exercise strenuously
Always (Always)
Never (Never)
Often (Often)
Rarely (Rarely)
Sometimes (Sometimes)
To Be Completed By Clinical Staff
Fatigue Grade (Please indicate the - at the time
of assessment)
None (0)
Mild Fatigue Over Baseline (1)
Moderate Or Causing Difficulty
Performing Some Adl (2)
Severe Fatigue Interfering With Adl (3)
Disabling (4)
Status of the QOL assessment (Please indicate
the)
Other (Other)
Patient Died (Patient died)
Patient Kept Appointment, But Could Not
Complete Questionnaire Due To Illness
(Patient kept appointment, but could not
complete questionnaire due to illness)
Patient Kept Appointment, But Refused
To Complete Questionnaire For Reasons
Other Than Illness (Patient kept
appointment, but refused to complete
questionnaire for reasons other than
illness)
Patient Off Study Treatment And Cannot
Be Contacted For Follow-up (Patient off
study treatment and cannot be contacted
for follow-up)
Questionnaire Not Administered Due To
Clinical Staff Error (Questionnaire not
administered due to clinical staff error)
The Questionnaire Is Complete (The
questionnaire is complete)
Other, specify
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Extent of Disease Measurement
Extent Of Disease Measurement
Lesion # (Select a lesion number from the pick
list.)
Course #
Day in Course (Cycle)
Evaluation Date (Enter the date of the evaluation
i.e.: date of CT scan.)
How Measured (Select how the lesion
measurement was determined. The same
method should be used to measure a specific
lesion throughout the study.)
Alpha-lipoic Acid (Alpha-Lipoic Acid)
Apheresis (Apheresis)
Arteriogram (Arteriogram)
Arthroscopy (Arthroscopy)
Aspirate, Bone Marrow (Aspirate, Bone
Marrow)
Aspirate, Ultrasound Guided (Aspirate,
Us Guided)
Audiogram (Audiogram)
Barium Enema (Barium Enema)
Barium Swallow (Barium Swallow)
Biopsy (Biopsy)
Biopsy, Core Needle (Biopsy, Core
Needle)
Biopsy, Image Guided (Biopsy, Image
Guided)
Blister Induction (Blister Induction)
Bone Marrow Cellularity (BM Cellularity)
Biopsy, Bone Marrow (Bone Marrow
Biopsy)
Bone Mineral Density (Bone Mineral
Density)
Bone Scan (Bone Scan)
Bone Spectometry (Bone Spectometry)
Bronchoalveolar Lavage
(Bronchoalveolar Lavage)
Bronchogram (Bronchogram)
Bronchoscopy (Bronchoscopy)
Bronchoscopy/lavage
(Bronchoscopy/Lavage)
Cardiac Catheterization (Cardiac
Catheterization)
Computerized Axial Tomography (CAT
(CT))
Cathetergram (Cathetergram)
Cauterization (Cautery, AgNO3 (Silver
nitrate))
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Central Line Insertion (Central Line
Insertion)
Colonoscopy (Colonoscopy)
Craniotomy (Craniotomy)
Culture Procedure (Culture)
Curative Surgery (Curative Surgery)
X-ray, Chest (CXR)
Cystectomy (Cystectomy)
Cystogram (Cystogram)
Cystoscopy (Cystoscopy)
Cytology (Cytology)
Debridement Of Wound Of Skin
(Debridement)
Dental Examination (Dental
Examination)
Dental Procedure (Dental Procedure)
Dissection (Dissection)
Doppler Study (Doppler)
Electrocardiogram (ECG)
Echocardiogram (Echocardiogram)
Electroencephalogram (EEG)
Upper Endoscopy
Esophagogastroduodenoscopy (EGD)
Electrocardiogram (EKG)
Electromyography (EMG)
Endoscopy (Endoscopy)
Esophageal Dilation (Esophageal
dilation)
Esophagoscopy (Esophagoscopy)
Examination Under Anesthesia (EUA)
Excision (Excision)
Exercise Thallium (Exercise Thallium)
Eye Exam (Eye Exam)
Aspirate, Fine Needle (Fine Needle
Aspiration)
Flexible Fiberoptic Sigmoidoscopy
(Flexible Fiberoptic Sigmoidoscopy)
Fluoroscopy (Fluoroscopy)
Flow Cytometry (Flw Cyt)
Flow Cytometry, Blood (Flw Cyt Bld)
Flow Cytometry, Bone Marrow (Flw Cyt
BM)
Holter Monitor (Holter Monitor)
Hyperbaric Treatment(s) (Hyperbaric
Treatment(s))
Hyperthermia (Hyperthermia)
Hysterosonogram (Hysterosonogram)
Incision & Drainage (I&D)
Ice Application (Ice Application)
Laser Doppler Imaging (Imaging, Laser
Doppler)
Multispectral Imaging (Imaging,
Multispectral)
Near Infrared Imaging (Imaging, Near
Infrared)
Immunohistochemical Detection/staining
(Immunohistochemical Detection)
Infrared (Infrared)
Irrigation (Irrigation)
Intravenous Pyelogram (IVP)
2 / 5
Follow-Up - Extent of Disease Measurement - 3277717v1.0
X-ray, Abdominal (KUB)
Lymphangiogram (LAG)
Laparoscopy (Laparoscopy)
Laryngoscopy (Laryngoscopy)
Leukapheresis (Leukopheresis)
Lower Gastrointestinal Series (Lower GI)
Lumbar Puncture (LP)
Lumpectomy (Lumpectomy)
Lymphadenectomy (Lymphadenectomy)
Lymphocyte Harvest (Lymphocyte
Harvest)
Lymphocyte Infusion (Lymphocyte
Infusion)
Lymphopheresis With Scda Solution
(Lymphopheresis w/SCDA)
Mammogram (Mammogram)
Mammogram, Birad (Mammogram,
BIRAD)
Mammogram, Digitized (Mammogram,
DIGITIZED)
Mammogram, Wolfe (Mammogram,
WOLFE)
Mastectomy (Mastectomy)
Magnetic Resonance Imaging (MRI)
Magnetic Resonance Spectroscopy
(MRS)
Multi-gated Acquisition Scan (MUGA)
Nasopharyngeal Laryngoscopy
(Nasopharyngeal Laryngoscopy)
Nasopharyngoscopy
(Nasopharyngoscopy)
Nipple Suction Aspirate (Nipple Suction
Aspirate)
Nuclear Stress Test (Nuclear stress test)
In 111 Pentetreotide (Octreoscan)
Ommaya Resevoir Tap (Ommaya
Resevoir Tap)
Papanicolaou Test (PAP)
Paracentesis (Paracentesis)
Physical Examination (PE)
Pelvic Exam (Pelvic Exam)
Peritoneoscopy (Peritoneoscopy)
Positron Emission Tomography (PET)
Positron Emission Tomography
Computerized Tomography (PET CT)
Positron Emission Tomography With
Sestamibi (PET w/Sestamibi)
Pet, Dlop (PET, dLop)
Positron Emission Tomography With Fdg
(PET, FDG)
Positron Emission Tomography With O-
15 Water (h2o15) (PET, H2O15)
Pulmonary Function Test Interpretation
(PFT Interpretation)
Pulmonary Function Test/carbon
Monoxide Diffusing Capability
(PFT/DLCO)
Pulmonary Function Test/forced
Expiratory Volume 1 (PFT/FEV1)
Pulmonary Function Test/ Inspired
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Oxygen Fraction (PFT/FIO2)
Pulmonary Function Test/forced Vital
Capacity (fvc) (PFT/FVC)
Photography (Photography)
Pleurodesis (Pleurodesis)
Portacath Placement (Portacath
Placement)
Percutaneous Transluminal Coronary
Angioplasty (PTCA)
Pulse Oximetry (Pulse Oximetry)
Renogram (Renogram)
Resection (Resection)
Radiofrequency Ablation (RFA)
Imaging Scan (Scan)
Scan, Blood Oxygenated Level
Dependant (bold) (Scan, BOLD)
Bone Scan (Scan, Bone)
Scan, Dynamic Contrast-enhanced
Magnetic Resonance Imaging (Scan,
DCE MRI)
Scan, Dual-energy X-ray Absorpitometry
(Scan, DEXA)
Scan, Dynamic Optical Breast Imaging
(Scan, Dynamic Optical Breast Imaging)
Scan, Gallium (Scan, Gallium)
Scan, Iodine 123 Uptake (Scan, I 123
Uptake)
Scan, I 131 Uptake (Scan, I 131 Uptake)
Scan, Indium (Scan, Indium WBC)
Scan, Lung Perfusion (Scan, Lung
Perfusion)
Scan, Single Photon Emission
Computed Tomography (Scan, PET CT)
Scan, Sestamibi (Scan, Sestamibi)
Scan, Spiral Ct (Scan, Spiral CT)
Ventilation-perfusion Scan (Scan, VQ)
Scraping (Scraping)
Sigmoidoscopy (Sigmoidoscopy)
Skeletal Survey (Skeletal Survey)
Skin Test (Skin Test)
Splenectomy (Splenectomy)
Stress Thallium Test (Stress Thallium
Test)
Swallow Evaluation (Swallow Evaluation)
Thoracentesis (Thoracentesis)
Tomogram (Tomogram)
Transrectal Ultrasound (Transrect US)
Transurethral Resection Bladder
Neoplasm (TURBT)
Upper Gastrointestinal Series (UGI)
Upper Gastrointestinal Series W/small
Bowel Follow Through (UGI/w sm bowel
f/t)
Ultrasound (Ultrasound)
Urine Casts (Urine Casts)
Vascular Access Device Placement (VAD
Placement)
Vaginogram (Vaginogram)
Venacavagrm (Venacavagrm)
Venogram (Venogram)
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Video Recording (Videography)
X-ray (X-Ray)
Measurement (First Longest - Enter the longest
lesion measurement in centimeters.)
Measurement (Second Longest) (Enter the
second longest lesion measurement in
centimeters.)
Measurement (Third Longest) (Enter the third
longest lesion measurement in centimeters.)
Product (Enter the tumor product which is the
multiplication of the First and Second Longest
Measurements.)
Total Tumor Volume (Enter the total tumor volume
which is the multiplication of all three
measurements.)
Evaluation # (Note: this is the number of the set
of scans done after the baseline. For example, if
a new lesion was found on the third set of scans
that occurred at the end of the course 4, the
evaluation number should be 3.)
Evaluation Code (Select the status of non-
measurable lesions at the time of each
evaluation.)
Baseline (B)
Decreasing (D)
Increasing (I)
New (N)
Resolved (R)
Stable (S)
Not Examined For (X)
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All rights reserved. Please visit https://medical-data-
models.org/forms/1656
Concomitant Measures/Medications
Concomitant Measures / Medications
Visit Date
Course #
Day in Course (Cycle)
Start Date (Enter the start date of the measure or
medication.)
Stop Date (Enter the stop date of the measure /
medication.)
Agent Name (In the case of agents, state the
generic name of the medication administered, or,
in the case of combinations such as trimethoprim
/ sulfamethoxazole, state the brand name i.e.,
Bactrim.)
3tc (lamivudine) (3TC)
Fluorouracil (5-Fluorouracil)
Aminocamptothecin (9-AC)
A And D Ointment (A&D Ointment)
Abacavir Sulfate (Abacavir)
Amphotericin B-lipid Complex (Abelcet)
Acarbose (Acarbose)
Acid Citrate Dextrose (ACDA Solution)
Acebutolol Hydrochloride (Acebutolol)
Acepromazine (Acepromazine)
Acetaminophen (Acetaminophen)
Acetaminophen #3 (Acetaminophen #3)
Acetaminophen + Butalbital + Caffeine
(Acetaminophen/Caffeine/Butalbital)
Acetaminophen/diphenhydramine
(Acetaminophen/Diphenhydramine)
Acetaminophen + Oxycodone
Hydrochloride
(Acetaminophen/Oxycodone HCL
(Percocet))
Acetazolamide (Acetazolamide)
Acetylcysteine (Acetylcysteine)
Acetylsalicylic Acid (Acetylsalicylic Acid)
Anacin (Acetylsalicylic Acid/Caffeine
(Anacin))
Acitretin (Acitretin)
Acyclovir (Acyclovir)
Adapalene (Adapalene)
Dextroamphetamine-amphetamine
(Adderall)
Adefovir Dipivoxil (Adefovir)
Adenosine (Adenosine)
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Albumin (Albumin)
Albuterol (proventil, Ventolin, Volmax)
(Albuterol)
Albuterol+ipratropium Bromide
(Albuterolsulfide/Ipratropium)
Alclometasone Dipropionate 0.05%
(aclovate) (Alclometasone Dipropionate
0.05%)
Alendronate Sodium (Alendronate
Sodium)
Alfuzosin (Alfuzosin HCL)
Aliskiren Aliskiren Aliskiren (Aliskiren)
9-cis-retinoic Acid (Alitretinoin)
Sodium Bicarbonate/aspirin/citric Acid
(Alka Seltzer)
Allergy Shot (Allergy Shot)
Allopurinol (Allopurinol)
Aloe Vera Preparation (Aloe Vera)
Alosetron (Alosetron HCL (Lotronex))
Alpha-lipoic Acid (Alpha-Lipoic Acid)
Alprazolam (Alprazolam)
Alprostadil (Alprostadil)
Tissue Plasminogen Activator (Alteplase)
Complementary And Alternative
Medicine (Alternative Therapy)
Altretamine (Altretamine)
Aluminum Hydroxide (Aluminum
Hydroxide)
Aluminum Magnesium (Aluminum
Magnesium)
Aluminum Sulfate (Aluminum Sulfate)
Amantadine Hydrochloride (Amantadine
HCL)
Amcinonide 0.1% (cyclocort)
(Amcinonide 0.1%)
Amikacin Sulfate (Amikacin)
Amiloride (Amiloride)
Aminocaproic Acid (Aminocaproic Acid)
Aminoglutethimide (Aminoglutethimide)
Amiodarone Hydrochloride (Amiodarone)
Amisulpride (Amisulpride)
Amitriptyline Hydrochloride
(Amitriptyline)
Amlodipine Besylate (Amlodipine
Besylate)
Ammonium Lactate (Ammonium lactate)
Amoxicillin (Amoxicillin)
Amoxicillin-clavulanate Potassium
(Amoxicillin/Clavulonate Potassium)
Amphetamine Sulfate (Amphetamine)
Amphotercin B (Amphotericin B)
Amphotericin B Liposomal (Amphotericin
B Liposomal)
Ampicillin (Ampicillin)
Ampicillin Sodium/sulbactam Sodium
(Ampicillin Sodium/Sulbactam Sodium)
Amprenavir (Amprenavir)
Anagrelide (Anagrelide)
Analgesic Balm (Analgesic Balm)
Anastrozole (Anastrozole)
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Anidulafungin (Anidulafungin)
Pheresis (Apharesis)
Apolizumab (Apolizumab)
Aprepitant (Aprepitant)
Aquaphor (Aquaphor)
Argatroban: C28833 (Argatroban)
Arginine (Arginine)
Aripiprazole (Aripiprazole)
Arthro Joint Complex (Arthro Joint
Complex)
Arthro-7 (Arthro-7)
Ascorbic Acid (Ascorbic Acid)
Aspartic Acid (Aspartic Acid)
Astemizole (Astemizole)
Atazanavir Sulfate (Atazanavir)
Atenolol (Atenolol)
Atipamizole (Atipamizole)
Atomoxetine Hydrochloride (Atomoxetine
HCL)
Atorvastatin (Atorvastatin Calcium)
Atovoquone (Atovoquone)
Atracurium Besylate (Atracurium
Besylate)
Emtricitabine/tenofovir/efavirenz (Atripla)
Atropine (Atropine)
Attapulgite (Attapulgite)
Oatmeal Powder (Aveeno)
Azacitidine (Azacitidine)
Azathioprine (Azathioprine)
Azelastine Hydrochloride (Azelastine
HCL)
Azithromycin (Azithromycin)
Azor (amlodipine/olmesartan) (Azor)
Aztreonam (Aztreonam)
Bacitracin (Bacitracin)
Bacitracin Zinc (Bacitracin Zinc)
Baclofen (Baclofen)
Trimethoprim-sulfamethoxazole (Bactrim)
Bactrim Ds (Bactrim DS)
Barium Sulfate (Barium Sulfate)
Barley Grain (Barley Grain)
Becaplermin (Becaplermin)
Beclomethasone Dipropionate
(Beclomethasone Dipropionate)
Belladonna-phenobarbital (Belladona
Alkaloids/Phenobarb)
Belladonna/phenobarbital/ergotamine
(Belladona/Phenobarb/Ergotamine)
Benazepril Hydrochloride (Benazepril
HCL)
Fiber (BeneFiber)
Benzocaines (Benzocaine)
Benzonatate (Benzonatate)
Benzoyl Peroxide (Benzoyl Peroxide)
Benztropine Mesylate (Benztropine
Mesylate)
Benzylpenicillin Sodium (Benzylpenicillin
Sodium)
Beta Carotene (Beta Carotene)
Betaine (Betaine HCL)
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Betamethasone (Betamethasone)
Betamethasone Dipropionate 0.05%
(diprolene, Diprolene Af, Maxivate,
Diprosone) (Betamethasone
Dipropionate 0.05%)
Betamethasone Valerate 0.01% Lotion
(valisone) (Betamethasone Valerate
0.01%)
Betamethasone Valerate 0.1%
(Betamethasone Valerate 0.1%)
Bethanechol Chloride (Bethanechol
Chloride)
Bevacizumab (Bevacizumab)
Bexarotene (Bexarotene)
Bicalutamide (Bicalutamide)
Sodium Bicarbonate/aspirin/citric Acid
(Bicarb/ASA/Citric Acid)
Bimatoprost (Bimatoprost)
Biotene Dental Chewing Gum (Biotene
Gum)
Biotene Mouthwash (Biotene
Mouthwash)
Biotene Toothpaste (Biotene Toothpaste)
Birth Control (Birth Control)
Bisacodyl (Bisacodyl)
Bismuth Subsalicylate (Bismuth
Subsalicylate)
Bisoprolol Fumarate (Bisoprolol
Fumarate)
Bisoprolol Fumarate/hydrochlorothiazide
(Bisoprolol/Hydrochlorthiazide)
Blephamide (Blephamide)
Bovine Cartilage (Bovine Cartilage)
Brimodine (Brimodine)
Bromocriptine (Bromocriptine)
Dextromethorphan Elixir (Bromphenex)
Brompheniramine Maleate +
Pseudoephedrine Hydrochloride
(Brompheniramine Maleate/Pseudo)
Brotizolam (Brotizolam)
Pulmicort (budesonide) (Budesonide)
Budesonide/formoterol Fumarate
Dihydrate Inhalation Aerosol
(Budesonide/Formoterol Fumarate
Dihydrate Inhalation Aerosol
(Symbicort))
Bumetanide (Bumetanide)
Bupivacaine Hydrochloride (Bupivacaine)
Buprepinorphine Hydrochloride
(Buprepinorphine HCL)
Bupropion Hydrochloride (Bupropion
HCL)
Burow's Solution (Burow's Solution)
Buspirone Hcl (Buspirone HCL)
Butorphanol Tartrate (Butorphanol
Tartrate)
Caffeine (Caffeine)
Calcitonin (Calcitonin)
Calcitriol (Calcitriol)
Calcium (Calcium)
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Calcium Carbonate (Calcium Carbonate)
Calcium Chloride (Calcium Chloride)
Calcium Citrate (Calcium Citrate)
Calcium Gluconate (Calcium Gluconate)
Calcium Polycarbophil (Calcium
Polycarbophil)
Calcium-vitamin D (Calcium/Vitamin D)
Calmol-4 (Calmol-4)
Calmoseptine Oint (Calmoseptine
Ointment)
Alemtuzumab (Campath)
Candesartan Cilexetil (Candesartan
Cilexetil)
Candida Albicans Skin Test Reagent
(Candida albicans test antigen)
Capecitabine (Capecitabine)
Capsaicin (Capsaicin)
Captopril (Captopril)
Carbamazepine (Carbamazepine)
Carbamide Peroxide (Carbamide
Peroxide)
Carboxymethylcellulose
(Carboxymethylcellulose)
Carisoprodol (Carisoprodol)
Carprofen (Carprofen)
Carteolol Hydrochloride (Carteolol HCL)
Carvedilol (Carvedilol)
Casanthranol (Casanthranol)
Casanthranol/docusate
(Casanthranol/Docusate)
Cascara (Cascara)
Caspofungin (Caspofungin)
Cefaclor (Cefaclor)
Cefadroxil (Cefadroxil)
Cefazolin (Cefazolin)
Cefdinir (Cefdinir)
Cefepime (Cefepime)
Cefotaxime Sodium (Cefotaxime
Sodium)
Cefoxitin Sodium (Cefoxitin Sodium)
Cefpodoxime Proxetil (Cefpodoxime)
Cefprozil (Cefprozil)
Ceftazidime Sodium (Ceftazidime)
Ceftriaxone Sodium (Ceftriaxone)
Cefuroxime Axetil (Cefurexine Axetil)
Celecoxib (Celecoxib)
Cephalexin (Cephalexin)
Cerivastatin Sodium (Cerivastatin
Sodium)
Cetirizine (Cetirizine HCL)
Cetuximab (Cetuximab (Erbitux))
Cevimelline Hcl (Cevimelline HCL)
Chloral Hydrate (Chloral Hydrate)
Chlorambucil (Chlorambucil)
Chloraseptic Spray (Chloraseptic)
Chlordiazepoxide (Chlordiazepoxide)
Chlorhexidine Gluconate (Chlorhexidine
Gluconate)
Chlorothiazide (Chlorothiazide)
Chlorpheniramine Maleate
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(Chlorpheniramine Maleate)
Chlorpromazine (Chlorpromazine)
Chlorthalidone (Chlorthalidone)
Chlorzoxazone (Chlorzoxazone)
Chlorzoxazone/acetaminophen
(Chlorzoxazone/Acetaminophen)
Clotrimazole (Chlotrimazole)
Cholecalciferol (Cholecalciferol)
Cholestyramine (Cholestyramine)
Chondroitin Sulfate (Chondroitin)
Human Chorionic Gonadotropin
(Chorionic Gonadotropin)
Chromium Piccolinate (Chromium
Piccolinate)
Ciclopirox (Ciclopirox)
Cidofovir (Cidofovir)
Cilostazol (Cilostazol)
Cimetidine (Cimetidine)
Cinnarizine (Cinnarizine)
Ciprofloxacin (Ciprofloxacin)
Cisapride (Cisapride)
Citalopram Hydrobromide (Citalopram
Hydrobromide)
Methylcellulose (Citrucel)
Clarithromycin (Clarithromycin)
Clindamycin (Clindamycin)
Clobetasol Propionate 0.05% (temovate)
(Clobetasol Propionate)
Clobetasol Propionate 0.05% (temovate)
(Clobetasol Proprionate 0.05%)
Clomid (Clomiphene Citrate)
Clonazepam (Clonazepam)
Clonidine (Clonidine)
Clopidogrel Bisulfate (Clopidogrel
Bisulfate)
Clotrimazole (Clotrimazole)
Clozapine (Clozapine)
Factor Viia Human (Coagulation Factor
Viia)
Codeine Phosphate (Codeine
Phosphate)
Codeine Sulfate (Codeine Sulfate)
Coenzyme-q (Coenzyme Q10)
Colchicine (Colchicine)
Colesevelam Hydrochloride
(Colesevelam HCL)
Colestipol Hydrochloride (Colestipol
HCL)
Colistimethate Sodium (Colistimethate
Sodium)
Colostrum (Colostrum)
Lamivudine/zidovudine (Combivir)
Comtrex (Comtrex)
Cortisone Acetate (Cortisone Acetate)
Cortisporin (Cortisporin)
Cortrosyn (Cortrosyn)
Casanthranol: C0205705 (Cosanthranol)
Trimethoprim-sulfamethoxazole
(Cotrimoxazole)
Cranberry (Cranberry)
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Cream (Cream)
Creatine Supplement (Creatine
Supplement)
Cromolyn Sodium (Cromolyn Sodium)
Vitamin B12 (Cyanocobalamin)
Cyclobenzaprine (Cyclobenzaprine)
Cyclopentolate Hydrochloride
(Cyclopentolate HCL)
Cyclosporine (Cyclosporine)
Cyproheptadine Hydrochloride
(Cyproheptadine HCL)
Cytarabine (Cytarabine)
Cytarabine (ara C, Cytosine Arabinoside)
(Cytarabine)
Dextrose 5% In 1/2 Strength Saline (D5
1/2 Normal Saline)
Dextrose 0.2 Gm / Sodium Chloride 0.9
Gm Solution (D5 1/4 Normal Saline)
Dextrose Saline (D5 Normal Saline)
Dextrose 50 % (D50W)
Dextrose 5 % (D5W)
Daclizumab (Daclizumab)
Dakins Solution (Dakins)
Dalteparin (Dalteparin Sodium)
Danaparoid Sodium (Danaparoid
Sodium)
Danazol (Danazol)
Dantrolene Sodium (Dantrolene Sodium)
Dapsone (Dapsone)
Daptomycin (Daptomycin)
Darbepoetin Alfa (Darbepoetin Alfa)
Darunavir (Darunavir)
Dayquil (Dayquil)
Zalcitabine (ddC)
Didanosine (ddI)
Decitabine (Decitabine)
Deferasirox (Deferasirox)
Delavirdine Mesylate (Delavirdine
Mesylate)
Demeclocycline Hydrochloride
(Demeclocycline HCL)
Denileukin Diftitox (Deniluekin)
Pentostatin (Deoxycoformycin)
Derecoxib (Derecoxib)
Dermeze (Dermeze)
Diethylstilbestrol (DES)
Desipramine Hydrochloride
(Desipramine HCL)
Desloratadine (Desloratadine)
Desmopressin Acetate (Desmopressin
Acetate)
Desogestrel-ethinyl Estradiol
(Desogestrel/Ethinyl Estradiol)
Desonide 0.05% (tridesilon) (Desonide
0.05%)
Desoximetasone 0.05% (topicort,
Topicort Lp) (Desoximetasone 0.05%)
Desoximetasone 0.25% (topicort)
(Desoximetasone 0.25%)
Desvenlafaxine (Desvenlafaxine)
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Devil's Foot/jambul (Devil's Foot/Jambul)
Dexamethasone (Dexamethasone)
Dexmedetomidine Hydrochloride
(Dexmedetomidine HCL  (Precedex))
Dextroamphetamine
(Dextroamphetamine)
Dextromethorphan Hydrobromide
(Dextromethorphan Hydrobromide)
Glucose (Dextrose)
Dextrose Oral Solution (Dextrose
Solution)
Therapeutic Dehydroepiandrosterone
(DHEA)
Diazepam (Diazepam)
Dibucaine (Dibucaine)
Diclofenac (Diclofenac)
Dicloxacillin (Dicloxacillin)
Dicyclomine (Dicyclomine HCL)
Didanosine (Didanosine)
Difenoxin (Didanosine EC)
Difenoxin (Difenoxin)
Adapalene (Differin)
Diflorasone Diacetate 0.05% (psorcon,
Florone, Maxiflor) (Diflorasone Diacetate
0.05%)
Digestion Enzyme (Digestive Enzyme,
NOS)
Digoxin (Digoxin)
2-(indol-3-ylmethyl)-3,3'-
diindolylmethane (Diindolylmethane
(DIM) Complex)
Diltiazem Hydrochloride (Diltiazem HCL)
Dimenhydrinate (Dimenhydrinate)
Dimetapp (DImetapp)
Diphencyprone (Diphencyprone)
Diphenhydramine Hydrochloride
(Diphenhydramine HCL)
Diphenoxylate Hydrochloride
(Diphenoxylate)
Difenoxin Hcl/atropine Sulfate Tablet
(Diphenoxylate HCL/Atropine)
Dipyridamole (Dipyridamole)
Disopyramide Phosphate (Disopyramide
Phosphate)
Divalproex Sodium (Divalproex Sodium)
Dobutamine Hydrochloride (Dobutamine
HCL)
Docosahexaenoic Acid (all-z Isomer)
(Docosahexaenoic Acid)
Docosanol (Docosanol)
Docusate Calcium (Docusate Calcium)
Docusate Sodium (Docusate Sodium)
Dolasetron Mesylate (Dolasetron)
Domeboro Solution (Domeboro Solution)
Domperidone (Domperidone)
Donepezil Hydrochloride (Donepezil HCL
(Aricept))
Donnatol (Donnatol)
Dopamine Hydrochloride (Dopamine)
Dorzolamide Sodium (Dorzolamide
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Sodium)
Doxazosin (Doxazosin)
Doxazosin Mesylate (Doxazosin
Mesylate)
Doxepin Hydrochloride (Doxepin HCL)
Doxycycline Hyclate (Doxycline Hyclate)
Doxycycline Calcium (Doxycycline
Calcium)
Doxycycline Monohydrate (Doxycycline
Chloride)
Doxycycline Hydrochloride (Doxycycline
HCL)
Doxycycline Monohydrate (Doxycycline
Monohydrate)
Dronabinol (Dronabinol)
Droperidol (Droperidol)
Drops: C29012 (Drops)
Drotrecogin Alfa (activated) (Drotrecogin
Alfa)
Dry Mouth Oral Agent, Not Otherwise
Specified (Dry mouth oral agent, NOS)
Deodorized Tincture Of Opium (DTO)
Duloxetine Hydrochloride (Duloxetine
HCL)
Duratec (Duratec)
Duravent Da (DuraVent/DA)
Dutasteride (Dutasteride)
Dyclonine (Dyclonine)
Echinacea <asteraceae> (Echinacea)
Econazole Nitrate (Econazole Nitrate)
Efavirenz (Efavirenz)
Eletriptan Hydrobromide (Eletriptan
Hydrobromide)
Eltrombopag (Eltrombopag)
Eutectic Mixture Of Local Anesthetics
(EMLA)
Enalapril Maleate (Enalapril Maleate)
Enalaprilat (Enalaprilat)
Enema (Enema)
Enoxaparin (Enoxaparin Sodium)
Entex (Entex)
Epinephrine (Epinephrine)
Epoetin Alfa (Epoetin Alfa)
Eptifibatide (Eptifibatide)
Ergocalciferol (Ergocalciferol)
Caffeine + Ergotamine Tartrate
(Ergotamine Tartrate/Caffeine)
Erythromycin (Erythromycin)
Erythromycin Stearate (Erythromycin
Stearate)
Escitalopram Oxalate (Escitalopram
Oxalate)
Esomeprazole Magnesium
(Esomeprazole Magnesium)
Essential Amino Acid (Essential Amino
Acids)
Estradiol (Estradiol)
Estrogen (Estrogen)
Etanercept (Etanercept)
Ethacrynic Acid (Ethacrymic Acid)
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Ethambutol Hydrochloride (Ethambutol
HCL)
Ethinyl Estradiol (Ethinyl Estradiol)
Ethinyl Estradiol/ethynodiol Diacetate
(Ethinyl Estradiol/Ethynodiol Diacetate)
Ethinyl Estradiol/levonorgestrel (Ethinyl
Estradiol/Levonorgestrel)
Ethinyl Estradiol/norethindrone (Ethinyl
Estradiol/Norethindrone)
Ethinyl Estradiol/norethindrone:
C1260235 (Ethinyl
Estradiol/Norethindrone Acetate)
Ethinyl Estradiol/norgestrel (Ethinyl
Estradiol/Norgestrel)
Etodolac (Etodolac)
Etomidate (Etomidate)
Eucerin (Eucerin)
Evening Primrose Oil (Evening Primrose
Oil)
Ex-lax (Ex-Lax)
Excedrin (Excedrin)
Exemestane (Exemestane)
Ezetimibe (Ezetimibe)
Ezetimibe/simvastatin (vytorin)
(Ezetimibe/Simvastatin)
Famciclovir (Famciclovir)
Famotidine (Famotidine)
Famotidine (Famotina)
Fat Emulsion (Fat Emulsion)
Fazarabine (Fazarabine)
Felodipine (Felodipine)
Fenofibrate (Fenofibrate)
Fentanyl (Fentanyl)
Ferrous Gluconate (Ferrous Gluconate)
Ferrous Sulfate (Ferrous Sulfate)
Fexofenadine Hydrochloride
(Fexofenadine HCL)
Fexofenadine
Hydrochloride+pseudoephedrine
Hydrochloride (Fexofenadine
HCL/Pseudoephedrine HCL)
Filgrastim (Filgrastim)
Finasteride (Finasteride)
Fioricet (Fioricet)
Fish Oil (Fish Oil)
Flavopiridol (Flavopiridol)
Flax Seed Oil (Flax Oil)
Fleets Phospho-soda (Fleets Phospho-
Soda)
Flucinolone (Flucinolone)
Fluconazole (Fluconazole)
Fludarabine (Fludarabine)
Fludrocortisone Acetate
(Fludrocortisone)
Flumethasone Pivalate 0.03% (locorten)
(Flumethasone Pivalate)
Flunisolide (Flunisolide)
Fluocinolone Acetonide (Fluocinolone
Acetonide)
Fluocinolone Acetonide 0.01% (synalar)
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(Fluocinolone Acetonide 0.01%)
Fluocinolone Acetonide 0.025% (synalar)
(Fluocinolone Acetonide 0.025%)
Fluocinonide (Fluocinonide)
Fluocinonode 0.05% (fluonex, Lidex,
Lidex-e, Lonide, Lyderm) (Fluocinonode
0.05%)
Fluorometholone (Fluorometholone)
Fluvoxamine Maleate (Fluoxamine)
Fluoxetine Hydrochloride (Fluoxetine
HCL)
Fluoxymesterone (Fluoxymesterone)
Flurandrenolide (Flurandrenolide)
Flurazepam Hydrochloride (Flurazepam)
Flurbiprofen (Flurbiprofen)
Flutamide (Flutamide)
Fluticasone Propionate (Fluticasone
Propionate)
Fluticasone Proprionate 0.005%
(cutivate) (Fluticasone Propionate
0.005%)
Fluticasone Propionate 0.05% (cutivate)
(Fluticasone Propionate 0.05%)
Fluticasone Propionate - Salmeterol
Combination (Fluticasone
Propionate/Salmeterol)
Fluvastatin Sodium (Fluvastatin Sodium)
Fluvoxamine Maleate (Fluvoxamine
Maleate)
Folic Acid (Folic Acid)
Leucovorin Calcium (Folinic Acid)
Fondaparinux (Fondaparinux)
Formoterol Fumarate (Formoterol
Fumarate)
Foscarnet Sodium (Foscarnet)
Fosinopril Sodium: C47542 (Fosinopril)
Frovatriptan Succinate (frova)
(Frovatriptan Succinate)
Fulvestrant (Fulvestrant)
Furosemide (Furosemide)
Colony Stimulating Factor 3 (G-CSF)
Gabapentin (Gabapentin)
Gamma Globulin (Gamma Globulin)
Ganciclovir (Ganciclovir)
Garcinia Cambogia Preparation
(Garcinia Cambogia)
Garlic Extract (Garlic Extract)
Gatifloxacin (Gatifloxacin)
Gelclair (Gelclair)
Gemfibrozil (Gemfibrozil)
Gentamicin (Gentamicin)
Ginkgo (Gingko)
Ginseng (Ginseng)
Glimepiride (Glimepiride)
Glipizide (Glipizide)
Glucosamine Sulfate (Glucosamine
Sulfate)
Chondroitin-glucosamine
(Glucosamine/Chondroitin)
Glutamine (Glutamine/L-Glutamine)
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Glyburide (Glyburide)
Glycerin (Glycerin)
Glycopyrrolate (Glycopyrrolate)
Glyoktyl (Glyoktyl)
Recombinant Granulocyte-macrophage
Colony-stimulating Factor (GM-CSF)
Golytely (Go LYTELY)
Goserelin (Goserelin)
Granisetron Hydrochloride (Granisetron)
Grape Seed Extract (Grape Seed
Extract)
Guaifenesin (Guaifenesin)
Guaifenesin/codeine
(Guaifenesin/Codeine)
Guaifenisin-dm (Guaifenisin-DM)
Guaifenisin/pseudoephedrine
(Guaifenisin/Pseudoephedrine)
Guanfacine (Guanfacine)
Hydrogen Peroxide (H2O2)
Halcinonide 0.1% (halog) (Halcinonide
0,1%)
Halobetasol Propionate 0.05% (ultravate)
(Halobetasol Propionate 0.05%)
Haloperidol (Haloperidol)
Heparin Sodium (Heparin Sodium)
Hepatitis A Vaccine (Hepatitis A Vaccine)
Hepatitis B Vaccine (Hepatitis B Vaccine)
Hepatitis B Vaccine (Hepatox)
Hexylresorcinol (Hexylresorcinol)
Histussin-hc (Histussin-HC)
Hydralazine Hydrochloride (Hydralazine)
Hydrochlorothiazide
(Hydrochlorothiazide)
Hydrochlorothiazide-triamterene
(Hydrochlorthiazide/Triamterene)
Hydrocodone Bitartrate (Hydrocodone)
Hydrocodone/acetaminophen
(Hydrocodone/Acetaminophen)
Therapeutic Hydrocortisone
(Hydrocortisone)
Hydrocortisone Acetate 1% (hytone)
(Hydrocortisone Acetate 1%)
Hydrocortisone Acetate 2.5% (hytone)
(Hydrocortisone Acetate 2.5%)
Hydrocortisone Butyrate 0.1% (locoid)
(Hydrocortisone Butyrate 0.1%)
Hydrocortisone Valerate 0.1% (westcort)
(Hydrocortisone Valerate 0.1%)
Hydromorphone Hydrochloride
(Hydromorphone Hydrochloride)
Hydroxychloroquine Sulfate
(Hydroxychloroquine Sulfate)
Hydroxypropyl Methylcellulose D
(Hydroxypropyl Methylcellulose D)
Hydroxyurea (Hydroxyurea)
Hydroxyzine (Hydroxyzine)
Hydroxyzine Hydrochloride (Hydroxyzine
HCL)
Hyoscyamine Sulfate (Hyoscyamine
Sulfate)
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Hypromellose (Hypromellose)
Ibuprofen (Ibuprofen)
Ibutilide Fumarate (Ibutilide)
Interleukin-1 (IL-1)
Interleukin-2 (IL-2)
Interleukin-3 (IL-3)
Interleukin-6 (IL-6)
Interleukin-12 (IL12)
Imatinib (Imatinib)
Imipenem (Imipenem)
Imipenem-cilastatin Sodium
(Imipenem/Cilastatin)
Imipramine Hydrochloride (Imipramine)
Imiquimod (Imiquimod)
Immutol (Immutol)
Indapamide (Indapamide)
Indinavir Sulfate (Indinavir)
Indomethacin (Indomethicin)
Infliximab (Infliximab)
Influenza Vaccines (Influenza Vaccine)
Inositol (Inositol)
Insulin, 70/30 (Insulin, 70/30)
Insulin Glargine Recombinant (Insulin,
Glargine)
Insulin, Lente (Insulin, Lente)
Insulin, Lispro (Insulin, Lispro)
Insulin, Nph (Insulin, NPH)
Insulin, Regular (Insulin, Regular)
Insulin, Ultralente (Insulin, Ultralente)
Interferon Alpha (Interferon Alpha)
Interferon Beta (Interferon Beta)
Interferon Gamma (Interferon Gamma)
Iodine (Iodine)
Iopamidol (Iopamidol)
Ipratropium Bromide (Ipratropium
Bromide)
Ipratropium/albuterol
(Ipratropium/Albuterol)
Irbesartan (Irbesartan)
Iron Dextran Complex (Iron Dextran)
Isoniazid (Isoniazid)
Isoproterenol Hydrochloride
(Isoproterenol Hydrochloride)
Isosorbide Dinitrate (Isosorbide Dinitrate)
13-cis Retinoic Acid (Isotretinoin)
Isradipine (Isradipine)
Itraconazole (Itraconazole)
Iv Fluid (IV Fluid)
Ivermectin (Ivermectin)
Lopinavir/ritonavir (Kaletra)
Anise Oil Misc. Oil (Kamillosan Sol)
Kava (Kava)
Ketamine Hydrochloride (Ketamine HCL)
Ketoconazole (Ketoconazole)
Ketoprofen (Ketoprofen)
Ketorolac (Ketorolac)
Ketotifen Fumarate (Ketotifen Fumarate)
Levocarnitine (L-Carnitine)
Labetalol (Labetalol)
Lacosamide (Lacosamide)
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Lactase Enzyme (Lactaid)
Lactobacillus (Lactobacillus)
Lactulose (Lactulose)
Laetrille (Laetrille)
3tc (lamivudine) (Lamivudine)
Lamotrigine (Lamotrigine)
Lansoprazole (Lansoprazole)
Latanoprost (Latanoprost)
Lecithin (Lecithin)
Letrozole (Letrozole)
Leucovorin Calcium (Leucovorin
Calcium)
Leuprolide Acetate (Leuprolide Acetate)
Levalbuterol (Levalbuterol)
Levamisole (Levamisole)
Levarterenol Bitartrate (Levarterenol
Bitartrate)
Levetiracetam (Levetiracetam)
Levobunolol Hydrochloride (Levobunolol)
Levocetirize Dihydrochloride (xyzal)
(Levocetirize Dihydrochloride)
Carbidopa / Levodopa Oral Tablet
(Levodopa/Carbidopa)
Levofloxacin (Levofloxacin)
Levothyroxine Sodium (Levothyroxine)
Librax (Librax)
Lidobenalox (Lidobenalox)
Lidocaine Hydrochloride (Lidocaine HCL)
Lidocaine Oral Solution (Lidocaine Oral
Solution)
Lidocaine Patch (Lidocaine Patch)
Lidocaine Topical (Lidocaine Topical)
Eutectic Mixture Of Local Anesthetics
(Lidocaine/Prilocaine)
Linezolid (Linezolid)
Liothyronine Sodium (Liothyronine
Sodium)
Lipid (Lipid)
Lisdexamfetamine (Lisdexamfetamine)
Lisinopril (Lisinopril)
Lithium Carbonate (Lithium Carbonate)
Lodoxamide Tromethamine (Lodoxamide
Tromethamine)
Loperamide (Loperamide)
Lopinavir (Lopinavir)
Loratadine (Loratadine)
Loratadine/pseudoephedrine
(Loratadine/Pseudoephedrine)
Lorazepam (Lorazepam)
Hydrocodone/acetaminophen (Lorcet)
Losartan Potassium (Losartan
Potassium)
Losartan/hydrochlorothiazide
(Losartan/Hydrochlorothiazide)
Lotion (Lotion)
Amlodipine Besylate/benazepril
Hydrochloride (Lotrel)
Lovastatin (Lovastatin)
Lubriderm (Lubriderm)
Lubrin (Lubrin)
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Lutein (Lutein)
Lycopene (Lycopene)
Lysine (Lysine)
Maalox (Maalox)
Magic Mouthwash (Magic Mouthwash)
Magnesium (Magnesium)
Magnesium Chloride (Magnesium
Chloride)
Magnesium Citrate (Magnesium Citrate)
Magnesium Gluconate (Magnesium
Gluconate)
Magnesium Hydroxide (Magnesium
Hydroxide)
Magnesium Oxide (Magnesium Oxide)
Magnesium Sulfate (Magnesium Sulfate)
Choline Magnesium Trisalicylate
(Magnesium Trisalicylate)
Mannitol (Mannitol)
Maxzide (Maxzide)
Meclizine Hydrochloride (Meclizine HCL)
Medactive Oral Product (MedActive)
Medroxyprogesterone
(Medroxyprogesterone)
Medroxyprogesterone 17-acetate
(Medroxyprogesterone Acetate)
Megestrol (Megestrol)
Meglumine Amidotrizoate (Meglumine
Amidotrizoate)
Melatonin (Melatonin)
Meloxicam (Meloxicam)
Meperidine Hydrochloride (Meperidine)
Mephenytoin (Mephenytoin)
Meropenem (Meropenem)
Mesalamine (Mesalamine)
Mesna (Mesna)
Psyllium (Metamucil)
Metformin Hydrochloride (Metformin
HCL)
Methadone Hydrochloride (Methadone
HCL)
Methenamine Hippurate (Methenamine)
Methimazole (Methimazole)
Methocarbamol (Methocarbamol)
Methotrexate (Methotrexate)
Methylcellulose (Methylcellulose)
Methylnaltrexone Bromide
(Methylnaltrexone Bromide)
Methylphenidate Hydrochloride
(Methylphenidate HCL)
Methylprednisolone (Methylprednisolone)
Dimethyl Sulfone (Methylsulfonyl
Methane)
Methyltestosterone (Methyltestosterone)
Metoclopramide Hydrochloride
(Metoclopramide)
Metolazone (Metolazone)
Metoprolol Succinate (Metoprolol
Succinate)
Metoprolol Tartrate (Metoprolol Tartrate)
Metronidazole (Metronidazole)
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Mexiletine Hydrochloride (Mexiletine)
Milk Thistle (Milk Thistle)
Milrinone Lactate (Milrinone Lactate)
Mineral Oil (Mineral Oil)
Minoxidil (Minoxidil)
Mirtazapine (Mirtazapine)
Misoprostol (Misoprostol)
Mitotane (Mitotane)
Mivopenim (Mivopenim)
Modafinil (Modafinil)
Mometasone Furoate 0.1% (elocon)
(Mometasone Furoate)
Montelukast Sodium (singulair)
(Montelukast Sodium)
Morphine Sulfate (Morphine Sulfate)
Multivitamin (Multivitamin)
Multivitamins/minerals
(Multivitamins/Minerals)
Mumps Vaccination (Mumps vaccination)
Mupirocin (Mupirocin)
Mycophenolate (Mycophenolate)
Mylanta (Mylanta)
Nabumetone (Nabumetone)
Nadolol (Nadolol)
Naproxen (Naproxen)
Natures Remedy Oral Tablet (Natures
Remedy Oral Tablet)
Nebivolol (Nebivolol)
Nelfinavir (Nelfinavir)
Neosporin Cream (Neosporin Cream)
Neosporin Ophthalmic (Neosporin
Ophthalmic)
Nevirapine (Nevirapine)
Niacin (Niacin)
Nicotine Patch (Nicotine Patch)
Nifedipine (Nifedipine)
Omega-3 Fatty Acid (Omega-3)
Omega-3-6-9 Fatty Acid (Omega-3-6-9)
Omega-6 Fatty Acid (Omega-6)
Omega-9 Fatty Acid (Omega-9)
Oxaliplatin (Oxaliplatin)
Pimecrolimus (elidel Cream)
(Pimecrolimus)
Pramocaine (Pramoxine)
Prasugrel (Prasugrel)
Rasburicase (Rasburicase)
Romiplostim (Romiplostim)
Sevelamer (Sevelamer)
Sevelamer Carbonate (Sevelamer
Carbonate)
Sirolimus (Sirolimus)
Stemenhance (StemEnhance)
Stemflo (Stemflo)
Tacrolimus (prograf, Protopic Ointment,
Advagraf) (Tacrolimus)
Tigecycline (Tigecycline)
Tranexamic Acid (Tranexamic Acid)
Triamcinolone Acetonide 0.025%
(kenalog) (Triamcinolone Acetonide
0.025%)
16 / 26
Follow-Up - Concomitant Measures/Medications - 3273516v1.0
Triamcinolone Acetonide 0.1% (aristocort
A, Aristocort, Kenalog) (Triamcinolone
Acetonide 0.1%)
Trichloracetic Acid (tca) (Trichloracetic
Acid)
Trifluridine (Trifluridine)
Vardenafil (Vardenafil)
Vasopressin (Vasopressin)
Venlafaxine (Venlafaxine HCL)
Verapamil (Verapamil)
Vitamin B Complex (Vitamin B Complex)
Vitamin D (Vitamin D)
Voriconazole (Voriconazole)
Warfarin (Warfarin)
Xenaderm (Xenaderm)
Zaleplon (Zaleplon)
Zidovudine (Zidovudine)
Zinc (Zinc)
Zinc Oxide (Zinc Oxide)
Zinc Sulfate (Zinc Sulfate)
Zinc Undecylenate (Zinc Undecylenate)
Zoledronate (Zoledronate)
Zolmitriptan (Zolmitriptan)
Zolpidem Tartrate (Zolpidem Tartrate)
Procedure/Measure (Note: Do not select a
procedure if an agent name has been entered.)
Complementary And Alternative
Medicine (Alternative Therapy)
Pheresis (Apheresis)
Arterial Access Port Removed (Arterial
Access Port Removal)
Contraception (Birth Control)
Bronchoalveolar Lavage
(Bronchoscopy/Bronch Lavage)
Cauterization (Cauterization)
Dental Procedure (Dental Procedure)
Direct Current Cardioversion (Direct
Current Cardioversion (DCCV))
Ear Tube Placement (Ear Tube(s)
Insertion)
Oesophageal Dilation Procedure
(Esophageal Dilation)
Partial Colectomy (Hemicolectomy)
Hemodialysis (Hemodialysis)
Whole Body Hyperbaric Oxygen Therapy
(Hyperbaric Treatment(s))
Intraaortic Balloon Pump/stent
Placement (IABP/Stent Placement)
Incision And Drainage (Incision &
Drainage)
Intraventricular Shunt Access
(Intraventricular Shunt Access)
Irrigation - Action (Irrigation)
Lymphocyte Infusion (Lymphocyte
Infusion)
Ventilation, Mechanical (Mechanical
Ventilation)
Tubes, Gastrointestinal Decompression
(NG Decompression)
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Masks, Air-oxygen, Aerosol
Administration (Oxygen Administration)
Paracentesis (Paracentesis)
Pleurodesis (Pleurodesis)
Partial Airway Pressure Treatment
(includes Bipap And Cpap) (Positive
Partial Airway Pressure Treatment)
Radiation (Radiation)
Stent/catheter Change (Stent/Catheter
Change)
Catheterization (Stent/Catheter
Placement)
Removal Of Stent (Stent/Catheter
Removal)
Surgical Procedure (Surgical Procedure)
Thoracentesis (Thoracentesis)
Platelet Transfusion (Transfusion,
Platelet)
Packed Red Blood Cell Transfusion
(Transfusion, RBC)
Venous Access Device Placement
(Venous Access/IV Placement)
Venous Access Device Removal (Venous
Access/IV Removal)
Total Daily Dose (Enter the total daily dose of the
agent as appropriate. In the case of combinations
such as Bactrim, enter the total number of
combination tablets taken daily. -  - Note: If a
procedure/measure, leave blank.)
UOM (Select the total daily dose units of
measurement. - Note: If a procedure/measure,
leave blank.)
Percent (%)
10e10 Cells (10E10 Cells)
10e3 Cells (10E3 Cells)
10e4 Cells Per Kilogram (10E4 Cell/kg)
10e4 Cells (10E4 Cells)
10e5 Cells Per Kilogram (10E5 Cell/kg)
10e5 Cells (10E5 Cells)
10e6 Cells Per Kilogram (10E6 Cell/kg)
10e6 Cells (10E6 Cells)
10e7 Cells Per Kilogram (10E7 Cell/kg)
10e7 Cells (10E7 Cells)
10e7 Plaque Forming Units (10E7 PFU)
10e8 Cells (10E8 Cells)
10e8 Plaque Forming Units (10E8 PFU)
10e9 Cells (10E9 Cells)
10e9 Plaque Forming Units (10E9 PFU)
Ampule (Ampule)
Application (Applcatn)
Atomic Unit (au)
Area Under The Curve (AUC)
Billion Pfu (bill PFU)
Bottle (Bottle)
Breaths Per Minute (BPM)
Capful (Capful)
Caplet (Caplet)
Capsule (Capsule)
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Cells (Cells)
Cells Per Kilogram (Cells/kg)
Centigray (cGy)
Curie (Ci)
Cycle (Course)
Course (Course)
Deciliter (dL)
Dose (Dose)
Equivalent (Eq)
Grams (g) (g)
Gram Per M2 (g/m2)
Gallon (Gallon)
Drops (gtts)
Gray (Gy)
Hertz (Hz)
Inch (Inch)
Inhalation (Inhalatn)
Iu Vitamin A (IU Vit A)
International Unit Per Milligram (IU/mg)
International Units Or Milligram Alpha
Tocopherol (IU/mg A-TE)
International Unit (IUnit)
International Unit Per Kilogram (IUnit/kg)
International Unit Per Liter (IUnit/L)
Intravenous Bag (IV Bag)
Infectious Viral Replicon Particles (IVRP)
Joules Per Centimeter Squared (Jcm2)
Kib-electron Volt (KeV)
Kilograms (kg)
Kilohertz (kHz)
Kilopascal (kPa)
Kilounit (kU)
Kilounit Per Kilogram (kU/kg)
Kilounit Per Liter (kU/L)
Liter (L)
Liters Per Minute (L/min)
Megabecquerel (MBq)
Millibecquerel (mBq)
Microgram (mcg)
Microgram Per Centimeter Squared
(mcg/cm2)
Microgram Per Hour (mcg/hr)
Microgram Per Kilogram (mcg/kg)
Microgram Per Meter Squared (mcg/m2)
Millicurie (mCi)
Measure (Measure)
Milliequivalent (mEq)
Milliequivalents Per 24 Hours (mEq/24hr)
Milliequivalent Per Deciliter (mEq/dL)
Milliequivalent Per Hour (mEq/hr)
Milliequivalent Per Liter (mEq/L)
Million Electron Volt (MeV)
Milligram (mg)
Milligram Per 24 Hours (mg/24hr)
Milligram Per Deciliter (mg/dL)
Milligram Per Hour (mg/hr)
Milligram Per Inhalation (mg/inh)
Milligram Per Kilogram (mg/kg)
Milligram Per Kilogram Per Day
(mg/kg/day)
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Milligram Per Meter Squared (mg/m2)
Milligram Per Milliliter (mg/mL)
Milligram Per Week (mg/wk)
Megahertz (MHz)
Microcurie (microCi)
Microliter (microL)
Micromole (micromol)
Million Plaque Forming Units (mill PFU)
Million (Million)
Milliunit (millunit)
Milliinternational Unit (miu)
Milliinternational Units Per Meter
Squared (miu/m2)
Milliliter (mL)
Cubic Centimeter (cc) (mL)
Milliliter Per Hour (mL/hr)
Milliliter Per Kilogram (mL/kg)
Millimoles Per Liter (mM/L)
Millimole (mmol)
Mole (Mole)
Milliosmole (mosmol)
Megarad (Mrad)
Million Units (MU)
Millivolt (mV)
Million Viral Particles (MVP)
Nanocurie (nCi)
Nanogram (ng)
Nanogram Per Kilogram (ng/kg)
Nanogram Per Liter (ng/L)
Nanograms Per Milliliter (ng/mL)
Nanometer Of Light (nm light)
Nanomole (nmol)
No Source Data (No Srce)
Osmolality (osmol)
Ounce (oz)
Pascal (Pa)
Packet (packet)
Patch (Patch)
Plaque Forming Units (PFU)
Picograms (pg)
Pounds Per Square Inch (psi)
Puff (puff)
Radiation Absorbed Dose (Rad)
Vitamin A Retinol (RAE)
Retinol Equivalents (RE)
Seed (Seed)
Session (Session)
Spray (Spray)
Suppository (Suppstry)
Tablets (Tablet)
Tablespoon (Tbsp)
Tissue Culture Infection Dose (TCID)
Thousand (Thousand)
Troche (Troche)
Teaspoon (tsp)
Unit (Unit)
Unit Per Gram (Unit/g)
Unit Per Kilogram (Unit/kg)
Unit Per Meter Squared (Unit/m2)
Unit Per Milliliter (Unit/mL)
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Unknown (Unknown)
Viral Particles (VP)
Yeast Units (YU)
Schedule (Select the frequency of medication
administration or measure under schedule.)
Route (Select the route given:)
Continuous Intravenous Infusion (CIV)
Endotracheal Route Of Administration
(ENDOTR)
Gastrostomy Tube (G Tube)
Intra-arterial (IA)
Intradermal (ID)
Intrahepatic (IH)
Intrahepatic Infusion (IHI)
Intramuscular (IM)
Inhalation (Inhalatn)
Interstitial Route Of Administration
(Interstl)
Intraventricular Route Of Administration
(Intraventricular)
Intravesical (Intravesical)
Intratumoral (INTUM)
Intraperitoneal (IP)
Intrathecal (IT)
Intravenous Bolus (IV)
Intravenous Infusion (IVI)
Nasal (NASAL)
Nasogastric (NG)
Ophthalmic, Each Eye (Oph Each)
Ophthalmic, Left Eye (Oph Left)
Ophthalmic, Right Eye (Oph Rt)
Auricular Route Of Administration (Otic)
Oral (PO)
Rectal (PR)
Radiation (RT)
Subcutaneous (SC)
Sublingual (Sublingual)
Swish & Spit (SWSP)
Swish & Swallow (SWSW)
Topical (TOP)
Transdermal (Transdermal)
Transmucosal Route (Transmucosal)
Unknown Route Of Administration
(Unknown)
Vaginal Route (Vaginal)
Reason (Select the reason the medication is
being administered or why measure done. For
example, if Bactrim is being given as a
prophylactic, select "pneumocystis prophylaxis".)
Accelerate Hematopoietic Recovery
(Accelerate Hematopoietic Recovery)
Acidity (Acidity)
Adrenal Suppression (Adrenal
Suppression)
Hypersensitivity (Allergic Reaction)
Allergy (Allergy)
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Alopecia (Alopecia)
Anemia (Anemia)
Anesthetic Agent (Anesthesia)
Angina (Anti-angina)
Anticoagulation (Anticoagulation)
Antipsychotic (Antipsychotic)
Anxiety (Anxiety)
Pheresis (Apheresis)
Appetite (Appetite)
Arrhythmia (Arrhythmia)
Arthralgia (Arthralgia)
Arthritis (Arthritis)
Ascites (Ascites)
Asthma (Asthma)
Attention Deficit Disorder (Attention
Deficit Disorder)
Benign Prostatic Hyperplasia (Benign
Prostatic Hyperplasia)
Bipolar Disorder (Bipolar Disorder)
Contraception (Birth Control)
Blepharitis (Blepharitis (Eyelid
Inflammation))
Bloating (Bloating)
Bony Disease (Bony Disease)
Bronchitis (Bronchitis)
Bronchospasm (Bronchospasm)
Bursitis (Bursitis)
Cardiac (Cardiac)
Cellulitis (Cellulitis)
Chronic Obstructive Pulmonary Disease
(Chronic Obstructive Pulmonary Disease
(COPD))
Cytomegalovirus Therapy (CMV
Therapy)
Central Nervous System Disease Or
Disorder (CNS Disease)
Complicating Disease Or Condition
(Complicating Disease or Condition)
Congestion (Congestion)
Conjunctivitis (Conjunctivitis)
Constipation (Constipation)
Contrast Agent Image Study (Contrast
Study)
Cough (Cough)
Dehydration (Dehydration)
Depression (Depression)
Dermatitis (Dermatitis)
Diabetes Mellitus (Diabetes)
Diarrhea (Diarrhea)
Dryness Skin (Dry Skin)
Dyspepsia (Dyspepsia)
Dysphagia (Dysphagia)
Dyspnea (Dyspnea)
Dysuria (Dysuria)
Earache (Earache)
Edema (Edema)
Electrolyte Imbalance (Electrolyte
Imbalance)
Empirical Coverage (Empirical
Coverage)
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Engraftment (Engraftment)
Epiphora (watery Eyes) (Epiphora
(Watery Eyes))
Epistaxis (Epistaxis)
Impotence (Erectile Dysfunction)
Erythema (Erythema)
Esophagitis (Esophagitis)
Extrapyramidal Symptoms
(Extrapyramidal)
Eye Redness (Eye Redness)
Fatigue (Fatigue)
Fever (Fever)
Fever Leukocyte (Fever w/Low WBC)
Flatulence (Flatulence)
Influenza Symptom (Flu Symptoms)
Fluid Overload (Fluid Overload)
Fluid Retention (Fluid Retention)
Gastric Ulcer (Gastric Ulcer)
Gastritis (Gastritis)
Gastroesophageal Reflux Disease
(Gastroesophageal Reflux Disease)
Gastrointestinal Distress
(Gastrointestinal distress)
Gastrointestinal Decontamination (GI
Decontamination)
Glaucoma (Glaucoma)
Gout (Gout)
Granulocytopenia (Granulocytopenia)
Graft Versus Host Disease Preventive
Intervention (GVHD Prophylaxis)
Graft Versus Host Disease Therapy
(GVHD Therapy)
Palmar-plantar Erythodysthesia (Hand
Foot Syndrome (HFS))
Headache (Headache)
Hemolytic Uremic Syndrome Symptoms
(Hemolytic Urem Syndrome)
Hemorrhage (Hemorrhage)
Hemorrhoid (Hemorrhoids)
Heparin Reversal (Heparin Reversal)
Laboratory Hepatic Abnormality (Hepatic
Lab abnormality)
Hiatal Hernia (Hiatal hernia)
Hiccough (Hiccoughs)
Human Immunodeficiency Virus (HIV)
Hormonal Manipulation (Hormonal
Manipulation)
Hot Flashes (Hot Flashes)
Hypercalcemia (Hypercalcemia)
Hypercholesterolemia
(Hypercholesterolemia)
Hyperglycemia (Hyperglycemia)
Hyperkalemia (Hyperkalemia)
Hyperlipidemia (Hyperlipidemia)
Hyperparathyroidism
(Hyperparathyroidism)
Hypertension (Hypertension)
Hyperthyroidism (Hyperthyroidism)
Hyperuricemia (Hyperuricemia)
Hypoalbuminemia (Hypoalbuminemia)
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Hypocalcemia (Hypocalcemia)
Hypokalemia (Hypokalemia)
Hypomagnesemia (Hypomagnesemia)
Hypophosphatemia (Hypophosphatemia)
Hypotension (Hypotension)
Hypothyroidism (Hypothyroidism)
Hypoxia (Hypoxia)
Immunosuppression
(Immunosuppression)
Indigestion (Indigestion)
Sedation (Induce Sedation)
Infection And Infestation (Infection)
Inflammation (Inflammation)
Injection Site Reaction (Injection Site
Reaction)
Insomnia (Insomnia)
Itching Sensation (Itching)
Dry Eyes (Keratitis sicca (Dry Eyes))
Lactose Intolerance (Lactose
Intolerance)
Leg Cramps (Leg cramps)
Line Occlusion (Line Occlusion)
Line Patency (Line Patency)
Local Anesthesia (Local Anesthesia)
Macular Degeneration (Macular
degeneration)
Malignant Neoplasm (Malignancy)
Malignant Hyperthermia (Malignant
Hyperthermia)
Natural Menopause (Menopausal
symptoms)
Metabolic Imbalance (Metabolic
Imbalance)
Mood (Mood)
Mouth Sores (Mouth Sores)
Mucositis (Mucositis)
Muscle Spasm (Muscle Spasm)
Myalgia (Myalgia)
Myasthenia Gravis (Myasthenia Gravis)
Nail Changes (Nail Changes)
Narcolepsy (Narcolepsy)
Nasal Symptom (Nasal Symptom)
Nausea (Nausea)
Nausea And Vomiting (Nausea and
vomiting)
Neuropathy (Neuropathy)
Neutropenia (Neutropenia)
Nutrition (Nutrition)
Osteoporosis (Osteoporosis)
Pain (Pain)
Palliative Therapy (Palliation)
Pancreatic Insufficiency (Pancreatic
insufficiency)
Parkinson's Disease (Parkinson's
Disease)
Partial Thromboplastin Time (ptt)
Prolongation (Partial Thromboplastin
Time (PTT) Prolongation)
Periodontal Disease (Periodontal
Disease)
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Petechia (Petechiae)
Pharyngitis (Pharyngitis)
Phlebitis (Phlebitis)
Pleural Effusion (Pleural Effusion)
Pneumonia (Pneumonitis)
Occlusion Within Medical Device (Port
Occlusion)
Post Traumatic Stress Disorder (Post
Traumatic Stress Disorder)
After Treatment Completion
(PostTreatment)
Before Chemotherapy
(Prechemotherapy)
Before A Procedure Or Diagnostic
Testing (Preprocedure/Diagnostic
Testing)
Before Treatment (PreTreatment)
Preventive Intervention (Prophylaxis)
Pruritus (Pruritus)
Pseudogout (Pseudogout)
Psoriasis (Psoriasis)
Pulmonary Embolus (Pulmonary
Embolus)
Skin Rash (Rash)
Rectal Bleeding (Rectal Bleeding)
Reflux (Reflux)
Renal Urinary (Renal/Urinary)
Replacement (Replacement)
Respiratory Distress Dyspnea
(Respiratory Distress/Dyspnea)
Restless Leg Syndrome (Restless Leg
Syndrome)
Restlessness (Restlessness)
Rhinorrhea (Rhinorrhea)
Rigors And Shaking (Rigors)
Scabies (Scabies)
Seizure (Seizures)
Sinusitis (Sinusitis)
Skin Irritation (Skin Irritation)
Sleep (Sleep)
Sleep Apnea (Sleep Apnea)
Smoking Cessation (Smoking Cessation)
Stomach Cramps (Stomach Cramps)
Stomatitis (Stomatitis)
Supplement (Supplement)
Thrombocytopenia (Thrombocytopenia)
Blood Clot (Thrombus)
Oral Candidiasis (Thrush)
Tremors (Tremors)
Urinary Urinary (Urinary)
Urticaria (Urticaria)
Dryness Of The Vagina (Vaginal
Dryness)
Vascular Access (Vascular Access)
Vasodilitation (flush) (Vasodilitation
(Flush))
Venous Thrombosis (Venous
Thrombosis)
Vertigo (Vertigo)
Vitamin (Vitamins)
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Vomiting (Vomiting)
Weight Gain (Weight Gain)
Weight Loss (Weight Loss)
Wheezing (Wheezing)
Xerosis (Xerosis)
Dry Mouth (Xerostomia)
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Follow-Up - Adverse Events - 3271596v1.0
All rights reserved. Please visit https://medical-data-
models.org/forms/1657
Adverse Events
Adverse Events
Visit Date
Course #
Day in Course (Cycle)
Prior Course (Cycle) AE? (For an adverse event
that begins on the first day of the course PRIOR
to any study medications being given, select "Y".
- For an adverse event that begins on the first day
of the course AFTER study medications have
been given, select "N".)
No (No)
Yes (Yes)
Date of Onset
Date Resolved (Leave this field as well as the
Outcome field blank if the adverse event is
ongoing.)
CTCAE Term (Using the pick list to select a
CTCAE Common Terminology Criteria for
Adverse Events Term. -  - In the absence of a
specific adverse event term, choose the "Other"
term from the appropriate general category and
be sure a meaningful adverse event description is
entered in the "adverse event description" field.)
Abdominal Distension (Abdominal
distension)
Abdominal Infection (Abdominal
infection)
Abdominal Pain (Abdominal pain)
Abdominal Soft Tissue Necrosis
(Abdominal soft tissue necrosis)
Abducens Nerve Disorder (Abducens
nerve disorder)
Accessory Nerve Disorder (Accessory
nerve disorder)
Acidosis (Acidosis)
Acoustic Nerve Disorder Nos (Acoustic
nerve disorder NOS)
Activated Partial Thromboplastin Time
Prolonged (Activated partial
thromboplastin time prolonged)
Acute Coronary Syndrome (Acute
coronary syndrome)
Acute Kidney Injury (Acute kidney injury)
Adrenal Insufficiency (Adrenal
insufficiency)
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Adult Respiratory Distress Syndrome
(Adult respiratory distress syndrome)
Agitation (Agitation)
Akathisia (Akathisia)
Alanine Aminotransferase Increased
(Alanine aminotransferase increased)
Alcohol Intolerance (Alcohol intolerance)
Alkaline Phosphatase Increased
(Alkaline phosphatase increased)
Alkalosis (Alkalosis)
Allergic Reaction (Allergic reaction)
Allergic Rhinitis (Allergic rhinitis)
Alopecia (Alopecia)
Amnesia (Amnesia)
Anal Fistula (Anal fistula)
Anal Hemorrhage (Anal hemorrhage)
Anal Mucositis (Anal mucositis)
Anal Necrosis (Anal necrosis)
Anal Pain (Anal pain)
Anal Stenosis (Anal stenosis)
Anal Ulcer (Anal ulcer)
Anaphylaxis (Anaphylaxis)
Anemia (Anemia)
Ankle Fracture (Ankle fracture)
Anorectal Infection (Anorectal infection)
Anorexia (Anorexia)
Anorgasmia (Anorgasmia)
Anxiety (Anxiety)
Aortic Injury (Aortic injury)
Aortic Valve Disease (Aortic valve
disease)
Aphonia (Aphonia)
Apnea (Apnea)
Appendicitis (Appendicitis)
Appendicitis Perforated (Appendicitis
perforated)
Arachnoiditis (Arachnoiditis)
Arterial Injury (Arterial injury)
Arteritis Infective (Arteritis infective)
Arthralgia (Arthralgia)
Arthritis (Arthritis)
Ascites (Ascites)
Aspartate Aminotransferase Increased
(Aspartate aminotransferase increased)
Aspiration (Aspiration)
Asystole (Asystole)
Ataxia (Ataxia)
Atelectasis (Atelectasis)
Atrial Fibrillation (Atrial fibrillation)
Atrial Flutter (Atrial flutter)
Atrioventricular Block Complete
(Atrioventricular block complete)
Atrioventricular Block First Degree
(Atrioventricular block first degree)
Autoimmune Disorder (Autoimmune
disorder)
Avascular Necrosis (Avascular necrosis)
Azoospermia (Azoospermia)
Back Pain (Back pain)
Bile Duct Stenosis (Bile duct stenosis)
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Biliary Anastomotic Leak (Biliary
anastomotic leak)
Biliary Fistula (Biliary fistula)
Biliary Tract Infection (Biliary tract
infection)
Bladder Anastomotic Leak (Bladder
anastomotic leak)
Bladder Infection (Bladder infection)
Bladder Perforation (Bladder perforation)
Bladder Spasm (Bladder spasm)
Bloating (Bloating)
Blood And Lymphatic System Disorders -
Other, Specify (Blood and lymphatic
system disorders - Other, Specify)
Blood Antidiuretic Hormone Abnormal
(Blood antidiuretic hormone abnormal)
Blood Bilirubin Increased (Blood bilirubin
increased)
Blood Corticotrophin Decreased (Blood
corticotrophin decreased)
Blood Gonadotrophin Abnormal (Blood
gonadotrophin abnormal)
Blood Prolactin Abnormal (Blood
prolactin abnormal)
Blurred Vision (Blurred vision)
Body Odor (Body odor)
Bone Infection (Bone infection)
Bone Marrow Hypocellular (Bone
marrow hypocellular)
Bone Pain (Bone pain)
Brachial Plexopathy (Brachial
plexopathy)
Breast Atrophy (Breast atrophy)
Breast Infection (Breast infection)
Breast Pain (Breast pain)
Bronchial Fistula (Bronchial fistula)
Bronchial Infection (Bronchial infection)
Bronchial Obstruction (Bronchial
obstruction)
Bronchial Stricture (Bronchial stricture)
Bronchopleural Fistula (Bronchopleural
fistula)
Bronchopulmonary Hemorrhage
(Bronchopulmonary hemorrhage)
Bronchospasm (Bronchospasm)
Bruising (Bruising)
Bullous Dermatitis (Bullous dermatitis)
Burn (Burn)
Buttock Pain (Buttock pain)
Capillary Leak Syndrome (Capillary leak
syndrome)
Carbon Monoxide Diffusing Capacity
Decreased (Carbon monoxide diffusing
capacity decreased)
Cardiac Arrest (Cardiac arrest)
Cardiac Disorders - Other, Specify
(Cardiac disorders - Other, Specify)
Cardiac Troponin I Increased (Cardiac
troponin I increased)
Cardiac Troponin T Increased (Cardiac
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troponin T increased)
Cataract (Cataract)
Catheter Related Infection (Catheter
related infection)
Cd4 Lymphocytes Decreased (CD4
lymphocytes decreased)
Cecal Hemorrhage (Cecal hemorrhage)
Cecal Infection (Cecal infection)
Central Nervous System Necrosis
(Central nervous system necrosis)
Cerebrospinal Fluid Leakage
(Cerebrospinal fluid leakage)
Cervicitis Infection (Cervicitis infection)
Cheilitis (Cheilitis)
Chest Pain - Cardiac (Chest pain -
cardiac)
Chest Wall Pain (Chest wall pain)
Chills (Chills)
Cholecystitis (Cholecystitis)
Cholesterol High (Cholesterol high)
Chronic Kidney Disease (Chronic kidney
disease)
Chylothorax (Chylothorax)
Cognitive Disturbance (Cognitive
disturbance)
Colitis (Colitis)
Colonic Fistula (Colonic fistula)
Colonic Hemorrhage (Colonic
hemorrhage)
Colonic Obstruction (Colonic obstruction)
Colonic Perforation (Colonic perforation)
Colonic Stenosis (Colonic stenosis)
Colonic Ulcer (Colonic ulcer)
Concentration Impairment
(Concentration impairment)
Conduction Disorder (Conduction
disorder)
Confusion (Confusion)
Congenital, Familial And Genetic
Disorders - Other, Specify (Congenital,
familial and genetic disorders - Other,
Specify)
Conjunctivitis (Conjunctivitis)
Conjunctivitis Infective (Conjunctivitis
infective)
Constipation (Constipation)
Constrictive Pericarditis (Constrictive
pericarditis)
Corneal Infection (Corneal infection)
Corneal Ulcer (Corneal ulcer)
Cough (Cough)
Cpk Increased (CPK increased)
Cranial Nerve Infection (Cranial nerve
infection)
Creatinine Increased (Creatinine
increased)
Cushingoid (Cushingoid)
Cystitis Noninfective (Cystitis
noninfective)
Cytokine Release Syndrome (Cytokine
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release syndrome)
Death Neonatal (Death neonatal)
Death Nos (Death NOS)
Dehydration (Dehydration)
Delayed Orgasm (Delayed orgasm)
Delayed Puberty (Delayed puberty)
Delirium (Delirium)
Delusions (Delusions)
Dental Caries (Dental caries)
Depressed Level Of Consciousness
(Depressed level of consciousness)
Depression (Depression)
Dermatitis Radiation (Dermatitis
radiation)
Device Related Infection (Device related
infection)
Diarrhea (Diarrhea)
Disseminated Intravascular Coagulation
(Disseminated intravascular coagulation)
Dizziness (Dizziness)
Dry Eye (Dry eye)
Dry Mouth (Dry mouth)
Dry Skin (Dry skin)
Duodenal Fistula (Duodenal fistula)
Duodenal Hemorrhage (Duodenal
hemorrhage)
Duodenal Infection (Duodenal infection)
Duodenal Obstruction (Duodenal
obstruction)
Duodenal Perforation (Duodenal
perforation)
Duodenal Stenosis (Duodenal stenosis)
Duodenal Ulcer (Duodenal ulcer)
Dysarthria (Dysarthria)
Dysesthesia (Dysesthesia)
Dysgeusia (Dysgeusia)
Dysmenorrhea (Dysmenorrhea)
Dyspareunia (Dyspareunia)
Dyspepsia (Dyspepsia)
Dysphagia (Dysphagia)
Dysphasia (Dysphasia)
Dyspnea (Dyspnea)
Ear And Labyrinth Disorders - Other,
Specify (Ear and labyrinth disorders -
Other, Specify)
Ear Pain (Ear pain)
Edema Cerebral (Edema cerebral)
Edema Face (Edema face)
Edema Limbs (Edema limbs)
Edema Trunk (Edema trunk)
Ejaculation Disorder (Ejaculation
disorder)
Ejection Fraction Decreased (Ejection
fraction decreased)
Electrocardiogram Qt Corrected Interval
Prolonged (Electrocardiogram QT
corrected interval prolonged)
Encephalitis Infection (Encephalitis
infection)
Encephalomyelitis Infection
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(Encephalomyelitis infection)
Encephalopathy (Encephalopathy)
Endocarditis Infective (Endocarditis
infective)
Endocrine Disorders - Other, Specify
(Endocrine disorders - Other, Specify)
Endophthalmitis (Endophthalmitis)
Enterocolitis (Enterocolitis)
Enterocolitis Infectious (Enterocolitis
infectious)
Enterovesical Fistula (Enterovesical
fistula)
Epistaxis (Epistaxis)
Erectile Dysfunction (Erectile
dysfunction)
Erythema Multiforme (Erythema
multiforme)
Erythroderma (Erythroderma)
Esophageal Anastomotic Leak
(Esophageal anastomotic leak)
Esophageal Fistula (Esophageal fistula)
Esophageal Hemorrhage (Esophageal
hemorrhage)
Esophageal Infection (Esophageal
infection)
Esophageal Necrosis (Esophageal
necrosis)
Esophageal Obstruction (Esophageal
obstruction)
Esophageal Pain (Esophageal pain)
Esophageal Perforation (Esophageal
perforation)
Esophageal Stenosis (Esophageal
stenosis)
Esophageal Ulcer (Esophageal ulcer)
Esophageal Varices Hemorrhage
(Esophageal varices hemorrhage)
Esophagitis (Esophagitis)
Euphoria (Euphoria)
Exostosis (Exostosis)
External Ear Inflammation (External ear
inflammation)
External Ear Pain (External ear pain)
Extraocular Muscle Paresis (Extraocular
muscle paresis)
Extrapyramidal Disorder (Extrapyramidal
disorder)
Eye Disorders - Other, Specify (Eye
disorders - Other, Specify)
Eye Infection (Eye infection)
Eye Pain (Eye pain)
Eyelid Function Disorder (Eyelid function
disorder)
Facial Muscle Weakness (Facial muscle
weakness)
Facial Nerve Disorder (Facial nerve
disorder)
Facial Pain (Facial pain)
Fall (Fall)
Fallopian Tube Anastomotic Leak
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(Fallopian tube anastomotic leak)
Fallopian Tube Obstruction (Fallopian
tube obstruction)
Fallopian Tube Perforation (Fallopian
tube perforation)
Fallopian Tube Stenosis (Fallopian tube
stenosis)
Fat Atrophy (Fat atrophy)
Fatigue (Fatigue)
Febrile Neutropenia (Febrile
neutropenia)
Fecal Incontinence (Fecal incontinence)
Female Genital Tract Fistula (Female
genital tract fistula)
Feminization Acquired (Feminization
acquired)
Fetal Death (Fetal death)
Fetal Growth Retardation (Fetal growth
retardation)
Fever (Fever)
Fibrinogen Decreased (Fibrinogen
decreased)
Fibrosis Deep Connective Tissue
(Fibrosis deep connective tissue)
Flank Pain (Flank pain)
Flashing Lights (Flashing lights)
Flatulence (Flatulence)
Floaters (Floaters)
Flu Like Symptoms (Flu like symptoms)
Flushing (Flushing)
Forced Expiratory Volume Decreased
(Forced expiratory volume decreased)
Fracture (Fracture)
Gait Disturbance (Gait disturbance)
Gallbladder Fistula (Gallbladder fistula)
Gallbladder Infection (Gallbladder
infection)
Gallbladder Necrosis (Gallbladder
necrosis)
Gallbladder Obstruction (Gallbladder
obstruction)
Gallbladder Pain (Gallbladder pain)
Gallbladder Perforation (Gallbladder
perforation)
Gastric Anastomotic Leak (Gastric
anastomotic leak)
Gastric Fistula (Gastric fistula)
Gastric Hemorrhage (Gastric
hemorrhage)
Gastric Necrosis (Gastric necrosis)
Gastric Perforation (Gastric perforation)
Gastric Stenosis (Gastric stenosis)
Gastric Ulcer (Gastric ulcer)
Gastritis (Gastritis)
Gastroesophageal Reflux Disease
(Gastroesophageal reflux disease)
Gastrointestinal Anastomotic Leak
(Gastrointestinal anastomotic leak)
Gastrointestinal Disorders - Other,
Specify (Gastrointestinal disorders -
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Other, Specify)
Gastrointestinal Fistula (Gastrointestinal
fistula)
Gastrointestinal Pain (Gastrointestinal
pain)
Gastrointestinal Stoma Necrosis
(Gastrointestinal stoma necrosis)
Gastroparesis (Gastroparesis)
General Disorders And Administration
Site Conditions - Other, Specify (General
disorders and administration site
conditions - Other, Specify)
Generalized Muscle Weakness
(Generalized muscle weakness)
Genital Edema (Genital edema)
Ggt Increased (GGT increased)
Gingival Pain (Gingival pain)
Glaucoma (Glaucoma)
Glossopharyngeal Nerve Disorder
(Glossopharyngeal nerve disorder)
Glucose Intolerance (Glucose
intolerance)
Growth Accelerated (Growth
accelerated)
Growth Hormone Abnormal (Growth
hormone abnormal)
Growth Suppression (Growth
suppression)
Gum Infection (Gum infection)
Gynecomastia (Gynecomastia)
Hallucinations (Hallucinations)
Haptoglobin Decreased (Haptoglobin
decreased)
Head Soft Tissue Necrosis (Head soft
tissue necrosis)
Headache (Headache)
Hearing Impaired (Hearing impaired)
Heart Failure (Heart failure)
Hematoma (Hematoma)
Hematosalpinx (Hematosalpinx)
Hematuria (Hematuria)
Hemoglobin Increased (Hemoglobin
increased)
Hemoglobinuria (Hemoglobinuria)
Hemolysis (Hemolysis)
Hemolytic Uremic Syndrome (Hemolytic
uremic syndrome)
Hemorrhoidal Hemorrhage
(Hemorrhoidal hemorrhage)
Hemorrhoids (Hemorrhoids)
Hepatic Failure (Hepatic failure)
Hepatic Hemorrhage (Hepatic
hemorrhage)
Hepatic Infection (Hepatic infection)
Hepatic Necrosis (Hepatic necrosis)
Hepatic Pain (Hepatic pain)
Hepatitis Viral (Hepatitis viral)
Hepatobiliary Disorders - Other, Specify
(Hepatobiliary disorders - Other, Specify)
Hiccups (Hiccups)
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Hip Fracture (Hip fracture)
Hirsutism (Hirsutism)
Hoarseness (Hoarseness)
Hot Flashes (Hot flashes)
Hydrocephalus (Hydrocephalus)
Hypercalcemia (Hypercalcemia)
Hyperglycemia (Hyperglycemia)
Hyperhidrosis (Hyperhidrosis)
Hyperkalemia (Hyperkalemia)
Hypermagnesemia (Hypermagnesemia)
Hypernatremia (Hypernatremia)
Hyperparathyroidism
(Hyperparathyroidism)
Hypersomnia (Hypersomnia)
Hypertension (Hypertension)
Hyperthyroidism (Hyperthyroidism)
Hypertrichosis (Hypertrichosis)
Hypertriglyceridemia
(Hypertriglyceridemia)
Hyperuricemia (Hyperuricemia)
Hypoalbuminemia (Hypoalbuminemia)
Hypocalcemia (Hypocalcemia)
Hypoglossal Nerve Disorder
(Hypoglossal nerve disorder)
Hypoglycemia (Hypoglycemia)
Hypohidrosis (Hypohidrosis)
Hypokalemia (Hypokalemia)
Hypomagnesemia (Hypomagnesemia)
Hyponatremia (Hyponatremia)
Hypoparathyroidism
(Hypoparathyroidism)
Hypophosphatemia (Hypophosphatemia)
Hypotension (Hypotension)
Hypothermia (Hypothermia)
Hypothyroidism (Hypothyroidism)
Hypoxia (Hypoxia)
Ileal Fistula (Ileal fistula)
Ileal Hemorrhage (Ileal hemorrhage)
Ileal Obstruction (Ileal obstruction)
Ileal Perforation (Ileal perforation)
Ileal Stenosis (Ileal stenosis)
Ileal Ulcer (Ileal ulcer)
Ileus (Ileus)
Immune System Disorders - Other,
Specify (Immune system disorders -
Other, Specify)
Infections And Infestations - Other,
Specify (Infections and infestations -
Other, Specify)
Infective Myositis (Infective myositis)
Infusion Related Reaction (Infusion
related reaction)
Infusion Site Extravasation (Infusion site
extravasation)
Injection Site Reaction (Injection site
reaction)
Injury To Carotid Artery (Injury to carotid
artery)
Injury To Inferior Vena Cava (Injury to
inferior vena cava)
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Injury To Jugular Vein (Injury to jugular
vein)
Injury To Superior Vena Cava (Injury to
superior vena cava)
Injury, Poisoning And Procedural
Complications - Other, Specify (Injury,
poisoning and procedural complications -
Other, Specify)
Inr Increased (INR increased)
Insomnia (Insomnia)
Intestinal Stoma Leak (Intestinal stoma
leak)
Intestinal Stoma Obstruction (Intestinal
stoma obstruction)
Intestinal Stoma Site Bleeding (Intestinal
stoma site bleeding)
Intra-abdominal Hemorrhage (Intra-
abdominal hemorrhage)
Intracranial Hemorrhage (Intracranial
hemorrhage)
Intraoperative Arterial Injury
(Intraoperative arterial injury)
Intraoperative Breast Injury
(Intraoperative breast injury)
Intraoperative Cardiac Injury
(Intraoperative cardiac injury)
Intraoperative Ear Injury (Intraoperative
ear injury)
Intraoperative Endocrine Injury
(Intraoperative endocrine injury)
Intraoperative Gastrointestinal Injury
(Intraoperative gastrointestinal injury)
Intraoperative Head And Neck Injury
(Intraoperative head and neck injury)
Intraoperative Hemorrhage
(Intraoperative hemorrhage)
Intraoperative Hepatobiliary Injury
(Intraoperative hepatobiliary injury)
Intraoperative Musculoskeletal Injury
(Intraoperative musculoskeletal injury)
Intraoperative Neurological Injury
(Intraoperative neurological injury)
Intraoperative Ocular Injury
(Intraoperative ocular injury)
Intraoperative Renal Injury
(Intraoperative renal injury)
Intraoperative Reproductive Tract Injury
(Intraoperative reproductive tract injury)
Intraoperative Respiratory Injury
(Intraoperative respiratory injury)
Intraoperative Skin Injury (Intraoperative
skin injury)
Intraoperative Splenic Injury
(Intraoperative splenic injury)
Intraoperative Urinary Injury
(Intraoperative urinary injury)
Intraoperative Venous Injury
(Intraoperative venous injury)
Investigations - Other, Specify
(Investigations - Other, Specify)
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Iron Overload (Iron overload)
Irregular Menstruation (Irregular
menstruation)
Irritability (Irritability)
Ischemia Cerebrovascular (Ischemia
cerebrovascular)
Ivth Nerve Disorder (IVth nerve disorder)
Jejunal Fistula (Jejunal fistula)
Jejunal Hemorrhage (Jejunal
hemorrhage)
Jejunal Obstruction (Jejunal obstruction)
Jejunal Perforation (Jejunal perforation)
Jejunal Stenosis (Jejunal stenosis)
Jejunal Ulcer (Jejunal ulcer)
Joint Effusion (Joint effusion)
Joint Infection (Joint infection)
Joint Range Of Motion Decreased (Joint
range of motion decreased)
Joint Range Of Motion Decreased
Cervical Spine (Joint range of motion
decreased cervical spine)
Joint Range Of Motion Decreased
Lumbar Spine (Joint range of motion
decreased lumbar spine)
Keratitis (Keratitis)
Kidney Anastomotic Leak (Kidney
anastomotic leak)
Kidney Infection (Kidney infection)
Kyphosis (Kyphosis)
Lactation Disorder (Lactation disorder)
Large Intestinal Anastomotic Leak (Large
intestinal anastomotic leak)
Laryngeal Edema (Laryngeal edema)
Laryngeal Fistula (Laryngeal fistula)
Laryngeal Hemorrhage (Laryngeal
hemorrhage)
Laryngeal Inflammation (Laryngeal
inflammation)
Laryngeal Mucositis (Laryngeal
mucositis)
Laryngeal Obstruction (Laryngeal
obstruction)
Laryngeal Stenosis (Laryngeal stenosis)
Laryngitis (Laryngitis)
Laryngopharyngeal Dysesthesia
(Laryngopharyngeal dysesthesia)
Laryngospasm (Laryngospasm)
Left Ventricular Systolic Dysfunction (Left
ventricular systolic dysfunction)
Lethargy (Lethargy)
Leukemia Secondary To Oncology
Chemotherapy (Leukemia secondary to
oncology chemotherapy)
Leukocytosis (Leukocytosis)
Leukoencephalopathy
(Leukoencephalopathy)
Libido Decreased (Libido decreased)
Libido Increased (Libido increased)
Lip Infection (Lip infection)
Lip Pain (Lip pain)
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Lipase Increased (Lipase increased)
Lipohypertrophy (Lipohypertrophy)
Localized Edema (Localized edema)
Lordosis (Lordosis)
Lower Gastrointestinal Hemorrhage
(Lower gastrointestinal hemorrhage)
Lung Infection (Lung infection)
Lymph Gland Infection (Lymph gland
infection)
Lymph Leakage (Lymph leakage)
Lymph Node Pain (Lymph node pain)
Lymphedema (Lymphedema)
Lymphocele (Lymphocele)
Lymphocyte Count Decreased
(Lymphocyte count decreased)
Lymphocyte Count Increased
(Lymphocyte count increased)
Malabsorption (Malabsorption)
Malaise (Malaise)
Mania (Mania)
Mediastinal Hemorrhage (Mediastinal
hemorrhage)
Mediastinal Infection (Mediastinal
infection)
Memory Impairment (Memory
impairment)
Meningismus (Meningismus)
Meningitis (Meningitis)
Menopause (Menopause)
Menorrhagia (Menorrhagia)
Metabolism And Nutrition Disorders -
Other, Specify (Metabolism and nutrition
disorders - Other, Specify)
Middle Ear Inflammation (Middle ear
inflammation)
Mitral Valve Disease (Mitral valve
disease)
Mobitz (type) Ii Atrioventricular Block
(Mobitz (type) II atrioventricular block)
Mobitz Type I (Mobitz type I)
Movements Involuntary (Movements
involuntary)
Mucosal Infection (Mucosal infection)
Mucositis Oral (Mucositis oral)
Multi-organ Failure (Multi-organ failure)
Muscle Weakness Left-sided (Muscle
weakness left-sided)
Muscle Weakness Lower Limb (Muscle
weakness lower limb)
Muscle Weakness Right-sided (Muscle
weakness right-sided)
Muscle Weakness Trunk (Muscle
weakness trunk)
Muscle Weakness Upper Limb (Muscle
weakness upper limb)
Musculoskeletal And Connective Tissue
Disorder - Other, Specify
(Musculoskeletal and connective tissue
disorders - Other, Specify)
Musculoskeletal Deformity
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(Musculoskeletal deformity)
Myalgia (Myalgia)
Myelitis (Myelitis)
Myelodysplastic Syndrome
(Myelodysplastic syndrome)
Myocardial Infarction (Myocardial
infarction)
Myocarditis (Myocarditis)
Myositis (Myositis)
Nail Discoloration (Nail discoloration)
Nail Infection (Nail infection)
Nail Loss (Nail loss)
Nail Ridging (Nail ridging)
Nasal Congestion (Nasal congestion)
Nausea (Nausea)
Neck Edema (Neck edema)
Neck Pain (Neck pain)
Neck Soft Tissue Necrosis (Neck soft
tissue necrosis)
Neoplasms Benign, Malignant And
Unspecified (incl Cysts And Polyps) -
Other, Specify (Neoplasms benign,
malignant and unspecified (incl cysts and
polyps) - Other, Specify)
Nervous System Disorders - Other,
Specify (Nervous system disorders -
Other, Specify)
Neuralgia (Neuralgia)
Neutrophil Count Decreased (Neutrophil
count decreased)
Night Blindness (Night blindness)
Nipple Deformity (Nipple deformity)
Non-cardiac Chest Pain (Non-cardiac
chest pain)
Nystagmus (Nystagmus)
Obesity (Obesity)
Obstruction Gastric (Obstruction gastric)
Oculomotor Nerve Disorder (Oculomotor
nerve disorder)
Olfactory Nerve Disorder (Olfactory
nerve disorder)
Oligospermia (Oligospermia)
Optic Nerve Disorder (Optic nerve
disorder)
Oral Cavity Fistula (Oral cavity fistula)
Oral Dysesthesia (Oral dysesthesia)
Oral Hemorrhage (Oral hemorrhage)
Oral Pain (Oral pain)
Osteonecrosis Of Jaw (Osteonecrosis of
jaw)
Osteoporosis (Osteoporosis)
Otitis Externa (Otitis externa)
Otitis Media (Otitis media)
Ovarian Hemorrhage (Ovarian
hemorrhage)
Ovarian Infection (Ovarian infection)
Ovarian Rupture (Ovarian rupture)
Ovulation Pain (Ovulation pain)
Pain (Pain)
Pain In Extremity (Pain in extremity)
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Pain Of Skin (Pain of skin)
Palmar-plantar Erythrodysesthesia
Syndrome (Palmar-plantar
erythrodysesthesia syndrome)
Palpitations (Palpitations)
Pancreas Infection (Pancreas infection)
Pancreatic Anastomotic Leak (Pancreatic
anastomotic leak)
Pancreatic Duct Stenosis (Pancreatic
duct stenosis)
Pancreatic Enzymes Decreased
(Pancreatic enzymes decreased)
Pancreatic Fistula (Pancreatic fistula)
Pancreatic Hemorrhage (Pancreatic
hemorrhage)
Pancreatic Necrosis (Pancreatic
necrosis)
Pancreatitis (Pancreatitis)
Papilledema (Papilledema)
Papulopustular Rash (Papulopustular
rash)
Paresthesia (Paresthesia)
Paronychia (Paronychia)
Paroxysmal Atrial Tachycardia
(Paroxysmal atrial tachycardia)
Pelvic Floor Muscle Weakness (Pelvic
floor muscle weakness)
Pelvic Infection (Pelvic infection)
Pelvic Pain (Pelvic pain)
Pelvic Soft Tissue Necrosis (Pelvic soft
tissue necrosis)
Penile Infection (Penile infection)
Penile Pain (Penile pain)
Perforation Bile Duct (Perforation bile
duct)
Pericardial Effusion (Pericardial effusion)
Pericardial Tamponade (Pericardial
tamponade)
Pericarditis (Pericarditis)
Perineal Pain (Perineal pain)
Periodontal Disease (Periodontal
disease)
Periorbital Edema (Periorbital edema)
Periorbital Infection (Periorbital infection)
Peripheral Ischemia (Peripheral
ischemia)
Peripheral Motor Neuropathy (Peripheral
motor neuropathy)
Peripheral Nerve Infection (Peripheral
nerve infection)
Peripheral Sensory Neuropathy
(Peripheral sensory neuropathy)
Peritoneal Infection (Peritoneal infection)
Peritoneal Necrosis (Peritoneal necrosis)
Personality Change (Personality change)
Phantom Pain (Phantom pain)
Pharyngeal Anastomotic Leak
(Pharyngeal anastomotic leak)
Pharyngeal Fistula (Pharyngeal fistula)
Pharyngeal Hemorrhage (Pharyngeal
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hemorrhage)
Pharyngeal Mucositis (Pharyngeal
mucositis)
Pharyngeal Necrosis (Pharyngeal
necrosis)
Pharyngeal Stenosis (Pharyngeal
stenosis)
Pharyngitis (Pharyngitis)
Pharyngolaryngeal Pain
(Pharyngolaryngeal pain)
Phlebitis (Phlebitis)
Phlebitis Infective (Phlebitis infective)
Photophobia (Photophobia)
Photosensitivity (Photosensitivity)
Platelet Count Decreased (Platelet count
decreased)
Pleural Effusion (Pleural effusion)
Pleural Hemorrhage (Pleural
hemorrhage)
Pleural Infection (Pleural infection)
Pleuritic Pain (Pleuritic pain)
Pneumonitis (Pneumonitis)
Pneumothorax (Pneumothorax)
Portal Hypertension (Portal
hypertension)
Portal Vein Thrombosis (Portal vein
thrombosis)
Postnasal Drip (Postnasal drip)
Postoperative Hemorrhage
(Postoperative hemorrhage)
Postoperative Thoracic Procedure
Complication (Postoperative thoracic
procedure complication)
Precocious Puberty (Precocious
puberty)
Pregnancy, Puerperium And Perinatal
Conditions - Other, Specify (Pregnancy,
puerperium and perinatal conditions -
Other, Specify)
Premature Delivery (Premature delivery)
Premature Menopause (Premature
menopause)
Presyncope (Presyncope)
Proctitis (Proctitis)
Productive Cough (Productive cough)
Prolapse Of Intestinal Stoma (Prolapse
of intestinal stoma)
Prolapse Of Urostomy (Prolapse of
urostomy)
Prostate Infection (Prostate infection)
Prostatic Hemorrhage (Prostatic
hemorrhage)
Prostatic Obstruction (Prostatic
obstruction)
Prostatic Pain (Prostatic pain)
Proteinuria (Proteinuria)
Pruritus (Pruritus)
Psychiatric Disorders - Other, Specify
(Psychiatric disorders - Other, Specify)
Psychosis (Psychosis)
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Pulmonary Edema (Pulmonary edema)
Pulmonary Fibrosis (Pulmonary fibrosis)
Pulmonary Fistula (Pulmonary fistula)
Pulmonary Hypertension (Pulmonary
hypertension)
Pulmonary Valve Disease (Pulmonary
valve disease)
Purpura (Purpura)
Pyramidal Tract Syndrome (Pyramidal
tract syndrome)
Radiation Recall Reaction (dermatologic)
(Radiation recall reaction (dermatologic))
Radiculitis (Radiculitis)
Rash Acneiform (Rash acneiform)
Rash Maculo-papular (Rash maculo-
papular)
Rash Pustular (Rash pustular)
Rectal Anastomotic Leak (Rectal
anastomotic leak)
Rectal Fistula (Rectal fistula)
Rectal Hemorrhage (Rectal hemorrhage)
Rectal Mucositis (Rectal mucositis)
Rectal Necrosis (Rectal necrosis)
Rectal Obstruction (Rectal obstruction)
Rectal Pain (Rectal pain)
Rectal Perforation (Rectal perforation)
Rectal Stenosis (Rectal stenosis)
Rectal Ulcer (Rectal ulcer)
Recurrent Laryngeal Nerve Palsy
(Recurrent laryngeal nerve palsy)
Renal And Urinary Disorders - Other,
Specify (Renal and urinary disorders -
Other, Specify)
Renal Calculi (Renal calculi)
Renal Colic (Renal colic)
Renal Hemorrhage (Renal hemorrhage)
Reproductive System And Breast
Disorders - Other, Specify (Reproductive
system and breast disorders - Other,
Specify)
Respiratory Failure (Respiratory failure)
Respiratory, Thoracic And Mediastinal
Disorders - Other, Specify (Respiratory,
thoracic and mediastinal disorders -
Other, Specify)
Restlessness (Restlessness)
Restrictive Cardiomyopathy (Restrictive
cardiomyopathy)
Retinal Detachment (Retinal
detachment)
Retinal Tear (Retinal tear)
Retinal Vascular Disorder (Retinal
vascular disorder)
Retinoic Acid Syndrome (Retinoic acid
syndrome)
Retinopathy (Retinopathy)
Retroperitoneal Hemorrhage
(Retroperitoneal hemorrhage)
Reversible Posterior
Leukoencephalopathy Syndrome
16 / 24
Follow-Up - Adverse Events - 3271596v1.0
(Reversible posterior
leukoencephalopathy syndrome)
Rhinitis Infective (Rhinitis infective)
Right Ventricular Dysfunction (Right
ventricular dysfunction)
Salivary Duct Inflammation (Salivary duct
inflammation)
Salivary Gland Fistula (Salivary gland
fistula)
Salivary Gland Infection (Salivary gland
infection)
Scalp Pain (Scalp pain)
Scleral Disorder (Scleral disorder)
Scoliosis (Scoliosis)
Scrotal Infection (Scrotal infection)
Scrotal Pain (Scrotal pain)
Seizure (Seizure)
Sepsis (Sepsis)
Seroma (Seroma)
Serum Amylase Increased (Serum
amylase increased)
Serum Sickness (Serum sickness)
Sick Sinus Syndrome (Sick sinus
syndrome)
Sinus Bradycardia (Sinus bradycardia)
Sinus Disorder (Sinus disorder)
Sinus Pain (Sinus pain)
Sinus Tachycardia (Sinus tachycardia)
Sinusitis (Sinusitis)
Skin And Subcutaneous Tissue
Disorders - Other, Specify (Skin and
subcutaneous tissue disorders - Other,
Specify)
Skin Atrophy (Skin atrophy)
Skin Hyperpigmentation (Skin
hyperpigmentation)
Skin Hypopigmentation (Skin
hypopigmentation)
Skin Induration (Skin induration)
Skin Infection (Skin infection)
Skin Ulceration (Skin ulceration)
Sleep Apnea (Sleep apnea)
Small Intestinal Anastomotic Leak (Small
intestinal anastomotic leak)
Small Intestinal Mucositis (Small
intestinal mucositis)
Small Intestinal Obstruction (Small
intestinal obstruction)
Small Intestinal Perforation (Small
intestinal perforation)
Small Intestinal Stenosis (Small intestinal
stenosis)
Small Intestine Infection (Small intestine
infection)
Small Intestine Ulcer (Small intestine
ulcer)
Sneezing (Sneezing)
Social Circumstances - Other, Specify
(Social circumstances - Other, Specify)
Soft Tissue Infection (Soft tissue
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infection)
Soft Tissue Necrosis Lower Limb (Soft
tissue necrosis lower limb)
Soft Tissue Necrosis Upper Limb (Soft
tissue necrosis upper limb)
Somnolence (Somnolence)
Sore Throat (Sore throat)
Spasticity (Spasticity)
Spermatic Cord Anastomotic Leak
(Spermatic cord anastomotic leak)
Spermatic Cord Hemorrhage (Spermatic
cord hemorrhage)
Spermatic Cord Obstruction (Spermatic
cord obstruction)
Spinal Fracture (Spinal fracture)
Spleen Disorder (Spleen disorder)
Splenic Infection (Splenic infection)
Stenosis Of Gastrointestinal Stoma
(Stenosis of gastrointestinal stoma)
Stevens-johnson Syndrome (Stevens-
Johnson syndrome)
Stoma Site Infection (Stoma site
infection)
Stomach Pain (Stomach pain)
Stomal Ulcer (Stomal ulcer)
Stridor (Stridor)
Stroke (Stroke)
Sudden Death Nos (Sudden death NOS)
Suicidal Ideation (Suicidal ideation)
Suicide Attempt (Suicide attempt)
Superficial Soft Tissue Fibrosis
(Superficial soft tissue fibrosis)
Superficial Thrombophlebitis (Superficial
thrombophlebitis)
Superior Vena Cava Syndrome (Superior
vena cava syndrome)
Supraventricular Tachycardia
(Supraventricular tachycardia)
Surgical And Medical Procedures -
Other, Specify (Surgical and medical
procedures - Other, Specify)
Syncope (Syncope)
Telangiectasia (Telangiectasia)
Testicular Disorder (Testicular disorder)
Testicular Hemorrhage (Testicular
hemorrhage)
Testicular Pain (Testicular pain)
Thromboembolic Event
(Thromboembolic event)
Thrombotic Thrombocytopenic Purpura
(Thrombotic thrombocytopenic purpura)
Tinnitus (Tinnitus)
Tooth Development Disorder (Tooth
development disorder)
Tooth Discoloration (Tooth discoloration)
Tooth Infection (Tooth infection)
Toothache (Toothache)
Toxic Epidermal Necrolysis (Toxic
epidermal necrolysis)
Tracheal Fistula (Tracheal fistula)
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Tracheal Hemorrhage (Tracheal
hemorrhage)
Tracheal Mucositis (Tracheal mucositis)
Tracheal Obstruction (Tracheal
obstruction)
Tracheal Stenosis (Tracheal stenosis)
Tracheitis (Tracheitis)
Tracheostomy Site Bleeding
(Tracheostomy site bleeding)
Transient Ischemic Attacks (Transient
ischemic attacks)
Treatment Related Secondary
Malignancy (Treatment related
secondary malignancy)
Tremor (Tremor)
Tricuspid Valve Disease (Tricuspid valve
disease)
Trigeminal Nerve Disorder (Trigeminal
nerve disorder)
Trismus (Trismus)
Tumor Lysis Syndrome (Tumor lysis
syndrome)
Tumor Pain (Tumor pain)
Typhlitis (Typhlitis)
Unequal Limb Length (Unequal limb
length)
Unintended Pregnancy (Unintended
pregnancy)
Upper Gastrointestinal Hemorrhage
(Upper gastrointestinal hemorrhage)
Upper Respiratory Infection (Upper
respiratory infection)
Ureteric Anastomotic Leak (Ureteric
anastomotic leak)
Urethral Anastomotic Leak (Urethral
anastomotic leak)
Urethral Infection (Urethral infection)
Urinary Fistula (Urinary fistula)
Urinary Frequency (Urinary frequency)
Urinary Incontinence (Urinary
incontinence)
Urinary Retention (Urinary retention)
Urinary Tract Infection (Urinary tract
infection)
Urinary Tract Obstruction (Urinary tract
obstruction)
Urinary Tract Pain (Urinary tract pain)
Urinary Urgency (Urinary urgency)
Urine Discoloration (Urine discoloration)
Urine Output Decreased (Urine output
decreased)
Urostomy Leak (Urostomy leak)
Urostomy Obstruction (Urostomy
obstruction)
Urostomy Site Bleeding (Urostomy site
bleeding)
Urostomy Stenosis (Urostomy stenosis)
Urticaria (Urticaria)
Uterine Anastomotic Leak (Uterine
anastomotic leak)
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Uterine Fistula (Uterine fistula)
Uterine Hemorrhage (Uterine
hemorrhage)
Uterine Infection (Uterine infection)
Uterine Obstruction (Uterine obstruction)
Uterine Pain (Uterine pain)
Uterine Perforation (Uterine perforation)
Uveitis (Uveitis)
Vaginal Anastomotic Leak (Vaginal
anastomotic leak)
Vaginal Discharge (Vaginal discharge)
Vaginal Dryness (Vaginal dryness)
Vaginal Fistula (Vaginal fistula)
Vaginal Hemorrhage (Vaginal
hemorrhage)
Vaginal Infection (Vaginal infection)
Vaginal Inflammation (Vaginal
inflammation)
Vaginal Obstruction (Vaginal obstruction)
Vaginal Pain (Vaginal pain)
Vaginal Perforation (Vaginal perforation)
Vaginal Stricture (Vaginal stricture)
Vaginismus (Vaginismus)
Vagus Nerve Disorder (Vagus nerve
disorder)
Vas Deferens Anastomotic Leak (Vas
deferens anastomotic leak)
Vascular Access Complication (Vascular
access complication)
Vascular Disorders - Other, Specify
(Vascular disorders - Other, Specify)
Vasculitis (Vasculitis)
Vasovagal Reaction (Vasovagal reaction)
Venous Injury (Venous injury)
Ventricular Arrhythmia (Ventricular
arrhythmia)
Ventricular Fibrillation (Ventricular
fibrillation)
Ventricular Tachycardia (Ventricular
tachycardia)
Vertigo (Vertigo)
Vestibular Disorder (Vestibular disorder)
Virilization (Virilization)
Visceral Arterial Ischemia (Visceral
arterial ischemia)
Vital Capacity Abnormal (Vital capacity
abnormal)
Vitreous Hemorrhage (Vitreous
hemorrhage)
Voice Alteration (Voice alteration)
Vomiting (Vomiting)
Vulval Infection (Vulval infection)
Watering Eyes (Watering eyes)
Weight Gain (Weight gain)
Weight Loss (Weight loss)
Wheezing (Wheezing)
White Blood Cell Decreased (White
blood cell decreased)
Wolff-parkinson-white Syndrome (Wolff-
Parkinson-White syndrome)
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Wound Complication (Wound
complication)
Wound Dehiscence (Wound dehiscence)
Wound Infection (Wound infection)
Wrist Fracture (Wrist fracture)
System Organ Class (SOC) (Note: For studies
using CTCAE version 3.0, this field is CTC
category. This field is derived from the selected
CTCAE Term.)
Hematopoietic And Lymphoid System
Disorder (Blood and lymphatic system
disorders)
Cardiac Disorders (Cardiac disorders)
Congenital, Familial And Genetic
Disorder Class (Congenital, familial and
genetic disorders)
Ear And Labyrinth Disorder Class (Ear
and labyrinth disorders)
Endocrine Disorder (Endocrine
disorders)
Eye Disorder (Eye disorders)
Gastrointestinal Disorder
(Gastrointestinal disorders)
General Disorders And Administration
Site Conditions Class (General disorders
and administration site conditions)
Liver And Biliary Tract Disorder
(Hepatobiliary disorders)
Immune System Disorder (Immune
system disorders)
Infection And Infestation (Infections and
infestations)
Injury, Poisoning And Procedural
Complication Class (Injury, poisoning
and procedural complications)
Investigation (Investigations)
Metabolism And Nutrition Disorder Class
(Metabolism and nutrition disorders)
Connective And Soft Tissue Disorder
(Musculoskeletal and connective tissue
disorders)
Neoplasm (Neoplasms benign,
malignant and unspecified (incl cysts and
polyps))
Nervous System Disorder (Nervous
system disorders)
Pregnancy, Puerperium And Perinatal
Condition Class (Pregnancy, puerperium
and perinatal conditions)
Psychiatric Disorder (Psychiatric
disorders)
Urinary Tract Disorder (Renal and
urinary disorders)
Reproductive System And Breast
Disorder Class (Reproductive system
and breast disorders)
Respiratory And Thoracic Disorder
(Respiratory, thoracic and mediastinal
disorders)
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Skin Disorder (Skin and subcutaneous
tissue disorders)
Social Circumstances (Social
circumstances)
Intervention Or Procedure (Surgical and
medical procedures)
Vascular Disorder (Vascular disorders)
Adverse Event Description (Enter a succinct
clinical description of the adverse event. -  - Note:
This field is mandatory, unless the CTCAE term
is the same as the description e.g. nausea,
diarrhea.)
Grade (Note: Some grades are disallowed for
some categories in the CTCAE. )
Absent Adverse Event (0)
Mild Adverse Event (1)
Moderate Adverse Event (2)
Severe Adverse Event (3)
Life Threatening Adverse Event (4)
Death Related To Adverse Event (5)
Attribution to Research (Select one of the
following codes to record this evaluation:)
Unrelated (1)
Unlikely (2)
Possible (3)
Probable (4)
Definite (5)
Atrribution to IND (Select one of the following
codes to record this evaluation:)
Unrelated (1)
Unlikely (2)
Possible (3)
Probable (4)
Definite (5)
Attribution to Investigational Device Exemption
(IDE) (Select one of the following codes to record
this evaluation:)
Unrelated (1)
Unlikely (2)
Possible (3)
Probable (4)
Definite (5)
Attribution to Commercial (Select one of the
following codes to record this evaluation:)
Unrelated (1)
Unlikely (2)
Possible (3)
Probable (4)
Definite (5)
Attribution to Radiation (Select one of the
following codes to record this evaluation:)
Unrelated (1)
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Unlikely (2)
Possible (3)
Probable (4)
Definite (5)
Attribution to Surgery (Select one of the following
codes to record this evaluation:)
Unrelated (1)
Unlikely (2)
Possible (3)
Probable (4)
Definite (5)
Attribution to Disease (Select one of the following
codes to record this evaluation:)
Unrelated (1)
Unlikely (2)
Possible (3)
Probable (4)
Definite (5)
Attribution to Other (Select one of the following
codes to record this evaluation:)
Unrelated (1)
Unlikely (2)
Possible (3)
Probable (4)
Definite (5)
Other, Specify (Enter an explanation when
Attribute to Other is selected.)
Unexpected Adverse Event
No (N)
Yes (Y)
Dose-Limiting Toxicity? (Note: Refer to the
protocol for the definition of a dose limiting
toxicity which should include the grade of the
events and the duration of the event. - Note:
Mandatory for Phase I Clinical Trials.)
No (N)
Yes (Y)
Serious (Indicate if the adverse event was a
"serious" event by selecting from the following
codes, as per the Code of Federal Regulations
21 Part 312. If multiple categories are applicable,
select the worst.)
No (1)
Life-threatening (2)
Death (3)
Disability (4)
Hospitalized (5)
Congenital Anomaly (6)
Jeopardizes Patient/ Requires
Intervention (7)
Action (Indicate any changes made to the study
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regimen in response to the adverse event using
the following codes.)
None (1)
Dose Reduced (2)
Regimen Interrupted (3)
Therapy Discontinued (4)
Interrupted And Then Reduced (5)
Intervention Using Medication (6)
Therapy (Indicate if additional therapy is required
to treat the adverse event.)
None (1)
Symptomatic (2)
Supportive (3)
Vigorous Supportive (4)
Outcome (Select the final status of the patient
when the adverse event is considered
"resolved".)
Recovered (1)
Still Under Treatment/ Observation (2)
Alive With Sequelae (3)
Died (4)
Expedited Report to IRB?
No (N)
Yes (Y)
Expedited Report to Sponsor?
No (No)
Yes (Yes)
Expedited Report to FDA?
No (No)
Yes (Yes)
Expedited Report to OBA?
No (No)
Yes (Yes)
Expedited Report to Manufacturer
No (No)
Yes (Yes)
24 / 24
Follow-Up - Adverse Events - 3271596v1.0
Follow-Up - Off Study - 3278634v1.0
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All rights reserved. Please visit https://medical-data-
models.org/forms/1665
Off Study
Off Study
Visit Date (Enter the date the form is being
completed.)
Date Off Study (For protocols with a specific
follow-up period, enter the date that corresponds
to the date when all protocol specific follow-up
has been completed.)
Reason off study (For protocols without a
protocol specific follow-up, use the same 'Reason
Off Treatment' entered on the Off Treatment case
report form.)
Patient Noncompliance (2)
Withdrawal Of Informed Consent (3)
Alternative Medicine (A)
Disease Progression Before Treatment
(B)
Study Complete (C)
Death (D)
Late Adverse Events/side Effects (E)
Cytogenetic Resistance (G)
Follow-up Period Completed (H)
Ineligible (I)
Lost To Follow-up (L)
Death During Follow-up Period (M)
Not Treated (N)
Other (O)
Disease Progression (P)
Refused Further Treatment (R)
Complicating Disease (S)
Toxicity (T)
Not Treated - Other Reasons (U)
Protocol Violation (V)
Refused Further Follow-up (W)
Declined To Participate (X)
No Treatment, Per Protocol Criteria (Z)
Explain 'Other' Reason
Date of Disease Progression
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2100 Revision 2 - 100 Days Post-
HSCT Data
Registry Use Only
Sequence number:
Date received:
Identification Data
CIBMTR Center Number:
CIBMTR Recipient ID:
Today's date:
Date of hematopoietic stem cell transplantation
(HSCT) for which this form is being completed:
Hsct Type
HSCT type
Related Allogenic (Allogeneic, related)
Unrelated Allogenic (Allogeneic,
unrelated)
Autologous (Autologous)
Syngeneic (Syngeneic (identical twin))
Was a particular hematopoietic stem cell source
used?
Yes (Yes)
Product Type
What type of hematopoietic stem cell transplant
was used?
Umbilical Cord Blood (Cord blood)
Bone Marrow (Marrow)
Multiple Umbilical Cord Blood (Multiple
cord blood units infused)
Other (Other)
Peripheral Blood Stem Cell (PBSC)
Was a particular hematopoietic stem cell
transplant type used?
Yes (Yes)
Specify the other hematopoietic stem cell
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transplant type: (Answer only if the response to
CDE 2730912 is "Other" )
Vital Status
Date of actual contact with the recipient to
determine the medical status for this follow-up
report:
Did this patient receive the scheduled HSCT?
No (No)
Yes (Yes)
Reason:
Patient Life Cancel Hematopoietic Stem
Cell Transplantation (HSCT was
canceled, but patient is alive)
Patient Death Post Begin Preparative
Regimen And Hematopoietic Stem Cell
Transplantation (Patient died between
start of preparative regimen and HSCT)
Reason for cancellation:
Did the recipient receive a subsequent HSCT?
(Prior to day 100 after the HSCT for which this
form is being completed. Bone marrow, mobilized
peripheral blood stem cells, cord blood.)
No (No)
Yes (Yes)
Specify the recipient's survival status at the date
of last contact:
Life (Alive)
Death (Dead)
Has the recipient received a donor cellular
infusion? (DCI)
No (No)
Yes (Yes)
Hematopoietic Reconstitution Post-hsct
Did the recipient receive hematopoietic, lymphoid
growth factors or cytokines? (After the start of the
preparatory regimen)
No (No)
Yes (Yes)
Hematopoietic Reconstitution Post-hsct
Part 2 Of 2
Type(s) of hematopoietic, lymphoid growth factor
or cytokine agents given: (For the first course of
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each agent given in this reporting period)
Hematopoietic Growth Factor Or
Cytokine Blinded Clinical Study (Blinded
growth factor or cytokine trial)
Recombinant Erythropoietin
(Erythropoietin)
Recombinant Granulocyte Colony
Stimulating Factor (G-CSF)
Recombinant Granulocyte-macrophage
Colony-stimulating Factor (GM-CSF)
Palifermin (KGF)
Other Pharmacologic Substance (Other
agent)
Velafermin (Velafermin)
Did the recipient receive hematopoietic, lymphoid
growth factors or cytokines? (After the start of the
preparatory regimen)
No (No)
Yes (Yes)
Specify the date for the first course of each agent
administered:
Specify the indication for the therapy: (Therapy
code)
Anti-leukemic Or Tumor Agent To
Prevent Relapse (Anti-leukemic or tumor
agent to prevent relapse)
Anti-leukemic Or Tumor Agent To Treat
Relapse (Anti-leukemic or tumor agent to
treat relapse)
Intervention For Delay / Decline In
Absolute Neutrophil Count (anc)
(Intervention for delay / decline in
absolute neutrophil count (ANC))
Intervention For Delay / Decline In Both
Anc And Platelets (Intervention for delay
/ decline in both ANC and platelets)
Intervention For Delay / Decline In
Platelets (Intervention for delay / decline
in platelets)
Intervention For Delay / Decline In Red
Blood Cell Counts (Intervention for delay
/ decline in red blood cell counts)
Other (Other)
Planned Therapy Per Protocol (note: For
Planned Therapy To Prevent Mucositis,
Use 10) (Planned therapy per protocol)
Planned Therapy To Prevent Mucositis
(Planned therapy to prevent mucositis)
Specify the specific G-CSF drug given: (Respond
only if the answer to CDE 2775782 is "G-CSF")
Lenograstim (Lenograstim)
Pegfilgrastim (Neulasta)
Filgrastim (Neupogen)
Specify the specific erythropoietin drug given:
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(Respond only if the answer to CDE 2775782 is
"Erythropoietin")
Darbepoetin Alfa (Aranesp)
Epoetin Alfa (Epogen)
Specify agent: (Respond only if the answer to
CDE 2775782 is "Blinded growth factor or
cytokine trial" or "Other agent")
Granulopoiesis / Neutrophil Recovery
Was there evidence of hematopoietic recovery?
(Following the initial HSCT)
Anc Never Dropped Below 500/mm^3 At
Any Time After The Start Of The
Preparative Regimen (Never below)
No, Anc >= 500/mm^3 Was Not
Achieved And There Was Documented
Persistent Disease In The Bone Marrow
Post-hsct (No, ANC recovery was not
achieved and there was evidence of
persistent disease)
No, Anc >= 500/mm^3 Was Not
Achieved And There Was No Evidence
Of Recurrent Disease In The Bone
Marrow (No, ANC recovery was not
achieved and there was no evidence of
recurrent disease)
Yes, Anc >= 500/mm^3 Achieved And
Sustained For 3 Lab Values With No
Subsequent Decline (Yes, ANC recovery
was achieved with no subsequent
decline)
Yes, Anc >= 500/mm^3 For 3 Lab Values
With Subsequent Decline In Anc To <
500/mm^3 For >= 3 Days (Yes, ANC
recovery was achieved with subsequent
decline)
Date ANC was greater than or equal to
500/mmE3: (First of 3 lab values)
Granulopoiesis / Neutrophil Recovery #2
Date ANC was greater than or equal to
500/mmE3: (First of 3 lab values)
Date of decline in ANC to less than 500/mmE3
for 3 days or more: (First of 3 days that the ANC
declined)
What is the value of WBC: (Actual CBC on first
day of decline)
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What is the unit of measure for WBC? (Actual
CBC on first day of decline)
10e6 Per Liter (10E6/L)
10e9 Cells Per Liter (10E9 Cells/L)
What is the percentage of neutrophils? (Actual
CBC on first day of decline)
Granulopoiesis / Neutrophil Recovery
Did the recipient recover and maintain ANC
greater than or equal to 500/mmE3 following the
decline?
No (No)
Yes (Yes)
Date ANC was greater than or equal to
500/mmE3: (First of 3 lab values)
If necessary, please validate the neutrophil
recovery date response.
Date Unknown (Date unknown)
What is the value of WBC: (Actual CBC on first
day of decline)
What is the unit of measure for WBC? (Actual
CBC on first day of decline)
10e6 Per Liter (10E6/L)
10e9 Cells Per Liter (10E9 Cells/L)
What is the percentage of neutrophils? (Actual
CBC on first day of decline)
Megakaryopoiesis / Platelet Recovery
Was an initial platelet count greater than or equal
to 20 x 10E9/L achieved?
No (No)
Never Less Than Platelet Count 20000
(platelet count never dropped below 20 x
10^9/L)
Yes (Yes)
Date platelet count greater than or equal to 20 x
10E9/L
If necessary, please validate the date of platelets
greater than or equal to 20 x 10E9/L response.
Date Estimate (Date estimated)
Date Unknown (Date unknown)
Was an initial platelet count greater than or equal
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to 50 x 10E9/L achieved?
No (No)
Never Less Than Platelet Count 50000
(platelet count never dropped below 50 x
10^9/L)
Yes (Yes)
Date platelets greater than or equal to 50 x
10E9/L:
If necessary, please validate the date of platelets
greater than or equal to 50 x 10E9/L response.
Date Estimate (Date estimated)
Date Unknown (Date unknown)
Current Hematologic Findings
What is the value of WBC: (Actual CBC on first
day of decline)
What is the unit of measure for WBC? (Actual
CBC on first day of decline)
10e6 Per Liter (10E6/L)
10e9 Cells Per Liter (10E9 Cells/L)
What is the reason for the WBC missing value?
Negation Test (Not tested)
What is the percentage of neutrophils? (Actual
CBC on first day of decline)
What is the value of platelets?
What is the reason for the neutrophils missing
value?
Negation Test (Not tested)
What is the percentage of lymphocytes?
What is the unit of measure for platelets?
10e6 Per Liter (10E6/L)
10e9 Cells Per Liter (10E9 Cells/L)
Sample (specimen) collection date. (Date of most
recent hematologic testing)
What is the reason for the lymphocytes missing
value?
Negation Test (Not tested)
What is the value of hemoglobin? (2 decimal
place value)
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What is the unit of measure for hemoglobin?
Gram Per Deciliter (g/dL)
Gram Per Liter (g/L)
Millimole Per Liter (mmol/L)
What is the reason for the hemoglobin missing
value?
Negation Test (Not tested)
If necessary, please validate the hemoglobin
response.
Transfused Rbc Less Than 30 Days
From Date Of Most Current Testing
(Transfused RBC less than 30 days from
date of most current testing)
What is the percentage of hematocrit?
What is the reason for the hematocrit missing
value?
Negation Test (Not tested)
If necessary, please validate the hematocrit
response.
Transfused Rbc Less Than 30 Days
From Date Of Most Current Testing
(Transfused RBC less than 30 days from
date of most current testing)
What is the reason for the platelets missing
value?
Negation Test (Not tested)
If necessary, please validate the platelet
response.
Transfused Platelets Less Than 7 Days
From Date Of Most Current Testing
(Transfused platelets less than 7 days
from date of most current testing)
Immune Reconstitution Part 1 Of 5
Type of immunologic laboratory procedure
performed:
Iga (IgA)
Igg (IgG)
Igm (IgM)
What is the value of the immunoglobulin test?
(Specify the immunoglobulin values from the
most recent testing)
Specify the unit of measure for the
immunoglobulin test:
Gram Per Deciliter (g/dL)
Gram Per Liter (g/L)
Milligram Per Deciliter (mg/dL)
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What is the reason for the immunoglobulin
missing value?
Negation Test (Not tested)
Sample (specimen) collection date. (Date of most
recent hematologic testing)
Immune Reconstitution Part 2 Of 5
Did the recipient receive supplemental
intravenous immunoglobulins? (IVIG)
No (No)
Yes (Yes)
Was therapy ongoing within one month of
immunoglobulin testing?
No (No)
Yes (Yes)
Immune Reconstitution Part 3 Of 5
Specify the indication(s) for the supplemental
intravenous immunoglobulin therapy:
Other (Other Indication)
Preventive Intervention Cytomegalovirus
(Prophylaxis for cytomegalovirus
infection)
Preventive Intervention Low Igg No
Active Infection (Prophylaxis for low IgG
with no active infection)
Therapeutic Procedure Cytomegalovirus
(Treatment for CMV infection)
Therapeutic Procedure Infection Low Igg
(Treatment for infection with low IgG)
Therapeutic Procedure Respiratory
Syncytial Virus (Treatment for respiratory
syncytial virus (RSV) infection)
Specify if there was an indication for the
supplemental intravenous immunoglobulin
therapy:
No (No)
Yes (Yes)
Specify (Answer only if the response to CDE
2775979 is "Other indication")
Immune Reconstitution Part 4 Of 5
Were lymphocyte analyses performed?
No (No)
Yes (Yes)
Sample (specimen) collection date. (Date of most
recent hematologic testing)
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Immune Reconstitution Part 5 Of 5
Specify cluster of differentiation type:
Cd20 Antigen (CD20)
Cd3 Complex (CD3)
Cd4 Antigen (CD4)
Neural Cell Adhesion Molecule (CD56)
Cd8 Antigen, Beta Polypeptide 1 (CD8)
What is the value of the cluster of differentiation?
What is the unit of measure for the cluster of
differentiation?
10e6 Per Liter (10E6/L)
10e9 Cells Per Liter (10E9 Cells/L)
What is the reason for the cluster of
differentiation missing value?
Negation Test (Not tested)
Chimerism Studies
Were chimerism studies performed? (Post-HSCT)
No (No)
Yes (Yes)
Were infusions from more than one donor given?
No (No)
Yes (Yes)
Are chimerism laboratory reports attached to this
form?
No (No)
Yes (Yes)
Specify donor gender:
Female (female)
Male (male)
Chimerism Studies
Sample (specimen) collection date. (Date of most
recent hematologic testing)
Method
Cytogenetics (Conventional (Standard)
Cytogenetics)
Fluorescence In Situ Hybridization
(Fluorescence in situ Hybridization
(FISH))
Human Leukocyte Antigen Test (HLA
Typing)
Other (Other)
Restriction Fragment Length
Polymorphism (Restriction Fragment
Length Polymorphism (RFLP))
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Minisatellite Repeat (VNTR or STR,
micro or mini satellite)
Specify (Specify the chimerism laboratory
procedure method type)
Cell type
B-lymphocyte (B-cells)
Bone Marrow (Bone marrow (BM))
Lymphocyte Not Otherwise Specified
(Lymphocytes, not otherwise specified)
Monocyte (Monocytes)
Myeloid Not Otherwise Specified
(Myeloid cells, not otherwise specified)
Other (Other)
Peripheral Blood Mononuclear Cell
(Peripheral blood mononuclear cells
(PBMC))
Neutrophil (PMNs (neutrophils))
Erythrocyte (Red blood cells)
T-lymphocyte (T-cell)
Specify (Specify the chimerism laboratory
procedure cell type)
Total cells examined
Number of donor cells
Number of host cells
Percent donor cells, quantitative method
Were donor cells present as determined by non-
quantitative means? (If performed by non-
quantitative method, indicate the presence of
donor cells.)
Present (Present)
Percent host cells, quantitative method
Were host cells present as determined by non-
quantitative means? (If performed by non-
quantitative method, indicate the presence of
donor cells.)
Present (Present)
Chimerism Studies
NMDP donor ID:
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NMDP Cord Blood Unit ID:
Non-NMDP Cord Blood Unit (CBU) ID:
What is the transplant donor or infant date of
birth?
Non-NMDP donor ID: (Unrelated)
What is the transplant donor or infant gender?
Female (female)
Male (male)
Sample (specimen) collection date. (Date of most
recent hematologic testing)
Method
Cytogenetics (Conventional (Standard)
Cytogenetics)
Fluorescence In Situ Hybridization
(Fluorescence in situ Hybridization
(FISH))
Human Leukocyte Antigen Test (HLA
Typing)
Other (Other)
Restriction Fragment Length
Polymorphism (Restriction Fragment
Length Polymorphism (RFLP))
Minisatellite Repeat (VNTR or STR,
micro or mini satellite)
Specify (Specify the chimerism laboratory
procedure method type)
Cell type
B-lymphocyte (B-cells)
Bone Marrow (Bone marrow (BM))
Lymphocyte Not Otherwise Specified
(Lymphocytes, not otherwise specified)
Monocyte (Monocytes)
Myeloid Not Otherwise Specified
(Myeloid cells, not otherwise specified)
Other (Other)
Peripheral Blood Mononuclear Cell
(Peripheral blood mononuclear cells
(PBMC))
Neutrophil (PMNs (neutrophils))
Erythrocyte (Red blood cells)
T-lymphocyte (T-cell)
Specify (Specify the chimerism laboratory
procedure cell type)
11 / 55
Follow-Up - 2100 Revision 2 - 100 Days Post-HSCT Data - 3061622v2.0
Total cells examined
Number of donor cells
Number of host cells
Percent donor cells, quantitative method
Were donor cells present as determined by non-
quantitative means? (If performed by non-
quantitative method, indicate the presence of
donor cells.)
Present (Present)
Percent host cells, quantitative method
Were host cells present as determined by non-
quantitative means? (If performed by non-
quantitative method, indicate the presence of
donor cells.)
Present (Present)
Engraftment Syndrome
Did engraftment syndrome occur?
No (No)
Yes (Yes)
Date of onset:
Engraftment Syndrome 2 Of 2
Specify the symptoms of engraftment syndrome:
Capillary Leak Syndrome (Capillary leak
syndrome)
Fever (Fever)
Skin Rash (Skin rash)
Specify if symptoms of engraftment syndrome
occurred:
No (No)
Yes (Yes)
Specify amount of body surface affected (Answer
only if the response to CDE 2782511 is "Skin
rash")
Engraftment Syndrome Part 3 Of 3
Was engraftment syndrome treated with
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corticosteroids
No (No)
Yes (Yes)
Acute Graft Vs. Host Disease (gvhd)
Was specific therapy used to prevent acute
GVHD or graft rejection, or for autologous HSCT
to induce acute GVHD? (After the start of the
preparative regimen. Do not include growth
factors reported in module "Hematopoietic
Reconstitution Post-HSCT Part 2 of 2," or ex vivo
T-cell depletion reported on the Product Insert.)
No (No)
Yes (Yes)
Date of diagnosis: (Of acute GVHD)
ALS, ALG, ATS, ATG
No (No)
Yes (Yes)
Specify source:
Horse (Horse)
Other Source (Other source)
Rabbit (Rabbit)
Specify source (Specify other source)
Corticosteroids (Systemic)
No (No)
Yes (Yes)
Cyclosporine (CSA, Sandimmune, Neoral)
No (No)
Yes (Yes)
ECP (Extra-corporeal photopheresis)
No (No)
Yes (Yes)
FK 506 (Tacrolimus, Prograf)
No (No)
Yes (Yes)
KGF (Palifermin, Kepivance. If used to prevent
mucositis, report at question 20 in module
"Hematopoietic Reconstitution Post-HSCT Part 2
of 2," CDE 2775782.)
No (No)
Yes (Yes)
Specify date started:
Velafermin (If used to prevent mucositis, report at
question 23 in module "Hematopoietic
Reconstitution Post-HSCT Part 2 of 2," CDE
2775782.)
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No (No)
Yes (Yes)
Specify date started:
In vivo monoclonal antibody
No (No)
Yes (Yes)
Anti CD 25 (Zenapax, Daclizumab, AntiTAC)
No (No)
Yes (Yes)
Specify:
Campath
No (No)
Yes (Yes)
Etanercept (Enbrel)
No (No)
Yes (Yes)
Infliximab (Remicade)
No (No)
Yes (Yes)
Other in vivo monoclonal antibody
No (No)
Yes (Yes)
Specify antibody
In vivo immunotoxin
No (No)
Yes (Yes)
Specify immunotoxin
Methotrexate (MTX, Amethopterin)
No (No)
Yes (Yes)
Mycophenolate mofetil (MMF, CellCept)
No (No)
Yes (Yes)
Sirolimus (Rapamycin, Rapamune)
No (No)
Yes (Yes)
Ursodiol
No (No)
Yes (Yes)
Blinded randomized trial
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No (No)
Yes (Yes)
Specify trial agent
Other agent
No (No)
Yes (Yes)
Specify other agent
Did acute GVHD occur?
Acute Graft Versus Host Disease
Persistent Prior Hematopoietic Stem Cell
Transplantation And/or Donor Cell
Infusion Procedure (Acute GVHD
persists from prior HSCT/DCI)
No (No)
Unknown (Unknown)
Yes (Yes)
If necessary, please validate the diagnosis date
response. (Of acute GVHD)
Greater Than Integer::100 Day Date
(Date greater than 100 days, date is
correct)
Was the diagnosis based on evidence from a
biopsy? (Histology)
No (No)
Yes (Yes)
Acute Graft Vs. Host Disease (gvhd) Part
2 Of 6
What is the biopsy site used to indicate the
diagnostic evidence:
Gastrointestinal (Gastrointestinal (GI))
Liver (Liver)
Lung (Lung)
Other (Other)
Skin (Skin)
Specify result(s):
Uncertain (Inconclusive)
Negative Finding (Negative)
Not Done: C49484 (Not Done)
Positive Finding (Positive)
Specify other site: (Answer only if the response to
CDE 2787340 is "Other")
Acute Graft Vs. Host Disease (gvhd) Part
3 Of
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Is a copy of the pathology report attached?
No (No)
Yes (Yes)
Was the diagnosis based on clinical evidence?
No (No)
Yes (Yes)
Maximum overall grade of acute GVHD:
Agvhd Grade I (I)
Agvhd Grade Ii (II)
Agvhd Grade Iii (III)
Agvhd Grade Iv (IV)
Is acute GVHD still present at the date of contact
for this report?
No (No)
Progressive Chronic Graft Versus Host
Disease (Progressed to chronic GVHD)
Unknown (Unknown)
Yes (Yes)
List the maximum severity of skin involvement:
No Skin Acute Gvhd / Rash Not
Attributable To Acute Gvhd (None)
No Rash (Stage 0)
Maculopapular Rash, Less Than 25
Percent Of Body Surface (Stage 1)
Maculopapular Rash, 25 To 50 Percent
Of Body Surface (Stage 2)
Generalized Erythroderma (Stage 3)
Generalized Erythroderma With Bullae
Formation And Desquamation (Stage 4)
List the maximum severity of lower intestinal tract
involvement (Use mL/day for adult recipients and
mL/mE2/day for pediatric recipients)
No Gut Acute Gvhd / Diarrhea Not
Attributable To Acute Gvhd (None)
Diarrhea Less Than Or Equal To 500
Ml/day Or Less Than 280 Ml/me2 Day
(Stage 0)
No Diarrhea (Stage 0 - no diarrhea)
Diarrhea Greater Than 500 But Less
Than Or Equal To 1000 Ml/day Or 280-
555 Ml/me2 /day (Stage 1)
Diarrhea Greater Than 1000 But Less
Than Or Equal To 1500 Ml/day Or 556-
833 Ml/me2 /day (Stage 2)
Diarrhea Greater Than 1500 Ml/day Or
Greater Than 833 Ml/me2 /day (Stage 3)
Severe Abdominal Pain, With Or Without
Ileus (Stage 4)
List the maximum severity of upper intestinal tract
involvement:
No Persistant Nausea Or Vomiting
(Stage 0)
Persistant Nausea Or Vomiting (Stage 1)
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List the maximum severity of liver involvement:
No Liver Acute Gvhd / Bilirubin Level Not
Attributable To Acute Gvhd (None)
Bilirubin Less Than 2.0 Mg/dl (less Than
34 Micro Mol/l) (Stage 0)
Bilirubin 2.0 To 3.0 Mg/dl (34 To 52 Micro
Mol/l) (Stage 1)
Bilirubin 3.1 To 6.0 Mg/dl (53 To 103
Micro Mol/l) (Stage 2)
Bilirubin 6.1 To 15.0 Mg/dl (104 To 256
Micro Mol/l) (Stage 3)
Bilirubin Greater Than 15.0 Mg/dl
(greater Than 256 Micro Mol/l) (Stage 4)
Other clinical organ involvement?
No (No)
Yes (Yes)
Acute Graft Vs. Host Disease (gvhd) Part
3 Of
Specify the site of organ involvement
Lung (Lung)
Other (Other)
Was a particular site of organ involvement
present?
No (No)
Yes (Yes)
Specify other site (Answer only if the response to
CDE 2793699 is "Other")
Acute Graft Vs. Host Disease (gvhd) Part
7 Of
Was specific therapy used to treat acute GVHD?
No (No)
Yes (Yes)
ALS, ALG, ATS, ATG
No (No)
Yes (Yes)
Specify source:
Horse (Horse)
Other Source (Other source)
Rabbit (Rabbit)
Specify source (Specify other source)
Corticosteroids (Systemic)
No (No)
Yes (Yes)
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Cyclosporine (CSA, Sandimmune, Neoral)
No (No)
Yes (Yes)
Corticosteroids (Topical)
No (No)
Yes (Yes)
ECP (Extra-corporeal photopheresis)
No (No)
Yes (Yes)
FK 506 (Tacrolimus, Prograf)
No (No)
Yes (Yes)
In vivo monoclonal antibody
No (No)
Yes (Yes)
Anti CD 25 (Zenapax, Daclizumab, AntiTAC)
No (No)
Yes (Yes)
Specify:
Campath
No (No)
Yes (Yes)
Etanercept (Enbrel)
No (No)
Yes (Yes)
Infliximab (Remicade)
No (No)
Yes (Yes)
Other in vivo monoclonal antibody
No (No)
Yes (Yes)
Specify antibody
In vivo immunotoxin
No (No)
Yes (Yes)
Specify immunotoxin
Methotrexate (MTX, Amethopterin)
No (No)
Yes (Yes)
Mycophenolate mofetil (MMF, CellCept)
No (No)
Yes (Yes)
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Sirolimus (Rapamycin, Rapamune)
No (No)
Yes (Yes)
Ursodiol
No (No)
Yes (Yes)
Blinded randomized trial
No (No)
Yes (Yes)
Specify trial agent
Other agent
No (No)
Yes (Yes)
Specify other agent
Chronic Graft Vs. Host Disease (gvhd)
Has the recipient developed clinical chronic
GVHD?
Chronic Graft Versus Host Disease
Persistent Prior Hematopoietic Stem Cell
Transplantation And/or Donor Cell
Infusion Procedure (Chronic GVHD
persists from prior HSCT/DCI)
No (No)
Unknown (Unknown)
Yes (Yes)
Date of diagnosis: (Of acute GVHD)
Onset of chronic GVHD was:
Symptoms Reactivated Within 30 Days
Of Drug Tapering Or Discontinuation
(Chronic GVHD flare)
Acute Gvhd Never Developed (De novo)
Acute Gvhd Resolved, Then Chronic
Gvhd Developed (Interrupted)
Acute Gvhd Progressed Directly To
Chronic Gvhd (Progressive)
Karnofsky / Lansky score (At diagnosis of chronic
GVHD. If the recipient is 16 years of age or older,
complete the Karnofsky Scale. If the recipient is
younger than 16 years of age, complete the
Lansky Scale.)
Karnofsky Scale - Moribund, Fatal
Process Progressing Rapidly; Lansky
Scale - Completely Disabled, Not Even
Passive Play. (10)
Karnofsky Scale - Normal, No
Complaints, No Evidence Of Disease;
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Lansky Scale - Fully Active. (100)
Karnofsky Scale - Very Sick,
Hospitalization Necessary; Lansky Scale
- Limited To Very Passive Activity
Initiated By Others (e.g., Tv) (20)
Karnofsky Scale - Severely Disabled,
Hospitalization Indicated, Although
Death Not Imminent. Lansky Scale -
Needs Considerable Assistance For
Quiet Activity. (30)
Karnofsky Scale - Disabled, Requires
Special Care And Assistance. Lansky
Scale - Able To Initiate Quiet Activities.
(40)
Karnofsky Scale - Requires
Considerable Assistance And Frequent
Medical Care; Lansky Scale -
Considerable Assistance Required For
Any Active Play; Fully Able To Engage In
Quiet Play. (50)
Karnofsky Scale - Requires Occasional
Assistance, But Is Able To Care For Most
Needs; Lansky Scale - Ambulatory Up To
50r Of Time, Limited Active Play With
Assistance / Supervision. (60)
Karnofsky Scale - Cares For Self, Unable
To Carry On Normal Activity Or To Do
Active Work.; Lansky Score - Both
Greater Restrictions Of, And Less Time
Spent In, Active Play. (70)
Karnofsky Scale - Normal Activity With
Effort; Lansky Scale - Restricted In
Strenuous Play, Tires More Easily,
Otherwise Active. (80)
Karnofsky Scale - Able To Carry On
Normal Activity; Lansky Scale - Minor
Restriction In Physically Strenuous Play.
(90)
What is the value of platelets?
What is the unit of measure for platelets?
10e6 Per Liter (10E6/L)
10e9 Cells Per Liter (10E9 Cells/L)
Diagnosis was based on:
Clinical And Histologic Finding (Both
clinical and histologic evidence)
Clinical Finding (Clinical evidence)
Histologic Finding And/or Biopsy
Confirmed (Histologic evidence / biopsy
proven)
Unknown (Unknown)
Maximum grade of chronic GVHD:
Extensive Gvhd Involvement (Extensive)
Limited Gvhd Involvement (Limited)
Overall severity of chronic GVHD:
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Mild (Mild)
Moderate (Moderate)
Severe (Severe)
If necessary, please validate the diagnosis date
response. (Of acute GVHD)
Greater Than Integer::100 Day Date
(Date greater than 100 days, date is
correct)
Chronic Graft Vs. Host Disease (gvhd) -
Organ Involvement
Specify the type of organ / system involvement
with chronic GVHD:
Autoantibody (Autoantibodies)
Bronchiolitis Obliterans (Bronchiolitis
obliterans)
Eosinophilia (Eosinophilia)
Eye (Eyes)
Gastrointestinal Tract (Gastrointestinal
tract)
Genitourinary System (Genitourinary
tract)
Liver (Liver)
Oral Cavity (Mouth)
Musculoskeletal (Musculoskeletal)
Other Hematopoietic Involvement (Other
hematologic involvement)
Other Lung Involvement (Other lung
involvement)
Other Organ Involvement (Other organ
involvement)
Other Skin Or Hair Involvement (Other
skin or hair involvement)
Skin Sclerosis (Sclerosis of skin)
Serositis (Serositis)
Thrombocytopenia (Thrombocytopenia)
Weight Loss (Weight loss)
Indicate if there was an organ / system
involvement with chronic GVHD:
No (No)
Yes (Yes)
Indicate if the organ / system involvement was
proven by biopsy:
No (No)
Yes (Yes)
Specify the other site of the organ / system
involvement with chronic GVHD: (Answer only if
the response to CDE 2793857 is "Other organ
involvement")
Chronic Graft Vs. Host Disease (gvhd)
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Was specific therapy used to treat chronic
GVHD?
No (No)
Yes (Yes)
ALS, ALG, ATS, ATG
No (No)
Yes (Yes)
Specify source:
Horse (Horse)
Other Source (Other source)
Rabbit (Rabbit)
Specify source (Specify other source)
Azathioprine
No (No)
Yes (Yes)
Corticosteroids (Systemic)
No (No)
Yes (Yes)
Cyclosporine (CSA, Sandimmune, Neoral)
No (No)
Yes (Yes)
ECP (Extra-corporeal photopheresis)
No (No)
Yes (Yes)
Corticosteroids (Topical)
No (No)
Yes (Yes)
FK 506 (Tacrolimus, Prograf)
No (No)
Yes (Yes)
Etretinate
No (No)
Yes (Yes)
Hydroxychloroquine (Plaquenil)
No (No)
Yes (Yes)
In vivo monoclonal antibody
No (No)
Yes (Yes)
Anti CD 25 (Zenapax, Daclizumab, AntiTAC)
No (No)
Yes (Yes)
Specify:
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Campath
No (No)
Yes (Yes)
Etanercept (Enbrel)
No (No)
Yes (Yes)
Infliximab (Remicade)
No (No)
Yes (Yes)
Other in vivo monoclonal antibody
No (No)
Yes (Yes)
Specify antibody
Lamprene (Clofazimine)
No (No)
Yes (Yes)
Pentostatin
No (No)
Yes (Yes)
Mycophenolate mofetil (MMF, CellCept)
No (No)
Yes (Yes)
PUVA (Psoralen and UVA)
No (No)
Yes (Yes)
Sirolimus (Rapamycin, Rapamune)
No (No)
Yes (Yes)
Ursodiol
No (No)
Yes (Yes)
Thalidomide
No (No)
Yes (Yes)
Blinded randomized trial
No (No)
Yes (Yes)
Specify trial agent
Other agent
No (No)
Yes (Yes)
Specify other agent
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Are symptoms of chronic GVHD still present?
(On the date of actual contact or present at the
time of death)
No (No)
Yes (Yes)
Is the recipient still taking immunosuppressive
agents to treat or prevent GVHD? (Including
PUVA)
No (No)
Unknown (Unknown)
Yes (Yes)
Date final treatment administered:
If necessary, please validate the final date of
immunosuppressant administration response.
Date Unknown (Date unknown)
Infection
Did the recipient receive any of the following
agents for infection prophylaxis? (After the start
of the preparative regimen. Report prophylaxis
immunoglobulins at questions 63-64 in module
"Immune Reconstitution Part 3 of 5")
No (No)
Unknown (Unknown)
Yes (Yes)
Infection Part 2 Of 3
Specify the agent types received for infection
prophylaxis:
Acyclovir (Acyclovir)
Amphotericin B-lipid Complex
(Amphotericin (lipid formulation))
Amphotericin B Deoxycholate
(Amphotericin (non-lipid formulation))
Atovoquone (Atovaquone)
Caspofungin (Caspofungin)
Dapsone (Dapsone)
Fluconazole (Fluconazole)
Foscarnet (Foscarnet)
Ganciclovir (Ganciclovir)
Itraconazole (Itraconazole)
Micafungin (Micafungin)
Negation Absorbable Oral Route Of
Administration Antibiotic (Nonabsorbable
oral antibiotics)
Other Pharmacologic Substance (Other
agent)
Other Antiviral Agent (Other antiviral
agent)
Other Pneumocystis Pneumonia
Preventive Intervention (Other
pneumocystis prophylaxis)
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Other Systemic Antifungal Agent (Other
systemic antifungal agent)
Pentamidine Inhaler (Pentamidine
inhaled)
Pentamidine Intravenous Route Of
Administration (Pentamidine IV)
Posaconazole (Posaconazole)
Ravuconazole (Ravuconazole)
Systemic Antibiotic (Systemic
antibacterial antibiotics)
Trimethoprim-sulfamethoxazole
(Trimethoprim/sulfamethoxazole)
Valacyclovir (Valacyclovir)
Valganciclovir (Valganciclovir)
Voriconazole (Voriconazole)
Did the recipient receive any of the following
agents for infection prophylaxis? (After the start
of the preparative regimen. Report prophylaxis
immunoglobulins at questions 63-64 in module
"Immune Reconstitution Part 3 of 5")
No (No)
Unknown (Unknown)
Yes (Yes)
Specify the other agent received for infection
prophylaxis: (Answer only if the response to CDE
2794436 is "Other systemic antifungal agent,"
"Other antiviral agent," "Other pneumocystis
prophylaxis," or "Other agent")
Infection Part 3 Of 4
Did the recipient receive irradiated granulocyte
infusions? (After the start of the preparative
regimen to 60 days post-HSCT.)
No (No)
Yes (Yes)
Did the recipient develop a clinically significant
infection? (After the start of the preparative
regimen)
No (No)
Yes (Yes)
Infection Part 3 Of 3
Organism
Acinetobacter (Acinetobacter)
Actinomyces (Actinomyces)
Adenovirus (Adenovirus)
Aspergillus Flavus (Aspergillus flavus)
Aspergillus Fumigatus (Aspergillus
fumigatus)
Aspergillus Niger (Aspergillus niger)
Aspergillus Not Otherwise Specified
(Aspergillus, NOS)
Bacillus (Bacillus)
Bacteroides (Bacteroides (gracillis,
uniformis, vulgaris, other species))
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Bordetella Pertussis (Bordetella
pertussis (whooping cough))
Borrelia Burgdorferi (Borrelia (lyme
disease))
Moraxella Catarrhalis (Branhamella or
Moraxella catarrhalis (other species))
Campylobacter (Campylobacter (all
species))
Candida Glabrata (Candida (Torulopsis)
glabrata)
Candida Albicans (Candida albicans)
Pichia Guilliermondii (Candida
guillermondi)
Issatchenkia Orientalis (Candida krusei)
Clavispora Lusitaniae (Candida
lusitaniae)
Candida Parapsilosis (Candida
parapsilosis)
Candida Tropicalis (Candida tropicalis)
Candida Not Otherwise Specified
(Candida, NOS)
Capnocytophaga (Capnocytophaga)
Chlamydophila Pneumoniae (Chlamydia
(pneumoniae))
Chlamydia Not Otherwise Specified
(Chlamydia, NOS)
Citrobacter (Citrobacter (freundii, other
species))
Clostridium (Clostridium (all species
except difficile))
Clostridium Difficile (Clostridium difficile)
Corynebacterium (Corynebacterium (all
non-diptheria species))
Corynebacterium Jeikeium
(Corynebacterium (jeikeium))
Coxiella (Coxiella)
Cryptococcosis (Cryptococcosus
species)
Cryptosporidium (Cryptosporidium)
Cytomegalovirus (Cytomegalovirus)
Enterobacter (Enterobacter)
Enterococcus (Enterococcus (all
species))
Vancomycin Resistant Enterococcus
(Enterococcus, vancomycin resistant
(VRE))
Enterovirus (Enterovirus)
Epstein-barr Virus (Epstein-Barr Virus)
Escherichia Coli (Escherichia (also E.
coli))
Pseudomonas Oryzihabitans
(Flavimonas oryzihabitans)
Flavobacterium (Flavobacterium)
Fusarium (Fusarium species)
Fusobacterium (Fusobacterium)
Giardia (Giardia)
Haemophilus (Haemophilus (all species,
including influenzae))
Helicobacter Pylori (Helicobacter pylori)
Hepatitis A Virus (Hepatitis A Virus)
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Hepatitis B Virus (Hepatitis B Virus)
Hepatitis C Virus (Hepatitis C Virus)
Herpes Simplex Virus (Herpes Simplex
Virus)
Herpes Zoster (Herpes Zoster)
Histoplasmosis (Histoplasmosis)
Human Herpesvirus 6 (Human
Herpesvirus 6)
Human Immunodeficiency Virus 1
(Human Immunodeficiency Virus 1)
Human Papillomavirus (Human
Papillomavirus)
Influenza A Virus (Influenza A Virus)
Influenza B Virus (Influenza B Virus)
Other Influenza (Influenza, NOS)
Klebsiella (Klebsiella)
Lactobacillus (Lactobacillus (bulgaricus,
acidophilus, other species))
Legionella (Legionella)
Leptospira (Leptospira)
C76356 (Leptotrichia buccalis)
Leuconostoc (Leuconostoc (all species))
Listeria (Listeria)
Measles Virus (Measles Virus)
Methylobacterium (Methylobacterium)
Micrococcus Not Otherwise Specified
(Micrococcus, NOS)
Zygomycosis (Mucormycosis)
Multiple Bacteria (Multiple bacteria at a
single site)
Mumps Virus (Mumps Virus)
Mycobacterium Avium Complex
(Mycobacterium avium - intracellulare
(MAC, MAI))
Mycobacterium Species (Mycobacterium
species (cheloneae, fortuitum,
haemophilum, kansasii, mucogenicum))
Mycobacterium Tuberculosis
(Mycobacterium tuberculosis
(tuberculosis, Koch bacillus))
Mycobacterium Not Otherwise Specified
(Mycobacterium, NOS)
Mycoplasma (Mycoplasma)
Neisseria (Neisseria (gonorrhoeae,
meningitidis, other species))
Not Identified Organism (No organism
identified)
Nocardia (Nocardia)
Other Aspergillus (Other Aspergillus)
Other Bacteria (Other bacteria)
Other Candida (Other Candida)
Other Chlamydia (Other chlamydia)
Other Fungi (Other fungus)
Other Mycobacterium (Other
mycobacterium)
Other Parasite (Other parasite)
Other Virus (Other Virus)
Parainfluenza Virus (Parainfluenza Virus)
Pasteurella Multocida (Pasteurella
multocida)
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Pneumocystis Pneumonia
(Pneumocystis (PCP / PJP))
Polyomavirus (Polyomavirus)
Progressive Multifocal
Leukoencephalopathy (Progressive
Multifocal Leukoencephalopathy)
Propionibacterium Acnes
(Propionibacterium (acnes, avidum,
granulosum, other species))
Proteus (Proteus)
Pseudomonas (Pseudomonas (all
species except cepacia & maltophilia))
Burkholderia Cepacia (Pseudomonas or
Burkholder cepacia)
Stenotrophomonas Maltophilia
(Pseudomonas or Stenotrophomonas or
Xanthomonas maltophilia)
Respiratory Syncytial Virus (Respiratory
Syncytial Virus (RSV))
Rhinovirus (Rhinovirus)
Rhizopus (Rhizopus)
Rhodococcus (Rhodococcus)
Rickettsia (Rickettsia)
Rotavirus (Rotavirus)
Rubella Virus (Rubella Virus)
Salmonella (Salmonella (all species))
Serratia Marcescens (Serratia
marcescens)
Shigella (Shigella)
Staphylococcus Aureus (Staphylococcus
aureus)
Staphylococcus Coag Negative
(Staphylococcus, coagulase negative)
Streptococcus Not Otherwise Specified
(Staphylococcus, NOS)
Rothia Mucilaginosa (Stomatococcus
mucilaginosis)
Streptococcus (Streptococcus (all
species except Enterococcus))
Streptococcus Pneumoniae
(Streptococcus pneumoniae)
Suspected Atypical Bacteria Infection
(Suspected atypical bacterial infection)
Suspected Bacteria Infection (Suspected
bacterial infection)
Suspected Fungal Infection (Suspected
fungal infection)
Suspected Parasitic Infection (Suspected
parasite infection)
Suspected Viral Infection (Suspected
viral infection)
Toxoplasma (Toxoplasma)
Treponema (Treponema (syphilis))
Vibrio (Vibrio (all species))
Yeast Not Otherwise Specified (Yeast,
NOS)
Zygomycota Not Otherwise Specified
(Zygomycetes, NOS)
Specify the infection organism: (Answer only if
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the response to CDE 2934613 is "Other
chlamydia," "Other mycobacterium," "Multiple
bacteria at a single site," "Other bacteria," "Other
Candida," "Other Aspergillus," "Other fungus,"
Other virus," or "Other parasite.")
Date of diagnosis: (Of acute GVHD)
Select the infection organism site: (Do not report
fever in the absence of infection. Report the most
specific site of infection.)
Blood And/or Buffy Coat (Blood / buffy
coat)
Osteomyelitis (Bone cortex)
Bone Marrow (Bone marrow)
Brain (Brain)
Endocardium Myocardium Pericardium
(Cardiac)
Application Site Catheter (Catheter
insertion or exit site)
Catheter Tip Device Component
(Catheter tip)
Cellulitis (Cellulitis)
Not Otherwise Specified Central Nervous
System (Central nervous system, not
specified)
Not Otherwise Specified Central Venous
Access Catheter (Central venous
catheter, NOS)
Isolation Greater Than Or Equal To
Integer::3 Anatomic Site (Disseminated -
generalized, isolated at 3 or more distinct
sites)
Ear (Ears)
Esophagus (Esophagus)
Eye (Eyes)
Fallopian Tube Uterus Cervix Uteri
(Fallopian tubes, uterus, cervix)
Feces (Feces / stool)
Gallbladder Biliary Tract Pancreas
(Gallbladder and biliary tree, pancreas)
Gastrointestinal Tract Not Otherwise
Specified (Gastrointestinal tract, NOS)
Genital (Genital area)
Genitourinary System Not Otherwise
Specified (Genito-urinary tract, NOS)
Herpes Zoster (Herpes zoster)
Joint (Joints)
Large Intestine (Large intestine)
Laryngitis And/or Larynx (Laryngitis /
larynx)
Lip (Lips)
Liver (Liver)
Trachea Bronchus And/or Lung (Lower
respiratory tract)
Lymph Node (Lymph nodes)
Meninges And Cerebrospinal Fluid
(Meninges and CSF)
29 / 55
Follow-Up - 2100 Revision 2 - 100 Days Post-HSCT Data - 3061622v2.0
Muscle (Muscle)
Peritoneum (Peritoneum)
Pleural Fluid Pleural Cavity (Pleural
cavity, pleural fluid)
Prostate Gland (Prostate)
Pustular Lesion Or Abscess Skin Rash
(Rash, pustules or abscesses)
Not Otherwise Specified Respiratory
System (Respiratory tract, NOS)
Paranasal Sinus (Sinuses)
Not Otherwise Specified Skin (Skin,
NOS)
Small Bowel (Small intestine)
Spinal Cord (Spinal cord)
Spleen (Spleen)
Stomach (Stomach)
Testis (Testes)
Tongue Oral Cavity And Oropharynx
(Tongue, oral cavity and oropharynx)
Nasopharynx (Upper airway and
nasopharynx)
Urine Kidney Renal Pelvis Ureter And
Bladder (Urine, kidneys, renal pelvis,
ureters and bladder)
Vagina (Vagina)
Infection Part 5 Of 5
Did the recipient develop more than 7 infections?
(Post-HSCT)
No (No)
Yes (Yes)
Are extra pages attached?
No (No)
Yes (Yes)
Organ Function - Pulmonary Function Part
1 Of 10
Did the recipient develop interstitial pneumonitis /
idiopathic pneumonia syndrome? (IPn or ARDS /
IPS. After the start of the preparative regimen to
the date of last contact. Interstitial pneumonitis /
idiopathic pneumonia syndrome is characterized
on chest x-ray by hypoxia and diffuse interstitial
infiltrates not caused by fluid overload. Report
bacterial and fungal pneumonia in Infection
section questions 379-407 in module "Infection
Part 3 of 5," CDE 2795691, and all of module
"Infection Part 4 of 5.")
No (No)
Yes (Yes)
Organ Function - Pulmonary Function Part
2 Of
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Date of diagnosis: (Of acute GVHD)
Were diagnostic tests done? (Other than
radiographic studies)
No (No)
Yes (Yes)
Bronchoalveolar lavage (BAL)
No (No)
Yes (Yes)
Transbronchial biopsy
No (No)
Yes (Yes)
Open / thorascopic lung biopsy (VATS)
No (No)
Yes (Yes)
Autopsy
No (No)
Yes (Yes)
Other test
No (No)
Yes (Yes)
Specify other test
Was an organism isolated?
No (No)
Yes (Yes)
Adenovirus
No (No)
Yes (Yes)
Cytomegalovirus (CMV)
No (No)
Yes (Yes)
Herpes simplex (HSV1, HSV2)
No (No)
Yes (Yes)
Human herpes virus type 6 (HHV6)
No (No)
Yes (Yes)
Parainfluenza
No (No)
Yes (Yes)
Respiratory syncytial virus (RSV)
No (No)
Yes (Yes)
Toxoplasma
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No (No)
Yes (Yes)
Other virus
No (No)
Yes (Yes)
Specify other virus
Other organism
No (No)
Yes (Yes)
Specify organism
Did the recipient experience two or more
episodes of IPn / IPS? (After the start of the
preparative regimen to the date of last contact.)
No (No)
Yes (Yes)
Are extra pages attached?
No (No)
Yes (Yes)
Organ Function - Pulmonary Function Part
5 Of 11
Did the recipient develop non-infectious
pulmonary abnormalities? (Other than IPn / IPS /
ARDS. After the start of the preparative regimen
to the date of last contact.)
No (No)
Yes (Yes)
Organ Function - Pulmonary Function Part
4 Of
Did the recipient develop bronchiolitis obliterans?
(After the start of the preparative regimen to the
date of last contact)
No (No)
Yes (Yes)
Date of diagnosis: (Of acute GVHD)
Were diagnostic tests done?
No (No)
Yes (Yes)
Bronchoalveolar lavage (BAL)
No (No)
Yes (Yes)
Transbronchial biopsy
No (No)
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Yes (Yes)
Open / thorascopic lung biopsy (VATS)
No (No)
Yes (Yes)
Autopsy
No (No)
Yes (Yes)
Other test
No (No)
Yes (Yes)
Specify other test
Organ Function - Pulmonary Function Part
4 Of
Did the recipient develop pulmonary
hemorrhage?
No (No)
Yes (Yes)
Date of diagnosis: (Of acute GVHD)
Were diagnostic tests done?
No (No)
Yes (Yes)
Bronchoalveolar lavage (BAL)
No (No)
Yes (Yes)
Transbronchial biopsy
No (No)
Yes (Yes)
Open / thorascopic lung biopsy (VATS)
No (No)
Yes (Yes)
Autopsy
No (No)
Yes (Yes)
Other test
No (No)
Yes (Yes)
Specify other test
Organ Function - Pulmonary Function Part
4 Of
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Did the recipient develop cryptogenic organizing
pneumonia? (COP)
No (No)
Yes (Yes)
Date of diagnosis: (Of acute GVHD)
Were diagnostic tests done?
No (No)
Yes (Yes)
Bronchoalveolar lavage (BAL)
No (No)
Yes (Yes)
Transbronchial biopsy
No (No)
Yes (Yes)
Open / thorascopic lung biopsy (VATS)
No (No)
Yes (Yes)
Autopsy
No (No)
Yes (Yes)
Other test
No (No)
Yes (Yes)
Specify other test
Organ Function - Pulmonary Function Part
11 Of 11
Did the recipient develop any other non-infectious
pulmonary abnormalities?
No (No)
Yes (Yes)
Specify other pulmonary abnormality
Did the recipient receive endotracheal intubation
or mechanical ventilation? (Post-HSCT)
No (No)
Yes (Yes)
Organ Function - Liver Function Part 1 Of
2
Did the recipient develop non-infectious liver
toxicity? (Excluding GVHD. After the start of the
preparative regimen to the date of last contact)
No (No)
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Yes (Yes)
Date of diagnosis: (Of acute GVHD)
Cirrhosis
No (No)
Yes (Yes)
Veno-occlusive disease / sinusodial obstruction
syndrome (VOD / SOS)
No (No)
Yes (Yes)
Did the recipient receive treatment for VOD?
No (No)
Yes (Yes)
Specify:
Did VOD resolve? (By day 100)
No (No)
Yes (Yes)
Maximum bilirubin: (In first 100 days)
Other
No (No)
Yes (Yes)
Specify other etiology
Unknown
No (No)
Yes (Yes)
Organ Function - Liver Function Part 2 Of
2
Specify diagnosis of liver toxicity by clinical signs
and symptoms / evaluation:
Ascites (Ascites)
Autopsy (Autopsy)
Greater Than Integer::2.0 Milligram
Bilirubin (Bilirubin greater than 2.0 mg)
Biopsy (Biopsy)
Elevated Hepatic Venous Pressure
Gradient (Elevated hepatic venous
pressure gradient)
Elevated Liver Enzyme (Elevated liver
enzymes)
Hepatomegaly (Hepatomegaly)
Other (Other)
Right Upper Quadrant Pain Or
Tenderness (Right upper quadrant pain
or tenderness)
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Doppler Echocardiography And/or
Ultrasound Imaging (Ultrasonography /
doppler)
Greater Than Integer::5 Percentage
Weight Gain (Weight gain greater than 5
percent)
Was the diagnosis of liver toxicity determined by
clinical signs and symptoms / evaluation:
No (No)
Yes (Yes)
Specify other evaluation (Answer only if the
response to CDE 2801066 is "Other")
Organ Function - Other Organ Impairment
/ Disorder Paer 1 Of 2
Has the recipient developed any other clinically
significant organ impairment or disorder? (After
the start of the preparative regimen to the date of
last contact.)
No (No)
Yes (Yes)
Organ Function - Other Organ Impairment
/ Disorder Part 2 Of 2
Specify impairment / disorder:
A Condition In Which The Poor Blood
Supply To An Area Of Bone Leads To
Bone Death. (Avascular necrosis)
Cataract (Cataracts)
Congestive Heart Failure (Congestive
heart failure)
Diabetes Mellitus And/or Hyperglycemia
(Diabetes/hyperglycemia)
Gonadal Disorder And/or Infertility
Required Testosterone Or Estrogen
Replacement Therapy (Gonadal
dysfunction/infertility requiring hormone
replacement)
Growth Hormone Deficit And/or Growth
Disturbance (Growth hormone
deficiency/growth disturbance)
Hemorrhage Cystitis And/or Hematuria
(Hemorraghic cystitis/hematuria requiring
medical intervention)
Hypothyroidism (Hypothyroidism)
Myocardial Infarction (Myocardial
infarction)
Other (Other)
Pancreatitis (Pancreatitis)
Post Graft Thrombotic Microangiopathy
Hemolytic Uremic Syndrome Or
Similarity (Post-transplant
microangiopathy-thrombotic
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thrombocytopenic purpura (TTP),
hemolytic uremic syndrome (HUS), or
similar syndrome)
Renal Failure Severe Need Dialysis
(Renal failure severe enough to warrant
dialysis)
Cerebrovascular Accident And/or
Seizure (Stroke/seizure)
Did a particular type of organ impairment /
disorder occur?
No (No)
Yes (Yes)
Date of diagnosis: (Of acute GVHD)
Did the recipient receive plasmapheresis?
(Answer only if the response to CDE 2797538 is
"Post-transplant microangiopathy-thrombotic
thrombocytopenic purpura TTP, hemolytic uremic
syndrome HUS, or similar syndrome")
No (No)
Yes (Yes)
Did the recipient receive dialysis? (Answer only if
the response to CDE 2797538 is "Renal failure
severe enough to warrant dialysis")
No (No)
Yes (Yes)
Specify other impairment / disorder (Answer only
if the response to CDE 2797538 is "Other")
Organ Function - New Malignancy
Did a new malignancy, lymphoproliferative or
myeloproliferative disorder appear that is different
from the disease for which the HSCT was
performed?
No (No)
Yes (Yes)
For all new malignancies except for "other skin
malignancy (basal cell, squamous)," was testing
performed to determine the cell of origin?
No (No)
Other Skin Malignant Neoplasm (The
only new malignancy in this reporting
period was "other skin malignancy(basal
cell, squamous)")
Yes (Yes)
Specify the cell origin of the new malignancy:
Donor (Donor)
Origin Unknown (Origin unknown)
Hematopoietic Stem Cell Graft Recipient
(Recipient)
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Are chimerism laboratory reports attached to this
form?
No (No)
Yes (Yes)
New Malignancy, Lymphoproliferative Or
Myeloproliferative Disorder
Specify which new disease(s) occurred:
Acute Myeloid Leukemia (Acute myeloid
leukemia (AML / ANLL))
Breast Carcinoma (Breast cancer)
Central Nervous System Neoplasm
(Central nervous system (CNS)
malignancy (glioblastoma, astrocytoma))
Malignant Gastrointestinal Neoplasm
(Gastrointestinal malignancy (colon,
rectum, stomach, pancreas, intestine))
Genitourinary System Malignant
Neoplasm (Genitourinary malignancy
(kidney, bladder, ovary, testicle, genitalia,
uterus, cervix))
Hodgkin's Lymphoma (Hodgkin disease)
Lung Carcinoma (Lung cancer)
Lymphoma Or Lymphoproliferative
Disorder (Lymphoma or
lymphoproliferative disease)
Melanoma (Melanoma)
Myelodysplastic/myeloproliferative
Disease (Myelodysplasia (MDS),
myeloproliferative (MPS) disorder)
Oropharyngeal Carcinoma
(Oropharyngeal cancer (tongue, buccal
mucosa))
Other Leukemia (Other leukemia
including ALL)
Other Malignant Neoplasm (Other
malignancy)
Other Malignant Skin Neoplasm (Other
skin malignancy (basal cell, squamous))
Clonality Cytogenetic Abnormality
(Related by descent from clonal
cytogenetic abnormality without leukemia
or MDS)
Sarcoma (Sarcoma)
Thyroid Gland Carcinoma (Thyroid
cancer)
Did a new malignancy, lymphoproliferative or
myeloproliferative disorder appear that is different
from the disease for which the HSCT was
performed?
No (No)
Yes (Yes)
Date of diagnosis: (Of acute GVHD)
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Is the tumor EBV positive? (Answer only if the
response to CDE 2677021 is "Lymphoma or
lymphoproliferative disease.")
No (No)
Yes (Yes)
Specify the new malignancy, lymphoproliferative
or myeloproliferative disorder: (Answer only if the
response to CDE 2677021 is "Other leukemia,
including ALL," "Other skin malignancy basal cell,
squamous," or "Other new malignancy.")
Organ Function - New Malignancy Part 3
Of 3
Is a pathology / autopsy report or other
documentation attached?
No (No)
Yes (Yes)
Functional Status
Was the recipient discharged from the hospital
after HSCT?
No (No)
Not Applicable (Not Applicable)
Yes (Yes)
Date first discharged from hospital post-HSCT:
Total number of inpatient days (day 0 to day 100)
in first 100 days post-HSCT
Which scale was used to measure/report the
functional status? (If the recipient is 16 years of
age or older, complete the Karnofsky Scale. If the
recipient is younger than 16 years of age,
complete the Lansky Scale. If the recipient has
died, skip this question.)
Karnofsky Performance Status
(Karnofsky)
Lansky Play-performance Status
(Lansky)
Karnofsky Performance Status Score (On the
date of last actual contact. If the recipient is 16
years of age or older, complete the Karnofsky
Scale.)
Moribund, Fatal Processes Progressing
Rapidly (10)
Normal, No Complaints, No Evidence Of
Disease (100)
Very Sick, Hospitalization Indicated.
Death Not Imminent (20)
Severely Disabled, Hospitalization
Indicated. Death Not Imminent (30)
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Disabled, Requires Special Care And
Assistance (40)
Requires Considerable Assistance And
Frequent Medical Care (50)
Requires Occasional Assistance, But Is
Able To Care For Most Of His/her Needs
(60)
Cares For Self, Unable To Carry On
Normal Activity Or To Do Active Work
(70)
Normal Activity With Effort; Some Signs
Or Symptoms Of Disease (80)
Able To Carry On Normal Activity; Minor
Signs Or Symptoms Of Disease (90)
Lansky Performance Status Score (On the date
of last actual contact. If the recipient is younger
than 16 years of age, complete the Lansky
Scale.)
No Play; Does Not Get Out Of Bed. (10)
Fully Active, Normal (100)
Often Sleeping; Play Entirely Limited To
Very Passive Activities (20)
In Bed; Needs Assistance Even For
Quiet Play. (30)
Mostly In Bed; Participates In Quiet
Activities. (40)
Gets Dressed, But Lies Around Much Of
The Day; No Active Play, Able To
Participate In All Quiet Play And
Activities. (50)
Up And Around, But Minimal Active Play;
Keeps Busy With Quieter Activities. (60)
Both Greater Restriction Of And Less
Time Spent In Play Activity (70)
Active, But Tires More Quickly (80)
Minor Restrictions In Physically
Strenuous Activity (90)
Subsequent Hsct
Date of subsequent HSCT:
Was the subsequent HSCT performed at a
different institution?
No (No)
Yes (Yes)
Name: (Of the institution that performed the
subsequent HSCT)
City: (Of the institution that performed the
subsequent HSCT)
State / Country: (Of the institution that performed
the subsequent HSCT)
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What was the indication for the subsequent
HSCT? (Subsequent autologous HSCTs
performed for engraftment reasons "No
hematopoietic recovery," "Partial hematopoietic
recovery," and "Graft failure / rejection after
achieving initial hematopoietic recovery" do not
require separate report forms to - be completed.
All other subsequent HSCTs will require a
separate follow-up report form completed for
each infusion.)
Loss Or Reduced Donor Chimerism
(Declining chimerism)
Graft Failure Post First Hematopoietic
Recovery (Graft failure / rejection after
achieving initial hematopoietic recovery)
New Malignant Neoplasm (New
malignancy)
Hematopoietic Stem Cell No Recovery
(No hematopoietic recovery)
Other (Other)
Hematopoietic Stem Cell Partial
Recovery (Partial hematopoietic
recovery)
Persistent Primary Disease Or Disorder
(Persistent primary disease)
Hematopoietic Stem Cell Second Plan
Transplantation (Planned second HSCT,
per protocol)
Recurrent Primary Disease Or Disorder
(Recurrent primary disease)
Mixed Stable Chimerism (Stable, mixed
chimerism)
Specify other indication
Subsequent Hsct
Source of HSCs:
Related Allogenic (Allogeneic, related)
Unrelated Allogenic (Allogeneic,
unrelated)
Autologous (Autologous)
Was the same donor used?
No (No)
Yes (Yes)
Specify:
Cryopreservation Original Donor Bone
Marrow (Cryopreserved original donor
bone marrow)
Cryopreservation Original Donor
Mobilized Peripheral Blood Stem Cell
(Cryopreserved original donor mobilized
peripheral blood stem cells)
Tissue, Fresh Original Donor National
Marrow Donor Program Bone Marrow
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(Fresh, original NMDP donor bone
marrow)
Tissue, Fresh Original Donor National
Marrow Donor Program Mobilized
Peripheral Blood Stem Cell (Fresh,
original NMDP donor mobilized
peripheral blood stem cells)
Tissue, Fresh Original Negation National
Marrow Donor Program Donor Bone
Marrow (Fresh, original non-NMDP
donor bone marrow)
Tissue, Fresh Original Negation National
Marrow Donor Program Donor Mobilized
Peripheral Blood Stem Cell (Fresh,
original non-NMDP donor mobilized
peripheral blood stem cells)
Tissue, Fresh Next National Marrow
Donor Program Donor Bone Marrow
(Fresh, subsequent NMDP donor bone
marrow)
Tissue, Fresh Next National Marrow
Donor Program Donor Mobilized
Peripheral Blood Stem Cell (Fresh,
subsequent NMDP donor mobilized
peripheral blood stem cells)
Tissue, Fresh Next Negation National
Marrow Donor Program Donor Bone
Marrow (Fresh, subsequent non-NMDP
donor bone marrow)
Tissue, Fresh Next Negation National
Marrow Donor Program Donor Mobilized
Peripheral Blood Stem Cell (Fresh,
subsequent non-NMDP donor mobilized
peripheral blood stem cells)
National Marrow Donor Program
Umbilical Cord Blood (NMDP cord blood)
Negation National Marrow Donor
Program Umbilical Cord Blood (Non-
NMDP cord blood)
Donor Cellular Infusion (dci) Information
Date of DCI:
Organism
Acinetobacter (Acinetobacter)
Actinomyces (Actinomyces)
Adenovirus (Adenovirus)
Aspergillus Flavus (Aspergillus flavus)
Aspergillus Fumigatus (Aspergillus
fumigatus)
Aspergillus Niger (Aspergillus niger)
Aspergillus Not Otherwise Specified
(Aspergillus, NOS)
Bacillus (Bacillus)
Bacteroides (Bacteroides (gracillis,
uniformis, vulgaris, other species))
Bordetella Pertussis (Bordetella
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pertussis (whooping cough))
Borrelia Burgdorferi (Borrelia (lyme
disease))
Moraxella Catarrhalis (Branhamella or
Moraxella catarrhalis (other species))
Campylobacter (Campylobacter (all
species))
Candida Glabrata (Candida (Torulopsis)
glabrata)
Candida Albicans (Candida albicans)
Pichia Guilliermondii (Candida
guillermondi)
Issatchenkia Orientalis (Candida krusei)
Clavispora Lusitaniae (Candida
lusitaniae)
Candida Parapsilosis (Candida
parapsilosis)
Candida Tropicalis (Candida tropicalis)
Candida Not Otherwise Specified
(Candida, NOS)
Capnocytophaga (Capnocytophaga)
Chlamydophila Pneumoniae (Chlamydia
(pneumoniae))
Chlamydia Not Otherwise Specified
(Chlamydia, NOS)
Citrobacter (Citrobacter (freundii, other
species))
Clostridium (Clostridium (all species
except difficile))
Clostridium Difficile (Clostridium difficile)
Corynebacterium (Corynebacterium (all
non-diptheria species))
Corynebacterium Jeikeium
(Corynebacterium (jeikeium))
Coxiella (Coxiella)
Cryptococcosis (Cryptococcosus
species)
Cryptosporidium (Cryptosporidium)
Cytomegalovirus (Cytomegalovirus)
Enterobacter (Enterobacter)
Enterococcus (Enterococcus (all
species))
Vancomycin Resistant Enterococcus
(Enterococcus, vancomycin resistant
(VRE))
Enterovirus (Enterovirus)
Epstein-barr Virus (Epstein-Barr Virus)
Escherichia Coli (Escherichia (also E.
coli))
Pseudomonas Oryzihabitans
(Flavimonas oryzihabitans)
Flavobacterium (Flavobacterium)
Fusarium (Fusarium species)
Fusobacterium (Fusobacterium)
Giardia (Giardia)
Haemophilus (Haemophilus (all species,
including influenzae))
Helicobacter Pylori (Helicobacter pylori)
Hepatitis A Virus (Hepatitis A Virus)
Hepatitis B Virus (Hepatitis B Virus)
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Hepatitis C Virus (Hepatitis C Virus)
Herpes Simplex Virus (Herpes Simplex
Virus)
Herpes Zoster (Herpes Zoster)
Histoplasmosis (Histoplasmosis)
Human Herpesvirus 6 (Human
Herpesvirus 6)
Human Immunodeficiency Virus 1
(Human Immunodeficiency Virus 1)
Human Papillomavirus (Human
Papillomavirus)
Influenza A Virus (Influenza A Virus)
Influenza B Virus (Influenza B Virus)
Other Influenza (Influenza, NOS)
Klebsiella (Klebsiella)
Lactobacillus (Lactobacillus (bulgaricus,
acidophilus, other species))
Legionella (Legionella)
Leptospira (Leptospira)
C76356 (Leptotrichia buccalis)
Leuconostoc (Leuconostoc (all species))
Listeria (Listeria)
Measles Virus (Measles Virus)
Methylobacterium (Methylobacterium)
Micrococcus Not Otherwise Specified
(Micrococcus, NOS)
Zygomycosis (Mucormycosis)
Multiple Bacteria (Multiple bacteria at a
single site)
Mumps Virus (Mumps Virus)
Mycobacterium Avium Complex
(Mycobacterium avium - intracellulare
(MAC, MAI))
Mycobacterium Species (Mycobacterium
species (cheloneae, fortuitum,
haemophilum, kansasii, mucogenicum))
Mycobacterium Tuberculosis
(Mycobacterium tuberculosis
(tuberculosis, Koch bacillus))
Mycobacterium Not Otherwise Specified
(Mycobacterium, NOS)
Mycoplasma (Mycoplasma)
Neisseria (Neisseria (gonorrhoeae,
meningitidis, other species))
Not Identified Organism (No organism
identified)
Nocardia (Nocardia)
Other Aspergillus (Other Aspergillus)
Other Bacteria (Other bacteria)
Other Candida (Other Candida)
Other Chlamydia (Other chlamydia)
Other Fungi (Other fungus)
Other Mycobacterium (Other
mycobacterium)
Other Parasite (Other parasite)
Other Virus (Other Virus)
Parainfluenza Virus (Parainfluenza Virus)
Pasteurella Multocida (Pasteurella
multocida)
Pneumocystis Pneumonia
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(Pneumocystis (PCP / PJP))
Polyomavirus (Polyomavirus)
Progressive Multifocal
Leukoencephalopathy (Progressive
Multifocal Leukoencephalopathy)
Propionibacterium Acnes
(Propionibacterium (acnes, avidum,
granulosum, other species))
Proteus (Proteus)
Pseudomonas (Pseudomonas (all
species except cepacia & maltophilia))
Burkholderia Cepacia (Pseudomonas or
Burkholder cepacia)
Stenotrophomonas Maltophilia
(Pseudomonas or Stenotrophomonas or
Xanthomonas maltophilia)
Respiratory Syncytial Virus (Respiratory
Syncytial Virus (RSV))
Rhinovirus (Rhinovirus)
Rhizopus (Rhizopus)
Rhodococcus (Rhodococcus)
Rickettsia (Rickettsia)
Rotavirus (Rotavirus)
Rubella Virus (Rubella Virus)
Salmonella (Salmonella (all species))
Serratia Marcescens (Serratia
marcescens)
Shigella (Shigella)
Staphylococcus Aureus (Staphylococcus
aureus)
Staphylococcus Coag Negative
(Staphylococcus, coagulase negative)
Streptococcus Not Otherwise Specified
(Staphylococcus, NOS)
Rothia Mucilaginosa (Stomatococcus
mucilaginosis)
Streptococcus (Streptococcus (all
species except Enterococcus))
Streptococcus Pneumoniae
(Streptococcus pneumoniae)
Suspected Atypical Bacteria Infection
(Suspected atypical bacterial infection)
Suspected Bacteria Infection (Suspected
bacterial infection)
Suspected Fungal Infection (Suspected
fungal infection)
Suspected Parasitic Infection (Suspected
parasite infection)
Suspected Viral Infection (Suspected
viral infection)
Toxoplasma (Toxoplasma)
Treponema (Treponema (syphilis))
Vibrio (Vibrio (all species))
Yeast Not Otherwise Specified (Yeast,
NOS)
Zygomycota Not Otherwise Specified
(Zygomycetes, NOS)
Specify the number of cell infusions given within
10 weeks of the DCI
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Was the DCI infusion performed at a different
institution?
No (No)
Yes (Yes)
Name: (Of the institution that performed the DCI)
City: (Of the institution that performed the DCI)
Karnofsky / Lansky score (At diagnosis of chronic
GVHD. If the recipient is 16 years of age or older,
complete the Karnofsky Scale. If the recipient is
younger than 16 years of age, complete the
Lansky Scale.)
Karnofsky Scale - Moribund, Fatal
Process Progressing Rapidly; Lansky
Scale - Completely Disabled, Not Even
Passive Play. (10)
Karnofsky Scale - Normal, No
Complaints, No Evidence Of Disease;
Lansky Scale - Fully Active. (100)
Karnofsky Scale - Very Sick,
Hospitalization Necessary; Lansky Scale
- Limited To Very Passive Activity
Initiated By Others (e.g., Tv) (20)
Karnofsky Scale - Severely Disabled,
Hospitalization Indicated, Although
Death Not Imminent. Lansky Scale -
Needs Considerable Assistance For
Quiet Activity. (30)
Karnofsky Scale - Disabled, Requires
Special Care And Assistance. Lansky
Scale - Able To Initiate Quiet Activities.
(40)
Karnofsky Scale - Requires
Considerable Assistance And Frequent
Medical Care; Lansky Scale -
Considerable Assistance Required For
Any Active Play; Fully Able To Engage In
Quiet Play. (50)
Karnofsky Scale - Requires Occasional
Assistance, But Is Able To Care For Most
Needs; Lansky Scale - Ambulatory Up To
50r Of Time, Limited Active Play With
Assistance / Supervision. (60)
Karnofsky Scale - Cares For Self, Unable
To Carry On Normal Activity Or To Do
Active Work.; Lansky Score - Both
Greater Restrictions Of, And Less Time
Spent In, Active Play. (70)
Karnofsky Scale - Normal Activity With
Effort; Lansky Scale - Restricted In
Strenuous Play, Tires More Easily,
Otherwise Active. (80)
Karnofsky Scale - Able To Carry On
Normal Activity; Lansky Scale - Minor
Restriction In Physically Strenuous Play.
(90)
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State / Country: (Of the institution that performed
the DCI)
Indication for DCI
Loss Reduced Donor T-lymphocyte
Chimerism (Loss of / decreased donor T-
cell chimerism)
Other (Other)
Part First Hematopoietic Stem Cell
Transplantation Protocol Plan (Planned
as part of initial HSCT protocol)
Mixed Stable Chimerism (Stable, mixed
chimerism)
Therapeutic Procedure Graft Versus
Host Disease (Treatment for GVHD)
Post-transplant Lymphoproliferative
Disorder Epstein-barr Virus Therapeutic
Procedure (Treatment for PTLD, EBV
lymphoma)
Therapeutic Procedure Recurrent
Disease Persistent Pd Disease Or
Disorder (Treatment for relapsed,
persistent or progressive disease)
Therapeutic Procedure Viral Infection
(Viral infection)
Molecular (Method of disease detection)
Negative Finding (Negative)
Not Done Unknown (Not done /
Unknown)
Positive Finding (Positive)
Date: ( If the result was positive report the first
date the disease was detected; if the result was
negative report the last date the method was
used prior to DCI.)
Cytogenetic (Method of disease detection)
Negative Finding (Negative)
Not Done Unknown (Not done /
Unknown)
Positive Finding (Positive)
Date: ( If the result was positive report the first
date the disease was detected; if the result was
negative report the last date the method was
used prior to DCI.)
Clinical evidence / hematologic (Method of
disease detection)
Negative Finding (Negative)
Not Done Unknown (Not done /
Unknown)
Positive Finding (Positive)
Date: ( If the result was positive report the first
date the disease was detected; if the result was
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negative report the last date the method was
used prior to DCI.)
Was chemotherapy used to attempt to induce
disease response? (Prior to the DCI)
No (No)
Yes (Yes)
Date of administration of final chemotherapy dose
Date documented:
Specify other indication
What was the recipient's disease status?
(Immediately prior to the DCI)
First Complete Remission (First
complete remission)
Negation Evaluation (Not evaluated post-
HSCT)
Persistent Disease Or Disorder
(Persistent disease)
Recurrent Disease Or Disease
Progression (Relapse or progression)
Therapeutic Procedure Induction
Complete Remission (Therapy-induced
complete remission after persistent
disease or relapse post-HSCT)
Date the disease status was established: (Prior to
the DCI)
Collected at the time of PBSC mobilization and
collection (DCI source)
No (No)
Yes (Yes)
Negative fraction of CD34 selected PBSC (DCI
source)
No (No)
Yes (Yes)
Negative fraction of CD34 selected bone marrow
(DCI source)
No (No)
Yes (Yes)
Apheresis at a different time than collection of
PBSC used for allogeneic HSCT (DCI source)
No (No)
Yes (Yes)
Date of apheresis:
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Isolated from a unit(s) of whole blood (DCI
source)
No (No)
Yes (Yes)
Specify number of units:
Were the donor cells collected by leukapheresis?
No (No)
Yes (Yes)
Date of first leukapheresis:
Date of last leukapheresis:
Number of leukaphereses:
Did the donor receive treatment to enhance cell
collection prior to donation?
No (No)
Yes (Yes)
Growth factor(s)
No (No)
Yes (Yes)
G-CSF
No (No)
Yes (Yes)
GM-CSF
No (No)
Yes (Yes)
Other agent
No (No)
Yes (Yes)
Specify other agent
Other treatment
No (No)
Yes (Yes)
Specify other treatment
CD3+ cells: (For each DCI given, report the total
number of cells infused. If the cells were
cryopreserved, report the totals after processing,
but before cryopreservation.)
CD3+ cells exponent value:
49 / 55
Follow-Up - 2100 Revision 2 - 100 Days Post-HSCT Data - 3061622v2.0
What is the reason for the CD3+ cells missing
value?
Negation Test (Not tested)
CD4+ cells: (For each DCI given, report the total
number of cells infused. If the cells were
cryopreserved, report the totals after processing,
but before cryopreservation.)
CD4+ cells exponent value:
What is the reason for the CD4+ cells missing
value?
Negation Test (Not tested)
CD8+ cells: (For each DCI given, report the total
number of cells infused. If the cells were
cryopreserved, report the totals after processing,
but before cryopreservation.)
CD8+ cells exponent value:
What is the reason for the CD8+ cells missing
value?
Negation Test (Not tested)
CD34+ cells: (For each DCI given, report the total
number of cells infused. If the cells were
cryopreserved, report the totals after processing,
but before cryopreservation.)
CD34+ cells exponent value:
What is the reason for the CD34+ cells missing
value?
Negation Test (Not tested)
NK cells: (For each DCI given, report the total
number of cells infused. If the cells were
cryopreserved, report the totals after processing,
but before cryopreservation.)
NK cells exponent value:
What is the reason for the NK cells missing
value?
Negation Test (Not tested)
Nucleated cells: (For each DCI given, report the
total number of cells infused. If the cells were
cryopreserved, report the totals after processing,
but before cryopreservation.)
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Nucleated cells exponent value:
What is the reason for the nucleated cells missing
value?
Negation Test (Not tested)
Mesenchymal cells: (For each DCI given, report
the total number of cells infused. If the cells were
cryopreserved, report the totals after processing,
but before cryopreservation.)
Mesenchymal cells exponent value:
What is the reason for the mesenchymal cells
missing value?
Negation Test (Not tested)
Were dendritic cells infused?
No (No)
Yes (Yes)
Were fibroblasts infused?
No (No)
Yes (Yes)
Were any other cell types infused? (Not including
cell types reported in questions 612-620 CDEs
2760303, 2760372, 2772153, 2760286, 2771962,
2760234, 2771985, 2614541, and 2680329.)
No (No)
Yes (Yes)
Specify other cell type(s)
Were the cells cryopreserved prior to infusion?
No (No)
Yes (Yes)
Specify portion of cells cryopreserved prior to
infusion
Entire Hematopoietic Stem Cell
Collection (Entire product)
Part Hematopoietic Stem Cell Collection
(Portion of product)
Was the product manipulated prior to infusion?
No (No)
Yes (Yes)
Specify portion manipulated:
Entire Hematopoietic Stem Cell
Collection (Entire product)
Part Hematopoietic Stem Cell Collection
(Portion of product)
ABO incompatibility
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No (No)
Yes (Yes)
Buffy coat preparation
No (No)
Yes (Yes)
Cell separator (i.e., COBE Spectra)
No (No)
Yes (Yes)
Density gradient separation (i.e., Ficoll)
No (No)
Yes (Yes)
Plasma removal
No (No)
Yes (Yes)
Sedimentation (i.e., Hetastarch)
No (No)
Yes (Yes)
Other
No (No)
Yes (Yes)
Specify other method:
Dextran-albumin wash
No (No)
Yes (Yes)
Ex-vivo expansion
No (No)
Yes (Yes)
Genetic manipulation (Gene transfer /
transduction)
No (No)
Yes (Yes)
Volume reduction
No (No)
Yes (Yes)
CD34+ selection
No (No)
Yes (Yes)
Specify manufacturer:
Clinimax Cell Selection System
(CliniMACS / CliniMax)
Isolex Cell Selection System (Isolex)
Other (Other)
Specify other manufacturer:
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T-cell depletion
No (No)
Yes (Yes)
Antibody affinity column
No (No)
Yes (Yes)
Antibody coated plates
No (No)
Yes (Yes)
Antibody coated plates and soybean lectin
No (No)
Yes (Yes)
Antibody and complement
No (No)
Yes (Yes)
Antibody and toxin
No (No)
Yes (Yes)
Immunomagnetic beads
No (No)
Yes (Yes)
Elutriation
No (No)
Yes (Yes)
CD34 affinity column plus sheep red blood cell
rosetting
No (No)
Yes (Yes)
Other
No (No)
Yes (Yes)
Specify other method
Other cell manipulation
No (No)
Yes (Yes)
Specify other cell manipulation:
Were antibodies used during graft manipulation?
No (No)
Yes (Yes)
Anti CD2
No (No)
Yes (Yes)
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Anti CD4
No (No)
Yes (Yes)
Anti CD5
No (No)
Yes (Yes)
Anti CD6
No (No)
Yes (Yes)
Anti CD7
No (No)
Yes (Yes)
Anti CD8
No (No)
Yes (Yes)
Anti CD34
No (No)
Yes (Yes)
Anti TCR alpha / beta (T10-B9)
No (No)
Yes (Yes)
OKT-3
No (No)
Yes (Yes)
Other CD3
No (No)
Yes (Yes)
Specify other CD3:
Anti CD52
No (No)
Yes (Yes)
Campath-NOS
No (No)
Yes (Yes)
Campath-1G
No (No)
Yes (Yes)
Campath-1H
No (No)
Yes (Yes)
Other antibody
No (No)
Yes (Yes)
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Specify other antibody:
Donor Cellular Infusion (dci) Information
Part 2 Of 2
First Name
Last Name:
Telephone number:
Fax number:
E-mail address:
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All rights reserved. Please visit https://medical-data-
models.org/forms/1682
2300 Revision 2 - Yearly Follow-Up
for Greater Than Two Years Post-
HSCT Data
Registry Use Only
Sequence number:
Date received:
Identification Data
CIBMTR Center Number:
CIBMTR Recipient ID:
Today's date:
Date of hematopoietic stem cell transplantation
(HSCT) for which this form is being completed:
Hsct Type
HSCT type
Related Allogenic (Allogeneic, related)
Unrelated Allogenic (Allogeneic,
unrelated)
Autologous (Autologous)
Syngeneic (Syngeneic (identical twin))
Was a particular hematopoietic stem cell source
used?
Yes (Yes)
Product Type
What type of hematopoietic stem cell transplant
was used?
Umbilical Cord Blood (Cord blood)
Bone Marrow (Marrow)
Multiple Umbilical Cord Blood (Multiple
cord blood units infused)
Other (Other)
Peripheral Blood Stem Cell (PBSC)
Was a particular hematopoietic stem cell
transplant type used?
Yes (Yes)
Specify the other hematopoietic stem cell
1 / 29
transplant type: (Answer only if the response to
CDE 2730912 is "Other")
Follow Up Visit
Follow-up visit (years after transplant)
Vital Status
Is the data reported on this form based on
contact with the physician?
No (No)
Yes (Yes)
Date of actual contact with the recipient to
determine the medical status for this follow-up
report:
Did the recipient receive a subsequent HSCT?
(Since the date of contact from the last report.
Bone marrow, mobilized peripheral blood stem
cells, cord blood.)
No (No)
Yes (Yes)
Specify the recipient's survival status at the date
of actual contact:
Life (Alive)
Death (Dead)
Has the recipient received a donor cellular
infusion? (DCI. Since the date of contact from the
last report.)
No (No)
Yes (Yes)
Functional Status
Which scale was used to measure/report the
functional status? (If the recipient is 16 years of
age or older, complete the Karnofsky Scale. If the
recipient is younger than 16 years of age,
complete the Lansky Scale. If the recipient has
died, continue with question 7 on the PDF version
of the form, CDE 2815112.)
Karnofsky Performance Status
(Karnofsky)
Lansky Play-performance Status
(Lansky)
Karnofsky Performance Status Score (On the
date of last actual contact. If the recipient is 16
years of age or older, complete the Karnofsky
Scale.)
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Moribund, Fatal Processes Progressing
Rapidly (10)
Normal, No Complaints, No Evidence Of
Disease (100)
Very Sick, Hospitalization Indicated.
Death Not Imminent (20)
Severely Disabled, Hospitalization
Indicated. Death Not Imminent (30)
Disabled, Requires Special Care And
Assistance (40)
Requires Considerable Assistance And
Frequent Medical Care (50)
Requires Occasional Assistance, But Is
Able To Care For Most Of His/her Needs
(60)
Cares For Self, Unable To Carry On
Normal Activity Or To Do Active Work
(70)
Normal Activity With Effort; Some Signs
Or Symptoms Of Disease (80)
Able To Carry On Normal Activity; Minor
Signs Or Symptoms Of Disease (90)
Lansky Performance Status Score (On the date
of last actual contact. If the recipient is younger
than 16 years of age, complete the Lansky
Scale.)
No Play; Does Not Get Out Of Bed. (10)
Fully Active, Normal (100)
Often Sleeping; Play Entirely Limited To
Very Passive Activities (20)
In Bed; Needs Assistance Even For
Quiet Play. (30)
Mostly In Bed; Participates In Quiet
Activities. (40)
Gets Dressed, But Lies Around Much Of
The Day; No Active Play, Able To
Participate In All Quiet Play And
Activities. (50)
Up And Around, But Minimal Active Play;
Keeps Busy With Quieter Activities. (60)
Both Greater Restriction Of And Less
Time Spent In Play Activity (70)
Active, But Tires More Quickly (80)
Minor Restrictions In Physically
Strenuous Activity (90)
Specify the category which best describes the
occupation of the recipient (Current occupation. If
the recipient is not currently employed, select
which best describes his/her last job.)
Clerk (Clerical or related occupation)
Equipment Operator (Equipment /
vehicle operator or related occupation)
Farmer (Farmer)
Homemaker (Homemaker)
Laborer (Laborer)
Manager (Manager, administrator, or
proprietor)
Military Personnel (Member of the
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military)
Negation Previous Employment (Not
previously employed)
Other (Other)
Professional Occupation (Professional,
technical, or related occupation)
Salesperson (Sales occupation)
Service Occupation (Service occupation)
Skilled Worker (Skilled craft or related
occupation)
Student (Student)
Less Than School Age Child (Under
school age)
Unknown (Unknown)
Specify other occupation:
What is the current or most recent work status?
(During this reporting period.)
Full Time Employment (Full time)
Less Than Integer::16 Year Age (Less
than 16 years old)
Employment Disability (Medical
disability)
Part Time Employment (Part time)
Retirement (Retired)
Unemployment (Unemployed)
Employment Unknown (Unknown)
Specify retirement level:
With Source Income (With a source of
income)
Without Source Income (Without a
source of income)
Acute Graft Vs. Host Disease (gvhd)
Did acute GVHD develop or persist? (Or a flare-
up that was more severe since the date of the last
report)
No (No)
Unknown (Unknown)
Yes (Yes)
Date of diagnosis: (Of acute GVHD)
If necessary, please validate the diagnosis date
response. (Of acute GVHD)
Date Previous Report (Date previously
reported)
Was the diagnosis based on evidence from a
biopsy? (Histology)
No (No)
Yes (Yes)
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Acute Graft Vs. Host Disease (gvhd) Part
2 Of 6
What is the biopsy site used to indicate the
diagnostic evidence:
Gastrointestinal (Gastrointestinal (GI))
Liver (Liver)
Lung (Lung)
Other (Other)
Skin (Skin)
Specify result(s):
Uncertain (Inconclusive)
Negative Finding (Negative)
Not Done: C49484 (Not Done)
Positive Finding (Positive)
Specify other site: (Answer only if the response to
CDE 2787340 is "Other")
Acute Graft Vs. Host Disease (gvhd) Part
3 Of
Is a copy of the pathology report attached?
No (No)
Yes (Yes)
Was the diagnosis based on clinical evidence?
No (No)
Yes (Yes)
Maximum overall grade of acute GVHD:
Agvhd Grade I (I)
Agvhd Grade Ii (II)
Agvhd Grade Iii (III)
Agvhd Grade Iv (IV)
Is acute GVHD still present at the date of contact
for this report?
No (No)
Progressive Chronic Graft Versus Host
Disease (Progressed to chronic GVHD)
Unknown (Unknown)
Yes (Yes)
List the maximum severity of skin involvement:
No Skin Acute Gvhd / Rash Not
Attributable To Acute Gvhd (None)
No Rash (Stage 0)
Maculopapular Rash, Less Than 25
Percent Of Body Surface (Stage 1)
Maculopapular Rash, 25 To 50 Percent
Of Body Surface (Stage 2)
Generalized Erythroderma (Stage 3)
Generalized Erythroderma With Bullae
Formation And Desquamation (Stage 4)
List the maximum severity of lower intestinal tract
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involvement (Use mL/day for adult recipients and
mL/mE2/day for pediatric recipients)
No Gut Acute Gvhd / Diarrhea Not
Attributable To Acute Gvhd (None)
Diarrhea Less Than Or Equal To 500
Ml/day Or Less Than 280 Ml/me2 Day
(Stage 0)
No Diarrhea (Stage 0 - no diarrhea)
Diarrhea Greater Than 500 But Less
Than Or Equal To 1000 Ml/day Or 280-
555 Ml/me2 /day (Stage 1)
Diarrhea Greater Than 1000 But Less
Than Or Equal To 1500 Ml/day Or 556-
833 Ml/me2 /day (Stage 2)
Diarrhea Greater Than 1500 Ml/day Or
Greater Than 833 Ml/me2 /day (Stage 3)
Severe Abdominal Pain, With Or Without
Ileus (Stage 4)
List the maximum severity of upper intestinal tract
involvement:
No Persistant Nausea Or Vomiting
(Stage 0)
Persistant Nausea Or Vomiting (Stage 1)
List the maximum severity of liver involvement:
No Liver Acute Gvhd / Bilirubin Level Not
Attributable To Acute Gvhd (None)
Bilirubin Less Than 2.0 Mg/dl (less Than
34 Micro Mol/l) (Stage 0)
Bilirubin 2.0 To 3.0 Mg/dl (34 To 52 Micro
Mol/l) (Stage 1)
Bilirubin 3.1 To 6.0 Mg/dl (53 To 103
Micro Mol/l) (Stage 2)
Bilirubin 6.1 To 15.0 Mg/dl (104 To 256
Micro Mol/l) (Stage 3)
Bilirubin Greater Than 15.0 Mg/dl
(greater Than 256 Micro Mol/l) (Stage 4)
Other clinical organ involvement?
No (No)
Yes (Yes)
Acute Graft Vs. Host Disease (gvhd) Part
3 Of
Specify the site of organ involvement
Lung (Lung)
Other (Other)
Was a particular site of organ involvement
present?
No (No)
Yes (Yes)
Specify other site (Answer only if the response to
CDE 2793699 is "Other")
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Acute Graft Vs. Host Disease (gvhd) Part
7 Of
Was specific therapy used to treat acute GVHD?
(Since the date of the last report)
No (No)
Yes (Yes)
ALS, ALG, ATS, ATG
No (No)
Yes (Yes)
Specify source:
Horse (Horse)
Other Source (Other source)
Rabbit (Rabbit)
Specify source (Specify other source)
Corticosteroids (Systemic)
No (No)
Yes (Yes)
Corticosteroids (Topical)
No (No)
Yes (Yes)
Cyclosporine (CSA, Sandimmune, Neoral)
No (No)
Yes (Yes)
ECP (Extra-corporeal photopheresis)
No (No)
Yes (Yes)
FK 506 (Tacrolimus, Prograf)
No (No)
Yes (Yes)
In vivo monoclonal antibody
No (No)
Yes (Yes)
Anti CD 25 (Zenapax, Daclizumab, AntiTAC)
No (No)
Yes (Yes)
Specify anti CD25
Campath
No (No)
Yes (Yes)
Etanercept (Enbrel)
No (No)
Yes (Yes)
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Infliximab (Remicade)
No (No)
Yes (Yes)
Other in vivo monoclonal antibody
No (No)
Yes (Yes)
Specify antibody
In vivo immunotoxin
No (No)
Yes (Yes)
Specify immunotoxin
Methotrexate (MTX, Amethopterin)
No (No)
Yes (Yes)
Mycophenolate mofetil (MMF, CellCept)
No (No)
Yes (Yes)
Sirolimus (Rapamycin, Rapamune)
No (No)
Yes (Yes)
Ursodiol
No (No)
Yes (Yes)
Blinded randomized trial
No (No)
Yes (Yes)
Specify trial agent
Other agent
No (No)
Yes (Yes)
Specify other agent
Chronic Graft Vs. Host Disease (gvhd)
Did chronic GVHD develop or persist? (Or a flare-
up that was more severe since the date of the last
report)
No (No)
Current Therapy Negation Symptom (No
symptoms, but recipient is receiving
treatment)
Unknown (Unknown)
Yes (Yes)
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Date of diagnosis: (Of acute GVHD)
If necessary, please validate the diagnosis date
response. (Of acute GVHD)
Date Previous Report (Date previously
reported)
Onset of chronic GVHD was:
Symptoms Reactivated Within 30 Days
Of Drug Tapering Or Discontinuation
(Chronic GVHD flare)
Acute Gvhd Never Developed (De novo)
Acute Gvhd Resolved, Then Chronic
Gvhd Developed (Interrupted)
Acute Gvhd Progressed Directly To
Chronic Gvhd (Progressive)
Karnofsky / Lansky score (At diagnosis of chronic
GVHD. If the recipient is 16 years of age or older,
complete the Karnofsky Scale. If the recipient is
younger than 16 years of age, complete the
Lansky Scale.)
Karnofsky Scale - Moribund, Fatal
Process Progressing Rapidly; Lansky
Scale - Completely Disabled, Not Even
Passive Play. (10)
Karnofsky Scale - Normal, No
Complaints, No Evidence Of Disease;
Lansky Scale - Fully Active. (100)
Karnofsky Scale - Very Sick,
Hospitalization Necessary; Lansky Scale
- Limited To Very Passive Activity
Initiated By Others (e.g., Tv) (20)
Karnofsky Scale - Severely Disabled,
Hospitalization Indicated, Although
Death Not Imminent. Lansky Scale -
Needs Considerable Assistance For
Quiet Activity. (30)
Karnofsky Scale - Disabled, Requires
Special Care And Assistance. Lansky
Scale - Able To Initiate Quiet Activities.
(40)
Karnofsky Scale - Requires
Considerable Assistance And Frequent
Medical Care; Lansky Scale -
Considerable Assistance Required For
Any Active Play; Fully Able To Engage In
Quiet Play. (50)
Karnofsky Scale - Requires Occasional
Assistance, But Is Able To Care For Most
Needs; Lansky Scale - Ambulatory Up To
50r Of Time, Limited Active Play With
Assistance / Supervision. (60)
Karnofsky Scale - Cares For Self, Unable
To Carry On Normal Activity Or To Do
Active Work.; Lansky Score - Both
Greater Restrictions Of, And Less Time
Spent In, Active Play. (70)
Karnofsky Scale - Normal Activity With
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Effort; Lansky Scale - Restricted In
Strenuous Play, Tires More Easily,
Otherwise Active. (80)
Karnofsky Scale - Able To Carry On
Normal Activity; Lansky Scale - Minor
Restriction In Physically Strenuous Play.
(90)
What is the value of platelets? (At diagnosis of
chronic GVHD)
What is the unit of measure for platelets? (At
diagnosis of chronic GVHD)
10e6 Per Liter (10E6/L)
10e9 Cells Per Liter (10E9 Cells/L)
Diagnosis was based on:
Clinical And Histologic Finding (Both
clinical and histologic evidence)
Clinical Finding (Clinical evidence)
Histologic Finding And/or Biopsy
Confirmed (Histologic evidence / biopsy
proven)
Unknown (Unknown)
Maximum grade of chronic GVHD:
Extensive Gvhd Involvement (Extensive)
Limited Gvhd Involvement (Limited)
Overall severity of chronic GVHD:
Mild (Mild)
Moderate (Moderate)
Severe (Severe)
Chronic Graft Vs. Host Disease (gvhd) -
Organ Involvement
Specify the type of organ / system involvement
with chronic GVHD:
Autoantibody (Autoantibodies)
Bronchiolitis Obliterans (Bronchiolitis
obliterans)
Eosinophilia (Eosinophilia)
Eye (Eyes)
Gastrointestinal Tract (Gastrointestinal
tract)
Genitourinary System (Genitourinary
tract)
Liver (Liver)
Oral Cavity (Mouth)
Musculoskeletal (Musculoskeletal)
Other Hematopoietic Involvement (Other
hematologic involvement)
Other Lung Involvement (Other lung
involvement)
Other Organ Involvement (Other organ
involvement)
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Other Skin Or Hair Involvement (Other
skin or hair involvement)
Skin Sclerosis (Sclerosis of skin)
Serositis (Serositis)
Thrombocytopenia (Thrombocytopenia)
Weight Loss (Weight loss)
Indicate if there was an organ / system
involvement with chronic GVHD:
No (No)
Yes (Yes)
Indicate if the organ / system involvement was
proven by biopsy:
No (No)
Yes (Yes)
Specify the other site of the organ / system
involvement with chronic GVHD: (Answer only if
the response to CDE 2793857 is "Other organ
involvement")
Chronic Graft Vs. Host Disease (gvhd)
Was specific therapy used to treat chronic
GVHD?
No (No)
Yes (Yes)
ALS, ALG, ATS, ATG
No (No)
Yes (Yes)
Specify source:
Horse (Horse)
Other Source (Other source)
Rabbit (Rabbit)
Specify source (Specify other source)
Azathioprine
No (No)
Yes (Yes)
Corticosteroids (Systemic)
No (No)
Yes (Yes)
Corticosteroids (Topical)
No (No)
Yes (Yes)
Cyclosporine (CSA, Sandimmune, Neoral)
No (No)
Yes (Yes)
ECP (Extra-corporeal photopheresis)
No (No)
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Yes (Yes)
FK 506 (Tacrolimus, Prograf)
No (No)
Yes (Yes)
Etretinate
No (No)
Yes (Yes)
In vivo monoclonal antibody
No (No)
Yes (Yes)
Anti CD 25 (Zenapax, Daclizumab, AntiTAC)
No (No)
Yes (Yes)
Hydroxychloroquine (Plaquenil)
No (No)
Yes (Yes)
Specify anti CD25
Campath
No (No)
Yes (Yes)
Etanercept (Enbrel)
No (No)
Yes (Yes)
Infliximab (Remicade)
No (No)
Yes (Yes)
Other in vivo monoclonal antibody
No (No)
Yes (Yes)
Specify antibody
Lamprene (Clofazimine)
No (No)
Yes (Yes)
Mycophenolate mofetil (MMF, CellCept)
No (No)
Yes (Yes)
Sirolimus (Rapamycin, Rapamune)
No (No)
Yes (Yes)
Ursodiol
No (No)
Yes (Yes)
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Pentostatin
No (No)
Yes (Yes)
PUVA (Psoralen and UVA)
No (No)
Yes (Yes)
Blinded randomized trial
No (No)
Yes (Yes)
Specify trial agent
Other agent
No (No)
Yes (Yes)
Thalidomide
No (No)
Yes (Yes)
Specify other agent
Are symptoms of chronic GVHD still present?
(On the date of actual contact or present at the
time of death)
No (No)
Yes (Yes)
Is the recipient still taking immunosuppressive
agents to treat or prevent GVHD? (Including
PUVA)
No (No)
Unknown (Unknown)
Yes (Yes)
Date final treatment administered:
If necessary, please validate the final date of
immunosuppressant administration response.
Date Previous Report (Date previously
reported)
Date Unknown (Date unknown)
Organ Function - New Malignancy
Did a new malignancy, lymphoproliferative or
myeloproliferative disorder appear that is different
from the disease for which the HSCT was
performed? (Since the date of the last report)
No (No)
Yes (Yes)
For all new malignancies except for "other skin
malignancy (basal cell, squamous)," was testing
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performed to determine the cell of origin?
No (No)
Other Skin Malignant Neoplasm (The
only new malignancy in this reporting
period was "other skin malignancy(basal
cell, squamous)")
Yes (Yes)
Specify the cell origin of the new malignancy:
Donor (Donor)
Origin Unknown (Origin unknown)
Hematopoietic Stem Cell Graft Recipient
(Recipient)
Is a copy of the lab report attached?
No (No)
Yes (Yes)
New Malignancy, Lymphoproliferative Or
Myeloproliferative Disorder
Specify which new disease(s) occurred:
Acute Myeloid Leukemia (Acute myeloid
leukemia (AML / ANLL))
Breast Carcinoma (Breast cancer)
Central Nervous System Neoplasm
(Central nervous system (CNS)
malignancy (glioblastoma, astrocytoma))
Malignant Gastrointestinal Neoplasm
(Gastrointestinal malignancy (colon,
rectum, stomach, pancreas, intestine))
Genitourinary System Malignant
Neoplasm (Genitourinary malignancy
(kidney, bladder, ovary, testicle, genitalia,
uterus, cervix))
Hodgkin's Lymphoma (Hodgkin disease)
Lung Carcinoma (Lung cancer)
Lymphoma Or Lymphoproliferative
Disorder (Lymphoma or
lymphoproliferative disease)
Melanoma (Melanoma)
Myelodysplastic/myeloproliferative
Disease (Myelodysplasia (MDS),
myeloproliferative (MPS) disorder)
Oropharyngeal Carcinoma
(Oropharyngeal cancer (tongue, buccal
mucosa))
Other Leukemia (Other leukemia
including ALL)
Other Malignant Neoplasm (Other
malignancy)
Other Malignant Skin Neoplasm (Other
skin malignancy (basal cell, squamous))
Clonality Cytogenetic Abnormality
(Related by descent from clonal
cytogenetic abnormality without leukemia
or MDS)
Sarcoma (Sarcoma)
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Thyroid Gland Carcinoma (Thyroid
cancer)
Did a new malignancy, lymphoproliferative or
myeloproliferative disorder appear that is different
from the disease for which the HSCT was
performed? (Since the date of the last report)
No (No)
Yes (Yes)
Date of diagnosis: (Of acute GVHD)
Is the tumor EBV positive? (Answer only if the
response to CDE 2677021 is "Lymphoma or
lymphoproliferative disease.")
No (No)
Yes (Yes)
Specify the new malignancy, lymphoproliferative
or myeloproliferative disorder: (Answer only if the
response to CDE 2677021 is "Other leukemia,
including ALL," "Other skin malignancy basal cell,
squamous," or "Other new malignancy.")
Organ Function - New Malignancy Part 3
Of 3
Is a pathology / autopsy report or other
documentation attached?
No (No)
Yes (Yes)
Organ Function - Other Organ Impairment
/ Disorder Paer 1 Of 2
Has the recipient developed any other clinically
significant organ impairment or disorder? (Since
the date of the last report)
No (No)
Yes (Yes)
Organ Function - Other Organ Impairment
/ Disorder Part 2 Of 2
Specify impairment / disorder:
A Condition In Which The Poor Blood
Supply To An Area Of Bone Leads To
Bone Death. (Avascular necrosis)
Bronchiolitis Obliterans (Bronchiolitis
obliterans)
Cataract (Cataracts)
Congestive Heart Failure (Congestive
heart failure)
Cryptogenic Organizing Pneumonia
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(Cryptogenic organizing pneumonia)
Diabetes Mellitus And/or Hyperglycemia
(Diabetes/hyperglycemia)
Gonadal Disorder And/or Infertility
Required Testosterone Or Estrogen
Replacement Therapy (Gonadal
dysfunction/infertility requiring hormone
replacement)
Growth Hormone Deficit And/or Growth
Disturbance (Growth hormone
deficiency/growth disturbance)
Hemorrhage Cystitis And/or Hematuria
(Hemorraghic cystitis/hematuria requiring
medical intervention)
Hypothyroidism (Hypothyroidism)
Idiopathic Pneumonia Syndrome Or
Adult Respiratory Distress Syndrome
(Interstitial pneumonitis (IPn) or ARDS)
Myocardial Infarction (Myocardial
infarction)
Negation Infection Liver Toxicity (Non-
infectious liver toxicity)
Other (Other)
Pancreatitis (Pancreatitis)
Post Graft Thrombotic Microangiopathy
Hemolytic Uremic Syndrome Or
Similarity (Post-transplant
microangiopathy-thrombotic
thrombocytopenic purpura (TTP),
hemolytic uremic syndrome (HUS), or
similar syndrome)
Pulmonary Hemorrhage (Pulmonary
hemorrhage)
Renal Failure Severe Need Dialysis
(Renal failure severe enough to warrant
dialysis)
Cerebrovascular Accident And/or
Seizure (Stroke/seizure)
Did a particular type of organ impairment /
disorder occur?
No (No)
Yes (Yes)
Date of diagnosis: (Of acute GVHD)
Did the recipient receive plasmapheresis?
(Answer only if the response to CDE 2797538 is
"Post-transplant microangiopathy-thrombotic
thrombocytopenic purpura TTP, hemolytic uremic
syndrome HUS, or similar syndrome")
No (No)
Yes (Yes)
Did the recipient receive dialysis? (Answer only if
the response to CDE 2797538 is "Renal failure
severe enough to warrant dialysis")
No (No)
Yes (Yes)
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Specify impairment / disorder: (Answer only if the
response to CDE 2797538 is "Other")
Subsequent Hsct
Date of subsequent HSCT:
Was the subsequent HSCT performed at a
different institution?
No (No)
Yes (Yes)
Name: (Of the institution that performed the
subsequent HSCT)
City: (Of the institution that performed the
subsequent HSCT)
State / Country: (Of the institution that performed
the subsequent HSCT)
What was the indication for the subsequent
HSCT? (Subsequent autologous HSCTs
performed for engraftment reasons "No
hematopoietic recovery," "Partial hematopoietic
recovery," and "Graft failure / rejection after
achieving initial hematopoietic recovery" do not
require separate report forms to - be completed.
All other subsequent HSCTs will require a
separate follow-up report form completed for
each infusion.)
Loss Or Reduced Donor Chimerism
(Declining chimerism)
Graft Failure Post First Hematopoietic
Recovery (Graft failure / rejection after
achieving initial hematopoietic recovery)
New Malignant Neoplasm (New
malignancy)
Hematopoietic Stem Cell No Recovery
(No hematopoietic recovery)
Other (Other)
Hematopoietic Stem Cell Partial
Recovery (Partial hematopoietic
recovery)
Persistent Primary Disease Or Disorder
(Persistent primary disease)
Hematopoietic Stem Cell Second Plan
Transplantation (Planned second HSCT,
per protocol)
Recurrent Primary Disease Or Disorder
(Recurrent primary disease)
Mixed Stable Chimerism (Stable, mixed
chimerism)
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Specify other indication
Subsequent Hsct
Source of HSCs:
Related Allogenic (Allogeneic, related)
Unrelated Allogenic (Allogeneic,
unrelated)
Autologous (Autologous)
Was the same donor used?
No (No)
Yes (Yes)
Specify:
Cryopreservation Original Donor Bone
Marrow (Cryopreserved original donor
bone marrow)
Cryopreservation Original Donor
Mobilized Peripheral Blood Stem Cell
(Cryopreserved original donor mobilized
peripheral blood stem cells)
Tissue, Fresh Original Donor National
Marrow Donor Program Bone Marrow
(Fresh, original NMDP donor bone
marrow)
Tissue, Fresh Original Donor National
Marrow Donor Program Mobilized
Peripheral Blood Stem Cell (Fresh,
original NMDP donor mobilized
peripheral blood stem cells)
Tissue, Fresh Original Negation National
Marrow Donor Program Donor Bone
Marrow (Fresh, original non-NMDP
donor bone marrow)
Tissue, Fresh Original Negation National
Marrow Donor Program Donor Mobilized
Peripheral Blood Stem Cell (Fresh,
original non-NMDP donor mobilized
peripheral blood stem cells)
Tissue, Fresh Next National Marrow
Donor Program Donor Bone Marrow
(Fresh, subsequent NMDP donor bone
marrow)
Tissue, Fresh Next National Marrow
Donor Program Donor Mobilized
Peripheral Blood Stem Cell (Fresh,
subsequent NMDP donor mobilized
peripheral blood stem cells)
Tissue, Fresh Next Negation National
Marrow Donor Program Donor Bone
Marrow (Fresh, subsequent non-NMDP
donor bone marrow)
Tissue, Fresh Next Negation National
Marrow Donor Program Donor Mobilized
Peripheral Blood Stem Cell (Fresh,
subsequent non-NMDP donor mobilized
peripheral blood stem cells)
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National Marrow Donor Program
Umbilical Cord Blood (NMDP cord blood)
Negation National Marrow Donor
Program Umbilical Cord Blood (Non-
NMDP cord blood)
Donor Cellular Infusion (dci) Information
Date of DCI:
Specify the total number of cell infusions given
within 10 weeks of the DCI
Was the DCI infusion performed at a different
institution?
No (No)
Yes (Yes)
Name: (Of the institution that performed the DCI)
Karnofsky / Lansky score (At diagnosis of chronic
GVHD. If the recipient is 16 years of age or older,
complete the Karnofsky Scale. If the recipient is
younger than 16 years of age, complete the
Lansky Scale.)
Karnofsky Scale - Moribund, Fatal
Process Progressing Rapidly; Lansky
Scale - Completely Disabled, Not Even
Passive Play. (10)
Karnofsky Scale - Normal, No
Complaints, No Evidence Of Disease;
Lansky Scale - Fully Active. (100)
Karnofsky Scale - Very Sick,
Hospitalization Necessary; Lansky Scale
- Limited To Very Passive Activity
Initiated By Others (e.g., Tv) (20)
Karnofsky Scale - Severely Disabled,
Hospitalization Indicated, Although
Death Not Imminent. Lansky Scale -
Needs Considerable Assistance For
Quiet Activity. (30)
Karnofsky Scale - Disabled, Requires
Special Care And Assistance. Lansky
Scale - Able To Initiate Quiet Activities.
(40)
Karnofsky Scale - Requires
Considerable Assistance And Frequent
Medical Care; Lansky Scale -
Considerable Assistance Required For
Any Active Play; Fully Able To Engage In
Quiet Play. (50)
Karnofsky Scale - Requires Occasional
Assistance, But Is Able To Care For Most
Needs; Lansky Scale - Ambulatory Up To
50r Of Time, Limited Active Play With
Assistance / Supervision. (60)
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Karnofsky Scale - Cares For Self, Unable
To Carry On Normal Activity Or To Do
Active Work.; Lansky Score - Both
Greater Restrictions Of, And Less Time
Spent In, Active Play. (70)
Karnofsky Scale - Normal Activity With
Effort; Lansky Scale - Restricted In
Strenuous Play, Tires More Easily,
Otherwise Active. (80)
Karnofsky Scale - Able To Carry On
Normal Activity; Lansky Scale - Minor
Restriction In Physically Strenuous Play.
(90)
City: (Of the institution that performed the DCI)
State / Country: (Of the institution that performed
the DCI)
Indication for DCI
Loss Reduced Donor T-lymphocyte
Chimerism (Loss of / decreased donor T-
cell chimerism)
Other (Other)
Part First Hematopoietic Stem Cell
Transplantation Protocol Plan (Planned
as part of initial HSCT protocol)
Mixed Stable Chimerism (Stable, mixed
chimerism)
Therapeutic Procedure Graft Versus
Host Disease (Treatment for GVHD)
Post-transplant Lymphoproliferative
Disorder Epstein-barr Virus Therapeutic
Procedure (Treatment for PTLD, EBV
lymphoma)
Therapeutic Procedure Recurrent
Disease Persistent Pd Disease Or
Disorder (Treatment for relapsed,
persistent or progressive disease)
Therapeutic Procedure Viral Infection
(Viral infection)
Molecular (Method of disease detection)
Negative Finding (Negative)
Not Done Unknown (Not done /
Unknown)
Positive Finding (Positive)
Date: (If the result was positive report the first
date the disease was detected; if the result was
negative report the last date the method was
used prior to DCI.)
Cytogenetic (Method of disease detection)
Negative Finding (Negative)
Not Done Unknown (Not done /
Unknown)
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Positive Finding (Positive)
Date: (If the result was positive report the first
date the disease was detected; if the result was
negative report the last date the method was
used prior to DCI.)
Clinical evidence / hematologic (Method of
disease detection)
Negative Finding (Negative)
Not Done Unknown (Not done /
Unknown)
Positive Finding (Positive)
Date: (If the result was positive report the first
date the disease was detected; if the result was
negative report the last date the method was
used prior to DCI.)
Was chemotherapy used to attempt to induce
disease response? (Prior to the DCI)
No (No)
Yes (Yes)
Date of administration of final chemotherapy dose
Specify the viral organism
Adenovirus (Adenovirus)
Cytomegalovirus (Cytomegalovirus)
Enterovirus (Enterovirus)
Epstein-barr Virus (Epstein-Barr Virus)
Hepatitis A Virus (Hepatitis A Virus)
Hepatitis B Virus (Hepatitis B Virus)
Hepatitis C Virus (Hepatitis C Virus)
Herpes Simplex Virus (Herpes Simplex
Virus)
Herpes Zoster (Herpes Zoster)
Human Herpesvirus 6 (Human
Herpesvirus 6)
Human Immunodeficiency Virus 1
(Human Immunodeficiency Virus 1)
Human Papillomavirus (Human
Papillomavirus)
Influenza A Virus (Influenza A Virus)
Influenza B Virus (Influenza B Virus)
Other Influenza (Influenza, NOS)
Measles Virus (Measles Virus)
Mumps Virus (Mumps Virus)
Other Virus (Other Virus)
Parainfluenza Virus (Parainfluenza Virus)
Polyomavirus (Polyomavirus)
Progressive Multifocal
Leukoencephalopathy (Progressive
Multifocal Leukoencephalopathy)
Respiratory Syncytial Virus (Respiratory
Syncytial Virus (RSV))
Rhinovirus (Rhinovirus)
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Rotavirus (Rotavirus)
Rubella Virus (Rubella Virus)
Suspected Viral Infection (Suspected
viral infection)
Date documented:
Specify other indication
What was the recipient's disease status?
(Immediately prior to the DCI)
First Complete Remission (First
complete remission)
Negation Evaluation (Not evaluated post-
HSCT)
Persistent Disease Or Disorder
(Persistent disease)
Recurrent Disease Or Disease
Progression (Relapse or progression)
Therapeutic Procedure Induction
Complete Remission (Therapy-induced
complete remission after persistent
disease or relapse post-HSCT)
Date the disease status was established: (Prior to
the DCI)
Collected at the time of PBSC mobilization and
collection (DCI source)
No (No)
Yes (Yes)
Negative fraction of CD34 selected PBSC (DCI
source)
No (No)
Yes (Yes)
Negative fraction of CD34 selected bone marrow
(DCI source)
No (No)
Yes (Yes)
Apheresis at a different time than collection of
PBSC used for allogeneic HSCT (DCI source)
No (No)
Yes (Yes)
Date of apheresis:
Isolated from a unit(s) of whole blood (DCI
source)
No (No)
Yes (Yes)
Specify number of units:
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Were the donor cells collected by leukapheresis?
No (No)
Yes (Yes)
Date of first leukapheresis:
Date of last leukapheresis:
Number of leukaphereses:
Did the donor receive treatment to enhance cell
collection prior to donation?
No (No)
Yes (Yes)
Growth factor(s)
No (No)
Yes (Yes)
G-CSF
No (No)
Yes (Yes)
GM-CSF
No (No)
Yes (Yes)
Other agent
No (No)
Yes (Yes)
Specify other agent
Other treatment
No (No)
Yes (Yes)
Specify other treatment
CD3+ cells: (For each DCI given, report the total
number of cells infused. If the cells were
cryopreserved, report the totals after processing,
but before cryopreservation.)
CD3+ cells exponent value:
What is the reason for the CD3+ cells missing
value?
Negation Test (Not tested)
CD4+ cells: (For each DCI given, report the total
number of cells infused. If the cells were
cryopreserved, report the totals after processing,
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but before cryopreservation.)
CD4+ cells exponent value:
What is the reason for the CD4+ cells missing
value?
Negation Test (Not tested)
CD8+ cells: (For each DCI given, report the total
number of cells infused. If the cells were
cryopreserved, report the totals after processing,
but before cryopreservation.)
CD8+ cells exponent value:
What is the reason for the CD8+ cells missing
value?
Negation Test (Not tested)
CD34+ cells: (For each DCI given, report the total
number of cells infused. If the cells were
cryopreserved, report the totals after processing,
but before cryopreservation.)
CD34+ cells exponent value:
What is the reason for the CD34+ cells missing
value?
Negation Test (Not tested)
NK cells: (For each DCI given, report the total
number of cells infused. If the cells were
cryopreserved, report the totals after processing,
but before cryopreservation.)
NK cells exponent value:
What is the reason for the NK cells missing
value?
Negation Test (Not tested)
Nucleated cells: (For each DCI given, report the
total number of cells infused. If the cells were
cryopreserved, report the totals after processing,
but before cryopreservation.)
Nucleated cells exponent value:
What is the reason for the nucleated cells missing
value?
Negation Test (Not tested)
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Mesenchymal cells: (For each DCI given, report
the total number of cells infused. If the cells were
cryopreserved, report the totals after processing,
but before cryopreservation.)
Mesenchymal cells exponent value:
What is the reason for the mesenchymal cells
missing value?
Negation Test (Not tested)
Were dendritic cells infused?
No (No)
Yes (Yes)
Were fibroblasts infused?
No (No)
Yes (Yes)
Were any other cell types infused? (Not including
cell types reported in questions 262-268 CDEs
2760303, 2760372, 2772153, 2760286, 2771962,
2760234, and 2771985.)
No (No)
Yes (Yes)
Specify cell type(s):
Were the cells cryopreserved prior to infusion?
No (No)
Yes (Yes)
Specify portion of cells cryopreserved prior to
infusion
Entire Hematopoietic Stem Cell
Collection (Entire product)
Part Hematopoietic Stem Cell Collection
(Portion of product)
Was the product manipulated prior to infusion?
No (No)
Yes (Yes)
Specify portion manipulated:
Entire Hematopoietic Stem Cell
Collection (Entire product)
Part Hematopoietic Stem Cell Collection
(Portion of product)
ABO incompatibility
No (No)
Yes (Yes)
Buffy coat preparation
No (No)
Yes (Yes)
Cell separator (i.e., COBE Spectra)
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No (No)
Yes (Yes)
Density gradient separation (i.e., Ficoll)
No (No)
Yes (Yes)
Plasma removal
No (No)
Yes (Yes)
Sedimentation (i.e., Hetastarch)
No (No)
Yes (Yes)
Other
No (No)
Yes (Yes)
Specify other method:
Dextran-albumin wash
No (No)
Yes (Yes)
Ex-vivo expansion
No (No)
Yes (Yes)
Genetic manipulation (Gene transfer /
transduction)
No (No)
Yes (Yes)
Volume reduction
No (No)
Yes (Yes)
CD34+ selection
No (No)
Yes (Yes)
Specify manufacturer:
Clinimax Cell Selection System
(CliniMACS / CliniMax)
Isolex Cell Selection System (Isolex)
Other (Other)
Specify other manufacturer:
T-cell depletion
No (No)
Yes (Yes)
Antibody affinity column
No (No)
Yes (Yes)
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Antibody coated plates
No (No)
Yes (Yes)
Antibody coated plates and soybean lectin
No (No)
Yes (Yes)
Antibody and complement
No (No)
Yes (Yes)
Antibody and toxin
No (No)
Yes (Yes)
Immunomagnetic beads
No (No)
Yes (Yes)
Elutriation
No (No)
Yes (Yes)
CD34 affinity column plus sheep red blood cell
rosetting
No (No)
Yes (Yes)
Other
No (No)
Yes (Yes)
Specify other method
Other manipulation
No (No)
Yes (Yes)
Specify other cell manipulation:
Were antibodies used during graft manipulation?
No (No)
Yes (Yes)
Anti CD2
No (No)
Yes (Yes)
Anti CD4
No (No)
Yes (Yes)
Anti CD5
No (No)
Yes (Yes)
Anti CD6
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No (No)
Yes (Yes)
Anti CD7
No (No)
Yes (Yes)
Anti CD8
No (No)
Yes (Yes)
Anti CD34
No (No)
Yes (Yes)
Anti TCR alpha / beta (T10-B9)
No (No)
Yes (Yes)
OKT-3
No (No)
Yes (Yes)
Other CD3
No (No)
Yes (Yes)
Specify other CD3:
Anti CD52
No (No)
Yes (Yes)
Campath-NOS
No (No)
Yes (Yes)
Campath-1G
No (No)
Yes (Yes)
Campath-1H
No (No)
Yes (Yes)
Other antibody
No (No)
Yes (Yes)
Specify other antibody:
Donor Cellular Infusion (dci) Information
Part 2 Of 2
First Name
28 / 29
Follow-Up - 2300 Revision 2 - Yearly Follow-Up for Greater Than Two
Years Post-HSCT Data - 3069537v1.0
Last Name:
Telephone number:
Fax number:
E-mail address:
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Follow-Up - Course Assessment -
3274692v1.0
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models.org/forms/1684
Course Assessment
Course Assessment
Visit Date (Enter the date the course started.)
Start Date of Course (Cycle)
Dose Change from TAC Entered on Course
Initiation CRF?
Yes, Planned (1)
Yes, Unplanned (2)
No (3)
Unknown (9)
Course Disposition (Select one of the following
values:)
Completed (Completed)
Discontinued (Discontinued)
Response Assessment
Complete Response (CR)
Complete Response Unconfirmed (CRU)
Disease Unchanged (DU)
Less Than Partial Response (MR)
Not Assessed (NA)
Not Evauable (NE)
Not Applicable Per Protocol (NP)
Progressive Disease (PD)
Partial Response (PR)
Stable Disease (SD)
Too Early (TE)
Response Note (Enter the reason why the
Response Assessment is Not Evaluable NE or
Not Assessed NA.)
Date of Response (Note: The original date of
onset of response should be used for responses
that persist through several courses.)
Date of Progression
Any Adverse Events in this Course? (Note: The
events must be recorded on the Adverse Events
case report form.)
No (No)
Yes (Yes)
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Course Initiation
Course Initiation
Visit Date (Enter the date the course started.)
Course #
Start Date of Course (Enter the date on which the
course was started.)
Arm
Treatment Assignment Code (Select the
appropriate code for the patient's treatment
assignment as specified.)
Treating Institution
1 / 1
Follow-Up - Follow-up - 3277911v1.0
Follow-Up - Follow-up - 3277911v1.0
All rights reserved. Please visit https://medical-data-
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Follow-up
Follow-up
Visit Date
Date of Last Contact (Enter the date the patient
was last contacted.)
Type of Contact (Select how the information was
obtained:)
Clinic Appointment (Clinic Appointment)
Email Contact With Patient/participant
(Email contact with Patient/Participant)
Mail Contact With Patient/participant
(Mail contact with Patient/Participant)
Social Security Death Index (ssdi)
(Social Security Death Index (SSDI))
Telephone Contact With
Patient/participant (Telephone contact
with Patient/Participant)
Telephone Contact With
Patient/participant Family (Telephone
contact with Patient/Participant Family)
Telephone Contact With
Patient/participant Local Physician
(Telephone contact with
Patient/Participant Local Physician)
Received Treatment Since Last Contact? (Note:
When answering 'Yes' and the patient has died
during the follow-up period, only the Date of
Death, entered on the Survival case report form,
is sent to CTMS.)
No (No)
Yes (Yes)
Patient Status (Select one of the options below
that indicates the patient's last known status. If
the patient has died, enter the date in the Date of
Death field.)
Alive With Disease (1)
Alive With No Evidence Of Disease (2)
Alive Disease Status Unknown (3)
Unknown (4)
Died (5)
Explain 'Unknown' Patient Status (If Patient
Status is unknown, enter some explanation here.
Include what attempts were made and how many
attempts where made in order to obtain the
patient's status i.e.: no response to 5 messages
left.)
1 / 1
Follow-Up - Extent of Disease Identification
- 3277353v1.0
Follow-Up - Extent of Disease Identification - 3277353v1.0
All rights reserved. Please visit https://medical-data-
models.org/forms/1697
Extent of Disease Identification
Extent Of Disease Identification
Visit Date
Lesion # (Select a unique number for each lesion.
Once a lesion number is designated for a specific
lesion, that number may not change or be used to
denote a different lesion.)
Anatomic Site (Select the anatomic position
where the lesion is located, i.e. Lung, Skull, etc.)
Abdomen (Abdomen)
Abdomen/pelvis (Abdomen/Pelvis)
Abdominal Wall (Abdominal wall)
Acetabulum (Acetabulum)
Pharyngeal Tonsil (Adenoid)
Adipose Tissue (Adipose)
Adrenal Gland (Adrenal gland)
Alveolar Ridge (Alveolar Ridge)
Amniotic Fluid (Amniotic Fluid)
Ampulla Of Vater (Ampulla of Vater)
Anal Canal (Anal canal)
Anal Sphincter (Anal sphincter)
Ankle (Ankle)
Anorectum (Anorectum)
Antecubital Fossa (Antecubital fossa)
Antrum Pylori (Antrum)
Anus (Anus)
Aorta (Aorta)
Aortic Body (Aortic Body)
Appendix (Appendix)
Aqueous Fluid (Aqueous Fluid)
Arm (Arm)
Artery (Artery)
Ascending Colon (Ascending colon)
Ascending Colon Hepatic Flexure
(Ascending Colon Hepatic Flexure)
Auditory Canal (Auditory canal)
Autonomic Nervous System (Autonomic
nervous system)
Axilla (Axilla)
Back (Back)
Bile Duct (Bile duct)
Bladder (Bladder)
Blood (Blood)
Blood Vessel (Blood vessel)
Bone (Bone)
Bone Marrow (Bone marrow)
Bowel (Bowel)
Brain (Brain)
Brain Stem (Brain stem)
Breast (Breast)
Broad Ligament (Broad ligament)
Bronchiole (Bronchiole)
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Bronchus (Bronchus)
Bronchus And Lung (Bronchus and
Lung)
Brow (Brow)
Buccal Cavity (Buccal cavity)
Buccal Mucosa (Buccal mucosa)
Buttock (Buttock)
Calf (Calf)
Capillary (Capillary)
Gastric Cardia (Cardia)
Carina (Carina)
Carotid Artery (Carotid artery)
Carotid Body (Carotid body)
Cartilage (Cartilage)
Cecum (Cecum)
Central Line Catheter (Central Line
Catheter)
Central Nervous System (Central
nervous system)
Cerebellum (Cerebellum)
Cerebral Cortex (Cerebral cortex)
Cerebrospinal Fluid (Cerebrospinal fluid)
Cerebrum (Cerebrum)
Cervical Spine (Cervical spine)
Cervical/thoracic/lumbar Spine
(Cervical/Thoracic/Lumbar spine)
Cervix (Cervix)
Chest (Chest)
Chest Wall (Chest wall)
Chest/abdomen/pelvis
(Chest/Abdomen/Pelvis)
Chest/pelvis (Chest/Pelvis)
Chin (Chin)
Clavicle (Clavicle)
Clitoris (Clitoris)
Colon (Colon)
Colon And Rectum (Colon and rectum)
Colon Mucosa (Colon, mucosa only)
Common Duct (Common duct)
Conjunctiva (Conjunctiva)
Connective Tissue (Connective tissue)
Descending Colon (Descending colon)
Diaphragm (Diaphragm)
Duodenum (Duodenum)
Ear (Ear)
Ear Canal (Ear canal)
External Ear (Ear, Pinna (External))
Effusion (Effusion)
Elbow (Elbow)
Endocrine Gland (Endocrine gland)
Epididymis (Epididymis)
Epidural Spinal Canal Space (Epidural
space)
Esophagogastric Junction
(Esophagogastric junction)
Esophagus (Esophagus)
Esophageal Mucosa (Esophagus,
Mucosa only)
Extremities (Extremities)
Eye (Eye)
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Fallopian Tube (Fallopian tube)
Femur (Femur)
Fibula (Fibula)
Finger (Finger)
Floor Of Mouth (Floor of Mouth)
Body Fluid Or Substance (Fluid)
Foot (Foot)
Forearm (Forearm)
Forehead (Forehead)
Foreskin (Foreskin)
Frontal Lobe (Frontal lobe)
Fundus Of Stomach (Fundus of
stomach)
Gallbladder (Gallbladder)
Ganglion (Ganglia)
Gastroesophageal Junction
(Gastroesophageal Junction)
Gastrointestinal Tract (Gastrointestinal
tract)
Genitourinary (Genitourinary)
Groin (Groin)
Gum (Gum)
Hand (Hand)
Hard Palate (Hard palate)
Head - Face Or Neck, Nos (Head - face
or neck, NOS)
Head/neck (Head/Neck)
Head/neck/chest/adb/pelvis
(Head/Neck/Chest/Adb/Pelvis)
Heart (Heart)
Hepatic Duct (Hepatic duct)
Hip (Hip)
Humerus (Humerus)
Hypopharynx (Hypopharynx)
Ileum (Ileum)
Ilium (Ilium)
Intestine (Intestine)
Ischium (Ischium)
Jaw (Jaw)
Jejunum (Jejunum)
Joints (Joints)
Kidney (Kidney)
Knee (Knee)
Lacrimal Gland (Lacrimal Gland)
Large Bowel (Large bowel)
Laryngopharynx (Laryngopharynx)
Larynx (Larynx)
Leg (Leg)
Ligament (Ligament)
Lip (Lip)
Liver (Liver)
Liver And Intrahepatic Duct (Liver and
intrahepatic duct)
Liver/spleen (Liver/Spleen)
Lumbar Spine (Lumbar spine)
Lung (Lung)
Lymph Node (Lymph node)
Lymph Node(s) Axilla (Lymph Node(s)
Axilla)
Lymph Node(s) Cervical (Lymph Node(s)
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Cervical)
Distant Lymph Node (Lymph node(s)
Distant)
Lymph Node(s) Hilar (Lymph Node(s)
Hilar)
Lymph Node(s) Inguinal (Lymph Node(s)
Inguinal)
Lymph Node(s) Int Mammary (Lymph
Node(s) Int Mammary)
Lymph Node(s) Mammary (Lymph
Node(s) Mammary)
Paraaortic Region Lymph Node (Lymph
node(s) Para aortic)
Lymph Node(s) Pelvic (Lymph Node(s)
Pelvic)
Regional Lymph Node (Lymph node(s)
Regional)
Scalene Lymph Node (Lymph node(s)
Scalene)
Lymph Node(s) Subclavicular (Lymph
Node(s) Subclavicular)
Lymph Node(s) Supraclav (Lymph
Node(s) Supraclav)
Lymph Nodes (Lymph nodes)
Mediastinal Lymph Node (Lymph
nodes(s) Mediastinal)
Lymphoma (Lymphoma)
Mammary Gland (Mammary Gland)
Mandible (Mandible)
Maxilla (Maxilla)
Mediastinum (Mediastinum)
Mesentery (Mesentery)
Mesothelium (Mesothelium)
Mini Mantle (Mini Mantle)
Mouth (Mouth)
Muscle (Muscle)
Nail (Nails)
Nasal Cavity (Nasal Cavity)
Nasopharynx (Nasopharynx)
Neck (Neck)
Neck Chest (Neck/Chest)
Neck/chest/abdomen/pelvis
(Neck/Chest/Abdomen/Pelvis)
Nerve (Nerve)
Cranial Nerve (Nerve(s) Cranial)
Not Applicable (Not Applicable)
Ocular Orbits (Ocular Orbits)
Omentum (Omentum)
Oral Cavity (Oral cavity)
Oral Cavity Mucosa (Oral Cavity, Mucosa
only)
Oropharynx (Oropharynx)
Other (Other)
Ovary (Ovary)
Posterior Anterior/lateral (PA/Lat)
Palate (Palate)
Pancreas (Pancreas)
Paraspinal Ganglion (Paraspinal
Ganglion)
Parathyroid Gland (Parathyroid)
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Parotid Gland (Parotid gland)
Patella (Patella)
Pelvis (Pelvis)
Penis (Penis)
Perianus (Perianus)
Pericardium (Pericardium)
Peritoneal Cavity (Peritoneal cavity)
Peritoneum (Peritoneum)
Pharynx (Pharynx)
Pineal Gland (Pineal Gland)
Pituitary Gland (Pituitary gland)
Placenta (Placenta)
Pleura (Pleura)
Popliteal Fossa (Popliteal fossa)
Prostate (Prostate)
Pylorus (Pylorus)
Rectosigmoid Junction (Rectosigmoid
Junction)
Rectum (Rectum)
Retina (Retina)
Retro-orbital Area (Retro-orbital Area)
Retroperitoneum (Retroperitoneum)
Ribs (Ribs)
Round Ligament (Round ligament)
Sacrum (Sacrum)
Salivary Gland (Salivary gland)
Scalp (Scalp)
Scapula (Scapula)
Scrotum (Scrotum)
Shoulder Joint (Shoulder)
Sigmoid Colon (Sigmoid colon)
Sinus(es) (Sinus(es))
Sinus(es), Maxillary (Sinus(es),
Maxillary)
Skeletal Muscle Tissue (Skeletal Muscle)
Skin (Skin)
Skull (Skull)
Small Bowel Mucosa (Small Bowel,
Mucosa only)
Small Intestine (Small intestine)
Soft Tissue (Soft Tissue)
Spinal Cord (Spinal Cord)
Spine (Spine)
Spine/femur (Spine/Femur)
Spine/femur/radius
(Spine/Femur/Radius)
Spleen (Spleen)
Splenic Flexure (Splenic Flexure)
Sternum (Sternum)
Stomach (Stomach)
Stomach Mucosa (Stomach, Mucosa
only)
Subcutaneous Tissue (Subcutaneous
tissue)
Synovial Membrane (Synovium)
Tendon (Tendon)
Testicle (Testicle)
Testis (Testicle)
Thigh (Thigh)
Thoracic Spine (Thoracic spine)
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Thoracic/lumbar Spine (Thoracic/Lumbar
spine)
Thorax (Thorax)
Throat (Throat)
Thymus (Thymus)
Thyroid Gland (Thyroid gland)
Tibia (Tibia)
Tongue (Tongue)
Tongue, Base Of Tongue (Tongue, Base
of tongue)
Tonsil (Tonsil)
Pharyngeal Tonsil (Tonsil, Pharyngeal)
Trachea (Trachea)
Trachea Main Bronchus (Trachea/Major
Bronchi)
Transverse Colon (Transverse Colon)
Trunk (Trunk)
Superficial Trunk (Trunk, Superficial)
Umbilical Cord (Umbilical Cord)
Upper Extremity (Upper extremity)
Ureter (Ureter)
Urethra (Urethra)
Urinary Tract (Urinary tract)
Uterus (Uterus)
Uvula (Uvula)
Vagina (Vagina)
Vas Deferens (Vas Deferens)
Vein (Vein)
Vena Cava (Vena Cava,
Inferior/Superior)
Vertebra (Vertebra)
Vertebral Column (Vertebral column)
Vulva (Vulva)
Whole Body (Whole body)
Wrist (Wrist)
Description of Location (Select a brief description
of the lesion location.)
Above (Above)
Anterior (Anterior)
Highest (Apex)
Base Of Site (Base)
Below (Below)
Bilateral (Bilateral)
Bladder (Bladder, NOS)
Body (Body)
Both (Both)
Bronchial (Bronchial)
Center (Central)
Cerebellar (Cerebellar)
Cervical (Cervical)
Distal (Distal)
Dome Of The Bladder (Dome)
Ectopia (Ectopic)
Frontal (Frontal)
Fronto-parietal (Fronto-parietal)
Head (Head)
Left Lower (L-Lower)
Left Upper (L-Upper)
Lateral (Lateral)
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Left (Left)
Left Lower Inner Quadrant (Left Lower
Inner Quadrant)
Left Lower Outer Quadrant (Left Lower
Outer Quadrant)
Left Upper Inner Quadrant (Left Upper
Inner Quadrant)
Left Upper Outer Quadrant (Left Upper
Outer Quadrant)
Lower (Lower)
Lower Inner Quadrant (liq) (Lower Inner
Quadrant)
Lower Outer Quadrant (loq) (Lower
Outer Quadrant)
Lumbar (Lumbar)
Medial (Medial)
Mediastinal (Mediastinal)
Middle (Mid)
Midline (Midline)
Not Applicable (N/A)
Bladder Neck (Neck)
Not A Paired Site (Not a Paired Site)
Occipital (Occipital)
Parietal (Parietal)
Posterior (Posterior)
Proximal (Proximal)
Right Lower (R-Lower)
Right Middle (R-Middle)
Right Upper (R-Upper)
Right (Right)
Right Lower Inner Quadrant (Right Lower
Inner Quadrant)
Right Lower Outer Quadrant (Right
Lower Outer Quadrant)
Right Upper Inner Quadrant (Right
Upper Inner Quadrant)
Right Upper Outer Quadrant (Right
Upper Outer Quadrant)
Supratentorial (Supratentorial)
Tail (Tail)
Temporal (Temporal)
Thoracic (Thoracic)
Bladder Trigone (Trigone)
Upper (Upper)
Upper Inner Quadrant (uiq) (Upper Inner
Quadrant)
Upper Outer Quadrant (uoq) (Upper
Outer Quadrant)
Urinary (Urinary, NOS)
Anterior Bladder Wall (Wall, Anterior)
Lateral Bladder Wall (Wall, Lateral)
Bladder Wall, Not Otherwise Specified
(Wall, NOS)
Posterior Bladder Wall (Wall, Posterior)
Description of Lesion (If applicable, enter a brief
description of each lesion, e.g. cystic, well-
defined, encapsulated, necrotic appearing
center.)
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Previously Irradiated
No (N)
Yes (Y)
Measurable/Non-Measurable
Measurable (M)
Non-measurable (N)
Target/Nontarget
Nontarget Lesion (Nontarget)
Target Lesion (Target)
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All rights reserved. Please visit https://medical-data-
models.org/forms/1698
2005 - Confirmation of HLA typing
ISO Date Format  Version 1
Registry Use Only
Sequence number:
Date received:
Identification Data
CIBMTR Center Number:
CIBMTR Recipient ID:
Identification Data
Non-NMDP donor ID:
Donor Gender
Female (female)
Male (male)
Donor date of birth:
Identification Data
Non-NMDP Cord Blood Unit (CBU) ID:
Identification Data
Today's date:
Date of hematopoietic stem cell transplantation
(HSCT) for which this form is being completed:
Hsct Type
What source was used for the hematopoietic
stem cell transplantation?
Related Allogenic (Allogeneic, related)
Unrelated Allogenic (Allogeneic,
unrelated)
Syngeneic (Syngeneic (identical twin))
1 / 11
Was a particular hematopoietic stem cell source
used?
No (No)
Yes (Yes)
Product Type
What type of hematopoietic stem cell transplant
was used?
Umbilical Cord Blood (Cord blood)
Bone Marrow (Marrow)
Other (Other)
Peripheral Blood Stem Cell (PBSC)
Was a particular hematopoietic stem cell
transplant type used?
No (No)
Yes (Yes)
Specify the other hematopoietic stem cell
transplant type: (Answer only if the value for
2730912 is "Other". )
Hla Typing Source
Please specify the person for whom this typing is
being done:
Umbilical Cord Blood Confirmed Hla
Typing (Cord blood unit--confirmatory
typing)
Donor Confirmed Hla Typing (Donor--
confirmatory typing)
Umbilical Cord Blood Mother Hla Typing
(Maternal HLA typing)
Other (Other)
Recipient Final Hla Typing (Recipient--
final typing)
Recipient Father Confirmed Hla Typing
(Recipient's father--confirmatory typing)
Recipient Mother Confirmed Hla Typing
(Recipient's mother--confirmatory typing)
Was the recipient's mother used as the donor?
No (No)
Yes (Yes)
Was the recipient's father used as the donor?
No (No)
Yes (Yes)
Specify person and typing:
Hlatyping By Dna Technology
Is a copy of the lab report attached?
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No (No)
Yes (Yes)
Hla Typing By Dna Technology: Class I
Number of A alleles provided:
Without Analysis (Not tested)
Integer::1 (One)
Integer::2 (Two)
First A* allele designations:
Second A* allele designations:
Number of B alleles provided:
Without Analysis (Not tested)
Integer::1 (One)
Integer::2 (Two)
First B* allele designations:
Second B* allele designations:
Number of C alleles provided:
Without Analysis (Not tested)
Integer::1 (One)
Integer::2 (Two)
First C* allele designations:
Second C* allele designations:
Hla Typing By Dna Technology: Class I
Number of  DRB1 alleles provided:
Without Analysis (Not tested)
Integer::1 (One)
Integer::2 (Two)
First DRB1* allele designations:
Second DRB1* allele designations:
Hla Typing By Dna Technology: Class Ii
(optional)
Number of DRB3 alleles provided:
None (None)
Without Analysis (Not tested)
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Integer::1 (One)
Integer::2 (Two)
First DRB3* allele designations:
Second DRB3* allele designations:
Number of DRB4 alleles provided:
None (None)
Without Analysis (Not tested)
Integer::1 (One)
Integer::2 (Two)
First DRB4* allele designations:
Second DRB4* allele designations:
Number of DRB5 alleles provided:
None (None)
Without Analysis (Not tested)
Integer::1 (One)
Integer::2 (Two)
First DRB5 * allele designations:
Second DRB5 * allele designations:
Number of  DQB1 alleles provided:
Integer::1 (One)
Integer::2 (Two)
First DQB1* allele designations:
Second DQB1* allele designations:
Number of DPB1 alleles provided:
Integer::1 (One)
Integer::2 (Two)
First DPB1* allele designations:
Second DPB1* allele designations:
Number of DQA1 alleles provided?
Integer::1 (One)
Integer::2 (Two)
First DQA1* allele designations:
Second DQA1* allele designations:
Number of DPA1 alleles provided:
4 / 11
Follow-Up - 2005 - Confirmation of HLA typing ISO Date Format  Version
1 - 2884460v1.0
Integer::1 (One)
Integer::2 (Two)
First DPA1* allele designations:
Second DPA1* allele designations:
Antigens Defined By Serologic Typing
Number of A antigens provided:
Integer::1 (One)
Integer::2 (Two)
1st A antigen specificity:
A1 Antigen (A1)
A10 Antigen (A10)
A11 Antigen (A11)
A19 Antigen (A19)
A2 Antigen 1st A2 Antigen (A2)
A203 Antigen (A203)
A210 Antigen (A210)
A23(9) Antigen (A23(9))
A24(9) Antigen (A24(9))
A2403 Antigen (A2403)
A25(10) Antigen (A25(10))
A26(10) Antigen (A26(10))
A28 Antigen (A28)
A29(19) Antigen (A29(19))
A3 Antigen (A3)
A30(19) Antigen (A30(19))
A31(19) Antigen (A31(19))
A32(19) Antigen (A32(19))
A33(19) Antigen (A33(19))
A34(10) Antigen (A34(10))
A36 Antigen (A36)
A43 Antigen (A43)
A66(10) Antigen (A66(10))
A68(28) Antigen (A68(28))
A69(28) Antigen (A69(28))
A74(19) Antigen (A74(19))
A80 Antigen (A80)
A9 Antigen (A9)
Ax Antigen (AX)
2nd A antigen specificity
A1 Antigen (A1)
A10 Antigen (A10)
A11 Antigen (A11)
A19 Antigen (A19)
A2 Antigen 1st A2 Antigen (A2)
A203 Antigen (A203)
A210 Antigen (A210)
A23(9) Antigen (A23(9))
A24(9) Antigen (A24(9))
A2403 Antigen (A2403)
A25(10) Antigen (A25(10))
A26(10) Antigen (A26(10))
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A28 Antigen (A28)
A29(19) Antigen (A29(19))
A3 Antigen (A3)
A30(19) Antigen (A30(19))
A31(19) Antigen (A31(19))
A32(19) Antigen (A32(19))
A33(19) Antigen (A33(19))
A34(10) Antigen (A34(10))
A36 Antigen (A36)
A43 Antigen (A43)
A66(10) Antigen (A66(10))
A68(28) Antigen (A68(28))
A69(28) Antigen (A69(28))
A74(19) Antigen (A74(19))
A80 Antigen (A80)
A9 Antigen (A9)
Ax Antigen (AX)
Number of B antigens provided:
Integer::1 (One)
Integer::2 (Two)
First B antigen specificity:
B12 Antigen Specificity (B12)
B13 Antigen (B13)
B14 Antigen (B14)
B15 Antigen (B15)
B16 Antigen (B16)
B17 Antigen (B17)
B18 Antigen (B18)
B21 Antigen (B21)
B22 Antigen (B22)
B27 Antigen (B27)
B2708 Antigen (B2708)
B35 Antigen (B35)
B37 Antigen (B37)
B38(16) Antigen (B38(16))
B39(16) Antigen (B39(16))
B3901 Antigen (B3901)
B3902 Antigen (B3902)
B40 Antigen (B40)
B4005 Antigen (B4005)
B41 Antigen (B41)
B42 Antigen (B42)
B44(12) Antigen (B44(12))
B45(12) Antigen (B45(12))
B46 Antigen (B46)
B47 Antigen (B47)
B48 Antigen (B48)
B49(21) Antigen (B49(21))
B5 Antigen (B5)
B50(21) Antigen (B50(21))
B51(5) Antigen (B51(5))
B5102 Antigen (B5102)
B5103 Antigen (B5103)
B52(5) Antigen (B52(5))
B53 Antigen (B53)
B54(22) Antigen (B54(22))
B55(22) Antigen (B55(22))
B56(22) Antigen (B56(22))
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B57(17) Antigen (B57(17))
B58(17) Antigen (B58(17))
B59 Antigen (B59)
B60(40) Antigen (B60(40))
B61(40) Antigen (B61(40))
B62(15) Antigen (B62(15))
B63(15) Antigen (B63(15))
B64(14) Antigen (B64(14))
B65(14) Antigen (B65(14))
B67 Antigen (B67)
B7 Antigen (B7)
B70 Antigen (B70)
B703 Antigen (B703)
B71(70) Antigen (B71(70))
B72(70) Antigen (B72(70))
B73 Antigen (B73)
B75(15) Antigen (B75(15))
B76(15) Antigen (B76(15))
B77(15) Antigen (B77(15))
B78 Antigen (B78)
B8 Antigen (B8)
B81 Antigen (B81)
B82 Antigen (B82)
Bx Antigen (BX)
Second B antigen specificity:
B12 Antigen Specificity (B12)
B13 Antigen (B13)
B14 Antigen (B14)
B15 Antigen (B15)
B16 Antigen (B16)
B17 Antigen (B17)
B18 Antigen (B18)
B21 Antigen (B21)
B22 Antigen (B22)
B27 Antigen (B27)
B2708 Antigen (B2708)
B35 Antigen (B35)
B37 Antigen (B37)
B38(16) Antigen (B38(16))
B39(16) Antigen (B39(16))
B3901 Antigen (B3901)
B3902 Antigen (B3902)
B40 Antigen (B40)
B4005 Antigen (B4005)
B41 Antigen (B41)
B42 Antigen (B42)
B44(12) Antigen (B44(12))
B45(12) Antigen (B45(12))
B46 Antigen (B46)
B47 Antigen (B47)
B48 Antigen (B48)
B49(21) Antigen (B49(21))
B5 Antigen (B5)
B50(21) Antigen (B50(21))
B51(5) Antigen (B51(5))
B5102 Antigen (B5102)
B5103 Antigen (B5103)
B52(5) Antigen (B52(5))
B53 Antigen (B53)
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B54(22) Antigen (B54(22))
B55(22) Antigen (B55(22))
B56(22) Antigen (B56(22))
B57(17) Antigen (B57(17))
B58(17) Antigen (B58(17))
B59 Antigen (B59)
B60(40) Antigen (B60(40))
B61(40) Antigen (B61(40))
B62(15) Antigen (B62(15))
B63(15) Antigen (B63(15))
B64(14) Antigen (B64(14))
B65(14) Antigen (B65(14))
B67 Antigen (B67)
B7 Antigen (B7)
B70 Antigen (B70)
B703 Antigen (B703)
B71(70) Antigen (B71(70))
B72(70) Antigen (B72(70))
B73 Antigen (B73)
B75(15) Antigen (B75(15))
B76(15) Antigen (B76(15))
B77(15) Antigen (B77(15))
B78 Antigen (B78)
B8 Antigen (B8)
B81 Antigen (B81)
B82 Antigen (B82)
Bx Antigen (BX)
Optional Antigen Reporting: Antigens
Defined By Serologic Typing
Number of C antigens provided:
Integer::1 (One)
Integer::2 (Two)
First C antigen specificity
Cw1 Antigen (Cw1)
Cw10(w3) Antigen (Cw10(w3))
Cw2 Antigen (Cw2)
Cw3 Antigen (Cw3)
Cw4 Antigen (Cw4)
Cw5 Antigen (Cw5)
Cw6 Antigen (Cw6)
Cw7 Antigen (Cw7)
Cw8 Antigen (Cw8)
Cw9(w3) Antigen (Cw9(w3))
Cx Antigen (CX)
Second C antigen specificity:
Cw1 Antigen (Cw1)
Cw10(w3) Antigen (Cw10(w3))
Cw2 Antigen (Cw2)
Cw3 Antigen (Cw3)
Cw4 Antigen (Cw4)
Cw5 Antigen (Cw5)
Cw6 Antigen (Cw6)
Cw7 Antigen (Cw7)
Cw8 Antigen (Cw8)
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Cw9(w3) Antigen (Cw9(w3))
Cx Antigen (CX)
Bw4 specificity present?
No (No)
Yes (Yes)
Bw6 specificity present?
No (No)
Yes (Yes)
Number of DR antigens provided
Integer::1 (One)
Integer::2 (Two)
First DR  antigen specificity:
Dr1 Antigen (DR1)
Dr10 Antigen (DR10)
Dr103 Antigen (DR103)
Dr11(5) Antigen (DR11(5))
Dr12(5) Antigen (DR12(5))
Dr13(6) Antigen (DR13(6))
Dr14(6) Antigen (DR14(6))
Dr1403 Antigen (DR1403)
Dr1404 Antigen (DR1404)
Dr15(2) Antigen (DR15(2))
Dr16(2) Antigen (DR16(2))
Dr17(3) Antigen (DR17(3))
Dr18(3) Antigen (DR18(3))
Dr2 Antigen (DR2)
Dr3 Antigen (DR3)
Dr4 Antigen (DR4)
Dr5 Antigen (DR5)
Dr6 Antigen (DR6)
Dr7 Antigen (DR7)
Dr8 Antigen (DR8)
Dr9 Antigen (DR9)
Drx Antigen (DRX)
Second DR antigen specificity:
Dr1 Antigen (DR1)
Dr10 Antigen (DR10)
Dr103 Antigen (DR103)
Dr11(5) Antigen (DR11(5))
Dr12(5) Antigen (DR12(5))
Dr13(6) Antigen (DR13(6))
Dr14(6) Antigen (DR14(6))
Dr1403 Antigen (DR1403)
Dr1404 Antigen (DR1404)
Dr15(2) Antigen (DR15(2))
Dr16(2) Antigen (DR16(2))
Dr17(3) Antigen (DR17(3))
Dr18(3) Antigen (DR18(3))
Dr2 Antigen (DR2)
Dr3 Antigen (DR3)
Dr4 Antigen (DR4)
Dr5 Antigen (DR5)
Dr6 Antigen (DR6)
Dr7 Antigen (DR7)
Dr8 Antigen (DR8)
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Dr9 Antigen (DR9)
Drx Antigen (DRX)
DR51 specificity present?
No (No)
Yes (Yes)
DR52 specificity present?
No (No)
Yes (Yes)
DR53 specificity present?
No (No)
Yes (Yes)
Number of DQ antigens provided:
Integer::1 (One)
Integer::2 (Two)
First DQ antigen specificity:
Dq1 Antigen (DQ1)
Dq2 Antigen (DQ2)
Dq3 Antigen (DQ3)
Dq4 Antigen (DQ4)
Dq5(1) Antigen (DQ5(1))
Dq6(1) (DQ6(1))
Dq7(3) Antigen (DQ7(3))
Dq8(3) Antigen (DQ8(3))
Dq9(3) Antigen (DQ9(3))
Dqx Antigen (DQX)
Second DQ antigen specificity:
Dq1 Antigen (DQ1)
Dq2 Antigen (DQ2)
Dq3 Antigen (DQ3)
Dq4 Antigen (DQ4)
Dq5(1) Antigen (DQ5(1))
Dq6(1) (DQ6(1))
Dq7(3) Antigen (DQ7(3))
Dq8(3) Antigen (DQ8(3))
Dq9(3) Antigen (DQ9(3))
Dqx Antigen (DQX)
Number of DP antigens provided:
Integer::1 (One)
Integer::2 (Two)
First DP antigen specificity:
Dpw1 Antigen (DPw1)
Dpw2 Antigen (DPw2)
Dpw3 Antigen (DPw3)
Dpw4 Antigen (DPw4)
Dpw5 Antigen (DPw5)
Dpw6 Antigen (DPw6)
Dpx Antigen (DPX)
Second DP antigen specificity:
Dpw1 Antigen (DPw1)
Dpw2 Antigen (DPw2)
Dpw3 Antigen (DPw3)
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Dpw4 Antigen (DPw4)
Dpw5 Antigen (DPw5)
Dpw6 Antigen (DPw6)
Dpx Antigen (DPX)
Author Information
First Name
Last Name
Telephone number:
Fax number:
EMail Address
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Baseline Medical History
Baseline Medical History
Visit Date
Date of Examination (Enter the date that the
patient was examined and the medical history
was documented. Since only one Baseline
Medical History form is used, if the information
has been assembled over a period of time, enter
the date of the latest examination.)
Medical History System
Abdomen (Abdomen)
Breast (Breasts)
Cardiovascular System (Cardiovascular)
Dermatologic (Dermatologic)
Endocrine System (Endocrine/Metabolic)
Gastrointestinal System
(Gastrointestinal)
Genitourinary System (Genitourinary)
Head, Ears, Eyes, Nose And Throat
(HEENT)
Hematopoietic And Lymphatic System
(Hematopoietic/Lymph Nodes(s))
Immune System (Immune)
Musculoskeletal System
(Musculoskeletal)
Neck (Neck)
Neurologic Examination (Neurologic)
Other (Other)
Pelvic Examination (Pelvis)
Psychological (Psychologic)
Respiratory System (Respiratory)
Finding Result (Comments are required for
abnormal finding results. -  - Note: Do not select
Normal if the body system was not specifically
assessed i.e.: not mentioned in the progress note
in the medical record. Not Assessed means a
discussion on the body system was not raised or
the body system was not assessed.)
Abnormal (A)
Normal (N)
Not Assessed (Z)
Medical History If Abnormal
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2900 - RECIPIENT DEATH DATA
Registry Use Only
Sequence number:
Date received:
Identification Data
CIBMTR Center Number:
CIBMTR Recipient ID:
Today's date:
Date of Hematopoietic Stem Cell Transplantation
(HSCT) for which this form is being completed:
Hsct Type
What source was used for the hematopoietic
stem cell transplantation?
Related Allogenic (Allogeneic, related)
Unrelated Allogenic (Allogeneic,
unrelated)
Autologous (Autologous)
Syngeneic (Syngeneic (identical twin))
Was a particular hematopoietic stem cell source
used?
No (No)
Yes (Yes)
Product Type
What type of hematopoietic stem cell transplant
was used?
Umbilical Cord Blood (Cord blood)
Bone Marrow (Marrow)
Multiple Umbilical Cord Blood (Multiple
cord blood units infused)
Other (Other)
Peripheral Blood Stem Cell (PBSC)
Was a particular hematopoietic stem cell
transplant type used?
No (No)
Yes (Yes)
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Specify the other hematopoietic stem cell
transplant type: (Answer only if the value for
2730912 is "Other".)
Death Date
Date of death:
Date of death is estimated:
Date Estimate (Date estimated)
Autopsy Report
Was cause of death confirmed by autopsy?
Autopsy Pending (Autopsy pending)
No (No)
Unknown (Unknown)
Yes (Yes)
Is an autopsy report attached?
No (No)
Yes (Yes)
Cause Of Death
Primary cause of death:
Accident Death (Accidental death)
Acute Graft Versus Host Disease (Acute
GVHD)
Adult Respiratory Distress Syndrome
(Adult Respiratory Distress Syndrome
(ARDS))
Bacterial Infection (Bacterial infection)
Heart Failure (Cardiac failure)
Central Nervous System Failure (Central
nervous system(CNS) failure)
Chronic Graft Versus Host Disease
(Chronic GVHD)
Dic (Disseminated intravascular
coagulation (DIC))
Fungal Infection (Fungal infection)
Gastrointestinal Failure (Gastrointestinal
(GI) failure (not liver))
Gastrointestinal Hemorrhage
(Gastrointestinal hemorrhage)
Graft Rejection (Graft rejection or failure)
Hemorrhage Not Otherwise Specified
(Hemorrhage, not otherwise specified)
Hemorrhage Cystitis (Hemorrhagic
cystitis)
Infection Organism Not Identified
(Infection, organism not identified)
Intracranial Hemorrhage (Intracranial
hemorrhage)
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Idiopathic Pneumonia Syndrome
Idiopathic (IPS, idiopathic)
Idiopathic Pneumonia Syndrome Viral
Cytomegalovirus (IPS, viral,
cytomegalovirus(CMV))
Idiopathic Pneumonia Syndrome Viral
Other (IPS, viral, other)
Liver Failure (Liver failure (not VOD))
Multiple Organ Failure (Multiple Organ
Failure)
Organ Failure Not Otherwise Specified
(Organ failure, not otherwise specified)
Other Reason (Other cause)
Other Hemorrhage (Other hemorrhage)
Other Infection (Other infection)
Other Idiopathic Pneumonia Syndrome
(Other IPS)
Other Organ Failure (Other organ failure)
Other Vascular (Other vascular)
Prior Malignant Neoplasm (Prior
malignancy)
Protozoal Infection (Protozoal infection)
Pulmonary Failure (Pulmonary failure)
Pulmonary Hemorrhage (Pulmonary
hemorrhage)
Recurrence Persistent Pd
(Recurrence/persistence/progression of
disease reported for first HSCT)
Renal Failure (Renal failure)
Secondary Malignant Neoplasm
(Secondary malignancy)
Suicide (Suicide)
Thromboembolism (Thromboembolic)
Thrombocytopenic Purpura (Thrombotic
thrombocytopenic purpura (HUS/TTP))
Vascular Not Otherwise Specified
(Vascular, not otherwise specified)
Hepatic Veno-occlusive Disease (Veno-
occlusive disease (VOD) / sinusodial
obstruction syndrome (SOS))
Viral Infection (Viral infection)
Specify primary cause of death:
Cause Of Death
Contributing cause of death:
Accident Death (Accidental death)
Acute Graft Versus Host Disease (Acute
GVHD)
Adult Respiratory Distress Syndrome
(Adult Respiratory Distress Syndrome
(ARDS))
Bacterial Infection (Bacterial infection)
Heart Failure (Cardiac failure)
Central Nervous System Failure (Central
nervous system(CNS) failure)
Chronic Graft Versus Host Disease
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(Chronic GVHD)
Dic (Disseminated intravascular
coagulation (DIC))
Fungal Infection (Fungal infection)
Gastrointestinal Failure (Gastrointestinal
(GI) failure (not liver))
Gastrointestinal Hemorrhage
(Gastrointestinal hemorrhage)
Graft Rejection (Graft rejection or failure)
Hemorrhage Not Otherwise Specified
(Hemorrhage, not otherwise specified)
Hemorrhage Cystitis (Hemorrhagic
cystitis)
Infection Organism Not Identified
(Infection, organism not identified)
Intracranial Hemorrhage (Intracranial
hemorrhage)
Idiopathic Pneumonia Syndrome
Idiopathic (IPS, idiopathic)
Idiopathic Pneumonia Syndrome Viral
Cytomegalovirus (IPS, viral,
cytomegalovirus(CMV))
Idiopathic Pneumonia Syndrome Viral
Other (IPS, viral, other)
Liver Failure (Liver failure (not VOD))
Multiple Organ Failure (Multiple Organ
Failure)
Organ Failure Not Otherwise Specified
(Organ failure, not otherwise specified)
Other Reason (Other cause)
Other Hemorrhage (Other hemorrhage)
Other Infection (Other infection)
Other Idiopathic Pneumonia Syndrome
(Other IPS)
Other Organ Failure (Other organ failure)
Other Vascular (Other vascular)
Prior Malignant Neoplasm (Prior
malignancy)
Protozoal Infection (Protozoal infection)
Pulmonary Failure (Pulmonary failure)
Pulmonary Hemorrhage (Pulmonary
hemorrhage)
Recurrence Persistent Pd
(Recurrence/persistence/progression of
disease reported for first HSCT)
Renal Failure (Renal failure)
Secondary Malignant Neoplasm
(Secondary malignancy)
Suicide (Suicide)
Thromboembolism (Thromboembolic)
Thrombocytopenic Purpura (Thrombotic
thrombocytopenic purpura (HUS/TTP))
Vascular Not Otherwise Specified
(Vascular, not otherwise specified)
Hepatic Veno-occlusive Disease (Veno-
occlusive disease (VOD) / sinusodial
obstruction syndrome (SOS))
Viral Infection (Viral infection)
Specify contributing cause of death: (Answer only
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if the value for 2730912 is "Other
Infection","Other Idiopathic Pneumonia
Syndrome","Other Organ Failure","Other
Hemorrhage","Other Vascular" or "Other
Reason".)
Author Information
First Name
Last Name
Telephone number:
Fax number:
Email Address
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FOLLOW-UP
Follow-up
Last Contact Date
Patient Contact Type
Clinic Appointment (Clinic Appointment)
Email Contact With Patient (Email
Contact w/Patient)
Mail Contact With Patient (Mail Contact
w/Patient)
Social Security Death Index (ssdi)
(Social Security Death Index (SSDI))
Telephone Contact With Patient
(Telephone Contact w/Patient)
Telephone Contact With Patient's Family
(Telephone Contact w/Patient's Family)
Telephone Contact With Patient's Local
Physician (Telephone Contact w/Patient's
Local Physician)
Treatment Since Last Contact Indicator
No (No)
Yes (Yes)
Patient Survival Status
Alive With Disease (1)
Alive With No Evidence Of Disease (2)
Alive Disease Status Unknown (3)
Unknown (4)
Died (5)
Survival Status, unknown explanation
Comments
Note Date
Research Comments Text
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models.org/forms/1725
2005 Revision 2 - Confirmation of
HLA Typing
Registry Use Only
Sequence number:
Date received:
Identification Data
CIBMTR Center Number:
CIBMTR Recipient ID:
Specify non-NMDP donor:
Negation National Marrow Donor
Program Umbilical Cord Blood Unit
(Non-NMDP cord blood unit)
Negation National Marrow Donor
Program Donor Unrelated (Non-NMDP
unrelated donor)
Donor Relationship (Related donor)
What is the transplant donor or infant date of
birth?
What is the transplant donor or infant gender?
Female (female)
Male (male)
Non-NMDP unrelated donor / cord blood unit ID:
(not applicable for related donor)
Today's date:
Date of hematopoietic stem cell transplantation
(HSCT) for which this form is being completed:
What source was used for the hematopoietic
stem cell transplantation?
Related Allogenic (Allogeneic, related)
Unrelated Allogenic (Allogeneic,
unrelated)
Syngeneic (Syngeneic (identical twin))
What type of hematopoietic stem cell transplant
was used?
Umbilical Cord Blood (Cord blood)
Bone Marrow (Marrow)
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Other (Other)
Peripheral Blood Stem Cell (PBSC)
Specify the other hematopoietic stem cell
transplant type:
Hla Typing Source
Please specify the person for whom this typing is
being done:
Umbilical Cord Blood Confirmed Hla
Typing (Cord blood unit--confirmatory
typing)
Donor Confirmed Hla Typing (Donor--
confirmatory typing)
Umbilical Cord Blood Mother Hla Typing
(Maternal HLA typing)
Other (Other)
Recipient Final Hla Typing (Recipient--
final typing)
Recipient Father Confirmed Hla Typing
(Recipient's father--confirmatory typing)
Recipient Mother Confirmed Hla Typing
(Recipient's mother--confirmatory typing)
Was the recipient's mother used as the donor?
No (No)
Yes (Yes)
Was the recipient's father used as the donor?
No (No)
Yes (Yes)
Specify person and typing:
Hlatyping By Dna Technology
Is a copy of the lab report attached?
No (No)
Yes (Yes)
Hla Typing By Dna Technology: Class I
Number of A alleles provided:
Without Analysis (Not tested)
Integer::1 (One)
Integer::2 (Two)
First A* allele designations:
Second A* allele designations:
Number of B alleles provided:
Without Analysis (Not tested)
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Integer::1 (One)
Integer::2 (Two)
First B* allele designations:
Second B* allele designations:
Number of C alleles provided:
Without Analysis (Not tested)
Integer::1 (One)
Integer::2 (Two)
First C* allele designations:
Second C* allele designations:
Hla Typing By Dna Technology: Class I
Number of  DRB1 alleles provided:
Without Analysis (Not tested)
Integer::1 (One)
Integer::2 (Two)
First DRB1* allele designations:
Second DRB1* allele designations:
Hla Typing By Dna Technology: Class Ii
(optional)
Number of DRB3 alleles provided:
None (None)
Without Analysis (Not tested)
Integer::1 (One)
Integer::2 (Two)
First DRB3* allele designations:
Second DRB3* allele designations:
Number of DRB4 alleles provided:
None (None)
Without Analysis (Not tested)
Integer::1 (One)
Integer::2 (Two)
First DRB4* allele designations:
Second DRB4* allele designations:
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Number of DRB5 alleles provided:
None (None)
Without Analysis (Not tested)
Integer::1 (One)
Integer::2 (Two)
First DRB5 * allele designations:
Second DRB5 * allele designations:
Number of  DQB1 alleles provided:
Integer::1 (One)
Integer::2 (Two)
First DQB1* allele designations:
Second DQB1* allele designations:
Number of DPB1 alleles provided:
Integer::1 (One)
Integer::2 (Two)
First DPB1* allele designations:
Second DPB1* allele designations:
Number of DQA1 alleles provided?
Integer::1 (One)
Integer::2 (Two)
First DQA1* allele designations:
Second DQA1* allele designations:
Number of DPA1 alleles provided:
Integer::1 (One)
Integer::2 (Two)
First DPA1* allele designations:
Second DPA1* allele designations:
Antigens Defined By Serologic Typing
Number of A antigens provided:
Integer::1 (One)
Integer::2 (Two)
1st A antigen specificity:
A1 Antigen (A1)
A10 Antigen (A10)
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A11 Antigen (A11)
A19 Antigen (A19)
A2 Antigen 1st A2 Antigen (A2)
A203 Antigen (A203)
A210 Antigen (A210)
A23(9) Antigen (A23(9))
A24(9) Antigen (A24(9))
A2403 Antigen (A2403)
A25(10) Antigen (A25(10))
A26(10) Antigen (A26(10))
A28 Antigen (A28)
A29(19) Antigen (A29(19))
A3 Antigen (A3)
A30(19) Antigen (A30(19))
A31(19) Antigen (A31(19))
A32(19) Antigen (A32(19))
A33(19) Antigen (A33(19))
A34(10) Antigen (A34(10))
A36 Antigen (A36)
A43 Antigen (A43)
A66(10) Antigen (A66(10))
A68(28) Antigen (A68(28))
A69(28) Antigen (A69(28))
A74(19) Antigen (A74(19))
A80 Antigen (A80)
A9 Antigen (A9)
Ax Antigen (AX)
2nd A antigen specificity
A1 Antigen (A1)
A10 Antigen (A10)
A11 Antigen (A11)
A19 Antigen (A19)
A2 Antigen 1st A2 Antigen (A2)
A203 Antigen (A203)
A210 Antigen (A210)
A23(9) Antigen (A23(9))
A24(9) Antigen (A24(9))
A2403 Antigen (A2403)
A25(10) Antigen (A25(10))
A26(10) Antigen (A26(10))
A28 Antigen (A28)
A29(19) Antigen (A29(19))
A3 Antigen (A3)
A30(19) Antigen (A30(19))
A31(19) Antigen (A31(19))
A32(19) Antigen (A32(19))
A33(19) Antigen (A33(19))
A34(10) Antigen (A34(10))
A36 Antigen (A36)
A43 Antigen (A43)
A66(10) Antigen (A66(10))
A68(28) Antigen (A68(28))
A69(28) Antigen (A69(28))
A74(19) Antigen (A74(19))
A80 Antigen (A80)
A9 Antigen (A9)
Ax Antigen (AX)
Number of B antigens provided:
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Integer::1 (One)
Integer::2 (Two)
First B antigen specificity:
B12 Antigen Specificity (B12)
B13 Antigen (B13)
B14 Antigen (B14)
B15 Antigen (B15)
B16 Antigen (B16)
B17 Antigen (B17)
B18 Antigen (B18)
B21 Antigen (B21)
B22 Antigen (B22)
B27 Antigen (B27)
B2708 Antigen (B2708)
B35 Antigen (B35)
B37 Antigen (B37)
B38(16) Antigen (B38(16))
B39(16) Antigen (B39(16))
B3901 Antigen (B3901)
B3902 Antigen (B3902)
B40 Antigen (B40)
B4005 Antigen (B4005)
B41 Antigen (B41)
B42 Antigen (B42)
B44(12) Antigen (B44(12))
B45(12) Antigen (B45(12))
B46 Antigen (B46)
B47 Antigen (B47)
B48 Antigen (B48)
B49(21) Antigen (B49(21))
B5 Antigen (B5)
B50(21) Antigen (B50(21))
B51(5) Antigen (B51(5))
B5102 Antigen (B5102)
B5103 Antigen (B5103)
B52(5) Antigen (B52(5))
B53 Antigen (B53)
B54(22) Antigen (B54(22))
B55(22) Antigen (B55(22))
B56(22) Antigen (B56(22))
B57(17) Antigen (B57(17))
B58(17) Antigen (B58(17))
B59 Antigen (B59)
B60(40) Antigen (B60(40))
B61(40) Antigen (B61(40))
B62(15) Antigen (B62(15))
B63(15) Antigen (B63(15))
B64(14) Antigen (B64(14))
B65(14) Antigen (B65(14))
B67 Antigen (B67)
B7 Antigen (B7)
B70 Antigen (B70)
B703 Antigen (B703)
B71(70) Antigen (B71(70))
B72(70) Antigen (B72(70))
B73 Antigen (B73)
B75(15) Antigen (B75(15))
B76(15) Antigen (B76(15))
B77(15) Antigen (B77(15))
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B78 Antigen (B78)
B8 Antigen (B8)
B81 Antigen (B81)
B82 Antigen (B82)
Bx Antigen (BX)
Second B antigen specificity:
B12 Antigen Specificity (B12)
B13 Antigen (B13)
B14 Antigen (B14)
B15 Antigen (B15)
B16 Antigen (B16)
B17 Antigen (B17)
B18 Antigen (B18)
B21 Antigen (B21)
B22 Antigen (B22)
B27 Antigen (B27)
B2708 Antigen (B2708)
B35 Antigen (B35)
B37 Antigen (B37)
B38(16) Antigen (B38(16))
B39(16) Antigen (B39(16))
B3901 Antigen (B3901)
B3902 Antigen (B3902)
B40 Antigen (B40)
B4005 Antigen (B4005)
B41 Antigen (B41)
B42 Antigen (B42)
B44(12) Antigen (B44(12))
B45(12) Antigen (B45(12))
B46 Antigen (B46)
B47 Antigen (B47)
B48 Antigen (B48)
B49(21) Antigen (B49(21))
B5 Antigen (B5)
B50(21) Antigen (B50(21))
B51(5) Antigen (B51(5))
B5102 Antigen (B5102)
B5103 Antigen (B5103)
B52(5) Antigen (B52(5))
B53 Antigen (B53)
B54(22) Antigen (B54(22))
B55(22) Antigen (B55(22))
B56(22) Antigen (B56(22))
B57(17) Antigen (B57(17))
B58(17) Antigen (B58(17))
B59 Antigen (B59)
B60(40) Antigen (B60(40))
B61(40) Antigen (B61(40))
B62(15) Antigen (B62(15))
B63(15) Antigen (B63(15))
B64(14) Antigen (B64(14))
B65(14) Antigen (B65(14))
B67 Antigen (B67)
B7 Antigen (B7)
B70 Antigen (B70)
B703 Antigen (B703)
B71(70) Antigen (B71(70))
B72(70) Antigen (B72(70))
B73 Antigen (B73)
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B75(15) Antigen (B75(15))
B76(15) Antigen (B76(15))
B77(15) Antigen (B77(15))
B78 Antigen (B78)
B8 Antigen (B8)
B81 Antigen (B81)
B82 Antigen (B82)
Bx Antigen (BX)
Optional Antigen Reporting: Antigens
Defined By Serologic Typing
Number of C antigens provided:
Integer::1 (One)
Integer::2 (Two)
First C antigen specificity
Cw1 Antigen (Cw1)
Cw10(w3) Antigen (Cw10(w3))
Cw2 Antigen (Cw2)
Cw3 Antigen (Cw3)
Cw4 Antigen (Cw4)
Cw5 Antigen (Cw5)
Cw6 Antigen (Cw6)
Cw7 Antigen (Cw7)
Cw8 Antigen (Cw8)
Cw9(w3) Antigen (Cw9(w3))
Cx Antigen (CX)
Second C antigen specificity:
Cw1 Antigen (Cw1)
Cw10(w3) Antigen (Cw10(w3))
Cw2 Antigen (Cw2)
Cw3 Antigen (Cw3)
Cw4 Antigen (Cw4)
Cw5 Antigen (Cw5)
Cw6 Antigen (Cw6)
Cw7 Antigen (Cw7)
Cw8 Antigen (Cw8)
Cw9(w3) Antigen (Cw9(w3))
Cx Antigen (CX)
Bw4 specificity present?
No (No)
Yes (Yes)
Bw6 specificity present?
No (No)
Yes (Yes)
Number of DR antigens provided
Integer::1 (One)
Integer::2 (Two)
First DR  antigen specificity:
Dr1 Antigen (DR1)
Dr10 Antigen (DR10)
Dr103 Antigen (DR103)
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Dr11(5) Antigen (DR11(5))
Dr12(5) Antigen (DR12(5))
Dr13(6) Antigen (DR13(6))
Dr14(6) Antigen (DR14(6))
Dr1403 Antigen (DR1403)
Dr1404 Antigen (DR1404)
Dr15(2) Antigen (DR15(2))
Dr16(2) Antigen (DR16(2))
Dr17(3) Antigen (DR17(3))
Dr18(3) Antigen (DR18(3))
Dr2 Antigen (DR2)
Dr3 Antigen (DR3)
Dr4 Antigen (DR4)
Dr5 Antigen (DR5)
Dr6 Antigen (DR6)
Dr7 Antigen (DR7)
Dr8 Antigen (DR8)
Dr9 Antigen (DR9)
Drx Antigen (DRX)
Second DR antigen specificity:
Dr1 Antigen (DR1)
Dr10 Antigen (DR10)
Dr103 Antigen (DR103)
Dr11(5) Antigen (DR11(5))
Dr12(5) Antigen (DR12(5))
Dr13(6) Antigen (DR13(6))
Dr14(6) Antigen (DR14(6))
Dr1403 Antigen (DR1403)
Dr1404 Antigen (DR1404)
Dr15(2) Antigen (DR15(2))
Dr16(2) Antigen (DR16(2))
Dr17(3) Antigen (DR17(3))
Dr18(3) Antigen (DR18(3))
Dr2 Antigen (DR2)
Dr3 Antigen (DR3)
Dr4 Antigen (DR4)
Dr5 Antigen (DR5)
Dr6 Antigen (DR6)
Dr7 Antigen (DR7)
Dr8 Antigen (DR8)
Dr9 Antigen (DR9)
Drx Antigen (DRX)
DR51 specificity present?
No (No)
Yes (Yes)
DR52 specificity present?
No (No)
Yes (Yes)
DR53 specificity present?
No (No)
Yes (Yes)
Number of DQ antigens provided:
Integer::1 (One)
Integer::2 (Two)
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First DQ antigen specificity:
Dq1 Antigen (DQ1)
Dq2 Antigen (DQ2)
Dq3 Antigen (DQ3)
Dq4 Antigen (DQ4)
Dq5(1) Antigen (DQ5(1))
Dq6(1) (DQ6(1))
Dq7(3) Antigen (DQ7(3))
Dq8(3) Antigen (DQ8(3))
Dq9(3) Antigen (DQ9(3))
Dqx Antigen (DQX)
Second DQ antigen specificity:
Dq1 Antigen (DQ1)
Dq2 Antigen (DQ2)
Dq3 Antigen (DQ3)
Dq4 Antigen (DQ4)
Dq5(1) Antigen (DQ5(1))
Dq6(1) (DQ6(1))
Dq7(3) Antigen (DQ7(3))
Dq8(3) Antigen (DQ8(3))
Dq9(3) Antigen (DQ9(3))
Dqx Antigen (DQX)
Number of DP antigens provided:
Integer::1 (One)
Integer::2 (Two)
First DP antigen specificity:
Dpw1 Antigen (DPw1)
Dpw2 Antigen (DPw2)
Dpw3 Antigen (DPw3)
Dpw4 Antigen (DPw4)
Dpw5 Antigen (DPw5)
Dpw6 Antigen (DPw6)
Dpx Antigen (DPX)
Second DP antigen specificity:
Dpw1 Antigen (DPw1)
Dpw2 Antigen (DPw2)
Dpw3 Antigen (DPw3)
Dpw4 Antigen (DPw4)
Dpw5 Antigen (DPw5)
Dpw6 Antigen (DPw6)
Dpx Antigen (DPX)
Author Information
First Name
Last Name
Telephone number:
Fax number:
10 / 11
Follow-Up - 2005 Revision 2 - Confirmation of HLA Typing - 2920322v1.0
EMail Address
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Follow-Up - 2200 Revision 2 - Six Months to Two Years
Post-HSCT Data - 3065877v1.0
All rights reserved. Please visit https://medical-data-
models.org/forms/1728
2200 Revision 2 - Six Months to Two
Years Post-HSCT Data
Registry Use Only
Sequence number:
Date received:
Identification Data
CIBMTR Center Number:
CIBMTR Recipient ID:
Today's date:
Date of hematopoietic stem cell transplantation
(HSCT) for which this form is being completed:
Hsct Type
HSCT type
Related Allogenic (Allogeneic, related)
Unrelated Allogenic (Allogeneic,
unrelated)
Autologous (Autologous)
Syngeneic (Syngeneic (identical twin))
Was a particular hematopoietic stem cell source
used?
Yes (Yes)
Product Type
What type of hematopoietic stem cell transplant
was used?
Umbilical Cord Blood (Cord blood)
Bone Marrow (Marrow)
Multiple Umbilical Cord Blood (Multiple
cord blood units infused)
Other (Other)
Peripheral Blood Stem Cell (PBSC)
Was a particular hematopoietic stem cell
transplant type used?
Yes (Yes)
Specify the other hematopoietic stem cell
1 / 52
transplant type: (Answer only if the response to
CDE 2730912 is "Other")
Follow Up Visit
Visit
Integer::1 Year Report (1 year)
Integer::2 Year Report (2 years)
Integer::6 Month Report (6 Months)
Vital Status
Date of actual contact with the recipient to
determine the medical status for this follow-up
report:
Did the recipient receive a subsequent HSCT?
(Since the date of contact from the last report.
Bone marrow, mobilized peripheral blood stem
cells, cord blood.)
No (No)
Yes (Yes)
Specify the recipient's survival status at the date
of actual contact:
Life (Alive)
Death (Dead)
Has the recipient received a donor cellular
infusion? (DCI. Since the date of contact from the
last report)
No (No)
Yes (Yes)
Granulopoiesis / Neutrophil Recovery
Did the recipient achieve an initial hematopoietic
recovery? (ANC greater than or equal to
500/mmE3 for three consecutive lab values
obtained on different days since the date of the
last report.)
Anc Never Dropped Below 500/mm^3 At
Any Time After The Start Of The
Preparative Regimen (Never below)
No, Anc >= 500/mm^3 Was Not
Achieved And There Was Documented
Persistent Disease In The Bone Marrow
Post-hsct (No, ANC recovery was not
achieved and there was evidence of
persistent disease)
No, Anc >= 500/mm^3 Was Not
Achieved And There Was No Evidence
Of Recurrent Disease In The Bone
Marrow (No, ANC recovery was not
achieved and there was no evidence of
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recurrent disease)
No, Recipients Initial Hematopoietic
Recovery Was Recorded On A Previous
Report (No, recipients initial
hematopoietic recovery was recorded on
a previous report)
Yes (Yes)
Date ANC was greater than or equal to
500/mmE3: (First of 3 lab values)
Granulopoiesis / Neutrophil Recovery #2
Following the initial hematopoietic recovery, did
the recipient experience a subsequent decline in
ANC? (ANC greater than or equal to 500/mmE3
for three consecutive lab values obtained on
different days with a subsequent decline in ANC
to less than 500/mmE3 for greater than or equal
to 3 days since the date of the last report)
No (No)
Yes (Yes)
Date of decline in ANC to less than 500/mmE3
for 3 days or more: (First of 3 days that the ANC
declined)
What is the value of WBC: (Actual CBC on first
day of decline)
What is the unit of measure for WBC? (Actual
CBC on first day of decline)
10e6 Per Liter (10E6/L)
10e9 Cells Per Liter (10E9 Cells/L)
What is the percentage of neutrophils? (Actual
CBC on first day of decline)
Granulopoiesis / Neutrophil Recovery
Did the recipient recover and maintain ANC
greater than or equal to 500/mmE3 following the
decline?
No (No)
Yes (Yes)
Date ANC was greater than or equal to
500/mmE3: (First of 3 lab values)
If necessary, please validate the neutrophil
recovery date response.
Date Unknown (Date unknown)
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What is the value of WBC: (Actual CBC on first
day of decline)
What is the unit of measure for WBC? (Actual
CBC on first day of decline)
10e6 Per Liter (10E6/L)
10e9 Cells Per Liter (10E9 Cells/L)
What is the percentage of neutrophils? (Actual
CBC on first day of decline)
Megakaryopoiesis / Platelet Recovery
Was an initial platelet count greater than or equal
to 20 x 10E9/L achieved? (Since the date of the
last report)
No (No)
Never Less Than Platelet Count 20000
(platelet count never dropped below 20 x
10^9/L)
Previous Report (Previously reported)
Yes (Yes)
Date platelet count greater than or equal to 20 x
10E9/L
If necessary, please validate the date of platelets
greater than or equal to 20 x 10E9/L response.
Date Estimate (Date estimated)
Date Unknown (Date unknown)
Was an initial platelet count greater than or equal
to 50 x 10E9/L achieved? (Since the date of the
last report)
No (No)
Never Less Than Platelet Count 50000
(platelet count never dropped below 50 x
10^9/L)
Previous Report (Previously reported)
Yes (Yes)
Date platelets greater than or equal to 50 x
10E9/L:
If necessary, please validate the date of platelets
greater than or equal to 50 x 10E9/L response.
Date Estimate (Date estimated)
Date Unknown (Date unknown)
Current Hematologic Findings
Sample (specimen) collection date. (Date of most
recent hematologic testing)
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What is the value of WBC: (Actual CBC on first
day of decline)
What is the reason for the WBC missing value?
Negation Test (Not tested)
What is the unit of measure for WBC? (Actual
CBC on first day of decline)
10e6 Per Liter (10E6/L)
10e9 Cells Per Liter (10E9 Cells/L)
What is the percentage of neutrophils? (Actual
CBC on first day of decline)
What is the reason for the neutrophils missing
value?
Negation Test (Not tested)
What is the percentage of lymphocytes?
What is the reason for the lymphocytes missing
value?
Negation Test (Not tested)
What is the value of hemoglobin? (2 decimal
place value)
What is the unit of measure for hemoglobin?
Gram Per Deciliter (g/dL)
Gram Per Liter (g/L)
Millimole Per Liter (mmol/L)
What is the reason for the hemoglobin missing
value?
Negation Test (Not tested)
If necessary, please validate the hemoglobin
response.
Transfused Rbc Less Than 30 Days
From Date Of Most Current Testing
(Transfused RBC less than 30 days from
date of most current testing)
What is the percentage of hematocrit?
What is the reason for the hematocrit missing
value?
Negation Test (Not tested)
If necessary, please validate the hematocrit
response.
Transfused Rbc Less Than 30 Days
From Date Of Most Current Testing
(Transfused RBC less than 30 days from
date of most current testing)
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What is the value of platelets?
What is the unit of measure for platelets?
10e6 Per Liter (10E6/L)
10e9 Cells Per Liter (10E9 Cells/L)
What is the reason for the platelets missing
value?
Negation Test (Not tested)
If necessary, please validate the platelet
response.
Transfused Platelets Less Than 7 Days
From Date Of Most Current Testing
(Transfused platelets less than 7 days
from date of most current testing)
Immune Reconstitution Part 1 Of 5
Type of immunologic laboratory procedure
performed:
Iga (IgA)
Igg (IgG)
Igm (IgM)
Sample (specimen) collection date. (Date of most
recent hematologic testing)
What is the value of the immunoglobulin test?
(Specify the immunoglobulin values from the
most recent testing)
Specify the unit of measure for the
immunoglobulin test:
Gram Per Deciliter (g/dL)
Gram Per Liter (g/L)
Milligram Per Deciliter (mg/dL)
What is the reason for the immunoglobulin
missing value?
Negation Test (Not tested)
Immune Reconstitution Part 2 Of 5
Did the recipient receive supplemental
intravenous immunoglobulins? (IVIG. Since the
date of the last report)
No (No)
Yes (Yes)
Was therapy ongoing within one month of
immunoglobulin testing?
No (No)
Yes (Yes)
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Immune Reconstitution Part 3 Of 5
Specify the indication(s) for the supplemental
intravenous immunoglobulin therapy:
Other (Other Indication)
Preventive Intervention Cytomegalovirus
(Prophylaxis for cytomegalovirus
infection)
Preventive Intervention Low Igg No
Active Infection (Prophylaxis for low IgG
with no active infection)
Therapeutic Procedure Cytomegalovirus
(Treatment for CMV infection)
Therapeutic Procedure Infection Low Igg
(Treatment for infection with low IgG)
Therapeutic Procedure Respiratory
Syncytial Virus (Treatment for respiratory
syncytial virus (RSV) infection)
Specify if there was an indication for the
supplemental intravenous immunoglobulin
therapy:
No (No)
Yes (Yes)
Specify other indication (Answer only if the
response to CDE 2775979 is "Other indication")
Immune Reconstitution Part 4 Of 5
Were lymphocyte analyses performed? (Since
the date of the last report)
No (No)
Yes (Yes)
Sample (specimen) collection date. (Date of most
recent hematologic testing)
Immune Reconstitution Part 5 Of 5
Specify cluster of differentiation type:
Cd20 Antigen (CD20)
Cd3 Complex (CD3)
Cd4 Antigen (CD4)
Neural Cell Adhesion Molecule (CD56)
Cd8 Antigen, Beta Polypeptide 1 (CD8)
What is the value of the cluster of differentiation?
What is the unit of measure for the cluster of
differentiation?
10e6 Per Liter (10E6/L)
10e9 Cells Per Liter (10E9 Cells/L)
What is the reason for the cluster of
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differentiation missing value?
Negation Test (Not tested)
Chimerism Studies
Were chimerism studies performed? (Since the
date of the last report)
No (No)
Yes (Yes)
Were infusions from more than one donor given?
No (No)
Yes (Yes)
Are chimerism laboratory reports attached to this
form?
No (No)
Yes (Yes)
Specify donor gender:
Female (female)
Male (male)
Chimerism Studies
Sample (specimen) collection date. (Date of most
recent hematologic testing)
Method
Cytogenetics (Conventional (Standard)
Cytogenetics)
Fluorescence In Situ Hybridization
(Fluorescence in situ Hybridization
(FISH))
Human Leukocyte Antigen Test (HLA
Typing)
Other (Other)
Restriction Fragment Length
Polymorphism (Restriction Fragment
Length Polymorphism (RFLP))
Minisatellite Repeat (VNTR or STR,
micro or mini satellite)
Specify the chimerism laboratory procedure
method type:
Cell type
B-lymphocyte (B-cells)
Bone Marrow (Bone marrow (BM))
Lymphocyte Not Otherwise Specified
(Lymphocytes, not otherwise specified)
Monocyte (Monocytes)
Myeloid Not Otherwise Specified
(Myeloid cells, not otherwise specified)
Other (Other)
Peripheral Blood Mononuclear Cell
(Peripheral blood mononuclear cells
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(PBMC))
Neutrophil (PMNs (neutrophils))
Erythrocyte (Red blood cells)
T-lymphocyte (T-cell)
Specify the chimerism laboratory procedure cell
type:
Total cells examined
Number of donor cells
Number of host cells
Percent donor cells, quantitative method
Were donor cells present as determined by non-
quantitative means? (If performed by non-
quantitative method, indicate the presence of
donor cells.)
Present (Present)
Percent host cells, quantitative method
Were host cells present as determined by non-
quantitative means? (If performed by non-
quantitative method, indicate the presence of
host cells.)
Present (Present)
Chimerism Studies
NMDP donor ID:
Sample (specimen) collection date. (Date of most
recent hematologic testing)
NMDP Cord Blood Unit ID:
Non-NMDP Cord Blood Unit (CBU) ID:
Donor / Infant date of birth:
Non-NMDP donor ID:
Donor / Infant gender:
Female (female)
Male (male)
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Method
Cytogenetics (Conventional (Standard)
Cytogenetics)
Fluorescence In Situ Hybridization
(Fluorescence in situ Hybridization
(FISH))
Human Leukocyte Antigen Test (HLA
Typing)
Other (Other)
Restriction Fragment Length
Polymorphism (Restriction Fragment
Length Polymorphism (RFLP))
Minisatellite Repeat (VNTR or STR,
micro or mini satellite)
Specify the chimerism laboratory procedure
method type:
Cell type
B-lymphocyte (B-cells)
Bone Marrow (Bone marrow (BM))
Lymphocyte Not Otherwise Specified
(Lymphocytes, not otherwise specified)
Monocyte (Monocytes)
Myeloid Not Otherwise Specified
(Myeloid cells, not otherwise specified)
Other (Other)
Peripheral Blood Mononuclear Cell
(Peripheral blood mononuclear cells
(PBMC))
Neutrophil (PMNs (neutrophils))
Erythrocyte (Red blood cells)
T-lymphocyte (T-cell)
Specify the chimerism laboratory procedure cell
type:
Total cells examined
Number of donor cells
Number of host cells
Percent donor cells, quantitative method
Were donor cells present as determined by non-
quantitative means? (If performed by non-
quantitative method, indicate the presence of
donor cells.)
Present (Present)
Percent host cells, quantitative method
Were host cells present as determined by non-
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quantitative means? (If performed by non-
quantitative method, indicate the presence of
host cells.)
Present (Present)
Engraftment Syndrome
Did engraftment syndrome occur? (Since the
date of the last report)
No (No)
Yes (Yes)
Date of onset:
Engraftment Syndrome 2 Of 2
Specify the symptoms of engraftment syndrome:
Capillary Leak Syndrome (Capillary leak
syndrome)
Fever (Fever)
Skin Rash (Skin rash)
Specify if symptoms of engraftment syndrome
occurred:
No (No)
Yes (Yes)
Specify amount of body surface affected (Answer
only if the response to CDE 2782511 is "Skin
rash")
Engraftment Syndrome Part 3 Of 3
Was engraftment syndrome treated with
corticosteroids
No (No)
Yes (Yes)
Acute Graft Vs. Host Disease (gvhd)
Did acute GVHD develop or persist? (Or a flare-
up that was more severe since the date of the last
report)
No (No)
Unknown (Unknown)
Yes (Yes)
Date of diagnosis: (Of acute GVHD)
If necessary, please validate the diagnosis date
response. (Of acute GVHD)
Date Previous Report (Date previously
reported)
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Was the diagnosis based on evidence from a
biopsy? (Histology)
No (No)
Yes (Yes)
Acute Graft Vs. Host Disease (gvhd) Part
2 Of 6
What is the biopsy site used to indicate the
diagnostic evidence:
Gastrointestinal (Gastrointestinal (GI))
Liver (Liver)
Lung (Lung)
Other (Other)
Skin (Skin)
Specify result(s):
Uncertain (Inconclusive)
Negative Finding (Negative)
Not Done: C49484 (Not Done)
Positive Finding (Positive)
Specify other site: (Answer only if the response to
CDE 2787340 is "Other")
Acute Graft Vs. Host Disease (gvhd) Part
3 Of
Is a copy of the pathology report attached?
No (No)
Yes (Yes)
Was the diagnosis based on clinical evidence?
No (No)
Yes (Yes)
Maximum overall grade of acute GVHD:
Agvhd Grade I (I)
Agvhd Grade Ii (II)
Agvhd Grade Iii (III)
Agvhd Grade Iv (IV)
Is acute GVHD still present at the date of contact
for this report?
No (No)
Progressive Chronic Graft Versus Host
Disease (Progressed to chronic GVHD)
Unknown (Unknown)
Yes (Yes)
List the maximum severity of skin involvement:
No Skin Acute Gvhd / Rash Not
Attributable To Acute Gvhd (None)
No Rash (Stage 0)
Maculopapular Rash, Less Than 25
Percent Of Body Surface (Stage 1)
Maculopapular Rash, 25 To 50 Percent
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Of Body Surface (Stage 2)
Generalized Erythroderma (Stage 3)
Generalized Erythroderma With Bullae
Formation And Desquamation (Stage 4)
List the maximum severity of lower intestinal tract
involvement (Use mL/day for adult recipients and
mL/mE2/day for pediatric recipients)
No Gut Acute Gvhd / Diarrhea Not
Attributable To Acute Gvhd (None)
Diarrhea Less Than Or Equal To 500
Ml/day Or Less Than 280 Ml/me2 Day
(Stage 0)
No Diarrhea (Stage 0 - no diarrhea)
Diarrhea Greater Than 500 But Less
Than Or Equal To 1000 Ml/day Or 280-
555 Ml/me2 /day (Stage 1)
Diarrhea Greater Than 1000 But Less
Than Or Equal To 1500 Ml/day Or 556-
833 Ml/me2 /day (Stage 2)
Diarrhea Greater Than 1500 Ml/day Or
Greater Than 833 Ml/me2 /day (Stage 3)
Severe Abdominal Pain, With Or Without
Ileus (Stage 4)
List the maximum severity of upper intestinal tract
involvement:
No Persistant Nausea Or Vomiting
(Stage 0)
Persistant Nausea Or Vomiting (Stage 1)
List the maximum severity of liver involvement:
No Liver Acute Gvhd / Bilirubin Level Not
Attributable To Acute Gvhd (None)
Bilirubin Less Than 2.0 Mg/dl (less Than
34 Micro Mol/l) (Stage 0)
Bilirubin 2.0 To 3.0 Mg/dl (34 To 52 Micro
Mol/l) (Stage 1)
Bilirubin 3.1 To 6.0 Mg/dl (53 To 103
Micro Mol/l) (Stage 2)
Bilirubin 6.1 To 15.0 Mg/dl (104 To 256
Micro Mol/l) (Stage 3)
Bilirubin Greater Than 15.0 Mg/dl
(greater Than 256 Micro Mol/l) (Stage 4)
Other clinical organ involvement?
No (No)
Yes (Yes)
Acute Graft Vs. Host Disease (gvhd) Part
3 Of
Specify the site of organ involvement
Lung (Lung)
Other (Other)
Was a particular site of organ involvement
present?
No (No)
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Yes (Yes)
Specify other site (Answer only if the response to
CDE 2793699 is "Other")
Acute Graft Vs. Host Disease (gvhd) Part
7 Of
Was specific therapy used to treat acute GVHD?
(Since the date of the last report)
No (No)
Yes (Yes)
ALS, ALG, ATS, ATG
No (No)
Yes (Yes)
Specify source:
Horse (Horse)
Other Source (Other source)
Rabbit (Rabbit)
Specify source (Specify other source)
Corticosteroids (Systemic)
No (No)
Yes (Yes)
Corticosteroids (Topical)
No (No)
Yes (Yes)
Cyclosporine (CSA, Sandimmune, Neoral)
No (No)
Yes (Yes)
ECP (Extra-corporeal photopheresis)
No (No)
Yes (Yes)
FK 506 (Tacrolimus, Prograf)
No (No)
Yes (Yes)
In vivo monoclonal antibody
No (No)
Yes (Yes)
Anti CD 25 (Zenapax, Daclizumab, AntiTAC)
No (No)
Yes (Yes)
Specify anti CD25
Campath
No (No)
Yes (Yes)
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Etanercept (Enbrel)
No (No)
Yes (Yes)
Infliximab (Remicade)
No (No)
Yes (Yes)
Other in vivo monoclonal antibody
No (No)
Yes (Yes)
Specify antibody
In vivo immunotoxin
No (No)
Yes (Yes)
Specify immunotoxin
Methotrexate (MTX, Amethopterin)
No (No)
Yes (Yes)
Mycophenolate mofetil (MMF, CellCept)
No (No)
Yes (Yes)
Sirolimus (Rapamycin, Rapamune)
No (No)
Yes (Yes)
Ursodiol
No (No)
Yes (Yes)
Blinded randomized trial
No (No)
Yes (Yes)
Specify trial agent
Other agent
No (No)
Yes (Yes)
Specify other agent
Chronic Graft Vs. Host Disease (gvhd)
Did chronic GVHD develop or persist? (Or a flare-
up that was more severe since the date of the last
report)
No (No)
Current Therapy Negation Symptom (No
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symptoms, but recipient is receiving
treatment)
Unknown (Unknown)
Yes (Yes)
Date of diagnosis: (Of acute GVHD)
If necessary, please validate the diagnosis date
response. (Of acute GVHD)
Date Previous Report (Date previously
reported)
Onset of chronic GVHD was:
Symptoms Reactivated Within 30 Days
Of Drug Tapering Or Discontinuation
(Chronic GVHD flare)
Acute Gvhd Never Developed (De novo)
Acute Gvhd Resolved, Then Chronic
Gvhd Developed (Interrupted)
Acute Gvhd Progressed Directly To
Chronic Gvhd (Progressive)
Karnofsky / Lansky score (At diagnosis of chronic
GVHD. If the recipient is 16 years of age or older,
complete the Karnofsky Scale. If the recipient is
younger than 16 years of age, complete the
Lansky Scale.)
Karnofsky Scale - Moribund, Fatal
Process Progressing Rapidly; Lansky
Scale - Completely Disabled, Not Even
Passive Play. (10)
Karnofsky Scale - Normal, No
Complaints, No Evidence Of Disease;
Lansky Scale - Fully Active. (100)
Karnofsky Scale - Very Sick,
Hospitalization Necessary; Lansky Scale
- Limited To Very Passive Activity
Initiated By Others (e.g., Tv) (20)
Karnofsky Scale - Severely Disabled,
Hospitalization Indicated, Although
Death Not Imminent. Lansky Scale -
Needs Considerable Assistance For
Quiet Activity. (30)
Karnofsky Scale - Disabled, Requires
Special Care And Assistance. Lansky
Scale - Able To Initiate Quiet Activities.
(40)
Karnofsky Scale - Requires
Considerable Assistance And Frequent
Medical Care; Lansky Scale -
Considerable Assistance Required For
Any Active Play; Fully Able To Engage In
Quiet Play. (50)
Karnofsky Scale - Requires Occasional
Assistance, But Is Able To Care For Most
Needs; Lansky Scale - Ambulatory Up To
50r Of Time, Limited Active Play With
Assistance / Supervision. (60)
Karnofsky Scale - Cares For Self, Unable
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To Carry On Normal Activity Or To Do
Active Work.; Lansky Score - Both
Greater Restrictions Of, And Less Time
Spent In, Active Play. (70)
Karnofsky Scale - Normal Activity With
Effort; Lansky Scale - Restricted In
Strenuous Play, Tires More Easily,
Otherwise Active. (80)
Karnofsky Scale - Able To Carry On
Normal Activity; Lansky Scale - Minor
Restriction In Physically Strenuous Play.
(90)
Diagnosis was based on:
Clinical And Histologic Finding (Both
clinical and histologic evidence)
Clinical Finding (Clinical evidence)
Histologic Finding And/or Biopsy
Confirmed (Histologic evidence / biopsy
proven)
Unknown (Unknown)
Maximum grade of chronic GVHD:
Extensive Gvhd Involvement (Extensive)
Limited Gvhd Involvement (Limited)
Overall severity of chronic GVHD:
Mild (Mild)
Moderate (Moderate)
Severe (Severe)
What is the value of platelets?
What is the unit of measure for platelets?
10e6 Per Liter (10E6/L)
10e9 Cells Per Liter (10E9 Cells/L)
Chronic Graft Vs. Host Disease (gvhd) -
Organ Involvement
Specify the type of organ / system involvement
with chronic GVHD:
Autoantibody (Autoantibodies)
Bronchiolitis Obliterans (Bronchiolitis
obliterans)
Eosinophilia (Eosinophilia)
Eye (Eyes)
Gastrointestinal Tract (Gastrointestinal
tract)
Genitourinary System (Genitourinary
tract)
Liver (Liver)
Oral Cavity (Mouth)
Musculoskeletal (Musculoskeletal)
Other Hematopoietic Involvement (Other
hematologic involvement)
Other Lung Involvement (Other lung
involvement)
Other Organ Involvement (Other organ
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involvement)
Other Skin Or Hair Involvement (Other
skin or hair involvement)
Skin Sclerosis (Sclerosis of skin)
Serositis (Serositis)
Thrombocytopenia (Thrombocytopenia)
Weight Loss (Weight loss)
Indicate if there was an organ / system
involvement with chronic GVHD:
No (No)
Yes (Yes)
Indicate if the organ / system involvement was
proven by biopsy:
No (No)
Yes (Yes)
Specify the other site of the organ / system
involvement with chronic GVHD: (Answer only if
the response to CDE 2793857 is "Other organ
involvement")
Chronic Graft Vs. Host Disease (gvhd)
Was specific therapy used to treat chronic
GVHD?
No (No)
Yes (Yes)
ALS, ALG, ATS, ATG
No (No)
Yes (Yes)
Specify source:
Horse (Horse)
Other Source (Other source)
Rabbit (Rabbit)
Specify source (Specify other source)
Azathioprine
No (No)
Yes (Yes)
Corticosteroids (Systemic)
No (No)
Yes (Yes)
Corticosteroids (Topical)
No (No)
Yes (Yes)
Cyclosporine (CSA, Sandimmune, Neoral)
No (No)
Yes (Yes)
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ECP (Extra-corporeal photopheresis)
No (No)
Yes (Yes)
FK 506 (Tacrolimus, Prograf)
No (No)
Yes (Yes)
Etretinate
No (No)
Yes (Yes)
In vivo monoclonal antibody
No (No)
Yes (Yes)
Anti CD 25 (Zenapax, Daclizumab, AntiTAC)
No (No)
Yes (Yes)
Hydroxychloroquine (Plaquenil)
No (No)
Yes (Yes)
Specify anti CD25
Campath
No (No)
Yes (Yes)
Etanercept (Enbrel)
No (No)
Yes (Yes)
Infliximab (Remicade)
No (No)
Yes (Yes)
Other in vivo monoclonal antibody
No (No)
Yes (Yes)
Specify antibody
Lamprene (Clofazimine)
No (No)
Yes (Yes)
Mycophenolate mofetil (MMF, CellCept)
No (No)
Yes (Yes)
Sirolimus (Rapamycin, Rapamune)
No (No)
Yes (Yes)
Ursodiol
No (No)
Yes (Yes)
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Pentostatin
No (No)
Yes (Yes)
PUVA (Psoralen and UVA)
No (No)
Yes (Yes)
Blinded randomized trial
No (No)
Yes (Yes)
Specify trial agent
Other agent
No (No)
Yes (Yes)
Thalidomide
No (No)
Yes (Yes)
Specify other agent
Are symptoms of chronic GVHD still present?
(On the date of actual contact or present at the
time of death)
No (No)
Yes (Yes)
Is the recipient still taking immunosuppressive
agents to treat or prevent GVHD? (Including
PUVA)
No (No)
Unknown (Unknown)
Yes (Yes)
Date final treatment administered:
If necessary, please validate the final date of
immunosuppressant administration response.
Date Previous Report (Date previously
reported)
Date Unknown (Date unknown)
Infection
Did the recipient receive any of the following
agents for infection prophylaxis? (Since the date
of the last report. Report prophylaxis
immunoglobulins at questions 34-35 in module
"Immune Reconstitution Part 3 of 5")
No (No)
Unknown (Unknown)
Yes (Yes)
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Infection Part 2 Of 3
Specify the agent types received for infection
prophylaxis:
Acyclovir (Acyclovir)
Amphotericin B-lipid Complex
(Amphotericin (lipid formulation))
Amphotericin B Deoxycholate
(Amphotericin (non-lipid formulation))
Atovoquone (Atovaquone)
Caspofungin (Caspofungin)
Dapsone (Dapsone)
Fluconazole (Fluconazole)
Foscarnet (Foscarnet)
Ganciclovir (Ganciclovir)
Itraconazole (Itraconazole)
Micafungin (Micafungin)
Negation Absorbable Oral Route Of
Administration Antibiotic (Nonabsorbable
oral antibiotics)
Other Pharmacologic Substance (Other
agent)
Other Antiviral Agent (Other antiviral
agent)
Other Pneumocystis Pneumonia
Preventive Intervention (Other
pneumocystis prophylaxis)
Other Systemic Antifungal Agent (Other
systemic antifungal agent)
Pentamidine Inhaler (Pentamidine
inhaled)
Pentamidine Intravenous Route Of
Administration (Pentamidine IV)
Posaconazole (Posaconazole)
Ravuconazole (Ravuconazole)
Systemic Antibiotic (Systemic
antibacterial antibiotics)
Trimethoprim-sulfamethoxazole
(Trimethoprim/sulfamethoxazole)
Valacyclovir (Valacyclovir)
Valganciclovir (Valganciclovir)
Voriconazole (Voriconazole)
Did the recipient receive any of the following
agents for infection prophylaxis? (Since the date
of the last report. Report prophylaxis
immunoglobulins at questions 34-35 in module
"Immune Reconstitution Part 3 of 5")
No (No)
Unknown (Unknown)
Yes (Yes)
Specify the other agent received for infection
prophylaxis: (Answer only if the response to CDE
2794436 is "Other systemic antifungal agent,"
"Other antiviral agent," "Other pneumocystis
prophylaxis," or "Other agent")
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Infection Part 3 Of 4
Did the recipient develop a clinically significant
infection? (Since the date of the last report)
No (No)
Yes (Yes)
Infection Part 3 Of 3
Organism
Acinetobacter (Acinetobacter)
Actinomyces (Actinomyces)
Adenovirus (Adenovirus)
Aspergillus Flavus (Aspergillus flavus)
Aspergillus Fumigatus (Aspergillus
fumigatus)
Aspergillus Niger (Aspergillus niger)
Aspergillus Not Otherwise Specified
(Aspergillus, NOS)
Bacillus (Bacillus)
Bacteroides (Bacteroides (gracillis,
uniformis, vulgaris, other species))
Bordetella Pertussis (Bordetella
pertussis (whooping cough))
Borrelia Burgdorferi (Borrelia (lyme
disease))
Moraxella Catarrhalis (Branhamella or
Moraxella catarrhalis (other species))
Campylobacter (Campylobacter (all
species))
Candida Glabrata (Candida (Torulopsis)
glabrata)
Candida Albicans (Candida albicans)
Pichia Guilliermondii (Candida
guillermondi)
Issatchenkia Orientalis (Candida krusei)
Clavispora Lusitaniae (Candida
lusitaniae)
Candida Parapsilosis (Candida
parapsilosis)
Candida Tropicalis (Candida tropicalis)
Candida Not Otherwise Specified
(Candida, NOS)
Capnocytophaga (Capnocytophaga)
Chlamydophila Pneumoniae (Chlamydia
(pneumoniae))
Chlamydia Not Otherwise Specified
(Chlamydia, NOS)
Citrobacter (Citrobacter (freundii, other
species))
Clostridium (Clostridium (all species
except difficile))
Clostridium Difficile (Clostridium difficile)
Corynebacterium (Corynebacterium (all
non-diptheria species))
Corynebacterium Jeikeium
(Corynebacterium (jeikeium))
Coxiella (Coxiella)
Cryptococcosis (Cryptococcosus
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species)
Cryptosporidium (Cryptosporidium)
Cytomegalovirus (Cytomegalovirus)
Enterobacter (Enterobacter)
Enterococcus (Enterococcus (all
species))
Vancomycin Resistant Enterococcus
(Enterococcus, vancomycin resistant
(VRE))
Enterovirus (Enterovirus)
Epstein-barr Virus (Epstein-Barr Virus)
Escherichia Coli (Escherichia (also E.
coli))
Pseudomonas Oryzihabitans
(Flavimonas oryzihabitans)
Flavobacterium (Flavobacterium)
Fusarium (Fusarium species)
Fusobacterium (Fusobacterium)
Giardia (Giardia)
Haemophilus (Haemophilus (all species,
including influenzae))
Helicobacter Pylori (Helicobacter pylori)
Hepatitis A Virus (Hepatitis A Virus)
Hepatitis B Virus (Hepatitis B Virus)
Hepatitis C Virus (Hepatitis C Virus)
Herpes Simplex Virus (Herpes Simplex
Virus)
Herpes Zoster (Herpes Zoster)
Histoplasmosis (Histoplasmosis)
Human Herpesvirus 6 (Human
Herpesvirus 6)
Human Immunodeficiency Virus 1
(Human Immunodeficiency Virus 1)
Human Papillomavirus (Human
Papillomavirus)
Influenza A Virus (Influenza A Virus)
Influenza B Virus (Influenza B Virus)
Other Influenza (Influenza, NOS)
Klebsiella (Klebsiella)
Lactobacillus (Lactobacillus (bulgaricus,
acidophilus, other species))
Legionella (Legionella)
Leptospira (Leptospira)
C76356 (Leptotrichia buccalis)
Leuconostoc (Leuconostoc (all species))
Listeria (Listeria)
Measles Virus (Measles Virus)
Methylobacterium (Methylobacterium)
Micrococcus Not Otherwise Specified
(Micrococcus, NOS)
Zygomycosis (Mucormycosis)
Multiple Bacteria (Multiple bacteria at a
single site)
Mumps Virus (Mumps Virus)
Mycobacterium Avium Complex
(Mycobacterium avium - intracellulare
(MAC, MAI))
Mycobacterium Species (Mycobacterium
species (cheloneae, fortuitum,
haemophilum, kansasii, mucogenicum))
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Mycobacterium Tuberculosis
(Mycobacterium tuberculosis
(tuberculosis, Koch bacillus))
Mycobacterium Not Otherwise Specified
(Mycobacterium, NOS)
Mycoplasma (Mycoplasma)
Neisseria (Neisseria (gonorrhoeae,
meningitidis, other species))
Not Identified Organism (No organism
identified)
Nocardia (Nocardia)
Other Aspergillus (Other Aspergillus)
Other Bacteria (Other bacteria)
Other Candida (Other Candida)
Other Chlamydia (Other chlamydia)
Other Fungi (Other fungus)
Other Mycobacterium (Other
mycobacterium)
Other Parasite (Other parasite)
Other Virus (Other Virus)
Parainfluenza Virus (Parainfluenza Virus)
Pasteurella Multocida (Pasteurella
multocida)
Pneumocystis Pneumonia
(Pneumocystis (PCP / PJP))
Polyomavirus (Polyomavirus)
Progressive Multifocal
Leukoencephalopathy (Progressive
Multifocal Leukoencephalopathy)
Propionibacterium Acnes
(Propionibacterium (acnes, avidum,
granulosum, other species))
Proteus (Proteus)
Pseudomonas (Pseudomonas (all
species except cepacia & maltophilia))
Burkholderia Cepacia (Pseudomonas or
Burkholder cepacia)
Stenotrophomonas Maltophilia
(Pseudomonas or Stenotrophomonas or
Xanthomonas maltophilia)
Respiratory Syncytial Virus (Respiratory
Syncytial Virus (RSV))
Rhinovirus (Rhinovirus)
Rhizopus (Rhizopus)
Rhodococcus (Rhodococcus)
Rickettsia (Rickettsia)
Rotavirus (Rotavirus)
Rubella Virus (Rubella Virus)
Salmonella (Salmonella (all species))
Serratia Marcescens (Serratia
marcescens)
Shigella (Shigella)
Staphylococcus Aureus (Staphylococcus
aureus)
Staphylococcus Coag Negative
(Staphylococcus, coagulase negative)
Streptococcus Not Otherwise Specified
(Staphylococcus, NOS)
Rothia Mucilaginosa (Stomatococcus
mucilaginosis)
24 / 52
Follow-Up - 2200 Revision 2 - Six Months to Two Years Post-HSCT Data
- 3065877v1.0
Streptococcus (Streptococcus (all
species except Enterococcus))
Streptococcus Pneumoniae
(Streptococcus pneumoniae)
Suspected Atypical Bacteria Infection
(Suspected atypical bacterial infection)
Suspected Bacteria Infection (Suspected
bacterial infection)
Suspected Fungal Infection (Suspected
fungal infection)
Suspected Parasitic Infection (Suspected
parasite infection)
Suspected Viral Infection (Suspected
viral infection)
Toxoplasma (Toxoplasma)
Treponema (Treponema (syphilis))
Vibrio (Vibrio (all species))
Yeast Not Otherwise Specified (Yeast,
NOS)
Zygomycota Not Otherwise Specified
(Zygomycetes, NOS)
Specify the infection organism: (Answer only if
the response to CDE 2934613 is "Other
chlamydia," "Other mycobacterium," "Multiple
bacteria at a single site," "Other bacteria," "Other
Candida," "Other Aspergillus," "Other fungus,"
Other virus," or "Other parasite.")
Date of diagnosis: (Of acute GVHD)
Select the infection organism site: (Do not report
fever in the absence of infection. Report the most
specific site of infection.)
Blood And/or Buffy Coat (Blood / buffy
coat)
Osteomyelitis (Bone cortex)
Bone Marrow (Bone marrow)
Brain (Brain)
Endocardium Myocardium Pericardium
(Cardiac)
Application Site Catheter (Catheter
insertion or exit site)
Catheter Tip Device Component
(Catheter tip)
Cellulitis (Cellulitis)
Not Otherwise Specified Central Nervous
System (Central nervous system, not
specified)
Not Otherwise Specified Central Venous
Access Catheter (Central venous
catheter, NOS)
Isolation Greater Than Or Equal To
Integer::3 Anatomic Site (Disseminated -
generalized, isolated at 3 or more distinct
sites)
Ear (Ears)
Esophagus (Esophagus)
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Eye (Eyes)
Fallopian Tube Uterus Cervix Uteri
(Fallopian tubes, uterus, cervix)
Feces (Feces / stool)
Gallbladder Biliary Tract Pancreas
(Gallbladder and biliary tree, pancreas)
Gastrointestinal Tract Not Otherwise
Specified (Gastrointestinal tract, NOS)
Genital (Genital area)
Genitourinary System Not Otherwise
Specified (Genito-urinary tract, NOS)
Herpes Zoster (Herpes zoster)
Joint (Joints)
Large Intestine (Large intestine)
Laryngitis And/or Larynx (Laryngitis /
larynx)
Lip (Lips)
Liver (Liver)
Trachea Bronchus And/or Lung (Lower
respiratory tract)
Lymph Node (Lymph nodes)
Meninges And Cerebrospinal Fluid
(Meninges and CSF)
Muscle (Muscle)
Peritoneum (Peritoneum)
Pleural Fluid Pleural Cavity (Pleural
cavity, pleural fluid)
Prostate Gland (Prostate)
Pustular Lesion Or Abscess Skin Rash
(Rash, pustules or abscesses)
Not Otherwise Specified Respiratory
System (Respiratory tract, NOS)
Paranasal Sinus (Sinuses)
Not Otherwise Specified Skin (Skin,
NOS)
Small Bowel (Small intestine)
Spinal Cord (Spinal cord)
Spleen (Spleen)
Stomach (Stomach)
Testis (Testes)
Tongue Oral Cavity And Oropharynx
(Tongue, oral cavity and oropharynx)
Nasopharynx (Upper airway and
nasopharynx)
Urine Kidney Renal Pelvis Ureter And
Bladder (Urine, kidneys, renal pelvis,
ureters and bladder)
Vagina (Vagina)
Infection Part 5 Of 5
Did the recipient develop more than 7 infections?
(Post-HSCT)
No (No)
Yes (Yes)
Are extra pages attached?
No (No)
Yes (Yes)
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Organ Function - Pulmonary Function Part
1 Of 10
Did the recipient develop interstitial pneumonitis /
idiopathic pneumonia syndrome? (IPn or ARDS /
IPS. Since the date of the last report. Interstitial
pneumonitis / idiopathic pneumonia syndrome is
characterized on chest x-ray by hypoxia and
diffuse interstitial infiltrates not caused by fluid
overload. Report bacterial and fungal pneumonia
in Infection section questions 319-347 in module
"Infection Part 3 of 5," CDE 2795691, and module
"Infection Part 4 of 5.")
No (No)
Yes (Yes)
Organ Function - Pulmonary Function Part
2 Of
Date of diagnosis: (Of acute GVHD)
Were diagnostic tests done? (Other than
radiographic studies)
No (No)
Yes (Yes)
Bronchoalveolar lavage (BAL)
No (No)
Yes (Yes)
Transbronchial biopsy
No (No)
Yes (Yes)
Open / thorascopic lung biopsy (VATS)
No (No)
Yes (Yes)
Autopsy
No (No)
Yes (Yes)
Other
No (No)
Yes (Yes)
Specify other test
Was an organism isolated?
No (No)
Yes (Yes)
Adenovirus
No (No)
Yes (Yes)
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Cytomegalovirus (CMV)
No (No)
Yes (Yes)
Herpes simplex (HSV1, HSV2)
No (No)
Yes (Yes)
Human herpes virus type 6 (HHV6)
No (No)
Yes (Yes)
Parainfluenza
No (No)
Yes (Yes)
Respiratory syncytial virus (RSV)
No (No)
Yes (Yes)
Toxoplasma
No (No)
Yes (Yes)
Other virus
No (No)
Yes (Yes)
Specify other virus
Other organism
No (No)
Yes (Yes)
Specify organism
Did the recipient experience two or more
episodes of IPn / IPS? (Since the date of the last
report)
No (No)
Yes (Yes)
Are extra pages attached?
No (No)
Yes (Yes)
Organ Function - Pulmonary Function Part
5 Of 11
Did the recipient develop non-infectious
pulmonary abnormalities? (Other than IPn / IPS /
ARDS. Since the date of the last report.)
No (No)
Yes (Yes)
Organ Function - Pulmonary Function Part
4 Of
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Did the recipient develop bronchiolitis obliterans?
(Since the date of the last report)
No (No)
Yes (Yes)
Date of diagnosis: (Of acute GVHD)
Were diagnostic tests done?
No (No)
Yes (Yes)
Bronchoalveolar lavage (BAL)
No (No)
Yes (Yes)
Transbronchial biopsy
No (No)
Yes (Yes)
Open / thorascopic lung biopsy (VATS)
No (No)
Yes (Yes)
Autopsy
No (No)
Yes (Yes)
Other
No (No)
Yes (Yes)
Specify other test
Organ Function - Pulmonary Function Part
4 Of
Did the recipient develop pulmonary
hemorrhage?
No (No)
Yes (Yes)
Date of diagnosis: (Of acute GVHD)
Were diagnostic tests done?
No (No)
Yes (Yes)
Bronchoalveolar lavage (BAL)
No (No)
Yes (Yes)
Transbronchial biopsy
No (No)
Yes (Yes)
Open / thorascopic lung biopsy (VATS)
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No (No)
Yes (Yes)
Autopsy
No (No)
Yes (Yes)
Other
No (No)
Yes (Yes)
Specify other test
Organ Function - Pulmonary Function Part
4 Of
Did the recipient develop cryptogenic organizing
pneumonia? (COP)
No (No)
Yes (Yes)
Date of diagnosis: (Of acute GVHD)
Were diagnostic tests done?
No (No)
Yes (Yes)
Bronchoalveolar lavage (BAL)
No (No)
Yes (Yes)
Transbronchial biopsy
No (No)
Yes (Yes)
Open / thorascopic lung biopsy (VATS)
No (No)
Yes (Yes)
Autopsy
No (No)
Yes (Yes)
Other
No (No)
Yes (Yes)
Specify other test
Organ Function - Pulmonary Function Part
11 Of 11
Did the recipient develop any other non-infectious
pulmonary abnormalities?
No (No)
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Yes (Yes)
Specify other pulmonary abnormality
Did the recipient receive endotracheal intubation
or mechanical ventilation? (Since the date of the
last report)
No (No)
Yes (Yes)
Organ Function - Liver Function Part 1 Of
2
Did the recipient develop non-infectious liver
toxicity? (Excluding GVHD. Since the date of the
last report)
No (No)
Yes (Yes)
Date of diagnosis: (Of acute GVHD)
Cirrhosis
No (No)
Yes (Yes)
Veno-occlusive disease / sinusodial obstruction
syndrome (VOD / SOS)
No (No)
Yes (Yes)
Did the recipient receive treatment for VOD?
No (No)
Yes (Yes)
Specify:
Did VOD resolve?
No (No)
Yes (Yes)
Maximum bilirubin: (Since last report)
Other
No (No)
Yes (Yes)
Specify other etiology
Unknown
No (No)
Yes (Yes)
Organ Function - Liver Function Part 2 Of
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2Specify diagnosis of liver toxicity by clinical signs
and symptoms / evaluation:
Ascites (Ascites)
Autopsy (Autopsy)
Greater Than Integer::2.0 Milligram
Bilirubin (Bilirubin greater than 2.0 mg)
Biopsy (Biopsy)
Elevated Hepatic Venous Pressure
Gradient (Elevated hepatic venous
pressure gradient)
Elevated Liver Enzyme (Elevated liver
enzymes)
Hepatomegaly (Hepatomegaly)
Other (Other)
Right Upper Quadrant Pain Or
Tenderness (Right upper quadrant pain
or tenderness)
Doppler Echocardiography And/or
Ultrasound Imaging (Ultrasonography /
doppler)
Greater Than Integer::5 Percentage
Weight Gain (Weight gain greater than 5
percent)
Was the diagnosis of liver toxicity determined by
clinical signs and symptoms / evaluation:
No (No)
Yes (Yes)
Specify other evaluation (Answer only if the
response to CDE 2801066 is "Other")
Organ Function - Other Organ Impairment
/ Disorder Paer 1 Of 2
Has the recipient developed any other clinically
significant organ impairment or disorder? (Since
the date of the last report)
No (No)
Yes (Yes)
Organ Function - Other Organ Impairment
/ Disorder Part 2 Of 2
Specify impairment / disorder:
A Condition In Which The Poor Blood
Supply To An Area Of Bone Leads To
Bone Death. (Avascular necrosis)
Cataract (Cataracts)
Congestive Heart Failure (Congestive
heart failure)
Diabetes Mellitus And/or Hyperglycemia
(Diabetes/hyperglycemia)
Gonadal Disorder And/or Infertility
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Required Testosterone Or Estrogen
Replacement Therapy (Gonadal
dysfunction/infertility requiring hormone
replacement)
Growth Hormone Deficit And/or Growth
Disturbance (Growth hormone
deficiency/growth disturbance)
Hemorrhage Cystitis And/or Hematuria
(Hemorraghic cystitis/hematuria requiring
medical intervention)
Hypothyroidism (Hypothyroidism)
Myocardial Infarction (Myocardial
infarction)
Other (Other)
Pancreatitis (Pancreatitis)
Post Graft Thrombotic Microangiopathy
Hemolytic Uremic Syndrome Or
Similarity (Post-transplant
microangiopathy-thrombotic
thrombocytopenic purpura (TTP),
hemolytic uremic syndrome (HUS), or
similar syndrome)
Renal Failure Severe Need Dialysis
(Renal failure severe enough to warrant
dialysis)
Cerebrovascular Accident And/or
Seizure (Stroke/seizure)
Did a particular type of organ impairment /
disorder occur?
No (No)
Yes (Yes)
Date of diagnosis: (Of acute GVHD)
Did the recipient receive plasmapheresis?
(Answer only if the response to CDE 2797538 is
"Post-transplant microangiopathy-thrombotic
thrombocytopenic purpura TTP, hemolytic uremic
syndrome HUS, or similar syndrome")
No (No)
Yes (Yes)
Did the recipient receive dialysis? (Answer only if
the response to CDE 2797538 is "Renal failure
severe enough to warrant dialysis")
No (No)
Yes (Yes)
Specify other impairment or disorder (Answer
only if the response to CDE 2797538 is "Other
impairment or disorder")
Organ Function - New Malignancy
Did a new malignancy, lymphoproliferative or
myeloproliferative disorder appear that is different
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from the disease for which the HSCT was
performed? (Since the date of the last report)
No (No)
Yes (Yes)
For all new malignancies except for "other skin
malignancy (basal cell, squamous)," was testing
performed to determine the cell of origin?
No (No)
Other Skin Malignant Neoplasm (The
only new malignancy in this reporting
period was "other skin malignancy(basal
cell, squamous)")
Yes (Yes)
What type of  the cell origin of the new
malignancy is it?
Donor (Donor)
Origin Unknown (Origin unknown)
Hematopoietic Stem Cell Graft Recipient
(Recipient)
Are chimerism laboratory reports attached to this
form?
No (No)
Yes (Yes)
New Malignancy, Lymphoproliferative Or
Myeloproliferative Disorder
Specify which new disease(s) occurred:
Acute Myeloid Leukemia (Acute myeloid
leukemia (AML / ANLL))
Breast Carcinoma (Breast cancer)
Central Nervous System Neoplasm
(Central nervous system (CNS)
malignancy (glioblastoma, astrocytoma))
Malignant Gastrointestinal Neoplasm
(Gastrointestinal malignancy (colon,
rectum, stomach, pancreas, intestine))
Genitourinary System Malignant
Neoplasm (Genitourinary malignancy
(kidney, bladder, ovary, testicle, genitalia,
uterus, cervix))
Hodgkin's Lymphoma (Hodgkin disease)
Lung Carcinoma (Lung cancer)
Lymphoma Or Lymphoproliferative
Disorder (Lymphoma or
lymphoproliferative disease)
Melanoma (Melanoma)
Myelodysplastic/myeloproliferative
Disease (Myelodysplasia (MDS),
myeloproliferative (MPS) disorder)
Oropharyngeal Carcinoma
(Oropharyngeal cancer (tongue, buccal
mucosa))
Other Leukemia (Other leukemia
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including ALL)
Other Malignant Neoplasm (Other
malignancy)
Other Malignant Skin Neoplasm (Other
skin malignancy (basal cell, squamous))
Clonality Cytogenetic Abnormality
(Related by descent from clonal
cytogenetic abnormality without leukemia
or MDS)
Sarcoma (Sarcoma)
Thyroid Gland Carcinoma (Thyroid
cancer)
Did a new malignancy, lymphoproliferative or
myeloproliferative disorder appear that is different
from the disease for which the HSCT was
performed? (Since the date of the last report)
No (No)
Yes (Yes)
Date of diagnosis: (Of acute GVHD)
Is the tumor EBV positive? (Answer only if the
response to CDE 2677021 is "Lymphoma or
lymphoproliferative disease.")
No (No)
Yes (Yes)
Specify the new malignancy, lymphoproliferative
or myeloproliferative disorder: (Answer only if the
response to CDE 2677021 is "Other leukemia,
including ALL," "Other skin malignancy basal cell,
squamous," or "Other new malignancy.")
Organ Function - New Malignancy Part 3
Of 3
Is a pathology / autopsy report or other
documentation attached?
No (No)
Yes (Yes)
Functional Status
Which scale was used to measure/report the
functional status? (If the recipient is 16 years of
age or older, complete the Karnofsky Scale. If the
recipient is younger than 16 years of age,
complete the Lansky Scale. If the recipient has
died, continue with question 505 on the PDF
version of the form, CDE 2798174.)
Karnofsky Performance Status
(Karnofsky)
Lansky Play-performance Status
(Lansky)
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Karnofsky Performance Status Score (On the
date of last actual contact. If the recipient is 16
years of age or older, complete the Karnofsky
Scale.)
Moribund, Fatal Processes Progressing
Rapidly (10)
Normal, No Complaints, No Evidence Of
Disease (100)
Very Sick, Hospitalization Indicated.
Death Not Imminent (20)
Severely Disabled, Hospitalization
Indicated. Death Not Imminent (30)
Disabled, Requires Special Care And
Assistance (40)
Requires Considerable Assistance And
Frequent Medical Care (50)
Requires Occasional Assistance, But Is
Able To Care For Most Of His/her Needs
(60)
Cares For Self, Unable To Carry On
Normal Activity Or To Do Active Work
(70)
Normal Activity With Effort; Some Signs
Or Symptoms Of Disease (80)
Able To Carry On Normal Activity; Minor
Signs Or Symptoms Of Disease (90)
Lansky Performance Status Score (On the date
of last actual contact. If the recipient is younger
than 16 years of age, complete the Lansky
Scale.)
No Play; Does Not Get Out Of Bed. (10)
Fully Active, Normal (100)
Often Sleeping; Play Entirely Limited To
Very Passive Activities (20)
In Bed; Needs Assistance Even For
Quiet Play. (30)
Mostly In Bed; Participates In Quiet
Activities. (40)
Gets Dressed, But Lies Around Much Of
The Day; No Active Play, Able To
Participate In All Quiet Play And
Activities. (50)
Up And Around, But Minimal Active Play;
Keeps Busy With Quieter Activities. (60)
Both Greater Restriction Of And Less
Time Spent In Play Activity (70)
Active, But Tires More Quickly (80)
Minor Restrictions In Physically
Strenuous Activity (90)
Specify the category which best describes the
occupation of the recipient (Current occupation. If
the recipient is not currently employed, select
which best describes his/her last job:)
Clerk (Clerical or related occupation)
Equipment Operator (Equipment /
vehicle operator or related occupation)
Farmer (Farmer)
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Homemaker (Homemaker)
Laborer (Laborer)
Manager (Manager, administrator, or
proprietor)
Military Personnel (Member of the
military)
Negation Previous Employment (Not
previously employed)
Other (Other)
Professional Occupation (Professional,
technical, or related occupation)
Salesperson (Sales occupation)
Service Occupation (Service occupation)
Skilled Worker (Skilled craft or related
occupation)
Student (Student)
Less Than School Age Child (Under
school age)
Unknown (Unknown)
Specify other occupation:
What is the current or most recent work status?
(During this reporting period)
Full Time Employment (Full time)
Less Than Integer::16 Year Age (Less
than 16 years old)
Employment Disability (Medical
disability)
Part Time Employment (Part time)
Retirement (Retired)
Unemployment (Unemployed)
Employment Unknown (Unknown)
Specify retirement level:
With Source Income (With a source of
income)
Without Source Income (Without a
source of income)
Subsequent Hsct
Date of subsequent HSCT:
Was the subsequent HSCT performed at a
different institution?
No (No)
Yes (Yes)
Name: (Of the institution that performed the
subsequent HSCT)
City: (Of the institution that performed the
subsequent HSCT)
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State / Country: (Of the institution that performed
the subsequent HSCT)
What was the indication for the subsequent
HSCT? (Subsequent autologous HSCTs
performed for engraftment reasons "No
hematopoietic recovery," "Partial hematopoietic
recovery," and "Graft failure / rejection after
achieving initial hematopoietic recovery" do not
require separate report forms to be completed.
All other subsequent HSCTs will require a
separate follow-up report form completed for
each infusion.)
Loss Or Reduced Donor Chimerism
(Declining chimerism)
Graft Failure Post First Hematopoietic
Recovery (Graft failure / rejection after
achieving initial hematopoietic recovery)
New Malignant Neoplasm (New
malignancy)
Hematopoietic Stem Cell No Recovery
(No hematopoietic recovery)
Other (Other)
Hematopoietic Stem Cell Partial
Recovery (Partial hematopoietic
recovery)
Persistent Primary Disease Or Disorder
(Persistent primary disease)
Hematopoietic Stem Cell Second Plan
Transplantation (Planned second HSCT,
per protocol)
Recurrent Primary Disease Or Disorder
(Recurrent primary disease)
Mixed Stable Chimerism (Stable, mixed
chimerism)
Specify other indication
Subsequent Hsct
Source of HSCs:
Related Allogenic (Allogeneic, related)
Unrelated Allogenic (Allogeneic,
unrelated)
Autologous (Autologous)
Was the same donor used?
No (No)
Yes (Yes)
Specify:
Cryopreservation Original Donor Bone
Marrow (Cryopreserved original donor
bone marrow)
Cryopreservation Original Donor
Mobilized Peripheral Blood Stem Cell
(Cryopreserved original donor mobilized
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peripheral blood stem cells)
Tissue, Fresh Original Donor National
Marrow Donor Program Bone Marrow
(Fresh, original NMDP donor bone
marrow)
Tissue, Fresh Original Donor National
Marrow Donor Program Mobilized
Peripheral Blood Stem Cell (Fresh,
original NMDP donor mobilized
peripheral blood stem cells)
Tissue, Fresh Original Negation National
Marrow Donor Program Donor Bone
Marrow (Fresh, original non-NMDP
donor bone marrow)
Tissue, Fresh Original Negation National
Marrow Donor Program Donor Mobilized
Peripheral Blood Stem Cell (Fresh,
original non-NMDP donor mobilized
peripheral blood stem cells)
Tissue, Fresh Next National Marrow
Donor Program Donor Bone Marrow
(Fresh, subsequent NMDP donor bone
marrow)
Tissue, Fresh Next National Marrow
Donor Program Donor Mobilized
Peripheral Blood Stem Cell (Fresh,
subsequent NMDP donor mobilized
peripheral blood stem cells)
Tissue, Fresh Next Negation National
Marrow Donor Program Donor Bone
Marrow (Fresh, subsequent non-NMDP
donor bone marrow)
Tissue, Fresh Next Negation National
Marrow Donor Program Donor Mobilized
Peripheral Blood Stem Cell (Fresh,
subsequent non-NMDP donor mobilized
peripheral blood stem cells)
National Marrow Donor Program
Umbilical Cord Blood (NMDP cord blood)
Negation National Marrow Donor
Program Umbilical Cord Blood (Non-
NMDP cord blood)
Donor Cellular Infusion (dci) Information
Date of DCI:
Organism
Acinetobacter (Acinetobacter)
Actinomyces (Actinomyces)
Adenovirus (Adenovirus)
Aspergillus Flavus (Aspergillus flavus)
Aspergillus Fumigatus (Aspergillus
fumigatus)
Aspergillus Niger (Aspergillus niger)
Aspergillus Not Otherwise Specified
(Aspergillus, NOS)
Bacillus (Bacillus)
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Bacteroides (Bacteroides (gracillis,
uniformis, vulgaris, other species))
Bordetella Pertussis (Bordetella
pertussis (whooping cough))
Borrelia Burgdorferi (Borrelia (lyme
disease))
Moraxella Catarrhalis (Branhamella or
Moraxella catarrhalis (other species))
Campylobacter (Campylobacter (all
species))
Candida Glabrata (Candida (Torulopsis)
glabrata)
Candida Albicans (Candida albicans)
Pichia Guilliermondii (Candida
guillermondi)
Issatchenkia Orientalis (Candida krusei)
Clavispora Lusitaniae (Candida
lusitaniae)
Candida Parapsilosis (Candida
parapsilosis)
Candida Tropicalis (Candida tropicalis)
Candida Not Otherwise Specified
(Candida, NOS)
Capnocytophaga (Capnocytophaga)
Chlamydophila Pneumoniae (Chlamydia
(pneumoniae))
Chlamydia Not Otherwise Specified
(Chlamydia, NOS)
Citrobacter (Citrobacter (freundii, other
species))
Clostridium (Clostridium (all species
except difficile))
Clostridium Difficile (Clostridium difficile)
Corynebacterium (Corynebacterium (all
non-diptheria species))
Corynebacterium Jeikeium
(Corynebacterium (jeikeium))
Coxiella (Coxiella)
Cryptococcosis (Cryptococcosus
species)
Cryptosporidium (Cryptosporidium)
Cytomegalovirus (Cytomegalovirus)
Enterobacter (Enterobacter)
Enterococcus (Enterococcus (all
species))
Vancomycin Resistant Enterococcus
(Enterococcus, vancomycin resistant
(VRE))
Enterovirus (Enterovirus)
Epstein-barr Virus (Epstein-Barr Virus)
Escherichia Coli (Escherichia (also E.
coli))
Pseudomonas Oryzihabitans
(Flavimonas oryzihabitans)
Flavobacterium (Flavobacterium)
Fusarium (Fusarium species)
Fusobacterium (Fusobacterium)
Giardia (Giardia)
Haemophilus (Haemophilus (all species,
including influenzae))
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Helicobacter Pylori (Helicobacter pylori)
Hepatitis A Virus (Hepatitis A Virus)
Hepatitis B Virus (Hepatitis B Virus)
Hepatitis C Virus (Hepatitis C Virus)
Herpes Simplex Virus (Herpes Simplex
Virus)
Herpes Zoster (Herpes Zoster)
Histoplasmosis (Histoplasmosis)
Human Herpesvirus 6 (Human
Herpesvirus 6)
Human Immunodeficiency Virus 1
(Human Immunodeficiency Virus 1)
Human Papillomavirus (Human
Papillomavirus)
Influenza A Virus (Influenza A Virus)
Influenza B Virus (Influenza B Virus)
Other Influenza (Influenza, NOS)
Klebsiella (Klebsiella)
Lactobacillus (Lactobacillus (bulgaricus,
acidophilus, other species))
Legionella (Legionella)
Leptospira (Leptospira)
C76356 (Leptotrichia buccalis)
Leuconostoc (Leuconostoc (all species))
Listeria (Listeria)
Measles Virus (Measles Virus)
Methylobacterium (Methylobacterium)
Micrococcus Not Otherwise Specified
(Micrococcus, NOS)
Zygomycosis (Mucormycosis)
Multiple Bacteria (Multiple bacteria at a
single site)
Mumps Virus (Mumps Virus)
Mycobacterium Avium Complex
(Mycobacterium avium - intracellulare
(MAC, MAI))
Mycobacterium Species (Mycobacterium
species (cheloneae, fortuitum,
haemophilum, kansasii, mucogenicum))
Mycobacterium Tuberculosis
(Mycobacterium tuberculosis
(tuberculosis, Koch bacillus))
Mycobacterium Not Otherwise Specified
(Mycobacterium, NOS)
Mycoplasma (Mycoplasma)
Neisseria (Neisseria (gonorrhoeae,
meningitidis, other species))
Not Identified Organism (No organism
identified)
Nocardia (Nocardia)
Other Aspergillus (Other Aspergillus)
Other Bacteria (Other bacteria)
Other Candida (Other Candida)
Other Chlamydia (Other chlamydia)
Other Fungi (Other fungus)
Other Mycobacterium (Other
mycobacterium)
Other Parasite (Other parasite)
Other Virus (Other Virus)
Parainfluenza Virus (Parainfluenza Virus)
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Pasteurella Multocida (Pasteurella
multocida)
Pneumocystis Pneumonia
(Pneumocystis (PCP / PJP))
Polyomavirus (Polyomavirus)
Progressive Multifocal
Leukoencephalopathy (Progressive
Multifocal Leukoencephalopathy)
Propionibacterium Acnes
(Propionibacterium (acnes, avidum,
granulosum, other species))
Proteus (Proteus)
Pseudomonas (Pseudomonas (all
species except cepacia & maltophilia))
Burkholderia Cepacia (Pseudomonas or
Burkholder cepacia)
Stenotrophomonas Maltophilia
(Pseudomonas or Stenotrophomonas or
Xanthomonas maltophilia)
Respiratory Syncytial Virus (Respiratory
Syncytial Virus (RSV))
Rhinovirus (Rhinovirus)
Rhizopus (Rhizopus)
Rhodococcus (Rhodococcus)
Rickettsia (Rickettsia)
Rotavirus (Rotavirus)
Rubella Virus (Rubella Virus)
Salmonella (Salmonella (all species))
Serratia Marcescens (Serratia
marcescens)
Shigella (Shigella)
Staphylococcus Aureus (Staphylococcus
aureus)
Staphylococcus Coag Negative
(Staphylococcus, coagulase negative)
Streptococcus Not Otherwise Specified
(Staphylococcus, NOS)
Rothia Mucilaginosa (Stomatococcus
mucilaginosis)
Streptococcus (Streptococcus (all
species except Enterococcus))
Streptococcus Pneumoniae
(Streptococcus pneumoniae)
Suspected Atypical Bacteria Infection
(Suspected atypical bacterial infection)
Suspected Bacteria Infection (Suspected
bacterial infection)
Suspected Fungal Infection (Suspected
fungal infection)
Suspected Parasitic Infection (Suspected
parasite infection)
Suspected Viral Infection (Suspected
viral infection)
Toxoplasma (Toxoplasma)
Treponema (Treponema (syphilis))
Vibrio (Vibrio (all species))
Yeast Not Otherwise Specified (Yeast,
NOS)
Zygomycota Not Otherwise Specified
(Zygomycetes, NOS)
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Specify the total number of cell infusions given
within 10 weeks of the DCI
Was the DCI infusion performed at a different
institution?
No (No)
Yes (Yes)
Name: (Of the institution that performed the DCI)
City: (Of the institution that performed the DCI)
Karnofsky / Lansky score (At diagnosis of chronic
GVHD. If the recipient is 16 years of age or older,
complete the Karnofsky Scale. If the recipient is
younger than 16 years of age, complete the
Lansky Scale.)
Karnofsky Scale - Moribund, Fatal
Process Progressing Rapidly; Lansky
Scale - Completely Disabled, Not Even
Passive Play. (10)
Karnofsky Scale - Normal, No
Complaints, No Evidence Of Disease;
Lansky Scale - Fully Active. (100)
Karnofsky Scale - Very Sick,
Hospitalization Necessary; Lansky Scale
- Limited To Very Passive Activity
Initiated By Others (e.g., Tv) (20)
Karnofsky Scale - Severely Disabled,
Hospitalization Indicated, Although
Death Not Imminent. Lansky Scale -
Needs Considerable Assistance For
Quiet Activity. (30)
Karnofsky Scale - Disabled, Requires
Special Care And Assistance. Lansky
Scale - Able To Initiate Quiet Activities.
(40)
Karnofsky Scale - Requires
Considerable Assistance And Frequent
Medical Care; Lansky Scale -
Considerable Assistance Required For
Any Active Play; Fully Able To Engage In
Quiet Play. (50)
Karnofsky Scale - Requires Occasional
Assistance, But Is Able To Care For Most
Needs; Lansky Scale - Ambulatory Up To
50r Of Time, Limited Active Play With
Assistance / Supervision. (60)
Karnofsky Scale - Cares For Self, Unable
To Carry On Normal Activity Or To Do
Active Work.; Lansky Score - Both
Greater Restrictions Of, And Less Time
Spent In, Active Play. (70)
Karnofsky Scale - Normal Activity With
Effort; Lansky Scale - Restricted In
Strenuous Play, Tires More Easily,
Otherwise Active. (80)
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Karnofsky Scale - Able To Carry On
Normal Activity; Lansky Scale - Minor
Restriction In Physically Strenuous Play.
(90)
State / Country: (Of the institution that performed
the DCI)
Indication for DCI
Loss Reduced Donor T-lymphocyte
Chimerism (Loss of / decreased donor T-
cell chimerism)
Other (Other)
Part First Hematopoietic Stem Cell
Transplantation Protocol Plan (Planned
as part of initial HSCT protocol)
Mixed Stable Chimerism (Stable, mixed
chimerism)
Therapeutic Procedure Graft Versus
Host Disease (Treatment for GVHD)
Post-transplant Lymphoproliferative
Disorder Epstein-barr Virus Therapeutic
Procedure (Treatment for PTLD, EBV
lymphoma)
Therapeutic Procedure Recurrent
Disease Persistent Pd Disease Or
Disorder (Treatment for relapsed,
persistent or progressive disease)
Therapeutic Procedure Viral Infection
(Viral infection)
Molecular (Method of disease detection)
Negative Finding (Negative)
Not Done Unknown (Not done /
Unknown)
Positive Finding (Positive)
Date: (If the result was positive report the first
date the disease was detected; if the result was
negative report the last date the method was
used prior to DCI.)
Cytogenetic (Method of disease detection)
Negative Finding (Negative)
Not Done Unknown (Not done /
Unknown)
Positive Finding (Positive)
Date: (If the result was positive report the first
date the disease was detected; if the result was
negative report the last date the method was
used prior to DCI.)
Clinical evidence / hematologic (Method of
disease detection)
Negative Finding (Negative)
Not Done Unknown (Not done /
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Unknown)
Positive Finding (Positive)
Date: (If the result was positive report the first
date the disease was detected; if the result was
negative report the last date the method was
used prior to DCI.)
Was chemotherapy used to attempt to induce
disease response? (Prior to the DCI)
No (No)
Yes (Yes)
Date of administration of final chemotherapy dose
Date documented:
Specify other indication
What was the recipient's disease status?
(Immediately prior to the DCI)
First Complete Remission (First
complete remission)
Negation Evaluation (Not evaluated post-
HSCT)
Persistent Disease Or Disorder
(Persistent disease)
Recurrent Disease Or Disease
Progression (Relapse or progression)
Therapeutic Procedure Induction
Complete Remission (Therapy-induced
complete remission after persistent
disease or relapse post-HSCT)
Date the disease status was established: (Prior to
the DCI)
Collected at the time of PBSC mobilization and
collection (DCI source)
No (No)
Yes (Yes)
Negative fraction of CD34 selected PBSC (DCI
source)
No (No)
Yes (Yes)
Negative fraction of CD34 selected bone marrow
(DCI source)
No (No)
Yes (Yes)
Apheresis at a different time than collection of
PBSC used for allogeneic HSCT (DCI source)
No (No)
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Yes (Yes)
Date of apheresis:
Isolated from a unit(s) of whole blood (DCI
source)
No (No)
Yes (Yes)
Specify number of units:
Were the donor cells collected by leukapheresis?
No (No)
Yes (Yes)
Date of first leukapheresis:
Date of last leukapheresis:
Number of leukaphereses:
Did the donor receive treatment to enhance cell
collection prior to donation?
No (No)
Yes (Yes)
Growth factor(s)
No (No)
Yes (Yes)
G-CSF
No (No)
Yes (Yes)
GM-CSF
No (No)
Yes (Yes)
Other agent
No (No)
Yes (Yes)
Specify other agent
Other treatment
No (No)
Yes (Yes)
Specify other treatment
CD3+ cells: (For each DCI given, report the total
number of cells infused. If the cells were
cryopreserved, report the totals after processing,
but before cryopreservation.)
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CD3+ cells exponent value:
What is the reason for the CD3+ cells missing
value?
Negation Test (Not tested)
CD4+ cells: (For each DCI given, report the total
number of cells infused. If the cells were
cryopreserved, report the totals after processing,
but before cryopreservation.)
CD4+ cells exponent value:
What is the reason for the CD4+ cells missing
value?
Negation Test (Not tested)
CD8+ cells: (For each DCI given, report the total
number of cells infused. If the cells were
cryopreserved, report the totals after processing,
but before cryopreservation.)
CD8+ cells exponent value:
What is the reason for the CD8+ cells missing
value?
Negation Test (Not tested)
CD34+ cells: (For each DCI given, report the total
number of cells infused. If the cells were
cryopreserved, report the totals after processing,
but before cryopreservation.)
CD34+ cells exponent value:
What is the reason for the CD34+ cells missing
value?
Negation Test (Not tested)
NK cells: (For each DCI given, report the total
number of cells infused. If the cells were
cryopreserved, report the totals after processing,
but before cryopreservation.)
NK cells exponent value:
What is the reason for the NK cells missing
value?
Negation Test (Not tested)
Nucleated cells: (For each DCI given, report the
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total number of cells infused. If the cells were
cryopreserved, report the totals after processing,
but before cryopreservation.)
Nucleated cells exponent value:
What is the reason for the nucleated cells missing
value?
Negation Test (Not tested)
Mesenchymal cells: (For each DCI given, report
the total number of cells infused. If the cells were
cryopreserved, report the totals after processing,
but before cryopreservation.)
Mesenchymal cells exponent value:
What is the reason for the mesenchymal cells
missing value?
Negation Test (Not tested)
Were dendritic cells infused?
No (No)
Yes (Yes)
Were fibroblasts infused?
No (No)
Yes (Yes)
Were any other cell types infused? (Not including
cell types reported in questions 553-559 CDEs
2760303, 2760372, 2772153, 2760286, 2771962,
2760234, and 2771985.)
No (No)
Yes (Yes)
Specify other cell type(s)
Were the cells cryopreserved prior to infusion?
No (No)
Yes (Yes)
Specify portion of cells cryopreserved prior to
infusion
Entire Hematopoietic Stem Cell
Collection (Entire product)
Part Hematopoietic Stem Cell Collection
(Portion of product)
Was the product manipulated prior to infusion?
No (No)
Yes (Yes)
Specify portion manipulated:
Entire Hematopoietic Stem Cell
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Collection (Entire product)
Part Hematopoietic Stem Cell Collection
(Portion of product)
ABO incompatibility
No (No)
Yes (Yes)
Buffy coat preparation
No (No)
Yes (Yes)
Cell separator (i.e., COBE Spectra)
No (No)
Yes (Yes)
Density gradient separation (i.e., Ficoll)
No (No)
Yes (Yes)
Plasma removal
No (No)
Yes (Yes)
Sedimentation (i.e., Hetastarch)
No (No)
Yes (Yes)
Other
No (No)
Yes (Yes)
Specify other method:
Dextran-albumin wash
No (No)
Yes (Yes)
Ex-vivo expansion
No (No)
Yes (Yes)
Genetic manipulation (Gene transfer /
transduction)
No (No)
Yes (Yes)
Volume reduction
No (No)
Yes (Yes)
CD34+ selection
No (No)
Yes (Yes)
Specify manufacturer:
Clinimax Cell Selection System
(CliniMACS / CliniMax)
Isolex Cell Selection System (Isolex)
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Other (Other)
Specify other manufacturer:
T-cell depletion
No (No)
Yes (Yes)
Antibody affinity column
No (No)
Yes (Yes)
Antibody coated plates
No (No)
Yes (Yes)
Antibody coated plates and soybean lectin
No (No)
Yes (Yes)
Antibody and complement
No (No)
Yes (Yes)
Antibody and toxin
No (No)
Yes (Yes)
Immunomagnetic beads
No (No)
Yes (Yes)
Elutriation
No (No)
Yes (Yes)
CD34 affinity column plus sheep red blood cell
rosetting
No (No)
Yes (Yes)
Other
No (No)
Yes (Yes)
Specify other method
Other manipulation
No (No)
Yes (Yes)
Specify other cell manipulation:
Were antibodies used during graft manipulation?
No (No)
Yes (Yes)
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Anti CD2
No (No)
Yes (Yes)
Anti CD4
No (No)
Yes (Yes)
Anti CD5
No (No)
Yes (Yes)
Anti CD6
No (No)
Yes (Yes)
Anti CD7
No (No)
Yes (Yes)
Anti CD8
No (No)
Yes (Yes)
Anti CD34
No (No)
Yes (Yes)
Anti TCR alpha / beta (T10-B9)
No (No)
Yes (Yes)
OKT-3
No (No)
Yes (Yes)
Other CD3
No (No)
Yes (Yes)
Specify other CD3:
Anti CD52
No (No)
Yes (Yes)
Campath-NOS
No (No)
Yes (Yes)
Campath-1G
No (No)
Yes (Yes)
Campath-1H
No (No)
Yes (Yes)
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Other antibody
No (No)
Yes (Yes)
Specify other antibody:
Donor Cellular Infusion (dci) Information
Part 2 Of 2
First Name
Last Name:
Telephone number:
Fax number:
E-mail address:
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Follow-Up - 2005 - Confirmation of HLA
typing - 2626421v4.0
Follow-Up - 2005 - Confirmation of HLA typing -
2626421v4.0
All rights reserved. Please visit https://medical-data-
models.org/forms/1731
2005 - Confirmation of HLA typing
Registry Use Only
Sequence number:
Date received:
Identification Data
CIBMTR Center Number:
CIBMTR Recipient ID:
Identification Data
Non-NMDP donor ID:
Donor Gender
Female (female)
Male (male)
Donor date of birth:
Identification Data
Non-NMDP Cord Blood Unit (CBU) ID:
Identification Data
Today's date:
Date of Hematopoietic Stem Cell Transplantation
(HSCT) for which this form is being completed:
Hsct Type
What source was used for the hematopoietic
stem cell transplantation?
Related Allogenic (Allogeneic, related)
Unrelated Allogenic (Allogeneic,
unrelated)
Syngeneic (Syngeneic (identical twin))
Was a particular hematopoietic stem cell source
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used?
No (No)
Yes (Yes)
Product Type
What type of hematopoietic stem cell transplant
was used?
Umbilical Cord Blood (Cord blood)
Bone Marrow (Marrow)
Other (Other)
Peripheral Blood Stem Cell (PBSC)
Was a particular hematopoietic stem cell
transplant type used?
No (No)
Yes (Yes)
Specify the other hematopoietic stem cell
transplant type: (Answer only if the value for
2730912 is "Other". )
Hla Typing Source
Please specify the person for whom this typing is
being done:
Umbilical Cord Blood Confirmed Hla
Typing (Cord blood unit--confirmatory
typing)
Donor Confirmed Hla Typing (Donor--
confirmatory typing)
Umbilical Cord Blood Mother Hla Typing
(Maternal HLA typing)
Other (Other)
Recipient Final Hla Typing (Recipient--
final typing)
Recipient Father Confirmed Hla Typing
(Recipient's father--confirmatory typing)
Recipient Mother Confirmed Hla Typing
(Recipient's mother--confirmatory typing)
Was the recipient's mother used as the donor?
No (No)
Yes (Yes)
Was the recipient's father used as the donor?
No (No)
Yes (Yes)
Specify person and typing:
Hlatyping By Dna Technology
Is a copy of the lab report attached?
No (No)
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Yes (Yes)
Hla Typing By Dna Technology: Class I
Number of A alleles provided:
Without Analysis (Not tested)
Integer::1 (One)
Integer::2 (Two)
First A* allele designations:
Second A* allele designations:
Number of B alleles provided:
Without Analysis (Not tested)
Integer::1 (One)
Integer::2 (Two)
First B* allele designations:
Second B* allele designations:
Number of C alleles provided:
Without Analysis (Not tested)
Integer::1 (One)
Integer::2 (Two)
First C* allele designations:
Second C* allele designations:
Hla Typing By Dna Technology: Class I
Number of  DRB1 alleles provided:
Without Analysis (Not tested)
Integer::1 (One)
Integer::2 (Two)
First DRB1* allele designations:
Second DRB1* allele designations:
Hla Typing By Dna Technology: Class Ii
(optional)
Number of DRB3 alleles provided:
None (None)
Without Analysis (Not tested)
Integer::1 (One)
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Integer::2 (Two)
First DRB3* allele designations:
Second DRB3* allele designations:
Number of DRB4 alleles provided:
None (None)
Without Analysis (Not tested)
Integer::1 (One)
Integer::2 (Two)
First DRB4* allele designations:
Second DRB4* allele designations:
Number of DRB5 alleles provided:
None (None)
Without Analysis (Not tested)
Integer::1 (One)
Integer::2 (Two)
First DRB5 * allele designations:
Second DRB5 * allele designations:
Number of  DQB1 alleles provided:
Integer::1 (One)
Integer::2 (Two)
First DQB1* allele designations:
Second DQB1* allele designations:
Number of DPB1 alleles provided:
Integer::1 (One)
Integer::2 (Two)
First DPB1* allele designations:
Second DPB1* allele designations:
Number of DQA1 alleles provided?
Integer::1 (One)
Integer::2 (Two)
First DQA1* allele designations:
Second DQA1* allele designations:
Number of DPA1 alleles provided:
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Integer::1 (One)
Integer::2 (Two)
First DPA1* allele designations:
Second DPA1* allele designations:
Antigens Defined By Serologic Typing
Number of A antigens provided:
Integer::1 (One)
Integer::2 (Two)
1st A antigen specificity:
A1 Antigen (A1)
A10 Antigen (A10)
A11 Antigen (A11)
A19 Antigen (A19)
A2 Antigen 1st A2 Antigen (A2)
A203 Antigen (A203)
A210 Antigen (A210)
A23(9) Antigen (A23(9))
A24(9) Antigen (A24(9))
A2403 Antigen (A2403)
A25(10) Antigen (A25(10))
A26(10) Antigen (A26(10))
A28 Antigen (A28)
A29(19) Antigen (A29(19))
A3 Antigen (A3)
A30(19) Antigen (A30(19))
A31(19) Antigen (A31(19))
A32(19) Antigen (A32(19))
A33(19) Antigen (A33(19))
A34(10) Antigen (A34(10))
A36 Antigen (A36)
A43 Antigen (A43)
A66(10) Antigen (A66(10))
A68(28) Antigen (A68(28))
A69(28) Antigen (A69(28))
A74(19) Antigen (A74(19))
A80 Antigen (A80)
A9 Antigen (A9)
Ax Antigen (AX)
2nd A antigen specificity
A1 Antigen (A1)
A10 Antigen (A10)
A11 Antigen (A11)
A19 Antigen (A19)
A2 Antigen 1st A2 Antigen (A2)
A203 Antigen (A203)
A210 Antigen (A210)
A23(9) Antigen (A23(9))
A24(9) Antigen (A24(9))
A2403 Antigen (A2403)
A25(10) Antigen (A25(10))
A26(10) Antigen (A26(10))
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A28 Antigen (A28)
A29(19) Antigen (A29(19))
A3 Antigen (A3)
A30(19) Antigen (A30(19))
A31(19) Antigen (A31(19))
A32(19) Antigen (A32(19))
A33(19) Antigen (A33(19))
A34(10) Antigen (A34(10))
A36 Antigen (A36)
A43 Antigen (A43)
A66(10) Antigen (A66(10))
A68(28) Antigen (A68(28))
A69(28) Antigen (A69(28))
A74(19) Antigen (A74(19))
A80 Antigen (A80)
A9 Antigen (A9)
Ax Antigen (AX)
Number of B antigens provided:
Integer::1 (One)
Integer::2 (Two)
First B antigen specificity:
B12 Antigen Specificity (B12)
B13 Antigen (B13)
B14 Antigen (B14)
B15 Antigen (B15)
B16 Antigen (B16)
B17 Antigen (B17)
B18 Antigen (B18)
B21 Antigen (B21)
B22 Antigen (B22)
B27 Antigen (B27)
B2708 Antigen (B2708)
B35 Antigen (B35)
B37 Antigen (B37)
B38(16) Antigen (B38(16))
B39(16) Antigen (B39(16))
B3901 Antigen (B3901)
B3902 Antigen (B3902)
B40 Antigen (B40)
B4005 Antigen (B4005)
B41 Antigen (B41)
B42 Antigen (B42)
B44(12) Antigen (B44(12))
B45(12) Antigen (B45(12))
B46 Antigen (B46)
B47 Antigen (B47)
B48 Antigen (B48)
B49(21) Antigen (B49(21))
B5 Antigen (B5)
B50(21) Antigen (B50(21))
B51(5) Antigen (B51(5))
B5102 Antigen (B5102)
B5103 Antigen (B5103)
B52(5) Antigen (B52(5))
B53 Antigen (B53)
B54(22) Antigen (B54(22))
B55(22) Antigen (B55(22))
B56(22) Antigen (B56(22))
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B57(17) Antigen (B57(17))
B58(17) Antigen (B58(17))
B59 Antigen (B59)
B60(40) Antigen (B60(40))
B61(40) Antigen (B61(40))
B62(15) Antigen (B62(15))
B63(15) Antigen (B63(15))
B64(14) Antigen (B64(14))
B65(14) Antigen (B65(14))
B67 Antigen (B67)
B7 Antigen (B7)
B70 Antigen (B70)
B703 Antigen (B703)
B71(70) Antigen (B71(70))
B72(70) Antigen (B72(70))
B73 Antigen (B73)
B75(15) Antigen (B75(15))
B76(15) Antigen (B76(15))
B77(15) Antigen (B77(15))
B78 Antigen (B78)
B8 Antigen (B8)
B81 Antigen (B81)
B82 Antigen (B82)
Bx Antigen (BX)
Second B antigen specificity:
B12 Antigen Specificity (B12)
B13 Antigen (B13)
B14 Antigen (B14)
B15 Antigen (B15)
B16 Antigen (B16)
B17 Antigen (B17)
B18 Antigen (B18)
B21 Antigen (B21)
B22 Antigen (B22)
B27 Antigen (B27)
B2708 Antigen (B2708)
B35 Antigen (B35)
B37 Antigen (B37)
B38(16) Antigen (B38(16))
B39(16) Antigen (B39(16))
B3901 Antigen (B3901)
B3902 Antigen (B3902)
B40 Antigen (B40)
B4005 Antigen (B4005)
B41 Antigen (B41)
B42 Antigen (B42)
B44(12) Antigen (B44(12))
B45(12) Antigen (B45(12))
B46 Antigen (B46)
B47 Antigen (B47)
B48 Antigen (B48)
B49(21) Antigen (B49(21))
B5 Antigen (B5)
B50(21) Antigen (B50(21))
B51(5) Antigen (B51(5))
B5102 Antigen (B5102)
B5103 Antigen (B5103)
B52(5) Antigen (B52(5))
B53 Antigen (B53)
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B54(22) Antigen (B54(22))
B55(22) Antigen (B55(22))
B56(22) Antigen (B56(22))
B57(17) Antigen (B57(17))
B58(17) Antigen (B58(17))
B59 Antigen (B59)
B60(40) Antigen (B60(40))
B61(40) Antigen (B61(40))
B62(15) Antigen (B62(15))
B63(15) Antigen (B63(15))
B64(14) Antigen (B64(14))
B65(14) Antigen (B65(14))
B67 Antigen (B67)
B7 Antigen (B7)
B70 Antigen (B70)
B703 Antigen (B703)
B71(70) Antigen (B71(70))
B72(70) Antigen (B72(70))
B73 Antigen (B73)
B75(15) Antigen (B75(15))
B76(15) Antigen (B76(15))
B77(15) Antigen (B77(15))
B78 Antigen (B78)
B8 Antigen (B8)
B81 Antigen (B81)
B82 Antigen (B82)
Bx Antigen (BX)
Optional Antigen Reporting: Antigens
Defined By Serologic Typing
Number of C antigens provided:
Integer::1 (One)
Integer::2 (Two)
First C antigen specificity
Cw1 Antigen (Cw1)
Cw10(w3) Antigen (Cw10(w3))
Cw2 Antigen (Cw2)
Cw3 Antigen (Cw3)
Cw4 Antigen (Cw4)
Cw5 Antigen (Cw5)
Cw6 Antigen (Cw6)
Cw7 Antigen (Cw7)
Cw8 Antigen (Cw8)
Cw9(w3) Antigen (Cw9(w3))
Cx Antigen (CX)
Second C antigen specificity:
Cw1 Antigen (Cw1)
Cw10(w3) Antigen (Cw10(w3))
Cw2 Antigen (Cw2)
Cw3 Antigen (Cw3)
Cw4 Antigen (Cw4)
Cw5 Antigen (Cw5)
Cw6 Antigen (Cw6)
Cw7 Antigen (Cw7)
Cw8 Antigen (Cw8)
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Cw9(w3) Antigen (Cw9(w3))
Cx Antigen (CX)
Bw4 specificity present?
No (No)
Yes (Yes)
Bw6 specificity present?
No (No)
Yes (Yes)
Number of DR antigens provided
Integer::1 (One)
Integer::2 (Two)
First DR  antigen specificity:
Dr1 Antigen (DR1)
Dr10 Antigen (DR10)
Dr103 Antigen (DR103)
Dr11(5) Antigen (DR11(5))
Dr12(5) Antigen (DR12(5))
Dr13(6) Antigen (DR13(6))
Dr14(6) Antigen (DR14(6))
Dr1403 Antigen (DR1403)
Dr1404 Antigen (DR1404)
Dr15(2) Antigen (DR15(2))
Dr16(2) Antigen (DR16(2))
Dr17(3) Antigen (DR17(3))
Dr18(3) Antigen (DR18(3))
Dr2 Antigen (DR2)
Dr3 Antigen (DR3)
Dr4 Antigen (DR4)
Dr5 Antigen (DR5)
Dr6 Antigen (DR6)
Dr7 Antigen (DR7)
Dr8 Antigen (DR8)
Dr9 Antigen (DR9)
Drx Antigen (DRX)
Second DR antigen specificity:
Dr1 Antigen (DR1)
Dr10 Antigen (DR10)
Dr103 Antigen (DR103)
Dr11(5) Antigen (DR11(5))
Dr12(5) Antigen (DR12(5))
Dr13(6) Antigen (DR13(6))
Dr14(6) Antigen (DR14(6))
Dr1403 Antigen (DR1403)
Dr1404 Antigen (DR1404)
Dr15(2) Antigen (DR15(2))
Dr16(2) Antigen (DR16(2))
Dr17(3) Antigen (DR17(3))
Dr18(3) Antigen (DR18(3))
Dr2 Antigen (DR2)
Dr3 Antigen (DR3)
Dr4 Antigen (DR4)
Dr5 Antigen (DR5)
Dr6 Antigen (DR6)
Dr7 Antigen (DR7)
Dr8 Antigen (DR8)
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Dr9 Antigen (DR9)
Drx Antigen (DRX)
DR51 specificity present?
No (No)
Yes (Yes)
DR52 specificity present?
No (No)
Yes (Yes)
DR53 specificity present?
No (No)
Yes (Yes)
Number of DQ antigens provided:
Integer::1 (One)
Integer::2 (Two)
First DQ antigen specificity:
Dq1 Antigen (DQ1)
Dq2 Antigen (DQ2)
Dq3 Antigen (DQ3)
Dq4 Antigen (DQ4)
Dq5(1) Antigen (DQ5(1))
Dq6(1) (DQ6(1))
Dq7(3) Antigen (DQ7(3))
Dq8(3) Antigen (DQ8(3))
Dq9(3) Antigen (DQ9(3))
Dqx Antigen (DQX)
Second DQ antigen specificity:
Dq1 Antigen (DQ1)
Dq2 Antigen (DQ2)
Dq3 Antigen (DQ3)
Dq4 Antigen (DQ4)
Dq5(1) Antigen (DQ5(1))
Dq6(1) (DQ6(1))
Dq7(3) Antigen (DQ7(3))
Dq8(3) Antigen (DQ8(3))
Dq9(3) Antigen (DQ9(3))
Dqx Antigen (DQX)
Number of DP antigens provided:
Integer::1 (One)
Integer::2 (Two)
First DP antigen specificity:
Dpw1 Antigen (DPw1)
Dpw2 Antigen (DPw2)
Dpw3 Antigen (DPw3)
Dpw4 Antigen (DPw4)
Dpw5 Antigen (DPw5)
Dpw6 Antigen (DPw6)
Dpx Antigen (DPX)
Second DP antigen specificity:
Dpw1 Antigen (DPw1)
Dpw2 Antigen (DPw2)
Dpw3 Antigen (DPw3)
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Dpw4 Antigen (DPw4)
Dpw5 Antigen (DPw5)
Dpw6 Antigen (DPw6)
Dpx Antigen (DPX)
Author Information
First Name
Last Name
Telephone number:
Fax number:
EMail Address
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Follow-Up - 2900 - RECIPIENT DEATH DATA ISO DATE
FORMAT VERSION 1 - 2892254v1.0
All rights reserved. Please visit https://medical-data-
models.org/forms/1743
2900 - RECIPIENT DEATH DATA
ISO DATE FORMAT VERSION 1
Registry Use Only
Sequence number:
Date received:
Identification Data
CIBMTR Center Number:
CIBMTR Recipient ID:
Today's date:
Date of hematopoietic stem cell transplantation
(HSCT) for which this form is being completed:
Hsct Type
What source was used for the hematopoietic
stem cell transplantation?
Related Allogenic (Allogeneic, related)
Unrelated Allogenic (Allogeneic,
unrelated)
Autologous (Autologous)
Syngeneic (Syngeneic (identical twin))
Was a particular hematopoietic stem cell source
used?
No (No)
Yes (Yes)
Product Type
What type of hematopoietic stem cell transplant
was used?
Umbilical Cord Blood (Cord blood)
Bone Marrow (Marrow)
Multiple Umbilical Cord Blood (Multiple
cord blood units infused)
Other (Other)
Peripheral Blood Stem Cell (PBSC)
Was a particular hematopoietic stem cell
transplant type used?
No (No)
1 / 5
Yes (Yes)
Specify the other hematopoietic stem cell
transplant type: (Answer only if the value for
2730912 is "Other".)
Death Date
Date of death:
Date of death is estimated:
Date Estimate (Date estimated)
Autopsy Report
Was cause of death confirmed by autopsy?
Autopsy Pending (Autopsy pending)
No (No)
Unknown (Unknown)
Yes (Yes)
Is an autopsy report attached?
No (No)
Yes (Yes)
Cause Of Death
Primary cause of death:
Accident Death (Accidental death)
Acute Graft Versus Host Disease (Acute
GVHD)
Adult Respiratory Distress Syndrome
(Adult Respiratory Distress Syndrome
(ARDS))
Bacterial Infection (Bacterial infection)
Heart Failure (Cardiac failure)
Central Nervous System Failure (Central
nervous system(CNS) failure)
Chronic Graft Versus Host Disease
(Chronic GVHD)
Dic (Disseminated intravascular
coagulation (DIC))
Fungal Infection (Fungal infection)
Gastrointestinal Failure (Gastrointestinal
(GI) failure (not liver))
Gastrointestinal Hemorrhage
(Gastrointestinal hemorrhage)
Graft Rejection (Graft rejection or failure)
Hemorrhage Not Otherwise Specified
(Hemorrhage, not otherwise specified)
Hemorrhage Cystitis (Hemorrhagic
cystitis)
Infection Organism Not Identified
(Infection, organism not identified)
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Intracranial Hemorrhage (Intracranial
hemorrhage)
Idiopathic Pneumonia Syndrome
Idiopathic (IPS, idiopathic)
Idiopathic Pneumonia Syndrome Viral
Cytomegalovirus (IPS, viral,
cytomegalovirus(CMV))
Idiopathic Pneumonia Syndrome Viral
Other (IPS, viral, other)
Liver Failure (Liver failure (not VOD))
Multiple Organ Failure (Multiple Organ
Failure)
Organ Failure Not Otherwise Specified
(Organ failure, not otherwise specified)
Other Reason (Other cause)
Other Hemorrhage (Other hemorrhage)
Other Infection (Other infection)
Other Idiopathic Pneumonia Syndrome
(Other IPS)
Other Organ Failure (Other organ failure)
Other Vascular (Other vascular)
Prior Malignant Neoplasm (Prior
malignancy)
Protozoal Infection (Protozoal infection)
Pulmonary Failure (Pulmonary failure)
Pulmonary Hemorrhage (Pulmonary
hemorrhage)
Recurrence Persistent Pd
(Recurrence/persistence/progression of
disease reported for first HSCT)
Renal Failure (Renal failure)
Secondary Malignant Neoplasm
(Secondary malignancy)
Suicide (Suicide)
Thromboembolism (Thromboembolic)
Thrombocytopenic Purpura (Thrombotic
thrombocytopenic purpura (HUS/TTP))
Vascular Not Otherwise Specified
(Vascular, not otherwise specified)
Hepatic Veno-occlusive Disease (Veno-
occlusive disease (VOD) / sinusodial
obstruction syndrome (SOS))
Viral Infection (Viral infection)
Specify primary cause of death:
Cause Of Death
Contributing cause of death:
Accident Death (Accidental death)
Acute Graft Versus Host Disease (Acute
GVHD)
Adult Respiratory Distress Syndrome
(Adult Respiratory Distress Syndrome
(ARDS))
Bacterial Infection (Bacterial infection)
Heart Failure (Cardiac failure)
Central Nervous System Failure (Central
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nervous system(CNS) failure)
Chronic Graft Versus Host Disease
(Chronic GVHD)
Dic (Disseminated intravascular
coagulation (DIC))
Fungal Infection (Fungal infection)
Gastrointestinal Failure (Gastrointestinal
(GI) failure (not liver))
Gastrointestinal Hemorrhage
(Gastrointestinal hemorrhage)
Graft Rejection (Graft rejection or failure)
Hemorrhage Not Otherwise Specified
(Hemorrhage, not otherwise specified)
Hemorrhage Cystitis (Hemorrhagic
cystitis)
Infection Organism Not Identified
(Infection, organism not identified)
Intracranial Hemorrhage (Intracranial
hemorrhage)
Idiopathic Pneumonia Syndrome
Idiopathic (IPS, idiopathic)
Idiopathic Pneumonia Syndrome Viral
Cytomegalovirus (IPS, viral,
cytomegalovirus(CMV))
Idiopathic Pneumonia Syndrome Viral
Other (IPS, viral, other)
Liver Failure (Liver failure (not VOD))
Multiple Organ Failure (Multiple Organ
Failure)
Organ Failure Not Otherwise Specified
(Organ failure, not otherwise specified)
Other Reason (Other cause)
Other Hemorrhage (Other hemorrhage)
Other Infection (Other infection)
Other Idiopathic Pneumonia Syndrome
(Other IPS)
Other Organ Failure (Other organ failure)
Other Vascular (Other vascular)
Prior Malignant Neoplasm (Prior
malignancy)
Protozoal Infection (Protozoal infection)
Pulmonary Failure (Pulmonary failure)
Pulmonary Hemorrhage (Pulmonary
hemorrhage)
Recurrence Persistent Pd
(Recurrence/persistence/progression of
disease reported for first HSCT)
Renal Failure (Renal failure)
Secondary Malignant Neoplasm
(Secondary malignancy)
Suicide (Suicide)
Thromboembolism (Thromboembolic)
Thrombocytopenic Purpura (Thrombotic
thrombocytopenic purpura (HUS/TTP))
Vascular Not Otherwise Specified
(Vascular, not otherwise specified)
Hepatic Veno-occlusive Disease (Veno-
occlusive disease (VOD) / sinusodial
obstruction syndrome (SOS))
Viral Infection (Viral infection)
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Specify contributing cause of death: (Answer only
if the value for 2730912 is "Other
Infection","Other Idiopathic Pneumonia
Syndrome","Other Organ Failure","Other
Hemorrhage","Other Vascular" or "Other
Reason".)
Author Information
First Name
Last Name
Telephone number:
Fax number:
EMail Address
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3075541v1.0
All rights reserved. Please visit https://medical-data-
models.org/forms/1746
2005 Revision 3 - Confirmation of
HLA Typing
Registry Use Only
Sequence number:
Date received:
Identification Data
CIBMTR Center Number:
CIBMTR Recipient ID:
Specify non-NMDP donor:
Negation National Marrow Donor
Program Umbilical Cord Blood Unit
(Non-NMDP cord blood unit)
Negation National Marrow Donor
Program Donor Unrelated (Non-NMDP
unrelated donor)
Donor Relationship (Related donor)
Donor / Infant date of birth:
Donor / Infant gender:
Female (female)
Male (male)
Non-NMDP unrelated donor / cord blood unit ID:
(not applicable for related donor)
Today's date:
Date of hematopoietic stem cell transplantation
(HSCT) for which this form is being completed:
HSCT type (check only one)
Related Allogenic (Allogeneic, related)
Unrelated Allogenic (Allogeneic,
unrelated)
Syngeneic (Syngeneic (identical twin))
Product type (check only one)
Umbilical Cord Blood (Cord blood)
Bone Marrow (Marrow)
Other (Other)
Peripheral Blood Stem Cell (PBSC)
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Specify the other hematopoietic stem cell
transplant type:
Hla Typing Source
Please specify the person for whom this typing is
being done:
Umbilical Cord Blood Confirmed Hla
Typing (Cord blood unit--confirmatory
typing)
Donor Confirmed Hla Typing (Donor--
confirmatory typing)
Umbilical Cord Blood Mother Hla Typing
(Maternal HLA typing)
Other (Other)
Recipient Final Hla Typing (Recipient--
final typing)
Recipient Father Confirmed Hla Typing
(Recipient's father--confirmatory typing)
Recipient Mother Confirmed Hla Typing
(Recipient's mother--confirmatory typing)
Was the recipient's mother used as the donor?
No (No)
Yes (Yes)
Was the recipient's father used as the donor?
No (No)
Yes (Yes)
Specify person and typing:
Hlatyping By Dna Technology
Is a copy of the lab report attached?
No (No)
Yes (Yes)
Hla Typing By Dna Technology: Class I
What is the reason for the A alleles missing
value?
Negation Test (Not tested)
First A* allele designations:
Second A* allele designations:
What is the reason for the B alleles missing
value?
Negation Test (Not tested)
First B* allele designations:
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Second B* allele designations:
What is the reason for the C alleles missing
value?
Negation Test (Not tested)
First C* allele designations:
Second C* allele designations:
Hla Typing By Dna Technology: Class I
What is the reason for the DRB1 allelles missing
value?
Negation Test (Not tested)
First DRB1* allele designations:
Second DRB1* allele designations:
Hla Typing By Dna Technology: Class II
(optional)
What is the reason for the DRB3 allelles missing
value?
Negation Test (Not tested)
First DRB3* allele designations:
Second DRB3* allele designations:
What is the reason for the DRB4 alleles missing
value?
Negation Test (Not tested)
First DRB4* allele designations:
Second DRB4* allele designations:
What is the reason for the DRB5 allelles missing
value?
Negation Test (Not tested)
First DRB5 * allele designations:
Second DRB5 * allele designations:
What is the reason for the DQB1 allelles missing
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value?
Negation Test (Not tested)
First DQB1* allele designations:
Second DQB1* allele designations:
What is the reason for the DPB1 allelles missing
value?
Negation Test (Not tested)
First DPB1* allele designations:
Second DPB1* allele designations:
What is the reason for the DQA1 allelles missing
value?
Negation Test (Not tested)
First DQA1* allele designations:
Second DQA1* allele designations:
What is the reason for the DPA1 allelles missing
value?
Negation Test (Not tested)
First DPA1* allele designations:
Second DPA1* allele designations:
Antigens Defined By Serologic Typing
Number of A antigens provided:
Integer::1 (One)
Integer::2 (Two)
1st A antigen specificity:
A1 Antigen (A1)
A10 Antigen (A10)
A11 Antigen (A11)
A19 Antigen (A19)
A2 Antigen 1st A2 Antigen (A2)
A203 Antigen (A203)
A210 Antigen (A210)
A23(9) Antigen (A23(9))
A24(9) Antigen (A24(9))
A2403 Antigen (A2403)
A25(10) Antigen (A25(10))
A26(10) Antigen (A26(10))
A28 Antigen (A28)
A29(19) Antigen (A29(19))
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A3 Antigen (A3)
A30(19) Antigen (A30(19))
A31(19) Antigen (A31(19))
A32(19) Antigen (A32(19))
A33(19) Antigen (A33(19))
A34(10) Antigen (A34(10))
A36 Antigen (A36)
A43 Antigen (A43)
A66(10) Antigen (A66(10))
A68(28) Antigen (A68(28))
A69(28) Antigen (A69(28))
A74(19) Antigen (A74(19))
A80 Antigen (A80)
A9 Antigen (A9)
Ax Antigen (AX)
2nd A antigen specificity
A1 Antigen (A1)
A10 Antigen (A10)
A11 Antigen (A11)
A19 Antigen (A19)
A2 Antigen 1st A2 Antigen (A2)
A203 Antigen (A203)
A210 Antigen (A210)
A23(9) Antigen (A23(9))
A24(9) Antigen (A24(9))
A2403 Antigen (A2403)
A25(10) Antigen (A25(10))
A26(10) Antigen (A26(10))
A28 Antigen (A28)
A29(19) Antigen (A29(19))
A3 Antigen (A3)
A30(19) Antigen (A30(19))
A31(19) Antigen (A31(19))
A32(19) Antigen (A32(19))
A33(19) Antigen (A33(19))
A34(10) Antigen (A34(10))
A36 Antigen (A36)
A43 Antigen (A43)
A66(10) Antigen (A66(10))
A68(28) Antigen (A68(28))
A69(28) Antigen (A69(28))
A74(19) Antigen (A74(19))
A80 Antigen (A80)
A9 Antigen (A9)
Ax Antigen (AX)
Number of B antigens provided:
Integer::1 (One)
Integer::2 (Two)
First B antigen specificity:
B12 Antigen Specificity (B12)
B13 Antigen (B13)
B14 Antigen (B14)
B15 Antigen (B15)
B16 Antigen (B16)
B17 Antigen (B17)
B18 Antigen (B18)
B21 Antigen (B21)
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B22 Antigen (B22)
B27 Antigen (B27)
B2708 Antigen (B2708)
B35 Antigen (B35)
B37 Antigen (B37)
B38(16) Antigen (B38(16))
B39(16) Antigen (B39(16))
B3901 Antigen (B3901)
B3902 Antigen (B3902)
B40 Antigen (B40)
B4005 Antigen (B4005)
B41 Antigen (B41)
B42 Antigen (B42)
B44(12) Antigen (B44(12))
B45(12) Antigen (B45(12))
B46 Antigen (B46)
B47 Antigen (B47)
B48 Antigen (B48)
B49(21) Antigen (B49(21))
B5 Antigen (B5)
B50(21) Antigen (B50(21))
B51(5) Antigen (B51(5))
B5102 Antigen (B5102)
B5103 Antigen (B5103)
B52(5) Antigen (B52(5))
B53 Antigen (B53)
B54(22) Antigen (B54(22))
B55(22) Antigen (B55(22))
B56(22) Antigen (B56(22))
B57(17) Antigen (B57(17))
B58(17) Antigen (B58(17))
B59 Antigen (B59)
B60(40) Antigen (B60(40))
B61(40) Antigen (B61(40))
B62(15) Antigen (B62(15))
B63(15) Antigen (B63(15))
B64(14) Antigen (B64(14))
B65(14) Antigen (B65(14))
B67 Antigen (B67)
B7 Antigen (B7)
B70 Antigen (B70)
B703 Antigen (B703)
B71(70) Antigen (B71(70))
B72(70) Antigen (B72(70))
B73 Antigen (B73)
B75(15) Antigen (B75(15))
B76(15) Antigen (B76(15))
B77(15) Antigen (B77(15))
B78 Antigen (B78)
B8 Antigen (B8)
B81 Antigen (B81)
B82 Antigen (B82)
Bx Antigen (BX)
Second B antigen specificity:
B12 Antigen Specificity (B12)
B13 Antigen (B13)
B14 Antigen (B14)
B15 Antigen (B15)
B16 Antigen (B16)
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B17 Antigen (B17)
B18 Antigen (B18)
B21 Antigen (B21)
B22 Antigen (B22)
B27 Antigen (B27)
B2708 Antigen (B2708)
B35 Antigen (B35)
B37 Antigen (B37)
B38(16) Antigen (B38(16))
B39(16) Antigen (B39(16))
B3901 Antigen (B3901)
B3902 Antigen (B3902)
B40 Antigen (B40)
B4005 Antigen (B4005)
B41 Antigen (B41)
B42 Antigen (B42)
B44(12) Antigen (B44(12))
B45(12) Antigen (B45(12))
B46 Antigen (B46)
B47 Antigen (B47)
B48 Antigen (B48)
B49(21) Antigen (B49(21))
B5 Antigen (B5)
B50(21) Antigen (B50(21))
B51(5) Antigen (B51(5))
B5102 Antigen (B5102)
B5103 Antigen (B5103)
B52(5) Antigen (B52(5))
B53 Antigen (B53)
B54(22) Antigen (B54(22))
B55(22) Antigen (B55(22))
B56(22) Antigen (B56(22))
B57(17) Antigen (B57(17))
B58(17) Antigen (B58(17))
B59 Antigen (B59)
B60(40) Antigen (B60(40))
B61(40) Antigen (B61(40))
B62(15) Antigen (B62(15))
B63(15) Antigen (B63(15))
B64(14) Antigen (B64(14))
B65(14) Antigen (B65(14))
B67 Antigen (B67)
B7 Antigen (B7)
B70 Antigen (B70)
B703 Antigen (B703)
B71(70) Antigen (B71(70))
B72(70) Antigen (B72(70))
B73 Antigen (B73)
B75(15) Antigen (B75(15))
B76(15) Antigen (B76(15))
B77(15) Antigen (B77(15))
B78 Antigen (B78)
B8 Antigen (B8)
B81 Antigen (B81)
B82 Antigen (B82)
Bx Antigen (BX)
Optional Antigen Reporting: Antigens
Defined By Serologic Typing
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Number of C antigens provided:
Integer::1 (One)
Integer::2 (Two)
First C antigen specificity
Cw1 Antigen (Cw1)
Cw10(w3) Antigen (Cw10(w3))
Cw2 Antigen (Cw2)
Cw3 Antigen (Cw3)
Cw4 Antigen (Cw4)
Cw5 Antigen (Cw5)
Cw6 Antigen (Cw6)
Cw7 Antigen (Cw7)
Cw8 Antigen (Cw8)
Cw9(w3) Antigen (Cw9(w3))
Cx Antigen (CX)
Second C antigen specificity:
Cw1 Antigen (Cw1)
Cw10(w3) Antigen (Cw10(w3))
Cw2 Antigen (Cw2)
Cw3 Antigen (Cw3)
Cw4 Antigen (Cw4)
Cw5 Antigen (Cw5)
Cw6 Antigen (Cw6)
Cw7 Antigen (Cw7)
Cw8 Antigen (Cw8)
Cw9(w3) Antigen (Cw9(w3))
Cx Antigen (CX)
Bw4 specificity present?
No (No)
Yes (Yes)
Bw6 specificity present?
No (No)
Yes (Yes)
Number of DR antigens provided
Integer::1 (One)
Integer::2 (Two)
First DR  antigen specificity:
Dr1 Antigen (DR1)
Dr10 Antigen (DR10)
Dr103 Antigen (DR103)
Dr11(5) Antigen (DR11(5))
Dr12(5) Antigen (DR12(5))
Dr13(6) Antigen (DR13(6))
Dr14(6) Antigen (DR14(6))
Dr1403 Antigen (DR1403)
Dr1404 Antigen (DR1404)
Dr15(2) Antigen (DR15(2))
Dr16(2) Antigen (DR16(2))
Dr17(3) Antigen (DR17(3))
Dr18(3) Antigen (DR18(3))
Dr2 Antigen (DR2)
Dr3 Antigen (DR3)
Dr4 Antigen (DR4)
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Dr5 Antigen (DR5)
Dr6 Antigen (DR6)
Dr7 Antigen (DR7)
Dr8 Antigen (DR8)
Dr9 Antigen (DR9)
Drx Antigen (DRX)
Second DR antigen specificity:
Dr1 Antigen (DR1)
Dr10 Antigen (DR10)
Dr103 Antigen (DR103)
Dr11(5) Antigen (DR11(5))
Dr12(5) Antigen (DR12(5))
Dr13(6) Antigen (DR13(6))
Dr14(6) Antigen (DR14(6))
Dr1403 Antigen (DR1403)
Dr1404 Antigen (DR1404)
Dr15(2) Antigen (DR15(2))
Dr16(2) Antigen (DR16(2))
Dr17(3) Antigen (DR17(3))
Dr18(3) Antigen (DR18(3))
Dr2 Antigen (DR2)
Dr3 Antigen (DR3)
Dr4 Antigen (DR4)
Dr5 Antigen (DR5)
Dr6 Antigen (DR6)
Dr7 Antigen (DR7)
Dr8 Antigen (DR8)
Dr9 Antigen (DR9)
Drx Antigen (DRX)
DR51 specificity present?
No (No)
Yes (Yes)
DR52 specificity present?
No (No)
Yes (Yes)
DR53 specificity present?
No (No)
Yes (Yes)
Number of DQ antigens provided:
Integer::1 (One)
Integer::2 (Two)
First DQ antigen specificity:
Dq1 Antigen (DQ1)
Dq2 Antigen (DQ2)
Dq3 Antigen (DQ3)
Dq4 Antigen (DQ4)
Dq5(1) Antigen (DQ5(1))
Dq6(1) (DQ6(1))
Dq7(3) Antigen (DQ7(3))
Dq8(3) Antigen (DQ8(3))
Dq9(3) Antigen (DQ9(3))
Dqx Antigen (DQX)
Second DQ antigen specificity:
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Dq1 Antigen (DQ1)
Dq2 Antigen (DQ2)
Dq3 Antigen (DQ3)
Dq4 Antigen (DQ4)
Dq5(1) Antigen (DQ5(1))
Dq6(1) (DQ6(1))
Dq7(3) Antigen (DQ7(3))
Dq8(3) Antigen (DQ8(3))
Dq9(3) Antigen (DQ9(3))
Dqx Antigen (DQX)
Number of DP antigens provided:
Integer::1 (One)
Integer::2 (Two)
First DP antigen specificity:
Dpw1 Antigen (DPw1)
Dpw2 Antigen (DPw2)
Dpw3 Antigen (DPw3)
Dpw4 Antigen (DPw4)
Dpw5 Antigen (DPw5)
Dpw6 Antigen (DPw6)
Dpx Antigen (DPX)
Second DP antigen specificity:
Dpw1 Antigen (DPw1)
Dpw2 Antigen (DPw2)
Dpw3 Antigen (DPw3)
Dpw4 Antigen (DPw4)
Dpw5 Antigen (DPw5)
Dpw6 Antigen (DPw6)
Dpx Antigen (DPX)
Author Information
First Name
Last Name
Telephone number:
Fax number:
EMail Address
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Follow-Up - 2100 Revision 1 - 100 Days Post-HSCT Data -
3057709v2.0
All rights reserved. Please visit https://medical-data-
models.org/forms/1749
2100 Revision 1 - 100 Days Post-
HSCT Data
Registry Use Only
Sequence number:
Date received:
Identification Data
CIBMTR Center Number:
CIBMTR Recipient ID:
Today's date:
Date of hematopoietic stem cell transplantation
(HSCT) for which this form is being completed:
Hsct Type
HSCT type
Related Allogenic (Allogeneic, related)
Unrelated Allogenic (Allogeneic,
unrelated)
Autologous (Autologous)
Syngeneic (Syngeneic (identical twin))
Was a particular hematopoietic stem cell source
used?
Yes (Yes)
Product Type
What type of hematopoietic stem cell transplant
was used?
Umbilical Cord Blood (Cord blood)
Bone Marrow (Marrow)
Multiple Umbilical Cord Blood (Multiple
cord blood units infused)
Other (Other)
Peripheral Blood Stem Cell (PBSC)
Was a particular hematopoietic stem cell
transplant type used?
Yes (Yes)
Specify the other hematopoietic stem cell
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transplant type: (Answer only if the response to
CDE 2730912 is "Other")
Vital Status
Date of actual contact with the recipient to
determine the medical status for this follow-up
report:
Did this patient receive the scheduled HSCT?
No (No)
Yes (Yes)
Reason:
Patient Life Cancel Hematopoietic Stem
Cell Transplantation (HSCT was
canceled, but patient is alive)
Patient Death Post Begin Preparative
Regimen And Hematopoietic Stem Cell
Transplantation (Patient died between
start of preparative regimen and HSCT)
Reason for cancellation:
Did the recipient receive a subsequent HSCT?
(Prior to day 100 after the HSCT for which this
form is being completed. Bone marrow, mobilized
peripheral blood stem cells, cord blood.)
No (No)
Yes (Yes)
Specify the recipient's survival status at the date
of last contact:
Life (Alive)
Death (Dead)
Has the recipient received a donor cellular
infusion? (DCI)
No (No)
Yes (Yes)
Hematopoietic Reconstitution Post-hsct
Did the recipient receive hematopoietic, lymphoid
growth factors or cytokines? (After the start of the
preparatory regimen)
No (No)
Yes (Yes)
Hematopoietic Reconstitution Post-hsct
Part 2 Of 2
Type(s) of hematopoietic, lymphoid growth factor
or cytokine agents given: (For the first course of
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each agent given in this reporting period)
Hematopoietic Growth Factor Or
Cytokine Blinded Clinical Study (Blinded
growth factor or cytokine trial)
Recombinant Erythropoietin
(Erythropoietin)
Recombinant Granulocyte Colony
Stimulating Factor (G-CSF)
Recombinant Granulocyte-macrophage
Colony-stimulating Factor (GM-CSF)
Palifermin (KGF)
Other Pharmacologic Substance (Other
agent)
Velafermin (Velafermin)
Did the recipient receive hematopoietic, lymphoid
growth factors or cytokines? (After the start of the
preparatory regimen)
No (No)
Yes (Yes)
Specify the date for the first course of each agent
administered:
Specify the indication for the therapy: (Therapy
code)
Anti-leukemic Or Tumor Agent To
Prevent Relapse (Anti-leukemic or tumor
agent to prevent relapse)
Anti-leukemic Or Tumor Agent To Treat
Relapse (Anti-leukemic or tumor agent to
treat relapse)
Intervention For Delay / Decline In
Absolute Neutrophil Count (anc)
(Intervention for delay / decline in
absolute neutrophil count (ANC))
Intervention For Delay / Decline In Both
Anc And Platelets (Intervention for delay
/ decline in both ANC and platelets)
Intervention For Delay / Decline In
Platelets (Intervention for delay / decline
in platelets)
Intervention For Delay / Decline In Red
Blood Cell Counts (Intervention for delay
/ decline in red blood cell counts)
Other (Other)
Planned Therapy Per Protocol (note: For
Planned Therapy To Prevent Mucositis,
Use 10) (Planned therapy per protocol)
Planned Therapy To Prevent Mucositis
(Planned therapy to prevent mucositis)
Specify the specific G-CSF drug given: (Respond
only if the answer to CDE 2775782 is "G-CSF")
Lenograstim (Lenograstim)
Pegfilgrastim (Neulasta)
Filgrastim (Neupogen)
Specify the specific erythropoietin drug given:
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(Respond only if the answer to CDE 2775782 is
"Erythropoietin")
Darbepoetin Alfa (Aranesp)
Epoetin Alfa (Epogen)
Specify agent: (Respond only if the answer to
CDE 2775782 is "Blinded growth factor or
cytokine trial" or "Other agent")
Granulopoiesis / Neutrophil Recovery
Was there evidence of hematopoietic recovery?
(Following the initial HSCT)
Anc Never Dropped Below 500/mm^3 At
Any Time After The Start Of The
Preparative Regimen (Never below)
No, Anc >= 500/mm^3 Was Not
Achieved And There Was Documented
Persistent Disease In The Bone Marrow
Post-hsct (No, ANC recovery was not
achieved and there was evidence of
persistent disease)
No, Anc >= 500/mm^3 Was Not
Achieved And There Was No Evidence
Of Recurrent Disease In The Bone
Marrow (No, ANC recovery was not
achieved and there was no evidence of
recurrent disease)
Yes, Anc >= 500/mm^3 Achieved And
Sustained For 3 Lab Values With No
Subsequent Decline (Yes, ANC recovery
was achieved with no subsequent
decline)
Yes, Anc >= 500/mm^3 For 3 Lab Values
With Subsequent Decline In Anc To <
500/mm^3 For >= 3 Days (Yes, ANC
recovery was achieved with subsequent
decline)
Date ANC was greater than or equal to
500/mmE3: (First of 3 lab values)
Granulopoiesis / Neutrophil Recovery #2
Date ANC was greater than or equal to
500/mmE3: (First of 3 lab values)
Date of decline in ANC to less than 500/mmE3
for 3 days or more: (First of 3 days that the ANC
declined)
What is the value of WBC: (Actual CBC on first
day of decline)
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What is the unit of measure for WBC? (Actual
CBC on first day of decline)
10e6 Per Liter (10E6/L)
10e9 Cells Per Liter (10E9 Cells/L)
What is the percentage of neutrophils? (Actual
CBC on first day of decline)
Granulopoiesis / Neutrophil Recovery
Did the recipient recover and maintain ANC
greater than or equal to 500/mmE3 following the
decline?
No (No)
Yes (Yes)
Date ANC was greater than or equal to
500/mmE3: (First of 3 lab values)
If necessary, please validate the neutrophil
recovery date response.
Date Unknown (Date unknown)
What is the value of WBC: (Actual CBC on first
day of decline)
What is the unit of measure for WBC? (Actual
CBC on first day of decline)
10e6 Per Liter (10E6/L)
10e9 Cells Per Liter (10E9 Cells/L)
What is the percentage of neutrophils? (Actual
CBC on first day of decline)
Megakaryopoiesis / Platelet Recovery
Was an initial platelet count greater than or equal
to 20 x 10E9/L achieved?
No (No)
Never Less Than Platelet Count 20000
(platelet count never dropped below 20 x
10^9/L)
Yes (Yes)
Date platelet count greater than or equal to 20 x
10E9/L
If necessary, please validate the date of platelets
greater than or equal to 20 x 10E9/L response.
Date Estimate (Date estimated)
Date Unknown (Date unknown)
Was an initial platelet count greater than or equal
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to 50 x 10E9/L achieved?
No (No)
Never Less Than Platelet Count 50000
(platelet count never dropped below 50 x
10^9/L)
Yes (Yes)
Date platelets greater than or equal to 50 x
10E9/L:
If necessary, please validate the date of platelets
greater than or equal to 50 x 10E9/L response.
Date Estimate (Date estimated)
Date Unknown (Date unknown)
Current Hematologic Findings
What is the value of WBC: (Actual CBC on first
day of decline)
Sample (specimen) collection date. (Date of most
recent hematologic testing)
What is the unit of measure for WBC? (Actual
CBC on first day of decline)
10e6 Per Liter (10E6/L)
10e9 Cells Per Liter (10E9 Cells/L)
What is the reason for the WBC missing value?
Negation Test (Not tested)
What is the percentage of neutrophils? (Actual
CBC on first day of decline)
What is the reason for the neutrophils missing
value?
Negation Test (Not tested)
What is the value of platelets?
What is the percentage of lymphocytes?
What is the unit of measure for platelets?
10e6 Per Liter (10E6/L)
10e9 Cells Per Liter (10E9 Cells/L)
What is the reason for the lymphocytes missing
value?
Negation Test (Not tested)
What is the value of hemoglobin? (2 decimal
place value)
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What is the unit of measure for hemoglobin?
Gram Per Deciliter (g/dL)
Gram Per Liter (g/L)
Millimole Per Liter (mmol/L)
What is the reason for the hemoglobin missing
value?
Negation Test (Not tested)
If necessary, please validate the hemoglobin
response.
Transfused Rbc Less Than 30 Days
From Date Of Most Current Testing
(Transfused RBC less than 30 days from
date of most current testing)
What is the percentage of hematocrit?
What is the reason for the hematocrit missing
value?
Negation Test (Not tested)
If necessary, please validate the hematocrit
response.
Transfused Rbc Less Than 30 Days
From Date Of Most Current Testing
(Transfused RBC less than 30 days from
date of most current testing)
What is the reason for the platelets missing
value?
Negation Test (Not tested)
If necessary, please validate the platelet
response.
Transfused Platelets Less Than 7 Days
From Date Of Most Current Testing
(Transfused platelets less than 7 days
from date of most current testing)
Immune Reconstitution Part 1 Of 5
Type of immunologic laboratory procedure
performed:
Iga (IgA)
Igg (IgG)
Igm (IgM)
What is the value of the immunoglobulin test?
(Specify the immunoglobulin values from the
most recent testing)
Specify the unit of measure for the
immunoglobulin test:
Gram Per Deciliter (g/dL)
Gram Per Liter (g/L)
Milligram Per Deciliter (mg/dL)
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Sample (specimen) collection date. (Date of most
recent hematologic testing)
What is the reason for the immunoglobulin
missing value?
Negation Test (Not tested)
Immune Reconstitution Part 2 Of 5
Did the recipient receive supplemental
intravenous immunoglobulins? (IVIG)
No (No)
Yes (Yes)
Was therapy ongoing within one month of
immunoglobulin testing?
No (No)
Yes (Yes)
Immune Reconstitution Part 3 Of 5
Specify the indication(s) for the supplemental
intravenous immunoglobulin therapy:
Other (Other Indication)
Preventive Intervention Cytomegalovirus
(Prophylaxis for cytomegalovirus
infection)
Preventive Intervention Low Igg No
Active Infection (Prophylaxis for low IgG
with no active infection)
Therapeutic Procedure Cytomegalovirus
(Treatment for CMV infection)
Therapeutic Procedure Infection Low Igg
(Treatment for infection with low IgG)
Therapeutic Procedure Respiratory
Syncytial Virus (Treatment for respiratory
syncytial virus (RSV) infection)
Specify if there was an indication for the
supplemental intravenous immunoglobulin
therapy:
No (No)
Yes (Yes)
Specify (Answer only if the response to CDE
2775979 is "Other indication")
Immune Reconstitution Part 4 Of 5
Were lymphocyte analyses performed?
No (No)
Yes (Yes)
Sample (specimen) collection date. (Date of most
recent hematologic testing)
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Immune Reconstitution Part 5 Of 5
Specify cluster of differentiation type:
Cd20 Antigen (CD20)
Cd3 Complex (CD3)
Cd4 Antigen (CD4)
Neural Cell Adhesion Molecule (CD56)
Cd8 Antigen, Beta Polypeptide 1 (CD8)
What is the value of the cluster of differentiation?
What is the unit of measure for the cluster of
differentiation?
10e6 Per Liter (10E6/L)
10e9 Cells Per Liter (10E9 Cells/L)
What is the reason for the cluster of
differentiation missing value?
Negation Test (Not tested)
Chimerism Studies
Were chimerism studies performed? (Post-HSCT)
No (No)
Yes (Yes)
Are chimerism laboratory reports attached to this
form?
No (No)
Yes (Yes)
Were infusions from more than one donor given?
No (No)
Yes (Yes)
Specify donor gender:
Female (female)
Male (male)
Chimerism Studies
Method
Cytogenetics (Conventional (Standard)
Cytogenetics)
Fluorescence In Situ Hybridization
(Fluorescence in situ Hybridization
(FISH))
Human Leukocyte Antigen Test (HLA
Typing)
Other (Other)
Restriction Fragment Length
Polymorphism (Restriction Fragment
Length Polymorphism (RFLP))
Minisatellite Repeat (VNTR or STR,
micro or mini satellite)
Cell type
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B-lymphocyte (B-cells)
Bone Marrow (Bone marrow (BM))
Lymphocyte Not Otherwise Specified
(Lymphocytes, not otherwise specified)
Monocyte (Monocytes)
Myeloid Not Otherwise Specified
(Myeloid cells, not otherwise specified)
Other (Other)
Peripheral Blood Mononuclear Cell
(Peripheral blood mononuclear cells
(PBMC))
Neutrophil (PMNs (neutrophils))
Erythrocyte (Red blood cells)
T-lymphocyte (T-cell)
Sample (specimen) collection date. (Date of most
recent hematologic testing)
Total cells examined
Number of donor cells
Number of host cells
Percent donor cells, quantitative method
Were donor cells present as determined by non-
quantitative means? (If performed by non-
quantitative method, indicate the presence of
donor cells.)
Present (Present)
Percent host cells, quantitative method
Were host cells present as determined by non-
quantitative means? (If performed by non-
quantitative method, indicate the presence of
host cells.)
Present (Present)
Chimerism Studies
Chimerism study donor type:
National Marrow Donor Program Legal
Adult Donor (NMDP adult donor)
National Marrow Donor Program
Umbilical Cord Blood Unit (NMDP Cord
Blood Unit)
Negation National Marrow Donor
Program Donor (Non-NMDP Donor)
NMDP donor ID:
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Method
Cytogenetics (Conventional (Standard)
Cytogenetics)
Fluorescence In Situ Hybridization
(Fluorescence in situ Hybridization
(FISH))
Human Leukocyte Antigen Test (HLA
Typing)
Other (Other)
Restriction Fragment Length
Polymorphism (Restriction Fragment
Length Polymorphism (RFLP))
Minisatellite Repeat (VNTR or STR,
micro or mini satellite)
Cell type
B-lymphocyte (B-cells)
Bone Marrow (Bone marrow (BM))
Lymphocyte Not Otherwise Specified
(Lymphocytes, not otherwise specified)
Monocyte (Monocytes)
Myeloid Not Otherwise Specified
(Myeloid cells, not otherwise specified)
Other (Other)
Peripheral Blood Mononuclear Cell
(Peripheral blood mononuclear cells
(PBMC))
Neutrophil (PMNs (neutrophils))
Erythrocyte (Red blood cells)
T-lymphocyte (T-cell)
NMDP Cord Blood Unit ID:
Specify donor gender:
Female (female)
Male (male)
Sample (specimen) collection date. (Date of most
recent hematologic testing)
Donor date of birth:
Total cells examined
Number of donor cells
Number of host cells
Percent donor cells, quantitative method
Were donor cells present as determined by non-
quantitative means? (If performed by non-
quantitative method, indicate the presence of
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donor cells.)
Present (Present)
Percent host cells, quantitative method
Were host cells present as determined by non-
quantitative means? (If performed by non-
quantitative method, indicate the presence of
host cells.)
Present (Present)
Engraftment Syndrome
Did engraftment syndrome occur?
No (No)
Yes (Yes)
Date of onset:
Engraftment Syndrome 2 Of 2
Specify the symptoms of engraftment syndrome:
Capillary Leak Syndrome (Capillary leak
syndrome)
Fever (Fever)
Skin Rash (Skin rash)
Specify if symptoms of engraftment syndrome
occurred:
No (No)
Yes (Yes)
Specify amount of body surface affected (Answer
only if the response to CDE 2782511 is "Skin
rash")
Engraftment Syndrome Part 3 Of 3
Was engraftment syndrome treated with
corticosteroids
No (No)
Yes (Yes)
Acute Graft Vs. Host Disease (gvhd)
Was specific therapy used to prevent acute
GVHD or graft rejection, or for autologous HSCT
to induce acute GVHD? (After the start of the
preparative regimen. Do not include growth
factors reported in module "Hematopoietic
Reconstitution Post-HSCT Part 2 of 2," or ex vivo
T-cell depletion reported on the Product Insert.)
No (No)
Yes (Yes)
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Date of diagnosis: (Of acute GVHD)
ALS, ALG, ATS, ATG
No (No)
Yes (Yes)
Specify source:
Horse (Horse)
Other Source (Other source)
Rabbit (Rabbit)
If necessary, please validate the diagnosis date
response. (Of acute GVHD)
Greater Than Integer::100 Day Date
(Date greater than 100 days, date is
correct)
Specify: (Specify other source)
Corticosteroids (Systemic)
No (No)
Yes (Yes)
Cyclosporine (CSA, Sandimmune, Neoral)
No (No)
Yes (Yes)
ECP (Extra-corporeal photopheresis)
No (No)
Yes (Yes)
FK 506 (Tacrolimus, Prograf)
No (No)
Yes (Yes)
KGF (Palifermin, Kepivance. If used to prevent
mucositis, report at question 20 in module
"Hematopoietic Reconstitution Post-HSCT Part 2
of 2," CDE 2775782.)
No (No)
Yes (Yes)
Specify date started:
Velafermin (If used to prevent mucositis, report at
question 23 in module "Hematopoietic
Reconstitution Post-HSCT Part 2 of 2," CDE
2775782.)
No (No)
Yes (Yes)
Specify date started:
In vivo monoclonal antibody
No (No)
Yes (Yes)
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Anti CD 25 (Zenapax, Daclizumab, AntiTAC)
No (No)
Yes (Yes)
Specify:
Campath
No (No)
Yes (Yes)
Etanercept (Enbrel)
No (No)
Yes (Yes)
Infliximab (Remicade)
No (No)
Yes (Yes)
Other in vivo monoclonal antibody
No (No)
Yes (Yes)
Specify:
In vivo immunotoxin
No (No)
Yes (Yes)
Specify:
Methotrexate (MTX, Amethopterin)
No (No)
Yes (Yes)
Mycophenolate mofetil (MMF, CellCept)
No (No)
Yes (Yes)
Sirolimus (Rapamycin, Rapamune)
No (No)
Yes (Yes)
Ursodiol
No (No)
Yes (Yes)
Blinded randomized trial
No (No)
Yes (Yes)
Specify agent:
Other agent
No (No)
Yes (Yes)
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Specify:
Did acute GVHD occur?
Acute Graft Versus Host Disease
Persistent Prior Hematopoietic Stem Cell
Transplantation And/or Donor Cell
Infusion Procedure (Acute GVHD
persists from prior HSCT/DCI)
No (No)
Unknown (Unknown)
Yes (Yes)
Was the diagnosis based on evidence from a
biopsy? (Histology)
No (No)
Yes (Yes)
Acute Graft Vs. Host Disease (gvhd) Part
2 Of 6
What is the biopsy site used to indicate the
diagnostic evidence:
Gastrointestinal (Gastrointestinal (GI))
Liver (Liver)
Lung (Lung)
Other (Other)
Skin (Skin)
Specify result(s):
Uncertain (Inconclusive)
Negative Finding (Negative)
Not Done: C49484 (Not Done)
Positive Finding (Positive)
Specify other site: (Answer only if the response to
CDE 2787340 is "Other")
Acute Graft Vs. Host Disease (gvhd) Part
3 Of
Is a copy of the pathology report attached?
No (No)
Yes (Yes)
Was the diagnosis based on clinical evidence?
No (No)
Yes (Yes)
Maximum overall grade of acute GVHD:
Agvhd Grade I (I)
Agvhd Grade Ii (II)
Agvhd Grade Iii (III)
Agvhd Grade Iv (IV)
Is acute GVHD still present at the date of contact
for this report?
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No (No)
Progressive Chronic Graft Versus Host
Disease (Progressed to chronic GVHD)
Unknown (Unknown)
Yes (Yes)
List the maximum severity of skin involvement:
No Skin Acute Gvhd / Rash Not
Attributable To Acute Gvhd (None)
No Rash (Stage 0)
Maculopapular Rash, Less Than 25
Percent Of Body Surface (Stage 1)
Maculopapular Rash, 25 To 50 Percent
Of Body Surface (Stage 2)
Generalized Erythroderma (Stage 3)
Generalized Erythroderma With Bullae
Formation And Desquamation (Stage 4)
List the maximum severity of lower intestinal tract
involvement (Use mL/day for adult recipients and
mL/mE2/day for pediatric recipients)
No Gut Acute Gvhd / Diarrhea Not
Attributable To Acute Gvhd (None)
Diarrhea Less Than Or Equal To 500
Ml/day Or Less Than 280 Ml/me2 Day
(Stage 0)
No Diarrhea (Stage 0 - no diarrhea)
Diarrhea Greater Than 500 But Less
Than Or Equal To 1000 Ml/day Or 280-
555 Ml/me2 /day (Stage 1)
Diarrhea Greater Than 1000 But Less
Than Or Equal To 1500 Ml/day Or 556-
833 Ml/me2 /day (Stage 2)
Diarrhea Greater Than 1500 Ml/day Or
Greater Than 833 Ml/me2 /day (Stage 3)
Severe Abdominal Pain, With Or Without
Ileus (Stage 4)
List the maximum severity of upper intestinal tract
involvement:
No Persistant Nausea Or Vomiting
(Stage 0)
Persistant Nausea Or Vomiting (Stage 1)
List the maximum severity of liver involvement:
No Liver Acute Gvhd / Bilirubin Level Not
Attributable To Acute Gvhd (None)
Bilirubin Less Than 2.0 Mg/dl (less Than
34 Micro Mol/l) (Stage 0)
Bilirubin 2.0 To 3.0 Mg/dl (34 To 52 Micro
Mol/l) (Stage 1)
Bilirubin 3.1 To 6.0 Mg/dl (53 To 103
Micro Mol/l) (Stage 2)
Bilirubin 6.1 To 15.0 Mg/dl (104 To 256
Micro Mol/l) (Stage 3)
Bilirubin Greater Than 15.0 Mg/dl
(greater Than 256 Micro Mol/l) (Stage 4)
Other clinical organ involvement?
No (No)
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Yes (Yes)
Acute Graft Vs. Host Disease (gvhd) Part
3 Of
Specify the site of organ involvement
Lung (Lung)
Other (Other)
Was a particular site of organ involvement
present?
No (No)
Yes (Yes)
Specify other site (Answer only if the response to
CDE 2793699 is "Other")
Acute Graft Vs. Host Disease (gvhd) Part
7 Of
Was specific therapy used to treat acute GVHD?
No (No)
Yes (Yes)
ALS, ALG, ATS, ATG
No (No)
Yes (Yes)
Specify source:
Horse (Horse)
Other Source (Other source)
Rabbit (Rabbit)
Specify: (Specify other source)
Corticosteroids (Systemic)
No (No)
Yes (Yes)
Cyclosporine (CSA, Sandimmune, Neoral)
No (No)
Yes (Yes)
Corticosteroids (Topical)
No (No)
Yes (Yes)
ECP (Extra-corporeal photopheresis)
No (No)
Yes (Yes)
FK 506 (Tacrolimus, Prograf)
No (No)
Yes (Yes)
In vivo monoclonal antibody
No (No)
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Yes (Yes)
Anti CD 25 (Zenapax, Daclizumab, AntiTAC)
No (No)
Yes (Yes)
Specify:
Campath
No (No)
Yes (Yes)
Etanercept (Enbrel)
No (No)
Yes (Yes)
Infliximab (Remicade)
No (No)
Yes (Yes)
Other in vivo monoclonal antibody
No (No)
Yes (Yes)
Specify:
In vivo immunotoxin
No (No)
Yes (Yes)
Specify:
Methotrexate (MTX, Amethopterin)
No (No)
Yes (Yes)
Mycophenolate mofetil (MMF, CellCept)
No (No)
Yes (Yes)
Sirolimus (Rapamycin, Rapamune)
No (No)
Yes (Yes)
Ursodiol
No (No)
Yes (Yes)
Blinded randomized trial
No (No)
Yes (Yes)
Specify agent:
Other agent
No (No)
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Yes (Yes)
Specify:
Chronic Graft Vs. Host Disease (gvhd)
Has the recipient developed clinical chronic
GVHD?
Chronic Graft Versus Host Disease
Persistent Prior Hematopoietic Stem Cell
Transplantation And/or Donor Cell
Infusion Procedure (Chronic GVHD
persists from prior HSCT/DCI)
No (No)
Unknown (Unknown)
Yes (Yes)
Date of diagnosis: (Of acute GVHD)
If necessary, please validate the diagnosis date
response. (Of acute GVHD)
Greater Than Integer::100 Day Date
(Date greater than 100 days, date is
correct)
Onset of chronic GVHD was:
Symptoms Reactivated Within 30 Days
Of Drug Tapering Or Discontinuation
(Chronic GVHD flare)
Acute Gvhd Never Developed (De novo)
Acute Gvhd Resolved, Then Chronic
Gvhd Developed (Interrupted)
Acute Gvhd Progressed Directly To
Chronic Gvhd (Progressive)
Karnofsky / Lansky score (At diagnosis of chronic
GVHD. If the recipient is 16 years of age or older,
complete the Karnofsky Scale. If the recipient is
younger than 16 years of age, complete the
Lansky Scale.)
Karnofsky Scale - Moribund, Fatal
Process Progressing Rapidly; Lansky
Scale - Completely Disabled, Not Even
Passive Play. (10)
Karnofsky Scale - Normal, No
Complaints, No Evidence Of Disease;
Lansky Scale - Fully Active. (100)
Karnofsky Scale - Very Sick,
Hospitalization Necessary; Lansky Scale
- Limited To Very Passive Activity
Initiated By Others (e.g., Tv) (20)
Karnofsky Scale - Severely Disabled,
Hospitalization Indicated, Although
Death Not Imminent. Lansky Scale -
Needs Considerable Assistance For
Quiet Activity. (30)
Karnofsky Scale - Disabled, Requires
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Special Care And Assistance. Lansky
Scale - Able To Initiate Quiet Activities.
(40)
Karnofsky Scale - Requires
Considerable Assistance And Frequent
Medical Care; Lansky Scale -
Considerable Assistance Required For
Any Active Play; Fully Able To Engage In
Quiet Play. (50)
Karnofsky Scale - Requires Occasional
Assistance, But Is Able To Care For Most
Needs; Lansky Scale - Ambulatory Up To
50r Of Time, Limited Active Play With
Assistance / Supervision. (60)
Karnofsky Scale - Cares For Self, Unable
To Carry On Normal Activity Or To Do
Active Work.; Lansky Score - Both
Greater Restrictions Of, And Less Time
Spent In, Active Play. (70)
Karnofsky Scale - Normal Activity With
Effort; Lansky Scale - Restricted In
Strenuous Play, Tires More Easily,
Otherwise Active. (80)
Karnofsky Scale - Able To Carry On
Normal Activity; Lansky Scale - Minor
Restriction In Physically Strenuous Play.
(90)
What is the value of platelets?
What is the unit of measure for platelets?
10e6 Per Liter (10E6/L)
10e9 Cells Per Liter (10E9 Cells/L)
Diagnosis was based on:
Clinical And Histologic Finding (Both
clinical and histologic evidence)
Clinical Finding (Clinical evidence)
Histologic Finding And/or Biopsy
Confirmed (Histologic evidence / biopsy
proven)
Unknown (Unknown)
Maximum grade of chronic GVHD:
Extensive Gvhd Involvement (Extensive)
Limited Gvhd Involvement (Limited)
Overall severity of chronic GVHD:
Mild (Mild)
Moderate (Moderate)
Severe (Severe)
Chronic Graft Vs. Host Disease (gvhd) -
Organ Involvement
Specify the type of organ / system involvement
with chronic GVHD:
Autoantibody (Autoantibodies)
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Bronchiolitis Obliterans (Bronchiolitis
obliterans)
Eosinophilia (Eosinophilia)
Eye (Eyes)
Gastrointestinal Tract (Gastrointestinal
tract)
Genitourinary System (Genitourinary
tract)
Liver (Liver)
Oral Cavity (Mouth)
Musculoskeletal (Musculoskeletal)
Other Hematopoietic Involvement (Other
hematologic involvement)
Other Lung Involvement (Other lung
involvement)
Other Organ Involvement (Other organ
involvement)
Other Skin Or Hair Involvement (Other
skin or hair involvement)
Skin Sclerosis (Sclerosis of skin)
Serositis (Serositis)
Thrombocytopenia (Thrombocytopenia)
Weight Loss (Weight loss)
Indicate if there was an organ / system
involvement with chronic GVHD:
No (No)
Yes (Yes)
Indicate if the organ / system involvement was
proven by biopsy:
No (No)
Yes (Yes)
Specify the other site of the organ / system
involvement with chronic GVHD: (Answer only if
the response to CDE 2793857 is "Other organ
involvement")
Chronic Graft Vs. Host Disease (gvhd)
Was specific therapy used to treat chronic
GVHD?
No (No)
Yes (Yes)
ALS, ALG, ATS, ATG
No (No)
Yes (Yes)
Specify source:
Horse (Horse)
Other Source (Other source)
Rabbit (Rabbit)
Specify: (Specify other source)
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Azathioprine
No (No)
Yes (Yes)
Corticosteroids (Systemic)
No (No)
Yes (Yes)
Cyclosporine (CSA, Sandimmune, Neoral)
No (No)
Yes (Yes)
ECP (Extra-corporeal photopheresis)
No (No)
Yes (Yes)
Corticosteroids (Topical)
No (No)
Yes (Yes)
FK 506 (Tacrolimus, Prograf)
No (No)
Yes (Yes)
Etretinate
No (No)
Yes (Yes)
Hydroxychloroquine (Plaquenil)
No (No)
Yes (Yes)
In vivo monoclonal antibody
No (No)
Yes (Yes)
Anti CD 25 (Zenapax, Daclizumab, AntiTAC)
No (No)
Yes (Yes)
Specify:
Campath
No (No)
Yes (Yes)
Etanercept (Enbrel)
No (No)
Yes (Yes)
Infliximab (Remicade)
No (No)
Yes (Yes)
Other in vivo monoclonal antibody
No (No)
Yes (Yes)
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Specify:
Lamprene (Clofazimine)
No (No)
Yes (Yes)
Pentostatin
No (No)
Yes (Yes)
Mycophenolate mofetil (MMF, CellCept)
No (No)
Yes (Yes)
PUVA (Psoralen and UVA)
No (No)
Yes (Yes)
Sirolimus (Rapamycin, Rapamune)
No (No)
Yes (Yes)
Ursodiol
No (No)
Yes (Yes)
Thalidomide
No (No)
Yes (Yes)
Blinded randomized trial
No (No)
Yes (Yes)
Specify agent:
Other agent
No (No)
Yes (Yes)
Specify:
Are symptoms of chronic GVHD still present?
(On the date of actual contact or present at the
time of death)
No (No)
Yes (Yes)
Is the recipient still taking immunosuppressive
agents to treat or prevent GVHD? (Including
PUVA)
No (No)
Unknown (Unknown)
Yes (Yes)
Date final treatment administered:
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If necessary, please validate the final date of
immunosuppressant administration response.
Date Unknown (Date unknown)
Infection
Did the recipient receive any of the following
agents for infection prophylaxis? (After the start
of the preparative regimen. Report prophylaxis
immunoglobulins at questions 63-64 in module
"Immune Reconstitution Part 3 of 5")
No (No)
Unknown (Unknown)
Yes (Yes)
Infection Part 2 Of 3
Specify the agent types received for infection
prophylaxis:
Acyclovir (Acyclovir)
Amphotericin B-lipid Complex
(Amphotericin (lipid formulation))
Amphotericin B Deoxycholate
(Amphotericin (non-lipid formulation))
Atovoquone (Atovaquone)
Caspofungin (Caspofungin)
Dapsone (Dapsone)
Fluconazole (Fluconazole)
Foscarnet (Foscarnet)
Ganciclovir (Ganciclovir)
Itraconazole (Itraconazole)
Micafungin (Micafungin)
Negation Absorbable Oral Route Of
Administration Antibiotic (Nonabsorbable
oral antibiotics)
Other Pharmacologic Substance (Other
agent)
Other Antiviral Agent (Other antiviral
agent)
Other Pneumocystis Pneumonia
Preventive Intervention (Other
pneumocystis prophylaxis)
Other Systemic Antifungal Agent (Other
systemic antifungal agent)
Pentamidine Inhaler (Pentamidine
inhaled)
Pentamidine Intravenous Route Of
Administration (Pentamidine IV)
Posaconazole (Posaconazole)
Ravuconazole (Ravuconazole)
Systemic Antibiotic (Systemic
antibacterial antibiotics)
Trimethoprim-sulfamethoxazole
(Trimethoprim/sulfamethoxazole)
Valacyclovir (Valacyclovir)
Valganciclovir (Valganciclovir)
Voriconazole (Voriconazole)
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Did the recipient receive any of the following
agents for infection prophylaxis? (After the start
of the preparative regimen. Report prophylaxis
immunoglobulins at questions 63-64 in module
"Immune Reconstitution Part 3 of 5")
No (No)
Unknown (Unknown)
Yes (Yes)
Specify the other agent received for infection
prophylaxis: (Answer only if the response to CDE
2794436 is "Other systemic antifungal agent,"
"Other antiviral agent," "Other pneumocystis
prophylaxis," or "Other agent")
Infection Part 3 Of 4
Did the recipient receive irradiated granulocyte
infusions? (After the start of the preparative
regimen to 60 days post-HSCT.)
No (No)
Yes (Yes)
Did the recipient develop a clinically significant
infection? (After the start of the preparative
regimen)
No (No)
Yes (Yes)
Infection Part 3 Of 3
Organism
Acinetobacter (Acinetobacter)
Actinomyces (Actinomyces)
Adenovirus (Adenovirus)
Aspergillus Flavus (Aspergillus flavus)
Aspergillus Fumigatus (Aspergillus
fumigatus)
Aspergillus Niger (Aspergillus niger)
Aspergillus Not Otherwise Specified
(Aspergillus, NOS)
Bacillus (Bacillus)
Bacteroides (Bacteroides (gracillis,
uniformis, vulgaris, other species))
Bordetella Pertussis (Bordetella
pertussis (whooping cough))
Borrelia Burgdorferi (Borrelia (lyme
disease))
Moraxella Catarrhalis (Branhamella or
Moraxella catarrhalis (other species))
Campylobacter (Campylobacter (all
species))
Candida Glabrata (Candida (Torulopsis)
glabrata)
Candida Albicans (Candida albicans)
Pichia Guilliermondii (Candida
guillermondi)
Issatchenkia Orientalis (Candida krusei)
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Clavispora Lusitaniae (Candida
lusitaniae)
Candida Parapsilosis (Candida
parapsilosis)
Candida Tropicalis (Candida tropicalis)
Candida Not Otherwise Specified
(Candida, NOS)
Capnocytophaga (Capnocytophaga)
Chlamydophila Pneumoniae (Chlamydia
(pneumoniae))
Chlamydia Not Otherwise Specified
(Chlamydia, NOS)
Citrobacter (Citrobacter (freundii, other
species))
Clostridium (Clostridium (all species
except difficile))
Clostridium Difficile (Clostridium difficile)
Corynebacterium (Corynebacterium (all
non-diptheria species))
Corynebacterium Jeikeium
(Corynebacterium (jeikeium))
Coxiella (Coxiella)
Cryptococcosis (Cryptococcosus
species)
Cryptosporidium (Cryptosporidium)
Cytomegalovirus (Cytomegalovirus)
Enterobacter (Enterobacter)
Enterococcus (Enterococcus (all
species))
Vancomycin Resistant Enterococcus
(Enterococcus, vancomycin resistant
(VRE))
Enterovirus (Enterovirus)
Epstein-barr Virus (Epstein-Barr Virus)
Escherichia Coli (Escherichia (also E.
coli))
Pseudomonas Oryzihabitans
(Flavimonas oryzihabitans)
Flavobacterium (Flavobacterium)
Fusarium (Fusarium species)
Fusobacterium (Fusobacterium)
Giardia (Giardia)
Haemophilus (Haemophilus (all species,
including influenzae))
Helicobacter Pylori (Helicobacter pylori)
Hepatitis A Virus (Hepatitis A Virus)
Hepatitis B Virus (Hepatitis B Virus)
Hepatitis C Virus (Hepatitis C Virus)
Herpes Simplex Virus (Herpes Simplex
Virus)
Herpes Zoster (Herpes Zoster)
Histoplasmosis (Histoplasmosis)
Human Herpesvirus 6 (Human
Herpesvirus 6)
Human Immunodeficiency Virus 1
(Human Immunodeficiency Virus 1)
Human Papillomavirus (Human
Papillomavirus)
Influenza A Virus (Influenza A Virus)
Influenza B Virus (Influenza B Virus)
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Other Influenza (Influenza, NOS)
Klebsiella (Klebsiella)
Lactobacillus (Lactobacillus (bulgaricus,
acidophilus, other species))
Legionella (Legionella)
Leptospira (Leptospira)
C76356 (Leptotrichia buccalis)
Leuconostoc (Leuconostoc (all species))
Listeria (Listeria)
Measles Virus (Measles Virus)
Methylobacterium (Methylobacterium)
Micrococcus Not Otherwise Specified
(Micrococcus, NOS)
Zygomycosis (Mucormycosis)
Multiple Bacteria (Multiple bacteria at a
single site)
Mumps Virus (Mumps Virus)
Mycobacterium Avium Complex
(Mycobacterium avium - intracellulare
(MAC, MAI))
Mycobacterium Species (Mycobacterium
species (cheloneae, fortuitum,
haemophilum, kansasii, mucogenicum))
Mycobacterium Tuberculosis
(Mycobacterium tuberculosis
(tuberculosis, Koch bacillus))
Mycobacterium Not Otherwise Specified
(Mycobacterium, NOS)
Mycoplasma (Mycoplasma)
Neisseria (Neisseria (gonorrhoeae,
meningitidis, other species))
Not Identified Organism (No organism
identified)
Nocardia (Nocardia)
Other Aspergillus (Other Aspergillus)
Other Bacteria (Other bacteria)
Other Candida (Other Candida)
Other Chlamydia (Other chlamydia)
Other Fungi (Other fungus)
Other Mycobacterium (Other
mycobacterium)
Other Parasite (Other parasite)
Other Virus (Other Virus)
Parainfluenza Virus (Parainfluenza Virus)
Pasteurella Multocida (Pasteurella
multocida)
Pneumocystis Pneumonia
(Pneumocystis (PCP / PJP))
Polyomavirus (Polyomavirus)
Progressive Multifocal
Leukoencephalopathy (Progressive
Multifocal Leukoencephalopathy)
Propionibacterium Acnes
(Propionibacterium (acnes, avidum,
granulosum, other species))
Proteus (Proteus)
Pseudomonas (Pseudomonas (all
species except cepacia & maltophilia))
Burkholderia Cepacia (Pseudomonas or
Burkholder cepacia)
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Stenotrophomonas Maltophilia
(Pseudomonas or Stenotrophomonas or
Xanthomonas maltophilia)
Respiratory Syncytial Virus (Respiratory
Syncytial Virus (RSV))
Rhinovirus (Rhinovirus)
Rhizopus (Rhizopus)
Rhodococcus (Rhodococcus)
Rickettsia (Rickettsia)
Rotavirus (Rotavirus)
Rubella Virus (Rubella Virus)
Salmonella (Salmonella (all species))
Serratia Marcescens (Serratia
marcescens)
Shigella (Shigella)
Staphylococcus Aureus (Staphylococcus
aureus)
Staphylococcus Coag Negative
(Staphylococcus, coagulase negative)
Streptococcus Not Otherwise Specified
(Staphylococcus, NOS)
Rothia Mucilaginosa (Stomatococcus
mucilaginosis)
Streptococcus (Streptococcus (all
species except Enterococcus))
Streptococcus Pneumoniae
(Streptococcus pneumoniae)
Suspected Atypical Bacteria Infection
(Suspected atypical bacterial infection)
Suspected Bacteria Infection (Suspected
bacterial infection)
Suspected Fungal Infection (Suspected
fungal infection)
Suspected Parasitic Infection (Suspected
parasite infection)
Suspected Viral Infection (Suspected
viral infection)
Toxoplasma (Toxoplasma)
Treponema (Treponema (syphilis))
Vibrio (Vibrio (all species))
Yeast Not Otherwise Specified (Yeast,
NOS)
Zygomycota Not Otherwise Specified
(Zygomycetes, NOS)
Specify the infection organism: (Answer only if
the response to CDE 2934613 is "Other
chlamydia," "Other mycobacterium," "Multiple
bacteria at a single site," "Other bacteria," "Other
Candida," "Other Aspergillus," "Other fungus,"
Other virus," or "Other parasite.")
Date of diagnosis: (Of acute GVHD)
Select the infection organism site: (Do not report
fever in the absence of infection. Report the most
specific site of infection.)
Blood And/or Buffy Coat (Blood / buffy
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coat)
Osteomyelitis (Bone cortex)
Bone Marrow (Bone marrow)
Brain (Brain)
Endocardium Myocardium Pericardium
(Cardiac)
Application Site Catheter (Catheter
insertion or exit site)
Catheter Tip Device Component
(Catheter tip)
Cellulitis (Cellulitis)
Not Otherwise Specified Central Nervous
System (Central nervous system, not
specified)
Not Otherwise Specified Central Venous
Access Catheter (Central venous
catheter, NOS)
Isolation Greater Than Or Equal To
Integer::3 Anatomic Site (Disseminated -
generalized, isolated at 3 or more distinct
sites)
Ear (Ears)
Esophagus (Esophagus)
Eye (Eyes)
Fallopian Tube Uterus Cervix Uteri
(Fallopian tubes, uterus, cervix)
Feces (Feces / stool)
Gallbladder Biliary Tract Pancreas
(Gallbladder and biliary tree, pancreas)
Gastrointestinal Tract Not Otherwise
Specified (Gastrointestinal tract, NOS)
Genital (Genital area)
Genitourinary System Not Otherwise
Specified (Genito-urinary tract, NOS)
Herpes Zoster (Herpes zoster)
Joint (Joints)
Kidney Renal Pelvis Ureter And Bladder
(Kidneys, renal pelvis, ureters and
bladder)
Large Intestine (Large intestine)
Laryngitis And/or Larynx (Laryngitis /
larynx)
Lip (Lips)
Liver (Liver)
Trachea Bronchus And/or Lung (Lower
respiratory tract)
Lymph Node (Lymph nodes)
Meninges And Cerebrospinal Fluid
(Meninges and CSF)
Muscle (Muscle)
Peritoneum (Peritoneum)
Pleural Fluid Pleural Cavity (Pleural
cavity, pleural fluid)
Prostate Gland (Prostate)
Pustular Lesion Or Abscess Skin Rash
(Rash, pustules or abscesses)
Not Otherwise Specified Respiratory
System (Respiratory tract, NOS)
Paranasal Sinus (Sinuses)
Not Otherwise Specified Skin (Skin,
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NOS)
Small Bowel (Small intestine)
Spinal Cord (Spinal cord)
Spleen (Spleen)
Stomach (Stomach)
Testis (Testes)
Tongue Oral Cavity And Oropharynx
(Tongue, oral cavity and oropharynx)
Nasopharynx (Upper airway and
nasopharynx)
Vagina (Vagina)
Infection Part 5 Of 5
Did the recipient develop more than 7 infections?
(Post-HSCT)
No (No)
Yes (Yes)
Are extra pages attached?
No (No)
Yes (Yes)
Organ Function - Pulmonary Function Part
1 Of 10
Did the recipient develop interstitial pneumonitis /
idiopathic pneumonia syndrome? (IPn or ARDS /
IPS. After the start of the preparative regimen to
the date of last contact. Interstitial pneumonitis /
idiopathic pneumonia syndrome is characterized
on chest x-ray by hypoxia and diffuse interstitial
infiltrates not caused by fluid overload. Report
bacterial and fungal pneumonia in Infection
section questions 389-417 in module "Infection
Part 3 of 5," CDE 2795691, and module "Infection
Part 4 of 5.")
No (No)
Yes (Yes)
Organ Function - Pulmonary Function Part
2 Of
Date of diagnosis: (Of acute GVHD)
Were diagnostic tests done? (Other than
radiographic studies)
No (No)
Yes (Yes)
Bronchoalveolar lavage (BAL)
No (No)
Yes (Yes)
Transbronchial biopsy
No (No)
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Yes (Yes)
Open / thorascopic lung biopsy (VATS)
No (No)
Yes (Yes)
Autopsy
No (No)
Yes (Yes)
Other
No (No)
Yes (Yes)
Specify:
Was an organism isolated?
No (No)
Yes (Yes)
Adenovirus
No (No)
Yes (Yes)
Cytomegalovirus (CMV)
No (No)
Yes (Yes)
Herpes simplex (HSV1, HSV2)
No (No)
Yes (Yes)
Human herpes virus type 6 (HHV6)
No (No)
Yes (Yes)
Parainfluenza
No (No)
Yes (Yes)
Respiratory syncytial virus (RSV)
No (No)
Yes (Yes)
Toxoplasma
No (No)
Yes (Yes)
Other virus
No (No)
Yes (Yes)
Specify:
Other organism
No (No)
Yes (Yes)
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Specify:
Did the recipient experience two or more
episodes of IPn / IPS? (After the start of the
preparative regimen to the date of last contact.)
No (No)
Yes (Yes)
Are extra pages attached?
No (No)
Yes (Yes)
Organ Function - Pulmonary Function Part
5 Of 11
Did the recipient develop non-infectious
pulmonary abnormalities? (Other than IPn / IPS /
ARDS. After the start of the preparative regimen
to the date of last contact.)
No (No)
Yes (Yes)
Organ Function - Pulmonary Function Part
4 Of
Did the recipient develop bronchiolitis obliterans?
(After the start of the preparative regimen to the
date of last contact)
No (No)
Yes (Yes)
Date of diagnosis: (Of acute GVHD)
Were diagnostic tests done?
No (No)
Yes (Yes)
Bronchoalveolar lavage (BAL)
No (No)
Yes (Yes)
Transbronchial biopsy
No (No)
Yes (Yes)
Open / thorascopic lung biopsy (VATS)
No (No)
Yes (Yes)
Autopsy
No (No)
Yes (Yes)
Other
No (No)
Yes (Yes)
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Specify:
Organ Function - Pulmonary Function Part
4 Of
Did the recipient develop pulmonary
hemorrhage?
No (No)
Yes (Yes)
Date of diagnosis: (Of acute GVHD)
Were diagnostic tests done?
No (No)
Yes (Yes)
Bronchoalveolar lavage (BAL)
No (No)
Yes (Yes)
Transbronchial biopsy
No (No)
Yes (Yes)
Open / thorascopic lung biopsy (VATS)
No (No)
Yes (Yes)
Autopsy
No (No)
Yes (Yes)
Other
No (No)
Yes (Yes)
Specify:
Organ Function - Pulmonary Function Part
4 Of
Did the recipient develop cryptogenic organizing
pneumonia? (COP)
No (No)
Yes (Yes)
Date of diagnosis: (Of acute GVHD)
Were diagnostic tests done?
No (No)
Yes (Yes)
Bronchoalveolar lavage (BAL)
No (No)
Yes (Yes)
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Transbronchial biopsy
No (No)
Yes (Yes)
Open / thorascopic lung biopsy (VATS)
No (No)
Yes (Yes)
Autopsy
No (No)
Yes (Yes)
Other
No (No)
Yes (Yes)
Specify:
Organ Function - Pulmonary Function Part
11 Of 11
Did the recipient develop any other non-infectious
pulmonary abnormalities?
No (No)
Yes (Yes)
Specify:
Did the recipient receive endotracheal intubation
or mechanical ventilation? (Post-HSCT)
No (No)
Yes (Yes)
Organ Function - Liver Function Part 1 Of
2
Did the recipient develop non-infectious liver
toxicity? (Excluding GVHD. After the start of the
preparative regimen to the date of last contact)
No (No)
Yes (Yes)
Date of diagnosis: (Of acute GVHD)
Cirrhosis
No (No)
Yes (Yes)
Veno-occlusive disease / sinusodial obstruction
syndrome (VOD / SOS)
No (No)
Yes (Yes)
Did the recipient receive treatment for VOD?
No (No)
Yes (Yes)
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Specify:
Did VOD resolve? (By day 100)
No (No)
Yes (Yes)
Maximum bilirubin: (In first 100 days)
Other
No (No)
Yes (Yes)
Specify:
Unknown
No (No)
Yes (Yes)
Organ Function - Liver Function Part 2 Of
2
Specify diagnosis of liver toxicity by clinical signs
and symptoms / evaluation:
Ascites (Ascites)
Autopsy (Autopsy)
Greater Than Integer::2.0 Milligram
Bilirubin (Bilirubin greater than 2.0 mg)
Biopsy (Biopsy)
Elevated Hepatic Venous Pressure
Gradient (Elevated hepatic venous
pressure gradient)
Elevated Liver Enzyme (Elevated liver
enzymes)
Hepatomegaly (Hepatomegaly)
Other (Other)
Right Upper Quadrant Pain Or
Tenderness (Right upper quadrant pain
or tenderness)
Doppler Echocardiography And/or
Ultrasound Imaging (Ultrasonography /
doppler)
Greater Than Integer::5 Percentage
Weight Gain (Weight gain greater than 5
percent)
Was the diagnosis of liver toxicity determined by
clinical signs and symptoms / evaluation:
No (No)
Yes (Yes)
Specify: (Answer only if the response to CDE
2801066 is "Other")
Organ Function - Other Organ Impairment
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/ Disorder Paer 1 Of 2
Has the recipient developed any other clinically
significant organ impairment or disorder? (After
the start of the preparative regimen to the date of
last contact.)
No (No)
Yes (Yes)
Organ Function - Other Organ Impairment
/ Disorder Part 2 Of 2
Specify impairment / disorder:
A Condition In Which The Poor Blood
Supply To An Area Of Bone Leads To
Bone Death. (Avascular necrosis)
Cataract (Cataracts)
Congestive Heart Failure (Congestive
heart failure)
Diabetes Mellitus And/or Hyperglycemia
(Diabetes/hyperglycemia)
Gonadal Disorder And/or Infertility
Required Testosterone Or Estrogen
Replacement Therapy (Gonadal
dysfunction/infertility requiring hormone
replacement)
Growth Hormone Deficit And/or Growth
Disturbance (Growth hormone
deficiency/growth disturbance)
Hemorrhage Cystitis And/or Hematuria
(Hemorraghic cystitis/hematuria requiring
medical intervention)
Hypothyroidism (Hypothyroidism)
Myocardial Infarction (Myocardial
infarction)
Other (Other)
Pancreatitis (Pancreatitis)
Post Graft Thrombotic Microangiopathy
Hemolytic Uremic Syndrome Or
Similarity (Post-transplant
microangiopathy-thrombotic
thrombocytopenic purpura (TTP),
hemolytic uremic syndrome (HUS), or
similar syndrome)
Renal Failure Severe Need Dialysis
(Renal failure severe enough to warrant
dialysis)
Cerebrovascular Accident And/or
Seizure (Stroke/seizure)
Did a particular type of organ impairment /
disorder occur?
No (No)
Yes (Yes)
Date of diagnosis: (Of acute GVHD)
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Did the recipient receive plasmapheresis?
(Answer only if the response to CDE 2797538 is
"Post-transplant microangiopathy-thrombotic
thrombocytopenic purpura TTP, hemolytic uremic
syndrome HUS, or similar syndrome")
No (No)
Yes (Yes)
Did the recipient receive dialysis? (Answer only if
the response to CDE 2797538 is "Renal failure
severe enough to warrant dialysis")
No (No)
Yes (Yes)
Specify impairment / disorder: (Answer only if the
response to CDE 2797538 is "Other")
Organ Function - New Malignancy
Did a new malignancy, lymphoproliferative or
myeloproliferative disorder appear that is different
from the disease for which the HSCT was
performed?
No (No)
Yes (Yes)
New Malignancy, Lymphoproliferative Or
Myeloproliferative Disorder
Specify which new disease(s) occurred:
Acute Myeloid Leukemia (Acute myeloid
leukemia (AML / ANLL))
Breast Carcinoma (Breast cancer)
Central Nervous System Neoplasm
(Central nervous system (CNS)
malignancy (glioblastoma, astrocytoma))
Malignant Gastrointestinal Neoplasm
(Gastrointestinal malignancy (colon,
rectum, stomach, pancreas, intestine))
Genitourinary System Malignant
Neoplasm (Genitourinary malignancy
(kidney, bladder, ovary, testicle, genitalia,
uterus, cervix))
Hodgkin's Lymphoma (Hodgkin disease)
Lung Carcinoma (Lung cancer)
Lymphoma Or Lymphoproliferative
Disorder (Lymphoma or
lymphoproliferative disease)
Melanoma (Melanoma)
Myelodysplastic/myeloproliferative
Disease (Myelodysplasia (MDS),
myeloproliferative (MPS) disorder)
Oropharyngeal Carcinoma
(Oropharyngeal cancer (tongue, buccal
mucosa))
Other Leukemia (Other leukemia
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including ALL)
Other Malignant Neoplasm (Other
malignancy)
Other Malignant Skin Neoplasm (Other
skin malignancy (basal cell, squamous))
Clonality Cytogenetic Abnormality
(Related by descent from clonal
cytogenetic abnormality without leukemia
or MDS)
Sarcoma (Sarcoma)
Thyroid Gland Carcinoma (Thyroid
cancer)
Did a new malignancy, lymphoproliferative or
myeloproliferative disorder appear that is different
from the disease for which the HSCT was
performed?
No (No)
Yes (Yes)
Date of diagnosis: (Of acute GVHD)
Is the tumor EBV positive? (Answer only if the
response to CDE 2677021 is "Lymphoma or
lymphoproliferative disease.")
No (No)
Yes (Yes)
Specify the new malignancy, lymphoproliferative
or myeloproliferative disorder: (Answer only if the
response to CDE 2677021 is "Other leukemia,
including ALL," "Other skin malignancy basal cell,
squamous," or "Other new malignancy.")
Organ Function - New Malignancy Part 3
Of 3
Is a pathology / autopsy report or other
documentation attached?
No (No)
Yes (Yes)
Functional Status
Was the recipient discharged from the hospital
after HSCT?
No (No)
Not Applicable (Not Applicable)
Yes (Yes)
Date first discharged from hospital post-HSCT:
Total number of inpatient days (day 0 to day 100)
in first 100 days post-HSCT
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Which scale was used to measure/report the
functional status? (If the recipient is 16 years of
age or older, complete the Karnofsky Scale. If the
recipient is younger than 16 years of age,
complete the Lansky Scale. If the recipient has
died, skip this question.)
Karnofsky Performance Status
(Karnofsky)
Lansky Play-performance Status
(Lansky)
Karnofsky Performance Status Score (On the
date of last actual contact. If the recipient is 16
years of age or older, complete the Karnofsky
Scale.)
Moribund, Fatal Processes Progressing
Rapidly (10)
Normal, No Complaints, No Evidence Of
Disease (100)
Very Sick, Hospitalization Indicated.
Death Not Imminent (20)
Severely Disabled, Hospitalization
Indicated. Death Not Imminent (30)
Disabled, Requires Special Care And
Assistance (40)
Requires Considerable Assistance And
Frequent Medical Care (50)
Requires Occasional Assistance, But Is
Able To Care For Most Of His/her Needs
(60)
Cares For Self, Unable To Carry On
Normal Activity Or To Do Active Work
(70)
Normal Activity With Effort; Some Signs
Or Symptoms Of Disease (80)
Able To Carry On Normal Activity; Minor
Signs Or Symptoms Of Disease (90)
Lansky Performance Status Score (On the date
of last actual contact. If the recipient is younger
than 16 years of age, complete the Lansky
Scale.)
No Play; Does Not Get Out Of Bed. (10)
Fully Active, Normal (100)
Often Sleeping; Play Entirely Limited To
Very Passive Activities (20)
In Bed; Needs Assistance Even For
Quiet Play. (30)
Mostly In Bed; Participates In Quiet
Activities. (40)
Gets Dressed, But Lies Around Much Of
The Day; No Active Play, Able To
Participate In All Quiet Play And
Activities. (50)
Up And Around, But Minimal Active Play;
Keeps Busy With Quieter Activities. (60)
Both Greater Restriction Of And Less
Time Spent In Play Activity (70)
Active, But Tires More Quickly (80)
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Minor Restrictions In Physically
Strenuous Activity (90)
Subsequent Hsct
Date of subsequent HSCT:
Was the subsequent HSCT performed at a
different institution?
No (No)
Yes (Yes)
Name: (Of the institution that performed the
subsequent HSCT)
City: (Of the institution that performed the
subsequent HSCT)
State / Country: (Of the institution that performed
the subsequent HSCT)
What was the indication for the subsequent
HSCT? (Subsequent autologous HSCTs
performed for engraftment reasons "No
hematopoietic recovery," "Partial hematopoietic
recovery," and "Graft failure / rejection after
achieving initial hematopoietic recovery" do not
require separate report forms to be completed.
All other subsequent HSCTs will require a
separate follow-up report form completed for
each infusion.)
Loss Or Reduced Donor Chimerism
(Declining chimerism)
Graft Failure Post First Hematopoietic
Recovery (Graft failure / rejection after
achieving initial hematopoietic recovery)
New Malignant Neoplasm (New
malignancy)
Hematopoietic Stem Cell No Recovery
(No hematopoietic recovery)
Other (Other)
Hematopoietic Stem Cell Partial
Recovery (Partial hematopoietic
recovery)
Persistent Primary Disease Or Disorder
(Persistent primary disease)
Hematopoietic Stem Cell Second Plan
Transplantation (Planned second HSCT,
per protocol)
Recurrent Primary Disease Or Disorder
(Recurrent primary disease)
Mixed Stable Chimerism (Stable, mixed
chimerism)
Specify:
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Source of HSCs:
Related Allogenic (Allogeneic, related)
Unrelated Allogenic (Allogeneic,
unrelated)
Autologous (Autologous)
Was the same donor used?
No (No)
Yes (Yes)
Specify:
Cryopreservation Original Donor Bone
Marrow (Cryopreserved original donor
bone marrow)
Cryopreservation Original Donor
Mobilized Peripheral Blood Stem Cell
(Cryopreserved original donor mobilized
peripheral blood stem cells)
Tissue, Fresh Original Donor National
Marrow Donor Program Bone Marrow
(Fresh, original NMDP donor bone
marrow)
Tissue, Fresh Original Donor National
Marrow Donor Program Mobilized
Peripheral Blood Stem Cell (Fresh,
original NMDP donor mobilized
peripheral blood stem cells)
Tissue, Fresh Original Negation National
Marrow Donor Program Donor Bone
Marrow (Fresh, original non-NMDP
donor bone marrow)
Tissue, Fresh Original Negation National
Marrow Donor Program Donor Mobilized
Peripheral Blood Stem Cell (Fresh,
original non-NMDP donor mobilized
peripheral blood stem cells)
Tissue, Fresh Next National Marrow
Donor Program Donor Bone Marrow
(Fresh, subsequent NMDP donor bone
marrow)
Tissue, Fresh Next National Marrow
Donor Program Donor Mobilized
Peripheral Blood Stem Cell (Fresh,
subsequent NMDP donor mobilized
peripheral blood stem cells)
Tissue, Fresh Next Negation National
Marrow Donor Program Donor Bone
Marrow (Fresh, subsequent non-NMDP
donor bone marrow)
Tissue, Fresh Next Negation National
Marrow Donor Program Donor Mobilized
Peripheral Blood Stem Cell (Fresh,
subsequent non-NMDP donor mobilized
peripheral blood stem cells)
National Marrow Donor Program
Umbilical Cord Blood (NMDP cord blood)
Negation National Marrow Donor
Program Umbilical Cord Blood (Non-
NMDP cord blood)
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Donor Cellular Infusion (dci) Information
Date of DCI:
Organism
Acinetobacter (Acinetobacter)
Actinomyces (Actinomyces)
Adenovirus (Adenovirus)
Aspergillus Flavus (Aspergillus flavus)
Aspergillus Fumigatus (Aspergillus
fumigatus)
Aspergillus Niger (Aspergillus niger)
Aspergillus Not Otherwise Specified
(Aspergillus, NOS)
Bacillus (Bacillus)
Bacteroides (Bacteroides (gracillis,
uniformis, vulgaris, other species))
Bordetella Pertussis (Bordetella
pertussis (whooping cough))
Borrelia Burgdorferi (Borrelia (lyme
disease))
Moraxella Catarrhalis (Branhamella or
Moraxella catarrhalis (other species))
Campylobacter (Campylobacter (all
species))
Candida Glabrata (Candida (Torulopsis)
glabrata)
Candida Albicans (Candida albicans)
Pichia Guilliermondii (Candida
guillermondi)
Issatchenkia Orientalis (Candida krusei)
Clavispora Lusitaniae (Candida
lusitaniae)
Candida Parapsilosis (Candida
parapsilosis)
Candida Tropicalis (Candida tropicalis)
Candida Not Otherwise Specified
(Candida, NOS)
Capnocytophaga (Capnocytophaga)
Chlamydophila Pneumoniae (Chlamydia
(pneumoniae))
Chlamydia Not Otherwise Specified
(Chlamydia, NOS)
Citrobacter (Citrobacter (freundii, other
species))
Clostridium (Clostridium (all species
except difficile))
Clostridium Difficile (Clostridium difficile)
Corynebacterium (Corynebacterium (all
non-diptheria species))
Corynebacterium Jeikeium
(Corynebacterium (jeikeium))
Coxiella (Coxiella)
Cryptococcosis (Cryptococcosus
species)
Cryptosporidium (Cryptosporidium)
Cytomegalovirus (Cytomegalovirus)
Enterobacter (Enterobacter)
Enterococcus (Enterococcus (all
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species))
Vancomycin Resistant Enterococcus
(Enterococcus, vancomycin resistant
(VRE))
Enterovirus (Enterovirus)
Epstein-barr Virus (Epstein-Barr Virus)
Escherichia Coli (Escherichia (also E.
coli))
Pseudomonas Oryzihabitans
(Flavimonas oryzihabitans)
Flavobacterium (Flavobacterium)
Fusarium (Fusarium species)
Fusobacterium (Fusobacterium)
Giardia (Giardia)
Haemophilus (Haemophilus (all species,
including influenzae))
Helicobacter Pylori (Helicobacter pylori)
Hepatitis A Virus (Hepatitis A Virus)
Hepatitis B Virus (Hepatitis B Virus)
Hepatitis C Virus (Hepatitis C Virus)
Herpes Simplex Virus (Herpes Simplex
Virus)
Herpes Zoster (Herpes Zoster)
Histoplasmosis (Histoplasmosis)
Human Herpesvirus 6 (Human
Herpesvirus 6)
Human Immunodeficiency Virus 1
(Human Immunodeficiency Virus 1)
Human Papillomavirus (Human
Papillomavirus)
Influenza A Virus (Influenza A Virus)
Influenza B Virus (Influenza B Virus)
Other Influenza (Influenza, NOS)
Klebsiella (Klebsiella)
Lactobacillus (Lactobacillus (bulgaricus,
acidophilus, other species))
Legionella (Legionella)
Leptospira (Leptospira)
C76356 (Leptotrichia buccalis)
Leuconostoc (Leuconostoc (all species))
Listeria (Listeria)
Measles Virus (Measles Virus)
Methylobacterium (Methylobacterium)
Micrococcus Not Otherwise Specified
(Micrococcus, NOS)
Zygomycosis (Mucormycosis)
Multiple Bacteria (Multiple bacteria at a
single site)
Mumps Virus (Mumps Virus)
Mycobacterium Avium Complex
(Mycobacterium avium - intracellulare
(MAC, MAI))
Mycobacterium Species (Mycobacterium
species (cheloneae, fortuitum,
haemophilum, kansasii, mucogenicum))
Mycobacterium Tuberculosis
(Mycobacterium tuberculosis
(tuberculosis, Koch bacillus))
Mycobacterium Not Otherwise Specified
(Mycobacterium, NOS)
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Mycoplasma (Mycoplasma)
Neisseria (Neisseria (gonorrhoeae,
meningitidis, other species))
Not Identified Organism (No organism
identified)
Nocardia (Nocardia)
Other Aspergillus (Other Aspergillus)
Other Bacteria (Other bacteria)
Other Candida (Other Candida)
Other Chlamydia (Other chlamydia)
Other Fungi (Other fungus)
Other Mycobacterium (Other
mycobacterium)
Other Parasite (Other parasite)
Other Virus (Other Virus)
Parainfluenza Virus (Parainfluenza Virus)
Pasteurella Multocida (Pasteurella
multocida)
Pneumocystis Pneumonia
(Pneumocystis (PCP / PJP))
Polyomavirus (Polyomavirus)
Progressive Multifocal
Leukoencephalopathy (Progressive
Multifocal Leukoencephalopathy)
Propionibacterium Acnes
(Propionibacterium (acnes, avidum,
granulosum, other species))
Proteus (Proteus)
Pseudomonas (Pseudomonas (all
species except cepacia & maltophilia))
Burkholderia Cepacia (Pseudomonas or
Burkholder cepacia)
Stenotrophomonas Maltophilia
(Pseudomonas or Stenotrophomonas or
Xanthomonas maltophilia)
Respiratory Syncytial Virus (Respiratory
Syncytial Virus (RSV))
Rhinovirus (Rhinovirus)
Rhizopus (Rhizopus)
Rhodococcus (Rhodococcus)
Rickettsia (Rickettsia)
Rotavirus (Rotavirus)
Rubella Virus (Rubella Virus)
Salmonella (Salmonella (all species))
Serratia Marcescens (Serratia
marcescens)
Shigella (Shigella)
Staphylococcus Aureus (Staphylococcus
aureus)
Staphylococcus Coag Negative
(Staphylococcus, coagulase negative)
Streptococcus Not Otherwise Specified
(Staphylococcus, NOS)
Rothia Mucilaginosa (Stomatococcus
mucilaginosis)
Streptococcus (Streptococcus (all
species except Enterococcus))
Streptococcus Pneumoniae
(Streptococcus pneumoniae)
Suspected Atypical Bacteria Infection
44 / 54
Follow-Up - 2100 Revision 1 - 100 Days Post-HSCT Data - 3057709v2.0
(Suspected atypical bacterial infection)
Suspected Bacteria Infection (Suspected
bacterial infection)
Suspected Fungal Infection (Suspected
fungal infection)
Suspected Parasitic Infection (Suspected
parasite infection)
Suspected Viral Infection (Suspected
viral infection)
Toxoplasma (Toxoplasma)
Treponema (Treponema (syphilis))
Vibrio (Vibrio (all species))
Yeast Not Otherwise Specified (Yeast,
NOS)
Zygomycota Not Otherwise Specified
(Zygomycetes, NOS)
Specify the number of cell infusions given within
10 weeks of the DCI
Was the DCI infusion performed at a different
institution?
No (No)
Yes (Yes)
Name: (Of the institution that performed the DCI)
City: (Of the institution that performed the DCI)
Karnofsky / Lansky score (At diagnosis of chronic
GVHD. If the recipient is 16 years of age or older,
complete the Karnofsky Scale. If the recipient is
younger than 16 years of age, complete the
Lansky Scale.)
Karnofsky Scale - Moribund, Fatal
Process Progressing Rapidly; Lansky
Scale - Completely Disabled, Not Even
Passive Play. (10)
Karnofsky Scale - Normal, No
Complaints, No Evidence Of Disease;
Lansky Scale - Fully Active. (100)
Karnofsky Scale - Very Sick,
Hospitalization Necessary; Lansky Scale
- Limited To Very Passive Activity
Initiated By Others (e.g., Tv) (20)
Karnofsky Scale - Severely Disabled,
Hospitalization Indicated, Although
Death Not Imminent. Lansky Scale -
Needs Considerable Assistance For
Quiet Activity. (30)
Karnofsky Scale - Disabled, Requires
Special Care And Assistance. Lansky
Scale - Able To Initiate Quiet Activities.
(40)
Karnofsky Scale - Requires
Considerable Assistance And Frequent
Medical Care; Lansky Scale -
Considerable Assistance Required For
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Any Active Play; Fully Able To Engage In
Quiet Play. (50)
Karnofsky Scale - Requires Occasional
Assistance, But Is Able To Care For Most
Needs; Lansky Scale - Ambulatory Up To
50r Of Time, Limited Active Play With
Assistance / Supervision. (60)
Karnofsky Scale - Cares For Self, Unable
To Carry On Normal Activity Or To Do
Active Work.; Lansky Score - Both
Greater Restrictions Of, And Less Time
Spent In, Active Play. (70)
Karnofsky Scale - Normal Activity With
Effort; Lansky Scale - Restricted In
Strenuous Play, Tires More Easily,
Otherwise Active. (80)
Karnofsky Scale - Able To Carry On
Normal Activity; Lansky Scale - Minor
Restriction In Physically Strenuous Play.
(90)
State / Country: (Of the institution that performed
the DCI)
Indication for DCI
Loss Reduced Donor T-lymphocyte
Chimerism (Loss of / decreased donor T-
cell chimerism)
Other (Other)
Part First Hematopoietic Stem Cell
Transplantation Protocol Plan (Planned
as part of initial HSCT protocol)
Mixed Stable Chimerism (Stable, mixed
chimerism)
Therapeutic Procedure Graft Versus
Host Disease (Treatment for GVHD)
Post-transplant Lymphoproliferative
Disorder Epstein-barr Virus Therapeutic
Procedure (Treatment for PTLD, EBV
lymphoma)
Therapeutic Procedure Recurrent
Disease Persistent Pd Disease Or
Disorder (Treatment for relapsed,
persistent or progressive disease)
Therapeutic Procedure Viral Infection
(Viral infection)
Molecular (Method of disease detection)
Negative Finding (Negative)
Not Done Unknown (Not done /
Unknown)
Positive Finding (Positive)
Date: (If the result was positive report the first
date the disease was detected; if the result was
negative report the last date the method was
used prior to DCI.)
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Cytogenetic (Method of disease detection)
Negative Finding (Negative)
Not Done Unknown (Not done /
Unknown)
Positive Finding (Positive)
Date: (If the result was positive report the first
date the disease was detected; if the result was
negative report the last date the method was
used prior to DCI.)
Clinical evidence / hematologic (Method of
disease detection)
Negative Finding (Negative)
Not Done Unknown (Not done /
Unknown)
Positive Finding (Positive)
Date: (If the result was positive report the first
date the disease was detected; if the result was
negative report the last date the method was
used prior to DCI.)
Was chemotherapy used to attempt to induce
disease response? (Prior to the DCI)
No (No)
Yes (Yes)
Date of administration of final chemotherapy dose
Date documented:
Specify indication:
What was the recipient's disease status?
(Immediately prior to the DCI)
First Complete Remission (First
complete remission)
Negation Evaluation (Not evaluated post-
HSCT)
Persistent Disease Or Disorder
(Persistent disease)
Recurrent Disease Or Disease
Progression (Relapse or progression)
Therapeutic Procedure Induction
Complete Remission (Therapy-induced
complete remission after persistent
disease or relapse post-HSCT)
Date the disease status was established: (Prior to
the DCI)
Collected at the time of PBSC mobilization and
collection (DCI source)
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No (No)
Yes (Yes)
Negative fraction of CD34 selected PBSC (DCI
source)
No (No)
Yes (Yes)
Negative fraction of CD34 selected bone marrow
(DCI source)
No (No)
Yes (Yes)
Apheresis at a different time than collection of
PBSC used for allogeneic HSCT (DCI source)
No (No)
Yes (Yes)
Date of apheresis:
Isolated from a unit(s) of whole blood (DCI
source)
No (No)
Yes (Yes)
Specify number of units:
Were the donor cells collected by leukapheresis?
No (No)
Yes (Yes)
Date of first leukapheresis:
Date of last leukapheresis:
Number of leukaphereses:
Did the donor receive treatment to enhance cell
collection prior to donation?
No (No)
Yes (Yes)
Growth factor(s)
No (No)
Yes (Yes)
G-CSF
No (No)
Yes (Yes)
GM-CSF
No (No)
Yes (Yes)
Other agent
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No (No)
Yes (Yes)
Specify agent:
Other treatment
No (No)
Yes (Yes)
Specify treatment:
CD3+ cells: (For each DCI given, report the total
number of cells infused. If the cells were
cryopreserved, report the totals after processing,
but before cryopreservation.)
CD3+ cells exponent value:
What is the reason for the CD3+ cells missing
value?
Negation Test (Not tested)
CD4+ cells: (For each DCI given, report the total
number of cells infused. If the cells were
cryopreserved, report the totals after processing,
but before cryopreservation.)
CD4+ cells exponent value:
What is the reason for the CD4+ cells missing
value?
Negation Test (Not tested)
CD8+ cells: (For each DCI given, report the total
number of cells infused. If the cells were
cryopreserved, report the totals after processing,
but before cryopreservation.)
CD8+ cells exponent value:
What is the reason for the CD8+ cells missing
value?
Negation Test (Not tested)
CD34+ cells: (For each DCI given, report the total
number of cells infused. If the cells were
cryopreserved, report the totals after processing,
but before cryopreservation.)
CD34+ cells exponent value:
What is the reason for the CD34+ cells missing
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value?
Negation Test (Not tested)
NK cells: (For each DCI given, report the total
number of cells infused. If the cells were
cryopreserved, report the totals after processing,
but before cryopreservation.)
NK cells exponent value:
What is the reason for the NK cells missing
value?
Negation Test (Not tested)
Nucleated cells: (For each DCI given, report the
total number of cells infused. If the cells were
cryopreserved, report the totals after processing,
but before cryopreservation.)
Nucleated cells exponent value:
What is the reason for the nucleated cells missing
value?
Negation Test (Not tested)
Mesenchymal cells: (For each DCI given, report
the total number of cells infused. If the cells were
cryopreserved, report the totals after processing,
but before cryopreservation.)
Mesenchymal cells exponent value:
What is the reason for the mesenchymal cells
missing value?
Negation Test (Not tested)
Were dendritic cells infused?
No (No)
Yes (Yes)
Were fibroblasts infused?
No (No)
Yes (Yes)
Were any other cell types infused? (Not including
cell types reported in questions 620-628 CDEs
2760303, 2760372, 2772153, 2760286, 2771962,
2760234, 2771985, 2614541, and 2680329.)
No (No)
Yes (Yes)
Specify cell type(s):
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Were the cells cryopreserved prior to infusion?
No (No)
Yes (Yes)
Specify portion of cells cryopreserved prior to
infusion
Entire Hematopoietic Stem Cell
Collection (Entire product)
Part Hematopoietic Stem Cell Collection
(Portion of product)
Was the product manipulated prior to infusion?
No (No)
Yes (Yes)
Specify portion manipulated:
Entire Hematopoietic Stem Cell
Collection (Entire product)
Part Hematopoietic Stem Cell Collection
(Portion of product)
ABO incompatibility
No (No)
Yes (Yes)
Buffy coat preparation
No (No)
Yes (Yes)
Cell separator (i.e., COBE Spectra)
No (No)
Yes (Yes)
Density gradient separation (i.e., Ficoll)
No (No)
Yes (Yes)
Plasma removal
No (No)
Yes (Yes)
Sedimentation (i.e., Hetastarch)
No (No)
Yes (Yes)
Other
No (No)
Yes (Yes)
Specify:
Dextran-albumin wash
No (No)
Yes (Yes)
Ex-vivo expansion
No (No)
Yes (Yes)
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Genetic manipulation (Gene transfer /
transduction)
No (No)
Yes (Yes)
Volume reduction
No (No)
Yes (Yes)
CD34+ selection
No (No)
Yes (Yes)
Specify manufacturer:
Clinimax Cell Selection System
(CliniMACS / CliniMax)
Isolex Cell Selection System (Isolex)
Other (Other)
Specify:
T-cell depletion
No (No)
Yes (Yes)
Antibody affinity column
No (No)
Yes (Yes)
Antibody coated plates
No (No)
Yes (Yes)
Antibody coated plates and soybean lectin
No (No)
Yes (Yes)
Antibody and complement
No (No)
Yes (Yes)
Antibody and toxin
No (No)
Yes (Yes)
Immunomagnetic beads
No (No)
Yes (Yes)
Elutriation
No (No)
Yes (Yes)
CD34 affinity column plus sheep red blood cell
rosetting
No (No)
Yes (Yes)
Other
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No (No)
Yes (Yes)
Specify
Other manipulation
No (No)
Yes (Yes)
Specify:
Were antibodies used during graft manipulation?
No (No)
Yes (Yes)
Anti CD2
No (No)
Yes (Yes)
Anti CD4
No (No)
Yes (Yes)
Anti CD5
No (No)
Yes (Yes)
Anti CD6
No (No)
Yes (Yes)
Anti CD7
No (No)
Yes (Yes)
Anti CD8
No (No)
Yes (Yes)
Anti CD34
No (No)
Yes (Yes)
Anti TCR alpha / beta (T10-B9)
No (No)
Yes (Yes)
OKT-3
No (No)
Yes (Yes)
Other CD3
No (No)
Yes (Yes)
Specify
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Anti CD52
No (No)
Yes (Yes)
Campath-NOS
No (No)
Yes (Yes)
Campath-1G
No (No)
Yes (Yes)
Campath-1H
No (No)
Yes (Yes)
Other antibody
No (No)
Yes (Yes)
Specify:
Donor Cellular Infusion (dci) Information
Part 2 Of 2
First Name
Last Name:
Telephone number:
Fax number:
E-mail address:
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Infection NCT00513526 On-Study - AMC-052 History
of AIDS Defining Disease Form (F03) - 2677022v1.0
Infection NCT00513526 On-Study - AMC-052 History of
AIDS Defining Disease Form (F03) - 2677022v1.0
All rights reserved. Please visit https://medical-data-
models.org/forms/1754
AMC-052 History of AIDS Defining
Disease Form (F03)
Unnamed1
Date of Evaluation (mm/dd/yyyy)
History of opportunistic diseases and
predisposing disease
No (No)
Yes (Yes)
Disease Type
Candidiasis Of Bronchi, Trachea Or
Lungs (Candidiasis of bronchi, trachea or
lungs)
Candidiasis, Esophageal (Candidiasis,
esophageal)
Cervical Cancer (Cervical cancer,
invasive)
Cmv Other Than Liver, Spleen Or Nodes,
Onset At Age >1month (CMV other than
liver, spleen or nodes, onset at age
>1month)
Cmv Retinitis (CMV retinitis)
Coccidioidomycosis, Disseminated Or
Extrapulmonary (Coccidioidomycosis,
disseminated or extrapulmonary)
Cryptococcosis (Cryptococcosis,
extrapulmonary)
Cryptosporidiosis, Chronic Intestinal
(Cryptosporidiosis, chronic intestinal)
Encephalopathy (Encephalopathy, HIV-
related)
Herpes Simplex: Chronic Ulcers (> 1
Month's Duration) Or Bronchitis,
Pneumonitis Or Esophagitis (onset At
Age > 1 Month) (Herpes simplex: chronic
ulcers (> 1 month's duration) or
bronchitis, pneumonitis or esophagitis
(onset at age > 1 month))
Histoplasmosis, Disseminated Or
Extrapulmonary (Histoplasmosis,
disseminated or extrapulmonary)
Isosporiasis, Chronic Intestinal (> 1 Mon)
(Isosporiasis, chronic intestinal (> 1
mon))
Kaposi's Sarcoma Aids Related
(Kaposi's sarcoma)
Lymphoma, Primary, Of Brain
(Lymphoma, primary, of brain)
Non-hodgkin's Lymphoma (Lymphoma,
systemic non-Hodgkin's)
Mycobacterium Avium Complex Or
Mycobacterium Kansasii Disseminated
Or Extrapulmonary (Mycobacterium
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avium complex or Mycobacterium
kansasii disseminated or
extrapulmonary)
Mycobacterium Tuberculosis Of Any Site,
Pulmonary, Disseminated Or
Extrapulmonary (Mycobacterium
tuberculosis of any site, pulmonary,
disseminated or extrapulmonary)
Mycobacterium, Other Species Or
Unidentified Species, Disseminated Or
Extrapulmonary (Mycobacterium, other
species or unidentified species,
disseminated or extrapulmonary)
Pneumocystis Jirovecii Pneumonia
(Pneumocystis jirovecii pneumonia)
Pneumonia (Pneumonia, recurrent)
Progressive Multifocal
Leukoencephalopathy (pml) (Progressive
multifocal leukoencephalopathy)
Salmonella Septicemia, Recurrent
(Salmonella septicemia, recurrent)
Toxoplasmosis Of The Brain, Onset At
Age >1month (Toxoplasmosis of the
brain, onset at age >1month)
Wasting Syndrome, Due To Hiv (Wasting
syndrome, due to HIV)
Disease status (Please select the disease status
of the diseases listed)
Active (Currently active)
Present (Ever present)
Never Present (Never present)
Unnamed2
Comments
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Infection NCT00513526 Lab - AMC-052 HIV
T-Cell Laboratory Values (F24) - 2676697v1.0
Infection NCT00513526 Lab - AMC-052 HIV T-Cell
Laboratory Values (F24) - 2676697v1.0
All rights reserved. Please visit https://medical-data-
models.org/forms/1767
AMC-052 HIV T-Cell Laboratory
Values (F24)
Unnamed1
Visit number
Sequence number
Unnamed2
Date of Evaluation (mm/dd/yyyy)
T-cell Laboratory Values
T-Helper CD4+ %
T-Helper CD4+ absolute count
T-Suppressor CD8+ %
T-Suppressor CD8+ absolute count
Other, specify
Percent Positive Lymphocytes
Absolute Count
Comments
Comments
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Infection NCT00513526 Lab - AMC-052 Cytology Result
Form - 2676560v1.0
All rights reserved. Please visit https://medical-data-
models.org/forms/1785
AMC-052 Cytology Result Form
Unnamed1
Date anal cytology obtained
Swab used
Cytobrush (Cytobrush)
Dacron Swab (Dacron swab)
Anal cytology result
Asc-h (ASC-H)
Ascus (ASCUS)
High Grade Sil (High grade SIL)
Invasive Cancer (Invasive cancer)
Low Grade Sil (Low grade SIL)
Normal (Normal)
Unevaluable (Unevaluable)
Unnamed2
Comments
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Infection NCT00513526 Lab - AMC-052 HIV Viral Load
Form (F40) - 2676767v1.0
All rights reserved. Please visit https://medical-data-
models.org/forms/1788
AMC-052 HIV Viral Load Form (F40)
Unnamed1
Visit number
Unnamed2
Results of HIV viral load assay  (Enter results
from right to left.)
Equal To (Equal to (=))
Greater Than (>) (Greater than (>))
Less Than (Less than (<))
Undetectable (Undetectable)
HIV viral load value
Method of detection
Abbott Realtime Hiv-1 Assay (Abbott
RealTime HIV-1 assay)
Cobas Ampliprep/taqman Hiv-1 Assay
(COBAS AmpliPrep/TAQMAN HIV-1
assay)
Other (Other)
Roche Amplicor Monitor Assay (Roche
Amplicor Monitor Assay)
Versant Hiv-1 Rna Assay By Branched
Dna (Versant HIV-1 RNA assay by
branched DNA)
Other, specify
HIV viral load assay type
Standard (Standard)
Ultra (Ultra)
Limits of detection (Copies/mL)
Lab Facility Name (Testing Laboratory
information)
Comments
Comments
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T-Cell Laboratory Values Form (F24) - 2933243v1.0
Kaposi's Sarcoma NCT00686842 Lab - AMC-059 HIV T-
Cell Laboratory Values Form (F24) - 2933243v1.0
All rights reserved. Please visit https://medical-data-
models.org/forms/1797
AMC-059 HIV T-Cell Laboratory
Values Form (F24)
Unnamed1
Visit number
Sequence number
Unnamed2
Date of Evaluation (mm/dd/yyyy)
T-cell Laboratory Values
T-Helper CD4+ %
T-Helper CD4+ absolute count
Other, specify
Percent Positive Lymphocytes
Absolute Count
Comments
Comments
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Infection NCT00513526 Pathology - AMC-052 AIDS and Cancer
Specimen Resource (ACSR) Procurement Form (F37) - 2676606v1.0
Infection NCT00513526 Pathology - AMC-052 AIDS and
Cancer Specimen Resource (ACSR) Procurement Form
(F37) - 2676606v1.0
All rights reserved. Please visit https://medical-data-
models.org/forms/1804
AMC-052 AIDS and Cancer
Specimen Resource (ACSR)
Procurement Form (F37)
Unnamed1
Visit number
Unnamed2
Date Specimen Obtained (mm/dd/yyyy)
Date Specimen Obtained (mm/dd/yyyy)
Specimen(s) obtained for donation to ACSR
No (No)
Yes (Yes)
Specimen Type (check all that apply)
Peripheral Blood (Blood)
Other (Other)
Pbmc (peripheral Blood Mononuclear
Cells) (PBMC)
Plasma (Plasma)
Serum (Serum)
Tissue (Tissue)
Other specify
ACSR site the specimen(s) shipped to
Gwu (GWU)
Jhu (JHU)
Osu (OSU)
Other (Other)
Suny/hscb (SUNY/HSCB)
Ucla (UCLA)
Ucsf (UCSF)
Other, specify
If specimens were not obtained for ACSR, please
indicate reason
Other (Other)
Patient Had Previously Donated
Specimen To Acsr (Patient had
previously donated specimen to ACSR)
Patient Refused To Give Informed
Consent For Acsr Specimen Donation
(Patient refused to give informed consent
for ACSR specimen donation)
Patient Was Not Asked To Consider Acsr
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Specimen Donation (Patient was not
asked to consider ACSR specimen
donation)
Other, specify
Study Coordinator
Study Coordinator's name
E-mail
Phone Number (xxx-xxx-xxxx)
Comments
Comments
2 / 2
Infection NCT00513526 Pathology - AMC-052 AIDS and Cancer
Specimen Resource (ACSR) Procurement Form (F37) - 2676606v1.0
Kaposi's Sarcoma NCT00686842 Lab - AMC-
059 Pharmacodynamics Form - 2774589v1.0
Kaposi's Sarcoma NCT00686842 Lab - AMC-059
Pharmacodynamics Form - 2774589v1.0
All rights reserved. Please visit https://medical-data-
models.org/forms/1806
AMC-059 Pharmacodynamics Form
Header Module
Visit number
Cycle Start Date (mm/dd/yyyy)
Pharmacodynamics
Cycle Number
1 (1)
2 (2)
Day of cycle
Day 1 (Day 1)
Day 15 (Day 15)
Day 28 (Day 28)
Date Agent Administered (mm/dd/yyyy)
Time Collected (hh:mm)
Collection period (Post-dose)
Baseline (Baseline)
Hour 1 (Hour 1)
Hour 2 (Hour 2)
Hour 3 (Hour 3)
Hour 4 (Hour 4)
Hour 5 (Hour 5)
Hour 6 (Hour 6)
Hour 8 (Hour 8)
Comments
Comments
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059 HIV Viral Load Form (F40) - 2933300v1.0
Kaposi's Sarcoma NCT00686842 Lab - AMC-059 HIV Viral
Load Form (F40) - 2933300v1.0
All rights reserved. Please visit https://medical-data-
models.org/forms/1814
AMC-059 HIV Viral Load Form (F40)
Unnamed1
Visit number
Unnamed2
Results of HIV viral load assay  (Enter results
from right to left.)
Equal To (Equal to (=))
Greater Than (>) (Greater than (>))
Less Than (Less than (<))
Undetectable (Undetectable)
HIV viral load value
Method of detection
Abbott Realtime Hiv-1 Assay (Abbott
RealTime HIV-1 assay)
Cobas Ampliprep/taqman Hiv-1 Assay
(COBAS AmpliPrep/TAQMAN HIV-1
assay)
Other (Other)
Roche Amplicor Monitor Assay (Roche
Amplicor Monitor Assay)
Versant Hiv-1 Rna Assay By Branched
Dna (Versant HIV-1 RNA assay by
branched DNA)
Other, specify
HIV viral load assay type
Standard (Standard)
Ultra (Ultra)
Limits of detection (Copies/mL)
Lab Facility Name (Testing Laboratory
information)
Comments
Comments
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Infection NCT00513526 On-Study - AMC-052 High
Resolution Anoscopy (HRA) Form - 2676571v1.0
All rights reserved. Please visit https://medical-data-
models.org/forms/1821
AMC-052 High Resolution Anoscopy
(HRA) Form
Unnamed1
Anal symptoms present
No (No)
Yes (Yes)
Anal symptoms
Bleeding (Bleeding)
Irritation (Irritation)
Itching (Itching)
Lump (Lump)
Other (Other)
Pain During Bowel Movement (Pain
during bowel movement)
Pain Or Discomfort (Pain or discomfort)
Painful During Receptive Anal Sex
(Painful during receptive anal sex)
Other, specify
Abnormal digital rectal exam
No (No)
Not Done (Not done)
Yes (Yes)
Digital rectal exam results
Anal Papilla (Anal papilla)
Granularity (Granularity)
Induration (Induration)
Mass Abnormality (Mass)
Other (Other)
Thickening (Thickening)
Warty Nodularity (Warty nodularity)
Other, specify
Entire squamocolumnar junction visualized
No (no)
Yes (yes)
Unnamed2
Number of anal biopsies
Number of perianal biopsies
Intraanal lesions present
No (No)
Yes (Yes)
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Perianal lesions present
No (No)
Yes (Yes)
Intraanal condyloma present
No (No)
Yes (Yes)
Intraanal lesions suspicious for anal intraepithelial
neoplasia present
No (No)
Yes (Yes)
Perianal condyloma present
No (No)
Yes (Yes)
Perianal lesions suspicious for anal intraepithelial
neoplasia present
No (No)
Yes (Yes)
Genital exam performed
No (No)
Yes (Yes)
Penile or genital condyloma present
No (No)
Yes (Yes)
Other, specify
Unnamed4
Comments
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Failure Predictor Variables Survey Form - 2958715v1.0
Infection NCT00513526 Registration - AMC-052 Screen
Failure Predictor Variables Survey Form - 2958715v1.0
All rights reserved. Please visit https://medical-data-
models.org/forms/1837
AMC-052 Screen Failure Predictor
Variables Survey Form
Verbal Consent
Was verbal consent obtained from the subject
No (No)
Yes (Yes)
Date verbal consent obtained (mm/dd/yyyy)
Cd4+
CD4+ Count
Lowest CD4+ count ever reported (i.e. nadir CD4)
Unnamed2
Results of HIV viral load assay  (Enter results
from right to left.)
Equal To (Equal to (=))
Greater Than (>) (Greater than (>))
Less Than (Less than (<))
Undetectable (Undetectable)
HIV viral load value
Method of detection
Abbott Realtime Hiv-1 Assay (Abbott
RealTime HIV-1 assay)
Cobas Ampliprep/taqman Hiv-1 Assay
(COBAS AmpliPrep/TAQMAN HIV-1
assay)
Other (Other)
Roche Amplicor Monitor Assay (Roche
Amplicor Monitor Assay)
Versant Hiv-1 Rna Assay By Branched
Dna (Versant HIV-1 RNA assay by
branched DNA)
Other, specify
HIV viral load assay type
Standard (Standard)
Ultra (Ultra)
Limits of detection (Copies/mL)
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Comments
Comments
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Follow-Up - Urinary Excretion -
3281194v1.0
Follow-Up - Urinary Excretion - 3281194v1.0
All rights reserved. Please visit https://medical-data-
models.org/forms/1842
Urinary Excretion
Urinary Excretion
Visit Date
Course #
Day in Course (Cycle)
Study Agent (Enter the name of the study agent
investigational or commercial which is the subject
of the urinary excretion study.)
Planned Interval (Planned interval pre-
determined per protocol.)
Sample Collected? (Indicate whether or not the
specimen is collected.)
No (No)
Unknown (Unknown)
Yes (Yes)
Start Date of Dosing (Enter the date the study
agent was administered.)
Start Date of Dosing (Enter the date the study
agent was administered.)
Start Time of First Injection (Enter the time of the
first injection of the study agent, or if appropriate,
for taking the study agent via any "non-IV" route
of administration for example, enter the time that
the agent is administered orally or rectally.)
Start Time of First Injection (Enter the time of the
first injection of the study agent, or if appropriate,
for taking the study agent via any "non-IV" route
of administration for example, enter the time that
the agent is administered orally or rectally.)
Stop Date of Dosing (Enter the date the study
agent administration was stopped.)
Stop Date of Dosing (Enter the date the study
agent administration was stopped.)
Stop Time of First Injection (Enter the stop time
of the first injection of the study agent, or if
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appropriate, for taking the study agent via any
"non-IV" route of administration for example,
enter the time that the agent is administered
orally or rectally.)
Stop Time of First Injection (Enter the stop time
of the first injection of the study agent, or if
appropriate, for taking the study agent via any
"non-IV" route of administration for example,
enter the time that the agent is administered
orally or rectally.)
Urine Volume ml (Enter the urine volume
collected in milliliters.)
Parent Study Agent Assay 1 (Enter the first
parent study agent assay results in the biological
samples.)
Parent Study Agent Assay 1 (Enter the first
parent study agent assay results in the biological
samples.)
Parent Study Agent Mean Conc. (Enter the
parent study agent assay mean concentration, if
available.)
Parent Study Agent in Void (Enter the parent
study agent assay in void results in the biological
samples. - If results are not available, record at
least the collection times on the case report
form.)
Parent Study Agent UOM (Select the appropriate
Study Agent units of measurement e.g.: mg/dL or
mmol/l.)
Metabolite Assay 1 (Enter the first metabolite
assay results in the biological samples.)
Metabolite Assay 1 (Enter the first metabolite
assay results in the biological samples.)
Metabolite Mean Concentration (Enter the
metabolite mean concentration, if available.)
Metabolite in Void (Enter the metabolite in void
results in the biological samples.)
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Metabolite UOM (Enter the appropriate
Metabolite units of measurement e.g.: mg/dL or
mmol/l.)
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Follow-Up - SURVIVAL - 2407587v1.0
All rights reserved. Please visit https://medical-data-
models.org/forms/1855
SURVIVAL
Survival
Death Date
Death Cause
Infection (I)
Malignant Disease (M)
Other (O)
Toxicity From Protocol Treatment (T)
Unknown (U)
Death Cause Text
Autopsy Performed Indicator
No (N)
Unknown (U)
Yes (Y)
Cause of Death at Autopsy
Infection (I)
Malignant Disease (M)
Other (explain) (O)
Toxicity From Protocol Treatment (T)
Autopsy Death Cause Text
Autopsy Sites of Disease Name
Abdomen (Abdomen)
Abdomen/pelvis (Abdomen/Pelvis)
Abdominal Wall (Abdominal wall)
Acetabulum (Acetabulum)
Adrenal Gland (Adrenal gland)
Anal Canal (Anal canal)
Anal Sphincter (Anal sphincter)
Ankle (Ankle)
Anorectum (Anorectum)
Antecubital Fossa (Antecubital fossa)
Anus (Anus)
Aorta (Aorta)
Appendix (Appendix)
Aqueous Fluid (Aqueous Fluid)
Arm (Arm)
Artery (Artery)
Ascending Colon (Ascending colon)
Auditory Canal (Auditory canal)
Autonomic Nervous System (Autonomic
nervous system)
Axilla (Axilla)
Back (Back)
Bile Duct (Bile duct)
Bladder (Bladder)
Blood (Blood)
Blood Vessel (Blood vessel)
Bone (Bone)
Bone Marrow (Bone marrow)
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Bowel (Bowel)
Brain (Brain)
Brain Stem (Brain stem)
Breast (Breast)
Broad Ligament (Broad ligament)
Bronchiole (Bronchiole)
Bronchus (Bronchus)
Bronchus And Lung (Bronchus and
Lung)
Brow (Brow)
Buccal Cavity (Buccal cavity)
Buccal Mucosa (Buccal mucosa)
Buttock (Buttock)
Calf (Calf)
Carina (Carina)
Carotid Artery (Carotid artery)
Cecum (Cecum)
Central Line Catheter (Central Line
Catheter)
Central Nervous System (Central
nervous system)
Cerebellum (Cerebellum)
Cerebral Cortex (Cerebral cortex)
Cerebrospinal Fluid (Cerebrospinal fluid)
Cerebrum (Cerebrum)
Cervical Spine (Cervical spine)
Cervical/thoracic/lumbar Spine
(Cervical/Thoracic/Lumbar spine)
Cervix (Cervix)
Chest (Chest)
Chest Wall (Chest wall)
Chest/abdomen/pelvis
(Chest/Abdomen/Pelvis)
Chest/pelvis (Chest/Pelvis)
Chin (Chin)
Clavicle (Clavicle)
Colon (Colon)
Colon And Rectum (Colon and rectum)
Common Duct (Common duct)
Conjunctiva (Conjunctiva)
Connective Tissue (Connective tissue)
Descending Colon (Descending colon)
Diaphragm (Diaphragm)
Duodenum (Duodenum)
Ear (Ear)
Ear Canal (Ear canal)
Elbow (Elbow)
Endocrine Gland (Endocrine gland)
Epididymis (Epididymis)
Esophagogastric Junction
(Esophagogastric junction)
Esophagus (Esophagus)
Eye (Eye)
Fallopian Tube (Fallopian tube)
Femur (Femur)
Fibula (Fibula)
Finger (Finger)
Foot (Foot)
Forearm (Forearm)
Forehead (Forehead)
2 / 5
Follow-Up - SURVIVAL - 2407587v1.0
Frontal Lobe (Frontal lobe)
Fundus Of Stomach (Fundus of
stomach)
Gallbladder (Gallbladder)
Gastrointestinal Tract (Gastrointestinal
tract)
Genitourinary (Genitourinary)
Groin (Groin)
Gum (Gum)
Hand (Hand)
Hard Palate (Hard palate)
Head - Face Or Neck, Nos (Head - face
or neck, NOS)
Head/neck (Head/Neck)
Head/neck/chest/adb/pelvis
(Head/Neck/Chest/Adb/Pelvis)
Heart (Heart)
Hepatic Duct (Hepatic duct)
Hip (Hip)
Humerus (Humerus)
Hypopharynx (Hypopharynx)
Ileum (Ileum)
Ilium (Ilium)
Intestine (Intestine)
Ischium (Ischium)
Jaw (Jaw)
Jejunum (Jejunum)
Joints (Joints)
Kidney (Kidney)
Knee (Knee)
Large Bowel (Large bowel)
Laryngopharynx (Laryngopharynx)
Larynx (Larynx)
Leg (Leg)
Lip (Lip)
Liver (Liver)
Liver And Intrahepatic Duct (Liver and
intrahepatic duct)
Liver/spleen (Liver/Spleen)
Lumbar Spine (Lumbar spine)
Lung (Lung)
Lymph Node (Lymph node)
Lymph Node(s) Axilla (Lymph Node(s)
Axilla)
Lymph Node(s) Cervical (Lymph Node(s)
Cervical)
Lymph Node(s) Hilar (Lymph Node(s)
Hilar)
Lymph Node(s) Inguinal (Lymph Node(s)
Inguinal)
Lymph Node(s) Int Mammary (Lymph
Node(s) Int Mammary)
Lymph Node(s) Mammary (Lymph
Node(s) Mammary)
Lymph Node(s) Pelvic (Lymph Node(s)
Pelvic)
Lymph Node(s) Supraclav (Lymph
Node(s) Supraclav)
Lymph Nodes (Lymph nodes)
Lymphoma (Lymphoma)
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Mandible (Mandible)
Maxilla (Maxilla)
Mediastinum (Mediastinum)
Mesentery (Mesentery)
Mini Mantle (Mini Mantle)
Mouth (Mouth)
Muscle (Muscle)
Nasopharynx (Nasopharynx)
Neck (Neck)
Neck/chest/abdomen/pelvis
(Neck/Chest/Abdomen/Pelvis)
Nerve (Nerve)
Ocular Orbits (Ocular Orbits)
Omentum (Omentum)
Oral Cavity (Oral cavity)
Ovary (Ovary)
Posterior Anterior/lateral (PA/Lat)
Palate (Palate)
Pancreas (Pancreas)
Parotid Gland (Parotid gland)
Patella (Patella)
Pelvis (Pelvis)
Penis (Penis)
Perianus (Perianus)
Pericardium (Pericardium)
Peritoneal Cavity (Peritoneal cavity)
Pharynx (Pharynx)
Pituitary Gland (Pituitary gland)
Pleura (Pleura)
Popliteal Fossa (Popliteal fossa)
Prostate (Prostate)
Pylorus (Pylorus)
Rectum (Rectum)
Retina (Retina)
Retroperitoneum (Retroperitoneum)
Ribs (Ribs)
Round Ligament (Round ligament)
Sacrum (Sacrum)
Salivary Gland (Salivary gland)
Scalp (Scalp)
Scapula (Scapula)
Scrotum (Scrotum)
Shoulder (Shoulder)
Sigmoid Colon (Sigmoid colon)
Sinus(es) (Sinus(es))
Sinus(es), Maxillary (Sinus(es),
Maxillary)
Skin (Skin)
Skull (Skull)
Small Intestine (Small intestine)
Spine (Spine)
Spine/femur (Spine/Femur)
Spine/femur/radius
(Spine/Femur/Radius)
Spleen (Spleen)
Sternum (Sternum)
Stomach (Stomach)
Subcutaneous Tissue (Subcutaneous
tissue)
Testicle (Testicle)
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Thigh (Thigh)
Thoracic Spine (Thoracic spine)
Thoracic/lumbar Spine (Thoracic/Lumbar
spine)
Thorax (Thorax)
Throat (Throat)
Thymus (Thymus)
Thyroid Gland (Thyroid gland)
Tongue (Tongue)
Tongue, Base Of Tongue (Tongue, Base
of tongue)
Tonsil (Tonsil)
Trachea (Trachea)
Trunk (Trunk)
Ureter (Ureter)
Urinary Tract (Urinary tract)
Uterus (Uterus)
Uvula (Uvula)
Vagina (Vagina)
Vertebra (Vertebra)
Vertebral Column (Vertebral column)
Vulva (Vulva)
Whole Body (Whole body)
Wrist (Wrist)
Comments
Note Date
Research Comments Text
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BONE MARROW
Bone Marrow
Course Number
Course Day Number
Sample Collection Date
Time
Lab Test
Cellularity, %, Bone Marrow (Cellularity,
%, Bone Marrow)
Fab Marrow Rating, Bone Marrow (FAB
Marrow Rating, Bone Marrow)
Lymphocytes, %, Blood (Lymphocytes,
%, Blood)
Megakaryocytes, %, Bone Marrow
(Megakaryocytes, %, Bone Marrow)
Metamyelocytes, %, Bone Marrow
(Metamyelocytes, %, Bone Marrow)
Monocytes, %, Blood (Monocytes, %,
Blood)
Plasma Cells, %, Bone Marrow (Plasma
Cells, %, Bone Marrow)
Promyelocytes, %, Bone Marrow
(Promyelocytes, %, Bone Marrow)
Reticulocytes, %, Bone Marrow
(Reticulocytes, %, Bone Marrow)
Lab Value
Lab Unit of Measure Name
Per 100 Identifiable White Blood Cells
(/100 WBC)
Per Millimeter Cubed (/mm3)
Percent (%)
Percent Per 100 Wbc (%/100 WBC)
10e12 Cells Per Liter (10E12 Cells/L)
10e3 Cells Per Microliter (10E3
Cells/microL)
10e6 Cells (10E6 Cells)
10e6 Cells Per Microliter (10E6
Cells/microL)
10e6 Cells Per Millimeter Cubed (10E6
Cells/mm3)
10e7 Cells Per Kilogram (10E7 Cells/kg)
10e8 Cells (10E8 Cells)
10e9 Cells (10E9 Cells)
10e9 Cells Per Liter (10E9 Cells/L)
Complement Activity Enzyme Unit (CAE
Unit)
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Cells Per Microliter (Cells/microL)
Copies (Copies)
Cubic Microns (cubic microns)
Enzyme Unit (EU)
Enzyme Units Per Deciliter (EU/dL)
Enzyme Units Per Milliliter (EU/mL)
Femtoliter (fL)
Grams (g) (g)
Gram Per 24 Hours (g/24hr)
Gram Per Deciliter (g/dL)
Gram Per Liter (g/L)
Gram Per Microliter (g/microL)
Per High Power Field (HPF)
International Unit (Iunit)
International Unit Per Liter (IUnit/L)
International Unit Per Meter Squared
(IUnit/m2)
International Unit Per Milliliter (IUnit/mL)
Iu/ml (IUnit/mL)
Kilounit Per Liter (kU/L)
Liter (L)
Liters Per Minute (L/min)
Per Low Power Field (LPF)
Microgram Per 24 Hours (mcg/24hr)
Microgram Per Deciliter (mcg/dL)
Microgram Per Liter (mcg/L)
Microgram Per Milliliter (mcg/mL)
Microgram Per Specimen (mcg/spec)
Milliequivalent (mEq)
Milliequivalents Per 24 Hours (mEq/24hr)
Milliequivalent Per Deciliter (mEq/dL)
Milliequivalent Per Kilogram (mEq/kg)
Milliequivalent Per Liter (mEq/L)
Milligram (mg)
Milligram Per 24 Hours (mg/24hr)
Milligram Per Deciliter (mg/dL)
Milligram Per Kilogram (mg/kg)
Milligram Per Liter (mg/L)
Milligram Per Milliliter (mg/mL)
Milligram Per Milliliter Per Minute
(mg/mL/min)
Micro International Unit Per Milliliter
(microIU/mL)
Microliter (microL)
Micromole Per 24 Hours (micromol/24hr)
Micromole Per Deciliter (micromol/dL)
Micromole Per Liter (micromol/L)
Million Plaque Forming Units (mill PFU)
Million (Million)
Million Per Microliter (Million/microL)
Million Per Millimeter Cubed
(Million/mm3)
Milliinternational Unit (miu)
Milliinternational Units Per Meter
Squared (miu/m2)
Milliinternational Unit Per Milliliter
(miu/mL)
Milliter (mL)
Milliliter Per Minute (mL/min)
Milliliter Per Minute Times 1.73 Times
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Bsa (mL/min/1.73/BSA)
Milliter Per Minute Per Millimeters Of
Mercury (mL/minute/mmHg)
Millimeter Per Hour (mm/hr)
Millimeter Cubed (mm3)
Millimeter Of Mercury (mmHg)
Millimole (mmol)
Millimole Per 24 Hours (mmol/24hr)
Millimole Per Liter (mmol/L)
Milliosmole Per Kilogram (mosmol/kg)
Million Units Per Milliliter (MU/mL)
Not Applicable; No Uom Required (NA)
Nanogram Per Deciliter (ng/dL)
Nanograms Per Milliliter (ng/mL)
Nanogram Per Milliliter Per Hour
(ng/mL/hr)
Nanomole Per Liter (nmol/L)
Nanomole Per Milligram Of Protein
(nMol/mg protein)
Nanomole Per Milliliter (nmol/mL)
No Source Data (No Srce)
Picograms (pg)
Picogram Per Deciliter (pg/dL)
Picrogram Per Milliliter (pg/mL)
Pgpge2/mg Protein (pgPGE2/mg
protein)
Picomole Per Liter (pmol/L)
Ratio (Ratio)
Rna Copies Per Milliliter (RNA
copies/mL)
Seconds (sec)
Thousand (Thousand)
Thousand Per Microliter
(Thousand/microL)
Thousand Per Millimeter Squared
(Thousand/mm2)
Thousand Per Millimeter Cubed
(Thousand/mm3)
Titer (Titer)
Unit (Unit)
Unit Per 24 Hours (Unit/24hr)
Unit Per Liter (Unit/L)
Unit Per Meter Squared (Unit/m2)
Unit Per Millilliter (Unit/mL)
Unit Per Millimeters Cubed (Unit/mm3)
Unknown (Unknown)
Test Result Significance Indicator
No (N)
Yes (Y)
Laboratory Test Normal Reference Range Text
Laboratory Test Normal Range Indicator
High (High)
Low (Low)
Nonnumeric (Nonnum)
No Range (Norang)
Normal (Normal)
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Common Toxicity Criteria Adverse Event Grade
No Adverse Event Or Within Normal
Limits (0)
Mild Adverse Event (1)
Moderate Adverse Event (2)
Severe And Undesirable Adverse Event
(3)
Life-threatening Or Disabling Adverse
Event (4)
Death Related To Adverse Event (5)
Comments
Note Date
Research Comments Text
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2004 - Infectious Disease Markers
ISO Date Format Version 1
Registry Use Only
Sequence number:
Date received:
Identification Data
CIBMTR Center Number:
CIBMTR Recipient ID:
Identification Data
Non-NMDP donor ID:
Donor Gender
Female (female)
Male (male)
Donor date of birth:
Identification Data
Non-NMDP Cord Blood Unit (CBU) ID:
Identification Data
Today's date:
Date of hematopoietic stem cell transplantation
(HSCT) for which this form is being completed:
Hsct Type
What source was used for the hematopoietic
stem cell transplantation?
Related Allogenic (Allogeneic, related)
Unrelated Allogenic (Allogeneic,
unrelated)
Syngeneic (Syngeneic (identical twin))
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Was a particular hematopoietic stem cell source
used?
No (No)
Yes (Yes)
Product Type
What type of hematopoietic stem cell transplant
was used?
Umbilical Cord Blood (Cord blood)
Bone Marrow (Marrow)
Other (Other)
Peripheral Blood Stem Cell (PBSC)
Was a particular hematopoietic stem cell
transplant type used?
No (No)
Yes (Yes)
Specify the other hematopoietic stem cell
transplant type: (Answer only if the value for
2730912 is "Other". )
Source Information
Who is being tested for IDMs?
Disease Marker Umbilical Cord Blood
(Cord Blood Unit (IDM))
Disease Marker Donor (Donor IDM
(Marrow or PBSC))
Umbilical Cord Blood Disease Marker
Mother (Maternal IDM (Cord Blood))
Infectious Disease Marker
Test results of infectious disease marker for
hepatitis B virus (HBV)  surface antigen(HBsAG)
Not Reaction (Non-reactive)
Not Done: C49484 (Not Done)
Reaction (Reactive)
Date that the test for hepatitis B surface antigen
(HBsAG) was performed:
Test results of infectious disease marker for
hepatitis B virus (HBV) core antibody (Anti HBc)
(No confirmatory test available)
Not Reaction (Non-reactive)
Not Done: C49484 (Not Done)
Reaction (Reactive)
Date that the test for hepatitis B virus core
antibody (Anti HBc) was performed:
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Hepatitis C Virus (hcv)
Test results of infectious disease marker for
hepatitis C virus (HCV) antibody (Anti-HCV)
Not Reaction (Non-reactive)
Not Done: C49484 (Not Done)
Reaction (Reactive)
Date that the test for hepatitis C virus antibody
(Anti-HCV) was performed:
Human T-lymphotropic Virus
Test results of infectious disease marker for
human T-Lymphotropic virus antibody(Anti-HTLV
I/II):
Not Reaction (Non-reactive)
Not Done: C49484 (Not Done)
Reaction (Reactive)
Date that the test for human T-Lymphotropic virus
antibody (Anti-HTLV I/II) was performed:
Human Immunodeficiency Virus (hiv)
Test results of infectious disease marker for
human immunodeficiency virus(HIV)-1 p24
antigen:
Not Reaction (Non-reactive)
Human Immunodeficiency Virus Nucleic
Acid Amplification Test Performed (Not
performed; HIV NAT testing performed)
Not Report (Not reported)
Reaction (Reactive)
Date that the test for HIV-1 p24 antigen was
performed:
Was FDA licensed nucleic acid amplification test
(NAT)for human immunodeficiency virus(HIV)-1
or hepatitis C virus performed?
No (No)
Yes (Yes)
If FDA licensed nucleic acid amplification test
(NAT)for human immunodeficiency virus(HIV)-1
performed; specify results
Negative Finding (Negative)
Not Report (Not reported)
Positive Finding (Positive)
Date that the FDA licensed nucleic acid
amplification test (NAT) for human
immunodeficiency virus (HIV-1) was performed:
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Was FDA licensed nucleic acid amplification test
(NAT)for hepatitis C virus performed; specify
results
Negative Finding (Negative)
Positive Finding (Positive)
Date that the FDA licensed nucleic acid
amplification test (NAT) for hepatitis C virus was
performed:
Test results of infectious disease marker for Anti-
HIV 1 and anti-HIV 2 (antibodies to Human
Immunodeficiency Viruses): (Testing for both HIV
antibodies is required. This testing may be
performed as separate tests or done using a
combined assay.)
Not Reaction (Non-reactive)
Not Done: C49484 (Not Done)
Not Report (Not reported)
Reaction (Reactive)
Date that the test for Anti-HIV 1 and anti-HIV 2
(antibodies to Human Immunodeficiency Viruses)
was performed:
Syphilis
Test results of infectious disease marker for
syphilis using serologic testing for syphilis(STS)
Not Reaction (Non-reactive)
Not Done: C49484 (Not Done)
Reaction (Reactive)
Date that the the serologic test for syphilis (STS)
was performed:
Cytomegalovirus (cmv)
Test results of infectious disease marker for
cytomegalovirus(CMV) antibody (IgG or total):
Not Reaction (Non-reactive)
Not Done: C49484 (Not Done)
Previous Report Reaction (Previously
reported reactive, not tested)
Reaction (Reactive)
Date that the test for cytomegalovirus (CMV)
antibody (IgG or total) was performed:
West Nile Virus (wnv)
Test results of infectious disease marker for west
nile virus(WNV) using nucleic acid amplification
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test (NAT)
Negative Finding (Negative)
Not Applicable (Not applicable)
Not Done: C49484 (Not Done)
Positive Finding (Positive)
Date that the nucleic acid amplification test (NAT)
for West Nile Viruse (WNV) was performed:
Other Infectious Disease Marker
Other infectious disease marker?
No (NO)
Yes (YES)
Date test performed on other infectious disease
marker:
Specify test and method for test performed on
other infectious disease marker:
Specify test results for  test performed on other
infectious disease marker
Author Information
First Name
Last Name
Telephone number:
Fax number:
EMail Address
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2004 Revision 2 - Infectious Disease
Markers
Registry Use Only
Sequence number:
Date received:
Identification Data
CIBMTR Center Number:
CIBMTR Recipient ID:
Specify non-NMDP donor:
Negation National Marrow Donor
Program Umbilical Cord Blood Unit
(Non-NMDP cord blood unit)
Negation National Marrow Donor
Program Donor Unrelated (Non-NMDP
unrelated donor)
Donor Relationship (Related donor)
What is the transplant donor or infant date of
birth?
What is the transplant donor or infant gender?
Female (female)
Male (male)
Non-NMDP unrelated donor / cord blood unit ID:
(not applicable for related donor)
Today's date:
Date of hematopoietic stem cell transplantation
(HSCT) for which this form is being completed:
What source was used for the hematopoietic
stem cell transplantation?
Related Allogenic (Allogeneic, related)
Unrelated Allogenic (Allogeneic,
unrelated)
Syngeneic (Syngeneic (identical twin))
What type of hematopoietic stem cell transplant
was used?
Umbilical Cord Blood (Cord blood)
Bone Marrow (Marrow)
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Other (Other)
Peripheral Blood Stem Cell (PBSC)
Specify the other hematopoietic stem cell
transplant type:
Source Information
Who is being tested for IDMs?
Disease Marker Umbilical Cord Blood
(Cord Blood Unit (IDM))
Disease Marker Donor (Donor IDM
(Marrow or PBSC))
Umbilical Cord Blood Disease Marker
Mother (Maternal IDM (Cord Blood))
Infectious Disease Marker
Test results of infectious disease marker for
hepatitis B virus (HBV)  surface antigen(HBsAG)
Not Reaction (Non-reactive)
Not Done: C49484 (Not Done)
Reaction (Reactive)
Date that the test for hepatitis B surface antigen
(HBsAG) was performed:
Test results of infectious disease marker for
hepatitis B virus (HBV) core antibody (Anti HBc)
(No confirmatory test available)
Not Reaction (Non-reactive)
Not Done: C49484 (Not Done)
Reaction (Reactive)
Date that the test for hepatitis B virus core
antibody (Anti HBc) was performed:
Hepatitis C Virus (hcv)
Test results of infectious disease marker for
hepatitis C virus (HCV) antibody (Anti-HCV)
Not Reaction (Non-reactive)
Not Done: C49484 (Not Done)
Reaction (Reactive)
Date that the test for hepatitis C virus antibody
(Anti-HCV) was performed:
Human T-lymphotropic Virus
Test results of infectious disease marker for
human T-Lymphotropic virus antibody (Anti-HTLV
I / II):
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Not Reaction (Non-reactive)
Not Done: C49484 (Not Done)
Reaction (Reactive)
Date that the test for human T-Lymphotropic virus
antibody (Anti-HTLV I / II) was performed:
Human Immunodeficiency Virus (hiv)
Test results of infectious disease marker for
human immunodeficiency virus(HIV)-1 p24
antigen:
Not Reaction (Non-reactive)
Human Immunodeficiency Virus Nucleic
Acid Amplification Test Performed (Not
performed; HIV NAT testing performed)
Not Report (Not reported)
Reaction (Reactive)
Date that the test for HIV-1 p24 antigen was
performed:
Was FDA licensed nucleic acid amplification test
(NAT)for human immunodeficiency virus(HIV)-1
or hepatitis C virus performed?
No (No)
Yes (Yes)
If FDA licensed nucleic acid amplification test
(NAT)for human immunodeficiency virus(HIV)-1
performed; specify results
Negative Finding (Negative)
Not Report (Not reported)
Positive Finding (Positive)
Date that the FDA licensed nucleic acid
amplification test (NAT) for human
immunodeficiency virus (HIV-1) was performed:
Was FDA licensed nucleic acid amplification test
(NAT)for hepatitis C virus performed; specify
results
Negative Finding (Negative)
Positive Finding (Positive)
Date that the FDA licensed nucleic acid
amplification test (NAT) for hepatitis C virus was
performed:
Test results of infectious disease marker for Anti-
HIV 1 and anti-HIV 2 (antibodies to Human
Immunodeficiency Viruses): (Testing for both HIV
antibodies is required. This testing may be
performed as separate tests or done using a
combined assay.)
Not Reaction (Non-reactive)
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Not Done: C49484 (Not Done)
Not Report (Not reported)
Reaction (Reactive)
Date that the test for Anti-HIV 1 and anti-HIV 2
(antibodies to Human Immunodeficiency Viruses)
was performed:
Syphilis
Test results of infectious disease marker for
syphilis using serologic testing for syphilis(STS)
Not Reaction (Non-reactive)
Not Done: C49484 (Not Done)
Reaction (Reactive)
Date that the the serologic test for syphilis (STS)
was performed:
Cytomegalovirus (cmv)
Test results of infectious disease marker for
cytomegalovirus(CMV) antibody (IgG or total):
Not Reaction (Non-reactive)
Not Done: C49484 (Not Done)
Reaction (Reactive)
Date that the test for cytomegalovirus (CMV)
antibody (IgG or total) was performed:
West Nile Virus (wnv)
Test results of infectious disease marker for west
nile virus (WNV) using nucleic acid amplification
test (NAT)
Negative Finding (Negative)
Not Applicable (Not applicable)
Not Done: C49484 (Not Done)
Positive Finding (Positive)
Date that the nucleic acid amplification test (NAT)
for West Nile Virus (WNV) was performed:
Other Infectious Disease Marker
Other infectious disease marker?
No (NO)
Yes (YES)
Date test performed on other infectious disease
marker:
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Specify test and method for test performed on
other infectious disease marker:
Specify test results for  test performed on other
infectious disease marker
Author Information
First Name
Last Name
Telephone number:
Fax number:
EMail Address
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OTHER LABS
Other Labs
Course Number
Course Day Number
Sample Collection Date
Time
Lab Test
Abnormal Lymphocytes, %, Blood
(Abnormal Lymphocytes, %, Blood)
Abo Group, Rh Type, Blood (ABO Group,
Rh Type, Blood)
Absolute Neutrophil Count (Absolute
Neutrophil Count (ANC), Blood)
Acid Phosphatase (acp), Serum (Acid
Phosphatase (ACP), Serum)
Adenovirus Antibody, Serum (Adenovirus
Antibody, Serum)
Adrenocorticotropin, Serum
(Adrenocorticotropin, Serum)
Serum Alanine Aminotransferase Ialt Or
Sgpt) (Alanine Aminostransferase (ALT
or SGPT), Serum)
Albumin, Electrophoresis, Timed Urine
(Albumin, Electrophoresis, Timed Urine)
Albumin, Serum (Albumin, Serum)
Alkaline Phosphatase, Serum (Alkaline
Phosphatase, Serum)
Alpha 1 Globulin, Electrophoresis, Timed
Urine (Alpha 1 Globulin, Electrophoresis,
Timed Urine)
Alpha 1 Globulin, Protein
Electrophoresis, Serum (Alpha 1
Globulin, Protein Electrophoresis,
Serum)
Alpha 2 Globulin, Electrophoresis, Timed
Urine (Alpha 2 Globulin, Electrophoresis,
Timed Urine)
Alpha 2 Globulin, Protein
Electrophoresis, Serum (Alpha 2
Globulin, Protein Electrophoresis,
Serum)
Alpha-1 Fetoprotein, Serum (Alpha-1
Fetoprotein, Serum)
Serum Amylase (Amylase, Serum)
Antiadrenal Antibody, Serum
(Antiadrenal Antibody, Serum)
Antibody Screen, Serum (Antibody
Screen, Serum)
Antibody To Hepatitis B Surface Antigen
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(hbsab), Serum (Antibody to Hepatitis B
surface antigen (HBSAb), Serum)
Antinuclear Antibody (ana), Serum
(Antinuclear Antibody (ANA), Serum)
Appearance, Cerebrospinal Fluid
(Appearance, Cerebrospinal Fluid)
Appearance, Urine (Appearance, Urine)
Serum Aspartate Aminotransferase (ast
Or Sgot) (Aspartate Aminotransferase
(AST or SGOT), Serum)
Atypical Lymphocytes, #, Blood (Atypical
Lymphocytes, #, Blood)
B Lymphocytes, #, Blood (B
Lymphocytes, #, Blood)
Bacteria, Microscopic, Spot Urine
(Bacteria, Microscopic, Spot Urine)
Basophils, #, Blood (Basophils, #, Blood)
Basophils, %, Blood (Basophils, %,
Blood)
Bcr-abl P210 Assay, Blood (BCR-ABL
P210 Assay, Blood)
Bcr-abl Sensitivity, Blood (BCR-ABL
Sensitivity, Blood)
Bcr-abl/g6pdh Ratio, Blood (BCR-
ABL/G6PDH Ratio, Blood)
Beta Choriogonadotropin (bhcg), Or
Pregnancy Test, Spot Urine (Beta
Choriogonadotropin (BHCG), or
Pregnancy Test, Spot Urine)
Beta Choriogonadotropin Bhcg, Or
Pregnancy Test, Serum (Beta
Choriogonadotropin BHCG, or
Pregnancy Test, Serum)
Beta Globulin, Electrophoresis, Timed
Urine (Beta Globulin, Electrophoresis,
Timed Urine)
Beta Globulin, Protein Electrophoresis,
Serum (Beta Globulin, Protein
Electrophoresis, Serum)
Beta-2 Microglobulin, Serum (Beta-2
Microglobulin, Serum)
Bicarbonate (hco3), Arterial Blood
(Bicarbonate (HCO3), Arterial Blood)
Bicarbonate, Serum (Bicarbonate,
Serum)
Bile (biliary Obstruction), Spot Urine (Bile
(Biliary Obstruction), Spot Urine)
Bilirubin (bile), Spot Urine (Bilirubin
(Bile), Spot Urine)
Serum Direct Bilirubin (Bilirubin, Direct,
Serum)
Serum Total Bilirubin (Bilirubin, Total,
Serum)
Bk Virus, Polymerase Chain Reaction
(pcr), #, Blood (BK Virus, Polymerase
Chain Reaction (PCR), #, Blood)
Bk Virus, Polymerase Chain Reaction
(pcr), #, Urine (BK Virus, Polymerase
Chain Reaction (PCR), #, Urine)
Blasts, #, Blood (Blasts, #, Blood)
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Serum Blood Urea (Blood Urea Nitrogen
(BUN), Serum)
Blood Urea Nitrogen (bun)/creatinine
Ratio, Serum (Blood Urea Nitrogen
(BUN)/Creatinine Ratio, Serum)
C Reactive Protein, High Sensitivity,
Serum (C Reactive Protein, High
Sensitivity, Serum)
C Reactive Protein, Serum (C Reactive
Protein, Serum)
C-telopeptide, Serum (C-Telopeptide,
Serum)
Cadaverine, Tissue (Cadaverine, Tissue)
Calcitonin, Serum (Calcitonin, Serum)
Calcium Oxalate Crystals, Urine
(Calcium Oxalate Crystals, Urine)
Calcium, 24 Hour, Urine (Calcium, 24
hour, Urine)
Calcium, Ionized, Arterial Blood
(Calcium, Ionized, Arterial Blood)
Calcium, Ionized, Serum (Calcium,
Ionized, Serum)
Calcium, Serum (Calcium, Serum)
Cancer Antigen 27-29 (ca27-29), Serum
(Cancer Antigen 27-29 (CA27-29),
Serum)
Carbon Monoxide Diffusing Capacity,
Respiratory System (Carbon Monoxide
Diffusing Capacity, Respiratory System)
Carboxyhemoglobin, Arterial Blood
(Carboxyhemoglobin, Arterial Blood)
Carcinoembryonic Antigen (cea), Serum
(Carcinoembryonic Antigen (CEA),
Serum)
Carcinogenic Antigen 125 (ca125),
Serum (Carcinogenic Antigen 125
(CA125), Serum)
Carcinogenic Antigen 15-3 (ca15-3),
Serum (Carcinogenic Antigen 15-3
(CA15-3), Serum)
Carcinogenic Antigen 19-9 (ca19-9),
Serum (Carcinogenic Antigen 19-9
(CA19-9), Serum)
Cardiolipin Antibody, Igg, Serum
(Cardiolipin Antibody, IgG, Serum)
Cardiolipin Antibody, Igm, Serum
(Cardiolipin Antibody, IgM, Serum)
Casts, Spot Urine (Casts, Spot Urine)
Cd10 Cells, Blood (CD10 Cells, Blood)
Cd103 Cells, Blood (CD103 Cells, Blood)
Cd14, %, Peripheral Mononuclear Cells
(pbmc), Blood (CD14, %, Peripheral
Mononuclear Cells (PBMC), Blood)
Cd16 Or Cd56/cd3-, #, Blood (CD16 or
CD56/CD3-, #, Blood)
Cd16 Or Cd56/cd3-, %, Blood (CD16 or
CD56/CD3-, %, Blood)
Cd16 Or Cd56/cd3, #, Blood (CD16 or
CD56/CD3, #, Blood)
Cd16 Or Cd56/cd3, %, Blood (CD16 or
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CD56/CD3, %, Blood)
Cd19 Cells, #, Blood (CD19 Cells, #,
Blood)
Cd19 Cells, %, Blood (CD19 Cells, %,
Blood)
Cd2 Cells, %, Blood (CD2 Cells, %,
Blood)
Cd20, #, Blood (CD20, #, Blood)
Cd20, %, Blood (CD20, %, Blood)
Cd22 Cells, Antibody, #, Blood (CD22
Cells, Antibody, #, Blood)
Cd22, #, Blood (CD22, #, Blood)
Cd25 Cells Pe, #, Blood (CD25 Cells PE,
#, Blood)
Cd25 Cells Pe, %, Blood (CD25 Cells
PE, %, Blood)
Cd25 Cells, #, Blood (CD25 Cells, #,
Blood)
Cd25 Cells, %, Blood (CD25 Cells, %,
Blood)
Cd3 Cells, #, Blood (CD3 Cells, #, Blood)
Cd3 Cells, %, Flow Cytometry, Blood
(CD3 Cells, %, Flow Cytometry, Blood)
Cd3/7g7, #, Blood (CD3/7G7, #, Blood)
Cd3/7g7, %, Blood (CD3/7G7, %, Blood)
Cd3/cd25 Cells Pe, #, Blood (CD3/CD25
Cells PE, #, Blood)
Cd3/cd25 Cells Pe, %, Blood (CD3/CD25
Cells PE, %, Blood)
Cd3/cd25 Cells, #, Blood (CD3/CD25
Cells, #, Blood)
Cd3/cd25 Cells, %, Blood (CD3/CD25
Cells, %, Blood)
Cd3/cd30 Cells, #, Blood (CD3/CD30
Cells, #, Blood)
Cd3/cd30 Cells, %, Blood (CD3/CD30
Cells, %, Blood)
Cd3/cd4-/cd8-, #, Blood (CD3/CD4-
/CD8-, #, Blood)
Cd3/cd4-/cd8-, %, Blood (CD3/CD4-
/CD8-, %, Blood)
Cd3/cd8/cd28 Cells, #, Blood
(CD3/CD8/CD28 Cells, #, Blood)
Cd3/cd8/cd28, %, Blood
(CD3/CD8/CD28, %, Blood)
Cd3/cd8/cd57 Cells, #, Blood
(CD3/CD8/CD57 Cells, #, Blood)
Cd3/cd8/cd57, %, Blood
(CD3/CD8/CD57, %, Blood)
Cd3/hla-dr, #, Blood (CD3/HLA-DR, #,
Blood)
Cd3/hla-dr, %, Blood (CD3/HLA-DR, %,
Blood)
Cd38 Cells, #, Blood (CD38 Cells, #,
Blood)
Cd4 Cells To Cd3 Cells, #, Blood (CD4
Cells to CD3 Cells, #, Blood)
Cd4 Cells To Cd3 Cells, %, Blood (CD4
Cells to CD3 Cells, %, Blood)
Cd4 Cells To Cd8 Cells Ratio, Blood
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(CD4 Cells to CD8 Cells Ratio, Blood)
Cd4 Cells, #, Blood (CD4 Cells, #, Blood)
Cd4 Cells, %, Flow Cytometry, Blood
(CD4 Cells, %, Flow Cytometry, Blood)
Cd4/7g7 Cells, #, Blood (CD4/7G7 Cells,
#, Blood)
Cd4/7g7 Cells, %, Blood (CD4/7G7
Cells, %, Blood)
Cd4/cd25 Cells, #, Blood (CD4/CD25
Cells, #, Blood)
Cd4/cd25 Cells, %, Blood (CD4/CD25
Cells, %, Blood)
Cd4/cd25 Pe Cells, #, Blood (CD4/CD25
PE Cells, #, Blood)
Cd4/cd25 Pe Cells, %, Blood (CD4/CD25
PE Cells, %, Blood)
Cd4/cd25/cd62l Cells, #, Blood
(CD4/CD25/CD62L Cells, #, Blood)
Cd4/cd25/cd62l Cells, %, Blood
(CD4/CD25/CD62L Cells, %, Blood)
Cd4/cd25/cd69 Cells, #, Blood
(CD4/CD25/CD69 Cells, #, Blood)
Cd4/cd25/cd69 Cells, %, Blood
(CD4/CD25/CD69 Cells, %, Blood)
Cd4/cd30 Cells, #, Blood (CD4/CD30
Cells, #, Blood)
Cd4/cd30 Cells, %, Blood (CD4/CD30
Cells, %, Blood)
Cd4/cd45ra, #, Blood (CD4/CD45RA, #,
Blood)
Cd4/cd45ra, %, Blood (CD4/CD45RA,
%, Blood)
Cd4/cd45ra+cd45ro, #, Blood
(CD4/CD45RA+CD45RO, #, Blood)
Cd4/cd45ra+cd45ro, %, Blood
(CD4/CD45RA+CD45RO, %, Blood)
Cd4/cd45ro, #, Blood (CD4/CD45RO, #,
Blood)
Cd4/cd45ro, %, Blood (CD4/CD45RO,
%, Blood)
Cd4/cd62l-/cd45ra, #, Blood
(CD4/CD62L-/CD45RA, #, Blood)
Cd4/cd62l-/cd45ra, %, Blood
(CD4/CD62L-/CD45RA, %, Blood)
Cd4/cd62l, #, Blood (CD4/CD62L, #,
Blood)
Cd4/cd62l, %, Blood (CD4/CD62L, %,
Blood)
Cd4/cd62l/cd45ra, #, Blood
(CD4/CD62L/CD45RA, #, Blood)
Cd4/cd62l/cd45ra, %, Blood
(CD4/CD62L/CD45RA, %, Blood)
Cd4/hla-dr, #, Blood (CD4/HLA-DR, #,
Blood)
Cd4/hla-dr, %, Blood (CD4/HLA-DR, %,
Blood)
Cd45 Cells, #, Blood (CD45 Cells, #,
Blood)
Cd5 Cells, %, Blood (CD5 Cells, %,
Blood)
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Cd52 Cells, #, Blood (CD52 Cells, #,
Blood)
Cd7 Cells, #, Blood (CD7 Cells, #, Blood)
Cd7 Cells, %, Blood (CD7 Cells, %,
Blood)
Cd7-/cd25 Pe Cells, #, Blood (CD7-
/CD25 PE Cells, #, Blood)
Cd7-/cd25 Pe Cells, %, Blood (CD7-
/CD25 PE Cells, %, Blood)
Cd7/cd25 Pe Cells, #, Blood (CD7/CD25
PE Cells, #, Blood)
Cd7/cd25 Pe Cells, %, Blood (CD7/CD25
PE Cells, %, Blood)
Cd8 Cells, #, Blood (CD8 Cells, #, Blood)
Cd8 Cells, %, Flow Cytometry, Blood
(CD8 Cells, %, Flow Cytometry, Blood)
Cd8/cd25 Pe, #, Blood (CD8/CD25 PE,
#, Blood)
Cd8/cd25 Pe, %, Blood (CD8/CD25 PE,
%, Blood)
Cd8/cd25, #, Blood (CD8/CD25, #,
Blood)
Cd8/cd25, %, Blood (CD8/CD25, %,
Blood)
Cd8/cd3, #, Blood (CD8/CD3, #, Blood)
Cd8/cd3, %, Blood (CD8/CD3, %, Blood)
Cd8/cd45ra, #, Blood (CD8/CD45RA, #,
Blood)
Cd8/cd45ra, %, Blood (CD8/CD45RA,
%, Blood)
Cd8/cd45ra+cd45ro, #, Blood
(CD8/CD45RA+CD45RO, #, Blood)
Cd8/cd45ra+cd45ro, %, Blood
(CD8/CD45RA+CD45RO, %, Blood)
Cd8/cd45ro, #, Blood (CD8/CD45RO, #,
Blood)
Cd8/cd45ro, %, Blood (CD8/CD45RO,
%, Blood)
Cd8/cd57, #, Blood (CD8/CD57, #,
Blood)
Cd8/cd57, %, Blood (CD8/CD57, %,
Blood)
Cd8/cd62l-/cd45ra, #, Blood
(CD8/CD62L-/CD45RA, #, Blood)
Cd8/cd62l-/cd45ra, %, Blood
(CD8/CD62L-/CD45RA, %, Blood)
Cd8/cd62l, #, Blood (CD8/CD62L, #,
Blood)
Cd8/cd62l, %, Blood (CD8/CD62L, %,
Blood)
Cd8/cd62l/cd45ra, #, Blood
(CD8/CD62L/CD45RA, #, Blood)
Cd8/cd62l/cd45ra, %, Blood
(CD8/CD62L/CD45RA, %, Blood)
Cd8/hla-dr, #, Blood (CD8/HLA-DR, #,
Blood)
Cd8/hla-dr, %, Blood (CD8/HLA-DR, %,
Blood)
Cell Count, Cerebrospinal Fluid (Cell
Count, Cerebrospinal Fluid)
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Cellularity, %, Bone Marrow (Cellularity,
%, Bone Marrow)
Centromere, Antibody, Serum
(Centromere, Antibody, Serum)
Ch50 Complement, Serum (CH50
Complement, Serum)
Chloride, 24 Hour, Urine (Chloride, 24
hour, Urine)
Chloride, Serum (Chloride, Serum)
Cholestanol, Serum (Cholestanol,
Serum)
Cholesterol To High Density Lipids (hdl),
Ratio, Serum (Cholesterol to High
Density Lipids (HDL), Ratio, Serum)
Cholesterol, Serum (Cholesterol, Serum)
Clean Catch Culture, Urine (Clean Catch
Culture, Urine)
Co2 (carbon Dioxide), Exhaled Gas
(CO2 (Carbon Dioxide), Exhaled Gas)
Coarse Granular Casts, Spot Urine
(Coarse Granular Casts, Spot Urine)
Color, Cerebrospinal Fluid (Color,
Cerebrospinal Fluid)
Color, Urine (Color, Urine)
Complement, C3, Serum (Complement,
C3, Serum)
Complement, C4, Serum (Complement,
C4, Serum)
Cortisol, Blood (Cortisol, Blood)
24 Hours Urine Creatinine Clearance
(Creatinine Clearance, 24 hour, Urine)
Creatinine Kinase (ck), Serum
(Creatinine Kinase (CK), Serum)
Creatinine, Serum (Creatinine, Serum)
Serum Creatinine (Creatinine, Serum)
Creatinine, Spot Or Timed Sample, Urine
(Creatinine, Spot or Timed Sample,
Urine)
Crystrals, Spot Urine (Crystrals, Spot
Urine)
Culture, Blood (Culture, Blood)
Culture, Cerebrospinal Fluid (Culture,
Cerebrospinal Fluid)
Culture, Respiratory Virus, Nasopharynx
(Culture, Respiratory Virus,
Nasopharynx)
Culture, Sputum (Culture, Sputum)
Culture, Stool (Culture, Stool)
Cyclic Citrullinated Peptide (ccp),
Antibody, Serum (Cyclic Citrullinated
Peptide (CCP), Antibody, Serum)
Cyclosporine, Blood (Cyclosporine,
Blood)
Cytomegalovirus (cmv) Antibody, Igg,
Serum (Cytomegalovirus (CMV)
Antibody, IgG, Serum)
Cytomegalovirus (cmv) Antibody, Igm,
Serum (Cytomegalovirus (CMV)
Antibody, IgM, Serum)
Cytomegalovirus (cmv) Antigenemia,
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Blood (Cytomegalovirus (CMV)
Antigenemia, Blood)
Cytomegalovirus, Dna, Polymerase
Chain Reaction, Cerebrospinal Fluid
(Cytomegalovirus, DNA, Polymerase
Chain Reaction, Cerebrospinal Fluid)
Dako Egfr Pharmdx
Immunohistochemical Labeling, Tissue
(Dako EGFR Pharmdx
Immunohistochemical Labeling, Tissue)
Diffuse Cytoplasmic Anti-neutrophil
Cytoplasmic Antibody, Serum (Diffuse
Cytoplasmic Anti-Neutrophil Cytoplasmic
Antibody, Serum)
Diffusing Capacity % Predicted,
Respiratory System (Diffusing Capacity
% Predicted, Respiratory System)
Diffusing Capacity To Alveolar Ventilation
Ratio %, Respiratory System (Diffusing
Capacity to Alveolar Ventilation Ratio %,
Respiratory System)
Diffusing Capacity To Alveolar Ventilation
Ratio, Respiratory System (Diffusing
Capacity to Alveolar Ventilation Ratio,
Respiratory System)
Diffusion Capacity Carbon Monoxide (dl)
Adjusted, % Predicted, Respiratory
System (Diffusion Capacity Carbon
Monoxide (DL) Adjusted, % Predicted,
Respiratory System)
Diffusion Capacity Carbon Monoxide (dl)
Adjusted, Respiratory System (Diffusion
Capacity Carbon Monoxide (DL)
Adjusted, Respiratory System)
Diffusion Capacity, Respiratory System
(Diffusion Capacity, Respiratory System)
Diphtheriae Antibody, Serum
(Diphtheriae Antibody, Serum)
Direct Antiglobulin Test (coombs), Red
Blood Cells (Direct Antiglobulin Test
(Coombs), Red Blood Cells)
Dna-tcr B Chain, Blood (DNA-TCR B
Chain, Blood)
Dopamine, 24 Hour, Urine (Dopamine,
24 hour, Urine)
Double Negative T (dnt) Cells, #, Blood
(Double Negative T (DNT) Cells, #,
Blood)
Double Negative T (dnt) Cells, %, Blood
(Double Negative T (DNT) Cells, %,
Blood)
Double Strand Dna (dsdna) Antibody,
Serum (Double Strand DNA (DSDNA)
Antibody, Serum)
Egfr Vxxi Immunohistochemical
Labeling, Tissue (EGFR vXXI
Immunohistochemical Labeling, Tissue)
Egfr Vxxi Immunohistochemical
Labeling, Tissue (EGFR vXXI
Immunohistochemical Labeling, Tissue)
8 / 23
Lab - OTHER LABS - 2403698v1.0
Eosinophils, #, Blood (Eosinophils, #,
Blood)
Eosinophils, %, Blood (Eosinophils, %,
Blood)
Epinephrine, 24 Hour, Urine
(Epinephrine, 24 hour, Urine)
Epstein Barr Virus (ebv) Antibody, Serum
(Epstein Barr Virus (EBV) Antibody,
Serum)
Epstein Barr Virus (ebv) Nuclear
Antibody, Serum (Epstein Barr Virus
(EBV) Nuclear Antibody, Serum)
Epstein-barr Virus (ebv) Early Antigen,
Serum (Epstein-Barr Virus (EBV) Early
Antigen, Serum)
Epstein-barr Virus (ebv), Igm , Serum
(Epstein-Barr Virus (EBV), IgM , Serum)
Epstein-barr Virus (ebv), Nuclear
Antibody, Igg, Serum (Epstein-Barr Virus
(EBV), Nuclear Antibody, IgG, Serum)
Erythrocyte Sedimentation Rate (esr),
Blood (Erythrocyte Sedimentation Rate
(ESR), Blood)
Estimated Creatinine Renal Clearance,
Urine (Estimated Creatinine Renal
Clearance, Urine)
Estradiol, Serum (Estradiol, Serum)
Expiratory Reserve Volume (erv), %
Predicted, Respiratory System
(Expiratory Reserve Volume (ERV), %
Predicted, Respiratory System)
Expiratory Reserve Volume (erv),
Respiratory System (Expiratory Reserve
Volume (ERV), Respiratory System)
Expiratory Volume, Respiratory System
(Expiratory Volume, Respiratory System)
Extractable Nuclear Antigens (ena)
Screen, Blood (Extractable Nuclear
Antigens (ENA) Screen, Blood)
Fab Marrow Rating, Bone Marrow (FAB
Marrow Rating, Bone Marrow)
Ferritin, Serum (Ferritin, Serum)
Fetal Hemoglobin, Blood (Fetal
Hemoglobin, Blood)
Fev1 To Fvc Predicted Ratio, Respiratory
System (FEV1 to FVC Predicted Ratio,
Respiratory System)
Fev1 To Fvc Ratio, Post, Respiratory
System (FEV1 to FVC Ratio, Post,
Respiratory System)
Fev1 To Fvc Ratio, Pre, Respiratory
System (FEV1 to FVC Ratio, Pre,
Respiratory System)
Fev1 To Fvc Ratio, Respiratory System
(FEV1 to FVC Ratio, Respiratory
System)
Fibrin Degradation Products (fdp), Blood
(Fibrin Degradation Products (FDP),
Blood)
Fibrinogen, Auto, Platelet Poor Plasma
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(Fibrinogen, Auto, Platelet Poor Plasma)
Fibrinogen, Blood (Fibrinogen, Blood)
Fibrinogen, Fibrometer, Platelet Poor
Plasma (Fibrinogen, Fibrometer, Platelet
Poor Plasma)
Fine Granular Casts, Spot Urine (Fine
Granular Casts, Spot Urine)
Fluorescent Activated Cell Sorting (facs)
Lymphoid Cells, #, Blood (Fluorescent
Activated Cell Sorting (FACS) Lymphoid
Cells, #, Blood)
Folate, Serum (Folate, Serum)
Forced Expiratory Flow (fef), During
Midportion Of Expiratory Cycle, Post, %
Change, Respiratory System (Forced
Expiratory Flow (FEF), during midportion
of expiratory cycle, Post, % Change,
Respiratory System)
Forced Expiratory Flow (fef), During
Midportion Of Expiratory Cycle, Post, %
Predicted, Respiratory System (Forced
Expiratory Flow (FEF), during midportion
of expiratory cycle, Post, % Predicted,
Respiratory System)
Forced Expiratory Flow (fef), During
Midportion Of Expiratory Cycle, Post,
Respiratory System (Forced Expiratory
Flow (FEF), during midportion of
expiratory cycle, Post, Respiratory
System)
Forced Expiratory Flow (fef), During
Midportion Of Expiratory Cycle, Pre, %
Predicted, Respiratory System (Forced
Expiratory Flow (FEF), during midportion
of expiratory cycle, Pre, % Predicted,
Respiratory System)
Forced Expiratory Flow (fef), During
Midportion Of Expiratory Cycle, Pre,
Respiratory System (Forced Expiratory
Flow (FEF), during midportion of
expiratory cycle, Pre, Respiratory
System)
Forced Expiratory Technique (fet), 100%,
Post, Respiratory System (Forced
Expiratory Technique (FET), 100%, Post,
Respiratory System)
Forced Expiratory Technique (fet), 100%,
Pre, Respiratory System (Forced
Expiratory Technique (FET), 100%, Pre,
Respiratory System)
Forced Expiratory Volume % Predicted,
Respiratory System (Forced Expiratory
Volume % Predicted, Respiratory
System)
Forced Expiratory Volume 1 Second
(fev1) Slope, Respiratory System
(Forced Expiratory Volume 1 Second
(FEV1) Slope, Respiratory System)
Forced Expiratory Volume 1 Second
(fev1), Post, % Change, Respiratory
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System (Forced Expiratory Volume 1
Second (FEV1), Post, % Change,
Respiratory System)
Forced Expiratory Volume 1 Second
(fev1), Post, % Predicted, Respiratory
System (Forced Expiratory Volume 1
Second (FEV1), Post, % Predicted,
Respiratory System)
Forced Expiratory Volume 1 Second
(fev1), Post, Respiratory System (Forced
Expiratory Volume 1 Second (FEV1),
Post, Respiratory System)
Forced Expiratory Volume 1 Second
(fev1), Pre, % Predicted, Respiratory
System (Forced Expiratory Volume 1
Second (FEV1), Pre, % Predicted,
Respiratory System)
Forced Expiratory Volume 1 Second
(fev1), Pre, Respiratory System (Forced
Expiratory Volume 1 Second (FEV1),
Pre, Respiratory System)
Forced Expiratory Volume, Respiratory
System (Forced Expiratory Volume,
Respiratory System)
Forced Vital Capacity (fvc) % Predicted,
Respiratory System (Forced Vital
Capacity (FVC) % Predicted, Respiratory
System)
Forced Vital Capacity (fvc), Post, %
Change, Respiratory System (Forced
Vital Capacity (FVC), Post, % Change,
Respiratory System)
Forced Vital Capacity (fvc), Post, %
Predicted, Respiratory System (Forced
Vital Capacity (FVC), Post, % Predicted,
Respiratory System)
Forced Vital Capacity (fvc), Post,
Respiratory System (Forced Vital
Capacity (FVC), Post, Respiratory
System)
Forced Vital Capacity (fvc), Pre, %
Predicted, Respiratory System (Forced
Vital Capacity (FVC), Pre, % Predicted,
Respiratory System)
Forced Vital Capacity (fvc), Pre,
Respiratory System (Forced Vital
Capacity (FVC), Pre, Respiratory
System)
Forced Vital Capacity (fvc), Respiratory
System (Forced Vital Capacity (FVC),
Respiratory System)
Forced Vital Capacity (maximum),
Respiratory System (Forced Vital
Capacity (Maximum), Respiratory
System)
Functional Residual Capacity (frc), %
Predicted, Respiratory System
(Functional Residual Capacity (FRC), %
Predicted, Respiratory System)
Functional Residual Capacity,
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Respiratory System (Functional Residual
Capacity, Respiratory System)
Gamma Globulin, Electrophoresis, Timed
Urine (Gamma Globulin, Electrophoresis,
Timed Urine)
Gamma Globulin, Protein
Electrophoresis, Serum (Gamma
Globulin, Protein Electrophoresis,
Serum)
Gamma Glutamyl Transferase (ggt),
Serum (Gamma Glutamyl Transferase
(GGT), Serum)
Glomerular Filtration Rate, Manual
Calculation, Blood (Glomerular Filtration
Rate, Manual Calculation, Blood)
Glucose, Csf (Glucose, CSF)
Glucose, Fasting, Serum (Glucose,
Fasting, Serum)
Glucose, Non-fasting, Serum (Glucose,
Non-fasting, Serum)
Serum Glucose (Glucose, Serum)
Glucose, Spot Urine (Glucose, Spot
Urine)
Haptoglobin, Serum (Haptoglobin,
Serum)
Helicobactor Pylori Antibody, Igg, Serum
(Helicobactor Pylori Antibody, IgG,
Serum)
Hematocrit, %, Blood (Hematocrit, %,
Blood)
Hemoglobin (hgb) A1c, Blood
(Hemoglobin (Hgb) A1C, Blood)
Hemoglobin, Blood (Hemoglobin, Blood)
Hemoglobin, Spot Urine (Hemoglobin,
Spot Urine)
Hepatitis A Virus Antibody (hav), Igm,
Serum (Hepatitis A Virus Antibody
(HAV), IgM, Serum)
Hepatitis A Virus Antibody (hav), Total,
Serum (Hepatitis A Virus Antibody
(HAV), Total, Serum)
Hepatitis B Core Antibody, Serum
(Hepatitis B Core Antibody, Serum)
Hepatitis B Surface Antigen, Serum
(Hepatitis B Surface Antigen, Serum)
Hepatitis C Antibody, Serum (Hepatitis C
Antibody, Serum)
Hepatitis C Virus, Rna, Reverse
Transcriptase (rt), Polymerase Chain
Reaction (pcr), Serum (Hepatitis C Virus,
RNA, Reverse Transcriptase (RT),
Polymerase Chain Reaction (PCR),
Serum)
Herpes Simplex Virus (hsv) 1/2, Igm,
Serum (Herpes Simplex Virus (HSV) 1/2,
IgM, Serum)
Herpes Simplex Virus 1 (hsv1) Igg,
Serum (Herpes Simplex Virus 1 (HSV1)
IgG, Serum)
Herpes Simplex Virus 2 (hsv2) Igg,
12 / 23
Lab - OTHER LABS - 2403698v1.0
Serum (Herpes Simplex Virus 2 (HSV2)
IgG, Serum)
High Density Lipoprotein, Cholesterol,
Serum (High Density Lipoprotein,
Cholesterol, Serum)
Histamine, Tissue (Histamine, Tissue)
Hiv Viral Load, Cerebrospinal Fluid (HIV
Viral Load, Cerebrospinal Fluid)
Hiv Viral Load, Serum (HIV Viral Load,
Serum)
Hiv1 Log Viral Load, Polymerase Chain
Reaction (pcr), Cerebrospinal Fluid
(HIV1 Log Viral Load, Polymerase Chain
Reaction (PCR), Cerebrospinal Fluid)
Hiv1 Log Viral Load, Polymerase Chain
Reaction (pcr), Plasma (HIV1 Log Viral
Load, Polymerase Chain Reaction
(PCR), Plasma)
Hla A Antigen, White Blood Cells (HLA A
Antigen, White Blood Cells)
Hla B Antigen, White Blood Cells (HLA B
Antigen, White Blood Cells)
Hla Cw Antigen, White Blood Cells (HLA
Cw Antigen, White Blood Cells)
Hla Dqb1 Antigen, White Blood Cells
(HLA DQB1 Antigen, White Blood Cells)
Hla Dr Antigen, White Blood Cells (HLA
DR Antigen, White Blood Cells)
Hla Drb Antigen, White Blood Cells (HLA
DRB Antigen, White Blood Cells)
Hla Drb1 Antigen, White Blood Cells
(HLA DRB1 Antigen, White Blood Cells)
Hla-a03 Subtype Antigen, White Blood
Cells (HLA-A03 Subtype Antigen, White
Blood Cells)
Hla-a2 Antigen, White Blood Cells (HLA-
A2 Antigen, White Blood Cells)
Hla-a24 Subtype Antigen (HLA-A24
Subtype Antigen)
Hla-a3 Subtype Antigen (HLA-A3
Subtype Antigen)
Htlv1/htlv2 Antibody, Serum
(HTLV1/HTLV2 Antibody, Serum)
Human Anti-mouse Antibody, Blood
(Human Anti-Mouse Antibody, Blood)
Human Choriogonadotropin (hcg),
Serum (Human Choriogonadotropin
(HCG), Serum)
Human Growth Hormone (hgh), Serum
(Human Growth Hormone (HGH),
Serum)
Human Immunodeficiency Virus (hiv) 1,
Antibody, Western Blot, Serum (Human
Immunodeficiency Virus (HIV) 1,
Antibody, Western Blot, Serum)
Human Immunodeficiency Virus (hiv) 1,
Western Blot, Serum (Human
Immunodeficiency Virus (HIV) 1,
Western Blot, Serum)
Human Immunodeficiency Virus (hiv), 1-
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2 Antibody, Serum (Human
Immunodeficiency Virus (HIV), 1-2
Antibody, Serum)
Hyaline Casts, Spot Urine (Hyaline
Casts, Spot Urine)
Igf-1 (human Growth Hormone), Blood
(IGF-1 (Human Growth Hormone),
Blood)
Immunoglobulin A (iga), Serum
(Immunoglobulin A (IgA), Serum)
Immunoglobulin D (igd), Serum
(Immunoglobulin D (IgD), Serum)
Immunoglobulin E (ige), Serum
(Immunoglobulin E (IgE), Serum)
Immunoglobulin G (igg), Serum
(Immunoglobulin G (IgG), Serum)
Immunoglobulin M (igm),
Immunoelectrophoresis, Spot Urine
(Immunoglobulin M (IgM),
Immunoelectrophoresis, Spot Urine)
Immunoglobulin M (igm), Serum
(Immunoglobulin M (IgM), Serum)
Inhibin A, Blood (Inhibin A, Blood)
Inhibin B, Blood (Inhibin B, Blood)
Inspiratory Capacity (ic), % Predicted,
Respiratory System (Inspiratory Capacity
(IC), % Predicted, Respiratory System)
Inspiratory Capacity (ic), Respiratory
System (Inspiratory Capacity (IC),
Respiratory System)
Insulin-life Growth Factor Binding Protein
3, Serum (Insulin-life Growth Factor
Binding Protein 3, Serum)
Insulin, Serum (Insulin, Serum)
International Normalized Ratio (inr),
Prothrombin Time, Blood (International
Normalized Ratio (INR), Prothrombin
Time, Blood)
Iodine, 24 Hour, Urine (Iodine, 24 hour,
Urine)
Iodine, Concentration, 24 Hour, Urine
(Iodine, Concentration, 24 hour, Urine)
Iodine, Free, 24 Hour, Urine (Iodine,
Free, 24 hour, Urine)
Iron Saturation, Ratio, Serum (Iron
Saturation, Ratio, Serum)
Iron, Serum (Iron, Serum)
Ketones, Spot Urine (Ketones, Spot
Urine)
Lactate Dehydrogenase (ldh), Serum
(Lactate Dehydrogenase (LDH), Serum)
Lactate, Cerebrospinal Fluid (Lactate,
Cerebrospinal Fluid)
Lamotrigine, Serum (Lamotrigine,
Serum)
Large Unstained Cells, #, Blood (Large
Unstained Cells, #, Blood)
Large Unstained Cells, %, Blood (Large
Unstained Cells, %, Blood)
Leukocyte Esterase, Spot Urine
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(Leukocyte Esterase, Spot Urine)
Levetiracetam, Serum (Levetiracetam,
Serum)
Lipase, Serum (Lipase, Serum)
Liver Kidney Microsomal Antibody,
Serum (Liver Kidney Microsomal
Antibody, Serum)
Low Density Lipoproteins, Cholesterol,
Serum (Low Density Lipoproteins,
Cholesterol, Serum)
Lupus Anticoagulant, Platelet Poor
Plasma (Lupus Anticoagulant, Platelet
Poor Plasma)
Lupus Anticoagulant, Staclot, Platelet
Poor Plasma (Lupus Anticoagulant,
Staclot, Platelet Poor Plasma)
Lymphocytes Variants, %, Blood
(Lymphocytes Variants, %, Blood)
Lymphocytes, #, Blood (Lymphocytes, #,
Blood)
Lymphocytes, %, Blood (Lymphocytes,
%, Blood)
Lymphocytes, %, Bone Marrow
(Lymphocytes, %, Bone Marrow)
Lymphocytes, %, Cerebrospinal Fluid
(Lymphocytes, %, Cerebrospinal Fluid)
Lymphocytes, Variant, #, Blood
(Lymphocytes, Variant, #, Blood)
Magnesium, Serum (Magnesium,
Serum)
Maximum Forced Expiratory Flow,
Respiratory System (Maximum Forced
Expiratory Flow, Respiratory System)
Mean Corpuscular Hemoglobin (mch),
Red Blood Cells (Mean Corpuscular
Hemoglobin (MCH), Red Blood Cells)
Mean Corpuscular Hemoglobin
Concentration (mchc), Red Blood Cells
(Mean Corpuscular Hemoglobin
Concentration (MCHC), Red Blood Cells)
Mean Corpuscular Volume (mcv), Red
Blood Cells (Mean Corpuscular Volume
(MCV), Red Blood Cells)
Megakaryocytes, %, Bone Marrow
(Megakaryocytes, %, Bone Marrow)
Metamyelocytes, %, Bone Marrow
(Metamyelocytes, %, Bone Marrow)
Metanephrine, 24 Hour, Urine
(Metanephrine, 24 hour, Urine)
Metanephrine, Unconjugated, 24 Hour,
Urine (Metanephrine, Unconjugated, 24
hour, Urine)
Mgmt (o6-methylguanine-dna
Methyltransferase) Immunohistochemical
Labeling, Tissue (MGMT (O6-
methylguanine-DNA methyltransferase)
Immunohistochemical Labeling, Tissue)
Mitochondrial Antibody, Serum
(Mitochondrial Antibody, Serum)
Monocytes, #, Blood (Monocytes, #,
15 / 23
Lab - OTHER LABS - 2403698v1.0
Blood)
Monocytes, %, Blood (Monocytes, %,
Blood)
Monocytes, %, Bone Marrow
(Monocytes, %, Bone Marrow)
Mucous, Spot Urine (Mucous, Spot
Urine)
Mullerian Inhibiting Substance, Serum
(Mullerian inhibiting substance, Serum)
Myelin Basic Protein, Cerebrospinal
Fluid (Myelin Basic Protein,
Cerebrospinal Fluid)
Myelocytes, %, Bone Marrow
(Myelocytes, %, Bone Marrow)
Myelocytes, %, Bone Marrow
(Myelocytes, %, Bone Marrow)
N1 Acetylspermidine, Tissue (N1
Acetylspermidine, Tissue)
N1 Acetylspermine, Tissue (N1
Acetylspermine, Tissue)
N8 Acetylspermidine, Tissue (N8
Acetylspermidine, Tissue)
Natural Killer (nk) Cells, #, Blood (Natural
Killer (NK) Cells, #, Blood)
Natural Killer (nk) Cells, %, Blood
(Natural Killer (NK) Cells, %, Blood)
Natural Killer T Cells, #, Blood (Natural
Killer T Cells, #, Blood)
Natural Killer T Cells, %, Blood (Natural
Killer T Cells, %, Blood)
Neutralizing Antibody Bl22, Serum
(Neutralizing Antibody BL22, Serum)
Neutralizing Antibody Lmb-2, Serum
(Neutralizing Antibody LMB-2, Serum)
Neutrophil Bands, #, Blood (Neutrophil
Bands, #, Blood)
Neutrophil Bands, %, Blood (Neutrophil
Bands, %, Blood)
Neutrophils, %, Blood (Neutrophils, %,
Blood)
Nitrite, Spot Urine (Nitrite, Spot Urine)
Norepinephrine, 24 Hour, Urine
(Norepinephrine, 24 hour, Urine)
Normetanephrine, 24 Hour, Urine
(Normetanephrine, 24 hour, Urine)
Nucleated Red Blood Cells (nrbc), #,
Blood (Nucleated Red Blood Cells
(NRBC), #, Blood)
Osmolality, 24 Hour, Urine (Osmolality,
24 hour, Urine)
Osmolality, Serum (Osmolality, Serum)
Other Cell Count, Cerebrospinal Fluid
(Other Cell Count, Cerebrospinal Fluid)
Pakt Immunohistochemical Labeling,
Tissue (pAKT Immunohistochemical
Labeling, Tissue)
Parathyroid Hormone, Intact, Blood
(Parathyroid Hormone, Intact, Blood)
Parietal Cell Antibody, Serum (Parietal
Cell Antibody, Serum)
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Partial Thromboplastin Time (Partial
Prothromboplastin Time (PTT), Blood)
Percent Carbon Dioxide (pco2), Arterial
Blood (Percent Carbon Dioxide (pCO2),
Arterial Blood)
Percent Oxygen (po2), Arterial Blood
(Percent Oxygen (pO2), Arterial Blood)
Ph, Arterial Blood (pH, Arterial Blood)
Ph, Spot Urine (pH, Spot Urine)
Ph, Venous Blood (pH, Venous Blood)
Phenytoin, Serum (Phenytoin, Serum)
Phosphate (inorganic Phosphorus),
Serum (Phosphate (inorganic
Phosphorus), Serum)
Plasma Cells, %, Bone Marrow (Plasma
Cells, %, Bone Marrow)
Platelet Mean Volume (pmv), Blood
(Platelet Mean Volume (PMV), Blood)
Blood Platelets (Platelets, Blood)
Polymorphonuclear Cells (polys), #,
Blood (Polymorphonuclear Cells (Polys),
#, Blood)
Polymorphonuclear Cells (polys), %,
Blood (Polymorphonuclear Cells (Polys),
%, Blood)
Potassium, 24 Hour, Urine (Potassium,
24 hour, Urine)
Potassium, Serum (Potassium, Serum)
Prealbumin, Serum (Prealbumin, Serum)
Progesterone, Serum/plasma
(Progesterone, Serum/Plasma)
Promyelocytes, %, Bone Marrow
(Promyelocytes, %, Bone Marrow)
Prostaglandin E2, Tissue (Prostaglandin
E2, Tissue)
Prostate Specific Antigen (psa), Serum
(Prostate Specific Antigen (PSA),
Serum)
Protein Excretion, 24 Hour, Urine
(Protein excretion, 24 hour, Urine)
Protein-creatinine Ratio, Urine (Protein-
Creatinine Ratio, Urine)
Protein, 24 Hour, Urine (Protein, 24 hour,
Urine)
Protein, Csf (Protein, CSF)
Protein, Qualitative, Urine (Protein,
Qualitative, Urine)
Prothrombin Time (Prothrombin Time
(PT), Blood)
Pten Immunohistochemical Labeling,
Tissue (PTEN Immunohistochemical
Labeling, Tissue)
Putrescine, Tissue (Putrescine, Tissue)
Rapid Plasma Reagin (rpr), Serum
(Rapid Plasma Reagin (RPR), Serum)
Red Blood Cells (rbc), #, Blood (Red
Blood Cells (RBC), #, Blood)
Red Blood Cells (rbc), #, Cerebrospinal
Fluid (Red Blood Cells (RBC), #,
Cerebrospinal Fluid)
17 / 23
Lab - OTHER LABS - 2403698v1.0
Red Blood Cells (rbc), Microscopy, #,
Spot Urine (Red Blood Cells (RBC),
Microscopy, #, Spot Urine)
Red Blood Cells (rbc), Microscopy, Spot
Urine (Red Blood Cells (RBC),
Microscopy, Spot Urine)
Red Cell Distribution Width (rdw), Red
Blood Cells (Red Cell Distribution Width
(RDW), Red Blood Cells)
Renal Epithelial Cells, Spot Urine (Renal
Epithelial Cells, Spot Urine)
Residual Volume To Total Lung Capacity
Ratio, Respiratory System (Residual
Volume to Total Lung Capacity Ratio,
Respiratory System)
Respiratory Volume (rv), % Predicted,
Respiratory System (Respiratory Volume
(RV), % Predicted, Respiratory System)
Reticulocytes, %, Bone Marrow
(Reticulocytes, %, Bone Marrow)
Reticulocytes, %, Red Blood Cells
(Reticulocytes, %, Red Blood Cells)
Rheumatoid Factor, Serum (Rheumatoid
Factor, Serum)
Ribonucleoprotein Extractable Nuclear
(rnp) Antibody, Serum
(Ribonucleoprotein Extractable Nuclear
(RNP) Antibody, Serum)
Sirolimus (rapamycin), Blood (Sirolimus
(Rapamycin), Blood)
Sjogren's Syndrome-a Extractable
Antibody, Serum (Sjogren's Syndrome-A
Extractable Antibody, Serum)
Sjogren's Syndrome-b Extractable
Antibody, Serum (Sjogren's Syndrome-B
Extractable Antibody, Serum)
Smith Extractable Nuclear Antibody,
Serum (Smith Extractable Nuclear
Antibody, Serum)
Sodium, 24 Hour, Urine (Sodium, 24
hour, Urine)
Sodium, Serum (Sodium, Serum)
Sodium/potassium Ratio, Serum
(Sodium/Potassium Ratio, Serum)
Specific Gravity, Spot Urine (Specific
Gravity, Spot Urine)
Specimen Collection Period, Urine
(Specimen Collection Period, Urine)
Spermidine, Tissue (Spermidine, Tissue)
Spermine, Tissue (Spermine, Tissue)
Squamous Epithelial Cells, Spot Urine
(Squamous Epithelial Cells, Spot Urine)
T Lymphocyte Helper Cells, Blood (T
Lymphocyte Helper Cells, Blood)
T Lymphocyte Suppressor Cells , Blood
(T Lymphocyte Suppressor Cells , Blood)
T Lymphocytes, %, Blood (T
Lymphocytes, %, Blood)
Tacrolimus, Blood (Tacrolimus, Blood)
Testosterone, Total, Serum
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(Testosterone, Total, Serum)
Thrombin Time, Blood (Thrombin Time,
Blood)
Thyroglobulin Antibody, Serum
(Thyroglobulin Antibody, Serum)
Thyroperoxidase Antibody, Serum
(Thyroperoxidase Antibody, Serum)
Thyrotropin (thyroid Stimulating Hormone
Or Tsh), Serum (Thyrotropin (Thyroid
Stimulating Hormone or TSH), Serum)
Thyroxine (t4), Free, Serum (Thyroxine
(T4), Free,  Serum)
Thyroxine (t4), Free, Dialysis, Serum
(Thyroxine (T4), Free, Dialysis, Serum)
Thyroxine (t4), Serum (Thyroxine (T4),
Serum)
Thyroxine Binding Globulin (tbg), Serum
(Thyroxine Binding Globulin (TBG),
Serum)
Total Lung Capacity %, Predicted,
Respiratory System (Total Lung Capacity
%, Predicted, Respiratory System)
Total Lung Capacity %, Respiratory
System (Total Lung Capacity %,
Respiratory System)
Total Protein Electrophoresis, Serum
(Total Protein Electrophoresis, Serum)
Total Protein, Serum (Total Protein,
Serum)
Toxoplasmosa Gondii, Antibody, Igm,
Serum (Toxoplasmosa Gondii, Antibody,
IgM, Serum)
Transferrin, Serum (Transferrin, Serum)
Transitional Cells, Spot Urine
(Transitional Cells, Spot Urine)
Trefoil Factor 1, Tissue (Trefoil Factor 1,
Tissue)
Triglycerides, Serum (Triglycerides,
Serum)
Triiodothyronine (t3), Free, Serum
(Triiodothyronine (T3), Free, Serum)
Triiodothyronine (t3), Serum
(Triiodothyronine (T3), Serum)
Troponin T, Blood (Troponin T, Blood)
Trypanosoma Cruzi Antibody, Igg, Serum
(Trypanosoma cruzi Antibody, IgG,
Serum)
Urate (uric Acid), Serum (Urate (Uric
Acid), Serum)
Uric Acid (urate), 24 Hour, Urine (Uric
Acid (Urate), 24 hour, Urine)
Urobilinogen, Spot Urine (Urobilinogen,
Spot Urine)
Vaccinia Culture, Serum (Vaccinia
Culture, Serum)
Vaccinia Culture, Spot Urine (Vaccinia
Culture, Spot Urine)
Valproate (valproic Acid), Serum
(Valproate (Valproic Acid), Serum)
Varicella Zoster Virus (vzv) Antigen,
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Immunofluorescence, Skin (Varicella
Zoster Virus (VZV) Antigen,
Immunofluorescence, Skin)
Varicella Zoster Virus (vzv) Dna,
Cerebrospinal Fluid (Varicella Zoster
Virus (VZV) DNA, Cerebrospinal Fluid)
Varicella Zoster Virus (vzv), Igg,
Antibody, Serum (Varicella Zoster Virus
(VZV), IgG, Antibody, Serum)
Very Low Density Lipoprotein (vldl)
Cholesterol, Serum (Very Low Density
Lipoprotein (VLDL) Cholesterol, Serum)
Vital Capacity (vc), % Predicted,
Respiratory System (Vital Capacity (VC),
% Predicted, Respiratory System)
Vital Capacity (vc), Respiratory System
(Vital Capacity (VC), Respiratory
System)
Vitamin B12, Serum (Vitamin B12,
Serum)
Vitamin D, 1, 25-dihydroxy, Blood
(Vitamin D, 1, 25-Dihydroxy, Blood)
Vitamin D, 25-dihydroxy, Blood (Vitamin
D, 25-Dihydroxy, Blood)
Volume Expelled During Midportion Of
Expiration % Predicted, Respiratory
System (Volume expelled during
midportion of expiration % Predicted,
Respiratory System)
Volume Expelled During Midportion Of
Expiration, Respiratory System (Volume
expelled during midportion of expiration,
Respiratory System)
Volume Residual, Respiratory System
(Volume Residual, Respiratory System)
Volume, Urine (Volume, Urine)
Blood Leukocyte Count (White Blood
Cells (WBC), #, Blood)
White Blood Cells (wbc), #,
Cerebrospinal Fluid (White Blood Cells
(WBC), #, Cerebrospinal Fluid)
White Blood Cells (wbc), Microscopy,
Spot Urine (White Blood Cells (WBC),
Microscopy, Spot Urine)
White Blood Cells (wbc), Other, % Blood
(White Blood Cells (WBC), Other, %
Blood)
Lab Value
Lab Unit of Measure Name
Per 100 Identifiable White Blood Cells
(/100 WBC)
Per Millimeter Cubed (/mm3)
Percent (%)
Percent Per 100 Wbc (%/100 WBC)
10e12 Cells Per Liter (10E12 Cells/L)
10e3 Cells Per Microliter (10E3
Cells/microL)
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10e6 Cells (10E6 Cells)
10e6 Cells Per Microliter (10E6
Cells/microL)
10e6 Cells Per Millimeter Cubed (10E6
Cells/mm3)
10e7 Cells Per Kilogram (10E7 Cells/kg)
10e8 Cells (10E8 Cells)
10e9 Cells (10E9 Cells)
10e9 Cells Per Liter (10E9 Cells/L)
Complement Activity Enzyme Unit (CAE
Unit)
Cells Per Microliter (Cells/microL)
Copies (Copies)
Cubic Microns (cubic microns)
Enzyme Unit (EU)
Enzyme Units Per Deciliter (EU/dL)
Enzyme Units Per Milliliter (EU/mL)
Femtoliter (fL)
Grams (g) (g)
Gram Per 24 Hours (g/24hr)
Gram Per Deciliter (g/dL)
Gram Per Liter (g/L)
Gram Per Microliter (g/microL)
Per High Power Field (HPF)
International Unit (Iunit)
International Unit Per Liter (IUnit/L)
International Unit Per Meter Squared
(IUnit/m2)
International Unit Per Milliliter (IUnit/mL)
Iu/ml (IUnit/mL)
Kilounit Per Liter (kU/L)
Liter (L)
Liters Per Minute (L/min)
Per Low Power Field (LPF)
Microgram Per 24 Hours (mcg/24hr)
Microgram Per Deciliter (mcg/dL)
Microgram Per Liter (mcg/L)
Microgram Per Milliliter (mcg/mL)
Microgram Per Specimen (mcg/spec)
Milliequivalent (mEq)
Milliequivalents Per 24 Hours (mEq/24hr)
Milliequivalent Per Deciliter (mEq/dL)
Milliequivalent Per Kilogram (mEq/kg)
Milliequivalent Per Liter (mEq/L)
Milligram (mg)
Milligram Per 24 Hours (mg/24hr)
Milligram Per Deciliter (mg/dL)
Milligram Per Kilogram (mg/kg)
Milligram Per Liter (mg/L)
Milligram Per Milliliter (mg/mL)
Milligram Per Milliliter Per Minute
(mg/mL/min)
Micro International Unit Per Milliliter
(microIU/mL)
Microliter (microL)
Micromole Per 24 Hours (micromol/24hr)
Micromole Per Deciliter (micromol/dL)
Micromole Per Liter (micromol/L)
Million Plaque Forming Units (mill PFU)
Million (Million)
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Million Per Microliter (Million/microL)
Million Per Millimeter Cubed
(Million/mm3)
Milliinternational Unit (miu)
Milliinternational Units Per Meter
Squared (miu/m2)
Milliinternational Unit Per Milliliter
(miu/mL)
Milliter (mL)
Milliliter Per Minute (mL/min)
Milliliter Per Minute Times 1.73 Times
Bsa (mL/min/1.73/BSA)
Milliter Per Minute Per Millimeters Of
Mercury (mL/minute/mmHg)
Millimeter Per Hour (mm/hr)
Millimeter Cubed (mm3)
Millimeter Of Mercury (mmHg)
Millimole (mmol)
Millimole Per 24 Hours (mmol/24hr)
Millimole Per Liter (mmol/L)
Milliosmole Per Kilogram (mosmol/kg)
Million Units Per Milliliter (MU/mL)
Not Applicable; No Uom Required (NA)
Nanogram Per Deciliter (ng/dL)
Nanograms Per Milliliter (ng/mL)
Nanogram Per Milliliter Per Hour
(ng/mL/hr)
Nanomole Per Liter (nmol/L)
Nanomole Per Milligram Of Protein
(nMol/mg protein)
Nanomole Per Milliliter (nmol/mL)
No Source Data (No Srce)
Picograms (pg)
Picogram Per Deciliter (pg/dL)
Picrogram Per Milliliter (pg/mL)
Pgpge2/mg Protein (pgPGE2/mg
protein)
Picomole Per Liter (pmol/L)
Ratio (Ratio)
Rna Copies Per Milliliter (RNA
copies/mL)
Seconds (sec)
Thousand (Thousand)
Thousand Per Microliter
(Thousand/microL)
Thousand Per Millimeter Squared
(Thousand/mm2)
Thousand Per Millimeter Cubed
(Thousand/mm3)
Titer (Titer)
Unit (Unit)
Unit Per 24 Hours (Unit/24hr)
Unit Per Liter (Unit/L)
Unit Per Meter Squared (Unit/m2)
Unit Per Millilliter (Unit/mL)
Unit Per Millimeters Cubed (Unit/mm3)
Unknown (Unknown)
Test Result Significance Indicator
No (N)
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Yes (Y)
Laboratory Test Normal Reference Range Text
Laboratory Test Normal Range Indicator
High (High)
Low (Low)
Nonnumeric (Nonnum)
No Range (Norang)
Normal (Normal)
Common Toxicity Criteria Adverse Event Grade
No Adverse Event Or Within Normal
Limits (0)
Mild Adverse Event (1)
Moderate Adverse Event (2)
Severe And Undesirable Adverse Event
(3)
Life-threatening Or Disabling Adverse
Event (4)
Death Related To Adverse Event (5)
Comments
Note Date
Research Comments Text
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Leukemia NCT00085124 Off Treatment - CALGB:
OFF TREATMENT NOTICE - 2076876v3.0
Leukemia NCT00085124 Off Treatment - CALGB: OFF
TREATMENT NOTICE - 2076876v3.0
All rights reserved. Please visit https://medical-data-
models.org/forms/1879
CALGB: OFF TREATMENT NOTICE
Ccrr Module For Calgb: Off Treatment
Notice
(Print or Type Name)
CALGB Form
CALGB Study No
CALGB Patient ID
Amended data?
Yes (Yes)
Patient's Name
Participating Group
Patient Hospital Number
Participating Group Protocol No
Main Member Institution/Adjunct
Participating Group Patient No
REASON OFF TREATMENT (select ONE
REASON ONLY by placing an X in the
appropriate box)
Adverse event (Adverse event)
Other, Specify (Other, specify)
Patient developed other disease. (Patient
developed other disease.)
Patient did not respond to therapy
(Patient did not respond to therapy)
Patient died during treatment (Patient
died during treatment)
Patient had disease progression or
relapse during active treatment. (Patient
had disease progression or relapse
during active treatment.)
Patient refused further protocol
treatment, but consented to be followed.
(Patient refused further protocol
treatment, but consented to be followed.)
Patient refused further protocol
treatment, withdrew consent to be
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followed. Patient is lost to follow-up.
(Patient refused further protocol
treatment, withdrew consent to be
followed. Patient is lost to follow-up.)
Patient taken off of protocol treatment to
receive non-protocol therapy during
active protocol treatment. (Patient taken
off of protocol treatment to receive non-
protocol therapy during active protocol
treatment.)
Patient Withdrawal Or Refusal Prior To
Beginning Protocol Therapy (Patient
withdrawal or refusal prior to beginning
protocol therapy.)
Treatment completed per protocol.
(Treatment completed per protocol.)
Treatment never started (Treatment
never started)
Patient developed other disease. Specify
Reason why treatment was not started:
Specify type of non-protocol treatment:
Other, specify (off treatment reason)
LAST DATE OF PROTOCOL TREATMENT (M D
Y)
Comments
Completed By
Date Completed
2 / 2
Leukemia NCT00085124 Off Treatment - CALGB: OFF TREATMENT
NOTICE - 2076876v3.0
Lab - URINE IMMUNE ELECTRO -
2403564v1.0
Lab - URINE IMMUNE ELECTRO - 2403564v1.0
All rights reserved. Please visit https://medical-data-
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URINE IMMUNE ELECTRO
Urine Immune Electro
Course Number
Course Day Number
Sample Collection Date
Time
Lab Test
Immunoglobulin M (igm),
Immunoelectrophoresis, Spot Urine
(Immunoglobulin M (IgM),
Immunoelectrophoresis, Spot Urine)
Lab Value
Lab Unit of Measure Name
Per 100 Identifiable White Blood Cells
(/100 WBC)
Per Millimeter Cubed (/mm3)
Percent (%)
Percent Per 100 Wbc (%/100 WBC)
10e12 Cells Per Liter (10E12 Cells/L)
10e3 Cells Per Microliter (10E3
Cells/microL)
10e6 Cells (10E6 Cells)
10e6 Cells Per Microliter (10E6
Cells/microL)
10e6 Cells Per Millimeter Cubed (10E6
Cells/mm3)
10e7 Cells Per Kilogram (10E7 Cells/kg)
10e8 Cells (10E8 Cells)
10e9 Cells (10E9 Cells)
10e9 Cells Per Liter (10E9 Cells/L)
Complement Activity Enzyme Unit (CAE
Unit)
Cells Per Microliter (Cells/microL)
Copies (Copies)
Cubic Microns (cubic microns)
Enzyme Unit (EU)
Enzyme Units Per Deciliter (EU/dL)
Enzyme Units Per Milliliter (EU/mL)
Femtoliter (fL)
Grams (g) (g)
Gram Per 24 Hours (g/24hr)
Gram Per Deciliter (g/dL)
Gram Per Liter (g/L)
Gram Per Microliter (g/microL)
Per High Power Field (HPF)
International Unit (Iunit)
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International Unit Per Liter (IUnit/L)
International Unit Per Meter Squared
(IUnit/m2)
International Unit Per Milliliter (IUnit/mL)
Iu/ml (IUnit/mL)
Kilounit Per Liter (kU/L)
Liter (L)
Liters Per Minute (L/min)
Per Low Power Field (LPF)
Microgram Per 24 Hours (mcg/24hr)
Microgram Per Deciliter (mcg/dL)
Microgram Per Liter (mcg/L)
Microgram Per Milliliter (mcg/mL)
Microgram Per Specimen (mcg/spec)
Milliequivalent (mEq)
Milliequivalents Per 24 Hours (mEq/24hr)
Milliequivalent Per Deciliter (mEq/dL)
Milliequivalent Per Kilogram (mEq/kg)
Milliequivalent Per Liter (mEq/L)
Milligram (mg)
Milligram Per 24 Hours (mg/24hr)
Milligram Per Deciliter (mg/dL)
Milligram Per Kilogram (mg/kg)
Milligram Per Liter (mg/L)
Milligram Per Milliliter (mg/mL)
Milligram Per Milliliter Per Minute
(mg/mL/min)
Micro International Unit Per Milliliter
(microIU/mL)
Microliter (microL)
Micromole Per 24 Hours (micromol/24hr)
Micromole Per Deciliter (micromol/dL)
Micromole Per Liter (micromol/L)
Million Plaque Forming Units (mill PFU)
Million (Million)
Million Per Microliter (Million/microL)
Million Per Millimeter Cubed
(Million/mm3)
Milliinternational Unit (miu)
Milliinternational Units Per Meter
Squared (miu/m2)
Milliinternational Unit Per Milliliter
(miu/mL)
Milliter (mL)
Milliliter Per Minute (mL/min)
Milliliter Per Minute Times 1.73 Times
Bsa (mL/min/1.73/BSA)
Milliter Per Minute Per Millimeters Of
Mercury (mL/minute/mmHg)
Millimeter Per Hour (mm/hr)
Millimeter Cubed (mm3)
Millimeter Of Mercury (mmHg)
Millimole (mmol)
Millimole Per 24 Hours (mmol/24hr)
Millimole Per Liter (mmol/L)
Milliosmole Per Kilogram (mosmol/kg)
Million Units Per Milliliter (MU/mL)
Not Applicable; No Uom Required (NA)
Nanogram Per Deciliter (ng/dL)
Nanograms Per Milliliter (ng/mL)
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Nanogram Per Milliliter Per Hour
(ng/mL/hr)
Nanomole Per Liter (nmol/L)
Nanomole Per Milligram Of Protein
(nMol/mg protein)
Nanomole Per Milliliter (nmol/mL)
No Source Data (No Srce)
Picograms (pg)
Picogram Per Deciliter (pg/dL)
Picrogram Per Milliliter (pg/mL)
Pgpge2/mg Protein (pgPGE2/mg
protein)
Picomole Per Liter (pmol/L)
Ratio (Ratio)
Rna Copies Per Milliliter (RNA
copies/mL)
Seconds (sec)
Thousand (Thousand)
Thousand Per Microliter
(Thousand/microL)
Thousand Per Millimeter Squared
(Thousand/mm2)
Thousand Per Millimeter Cubed
(Thousand/mm3)
Titer (Titer)
Unit (Unit)
Unit Per 24 Hours (Unit/24hr)
Unit Per Liter (Unit/L)
Unit Per Meter Squared (Unit/m2)
Unit Per Millilliter (Unit/mL)
Unit Per Millimeters Cubed (Unit/mm3)
Unknown (Unknown)
Test Result Significance Indicator
No (N)
Yes (Y)
Laboratory Test Normal Reference Range Text
Laboratory Test Normal Range Indicator
High (High)
Low (Low)
Nonnumeric (Nonnum)
No Range (Norang)
Normal (Normal)
Common Toxicity Criteria Adverse Event Grade
No Adverse Event Or Within Normal
Limits (0)
Mild Adverse Event (1)
Moderate Adverse Event (2)
Severe And Undesirable Adverse Event
(3)
Life-threatening Or Disabling Adverse
Event (4)
Death Related To Adverse Event (5)
Comments
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Note Date
Research Comments Text
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Leukemia NCT00085124 Pathology - CALGB: LEUKEMIA
TISSUE BANK SPECIMEN ROUTING FORM - 2076722v3.0
Leukemia NCT00085124 Pathology - CALGB: LEUKEMIA
TISSUE BANK SPECIMEN ROUTING FORM -
2076722v3.0
All rights reserved. Please visit https://medical-data-
models.org/forms/1884
CALGB: LEUKEMIA TISSUE BANK
SPECIMEN ROUTING FORM
To Be Completed By Institution
Specimen Type
Tubes Of Bone Marrow (Bone Marrow)
Other, Specify (Buccal Cells)
Tubes Of Blood (Peripheral Blood)
Tissue, Specify Site(s) (Tissue)
Time Specimen Collected (24 hour clock)
Date Specimen Collected (M D Y)
Diagnosis
ALL (ALL)
AML (AML)
APL (APL)
AUL (AUL)
CLL (CLL)
CML (CML)
MDS (MDS)
Sample Period
3 months (3 months)
3 years post diagnosis (3 years post
diagnosis)
6 months (6 months)
9 months (9 months)
After Course I (After Course I)
After Course III (After Course III)
After Course VI (After Course VI)
At Diagnosis (At Diagnosis)
Every 4 months (Every 4 months)
Follow-up (Follow-up)
Follow-up Off Treatment (Follow-up Off
Treatment)
Follow-up Sample (q 12 months) (Follow-
up Sample (q 12 months))
Follow-up Sample (q 6 months) (Follow-
up Sample (q 6 months))
Initial Treatment (Initial Treatment)
Maintenance (Maintenance)
Post Completion of Intensification (Post
Completion of Intensification)
Post IL-2 (Post IL-2)
Sample Or Specimen Collected After
Patient Received Treatment For Cancer
(Post-treatment)
Sample Or Specimen Collected Before
Patient Received Treatment For Cancer
(Pre-treatment)
Prior to Intensification (Prior to
Intensification)
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Relapse (Relapse)
Remission (Remission)
Residual Disease (Residual Disease)
Sample Extraction Method
Large Bore Aspirate (Large Bore
Aspirate)
Small Bore Aspirate (Small Bore
Aspirate)
Swab (Swab)
Venous (Venous)
Sample Preparation Method
Air Dry Smear (Air Dry Smear)
Buccal Swab (Buccal Swab)
Fresh (Fresh)
Touch Prep (Touch Prep)
Sample Container
Conical Screw Top Vial (Conical Screw
Top Vial)
Green Top Vial (Green Top Vial)
Purple Top Vial (Purple Top Vial)
Number of Tubes Submitted
Are the tubes labeled
No (No)
Yes (Yes)
If not, please explain (why tubes are not labeled)
Pathology Report Submitted to Data
Management Center for this Sample Period
No (No)
Yes (Yes)
Completed By
Date Completed
Phone Number (Include Beeper # or Extension)
Lab Use Only
LAB SAMPLE ID #
Number of Tubes Banked
Average Volume Per Tube (ml)
Sample Storage
4 Degrees Celsius (4 degrees celsius)
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Fresh-wet Ice (fresh-wet ice)
Frozen-dry Ice (frozen-dry ice)
Frozen-ice Packs (frozen-ice packs)
Frozen-liquid Nitrogen (frozen-liquid
nitrogen)
Minus 20 Degrees Celsius (minus 20
degrees celsius)
Minus 70 Degrees Celsius (minus 70
degrees celsius)
Room Temperature (room temperature)
Sample Condition
clotted (clotted)
Damaged Or Unusable (damaged)
frozen (frozen)
insufficient amount (insufficient amount)
low blast count (low blast count)
low tumor count (low tumor count)
No Specimen Received (missing)
no positive tumor (no positive tumor)
Useable (OK)
poor fixation (poor fixation)
poor viability (poor viability)
thawed (thawed)
thawed, cold (thawed, cold)
thawed, warm (thawed, warm)
too old (too old)
Completed By
Date Completed
Ccrr Module For Calgb: Leukemia Tissue
Bank Specimen Routing Form
CALGB Form
CALGB Study No
CALGB Patient ID
Amended data
Yes (Yes)
Patient?s Name
Patient Hospital Number
Main Member Institution/Adjunct
Participating Group
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Participating Group Protocol No.
Participating Group Patient No.
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All rights reserved. Please visit https://medical-data-
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IMMUNE PARAMETERS
Immune Parameters
Course Number
Course Day Number
Sample Collection Date
Time
Lab Test
B Lymphocytes, #, Blood (B
Lymphocytes, #, Blood)
T Lymphocyte Helper Cells, Blood (T
Lymphocyte Helper Cells, Blood)
T Lymphocyte Suppressor Cells , Blood
(T Lymphocyte Suppressor Cells , Blood)
T Lymphocytes, %, Blood (T
Lymphocytes, %, Blood)
Lab Value
Lab Unit of Measure Name
Per 100 Identifiable White Blood Cells
(/100 WBC)
Per Millimeter Cubed (/mm3)
Percent (%)
Percent Per 100 Wbc (%/100 WBC)
10e12 Cells Per Liter (10E12 Cells/L)
10e3 Cells Per Microliter (10E3
Cells/microL)
10e6 Cells (10E6 Cells)
10e6 Cells Per Microliter (10E6
Cells/microL)
10e6 Cells Per Millimeter Cubed (10E6
Cells/mm3)
10e7 Cells Per Kilogram (10E7 Cells/kg)
10e8 Cells (10E8 Cells)
10e9 Cells (10E9 Cells)
10e9 Cells Per Liter (10E9 Cells/L)
Complement Activity Enzyme Unit (CAE
Unit)
Cells Per Microliter (Cells/microL)
Copies (Copies)
Cubic Microns (cubic microns)
Enzyme Unit (EU)
Enzyme Units Per Deciliter (EU/dL)
Enzyme Units Per Milliliter (EU/mL)
Femtoliter (fL)
Grams (g) (g)
Gram Per 24 Hours (g/24hr)
1 / 4
Gram Per Deciliter (g/dL)
Gram Per Liter (g/L)
Gram Per Microliter (g/microL)
Per High Power Field (HPF)
International Unit (Iunit)
International Unit Per Liter (IUnit/L)
International Unit Per Meter Squared
(IUnit/m2)
International Unit Per Milliliter (IUnit/mL)
Iu/ml (IUnit/mL)
Kilounit Per Liter (kU/L)
Liter (L)
Liters Per Minute (L/min)
Per Low Power Field (LPF)
Microgram Per 24 Hours (mcg/24hr)
Microgram Per Deciliter (mcg/dL)
Microgram Per Liter (mcg/L)
Microgram Per Milliliter (mcg/mL)
Microgram Per Specimen (mcg/spec)
Milliequivalent (mEq)
Milliequivalents Per 24 Hours (mEq/24hr)
Milliequivalent Per Deciliter (mEq/dL)
Milliequivalent Per Kilogram (mEq/kg)
Milliequivalent Per Liter (mEq/L)
Milligram (mg)
Milligram Per 24 Hours (mg/24hr)
Milligram Per Deciliter (mg/dL)
Milligram Per Kilogram (mg/kg)
Milligram Per Liter (mg/L)
Milligram Per Milliliter (mg/mL)
Milligram Per Milliliter Per Minute
(mg/mL/min)
Micro International Unit Per Milliliter
(microIU/mL)
Microliter (microL)
Micromole Per 24 Hours (micromol/24hr)
Micromole Per Deciliter (micromol/dL)
Micromole Per Liter (micromol/L)
Million Plaque Forming Units (mill PFU)
Million (Million)
Million Per Microliter (Million/microL)
Million Per Millimeter Cubed
(Million/mm3)
Milliinternational Unit (miu)
Milliinternational Units Per Meter
Squared (miu/m2)
Milliinternational Unit Per Milliliter
(miu/mL)
Milliter (mL)
Milliliter Per Minute (mL/min)
Milliliter Per Minute Times 1.73 Times
Bsa (mL/min/1.73/BSA)
Milliter Per Minute Per Millimeters Of
Mercury (mL/minute/mmHg)
Millimeter Per Hour (mm/hr)
Millimeter Cubed (mm3)
Millimeter Of Mercury (mmHg)
Millimole (mmol)
Millimole Per 24 Hours (mmol/24hr)
Millimole Per Liter (mmol/L)
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Milliosmole Per Kilogram (mosmol/kg)
Million Units Per Milliliter (MU/mL)
Not Applicable; No Uom Required (NA)
Nanogram Per Deciliter (ng/dL)
Nanograms Per Milliliter (ng/mL)
Nanogram Per Milliliter Per Hour
(ng/mL/hr)
Nanomole Per Liter (nmol/L)
Nanomole Per Milligram Of Protein
(nMol/mg protein)
Nanomole Per Milliliter (nmol/mL)
No Source Data (No Srce)
Picograms (pg)
Picogram Per Deciliter (pg/dL)
Picrogram Per Milliliter (pg/mL)
Pgpge2/mg Protein (pgPGE2/mg
protein)
Picomole Per Liter (pmol/L)
Ratio (Ratio)
Rna Copies Per Milliliter (RNA
copies/mL)
Seconds (sec)
Thousand (Thousand)
Thousand Per Microliter
(Thousand/microL)
Thousand Per Millimeter Squared
(Thousand/mm2)
Thousand Per Millimeter Cubed
(Thousand/mm3)
Titer (Titer)
Unit (Unit)
Unit Per 24 Hours (Unit/24hr)
Unit Per Liter (Unit/L)
Unit Per Meter Squared (Unit/m2)
Unit Per Millilliter (Unit/mL)
Unit Per Millimeters Cubed (Unit/mm3)
Unknown (Unknown)
Test Result Significance Indicator
No (N)
Yes (Y)
Laboratory Test Normal Reference Range Text
Laboratory Test Normal Range Indicator
High (High)
Low (Low)
Nonnumeric (Nonnum)
No Range (Norang)
Normal (Normal)
Common Toxicity Criteria Adverse Event Grade
No Adverse Event Or Within Normal
Limits (0)
Mild Adverse Event (1)
Moderate Adverse Event (2)
Severe And Undesirable Adverse Event
(3)
Life-threatening Or Disabling Adverse
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Event (4)
Death Related To Adverse Event (5)
Comments
Note Date
Research Comments Text
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Lab - Laboratory - 3291794v1.0
All rights reserved. Please visit https://medical-data-
models.org/forms/1899
Laboratory
Laboratory
Visit Date (Enter the date the lab sample was
collected.)
Time (Enter the time the lab sample was
collected.)
Source of the Lab Data (Select the source of the
lab results.)
Cdw (clinical Data Warehouse) (CDW)
Northwest Medical Center (Northwest
Med Center)
Other - Non Cdw (clinical Data
Warehouse) (OTH)
Outside Lab (Outside Lab)
University Medical Center/university
Physicians Health Care (UMC/UPH)
Unknown (Unknown)
Course # (Indicates the course number this lab is
related to.)
Day in Course (Cycle) (Indicates the day since
the beginning of course this lab is related to.)
Lab Test (Pre-defined name of the lab test.)
4 Hydroxytestosterone (4-oh),
Serum/plasma (4 Hydroxytestosterone
(4-OH), Serum/Plasma)
4 Hydroxytestosterone (4-oh), Tissue (4
Hydroxytestosterone (4-OH), Tissue)
Abnormal Lymphocytes, %, Blood
(Abnormal Lymphocytes, %, Blood)
Abo Group, Rh Type, Blood (ABO Group,
Rh Type, Blood)
Absolute Neutrophil Count (Absolute
Neutrophil Count (ANC), Blood)
Acid Phosphatase (acp), Serum (Acid
Phosphatase (ACP), Serum)
Activated Partial Thromboplastin Time
(aptt) (Activated Partial Thromboplastin
Time (APTT))
Adenovirus Antibody, Serum (Adenovirus
Antibody, Serum)
Adiponectin, Serum (Adiponectin,
Serum)
Adrenocorticotropin, Serum
(Adrenocorticotropin, Serum)
Serum Alanine Aminotransferase Ialt Or
Sgpt) (Alanine Aminostransferase (ALT
or SGPT), Serum)
Albumin-creatinine Ratio, Urine
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(Albumin-Creatinine Ratio, Urine)
Albumin, Electrophoresis, Timed Urine
(Albumin, Electrophoresis, Timed Urine)
Albumin, Serum (Albumin, Serum)
Alkaline Phosphatase, Bone, Serum
(Alkaline Phosphatase, Bone, Serum)
Alkaline Phosphatase, Serum (Alkaline
Phosphatase, Serum)
Alpha 1 Globulin, Electrophoresis, Timed
Urine (Alpha 1 Globulin, Electrophoresis,
Timed Urine)
Alpha 1 Globulin, Protein
Electrophoresis, Serum (Alpha 1
Globulin, Protein Electrophoresis,
Serum)
Alpha 2 Globulin, Electrophoresis, Timed
Urine (Alpha 2 Globulin, Electrophoresis,
Timed Urine)
Alpha 2 Globulin, Protein
Electrophoresis, Serum (Alpha 2
Globulin, Protein Electrophoresis,
Serum)
Alpha-1 Fetoprotein, Serum (Alpha-1
Fetoprotein, Serum)
Serum Amylase (Amylase, Serum)
Interleukin 2 S-receptor-alpha, Serum
(Anti-Interleukin 15 Antibody, Serum)
Anti-saccharomyces Cerevisiae
Antibodies (asca), Iga, Serum (Anti-
Saccharomyces cerevisiae Antibodies
(ASCA), IgA, Serum)
Anti-saccharomyces Cerevisiae
Antibodies (asca), Igg, Serum (Anti-
Saccharomyces cerevisiae Antibodies
(ASCA), IgG, Serum)
Antiadrenal Antibody, Serum
(Antiadrenal Antibody, Serum)
Antibody Screen, Serum (Antibody
Screen, Serum)
Antibody To Hepatitis B Surface Antigen
(hbsab), Serum (Antibody to Hepatitis B
surface antigen (HBSAb), Serum)
Antinuclear Antibody (ana), Serum
(Antinuclear Antibody (ANA), Serum)
Appearance, Cerebrospinal Fluid
(Appearance, Cerebrospinal Fluid)
Appearance, Urine (Appearance, Urine)
Serum Aspartate Aminotransferase (ast
Or Sgot) (Aspartate Aminotransferase
(AST or SGOT), Serum)
Atypical Lymphocytes, #, Blood (Atypical
Lymphocytes, #, Blood)
B Lymphocytes, #, Blood (B
Lymphocytes, #, Blood)
Bacteria, Microscopic, Spot Urine
(Bacteria, Microscopic, Spot Urine)
Basophils, #, Blood (Basophils, #, Blood)
Basophils, %, Blood (Basophils, %,
Blood)
Bcr-abl P210 Assay, Blood (BCR-ABL
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P210 Assay, Blood)
Bcr-abl Sensitivity, Blood (BCR-ABL
Sensitivity, Blood)
Bcr-abl/g6pdh Ratio, Blood (BCR-
ABL/G6PDH Ratio, Blood)
Beta Choriogonadotropin (bhcg), Or
Pregnancy Test, Spot Urine (Beta
Choriogonadotropin (BHCG), or
Pregnancy Test, Spot Urine)
Beta Choriogonadotropin Bhcg, Or
Pregnancy Test, Serum (Beta
Choriogonadotropin BHCG, or
Pregnancy Test, Serum)
Beta Globulin, Electrophoresis, Timed
Urine (Beta Globulin, Electrophoresis,
Timed Urine)
Beta Globulin, Protein Electrophoresis,
Serum (Beta Globulin, Protein
Electrophoresis, Serum)
Beta-2 Microglobulin, Serum (Beta-2
Microglobulin, Serum)
Bicarbonate (hco3), Arterial Blood
(Bicarbonate (HCO3), Arterial Blood)
Bicarbonate, Serum (Bicarbonate,
Serum)
Bile (biliary Obstruction), Spot Urine (Bile
(Biliary Obstruction), Spot Urine)
Bilirubin (bile), Spot Urine (Bilirubin
(Bile), Spot Urine)
Serum Direct Bilirubin (Bilirubin, Direct,
Serum)
Serum Total Bilirubin (Bilirubin, Total,
Serum)
Bisphenol, Serum/plasma (Bisphenol,
Serum/Plasma)
Bisphenol, Tissue (Bisphenol, Tissue)
Bk Virus, Polymerase Chain Reaction
(pcr), #, Blood (BK Virus, Polymerase
Chain Reaction (PCR), #, Blood)
Bk Virus, Polymerase Chain Reaction
(pcr), #, Urine (BK Virus, Polymerase
Chain Reaction (PCR), #, Urine)
Blasts, #, Blood (Blasts, #, Blood)
Serum Blood Urea (Blood Urea Nitrogen
(BUN), Serum)
Blood Urea Nitrogen (bun)/creatinine
Ratio, Serum (Blood Urea Nitrogen
(BUN)/Creatinine Ratio, Serum)
C Reactive Protein, High Sensitivity,
Serum (C Reactive Protein, High
Sensitivity, Serum)
C Reactive Protein, Serum (C Reactive
Protein, Serum)
C-peptide, Serum (C-Peptide, Serum)
C-telopeptide, Serum (C-Telopeptide,
Serum)
Cadaverine, Tissue (Cadaverine, Tissue)
Calcitonin, Serum (Calcitonin, Serum)
Calcium Oxalate Crystals, Urine
(Calcium Oxalate Crystals, Urine)
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Calcium, 24 Hour, Urine (Calcium, 24
hour, Urine)
Calcium, Ionized, Arterial Blood
(Calcium, Ionized, Arterial Blood)
Calcium, Ionized, Serum (Calcium,
Ionized, Serum)
Calcium, Serum (Calcium, Serum)
Cancer Antigen 27-29 (ca27-29), Serum
(Cancer Antigen 27-29 (CA27-29),
Serum)
Carbon Monoxide Diffusing Capacity,
Respiratory System (Carbon Monoxide
Diffusing Capacity, Respiratory System)
Carboxyhemoglobin, Arterial Blood
(Carboxyhemoglobin, Arterial Blood)
Carcinoembryonic Antigen (cea), Serum
(Carcinoembryonic Antigen (CEA),
Serum)
Carcinogenic Antigen 125 (ca125),
Serum (Carcinogenic Antigen 125
(CA125), Serum)
Carcinogenic Antigen 15-3 (ca15-3),
Serum (Carcinogenic Antigen 15-3
(CA15-3), Serum)
Carcinogenic Antigen 19-9 (ca19-9),
Serum (Carcinogenic Antigen 19-9
(CA19-9), Serum)
Cardiolipin Antibody, Igg, Serum
(Cardiolipin Antibody, IgG, Serum)
Cardiolipin Antibody, Igm, Serum
(Cardiolipin Antibody, IgM, Serum)
Casts, Spot Urine (Casts, Spot Urine)
Cd10 Cells, Blood (CD10 Cells, Blood)
Cd103 Cells, Blood (CD103 Cells, Blood)
Cd14, %, Peripheral Mononuclear Cells
(pbmc), Blood (CD14, %, Peripheral
Mononuclear Cells (PBMC), Blood)
Cd16 Or Cd56/cd3-, #, Blood (CD16 or
CD56/CD3-, #, Blood)
Cd16 Or Cd56/cd3-, %, Blood (CD16 or
CD56/CD3-, %, Blood)
Cd16 Or Cd56/cd3, #, Blood (CD16 or
CD56/CD3, #, Blood)
Cd16 Or Cd56/cd3, %, Blood (CD16 or
CD56/CD3, %, Blood)
Cd19 Cells, #, Blood (CD19 Cells, #,
Blood)
Cd19 Cells, %, Blood (CD19 Cells, %,
Blood)
Cd2 Cells, %, Blood (CD2 Cells, %,
Blood)
Cd20, #, Blood (CD20, #, Blood)
Cd20, %, Blood (CD20, %, Blood)
Cd22 Cells, Antibody, #, Blood (CD22
Cells, Antibody, #, Blood)
Cd22, #, Blood (CD22, #, Blood)
Cd25 Cells Pe, #, Blood (CD25 Cells PE,
#, Blood)
Cd25 Cells Pe, %, Blood (CD25 Cells
PE, %, Blood)
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Cd25 Cells, #, Blood (CD25 Cells, #,
Blood)
Cd25 Cells, %, Blood (CD25 Cells, %,
Blood)
Cd3 Cells, #, Blood (CD3 Cells, #, Blood)
Cd3 Cells, %, Flow Cytometry, Blood
(CD3 Cells, %, Flow Cytometry, Blood)
Cd3/7g7, #, Blood (CD3/7G7, #, Blood)
Cd3/7g7, %, Blood (CD3/7G7, %, Blood)
Cd3/cd25 Cells Pe, #, Blood (CD3/CD25
Cells PE, #, Blood)
Cd3/cd25 Cells Pe, %, Blood (CD3/CD25
Cells PE, %, Blood)
Cd3/cd25 Cells, #, Blood (CD3/CD25
Cells, #, Blood)
Cd3/cd25 Cells, %, Blood (CD3/CD25
Cells, %, Blood)
Cd3/cd30 Cells, #, Blood (CD3/CD30
Cells, #, Blood)
Cd3/cd30 Cells, %, Blood (CD3/CD30
Cells, %, Blood)
Cd3/cd4-/cd8-, #, Blood (CD3/CD4-
/CD8-, #, Blood)
Cd3/cd4-/cd8-, %, Blood (CD3/CD4-
/CD8-, %, Blood)
Cd3/cd8/cd28 Cells, #, Blood
(CD3/CD8/CD28 Cells, #, Blood)
Cd3/cd8/cd28, %, Blood
(CD3/CD8/CD28, %, Blood)
Cd3/cd8/cd57 Cells, #, Blood
(CD3/CD8/CD57 Cells, #, Blood)
Cd3/cd8/cd57, %, Blood
(CD3/CD8/CD57, %, Blood)
Cd3/hla-dr, #, Blood (CD3/HLA-DR, #,
Blood)
Cd3/hla-dr, %, Blood (CD3/HLA-DR, %,
Blood)
Cd38 Cells, #, Blood (CD38 Cells, #,
Blood)
Cd4 Cells To Cd3 Cells, #, Blood (CD4
Cells to CD3 Cells, #, Blood)
Cd4 Cells To Cd3 Cells, %, Blood (CD4
Cells to CD3 Cells, %, Blood)
Cd4 Cells To Cd8 Cells Ratio, Blood
(CD4 Cells to CD8 Cells Ratio, Blood)
Cd4 Cells, #, Blood (CD4 Cells, #, Blood)
Cd4 Cells, %, Flow Cytometry, Blood
(CD4 Cells, %, Flow Cytometry, Blood)
Cd4/7g7 Cells, #, Blood (CD4/7G7 Cells,
#, Blood)
Cd4/7g7 Cells, %, Blood (CD4/7G7
Cells, %, Blood)
Cd4/cd25 Cells, #, Blood (CD4/CD25
Cells, #, Blood)
Cd4/cd25 Cells, %, Blood (CD4/CD25
Cells, %, Blood)
Cd4/cd25 Pe Cells, #, Blood (CD4/CD25
PE Cells, #, Blood)
Cd4/cd25 Pe Cells, %, Blood (CD4/CD25
PE Cells, %, Blood)
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Cd4/cd25/cd62l Cells, #, Blood
(CD4/CD25/CD62L Cells, #, Blood)
Cd4/cd25/cd62l Cells, %, Blood
(CD4/CD25/CD62L Cells, %, Blood)
Cd4/cd25/cd69 Cells, #, Blood
(CD4/CD25/CD69 Cells, #, Blood)
Cd4/cd25/cd69 Cells, %, Blood
(CD4/CD25/CD69 Cells, %, Blood)
Cd4/cd30 Cells, #, Blood (CD4/CD30
Cells, #, Blood)
Cd4/cd30 Cells, %, Blood (CD4/CD30
Cells, %, Blood)
Cd4/cd45ra, #, Blood (CD4/CD45RA, #,
Blood)
Cd4/cd45ra, %, Blood (CD4/CD45RA,
%, Blood)
Cd4/cd45ra+cd45ro, #, Blood
(CD4/CD45RA+CD45RO, #, Blood)
Cd4/cd45ra+cd45ro, %, Blood
(CD4/CD45RA+CD45RO, %, Blood)
Cd4/cd45ro, #, Blood (CD4/CD45RO, #,
Blood)
Cd4/cd45ro, %, Blood (CD4/CD45RO,
%, Blood)
Cd4/cd62l-/cd45ra, #, Blood
(CD4/CD62L-/CD45RA, #, Blood)
Cd4/cd62l-/cd45ra, %, Blood
(CD4/CD62L-/CD45RA, %, Blood)
Cd4/cd62l, #, Blood (CD4/CD62L, #,
Blood)
Cd4/cd62l, %, Blood (CD4/CD62L, %,
Blood)
Cd4/cd62l/cd45ra, #, Blood
(CD4/CD62L/CD45RA, #, Blood)
Cd4/cd62l/cd45ra, %, Blood
(CD4/CD62L/CD45RA, %, Blood)
Cd4/hla-dr, #, Blood (CD4/HLA-DR, #,
Blood)
Cd4/hla-dr, %, Blood (CD4/HLA-DR, %,
Blood)
Cd45 Cells, #, Blood (CD45 Cells, #,
Blood)
Cd5 Cells, %, Blood (CD5 Cells, %,
Blood)
Cd52 Cells, #, Blood (CD52 Cells, #,
Blood)
Cd7 Cells, #, Blood (CD7 Cells, #, Blood)
Cd7 Cells, %, Blood (CD7 Cells, %,
Blood)
Cd7-/cd25 Pe Cells, #, Blood (CD7-
/CD25 PE Cells, #, Blood)
Cd7-/cd25 Pe Cells, %, Blood (CD7-
/CD25 PE Cells, %, Blood)
Cd7/cd25 Pe Cells, #, Blood (CD7/CD25
PE Cells, #, Blood)
Cd7/cd25 Pe Cells, %, Blood (CD7/CD25
PE Cells, %, Blood)
Cd8 Cells, #, Blood (CD8 Cells, #, Blood)
Cd8 Cells, %, Flow Cytometry, Blood
(CD8 Cells, %, Flow Cytometry, Blood)
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Cd8/cd25 Pe, #, Blood (CD8/CD25 PE,
#, Blood)
Cd8/cd25 Pe, %, Blood (CD8/CD25 PE,
%, Blood)
Cd8/cd25, #, Blood (CD8/CD25, #,
Blood)
Cd8/cd25, %, Blood (CD8/CD25, %,
Blood)
Cd8/cd3, #, Blood (CD8/CD3, #, Blood)
Cd8/cd3, %, Blood (CD8/CD3, %, Blood)
Cd8/cd45ra, #, Blood (CD8/CD45RA, #,
Blood)
Cd8/cd45ra, %, Blood (CD8/CD45RA,
%, Blood)
Cd8/cd45ra+cd45ro, #, Blood
(CD8/CD45RA+CD45RO, #, Blood)
Cd8/cd45ra+cd45ro, %, Blood
(CD8/CD45RA+CD45RO, %, Blood)
Cd8/cd45ro, #, Blood (CD8/CD45RO, #,
Blood)
Cd8/cd45ro, %, Blood (CD8/CD45RO,
%, Blood)
Cd8/cd57, #, Blood (CD8/CD57, #,
Blood)
Cd8/cd57, %, Blood (CD8/CD57, %,
Blood)
Cd8/cd62l-/cd45ra, #, Blood
(CD8/CD62L-/CD45RA, #, Blood)
Cd8/cd62l-/cd45ra, %, Blood
(CD8/CD62L-/CD45RA, %, Blood)
Cd8/cd62l, #, Blood (CD8/CD62L, #,
Blood)
Cd8/cd62l, %, Blood (CD8/CD62L, %,
Blood)
Cd8/cd62l/cd45ra, #, Blood
(CD8/CD62L/CD45RA, #, Blood)
Cd8/cd62l/cd45ra, %, Blood
(CD8/CD62L/CD45RA, %, Blood)
Cd8/hla-dr, #, Blood (CD8/HLA-DR, #,
Blood)
Cd8/hla-dr, %, Blood (CD8/HLA-DR, %,
Blood)
Cell Count, Cerebrospinal Fluid (Cell
Count, Cerebrospinal Fluid)
Cellularity, %, Bone Marrow (Cellularity,
%, Bone Marrow)
Centromere, Antibody, Serum
(Centromere, Antibody, Serum)
Ch50 Complement, Serum (CH50
Complement, Serum)
Chloride, 24 Hour, Urine (Chloride, 24
hour, Urine)
Chloride, Serum (Chloride, Serum)
Cholestanol, Serum (Cholestanol,
Serum)
Cholesterol To High Density Lipids (hdl),
Ratio, Serum (Cholesterol to High
Density Lipids (HDL), Ratio, Serum)
Cholesterol, Serum (Cholesterol, Serum)
Clean Catch Culture, Urine (Clean Catch
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Culture, Urine)
Co2 (carbon Dioxide), Exhaled Gas
(CO2 (Carbon Dioxide), Exhaled Gas)
Coarse Granular Casts, Spot Urine
(Coarse Granular Casts, Spot Urine)
Color, Cerebrospinal Fluid (Color,
Cerebrospinal Fluid)
Color, Urine (Color, Urine)
Complement, C3, Serum (Complement,
C3, Serum)
Complement, C4, Serum (Complement,
C4, Serum)
Cortisol, Blood (Cortisol, Blood)
Cortisol, Serum (Cortisol, Serum)
24 Hours Urine Creatinine Clearance
(Creatinine Clearance, 24 hour, Urine)
Creatinine Kinase (ck), Serum
(Creatinine Kinase (CK), Serum)
Serum Creatinine (Creatinine, Serum)
Creatinine, Serum (Creatinine, Serum)
Creatinine, Spot Or Timed Sample, Urine
(Creatinine, Spot or Timed Sample,
Urine)
Crystrals, Spot Urine (Crystrals, Spot
Urine)
Culture, Blood (Culture, Blood)
Culture, Cerebrospinal Fluid (Culture,
Cerebrospinal Fluid)
Culture, Respiratory Virus, Nasopharynx
(Culture, Respiratory Virus,
Nasopharynx)
Culture, Sputum (Culture, Sputum)
Culture, Stool (Culture, Stool)
Cyclic Citrullinated Peptide (ccp),
Antibody, Serum (Cyclic Citrullinated
Peptide (CCP), Antibody, Serum)
Cyclosporine, Blood (Cyclosporine,
Blood)
Cytomegalovirus (cmv) Antibody, Igg,
Serum (Cytomegalovirus (CMV)
Antibody, IgG, Serum)
Cytomegalovirus (cmv) Antibody, Igm,
Serum (Cytomegalovirus (CMV)
Antibody, IgM, Serum)
Cytomegalovirus (cmv) Antigenemia,
Blood (Cytomegalovirus (CMV)
Antigenemia, Blood)
Cytomegalovirus, Dna, Polymerase
Chain Reaction, Cerebrospinal Fluid
(Cytomegalovirus, DNA, Polymerase
Chain Reaction, Cerebrospinal Fluid)
Dako Egfr Pharmdx
Immunohistochemical Labeling, Tissue
(Dako EGFR Pharmdx
Immunohistochemical Labeling, Tissue)
Diffuse Cytoplasmic Anti-neutrophil
Cytoplasmic Antibody, Serum (Diffuse
Cytoplasmic Anti-Neutrophil Cytoplasmic
Antibody, Serum)
Diffusing Capacity % Predicted,
8 / 29
Lab - Laboratory - 3291794v1.0
Respiratory System (Diffusing Capacity
% Predicted, Respiratory System)
Diffusing Capacity To Alveolar Ventilation
Ratio %, Respiratory System (Diffusing
Capacity to Alveolar Ventilation Ratio %,
Respiratory System)
Diffusing Capacity To Alveolar Ventilation
Ratio, Respiratory System (Diffusing
Capacity to Alveolar Ventilation Ratio,
Respiratory System)
Diffusion Capacity Carbon Monoxide (dl)
Adjusted, % Predicted, Respiratory
System (Diffusion Capacity Carbon
Monoxide (DL) Adjusted, % Predicted,
Respiratory System)
Diffusion Capacity Carbon Monoxide (dl)
Adjusted, Respiratory System (Diffusion
Capacity Carbon Monoxide (DL)
Adjusted, Respiratory System)
Diffusion Capacity, Respiratory System
(Diffusion Capacity, Respiratory System)
Diphtheriae Antibody, Serum
(Diphtheriae Antibody, Serum)
Direct Antiglobulin Test (coombs), Red
Blood Cells (Direct Antiglobulin Test
(Coombs), Red Blood Cells)
Dna-tcr B Chain, Blood (DNA-TCR B
Chain, Blood)
Dopamine, 24 Hour, Urine (Dopamine,
24 hour, Urine)
Double Negative T (dnt) Cells, #, Blood
(Double Negative T (DNT) Cells, #,
Blood)
Double Negative T (dnt) Cells, %, Blood
(Double Negative T (DNT) Cells, %,
Blood)
Double Strand Dna (dsdna) Antibody,
Serum (Double Strand DNA (DSDNA)
Antibody, Serum)
Egfr Vxxi Immunohistochemical
Labeling, Tissue (EGFR vXXI
Immunohistochemical Labeling, Tissue)
Egfr Vxxi Immunohistochemical
Labeling, Tissue (EGFR vXXI
Immunohistochemical Labeling, Tissue)
Endoxifen, Serum/plasma (Endoxifen,
Serum/Plasma)
Endoxifen, Tissue (Endoxifen, Tissue)
Eosinophils, #, Blood (Eosinophils, #,
Blood)
Eosinophils, %, Blood (Eosinophils, %,
Blood)
Epinephrine, 24 Hour, Urine
(Epinephrine, 24 hour, Urine)
Epstein Barr Virus (ebv) Antibody, Serum
(Epstein Barr Virus (EBV) Antibody,
Serum)
Epstein Barr Virus (ebv) Nuclear
Antibody, Serum (Epstein Barr Virus
(EBV) Nuclear Antibody, Serum)
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Epstein-barr Virus (ebv) Early Antigen,
Serum (Epstein-Barr Virus (EBV) Early
Antigen, Serum)
Epstein-barr Virus (ebv), Igm , Serum
(Epstein-Barr Virus (EBV), IgM , Serum)
Epstein-barr Virus (ebv), Nuclear
Antibody, Igg, Serum (Epstein-Barr Virus
(EBV), Nuclear Antibody, IgG, Serum)
Erythrocyte Sedimentation Rate (esr),
Blood (Erythrocyte Sedimentation Rate
(ESR), Blood)
Estimated Creatinine Renal Clearance,
Urine (Estimated Creatinine Renal
Clearance, Urine)
Estradiol, Serum/plasma (Estradiol,
Serum)
Estradiol, Serum (Estradiol, Serum)
Estradiol, Tissue (Estradiol, Tissue)
Expiratory Reserve Volume (erv), %
Predicted, Respiratory System
(Expiratory Reserve Volume (ERV), %
Predicted, Respiratory System)
Expiratory Reserve Volume (erv),
Respiratory System (Expiratory Reserve
Volume (ERV), Respiratory System)
Expiratory Volume, Respiratory System
(Expiratory Volume, Respiratory System)
Extractable Nuclear Antigens (ena)
Screen, Blood (Extractable Nuclear
Antigens (ENA) Screen, Blood)
Fab Marrow Rating, Bone Marrow (FAB
Marrow Rating, Bone Marrow)
Ferritin, Serum (Ferritin, Serum)
Fetal Hemoglobin, Blood (Fetal
Hemoglobin, Blood)
Fev1 To Fvc Predicted Ratio, Respiratory
System (FEV1 to FVC Predicted Ratio,
Respiratory System)
Fev1 To Fvc Ratio, Post, Respiratory
System (FEV1 to FVC Ratio, Post,
Respiratory System)
Fev1 To Fvc Ratio, Pre, Respiratory
System (FEV1 to FVC Ratio, Pre,
Respiratory System)
Fev1 To Fvc Ratio, Respiratory System
(FEV1 to FVC Ratio, Respiratory
System)
Fibrin Degradation Products (fdp), Blood
(Fibrin Degradation Products (FDP),
Blood)
Fibrinogen, Auto, Platelet Poor Plasma
(Fibrinogen, Auto, Platelet Poor Plasma)
Fibrinogen, Blood (Fibrinogen, Blood)
Fibrinogen, Fibrometer, Platelet Poor
Plasma (Fibrinogen, Fibrometer, Platelet
Poor Plasma)
Fine Granular Casts, Spot Urine (Fine
Granular Casts, Spot Urine)
Fluorescent Activated Cell Sorting (facs)
Lymphoid Cells, #, Blood (Fluorescent
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Activated Cell Sorting (FACS) Lymphoid
Cells, #, Blood)
Folate, Serum (Folate, Serum)
Follicle Stimulating Hormone (fsh),
Serum (Follicle Stimulating Hormone
(FSH), Serum)
Forced Expiratory Flow (fef), During
Midportion Of Expiratory Cycle, Post, %
Change, Respiratory System (Forced
Expiratory Flow (FEF), during midportion
of expiratory cycle, Post, % Change,
Respiratory System)
Forced Expiratory Flow (fef), During
Midportion Of Expiratory Cycle, Post, %
Predicted, Respiratory System (Forced
Expiratory Flow (FEF), during midportion
of expiratory cycle, Post, % Predicted,
Respiratory System)
Forced Expiratory Flow (fef), During
Midportion Of Expiratory Cycle, Post,
Respiratory System (Forced Expiratory
Flow (FEF), during midportion of
expiratory cycle, Post, Respiratory
System)
Forced Expiratory Flow (fef), During
Midportion Of Expiratory Cycle, Pre, %
Predicted, Respiratory System (Forced
Expiratory Flow (FEF), during midportion
of expiratory cycle, Pre, % Predicted,
Respiratory System)
Forced Expiratory Flow (fef), During
Midportion Of Expiratory Cycle, Pre,
Respiratory System (Forced Expiratory
Flow (FEF), during midportion of
expiratory cycle, Pre, Respiratory
System)
Forced Expiratory Technique (fet), 100%,
Post, Respiratory System (Forced
Expiratory Technique (FET), 100%, Post,
Respiratory System)
Forced Expiratory Technique (fet), 100%,
Pre, Respiratory System (Forced
Expiratory Technique (FET), 100%, Pre,
Respiratory System)
Forced Expiratory Volume % Predicted,
Respiratory System (Forced Expiratory
Volume % Predicted, Respiratory
System)
Forced Expiratory Volume 1 Second
(fev1) Slope, Respiratory System
(Forced Expiratory Volume 1 Second
(FEV1) Slope, Respiratory System)
Forced Expiratory Volume 1 Second
(fev1), Post, % Change, Respiratory
System (Forced Expiratory Volume 1
Second (FEV1), Post, % Change,
Respiratory System)
Forced Expiratory Volume 1 Second
(fev1), Post, % Predicted, Respiratory
System (Forced Expiratory Volume 1
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Second (FEV1), Post, % Predicted,
Respiratory System)
Forced Expiratory Volume 1 Second
(fev1), Post, Respiratory System (Forced
Expiratory Volume 1 Second (FEV1),
Post, Respiratory System)
Forced Expiratory Volume 1 Second
(fev1), Pre, % Predicted, Respiratory
System (Forced Expiratory Volume 1
Second (FEV1), Pre, % Predicted,
Respiratory System)
Forced Expiratory Volume 1 Second
(fev1), Pre, Respiratory System (Forced
Expiratory Volume 1 Second (FEV1),
Pre, Respiratory System)
Forced Expiratory Volume, Respiratory
System (Forced Expiratory Volume,
Respiratory System)
Forced Vital Capacity (fvc) % Predicted,
Respiratory System (Forced Vital
Capacity (FVC) % Predicted, Respiratory
System)
Forced Vital Capacity (fvc), Post, %
Change, Respiratory System (Forced
Vital Capacity (FVC), Post, % Change,
Respiratory System)
Forced Vital Capacity (fvc), Post, %
Predicted, Respiratory System (Forced
Vital Capacity (FVC), Post, % Predicted,
Respiratory System)
Forced Vital Capacity (fvc), Post,
Respiratory System (Forced Vital
Capacity (FVC), Post, Respiratory
System)
Forced Vital Capacity (fvc), Pre, %
Predicted, Respiratory System (Forced
Vital Capacity (FVC), Pre, % Predicted,
Respiratory System)
Forced Vital Capacity (fvc), Pre,
Respiratory System (Forced Vital
Capacity (FVC), Pre, Respiratory
System)
Forced Vital Capacity (fvc), Respiratory
System (Forced Vital Capacity (FVC),
Respiratory System)
Forced Vital Capacity (maximum),
Respiratory System (Forced Vital
Capacity (Maximum), Respiratory
System)
Functional Residual Capacity (frc), %
Predicted, Respiratory System
(Functional Residual Capacity (FRC), %
Predicted, Respiratory System)
Functional Residual Capacity,
Respiratory System (Functional Residual
Capacity, Respiratory System)
Gamma Globulin, Electrophoresis, Timed
Urine (Gamma Globulin, Electrophoresis,
Timed Urine)
Gamma Globulin, Protein
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Electrophoresis, Serum (Gamma
Globulin, Protein Electrophoresis,
Serum)
Gamma Glutamyl Transferase (ggt),
Serum (Gamma Glutamyl Transferase
(GGT), Serum)
Glomerular Filtration Rate, Manual
Calculation, Blood (Glomerular Filtration
Rate, Manual Calculation, Blood)
Glucose, Csf (Glucose, CSF)
Glucose, Fasting, Serum (Glucose,
Fasting, Serum)
Glucose, Non-fasting, Serum (Glucose,
Non-fasting, Serum)
Serum Glucose (Glucose, Serum)
Glucose, Spot Urine (Glucose, Spot
Urine)
Haptoglobin, Serum (Haptoglobin,
Serum)
Helicobactor Pylori Antibody, Igg, Serum
(Helicobactor Pylori Antibody, IgG,
Serum)
Hematocrit, %, Blood (Hematocrit, %,
Blood)
Hemoglobin (hgb) A1c, Blood
(Hemoglobin (Hgb) A1C, Blood)
Hemoglobin, Blood (Hemoglobin, Blood)
Hemoglobin, Spot Urine (Hemoglobin,
Spot Urine)
Hepatitis A Virus Antibody (hav), Igm,
Serum (Hepatitis A Virus Antibody
(HAV), IgM, Serum)
Hepatitis A Virus Antibody (hav), Total,
Serum (Hepatitis A Virus Antibody
(HAV), Total, Serum)
Hepatitis B Core Antibody, Serum
(Hepatitis B Core Antibody, Serum)
Hepatitis B Surface Antigen, Serum
(Hepatitis B Surface Antigen, Serum)
Hepatitis B Viral Load (hbv), Dna, Blood
(Hepatitis B Viral Load (HBV), DNA,
Blood)
Hepatitis C Antibody, Serum (Hepatitis C
Antibody, Serum)
Hepatitis C Virus, Rna, Quantitative,
Copies/ml, Serum (Hepatitis C Virus,
RNA, Quantitative, Copies/mL, Serum)
Hepatitis C Virus, Rna, Quantitative,
Iu/ml, Serum (Hepatitis C Virus, RNA,
Quantitative, IU/mL, Serum)
Hepatitis C Virus, Rna, Reverse
Transcriptase (rt), Polymerase Chain
Reaction (pcr), Serum (Hepatitis C Virus,
RNA, Reverse Transcriptase (RT),
Polymerase Chain Reaction (PCR),
Serum)
Herpes Simplex Virus (hsv) 1/2, Igm,
Serum (Herpes Simplex Virus (HSV) 1/2,
IgM, Serum)
Herpes Simplex Virus 1 (hsv1) Igg,
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Serum (Herpes Simplex Virus 1 (HSV1)
IgG, Serum)
Herpes Simplex Virus 2 (hsv2) Igg,
Serum (Herpes Simplex Virus 2 (HSV2)
IgG, Serum)
High Density Lipoprotein, Cholesterol,
Serum (High Density Lipoprotein,
Cholesterol, Serum)
Histamine, Tissue (Histamine, Tissue)
Hiv Viral Load, Cerebrospinal Fluid (HIV
Viral Load, Cerebrospinal Fluid)
Hiv Viral Load, Serum (HIV Viral Load,
Serum)
Hiv1 Log Viral Load, Polymerase Chain
Reaction (pcr), Cerebrospinal Fluid
(HIV1 Log Viral Load, Polymerase Chain
Reaction (PCR), Cerebrospinal Fluid)
Hiv1 Log Viral Load, Polymerase Chain
Reaction (pcr), Plasma (HIV1 Log Viral
Load, Polymerase Chain Reaction
(PCR), Plasma)
Hla A Antigen, White Blood Cells (HLA A
Antigen, White Blood Cells)
Hla B Antigen, White Blood Cells (HLA B
Antigen, White Blood Cells)
Hla Cw Antigen, White Blood Cells (HLA
Cw Antigen, White Blood Cells)
Hla Dqb1 Antigen, White Blood Cells
(HLA DQB1 Antigen, White Blood Cells)
Hla Dr Antigen, White Blood Cells (HLA
DR Antigen, White Blood Cells)
Hla Drb Antigen, White Blood Cells (HLA
DRB Antigen, White Blood Cells)
Hla Drb1 Antigen, White Blood Cells
(HLA DRB1 Antigen, White Blood Cells)
Hla-a03 Subtype Antigen, White Blood
Cells (HLA-A03 Subtype Antigen, White
Blood Cells)
Hla-a2 Antigen, White Blood Cells (HLA-
A2 Antigen, White Blood Cells)
Hla-a24 Subtype Antigen (HLA-A24
Subtype Antigen)
Hla-a3 Subtype Antigen (HLA-A3
Subtype Antigen)
Htlv1/htlv2 Antibody, Serum
(HTLV1/HTLV2 Antibody, Serum)
Human Anti-mouse Antibody, Blood
(Human Anti-Mouse Antibody, Blood)
Human Choriogonadotropin (hcg),
Serum (Human Choriogonadotropin
(HCG), Serum)
Human Growth Hormone (hgh), Serum
(Human Growth Hormone (HGH),
Serum)
Human Immunodeficiency Virus (hiv) 1,
Antibody, Western Blot, Serum (Human
Immunodeficiency Virus (HIV) 1,
Antibody, Western Blot, Serum)
Human Immunodeficiency Virus (hiv) 1,
Western Blot, Serum (Human
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Immunodeficiency Virus (HIV) 1,
Western Blot, Serum)
Human Immunodeficiency Virus (hiv), 1-
2 Antibody, Serum (Human
Immunodeficiency Virus (HIV), 1-2
Antibody, Serum)
Hyaline Casts, Spot Urine (Hyaline
Casts, Spot Urine)
Igf-1 (human Growth Hormone), Blood
(IGF-1 (Human Growth Hormone),
Blood)
Immunofixation Electrophoresis, Serum
(Immunofixation Electrophoresis, Serum)
Immunoglobulin A (iga), Serum
(Immunoglobulin A (IgA), Serum)
Immunoglobulin D (igd), Serum
(Immunoglobulin D (IgD), Serum)
Immunoglobulin E (ige), Serum
(Immunoglobulin E (IgE), Serum)
Immunoglobulin G (igg), Serum
(Immunoglobulin G (IgG), Serum)
Immunoglobulin M (igm),
Immunoelectrophoresis, Spot Urine
(Immunoglobulin M (IgM),
Immunoelectrophoresis, Spot Urine)
Immunoglobulin M (igm), Serum
(Immunoglobulin M (IgM), Serum)
Inhibin A, Blood (Inhibin A, Blood)
Inhibin B, Blood (Inhibin B, Blood)
Inspiratory Capacity (ic), % Predicted,
Respiratory System (Inspiratory Capacity
(IC), % Predicted, Respiratory System)
Inspiratory Capacity (ic), Respiratory
System (Inspiratory Capacity (IC),
Respiratory System)
Insulin-life Growth Factor Binding Protein
3, Serum (Insulin-life Growth Factor
Binding Protein 3, Serum)
Insulin, Serum (Insulin, Serum)
Interleukin 2 S-receptor-alpha, Serum
(Interleukin 2 s-Receptor-Alpha, Serum)
International Normalized Ratio (inr),
Prothrombin Time, Blood (International
Normalized Ratio (INR), Prothrombin
Time, Blood)
Iodine, 24 Hour, Urine (Iodine, 24 hour,
Urine)
Iodine, Concentration, 24 Hour, Urine
(Iodine, Concentration, 24 hour, Urine)
Iodine, Free, 24 Hour, Urine (Iodine,
Free, 24 hour, Urine)
Iron Saturation, Ratio, Serum (Iron
Saturation, Ratio, Serum)
Iron, Serum (Iron, Serum)
Ketones, Spot Urine (Ketones, Spot
Urine)
Lactate Dehydrogenase (ldh), Serum
(Lactate Dehydrogenase (LDH), Serum)
Lactate, Cerebrospinal Fluid (Lactate,
Cerebrospinal Fluid)
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Lamotrigine, Serum (Lamotrigine,
Serum)
Large Unstained Cells, #, Blood (Large
Unstained Cells, #, Blood)
Large Unstained Cells, %, Blood (Large
Unstained Cells, %, Blood)
Leptin, Serum (Leptin, Serum)
Leukocyte Esterase, Spot Urine
(Leukocyte Esterase, Spot Urine)
Levetiracetam, Serum (Levetiracetam,
Serum)
Lipase, Serum (Lipase, Serum)
Liver Kidney Microsomal Antibody,
Serum (Liver Kidney Microsomal
Antibody, Serum)
Low Density Lipoproteins, Cholesterol,
Serum (Low Density Lipoproteins,
Cholesterol, Serum)
Lupus Anticoagulant, Platelet Poor
Plasma (Lupus Anticoagulant, Platelet
Poor Plasma)
Lupus Anticoagulant, Staclot, Platelet
Poor Plasma (Lupus Anticoagulant,
Staclot, Platelet Poor Plasma)
Luteinizing Hormone (lh), Serum
(Luteinizing Hormone (LH), Serum)
Lymphocytes Variants, %, Blood
(Lymphocytes Variants, %, Blood)
Lymphocytes, #, Blood (Lymphocytes, #,
Blood)
Lymphocytes, %, Blood (Lymphocytes,
%, Blood)
Lymphocytes, %, Bone Marrow
(Lymphocytes, %, Bone Marrow)
Lymphocytes, %, Cerebrospinal Fluid
(Lymphocytes, %, Cerebrospinal Fluid)
Lymphocytes, Variant, #, Blood
(Lymphocytes, Variant, #, Blood)
Magnesium, Serum (Magnesium,
Serum)
Maximum Forced Expiratory Flow,
Respiratory System (Maximum Forced
Expiratory Flow, Respiratory System)
Mean Corpuscular Hemoglobin (mch),
Red Blood Cells (Mean Corpuscular
Hemoglobin (MCH), Red Blood Cells)
Mean Corpuscular Hemoglobin
Concentration (mchc), Red Blood Cells
(Mean Corpuscular Hemoglobin
Concentration (MCHC), Red Blood Cells)
Mean Corpuscular Volume (mcv), Red
Blood Cells (Mean Corpuscular Volume
(MCV), Red Blood Cells)
Megakaryocytes, %, Bone Marrow
(Megakaryocytes, %, Bone Marrow)
Metamyelocytes, %, Bone Marrow
(Metamyelocytes, %, Bone Marrow)
Metanephrine, 24 Hour, Urine
(Metanephrine, 24 hour, Urine)
Metanephrine, Unconjugated, 24 Hour,
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Urine (Metanephrine, Unconjugated, 24
hour, Urine)
Methotrexate, Serum (Methotrexate,
Serum)
Mgmt (o6-methylguanine-dna
Methyltransferase) Immunohistochemical
Labeling, Tissue (MGMT (O6-
methylguanine-DNA methyltransferase)
Immunohistochemical Labeling, Tissue)
Mitochondrial Antibody, Serum
(Mitochondrial Antibody, Serum)
Monocytes, #, Blood (Monocytes, #,
Blood)
Monocytes, %, Blood (Monocytes, %,
Blood)
Monocytes, %, Bone Marrow
(Monocytes, %, Bone Marrow)
Mucous, Spot Urine (Mucous, Spot
Urine)
Mullerian Inhibiting Substance, Serum
(Mullerian inhibiting substance, Serum)
Myelin Basic Protein, Cerebrospinal
Fluid (Myelin Basic Protein,
Cerebrospinal Fluid)
Myelocytes, %, Bone Marrow
(Myelocytes, %, Bone Marrow)
Myelocytes, %, Bone Marrow
(Myelocytes, %, Bone Marrow)
N1 Acetylspermidine, Tissue (N1
Acetylspermidine, Tissue)
N1 Acetylspermine, Tissue (N1
Acetylspermine, Tissue)
N8 Acetylspermidine, Tissue (N8
Acetylspermidine, Tissue)
Natural Killer (nk) Cells, #, Blood (Natural
Killer (NK) Cells, #, Blood)
Natural Killer (nk) Cells, %, Blood
(Natural Killer (NK) Cells, %, Blood)
Natural Killer T Cells, #, Blood (Natural
Killer T Cells, #, Blood)
Natural Killer T Cells, %, Blood (Natural
Killer T Cells, %, Blood)
Neutralizing Antibody Bl22, Serum
(Neutralizing Antibody BL22, Serum)
Neutralizing Antibody Lmb-2, Serum
(Neutralizing Antibody LMB-2, Serum)
Neutrophil Bands, #, Blood (Neutrophil
Bands, #, Blood)
Neutrophil Bands, %, Blood (Neutrophil
Bands, %, Blood)
Neutrophils, %, Blood (Neutrophils, %,
Blood)
Nitrite, Spot Urine (Nitrite, Spot Urine)
Nonseparated Short Tandem Repeat
Chimerism, %, Bone Marrow
(Nonseparated Short Tandem Repeat
Chimerism, %, Bone Marrow)
Nonseparated Short Tandem Repeat
Chimerism, %, Whole Blood
(Nonseparated Short Tandem Repeat
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Chimerism, %, Whole Blood)
Norepinephrine, 24 Hour, Urine
(Norepinephrine, 24 hour, Urine)
Normetanephrine, 24 Hour, Urine
(Normetanephrine, 24 hour, Urine)
Nucleated Red Blood Cells (nrbc), #,
Blood (Nucleated Red Blood Cells
(NRBC), #, Blood)
Osmolality, 24 Hour, Urine (Osmolality,
24 hour, Urine)
Osmolality, Serum (Osmolality, Serum)
Other Cell Count, Cerebrospinal Fluid
(Other Cell Count, Cerebrospinal Fluid)
Pakt Immunohistochemical Labeling,
Tissue (pAKT Immunohistochemical
Labeling, Tissue)
Parathyroid (parathyrin Intact) Hormone,
Serum (Parathyroid (Parathyrin intact)
Hormone, Serum)
Parathyroid Hormone, Intact, Blood
(Parathyroid Hormone, Intact, Blood)
Parietal Cell Antibody, Serum (Parietal
Cell Antibody, Serum)
Partial Thromboplastin Time (Partial
Prothromboplastin Time (PTT), Blood)
Percent Carbon Dioxide (pco2), Arterial
Blood (Percent Carbon Dioxide (pCO2),
Arterial Blood)
Percent Oxygen (po2), Arterial Blood
(Percent Oxygen (pO2), Arterial Blood)
Ph, Arterial Blood (pH, Arterial Blood)
Ph, Spot Urine (pH, Spot Urine)
Ph, Venous Blood (pH, Venous Blood)
Phenytoin, Serum (Phenytoin, Serum)
Phosphate (inorganic Phosphorus),
Serum (Phosphate (inorganic
Phosphorus), Serum)
Plasma Cells, %, Bone Marrow (Plasma
Cells, %, Bone Marrow)
Platelet Mean Volume (pmv), Blood
(Platelet Mean Volume (PMV), Blood)
Blood Platelets (Platelets, Blood)
Polymorphonuclear Cells (polys), #,
Blood (Polymorphonuclear Cells (Polys),
#, Blood)
Polymorphonuclear Cells (polys), %,
Blood (Polymorphonuclear Cells (Polys),
%, Blood)
Potassium, 24 Hour, Urine (Potassium,
24 hour, Urine)
Potassium, Serum (Potassium, Serum)
Prealbumin, Serum (Prealbumin, Serum)
Progesterone, Serum/plasma
(Progesterone, Serum/Plasma)
Promyelocytes, %, Bone Marrow
(Promyelocytes, %, Bone Marrow)
Prostaglandin E2, Tissue (Prostaglandin
E2, Tissue)
Prostate Specific Antigen (psa), Serum
(Prostate Specific Antigen (PSA),
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Serum)
Protein Excretion, 24 Hour, Urine
(Protein excretion, 24 hour, Urine)
Protein-creatinine Ratio, Urine (Protein-
Creatinine Ratio, Urine)
Protein, 24 Hour, Urine (Protein, 24 hour,
Urine)
Protein, Csf (Protein, CSF)
Protein, Qualitative, Urine (Protein,
Qualitative, Urine)
Prothrombin Time (Prothrombin Time
(PT), Blood)
Pten Immunohistochemical Labeling,
Tissue (PTEN Immunohistochemical
Labeling, Tissue)
Putrescine, Tissue (Putrescine, Tissue)
Quantiferon-tb Gold (qft), Blood
(QuantiFERON-TB Gold (QFT), Blood)
Rapid Plasma Reagin (rpr), Serum
(Rapid Plasma Reagin (RPR), Serum)
Red Blood Cells (rbc), #, Blood (Red
Blood Cells (RBC), #, Blood)
Red Blood Cells (rbc), #, Cerebrospinal
Fluid (Red Blood Cells (RBC), #,
Cerebrospinal Fluid)
Red Blood Cells (rbc), Microscopy, #,
Spot Urine (Red Blood Cells (RBC),
Microscopy, #, Spot Urine)
Red Blood Cells (rbc), Microscopy, Spot
Urine (Red Blood Cells (RBC),
Microscopy, Spot Urine)
Red Cell Distribution Width (rdw), Red
Blood Cells (Red Cell Distribution Width
(RDW), Red Blood Cells)
Renal Epithelial Cells, Spot Urine (Renal
Epithelial Cells, Spot Urine)
Residual Volume To Total Lung Capacity
Ratio, Respiratory System (Residual
Volume to Total Lung Capacity Ratio,
Respiratory System)
Respiratory Volume (rv), % Predicted,
Respiratory System (Respiratory Volume
(RV), % Predicted, Respiratory System)
Reticulocytes, %, Bone Marrow
(Reticulocytes, %, Bone Marrow)
Reticulocytes, %, Red Blood Cells
(Reticulocytes, %, Red Blood Cells)
Rheumatoid Factor, Serum (Rheumatoid
Factor, Serum)
Ribonucleoprotein Extractable Nuclear
(rnp) Antibody, Serum
(Ribonucleoprotein Extractable Nuclear
(RNP) Antibody, Serum)
Short Tandem Repeat Chimerism, %,
Other Source (Short Tandem Repeat
Chimerism, %, Other Source)
Short Tandem Repeat Chimerism, %,
White Blood Cells (Short Tandem
Repeat Chimerism, %, White Blood
Cells)
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Short Tandem Repeat Chimerism,
Clusters Of Differentiation 14 (cd14), %,
Whole Blood (Short Tandem Repeat
Chimerism, Clusters of Differentiation 14
(CD14), %, Whole Blood)
Short Tandem Repeat Chimerism,
Clusters Of Differentiation 19 (cd19), %,
Whole Blood (Short Tandem Repeat
Chimerism, Clusters of Differentiation 19
(CD19), %, Whole Blood)
Short Tandem Repeat Chimerism,
Clusters Of Differentiation 3 (cd3), %,
Whole Blood (Short Tandem Repeat
Chimerism, Clusters of Differentiation 3
(CD3), %, Whole Blood)
Short Tandem Repeat Chimerism, Dual
Cord, %, Whole Blood (Short Tandem
Repeat Chimerism, Dual Cord, %, Whole
Blood)
Short Tandem Repeat Chimerism,
Monomac, %, Whole Blood (Short
Tandem Repeat Chimerism, MonoMac,
%, Whole Blood)
Short Tandem Repeat Chimerism,
Multiple Donor, %, Bone Marrow (Short
Tandem Repeat Chimerism, Multiple
Donor, %, Bone Marrow)
Short Tandem Repeat Chimerism,
Multiple Donor, %, Other Source (Short
Tandem Repeat Chimerism, Multiple
Donor, %, Other Source)
Short Tandem Repeat Chimerism,
Multiple Donor, %, White Blood Cells
(Short Tandem Repeat Chimerism,
Multiple Donor, %, White Blood Cells)
Short Tandem Repeat Chimerism,
Multiple Donor, %, Whole Blood (Short
Tandem Repeat Chimerism, Multiple
Donor, %, Whole Blood)
Short Tandem Repeat Chimerism,
Natural Killers, %, Whole Blood (Short
Tandem Repeat Chimerism, Natural
Killers, %, Whole Blood)
Sirolimus (rapamycin), Blood (Sirolimus
(Rapamycin), Blood)
Sjogren's Syndrome-a Extractable
Antibody, Serum (Sjogren's Syndrome-A
Extractable Antibody, Serum)
Sjogren's Syndrome-b Extractable
Antibody, Serum (Sjogren's Syndrome-B
Extractable Antibody, Serum)
Smith Extractable Nuclear Antibody,
Serum (Smith Extractable Nuclear
Antibody, Serum)
Sodium, 24 Hour, Urine (Sodium, 24
hour, Urine)
Sodium, Serum (Sodium, Serum)
Sodium/potassium Ratio, Serum
(Sodium/Potassium Ratio, Serum)
Specific Gravity, Spot Urine (Specific
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Gravity, Spot Urine)
Specimen Collection Period, Urine
(Specimen Collection Period, Urine)
Spermidine, Tissue (Spermidine, Tissue)
Spermine, Tissue (Spermine, Tissue)
Squamous Epithelial Cells, Spot Urine
(Squamous Epithelial Cells, Spot Urine)
T Lymphocyte Helper Cells, Blood (T
Lymphocyte Helper Cells, Blood)
T Lymphocyte Suppressor Cells , Blood
(T Lymphocyte Suppressor Cells , Blood)
T Lymphocytes, %, Blood (T
Lymphocytes, %, Blood)
Tacrolimus, Blood (Tacrolimus, Blood)
Tamoxifen, Serum/plasma (Tamoxifen,
Serum/Plasma)
Tamoxifen, Tissue (Tamoxifen, Tissue)
Testosterone, Total, Serum
(Testosterone, Total, Serum)
Thrombin Time, Blood (Thrombin Time,
Blood)
Thyroglobulin Antibody, Serum
(Thyroglobulin Antibody, Serum)
Thyroid Stimulating Immunoglobulins
(tsi), Serum (Thyroid Stimulating
Immunoglobulins (TSI), Serum)
Thyroperoxidase Antibody, Serum
(Thyroperoxidase Antibody, Serum)
Thyrotropin (thyroid Stimulating Hormone
Or Tsh), Serum (Thyrotropin (Thyroid
Stimulating Hormone or TSH), Serum)
Thyroxine (t4), Free, Serum (Thyroxine
(T4), Free,  Serum)
Thyroxine (t4), Free, Dialysis, Serum
(Thyroxine (T4), Free, Dialysis, Serum)
Thyroxine (t4), Serum (Thyroxine (T4),
Serum)
Thyroxine Binding Globulin (tbg), Serum
(Thyroxine Binding Globulin (TBG),
Serum)
Total Lung Capacity %, Predicted,
Respiratory System (Total Lung Capacity
%, Predicted, Respiratory System)
Total Lung Capacity %, Respiratory
System (Total Lung Capacity %,
Respiratory System)
Total Protein Electrophoresis, Serum
(Total Protein Electrophoresis, Serum)
Total Protein, Serum (Total Protein,
Serum)
Toxoplasmosa Gondii, Antibody, Igm,
Serum (Toxoplasmosa Gondii, Antibody,
IgM, Serum)
Transferrin, Serum (Transferrin, Serum)
Transitional Cells, Spot Urine
(Transitional Cells, Spot Urine)
Trefoil Factor 1, Tissue (Trefoil Factor 1,
Tissue)
Triglycerides, Serum (Triglycerides,
Serum)
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Triiodothyronine (t3), Free, Serum
(Triiodothyronine (T3), Free, Serum)
Triiodothyronine (t3), Serum
(Triiodothyronine (T3), Serum)
Troponin T, Blood (Troponin T, Blood)
Trypanosoma Cruzi Antibody, Igg, Serum
(Trypanosoma cruzi Antibody, IgG,
Serum)
Urate (uric Acid), Serum (Urate (Uric
Acid), Serum)
Uric Acid (urate), 24 Hour, Urine (Uric
Acid (Urate), 24 hour, Urine)
Urobilinogen, Spot Urine (Urobilinogen,
Spot Urine)
Vaccinia Culture, Serum (Vaccinia
Culture, Serum)
Vaccinia Culture, Spot Urine (Vaccinia
Culture, Spot Urine)
Valproate (valproic Acid), Serum
(Valproate (Valproic Acid), Serum)
Varicella Zoster Virus (vzv) Antigen,
Immunofluorescence, Skin (Varicella
Zoster Virus (VZV) Antigen,
Immunofluorescence, Skin)
Varicella Zoster Virus (vzv) Dna,
Cerebrospinal Fluid (Varicella Zoster
Virus (VZV) DNA, Cerebrospinal Fluid)
Varicella Zoster Virus (vzv), Igg,
Antibody, Serum (Varicella Zoster Virus
(VZV), IgG, Antibody, Serum)
Very Low Density Lipoprotein (vldl)
Cholesterol, Serum (Very Low Density
Lipoprotein (VLDL) Cholesterol, Serum)
Vital Capacity (vc), % Predicted,
Respiratory System (Vital Capacity (VC),
% Predicted, Respiratory System)
Vital Capacity (vc), Respiratory System
(Vital Capacity (VC), Respiratory
System)
Vitamin B12, Serum (Vitamin B12,
Serum)
Vitamin D, 1, 25-dihydroxy, Blood
(Vitamin D, 1, 25-Dihydroxy, Blood)
Vitamin D, 25-dihydroxy, Blood (Vitamin
D, 25-Dihydroxy, Blood)
Volume Expelled During Midportion Of
Expiration % Predicted, Respiratory
System (Volume expelled during
midportion of expiration % Predicted,
Respiratory System)
Volume Expelled During Midportion Of
Expiration, Respiratory System (Volume
expelled during midportion of expiration,
Respiratory System)
Volume Residual, Respiratory System
(Volume Residual, Respiratory System)
Volume, Urine (Volume, Urine)
Blood Leukocyte Count (White Blood
Cells (WBC), #, Blood)
White Blood Cells (wbc), #,
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Cerebrospinal Fluid (White Blood Cells
(WBC), #, Cerebrospinal Fluid)
White Blood Cells (wbc), Microscopy,
Spot Urine (White Blood Cells (WBC),
Microscopy, Spot Urine)
White Blood Cells (wbc), Other, % Blood
(White Blood Cells (WBC), Other, %
Blood)
Value (Enter the lab test result value as
reported.)
UOM (Select the appropriate lab test value unit of
measurement.)
Per 100 Identifiable White Blood Cells
(/100 WBC)
Per Millimeter Cubed (/mm3)
Percent (%)
Percent Per 100 Wbc (%/100 WBC)
10e12 Cells Per Liter (10E12 Cells/L)
10e3 Cells Per Microliter (10E3
Cells/microL)
10e6 Cells (10E6 Cells)
10e6 Cells Per Microliter (10E6
Cells/microL)
10e6 Cells Per Millimeter Cubed (10E6
Cells/mm3)
10e6 Per Liter (10E6/L)
10e7 Cells Per Kilogram (10E7 Cells/kg)
10e8 Cells (10E8 Cells)
10e9 Cells (10E9 Cells)
10e9 Cells Per Liter (10E9 Cells/L)
Billion/liter (Billion/L)
Complement Activity Enzyme Unit (CAE
Unit)
Cells Per Microliter (Cells/microL)
Copies (Copies)
Cu Micron (cubic microns)
Cu Micr (cubic microns)
Cu Mic (cubic microns)
Cubic Microns (cubic microns)
Enzyme Unit (EU)
Enzyme Units Per Deciliter (EU/dL)
Enzyme Units Per Milliliter (EU/mL)
Femtoliter (fL)
Grams (g) (g)
Gram Per 24 Hours (g/24hr)
Gram Per Deciliter (g/dL)
Gram Per Liter (g/L)
Gram Per Microliter (g/microL)
Igg Anti-cardiolipin Antibodies (GPL)
Per High Power Field (HPF)
Index Value (Index value)
International Unit (Iunit)
International Unit Per Liter (IUnit/L)
International Unit Per Meter Squared
(IUnit/m2)
Iu/ml (IUnit/mL)
International Unit Per Milliliter (IUnit/mL)
23 / 29
Lab - Laboratory - 3291794v1.0
Kilounit Per Liter (kU/L)
Liter (L)
Liters Per Minute (L/min)
Liter Per Second (L/sec)
Per Low Power Field (LPF)
Microgram Per 24 Hours (mcg/24hr)
Microgram Per Deciliter (mcg/dL)
Microgram Per Liter (mcg/L)
Microgram Per Milliliter (mcg/mL)
Microgram Per Specimen (mcg/spec)
Milliequivalent (mEq)
Milliequivalents Per 24 Hours (mEq/24hr)
Milliequivalent Per Deciliter (mEq/dL)
Milliequivalent Per Kilogram (mEq/kg)
Milliequivalent Per Liter (mEq/L)
Milligram (mg)
Milligram Per 24 Hours (mg/24hr)
Milligram Per Deciliter (mg/dL)
Milligram Per Gram (mg/g)
Milligram Per Kilogram (mg/kg)
Milligram Per Liter (mg/L)
Milligram Per Milliliter (mg/mL)
Milligram Per Milliliter Per Minute
(mg/mL/min)
Micro International Unit Per Milliliter
(microIU/mL)
Microliter (microL)
Micromole Per 24 Hours (micromol/24hr)
Micromole Per Deciliter (micromol/dL)
Micromole Per Liter (micromol/L)
Microunit Per Milliliter (microU/mL)
Million Plaque Forming Units (mill PFU)
Million (Million)
M/mcl (Million/microL)
M/microl (Million/microL)
M/ui (Million/microL)
Million Per Microliter (Million/microL)
Mill/mcl (Million/microL)
M/ul (Million/microL)
Mil/ui (Million/microL)
Million Per Millimeter Cubed
(Million/mm3)
M/mm3 (Million/mm3)
Mill/cmm (Million/mm3)
M/cmm (Million/mm3)
Milliinternational Unit (miu)
Milliinternational Units Per Meter
Squared (miu/m2)
Milliinternational Unit Per Milliliter
(miu/mL)
Milliter (mL)
Milliliter Per Minute (mL/min)
Milliliter Per Minute Times 1.73 Times
Bsa (mL/min/1.73/BSA)
Milliter Per Minute Per Millimeters Of
Mercury (mL/minute/mmHg)
Milliliter Per Minute Per Millimeter Hg Per
Liter (mL/minute/mmHg/L)
Millimeter Per Hour (mm/hr)
Millimeter Cubed (mm3)
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Millimeter Of Mercury (mmHg)
Millimole (mmol)
Millimole Per 24 Hours (mmol/24hr)
Millimole Per Liter (mmol/L)
Millimole Per Minute Per Thousand
Pascal Per Liter (mmol/min/kPa/L)
Milliosmole Per Kilogram (mosmol/kg)
Igm Anti-cardiolipin Antibodies (MPL)
Million Units Per Milliliter (MU/mL)
Not Applicable; No Uom Required (NA)
Nanogram Per Deciliter (ng/dL)
Nanograms Per Milliliter (ng/mL)
Nanogram Per Milliliter Per Hour
(ng/mL/hr)
Nanomole Per Hour Per Milligram Of
Protein (nmol/hr/mg protein)
Nanomole Per Liter (nmol/L)
Nanomole Per Milligram Of Protein
(nMol/mg protein)
Nanomole Per Milliliter (nmol/mL)
No Source Data (No Srce)
Picograms (pg)
Picogram Per Deciliter (pg/dL)
Picrogram Per Milliliter (pg/mL)
Pgpge2/mg Protein (pgPGE2/mg
protein)
Picomole Per Hour Per Milligram Of
Protein (pmol/hr/mg protein)
Picomole Per Liter (pmol/L)
Ratio (Ratio)
Rna Copies Per Milliliter (RNA
copies/mL)
Seconds (sec)
Thousand (Thousand)
K/microl (Thousand/microL)
K/ul (Thousand/microL)
Thous/mcl (Thousand/microL)
Thou/ul (Thousand/microL)
Thou/mcl (Thousand/microL)
Thousand Per Microliter
(Thousand/microL)
1000/microl (Thousand/microL)
1000/mm2 (Thousand/mm2)
Thousand Per Millimeter Squared
(Thousand/mm2)
K/mm2 (Thousand/mm2)
Thousand Per Millimeter Cubed
(Thousand/mm3)
K/cmm (Thousand/mm3)
Thous/cmm (Thousand/mm3)
1000/mm3 (Thousand/mm3)
Thou/cmm (Thousand/mm3)
K/mm3 (Thousand/mm3)
Threshold (Threshold)
Titer (Titer)
Trillion/liter (Trillion/L)
Microkatal Per Liter (ukat/L)
Unit (Unit)
Unit Per 24 Hours (Unit/24hr)
Unit Per Liter (Unit/L)
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Unit Per Meter Squared (Unit/m2)
Unit Per Millilliter (Unit/mL)
Unit Per Millimeters Cubed (Unit/mm3)
Unknown (Unknown)
Normal Range
Range Indicator (Indicates how the lab result
value compares to the lab test normal range.)
High (High)
Low (Low)
Nonnumeric (Nonnum)
No Range (Norang)
Normal (Normal)
Grade
Mild Adverse Event (1)
Moderate Adverse Event (2)
Severe Adverse Event (3)
Life Threatening Adverse Event (4)
Death Related To Adverse Event (5)
Value (Derived from lab test result value.)
Value in Preferred UOM
Preferred UOM (The preferred unit of
measurement for the specified lab test.)
Per 100 Identifiable White Blood Cells
(/100 WBC)
Per Millimeter Cubed (/mm3)
Percent (%)
Percent Per 100 Wbc (%/100 WBC)
10e12 Cells Per Liter (10E12 Cells/L)
10e3 Cells Per Microliter (10E3
Cells/microL)
10e6 Cells (10E6 Cells)
10e6 Cells Per Microliter (10E6
Cells/microL)
10e6 Cells Per Millimeter Cubed (10E6
Cells/mm3)
10e6 Per Liter (10E6/L)
10e7 Cells Per Kilogram (10E7 Cells/kg)
10e8 Cells (10E8 Cells)
10e9 Cells (10E9 Cells)
10e9 Cells Per Liter (10E9 Cells/L)
Billion/liter (Billion/L)
Complement Activity Enzyme Unit (CAE
Unit)
Cells Per Microliter (Cells/microL)
Copies (Copies)
Cu Micron (cubic microns)
Cu Micr (cubic microns)
Cu Mic (cubic microns)
Cubic Microns (cubic microns)
Enzyme Unit (EU)
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Enzyme Units Per Deciliter (EU/dL)
Enzyme Units Per Milliliter (EU/mL)
Femtoliter (fL)
Grams (g) (g)
Gram Per 24 Hours (g/24hr)
Gram Per Deciliter (g/dL)
Gram Per Liter (g/L)
Gram Per Microliter (g/microL)
Igg Anti-cardiolipin Antibodies (GPL)
Per High Power Field (HPF)
Index Value (Index value)
International Unit (Iunit)
International Unit Per Liter (IUnit/L)
International Unit Per Meter Squared
(IUnit/m2)
Iu/ml (IUnit/mL)
International Unit Per Milliliter (IUnit/mL)
Kilounit Per Liter (kU/L)
Liter (L)
Liters Per Minute (L/min)
Liter Per Second (L/sec)
Per Low Power Field (LPF)
Microgram Per 24 Hours (mcg/24hr)
Microgram Per Deciliter (mcg/dL)
Microgram Per Liter (mcg/L)
Microgram Per Milliliter (mcg/mL)
Microgram Per Specimen (mcg/spec)
Milliequivalent (mEq)
Milliequivalents Per 24 Hours (mEq/24hr)
Milliequivalent Per Deciliter (mEq/dL)
Milliequivalent Per Kilogram (mEq/kg)
Milliequivalent Per Liter (mEq/L)
Milligram (mg)
Milligram Per 24 Hours (mg/24hr)
Milligram Per Deciliter (mg/dL)
Milligram Per Gram (mg/g)
Milligram Per Kilogram (mg/kg)
Milligram Per Liter (mg/L)
Milligram Per Milliliter (mg/mL)
Milligram Per Milliliter Per Minute
(mg/mL/min)
Micro International Unit Per Milliliter
(microIU/mL)
Microliter (microL)
Micromole Per 24 Hours (micromol/24hr)
Micromole Per Deciliter (micromol/dL)
Micromole Per Liter (micromol/L)
Microunit Per Milliliter (microU/mL)
Million Plaque Forming Units (mill PFU)
Million (Million)
M/mcl (Million/microL)
M/microl (Million/microL)
M/ui (Million/microL)
Million Per Microliter (Million/microL)
Mill/mcl (Million/microL)
M/ul (Million/microL)
Mil/ui (Million/microL)
Million Per Millimeter Cubed
(Million/mm3)
M/mm3 (Million/mm3)
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Mill/cmm (Million/mm3)
M/cmm (Million/mm3)
Milliinternational Unit (miu)
Milliinternational Units Per Meter
Squared (miu/m2)
Milliinternational Unit Per Milliliter
(miu/mL)
Milliter (mL)
Milliliter Per Minute (mL/min)
Milliliter Per Minute Times 1.73 Times
Bsa (mL/min/1.73/BSA)
Milliter Per Minute Per Millimeters Of
Mercury (mL/minute/mmHg)
Milliliter Per Minute Per Millimeter Hg Per
Liter (mL/minute/mmHg/L)
Millimeter Per Hour (mm/hr)
Millimeter Cubed (mm3)
Millimeter Of Mercury (mmHg)
Millimole (mmol)
Millimole Per 24 Hours (mmol/24hr)
Millimole Per Liter (mmol/L)
Millimole Per Minute Per Thousand
Pascal Per Liter (mmol/min/kPa/L)
Milliosmole Per Kilogram (mosmol/kg)
Igm Anti-cardiolipin Antibodies (MPL)
Million Units Per Milliliter (MU/mL)
Not Applicable; No Uom Required (NA)
Nanogram Per Deciliter (ng/dL)
Nanograms Per Milliliter (ng/mL)
Nanogram Per Milliliter Per Hour
(ng/mL/hr)
Nanomole Per Hour Per Milligram Of
Protein (nmol/hr/mg protein)
Nanomole Per Liter (nmol/L)
Nanomole Per Milligram Of Protein
(nMol/mg protein)
Nanomole Per Milliliter (nmol/mL)
No Source Data (No Srce)
Picograms (pg)
Picogram Per Deciliter (pg/dL)
Picrogram Per Milliliter (pg/mL)
Pgpge2/mg Protein (pgPGE2/mg
protein)
Picomole Per Hour Per Milligram Of
Protein (pmol/hr/mg protein)
Picomole Per Liter (pmol/L)
Ratio (Ratio)
Rna Copies Per Milliliter (RNA
copies/mL)
Seconds (sec)
Thousand (Thousand)
K/microl (Thousand/microL)
K/ul (Thousand/microL)
Thous/mcl (Thousand/microL)
Thou/ul (Thousand/microL)
Thou/mcl (Thousand/microL)
Thousand Per Microliter
(Thousand/microL)
1000/microl (Thousand/microL)
1000/mm2 (Thousand/mm2)
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Thousand Per Millimeter Squared
(Thousand/mm2)
K/mm2 (Thousand/mm2)
Thousand Per Millimeter Cubed
(Thousand/mm3)
K/cmm (Thousand/mm3)
Thous/cmm (Thousand/mm3)
1000/mm3 (Thousand/mm3)
Thou/cmm (Thousand/mm3)
K/mm3 (Thousand/mm3)
Threshold (Threshold)
Titer (Titer)
Trillion/liter (Trillion/L)
Microkatal Per Liter (ukat/L)
Unit (Unit)
Unit Per 24 Hours (Unit/24hr)
Unit Per Liter (Unit/L)
Unit Per Meter Squared (Unit/m2)
Unit Per Millilliter (Unit/mL)
Unit Per Millimeters Cubed (Unit/mm3)
Unknown (Unknown)
29 / 29
Lab - Laboratory - 3291794v1.0
Kaposi's Sarcoma NCT00686842 Pathology - AMC-059 AIDS and Cancer
Specimen Resource (ACSR) Procurement Form (F37) - 2932913v1.0
Kaposi's Sarcoma NCT00686842 Pathology - AMC-059
AIDS and Cancer Specimen Resource (ACSR)
Procurement Form (F37) - 2932913v1.0
All rights reserved. Please visit https://medical-data-
models.org/forms/1911
AMC-059 AIDS and Cancer
Specimen Resource (ACSR)
Procurement Form (F37)
Unnamed1
Visit number
Unnamed2
Date Specimen Obtained (mm/dd/yyyy)
Date Specimen Obtained (mm/dd/yyyy)
Specimen(s) obtained for donation to ACSR
No (No)
Yes (Yes)
Specimen Type (check all that apply)
Peripheral Blood (Blood)
Other (Other)
Pbmc (peripheral Blood Mononuclear
Cells) (PBMC)
Plasma (Plasma)
Serum (Serum)
Tissue (Tissue)
Other specify
ACSR site the specimen(s) shipped to
Gwu (GWU)
Jhu (JHU)
Osu (OSU)
Other (Other)
Suny/hscb (SUNY/HSCB)
Ucla (UCLA)
Ucsf (UCSF)
Other, specify
If specimens were not obtained for ACSR, please
indicate reason
Other (Other)
Patient Had Previously Donated
Specimen To Acsr (Patient had
previously donated specimen to ACSR)
Patient Refused To Give Informed
Consent For Acsr Specimen Donation
(Patient refused to give informed consent
for ACSR specimen donation)
Patient Was Not Asked To Consider Acsr
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Specimen Donation (Patient was not
asked to consider ACSR specimen
donation)
Other, specify
Study Coordinator
Study Coordinator's name
E-mail
Phone Number (xxx-xxx-xxxx)
Comments
Comments
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Specimen Resource (ACSR) Procurement Form (F37) - 2932913v1.0
Lab - RED CELL INDICES - 2402955v1.0
Lab - RED CELL INDICES - 2402955v1.0
All rights reserved. Please visit https://medical-data-
models.org/forms/1912
RED CELL INDICES
Red Cell Indices
Course Number
Course Day Number
Sample Collection Date
Time
Lab Test
Albumin, Serum (Albumin, Serum)
Alpha 1 Globulin, Protein
Electrophoresis, Serum (Alpha 1
Globulin, Protein Electrophoresis,
Serum)
Alpha 2 Globulin, Protein
Electrophoresis, Serum (Alpha 2
Globulin, Protein Electrophoresis,
Serum)
Beta Globulin, Protein Electrophoresis,
Serum (Beta Globulin, Protein
Electrophoresis, Serum)
Ch50 Complement, Serum (CH50
Complement, Serum)
Direct Antiglobulin Test (coombs), Red
Blood Cells (Direct Antiglobulin Test
(Coombs), Red Blood Cells)
Fibrin Degradation Products (fdp), Blood
(Fibrin Degradation Products (FDP),
Blood)
Fibrinogen, Blood (Fibrinogen, Blood)
Gamma Globulin, Protein
Electrophoresis, Serum (Gamma
Globulin, Protein Electrophoresis,
Serum)
Mean Corpuscular Hemoglobin (mch),
Red Blood Cells (Mean Corpuscular
Hemoglobin (MCH), Red Blood Cells)
Mean Corpuscular Hemoglobin
Concentration (mchc), Red Blood Cells
(Mean Corpuscular Hemoglobin
Concentration (MCHC), Red Blood Cells)
Mean Corpuscular Volume (mcv), Red
Blood Cells (Mean Corpuscular Volume
(MCV), Red Blood Cells)
Nucleated Red Blood Cells (nrbc), #,
Blood (Nucleated Red Blood Cells
(NRBC), #, Blood)
Thrombin Time, Blood (Thrombin Time,
Blood)
Total Protein, Serum (Total Protein,
Serum)
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Lab Value
Lab Unit of Measure Name
Per 100 Identifiable White Blood Cells
(/100 WBC)
Per Millimeter Cubed (/mm3)
Percent (%)
Percent Per 100 Wbc (%/100 WBC)
10e12 Cells Per Liter (10E12 Cells/L)
10e3 Cells Per Microliter (10E3
Cells/microL)
10e6 Cells (10E6 Cells)
10e6 Cells Per Microliter (10E6
Cells/microL)
10e6 Cells Per Millimeter Cubed (10E6
Cells/mm3)
10e7 Cells Per Kilogram (10E7 Cells/kg)
10e8 Cells (10E8 Cells)
10e9 Cells (10E9 Cells)
10e9 Cells Per Liter (10E9 Cells/L)
Complement Activity Enzyme Unit (CAE
Unit)
Cells Per Microliter (Cells/microL)
Copies (Copies)
Cubic Microns (cubic microns)
Enzyme Unit (EU)
Enzyme Units Per Deciliter (EU/dL)
Enzyme Units Per Milliliter (EU/mL)
Femtoliter (fL)
Grams (g) (g)
Gram Per 24 Hours (g/24hr)
Gram Per Deciliter (g/dL)
Gram Per Liter (g/L)
Gram Per Microliter (g/microL)
Per High Power Field (HPF)
International Unit (Iunit)
International Unit Per Liter (IUnit/L)
International Unit Per Meter Squared
(IUnit/m2)
International Unit Per Milliliter (IUnit/mL)
Iu/ml (IUnit/mL)
Kilounit Per Liter (kU/L)
Liter (L)
Liters Per Minute (L/min)
Per Low Power Field (LPF)
Microgram Per 24 Hours (mcg/24hr)
Microgram Per Deciliter (mcg/dL)
Microgram Per Liter (mcg/L)
Microgram Per Milliliter (mcg/mL)
Microgram Per Specimen (mcg/spec)
Milliequivalent (mEq)
Milliequivalents Per 24 Hours (mEq/24hr)
Milliequivalent Per Deciliter (mEq/dL)
Milliequivalent Per Kilogram (mEq/kg)
Milliequivalent Per Liter (mEq/L)
Milligram (mg)
Milligram Per 24 Hours (mg/24hr)
Milligram Per Deciliter (mg/dL)
Milligram Per Kilogram (mg/kg)
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Milligram Per Liter (mg/L)
Milligram Per Milliliter (mg/mL)
Milligram Per Milliliter Per Minute
(mg/mL/min)
Micro International Unit Per Milliliter
(microIU/mL)
Microliter (microL)
Micromole Per 24 Hours (micromol/24hr)
Micromole Per Deciliter (micromol/dL)
Micromole Per Liter (micromol/L)
Million Plaque Forming Units (mill PFU)
Million (Million)
Million Per Microliter (Million/microL)
Million Per Millimeter Cubed
(Million/mm3)
Milliinternational Unit (miu)
Milliinternational Units Per Meter
Squared (miu/m2)
Milliinternational Unit Per Milliliter
(miu/mL)
Milliter (mL)
Milliliter Per Minute (mL/min)
Milliliter Per Minute Times 1.73 Times
Bsa (mL/min/1.73/BSA)
Milliter Per Minute Per Millimeters Of
Mercury (mL/minute/mmHg)
Millimeter Per Hour (mm/hr)
Millimeter Cubed (mm3)
Millimeter Of Mercury (mmHg)
Millimole (mmol)
Millimole Per 24 Hours (mmol/24hr)
Millimole Per Liter (mmol/L)
Milliosmole Per Kilogram (mosmol/kg)
Million Units Per Milliliter (MU/mL)
Not Applicable; No Uom Required (NA)
Nanogram Per Deciliter (ng/dL)
Nanograms Per Milliliter (ng/mL)
Nanogram Per Milliliter Per Hour
(ng/mL/hr)
Nanomole Per Liter (nmol/L)
Nanomole Per Milligram Of Protein
(nMol/mg protein)
Nanomole Per Milliliter (nmol/mL)
No Source Data (No Srce)
Picograms (pg)
Picogram Per Deciliter (pg/dL)
Picrogram Per Milliliter (pg/mL)
Pgpge2/mg Protein (pgPGE2/mg
protein)
Picomole Per Liter (pmol/L)
Ratio (Ratio)
Rna Copies Per Milliliter (RNA
copies/mL)
Seconds (sec)
Thousand (Thousand)
Thousand Per Microliter
(Thousand/microL)
Thousand Per Millimeter Squared
(Thousand/mm2)
Thousand Per Millimeter Cubed
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(Thousand/mm3)
Titer (Titer)
Unit (Unit)
Unit Per 24 Hours (Unit/24hr)
Unit Per Liter (Unit/L)
Unit Per Meter Squared (Unit/m2)
Unit Per Millilliter (Unit/mL)
Unit Per Millimeters Cubed (Unit/mm3)
Unknown (Unknown)
Test Result Significance Indicator
No (N)
Yes (Y)
Laboratory Test Normal Reference Range Text
Laboratory Test Normal Range Indicator
High (High)
Low (Low)
Nonnumeric (Nonnum)
No Range (Norang)
Normal (Normal)
Common Toxicity Criteria Adverse Event Grade
No Adverse Event Or Within Normal
Limits (0)
Mild Adverse Event (1)
Moderate Adverse Event (2)
Severe And Undesirable Adverse Event
(3)
Life-threatening Or Disabling Adverse
Event (4)
Death Related To Adverse Event (5)
Comments
Note Date
Research Comments Text
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Leukemia NCT00085124 Follow-Up - CALGB: C-1001
NEW PRIMARY CANCER FORM - 2076934v3.0
Leukemia NCT00085124 Follow-Up - CALGB: C-1001
NEW PRIMARY CANCER FORM - 2076934v3.0
All rights reserved. Please visit https://medical-data-
models.org/forms/1925
CALGB: C-1001 NEW PRIMARY
CANCER FORM
Ccrr Module For Calgb: C-1001 New
Primary Cancer Form
CALGB Form
CALGB Study No
CALGB Patient ID
Are data amended
Yes (yes)
Patient?s Name
Patient Hospital Number
Main Member Institution/Adjunct
Participating Group
Participating Group Protocol No.
Participating Group Patient No.
Site(s) of New Primary
New Primary, Histologic Type
Date of Diagnosis
Comments
Completed by (First Name. Last Name)
Date Form Completed (Y Y Y Y D D M M)
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All rights reserved. Please visit https://medical-data-
models.org/forms/1926
SERUM ELECTRO
Serum Electro
Course Number
Course Day Number
Sample Collection Date
Time
Lab Test
Immunoglobulin A (iga), Serum
(Immunoglobulin A (IgA), Serum)
Immunoglobulin D (igd), Serum
(Immunoglobulin D (IgD), Serum)
Immunoglobulin E (ige), Serum
(Immunoglobulin E (IgE), Serum)
Immunoglobulin G (igg), Serum
(Immunoglobulin G (IgG), Serum)
Immunoglobulin M (igm), Serum
(Immunoglobulin M (IgM), Serum)
Lab Value
Lab Unit of Measure Name
Per 100 Identifiable White Blood Cells
(/100 WBC)
Per Millimeter Cubed (/mm3)
Percent (%)
Percent Per 100 Wbc (%/100 WBC)
10e12 Cells Per Liter (10E12 Cells/L)
10e3 Cells Per Microliter (10E3
Cells/microL)
10e6 Cells (10E6 Cells)
10e6 Cells Per Microliter (10E6
Cells/microL)
10e6 Cells Per Millimeter Cubed (10E6
Cells/mm3)
10e7 Cells Per Kilogram (10E7 Cells/kg)
10e8 Cells (10E8 Cells)
10e9 Cells (10E9 Cells)
10e9 Cells Per Liter (10E9 Cells/L)
Complement Activity Enzyme Unit (CAE
Unit)
Cells Per Microliter (Cells/microL)
Copies (Copies)
Cubic Microns (cubic microns)
Enzyme Unit (EU)
Enzyme Units Per Deciliter (EU/dL)
Enzyme Units Per Milliliter (EU/mL)
Femtoliter (fL)
Grams (g) (g)
Gram Per 24 Hours (g/24hr)
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Gram Per Deciliter (g/dL)
Gram Per Liter (g/L)
Gram Per Microliter (g/microL)
Per High Power Field (HPF)
International Unit (Iunit)
International Unit Per Liter (IUnit/L)
International Unit Per Meter Squared
(IUnit/m2)
International Unit Per Milliliter (IUnit/mL)
Iu/ml (IUnit/mL)
Kilounit Per Liter (kU/L)
Liter (L)
Liters Per Minute (L/min)
Per Low Power Field (LPF)
Microgram Per 24 Hours (mcg/24hr)
Microgram Per Deciliter (mcg/dL)
Microgram Per Liter (mcg/L)
Microgram Per Milliliter (mcg/mL)
Microgram Per Specimen (mcg/spec)
Milliequivalent (mEq)
Milliequivalents Per 24 Hours (mEq/24hr)
Milliequivalent Per Deciliter (mEq/dL)
Milliequivalent Per Kilogram (mEq/kg)
Milliequivalent Per Liter (mEq/L)
Milligram (mg)
Milligram Per 24 Hours (mg/24hr)
Milligram Per Deciliter (mg/dL)
Milligram Per Kilogram (mg/kg)
Milligram Per Liter (mg/L)
Milligram Per Milliliter (mg/mL)
Milligram Per Milliliter Per Minute
(mg/mL/min)
Micro International Unit Per Milliliter
(microIU/mL)
Microliter (microL)
Micromole Per 24 Hours (micromol/24hr)
Micromole Per Deciliter (micromol/dL)
Micromole Per Liter (micromol/L)
Million Plaque Forming Units (mill PFU)
Million (Million)
Million Per Microliter (Million/microL)
Million Per Millimeter Cubed
(Million/mm3)
Milliinternational Unit (miu)
Milliinternational Units Per Meter
Squared (miu/m2)
Milliinternational Unit Per Milliliter
(miu/mL)
Milliter (mL)
Milliliter Per Minute (mL/min)
Milliliter Per Minute Times 1.73 Times
Bsa (mL/min/1.73/BSA)
Milliter Per Minute Per Millimeters Of
Mercury (mL/minute/mmHg)
Millimeter Per Hour (mm/hr)
Millimeter Cubed (mm3)
Millimeter Of Mercury (mmHg)
Millimole (mmol)
Millimole Per 24 Hours (mmol/24hr)
Millimole Per Liter (mmol/L)
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Milliosmole Per Kilogram (mosmol/kg)
Million Units Per Milliliter (MU/mL)
Not Applicable; No Uom Required (NA)
Nanogram Per Deciliter (ng/dL)
Nanograms Per Milliliter (ng/mL)
Nanogram Per Milliliter Per Hour
(ng/mL/hr)
Nanomole Per Liter (nmol/L)
Nanomole Per Milligram Of Protein
(nMol/mg protein)
Nanomole Per Milliliter (nmol/mL)
No Source Data (No Srce)
Picograms (pg)
Picogram Per Deciliter (pg/dL)
Picrogram Per Milliliter (pg/mL)
Pgpge2/mg Protein (pgPGE2/mg
protein)
Picomole Per Liter (pmol/L)
Ratio (Ratio)
Rna Copies Per Milliliter (RNA
copies/mL)
Seconds (sec)
Thousand (Thousand)
Thousand Per Microliter
(Thousand/microL)
Thousand Per Millimeter Squared
(Thousand/mm2)
Thousand Per Millimeter Cubed
(Thousand/mm3)
Titer (Titer)
Unit (Unit)
Unit Per 24 Hours (Unit/24hr)
Unit Per Liter (Unit/L)
Unit Per Meter Squared (Unit/m2)
Unit Per Millilliter (Unit/mL)
Unit Per Millimeters Cubed (Unit/mm3)
Unknown (Unknown)
Test Result Significance Indicator
No (N)
Yes (Y)
Laboratory Test Normal Reference Range Text
Laboratory Test Normal Range Indicator
High (High)
Low (Low)
Nonnumeric (Nonnum)
No Range (Norang)
Normal (Normal)
Common Toxicity Criteria Adverse Event Grade
No Adverse Event Or Within Normal
Limits (0)
Mild Adverse Event (1)
Moderate Adverse Event (2)
Severe And Undesirable Adverse Event
(3)
Life-threatening Or Disabling Adverse
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Event (4)
Death Related To Adverse Event (5)
Comments
Note Date
Research Comments Text
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BLOOD CHEMISTRY
Blood Chemistry
Course Number
Course Day Number
Sample Collection Date
Time
Lab Test
Serum Alanine Aminotransferase Ialt Or
Sgpt) (Alanine Aminostransferase (ALT
or SGPT), Serum)
Albumin, Serum (Albumin, Serum)
Alkaline Phosphatase, Serum (Alkaline
Phosphatase, Serum)
Serum Amylase (Amylase, Serum)
Serum Aspartate Aminotransferase (ast
Or Sgot) (Aspartate Aminotransferase
(AST or SGOT), Serum)
Bicarbonate, Serum (Bicarbonate,
Serum)
Serum Total Bilirubin (Bilirubin, Total,
Serum)
Serum Blood Urea (Blood Urea Nitrogen
(BUN), Serum)
Calcium, Serum (Calcium, Serum)
Chloride, Serum (Chloride, Serum)
Cholesterol, Serum (Cholesterol, Serum)
Creatinine Kinase (ck), Serum
(Creatinine Kinase (CK), Serum)
Creatinine, Serum (Creatinine, Serum)
Serum Creatinine (Creatinine, Serum)
Gamma Globulin, Protein
Electrophoresis, Serum (Gamma
Globulin, Protein Electrophoresis,
Serum)
Gamma Glutamyl Transferase (ggt),
Serum (Gamma Glutamyl Transferase
(GGT), Serum)
Glucose, Fasting, Serum (Glucose,
Fasting, Serum)
Glucose, Non-fasting, Serum (Glucose,
Non-fasting, Serum)
Lactate Dehydrogenase (ldh), Serum
(Lactate Dehydrogenase (LDH), Serum)
Magnesium, Serum (Magnesium,
Serum)
Phosphate (inorganic Phosphorus),
Serum (Phosphate (inorganic
Phosphorus), Serum)
Potassium, Serum (Potassium, Serum)
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Sodium, Serum (Sodium, Serum)
Total Protein, Serum (Total Protein,
Serum)
Urate (uric Acid), Serum (Urate (Uric
Acid), Serum)
Lab Value
Lab Unit of Measure Name
Per 100 Identifiable White Blood Cells
(/100 WBC)
Per Millimeter Cubed (/mm3)
Percent (%)
Percent Per 100 Wbc (%/100 WBC)
10e12 Cells Per Liter (10E12 Cells/L)
10e3 Cells Per Microliter (10E3
Cells/microL)
10e6 Cells (10E6 Cells)
10e6 Cells Per Microliter (10E6
Cells/microL)
10e6 Cells Per Millimeter Cubed (10E6
Cells/mm3)
10e7 Cells Per Kilogram (10E7 Cells/kg)
10e8 Cells (10E8 Cells)
10e9 Cells (10E9 Cells)
10e9 Cells Per Liter (10E9 Cells/L)
Complement Activity Enzyme Unit (CAE
Unit)
Cells Per Microliter (Cells/microL)
Copies (Copies)
Cubic Microns (cubic microns)
Enzyme Unit (EU)
Enzyme Units Per Deciliter (EU/dL)
Enzyme Units Per Milliliter (EU/mL)
Femtoliter (fL)
Grams (g) (g)
Gram Per 24 Hours (g/24hr)
Gram Per Deciliter (g/dL)
Gram Per Liter (g/L)
Gram Per Microliter (g/microL)
Per High Power Field (HPF)
International Unit (Iunit)
International Unit Per Liter (IUnit/L)
International Unit Per Meter Squared
(IUnit/m2)
International Unit Per Milliliter (IUnit/mL)
Iu/ml (IUnit/mL)
Kilounit Per Liter (kU/L)
Liter (L)
Liters Per Minute (L/min)
Per Low Power Field (LPF)
Microgram Per 24 Hours (mcg/24hr)
Microgram Per Deciliter (mcg/dL)
Microgram Per Liter (mcg/L)
Microgram Per Milliliter (mcg/mL)
Microgram Per Specimen (mcg/spec)
Milliequivalent (mEq)
Milliequivalents Per 24 Hours (mEq/24hr)
Milliequivalent Per Deciliter (mEq/dL)
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Milliequivalent Per Kilogram (mEq/kg)
Milliequivalent Per Liter (mEq/L)
Milligram (mg)
Milligram Per 24 Hours (mg/24hr)
Milligram Per Deciliter (mg/dL)
Milligram Per Kilogram (mg/kg)
Milligram Per Liter (mg/L)
Milligram Per Milliliter (mg/mL)
Milligram Per Milliliter Per Minute
(mg/mL/min)
Micro International Unit Per Milliliter
(microIU/mL)
Microliter (microL)
Micromole Per 24 Hours (micromol/24hr)
Micromole Per Deciliter (micromol/dL)
Micromole Per Liter (micromol/L)
Million Plaque Forming Units (mill PFU)
Million (Million)
Million Per Microliter (Million/microL)
Million Per Millimeter Cubed
(Million/mm3)
Milliinternational Unit (miu)
Milliinternational Units Per Meter
Squared (miu/m2)
Milliinternational Unit Per Milliliter
(miu/mL)
Milliter (mL)
Milliliter Per Minute (mL/min)
Milliliter Per Minute Times 1.73 Times
Bsa (mL/min/1.73/BSA)
Milliter Per Minute Per Millimeters Of
Mercury (mL/minute/mmHg)
Millimeter Per Hour (mm/hr)
Millimeter Cubed (mm3)
Millimeter Of Mercury (mmHg)
Millimole (mmol)
Millimole Per 24 Hours (mmol/24hr)
Millimole Per Liter (mmol/L)
Milliosmole Per Kilogram (mosmol/kg)
Million Units Per Milliliter (MU/mL)
Not Applicable; No Uom Required (NA)
Nanogram Per Deciliter (ng/dL)
Nanograms Per Milliliter (ng/mL)
Nanogram Per Milliliter Per Hour
(ng/mL/hr)
Nanomole Per Liter (nmol/L)
Nanomole Per Milligram Of Protein
(nMol/mg protein)
Nanomole Per Milliliter (nmol/mL)
No Source Data (No Srce)
Picograms (pg)
Picogram Per Deciliter (pg/dL)
Picrogram Per Milliliter (pg/mL)
Pgpge2/mg Protein (pgPGE2/mg
protein)
Picomole Per Liter (pmol/L)
Ratio (Ratio)
Rna Copies Per Milliliter (RNA
copies/mL)
Seconds (sec)
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Thousand (Thousand)
Thousand Per Microliter
(Thousand/microL)
Thousand Per Millimeter Squared
(Thousand/mm2)
Thousand Per Millimeter Cubed
(Thousand/mm3)
Titer (Titer)
Unit (Unit)
Unit Per 24 Hours (Unit/24hr)
Unit Per Liter (Unit/L)
Unit Per Meter Squared (Unit/m2)
Unit Per Millilliter (Unit/mL)
Unit Per Millimeters Cubed (Unit/mm3)
Unknown (Unknown)
Test Result Significance Indicator
No (N)
Yes (Y)
Laboratory Test Normal Reference Range Text
Laboratory Test Normal Range Indicator
High (High)
Low (Low)
Nonnumeric (Nonnum)
No Range (Norang)
Normal (Normal)
Common Toxicity Criteria Adverse Event Grade
No Adverse Event Or Within Normal
Limits (0)
Mild Adverse Event (1)
Moderate Adverse Event (2)
Severe And Undesirable Adverse Event
(3)
Life-threatening Or Disabling Adverse
Event (4)
Death Related To Adverse Event (5)
Comments
Note Date
Research Comments Text
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SEROLOGY
Serology
Course Number
Course Day Number
Sample Collection Date
Time
Lab Test
Alpha-1 Fetoprotein, Serum (Alpha-1
Fetoprotein, Serum)
Beta Choriogonadotropin Bhcg, Or
Pregnancy Test, Serum (Beta
Choriogonadotropin BHCG, or
Pregnancy Test, Serum)
Cancer Antigen 27-29 (ca27-29), Serum
(Cancer Antigen 27-29 (CA27-29),
Serum)
Carcinoembryonic Antigen (cea), Serum
(Carcinoembryonic Antigen (CEA),
Serum)
Carcinogenic Antigen 125 (ca125),
Serum (Carcinogenic Antigen 125
(CA125), Serum)
Carcinogenic Antigen 15-3 (ca15-3),
Serum (Carcinogenic Antigen 15-3
(CA15-3), Serum)
Carcinogenic Antigen 19-9 (ca19-9),
Serum (Carcinogenic Antigen 19-9
(CA19-9), Serum)
Hepatitis B Surface Antigen, Serum
(Hepatitis B Surface Antigen, Serum)
Human Choriogonadotropin (hcg),
Serum (Human Choriogonadotropin
(HCG), Serum)
Human Immunodeficiency Virus (hiv), 1-
2 Antibody, Serum (Human
Immunodeficiency Virus (HIV), 1-2
Antibody, Serum)
Neutralizing Antibody Bl22, Serum
(Neutralizing Antibody BL22, Serum)
Prostate Specific Antigen (psa), Serum
(Prostate Specific Antigen (PSA),
Serum)
Lab Value
Lab Unit of Measure Name
Per 100 Identifiable White Blood Cells
(/100 WBC)
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Per Millimeter Cubed (/mm3)
Percent (%)
Percent Per 100 Wbc (%/100 WBC)
10e12 Cells Per Liter (10E12 Cells/L)
10e3 Cells Per Microliter (10E3
Cells/microL)
10e6 Cells (10E6 Cells)
10e6 Cells Per Microliter (10E6
Cells/microL)
10e6 Cells Per Millimeter Cubed (10E6
Cells/mm3)
10e7 Cells Per Kilogram (10E7 Cells/kg)
10e8 Cells (10E8 Cells)
10e9 Cells (10E9 Cells)
10e9 Cells Per Liter (10E9 Cells/L)
Complement Activity Enzyme Unit (CAE
Unit)
Cells Per Microliter (Cells/microL)
Copies (Copies)
Cubic Microns (cubic microns)
Enzyme Unit (EU)
Enzyme Units Per Deciliter (EU/dL)
Enzyme Units Per Milliliter (EU/mL)
Femtoliter (fL)
Grams (g) (g)
Gram Per 24 Hours (g/24hr)
Gram Per Deciliter (g/dL)
Gram Per Liter (g/L)
Gram Per Microliter (g/microL)
Per High Power Field (HPF)
International Unit (Iunit)
International Unit Per Liter (IUnit/L)
International Unit Per Meter Squared
(IUnit/m2)
International Unit Per Milliliter (IUnit/mL)
Iu/ml (IUnit/mL)
Kilounit Per Liter (kU/L)
Liter (L)
Liters Per Minute (L/min)
Per Low Power Field (LPF)
Microgram Per 24 Hours (mcg/24hr)
Microgram Per Deciliter (mcg/dL)
Microgram Per Liter (mcg/L)
Microgram Per Milliliter (mcg/mL)
Microgram Per Specimen (mcg/spec)
Milliequivalent (mEq)
Milliequivalents Per 24 Hours (mEq/24hr)
Milliequivalent Per Deciliter (mEq/dL)
Milliequivalent Per Kilogram (mEq/kg)
Milliequivalent Per Liter (mEq/L)
Milligram (mg)
Milligram Per 24 Hours (mg/24hr)
Milligram Per Deciliter (mg/dL)
Milligram Per Kilogram (mg/kg)
Milligram Per Liter (mg/L)
Milligram Per Milliliter (mg/mL)
Milligram Per Milliliter Per Minute
(mg/mL/min)
Micro International Unit Per Milliliter
(microIU/mL)
2 / 4
Lab - SEROLOGY - 2400415v1.0
Microliter (microL)
Micromole Per 24 Hours (micromol/24hr)
Micromole Per Deciliter (micromol/dL)
Micromole Per Liter (micromol/L)
Million Plaque Forming Units (mill PFU)
Million (Million)
Million Per Microliter (Million/microL)
Million Per Millimeter Cubed
(Million/mm3)
Milliinternational Unit (miu)
Milliinternational Units Per Meter
Squared (miu/m2)
Milliinternational Unit Per Milliliter
(miu/mL)
Milliter (mL)
Milliliter Per Minute (mL/min)
Milliliter Per Minute Times 1.73 Times
Bsa (mL/min/1.73/BSA)
Milliter Per Minute Per Millimeters Of
Mercury (mL/minute/mmHg)
Millimeter Per Hour (mm/hr)
Millimeter Cubed (mm3)
Millimeter Of Mercury (mmHg)
Millimole (mmol)
Millimole Per 24 Hours (mmol/24hr)
Millimole Per Liter (mmol/L)
Milliosmole Per Kilogram (mosmol/kg)
Million Units Per Milliliter (MU/mL)
Not Applicable; No Uom Required (NA)
Nanogram Per Deciliter (ng/dL)
Nanograms Per Milliliter (ng/mL)
Nanogram Per Milliliter Per Hour
(ng/mL/hr)
Nanomole Per Liter (nmol/L)
Nanomole Per Milligram Of Protein
(nMol/mg protein)
Nanomole Per Milliliter (nmol/mL)
No Source Data (No Srce)
Picograms (pg)
Picogram Per Deciliter (pg/dL)
Picrogram Per Milliliter (pg/mL)
Pgpge2/mg Protein (pgPGE2/mg
protein)
Picomole Per Liter (pmol/L)
Ratio (Ratio)
Rna Copies Per Milliliter (RNA
copies/mL)
Seconds (sec)
Thousand (Thousand)
Thousand Per Microliter
(Thousand/microL)
Thousand Per Millimeter Squared
(Thousand/mm2)
Thousand Per Millimeter Cubed
(Thousand/mm3)
Titer (Titer)
Unit (Unit)
Unit Per 24 Hours (Unit/24hr)
Unit Per Liter (Unit/L)
Unit Per Meter Squared (Unit/m2)
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Unit Per Millilliter (Unit/mL)
Unit Per Millimeters Cubed (Unit/mm3)
Unknown (Unknown)
Test Result Significance Indicator
No (N)
Yes (Y)
Laboratory Test Normal Reference Range Text
Laboratory Test Normal Range Indicator
High (High)
Low (Low)
Nonnumeric (Nonnum)
No Range (Norang)
Normal (Normal)
Common Toxicity Criteria Adverse Event Grade
No Adverse Event Or Within Normal
Limits (0)
Mild Adverse Event (1)
Moderate Adverse Event (2)
Severe And Undesirable Adverse Event
(3)
Life-threatening Or Disabling Adverse
Event (4)
Death Related To Adverse Event (5)
Comments
Note Date
Research Comments Text
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2451 Revision 1 - Chimerism Studies
Registry Use Only
Sequence number:
Date received:
Identification Data
CIBMTR Center Number:
CIBMTR Recipient ID:
Today's date:
Date of hematopoietic stem cell transplantation
(HSCT) for which this form is being completed:
Hsct Type
HSCT type
Related Allogenic (Allogeneic, related)
Unrelated Allogenic (Allogeneic,
unrelated)
Autologous (Autologous)
Syngeneic (Syngeneic (identical twin))
Was a particular hematopoietic stem cell source
used?
Yes (Yes)
Product Type
What type of hematopoietic stem cell transplant
was used?
Umbilical Cord Blood (Cord blood)
Bone Marrow (Marrow)
Multiple Umbilical Cord Blood (Multiple
cord blood units infused)
Other (Other)
Peripheral Blood Stem Cell (PBSC)
Was a particular hematopoietic stem cell
transplant type used?
Yes (Yes)
Specify the other hematopoietic stem cell
transplant type: (Answer only if the response to
CDE 2730912 is "Other" )
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Follow Up Visit
Visit
Integer::1 Year Report (1 year)
Integer::100 Day Report (100 day)
Integer::2 Year Report (2 years)
Integer::6 Month Report (6 Months)
Vital Status
Date of actual contact with the recipient to
determine the medical status for this follow-up
report:
Chimerism Studies
Were chimerism studies performed? (Post-HSCT)
No (No)
Yes (Yes)
Are chimerism laboratory reports attached to this
form?
No (No)
Yes (Yes)
Were infusions from more than one donor given?
No (No)
Yes (Yes)
Specify donor gender:
Female (female)
Male (male)
Chimerism Studies
Date
Method
Cytogenetics (Conventional (Standard)
Cytogenetics)
Fluorescence In Situ Hybridization
(Fluorescence in situ Hybridization
(FISH))
Human Leukocyte Antigen Test (HLA
Typing)
Other (Other)
Restriction Fragment Length
Polymorphism (Restriction Fragment
Length Polymorphism (RFLP))
Minisatellite Repeat (VNTR or STR,
micro or mini satellite)
Specify (Specify the chimerism laboratory
procedure method type)
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Cell type
B-lymphocyte (B-cells)
Bone Marrow (Bone marrow (BM))
Lymphocyte Not Otherwise Specified
(Lymphocytes, not otherwise specified)
Monocyte (Monocytes)
Myeloid Not Otherwise Specified
(Myeloid cells, not otherwise specified)
Other (Other)
Peripheral Blood Mononuclear Cell
(Peripheral blood mononuclear cells
(PBMC))
Neutrophil (PMNs (neutrophils))
Erythrocyte (Red blood cells)
T-lymphocyte (T-cell)
Specify (Specify the chimerism laboratory
procedure cell type)
Total cells examined
Number of donor cells
Number of host cells
Percent donor cells, quantitative method
Were donor cells present as determined by non-
quantitative means? (If performed by non-
quantitative method, indicate the presence of
donor cells.)
Present (Present)
Percent host cells, quantitative method
Were host cells present as determined by non-
quantitative means? (If performed by non-
quantitative method, indicate the presence of
donor cells.)
Present (Present)
Chimerism Studies
NMDP donor ID:
NMDP Cord Blood Unit ID:
Non-NMDP Cord Blood Unit (CBU) ID:
What is the transplant donor or infant date of
birth?
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Non-NMDP donor ID: (Unrelated)
What is the transplant donor or infant gender?
Female (female)
Male (male)
Date
Method
Cytogenetics (Conventional (Standard)
Cytogenetics)
Fluorescence In Situ Hybridization
(Fluorescence in situ Hybridization
(FISH))
Human Leukocyte Antigen Test (HLA
Typing)
Other (Other)
Restriction Fragment Length
Polymorphism (Restriction Fragment
Length Polymorphism (RFLP))
Minisatellite Repeat (VNTR or STR,
micro or mini satellite)
Specify (Specify the chimerism laboratory
procedure method type)
Cell type
B-lymphocyte (B-cells)
Bone Marrow (Bone marrow (BM))
Lymphocyte Not Otherwise Specified
(Lymphocytes, not otherwise specified)
Monocyte (Monocytes)
Myeloid Not Otherwise Specified
(Myeloid cells, not otherwise specified)
Other (Other)
Peripheral Blood Mononuclear Cell
(Peripheral blood mononuclear cells
(PBMC))
Neutrophil (PMNs (neutrophils))
Erythrocyte (Red blood cells)
T-lymphocyte (T-cell)
Specify (Specify the chimerism laboratory
procedure cell type)
Total cells examined
Number of donor cells
Number of host cells
Percent donor cells, quantitative method
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Were donor cells present as determined by non-
quantitative means? (If performed by non-
quantitative method, indicate the presence of
donor cells.)
Present (Present)
Percent host cells, quantitative method
Were host cells present as determined by non-
quantitative means? (If performed by non-
quantitative method, indicate the presence of
donor cells.)
Present (Present)
Donor Cellular Infusion (dci) Information
Part 2 Of 2
First Name
Last Name:
Telephone number:
Fax number:
E-mail address:
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Lab - OTHER SERUM CHEMISTRIES -
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OTHER SERUM CHEMISTRIES
Other Serum Chemistries
Course Number
Course Day Number
Sample Collection Date
Time
Lab Test
Acid Phosphatase (acp), Serum (Acid
Phosphatase (ACP), Serum)
Calcium, Ionized, Serum (Calcium,
Ionized, Serum)
Ferritin, Serum (Ferritin, Serum)
High Density Lipoprotein, Cholesterol,
Serum (High Density Lipoprotein,
Cholesterol, Serum)
Insulin, Serum (Insulin, Serum)
Iron Saturation, Ratio, Serum (Iron
Saturation, Ratio, Serum)
Iron, Serum (Iron, Serum)
Lipase, Serum (Lipase, Serum)
Low Density Lipoproteins, Cholesterol,
Serum (Low Density Lipoproteins,
Cholesterol, Serum)
Osmolality, Serum (Osmolality, Serum)
Thyrotropin (thyroid Stimulating Hormone
Or Tsh), Serum (Thyrotropin (Thyroid
Stimulating Hormone or TSH), Serum)
Thyroxine (t4), Free, Serum (Thyroxine
(T4), Free,  Serum)
Transferrin, Serum (Transferrin, Serum)
Triglycerides, Serum (Triglycerides,
Serum)
Triiodothyronine (t3), Free, Serum
(Triiodothyronine (T3), Free, Serum)
Lab Value
Lab Unit of Measure Name
Per 100 Identifiable White Blood Cells
(/100 WBC)
Per Millimeter Cubed (/mm3)
Percent (%)
Percent Per 100 Wbc (%/100 WBC)
10e12 Cells Per Liter (10E12 Cells/L)
10e3 Cells Per Microliter (10E3
Cells/microL)
10e6 Cells (10E6 Cells)
10e6 Cells Per Microliter (10E6
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Cells/microL)
10e6 Cells Per Millimeter Cubed (10E6
Cells/mm3)
10e7 Cells Per Kilogram (10E7 Cells/kg)
10e8 Cells (10E8 Cells)
10e9 Cells (10E9 Cells)
10e9 Cells Per Liter (10E9 Cells/L)
Complement Activity Enzyme Unit (CAE
Unit)
Cells Per Microliter (Cells/microL)
Copies (Copies)
Cubic Microns (cubic microns)
Enzyme Unit (EU)
Enzyme Units Per Deciliter (EU/dL)
Enzyme Units Per Milliliter (EU/mL)
Femtoliter (fL)
Grams (g) (g)
Gram Per 24 Hours (g/24hr)
Gram Per Deciliter (g/dL)
Gram Per Liter (g/L)
Gram Per Microliter (g/microL)
Per High Power Field (HPF)
International Unit (Iunit)
International Unit Per Liter (IUnit/L)
International Unit Per Meter Squared
(IUnit/m2)
International Unit Per Milliliter (IUnit/mL)
Iu/ml (IUnit/mL)
Kilounit Per Liter (kU/L)
Liter (L)
Liters Per Minute (L/min)
Per Low Power Field (LPF)
Microgram Per 24 Hours (mcg/24hr)
Microgram Per Deciliter (mcg/dL)
Microgram Per Liter (mcg/L)
Microgram Per Milliliter (mcg/mL)
Microgram Per Specimen (mcg/spec)
Milliequivalent (mEq)
Milliequivalents Per 24 Hours (mEq/24hr)
Milliequivalent Per Deciliter (mEq/dL)
Milliequivalent Per Kilogram (mEq/kg)
Milliequivalent Per Liter (mEq/L)
Milligram (mg)
Milligram Per 24 Hours (mg/24hr)
Milligram Per Deciliter (mg/dL)
Milligram Per Kilogram (mg/kg)
Milligram Per Liter (mg/L)
Milligram Per Milliliter (mg/mL)
Milligram Per Milliliter Per Minute
(mg/mL/min)
Micro International Unit Per Milliliter
(microIU/mL)
Microliter (microL)
Micromole Per 24 Hours (micromol/24hr)
Micromole Per Deciliter (micromol/dL)
Micromole Per Liter (micromol/L)
Million Plaque Forming Units (mill PFU)
Million (Million)
Million Per Microliter (Million/microL)
Million Per Millimeter Cubed
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(Million/mm3)
Milliinternational Unit (miu)
Milliinternational Units Per Meter
Squared (miu/m2)
Milliinternational Unit Per Milliliter
(miu/mL)
Milliter (mL)
Milliliter Per Minute (mL/min)
Milliliter Per Minute Times 1.73 Times
Bsa (mL/min/1.73/BSA)
Milliter Per Minute Per Millimeters Of
Mercury (mL/minute/mmHg)
Millimeter Per Hour (mm/hr)
Millimeter Cubed (mm3)
Millimeter Of Mercury (mmHg)
Millimole (mmol)
Millimole Per 24 Hours (mmol/24hr)
Millimole Per Liter (mmol/L)
Milliosmole Per Kilogram (mosmol/kg)
Million Units Per Milliliter (MU/mL)
Not Applicable; No Uom Required (NA)
Nanogram Per Deciliter (ng/dL)
Nanograms Per Milliliter (ng/mL)
Nanogram Per Milliliter Per Hour
(ng/mL/hr)
Nanomole Per Liter (nmol/L)
Nanomole Per Milligram Of Protein
(nMol/mg protein)
Nanomole Per Milliliter (nmol/mL)
No Source Data (No Srce)
Picograms (pg)
Picogram Per Deciliter (pg/dL)
Picrogram Per Milliliter (pg/mL)
Pgpge2/mg Protein (pgPGE2/mg
protein)
Picomole Per Liter (pmol/L)
Ratio (Ratio)
Rna Copies Per Milliliter (RNA
copies/mL)
Seconds (sec)
Thousand (Thousand)
Thousand Per Microliter
(Thousand/microL)
Thousand Per Millimeter Squared
(Thousand/mm2)
Thousand Per Millimeter Cubed
(Thousand/mm3)
Titer (Titer)
Unit (Unit)
Unit Per 24 Hours (Unit/24hr)
Unit Per Liter (Unit/L)
Unit Per Meter Squared (Unit/m2)
Unit Per Millilliter (Unit/mL)
Unit Per Millimeters Cubed (Unit/mm3)
Unknown (Unknown)
Test Result Significance Indicator
No (N)
Yes (Y)
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Laboratory Test Normal Reference Range Text
Laboratory Test Normal Range Indicator
High (High)
Low (Low)
Nonnumeric (Nonnum)
No Range (Norang)
Normal (Normal)
Common Toxicity Criteria Adverse Event Grade
No Adverse Event Or Within Normal
Limits (0)
Mild Adverse Event (1)
Moderate Adverse Event (2)
Severe And Undesirable Adverse Event
(3)
Life-threatening Or Disabling Adverse
Event (4)
Death Related To Adverse Event (5)
Comments
Note Date
Research Comments Text
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Leukemia NCT00085124 Follow-Up - CALGB:
C-215 Secondary Form - 2076910v3.0
Leukemia NCT00085124 Follow-Up - CALGB: C-215
Secondary Form - 2076910v3.0
All rights reserved. Please visit https://medical-data-
models.org/forms/1980
CALGB: C-215 Secondary Form
Ccrr Module For Calgb: C-215 Secondary
Form
CALGB Form
CALGB Study No
CALGB Patient ID
Are data amended
Yes (yes)
Patient?s Name
Patient Hospital Number
Main Member Institution/Adjunct
Participating Group
Participating Group Protocol No.
Participating Group Patient No.
Date of diagnosis of secondary AML/MDS
Has the NCI/CTEP secondary AML/MDS report
form been sent to the CALGB central office?
no (no)
yes (yes)
Explain why the form was not sent
Date the form was sent
Comments
Completed by (First Name. Last Name)
Date Form Completed (Y Y Y Y D D M M)
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OTHER URINARY RESULTS
Other Urinary Results
Course Number
Course Day Number
Sample Collection Date
Time
Lab Test
Calcium Oxalate Crystals, Urine
(Calcium Oxalate Crystals, Urine)
Chloride, 24 Hour, Urine (Chloride, 24
hour, Urine)
Osmolality, 24 Hour, Urine (Osmolality,
24 hour, Urine)
Potassium, 24 Hour, Urine (Potassium,
24 hour, Urine)
Sodium, 24 Hour, Urine (Sodium, 24
hour, Urine)
Uric Acid (urate), 24 Hour, Urine (Uric
Acid (Urate), 24 hour, Urine)
Lab Value
Lab Unit of Measure Name
Per 100 Identifiable White Blood Cells
(/100 WBC)
Per Millimeter Cubed (/mm3)
Percent (%)
Percent Per 100 Wbc (%/100 WBC)
10e12 Cells Per Liter (10E12 Cells/L)
10e3 Cells Per Microliter (10E3
Cells/microL)
10e6 Cells (10E6 Cells)
10e6 Cells Per Microliter (10E6
Cells/microL)
10e6 Cells Per Millimeter Cubed (10E6
Cells/mm3)
10e7 Cells Per Kilogram (10E7 Cells/kg)
10e8 Cells (10E8 Cells)
10e9 Cells (10E9 Cells)
10e9 Cells Per Liter (10E9 Cells/L)
Complement Activity Enzyme Unit (CAE
Unit)
Cells Per Microliter (Cells/microL)
Copies (Copies)
Cubic Microns (cubic microns)
Enzyme Unit (EU)
Enzyme Units Per Deciliter (EU/dL)
Enzyme Units Per Milliliter (EU/mL)
Femtoliter (fL)
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Grams (g) (g)
Gram Per 24 Hours (g/24hr)
Gram Per Deciliter (g/dL)
Gram Per Liter (g/L)
Gram Per Microliter (g/microL)
Per High Power Field (HPF)
International Unit (Iunit)
International Unit Per Liter (IUnit/L)
International Unit Per Meter Squared
(IUnit/m2)
International Unit Per Milliliter (IUnit/mL)
Iu/ml (IUnit/mL)
Kilounit Per Liter (kU/L)
Liter (L)
Liters Per Minute (L/min)
Per Low Power Field (LPF)
Microgram Per 24 Hours (mcg/24hr)
Microgram Per Deciliter (mcg/dL)
Microgram Per Liter (mcg/L)
Microgram Per Milliliter (mcg/mL)
Microgram Per Specimen (mcg/spec)
Milliequivalent (mEq)
Milliequivalents Per 24 Hours (mEq/24hr)
Milliequivalent Per Deciliter (mEq/dL)
Milliequivalent Per Kilogram (mEq/kg)
Milliequivalent Per Liter (mEq/L)
Milligram (mg)
Milligram Per 24 Hours (mg/24hr)
Milligram Per Deciliter (mg/dL)
Milligram Per Kilogram (mg/kg)
Milligram Per Liter (mg/L)
Milligram Per Milliliter (mg/mL)
Milligram Per Milliliter Per Minute
(mg/mL/min)
Micro International Unit Per Milliliter
(microIU/mL)
Microliter (microL)
Micromole Per 24 Hours (micromol/24hr)
Micromole Per Deciliter (micromol/dL)
Micromole Per Liter (micromol/L)
Million Plaque Forming Units (mill PFU)
Million (Million)
Million Per Microliter (Million/microL)
Million Per Millimeter Cubed
(Million/mm3)
Milliinternational Unit (miu)
Milliinternational Units Per Meter
Squared (miu/m2)
Milliinternational Unit Per Milliliter
(miu/mL)
Milliter (mL)
Milliliter Per Minute (mL/min)
Milliliter Per Minute Times 1.73 Times
Bsa (mL/min/1.73/BSA)
Milliter Per Minute Per Millimeters Of
Mercury (mL/minute/mmHg)
Millimeter Per Hour (mm/hr)
Millimeter Cubed (mm3)
Millimeter Of Mercury (mmHg)
Millimole (mmol)
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Millimole Per 24 Hours (mmol/24hr)
Millimole Per Liter (mmol/L)
Milliosmole Per Kilogram (mosmol/kg)
Million Units Per Milliliter (MU/mL)
Not Applicable; No Uom Required (NA)
Nanogram Per Deciliter (ng/dL)
Nanograms Per Milliliter (ng/mL)
Nanogram Per Milliliter Per Hour
(ng/mL/hr)
Nanomole Per Liter (nmol/L)
Nanomole Per Milligram Of Protein
(nMol/mg protein)
Nanomole Per Milliliter (nmol/mL)
No Source Data (No Srce)
Picograms (pg)
Picogram Per Deciliter (pg/dL)
Picrogram Per Milliliter (pg/mL)
Pgpge2/mg Protein (pgPGE2/mg
protein)
Picomole Per Liter (pmol/L)
Ratio (Ratio)
Rna Copies Per Milliliter (RNA
copies/mL)
Seconds (sec)
Thousand (Thousand)
Thousand Per Microliter
(Thousand/microL)
Thousand Per Millimeter Squared
(Thousand/mm2)
Thousand Per Millimeter Cubed
(Thousand/mm3)
Titer (Titer)
Unit (Unit)
Unit Per 24 Hours (Unit/24hr)
Unit Per Liter (Unit/L)
Unit Per Meter Squared (Unit/m2)
Unit Per Millilliter (Unit/mL)
Unit Per Millimeters Cubed (Unit/mm3)
Unknown (Unknown)
Test Result Significance Indicator
No (N)
Yes (Y)
Laboratory Test Normal Reference Range Text
Laboratory Test Normal Range Indicator
High (High)
Low (Low)
Nonnumeric (Nonnum)
No Range (Norang)
Normal (Normal)
Common Toxicity Criteria Adverse Event Grade
No Adverse Event Or Within Normal
Limits (0)
Mild Adverse Event (1)
Moderate Adverse Event (2)
Severe And Undesirable Adverse Event
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(3)
Life-threatening Or Disabling Adverse
Event (4)
Death Related To Adverse Event (5)
Comments
Note Date
Research Comments Text
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Leukemia NCT00085124 Pathology - CALGB:
CYTOGENETICS REFERRAL FORM - 2076684v3.0
Leukemia NCT00085124 Pathology - CALGB:
CYTOGENETICS REFERRAL FORM - 2076684v3.0
All rights reserved. Please visit https://medical-data-
models.org/forms/1989
CALGB: CYTOGENETICS
REFERRAL FORM
Ccrr Module For Calgb: Cytogenetics
Referral Form
Time sample obtained
blood (blood)
bone marrow aspirate (bone marrow
aspirate)
other, specify (other, specify)
sample obtained (sample obtained)
If bone marrow not submitted, give reason
inaspirable (inaspirable)
other, specify (other, specify)
CALGB Form
CALGB Treatment Study #
CALGB Companion Study #
CALGB Patient ID
Amended Data?
Yes (Yes)
Patient?s Name
Patient Hospital Number
Main Member Institution/Adjunct
Participating Group
Participating Group Protocol No.
Participating Group Patient No.
Sex
Female (female)
Male (male)
Diagnosis
ALL (ALL)
AML (AML)
CML (CML)
MDS (MDS)
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Other, specify (Other, specify)
Other, specify (diagnosis)
Date sample obtained
other, specify (sample obtained)
other, specify (reason)
WBC (blood)
% Blasts (blood)
% Blasts (bone marrow)
Completed By (Print or Type Name)
Date Completed
Telephone Number
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BLOOD GASES
Blood Gases
Course Number
Course Day Number
Sample Collection Date
Time
Lab Test
Bicarbonate, Serum (Bicarbonate,
Serum)
Carboxyhemoglobin, Arterial Blood
(Carboxyhemoglobin, Arterial Blood)
Percent Carbon Dioxide (pco2), Arterial
Blood (Percent Carbon Dioxide (pCO2),
Arterial Blood)
Percent Oxygen (po2), Arterial Blood
(Percent Oxygen (pO2), Arterial Blood)
Ph, Arterial Blood (pH, Arterial Blood)
Lab Value
Lab Unit of Measure Name
Per Millimeter Cubed (/100 WBC)
10e12 Cells Per Liter (/mm3)
Percent Per 100 Wbc (%)
Per 100 Identifiable White Blood Cells
(%/100 WBC)
10e3 Cells Per Microliter (10E12 Cells/L)
10e6 Cells (10E3 Cells/microL)
10e6 Cells Per Microliter (10E6 Cells)
10e6 Cells Per Millimeter Cubed (10E6
Cells/microL)
10e7 Cells Per Kilogram (10E6
Cells/mm3)
10e8 Cells (10E7 Cells/kg)
10e9 Cells (10E8 Cells)
10e9 Cells Per Liter (10E9 Cells)
Complement Activity Enzyme Unit (10E9
Cells/L)
Cells Per Microliter (CAE Unit)
Copies (Cells/microL)
Cubic Microns (Copies)
Enzyme Unit (cubic microns)
Enzyme Units Per Deciliter (EU)
Enzyme Units Per Milliliter (EU/dL)
Femtoliter (EU/mL)
Grams (g) (fL)
Gram Per 24 Hours (g)
Gram Per Deciliter (g/24hr)
Gram Per Liter (g/dL)
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Gram Per Microliter (g/L)
Per High Power Field (g/microL)
International Unit (HPF)
International Unit Per Liter (Iunit)
International Unit Per Meter Squared
(IUnit/L)
International Unit Per Milliliter (IUnit/m2)
Iu/ml (IUnit/mL)
Kilounit Per Liter (IUnit/mL)
Liter (kU/L)
Liters Per Minute (L)
Per Low Power Field (L/min)
Microgram Per 24 Hours (LPF)
Microgram Per Deciliter (mcg/24hr)
Microgram Per Liter (mcg/dL)
Microgram Per Milliliter (mcg/L)
Microgram Per Specimen (mcg/mL)
Milliequivalent (mcg/spec)
Milliequivalents Per 24 Hours (mEq)
Milliequivalent Per Deciliter (mEq/24hr)
Milliequivalent Per Kilogram (mEq/dL)
Milliequivalent Per Liter (mEq/kg)
Milligram (mEq/L)
Milligram Per 24 Hours (mg)
Milligram Per Deciliter (mg/24hr)
Milligram Per Kilogram (mg/dL)
Milligram Per Liter (mg/kg)
Milligram Per Milliliter (mg/L)
Milligram Per Milliliter Per Minute
(mg/mL)
Micro International Unit Per Milliliter
(mg/mL/min)
Microliter (microIU/mL)
Micromole Per 24 Hours (microL)
Micromole Per Deciliter (micromol/24hr)
Micromole Per Liter (micromol/dL)
Million Plaque Forming Units
(micromol/L)
Million (mill PFU)
Million Per Microliter (Million)
Million Per Millimeter Cubed
(Million/microL)
Milliinternational Unit (Million/mm3)
Milliinternational Units Per Meter
Squared (miu)
Milliinternational Unit Per Milliliter
(miu/m2)
Milliter (miu/mL)
Milliliter Per Minute (mL)
Milliliter Per Minute Times 1.73 Times
Bsa (mL/min)
Milliter Per Minute Per Millimeters Of
Mercury (mL/min/1.73/BSA)
Millimeter Per Hour (mL/minute/mmHg)
Millimeter Cubed (mm/hr)
Millimeter Of Mercury (mm3)
Millimole (mmHg)
Millimole Per 24 Hours (mmol)
Millimole Per Liter (mmol/24hr)
Milliosmole Per Kilogram (mmol/L)
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Million Units Per Milliliter (mosmol/kg)
Not Applicable; No Uom Required
(MU/mL)
Nanogram Per Deciliter (NA)
Nanograms Per Milliliter (ng/dL)
Nanogram Per Milliliter Per Hour (ng/mL)
Nanomole Per Liter (ng/mL/hr)
Nanomole Per Milligram Of Protein
(nmol/L)
Nanomole Per Milliliter (nMol/mg protein)
No Source Data (nmol/mL)
Picograms (No Srce)
Picogram Per Deciliter (pg)
Picrogram Per Milliliter (pg/dL)
Pgpge2/mg Protein (pg/mL)
Picomole Per Liter (pgPGE2/mg protein)
Ratio (pmol/L)
Rna Copies Per Milliliter (Ratio)
Seconds (RNA copies/mL)
Thousand (sec)
Thousand Per Microliter (Thousand)
Thousand Per Millimeter Squared
(Thousand/microL)
Thousand Per Millimeter Cubed
(Thousand/mm2)
Titer (Thousand/mm3)
Unit (Titer)
Unit Per 24 Hours (Unit)
Unit Per Liter (Unit/24hr)
Unit Per Meter Squared (Unit/L)
Unit Per Millilliter (Unit/m2)
Unit Per Millimeters Cubed (Unit/mL)
Unknown (Unit/mm3)
No (Unknown)
Test Result Significance Indicator
Yes (N)
High (Y)
Laboratory Test Normal Reference Range Text
Laboratory Test Normal Range Indicator
Low (High)
Nonnumeric (Low)
No Range (Nonnum)
Normal (Norang)
No Adverse Event Or Within Normal
Limits (Normal)
Common Toxicity Criteria Adverse Event Grade
Mild Adverse Event (0)
Moderate Adverse Event (1)
Severe And Undesirable Adverse Event
(2)
Life-threatening Or Disabling Adverse
Event (3)
Death Related To Adverse Event (4)
Death Related To Adverse Event (5)
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Comments
Note Date
Research Comments Text
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Lab - URINALYSIS - 2399480v1.0
All rights reserved. Please visit https://medical-data-
models.org/forms/1994
URINALYSIS
Urinalysis
Course Number
Course Day Number
Sample Collection Date
Time
Lab Test
Bilirubin (bile), Spot Urine (Bilirubin
(Bile), Spot Urine)
Casts, Spot Urine (Casts, Spot Urine)
24 Hours Urine Creatinine Clearance
(Creatinine Clearance, 24 hour, Urine)
Creatinine, Spot Or Timed Sample, Urine
(Creatinine, Spot or Timed Sample,
Urine)
Glucose, Spot Urine (Glucose, Spot
Urine)
Ketones, Spot Urine (Ketones, Spot
Urine)
Ph, Spot Urine (pH, Spot Urine)
Protein Excretion, 24 Hour, Urine
(Protein excretion, 24 hour, Urine)
Red Blood Cells (rbc), Microscopy, #,
Spot Urine (Red Blood Cells (RBC),
Microscopy, #, Spot Urine)
Specific Gravity, Spot Urine (Specific
Gravity, Spot Urine)
Specimen Collection Period, Urine
(Specimen Collection Period, Urine)
Volume, Urine (Volume, Urine)
White Blood Cells (wbc), Microscopy,
Spot Urine (White Blood Cells (WBC),
Microscopy, Spot Urine)
Lab Value
Lab Value
Lab Unit of Measure Name
Per 100 Identifiable White Blood Cells
(/100 WBC)
Per Millimeter Cubed (/mm3)
Percent (%)
Percent Per 100 Wbc (%/100 WBC)
10e12 Cells Per Liter (10E12 Cells/L)
10e3 Cells Per Microliter (10E3
Cells/microL)
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10e6 Cells (10E6 Cells)
10e6 Cells Per Microliter (10E6
Cells/microL)
10e6 Cells Per Millimeter Cubed (10E6
Cells/mm3)
10e7 Cells Per Kilogram (10E7 Cells/kg)
10e8 Cells (10E8 Cells)
10e9 Cells (10E9 Cells)
10e9 Cells Per Liter (10E9 Cells/L)
Complement Activity Enzyme Unit (CAE
Unit)
Cells Per Microliter (Cells/microL)
Copies (Copies)
Cubic Microns (cubic microns)
Enzyme Unit (EU)
Enzyme Units Per Deciliter (EU/dL)
Enzyme Units Per Milliliter (EU/mL)
Femtoliter (fL)
Grams (g) (g)
Gram Per 24 Hours (g/24hr)
Gram Per Deciliter (g/dL)
Gram Per Liter (g/L)
Gram Per Microliter (g/microL)
Per High Power Field (HPF)
International Unit (Iunit)
International Unit Per Liter (IUnit/L)
International Unit Per Meter Squared
(IUnit/m2)
International Unit Per Milliliter (IUnit/mL)
Iu/ml (IUnit/mL)
Kilounit Per Liter (kU/L)
Liter (L)
Liters Per Minute (L/min)
Per Low Power Field (LPF)
Microgram Per 24 Hours (mcg/24hr)
Microgram Per Deciliter (mcg/dL)
Microgram Per Liter (mcg/L)
Microgram Per Milliliter (mcg/mL)
Microgram Per Specimen (mcg/spec)
Milliequivalent (mEq)
Milliequivalents Per 24 Hours (mEq/24hr)
Milliequivalent Per Deciliter (mEq/dL)
Milliequivalent Per Kilogram (mEq/kg)
Milliequivalent Per Liter (mEq/L)
Milligram (mg)
Milligram Per 24 Hours (mg/24hr)
Milligram Per Deciliter (mg/dL)
Milligram Per Kilogram (mg/kg)
Milligram Per Liter (mg/L)
Milligram Per Milliliter (mg/mL)
Milligram Per Milliliter Per Minute
(mg/mL/min)
Micro International Unit Per Milliliter
(microIU/mL)
Microliter (microL)
Micromole Per 24 Hours (micromol/24hr)
Micromole Per Deciliter (micromol/dL)
Micromole Per Liter (micromol/L)
Million Plaque Forming Units (mill PFU)
Million (Million)
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Million Per Microliter (Million/microL)
Million Per Millimeter Cubed
(Million/mm3)
Milliinternational Unit (miu)
Milliinternational Units Per Meter
Squared (miu/m2)
Milliinternational Unit Per Milliliter
(miu/mL)
Milliter (mL)
Milliliter Per Minute (mL/min)
Milliliter Per Minute Times 1.73 Times
Bsa (mL/min/1.73/BSA)
Milliter Per Minute Per Millimeters Of
Mercury (mL/minute/mmHg)
Millimeter Per Hour (mm/hr)
Millimeter Cubed (mm3)
Millimeter Of Mercury (mmHg)
Millimole (mmol)
Millimole Per 24 Hours (mmol/24hr)
Millimole Per Liter (mmol/L)
Milliosmole Per Kilogram (mosmol/kg)
Million Units Per Milliliter (MU/mL)
Not Applicable; No Uom Required (NA)
Nanogram Per Deciliter (ng/dL)
Nanograms Per Milliliter (ng/mL)
Nanogram Per Milliliter Per Hour
(ng/mL/hr)
Nanomole Per Liter (nmol/L)
Nanomole Per Milligram Of Protein
(nMol/mg protein)
Nanomole Per Milliliter (nmol/mL)
No Source Data (No Srce)
Picograms (pg)
Picogram Per Deciliter (pg/dL)
Picrogram Per Milliliter (pg/mL)
Pgpge2/mg Protein (pgPGE2/mg
protein)
Picomole Per Liter (pmol/L)
Ratio (Ratio)
Rna Copies Per Milliliter (RNA
copies/mL)
Seconds (sec)
Thousand (Thousand)
Thousand Per Microliter
(Thousand/microL)
Thousand Per Millimeter Squared
(Thousand/mm2)
Thousand Per Millimeter Cubed
(Thousand/mm3)
Titer (Titer)
Unit (Unit)
Unit Per 24 Hours (Unit/24hr)
Unit Per Liter (Unit/L)
Unit Per Meter Squared (Unit/m2)
Unit Per Millilliter (Unit/mL)
Unit Per Millimeters Cubed (Unit/mm3)
Unknown (Unknown)
Test Result Significance Indicator
No (N)
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Yes (Y)
Laboratory Test Normal Range Indicator
High (High)
Low (Low)
Nonnumeric (Nonnum)
No Range (Norang)
Normal (Normal)
Laboratory Test Normal Range Indicator
High (High)
Low (Low)
Nonnumeric (Nonnum)
No Range (Norang)
Normal (Normal)
Common Toxicity Criteria Adverse Event Grade
No Adverse Event Or Within Normal
Limits (0)
Mild Adverse Event (1)
Moderate Adverse Event (2)
Severe And Undesirable Adverse Event
(3)
Life-threatening Or Disabling Adverse
Event (4)
Death Related To Adverse Event (5)
Comments
Note Date
Research Comments Text
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Leukemia null Registration - S0100
Registration Form-3 - 2031484v3.0
Leukemia null Registration - S0100 Registration Form-3 -
2031484v3.0
All rights reserved. Please visit https://medical-data-
models.org/forms/2032
S0100 Registration Form-3
Ccrr Module For S0100 Registration
Form-3
SWOG Study No.
Registration Step
Assigned Treatment Arm
Activation Date
Last Amended Date
Patient's Name
SWOG Patient ID
Caller's SWOG Roster ID
SWOG Treating Institution Number
Date Informed Consent Signed
SWOG Investigator Number
IRB Approval Date
Projected Start Date of Treatment
Did patient receive induction regimen 1 as either
initial or crossover induction therapy?
No (No)
Yes (Yes)
Comments
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Leukemia null On-Study - S0100 PREVIOUSLY UNTREATED ACUTE
LYMPHOBLASTIC LEUKEMIA PRESTUDY FORM - 2070619v3.0
Leukemia null On-Study - S0100 PREVIOUSLY
UNTREATED ACUTE LYMPHOBLASTIC LEUKEMIA
PRESTUDY FORM - 2070619v3.0
All rights reserved. Please visit https://medical-data-
models.org/forms/2043
S0100 PREVIOUSLY UNTREATED
ACUTE LYMPHOBLASTIC
LEUKEMIA PRESTUDY FORM
Patient And Disease Description
Zubrod performance status
Height (cm:)
Date of First Pathologic Diagnosis
FAB Classification (select one:)
Disease Classified As Acute
Lympoblastic Leukemia (fab L1) (L1)
Disease Classified As Acute
Lymphoblastic Leukemia (fab L2) (L2)
Disease Is A Mixed Lineage Acute
Leukemia (Mixed lineage ALL)
Extramedullary Disease Involvement (check all
that apply)
Pathology Or Disease Involving The
Central Nervous System Present
(Central Nervous System)
Gingival Hypertrophy Present (Gingival
Hypertrophy)
Mediastinal Mass Present (Mediastinal
Mass)
Other Specified Extramedullary Disease
Present (Other, specify)
Pathology Or Disease Involving The
Peripheral Nervous System Present
(Peripheral Nervous System)
Pathology Or Disease Involving The Skin
Present (Skin)
Other specify (extramedullary disease inv)
Organ Involvement
Palpable Splenomegaly?
Palpation Performed And Splenomegaly
Absent (No)
Palpation Of Spleen Not Performed (Not
examined)
Surgically absent (Surgically absent)
Palpation Performed And Splenomegaly
Present (Yes)
Splenomegaly by scan or x-ray?
Imaging Performed And Splenomegaly
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Absent (No)
Imaging Of Spleen Not Performed (Not
examined)
Spleen Removed Via Prior Surgery
(Surgically absent)
Imaging Performed And Splenomegaly
Present (Yes)
Palpable Hepatomegaly?
No (No)
Not examined (Not examined)
Yes (Yes)
Hepatomegaly by scan or x-ray?
No (No)
Not examined (Not examined)
Yes (Yes)
Palpable Lymphadenopathy?
No (No)
Yes (Yes)
Lymphadenopathy by scan or x-ray?
No (No)
Not examined (Not examined)
Yes (Yes)
Immunophenotype
B-cell Immunophenotype (B-cell)
Indeterminate Immunophenotype
(Indeterminate)
Mixed Cells Immunophenotype (Mixed)
Non-t/non-b Cell Immunophenotype
(Non-T/Non-B)
Other Specified Immunophenotype
(Other, specify)
pre B-cell (pre B-cell)
T-cell Immunophenotype (T-cell)
Unknown (Unknown)
Other, specify (immunophenotype)
Current Laboratory Values
Date of Blood Values
HGB (g%)
PLTS (x10 : 3)
WBC (x10 : 3)
Peripheral Blasts (%)
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Peripheral Neutrophils (%)
Peripheral Lymphocytes (%)
Peripheral Monocytes (%)
Date of Bone Marrow Biopsy/Aspiration
Marrow Cellularity (%)
Marrow Blasts (%)
Marrow Lymphocytes (%)
Cellularity Status (select one:)
Cellularity Status Of Bone Marrow Is
Aplasitc (severely Hypocellular)
(Aplastic)
Cellularity Status Of Bone Marrow
Unknown, Procedure Resulted In No
Material To Analyze (Dry tap or
inaspirable)
Cellularity Status Of Bone Marrow Is
Hypercellular (Hypercellular)
Cellularity Status Of Bone Marrow Is
Hypocellular (Hypocellular)
Cellularity Status Of Bone Marrow Is
Normocellular (Normocellular)
Cellularity Status Of Bone Marrow Is
Packed (intensely Hypercellular)
(Packed)
Comments
Ccrr Module For S0100 Previously
Untreated Acute Lymphoblastic Leukemia
Prestudy Form
SWOG Patient ID
SWOG Study No.
Registration Step
Patient Initials (L, F, M)
Institution/Affiliate
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Physician
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Leukemia null Pathology - S0100 PATHOLOGY SUBMISSION
FORM - LEUKEMIA ADDENDUM - 2070739v3.0
Leukemia null Pathology - S0100 PATHOLOGY
SUBMISSION FORM - LEUKEMIA ADDENDUM -
2070739v3.0
All rights reserved. Please visit https://medical-data-
models.org/forms/2048
S0100 PATHOLOGY SUBMISSION
FORM - LEUKEMIA ADDENDUM
Ccrr Module For S0100 Pathology
Submission Form - Leukemia Addendum
SWOG Patient No.
Protocol Step
Patient Initials (L, F, M)
Institution/Member
Physician
Date Registered (month, day, year)
Date sample obtained
Time sample obtained (24 hour)
Disease (check only one disease; check one
subcategory for that disease {if appropriate})
Disease Classified As All, Not Otherwise
Specified (nos); (Acute lymphocytic
leukemia (ALL))
Disease Classified As Acute
Lympoblastic Leukemia (fab L1) (Acute
lymphocytic leukemia L1)
Disease Classified As Acute
Lymphoblastic Leukemia (fab L2) (Acute
lymphocytic leukemia L2)
Disease Classified As Acute
Lymphoblastic Leukemia (fab L3) (Acute
lymphocytic leukemia L3)
Disease Classified As Aml, Not
Otherwise Specified (nos) (Acute
myelogenous leukemia (AML))
Acute myelogenous leukemia M0 (Acute
myelogenous leukemia M0)
Disease Classified As Acute Myeloid
Leukemia W/o Maturation (fab M1)
(Acute myelogenous leukemia M1)
Disease Classified As Acute Myeloid
Leukemia W/ Maturation (fab M2) (Acute
myelogenous leukemia M2)
Disease Classified As Acute
Promyelocytic Leukemia (fab M3) (Acute
myelogenous leukemia M3)
Acute myelogenous leukemia M3m
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(Acute myelogenous leukemia M3m)
Disease Classified As Acute
Myelomonocytic Leukemia (fab M4)
(Acute myelogenous leukemia M4)
Acute myelogenous leukemia M4eos
(Acute myelogenous leukemia M4eos)
Disease Classified As Acute Monocytic
Leukemia (fab M5) (Acute myelogenous
leukemia M5)
Acute myelogenous leukemia M5a
(Acute myelogenous leukemia M5a)
Acute myelogenous leukemia M5b
(Acute myelogenous leukemia M5b)
Acute myelogenous leukemia M6 (Acute
myelogenous leukemia M6)
Disease Classified As Acute
Megakaryoblastic Leukemia (fab M7)
(Acute myelogenous leukemia M7)
Disease Classified As All, Not Otherwise
Specified (nos); (ALL, Other)
AML, Other (AML, Other)
Biphenotypic (Biphenotypic)
Disease Classified As Chronic
Lymphocytic Leukemia (cll) (Chronic
lymphocytic leukemia (CLL))
Disease Classified As Cml, Not
Otherwise Specified (nos); (Chronic
myelogenous leukemia (CML))
Chronic Myelogenous Leukemia (cml),
Accelerating Phase, Lymphoid (Chronic
myelogenous leukemia Accelerating
phase)
Disease Classified As Chronic
Myelogenous Leukemia, (cml), Blast
Crisis (Chronic myelogenous leukemia
Blast phase/crisis)
Disease Classified As Chronic
Myelogenous Leukemia (cml), Chronic
Phase (Chronic myelogenous leukemia
Chronic phase)
Disease Classified As Cml, Not
Otherwise Specified (nos); (CML, Other
specify)
Disease Classified As Hairy Cell
Leukemia (Hairy cell leukemia)
Disease Classified As Myelodysplastic
Syndrome (mds) Nos (Myelodysplastic
Syndrome (MDS))
Disease Classified As Chronic
Myelomonocytic Leukemia (cmml)
(Myelodysplastic Syndrome Chronic
myelomonocytic leukemia (CMMoL or
CMML))
Disease Classified As Refractory Anemia
(ra) (Myelodysplastic Syndrome
Refractory anemia (RA))
Disease Classified As Refractory Anemia
W/excess Blasts (raeb) (Myelodysplastic
Syndrome Refractory anemia with
excess blasts (RAEB))
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Leukemia null Pathology - S0100 PATHOLOGY SUBMISSION FORM -
LEUKEMIA ADDENDUM - 2070739v3.0
Disease Classified As Refractory Anemia
W/ Excess Blasts In Transformation
(raeb-t) (Myelodysplastic Syndrome
Refractory anemia with excess blasts in
transformation (RAEB-T))
Disease Classified As Refractory Anemia
W/ Ring Sideroblasts (rars)
(Myelodysplastic Syndrome Refractory
anemia with ring sideroblasts (RARS))
Disease Classified As Myelodysplastic
Syndrome (mds) Nos (Myelodysplastic
syndrome, other specify)
Disease Classified As Specified Other
Leukemia (Other disease)
ALL, Other
ALL, Other
ALL, Other
ALL, Other
ALL, Other
Other disease, specify
Special Stains used at Institution and Results
Myeloperoxidase Chloroacetate
(Myeloperoxidase chloroacetate)
Non Specific Esterase (Non specific
esterase)
Other, Specify Stain (Other, specify
stain)
Specific Esterase (Specific esterase)
Sudan Black (Sudan black)
Other, specify stain
Sudan black, Result
Myeloperoxidase chloroacetate, Result
Specific esterase, Result
Non specific esterase, Result
Other, specify stain, Result
Non-specific esterase
Alpha-naphthyl Acetate (alpha-naphthyl
acetate)
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Leukemia null Pathology - S0100 PATHOLOGY SUBMISSION FORM -
LEUKEMIA ADDENDUM - 2070739v3.0
Alpha-naphthyl Butyrate (alpha-naphthyl
butyrate)
Naphtyl-asd-acetate (naphtyl-ASD-
acetate)
Other, Specify (other, specify)
other, specify (non-specific esterase)
Notes
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Leukemia null Pathology - S0100 PATHOLOGY SUBMISSION FORM -
LEUKEMIA ADDENDUM - 2070739v3.0
Leukemia NCT01190930 Registration - COG AALL0932
OPEN Registration Worksheet - 3192487v1.0
Leukemia NCT01190930 Registration - COG AALL0932
OPEN Registration Worksheet - 3192487v1.0
All rights reserved. Please visit https://medical-data-
models.org/forms/2049
COG AALL0932 OPEN Registration
Worksheet
Stratification
AALL0932 Stratum (Select appropriate stratum)
Down Syndrome Patient (Down
Syndrome Patient)
Non-down Syndrome Patient (Non-Down
Syndrome Patient)
Projected Treatment Start Date of systemic
chemotherapy drug/treatment delivery
(MM/DD/CCYY Study enrollment must take place
within five 5 days of beginning protocol therapy.  If
enrollment takes place before starting therapy,
the date protocol therapy is projected to start
must be no later than five 5 calendar days after
enrollment. Do not report intrathecal IT
cytarabine as start date for Induction therapy,
however, systemic drug/treatment delivery must
begin within 72 hours of administering this IT
therapy)
Inclusion Criteria
Is the patient enrolled on study AALL08B1 (To be
eligible, patients must be enrolled on COG
AALL08B1 before treatment on AALL0932 begins
with the exception of the first dose of intrathecal
chemotherapy.)
No (No)
Yes (Yes)
Was the patient in the indicated age range at time
of diagnosis (Indicated age range: >365 days and
<10 years of age To be eligible, patient must be
>365 days and <10 years of age at time of
diagnosis)
No (No)
Yes (Yes)
Does patient have WBC in the indicated range
(Initial WBC is <50,000/microl. To be eligible,
answer must be 'yes.')
No (No)
Yes (Yes)
Does the patient have newly diagnosed B-
precursor ALL (To be eligible, patient must be
newly diagnosed with NCI Standard Risk B-
precursor acute lymphoblastic leukemia ALL.)
No (No)
Yes (Yes)
1 / 2
Exclusion Criteria
Has the patient received Prior Treatment with
cytotoxic chemotherapy for the current diagnosis
of ALL or any cancer diagnosed previously (with
exception of intrathecal cytarabine [Section 3.2.4]
or steroids [Section 3.3.2] for the current ALL
diagnosis)
No (No)
Yes (Yes)
Does patient have CNS 3 involvement (CNS
status must be known prior to enrollment as
patients with CNS3 involvement are not eligible
for this study. See Section 3.2.4 for details)
No (No)
Yes (Yes)
Does the patient have testicular disease (Patient
is not eligible if he has testicular disease)
N/a, Female (N/A, female)
No (No)
Yes (Yes)
Regulatory Information
Have all institutional, FDA, and NCI requirements
for human studies been met?
No (No)
Yes (Yes)
Date Informed Consent Signed (MM/DD/CCYY
Date entered is the date last authorized signature
is obtained)
Comments Module
Comments
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Leukemia NCT01190930 Registration - COG AALL0932 OPEN
Registration Worksheet - 3192487v1.0
Leukemia null Response - SOUTHWEST ONCOLOGY
GROUP LEUKEMIA RESPONSE FORM - 2070922v3.0
Leukemia null Response - SOUTHWEST ONCOLOGY
GROUP LEUKEMIA RESPONSE FORM - 2070922v3.0
All rights reserved. Please visit https://medical-data-
models.org/forms/2054
SOUTHWEST ONCOLOGY GROUP
LEUKEMIA RESPONSE FORM
Response
Has the patient had a documented clinical
assessment for this cancer?
No (No)
Unknown (Unknown)
Yes (Yes)
Date of Last Clinical Assessment (only provide
date if assessment during this reporting period)
Did the patient achieve a complete response
according to clinical/hematologic criteria during
this recording period?
Null (No)
Null (Unknown)
Null (Yes)
Date of Complete Response (only provide date if
CR was achieved during this reporting period)
Laboratory Values And Extramedullary
Disease Involvement
Date of Blood Values
HGB (g%)
PLTS (x10 : 3)
WBC (x10 : 3)
Peripheral Blasts (%)
Peripheral Neutrophils (%)
Peripheral Lymphocytes (%)
Peripheral Monocytes (%)
Date of Bone Marrow Biopsy/Aspiration
Marrow Cellularity (%)
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Marrow Blasts (%)
Marrow Lymphocytes (%)
Cellularity Status (select one:)
Cellularity Status Of Bone Marrow Is
Aplasitc (severely Hypocellular)
(Aplastic)
Cellularity Status Of Bone Marrow
Unknown, Procedure Resulted In No
Material To Analyze (Dry tap or
inaspirable)
Cellularity Status Of Bone Marrow Is
Hypercellular (Hypercellular)
Cellularity Status Of Bone Marrow Is
Hypocellular (Hypocellular)
Cellularity Status Of Bone Marrow Is
Normocellular (Normocellular)
Cellularity Status Of Bone Marrow Is
Packed (intensely Hypercellular)
(Packed)
Date of Examination for Extramedullary Disease
Extramedullary Disease Involvement: (check all
that apply)
Gingival Hypertrophy Present (Gingival
Hypertrophy)
Mediastinal Mass Present (Mediastinal
Mass)
Other Specified Extramedullary Disease
Present (Other,)
Pathology Or Disease Involving The
Peripheral Nervous System Present
(Peripheral Nervous System)
Pathology Or Disease Involving The Skin
Present (Skin (leukemia cutis))
Other, specify (extramedullary disease)
Did the patient receive a lumbar puncture during
this reporting period? (If yes,)
No (No)
Yes (Yes)
date of Lumbar Puncture
CNS Disease
No (Absent)
Unknown (Indeterminate)
Present (Present)
Notes
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Leukemia null Response - SOUTHWEST ONCOLOGY GROUP
LEUKEMIA RESPONSE FORM - 2070922v3.0
Ccrr Module For Southwest Oncology
Group Leukemia Response Form
SWOG Patient ID
SWOG Study No.
Registration Step
Patient Initials (L, F, M)
Institution/Affiliate
Physician
Cycle
Current Phase Of Leukemia Treatment
For Patient Is Consolidation
(Consolidation)
Cross-over Induction (Cross-over
Induction)
Current Phase Of Leukemia Treatment
For Patient Is Induction (First Induction)
Reporting Period Start Date
Reporting Period End Date
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Leukemia null Response - SOUTHWEST ONCOLOGY GROUP
LEUKEMIA RESPONSE FORM - 2070922v3.0
Leukemia null Pathology - S0100 SPECIMEN
SUBMISSION FORM - 2070809v3.0
Leukemia null Pathology - S0100 SPECIMEN
SUBMISSION FORM - 2070809v3.0
All rights reserved. Please visit https://medical-data-
models.org/forms/2056
S0100 SPECIMEN SUBMISSION
FORM
Specimen
Other, specify (type of specimen)
Type of Specimen (select only one:)
Karyotype(s), Number (Karyotype(s))
Other, Specify (Other)
Slides, Type And Number (Slides)
Tissue, Specify Site(s) (Tissue)
Tubes Of Blood (Tubes of blood)
Tubes Of Bone Marrow (Tubes of bone
marrow)
Tubes Of Serum (Tubes of serum)
Tissue, specify site(s)
Tissue state
Fresh (fresh)
Frozen (frozen)
Fixed (paraffin embedded)
Slides, type and number
Karotype(s), number
Date specimen collected
Time specimen collected (24 hour time)
Reasons For Specimen Submission
Status (select all that apply:)
Complete remission/response specimen
(Complete remission/response
specimen)
Other specimen (Other specimen)
Prestudy specimen (Prestudy specimen)
Relapse/recurrence specimen
(Relapse/recurrence specimen)
Other specimen, specify
Completed By
Date form completed
Notes from submitting institution
1 / 3
For Central Laboratory Use Only
Central laboratory identification number
Date specimen received
Completed By
Time specimen received
Date form completed
Condition of specimen (select only one:)
Damaged Or Unusable (not usable as
received; adequate submission)
not usable as received; inadequate
submission (not usable as received;
inadequate submission)
Useable (usable as received)
Notes From Central Laboratory
Ccrr Module For S0100 Specimen
Submission Form
SWOG Patient ID
SWOG Study No.
Registration Step
Patient Initials (L, F, M)
Disease
Institution/Affiliate
Physician
Contact Person at Institution
Phone Number (Groups other than SWOG)
Group Name
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Leukemia null Pathology - S0100 SPECIMEN SUBMISSION FORM -
2070809v3.0
Study No.
Pt. ID
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Leukemia null Pathology - S0100 SPECIMEN SUBMISSION FORM -
2070809v3.0
Lung Cancer null Follow-Up - ECOG 4599 Baseline
Disease Evaluation Form (RECIST) - 2035976v3.0
Lung Cancer null Follow-Up - ECOG 4599 Baseline
Disease Evaluation Form (RECIST) - 2035976v3.0
All rights reserved. Please visit https://medical-data-
models.org/forms/2075
ECOG 4599 Baseline Disease
Evaluation Form (RECIST)
Long Name
Definition
Context
Protocol Long Name
Workflow
Type
Public ID
Version
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Leukemia null Toxicity - S0100 INDUCTION AND
CONSOLIDATION TOXICITY FORM - 2071052v3.0
Leukemia null Toxicity - S0100 INDUCTION AND
CONSOLIDATION TOXICITY FORM - 2071052v3.0
All rights reserved. Please visit https://medical-data-
models.org/forms/2086
S0100 INDUCTION AND
CONSOLIDATION TOXICITY FORM
Toxicity
Were toxicities assessed for this treatment cycle?
No (No)
Yes (Yes)
Date of most recent toxicity assessment: (If No)
why were toxicities not assessed?
Code
Toxicity
Allergic reaction (Allergic reaction)
Alopecia (Alopecia)
Anorexia (Anorexia)
ARDS (ARDS)
Arthralgia (Arthralgia)
Bilirubin increase (Bilirubin increase)
Bone pain (Bone pain)
Bruising (Bruising)
Cardiac ischemia/infarction (Cardiac
ischemia/infarction)
Cardiac left ventricular function (Cardiac
left ventricular function)
Chills (Chills)
Conjunctivitis (Conjunctivitis)
Constipation (Constipation)
Cough (Cough)
Creatinine increase (Creatinine increase)
Dehydration (Dehydration)
Diarrhea (Diarrhea)
Dizziness/lightheadedness
(Dizziness/lightheadedness)
Duodenal ulcer (Duodenal ulcer)
Fatigue/malaise/lethargy
(Fatigue/malaise/lethargy)
Fever (Fever)
Flushing (Flushing)
Gastric ulcer (Gastric ulcer)
Gastritis (Gastritis)
Headache (Headache)
Hematuria (Hematuria)
Hemorrhage (Hemorrhage)
Hypercalcemia (Hypercalcemia)
Hyperglycemia (Hyperglycemia)
Hyperkalemia (Hyperkalemia)
Hypertension (Hypertension)
Hypocalcemia (Hypocalcemia)
Hypotension (Hypotension)
Infection w/ neutropenia (Infection w/
neutropenia)
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Infection w/o neutropenia (Infection w/o
neutropenia)
Libido loss (Libido loss)
Melana/GI bleeding (Melana/GI bleeding)
Mood alteration-depression (Mood
alteration-depression)
Motor neuropathy (Motor neuropathy)
Myalgia (Myalgia)
Nausea (Nausea)
Other (Other)
Pancreatitis (Pancreatitis)
Personality/ behavioral change
(Personality/ behavioral change)
Photophobia (Photophobia)
Photosensitivity (Photosensitivity)
Pneumonitis/infiltrates
(Pneumonitis/infiltrates)
Pruritis (Pruritis)
Rash/desquamation
(Rash/desquamation)
Renal failure (Renal failure)
Seizures (Seizures)
Sensory neuropathy (Sensory
neuropathy)
SGOT increase (SGOT increase)
SGPT increase (SGPT increase)
Somnolence (Somnolence)
Speech impairment (Speech impairment)
Stomatitis/pharyngitis
(Stomatitis/pharyngitis)
Sweating (Sweating)
Urticaria (Urticaria)
Vomiting (Vomiting)
Weight loss (Weight loss)
Grade
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
Treatment Relation (* Treatment Relation codes:)
Definite (definite)
Possible (possible)
Probable (probable)
Unlikely (unlikely)
Unrelated (unrelated)
Notes
Ccrr Module For S0100 Induction And
Consolidation Toxicity Form
SWOG Patient ID
SWOG Study No.
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Leukemia null Toxicity - S0100 INDUCTION AND CONSOLIDATION
TOXICITY FORM - 2071052v3.0
Registration Step
Patient Initials (L, F, M)
Institution/Affiliate
Physician
Cycle
Current Phase Of Leukemia Treatment
For Patient Is Consolidation
(Consolidation)
Current Phase Of Leukemia Treatment
For Patient Is Crossover (Cross-over
Induction)
Current Phase Of Leukemia Treatment
For Patient Is Induction (First Induction)
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Leukemia null Toxicity - S0100 INDUCTION AND CONSOLIDATION
TOXICITY FORM - 2071052v3.0
Leukemia null Pathology - S0100 PATHOLOGY
SUBMISSION FORM - 2070699v3.0
Leukemia null Pathology - S0100 PATHOLOGY
SUBMISSION FORM - 2070699v3.0
All rights reserved. Please visit https://medical-data-
models.org/forms/2087
S0100 PATHOLOGY SUBMISSION
FORM
Ccrr Module For S0100 Pathology
Submission Form
SWOG Study No.
Registration Step
SWOG Patient ID
Patient Initials (L, F, M)
Institution/Affiliate
Physician
Reason for Submission
Prestudy (Prestudy)
No. of Slides
Date Sample Obtained (month, day, year)
1 W Peripheral Smear Slide, Enclosed
No (No)
Yes (Yes)
1 WG Stained BM Aspirate Slide, Enclosed
No (No)
Yes (Yes)
5 Unstained Smear Slides, Enclosed
No (No)
Yes (Yes)
BM Report, Enclosed
No (No)
Yes (Yes)
Pathology Submission form - Leukemia
Addendum, Enclosed
No (No)
Yes (Yes)
1 Stained biopsy touch prep, Enclosed
No (No)
Yes (Yes)
4 Unstained biopsy touch preps, Enclosed
No (No)
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Yes (Yes)
1 H&E section of the biopsy, Enclosed
No (No)
Yes (Yes)
4 Unstained peripheral blood smears, Enclosed
No (No)
Yes (Yes)
Specimen #
Notes
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Leukemia null Pathology - S0100 PATHOLOGY SUBMISSION FORM -
2070699v3.0
Leukemia null Toxicity - S0100 ALLOGENEIC
PBSCT TOXICITY FORM - 2071336v3.0
Leukemia null Toxicity - S0100 ALLOGENEIC PBSCT
TOXICITY FORM - 2071336v3.0
All rights reserved. Please visit https://medical-data-
models.org/forms/2094
S0100 ALLOGENEIC PBSCT
TOXICITY FORM
Toxicity
Were toxicities assessed for this treatment cycle?
No (No)
Yes (Yes)
Date of most recent toxicity assessment
why were toxicities not assessed?
Code
Toxicity
Abdominal pain (Abdominal pain)
Allergic reaction (Allergic reaction)
Alopecia (Alopecia)
Anorexia (Anorexia)
Arrhythmia (Arrhythmia)
Arthralgia (Arthralgia)
Bilirubin increase (Bilirubin increase)
Bone pain (Bone pain)
Cardiac ischemia/infarction (Cardiac
ischemia/infarction)
Chills (Chills)
Constipation (Constipation)
Diarrhea (Diarrhea)
Dizziness/lightheadedness
(Dizziness/lightheadedness)
Dyspnea (Dyspnea)
Edema (Edema)
Esophagitis (Esophagitis)
Fatigue/malaise/lethargy
(Fatigue/malaise/lethargy)
Female sterility (Female sterility)
Fever (Fever)
Gastritis (Gastritis)
Headache (Headache)
Hypotension (Hypotension)
Infection w/neutropenia (Infection
w/neutropenia)
Infection w/o neutropenia (Infection w/o
neutropenia)
Male infertility (Male infertility)
Motor neuropathy (Motor neuropathy)
Myalgia (Myalgia)
Nausea (Nausea)
Pigmentation changes (Pigmentation
changes)
Pleural effusion (Pleural effusion)
Pneumonitis/infiltrates
(Pneumonitis/infiltrates)
Pruritis (Pruritis)
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Rash/desquamation
(Rash/desquamation)
Renal failure (Renal failure)
RT-dermatitis (RT-dermatitis)
Salivary gland changes (Salivary gland
changes)
Sensory neuropathy (Sensory
neuropathy)
SGOT increase (SGOT increase)
SGPT increase (SGPT increase)
Somnolence (Somnolence)
Speech impairment (Speech impairment)
Stomatitis/pharyngitis
(Stomatitis/pharyngitis)
Sweating (Sweating)
Taste disturbance (Taste disturbance)
Urticaria (Urticaria)
Vomiting (Vomiting)
Other:
Grade
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
Treatment Relation (* Treatment Relation codes:)
Definite (definite)
Possible (possible)
Probable (probable)
Unlikely (unlikely)
Unrelated (unrelated)
Comments
Ccrr Module For S0100 Allogeneic Pbsct
Toxicity Form
SWOG Patient ID
SWOG Study No.
Registration Step
Patient Initials (L, F, M)
Institution/Affiliate
Physician
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Leukemia null Toxicity - S0100 ALLOGENEIC PBSCT TOXICITY FORM -
2071336v3.0
Leukemia null Registration - S0100
Registration Form-1 - 2031615v3.0
Leukemia null Registration - S0100 Registration Form-1 -
2031615v3.0
All rights reserved. Please visit https://medical-data-
models.org/forms/2098
S0100 Registration Form-1
Patient Consent For Specimen Use:
Patient's tissue may be kept for use in research to
learn about, prevent, treat, or cure cancer.
Null (No)
Null (Yes)
Patient's tissue may be kept for research about
other health problems   (for example: causes of
diabetes, Alzheimer's disease, and heart
disease.)
Null (No)
Null (Yes)
Someone from the Southwest Oncology Group
may contact the patient in the future to ask him or
her to take part in more research.
Null (No)
Null (Yes)
Patient's Date of Birth
Patient's Sex
Female (Female)
Male (Male)
Method of Payment:
Medicaid (Medicaid)
Medicaid And Medicare (Medicaid and
Medicare)
Medicare (Medicare)
Medicare And Private Insurance
(Medicare and Private)
Military Sponsored (including Champus
& Tricare) (Military)
No Means Of Payment (no Insurance)
(No insurance (no means))
Self Pay (no Insurance) (No insurance
(self-pay))
Other (Other, specify at registration)
Private Insurance (Private)
Unknown (Unknown)
Veterans Sponsored (Veterans Admin)
Patient's Ethnicity
Hispanic_or_latino (HISPANIC OR
LATINO)
No (not Spanish) (No (not Spanish))
Non_hispanic (NON-HISPANIC)
Unknown (Unknown)
Yes, Central American (Yes, Central
American)
Yes, Cuban (Yes, Cuban)
Yes, Mexican (Yes, Mexican)
Yes, NOS (Yes, NOS)
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Yes, South American (Yes, South
American)
Yes,Other (Yes,Other)
Yes,Puerto Rican (Yes,Puerto Rican)
Patient's Race (select all that apply:)
Native_american_cdus (American Indian
or Alaska Native)
Asian_cdus (Asian)
Black_cdus (Black or African American)
Pacific_islander_cdus (Native Hawaiian
or Other Pacific Islander)
Other, (Other,)
Unknown (Unknown)
White_cdus (White or Caucasian)
specify: (If a U.S. resident)
Patient's Social Security Number
Patient's ZIP Code
Country of Residence, if not USA (If a resident of
Canada)
Social Insurance Number
Postal Code
Stratification Factors
Age
<30 (<30)
30-49 (30-49)
50+ (50+)
Phenotype
Pre-b (pre-B)
T-cell (T-cell)
Notes
Ccrr Module For S0100 Registration
Form-1
SWOG Study No.
Registration Step
Assigned Treatment Arm
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Leukemia null Registration - S0100 Registration Form-1 - 2031615v3.0
Activation Date
Last Amended Date
Patient's Name
SWOG Patient ID
Caller's SWOG Roster ID
SWOG Treating Institution Number
Date Informed Consent Signed
SWOG Investigator Number
IRB Approval Date
Projected Start Date of Treatment
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Leukemia null Registration - S0100 Registration Form-1 - 2031615v3.0
Leukemia null Registration - S0100
Registration Form-4 - 2031861v3.0
Leukemia null Registration - S0100 Registration Form-4 -
2031861v3.0
All rights reserved. Please visit https://medical-data-
models.org/forms/2100
S0100 Registration Form-4
Ccrr Module For S0100 Registration
Form-4
SWOG Study No.
Registration Step
Assigned Treatment Arm
Activation Date
Last Amended Date
Patient's Name
SWOG Patient ID
Caller's SWOG Roster ID
SWOG Treating Institution Number
Date Informed Consent Signed
SWOG Investigator Number
IRB Approval Date
Projected Start Date of Treatment
Candidate for allogeneic PBSCT?
No (No)
Yes (Yes)
Comments
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Leukemia null Toxicity - S0100 MAINTENANCE
TOXICITY FORM - 2071610v3.0
Leukemia null Toxicity - S0100 MAINTENANCE TOXICITY
FORM - 2071610v3.0
All rights reserved. Please visit https://medical-data-
models.org/forms/2110
S0100 MAINTENANCE TOXICITY
FORM
Toxicity
Were toxicities assessed for this treatment cycle?
No (No)
Yes (Yes)
Date of most recent toxicity assessment (If No,)
why were toxicities not assessed?
Code
Toxicity
Abdominal pain (Abdominal pain)
Allergic reaction (Allergic reaction)
Alopecia (Alopecia)
Anorexia (Anorexia)
Arrhythmia (Arrhythmia)
Arthralgia (Arthralgia)
Bilirubin increase (Bilirubin increase)
Blurred vision (Blurred vision)
Bone pain (Bone pain)
Bruising (Bruising)
Cardiac ischemia/infarction (Cardiac
ischemia/infarction)
Chest pain (Chest pain)
Chills (Chills)
Conjunctivitis (Conjunctivitis)
Constipation (Constipation)
Diarrhea (Diarrhea)
Dizziness/ lightheadedness (Dizziness/
lightheadedness)
Duodenal ulcer (Duodenal ulcer)
Dyspnea (Dyspnea)
Edema (Edema)
Esophagitis (Esophagitis)
Fatigue/malaise/lethargy
(Fatigue/malaise/lethargy)
Fever (Fever)
Gastric ulcer (Gastric ulcer)
Gastritis (Gastritis)
Headache (Headache)
Hematuria (Hematuria)
Hemorrhage (Hemorrhage)
Hypercalcemia (Hypercalcemia)
Hyperglycemia (Hyperglycemia)
Hyperkalemia (Hyperkalemia)
Hypertension (Hypertension)
Hypocalcemia (Hypocalcemia)
Hypotension (Hypotension)
Infection w/neutropenia (Infection
w/neutropenia)
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Infection w/o neutropenia (Infection w/o
neutropenia)
Insomnia (Insomnia)
Melana/GI bleeding (Melana/GI bleeding)
Mood alteration -euphoric (Mood
alteration -euphoric)
Motor neuropathy (Motor neuropathy)
Myalgia (Myalgia)
Nausea (Nausea)
Pancreatitis (Pancreatitis)
Personality/behavioral change
(Personality/behavioral change)
Photophobia (Photophobia)
Photosensitivity (Photosensitivity)
Pneumonitis/infiltrates
(Pneumonitis/infiltrates)
Pruritis (Pruritis)
Rash/desquamation
(Rash/desquamation)
Renal failure (Renal failure)
Seizures (Seizures)
Sensory neuropathy (Sensory
neuropathy)
SGOT increase (SGOT increase)
SGPT increase (SGPT increase)
Somnolence (Somnolence)
Stomatitis/pharyngitis
(Stomatitis/pharyngitis)
Sweating (Sweating)
Taste disturbance (Taste disturbance)
Urticaria (Urticaria)
Vomiting (Vomiting)
Other (toxicity)
Grade
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
Treatment Relation (* Treatment Relation codes:)
Definite (definite)
Possible (possible)
Probable (probable)
Unlikely (unlikely)
Unrelated (unrelated)
Notes
Ccrr Module For S0100 Maintenance
Toxicity Form
SWOG Patient ID
2 / 3
Leukemia null Toxicity - S0100 MAINTENANCE TOXICITY FORM -
2071610v3.0
SWOG Study No.
Registration Step
Patient Initials (L, F, M)
Institution/Affiliate
Physician
Cycle (check only one)
1 (1)
2 (2)
3 (3)
4 (4)
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Leukemia null Toxicity - S0100 MAINTENANCE TOXICITY FORM -
2071610v3.0
Leukemia null Toxicity - S0100 CNS LEUKEMIA CRANIAL
IRRADIATION TOXICITY FORM - 2071222v3.0
Leukemia null Toxicity - S0100 CNS LEUKEMIA CRANIAL
IRRADIATION TOXICITY FORM - 2071222v3.0
All rights reserved. Please visit https://medical-data-
models.org/forms/2118
S0100 CNS LEUKEMIA CRANIAL
IRRADIATION TOXICITY FORM
Toxicity
Were toxicities assessed for this treatment cycle?
No (No)
Yes (Yes)
Date of most recent toxicity assessment (If No,)
why were toxicities not assessed?
Code
Toxicity
Alopecia (Alopecia)
Anorexia (Anorexia)
Arthralgia (Arthralgia)
Cataract (Cataract)
Confusion (Confusion)
Cough (Cough)
Dehydration (Dehydration)
Diarrhea (Diarrhea)
Dizziness/lightheadedness
(Dizziness/lightheadedness)
Fatigue/malaise/lethargy
(Fatigue/malaise/lethargy)
Flushing (Flushing)
Headache (Headache)
Hypertension (Hypertension)
Hypotension (Hypotension)
Mood alteration -depression (Mood
alteration -depression)
Motor neuropathy (Motor neuropathy)
Mouth dryness (Mouth dryness)
Myalgia (Myalgia)
Nausea (Nausea)
Personality/behavioral change
(Personality/behavioral change)
Pneumonitis/infiltrates
(Pneumonitis/infiltrates)
Rash/desquamation
(Rash/desquamation)
RT-dermatitis (RT-dermatitis)
Seizures (Seizures)
Speech impairment (Speech impairment)
Vomiting (Vomiting)
Weight loss (Weight loss)
Other:
Grade
1 (1)
1 / 2
2 (2)
3 (3)
4 (4)
5 (5)
Treatment Relation (* Treatment Relation codes:)
Definite (definite)
Possible (possible)
Probable (probable)
Unlikely (unlikely)
Unrelated (unrelated)
Comments
Ccrr Module For S0100 Cns Leukemia
Cranial Irradiation Toxicity Form
SWOG Patient ID
SWOG Study No.
Registration Step
Patient Initials (L, F, M)
Institution/Affiliate
Physician
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Leukemia null Toxicity - S0100 CNS LEUKEMIA CRANIAL IRRADIATION
TOXICITY FORM - 2071222v3.0
Leukemia null Toxicity - S0100 POST-
PBSCT TOXICITY FORM - 2071464v3.0
Leukemia null Toxicity - S0100 POST- PBSCT TOXICITY
FORM - 2071464v3.0
All rights reserved. Please visit https://medical-data-
models.org/forms/2126
S0100 POST- PBSCT TOXICITY
FORM
Toxicity
Were toxicities assessed for this treatment cycle?
No (No)
Yes (Yes)
Date of most recent toxicity assessment (If No, )
why were toxicities not assessed?
Code
Toxicity
Acute vascular leak syndrome (Acute
vascular leak syndrome)
Alopecia (Alopecia)
Anorexia (Anorexia)
Arrythmia (Arrythmia)
Arthralgia (Arthralgia)
Bilirubin increase (Bilirubin increase)
Blurred vision (Blurred vision)
Bone pain (Bone pain)
Bruising (Bruising)
Chills (Chills)
Cough (Cough)
Creatinine increase (Creatinine increase)
Diarrhea (Diarrhea)
Dizziness/lightheadedness
(Dizziness/lightheadedness)
Dyspepsia/heartburn
(Dyspepsia/heartburn)
Dyspnea (Dyspnea)
Edema (Edema)
Fatigue/malaise/lethargy
(Fatigue/malaise/lethargy)
Fever (Fever)
Flushing (Flushing)
Headache (Headache)
Hematuria (Hematuria)
Hyperglycemia (Hyperglycemia)
Hyperkalemia (Hyperkalemia)
Hypertension (Hypertension)
Hyperuricemia (Hyperuricemia)
Hypomagnesemia (Hypomagnesemia)
Hypotension (Hypotension)
Infection w/ neutropenia (Infection w/
neutropenia)
Infection w/o neutropenia (Infection w/o
neutropenia)
Injection site reaction (Injection site
reaction)
Libido loss (Libido loss)
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Melana/GI bleeding (Melana/GI bleeding)
Menses changes (Menses changes)
Mood alteration -depression (Mood
alteration -depression)
Motor neuropathy (Motor neuropathy)
Muscle weakness (not neuropathy)
(Muscle weakness (not neuropathy))
Myalgia (Myalgia)
Nausea (Nausea)
Personality/behavioral change
(Personality/behavioral change)
Phlebitis (Phlebitis)
Photosensitivity (Photosensitivity)
Pigmentation changes (Pigmentation
changes)
Pleural effusion (Pleural effusion)
Pneumonitis/infiltrates
(Pneumonitis/infiltrates)
Pruritis (Pruritis)
Rash/desquamation
(Rash/desquamation)
Renal failure (Renal failure)
Seizures (Seizures)
Sensory neuropathy (Sensory
neuropathy)
SGOT increase (SGOT increase)
SGPT increase (SGPT increase)
Somnolence (Somnolence)
Speech impairment (Speech impairment)
Stomatitis/pharyngitis
(Stomatitis/pharyngitis)
Sweating (Sweating)
Thrombosis/embolism
(Thrombosis/embolism)
Tremor (Tremor)
Urticaria (Urticaria)
Vomiting (Vomiting)
Other (toxicity)
Grade
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
Treatment Relation
Definite (definite)
Possible (possible)
Probable (probable)
Unlikely (unlikely)
Unrelated (unrelated)
Comments
Ccrr Module For S0100 Post- Pbsct
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Leukemia null Toxicity - S0100 POST- PBSCT TOXICITY FORM -
2071464v3.0
Toxicity Form
SWOG Patient ID
SWOG Study No.
Registration Step
Patient Initials (L, F, M)
Institution/Affiliate
Physician
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Leukemia null Toxicity - S0100 POST- PBSCT TOXICITY FORM -
2071464v3.0
Leukemia null Registration - S0100
Registration Form-2 - 2031499v3.0
Leukemia null Registration - S0100 Registration Form-2 -
2031499v3.0
All rights reserved. Please visit https://medical-data-
models.org/forms/2128
S0100 Registration Form-2
Ccrr Module For S0100 Registration
Form-2
SWOG Study No.
Registration Step
Assigned Treatment Arm
Activation Date
Last Amended Date
Patient's Name
SWOG Patient ID
Caller's SWOG Roster ID
SWOG Treating Institution Number
Date Informed Consent Signed
SWOG Investigator Number
IRB Approval Date
Projected Start Date of Treatment
Initial induction arm
Daunorubicin/vincristine/prednisone/l-
asparaginase
(daunorubicin/vincristine/prednisone/l-
asparaginase)
High Dose Ara-c/mixoxantrone (high
dose Ara-C/mixoxantrone)
Comments
1 / 1
Lung Cancer null Follow-Up - ECOG 4599 Follow-Up
Disease Evaluation Form (RECIST) - 2036006v3.0
Lung Cancer null Follow-Up - ECOG 4599 Follow-Up
Disease Evaluation Form (RECIST) - 2036006v3.0
All rights reserved. Please visit https://medical-data-
models.org/forms/2143
ECOG 4599 Follow-Up Disease
Evaluation Form (RECIST)
Date Of Data Transfer
Transfer Method
Specify other transfer method
Step No.
Course Identification
Patient Name
Particip. Group Protocol Number
Patient Study ID, Participating Group
Institution Name
Affiliate Name
Amended Data Ind
Amended Data Ind
Lesion, Reference Number, Target
Lesion, Anatomic Site, Target
Site Code, Target
Assessment Type, Target
Assessment Date, Target
Lesion, Tumor Diameter
Lesion, Baseline Tumor Diameter
Lesion, Diameter, Longest Sum
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Lesion, Reference Number, Nontarget
Lesion, Anatomic Site, Nontarget
Site Code, Nontarget
Assessment Type, Nontarget
Assessment Date, Nontarget
Lesion, Follow-up Status
Cytology Result, Nontarget
Other Specify
New Lesion Ind
Lesion, Reference Number, New
Lesion, Anatomic Site, New
Site Code, New
Assessment Type, New
Assessment Date, New
Cytology Result, New
Has Target Lesion Response Status Change
Target Lesion Response Status
Response Status Change
Overall Tumor Response
Progressive Disease Observed Date
Progressive Disease Observed Date
Response Confirmed Ind
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Lung Cancer null Follow-Up - ECOG 4599 Follow-Up Disease Evaluation
Form (RECIST) - 2036006v3.0
PR/CR First Observed Date
PR/CR First Observed Date
Symptomatic Deterioration Ind
Symptomatic Deterioration Specify
Symptomatic Deterioration Date
Comments
Comments2
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Lung Cancer null Follow-Up - ECOG 4599 Follow-Up Disease Evaluation
Form (RECIST) - 2036006v3.0
Lymphoma NCT00392834 Lab - AMC-048 HIV
T-Cell Laboratory Values (F24) - 2655321v1.0
Lymphoma NCT00392834 Lab - AMC-048 HIV T-Cell
Laboratory Values (F24) - 2655321v1.0
All rights reserved. Please visit https://medical-data-
models.org/forms/2292
AMC-048 HIV T-Cell Laboratory
Values (F24)
Unnamed1
Visit number
Sequence number
Unnamed2
Date of Evaluation (mm/dd/yyyy)
T-cell Laboratory Values
T-Helper CD4+ %
T-Helper CD4+ absolute count
T-Suppressor CD8+ %
T-Suppressor CD8+ absolute count
B-Cell CD19+ %
B-Cell CD19+ absolute count
T-Cell CD20+ %
T-Cell CD20+ absolute count
Other, specify
Percent Positive Lymphocytes
Absolute Count
Comments
Comments
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NCT00324415 Pre-Study - AMC-045 Anal Cancer
Initial Evaluation Form (IEF) - 2516530v1.0
NCT00324415 Pre-Study - AMC-045 Anal Cancer Initial
Evaluation Form (IEF) - 2516530v1.0
All rights reserved. Please visit https://medical-data-
models.org/forms/2302
AMC-045 Anal Cancer Initial
Evaluation Form (IEF)
Unnamed1
Visit number
Anal Cancer Tumor Characteristics
Evidence of Bowel Obstruction from Anal Cancer
Complete (Complete)
No (No)
Partial (Partial)
Unknown (Unknown)
Tumor Location
Above Dentate Line (Above dentate line)
Anal Canal (Anal Canal)
Anal Canal And Perianal Skin (Anal
Canal and Perianal skin)
Perianal Skin (Perianal skin)
Anterior (Tumor position)
No (No)
Unknown (Unknown)
Yes (Yes)
Posterior (Tumor position)
No (No)
Unknown (Unknown)
Yes (Yes)
Right Lateral (Tumor position)
No (No)
Unknown (Unknown)
Yes (Yes)
Left Lateral (Tumor position)
No (No)
Unknown (Unknown)
Yes (Yes)
Circumferential Involvement
<1/2 (<1/2)
>1/2 (>1/2)
Unknown (Unknown)
Longest Diameter of Lesion(s) (cm)
Date of Definitive Histologic Diagnosis of Primary
Tumor (mm/dd/yyyy)
Histology
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Anal Basaloid Carcinoma (Basaloid)
Anal Cloacogenic Carcinoma
(Cloacogenic)
Other (Other)
Anal Squamous Cell Carcinoma
(Squamous Cell)
Other, specify
Differentiation
High Grade (High Grade (poorly
differentiated))
Intermediate Grade (Intermediate Grade
(moderately differentiated))
Low Grade (Low Grade (well
differentiated))
Unknown (Unknown)
Needle Aspiration (Biopsy of palpably enlarged
inguinal nodes)
Equivocal (Equivocal)
Negative (Negative)
Not Applicable (Not Applicable (not
palpable))
Not Done (Not done)
Positive (Positive)
Unknown (Unknown)
Date of Biopsy (mm/dd/yyyy)
Date of Biopsy (mm/dd/yyyy)
Excisional (required if needle aspiration is
negative) (Biopsy of palpably enlarged inguinal
nodes)
Equivocal (Equivocal)
Negative (Negative)
Not Applicable (Not Applicable (not
palpable))
Not Done (Not done)
Positive (Positive)
Unknown (Unknown)
Pelvic Lymph Nodes Suspected
Absent (Absent)
Present (Present)
Method of Evaluation (If "Present",)
Other (Other)
Pathologic (Pathologic)
Radiographic (Radiographic)
Other Specify
Fecal Continence
Gas Incontinence Only; Able To Control
Stool Movements But Not Gas (Gas
incontinence only; able to control stool
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NCT00324415 Pre-Study - AMC-045 Anal Cancer Initial Evaluation Form
(IEF) - 2516530v1.0
movements but not gas)
Minor Spotting Or Leakage Of Stool (up
To Coin Size) About Once Per Week
(Minor spotting or leakage of stool (up to
coin size) about once per week)
Minor Spotting Or Leakage Of Stool (up
To Coin Size) More Than Once Per
Week (Minor spotting or leakage of stool
(up to coin size) more than once per
week)
Normal Continence; Able To Control
Stool Movements At All Times (Normal
continence; able to control stool
movements at all times)
Not Applicable (Not applicable)
Significant Leakage Of Stool (larger
Than Coin Size) About Once Per Week
(Significant leakage of stool (larger than
coin size) about once per week)
Significant Leakage Of Stool (larger
Than Coin Size) More Than Once Per
Week (Significant leakage of stool (larger
than coin size) more than once per
week)
Unknown (Unknown)
Procedures
Proctoscopy or Sigmoidoscopy
Equivocal (Equivocal)
Negative (Negative)
Not Done (Not done)
Positive, Cancer (Positive, cancer)
Positive, Other Dysfunction (Positive,
other dysfunction)
Unknown (Unknown)
CT/MRI Scan of Pelvis and Abdomen, including
Liver
Equivocal (Equivocal)
Negative (Negative)
Not Done (Not done)
Positive, Cancer (Positive, cancer)
Positive, Other Dysfunction (Positive,
other dysfunction)
Unknown (Unknown)
Chest X-ray
Equivocal (Equivocal)
Negative (Negative)
Not Done (Not done)
Positive, Cancer (Positive, cancer)
Positive, Other Dysfunction (Positive,
other dysfunction)
Unknown (Unknown)
Inguinal Lymphangiogram
Equivocal (Equivocal)
Negative (Negative)
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(IEF) - 2516530v1.0
Not Done (Not done)
Positive, Cancer (Positive, cancer)
Positive, Other Dysfunction (Positive,
other dysfunction)
Unknown (Unknown)
Other procedures
Equivocal (Equivocal)
Negative (Negative)
Not Done (Not done)
Positive, Cancer (Positive, cancer)
Positive, Other Dysfunction (Positive,
other dysfunction)
Unknown (Unknown)
Other specify
Tnm Pre-treatment Clinical Classification
Clinical T Stage
T0 Anal Cancer (T0)
T1 Anal Cancer (T1)
T2 Anal Cancer (T2)
T3 Anal Cancer (T3)
T4 Anal Cancer (T4)
Tis Anal Cancer (Tis)
Tx Anal Cancer (TX)
Clinical N Stage
N0 Anal Cancer (N0)
N1 Anal Cancer (N1)
N2 Anal Cancer (N2)
N3 Anal Cancer (N3)
Nx Anal Cancer (NX)
Clinical M Stage
M0 Anal Cancer (M0)
M1 Anal Cancer (M1)
Mx Anal Cancer (MX)
Stage
Stage 0 Anal Canal Cancer (Stage 0)
Stage I Anal Canal Cancer (Stage I)
Stage Ii Anal Canal Cancer (Stage II)
Stage Iiia Anal Cancer (Stage IIIA)
Stage Iiib Anal Cancer (Stage IIIB)
Stage Iv Anal Canal Cancer (Stage IV)
Comments
Comments
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NCT00324415 Pre-Study - AMC-045 Anal Cancer Initial Evaluation Form
(IEF) - 2516530v1.0
Lymphoma NCT01193842 Lab - AMC-075 HIV T-
Cell Laboratory Values Form (F24) - 3206347v1.0
Lymphoma NCT01193842 Lab - AMC-075 HIV T-Cell
Laboratory Values Form (F24) - 3206347v1.0
All rights reserved. Please visit https://medical-data-
models.org/forms/2322
AMC-075 HIV T-Cell Laboratory
Values Form (F24)
Unnamed1
Visit number
Sequence number
Unnamed2
Date of Evaluation (mm/dd/yyyy)
T-cell Laboratory Values
T-Helper CD4+ %
T-Helper CD4+ absolute count
T-Suppressor CD8+ %
T-Suppressor CD8+ absolute count
Other, specify
Percent Positive Lymphocytes
Absolute Count
Comments
Comments
1 / 1
Multiple Myeloma and Plasma Cell Neoplasm NCT01055301 Registration -
Southwest Oncology Group S0833 Registration Worksheet - Step 4 - 3189876v1.0
Multiple Myeloma and Plasma Cell Neoplasm
NCT01055301 Registration - Southwest Oncology Group
S0833 Registration Worksheet - Step 4 - 3189876v1.0
All rights reserved. Please visit https://medical-data-
models.org/forms/2339
Southwest Oncology Group S0833
Registration Worksheet - Step 4
Unnamed1
Activation Date (MM DD YYYY)
Last Amended Date (MM DD YYYY)
Registration Step
Swog Patient Id
SWOG Patient ID
Unnamed2
Registrar's SWOG Roster ID Number
SWOG Investigator Number
SWOG Treating Institution Number
Unnamed5
Projected Start Date of Treatment (MM DD
YYYY)
Unnamed 7
Has the Southwest Oncology Group Registration
Worksheet been completed entirely and is the
patient eligible according to the current version of
protocol section 5.0?
No (No)
Yes (Yes)
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Lymphoma NCT00981097 Off Treatment - AMC-
064 Off-Study Summary Form (F50) - 2983033v1.0
Lymphoma NCT00981097 Off Treatment - AMC-064 Off-
Study Summary Form (F50) - 2983033v1.0
All rights reserved. Please visit https://medical-data-
models.org/forms/2340
AMC-064 Off-Study Summary Form
(F50)
Ccrr Module For Off Study Summary -
Rf50
Off Study Date (mm/dd/yyyy)
Off Study Reason (select the primary reason)
Adverse Event/side Effects/complications
(Adverse Event/Side
Effects/Complications)
Death (Death)
Other (Other)
Lost To Follow-up (Patient lost to follow-
up)
Patient Refused Follow-up (Patient
refused follow-up)
Protocol-defined Follow-up Completed
(Protocol-defined follow-up completed)
Other, specify
Comments
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Lymphoma NCT00598169 Lab - AMC-053 HIV T-
Cell Laboratory Values Form (F24) - 2933221v1.0
Lymphoma NCT00598169 Lab - AMC-053 HIV T-Cell
Laboratory Values Form (F24) - 2933221v1.0
All rights reserved. Please visit https://medical-data-
models.org/forms/2342
AMC-053 HIV T-Cell Laboratory
Values Form (F24)
Unnamed1
Visit number
Sequence number
Unnamed2
Date of Evaluation (mm/dd/yyyy)
Reporting Period (select one)
Baseline (Baseline)
On Treatment (On treatment)
Post-therapy (Post therapy)
T-cell Laboratory Values
T-Helper CD4+ %
T-Helper CD4+ absolute count
T-Suppressor CD8+ %
T-Suppressor CD8+ absolute count
B-Cell CD20+ %
B-Cell CD20+ absolute count
Other, specify
Percent Positive Lymphocytes
Absolute Count
Comments
Comments
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Lymphoma NCT01190449 Treatment - CALGB
50901 Non-Protocol Treatment Form - 3210177v1.0
Lymphoma NCT01190449 Treatment - CALGB 50901 Non-
Protocol Treatment Form - 3210177v1.0
All rights reserved. Please visit https://medical-data-
models.org/forms/2356
CALGB 50901 Non-Protocol
Treatment Form
Non-protocol Treatment
Name of non-protocol cancer therapy
Date of First Non-Protocol Therapy
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Lymphoma NCT01190449 Response - CALGB
50901 Response Assessment Form - 3210253v1.0
Lymphoma NCT01190449 Response - CALGB 50901
Response Assessment Form - 3210253v1.0
All rights reserved. Please visit https://medical-data-
models.org/forms/2361
CALGB 50901 Response
Assessment Form
Response Assessment
Objective Status at This Evaluation
Complete Response (complete
response)
Partial Response (partial response)
Progressive Disease (progressive
disease)
Stable Disease (stable disease)
Progressive Disease First Observed Date (PD)
Modified Ann Arbor Stage (at time of relapse
Mark one with an X.)
I (I)
Ie (IE)
Ii (II)
Iie (IIE)
Iii (III)
Iiie (IIIE)
Iiie+s (IIIE+S)
Iiis (IIIS)
Iv (IV)
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Multiple Myeloma and Plasma Cell Neoplasm NCT01055301 Registration -
Southwest Oncology Group S0833 Registration Worksheet - Step 2 - 3189803v1.0
Multiple Myeloma and Plasma Cell Neoplasm
NCT01055301 Registration - Southwest Oncology Group
S0833 Registration Worksheet - Step 2 - 3189803v1.0
All rights reserved. Please visit https://medical-data-
models.org/forms/2364
Southwest Oncology Group S0833
Registration Worksheet - Step 2
Unnamed1
Activation Date (MM DD YYYY)
Last Amended Date (MM DD YYYY)
Registration Step
Swog Patient Id
SWOG Patient ID
Unnamed2
Registrar's SWOG Roster ID Number
SWOG Investigator Number
SWOG Treating Institution Number
Unnamed5
Projected Start Date of Treatment (MM DD
YYYY)
Unnamed 7
Has the Southwest Oncology Group Registration
Worksheet been completed entirely and is the
patient eligible according to the current version of
protocol section 5.0?
No (No)
Yes (Yes)
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Lymphoma NCT01359592 Registration - S1001
Registration Worksheet Step 2 - 3243583v1.0
Lymphoma NCT01359592 Registration - S1001
Registration Worksheet Step 2 - 3243583v1.0
All rights reserved. Please visit https://medical-data-
models.org/forms/2367
S1001 Registration Worksheet Step
2
Unnamed1
Activation Date (MM DD YYYY)
Last Amended Date (MM DD YYYY)
Registration Step
Swog Patient Id
SWOG Patient ID
Unnamed2
Registrar's SWOG Roster ID Number
SWOG Investigator Number
SWOG Treating Institution Number
Unnamed5
Projected Start Date of Treatment (MM DD
YYYY)
Stratification Questions
Based on centralized review, is the patient PET-
positive after 3 cycles of R-CHOP?
Yes (1)
No (2)
Unnamed 7
Has the SWOG Registration Worksheet been
completed entirely and is the patient eligible
according to the current version of protocol
section 5.0?
No (No)
Yes (Yes)
Auxiliary Questions
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RT Start Date
RT Facility Name
RT Physician
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Lymphoma NCT01359592 Registration - S1001 Registration Worksheet
Step 2 - 3243583v1.0
Lymphoma NCT00598169 Quality of Life - AMC-053
FACT/GOG-Neurotoxicity Questionnaire - 2798056v1.0
Lymphoma NCT00598169 Quality of Life - AMC-053
FACT/GOG-Neurotoxicity Questionnaire - 2798056v1.0
All rights reserved. Please visit https://medical-data-
models.org/forms/2369
AMC-053 FACT/GOG-Neurotoxicity
Questionnaire
Unnamed2
I have numbness or tingling in my hands
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have numbness or tingling in my feet
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I feel discomfort in my hands
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I feel discomfort in my feet
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have joint pain or muscle cramps
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I feel weak all over
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have trouble hearing
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I get a ringing or buzzing in my ears
A Little Bit (A little bit)
Not At All (Not at all)
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Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have trouble buttoning buttons
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have trouble feeling the shape of small objects
when they are in my hand
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have trouble walking
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
Comments
Comments
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Lymphoma NCT00598169 Quality of Life - AMC-053 FACT/GOG-
Neurotoxicity Questionnaire - 2798056v1.0
Lymphoma NCT00598169 Off Treatment - AMC-
053 Off-Study Summary Form (F50) - 3122128v1.0
Lymphoma NCT00598169 Off Treatment - AMC-053 Off-
Study Summary Form (F50) - 3122128v1.0
All rights reserved. Please visit https://medical-data-
models.org/forms/2373
AMC-053 Off-Study Summary Form
(F50)
Ccrr Module For Off Study Summary -
Rf50
Off Study Date (mm/dd/yyyy)
Off Study Reason (select the primary reason)
Adverse Event/side Effects/complications
(Adverse Event/Side
Effects/Complications)
Death (Death)
Other (Other)
Lost To Follow-up (Patient lost to follow-
up)
Patient Refused Follow-up (Patient
refused follow-up)
Protocol-defined Follow-up Completed
(Protocol-defined follow-up completed)
Other, specify
Comments
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Lymphoma NCT00598169 On-Study - AMC-
053 Missed Visit Form (F35) - 3122223v1.0
Lymphoma NCT00598169 On-Study - AMC-053 Missed
Visit Form (F35) - 3122223v1.0
All rights reserved. Please visit https://medical-data-
models.org/forms/2385
AMC-053 Missed Visit Form (F35)
Unnamed1
Visit number
Unnamed2
Missed Visit Date (mm/dd/yyyy)
Reason patient missed visit
Health Reasons (Health reasons)
Other (Other)
Patient Could Not Get Off Work (Patient
could not get off work)
Patient Decided To Discontinue Study
(Patient decided to discontinue study)
Patient Experienced An Adverse Event
(Patient experienced an Adverse Event)
Patient Forgot (Patient forgot)
Patient Had Transportation Problems
(Patient had transportation problems)
Patient Unable To Obtain Dependent
Care (Patient unable to obtain dependent
care)
Patient Unhappy With Frequency Of
Visits (Patient unhappy with frequency of
visits)
Scheduling Difficulties (Scheduling
difficulties)
Other, specify
Next visit scheduled (Items missed will be made
up at the new visit.)
No (No)
Yes (Yes)
Comments
Comments
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Lymphoma NCT01190449 Response - CALGB 50901
Non-Target Lesion Measurement Form - 3209030v1.0
Lymphoma NCT01190449 Response - CALGB 50901 Non-
Target Lesion Measurement Form - 3209030v1.0
All rights reserved. Please visit https://medical-data-
models.org/forms/2388
CALGB 50901 Non-Target Lesion
Measurement Form
Unnamed3
Assessment Date (Assessment date is the date
reflecting type of assessment, not the physician
interpretation date.)
Lesion Number
Site of Lesion
Method of Evaluation
Ct Scan (CT Scan)
Mri Scan (MRI scan)
Physical Exam (Physical exam)
Lesion status
Absent/resolved (Absent/resolved)
Decrease/improve (Decrease/improve)
Increase/worsen (Increase/worsen)
Indeterminate (Indeterminate)
No Change/stable (No change/stable)
Not Done/not Applicable (Not done/not
applicable)
Present (Present)
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Lymphoma NCT01190449 Treatment - CALGB
50901 Prior Therapy Form - 3210308v1.0
Lymphoma NCT01190449 Treatment - CALGB 50901 Prior
Therapy Form - 3210308v1.0
All rights reserved. Please visit https://medical-data-
models.org/forms/2401
CALGB 50901 Prior Therapy Form
Prior Therapy
Prior therapy type (Mark all that apply with an X.)
Agents Administered To Control The
Replication And/or Spread Of Viruses
(Anti-retroviral therapy)
Treatment With An Agent That Prevents
Or Impairs The Translation Of The
Genetic Message For Production Of A
Specific Protein (Antisense)
High Dose Chemotherapy Combined
With Transplantation Of Bone Marrow
Cells (Bone marrow transplant)
Non-systemic Chemotherapy Treatment
Or Chemotherapy Not Described By
Chemotherapy Single Agent Systemic Or
Multi-agent Systemic (Chemotherapy
(NOS))
Systemic Chemotherapy With A
Regimen Containing Multiple Agents
(Chemotherapy multiple agents
systemic)
Prior Therapy With Agents That Are Not
Known To Cause Damage To Cycling
Cells (Chemotherapy non-cytotoxic)
Systemic Chemotherapy With A Single
Agent Regimen (Chemotherapy single
agent systemic)
Drug And/or Immunotherapy (Drug
and/or Immunotherapy)
Treatment Of Human Disease By Gene
Transfer (Gene transfer)
Hematopoietic Stem Cell Transplantation
(Hematopoietic Stem Cell
Transplantation)
Cancer Therapy Which Incorporates
Hormonal Manipulation (Hormonal
therapy)
Image Directed Local Therapy (Image
Directed Local Therapy)
No Previous Exposure To Drug (nos) (No
prior therapy)
Anticancer Treatment With A Live,
Replication-competent Virus (Oncolytic
virotherapy)
Prior Therapy (nos) (Prior therapy NOS)
Targeted Ionizing Radiation Therapy
Utilizing Radioactive Implants Or Seeds
(Radiation therapy)
Surgical Procedure, Or Operation, With
Therapeutic Intent (Surgery)
Therapy Nos (Therapy (NOS))
Substance Or Group Of Substances
Administered To Induce The Immune
System To Recognize And Destroy
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Tumors Or Microorganisms (Vaccine)
Number of prior chemotherapy regimens
MedDRA Disease Code (CODE NAME verbiage)
Assigned Treatment Arm
Ofatumumab 1000 Mg (Ofatumumab
1000 mg)
Ofatumumab 500 Mg (Ofatumumab 500
mg)
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Lymphoma NCT01190449 Treatment - CALGB 50901 Prior Therapy
Form - 3210308v1.0
Lymphoma NCT00598169 Pathology - AMC-053 AIDS and Cancer
Specimen Resource (ACSR) Procurement Form (F37) - 2932957v1.0
Lymphoma NCT00598169 Pathology - AMC-053 AIDS and
Cancer Specimen Resource (ACSR) Procurement Form
(F37) - 2932957v1.0
All rights reserved. Please visit https://medical-data-
models.org/forms/2420
AMC-053 AIDS and Cancer
Specimen Resource (ACSR)
Procurement Form (F37)
Unnamed1
Visit number
Unnamed2
Date Specimen Obtained (mm/dd/yyyy)
Date Specimen Obtained (mm/dd/yyyy)
Specimen(s) obtained for donation to ACSR
No (No)
Yes (Yes)
Specimen Type (check all that apply)
Peripheral Blood (Blood)
Other (Other)
Pbmc (peripheral Blood Mononuclear
Cells) (PBMC)
Plasma (Plasma)
Serum (Serum)
Tissue (Tissue)
Other specify
ACSR site the specimen(s) shipped to
Gwu (GWU)
Jhu (JHU)
Osu (OSU)
Other (Other)
Suny/hscb (SUNY/HSCB)
Ucla (UCLA)
Ucsf (UCSF)
Other, specify
If specimens were not obtained for ACSR, please
indicate reason
Other (Other)
Patient Had Previously Donated
Specimen To Acsr (Patient had
previously donated specimen to ACSR)
Patient Refused To Give Informed
Consent For Acsr Specimen Donation
(Patient refused to give informed consent
for ACSR specimen donation)
Patient Was Not Asked To Consider Acsr
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Specimen Donation (Patient was not
asked to consider ACSR specimen
donation)
Other, specify
Study Coordinator
Study Coordinator's name
E-mail
Phone Number (xxx-xxx-xxxx)
Comments
Comments
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Lymphoma NCT00598169 Pathology - AMC-053 AIDS and Cancer
Specimen Resource (ACSR) Procurement Form (F37) - 2932957v1.0
NCT00598169 On-Study - AMC-053 Lymphoma
Disease Activity and Measurement (L01) - 2823721v1.0
NCT00598169 On-Study - AMC-053 Lymphoma Disease
Activity and Measurement (L01) - 2823721v1.0
All rights reserved. Please visit https://medical-data-
models.org/forms/2421
AMC-053 Lymphoma Disease
Activity and Measurement (L01)
Unnamed1
Visit Number
Unnamed2
Reporting Period
Baseline (Baseline)
Follow-up (Follow-up)
On Treatment (On treatment)
Date of Evaluation (mm/dd/yyyy)
Is there bone marrow involvement
No (No)
Yes (Yes)
Is there CNS involvement
No (NO)
Yes (YES)
Method of Evaluation (If yes indicate all that
apply)
Biopsy (Biopsy)
Diagnostic Imaging (Diagnostic Imaging)
Flow Cytometry, Cerebrospinal Fluid
(Flow cytometry, cerebrospinal fluid)
Fluid Cytology, Cerebrospinal Fluid (Fluid
cytology, cerebrospinal fluid)
Nodal Involvement Evaluation
Is there lymph node involvement (If Yes, continue.
Otherwise, stop)
No (NO)
Yes (YES)
Lymph Node Type
Celiac Axis/retrocrural/upper Para-aortic
(Celiac Axis/Retrocrular/Upper Para-
Aortic)
Cervical (Cervical)
Epitrochlear/brachial
(Epitrochlear/Brachial)
Hilar (Hilar)
Infraclavicular/axillary/pectoral
(Infraclavicular/Axiliary/Pectoral)
Inguinal/femoral/iliac
(inguinal/femoral/iliac)
Lower Para-aortic (Lower Para-Aortic)
Mediastinal (Mediastinal)
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Mesenteric (Mesenteric)
Other Nodal (Other Nodal)
Porta Hepatis (Porta Hepatis)
Pre-auricular (Pre-Auricular)
Spleen (Spleen)
Splenic Hilar (Splenic Hilar)
Supraclavicular (Supraclavicular)
Waldeyer's Ring (Waldeyer's Ring)
Other specify
Dimension 1 (cm)
Dimension 2 (cm)
Method of Evaluation (If yes indicate all that
apply)
Biopsy (Biopsy)
Diagnostic Imaging (Diagnostic Imaging)
Flow Cytometry, Cerebrospinal Fluid
(Flow cytometry, cerebrospinal fluid)
Fluid Cytology, Cerebrospinal Fluid (Fluid
cytology, cerebrospinal fluid)
Other, specify
PET scan (status for this visit)
Negative (Negative)
Positive Finding (Positive)
Extra Nodal Involvement Evaluation
Lesion completely resolved (For "On treatment"
and "Follow up" cycles only)
No (NO)
Yes (YES)
Is measurable disease present? (For "On
treatment" and "Follow up" cycles only)
No (No)
Yes (Yes)
Has the patient been diagnosed with a new
progression? (For "On treatment" and "Follow up"
cycles only)
No (No)
Yes (Yes)
Evaluation documented (For "On treatment" and
"Follow up" cycles only)
No (No)
Yes (Yes)
Lesion Assessment (For "On treatment" and
"Follow up" cycles only)
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Measurement (L01) - 2823721v1.0
Improvement (improvement)
No Change (no change)
Not Evaluated (Not evaluated)
Progression - Increase (progression -
increase)
Comments
Comments
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NCT00598169 On-Study - AMC-053 Lymphoma Disease Activity and
Measurement (L01) - 2823721v1.0
Multiple Myeloma and Plasma Cell Neoplasm NCT01055301 Registration -
Southwest Oncology Group S0833 Registration Worksheet - Step 3 - 3189854v1.0
Multiple Myeloma and Plasma Cell Neoplasm
NCT01055301 Registration - Southwest Oncology Group
S0833 Registration Worksheet - Step 3 - 3189854v1.0
All rights reserved. Please visit https://medical-data-
models.org/forms/2439
Southwest Oncology Group S0833
Registration Worksheet - Step 3
Unnamed1
Activation Date (MM DD YYYY)
Last Amended Date (MM DD YYYY)
Registration Step
Swog Patient Id
SWOG Patient ID
Unnamed2
Registrar's SWOG Roster ID Number
SWOG Investigator Number
SWOG Treating Institution Number
Unnamed5
Projected Start Date of Treatment (MM DD
YYYY)
Unnamed 7
Has the Southwest Oncology Group Registration
Worksheet been completed entirely and is the
patient eligible according to the current version of
protocol section 5.0?
No (No)
Yes (Yes)
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Lymphoma NCT01190449 On-Study - CALGB 50901 Bone
Marrow, Liver, & Spleen Evaluation Form - 3211724v1.0
Lymphoma NCT01190449 On-Study - CALGB 50901 Bone
Marrow, Liver, & Spleen Evaluation Form - 3211724v1.0
All rights reserved. Please visit https://medical-data-
models.org/forms/2445
CALGB 50901 Bone Marrow, Liver, &
Spleen Evaluation Form
Unnamed3
Assessment Date (Assessment date is the date
reflecting type of assessment, not the physician
interpretation date.)
Lesion Number
Site of Lesion (Bone Marrow)
Method of Evaluation
Aspirate, Bone Marrow (Bone Marrow
Aspirate)
Bone Marrow Biopsy (Bone Marrow
Biopsy)
Not Evaluated (Not evaluated)
Results
Indeterminate (Indeterminate)
Negative (Negative)
Positive (Positive)
Marrow Malignant Cells (% percent involved by
lymphoma)
Unnamed3
Assessment Date (Assessment date is the date
reflecting type of assessment, not the physician
interpretation date.)
Lesion Number
Site of Lesion (Bone Marrow)
Method of Evaluation
Aspirate, Bone Marrow (Bone Marrow
Aspirate)
Bone Marrow Biopsy (Bone Marrow
Biopsy)
Not Evaluated (Not evaluated)
Results
Indeterminate (Indeterminate)
Negative (Negative)
Positive (Positive)
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Lesion status
Absent/resolved (Absent/resolved)
Decrease/improve (Decrease/improve)
Increase/worsen (Increase/worsen)
Indeterminate (Indeterminate)
No Change/stable (No change/stable)
Not Done/not Applicable (Not done/not
applicable)
Present (Present)
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Lymphoma NCT01190449 On-Study - CALGB 50901 Bone Marrow,
Liver, & Spleen Evaluation Form - 3211724v1.0
Multiple Myeloma and Plasma Cell Neoplasm NCT00644228 Registration -
Southwest Oncology Group S0777 Registration Worksheet (Step 2) - Not for OPEN
- 2697459v1.0
Multiple Myeloma and Plasma Cell Neoplasm
NCT00644228 Registration - Southwest Oncology Group
S0777 Registration Worksheet (Step 2) - Not for OPEN -
2697459v1.0
All rights reserved. Please visit https://medical-data-
models.org/forms/2447
Southwest Oncology Group S0777
Registration Worksheet (Step 2) -
Not for OPEN
Unnamed1
Activation Date
Last Amended Date
Registration Step
Unnamed2
Registrar's SWOG Roster ID Number
SWOG Investigator Number
SWOG Treating Institution Number
Unnamed2
Registering Group Name
Investigator Name
Institution Name
NCI Institution Number
Participating Group Patient ID
Unnamed Module 3
SWOG Patient ID Status
New Patient (New patient)
Previous Patient (Previous patient)
SWOG Patient ID
Projected Start Date of Treatment
Method of Payment
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Medicaid (Medicaid)
Medicaid And Medicare (Medicaid and
Medicare)
Medicare (Medicare)
Medicare And Private Insurance
(Medicare and Private Insurance)
Military Or Veterans Sponsored Nos
(Military or Veterans Sponsored, Not
Otherwise Specified (NOS))
No Means Of Payment (no Insurance)
(No means of payment (no insurance))
Other (Other)
Private Insurance (Private Insurance)
Self Pay (no Insurance) (Self Pay (No
Insurance))
Unknown (Unknown)
Veterans Sponsored (Veterans
Sponsored)
Other, specify
Unnamed 7
Has the Southwest Oncology Group Registration
Worksheet been completed entirely and is the
patient eligible according to the current version of
protocol section 5.0
No (No)
Yes (Yes)
Comments
Assigned Treatment Arm
Treatment name
Other Notes
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Southwest Oncology Group S0777 Registration Worksheet (Step 2) - Not for OPEN
- 2697459v1.0
Lymphoma NCT01193842 On-Study - AMC-075
Pregnancy Outcome Form (PRO) - 3228008v1.0
Lymphoma NCT01193842 On-Study - AMC-075 Pregnancy
Outcome Form (PRO) - 3228008v1.0
All rights reserved. Please visit https://medical-data-
models.org/forms/2451
AMC-075 Pregnancy Outcome Form
(PRO)
Unnamed1
Sequence number
Pregnancy Status
Pregnancy Status
Elective Abortion (Elective abortion)
Live Birth (Live birth)
Pregnancy Ongoing (Pregnancy
ongoing)
Spontaneous Abortion/miscarriage
(Spontaneous abortion/miscarriage)
Still Birth (Still birth)
Unknown (Unknown)
Pregnancy Outcome - Live Birth Only
Delivery Date
Gestational age, Weeks
Gestational age, Days
Birth weight, pounds
Birth weight, ounces
Birth length, Inches
One minute Apgar Score
Five minute Apgar Score
Unknown
Were there any clinical problems with the infant
No (No)
Unknown (Unknown)
Yes (Yes)
Specify (If yes)
Were there any problems with delivery
No (No)
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Unknown (Unknown)
Yes (Yes)
Specify (If yes)
Is there a congenital anomaly (If Yes, report as
an SAE.)
No (No)
Unknown (Unknown)
Yes (Yes)
Specify (If yes)
Was neonatal testing performed
No (No)
Unknown (Unknown)
Yes (Yes)
Were there any abnormal test results (If yes)
No (No)
Unknown (Unknown)
Yes (Yes)
Specify (If yes including dates)
Pregnancy Outcome - Spontaneous
Abortion, Still Birth, Or Elective Abortion
Only
Date (mm/dd/yyyy)
Gestational age, Weeks
Gestational age, Days
If spontaneous abortion or still birth, specify
circumstances
Was any congenital anomaly evident in the fetus
(If Yes, report as an SAE.)
No (No)
Unknown (Unknown)
Yes (Yes)
Specify (If yes)
Comments
Comments
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Lymphoma NCT01193842 On-Study - AMC-075 Pregnancy Outcome
Form (PRO) - 3228008v1.0
Lymphoma NCT00389818 Lab - AMC-047 HIV T-
Cell Laboratory Values Form (F24) - 2541038v1.0
Lymphoma NCT00389818 Lab - AMC-047 HIV T-Cell
Laboratory Values Form (F24) - 2541038v1.0
All rights reserved. Please visit https://medical-data-
models.org/forms/2454
AMC-047 HIV T-Cell Laboratory
Values Form (F24)
Unnamed1
Visit number
Sequence number
Unnamed2
Date of Evaluation (mm/dd/yyyy)
T-cell Laboratory Values
T-Helper CD4+ %
T-Helper CD4+ absolute count
T-Suppressor CD8+ %
T-Suppressor CD8+ absolute count
Other, specify
Percent Positive Lymphocytes
Absolute Count
Comments
Comments
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NCT00598169 On-Study - AMC-053 Lymphoma Disease
Activity and Measurement Form (L02) - 3127875v1.0
NCT00598169 On-Study - AMC-053 Lymphoma Disease
Activity and Measurement Form (L02) - 3127875v1.0
All rights reserved. Please visit https://medical-data-
models.org/forms/2471
AMC-053 Lymphoma Disease
Activity and Measurement Form
(L02)
Unnamed1
Visit Number
Extra Nodal Involvement Evaluation
Extranodal extension
No (NO)
Yes (YES)
Site of Involvement
Ascites (Ascites)
Bone (Bone)
Bone Marrow (Bone Marrow)
Brain (Brain)
Epidural (Epidural)
Gastrointestinal Tract (GI Tract)
Kidney (Kidney)
Liver (Liver)
Lung (Lung)
Meninges (Meninges)
Other Specify (Other)
Pleura (Pleura)
Skin (Skin)
Thyroid (Thyroid)
Other, specify
Dimension 1 (cm)
Dimension 2 (cm)
Method of Evaluation
Biopsy (Biopsy)
Aspirate, Bone Marrow (Bone Marrow
Aspirate)
Bone Marrow Biopsy (Bone Marrow
Biopsy)
Bone Scan (Bone Scan)
Ct Scan (CT scan)
Gallium Scan (Gallium scan)
IVP (IVP)
Lymphangiogram (Lymphangiogram)
Mri Scan (MRI scan)
Other (Other)
Palpation (Palpation)
Peripheral Blood Counts (Peripheral
Blood Counts)
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Pet Scan (PET scan)
Pet/ct Scan (PET/CT scan)
Ultrasound (Ultrasound)
X-ray (X-Ray)
Other, specify
PET scan
Negative (Negative)
Positive Finding (Positive)
Lesion completely resolved (For "On treatment"
and "Follow up" cycles only)
No (NO)
Yes (YES)
Is measurable disease present? (For "On
treatment" and "Follow up" cycles only)
No (No)
Yes (Yes)
Has the patient been diagnosed with a new
progression? (For "On treatment" and "Follow up"
cycles only)
No (No)
Yes (Yes)
Evaluation documented (For "On treatment" and
"Follow up" cycles only)
No (No)
Yes (Yes)
Lesion Assessment (For "On treatment" and
"Follow up" cycles only)
Improvement (improvement)
No Change (no change)
Not Evaluated (Not evaluated)
Progression - Increase (progression -
increase)
Comments
Comments
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NCT00598169 On-Study - AMC-053 Lymphoma Disease Activity and
Measurement Form (L02) - 3127875v1.0
Lymphoma NCT01190449 Treatment - CALGB 50901
Protocol Treatment Yes/No Form - 3208940v1.0
Lymphoma NCT01190449 Treatment - CALGB 50901
Protocol Treatment Yes/No Form - 3208940v1.0
All rights reserved. Please visit https://medical-data-
models.org/forms/2480
CALGB 50901 Protocol Treatment
Yes/No Form
Protocol Treatment
Did the patient receive any protocol treatment
No (No)
Yes (Yes)
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Lymphoma NCT00598169 On-Study - AMC-053 Physical
Exam Tumor Assessment Form (PE2) - 2958931v1.0
Lymphoma NCT00598169 On-Study - AMC-053 Physical
Exam Tumor Assessment Form (PE2) - 2958931v1.0
All rights reserved. Please visit https://medical-data-
models.org/forms/2486
AMC-053 Physical Exam Tumor
Assessment Form (PE2)
Unnamed1
Visit number
Physical Exam
Date of Evaluation (mm/dd/yyyy)
Does the patient have measurable disease
No (No)
Yes (Yes)
Nodal Information
Lymph Node Type
Cervical (cervical)
Epitrochlear/brachial
(epitrochlear/brachial)
Infraclavicular/axillary/pectoral
(infraclavicular/axillary/pectoral)
Inguinal/femoral/iliac
(inguinal/femoral/iliac)
Other Nodal (Other Nodal)
Pre-auricular (pre-auricular)
Spleen (Spleen)
Supraclavicular (supraclavicular)
Waldeyer's Ring (waldeyer's ring)
Other specify
Dimension 1 (cm)
Dimension 2 (cm)
Comments
Comments
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Lymphoma NCT00981097 Pathology - AMC-064 AIDS and Cancer
Specimen Resource (ACSR) Procurement Form (F37) - 2982989v1.0
Lymphoma NCT00981097 Pathology - AMC-064 AIDS and
Cancer Specimen Resource (ACSR) Procurement Form
(F37) - 2982989v1.0
All rights reserved. Please visit https://medical-data-
models.org/forms/2502
AMC-064 AIDS and Cancer
Specimen Resource (ACSR)
Procurement Form (F37)
Unnamed1
Visit number
Unnamed2
Specimen(s) obtained for donation to ACSR
No (No)
Yes (Yes)
Specimen Type (check all that apply)
Peripheral Blood (Blood)
Other (Other)
Pbmc (peripheral Blood Mononuclear
Cells) (PBMC)
Plasma (Plasma)
Serum (Serum)
Tissue (Tissue)
Other specify
ACSR site the specimen(s) shipped to
Gwu (GWU)
Jhu (JHU)
Osu (OSU)
Other (Other)
Suny/hscb (SUNY/HSCB)
Ucla (UCLA)
Ucsf (UCSF)
Other, specify
If specimens were not obtained for ACSR, please
indicate reason
Other (Other)
Patient Had Previously Donated
Specimen To Acsr (Patient had
previously donated specimen to ACSR)
Patient Refused To Give Informed
Consent For Acsr Specimen Donation
(Patient refused to give informed consent
for ACSR specimen donation)
Patient Was Not Asked To Consider Acsr
Specimen Donation (Patient was not
asked to consider ACSR specimen
donation)
Other, specify
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Date Specimen Obtained (mm/dd/yyyy)
Date Specimen Obtained (mm/dd/yyyy)
Study Coordinator
Study Coordinator's name
E-mail
Phone Number (xxx-xxx-xxxx)
Comments
Comments
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Lymphoma NCT00981097 Pathology - AMC-064 AIDS and Cancer
Specimen Resource (ACSR) Procurement Form (F37) - 2982989v1.0
Lymphoma NCT01190449 Off Treatment -
CALGB 50901 Off-Treatment Form - 3210189v1.0
Lymphoma NCT01190449 Off Treatment - CALGB 50901
Off-Treatment Form - 3210189v1.0
All rights reserved. Please visit https://medical-data-
models.org/forms/2542
CALGB 50901 Off-Treatment Form
Treatment Schedule (oral Antiandrogen)
Date of Last Dose of Protocol Systemic Therapy
Reason Treatment Ended
Adverse Event/side Effects/complications
(Adverse Event/Side
Effects/Complications)
Alternative Therapy (Alternative therapy)
Death On Study (Death on study)
Disease Progression Before Active
Treatment (Disease Progression before
active treatment)
Disease Progression, Relapse During
Active Treatment (Disease progression,
relapse during active treatment)
Other (Other)
Patient Off-treatment For Other
Complicating Disease (Patient off-
treatment for other complicating disease)
Patient Withdrawal Or Refusal After
Beginning Protocol Therapy (Patient
withdrawal/refusal after beginning
protocol therapy)
Patient Withdrawal Or Refusal Before
Beginning Protocol Therapy (Patient
withdrawal/refusal prior to beginning
protocol therapy)
Treatment Completed Per Protocol
Criteria (Treatment completed per
protocol criteria)
Adverse event/side effects/complications specify
Patient off-treatment for other complicating
disease, specify
Other specify
Reason Treatment Ended
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NCT00392834 Response - AMC-048 Lymphoma
Response Form (LYR) - 2656662v1.0
NCT00392834 Response - AMC-048 Lymphoma Response
Form (LYR) - 2656662v1.0
All rights reserved. Please visit https://medical-data-
models.org/forms/2552
AMC-048 Lymphoma Response
Form (LYR)
Extra Nodal Involvement Evaluation
Date of Last Clinical Assessment (mm/dd/yyyy)
Extra Nodal Involvement Evaluation
Is complete response first observed (CR)
No (No)
Yes (Yes)
Complete Response (CR) First Observed Date (If
yes)
Is complete response confirmed (CR)
No (No)
Yes (Yes)
Complete Response Confirmed Date
(mm/dd/yyyy)
Extra Nodal Involvement Evaluation
Is complete response uncertain first observed
No (No)
Yes (Yes)
Complete Response uncertain (CRu) First
Observed Date
Is complete response, uncertain, confirmed
(CRU)
No (No)
Yes (Yes)
Complete Response Uncertain (CRu) Confirmed
Date
Extra Nodal Involvement Evaluation
Is partial response first observed (PR)
No (No)
Yes (Yes)
Partial Response (PR) First Observed Date
(mm/dd/yyyy)
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Is partial response confirmed (PR)
No (No)
Yes (Yes)
Partial Response Confirmed Date (mm/dd/yyyy)
Extra Nodal Involvement Evaluation
Has the patient been diagnosed with a new
progression? (If Yes, continue. Otherwise, stop)
No (No)
Yes (Yes)
Progressive Disease First Observed Date (PD
mm/dd/yyyy)
Please indicate the site of progression
New Site Only (New site only)
New Site Plus Original Site (New site
plus original site)
Original Site Only (Original site only)
Central Nervous System Progression (If Yes,
continue. Otherwise, stop)
No (No)
Yes (Yes)
CNS - leptomeninges
No (No)
Yes (Yes)
Brain - parenchymal
No (No)
Yes (Yes)
Comments
Comments
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NCT00392834 Response - AMC-048 Lymphoma Response Form (LYR) -
2656662v1.0
Lymphoma NCT01190449 Response - CALGB 50901
Target Lesion Measurement Form - 3208957v1.0
Lymphoma NCT01190449 Response - CALGB 50901
Target Lesion Measurement Form - 3208957v1.0
All rights reserved. Please visit https://medical-data-
models.org/forms/2555
CALGB 50901 Target Lesion
Measurement Form
Unnamed3
Assessment Date (Assessment date is the date
reflecting type of assessment, not the physician
interpretation date.)
Lesion Number
Site of Lesion
Method of Evaluation
Ct Scan (CT Scan)
Mri Scan (MRI scan)
Physical Exam (Physical exam)
Greatest Perpendicular Measurements (cm x cm)
Greatest Perpendicular Measurements (cm x cm)
Product of Measurements (cm^2)
Sum of Products of Greatest Diameters (SPD)
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Lymphoma NCT00598169 Lab - AMC-053 Quantitative
Immunoglobulins Form (QIM) - 3122717v1.0
Lymphoma NCT00598169 Lab - AMC-053 Quantitative
Immunoglobulins Form (QIM) - 3122717v1.0
All rights reserved. Please visit https://medical-data-
models.org/forms/2568
AMC-053 Quantitative
Immunoglobulins Form (QIM)
Unnamed 1
Visit number
Sequence number
Quantitative Immunoglobulins
IgG (mg/dL)
IgM (mg/dL)
IgA (mg/dL)
Comments
Comments
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NCT00598169 Response - AMC-053 Lymphoma
Response Form (LYR) - 3122916v1.0
NCT00598169 Response - AMC-053 Lymphoma Response
Form (LYR) - 3122916v1.0
All rights reserved. Please visit https://medical-data-
models.org/forms/2577
AMC-053 Lymphoma Response
Form (LYR)
Extra Nodal Involvement Evaluation
Date of Last Clinical Assessment (mm/dd/yyyy)
Extra Nodal Involvement Evaluation
Complete response first observed
No (No)
Yes (Yes)
Complete Response (CR) First Observed Date
(mm/dd/yyyy)
Complete response confirmed (CR)
No (No)
Yes (Yes)
Complete Response Confirmed Date
(mm/dd/yyyy)
Extra Nodal Involvement Evaluation
Complete Response, Unconfirmed (CRu) First
Observed
No (No)
Yes (Yes)
Complete Response, Unconfirmed (CRu) First
Observed Date (mm/dd/yyyy)
Complete Response, Unconfirmed (CRu)
Confirmed
No (No)
Yes (Yes)
Complete Response, Unconfirmed (CRu)
Confirmed Date (mm/dd/yyyy)
Extra Nodal Involvement Evaluation
Partial response first observed
No (No)
Yes (Yes)
Partial Response (PR) First Observed Date
(mm/dd/yyyy)
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Partial response confirmed
No (No)
Yes (Yes)
Partial Response Confirmed Date (mm/dd/yyyy)
Extra Nodal Involvement Evaluation
Has the patient been diagnosed with a new
progression? (If Yes, continue. Otherwise, stop)
No (No)
Yes (Yes)
Progressive Disease First Observed Date
(mm/dd/yyyy)
Please indicate the site of progression
New Site Only (New site only)
New Site Plus Original Site (New site
plus original site)
Original Site Only (Original site only)
Central Nervous System Progression
No (No)
Yes (Yes)
CNS - leptomeninges
No (No)
Yes (Yes)
Brain - parenchymal
No (No)
Yes (Yes)
Comments
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NCT00598169 Response - AMC-053 Lymphoma Response Form (LYR) -
3122916v1.0
Lymphoma NCT01190449 Off Treatment - CALGB
50901 Withdrawn Consent Form - 3210273v1.0
Lymphoma NCT01190449 Off Treatment - CALGB 50901
Withdrawn Consent Form - 3210273v1.0
All rights reserved. Please visit https://medical-data-
models.org/forms/2584
CALGB 50901 Withdrawn Consent
Form
Withdrawn Consent
Patient has withdrawn consent for clinical follow-
up
No (No)
Yes (Yes)
Patient has withdrawn consent for survival follow-
up
No (No)
Yes (Yes)
Withdrawn consent date
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Melanoma (Skin) null Registration -
Registration Worksheet (RW) - 2073173v3.0
Melanoma (Skin) null Registration - Registration Worksheet
(RW) - 2073173v3.0
All rights reserved. Please visit https://medical-data-
models.org/forms/2613
Registration Worksheet (RW)
Patient Information
Birthdate: (Year Month Day)
Sex:
Female (Female)
Male (Male)
Race: (Mark all that apply)
Native_american_cdus (American Indian
or Alaska native)
Asian_cdus (Asian)
Black_cdus (Black)
Pacific_islander_cdus (Native Hawaiian
or other Pacific Islander)
Unknown (Unknown)
White_cdus (White)
Visit Date: (Year Month Day)
Ethnicity: (Mark all that apply)
Hispanic_or_latino (Hispanic or Latino)
Non_hispanic (Non-Hispanic)
Unknown (Unknown)
Completed by:
Weight: (kg)
Date: (Year Month Day)
Height: (cm)
Social Security Number
USA Zip Code:
USA Zip Code:
USA Zip Code:
Method of Payment (Mark all that apply:)
Medicaid (Medicaid)
Medicaid And Medicare (Medicaid and
Medicare)
Medicare (Medicare)
Medicare And Private Insurance
(Medicare and Private Insurance)
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Military Or Veterans Sponsored Nos
(Military or Veterans Sponsored NOS)
Military Sponsored (including Champus
& Tricare) (Military Sponsored)
No Means Of Payment (no Insurance)
(No means of payment)
Private Insurance (Private Insurance)
Other (Provincial Insurance Plan)
Self Pay (no Insurance) (Self pay)
Veterans Sponsored (Veterans
Sponsored)
Other, (specify:)
Medical Record Number:
Country:
Study Informed Consent signed: (Year Month
Day)
No (No)
Yes (Yes)
Inclusion Criteria:
Patient must be >18 years of age at study
registration.
N (N)
Y (Y)
Patient must have primary invasive cutaneous
melanoma of Breslow thickness 2 mm or greater,
as determined by diagnostic biopsy (excisional,
punch, or shave), within 90 days prior to
registration. (Patient must have the following
prestudy staging evaluations completed within 60
days prior to registration:)
N (N)
Y (Y)
History and physical examination. Patient with
signs, symptoms, or physical exam findings
suspicious for metastatic disease must undergo
further evaluation in order to maintain eligibility
(see Recommendations for Evaluation of
Potential Metastatic Diseas
N (N)
Y (Y)
P/A and lateral chest X-ray (CXR). Patient with
abnormal CXR findings suspicious for metastatic
disease must have a negative or equivocal chest
CT or FDG-PET in order to maintain eligibility.
N (N)
Y (Y)
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2073173v3.0
Serum lactate dehydrogenase (LDH) level.
Patient with an elevated serum LDH, defined as a
serum level greater than the upper limit of
institutional normal, must have a negative or
equivocal CT scan, MRI, ultrasound, or FDG-PET
of the abdomen in order to m
N (N)
Y (Y)
Patient or the patient?s legally acceptable
representative must provide a signed and dated
written informed consent prior to registration and
any study-related procedures.
N (N)
Y (Y)
A survivor of prior cancer is eligible provided that
ALL of the following criteria are met and
documented: (The patient has undergone
potentially curative therapy for all prior
malignancies,)
Exclusion Criteria:
Patient has primary melanoma of mucosal or
ocular origin, or located on a finger distal to the
metacarpophalangeal joint, on a toe distal to the
metatarsophalangeal joint, on the tip of the nose,
on the eyelids or on the ear.
N (N)
Y (Y)
Patient has a history of a non-index primary
melanoma of Breslow thickness 1 mm or greater,
or any prior melanoma with a history of
lymphatic, in-transit, or distant metastases.
N (N)
Y (Y)
Patient has clinical evidence of regional lymph
node metastases as evidenced by suspicious
palpable regional lymphadenopathy or biopsy.
N (N)
Y (Y)
Patient has cutaneous in-transit metastases
(more than 2 cm from the primary tumor) or gross
clinical evidence of satellitosis (less than 2 cm
from primary tumor).
N (N)
Y (Y)
Patient previously has had a wide excision of a
melanoma at the site of the index lesion.
N (N)
Y (Y)
Patient has had prior lymphatic surgery (i.e.,
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lymph node dissections or open lymph node
biopsies, including sentinel lymph node biopsies),
in the area(s) of potential lymphatic drainage of
the index melanoma.
N (N)
Y (Y)
Patient has clinical or radiographic evidence of
probable metastatic disease.
N (N)
Y (Y)
Patient meets all eligibility criteria:
No (No)
Yes (Yes)
Randomization
Indicate arm assigned:
(arm 1) ((Arm 1))
(arm 2) ((Arm 2))
Date of Diagnostic Biopsy: (within 90 days prior
to registration)
Visit Date: (Year Month Day)
Date of P/A and Lateral Chest X-ray: (within 60
days prior to registration)
Date of LDH: (within 60 days prior to registration)
Is LDH greater than upper limit of institutional
norm:
No (No)
Yes (Yes)
Stratification
Tumor thickness (on biopsy:)
Ulceration: (As documented in pathology report)
No (absent)
Yes (present)
Unknown (unknown)
Location: (Axial:)
distal to elbows or knees (distal to
elbows or knees)
head/neck (head/neck)
proximal (proximal)
trunk, shoulders, hips, buttocks, genitalia
(trunk, shoulders, hips, buttocks,
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Melanoma (Skin) null Registration - Registration Worksheet (RW) -
2073173v3.0
genitalia)
Completed by:
Date: (Year Month Day)
Ccrr Module For Registration Worksheet
(rw)
Patient ID (Pt. ID issued during registration or
previously issued patient ID)
Institution ID:
Patient Name:
Institution:
Registration Date: (Year Month Day)
Has patient previously been registered to an
ACOSOG study?
No (No)
Yes (Yes)
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Melanoma (Skin) null Registration - Registration Worksheet (RW) -
2073173v3.0
NCT00389818 Response - AMC-047 Lymphoma
Response Form (LYR) - 3006312v1.0
NCT00389818 Response - AMC-047 Lymphoma Response
Form (LYR) - 3006312v1.0
All rights reserved. Please visit https://medical-data-
models.org/forms/2616
AMC-047 Lymphoma Response
Form (LYR)
Extra Nodal Involvement Evaluation
Date of Last Clinical Assessment (mm/dd/yyyy)
Extra Nodal Involvement Evaluation
Complete response first observed
No (No)
Yes (Yes)
Complete Response (CR) First Observed Date
(mm/dd/yyyy)
Complete response confirmed (CR)
No (No)
Yes (Yes)
Complete Response Confirmed Date
(mm/dd/yyyy)
Extra Nodal Involvement Evaluation
Complete Response, Unconfirmed (CRu) First
Observed
No (No)
Yes (Yes)
Complete Response, Unconfirmed (CRu) First
Observed Date (mm/dd/yyyy)
Complete Response, Unconfirmed (CRu)
Confirmed
No (No)
Yes (Yes)
Complete Response, Unconfirmed (CRu)
Confirmed Date (mm/dd/yyyy)
Extra Nodal Involvement Evaluation
Partial response first observed
No (No)
Yes (Yes)
Partial Response (PR) First Observed Date
(mm/dd/yyyy)
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Partial response confirmed
No (No)
Yes (Yes)
Partial Response Confirmed Date (mm/dd/yyyy)
Extra Nodal Involvement Evaluation
Has the patient been diagnosed with a new
progression? (If Yes, continue. Otherwise, stop)
No (No)
Yes (Yes)
Progressive Disease First Observed Date
(mm/dd/yyyy)
Please indicate the site of progression
New Site Only (New site only)
New Site Plus Original Site (New site
plus original site)
Original Site Only (Original site only)
Central Nervous System Progression
No (No)
Yes (Yes)
CNS - leptomeninges
No (No)
Yes (Yes)
Brain - parenchymal
No (No)
Yes (Yes)
Comments
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NCT00389818 Response - AMC-047 Lymphoma Response Form (LYR) -
3006312v1.0
Lymphoma NCT01190449 On-Study - CALGB 50901
Clinical Assessment Yes/No Form - 3210396v1.0
Lymphoma NCT01190449 On-Study - CALGB 50901
Clinical Assessment Yes/No Form - 3210396v1.0
All rights reserved. Please visit https://medical-data-
models.org/forms/2621
CALGB 50901 Clinical Assessment
Yes/No Form
Clinical Assessment
Has the patient had a documented clinical
assessment for this cancer? (Mark one with an
X.)
No (No)
Yes (Yes)
Date of Last Clinical Assessment
Were the target lesions measured on this
evaluation
No (No)
Yes (Yes)
Were the non-target lesions measured on this
evaluation (Non-target sites may include sub-
centimeter lesions, bone lesions, ascites, and
pleural or pericardial effusion.)
No (No)
Yes (Yes)
Were bone marrow, liver, and/or spleen evaluated
No (No)
Yes (Yes)
Was the appearance of any new lesions
documented
No (No)
Yes (Yes)
Are new lesions judged to be progressive disease
No (No)
Yes (Yes)
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Lymphoma NCT00392834 Lab - AMC-048
HIV Viral Load Form (F40) - 2655348v1.0
Lymphoma NCT00392834 Lab - AMC-048 HIV Viral Load
Form (F40) - 2655348v1.0
All rights reserved. Please visit https://medical-data-
models.org/forms/2628
AMC-048 HIV Viral Load Form (F40)
Unnamed1
Visit number
Unnamed2
Results of HIV viral load assay  (Enter results
from right to left.)
Equal To (Equal to (=))
Greater Than (>) (Greater than (>))
Less Than (Less than (<))
Undetectable (Undetectable)
HIV viral load value
Method of detection
Abbott Realtime Hiv-1 Assay (Abbott
RealTime HIV-1 assay)
Cobas Ampliprep/taqman Hiv-1 Assay
(COBAS AmpliPrep/TAQMAN HIV-1
assay)
Other (Other)
Roche Amplicor Monitor Assay (Roche
Amplicor Monitor Assay)
Versant Hiv-1 Rna Assay By Branched
Dna (Versant HIV-1 RNA assay by
branched DNA)
Other, specify
HIV viral load assay type
Standard (Standard)
Ultra (Ultra)
Limits of detection
Lab Facility Name (Testing Laboratory
information)
Comments
Comments
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Lymphoma NCT00392834 Pathology - AMC-048 AIDS and Cancer
Specimen Resource (ACSR) Procurement Form (F37) - 2654993v1.0
Lymphoma NCT00392834 Pathology - AMC-048 AIDS and
Cancer Specimen Resource (ACSR) Procurement Form
(F37) - 2654993v1.0
All rights reserved. Please visit https://medical-data-
models.org/forms/2629
AMC-048 AIDS and Cancer
Specimen Resource (ACSR)
Procurement Form (F37)
Unnamed1
Visit number
Unnamed2
Date Specimen Obtained (mm/dd/yyyy)
Date Specimen Obtained (mm/dd/yyyy)
Specimen(s) obtained for donation to ACSR
No (No)
Yes (Yes)
Specimen Type (check all that apply)
Peripheral Blood (Blood)
Other (Other)
Pbmc (peripheral Blood Mononuclear
Cells) (PBMC)
Plasma (Plasma)
Serum (Serum)
Tissue (Tissue)
Other specify
ACSR site the specimen(s) shipped to
Gwu (GWU)
Jhu (JHU)
Osu (OSU)
Other (Other)
Suny/hscb (SUNY/HSCB)
Ucla (UCLA)
Ucsf (UCSF)
Other, specify
If specimens were not obtained for ACSR, please
indicate reason
Other (Other)
Patient Had Previously Donated
Specimen To Acsr (Patient had
previously donated specimen to ACSR)
Patient Refused To Give Informed
Consent For Acsr Specimen Donation
(Patient refused to give informed consent
for ACSR specimen donation)
Patient Was Not Asked To Consider Acsr
1 / 2
Specimen Donation (Patient was not
asked to consider ACSR specimen
donation)
Other, specify
Study Coordinator
Study Coordinator's name
E-mail
Phone Number (xxx-xxx-xxxx)
Comments
Comments
2 / 2
Lymphoma NCT00392834 Pathology - AMC-048 AIDS and Cancer
Specimen Resource (ACSR) Procurement Form (F37) - 2654993v1.0
Lymphoma NCT01190449 On-Study - CALGB
50901 New Malignancy Form - 3210573v1.0
Lymphoma NCT01190449 On-Study - CALGB 50901 New
Malignancy Form - 3210573v1.0
All rights reserved. Please visit https://medical-data-
models.org/forms/2637
CALGB 50901 New Malignancy
Form
New Malignancy
New Malignancy Type
New Primary Malignancy (New primary
malignancy)
New Secondary Malignancy (New
secondary malignancy)
Recurrence Of Previous Malignancy
(Recurrence of previous malignancy)
Specify Type
Specify histologic type
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Lymphoma NCT00598169 Lab - AMC-053
Chemistries, LFT's Form (F23) - 3122834v1.0
Lymphoma NCT00598169 Lab - AMC-053 Chemistries,
LFT's Form (F23) - 3122834v1.0
All rights reserved. Please visit https://medical-data-
models.org/forms/2651
AMC-053 Chemistries, LFT's Form
(F23)
Header Module
Visit number
Sequence number
Date of evaluation (mm/dd/yyyy)
Ccrr Module For Chemistries, Lft's - Rf23
Sodium (mEq/L)
Potassium (mEq/L)
Chloride (mEq/L)
Calcium (mg/dl)
Magnesium
Phosphorus (mg/dl)
Bicarbonate (mEq/L)
Alkaline Phosphatase (mU/ml)
SGOT (AST) (mU/ml)
SGPT (ALT) (mU/ml)
LDH (Lactic Dehydrogenase mU/ml)
BUN (mg/dl)
Creatinine (mg/dl)
Total Bilirubin (mg/dl)
Indirect Bilirubin (mg/dl)
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Direct Bilirubin (mg/dl)
Total Protein (mg/dl)
Albumin (g/dl)
Other, specify test
Other specify value
Units (other, specify test)
Comments Module
Comments
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Lymphoma NCT00598169 Lab - AMC-053 Chemistries, LFT's Form
(F23) - 3122834v1.0
Lymphoma NCT00598169 Lab - AMC-053
HIV Viral Load Form (F40) - 2933327v1.0
Lymphoma NCT00598169 Lab - AMC-053 HIV Viral Load
Form (F40) - 2933327v1.0
All rights reserved. Please visit https://medical-data-
models.org/forms/2664
AMC-053 HIV Viral Load Form (F40)
Unnamed1
Visit number
Unnamed2
Date Specimen Obtained (mm/dd/yyyy)
Was the viral load specimen sent to the Central
Laboratory (Subjects with HIV-1 viral loads
"undetectable" by clinical laboratories must have
their specimens sent to Dr. Frank Maldarelli at the
NIH for single-copy viral load testing to increase
the sensitivity for detecting HIV viral load
changes see Protocol Appendix)
No (no)
Yes (yes)
Results of HIV viral load assay  (Enter results
from right to left.)
Equal To (Equal to (=))
Greater Than (>) (Greater than (>))
Less Than (Less than (<))
Undetectable (Undetectable)
HIV viral load value
Method of detection
Abbott Realtime Hiv-1 Assay (Abbott
RealTime HIV-1 assay)
Cobas Ampliprep/taqman Hiv-1 Assay
(COBAS AmpliPrep/TAQMAN HIV-1
assay)
Other (Other)
Roche Amplicor Monitor Assay (Roche
Amplicor Monitor Assay)
Versant Hiv-1 Rna Assay By Branched
Dna (Versant HIV-1 RNA assay by
branched DNA)
Other, specify
HIV viral load assay type
Standard (Standard)
Ultra (Ultra)
Limits of detection (Copies/mL)
Lab Facility Name (Testing Laboratory
information)
1 / 2
Comments
Comments
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Lymphoma NCT00598169 Lab - AMC-053 HIV Viral Load Form (F40) -
2933327v1.0
Lymphoma NCT00389818 Lab - AMC-047
HIV Viral Load Form (F40) - 2541039v1.0
Lymphoma NCT00389818 Lab - AMC-047 HIV Viral Load
Form (F40) - 2541039v1.0
All rights reserved. Please visit https://medical-data-
models.org/forms/2669
AMC-047 HIV Viral Load Form (F40)
Unnamed1
Visit number
Unnamed2
Results of HIV viral load assay  (Enter results
from right to left.)
Equal To (Equal to (=))
Greater Than (>) (Greater than (>))
Less Than (Less than (<))
Undetectable (Undetectable)
HIV viral load value
Method of detection
Abbott Realtime Hiv-1 Assay (Abbott
RealTime HIV-1 assay)
Cobas Ampliprep/taqman Hiv-1 Assay
(COBAS AmpliPrep/TAQMAN HIV-1
assay)
Other (Other)
Roche Amplicor Monitor Assay (Roche
Amplicor Monitor Assay)
Versant Hiv-1 Rna Assay By Branched
Dna (Versant HIV-1 RNA assay by
branched DNA)
Other, specify
HIV viral load assay type
Standard (Standard)
Ultra (Ultra)
Limits of detection (Copies/mL)
Lab Facility Name (Testing Laboratory
information)
Comments
Comments
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Lymphoma NCT00389818 Pathology - AMC-047 AIDS and Cancer
Specimen Resource (ACSR) Procurement Form (F37) - 2541040v1.0
Lymphoma NCT00389818 Pathology - AMC-047 AIDS and
Cancer Specimen Resource (ACSR) Procurement Form
(F37) - 2541040v1.0
All rights reserved. Please visit https://medical-data-
models.org/forms/2672
AMC-047 AIDS and Cancer
Specimen Resource (ACSR)
Procurement Form (F37)
Unnamed1
Visit number
Unnamed2
Specimen(s) obtained for donation to ACSR
No (No)
Yes (Yes)
Specimen Type (check all that apply)
Peripheral Blood (Blood)
Other (Other)
Pbmc (peripheral Blood Mononuclear
Cells) (PBMC)
Plasma (Plasma)
Serum (Serum)
Tissue (Tissue)
Other specify
ACSR site the specimen(s) shipped to
Gwu (GWU)
Jhu (JHU)
Osu (OSU)
Other (Other)
Suny/hscb (SUNY/HSCB)
Ucla (UCLA)
Ucsf (UCSF)
Other, specify
If specimens were not obtained for ACSR, please
indicate reason
Other (Other)
Patient Had Previously Donated
Specimen To Acsr (Patient had
previously donated specimen to ACSR)
Patient Refused To Give Informed
Consent For Acsr Specimen Donation
(Patient refused to give informed consent
for ACSR specimen donation)
Patient Was Not Asked To Consider Acsr
Specimen Donation (Patient was not
asked to consider ACSR specimen
donation)
Other, specify
1 / 2
Date Specimen Obtained (mm/dd/yyyy)
Date Specimen Obtained (mm/dd/yyyy)
Study Coordinator
Study Coordinator's name
E-mail
Phone Number (xxx-xxx-xxxx)
Comments
Comments
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Lymphoma NCT00389818 Pathology - AMC-047 AIDS and Cancer
Specimen Resource (ACSR) Procurement Form (F37) - 2541040v1.0
Lymphoma NCT00822120 Registration - Southwest Oncology Group
S0816 REGISTRATION WORKSHEET - Step 2 - 3197172v1.0
Lymphoma NCT00822120 Registration - Southwest
Oncology Group S0816 REGISTRATION WORKSHEET -
Step 2 - 3197172v1.0
All rights reserved. Please visit https://medical-data-
models.org/forms/2676
Southwest Oncology Group S0816
REGISTRATION WORKSHEET -
Step 2
Unnamed1
Activation Date (MM DD YYYY)
Last Amended Date (MM DD YYYY)
Registration Step
Swog Patient Id
SWOG Patient ID
Unnamed2
Registrar's SWOG Roster ID Number
SWOG Investigator Number
SWOG Treating Institution Number
Unnamed5
Projected Start Date of Treatment (MM DD
YYYY)
Stratification Questions
Based on centralized review, is the patient PET-
positive after 2 cycles of ABVD?
Yes (1)
No (2)
Unnamed 7
Has the Southwest Oncology Group Registration
Worksheet been completed entirely and is the
patient eligible according to the current version of
protocol section 5.0
No (No)
Yes (Yes)
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Lymphoma NCT01190449 Treatment - CALGB
50901 Patient Status Form - 3208878v1.0
Lymphoma NCT01190449 Treatment - CALGB 50901
Patient Status Form - 3208878v1.0
All rights reserved. Please visit https://medical-data-
models.org/forms/2677
CALGB 50901 Patient Status Form
Unnamed 3
Vital Status (Mark one with an X.)
Alive (Alive)
Dead (Dead)
Date of Death
Primary Cause of Death (Mark one with an X.)
Due To Other Cause (Due to other
cause)
Due To Protocol Treatment (Due to
protocol treatment)
Due To This Disease (Due to this
disease)
Unknown (Unknown)
Describe cause of death
Is the patient receiving any non-protocol cancer
therapy not previously reported?
No (No)
Yes (Yes)
Has a new primary cancer or MDS been
diagnosed that has not been previously reported?
No (No)
Yes (Yes)
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NCT00598169 On-Study - AMC-053 Baseline Lymphoma
Disease Activity and Assessment Form (LAA) - 3122745v1.0
NCT00598169 On-Study - AMC-053 Baseline Lymphoma
Disease Activity and Assessment Form (LAA) -
3122745v1.0
All rights reserved. Please visit https://medical-data-
models.org/forms/2686
AMC-053 Baseline Lymphoma
Disease Activity and Assessment
Form (LAA)
Unnamed1
Visit Number
Unnamed2
Modified Ann Arbor Stage
I (I)
Ie (IE)
Ii (II)
Iie (IIE)
Iii (III)
Iiie (IIIE)
Iiie+s (IIIE+S)
Iiis (IIIS)
Iv (IV)
Recurring, drenching night sweats during the
previous month (Does the participant have any of
the following symptoms at the time of registration)
No (No)
Yes (Yes)
Unexplained, persistent fever >38 degrees C (or
>100 degrees F) in the previous month (Does the
participant have any of the following symptoms at
the time of registration)
No (No)
Yes (Yes)
Unexplained weight loss >10% of body weight in
the previous 6 months (Does the participant have
any of the following symptoms at the time of
registration)
No (No)
Yes (Yes)
Hematopoietic Diagnosis
Burkitt Lymphoma/leukemia (Burkitt
lymphoma/leukemia)
Diffuse Large B-cell Lymphoma (Diffuse
large B-cell lymphoma)
Hodgkin's Lymphoma (Hodgkin
lymphoma)
Kshv/hhv-8+ Plasmablastic Lymphoma
(lymph Node) (KSHV/HHV-8+
plasmablastic lymphoma (lymph node))
Other (Other)
Plasma Lymphoma Of Oral Cavity
(Plasma lymphoma of oral cavity)
Polymorphic B Cell Lymphoma-ptld Type
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(Polymorphic B cell lymphoma-PTLD
type)
Primary Effusion Lymphoma (Primary
effusion lymphoma)
If diffuse large B-cell lymphoma, specify
morphologic type
Centroblastic (Centroblastic)
Immunoblastic (Immunoblastic)
Not Specified (Not specified)
Other (Other)
If Burkitt lymphoma/leukemia, specify
morphologic type
B Cell Lymphoma Unclassifiable,
W/features Intermediate Between Dlbcl
And Burkitt's. (atypical) (B cell lymphoma
unclassifiable, w/features intermediate
between DLBCL and Burkitt's. (Atypical))
Classical (Classical)
Other (Other)
Plasmacytoid (Plasmacytoid)
Other specify
Other specify
Other specify
If Hodgkin lymphoma, specify morphologic type
Lymphocyte Depleted (Lymphocyte
depleted)
Lymphocyte Rich (Lymphocyte rich)
Mixed Cellularity (Mixed cellularity)
Nodular Sclerosis (Nodular sclerosis)
Unclassified (Unclassified)
Date of Initial Pathologic Diagnosis (mm/dd/yyyy)
Method of Evaluation
Biopsy (Biopsy)
Cytology (Cytology)
Other (Other)
Other Specify
Is the participant >60 years of age (Please enter
the information below to obtain International
Prognostic Index poor risk features)
No (No)
Yes (Yes)
Does the participant have Stage III or IV disease
(Please enter the information below to obtain
International Prognostic Index poor risk features)
No (No)
Yes (Yes)
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NCT00598169 On-Study - AMC-053 Baseline Lymphoma Disease
Activity and Assessment Form (LAA) - 3122745v1.0
Is the serum LDH elevated (Please enter the
information below to obtain International
Prognostic Index poor risk features)
No (No)
Yes (Yes)
Is the ECOG Performance Status 2, 3, or 4
(Please enter the information below to obtain
International Prognostic Index poor risk features)
No (No)
Yes (Yes)
Does the participant have two or more extranodal
disease sites (Please enter the information below
to obtain International Prognostic Index poor risk
features)
No (No)
Yes (Yes)
International Prognostic Index
0 (0)
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
IPI Risk Category
High Risk (High risk)
High-intermediate Risk (High-
intermediate risk)
Low Risk (Low risk)
Low-intermediate Risk (Low-intermediate
risk)
Histogenetic Subtyping Markers
Histogenetic Subtyping Markers
Bcl6 (BCL6)
Cd10 (CD10)
Foxp1 (FOXP1)
Gcet1 (GCET1)
Mum1 (MUM1)
Finding Result
Negative (Negative)
Not Assessed (Not assessed)
Positive (Positive)
EBV Status
Eber Negative (EBER negative)
Eber Positive (EBER positive)
Not Done (Not done)
Comments
Comments
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NCT00598169 On-Study - AMC-053 Baseline Lymphoma Disease
Activity and Assessment Form (LAA) - 3122745v1.0
Lymphoma NCT01193842 Lab - AMC-075
Pharmacodynamics Form (PD1) - 3227423v1.0
Lymphoma NCT01193842 Lab - AMC-075
Pharmacodynamics Form (PD1) - 3227423v1.0
All rights reserved. Please visit https://medical-data-
models.org/forms/2687
AMC-075 Pharmacodynamics Form
(PD1)
Header Module
Visit number
Pharmacodynamics
Infusion start date (mm/dd/yyyy)
Infusion Start Time (hh:mm 24 hour clock)
Date Specimen collected (24-48 hour specimen
draw 48-72 hour specimen draw 72-96 hour
specimen draw mm/dd/yyyy)
Time Specimen Collected (24-48 hour specimen
draw 48-72 hour specimen draw 72-96 hour
specimen draw hh:mm 24 hour clock)
Infusion Stop Date (mm/dd/yyyy)
Infusion Stop Time (hh:mm 24 hour clock)
Comments
Comments
1 / 1
Multiple Myeloma and Plasma Cell Neoplasm NCT00644228 Registration -
Southwest Oncology Group S0777 Registration Worksheet - Step 2 - 2920797v1.0
Multiple Myeloma and Plasma Cell Neoplasm
NCT00644228 Registration - Southwest Oncology Group
S0777 Registration Worksheet - Step 2 - 2920797v1.0
All rights reserved. Please visit https://medical-data-
models.org/forms/2694
Southwest Oncology Group S0777
Registration Worksheet - Step 2
Unnamed2
SWOG Patient ID
For All Institutions
Is registering institution a SWOG institution
No (No)
Yes (Yes)
Unnamed4
Registrar's SWOG Roster ID Number
SWOG Investigator Number
SWOG Treating Institution Number
Patient Information
Projected Start Date of Treatment
Patient Eligibility
Has the Southwest Oncology Group Registration
Worksheet been completed entirely and is the
patient eligible according to the current version of
protocol section 5.0
No (No)
Yes (Yes)
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Lymphoma NCT01193842 On-Study - AMC-075
Pregnancy Report Form (PRF) - 3228000v1.0
Lymphoma NCT01193842 On-Study - AMC-075 Pregnancy
Report Form (PRF) - 3228000v1.0
All rights reserved. Please visit https://medical-data-
models.org/forms/2700
AMC-075 Pregnancy Report Form
(PRF)
Unnamed1
Sequence number
Current Pregnancy Information
Date of pregnancy test  (initial mm/dd/yyyy)
Type of pregnancy test
Clinic Urine Test (Clinic urine test)
Home Urine Test (Home urine test)
Serum Test (Serum test)
If a urine test was used to make the initial
diagnosis, was the diagnosis confirmed by a
serum test
No (no)
Unknown (unknown)
Yes (yes)
Serum pregnancy test date (If yes mm/dd/yyyy)
Date of last menstrual period (mm/dd/yyyy)
Estimated date of conception (mm/dd/yyyy)
Due Date (mm/dd/yyyy)
Previous Pregnancy Information
Number of Pregnancies (Gravida If Gravida >0,
complete the following)
Number of live births (Para)
Number of Spontaneous abortions
Number of Elective abortions
Unknown
Did the participant experience complications with
a previous pregnancy
No (No)
1 / 2
Unknown (Unknown)
Yes (Yes)
Specify (If yes)
Were there any congenital anomalies with
previous pregnancies
No (No)
Unknown (Unknown)
Yes (Yes)
Specify (If yes)
Relevant Medical History
Specify relevant medical history of the mother
(include alcohol/tobacco and substance abuse,
illness during this pregnancy, assisted
conception; specify other disorders including
familial birth defects/genetic/chromosomal
disorders/methods of diagnosis, etc)
Is the father known
No (No)
Participant Declines To Answer
(Participant declines to answer)
Yes (Yes)
Number of children father has
Father's Age (in years)
Unknown
Specify relevant medical history of the father
(include chronic illnesses; specify familial birth
defects/genetic/chromosomal disorders, habitual
exposure; specify alcohol/tobacco and substance
exposure; specify substance abuse and
medication use)
Comments
Comments
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Lymphoma NCT01193842 On-Study - AMC-075 Pregnancy Report Form
(PRF) - 3228000v1.0
Lymphoma NCT00981097 On-Study - AMC-
064 Missed Visit Form (F35) - 2983048v1.0
Lymphoma NCT00981097 On-Study - AMC-064 Missed
Visit Form (F35) - 2983048v1.0
All rights reserved. Please visit https://medical-data-
models.org/forms/2708
AMC-064 Missed Visit Form (F35)
Unnamed1
Visit number
Unnamed2
Missed Visit Date (mm/dd/yyyy)
Reason patient missed visit
Health Reasons (Health reasons)
Other (Other)
Patient Could Not Get Off Work (Patient
could not get off work)
Patient Decided To Discontinue Study
(Patient decided to discontinue study)
Patient Experienced An Adverse Event
(Patient experienced an Adverse Event)
Patient Forgot (Patient forgot)
Patient Had Transportation Problems
(Patient had transportation problems)
Patient Unable To Obtain Dependent
Care (Patient unable to obtain dependent
care)
Patient Unhappy With Frequency Of
Visits (Patient unhappy with frequency of
visits)
Scheduling Difficulties (Scheduling
difficulties)
Other, specify
Next visit scheduled (Items missed will be made
up at the new visit.)
No (No)
Yes (Yes)
Comments
Comments
1 / 1
Sarcoma, Kaposi xxx Treatment - Concomitant Medications
Excluding Antiretroviral Therapy - RF09 - 2266246v3.0
Sarcoma, Kaposi xxx Treatment - Concomitant Medications
Excluding Antiretroviral Therapy - RF09 - 2266246v3.0
All rights reserved. Please visit https://medical-data-
models.org/forms/2730
Concomitant Medications Excluding
Antiretroviral Therapy - RF09
Ccrr Module For Concomitant Medications
Excluding Antiretroviral Therapy - Rf09
Patient Initials
Stopped?
No (No)
Yes (Yes)
Date Started
Started prior to study?
No (No)
Yes (Yes)
Frequency (per day)
Units
Amount
ACTG Drug Code
Medication (Generic Name Only)
During this cycle, has the subject started or
stopped any medications?
No (No)
Yes (Yes)
First day of cycle
Cycle #
ID#
Site#
Study#
Date Stopped
1 / 1
Treatment - Transfusion - 3281161v1.0
Treatment - Transfusion - 3281161v1.0
All rights reserved. Please visit https://medical-data-
models.org/forms/2737
Transfusion
Transfusion
Visit Date
Course #
Day in Course (Cycle)
Date (Enter the date that the transfusion was
done.)
Time (Enter the time the transfusion was done.)
Transfusion Component (Select the transfusion
component from the pick list.)
Albumin (Albumin)
Cryoprecipitate (Cryoprecipitate)
Fresh Frozen Plasma (FFP)
No Blood Product (No Blood Products)
Packed Red Blood Cells Transfusion
(Packed RBC)
Packed Autologous Red Blood Cells
Transfusion (Packed RBC, Autologous)
Packed Autologous Irradiated Red Blood
Cells Transfusion (Packed RBC,
Autologous, Irradiated)
Packed Autologous Leukoreduced Red
Blood Cells Transfusion (Packed RBC,
Autologous, Leukoreduced)
Packed Irradiated Red Blood Cells
Transfusion (Packed RBC, Irradiated)
Irradiated Leukocyte-reduced Packed
Red Blood Cell Transfusion (Packed
RBC, Irradiated and Leukoreduced)
Packed Leukopoor Red Blood Cells
Transfusion (Packed RBC, Leukopoor)
Packed Leukoreduced Red Blood Cells
Transfusion (Packed RBC,
Leukoreduced)
Platelet (Platelet)
Platelets, Hla-matched (Platelets, HLA
Match)
Platelets, Irradiated (Platelets, Irradiated)
Irradiated Leukocyte-reduced Platelet
Transfusion (Platelets, Irradiated and
Leukoreduced)
Platelets, Leukoreduced (Platelets,
Leukoreduced)
White Blood Cells (WBC)
White Blood Cells, Irradiated (WBC,
Irradiated)
Whole Blood (Whole Blood)
1 / 2
# of Units (Enter the blood component number of
units transfused in Units)
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Treatment - Transfusion - 3281161v1.0
Treatment - 2006 Revision 2 - Hematopoietic Stem
Cell Transplant (HSCT) Infusion - 2914060v1.0
Treatment - 2006 Revision 2 - Hematopoietic Stem Cell
Transplant (HSCT) Infusion - 2914060v1.0
All rights reserved. Please visit https://medical-data-
models.org/forms/2756
2006 Revision 2 - Hematopoietic
Stem Cell Transplant (HSCT)
Infusion
Registry Use Only
Sequence number:
Date received:
Identification Data
CIBMTR Center Number:
CIBMTR Recipient ID:
Specify tissue donor type:
Autologous Stem Cell Transplantation
(Autologous)
National Marrow Donor Program
Unrelated Umbilical Cord Blood Unit
(NMDP unrelated cord blood unit)
National Marrow Donor Program
Unrelated Donor (NMDP unrelated
donor)
Negation National Marrow Donor
Program Umbilical Cord Blood Unit
(Non-NMDP cord blood unit)
Negation National Marrow Donor
Program Donor Unrelated (Non-NMDP
unrelated donor)
Donor Relationship (Related donor)
NMDP Cord Blood Unit ID:
NMDP Donor ID:
Donor's / infant's date of birth:
Donor's / infant's gender:
Female (female)
Male (male)
Non-NMDP unrelated donor / cord blood unit ID:
(not applicable for related donor)
Is the CBU ID number also the ICCBBA ISBT 128
number?
No (No)
1 / 39
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Registry or UCB Bank ID:
(a) Austrian Bone Marrow Donors (A)
(acb) Austrian Cord Blood Registry
(ACB)
(accb) Stemcyte, Inc. (ACCB)
(ae) Emirates Bone Marrow Donor
Registry (AE)
(am) Armenian Bone Marrow Donor
Registry Charitable Trust (AM)
(aocb) University Of Colorado Cord
Blood Bank (AOCB)
(ar) Argentine Cph Donors Registry (AR)
(arcb) Bancel - Argentina Cord Blood
Bank (ARCB)
(aucb) Australian Cord Blood Registry
(AUCB)
(aus) Australia / New Zealand Bone
Marrow Donor Registry (AUS)
(b) Marrow Donor Program Belgium (B)
(bcb) Belgium Cord Blood Registry
(BCB)
(bg) Bulgarian Bone Marrow Donor
Registry (BG)
(br) Inca/redomo (BR)
(bscb) British Bone Marrow Registry -
Cord Blood (BSCB)
(ch) Swiss Bloodstem Cells - Adult
Donors (CH)
(chcb) Swiss Blood Stem Cells - Cord
Blood (CHCB)
(ckcb) Celgene Cord Blood Bank
(CKCB)
(cn) China Marrow Donor Program
(cmdp) (CN)
(cncb) Shan Dong Cord Blood Bank
(CNCB)
(cnd) Canadian Blood Services Bone
Marrow Donor Registry (CND)
(cs2) Czech National Marrow Donor
Registry (CS2)
(cscr) Czech Stem Cells Registry
(CSCR)
(cy) Cyprus Paraskevaidio Bone Marrow
Donor Registry (CY)
(cy2) The Cyprus Bone Marrow Donor
Registry (CY2)
(d) Zkrd - Zentrales
Knochenmarkspender - Register
Deutschland Adult Donors (D)
(dcb) Zkrd - Zentrales
Knochenmarkspender - Register
Deutschland Cord Blood (DCB)
(dk) The Danish Bone Marrow Donor
Registry (DK)
(dk2) Bone Marrow Donors Copenhagen
(bmdc) (DK2)
(ducb) German Branch Of The European
Cord Blood Bank (DUCB)
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(e) Redmo (E)
(ecb) Spanish Cord Blood Registry
(ECB)
(f) France Greffe De Moelle - Adult
Donors (F)
(fcb) France Greffe De Moelle - Cord
Blood (FCB)
(fi) Finnish Bone Marrow Donor Registry
(FI)
(ficb) Finnish Cord Blood Registry (FICB)
(gb) The Anthony Nolan Trust (GB)
(gb3) Welsh Bone Marrow Donor
Registry (GB3)
(gb4) British Bone Marrow Registry
(GB4)
(gr) Unrelated Hematopoietic Stem Cell
Donor Registry Greece (GR)
(grcb) Michigan Community Blood
Centers Cord Blood Bank (GRCB)
(h) Hungarian Bone Marrow Donor
Registry (H)
(hk) Hong Kong Bone Marrow Donor
Registry (HK)
(hr) Croatian Bone Marrow Donor
Registry (HR)
(i) Italian Bone Marrow Donor Registry (I)
(i3cb) Sheba Medical Centre Cord Blood
Registry (I3CB)
(icb) Italian Cord Blood Bank Network
(ICB)
(il) Hadassah Bmdr (IL)
(il2) Ezer Mizion Bone Marrow Donor
Registry (IL2)
(il3) Sheba Medical Center Donor
Registry (IL3)
(ilcb) Isreal Cord Blood Bank (ILCB)
(in) Asian Indian Donor Marrow Registry
(IN)
(in2) Dept. Of Transfusion Medicine (IN2)
International-unable To Answer
(INTL_UA)
(irl) The Irish Unrelated Bone Marrow
Panel (IRL)
(jp) Japan Marrow Donor Program (JP)
(kr) Korea Marrow Donor Program (KR)
(lt) Lithuanian National Bone Marrow
Donor Registry (LT)
(lvcb) Leuven Cord Blood Bank (LVCB)
(macb) Victoria Angel Registry Of Hope
(MACB)
(mx) Mexican Bone Marrow Donor
Registry (MX)
(n) The Norwegian Bone Marrow Donor
Registry (N)
(nl) Europdonor Foundation- Adult
Donors (NL)
(nlcb) Europdonor Foundation - Cord
Blood (NLCB)
(nycb) National Cord Blood Program,
New York Blood Center (NYCB)
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(p) Portuguese Bone Marrow Donors
Registry (P)
(pl) National Polish Bone Marrow
Registry (PL)
(pl2) Unrelated Bone Marrow Donor
Registry -adult Donors (PL2)
(pl3) Against Leukemia Foundation
Marrow Donor Registry (PL3)
(pl4) Ursula Jaworska Foundation - Bone
Marrow Donor Registry (PL4)
(pl5) Polish Central Bone Marrow Donor
Registry - Adult Donors (PL5)
(pmcb) Elie Katz Umbilical Cord Blood
Program (PMCB)
(r) Russian Bone Marrow Donor Registry
(R)
(r2) Karelian Registry Of Unrelated
Donors Of Hematopoietic Stem Cells
(R2)
(s) Tobias Registry Of Swedish Bone
Marrow Donors (S)
(sg) Singapore Bone Marrow Donor
Programme (bmdp) (SG)
(sk) Slovak National Bone Marrow Donor
Registry (SK)
(skcb) Eurocord Slovakia / Slovak
Pacental Stem Cell Registry (SKCB)
(slo) Slovenia Donor (SLO)
(sm) San Marino Bone Marrow Donor
Registry (SM)
(t1cb) Tran - Cord Blood (T1CB)
(tacb) Stemcyte, Inc. Taiwan (TACB)
(tecb) Healthbanks Biotech, Co., Ltd
(TECB)
(th) Thai Stem Cell Donor Registry
(tscdr) (TH)
(tocb) Tokyo Cord Blood Bank (TOCB)
(tpcb) Bionet / Babybanks (TPCB)
(tran) Tran - Adult Donors (TRAN)
(tris) Bone Marrow Bank Of Istanbul
Medical Faculty (TRIS)
(tw) Buddhist Tzu Chi Stem Cells Center
- Adult Donors (TW)
(twcb) Buddhist Tzu Chi Stem Cells
Center - Cord Blood (TWCB)
(u1cb) National Marrow Donor Program -
Cord Blood (U1CB)
(u3cb) Caitlin Raymond International
Registry - Cord Blood (U3CB)
(u4cb) Gift Of Life Bone Marrow
Foundation - Cord Blood (U4CB)
(usa1) National Marrow Donor Program -
Adult Donors (USA1)
(usa2) America Bone Marrow Donor
Registry (USA2)
(usa3) Caitlin Raymond International
Registry -adult Donors (USA3)
(usa4) Gift Of Life Bone Marrow
Foundation - Adult Donors (USA4)
(uy) Sindome (UY)
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(w3cb) Polish Central Bone Marrow
Donor Registry - Cord Blood (W3CB)
(wacb) Unrelated Bone Marrow Donor
Registry - Cord Blood (WACB)
(za) South African Bone Marrow Registry
(ZA)
Specify other Registry or UCB Bank:
Mother's age at donation
What is the reason for the mother's missing age?
Unknown Not Applicable (Unknown/not
applicable)
Today's date:
Date of hematopoietic stem cell transplantation
(HSCT) for which this form is being completed:
HSCT type (Check only one)
Related Allogenic (Allogeneic, related)
Unrelated Allogenic (Allogeneic,
unrelated)
Autologous (Autologous)
Syngeneic (Syngeneic (identical twin))
Product type (Check only one)
Umbilical Cord Blood (Cord blood)
Bone Marrow (Marrow)
Other (Other)
Peripheral Blood Stem Cell (PBSC)
Specify (Answer only if the value for 2730912 is
"other")
Pre-collection Therapy
Did the donor receive treatment, prior to any stem
cell harvest, to enhance the product collection for
this HSCT?
Umbilical Cord Blood Unit (Cord blood
unit)
National Marrow Donor Program Donor
(NMDP donor)
No (No)
Yes (Yes)
Chemotherapy (autologous only)
No (No)
Yes (Yes)
Anti-CD20(rituximab,Rituxan) (autologous only)
No (No)
Yes (Yes)
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Growth factor(s)
No (No)
Yes (Yes)
G-CSF
No (No)
Yes (Yes)
GM-CSF
No (No)
Yes (Yes)
Other growth factor(s)
No (No)
Yes (Yes)
Specify (Answer only if the value for 2772114 is
"Yes")
Other treatment
No (No)
Yes (Yes)
Specify treatment: (Answer only if the value for
2773751 is "Yes")
Product Collection
Date of product collection:
Was more than one collection required for this
HSCT?
No (No)
Yes (Yes)
Specify the number of subsequent days of
collection in this episode: (Complete a separate
product form for each subsequent collection that
was not part of this mobilization.)
Were anticoagulants added to the product during
collection?
No (No)
Yes (Yes)
Product Collection
What anticoagulants were added to the product
during collection?
Acid-citrate-dextrose (Acid-Citrate-
Dextrose (ACD))
Citrate Phosphate Dextrose (Citrate
Phosphate Dextrose (CPD))
Heparin (Heparin)
Other (Other)
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Were particular anticoagulants added to the
product during collection?
No (No)
Yes (Yes)
Specify the other anticoagulants (Answer only if
the value for 2741578 is "Other")
Product Transport And Receipt
Was this product collected off-site and shipped to
your facility?
No (No)
Yes (Yes)
Date of receipt of product at your facility:
Time of receipt of product: (24-hour clock)
Is time of receipt of product standard time or
daylight savings time?
Daylight Savings Time (Daylight Savings
Time)
Standard Time (Standard time)
Specify the shipping environment of the
product(s):
Freezing Umbilical Cord Blood Storage
Unit (Frozen Cord Blood Unit (s))
Freezing Gel Pack (Frozen Gel Pack)
Other Temperature (Other Temperature)
Ambient Temperature (Room
Temperature per Transplant Center
Request)
Specify shipping environment: (Answer only if the
value of 2785775 is "other temperature")
Were the secondary containers (e.g., insulated
shipping containers and unit cassette) intact
when they arrived at your center? (Cord blood
product only)
No (No)
Yes (Yes)
Was the cord blood unit completely frozen when it
arrived at your center? (Cord blood product only)
No (No)
Yes (Yes)
Was the cord blood unit stored at your center
prior to thawing? (Cord blood product only)
No (No)
Yes (Yes)
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Specify the storage method used for the cord
blood unit:
Electricity Freezing (Electric Freezer)
Liquid Nitrogen (Liquid Nitrogen)
Vapor Phase Cooling (Vapor Phase)
Temperature during storage:
Date storage started:
Product Processing / Manipulation
Was a fresh product received, then
cryopreserved at your facility prior to infusion?
No (No)
Not Applicable (Not Applicable)
Yes (Yes)
Was the product thawed from a cryopreserved
state prior to infusion?
No (No)
Yes (Yes)
Was the entire product thawed?
No (No)
Yes (Yes)
Was a compartment of the bag thawed?
No (No)
Yes (Yes)
Were there multiple product bags?
No (No)
Yes (Yes)
Specify number of bags thawed:
Date thawing process initiated:
Time at initiation of thaw: (24-hour clock)
Is the thawing begin time standard time or
daylight savings time?
Daylight Savings Time (Daylight Savings
Time)
Standard Time (Standard time)
Time at completion of thaw : (24-hour clock)
Is the thawing end time standard time or daylight
savings time?
Daylight Savings Time (Daylight Savings
Time)
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Standard Time (Standard time)
Was the primary container (e.g.,cord blood unit
bag) intact upon thawing?
No (No)
Yes (Yes)
What method was used to thaw the product?
Dimethyl Sulfoxide Dilute (DMSO dilution
- thawed in lab (added dextran and
albumin), then infused)
No Cell Wash (no wash - thawed at
bedside,then infused)
Other Method (other method)
Cell Wash (washed - thawed in lab
(added dextran and albumin),spun and
reconstituted in dextran albumin,then
infused)
Specify other thaw method: (Answer only if the
value for 2789998 is "Other method")
Did any adverse events or incidents occur while
thawing the product?
No (No)
Yes (Yes)
Product Processing / Manipulation - Part 2
Was the product manipulated prior to infusion?
No (No)
Yes (Yes)
Specify portion manipulated:
Entire Hematopoietic Stem Cell
Collection (Entire product)
Part Hematopoietic Stem Cell Collection
(Portion of product)
ABO incompatibility (RBC depletion)
No (No)
Yes (Yes)
Buffy coat preparation
No (No)
Yes (Yes)
Cell separator (i.e., COBE Spectra)
No (No)
Yes (Yes)
Density gradient separation (i.e., Ficoll)
No (No)
Yes (Yes)
Plasma removal
No (No)
Yes (Yes)
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Sedimentation (i.e., hetastarch)
No (No)
Yes (Yes)
Other
No (No)
Yes (Yes)
Specify other method: (Answer only if the value
for 2774524 is "Yes" )
Ex-vivo expansion
No (No)
Yes (Yes)
Genetic manipulation (gene transfer /
transduction)
No (No)
Yes (Yes)
Volume reduction
No (No)
Yes (Yes)
CD34+ selection
No (No)
Yes (Yes)
Specify manufacturer:
Clinimax Cell Selection System
(CliniMACS / CliniMax)
Isolex Cell Selection System (Isolex)
Other (Other)
Specify other manufacturer: (Answer only if the
value for 2786700 is "Other" )
T-cell depletion
No (No)
Yes (Yes)
antibody affinity column
No (No)
Yes (Yes)
antibody coated plates
No (No)
Yes (Yes)
antibody coated plates and soybean lectin
No (No)
Yes (Yes)
antibody and complement
No (No)
Yes (Yes)
antibody and toxin
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No (No)
Yes (Yes)
immunomagnetic beads
No (No)
Yes (Yes)
elutriation
No (No)
Yes (Yes)
CD34 affinity column plus sheep red blood cell
rosetting
No (No)
Yes (Yes)
Other (Other T-cell depletion)
No (No)
Yes (Yes)
Specify other method (Answer only if the value for
2774740 is "Yes" )
Other cell manipulation
No (No)
Yes (Yes)
Specify other cell manipulation: (Answer only if
the value for 2744934 is "Yes" )
Were antibodies used during product
manipulation?
No (No)
Yes (Yes)
anti CD2
No (No)
Yes (Yes)
anti CD3
No (No)
Yes (Yes)
anti CD4
No (No)
Yes (Yes)
anti CD5
No (No)
Yes (Yes)
anti CD6
No (No)
Yes (Yes)
anti CD7
No (No)
Yes (Yes)
anti CD8
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No (No)
Yes (Yes)
anti CD34
No (No)
Yes (Yes)
anti TCR alpha / beta (T10-B9)
No (No)
Yes (Yes)
OKT-3
No (No)
Yes (Yes)
other CD3
No (No)
Yes (Yes)
Specify other CD3: (Answer only if the value for
2746342 is "Yes" )
anti CD52
No (No)
Yes (Yes)
campath-NOS
No (No)
Yes (Yes)
campath-1G
No (No)
Yes (Yes)
campath-1H
No (No)
Yes (Yes)
Other antibody
No (No)
Yes (Yes)
Specify other antibody: (Answer only if the value
for 2746486 is "Yes" )
Autologous Products Only - Part 1 / 2
Were tumor cells detected in the recipient or
autologous product prior to HSCT?
No (No)
Yes (Yes)
Autologous Products Only
What tumor cell detection method was used ?
Cell Culture Techniques (Cell culture
technique)
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Ihc, Immunohistochemistry
(Immunohistochemistry)
Other (Other)
Other Molecular Techniques (Other
molecular technique)
Pcr, Polymerase Chain Reaction
(Polymerase chain reaction(PCR))
Histopathology (Routine histopathology)
Were particular tumor cell detection method used
prior to HSCT?
No (No)
Yes (Yes)
Were tumor cells detected in circulating blood
cells prior to HSCT?
No (No)
Not Done: C49484 (Not Done)
Yes (Yes)
Were tumor cells detected in bone marrow, in the
interval between last systemic therapy and
collection prior to HSCT?
No (No)
Not Done: C49484 (Not Done)
Yes (Yes)
Were tumor cells detected in collected cells,
before purging prior to HSCT?
No (No)
Not Done: C49484 (Not Done)
Yes (Yes)
Specify method (Answer only if the value for
2775544 is "Other molecular technique" OR
"Other technique"  )
Autologous Products Only - Part 3 / 5
Was the product treated to remove malignant
cells (purged) ? (autologous product only)
No (No)
Yes (Yes)
Autologous Products Only - 3 / 4
What malignant cell removal method was used to
treat the product?
Perfosfamide (4-
hydroperoxycyclophosphamide(4HC))
Elutriative Centrifugation (Elutriation)
Immunomagnetic Column
(Immunomagnetic column)
Mafosfamide (Mafosfamide)
Monoclonal Antibody (Monoclonal
antibody)
Other Medication (Other drug)
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Other Method (Other method)
Hematopoietic Stem Cell Positive
Selection (Positive stem cell
selection(other than preparation of
mononuclear fraction))
Toxin (Toxin)
Was a particular malignant cell removal method
used for product treatment?
No (No)
Yes (Yes)
Specify the other malignant cell removal method:
(Answer only if the value for 2748795 is
"Monoclonal antibody","Other drug",
"Toxin","Positive stem cell selection" or "Other
method".)
Autologous Products Only Part 4 / 4
What kind of method was used to detect tumor
cells after purging?
Cell Culture Techniques (Cell culture
technique)
Ihc, Immunohistochemistry
(Immunohistochemistry)
Other (Other)
Other Molecular Techniques (Other
molecular technique)
Pcr, Polymerase Chain Reaction
(Polymerase chain reaction(PCR))
Histopathology (Routine histopathology)
Was a particular tumor cell detection method
used after purging?
No (No)
Not Done: C49484 (Not Done)
Yes (Yes)
Specify the other tumor cells detection method
(Answer only if the value for 2778929 is "Other")
Product Analysis (all Products)
Specify the time point in the product preparation
that the product was analyzed:
Infusion Timepoint (At infusion (final
quantity infused))
Post Manipulation (Post-manipulation)
Post Processing Prior Cryopreservation
Prior Manipulation (Post-processing, pre-
cryopreservation / manipulation)
Post Thaw (Post-thaw)
Arrival (Product arrival)
Date of product analysis:
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Total volume of product: (one decimal place)
What was the unit of measure for the total volume
of the product being analyzed?
Gram (g)
Milliliter (mL)
Nucleated cells: (Report the total number of cells
not cells per kilogram)
Nucleated cells exponent value:
Not tested (Not tested for nucleated cells)
Negation Test (Not tested)
Mononucleated cells: (Report the total number of
cells not cells per kilogram)
Mononucleated cells exponent value:
Not tested (Not tested for mononucleated cells)
Negation Test (Not tested)
Nucleated red blood cells: (Report the total
number of cells not cells per kilogram)
Nucleated red blood cells exponent value:
Not tested (Not tested for nucleated red blood
cells)
Negation Test (Not tested)
CD34+ cells: (Report the total number of cells not
cells per kilogram)
CD34+  cells exponent value:
Not tested (Not tested for CD34+ cells)
Negation Test (Not tested)
CD3+ cells: (Report the total number of cells not
cells per kilogram)
CD3+  cells exponent value:
Not tested (Not tested for CD3+ cells)
Negation Test (Not tested)
CD4+ cells: (Report the total number of cells not
cells per kilogram)
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CD4+  cells exponent value:
Not tested (Not tested for CD4+ cells)
Negation Test (Not tested)
CD8+ cells: (Report the total number of cells not
cells per kilogram)
CD8+  cells exponent value:
Not tested (Not tested for CD8+ cells)
Negation Test (Not tested)
Viability of cells
Not tested (The cell viability not tested)
Negation Test (Not tested)
Method of testing cell viability:
7-aminoactinomycin D (7-AAD)
Other Method (Other method)
Propidium Iodide (Propidium iodide)
Trypan Blue (Trypan blue)
Specify other method: (Answer only if the value
for 2760530 is "Other method")
Were the colony-forming units (CFU) assessed
after thawing? (cord blood product only)
No (No)
Yes (Yes)
Was there growth?
No (No)
Yes (Yes)
Total colonies per product: (One decimal place
with exponent "x10E5")
Unknown (Total colonies per productunknown )
Unknown Not Applicable (Unknown/not
applicable)
Total CFU-GM: (One decimal place with exponent
"x10E5")
Unknown (Total CFU-GMUnknown  )
Unknown Not Applicable (Unknown/not
applicable)
Were cultures performed before infusion to test
the product(s) for bacterial or fungal infection?
(complete for all cell products)
No (No)
Yes (Yes)
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Specify results:
Negative Finding (Negative)
Positive Finding (Positive)
Unknown (Unknown)
Specify organism names: (1st Organism Name )
Acinetobacter (Acinetobacter)
Actinomyces (Actinomyces)
Aspergillus Flavus (Aspergillus flavus)
Aspergillus Fumigatus (Aspergillus
fumigatus)
Aspergillus Niger (Aspergillus niger)
Aspergillus Not Otherwise Specified
(Aspergillus, NOS)
Bacillus (Bacillus)
Bacteroides (Bacteroides (gracillis,
uniformis, vulgaris, other species))
Bordetella Pertussis (Bordetella
pertussis (whooping cough))
Borrelia Burgdorferi (Borrelia (lyme
disease))
Moraxella Catarrhalis (Branhamella or
Moraxella catarrhalis (other species))
Campylobacter (Campylobacter (all
species))
Candida Glabrata (Candida (Torulopsis)
glabrata)
Candida Albicans (Candida albicans)
Pichia Guilliermondii (Candida
guillermondi)
Issatchenkia Orientalis (Candida krusei)
Clavispora Lusitaniae (Candida
lusitaniae)
Candida Parapsilosis (Candida
parapsilosis)
Candida Tropicalis (Candida tropicalis)
Candida Not Otherwise Specified
(Candida, NOS)
Capnocytophaga (Capnocytophaga)
Chlamydophila Pneumoniae (Chlamydia
(pneumoniae))
Chlamydia Not Otherwise Specified
(Chlamydia, NOS)
Citrobacter (Citrobacter (freundii, other
species))
Clostridium (Clostridium (all species
except difficile))
Clostridium Difficile (Clostridium difficile)
Corynebacterium (Corynebacterium (all
non-diptheria species))
Corynebacterium Jeikeium
(Corynebacterium (jeikeium))
Coxiella (Coxiella)
Cryptococcosis (Cryptococcosus
species)
Enterobacter (Enterobacter)
Enterococcus (Enterococcus (all
species))
Vancomycin Resistant Enterococcus
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(Enterococcus, vancomycin resistant
(VRE))
Escherichia Coli (Escherichia (also E.
coli))
Pseudomonas Oryzihabitans
(Flavimonas oryzihabitans)
Flavobacterium (Flavobacterium)
Fusarium (Fusarium species)
Fusobacterium (Fusobacterium)
Haemophilus (Haemophilus (all species,
including influenzae))
Helicobacter Pylori (Helicobacter pylori)
Histoplasmosis (Histoplasmosis)
Klebsiella (Klebsiella)
Lactobacillus (Lactobacillus (bulgaricus,
acidophilus, other species))
Legionella (Legionella)
Leptospira (Leptospira)
C76356 (Leptotrichia buccalis)
Leuconostoc (Leuconostoc (all species))
Listeria (Listeria)
Methylobacterium (Methylobacterium)
Micrococcus Not Otherwise Specified
(Micrococcus, NOS)
Zygomycosis (Mucormycosis)
Multiple Bacteria (Multiple bacteria at a
single site)
Mycobacterium Avium Complex
(Mycobacterium avium - intracellulare
(MAC, MAI))
Mycobacterium Species (Mycobacterium
species (cheloneae, fortuitum,
haemophilum, kansasii, mucogenicum))
Mycobacterium Tuberculosis
(Mycobacterium tuberculosis
(tuberculosis, Koch bacillus))
Mycobacterium Not Otherwise Specified
(Mycobacterium, NOS)
Mycoplasma (Mycoplasma)
Neisseria (Neisseria (gonorrhoeae,
meningitidis, other species))
Nocardia (Nocardia)
Other Aspergillus (Other Aspergillus)
Other Bacteria (Other bacteria)
Other Candida (Other Candida)
Other Chlamydia (Other chlamydia)
Other Fungi (Other fungus)
Other Mycobacterium (Other
mycobacterium)
Pasteurella Multocida (Pasteurella
multocida)
Pneumocystis Pneumonia
(Pneumocystis (PCP / PJP))
Propionibacterium Acnes
(Propionibacterium (acnes, avidum,
granulosum, other species))
Proteus (Proteus)
Pseudomonas (Pseudomonas (all
species except cepacia & maltophilia))
Burkholderia Cepacia (Pseudomonas or
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Burkholder cepacia)
Stenotrophomonas Maltophilia
(Pseudomonas or Stenotrophomonas or
Xanthomonas maltophilia)
Rhizopus (Rhizopus)
Rhodococcus (Rhodococcus)
Rickettsia (Rickettsia)
Salmonella (Salmonella (all species))
Serratia Marcescens (Serratia
marcescens)
Shigella (Shigella)
Staphylococcus Aureus (Staphylococcus
aureus)
Staphylococcus Coag Negative
(Staphylococcus, coagulase negative)
Streptococcus Not Otherwise Specified
(Staphylococcus, NOS)
Rothia Mucilaginosa (Stomatococcus
mucilaginosis)
Streptococcus (Streptococcus (all
species except Enterococcus))
Streptococcus Pneumoniae
(Streptococcus pneumoniae)
Suspected Atypical Bacteria Infection
(Suspected atypical bacterial infection)
Suspected Bacteria Infection (Suspected
bacterial infection)
Suspected Fungal Infection (Suspected
fungal infection)
Treponema (Treponema (syphilis))
Vibrio (Vibrio (all species))
Yeast Not Otherwise Specified (Yeast,
NOS)
Zygomycota Not Otherwise Specified
(Zygomycetes, NOS)
Specify organism names: (2nd Organism Name )
Acinetobacter (Acinetobacter)
Actinomyces (Actinomyces)
Aspergillus Flavus (Aspergillus flavus)
Aspergillus Fumigatus (Aspergillus
fumigatus)
Aspergillus Niger (Aspergillus niger)
Aspergillus Not Otherwise Specified
(Aspergillus, NOS)
Bacillus (Bacillus)
Bacteroides (Bacteroides (gracillis,
uniformis, vulgaris, other species))
Bordetella Pertussis (Bordetella
pertussis (whooping cough))
Borrelia Burgdorferi (Borrelia (lyme
disease))
Moraxella Catarrhalis (Branhamella or
Moraxella catarrhalis (other species))
Campylobacter (Campylobacter (all
species))
Candida Glabrata (Candida (Torulopsis)
glabrata)
Candida Albicans (Candida albicans)
Pichia Guilliermondii (Candida
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guillermondi)
Issatchenkia Orientalis (Candida krusei)
Clavispora Lusitaniae (Candida
lusitaniae)
Candida Parapsilosis (Candida
parapsilosis)
Candida Tropicalis (Candida tropicalis)
Candida Not Otherwise Specified
(Candida, NOS)
Capnocytophaga (Capnocytophaga)
Chlamydophila Pneumoniae (Chlamydia
(pneumoniae))
Chlamydia Not Otherwise Specified
(Chlamydia, NOS)
Citrobacter (Citrobacter (freundii, other
species))
Clostridium (Clostridium (all species
except difficile))
Clostridium Difficile (Clostridium difficile)
Corynebacterium (Corynebacterium (all
non-diptheria species))
Corynebacterium Jeikeium
(Corynebacterium (jeikeium))
Coxiella (Coxiella)
Cryptococcosis (Cryptococcosus
species)
Enterobacter (Enterobacter)
Enterococcus (Enterococcus (all
species))
Vancomycin Resistant Enterococcus
(Enterococcus, vancomycin resistant
(VRE))
Escherichia Coli (Escherichia (also E.
coli))
Pseudomonas Oryzihabitans
(Flavimonas oryzihabitans)
Flavobacterium (Flavobacterium)
Fusarium (Fusarium species)
Fusobacterium (Fusobacterium)
Haemophilus (Haemophilus (all species,
including influenzae))
Helicobacter Pylori (Helicobacter pylori)
Histoplasmosis (Histoplasmosis)
Klebsiella (Klebsiella)
Lactobacillus (Lactobacillus (bulgaricus,
acidophilus, other species))
Legionella (Legionella)
Leptospira (Leptospira)
C76356 (Leptotrichia buccalis)
Leuconostoc (Leuconostoc (all species))
Listeria (Listeria)
Methylobacterium (Methylobacterium)
Micrococcus Not Otherwise Specified
(Micrococcus, NOS)
Zygomycosis (Mucormycosis)
Multiple Bacteria (Multiple bacteria at a
single site)
Mycobacterium Avium Complex
(Mycobacterium avium - intracellulare
(MAC, MAI))
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Mycobacterium Species (Mycobacterium
species (cheloneae, fortuitum,
haemophilum, kansasii, mucogenicum))
Mycobacterium Tuberculosis
(Mycobacterium tuberculosis
(tuberculosis, Koch bacillus))
Mycobacterium Not Otherwise Specified
(Mycobacterium, NOS)
Mycoplasma (Mycoplasma)
Neisseria (Neisseria (gonorrhoeae,
meningitidis, other species))
Nocardia (Nocardia)
Other Aspergillus (Other Aspergillus)
Other Bacteria (Other bacteria)
Other Candida (Other Candida)
Other Chlamydia (Other chlamydia)
Other Fungi (Other fungus)
Other Mycobacterium (Other
mycobacterium)
Pasteurella Multocida (Pasteurella
multocida)
Pneumocystis Pneumonia
(Pneumocystis (PCP / PJP))
Propionibacterium Acnes
(Propionibacterium (acnes, avidum,
granulosum, other species))
Proteus (Proteus)
Pseudomonas (Pseudomonas (all
species except cepacia & maltophilia))
Burkholderia Cepacia (Pseudomonas or
Burkholder cepacia)
Stenotrophomonas Maltophilia
(Pseudomonas or Stenotrophomonas or
Xanthomonas maltophilia)
Rhizopus (Rhizopus)
Rhodococcus (Rhodococcus)
Rickettsia (Rickettsia)
Salmonella (Salmonella (all species))
Serratia Marcescens (Serratia
marcescens)
Shigella (Shigella)
Staphylococcus Aureus (Staphylococcus
aureus)
Staphylococcus Coag Negative
(Staphylococcus, coagulase negative)
Streptococcus Not Otherwise Specified
(Staphylococcus, NOS)
Rothia Mucilaginosa (Stomatococcus
mucilaginosis)
Streptococcus (Streptococcus (all
species except Enterococcus))
Streptococcus Pneumoniae
(Streptococcus pneumoniae)
Suspected Atypical Bacteria Infection
(Suspected atypical bacterial infection)
Suspected Bacteria Infection (Suspected
bacterial infection)
Suspected Fungal Infection (Suspected
fungal infection)
Treponema (Treponema (syphilis))
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Vibrio (Vibrio (all species))
Yeast Not Otherwise Specified (Yeast,
NOS)
Zygomycota Not Otherwise Specified
(Zygomycetes, NOS)
Specify organism names: (3rd Organism Name )
Acinetobacter (Acinetobacter)
Actinomyces (Actinomyces)
Aspergillus Flavus (Aspergillus flavus)
Aspergillus Fumigatus (Aspergillus
fumigatus)
Aspergillus Niger (Aspergillus niger)
Aspergillus Not Otherwise Specified
(Aspergillus, NOS)
Bacillus (Bacillus)
Bacteroides (Bacteroides (gracillis,
uniformis, vulgaris, other species))
Bordetella Pertussis (Bordetella
pertussis (whooping cough))
Borrelia Burgdorferi (Borrelia (lyme
disease))
Moraxella Catarrhalis (Branhamella or
Moraxella catarrhalis (other species))
Campylobacter (Campylobacter (all
species))
Candida Glabrata (Candida (Torulopsis)
glabrata)
Candida Albicans (Candida albicans)
Pichia Guilliermondii (Candida
guillermondi)
Issatchenkia Orientalis (Candida krusei)
Clavispora Lusitaniae (Candida
lusitaniae)
Candida Parapsilosis (Candida
parapsilosis)
Candida Tropicalis (Candida tropicalis)
Candida Not Otherwise Specified
(Candida, NOS)
Capnocytophaga (Capnocytophaga)
Chlamydophila Pneumoniae (Chlamydia
(pneumoniae))
Chlamydia Not Otherwise Specified
(Chlamydia, NOS)
Citrobacter (Citrobacter (freundii, other
species))
Clostridium (Clostridium (all species
except difficile))
Clostridium Difficile (Clostridium difficile)
Corynebacterium (Corynebacterium (all
non-diptheria species))
Corynebacterium Jeikeium
(Corynebacterium (jeikeium))
Coxiella (Coxiella)
Cryptococcosis (Cryptococcosus
species)
Enterobacter (Enterobacter)
Enterococcus (Enterococcus (all
species))
Vancomycin Resistant Enterococcus
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(Enterococcus, vancomycin resistant
(VRE))
Escherichia Coli (Escherichia (also E.
coli))
Pseudomonas Oryzihabitans
(Flavimonas oryzihabitans)
Flavobacterium (Flavobacterium)
Fusarium (Fusarium species)
Fusobacterium (Fusobacterium)
Haemophilus (Haemophilus (all species,
including influenzae))
Helicobacter Pylori (Helicobacter pylori)
Histoplasmosis (Histoplasmosis)
Klebsiella (Klebsiella)
Lactobacillus (Lactobacillus (bulgaricus,
acidophilus, other species))
Legionella (Legionella)
Leptospira (Leptospira)
C76356 (Leptotrichia buccalis)
Leuconostoc (Leuconostoc (all species))
Listeria (Listeria)
Methylobacterium (Methylobacterium)
Micrococcus Not Otherwise Specified
(Micrococcus, NOS)
Zygomycosis (Mucormycosis)
Multiple Bacteria (Multiple bacteria at a
single site)
Mycobacterium Avium Complex
(Mycobacterium avium - intracellulare
(MAC, MAI))
Mycobacterium Species (Mycobacterium
species (cheloneae, fortuitum,
haemophilum, kansasii, mucogenicum))
Mycobacterium Tuberculosis
(Mycobacterium tuberculosis
(tuberculosis, Koch bacillus))
Mycobacterium Not Otherwise Specified
(Mycobacterium, NOS)
Mycoplasma (Mycoplasma)
Neisseria (Neisseria (gonorrhoeae,
meningitidis, other species))
Nocardia (Nocardia)
Other Aspergillus (Other Aspergillus)
Other Bacteria (Other bacteria)
Other Candida (Other Candida)
Other Chlamydia (Other chlamydia)
Other Fungi (Other fungus)
Other Mycobacterium (Other
mycobacterium)
Pasteurella Multocida (Pasteurella
multocida)
Pneumocystis Pneumonia
(Pneumocystis (PCP / PJP))
Propionibacterium Acnes
(Propionibacterium (acnes, avidum,
granulosum, other species))
Proteus (Proteus)
Pseudomonas (Pseudomonas (all
species except cepacia & maltophilia))
Burkholderia Cepacia (Pseudomonas or
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Burkholder cepacia)
Stenotrophomonas Maltophilia
(Pseudomonas or Stenotrophomonas or
Xanthomonas maltophilia)
Rhizopus (Rhizopus)
Rhodococcus (Rhodococcus)
Rickettsia (Rickettsia)
Salmonella (Salmonella (all species))
Serratia Marcescens (Serratia
marcescens)
Shigella (Shigella)
Staphylococcus Aureus (Staphylococcus
aureus)
Staphylococcus Coag Negative
(Staphylococcus, coagulase negative)
Streptococcus Not Otherwise Specified
(Staphylococcus, NOS)
Rothia Mucilaginosa (Stomatococcus
mucilaginosis)
Streptococcus (Streptococcus (all
species except Enterococcus))
Streptococcus Pneumoniae
(Streptococcus pneumoniae)
Suspected Atypical Bacteria Infection
(Suspected atypical bacterial infection)
Suspected Bacteria Infection (Suspected
bacterial infection)
Suspected Fungal Infection (Suspected
fungal infection)
Treponema (Treponema (syphilis))
Vibrio (Vibrio (all species))
Yeast Not Otherwise Specified (Yeast,
NOS)
Zygomycota Not Otherwise Specified
(Zygomycetes, NOS)
Specify organism names: (4th Organism Name )
Acinetobacter (Acinetobacter)
Actinomyces (Actinomyces)
Aspergillus Flavus (Aspergillus flavus)
Aspergillus Fumigatus (Aspergillus
fumigatus)
Aspergillus Niger (Aspergillus niger)
Aspergillus Not Otherwise Specified
(Aspergillus, NOS)
Bacillus (Bacillus)
Bacteroides (Bacteroides (gracillis,
uniformis, vulgaris, other species))
Bordetella Pertussis (Bordetella
pertussis (whooping cough))
Borrelia Burgdorferi (Borrelia (lyme
disease))
Moraxella Catarrhalis (Branhamella or
Moraxella catarrhalis (other species))
Campylobacter (Campylobacter (all
species))
Candida Glabrata (Candida (Torulopsis)
glabrata)
Candida Albicans (Candida albicans)
Pichia Guilliermondii (Candida
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guillermondi)
Issatchenkia Orientalis (Candida krusei)
Clavispora Lusitaniae (Candida
lusitaniae)
Candida Parapsilosis (Candida
parapsilosis)
Candida Tropicalis (Candida tropicalis)
Candida Not Otherwise Specified
(Candida, NOS)
Capnocytophaga (Capnocytophaga)
Chlamydophila Pneumoniae (Chlamydia
(pneumoniae))
Chlamydia Not Otherwise Specified
(Chlamydia, NOS)
Citrobacter (Citrobacter (freundii, other
species))
Clostridium (Clostridium (all species
except difficile))
Clostridium Difficile (Clostridium difficile)
Corynebacterium (Corynebacterium (all
non-diptheria species))
Corynebacterium Jeikeium
(Corynebacterium (jeikeium))
Coxiella (Coxiella)
Cryptococcosis (Cryptococcosus
species)
Enterobacter (Enterobacter)
Enterococcus (Enterococcus (all
species))
Vancomycin Resistant Enterococcus
(Enterococcus, vancomycin resistant
(VRE))
Escherichia Coli (Escherichia (also E.
coli))
Pseudomonas Oryzihabitans
(Flavimonas oryzihabitans)
Flavobacterium (Flavobacterium)
Fusarium (Fusarium species)
Fusobacterium (Fusobacterium)
Haemophilus (Haemophilus (all species,
including influenzae))
Helicobacter Pylori (Helicobacter pylori)
Histoplasmosis (Histoplasmosis)
Klebsiella (Klebsiella)
Lactobacillus (Lactobacillus (bulgaricus,
acidophilus, other species))
Legionella (Legionella)
Leptospira (Leptospira)
C76356 (Leptotrichia buccalis)
Leuconostoc (Leuconostoc (all species))
Listeria (Listeria)
Methylobacterium (Methylobacterium)
Micrococcus Not Otherwise Specified
(Micrococcus, NOS)
Zygomycosis (Mucormycosis)
Multiple Bacteria (Multiple bacteria at a
single site)
Mycobacterium Avium Complex
(Mycobacterium avium - intracellulare
(MAC, MAI))
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Mycobacterium Species (Mycobacterium
species (cheloneae, fortuitum,
haemophilum, kansasii, mucogenicum))
Mycobacterium Tuberculosis
(Mycobacterium tuberculosis
(tuberculosis, Koch bacillus))
Mycobacterium Not Otherwise Specified
(Mycobacterium, NOS)
Mycoplasma (Mycoplasma)
Neisseria (Neisseria (gonorrhoeae,
meningitidis, other species))
Nocardia (Nocardia)
Other Aspergillus (Other Aspergillus)
Other Bacteria (Other bacteria)
Other Candida (Other Candida)
Other Chlamydia (Other chlamydia)
Other Fungi (Other fungus)
Other Mycobacterium (Other
mycobacterium)
Pasteurella Multocida (Pasteurella
multocida)
Pneumocystis Pneumonia
(Pneumocystis (PCP / PJP))
Propionibacterium Acnes
(Propionibacterium (acnes, avidum,
granulosum, other species))
Proteus (Proteus)
Pseudomonas (Pseudomonas (all
species except cepacia & maltophilia))
Burkholderia Cepacia (Pseudomonas or
Burkholder cepacia)
Stenotrophomonas Maltophilia
(Pseudomonas or Stenotrophomonas or
Xanthomonas maltophilia)
Rhizopus (Rhizopus)
Rhodococcus (Rhodococcus)
Rickettsia (Rickettsia)
Salmonella (Salmonella (all species))
Serratia Marcescens (Serratia
marcescens)
Shigella (Shigella)
Staphylococcus Aureus (Staphylococcus
aureus)
Staphylococcus Coag Negative
(Staphylococcus, coagulase negative)
Streptococcus Not Otherwise Specified
(Staphylococcus, NOS)
Rothia Mucilaginosa (Stomatococcus
mucilaginosis)
Streptococcus (Streptococcus (all
species except Enterococcus))
Streptococcus Pneumoniae
(Streptococcus pneumoniae)
Suspected Atypical Bacteria Infection
(Suspected atypical bacterial infection)
Suspected Bacteria Infection (Suspected
bacterial infection)
Suspected Fungal Infection (Suspected
fungal infection)
Treponema (Treponema (syphilis))
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Vibrio (Vibrio (all species))
Yeast Not Otherwise Specified (Yeast,
NOS)
Zygomycota Not Otherwise Specified
(Zygomycetes, NOS)
Specify organism names: (5th Organism Name )
Acinetobacter (Acinetobacter)
Actinomyces (Actinomyces)
Aspergillus Flavus (Aspergillus flavus)
Aspergillus Fumigatus (Aspergillus
fumigatus)
Aspergillus Niger (Aspergillus niger)
Aspergillus Not Otherwise Specified
(Aspergillus, NOS)
Bacillus (Bacillus)
Bacteroides (Bacteroides (gracillis,
uniformis, vulgaris, other species))
Bordetella Pertussis (Bordetella
pertussis (whooping cough))
Borrelia Burgdorferi (Borrelia (lyme
disease))
Moraxella Catarrhalis (Branhamella or
Moraxella catarrhalis (other species))
Campylobacter (Campylobacter (all
species))
Candida Glabrata (Candida (Torulopsis)
glabrata)
Candida Albicans (Candida albicans)
Pichia Guilliermondii (Candida
guillermondi)
Issatchenkia Orientalis (Candida krusei)
Clavispora Lusitaniae (Candida
lusitaniae)
Candida Parapsilosis (Candida
parapsilosis)
Candida Tropicalis (Candida tropicalis)
Candida Not Otherwise Specified
(Candida, NOS)
Capnocytophaga (Capnocytophaga)
Chlamydophila Pneumoniae (Chlamydia
(pneumoniae))
Chlamydia Not Otherwise Specified
(Chlamydia, NOS)
Citrobacter (Citrobacter (freundii, other
species))
Clostridium (Clostridium (all species
except difficile))
Clostridium Difficile (Clostridium difficile)
Corynebacterium (Corynebacterium (all
non-diptheria species))
Corynebacterium Jeikeium
(Corynebacterium (jeikeium))
Coxiella (Coxiella)
Cryptococcosis (Cryptococcosus
species)
Enterobacter (Enterobacter)
Enterococcus (Enterococcus (all
species))
Vancomycin Resistant Enterococcus
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(Enterococcus, vancomycin resistant
(VRE))
Escherichia Coli (Escherichia (also E.
coli))
Pseudomonas Oryzihabitans
(Flavimonas oryzihabitans)
Flavobacterium (Flavobacterium)
Fusarium (Fusarium species)
Fusobacterium (Fusobacterium)
Haemophilus (Haemophilus (all species,
including influenzae))
Helicobacter Pylori (Helicobacter pylori)
Histoplasmosis (Histoplasmosis)
Klebsiella (Klebsiella)
Lactobacillus (Lactobacillus (bulgaricus,
acidophilus, other species))
Legionella (Legionella)
Leptospira (Leptospira)
C76356 (Leptotrichia buccalis)
Leuconostoc (Leuconostoc (all species))
Listeria (Listeria)
Methylobacterium (Methylobacterium)
Micrococcus Not Otherwise Specified
(Micrococcus, NOS)
Zygomycosis (Mucormycosis)
Multiple Bacteria (Multiple bacteria at a
single site)
Mycobacterium Avium Complex
(Mycobacterium avium - intracellulare
(MAC, MAI))
Mycobacterium Species (Mycobacterium
species (cheloneae, fortuitum,
haemophilum, kansasii, mucogenicum))
Mycobacterium Tuberculosis
(Mycobacterium tuberculosis
(tuberculosis, Koch bacillus))
Mycobacterium Not Otherwise Specified
(Mycobacterium, NOS)
Mycoplasma (Mycoplasma)
Neisseria (Neisseria (gonorrhoeae,
meningitidis, other species))
Nocardia (Nocardia)
Other Aspergillus (Other Aspergillus)
Other Bacteria (Other bacteria)
Other Candida (Other Candida)
Other Chlamydia (Other chlamydia)
Other Fungi (Other fungus)
Other Mycobacterium (Other
mycobacterium)
Pasteurella Multocida (Pasteurella
multocida)
Pneumocystis Pneumonia
(Pneumocystis (PCP / PJP))
Propionibacterium Acnes
(Propionibacterium (acnes, avidum,
granulosum, other species))
Proteus (Proteus)
Pseudomonas (Pseudomonas (all
species except cepacia & maltophilia))
Burkholderia Cepacia (Pseudomonas or
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Burkholder cepacia)
Stenotrophomonas Maltophilia
(Pseudomonas or Stenotrophomonas or
Xanthomonas maltophilia)
Rhizopus (Rhizopus)
Rhodococcus (Rhodococcus)
Rickettsia (Rickettsia)
Salmonella (Salmonella (all species))
Serratia Marcescens (Serratia
marcescens)
Shigella (Shigella)
Staphylococcus Aureus (Staphylococcus
aureus)
Staphylococcus Coag Negative
(Staphylococcus, coagulase negative)
Streptococcus Not Otherwise Specified
(Staphylococcus, NOS)
Rothia Mucilaginosa (Stomatococcus
mucilaginosis)
Streptococcus (Streptococcus (all
species except Enterococcus))
Streptococcus Pneumoniae
(Streptococcus pneumoniae)
Suspected Atypical Bacteria Infection
(Suspected atypical bacterial infection)
Suspected Bacteria Infection (Suspected
bacterial infection)
Suspected Fungal Infection (Suspected
fungal infection)
Treponema (Treponema (syphilis))
Vibrio (Vibrio (all species))
Yeast Not Otherwise Specified (Yeast,
NOS)
Zygomycota Not Otherwise Specified
(Zygomycetes, NOS)
Specify organism names: (6th Organism Name )
Acinetobacter (Acinetobacter)
Actinomyces (Actinomyces)
Aspergillus Flavus (Aspergillus flavus)
Aspergillus Fumigatus (Aspergillus
fumigatus)
Aspergillus Niger (Aspergillus niger)
Aspergillus Not Otherwise Specified
(Aspergillus, NOS)
Bacillus (Bacillus)
Bacteroides (Bacteroides (gracillis,
uniformis, vulgaris, other species))
Bordetella Pertussis (Bordetella
pertussis (whooping cough))
Borrelia Burgdorferi (Borrelia (lyme
disease))
Moraxella Catarrhalis (Branhamella or
Moraxella catarrhalis (other species))
Campylobacter (Campylobacter (all
species))
Candida Glabrata (Candida (Torulopsis)
glabrata)
Candida Albicans (Candida albicans)
Pichia Guilliermondii (Candida
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guillermondi)
Issatchenkia Orientalis (Candida krusei)
Clavispora Lusitaniae (Candida
lusitaniae)
Candida Parapsilosis (Candida
parapsilosis)
Candida Tropicalis (Candida tropicalis)
Candida Not Otherwise Specified
(Candida, NOS)
Capnocytophaga (Capnocytophaga)
Chlamydophila Pneumoniae (Chlamydia
(pneumoniae))
Chlamydia Not Otherwise Specified
(Chlamydia, NOS)
Citrobacter (Citrobacter (freundii, other
species))
Clostridium (Clostridium (all species
except difficile))
Clostridium Difficile (Clostridium difficile)
Corynebacterium (Corynebacterium (all
non-diptheria species))
Corynebacterium Jeikeium
(Corynebacterium (jeikeium))
Coxiella (Coxiella)
Cryptococcosis (Cryptococcosus
species)
Enterobacter (Enterobacter)
Enterococcus (Enterococcus (all
species))
Vancomycin Resistant Enterococcus
(Enterococcus, vancomycin resistant
(VRE))
Escherichia Coli (Escherichia (also E.
coli))
Pseudomonas Oryzihabitans
(Flavimonas oryzihabitans)
Flavobacterium (Flavobacterium)
Fusarium (Fusarium species)
Fusobacterium (Fusobacterium)
Haemophilus (Haemophilus (all species,
including influenzae))
Helicobacter Pylori (Helicobacter pylori)
Histoplasmosis (Histoplasmosis)
Klebsiella (Klebsiella)
Lactobacillus (Lactobacillus (bulgaricus,
acidophilus, other species))
Legionella (Legionella)
Leptospira (Leptospira)
C76356 (Leptotrichia buccalis)
Leuconostoc (Leuconostoc (all species))
Listeria (Listeria)
Methylobacterium (Methylobacterium)
Micrococcus Not Otherwise Specified
(Micrococcus, NOS)
Zygomycosis (Mucormycosis)
Multiple Bacteria (Multiple bacteria at a
single site)
Mycobacterium Avium Complex
(Mycobacterium avium - intracellulare
(MAC, MAI))
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Mycobacterium Species (Mycobacterium
species (cheloneae, fortuitum,
haemophilum, kansasii, mucogenicum))
Mycobacterium Tuberculosis
(Mycobacterium tuberculosis
(tuberculosis, Koch bacillus))
Mycobacterium Not Otherwise Specified
(Mycobacterium, NOS)
Mycoplasma (Mycoplasma)
Neisseria (Neisseria (gonorrhoeae,
meningitidis, other species))
Nocardia (Nocardia)
Other Aspergillus (Other Aspergillus)
Other Bacteria (Other bacteria)
Other Candida (Other Candida)
Other Chlamydia (Other chlamydia)
Other Fungi (Other fungus)
Other Mycobacterium (Other
mycobacterium)
Pasteurella Multocida (Pasteurella
multocida)
Pneumocystis Pneumonia
(Pneumocystis (PCP / PJP))
Propionibacterium Acnes
(Propionibacterium (acnes, avidum,
granulosum, other species))
Proteus (Proteus)
Pseudomonas (Pseudomonas (all
species except cepacia & maltophilia))
Burkholderia Cepacia (Pseudomonas or
Burkholder cepacia)
Stenotrophomonas Maltophilia
(Pseudomonas or Stenotrophomonas or
Xanthomonas maltophilia)
Rhizopus (Rhizopus)
Rhodococcus (Rhodococcus)
Rickettsia (Rickettsia)
Salmonella (Salmonella (all species))
Serratia Marcescens (Serratia
marcescens)
Shigella (Shigella)
Staphylococcus Aureus (Staphylococcus
aureus)
Staphylococcus Coag Negative
(Staphylococcus, coagulase negative)
Streptococcus Not Otherwise Specified
(Staphylococcus, NOS)
Rothia Mucilaginosa (Stomatococcus
mucilaginosis)
Streptococcus (Streptococcus (all
species except Enterococcus))
Streptococcus Pneumoniae
(Streptococcus pneumoniae)
Suspected Atypical Bacteria Infection
(Suspected atypical bacterial infection)
Suspected Bacteria Infection (Suspected
bacterial infection)
Suspected Fungal Infection (Suspected
fungal infection)
Treponema (Treponema (syphilis))
31 / 39
Treatment - 2006 Revision 2 - Hematopoietic Stem Cell Transplant
(HSCT) Infusion - 2914060v1.0
Vibrio (Vibrio (all species))
Yeast Not Otherwise Specified (Yeast,
NOS)
Zygomycota Not Otherwise Specified
(Zygomycetes, NOS)
If codes 198, 209, 219, or 259, specify organism:
(Answer only if the value for 2784429,
2784431,2784433,2784435,2784437 and
2784439 is "Other bacteria, specify","Other
Candida, specify",Other Aspergillus, specify" or
"Other fungus, specify".)
Product Infusion
Was more than one product infused? (e.g.,
marrow and PBSC,PBSC and cord blood, two
different cords, etc.)
No (No)
Yes (Yes)
Was the product infusion described on this insert
intended to produce hematopoietic engraftment?
No (No)
Yes (Yes)
Date of this product infusion:
Time product infusion initiated (24-hour clock):
Is it the standard time or daylight savings time?
Daylight Savings Time (Daylight Savings
Time)
Standard Time (Standard time)
Time product infusion completed (24-hour clock):
Is it the standard time or daylight savings time?
Daylight Savings Time (Daylight Savings
Time)
Standard Time (Standard time)
Total volume of product plus additives infused:
(One decimal place with Unit of Measure "ml")
Specify the route of product infusion:
Intramedullary Route Of Administration
(Intramedullary)
Intraperitoneal Route Of Administration
(Intraperitoneal)
Intravenous Route Of Administration
(Intravenous)
Other Route Of Administration (Other
route of infusion)
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Specify route of infusion:
Did the volume of infused product include any
added agents?
No (No)
Yes (Yes)
Product Infusion - Part 2 / 3
What kind of additives are included in volume of
infused product?
Acid-citrate-dextrose (Acid-Citrate-
Dextrose (ACD))
Albumin (Albumin)
Antibiotic (Antibiotic)
Dextran Sulfate Sodium (Dextran)
Heparin (Heparin)
Other (Other)
Were particular additives included in volume of
infused product?
No (No)
Yes (Yes)
Specify agent: (Answer only if the value for
2740356 is "Other")
Product Infusion
Was the entire volume of product infused?
No (No)
Yes (Yes)
Specify what happened to the reserved portion:
Cryopreservation (Cryopreserved for
future use)
Destruction (Discarded)
Other Endpoints (Other fate)
Specify: (Answer only if the value for 2769592 is
"Other fate")
Were there any adverse events or incidents
associated with the stem cell infusion? (The
question refers to all stem cell products except for
autologous marrow or autologous PBSC
products.)
No (No)
Yes (Yes)
Product Infusion
What type of Adverse Events associated with the
stem cell infusion?
Bradycardia (Brachycardia)
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Chest Pain (Chest tightness/pain)
At Infusion Time Chills (Chills at time of
infusion)
Fever > 103 F Within 24 Hours Of
Infusion (Fever greater than 103 F within
24 hours of infusion)
Fever <= 103 F Within 24 Hours Of
Infusion (Fever less than or equal to 103
F within 24 hours of infusion)
Whole Hemoglobinuria (Gross
hemoglobinuria)
Headache (Headache)
Urticaria (Hives)
Hypertension (Hypertension)
Hypotension (Hypotension)
Required Oxygen Hypoxia (Hypoxia
requiring oxygen(O2) support)
Nausea (Nausea)
Other Expected Adverse Event (Other
expected AE)
Other Unexpected Adverse Event (Other
unexpected AE)
Ctcae Grade 1 Rigors And Chills (Rigors,
mild)
Ctcae Grade 3 Rigors And Chills (Rigors,
severe)
Dyspnea (Shortness of breath(SOB))
Tachycardia (Tachycardia)
Vomiting (Vomiting)
Did a particular stem cell infusion associated
adverse event occur?
No (No)
Yes (Yes)
Did particular adverse events require medical
intervention?
No (No)
Yes (Yes)
Were particular adverse events resolved?
No (No)
Yes (Yes)
Specify (Answer only if the value for 2739534 is
"Other expected AE" or "Other unexpected AE")
Product Infusion
In the Medical Director's judgement, was the
adverse event a direct result of the infusion?
No (No)
Yes (Yes)
Specify the most likely cause of the adverse
event :
Medication Reaction (Drug reaction)
Other Diseases And Disorders (Other
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illness)
Other Reason (Other reason)
Hematopoietic Stem Cell Transplant
Reaction (Product reaction)
Relationship Regimen (Regimen related)
Specify illness: (Answer only if the value for
2769598 is "Other illness")
Specify reason: (Answer only if the value for
2769598 is "Other reason")
Donor Demographic Information
Was the donor ever pregnant? (Female donor
only)
No (No)
Not Applicable (Not Applicable)
Unknown (Unknown)
Yes (Yes)
Specify number of pregnancies: (Female donor
only)
What is the reason for the missing number of
pregnancies?
Unknown Not Applicable (Unknown/not
applicable)
Donor's blood type and Rh factor:
Blood Group A Rh Negative Blood Group
(A negative)
Blood Group A Rh Positive Blood Group
(A positive)
Blood Group Ab Rh Negative Blood
Group (AB negative)
Blood Group Ab Rh Positive Blood
Group (AB positive)
Blood Group B Rh Negative Blood Group
(B negative)
Blood Group B Rh Positive Blood Group
(B positive)
Blood Group O Rh Negative Blood
Group (O negative)
Blood Group O Rh Positive Blood Group
(O positive)
Unknown (unknown)
Did this donor have a central line placed?
No (No)
Not Applicable (Not Applicable)
Yes (Yes)
Specify the site of the central line placement:
Femoral Vein (Femoral)
Internal Jugular Vein (Internal jugular)
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Other Anatomic Site (Other site)
Subclavian Vein (Subclavian)
Specify site: (Answer only if the value for
2769666 is "Other site")
Donor's ethnicity:
A Person Of Mexican, Puerto Rican,
Cuban, Central Or South American Or
Other Spanish Culture Or Origin,
Regardless Of Race. (Hispanic or Latino)
A Person Not Meeting The Definition For
Hispanic Or Latino. (Not Hispanic or
Latino)
Could Not Be Determined Or Unsure
(Unknown)
Donor Demographic Information Part 2 / 2
Donor's race (Mark the groups in which the donor
is a member. Check all that apply )
African (African (both parents born in
Africa))
African American (African American)
Alaska Native (Alaskan Native or Aleut)
South Or Central American Indian
(American Indian, South or Central
America)
African Caribbean (Black Caribbean)
Black South Or Central American (Black
South or Central American)
Caribbean Indian (Caribbean Indian)
Chinese (Chinese)
Response Declined (Declines to provide
race)
Eastern European (Eastern European)
Filipino (Filipino (Pilipino))
Guamanian (Guamanian)
Hawaiian (Hawaiian)
Japanese (Japanese)
Korean (Korean)
Mediterranean (Mediterranean)
Middle Eastern (Middle Eastern)
North American (North American)
American Indian (North American Indian)
North Coast Of Africa (North Coast of
Africa)
Northern European (Northern European)
Other Native Hawaiian Or Other Pacific
Islander (Other Pacific Islander)
Other South Asian (Other Southeast
Asian)
Other White (Other White)
Unknown (Race unknown)
Samoan (Samoan)
South Asian (South Asian)
Vietnamese (Vietnamese)
Western European (Western European)
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White Caribbean (White Caribbean)
White South Or Central American (White
South or Central American)
Donor Demographic Information
What is the relationship of the donor to the
recipient?
Other Relative (Other relative)
Recipient Child (Recipient's child)
Sibling (Sibling)
Unrelated (Unrelated)
Specify the relationship of the donor to the
recipient: (Answer only if the value for 2784447 is
"Other relative")
Aunt (Aunt)
Cousin (Cousin)
Other Relative (Other relative)
Parent (Parent)
Uncle (Uncle)
Specify relationship: (Answer only if the value for
2728852 is "Other relative")
Was the donor / product tested for potentially
transplantable genetic diseases?
No (No)
Unknown (Unknown)
Yes (Yes)
Sickle cell anemia
No (No)
Yes (Yes)
Thalassemia
No (No)
Yes (Yes)
Other
No (No)
Yes (Yes)
Specify genetic disease: (Answer only if the value
for 2772022 is "Yes")
Was the donor hospitalized (inpatient) during or
after the collection? (Question applies only to
allogeneic non-NMDP donors)
No (No)
Yes (Yes)
Did the donor experience any life-threatening
complications during or after the collection?
(Question applies only to allogeneic non-NMDP
donors)
No (No)
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Yes (Yes)
Specify complications: (Question applies only to
allogeneic non-NMDP donors. Answer only if the
value of CDE 2728986 is "Yes".)
Did the donor receive blood transfusions as a
result of the collection? (Question applies only to
allogeneic non-NMDP donors)
No (No)
Yes (Yes)
Was the blood transfusion product autologous?
(Question applies only to allogeneic non-NMDP
donors )
No (No)
Yes (Yes)
Specify number of units: (For the autologous
blood transfusion)
Was the blood transfusion product allogeneic
(homologous)? (Question applies only to
allogeneic non-NMDP donors)
No (No)
Yes (Yes)
Specify number of units: (For the allogeneic
homologous blood transfusion)
Did the donor die as a result of the collection?
(Question applies only to allogeneic non-NMDP
donors)
No (No)
Yes (Yes)
Specify cause of death: (Question applies only to
allogeneic non-NMDP donors)
Did the recipient submit a research sample?
(Related donors only)
No (No)
Yes (Yes)
Research sample recipient ID: (Related donors
only)
Did the donor submit a research sample?
(Related donors only)
No (No)
Yes (Yes)
Research sample donor ID: (Related donors
only)
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Author Information
First Name
Last Name
Telephone number:
Fax number:
E-mail address:
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AMC-063 Protocol Deviation Form
(DEV)
Header Module
AMC Protocol Number
Date Protocol Deviation Occurred (mm/dd/yyyy)
Specify deviation
Protocol Deviation Information
Protocol Deviation Description (Reason for
deviation from the protocol)
Action Taken (What steps were taken to resolve
this deviation)
Is the protocol deviation associated with a
particular participant
No (no)
Yes (yes)
Participant ID
Did the protocol deviation result in an adverse
event
No (no)
Yes (yes)
Is the participant still being followed (will the
participant continue in the study)
No (no)
Yes (yes)
Participating Investigator or Physician Name
(printed investigator name)
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Breast Cancer DataMart Common
Data Elements Surgical Template
Pathologic Disease Classification
Tumor Laterality
Left (Left)
Right (Right)
Is the tumor inoperable or unresectable
No (No)
Yes (Yes)
Longest Diameter of Lesion(s)
Pathology: Assessment Of Lymph Nodes
Did the patient undergo lymph node biopsy prior
to preoperative systemic therapy
No (No)
Yes (Yes)
Date of lymph node biopsy
Method of Evaluation
Core Biopsy (Core biopsy)
Excisional Biopsy Or Lumpectomy
(Excisional biopsy or lumpectomy)
Excisional Biopsy With Frozen Section
(Excisional biopsy with frozen section)
Fine Needle Aspiration Biopsy (Fine
needle aspiration biopsy)
Incisional Biopsy (Incisional biopsy)
Skin Biopsy (Skin biopsy)
Was sentinel node sampling performed
No (No)
Unknown (Unknown)
Yes (Yes)
Sentinel Node Site (If yes,)
Axillary (Axillary)
Internal Mammary (Internal Mammary)
Supraclavicular (Supraclavicular)
Unknown (Unknown)
Number of Sentinel Nodes Examined (If yes,)
Sentinel Node Biopsy Date
Fine Needle Aspiration or Biopsy performed for
axillary lymph nodes
No (No)
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Yes (Yes)
Number of Lymph Nodes Examined (If yes,)
Date of Axillary Dissection
Is metastatic breast cancer present
No (No)
Yes (Yes)
Surgical Procedures
Surgery Site
Axilla (Axilla)
Breast (Breast)
Internal Mammary Lymph Node (Internal
Mammary Lymph Node)
Most extensive definitive surgery
Mastectomy, Nos (Mastectomy NOS)
None (None)
Partial Mastectomy, Lumpectomy Or
Excisional Biopsy (Partial
mastectomy/lumpectomy/excisional
biopsy)
Radical Mastectomy (Radical
Mastectomy)
Date of Most Extensive Primary Surgery
Did the patient undergo contralateral prophylactic
mastectomy (bilateral mastectomy)
No (No)
Yes (Yes)
Margins
Does the tumor involve the surgical margin
No (No)
Unknown (Unknown)
Yes (Yes)
Margin status, on final definitive surgery
Close (Close)
Negative (Negative)
Positive (Positive)
Margin information based on re-excision
No (No)
Yes (Yes)
Breast Reconstruction
Did the patient receive breast reconstruction
No (No)
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Yes (Yes)
Type of breast reconstruction
Breast Implant (Breast Implant)
Free Flap (Free Flap)
Tissue Flap (Tissue Flap)
Date of breast reconstruction
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Survival
Survival
Visit Date
Date of Death (Enter the date the patient has
died.)
Cause of Death (Categorize the cause as due
to:)
Infection (I)
Malignant Disease (M)
Other (O)
Toxicity From Protocol Treatment (T)
Explain 'Other' Cause of Death (Enter a succinct
description if option "Other" is selected as
presumed cause of death. For example:
Concurrent illness/MI".)
Autopsy Results Available? (Select an option
indicating whether the results of an autopsy are
available.)
No (N)
Unknown (U)
Yes (Y)
Cause of Death (Autopsy Finding) (If an autopsy
was performed and a cause of death was
determined at autopsy, it should be categorized
according to:)
Infection (I)
Malignant Disease (M)
Other (explain) (O)
Toxicity From Protocol Treatment (T)
Explain 'Other' Cause of Death (Autopsy Finding)
(If option "Other" is selected as autopsy finding
cause of death, enter a succinct description, i.e.,
MI.)
Sites of Disease (Autopsy Finding) (Select the
major sites of malignant disease involvement
found at the autopsy, i.e., heart, brain, lungs, etc.)
Abdomen (Abdomen)
Abdomen/pelvis (Abdomen/Pelvis)
Abdominal Wall (Abdominal wall)
Acetabulum (Acetabulum)
Pharyngeal Tonsil (Adenoid)
Adipose Tissue (Adipose)
Adrenal Gland (Adrenal gland)
Alveolar Ridge (Alveolar Ridge)
Amniotic Fluid (Amniotic Fluid)
Ampulla Of Vater (Ampulla of Vater)
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Anal Canal (Anal canal)
Anal Sphincter (Anal sphincter)
Ankle (Ankle)
Anorectum (Anorectum)
Antecubital Fossa (Antecubital fossa)
Antrum Pylori (Antrum)
Anus (Anus)
Aorta (Aorta)
Aortic Body (Aortic Body)
Appendix (Appendix)
Aqueous Fluid (Aqueous Fluid)
Arm (Arm)
Artery (Artery)
Ascending Colon (Ascending colon)
Ascending Colon Hepatic Flexure
(Ascending Colon Hepatic Flexure)
Auditory Canal (Auditory canal)
Autonomic Nervous System (Autonomic
nervous system)
Axilla (Axilla)
Back (Back)
Bile Duct (Bile duct)
Bladder (Bladder)
Blood (Blood)
Blood Vessel (Blood vessel)
Bone (Bone)
Bone Marrow (Bone marrow)
Bowel (Bowel)
Brain (Brain)
Brain Stem (Brain stem)
Breast (Breast)
Broad Ligament (Broad ligament)
Bronchiole (Bronchiole)
Bronchus (Bronchus)
Bronchus And Lung (Bronchus and
Lung)
Brow (Brow)
Buccal Cavity (Buccal cavity)
Buccal Mucosa (Buccal mucosa)
Buttock (Buttock)
Calf (Calf)
Capillary (Capillary)
Gastric Cardia (Cardia)
Carina (Carina)
Carotid Artery (Carotid artery)
Carotid Body (Carotid body)
Cartilage (Cartilage)
Cecum (Cecum)
Central Line Catheter (Central Line
Catheter)
Central Nervous System (Central
nervous system)
Cerebellum (Cerebellum)
Cerebral Cortex (Cerebral cortex)
Cerebrospinal Fluid (Cerebrospinal fluid)
Cerebrum (Cerebrum)
Cervical Spine (Cervical spine)
Cervical/thoracic/lumbar Spine
(Cervical/Thoracic/Lumbar spine)
Cervix (Cervix)
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Chest (Chest)
Chest Wall (Chest wall)
Chest/abdomen/pelvis
(Chest/Abdomen/Pelvis)
Chest/pelvis (Chest/Pelvis)
Chin (Chin)
Clavicle (Clavicle)
Clitoris (Clitoris)
Colon (Colon)
Colon And Rectum (Colon and rectum)
Colon Mucosa (Colon, mucosa only)
Common Duct (Common duct)
Conjunctiva (Conjunctiva)
Connective Tissue (Connective tissue)
Descending Colon (Descending colon)
Diaphragm (Diaphragm)
Duodenum (Duodenum)
Ear (Ear)
Ear Canal (Ear canal)
External Ear (Ear, Pinna (External))
Effusion (Effusion)
Elbow (Elbow)
Endocrine Gland (Endocrine gland)
Epididymis (Epididymis)
Epidural Spinal Canal Space (Epidural
space)
Esophagogastric Junction
(Esophagogastric junction)
Esophagus (Esophagus)
Esophageal Mucosa (Esophagus,
Mucosa only)
Extremities (Extremities)
Eye (Eye)
Fallopian Tube (Fallopian tube)
Femur (Femur)
Fibula (Fibula)
Finger (Finger)
Floor Of Mouth (Floor of Mouth)
Body Fluid Or Substance (Fluid)
Foot (Foot)
Forearm (Forearm)
Forehead (Forehead)
Foreskin (Foreskin)
Frontal Lobe (Frontal lobe)
Fundus Of Stomach (Fundus of
stomach)
Gallbladder (Gallbladder)
Ganglion (Ganglia)
Gastroesophageal Junction
(Gastroesophageal Junction)
Gastrointestinal Tract (Gastrointestinal
tract)
Genitourinary (Genitourinary)
Groin (Groin)
Gum (Gum)
Hand (Hand)
Hard Palate (Hard palate)
Head - Face Or Neck, Nos (Head - face
or neck, NOS)
Head/neck (Head/Neck)
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Head/neck/chest/adb/pelvis
(Head/Neck/Chest/Adb/Pelvis)
Heart (Heart)
Hepatic Duct (Hepatic duct)
Hip (Hip)
Humerus (Humerus)
Hypopharynx (Hypopharynx)
Ileum (Ileum)
Ilium (Ilium)
Intestine (Intestine)
Ischium (Ischium)
Jaw (Jaw)
Jejunum (Jejunum)
Joints (Joints)
Kidney (Kidney)
Knee (Knee)
Lacrimal Gland (Lacrimal Gland)
Large Bowel (Large bowel)
Laryngopharynx (Laryngopharynx)
Larynx (Larynx)
Leg (Leg)
Ligament (Ligament)
Lip (Lip)
Liver (Liver)
Liver And Intrahepatic Duct (Liver and
intrahepatic duct)
Liver/spleen (Liver/Spleen)
Lumbar Spine (Lumbar spine)
Lung (Lung)
Lymph Node (Lymph node)
Lymph Node(s) Axilla (Lymph Node(s)
Axilla)
Lymph Node(s) Cervical (Lymph Node(s)
Cervical)
Distant Lymph Node (Lymph node(s)
Distant)
Lymph Node(s) Hilar (Lymph Node(s)
Hilar)
Lymph Node(s) Inguinal (Lymph Node(s)
Inguinal)
Lymph Node(s) Int Mammary (Lymph
Node(s) Int Mammary)
Lymph Node(s) Mammary (Lymph
Node(s) Mammary)
Paraaortic Region Lymph Node (Lymph
node(s) Para aortic)
Lymph Node(s) Pelvic (Lymph Node(s)
Pelvic)
Regional Lymph Node (Lymph node(s)
Regional)
Scalene Lymph Node (Lymph node(s)
Scalene)
Lymph Node(s) Subclavicular (Lymph
Node(s) Subclavicular)
Lymph Node(s) Supraclav (Lymph
Node(s) Supraclav)
Lymph Nodes (Lymph nodes)
Mediastinal Lymph Node (Lymph
nodes(s) Mediastinal)
Lymphoma (Lymphoma)
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Mammary Gland (Mammary Gland)
Mandible (Mandible)
Maxilla (Maxilla)
Mediastinum (Mediastinum)
Mesentery (Mesentery)
Mesothelium (Mesothelium)
Mini Mantle (Mini Mantle)
Mouth (Mouth)
Muscle (Muscle)
Nail (Nails)
Nasal Cavity (Nasal Cavity)
Nasopharynx (Nasopharynx)
Neck (Neck)
Neck Chest (Neck/Chest)
Neck/chest/abdomen/pelvis
(Neck/Chest/Abdomen/Pelvis)
Nerve (Nerve)
Cranial Nerve (Nerve(s) Cranial)
Not Applicable (Not Applicable)
Ocular Orbits (Ocular Orbits)
Omentum (Omentum)
Oral Cavity (Oral cavity)
Oral Cavity Mucosa (Oral Cavity, Mucosa
only)
Oropharynx (Oropharynx)
Other (Other)
Ovary (Ovary)
Posterior Anterior/lateral (PA/Lat)
Palate (Palate)
Pancreas (Pancreas)
Paraspinal Ganglion (Paraspinal
Ganglion)
Parathyroid Gland (Parathyroid)
Parotid Gland (Parotid gland)
Patella (Patella)
Pelvis (Pelvis)
Penis (Penis)
Perianus (Perianus)
Pericardium (Pericardium)
Peritoneal Cavity (Peritoneal cavity)
Peritoneum (Peritoneum)
Pharynx (Pharynx)
Pineal Gland (Pineal Gland)
Pituitary Gland (Pituitary gland)
Placenta (Placenta)
Pleura (Pleura)
Popliteal Fossa (Popliteal fossa)
Prostate (Prostate)
Pylorus (Pylorus)
Rectosigmoid Junction (Rectosigmoid
Junction)
Rectum (Rectum)
Retina (Retina)
Retro-orbital Area (Retro-orbital Area)
Retroperitoneum (Retroperitoneum)
Ribs (Ribs)
Round Ligament (Round ligament)
Sacrum (Sacrum)
Salivary Gland (Salivary gland)
Scalp (Scalp)
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Scapula (Scapula)
Scrotum (Scrotum)
Shoulder Joint (Shoulder)
Sigmoid Colon (Sigmoid colon)
Sinus(es) (Sinus(es))
Sinus(es), Maxillary (Sinus(es),
Maxillary)
Skeletal Muscle Tissue (Skeletal Muscle)
Skin (Skin)
Skull (Skull)
Small Bowel Mucosa (Small Bowel,
Mucosa only)
Small Intestine (Small intestine)
Soft Tissue (Soft Tissue)
Spinal Cord (Spinal Cord)
Spine (Spine)
Spine/femur (Spine/Femur)
Spine/femur/radius
(Spine/Femur/Radius)
Spleen (Spleen)
Splenic Flexure (Splenic Flexure)
Sternum (Sternum)
Stomach (Stomach)
Stomach Mucosa (Stomach, Mucosa
only)
Subcutaneous Tissue (Subcutaneous
tissue)
Synovial Membrane (Synovium)
Tendon (Tendon)
Testis (Testicle)
Testicle (Testicle)
Thigh (Thigh)
Thoracic Spine (Thoracic spine)
Thoracic/lumbar Spine (Thoracic/Lumbar
spine)
Thorax (Thorax)
Throat (Throat)
Thymus (Thymus)
Thyroid Gland (Thyroid gland)
Tibia (Tibia)
Tongue (Tongue)
Tongue, Base Of Tongue (Tongue, Base
of tongue)
Tonsil (Tonsil)
Pharyngeal Tonsil (Tonsil, Pharyngeal)
Trachea (Trachea)
Trachea Main Bronchus (Trachea/Major
Bronchi)
Transverse Colon (Transverse Colon)
Trunk (Trunk)
Superficial Trunk (Trunk, Superficial)
Umbilical Cord (Umbilical Cord)
Upper Extremity (Upper extremity)
Ureter (Ureter)
Urethra (Urethra)
Urinary Tract (Urinary tract)
Uterus (Uterus)
Uvula (Uvula)
Vagina (Vagina)
Vas Deferens (Vas Deferens)
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Vein (Vein)
Vena Cava (Vena Cava,
Inferior/Superior)
Vertebra (Vertebra)
Vertebral Column (Vertebral column)
Vulva (Vulva)
Whole Body (Whole body)
Wrist (Wrist)
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Procurement Form - RF37
Ccrr Module For Procurement Form - Rf37
Patient Initials
Phone Number
Study Coordinator's Name
Other, Specify
Patient previously donated specimens to ACSB,
Indicate date
If specimens were not obtained for ACSB, please
indicate reason
Other, Specify (Other, Specify)
Patient had previously donated
specimens to ACSB. (Patient had
previously donated specimens to ACSB.)
Patient refused to give informed consent
for ACSB specimen donation (Patient
refused to give informed consent for
ACSB specimen donation)
Patient was not asked to consider ACSB
specimen donation (Patient was not
asked to consider ACSB specimen
donation)
ACSB site the specimen(s) shipped to
GWU (GWU)
OSU (OSU)
Other, Specify (Other, Specify)
SUNY/HSCB (SUNY/HSCB)
UCLA (UCLA)
UCSF (UCSF)
Types of specimens collected:
Other, Specify (Other, Specify)
PBMC (PBMC)
Plasma (Plasma)
Serum (Serum)
Tissue (Tissue)
Whole Blood (Whole Blood)
Specimen(s) obtained for donation to ACSB?
No (No)
Yes (Yes)
Date Specimen Obtained
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Cycle #
ID#
Site#
Study#
E-mail Address
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PATIENT IDENTIFICATION
Patient Identification
National Cancer Institute Institute Code
Patient Identifier
1 / 1
Nonneoplastic Condition NCT01057121 Treatment -
AMC-070 Interventions Form (RK5) - 3146870v1.0
Nonneoplastic Condition NCT01057121 Treatment - AMC-
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AMC-070 Interventions Form (RK5)
Header Module
Visit number
Unnamed1
Interventions for Oral Cavity Lesions
Local Anesthetic/analgesic (Local
anesthetic/analgesic)
Local Intervention To Ks Lesions (Local
intervention to KS lesions)
Other (Other)
Other, specify
Interventions for gastrointestinal (GI) lesions
Antiemetics (Antiemetics)
Blood Transfusion (Blood transfusions)
Other (Other)
Other, specify
Interventions for Pulmonary Lesions
Bronchodilators (Bronchodilators)
Cough Suppressant (Cough
suppressant)
Other (Other)
Oxygen (Oxygen)
Steroids (Steroids)
Other, specify
Interventions for Extremity Edema
Diuretic (Diuretics)
Other (Other)
Other, specify
Interventions for Periorbital Edema
Analgesics (Analgesics)
Local Therapy (Local therapy)
Other (Other)
Other, specify
Interventions for Scrotal/Genital Edema
Analgesics (Analgesics)
Other (Other)
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Other, specify
Interventions for Foot Kaposi's Sarcoma (KS)
Analgesics (Analgesics)
Other (Other)
Uses Cane, Wheelchair (Uses cane,
wheelchair)
Other, specify
Footer Module
Comments
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NCI Standard Enrollment Template
Mandatory
Study Participant Identifier (Enter the identifier
assigned to a participant.)
Enrollment Date (Enter the date the participant is
accepted into the study.)
Conditional Module
Treatment Arm (Enter the term that describes the
assigned treatment arm.)
Intergroup Participant Identifier (Enter the
identifier assigned to an intergroup clinical
protocol participant.)
Optional Participant Id Questions
Site Registrar
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PHYSICAL EXAM SCREEN
Physical Exam--screening
Evaluation Date
Body System Type
Abdomen (ABDOMEN)
Allergy Or Drug Sensitivity History
(Allergy/Drug Sensitivity)
Appearance (Appearance)
Body As A Whole (Body as a Whole)
Breasts (BREASTS)
Cardiovascular (CARDIOVASCULAR)
Central Nervous System (Central
Nervous System)
Chest (Chest)
Constitutional (Constitutional)
Dermatologic (DERMATOLOGIC)
Endocrine/metabolic
(ENDOCRINE/METABOLIC)
Extremities (Extremities)
Gastrointestinal (GASTROINTESTINAL)
Genitalia (GENITALIA)
Genitourinary (Genitourinary)
H/e/e/n/t (H/E/E/N/T)
Hematologic (HEMATOLOGIC)
Hematopoietic/lymph
(HEMATOPOIETIC/LYMPH)
Hepatic (Hepatic)
Immune (IMMUNE)
Integumentary/hair (Integumentary/Hair)
Musculoskeletal (MUSCULOSKELETAL)
Neck (NECK)
Neurologic (NEUROLOGIC)
Other (OTHER)
Pelvis (PELVIS)
Peripheral Vascular System (Peripheral
Vascular)
Psychologic (PSYCHOLOGIC)
Pulmonary (Pulmonary)
Rectal (Rectal)
Renal (Renal)
Reproductive History (Reproductive
History)
Respiratory (RESPIRATORY)
Spleen (Spleen)
Substance Abuse/dependency
(Substance abuse/Dependency)
Transfusion History (Transfusion History)
Urinary (URINARY)
Finding Results Indicator
Abnormal (A)
No Change (C)
Equivocal (E)
Negative (G)
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Improving (I)
Not Applicable (L)
Normal (N)
No Source Data (O)
Positive (P)
Stable (S)
Unstable (U)
Not Evaluable (V)
Worse (W)
Not Examined (X)
Comment Change From Baseline Text
Comments
Note Date
Research Comments Text
2 / 2
On-Study - PHYSICAL EXAM SCREEN - 2390964v1.0
Sarcoma NCT00450320 On-Study - AMC-051
Evaluation of KS Lesions Form (RK3) - 2636855v1.0
Sarcoma NCT00450320 On-Study - AMC-051 Evaluation
of KS Lesions Form (RK3) - 2636855v1.0
All rights reserved. Please visit https://medical-data-
models.org/forms/2843
AMC-051 Evaluation of KS Lesions
Form (RK3)
Header Module
Visit number
Unnamed1
Foot Kaposi's Sarcoma (KS)
Absent (Absent)
Present (Present)
Compared to Previous Evaluation
Better (Better)
Same (Same)
Worse (Worse)
Photos Taken (Documentation)
No (No)
Yes (Yes)
Photos Taken Date
Physical findings
No (No)
Yes (Yes)
Specify (If Yes,)
Unnamed2
Are there any oral cavity lesions present at this
evaluation (If NO, go to GI EVALUATION section)
No (No)
Not Evaluated (Not evaluated)
Yes (Yes)
Total Number Raised Lesions
Total Number Flat Lesions (which are countable
or measurable)
Photos Taken (Documentation)
No (No)
Yes (Yes)
Is non-measurable disease present?
No (No)
Yes (Yes)
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Photos Taken Date
Are oral symptoms related to Kaposi's Sarcoma
No (No)
No Symptom (No symptoms)
Yes (Yes)
Explain (If not,)
Oral Site
Buccal Mucosa (Buccal mucosa)
Floor Of Mouth (Floor of mouth)
Gingiva (Gingiva/gums)
Hard Palate (Hard palate)
Pharynx (Posterior pharynx)
Soft Palate (Soft palate)
Tongue (Tongue)
Tonsil (Tonsils)
Uvula (Uvula)
Kaposi's Sarcoma present
No (No)
Yes (Yes)
Oral lesions
A Resolution Of All Oral Lesions Since
Baseline (A resolution of all oral lesions
since baseline)
A Worsening Of Oral Lesions Since
Baseline Or Best Response (A
worsening of oral lesions since baseline
or best response)
An Improvement Of Oral Lesions Since
Baseline (An improvement of oral lesions
since baseline)
New Oral Lesions (New oral lesions)
None Of The Above (None of the above)
Unnamed3
Are there any gastrointestinal (GI) lesions present
at this evaluation (If NO, go to PULMONARY
EVALUATION section)
No (No)
Not Evaluated (Not evaluated)
Yes (Yes)
Are there gastrointestinal (GI) symptoms related
to Kaposi's Sarcoma
No (No)
Yes (Yes)
Explain (If not,)
Method of Evaluation
Endoscopy (Endoscopy)
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Sarcoma NCT00450320 On-Study - AMC-051 Evaluation of KS Lesions
Form (RK3) - 2636855v1.0
Radiology (Radiological)
Performed
No (No)
Yes (Yes)
Assessment Date (mm/dd/yyyy)
Findings
Unnamed4
Are there any pulmonary lesions present at this
evaluation (If NO, go to EDEMA EVALUATION
section)
No (No)
Not Evaluated (Not evaluated)
Yes (Yes)
Indicate if the lesions are measurable or non-
measurable
Both Measurable And Non-measurable
(Both Measurable and Non-measurable)
Measurable Disease (Measurable)
Non-measurable (Non-measurable)
Are the pulmonary symptoms related to Kaposi's
Sarcoma
No (No)
Yes (Yes)
Explain (If not,)
Method of Evaluation
Endoscopy (Endoscopy)
Radiology (Radiological)
Performed
No (No)
Yes (Yes)
Assessment Date (mm/dd/yyyy)
Pleural Effusion
No (NO)
Yes (YES)
Specify number of lesions
Total Number New Lesions
Lesion Measurements
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Form (RK3) - 2636855v1.0
Site of Lesion
Dimension 1 (cm)
Dimension 2 (cm)
Bronchoscopy And Other Tests
Bronchoscopy Performed
No (No)
Yes (Yes)
Date of Bronchoscopy
Findings
Any Other Tests Performed
No (No)
Yes (Yes)
Other Tests
Findings
Footer Module
Comments
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Sarcoma NCT00450320 On-Study - AMC-051 Evaluation of KS Lesions
Form (RK3) - 2636855v1.0
Sarcoma NCT01016730 Treatment - AMC-
063 Interventions Form (RK5) - 3020573v1.0
Sarcoma NCT01016730 Treatment - AMC-063
Interventions Form (RK5) - 3020573v1.0
All rights reserved. Please visit https://medical-data-
models.org/forms/2844
AMC-063 Interventions Form (RK5)
Header Module
Visit number
Unnamed1
Interventions for Oral Cavity Lesions
Local Anesthetic/analgesic (Local
anesthetic/analgesic)
Local Intervention To Ks Lesions (Local
intervention to KS lesions)
Other (Other)
Other, specify
Interventions for gastrointestinal (GI) lesions
Antiemetics (Antiemetics)
Blood Transfusion (Blood transfusions)
Other (Other)
Other, specify
Interventions for Pulmonary Lesions
Bronchodilators (Bronchodilators)
Cough Suppressant (Cough
suppressant)
Other (Other)
Oxygen (Oxygen)
Steroids (Steroids)
Other, specify
Interventions for Extremity Edema
Diuretic (Diuretics)
Other (Other)
Other, specify
Interventions for Periorbital Edema
Analgesics (Analgesics)
Local Therapy (Local therapy)
Other (Other)
Other, specify
Interventions for Scrotal/Genital Edema
Analgesics (Analgesics)
Other (Other)
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Other, specify
Interventions for Foot Kaposi's Sarcoma (KS)
Analgesics (Analgesics)
Other (Other)
Uses Cane, Wheelchair (Uses cane,
wheelchair)
Other, specify
Footer Module
Comments
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Sarcoma NCT01016730 Treatment - AMC-063 Interventions Form (RK5)
- 3020573v1.0
Pre-Study - PRIOR TREATMENT
SUMMARY - 2394184v1.0
Pre-Study - PRIOR TREATMENT SUMMARY -
2394184v1.0
All rights reserved. Please visit https://medical-data-
models.org/forms/2861
PRIOR TREATMENT SUMMARY
Comments
Therapy Type
Anti-retroviral Therapy (AR)
Antisense Therapy (AS)
Bone Marrow Transplantation (BM)
Chemotherapy, Nos (C)
Chemotherapy, Multiple Agents Systemic
(CM)
Single Agent Systemic Chemotherapy
(CS)
Extensive Radiation (ER)
Gene Transfer (G)
Hormone Therapy (H)
Hematopoietic Stem Cell Transplantation
(HE)
Immunotherapy (I)
Image Directed Local Therapy (ID)
Limited Radiation Therapy (LR)
No Prior Therapy (N)
Chemotherapy, Non-cytotoxic (NC)
Oncolytic Virotherapy (OV)
Prior Therapy (PT)
Radiation Therapy (R)
Surgery (S)
Vaccine Therapy (V)
Note Date
Research Comments Text
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Pharmacokinetics - 3281312v1.0
Pharmacokinetics - 3281312v1.0
All rights reserved. Please visit https://medical-data-
models.org/forms/2869
Pharmacokinetics
Pharmacokinetics
Visit Date (Enter the date the study agent
administration was started.)
Course Number
Day in Course (Cycle)
Study Agent (Enter the name of the study agent
investigational or commercial  which is the
subject of the pharmacokinetic study.)
Start Date (Enter the date the study agent
administration was started.)
Start Time (Enter the time the study agent
administration began.)
Stop Date (Enter the date the study agent
administration was stopped. - Note: This field will
be used for infusional therapies only.)
Stop Time (Enter the time the study agent
administration was stopped. - Note: This field will
be used for infusional therapies only.)
Specimen Sampled (Select the body fluid that is
being collected for the biological samples.)
Abdominal Effusion (Abdominal Effusion)
Pheresis Cell (Apheresis Cells)
Cerebrospinal Fluid (Cerebrospinal Fluid
(CSF))
Pericardial Effusion (Pericardial Effusion)
Peripheral Blood Mononuclear Cell
(Peripheral Blood Mononuclear Cells
(PBMC))
Plasma (Plasma)
Pleural Effusion (Pleural Effusion)
Saliva (Saliva)
Serum (Serum)
Tumor Tissue (Tumor Tissue)
Whole Blood (Whole Blood)
Sample ID Number (If the specimen acquisition
labeling process uses a bar code or similar
system, enter the unique sample identification
number for each of the planned interval time
points samples.)
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Planned Interval (Planned interval pre-
determined per protocol.)
Sample Collected?
No (No)
Unknown (Unknown)
Yes (Yes)
Actual Start Date (Enter the specimen collection
date.)
Actual Start Time (Enter the specimen collection
time.)
Actual Start Time (Enter the specimen collection
time.)
Parent Study Agent Assay 1 (Enter the results of
the parent assay for the study agent indicated in
the study agent field.)
Parent Study Agent Assay 1 (Enter the results of
the parent assay for the study agent indicated in
the study agent field.)
Parent Study Agent Assay Mean (Enter the
parent study agent assay mean concentration, if
available.)
Parent Study Agent Assay UOM (Select the
appropriate concentration units of measurement
for the parent study agent assays e.g.: mg/dL or
mmol/l.)
Percent (%)
10e10 Cells (10E10 Cells)
10e3 Cells (10E3 Cells)
10e4 Cells Per Kilogram (10E4 Cell/kg)
10e4 Cells (10E4 Cells)
10e5 Cells Per Kilogram (10E5 Cell/kg)
10e5 Cells (10E5 Cells)
10e6 Cells Per Kilogram (10E6 Cell/kg)
10e6 Cells (10E6 Cells)
10e7 Cells Per Kilogram (10E7 Cell/kg)
10e7 Cells (10E7 Cells)
10e7 Plaque Forming Units (10E7 PFU)
10e8 Cells (10E8 Cells)
10e8 Plaque Forming Units (10E8 PFU)
10e9 Cells (10E9 Cells)
10e9 Plaque Forming Units (10E9 PFU)
Ampule (Ampule)
Application (Applcatn)
Atomic Unit (au)
Area Under The Curve (AUC)
Billion Pfu (bill PFU)
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Bottle (Bottle)
Breaths Per Minute (BPM)
Capful (Capful)
Caplet (Caplet)
Capsule (Capsule)
Cells (Cells)
Cells Per Kilogram (Cells/kg)
Centigray (cGy)
Curie (Ci)
Course (Course)
Cycle (Course)
Deciliter (dL)
Dose (Dose)
Equivalent (Eq)
Grams (g) (g)
Gram Per M2 (g/m2)
Gallon (Gallon)
Drops (gtts)
Gray (Gy)
Hertz (Hz)
Inch (Inch)
Inhalation (Inhalatn)
Iu Vitamin A (IU Vit A)
International Unit Per Milligram (IU/mg)
International Units Or Milligram Alpha
Tocopherol (IU/mg A-TE)
International Unit (IUnit)
International Unit Per Kilogram (IUnit/kg)
International Unit Per Liter (IUnit/L)
Intravenous Bag (IV Bag)
Infectious Viral Replicon Particles (IVRP)
Joules Per Centimeter Squared (Jcm2)
Kib-electron Volt (KeV)
Kilograms (kg)
Kilohertz (kHz)
Kilopascal (kPa)
Kilounit (kU)
Kilounit Per Kilogram (kU/kg)
Kilounit Per Liter (kU/L)
Liter (L)
Liters Per Minute (L/min)
Millibecquerel (mBq)
Megabecquerel (MBq)
Microgram (mcg)
Microgram Per Centimeter Squared
(mcg/cm2)
Microgram Per Hour (mcg/hr)
Microgram Per Kilogram (mcg/kg)
Microgram Per Meter Squared (mcg/m2)
Millicurie (mCi)
Measure (Measure)
Milliequivalent (mEq)
Milliequivalents Per 24 Hours (mEq/24hr)
Milliequivalent Per Deciliter (mEq/dL)
Milliequivalent Per Hour (mEq/hr)
Milliequivalent Per Liter (mEq/L)
Million Electron Volt (MeV)
Milligram (mg)
Milligram Per 24 Hours (mg/24hr)
Milligram Per Deciliter (mg/dL)
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Milligram Per Hour (mg/hr)
Milligram Per Inhalation (mg/inh)
Milligram Per Kilogram (mg/kg)
Milligram Per Kilogram Per Day
(mg/kg/day)
Milligram Per Meter Squared (mg/m2)
Milligram Per Milliliter (mg/mL)
Milligram Per Week (mg/wk)
Megahertz (MHz)
Microcurie (microCi)
Microliter (microL)
Micromole (micromol)
Million Plaque Forming Units (mill PFU)
Million (Million)
Milliunit (millunit)
Milliinternational Unit (miu)
Milliinternational Units Per Meter
Squared (miu/m2)
Milliliter (mL)
Cubic Centimeter (cc) (mL)
Milliliter Per Hour (mL/hr)
Milliliter Per Kilogram (mL/kg)
Millimoles Per Liter (mM/L)
Millimole (mmol)
Mole (Mole)
Milliosmole (mosmol)
Megarad (Mrad)
Million Units (MU)
Millivolt (mV)
Million Viral Particles (MVP)
Nanocurie (nCi)
Nanogram (ng)
Nanogram Per Kilogram (ng/kg)
Nanogram Per Liter (ng/L)
Nanograms Per Milliliter (ng/mL)
Nanometer Of Light (nm light)
Nanomole (nmol)
No Source Data (No Srce)
Osmolality (osmol)
Ounce (oz)
Pascal (Pa)
Packet (packet)
Patch (Patch)
Plaque Forming Units (PFU)
Picograms (pg)
Pounds Per Square Inch (psi)
Puff (puff)
Radiation Absorbed Dose (Rad)
Vitamin A Retinol (RAE)
Retinol Equivalents (RE)
Seed (Seed)
Session (Session)
Spray (Spray)
Suppository (Suppstry)
Tablets (Tablet)
Tablespoon (Tbsp)
Tissue Culture Infection Dose (TCID)
Thousand (Thousand)
Troche (Troche)
Teaspoon (tsp)
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Unit (Unit)
Unit Per Gram (Unit/g)
Unit Per Kilogram (Unit/kg)
Unit Per Meter Squared (Unit/m2)
Unit Per Milliliter (Unit/mL)
Unknown (Unknown)
Viral Particles (VP)
Yeast Units (YU)
Metabolite Assay 1 (If applicable, enter the first
metabolite assay results for the parent study
agent.)
Metabolite Assay 1 (If applicable, enter the first
metabolite assay results for the parent study
agent.)
Metabolite Assay Mean (Enter the metabolite
assay mean concentration, if available.)
Metabolite Assay UOM (Select the appropriate
concentration units of measurement for the
metabolite assays e.g.: mg/dL or mmol/l.)
Percent (%)
10e10 Cells (10E10 Cells)
10e3 Cells (10E3 Cells)
10e4 Cells Per Kilogram (10E4 Cell/kg)
10e4 Cells (10E4 Cells)
10e5 Cells Per Kilogram (10E5 Cell/kg)
10e5 Cells (10E5 Cells)
10e6 Cells Per Kilogram (10E6 Cell/kg)
10e6 Cells (10E6 Cells)
10e7 Cells Per Kilogram (10E7 Cell/kg)
10e7 Cells (10E7 Cells)
10e7 Plaque Forming Units (10E7 PFU)
10e8 Cells (10E8 Cells)
10e8 Plaque Forming Units (10E8 PFU)
10e9 Cells (10E9 Cells)
10e9 Plaque Forming Units (10E9 PFU)
Ampule (Ampule)
Application (Applcatn)
Atomic Unit (au)
Area Under The Curve (AUC)
Billion Pfu (bill PFU)
Bottle (Bottle)
Breaths Per Minute (BPM)
Capful (Capful)
Caplet (Caplet)
Capsule (Capsule)
Cells (Cells)
Cells Per Kilogram (Cells/kg)
Centigray (cGy)
Curie (Ci)
Course (Course)
Cycle (Course)
Deciliter (dL)
Dose (Dose)
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Equivalent (Eq)
Grams (g) (g)
Gram Per M2 (g/m2)
Gallon (Gallon)
Drops (gtts)
Gray (Gy)
Hertz (Hz)
Inch (Inch)
Inhalation (Inhalatn)
Iu Vitamin A (IU Vit A)
International Unit Per Milligram (IU/mg)
International Units Or Milligram Alpha
Tocopherol (IU/mg A-TE)
International Unit (IUnit)
International Unit Per Kilogram (IUnit/kg)
International Unit Per Liter (IUnit/L)
Intravenous Bag (IV Bag)
Infectious Viral Replicon Particles (IVRP)
Joules Per Centimeter Squared (Jcm2)
Kib-electron Volt (KeV)
Kilograms (kg)
Kilohertz (kHz)
Kilopascal (kPa)
Kilounit (kU)
Kilounit Per Kilogram (kU/kg)
Kilounit Per Liter (kU/L)
Liter (L)
Liters Per Minute (L/min)
Millibecquerel (mBq)
Megabecquerel (MBq)
Microgram (mcg)
Microgram Per Centimeter Squared
(mcg/cm2)
Microgram Per Hour (mcg/hr)
Microgram Per Kilogram (mcg/kg)
Microgram Per Meter Squared (mcg/m2)
Millicurie (mCi)
Measure (Measure)
Milliequivalent (mEq)
Milliequivalents Per 24 Hours (mEq/24hr)
Milliequivalent Per Deciliter (mEq/dL)
Milliequivalent Per Hour (mEq/hr)
Milliequivalent Per Liter (mEq/L)
Million Electron Volt (MeV)
Milligram (mg)
Milligram Per 24 Hours (mg/24hr)
Milligram Per Deciliter (mg/dL)
Milligram Per Hour (mg/hr)
Milligram Per Inhalation (mg/inh)
Milligram Per Kilogram (mg/kg)
Milligram Per Kilogram Per Day
(mg/kg/day)
Milligram Per Meter Squared (mg/m2)
Milligram Per Milliliter (mg/mL)
Milligram Per Week (mg/wk)
Megahertz (MHz)
Microcurie (microCi)
Microliter (microL)
Micromole (micromol)
Million Plaque Forming Units (mill PFU)
6 / 7
Pharmacokinetics - 3281312v1.0
Million (Million)
Milliunit (millunit)
Milliinternational Unit (miu)
Milliinternational Units Per Meter
Squared (miu/m2)
Milliliter (mL)
Cubic Centimeter (cc) (mL)
Milliliter Per Hour (mL/hr)
Milliliter Per Kilogram (mL/kg)
Millimoles Per Liter (mM/L)
Millimole (mmol)
Mole (Mole)
Milliosmole (mosmol)
Megarad (Mrad)
Million Units (MU)
Millivolt (mV)
Million Viral Particles (MVP)
Nanocurie (nCi)
Nanogram (ng)
Nanogram Per Kilogram (ng/kg)
Nanogram Per Liter (ng/L)
Nanograms Per Milliliter (ng/mL)
Nanometer Of Light (nm light)
Nanomole (nmol)
No Source Data (No Srce)
Osmolality (osmol)
Ounce (oz)
Pascal (Pa)
Packet (packet)
Patch (Patch)
Plaque Forming Units (PFU)
Picograms (pg)
Pounds Per Square Inch (psi)
Puff (puff)
Radiation Absorbed Dose (Rad)
Vitamin A Retinol (RAE)
Retinol Equivalents (RE)
Seed (Seed)
Session (Session)
Spray (Spray)
Suppository (Suppstry)
Tablets (Tablet)
Tablespoon (Tbsp)
Tissue Culture Infection Dose (TCID)
Thousand (Thousand)
Troche (Troche)
Teaspoon (tsp)
Unit (Unit)
Unit Per Gram (Unit/g)
Unit Per Kilogram (Unit/kg)
Unit Per Meter Squared (Unit/m2)
Unit Per Milliliter (Unit/mL)
Unknown (Unknown)
Viral Particles (VP)
Yeast Units (YU)
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Sarcoma NCT00450320 On-Study - AMC-051
Overall Assessment Form (RK6) - 2636888v1.0
Sarcoma NCT00450320 On-Study - AMC-051 Overall
Assessment Form (RK6) - 2636888v1.0
All rights reserved. Please visit https://medical-data-
models.org/forms/2871
AMC-051 Overall Assessment Form
(RK6)
Header Module
Visit number
Unnamed1
Best Response (since Entry/Baseline)
Clinical Complete Response (Clinical
complete response)
Complete Response (Complete
response)
Partial Response (Partial response)
Progressive Disease (Progressive
disease)
Stable Disease (Stable disease)
Unevaluable (Unevaluable)
Unknown (Unknown)
What is the present status of the best response
No Relapse Observed, But Patent Died
(No relapse observed, but patent died)
Not Applicable (Not applicable)
Relapse Occurred After A Response
Was Achieved (Relapse occurred after a
response was achieved)
Response Continuing Or First Time At
This Response (Response continuing or
first time at this response)
Date of Relapse or Progression (if applicable
mm/dd/yyyy)
Unnamed2
Is complete response confirmed (During this
reporting period,)
No (No)
Yes (Yes)
Complete Response Confirmed Date (If Yes,)
Is clinical complete response confirmed (During
this reporting period,)
No (No)
Yes (Yes)
Clinical Complete Response Confirmed Date (If
Yes,)
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Is partial response confirmed (During this
reporting period,)
No (no)
Yes (yes)
Partial Response Confirmed Date (If Yes,)
Is progression confirmed (During this reporting
period, with no response)
No (No)
Yes (Yes)
Progressive Disease Confirmed Date (If Yes,)
Footer Module
Comments
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Sarcoma NCT00450320 On-Study - AMC-051 Overall Assessment Form
(RK6) - 2636888v1.0
Treatment - Prior Radiation Supplement -
3278747v1.0
Treatment - Prior Radiation Supplement - 3278747v1.0
All rights reserved. Please visit https://medical-data-
models.org/forms/2891
Prior Radiation Supplement
Prior Radiation Supplement
Visit Date (Enter the date the form was
completed. - Note: If the information was
obtained at multiple visits, please enter the date
the form was completed.)
Date of First Dose (Enter the date of the first
dose of the radiation therapy. Partial dates are
acceptable when the day is not known.)
Date of Last Dose (Enter the date of the last dose
of the radiation therapy. Partial dates are
acceptable when the day is not known. Leave it
blank if the therapy is currently being received.)
Radiation Type (Select the type of radiation
therapy, e.g.: "proton beam", "external beam" or
"implant".)
3d Conformal (3D conformal)
3d Conformal + Imrt Boost (3D
Conformal + IMRT Boost)
High-dose Rate Brachytherapy 3-
dimensional Conformal Radiation
Therapy (3DCRT + Brachytherapy HDR)
Low-dose Treatment Brachytherapy 3-
dimensional Conformal Radiation
Therapy (3DCRT + Brachytherapy LDR)
Adjuvant (Adjuvant RT)
Brachytherapy (Brachytherapy)
Conformal (conformal)
Electron Beam (electron beam)
External Beam Radiation (External beam
radiation)
Hyperfractionated (hyperfractionated)
Imrt (IMRT)
High-dose Rate Brachytherapy Imrt
(IMRT + Brachytherapy HDR)
Low-dose Treatment Brachytherapy Imrt
(IMRT + Brachytherapy LDR)
Imrt And Igrt (IMRT and IGRT)
Neoadjuvant (Neoadjuvant RT)
Not Applicable (Not Applicable)
Other (Other)
Other (Other specify)
Palliative Radiation Therapy (Palliative
RT)
Photodynamic Therapy (Photodynamic
therapy)
Photon Beam (photon beam)
Proton Beam (proton beam)
Radiofrequency Ablation
(Radiofrequency ablation)
Radiosurgery (radiosurgery)
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Tomotherapy (Tomotherapy)
Other, Specify (Enter an explanation when Other,
Specify is selected as a Radiation Type.)
Radiation Extent (Select the extent of the
radiation therapy as follows:)
Chemotherapy Multiple Agents Systemic
(10008452)
Chemotherapy Single Agent Systemic
(10008456)
Homeopathic Therapy (10020363)
Vaccine (10021430)
Extensive Radiation (10037770)
Limited Radiation (10037770)
Radiation (nos) (10037770)
Srugery (10042609)
Chemotherapy (nos) (10050693)
No Prior Therapy (10052052)
Bone Marrow Transplant (10061730)
Hematopoietic Stem Cell Transplantation
(10063581)
Hormonal Therapy (10065646)
Anti-retroviral Therapy (90003000)
Antisense (90003002)
Gene Transfer (90003004)
Drug And/or Immunotherapy (90003006)
Oncolytic Virotherapy (90003008)
Prior Therapy (nos) (90003010)
Chemotherapy Non-cytotoxic (90003014)
Image Directed Local Therapy
(90003016)
Site (Select the site of the radiation therapy.)
Total Abdomen (Abdomen, total)
Arm (Arm)
Total Body (Body, total)
Bone, Non-spine (Bone, non-spine)
Brain To Cervical 2 (Brain-C2)
Brain, Focal (Brain, focal)
Brain, Whole (Brain, whole)
Breast (Breast)
Chest Wall, Nos (Chest Wall)
Eye (Eye)
Colon (Gastrointestinal, Colon)
Gallbladder (Gastrointestinal,
Gallbladder)
Intestine (Gastrointestinal, Intestine)
Liver (Gastrointestinal, Liver)
Gastrointestinal, Not Otherwise Specified
(Gastrointestinal, NOS)
Pancreas (Gastrointestinal, Pancreas)
Rectum (Gastrointestinal, Rectum)
Stomach (Gastrointestinal, Stomach)
Bladder (Genitourinary, Bladder)
Kidney (Genitourinary, Kidney)
Genitourinary, Not Otherwise Specified
(Genitourinary, NOS)
Prostate Gland (Genitourinary, Prostate)
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Genitourinary, Prostate And Seminal
Vesicles (Genitourinary, Prostate and
Seminal Vesicles)
Head (Head)
Head, Face, Or Neck (Head, Face, or
Neck)
Leg (Leg)
Lung (Lung)
Lymph Node, Distant (specify Site)
(Lymph node, distant (specify site))
Lymph Node, Locoregional (specify Site)
(Lymph node, locoregional (specify site))
Lymph Nodes (Lymph Nodes)
Mantle Field (Mantle)
Mediastinum (Mediastinum)
Parametrium (Parametrium)
Pelvis (ilium, Ischium, And Pubis Bones)
(Pelvis)
Prostate Gland (Prostate)
Anatomic Area Irradiated After The
Prostate Is Surgically Resected (Prostate
Bed)
Rectum (Rectum)
Sacrum (Sacrum)
Seminal Vesicle (Seminal vesicles)
Skin, Lower Extremity, Local (Skin, lower
extremity, local)
Entire Skin (Skin, total)
Skin, Trunk, Local (Skin, trunk, local)
Skin, Upper Extremity, Local (Skin, upper
extremity, local)
Spine (Spine)
Spine (Spine, whole)
Supraclavicular Field (Supraclavicular)
Thorax (Thorax)
Trunk (Trunk)
Schedule (Select the radiation therapy schedule
on which it was given.)
Twice A Week (2 times/week)
Twice A Week As Needed (2 times/week
PRN)
Three Times A Week (3 times/week)
Three Times A Week As Needed (3
times/week PRN)
Five Times Per Day (5 times/day)
Five Times A Day As Needed (5
times/day PRN)
Six Times A Day As Needed (6
times/day PRN)
Six Times Per Day (6 times/day)
Seven Times Per Day (7 times/day)
Seven Times A Day As Needed (7
times/day PRN)
Eight Times Per Day (8 times/day)
Eight Times A Day As Needed (8
times/day PRN)
Before Meals (ac)
Before Meals As Needed (ac PRN)
Twice A Day (BID)
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Two Times A Day As Needed (bid PRN)
Two Times A Day Every Monday,
Tuesday And Wednesday (bid qMTW)
Two Times A Day Every Monday,
Wednesday And Thursday (bid qMWTh)
Two Times A Day, Every Other Day, For
3 Days (bid qod x3 days)
Two Times A Day, Every Other Day, For
6 Doses (bid qod x6 doses)
Twice A Week (BIW)
Continuous (Continuous)
Continuous As Needed (Continuous
PRN)
At Bedtime (hs)
At Bedtime As Needed (hs PRN)
After Meals (pc)
After Meals As Needed (pc PRN)
As Needed (PRN)
Every 1 To 2 Hours As Needed (q1-2h
PRN)
Every Ten Days (q10d)
Every 10 Days As Needed (q10d PRN)
Every Ten Hours (q10h)
Every 10 Hours As Needed (q10h PRN)
Every Eleven Hours (q11h)
Every 11 Hours As Needed (q11h PRN)
Every Twelve Hours (q12h)
Every 12 Hours As Needed (q12h PRN)
Every 12 Months (q12month)
Every Thirteen Hours (q13h)
Every 13 Hours As Needed (q13h PRN)
Every 14 Days (q14d)
Every Fourteen Hours (q14h)
Every 14 Hours As Needed (q14h PRN)
Every Fifteen Hours (q15h)
Every 15 Hours As Needed (q15h PRN)
Every Sixteen Hours (q16h)
Every 16 Hours As Needed (q16h PRN)
Every Seventeen Hours (q17h)
Every 17 Hours As Needed (q17h PRN)
Every Eighteen Hours (q18h)
Every 18 Hours As Needed (q18h PRN)
Every Nineteen Hours (q19h)
Every 19 Hours As Needed (q19h PRN)
Every One Hour (q1h)
Every One Hour As Needed (q1h PRN)
Every 2 To 3 Hours As Needed (q2-3h
PRN)
Every 2 To 4 Hours As Needed (q2-4h
PRN)
Every Twenty Hours (q20h)
Every 20 Hours As Needed (q20h PRN)
Every Twenty-one Hours (q21h)
Every 21 Hours As Needed (q21h PRN)
Every Twenty-two Hours (q22h)
Every 22 Hours As Needed (q22h PRN)
Every Twenty-three Hours (q23h)
Every 23 Hours As Needed (q23h PRN)
Every Twenty Four Hours (q24h)
Every 24 Hours As Needed (q24h PRN)
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Every Two Days (q2d)
Every 2 Days As Needed (q2d PRN)
Every Two Hours (q2h)
Every 2 Hours As Needed (q2h PRN)
Every Two Months (q2month)
Every 2 Months As Needed (q2month
PRN)
Every Two Weeks (q2wk)
Every 2 Weeks As Needed (q2wk PRN)
Every 3-4 Hours As Needed (q3-4h
PRN)
Every Thirty Six Hours (q36h)
Every 36 Hours As Needed (q36h PRN)
Every Three Days (q3d)
Every 3 Days As Needed (q3d PRN)
Every Two Hours (q3h)
Every 3 Hours As Needed (q3h PRN)
Every Three Months (q3month)
Every 3 Months As Needed (q3month
PRN)
Every Three Weeks (q3wk)
Every Three Weeks As Needed (q3wk
PRN)
Every 4 To 6 Hours (q4-6h)
Every 4 To 6 Hours As Needed (q4-6h
PRN)
Every Forty Eight Hours (q48h)
Every 48 Hours As Needed (q48h PRN)
Every Four Days (q4d)
Every 4 Days As Needed (q4d PRN)
Every 4 Hours As Needed (q4h PRN)
Every 4 Hours Every Other Day, For 3
Days (q4h qod x3 days)
Every 4 Hours (Q4HR)
Every Four Months (q4month)
Every 4 Months As Needed (q4month
PRN)
Every Four Weeks (q4wk)
Every 4 Weeks As Needed (q4wk PRN)
Every Five Days (q5d)
Every 5 Days As Needed (q5d PRN)
Every Five Hours (q5h)
Every 5 Hours As Needed (q5h PRN)
Every Five Months (q5month)
Every 5 Months As Needed (q5month
PRN)
Every Five Weeks (q5wk)
Every 5 Weeks As Needed (q5wk PRN)
Every 6 To 8 Hours As Needed (q6-8h
PRN)
Every Six Days (q6d)
Every 6 Days As Needed (q6d PRN)
Every 6 Hours As Needed (q6h PRN)
Every 6 Hours Every Other Day, For 3
Days (q6h qod x3 days)
Every 6 Hours (Q6HR)
Every Six Months (q6month)
Every 6 Months As Needed (q6month
PRN)
Every Six Weeks (q6wk)
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Every 6 Weeks As Needed (q6wk PRN)
Every Seven Days (q7d)
Every 7 Days As Needed (q7d PRN)
Every Seven Hours (q7h)
Every 7 Hours As Needed (q7h PRN)
Every Seven Weeks (q7wk)
Every 7 Weeks As Needed (q7wk PRN)
Every 8 Days (q8d)
Every 8 Days As Needed (q8d PRN)
Every 8 Hours As Needed (q8h PRN)
Every 8 Hours (Q8HR)
Every 8 Weeks (q8wk)
Every 8 Weeks As Needed (q8wk PRN)
Every 9 Days (q9d)
Every 9 Days As Needed (q9d PRN)
Every 9 Hours (q9h)
Every 9 Hours As Needed (q9h PRN)
Every Morning (qam)
Every Morning As Needed (qam PRN)
Every Day (qd)
One Time A Day As Needed (qd PRN)
Once A Day For 3 Days (qd x3)
Every Day For 4 Days (qd x4)
Once A Day For 5 Days (qd x5)
Once A Day For 7 Days (qd x7)
Every Night (qhs)
Every Night As Needed (qhs PRN)
Four Times A Day (qid)
Four Times A Day As Needed (qid PRN)
Monthly (qmonth)
Every Month As Needed (qmonth PRN)
Every Monday, Tuesday And Wednesday
(qMTW)
Every Monday, Wednesday And Friday
(qMWF)
Every Other Day (QOD)
Every Other Day As Needed (qod PRN)
Every Other Day For 3 Days (qod x3
days)
Weekly (qwk)
Every Week As Needed (qwk PRN)
Every Week For 4 Weeks (qwk x4)
Every Week For 8 Courses (cycles) (qwk
x8 courses)
Tapering Doses (Tapering Doses)
Three Times A Day (tid)
Three Times A Day As Needed (tid PRN)
Three Times In A Day, Every Other Day
(tid qod)
Three Times A Week (TIW)
Unknown (Unknown)
One Time (x1)
For 1 Course (cycle) (x1 Course)
One Time As Needed (x1 PRN)
For 12 Courses (cycles) (x12 Courses)
Two Times (x2)
For 2 Courses (cycles) (x2 Courses)
Two Times As Needed (x2 PRN)
Three Times (x3)
For 3 Courses (cycles) (x3 Courses)
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Three Times As Needed (x3 PRN)
Four Times (x4)
For 4 Courses (cycles) (x4 Courses)
Four Times As Needed (x4 PRN)
Five Times (x5)
For 5 Courses (cycles) (x5 Courses)
Five Times As Needed (x5 PRN)
For 6 Courses (cycles) (x6 Courses)
For 8 Courses (cycles) (x8 Courses)
For 8 Days (x8 days)
Total Dose (State the total radiation dose the
patient received during the treatment period.
Leave this field as well as the Total Dose UOM
blank if the radiation therapy is ongoing.)
Total Dose UOM (Select the radiation dose units
of measurement e.g. cGy or rad, or cSv or rem.)
Percent (%)
10e10 Cells (10E10 Cells)
10e3 Cells (10E3 Cells)
10e4 Cells Per Kilogram (10E4 Cell/kg)
10e4 Cells (10E4 Cells)
10e5 Cells Per Kilogram (10E5 Cell/kg)
10e5 Cells (10E5 Cells)
10e6 Cells Per Kilogram (10E6 Cell/kg)
10e6 Cells (10E6 Cells)
10e7 Cells Per Kilogram (10E7 Cell/kg)
10e7 Cells (10E7 Cells)
10e7 Plaque Forming Units (10E7 PFU)
10e8 Cells (10E8 Cells)
10e8 Plaque Forming Units (10E8 PFU)
10e9 Cells (10E9 Cells)
10e9 Plaque Forming Units (10E9 PFU)
Ampule (Ampule)
Application (Applcatn)
Atomic Unit (au)
Area Under The Curve (AUC)
Billion Pfu (bill PFU)
Bottle (Bottle)
Breaths Per Minute (BPM)
Capful (Capful)
Caplet (Caplet)
Capsule (Capsule)
Cells (Cells)
Cells Per Kilogram (Cells/kg)
Centigray (cGy)
Curie (Ci)
Cycle (Course)
Course (Course)
Deciliter (dL)
Dose (Dose)
Equivalent (Eq)
Grams (g) (g)
Gram Per M2 (g/m2)
Gallon (Gallon)
Drops (gtts)
Gray (Gy)
Hertz (Hz)
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Inch (Inch)
Inhalation (Inhalatn)
Iu Vitamin A (IU Vit A)
International Unit Per Milligram (IU/mg)
International Units Or Milligram Alpha
Tocopherol (IU/mg A-TE)
International Unit (IUnit)
International Unit Per Kilogram (IUnit/kg)
International Unit Per Liter (IUnit/L)
Intravenous Bag (IV Bag)
Infectious Viral Replicon Particles (IVRP)
Joules Per Centimeter Squared (Jcm2)
Kib-electron Volt (KeV)
Kilograms (kg)
Kilohertz (kHz)
Kilopascal (kPa)
Kilounit (kU)
Kilounit Per Kilogram (kU/kg)
Kilounit Per Liter (kU/L)
Liter (L)
Liters Per Minute (L/min)
Megabecquerel (MBq)
Millibecquerel (mBq)
Microgram (mcg)
Microgram Per Centimeter Squared
(mcg/cm2)
Microgram Per Hour (mcg/hr)
Microgram Per Kilogram (mcg/kg)
Microgram Per Meter Squared (mcg/m2)
Millicurie (mCi)
Measure (Measure)
Milliequivalent (mEq)
Milliequivalents Per 24 Hours (mEq/24hr)
Milliequivalent Per Deciliter (mEq/dL)
Milliequivalent Per Hour (mEq/hr)
Milliequivalent Per Liter (mEq/L)
Million Electron Volt (MeV)
Milligram (mg)
Milligram Per 24 Hours (mg/24hr)
Milligram Per Deciliter (mg/dL)
Milligram Per Hour (mg/hr)
Milligram Per Inhalation (mg/inh)
Milligram Per Kilogram (mg/kg)
Milligram Per Kilogram Per Day
(mg/kg/day)
Milligram Per Meter Squared (mg/m2)
Milligram Per Milliliter (mg/mL)
Milligram Per Week (mg/wk)
Megahertz (MHz)
Microcurie (microCi)
Microliter (microL)
Micromole (micromol)
Million Plaque Forming Units (mill PFU)
Million (Million)
Milliunit (millunit)
Milliinternational Unit (miu)
Milliinternational Units Per Meter
Squared (miu/m2)
Cubic Centimeter (cc) (mL)
Milliliter (mL)
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Milliliter Per Hour (mL/hr)
Milliliter Per Kilogram (mL/kg)
Millimoles Per Liter (mM/L)
Millimole (mmol)
Mole (Mole)
Milliosmole (mosmol)
Megarad (Mrad)
Million Units (MU)
Millivolt (mV)
Million Viral Particles (MVP)
Nanocurie (nCi)
Nanogram (ng)
Nanogram Per Kilogram (ng/kg)
Nanogram Per Liter (ng/L)
Nanograms Per Milliliter (ng/mL)
Nanometer Of Light (nm light)
Nanomole (nmol)
No Source Data (No Srce)
Osmolality (osmol)
Ounce (oz)
Pascal (Pa)
Packet (packet)
Patch (Patch)
Plaque Forming Units (PFU)
Picograms (pg)
Pounds Per Square Inch (psi)
Puff (puff)
Radiation Absorbed Dose (Rad)
Vitamin A Retinol (RAE)
Retinol Equivalents (RE)
Seed (Seed)
Session (Session)
Spray (Spray)
Suppository (Suppstry)
Tablets (Tablet)
Tablespoon (Tbsp)
Tissue Culture Infection Dose (TCID)
Thousand (Thousand)
Troche (Troche)
Teaspoon (tsp)
Unit (Unit)
Unit Per Gram (Unit/g)
Unit Per Kilogram (Unit/kg)
Unit Per Meter Squared (Unit/m2)
Unit Per Milliliter (Unit/mL)
Unknown (Unknown)
Viral Particles (VP)
Yeast Units (YU)
Best Response
Complete Response (CR)
Less Than Partial Response (MR)
Not Assessed (NA)
Not Evauable (NE)
No Response (NR)
Progressive Disease (PD)
Partial Response (PR)
Stable Disease (SD)
Unknown (UK)
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NonResponse Therapy Type
Adjuvant Therapy (AJ)
Neoadjuvant Therapy (NJ)
Palliative Therapy (PA)
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Sarcoma, Kaposi xxx Transmittal - Specimen
Shipping Log - RF31 - 2267315v3.0
Sarcoma, Kaposi xxx Transmittal - Specimen Shipping Log
- RF31 - 2267315v3.0
All rights reserved. Please visit https://medical-data-
models.org/forms/2900
Specimen Shipping Log - RF31
Ccrr Module For Specimen Shipping Log -
Rf31
Fedex Tracking Number
Name/phone number
Name of person verifying contents
Condition upon arrival
Backup stored at local site?
No (No)
Yes (Yes)
Date Drawn
Time Drawn
Cycle/Week#
Purpose
Specimen Type
Initials
Patient ID#
Date Shipped
Destination
Site name/fax number
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Sarcoma, Kaposi xxx On-Study - Specimen
Procurement Form - RF36 - 2267294v3.0
Sarcoma, Kaposi xxx On-Study - Specimen Procurement
Form - RF36 - 2267294v3.0
All rights reserved. Please visit https://medical-data-
models.org/forms/2917
Specimen Procurement Form - RF36
Ccrr Module For Specimen Procurement
Form - Rf36
Patient Initials
Person Responsible for Sample(s)
Specify Other
Reason Sample Obtained Code
Specify Other
Stored/Shipped Code
Total Volume (ml)
Specify Other
Specimen Type Code
Were specimens collected
No (No)
Yes (Yes)
Date Specimen Obtained
Seq #
Cycle #
ID#
Site#
Study#
Date Form Completed
1 / 1
Sarcoma NCT00450320 On-Study - AMC-051
Physical Exam Form (RK2) - 2636848v1.0
Sarcoma NCT00450320 On-Study - AMC-051 Physical
Exam Form (RK2) - 2636848v1.0
All rights reserved. Please visit https://medical-data-
models.org/forms/2935
AMC-051 Physical Exam Form
(RK2)
Header Module
Visit number
Unnamed2
At entry, does the participant have >=50 lesions
No (No)
Yes (Yes)
Representative Area
Abdomen (Abdomen)
Back (Back)
Chest (Chest)
Genital Area (Genital)
Head (Head)
Left Arm (Left arm)
Left Foot (Left foot)
Left Hand (Left hand)
Left Leg (Left leg)
Neck (Neck)
Periorbital (Periorbital)
Right Arm (Right arm)
Right Foot (Right foot)
Right Hand (Right hand)
Right Leg (Right leg)
Total Body (Total body)
Total Number Raised Lesions
Total Number Flat Lesions
Total Number New Lesions
Number of cutaneous lesions
>=25% Increase In The Number Of
Lesions Since Baseline Or Since Best
Response (>=25% increase in the
number of lesions since baseline or
since best response)
>=50% Decrease In The Number Of
Lesions Since Baseline (>=50%
decrease in the number of lesions since
baseline)
Complete Resolution (Complete
resolution)
None Of The Above (None of the above)
Character of cutaneous lesions
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>=25% Increase In The Number Of
Raised Lesions (>=25% increase in the
number of raised lesions)
None Of The Above (None of the above)
Since Baseline, >=50% Of Raised Have
Become Flat (Since baseline, >=50% of
raised have become flat)
Unnamed3
Representative Area
Abdomen (Abdomen)
Back (Back)
Chest (Chest)
Genital Area (Genital)
Head (Head)
Left Arm (Left arm)
Left Foot (Left foot)
Left Hand (Left hand)
Left Leg (Left leg)
Neck (Neck)
Periorbital (Periorbital)
Right Arm (Right arm)
Right Foot (Right foot)
Right Hand (Right hand)
Right Leg (Right leg)
Total Body (Total body)
Specify
Dimension 1
Dimension 2
Product of Diameters
Photos Taken
No (No)
Yes (Yes)
Sum of Products of Greatest Diameters
Evaluation of Marker Lesions
>=25% Inc In Sum Of The Products Of
The Diam Of All Marker Lesions Since
Baseline/best Response (>=25% inc in
sum of the products of the diam of all
marker lesions since baseline/best
response)
>=50% Decrease In The Sum Of The
Products Of The Diameters Of All Marker
Lesions Since Baseline (>=50%
decrease in the sum of the products of
the diameters of all marker lesions since
baseline)
Complete Resolution (Complete
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resolution)
None Of The Above (None of the above)
Footer Module
Comments
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Sarcoma, Kaposi xxx Lab - Hematology & Chemistries
Lab Normal Ranges Form - RF39 - 2266501v3.0
Sarcoma, Kaposi xxx Lab - Hematology & Chemistries Lab
Normal Ranges Form - RF39 - 2266501v3.0
All rights reserved. Please visit https://medical-data-
models.org/forms/2959
Hematology & Chemistries Lab
Normal Ranges Form - RF39
Ccrr Module For Hematology &
Chemistries Lab Normal Ranges Form -
Rf39
Calcium from (mg/dl)
LDH (Lactic Dehydrogenase) from (mU/ml)
LDH (Lactic Dehydrogenase) to (mU/ml)
Urea Nitrogen (BUN) from (mg/dl)
Urea Nitrogen (BUN) to (mg/dl)
Creatinine from (mg/dl)
Creatinine to (mg/dl)
Uric Acid from (mg/dl)
Uric Acid to (mg/dl)
Glucose from (mg/dl)
Glucose to (mg/dl)
SGPT (ALT) to (mU/ml)
SGPT (ALT) from (mU/ml)
SGOT (AST) to (mU/ml)
Calcium to (mg/dl)
Magnesium from (mg/dl)
Magnesium to (mg/dl)
Phosphorous from (mg/dl)
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Phosphorous to (mg/dl)
CO2 (Bicarbonate) from (mEq/L)
CO2 (Bicarbonate) to (mEq/L)
Alkaline Phosphatase from (mU/ml)
Alkaline Phosphatase to (mU/ml)
SGOT (AST) from (mU/ml)
Total Bilirubin from (mg/dl)
Total Bilirubin to (mg/dl)
Total Triglycerides to (mg/dl)
LDL from (mg/dl)
LDL to (mg/dl)
HDL from (mg/dl)
HDL to (mg/dl)
Total Cholesterol from (mg/dl)
Total Cholesterol to (mg/dl)
Other chemistry test from
Other chemistry test to
Other chemistry test specify
Total Triglycerides from (mg/dl)
CPK (Creatinine Phosphokinase) to (U/L)
CPK (Creatinine Phosphokinase) from (U/L)
Total Protein from (mg/dl)
2 / 5
Sarcoma, Kaposi xxx Lab - Hematology & Chemistries Lab Normal
Ranges Form - RF39 - 2266501v3.0
Total Protein to (mg/dl)
Albumin from (g/dl)
Albumin to (g/dl)
Globulin from (g/dl)
Globulin to (g/dl)
Lipase from (U/L)
Lipase to (U/L)
Amylase from (U/L)
Amylase to (U/L)
Other chemistry test Units, specify
Patient Initials
WBC to (1000/cu mm)
Neutrophils (includings Bands) from (%)
Neutrophils (includings Bands) to (%)
Absolute Neutrophil Count (1000/cu mm) WBC x
(%Neutrophils including Bands)/100 from
Absolute Neutrophil Count (1000/cu mm) WBC x
(%Neutrophils including Bands)/100 to
Lymphocytes from (%)
Lymphocytes to (%)
Monocytes from (%)
Monocytes to (%)
Eosinophils from (%)
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WBC from (1000/cu mm)
Hematocrit to (%)
Hematocrit from (%)
Study#
Site#
ID#
Report Date
Is more than one laboratory used by your site for
the patient?
No (No)
Yes (Yes)
If "Yes", the name of the laboratory that is used.
Is this an initial report by your site for the patient?
No (No)
Yes (Yes)
If "No", date of change.
Hemoglobin from (g/dl)
Hemaoglobin to (g/dl)
Eosinophils to (%)
Basophils from (%)
PTT (Partial Thromboplastin Time) to
Other hematology test from
Other hematology test to
Other hematology test, specify
Other hematology test Units, specify
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Sodium from (mEq/L)
Sodium to (mEq/L)
Potassium from (mEq/L)
Potassium to (mEq/L)
Chloride from (mEq/L)
PTT (Partial Thromboplastin Time) from
PT (Prothrombin Time) to
PT (Prothrombin Time) from
Basophils to (%)
Other from (%)
Other to (%)
Other specify
Platelets from (1000/cu mm)
Platelets to (1000/cu mm)
RBC from (cmm)
RBC to (ccm)
Reticulocyte count from (%)
Reticulocyte count to (%)
Chloride to (mEq/L)
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Nonneoplastic Condition NCT01057121 Lab -
AMC-070 HIV Viral Load Form (F40) - 3146836v1.0
Nonneoplastic Condition NCT01057121 Lab - AMC-070
HIV Viral Load Form (F40) - 3146836v1.0
All rights reserved. Please visit https://medical-data-
models.org/forms/2962
AMC-070 HIV Viral Load Form (F40)
Unnamed1
Visit number
Specimen Information
Date Specimen Obtained (mm/dd/yyyy)
Unnamed2
Results of HIV viral load assay  (Enter results
from right to left.)
Equal To (Equal to (=))
Greater Than (>) (Greater than (>))
Less Than (Less than (<))
Undetectable (Undetectable)
HIV viral load value
Method of detection
Abbott Realtime Hiv-1 Assay (Abbott
RealTime HIV-1 assay)
Cobas Ampliprep/taqman Hiv-1 Assay
(COBAS AmpliPrep/TAQMAN HIV-1
assay)
Other (Other)
Roche Amplicor Monitor Assay (Roche
Amplicor Monitor Assay)
Versant Hiv-1 Rna Assay By Branched
Dna (Versant HIV-1 RNA assay by
branched DNA)
Other, specify
HIV viral load assay type
Standard (Standard)
Ultra (Ultra)
Limits of detection (Copies/mL)
Lab Facility Name (Testing Laboratory
information)
Comments
Comments
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Sarcoma NCT00450320 Pathology - AMC-051 AIDS and
Cancer Specimen Resource (ACSR) Procurement Form
(F37) - 2635824v1.0
All rights reserved. Please visit https://medical-data-
models.org/forms/2968
AMC-051 AIDS and Cancer
Specimen Resource (ACSR)
Procurement Form (F37)
Unnamed1
Visit number
Unnamed2
Specimen(s) obtained for donation to ACSR
No (No)
Yes (Yes)
Specimen Type (check all that apply)
Peripheral Blood (Blood)
Other (Other)
Pbmc (peripheral Blood Mononuclear
Cells) (PBMC)
Plasma (Plasma)
Serum (Serum)
Tissue (Tissue)
Other specify
ACSR site the specimen(s) shipped to
Gwu (GWU)
Jhu (JHU)
Osu (OSU)
Other (Other)
Suny/hscb (SUNY/HSCB)
Ucla (UCLA)
Ucsf (UCSF)
Other, specify
If specimens were not obtained for ACSR, please
indicate reason
Other (Other)
Patient Had Previously Donated
Specimen To Acsr (Patient had
previously donated specimen to ACSR)
Patient Refused To Give Informed
Consent For Acsr Specimen Donation
(Patient refused to give informed consent
for ACSR specimen donation)
Patient Was Not Asked To Consider Acsr
Specimen Donation (Patient was not
asked to consider ACSR specimen
donation)
Other, specify
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Date Specimen Obtained (mm/dd/yyyy)
Date Specimen Obtained (mm/dd/yyyy)
Study Coordinator
Study Coordinator's name
E-mail
Phone Number (xxx-xxx-xxxx)
Comments
Comments
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Pre-Study - PRIOR RADIATION
SUPPLEMENT - 2398684v1.0
Pre-Study - PRIOR RADIATION SUPPLEMENT -
2398684v1.0
All rights reserved. Please visit https://medical-data-
models.org/forms/2981
PRIOR RADIATION SUPPLEMENT
Prior Radiation Supplement
Treatment Start Date
Stop Date
RT Administered Type
3d Conformal (3D conformal)
Adjuvant (Adjuvant RT)
Brachytherapy (Brachytherapy)
Conformal (conformal)
Electron Beam (electron beam)
External Beam Radiation (External beam
radiation)
Hyperfractionated (hyperfractionated)
Imrt (IMRT)
Neoadjuvant (Neoadjuvant RT)
Other (Other specify)
Palliative Radiation Therapy (Palliative
RT)
Photodynamic Therapy (Photodynamic
therapy)
Photon Beam (photon beam)
Proton Beam (proton beam)
Radiofrequency Ablation
(Radiofrequency ablation)
Radiosurgery (radiosurgery)
CDUS Therapy Code
Chemotherapy Multiple Agents Systemic
(10008452)
Chemotherapy Single Agent Systemic
(10008456)
Homeopathic Therapy (10020363)
Vaccine (10021430)
Extensive Radiation (10037770)
Radiation (nos) (10037770)
Limited Radiation (10037770)
Srugery (10042609)
Chemotherapy (nos) (10050693)
No Prior Therapy (10052052)
Bone Marrow Transplant (10061730)
Hematopoietic Stem Cell Transplantation
(10063581)
Hormonal Therapy (10065646)
Anti-retroviral Therapy (90003000)
Antisense (90003002)
Gene Transfer (90003004)
Drug And/or Immunotherapy (90003006)
Oncolytic Virotherapy (90003008)
Prior Therapy (nos) (90003010)
Chemotherapy Non-cytotoxic (90003014)
Image Directed Local Therapy
(90003016)
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Radiation Field
Total Abdomen (Abdomen, total)
Arm (Arm)
Total Body (Body, total)
Bone, Non-spine (Bone, non-spine)
Brain To Cervical 2 (Brain-C2)
Brain, Focal (Brain, focal)
Brain, Whole (Brain, whole)
Breast (Breast)
Chest Wall, Nos (Chest Wall)
Eye (Eye)
Colon (Gastrointestinal, Colon)
Gallbladder (Gastrointestinal,
Gallbladder)
Intestine (Gastrointestinal, Intestine)
Liver (Gastrointestinal, Liver)
Gastrointestinal, Not Otherwise Specified
(Gastrointestinal, NOS)
Pancreas (Gastrointestinal, Pancreas)
Rectum (Gastrointestinal, Rectum)
Stomach (Gastrointestinal, Stomach)
Bladder (Genitourinary, Bladder)
Kidney (Genitourinary, Kidney)
Genitourinary, Not Otherwise Specified
(Genitourinary, NOS)
Prostate Gland (Genitourinary, Prostate)
Genitourinary, Prostate And Seminal
Vesicles (Genitourinary, Prostate and
Seminal Vesicles)
Head (Head)
Head, Face, Or Neck (Head, Face, or
Neck)
Leg (Leg)
Lung (Lung)
Lymph Node, Distant (specify Site)
(Lymph node, distant (specify site))
Lymph Node, Locoregional (specify Site)
(Lymph node, locoregional (specify site))
Lymph Nodes (Lymph Nodes)
Mantle Field (Mantle)
Mediastinum (Mediastinum)
Parametrium (Parametrium)
Pelvis (Pelvis)
Prostate Gland (Prostate)
Sacrum (Sacrum)
Seminal Vesicle (Seminal vesicles)
Skin, Lower Extremity, Local (Skin, lower
extremity, local)
Entire Skin (Skin, total)
Skin, Trunk, Local (Skin, trunk, local)
Skin, Upper Extremity, Local (Skin, upper
extremity, local)
Spine (Spine)
Spine (Spine, whole)
Supraclavicular Field (Supraclavicular)
Thorax (Thorax)
Trunk (Trunk)
RT Administered Total Dose
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Radiation Therapy Schedule
Actual Dose Administered Unit of Measure Name
Percent (%)
10e4 Cells Per Kilogram (10E4 Cell/kg)
10e5 Cells Per Kilogram (10E5 Cell/kg)
10e6 Cells Per Kilogram (10E6 Cell/kg)
10e7 Cells Per Kilogram (10E7 Cell/kg)
10e7 Plaque Forming Units (10E7 PFU)
10e8 Plaque Forming Units (10E8 PFU)
10e9 Plaque Forming Units (10E9 PFU)
Application (Applcatn)
Atomic Unit (au)
Area Under The Curve (AUC)
Billion Pfu (bill PFU)
Bottle (Bottle)
Caplet (Caplet)
Capsule (Capsule)
Cells (Cells)
Centigray (cGy)
Curie (Ci)
Course (Course)
Cycle (Course)
Deciliter (dL)
Dose (Dose)
Equivalent (Eq)
Grams (g) (g)
Gram Per M2 (g/m2)
Gallon (Gallon)
Drops (gtts)
Gray (Gy)
Hertz (Hz)
Inhalation (Inhalatn)
Iu Vitamin A (IU Vit A)
International Units Or Milligram Alpha
Tocopherol (IU/mg A-TE)
International Unit (IUnit)
International Unit Per Kilogram (IUnit/kg)
International Unit Per Liter (IUnit/L)
Intravenous Bag (IV Bag)
Joules Per Centimeter Squared (Jcm2)
Kib-electron Volt (KeV)
Kilograms (kg)
Kilohertz (kHz)
Kilopascal (kPa)
Kilounit (kU)
Kilounit Per Kilogram (kU/kg)
Kilounit Per Liter (kU/L)
Liter (L)
Liters Per Minute (L/min)
Microgram (mcg)
Microgram Per Centimeter Squared
(mcg/cm2)
Microgram Per Hour (mcg/hr)
Microgram Per Kilogram (mcg/kg)
Microgram Per Meter Squared (mcg/m2)
Millicurie (mCi)
Measure (Measure)
Milliequivalent (mEq)
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Milliequivalents Per 24 Hours (mEq/24hr)
Milliequivalent Per Deciliter (mEq/dL)
Milliequivalent Per Hour (mEq/hr)
Milliequivalent Per Liter (mEq/L)
Million Electron Volt (MeV)
Milligram (mg)
Milligram Per 24 Hours (mg/24hr)
Milligram Per Deciliter (mg/dL)
Milligram Per Hour (mg/hr)
Milligram Per Inhalation (mg/inh)
Milligram Per Kilogram (mg/kg)
Milligram Per Meter Squared (mg/m2)
Milligram Per Milliliter (mg/mL)
Milligram Per Week (mg/wk)
Megahertz (MHz)
Microcurie (microCi)
Microliter (microL)
Micromole (micromol)
Million Plaque Forming Units (mill PFU)
Million (Million)
Milliunit (millunit)
Milliinternational Unit (miu)
Milliinternational Units Per Meter
Squared (miu/m2)
Milliliter (mL)
Cubic Centimeter (cc) (mL)
Milliliter Per Hour (mL/hr)
Milliliter Per Kilogram (mL/kg)
Millimole (mmol)
Mole (Mole)
Milliosmole (mosmol)
Megarad (Mrad)
Million Units (MU)
Millivolt (mV)
Million Viral Particles (MVP)
Nanocurie (nCi)
Nanogram (ng)
Nanogram Per Kilogram (ng/kg)
Nanogram Per Liter (ng/L)
Nanograms Per Milliliter (ng/mL)
Nanometer Of Light (nm light)
Nanomole (nmol)
No Source Data (No Srce)
Osmolality (osmol)
Ounce (oz)
Pascal (Pa)
Packet (packet)
Patch (Patch)
Plaque Forming Units (PFU)
Picograms (pg)
Pounds Per Square Inch (psi)
Puff (puff)
Radiation Absorbed Dose (Rad)
Vitamin A Retinol (RAE)
Retinol Equivalents (RE)
Seed (Seed)
Session (Session)
Spray (Spray)
Suppository (Suppstry)
Tablets (Tablet)
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Tablespoon (Tbsp)
Tissue Culture Infection Dose (TCID)
Thousand (Thousand)
Troche (Troche)
Teaspoon (tsp)
Unit (Unit)
Unit Per Gram (Unit/g)
Unit Per Kilogram (Unit/kg)
Unit Per Meter Squared (Unit/m2)
Unknown (Unknown)
Viral Particles (VP)
Best Response Assessment Type
Complete Response (CR)
Complete Response Unconfirmed (CRU)
Disease Unchanged (DU)
Less Than Partial Response (MR)
Not Assessed (NA)
Not Evauable (NE)
Not Applicable Per Protocol (NP)
No Response (NR)
Progressive Disease (PD)
Partial Response (PR)
Stable Disease (SD)
Too Early (TE)
Unknown (UK)
Therapy Intent Text Name
Adjuvant (Adjuvant)
Bm Ablation (BM Ablation)
Curative (Curative)
Local Control (Local Control)
Metastatic (Metastatic)
Neo-adjuvant (Neo-Adjuvant)
Palliative (Palliative)
Preventive (Preventive)
Radiation Type
Extensive Radiation (Extensive
Radiation)
Limited Radiation Therapy (Limited
Radiation)
Radiation Therapy (Radiation, NOS)
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Sarcoma NCT01016730 On-Study - AMC-
063 Missed Visit Form (F35) - 3020209v1.0
Sarcoma NCT01016730 On-Study - AMC-063 Missed Visit
Form (F35) - 3020209v1.0
All rights reserved. Please visit https://medical-data-
models.org/forms/2984
AMC-063 Missed Visit Form (F35)
Unnamed1
Visit number
Unnamed2
Missed Visit Date (mm/dd/yyyy)
Reason patient missed visit
Health Reasons (Health reasons)
Other (Other)
Patient Could Not Get Off Work (Patient
could not get off work)
Patient Decided To Discontinue Study
(Patient decided to discontinue study)
Patient Experienced An Adverse Event
(Patient experienced an Adverse Event)
Patient Forgot (Patient forgot)
Patient Had Transportation Problems
(Patient had transportation problems)
Patient Unable To Obtain Dependent
Care (Patient unable to obtain dependent
care)
Patient Unhappy With Frequency Of
Visits (Patient unhappy with frequency of
visits)
Scheduling Difficulties (Scheduling
difficulties)
Other, specify
Next visit scheduled (Items missed will be made
up at the new visit.)
No (No)
Yes (Yes)
Comments
Comments
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Sarcoma NCT01016730 Pathology - AMC-063 AIDS and Cancer
Specimen Resource (ACSR) Procurement Form (F37) - 3020081v1.0
Sarcoma NCT01016730 Pathology - AMC-063 AIDS and
Cancer Specimen Resource (ACSR) Procurement Form
(F37) - 3020081v1.0
All rights reserved. Please visit https://medical-data-
models.org/forms/2993
AMC-063 AIDS and Cancer
Specimen Resource (ACSR)
Procurement Form (F37)
Unnamed1
Visit number
Unnamed2
Specimen(s) obtained for donation to ACSR
No (No)
Yes (Yes)
Specimen Type (check all that apply)
Peripheral Blood (Blood)
Other (Other)
Pbmc (peripheral Blood Mononuclear
Cells) (PBMC)
Plasma (Plasma)
Serum (Serum)
Tissue (Tissue)
Other specify
ACSR site the specimen(s) shipped to
Gwu (GWU)
Jhu (JHU)
Osu (OSU)
Other (Other)
Suny/hscb (SUNY/HSCB)
Ucla (UCLA)
Ucsf (UCSF)
Other, specify
If specimens were not obtained for ACSR, please
indicate reason
Other (Other)
Patient Had Previously Donated
Specimen To Acsr (Patient had
previously donated specimen to ACSR)
Patient Refused To Give Informed
Consent For Acsr Specimen Donation
(Patient refused to give informed consent
for ACSR specimen donation)
Patient Was Not Asked To Consider Acsr
Specimen Donation (Patient was not
asked to consider ACSR specimen
donation)
Other, specify
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Date Specimen Obtained (mm/dd/yyyy)
Date Specimen Obtained (mm/dd/yyyy)
Study Coordinator
Study Coordinator's name
E-mail
Phone Number (xxx-xxx-xxxx)
Comments
Comments
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Nonneoplastic Condition NCT01057121 On-Study - AMC-
070 Evaluation of KS Lesions Form (RK3) - 3146676v1.0
Nonneoplastic Condition NCT01057121 On-Study - AMC-
070 Evaluation of KS Lesions Form (RK3) - 3146676v1.0
All rights reserved. Please visit https://medical-data-
models.org/forms/3009
AMC-070 Evaluation of KS Lesions
Form (RK3)
Header Module
Visit number
Unnamed1
Foot Kaposi's Sarcoma (KS)
Absent (Absent)
Present (Present)
Compared to Previous Evaluation
Better (Better)
Same (Same)
Worse (Worse)
Photos Taken (Documentation)
No (No)
Yes (Yes)
Photos Taken Date
Physical findings
No (No)
Yes (Yes)
Specify (If Yes,)
Unnamed2
Are there any oral cavity lesions present at this
evaluation (If NO, go to GI EVALUATION section)
No (No)
Not Evaluated (Not evaluated)
Yes (Yes)
Total Number Raised Lesions
Total Number Flat Lesions (which are countable
or measurable)
Photos Taken (Documentation)
No (No)
Yes (Yes)
Is non-measurable disease present?
No (No)
Yes (Yes)
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Photos Taken Date
Are oral symptoms related to Kaposi's Sarcoma
No (No)
No Symptom (No symptoms)
Yes (Yes)
Explain (If not,)
Oral Site
Buccal Mucosa (Buccal mucosa)
Floor Of Mouth (Floor of mouth)
Gingiva (Gingiva/gums)
Hard Palate (Hard palate)
Pharynx (Posterior pharynx)
Soft Palate (Soft palate)
Tongue (Tongue)
Tonsil (Tonsils)
Uvula (Uvula)
Kaposi's Sarcoma present
No (No)
Yes (Yes)
Oral lesions
A Resolution Of All Oral Lesions Since
Baseline (A resolution of all oral lesions
since baseline)
A Worsening Of Oral Lesions Since
Baseline Or Best Response (A
worsening of oral lesions since baseline
or best response)
An Improvement Of Oral Lesions Since
Baseline (An improvement of oral lesions
since baseline)
New Oral Lesions (New oral lesions)
None Of The Above (None of the above)
Unnamed3
Are there any gastrointestinal (GI) lesions present
at this evaluation (If NO, go to PULMONARY
EVALUATION section)
No (No)
Not Evaluated (Not evaluated)
Yes (Yes)
Are there gastrointestinal (GI) symptoms related
to Kaposi's Sarcoma
No (No)
Yes (Yes)
Explain (If not,)
Method of Evaluation
Endoscopy (Endoscopy)
2 / 4
Nonneoplastic Condition NCT01057121 On-Study - AMC-070 Evaluation
of KS Lesions Form (RK3) - 3146676v1.0
Radiology (Radiological)
Performed
No (No)
Yes (Yes)
Assessment Date (mm/dd/yyyy)
Findings
Unnamed4
Are there any pulmonary Kaposi's Sarcoma (KS)
lesions present at this evaluation (If NO, go to
EDEMA EVALUATION section)
No (No)
Not Evaluated (Not evaluated)
Yes (Yes)
Indicate if the lesions are measurable or non-
measurable
Both Measurable And Non-measurable
(Both Measurable and Non-measurable)
Measurable Disease (Measurable)
Non-measurable (Non-measurable)
Are the pulmonary symptoms related to Kaposi's
Sarcoma
No (No)
Yes (Yes)
Explain (If not,)
Method of Evaluation
Endoscopy (Endoscopy)
Radiology (Radiological)
Performed
No (No)
Yes (Yes)
Assessment Date (mm/dd/yyyy)
Pleural Effusion
No (NO)
Yes (YES)
Specify number of lesions
Total Number New Lesions
Lesion Measurements
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Site of Lesion
Dimension 1 (cm)
Dimension 2 (cm)
Bronchoscopy And Other Tests
Bronchoscopy Performed
No (No)
Yes (Yes)
Date the bronchoscopy was performed
(mm/dd/yyyy)
Findings
Any Other Tests Performed
No (No)
Yes (Yes)
Other Tests
Findings
Footer Module
Comments
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Sarcoma NCT01016730 Quality of Life - AMC-063 FACT/GOG-
Neurotoxicity Questionnaire Form (NTQ) - 3021065v1.0
Sarcoma NCT01016730 Quality of Life - AMC-063
FACT/GOG-Neurotoxicity Questionnaire Form (NTQ) -
3021065v1.0
All rights reserved. Please visit https://medical-data-
models.org/forms/3033
AMC-063 FACT/GOG-Neurotoxicity
Questionnaire Form (NTQ)
Visit Number
Visit number
Unnamed2
I have numbness or tingling in my hands
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have numbness or tingling in my feet
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I feel discomfort in my hands
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I feel discomfort in my feet
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have joint pain or muscle cramps
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I feel weak all over
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have trouble hearing
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
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Somewhat (Somewhat)
Very Much (Very much)
I get a ringing or buzzing in my ears
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have trouble buttoning buttons
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have trouble feeling the shape of small objects
when they are in my hand
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have trouble walking
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
Comments
Comments
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Neurotoxicity Questionnaire Form (NTQ) - 3021065v1.0
Treatment - Infection Episode -
3277947v1.0
Treatment - Infection Episode - 3277947v1.0
All rights reserved. Please visit https://medical-data-
models.org/forms/3035
Infection Episode
Infection Episode
Visit Date
Course #
Day in Course (Cycle)
Date of Onset (Enter the date the infection
episode began.)
Date Resolved (Enter the date the infection
episode resolved.)
Infection Type (Select the infection type. For
example: pneumonia, UTI, URI, etc.)
Bacterial Infection (Bacterial)
Fungal Infection (Fungal)
Microbacterial Infection (Microbacterial)
No Isolated Organism (No Isolated
Organism)
Parasitic Infection (Parasitic)
Pneumonia (Pneumonia)
Protozoal Infection (Protozoal)
Unknown Infection Type (Unknown)
Upper Respiratory Infection (URI)
Urinary Tract Infection (UTI)
Viral Infection (Viral)
Primary Site (Select the primary site of the
infection.)
Abdomen (Abdomen)
Abdomen/pelvis (Abdomen/Pelvis)
Abdominal Wall (Abdominal wall)
Acetabulum (Acetabulum)
Pharyngeal Tonsil (Adenoid)
Adipose Tissue (Adipose)
Adrenal Gland (Adrenal gland)
Alveolar Ridge (Alveolar Ridge)
Amniotic Fluid (Amniotic Fluid)
Ampulla Of Vater (Ampulla of Vater)
Anal Canal (Anal canal)
Anal Sphincter (Anal sphincter)
Ankle (Ankle)
Anorectum (Anorectum)
Antecubital Fossa (Antecubital fossa)
Antrum Pylori (Antrum)
Anus (Anus)
Aorta (Aorta)
Aortic Body (Aortic Body)
Appendix (Appendix)
Aqueous Fluid (Aqueous Fluid)
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Arm (Arm)
Artery (Artery)
Ascending Colon (Ascending colon)
Ascending Colon Hepatic Flexure
(Ascending Colon Hepatic Flexure)
Auditory Canal (Auditory canal)
Autonomic Nervous System (Autonomic
nervous system)
Axilla (Axilla)
Back (Back)
Bile Duct (Bile duct)
Bladder (Bladder)
Blood (Blood)
Blood Vessel (Blood vessel)
Bone (Bone)
Bone Marrow (Bone marrow)
Bowel (Bowel)
Brain (Brain)
Brain Stem (Brain stem)
Breast (Breast)
Broad Ligament (Broad ligament)
Bronchiole (Bronchiole)
Bronchus (Bronchus)
Bronchus And Lung (Bronchus and
Lung)
Brow (Brow)
Buccal Cavity (Buccal cavity)
Buccal Mucosa (Buccal mucosa)
Buttock (Buttock)
Calf (Calf)
Capillary (Capillary)
Gastric Cardia (Cardia)
Carina (Carina)
Carotid Artery (Carotid artery)
Carotid Body (Carotid body)
Cartilage (Cartilage)
Cecum (Cecum)
Central Line Catheter (Central Line
Catheter)
Central Nervous System (Central
nervous system)
Cerebellum (Cerebellum)
Cerebral Cortex (Cerebral cortex)
Cerebrospinal Fluid (Cerebrospinal fluid)
Cerebrum (Cerebrum)
Cervical Spine (Cervical spine)
Cervical/thoracic/lumbar Spine
(Cervical/Thoracic/Lumbar spine)
Cervix (Cervix)
Chest (Chest)
Chest Wall (Chest wall)
Chest/abdomen/pelvis
(Chest/Abdomen/Pelvis)
Chest/pelvis (Chest/Pelvis)
Chin (Chin)
Clavicle (Clavicle)
Clitoris (Clitoris)
Colon (Colon)
Colon And Rectum (Colon and rectum)
Colon Mucosa (Colon, mucosa only)
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Common Duct (Common duct)
Conjunctiva (Conjunctiva)
Connective Tissue (Connective tissue)
Descending Colon (Descending colon)
Diaphragm (Diaphragm)
Duodenum (Duodenum)
Ear (Ear)
Ear Canal (Ear canal)
External Ear (Ear, Pinna (External))
Effusion (Effusion)
Elbow (Elbow)
Endocrine Gland (Endocrine gland)
Epididymis (Epididymis)
Epidural Spinal Canal Space (Epidural
space)
Esophagogastric Junction
(Esophagogastric junction)
Esophagus (Esophagus)
Esophageal Mucosa (Esophagus,
Mucosa only)
Extremities (Extremities)
Eye (Eye)
Fallopian Tube (Fallopian tube)
Femur (Femur)
Fibula (Fibula)
Finger (Finger)
Floor Of Mouth (Floor of Mouth)
Body Fluid Or Substance (Fluid)
Foot (Foot)
Forearm (Forearm)
Forehead (Forehead)
Foreskin (Foreskin)
Frontal Lobe (Frontal lobe)
Fundus Of Stomach (Fundus of
stomach)
Gallbladder (Gallbladder)
Ganglion (Ganglia)
Gastroesophageal Junction
(Gastroesophageal Junction)
Gastrointestinal Tract (Gastrointestinal
tract)
Genitourinary (Genitourinary)
Groin (Groin)
Gum (Gum)
Hand (Hand)
Hard Palate (Hard palate)
Head - Face Or Neck, Nos (Head - face
or neck, NOS)
Head/neck (Head/Neck)
Head/neck/chest/adb/pelvis
(Head/Neck/Chest/Adb/Pelvis)
Heart (Heart)
Hepatic Duct (Hepatic duct)
Hip (Hip)
Humerus (Humerus)
Hypopharynx (Hypopharynx)
Ileum (Ileum)
Ilium (Ilium)
Intestine (Intestine)
Ischium (Ischium)
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Jaw (Jaw)
Jejunum (Jejunum)
Joints (Joints)
Kidney (Kidney)
Knee (Knee)
Lacrimal Gland (Lacrimal Gland)
Large Bowel (Large bowel)
Laryngopharynx (Laryngopharynx)
Larynx (Larynx)
Leg (Leg)
Ligament (Ligament)
Lip (Lip)
Liver (Liver)
Liver And Intrahepatic Duct (Liver and
intrahepatic duct)
Liver/spleen (Liver/Spleen)
Lumbar Spine (Lumbar spine)
Lung (Lung)
Lymph Node (Lymph node)
Lymph Node(s) Axilla (Lymph Node(s)
Axilla)
Lymph Node(s) Cervical (Lymph Node(s)
Cervical)
Distant Lymph Node (Lymph node(s)
Distant)
Lymph Node(s) Hilar (Lymph Node(s)
Hilar)
Lymph Node(s) Inguinal (Lymph Node(s)
Inguinal)
Lymph Node(s) Int Mammary (Lymph
Node(s) Int Mammary)
Lymph Node(s) Mammary (Lymph
Node(s) Mammary)
Paraaortic Region Lymph Node (Lymph
node(s) Para aortic)
Lymph Node(s) Pelvic (Lymph Node(s)
Pelvic)
Regional Lymph Node (Lymph node(s)
Regional)
Scalene Lymph Node (Lymph node(s)
Scalene)
Lymph Node(s) Subclavicular (Lymph
Node(s) Subclavicular)
Lymph Node(s) Supraclav (Lymph
Node(s) Supraclav)
Lymph Nodes (Lymph nodes)
Mediastinal Lymph Node (Lymph
nodes(s) Mediastinal)
Lymphoma (Lymphoma)
Mammary Gland (Mammary Gland)
Mandible (Mandible)
Maxilla (Maxilla)
Mediastinum (Mediastinum)
Mesentery (Mesentery)
Mesothelium (Mesothelium)
Mini Mantle (Mini Mantle)
Mouth (Mouth)
Muscle (Muscle)
Nail (Nails)
Nasal Cavity (Nasal Cavity)
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Nasopharynx (Nasopharynx)
Neck (Neck)
Neck Chest (Neck/Chest)
Neck/chest/abdomen/pelvis
(Neck/Chest/Abdomen/Pelvis)
Nerve (Nerve)
Cranial Nerve (Nerve(s) Cranial)
Not Applicable (Not Applicable)
Ocular Orbits (Ocular Orbits)
Omentum (Omentum)
Oral Cavity (Oral cavity)
Oral Cavity Mucosa (Oral Cavity, Mucosa
only)
Oropharynx (Oropharynx)
Other (Other)
Ovary (Ovary)
Posterior Anterior/lateral (PA/Lat)
Palate (Palate)
Pancreas (Pancreas)
Paraspinal Ganglion (Paraspinal
Ganglion)
Parathyroid Gland (Parathyroid)
Parotid Gland (Parotid gland)
Patella (Patella)
Pelvis (Pelvis)
Penis (Penis)
Perianus (Perianus)
Pericardium (Pericardium)
Peritoneal Cavity (Peritoneal cavity)
Peritoneum (Peritoneum)
Pharynx (Pharynx)
Pineal Gland (Pineal Gland)
Pituitary Gland (Pituitary gland)
Placenta (Placenta)
Pleura (Pleura)
Popliteal Fossa (Popliteal fossa)
Prostate (Prostate)
Pylorus (Pylorus)
Rectosigmoid Junction (Rectosigmoid
Junction)
Rectum (Rectum)
Retina (Retina)
Retro-orbital Area (Retro-orbital Area)
Retroperitoneum (Retroperitoneum)
Ribs (Ribs)
Round Ligament (Round ligament)
Sacrum (Sacrum)
Salivary Gland (Salivary gland)
Scalp (Scalp)
Scapula (Scapula)
Scrotum (Scrotum)
Shoulder Joint (Shoulder)
Sigmoid Colon (Sigmoid colon)
Sinus(es) (Sinus(es))
Sinus(es), Maxillary (Sinus(es),
Maxillary)
Skeletal Muscle Tissue (Skeletal Muscle)
Skin (Skin)
Skull (Skull)
Small Bowel Mucosa (Small Bowel,
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Mucosa only)
Small Intestine (Small intestine)
Soft Tissue (Soft Tissue)
Spinal Cord (Spinal Cord)
Spine (Spine)
Spine/femur (Spine/Femur)
Spine/femur/radius
(Spine/Femur/Radius)
Spleen (Spleen)
Splenic Flexure (Splenic Flexure)
Sternum (Sternum)
Stomach (Stomach)
Stomach Mucosa (Stomach, Mucosa
only)
Subcutaneous Tissue (Subcutaneous
tissue)
Synovial Membrane (Synovium)
Tendon (Tendon)
Testis (Testicle)
Testicle (Testicle)
Thigh (Thigh)
Thoracic Spine (Thoracic spine)
Thoracic/lumbar Spine (Thoracic/Lumbar
spine)
Thorax (Thorax)
Throat (Throat)
Thymus (Thymus)
Thyroid Gland (Thyroid gland)
Tibia (Tibia)
Tongue (Tongue)
Tongue, Base Of Tongue (Tongue, Base
of tongue)
Tonsil (Tonsil)
Pharyngeal Tonsil (Tonsil, Pharyngeal)
Trachea (Trachea)
Trachea Main Bronchus (Trachea/Major
Bronchi)
Transverse Colon (Transverse Colon)
Trunk (Trunk)
Superficial Trunk (Trunk, Superficial)
Umbilical Cord (Umbilical Cord)
Upper Extremity (Upper extremity)
Ureter (Ureter)
Urethra (Urethra)
Urinary Tract (Urinary tract)
Uterus (Uterus)
Uvula (Uvula)
Vagina (Vagina)
Vas Deferens (Vas Deferens)
Vein (Vein)
Vena Cava (Vena Cava,
Inferior/Superior)
Vertebra (Vertebra)
Vertebral Column (Vertebral column)
Vulva (Vulva)
Whole Body (Whole body)
Wrist (Wrist)
Infectious Agent (Select the actual infectious
agent, determined from culture or other
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appropriate test.)
Achromobacter Spanius (Achromobacter
spanius)
Acinetobacter (Acinetobacter)
Actinomyces (Actinomyces)
Adenovirus (Adenovirus)
Agrobacterium (Agrobacterium)
Alcaligenes (Alcaligenes)
Amebiasis (Amebiasis)
Aspergillus Flavus (Aspergillus flavus)
Aspergillus Fumigatus (Aspergillus
fumigatus)
Aspergillus Niger (Aspergillus niger)
Aspergillus Terreus (Aspergillus terreus)
Aspergillus, Not Otherwise Specified
(Aspergillus, NOS)
Atypical Bacteria, Nos (Atypical bacteria,
NOS)
Bacillus (Bacillus)
Bacteria (Bacterium)
Bacteroides (Bacteroides)
Bk Virus (BK Virus)
Bordetella (Bordetella)
Bordetella Pertussis Bacterium
(Bordetella pertussis Bacterium)
Borrelia (Borrelia)
Branhamella Catarrhalis (Branhamella
catarrhalis)
Burkholderia Cepacia (Burkholderia
cepacia)
Campylobacter (Campylobacter)
Candida Albicans (Candida albicans)
Candida Glabrata (Candida glabrata)
Candida Guillermondi (Candida
guillermondi)
Candida Krusei (Candida krusei)
Candida Lusitaniae (Candida lusitaniae)
Candida Parapsilosis (Candida
parapsilosis)
Candida Tropicalis (Candida tropicalis)
Candida, Not Otherwise Specified
(Candida, NOS)
Capnocytophaga (Capnocytophaga)
Chlamydia (Chlamydia)
Chlamydia Pneumoniae (Chlamydia
pneumoniae)
Chlamydia, Not Otherwise Specified
(Chlamydia, NOS)
Chryseobacterium (Chryseobacterium)
Citrobacter (Citrobacter)
Clavispora Lusitaniae (Clavispora
lusitaniae)
Clostridium Difficile (Clostridium difficile)
Clostridium Non-difficile (Clostridium
non-difficile)
Condyloma/warts (Condyloma/Warts)
Corynebacterium (Corynebacterium)
Corynebacterium Jeikeium
(Corynebacterium jeikeium)
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Coxiella (Coxiella)
Cryptococcosis (Cryptococcosis)
Cryptococcus Species (Cryptococcus
species)
Cryptosporidium (Cryptosporidium)
Cytomegalovirus (Cytomegalovirus)
Dactylaria (Dactylaria)
Echinocoocal Cyst (Echinocoocal cyst)
Enterobacter (Enterobacter)
Enterococcus (Enterococcus)
Enterococcus Faecalis (enterococcus
Faecium) (Enterococcus faecalis)
Enterococcus, Vancomycin Resistant
(vre) (Enterococcus, vancomycin
resistant (VRE))
Enterovirus (Enterovirus)
Epstein-barr Virus (Epstein-Barr Virus)
Escherichia Coli (Escherichia coli)
Exserohilum Species (Exserohilum
Species)
Fungi, Filamentous (Filamentous fungus,
NOS)
Flavimonas Flavimonas Flavimonas
(Flavimonas)
Flavimonas Oryzihabitans (Flavimonas
oryzihabitans)
Flavobacterium (Flavobacterium)
Fusarium (Fusarium)
Fusarium Species (Fusarium species)
Fusobacteria (Fusobacterium)
Fusobacterium Nucleatum
(Fusobacterium nucleatum)
Giardia (Giardia)
Gonorrhea (Gonorrhea)
Gram Negative Cocci (Gram negative
cocci)
Gram Negative Diplococci (Gram
negative diplococci)
Gram Negative Rod (Gram negative rod)
Gram Positive Bacillus (Gram positive
bacillus)
Gram Positive Cocci (Gram positive
cocci)
Gram Positive Rod (Gram positive rod)
Haemophilus Influenzae (Haemophilus
influenzae)
Helicobacter Pylori (Helicobacter pylori)
Hepatitis A (Hepatitis A)
Hepatitis B Virus (Hepatitis B Virus)
Hepatitis C (Hepatitis C)
Hepatitis G (hepatitis G)
Hepatitis, Not Otherwise Specified
(Hepatitis, NOS)
Herpes Simplex (Herpes Simplex)
Herpes Zoster (Herpes Zoster)
Histoplasma (Histoplasma)
Histoplasmin (Histoplasmin)
Histoplasmosis (Histoplasmosis)
Human Herpesvirus-6 (hhv-6) (Human
herpesvirus-6 (HHV-6))
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Human Immunodeficiency Virus (Human
Immunodeficiency Virus)
Human Papilloma Virus (hpv) (Human
papilloma virus (HPV))
Hyphae (Hyphae)
Influenza (Influenza)
Influenza (a) (Influenza (A))
Influenza (b) (Influenza (B))
Jc Virus / Progressive Multifocal
Leukoencephalopathy (pml) (JC
virus/progress multfoc leukoenc (PML))
Klebsiella (Klebsiella)
Lactobacillus (Lactobacillus)
Legionella (Legionella)
Leptospira (Leptospira)
Leptotrichia (Leptotrichia)
Leptotrichia Buccalis (Leptotrichia
buccalis)
Leuconostoc (Leuconostoc)
Listeria (Listeria)
Maltophilia (Maltophilia)
Measles (rubeola) (Measles (Rubeola))
Methylobacterium (Methylobacterium)
Micrococcus (Micrococcus)
Microsporidia (Microsporidia)
Mold, Not Otherwise Specified (Mold,
NOS)
Moraxella (Moraxella)
Moraxella (branhamella) Catarrhalis
(Moraxella (Branhamella) catarrhalis)
Morganella Morganii (Morganella
morganii)
Mucor Species Mucor Species (Mucor
Species)
Mucormycosis (Mucormycosis)
Mumps (Mumps)
Mycobacterium Infection
(Mycobacterium)
Mycobacterium Avium Intracellulare
(mac, Mai) (Mycobacterium avium
intracell (MAC, MAI))
Mycobacterium Species (cheloneae,
Fortuitum, Haemophilum, Kansasii,
Mucogenicum) (Mycobacterium species)
Mycobacterium Tuberculosis
(Mycobacterium Tuberculosis)
Mycoplasma (Mycoplasma)
Neisseria Gonorrhoeae (Neisseria
gonorrhoeae)
Neisseria Meningitidis (Neisseria
meningitidis)
Neisseria, Not Otherwise Specified
(Neisseria, NOS)
No Growth (No growth)
No Organism Identified (No organism
identified)
Nocardia (Nocardia)
Norovirus (Norovirus)
Other Microorganism, Specify (Other)
Other Aspergillus, Specify (Other
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Aspergillus, specify)
Other Bacteria, Not Otherwise Specified
(Other Bacteria, NOS)
Other Bacteria, Specify (Other Bacteria,
specify)
Other Candida, Not Otherwise Specified
(Other Candida, NOS)
Other Candida, Specify (Other Candida,
specify)
Other Chlamydia, Specify (Other
Chlamydia, specify)
Other Fungus (Other Fungus)
Other Mycobacterium (Other
Mycobacterium)
Other Mycobacterium, Specify (Other
Mycobacterium, specify)
Other Organism (Other Organism)
Other Parasite (amebiasis, Echinococcal
Cyst, Trichomonas Either Vaginal Or
Gingivitis), Specify (Other Parasite,
specify)
Other Protozoal (parasite) (Other
Protozoal (Parasite))
Other Viral (Other Viral)
Other Virus, Specify (Other Virus,
specify)
Papillomavirus (Papillomavirus)
Parainfluenza (Parainfluenza)
Parvovirus B19, Human (Parvovirus B19,
Human)
Pasteurella Multocida (Pasteurella
multocida)
Pharyngeal/respiratory Flora
(Pharyngeal/Respiratory flora)
Pneumocystis Carinii (Pneumocystis
carinii)
Polyomavirus (Polyomavirus)
Propionibacterium (Propionibacterium)
Proteus (Proteus)
Proteus Mirabilis (Proteus mirabilis)
Protozoa, Not Otherwise Specified
(Protozoa, NOS)
Pseudomonas (Pseudomonas)
Pseudomonas Aeruginosa
(Pseudomonas aeruginosa)
Respiratory Syncytial Virus (Respiratory
Syncytial Virus)
Rhinovirus (common Cold) (Rhinovirus
(Common Cold))
Rhizopus (Rhizopus)
Rhodococcus (Rhodococcus)
Rhodotorula Mucilaginosa (Rhodotorula
mucilaginosa)
Rickettsia (Rickettsia)
Rotavirus (Rotavirus)
Rubella (german Measles) (Rubella
(German Measles))
Salmonella (Salmonella)
Scabies (Scabies)
Septate Hyphae (Septate hyphae)
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Serratia (Serratia)
Serratia Marcescens (Serratia
marcescens)
Serratia, Not Otherwise Specified
(Serratia, NOS)
Shigella (Shigella)
Staphylococcus (Staphylococcus)
Staphylococcus Aureus (Staphylococcus
aureus)
Staphylococcus Coag Negative
(Staphylococcus coag negative)
Staphylococcus Coag Positive
(Staphylococcus coag positive)
Staphylococcus Epidermidis
(Staphylococcus epidermidis)
Staphylococcus Haemolyticus
Staphylococcus Haemolyticus
(Staphylococcus haemolyticus)
Staphylococcus Hominus
(Staphylococcus hominus)
Staphylococcus Hyphae
(Staphylococcus hyphae)
Staphylococcus Intermedius
(Staphylococcus intermedius)
Staphylococcus Maltophilia
(Staphylococcus maltophilia)
Staphylococcus Warneri
(Staphylococcus warneri)
Staphylococcus, Not Otherwise Specified
(Staphylococcus, NOS)
Stenotrophomonas Maltophilia
(Stenotrophomonas maltophilia)
Stomatococcus Mucilaginosis
(Stomatococcus mucilaginosis)
Strep Alpha Hemolytic (Streptococcul
alpha hemolytic)
Streptococcus (Streptococcus)
Streptococcus Mitis (Streptococcus
mitis)
Streptococcus Pneumoniae
(Streptococcus pneumoniae)
Streptococcus Pyogenes (Streptococcus
pyogenes)
Streptococcus Salivarius (Streptococcus
salivarius)
Streptococcus Viridans (Streptococcus
viridans)
Suspected Atypical Bacterial Infection
(Suspected atypical bacterial infection)
Suspected Bacterial Infection
(Suspected bacterial infection)
Suspected Fungal Infection (Suspected
fungal infection)
Suspected Parasite Infection (Suspected
parasite infection)
Tetanus Toxoid (Tetanus toxoid)
Torulopsis Glabrata (candida
Subspecies) (Torulopsis glabrata
(candida subspecies))
Toxoplasma (Toxoplasma)
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Treponema (Treponema)
Trichomonas (Trichomonas)
Tuberculosis, Not Otherwise Specified
(Tuberculosis, NOS)
Varicella (Varicella)
Varicella-zoster Virus (Varicella-Zoster
Virus)
Vibrio (Vibrio)
Xanthomonas (Xanthomonas)
Yeast (Yeast)
Yeast, Not Otherwise Specified (Yeast,
NOS)
Zygomycetes (Zygomycetes)
Zygomycetes (mucomycosis, Rhizopus)
(Zygomycetes (Mucomycosis,
Rhizopus))
Treatment (Select the treatment or lack of given
for this infection.)
3tc (lamivudine) (3TC)
Abacavir (Abacavir)
Acyclovir (Acyclovir)
Adefovir (Adefovir)
Amantadine Hydrochloride (Amantadine
HCL)
Amikacin (Amikacin)
Amoxicillin (Amoxicillin)
Amoxicillin-clavulanate Potassium
(Amoxicillin/Clavulanate Potassium)
Amphotercin B (Amphotericin B)
Amphotericin B Liposomal (Amphotericin
B Liposomal)
Ampicillin (Ampicillin)
Ampicillin Sodium/sulbactam Sodium
(Ampicillin Sodium/Sulbactam Sodium)
Amprenavir (Amprenavir)
Anidulafungin (Anidulafungin)
Atovoquone (Atovoquone)
Azithromycin (Azithromycin)
Aztreonam (Aztreonam)
Bacitracin (Bacitracin)
Bacitracin Zinc (Bacitracin Zinc)
Benzylpenicillin Sodium (Benzylpenicillin
Sodium)
Caspofungin (Caspofungin)
Cefaclor (Cefaclor)
Cefadroxil (Cefadroxil)
Cefazolin (Cefazolin)
Cefdinir (Cefdinir)
Cefepime (Cefepime HCL)
Cefotaxime Sodium (Cefotaxime
Sodium)
Cefoxitin Sodium (Cefoxitin Sodium)
Cefpodoxime (Cefpodoxime)
Cefprozil (Cefprozil)
Ceftazidime (Ceftazidime)
Ceftriaxone (Ceftriaxone)
Cefuroxime Axetil (Cefuroxime Axetil)
Cephalexin (Cephalexin)
Cidofovir (Cidofovir)
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Ciprofloxacin (Ciprofloxacin)
Clarithromycin (Clarithromycin)
Clindamycin (Clindamycin)
Clotrimazole (Clotrimazole)
Colistimethate (Colistimethate)
Lamivudine/zidovudine (Combivir)
Trimethoprim-sulfamethoxazole
(Cotrimoxazole)
Dapsone (Dapsone)
Daptomycin (Daptomycin)
Zalcitabine (ddC)
Didanosine (ddI)
Double Pharmaceutical Strength
Didanosine (ddi DS)
Delavirdine Mesylate (Delavirdine
Mesylate)
Demeclocycline (Demeclocycline HCL)
Dicloxacillin (Dicloxacillin)
Extended Release Dosage Form
Didanosine (Didanosine EC)
Doxycycline Calcium (Doxycycline
Calcium)
Doxycycline Monohydrate (Doxycycline
Chloride)
Doxycycline Hyclate (Doxycycline
Hyclate)
Doxycycline Monohydrate (Doxycycline
Monohydrate)
Efavirenz (Efavirenz)
Ertapenem (Ertapenem)
Erythromycin (Erythromycin)
Ethambutol (Ethambutol HCL)
Famciclovir (Famciclovir)
Fluconazole (Fluconazole)
Foscarnet Sodium (Foscarnet Sodium)
Ganciclovir (Ganciclovir)
Gatifloxacin (Gatifloxacin)
Gentamicin (Gentamicin)
Imipenem (Imipenem)
Imipenem-cilastatin Sodium
(Imipenem/Cilastatin)
Indinavir Sulfate (Indinavir)
Isoniazid (Isoniazid)
Itraconazole (Itraconazole)
Ivermectin (Ivermectin)
Ketoconazole (Ketoconazole)
Levofloxacin (Levofloxacin)
Linezolid (Linezolid)
Lopinavir (Lopinavir)
Lopinavir/ritonavir (Lopinavir/Ritonavir)
Meropenem (Meropenem)
Metronidazole (Metronidazole)
Micafungin (Micafungin Sodium)
Miconazole (Miconazole)
Moxifloxacin (Moxifloxacin HCL)
Mupirocin (Mupirocin)
Nafcillin (Nafcillin)
Nelfinavir (Nelfinavir)
Neosporin Cream (Neosporin)
Nevirapine (Nevirapine)
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Nitrofurantoin (Nitrofurantoin)
Nystatin (Nystatin)
Ofloxacin (Ofloxacin)
Oseltamivir (Oseltamivir)
Oxacillin Sodium (Oxacillin Sodium)
Penicillin V (Penicillin V)
Pentamidine (Pentamidine Isethionate)
Permethrin (Permethrin)
Penicillin V (Phenoxymethylpenicillin)
Piperacillin Sodium (Piperacillin)
Piperacillin-tazobactam (Piperacillin
Sodium/Tazobactam Sodium)
Pyrimethamine (Pyrimethamine)
Ribavirin (Ribavirin)
Rifabutin (Rifabutin)
Rifampin (Rifampin)
Ritonavir (Ritonavir)
Saquinavir (Saquinavir)
Sulfacetamide (Sulfacetamide)
Sulfadiazine (Sulfadiazine)
Trimethoprim-sulfamethoxazole
(Sulfamethoxazole/Trimethoprim)
Double Pharmaceutical Strength
Trimethoprim-sulfamethoxazole
(Sulfamethoxazole/Trimethoprim
(Bactrim) DS)
Tenofovir (Tenofovir)
Terbinafine (Terbinafine HCL)
Terconazole (Terconazole)
Tetracycline (Tetracycline HCL)
Ticarcillin Disodium (Ticarcillin Disodium)
Tobramycin (Tobramycin)
Undecylenic Acid (Undecyclenic Acid)
Urised (Urised)
Valacyclovir (Valacyclovir HCL)
Valganciclovir (Valganciclovir)
Vancomycin (Vancomycin)
Voriconazole (Voriconazole)
(Concomitant) Procedure (Select the procedure
or lack of done for this infection.)
Complementary And Alternative
Medicine (Alternative Therapy)
Pheresis (Apheresis)
Arterial Access Port Removed (Arterial
Access Port Removal)
Contraception (Birth Control)
Bronchoalveolar Lavage
(Bronchoscopy/Bronch Lavage)
Cauterization (Cauterization)
Dental Procedure (Dental Procedure)
Direct Current Cardioversion (Direct
Current Cardioversion (DCCV))
Ear Tube Placement (Ear Tube(s)
Insertion)
Oesophageal Dilation Procedure
(Esophageal Dilation)
Partial Colectomy (Hemicolectomy)
Hemodialysis (Hemodialysis)
Whole Body Hyperbaric Oxygen Therapy
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(Hyperbaric Treatment(s))
Intraaortic Balloon Pump/stent
Placement (IABP/Stent Placement)
Incision And Drainage (Incision &
Drainage)
Intraventricular Shunt Access
(Intraventricular Shunt Access)
Irrigation - Action (Irrigation)
Lymphocyte Infusion (Lymphocyte
Infusion)
Ventilation, Mechanical (Mechanical
Ventilation)
Tubes, Gastrointestinal Decompression
(NG Decompression)
Masks, Air-oxygen, Aerosol
Administration (Oxygen Administration)
Paracentesis (Paracentesis)
Pleurodesis (Pleurodesis)
Partial Airway Pressure Treatment
(includes Bipap And Cpap) (Positive
Partial Airway Pressure Treatment)
Radiation (Radiation)
Stent/catheter Change (Stent/Catheter
Change)
Catheterization (Stent/Catheter
Placement)
Removal Of Stent (Stent/Catheter
Removal)
Surgical Procedure (Surgical Procedure)
Thoracentesis (Thoracentesis)
Platelet Transfusion (Transfusion,
Platelet)
Packed Red Blood Cell Transfusion
(Transfusion, RBC)
Venous Access Device Placement
(Venous Access/IV Placement)
Venous Access Device Removal (Venous
Access/IV Removal)
Outcome (Select the outcome of this episode.)
Recovered (1)
Still Under Treatment/ Observation (2)
Alive With Sequelae (3)
Died (4)
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Nonneoplastic Condition NCT01057121 Response - AMC-
070 Overall Assessment Form (RK6) - 3147277v1.0
Nonneoplastic Condition NCT01057121 Response - AMC-
070 Overall Assessment Form (RK6) - 3147277v1.0
All rights reserved. Please visit https://medical-data-
models.org/forms/3037
AMC-070 Overall Assessment Form
(RK6)
Header Module
Visit number
Unnamed1
Best Response (since Entry/Baseline)
Clinical Complete Response (Clinical
complete response)
Complete Response (Complete
response)
Partial Response (Partial response)
Progressive Disease (Progressive
disease)
Stable Disease (Stable disease)
Unevaluable (Unevaluable)
Unknown (Unknown)
What is the present status of the best response
No Relapse Observed, But Patent Died
(No relapse observed, but patent died)
Not Applicable (Not applicable)
Relapse Occurred After A Response
Was Achieved (Relapse occurred after a
response was achieved)
Response Continuing Or First Time At
This Response (Response continuing or
first time at this response)
Date of Relapse or Progression (if applicable
mm/dd/yyyy)
Unnamed2
Is complete response observed (During this
reporting period)
No (No)
Yes (Yes)
Complete Response Observed Date
(mm/dd/yyyy)
Is Clinical Complete Response observed (During
this reporting period)
No (NO)
Yes (YES)
Clinical Complete Response observed date
(mm/dd/yyyy)
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Is partial response observed (During this
reporting period)
No (No)
Yes (Yes)
Partial Response Observed Date (mm/dd/yyyy)
Is progression observed (During this reporting
period)
No (No)
Yes (Yes)
Progressive Disease Observed Date
(mm/dd/yyyy)
Footer Module
Comments
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AMC-063 Physical Exam Form
(RK2)
Header Module
Visit number
Unnamed2
At entry, does the participant have >=50 lesions
No (No)
Yes (Yes)
Representative Area
Abdomen (Abdomen)
Back (Back)
Chest (Chest)
Genital Area (Genital)
Head (Head)
Left Arm (Left arm)
Left Foot (Left foot)
Left Hand (Left hand)
Left Leg (Left leg)
Neck (Neck)
Right Arm (Right arm)
Right Foot (Right foot)
Right Hand (Right hand)
Right Leg (Right leg)
Total Body (Total body)
Total Number Raised Lesions
Total Number Flat Lesions
Total Number New Lesions
Number of cutaneous lesions
>=25% Increase In The Number Of
Lesions Since Baseline Or Since Best
Response (>=25% increase in the
number of lesions since baseline or
since best response)
>=50% Decrease In The Number Of
Lesions Since Baseline (>=50%
decrease in the number of lesions since
baseline)
Complete Resolution (Complete
resolution)
None Of The Above (None of the above)
Character of cutaneous lesions (since baseline or
best response)
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>=25% Increase In The Number Of
Raised Lesions (>=25% increase in the
number of raised lesions)
None Of The Above (None of the above)
Since Baseline, >=50% Of Raised Have
Become Flat (Since baseline, >=50% of
raised have become flat)
Unnamed3
Representative Area
Abdomen (Abdomen)
Back (Back)
Chest (Chest)
Genital Area (Genital)
Head (Head)
Left Arm (Left arm)
Left Foot (Left foot)
Left Hand (Left hand)
Left Leg (Left leg)
Neck (Neck)
Right Arm (Right arm)
Right Foot (Right foot)
Right Hand (Right hand)
Right Leg (Right leg)
Total Body (Total body)
Specify
Dimension 1 (cm)
Dimension 2 (cm)
Product of Diameters
Photos Taken
No (No)
Yes (Yes)
Sum of Products of Greatest Diameters
Evaluation of Marker Lesions
>=25% Inc In Sum Of The Products Of
The Diam Of All Marker Lesions Since
Baseline/best Response (>=25% inc in
sum of the products of the diam of all
marker lesions since baseline/best
response)
>=50% Decrease In The Sum Of The
Products Of The Diameters Of All Marker
Lesions Since Baseline (>=50%
decrease in the sum of the products of
the diameters of all marker lesions since
baseline)
Complete Resolution (Complete
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resolution)
None Of The Above (None of the above)
Footer Module
Comments
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Nonneoplastic Condition NCT01057121 Off Treatment -
AMC-070 Off-Study Summary Form (F50) - 3147123v1.0
Nonneoplastic Condition NCT01057121 Off Treatment -
AMC-070 Off-Study Summary Form (F50) - 3147123v1.0
All rights reserved. Please visit https://medical-data-
models.org/forms/3047
AMC-070 Off-Study Summary Form
(F50)
Ccrr Module For Off Study Summary -
Rf50
Off Study Date (mm/dd/yyyy)
Off Study Reason (select the primary reason)
Adverse Event/side Effects/complications
(Adverse Event/Side
Effects/Complications)
Death (Death)
Other (Other)
Lost To Follow-up (Patient lost to follow-
up)
Patient Refused Follow-up (Patient
refused follow-up)
Protocol-defined Follow-up Completed
(Protocol-defined follow-up completed)
Other, specify
Comments
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AMC-051 HIV Viral Load Form (F40)
Unnamed1
Visit number
Unnamed2
Results of HIV viral load assay  (Enter results
from right to left.)
Equal To (Equal to (=))
Greater Than (>) (Greater than (>))
Less Than (Less than (<))
Undetectable (Undetectable)
HIV viral load value
Method of detection
Abbott Realtime Hiv-1 Assay (Abbott
RealTime HIV-1 assay)
Cobas Ampliprep/taqman Hiv-1 Assay
(COBAS AmpliPrep/TAQMAN HIV-1
assay)
Other (Other)
Roche Amplicor Monitor Assay (Roche
Amplicor Monitor Assay)
Versant Hiv-1 Rna Assay By Branched
Dna (Versant HIV-1 RNA assay by
branched DNA)
Other, specify
HIV viral load assay type
Standard (Standard)
Ultra (Ultra)
Limits of detection (Copies/mL)
Lab Facility Name (Testing Laboratory
information)
Comments
Comments
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BASELINE SYMP
Baseline Symptoms
Adverse Event Onset Date
Resolved Date
Common Toxicity Criteria Adverse Event Term
Type
Retinoic Acid Syndrome (aaRetinoic acid
syndrome")
Acidosis Nos (Acidosis (metabolic or
respiratory))
Capillary Leak Syndrome (Acute
vascular leak syndrome)
Adrenal Insufficiency (Adrenal
insufficiency)
Adult Respiratory Distress Syndrome
(Adult respiratory distress syndrome
(ARDS))
Blood Albumin Decreased (Albumin,
serum-low (hypoalbuminemia))
Alcohol Intolerance Syndrome
(antabuse-like Syndrome) (Alcohol
intolerance syndrome (antabuse-like
syndrome))
Blood Alkaline Phosphatase Nos
Increased (Alkaline phosphatase)
Alkalosis Nos (Alkalosis (metabolic or
respiratory))
Hypersensitivity Nos (Allergic
reaction/hypersensitivity (including drug
fever))
Rhinitis Allergic Nos (Allergic rhinitis
(including sneezing, nasal stuffiness,
postnasal drip))
Allergy/immunology Other
(Allergy/Immunology-Other (Specify))
Alanine Aminotransferase Increased
(ALT, SGPT (serum glutamic pyruvic
transaminase))
Blood Amylase Increased (Amylase)
Anorexia (Anorexia)
Apnoea (Apnea)
Arachnoiditis
(Arachnoiditis/meningismus/radiculitis)
Arthritis Nos (Arthritis (non-septic))
Ascites (Ascites (non-malignant))
Aspiration (Aspiration)
Aspartate Aminotransferase Increased
(AST, SGOT (serum glutamic oxaloacetic
transaminase))
Ataxia Nec (Ataxia (incoordination))
Atelectasis (Atelectasis)
Atrophy, Skin (Atrophy, skin)
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Atrophy, Subcutaneous Fat (Atrophy,
subcutaneous fat)
Auditory/ear Other (Auditory/Ear-Other
(Specify))
Autoimmune Disorder Nos (Autoimmune
reaction)
Blood Bicarbonate Decreased
(Bicarbonate, serum-low)
Blood Bilirubin Increased (Bilirubin
(hyperbilirubinemia))
Bladder Disorder Nos (Bladder spasms)
Blood/bone Marrow Other (Blood/Bone
Marrow-Other (Specify))
Bone Age (alteration In Bone Age) (Bone
age (alteration in bone age))
Bone Growth: Femoral Head; Slipped
Capital Femoral Epiphysis (Bone growth:
femoral head; slipped capital femoral
epiphysis)
Bone Growth: Limb Length Discrepancy
(Bone growth: limb length discrepancy)
Bone Growth: Spine Kyphosis/lordosis
(Bone growth: spine kyphosis/lordosis)
Bone Marrow Depression Nos (Bone
marrow cellularity)
Bone: Spine-scoliosis (Bone: spine-
scoliosis)
Brachial Plexopathy (Brachial
plexopathy)
Breast Function/lactation (Breast
function/lactation)
Breast Nipple/areolar Deformity (Breast
nipple/areolar deformity)
Breast Volume/hypoplasia (Breast
volume/hypoplasia)
Bronchospasm, Wheezing
(Bronchospasm, wheezing)
Ecchymosis (Bruising (in absence of
grade 3 or 4 thrombocytopenia))
Burn (Burn)
Hypercalcaemia (Calcium, serum-high
(hypercalcemia))
Hypocalcaemia (Calcium, serum-low
(hypocalcemia))
Pulmonary Function Test Nos Decreased
(Carbon monoxide diffusion capacity
(DL(co)))
Arrhythmia Nos (Cardiac Arrhythmia-
Other (Specify))
Cardiac General Other (Cardiac
General-Other (Specify))
Myocardial Ischaemia (Cardiac
ischemia/infarction)
Cardiac Troponin I Increased (Cardiac
troponin I (cTnI))
Cardiac Troponin T Increased (Cardiac
troponin T (cTnT))
Cardiopulmonary Arrest, Cause
Unknown (non-fatal) (Cardiopulmonary
arrest, cause unknown (non-fatal))
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Cataract Nec (Cataract)
Cd4 Lymphocytes Decreased (CD4
count)
Cervical Spine-range Of Motion (Cervical
spine-range of motion)
Chelitis (Cheilitis)
Cholecystitis (Cholecystitis)
Hypercholesteraemia (Cholesterol,
serum-high (hypercholesteremia))
Chyle Or Lymph Leakage (Chyle or
lymph leakage)
Chylothorax (Chylothorax)
Cerebral Ischaemia (CNS
cerebrovascular ischemia)
Cns Necrosis/cystic Progression (CNS
necrosis/cystic progression)
Coagulation Disorder Nos (Coagulation-
Other (Specify))
Learning Disorder Nos (Cognitive
disturbance)
Colitis Nos (Colitis)
Colitis, Infectious (e.g., Clostridium
Difficile) (Colitis, infectious (e.g.,
Clostridium difficile))
Ventricular Asystole (Conduction
abnormality/Atrioventricular heart block -
Asystole)
Conduction Abnormality/atrioventricular
Heart Block (Conduction
abnormality/Atrioventricular heart block -
AV block-first degree)
Conduction Abnormality/atrioventricular
Heart Block - Av Block-second Degree
Mobitz Type I (wenckebach) (Conduction
abnormality/Atrioventricular heart block -
AV block-Second degree Mobitz Type I
(Wenckebach))
Conduction Abnormality/atrioventricular
Heart Block (Conduction
abnormality/Atrioventricular heart block -
AV block-second degree Mobitz Type II)
Conduction Abnormality/atrioventricular
Heart Block (Conduction
abnormality/Atrioventricular heart block -
AV block-third degree (complete AV
block))
Conduction Abnormality/atrioventricular
Heart Block (Conduction
abnormality/Atrioventricular heart block -
Conduction abnormality NOS)
Conduction Abnormality/atrioventricular
Heart Block (Conduction
abnormality/Atrioventricular heart block -
Sick sinus syndrome)
Conduction Abnormality/atrioventricular
Heart Block (Conduction
abnormality/Atrioventricular heart block -
Stokes-Adams syndrome)
Conduction Abnormality/atrioventricular
Heart Block (Conduction
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abnormality/Atrioventricular heart block -
Wolff-Parkinson-White syndrome)
Confusion (Confusion)
Constipation (Constipation)
Constitutional Symptoms Other
(Constitutional Symptoms-Other
(Specify))
Cough (Cough)
Blood Creatine Phosphokinase
Increased (CPK (creatine
phosphokinase))
Blood Creatinine Increased (Creatinine)
Cushingoid (Cushingoid appearance
(e.g., moon face, buffalo hump,
centripetal obesity, cutaneous striae))
Cystitis (Cystitis)
Cytokine Release Syndrome/acute
Infusion Reaction (Cytokine release
syndrome/acute infusion reaction)
Death Not Associated With Ctcae Term
(Death not associated with CTCAE term
- Death NOS)
Death Not Associated With Ctcae Term
(Death not associated with CTCAE term
- Disease progression NOS)
Death Not Associated With Ctcae Term
(Death not associated with CTCAE term
- Multi-organ failure)
Death Not Associated With Ctcae Term
(Death not associated with CTCAE term
- Sudden death)
Dehydration (Dehydration)
Dental: Dentures Or Prosthesis (Dental:
dentures or prosthesis)
Dental: Periodontal Disease (Dental:
periodontal disease)
Dental: Teeth (Dental: teeth)
Dental: Teeth Development (Dental:
teeth development)
Dermal Change Lymphedema,
Phlebolymphedema (Dermal change
lymphedema, phlebolymphedema)
Dermatology/skin Other
(Dermatology/Skin-Other (Specify))
Diarrhoea Nos (Diarrhea)
Disseminated Intravascular Coagulation
(DIC (disseminated intravascular
coagulation))
Distention/bloating, Abdominal
(Distention/bloating, abdominal)
Dizziness (exc Vertigo) (Dizziness)
Dry Eye Nec (Dry eye syndrome)
Dry Mouth (Dry mouth/salivary gland
(xerostomia))
Dry Skin (Dry skin)
Dysphagia (Dysphagia (difficulty
swallowing))
Dyspnoea Nos (Dyspnea (shortness of
breath))
Edema, Larynx (Edema, larynx)
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Edema: Head And Neck (Edema: head
and neck)
Oedema Nos (Edema: limb)
Edema: Trunk/genital (Edema:
trunk/genital)
Edema: Viscera (Edema: viscera)
Ejaculatory Dysfunction (Ejaculatory
dysfunction)
Encephalopathy (Encephalopathy)
Endocrine Other (Endocrine-Other
(Specify))
Enteritis (inflammation Of The Small
Bowel) (Enteritis (inflammation of the
small bowel))
Impotence (Erectile dysfunction)
Oesophagitis Nos (Esophagitis)
Exostosis (Exostosis)
Extrapyramidal Disorder Nec
(Extrapyramidal/involuntary
movement/restlessness)
Extremity-lower (gait/walking) (Extremity-
lower (gait/walking))
Extremity-upper (function) (Extremity-
upper (function))
Eyelid Dysfunction (Eyelid dysfunction)
Fatigue (Fatigue (asthenia, lethargy,
malaise))
Febrile Neutropenia (fever Of Unknown
Origin Without Clinically Or
Microbiologically Documented Infection)
(anc <1.0 X 10^9/l, Fever >=38.5
Degrees C) (Febrile neutropenia)
Feminization (Feminization of male)
Forced Expiratory Volume Decreased
(FEV(1))
Pyrexia (Fever (in the absence of
neutropenia, where neutropenia is
defined as ANC <1.0 x 10^9/L))
Blood Fibrinogen Decreased
(Fibrinogen)
Fibrosis-cosmesis (Fibrosis-cosmesis)
Fibrosis-deep Connective Tissue
(Fibrosis-deep connective tissue)
Fistula, Gi (Fistula, GI - Abdomen NOS)
Anal Fistula (Fistula, GI - Anus)
Fistula, Gi (Fistula, GI - Biliary tree)
Fistula, Gi (Fistula, GI -
Colon/cecum/appendix)
Intestinal Fistula (Fistula, GI -
Duodenum)
Tracheo-oesophageal Fistula Nos
(Fistula, GI - Esophagus)
Fistula, Gi (Fistula, GI - Gallbladder)
Fistula, Gi (Fistula, GI - Ileum)
Fistula, Gi (Fistula, GI - Jejunum)
Fistula, Gi (Fistula, GI - Oral cavity)
Fistula, Gi (Fistula, GI - Pancreas)
Fistula, Gi (Fistula, GI - Pharynx)
Fistula, Gi (Fistula, GI - Rectum)
Fistula, Gi (Fistula, GI - Salivary gland)
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Fistula, Gi (Fistula, GI - Small bowel
NOS)
Fistula, Gi (Fistula, GI - Stomach)
Fistula, Gu (Fistula, GU - Bladder)
Fistula, Gu (Fistula, GU - Genital tract-
female)
Fistula, Gu (Fistula, GU - Kidney)
Fistula, Gu (Fistula, GU - Ureter)
Fistula, Gu (Fistula, GU - Urethra)
Fistula, Gu (Fistula, GU - Uterus)
Urogenital Fistula (Fistula, GU - Vagina)
Fistula, Pulmonary/upper Respiratory
(Fistula, pulmonary/upper respiratory -
Bronchus)
Fistula, Pulmonary/upper Respiratory
(Fistula, pulmonary/upper respiratory -
Larynx)
Fistula, Pulmonary/upper Respiratory
(Fistula, pulmonary/upper respiratory -
Lung)
Fistula, Pulmonary/upper Respiratory
(Fistula, pulmonary/upper respiratory -
Oral cavity)
Fistula, Pulmonary/upper Respiratory
(Fistula, pulmonary/upper respiratory -
Pharynx)
Fistula, Pulmonary/upper Respiratory
(Fistula, pulmonary/upper respiratory -
Pleura)
Fistula, Pulmonary/upper Respiratory
(Fistula, pulmonary/upper respiratory -
Trachea)
Flatulence (Flatulence)
Flu-like Syndrome (Flu-like syndrome)
Flushing (Flushing)
Fracture (Fracture)
Gastritis Nos (Gastritis (including bile
reflux gastritis))
Gastrointestinal Other (Gastrointestinal-
Other (Specify))
Gamma-glutamyltransferase Increased
(GGT (gamma-glutamyl transpeptidase))
Glaucoma Nos (Glaucoma)
Glomerular Filtration Rate (Glomerular
filtration rate)
Hyperglycaemia Nos (Glucose, serum-
high (hyperglycemia))
Hypoglycaemia Nos (Glucose, serum-
low (hypoglycemia))
Growth And Development Other (Growth
and Development-Other (Specify))
Growth Velocity (reduction In Growth
Velocity) (Growth velocity (reduction in
growth velocity))
Gynaecomastia (Gynecomastia)
Alopecia (Hair loss/Alopecia (scalp or
body))
Haptoglobin Decreased (Haptoglobin)
Hearing: Patients With/without Baseline
Audiogram And Enrolled In A Monitoring
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Program (Hearing: patients with/without
baseline audiogram and enrolled in a
monitoring program)
Hearing: Patients Without Baseline
Audiogram And Not Enrolled In A
Monitoring Program (Hearing: patients
without baseline audiogram and not
enrolled in a monitoring program)
Dyspepsia (Heartburn/dyspepsia)
Hematoma (Hematoma)
Haemoglobin Decreased (Hemoglobin)
Haemoglobinuria Present
(Hemoglobinuria)
Hemolysis Nos (Hemolysis (e.g.,
immune hemolytic anemia, drug related
hemolysis))
Haemorrhagic Stroke (Hemorrhage,
CNS)
Melaena (Hemorrhage, GI - Abdomen
NOS)
Hemorrhage, Gi (Hemorrhage, GI -
Anus)
Hemorrhage, Gi (Hemorrhage, GI -
Biliary tree)
Hemorrhage, Gi (Hemorrhage, GI -
Cecum/appendix)
Hemorrhage, Gi (Hemorrhage, GI -
Colon)
Hemorrhage, Gi (Hemorrhage, GI -
Duodenum)
Hemorrhage, Gi (Hemorrhage, GI -
Esophagus)
Hemorrhage, Gi (Hemorrhage, GI -
Ileum)
Hemorrhage, Gi (Hemorrhage, GI -
Jejunum)
Hemorrhage, Gi (Hemorrhage, GI - Liver)
Hemorrhage, Gi (Hemorrhage, GI -
Lower GI NOS)
Hemorrhage, Gi (Hemorrhage, GI - Oral
cavity)
Hemorrhage, Gi (Hemorrhage, GI -
Pancreas)
Hemorrhage, Gi (Hemorrhage, GI -
Peritoneal cavity)
Rectal Bleeding (Hemorrhage, GI -
Rectum)
Hemorrhage, Gi (Hemorrhage, GI -
Stoma)
Haematemesis (Hemorrhage, GI -
Stomach)
Hemorrhage, Gi (Hemorrhage, GI -
Upper GI NOS)
Hemorrhage, Gi (Hemorrhage, GI -
Varices (esophageal))
Hemorrhage, Gi (Hemorrhage, GI -
Varices (rectal))
Hemorrhage, Gu (Hemorrhage, GU -
Bladder)
Hemorrhage, Gu (Hemorrhage, GU -
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Fallopian tube)
Hemorrhage, Gu (Hemorrhage, GU -
Kidney)
Hemorrhage, Gu (Hemorrhage, GU -
Ovary)
Hemorrhage, Gu (Hemorrhage, GU -
Prostate)
Hemorrhage, Gu (Hemorrhage, GU -
Retroperitoneum)
Hemorrhage, Gu (Hemorrhage, GU -
Spermatic cord)
Hemorrhage, Gu (Hemorrhage, GU -
Stoma)
Hemorrhage, Gu (Hemorrhage, GU -
Testes)
Hemorrhage, Gu (Hemorrhage, GU -
Ureter)
Hemorrhage, Gu (Hemorrhage, GU -
Urethra)
Haematuria Present (Hemorrhage, GU -
Urinary NOS)
Hemorrhage, Gu (Hemorrhage, GU -
Uterus)
Vaginal Haemorrhage (Hemorrhage, GU
- Vagina)
Hemorrhage, Gu (Hemorrhage, GU - Vas
deferens)
Hemorrhage, Pulmonary/upper
Respiratory (Hemorrhage,
pulmonary/upper respiratory -
Bronchopulmonary NOS)
Hemorrhage, Pulmonary/upper
Respiratory (Hemorrhage,
pulmonary/upper respiratory - Bronchus)
Hemorrhage, Pulmonary/upper
Respiratory (Hemorrhage,
pulmonary/upper respiratory - Larynx)
Hemorrhage, Pulmonary/upper
Respiratory (Hemorrhage,
pulmonary/upper respiratory - Lung)
Hemorrhage, Pulmonary/upper
Respiratory (Hemorrhage,
pulmonary/upper respiratory -
Mediastinum)
Epistaxis (Hemorrhage, pulmonary/upper
respiratory - Nose)
Hemorrhage, Pulmonary/upper
Respiratory (Hemorrhage,
pulmonary/upper respiratory - Pharynx)
Hemorrhage, Pulmonary/upper
Respiratory (Hemorrhage,
pulmonary/upper respiratory - Pleura)
Haemoptysis (Hemorrhage,
pulmonary/upper respiratory -
Respiratory tract NOS)
Hemorrhage, Pulmonary/upper
Respiratory (Hemorrhage,
pulmonary/upper respiratory - Stoma)
Hemorrhage, Pulmonary/upper
Respiratory (Hemorrhage,
8 / 44
Pre-Study - BASELINE SYMP - 2393103v1.0
pulmonary/upper respiratory - Trachea)
Post-operative Haemorrhage
(Hemorrhage/bleeding associated with
surgery, intra-operative or post-operative)
Hemorrhage/bleeding Other
(Hemorrhage/Bleeding-Other (Specify))
Hemorrhoids (Hemorrhoids)
Hepatobiliary/pancreas Other
(Hepatobiliary/Pancreas-Other (Specify))
Hiccups (Hiccoughs (hiccups, singultus))
Menopausal Symptoms (Hot
flashes/flushes)
Hydrocephalus (Hydrocephalus)
Skin Discolouration (Hyperpigmentation)
Hypertension Nos (Hypertension)
Hypopigmentation (Hypopigmentation)
Hypotension Nos (Hypotension)
Hypothermia (Hypothermia)
Hypoxia (Hypoxia)
Ileus (Ileus, GI (functional obstruction of
bowel, i.e., neuroconstipation))
Incontinence, Anal (Incontinence, anal)
Urinary Incontinence (Incontinence,
urinary)
Induration/fibrosis (skin And
Subcutaneous Tissue)
(Induration/fibrosis (skin and
subcutaneous tissue))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Abdomen NOS)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Anal/perianal)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Appendix)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Artery)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Biliary tree)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
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Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Bladder (urinary))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Blood)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Bone (osteomyelitis))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Brain (encephalitis,
infectious))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Brain + Spinal cord
(encephalomyelitis))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Bronchus)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Catheter-related)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Cecum)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Cervix)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Colon)
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Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Conjunctiva)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Cornea)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Dental-tooth)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Duodenum)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Esophagus)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - External ear (otitis externa))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Eye NOS)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Fallopian tube)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Foreign body (e.g., graft,
implant, prosthesis, stent))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
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neutrophils - Gallbladder (cholecystitis))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Heart (endocarditis))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Ileum)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Jejunum)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Joint)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Kidney)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Larynx)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Lens)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Lip/perioral)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Liver)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
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neutrophils - Lung (pneumonia))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Lymphatic)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Mediastinum NOS)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Meninges (meningitis))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Middle ear (otitis media))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Mucosa)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Muscle (infection myositis))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Neck NOS)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Nerve-cranial)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Nerve-peripheral)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
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neutrophils - Nose)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Oral cavity-gums
(gingivitis))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Pancreas)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Paranasal)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Pelvis NOS)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Penis)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Peristomal)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Peritoneal cavity)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Pharynx)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Pleura (empyema))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
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microbiologically) with Grade 3 or 4
neutrophils - Prostate)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Rectum)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Salivary gland)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Scrotum)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Sinus)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Skin (cellulitis))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Small bowel NOS)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Soft tissue NOS)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Spinal cord (myelitis))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Spleen)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
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microbiologically) with Grade 3 or 4
neutrophils - Stomach)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Trachea)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Ungual (nails))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Upper aerodigestive NOS)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Upper airway NOS)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Ureter)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Urethra)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Urinary tract NOS)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Uterus)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Vagina)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
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microbiologically) with Grade 3 or 4
neutrophils - Vein)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Vulva)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Wound)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Abdomen
NOS)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils -
Anal/perianal)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Appendix)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Artery)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Biliary tree)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Bladder
(urinary))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Blood)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Bone
(osteomyelitis))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Brain
(encephalitis, infectious))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Brain +
Spinal cord (encephalomyelitis))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Bronchus)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Catheter-
related)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Cecum)
17 / 44
Pre-Study - BASELINE SYMP - 2393103v1.0
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Cervix)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Colon)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils -
Conjunctiva)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Cornea)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Dental-
tooth)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Duodenum)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Esophagus)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - External ear
(otitis externa))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Eye NOS)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Fallopian
tube)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Foreign
body (e.g., graft, implant, prosthesis,
stent))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Gallbladder
(cholecystitis))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Heart
(endocarditis))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Ileum)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Jejunum)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Joint)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Kidney)
Infection With Normal Anc Or Grade 1 Or
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2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Larynx)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Lens)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Lip/perioral)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Liver)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Lung
(pneumonia))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Lymphatic)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils -
Mediastinum NOS)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Meninges
(meningitis))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Middle ear
(otitis media))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Mucosa)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Muscle
(infection myositis))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Neck NOS)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Nerve-
cranial)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Nerve-
peripheral)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Nose)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Oral cavity-
gums (gingivitis))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Pancreas)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
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or Grade 1 or 2 neutrophils - Paranasal)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Pelvis NOS)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Penis)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Peristomal)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Peritoneal
cavity)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Pharynx)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Pleura
(empyema))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Prostate)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Rectum)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Salivary
gland)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Scrotum)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Sinus)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Skin
(cellulitis))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Small bowel
NOS)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Soft tissue
NOS)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Spinal cord
(myelitis))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Spleen)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Stomach)
Infection With Normal Anc Or Grade 1 Or
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2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Trachea)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Ungual
(nails))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Upper
aerodigestive NOS)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Upper
airway NOS)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Ureter)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Urethra)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Urinary
tract NOS)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Uterus)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Vagina)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Vein)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Vulva)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Wound)
Infection With Unknown Anc (Infection
with unknown ANC - Abdomen NOS)
Infection With Unknown Anc (Infection
with unknown ANC - Anal/perianal)
Infection With Unknown Anc (Infection
with unknown ANC - Appendix)
Infection With Unknown Anc (Infection
with unknown ANC - Artery)
Infection With Unknown Anc (Infection
with unknown ANC - Biliary tree)
Infection With Unknown Anc (Infection
with unknown ANC - Bladder (urinary))
Infection With Unknown Anc (Infection
with unknown ANC - Blood)
Infection With Unknown Anc (Infection
with unknown ANC - Bone
(osteomyelitis))
Infection With Unknown Anc (Infection
with unknown ANC - Brain (encephalitis,
infectious))
Infection With Unknown Anc (Infection
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with unknown ANC - Brain + Spinal cord
(encephalomyelitis))
Infection With Unknown Anc (Infection
with unknown ANC - Bronchus)
Implant Infection (Infection with unknown
ANC - Catheter-related)
Infection With Unknown Anc (Infection
with unknown ANC - Cecum)
Infection With Unknown Anc (Infection
with unknown ANC - Cervix)
Infection With Unknown Anc (Infection
with unknown ANC - Colon)
Infection With Unknown Anc (Infection
with unknown ANC - Conjunctiva)
Infection With Unknown Anc (Infection
with unknown ANC - Cornea)
Infection With Unknown Anc (Infection
with unknown ANC - Dental-tooth)
Infection With Unknown Anc (Infection
with unknown ANC - Duodenum)
Infection With Unknown Anc (Infection
with unknown ANC - Esophagus)
Infection With Unknown Anc (Infection
with unknown ANC - External ear (otitis
externa))
Infection With Unknown Anc (Infection
with unknown ANC - Eye NOS)
Infection With Unknown Anc (Infection
with unknown ANC - Fallopian tube)
Infection With Unknown Anc (Infection
with unknown ANC - Foreign body (e.g.,
graft, implant, prosthesis, stent))
Infection With Unknown Anc (Infection
with unknown ANC - Gallbladder
(cholecystitis))
Infection With Unknown Anc (Infection
with unknown ANC - Heart
(endocarditis))
Infection With Unknown Anc (Infection
with unknown ANC - Ileum)
Infection With Unknown Anc (Infection
with unknown ANC - Jejunum)
Infection With Unknown Anc (Infection
with unknown ANC - Joint)
Infection With Unknown Anc (Infection
with unknown ANC - Kidney)
Infection With Unknown Anc (Infection
with unknown ANC - Larynx)
Infection With Unknown Anc (Infection
with unknown ANC - Lens)
Infection With Unknown Anc (Infection
with unknown ANC - Lip/perioral)
Infection With Unknown Anc (Infection
with unknown ANC - Liver)
Infection With Unknown Anc (Infection
with unknown ANC - Lung (pneumonia))
Infection With Unknown Anc (Infection
with unknown ANC - Lymphatic)
Infection With Unknown Anc (Infection
with unknown ANC - Mediastinum NOS)
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Infection With Unknown Anc (Infection
with unknown ANC - Meninges
(meningitis))
Infection With Unknown Anc (Infection
with unknown ANC - Middle ear (otitis
media))
Infection With Unknown Anc (Infection
with unknown ANC - Mucosa)
Infection With Unknown Anc (Infection
with unknown ANC - Muscle (infection
myositis))
Infection With Unknown Anc (Infection
with unknown ANC - Neck NOS)
Infection With Unknown Anc (Infection
with unknown ANC - Nerve-cranial)
Infection With Unknown Anc (Infection
with unknown ANC - Nerve-peripheral)
Infection With Unknown Anc (Infection
with unknown ANC - Nose)
Infection With Unknown Anc (Infection
with unknown ANC - Oral cavity-gums
(gingivitis))
Infection With Unknown Anc (Infection
with unknown ANC - Pancreas)
Infection With Unknown Anc (Infection
with unknown ANC - Paranasal)
Infection With Unknown Anc (Infection
with unknown ANC - Pelvis NOS)
Infection With Unknown Anc (Infection
with unknown ANC - Penis)
Infection With Unknown Anc (Infection
with unknown ANC - Peristomal)
Infection With Unknown Anc (Infection
with unknown ANC - Peritoneal cavity)
Infection With Unknown Anc (Infection
with unknown ANC - Pharynx)
Infection With Unknown Anc (Infection
with unknown ANC - Pleura (empyema))
Infection With Unknown Anc (Infection
with unknown ANC - Prostate)
Infection With Unknown Anc (Infection
with unknown ANC - Rectum)
Infection With Unknown Anc (Infection
with unknown ANC - Salivary gland)
Infection With Unknown Anc (Infection
with unknown ANC - Scrotum)
Infection With Unknown Anc (Infection
with unknown ANC - Sinus)
Infection With Unknown Anc (Infection
with unknown ANC - Skin (cellulitis))
Infection With Unknown Anc (Infection
with unknown ANC - Small bowel NOS)
Infection With Unknown Anc (Infection
with unknown ANC - Soft tissue NOS)
Infection With Unknown Anc (Infection
with unknown ANC - Spinal cord
(myelitis))
Infection With Unknown Anc (Infection
with unknown ANC - Spleen)
Infection With Unknown Anc (Infection
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with unknown ANC - Stomach)
Infection With Unknown Anc (Infection
with unknown ANC - Trachea)
Infection With Unknown Anc (Infection
with unknown ANC - Ungual (nails))
Infection With Unknown Anc (Infection
with unknown ANC - Upper aerodigestive
NOS)
Infection With Unknown Anc (Infection
with unknown ANC - Upper airway NOS)
Infection With Unknown Anc (Infection
with unknown ANC - Ureter)
Infection With Unknown Anc (Infection
with unknown ANC - Urethra)
Infection With Unknown Anc (Infection
with unknown ANC - Urinary tract NOS)
Infection With Unknown Anc (Infection
with unknown ANC - Uterus)
Infection With Unknown Anc (Infection
with unknown ANC - Vagina)
Infection With Unknown Anc (Infection
with unknown ANC - Vein)
Infection With Unknown Anc (Infection
with unknown ANC - Vulva)
Culture Wound Positive (Infection with
unknown ANC - Wound)
Infection Nos (Infection-Other (Specify))
Infertility/sterility (Infertility/sterility)
Injection Site Reaction Nos (Injection site
reaction/extravasation changes)
Prothrombin Time Prolonged (INR
(International Normalized Ratio of
prothrombin time))
Insomnia Nec (Insomnia)
Intra-operative Injury (Intra-operative
injury - Abdomen NOS)
Intra-operative Injury (Intra-operative
injury - Adrenal gland)
Intra-operative Injury (Intra-operative
injury - Anal sphincter)
Intra-operative Injury (Intra-operative
injury - Anus)
Intra-operative Injury (Intra-operative
injury - Appendix)
Intra-operative Injury (Intra-operative
injury - Artery NOS)
Intra-operative Injury (Intra-operative
injury - Artery-aorta)
Intra-operative Injury (Intra-operative
injury - Artery-carotid)
Intra-operative Injury (Intra-operative
injury - Artery-cerebral)
Intra-operative Injury (Intra-operative
injury - Artery-extremity (lower))
Intra-operative Injury (Intra-operative
injury - Artery-extremity (upper))
Intra-operative Injury (Intra-operative
injury - Artery-hepatic)
Intra-operative Injury (Intra-operative
injury - Artery-major visceral artery)
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Intra-operative Injury (Intra-operative
injury - Artery-pulmonary)
Intra-operative Injury (Intra-operative
injury - Biliary tree NOS)
Intra-operative Injury (Intra-operative
injury - Biliary tree-common bile duct)
Intra-operative Injury (Intra-operative
injury - Biliary tree-common hepatic duct)
Intra-operative Injury (Intra-operative
injury - Biliary tree-left hepatic duct)
Intra-operative Injury (Intra-operative
injury - Biliary tree-right hepatic duct)
Bladder Perforation Postoperative (Intra-
operative injury - Bladder)
Intra-operative Injury (Intra-operative
injury - Bone)
Intra-operative Injury (Intra-operative
injury - Brachial plexus)
Intra-operative Injury (Intra-operative
injury - Brain)
Intra-operative Injury (Intra-operative
injury - Breast)
Intra-operative Injury (Intra-operative
injury - Bronchus)
Intra-operative Injury (Intra-operative
injury - Cartilage)
Intra-operative Injury (Intra-operative
injury - Cecum)
Intra-operative Injury (Intra-operative
injury - Cervix)
Intra-operative Injury (Intra-operative
injury - CN I (olfactory))
Intra-operative Injury (Intra-operative
injury - CN II (optic))
Intra-operative Injury (Intra-operative
injury - CN III (oculomotor))
Intra-operative Injury (Intra-operative
injury - CN IV (trochlear))
Intra-operative Injury (Intra-operative
injury - CN IX (glossopharyngeal) motor
pharynx)
Intra-operative Injury (Intra-operative
injury - CN IX (glossopharyngeal)
sensory ear-pharynx-tongue)
Intra-operative Injury (Intra-operative
injury - CN V (trigeminal) motor)
Intra-operative Injury (Intra-operative
injury - CN V (trigeminal) sensory)
Intra-operative Injury (Intra-operative
injury - CN VI (abducens))
Intra-operative Injury (Intra-operative
injury - CN VII (facial) motor-face)
Intra-operative Injury (Intra-operative
injury - CN VII (facial) sensory-taste)
Intra-operative Injury (Intra-operative
injury - CN VIII (vestibulocochlear))
Intra-operative Injury (Intra-operative
injury - CN X (vagus))
Intra-operative Injury (Intra-operative
injury - CN XI (spinal accessory))
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Intra-operative Injury (Intra-operative
injury - CN XII (hypoglossal))
Intra-operative Injury (Intra-operative
injury - Colon)
Intra-operative Injury (Intra-operative
injury - Conjunctiva)
Intra-operative Injury (Intra-operative
injury - Cornea)
Intra-operative Injury (Intra-operative
injury - Cranial nerve or branch NOS)
Intra-operative Injury (Intra-operative
injury - Duodenum)
Intra-operative Injury (Intra-operative
injury - Esophagus)
Intra-operative Injury (Intra-operative
injury - Extremity-lower)
Intra-operative Injury (Intra-operative
injury - Extremity-upper)
Intra-operative Injury (Intra-operative
injury - Eye NOS)
Intra-operative Injury (Intra-operative
injury - Face NOS)
Intra-operative Injury (Intra-operative
injury - Fallopian tube)
Intra-operative Injury (Intra-operative
injury - Gallbladder)
Intra-operative Injury (Intra-operative
injury - Gingiva)
Intra-operative Injury (Intra-operative
injury - Heart)
Intra-operative Injury (Intra-operative
injury - Ileum)
Intra-operative Injury (Intra-operative
injury - Inner ear)
Intra-operative Injury (Intra-operative
injury - Jejunum)
Intra-operative Injury (Intra-operative
injury - Joint)
Intra-operative Injury (Intra-operative
injury - Kidney)
Intra-operative Injury (Intra-operative
injury - Larynx)
Intra-operative Injury (Intra-operative
injury - Lens)
Intra-operative Injury (Intra-operative
injury - Ligament)
Intra-operative Injury (Intra-operative
injury - Lingual)
Intra-operative Injury (Intra-operative
injury - Lip/perioral area)
Intra-operative Injury (Intra-operative
injury - Liver)
Intra-operative Injury (Intra-operative
injury - Lung)
Intra-operative Injury (Intra-operative
injury - Lung thoracic)
Intra-operative Injury (Intra-operative
injury - Mediastinum)
Intra-operative Injury (Intra-operative
injury - Meninges)
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Intra-operative Injury (Intra-operative
injury - Middle ear)
Intra-operative Injury (Intra-operative
injury - Muscle)
Intra-operative Injury (Intra-operative
injury - Nails)
Intra-operative Injury (Intra-operative
injury - Nasal cavity)
Intra-operative Injury (Intra-operative
injury - Nasopharynx)
Intra-operative Injury (Intra-operative
injury - Neck NOS)
Intra-operative Injury (Intra-operative
injury - Nose)
Intra-operative Injury (Intra-operative
injury - Oral)
Intra-operative Injury (Intra-operative
injury - Oral cavity NOS)
Intra-operative Injury (Intra-operative
injury - Outer ear NOS)
Intra-operative Injury (Intra-operative
injury - Outer ear-pinna)
Intra-operative Injury (Intra-operative
injury - Ovary)
Intra-operative Injury (Intra-operative
injury - Pancreas)
Intra-operative Injury (Intra-operative
injury - Pancreatic duct)
Intra-operative Injury (Intra-operative
injury - Parathyroid)
Intra-operative Injury (Intra-operative
injury - Parotid gland)
Intra-operative Injury (Intra-operative
injury - Pelvis NOS)
Intra-operative Injury (Intra-operative
injury - Penis)
Intra-operative Injury (Intra-operative
injury - Peripheral motor NOS)
Intra-operative Injury (Intra-operative
injury - Peripheral sensory NOS)
Intra-operative Injury (Intra-operative
injury - Peritoneal cavity)
Intra-operative Injury (Intra-operative
injury - Pharynx)
Intra-operative Injury (Intra-operative
injury - Pituitary)
Intra-operative Injury (Intra-operative
injury - Pleura)
Intra-operative Injury (Intra-operative
injury - Prostate)
Intra-operative Injury (Intra-operative
injury - Rectum)
Intra-operative Injury (Intra-operative
injury - Recurrent laryngeal)
Intra-operative Injury (Intra-operative
injury - Retina)
Intra-operative Injury (Intra-operative
injury - Sacral plexus)
Intra-operative Injury (Intra-operative
injury - Salivary duct)
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Intra-operative Injury (Intra-operative
injury - Salivary gland)
Intra-operative Injury (Intra-operative
injury - Sciatic)
Intra-operative Injury (Intra-operative
injury - Scrotum)
Intra-operative Injury (Intra-operative
injury - Sinus)
Intra-operative Injury (Intra-operative
injury - Skin)
Intra-operative Injury (Intra-operative
injury - Small bowel NOS)
Intra-operative Injury (Intra-operative
injury - Soft tissue NOS)
Intra-operative Injury (Intra-operative
injury - Spinal cord)
Intra-operative Injury (Intra-operative
injury - Spleen)
Intra-operative Injury (Intra-operative
injury - Stoma (GI))
Intra-operative Injury (Intra-operative
injury - Stomach)
Intra-operative Injury (Intra-operative
injury - Teeth)
Intra-operative Injury (Intra-operative
injury - Tendon)
Intra-operative Injury (Intra-operative
injury - Testis)
Intra-operative Injury (Intra-operative
injury - Thoracic duct)
Intra-operative Injury (Intra-operative
injury - Thoracodorsal)
Intra-operative Injury (Intra-operative
injury - Thyroid)
Intra-operative Injury (Intra-operative
injury - Tongue)
Intra-operative Injury (Intra-operative
injury - Trachea)
Intra-operative Injury (Intra-operative
injury - Upper aerodigestive NOS)
Intra-operative Injury (Intra-operative
injury - Upper airway NOS)
Intra-operative Injury (Intra-operative
injury - Ureter)
Intra-operative Injury (Intra-operative
injury - Urethra)
Intra-operative Injury (Intra-operative
injury - Urinary conduit)
Intra-operative Injury (Intra-operative
injury - Urinary tract NOS)
Intra-operative Injury (Intra-operative
injury - Uterus)
Intra-operative Injury (Intra-operative
injury - Vagina)
Intra-operative Injury - Vein (Intra-
operative injury - Vein NOS)
Intra-operative Injury (Intra-operative
injury - Vein-extremity (lower))
Intra-operative Injury (Intra-operative
injury - Vein-extremity (upper))
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Intra-operative Injury (Intra-operative
injury - Vein-hepatic)
Intra-operative Injury (Intra-operative
injury - Vein-inferior vena cava)
Intra-operative Injury (Intra-operative
injury - Vein-jugular)
Intra-operative Injury (Intra-operative
injury - Vein-major visceral vein)
Intra-operative Injury (Intra-operative
injury - Vein-portal vein)
Intra-operative Injury (Intra-operative
injury - Vein-pulmonary)
Intra-operative Injury (Intra-operative
injury - Vein-superior vena cava)
Intra-operative Injury (Intra-operative
injury - Vulva)
Intra-operative Injury Other (Intra-
operative Injury-Other (Specify))
Iron Overload (Iron overload)
Menstruation Irregular (Irregular menses
(change from baseline))
Irritability (Irritability (children <3 years of
age))
Joint-effusion (Joint-effusion)
Joint-effusion (Joint-function)
Keratitis Nec (Keratitis (corneal
inflammation/corneal ulceration))
Laryngeal Nerve Dysfunction (Laryngeal
nerve dysfunction)
Leak (including Anastomotic), Gi (Leak
(including anastomotic), GI - Biliary tree)
Leak (including Anastomotic), Gi (Leak
(including anastomotic), GI - Esophagus)
Leak (including Anastomotic), Gi (Leak
(including anastomotic), GI - Large
bowel)
Leak (including Anastomotic), Gi (Leak
(including anastomotic), GI - Leak NOS)
Leak (including Anastomotic), Gi (Leak
(including anastomotic), GI - Pancreas)
Leak (including Anastomotic), Gi (Leak
(including anastomotic), GI - Pharynx)
Leak (including Anastomotic), Gi (Leak
(including anastomotic), GI - Rectum)
Leak (including Anastomotic), Gi (Leak
(including anastomotic), GI - Small
bowel)
Leak (including Anastomotic), Gi (Leak
(including anastomotic), GI - Stoma)
Leak (including Anastomotic), Gi (Leak
(including anastomotic), GI - Stomach)
Leak (including Anastomotic), Gu (Leak
(including anastomotic), GU - Bladder)
Leak (including Anastomotic), Gu (Leak
(including anastomotic), GU - Fallopian
tube)
Leak (including Anastomotic), Gu (Leak
(including anastomotic), GU - Kidney)
Leak (including Anastomotic), Gu (Leak
(including anastomotic), GU - Spermatic
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cord)
Leak (including Anastomotic), Gu (Leak
(including anastomotic), GU - Stoma)
Leak (including Anastomotic), Gu (Leak
(including anastomotic), GU - Ureter)
Leak (including Anastomotic), Gu (Leak
(including anastomotic), GU - Urethra)
Leak (including Anastomotic), Gu (Leak
(including anastomotic), GU - Uterus)
Leak (including Anastomotic), Gu (Leak
(including anastomotic), GU - Vagina)
Leak (including Anastomotic), Gu (Leak
(including anastomotic), GU - Vas
deferens)
Leak, Cerebrospinal Fluid (csf) (Leak,
cerebrospinal fluid (CSF))
Left Ventricular Diastolic Dysfunction
(Left ventricular diastolic dysfunction)
Left Ventricular Failure (Left ventricular
systolic dysfunction)
Leucopenia Nos (Leukocytes (total
WBC))
Encephalopathy Nos
(Leukoencephalopathy (radiolographic
findings))
Libido Decreased (Libido)
Lipase Increased (Lipase)
Hepatic Failure (Liver dysfunction/failure
(clinical))
Local Complication - Device/prosthesis-
related (Local complication -
device/prosthesis-related)
Lumbar Spine-range Of Motion (Lumbar
spine-range of motion)
Lymphatics Other (Lymphatics-Other
(Specify))
Lymphedema-related Fibrosis
(Lymphedema-related fibrosis)
Lymphocele (Lymphocele)
Lymphopenia (Lymphopenia)
Hypermagnesaemia (Magnesium,
serum-high (hypermagnesemia))
Blood Magnesium Decreased
(Magnesium, serum-low
(hypomagnesemia))
Malabsorption (Malabsorption)
Virilism (Masculinization of female)
Amnesia Nec (Memory impairment)
Mental Status (Mental status)
Metabolic/laboratory Other
(Metabolic/Laboratory-Other (Specify))
Mood Alteration - Agitation (Mood
alteration - agitation)
Anxiety Nec (Mood alteration - anxiety)
Depression Nec (Mood alteration -
depression)
Euphoric Mood (Mood alteration -
euphoria)
Mucositis/stomatitis (clinical Exam)
(Mucositis/stomatitis (clinical exam) -
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Anus)
Mucositis/stomatitis (clinical Exam)
(Mucositis/stomatitis (clinical exam) -
Esophagus)
Mucositis/stomatitis (clinical Exam)
(Mucositis/stomatitis (clinical exam) -
Large bowel)
Mucositis/stomatitis (clinical Exam)
(Mucositis/stomatitis (clinical exam) -
Larynx)
Mucositis/stomatitis (clinical Exam)
(Mucositis/stomatitis (clinical exam) -
Oral cavity)
Stomatitis (Mucositis/stomatitis (clinical
exam) - Pharynx)
Mucositis/stomatitis (clinical Exam)
(Mucositis/stomatitis (clinical exam) -
Rectum)
Mucositis/stomatitis (clinical Exam)
(Mucositis/stomatitis (clinical exam) -
Small bowel)
Mucositis/stomatitis (clinical Exam)
(Mucositis/stomatitis (clinical exam) -
Stomach)
Mucositis/stomatitis (clinical Exam)
(Mucositis/stomatitis (clinical exam) -
Trachea)
Mucositis/stomatitis
(functional/symptomatic)
(Mucositis/stomatitis
(functional/symptomatic) - Anus)
Mucositis/stomatitis
(functional/symptomatic)
(Mucositis/stomatitis
(functional/symptomatic) - Esophagus)
Mucositis/stomatitis
(functional/symptomatic)
(Mucositis/stomatitis
(functional/symptomatic) - Large bowel)
Mucositis/stomatitis
(functional/symptomatic)
(Mucositis/stomatitis
(functional/symptomatic) - Larynx)
Mucositis/stomatitis
(functional/symptomatic)
(Mucositis/stomatitis
(functional/symptomatic) - Oral cavity)
Mucositis/stomatitis
(functional/symptomatic)
(Mucositis/stomatitis
(functional/symptomatic) - Pharynx)
Mucositis/stomatitis
(functional/symptomatic)
(Mucositis/stomatitis
(functional/symptomatic) - Rectum)
Mucositis/stomatitis
(functional/symptomatic)
(Mucositis/stomatitis
(functional/symptomatic) - Small bowel)
Mucositis/stomatitis
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(functional/symptomatic)
(Mucositis/stomatitis
(functional/symptomatic) - Stomach)
Mucositis/stomatitis
(functional/symptomatic)
(Mucositis/stomatitis
(functional/symptomatic) - Trachea)
Muscle Weakness, Generalized Or
Specific Area (not Due To Neuropathy)
(Muscle weakness, generalized or
specific area (not due to neuropathy) -
Extraocular)
Muscle Weakness, Generalized Or
Specific Area (not Due To Neuropathy)
(Muscle weakness, generalized or
specific area (not due to neuropathy) -
Extremity-lower)
Muscle Weakness, Generalized Or
Specific Area (not Due To Neuropathy)
(Muscle weakness, generalized or
specific area (not due to neuropathy) -
Extremity-upper)
Muscle Weakness, Generalized Or
Specific Area (not Due To Neuropathy)
(Muscle weakness, generalized or
specific area (not due to neuropathy) -
Facial)
Muscle Weakness, Generalized Or
Specific Area (not Due To Neuropathy)
(Muscle weakness, generalized or
specific area (not due to neuropathy) -
Left-sided)
Muscle Weakness, Generalized Or
Specific Area (not Due To Neuropathy)
(Muscle weakness, generalized or
specific area (not due to neuropathy) -
Ocular)
Muscle Weakness, Generalized Or
Specific Area (not Due To Neuropathy)
(Muscle weakness, generalized or
specific area (not due to neuropathy) -
Pelvic)
Muscle Weakness, Generalized Or
Specific Area (not Due To Neuropathy)
(Muscle weakness, generalized or
specific area (not due to neuropathy) -
Right-sided)
Muscle Weakness, Generalized Or
Specific Area (not Due To Neuropathy)
(Muscle weakness, generalized or
specific area (not due to neuropathy) -
Trunk)
Muscle Weakness Nos (Muscle
weakness, generalized or specific area
(not due to neuropathy) - Whole
body/generalized)
Muscular/skeletal Hypoplasia
(Muscular/skeletal hypoplasia)
Musculoskeletal/soft Tissue Other
(Musculoskeletal/Soft Tissue-Other
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(Specify))
Myelitis (Myelitis)
Myelodysplasia (Myelodysplasia)
Myocarditis Nos (Myocarditis)
Myositis (Myositis (inflammation/damage
of muscle))
Nail Abnormality Nos (Nail changes)
Nasal Cavity/paranasal Sinus Reactions
(Nasal cavity/paranasal sinus reactions)
Nausea (Nausea)
Necrosis, Gi (Necrosis, GI - Anus)
Necrosis, Gi (Necrosis, GI -
Colon/cecum/appendix)
Necrosis, Gi (Necrosis, GI - Duodenum)
Necrosis, Gi (Necrosis, GI - Esophagus)
Necrosis, Gi (Necrosis, GI - Gallbladder)
Necrosis, Gi (Necrosis, GI - Hepatic)
Necrosis, Gi (Necrosis, GI - Ileum)
Necrosis, Gi (Necrosis, GI - Jejunum)
Necrosis, Gi (Necrosis, GI - Oral)
Necrosis, Gi (Necrosis, GI - Pancreas)
Necrosis, Gi (Necrosis, GI - Peritoneal
cavity)
Necrosis, Gi (Necrosis, GI - Pharynx)
Necrosis, Gi (Necrosis, GI - Rectum)
Necrosis, Gi (Necrosis, GI - Small bowel
NOS)
Necrosis, Gi (Necrosis, GI - Stoma)
Necrosis, Gi (Necrosis, GI - Stomach)
Neuroendocrine: Acth Deficiency
(Neuroendocrine: ACTH deficiency)
Inappropriate Adh Secretion
(Neuroendocrine: ADH secretion
abnormality (e.g., SIADH or low ADH))
Neuroendocrine: Gonadotropin Secretion
Abnormality (Neuroendocrine:
gonadotropin secretion abnormality)
Neuroendocrine: Growth Hormone
Secretion Abnormality (Neuroendocrine:
growth hormone secretion abnormality)
Neuroendocrine: Prolactin Hormone
Secretion Abnormality (Neuroendocrine:
prolactin hormone secretion abnormality)
Neurology Other (Neurology-Other
(Specify))
Parosmia (Neuropathy: cranial - CN I
Smell)
Cranial Nerve Injury Nos (Neuropathy:
cranial - CN II Vision)
Neuropathy: Cranial (Neuropathy: cranial
- CN III Pupil, upper eyelid, extra ocular
movements)
Neuropathy: Cranial (Neuropathy: cranial
- CN IV Downward, inward movement of
eye)
Neuropathy: Cranial (Neuropathy: cranial
- CN IX Motor-pharynx; Sensory-ear,
pharynx, tongue)
Neuropathy: Cranial (Neuropathy: cranial
- CN V Motor-jaw muscles; Sensory-
33 / 44
Pre-Study - BASELINE SYMP - 2393103v1.0
facial)
Neuropathy: Cranial (Neuropathy: cranial
- CN VI Lateral deviation of eye)
Neuropathy: Cranial (Neuropathy: cranial
- CN VII Motor-face; Sensory-taste)
Neuropathy: Cranial (Neuropathy: cranial
- CN VIII Hearing and balance)
Neuropathy: Cranial (Neuropathy: cranial
- CN X Motor-palate; pharynx, larynx)
Neuropathy: Cranial (Neuropathy: cranial
- CN XI Motor-sternomastoid and
trapezius)
Neuropathy: Cranial (Neuropathy: cranial
- CN XII Motor-tongue)
Peripheral Motor Neuropathy
(Neuropathy: motor)
Peripheral Sensory Neuropathy
(Neuropathy: sensory)
Neutropenia (Neutrophils/granulocytes
(ANC/AGC))
Blindness Night (Night blindness
(nyctalopia))
Nystagmus Nos (Nystagmus)
Obesity (Obesity)
Obstruction, Gi (Obstruction, GI -
Cecum)
Obstruction, Gi (Obstruction, GI - Colon)
Obstruction, Gi (Obstruction, GI -
Duodenum)
Obstruction, Gi (Obstruction, GI -
Esophagus)
Obstruction, Gi (Obstruction, GI -
Gallbladder)
Obstruction, Gi (Obstruction, GI - Ileum)
Obstruction, Gi (Obstruction, GI -
Jejunum)
Obstruction, Gi (Obstruction, GI -
Rectum)
Obstruction, Gi (Obstruction, GI - Small
bowel NOS)
Obstruction, Gi (Obstruction, GI - Stoma)
Obstruction, Gi (Obstruction, GI -
Stomach)
Obstruction, Gu (Obstruction, GU -
Bladder)
Obstruction, Gu (Obstruction, GU -
Fallopian tube)
Obstruction, Gu (Obstruction, GU -
Prostate)
Obstruction, Gu (Obstruction, GU -
Spermatic cord)
Obstruction, Gu (Obstruction, GU -
Stoma)
Obstruction, Gu (Obstruction, GU -
Testes)
Ureteric Obstruction (Obstruction, GU -
Ureter)
Obstruction, Gu (Obstruction, GU -
Urethra)
Obstruction, Gu (Obstruction, GU -
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Uterus)
Obstruction, Gu (Obstruction, GU -
Vagina)
Obstruction, Gu (Obstruction, GU - Vas
deferens)
Obstruction/stenosis Of Airway
(Obstruction/stenosis of airway -
Bronchus)
Obstruction/stenosis Of Airway
(Obstruction/stenosis of airway - Larynx)
Obstruction/stenosis Of Airway
(Obstruction/stenosis of airway -
Pharynx)
Obstruction/stenosis Of Airway
(Obstruction/stenosis of airway -
Trachea)
Conjunctivitis Nec (Ocular surface
disease)
Ocular/visual Other (Ocular/Visual-Other
(Specify))
Odor (patient Odor) (Odor (patient odor))
Diplopia (Ophthalmoplegia/diplopia
(double vision))
Opportunistic Infection Associated With
>=grade 2 Lymphopenia (Opportunistic
infection associated with >=Grade 2
lymphopenia)
Optic Disc Edema (Optic disc edema)
Orgasmic Dysfunction (Orgasmic
dysfunction)
Osteonecrosis (Osteonecrosis (avascular
necrosis))
Osteoporosis (Osteoporosis)
Otitis Externa (exc Boil Of Meatus) Nos
(Otitis, external ear (non-infectious))
Otitis Media Serous Nos (Otitis, middle
ear (non-infectious))
Abdominal Pain Nos (Pain - Abdomen
NOS)
Pain (Pain - Anus)
Pain (Pain - Back)
Pain (Pain - Bladder)
Bone Pain (Pain - Bone)
Pain (Pain - Breast)
Pain (Pain - Buttock)
Pain (Pain - Cardiac/heart)
Pain (Pain - Chest wall)
Chest Pain (Pain - Chest/thorax NOS)
Pain (Pain - Dental/teeth/peridontal)
Pain (Pain - Esophagus)
Earache (Pain - External ear)
Pain (Pain - Extremity-limb)
Pain (Pain - Eye)
Pain (Pain - Face)
Pain (Pain - Gallbladder)
Headache Nos (Pain - Head/headache)
Pain (Pain - Intestine)
Arthralgia (Pain - Joint)
Pain (Pain - Kidney)
Pain (Pain - Larynx)
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Pain (Pain - Lip)
Hepatic Pain (Pain - Liver)
Pain (Pain - Lymph node)
Pain (Pain - Middle ear)
Myalgia (Pain - Muscle)
Pain (Pain - Neck)
Neuralgia Nos (Pain -
Neuralgia/peripheral nerve)
Pain (Pain - Oral cavity)
Pain (Pain - Oral-gums)
Pain (Pain - Ovulatory)
Pain (Pain - Pain NOS)
Pelvic Pain Nos (Pain - Pelvis)
Pain (Pain - Penis)
Pain (Pain - Pericardium)
Pain (Pain - Perineum)
Pain (Pain - Peritoneum)
Pain (Pain - Phantom (pain associated
with missing limb))
Pleuritic Pain (Pain - Pleura)
Pain (Pain - Prostate)
Proctalgia (Pain - Rectum)
Pain (Pain - Scalp)
Pain (Pain - Scrotum)
Pain (Pain - Sinus)
Pain (Pain - Skin)
Pain (Pain - Stomach)
Pain (Pain - Testicle)
Pain (Pain - Throat/pharynx/larynx)
Tumour Pain (Pain - Tumor pain)
Dysuria (Pain - Urethra)
Dysmenorrhoea (Pain - Uterus)
Pain (Pain - Vagina)
Pain Other (Pain-Other (Specify))
Palpitations (Palpitations)
Pancreas, Exocrine Enzyme Deficiency
(Pancreas, exocrine enzyme deficiency)
Pancreatic Endocrine: Glucose
Intolerance (Pancreatic endocrine:
glucose intolerance)
Pancreatitis Nos (Pancreatitis)
Parathyroid Function, Low
(hypoparathyroidism) (Parathyroid
function, low (hypoparathyroidism))
Perforation, Gi (Perforation, GI -
Appendix)
Perforation, Gi (Perforation, GI - Biliary
tree)
Perforation, Gi (Perforation, GI - Cecum)
Perforation, Gi (Perforation, GI - Colon)
Perforation, Gi (Perforation, GI -
Duodenum)
Perforation, Gi (Perforation, GI -
Esophagus)
Perforation, Gi (Perforation, GI -
Gallbladder)
Perforation, Gi (Perforation, GI - Ileum)
Perforation, Gi (Perforation, GI -
Jejunum)
Perforation, Gi (Perforation, GI - Rectum)
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Perforation, Gi (Perforation, GI - Small
bowel NOS)
Perforation, Gi (Perforation, GI -
Stomach)
Perforation, Gu (Perforation, GU -
Bladder)
Perforation, Gu (Perforation, GU -
Fallopian tube)
Perforation, Gu (Perforation, GU -
Kidney)
Perforation, Gu (Perforation, GU - Ovary)
Perforation, Gu (Perforation, GU -
Prostate)
Perforation, Gu (Perforation, GU -
Spermatic cord)
Perforation, Gu (Perforation, GU -
Stoma)
Perforation, Gu (Perforation, GU -
Testes)
Perforation, Gu (Perforation, GU - Ureter)
Perforation, Gu (Perforation, GU -
Urethra)
Perforation, Gu (Perforation, GU -
Uterus)
Perforation, Gu (Perforation, GU -
Vagina)
Perforation, Gu (Perforation, GU - Vas
deferens)
Pericardial Effusion (Pericardial effusion
(non-malignant))
Pericarditis (Pericarditis)
Peripheral Ischaemia Nos (Peripheral
arterial ischemia)
Personality Change
(Personality/behavioral)
Petechiae (Petechiae/purpura
(hemorrhage/bleeding into skin or
mucosa))
Phlebitis Superficial (Phlebitis (including
superficial thrombosis))
Phlebolymphatic Cording
(Phlebolymphatic cording)
Hypophosphataemia (Phosphate, serum-
low (hypophosphatemia))
Photosensitivity Reaction Nos
(Photosensitivity)
Phrenic Nerve Dysfunction (Phrenic
nerve dysfunction)
Platelet Count Decreased (Platelets)
Pleural Effusion (Pleural effusion (non-
malignant))
Pneumonitis Nos
(Pneumonitis/pulmonary infiltrates)
Pneumothorax Nos (Pneumothorax)
Portal Hypertension (Portal vein flow)
Hyperkalaemia (Potassium, serum-high
(hyperkalemia))
Hypokalaemia (Potassium, serum-low
(hypokalemia))
Proctitis Nos (Proctitis)
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Prolapse Of Stoma, Gi (Prolapse of
stoma, GI)
Prolapse Of Stoma, Gu (Prolapse of
stoma, GU)
Prolonged Chest Tube Drainage Or Air
Leak After Pulmonary Resection
(Prolonged chest tube drainage or air
leak after pulmonary resection)
Prolonged Intubation After Pulmonary
Resection (>24 Hrs After Surgery)
(Prolonged intubation after pulmonary
resection (>24 hrs after surgery))
Electrocardiogram Qt Prolonged
(Prolonged QTc interval)
Proptosis/enophthalmos
(Proptosis/enophthalmos)
Proteinuria Present (Proteinuria)
Pruritus Nos (Pruritus/itching)
Delusion Nos (Psychosis
(hallucinations/delusions))
Activated Partial Thromboplastin Time
Prolonged (PTT (Partial thromboplastin
time))
Puberty (delayed) (Puberty (delayed))
Puberty (precocious) (Puberty
(precocious))
Pulmonary Fibrosis (Pulmonary fibrosis
(radiographic changes))
Pulmonary Hypertension (Pulmonary
hypertension)
Pulmonary/upper Respiratory Other
(Pulmonary/Upper Respiratory-Other
(Specify))
Upper Motor Neurone Lesion (Pyramidal
tract dysfunction (e.g., increased tone,
hyperreflexia, positive Babinski,
decreased fine motor coordination))
Rash: Acne/acneiform (Rash:
acne/acneiform)
Radiation Recall Syndrome (Rash:
dermatitis associated with radiation -
Chemoradiation)
Dermatitis Radiation Nos (Rash:
dermatitis associated with radiation -
Radiation)
Erythema Multiforme (Rash: erythema
multiforme (e.g., Stevens-Johnson
syndrome, toxic epidermal necrolysis))
Localised Exfoliation (Rash: hand-foot
skin reaction)
Dermatitis Exfoliative Nos
(Rash/desquamation)
Renal Failure Nos (Renal failure)
Renal/genitourinary Other
(Renal/Genitourinary-Other (Specify))
Restrictive Cardiomyopathy (Restrictive
cardiomyopathy)
Retinal Detachment (Retinal
detachment)
Retinopathy (Retinopathy)
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Right Ventricular Dysfunction (cor
Pulmonale) (Right ventricular dysfunction
(cor pulmonale))
Rigors (Rigors/chills)
Salivary Gland Disorder Nos (Salivary
gland changes/saliva)
Scleral Necrosis/melt (Scleral
necrosis/melt)
Secondary Malignancy Possibly Related
To Cancer Treatment (Secondary
Malignancy-possibly related to cancer
treatment (Specify))
Convulsions Nos (Seizure)
Seroma (Seroma)
Serum Sickness (Serum sickness)
Sexual/reproductive Function Other
(Sexual/Reproductive Function-Other
(Specify))
Short Stature (Short stature)
Skin Breakdown/decubitus Ulcer (Skin
breakdown/decubitus ulcer)
Hypernatraemia (Sodium, serum-high
(hypernatremia))
Hyponatraemia (Sodium, serum-low
(hyponatremia))
Soft Tissue Necrosis (Soft tissue
necrosis - Abdomen)
Soft Tissue Necrosis (Soft tissue
necrosis - Extremity-lower)
Soft Tissue Necrosis (Soft tissue
necrosis - Extremity-upper)
Soft Tissue Necrosis (Soft tissue
necrosis - Head)
Soft Tissue Necrosis (Soft tissue
necrosis - Neck)
Soft Tissue Necrosis (Soft tissue
necrosis - Pelvic)
Soft Tissue Necrosis (Soft tissue
necrosis - Thorax)
Depressed Level Of Consciousness
(Somnolence/depressed level of
consciousness)
Speech Disorder Nec (Speech
impairment (e.g., dysphasia or aphasia))
Splenic Function (Splenic function)
Striae (Striae)
Stricture/stenosis (including
Anastomotic), Gi (Stricture/stenosis
(including anastomotic), GI - Anus)
Stricture/stenosis (including
Anastomotic), Gi (Stricture/stenosis
(including anastomotic), GI - Biliary tree)
Stricture/stenosis (including
Anastomotic), Gi (Stricture/stenosis
(including anastomotic), GI - Cecum)
Stricture/stenosis (including
Anastomotic), Gi (Stricture/stenosis
(including anastomotic), GI - Colon)
Stricture/stenosis (including
Anastomotic), Gi (Stricture/stenosis
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(including anastomotic), GI - Duodenum)
Stricture/stenosis (including
Anastomotic), Gi (Stricture/stenosis
(including anastomotic), GI - Esophagus)
Stricture/stenosis (including
Anastomotic), Gi (Stricture/stenosis
(including anastomotic), GI - Ileum)
Stricture/stenosis (including
Anastomotic), Gi (Stricture/stenosis
(including anastomotic), GI - Jejunum)
Stricture/stenosis (including
Anastomotic), Gi (Stricture/stenosis
(including anastomotic), GI -
Pancreas/pancreatic duct)
Stricture/stenosis (including
Anastomotic), Gi (Stricture/stenosis
(including anastomotic), GI - Pharynx)
Stricture/stenosis (including
Anastomotic), Gi (Stricture/stenosis
(including anastomotic), GI - Rectum)
Stricture/stenosis (including
Anastomotic), Gi (Stricture/stenosis
(including anastomotic), GI - Small bowel
NOS)
Stricture/stenosis (including
Anastomotic), Gi (Stricture/stenosis
(including anastomotic), GI - Stoma)
Stricture/stenosis (including
Anastomotic), Gi (Stricture/stenosis
(including anastomotic), GI - Stomach)
Stricture/stenosis (including
Anastomotic), Gu (Stricture/stenosis
(including anastomotic), GU - Bladder)
Stricture/stenosis (including
Anastomotic), Gu (Stricture/stenosis
(including anastomotic), GU - Fallopian
tube)
Stricture/stenosis (including
Anastomotic), Gu (Stricture/stenosis
(including anastomotic), GU - Prostate)
Stricture/stenosis (including
Anastomotic), Gu (Stricture/stenosis
(including anastomotic), GU - Spermatic
cord)
Stricture/stenosis (including
Anastomotic), Gu (Stricture/stenosis
(including anastomotic), GU - Stoma)
Stricture/stenosis (including
Anastomotic), Gu (Stricture/stenosis
(including anastomotic), GU - Testes)
Stricture/stenosis (including
Anastomotic), Gu (Stricture/stenosis
(including anastomotic), GU - Ureter)
Stricture/stenosis (including
Anastomotic), Gu (Stricture/stenosis
(including anastomotic), GU - Urethra)
Stricture/stenosis (including
Anastomotic), Gu (Stricture/stenosis
(including anastomotic), GU - Uterus)
Stricture/stenosis (including
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Anastomotic), Gu (Stricture/stenosis
(including anastomotic), GU - Vagina)
Stricture/stenosis (including
Anastomotic), Gu (Stricture/stenosis
(including anastomotic), GU - Vas
deferens)
Supraventricular And Nodal Arrhythmia
(Supraventricular and nodal arrhythmia -
Atrial fibrillation)
Supraventricular And Nodal Arrhythmia
(Supraventricular and nodal arrhythmia -
Atrial flutter)
Supraventricular And Nodal Arrhythmia
(Supraventricular and nodal arrhythmia -
Atrial tachycardia/paroxysmal atrial
tachycardia)
Supraventricular And Nodal Arrhythmia
(Supraventricular and nodal arrhythmia -
Nodal/junctional)
Supraventricular And Nodal Arrhythmia
(Supraventricular and nodal arrhythmia -
Sinus arrhythmia)
Sinus Bradycardia (Supraventricular and
nodal arrhythmia - Sinus bradycardia)
Sinus Tachycardia (Supraventricular and
nodal arrhythmia - Sinus tachycardia)
Supraventricular Arrhythmia Nos
(Supraventricular and nodal arrhythmia -
Supraventricular arrhythmia NOS)
Supraventricular And Nodal Arrhythmia -
Supraventricular Extrasystoles
(premature Atrial Contractions;
Premature Nodal/junctional
Contractions) (Supraventricular and
nodal arrhythmia - Supraventricular
extrasystoles (premature atrial
contractions; premature nodal/junctional
contractions))
Supraventricular And Nodal Arrhythmia
(Supraventricular and nodal arrhythmia -
Supraventricular tachycardia)
Sweating Increased (Sweating
(diaphoresis))
Syncope (Syncope (fainting))
Syndromes Other (Syndromes-Other
(Specify))
Taste Disturbance (Taste alteration
(dysgeusia))
Telangiectasia (Telangiectasia)
Thrombosis/embolism (vascular Access-
related) (Thrombosis/embolism (vascular
access-related))
Thrombosis Nos
(Thrombosis/thrombus/embolism)
Thrombotic Microangiopathy (e.g.,
Thrombotic Thrombocytopenic
Purpura[ttp] Or Hemolytic Uremic
Syndrome[hus]) (Thrombotic
microangiopathy (e.g., thrombotic
thrombocytopenic purpura or hemolytic
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uremic syndrome))
Thyroid Function, High (hyperthyroidism,
Thyrotoxicosis) (Thyroid function, high
(hyperthyroidism, thyrotoxicosis))
Hypothyroidism (Thyroid function, low
(hypothyroidism))
Tinnitus (Tinnitus)
Tremor Nec (Tremor)
Hypertriglyceridaemia (Triglyceride,
serum-high (hypertriglyceridemia))
Trismus (difficulty, Restriction Or Pain
When Opening Mouth) (Trismus
(difficulty, restriction or pain when
opening mouth))
Tumour Flare (Tumor flare)
Tumour Lysis Syndrome (Tumor lysis
syndrome)
Caecitis (Typhlitis (cecal inflammation))
Ulcer, Gi (Ulcer, GI - Anus)
Ulcer, Gi (Ulcer, GI - Cecum)
Ulcer, Gi (Ulcer, GI - Colon)
Duodenal Ulcer (Ulcer, GI - Duodenum)
Ulcer, Gi (Ulcer, GI - Esophagus)
Ulcer, Gi (Ulcer, GI - Ileum)
Ulcer, Gi (Ulcer, GI - Jejunum)
Ulcer, Gi (Ulcer, GI - Rectum)
Ulcer, Gi (Ulcer, GI - Small bowel NOS)
Ulcer, Gi (Ulcer, GI - Stoma)
Gastric Ulcer (Ulcer, GI - Stomach)
Ulceration (Ulceration)
Hyperuricaemia (Uric acid, serum-high
(hyperuricemia))
Fanconi Syndrome (Urinary electrolyte
wasting (e.g., Fanconi's syndrome, renal
tubular acidosis))
Urinary Frequency (Urinary
frequency/urgency)
Urinary Retention (Urinary retention
(including neurogenic bladder))
Urine Discolouration (Urine color
change)
Urticaria Nos (Urticaria (hives, welts,
wheals))
Uveitis (Uveitis)
Vaginal Discharge (non-infectious)
(Vaginal discharge (non-infectious))
Vulvovaginal Dryness (Vaginal dryness)
Vaginal Mucositis (Vaginal mucositis)
Vaginal Stenosis/length (Vaginal
stenosis/length)
Vaginitis (Vaginitis (not due to infection))
Valvular Heart Disease (Valvular heart
disease)
Vascular Other (Vascular-Other
(Specify))
Vasculitis Nos (Vasculitis)
Vasovagal Attack (Vasovagal episode)
Ventricular Arrhythmia (Ventricular
arrhythmia - Bigeminy)
Ventricular Arrhythmia (Ventricular
42 / 44
Pre-Study - BASELINE SYMP - 2393103v1.0
arrhythmia - Idioventricular rhythm)
Ventricular Arrhythmia (Ventricular
arrhythmia - PVCs)
Ventricular Arrhythmia (Ventricular
arrhythmia - Torsade de pointes)
Ventricular Arrhythmia (Ventricular
arrhythmia - Trigeminy)
Ventricular Arrhythmia Nos (Ventricular
arrhythmia - Ventricular arrhythmia NOS)
Ventricular Arrhythmia (Ventricular
arrhythmia - Ventricular fibrillation)
Ventricular Arrhythmia (Ventricular
arrhythmia - Ventricular flutter)
Ventricular Arrhythmia (Ventricular
arrhythmia - Ventricular tachycardia)
Vessel Injury-artery (Vessel injury-artery
- Aorta)
Vessel Injury-artery (Vessel injury-artery
- Carotid)
Vessel Injury-artery (Vessel injury-artery
- Extremity-lower)
Vessel Injury-artery (Vessel injury-artery
- Extremity-upper)
Vessel Injury-artery (Vessel injury-artery
- Other NOS)
Vessel Injury-artery (Vessel injury-artery
- Visceral)
Vessel Injury-vein (Vessel injury-vein -
Extremity-lower)
Vessel Injury-vein (Vessel injury-vein -
Extremity-upper)
Vessel Injury-vein (Vessel injury-vein -
IVC)
Vessel Injury-vein (Vessel injury-vein -
Jugular)
Vessel Injury-vein (Vessel injury-vein -
Other NOS)
Vessel Injury-vein (Vessel injury-vein -
SVC)
Vessel Injury-vein (Vessel injury-vein -
Viscera)
Viral Hepatitis (Viral hepatitis)
Visceral Arterial Ischaemia (Visceral
arterial ischemia (non-myocardial))
Vision Blurred (Vision-blurred vision)
Photopsia (Vision-flashing lights/floaters)
Photophobia (Vision-photophobia)
Vital Capacity (Vital capacity)
Vitreous Hemorrhage (Vitreous
hemorrhage)
Dysphonia (Voice changes/dysarthria
(e.g., hoarseness, loss or alteration in
voice, laryngitis))
Vomiting Nos (Vomiting)
Lacrimation Increased (Watery eye
(epiphora, tearing))
Weight Increased (Weight gain)
Weight Decreased (Weight loss)
Culture Wound Negative (Wound
complication, non-infectious)
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Adverse Event Description Text
Common Toxicity Criteria Adverse Event Grade
No Adverse Event Or Within Normal
Limits (0)
Mild Adverse Event (1)
Moderate Adverse Event (2)
Severe And Undesirable Adverse Event
(3)
Life-threatening Or Disabling Adverse
Event (4)
Death Related To Adverse Event (5)
Disease Attribution? (Y/N)
No (No)
Unknown (Unknown)
Yes (Yes)
MedDRA Code (This is a derived field and may
be displayed on the form, if needed.)
Comments
Note Date
Research Comments Text
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Treatment - COURSE INITIATION -
2411443v1.0
Treatment - COURSE INITIATION - 2411443v1.0
All rights reserved. Please visit https://medical-data-
models.org/forms/3087
COURSE INITIATION
Course Initiation
Course Number
Course Start Date
Arm
Treatment Assignment Code at Enrollment
Treating Institution Text Code
Stop Date (This is a derived field and may be
displayed on the form, if needed.)
Vital Signs
Evaluation Date
Lab Collection Time
Height (cm)
Body Weight in Kilograms
BSA
Zubrod Performance Status Score
Normal Activity (0)
Symptoms, But Nearly Fully Ambulatory
(1)
Some Bed Time, But Needs To Be In
Bed <50% Of Normal Daytime (2)
Needs To Be In Bed > 50% Of Normal
Daytime (3)
Unable To Get Out Of Bed (4)
Karnofsky Performance Status Score
Dead (0)
Moribund, Fatal Processes Progressing
Rapidly (10)
Normal, No Complaints, No Evidence Of
Disease (100)
Very Sick, Hospitalization Indicated.
Death Not Imminent (20)
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Severely Disabled, Hospitalization
Indicated. Death Not Imminent (30)
Disabled, Requires Special Care And
Assistance (40)
Requires Considerable Assistance And
Frequent Medical Care (50)
Requires Occasional Assistance, But Is
Able To Care For Most Of His/her Needs
(60)
Cares For Self, Unable To Carry On
Normal Activity Or To Do Active Work
(70)
Normal Activity With Effort; Some Signs
Or Symptoms Of Disease (80)
Able To Carry On Normal Activity; Minor
Signs Or Symptoms Of Disease (90)
Lansky Performance Status Score
Unresponsive (0)
No Play; Does Not Get Out Of Bed. (10)
Fully Active, Normal (100)
Often Sleeping; Play Entirely Limited To
Very Passive Activities. (20)
In Bed; Needs Assistance Even For
Quiet Play. (30)
Mostly In Bed; Participates In Quiet
Activities. (40)
Gets Dressed, But Lies Around Much Of
The Day; No Active Play, Able To
Participate In All Quiet Play And
Activities. (50)
Up And Around, But Minimal Active Play;
Keeps Busy With Quieter Activities. (60)
Both Greater Restriction Of And Less
Time Spent In Play Activity (70)
Active, But Tires More Quickly (80)
Minor Restrictions In Physically
Strenuous Activity (90)
Comments
Note Date
Research Comments Text
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NCT01193842 On-Study - AMC-075 Lymphoma Disease
Activity and Measurement Form (L01) - 3206408v1.0
NCT01193842 On-Study - AMC-075 Lymphoma Disease
Activity and Measurement Form (L01) - 3206408v1.0
All rights reserved. Please visit https://medical-data-
models.org/forms/3097
AMC-075 Lymphoma Disease
Activity and Measurement Form
(L01)
Unnamed1
Visit Number
Unnamed2
Reporting Period
Baseline (Baseline)
Follow-up (Follow-up)
On Treatment (On treatment)
Date of Evaluation (mm/dd/yyyy)
Nodal Involvement Evaluation
Is there lymph node involvement (If Yes, continue.
Otherwise, stop)
No (NO)
Yes (YES)
Lymph Node Type
Celiac Axis/retrocrural/upper Para-aortic
(Celiac Axis/Retrocrular/Upper Para-
Aortic)
Cervical (Cervical)
Epitrochlear/brachial
(Epitrochlear/Brachial)
Hilar (Hilar)
Infraclavicular/axillary/pectoral
(Infraclavicular/Axiliary/Pectoral)
Inguinal/femoral/iliac
(inguinal/femoral/iliac)
Lower Para-aortic (Lower Para-Aortic)
Mediastinal (Mediastinal)
Mesenteric (Mesenteric)
Other Nodal (Other Nodal)
Porta Hepatis (Porta Hepatis)
Pre-auricular (Pre-Auricular)
Spleen (Spleen)
Splenic Hilar (Splenic Hilar)
Supraclavicular (Supraclavicular)
Waldeyer's Ring (Waldeyer's Ring)
Other specify
Dimension 1 (cm)
Dimension 2 (cm)
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Method of Evaluation
Biopsy (Biopsy)
Aspirate, Bone Marrow (Bone Marrow
Aspirate)
Bone Marrow Biopsy (Bone Marrow
Biopsy)
Bone Scan (Bone Scan)
Ct Scan (CT scan)
Gallium Scan (Gallium scan)
Intravenous Pyelogram (IVP)
Lymphangiogram (Lymphangiogram)
Mri Scan (MRI scan)
Other (Other)
Palpation (Palpation)
Peripheral Blood Counts (Peripheral
Blood Counts)
Pet Scan (PET scan)
Pet/ct Scan (PET/CT scan)
Ultrasound (Ultrasound)
X-ray (X-Ray)
Other, specify
PET scan (status for this visit)
Negative (Negative)
Positive Finding (Positive)
Extra Nodal Involvement Evaluation
Lesion completely resolved (For "On treatment"
and "Follow up" cycles only)
No (NO)
Yes (YES)
Is measurable disease present? (For "On
treatment" and "Follow up" cycles only)
No (No)
Yes (Yes)
Has the patient been diagnosed with a new
progression? (For "On treatment" and "Follow up"
cycles only)
No (No)
Yes (Yes)
Evaluation documented (For "On treatment" and
"Follow up" cycles only)
No (No)
Yes (Yes)
Lesion Assessment (For "On treatment" and
"Follow up" cycles only)
Improvement (improvement)
No Change (no change)
Not Evaluated (Not evaluated)
Progression - Increase (progression -
increase)
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Comments
Comments
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NCT01193842 On-Study - AMC-075 Lymphoma Disease Activity and
Measurement Form (L01) - 3206408v1.0
Treatment - STUDY MEDICATION
ADMINISTRATION - 2392332v1.0
Treatment - STUDY MEDICATION ADMINISTRATION -
2392332v1.0
All rights reserved. Please visit https://medical-data-
models.org/forms/3100
STUDY MEDICATION
ADMINISTRATION
Study Medication Administration
Course Day Number
Course Start Date
Start Time
Agent
Stop Date
Dose UOM
Percent (%)
10e4 Cells Per Kilogram (10E4 Cell/kg)
10e5 Cells Per Kilogram (10E5 Cell/kg)
10e6 Cells Per Kilogram (10E6 Cell/kg)
10e7 Cells Per Kilogram (10E7 Cell/kg)
10e7 Plaque Forming Units (10E7 PFU)
10e8 Plaque Forming Units (10E8 PFU)
10e9 Plaque Forming Units (10E9 PFU)
Application (Applcatn)
Atomic Unit (au)
Area Under The Curve (AUC)
Billion Pfu (bill PFU)
Bottle (Bottle)
Caplet (Caplet)
Capsule (Capsule)
Cells (Cells)
Centigray (cGy)
Curie (Ci)
Course (Course)
Cycle (Course)
Deciliter (dL)
Dose (Dose)
Equivalent (Eq)
Grams (g) (g)
Gram Per M2 (g/m2)
Gallon (Gallon)
Drops (gtts)
Gray (Gy)
Hertz (Hz)
Inhalation (Inhalatn)
Iu Vitamin A (IU Vit A)
International Unit Per Milligram (IU/mg)
International Units Or Milligram Alpha
Tocopherol (IU/mg A-TE)
International Unit (IUnit)
International Unit Per Kilogram (IUnit/kg)
International Unit Per Liter (IUnit/L)
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Intravenous Bag (IV Bag)
Joules Per Centimeter Squared (Jcm2)
Kib-electron Volt (KeV)
Kilograms (kg)
Kilohertz (kHz)
Kilopascal (kPa)
Kilounit (kU)
Kilounit Per Kilogram (kU/kg)
Kilounit Per Liter (kU/L)
Liter (L)
Liters Per Minute (L/min)
Microgram (mcg)
Microgram Per Centimeter Squared
(mcg/cm2)
Microgram Per Hour (mcg/hr)
Microgram Per Kilogram (mcg/kg)
Microgram Per Meter Squared (mcg/m2)
Millicurie (mCi)
Measure (Measure)
Milliequivalent (mEq)
Milliequivalents Per 24 Hours (mEq/24hr)
Milliequivalent Per Deciliter (mEq/dL)
Milliequivalent Per Hour (mEq/hr)
Milliequivalent Per Liter (mEq/L)
Million Electron Volt (MeV)
Milligram (mg)
Milligram Per 24 Hours (mg/24hr)
Milligram Per Deciliter (mg/dL)
Milligram Per Hour (mg/hr)
Milligram Per Inhalation (mg/inh)
Milligram Per Kilogram (mg/kg)
Milligram Per Meter Squared (mg/m2)
Milligram Per Milliliter (mg/mL)
Milligram Per Week (mg/wk)
Megahertz (MHz)
Microcurie (microCi)
Microliter (microL)
Micromole (micromol)
Million Plaque Forming Units (mill PFU)
Million (Million)
Milliunit (millunit)
Milliinternational Unit (miu)
Milliinternational Units Per Meter
Squared (miu/m2)
Milliliter (mL)
Cubic Centimeter (cc) (mL)
Milliliter Per Hour (mL/hr)
Milliliter Per Kilogram (mL/kg)
Millimole (mmol)
Mole (Mole)
Milliosmole (mosmol)
Megarad (Mrad)
Million Units (MU)
Millivolt (mV)
Million Viral Particles (MVP)
Nanocurie (nCi)
Nanogram (ng)
Nanogram Per Kilogram (ng/kg)
Nanogram Per Liter (ng/L)
Nanograms Per Milliliter (ng/mL)
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Nanometer Of Light (nm light)
Nanomole (nmol)
No Source Data (No Srce)
Osmolality (osmol)
Ounce (oz)
Pascal (Pa)
Packet (packet)
Patch (Patch)
Plaque Forming Units (PFU)
Picograms (pg)
Pounds Per Square Inch (psi)
Puff (puff)
Radiation Absorbed Dose (Rad)
Vitamin A Retinol (RAE)
Retinol Equivalents (RE)
Seed (Seed)
Session (Session)
Spray (Spray)
Suppository (Suppstry)
Tablets (Tablet)
Tablespoon (Tbsp)
Tissue Culture Infection Dose (TCID)
Thousand (Thousand)
Troche (Troche)
Teaspoon (tsp)
Unit (Unit)
Unit Per Gram (Unit/g)
Unit Per Kilogram (Unit/kg)
Unit Per Meter Squared (Unit/m2)
Unknown (Unknown)
Viral Particles (VP)
Course Number (This is a derived field and may
be displayed on the form, if needed.)
Stop Time
Dose Level
Dose UOM
Percent (%)
10e4 Cells Per Kilogram (10E4 Cell/kg)
10e5 Cells Per Kilogram (10E5 Cell/kg)
10e6 Cells Per Kilogram (10E6 Cell/kg)
10e7 Cells Per Kilogram (10E7 Cell/kg)
10e7 Plaque Forming Units (10E7 PFU)
10e8 Plaque Forming Units (10E8 PFU)
10e9 Plaque Forming Units (10E9 PFU)
Application (Applcatn)
Atomic Unit (au)
Area Under The Curve (AUC)
Billion Pfu (bill PFU)
Bottle (Bottle)
Caplet (Caplet)
Capsule (Capsule)
Cells (Cells)
Centigray (cGy)
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Curie (Ci)
Course (Course)
Cycle (Course)
Deciliter (dL)
Dose (Dose)
Equivalent (Eq)
Grams (g) (g)
Gram Per M2 (g/m2)
Gallon (Gallon)
Drops (gtts)
Gray (Gy)
Hertz (Hz)
Inhalation (Inhalatn)
Iu Vitamin A (IU Vit A)
International Unit Per Milligram (IU/mg)
International Units Or Milligram Alpha
Tocopherol (IU/mg A-TE)
International Unit (IUnit)
International Unit Per Kilogram (IUnit/kg)
International Unit Per Liter (IUnit/L)
Intravenous Bag (IV Bag)
Joules Per Centimeter Squared (Jcm2)
Kib-electron Volt (KeV)
Kilograms (kg)
Kilohertz (kHz)
Kilopascal (kPa)
Kilounit (kU)
Kilounit Per Kilogram (kU/kg)
Kilounit Per Liter (kU/L)
Liter (L)
Liters Per Minute (L/min)
Microgram (mcg)
Microgram Per Centimeter Squared
(mcg/cm2)
Microgram Per Hour (mcg/hr)
Microgram Per Kilogram (mcg/kg)
Microgram Per Meter Squared (mcg/m2)
Millicurie (mCi)
Measure (Measure)
Milliequivalent (mEq)
Milliequivalents Per 24 Hours (mEq/24hr)
Milliequivalent Per Deciliter (mEq/dL)
Milliequivalent Per Hour (mEq/hr)
Milliequivalent Per Liter (mEq/L)
Million Electron Volt (MeV)
Milligram (mg)
Milligram Per 24 Hours (mg/24hr)
Milligram Per Deciliter (mg/dL)
Milligram Per Hour (mg/hr)
Milligram Per Inhalation (mg/inh)
Milligram Per Kilogram (mg/kg)
Milligram Per Meter Squared (mg/m2)
Milligram Per Milliliter (mg/mL)
Milligram Per Week (mg/wk)
Megahertz (MHz)
Microcurie (microCi)
Microliter (microL)
Micromole (micromol)
Million Plaque Forming Units (mill PFU)
Million (Million)
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Milliunit (millunit)
Milliinternational Unit (miu)
Milliinternational Units Per Meter
Squared (miu/m2)
Milliliter (mL)
Cubic Centimeter (cc) (mL)
Milliliter Per Hour (mL/hr)
Milliliter Per Kilogram (mL/kg)
Millimole (mmol)
Mole (Mole)
Milliosmole (mosmol)
Megarad (Mrad)
Million Units (MU)
Millivolt (mV)
Million Viral Particles (MVP)
Nanocurie (nCi)
Nanogram (ng)
Nanogram Per Kilogram (ng/kg)
Nanogram Per Liter (ng/L)
Nanograms Per Milliliter (ng/mL)
Nanometer Of Light (nm light)
Nanomole (nmol)
No Source Data (No Srce)
Osmolality (osmol)
Ounce (oz)
Pascal (Pa)
Packet (packet)
Patch (Patch)
Plaque Forming Units (PFU)
Picograms (pg)
Pounds Per Square Inch (psi)
Puff (puff)
Radiation Absorbed Dose (Rad)
Vitamin A Retinol (RAE)
Retinol Equivalents (RE)
Seed (Seed)
Session (Session)
Spray (Spray)
Suppository (Suppstry)
Tablets (Tablet)
Tablespoon (Tbsp)
Tissue Culture Infection Dose (TCID)
Thousand (Thousand)
Troche (Troche)
Teaspoon (tsp)
Unit (Unit)
Unit Per Gram (Unit/g)
Unit Per Kilogram (Unit/kg)
Unit Per Meter Squared (Unit/m2)
Unknown (Unknown)
Viral Particles (VP)
Administration Schedule Abbreviated Descriptive
Text
Route
Continuous Intravenous Infusion (CIV)
Endotracheal Route Of Administration
(ENDOTR)
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Gastrostomy Tube (G Tube)
Intra-arterial (IA)
Intradermal (ID)
Intrahepatic (IH)
Intrahepatic Infusion (IHI)
Intramuscular (IM)
Inhalation (Inhalatn)
Interstitial Route Of Administration
(Interstl)
Intratumoral (INTUM)
Intraperitoneal (IP)
Intrathecal (IT)
Intravenous Bolus (IV)
Intravenous Infusion (IVI)
Nasal (NASAL)
Nasogastric (NG)
Ophthalmic, Each Eye (Oph Each)
Ophthalmic, Left Eye (Oph Left)
Ophthalmic, Right Eye (Oph Rt)
Auricular Route Of Administration (Otic)
Oral (PO)
Rectal (PR)
Radiation (RT)
Subcutaneous (SC)
Sublingual (Sublingual)
Swish & Spit (SWSP)
Swish & Swallow (SWSW)
Topical (TOP)
Transdermal (Transdermal)
Transmucosal Route (Transmucosal)
Unknown Route Of Administration
(Unknown)
Vaginal Route (Vaginal)
Agent Actual Dose
Lot Number
Duration Value
Duration UOM
Course (CO)
Days (DY)
Hours (HR)
Minutes (MN)
Month (MO)
Second (SEC)
Weeks (WK)
Study Drug Missed
Missed Dose Date
Missed Dose Amount
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Agent
Dose UOM
Percent (%)
10e4 Cells Per Kilogram (10E4 Cell/kg)
10e5 Cells Per Kilogram (10E5 Cell/kg)
10e6 Cells Per Kilogram (10E6 Cell/kg)
10e7 Cells Per Kilogram (10E7 Cell/kg)
10e7 Plaque Forming Units (10E7 PFU)
10e8 Plaque Forming Units (10E8 PFU)
10e9 Plaque Forming Units (10E9 PFU)
Application (Applcatn)
Atomic Unit (au)
Area Under The Curve (AUC)
Billion Pfu (bill PFU)
Bottle (Bottle)
Caplet (Caplet)
Capsule (Capsule)
Cells (Cells)
Centigray (cGy)
Curie (Ci)
Course (Course)
Cycle (Course)
Deciliter (dL)
Dose (Dose)
Equivalent (Eq)
Grams (g) (g)
Gram Per M2 (g/m2)
Gallon (Gallon)
Drops (gtts)
Gray (Gy)
Hertz (Hz)
Inhalation (Inhalatn)
Iu Vitamin A (IU Vit A)
International Unit Per Milligram (IU/mg)
International Units Or Milligram Alpha
Tocopherol (IU/mg A-TE)
International Unit (IUnit)
International Unit Per Kilogram (IUnit/kg)
International Unit Per Liter (IUnit/L)
Intravenous Bag (IV Bag)
Joules Per Centimeter Squared (Jcm2)
Kib-electron Volt (KeV)
Kilograms (kg)
Kilohertz (kHz)
Kilopascal (kPa)
Kilounit (kU)
Kilounit Per Kilogram (kU/kg)
Kilounit Per Liter (kU/L)
Liter (L)
Liters Per Minute (L/min)
Microgram (mcg)
Microgram Per Centimeter Squared
(mcg/cm2)
Microgram Per Hour (mcg/hr)
Microgram Per Kilogram (mcg/kg)
Microgram Per Meter Squared (mcg/m2)
Millicurie (mCi)
Measure (Measure)
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Milliequivalent (mEq)
Milliequivalents Per 24 Hours (mEq/24hr)
Milliequivalent Per Deciliter (mEq/dL)
Milliequivalent Per Hour (mEq/hr)
Milliequivalent Per Liter (mEq/L)
Million Electron Volt (MeV)
Milligram (mg)
Milligram Per 24 Hours (mg/24hr)
Milligram Per Deciliter (mg/dL)
Milligram Per Hour (mg/hr)
Milligram Per Inhalation (mg/inh)
Milligram Per Kilogram (mg/kg)
Milligram Per Meter Squared (mg/m2)
Milligram Per Milliliter (mg/mL)
Milligram Per Week (mg/wk)
Megahertz (MHz)
Microcurie (microCi)
Microliter (microL)
Micromole (micromol)
Million Plaque Forming Units (mill PFU)
Million (Million)
Milliunit (millunit)
Milliinternational Unit (miu)
Milliinternational Units Per Meter
Squared (miu/m2)
Milliliter (mL)
Cubic Centimeter (cc) (mL)
Milliliter Per Hour (mL/hr)
Milliliter Per Kilogram (mL/kg)
Millimole (mmol)
Mole (Mole)
Milliosmole (mosmol)
Megarad (Mrad)
Million Units (MU)
Millivolt (mV)
Million Viral Particles (MVP)
Nanocurie (nCi)
Nanogram (ng)
Nanogram Per Kilogram (ng/kg)
Nanogram Per Liter (ng/L)
Nanograms Per Milliliter (ng/mL)
Nanometer Of Light (nm light)
Nanomole (nmol)
No Source Data (No Srce)
Osmolality (osmol)
Ounce (oz)
Pascal (Pa)
Packet (packet)
Patch (Patch)
Plaque Forming Units (PFU)
Picograms (pg)
Pounds Per Square Inch (psi)
Puff (puff)
Radiation Absorbed Dose (Rad)
Vitamin A Retinol (RAE)
Retinol Equivalents (RE)
Seed (Seed)
Session (Session)
Spray (Spray)
Suppository (Suppstry)
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Tablets (Tablet)
Tablespoon (Tbsp)
Tissue Culture Infection Dose (TCID)
Thousand (Thousand)
Troche (Troche)
Teaspoon (tsp)
Unit (Unit)
Unit Per Gram (Unit/g)
Unit Per Kilogram (Unit/kg)
Unit Per Meter Squared (Unit/m2)
Unknown (Unknown)
Viral Particles (VP)
Course Number (This is a derived field and may
be displayed on the form, if needed.)
Comments
Note Date
Research Comments Text
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Sarcoma NCT01016730 Lab - AMC-063 HIV T-
Cell Laboratory Values Form (F24) - 3020248v1.0
Sarcoma NCT01016730 Lab - AMC-063 HIV T-Cell
Laboratory Values Form (F24) - 3020248v1.0
All rights reserved. Please visit https://medical-data-
models.org/forms/3105
AMC-063 HIV T-Cell Laboratory
Values Form (F24)
Unnamed1
Visit number
Sequence number
Unnamed2
Date of Evaluation (mm/dd/yyyy)
T-cell Laboratory Values
T-Helper CD4+ %
T-Helper CD4+ absolute count
Other, specify
Percent Positive Lymphocytes
Absolute Count
Comments
Comments
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Nonneoplastic Condition NCT01057121 Pathology - AMC-070
KS Tape Stripping and Biopsy Form (TSB) - 3147648v1.0
Nonneoplastic Condition NCT01057121 Pathology - AMC-
070 KS Tape Stripping and Biopsy Form (TSB) -
3147648v1.0
All rights reserved. Please visit https://medical-data-
models.org/forms/3110
AMC-070 KS Tape Stripping and
Biopsy Form (TSB)
Header Module
Visit number
Unnamed1
Was the tape strip applied to this lesion
No (no)
Yes (yes)
Date of tape strip specimen collection
(mm/dd/yyyy)
Tape strip site
Abdomen (Abdomen)
Back (Back)
Chest (Chest)
Genital Area (Genital)
Head (Head)
Left Arm (Left arm)
Left Foot (Left foot)
Left Hand (Left hand)
Left Leg (Left leg)
Neck (Neck)
Right Arm (Right arm)
Right Foot (Right foot)
Right Hand (Right hand)
Right Leg (Right leg)
Specify the tape strip site (exact location)
Was this lesion also biopsied
No (No)
Yes (Yes)
Date of Biopsy (mm/dd/yyyy)
Biopsy Size (mm)
Biopsy site
Abdomen (Abdomen)
Back (Back)
Chest (Chest)
Genital Area (Genital)
Head (Head)
Left Arm (Left arm)
Left Foot (Left foot)
Left Hand (Left hand)
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Left Leg (Left leg)
Neck (Neck)
Right Arm (Right arm)
Right Foot (Right foot)
Right Hand (Right hand)
Right Leg (Right leg)
Specify the biopsy site (exact location)
Specimen Fixative
Formalin (Formalin)
Glutaraldehyde (Glutaraldehyde)
Oct Media (OCT media)
Rnalater (RNAlater)
Saline (Saline)
Unnamed1
Was the tape strip applied to this lesion
No (no)
Yes (yes)
Date of tape strip specimen collection
(mm/dd/yyyy)
Tape strip site
Abdomen (Abdomen)
Back (Back)
Chest (Chest)
Genital Area (Genital)
Head (Head)
Left Arm (Left arm)
Left Foot (Left foot)
Left Hand (Left hand)
Left Leg (Left leg)
Neck (Neck)
Right Arm (Right arm)
Right Foot (Right foot)
Right Hand (Right hand)
Right Leg (Right leg)
Specify the tape strip site (exact location)
Was this lesion also biopsied
No (No)
Yes (Yes)
Date of Biopsy (mm/dd/yyyy)
Biopsy Size (mm)
Biopsy site
Abdomen (Abdomen)
Back (Back)
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Chest (Chest)
Genital Area (Genital)
Head (Head)
Left Arm (Left arm)
Left Foot (Left foot)
Left Hand (Left hand)
Left Leg (Left leg)
Neck (Neck)
Right Arm (Right arm)
Right Foot (Right foot)
Right Hand (Right hand)
Right Leg (Right leg)
Specify the biopsy site (exact location)
Specimen Fixative
Formalin (Formalin)
Glutaraldehyde (Glutaraldehyde)
Oct Media (OCT media)
Rnalater (RNAlater)
Saline (Saline)
Unnamed1
Was the tape strip applied to this lesion
No (no)
Yes (yes)
Date of tape strip specimen collection
(mm/dd/yyyy)
Tape strip site
Abdomen (Abdomen)
Back (Back)
Chest (Chest)
Genital Area (Genital)
Head (Head)
Left Arm (Left arm)
Left Foot (Left foot)
Left Hand (Left hand)
Left Leg (Left leg)
Neck (Neck)
Right Arm (Right arm)
Right Foot (Right foot)
Right Hand (Right hand)
Right Leg (Right leg)
Specify the tape strip site (exact location)
Was this lesion also biopsied
No (No)
Yes (Yes)
Date of Biopsy (mm/dd/yyyy)
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Biopsy Size (mm)
Biopsy site
Abdomen (Abdomen)
Back (Back)
Chest (Chest)
Genital Area (Genital)
Head (Head)
Left Arm (Left arm)
Left Foot (Left foot)
Left Hand (Left hand)
Left Leg (Left leg)
Neck (Neck)
Right Arm (Right arm)
Right Foot (Right foot)
Right Hand (Right hand)
Right Leg (Right leg)
Specify the biopsy site (exact location)
Specimen Fixative
Formalin (Formalin)
Glutaraldehyde (Glutaraldehyde)
Oct Media (OCT media)
Rnalater (RNAlater)
Saline (Saline)
Unnamed1
Was the tape strip applied to an area of normal
skin
No (no)
Yes (yes)
Date of tape strip specimen collection
(mm/dd/yyyy)
Tape strip site
Abdomen (Abdomen)
Back (Back)
Chest (Chest)
Genital Area (Genital)
Head (Head)
Left Arm (Left arm)
Left Foot (Left foot)
Left Hand (Left hand)
Left Leg (Left leg)
Neck (Neck)
Right Arm (Right arm)
Right Foot (Right foot)
Right Hand (Right hand)
Right Leg (Right leg)
Specify the tape strip site (exact location)
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Footer Module
Comments
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Disease Activity and Assessment Form (LAA) - 3206533v1.0
NCT01193842 On-Study - AMC-075 Baseline Lymphoma
Disease Activity and Assessment Form (LAA) -
3206533v1.0
All rights reserved. Please visit https://medical-data-
models.org/forms/3114
AMC-075 Baseline Lymphoma
Disease Activity and Assessment
Form (LAA)
Unnamed1
Visit Number
Unnamed2
Recurring, drenching night sweats during the
previous month (Does the participant have any of
the following symptoms at the time of registration)
No (No)
Yes (Yes)
Unexplained, persistent fever >38 degrees C (or
>100 degrees F) in the previous month (Does the
participant have any of the following symptoms at
the time of registration)
No (No)
Yes (Yes)
Unexplained weight loss >10% of body weight in
the previous 6 months (Does the participant have
any of the following symptoms at the time of
registration)
No (No)
Yes (Yes)
Hematopoietic Diagnosis
B-cell Lymphoma Unclassifiable (B-cell
lymphoma unclassifiable)
Burkitt Lymphoma/leukemia (Burkitt
lymphoma/leukemia)
Diffuse Large B-cell Lymphoma (Diffuse
large B-cell lymphoma)
Hiv-related Polymorphic
Lymphoproliferative Disorder (HIV-
related polymorphic lymphoproliferative
disorder)
Hodgkin's Lymphoma (Hodgkin
lymphoma)
Kshv/hhv-8+ Plasmablastic Lymphoma
(lymph Node) (KSHV/HHV-8+
plasmablastic lymphoma (lymph node))
Large B-cell Lymphoma Arising In
Kshv/hhv-8 Associated Multicentric
Castleman Disease (Large B-cell
lymphoma arising in KSHV/HHV-8
associated multicentric Castleman
Disease)
Other (Other)
Plasma Lymphoma Of Oral Cavity
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(Plasma lymphoma of oral cavity)
Plasmablastic Lymphoma (Plasmablastic
lymphoma)
Primary Effusion Lymphoma (Primary
effusion lymphoma)
If diffuse large B-cell lymphoma, specify
morphologic type
Centroblastic (Centroblastic)
Immunoblastic (Immunoblastic)
Not Specified (Not specified)
Other (Other)
If Burkitt lymphoma/leukemia, specify
morphologic type
B Cell Lymphoma Unclassifiable,
W/features Intermediate Between Dlbcl
And Burkitt's. (atypical) (B cell lymphoma
unclassifiable, w/features intermediate
between DLBCL and Burkitt's. (Atypical))
Classical (Classical)
Other (Other)
Plasmacytoid (Plasmacytoid)
Other specify
Other specify
Other specify
If Hodgkin lymphoma, specify morphologic type
Lymphocyte Depleted (Lymphocyte
depleted)
Lymphocyte Rich (Lymphocyte rich)
Mixed Cellularity (Mixed cellularity)
Nodular Sclerosis (Nodular sclerosis)
Unclassified (Unclassified)
Date of Initial Pathologic Diagnosis (mm/dd/yyyy)
Method of Evaluation
Biopsy (Biopsy)
Cytology (Cytology)
Other (Other)
Other Specify
Histogenetic Subtyping Markers
Histogenetic Subtyping Markers
Bcl6 (BCL6)
Cd10 (CD10)
Foxp1 (FOXP1)
Gcet1 (GCET1)
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Mum1 (MUM1)
Finding Result
Negative (Negative)
Not Assessed (Not assessed)
Positive (Positive)
EBV Status
Eber Negative (EBER negative)
Eber Positive (EBER positive)
Not Done (Not done)
Lymphatic Involvement
Was there lymphomatous involvement of the
bone marrow, testes, paranasal sinuses, two or
more extranodal sites, and/or the epidural regions
(If there is lymphomatous involvement in these
regions at enrollment, CNS prophylaxis with IT
liposomal cytarabine Depocyt®, IT cytarabine, or
IT methotrexate is strongly encouraged. If CNS
involvement is observed after enrollment, the
participant must receive aggressive IT
chemotherapy per institutional standards. Please
record the IT chemotherapy administered for
CNS involvement on the Concomitant Medication
form)
No (No)
Not Evaluated (Not evaluated)
Yes (Yes)
Site of Involvement (Please indicate the locations
of lymphomatous involvement below)
Bone Marrow (Bone marrow)
Epidural Involvement (Epidural
involvement)
Paranasal Sinus (Paranasal sinuses)
Testis (Testes)
Two Or More Extranodal Sites (Two or
more extranodal sites)
Comments
Comments
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Ovarian Cancer null Quality of Life - FACT-0
(Version 4), GOG-0202 - 2101017v3.0
Ovarian Cancer null Quality of Life - FACT-0 (Version 4),
GOG-0202 - 2101017v3.0
All rights reserved. Please visit https://medical-data-
models.org/forms/3123
FACT-0 (Version 4), GOG-0202
Physical Well-being
I have a lack of energy
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have nausea
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
Because of my physical condition, I have trouble
meeting the needs of my family
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have pain
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am bothered by side effects of treatment
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I feel ill
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am forced to spend time in bed
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
Social/family Well-being
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I feel close to my friends
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I get emotional support from my family
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I get support from my friends
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
My family has accepted my illness
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am satisfied with family communication about
my illess
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I feel close to my partner
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am satisfied with my sex life
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
Emotional Well_being
I feel sad
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
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I am satisfied with how I am coping with my
illness
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am losing hope in the fight against my illness
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I feel nervous
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I worry about dying
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I worry that my condition will get worse
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
Functional Well-being
Iam able to work (include work at home)
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
My work (include work at home) is fulfilling
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am able to enjoy life
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
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I have accepted my illness
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am sleeping well
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am enjoying the things I usually do for fun
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am enjoying the things I usually do for fun
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
Additional Concerns
I have swelling in my stomach area
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am losing weight
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have control of my bowels
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have been vomiting
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am bothered by hair loss
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A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have a good appetite
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I like the appearance of my body
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am able to get around by myself
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am able to feel like a woman
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have cramps in my stomach area
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am interested in sex
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have concerns about my ability to have children
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
Ccrr Module For Fact-0 (version 4), Gog-
0202
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All rights reserved. Please visit https://medical-data-
models.org/forms/3128
Surgery
Surgery
Visit Date
Day in Course (Cycle)
Date of Surgery (Enter the date of the surgical
procedure.)
Procedure (Enter the type of procedure
performed to diagnose / to treat the patient's
disease.)
Findings (Briefly describe the findings of the
procedure.)
Residual Disease (Briefly describe the extent of
the residual disease, if any, at the conclusion of
the operation. i.e.: microscopic, macroscopic.)
Were margins clear? (Select the results of tissue
margin examination.)
Less Than 1mm (Close (<1 mm))
Dysplasia Present (Dysplasia present)
Negative Margin (Negative)
Not Applicable (Not Applicable)
Positive Margin (Positive)
Unknown (Unknown)
Margin Comments (Enter the comment for margin
examination.)
Total LN Involved (Enter the number of lymph
nodes involved with disease as determined by
pathologic examination.)
Total LN Evaluated (Enter the total number of
lymph nodes removed and pathologically
assessed for disease.)
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Nonneoplastic Condition NCT01057121 On-Study - AMC-
070 KS Evaluation and Clinical Benefit Form (RK1) -
3146987v1.0
All rights reserved. Please visit https://medical-data-
models.org/forms/3135
AMC-070 KS Evaluation and Clinical
Benefit Form (RK1)
Header Module
Visit number
Date of evaluation
Reporting Period
Baseline (Baseline)
On Treatment (On treatment)
Post-therapy (Post therapy)
Unnamed1
Oral cavity symptoms
No Symptom (No symptoms)
Oral Cavity Symptoms Interfering
W/function Most/all Of The Time, Or
Recurrent Bleeding (Oral cavity
symptoms interfering w/function most/all
of the time, or recurrent bleeding)
Oral Cavity Symptoms Not Interfering
With Function (Oral cavity symptoms not
interfering with function)
Symptoms Interfering W/function
Sometimes, Or Occasional Bleeding;
Can Take Adequate Nutrition (Symptoms
interfering w/function sometimes, or
occasional bleeding; can take adequate
nutrition)
Other related oral cavity symptoms
No (No)
Yes (Yes)
Specify (If yes)
Gastrointestinal (GI) symptoms
Gross Bleeding Requiring Transfusions,
Evidence Of Obstruction, Unable To
Maintain Adequate Intake (Gross
bleeding requiring transfusions, evidence
of obstruction, unable to maintain
adequate intake)
Gross Bleeding, Or Frequent Gi
Symptoms (Gross bleeding, or frequent
GI symptoms)
Minimal Gi Symptoms (Minimal GI
symptoms)
No Symptom (No symptoms)
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Other related gastrointestinal (GI) symptoms
No (No)
Yes (Yes)
Specify (If yes)
Pulmonary symptoms
No Symptom (No symptoms)
Severely Limited Activities, +/-
Hemoptysis (Severely limited activities,
+/- hemoptysis)
Symptoms At Rest, Requiring Oxygen Or
Hemoptysis (Symptoms at rest, requiring
oxygen or hemoptysis)
Symptoms On Exertion (Symptoms on
exertion)
Symptoms On Normal Activity
(Symptoms on normal activity)
Other related pulmonary symptoms
No (No)
Yes (Yes)
Specify (If yes)
Unnamed2
Is the participant experiencing tumor-related pain
No (No)
Yes (Yes)
Is the participant on analgesics
No (No)
Yes (Yes)
What was the average pain experienced by the
participant over the last 24 hours
Discomforting Pain (Discomforting pain)
Distressing Pain (Distressing pain)
Excruciating Pain (Excruciating pain)
Horrible Pain (Horrible pain)
Mild Pain (Mild pain)
No Pain (No pain)
Pain
Absent (Absent)
Present (Present)
Anatomic Site of Worst Pain
Unnamed3
Extremity Edema Symptoms
Completely Resolves With Limb
Elevation And Rings/shoes Fit Without
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Difficulty (Completely resolves with limb
elevation and rings/shoes fit without
difficulty)
Does Not Completely Resolve With Limb
Elevation Or Rings/shoes Do Not Fit
Normally (Does not completely resolve
with limb elevation or rings/shoes do not
fit normally)
No Edema, No Symptoms (No edema,
no symptoms)
No Improvement With Limb Elevation Or
Interferes With Normal Function (No
improvement with limb elevation or
interferes with normal function)
Significantly Reduced Function
(Significantly reduced function)
Periorbital Edema Symptoms
No Periorbital Edema (No periorbital
edema)
Swelling Of Eyes Noted At All Times And
Interferes With Eyesight Or Function At
All Times (Swelling of eyes noted at all
times and interferes with eyesight or
function at all times)
Swelling Of Eyes Noted At All Times And
Interferes With Eyesight Or Function
Sometimes (Swelling of eyes noted at all
times and interferes with eyesight or
function sometimes)
Swelling Of The Eyes Noted At All Times
But Does Not Interfere With Eyesight Or
Function (Swelling of the eyes noted at
all times but does not interfere with
eyesight or function)
Swelling Of The Eyes Noted
Occasionally Or Improves Over The Day
(Swelling of the eyes noted occasionally
or improves over the day)
Scrotal/Genital Edema Symptoms
No Scrotal/genital Edema (No
scrotal/genital edema)
Swelling Interferes With Urination,
Sexual Function, Withdrawing Foreskin
All The Time (Swelling interferes with
urination, sexual function, withdrawing
foreskin all the time)
Swelling Interferes With Urination,
Sexual Function, Withdrawing Foreskin
Sometimes (Swelling interferes with
urination, sexual function, withdrawing
foreskin sometimes)
Swelling Of The Scrotum Noted At All
Times But No Symptoms (Swelling of the
scrotum noted at all times but no
symptoms)
Swelling Of The Scrotum Noted
Occasionally (Swelling of the scrotum
noted occasionally)
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Foot Kaposi's Sarcoma (KS) symptoms
Active But Cannot Perform More Than
Normal Activities (Active but cannot
perform more than normal activities)
Lesions Present But No Symptoms. Able
To Perform Normal Activities (Lesions
present but no symptoms. Able to
perform normal activities)
Moderate Impairment Of Activity
Because Of Foot Ks (Moderate
impairment of activity because of foot
KS)
No Foot Ks (No Foot KS)
Normal Activities Mildly Limited Because
Of Foot Ks (Normal activities mildly
limited because of foot KS)
Severe Impairment Of Activity Due To
Foot Ks (Severe impairment of activity
due to foot KS)
Footer Module
Comments
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All rights reserved. Please visit https://medical-data-
models.org/forms/3146
Prior Treatment Summary
Prior Treatment Summary
Visit Date (Enter the date the form was
completed i.e. the date information was
gathered.)
Therapy Type (Name of the type of therapy. The
appropriate list of therapy types is provided by
CTMS.)
Anti-retroviral Therapy (AR)
Antisense Therapy (AS)
Bone Marrow Transplantation (BM)
Biphosphonate Therapy (BP)
Chemotherapy, Nos (C)
Chemotherapy, Multiple Agents Systemic
(CM)
Single Agent Systemic Chemotherapy
(CS)
Extensive Radiation (ER)
Gene Transfer (G)
Hormone Therapy (H)
Hematopoietic Stem Cell Transplantation
(HE)
Immunotherapy (I)
Image Directed Local Therapy (ID)
Limited Radiation Therapy (LR)
No Prior Therapy (N)
Chemotherapy, Non-cytotoxic (NC)
Oncolytic Virotherapy (OV)
Prior Therapy (PT)
Radiation Therapy (R)
Surgery (S)
Vaccine Therapy (V)
Any therapy? (Indicate whether or not the patient
has received any prior treatment for the type of
therapy listed.)
No (No)
Yes (Yes)
Number of Prior Chemotherapy Regimens (Enter
the number of prior regimes received for
chemotherapies types of therapy. Do not use for
other types of therapy..)
Date of Last Dose (Enter the date of the last dose
of the most recent prior treatment regimen for
each therapy type. Partial dates are acceptable
when the day is not known. Leave it blank if the
treatment is currently being received and
"Ongoing" will be reported to CTMS or CDS.)
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All rights reserved. Please visit https://medical-data-
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AMC-051 Evaluation of Edema Form
(RK4)
Header Module
Visit number
Unnamed1
Is there any tumor-associated edema at this
evaluation (If NO, go to EVALUATION OF
EXTREMITY EDEMA section)
No (No)
Yes (Yes)
Edema Site
Abdomen (Abdomen)
Back (Back)
Chest (Chest)
Genital Area (Genital)
Head (Head)
Left Arm (Left arm)
Left Foot (Left foot)
Left Hand (Left hand)
Left Leg (Left leg)
Neck (Neck)
Other (Other)
Periorbital (Periorbital)
Right Arm (Right arm)
Right Foot (Right foot)
Right Hand (Right hand)
Right Leg (Right leg)
Total Body (Total body)
Other, specify
Edema Present
No (No)
Yes (Yes)
Compared to Previous Evaluation
Better (Better)
Same (Same)
Worse (Worse)
Edema evaluation
A Resolution Of All Tumor-associated
Edema Since Baseline (A resolution of
all tumor-associated edema since
baseline)
A Worsening Of Tumor-associated
Edema Since Baseline Or Best
Response (A worsening of tumor-
associated edema since baseline or best
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response)
An Improvement Of Tumor-associated
Edema Since Baseline (An improvement
of tumor-associated edema since
baseline)
New Tumor-associated Edema (New
tumor-associated edema)
No Change (No change)
Unnamed2
Status of extremity edema
Absent (Absent)
Present (Present)
Specific Location
Limb Girth (cm)
Other Findings
Unnamed3
Photos Taken
No (No)
Yes (Yes)
Photos Taken Date
Physical findings
No (No)
Yes (Yes)
Specify (If yes,)
Unnamed4
Photos Taken
No (No)
Yes (Yes)
Photos Taken Date
Physical findings
No (No)
Yes (Yes)
Specify (If yes,)
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Evaluation Of Visceral Disease
Has a visceral disease evaluation been done
since the last Kaposi's Sarcoma (KS) evaluation
(If NO, please stop here. If NO, at Follow-up, go
to the section titled INTERVENTIONS on the
Intervention Form. Be sure to indicate the
procedure used to document presence, absence
or resolution of disease)
No (No)
Yes (Yes)
Visceral Disease Site
Abdomen (Abdomen)
Back (Back)
Chest (Chest)
Genital Area (Genital)
Head (Head)
Left Arm (Left arm)
Left Foot (Left foot)
Left Hand (Left hand)
Left Leg (Left leg)
Neck (Neck)
Periorbital (Periorbital)
Right Arm (Right arm)
Right Foot (Right foot)
Right Hand (Right hand)
Right Leg (Right leg)
Total Body (Total body)
Site of Lesion
Kaposi's Sarcoma present
No (No)
Yes (Yes)
Visceral Evaluation
A Complete Resolution Of Visceral
Disease Since Baseline (A complete
resolution of visceral disease since
baseline)
A Decrease In Visceral Disease Since
Baseline (A decrease in visceral disease
since baseline)
A Worsening Of Visceral Disease Since
Baseline, Or Since The Best Response
(A worsening of visceral disease since
baseline, or since the best response)
Evidence Of A New Site Of Visceral
Disease Since Baseline, Or Since The
Best Response (Evidence of a new site
of visceral disease since baseline, or
since the best response)
No Change (No change)
Not Applicable (Not applicable)
Method of Evaluation
Bronchoscopy (Bronchoscopy)
Chest X-ray (Chest x-ray)
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Colonoscopy (Colonoscopy)
Not Applicable (Not applicable)
Sigmoidoscopy (Sigmoidoscopy)
Upper Endoscopy
Esophagogastroduodenoscopy (Upper
endoscopy)
Other Specify
Date of Evaluation
Footer Module
Comments
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AMC-075 Lymphoma Disease
Activity and Measurement Form
(L02)
Unnamed1
Visit Number
Extra Nodal Involvement Evaluation
Extranodal extension
No (NO)
Yes (YES)
Site of Involvement
Ascites (Ascites)
Bone (Bone)
Bone Marrow (Bone Marrow)
Brain (Brain)
Epidural (Epidural)
Gastrointestinal Tract (GI Tract)
Kidney (Kidney)
Liver (Liver)
Lung (Lung)
Meninges (Meninges)
Other Specify (Other)
Pleura (Pleura)
Skin (Skin)
Thyroid (Thyroid)
Other, specify
Dimension 1 (cm)
Dimension 2 (cm)
Method of Evaluation
Biopsy (Biopsy)
Aspirate, Bone Marrow (Bone Marrow
Aspirate)
Bone Marrow Biopsy (Bone Marrow
Biopsy)
Bone Scan (Bone Scan)
Ct Scan (CT scan)
Gallium Scan (Gallium scan)
IVP (IVP)
Lymphangiogram (Lymphangiogram)
Mri Scan (MRI scan)
Other (Other)
Palpation (Palpation)
Peripheral Blood Counts (Peripheral
Blood Counts)
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Pet Scan (PET scan)
Pet/ct Scan (PET/CT scan)
Ultrasound (Ultrasound)
X-ray (X-Ray)
Other, specify
PET scan
Negative (Negative)
Positive Finding (Positive)
Lesion completely resolved (For "On treatment"
and "Follow up" cycles only)
No (NO)
Yes (YES)
Is measurable disease present? (For "On
treatment" and "Follow up" cycles only)
No (No)
Yes (Yes)
Has the patient been diagnosed with a new
progression? (For "On treatment" and "Follow up"
cycles only)
No (No)
Yes (Yes)
Evaluation documented (For "On treatment" and
"Follow up" cycles only)
No (No)
Yes (Yes)
Lesion Assessment (For "On treatment" and
"Follow up" cycles only)
Improvement (improvement)
No Change (no change)
Not Evaluated (Not evaluated)
Progression - Increase (progression -
increase)
Comments
Comments
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AMC-070 Missed Visit Form (F35)
Unnamed1
Visit number
Unnamed2
Missed Visit Date (mm/dd/yyyy)
Reason patient missed visit
Health Reasons (Health reasons)
Other (Other)
Patient Could Not Get Off Work (Patient
could not get off work)
Patient Decided To Discontinue Study
(Patient decided to discontinue study)
Patient Experienced An Adverse Event
(Patient experienced an Adverse Event)
Patient Forgot (Patient forgot)
Patient Had Transportation Problems
(Patient had transportation problems)
Patient Unable To Obtain Dependent
Care (Patient unable to obtain dependent
care)
Patient Unhappy With Frequency Of
Visits (Patient unhappy with frequency of
visits)
Scheduling Difficulties (Scheduling
difficulties)
Other, specify
Next visit scheduled (Items missed will be made
up at the new visit.)
No (No)
Yes (Yes)
Comments
Comments
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models.org/forms/3160
ADVERSE EVENTS
Adverse Events
Course Number
Course Day Number
Adverse Events Course Inclusion Indicator
No (No)
Yes (Yes)
Adverse Event Onset Date
Resolved Date
Common Toxicity Criteria Adverse Event Term
Type
Retinoic Acid Syndrome (aaRetinoic acid
syndrome")
Acidosis Nos (Acidosis (metabolic or
respiratory))
Capillary Leak Syndrome (Acute
vascular leak syndrome)
Adrenal Insufficiency (Adrenal
insufficiency)
Adult Respiratory Distress Syndrome
(Adult respiratory distress syndrome
(ARDS))
Blood Albumin Decreased (Albumin,
serum-low (hypoalbuminemia))
Alcohol Intolerance Syndrome
(antabuse-like Syndrome) (Alcohol
intolerance syndrome (antabuse-like
syndrome))
Blood Alkaline Phosphatase Nos
Increased (Alkaline phosphatase)
Alkalosis Nos (Alkalosis (metabolic or
respiratory))
Hypersensitivity Nos (Allergic
reaction/hypersensitivity (including drug
fever))
Rhinitis Allergic Nos (Allergic rhinitis
(including sneezing, nasal stuffiness,
postnasal drip))
Allergy/immunology Other
(Allergy/Immunology-Other (Specify))
Alanine Aminotransferase Increased
(ALT, SGPT (serum glutamic pyruvic
transaminase))
Blood Amylase Increased (Amylase)
Anorexia (Anorexia)
Apnoea (Apnea)
Arachnoiditis
(Arachnoiditis/meningismus/radiculitis)
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Arthritis Nos (Arthritis (non-septic))
Ascites (Ascites (non-malignant))
Aspiration (Aspiration)
Aspartate Aminotransferase Increased
(AST, SGOT (serum glutamic oxaloacetic
transaminase))
Ataxia Nec (Ataxia (incoordination))
Atelectasis (Atelectasis)
Atrophy, Skin (Atrophy, skin)
Atrophy, Subcutaneous Fat (Atrophy,
subcutaneous fat)
Auditory/ear Other (Auditory/Ear-Other
(Specify))
Autoimmune Disorder Nos (Autoimmune
reaction)
Blood Bicarbonate Decreased
(Bicarbonate, serum-low)
Blood Bilirubin Increased (Bilirubin
(hyperbilirubinemia))
Bladder Disorder Nos (Bladder spasms)
Blood/bone Marrow Other (Blood/Bone
Marrow-Other (Specify))
Bone Age (alteration In Bone Age) (Bone
age (alteration in bone age))
Bone Growth: Femoral Head; Slipped
Capital Femoral Epiphysis (Bone growth:
femoral head; slipped capital femoral
epiphysis)
Bone Growth: Limb Length Discrepancy
(Bone growth: limb length discrepancy)
Bone Growth: Spine Kyphosis/lordosis
(Bone growth: spine kyphosis/lordosis)
Bone Marrow Depression Nos (Bone
marrow cellularity)
Bone: Spine-scoliosis (Bone: spine-
scoliosis)
Brachial Plexopathy (Brachial
plexopathy)
Breast Function/lactation (Breast
function/lactation)
Breast Nipple/areolar Deformity (Breast
nipple/areolar deformity)
Breast Volume/hypoplasia (Breast
volume/hypoplasia)
Bronchospasm, Wheezing
(Bronchospasm, wheezing)
Ecchymosis (Bruising (in absence of
grade 3 or 4 thrombocytopenia))
Burn (Burn)
Hypercalcaemia (Calcium, serum-high
(hypercalcemia))
Hypocalcaemia (Calcium, serum-low
(hypocalcemia))
Pulmonary Function Test Nos Decreased
(Carbon monoxide diffusion capacity
(DL(co)))
Arrhythmia Nos (Cardiac Arrhythmia-
Other (Specify))
Cardiac General Other (Cardiac
General-Other (Specify))
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Myocardial Ischaemia (Cardiac
ischemia/infarction)
Cardiac Troponin I Increased (Cardiac
troponin I (cTnI))
Cardiac Troponin T Increased (Cardiac
troponin T (cTnT))
Cardiopulmonary Arrest, Cause
Unknown (non-fatal) (Cardiopulmonary
arrest, cause unknown (non-fatal))
Cataract Nec (Cataract)
Cd4 Lymphocytes Decreased (CD4
count)
Cervical Spine-range Of Motion (Cervical
spine-range of motion)
Chelitis (Cheilitis)
Cholecystitis (Cholecystitis)
Hypercholesteraemia (Cholesterol,
serum-high (hypercholesteremia))
Chyle Or Lymph Leakage (Chyle or
lymph leakage)
Chylothorax (Chylothorax)
Cerebral Ischaemia (CNS
cerebrovascular ischemia)
Cns Necrosis/cystic Progression (CNS
necrosis/cystic progression)
Coagulation Disorder Nos (Coagulation-
Other (Specify))
Learning Disorder Nos (Cognitive
disturbance)
Colitis Nos (Colitis)
Colitis, Infectious (e.g., Clostridium
Difficile) (Colitis, infectious (e.g.,
Clostridium difficile))
Ventricular Asystole (Conduction
abnormality/Atrioventricular heart block -
Asystole)
Conduction Abnormality/atrioventricular
Heart Block (Conduction
abnormality/Atrioventricular heart block -
AV block-first degree)
Conduction Abnormality/atrioventricular
Heart Block - Av Block-second Degree
Mobitz Type I (wenckebach) (Conduction
abnormality/Atrioventricular heart block -
AV block-Second degree Mobitz Type I
(Wenckebach))
Conduction Abnormality/atrioventricular
Heart Block (Conduction
abnormality/Atrioventricular heart block -
AV block-second degree Mobitz Type II)
Conduction Abnormality/atrioventricular
Heart Block (Conduction
abnormality/Atrioventricular heart block -
AV block-third degree (complete AV
block))
Conduction Abnormality/atrioventricular
Heart Block (Conduction
abnormality/Atrioventricular heart block -
Conduction abnormality NOS)
Conduction Abnormality/atrioventricular
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Heart Block (Conduction
abnormality/Atrioventricular heart block -
Sick sinus syndrome)
Conduction Abnormality/atrioventricular
Heart Block (Conduction
abnormality/Atrioventricular heart block -
Stokes-Adams syndrome)
Conduction Abnormality/atrioventricular
Heart Block (Conduction
abnormality/Atrioventricular heart block -
Wolff-Parkinson-White syndrome)
Confusion (Confusion)
Constipation (Constipation)
Constitutional Symptoms Other
(Constitutional Symptoms-Other
(Specify))
Cough (Cough)
Blood Creatine Phosphokinase
Increased (CPK (creatine
phosphokinase))
Blood Creatinine Increased (Creatinine)
Cushingoid (Cushingoid appearance
(e.g., moon face, buffalo hump,
centripetal obesity, cutaneous striae))
Cystitis (Cystitis)
Cytokine Release Syndrome/acute
Infusion Reaction (Cytokine release
syndrome/acute infusion reaction)
Death Not Associated With Ctcae Term
(Death not associated with CTCAE term
- Death NOS)
Death Not Associated With Ctcae Term
(Death not associated with CTCAE term
- Disease progression NOS)
Death Not Associated With Ctcae Term
(Death not associated with CTCAE term
- Multi-organ failure)
Death Not Associated With Ctcae Term
(Death not associated with CTCAE term
- Sudden death)
Dehydration (Dehydration)
Dental: Dentures Or Prosthesis (Dental:
dentures or prosthesis)
Dental: Periodontal Disease (Dental:
periodontal disease)
Dental: Teeth (Dental: teeth)
Dental: Teeth Development (Dental:
teeth development)
Dermal Change Lymphedema,
Phlebolymphedema (Dermal change
lymphedema, phlebolymphedema)
Dermatology/skin Other
(Dermatology/Skin-Other (Specify))
Diarrhoea Nos (Diarrhea)
Disseminated Intravascular Coagulation
(DIC (disseminated intravascular
coagulation))
Distention/bloating, Abdominal
(Distention/bloating, abdominal)
Dizziness (exc Vertigo) (Dizziness)
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Dry Eye Nec (Dry eye syndrome)
Dry Mouth (Dry mouth/salivary gland
(xerostomia))
Dry Skin (Dry skin)
Dysphagia (Dysphagia (difficulty
swallowing))
Dyspnoea Nos (Dyspnea (shortness of
breath))
Edema, Larynx (Edema, larynx)
Edema: Head And Neck (Edema: head
and neck)
Oedema Nos (Edema: limb)
Edema: Trunk/genital (Edema:
trunk/genital)
Edema: Viscera (Edema: viscera)
Ejaculatory Dysfunction (Ejaculatory
dysfunction)
Encephalopathy (Encephalopathy)
Endocrine Other (Endocrine-Other
(Specify))
Enteritis (inflammation Of The Small
Bowel) (Enteritis (inflammation of the
small bowel))
Impotence (Erectile dysfunction)
Oesophagitis Nos (Esophagitis)
Exostosis (Exostosis)
Extrapyramidal Disorder Nec
(Extrapyramidal/involuntary
movement/restlessness)
Extremity-lower (gait/walking) (Extremity-
lower (gait/walking))
Extremity-upper (function) (Extremity-
upper (function))
Eyelid Dysfunction (Eyelid dysfunction)
Fatigue (Fatigue (asthenia, lethargy,
malaise))
Febrile Neutropenia (fever Of Unknown
Origin Without Clinically Or
Microbiologically Documented Infection)
(anc <1.0 X 10^9/l, Fever >=38.5
Degrees C) (Febrile neutropenia)
Feminization (Feminization of male)
Forced Expiratory Volume Decreased
(FEV(1))
Pyrexia (Fever (in the absence of
neutropenia, where neutropenia is
defined as ANC <1.0 x 10^9/L))
Blood Fibrinogen Decreased
(Fibrinogen)
Fibrosis-cosmesis (Fibrosis-cosmesis)
Fibrosis-deep Connective Tissue
(Fibrosis-deep connective tissue)
Fistula, Gi (Fistula, GI - Abdomen NOS)
Anal Fistula (Fistula, GI - Anus)
Fistula, Gi (Fistula, GI - Biliary tree)
Fistula, Gi (Fistula, GI -
Colon/cecum/appendix)
Intestinal Fistula (Fistula, GI -
Duodenum)
Tracheo-oesophageal Fistula Nos
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(Fistula, GI - Esophagus)
Fistula, Gi (Fistula, GI - Gallbladder)
Fistula, Gi (Fistula, GI - Ileum)
Fistula, Gi (Fistula, GI - Jejunum)
Fistula, Gi (Fistula, GI - Oral cavity)
Fistula, Gi (Fistula, GI - Pancreas)
Fistula, Gi (Fistula, GI - Pharynx)
Fistula, Gi (Fistula, GI - Rectum)
Fistula, Gi (Fistula, GI - Salivary gland)
Fistula, Gi (Fistula, GI - Small bowel
NOS)
Fistula, Gi (Fistula, GI - Stomach)
Fistula, Gu (Fistula, GU - Bladder)
Fistula, Gu (Fistula, GU - Genital tract-
female)
Fistula, Gu (Fistula, GU - Kidney)
Fistula, Gu (Fistula, GU - Ureter)
Fistula, Gu (Fistula, GU - Urethra)
Fistula, Gu (Fistula, GU - Uterus)
Urogenital Fistula (Fistula, GU - Vagina)
Fistula, Pulmonary/upper Respiratory
(Fistula, pulmonary/upper respiratory -
Bronchus)
Fistula, Pulmonary/upper Respiratory
(Fistula, pulmonary/upper respiratory -
Larynx)
Fistula, Pulmonary/upper Respiratory
(Fistula, pulmonary/upper respiratory -
Lung)
Fistula, Pulmonary/upper Respiratory
(Fistula, pulmonary/upper respiratory -
Oral cavity)
Fistula, Pulmonary/upper Respiratory
(Fistula, pulmonary/upper respiratory -
Pharynx)
Fistula, Pulmonary/upper Respiratory
(Fistula, pulmonary/upper respiratory -
Pleura)
Fistula, Pulmonary/upper Respiratory
(Fistula, pulmonary/upper respiratory -
Trachea)
Flatulence (Flatulence)
Flu-like Syndrome (Flu-like syndrome)
Flushing (Flushing)
Fracture (Fracture)
Gastritis Nos (Gastritis (including bile
reflux gastritis))
Gastrointestinal Other (Gastrointestinal-
Other (Specify))
Gamma-glutamyltransferase Increased
(GGT (gamma-glutamyl transpeptidase))
Glaucoma Nos (Glaucoma)
Glomerular Filtration Rate (Glomerular
filtration rate)
Hyperglycaemia Nos (Glucose, serum-
high (hyperglycemia))
Hypoglycaemia Nos (Glucose, serum-
low (hypoglycemia))
Growth And Development Other (Growth
and Development-Other (Specify))
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Growth Velocity (reduction In Growth
Velocity) (Growth velocity (reduction in
growth velocity))
Gynaecomastia (Gynecomastia)
Alopecia (Hair loss/Alopecia (scalp or
body))
Haptoglobin Decreased (Haptoglobin)
Hearing: Patients With/without Baseline
Audiogram And Enrolled In A Monitoring
Program (Hearing: patients with/without
baseline audiogram and enrolled in a
monitoring program)
Hearing: Patients Without Baseline
Audiogram And Not Enrolled In A
Monitoring Program (Hearing: patients
without baseline audiogram and not
enrolled in a monitoring program)
Dyspepsia (Heartburn/dyspepsia)
Hematoma (Hematoma)
Haemoglobin Decreased (Hemoglobin)
Haemoglobinuria Present
(Hemoglobinuria)
Hemolysis Nos (Hemolysis (e.g.,
immune hemolytic anemia, drug related
hemolysis))
Haemorrhagic Stroke (Hemorrhage,
CNS)
Melaena (Hemorrhage, GI - Abdomen
NOS)
Hemorrhage, Gi (Hemorrhage, GI -
Anus)
Hemorrhage, Gi (Hemorrhage, GI -
Biliary tree)
Hemorrhage, Gi (Hemorrhage, GI -
Cecum/appendix)
Hemorrhage, Gi (Hemorrhage, GI -
Colon)
Hemorrhage, Gi (Hemorrhage, GI -
Duodenum)
Hemorrhage, Gi (Hemorrhage, GI -
Esophagus)
Hemorrhage, Gi (Hemorrhage, GI -
Ileum)
Hemorrhage, Gi (Hemorrhage, GI -
Jejunum)
Hemorrhage, Gi (Hemorrhage, GI - Liver)
Hemorrhage, Gi (Hemorrhage, GI -
Lower GI NOS)
Hemorrhage, Gi (Hemorrhage, GI - Oral
cavity)
Hemorrhage, Gi (Hemorrhage, GI -
Pancreas)
Hemorrhage, Gi (Hemorrhage, GI -
Peritoneal cavity)
Rectal Bleeding (Hemorrhage, GI -
Rectum)
Hemorrhage, Gi (Hemorrhage, GI -
Stoma)
Haematemesis (Hemorrhage, GI -
Stomach)
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Hemorrhage, Gi (Hemorrhage, GI -
Upper GI NOS)
Hemorrhage, Gi (Hemorrhage, GI -
Varices (esophageal))
Hemorrhage, Gi (Hemorrhage, GI -
Varices (rectal))
Hemorrhage, Gu (Hemorrhage, GU -
Bladder)
Hemorrhage, Gu (Hemorrhage, GU -
Fallopian tube)
Hemorrhage, Gu (Hemorrhage, GU -
Kidney)
Hemorrhage, Gu (Hemorrhage, GU -
Ovary)
Hemorrhage, Gu (Hemorrhage, GU -
Prostate)
Hemorrhage, Gu (Hemorrhage, GU -
Retroperitoneum)
Hemorrhage, Gu (Hemorrhage, GU -
Spermatic cord)
Hemorrhage, Gu (Hemorrhage, GU -
Stoma)
Hemorrhage, Gu (Hemorrhage, GU -
Testes)
Hemorrhage, Gu (Hemorrhage, GU -
Ureter)
Hemorrhage, Gu (Hemorrhage, GU -
Urethra)
Haematuria Present (Hemorrhage, GU -
Urinary NOS)
Hemorrhage, Gu (Hemorrhage, GU -
Uterus)
Vaginal Haemorrhage (Hemorrhage, GU
- Vagina)
Hemorrhage, Gu (Hemorrhage, GU - Vas
deferens)
Hemorrhage, Pulmonary/upper
Respiratory (Hemorrhage,
pulmonary/upper respiratory -
Bronchopulmonary NOS)
Hemorrhage, Pulmonary/upper
Respiratory (Hemorrhage,
pulmonary/upper respiratory - Bronchus)
Hemorrhage, Pulmonary/upper
Respiratory (Hemorrhage,
pulmonary/upper respiratory - Larynx)
Hemorrhage, Pulmonary/upper
Respiratory (Hemorrhage,
pulmonary/upper respiratory - Lung)
Hemorrhage, Pulmonary/upper
Respiratory (Hemorrhage,
pulmonary/upper respiratory -
Mediastinum)
Epistaxis (Hemorrhage, pulmonary/upper
respiratory - Nose)
Hemorrhage, Pulmonary/upper
Respiratory (Hemorrhage,
pulmonary/upper respiratory - Pharynx)
Hemorrhage, Pulmonary/upper
Respiratory (Hemorrhage,
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pulmonary/upper respiratory - Pleura)
Haemoptysis (Hemorrhage,
pulmonary/upper respiratory -
Respiratory tract NOS)
Hemorrhage, Pulmonary/upper
Respiratory (Hemorrhage,
pulmonary/upper respiratory - Stoma)
Hemorrhage, Pulmonary/upper
Respiratory (Hemorrhage,
pulmonary/upper respiratory - Trachea)
Post-operative Haemorrhage
(Hemorrhage/bleeding associated with
surgery, intra-operative or post-operative)
Hemorrhage/bleeding Other
(Hemorrhage/Bleeding-Other (Specify))
Hemorrhoids (Hemorrhoids)
Hepatobiliary/pancreas Other
(Hepatobiliary/Pancreas-Other (Specify))
Hiccups (Hiccoughs (hiccups, singultus))
Menopausal Symptoms (Hot
flashes/flushes)
Hydrocephalus (Hydrocephalus)
Skin Discolouration (Hyperpigmentation)
Hypertension Nos (Hypertension)
Hypopigmentation (Hypopigmentation)
Hypotension Nos (Hypotension)
Hypothermia (Hypothermia)
Hypoxia (Hypoxia)
Ileus (Ileus, GI (functional obstruction of
bowel, i.e., neuroconstipation))
Incontinence, Anal (Incontinence, anal)
Urinary Incontinence (Incontinence,
urinary)
Induration/fibrosis (skin And
Subcutaneous Tissue)
(Induration/fibrosis (skin and
subcutaneous tissue))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Abdomen NOS)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Anal/perianal)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Appendix)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
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neutrophils - Artery)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Biliary tree)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Bladder (urinary))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Blood)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Bone (osteomyelitis))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Brain (encephalitis,
infectious))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Brain + Spinal cord
(encephalomyelitis))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Bronchus)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Catheter-related)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Cecum)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
10 / 46
Toxicity - ADVERSE EVENTS - 2391190v1.0
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Cervix)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Colon)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Conjunctiva)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Cornea)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Dental-tooth)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Duodenum)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Esophagus)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - External ear (otitis externa))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Eye NOS)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Fallopian tube)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
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(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Foreign body (e.g., graft,
implant, prosthesis, stent))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Gallbladder (cholecystitis))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Heart (endocarditis))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Ileum)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Jejunum)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Joint)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Kidney)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Larynx)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Lens)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Lip/perioral)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
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Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Liver)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Lung (pneumonia))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Lymphatic)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Mediastinum NOS)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Meninges (meningitis))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Middle ear (otitis media))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Mucosa)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Muscle (infection myositis))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Neck NOS)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Nerve-cranial)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
13 / 46
Toxicity - ADVERSE EVENTS - 2391190v1.0
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Nerve-peripheral)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Nose)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Oral cavity-gums
(gingivitis))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Pancreas)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Paranasal)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Pelvis NOS)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Penis)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Peristomal)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Peritoneal cavity)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Pharynx)
Infection (documented Clinically Or
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Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Pleura (empyema))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Prostate)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Rectum)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Salivary gland)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Scrotum)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Sinus)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Skin (cellulitis))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Small bowel NOS)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Soft tissue NOS)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Spinal cord (myelitis))
Infection (documented Clinically Or
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Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Spleen)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Stomach)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Trachea)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Ungual (nails))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Upper aerodigestive NOS)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Upper airway NOS)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Ureter)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Urethra)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Urinary tract NOS)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Uterus)
Infection (documented Clinically Or
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Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Vagina)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Vein)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Vulva)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Wound)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Abdomen
NOS)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils -
Anal/perianal)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Appendix)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Artery)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Biliary tree)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Bladder
(urinary))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Blood)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Bone
(osteomyelitis))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Brain
(encephalitis, infectious))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Brain +
Spinal cord (encephalomyelitis))
Infection With Normal Anc Or Grade 1 Or
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2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Bronchus)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Catheter-
related)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Cecum)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Cervix)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Colon)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils -
Conjunctiva)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Cornea)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Dental-
tooth)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Duodenum)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Esophagus)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - External ear
(otitis externa))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Eye NOS)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Fallopian
tube)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Foreign
body (e.g., graft, implant, prosthesis,
stent))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Gallbladder
(cholecystitis))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Heart
(endocarditis))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Ileum)
Infection With Normal Anc Or Grade 1 Or
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2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Jejunum)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Joint)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Kidney)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Larynx)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Lens)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Lip/perioral)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Liver)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Lung
(pneumonia))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Lymphatic)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils -
Mediastinum NOS)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Meninges
(meningitis))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Middle ear
(otitis media))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Mucosa)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Muscle
(infection myositis))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Neck NOS)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Nerve-
cranial)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Nerve-
peripheral)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Nose)
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Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Oral cavity-
gums (gingivitis))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Pancreas)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Paranasal)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Pelvis NOS)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Penis)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Peristomal)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Peritoneal
cavity)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Pharynx)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Pleura
(empyema))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Prostate)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Rectum)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Salivary
gland)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Scrotum)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Sinus)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Skin
(cellulitis))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Small bowel
NOS)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Soft tissue
NOS)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
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or Grade 1 or 2 neutrophils - Spinal cord
(myelitis))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Spleen)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Stomach)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Trachea)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Ungual
(nails))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Upper
aerodigestive NOS)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Upper
airway NOS)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Ureter)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Urethra)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Urinary
tract NOS)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Uterus)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Vagina)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Vein)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Vulva)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Wound)
Infection With Unknown Anc (Infection
with unknown ANC - Abdomen NOS)
Infection With Unknown Anc (Infection
with unknown ANC - Anal/perianal)
Infection With Unknown Anc (Infection
with unknown ANC - Appendix)
Infection With Unknown Anc (Infection
with unknown ANC - Artery)
Infection With Unknown Anc (Infection
with unknown ANC - Biliary tree)
Infection With Unknown Anc (Infection
with unknown ANC - Bladder (urinary))
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Infection With Unknown Anc (Infection
with unknown ANC - Blood)
Infection With Unknown Anc (Infection
with unknown ANC - Bone
(osteomyelitis))
Infection With Unknown Anc (Infection
with unknown ANC - Brain (encephalitis,
infectious))
Infection With Unknown Anc (Infection
with unknown ANC - Brain + Spinal cord
(encephalomyelitis))
Infection With Unknown Anc (Infection
with unknown ANC - Bronchus)
Implant Infection (Infection with unknown
ANC - Catheter-related)
Infection With Unknown Anc (Infection
with unknown ANC - Cecum)
Infection With Unknown Anc (Infection
with unknown ANC - Cervix)
Infection With Unknown Anc (Infection
with unknown ANC - Colon)
Infection With Unknown Anc (Infection
with unknown ANC - Conjunctiva)
Infection With Unknown Anc (Infection
with unknown ANC - Cornea)
Infection With Unknown Anc (Infection
with unknown ANC - Dental-tooth)
Infection With Unknown Anc (Infection
with unknown ANC - Duodenum)
Infection With Unknown Anc (Infection
with unknown ANC - Esophagus)
Infection With Unknown Anc (Infection
with unknown ANC - External ear (otitis
externa))
Infection With Unknown Anc (Infection
with unknown ANC - Eye NOS)
Infection With Unknown Anc (Infection
with unknown ANC - Fallopian tube)
Infection With Unknown Anc (Infection
with unknown ANC - Foreign body (e.g.,
graft, implant, prosthesis, stent))
Infection With Unknown Anc (Infection
with unknown ANC - Gallbladder
(cholecystitis))
Infection With Unknown Anc (Infection
with unknown ANC - Heart
(endocarditis))
Infection With Unknown Anc (Infection
with unknown ANC - Ileum)
Infection With Unknown Anc (Infection
with unknown ANC - Jejunum)
Infection With Unknown Anc (Infection
with unknown ANC - Joint)
Infection With Unknown Anc (Infection
with unknown ANC - Kidney)
Infection With Unknown Anc (Infection
with unknown ANC - Larynx)
Infection With Unknown Anc (Infection
with unknown ANC - Lens)
Infection With Unknown Anc (Infection
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with unknown ANC - Lip/perioral)
Infection With Unknown Anc (Infection
with unknown ANC - Liver)
Infection With Unknown Anc (Infection
with unknown ANC - Lung (pneumonia))
Infection With Unknown Anc (Infection
with unknown ANC - Lymphatic)
Infection With Unknown Anc (Infection
with unknown ANC - Mediastinum NOS)
Infection With Unknown Anc (Infection
with unknown ANC - Meninges
(meningitis))
Infection With Unknown Anc (Infection
with unknown ANC - Middle ear (otitis
media))
Infection With Unknown Anc (Infection
with unknown ANC - Mucosa)
Infection With Unknown Anc (Infection
with unknown ANC - Muscle (infection
myositis))
Infection With Unknown Anc (Infection
with unknown ANC - Neck NOS)
Infection With Unknown Anc (Infection
with unknown ANC - Nerve-cranial)
Infection With Unknown Anc (Infection
with unknown ANC - Nerve-peripheral)
Infection With Unknown Anc (Infection
with unknown ANC - Nose)
Infection With Unknown Anc (Infection
with unknown ANC - Oral cavity-gums
(gingivitis))
Infection With Unknown Anc (Infection
with unknown ANC - Pancreas)
Infection With Unknown Anc (Infection
with unknown ANC - Paranasal)
Infection With Unknown Anc (Infection
with unknown ANC - Pelvis NOS)
Infection With Unknown Anc (Infection
with unknown ANC - Penis)
Infection With Unknown Anc (Infection
with unknown ANC - Peristomal)
Infection With Unknown Anc (Infection
with unknown ANC - Peritoneal cavity)
Infection With Unknown Anc (Infection
with unknown ANC - Pharynx)
Infection With Unknown Anc (Infection
with unknown ANC - Pleura (empyema))
Infection With Unknown Anc (Infection
with unknown ANC - Prostate)
Infection With Unknown Anc (Infection
with unknown ANC - Rectum)
Infection With Unknown Anc (Infection
with unknown ANC - Salivary gland)
Infection With Unknown Anc (Infection
with unknown ANC - Scrotum)
Infection With Unknown Anc (Infection
with unknown ANC - Sinus)
Infection With Unknown Anc (Infection
with unknown ANC - Skin (cellulitis))
Infection With Unknown Anc (Infection
23 / 46
Toxicity - ADVERSE EVENTS - 2391190v1.0
with unknown ANC - Small bowel NOS)
Infection With Unknown Anc (Infection
with unknown ANC - Soft tissue NOS)
Infection With Unknown Anc (Infection
with unknown ANC - Spinal cord
(myelitis))
Infection With Unknown Anc (Infection
with unknown ANC - Spleen)
Infection With Unknown Anc (Infection
with unknown ANC - Stomach)
Infection With Unknown Anc (Infection
with unknown ANC - Trachea)
Infection With Unknown Anc (Infection
with unknown ANC - Ungual (nails))
Infection With Unknown Anc (Infection
with unknown ANC - Upper aerodigestive
NOS)
Infection With Unknown Anc (Infection
with unknown ANC - Upper airway NOS)
Infection With Unknown Anc (Infection
with unknown ANC - Ureter)
Infection With Unknown Anc (Infection
with unknown ANC - Urethra)
Infection With Unknown Anc (Infection
with unknown ANC - Urinary tract NOS)
Infection With Unknown Anc (Infection
with unknown ANC - Uterus)
Infection With Unknown Anc (Infection
with unknown ANC - Vagina)
Infection With Unknown Anc (Infection
with unknown ANC - Vein)
Infection With Unknown Anc (Infection
with unknown ANC - Vulva)
Culture Wound Positive (Infection with
unknown ANC - Wound)
Infection Nos (Infection-Other (Specify))
Infertility/sterility (Infertility/sterility)
Injection Site Reaction Nos (Injection site
reaction/extravasation changes)
Prothrombin Time Prolonged (INR
(International Normalized Ratio of
prothrombin time))
Insomnia Nec (Insomnia)
Intra-operative Injury (Intra-operative
injury - Abdomen NOS)
Intra-operative Injury (Intra-operative
injury - Adrenal gland)
Intra-operative Injury (Intra-operative
injury - Anal sphincter)
Intra-operative Injury (Intra-operative
injury - Anus)
Intra-operative Injury (Intra-operative
injury - Appendix)
Intra-operative Injury (Intra-operative
injury - Artery NOS)
Intra-operative Injury (Intra-operative
injury - Artery-aorta)
Intra-operative Injury (Intra-operative
injury - Artery-carotid)
Intra-operative Injury (Intra-operative
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injury - Artery-cerebral)
Intra-operative Injury (Intra-operative
injury - Artery-extremity (lower))
Intra-operative Injury (Intra-operative
injury - Artery-extremity (upper))
Intra-operative Injury (Intra-operative
injury - Artery-hepatic)
Intra-operative Injury (Intra-operative
injury - Artery-major visceral artery)
Intra-operative Injury (Intra-operative
injury - Artery-pulmonary)
Intra-operative Injury (Intra-operative
injury - Biliary tree NOS)
Intra-operative Injury (Intra-operative
injury - Biliary tree-common bile duct)
Intra-operative Injury (Intra-operative
injury - Biliary tree-common hepatic duct)
Intra-operative Injury (Intra-operative
injury - Biliary tree-left hepatic duct)
Intra-operative Injury (Intra-operative
injury - Biliary tree-right hepatic duct)
Bladder Perforation Postoperative (Intra-
operative injury - Bladder)
Intra-operative Injury (Intra-operative
injury - Bone)
Intra-operative Injury (Intra-operative
injury - Brachial plexus)
Intra-operative Injury (Intra-operative
injury - Brain)
Intra-operative Injury (Intra-operative
injury - Breast)
Intra-operative Injury (Intra-operative
injury - Bronchus)
Intra-operative Injury (Intra-operative
injury - Cartilage)
Intra-operative Injury (Intra-operative
injury - Cecum)
Intra-operative Injury (Intra-operative
injury - Cervix)
Intra-operative Injury (Intra-operative
injury - CN I (olfactory))
Intra-operative Injury (Intra-operative
injury - CN II (optic))
Intra-operative Injury (Intra-operative
injury - CN III (oculomotor))
Intra-operative Injury (Intra-operative
injury - CN IV (trochlear))
Intra-operative Injury (Intra-operative
injury - CN IX (glossopharyngeal) motor
pharynx)
Intra-operative Injury (Intra-operative
injury - CN IX (glossopharyngeal)
sensory ear-pharynx-tongue)
Intra-operative Injury (Intra-operative
injury - CN V (trigeminal) motor)
Intra-operative Injury (Intra-operative
injury - CN V (trigeminal) sensory)
Intra-operative Injury (Intra-operative
injury - CN VI (abducens))
Intra-operative Injury (Intra-operative
25 / 46
Toxicity - ADVERSE EVENTS - 2391190v1.0
injury - CN VII (facial) motor-face)
Intra-operative Injury (Intra-operative
injury - CN VII (facial) sensory-taste)
Intra-operative Injury (Intra-operative
injury - CN VIII (vestibulocochlear))
Intra-operative Injury (Intra-operative
injury - CN X (vagus))
Intra-operative Injury (Intra-operative
injury - CN XI (spinal accessory))
Intra-operative Injury (Intra-operative
injury - CN XII (hypoglossal))
Intra-operative Injury (Intra-operative
injury - Colon)
Intra-operative Injury (Intra-operative
injury - Conjunctiva)
Intra-operative Injury (Intra-operative
injury - Cornea)
Intra-operative Injury (Intra-operative
injury - Cranial nerve or branch NOS)
Intra-operative Injury (Intra-operative
injury - Duodenum)
Intra-operative Injury (Intra-operative
injury - Esophagus)
Intra-operative Injury (Intra-operative
injury - Extremity-lower)
Intra-operative Injury (Intra-operative
injury - Extremity-upper)
Intra-operative Injury (Intra-operative
injury - Eye NOS)
Intra-operative Injury (Intra-operative
injury - Face NOS)
Intra-operative Injury (Intra-operative
injury - Fallopian tube)
Intra-operative Injury (Intra-operative
injury - Gallbladder)
Intra-operative Injury (Intra-operative
injury - Gingiva)
Intra-operative Injury (Intra-operative
injury - Heart)
Intra-operative Injury (Intra-operative
injury - Ileum)
Intra-operative Injury (Intra-operative
injury - Inner ear)
Intra-operative Injury (Intra-operative
injury - Jejunum)
Intra-operative Injury (Intra-operative
injury - Joint)
Intra-operative Injury (Intra-operative
injury - Kidney)
Intra-operative Injury (Intra-operative
injury - Larynx)
Intra-operative Injury (Intra-operative
injury - Lens)
Intra-operative Injury (Intra-operative
injury - Ligament)
Intra-operative Injury (Intra-operative
injury - Lingual)
Intra-operative Injury (Intra-operative
injury - Lip/perioral area)
Intra-operative Injury (Intra-operative
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injury - Liver)
Intra-operative Injury (Intra-operative
injury - Lung)
Intra-operative Injury (Intra-operative
injury - Lung thoracic)
Intra-operative Injury (Intra-operative
injury - Mediastinum)
Intra-operative Injury (Intra-operative
injury - Meninges)
Intra-operative Injury (Intra-operative
injury - Middle ear)
Intra-operative Injury (Intra-operative
injury - Muscle)
Intra-operative Injury (Intra-operative
injury - Nails)
Intra-operative Injury (Intra-operative
injury - Nasal cavity)
Intra-operative Injury (Intra-operative
injury - Nasopharynx)
Intra-operative Injury (Intra-operative
injury - Neck NOS)
Intra-operative Injury (Intra-operative
injury - Nose)
Intra-operative Injury (Intra-operative
injury - Oral)
Intra-operative Injury (Intra-operative
injury - Oral cavity NOS)
Intra-operative Injury (Intra-operative
injury - Outer ear NOS)
Intra-operative Injury (Intra-operative
injury - Outer ear-pinna)
Intra-operative Injury (Intra-operative
injury - Ovary)
Intra-operative Injury (Intra-operative
injury - Pancreas)
Intra-operative Injury (Intra-operative
injury - Pancreatic duct)
Intra-operative Injury (Intra-operative
injury - Parathyroid)
Intra-operative Injury (Intra-operative
injury - Parotid gland)
Intra-operative Injury (Intra-operative
injury - Pelvis NOS)
Intra-operative Injury (Intra-operative
injury - Penis)
Intra-operative Injury (Intra-operative
injury - Peripheral motor NOS)
Intra-operative Injury (Intra-operative
injury - Peripheral sensory NOS)
Intra-operative Injury (Intra-operative
injury - Peritoneal cavity)
Intra-operative Injury (Intra-operative
injury - Pharynx)
Intra-operative Injury (Intra-operative
injury - Pituitary)
Intra-operative Injury (Intra-operative
injury - Pleura)
Intra-operative Injury (Intra-operative
injury - Prostate)
Intra-operative Injury (Intra-operative
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injury - Rectum)
Intra-operative Injury (Intra-operative
injury - Recurrent laryngeal)
Intra-operative Injury (Intra-operative
injury - Retina)
Intra-operative Injury (Intra-operative
injury - Sacral plexus)
Intra-operative Injury (Intra-operative
injury - Salivary duct)
Intra-operative Injury (Intra-operative
injury - Salivary gland)
Intra-operative Injury (Intra-operative
injury - Sciatic)
Intra-operative Injury (Intra-operative
injury - Scrotum)
Intra-operative Injury (Intra-operative
injury - Sinus)
Intra-operative Injury (Intra-operative
injury - Skin)
Intra-operative Injury (Intra-operative
injury - Small bowel NOS)
Intra-operative Injury (Intra-operative
injury - Soft tissue NOS)
Intra-operative Injury (Intra-operative
injury - Spinal cord)
Intra-operative Injury (Intra-operative
injury - Spleen)
Intra-operative Injury (Intra-operative
injury - Stoma (GI))
Intra-operative Injury (Intra-operative
injury - Stomach)
Intra-operative Injury (Intra-operative
injury - Teeth)
Intra-operative Injury (Intra-operative
injury - Tendon)
Intra-operative Injury (Intra-operative
injury - Testis)
Intra-operative Injury (Intra-operative
injury - Thoracic duct)
Intra-operative Injury (Intra-operative
injury - Thoracodorsal)
Intra-operative Injury (Intra-operative
injury - Thyroid)
Intra-operative Injury (Intra-operative
injury - Tongue)
Intra-operative Injury (Intra-operative
injury - Trachea)
Intra-operative Injury (Intra-operative
injury - Upper aerodigestive NOS)
Intra-operative Injury (Intra-operative
injury - Upper airway NOS)
Intra-operative Injury (Intra-operative
injury - Ureter)
Intra-operative Injury (Intra-operative
injury - Urethra)
Intra-operative Injury (Intra-operative
injury - Urinary conduit)
Intra-operative Injury (Intra-operative
injury - Urinary tract NOS)
Intra-operative Injury (Intra-operative
28 / 46
Toxicity - ADVERSE EVENTS - 2391190v1.0
injury - Uterus)
Intra-operative Injury (Intra-operative
injury - Vagina)
Intra-operative Injury - Vein (Intra-
operative injury - Vein NOS)
Intra-operative Injury (Intra-operative
injury - Vein-extremity (lower))
Intra-operative Injury (Intra-operative
injury - Vein-extremity (upper))
Intra-operative Injury (Intra-operative
injury - Vein-hepatic)
Intra-operative Injury (Intra-operative
injury - Vein-inferior vena cava)
Intra-operative Injury (Intra-operative
injury - Vein-jugular)
Intra-operative Injury (Intra-operative
injury - Vein-major visceral vein)
Intra-operative Injury (Intra-operative
injury - Vein-portal vein)
Intra-operative Injury (Intra-operative
injury - Vein-pulmonary)
Intra-operative Injury (Intra-operative
injury - Vein-superior vena cava)
Intra-operative Injury (Intra-operative
injury - Vulva)
Intra-operative Injury Other (Intra-
operative Injury-Other (Specify))
Iron Overload (Iron overload)
Menstruation Irregular (Irregular menses
(change from baseline))
Irritability (Irritability (children <3 years of
age))
Joint-effusion (Joint-effusion)
Joint-effusion (Joint-function)
Keratitis Nec (Keratitis (corneal
inflammation/corneal ulceration))
Laryngeal Nerve Dysfunction (Laryngeal
nerve dysfunction)
Leak (including Anastomotic), Gi (Leak
(including anastomotic), GI - Biliary tree)
Leak (including Anastomotic), Gi (Leak
(including anastomotic), GI - Esophagus)
Leak (including Anastomotic), Gi (Leak
(including anastomotic), GI - Large
bowel)
Leak (including Anastomotic), Gi (Leak
(including anastomotic), GI - Leak NOS)
Leak (including Anastomotic), Gi (Leak
(including anastomotic), GI - Pancreas)
Leak (including Anastomotic), Gi (Leak
(including anastomotic), GI - Pharynx)
Leak (including Anastomotic), Gi (Leak
(including anastomotic), GI - Rectum)
Leak (including Anastomotic), Gi (Leak
(including anastomotic), GI - Small
bowel)
Leak (including Anastomotic), Gi (Leak
(including anastomotic), GI - Stoma)
Leak (including Anastomotic), Gi (Leak
(including anastomotic), GI - Stomach)
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Leak (including Anastomotic), Gu (Leak
(including anastomotic), GU - Bladder)
Leak (including Anastomotic), Gu (Leak
(including anastomotic), GU - Fallopian
tube)
Leak (including Anastomotic), Gu (Leak
(including anastomotic), GU - Kidney)
Leak (including Anastomotic), Gu (Leak
(including anastomotic), GU - Spermatic
cord)
Leak (including Anastomotic), Gu (Leak
(including anastomotic), GU - Stoma)
Leak (including Anastomotic), Gu (Leak
(including anastomotic), GU - Ureter)
Leak (including Anastomotic), Gu (Leak
(including anastomotic), GU - Urethra)
Leak (including Anastomotic), Gu (Leak
(including anastomotic), GU - Uterus)
Leak (including Anastomotic), Gu (Leak
(including anastomotic), GU - Vagina)
Leak (including Anastomotic), Gu (Leak
(including anastomotic), GU - Vas
deferens)
Leak, Cerebrospinal Fluid (csf) (Leak,
cerebrospinal fluid (CSF))
Left Ventricular Diastolic Dysfunction
(Left ventricular diastolic dysfunction)
Left Ventricular Failure (Left ventricular
systolic dysfunction)
Leucopenia Nos (Leukocytes (total
WBC))
Encephalopathy Nos
(Leukoencephalopathy (radiolographic
findings))
Libido Decreased (Libido)
Lipase Increased (Lipase)
Hepatic Failure (Liver dysfunction/failure
(clinical))
Local Complication - Device/prosthesis-
related (Local complication -
device/prosthesis-related)
Lumbar Spine-range Of Motion (Lumbar
spine-range of motion)
Lymphatics Other (Lymphatics-Other
(Specify))
Lymphedema-related Fibrosis
(Lymphedema-related fibrosis)
Lymphocele (Lymphocele)
Lymphopenia (Lymphopenia)
Hypermagnesaemia (Magnesium,
serum-high (hypermagnesemia))
Blood Magnesium Decreased
(Magnesium, serum-low
(hypomagnesemia))
Malabsorption (Malabsorption)
Virilism (Masculinization of female)
Amnesia Nec (Memory impairment)
Mental Status (Mental status)
Metabolic/laboratory Other
(Metabolic/Laboratory-Other (Specify))
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Mood Alteration - Agitation (Mood
alteration - agitation)
Anxiety Nec (Mood alteration - anxiety)
Depression Nec (Mood alteration -
depression)
Euphoric Mood (Mood alteration -
euphoria)
Mucositis/stomatitis (clinical Exam)
(Mucositis/stomatitis (clinical exam) -
Anus)
Mucositis/stomatitis (clinical Exam)
(Mucositis/stomatitis (clinical exam) -
Esophagus)
Mucositis/stomatitis (clinical Exam)
(Mucositis/stomatitis (clinical exam) -
Large bowel)
Mucositis/stomatitis (clinical Exam)
(Mucositis/stomatitis (clinical exam) -
Larynx)
Mucositis/stomatitis (clinical Exam)
(Mucositis/stomatitis (clinical exam) -
Oral cavity)
Stomatitis (Mucositis/stomatitis (clinical
exam) - Pharynx)
Mucositis/stomatitis (clinical Exam)
(Mucositis/stomatitis (clinical exam) -
Rectum)
Mucositis/stomatitis (clinical Exam)
(Mucositis/stomatitis (clinical exam) -
Small bowel)
Mucositis/stomatitis (clinical Exam)
(Mucositis/stomatitis (clinical exam) -
Stomach)
Mucositis/stomatitis (clinical Exam)
(Mucositis/stomatitis (clinical exam) -
Trachea)
Mucositis/stomatitis
(functional/symptomatic)
(Mucositis/stomatitis
(functional/symptomatic) - Anus)
Mucositis/stomatitis
(functional/symptomatic)
(Mucositis/stomatitis
(functional/symptomatic) - Esophagus)
Mucositis/stomatitis
(functional/symptomatic)
(Mucositis/stomatitis
(functional/symptomatic) - Large bowel)
Mucositis/stomatitis
(functional/symptomatic)
(Mucositis/stomatitis
(functional/symptomatic) - Larynx)
Mucositis/stomatitis
(functional/symptomatic)
(Mucositis/stomatitis
(functional/symptomatic) - Oral cavity)
Mucositis/stomatitis
(functional/symptomatic)
(Mucositis/stomatitis
(functional/symptomatic) - Pharynx)
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Mucositis/stomatitis
(functional/symptomatic)
(Mucositis/stomatitis
(functional/symptomatic) - Rectum)
Mucositis/stomatitis
(functional/symptomatic)
(Mucositis/stomatitis
(functional/symptomatic) - Small bowel)
Mucositis/stomatitis
(functional/symptomatic)
(Mucositis/stomatitis
(functional/symptomatic) - Stomach)
Mucositis/stomatitis
(functional/symptomatic)
(Mucositis/stomatitis
(functional/symptomatic) - Trachea)
Muscle Weakness, Generalized Or
Specific Area (not Due To Neuropathy)
(Muscle weakness, generalized or
specific area (not due to neuropathy) -
Extraocular)
Muscle Weakness, Generalized Or
Specific Area (not Due To Neuropathy)
(Muscle weakness, generalized or
specific area (not due to neuropathy) -
Extremity-lower)
Muscle Weakness, Generalized Or
Specific Area (not Due To Neuropathy)
(Muscle weakness, generalized or
specific area (not due to neuropathy) -
Extremity-upper)
Muscle Weakness, Generalized Or
Specific Area (not Due To Neuropathy)
(Muscle weakness, generalized or
specific area (not due to neuropathy) -
Facial)
Muscle Weakness, Generalized Or
Specific Area (not Due To Neuropathy)
(Muscle weakness, generalized or
specific area (not due to neuropathy) -
Left-sided)
Muscle Weakness, Generalized Or
Specific Area (not Due To Neuropathy)
(Muscle weakness, generalized or
specific area (not due to neuropathy) -
Ocular)
Muscle Weakness, Generalized Or
Specific Area (not Due To Neuropathy)
(Muscle weakness, generalized or
specific area (not due to neuropathy) -
Pelvic)
Muscle Weakness, Generalized Or
Specific Area (not Due To Neuropathy)
(Muscle weakness, generalized or
specific area (not due to neuropathy) -
Right-sided)
Muscle Weakness, Generalized Or
Specific Area (not Due To Neuropathy)
(Muscle weakness, generalized or
specific area (not due to neuropathy) -
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Trunk)
Muscle Weakness Nos (Muscle
weakness, generalized or specific area
(not due to neuropathy) - Whole
body/generalized)
Muscular/skeletal Hypoplasia
(Muscular/skeletal hypoplasia)
Musculoskeletal/soft Tissue Other
(Musculoskeletal/Soft Tissue-Other
(Specify))
Myelitis (Myelitis)
Myelodysplasia (Myelodysplasia)
Myocarditis Nos (Myocarditis)
Myositis (Myositis (inflammation/damage
of muscle))
Nail Abnormality Nos (Nail changes)
Nasal Cavity/paranasal Sinus Reactions
(Nasal cavity/paranasal sinus reactions)
Nausea (Nausea)
Necrosis, Gi (Necrosis, GI - Anus)
Necrosis, Gi (Necrosis, GI -
Colon/cecum/appendix)
Necrosis, Gi (Necrosis, GI - Duodenum)
Necrosis, Gi (Necrosis, GI - Esophagus)
Necrosis, Gi (Necrosis, GI - Gallbladder)
Necrosis, Gi (Necrosis, GI - Hepatic)
Necrosis, Gi (Necrosis, GI - Ileum)
Necrosis, Gi (Necrosis, GI - Jejunum)
Necrosis, Gi (Necrosis, GI - Oral)
Necrosis, Gi (Necrosis, GI - Pancreas)
Necrosis, Gi (Necrosis, GI - Peritoneal
cavity)
Necrosis, Gi (Necrosis, GI - Pharynx)
Necrosis, Gi (Necrosis, GI - Rectum)
Necrosis, Gi (Necrosis, GI - Small bowel
NOS)
Necrosis, Gi (Necrosis, GI - Stoma)
Necrosis, Gi (Necrosis, GI - Stomach)
Neuroendocrine: Acth Deficiency
(Neuroendocrine: ACTH deficiency)
Inappropriate Adh Secretion
(Neuroendocrine: ADH secretion
abnormality (e.g., SIADH or low ADH))
Neuroendocrine: Gonadotropin Secretion
Abnormality (Neuroendocrine:
gonadotropin secretion abnormality)
Neuroendocrine: Growth Hormone
Secretion Abnormality (Neuroendocrine:
growth hormone secretion abnormality)
Neuroendocrine: Prolactin Hormone
Secretion Abnormality (Neuroendocrine:
prolactin hormone secretion abnormality)
Neurology Other (Neurology-Other
(Specify))
Parosmia (Neuropathy: cranial - CN I
Smell)
Cranial Nerve Injury Nos (Neuropathy:
cranial - CN II Vision)
Neuropathy: Cranial (Neuropathy: cranial
- CN III Pupil, upper eyelid, extra ocular
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movements)
Neuropathy: Cranial (Neuropathy: cranial
- CN IV Downward, inward movement of
eye)
Neuropathy: Cranial (Neuropathy: cranial
- CN IX Motor-pharynx; Sensory-ear,
pharynx, tongue)
Neuropathy: Cranial (Neuropathy: cranial
- CN V Motor-jaw muscles; Sensory-
facial)
Neuropathy: Cranial (Neuropathy: cranial
- CN VI Lateral deviation of eye)
Neuropathy: Cranial (Neuropathy: cranial
- CN VII Motor-face; Sensory-taste)
Neuropathy: Cranial (Neuropathy: cranial
- CN VIII Hearing and balance)
Neuropathy: Cranial (Neuropathy: cranial
- CN X Motor-palate; pharynx, larynx)
Neuropathy: Cranial (Neuropathy: cranial
- CN XI Motor-sternomastoid and
trapezius)
Neuropathy: Cranial (Neuropathy: cranial
- CN XII Motor-tongue)
Peripheral Motor Neuropathy
(Neuropathy: motor)
Peripheral Sensory Neuropathy
(Neuropathy: sensory)
Neutropenia (Neutrophils/granulocytes
(ANC/AGC))
Blindness Night (Night blindness
(nyctalopia))
Nystagmus Nos (Nystagmus)
Obesity (Obesity)
Obstruction, Gi (Obstruction, GI -
Cecum)
Obstruction, Gi (Obstruction, GI - Colon)
Obstruction, Gi (Obstruction, GI -
Duodenum)
Obstruction, Gi (Obstruction, GI -
Esophagus)
Obstruction, Gi (Obstruction, GI -
Gallbladder)
Obstruction, Gi (Obstruction, GI - Ileum)
Obstruction, Gi (Obstruction, GI -
Jejunum)
Obstruction, Gi (Obstruction, GI -
Rectum)
Obstruction, Gi (Obstruction, GI - Small
bowel NOS)
Obstruction, Gi (Obstruction, GI - Stoma)
Obstruction, Gi (Obstruction, GI -
Stomach)
Obstruction, Gu (Obstruction, GU -
Bladder)
Obstruction, Gu (Obstruction, GU -
Fallopian tube)
Obstruction, Gu (Obstruction, GU -
Prostate)
Obstruction, Gu (Obstruction, GU -
Spermatic cord)
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Obstruction, Gu (Obstruction, GU -
Stoma)
Obstruction, Gu (Obstruction, GU -
Testes)
Ureteric Obstruction (Obstruction, GU -
Ureter)
Obstruction, Gu (Obstruction, GU -
Urethra)
Obstruction, Gu (Obstruction, GU -
Uterus)
Obstruction, Gu (Obstruction, GU -
Vagina)
Obstruction, Gu (Obstruction, GU - Vas
deferens)
Obstruction/stenosis Of Airway
(Obstruction/stenosis of airway -
Bronchus)
Obstruction/stenosis Of Airway
(Obstruction/stenosis of airway - Larynx)
Obstruction/stenosis Of Airway
(Obstruction/stenosis of airway -
Pharynx)
Obstruction/stenosis Of Airway
(Obstruction/stenosis of airway -
Trachea)
Conjunctivitis Nec (Ocular surface
disease)
Ocular/visual Other (Ocular/Visual-Other
(Specify))
Odor (patient Odor) (Odor (patient odor))
Diplopia (Ophthalmoplegia/diplopia
(double vision))
Opportunistic Infection Associated With
>=grade 2 Lymphopenia (Opportunistic
infection associated with >=Grade 2
lymphopenia)
Optic Disc Edema (Optic disc edema)
Orgasmic Dysfunction (Orgasmic
dysfunction)
Osteonecrosis (Osteonecrosis (avascular
necrosis))
Osteoporosis (Osteoporosis)
Otitis Externa (exc Boil Of Meatus) Nos
(Otitis, external ear (non-infectious))
Otitis Media Serous Nos (Otitis, middle
ear (non-infectious))
Abdominal Pain Nos (Pain - Abdomen
NOS)
Pain (Pain - Anus)
Pain (Pain - Back)
Pain (Pain - Bladder)
Bone Pain (Pain - Bone)
Pain (Pain - Breast)
Pain (Pain - Buttock)
Pain (Pain - Cardiac/heart)
Pain (Pain - Chest wall)
Chest Pain (Pain - Chest/thorax NOS)
Pain (Pain - Dental/teeth/peridontal)
Pain (Pain - Esophagus)
Earache (Pain - External ear)
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Pain (Pain - Extremity-limb)
Pain (Pain - Eye)
Pain (Pain - Face)
Pain (Pain - Gallbladder)
Headache Nos (Pain - Head/headache)
Pain (Pain - Intestine)
Arthralgia (Pain - Joint)
Pain (Pain - Kidney)
Pain (Pain - Larynx)
Pain (Pain - Lip)
Hepatic Pain (Pain - Liver)
Pain (Pain - Lymph node)
Pain (Pain - Middle ear)
Myalgia (Pain - Muscle)
Pain (Pain - Neck)
Neuralgia Nos (Pain -
Neuralgia/peripheral nerve)
Pain (Pain - Oral cavity)
Pain (Pain - Oral-gums)
Pain (Pain - Ovulatory)
Pain (Pain - Pain NOS)
Pelvic Pain Nos (Pain - Pelvis)
Pain (Pain - Penis)
Pain (Pain - Pericardium)
Pain (Pain - Perineum)
Pain (Pain - Peritoneum)
Pain (Pain - Phantom (pain associated
with missing limb))
Pleuritic Pain (Pain - Pleura)
Pain (Pain - Prostate)
Proctalgia (Pain - Rectum)
Pain (Pain - Scalp)
Pain (Pain - Scrotum)
Pain (Pain - Sinus)
Pain (Pain - Skin)
Pain (Pain - Stomach)
Pain (Pain - Testicle)
Pain (Pain - Throat/pharynx/larynx)
Tumour Pain (Pain - Tumor pain)
Dysuria (Pain - Urethra)
Dysmenorrhoea (Pain - Uterus)
Pain (Pain - Vagina)
Pain Other (Pain-Other (Specify))
Palpitations (Palpitations)
Pancreas, Exocrine Enzyme Deficiency
(Pancreas, exocrine enzyme deficiency)
Pancreatic Endocrine: Glucose
Intolerance (Pancreatic endocrine:
glucose intolerance)
Pancreatitis Nos (Pancreatitis)
Parathyroid Function, Low
(hypoparathyroidism) (Parathyroid
function, low (hypoparathyroidism))
Perforation, Gi (Perforation, GI -
Appendix)
Perforation, Gi (Perforation, GI - Biliary
tree)
Perforation, Gi (Perforation, GI - Cecum)
Perforation, Gi (Perforation, GI - Colon)
Perforation, Gi (Perforation, GI -
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Duodenum)
Perforation, Gi (Perforation, GI -
Esophagus)
Perforation, Gi (Perforation, GI -
Gallbladder)
Perforation, Gi (Perforation, GI - Ileum)
Perforation, Gi (Perforation, GI -
Jejunum)
Perforation, Gi (Perforation, GI - Rectum)
Perforation, Gi (Perforation, GI - Small
bowel NOS)
Perforation, Gi (Perforation, GI -
Stomach)
Perforation, Gu (Perforation, GU -
Bladder)
Perforation, Gu (Perforation, GU -
Fallopian tube)
Perforation, Gu (Perforation, GU -
Kidney)
Perforation, Gu (Perforation, GU - Ovary)
Perforation, Gu (Perforation, GU -
Prostate)
Perforation, Gu (Perforation, GU -
Spermatic cord)
Perforation, Gu (Perforation, GU -
Stoma)
Perforation, Gu (Perforation, GU -
Testes)
Perforation, Gu (Perforation, GU - Ureter)
Perforation, Gu (Perforation, GU -
Urethra)
Perforation, Gu (Perforation, GU -
Uterus)
Perforation, Gu (Perforation, GU -
Vagina)
Perforation, Gu (Perforation, GU - Vas
deferens)
Pericardial Effusion (Pericardial effusion
(non-malignant))
Pericarditis (Pericarditis)
Peripheral Ischaemia Nos (Peripheral
arterial ischemia)
Personality Change
(Personality/behavioral)
Petechiae (Petechiae/purpura
(hemorrhage/bleeding into skin or
mucosa))
Phlebitis Superficial (Phlebitis (including
superficial thrombosis))
Phlebolymphatic Cording
(Phlebolymphatic cording)
Hypophosphataemia (Phosphate, serum-
low (hypophosphatemia))
Photosensitivity Reaction Nos
(Photosensitivity)
Phrenic Nerve Dysfunction (Phrenic
nerve dysfunction)
Platelet Count Decreased (Platelets)
Pleural Effusion (Pleural effusion (non-
malignant))
37 / 46
Toxicity - ADVERSE EVENTS - 2391190v1.0
Pneumonitis Nos
(Pneumonitis/pulmonary infiltrates)
Pneumothorax Nos (Pneumothorax)
Portal Hypertension (Portal vein flow)
Hyperkalaemia (Potassium, serum-high
(hyperkalemia))
Hypokalaemia (Potassium, serum-low
(hypokalemia))
Proctitis Nos (Proctitis)
Prolapse Of Stoma, Gi (Prolapse of
stoma, GI)
Prolapse Of Stoma, Gu (Prolapse of
stoma, GU)
Prolonged Chest Tube Drainage Or Air
Leak After Pulmonary Resection
(Prolonged chest tube drainage or air
leak after pulmonary resection)
Prolonged Intubation After Pulmonary
Resection (>24 Hrs After Surgery)
(Prolonged intubation after pulmonary
resection (>24 hrs after surgery))
Electrocardiogram Qt Prolonged
(Prolonged QTc interval)
Proptosis/enophthalmos
(Proptosis/enophthalmos)
Proteinuria Present (Proteinuria)
Pruritus Nos (Pruritus/itching)
Delusion Nos (Psychosis
(hallucinations/delusions))
Activated Partial Thromboplastin Time
Prolonged (PTT (Partial thromboplastin
time))
Puberty (delayed) (Puberty (delayed))
Puberty (precocious) (Puberty
(precocious))
Pulmonary Fibrosis (Pulmonary fibrosis
(radiographic changes))
Pulmonary Hypertension (Pulmonary
hypertension)
Pulmonary/upper Respiratory Other
(Pulmonary/Upper Respiratory-Other
(Specify))
Upper Motor Neurone Lesion (Pyramidal
tract dysfunction (e.g., increased tone,
hyperreflexia, positive Babinski,
decreased fine motor coordination))
Rash: Acne/acneiform (Rash:
acne/acneiform)
Radiation Recall Syndrome (Rash:
dermatitis associated with radiation -
Chemoradiation)
Dermatitis Radiation Nos (Rash:
dermatitis associated with radiation -
Radiation)
Erythema Multiforme (Rash: erythema
multiforme (e.g., Stevens-Johnson
syndrome, toxic epidermal necrolysis))
Localised Exfoliation (Rash: hand-foot
skin reaction)
Dermatitis Exfoliative Nos
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(Rash/desquamation)
Renal Failure Nos (Renal failure)
Renal/genitourinary Other
(Renal/Genitourinary-Other (Specify))
Restrictive Cardiomyopathy (Restrictive
cardiomyopathy)
Retinal Detachment (Retinal
detachment)
Retinopathy (Retinopathy)
Right Ventricular Dysfunction (cor
Pulmonale) (Right ventricular dysfunction
(cor pulmonale))
Rigors (Rigors/chills)
Salivary Gland Disorder Nos (Salivary
gland changes/saliva)
Scleral Necrosis/melt (Scleral
necrosis/melt)
Secondary Malignancy Possibly Related
To Cancer Treatment (Secondary
Malignancy-possibly related to cancer
treatment (Specify))
Convulsions Nos (Seizure)
Seroma (Seroma)
Serum Sickness (Serum sickness)
Sexual/reproductive Function Other
(Sexual/Reproductive Function-Other
(Specify))
Short Stature (Short stature)
Skin Breakdown/decubitus Ulcer (Skin
breakdown/decubitus ulcer)
Hypernatraemia (Sodium, serum-high
(hypernatremia))
Hyponatraemia (Sodium, serum-low
(hyponatremia))
Soft Tissue Necrosis (Soft tissue
necrosis - Abdomen)
Soft Tissue Necrosis (Soft tissue
necrosis - Extremity-lower)
Soft Tissue Necrosis (Soft tissue
necrosis - Extremity-upper)
Soft Tissue Necrosis (Soft tissue
necrosis - Head)
Soft Tissue Necrosis (Soft tissue
necrosis - Neck)
Soft Tissue Necrosis (Soft tissue
necrosis - Pelvic)
Soft Tissue Necrosis (Soft tissue
necrosis - Thorax)
Depressed Level Of Consciousness
(Somnolence/depressed level of
consciousness)
Speech Disorder Nec (Speech
impairment (e.g., dysphasia or aphasia))
Splenic Function (Splenic function)
Striae (Striae)
Stricture/stenosis (including
Anastomotic), Gi (Stricture/stenosis
(including anastomotic), GI - Anus)
Stricture/stenosis (including
Anastomotic), Gi (Stricture/stenosis
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(including anastomotic), GI - Biliary tree)
Stricture/stenosis (including
Anastomotic), Gi (Stricture/stenosis
(including anastomotic), GI - Cecum)
Stricture/stenosis (including
Anastomotic), Gi (Stricture/stenosis
(including anastomotic), GI - Colon)
Stricture/stenosis (including
Anastomotic), Gi (Stricture/stenosis
(including anastomotic), GI - Duodenum)
Stricture/stenosis (including
Anastomotic), Gi (Stricture/stenosis
(including anastomotic), GI - Esophagus)
Stricture/stenosis (including
Anastomotic), Gi (Stricture/stenosis
(including anastomotic), GI - Ileum)
Stricture/stenosis (including
Anastomotic), Gi (Stricture/stenosis
(including anastomotic), GI - Jejunum)
Stricture/stenosis (including
Anastomotic), Gi (Stricture/stenosis
(including anastomotic), GI -
Pancreas/pancreatic duct)
Stricture/stenosis (including
Anastomotic), Gi (Stricture/stenosis
(including anastomotic), GI - Pharynx)
Stricture/stenosis (including
Anastomotic), Gi (Stricture/stenosis
(including anastomotic), GI - Rectum)
Stricture/stenosis (including
Anastomotic), Gi (Stricture/stenosis
(including anastomotic), GI - Small bowel
NOS)
Stricture/stenosis (including
Anastomotic), Gi (Stricture/stenosis
(including anastomotic), GI - Stoma)
Stricture/stenosis (including
Anastomotic), Gi (Stricture/stenosis
(including anastomotic), GI - Stomach)
Stricture/stenosis (including
Anastomotic), Gu (Stricture/stenosis
(including anastomotic), GU - Bladder)
Stricture/stenosis (including
Anastomotic), Gu (Stricture/stenosis
(including anastomotic), GU - Fallopian
tube)
Stricture/stenosis (including
Anastomotic), Gu (Stricture/stenosis
(including anastomotic), GU - Prostate)
Stricture/stenosis (including
Anastomotic), Gu (Stricture/stenosis
(including anastomotic), GU - Spermatic
cord)
Stricture/stenosis (including
Anastomotic), Gu (Stricture/stenosis
(including anastomotic), GU - Stoma)
Stricture/stenosis (including
Anastomotic), Gu (Stricture/stenosis
(including anastomotic), GU - Testes)
Stricture/stenosis (including
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Anastomotic), Gu (Stricture/stenosis
(including anastomotic), GU - Ureter)
Stricture/stenosis (including
Anastomotic), Gu (Stricture/stenosis
(including anastomotic), GU - Urethra)
Stricture/stenosis (including
Anastomotic), Gu (Stricture/stenosis
(including anastomotic), GU - Uterus)
Stricture/stenosis (including
Anastomotic), Gu (Stricture/stenosis
(including anastomotic), GU - Vagina)
Stricture/stenosis (including
Anastomotic), Gu (Stricture/stenosis
(including anastomotic), GU - Vas
deferens)
Supraventricular And Nodal Arrhythmia
(Supraventricular and nodal arrhythmia -
Atrial fibrillation)
Supraventricular And Nodal Arrhythmia
(Supraventricular and nodal arrhythmia -
Atrial flutter)
Supraventricular And Nodal Arrhythmia
(Supraventricular and nodal arrhythmia -
Atrial tachycardia/paroxysmal atrial
tachycardia)
Supraventricular And Nodal Arrhythmia
(Supraventricular and nodal arrhythmia -
Nodal/junctional)
Supraventricular And Nodal Arrhythmia
(Supraventricular and nodal arrhythmia -
Sinus arrhythmia)
Sinus Bradycardia (Supraventricular and
nodal arrhythmia - Sinus bradycardia)
Sinus Tachycardia (Supraventricular and
nodal arrhythmia - Sinus tachycardia)
Supraventricular Arrhythmia Nos
(Supraventricular and nodal arrhythmia -
Supraventricular arrhythmia NOS)
Supraventricular And Nodal Arrhythmia -
Supraventricular Extrasystoles
(premature Atrial Contractions;
Premature Nodal/junctional
Contractions) (Supraventricular and
nodal arrhythmia - Supraventricular
extrasystoles (premature atrial
contractions; premature nodal/junctional
contractions))
Supraventricular And Nodal Arrhythmia
(Supraventricular and nodal arrhythmia -
Supraventricular tachycardia)
Sweating Increased (Sweating
(diaphoresis))
Syncope (Syncope (fainting))
Syndromes Other (Syndromes-Other
(Specify))
Taste Disturbance (Taste alteration
(dysgeusia))
Telangiectasia (Telangiectasia)
Thrombosis/embolism (vascular Access-
related) (Thrombosis/embolism (vascular
41 / 46
Toxicity - ADVERSE EVENTS - 2391190v1.0
access-related))
Thrombosis Nos
(Thrombosis/thrombus/embolism)
Thrombotic Microangiopathy (e.g.,
Thrombotic Thrombocytopenic
Purpura[ttp] Or Hemolytic Uremic
Syndrome[hus]) (Thrombotic
microangiopathy (e.g., thrombotic
thrombocytopenic purpura or hemolytic
uremic syndrome))
Thyroid Function, High (hyperthyroidism,
Thyrotoxicosis) (Thyroid function, high
(hyperthyroidism, thyrotoxicosis))
Hypothyroidism (Thyroid function, low
(hypothyroidism))
Tinnitus (Tinnitus)
Tremor Nec (Tremor)
Hypertriglyceridaemia (Triglyceride,
serum-high (hypertriglyceridemia))
Trismus (difficulty, Restriction Or Pain
When Opening Mouth) (Trismus
(difficulty, restriction or pain when
opening mouth))
Tumour Flare (Tumor flare)
Tumour Lysis Syndrome (Tumor lysis
syndrome)
Caecitis (Typhlitis (cecal inflammation))
Ulcer, Gi (Ulcer, GI - Anus)
Ulcer, Gi (Ulcer, GI - Cecum)
Ulcer, Gi (Ulcer, GI - Colon)
Duodenal Ulcer (Ulcer, GI - Duodenum)
Ulcer, Gi (Ulcer, GI - Esophagus)
Ulcer, Gi (Ulcer, GI - Ileum)
Ulcer, Gi (Ulcer, GI - Jejunum)
Ulcer, Gi (Ulcer, GI - Rectum)
Ulcer, Gi (Ulcer, GI - Small bowel NOS)
Ulcer, Gi (Ulcer, GI - Stoma)
Gastric Ulcer (Ulcer, GI - Stomach)
Ulceration (Ulceration)
Hyperuricaemia (Uric acid, serum-high
(hyperuricemia))
Fanconi Syndrome (Urinary electrolyte
wasting (e.g., Fanconi's syndrome, renal
tubular acidosis))
Urinary Frequency (Urinary
frequency/urgency)
Urinary Retention (Urinary retention
(including neurogenic bladder))
Urine Discolouration (Urine color
change)
Urticaria Nos (Urticaria (hives, welts,
wheals))
Uveitis (Uveitis)
Vaginal Discharge (non-infectious)
(Vaginal discharge (non-infectious))
Vulvovaginal Dryness (Vaginal dryness)
Vaginal Mucositis (Vaginal mucositis)
Vaginal Stenosis/length (Vaginal
stenosis/length)
Vaginitis (Vaginitis (not due to infection))
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Valvular Heart Disease (Valvular heart
disease)
Vascular Other (Vascular-Other
(Specify))
Vasculitis Nos (Vasculitis)
Vasovagal Attack (Vasovagal episode)
Ventricular Arrhythmia (Ventricular
arrhythmia - Bigeminy)
Ventricular Arrhythmia (Ventricular
arrhythmia - Idioventricular rhythm)
Ventricular Arrhythmia (Ventricular
arrhythmia - PVCs)
Ventricular Arrhythmia (Ventricular
arrhythmia - Torsade de pointes)
Ventricular Arrhythmia (Ventricular
arrhythmia - Trigeminy)
Ventricular Arrhythmia Nos (Ventricular
arrhythmia - Ventricular arrhythmia NOS)
Ventricular Arrhythmia (Ventricular
arrhythmia - Ventricular fibrillation)
Ventricular Arrhythmia (Ventricular
arrhythmia - Ventricular flutter)
Ventricular Arrhythmia (Ventricular
arrhythmia - Ventricular tachycardia)
Vessel Injury-artery (Vessel injury-artery
- Aorta)
Vessel Injury-artery (Vessel injury-artery
- Carotid)
Vessel Injury-artery (Vessel injury-artery
- Extremity-lower)
Vessel Injury-artery (Vessel injury-artery
- Extremity-upper)
Vessel Injury-artery (Vessel injury-artery
- Other NOS)
Vessel Injury-artery (Vessel injury-artery
- Visceral)
Vessel Injury-vein (Vessel injury-vein -
Extremity-lower)
Vessel Injury-vein (Vessel injury-vein -
Extremity-upper)
Vessel Injury-vein (Vessel injury-vein -
IVC)
Vessel Injury-vein (Vessel injury-vein -
Jugular)
Vessel Injury-vein (Vessel injury-vein -
Other NOS)
Vessel Injury-vein (Vessel injury-vein -
SVC)
Vessel Injury-vein (Vessel injury-vein -
Viscera)
Viral Hepatitis (Viral hepatitis)
Visceral Arterial Ischaemia (Visceral
arterial ischemia (non-myocardial))
Vision Blurred (Vision-blurred vision)
Photopsia (Vision-flashing lights/floaters)
Photophobia (Vision-photophobia)
Vital Capacity (Vital capacity)
Vitreous Hemorrhage (Vitreous
hemorrhage)
Dysphonia (Voice changes/dysarthria
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(e.g., hoarseness, loss or alteration in
voice, laryngitis))
Vomiting Nos (Vomiting)
Lacrimation Increased (Watery eye
(epiphora, tearing))
Weight Increased (Weight gain)
Weight Decreased (Weight loss)
Culture Wound Negative (Wound
complication, non-infectious)
CTC Adverse Event Category
Allergy / Immunology
(Allergy/Immunology)
Auditory/ear (Auditory/Ear)
Blood/bone Marrow (Blood/Bone
Marrow)
Cardiac Arrhythmia (Cardiac Arrhythmia)
Cardiac General (Cardiac General)
Coagulation (Coagulation)
Constitutional Symptoms (Constitutional
Symptoms)
Death (Death)
Dermatology/skin (Dermatology/Skin)
Endocrine (Endocrine)
Gastrointestinal (Gastrointestinal)
Growth And Development (Growth and
Development)
Hemorrhage/bleeding
(Hemorrhage/Bleeding)
Hepatobiliary/pancreas
(Hepatobiliary/Pancreas)
Infection (Infection)
Lymphatics (Lymphatics)
Metabolic/laboratory
(Metabolic/Laboratory)
Musculoskeletal/soft Tissue
(Musculoskeletal/Soft Tissue)
Neurology (Neurology)
Ocular/visual (Ocular/Visual)
Pain (Pain)
Pulmonary/upper Respiratory
(Pulmonary/Upper Respiratory)
Renal/genitourinary
(Renal/Genitourinary)
Second Malignancy (Secondary
Malignancy)
Sexual/reproductive Functions
(Sexual/Reproductive Function)
Surgery/intra-operative Injury
(Surgery/Intra-operative Injury)
Syndromes (Syndromes)
Vascular (Vascular)
Adverse Event Description Text
Adverse Event Report Indicator
No (N)
Unknown (U)
Yes (Y)
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Common Toxicity Criteria Adverse Event Grade
No Adverse Event Or Within Normal
Limits (0)
Mild Adverse Event (1)
Moderate Adverse Event (2)
Severe And Undesirable Adverse Event
(3)
Life-threatening Or Disabling Adverse
Event (4)
Death Related To Adverse Event (5)
Attribution
Unrelated (1)
Unlikely (2)
Possible (3)
Probable (4)
Definite (5)
Unknown (6)
Dose Limiting Toxicity Ind
No (N)
Yes (Y)
SAE Reason
No (1)
Life-threatening (2)
Death (3)
Disability (4)
Hospitalized (5)
Congenital Anomaly (6)
Jeopardizes Patient/ Requires
Intervention (7)
Adverse Event Action
None (1)
Dose Reduced (2)
Regimen Interrupted (3)
Therapy Discontinued (4)
Interrupted And Then Reduced (5)
Adverse Event Therapy
None (1)
Symptomatic (2)
Supportive (3)
Vigorous Supportive (4)
Adverse Event Outcome
Recovered (1)
Still Under Treatment/ Observation (2)
Alive With Sequelae (3)
Died (4)
MedDRA Code (This is a derived field and may
be diplayed on the form, if needed.)
Comments
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Note Date
Research Comments Text
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Nonneoplastic Condition NCT01057121 Lab - AMC-070
HIV T-Cell Laboratory Values Form (F24) - 3146810v1.0
Nonneoplastic Condition NCT01057121 Lab - AMC-070
HIV T-Cell Laboratory Values Form (F24) - 3146810v1.0
All rights reserved. Please visit https://medical-data-
models.org/forms/3168
AMC-070 HIV T-Cell Laboratory
Values Form (F24)
Unnamed1
Visit number
Sequence number
Unnamed2
Date of Evaluation (mm/dd/yyyy)
T-cell Laboratory Values
T-Helper CD4+ %
T-Helper CD4+ absolute count
T-Suppressor CD8+ %
T-Suppressor CD8+ absolute count
Other, specify
Percent Positive Lymphocytes
Absolute Count
Comments
Comments
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3272568v1.0
Treatment - Baseline Symptoms - 3272568v1.0
All rights reserved. Please visit https://medical-data-
models.org/forms/3172
Baseline Symptoms
Baseline Symptoms
Visit Date (Enter the date the form was initiated.)
Date of Onset (Enter the date that the symptom
was first observed/experienced.)
Date Resolved (Enter the date the baseline
symptom was resolved. - i.e.: no longer exists at
any grade.)
CTCAE Term (Use the pick list to select a
CTCAE Common Terminology Criteria for
Adverse Events Term.)
Abdominal Distension (Abdominal
distension)
Abdominal Infection (Abdominal
infection)
Abdominal Pain (Abdominal pain)
Abdominal Soft Tissue Necrosis
(Abdominal soft tissue necrosis)
Abducens Nerve Disorder (Abducens
nerve disorder)
Accessory Nerve Disorder (Accessory
nerve disorder)
Acidosis (Acidosis)
Acoustic Nerve Disorder Nos (Acoustic
nerve disorder NOS)
Activated Partial Thromboplastin Time
Prolonged (Activated partial
thromboplastin time prolonged)
Acute Coronary Syndrome (Acute
coronary syndrome)
Acute Kidney Injury (Acute kidney injury)
Adrenal Insufficiency (Adrenal
insufficiency)
Adult Respiratory Distress Syndrome
(Adult respiratory distress syndrome)
Agitation (Agitation)
Akathisia (Akathisia)
Alanine Aminotransferase Increased
(Alanine aminotransferase increased)
Alcohol Intolerance (Alcohol intolerance)
Alkaline Phosphatase Increased
(Alkaline phosphatase increased)
Alkalosis (Alkalosis)
Allergic Reaction (Allergic reaction)
Allergic Rhinitis (Allergic rhinitis)
Alopecia (Alopecia)
Amnesia (Amnesia)
Anal Fistula (Anal fistula)
Anal Hemorrhage (Anal hemorrhage)
Anal Mucositis (Anal mucositis)
Anal Necrosis (Anal necrosis)
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Anal Pain (Anal pain)
Anal Stenosis (Anal stenosis)
Anal Ulcer (Anal ulcer)
Anaphylaxis (Anaphylaxis)
Anemia (Anemia)
Ankle Fracture (Ankle fracture)
Anorectal Infection (Anorectal infection)
Anorexia (Anorexia)
Anorgasmia (Anorgasmia)
Anxiety (Anxiety)
Aortic Injury (Aortic injury)
Aortic Valve Disease (Aortic valve
disease)
Aphonia (Aphonia)
Apnea (Apnea)
Appendicitis (Appendicitis)
Appendicitis Perforated (Appendicitis
perforated)
Arachnoiditis (Arachnoiditis)
Arterial Injury (Arterial injury)
Arteritis Infective (Arteritis infective)
Arthralgia (Arthralgia)
Arthritis (Arthritis)
Ascites (Ascites)
Aspartate Aminotransferase Increased
(Aspartate aminotransferase increased)
Aspiration (Aspiration)
Asystole (Asystole)
Ataxia (Ataxia)
Atelectasis (Atelectasis)
Atrial Fibrillation (Atrial fibrillation)
Atrial Flutter (Atrial flutter)
Atrioventricular Block Complete
(Atrioventricular block complete)
Atrioventricular Block First Degree
(Atrioventricular block first degree)
Autoimmune Disorder (Autoimmune
disorder)
Avascular Necrosis (Avascular necrosis)
Azoospermia (Azoospermia)
Back Pain (Back pain)
Bile Duct Stenosis (Bile duct stenosis)
Biliary Anastomotic Leak (Biliary
anastomotic leak)
Biliary Fistula (Biliary fistula)
Biliary Tract Infection (Biliary tract
infection)
Bladder Anastomotic Leak (Bladder
anastomotic leak)
Bladder Infection (Bladder infection)
Bladder Perforation (Bladder perforation)
Bladder Spasm (Bladder spasm)
Bloating (Bloating)
Blood And Lymphatic System Disorders -
Other, Specify (Blood and lymphatic
system disorders - Other, Specify)
Blood Antidiuretic Hormone Abnormal
(Blood antidiuretic hormone abnormal)
Blood Bilirubin Increased (Blood bilirubin
increased)
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Blood Corticotrophin Decreased (Blood
corticotrophin decreased)
Blood Gonadotrophin Abnormal (Blood
gonadotrophin abnormal)
Blood Prolactin Abnormal (Blood
prolactin abnormal)
Blurred Vision (Blurred vision)
Body Odor (Body odor)
Bone Infection (Bone infection)
Bone Marrow Hypocellular (Bone
marrow hypocellular)
Bone Pain (Bone pain)
Brachial Plexopathy (Brachial
plexopathy)
Breast Atrophy (Breast atrophy)
Breast Infection (Breast infection)
Breast Pain (Breast pain)
Bronchial Fistula (Bronchial fistula)
Bronchial Infection (Bronchial infection)
Bronchial Obstruction (Bronchial
obstruction)
Bronchial Stricture (Bronchial stricture)
Bronchopleural Fistula (Bronchopleural
fistula)
Bronchopulmonary Hemorrhage
(Bronchopulmonary hemorrhage)
Bronchospasm (Bronchospasm)
Bruising (Bruising)
Bullous Dermatitis (Bullous dermatitis)
Burn (Burn)
Buttock Pain (Buttock pain)
Capillary Leak Syndrome (Capillary leak
syndrome)
Carbon Monoxide Diffusing Capacity
Decreased (Carbon monoxide diffusing
capacity decreased)
Cardiac Arrest (Cardiac arrest)
Cardiac Disorders - Other, Specify
(Cardiac disorders - Other, Specify)
Cardiac Troponin I Increased (Cardiac
troponin I increased)
Cardiac Troponin T Increased (Cardiac
troponin T increased)
Cataract (Cataract)
Catheter Related Infection (Catheter
related infection)
Cd4 Lymphocytes Decreased (CD4
lymphocytes decreased)
Cecal Hemorrhage (Cecal hemorrhage)
Cecal Infection (Cecal infection)
Central Nervous System Necrosis
(Central nervous system necrosis)
Cerebrospinal Fluid Leakage
(Cerebrospinal fluid leakage)
Cervicitis Infection (Cervicitis infection)
Cheilitis (Cheilitis)
Chest Pain - Cardiac (Chest pain -
cardiac)
Chest Wall Pain (Chest wall pain)
Chills (Chills)
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Cholecystitis (Cholecystitis)
Cholesterol High (Cholesterol high)
Chronic Kidney Disease (Chronic kidney
disease)
Chylothorax (Chylothorax)
Cognitive Disturbance (Cognitive
disturbance)
Colitis (Colitis)
Colonic Fistula (Colonic fistula)
Colonic Hemorrhage (Colonic
hemorrhage)
Colonic Obstruction (Colonic obstruction)
Colonic Perforation (Colonic perforation)
Colonic Stenosis (Colonic stenosis)
Colonic Ulcer (Colonic ulcer)
Concentration Impairment
(Concentration impairment)
Conduction Disorder (Conduction
disorder)
Confusion (Confusion)
Congenital, Familial And Genetic
Disorders - Other, Specify (Congenital,
familial and genetic disorders - Other,
Specify)
Conjunctivitis (Conjunctivitis)
Conjunctivitis Infective (Conjunctivitis
infective)
Constipation (Constipation)
Constrictive Pericarditis (Constrictive
pericarditis)
Corneal Infection (Corneal infection)
Corneal Ulcer (Corneal ulcer)
Cough (Cough)
Cpk Increased (CPK increased)
Cranial Nerve Infection (Cranial nerve
infection)
Creatinine Increased (Creatinine
increased)
Cushingoid (Cushingoid)
Cystitis Noninfective (Cystitis
noninfective)
Cytokine Release Syndrome (Cytokine
release syndrome)
Death Neonatal (Death neonatal)
Death Nos (Death NOS)
Dehydration (Dehydration)
Delayed Orgasm (Delayed orgasm)
Delayed Puberty (Delayed puberty)
Delirium (Delirium)
Delusions (Delusions)
Dental Caries (Dental caries)
Depressed Level Of Consciousness
(Depressed level of consciousness)
Depression (Depression)
Dermatitis Radiation (Dermatitis
radiation)
Device Related Infection (Device related
infection)
Diarrhea (Diarrhea)
Disseminated Intravascular Coagulation
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(Disseminated intravascular coagulation)
Dizziness (Dizziness)
Dry Eye (Dry eye)
Dry Mouth (Dry mouth)
Dry Skin (Dry skin)
Duodenal Fistula (Duodenal fistula)
Duodenal Hemorrhage (Duodenal
hemorrhage)
Duodenal Infection (Duodenal infection)
Duodenal Obstruction (Duodenal
obstruction)
Duodenal Perforation (Duodenal
perforation)
Duodenal Stenosis (Duodenal stenosis)
Duodenal Ulcer (Duodenal ulcer)
Dysarthria (Dysarthria)
Dysesthesia (Dysesthesia)
Dysgeusia (Dysgeusia)
Dysmenorrhea (Dysmenorrhea)
Dyspareunia (Dyspareunia)
Dyspepsia (Dyspepsia)
Dysphagia (Dysphagia)
Dysphasia (Dysphasia)
Dyspnea (Dyspnea)
Ear And Labyrinth Disorders - Other,
Specify (Ear and labyrinth disorders -
Other, Specify)
Ear Pain (Ear pain)
Edema Cerebral (Edema cerebral)
Edema Face (Edema face)
Edema Limbs (Edema limbs)
Edema Trunk (Edema trunk)
Ejaculation Disorder (Ejaculation
disorder)
Ejection Fraction Decreased (Ejection
fraction decreased)
Electrocardiogram Qt Corrected Interval
Prolonged (Electrocardiogram QT
corrected interval prolonged)
Encephalitis Infection (Encephalitis
infection)
Encephalomyelitis Infection
(Encephalomyelitis infection)
Encephalopathy (Encephalopathy)
Endocarditis Infective (Endocarditis
infective)
Endocrine Disorders - Other, Specify
(Endocrine disorders - Other, Specify)
Endophthalmitis (Endophthalmitis)
Enterocolitis (Enterocolitis)
Enterocolitis Infectious (Enterocolitis
infectious)
Enterovesical Fistula (Enterovesical
fistula)
Epistaxis (Epistaxis)
Erectile Dysfunction (Erectile
dysfunction)
Erythema Multiforme (Erythema
multiforme)
Erythroderma (Erythroderma)
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Esophageal Anastomotic Leak
(Esophageal anastomotic leak)
Esophageal Fistula (Esophageal fistula)
Esophageal Hemorrhage (Esophageal
hemorrhage)
Esophageal Infection (Esophageal
infection)
Esophageal Necrosis (Esophageal
necrosis)
Esophageal Obstruction (Esophageal
obstruction)
Esophageal Pain (Esophageal pain)
Esophageal Perforation (Esophageal
perforation)
Esophageal Stenosis (Esophageal
stenosis)
Esophageal Ulcer (Esophageal ulcer)
Esophageal Varices Hemorrhage
(Esophageal varices hemorrhage)
Esophagitis (Esophagitis)
Euphoria (Euphoria)
Exostosis (Exostosis)
External Ear Inflammation (External ear
inflammation)
External Ear Pain (External ear pain)
Extraocular Muscle Paresis (Extraocular
muscle paresis)
Extrapyramidal Disorder (Extrapyramidal
disorder)
Eye Disorders - Other, Specify (Eye
disorders - Other, Specify)
Eye Infection (Eye infection)
Eye Pain (Eye pain)
Eyelid Function Disorder (Eyelid function
disorder)
Facial Muscle Weakness (Facial muscle
weakness)
Facial Nerve Disorder (Facial nerve
disorder)
Facial Pain (Facial pain)
Fall (Fall)
Fallopian Tube Anastomotic Leak
(Fallopian tube anastomotic leak)
Fallopian Tube Obstruction (Fallopian
tube obstruction)
Fallopian Tube Perforation (Fallopian
tube perforation)
Fallopian Tube Stenosis (Fallopian tube
stenosis)
Fat Atrophy (Fat atrophy)
Fatigue (Fatigue)
Febrile Neutropenia (Febrile
neutropenia)
Fecal Incontinence (Fecal incontinence)
Female Genital Tract Fistula (Female
genital tract fistula)
Feminization Acquired (Feminization
acquired)
Fetal Death (Fetal death)
Fetal Growth Retardation (Fetal growth
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retardation)
Fever (Fever)
Fibrinogen Decreased (Fibrinogen
decreased)
Fibrosis Deep Connective Tissue
(Fibrosis deep connective tissue)
Flank Pain (Flank pain)
Flashing Lights (Flashing lights)
Flatulence (Flatulence)
Floaters (Floaters)
Flu Like Symptoms (Flu like symptoms)
Flushing (Flushing)
Forced Expiratory Volume Decreased
(Forced expiratory volume decreased)
Fracture (Fracture)
Gait Disturbance (Gait disturbance)
Gallbladder Fistula (Gallbladder fistula)
Gallbladder Infection (Gallbladder
infection)
Gallbladder Necrosis (Gallbladder
necrosis)
Gallbladder Obstruction (Gallbladder
obstruction)
Gallbladder Pain (Gallbladder pain)
Gallbladder Perforation (Gallbladder
perforation)
Gastric Anastomotic Leak (Gastric
anastomotic leak)
Gastric Fistula (Gastric fistula)
Gastric Hemorrhage (Gastric
hemorrhage)
Gastric Necrosis (Gastric necrosis)
Gastric Perforation (Gastric perforation)
Gastric Stenosis (Gastric stenosis)
Gastric Ulcer (Gastric ulcer)
Gastritis (Gastritis)
Gastroesophageal Reflux Disease
(Gastroesophageal reflux disease)
Gastrointestinal Anastomotic Leak
(Gastrointestinal anastomotic leak)
Gastrointestinal Disorders - Other,
Specify (Gastrointestinal disorders -
Other, Specify)
Gastrointestinal Fistula (Gastrointestinal
fistula)
Gastrointestinal Pain (Gastrointestinal
pain)
Gastrointestinal Stoma Necrosis
(Gastrointestinal stoma necrosis)
Gastroparesis (Gastroparesis)
General Disorders And Administration
Site Conditions - Other, Specify (General
disorders and administration site
conditions - Other, Specify)
Generalized Muscle Weakness
(Generalized muscle weakness)
Genital Edema (Genital edema)
Ggt Increased (GGT increased)
Gingival Pain (Gingival pain)
Glaucoma (Glaucoma)
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Glossopharyngeal Nerve Disorder
(Glossopharyngeal nerve disorder)
Glucose Intolerance (Glucose
intolerance)
Growth Accelerated (Growth
accelerated)
Growth Hormone Abnormal (Growth
hormone abnormal)
Growth Suppression (Growth
suppression)
Gum Infection (Gum infection)
Gynecomastia (Gynecomastia)
Hallucinations (Hallucinations)
Haptoglobin Decreased (Haptoglobin
decreased)
Head Soft Tissue Necrosis (Head soft
tissue necrosis)
Headache (Headache)
Hearing Impaired (Hearing impaired)
Heart Failure (Heart failure)
Hematoma (Hematoma)
Hematosalpinx (Hematosalpinx)
Hematuria (Hematuria)
Hemoglobin Increased (Hemoglobin
increased)
Hemoglobinuria (Hemoglobinuria)
Hemolysis (Hemolysis)
Hemolytic Uremic Syndrome (Hemolytic
uremic syndrome)
Hemorrhoidal Hemorrhage
(Hemorrhoidal hemorrhage)
Hemorrhoids (Hemorrhoids)
Hepatic Failure (Hepatic failure)
Hepatic Hemorrhage (Hepatic
hemorrhage)
Hepatic Infection (Hepatic infection)
Hepatic Necrosis (Hepatic necrosis)
Hepatic Pain (Hepatic pain)
Hepatitis Viral (Hepatitis viral)
Hepatobiliary Disorders - Other, Specify
(Hepatobiliary disorders - Other, Specify)
Hiccups (Hiccups)
Hip Fracture (Hip fracture)
Hirsutism (Hirsutism)
Hoarseness (Hoarseness)
Hot Flashes (Hot flashes)
Hydrocephalus (Hydrocephalus)
Hypercalcemia (Hypercalcemia)
Hyperglycemia (Hyperglycemia)
Hyperhidrosis (Hyperhidrosis)
Hyperkalemia (Hyperkalemia)
Hypermagnesemia (Hypermagnesemia)
Hypernatremia (Hypernatremia)
Hyperparathyroidism
(Hyperparathyroidism)
Hypersomnia (Hypersomnia)
Hypertension (Hypertension)
Hyperthyroidism (Hyperthyroidism)
Hypertrichosis (Hypertrichosis)
Hypertriglyceridemia
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(Hypertriglyceridemia)
Hyperuricemia (Hyperuricemia)
Hypoalbuminemia (Hypoalbuminemia)
Hypocalcemia (Hypocalcemia)
Hypoglossal Nerve Disorder
(Hypoglossal nerve disorder)
Hypoglycemia (Hypoglycemia)
Hypohidrosis (Hypohidrosis)
Hypokalemia (Hypokalemia)
Hypomagnesemia (Hypomagnesemia)
Hyponatremia (Hyponatremia)
Hypoparathyroidism
(Hypoparathyroidism)
Hypophosphatemia (Hypophosphatemia)
Hypotension (Hypotension)
Hypothermia (Hypothermia)
Hypothyroidism (Hypothyroidism)
Hypoxia (Hypoxia)
Ileal Fistula (Ileal fistula)
Ileal Hemorrhage (Ileal hemorrhage)
Ileal Obstruction (Ileal obstruction)
Ileal Perforation (Ileal perforation)
Ileal Stenosis (Ileal stenosis)
Ileal Ulcer (Ileal ulcer)
Ileus (Ileus)
Immune System Disorders - Other,
Specify (Immune system disorders -
Other, Specify)
Infections And Infestations - Other,
Specify (Infections and infestations -
Other, Specify)
Infective Myositis (Infective myositis)
Infusion Related Reaction (Infusion
related reaction)
Infusion Site Extravasation (Infusion site
extravasation)
Injection Site Reaction (Injection site
reaction)
Injury To Carotid Artery (Injury to carotid
artery)
Injury To Inferior Vena Cava (Injury to
inferior vena cava)
Injury To Jugular Vein (Injury to jugular
vein)
Injury To Superior Vena Cava (Injury to
superior vena cava)
Injury, Poisoning And Procedural
Complications - Other, Specify (Injury,
poisoning and procedural complications -
Other, Specify)
Inr Increased (INR increased)
Insomnia (Insomnia)
Intestinal Stoma Leak (Intestinal stoma
leak)
Intestinal Stoma Obstruction (Intestinal
stoma obstruction)
Intestinal Stoma Site Bleeding (Intestinal
stoma site bleeding)
Intra-abdominal Hemorrhage (Intra-
abdominal hemorrhage)
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Intracranial Hemorrhage (Intracranial
hemorrhage)
Intraoperative Arterial Injury
(Intraoperative arterial injury)
Intraoperative Breast Injury
(Intraoperative breast injury)
Intraoperative Cardiac Injury
(Intraoperative cardiac injury)
Intraoperative Ear Injury (Intraoperative
ear injury)
Intraoperative Endocrine Injury
(Intraoperative endocrine injury)
Intraoperative Gastrointestinal Injury
(Intraoperative gastrointestinal injury)
Intraoperative Head And Neck Injury
(Intraoperative head and neck injury)
Intraoperative Hemorrhage
(Intraoperative hemorrhage)
Intraoperative Hepatobiliary Injury
(Intraoperative hepatobiliary injury)
Intraoperative Musculoskeletal Injury
(Intraoperative musculoskeletal injury)
Intraoperative Neurological Injury
(Intraoperative neurological injury)
Intraoperative Ocular Injury
(Intraoperative ocular injury)
Intraoperative Renal Injury
(Intraoperative renal injury)
Intraoperative Reproductive Tract Injury
(Intraoperative reproductive tract injury)
Intraoperative Respiratory Injury
(Intraoperative respiratory injury)
Intraoperative Skin Injury (Intraoperative
skin injury)
Intraoperative Splenic Injury
(Intraoperative splenic injury)
Intraoperative Urinary Injury
(Intraoperative urinary injury)
Intraoperative Venous Injury
(Intraoperative venous injury)
Investigations - Other, Specify
(Investigations - Other, Specify)
Iron Overload (Iron overload)
Irregular Menstruation (Irregular
menstruation)
Irritability (Irritability)
Ischemia Cerebrovascular (Ischemia
cerebrovascular)
Ivth Nerve Disorder (IVth nerve disorder)
Jejunal Fistula (Jejunal fistula)
Jejunal Hemorrhage (Jejunal
hemorrhage)
Jejunal Obstruction (Jejunal obstruction)
Jejunal Perforation (Jejunal perforation)
Jejunal Stenosis (Jejunal stenosis)
Jejunal Ulcer (Jejunal ulcer)
Joint Effusion (Joint effusion)
Joint Infection (Joint infection)
Joint Range Of Motion Decreased (Joint
range of motion decreased)
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Joint Range Of Motion Decreased
Cervical Spine (Joint range of motion
decreased cervical spine)
Joint Range Of Motion Decreased
Lumbar Spine (Joint range of motion
decreased lumbar spine)
Keratitis (Keratitis)
Kidney Anastomotic Leak (Kidney
anastomotic leak)
Kidney Infection (Kidney infection)
Kyphosis (Kyphosis)
Lactation Disorder (Lactation disorder)
Large Intestinal Anastomotic Leak (Large
intestinal anastomotic leak)
Laryngeal Edema (Laryngeal edema)
Laryngeal Fistula (Laryngeal fistula)
Laryngeal Hemorrhage (Laryngeal
hemorrhage)
Laryngeal Inflammation (Laryngeal
inflammation)
Laryngeal Mucositis (Laryngeal
mucositis)
Laryngeal Obstruction (Laryngeal
obstruction)
Laryngeal Stenosis (Laryngeal stenosis)
Laryngitis (Laryngitis)
Laryngopharyngeal Dysesthesia
(Laryngopharyngeal dysesthesia)
Laryngospasm (Laryngospasm)
Left Ventricular Systolic Dysfunction (Left
ventricular systolic dysfunction)
Lethargy (Lethargy)
Leukemia Secondary To Oncology
Chemotherapy (Leukemia secondary to
oncology chemotherapy)
Leukocytosis (Leukocytosis)
Leukoencephalopathy
(Leukoencephalopathy)
Libido Decreased (Libido decreased)
Libido Increased (Libido increased)
Lip Infection (Lip infection)
Lip Pain (Lip pain)
Lipase Increased (Lipase increased)
Lipohypertrophy (Lipohypertrophy)
Localized Edema (Localized edema)
Lordosis (Lordosis)
Lower Gastrointestinal Hemorrhage
(Lower gastrointestinal hemorrhage)
Lung Infection (Lung infection)
Lymph Gland Infection (Lymph gland
infection)
Lymph Leakage (Lymph leakage)
Lymph Node Pain (Lymph node pain)
Lymphedema (Lymphedema)
Lymphocele (Lymphocele)
Lymphocyte Count Decreased
(Lymphocyte count decreased)
Lymphocyte Count Increased
(Lymphocyte count increased)
Malabsorption (Malabsorption)
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Malaise (Malaise)
Mania (Mania)
Mediastinal Hemorrhage (Mediastinal
hemorrhage)
Mediastinal Infection (Mediastinal
infection)
Memory Impairment (Memory
impairment)
Meningismus (Meningismus)
Meningitis (Meningitis)
Menopause (Menopause)
Menorrhagia (Menorrhagia)
Metabolism And Nutrition Disorders -
Other, Specify (Metabolism and nutrition
disorders - Other, Specify)
Middle Ear Inflammation (Middle ear
inflammation)
Mitral Valve Disease (Mitral valve
disease)
Mobitz (type) Ii Atrioventricular Block
(Mobitz (type) II atrioventricular block)
Mobitz Type I (Mobitz type I)
Movements Involuntary (Movements
involuntary)
Mucosal Infection (Mucosal infection)
Mucositis Oral (Mucositis oral)
Multi-organ Failure (Multi-organ failure)
Muscle Weakness Left-sided (Muscle
weakness left-sided)
Muscle Weakness Lower Limb (Muscle
weakness lower limb)
Muscle Weakness Right-sided (Muscle
weakness right-sided)
Muscle Weakness Trunk (Muscle
weakness trunk)
Muscle Weakness Upper Limb (Muscle
weakness upper limb)
Musculoskeletal And Connective Tissue
Disorder - Other, Specify
(Musculoskeletal and connective tissue
disorders - Other, Specify)
Musculoskeletal Deformity
(Musculoskeletal deformity)
Myalgia (Myalgia)
Myelitis (Myelitis)
Myelodysplastic Syndrome
(Myelodysplastic syndrome)
Myocardial Infarction (Myocardial
infarction)
Myocarditis (Myocarditis)
Myositis (Myositis)
Nail Discoloration (Nail discoloration)
Nail Infection (Nail infection)
Nail Loss (Nail loss)
Nail Ridging (Nail ridging)
Nasal Congestion (Nasal congestion)
Nausea (Nausea)
Neck Edema (Neck edema)
Neck Pain (Neck pain)
Neck Soft Tissue Necrosis (Neck soft
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tissue necrosis)
Neoplasms Benign, Malignant And
Unspecified (incl Cysts And Polyps) -
Other, Specify (Neoplasms benign,
malignant and unspecified (incl cysts and
polyps) - Other, Specify)
Nervous System Disorders - Other,
Specify (Nervous system disorders -
Other, Specify)
Neuralgia (Neuralgia)
Neutrophil Count Decreased (Neutrophil
count decreased)
Night Blindness (Night blindness)
Nipple Deformity (Nipple deformity)
Non-cardiac Chest Pain (Non-cardiac
chest pain)
Nystagmus (Nystagmus)
Obesity (Obesity)
Obstruction Gastric (Obstruction gastric)
Oculomotor Nerve Disorder (Oculomotor
nerve disorder)
Olfactory Nerve Disorder (Olfactory
nerve disorder)
Oligospermia (Oligospermia)
Optic Nerve Disorder (Optic nerve
disorder)
Oral Cavity Fistula (Oral cavity fistula)
Oral Dysesthesia (Oral dysesthesia)
Oral Hemorrhage (Oral hemorrhage)
Oral Pain (Oral pain)
Osteonecrosis Of Jaw (Osteonecrosis of
jaw)
Osteoporosis (Osteoporosis)
Otitis Externa (Otitis externa)
Otitis Media (Otitis media)
Ovarian Hemorrhage (Ovarian
hemorrhage)
Ovarian Infection (Ovarian infection)
Ovarian Rupture (Ovarian rupture)
Ovulation Pain (Ovulation pain)
Pain (Pain)
Pain In Extremity (Pain in extremity)
Pain Of Skin (Pain of skin)
Palmar-plantar Erythrodysesthesia
Syndrome (Palmar-plantar
erythrodysesthesia syndrome)
Palpitations (Palpitations)
Pancreas Infection (Pancreas infection)
Pancreatic Anastomotic Leak (Pancreatic
anastomotic leak)
Pancreatic Duct Stenosis (Pancreatic
duct stenosis)
Pancreatic Enzymes Decreased
(Pancreatic enzymes decreased)
Pancreatic Fistula (Pancreatic fistula)
Pancreatic Hemorrhage (Pancreatic
hemorrhage)
Pancreatic Necrosis (Pancreatic
necrosis)
Pancreatitis (Pancreatitis)
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Papilledema (Papilledema)
Papulopustular Rash (Papulopustular
rash)
Paresthesia (Paresthesia)
Paronychia (Paronychia)
Paroxysmal Atrial Tachycardia
(Paroxysmal atrial tachycardia)
Pelvic Floor Muscle Weakness (Pelvic
floor muscle weakness)
Pelvic Infection (Pelvic infection)
Pelvic Pain (Pelvic pain)
Pelvic Soft Tissue Necrosis (Pelvic soft
tissue necrosis)
Penile Infection (Penile infection)
Penile Pain (Penile pain)
Perforation Bile Duct (Perforation bile
duct)
Pericardial Effusion (Pericardial effusion)
Pericardial Tamponade (Pericardial
tamponade)
Pericarditis (Pericarditis)
Perineal Pain (Perineal pain)
Periodontal Disease (Periodontal
disease)
Periorbital Edema (Periorbital edema)
Periorbital Infection (Periorbital infection)
Peripheral Ischemia (Peripheral
ischemia)
Peripheral Motor Neuropathy (Peripheral
motor neuropathy)
Peripheral Nerve Infection (Peripheral
nerve infection)
Peripheral Sensory Neuropathy
(Peripheral sensory neuropathy)
Peritoneal Infection (Peritoneal infection)
Peritoneal Necrosis (Peritoneal necrosis)
Personality Change (Personality change)
Phantom Pain (Phantom pain)
Pharyngeal Anastomotic Leak
(Pharyngeal anastomotic leak)
Pharyngeal Fistula (Pharyngeal fistula)
Pharyngeal Hemorrhage (Pharyngeal
hemorrhage)
Pharyngeal Mucositis (Pharyngeal
mucositis)
Pharyngeal Necrosis (Pharyngeal
necrosis)
Pharyngeal Stenosis (Pharyngeal
stenosis)
Pharyngitis (Pharyngitis)
Pharyngolaryngeal Pain
(Pharyngolaryngeal pain)
Phlebitis (Phlebitis)
Phlebitis Infective (Phlebitis infective)
Photophobia (Photophobia)
Photosensitivity (Photosensitivity)
Platelet Count Decreased (Platelet count
decreased)
Pleural Effusion (Pleural effusion)
Pleural Hemorrhage (Pleural
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hemorrhage)
Pleural Infection (Pleural infection)
Pleuritic Pain (Pleuritic pain)
Pneumonitis (Pneumonitis)
Pneumothorax (Pneumothorax)
Portal Hypertension (Portal
hypertension)
Portal Vein Thrombosis (Portal vein
thrombosis)
Postnasal Drip (Postnasal drip)
Postoperative Hemorrhage
(Postoperative hemorrhage)
Postoperative Thoracic Procedure
Complication (Postoperative thoracic
procedure complication)
Precocious Puberty (Precocious
puberty)
Pregnancy, Puerperium And Perinatal
Conditions - Other, Specify (Pregnancy,
puerperium and perinatal conditions -
Other, Specify)
Premature Delivery (Premature delivery)
Premature Menopause (Premature
menopause)
Presyncope (Presyncope)
Proctitis (Proctitis)
Productive Cough (Productive cough)
Prolapse Of Intestinal Stoma (Prolapse
of intestinal stoma)
Prolapse Of Urostomy (Prolapse of
urostomy)
Prostate Infection (Prostate infection)
Prostatic Hemorrhage (Prostatic
hemorrhage)
Prostatic Obstruction (Prostatic
obstruction)
Prostatic Pain (Prostatic pain)
Proteinuria (Proteinuria)
Pruritus (Pruritus)
Psychiatric Disorders - Other, Specify
(Psychiatric disorders - Other, Specify)
Psychosis (Psychosis)
Pulmonary Edema (Pulmonary edema)
Pulmonary Fibrosis (Pulmonary fibrosis)
Pulmonary Fistula (Pulmonary fistula)
Pulmonary Hypertension (Pulmonary
hypertension)
Pulmonary Valve Disease (Pulmonary
valve disease)
Purpura (Purpura)
Pyramidal Tract Syndrome (Pyramidal
tract syndrome)
Radiation Recall Reaction (dermatologic)
(Radiation recall reaction (dermatologic))
Radiculitis (Radiculitis)
Rash Acneiform (Rash acneiform)
Rash Maculo-papular (Rash maculo-
papular)
Rash Pustular (Rash pustular)
Rectal Anastomotic Leak (Rectal
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anastomotic leak)
Rectal Fistula (Rectal fistula)
Rectal Hemorrhage (Rectal hemorrhage)
Rectal Mucositis (Rectal mucositis)
Rectal Necrosis (Rectal necrosis)
Rectal Obstruction (Rectal obstruction)
Rectal Pain (Rectal pain)
Rectal Perforation (Rectal perforation)
Rectal Stenosis (Rectal stenosis)
Rectal Ulcer (Rectal ulcer)
Recurrent Laryngeal Nerve Palsy
(Recurrent laryngeal nerve palsy)
Renal And Urinary Disorders - Other,
Specify (Renal and urinary disorders -
Other, Specify)
Renal Calculi (Renal calculi)
Renal Colic (Renal colic)
Renal Hemorrhage (Renal hemorrhage)
Reproductive System And Breast
Disorders - Other, Specify (Reproductive
system and breast disorders - Other,
Specify)
Respiratory Failure (Respiratory failure)
Respiratory, Thoracic And Mediastinal
Disorders - Other, Specify (Respiratory,
thoracic and mediastinal disorders -
Other, Specify)
Restlessness (Restlessness)
Restrictive Cardiomyopathy (Restrictive
cardiomyopathy)
Retinal Detachment (Retinal
detachment)
Retinal Tear (Retinal tear)
Retinal Vascular Disorder (Retinal
vascular disorder)
Retinoic Acid Syndrome (Retinoic acid
syndrome)
Retinopathy (Retinopathy)
Retroperitoneal Hemorrhage
(Retroperitoneal hemorrhage)
Reversible Posterior
Leukoencephalopathy Syndrome
(Reversible posterior
leukoencephalopathy syndrome)
Rhinitis Infective (Rhinitis infective)
Right Ventricular Dysfunction (Right
ventricular dysfunction)
Salivary Duct Inflammation (Salivary duct
inflammation)
Salivary Gland Fistula (Salivary gland
fistula)
Salivary Gland Infection (Salivary gland
infection)
Scalp Pain (Scalp pain)
Scleral Disorder (Scleral disorder)
Scoliosis (Scoliosis)
Scrotal Infection (Scrotal infection)
Scrotal Pain (Scrotal pain)
Seizure (Seizure)
Sepsis (Sepsis)
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Seroma (Seroma)
Serum Amylase Increased (Serum
amylase increased)
Serum Sickness (Serum sickness)
Sick Sinus Syndrome (Sick sinus
syndrome)
Sinus Bradycardia (Sinus bradycardia)
Sinus Disorder (Sinus disorder)
Sinus Pain (Sinus pain)
Sinus Tachycardia (Sinus tachycardia)
Sinusitis (Sinusitis)
Skin And Subcutaneous Tissue
Disorders - Other, Specify (Skin and
subcutaneous tissue disorders - Other,
Specify)
Skin Atrophy (Skin atrophy)
Skin Hyperpigmentation (Skin
hyperpigmentation)
Skin Hypopigmentation (Skin
hypopigmentation)
Skin Induration (Skin induration)
Skin Infection (Skin infection)
Skin Ulceration (Skin ulceration)
Sleep Apnea (Sleep apnea)
Small Intestinal Anastomotic Leak (Small
intestinal anastomotic leak)
Small Intestinal Mucositis (Small
intestinal mucositis)
Small Intestinal Obstruction (Small
intestinal obstruction)
Small Intestinal Perforation (Small
intestinal perforation)
Small Intestinal Stenosis (Small intestinal
stenosis)
Small Intestine Infection (Small intestine
infection)
Small Intestine Ulcer (Small intestine
ulcer)
Sneezing (Sneezing)
Social Circumstances - Other, Specify
(Social circumstances - Other, Specify)
Soft Tissue Infection (Soft tissue
infection)
Soft Tissue Necrosis Lower Limb (Soft
tissue necrosis lower limb)
Soft Tissue Necrosis Upper Limb (Soft
tissue necrosis upper limb)
Somnolence (Somnolence)
Sore Throat (Sore throat)
Spasticity (Spasticity)
Spermatic Cord Anastomotic Leak
(Spermatic cord anastomotic leak)
Spermatic Cord Hemorrhage (Spermatic
cord hemorrhage)
Spermatic Cord Obstruction (Spermatic
cord obstruction)
Spinal Fracture (Spinal fracture)
Spleen Disorder (Spleen disorder)
Splenic Infection (Splenic infection)
Stenosis Of Gastrointestinal Stoma
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(Stenosis of gastrointestinal stoma)
Stevens-johnson Syndrome (Stevens-
Johnson syndrome)
Stoma Site Infection (Stoma site
infection)
Stomach Pain (Stomach pain)
Stomal Ulcer (Stomal ulcer)
Stridor (Stridor)
Stroke (Stroke)
Sudden Death Nos (Sudden death NOS)
Suicidal Ideation (Suicidal ideation)
Suicide Attempt (Suicide attempt)
Superficial Soft Tissue Fibrosis
(Superficial soft tissue fibrosis)
Superficial Thrombophlebitis (Superficial
thrombophlebitis)
Superior Vena Cava Syndrome (Superior
vena cava syndrome)
Supraventricular Tachycardia
(Supraventricular tachycardia)
Surgical And Medical Procedures -
Other, Specify (Surgical and medical
procedures - Other, Specify)
Syncope (Syncope)
Telangiectasia (Telangiectasia)
Testicular Disorder (Testicular disorder)
Testicular Hemorrhage (Testicular
hemorrhage)
Testicular Pain (Testicular pain)
Thromboembolic Event
(Thromboembolic event)
Thrombotic Thrombocytopenic Purpura
(Thrombotic thrombocytopenic purpura)
Tinnitus (Tinnitus)
Tooth Development Disorder (Tooth
development disorder)
Tooth Discoloration (Tooth discoloration)
Tooth Infection (Tooth infection)
Toothache (Toothache)
Toxic Epidermal Necrolysis (Toxic
epidermal necrolysis)
Tracheal Fistula (Tracheal fistula)
Tracheal Hemorrhage (Tracheal
hemorrhage)
Tracheal Mucositis (Tracheal mucositis)
Tracheal Obstruction (Tracheal
obstruction)
Tracheal Stenosis (Tracheal stenosis)
Tracheitis (Tracheitis)
Tracheostomy Site Bleeding
(Tracheostomy site bleeding)
Transient Ischemic Attacks (Transient
ischemic attacks)
Treatment Related Secondary
Malignancy (Treatment related
secondary malignancy)
Tremor (Tremor)
Tricuspid Valve Disease (Tricuspid valve
disease)
Trigeminal Nerve Disorder (Trigeminal
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nerve disorder)
Trismus (Trismus)
Tumor Lysis Syndrome (Tumor lysis
syndrome)
Tumor Pain (Tumor pain)
Typhlitis (Typhlitis)
Unequal Limb Length (Unequal limb
length)
Unintended Pregnancy (Unintended
pregnancy)
Upper Gastrointestinal Hemorrhage
(Upper gastrointestinal hemorrhage)
Upper Respiratory Infection (Upper
respiratory infection)
Ureteric Anastomotic Leak (Ureteric
anastomotic leak)
Urethral Anastomotic Leak (Urethral
anastomotic leak)
Urethral Infection (Urethral infection)
Urinary Fistula (Urinary fistula)
Urinary Frequency (Urinary frequency)
Urinary Incontinence (Urinary
incontinence)
Urinary Retention (Urinary retention)
Urinary Tract Infection (Urinary tract
infection)
Urinary Tract Obstruction (Urinary tract
obstruction)
Urinary Tract Pain (Urinary tract pain)
Urinary Urgency (Urinary urgency)
Urine Discoloration (Urine discoloration)
Urine Output Decreased (Urine output
decreased)
Urostomy Leak (Urostomy leak)
Urostomy Obstruction (Urostomy
obstruction)
Urostomy Site Bleeding (Urostomy site
bleeding)
Urostomy Stenosis (Urostomy stenosis)
Urticaria (Urticaria)
Uterine Anastomotic Leak (Uterine
anastomotic leak)
Uterine Fistula (Uterine fistula)
Uterine Hemorrhage (Uterine
hemorrhage)
Uterine Infection (Uterine infection)
Uterine Obstruction (Uterine obstruction)
Uterine Pain (Uterine pain)
Uterine Perforation (Uterine perforation)
Uveitis (Uveitis)
Vaginal Anastomotic Leak (Vaginal
anastomotic leak)
Vaginal Discharge (Vaginal discharge)
Vaginal Dryness (Vaginal dryness)
Vaginal Fistula (Vaginal fistula)
Vaginal Hemorrhage (Vaginal
hemorrhage)
Vaginal Infection (Vaginal infection)
Vaginal Inflammation (Vaginal
inflammation)
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Vaginal Obstruction (Vaginal obstruction)
Vaginal Pain (Vaginal pain)
Vaginal Perforation (Vaginal perforation)
Vaginal Stricture (Vaginal stricture)
Vaginismus (Vaginismus)
Vagus Nerve Disorder (Vagus nerve
disorder)
Vas Deferens Anastomotic Leak (Vas
deferens anastomotic leak)
Vascular Access Complication (Vascular
access complication)
Vascular Disorders - Other, Specify
(Vascular disorders - Other, Specify)
Vasculitis (Vasculitis)
Vasovagal Reaction (Vasovagal reaction)
Venous Injury (Venous injury)
Ventricular Arrhythmia (Ventricular
arrhythmia)
Ventricular Fibrillation (Ventricular
fibrillation)
Ventricular Tachycardia (Ventricular
tachycardia)
Vertigo (Vertigo)
Vestibular Disorder (Vestibular disorder)
Virilization (Virilization)
Visceral Arterial Ischemia (Visceral
arterial ischemia)
Vital Capacity Abnormal (Vital capacity
abnormal)
Vitreous Hemorrhage (Vitreous
hemorrhage)
Voice Alteration (Voice alteration)
Vomiting (Vomiting)
Vulval Infection (Vulval infection)
Watering Eyes (Watering eyes)
Weight Gain (Weight gain)
Weight Loss (Weight loss)
Wheezing (Wheezing)
White Blood Cell Decreased (White
blood cell decreased)
Wolff-parkinson-white Syndrome (Wolff-
Parkinson-White syndrome)
Wound Complication (Wound
complication)
Wound Dehiscence (Wound dehiscence)
Wound Infection (Wound infection)
Wrist Fracture (Wrist fracture)
MedDRA System Organ Class (SOC) (Note: For
studies using CTCAE version 3.0, this field is
CTC category. This field is derived from the
selected CTCAE Term.)
Hematopoietic And Lymphoid System
Disorder (Blood and lymphatic system
disorders)
Cardiac Disorders (Cardiac disorders)
Congenital, Familial And Genetic
Disorder Class (Congenital, familial and
genetic disorders)
Ear And Labyrinth Disorder Class (Ear
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and labyrinth disorders)
Endocrine Disorder (Endocrine
disorders)
Eye Disorder (Eye disorders)
Gastrointestinal Disorder
(Gastrointestinal disorders)
General Disorders And Administration
Site Conditions Class (General disorders
and administration site conditions)
Liver And Biliary Tract Disorder
(Hepatobiliary disorders)
Immune System Disorder (Immune
system disorders)
Infection And Infestation (Infections and
infestations)
Injury, Poisoning And Procedural
Complication Class (Injury, poisoning
and procedural complications)
Investigation (Investigations)
Metabolism And Nutrition Disorder Class
(Metabolism and nutrition disorders)
Connective And Soft Tissue Disorder
(Musculoskeletal and connective tissue
disorders)
Neoplasm (Neoplasms benign,
malignant and unspecified (incl cysts and
polyps))
Nervous System Disorder (Nervous
system disorders)
Pregnancy, Puerperium And Perinatal
Condition Class (Pregnancy, puerperium
and perinatal conditions)
Psychiatric Disorder (Psychiatric
disorders)
Urinary Tract Disorder (Renal and
urinary disorders)
Reproductive System And Breast
Disorder Class (Reproductive system
and breast disorders)
Respiratory And Thoracic Disorder
(Respiratory, thoracic and mediastinal
disorders)
Skin Disorder (Skin and subcutaneous
tissue disorders)
Social Circumstances (Social
circumstances)
Intervention Or Procedure (Surgical and
medical procedures)
Vascular Disorder (Vascular disorders)
Symptom Description (Enter a succinct clinical
description of the symptom.)
Grade (Enter the severity of the symptom by
using the protocols specified CTCAE Version. If
the symptom is not explicitly mentioned it should
be coded in the appropriate "other" category and
graded according to the general criteria:)
Mild Adverse Event (1)
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Moderate Adverse Event (2)
Severe Adverse Event (3)
Life Threatening Adverse Event (4)
Death Related To Adverse Event (5)
Related To Disease? (Indicate whether or not the
symptom is related to the study disease by
selecting one of the following options:)
No (No)
Unknown (Unknown)
Yes (Yes)
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Sarcoma NCT01016730 Response - AMC-063
Overall Assessment Form (RK6) - 3028267v1.0
Sarcoma NCT01016730 Response - AMC-063 Overall
Assessment Form (RK6) - 3028267v1.0
All rights reserved. Please visit https://medical-data-
models.org/forms/3176
AMC-063 Overall Assessment Form
(RK6)
Header Module
Visit number
Unnamed1
Best Response (since Entry/Baseline)
Clinical Complete Response (Clinical
complete response)
Complete Response (Complete
response)
Partial Response (Partial response)
Progressive Disease (Progressive
disease)
Stable Disease (Stable disease)
Unevaluable (Unevaluable)
Unknown (Unknown)
What is the present status of the best response
No Relapse Observed, But Patent Died
(No relapse observed, but patent died)
Not Applicable (Not applicable)
Relapse Occurred After A Response
Was Achieved (Relapse occurred after a
response was achieved)
Response Continuing Or First Time At
This Response (Response continuing or
first time at this response)
Date of Relapse or Progression (if applicable
mm/dd/yyyy)
Unnamed2
Is complete response observed (During this
reporting period)
No (No)
Yes (Yes)
Complete Response Observed Date
(mm/dd/yyyy)
Is Clinical Complete Response observed (During
this reporting period)
No (NO)
Yes (YES)
Clinical Complete Response observed date
(mm/dd/yyyy)
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Is partial response observed (During this
reporting period)
No (No)
Yes (Yes)
Partial Response Observed Date (mm/dd/yyyy)
Is progression observed (During this reporting
period)
No (No)
Yes (Yes)
Progressive Disease Observed Date
(mm/dd/yyyy)
Accelerated Disease
Acceleration in disease progression
No (No)
Yes (Yes)
Is accelerated progression confirmed (by the
investigator)
No (No)
Yes (Yes)
Footer Module
Comments
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Sarcoma NCT01016730 Lab - AMC-063
HIV Viral Load Form (F40) - 3028240v1.0
Sarcoma NCT01016730 Lab - AMC-063 HIV Viral Load
Form (F40) - 3028240v1.0
All rights reserved. Please visit https://medical-data-
models.org/forms/3179
AMC-063 HIV Viral Load Form (F40)
Unnamed1
Visit number
Specimen Information
Date Specimen Obtained (mm/dd/yyyy)
Was the viral load specimen sent to the Central
Laboratory (Subjects with HIV-1 viral loads <50
copies or "undetectable" by clinical laboratories
must have their specimens sent to Dr. Frank
Maldarelli at the NIH for single-copy viral load
testing to increase the sensitivity for detecting
HIV viral load changes see Appendix XI)
No (no)
Yes (yes)
Unnamed2
Results of HIV viral load assay  (Enter results
from right to left.)
Equal To (Equal to (=))
Greater Than (>) (Greater than (>))
Less Than (Less than (<))
Undetectable (Undetectable)
HIV viral load value
Method of detection
Abbott Realtime Hiv-1 Assay (Abbott
RealTime HIV-1 assay)
Cobas Ampliprep/taqman Hiv-1 Assay
(COBAS AmpliPrep/TAQMAN HIV-1
assay)
Other (Other)
Roche Amplicor Monitor Assay (Roche
Amplicor Monitor Assay)
Versant Hiv-1 Rna Assay By Branched
Dna (Versant HIV-1 RNA assay by
branched DNA)
Other, specify
HIV viral load assay type
Standard (Standard)
Ultra (Ultra)
Limits of detection (Copies/mL)
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Lab Facility Name (Testing Laboratory
information)
Comments
Comments
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Sarcoma NCT01016730 Off Treatment - AMC-063
Off-Study Summary Form (F50) - 3020233v1.0
Sarcoma NCT01016730 Off Treatment - AMC-063 Off-
Study Summary Form (F50) - 3020233v1.0
All rights reserved. Please visit https://medical-data-
models.org/forms/3184
AMC-063 Off-Study Summary Form
(F50)
Ccrr Module For Off Study Summary -
Rf50
Off Study Date (mm/dd/yyyy)
Off Study Reason (select the primary reason)
Adverse Event/side Effects/complications
(Adverse Event/Side
Effects/Complications)
Death (Death)
Other (Other)
Lost To Follow-up (Patient lost to follow-
up)
Patient Refused Follow-up (Patient
refused follow-up)
Protocol-defined Follow-up Completed
(Protocol-defined follow-up completed)
Other, specify
Comments
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Transplant Essential Data - 3160255v1.0
Treatment - 2455 Revision 2 - Selective Post-Transplant
Essential Data - 3160255v1.0
All rights reserved. Please visit https://medical-data-
models.org/forms/3196
2455 Revision 2 - Selective Post-
Transplant Essential Data
Registry Use Only
Sequence number:
Date received:
Center Identification
CIBMTR Center Number:
EBMT Code (CIC) Number
Date of this report:
Follow-Up:
Integer::6 Month (6 Months)
Annual (Annual)
Integer::100 Day (Day 100)
annual, specify year:
Recipient Identification
CIBMTR Recipient ID:
Chronological number of this: HSCT:
Chronological number of this:  DCI:
Date of HSCT for this follow - up:
Did the recipient receive a subsequent HSCT
since the date of contact from the last report?
No (No)
Yes (Yes)
Date of subsequent HSCT:
New Malignancy, Lymphoproliferative Or
Myeloproliferative Disorder
Did a new malignancy, lymphoproliferative or
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myeloproliferative disorder appear that is different
from the disease for which the HSCT was
performed?
No (No)
Yes (Yes)
For all new malignancies except for "other skin
malignancy (basal cell, squamous)," was testing
performed to determine the cell of origin?
No (No)
Other Skin Malignant Neoplasm (The
only new malignancy in this reporting
period was "other skin malignancy(basal
cell, squamous)")
Yes (Yes)
Specify the cell origin of the new malignancy:
Donor (Donor)
Origin Unknown (Origin unknown)
Hematopoietic Stem Cell Graft Recipient
(Recipient)
Is a copy of the lab report attached? (Is a copy of
the cell origin evaluation VNTR, cytogenetics,
FISH attached?)
No (No)
Yes (Yes)
New Malignancy, Lymphoproliferative Or
Myeloproliferative Disorder
Specify which new disease(s) occurred:
Acute Myeloid Leukemia (Acute myeloid
leukemia (AML / ANLL))
Breast Carcinoma (Breast cancer)
Central Nervous System Neoplasm
(Central nervous system (CNS)
malignancy (glioblastoma, astrocytoma))
Malignant Gastrointestinal Neoplasm
(Gastrointestinal malignancy (colon,
rectum, stomach, pancreas, intestine))
Genitourinary System Malignant
Neoplasm (Genitourinary malignancy
(kidney, bladder, ovary, testicle, genitalia,
uterus, cervix))
Hodgkin's Lymphoma (Hodgkin disease)
Lung Carcinoma (Lung cancer)
Lymphoma Or Lymphoproliferative
Disorder (Lymphoma or
lymphoproliferative disease)
Melanoma (Melanoma)
Myelodysplastic/myeloproliferative
Disease (Myelodysplasia (MDS),
myeloproliferative (MPS) disorder)
Oropharyngeal Carcinoma
(Oropharyngeal cancer (tongue, buccal
mucosa))
Other Leukemia (Other leukemia
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including ALL)
Other Malignant Neoplasm (Other
malignancy)
Other Malignant Skin Neoplasm (Other
skin malignancy (basal cell, squamous))
Clonality Cytogenetic Abnormality
(Related by descent from clonal
cytogenetic abnormality without leukemia
or MDS)
Sarcoma (Sarcoma)
Thyroid Gland Carcinoma (Thyroid
cancer)
Did a new malignancy, lymphoproliferative or
myeloproliferative disorder appear that is different
from the disease for which the HSCT was
performed?
No (No)
Yes (Yes)
Date of diagnosis:
Is the tumor EBV positive? (Answer only if the
response to CDE 2677021 is "Lymphoma or
lymphoproliferative disease.")
No (No)
Unknown (Unknown)
Yes (Yes)
Specify the new malignancy, lymphoproliferative
or myeloproliferative disorder: (Answer only if the
response to CDE 2677021 is "Other leukemia,
including ALL," "Other skin malignancy basal cell,
squamous," or "Other new malignancy.")
New Malignancy, Lymphoproliferative Or
Myeloproliferative Disorder ¿ Part 3 Of 3
Is a copy of the pathology report attached? (Is a
pathology / autopsy report or other
documentation attached?)
No (No)
Yes (Yes)
Survival
Survival status at latest follow-up:
Life (Alive)
Death (Dead)
Latest follow-up: (Last contact date:)
If necessary, please validate the last contact date
response
Date Estimate (Date estimated)
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Date of death:
If necessary, please validate the death date
response
Date Estimate (Date estimated)
Main cause of death: (Check only one)
And/or Persistent Recurrent Disease
Disease Progression (Disease
progression and/or persistent relapse)
Transplantation Relationship
Hematopoietic Stem Cell (HSCT related
causes)
New Malignant Neoplasm (New
malignancy)
Other (Other)
Unknown (Unknown)
Main cause of death: Other,specify (Specify other
main cause of death:)
Survival
What are the HSCT related main cause(s) of
death? (Check as many as appropriate)
Cardiotoxicity (Cardiac toxicity)
Graft Versus Host Disease (GVHD)
Infection (Infection)
Other (Other)
Toxicity Pulmonary (Pulmonary toxicity)
Graft Rejection (Rejection / poor graft
function)
Hepatic Veno-occlusive Disease (VOD)
Did a particular HSCT-related main cause of
death occur?
No (No)
Yes (Yes)
Specify the other HSCT related main cause(s) of
death: (Answer only if the response to CDE
2768637 is "Other.")
Author Information
First Name
Last Name
Telephone number:
Fax number:
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E-mail address:
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Nonneoplastic Condition NCT01057121 Pathology - AMC-070 AIDS and
Cancer Specimen Resource (ACSR) Procurement Form (F37) - 3145922v1.0
Nonneoplastic Condition NCT01057121 Pathology - AMC-
070 AIDS and Cancer Specimen Resource (ACSR)
Procurement Form (F37) - 3145922v1.0
All rights reserved. Please visit https://medical-data-
models.org/forms/3198
AMC-070 AIDS and Cancer
Specimen Resource (ACSR)
Procurement Form (F37)
Unnamed1
Visit number
Unnamed2
Specimen(s) obtained for donation to ACSR
No (No)
Yes (Yes)
Specimen Type (check all that apply)
Peripheral Blood (Blood)
Other (Other)
Pbmc (peripheral Blood Mononuclear
Cells) (PBMC)
Plasma (Plasma)
Serum (Serum)
Tissue (Tissue)
Other specify
ACSR site the specimen(s) shipped to
Gwu (GWU)
Jhu (JHU)
Osu (OSU)
Other (Other)
Suny/hscb (SUNY/HSCB)
Ucla (UCLA)
Ucsf (UCSF)
Other, specify
If specimens were not obtained for ACSR, please
indicate reason
Other (Other)
Patient Had Previously Donated
Specimen To Acsr (Patient had
previously donated specimen to ACSR)
Patient Refused To Give Informed
Consent For Acsr Specimen Donation
(Patient refused to give informed consent
for ACSR specimen donation)
Patient Was Not Asked To Consider Acsr
Specimen Donation (Patient was not
asked to consider ACSR specimen
donation)
Other, specify
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Date Specimen Obtained (mm/dd/yyyy)
Date Specimen Obtained (mm/dd/yyyy)
Study Coordinator
Study Coordinator's name
E-mail
Phone Number (xxx-xxx-xxxx)
Comments
Comments
2 / 2
Nonneoplastic Condition NCT01057121 Pathology - AMC-070 AIDS and
Cancer Specimen Resource (ACSR) Procurement Form (F37) - 3145922v1.0
Toxicity - OFF TREATMENT - 2453800v1.0
Toxicity - OFF TREATMENT - 2453800v1.0
All rights reserved. Please visit https://medical-data-
models.org/forms/3225
OFF TREATMENT
Off Treatment
Treatment Phase End Date
Reason off study
Patient Noncompliance (2)
Withdrawal Of Informed Consent (3)
Alternative Medicine (A)
Disease Progression Before Treatment
(B)
Study Complete (C)
Death (D)
Late Adverse Events/side Effects (E)
Cytogenetic Resistance (G)
Follow-up Period Completed (H)
Ineligible (I)
Lost To Follow-up (L)
Death During Follow-up Period (M)
Not Treated (N)
Other (O)
Disease Progression (P)
Refused Further Treatment (R)
Complicating Disease (S)
Toxicity (T)
Not Treated - Other Reasons (U)
Protocol Violation (V)
Refused Further Follow-up (W)
Declined To Participate (X)
No Treatment, Per Protocol Criteria (Z)
Off Study Followup Date
Off Study Other Reason
Off Study Other Reason
Response Assessment Type
Complete Response (CR)
Complete Response Unconfirmed (CRU)
Disease Unchanged (DU)
Less Than Partial Response (MR)
Not Assessed (NA)
Not Evauable (NE)
Not Applicable Per Protocol (NP)
No Response (NR)
Progressive Disease (PD)
Partial Response (PR)
Stable Disease (SD)
Too Early (TE)
Unknown (UK)
Best Response Date
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Administration Missed - 3280662v1.0
Treatment - Study Medication Administration Missed -
3280662v1.0
All rights reserved. Please visit https://medical-data-
models.org/forms/3226
Study Medication Administration
Missed
Study Medication Administration
Visit Date
Day in Course (Cycle)
Start Date of Missed Dose (Enter the start date
the medication was not administered.)
Stop Date of Missed Dose (Enter the stop date
the medication was not administered.)
Medication (Select the name of the missed
medication.)
Total Missed Dose Amount (Enter the actual
amount of medication missed for the date entered
above.)
UOM (Select the Missed Dose Amount unit of
measurement.)
Percent (%)
10e10 Cells (10E10 Cells)
10e3 Cells (10E3 Cells)
10e4 Cells Per Kilogram (10E4 Cell/kg)
10e4 Cells (10E4 Cells)
10e5 Cells Per Kilogram (10E5 Cell/kg)
10e5 Cells (10E5 Cells)
10e6 Cells Per Kilogram (10E6 Cell/kg)
10e6 Cells (10E6 Cells)
10e7 Cells Per Kilogram (10E7 Cell/kg)
10e7 Cells (10E7 Cells)
10e7 Plaque Forming Units (10E7 PFU)
10e8 Cells (10E8 Cells)
10e8 Plaque Forming Units (10E8 PFU)
10e9 Cells (10E9 Cells)
10e9 Plaque Forming Units (10E9 PFU)
Ampule (Ampule)
Application (Applcatn)
Atomic Unit (au)
Area Under The Curve (AUC)
Billion Pfu (bill PFU)
Bottle (Bottle)
Breaths Per Minute (BPM)
Capful (Capful)
Caplet (Caplet)
Capsule (Capsule)
Cells (Cells)
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Cells Per Kilogram (Cells/kg)
Centigray (cGy)
Curie (Ci)
Course (Course)
Cycle (Course)
Deciliter (dL)
Dose (Dose)
Equivalent (Eq)
Grams (g) (g)
Gram Per M2 (g/m2)
Gallon (Gallon)
Drops (gtts)
Gray (Gy)
Hertz (Hz)
Inch (Inch)
Inhalation (Inhalatn)
Iu Vitamin A (IU Vit A)
International Unit Per Milligram (IU/mg)
International Units Or Milligram Alpha
Tocopherol (IU/mg A-TE)
International Unit (IUnit)
International Unit Per Kilogram (IUnit/kg)
International Unit Per Liter (IUnit/L)
Intravenous Bag (IV Bag)
Infectious Viral Replicon Particles (IVRP)
Joules Per Centimeter Squared (Jcm2)
Kib-electron Volt (KeV)
Kilograms (kg)
Kilohertz (kHz)
Kilopascal (kPa)
Kilounit (kU)
Kilounit Per Kilogram (kU/kg)
Kilounit Per Liter (kU/L)
Liter (L)
Liters Per Minute (L/min)
Millibecquerel (mBq)
Megabecquerel (MBq)
Microgram (mcg)
Microgram Per Centimeter Squared
(mcg/cm2)
Microgram Per Hour (mcg/hr)
Microgram Per Kilogram (mcg/kg)
Microgram Per Meter Squared (mcg/m2)
Millicurie (mCi)
Measure (Measure)
Milliequivalent (mEq)
Milliequivalents Per 24 Hours (mEq/24hr)
Milliequivalent Per Deciliter (mEq/dL)
Milliequivalent Per Hour (mEq/hr)
Milliequivalent Per Liter (mEq/L)
Million Electron Volt (MeV)
Milligram (mg)
Milligram Per 24 Hours (mg/24hr)
Milligram Per Deciliter (mg/dL)
Milligram Per Hour (mg/hr)
Milligram Per Inhalation (mg/inh)
Milligram Per Kilogram (mg/kg)
Milligram Per Kilogram Per Day
(mg/kg/day)
Milligram Per Meter Squared (mg/m2)
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Milligram Per Milliliter (mg/mL)
Milligram Per Week (mg/wk)
Megahertz (MHz)
Microcurie (microCi)
Microliter (microL)
Micromole (micromol)
Million Plaque Forming Units (mill PFU)
Million (Million)
Milliunit (millunit)
Milliinternational Unit (miu)
Milliinternational Units Per Meter
Squared (miu/m2)
Milliliter (mL)
Cubic Centimeter (cc) (mL)
Milliliter Per Hour (mL/hr)
Milliliter Per Kilogram (mL/kg)
Millimoles Per Liter (mM/L)
Millimole (mmol)
Mole (Mole)
Milliosmole (mosmol)
Megarad (Mrad)
Million Units (MU)
Millivolt (mV)
Million Viral Particles (MVP)
Nanocurie (nCi)
Nanogram (ng)
Nanogram Per Kilogram (ng/kg)
Nanogram Per Liter (ng/L)
Nanograms Per Milliliter (ng/mL)
Nanometer Of Light (nm light)
Nanomole (nmol)
No Source Data (No Srce)
Osmolality (osmol)
Ounce (oz)
Pascal (Pa)
Packet (packet)
Patch (Patch)
Plaque Forming Units (PFU)
Picograms (pg)
Pounds Per Square Inch (psi)
Puff (puff)
Radiation Absorbed Dose (Rad)
Vitamin A Retinol (RAE)
Retinol Equivalents (RE)
Seed (Seed)
Session (Session)
Spray (Spray)
Suppository (Suppstry)
Tablets (Tablet)
Tablespoon (Tbsp)
Tissue Culture Infection Dose (TCID)
Thousand (Thousand)
Troche (Troche)
Teaspoon (tsp)
Unit (Unit)
Unit Per Gram (Unit/g)
Unit Per Kilogram (Unit/kg)
Unit Per Meter Squared (Unit/m2)
Unit Per Milliliter (Unit/mL)
Unknown (Unknown)
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Viral Particles (VP)
Yeast Units (YU)
Reason for Missed Dose (Select the reason the
medication was missed.)
Adverse Event (AE)
Medication Error (Medication Error)
Specify (Other, Specify)
Patient Compliance (Patient Compliance)
Serious Adverse Event (SAE)
Subject Error Resulting In A Missed
Dose (Subject error)
Toxicity (Toxicity)
Explain 'Other' Reason Missed (Enter an
explanation for selecting Other for Reason for
Missed Dose)
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Prior Surgery Supplement
Prior Surgery Supplement
Visit Date (Enter the date the form was
completed. -  - Note: If the information was
obtained at multiple visits, please enter the date
the form was completed.)
Date of Surgery (Enter the date of the surgical
procedure. Partial dates are acceptable when the
day is not known.)
Procedure (Enter the type of procedure
performed to diagnose / to treat the patient's
disease.)
Site (Select the anatomical site of the procedure.)
Abdomen (Abdomen)
Abdomen/pelvis (Abdomen/Pelvis)
Abdominal Wall (Abdominal wall)
Acetabulum (Acetabulum)
Pharyngeal Tonsil (Adenoid)
Adipose Tissue (Adipose)
Adrenal Gland (Adrenal gland)
Alveolar Ridge (Alveolar Ridge)
Amniotic Fluid (Amniotic Fluid)
Ampulla Of Vater (Ampulla of Vater)
Anal Canal (Anal canal)
Anal Sphincter (Anal sphincter)
Ankle (Ankle)
Anorectum (Anorectum)
Antecubital Fossa (Antecubital fossa)
Antrum Pylori (Antrum)
Anus (Anus)
Aorta (Aorta)
Aortic Body (Aortic Body)
Appendix (Appendix)
Aqueous Fluid (Aqueous Fluid)
Arm (Arm)
Artery (Artery)
Ascending Colon (Ascending colon)
Ascending Colon Hepatic Flexure
(Ascending Colon Hepatic Flexure)
Auditory Canal (Auditory canal)
Autonomic Nervous System (Autonomic
nervous system)
Axilla (Axilla)
Back (Back)
Bile Duct (Bile duct)
Bladder (Bladder)
Blood (Blood)
Blood Vessel (Blood vessel)
Bone (Bone)
Bone Marrow (Bone marrow)
Bowel (Bowel)
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Brain (Brain)
Brain Stem (Brain stem)
Breast (Breast)
Broad Ligament (Broad ligament)
Bronchiole (Bronchiole)
Bronchus (Bronchus)
Bronchus And Lung (Bronchus and
Lung)
Brow (Brow)
Buccal Cavity (Buccal cavity)
Buccal Mucosa (Buccal mucosa)
Buttock (Buttock)
Calf (Calf)
Capillary (Capillary)
Gastric Cardia (Cardia)
Carina (Carina)
Carotid Artery (Carotid artery)
Carotid Body (Carotid body)
Cartilage (Cartilage)
Cecum (Cecum)
Central Line Catheter (Central Line
Catheter)
Central Nervous System (Central
nervous system)
Cerebellum (Cerebellum)
Cerebral Cortex (Cerebral cortex)
Cerebrospinal Fluid (Cerebrospinal fluid)
Cerebrum (Cerebrum)
Cervical Spine (Cervical spine)
Cervical/thoracic/lumbar Spine
(Cervical/Thoracic/Lumbar spine)
Cervix (Cervix)
Chest (Chest)
Chest Wall (Chest wall)
Chest/abdomen/pelvis
(Chest/Abdomen/Pelvis)
Chest/pelvis (Chest/Pelvis)
Chin (Chin)
Clavicle (Clavicle)
Clitoris (Clitoris)
Colon (Colon)
Colon And Rectum (Colon and rectum)
Colon Mucosa (Colon, mucosa only)
Common Duct (Common duct)
Conjunctiva (Conjunctiva)
Connective Tissue (Connective tissue)
Descending Colon (Descending colon)
Diaphragm (Diaphragm)
Duodenum (Duodenum)
Ear (Ear)
Ear Canal (Ear canal)
External Ear (Ear, Pinna (External))
Effusion (Effusion)
Elbow (Elbow)
Endocrine Gland (Endocrine gland)
Epididymis (Epididymis)
Epidural Spinal Canal Space (Epidural
space)
Esophagogastric Junction
(Esophagogastric junction)
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Esophagus (Esophagus)
Esophageal Mucosa (Esophagus,
Mucosa only)
Extremities (Extremities)
Eye (Eye)
Fallopian Tube (Fallopian tube)
Femur (Femur)
Fibula (Fibula)
Finger (Finger)
Floor Of Mouth (Floor of Mouth)
Body Fluid Or Substance (Fluid)
Foot (Foot)
Forearm (Forearm)
Forehead (Forehead)
Foreskin (Foreskin)
Frontal Lobe (Frontal lobe)
Fundus Of Stomach (Fundus of
stomach)
Gallbladder (Gallbladder)
Ganglion (Ganglia)
Gastroesophageal Junction
(Gastroesophageal Junction)
Gastrointestinal Tract (Gastrointestinal
tract)
Genitourinary (Genitourinary)
Groin (Groin)
Gum (Gum)
Hand (Hand)
Hard Palate (Hard palate)
Head - Face Or Neck, Nos (Head - face
or neck, NOS)
Head/neck (Head/Neck)
Head/neck/chest/adb/pelvis
(Head/Neck/Chest/Adb/Pelvis)
Heart (Heart)
Hepatic Duct (Hepatic duct)
Hip (Hip)
Humerus (Humerus)
Hypopharynx (Hypopharynx)
Ileum (Ileum)
Ilium (Ilium)
Intestine (Intestine)
Ischium (Ischium)
Jaw (Jaw)
Jejunum (Jejunum)
Joints (Joints)
Kidney (Kidney)
Knee (Knee)
Lacrimal Gland (Lacrimal Gland)
Large Bowel (Large bowel)
Laryngopharynx (Laryngopharynx)
Larynx (Larynx)
Leg (Leg)
Ligament (Ligament)
Lip (Lip)
Liver (Liver)
Liver And Intrahepatic Duct (Liver and
intrahepatic duct)
Liver/spleen (Liver/Spleen)
Lumbar Spine (Lumbar spine)
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Lung (Lung)
Lymph Node (Lymph node)
Lymph Node(s) Axilla (Lymph Node(s)
Axilla)
Lymph Node(s) Cervical (Lymph Node(s)
Cervical)
Distant Lymph Node (Lymph node(s)
Distant)
Lymph Node(s) Hilar (Lymph Node(s)
Hilar)
Lymph Node(s) Inguinal (Lymph Node(s)
Inguinal)
Lymph Node(s) Int Mammary (Lymph
Node(s) Int Mammary)
Lymph Node(s) Mammary (Lymph
Node(s) Mammary)
Paraaortic Region Lymph Node (Lymph
node(s) Para aortic)
Lymph Node(s) Pelvic (Lymph Node(s)
Pelvic)
Regional Lymph Node (Lymph node(s)
Regional)
Scalene Lymph Node (Lymph node(s)
Scalene)
Lymph Node(s) Subclavicular (Lymph
Node(s) Subclavicular)
Lymph Node(s) Supraclav (Lymph
Node(s) Supraclav)
Lymph Nodes (Lymph nodes)
Mediastinal Lymph Node (Lymph
nodes(s) Mediastinal)
Lymphoma (Lymphoma)
Mammary Gland (Mammary Gland)
Mandible (Mandible)
Maxilla (Maxilla)
Mediastinum (Mediastinum)
Mesentery (Mesentery)
Mesothelium (Mesothelium)
Mini Mantle (Mini Mantle)
Mouth (Mouth)
Muscle (Muscle)
Nail (Nails)
Nasal Cavity (Nasal Cavity)
Nasopharynx (Nasopharynx)
Neck (Neck)
Neck Chest (Neck/Chest)
Neck/chest/abdomen/pelvis
(Neck/Chest/Abdomen/Pelvis)
Nerve (Nerve)
Cranial Nerve (Nerve(s) Cranial)
Not Applicable (Not Applicable)
Ocular Orbits (Ocular Orbits)
Omentum (Omentum)
Oral Cavity (Oral cavity)
Oral Cavity Mucosa (Oral Cavity, Mucosa
only)
Oropharynx (Oropharynx)
Other (Other)
Ovary (Ovary)
Posterior Anterior/lateral (PA/Lat)
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Palate (Palate)
Pancreas (Pancreas)
Paraspinal Ganglion (Paraspinal
Ganglion)
Parathyroid Gland (Parathyroid)
Parotid Gland (Parotid gland)
Patella (Patella)
Pelvis (Pelvis)
Penis (Penis)
Perianus (Perianus)
Pericardium (Pericardium)
Peritoneal Cavity (Peritoneal cavity)
Peritoneum (Peritoneum)
Pharynx (Pharynx)
Pineal Gland (Pineal Gland)
Pituitary Gland (Pituitary gland)
Placenta (Placenta)
Pleura (Pleura)
Popliteal Fossa (Popliteal fossa)
Prostate (Prostate)
Pylorus (Pylorus)
Rectosigmoid Junction (Rectosigmoid
Junction)
Rectum (Rectum)
Retina (Retina)
Retro-orbital Area (Retro-orbital Area)
Retroperitoneum (Retroperitoneum)
Ribs (Ribs)
Round Ligament (Round ligament)
Sacrum (Sacrum)
Salivary Gland (Salivary gland)
Scalp (Scalp)
Scapula (Scapula)
Scrotum (Scrotum)
Shoulder Joint (Shoulder)
Sigmoid Colon (Sigmoid colon)
Sinus(es) (Sinus(es))
Sinus(es), Maxillary (Sinus(es),
Maxillary)
Skeletal Muscle Tissue (Skeletal Muscle)
Skin (Skin)
Skull (Skull)
Small Bowel Mucosa (Small Bowel,
Mucosa only)
Small Intestine (Small intestine)
Soft Tissue (Soft Tissue)
Spinal Cord (Spinal Cord)
Spine (Spine)
Spine/femur (Spine/Femur)
Spine/femur/radius
(Spine/Femur/Radius)
Spleen (Spleen)
Splenic Flexure (Splenic Flexure)
Sternum (Sternum)
Stomach (Stomach)
Stomach Mucosa (Stomach, Mucosa
only)
Subcutaneous Tissue (Subcutaneous
tissue)
Synovial Membrane (Synovium)
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Tendon (Tendon)
Testis (Testicle)
Testicle (Testicle)
Thigh (Thigh)
Thoracic Spine (Thoracic spine)
Thoracic/lumbar Spine (Thoracic/Lumbar
spine)
Thorax (Thorax)
Throat (Throat)
Thymus (Thymus)
Thyroid Gland (Thyroid gland)
Tibia (Tibia)
Tongue (Tongue)
Tongue, Base Of Tongue (Tongue, Base
of tongue)
Tonsil (Tonsil)
Pharyngeal Tonsil (Tonsil, Pharyngeal)
Trachea (Trachea)
Trachea Main Bronchus (Trachea/Major
Bronchi)
Transverse Colon (Transverse Colon)
Trunk (Trunk)
Superficial Trunk (Trunk, Superficial)
Umbilical Cord (Umbilical Cord)
Upper Extremity (Upper extremity)
Ureter (Ureter)
Urethra (Urethra)
Urinary Tract (Urinary tract)
Uterus (Uterus)
Uvula (Uvula)
Vagina (Vagina)
Vas Deferens (Vas Deferens)
Vein (Vein)
Vena Cava (Vena Cava,
Inferior/Superior)
Vertebra (Vertebra)
Vertebral Column (Vertebral column)
Vulva (Vulva)
Whole Body (Whole body)
Wrist (Wrist)
Findings (Briefly describe the findings of the
procedure.)
Residual Disease Description (Briefly describe
the extent of the residual disease, if any, at the
conclusion of the operation. i.e.: microscopic,
macroscopic.)
Therapeutic? (Select if the surgical procedure
was performed with curative intent:)
No (N)
Yes (Y)
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Treatment - 2006 - Hematopoietic Stem Cell Transplant
(HSCT) Infusion - 2798767v1.0
All rights reserved. Please visit https://medical-data-
models.org/forms/3245
2006 - Hematopoietic Stem Cell
Transplant (HSCT) Infusion
Registry Use Only
Sequence number:
Date received:
Identification Data
CIBMTR Center Number:
CIBMTR Recipient ID:
Donor ID:
NMDP Cord Blood Unit ID:
Non-NMDP Cord Blood Unit :
No (No)
Yes (Yes)
Today's date:
Date of Hematopoietic Stem Cell Transplantation
(HSCT) for which this form is being completed:
Hsct Type
What source was used for the hematopoietic
stem cell transplantation?
Related Allogenic (Allogeneic, related)
Unrelated Allogenic (Allogeneic,
unrelated)
Autologous (Autologous)
Syngeneic (Syngeneic (identical twin))
Was a particular hematopoietic stem cell source
used?
No (No)
Yes (Yes)
Product Type
What type of hematopoietic stem cell transplant
was used?
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Umbilical Cord Blood (Cord blood)
Bone Marrow (Marrow)
Multiple Umbilical Cord Blood (Multiple
cord blood units infused)
Other (Other)
Peripheral Blood Stem Cell (PBSC)
Was a particular hematopoietic stem cell
transplant type used?
No (No)
Yes (Yes)
Specify the other hematopoietic stem cell
transplant type: (Answer only if the value for
2730912 is "Other". )
Pre-collection Therapy
Did the donor receive treatment, prior to any stem
cell harvest, to enhance the product collection for
this HSCT?
Umbilical Cord Blood Unit (Cord blood
unit)
National Marrow Donor Program Donor
(NMDP donor)
No (No)
Yes (Yes)
Chemotherapy (autologous only)
No (No)
Yes (Yes)
Anti-CD20(rituximab,Rituxan) (autologous only)
No (No)
Yes (Yes)
Growth factor(s)
No (No)
Yes (Yes)
G-CSF
No (No)
Yes (Yes)
GM-CSF
No (No)
Yes (Yes)
Other growth factor(s)
No (No)
Yes (Yes)
Specify (Answer only if the value for 2772114 is
"Yes")
Other treatment
No (No)
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Yes (Yes)
Specify treatment: (Answer only if the value for
2773751 is "Yes")
Product Collection
Date of product collection:
Was more than one collection required for this
HSCT?
No (No)
Yes (Yes)
Specify the number of subsequent days of
collection in this episode: (Complete a separate
product form for each subsequent collection that
was not part of this mobilization.)
Were anticoagulants added to the product during
collection?
No (No)
Yes (Yes)
Product Collection
What anticoagulants were added to the product
during collection?
Acid-citrate-dextrose (Acid-Citrate-
Dextrose (ACD))
Citrate Phosphate Dextrose (Citrate
Phosphate Dextrose (CPD))
Heparin (Heparin)
Other (Other)
Were particular anticoagulants added to the
product during collection?
No (No)
Yes (Yes)
Specify the other anticoagulants (Answer only if
the value for 2741578 is "Other")
Product Transport And Receipt
Was this product collected off-site and shipped to
your facility?
No (No)
Yes (Yes)
Date of receipt of product at your facility:
Time of receipt of product: (24-hour clock)
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Is time of receipt of product standard time or
daylight savings time?
Daylight Savings Time (Daylight Savings
Time)
Standard Time (Standard time)
Specify the shipping environment of the
product(s):
Freezing Umbilical Cord Blood Storage
Unit (Frozen Cord Blood Unit (s))
Freezing Gel Pack (Frozen Gel Pack)
Other Temperature (Other Temperature)
Ambient Temperature (Room
Temperature per Transplant Center
Request)
Specify shipping environment:
Were the secondary containers (e.g., insulated
shipping containers and unit cassette) intact
when they arrived at your center? (Cord blood
product only)
No (No)
Yes (Yes)
Was the cord blood unit completely frozen when it
arrived at your center? (Cord blood product only)
No (No)
Yes (Yes)
Was the cord blood unit stored at your center
prior to thawing? (Cord blood product only)
No (No)
Yes (Yes)
Specify the storage method used for the cord
blood unit:
Electricity Freezing (Electric Freezer)
Liquid Nitrogen (Liquid Nitrogen)
Vapor Phase Cooling (Vapor Phase)
Temperature during storage:
Date storage started:
Product Processing / Manipulation
Was a fresh product received, then
cryopreserved at your facility prior to infusion?
No (No)
Not Applicable (Not Applicable)
Yes (Yes)
Was the product thawed from a cryopreserved
state prior to infusion?
No (No)
Yes (Yes)
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Was the entire product thawed?
No (No)
Yes (Yes)
Was a compartment of the bag thawed?
No (No)
Yes (Yes)
Were there multiple product bags?
No (No)
Yes (Yes)
Specify number of bags thawed:
Date thawing process initiated:
Time at initiation of thaw: (24-hour clock)
Is the thawing begin time standard time or
daylight savings time?
Daylight Savings Time (Daylight Savings
Time)
Standard Time (Standard time)
Time at completion of thaw : (24-hour clock)
Is the thawing begin time standard time or
daylight savings time?
Daylight Savings Time (Daylight Savings
Time)
Standard Time (Standard time)
Was the primary container (e.g.,cord blood unit
bag) intact upon thawing?
No (No)
Yes (Yes)
What method was used to thaw the product?
Dimethyl Sulfoxide Dilute (DMSO dilution
- thawed in lab (added dextran and
albumin), then infused)
No Cell Wash (no wash - thawed at
bedside,then infused)
Other Method (other method)
Cell Wash (washed - thawed in lab
(added dextran and albumin),spun and
reconstituted in dextran albumin,then
infused)
Specify other thaw method: (Answer only if the
value for 2789998 is "Other method")
Did any adverse events or incidents occur while
thawing the product?
No (No)
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Yes (Yes)
Product Processing / Manipulation - Part 2
Was the product manipulated prior to infusion?
No (No)
Yes (Yes)
Specify portion manipulated:
Entire Hematopoietic Stem Cell
Collection (Entire product)
Part Hematopoietic Stem Cell Collection
(Portion of product)
ABO incompatibility (RBC depletion)
No (No)
Yes (Yes)
Buffy coat preparation
No (No)
Yes (Yes)
Cell separator (i.e., COBE Spectra)
No (No)
Yes (Yes)
Density gradient separation (i.e., Ficoll)
No (No)
Yes (Yes)
Plasma removal
No (No)
Yes (Yes)
Sedimentation (i.e., hetastarch)
No (No)
Yes (Yes)
Other
No (No)
Yes (Yes)
Specify: (Answer only if the value for 2774524 is
"Yes" )
Ex-vivo expansion
No (No)
Yes (Yes)
Genetic manipulation (gene transfer /
transduction)
No (No)
Yes (Yes)
Volume reduction
No (No)
Yes (Yes)
CD34+ selection
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No (No)
Yes (Yes)
Specify cell selection system used:
Clinimax Cell Selection System
(CliniMACS / CliniMax)
Isolex Cell Selection System (Isolex)
Other (Other)
Specify system: (Answer only if the value for
2786700 is "Other" )
T-cell depletion
No (No)
Yes (Yes)
antibody affinity column
No (No)
Yes (Yes)
antibody coated plates
No (No)
Yes (Yes)
antibody coated plates and soybean lectin
No (No)
Yes (Yes)
antibody and complement
No (No)
Yes (Yes)
antibody and toxin
No (No)
Yes (Yes)
immunomagnetic beads
No (No)
Yes (Yes)
elutriation
No (No)
Yes (Yes)
CD34 affinity column plus sheep red blood cell
rosetting
No (No)
Yes (Yes)
Other (Other T-cell depletion)
No (No)
Yes (Yes)
Specify: (Answer only if the value for 2774740 is
"Yes" )
Other manipulation
No (No)
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Yes (Yes)
Specify: (Answer only if the value for 2744934 is
"Yes" )
Were antibodies used during product
manipulation?
No (No)
Yes (Yes)
anti CD2
No (No)
Yes (Yes)
anti CD3
No (No)
Yes (Yes)
anti CD4
No (No)
Yes (Yes)
anti CD5
No (No)
Yes (Yes)
anti CD6
No (No)
Yes (Yes)
anti CD7
No (No)
Yes (Yes)
anti CD8
No (No)
Yes (Yes)
anti CD34
No (No)
Yes (Yes)
anti TCR alpha / beta (T10-B9)
No (No)
Yes (Yes)
OKT-3
No (No)
Yes (Yes)
other CD3
No (No)
Yes (Yes)
Specify (Answer only if the value for 2746342 is
"Yes" )
anti CD52
No (No)
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Yes (Yes)
campath-NOS
No (No)
Yes (Yes)
campath-1G
No (No)
Yes (Yes)
campath-1H
No (No)
Yes (Yes)
other antibody
No (No)
Yes (Yes)
Specify: (Answer only if the value for 2746486 is
"Yes" )
Autologous Products Only - Part 1 / 2
Were tumor cells detected in the recipient or
autologous product prior to HSCT?
No (No)
Yes (Yes)
Autologous Products Only
What tumor cell detection method was used ?
Cell Culture Techniques (Cell culture
technique)
Ihc, Immunohistochemistry
(Immunohistochemistry)
Other (Other)
Other Molecular Techniques (Other
molecular technique)
Pcr, Polymerase Chain Reaction
(Polymerase chain reaction(PCR))
Histopathology (Routine histopathology)
Were particular tumor cell detection method used
prior to HSCT?
No (No)
Yes (Yes)
Were tumor cells detected in circulating blood
cells prior to HSCT?
No (No)
Not Done: C49484 (Not Done)
Yes (Yes)
Were tumor cells detected in bone marrow, in the
interval between last systemic therapy and
collection prior to HSCT?
No (No)
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Not Done: C49484 (Not Done)
Yes (Yes)
Were tumor cells detected in collected cells,
before purging prior to HSCT?
No (No)
Not Done: C49484 (Not Done)
Yes (Yes)
Specify method (Answer only if the value for
2775544 is "Other molecular technique" OR
"Other technique"  )
Autologous Products Only - Part 3 / 5
Was the product treated to remove malignant
cells (purged) ? (autologous product only)
No (No)
Yes (Yes)
Autologous Products Only - 3 / 4
What malignant cell removal method was used to
treat the product?
Perfosfamide (4-
hydroperoxycyclophosphamide(4HC))
Elutriative Centrifugation (Elutriation)
Immunomagnetic Column
(Immunomagnetic column)
Mafosfamide (Mafosfamide)
Monoclonal Antibody (Monoclonal
antibody)
Other Medication (Other drug)
Other Method (Other method)
Hematopoietic Stem Cell Positive
Selection (Positive stem cell
selection(other than preparation of
mononuclear fraction))
Toxin (Toxin)
Was a particular malignant cell removal method
used for product treatment?
No (No)
Yes (Yes)
Specify the other malignant cell removal method:
(Answer only if the value for 2748795 is
"Monoclonal antibody","Other drug",
"Toxin","Positive stem cell selection" or "Other
method".)
Autologous Products Only Part 4 / 4
What kind of method was used to detect tumor
cells after purging?
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Cell Culture Techniques (Cell culture
technique)
Ihc, Immunohistochemistry
(Immunohistochemistry)
Other (Other)
Other Molecular Techniques (Other
molecular technique)
Pcr, Polymerase Chain Reaction
(Polymerase chain reaction(PCR))
Histopathology (Routine histopathology)
Was a particular tumor cell detection method
used after purging?
No (No)
Not Done: C49484 (Not Done)
Yes (Yes)
Specify the other tumor cells detection method
(Answer only if the value for 2778929 is "Other")
Product Analysis (all Products)
Specify the time point in the product preparation
that the product was analyzed:
Infusion Timepoint (At infusion (final
quantity infused))
Post Manipulation (Post-manipulation)
Post Processing Prior Cryopreservation
Prior Manipulation (Post-processing, pre-
cryopreservation / manipulation)
Post Thaw (Post-thaw)
Arrival (Product arrival)
Date of product analysis:
Total volume of product: (one decimal place)
What was the unit of measure for the total volume
of the product being analyzed?
Gram (g)
Milliliter (mL)
Nucleated cells: (Report the total number of cells
not cells per kilogram)
Nucleated cells exponent value:
Not tested (Not tested for nucleated cells)
Negation Test (Not tested)
Mononucleated cells: (Report the total number of
cells not cells per kilogram)
Mononucleated cells exponent value:
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Not tested (Not tested for mononucleated cells)
Negation Test (Not tested)
Nucleated red blood cells: (Report the total
number of cells not cells per kilogram)
Nucleated red blood cells exponent value:
Not tested (Not tested for nucleated red blood
cells)
Negation Test (Not tested)
CD34+ cells: (Report the total number of cells not
cells per kilogram)
CD34+  cells exponent value:
Not tested (Not tested for CD34+ cells)
Negation Test (Not tested)
CD3+ cells: (Report the total number of cells not
cells per kilogram)
CD3+  cells exponent value:
Not tested (Not tested for CD3+ cells)
Negation Test (Not tested)
CD4+ cells: (Report the total number of cells not
cells per kilogram)
CD4+  cells exponent value:
Not tested (Not tested for CD4+ cells)
Negation Test (Not tested)
CD8+ cells: (Report the total number of cells not
cells per kilogram)
CD8+  cells exponent value:
Not tested (Not tested for CD8+ cells)
Negation Test (Not tested)
Viability of cells
Not tested (The cell viability not tested)
Negation Test (Not tested)
Method of testing cell viability:
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7-aminoactinomycin D (7-AAD)
Other Method (Other method)
Propidium Iodide (Propidium iodide)
Trypan Blue (Trypan blue)
Specify other method: (Answer only if the value
for 2760530 is "Other method")
Were the colony-forming units (CFU) assessed
after thawing? (cord blood product only)
No (No)
Yes (Yes)
Was there growth?
No (No)
Yes (Yes)
Total colonies per product: (One decimal place
with exponent "x10E5")
Unknown (Total colonies per productunknown )
Unknown Not Applicable (Unknown/not
applicable)
Total CFU-GM: (One decimal place with exponent
"x10E5")
Unknown (Total CFU-GMUnknown  )
Unknown Not Applicable (Unknown/not
applicable)
Were cultures performed before infusion to test
the product(s) for bacterial or fungal infection?
(complete for all cell products)
No (No)
Yes (Yes)
Specify results:
Negative Finding (Negative)
Positive Finding (Positive)
Unknown (Unknown)
Specify organism names: (1st Organism Name )
Acinetobacter (Acinetobacter)
Actinomyces (Actinomyces)
Aspergillus Flavus (Aspergillus flavus)
Aspergillus Fumigatus (Aspergillus
fumigatus)
Aspergillus Niger (Aspergillus niger)
Aspergillus Not Otherwise Specified
(Aspergillus, NOS)
Bacillus (Bacillus)
Bacteroides (Bacteroides (gracillis,
uniformis, vulgaris, other species))
Bordetella Pertussis (Bordetella
pertussis (whooping cough))
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Borrelia Burgdorferi (Borrelia (lyme
disease))
Moraxella Catarrhalis (Branhamella or
Moraxella catarrhalis (other species))
Campylobacter (Campylobacter (all
species))
Candida Glabrata (Candida (Torulopsis)
glabrata)
Candida Albicans (Candida albicans)
Pichia Guilliermondii (Candida
guillermondi)
Issatchenkia Orientalis (Candida krusei)
Clavispora Lusitaniae (Candida
lusitaniae)
Candida Parapsilosis (Candida
parapsilosis)
Candida Tropicalis (Candida tropicalis)
Candida Not Otherwise Specified
(Candida, NOS)
Capnocytophaga (Capnocytophaga)
Chlamydophila Pneumoniae (Chlamydia
(pneumoniae))
Chlamydia Not Otherwise Specified
(Chlamydia, NOS)
Citrobacter (Citrobacter (freundii, other
species))
Clostridium (Clostridium (all species
except difficile))
Clostridium Difficile (Clostridium difficile)
Corynebacterium (Corynebacterium (all
non-diptheria species))
Corynebacterium Jeikeium
(Corynebacterium (jeikeium))
Coxiella (Coxiella)
Cryptococcosis (Cryptococcosus
species)
Enterobacter (Enterobacter)
Enterococcus (Enterococcus (all
species))
Vancomycin Resistant Enterococcus
(Enterococcus, vancomycin resistant
(VRE))
Escherichia Coli (Escherichia (also E.
coli))
Pseudomonas Oryzihabitans
(Flavimonas oryzihabitans)
Flavobacterium (Flavobacterium)
Fusarium (Fusarium species)
Fusobacterium (Fusobacterium)
Haemophilus (Haemophilus (all species,
including influenzae))
Helicobacter Pylori (Helicobacter pylori)
Histoplasmosis (Histoplasmosis)
Klebsiella (Klebsiella)
Lactobacillus (Lactobacillus (bulgaricus,
acidophilus, other species))
Legionella (Legionella)
Leptospira (Leptospira)
C76356 (Leptotrichia buccalis)
Leuconostoc (Leuconostoc (all species))
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Listeria (Listeria)
Methylobacterium (Methylobacterium)
Micrococcus Not Otherwise Specified
(Micrococcus, NOS)
Zygomycosis (Mucormycosis)
Multiple Bacteria (Multiple bacteria at a
single site)
Mycobacterium Avium Complex
(Mycobacterium avium - intracellulare
(MAC, MAI))
Mycobacterium Species (Mycobacterium
species (cheloneae, fortuitum,
haemophilum, kansasii, mucogenicum))
Mycobacterium Tuberculosis
(Mycobacterium tuberculosis
(tuberculosis, Koch bacillus))
Mycobacterium Not Otherwise Specified
(Mycobacterium, NOS)
Mycoplasma (Mycoplasma)
Neisseria (Neisseria (gonorrhoeae,
meningitidis, other species))
Nocardia (Nocardia)
Other Aspergillus (Other Aspergillus)
Other Bacteria (Other bacteria)
Other Candida (Other Candida)
Other Chlamydia (Other chlamydia)
Other Fungi (Other fungus)
Other Mycobacterium (Other
mycobacterium)
Pasteurella Multocida (Pasteurella
multocida)
Pneumocystis Pneumonia
(Pneumocystis (PCP / PJP))
Propionibacterium Acnes
(Propionibacterium (acnes, avidum,
granulosum, other species))
Proteus (Proteus)
Pseudomonas (Pseudomonas (all
species except cepacia & maltophilia))
Burkholderia Cepacia (Pseudomonas or
Burkholder cepacia)
Stenotrophomonas Maltophilia
(Pseudomonas or Stenotrophomonas or
Xanthomonas maltophilia)
Rhizopus (Rhizopus)
Rhodococcus (Rhodococcus)
Rickettsia (Rickettsia)
Salmonella (Salmonella (all species))
Serratia Marcescens (Serratia
marcescens)
Shigella (Shigella)
Staphylococcus Aureus (Staphylococcus
aureus)
Staphylococcus Coag Negative
(Staphylococcus, coagulase negative)
Streptococcus Not Otherwise Specified
(Staphylococcus, NOS)
Rothia Mucilaginosa (Stomatococcus
mucilaginosis)
Streptococcus (Streptococcus (all
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species except Enterococcus))
Streptococcus Pneumoniae
(Streptococcus pneumoniae)
Suspected Atypical Bacteria Infection
(Suspected atypical bacterial infection)
Suspected Bacteria Infection (Suspected
bacterial infection)
Suspected Fungal Infection (Suspected
fungal infection)
Treponema (Treponema (syphilis))
Vibrio (Vibrio (all species))
Yeast Not Otherwise Specified (Yeast,
NOS)
Zygomycota Not Otherwise Specified
(Zygomycetes, NOS)
Specify organism names: (2nd Organism Name )
Acinetobacter (Acinetobacter)
Actinomyces (Actinomyces)
Aspergillus Flavus (Aspergillus flavus)
Aspergillus Fumigatus (Aspergillus
fumigatus)
Aspergillus Niger (Aspergillus niger)
Aspergillus Not Otherwise Specified
(Aspergillus, NOS)
Bacillus (Bacillus)
Bacteroides (Bacteroides (gracillis,
uniformis, vulgaris, other species))
Bordetella Pertussis (Bordetella
pertussis (whooping cough))
Borrelia Burgdorferi (Borrelia (lyme
disease))
Moraxella Catarrhalis (Branhamella or
Moraxella catarrhalis (other species))
Campylobacter (Campylobacter (all
species))
Candida Glabrata (Candida (Torulopsis)
glabrata)
Candida Albicans (Candida albicans)
Pichia Guilliermondii (Candida
guillermondi)
Issatchenkia Orientalis (Candida krusei)
Clavispora Lusitaniae (Candida
lusitaniae)
Candida Parapsilosis (Candida
parapsilosis)
Candida Tropicalis (Candida tropicalis)
Candida Not Otherwise Specified
(Candida, NOS)
Capnocytophaga (Capnocytophaga)
Chlamydophila Pneumoniae (Chlamydia
(pneumoniae))
Chlamydia Not Otherwise Specified
(Chlamydia, NOS)
Citrobacter (Citrobacter (freundii, other
species))
Clostridium (Clostridium (all species
except difficile))
Clostridium Difficile (Clostridium difficile)
Corynebacterium (Corynebacterium (all
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non-diptheria species))
Corynebacterium Jeikeium
(Corynebacterium (jeikeium))
Coxiella (Coxiella)
Cryptococcosis (Cryptococcosus
species)
Enterobacter (Enterobacter)
Enterococcus (Enterococcus (all
species))
Vancomycin Resistant Enterococcus
(Enterococcus, vancomycin resistant
(VRE))
Escherichia Coli (Escherichia (also E.
coli))
Pseudomonas Oryzihabitans
(Flavimonas oryzihabitans)
Flavobacterium (Flavobacterium)
Fusarium (Fusarium species)
Fusobacterium (Fusobacterium)
Haemophilus (Haemophilus (all species,
including influenzae))
Helicobacter Pylori (Helicobacter pylori)
Histoplasmosis (Histoplasmosis)
Klebsiella (Klebsiella)
Lactobacillus (Lactobacillus (bulgaricus,
acidophilus, other species))
Legionella (Legionella)
Leptospira (Leptospira)
C76356 (Leptotrichia buccalis)
Leuconostoc (Leuconostoc (all species))
Listeria (Listeria)
Methylobacterium (Methylobacterium)
Micrococcus Not Otherwise Specified
(Micrococcus, NOS)
Zygomycosis (Mucormycosis)
Multiple Bacteria (Multiple bacteria at a
single site)
Mycobacterium Avium Complex
(Mycobacterium avium - intracellulare
(MAC, MAI))
Mycobacterium Species (Mycobacterium
species (cheloneae, fortuitum,
haemophilum, kansasii, mucogenicum))
Mycobacterium Tuberculosis
(Mycobacterium tuberculosis
(tuberculosis, Koch bacillus))
Mycobacterium Not Otherwise Specified
(Mycobacterium, NOS)
Mycoplasma (Mycoplasma)
Neisseria (Neisseria (gonorrhoeae,
meningitidis, other species))
Nocardia (Nocardia)
Other Aspergillus (Other Aspergillus)
Other Bacteria (Other bacteria)
Other Candida (Other Candida)
Other Chlamydia (Other chlamydia)
Other Fungi (Other fungus)
Other Mycobacterium (Other
mycobacterium)
Pasteurella Multocida (Pasteurella
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multocida)
Pneumocystis Pneumonia
(Pneumocystis (PCP / PJP))
Propionibacterium Acnes
(Propionibacterium (acnes, avidum,
granulosum, other species))
Proteus (Proteus)
Pseudomonas (Pseudomonas (all
species except cepacia & maltophilia))
Burkholderia Cepacia (Pseudomonas or
Burkholder cepacia)
Stenotrophomonas Maltophilia
(Pseudomonas or Stenotrophomonas or
Xanthomonas maltophilia)
Rhizopus (Rhizopus)
Rhodococcus (Rhodococcus)
Rickettsia (Rickettsia)
Salmonella (Salmonella (all species))
Serratia Marcescens (Serratia
marcescens)
Shigella (Shigella)
Staphylococcus Aureus (Staphylococcus
aureus)
Staphylococcus Coag Negative
(Staphylococcus, coagulase negative)
Streptococcus Not Otherwise Specified
(Staphylococcus, NOS)
Rothia Mucilaginosa (Stomatococcus
mucilaginosis)
Streptococcus (Streptococcus (all
species except Enterococcus))
Streptococcus Pneumoniae
(Streptococcus pneumoniae)
Suspected Atypical Bacteria Infection
(Suspected atypical bacterial infection)
Suspected Bacteria Infection (Suspected
bacterial infection)
Suspected Fungal Infection (Suspected
fungal infection)
Treponema (Treponema (syphilis))
Vibrio (Vibrio (all species))
Yeast Not Otherwise Specified (Yeast,
NOS)
Zygomycota Not Otherwise Specified
(Zygomycetes, NOS)
Specify organism names: (3rd Organism Name )
Acinetobacter (Acinetobacter)
Actinomyces (Actinomyces)
Aspergillus Flavus (Aspergillus flavus)
Aspergillus Fumigatus (Aspergillus
fumigatus)
Aspergillus Niger (Aspergillus niger)
Aspergillus Not Otherwise Specified
(Aspergillus, NOS)
Bacillus (Bacillus)
Bacteroides (Bacteroides (gracillis,
uniformis, vulgaris, other species))
Bordetella Pertussis (Bordetella
pertussis (whooping cough))
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Borrelia Burgdorferi (Borrelia (lyme
disease))
Moraxella Catarrhalis (Branhamella or
Moraxella catarrhalis (other species))
Campylobacter (Campylobacter (all
species))
Candida Glabrata (Candida (Torulopsis)
glabrata)
Candida Albicans (Candida albicans)
Pichia Guilliermondii (Candida
guillermondi)
Issatchenkia Orientalis (Candida krusei)
Clavispora Lusitaniae (Candida
lusitaniae)
Candida Parapsilosis (Candida
parapsilosis)
Candida Tropicalis (Candida tropicalis)
Candida Not Otherwise Specified
(Candida, NOS)
Capnocytophaga (Capnocytophaga)
Chlamydophila Pneumoniae (Chlamydia
(pneumoniae))
Chlamydia Not Otherwise Specified
(Chlamydia, NOS)
Citrobacter (Citrobacter (freundii, other
species))
Clostridium (Clostridium (all species
except difficile))
Clostridium Difficile (Clostridium difficile)
Corynebacterium (Corynebacterium (all
non-diptheria species))
Corynebacterium Jeikeium
(Corynebacterium (jeikeium))
Coxiella (Coxiella)
Cryptococcosis (Cryptococcosus
species)
Enterobacter (Enterobacter)
Enterococcus (Enterococcus (all
species))
Vancomycin Resistant Enterococcus
(Enterococcus, vancomycin resistant
(VRE))
Escherichia Coli (Escherichia (also E.
coli))
Pseudomonas Oryzihabitans
(Flavimonas oryzihabitans)
Flavobacterium (Flavobacterium)
Fusarium (Fusarium species)
Fusobacterium (Fusobacterium)
Haemophilus (Haemophilus (all species,
including influenzae))
Helicobacter Pylori (Helicobacter pylori)
Histoplasmosis (Histoplasmosis)
Klebsiella (Klebsiella)
Lactobacillus (Lactobacillus (bulgaricus,
acidophilus, other species))
Legionella (Legionella)
Leptospira (Leptospira)
C76356 (Leptotrichia buccalis)
Leuconostoc (Leuconostoc (all species))
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Listeria (Listeria)
Methylobacterium (Methylobacterium)
Micrococcus Not Otherwise Specified
(Micrococcus, NOS)
Zygomycosis (Mucormycosis)
Multiple Bacteria (Multiple bacteria at a
single site)
Mycobacterium Avium Complex
(Mycobacterium avium - intracellulare
(MAC, MAI))
Mycobacterium Species (Mycobacterium
species (cheloneae, fortuitum,
haemophilum, kansasii, mucogenicum))
Mycobacterium Tuberculosis
(Mycobacterium tuberculosis
(tuberculosis, Koch bacillus))
Mycobacterium Not Otherwise Specified
(Mycobacterium, NOS)
Mycoplasma (Mycoplasma)
Neisseria (Neisseria (gonorrhoeae,
meningitidis, other species))
Nocardia (Nocardia)
Other Aspergillus (Other Aspergillus)
Other Bacteria (Other bacteria)
Other Candida (Other Candida)
Other Chlamydia (Other chlamydia)
Other Fungi (Other fungus)
Other Mycobacterium (Other
mycobacterium)
Pasteurella Multocida (Pasteurella
multocida)
Pneumocystis Pneumonia
(Pneumocystis (PCP / PJP))
Propionibacterium Acnes
(Propionibacterium (acnes, avidum,
granulosum, other species))
Proteus (Proteus)
Pseudomonas (Pseudomonas (all
species except cepacia & maltophilia))
Burkholderia Cepacia (Pseudomonas or
Burkholder cepacia)
Stenotrophomonas Maltophilia
(Pseudomonas or Stenotrophomonas or
Xanthomonas maltophilia)
Rhizopus (Rhizopus)
Rhodococcus (Rhodococcus)
Rickettsia (Rickettsia)
Salmonella (Salmonella (all species))
Serratia Marcescens (Serratia
marcescens)
Shigella (Shigella)
Staphylococcus Aureus (Staphylococcus
aureus)
Staphylococcus Coag Negative
(Staphylococcus, coagulase negative)
Streptococcus Not Otherwise Specified
(Staphylococcus, NOS)
Rothia Mucilaginosa (Stomatococcus
mucilaginosis)
Streptococcus (Streptococcus (all
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species except Enterococcus))
Streptococcus Pneumoniae
(Streptococcus pneumoniae)
Suspected Atypical Bacteria Infection
(Suspected atypical bacterial infection)
Suspected Bacteria Infection (Suspected
bacterial infection)
Suspected Fungal Infection (Suspected
fungal infection)
Treponema (Treponema (syphilis))
Vibrio (Vibrio (all species))
Yeast Not Otherwise Specified (Yeast,
NOS)
Zygomycota Not Otherwise Specified
(Zygomycetes, NOS)
Specify organism names: (4th Organism Name )
Acinetobacter (Acinetobacter)
Actinomyces (Actinomyces)
Aspergillus Flavus (Aspergillus flavus)
Aspergillus Fumigatus (Aspergillus
fumigatus)
Aspergillus Niger (Aspergillus niger)
Aspergillus Not Otherwise Specified
(Aspergillus, NOS)
Bacillus (Bacillus)
Bacteroides (Bacteroides (gracillis,
uniformis, vulgaris, other species))
Bordetella Pertussis (Bordetella
pertussis (whooping cough))
Borrelia Burgdorferi (Borrelia (lyme
disease))
Moraxella Catarrhalis (Branhamella or
Moraxella catarrhalis (other species))
Campylobacter (Campylobacter (all
species))
Candida Glabrata (Candida (Torulopsis)
glabrata)
Candida Albicans (Candida albicans)
Pichia Guilliermondii (Candida
guillermondi)
Issatchenkia Orientalis (Candida krusei)
Clavispora Lusitaniae (Candida
lusitaniae)
Candida Parapsilosis (Candida
parapsilosis)
Candida Tropicalis (Candida tropicalis)
Candida Not Otherwise Specified
(Candida, NOS)
Capnocytophaga (Capnocytophaga)
Chlamydophila Pneumoniae (Chlamydia
(pneumoniae))
Chlamydia Not Otherwise Specified
(Chlamydia, NOS)
Citrobacter (Citrobacter (freundii, other
species))
Clostridium (Clostridium (all species
except difficile))
Clostridium Difficile (Clostridium difficile)
Corynebacterium (Corynebacterium (all
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non-diptheria species))
Corynebacterium Jeikeium
(Corynebacterium (jeikeium))
Coxiella (Coxiella)
Cryptococcosis (Cryptococcosus
species)
Enterobacter (Enterobacter)
Enterococcus (Enterococcus (all
species))
Vancomycin Resistant Enterococcus
(Enterococcus, vancomycin resistant
(VRE))
Escherichia Coli (Escherichia (also E.
coli))
Pseudomonas Oryzihabitans
(Flavimonas oryzihabitans)
Flavobacterium (Flavobacterium)
Fusarium (Fusarium species)
Fusobacterium (Fusobacterium)
Haemophilus (Haemophilus (all species,
including influenzae))
Helicobacter Pylori (Helicobacter pylori)
Histoplasmosis (Histoplasmosis)
Klebsiella (Klebsiella)
Lactobacillus (Lactobacillus (bulgaricus,
acidophilus, other species))
Legionella (Legionella)
Leptospira (Leptospira)
C76356 (Leptotrichia buccalis)
Leuconostoc (Leuconostoc (all species))
Listeria (Listeria)
Methylobacterium (Methylobacterium)
Micrococcus Not Otherwise Specified
(Micrococcus, NOS)
Zygomycosis (Mucormycosis)
Multiple Bacteria (Multiple bacteria at a
single site)
Mycobacterium Avium Complex
(Mycobacterium avium - intracellulare
(MAC, MAI))
Mycobacterium Species (Mycobacterium
species (cheloneae, fortuitum,
haemophilum, kansasii, mucogenicum))
Mycobacterium Tuberculosis
(Mycobacterium tuberculosis
(tuberculosis, Koch bacillus))
Mycobacterium Not Otherwise Specified
(Mycobacterium, NOS)
Mycoplasma (Mycoplasma)
Neisseria (Neisseria (gonorrhoeae,
meningitidis, other species))
Nocardia (Nocardia)
Other Aspergillus (Other Aspergillus)
Other Bacteria (Other bacteria)
Other Candida (Other Candida)
Other Chlamydia (Other chlamydia)
Other Fungi (Other fungus)
Other Mycobacterium (Other
mycobacterium)
Pasteurella Multocida (Pasteurella
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multocida)
Pneumocystis Pneumonia
(Pneumocystis (PCP / PJP))
Propionibacterium Acnes
(Propionibacterium (acnes, avidum,
granulosum, other species))
Proteus (Proteus)
Pseudomonas (Pseudomonas (all
species except cepacia & maltophilia))
Burkholderia Cepacia (Pseudomonas or
Burkholder cepacia)
Stenotrophomonas Maltophilia
(Pseudomonas or Stenotrophomonas or
Xanthomonas maltophilia)
Rhizopus (Rhizopus)
Rhodococcus (Rhodococcus)
Rickettsia (Rickettsia)
Salmonella (Salmonella (all species))
Serratia Marcescens (Serratia
marcescens)
Shigella (Shigella)
Staphylococcus Aureus (Staphylococcus
aureus)
Staphylococcus Coag Negative
(Staphylococcus, coagulase negative)
Streptococcus Not Otherwise Specified
(Staphylococcus, NOS)
Rothia Mucilaginosa (Stomatococcus
mucilaginosis)
Streptococcus (Streptococcus (all
species except Enterococcus))
Streptococcus Pneumoniae
(Streptococcus pneumoniae)
Suspected Atypical Bacteria Infection
(Suspected atypical bacterial infection)
Suspected Bacteria Infection (Suspected
bacterial infection)
Suspected Fungal Infection (Suspected
fungal infection)
Treponema (Treponema (syphilis))
Vibrio (Vibrio (all species))
Yeast Not Otherwise Specified (Yeast,
NOS)
Zygomycota Not Otherwise Specified
(Zygomycetes, NOS)
Specify organism names: (5th Organism Name )
Acinetobacter (Acinetobacter)
Actinomyces (Actinomyces)
Aspergillus Flavus (Aspergillus flavus)
Aspergillus Fumigatus (Aspergillus
fumigatus)
Aspergillus Niger (Aspergillus niger)
Aspergillus Not Otherwise Specified
(Aspergillus, NOS)
Bacillus (Bacillus)
Bacteroides (Bacteroides (gracillis,
uniformis, vulgaris, other species))
Bordetella Pertussis (Bordetella
pertussis (whooping cough))
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Borrelia Burgdorferi (Borrelia (lyme
disease))
Moraxella Catarrhalis (Branhamella or
Moraxella catarrhalis (other species))
Campylobacter (Campylobacter (all
species))
Candida Glabrata (Candida (Torulopsis)
glabrata)
Candida Albicans (Candida albicans)
Pichia Guilliermondii (Candida
guillermondi)
Issatchenkia Orientalis (Candida krusei)
Clavispora Lusitaniae (Candida
lusitaniae)
Candida Parapsilosis (Candida
parapsilosis)
Candida Tropicalis (Candida tropicalis)
Candida Not Otherwise Specified
(Candida, NOS)
Capnocytophaga (Capnocytophaga)
Chlamydophila Pneumoniae (Chlamydia
(pneumoniae))
Chlamydia Not Otherwise Specified
(Chlamydia, NOS)
Citrobacter (Citrobacter (freundii, other
species))
Clostridium (Clostridium (all species
except difficile))
Clostridium Difficile (Clostridium difficile)
Corynebacterium (Corynebacterium (all
non-diptheria species))
Corynebacterium Jeikeium
(Corynebacterium (jeikeium))
Coxiella (Coxiella)
Cryptococcosis (Cryptococcosus
species)
Enterobacter (Enterobacter)
Enterococcus (Enterococcus (all
species))
Vancomycin Resistant Enterococcus
(Enterococcus, vancomycin resistant
(VRE))
Escherichia Coli (Escherichia (also E.
coli))
Pseudomonas Oryzihabitans
(Flavimonas oryzihabitans)
Flavobacterium (Flavobacterium)
Fusarium (Fusarium species)
Fusobacterium (Fusobacterium)
Haemophilus (Haemophilus (all species,
including influenzae))
Helicobacter Pylori (Helicobacter pylori)
Histoplasmosis (Histoplasmosis)
Klebsiella (Klebsiella)
Lactobacillus (Lactobacillus (bulgaricus,
acidophilus, other species))
Legionella (Legionella)
Leptospira (Leptospira)
C76356 (Leptotrichia buccalis)
Leuconostoc (Leuconostoc (all species))
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Listeria (Listeria)
Methylobacterium (Methylobacterium)
Micrococcus Not Otherwise Specified
(Micrococcus, NOS)
Zygomycosis (Mucormycosis)
Multiple Bacteria (Multiple bacteria at a
single site)
Mycobacterium Avium Complex
(Mycobacterium avium - intracellulare
(MAC, MAI))
Mycobacterium Species (Mycobacterium
species (cheloneae, fortuitum,
haemophilum, kansasii, mucogenicum))
Mycobacterium Tuberculosis
(Mycobacterium tuberculosis
(tuberculosis, Koch bacillus))
Mycobacterium Not Otherwise Specified
(Mycobacterium, NOS)
Mycoplasma (Mycoplasma)
Neisseria (Neisseria (gonorrhoeae,
meningitidis, other species))
Nocardia (Nocardia)
Other Aspergillus (Other Aspergillus)
Other Bacteria (Other bacteria)
Other Candida (Other Candida)
Other Chlamydia (Other chlamydia)
Other Fungi (Other fungus)
Other Mycobacterium (Other
mycobacterium)
Pasteurella Multocida (Pasteurella
multocida)
Pneumocystis Pneumonia
(Pneumocystis (PCP / PJP))
Propionibacterium Acnes
(Propionibacterium (acnes, avidum,
granulosum, other species))
Proteus (Proteus)
Pseudomonas (Pseudomonas (all
species except cepacia & maltophilia))
Burkholderia Cepacia (Pseudomonas or
Burkholder cepacia)
Stenotrophomonas Maltophilia
(Pseudomonas or Stenotrophomonas or
Xanthomonas maltophilia)
Rhizopus (Rhizopus)
Rhodococcus (Rhodococcus)
Rickettsia (Rickettsia)
Salmonella (Salmonella (all species))
Serratia Marcescens (Serratia
marcescens)
Shigella (Shigella)
Staphylococcus Aureus (Staphylococcus
aureus)
Staphylococcus Coag Negative
(Staphylococcus, coagulase negative)
Streptococcus Not Otherwise Specified
(Staphylococcus, NOS)
Rothia Mucilaginosa (Stomatococcus
mucilaginosis)
Streptococcus (Streptococcus (all
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species except Enterococcus))
Streptococcus Pneumoniae
(Streptococcus pneumoniae)
Suspected Atypical Bacteria Infection
(Suspected atypical bacterial infection)
Suspected Bacteria Infection (Suspected
bacterial infection)
Suspected Fungal Infection (Suspected
fungal infection)
Treponema (Treponema (syphilis))
Vibrio (Vibrio (all species))
Yeast Not Otherwise Specified (Yeast,
NOS)
Zygomycota Not Otherwise Specified
(Zygomycetes, NOS)
Specify organism names: (6th Organism Name )
Acinetobacter (Acinetobacter)
Actinomyces (Actinomyces)
Aspergillus Flavus (Aspergillus flavus)
Aspergillus Fumigatus (Aspergillus
fumigatus)
Aspergillus Niger (Aspergillus niger)
Aspergillus Not Otherwise Specified
(Aspergillus, NOS)
Bacillus (Bacillus)
Bacteroides (Bacteroides (gracillis,
uniformis, vulgaris, other species))
Bordetella Pertussis (Bordetella
pertussis (whooping cough))
Borrelia Burgdorferi (Borrelia (lyme
disease))
Moraxella Catarrhalis (Branhamella or
Moraxella catarrhalis (other species))
Campylobacter (Campylobacter (all
species))
Candida Glabrata (Candida (Torulopsis)
glabrata)
Candida Albicans (Candida albicans)
Pichia Guilliermondii (Candida
guillermondi)
Issatchenkia Orientalis (Candida krusei)
Clavispora Lusitaniae (Candida
lusitaniae)
Candida Parapsilosis (Candida
parapsilosis)
Candida Tropicalis (Candida tropicalis)
Candida Not Otherwise Specified
(Candida, NOS)
Capnocytophaga (Capnocytophaga)
Chlamydophila Pneumoniae (Chlamydia
(pneumoniae))
Chlamydia Not Otherwise Specified
(Chlamydia, NOS)
Citrobacter (Citrobacter (freundii, other
species))
Clostridium (Clostridium (all species
except difficile))
Clostridium Difficile (Clostridium difficile)
Corynebacterium (Corynebacterium (all
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non-diptheria species))
Corynebacterium Jeikeium
(Corynebacterium (jeikeium))
Coxiella (Coxiella)
Cryptococcosis (Cryptococcosus
species)
Enterobacter (Enterobacter)
Enterococcus (Enterococcus (all
species))
Vancomycin Resistant Enterococcus
(Enterococcus, vancomycin resistant
(VRE))
Escherichia Coli (Escherichia (also E.
coli))
Pseudomonas Oryzihabitans
(Flavimonas oryzihabitans)
Flavobacterium (Flavobacterium)
Fusarium (Fusarium species)
Fusobacterium (Fusobacterium)
Haemophilus (Haemophilus (all species,
including influenzae))
Helicobacter Pylori (Helicobacter pylori)
Histoplasmosis (Histoplasmosis)
Klebsiella (Klebsiella)
Lactobacillus (Lactobacillus (bulgaricus,
acidophilus, other species))
Legionella (Legionella)
Leptospira (Leptospira)
C76356 (Leptotrichia buccalis)
Leuconostoc (Leuconostoc (all species))
Listeria (Listeria)
Methylobacterium (Methylobacterium)
Micrococcus Not Otherwise Specified
(Micrococcus, NOS)
Zygomycosis (Mucormycosis)
Multiple Bacteria (Multiple bacteria at a
single site)
Mycobacterium Avium Complex
(Mycobacterium avium - intracellulare
(MAC, MAI))
Mycobacterium Species (Mycobacterium
species (cheloneae, fortuitum,
haemophilum, kansasii, mucogenicum))
Mycobacterium Tuberculosis
(Mycobacterium tuberculosis
(tuberculosis, Koch bacillus))
Mycobacterium Not Otherwise Specified
(Mycobacterium, NOS)
Mycoplasma (Mycoplasma)
Neisseria (Neisseria (gonorrhoeae,
meningitidis, other species))
Nocardia (Nocardia)
Other Aspergillus (Other Aspergillus)
Other Bacteria (Other bacteria)
Other Candida (Other Candida)
Other Chlamydia (Other chlamydia)
Other Fungi (Other fungus)
Other Mycobacterium (Other
mycobacterium)
Pasteurella Multocida (Pasteurella
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multocida)
Pneumocystis Pneumonia
(Pneumocystis (PCP / PJP))
Propionibacterium Acnes
(Propionibacterium (acnes, avidum,
granulosum, other species))
Proteus (Proteus)
Pseudomonas (Pseudomonas (all
species except cepacia & maltophilia))
Burkholderia Cepacia (Pseudomonas or
Burkholder cepacia)
Stenotrophomonas Maltophilia
(Pseudomonas or Stenotrophomonas or
Xanthomonas maltophilia)
Rhizopus (Rhizopus)
Rhodococcus (Rhodococcus)
Rickettsia (Rickettsia)
Salmonella (Salmonella (all species))
Serratia Marcescens (Serratia
marcescens)
Shigella (Shigella)
Staphylococcus Aureus (Staphylococcus
aureus)
Staphylococcus Coag Negative
(Staphylococcus, coagulase negative)
Streptococcus Not Otherwise Specified
(Staphylococcus, NOS)
Rothia Mucilaginosa (Stomatococcus
mucilaginosis)
Streptococcus (Streptococcus (all
species except Enterococcus))
Streptococcus Pneumoniae
(Streptococcus pneumoniae)
Suspected Atypical Bacteria Infection
(Suspected atypical bacterial infection)
Suspected Bacteria Infection (Suspected
bacterial infection)
Suspected Fungal Infection (Suspected
fungal infection)
Treponema (Treponema (syphilis))
Vibrio (Vibrio (all species))
Yeast Not Otherwise Specified (Yeast,
NOS)
Zygomycota Not Otherwise Specified
(Zygomycetes, NOS)
If codes 198, 209, 219, or 259, specify organism:
(Answer only if the value for 2784429,
2784431,2784433,2784435,2784437 and
2784439 is "Other bacteria, specify","Other
Candida, specify",Other Aspergillus, specify" or
"Other fungus, specify".)
Product Infusion
Was more than one product infused? (e.g.,
marrow and PBSC,PBSC and cord blood, two
different cords, etc.)
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No (No)
Yes (Yes)
Was the product infusion described on this insert
intended to produce hematopoietic engraftment?
No (No)
Yes (Yes)
Date of this product infusion:
Time product infusion initiated (24-hour clock):
Is it the standard time or daylight savings time?
Daylight Savings Time (Daylight Savings
Time)
Standard Time (Standard time)
Time product infusion completed (24-hour clock):
Is it the standard time or daylight savings time?
Daylight Savings Time (Daylight Savings
Time)
Standard Time (Standard time)
Total volume of product plus additives infused:
(One decimal place with Unit of Measure "ml")
Specify the route of product infusion:
Intramedullary Route Of Administration
(Intramedullary)
Intraperitoneal Route Of Administration
(Intraperitoneal)
Intravenous Route Of Administration
(Intravenous)
Other Route Of Administration (Other
route of infusion)
Specify route of infusion:
Did the volume of infused product include any
added agents?
No (No)
Yes (Yes)
Product Infusion - Part 2 / 3
What kind of additives are included in volume of
infused product?
Acid-citrate-dextrose (Acid-Citrate-
Dextrose (ACD))
Albumin (Albumin)
Antibiotic (Antibiotic)
Dextran Sulfate Sodium (Dextran)
Heparin (Heparin)
Other (Other)
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Were particular additives included in volume of
infused product?
No (No)
Yes (Yes)
Specify agent: (Answer only if the value for
2740356 is "Other")
Product Infusion
Was the entire volume of product infused?
No (No)
Yes (Yes)
Specify what happened to the reserved portion:
Cryopreservation (Cryopreserved for
future use)
Destruction (Discarded)
Other Endpoints (Other fate)
Specify: (Answer only if the value for 2769592 is
"Other fate")
Were there any adverse events or incidents
associated with the stem cell infusion? (The
question refers to all stem cell products except for
autologous marrow or autologous PBSC
products.)
No (No)
Yes (Yes)
Product Infusion
What type of Adverse Events associated with the
stem cell infusion?
Bradycardia (Brachycardia)
Chest Pain (Chest tightness/pain)
At Infusion Time Chills (Chills at time of
infusion)
Fever > 103 F Within 24 Hours Of
Infusion (Fever greater than 103 F within
24 hours of infusion)
Fever <= 103 F Within 24 Hours Of
Infusion (Fever less than or equal to 103
F within 24 hours of infusion)
Whole Hemoglobinuria (Gross
hemoglobinuria)
Headache (Headache)
Urticaria (Hives)
Hypertension (Hypertension)
Hypotension (Hypotension)
Required Oxygen Hypoxia (Hypoxia
requiring oxygen(O2) support)
Nausea (Nausea)
Other Expected Adverse Event (Other
expected AE)
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Other Unexpected Adverse Event (Other
unexpected AE)
Ctcae Grade 1 Rigors And Chills (Rigors,
mild)
Ctcae Grade 3 Rigors And Chills (Rigors,
severe)
Dyspnea (Shortness of breath(SOB))
Tachycardia (Tachycardia)
Vomiting (Vomiting)
Did a particular stem cell infusion associated
adverse event occur?
No (No)
Yes (Yes)
Did particular adverse events require medical
intervention?
No (No)
Yes (Yes)
Were particular adverse events resolved?
No (No)
Yes (Yes)
Specify (Answer only if the value for 2739534 is
"Other expected AE" or "Other unexpected AE")
Product Infusion
In the Medical Director's judgement, was the
adverse event a direct result of the infusion?
No (No)
Yes (Yes)
Specify the most likely cause of the adverse
event :
Medication Reaction (Drug reaction)
Other Diseases And Disorders (Other
illness)
Other Reason (Other reason)
Hematopoietic Stem Cell Transplant
Reaction (Product reaction)
Relationship Regimen (Regimen related)
Specify illness: (Answer only if the value for
2769598 is "Other illness")
Specify reason: (Answer only if the value for
2769598 is "Other reason")
Donor Demographic Information
Donor's date of birth:
Date unknown
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Date Unknown (date unknown)
Age of mother (approximate): (Cord blood unit
only)
Age unknown
No (No)
Yes (yes)
Non-NMDP Cord Blood Unit (CBU) ID: (Cord
blood unit only)
Is the CBU ID number also the ICCBBA ISBT 128
number? (Cord blood unit only)
No (No)
Yes (Yes)
Name of cord blood bank providing CBU: (Cord
blood unit only)
Donor Gender
Female (female)
Male (male)
Was the donor ever pregnant?
No (No)
Not Applicable (Not Applicable)
Unknown (Unknown)
Yes (Yes)
Specify number of pregnancies:
Unknown (The number of pregnanciesUnknown)
No (No)
Yes (Yes)
Donor's blood type and Rh factor:
Blood Group A Rh Negative Blood Group
(A negative)
Blood Group A Rh Positive Blood Group
(A positive)
Blood Group Ab Rh Negative Blood
Group (AB negative)
Blood Group Ab Rh Positive Blood
Group (AB positive)
Blood Group B Rh Negative Blood Group
(B negative)
Blood Group B Rh Positive Blood Group
(B positive)
Blood Group O Rh Negative Blood
Group (O negative)
Blood Group O Rh Positive Blood Group
(O positive)
Unknown (unknown)
Did this donor have a central line placed?
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No (No)
Not Applicable (Not Applicable)
Yes (Yes)
Specify the site of the central line placement:
Femoral Vein (Femoral)
Internal Jugular Vein (Internal jugular)
Other Anatomic Site (Other site)
Subclavian Vein (Subclavian)
Specify site: (Answer only if the value for
2769666 is "Other site")
Donor's ethnicity:
A Person Of Mexican, Puerto Rican,
Cuban, Central Or South American Or
Other Spanish Culture Or Origin,
Regardless Of Race. (Hispanic or Latino)
A Person Not Meeting The Definition For
Hispanic Or Latino. (Not Hispanic or
Latino)
Could Not Be Determined Or Unsure
(Unknown)
Donor Demographic Information Part 2 / 2
Donor's race (Mark the groups in which the donor
is a member. Check all that apply )
African (African (both parents born in
Africa))
African American (African American)
Alaska Native (Alaskan Native or Aleut)
South Or Central American Indian
(American Indian, South or Central
America)
African Caribbean (Black Caribbean)
Black South Or Central American (Black
South or Central American)
Caribbean Indian (Caribbean Indian)
Chinese (Chinese)
Response Declined (Declines to provide
race)
Eastern European (Eastern European)
Filipino (Filipino (Pilipino))
Guamanian (Guamanian)
Hawaiian (Hawaiian)
Japanese (Japanese)
Korean (Korean)
Mediterranean (Mediterranean)
Middle Eastern (Middle Eastern)
North American (North American)
American Indian (North American Indian)
North Coast Of Africa (North Coast of
Africa)
Northern European (Northern European)
Other Native Hawaiian Or Other Pacific
Islander (Other Pacific Islander)
Other South Asian (Other Southeast
33 / 36
Treatment - 2006 - Hematopoietic Stem Cell Transplant (HSCT) Infusion -
2798767v1.0
Asian)
Other White (Other White)
Unknown (Race unknown)
Samoan (Samoan)
South Asian (South Asian)
Vietnamese (Vietnamese)
Western European (Western European)
White Caribbean (White Caribbean)
White South Or Central American (White
South or Central American)
Donor Demographic Information
What is the relationship of the donor to the
recipient?
Other Relative (Other relative)
Recipient Child (Recipient's child)
Sibling (Sibling)
Unrelated (Unrelated)
Specify the relationship of the donor to the
recipient: (Answer only if the value for 2784447 is
"Other relative")
Aunt (Aunt)
Cousin (Cousin)
Other Relative (Other relative)
Parent (Parent)
Uncle (Uncle)
Specify relationship: (Answer only if the value for
2728852 is "Other relative")
Was the donor / product tested for potentially
transplantable genetic diseases?
No (No)
Unknown (Unknown)
Yes (Yes)
Sickle cell anemia
No (No)
Yes (Yes)
Thalassemia
No (No)
Yes (Yes)
Other
No (No)
Yes (Yes)
Specify genetic disease: (Answer only if the value
for 2772022 is "Yes")
Was the donor hospitalized (inpatient) during or
after the collection? (Question applies only to
allogeneic non-NMDP donors)
No (No)
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Yes (Yes)
Did the donor experience any life-threatening
complications during or after the collection?
(Question applies only to allogeneic non-NMDP
donors)
No (No)
Yes (Yes)
Specify complications: (Question applies only to
allogeneic non-NMDP donors. Answer only if the
value of CDE 2728986 is "Yes".)
Did the donor receive blood transfusions as a
result of the collection? (Question applies only to
allogeneic non-NMDP donors)
No (No)
Yes (Yes)
Was the blood transfusion product autologous?
(Question applies only to allogeneic non-NMDP
donors )
No (No)
Yes (Yes)
Specify number of units: (For the autologous
blood transfusion)
Was the blood transfusion product allogeneic
(homologous)? (Question applies only to
allogeneic non-NMDP donors)
No (No)
Yes (Yes)
Specify number of units: (For the autologous
blood transfusion)
Did the donor die as a result of the collection?
(Question applies only to allogeneic non-NMDP
donors)
No (No)
Yes (Yes)
Specify cause of death: (Question applies only to
allogeneic non-NMDP donors)
Did the recipient submit a research sample?
(Related donors only)
No (No)
Yes (Yes)
Research sample recipient ID:
Did the donor submit a research sample?
(Related donors only)
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No (No)
Yes (Yes)
Research sample donor ID: (Related donors
only)
Author Information
First Name
Last Name
Telephone number:
Fax number:
E-mail address:
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PULMONARY FUNCTION
Pulmonary Test
Sample Collection Date
Time
Course Number
Course Day Number
Lab Test
Diffusion Capacity, Respiratory System
(Diffusion Capacity, Respiratory System)
Expiratory Volume, Respiratory System
(Expiratory Volume, Respiratory System)
Forced Expiratory Flow (fef), During
Midportion Of Expiratory Cycle, Pre,
Respiratory System (Forced Expiratory
Flow (FEF), during midportion of
expiratory cycle, Pre, Respiratory
System)
Forced Vital Capacity (maximum),
Respiratory System (Forced Vital
Capacity (Maximum), Respiratory
System)
Functional Residual Capacity,
Respiratory System (Functional Residual
Capacity, Respiratory System)
Residual Volume To Total Lung Capacity
Ratio, Respiratory System (Residual
Volume to Total Lung Capacity Ratio,
Respiratory System)
Vital Capacity (vc), Respiratory System
(Vital Capacity (VC), Respiratory
System)
Lab Value
Lab Unit of Measure Name
Per 100 Identifiable White Blood Cells
(/100 WBC)
Per Millimeter Cubed (/mm3)
Percent (%)
Percent Per 100 Wbc (%/100 WBC)
10e12 Cells Per Liter (10E12 Cells/L)
10e3 Cells Per Microliter (10E3
Cells/microL)
10e6 Cells (10E6 Cells)
10e6 Cells Per Microliter (10E6
Cells/microL)
10e6 Cells Per Millimeter Cubed (10E6
Cells/mm3)
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10e7 Cells Per Kilogram (10E7 Cells/kg)
10e8 Cells (10E8 Cells)
10e9 Cells (10E9 Cells)
10e9 Cells Per Liter (10E9 Cells/L)
Complement Activity Enzyme Unit (CAE
Unit)
Cells Per Microliter (Cells/microL)
Copies (Copies)
Cubic Microns (cubic microns)
Enzyme Unit (EU)
Enzyme Units Per Deciliter (EU/dL)
Enzyme Units Per Milliliter (EU/mL)
Femtoliter (fL)
Grams (g) (g)
Gram Per 24 Hours (g/24hr)
Gram Per Deciliter (g/dL)
Gram Per Liter (g/L)
Gram Per Microliter (g/microL)
Per High Power Field (HPF)
International Unit (Iunit)
International Unit Per Liter (IUnit/L)
International Unit Per Meter Squared
(IUnit/m2)
International Unit Per Milliliter (IUnit/mL)
Iu/ml (IUnit/mL)
Kilounit Per Liter (kU/L)
Liter (L)
Liters Per Minute (L/min)
Per Low Power Field (LPF)
Microgram Per 24 Hours (mcg/24hr)
Microgram Per Deciliter (mcg/dL)
Microgram Per Liter (mcg/L)
Microgram Per Milliliter (mcg/mL)
Microgram Per Specimen (mcg/spec)
Milliequivalent (mEq)
Milliequivalents Per 24 Hours (mEq/24hr)
Milliequivalent Per Deciliter (mEq/dL)
Milliequivalent Per Kilogram (mEq/kg)
Milliequivalent Per Liter (mEq/L)
Milligram (mg)
Milligram Per 24 Hours (mg/24hr)
Milligram Per Deciliter (mg/dL)
Milligram Per Kilogram (mg/kg)
Milligram Per Liter (mg/L)
Milligram Per Milliliter (mg/mL)
Milligram Per Milliliter Per Minute
(mg/mL/min)
Micro International Unit Per Milliliter
(microIU/mL)
Microliter (microL)
Micromole Per 24 Hours (micromol/24hr)
Micromole Per Deciliter (micromol/dL)
Micromole Per Liter (micromol/L)
Million Plaque Forming Units (mill PFU)
Million (Million)
Million Per Microliter (Million/microL)
Million Per Millimeter Cubed
(Million/mm3)
Milliinternational Unit (miu)
Milliinternational Units Per Meter
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Squared (miu/m2)
Milliinternational Unit Per Milliliter
(miu/mL)
Milliter (mL)
Milliliter Per Minute (mL/min)
Milliliter Per Minute Times 1.73 Times
Bsa (mL/min/1.73/BSA)
Milliter Per Minute Per Millimeters Of
Mercury (mL/minute/mmHg)
Millimeter Per Hour (mm/hr)
Millimeter Cubed (mm3)
Millimeter Of Mercury (mmHg)
Millimole (mmol)
Millimole Per 24 Hours (mmol/24hr)
Millimole Per Liter (mmol/L)
Milliosmole Per Kilogram (mosmol/kg)
Million Units Per Milliliter (MU/mL)
Not Applicable; No Uom Required (NA)
Nanogram Per Deciliter (ng/dL)
Nanograms Per Milliliter (ng/mL)
Nanogram Per Milliliter Per Hour
(ng/mL/hr)
Nanomole Per Liter (nmol/L)
Nanomole Per Milligram Of Protein
(nMol/mg protein)
Nanomole Per Milliliter (nmol/mL)
No Source Data (No Srce)
Picograms (pg)
Picogram Per Deciliter (pg/dL)
Picrogram Per Milliliter (pg/mL)
Pgpge2/mg Protein (pgPGE2/mg
protein)
Picomole Per Liter (pmol/L)
Ratio (Ratio)
Rna Copies Per Milliliter (RNA
copies/mL)
Seconds (sec)
Thousand (Thousand)
Thousand Per Microliter
(Thousand/microL)
Thousand Per Millimeter Squared
(Thousand/mm2)
Thousand Per Millimeter Cubed
(Thousand/mm3)
Titer (Titer)
Unit (Unit)
Unit Per 24 Hours (Unit/24hr)
Unit Per Liter (Unit/L)
Unit Per Meter Squared (Unit/m2)
Unit Per Millilliter (Unit/mL)
Unit Per Millimeters Cubed (Unit/mm3)
Unknown (Unknown)
Test Result Significance Indicator
No (N)
Yes (Y)
Laboratory Test Normal Reference Range Text
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Laboratory Test Normal Range Indicator
High (High)
Low (Low)
Nonnumeric (Nonnum)
No Range (Norang)
Normal (Normal)
Common Toxicity Criteria Adverse Event Grade
No Adverse Event Or Within Normal
Limits (0)
Mild Adverse Event (1)
Moderate Adverse Event (2)
Severe And Undesirable Adverse Event
(3)
Life-threatening Or Disabling Adverse
Event (4)
Death Related To Adverse Event (5)
Comments
Note Date
Research Comments Text
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EXTENT OF DISEASE
Extent Of Disease-identification
Lesion Number
Site
Abdomen (Abdomen)
Abdomen/pelvis (Abdomen/Pelvis)
Abdominal Wall (Abdominal wall)
Acetabulum (Acetabulum)
Adrenal Gland (Adrenal gland)
Anal Canal (Anal canal)
Anal Sphincter (Anal sphincter)
Ankle (Ankle)
Anorectum (Anorectum)
Antecubital Fossa (Antecubital fossa)
Anus (Anus)
Aorta (Aorta)
Appendix (Appendix)
Aqueous Fluid (Aqueous Fluid)
Arm (Arm)
Artery (Artery)
Ascending Colon (Ascending colon)
Auditory Canal (Auditory canal)
Autonomic Nervous System (Autonomic
nervous system)
Axilla (Axilla)
Back (Back)
Bile Duct (Bile duct)
Bladder (Bladder)
Blood (Blood)
Blood Vessel (Blood vessel)
Bone (Bone)
Bone Marrow (Bone marrow)
Bowel (Bowel)
Brain (Brain)
Brain Stem (Brain stem)
Breast (Breast)
Broad Ligament (Broad ligament)
Bronchiole (Bronchiole)
Bronchus (Bronchus)
Bronchus And Lung (Bronchus and
Lung)
Brow (Brow)
Buccal Cavity (Buccal cavity)
Buccal Mucosa (Buccal mucosa)
Buttock (Buttock)
Calf (Calf)
Carina (Carina)
Carotid Artery (Carotid artery)
Cecum (Cecum)
Central Line Catheter (Central Line
Catheter)
Central Nervous System (Central
nervous system)
Cerebellum (Cerebellum)
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Cerebral Cortex (Cerebral cortex)
Cerebrospinal Fluid (Cerebrospinal fluid)
Cerebrum (Cerebrum)
Cervical Spine (Cervical spine)
Cervical/thoracic/lumbar Spine
(Cervical/Thoracic/Lumbar spine)
Cervix (Cervix)
Chest (Chest)
Chest Wall (Chest wall)
Chest/abdomen/pelvis
(Chest/Abdomen/Pelvis)
Chest/pelvis (Chest/Pelvis)
Chin (Chin)
Clavicle (Clavicle)
Colon (Colon)
Colon And Rectum (Colon and rectum)
Common Duct (Common duct)
Conjunctiva (Conjunctiva)
Connective Tissue (Connective tissue)
Descending Colon (Descending colon)
Diaphragm (Diaphragm)
Duodenum (Duodenum)
Ear (Ear)
Ear Canal (Ear canal)
External Ear (Ear, Pinna (External))
Elbow (Elbow)
Endocrine Gland (Endocrine gland)
Epididymis (Epididymis)
Esophagogastric Junction
(Esophagogastric junction)
Esophagus (Esophagus)
Eye (Eye)
Fallopian Tube (Fallopian tube)
Femur (Femur)
Fibula (Fibula)
Finger (Finger)
Foot (Foot)
Forearm (Forearm)
Forehead (Forehead)
Frontal Lobe (Frontal lobe)
Fundus Of Stomach (Fundus of
stomach)
Gallbladder (Gallbladder)
Gastrointestinal Tract (Gastrointestinal
tract)
Genitourinary (Genitourinary)
Groin (Groin)
Gum (Gum)
Hand (Hand)
Hard Palate (Hard palate)
Head - Face Or Neck, Nos (Head - face
or neck, NOS)
Head/neck (Head/Neck)
Head/neck/chest/adb/pelvis
(Head/Neck/Chest/Adb/Pelvis)
Heart (Heart)
Hepatic Duct (Hepatic duct)
Hip (Hip)
Humerus (Humerus)
Hypopharynx (Hypopharynx)
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Ileum (Ileum)
Ilium (Ilium)
Intestine (Intestine)
Ischium (Ischium)
Jaw (Jaw)
Jejunum (Jejunum)
Joints (Joints)
Kidney (Kidney)
Knee (Knee)
Large Bowel (Large bowel)
Laryngopharynx (Laryngopharynx)
Larynx (Larynx)
Leg (Leg)
Lip (Lip)
Liver (Liver)
Liver And Intrahepatic Duct (Liver and
intrahepatic duct)
Liver/spleen (Liver/Spleen)
Lumbar Spine (Lumbar spine)
Lung (Lung)
Lymph Node (Lymph node)
Lymph Node(s) Axilla (Lymph Node(s)
Axilla)
Lymph Node(s) Cervical (Lymph Node(s)
Cervical)
Lymph Node(s) Hilar (Lymph Node(s)
Hilar)
Lymph Node(s) Inguinal (Lymph Node(s)
Inguinal)
Lymph Node(s) Int Mammary (Lymph
Node(s) Int Mammary)
Lymph Node(s) Mammary (Lymph
Node(s) Mammary)
Lymph Node(s) Pelvic (Lymph Node(s)
Pelvic)
Lymph Node(s) Supraclav (Lymph
Node(s) Supraclav)
Lymph Nodes (Lymph nodes)
Lymphoma (Lymphoma)
Mammary Gland (Mammary Gland)
Mandible (Mandible)
Maxilla (Maxilla)
Mediastinum (Mediastinum)
Mesentery (Mesentery)
Mini Mantle (Mini Mantle)
Mouth (Mouth)
Muscle (Muscle)
Nasal Cavity (Nasal Cavity)
Nasopharynx (Nasopharynx)
Neck (Neck)
Neck/chest/abdomen/pelvis
(Neck/Chest/Abdomen/Pelvis)
Nerve (Nerve)
Ocular Orbits (Ocular Orbits)
Omentum (Omentum)
Oral Cavity (Oral cavity)
Ovary (Ovary)
Posterior Anterior/lateral (PA/Lat)
Palate (Palate)
Pancreas (Pancreas)
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Parotid Gland (Parotid gland)
Patella (Patella)
Pelvis (Pelvis)
Penis (Penis)
Perianus (Perianus)
Pericardium (Pericardium)
Peritoneal Cavity (Peritoneal cavity)
Pharynx (Pharynx)
Pituitary Gland (Pituitary gland)
Pleura (Pleura)
Popliteal Fossa (Popliteal fossa)
Prostate (Prostate)
Pylorus (Pylorus)
Rectum (Rectum)
Retina (Retina)
Retroperitoneum (Retroperitoneum)
Ribs (Ribs)
Round Ligament (Round ligament)
Sacrum (Sacrum)
Salivary Gland (Salivary gland)
Scalp (Scalp)
Scapula (Scapula)
Scrotum (Scrotum)
Shoulder (Shoulder)
Sigmoid Colon (Sigmoid colon)
Sinus(es) (Sinus(es))
Sinus(es), Maxillary (Sinus(es),
Maxillary)
Skin (Skin)
Skull (Skull)
Small Intestine (Small intestine)
Soft Tissue (Soft Tissue)
Spine (Spine)
Spine/femur (Spine/Femur)
Spine/femur/radius
(Spine/Femur/Radius)
Spleen (Spleen)
Sternum (Sternum)
Stomach (Stomach)
Subcutaneous Tissue (Subcutaneous
tissue)
Testicle (Testicle)
Thigh (Thigh)
Thoracic Spine (Thoracic spine)
Thoracic/lumbar Spine (Thoracic/Lumbar
spine)
Thorax (Thorax)
Throat (Throat)
Thymus (Thymus)
Thyroid Gland (Thyroid gland)
Tibia (Tibia)
Tongue (Tongue)
Tongue, Base Of Tongue (Tongue, Base
of tongue)
Tonsil (Tonsil)
Trachea (Trachea)
Trunk (Trunk)
Ureter (Ureter)
Urinary Tract (Urinary tract)
Uterus (Uterus)
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Uvula (Uvula)
Vagina (Vagina)
Vertebra (Vertebra)
Vertebral Column (Vertebral column)
Vulva (Vulva)
Whole Body (Whole body)
Wrist (Wrist)
Lesion Anatomic Site Description
Previously Irradiated Indicator
No (N)
Unknown (U)
Yes (Y)
Measurable/Non-Measurable
Measurable (M)
Non-measurable (N)
Followed For Response Ind
No (N)
Unknown (U)
Yes (Y)
Extent Of Disease-evaluations
Lesion Number
Course Number
Course Day Number
Evaluation Date
Measurement Method
Apheresis (Apheresis)
Arteriogram (Arteriogram)
Arthroscopy (Arthroscopy)
Aspirate, Bone Marrow (Aspirate, Bone
Marrow)
Aspirate, Ultrasound Guided (Aspirate,
Us Guided)
Audiogram (Audiogram)
Barium Enema (Barium Enema)
Barium Swallow (Barium Swallow)
Biopsy (Biopsy)
Biopsy, Core Needle (Biopsy, Core
Needle)
Biopsy, Image Guided (Biopsy, Image
Guided)
Bone Marrow Cellularity (BM Cellularity)
Biopsy, Bone Marrow (Bone Marrow
Biopsy)
Bone Mineral Density (Bone Mineral
Density)
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Bone Scan (Bone Scan)
Bone Spectometry (Bone Spectometry)
Bronchoalveolar Lavage
(Bronchoalveolar Lavage)
Bronchogram (Bronchogram)
Bronchoscopy (Bronchoscopy)
Bronchoscopy/lavage
(Bronchoscopy/Lavage)
Cardiac Catheterization (Cardiac
Catheterization)
Computerized Axial Tomography (CAT
(CT))
Cathetergram (Cathetergram)
Central Line Insertion (Central Line
Insertion)
Colonoscopy (Colonoscopy)
Culture (Culture)
Curative Surgery (Curative Surgery)
X-ray, Chest (CXR)
Cystogram (Cystogram)
Cystoscopy (Cystoscopy)
Cytology (Cytology)
Dental Examination (Dental
Examination)
Dental Procedure (Dental Procedure)
Dissection (Dissection)
Doppler Study (Doppler)
Electrocardiogram (ECG)
Echocardiogram (Echocardiogram)
Electroencephalogram (EEG)
Upper Endoscopy
Esophagogastroduodenoscopy (EGD)
Electrocardiogram (EKG)
Electromyography (EMG)
Endoscopy (Endoscopy)
Esophageal Dilation (Esophageal
dilation)
Esophagoscopy (Esophagoscopy)
Examination Under Anesthesia (EUA)
Excision (Excision)
Exercise Thallium (Exercise Thallium)
Eye Exam (Eye Exam)
Aspirate, Fine Needle (Fine Needle
Aspiration)
Fluoroscopy (Fluoroscopy)
Flow Cytometry (Flw Cyt)
Flow Cytometry, Blood (Flw Cyt Bld)
Flow Cytometry, Bone Marrow (Flw Cyt
BM)
Holter Monitor (Holter Monitor)
Hyperbaric Treatment(s) (Hyperbaric
Treatment(s))
Hysterosonogram (Hysterosonogram)
Incision & Drainage (I&D)
Immunohistochemical Detection/staining
(Immunohistochemical Detection)
Irrigation (Irrigation)
Intravenous Pyelogram (IVP)
X-ray, Abdominal (KUB)
Lymphangiogram (LAG)
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Laparoscopy (Laparoscopy)
Laryngoscopy (Laryngoscopy)
Lower Gastrointestinal Series (Lower GI)
Lumbar Puncture (LP)
Lumpectomy (Lumpectomy)
Lymphadenectomy (Lymphadenectomy)
Lymphocyte Harvest (Lymphocyte
Harvest)
Lymphocyte Infusion (Lymphocyte
Infusion)
Lymphopheresis With Scda Solution
(Lymphopheresis w/SCDA)
Mammogram (Mammogram)
Mammogram, Birad (Mammogram,
BIRAD)
Mammogram, Digitized (Mammogram,
DIGITIZED)
Mammogram, Wolfe (Mammogram,
WOLFE)
Mastectomy (Mastectomy)
Magnetic Resonance Imaging (MRI)
Multi-gated Acquisition Scan (MUGA)
Nasopharyngeal Laryngoscopy
(Nasopharyngeal Laryngoscopy)
Nasopharyngoscopy
(Nasopharyngoscopy)
Nipple Suction Aspirate (Nipple Suction
Aspirate)
Ommaya Resevoir Tap (Ommaya
Resevoir Tap)
Papanicolaou Test (PAP)
Paracentesis (Paracentesis)
Physical Examination (PE)
Pelvic Exam (Pelvic Exam)
Peritoneoscopy (Peritoneoscopy)
Positron Emission Tomography (PET)
Positron Emission Tomography
Computerized Tomography (PET CT)
Positron Emission Tomography With Fdg
(PET, FDG)
Positron Emission Tomography With O-
15 Water (h2o15) (PET, H2O15)
Pulmonary Function Test Interpretation
(PFT Interpretation)
Pulmonary Function Test/carbon
Monoxide Diffusing Capability
(PFT/DLCO)
Pulmonary Function Test/forced
Expiratory Volume 1 (PFT/FEV1)
Pulmonary Function Test/ Inspired
Oxygen Fraction (PFT/FIO2)
Photography (Photography)
Pleurodesis (Pleurodesis)
Portacath Placement (Portacath
Placement)
Percutaneous Transluminal Coronary
Angioplasty (PTCA)
Pulse Oximetry (Pulse Oximetry)
Renogram (Renogram)
Resection (Resection)
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Radiofrequency Ablation (RFA)
Imaging Scan (Scan)
Scan, Dynamic Contrast-enhanced
Magnetic Resonance Imaging (Scan,
DCE MRI)
Scan, Dual-energy X-ray Absorpitometry
(Scan, DEXA)
Scan, Gallium (Scan, Gallium)
Scan, Iodine 123 Uptake (Scan, I 123
Uptake)
Scan, I 131 Uptake (Scan, I 131 Uptake)
Scan, Indium (Scan, Indium WBC)
Scan, Lung Perfusion (Scan, Lung
Perfusion)
Scan, Sestamibi (Scan, Sestamibi)
Ventilation-perfusion Scan (Scan, VQ)
Scraping (Scraping)
Sigmoidoscopy (Sigmoidoscopy)
Skeletal Survey (Skeletal Survey)
Skin Test (Skin Test)
Splenectomy (Splenectomy)
Stress Thallium Test (Stress Thallium
Test)
Thoracentesis (Thoracentesis)
Tomogram (Tomogram)
Transrectal Ultrasound (Transrect US)
Upper Gastrointestinal Series (UGI)
Upper Gastrointestinal Series W/small
Bowel Follow Through (UGI/w sm bowel
f/t)
Ultrasound (Ultrasound)
Urine Casts (Urine Casts)
Vascular Access Device Placement (VAD
Placement)
Vaginogram (Vaginogram)
Venacavagrm (Venacavagrm)
Venogram (Venogram)
X-ray (X-Ray)
Measurement X in Centimeters
Lesion Evaluation Number
Evaluation Code
Baseline (B)
Decreasing (D)
Increasing (I)
New (N)
Resolved (R)
Stable (S)
Comments
Note Date
Research Comments Text
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Radiation
Radiation
Visit Date
Day in Course (Cycle) (Indicates the day since
the beginning of course initiation. Derived from
the course initiation start date.)
Start Date (Enter the start date of the radiation
therapy.)
Start Time (Enter the start time of the radiation
therapy.)
Stop Date (Enter the date of the last dose of the
radiation therapy.)
Stop Time (Enter the stop time of the radiation
therapy.)
Radiation Type (Select the type of radiation
therapy, e.g.: "proton beam", "external beam" or
"implant".)
3d Conformal (3D conformal)
3d Conformal + Imrt Boost (3D
Conformal + IMRT Boost)
High-dose Rate Brachytherapy 3-
dimensional Conformal Radiation
Therapy (3DCRT + Brachytherapy HDR)
Low-dose Treatment Brachytherapy 3-
dimensional Conformal Radiation
Therapy (3DCRT + Brachytherapy LDR)
Adjuvant (Adjuvant RT)
Brachytherapy (Brachytherapy)
Conformal (conformal)
Electron Beam (electron beam)
External Beam Radiation (External beam
radiation)
Hyperfractionated (hyperfractionated)
Imrt (IMRT)
High-dose Rate Brachytherapy Imrt
(IMRT + Brachytherapy HDR)
Low-dose Treatment Brachytherapy Imrt
(IMRT + Brachytherapy LDR)
Imrt And Igrt (IMRT and IGRT)
Neoadjuvant (Neoadjuvant RT)
Not Applicable (Not Applicable)
Other (Other)
Other (Other specify)
Palliative Radiation Therapy (Palliative
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RT)
Photodynamic Therapy (Photodynamic
therapy)
Photon Beam (photon beam)
Proton Beam (proton beam)
Radiofrequency Ablation
(Radiofrequency ablation)
Radiosurgery (radiosurgery)
Tomotherapy (Tomotherapy)
Other, specify (Enter an explanation when Other,
Specify is selected as a Radiation Type.)
Radiation Field (Select the site of the radiation
therapy.)
Total Abdomen (Abdomen, total)
Arm (Arm)
Total Body (Body, total)
Bone, Non-spine (Bone, non-spine)
Brain To Cervical 2 (Brain-C2)
Brain, Focal (Brain, focal)
Brain, Whole (Brain, whole)
Breast (Breast)
Chest Wall, Nos (Chest Wall)
Eye (Eye)
Colon (Gastrointestinal, Colon)
Gallbladder (Gastrointestinal,
Gallbladder)
Intestine (Gastrointestinal, Intestine)
Liver (Gastrointestinal, Liver)
Gastrointestinal, Not Otherwise Specified
(Gastrointestinal, NOS)
Pancreas (Gastrointestinal, Pancreas)
Rectum (Gastrointestinal, Rectum)
Stomach (Gastrointestinal, Stomach)
Bladder (Genitourinary, Bladder)
Kidney (Genitourinary, Kidney)
Genitourinary, Not Otherwise Specified
(Genitourinary, NOS)
Prostate Gland (Genitourinary, Prostate)
Genitourinary, Prostate And Seminal
Vesicles (Genitourinary, Prostate and
Seminal Vesicles)
Head (Head)
Head, Face, Or Neck (Head, Face, or
Neck)
Leg (Leg)
Lung (Lung)
Lymph Node, Distant (specify Site)
(Lymph node, distant (specify site))
Lymph Node, Locoregional (specify Site)
(Lymph node, locoregional (specify site))
Lymph Nodes (Lymph Nodes)
Mantle Field (Mantle)
Mediastinum (Mediastinum)
Parametrium (Parametrium)
Pelvis (ilium, Ischium, And Pubis Bones)
(Pelvis)
Prostate Gland (Prostate)
2 / 6
Treatment - Radiation - 3279836v1.0
Anatomic Area Irradiated After The
Prostate Is Surgically Resected (Prostate
Bed)
Rectum (Rectum)
Sacrum (Sacrum)
Seminal Vesicle (Seminal vesicles)
Skin, Lower Extremity, Local (Skin, lower
extremity, local)
Entire Skin (Skin, total)
Skin, Trunk, Local (Skin, trunk, local)
Skin, Upper Extremity, Local (Skin, upper
extremity, local)
Spine (Spine)
Spine (Spine, whole)
Supraclavicular Field (Supraclavicular)
Thorax (Thorax)
Trunk (Trunk)
Dose (State the total radiation dose the patient
received during the treatment period.)
Dose UOM (Select the radiation dose units of
measurement e.g. cGy or rad, or cSv or rem.)
Percent (%)
10e10 Cells (10E10 Cells)
10e3 Cells (10E3 Cells)
10e4 Cells Per Kilogram (10E4 Cell/kg)
10e4 Cells (10E4 Cells)
10e5 Cells Per Kilogram (10E5 Cell/kg)
10e5 Cells (10E5 Cells)
10e6 Cells Per Kilogram (10E6 Cell/kg)
10e6 Cells (10E6 Cells)
10e7 Cells Per Kilogram (10E7 Cell/kg)
10e7 Cells (10E7 Cells)
10e7 Plaque Forming Units (10E7 PFU)
10e8 Cells (10E8 Cells)
10e8 Plaque Forming Units (10E8 PFU)
10e9 Cells (10E9 Cells)
10e9 Plaque Forming Units (10E9 PFU)
Ampule (Ampule)
Application (Applcatn)
Atomic Unit (au)
Area Under The Curve (AUC)
Billion Pfu (bill PFU)
Bottle (Bottle)
Breaths Per Minute (BPM)
Capful (Capful)
Caplet (Caplet)
Capsule (Capsule)
Cells (Cells)
Cells Per Kilogram (Cells/kg)
Centigray (cGy)
Curie (Ci)
Course (Course)
Cycle (Course)
Deciliter (dL)
Dose (Dose)
Equivalent (Eq)
Grams (g) (g)
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Gram Per M2 (g/m2)
Gallon (Gallon)
Drops (gtts)
Gray (Gy)
Hertz (Hz)
Inch (Inch)
Inhalation (Inhalatn)
Iu Vitamin A (IU Vit A)
International Unit Per Milligram (IU/mg)
International Units Or Milligram Alpha
Tocopherol (IU/mg A-TE)
International Unit (IUnit)
International Unit Per Kilogram (IUnit/kg)
International Unit Per Liter (IUnit/L)
Intravenous Bag (IV Bag)
Infectious Viral Replicon Particles (IVRP)
Joules Per Centimeter Squared (Jcm2)
Kib-electron Volt (KeV)
Kilograms (kg)
Kilohertz (kHz)
Kilopascal (kPa)
Kilounit (kU)
Kilounit Per Kilogram (kU/kg)
Kilounit Per Liter (kU/L)
Liter (L)
Liters Per Minute (L/min)
Megabecquerel (MBq)
Millibecquerel (mBq)
Microgram (mcg)
Microgram Per Centimeter Squared
(mcg/cm2)
Microgram Per Hour (mcg/hr)
Microgram Per Kilogram (mcg/kg)
Microgram Per Meter Squared (mcg/m2)
Millicurie (mCi)
Measure (Measure)
Milliequivalent (mEq)
Milliequivalents Per 24 Hours (mEq/24hr)
Milliequivalent Per Deciliter (mEq/dL)
Milliequivalent Per Hour (mEq/hr)
Milliequivalent Per Liter (mEq/L)
Million Electron Volt (MeV)
Milligram (mg)
Milligram Per 24 Hours (mg/24hr)
Milligram Per Deciliter (mg/dL)
Milligram Per Hour (mg/hr)
Milligram Per Inhalation (mg/inh)
Milligram Per Kilogram (mg/kg)
Milligram Per Kilogram Per Day
(mg/kg/day)
Milligram Per Meter Squared (mg/m2)
Milligram Per Milliliter (mg/mL)
Milligram Per Week (mg/wk)
Megahertz (MHz)
Microcurie (microCi)
Microliter (microL)
Micromole (micromol)
Million Plaque Forming Units (mill PFU)
Million (Million)
Milliunit (millunit)
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Milliinternational Unit (miu)
Milliinternational Units Per Meter
Squared (miu/m2)
Milliliter (mL)
Cubic Centimeter (cc) (mL)
Milliliter Per Hour (mL/hr)
Milliliter Per Kilogram (mL/kg)
Millimoles Per Liter (mM/L)
Millimole (mmol)
Mole (Mole)
Milliosmole (mosmol)
Megarad (Mrad)
Million Units (MU)
Millivolt (mV)
Million Viral Particles (MVP)
Nanocurie (nCi)
Nanogram (ng)
Nanogram Per Kilogram (ng/kg)
Nanogram Per Liter (ng/L)
Nanograms Per Milliliter (ng/mL)
Nanometer Of Light (nm light)
Nanomole (nmol)
No Source Data (No Srce)
Osmolality (osmol)
Ounce (oz)
Pascal (Pa)
Packet (packet)
Patch (Patch)
Plaque Forming Units (PFU)
Picograms (pg)
Pounds Per Square Inch (psi)
Puff (puff)
Radiation Absorbed Dose (Rad)
Vitamin A Retinol (RAE)
Retinol Equivalents (RE)
Seed (Seed)
Session (Session)
Spray (Spray)
Suppository (Suppstry)
Tablets (Tablet)
Tablespoon (Tbsp)
Tissue Culture Infection Dose (TCID)
Thousand (Thousand)
Troche (Troche)
Teaspoon (tsp)
Unit (Unit)
Unit Per Gram (Unit/g)
Unit Per Kilogram (Unit/kg)
Unit Per Meter Squared (Unit/m2)
Unit Per Milliliter (Unit/mL)
Unknown (Unknown)
Viral Particles (VP)
Yeast Units (YU)
Dose per Fraction (Enter the fractionated dose of
radiation therapy administered to a treatment field
or site according to protocol.)
Total Number of Fractions (Enter the number of
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dose-portions or fractions of radiation therapy
actually administered.)
Elapsed Days (Enter the actual number of days
radiation therapy was administered.)
Treatment Delivery Location (Select the institute
where the radiation therapy was administered.)
National Cancer Institute (NCI)
Other (Other)
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Sarcoma NCT01016730 On-Study - AMC-063
Evaluation of KS Lesions Form (RK3) - 3020698v1.0
Sarcoma NCT01016730 On-Study - AMC-063 Evaluation
of KS Lesions Form (RK3) - 3020698v1.0
All rights reserved. Please visit https://medical-data-
models.org/forms/3307
AMC-063 Evaluation of KS Lesions
Form (RK3)
Header Module
Visit number
Unnamed1
Foot Kaposi's Sarcoma (KS)
Absent (Absent)
Present (Present)
Compared to Previous Evaluation
Better (Better)
Same (Same)
Worse (Worse)
Photos Taken (Documentation)
No (No)
Yes (Yes)
Photos Taken Date
Physical findings
No (No)
Yes (Yes)
Specify (If Yes,)
Unnamed2
Are there any oral cavity lesions present at this
evaluation (If NO, go to GI EVALUATION section)
No (No)
Not Evaluated (Not evaluated)
Yes (Yes)
Total Number Raised Lesions
Total Number Flat Lesions (which are countable
or measurable)
Photos Taken (Documentation)
No (No)
Yes (Yes)
Is non-measurable disease present?
No (No)
Yes (Yes)
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Photos Taken Date
Are oral symptoms related to Kaposi's Sarcoma
No (No)
No Symptom (No symptoms)
Yes (Yes)
Explain (If not,)
Oral Site
Buccal Mucosa (Buccal mucosa)
Floor Of Mouth (Floor of mouth)
Gingiva (Gingiva/gums)
Hard Palate (Hard palate)
Pharynx (Posterior pharynx)
Soft Palate (Soft palate)
Tongue (Tongue)
Tonsil (Tonsils)
Uvula (Uvula)
Kaposi's Sarcoma present
No (No)
Yes (Yes)
Oral lesions
A Resolution Of All Oral Lesions Since
Baseline (A resolution of all oral lesions
since baseline)
A Worsening Of Oral Lesions Since
Baseline Or Best Response (A
worsening of oral lesions since baseline
or best response)
An Improvement Of Oral Lesions Since
Baseline (An improvement of oral lesions
since baseline)
New Oral Lesions (New oral lesions)
None Of The Above (None of the above)
Unnamed3
Are there any gastrointestinal (GI) lesions present
at this evaluation (If NO, go to PULMONARY
EVALUATION section)
No (No)
Not Evaluated (Not evaluated)
Yes (Yes)
Are there gastrointestinal (GI) symptoms related
to Kaposi's Sarcoma
No (No)
Yes (Yes)
Explain (If not,)
Method of Evaluation
Endoscopy (Endoscopy)
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Radiology (Radiological)
Performed
No (No)
Yes (Yes)
Assessment Date (mm/dd/yyyy)
Findings
Unnamed4
Are there any pulmonary Kaposi's Sarcoma (KS)
lesions present at this evaluation (If NO, go to
EDEMA EVALUATION section)
No (No)
Not Evaluated (Not evaluated)
Yes (Yes)
Indicate if the lesions are measurable or non-
measurable
Both Measurable And Non-measurable
(Both Measurable and Non-measurable)
Measurable Disease (Measurable)
Non-measurable (Non-measurable)
Are the pulmonary symptoms related to Kaposi's
Sarcoma
No (No)
Yes (Yes)
Explain (If not,)
Method of Evaluation
Endoscopy (Endoscopy)
Radiology (Radiological)
Performed
No (No)
Yes (Yes)
Assessment Date (mm/dd/yyyy)
Pleural Effusion
No (NO)
Yes (YES)
Specify number of lesions
Total Number New Lesions
Lesion Measurements
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Site of Lesion
Dimension 1 (cm)
Dimension 2 (cm)
Bronchoscopy And Other Tests
Bronchoscopy Performed
No (No)
Yes (Yes)
Date the bronchoscopy was performed
(mm/dd/yyyy)
Findings
Any Other Tests Performed
No (No)
Yes (Yes)
Other Tests
Findings
Footer Module
Comments
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Treatment - Colorectal Cancer - Surgery
Form - 2020211v2.31
Treatment - Colorectal Cancer - Surgery Form -
2020211v2.31
All rights reserved. Please visit https://medical-data-
models.org/forms/3318
Colorectal Cancer - Surgery Form
Colorectal: Surgical Procedure
Prior RT Ind
No (NO)
Unknown (UNKNOWN)
Yes (YES)
Prior Chemotherapy Ind
No (NO)
Unknown (UNKNOWN)
Yes (YES)
Prior Immunotherapy Ind
No (NO)
Unknown (UNKNOWN)
Yes (YES)
Tumor Location
Appendix (Appendix)
Ascending Colon (Ascending colon)
Cecum (Cecum)
Descending Colon (Descending colon)
Hepatic Flexure (Hepatic flexure)
Other, Specify (Other, specify)
Rectum (Rectum)
Sigmoid (Sigmoid)
Splenic Flexure (Splenic flexure)
Transverse Colon (Transverse colon)
Tumor Location, Other
Surgical Approach
Abdominal Perineal Resection
(Abdominal perineal resection)
Left Colectomy (Left colectomy)
Low Anterior Resection (Low anterior
resection)
Right Colectomy (Right colectomy)
Sigmoidectomy (Sigmoidectomy)
Sphincter-preserving Rectal Resection
(Sphincter-preserving rectal resection)
Total Colectomy (Total colectomy)
Transverse Colectomy (Transverse
colectomy)
Obstruction Ind
No (NO)
Unknown (UNKNOWN)
Yes (YES)
Tumor Spillage Ind
No (No)
Unknown (Unknown)
Yes (Yes)
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Lymph Nodes Removed Ind
No (No)
Unknown (Unknown)
Yes (Yes)
En Bloc Resection Ind
No (No)
Unknown (Unknown)
Yes (Yes)
Tumor Adherence Ind
No (No)
Unknown (unknown)
Yes (Yes)
Tumor Adherence, Specify Organ
Distance to Distal Bowel
Distance to Proximal Bowel
Distance to Distal Mesorectal
Radial Margins Disease Free Gross Ind
No (No)
Unknown (Unknown)
Yes (Yes)
Radial Margins Disease Free Micro Ind
No (No)
Unknown (Unknown)
Yes (Yes)
Assessment Site
Celiac (Celiac)
Liver (Liver)
Omentum (Omentum)
Ovaries (Ovaries)
Periaortic (Periaortic)
Peritoneal Surface (Peritoneal surface)
Portohepatic (Portohepatic)
Evaluation Ind
No (No)
Unknown (Unknown)
Yes (Yes)
Metastasis Confirmed
No (No)
Na (Not applicable)
Yes (Yes)
Metastasis Completely Resected
No (No)
Na (Not applicable)
Yes (Yes)
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Surgeon Name
Allows Documentation Of Any Additional
Cooments
Comments
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Nonneoplastic Condition NCT01057121 On-Study -
AMC-070 Physical Exam Form (RK2) - 3147341v1.0
Nonneoplastic Condition NCT01057121 On-Study - AMC-
070 Physical Exam Form (RK2) - 3147341v1.0
All rights reserved. Please visit https://medical-data-
models.org/forms/3323
AMC-070 Physical Exam Form
(RK2)
Header Module
Visit number
Unnamed2
At entry, does the participant have >=50 lesions
No (No)
Yes (Yes)
Representative Area
Abdomen (Abdomen)
Back (Back)
Chest (Chest)
Genital Area (Genital)
Head (Head)
Left Arm (Left arm)
Left Foot (Left foot)
Left Hand (Left hand)
Left Leg (Left leg)
Neck (Neck)
Right Arm (Right arm)
Right Foot (Right foot)
Right Hand (Right hand)
Right Leg (Right leg)
Total Body (Total body)
Total Number Raised Lesions
Total Number Flat Lesions
Total Number New Lesions
Number of cutaneous lesions
>=25% Increase In The Number Of
Lesions Since Baseline Or Since Best
Response (>=25% increase in the
number of lesions since baseline or
since best response)
>=50% Decrease In The Number Of
Lesions Since Baseline (>=50%
decrease in the number of lesions since
baseline)
Complete Resolution (Complete
resolution)
None Of The Above (None of the above)
Character of cutaneous lesions (since baseline or
best response)
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>=25% Increase In The Number Of
Raised Lesions (>=25% increase in the
number of raised lesions)
None Of The Above (None of the above)
Since Baseline, >=50% Of Raised Have
Become Flat (Since baseline, >=50% of
raised have become flat)
Unnamed3
Representative Area
Abdomen (Abdomen)
Back (Back)
Chest (Chest)
Genital Area (Genital)
Head (Head)
Left Arm (Left arm)
Left Foot (Left foot)
Left Hand (Left hand)
Left Leg (Left leg)
Neck (Neck)
Right Arm (Right arm)
Right Foot (Right foot)
Right Hand (Right hand)
Right Leg (Right leg)
Total Body (Total body)
Specify
Dimension 1 (cm)
Dimension 2 (cm)
Product of Diameters
Photos Taken
No (No)
Yes (Yes)
Sum of Products of Greatest Diameters
Evaluation of Marker Lesions
>=25% Inc In Sum Of The Products Of
The Diam Of All Marker Lesions Since
Baseline/best Response (>=25% inc in
sum of the products of the diam of all
marker lesions since baseline/best
response)
>=50% Decrease In The Sum Of The
Products Of The Diameters Of All Marker
Lesions Since Baseline (>=50%
decrease in the sum of the products of
the diameters of all marker lesions since
baseline)
Complete Resolution (Complete
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resolution)
None Of The Above (None of the above)
Footer Module
Comments
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Nonneoplastic Condition NCT01057121 On-Study - AMC-
070 Evaluation of Edema Form (RK4) - 3146480v1.0
Nonneoplastic Condition NCT01057121 On-Study - AMC-
070 Evaluation of Edema Form (RK4) - 3146480v1.0
All rights reserved. Please visit https://medical-data-
models.org/forms/3326
AMC-070 Evaluation of Edema Form
(RK4)
Header Module
Visit number
Unnamed1
Is there any tumor-associated edema at this
evaluation (If NO, go to EVALUATION OF
EXTREMITY EDEMA section)
No (No)
Yes (Yes)
Edema Site
Genital Area (Genital)
Left Arm (Left arm)
Left Foot (Left foot)
Left Hand (Left hand)
Left Leg (Left leg)
Other (Other)
Periorbital (Periorbital)
Right Arm (Right arm)
Right Foot (Right foot)
Right Hand (Right hand)
Right Leg (Right leg)
Other, specify
Edema Present
No (No)
Yes (Yes)
Compared to Previous Evaluation
Better (Better)
Same (Same)
Worse (Worse)
Edema evaluation
A Resolution Of All Tumor-associated
Edema Since Baseline (A resolution of
all tumor-associated edema since
baseline)
A Worsening Of Tumor-associated
Edema Since Baseline Or Best
Response (A worsening of tumor-
associated edema since baseline or best
response)
An Improvement Of Tumor-associated
Edema Since Baseline (An improvement
of tumor-associated edema since
baseline)
New Tumor-associated Edema (New
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tumor-associated edema)
No Change (No change)
Unnamed2
Status of extremity edema
Absent (Absent)
Present (Present)
Specific Location
Limb Girth (cm)
Other Findings
Unnamed3
Photos Taken
No (No)
Yes (Yes)
Photos Taken Date
Physical findings
No (No)
Yes (Yes)
Specify (If yes,)
Unnamed4
Photos Taken
No (No)
Yes (Yes)
Photos Taken Date
Physical findings
No (No)
Yes (Yes)
Specify (If yes,)
Evaluation Of Visceral Disease
Has an evaluation for visceral disease been done
(If NO, please stop here)
No (NO)
Yes (YES)
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Has a visceral disease evaluation been done
since the last Kaposi's Sarcoma (KS) evaluation
(If NO, please stop here. If NO, at Follow-up, go
to the section titled INTERVENTIONS on the
Intervention Form. Be sure to indicate the
procedure used to document presence, absence
or resolution of disease)
No (No)
Yes (Yes)
Visceral Disease Site
Abdomen (Abdomen)
Back (Back)
Chest (Chest)
Genital Area (Genital)
Head (Head)
Left Arm (Left arm)
Left Foot (Left foot)
Left Hand (Left hand)
Left Leg (Left leg)
Neck (Neck)
Right Arm (Right arm)
Right Foot (Right foot)
Right Hand (Right hand)
Right Leg (Right leg)
Total Body (Total body)
Site of Lesion
Kaposi's Sarcoma present
No (No)
Yes (Yes)
Visceral Evaluation
A Complete Resolution Of Visceral
Disease Since Baseline (A complete
resolution of visceral disease since
baseline)
A Decrease In Visceral Disease Since
Baseline (A decrease in visceral disease
since baseline)
A Worsening Of Visceral Disease Since
Baseline, Or Since The Best Response
(A worsening of visceral disease since
baseline, or since the best response)
Evidence Of A New Site Of Visceral
Disease Since Baseline, Or Since The
Best Response (Evidence of a new site
of visceral disease since baseline, or
since the best response)
No Change (No change)
Not Applicable (Not applicable)
Method of Evaluation (Be sure to indicate the
procedure used to document presence, absence
or resolution of disease.)
Bronchoscopy (Bronchoscopy)
Chest X-ray (Chest x-ray)
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Colonoscopy (Colonoscopy)
Other (Other)
Sigmoidoscopy (Sigmoidoscopy)
Upper Endoscopy
Esophagogastroduodenoscopy (Upper
endoscopy)
Other Specify
Date of Evaluation (mm/dd/yyyy)
Evaluation Of Visceral Disease
Visceral Disease Site
Abdomen (Abdomen)
Back (Back)
Chest (Chest)
Genital Area (Genital)
Head (Head)
Left Arm (Left arm)
Left Foot (Left foot)
Left Hand (Left hand)
Left Leg (Left leg)
Neck (Neck)
Right Arm (Right arm)
Right Foot (Right foot)
Right Hand (Right hand)
Right Leg (Right leg)
Total Body (Total body)
Site of Lesion
Kaposi's Sarcoma present
No (No)
Yes (Yes)
Visceral Evaluation
A Complete Resolution Of Visceral
Disease Since Baseline (A complete
resolution of visceral disease since
baseline)
A Decrease In Visceral Disease Since
Baseline (A decrease in visceral disease
since baseline)
A Worsening Of Visceral Disease Since
Baseline, Or Since The Best Response
(A worsening of visceral disease since
baseline, or since the best response)
Evidence Of A New Site Of Visceral
Disease Since Baseline, Or Since The
Best Response (Evidence of a new site
of visceral disease since baseline, or
since the best response)
No Change (No change)
Not Applicable (Not applicable)
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Method of Evaluation (Be sure to indicate the
procedure used to document presence, absence
or resolution of disease.)
Bronchoscopy (Bronchoscopy)
Chest X-ray (Chest x-ray)
Colonoscopy (Colonoscopy)
Other (Other)
Sigmoidoscopy (Sigmoidoscopy)
Upper Endoscopy
Esophagogastroduodenoscopy (Upper
endoscopy)
Other Specify
Date of Evaluation (mm/dd/yyyy)
Evaluation Of Visceral Disease
Visceral Disease Site
Abdomen (Abdomen)
Back (Back)
Chest (Chest)
Genital Area (Genital)
Head (Head)
Left Arm (Left arm)
Left Foot (Left foot)
Left Hand (Left hand)
Left Leg (Left leg)
Neck (Neck)
Right Arm (Right arm)
Right Foot (Right foot)
Right Hand (Right hand)
Right Leg (Right leg)
Total Body (Total body)
Site of Lesion
Kaposi's Sarcoma present
No (No)
Yes (Yes)
Visceral Evaluation
A Complete Resolution Of Visceral
Disease Since Baseline (A complete
resolution of visceral disease since
baseline)
A Decrease In Visceral Disease Since
Baseline (A decrease in visceral disease
since baseline)
A Worsening Of Visceral Disease Since
Baseline, Or Since The Best Response
(A worsening of visceral disease since
baseline, or since the best response)
Evidence Of A New Site Of Visceral
Disease Since Baseline, Or Since The
Best Response (Evidence of a new site
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of visceral disease since baseline, or
since the best response)
No Change (No change)
Not Applicable (Not applicable)
Method of Evaluation (Be sure to indicate the
procedure used to document presence, absence
or resolution of disease.)
Bronchoscopy (Bronchoscopy)
Chest X-ray (Chest x-ray)
Colonoscopy (Colonoscopy)
Other (Other)
Sigmoidoscopy (Sigmoidoscopy)
Upper Endoscopy
Esophagogastroduodenoscopy (Upper
endoscopy)
Other Specify
Date of Evaluation (mm/dd/yyyy)
Footer Module
Comments
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On-Study - SCINTIGRAPHY - 2411693v1.0
All rights reserved. Please visit https://medical-data-
models.org/forms/3328
SCINTIGRAPHY
Scintigraphy
Trial Number
Course Number
Course Day Number
Sample Collection Date
Nuclide Name
Aliquot count (ml)
Antibody Name
Corrected Aliquot Counter per Minute Number
Total Administered (ml)
Sample ID Number
Tissue Class
Normal (N)
Tumor (T)
Site type
Abnormal (Abnormal)
Normal (Normal)
Sample Description Text
Gamma Scan Positive Indicator
Equivocal (E)
No (N)
Yes (Y)
CT Scan Positive Ind
Equivocal (E)
No (N)
Yes (Y)
Surgical Biopsy Indicator
Identified But Not Biopsied (INB)
Not Found (NF)
Yes (Y)
Sample Weight In Gram Number
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Tumor Assessed Percentage
Corrected Radioniclude Counter per Minute
Corrected Radioniclude Counter per Minute
Comments
Note Date
Research Comments Text
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Sarcoma, Kaposi xxx Lab - Abnormal Liver
Function Tests - RF29 - 2266098v3.0
Sarcoma, Kaposi xxx Lab - Abnormal Liver Function Tests -
RF29 - 2266098v3.0
All rights reserved. Please visit https://medical-data-
models.org/forms/3329
Abnormal Liver Function Tests -
RF29
Ccrr Module For Abnormal Liver Function
Tests - Rf29
ID#
Alkaline Phosphatase (mU/ml) Value
Alkaline Phosphatase (mU/ml) LLN
Alkaline Phosphatase (mU/ml) ULN
Total Bilirubin (mg/dl) Value
Total Bilirubin (mg/dl) LLN
Total Bilirubin (mg/dl) ULN
Direct Bilirubin (mg/dl) Value
Direct Bilirubin (mg/dl) LLN
SGPT (ALT) (mU/ml) ULN
SGPT (ALT) (mU/ml) LLN
SGPT (ALT) (mU/ml) Value
Cycle#
Visit Date
Which evaluation does this represent?
Entry/Baseline (Entry/Baseline)
On Treatment (On Treatment)
Post Therapy Evaluation (Post Therapy
Evaluation)
Were any of the liver function tests outside of
normal limits?
No (No)
Yes (Yes)
Check if abnormal
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Alkaline Phosphatase (mU/ml) (Alkaline
Phosphatase (mU/ml))
Direct Bilirubin (mg/dl) (Direct Bilirubin
(mg/dl))
SGOT (AST) mU/ml (SGOT (AST)
mU/ml)
SGPT (ALT) (mU/ml) (SGPT (ALT)
(mU/ml))
Total Bilirubin (mg/dl) (Total Bilirubin
(mg/dl))
SGOT (AST) mU/ml Value
SGOT (AST) mU/ml LLN
SGOT (AST) mU/ml ULN
Direct Bilirubin (mg/dl) ULN
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All rights reserved. Please visit https://medical-data-
models.org/forms/3330
TRANSFUSION
Transfusion
Course Number
Course Day Number
Blood Component Transfusion Date
Lab Collection Time
Blood Component Transfusion Text Name
Cryoprecipitate (Cryoprecipitate)
Packed Red Blood Cells Transfusion
(Packed RBC)
Packed Autologous Red Blood Cells
Transfusion (Packed RBC, Autologous)
Packed Autologous Irradiated Red Blood
Cells Transfusion (Packed RBC,
Autologous, Irradiated)
Packed Autologous Leukoreduced Red
Blood Cells Transfusion (Packed RBC,
Autologous, Leukoreduced)
Packed Irradiated Red Blood Cells
Transfusion (Packed RBC, Irradiated)
Packed Leukopoor Red Blood Cells
Transfusion (Packed RBC, Leukopoor)
Packed Leukoreduced Red Blood Cells
Transfusion (Packed RBC,
Leukoreduced)
Platelet (Platelet)
Platelets, Hla-matched (Platelets, HLA
Match)
Platelets, Irradiated (Platelets, Irradiated)
Platelets, Leukoreduced (Platelets,
Leukoreduced)
White Blood Cells (WBC)
White Blood Cells, Irradiated (WBC,
Irradiated)
Whole Blood (Whole Blood)
Transfuse Blood Component Units
Comments
Note Date
Research Comments Text
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models.org/forms/3342
AMC-063 Evaluation of Edema Form
(RK4)
Header Module
Visit number
Unnamed1
Is there any tumor-associated edema at this
evaluation (If NO, go to EVALUATION OF
EXTREMITY EDEMA section)
No (No)
Yes (Yes)
Edema Site
Genital Area (Genital)
Left Arm (Left arm)
Left Foot (Left foot)
Left Hand (Left hand)
Left Leg (Left leg)
Other (Other)
Periorbital (Periorbital)
Right Arm (Right arm)
Right Foot (Right foot)
Right Hand (Right hand)
Right Leg (Right leg)
Other, specify
Edema Present
No (No)
Yes (Yes)
Compared to Previous Evaluation
Better (Better)
Same (Same)
Worse (Worse)
Edema evaluation
A Resolution Of All Tumor-associated
Edema Since Baseline (A resolution of
all tumor-associated edema since
baseline)
A Worsening Of Tumor-associated
Edema Since Baseline Or Best
Response (A worsening of tumor-
associated edema since baseline or best
response)
An Improvement Of Tumor-associated
Edema Since Baseline (An improvement
of tumor-associated edema since
baseline)
New Tumor-associated Edema (New
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tumor-associated edema)
No Change (No change)
Unnamed2
Status of extremity edema
Absent (Absent)
Present (Present)
Specific Location
Limb Girth (cm)
Other Findings
Unnamed3
Photos Taken
No (No)
Yes (Yes)
Photos Taken Date
Physical findings
No (No)
Yes (Yes)
Specify (If yes,)
Unnamed4
Photos Taken
No (No)
Yes (Yes)
Photos Taken Date
Physical findings
No (No)
Yes (Yes)
Specify (If yes,)
Evaluation Of Visceral Disease
Has an evaluation for visceral disease been done
(If NO, please stop here)
No (NO)
Yes (YES)
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Has a visceral disease evaluation been done
since the last Kaposi's Sarcoma (KS) evaluation
(If NO, please stop here. If NO, at Follow-up, go
to the section titled INTERVENTIONS on the
Intervention Form. Be sure to indicate the
procedure used to document presence, absence
or resolution of disease)
No (No)
Yes (Yes)
Visceral Disease Site
Abdomen (Abdomen)
Back (Back)
Chest (Chest)
Genital Area (Genital)
Head (Head)
Left Arm (Left arm)
Left Foot (Left foot)
Left Hand (Left hand)
Left Leg (Left leg)
Neck (Neck)
Right Arm (Right arm)
Right Foot (Right foot)
Right Hand (Right hand)
Right Leg (Right leg)
Total Body (Total body)
Site of Lesion
Kaposi's Sarcoma present
No (No)
Yes (Yes)
Visceral Evaluation
A Complete Resolution Of Visceral
Disease Since Baseline (A complete
resolution of visceral disease since
baseline)
A Decrease In Visceral Disease Since
Baseline (A decrease in visceral disease
since baseline)
A Worsening Of Visceral Disease Since
Baseline, Or Since The Best Response
(A worsening of visceral disease since
baseline, or since the best response)
Evidence Of A New Site Of Visceral
Disease Since Baseline, Or Since The
Best Response (Evidence of a new site
of visceral disease since baseline, or
since the best response)
No Change (No change)
Not Applicable (Not applicable)
Method of Evaluation (Be sure to indicate the
procedure used to document presence, absence
or resolution of disease.)
Bronchoscopy (Bronchoscopy)
Chest X-ray (Chest x-ray)
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Colonoscopy (Colonoscopy)
Other (Other)
Sigmoidoscopy (Sigmoidoscopy)
Upper Endoscopy
Esophagogastroduodenoscopy (Upper
endoscopy)
Other Specify
Date of Evaluation (mm/dd/yyyy)
Evaluation Of Visceral Disease
Visceral Disease Site
Abdomen (Abdomen)
Back (Back)
Chest (Chest)
Genital Area (Genital)
Head (Head)
Left Arm (Left arm)
Left Foot (Left foot)
Left Hand (Left hand)
Left Leg (Left leg)
Neck (Neck)
Right Arm (Right arm)
Right Foot (Right foot)
Right Hand (Right hand)
Right Leg (Right leg)
Total Body (Total body)
Site of Lesion
Kaposi's Sarcoma present
No (No)
Yes (Yes)
Visceral Evaluation
A Complete Resolution Of Visceral
Disease Since Baseline (A complete
resolution of visceral disease since
baseline)
A Decrease In Visceral Disease Since
Baseline (A decrease in visceral disease
since baseline)
A Worsening Of Visceral Disease Since
Baseline, Or Since The Best Response
(A worsening of visceral disease since
baseline, or since the best response)
Evidence Of A New Site Of Visceral
Disease Since Baseline, Or Since The
Best Response (Evidence of a new site
of visceral disease since baseline, or
since the best response)
No Change (No change)
Not Applicable (Not applicable)
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Method of Evaluation (Be sure to indicate the
procedure used to document presence, absence
or resolution of disease.)
Bronchoscopy (Bronchoscopy)
Chest X-ray (Chest x-ray)
Colonoscopy (Colonoscopy)
Other (Other)
Sigmoidoscopy (Sigmoidoscopy)
Upper Endoscopy
Esophagogastroduodenoscopy (Upper
endoscopy)
Other Specify
Date of Evaluation (mm/dd/yyyy)
Evaluation Of Visceral Disease
Visceral Disease Site
Abdomen (Abdomen)
Back (Back)
Chest (Chest)
Genital Area (Genital)
Head (Head)
Left Arm (Left arm)
Left Foot (Left foot)
Left Hand (Left hand)
Left Leg (Left leg)
Neck (Neck)
Right Arm (Right arm)
Right Foot (Right foot)
Right Hand (Right hand)
Right Leg (Right leg)
Total Body (Total body)
Site of Lesion
Kaposi's Sarcoma present
No (No)
Yes (Yes)
Visceral Evaluation
A Complete Resolution Of Visceral
Disease Since Baseline (A complete
resolution of visceral disease since
baseline)
A Decrease In Visceral Disease Since
Baseline (A decrease in visceral disease
since baseline)
A Worsening Of Visceral Disease Since
Baseline, Or Since The Best Response
(A worsening of visceral disease since
baseline, or since the best response)
Evidence Of A New Site Of Visceral
Disease Since Baseline, Or Since The
Best Response (Evidence of a new site
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of visceral disease since baseline, or
since the best response)
No Change (No change)
Not Applicable (Not applicable)
Method of Evaluation (Be sure to indicate the
procedure used to document presence, absence
or resolution of disease.)
Bronchoscopy (Bronchoscopy)
Chest X-ray (Chest x-ray)
Colonoscopy (Colonoscopy)
Other (Other)
Sigmoidoscopy (Sigmoidoscopy)
Upper Endoscopy
Esophagogastroduodenoscopy (Upper
endoscopy)
Other Specify
Date of Evaluation (mm/dd/yyyy)
Footer Module
Comments
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Pathology - Pathology Report -
3300776v1.0
Pathology - Pathology Report - 3300776v1.0
All rights reserved. Please visit https://medical-data-
models.org/forms/3350
Pathology Report
Pathology
Visit Date
Comments
Surgical pathology # (Enter the pathology
number.)
Surgery Date (Enter the date of the surgical
procedure.)
Pathology Results Date (Enter the pathology
results date.)
Specify Other Procedure
Body Site of Collection (Use Pick List)
Abdomen (Abdomen)
Abdomen/pelvis (Abdomen/Pelvis)
Abdominal Wall (Abdominal wall)
Acetabulum (Acetabulum)
Pharyngeal Tonsil (Adenoid)
Adipose Tissue (Adipose)
Adrenal Gland (Adrenal gland)
Alveolar Ridge (Alveolar Ridge)
Amniotic Fluid (Amniotic Fluid)
Ampulla Of Vater (Ampulla of Vater)
Anal Canal (Anal canal)
Anal Sphincter (Anal sphincter)
Ankle (Ankle)
Anorectum (Anorectum)
Antecubital Fossa (Antecubital fossa)
Antrum Pylori (Antrum)
Anus (Anus)
Aorta (Aorta)
Aortic Body (Aortic Body)
Appendix (Appendix)
Aqueous Fluid (Aqueous Fluid)
Arm (Arm)
Artery (Artery)
Ascending Colon (Ascending colon)
Ascending Colon Hepatic Flexure
(Ascending Colon Hepatic Flexure)
Auditory Canal (Auditory canal)
Autonomic Nervous System (Autonomic
nervous system)
Axilla (Axilla)
Back (Back)
Bile Duct (Bile duct)
Bladder (Bladder)
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Blood (Blood)
Blood Vessel (Blood vessel)
Bone (Bone)
Bone Marrow (Bone marrow)
Bowel (Bowel)
Brain (Brain)
Brain Stem (Brain stem)
Breast (Breast)
Broad Ligament (Broad ligament)
Bronchiole (Bronchiole)
Bronchus (Bronchus)
Bronchus And Lung (Bronchus and
Lung)
Brow (Brow)
Buccal Cavity (Buccal cavity)
Buccal Mucosa (Buccal mucosa)
Buttock (Buttock)
Calf (Calf)
Capillary (Capillary)
Gastric Cardia (Cardia)
Carina (Carina)
Carotid Artery (Carotid artery)
Carotid Body (Carotid body)
Cartilage (Cartilage)
Cecum (Cecum)
Central Line Catheter (Central Line
Catheter)
Central Nervous System (Central
nervous system)
Cerebellum (Cerebellum)
Cerebral Cortex (Cerebral cortex)
Cerebrospinal Fluid (Cerebrospinal fluid)
Cerebrum (Cerebrum)
Cervical Spine (Cervical spine)
Cervical/thoracic/lumbar Spine
(Cervical/Thoracic/Lumbar spine)
Cervix (Cervix)
Chest (Chest)
Chest Wall (Chest wall)
Chest/abdomen/pelvis
(Chest/Abdomen/Pelvis)
Chest/pelvis (Chest/Pelvis)
Chin (Chin)
Clavicle (Clavicle)
Clitoris (Clitoris)
Colon (Colon)
Colon And Rectum (Colon and rectum)
Colon Mucosa (Colon, mucosa only)
Common Duct (Common duct)
Conjunctiva (Conjunctiva)
Connective Tissue (Connective tissue)
Descending Colon (Descending colon)
Diaphragm (Diaphragm)
Duodenum (Duodenum)
Ear (Ear)
Ear Canal (Ear canal)
External Ear (Ear, Pinna (External))
Effusion (Effusion)
Elbow (Elbow)
Endocrine Gland (Endocrine gland)
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Epididymis (Epididymis)
Epidural Spinal Canal Space (Epidural
space)
Esophagogastric Junction
(Esophagogastric junction)
Esophagus (Esophagus)
Esophageal Mucosa (Esophagus,
Mucosa only)
Extremities (Extremities)
Eye (Eye)
Fallopian Tube (Fallopian tube)
Femur (Femur)
Fibula (Fibula)
Finger (Finger)
Floor Of Mouth (Floor of Mouth)
Body Fluid Or Substance (Fluid)
Foot (Foot)
Forearm (Forearm)
Forehead (Forehead)
Foreskin (Foreskin)
Frontal Lobe (Frontal lobe)
Fundus Of Stomach (Fundus of
stomach)
Gallbladder (Gallbladder)
Ganglion (Ganglia)
Gastroesophageal Junction
(Gastroesophageal Junction)
Gastrointestinal Tract (Gastrointestinal
tract)
Genitourinary (Genitourinary)
Groin (Groin)
Gum (Gum)
Hand (Hand)
Hard Palate (Hard palate)
Head - Face Or Neck, Nos (Head - face
or neck, NOS)
Head/neck (Head/Neck)
Head/neck/chest/adb/pelvis
(Head/Neck/Chest/Adb/Pelvis)
Heart (Heart)
Hepatic Duct (Hepatic duct)
Hip (Hip)
Humerus (Humerus)
Hypopharynx (Hypopharynx)
Ileum (Ileum)
Ilium (Ilium)
Intestine (Intestine)
Ischium (Ischium)
Jaw (Jaw)
Jejunum (Jejunum)
Joints (Joints)
Kidney (Kidney)
Knee (Knee)
Lacrimal Gland (Lacrimal Gland)
Large Bowel (Large bowel)
Laryngopharynx (Laryngopharynx)
Larynx (Larynx)
Leg (Leg)
Ligament (Ligament)
Lip (Lip)
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Liver (Liver)
Liver And Intrahepatic Duct (Liver and
intrahepatic duct)
Liver/spleen (Liver/Spleen)
Lumbar Spine (Lumbar spine)
Lung (Lung)
Lymph Node (Lymph node)
Lymph Node(s) Axilla (Lymph Node(s)
Axilla)
Lymph Node(s) Cervical (Lymph Node(s)
Cervical)
Distant Lymph Node (Lymph node(s)
Distant)
Lymph Node(s) Hilar (Lymph Node(s)
Hilar)
Lymph Node(s) Inguinal (Lymph Node(s)
Inguinal)
Lymph Node(s) Int Mammary (Lymph
Node(s) Int Mammary)
Lymph Node(s) Mammary (Lymph
Node(s) Mammary)
Paraaortic Region Lymph Node (Lymph
node(s) Para aortic)
Lymph Node(s) Pelvic (Lymph Node(s)
Pelvic)
Regional Lymph Node (Lymph node(s)
Regional)
Scalene Lymph Node (Lymph node(s)
Scalene)
Lymph Node(s) Subclavicular (Lymph
Node(s) Subclavicular)
Lymph Node(s) Supraclav (Lymph
Node(s) Supraclav)
Lymph Nodes (Lymph nodes)
Mediastinal Lymph Node (Lymph
nodes(s) Mediastinal)
Lymphoma (Lymphoma)
Mammary Gland (Mammary Gland)
Mandible (Mandible)
Maxilla (Maxilla)
Mediastinum (Mediastinum)
Mesentery (Mesentery)
Mesothelium (Mesothelium)
Mini Mantle (Mini Mantle)
Mouth (Mouth)
Muscle (Muscle)
Nail (Nails)
Nasal Cavity (Nasal Cavity)
Nasopharynx (Nasopharynx)
Neck (Neck)
Neck Chest (Neck/Chest)
Neck/chest/abdomen/pelvis
(Neck/Chest/Abdomen/Pelvis)
Nerve (Nerve)
Cranial Nerve (Nerve(s) Cranial)
Not Applicable (Not Applicable)
Ocular Orbits (Ocular Orbits)
Omentum (Omentum)
Oral Cavity (Oral cavity)
Oral Cavity Mucosa (Oral Cavity, Mucosa
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only)
Oropharynx (Oropharynx)
Other (Other)
Ovary (Ovary)
Posterior Anterior/lateral (PA/Lat)
Palate (Palate)
Pancreas (Pancreas)
Paraspinal Ganglion (Paraspinal
Ganglion)
Parathyroid Gland (Parathyroid)
Parotid Gland (Parotid gland)
Patella (Patella)
Pelvis (Pelvis)
Penis (Penis)
Perianus (Perianus)
Pericardium (Pericardium)
Peritoneal Cavity (Peritoneal cavity)
Peritoneum (Peritoneum)
Pharynx (Pharynx)
Pineal Gland (Pineal Gland)
Pituitary Gland (Pituitary gland)
Placenta (Placenta)
Pleura (Pleura)
Popliteal Fossa (Popliteal fossa)
Prostate (Prostate)
Pylorus (Pylorus)
Rectosigmoid Junction (Rectosigmoid
Junction)
Rectum (Rectum)
Retina (Retina)
Retro-orbital Area (Retro-orbital Area)
Retroperitoneum (Retroperitoneum)
Ribs (Ribs)
Round Ligament (Round ligament)
Sacrum (Sacrum)
Salivary Gland (Salivary gland)
Scalp (Scalp)
Scapula (Scapula)
Scrotum (Scrotum)
Shoulder Joint (Shoulder)
Sigmoid Colon (Sigmoid colon)
Sinus(es) (Sinus(es))
Sinus(es), Maxillary (Sinus(es),
Maxillary)
Skeletal Muscle Tissue (Skeletal Muscle)
Skin (Skin)
Skull (Skull)
Small Bowel Mucosa (Small Bowel,
Mucosa only)
Small Intestine (Small intestine)
Soft Tissue (Soft Tissue)
Spinal Cord (Spinal Cord)
Spine (Spine)
Spine/femur (Spine/Femur)
Spine/femur/radius
(Spine/Femur/Radius)
Spleen (Spleen)
Splenic Flexure (Splenic Flexure)
Sternum (Sternum)
Stomach (Stomach)
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Stomach Mucosa (Stomach, Mucosa
only)
Subcutaneous Tissue (Subcutaneous
tissue)
Synovial Membrane (Synovium)
Tendon (Tendon)
Testis (Testicle)
Testicle (Testicle)
Thigh (Thigh)
Thoracic Spine (Thoracic spine)
Thoracic/lumbar Spine (Thoracic/Lumbar
spine)
Thorax (Thorax)
Throat (Throat)
Thymus (Thymus)
Thyroid Gland (Thyroid gland)
Tibia (Tibia)
Tongue (Tongue)
Tongue, Base Of Tongue (Tongue, Base
of tongue)
Tonsil (Tonsil)
Pharyngeal Tonsil (Tonsil, Pharyngeal)
Trachea (Trachea)
Trachea Main Bronchus (Trachea/Major
Bronchi)
Transverse Colon (Transverse Colon)
Trunk (Trunk)
Superficial Trunk (Trunk, Superficial)
Umbilical Cord (Umbilical Cord)
Upper Extremity (Upper extremity)
Ureter (Ureter)
Urethra (Urethra)
Urinary Tract (Urinary tract)
Uterus (Uterus)
Uvula (Uvula)
Vagina (Vagina)
Vas Deferens (Vas Deferens)
Vein (Vein)
Vena Cava (Vena Cava,
Inferior/Superior)
Vertebra (Vertebra)
Vertebral Column (Vertebral column)
Vulva (Vulva)
Whole Body (Whole body)
Wrist (Wrist)
Gross Description
Visit Date
Comments
Pathology Sample Type (Select the Pathology
Sample Type.)
Apheresis Cells (A)
Whole Blood (B)
Csf (C)
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Cd33 Myeloid Cells (D)
Pericardial Effusion (E)
Abdominal Effusion (F)
Pax Gene Rna (G)
Lymph Node (H)
Hair (J)
Cd3 Lymphoid Cells (L)
Pbmc (peripheral Blood Mononuclear
Cells) (M)
Normal Tissue (N)
Bone Marrow (O)
Plasma (P)
Pleural Effusion (R)
Serum (S)
Tumor Tissue (T)
Urine (U)
Saliva (V)
Leukocytes Or White Blood Cells (W)
Cd14/cd15 Myeloid Cells (Y)
Cell Block (Z)
Condition of Margin (Use Pick List)
Less Than 1mm (Close (<1 mm))
Dysplasia Present (Dysplasia present)
Negative Margin (Negative)
Not Applicable (Not Applicable)
Positive Margin (Positive)
Unknown - To Be Answered At Next Data
Capture Interval (Unknown)
Number of Lymph Nodes Sampled
Number of Positive Lymph Nodes (Enter number
of positive nodes.)
Findings (Enter findings.)
Greatest Dimension of Specimen (cm)
Second Greatest Dimension of Specimen (cm)
Stage of Disease (Use Pick List)
Stage 0 (0)
Stage A (A)
Stage B (B)
Stage C (C)
Stage D (D)
Stage D0 (D0)
Stage D1 (D1)
Stage D2 (D2)
Stage D3 (D3)
Stage I (I)
Stage Ia (IA)
Stage Ib (IB)
Stage Ic (IC)
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Stage Ie (extranodal) (IE)
Stage Ii (II)
Stage Iia (IIA)
Stage Iib (IIB)
Stage Iic (IIC)
Stage Iie (extranodal) (IIE)
Stage Iii (III)
Stage Iiia (IIIA)
Stage Iiib (IIIB)
Iiic (IIIC)
Stage Iv (IV)
Stage Iva (IVA)
Stage Ivb (IVB)
Disease T Stage
Disease N Stage
Disease M Stage
Differentiation (Use Pick List)
High Grade (High Grade)
Low Grade (Low Grade)
Moderately Differentiated (Moderately)
Not Applicable (N/A)
Not Otherwise Specified (NOS)
Not Done (Not Done)
Poorly Differentiated (Poorly)
Undifferentiated (Undifferentiated)
Unknown - To Be Answered At Next Data
Capture Interval (Unknown)
Well Differentiated (Well)
Differentiation (Use Pick List)
High Grade (High Grade)
Low Grade (Low Grade)
Moderately Differentiated (Moderately)
Not Applicable (N/A)
Not Otherwise Specified (NOS)
Not Done (Not Done)
Poorly Differentiated (Poorly)
Undifferentiated (Undifferentiated)
Unknown - To Be Answered At Next Data
Capture Interval (Unknown)
Well Differentiated (Well)
Histology
Visit Date
Comments
Peritoneal Lavage result (Use Pick List)
Negative Finding (Negative)
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Not Performed (Not Done)
Positive Finding (Positive)
Lymphatic Invasion present (Use Pick List)
Indeterminate (Indeterminate)
No (No)
No Surgical Procedure (No Surgery)
No Information Available (Unavailable)
Yes (Yes)
Vascular Invasion present
Indeterminate (Indeterminate)
No (No)
No Surgical Procedure (No Surgery)
No Information Available (Unavailable)
Yes (Yes)
Microcalcification present (Use Pick List)
Indeterminate (Indeterminate)
No (No)
No Surgical Procedure (No Surgery)
No Information Available (Unavailable)
Yes (Yes)
Notable Benign changes (Use Pick List)
Adenoid Cystic (ADENOID CYSTIC)
Adh (ADH)
Apocrine (APOCRINE)
Carcinoma With Cartilaginous/osseous
Metaplasia (CA CARTIL OSSEOUS)
Carcinoma With Mixed Metaplasia (CA
MIX METAPLA)
Carcinoma With Spindle Cell (CA SPIN
CELL METAPLA)
Carcinoma With Squamous Metaplasia
(CA SQUAM METAPLA)
Carcinoma, Nos (not Otherwise
Specified) (CARCINOMA NOS)
Carcinoma In Situ, Nos (CIS NOS)
Comedo/mucinous (Comedo/Mucinous)
Cribiform (CRIBIFORM)
Ductal Hyperplasia, Usual Type (DUCT
HYPERPLASIA)
Ductal (DUCTAL CA)
Ductal Cis (DUCTAL CIS)
Extensive Ductal Cis (EXT DUCTAL CIS)
Infiltrating Ductal Carcinoma (Infiltrating
Ductal)
Infiltrating Lobular Carcinoma (Infiltrating
Lobular)
Lobular (LOBULAR CA)
Lobular Neoplasia (lcis, Alh) (LOBULAR
NEOPLA)
Medullary Carcinoma (MEDULLARY)
Mixed Ductal/lobular (Mixed
ductal/lobular)
Mucinous Adenocarcinoma
(MUCINOUS)
None (NONE)
Not Present (NOT PRESENT)
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Other (OTHER)
Paget Disease (PAGET DIS)
Papillary (PAPILLARY)
Poorly Differentiated, Not Otherwise
Specified (Poorly Differentiated NOS)
Secretory (SECRETORY)
Tubular Adenocarcinoma (TUBULAR)
If yes, Description
Microscopic Description
Visit Date
Comments
Is this patient evaluable for immunostaining (IHC)
No (No)
Yes, All (Yes)
Analyzed
No (No)
Yes (Yes)
Assay Date
Marker Test Method (Use Pick List)
Comparative Genomic Hybridization
(CGH)
Elisa (ELISA)
Fluorescence In Situ Hybridization (fish)
(Fluorescence in situ hybridization
(FISH))
Immunohistochemistry (ihc)
(Immunohistochemistry (IHC))
In Situ Hybridization (in situ
Hybridization)
Ligand Binding Assay (Ligand Binding
Assay)
Loss Of Heterozygosity (LOH)
Microarray (Microarray)
Other, Specify (Other)
Pcr, Polymerase Chain Reaction (PCR)
Rtpcr, Rt-pcr, Reverse Transcriptase-
polymerase Chain Reaction (RT-PCR)
Serum Extracellular Domain (ecd) Test
(Serum ECD test)
Intensity Score (Use Pick List)
No Staining (0)
Weak (1)
Moderate (2)
Strong (3)
Very Strong (4)
Cell Staining Percentage
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Mutation Detected
Indeterminate (Indeterminate)
No (No)
Yes (Yes)
Result
Negative (NEGATIVE)
Positive (POSITIVE)
Unknown - To Be Answered At Next Data
Capture Interval (UNKNOWN)
Biomarker Comments (Enter the comments.)
Path Report Description (Enter the description of
the pathology report.)
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Response - COURSE ASSESSMENT -
2399255v1.0
Response - COURSE ASSESSMENT - 2399255v1.0
All rights reserved. Please visit https://medical-data-
models.org/forms/3367
COURSE ASSESSMENT
Course Assessment
Course Start Date
Treatment Course End Date
Previous Dose Change Indicator
Na, This Is First Course (0)
Yes, Planned (1)
Yes, Unplanned (2)
No (3)
Unknown (9)
Course Disposition
Completed (Completed)
Discontinued (Discontinued)
Response Assessment Type
Complete Response (CR)
Complete Response Unconfirmed (CRU)
Disease Unchanged (DU)
Less Than Partial Response (MR)
Not Assessed (NA)
Not Evauable (NE)
Not Applicable Per Protocol (NP)
No Response (NR)
Progressive Disease (PD)
Partial Response (PR)
Stable Disease (SD)
Too Early (TE)
Unknown (UK)
Response Note Text
Best Response Date
Progression Date
Toxicity Indicator
No (N)
Yes (Y)
Course Number (This is a derived field and may
be displayed on the form, if needed.)
Comments
Note Date
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Sarcoma NCT01016730 Pathology - AMC-
063 KS Biopsy Form (BIO) - 3114182v1.0
Sarcoma NCT01016730 Pathology - AMC-063 KS Biopsy
Form (BIO) - 3114182v1.0
All rights reserved. Please visit https://medical-data-
models.org/forms/3370
AMC-063 KS Biopsy Form (BIO)
Header Module
Visit number
Unnamed2
Total Number of Biopsies (performed at this visit)
Unnamed1
Date of Biopsy (mm/dd/yyyy)
Biopsy site
Abdomen (Abdomen)
Back (Back)
Chest (Chest)
Genital Area (Genital)
Head (Head)
Left Arm (Left arm)
Left Foot (Left foot)
Left Hand (Left hand)
Left Leg (Left leg)
Neck (Neck)
Right Arm (Right arm)
Right Foot (Right foot)
Right Hand (Right hand)
Right Leg (Right leg)
Biopsy Size (mm)
Specify the biopsy site
Specimen Fixative
Formalin (Formalin)
Glutaraldehyde (Glutaraldehyde)
Oct Media (OCT media)
Rnalater (RNAlater)
Saline (Saline)
Unnamed1
Date of Biopsy (mm/dd/yyyy)
Biopsy site
Abdomen (Abdomen)
Back (Back)
Chest (Chest)
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Genital Area (Genital)
Head (Head)
Left Arm (Left arm)
Left Foot (Left foot)
Left Hand (Left hand)
Left Leg (Left leg)
Neck (Neck)
Right Arm (Right arm)
Right Foot (Right foot)
Right Hand (Right hand)
Right Leg (Right leg)
Biopsy Size (mm)
Specify the biopsy site
Specimen Fixative
Formalin (Formalin)
Glutaraldehyde (Glutaraldehyde)
Oct Media (OCT media)
Rnalater (RNAlater)
Saline (Saline)
Unnamed1
Date of Biopsy (mm/dd/yyyy)
Biopsy site
Abdomen (Abdomen)
Back (Back)
Chest (Chest)
Genital Area (Genital)
Head (Head)
Left Arm (Left arm)
Left Foot (Left foot)
Left Hand (Left hand)
Left Leg (Left leg)
Neck (Neck)
Right Arm (Right arm)
Right Foot (Right foot)
Right Hand (Right hand)
Right Leg (Right leg)
Biopsy Size (mm)
Specify the biopsy site
Specimen Fixative
Formalin (Formalin)
Glutaraldehyde (Glutaraldehyde)
Oct Media (OCT media)
Rnalater (RNAlater)
Saline (Saline)
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Unnamed1
Date of Biopsy (mm/dd/yyyy)
Biopsy site
Abdomen (Abdomen)
Back (Back)
Chest (Chest)
Genital Area (Genital)
Head (Head)
Left Arm (Left arm)
Left Foot (Left foot)
Left Hand (Left hand)
Left Leg (Left leg)
Neck (Neck)
Right Arm (Right arm)
Right Foot (Right foot)
Right Hand (Right hand)
Right Leg (Right leg)
Biopsy Size (mm)
Specify the biopsy site
Specimen Fixative
Formalin (Formalin)
Glutaraldehyde (Glutaraldehyde)
Oct Media (OCT media)
Rnalater (RNAlater)
Saline (Saline)
Unnamed1
Date of Biopsy (mm/dd/yyyy)
Biopsy site
Abdomen (Abdomen)
Back (Back)
Chest (Chest)
Genital Area (Genital)
Head (Head)
Left Arm (Left arm)
Left Foot (Left foot)
Left Hand (Left hand)
Left Leg (Left leg)
Neck (Neck)
Right Arm (Right arm)
Right Foot (Right foot)
Right Hand (Right hand)
Right Leg (Right leg)
Biopsy Size (mm)
Specify the biopsy site
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Specimen Fixative
Formalin (Formalin)
Glutaraldehyde (Glutaraldehyde)
Oct Media (OCT media)
Rnalater (RNAlater)
Saline (Saline)
Unnamed1
Date of Biopsy (mm/dd/yyyy)
Biopsy site
Abdomen (Abdomen)
Back (Back)
Chest (Chest)
Genital Area (Genital)
Head (Head)
Left Arm (Left arm)
Left Foot (Left foot)
Left Hand (Left hand)
Left Leg (Left leg)
Neck (Neck)
Right Arm (Right arm)
Right Foot (Right foot)
Right Hand (Right hand)
Right Leg (Right leg)
Biopsy Size (mm)
Specify the biopsy site
Specimen Fixative
Formalin (Formalin)
Glutaraldehyde (Glutaraldehyde)
Oct Media (OCT media)
Rnalater (RNAlater)
Saline (Saline)
Footer Module
Comments
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Form (SP) - 2843494v1.0
Sarcoma NCT01533207 Lab - Specimen Form (SP) -
2843494v1.0
All rights reserved. Please visit https://medical-data-
models.org/forms/3386
Specimen Form (SP)
Header Module
Date form originally completed
Date form amended
Person amending form, last name
Patient Study ID
GOG Bank ID #
Person Completing Form, Last Name
Site Contact Information
Phone number
Email address
General Specimen Information
Specimen Code
Time point
Collected
Not Submitted (No)
Submitted (Yes)
No, specify
Collection date
Collection time (when required by the protocol)
Specimen type
Buffy Coat (Buffy coat)
Cells (Cells)
Fixed Tissue (Fixed tissue)
Frozen Tissue (Frozen tissue)
Other (Other)
Plasma (Plasma)
Serum (Serum)
Urine (Urine)
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Whole Blood (Whole blood)
Other, specify
Other, specify
Items shipped
Block (Block)
Oct-mold (OCT-mold)
Other (Other)
Piece (Piece)
Slide (Slide)
Tube/vial (Tube/Vial)
Quantity of items shipped
Processing time
<1 Hour (<1 hour)
>4 Hours (>4 hours)
1-2 Hours (1-2 hours)
2-4 Hours (2-4 hours)
N/a (NA)
Storage type
Other (Other)
Refrigerator (Refrigerator)
Room Temperature (Room temperature)
Standard Non-cycling Freezer (Standard
non-cycling freezer)
Ultracold Freezer/liquid N2/dry Ice
(Ultracold freezer/liquid N2/dry ice)
Other specify
Date shipped
Courier tracking number
Comments
Blood/fluid Products
Type of blood collection tube
Acid Citrate Dextrose (acd) (ACD)
Citrate (Citrate)
Edta (EDTA)
Heparin (Heparin)
Other (Other)
Red Top (Red top)
Serum Separator (Serum separator)
Other specify
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Platelet count required?
No (No)
Yes (Yes)
Platelet count
Platelet Date
Preservative
No (No)
Yes (Yes)
Yes, specify below
Urine collection method
24-hour (24-hour)
Clean Catch (Clean catch)
Other (Other)
Other, specify
Tissue/cells
Tissue type
Metastatic Tumor (Metastatic tumor)
Normal (Normal)
Other (Other)
Pre-malignant (Pre-malignant)
Primary Tumor (Primary tumor)
Recurrent/persistent Tumor
(Recurrent/persistent tumor)
Other specify
Processing method
Ethanol-fixed (Ethanol-fixed)
Fixed & Paraffin-embedded (Fixed &
paraffin-embedded)
Formalin-fixed (Formalin-fixed)
Oct-frozen (OCT-frozen)
Other (Other)
Snap-frozen (Snap-frozen)
Other, specify
Cell type
Buccal (Buccal)
Cervical (Cervical)
Other (Other)
Other, specify
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Gog Tissue Bank/laboratory Information
Receiving institution
Gog Tissue Bank (GOG Tissue Bank)
Laboratory (Laboratory)
Specimen received date (m d y)
Phone number
Total volume/weight
Email address
Units
Additional processing required
No (No)
Yes (Yes)
Specify
Condition of received specimens
Satisfactory (Satisfactory)
Unsatisfactory (Unsatisfactory)
Unsatisfactory, specify
Staff name
Lab name
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Pre-Study - BASELINE MEDICAL
HISTORY - 2393057v1.0
Pre-Study - BASELINE MEDICAL HISTORY - 2393057v1.0
All rights reserved. Please visit https://medical-data-
models.org/forms/3390
BASELINE MEDICAL HISTORY
Baseline Medical History
Evaluation Date
Body System Type
Abdomen (ABDOMEN)
Allergy Or Drug Sensitivity History
(Allergy/Drug Sensitivity)
Appearance (Appearance)
Body As A Whole (Body as a Whole)
Breasts (BREASTS)
Cardiovascular (CARDIOVASCULAR)
Central Nervous System (Central
Nervous System)
Chest (Chest)
Constitutional (Constitutional)
Dermatologic (DERMATOLOGIC)
Endocrine/metabolic
(ENDOCRINE/METABOLIC)
Extremities (Extremities)
Gastrointestinal (GASTROINTESTINAL)
Genitalia (GENITALIA)
Genitourinary (Genitourinary)
H/e/e/n/t (H/E/E/N/T)
Hematologic (HEMATOLOGIC)
Hematopoietic/lymph
(HEMATOPOIETIC/LYMPH)
Hepatic (Hepatic)
Immune (IMMUNE)
Integumentary/hair (Integumentary/Hair)
Musculoskeletal (MUSCULOSKELETAL)
Neck (NECK)
Neurologic (NEUROLOGIC)
Other (OTHER)
Pelvis (PELVIS)
Peripheral Vascular System (Peripheral
Vascular)
Psychologic (PSYCHOLOGIC)
Pulmonary (Pulmonary)
Rectal (Rectal)
Renal (Renal)
Reproductive History (Reproductive
History)
Respiratory (RESPIRATORY)
Spleen (Spleen)
Substance Abuse/dependency
(Substance abuse/Dependency)
Transfusion History (Transfusion History)
Urinary (URINARY)
Medical History Description
Comments
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Note Date
Research Comments Text
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Sarcoma NCT01016730 On-Study - AMC-063 KS
Evaluation and Clinical Benefit Form (RK1) - 3020614v1.0
Sarcoma NCT01016730 On-Study - AMC-063 KS
Evaluation and Clinical Benefit Form (RK1) - 3020614v1.0
All rights reserved. Please visit https://medical-data-
models.org/forms/3414
AMC-063 KS Evaluation and Clinical
Benefit Form (RK1)
Header Module
Visit number
Date of evaluation
Reporting Period
Baseline (Baseline)
On Treatment (On treatment)
Post-therapy (Post therapy)
Unnamed1
Oral cavity symptoms
No Symptom (No symptoms)
Oral Cavity Symptoms Interfering
W/function Most/all Of The Time, Or
Recurrent Bleeding (Oral cavity
symptoms interfering w/function most/all
of the time, or recurrent bleeding)
Oral Cavity Symptoms Not Interfering
With Function (Oral cavity symptoms not
interfering with function)
Symptoms Interfering W/function
Sometimes, Or Occasional Bleeding;
Can Take Adequate Nutrition (Symptoms
interfering w/function sometimes, or
occasional bleeding; can take adequate
nutrition)
Other related oral cavity symptoms
No (No)
Yes (Yes)
Specify (If yes)
Gastrointestinal (GI) symptoms
Gross Bleeding Requiring Transfusions,
Evidence Of Obstruction, Unable To
Maintain Adequate Intake (Gross
bleeding requiring transfusions, evidence
of obstruction, unable to maintain
adequate intake)
Gross Bleeding, Or Frequent Gi
Symptoms (Gross bleeding, or frequent
GI symptoms)
Minimal Gi Symptoms (Minimal GI
symptoms)
No Symptom (No symptoms)
Other related gastrointestinal (GI) symptoms
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No (No)
Yes (Yes)
Specify (If yes)
Pulmonary symptoms
No Symptom (No symptoms)
Severely Limited Activities, +/-
Hemoptysis (Severely limited activities,
+/- hemoptysis)
Symptoms At Rest, Requiring Oxygen Or
Hemoptysis (Symptoms at rest, requiring
oxygen or hemoptysis)
Symptoms On Exertion (Symptoms on
exertion)
Symptoms On Normal Activity
(Symptoms on normal activity)
Other related pulmonary symptoms
No (No)
Yes (Yes)
Specify (If yes)
Unnamed2
Is the participant experiencing tumor-related pain
No (No)
Yes (Yes)
Is the participant on analgesics
No (No)
Yes (Yes)
What was the average pain experienced by the
participant over the last 24 hours
Discomforting Pain (Discomforting pain)
Distressing Pain (Distressing pain)
Excruciating Pain (Excruciating pain)
Horrible Pain (Horrible pain)
Mild Pain (Mild pain)
No Pain (No pain)
Pain
Absent (Absent)
Present (Present)
Anatomic Site of Worst Pain
Unnamed3
Extremity Edema Symptoms
Completely Resolves With Limb
Elevation And Rings/shoes Fit Without
Difficulty (Completely resolves with limb
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elevation and rings/shoes fit without
difficulty)
Does Not Completely Resolve With Limb
Elevation Or Rings/shoes Do Not Fit
Normally (Does not completely resolve
with limb elevation or rings/shoes do not
fit normally)
No Edema, No Symptoms (No edema,
no symptoms)
No Improvement With Limb Elevation Or
Interferes With Normal Function (No
improvement with limb elevation or
interferes with normal function)
Significantly Reduced Function
(Significantly reduced function)
Periorbital Edema Symptoms
No Periorbital Edema (No periorbital
edema)
Swelling Of Eyes Noted At All Times And
Interferes With Eyesight Or Function At
All Times (Swelling of eyes noted at all
times and interferes with eyesight or
function at all times)
Swelling Of Eyes Noted At All Times And
Interferes With Eyesight Or Function
Sometimes (Swelling of eyes noted at all
times and interferes with eyesight or
function sometimes)
Swelling Of The Eyes Noted At All Times
But Does Not Interfere With Eyesight Or
Function (Swelling of the eyes noted at
all times but does not interfere with
eyesight or function)
Swelling Of The Eyes Noted
Occasionally Or Improves Over The Day
(Swelling of the eyes noted occasionally
or improves over the day)
Scrotal/Genital Edema Symptoms
No Scrotal/genital Edema (No
scrotal/genital edema)
Swelling Interferes With Urination,
Sexual Function, Withdrawing Foreskin
All The Time (Swelling interferes with
urination, sexual function, withdrawing
foreskin all the time)
Swelling Interferes With Urination,
Sexual Function, Withdrawing Foreskin
Sometimes (Swelling interferes with
urination, sexual function, withdrawing
foreskin sometimes)
Swelling Of The Scrotum Noted At All
Times But No Symptoms (Swelling of the
scrotum noted at all times but no
symptoms)
Swelling Of The Scrotum Noted
Occasionally (Swelling of the scrotum
noted occasionally)
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Foot Kaposi's Sarcoma (KS) symptoms
Active But Cannot Perform More Than
Normal Activities (Active but cannot
perform more than normal activities)
Lesions Present But No Symptoms. Able
To Perform Normal Activities (Lesions
present but no symptoms. Able to
perform normal activities)
Moderate Impairment Of Activity
Because Of Foot Ks (Moderate
impairment of activity because of foot
KS)
Normal Activities Mildly Limited Because
Of Foot Ks (Normal activities mildly
limited because of foot KS)
Severe Impairment Of Activity Due To
Foot Ks (Severe impairment of activity
due to foot KS)
Footer Module
Comments
4 / 4
Sarcoma NCT01016730 On-Study - AMC-063 KS Evaluation and Clinical
Benefit Form (RK1) - 3020614v1.0
Sarcoma NCT00450320 Lab - AMC-051 HIV T-
Cell Laboratory Values Form (F24) - 2636088v1.0
Sarcoma NCT00450320 Lab - AMC-051 HIV T-Cell
Laboratory Values Form (F24) - 2636088v1.0
All rights reserved. Please visit https://medical-data-
models.org/forms/3418
AMC-051 HIV T-Cell Laboratory
Values Form (F24)
Unnamed1
Visit number
Sequence number
Unnamed2
Date of Evaluation (mm/dd/yyyy)
T-cell Laboratory Values
T-Helper CD4+ %
T-Helper CD4+ absolute count
Other, specify
Percent Positive Lymphocytes
Absolute Count
Comments
Comments
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Transplant Essential Data - 2855957v1.0
Treatment - 2455 Revision 1 - Selective Post-Transplant
Essential Data - 2855957v1.0
All rights reserved. Please visit https://medical-data-
models.org/forms/3419
2455 Revision 1 - Selective Post-
Transplant Essential Data
Registry Use Only
Sequence number:
Date received:
Center Identification
CIBMTR Center Number:
EBMT Code (CIC) Number
Date of this report:
Follow-Up:
Integer::6 Month (6 Months)
Annual (Annual)
Integer::100 Day (Day 100)
annual, specify year:
Recipient Identification
CIBMTR Recipient ID:
Chronological # of this:  HSCT #:
Chronological # of this:  DCI #:
Date of HSCT for this follow - up:
Did the recipient receive a subsequent HSCT
since the date of contact from the last report?
No (No)
Yes (Yes)
New Malignancy, Lymphoproliferative Or
Myeloproliferative Disorder
Did a new malignancy, lymphoproliferative or
myeloproliferative disorder occur? (Different from
the disease for which HSCT performed not
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recurrence or transformation.)
No (No)
Unknown (Unknown)
Yes (Yes)
New Malignancy, Lymphoproliferative Or
Myeloproliferative Disorder
Date of diagnosis:
Specify:
Acute Myeloid Leukemia (Acute myeloid
leukemia (AML / ANLL))
Breast Carcinoma (Breast cancer)
Central Nervous System Neoplasm
(Central nervous system (CNS)
malignancy (glioblastoma, astrocytoma))
Malignant Gastrointestinal Neoplasm
(Gastrointestinal malignancy (colon,
rectum, stomach, pancreas, intestine))
Genitourinary System Malignant
Neoplasm (Genitourinary malignancy
(kidney, bladder, ovary, testicle, genitalia,
uterus, cervix))
Hodgkin's Lymphoma (Hodgkin disease)
Lung Carcinoma (Lung cancer)
Lymphoma Or Lymphoproliferative
Disorder (Lymphoma or
lymphoproliferative disease)
Melanoma (Melanoma)
Myelodysplastic/myeloproliferative
Disease (Myelodysplasia (MDS),
myeloproliferative (MPS) disorder)
Oropharyngeal Carcinoma
(Oropharyngeal cancer (tongue, buccal
mucosa))
Other Leukemia (Other leukemia
including ALL)
Other Malignant Neoplasm (Other
malignancy)
Other Malignant Skin Neoplasm (Other
skin malignancy (basal cell, squamous))
Clonality Cytogenetic Abnormality
(Related by descent from clonal
cytogenetic abnormality without leukemia
or MDS)
Sarcoma (Sarcoma)
Thyroid Gland Carcinoma (Thyroid
cancer)
Please specify the new other leukemia disorder
that occurred.
Is the tumor EBV positive?
No (No)
Unknown (Unknown)
Yes (Yes)
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Specify the other new malignancy,
lymphoproliferative or myeloproliferative disorder .
Copy of pathology report / documentation
attached?
No (No)
Yes (Yes)
Survival
Survival status at latest follow-up:
Life (Alive)
Death (Dead)
Negation Follow-up (Lost to Follow-
up(LTF))
Latest follow-up:
Date of death:
Main cause of death: (check only one main
cause)
And/or Persistent Recurrent Disease
Disease Progression (Disease
progression and/or persistent relapse)
Transplantation Relationship
Hematopoietic Stem Cell (HSCT related
causes)
New Malignant Neoplasm (New
malignancy)
Other (Other)
Unknown (Unknown)
Main cause of death: Other,specify
Last known date alive:
Day of the month is estimated
Yes (Yes)
Survival
HSCT related causes (Check as many as
appropriate )
Cardiotoxicity (Cardiac toxicity)
Graft Versus Host Disease (GVHD)
Infection (Infection)
Other (Other)
Toxicity Pulmonary (Pulmonary toxicity)
Graft Rejection (Rejection / poor graft
function)
Hepatic Veno-occlusive Disease (VOD)
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What is the main cause of HSCT related death?
No (No)
Yes (Yes)
Specify: (Answer only if the response to CDE
2768637 is "Other".)
Author Information
First Name
Last Name
Phone number:
Fax number:
E-mail address:
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NCT00981097 On-Study - AMC-064 Baseline Lymphoma
Disease Activity and Assessment Form (LAA) - 2944124v1.0
NCT00981097 On-Study - AMC-064 Baseline Lymphoma
Disease Activity and Assessment Form (LAA) -
2944124v1.0
All rights reserved. Please visit https://medical-data-
models.org/forms/3421
AMC-064 Baseline Lymphoma
Disease Activity and Assessment
Form (LAA)
Unnamed1
Visit Number
Unnamed2
Modified Ann Arbor Stage
I (I)
Ie (IE)
Ii (II)
Iie (IIE)
Iii (III)
Iiie (IIIE)
Iiie+s (IIIE+S)
Iiis (IIIS)
Iv (IV)
Recurring, drenching night sweats during the
previous month (Does the participant have any of
the following symptoms at the time of registration)
No (No)
Yes (Yes)
Unexplained, persistent fever >38 degrees C (or
>100 degrees F) in the previous month (Does the
participant have any of the following symptoms at
the time of registration)
No (No)
Yes (Yes)
Unexplained weight loss >10% of body weight in
the previous 6 months (Does the participant have
any of the following symptoms at the time of
registration)
No (No)
Yes (Yes)
Hematopoietic Diagnosis
Burkitt Lymphoma/leukemia (Burkitt
lymphoma/leukemia)
Diffuse Large B-cell Lymphoma (Diffuse
large B-cell lymphoma)
Hodgkin's Lymphoma (Hodgkin
lymphoma)
Kshv/hhv-8+ Plasmablastic Lymphoma
(lymph Node) (KSHV/HHV-8+
plasmablastic lymphoma (lymph node))
Other (Other)
Plasma Lymphoma Of Oral Cavity
(Plasma lymphoma of oral cavity)
Polymorphic B Cell Lymphoma-ptld Type
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(Polymorphic B cell lymphoma-PTLD
type)
Primary Effusion Lymphoma (Primary
effusion lymphoma)
If diffuse large B-cell lymphoma, specify
morphologic type
Centroblastic (Centroblastic)
Immunoblastic (Immunoblastic)
Not Specified (Not specified)
Other (Other)
If Burkitt lymphoma/leukemia, specify
morphologic type
B Cell Lymphoma Unclassifiable,
W/features Intermediate Between Dlbcl
And Burkitt's. (atypical) (B cell lymphoma
unclassifiable, w/features intermediate
between DLBCL and Burkitt's. (Atypical))
Classical (Classical)
Other (Other)
Plasmacytoid (Plasmacytoid)
Other specify
Other specify
Other specify
If Hodgkin lymphoma, specify morphologic type
Lymphocyte Depleted (Lymphocyte
depleted)
Lymphocyte Rich (Lymphocyte rich)
Mixed Cellularity (Mixed cellularity)
Nodular Sclerosis (Nodular sclerosis)
Unclassified (Unclassified)
Date of Initial Pathologic Diagnosis (mm/dd/yyyy)
Method of Evaluation
Biopsy (Biopsy)
Cytology (Cytology)
Other (Other)
Other Specify
Is the participant >60 years of age (Please enter
the information below to obtain International
Prognostic Index poor risk features)
No (No)
Yes (Yes)
Does the participant have Stage III or IV disease
(Please enter the information below to obtain
International Prognostic Index poor risk features)
No (No)
Yes (Yes)
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Is the serum LDH elevated (Please enter the
information below to obtain International
Prognostic Index poor risk features)
No (No)
Yes (Yes)
Is the ECOG Performance Status 2, 3, or 4
(Please enter the information below to obtain
International Prognostic Index poor risk features)
No (No)
Yes (Yes)
Does the participant have two or more extranodal
disease sites (Please enter the information below
to obtain International Prognostic Index poor risk
features)
No (No)
Yes (Yes)
International Prognostic Index
0 (0)
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
IPI Risk Category
High Risk (High risk)
High-intermediate Risk (High-
intermediate risk)
Low Risk (Low risk)
Low-intermediate Risk (Low-intermediate
risk)
Histogenetic Subtyping Markers
Histogenetic Subtyping Markers
Bcl6 (BCL6)
Cd10 (CD10)
Foxp1 (FOXP1)
Gcet1 (GCET1)
Mum1 (MUM1)
Finding Result
Negative (Negative)
Not Assessed (Not assessed)
Positive (Positive)
Ki-67 Staining Index Score
0% To 29% (0% to 29%)
30% To 59% (30% to 59%)
60% To 79% (60% to 79%)
80% To 100% (80% to 100%)
Not Done (Not done)
EBV Status
Eber Negative (EBER negative)
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Eber Positive (EBER positive)
Not Done (Not done)
Bulky Disease
No (No)
Yes (Yes)
Comments
Comments
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Sarcoma NCT00450320 On-Study - AMC-051 KS
Evaluation and Clinical Benefit Form (RK1) - 2636841v1.0
Sarcoma NCT00450320 On-Study - AMC-051 KS
Evaluation and Clinical Benefit Form (RK1) - 2636841v1.0
All rights reserved. Please visit https://medical-data-
models.org/forms/3422
AMC-051 KS Evaluation and Clinical
Benefit Form (RK1)
Header Module
Visit number
Date of evaluation
Reporting Period
Baseline (Baseline)
On Treatment (On treatment)
Post-therapy (Post therapy)
Unnamed1
Symptoms of oral cavity lesions
No Symptom (No symptoms)
Oral Cavity Symptoms Interfering
W/function Most/all Of The Time, Or
Recurrent Bleeding (Oral cavity
symptoms interfering w/function most/all
of the time, or recurrent bleeding)
Oral Cavity Symptoms Not Interfering
With Function (Oral cavity symptoms not
interfering with function)
Symptoms Interfering W/function
Sometimes, Or Occasional Bleeding;
Can Take Adequate Nutrition (Symptoms
interfering w/function sometimes, or
occasional bleeding; can take adequate
nutrition)
Other related oral cavity symptoms
No (No)
Yes (Yes)
Specify
Gastrointestinal (GI) symptoms
Gross Bleeding Requiring Transfusions,
Evidence Of Obstruction, Unable To
Maintain Adequate Intake (Gross
bleeding requiring transfusions, evidence
of obstruction, unable to maintain
adequate intake)
Gross Bleeding, Or Frequent Gi
Symptoms (Gross bleeding, or frequent
GI symptoms)
Minimal Gi Symptoms (Minimal GI
symptoms)
No Symptom (No symptoms)
Other related gastrointestinal (GI) symptoms
1 / 4
No (No)
Yes (Yes)
Specify
Pulmonary symptoms
No Symptom (No symptoms)
Severely Limited Activities, +/-
Hemoptysis (Severely limited activities,
+/- hemoptysis)
Symptoms At Rest, Requiring Oxygen Or
Hemoptysis (Symptoms at rest, requiring
oxygen or hemoptysis)
Symptoms On Exertion (Symptoms on
exertion)
Symptoms On Normal Activity
(Symptoms on normal activity)
Other related pulmonary symptoms
No (No)
Unknown (Unknown)
Yes (Yes)
Specify
Unnamed2
Is the participant experiencing tumor-related pain
No (No)
Yes (Yes)
Is the participant on analgesics
No (No)
Yes (Yes)
What was the average pain experienced by the
participant over the last 24 hours
Discomforting Pain (Discomforting pain)
Distressing Pain (Distressing pain)
Excruciating Pain (Excruciating pain)
Horrible Pain (Horrible pain)
Mild Pain (Mild pain)
No Pain (No pain)
Pain
Absent (Absent)
Present (Present)
Anatomic Site of Worst Pain
Unnamed3
Symptoms of extremity edema
Completely Resolves With Limb
Elevation And Rings/shoes Fit Without
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Difficulty (Completely resolves with limb
elevation and rings/shoes fit without
difficulty)
Does Not Completely Resolve With Limb
Elevation Or Rings/shoes Do Not Fit
Normally (Does not completely resolve
with limb elevation or rings/shoes do not
fit normally)
No Edema, No Symptoms (No edema,
no symptoms)
No Improvement With Limb Elevation Or
Interferes With Normal Function (No
improvement with limb elevation or
interferes with normal function)
Significantly Reduced Function
(Significantly reduced function)
Symptoms of periorbital edema
No Periorbital Edema (No periorbital
edema)
Swelling Of Eyes Noted At All Times And
Interferes With Eyesight Or Function At
All Times (Swelling of eyes noted at all
times and interferes with eyesight or
function at all times)
Swelling Of Eyes Noted At All Times And
Interferes With Eyesight Or Function
Sometimes (Swelling of eyes noted at all
times and interferes with eyesight or
function sometimes)
Swelling Of The Eyes Noted At All Times
But Does Not Interfere With Eyesight Or
Function (Swelling of the eyes noted at
all times but does not interfere with
eyesight or function)
Swelling Of The Eyes Noted
Occasionally Or Improves Over The Day
(Swelling of the eyes noted occasionally
or improves over the day)
Symptoms of scrotal/genital edema
No Scrotal/genital Edema (No
scrotal/genital edema)
Swelling Interferes With Urination,
Sexual Function, Withdrawing Foreskin
All The Time (Swelling interferes with
urination, sexual function, withdrawing
foreskin all the time)
Swelling Interferes With Urination,
Sexual Function, Withdrawing Foreskin
Sometimes (Swelling interferes with
urination, sexual function, withdrawing
foreskin sometimes)
Swelling Of The Scrotum Noted At All
Times But No Symptoms (Swelling of the
scrotum noted at all times but no
symptoms)
Swelling Of The Scrotum Noted
Occasionally (Swelling of the scrotum
noted occasionally)
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Foot Kaposi's Sarcoma (KS) symptoms
Active But Cannot Perform More Than
Normal Activities (Active but cannot
perform more than normal activities)
Lesions Present But No Symptoms. Able
To Perform Normal Activities (Lesions
present but no symptoms. Able to
perform normal activities)
Moderate Impairment Of Activity
Because Of Foot Ks (Moderate
impairment of activity because of foot
KS)
Normal Activities Mildly Limited Because
Of Foot Ks (Normal activities mildly
limited because of foot KS)
Severe Impairment Of Activity Due To
Foot Ks (Severe impairment of activity
due to foot KS)
Footer Module
Comments
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Physical Exam (Courses) - 3292697v1.0
All rights reserved. Please visit https://medical-data-
models.org/forms/3437
Physical Exam (Courses)
Physical Exam - Courses
Visit Date (Enter the date the physical
examination took place.)
PE Done? (Indicate whether the physical
examination was performed.)
No (No)
Yes (Yes)
Date of Examination (Enter the date the physical
examination took place.)
Day in Course (Cycle) (Number of days since the
beginning of the course is derived from the
course initiation start date and examination date.)
Change from Baseline (Indicate whether the
finding results were changed compared with that
of baseline.)
No (No)
Yes (Yes)
Change from Previous Evaluation? (Indicate
whether the finding results were changed
compared with that of previous evaluation.)
No: C49487 (No)
Yes: C49488 (Yes)
Finding Result (Indicate whether the finding
results for the particular body system.)
Abnormal (A)
Normal (N)
Not Examined (X)
Comments (If the finding results of a particular
body system have changed from baseline, give a
brief description of the change.)
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Treatment - Proposed Breast Cancer DataMart Common
Data Elements for Pre-Operative Clinical Trials -
2722335v1.0
All rights reserved. Please visit https://medical-data-
models.org/forms/3444
Proposed Breast Cancer DataMart
Common Data Elements for Pre-
Operative Clinical Trials
Clinical/imaging Examination Of The
Breast
Time point
At Completion Of Planned Preoperative
Systemic Therapy (At completion of
planned preoperative systemic therapy)
Before Preoperative Systemic Therapy
(Before preoperative systemic therapy)
During Preoperative Systemic Therapy
(During preoperative systemic therapy)
Cycle Number (If during preoperative therapy or
at completion of planned therapy specify:)
Date of Evaluation
Clinical T Stage
No Evidence Of Primary Tumor (T0)
Tumor 2 Cm Or Less In Greatest
Dimension (T1)
Tumor More Than 0.1 Cm But Not More
Than 0.5 Cm In Greatest Dimension
(T1a)
Tumor More Than 0.5 Cm But Not More
Than 1 Cm In Greatest Dimension (T1b)
Tumor More Than 1 Cm But Not More
Than 2 Cm In Greatest Dimension (T1c)
Microinvasion 0.1 Cm Or Less In
Greatest Dimension (T1mic)
Tumor More Than 2 Cm But Not More
Than 5 Cm In Greatest Dimension (T2)
Tumor More Than 5 Cm In Greatest
Dimension (T3)
Tumor Of Any Size With Direct (T4)
Extension To Chest Wall (T4a)
Edema (including Peau D'orange) Or
Ulceration Of The Skin Of The Breast Or
Satellite Skin Nodules Confined To The
Same Breast (T4b)
Both T4a And T4b (T4c)
Inflammatory Carcinoma (T4d)
Carcinoma In Situ: Intraductal
Carcinoma, Lobular Carcinoma In Situ,
Or Paget's Disease Of The Nipple With
No Tumor (Tis)
Ductal Carcinoma In Situ (Tis (DCIS))
Lobular Carcinoma In Situ (Tis (LCIS))
Paget's Disease Of The Nipple With No
Tumor. [note: Paget's Disease
Associated With A Tumor Is Classified
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According To The Size Of The Tumor.]
(Tis (Paget's))
Primary Tumor Cannot Be Assessed
(TX)
Clinical T Stage
No Evidence Of Primary Tumor (yT0)
Tumor 2 Cm Or Less In Greatest
Dimension (yT1)
Tumor More Than 0.1 Cm But Not More
Than 0.5 Cm In Greatest Dimension
(yT1a)
Tumor More Than 0.5 Cm But Not More
Than 1 Cm In Greatest Dimension
(yT1b)
Tumor More Than 1 Cm But Not More
Than 2 Cm In Greatest Dimension
(yT1c)
Microinvasion 0.1 Cm Or Less In
Greatest Dimension (yT1mic)
Tumor More Than 2 Cm But Not More
Than 5 Cm In Greatest Dimension (yT2)
Tumor More Than 5 Cm In Greatest
Dimension (yT3)
Tumor Of Any Size With Direct (yT4)
Extension To Chest Wall (yT4a)
Edema (including Peau D'orange) Or
Ulceration Of The Skin Of The Breast Or
Satellite Skin Nodules Confined To The
Same Breast (yT4b)
Both T4a And T4b (yT4c)
Inflammatory Carcinoma (yT4d)
Carcinoma In Situ: Intraductal
Carcinoma, Lobular Carcinoma In Situ,
Or Paget's Disease Of The Nipple With
No Tumor (yTis)
Ductal Carcinoma In Situ (yTis (DCIS))
Lobular Carcinoma In Situ (yTis (LCIS))
Paget's Disease Of The Nipple With No
Tumor. [note: Paget's Disease
Associated With A Tumor Is Classified
According To The Size Of The Tumor.]
(yTis (Paget's))
Primary Tumor Cannot Be Assessed
(yTX)
Method of Evaluation (Note:  Use the same
method of evaluation at each time point)
Ct Scan (CT scan)
Mammogram (Mammogram)
Mri Scan (MRI scan)
Physical Exam (Physical exam)
Ultrasound (Ultrasound)
Longest Diameter of Lesion(s)
Clinical/imaging Examination Of The
Breast
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Time point
At Completion Of Planned Preoperative
Systemic Therapy (At completion of
planned preoperative systemic therapy)
Before Preoperative Systemic Therapy
(Before preoperative systemic therapy)
During Preoperative Systemic Therapy
(During preoperative systemic therapy)
Cycle Number (If during preoperative therapy or
at completion of planned therapy specify:)
Date of Evaluation
Is there clinical evidence of axillary node
involvement
No (No)
Yes (Yes)
Clinical N Stage
No Regional Lymph Node Metastasis
(N0)
Metastasis To Movable Ipsilateral Axillary
Lymph Node(s) (N1)
Metastasis To Ipsilateral Axillary Lymph
Node(s) Fixed Or Matted, Or In Clinically
Apparent* Ipsilateral Internal Mammary
Nodes In The Absence Of Clinically
Evident Lymph Node Metastasis (N2)
Metastasis In Ipsilateral Axillary Lymph
Nodes Fixed To One Another (matted) Or
To Other Structures (N2a)
Metastasis Only In Clinically Apparent*
Ipsilateral Internal Mammary Nodes And
In The Absence Of Clinically Evident
Axillary Lymph Node Metastasis (N2b)
Metastasis In Ipsilateral Infraclavicular
Lymph Node(s) With Or Without Axillary
Lymph Node Involvement, Or In Clinically
Apparent* Ipsilateral Internal Mammary
Lymph Node(s) And In The Presence Of
Clinically Evident Axillary Lymph Node
Metastasis; Or, Me (N3)
Metastasis In Ipsilateral Infraclavicular
Lymph Node(s) With Or Without Axillary
Lymph Node Involvement, Or In Clinically
Apparent* Ipsilateral Internal Mammary
Lymph Node(s) And In The Presence Of
Clinically Evident Axillary Lymph Node
Metastasis; Or, Me (N3a)
Metastasis In Ipsilateral Internal
Mammary Lymph Node(s) And Axillary
Lymph Node(s) (N3b)
Metastasis In Ipsilateral Supraclavicular
Lymph Node(s) (N3c)
Regional Lymph Nodes Cannot Be
Assessed (e.g., Previously Removed)
(NX)
3 / 10
Treatment - Proposed Breast Cancer DataMart Common Data Elements
for Pre-Operative Clinical Trials - 2722335v1.0
Clinical N Stage (Post Neoadjuvant)
No Regional Lymph Node Metastasis
(yN0)
Metastasis To Movable Ipsilateral Axillary
Lymph Node(s) (yN1)
Metastasis To Ipsilateral Axillary Lymph
Node(s) Fixed Or Matted, Or In Clinically
Apparent* Ipsilateral Internal Mammary
Nodes In The Absence Of Clinically
Evident Lymph Node Metastasis (yN2)
Metastasis In Ipsilateral Axillary Lymph
Nodes Fixed To One Another (matted) Or
To Other Structures (yN2a)
Metastasis Only In Clinically Apparent*
Ipsilateral Internal Mammary Nodes And
In The Absence Of Clinically Evident
Axillary Lymph Node Metastasis (yN2b)
Metastasis In Ipsilateral Infraclavicular
Lymph Node(s) With Or Without Axillary
Lymph Node Involvement, Or In Clinically
Apparent* Ipsilateral Internal Mammary
Lymph Node(s) And In The Presence Of
Clinically Evident Axillary Lymph Node
Metastasis; Or, Me (yN3)
Metastasis In Ipsilateral Infraclavicular
Lymph Node(s) With Or Without Axillary
Lymph Node Involvement, Or In Clinically
Apparent* Ipsilateral Internal Mammary
Lymph Node(s) And In The Presence Of
Clinically Evident Axillary Lymph Node
Metastasis; Or, Me (yN3a)
Metastasis In Ipsilateral Internal
Mammary Lymph Node(s) And Axillary
Lymph Node(s) (yN3b)
Metastasis In Ipsilateral Supraclavicular
Lymph Node(s) (yN3c)
Regional Lymph Nodes Cannot Be
Assessed (e.g., Previously Removed)
(yNX)
Method of Evaluation (Note:  Use the same
method of evaluation at each time point)
Ct Scan (CT scan)
Mammogram (Mammogram)
Mri Scan (MRI scan)
Physical Exam (Physical exam)
Ultrasound (Ultrasound)
Diameter of largest positive lymph node
metastasis
Does the patient have bilateral malignancy
(including DCIS)?
No (No)
Yes (Yes)
Pre-operative Surgical Evaluation
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Did the patient undergo lymph node sampling
prior to preoperative systemic therapy
No (No)
Yes (Yes)
Date of lymph node biopsy
Was there histologic or cytologic evidence of
lymph node involvement
Not Available (N/A)
No (NO)
Yes (YES)
Method of Evaluation (Note:  Use the same
method of evaluation at each time point)
Ct Scan (CT scan)
Mammogram (Mammogram)
Mri Scan (MRI scan)
Physical Exam (Physical exam)
Ultrasound (Ultrasound)
Clinical/imaging Examination Of The
Breast
Time point
At Completion Of Planned Preoperative
Systemic Therapy (At completion of
planned preoperative systemic therapy)
Before Preoperative Systemic Therapy
(Before preoperative systemic therapy)
During Preoperative Systemic Therapy
(During preoperative systemic therapy)
Cycle Number (If during preoperative therapy or
at completion of planned therapy specify:)
Date of Evaluation
Histologic Type
Apocrine (Apocrine)
Clinging (Clinging)
Comedo (Comedo)
Cribriform (Cribriform)
Intra-cystic (encysted Papillary) (Intra-
cystic (encysted papillary))
Micropapillary (Micropapillary)
Other Specify (Other)
Papillary Carcinoma In Situ (papillary)
(Papillary carcinoma in situ (papillary))
Other specify
Histologic Grade
High (High)
Intermediate (Intermediate)
5 / 10
Treatment - Proposed Breast Cancer DataMart Common Data Elements
for Pre-Operative Clinical Trials - 2722335v1.0
Low (Low)
Unknown (Unknown)
Method of Evaluation (Note:  Use the same
method of evaluation at each time point)
Ct Scan (CT scan)
Mammogram (Mammogram)
Mri Scan (MRI scan)
Physical Exam (Physical exam)
Ultrasound (Ultrasound)
Nuclear Grade
High (High)
Intermediate (Intermediate)
Low (Low)
Unknown (Unknown)
Is there lymphovascular invasion?
Indeterminate (INDETERMINATE)
Not Available (N/A)
No (NO)
No Source Documentation (No source
documentation)
Unknown (UNKNOWN)
Yes (YES)
Mitotic Count
Less Than 10 Mitoses Per 10 High Hpf
(25x Objective) Or 0 To 5 Mitoses Per 10
Hpf (40x Objective) (1)
10-20 Mitoses Per 10 High Power Fields
(25x Objective) Or 6 To 10 Mitoses Per
10 High Power Fields (40x Objective) (2)
Greater Than 20 Mitoses Per 10 Hpf
(25x Objective) Or Greater Than 10
Mitoses Per 10 Hpf (40x Objective) (3)
Percentage of tumor cells that are mitotic
Tubule Formation
Majority Of Tumor (greater Than 75%)
(1)
Moderate (10% To 75%) (2)
Minimal (less Than 10%) (3)
Marker Status
ER Status
Negative (Negative)
Not Done (NOT DONE)
Positive (Positive)
Unknown (Unknown)
Estrogen receptor value
PgR Status
Negative (Negative)
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Not Done (NOT DONE)
Positive (Positive)
Unknown (Unknown)
Progesterone receptor value
Her2/neu expression status by
immunohistochemistry
0 (0)
1+ (1+)
2+ (2+)
3+ (3+)
Not Done: C49484 (not done)
Her2/neu expression status by FISH
Amplified (Amplified)
Not Amplified (Not amplified)
FISH HER2/neu chromosome 17 Ratio
Final Diagnosis with HER2/neu
Equivocal (Equivocal)
Negative (Negative)
Positive (Positive)
Therapeutic Changes
Does analysis of the tissue show therapeutic
effects from preoperative therapy
No (No)
Yes (Yes)
Evidence of therapeutic effects?
Apocrine/eosinophilic Effect(s)
(Apocrine/eosinophilic)
Cytoplasmic Vacuolation Effect(s)
(Cytoplasmic vacuolation)
Hystiocytoid Effect(s) (Hystiocytoid)
Lobular Appearance (Lobular
appearance)
Other (Other)
Other, specify
Pathologic T Stage
No Evidence Of Primary Tumor (yT0)
Tumor 2 Cm Or Less In Greatest
Dimension (yT1)
Tumor More Than 0.1 Cm But Not More
Than 0.5 Cm In Greatest Dimension
(yT1a)
Tumor More Than 0.5 Cm But Not More
Than 1 Cm In Greatest Dimension
(yT1b)
Tumor More Than 1 Cm But Not More
Than 2 Cm In Greatest Dimension
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(yT1c)
Microinvasion 0.1 Cm Or Less In
Greatest Dimension (yT1mic)
Tumor More Than 2 Cm But Not More
Than 5 Cm In Greatest Dimension (yT2)
Tumor More Than 5 Cm In Greatest
Dimension (yT3)
Tumor Of Any Size With Direct (yT4)
Extension To Chest Wall (yT4a)
Edema (including Peau D'orange) Or
Ulceration Of The Skin Of The Breast Or
Satellite Skin Nodules Confined To The
Same Breast (yT4b)
Both T4a And T4b (yT4c)
Inflammatory Carcinoma (yT4d)
Carcinoma In Situ: Intraductal
Carcinoma, Lobular Carcinoma In Situ,
Or Paget's Disease Of The Nipple With
No Tumor (yTis)
Ductal Carcinoma In Situ (yTis (DCIS))
Lobular Carcinoma In Situ (yTis (LCIS))
Paget's Disease Of The Nipple With No
Tumor. [note: Paget's Disease
Associated With A Tumor Is Classified
According To The Size Of The Tumor.]
(yTis (Paget's))
Primary Tumor Cannot Be Assessed
(yTX)
Pathologic N Stage
No Regional Lymph Node Metastasis
Histologically, No Additional Examination
For Isolated Tumor Cells (itc) (ypN0)
No Regional Lymph Node Metastasis
Histologically, Negative Ihc (ypN0(i-))
No Regional Lymph Node Metastasis
Histologically, Positive Ihc, No Ihc Cluster
>0.2 Mm (ypN0(i+))
No Regional Lymph Node Metastasis
Histologically, Negative Molecular
Findings (rt-pcr) (ypN0(mol-))
No Regionally Lymph Node Metastasis
Histologically, Positive Molecular
Findings (rt-pcr) (ypN0(mol+))
Metastasis In 1 To 3 Axillary Lymph
Nodes, And/or In Internal Mammary
Nodes With Microscopic Disease
Detected By Sln Dissection But Not
Clinically Apparent (ypN1)
Metastasis In 1 To 3 Axillary Lymph
Nodes (ypN1a)
Metastasis In Internal Mammary Nodes
With Microscopic Disease Detected By
Sln Dissection But Not Clinically
Apparent (ypN1b)
Metastasis In 1 To 3 Axillary Lymph
Nodes And In Internal Mammary Lymph
Nodes With Microscopic Disease
Detected By Sln Dissection But Not
Clinically Apparent. (ypN1c)
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Micrometastasis (>0.2 Mm But <=2.0
Mm) (ypN1mi)
Metastasis In 4 To 9 Axillary Lymph
Nodes, Or In Clinically Apparent **
Internal Mammary Lymph Nodes In The
Absence Of Axillary Lymph Node
Metastasis To Ipsilateral Axillary Lymph
Node(s) Fixed To Each Other Or To
Other Structures (ypN2)
Metastasis In 4 To 9 Axillary Lymph
Nodes (at Least 1 Tumor Deposit >2.0
Mm) (ypN2a)
Metastasis In Clinically Apparent*
Internal Mammary Lymph Nodes In The
Absence Of Axillary Lymph Node
Metastasis (ypN2b)
Metastasis In >= Axillary Lymph Nodes,
Or In Infraclavicular Lymph Nodes, Or In
Clinically Apparent* Ipsilateral Internal
Mammary Lymph Node(s) In The
Presence Of 1 Or More Positive Axillary
Lymph Node(s); Or, In >3 Axillary Lymph
Nodes With Clinically N (ypN3)
Metastasis In >=10 Axillary Lymph
Nodes (at Least 1 Tumor Deposit >2.0
Mm); Or, Metastasis To The
Infraclavicular Lymph Nodes (ypN3a)
Metastasis In Clinically Apparent*
Ipsilateral Internal Mammary Lymph
Nodes In The Presence Of >=1 Positive
Axillary Lymph Node(s); Or, In >3
Axillary Lymph Nodes And In Internal
Mammary Lymph Nodes With
Microscopic Disease Detected By
Sentinel Lymph Node (ypN3b)
Metastasis In Ipsilateral Supraclavicular
Lymph Nodes (ypN3c)
Regional Lymph Nodes Cannot Be
Assessed (e.g., Not Removed For
Pathologic Study Or Previously
Removed) (ypNX)
Longest Diameter of Lesion(s)
Diameter of largest positive lymph node
metastasis
Residual Cancer Burden
Longest Bidimensional Measurements of the
Residual Tumor Bed (mm)
Longest Bidimensional Measurements of the
Residual Tumor Bed (mm)
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% of overall tumor that is In Situ disease
Cellularity of invasive cancer
Residual Cancer Burden Class
Rcb Index = 0 Up To Less Than Or Equal
To 1.36 (I)
Rcb Index = 1.36 Up To Less Thanor
Equal To 3.28 (II)
Rcb Index = 3.28 And Above (III)
Residual Cancer Burden Index
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On-Study - PHYSICAL EXAM -
2407645v1.0
On-Study - PHYSICAL EXAM - 2407645v1.0
All rights reserved. Please visit https://medical-data-
models.org/forms/3446
PHYSICAL EXAM
Physical Exam
Evaluation Date
Course Day Number
Body System Type
Abdomen (ABDOMEN)
Allergy Or Drug Sensitivity History
(Allergy/Drug Sensitivity)
Appearance (Appearance)
Body As A Whole (Body as a Whole)
Breasts (BREASTS)
Cardiovascular (CARDIOVASCULAR)
Central Nervous System (Central
Nervous System)
Chest (Chest)
Constitutional (Constitutional)
Dermatologic (DERMATOLOGIC)
Endocrine/metabolic
(ENDOCRINE/METABOLIC)
Extremities (Extremities)
Gastrointestinal (GASTROINTESTINAL)
Genitalia (GENITALIA)
Genitourinary (Genitourinary)
H/e/e/n/t (H/E/E/N/T)
Hematologic (HEMATOLOGIC)
Hematopoietic/lymph
(HEMATOPOIETIC/LYMPH)
Hepatic (Hepatic)
Immune (IMMUNE)
Integumentary/hair (Integumentary/Hair)
Musculoskeletal (MUSCULOSKELETAL)
Neck (NECK)
Neurologic (NEUROLOGIC)
Other (OTHER)
Pelvis (PELVIS)
Peripheral Vascular System (Peripheral
Vascular)
Psychologic (PSYCHOLOGIC)
Pulmonary (Pulmonary)
Rectal (Rectal)
Renal (Renal)
Reproductive History (Reproductive
History)
Respiratory (RESPIRATORY)
Spleen (Spleen)
Substance Abuse/dependency
(Substance abuse/Dependency)
Transfusion History (Transfusion History)
Urinary (URINARY)
Finding Results Indicator
Abnormal (A)
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No Change (C)
Equivocal (E)
Negative (G)
Improving (I)
Not Applicable (L)
Normal (N)
No Source Data (O)
Positive (P)
Stable (S)
Unstable (U)
Not Evaluable (V)
Worse (W)
Not Examined (X)
Research Comments Text
Course Number (This is a derived field and may
be displayed on the form, if needed.)
Comments
Note Date
Research Comments Text
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Template - 2745056v1.0
Pre-Study - NCI Standard Registration Template -
2745056v1.0
All rights reserved. Please visit https://medical-data-
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NCI Standard Registration Template
Mandatory
Study Identifier (Enter the numeric or
alphanumeric identification assigned to the
study.)
Date of Registration (Enter the date the
participant¿s information was sent to the
Coordinating Center)
Conditional
Was the participant on a prior study with this
group? (Enter yes, no or unknown to indicate if
the participant was on a prior study.)
No (No)
Unknown (Unknown)
Yes (Yes)
What was the prior study participant identifier? (If
the participant was on a prior study, enter the
identifier that was assigned to the participant.)
Stratification Factors (protocol specific) (Enter the
specific factors by which participants are
segregated before randomization to intervention
arms of a protocol.)
Participant Subgroup Code (Enter the CTEP
code designating the strata specifying a subgroup
that defines the stratum for a participant as
compared to the question Stratification Factor.
Both questions are NOT needed in the same
module.)
Registering Institution Name (Enter the name of
the Registering Institution.)
Participant Local Identifier (Enter the identifier
assigned by a healthcare facility used to link to
the participant's medical record number.)
Specialist Physician Name (Enter the first initial
and last name of the Radiation Therapist, Medical
Oncologist, Surgeon, etc.)
Optional
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Registering Institution Code (Enter the
organization code of the Registering Institution.)
Treating physician (Enter the name of the
physician that has primary responsibility or - the
care of the participant.)
Person Completing Form (Enter the first initial
and last name of the person who completed the
documentation.)
Person Completing Form, Phone (Enter the
telephone number of the person who completed
the documentation.)
Person Completing Form Fax (Enter the fax
machine number of the person who completed
the documentation.)
Person Completing Form Fax (Enter the fax
machine number of the person who completed
the documentation.)
Responsible CRA (Enter the name of the clinical
research associate who documented
information.)
CRA phone number (Enter the telephone number
of the clinical research associate.)
Projected Start Date of Treatment (Enter the text
that represents the day, month and year the
treatment is anticipated to begin.)
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CDA discharge letter VHitG 1.50
CDA_discharge_letter_1.50 any condition
ODM derived from http://www.bvitg.de/arztbrief.html
All rights reserved. Please visit https://medical-data-
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CDA discharge letter VHitG 1.50
CDA Header
Dokumenten-Id*
Dokumententyp*
Erstellungsdatum des Dokuments*
Vertraulichkeitsgrad*
normale Vertraulichkeit (N)
eingeschränkter Zugriff (R)
stark eingeschränkter Zugriff (V)
Sprache des Dokuments*
deutsch (de-DE)
englisch (en-EN)
Set-Kennung des Dokuments*
Versionsnummer*
Patienten-Identifikationsnummer*
Patientenadresse*
Telekommunikation-Kontakte*
Name des Patienten*
Geschlecht*
weiblich (F)
männlich (M)
nicht bestimmbar (UN)
Geburtsdatum*
Geburtsort*
den Patienten betreuende Organisation*
ID der Heilberufler-Organisation*
Name der Heilberufler-Organisation*
Telekommunikation-Kontakte der Heilberufler-
Organisation*
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Adresse der Heilberufler-Organisation*
Funktion des Autors*
Zeitpunkt der Dokumentation*
ID des Autors*
Adresse des Autors*
Telekommunikation-Kontakte des Autors*
Name des Autors*
ID der durch den Autor repräsentierten
Organisation*
Name der durch den Autor repräsentierten
Organisation*
Telekommunikation-Kontakte der durch den Autor
repräsentierten Organisation*
Adresse der durch den Autor repräsentierten
Organisation*
Typ des Empfängers*
primärer Empfänger des Dokuments
(PRCP)
sekundärer Empfänger des Dokuments
(TRC)
Zeitpunkt der Unterschrift*
Typisierung der Unterschrift*
Signatur ist beabsichtigt (I)
Signatur ist erforderlich (R)
Signatur ist vorhanden (S)
ID des Unterzeichners*
Adresse des Unterzeichners*
Telekommunikation-Kontakte des
Unterzeichners*
Name des Unterzeichners*
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Typisierung der Beteiligung*
Mitversichert (COV)
Inhaber (HLD)
indirekte Beziehung (IND)
Zeitraum der Beteiligung*
Klassifikation des Aufenthaltes*
Ambulanter Aufenthalt (AMB)
Stationärer Aufenthalt (IMP)
Virtueller Kontakt (VR)
Zeitraum des Aufenthaltes*
Identifikation der Einverständniserklärung*
Typ der Einverständniserklärung*
Status der Einverständniserklärung*
vollständig (completed)
nicht vollständig (not_completed)
CDA R2 Body
Anrede*
Fragestellung*
Anamnese*
Befund*
Diagnose*
Cave*
Therapien/ Behandlungsmaßnahmen*
Notizen*
Epikrise*
Anhang*
Schlusstext*
Externe Dokumente*
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level2 example CCD any condition
ODM derived from http://www.himssehra.org
All rights reserved. Please visit https://medical-data-
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level2 example
CDA Header
Dokumenten-Id*
Dokumententyp*
Erstellungsdatum des Dokuments*
Vertraulichkeitsgrad*
normale Vertraulichkeit (N)
eingeschränkter Zugriff (R)
stark eingeschränkter Zugriff (V)
Sprache des Dokuments*
deutsch (de-DE)
englisch (en-EN)
Set-Kennung des Dokuments*
Versionsnummer*
Patienten-Identifikationsnummer*
Name des Patienten*
Geschlecht*
weiblich (F)
männlich (M)
nicht bestimmbar (UN)
Geburtsdatum*
den Patienten betreuende Organisation*
ID des Autors*
Name des Autors*
ID der durch den Autor repräsentierten
Organisation*
Name der durch den Autor repräsentierten
Organisation*
ID der durch den Auskunftsgeber repräsentierten
Organisation*
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Name der durch den Auskunftsgeber
repräsentierten Organisation*
ID der Heilberufler-Organisation*
Name der Heilberufler-Organisation*
Zeitpunkt der Unterschrift*
Typisierung der Unterschrift*
Signatur ist beabsichtigt (I)
Signatur ist erforderlich (R)
Signatur ist vorhanden (S)
ID der Organisation des Unterzeichners*
Name der Organisation des Unterzeichners*
Typisierung der Beteiligung*
Mitversichert (COV)
Inhaber (HLD)
indirekte Beziehung (IND)
ID des Beteiligten*
Adresse des Beteiligten*
Telekommunikation-Kontakte des Beteiligten*
Name des Beteiligten*
Zeitraum der Behandlung*
Art der Behandlung*
Name des Behandlers*
CDA Body
Zweck des Dokuments*
Kostenträger*
Patientenverfügung*
Funktionsstatus*
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Probleme*
Familienanamnese*
Sozialanamnese*
Allergien, Nebenwirkungen und Warnhinweise*
Medikation*
medizinische Hilfsmittel*
Impfungen*
Befunde*
Prozeduren*
Besuche*
Pflegeplanung*
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Breast Cancer NCT01101438 On-Study - NCIC MA.32
Relapse/Progression Report Form - 3019298v1.0
NCIC MA.32 Relapse/Progression Report Form
A Phase III Randomized Trial of Metformin vs Placebo in
Early Stage Breast Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=80FF5860-
630C-7873-E040-BB89AD43136F
All rights reserved. Please visit https://medical-data-
models.org/forms/3555
NCIC MA.32 Relapse/Progression
Report Form
Recurrence/progression - Questions
Recurrent disease
No (0)
Yes (1)
Has a new primary cancer or MDS been
diagnosed that has not been previously reported?
No (0)
Yes (1)
Has the patient been diagnosed with opposite
breast cancer since submission of last follow-up
form?
No (0)
Yes (1)
Recurrence
Has the patient been diagnosed with first local-
regional recurrence (or progression)
No (0)
Yes (1)
Has the patient been diagnosed with first local-
regional recurrence (or progression)
No (0)
Yes (1)
Suspected Date (of new primary invasive non-
breast cancer)
Suspected Date (of new primary invasive non-
breast cancer)
Sites (progression or relapse)
Ipsilateral Breast (1)
Chest Wall (2)
Regional Nodes/axilla (3)
Sites (progression or relapse)
Ipsilateral Breast (1)
Chest Wall (2)
Regional Nodes/axilla (3)
Definite Date
1 / 5
Definite Date
Method of Evaluation
Radiology (1)
Physical Exam (2)
Other (3)
Method of Evaluation
Radiology (1)
Physical Exam (2)
Other (3)
Method of Evaluation
Radiology (1)
Physical Exam (2)
Other (3)
Method of Evaluation
Radiology (1)
Physical Exam (2)
Other (3)
Specify
Specify
Specify
Specify
Type of imaging
Mammography (1)
Ultrasound (2)
Computed Tomography (3)
Magnetic Resonance Imaging (4)
X-ray (5)
Other (6)
Type of imaging
Mammography (1)
Ultrasound (2)
Computed Tomography (3)
Magnetic Resonance Imaging (4)
X-ray (5)
Other (6)
Type of imaging
Mammography (1)
Ultrasound (2)
Computed Tomography (3)
Magnetic Resonance Imaging (4)
X-ray (5)
Other (6)
Type of imaging
Mammography (1)
Ultrasound (2)
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Computed Tomography (3)
Magnetic Resonance Imaging (4)
X-ray (5)
Other (6)
Specify
Specify
Specify
Specify
Has the patient been diagnosed with first distant
recurrence/progression?
No (0)
Yes (1)
Site of First Distant Recurrence
Lung (1)
Liver (2)
Bone (3)
Pleura (4)
Central Nervous System (e.g., brain,
meninges) (5)
Other (6)
Other specify
Date of recurrence
Recurrence
Site of New Primary (s  invasive non-breast
cancer)
Suspected Date (of new primary invasive non-
breast cancer)
Definite Date
Method of Evaluation
Radiology (1)
Physical Exam (2)
Other (3)
Method of Evaluation
Radiology (1)
Physical Exam (2)
Other (3)
3 / 5
Breast Cancer NCT01101438 On-Study - NCIC MA.32
Relapse/Progression Report Form - 3019298v1.0
Specify
Specify
Type of imaging
Mammography (1)
Ultrasound (2)
Computed Tomography (3)
Magnetic Resonance Imaging (4)
X-ray (5)
Other (6)
Type of imaging
Mammography (1)
Ultrasound (2)
Computed Tomography (3)
Magnetic Resonance Imaging (4)
X-ray (5)
Other (6)
Specify
Specify
Recurrence
Suspected Date (of new primary invasive non-
breast cancer)
Definite Date
Method of Evaluation
Radiology (1)
Physical Exam (2)
Other (3)
Method of Evaluation
Radiology (1)
Physical Exam (2)
Other (3)
Specify
Specify
Type of imaging
Mammography (1)
Ultrasound (2)
Computed Tomography (3)
Magnetic Resonance Imaging (4)
X-ray (5)
Other (6)
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Type of imaging
Mammography (1)
Ultrasound (2)
Computed Tomography (3)
Magnetic Resonance Imaging (4)
X-ray (5)
Other (6)
Specify
Specify
Date of Diagnosis of Contralateral Breast Cancer
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Der Notfalldatensatz der eGK nfdm
Der NFDM der eGK nach Lastenheft der BÄK, Version
1.2.0.
Momentan ohne Medikation, daher unvollständig.
All rights reserved. Please visit https://medical-data-
models.org/forms/3665
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Eligibility NCT01241396 Multiple Myeloma
ODM derived from
http://clinicaltrials.gov/show/NCT01241396
All rights reserved. Please visit https://medical-data-
models.org/forms/3680
Eligibility
Einschlusskriterien
Alter mindestens 18 Jahre*
Ja
Nein
Requires commencement of a new line of
treatment for MMY at any stage, regardless of
type of therapy selected. *
Ja
Nein
Ausschlusskriterien
Patients currently participating in another
investigational study or clinical trial.*
Ja
Nein
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Eligibility NCT01243177 Epilepsy
ODM derived from
http://clinicaltrials.gov/show/NCT01243177
All rights reserved. Please visit https://medical-data-
models.org/forms/3710
Eligibility
Einschlusskriterien
Alter mindestens 16 Jahre*
Ja
Nein
Subject able to comply with study requirements*
Ja
Nein
Subject is 16 years and older (female, male).
Minors will be included in countries only if legally
permitted*
Ja
Nein
Subject has newly or recently diagnosed epilepsy
experiencing partial onset seizures (POS) or
generalized tonic-clonic seizures with at least 2
unprovoked seizures separated by 48 hours in
the year before enrollment with 1 seizures 3
months before enrollment*
Ja
Nein
Subject has normal electroencephalogram (EEG)
which must be normal or consistent with partial
onset seizures (POS) and a Computerized Axial
Tomography (CT) scan or Magnetic Resonance
Imaging (MRI) with diagnosis of POS or
generalized tonic clonic seizures (without clear
focal origin) within year before enrollment *
Ja
Nein
Ausschlusskriterien
Subject has a history or presence of seizures of
other types than partial-onset (IA, IB, IC with
clear focal origin) and generalized tonic-clonic
(without clear focal origin) seizures (eg,
myoclonic, absence)*
Ja
Nein
Subject has a history or presence of seizures
occurring only in clustered patterns, defined as
repeated seizures occurring over a short period
of time (ie, <20 minutes) with or without function
regained between 2 ictal events*
Ja
Nein
Subject has a history, clinical, or
1 / 3
Electroencephalogram (EEG) finding suggestive
of idiopathic generalized epilepsy (IGE) at
randomization*
Ja
Nein
Subject has current or previous diagnosis of
pseudoseizures, conversion disorders, or other
nonepileptic ictal events which could be confused
with seizures*
Ja
Nein
Subject has any medical or psychiatric condition*
Ja
Nein
Subject has a history of suicide attempt, has
received professional counselling for suicidal
ideation, or is currently experiencing active
suicidal ideation*
Ja
Nein
Prior use of felbamate or vigabatrin is not
allowed*
Ja
Nein
Subject has received treatment with
phenobarbital or primidone within 28 days prior to
Visit 1*
Ja
Nein
Subject is taking benzodiazepines for a
nonepilepsy indication*
Ja
Nein
Benzodiazepines as rescue therapy for epilepsy
may have been used as needed in this time
period, but not more frequently than once per
week)*
Ja
Nein
Subject has been treated for epilepsy with any
antiepileptic drug (AED) (including
benzodiazepines) in the last 6 months before
Visit 1 (however, acute and subacute seizure
treatment is accepted with a maximum of 2
weeks duration and if treatment was stopped at
least 1 week before Visit 1*
Ja
Nein
Subject has a medical condition that could
reasonably be expected to interfere with drug
absorption, distribution, metabolism, or excretion,
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Eligibility NCT01243177 Epilepsy
has a history of alcohol or drug abuse within the
previous 2 years*
Ja
Nein
Asian ancestry and tests positive for HLA-B*1502
allele*
Ja
Nein
3 / 3
Eligibility NCT01243177 Epilepsy
Eligibility NCT01246752 Leukemia,
Myeloid, Acute
ODM derived from
http://clinicaltrials.gov/show/NCT01246752
All rights reserved. Please visit https://medical-data-
models.org/forms/3712
Eligibility
Einschlusskriterien
Alter 18 bis 60 Jahre*
Ja
Nein
AML in first remission*
Ja
Nein
cytological standard risk, i.e. karyotype not listed
under exclusion criteria*
Ja
Nein
Identification of HLA-identical sibling or HLA-
compatible related or unrelated donor (9/10 HLA-
alleles matched, high resolution typing for HLA-A,
B, Cw, DRB1 and DQB1)*
Ja
Nein
medically fit for allogeneic stem cell
transplantation*
Ja
Nein
CR / CRi after induction therapy *
Ja
Nein
Ausschlusskriterien
core-binding factor leukemia (t(8;21), inv16)*
Ja
Nein
APL*
Ja
Nein
komplexer Karyotyp*
Ja
Nein
karyotypes: -7, -5, del5q, t(3;3), t(6;11), t(6;9),
11q aberrations, trisomy 8 ± one single additional
aberration*
Ja
Nein
pregnancy / nursing*
Ja
Nein
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Non-Compliance*
Ja
Nein
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Eligibility NCT01246752 Leukemia, Myeloid, Acute
Eligibility NCT01261793 Systemic Lupus
Erythematosus
ODM derived from
http://clinicaltrials.gov/show/NCT01261793
All rights reserved. Please visit https://medical-data-
models.org/forms/3715
Eligibility
Einschlusskriterien
Alter mindestens 18 Jahre*
Ja
Nein
Positive antinuclear antibodies (ANA) at
Screening (Visit 1)*
Ja
Nein
Current clinical diagnosis of Systemic Lupus
Erythematosus (SLE) by American College of
Rheumatology (ACR) criteria such that at least 4
of the 11 criteria are met*
Ja
Nein
Active moderate to severe SLE activity as
demonstrated by the British Isles Lupus
Assessment Group Index (BILAG)*
Ja
Nein
Active moderate to severe SLE disease as
demonstrated by SLE disease activity index
(SLEDAI) total score*
Ja
Nein
On stable SLE treatment regimen, including
mandatory corticosteroids and
immunosuppressants or antimalarials *
Ja
Nein
Ausschlusskriterien
Subjects who are breastfeeding, pregnant, or
plan to become pregnant*
Ja
Nein
Subjects with active, severe SLE disease activity
which involves the renal system*
Ja
Nein
Subjects with active, severe, neuropsychiatric
SLE, defined as any neuropsychiatric element
scoring BILAG level A disease.*
Ja
Nein
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Subjects with the evidence of an
immunosuppressive state*
Ja
Nein
Subjects who, in the opinion of the investigator,
are at a particularly high risk of significant
infection*
Ja
Nein
History of malignant cancer, except the following
treated cancers: cervical carcinoma in situ, basal
cell carcinoma, or dermatological squamous cell
carcinoma.*
Ja
Nein
Subjects receiving any live vaccination within the
8 weeks prior to screening (Visit 1).*
Ja
Nein
Subjects with history of infections, including but
not limited to concurrent acute or chronic viral
hepatitis B or C*
Ja
Nein
Subjects with substance abuse or dependence or
other relevant concurrent medical condition*
Ja
Nein
Subjects with history of thromboembolic events
within 1 year of screening Visit.*
Ja
Nein
Subjects with significant hematologic
abnormalities*
Ja
Nein
Subject has received treatment with other anti-B
cell antibodies within 12 months prior to
screening (visit 1)*
Ja
Nein
Subject use of oral anticoagulant (not including)
nonsteroidal anti-inflammatory drugs (NSAIDs)
within 12 weeks prior to screening (Visit 1)*
Ja
Nein
Subject has previously participated in this study
or has previously received epratuzumab
treatment.*
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Eligibility NCT01261793 Systemic Lupus Erythematosus
Ja
Nein
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Eligibility NCT01261793 Systemic Lupus Erythematosus
Eligibility NCT01283724 Endometriosis
ODM derived from
http://clinicaltrials.gov/show/NCT01283724
All rights reserved. Please visit https://medical-data-
models.org/forms/3730
Eligibility
Einschlusskriterien
Alter 12 bis 17 Jahre*
Ja
Nein
Female adolescents after menarche (12 - < 18
years of age) at screening. For Finland:
Adolescents aged 12 - 14 years old who present
with clinical features of endometriosis will only be
enrolled into the study if their diagnosis of
endometriosis has been confirmed by
laparoscopy.*
Ja
Nein
Dysmenorrhea of at least moderate intensity, with
or without chronic pelvic pain, for at least 2 cycles
in the previous 4 months and one of the following
conditions:*
Ja
Nein
Clinically suspected endometriosis based on the
presence of pelvic pain  incompletely relieved by
non steroidal anti-inflammatory drugs and/or oral
contraceptives*
Ja
Nein
Any abdominal pain associated with ultrasound
findings suggestive of  endometriosis (abdominal,
vaginal or rectal - only after additional specific
consent and assent)*
Ja
Nein
Failure of surgical treatment for endometriosis
(with cyclic or chronic pelvic  pain of at least 4
months duration postsurgery)*
Ja
Nein
Threshold for endometriosis-associated pelvic
pain (EAPP) score: at least 30 on  a 100 units
visual analog scale retrospectively evaluated at
screening for the  last 4 weeks *
Ja
Nein
Ausschlusskriterien
Absence of endometriosis at laparoscopy*
Ja
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Nein
Previous application of hormonal agents
including oral contraceptives within 2 months,
progestins, danazol within 3 months, and
Gonadotropin Releasing Hormone (GnRH)
agonists within 6 months prior to start of
treatment*
Ja
Nein
Chronic pelvic pain that might be related to
genitourinary disease or to chronic or recurrent
gastrointestinal disease, including irritable bowel
syndrome (defined as a disease characterized by
pain relieved by defecation and irregular
defecation patterns lasting at least 3 months)*
Ja
Nein
Clinically established need for primary surgical
treatment of endometriosis*
Ja
Nein
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Eligibility NCT01283724 Endometriosis
Eligibility NCT01285167 Chronic
Obstructive Pulmonary Disease
ODM derived from
http://clinicaltrials.gov/show/NCT01285167
All rights reserved. Please visit https://medical-data-
models.org/forms/3731
Eligibility
Einschlusskriterien
Alter mindestens 18 Jahre*
Ja
Nein
severe COPD  *
Ja
Nein
Ausschlusskriterien
Child pugh (classified B and C)*
Ja
Nein
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Eligibility NCT01285180 Severe COPD
ODM derived from
http://clinicaltrials.gov/show/NCT01285180
All rights reserved. Please visit https://medical-data-
models.org/forms/3732
Eligibility
Einschlusskriterien
Alter mindestens 18 Jahre*
Ja
Nein
severe COPD *
Ja
Nein
Ausschlusskriterien
Child pugh (classified B and C)*
Ja
Nein
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Eligibility NCT01286779 Hemophilia B
ODM derived from
http://clinicaltrials.gov/show/NCT01286779
All rights reserved. Please visit https://medical-data-
models.org/forms/3734
Eligibility
Einschlusskriterien
Alter 12 bis 65 Jahre*
Ja
Nein
Subject and/or legal representative has/have
voluntarily provided signed informed consent*
Ja
Nein
Subject has completed Baxter clinical study
250901*
Ja
Nein
Subject has severe (FIX level < 1%) or
moderately severe (FIX level <= 2%) hemophilia
B (based on the one stage activated partial
thromboplastin time (aPTT) assay), as tested at
screening at the central laboratory*
Ja
Nein
Subject has not developed an inhibitory FIX
antibody during Baxter clinical study 250901  *
Ja
Nein
Ausschlusskriterien
Subject received factor IX product(s) other than
BAX 326 upon completion of Baxter protocol
250901*
Ja
Nein
Subject has been diagnosed with an acquired
hemostatic defect other than hemophilia B*
Ja
Nein
Körpergewicht*
Ja
Nein
Subject is planned to take part in any other
clinical study, with the exception of BAX 326
Surgery study as described in this protocol,
during the course of the continuation study*
Ja
Nein
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Eligibility NCT01290679 Hepatitis C
ODM derived from
http://clinicaltrials.gov/show/NCT01290679
All rights reserved. Please visit https://medical-data-
models.org/forms/3735
Eligibility
Einschlusskriterien
Alter mindestens 18 Jahre*
Ja
Nein
Genotype 1 hepatitis C infection (confirmed at
screening)*
Ja
Nein
patient has not received any prior treatment for
hepatitis C*
Ja
Nein
patient must have had a liver biopsy within 3
years before screening (or between the screening
and baseline visit) showing chronic hepatitis C
infection*
Ja
Nein
must agree to use 2 forms of effective
contraception throughout study (both males and
females). *
Ja
Nein
Ausschlusskriterien
Infection with HIV or non genotype 1 hepatitis C*
Ja
Nein
liver disease not related to hepatitic C infection*
Ja
Nein
Leberversagen, Leberausfall*
Ja
Nein
significant laboratory abnormalities or other
active diseases*
Ja
Nein
pregnant or planning to become pregnant*
Ja
Nein
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Eligibility NCT01294644 Healthy
ODM derived from
http://clinicaltrials.gov/show/NCT01294644
All rights reserved. Please visit https://medical-data-
models.org/forms/3738
Eligibility
Einschlusskriterien
Alter 18 bis 65 Jahre*
Ja
Nein
Submental fat graded by the investigator as 2 or
3 using the Clinician-Reported Submental Fat
Rating Scale (CR-SMFRS) as determined on
Visit 2.*
Ja
Nein
Dissatisfaction with the submental area rated by
the subject as 0, 1, 2, or 3 using the Subject Self
Rating Scale (SSRS).*
Ja
Nein
Males and nonpregnant, nonlactating females
between 18 and 65 years of age, inclusive on the
day of randomization. Females of childbearing
potential must have a negative human chorionic
gonadotropin (hCG) test result within 28 days
before randomization and agree to practice
medically acceptable birth control during the
course of the study. Medically acceptable birth
control includes: surgical sterilization, hormonal
contraceptives, barrier methods or an intrauterine
device (IUD).*
Ja
Nein
History of stable body weight, in the judgment of
the investigator, for at least 6 months before
randomization. No significant change, in the
judgment of the investigator, in diet or exercise
practices for at least 6 months before
randomization and agreement to not change diet
or exercise practices during the course of the
study.*
Ja
Nein
Expected to comply with and understand the visit
schedule and all protocol-specified tests and
procedures.*
Ja
Nein
Medically able to undergo the administration of
study material determined by clinical evaluations
made within 56 days before and laboratory tests
obtained within 28 days before randomization for
which the investigator identified no clinically
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significant abnormality.*
Ja
Nein
Signed informed consent obtained before any
study-specific procedure is performed.*
Ja
Nein
Ausschlusskriterien
History of any intervention to treat submental fat
(e.g., liposuction, surgery, or lipolytic agents) or
trauma associated with the chin or neck areas,
which in the judgment of the investigator may
affect evaluation of safety or efficacy of
treatment.*
Ja
Nein
Loose skin in the neck or chin area for which
reduction in submental fat may, in the judgment of
the investigator, result in an aesthetically
unacceptable outcome or a score of 4 on the Skin
Laxity Rating Scale (SLRS, Appendix C2).*
Ja
Nein
Prominent platysmal bands at rest or other
anatomical features that, in the judgment of the
investigator, may interfere with the evaluation of
submental fat or result in an aesthetically
unacceptable outcome.*
Ja
Nein
Evidence of any cause of enlargement in the
submental area (e.g., thyroid enlargement or
cervical adenopathy) other than localized
submental fat.*
Ja
Nein
BMI*
Ja
Nein
Currently on or considering starting a weight
reduction regimen.*
Ja
Nein
Any medical condition (e.g., respiratory,
cardiovascular, hepatic, neurological disease,
uncontrolled hypertension, or thyroid dysfunction)
that would interfere with assessment of safety or
efficacy or compromise the subject's ability to
undergo study procedures or provide informed
consent.*
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Eligibility NCT01294644 Healthy
Ja
Nein
Treatment with radio frequency, laser procedures,
chemical peels, or dermal fillers in the neck or
chin area within 12 months before randomization,
or botulinum toxin injections in the neck or chin
area within 6 months before randomization.*
Ja
Nein
History of sensitivity to any components of the
study material or to topical or local anesthetics
(e.g., lidocaine, benzocaine, or novocaine).*
Ja
Nein
Previous randomization into this study or previous
treatment with ATX-101.*
Ja
Nein
Treatment with an investigational device or agent
within 30 days of randomization.*
Ja
Nein
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Eligibility NCT01294644 Healthy
Eligibility NCT01294774 Subacute
Cutaneous Lupus Erythematosus
ODM derived from
http://clinicaltrials.gov/show/NCT01294774
All rights reserved. Please visit https://medical-data-
models.org/forms/3739
Eligibility
Einschlusskriterien
Alter 18 bis 65 Jahre*
Ja
Nein
Male and female patients,18 to 65 years of age
inclusive, who have been defined as having
SCLE based on the typical clinical picture and the
characteristic histopathological features as
described by Sontheimer et al. at least three
months before study entry (screening) *
Ja
Nein
Ausschlusskriterien
Patients with preexisting nephritis, central
nervous or pulmonary involvement or any major
internal organ damage, either related or
unrelated to lupus, which are deemed by the
Investigator to be clinically significant. Patients
having signs or symptoms of other autoimmune
diseases such as systemic lupus erythematosus
or Sjogren`s syndrome are allowed to enter the
study at the Investigator`s discretion. *
Ja
Nein
behandelt mit*
Ja
Nein
immunoglobulins and/or monoclonal antibodies
within 6 months prior to  randomization.*
Ja
Nein
rituximab, cyclophosphamide, or other
immunosuppressive treatments with effects
potentially lasting over 6 months, within 12
months prior to randomization.*
Ja
Nein
a medium or high dose (>= 1 mg prednisone or
equivalent per body weight kg)  corticosteroid
therapy in the last 8 weeks prior to
randomization.*
Ja
Nein
antimalarial agents (hydroxychloroquine,
chloroquine or quinacrine) in the last  6 weeks
prior to randomization.*
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Ja
Nein
biologic therapies, such as etanercept, within the
last 4 weeks prior to  randomization.*
Ja
Nein
any other immunosuppressive or
immunomodulatory therapy such as
methotrexate,  azathioprine, cyclosporin A or
mycophenolate, thalidomide, retinoids or
dapsone  in the last 4 weeks prior to
randomization.*
Ja
Nein
total lymphoid irradiation or bone marrow
transplantation.*
Ja
Nein
Pregnant, planning to get pregnant, and/or
lactating females or males planning to father a
child within time period of the study or
subsequent exclusionary period.*
Ja
Nein
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Eligibility NCT01294774 Subacute Cutaneous Lupus Erythematosus
Eligibility NCT01185223 Allogeneic Stem
Cell Transplantation
ODM derived from
http://clinicaltrials.gov/show/NCT01185223
All rights reserved. Please visit https://medical-data-
models.org/forms/3748
Eligibility
Einschlusskriterien
Alter mindestens 18 Jahre*
Ja
Nein
Patient following allogeneic SCT*
Ja
Nein
Patient with a first episode of positive CMV-PCR
(DNAemia) or pp65 antigenemia assay
(antigenemia) up to 100 days after SCT*
Ja
Nein
Absolute neutrophil count (ANC) >=1000
cells/microL on 2 consecutive follow-ups within 10
days before randomization*
Ja
Nein
Patient has a creatinine clearance of >=25
mL/min (calculated by the Cockcroft-Gault
formula, see Part I Section 6.1.2) with evidence
of improving renal function,*
Ja
Nein
None or gastrointestinal graft-versus-host
disease (GVHD) up to grade 2 *
Ja
Nein
Ausschlusskriterien
Patient has a suspected or diagnosed CMV
disease*
Ja
Nein
Patient has received syngeneic SCT*
Ja
Nein
Patient who received an investigational medicinal
product (IMP) within the last 30 days prior to
screening or who is simultaneously participating
in another clinical study with an IMP*
Ja
Nein
Körpergewicht*
Ja
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Nein
Patient has received anti-CMV therapy within the
past 30 days prior to screening (the use of
acyclovir, valacyclovir, or famciclovir is
permitted)*
Ja
Nein
Patient who has participated in this study before,*
Ja
Nein
Patient who shows a neutropenia,
thrombocytopenia, or anemia within 10 days
before or at the time point of randomization as
following:*
Ja
Nein
The ANC is <1000 cells/microL on 2 consecutive
follow-ups, or*
Ja
Nein
A platelet count of >=25000/microL can not be
achieved/maintained with platelet  transfusions*
Ja
Nein
A hemoglobin level of >=8g/dL can not be
achieved/maintained by red blood cell
transfusions*
Ja
Nein
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Eligibility NCT01185223 Allogeneic Stem Cell Transplantation
Eligibility NCT01190839 Crohn's Disease
ODM derived from
http://clinicaltrials.gov/show/NCT01190839
All rights reserved. Please visit https://medical-data-
models.org/forms/3750
Eligibility
Einschlusskriterien
Alter mindestens 18 Jahre*
Ja
Nein
Have a documented diagnosis of CD confirmed
by endoscopic, histologic and/or radiologic
studies prior to resection or by tissue obtained at
resection*
Ja
Nein
Have undergone an ileocolonic surgical
resection*
Ja
Nein
Patients must also be at an increased risk of
recurrence of active CD*
Ja
Nein
Patients must not have previously discontinued
infliximab as a result of tolerability issues or they
must be naive to treatment with infliximab.
Provided patients meet the above criteria
pertaining to infliximab, they are eligible to enroll
if they received prior treatment with adalimumab
and/or certolizumab*
Ja
Nein
Patients must undergo screening for HBV*
Ja
Nein
Baseline CDAI < 200*
Ja
Nein
Have adequate blood and liver test values *
Ja
Nein
Ausschlusskriterien
Have a history of latent or active granulomatous
infection, including histoplasmosis or
coccidioidomycosis, prior to screening*
Ja
Nein
Have a chest radiograph within 3 months prior to
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the first infusion of study agent that shows a
clinically significant abnormality, such as a
malignancy or infection, or any abnormalities
suggestive of TB*
Ja
Nein
Have macroscopically active CD which was not
resected at the time of surgery*
Ja
Nein
Do not meet the criteria for being at an increased
risk of postoperative recurrence of active CD as
outlined in the inclusion criteria*
Ja
Nein
Have evidence of an active infection at the time of
randomization or have had a serious infection not
related to CD (e.g., hepatitis, pneumonia, or
pyelonephritis), within 6 months prior to
screening*
Ja
Nein
Have or have had an opportunistic infection (e.g.,
herpes zoster [shingles], cytomegalovirus,
Pneumocystis carinii, aspergillosis,
histoplasmosis, or mycobacteria other than TB)
within 6 months prior to screening*
Ja
Nein
Have any known malignancy or history of
malignancy within the 5-year period prior to
screening (with the exception of squamous or
basal cell carcinoma of the skin that has been
completely excised without evidence of
recurrence)*
Ja
Nein
Have any condition that, in the opinion of the
investigator, would compromise the well-being of
the patient or the study or prevent the patient
from meeting or performing study requirements.*
Ja
Nein
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Eligibility NCT01190839 Crohn's Disease
Eligibility NCT01194154 Kidney Disease,
Chronic
ODM derived from
http://clinicaltrials.gov/show/NCT01194154
All rights reserved. Please visit https://medical-data-
models.org/forms/3751
Eligibility
Einschlusskriterien
Alter mindestens 18 Jahre*
Ja
Nein
Erwachsener, erwachsen*
Ja
Nein
For diabetic patients: Type 2 diabetes mellitus
with HbA1c >7% or anti-diabetic treatment*
Ja
Nein
For renal allograft recipients: Status between 6
months and 10 years post transplantation*
Ja
Nein
Chronic kidney disease stage III*
Ja
Nein
Urinary albumine-to-creatinine ratio between
>100 and <1000 mg/g creatinine *
Ja
Nein
Ausschlusskriterien
Hämoglobinmessung*
Ja
Nein
Initiation of angiotensin converting enzyme
inhibitor, angiotensin 2 receptor blocker or
aliskiren treatment less than 3 months before
enrolment*
Ja
Nein
Eisenmangel*
Ja
Nein
HbA1c*
Ja
Nein
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Eligibility NCT01194570 Multiple Sclerosis,
Primary Progressive
ODM derived from
http://clinicaltrials.gov/show/NCT01194570
All rights reserved. Please visit https://medical-data-
models.org/forms/3753
Eligibility
Einschlusskriterien
Alter 18 bis 55 Jahre*
Ja
Nein
Erwachsener, erwachsen*
Ja
Nein
Primary Progressive Multiple Sclerosis
(according to revised McDonald criteria)*
Ja
Nein
EDSS - Expanded disability status scale 3-6.5*
Ja
Nein
Disease duration from onset of MS symptoms <
15 years if EDSS > 5.0, < 10 years if EDSS >/=
5.0*
Ja
Nein
Sexually active male and female patients of
reproductive potential must use two methods of
contraception throughout the study treatment
phase and for 48 weeks after the last dose *
Ja
Nein
Ausschlusskriterien
History of relapsing remitting multiple sclerosis,
secondary progressive, or progressive relapsing
multiple sclerosis at screening*
Ja
Nein
Contraindications for Magnetic Resonance
Imaging (MRI)*
Ja
Nein
Known presence of other neurologic disorders*
Ja
Nein
Known active infection or history of or presence
of recurrent or chronic infection*
Ja
Nein
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History of cancer, including solid tumors and
hematological malignancies (except for basal cell,
in situ squamous cell carcinomas of the skin and
in situ carcinoma of the cervix that have been
excised and resolved)*
Ja
Nein
Previous treatment with B-cell targeted therapies
(e.g. rituximab, ocrelizumab, atacicept,
belimumab, or ofatumumab)*
Ja
Nein
Any previous treatment with lymphocyte
trafficking blockers, with alemtuzumab, anti-CD4,
cladribine, cyclophosphamide, mitoxantrone,
azathioprine, mycophenolate mofetil,
cyclosporine, methotrexate, total body irradiation,
or bone marrow transplantation*
Ja
Nein
Any concomitant disease that may require
chronic treatment with systemic corticosteroids or
immunosuppressants during the course of the
study*
Ja
Nein
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Eligibility NCT01194570 Multiple Sclerosis, Primary Progressive
Eligibility NCT01335399 Multiple Myeloma
ODM derived from
http://clinicaltrials.gov/show/NCT01335399
All rights reserved. Please visit https://medical-data-
models.org/forms/3766
Eligibility
Einschlusskriterien
Alter mindestens 18 Jahre*
Ja
Nein
Subjects who are newly diagnosed with
symptomatic Multiple Myeloma (MM) and who:*
Ja
Nein
have not received any prior systemic anti-
myeloma therapy AND*
Ja
Nein
Measurable Disease*
Ja
Nein
are not candidates for high-dose therapy plus
stem-cell transplantation because  of age (>= 65
years) or coexisting conditions *
Ja
Nein
Ausschlusskriterien
Subjects with non-secretory or oligo-secretory or
free light-chain only myeloma*
Ja
Nein
Smoldering MM, defined as asymptomatic MM
with absence of lytic bone lesions*
Ja
Nein
monoklonale Gammopathie unbestimmter
Signifikanz (MGUS)*
Ja
Nein
Active plasma cell leukemia*
Ja
Nein
Positive for Hepatitis B, C or Human
Immunodeficiency Virus (HIV)*
Ja
Nein
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Eligibility NCT01357681 Huntington's
Disease (HD)
ODM derived from
http://clinicaltrials.gov/show/NCT01357681
All rights reserved. Please visit https://medical-data-
models.org/forms/3805
Eligibility
Einschlusskriterien
Alter mindestens 18 Jahre*
Ja
Nein
Chorea Huntington (CAG repeats >39)*
Ja
Nein
UHDRS TFC >5*
Ja
Nein
Normal liver function laboratory test*
Ja
Nein
Stable concomitant medication regimen > 4
weeks prior to Baseline*
Ja
Nein
Motivation for women with childbearing potential
to use highly efficient contraception *
Ja
Nein
Ausschlusskriterien
Clinically relevant abnormal findings in the ECG,
vital signs, physical examination or laboratory
values at Screening,*
Ja
Nein
Long-term treatment with potentially hepatoxic
medication*
Ja
Nein
Any unstable medical condition*
Ja
Nein
Depression (BDI Depression score > 9)*
Ja
Nein
Cognitive dysfunction defined as a score < 23 in
the Mini-Mental State Examination (MMSE) at
Screening*
Ja
Nein
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Liver or renal disease*
Ja
Nein
Consumption of > two cups of black tea per day,
consumption of green tea, consumption of > 500
ml /day of grapefruit juice*
Ja
Nein
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Eligibility NCT01357681 Huntington's Disease (HD)
Eligibility NCT01369342 Crohn's Disease
ODM derived from
http://clinicaltrials.gov/show/NCT01369342
All rights reserved. Please visit https://medical-data-
models.org/forms/3813
Eligibility
Einschlusskriterien
Alter mindestens 18 Jahre*
Ja
Nein
Have Crohn's disease of at least 3 months'
duration with colitis, ileitis, or ileocolitis, confirmed
at some time in the past by radiography,
histology, or endoscopy*
Ja
Nein
Have active Crohn's disease, defined as a
baseline Crohn Disease Activity Index (CDAI)
score of >= 220 and <= 450, with confirmation of
active inflammation*
Ja
Nein
Has failed conventional therapy as demonstrated
by having received corticosteroids and/or
immunomodulators(ie, AZA, MTX, or 6-MP) at
adequate therapeutic doses OR Have a history of
failure to respond to or tolerate an adequate
course of corticosteroids and/or
immunomodulators (ie, AZA, MTX, or 6-MP) at
adequate therapeutic doses OR Is corticosteroid
dependent or has had a history of corticosteroid
dependency AND Has not previously
demonstrated failure of or intolerance to 1 or
more TNF-antagonist therapies (ie, infliximab,
adalimumab, or certolizumab pegol) per study
criteria*
Ja
Nein
Have screening laboratory test results within
protocol-specified parameters *
Ja
Nein
Ausschlusskriterien
Patients who have had any kind of bowel
resection within 6 months*
Ja
Nein
Are pregnant or planning pregnancy (both men
and women) while enrolled in the study or for 20
weeks after receiving study agent*
Ja
Nein
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Patients who have received infliximab,
adalimumab or certolizumab pegol < = 8 weeks
before the first administration of study drug*
Ja
Nein
Patients with certain complications of Crohn's
disease that would make it hard to assess
response to study drug*
Ja
Nein
Patients with a history of or ongoing chronic or
recurrent infectious disease*
Ja
Nein
Patients who have previously received a biologic
agent targeting IL-12 or IL-23, including but not
limited to ustekinumab (CNTO 1275) or
briakinumab (ABT-874)*
Ja
Nein
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Eligibility NCT01369342 Crohn's Disease
Eligibility NCT01376700 Hemophilia A
ODM derived from
http://clinicaltrials.gov/show/NCT01376700
All rights reserved. Please visit https://medical-data-
models.org/forms/3841
Eligibility
Einschlusskriterien
Alter bis 1 Jahr*
Ja
Nein
Subjects with severe and moderately severe
hemophilia A (FVIII <= 2%). Certain FVIII
mutation types (e.g., large multi-domain
deletions, nonsense mutations,
insertions/deletions/inversions that result in a
premature stop codon, intron 22 inversions) can
be used to corroborate a severe hemophilia A
phenotype when laboratory assays show FVIII
levels >= 1% because of rounding errors or
carryover effect from a previous FVIII
administration. A central laboratory FVIII assay is
required to confirm subject eligibility.*
Ja
Nein
Subjects must have <= 3 exposure days (EDs) to
any FVIII concentrate or FVIII-containing product
used for treatment of minor bleeds (bleeds
requiring no more than 2 infusions per event), or
for preventative or precautionary infusions
following possible injury*
Ja
Nein
Subjects with prior circumcision are allowed to
enroll only if bleeding issues related to
circumcision were the cause for the original
diagnosis of hemophilia A and no more than 2
EDs of FVIII treatment were required*
Ja
Nein
Adequate venous access (without need for
CVAD-placement) as determined by the
physician*
Ja
Nein
Written informed consent from legally authorized
representative(s) *
Ja
Nein
Ausschlusskriterien
Life-threatening conditions (intracranial
hemorrhage, severe trauma) or requirement for
surgery at the time of enrollment*
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Ja
Nein
Evidence of inhibitor >= 0.6 BU in Nijmegen-
modified Bethesda Assay at study start (samples
may be retested using lupus-insensitive inhibitor
tests to reduce the number of false positive
inhibitor test results)*
Ja
Nein
Inherited or acquired hemostatic defect other
than hemophilia A*
Ja
Nein
Any clinically significant, chronic disease other
than hemophilia A*
Ja
Nein
Known hypersensitivity to ADVATE or any of its
constituents*
Ja
Nein
Any planned elective surgery that cannot be
postponed until after the first 20 EDs*
Ja
Nein
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Eligibility NCT01376700 Hemophilia A
Eligibility NCT01386944 Restless Legs
Syndrome
ODM derived from
http://clinicaltrials.gov/show/NCT01386944
All rights reserved. Please visit https://medical-data-
models.org/forms/3845
Eligibility
Einschlusskriterien
Alter mindestens 18 Jahre*
Ja
Nein
The adult patient has a diagnosis of moderate to
severe idiopathic Restless Leg Syndrome (RLS)*
Ja
Nein
The patient must be experiencing augmentation
due to a prior dopaminergic treatment*
Ja
Nein
The decision to prescribe Neupro has been made
by the physician independently of his/her decision
to enroll the patient in the study*
Ja
Nein
Patient is informed and given ample time and
opportunity to think about his/her participation in
the study and has given written informed data
consent *
Ja
Nein
Ausschlusskriterien
Patients diagnosed with secondary Restless Leg
Syndrome (RLS) should not be enrolled in this
observational study*
Ja
Nein
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Eligibility NCT01396057 Visual Impairment
ODM derived from
http://clinicaltrials.gov/show/NCT01396057
All rights reserved. Please visit https://medical-data-
models.org/forms/3846
Eligibility
Einschlusskriterien
Alter mindestens 18 Jahre*
Ja
Nein
Patients diagnosed with visual impairment due to
macular edema following BRVO*
Ja
Nein
Diagnosis of BRVO at maximum 6 months prior
to Screening*
Ja
Nein
BCVA using ETDRS charts of 20/40 to 20/400 in
the study eye *
Ja
Nein
Ausschlusskriterien
Media clarity, pupillary dilation and patient
cooperation not sufficient for adequate fundus
photographs*
Ja
Nein
Central retinal thickness (CRT) < 250 microm in
the study eye*
Ja
Nein
Prior episode of RVO in the study eye*
Ja
Nein
Active formation of new vessels in the study eye*
Ja
Nein
Anti-VEGF-treatment in the study or the fellow
eye 3 months prior to Baseline*
Ja
Nein
IOP >= 30mmHg or uncontrolled glaucoma.
Patients may be re-screened after 1 month if they
have undergone glaucoma treatment*
Ja
Nein
Improvement of > 10 letters on BCVA between
Screening and Baseline*
1 / 2
Ja
Nein
2 / 2
Eligibility NCT01396057 Visual Impairment
Eligibility NCT01396083 Visual Impairment
ODM derived from
http://clinicaltrials.gov/show/NCT01396083
All rights reserved. Please visit https://medical-data-
models.org/forms/3847
Eligibility
Einschlusskriterien
Alter mindestens 18 Jahre*
Ja
Nein
Patients diagnosed with visual impairment due to
macular edema following CRVO*
Ja
Nein
Diagnosis of CRVO at maximum 6 months prior
to Screening*
Ja
Nein
BCVA using ETDRS charts of 20/40 to 20/400 in
the study eye *
Ja
Nein
Ausschlusskriterien
Media clarity, pupillary dilation and patient
cooperation not sufficient for adequate fundus
photographs*
Ja
Nein
Central retinal thickness (CRT) < 250 microm in
the study eye*
Ja
Nein
Prior episode of RVO in the study eye*
Ja
Nein
Active formation of new vessels in the study eye*
Ja
Nein
Anti-VEGF-treatment in the study or the fellow
eye 3 months prior to Baseline*
Ja
Nein
IOP >= 30mmHg or uncontrolled glaucoma.
Patients may be re-screened after 1 month if they
have undergone glaucoma treatment*
Ja
Nein
Improvement of > 10 letters on BCVA between
Screening and Baseline*
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Ja
Nein
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Eligibility NCT01396083 Visual Impairment
Unfallhergang SHT-Register
Unfallhergang SHT-Register
All rights reserved. Please visit https://medical-data-
models.org/forms/3877
Unfallhergang
Unfallgeschehen
Unfallgeschehen*
Wegeunfall (1)
Gewalteinwirkung, körperlich (2)
Gewalteinwirkung, gegenständlich (3)
Stürze (4)
Reiten (5)
Rad- / Ballsport (6)
Eissport (7)
Schütteltrauma (8)
Sonstiges Unfallgeschehen*
Sturzart*
Sturz von Leiter oder Gerüsten (1)
Sturz von Bäumen (2)
Treppensturz (3)
Sturz von Wickeltisch (4)
Sturz aus Hochbett / Stuhl (5)
Sonstige Sturzart*
Straßenverkehr
Fortbewegungsmittel*
Fußgänger (1)
Rad (2)
Motorrad (3)
Auto (4)
Sonstiges (5)
Sitzplatz*
Fahrer (1)
Beifahrer (2)
angeschnallt*
Ja
Nein
Helm*
Ja
Nein
Sicherheitskleidung*
Ja
Nein
Alkohol*
Ja
Nein
Promille*
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Fremdverschulden*
Ja
Nein
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Unfallhergang SHT-Register
HIS autopsy form prostate cancer
HIS autopsy form prostate cancer
All rights reserved. Please visit https://medical-data-
models.org/forms/3887
HIS
Admininstrative Daten
Patienten-Nachname*
Patienten-Vorname*
Patienten-Titel*
früherer Name*
Patienten-Geburtsdatum*
Alter des Patienten*
Nationalität/Staatsangehörigkeit*
Straße*
Postleitzahl Patient*
Wohnort*
Fallnummer*
Tumordiagnose
Tumordiagnose*
Datum der Diagnose*
Autopsiedaten
Datum der Autopsie*
Tumorausbreitung
Primärtumor*
fragliches Ergebnis (F = fraglicher
Befund)
kein Nachweis des Tumors (K = Kein
Tumornachweis)
Rezidiv (R = Rezidiv)
Tumor vorhanden (T = Tumornachweis)
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Unbekannt (X = unbekannt)
Metastase in regionären Lymphknoten*
fragliches Ergebnis (F = fraglicher
Befund)
kein Nachweis des Tumors (K = Kein
Tumornachweis)
Rezidiv (R = Rezidiv)
Tumor vorhanden (T = Tumornachweis)
Unbekannt (X = unbekannt)
Fernmetastasen
Metastase in Fern - Lymphknoten*
fragliches Ergebnis (F = fraglicher
Befund)
kein Nachweis des Tumors (K = Kein
Tumornachweis)
Rezidiv (R = Rezidiv)
Tumor vorhanden (T = Tumornachweis)
Unbekannt (X = unbekannt)
Metastase in der Lunge*
fragliches Ergebnis (F = fraglicher
Befund)
kein Nachweis des Tumors (K = Kein
Tumornachweis)
Rezidiv (R = Rezidiv)
Tumor vorhanden (T = Tumornachweis)
Unbekannt (X = unbekannt)
Metastase in der Leber*
fragliches Ergebnis (F = fraglicher
Befund)
kein Nachweis des Tumors (K = Kein
Tumornachweis)
Rezidiv (R = Rezidiv)
Tumor vorhanden (T = Tumornachweis)
Unbekannt (X = unbekannt)
Metastase im Gehirn*
fragliches Ergebnis (F = fraglicher
Befund)
kein Nachweis des Tumors (K = Kein
Tumornachweis)
Rezidiv (R = Rezidiv)
Tumor vorhanden (T = Tumornachweis)
Unbekannt (X = unbekannt)
Metastase in der Pleura*
fragliches Ergebnis (F = fraglicher
Befund)
kein Nachweis des Tumors (K = Kein
Tumornachweis)
Rezidiv (R = Rezidiv)
Tumor vorhanden (T = Tumornachweis)
Unbekannt (X = unbekannt)
Metastase in der Haut*
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HIS autopsy form prostate cancer
fragliches Ergebnis (F = fraglicher
Befund)
kein Nachweis des Tumors (K = Kein
Tumornachweis)
Rezidiv (R = Rezidiv)
Tumor vorhanden (T = Tumornachweis)
Unbekannt (X = unbekannt)
Metastase in den Knochen*
fragliches Ergebnis (F = fraglicher
Befund)
kein Nachweis des Tumors (K = Kein
Tumornachweis)
Rezidiv (R = Rezidiv)
Tumor vorhanden (T = Tumornachweis)
Unbekannt (X = unbekannt)
Metastase in der Nebenniere*
fragliches Ergebnis (F = fraglicher
Befund)
kein Nachweis des Tumors (K = Kein
Tumornachweis)
Rezidiv (R = Rezidiv)
Tumor vorhanden (T = Tumornachweis)
Unbekannt (X = unbekannt)
Metastase im Peritoneum*
fragliches Ergebnis (F = fraglicher
Befund)
kein Nachweis des Tumors (K = Kein
Tumornachweis)
Rezidiv (R = Rezidiv)
Tumor vorhanden (T = Tumornachweis)
Unbekannt (X = unbekannt)
Metastase in der Milz*
fragliches Ergebnis (F = fraglicher
Befund)
kein Nachweis des Tumors (K = Kein
Tumornachweis)
Rezidiv (R = Rezidiv)
Tumor vorhanden (T = Tumornachweis)
Unbekannt (X = unbekannt)
Metastase im Ovar*
fragliches Ergebnis (F = fraglicher
Befund)
kein Nachweis des Tumors (K = Kein
Tumornachweis)
Rezidiv (R = Rezidiv)
Tumor vorhanden (T = Tumornachweis)
Unbekannt (X = unbekannt)
Metastase im Knochenmark*
fragliches Ergebnis (F = fraglicher
Befund)
kein Nachweis des Tumors (K = Kein
Tumornachweis)
Rezidiv (R = Rezidiv)
Tumor vorhanden (T = Tumornachweis)
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Unbekannt (X = unbekannt)
Fernmestastase (andere Organe)*
Tumor vorhanden*
Unbekannt (F = fraglicher Befund)
Rezidiv (K = Kein Tumornachweis)
fragliches Ergebnis (R = Rezidiv)
kein Nachweis des Tumors (T =
Tumornachweis)
anderes Organ, welches? (X =
unbekannt)
TNM-Klassifikation
Tumorstaging-Symbole*
rezidiv Stadium (r)  (r-Symbol)
neoadjuvanter Therapie (y) (Y-Symbol)
T-Stadium*
T0 (T0)
T1 (T1)
T2 (T2)
T3 (T3)
T4 (T4)
TX (TX)
Multple*
Ja
Nein
N - Stadium der regionalen Lymphknoten*
N0 (N0)
N1 (N1)
N2 Stadium (N2)
N3 Stadium (N3)
NX (NX)
M- Stadium*
M0 (M0)
M1 (M1)
MX (MX)
Tumorhistologie
Pathologisches Institut*
Datum Pathologie Befund*
Histologie-Code ICD-0-3*
Histologisches Grading*
G1 (G1 = Gut differenziert)
G2 (G2 = Mäßig differenziert)
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G3 (G3 = Schlecht differenziert)
High grade (High grade)
Low grade (Low grade)
Grading nicht vorgesehen (O = Grading
nicht vorgesehen)
X = Differenzierungsgrad kann nicht
bestimmt werden (X =
Differenzierungsgrad kann nicht
bestimmt werden)
Seite Lymphknoten*
links (links)
rechts (rechts)
Anzahl der untersuchten Lymphknoten *
Anzahl der befallenen Lymphknoten *
Gesamt-Gleason-Score*
häufigstes Gleason-Muster*
zweithäufigstes Gleason-Muster*
Lymphgefäßinvasion*
L0 = keine Lymphgefäßinvasion (L0)
L1 = Lymphgefäßinvasion (L1)
LX = nicht beurteilbar (LX)
Veneninvasion*
V0 = keine Veneninvasion (V0)
V1 = mikroskopische Veneninvasion (V1)
V2 = makroskopische Veneninvasion
(V2)
VX = nicht beurteilbar (VX)
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HIS surgery complication prostate cancer
All rights reserved. Please visit https://medical-data-
models.org/forms/3888
HIS
Admininstrative Daten
Patienten-Nachname*
Patienten-Vorname*
Patienten-Titel*
früherer Name*
Patienten-Geburtsdatum*
Alter des Patienten*
Nationalität/Staatsangehörigkeit*
Straße*
Postleitzahl Patient*
Wohnort*
Fallnummer*
Komplikationsbogen
Tumordiagnose*
Datum der Diagnose*
Datum der OP*
postoperative Wundinfektion
postoperative Wundinfektion*
Ja
Nein
Fallnummer*
Postoperative Revisionseingriffe
1 / 2
chirurgische Revision*
Ja
Nein
Welche Revisionsoperation*
Lymphozelendrainage - ambulant
(ambulante Lymphozelendrainage)
Blutung (Hämatom)
Lymphozelendrainage - operativ
(operativ:
Lymphozelendrainage/Lymphozelenfenst
er)
Sonstiges (Sonstiges)
Sonstiges*
nicht_kodiert
nicht_kodiert*
nicht_kodiert (Grad I - Abweichung vom
normalen postoperativen Verlauf ohne
die Notwendigkeit einer Intervention)
nicht_kodiert (Grad II - Leichte
Komplikationen, die einer
medikamentösen Intervention,
Bluttransfusion oder parenteralen
Ernährung bedürfen)
nicht_kodiert (Grad III - Komplikationen,
bei denen eine chirurgische,
endoskopische oder radiologische
Intervention notwendig ist)
nicht_kodiert (Grad IIIa - wie zuvor
jedoch ohne Vollnarkose)
nicht_kodiert (Grad IIIb - wie zuvor
jedoch  mit Vollnarkose)
nicht_kodiert (Grad IV -
Lebensbedrohliche Komplikation, die
eine intensivmedizinische Behandlung
verlangten)
nicht_kodiert (Grad IVa - Versagen eines
Organs)
nicht_kodiert (Grad IVb - Versagen
mehrerer Organe)
nicht_kodiert (Grad V - Tod durch
Komplikationen hervorgerufen)
nicht_kodiert*
nicht_kodiert (individuell)
nicht_kodiert (schicksalhaft =
unvermeidbar)
nicht_kodiert (systemisch)
nicht_kodiert (vermeidbar)
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conference breast cancer
HIS pathology documtation cancer conference breast
cancer
All rights reserved. Please visit https://medical-data-
models.org/forms/3890
HIS
Admininstrative Daten
Patienten-Nachname*
Patienten-Vorname*
Patienten-Titel*
früherer Name*
Patienten-Geburtsdatum*
Alter des Patienten*
Nationalität/Staatsangehörigkeit*
Straße*
Postleitzahl Patient*
Wohnort*
Pathologie-Dokumentation für FK
Tumorboard
Histologie-Identifikationsnummer*
Präparate*
Präparate mit pathologischem Befund*
Histopathologie*
Pathologischer TNM
Tumorstaging-Symbole*
Tumorstaging Symbol r (r)
Tumorstaging Symbol y (y)
pT-Stadium*
pN - Stadium der regionalen Lymphknoten*
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Anzahl der befallenen Lymphknoten *
Anzahl der untersuchten Lymphknoten *
Anzahl der beteiligten Sentinellymphknoten *
Anzahl der untersuchten Sentinellymphknoten*
pM- Stadium*
Lymphgefäßinvasion*
Veneninvasion*
Perineurale Invasion*
Histologisches Grading*
Residualklassifikation*
Sicherheitsabstand DCIS*
Östrogen-Rezeptor*
Progesteron-Rezeptor*
Ki-67 Antigen *
Her-2/neu*
CISH*
negativ (negativ)
positiv (positiv)
Histologie-Code*
Histologie-Code ICD-0-3*
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HIS pathology report - biopsy prostate cancer
All rights reserved. Please visit https://medical-data-
models.org/forms/3893
HIS
Admininstrative Daten
Patienten-Nachname*
Patienten-Vorname*
Patienten-Titel*
früherer Name*
Patienten-Geburtsdatum*
Alter des Patienten*
Nationalität/Staatsangehörigkeit*
Straße*
Postleitzahl Patient*
Wohnort*
Fallnummer*
Tumorhistologie
Pathologisches Institut*
Histologie-Identifikationsnummer*
Aufnahme-Information*
Histopathologie
Datum der Histologie*
Eingangszeit*
Histologie-Code ICD-0-3*
Histopathologie*
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Histologie-Code ICD-0-3*
Stanzen
Ort der Biopsie*
links apikal lateral (LAL)
links apikal medial (LAM)
links basal lateral (LBL)
links basal medial (LBM)
links mittig lateral (LML)
links mittig medial (LMM)
rechts apikal lateral (RAL)
rechts apikal medial (RAM)
rechts basal lateral (RBL)
rechts basal medial (RBM)
rechts mittig lateral (RML)
rechts mittig medial (RMM)
Zusatz (Zusatz)
Stanze
durchgeführt*
Ja
Nein
kein Tumornachweis*
Ja
Nein
Gesamt-Gleason-Score*
vorangiges Gleason-Muster*
zweithäufigstes Gleason-Muster*
Tumor in % der Stanze*
Länge (in mm)*
sonstige nützliche Informationen*
atypische klein-azinäre Proliferation der Prostata*
Ja
Nein
PIN-High Grade*
Ja
Nein
Prostatitis*
Ja
Nein
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Nekrosen*
Ja
Nein
Samenblaseninfiltration*
Ja
Nein
extraprostatische Tumorausbreitung*
Ja
Nein
Perineurale Invasion*
Ja
Nein
p63 (negativ)*
Ja
Nein
Alpha-Methylacyl-CoA Racemase *
Ja
Nein
Lokalisation Fernmetastase
Lokalisation Fernmetastase*
Datum*
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All rights reserved. Please visit https://medical-data-
models.org/forms/3894
HIS
Patientenaufkleber groß
Aufnahmedatum*
Patientenidentifikationsnummer*
Geschlecht Patient*
Patienten-Nachname*
Patienten-Vorname*
Patienten-Geburtsdatum*
Aufnahmezeit*
Einweisender Arzt*
Patienteninformation
Datum*
verantwortliche Person*
Histologie*
Operation
Excisionsbiopsie*
Ja
Nein
Brusterhaltende Therapie*
Ja
Nein
rekonstruktive brusterhaltende Therapie*
Ja
Nein
Mastektomie*
Ja
Nein
Operation*
1 / 3
Sentinel Lymphknoten Biopsie*
Ja
Nein
Axilladissektion*
Ja
Nein
Rekonstruktion*
Tiefer inferiorer epigastrischer
Perforatorlappen (DIEP)
Expander (Implantat/Expander)
Ja (ja)
Latissimus dorsi Muskel-Unterhaut-
Lappen (Lat. Dorsi)
Nein (nein, aber Aufklärung erfolgt)
nicht notwendig (nicht notwendig)
Transverser Rectus Abdominis
Musculocutaneus-Lappen (TRAM)
Aufnahmedatum*
erster Operateur*
Patienteninformation II
Intent Chemotherapie*
Neoadjuvant (N = neoadjuvant)
klinische Studie*
Staging*
postoperativ (postoperativ)
präoperativ (präoperativ)
Röntgen Thorax*
Ja
Nein
Datum Röntgen Thorax*
Befund Röntgen Thorax - Freitext*
Befund Röntgen Thorax*
auffällig (auffällig)
unauffällig (unauffällig)
Sonographie Abdomen*
Ja
Nein
Datum Sonographie Abdomen*
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Befund Sonographie Abdomen - Freitext*
Befund Sonographie Abdomen*
auffällig (auffällig)
unauffällig (unauffällig)
Szinitgraphie*
Ja
Nein
Datum Szintigraphie*
Befund Szintigraphie - Freitext*
Befund Szintigraphie *
auffällig (auffällig)
unauffällig (unauffällig)
Computertomographie*
Ja
Nein
Datum Computertomographie*
Befund Computertomographie - Freitext*
Befund Computertomographie*
auffällig (auffällig)
unauffällig (unauffällig)
Fernmetastasen*
Zweitmeinung erwünscht*
Ja
Nein
Ort Zweitmeinung*
Unterschrift*
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All rights reserved. Please visit https://medical-data-
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HIS
Admininstrative Daten
Patienten-Nachname*
Patienten-Vorname*
Patienten-Titel*
früherer Name*
Patienten-Geburtsdatum*
Alter des Patienten*
Nationalität/Staatsangehörigkeit*
Straße*
Postleitzahl Patient*
Wohnort*
Anmeldung TB Mamma
Anamnese*
Tumorboard Indikation*
CIN (CIN)
Gynäkologische Tumore
(Gynäkologische Tumore)
Kurzvorstellung (Kurzvorstellung)
intern (Mamma intern)
Mamma Screenin Stadt (Mamma
Screenin Stadt)
Mamma Screening Land (Mamma
Screening Land)
gewünschte Präsentation*
Histologie (nur histologische Demo)
Radiologie (nur radiologische Demo)
Radiologie und Histologie (Radiologische
und histologische Demo)
bisherige Tumortherapie*
Kreatinin*
1 / 4
Datum Kreatinin*
Tumormarker und Hormonrezeptoren*
AFP (AFP)
CA-125 (CA-125)
CA15-3 (CA15-3)
CEA (CEA)
HCG (HCG)
SCC (SCC)
Wert*
Datum Tumormarker*
Zytologie-Befunde
Pap Test*
HPV-High Risk *
Ja
Nein
FIGO Stadium*
Biospie*
Ja (ja)
Nein (nicht durchgeführt)
betroffenes Organ*
Datum der Biopsieentnahme*
Histopathologie*
Operation*
Ja (ja)
nicht durchgeführt (nicht durchgeführt)
Datum Operation*
OP-Bezeichnung*
Erster Operateur*
Staging*
Ja (ja)
Nein (nein)
unbekannt (unbekannt)
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Röntgen Thorax*
auffällig (auffällig)
nicht durchgeführt (nicht durchgeführt)
unauffällig (unauffällig)
Befund Röntgen Thorax*
Sonographie Abdomen*
auffällig (auffällig)
nicht durchgeführt (nicht durchgeführt)
unauffällig (unauffällig)
Befund Sonographie Abdomen*
Szinitgraphie*
auffällig (auffällig)
nicht durchgeführt (nicht durchgeführt)
unauffällig (unauffällig)
Befund Szinitgraphie*
Computertomographie*
auffällig (auffällig)
nicht durchgeführt (nicht durchgeführt)
unauffällig (unauffällig)
Befund Computertomographie*
Kernspintomographie*
auffällig (auffällig)
nicht durchgeführt (nicht durchgeführt)
unauffällig (unauffällig)
Befund MRT*
MRT-Mamma*
auffällig (auffällig)
nicht durchgeführt (nicht durchgeführt)
unauffällig (unauffällig)
Befund MRT-Mamma*
Spülzytologie*
auffällig (auffällig)
nicht durchgeführt (nicht durchgeführt)
unauffällig (unauffällig)
Befund Spülzytologie*
andere Untersuchung*
auffällig (auffällig)
nicht durchgeführt (nicht durchgeführt)
unauffällig (unauffällig)
anderer Befund*
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Fragestellung*
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quality management Breast Center
requirements breast cancer
quality management Breast Center requirements breast
cancer
All rights reserved. Please visit https://medical-data-
models.org/forms/3899
quality management
breast cancer
Wartezeit Sprechstunde*
Wartezeit Termin*
Zeitlicher Abstand zwischen Diagnose und
Operationsdatum*
Mikroskopische Sicherung vor Operation*
Ja
Nein
Tumor Befund*
Histologischer Befund (histologisch)
Excisionsbiopsie*
Sentinel Lymphknoten Biopsie*
Ja
Nein
Histologie*
DCIS (DCIS)
invasives lobuläre Karzinom (IL)
invasives Karzinom (invasiv)
Intraoperatives Präparatröntgen*
Ja
Nein
Brusterhaltende Therapie*
Ja
Nein
pT-Stadium*
Axilladissektion*
Ja
Nein
Anzahl der untersuchten Lymphknoten*
Residualklassifikation*
Residualtumor Stadium R0 (R0 = kein
Residualtumor)
Komplikationen*
Ja
Nein
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chirurgische Revision*
postoperative Wundinfektion*
Östrogen-Rezeptor*
negativ (negativ)
positiv (positiv)
Progesteron-Rezeptor*
negativ (negativ)
positiv (positiv)
Her-2/neu*
Abstand des Tumors vom nächstgelegenen
Rand*
Einverständniserklärung*
Bestrahlung*
Chemotherapie*
Ja
Nein
Hormon- / endokrine Therapie*
Ja
Nein
pN - Stadium der regionalen Lymphknoten*
Zustimmung Evaluation Patientenzufriedenheit*
hohe Patientenzufriedenheit*
Patienten-Geburtsdatum*
Histologie-Code ICD-0-3*
Chirurgische und medizinische Prozeduren*
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All rights reserved. Please visit https://medical-data-
models.org/forms/3900
quality management
prostate cancer
Primärfall*
Prostata-spezifisches-Antigen*
Gesamt-Gleason-Score*
T-Stadium*
Tumorboard Typ*
Morbiditätskonferenz
(Morbiditätskonferenz)
posttherapeutisch (posttherapeut.
Konferenz )
prätherapeutisch (prätherapeut.
Konferenz )
Teilnehmer*
Pathologie (Pathologie)
Strahlentherapie (Strahlentherapie)
Urologie (Urologie)
pT-Stadium*
pN - Stadium der regionalen Lymphknoten*
pM- Stadium*
Residualklassifikation*
Residualtumor Stadium R0 (R0 = kein
Residualtumor)
Residualtumor Stadium R1 (R1 =
mikroskopischer Residualtumor)
Aufnahmeanlass*
Fernmetastasen (M-Fernmetastase)
Primärtumor (P-Primärtumor)
Rezidiv (R-Rezidiv)
active surveillance*
Strahlentherapie - Technik*
Brachytherapy (Brachytherapie)
Tele-Radiotherapie (P-perkutane
Therapie (Tele- und Brachyth.))
Interne Radiotherapie - permanente
Seeds (Permanente Seedimplantation)
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Hormon- / endokrine Therapie*
Ja
Nein
onkologische Psychotherapie*
Ja
Nein
Sozialdienst*
Ja
Nein
Studienpatient*
Prostatektomie*
Komplikationen*
Ja
Nein
postoperative Wundinfektion*
chirurgische Revision*
Nachblutung mit Revision*
Ja
Nein
Lymphozele*
Ja
Nein
Harnfistel*
Ja
Nein
Sonstige Komplikation*
Ja
Nein
Nerverhalt*
Bestrahlung*
D90 > 130 Gy erreicht?*
Chirurgische und medizinische Prozeduren*
Patientgesundheits-Fragebogen*
Ja
Nein
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HIS
Patientenaufkleber groß
Aufnahmedatum*
Patientenidentifikationsnummer*
Geschlecht Patient*
Patienten-Nachname*
Patienten-Vorname*
Patienten-Geburtsdatum*
Aufnahmezeit*
Einweisender Arzt*
Tumorkonferenz
Datum der Konferenz*
Ort der Konferenz*
Verantwortliche Person für die Anmeldung*
Datum der Anmeldung*
Teilnehmer*
Nuklearmedizin (Nuklearmedizin)
Pathologie (Pathologie)
Radiologie (Radiologie)
Gynäkologie (Senologie)
Strahlentherapie (Strahlentherapie)
Patientendaten
Status Patient*
Primärfall (Primärpatient)
Diagnose*
Karnofsky Index*
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klinische Studie*
Krankheitsverlauf
Krankheitsverlauf*
Pathologie Befund
Kommentar zu den Pathologie Proben*
Frage
Frage*
Subformular
MDT (MIB)
Kurativ*
Ja
Nein
Ultraschall-gestütze Biopsie*
Ja
Nein
Vakuumsaugbiopsie - Sonographie*
Ja
Nein
Mamma-Screening*
Ja
Nein
Biopsie bei Mammographie*
Ja
Nein
Vakuumsaugbiopsie - Mammographie*
Ja
Nein
Vakuumsaugbiopsie - MRT*
Ja
Nein
Datum Pathologie Befund*
Histologie Klassifikation (B)*
normales Brustgewebe (B1)
benigne (B2)
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unklar ob benigne oder maligne (B3)
Malignitätsverdacht (B4)
DCIS (B5a)
Invasive Karzinom (B5b)
Tumor Invasion kann nicht beurteilt
werden (B5c)
anderer Tumor (B5d)
nicht_kodiert*
nicht_kodiert (K1 (sicher))
nicht_kodiert (K2 (sicher))
nicht_kodiert (K3a (unsicher, aber
wahrscheinlich))
nicht_kodiert (K3b (unsicher und
wahrscheinlich))
Aktion
Wiederholung der Biopsie*
Ja
Nein
regülare Vorsorge*
Ja
Nein
geplante Kontrolle*
Ja
Nein
Monate Check-Up*
Check-Up Mammographie*
Ja
Nein
Check-Up Sonographie*
Ja
Nein
Check-Up MRT*
Ja
Nein
zusätzliche Biopsie*
Ja
Nein
Excisionsbiopsie*
Ja
Nein
onkologische Operation*
Ja
Nein
Audit*
Ja
Nein
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Tumorboardentscheidungen
Operation*
Ja
Nein
Intention*
Adjuvant (adjuvant)
Kurativ (kurativ)
Neoadjuvant (neoadjuvant)
Palliativ (palliativ)
sonstiges (sonstiges)
Chemotherapie*
Ja
Nein
Intention*
Adjuvant (adjuvant)
Kurativ (kurativ)
Neoadjuvant (neoadjuvant)
Palliativ (palliativ)
sonstiges (sonstiges)
Bestrahlung*
Ja
Nein
Intention*
Adjuvant (adjuvant)
Kurativ (kurativ)
Neoadjuvant (neoadjuvant)
Palliativ (palliativ)
sonstiges (sonstiges)
Hormon- / endokrine Therapie*
Ja
Nein
Intention*
Adjuvant (adjuvant)
Kurativ (kurativ)
Neoadjuvant (neoadjuvant)
Palliativ (palliativ)
sonstiges (sonstiges)
Immuntherapie*
Ja
Nein
Intention*
Adjuvant (adjuvant)
Kurativ (kurativ)
Neoadjuvant (neoadjuvant)
Palliativ (palliativ)
sonstiges (sonstiges)
Studienprotokoll*
Ja
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Nein
Studienprotokoll - Freitext*
Verlaufskontrolle*
Ja
Nein
Verlaufskontrolle - Freitext*
Analgetika*
Ja
Nein
Analgetika - Freitext*
andere Empfehlung*
Ja
Nein
andere Empfehlung - Freitext*
Re-Biopsie*
Ja
Nein
Bisphosphonate*
Ja
Nein
Bisphosphonate - Freitext*
Radioiodtherapie*
Ja
Nein
Wiedervorstellung nach Diagnostik*
Ja
Nein
Active Surveillance*
Ja
Nein
Diagnostik notwendig*
Therapie Freitext*
Datum der Arzt-Unterschrift*
Arzt-Unterschrift*
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HIS
Admininstrative Daten
Patienten-Nachname*
Patienten-Vorname*
Patienten-Titel*
früherer Name*
Patienten-Geburtsdatum*
Alter des Patienten*
Nationalität/Staatsangehörigkeit*
Straße*
Postleitzahl Patient*
Wohnort*
Dokumentation TB Mamma
nicht_sinnvoll_für_Untersuchung*
Ja
Nein
vorgestellt von*
Datum der Diagnose*
Anamnese*
bisherige Tumortherapie*
Fragestellung*
klinisches TNM-Staging
T-Stadium*
1 / 6
N - Stadium der regionalen Lymphknoten*
M- Stadium*
vorhandenes TNM
vorhandenes TNM*
Ja
Nein
pT-Stadium*
pN - Stadium der regionalen Lymphknoten*
pM- Stadium*
Pathologischer TNM
Pathologischer TNM*
Ja
Nein
pT-Stadium*
pN - Stadium der regionalen Lymphknoten*
pM- Stadium*
Residualklassifikation*
endgültiges TNM Stadium
T*
N*
M*
Residualklassifikation*
Änderung des TNM Stadiums*
Ja
Nein
Kommentar TNM*
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FIGO Stadium*
geplantes therapeutisches Vorgehen
Operation*
Ja
Nein
Intention*
Kurativ (Kura.)
Palliativ (Palli.)
Kommentar Operation*
Bestrahlung*
Ja
Nein
Intention*
Adjuvant (Adj.)
Kurativ (Kura.)
Neoadjuvant (Neoadj.)
Palliativ (Palli.)
Kommentar Strahlentherapie*
Chemotherapie*
Ja
Nein
Intention*
Adjuvant (Adj.)
Kurativ (Kura.)
Neoadjuvant (Neoadj.)
Palliativ (Palli.)
Name Chemotherapie*
Kommentar Chemotherapie*
Hormon- / endokrine Therapie*
Ja
Nein
Intention*
Adjuvant (Adj.)
Kurativ (Kura.)
Neoadjuvant (Neoadj.)
Palliativ (Palli.)
Name Hormontherapie*
Kommentar endokrine Therapie*
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Immuntherapie*
Ja
Nein
Intention*
Adjuvant (Adj.)
Kurativ (Kura.)
Neoadjuvant (Neoadj.)
Palliativ (Palli.)
Name Immuntherapie*
Kommentar Immuntherapie*
Interventionelle Radiologie*
Ja
Nein
Intention*
Adjuvant (Adj.)
Kurativ (Kura.)
Neoadjuvant (Neoadj.)
Palliativ (Palli.)
Kommentar interventionelle Radiologie*
Schmerztherapie / Schmerzmanagement*
Ja
Nein
Kommentar Schmerztherapie*
supportive Theapie*
Ja
Nein
Kommentar supportive Therapie*
Palliativmedizin*
Ja
Nein
Kommentar Palliativmedizin*
weitere Diagnostik*
Ja
Nein
Kommentar Diagnostik*
Watchful Waiting*
Ja
Nein
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keine Therapie*
Ja
Nein
onkologische Psychotherapie*
Ja
Nein
Target Therapie*
Ja
Nein
Name Target-Therapie*
Bemerkung Target Therapie*
medizinische Besonderheiten*
Ja
Nein
Bezeichung med. Besonderheiten*
Kommentar Besonderheiten*
Nachsorge*
Ja
Nein
Kommentar Nachsorge*
Wiedervorstellung*
Ja
Nein
Kommentar Wiedervorstellung*
Weiteres
Möglicher Studienpatient*
Ja
Nein
klinische Studie*
Kommentar klinische Studie*
Einhaltung der Leitlinen*
Ja (Ja)
keine Leitlinie (Keine Leitlinie vorhanden)
Nein (Nein)
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Kommentar Leitlinie*
Tumorboard Indikation*
Primärfall (Primärpatient (Erste Therapie
je Stadium))
nicht_kodiert (Verlaufstherapie (Weitere
Therapie je Stadium))
Zweitmeinung (Zweitmeinung/Externer
Patient)
Tumorboard Typ*
posttherapeutisch (Posttherapeutische
Konferenz)
prätherapeutisch (Prätherapeutische
Konferenz)
Teilnehmer*
Andere (Andere)
Gynäkologie (Frauenklinik (Vorsitz))
Radiologie (Gynäkologische Radiologie)
Intern. Onkologie (Medizin 5)
Palliativmedizin (Palliativmedizin)
Pathologie (Pathologie)
Strahlentherapie (Strahlentherapie)
Protokoll*
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HIS temporary and final report prostate cancer
All rights reserved. Please visit https://medical-data-
models.org/forms/3905
HIS
Admininstrative Daten
Patienten-Nachname*
Patienten-Vorname*
Patienten-Titel*
früherer Name*
Patienten-Geburtsdatum*
Alter des Patienten*
Nationalität/Staatsangehörigkeit*
Straße*
Postleitzahl Patient*
Wohnort*
Fallnummer*
Tumordiagnose
Tumordiagnose*
Datum der Diagnose*
Zwischen- und Endbericht
Letzter Kontakt - Nachsorge abgeschlossen*
Nachsorge*
Ja
Nein
Letzter Kontakt*
Nachsorge abgebrochen*
Patient nicht erschienen (Patient ist nicht
mehr erschienen)
1 / 2
Nachsorge nicht gewünscht (Patient
wünscht keine weitere Nachsorge)
Letzter Kontakt*
Tumorangaben
Tumorstatus*
Beurteilung nicht möglich (Beurteilung
nicht möglich)
stable disease (no change)
Tumor Progression (Progression)
Teilremission (Teilremission)
kein Tumor (Tumorfrei)
komplette Remission (Vollremission)
Vitalstatus*
Datum Vitalstatus*
Patient verstorben*
andere Todesursache (andere
Todesursache)
fraglich Patient verstorben (fraglich)
Todesursache tumorbedingt
(Todesursache Tumorbedingt)
unbekannt ob Patient verstorben
(unbekannt)
Todesdatum*
Autopsie*
Ja (J = Ja)
Nein (N = Nein)
Unbekannt (X = unbekannt)
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All rights reserved. Please visit https://medical-data-
models.org/forms/3907
HIS
Admininstrative Daten
Patienten-Nachname*
Patienten-Vorname*
Patienten-Titel*
früherer Name*
Patienten-Geburtsdatum*
Alter des Patienten*
Nationalität/Staatsangehörigkeit*
Straße*
Postleitzahl Patient*
Wohnort*
Fallnummer*
Tumordiagnose
Tumordiagnose*
Datum der Diagnose*
Tumorhistologie
Pathologisches Institut*
Histologie-Identifikationsnummer*
Aufnahme-Information*
Histopathologie
Datum der Histologie*
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Eingangszeit*
Histologie-Code ICD-0-3*
Histopathologie*
Histologie-Code ICD-0-3*
Histologisches Grading*
Grading nicht vorgesehen (0 = Grading
nicht vorgesehen)
G1 (G1 = Gut differenziert)
G2 (G2 = Mäßig differenziert)
G3 (G3 = Schlecht differenziert)
High grade (High grade)
Low grade (Low grade)
Differenzierungsgrad kann nicht
bestimmt werden (X =
Differenzierungsgrad kann nicht
bestimmt werden)
Gleason-Score
Gleason-Score*
vorhanden (Angaben vorhanden)
keine Gleason-Angabe (keine Angabe)
vorangiges Gleason-Muster*
zweithäufigstes Gleason-Muster*
Gesamt-Gleason-Score*
tertiäres Gleason-Muster*
Gleason Muster 1 (Gl1)
Gleason Muster 2 (Gl2)
Gleason Muster 3 (Gl3)
Gleason Muster 4 (Gl4)
Gleason Muster 5 (Gl5)
verschiedene Kriterien
Prostatitis*
Ja
Nein
Nekrosen*
Ja
Nein
Samenblaseninfiltration*
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Ja
Nein
Lokalisation Tumor*
Ja
Nein
extraprostatische Tumorausbreitung*
Ja
Nein
Tumorlokalisation Seite*
links (L)
multilokulär (multilokulär)
rechts (R)
unilokulär (unilokulär)
Transitionalzone*
Ja
Nein
Tumorlokalisation Höhe*
apikal (apikal)
basal (basal)
mittig (mittig)
Tumorvolumen (cm^3)*
Prostatagewicht*
sonstige nützliche Informationen*
Pathologischer TNM
Pathologischer TNM*
Ja
Nein
Tumorstaging-Symbole*
Tumorstaging Symbol r (r)
Tumorstaging Symbol y (y)
pT-Stadium*
pT1a (pT1a)
pT1b (pT1b)
pT1c (pT1c)
pT2a (pT2a)
pT2b (pT2b)
pT2c (pT2c)
pT3a (pT3a)
pT3b (pT3b)
pT0 Stadium (T0)
pT1 Stadium  (T1)
pT2 Stadium (T2)
pT3 Stadium  (T3)
pT4 Stadium  (T4)
pTa Stadium (Ta)
pTis Stadium (Tis)
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pTX Stadium (TX)
pN - Stadium der regionalen Lymphknoten*
pN0 Stadium (N0)
pN1 Stadium (N1)
pN2 Stadium (N2)
pN3 Stadium (N3)
pM- Stadium*
pM0 Stadium  (M0)
pM1 Stadium  (M1)
pMX Stadium (MX)
pM1a (pM1a)
pM1b (pM1b)
pM1c (pM1c)
Seite Lymphknoten*
links (links)
rechts (rechts)
Anzahl der untersuchten Lymphknoten *
Anzahl der befallenen Lymphknoten *
Lymphgefäßinvasion*
L0 = keine Lymphgefäßinvasion (L0 =
keine Lymphgefäßinvasion)
L1 = Lymphgefäßinvasion (L1)
LX = nicht beurteilbar (LX = nicht
beurteilbar)
Veneninvasion*
V0 = keine Veneninvasion (V0 = keine
Veneninvasion)
V1 = mikroskopische Veneninvasion (V1)
VX = nicht beurteilbar (VX = nicht
beurteilbar)
Residualklassifikation*
Residualtumor Stadium R0 (R0)
Residualtumor Stadium R1 (R1)
Residualtumor Stadium RX (RX = nicht
beurteilbar)
Gewebeprobe Anzahl
Gewebeprobe Anzahl*
Ja
Nein
Anzahl Gewebeproben ohne Tumor*
Anzahl Gewebeproben mit Tumor*
Anzahl unbekannter Gewebeproben*
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Größe der Gewebeprobe
Größe der Gewebeprobe*
Ja
Nein
Größe der Gewebeprobe, längste Abmessung*
Größe der Gewebeprobe, weitere Abmessung*
Schnellschnitt*
Ja
Nein
Verantwortliche Person für Gewebeproben-
Lagerung*
Lokalisation Fernmetastase
Lokalisation Fernmetastase*
Datum*
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All rights reserved. Please visit https://medical-data-
models.org/forms/3911
HIS
Admininstrative Daten
Patienten-Nachname*
Patienten-Vorname*
Patienten-Titel*
früherer Name*
Patienten-Geburtsdatum*
Alter des Patienten*
Nationalität/Staatsangehörigkeit*
Straße*
Postleitzahl Patient*
Wohnort*
Fallnummer*
Abteilung*
Nachsorgenummer*
Einverständniserklärung Krebsregister*
Ja
Nein
Studiendaten
klinische Studie*
Ja (ja)
Nein (nein)
unsicher (noch unklar)
Name der Studie*
Ein- und Ausschluss*
Ausschluss (Ausschluss)
Einschluss (Einschluss)
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Einschlussdatum*
Anamnese
Status Patient*
Primärfall (Primärpatient)
Sonstiges (sonstiges)
nicht_kodiert (Wiederkehrer)
Patienten-Geschlecht*
Nachkomme einer Mehrlingsschwangerschaft*
Ja (Ja)
Nein (Nein)
unbekannt (unbekannt)
letzte Beschäftigung*
Dauer der letzten Beschäftigung*
Längste Beschäftigung*
Dauer der längsten Beschäftigung*
Psychoonkologie*
Ja (Ja)
Nein (Nein)
unbekannt (unbekannt)
Sozialdienst*
Ja (Ja)
Nein (Nein)
unbekannt (unbekannt)
Tumorerkrankungen
Tumorvorgeschichte*
Ja (Ja)
Nein (Nein)
unbekannt (unbekannt)
Tumor-Vorerkrankung*
Tumor-Vorerkrankung*
Diagnosedatum*
Tumordaten
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Datum der ersten Diagnose*
Tumordiagnose*
Diagnosesicherheit*
Postmortem-Diagnose (a = autoptisch)
Histologischer Befund (h =
histologisch/Stanze)
klinische Diagnose (k = klinisch)
Sonstiges (s = sonstiges)
unbekannt (x = unbekannt)
Zytologischer Befund (z = zytologisch)
Datum der Diagnose*
Ort der Diagnose*
Grund des Arztbesuches *
nicht näher bezeichnete Untersuchung
(A = andere Untersuchungen)
Screening (C = Screening)
Krebs-Screeninguntersuchung (F =
Krebsfrüherkennung)
Nachsorge (L =
Langzeitbetreuung/Nachsorge)
Selbstuntersuchung (S =
Selbstuntersuchung)
Tumorsymptome (T = Tumorsymptome)
unbekannt (x = unbekannt)
Lokalisation Primärtumor*
Körperseite*
links (L = links)
Mittellinie (M = Mittellinienzone)
rechts (R = rechts)
beidseits (S = beidseits)
Systemerkrankung (S =
Systemerkrankung)
trifft nicht zu (t = trifft nicht zu)
unbekannt (x = unbekannt)
ECOG Leistungszustand*
0 (0)
1 (1)
2 (2)
3 (3)
4 (4)
X (X)
klinisches TNM-Staging
klinisches TNM-Staging*
Ja
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Nein
Tumorstaging-Symbole*
Tumorstaging Symbol r (r)
Tumorstaging Symbol y (y)
T-Stadium*
T0 Stadium (T0)
T1 Stadium  (T1)
T1a Stadium  (T1a)
T1b Stadium  (T1b)
T1c Stadium  (T1c)
T2 Stadium  (T2)
T2a Stadium  (T2a)
T2b Stadium  (T2b)
T2c Stadium  (T2c)
T3 Stadium (T3)
T3a Stadium (T3a)
T3b Stadium (T3b)
T4 Stadium   (T4)
Ta Stadium (Ta)
Tis Stadium (Tis)
TX Stadium (TX)
C-Faktor - Befundsicherung*
C-Faktor C1 (C1 = diagnostische
Standardmethoden)
C-Faktor C2 (C2 = bildgebende
Verfahren)
C-Faktor C3 (C3 = chirurgische
Exploration einschließlich Biopsie und
zytologischer Untersuchung)
N - Stadium der regionalen Lymphknoten*
N0 Stadium  (N0)
N1 Stadium  (N1)
N2 Stadium (N2)
N3 Stadium (N3)
NX Stadium  (NX)
C-Faktor - Befundsicherung*
C-Faktor C1 (C1 = diagnostische
Standardmethoden)
C-Faktor C2 (C2 = bildgebende
Verfahren)
C-Faktor C3 (C3 = chirurgische
Exploration einschließlich Biopsie und
zytologischer Untersuchung)
M- Stadium*
M0 Stadium  (M0)
M1 Stadium (M1)
M1a (M1a)
M1b (M1b)
M1c (M1c)
MX Stadium  (MX)
C-Faktor - Befundsicherung*
C-Faktor C1 (C1 = diagnostische
Standardmethoden)
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C-Faktor C2 (C2 = bildgebende
Verfahren)
C-Faktor C3 (C3 = chirurgische
Exploration einschließlich Biopsie und
zytologischer Untersuchung)
Freitext TNM*
Lokalisation Fernmetastase
Lokalisation Fernmetastase*
Ja
Nein
Metastase in der Haut*
Ja
Nein
Metastase im Gehirn*
Ja
Nein
Metastase in den Knochen*
Ja
Nein
Metastase im Knochenmark*
Ja
Nein
Metastase in der Leber*
Ja
Nein
Metastase in der Lunge*
Ja
Nein
Metastase im Lymphknoten*
Ja
Nein
Metastase in der Nebenniere*
Ja
Nein
Metastase im Peritoneum*
Ja
Nein
Metastase in der Pleura*
Ja
Nein
Generalisiere Metastasierung*
Ja
Nein
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Fernmestastase (andere Organe)*
Ja
Nein
Datum*
Freitext Lokalisation von Fernmetastasen*
Nebenlokalisation*
Anamnese Historie
Chemotherapie in der Anamnese*
Ja (Ja)
Nein (Nein)
unbekannt (unbekannt)
Strahlentherapie in der Anamnese*
Ja (Ja)
Nein (Nein)
unbekannt (unbekannt)
Komorbidität*
Zweitmalignom*
Ja (Ja)
Nein (Nein)
Unbekannt (unbekannt)
Zweitmalignom*
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All rights reserved. Please visit https://medical-data-
models.org/forms/3917
HIS
Admininstrative Daten
Patienten-Nachname*
Patienten-Vorname*
Patienten-Titel*
früherer Name*
Patienten-Geburtsdatum*
Alter des Patienten*
Nationalität/Staatsangehörigkeit*
Straße*
Postleitzahl Patient*
Wohnort*
Fallnummer*
Tumordiagnose
Tumordiagnose*
Datum der Diagnose*
Systemische Therapie
Einhaltung der Leitlinen*
Ja
Nein
Grund für Einhaltung Leitlinien*
Therapieart
Therapieart*
Ja
Nein
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Chemotherapie*
Ja
Nein
Hormon- / endokrine Therapie*
Ja
Nein
Immuntherapie*
Ja
Nein
Antikörper Therapie*
Ja
Nein
Aufnahmestatus*
ambulant (ambulant)
stationär (stationär)
nicht_kodiert (teilstationär)
Intention*
Ja
Nein
Intention - Chemotherapie*
Adjuvant (adjuvant)
Kurativ (kurativ)
Neoadjuvant (neoadjuvant)
Palliativ (palliativ)
Chemoradiotherapy *
Ja
Nein
Intention - endokrine Therapie*
Adjuvant (adjuvant)
Kurativ (kurativ)
Neoadjuvant (neoadjuvant)
Palliativ (palliativ)
Intention - Immuntherapie*
Adjuvant (adjuvant)
Kurativ (kurativ)
Neoadjuvant (neoadjuvant)
Palliativ (palliativ)
Intention - Antikörpertherapie*
Adjuvant (adjuvant)
Kurativ (kurativ)
Neoadjuvant (neoadjuvant)
Palliativ (palliativ)
Unterbrechung
Unterbrechung*
Ja
Nein
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Unterbrechung von*
Unterbrechung bis*
Grund für Unterbrecung*
Protokoll
Protokoll*
Chemotherapy cycle (procedure)
Chemotherapy cycle (procedure) *
Ja
Nein
Zyklen geplant*
aktueller Zyklus*
Datum Therapiebeginn - Chemotherapie*
Datum Therapiebeginn - endokrine Therapie*
Datum Therapiebeginn - Immuntherapie*
Voraussichtliche Beendigung*
pharmakologische Substanz
Chemotherapie Substanz*
Dosislevel der Chemotherapie reduziert*
Ja
Nein
Einzeldosis*
kumulative Dosis*
Einheit*
Begleitmedikation
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Begleitmedikation*
Ja
Nein
Antihomornelle Therapie*
LHRH (LHRH)
Orchiektomie*
Ja
Nein
Antiandrogen Therapie*
Ja
Nein
supportive Theapie*
sonstiges (andere)
Estramustin (Estramustin)
Prednison (Prednison)
Zoledronsäure (Zometa)
sonstiges*
Nebenwirkungen
Nebenwirkungen*
Ja
Nein
Leukozyten*
keine Nebenwirkungen (0 = keine
Nebenwirkungen)
leichte Nebenwirkungen (1 = milde
Nebenwirkungen)
mäßige Nebenwirkungen (2 = moderate
Nebenwirkungen)
starke Nebenwirkungen (3 = schwere
Nebenwirkungen)
lebensbedrohliche Nebenwirkungen (4 =
Lebensbedrohliche Nebenwirkungen)
letale Nebenwirkung (S = Tod)
Grad der Nebenwirkungen unbekannt (X
= Nebenwirkung unbekannt)
Hämoglobin*
keine Nebenwirkungen (0 = keine
Nebenwirkungen)
leichte Nebenwirkungen (1 = milde
Nebenwirkungen)
mäßige Nebenwirkungen (2 = moderate
Nebenwirkungen)
starke Nebenwirkungen (3 = schwere
Nebenwirkungen)
lebensbedrohliche Nebenwirkungen (4 =
Lebensbedrohliche Nebenwirkungen)
letale Nebenwirkung (S = Tod)
Grad der Nebenwirkungen unbekannt (X
= Nebenwirkung unbekannt)
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Granulozyten*
keine Nebenwirkungen (0 = keine
Nebenwirkungen)
leichte Nebenwirkungen (1 = milde
Nebenwirkungen)
mäßige Nebenwirkungen (2 = moderate
Nebenwirkungen)
starke Nebenwirkungen (3 = schwere
Nebenwirkungen)
lebensbedrohliche Nebenwirkungen (4 =
Lebensbedrohliche Nebenwirkungen)
letale Nebenwirkung (S = Tod)
Grad der Nebenwirkungen unbekannt (X
= Nebenwirkung unbekannt)
Thrombozyten*
keine Nebenwirkungen (0 = keine
Nebenwirkungen)
leichte Nebenwirkungen (1 = milde
Nebenwirkungen)
mäßige Nebenwirkungen (2 = moderate
Nebenwirkungen)
starke Nebenwirkungen (3 = schwere
Nebenwirkungen)
lebensbedrohliche Nebenwirkungen (4 =
Lebensbedrohliche Nebenwirkungen)
letale Nebenwirkung (S = Tod)
Grad der Nebenwirkungen unbekannt (X
= Nebenwirkung unbekannt)
Kreatinin*
keine Nebenwirkungen (0 = keine
Nebenwirkungen)
leichte Nebenwirkungen (1 = milde
Nebenwirkungen)
mäßige Nebenwirkungen (2 = moderate
Nebenwirkungen)
starke Nebenwirkungen (3 = schwere
Nebenwirkungen)
lebensbedrohliche Nebenwirkungen (4 =
Lebensbedrohliche Nebenwirkungen)
letale Nebenwirkung (S = Tod)
Grad der Nebenwirkungen unbekannt (X
= Nebenwirkung unbekannt)
Proteinurie*
keine Nebenwirkungen (0 = keine
Nebenwirkungen)
leichte Nebenwirkungen (1 = milde
Nebenwirkungen)
mäßige Nebenwirkungen (2 = moderate
Nebenwirkungen)
starke Nebenwirkungen (3 = schwere
Nebenwirkungen)
lebensbedrohliche Nebenwirkungen (4 =
Lebensbedrohliche Nebenwirkungen)
letale Nebenwirkung (S = Tod)
Grad der Nebenwirkungen unbekannt (X
= Nebenwirkung unbekannt)
5 / 11
HIS systemic therapy - form prostate cancer
Harnstoff*
keine Nebenwirkungen (0 = keine
Nebenwirkungen)
leichte Nebenwirkungen (1 = milde
Nebenwirkungen)
mäßige Nebenwirkungen (2 = moderate
Nebenwirkungen)
starke Nebenwirkungen (3 = schwere
Nebenwirkungen)
lebensbedrohliche Nebenwirkungen (4 =
Lebensbedrohliche Nebenwirkungen)
letale Nebenwirkung (S = Tod)
Grad der Nebenwirkungen unbekannt (X
= Nebenwirkung unbekannt)
Bilirubin*
keine Nebenwirkungen (0 = keine
Nebenwirkungen)
leichte Nebenwirkungen (1 = milde
Nebenwirkungen)
mäßige Nebenwirkungen (2 = moderate
Nebenwirkungen)
starke Nebenwirkungen (3 = schwere
Nebenwirkungen)
lebensbedrohliche Nebenwirkungen (4 =
Lebensbedrohliche Nebenwirkungen)
letale Nebenwirkung (S = Tod)
Grad der Nebenwirkungen unbekannt (X
= Nebenwirkung unbekannt)
Alkalische Phosphatase*
keine Nebenwirkungen (0 = keine
Nebenwirkungen)
leichte Nebenwirkungen (1 = milde
Nebenwirkungen)
mäßige Nebenwirkungen (2 = moderate
Nebenwirkungen)
starke Nebenwirkungen (3 = schwere
Nebenwirkungen)
lebensbedrohliche Nebenwirkungen (4 =
Lebensbedrohliche Nebenwirkungen)
letale Nebenwirkung (S = Tod)
Grad der Nebenwirkungen unbekannt (X
= Nebenwirkung unbekannt)
Alanin-Transaminase*
keine Nebenwirkungen (0 = keine
Nebenwirkungen)
leichte Nebenwirkungen (1 = milde
Nebenwirkungen)
mäßige Nebenwirkungen (2 = moderate
Nebenwirkungen)
starke Nebenwirkungen (3 = schwere
Nebenwirkungen)
lebensbedrohliche Nebenwirkungen (4 =
Lebensbedrohliche Nebenwirkungen)
only_in_connection with GOT
(only_in_connection with GOT)
letale Nebenwirkung (S = Tod)
6 / 11
HIS systemic therapy - form prostate cancer
Grad der Nebenwirkungen unbekannt (X
= Nebenwirkung unbekannt)
Aspartat-Transaminase*
keine Nebenwirkungen (0 = keine
Nebenwirkungen)
leichte Nebenwirkungen (1 = milde
Nebenwirkungen)
mäßige Nebenwirkungen (2 = moderate
Nebenwirkungen)
starke Nebenwirkungen (3 = schwere
Nebenwirkungen)
lebensbedrohliche Nebenwirkungen (4 =
Lebensbedrohliche Nebenwirkungen)
only_in_connection with GPT
(only_in_connection with GPT)
letale Nebenwirkung (S = Tod)
Grad der Nebenwirkungen unbekannt (X
= Nebenwirkung unbekannt)
Übelkeit*
keine Nebenwirkungen (0 = keine
Nebenwirkungen)
leichte Nebenwirkungen (1 = milde
Nebenwirkungen)
mäßige Nebenwirkungen (2 = moderate
Nebenwirkungen)
starke Nebenwirkungen (3 = schwere
Nebenwirkungen)
lebensbedrohliche Nebenwirkungen (4 =
Lebensbedrohliche Nebenwirkungen)
letale Nebenwirkung (S = Tod)
Grad der Nebenwirkungen unbekannt (X
= Nebenwirkung unbekannt)
Diarrhoe*
keine Nebenwirkungen (0 = keine
Nebenwirkungen)
leichte Nebenwirkungen (1 = milde
Nebenwirkungen)
mäßige Nebenwirkungen (2 = moderate
Nebenwirkungen)
starke Nebenwirkungen (3 = schwere
Nebenwirkungen)
lebensbedrohliche Nebenwirkungen (4 =
Lebensbedrohliche Nebenwirkungen)
letale Nebenwirkung (S = Tod)
Nebenwirkungen unbekannt (X =
Nebenwirkung unbekannt)
Schleimhaut*
keine Nebenwirkungen (0 = keine
Nebenwirkungen)
leichte Nebenwirkungen (1 = milde
Nebenwirkungen)
mäßige Nebenwirkungen (2 = moderate
Nebenwirkungen)
starke Nebenwirkungen (3 = schwere
Nebenwirkungen)
lebensbedrohliche Nebenwirkungen (4 =
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Lebensbedrohliche Nebenwirkungen)
letale Nebenwirkung (S = Tod)
Nebenwirkungen unbekannt (X =
Nebenwirkung unbekannt)
Vomiting*
keine Nebenwirkungen (0 = keine
Nebenwirkungen)
leichte Nebenwirkungen (1 = milde
Nebenwirkungen)
mäßige Nebenwirkungen (2 = moderate
Nebenwirkungen)
starke Nebenwirkungen (3 = schwere
Nebenwirkungen)
lebensbedrohliche Nebenwirkungen (4 =
Lebensbedrohliche Nebenwirkungen)
letale Nebenwirkung (S = Tod)
Nebenwirkungen unbekannt (X =
Nebenwirkung unbekannt)
Obstipation*
keine Nebenwirkungen (0 = keine
Nebenwirkungen)
leichte Nebenwirkungen (1 = milde
Nebenwirkungen)
mäßige Nebenwirkungen (2 = moderate
Nebenwirkungen)
starke Nebenwirkungen (3 = schwere
Nebenwirkungen)
lebensbedrohliche Nebenwirkungen (4 =
Lebensbedrohliche Nebenwirkungen)
letale Nebenwirkung (S = Tod)
Nebenwirkungen unbekannt (X =
Nebenwirkung unbekannt)
Peripherer Nerv*
keine Nebenwirkungen (0 = keine
Nebenwirkungen)
leichte Nebenwirkungen (1 = milde
Nebenwirkungen)
mäßige Nebenwirkungen (2 = moderate
Nebenwirkungen)
starke Nebenwirkungen (3 = schwere
Nebenwirkungen)
lebensbedrohliche Nebenwirkungen (4 =
Lebensbedrohliche Nebenwirkungen)
letale Nebenwirkung (S = Tod)
Nebenwirkungen unbekannt (X =
Nebenwirkung unbekannt)
Bewusstsein*
keine Nebenwirkungen (0 = keine
Nebenwirkungen)
leichte Nebenwirkungen (1 = milde
Nebenwirkungen)
mäßige Nebenwirkungen (2 = moderate
Nebenwirkungen)
starke Nebenwirkungen (3 = schwere
Nebenwirkungen)
lebensbedrohliche Nebenwirkungen (4 =
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Lebensbedrohliche Nebenwirkungen)
letale Nebenwirkung (S = Tod)
Nebenwirkungen unbekannt (X =
Nebenwirkung unbekannt)
Dyspnoe*
keine Nebenwirkungen (0 = keine
Nebenwirkungen)
leichte Nebenwirkungen (1 = milde
Nebenwirkungen)
mäßige Nebenwirkungen (2 = moderate
Nebenwirkungen)
starke Nebenwirkungen (3 = schwere
Nebenwirkungen)
lebensbedrohliche Nebenwirkungen (4 =
Lebensbedrohliche Nebenwirkungen)
letale Nebenwirkung (S = Tod)
Nebenwirkungen unbekannt (X =
Nebenwirkung unbekannt)
Infektion*
keine Nebenwirkungen (0 = keine
Nebenwirkungen)
leichte Nebenwirkungen (1 = milde
Nebenwirkungen)
mäßige Nebenwirkungen (2 = moderate
Nebenwirkungen)
starke Nebenwirkungen (3 = schwere
Nebenwirkungen)
lebensbedrohliche Nebenwirkungen (4 =
Lebensbedrohliche Nebenwirkungen)
letale Nebenwirkung (S = Tod)
Nebenwirkungen unbekannt (X =
Nebenwirkung unbekannt)
Herzrhythmus*
keine Nebenwirkungen (0 = keine
Nebenwirkungen)
leichte Nebenwirkungen (1 = milde
Nebenwirkungen)
mäßige Nebenwirkungen (2 = moderate
Nebenwirkungen)
starke Nebenwirkungen (3 = schwere
Nebenwirkungen)
lebensbedrohliche Nebenwirkungen (4 =
Lebensbedrohliche Nebenwirkungen)
letale Nebenwirkung (S = Tod)
Nebenwirkungen unbekannt (X =
Nebenwirkung unbekannt)
Herzfunktion*
keine Nebenwirkungen (0 = keine
Nebenwirkungen)
leichte Nebenwirkungen (1 = milde
Nebenwirkungen)
mäßige Nebenwirkungen (2 = moderate
Nebenwirkungen)
starke Nebenwirkungen (3 = schwere
Nebenwirkungen)
lebensbedrohliche Nebenwirkungen (4 =
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Lebensbedrohliche Nebenwirkungen)
letale Nebenwirkung (S = Tod)
Nebenwirkungen unbekannt (X =
Nebenwirkung unbekannt)
Perikarditis*
keine Nebenwirkungen (0 = keine
Nebenwirkungen)
leichte Nebenwirkungen (1 = milde
Nebenwirkungen)
mäßige Nebenwirkungen (2 = moderate
Nebenwirkungen)
starke Nebenwirkungen (3 = schwere
Nebenwirkungen)
lebensbedrohliche Nebenwirkungen (4 =
Lebensbedrohliche Nebenwirkungen)
letale Nebenwirkung (S = Tod)
Nebenwirkungen unbekannt (X =
Nebenwirkung unbekannt)
Fieber*
keine Nebenwirkungen (0 = keine
Nebenwirkungen)
leichte Nebenwirkungen (1 = milde
Nebenwirkungen)
mäßige Nebenwirkungen (2 = moderate
Nebenwirkungen)
starke Nebenwirkungen (3 = schwere
Nebenwirkungen)
lebensbedrohliche Nebenwirkungen (4 =
Lebensbedrohliche Nebenwirkungen)
letale Nebenwirkung (S = Tod)
Nebenwirkungen unbekannt (X =
Nebenwirkung unbekannt)
Allergie*
keine Nebenwirkungen (0 = keine
Nebenwirkungen)
leichte Nebenwirkungen (1 = milde
Nebenwirkungen)
mäßige Nebenwirkungen (2 = moderate
Nebenwirkungen)
starke Nebenwirkungen (3 = schwere
Nebenwirkungen)
lebensbedrohliche Nebenwirkungen (4 =
Lebensbedrohliche Nebenwirkungen)
letale Nebenwirkung (S = Tod)
Nebenwirkungen unbekannt (X =
Nebenwirkung unbekannt)
Schmerzen*
keine Nebenwirkungen (0 = keine
Nebenwirkungen)
leichte Nebenwirkungen (1 = milde
Nebenwirkungen)
mäßige Nebenwirkungen (2 = moderate
Nebenwirkungen)
starke Nebenwirkungen (3 = schwere
Nebenwirkungen)
lebensbedrohliche Nebenwirkungen (4 =
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Lebensbedrohliche Nebenwirkungen)
letale Nebenwirkung (S = Tod)
Nebenwirkungen unbekannt (X =
Nebenwirkung unbekannt)
Haut*
keine Nebenwirkungen (0 = keine
Nebenwirkungen)
leichte Nebenwirkungen (1 = milde
Nebenwirkungen)
mäßige Nebenwirkungen (2 = moderate
Nebenwirkungen)
starke Nebenwirkungen (3 = schwere
Nebenwirkungen)
lebensbedrohliche Nebenwirkungen (4 =
Lebensbedrohliche Nebenwirkungen)
letale Nebenwirkung (S = Tod)
Nebenwirkungen unbekannt (X =
Nebenwirkung unbekannt)
Zystitis*
keine Nebenwirkungen (0 = keine
Nebenwirkungen)
leichte Nebenwirkungen (1 = milde
Nebenwirkungen)
mäßige Nebenwirkungen (2 = moderate
Nebenwirkungen)
starke Nebenwirkungen (3 = schwere
Nebenwirkungen)
lebensbedrohliche Nebenwirkungen (4 =
Lebensbedrohliche Nebenwirkungen)
letale Nebenwirkung (S = Tod)
Nebenwirkungen unbekannt (X =
Nebenwirkung unbekannt)
Hämaturie*
keine Nebenwirkungen (0 = keine
Nebenwirkungen)
leichte Nebenwirkungen (1 = milde
Nebenwirkungen)
mäßige Nebenwirkungen (2 = moderate
Nebenwirkungen)
starke Nebenwirkungen (3 = schwere
Nebenwirkungen)
lebensbedrohliche Nebenwirkungen (4 =
Lebensbedrohliche Nebenwirkungen)
letale Nebenwirkung (S = Tod)
Nebenwirkungen unbekannt (X =
Nebenwirkung unbekannt)
11 / 11
HIS systemic therapy - form prostate cancer
HIS radiotherapy form prostate cancer
HIS radiotherapy form prostate cancer
All rights reserved. Please visit https://medical-data-
models.org/forms/3919
HIS
Admininstrative Daten
Patienten-Nachname*
Patienten-Vorname*
Patienten-Titel*
früherer Name*
Patienten-Geburtsdatum*
Alter des Patienten*
Nationalität/Staatsangehörigkeit*
Straße*
Postleitzahl Patient*
Wohnort*
Fallnummer*
Tumordiagnose
Tumordiagnose*
Datum der Diagnose*
Bestrahlung
Einhaltung der Leitlinen*
Ja
Nein
Grund für Einhaltung Leitlinien*
Tumortherapie allgemein
Intention*
Adjuvant (adjuvant)
Kurativ (kurativ)
1 / 4
Neoadjuvant (neoadjuvant)
Palliativ (palliativ)
Bestrahlung
Zielorgane*
Sonstiges (Other)
Prostata (Prostata)
nicht_sinnvoll_für_Untersuchung
(Prostata + LK kleines Becken)
nicht_sinnvoll_für_Untersuchung
(Prostata + pelvine paraaortale LK im
Bauchraum)
nicht_sinnvoll_für_Untersuchung
(Prostataloge)
nicht_sinnvoll_für_Untersuchung
(Prostataloge + LK kleines Becken)
nicht_sinnvoll_für_Untersuchung
(Prostataloge + pelvine paraaortale LK
im Bauchraum)
nicht_sinnvoll_für_Untersuchung
(sonstiges)
Strahlentherapie - Technik*
Brachytherapy (Brachytherapie)
HDR temporäre Brachytherapie (HDR
temporäre Brachytherapie)
PDR temporäre Brachytherapie (PDR
temporäre Brachytherapie)
Tele-Radiotherapie (percutane
Strahlentherapie)
Strahlenart*
Iridium-192 (IR-Iridium-192)
Jod-125 (J1-Jod-125)
Palladium Pd-103  (Palladium Pd-103 )
Beginn Strahlentherapie*
Ende Strahlentherapie*
Gesamtdosis*
Therapiebeurteilung
Beendigung der Strahlentherapie*
Abbruch wegen Nebenwirkungen
(Abbruch wegen Nebenwirkungen)
Verweigerung der Therapie (Patient
verweigert die Therapie)
reguläres Ende der Therapie (reguläres
Ende)
ECOG Leistungszustand*
0 (0)
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1 (1)
2 (2)
3 (3)
4 (4)
Nebenwirkungen nach CTC (Common
Toxicity Criteria)
Nebenwirkungen*
Ja
Nein
Urogenital-System*
keine Nebenwirkungen (0 = keine
Nebenwirkungen)
leichte Nebenwirkungen (1 =
geringe/leichte Nebenwirkungen)
mäßige Nebenwirkungen (2 = mäßige /
deutliche Nebenwirkungen)
starke Nebenwirkungen (3 = starke /
ausgeprägte Nebenwirkungen)
lebensbedrohliche Nebenwirkungen (4 =
lebensbedrohliche Nebenwirkungen)
Nebenwirkungen unbekannt (X = Grad
der Nebenwirkungen unbekannt)
Gastrointestinaltrakt*
keine Nebenwirkungen (0 = keine
Nebenwirkungen)
leichte Nebenwirkungen (1 =
geringe/leichte Nebenwirkungen)
mäßige Nebenwirkungen (2 = mäßige /
deutliche Nebenwirkungen)
starke Nebenwirkungen (3 = starke /
ausgeprägte Nebenwirkungen)
lebensbedrohliche Nebenwirkungen (4 =
lebensbedrohliche Nebenwirkungen)
Nebenwirkungen unbekannt (X = Grad
der Nebenwirkungen unbekannt)
Fieber*
keine Nebenwirkungen (0 = keine)
leichte Nebenwirkungen (1 =
gering/leicht)
mäßige Nebenwirkungen (2 =
mäßig/deutlich)
starke Nebenwirkungen (3 =
stark/ausgeprägt)
lebensbedrohliche Nebenwirkungen (4 =
lebensbedrohlich)
only in connection with Infection (only in
connection with Infection)
Nebenwirkungen unbekannt (X =
Nebenwirkungen unbekannt)
Infektion*
keine Nebenwirkungen (0 = keine)
leichte Nebenwirkungen (1 =
gering/leicht)
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mäßige Nebenwirkungen (2 =
mäßig/deutlich)
starke Nebenwirkungen (3 =
stark/ausgeprägt)
lebensbedrohliche Nebenwirkungen (4 =
lebensbedrohlich)
only in connection with fever (only in
connection with fever)
Nebenwirkungen unbekannt (X =
Nebenwirkungen unbekannt)
Laborwerte*
keine Nebenwirkungen (0 = keine
Nebenwirkungen)
leichte Nebenwirkungen (1 =
geringe/leichte Nebenwirkungen)
mäßige Nebenwirkungen (2 = mäßige /
deutliche Nebenwirkungen)
starke Nebenwirkungen (3 = starke /
ausgeprägte Nebenwirkungen)
lebensbedrohliche Nebenwirkungen (4 =
lebensbedrohliche Nebenwirkungen)
Nebenwirkungen unbekannt (X = Grad
der Nebenwirkungen unbekannt)
andere Nebenwirkung*
keine Nebenwirkungen (0 = keine
Nebenwirkungen)
leichte Nebenwirkungen (1 =
geringe/leichte Nebenwirkungen)
mäßige Nebenwirkungen (2 = mäßige /
deutliche Nebenwirkungen)
starke Nebenwirkungen (3 = starke /
ausgeprägte Nebenwirkungen)
lebensbedrohliche Nebenwirkungen (4 =
lebensbedrohliche Nebenwirkungen)
Nebenwirkungen unbekannt (X = Grad
der Nebenwirkungen unbekannt)
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register
MeldungDaten
Idenität
Patienten-Nachname*
Patienten-Vorname*
Patienten-Titel*
Geburtsname*
anderer früherer Name, wenn verschieden von
Familiennahme und Geburtsname*
Patienten-Geschlecht*
männlich (M)
Unbekannt (U)
weiblich (W)
Patienten-Geburtsdatum*
Straße*
Hausnummer*
Postleitzahl Patient*
Wohnort*
Nationalität/Staatsangehörigkeit*
Informationsstatus nach §4, Abs. 4*
Ja (J)
Nein (N)
Unbekannt (U)
Widerspruchstatus nach $4, Abs. 4*
Ja (J)
Nein (N)
Unbekannt (U)
Referenz*
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Patienten-Tod
Sterbedatum*
Gemeindekennziffer des Sterbeortes*
Todesursache nach ICD-10*
Standesamt*
Sterbebuchnummer*
Diagnose
Datum der Diagnose*
Handelt es sich bei Diagnosedatum um ein
exaktes Datum*
Ja
Nein
Körperseite*
beidseits (B)
links (L)
multilokulär (M)
rechts (R)
systemisch (S)
nicht zutreffend (T)
unbekannt (U)
Histopathologisches Grading*
G1 gut differenziert (1)
G2 mäßig differenziert (2)
G3 schlecht differenziert (3)
G4 undifferenziert (4)
High Grade (G3-G4) (H)
Low Grade (G1-G2) (L)
Intermediate Grade (G2-G3) (M)
unbekannt (U)
nicht bestimmbar (X)
Histopathologisches Grading*
G1 gut differenziert (1)
G2 mäßig differenziert (2)
G3 schlecht differenziert (3)
G4 undifferenziert (4)
High Grade (G3-G4) (H)
Low Grade (G1-G2) (L)
Intermediate Grade (G2-G3) (M)
unbekannt (U)
nicht bestimmbar (X)
Zelltyp*
B-Zell-Lymphom (B)
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Natural-Killer-Zell-Lymphom (K)
Null-Zell-Lymphom (N)
Borderline (O)
T-Zell-Lymphom (T)
Grund des Arztbesuches *
Selbstuntersuchung (E)
(gesetzl.) Früherkennung (F)
Hautkrebsfrüherkennung (H)
Nachsorge (N)
sonstiges (S)
Tumorsymptomatik (T)
unbekannt (U)
(nicht gesetzl. Vorsorge) (V)
Wurde schon früher eine bösartige Neubildung
diagnostiziert*
Ja (J)
Nein (N)
unbekannt (U)
Sicherung der Tumordiagnose*
autoptisch (A)
histologisch (H)
klinisch (K)
sonstiges (S)
unbekannt (U)
zytologisch (Z)
TNM-Klassifikation
Organgruppe der TNM-Klassfikation*
Liegt zur bösartigen Neubildung eine TNM-
Klassifikation vor*
Ja
Nein
Tumorstaging-Symbole*
Tumorstaging Symbol y (YSymbol)
Handelt es sich es bei der T-Kategorie um ein
klinisches Stadium (c) *
Ja
Nein
Handelt es sich es bei der T-Kategorie um ein
pathologisches Stadium (p) *
Ja
Nein
Enthält die T-Kategorie ein m-Symbol*
Ja
Nein
T-Kategorie*
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Liegt zur bösartigen Erkrankung eine T-Kategorie
vor*
Ja
Nein
Handelt es sich es bei der N-Kategorie um ein
klinisches Stadium (c) *
Ja
Nein
Handelt es sich es bei der N-Kategorie um ein
pathologisches Stadium (p) *
Ja
Nein
Enthält die T-Kategorie ein sn-Symbol*
Ja
Nein
N-Kategorie*
Liegt zur bösartigen Erkrankung eine N-
Kategorie vor*
Ja
Nein
Handelt es sich es bei der M-Kategorie um ein
klinisches Stadium (c) *
Ja
Nein
Handelt es sich es bei der M-Kategorie um ein
pathologisches Stadium (p) *
Ja
Nein
M-Kategorie*
Liegt zur bösartigen Erkrankung eine M-
Kategorie vor*
Ja
Nein
Anzahl der befallenen Lymphknoten*
Anzahl der untersuchten Lymphknoten*
Andere Tumorklassifikationen
Identifikationsnummer der Klassifikation*
Stadium der Klassifikation*
4 / 6
register epidemiogical cancer registry North-Rhine-Westphalia cancer
Tumormarker und Hormonrezeptoren
Identifikationsnummer des Tumormarkers bzw.
des Hormonrezeptors*
Gemessener Wert*
Angaben zur Primärtherapie
Mit welchem Ziel wurde die Therapie begonnen*
kurativ (K)
palliativ (P)
unbekannt (U)
Wurde eine Operation durchgeführt*
Ja (J)
Nein (N)
unbekannt (U)
Wurde eine Chemotherapie durchgeführt*
Ja (J)
Nein (N)
Unbekannt (U)
Wurde eine Strahlentherapie durchgeführt*
Ja (J)
Nein (N)
Unbekannt (U)
Wurde eine andere Therapie durchgeführt*
Ja (J)
Nein (N)
Unbekannt (U)
Verschlüsselungen der Tumordiagnosen
Verschlüssselung nach ICD*
Auflage des verwendeten ICD-Codes*
Verschlüsselung nach ICD-O-3*
Verschlüsselung nach ICD-O-3*
Daten von Pathologischen Instituten
Datum des histopathologischen Gutachtens*
Text des histopathologischenGutachtens*
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Einsender des Untersuchungsgutes im Klartext*
Identifikationsnummer der Meldequelle*
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Patientenaufkleber groß
Aufnahmedatum*
Patientenidentifikationsnummer*
Geschlecht Patient*
Patienten-Nachname*
Patienten-Vorname*
Patienten-Geburtsdatum*
Aufnahmezeit*
Einweisender Arzt*
Tumorkonferenz
Tumorboard Typ*
adjuvante Konferenz (interdisziplinäre
adjuvante Therapieempfehlung)
palliative Konferenz (interdisziplinäre
palliative Therapieempfehlung)
Datum der Konferenz*
Ort der Konferenz*
Verantwortliche Person für die Anmeldung*
Datum der Anmeldung*
Teilnehmer*
Nuklearmedizin (Nuklearmedizin)
Pathologie (Pathologie)
Radiologie (Radiologie)
Gynäkologie (Senologie)
Strahlentherapie (Strahlentherapie)
Patientendaten
Status Patient*
Primärfall (Primärpatient)
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Diagnose*
Karnofsky Index*
klinische Studie*
Krankheitsverlauf
Krankheitsverlauf*
Pathologie Befund
Kommentar zu den Pathologie Proben*
Frage
Frage*
Subformular
Tumorboardentscheidungen
Operation*
Ja
Nein
Intention*
Adjuvant (adjuvant)
Kurativ (kurativ)
Neoadjuvant (neoadjuvant)
Palliativ (palliativ)
sonstiges (sonstiges)
Chemotherapie*
Ja
Nein
Intention*
Adjuvant (adjuvant)
Kurativ (kurativ)
Neoadjuvant (neoadjuvant)
Palliativ (palliativ)
sonstiges (sonstiges)
Bestrahlung*
Ja
Nein
Intention*
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Adjuvant (adjuvant)
Kurativ (kurativ)
Neoadjuvant (neoadjuvant)
Palliativ (palliativ)
sonstiges (sonstiges)
Hormon- / endokrine Therapie*
Ja
Nein
Intention*
Adjuvant (adjuvant)
Kurativ (kurativ)
Neoadjuvant (neoadjuvant)
Palliativ (palliativ)
sonstiges (sonstiges)
Immuntherapie*
Ja
Nein
Intention*
Adjuvant (adjuvant)
Kurativ (kurativ)
Neoadjuvant (neoadjuvant)
Palliativ (palliativ)
sonstiges (sonstiges)
Studienprotokoll*
Ja
Nein
Studienprotokoll - Freitext*
Verlaufskontrolle*
Ja
Nein
Verlaufskontrolle - Freitext*
Analgetika*
Ja
Nein
Analgetika - Freitext*
andere Empfehlung*
Ja
Nein
andere Empfehlung - Freitext*
Re-Biopsie*
Ja
Nein
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Bisphosphonate*
Ja
Nein
Bisphosphonate - Freitext*
Radioiodtherapie*
Ja
Nein
Wiedervorstellung nach Diagnostik*
Ja
Nein
Active Surveillance*
Ja
Nein
Diagnostik notwendig*
Therapie Freitext*
Datum der Arzt-Unterschrift*
Arzt-Unterschrift*
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Patienteninformation
Patienten-Nachname*
Patienten-Vorname*
Patienten-Geburtsdatum*
Patientenidentifikationsnummer*
Zuweisender Arzt *
Anamnese
Alter Patientin*
Gewicht*
Größe*
Alter Menarche*
Menopausenstatus*
Nein (nein)
Postmenopause (Postmenopause)
Prämenopause (Prämenopause)
Senium (Senium)
Alter Menopause*
Hormonpräparat*
Ja (ja)
Nein (nein)
Hormonersatztherapie*
Ja
Nein
nicht_kodiert*
Ja
Nein
Dauer der Therapie*
Parität*
Ja (ja)
Nein (nein)
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Schwangerschaften*
Alter bei Erstparität*
Laktation*
Ja (ja)
Nein (nein)
Stillzeit (Monate)*
Mammakarzinom in der Familie*
Ja (ja, andere)
ja, Großmutter (mütterlicherseits) (ja,
Großmutter (mütterlicherseits))
ja, Mutter (ja, Mutter)
ja, Schwester (ja, Schwester)
Nein (nein)
Alter bei Erkrankungsbeginn*
Frühere andere maligne Tumore*
ja, in anderen Organen (ja, in anderen
Organen)
ja, Mamma, gegenseitig (ja, Mamma,
gegenseitig)
ja, Mamma, gleichseitig (ja, Mamma,
gleichseitig)
Nein (keine)
Pathologisches Institut*
Histologie-Identifikationsnummer*
Synchrone andere maligne Tumoren*
ja, in anderen Organen (ja, in anderen
Organen)
ja, Mamma der Gegenseite (ja, Mamma
der Gegenseite)
ja, Mamma Gegenseite und andere
Organe (ja, Mamma Gegenseite und
andere Organe)
Nein (keine)
Pathologisches Institut*
Histologie-Identifikationsnummer*
Lokalbefund des Tumors
Seite finding*
links (links)
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rechts (rechts)
Anzahl der Tumoren*
multiple (multiple)
solitär (solitär)
Anzahl *
Tastbefund*
Ja (ja)
Nein (kein)
klinisch unauffällig (klinisch nicht
suspekt)
klinisch suspekt (klinisch suspekt)
Topografie des Tastbefundes*
äußerer oberer Quadrant (äußerer
oberer Quadrant)
äußerer unterer Quadrant (äußerer
unterer Quadrant)
axillärer Anteil (axillärer Anteil)
innerer oberer Quadrant (innerer oberer
Quadrant)
innerer unterer Quadrant (innerer unterer
Quadrant)
Mamille (Mamille)
zentraler Anteil (zentraler Anteil)
Körbchengröße*
nicht_kodiert (A)
nicht_kodiert (B)
nicht_kodiert (C)
nicht_kodiert (D)
Ausdehnung auf Brustwand oder Haut*
Brustwand (Brustwand)
Brustwand, Hautödem, Ulzeration,
Hautsatelliten (Brustwand, Hautödem,
Ulzeration, Hautsatelliten)
entzündlich (inflammatorisches)
Karzinom (entzündlich
(inflammatorisches) Karzinom)
Hautödem / Ulzeration / Hautsatelliten
(Hautödem / Ulzeration / Hautsatelliten)
Nein (keine (im Sinne der TNM))
Haut*
Brustödem (Hautödem)
Hautmetastasen (Hautsatelliten)
Ulzeration der Brust (Ulzeration)
entzündlich (inflammatorisches) Karzinom*
Ja
Nein
Axilläre Lymphknotenmetastasen*
fixiert (klinisch ja, fixiiert)
verschiebbar (klinisch ja, verschieblich)
keine (klinisch keine)
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Fernmetastasen*
Ja (ja)
Nein (keine)
präoperativ keine Angabe (präoperativ
keine Angabe)
Lokalisation Fernmetastasen*
Untersuchung Fernmetastasen*
Histologie-Identifikationsnummer*
Bildgebende Diagnostik
Mammografie
Mammografie*
Ja
Nein
Herd*
Ja (ja)
Nein (nein)
nicht_kodiert (nicht beurteilbar,
(Überlagerung))
nicht_kodiert (seitendifferente
Verdichtung bzw. Gefügestörung)
Größe Läsion*
Begrenzung*
glatt (glatt)
nicht_kodiert (lobuliert)
nicht_kodiert (nicht beurteilbar,
(Überlagerung))
nicht_kodiert (sternförmige
Gefügestörung)
nicht_kodiert (strahlige Ausläufer)
unregelmäßig (unregelmäßig)
Mikrokalk*
Ja (ja)
Nein (nein)
Durchmesser Mikrokalk*
Form des Mikrokalk*
komplex (polymorph)
rund (rundlich)
linear (strichförmig)
oval (überwiegend rundlich)
Anordnung*
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diffus (diffus)
gruppiert (gruppiert)
segmental (segmental)
nicht_kodiert (straßenförmig)
Größe der Verkalkungen*
fein (fein)
fein und grob (fein und grob)
grob (grob)
Verlauf*
keine Voruntersuchungen (keine
Voruntersuchungen)
neu (neu aufgetreten)
progredient (progredient)
unverändert (unverändert zu
Voruntersuchung)
BI-RADS Mammographie*
nicht_kodiert (BI-RADS 0 = unauffällig)
nicht_kodiert (BI-RADS 1 = unauffällig)
nicht_kodiert (BI-RADS 2 = benigne)
nicht_kodiert (BI-RADS 3 =
wahrscheinlich benigne)
nicht_kodiert (BI-RADS 4  = verdächtig)
nicht_kodiert (BI-RADS 4A)
nicht_kodiert (BI-RADS 4B)
nicht_kodiert (BI-RADS 4C)
nicht_kodiert (BI-RADS 5 = maligne)
Sonografie
Sonografie*
Ja
Nein
Läsion*
nicht_kodiert (Areal mit
Schallauslöschung)
fraglich (fraglich)
Ja (ja)
Nein (nein)
Größe Läsion*
Begrenzung*
scharf (scharf begrenzt)
unscharf (unscharf begrenzt)
BI-RADS Sonographie*
nicht_kodiert (BI-RADS 0)
nicht_kodiert (BI-RADS I = unauffällig)
nicht_kodiert (BI-RADS II = benigne)
nicht_kodiert (BI-RADS III =
wahrscheinlich benigne)
nicht_kodiert (BI-RADS IV = verdächtig)
nicht_kodiert (BI-RADS V = maligne)
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MRT
Kernspintomographie Brust*
Ja
Nein
BI-RADS MRT*
nicht_kodiert (BI-RADS 0)
nicht_kodiert (BI-RADS I = unauffällig)
nicht_kodiert (BI-RADS II = benigne)
nicht_kodiert (BI-RADS III =
wahrscheinlich benigne)
nicht_kodiert (BI-RADS IV = verdächtig)
nicht_kodiert (BI-RADS V = maligne)
BI-RADS Klassifikation*
nicht_kodiert (AK I - retromamillär ohne
Befund)
nicht_kodiert (AK II - benigne)
nicht_kodiert (AK III - wahrscheinlich
benigne)
nicht_kodiert (AK IV - verdächtig)
nicht_kodiert (AK V - maligne
(invasiv/DCIS))
radiologische Verdachtsdiagnose*
Zeichnung*
Seite*
links (links)
rechts (rechts)
Topografie *
äußerer oberer Quadrant (äußerer
oberer Quadrant)
äußerer unterer Quadrant (äußerer
unterer Quadrant)
axillärer Anteil (axillärer Anteil)
innerer oberer Quadrant (innerer oberer
Quadrant)
innerer unterer Quadrant (innerer unterer
Quadrant)
Mamille (Mamille)
zentraler Drüsenkorper (zentraler
Drüsenkorper)
Biopsie
keine Biopsie*
Ja
Nein
Biopsie bei Mammographie*
Ja
Nein
Ultraschallgestütze Biopsie*
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Ja
Nein
Biopsie*
Ja
Nein
Mammotome*
Ja
Nein
Biospie Areal*
Biopsie Läsion (abklärungsbedüftige
Läsion)
mamillenwärts orientierte Biopsie
(mamillenwärts orientierte Biopsie)
behind nipple (Retromamillärregion)
Anzahl der Stanzen*
Distanz zwischen Biopsien*
Kalk in Mammotome*
Mikrokalk in Biopsie*
Ja (ja)
Nein (nein)
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HIS
Patientenaufkleber
Aufnahmedatum*
Patientenidentifikationsnummer*
Geschlecht Patient*
Patienten-Nachname*
Patienten-Vorname*
Patienten-Geburtsdatum*
Aufnahmezeit*
Einweisender Arzt*
OP Planung
Körperseite*
beidseits (beidseits)
rechts (links)
links (rechts)
Histologie*
B3 (B3)
benigne (benigne)
DCIS (DCIS)
invasives lobuläre Karzinom (IL)
invasives Karzinom (invasiv)
nicht anders spezifiziert (NOS)
Histologisches Grading*
G1 (1)
G2 (2)
G3 (3)
DCIS Kerngrad*
low (1)
intermediate (2)
high (3)
Durchmesser Herd*
Kernspintomographie*
Ja
Nein
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Befund MR*
zusätzlicher Herdbefund*
Ja
Nein
zusätzlicher Herdbefund - Freitext*
nicht_kodiert*
Durchmesser Mikrokalk*
Körbchengröße*
nicht_kodiert (2D)
nicht_kodiert (A)
nicht_kodiert (B)
nicht_kodiert (C)
nicht_kodiert (D)
Operation
Mastektomie*
Ja
Nein
Brusterhaltende Therapie*
Ja
Nein
rekonstruktive brusterhaltende Therapie*
Ja
Nein
Excisionsbiopsie*
Ja
Nein
Nachresektion*
Ja
Nein
sekundäre  Mastektomie*
Ja
Nein
Segmentgröße*
Prä-Biopsie Drahtmarkierung*
sonographische Markierung (sonograf.
Markierung)
mammograpische Markierung (stereotakt
Markierung)
Anzahl Markierungen*
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Kommentar Markierungen*
Intraoperatives Präparatröntgen*
Ja
Nein
intraoperative makroskopische Begutachtung*
Ja
Nein
Röntgen der pathologischen Präparate*
Ja
Nein
Sentinel Lymphknoten Biopsie*
Ja
Nein
Axilladissektion*
Ja
Nein
Intraoperative Strahlentherapie*
Ja
Nein
klinische Studie*
Freitext*
Verantwortlicher Arzt*
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HIS
Admininstrative Daten
Patienten-Nachname*
Patienten-Vorname*
Patienten-Titel*
früherer Name*
Patienten-Geburtsdatum*
Alter des Patienten*
Nationalität/Staatsangehörigkeit*
Straße*
Postleitzahl Patient*
Wohnort*
Mini-Anamnese für Tumorkonferenz
Patienten-Geburtsdatum*
Erstdiagnose*
Ja (Ja)
Nein (Nein)
Unbekannt (Unbekannt)
Datum der Diagnose*
Therapie Intention*
Adjuvant (adjuvant)
Neoadjuvant (neoadjuvant)
Stadium*
lokal-rezidiviert ((Lokal-)Rezidiv)
metastasiert (metastasiert)
anderes Stadium (sonstiges)
anderes Stadium*
betroffenes Organ*
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Corpus (Corpus)
Mamma (Mamma)
Ovar (Ovar)
anderes Organ (sonstiges)
Throphoblasttumore
(Throphoblasttumore)
Vulva (Vulva)
Zervix (Zervix)
anderes Organ - Freitext*
ECOG Leistungszustand*
FIGO Stadium*
klinisches TNM-Staging
klinisches TNM-Staging*
Ja
Nein
T-Stadium*
N - Stadium der regionalen Lymphknoten*
M- Stadium*
Pathologischer TNM
Pathologischer TNM*
Ja
Nein
pT-Stadium*
pathologisch ermitteltes N-Stadium*
pathologisch ermitteltes M-Stadium*
Anamnese
Anamnese - Freitext*
Menopausenstatus*
Perimenopause (perimenopausal)
Postmenopause (postmenopausal)
Prämenopause (prämenopausal)
Komorbidität*
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Ja (Ja)
Nein (Nein)
unbekannt (unbekannt)
Herzfunktion*
auffällig (auffällig)
unauffällig (unauffällig)
unbekannt (unbekannt)
Herzfunktion - Freitext*
Neuropathien*
auffällig (auffällig)
unauffällig (unauffällig)
unbekannt (unbekannt)
Neuropathien - Freitext*
anderes Malignom*
auffällig (auffällig)
unauffällig (unauffällig)
unbekannt (unbekannt)
anderes Malignom - Freitext*
andere Komorbidität*
auffällig (auffällig)
unauffällig (unauffällig)
unbekannt (unbekannt)
andere Komorbidität - Freitext*
Größe*
Körpergewicht*
Körbchengröße*
Familienanamnese*
negativ (negativ)
positiv (positiv)
unbekannt (unbekannt)
Familienanamnese - Freitext*
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HIS
Patientenaufkleber groß
Aufnahmedatum*
Patientenidentifikationsnummer*
Geschlecht Patient*
Patienten-Nachname*
Patienten-Vorname*
Patienten-Geburtsdatum*
Aufnahmezeit*
Einweisender Arzt*
Gespräch nach Tumorkonferenz
Datum*
verantwortliche Person*
Einverstädnis für Entscheidung Tumorkonferenz
vorhanden*
Ja
Nein
Änderung der Entscheidung Tumorkonferenz*
geplante Prozeduren*
Ja (ja)
externe Therapie (nein, da weitere
Therapie extern)
nicht erforderlich (nicht erforderlich)
Patient informiert Systemtherapie*
Ja
Nein
Patient informiert endokrine Therapie*
Ja
Nein
Patient informiert Chemotherapie*
Ja
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Nein
Patient informiert Immuntherapie*
Ja
Nein
Rezept endokrine Therapie*
Ja
Nein
Information endokrine Therapie*
Ja
Nein
Portimplantation*
Ja
Nein
Termin Tagesklnik*
Ja
Nein
Termin Strahlentherapie*
Ja
Nein
Information DMP*
Ja
Nein
sonstiges*
Datum der Arzt-Unterschrift*
Unterschrift*
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HIS
Patientenaufkleber groß
Aufnahmedatum*
Patientenidentifikationsnummer*
Geschlecht Patient*
Patienten-Nachname*
Patienten-Vorname*
Patienten-Geburtsdatum*
Aufnahmezeit*
Einweisender Arzt*
Tumorkonferenz
Datum der Konferenz*
Ort der Konferenz*
Verantwortliche Person für die Anmeldung*
Datum der Anmeldung*
Teilnehmer*
Nuklearmedizin (Nuklearmedizin)
Pathologie (Pathologie)
Radiologie (Radiologie)
Gynäkologie (Senologie)
Strahlentherapie (Strahlentherapie)
Patientendaten
Status Patient*
Primärfall (Primärpatient)
Diagnose*
Karnofsky Index*
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klinische Studie*
Krankheitsverlauf
Krankheitsverlauf*
Pathologie Befund
Kommentar zu den Pathologie Proben*
Frage
Frage*
Subformular
MDT (nur Bildgebung)
prätherapeutisch*
Befund Mammographie*
Ja
Nein
Befund MRT*
Ja
Nein
Befund Bildgebung*
Ja
Nein
Freitext*
Entscheidung Konferenz
Entscheidung Konferenz*
Ja
Nein
zusätzliche Bildgebung*
Ja
Nein
zusätzliche Bildgebung*
Kompression der Brust (Kompression)
radiologische Vergrößerung
(Vergrößerung)
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Mammographie*
Ja
Nein
MRT*
Ja
Nein
Sonographie*
Ja
Nein
Sonographie*
nicht_sinnvoll_für_Untersuchung (durch
Gyn)
nicht_sinnvoll_für_Untersuchung (durch
RAD)
Biopsie*
Ja
Nein
geplante Kontrolle*
Ja
Nein
Monate Check-Up*
Check-Up Mammographie*
Ja
Nein
Check-Up Sonographie*
Ja
Nein
Check-Up MRT*
Ja
Nein
Audit*
Ja
Nein
Tumorboardentscheidungen
Operation*
Ja
Nein
Intention*
Adjuvant (adjuvant)
Kurativ (kurativ)
Neoadjuvant (neoadjuvant)
Palliativ (palliativ)
sonstiges (sonstiges)
Chemotherapie*
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Ja
Nein
Intention*
Adjuvant (adjuvant)
Kurativ (kurativ)
Neoadjuvant (neoadjuvant)
Palliativ (palliativ)
sonstiges (sonstiges)
Bestrahlung*
Ja
Nein
Intention*
Adjuvant (adjuvant)
Kurativ (kurativ)
Neoadjuvant (neoadjuvant)
Palliativ (palliativ)
sonstiges (sonstiges)
Hormon- / endokrine Therapie*
Ja
Nein
Intention*
Adjuvant (adjuvant)
Kurativ (kurativ)
Neoadjuvant (neoadjuvant)
Palliativ (palliativ)
sonstiges (sonstiges)
Immuntherapie*
Ja
Nein
Intention*
Adjuvant (adjuvant)
Kurativ (kurativ)
Neoadjuvant (neoadjuvant)
Palliativ (palliativ)
sonstiges (sonstiges)
Studienprotokoll*
Ja
Nein
Studienprotokoll - Freitext*
Verlaufskontrolle*
Ja
Nein
Verlaufskontrolle - Freitext*
Analgetika*
Ja
Nein
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Analgetika - Freitext*
andere Empfehlung*
Ja
Nein
andere Empfehlung - Freitext*
Re-Biopsie*
Ja
Nein
Bisphosphonate*
Ja
Nein
Bisphosphonate - Freitext*
Radioiodtherapie*
Ja
Nein
Wiedervorstellung nach Diagnostik*
Ja
Nein
Active Surveillance*
Ja
Nein
Diagnostik notwendig*
Therapie Freitext*
Datum der Arzt-Unterschrift*
Arzt-Unterschrift*
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HIS
Patientenaufkleber groß
Patientenidentifikationsnummer*
Geschlecht Patient*
Patienten-Nachname*
Patienten-Vorname*
Patienten-Geburtsdatum*
Tumorverlaufsbogen
Patientenname*
Geburtstag*
verantwortliche Person*
Datum der Erhebung*
Frauenfacharzt *
Hausarzt*
Chemotherapiezyklus*
Studie*
Ja
Nein
Diagnose*
Verlauf der Erkrankung*
Verlauf der Therapie*
Stadium*
lokal-fortgeschritten (lokal-
fortgeschritten)
lokal-rezidiviert (lokal-rezidiviert)
metastasiert (metastasiert)
Primärtumor (Primärtumor)
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Bemerkung metastasiert*
Tumorbiologie
Hormonrezeptoren
Östrogen-Rezeptor*
negativ (negativ)
nicht bestätigt (nicht best.)
only_in_connection with PR
(only_in_connection with PR)
positiv (positiv)
Progesteron-Rezeptor*
negativ (negativ)
nicht bestätigt (nicht best.)
only_in_connection with ER
(only_in_connection with ER)
positiv (positiv)
Her-2/neu*
negative (neg)
nicht bestätigt (nicht best.)
positive (pos)
Diagnostik
Echokardiographie*
unauffällig (ja)
auffällig (nein)
nicht indiziert (nicht indiziert)
Bemerkung Sonographie*
Staging*
Ja (ja)
Nein (nein)
nicht indiziert (nicht indiziert)
Bemerkung staging*
unauffällig Laborwerte*
Ja
Nein
auffällige Laborwerte*
Ja
Nein
Laboruntersuchung nicht indiziert*
Ja
Nein
Bemerkung Labor*
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Urinstick Test*
unauffällig (ja)
auffällig (nein)
nicht indiziert (nicht indiziert)
Bemerkung Urinuntersuchung*
Anamnese
Karnofsky Index*
ECOG Leistungszustand*
Beschwerden*
Ja
Nein
Beschwerden*
Menstuationsbeschwerden*
Ja
Nein
Symptome*
Grad der Beschwerden*
mild (1)
moderat (2)
schwer (3)
sehr schwer (4)
Therapie
intravenös via Port*
Ja
Nein
intravenös via PVK*
Ja
Nein
Chemotherapie*
Ja
Nein
Chemotherapie*
Bisphosphonate*
Ja
Nein
Bisphosphonate*
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Hormon- / endokrine Therapie*
Ja
Nein
Hormon- / endokrine Therapie*
Medikamente*
Rezepte
Antiemetika*
Aprepitant  (Aprepitant (mitgegeben))
Dexamethason (Dexamethason)
Ondansetron (Ondansetron)
Mukositis management *
Ampho-Moronal-Suspension (Ampho-
Moronal-Susp)
therapeutische Gurgellösung (Mucositis-
Gurgellösung (mitgegeben))
andere Medikamente*
Antibiotikaprophylaxe
(Antibiotikaprophylaxe)
Neulasta (primäre GCSF-Prophylaxe
(Neulasta))
sonstige (Sonstige)
nächster Chemotherapiezyklus
Datum nächster Chemotherapie Zyklus*
Bildgebung*
sonstiges*
Unterschrift*
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registry
Meldestelle
Identifikationsnummer der Meldequelle*
Institution*
Name Arzt*
Arzt Adresse*
Arzt Postleitzahl*
Arzt Wohnort*
Meldedatum*
Idenität
Patienten-Titel*
Patienten-Nachname*
Patienten-Vorname*
Zusatz Patientenname*
früherer Name*
Geburtsname*
Patienten-Geschlecht*
männlich (M)
Unbekannt (U)
weiblich (W)
Patienten-Geburtsdatum*
Straße*
Hausnummer*
Zusatz Hausnummer*
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Postleitzahl Patient*
Wohnort*
Sterbedatum*
Einverständniserklärung Krebsregister*
Ja
Nein
Meldebegründung*
nicht_kodiert (Patientin / Patient hat einer
Kontaktaufnahme gemäß § 10(3)
widersprochen)
nicht_kodiert (Patientin / Patient wurde
über die pseudonymisierte Meldung an
das Krebsregister informiert)
Tumor Epidemiologie
Referenznummer*
Datum der Diagnose*
Verschlüssselung nach ICD*
Codebeschreibung ICD-10*
Verschlüsselung nach ICD-O-3*
Codebeschreibung ICD-O-3*
Verschlüsselung nach ICD-O-3*
Codebeschreibung ICD-O-3*
Tumorbiologie*
unsicher (1 = unsicher)
Ursprungsort (2 = in situ)
bösartige Neubildung (3 = bösartige
Neubildung)
Versionsnummer ICD*
Verschlüsselung nach ICD-O-3*
Version der Klassifikation*
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Histopathologisches Grading*
G1 gut differenziert (1 = gut differenziert)
G2 mäßig differenziert (2 = mäßig
differenziert)
G3 schlecht differenziert (3 = schlecht
differenziert)
G4 undifferenziert (4 =
undifferenziert/annapl.)
High Grade (G3-G4) (H = high grade
(hochmaligne))
Low Grade (G1-G2) (L = low grade
(niedrigmaligne))
Intermediate Grade (G2-G3) (M =
intermediate (mittelgradig maligne))
unbekannt (U = unbekannt)
X = Differenzierungsgrad kann nicht
bestimmt werden (X = nicht bestimmbar)
Histopathologisches Grading*
G1 gut differenziert (1 = gut differenziert)
G2 mäßig differenziert (2 = mäßig
differenziert)
G3 schlecht differenziert (3 = schlecht
differenziert)
G4 undifferenziert (4 =
undifferenziert/annapl.)
High Grade (G3-G4) (H = high grade
(hochmaligne))
Low Grade (G1-G2) (L = low grade
(niedrigmaligne))
Intermediate Grade (G2-G3) (M =
intermediate (mittelgradig maligne))
unbekannt (U = unbekannt)
X = Differenzierungsgrad kann nicht
bestimmt werden (X = nicht bestimmbar)
Zelltyp*
B-Zell-Lymphom (B = B-Zell-Typ)
Natural-Killer-Zell-Lymphom (K =
Natural-Killer-Zell-Typ)
Null-Zell-Lymphom (N = Null-Zell-Typ)
T-Zell-Lymphom (T = T-Zell-Typ)
unbekannt (U = unbekannt)
nicht bestimmbar (X = nicht bestimmbar)
Sicherung der Tumordiagnose*
klinische Diagnose (1 = klinisch ohne
spez. Diagnostik)
klinische Diagnose mit spezieller
Diagnostik (2 = klinische Diagnostik)
spezielle Tumormarker (4 = spez.
Tumormarker)
Zytologischer Befund (5 = Zytologie)
Nachweis Histologie Metastase (6 =
Histologie Metastase)
Nachweis Histologie Primärtumor (7 =
Histologie Primärtumor)
Sonstiges (8 = Sonstige)
unbekannt (9 = Unbekannt)
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Grund des Arztbesuches *
Anamnese (A = Anamnese)
Selbstuntersuchung (E =
Eigenuntersuchung
(Selbstuntersuchung))
(gesetzl.) Früherkennung (F = gesetzl.
Früherkennung)
Nachsorge (N = Nachsorge)
Tumorsymptome (T =
Tumorsymptomatik)
unbekannt (U = unbekannt)
(nicht gesetzl. Vorsorge) (V = nicht
gesetzl Vorsorge)
Körperseite*
beidseits (B = beidseits)
links (L = links)
rechts (R = rechts)
Not Applicable  (T = Trifft nicht zu)
unbekannt (U = unbekannt)
Stadium*
Fernmetastasen (F = Fernmetastasen)
Ursprungsort (I = in situ)
lokal (L = lokal)
regional (R = regional)
Systemerkrankung (S =
Systemerkrankung)
unbekannt (U = unbekannt)
TNM Klassifikation prätherapeutisch*
Ja
Nein
TNM Klassifikation nach der OP*
Ja
Nein
T Stadium*
N Stadium*
M Stadium*
TNM Auflage*
Operation*
Ja (J = Ja)
Nein (N = Nein)
Unbekannt (U = unbekannt)
Bestrahlung*
Ja (J = Ja)
Nein (N = Nein)
Unbekannt (U = unbekannt)
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Chemotherapie*
Ja (J = Ja)
Nein (N = Nein)
Unbekannt (U = unbekannt)
Hormon- / endokrine Therapie*
Ja (J = Ja)
Nein (N = Nein)
Unbekannt (U = unbekannt)
Immuntherapie*
Ja (J = Ja)
Nein (N = Nein)
Unbekannt (U = unbekannt)
Knochenmarkstransplantation*
Ja (J = Ja)
Nein (N = Nein)
Unbekannt (U = unbekannt)
andere Therapie*
Ja (J = Ja)
Nein (N = Nein)
Unbekannt (U = unbekannt)
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HIS
Patientenaufkleber groß
Aufnahmedatum*
Patientenidentifikationsnummer*
Geschlecht Patient*
Patienten-Nachname*
Patienten-Vorname*
Patienten-Geburtsdatum*
Aufnahmezeit*
Einweisender Arzt*
Postoperative MDT
Datum der Konferenz*
Histologischer Typ*
lobuläres Carcinoma in situ (CLIS ext.
Type)
DCIS (DCIS)
invasives lobuläre Karzinom (IL)
nicht anders spezifiziert (NOS)
andere histologischer Typ (sonstige)
sonstige Histologie*
Tumorgröße*
DCIS Größe*
Histologisches Grading*
G1 (G1)
G2 (G2)
G3 (G3)
Kernmalignitätsgrad*
high (high)
intermediate (intermediate)
low (low)
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Östrogen-Rezeptor*
negativ (negativ)
positiv (positiv)
% positiv*
Progesteron-Rezeptor*
negativ (negativ)
positiv (positiv)
% positiv*
Her-2/neu*
negativ (0)
negativ (1+)
Borderline (2+)
positiv (3+)
Fluoreszenz-in-situ-Hybridisierung*
negativ (neg.)
positiv (pos.)
Sicherheitsabstände
Sicherheitsabstand*
caudal (caudal)
cranial (cranial)
dorsal (dorsal)
lateral (lateral)
mamillär (mamillär)
medial (medial)
peripher (peripher)
ventral (ventral)
Sicherheitsabstand invasives Karzinom*
Sicherheitsabstand DCIS*
Revisionsoperation*
Ja
Nein
Sentinel Lymphknoten
Anzahl der untersuchten Sentinellymphknoten*
Befund Sentinel Lymphknoten*
histologisch (erst in endgültiger
Histologie festgestellt)
intraoperativ (intraoperativ festgestellt)
Makrometastasen (Makrometastasen)
Mikrometastasen (Micrometastasen)
kein Tumor (tumorfrei)
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Axilladissektion
Anzahl der untersuchten Lymphknoten*
Anzahl der befallenen Lymphknoten *
Tumorboardentscheidungen
Datum der Konferenz*
Operation*
Ja
Nein
sekundäre Lymphknotenentfernung*
Ja
Nein
Revisionsoperation*
Ja
Nein
sekundär totale Mastektomie*
Ja
Nein
pathologisches Stadium
pT Stadium*
pN Stadium*
Lymphgefäßinvasion*
Veneninvasion*
cM Stadium*
Histologisches Grading*
Unterschrift*
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HIS medical history - prostate prostate
cancer
HIS medical history - prostate prostate cancer
All rights reserved. Please visit https://medical-data-
models.org/forms/3937
HIS
Admininstrative Daten
Patientenname*
früherer Name*
Patienten-Geburtsdatum*
Alter des Patienten*
Nationalität/Staatsangehörigkeit*
Straße*
Postleitzahl Patient*
Wohnort*
Fallnummer*
Abteilung*
Nachsorgenummer*
Organspezifisch Prostata
Tumordiagnose*
Datum der Diagnose*
Therapien*
Operation (Operation)
Sonstiges (Sonstiges)
Bestrahlung (Strahlentherapie)
Systemische Therapie (Systemische
Therapie)
Gewebebank Einwilligung
Einverständniserklärung für Gewebebank*
Ja
Nein
nicht_kodiert*
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Ja
Nein
Einwolligung für Gewebebank*
Ja
Nein
Tumorspezifische Daten
Histologisches Grading*
G1 (G1)
G2 (G2)
G3 (G3)
High grade (High grade)
Low grade (Low grade)
0 = Grading nicht vorgesehen (O)
X = Differenzierungsgrad kann nicht
bestimmt werden (X)
Gleason-Score*
vorhanden (Angaben vorhanden)
keine Gleason-Angabe (keine Angabe)
vorangiges Gleason-Muster*
zweithäufigstes Gleason-Muster*
Gesamt-Gleason-Score*
digitale rektale Untersuchung*
nicht suspekt (nicht suspekt)
suspekt (suspekt)
unbekannt (unbekannt)
Prostata-spezifisches-Antigen*
Datum des PSA*
Szintigraphie*
Ja (Ja)
Nein (Nein)
unbekannt (unbekannt)
suspekt?*
Ja (Ja)
Nein (Nein)
unbekannt (unbekannt)
Lokalisation*
Patientenbefragung
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Vorerkrankungen in Familie*
Nein (keine Vorerkrankung in der
Familie)
unbekannt (unbekannt)
Ja (Vorerkrankung in der Familie)
Familienangehörige mit Tumorerkrankung*
Familienangehörige mit Prostatakarzinom*
Familienangehörige mit einer anderen
Tumorerkrankung*
Wunsch Nerve-Sparing Prostatektomie*
Ja
Nein
Score
Score IIEF*
Score ICIQ*
Score IPSS*
EORTC Fragen
(Kontinenzbogen Frage 4)*
(EQRTC QLQ-C30 Frage 29)*
(EQRTC QLQ-C30 Frage 30)*
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Ersterhebung OPAL-Studie NCT01619124
ALL
Osteonekrosen bei pädiatrischen Patienten mit ALL
Studienleitung: Dr. M. Kuhlen, Universitätsklinikum
Düsseldorf, Klinik für Kinder-Onkologie, -Hämatologie und
Klinische Immunologie, Moorenstr. 5, 40225 Düsseldorf,
Tel.: 0211 81 17687, Fax: 0211 81 04982, Email:
Michaela.Kuhlen@med.uni-duesseldorf.de
All rights reserved. Please visit https://medical-data-
models.org/forms/3970
Ersterhebung OPAL-Studie
Allgemeine Angaben
Name*
Vorname*
Geschlecht*
Geburtsdatum*
Pat.-Nr. (Studie)*
Klinik (DKKR)*
GPOH-PID*
Anamnese
Knochenschmerzen*
Ja
Nein
seit:*
Lokalisation:*
Gelenkschmerzen*
Ja
Nein
seit:*
Lokalisation:*
Weigerung zum Laufen*
Ja
Nein
seit:*
Nikotin*
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Ja
Nein
Zig./pro Tag:*
Kontrazeptivum*
Ja
Nein
Spezifizierung:*
Vorerkrankungen
Koagulopathie*
Ja
Nein
Spezifizierung:*
Autoimmunerkrankung*
Ja
Nein
Spezifizierung:*
(Fett-)stoffwechselstörung*
Ja
Nein
Spezifizierung:*
Speicherkrankheit*
Ja
Nein
Spezifizierung:*
System. Infektion *
Ja
Nein
Spezifizierung:*
Störung des Wachstums*
Ja
Nein
Spezifizierung:*
Erkrankung des Skelettsystems*
Ja
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Nein
Spezifizierung:*
Knöcherne Fraktur*
Ja
Nein
Spezifizierung:*
Maligne Erkrankung, Krebs*
Ja
Nein
Spezifizierung:*
Andere dauerhafte Erkrankung*
Ja
Nein
Spezifizierung:*
Vorbehandlung (systemisch verabreicht)
Steroide*
Ja
Nein
Zytostatika*
Ja
Nein
Gerinnungsaktive Medikamente*
Ja
Nein
Hormonbehandlung (inkl. Wachstumsfaktoren)*
Ja
Nein
Sonstige*
Ja
Nein
Falls ja, bitte Spezifizierung:*
Medikament*
Dosis pro Tag*
Beginn*
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Ende*
Datum der definitiven Diagnose*
Datum Beginn der Therapie*
Befunde bei Diagnose
Leukozyten (/µl)*
Thrombozyten (/µl)*
Körpergewicht (kg)*
Körperlänge (cm)*
Wachstumsgeschwindigkeit (cm/Jahr) (im letzten
Jahr vor Diagnose)*
Tannerstadium*
I (1)
II (2)
III (3)
IV (4)
V (5)
Bemerkungen
Name des dokumentierenden Arztes (Stempel)*
Datum*
Unterschrift*
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Symptomatische Osteonekrosen OPAL-
Studie NCT01619124 ALL
Osteonekrosen bei pädiatrischen Patienten mit ALL
Studienleitung: Dr. M. Kuhlen, Universitätsklinikum
Düsseldorf, Klinik für Kinder-Onkologie, -Hämatologie und
Klinische Immunologie, Moorenstr. 5, 40225 Düsseldorf,
Tel.: 0211 81 17687, Fax: 0211 81 04982, Email:
Michaela.Kuhlen@med.uni-duesseldorf.de
All rights reserved. Please visit https://medical-data-
models.org/forms/3972
Symptomatische Osteonekrosen
OPAL-Studie
Allgemeine Angaben
Name*
Vorname*
Geburtsdatum*
Untersuchungsdatum*
Nichtoperative Therapie
Analgetika*
keine Analgetika (0)
WHO I°  (1)
WHO II°  (2)
WHO III°  (3)
Analgetika nur bei Bedarf*
WHO I°  (1)
WHO II°  (2)
WHO III°  (3)
Analgetika regelmäßig / täglich*
WHO I°  (1)
WHO II°  (2)
WHO III°  (3)
Physikalische Therapie
mechanische Entlastung*
Ja
Nein
Beginn*
End*
andauernd*
Ja
Nein
Unterarmgehstützen*
Ja
Nein
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Rollstuhl*
Ja
Nein
Sonstiges*
Physiotherapie*
Ja
Nein
Beginn*
End*
andauernd*
Ja
Nein
manuelle Therapie*
Ja
Nein
Beginn*
End*
andauernd*
Ja
Nein
Massage*
Ja
Nein
Beginn*
End*
andauernd*
Ja
Nein
Sonstiges*
Beginn*
End*
andauernd*
Ja
Nein
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Medikamentöse Therapie
Gerinnungswirksame Substanzen (z.B. Heparin)*
Ja
Nein
Vasoaktive Substanzen (z.B. Iloprost)*
Ja
Nein
Biphosphonate*
Ja
Nein
Fettstoffwechselaktive Substanzen*
Ja
Nein
Wachstumsfaktoren*
Ja
Nein
Wenn ja, bitte Spezifizierung:*
Medikament*
Dosis pro Tag*
Beginn*
Ende*
Operative Therapie
Anbohrung*
Ja
Nein
+ autologes Knochenmark*
Ja
Nein
+ Mesenchymale Stammzellen*
Ja
Nein
+ Sonstiges*
Datum:*
Gelenk:*
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re*
Ja
Nein
li*
Ja
Nein
Ersatz nekrotischer Knochenanteile*
Ja
Nein
Spongiosaplastik*
Ja
Nein
Knochentransplantation*
Ja
Nein
osteochondrale Transplantation*
Ja
Nein
Datum:*
Gelenk:*
re*
Ja
Nein
li*
Ja
Nein
Umstellungs-Osteotomie*
Ja
Nein
Datum:*
Gelenk:*
re*
Ja
Nein
li*
Ja
Nein
Sonstige:*
Datum:*
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Gelenk:*
re*
Ja
Nein
li*
Ja
Nein
Operative Therapie - Gelenkersatz
Gelenkersatz*
Ja
Nein
Datum:*
Gelenk:*
re*
Ja
Nein
li*
Ja
Nein
Bemerkungen*
Name des dokumentierenden Arztes (Stempel)*
Datum*
Unterschrift*
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MRT-Referenzbefund OPAL-Studie
NCT01619124 ALL
Osteonekrosen bei pädiatrischen Patienten mit ALL
Studienleitung: Dr. M. Kuhlen, Universitätsklinikum
Düsseldorf, Klinik für Kinder-Onkologie, -Hämatologie und
Klinische Immunologie, Moorenstr. 5, 40225 Düsseldorf,
Tel.: 0211 81 17687, Fax: 0211 81 04982, Email:
Michaela.Kuhlen@med.uni-duesseldorf.de
All rights reserved. Please visit https://medical-data-
models.org/forms/3976
MRT-Referenzbefund OPAL-Studie
Allgemeine Angaben
Pat.-Nr. (Studie)*
Untersuchungsdatum*
Hüftgelenk rechts
ARCO-Stadium *
0 (0)
I (1)
II (2)
III (3)
IV (4)
Volumen Ödem (ml) *
Volumen Nekrose (ml) *
Gelenkflächenbeteiligung*
< 30% (0)
>= 30% (1)
Hüftgelenk links
ARCO-Stadium *
0 (0)
I (1)
II (2)
III (3)
IV (4)
Volumen Ödem (ml) *
Volumen Nekrose (ml) *
Gelenkflächenbeteiligung*
< 30% (0)
>= 30% (1)
Kniegelenk rechts
ARCO-Stadium *
0 (0)
I (1)
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II (2)
III (3)
IV (4)
Volumen Ödem (ml) *
Volumen Nekrose (ml) *
Gelenkflächenbeteiligung*
< 30% (0)
>= 30% (1)
Kniegelenk links
ARCO-Stadium *
0 (0)
I (1)
II (2)
III (3)
IV (4)
Volumen Ödem (ml) *
Volumen Nekrose (ml) *
Gelenkflächenbeteiligung*
< 30% (0)
>= 30% (1)
oberes Sprunggelenk rechts
ARCO-Stadium *
0 (0)
I (1)
II (2)
III (3)
IV (4)
Volumen Ödem (ml) *
Volumen Nekrose (ml) *
Gelenkflächenbeteiligung*
< 30% (0)
>= 30% (1)
oberes Sprunggelenk links
ARCO-Stadium *
0 (0)
I (1)
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II (2)
III (3)
IV (4)
Volumen Ödem (ml) *
Volumen Nekrose (ml) *
Gelenkflächenbeteiligung*
< 30% (0)
>= 30% (1)
unteres Sprunggelenk rechts
ARCO-Stadium *
0 (0)
I (1)
II (2)
III (3)
IV (4)
Volumen Ödem (ml) *
Volumen Nekrose (ml) *
Gelenkflächenbeteiligung*
< 30% (0)
>= 30% (1)
unteres Sprunggelenk links
ARCO-Stadium *
0 (0)
I (1)
II (2)
III (3)
IV (4)
Volumen Ödem (ml) *
Volumen Nekrose (ml) *
Gelenkflächenbeteiligung*
< 30% (0)
>= 30% (1)
Beteiligung der Metaphyse rechts
Femur (max. Längenausdehnung in cm)*
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Tibia (max. Längenausdehnung in cm)*
Beteiligung der Metaphyse links
Femur (max. Längenausdehnung in cm)*
Tibia (max. Längenausdehnung in cm)*
Bemerkungen
Bemerkungen*
Name des dokumentierenden Arztes (Stempel)*
Datum*
Unterschrift*
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Bogen 0 Ersterhebung_Diagnose
NCT01657604 CML
German CML Study Group
http://www.kompetenznetz-
leukaemie.de/content/teilprojekte/studiengruppen/cml_proj
ekt_7/projektleitung/index_ger.html
All rights reserved. Please visit https://medical-data-
models.org/forms/3983
Bogen 0 Ersterhebung_Diagnose
Allgemeine Angaben
Klinik-Nr.*
Patienten-Nr.*
Geburtsdatum Monat:*
Geburtsdatum Jahr:*
Beurteilungsdatum*
Diagnosedatum*
Geschlecht *
männlich (1)
weiblich (2)
ECOG-Status*
Laborwerte
am:*
Bei Wahl anderer Einheiten der Laborparameter,
diese bitte angeben.*
Leukozyten [10E9/l]*
Blasten [%]*
Promyelozyten [%]*
Myelozyten, Metamyelozyten  [%]*
Stabkernige [%]*
Segmentkernige [%]*
Eosinophile [%]*
Basophile [%]*
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Monozyten [%]*
Lymphozyten [%]*
Normoblasten [%]*
Thrombozyten [10E9/l]*
Hämoglobin [mmol/L]*
Hämoglobin [g/dL]*
Hämatokrit [%]*
Harnstoff [mg/dL]*
Kreatinin [mg/dL]*
Harnsäure [mg/dL]*
Albumin [g/dL]*
Protein [g/dL]*
Bilirubin (gesamt) [µmol/L]*
Bilirubin (gesamt) [mg/dL]*
Bilirubin (direkt) [µmol/L] (falls gesamt Bilirubin
größer oder gleich ULN (oberer Normwert))*
Bilirubin (direkt) [mg/dL] (falls gesamt Bilirubin
größer oder gleich ULN (oberer Normwert))*
Bilirubin (indirekt) [µmol/L] (falls gesamt Bilirubin
größer oder gleich ULN (oberer Normwert))*
Bilirubin (indirekt) [mg/dL] (falls gesamt Bilirubin
größer oder gleich ULN (oberer Normwert))*
ALAT (SGPT) [U/L]*
ASAT (SGOT) [U/L]*
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LDH [U/L]*
Natrium [mmol/L]*
Kalzium [mmol/L]*
Phosphat [mmol/L]*
Lipase [U/L]*
Amylase [U/L]*
Kalium [mmol/L]*
Magnesium [mmol/L]*
TSH [mU/L]*
Glukose [mg/dL]*
Glukose [mmol/L]*
HbA1c [mmol/L]*
Cholesterin [mg/dL]*
Cholesterin [mmol/L]*
Kommentar:*
Klinischer Befund
am:*
Körpergröße*
Gewicht*
Spleen size (palpated below costal arch)*
Milz im US, größter Durchmesser*
Blutdruck systolisch*
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Blutdruck diastolisch*
Herzfrequenz*
Extramedulläre Manifestation*
Ja
Nein
(z.B. LK, Haut, usw.) wenn ja, welche: *
Molekularbiologie
nicht durchgeführt*
Ja
Nein
am:*
BCR-ABL-Transkripte:*
b2a2 (1)
b3a2 (2)
b2a3 (3)
b3a3 (4)
e1a2 (5)
e6a2 (6)
e19a2 (7)
Sonstige (8)
welche:*
kein BCR-ABL-Transkript (9)
Untersucher/Ort:*
Labor Nr.:*
Knochenmarkanalyse
nicht durchgeführt*
Ja
Nein
nicht verwertbar*
Ja
Nein
am:*
Zellularität:*
Aplasie (1)
Normozellularität (2)
Hyperzellularität (3)
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Hypozellularität (4)
starke Hyperzellularität (5)
Blasten [%]*
Promyelozyten [%]*
Basophile [%]*
Zytogenetik
Ausgewertete Mitosen, Anzahl*
Normaler Karyotyp, Anzahl*
Normal, aber mit Zusatzaberrationen (Anzahl)*
Philadelphia-Chromosom t(9;22), Anzahl*
Philadelphia-Chromosom mit Zusatzaberrationen,
Anzahl*
Befunde nach ISCN:*
Nicht auswertbare Mitosen, Anzahl*
Untersucher/Ort:*
Labor Nr.:*
Klinik:*
Datum:*
Unterschrift:*
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Bogen 1 Bestehende medizinische
Symptome NCT01657604 CML
German CML Study Group
http://www.kompetenznetz-
leukaemie.de/content/teilprojekte/studiengruppen/cml_proj
ekt_7/projektleitung/index_ger.html
All rights reserved. Please visit https://medical-data-
models.org/forms/3989
Bogen 1 Bestehende medizinische
Symptome
Allgemeine Angaben
Klinik-Nr.*
Patienten-Nr.*
Geburtsdatum Monat:*
Geburtsdatum Jahr:*
Beurteilungsdatum*
Nummer des Verlaufsbogens*
Geschlecht *
männlich (1)
weiblich (2)
Symptome vorhanden:*
Ja
Nein
Symptome
Nr.*
CTCAE-Schweregrad*
Datum des 1. Auftretens*
Ende des Auftretens*
Bestehend*
Ja
Nein
Therapiebezug*
Ja
Nein
Maßnahmen*
keine Maßnahmen ergriffen (1)
Medikament abgesetzt (2)
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Einnahme von Begleitmedikament (3)
keine medikamentöse Therapie erhalten
(4)
stationäre Aufnahme/Verlängerung
bestehender stationärer Aufenthalt (5)
Schwerwiegende unerwünschte Nebenwirkung:*
Ja
Nein
Falls schwerwiegende unerwünschte
Nebenwirkung:
Verlauf*
Tödlich (1)
Lebensbedrohlich (2)
Folgen (Behinderung/Körperliche
Einschränkungen)*
Ja
Nein
Kongenitale Anomalie/Geburtsfehler*
Ja
Nein
stationäre Aufnahme/Verlängerung bestehender
stationärer Aufenthalt*
Ja
Nein
Medizinisch signifikant*
Ja
Nein
Kommentar
Kommentar:*
Klinik:*
Datum:*
Unterschrift:*
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Bogen 2 Adverse events NCT01657604
CML
German CML Study Group http://www.kompetenznetz-
leukaemie.de/content/teilprojekte/studiengruppen/cml_proj
ekt_7/projektleitung/index_ger.html
All rights reserved. Please visit https://medical-data-
models.org/forms/3992
Bogen 2 Adverse events
Allgemeine Angaben
Klinik-Nr.*
Patienten-Nr.*
Geburtsdatum Monat:*
Geburtsdatum Jahr:*
Beurteilungsdatum*
Nummer des Verlaufsbogens*
Geschlecht *
männlich (1)
weiblich (2)
Unerwünschte Nebenwirkungen sind
aufgetreten:*
Ja
Nein
Liegt eine Schwangerschaft vor:*
Ja
Nein
unerwünschte Nebenwirkungen
Nr.*
CTCAE-Schweregrad*
Datum des 1. Auftretens*
Ende des Auftretens*
Bestehend*
Ja
Nein
Therapiebezug*
Ja
Nein
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Maßnahmen*
keine Maßnahmen ergriffen (1)
Medikament abgesetzt (2)
Einnahme von Begleitmedikament (3)
keine medikamentöse Therapie erhalten
(4)
stationäre Aufnahme/Verlängerung
bestehender stationärer Aufenthalt (5)
Schwerwiegende unerwünschte Nebenwirkung:*
Ja
Nein
Falls schwerwiegende unerwünschte
Nebenwirkung:
Verlauf*
Tödlich (1)
Lebensbedrohlich (2)
Folgen (Behinderung/Körperliche
Einschränkungen)*
Ja
Nein
Kongenitale Anomalie/Geburtsfehler*
Ja
Nein
stationäre Aufnahme/Verlängerung bestehender
stationärer Aufenthalt*
Ja
Nein
Medizinisch signifikant*
Ja
Nein
Kommentar
Kommentar:*
Klinik:*
Datum:*
Unterschrift:*
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MPN-SAF (Patient) MPN-SAF
Protocol_7_1_13 MPN
Myeloproliferative Erkrankungen Symptom-
Erfassungsbogen (MPN-SAF) - German
Prof. Steffen Koschmieder
skoschmieder@ukaachen.de
All rights reserved. Please visit https://medical-data-
models.org/forms/3997
MPN-SAF (Patient)
Myeloproliferative Erkrankungen
Symptom-Erfassungsbogen - Eine
Validierungsstudie
Anonyme Patienten-Identifizierungs-Nummer:*
Diagnose:*
MF (PMF)*
MF(Post ET MF)*
MF(Post PV MF)*
Polycythaemia vera (PV)*
Essentielle Thrombozythämie (ET)*
Standort:*
Mayo-Klinik Arizona (1)
Guys and St. Thomas's UK (2)
Uniklinik Freiburg (3)
Uniklinik Ulm (4)
Uniklinik Aachen (5)
MPN-Symptome letzte Woche
Anleitung: Bitte füllen Sie diesen Fragebogen
nach bestem Wissen aus. Überlegen Sie dabei,
wie die aufgeführten Beschwerden (Symptome)
Sie (sofern nicht anders angegeben) in der
LETZTEN WOCHE beeinträchtigt haben. Füllen
Sie bitte den Fragebogen bis zum Wort "STOP"
am Ende der Seite 8 aus.*
Bitte bewerten Sie Ihre Müdigkeit
(Abgeschlagenheit/Erschöpfung) indem Sie
diejenige Zahl umranden,  die am ehesten Ihre
Müdigkeit in DIESEM AUGENBLICK beschreibt.*
keine Müdigkeit (0)
1 (1)
schlimmste vorstellbare Müdigkeit (10)
2 (2)
3 (3)
4 (4)
5 (5)
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6 (6)
7 (7)
8 (8)
9 (9)
Bitte bewerten Sie Ihre Müdigkeit
(Abgeschlagenheit/Erschöpfung) indem Sie
diejenige Zahl umranden,  die am ehesten den
ÜBLICHEN Grad Ihrer Müdigkeit während der
letzten 24 Stunden beschreibt.*
keine Müdigkeit (0)
1 (1)
schlimmste vorstellbare Müdigkeit (10)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
7 (7)
8 (8)
9 (9)
Bitte bewerten Sie Ihre Müdigkeit
(Abgeschlagenheit/Erschöpfung) indem Sie
diejenige Zahl umranden,  die am ehesten den
HÖCHSTEN Grad Ihrer Müdigkeit während der
letzten 24 Stunden beschreibt.*
keine Müdigkeit (0)
1 (1)
schlimmste vorstellbare Müdigkeit (10)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
7 (7)
8 (8)
9 (9)
Müdigkeit innerhalb der letzten 24
Stunden
Kreisen Sie bitte die Zahl ein, die beschreibt, wie
Ihre Müdigkeit Sie innerhalb der letzten 24
Stunden in folgenden Dingen beeinträchtigt hat:*
Allgemeine Aktivität*
keine Beeinträchtigung (0)
1 (1)
sehr starke Beeinträchtigung (10)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
7 (7)
8 (8)
9 (9)
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Stimmung*
keine Beeinträchtigung (0)
1 (1)
sehr starke Beeinträchtigung (10)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
7 (7)
8 (8)
9 (9)
Gehvermögen*
keine Beeinträchtigung (0)
1 (1)
sehr starke Beeinträchtigung (10)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
7 (7)
8 (8)
9 (9)
Normale Arbeit (sowohl außer Haus, als auch
tägliche Aufgaben im Haus)*
keine Beeinträchtigung (0)
1 (1)
sehr starke Beeinträchtigung (10)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
7 (7)
8 (8)
9 (9)
Beziehungen zu anderen Menschen*
keine Beeinträchtigung (0)
1 (1)
sehr starke Beeinträchtigung (10)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
7 (7)
8 (8)
9 (9)
Lebensfreude*
keine Beeinträchtigung (0)
1 (1)
sehr starke Beeinträchtigung (10)
2 (2)
3 (3)
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4 (4)
5 (5)
6 (6)
7 (7)
8 (8)
9 (9)
Beschwerden in der vergangenen Woche
Schnell 'voll' werden, wenn man isst (Frühes
Sättigungsgefühl)*
nicht vorhanden (0)
1 (1)
schlimmste vorstellbare Beschwerden
(10)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
7 (7)
8 (8)
9 (9)
Bauchschmerzen*
nicht vorhanden (0)
1 (1)
schlimmste vorstellbare Beschwerden
(10)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
7 (7)
8 (8)
9 (9)
Bauchbeschwerden*
nicht vorhanden (0)
1 (1)
schlimmste vorstellbare Beschwerden
(10)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
7 (7)
8 (8)
9 (9)
Trägheit*
nicht vorhanden (0)
1 (1)
schlimmste vorstellbare Beschwerden
(10)
2 (2)
3 (3)
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4 (4)
5 (5)
6 (6)
7 (7)
8 (8)
9 (9)
Kopfschmerzen*
nicht vorhanden (0)
1 (1)
schlimmste vorstellbare Beschwerden
(10)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
7 (7)
8 (8)
9 (9)
Konzentrationsschwierigkeiten im Vergleich zu
früher (vor der MPN Diagnose)*
nicht vorhanden (0)
1 (1)
schlimmste vorstellbare Beschwerden
(10)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
7 (7)
8 (8)
9 (9)
Schwindel, Gleichgewichtsstörungen,
Benommenheit*
nicht vorhanden (0)
1 (1)
schlimmste vorstellbare Beschwerden
(10)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
7 (7)
8 (8)
9 (9)
Taubheitsgefühl/Kribbeln an Händen und Füßen*
nicht vorhanden (0)
1 (1)
schlimmste vorstellbare Beschwerden
(10)
2 (2)
3 (3)
4 (4)
5 (5)
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6 (6)
7 (7)
8 (8)
9 (9)
Schlafprobleme, Ein-
/Durchschlafschwierigkeiten*
nicht vorhanden (0)
1 (1)
schlimmste vorstellbare Beschwerden
(10)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
7 (7)
8 (8)
9 (9)
Depression oder trübe Stimmung*
nicht vorhanden (0)
1 (1)
schlimmste vorstellbare Beschwerden
(10)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
7 (7)
8 (8)
9 (9)
Schwierigkeiten im Sexualbereich: Mangelndes
Interesse oder Funktionsstörungen*
nicht vorhanden (0)
1 (1)
schlimmste vorstellbare Beschwerden
(10)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
7 (7)
8 (8)
9 (9)
Husten*
nicht vorhanden (0)
1 (1)
schlimmste vorstellbare Beschwerden
(10)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
7 (7)
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8 (8)
9 (9)
Nächtliches Schwitzen*
nicht vorhanden (0)
1 (1)
schlimmste vorstellbare Beschwerden
(10)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
7 (7)
8 (8)
9 (9)
Juckreiz (Pruritus)*
nicht vorhanden (0)
1 (1)
schlimmste vorstellbare Beschwerden
(10)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
7 (7)
8 (8)
9 (9)
Knochenschmerzen (diffuser Art, nicht Gelenk-
oder Arthritis-Schmerzen)*
nicht vorhanden (0)
1 (1)
schlimmste vorstellbare Beschwerden
(10)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
7 (7)
8 (8)
9 (9)
Fieber (>37,8°C)*
nicht vorhanden (0)
1 (1)
täglich (10)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
7 (7)
8 (8)
9 (9)
Unbeabsichtigter Gewichtsverlust in den letzten 6
Monaten*
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nicht vorhanden (0)
1 (1)
schlimmster vorstellbarer
Gewichtsverlust (10)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
7 (7)
8 (8)
9 (9)
Wie empfinden Sie insgesamt Ihre
Lebensqualität?*
besser geht's nicht (0)
1 (1)
schlimmer geht's nicht (10)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
7 (7)
8 (8)
9 (9)
Zusätzliche Fragen für den Patienten:
1. Haben Sie zusätzliche Beschwerden durch
Ihre myeloproliferative Erkrankung, die in diesem
Fragebogen nicht angesprochen wurden? (bitte
tragen Sie hier Ihre Beschwerden ein)*
2. Der MPN-SAF Fragebogen war leicht zu
verstehen*
leichter geht's nicht (0)
1 (1)
schwieriger geht's nicht (10)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
7 (7)
8 (8)
9 (9)
3. Der MPN-SAF Fragebogen hat die meisten
Beschwerden, die durch die Krankheit entstehen,
abgefragt*
besser geht's nicht (0)
1 (1)
schlimmer geht's nicht (10)
2 (2)
3 (3)
4 (4)
5 (5)
8 / 9
MPN-SAF (Patient) MPN-SAF Protocol_7_1_13 MPN
6 (6)
7 (7)
8 (8)
9 (9)
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MPN-SAF (Doctor) MPN-SAF
Protocol_7_1_13 MPN
Myeloproliferative Erkrankungen Symptom-
Erfassungsbogen (MPN-SAF) - German
Prof. Steffen Koschmieder skoschmieder@ukaachen.de
All rights reserved. Please visit https://medical-data-
models.org/forms/4004
MPN-SAF (Doctor)
MPN-SAF Aerztliche Eintragungen
Aktuelles Alter*
Geschlecht*
männlich (1)
weiblich (2)
Art der MPN*
ET (1)
PV (2)
MF (3)
PMF  (4)
Post ET MF (5)
Post PV MF (6)
Datum der Diagnose MPN*
Datum der Diagnose MF*
aktuelle Milzgröße*
Frühere Thrombose durch Krankheit?*
Ja
Nein
Frühere Blutung durch Krankheit?*
Ja
Nein
Erythrozytentransfusion erforderlich?*
Ja
Nein
Aktuelle MPN-Therapien (Liste)*
Frühere MPN-Therapien (Liste)*
Blutbild
Hämoglobin (g/dL)*
WBC (x 10E9/L)*
ANC (x 10E9/L)*
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PLT (x 10E9/L)*
- Blasten präsent?*
Ja
Nein
Blastenanteil in Prozent*
Symptome
Nächtliches Schwitzen*
0 (0)
1 (1)
10 (10)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
7 (7)
8 (8)
9 (9)
Fieber*
0 (0)
1 (1)
10 (10)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
7 (7)
8 (8)
9 (9)
Müdigkeit*
0 (0)
1 (1)
10 (10)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
7 (7)
8 (8)
9 (9)
Gewichtsverlust*
0 (0)
1 (1)
10 (10)
2 (2)
3 (3)
4 (4)
5 (5)
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6 (6)
7 (7)
8 (8)
9 (9)
Knochenschmerz*
0 (0)
1 (1)
10 (10)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
7 (7)
8 (8)
9 (9)
Pruritus*
0 (0)
1 (1)
10 (10)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
7 (7)
8 (8)
9 (9)
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Teilhabescore SHT-Register
Teilhabescore SHT-Register
All rights reserved. Please visit https://medical-data-
models.org/forms/4025
Teilhabescore SHT-Register
Teilhabescore
Schulisch / berufliche Tätigkeit*
Förderschule mit vollst. Unterstützung (0)
Förderschule (1)
Integrationsklasse mit viel Hilfen (2)
Integrationsklasse mit geringer
Unterstützung (3)
Regelschule mit
Hausaufgabenbetreuung (4)
Regelschule (5)
Altersgerechte Freizeitgestaltung*
vollst. Abhängigkeit von Fremdhilfe (0)
mit prof. Kontakthilfe (KH) möglich (1)
mit Laien-KH möglich (2)
selbständig mit Supervision (3)
Selbständig mit Hilfsmittel (HiMi) (4)
selbständig ohne Hilfsmittel (5)
Altersgerechte Geld- & Finanzverwaltung*
nicht möglich (0)
nur einfache Mithilfe möglich (1)
nur mäßige Mithilfe möglich (2)
nur unter strenger Supervision (3)
mit leichter Supervision (4)
altersgerecht (5)
Altersgerechte Lebensführung /
Selbstversorgung Essen / Anziehen / Hygiene*
vollst. Abhängigkeit von Fremdhilfe (0)
mit prof. Kontakthilfe (KH) möglich (1)
mit Laien-KH möglich (2)
selbständig mit Supervision (3)
Selbständig mit Hilfsmittel (HiMi) (4)
selbständig ohne Hilfsmittel (5)
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Eligibility NCT00980135 Atopic Dermatitis
ODM derived from
http://clinicaltrials.gov/show/NCT00980135
All rights reserved. Please visit https://medical-data-
models.org/forms/4030
Eligibility
Einschlusskriterien
Alter 18 bis 65 Jahre*
Ja
Nein
Male or female Caucasians aged between 18 and
65 years*
Ja
Nein
Patients with mild AD presenting a scoring AD
(SCORAD) rating between 3-25*
Ja
Nein
Skin type I - IV according to Fitzpatrick*
Ja
Nein
Acute AD symptoms on each assessment areas
(local SCORAD >/=3 and <= 12)*
Ja
Nein
Acute symptom of pruritus at Baseline *
Ja
Nein
Ausschlusskriterien
Any other skin disease at the test area that would
interfere the clinical assessment in the opinion of
the investigator*
Ja
Nein
Moles, tattoos, strong pigmentation, or scars at
the test area that would interfere the clinical
assessment*
Ja
Nein
Regular intake of antiphlogistic drugs (for
example, NSAIDs)*
Ja
Nein
Any condition or treatment which might influence
the trial (e.g. any treatment with topical
antibiotics, antifungals, or corticoids) within 14
days prior to screening as well as during the trial
(exception: topical treatment of AD lesions other
than the test areas (for example, face) with low
1 / 2
potency steroids restricted to small areas)*
Ja
Nein
UV-therapy or the use of solarium within 30 days
before screening as well as during the trial*
Ja
Nein
Any alternative treatment of AD (e.g.
acupuncture, kinesiology, and homoeopathy)
within 30 days before screening as well as during
the trial*
Ja
Nein
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Eligibility NCT01104584 Breast Cancer
ODM derived from
http://clinicaltrials.gov/show/NCT01104584
All rights reserved. Please visit https://medical-data-
models.org/forms/4031
Eligibility
Einschlusskriterien
Alter mindestens 18 Jahre*
Ja
Nein
Recent histologically proven diagnosis of breast
cancer after having obtained X-Ray
Mammography (XRM) of both breasts (according
to American College of Radiology [ACR] and
performed no longer than 6 weeks prior to
enrollment into the study) and has been referred
for a contrast-enhanced Magnetic Resonance
Mammography (MRM) prior to surgery of the
breast.*
Ja
Nein
if female, a digital XRM is required if any of the
following criteria is met:*
Ja
Nein
Alter < 50 Jahre*
Ja
Nein
b. patient has heterogeneously or extremely
dense breasts*
Ja
Nein
c. is not post-menopausal (post-menopause
defined as at least 12 months prior to  inclusion
without menstruation).*
Ja
Nein
if female of childbearing potential, MRM should
be performed on the 7-14th day of the menstrual
cycle.*
Ja
Nein
has an estimated glomerular filtration rate
(eGFR) value >/= 60 mL/min/1.73m2 derived
from a serum creatinine result within 2 weeks
prior to study enrollment. *
Ja
Nein
Ausschlusskriterien
is a female patient who is pregnant or lactating*
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Ja
Nein
has any contraindication to the MRM examination
(e.g. metal implants, phobia) or the use of
gadolinium-containing contrast agents.*
Ja
Nein
has received any contrast agent within 24 hours
prior to the study MRM, or is scheduled to receive
any contrast agent within 24 hours after the study
MRM.*
Ja
Nein
has severe cardiovascular disease (e.g., known
long QT syndrome, acute myocardial infarction [<
14 days], unstable angina, congestive heart
failure New York Heart Association class IV) or
acute stroke (< 48 hours)).*
Ja
Nein
has acute renal insufficiency of any severity due
to hepato-renal syndrome or in the peri-operative
liver transplantation period or who has acute or
chronic moderate or severe renal insufficiency
(glomerular filtration rate < 60 mL/min/1.73m2).*
Ja
Nein
has received chemotherapy or hormonal therapy
for breast cancer within 6 months.*
Ja
Nein
has received hormone replacement therapy
within 4 weeks prior to study drug
administration.*
Ja
Nein
is scheduled or likely to require a surgery and/or
biopsy in the time period up to 24 hours following
study drug application*
Ja
Nein
has prior excisional biopsy or breast surgery < 6
months before enrollment and between XRM and
study MRM*
Ja
Nein
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Ersterhebung_Vor_Begleiterkrankungen
CRF AML2003 AML
Prospektive, randomisierte, multizentrische Therapie
optimierungsstudie - Studienprotokoll AML2003
http://clinicaltrials.gov/show/NCT00180102
All rights reserved. Please visit https://medical-data-
models.org/forms/4042
Ersterhebung_Vor_Begleiterkrankun
gen
Allgemeine Angaben
Klinik-Nr.:*
Patienten-Nr.: 2-*
Patienten-Initialen: (Nachname/Vorname)*
Vor- und Begleiterkrankungen
Erkrankung*
Beginn (Monat/Jahr)*
andauernd*
Ja
Nein
Intensität (1 = leicht, 2 = mäßig, 3 = schwer, 4 =
lebensbedrohlich, 0 = nicht beurteilbar)*
nicht beurteilbar (0) (0)
leicht (1) (1)
mäßig (2) (2)
schwer (3) (3)
lebensbedrohlich (4) (4)
Erkrankung*
Beginn (Monat/Jahr)*
andauernd*
Ja
Nein
Intensität (1 = leicht, 2 = mäßig, 3 = schwer, 4 =
lebensbedrohlich, 0 = nicht beurteilbar)*
nicht beurteilbar (0) (0)
leicht (1) (1)
mäßig (2) (2)
schwer (3) (3)
lebensbedrohlich (4) (4)
Erkrankung*
Beginn (Monat/Jahr)*
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andauernd*
Ja
Nein
Intensität (1 = leicht, 2 = mäßig, 3 = schwer, 4 =
lebensbedrohlich, 0 = nicht beurteilbar)*
nicht beurteilbar (0) (0)
leicht (1) (1)
mäßig (2) (2)
schwer (3) (3)
lebensbedrohlich (4) (4)
Unterschrift
Datum*
Name des Studienarztes/Unterschrift*
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Ersterhebung_Vor_Begleiterkrankungen CRF AML2003 AML
Diagnostik vor Therapiebeginn CRF
AML2003 AML
Prospektive, randomisierte, multizentrische
Therapieoptimierungsstudie - Studienprotokoll AML2003
http://clinicaltrials.gov/show/NCT00180102
All rights reserved. Please visit https://medical-data-
models.org/forms/4045
Diagnostik vor Therapiebeginn
Allgemeine Angaben
Klinik-Nr.:*
Patienten-Nr.: 2-*
Patienten-Initialen: (Nachname/Vorname)*
Materialversand an Studienzentrale
mind. 15 ml heparinisiertes KM*
Ja
Nein
Datum*
mind. 50 ml heparinisiertes pB*
Ja
Nein
Datum*
5 ungefärbte KM-Ausstriche*
Ja
Nein
Datum*
5 ungefärbte pB-Ausstriche*
Ja
Nein
Datum*
20 ml EDTA-Blut für HLA-Typisierung*
Ja
Nein
Datum*
Potentieller Familienspender vorhanden?*
Ja
Nein
Wenn ja, Anzahl der Geschwister*
20 ml EDTA-Blut für jeden Geschwister*
Ja
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Nein
Wenn nein, warum?*
Blutbild
Leukozyten [GPt/l]*
Datum:*
Leukozyten [/ul]*
Datum:*
Hämoglobin [mmol/l]*
Datum:*
Hämoglobin [g/dl]*
Datum:*
Thrombozyten [GPt/l]*
Datum:*
Thrombozyten [/ul]*
Datum:*
Differentialblutbild
Prozentanteil Neutrophile *
Datum:*
Prozentanteil Segmentkernige *
Datum:*
Prozentanteil Stabkernige *
Datum:*
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Prozentanteil Lymphozyten *
Datum:*
Prozentanteil Monozyten*
Datum:*
Prozentanteil Eosinophile *
Datum:*
Prozentanteil Basophile *
Datum:*
Prozentanteil Myeloblasten*
Datum:*
Prozentanteil Promyelozyten, Differentialblutbild*
Datum:*
Prozentanteil Myelozyten*
Datum:*
Prozentanteil Metamyelozyten*
Datum:*
Klinische Chemie
Kreatinin [mg/dl]*
Datum:*
Kreatinin [umol/l]*
Datum:*
Bilirubin [mg/dl]*
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Datum:*
Bilirubin [umol/l]*
Datum:*
AP [umol/s*l]*
Datum:*
AP [U/l]*
Datum:*
GOT/ASAT [umol/s*l]*
Datum:*
GOT/ASAT [U/l]*
Datum:*
GPT/ALAT [umol/s*l]*
Datum:*
GPT/ALAT [U/l]*
Datum:*
LDH [umol/s*l]*
Datum:*
LDH [U/l]*
Datum:*
Gesamteiweiß [g/l]*
Datum:*
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Diagnostik
KM-Morphologie durchgeführt?*
Ja
Nein
(wenn ja:) Datum*
(wenn nein:) Grund*
Labor*
Zytogenetik durchgeführt?*
Ja
Nein
(wenn ja:) Datum*
(wenn nein:) Grund*
Labor*
Immunphänotypisierung durchgeführt? (inkl.
CD56)*
Ja
Nein
(wenn ja:) Datum*
(wenn nein:) Grund*
Labor*
Molekulardiagnostik durchgeführt?*
Ja
Nein
(wenn ja:) Datum*
(wenn nein:) Grund*
Labor*
FLT3:*
negativ (1)
positiv (2)
nicht auswertbar (3)
unbekannt (4)
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Diagnostik vor Therapiebeginn CRF AML2003 AML
FLT3-ratio:*
Unterschrift
Datum:*
Name des Studienarztes/Unterschrift*
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Diagnostik vor Therapiebeginn CRF AML2003 AML
nach 1. Induktionstherapie CRF AML2003
AML
Prospektive, randomisierte, multizentrische
Therapieoptimierungsstudie - Studienprotokoll AML2003
http://www.clinicaltrials.gov/ct2/show/NCT00180102
All rights reserved. Please visit https://medical-data-
models.org/forms/4053
nach 1. Induktionstherapie
Allgemeine Angaben
Klinik-Nr.:*
Patienten-Nr.: 2-*
Patienten-Initialen: (Nachname/Vorname)*
Materialversand an Studienzentrale
mind. 10 ml heparinisiertes KM*
Ja
Nein
Datum*
mind. 40 ml heparinisiertes pB*
Ja
Nein
Datum*
5 ungefärbte KM-Ausstriche*
Ja
Nein
Datum*
5 ungefärbte pB-Ausstriche*
Ja
Nein
Datum*
Blutbild
Leukozyten [GPt/l]*
Datum:*
Leukozyten [/ul]*
Datum:*
Hämoglobin [mmol/l]*
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Datum:*
Hämoglobin [g/dl]*
Datum:*
Thrombozyten [GPt/l]*
Datum:*
Thrombozyten [/ul]*
Datum:*
Differentialblutbild
Datum Diff.-Blutbild*
Prozentanteil Neutrophile *
Prozentanteil Segmentkernige *
Prozentanteil Stabkernige *
Prozentanteil Lymphozyten *
Prozentanteil Monozyten*
Prozentanteil Eosinophile *
Prozentanteil Basophile *
Prozentanteil Myeloblasten*
Prozentanteil Promyelozyten, Differentialblutbild*
Prozentanteil Myelozyten*
Prozentanteil Metamyelozyten*
Klinische Chemie
Datum Klinische Chemie:*
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Kreatinin [mg/dl]*
Kreatinin [umol/l]*
Bilirubin [mg/dl]*
Bilirubin [umol/l]*
AP [umol/s*l]*
AP [U/l]*
GOT/ASAT [umol/s*l]*
GOT/ASAT [U/l]*
GPT/ALAT [umol/s*l]*
GPT/ALAT [U/l]*
LDH [umol/s*l]*
LDH [U/l]*
Gesamteiweiß [g/l]*
Knochenmark-Morphologie
KM-Morphologie durchgeführt?*
Ja
Nein
(wenn ja:) Datum*
(wenn nein:) Grund*
prozentualer Blastenanteil im KM*
Labor*
Beurteilung des Therapieerfolges:
Beurteilung des Therapieerfolges:*
Ansprechen (1)
kein Ansprechen (Therapieversagen) (2)
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nach 1. Induktionstherapie CRF AML2003 AML
in Aplasie  (3)
früher Todesfall (4)
keine Beurteilung möglich (5)
Grund*
Unterschrift
Datum*
Name des Studienarztes/Unterschrift*
Allgemeine Angaben
Klinik-Nr.:*
Patienten-Nr.: 2-*
Patienten-Initialen: (Nachname/Vorname)*
Risikogruppeneinteilung: (Nur für
Patienten der Randomisationsarme B und
D auszufüllen!)
Niedrigrisiko*
t(8;21) (1)
inv(16) (2)
t(16;16) (3)
Hochrisiko*
-5 (1)
t(3;3) (10)
t(11;19)(q23;p13.1) (11)
t(6;11) (12)
del(5q) (2)
+8 als Einzelaberration (3)
+8 mit einer weiteren Aberration (außer
t(9;11)) (4)
multiple Aberrationen (>= 3 unabhängige
Aberrationen) (5)
Blastenanteil im KM d15 >10% (6)
FLT3-ratio > 0,8 (7)
-7 (8)
t(6;9) (9)
Spender vorhanden?*
ja (1)
Familienspender (2)
Fremdspender (3)
nein (4)
unbekannt (5)
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Zur SZT angemeldet?*
ja (in Aplasie) (1)
nein (2)
unbekannt (3)
SZT-Zentrum:*
2. Induktionstherapie Arm B
DA (Arm B)*
DA P1 - Niedrigrisiko (1)
DA P1 - Standardrisiko (2)
DA P2 - Standardrisiko (3)
DA P3 - Standardrisiko (4)
DA P2 - Hochrisiko (5)
DA P3 - Hochrisiko (6)
DA P4 - Hochrisiko (7)
2. Induktionstherapie Arm D
DA (Arm D)*
DA P1 - Niedrigrisiko (1)
DA P1 - Standardrisiko (2)
DA P2 - Standardrisiko (3)
DA P3 - Standardrisiko (4)
DA P2 - Hochrisiko (5)
DA P3 - Hochrisiko (6)
DA P4 - Hochrisiko (7)
2. Induktionstherapie Arm A and C
DA (Arm A und C)*
DA t(8;21) (1)
DA ohne t(8;21), kein komplexer
Karyotyp, mit FamSpender (2)
DA ohne t(8;21), kein komplexer
Karyotyp, ohne FamSpender (3)
DA komplexer Karyotyp, mit
FamSpender (4)
DA komplexer Karyotyp, mit
FremdSpender (5)
DA komplexer Karyotyp, ohne Spender
(6)
Unterschrift
Datum*
Name des Studienarztes/Unterschrift*
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nach 1. Induktionstherapie CRF AML2003 AML
quality management ADT-autopsy cancer
base-dataset from ADT - autopsy, ODM derived from
http://www.tumorzentren.de/tl_files/dokumente/adt_basis.p
df
All rights reserved. Please visit https://medical-data-
models.org/forms/4054
quality management
Patient data
Patientennummer*
Krankenkasse*
Patienten-Telefonnummer*
Patienten-Nachname*
Geburtsname*
Patienten-Vorname*
Patienten-Geschlecht*
männlich (männlich)
weiblich (weiblich)
Patienten-Geburtsdatum*
Nationalität/Staatsangehörigkeit*
Patientenadresse
Straße*
Postleitzahl Patient*
Wohnort*
Autopsie
Datum der Autopsie*
TNM-Klassifikation
Tumorstaging-Symbole*
neoadjuvanter Therapie (y) (nach
Neoadjuvanter Therapie (y))
rezidiv Stadium (r)  (Rezidiv)
T-Stadium*
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N - Stadium der regionalen Lymphknoten*
M- Stadium*
Ann Arbor Klassifikation*
Sonstige Klassifikation*
Stadium*
Klartext Stadium/Klassifikation*
Tumorhistologie
Pathologisches Institut*
Datum Pathologie Befund*
Histologie-Code ICD-0-3*
Histologisches Grading*
Anzahl der untersuchten Lymphknoten*
Anzahl der beteiligten Lymphknoten *
Lymphgefäßinvasion
Lymphgefäßinvasion*
L0 = keine Lymphgefäßinvasion (L0 =
keine Lymphgefäßinvasion)
L1 = Lymphgefäßinvasion (L1)
LX = nicht beurteilbar (LX = nicht
beurteilbar)
Veneninvasion
Veneninvasion*
V0 = keine Veneninvasion (V0 = keine
Veneninvasion)
V1 = mikroskopische Veneninvasion (V1)
V2 = makroskopische Veneninvasion
(V2)
VX = nicht beurteilbar (VX = nicht
beurteilbar)
Tumorausbreitung
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Primärtumor*
fragliches Ergebnis (F = Fraglicher
Befund)
kein Nachweis des Tumors (K = Kein
Tumornachweis)
Rezidiv (R = Rezidiv)
Tumor vorhanden (T = Tumornachweis)
Unbekannt (x = unbekannt)
Metastase in regionären Lymphknoten*
fragliches Ergebnis (F = Fraglicher
Befund)
kein Nachweis des Tumors (K = Kein
Tumornachweis)
Rezidiv (R = Rezidiv)
Tumor vorhanden (T = Tumornachweis)
Unbekannt (x = unbekannt)
Fernmetastasen
Fernmetastasen*
Ja
Nein
Metastase in Fern - Lymphknoten*
fragliches Ergebnis (F = Fraglicher
Befund)
kein Nachweis des Tumors (K = Kein
Tumornachweis)
Rezidiv (R = Rezidiv)
Tumor vorhanden (T = Tumornachweis)
Unbekannt (x = unbekannt)
Metastase in der Lunge*
fragliches Ergebnis (F = Fraglicher
Befund)
kein Nachweis des Tumors (K = Kein
Tumornachweis)
Rezidiv (R = Rezidiv)
Tumor vorhanden (T = Tumornachweis)
Unbekannt (x = unbekannt)
Metastase in der Leber*
fragliches Ergebnis (F = Fraglicher
Befund)
kein Nachweis des Tumors (K = Kein
Tumornachweis)
Rezidiv (R = Rezidiv)
Tumor vorhanden (T = Tumornachweis)
Unbekannt (x = unbekannt)
Metastase im Gehirn*
fragliches Ergebnis (F = Fraglicher
Befund)
kein Nachweis des Tumors (K = Kein
Tumornachweis)
Rezidiv (R = Rezidiv)
Tumor vorhanden (T = Tumornachweis)
Unbekannt (x = unbekannt)
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Metastase in der Pleura*
fragliches Ergebnis (F = Fraglicher
Befund)
kein Nachweis des Tumors (K = Kein
Tumornachweis)
Rezidiv (R = Rezidiv)
Tumor vorhanden (T = Tumornachweis)
Unbekannt (x = unbekannt)
Metastase in der Haut*
fragliches Ergebnis (F = Fraglicher
Befund)
kein Nachweis des Tumors (K = Kein
Tumornachweis)
Rezidiv (R = Rezidiv)
Tumor vorhanden (T = Tumornachweis)
Unbekannt (x = unbekannt)
Metastase in den Knochen*
fragliches Ergebnis (F = Fraglicher
Befund)
kein Nachweis des Tumors (K = Kein
Tumornachweis)
Rezidiv (R = Rezidiv)
Tumor vorhanden (T = Tumornachweis)
Unbekannt (x = unbekannt)
Metastase in der Nebenniere*
fragliches Ergebnis (F = Fraglicher
Befund)
kein Nachweis des Tumors (K = Kein
Tumornachweis)
Rezidiv (R = Rezidiv)
Tumor vorhanden (T = Tumornachweis)
Unbekannt (x = unbekannt)
Metastase im Peritoneum*
fragliches Ergebnis (F = Fraglicher
Befund)
kein Nachweis des Tumors (K = Kein
Tumornachweis)
Rezidiv (R = Rezidiv)
Tumor vorhanden (T = Tumornachweis)
Unbekannt (x = unbekannt)
Metastase in der Milz*
fragliches Ergebnis (F = Fraglicher
Befund)
kein Nachweis des Tumors (K = Kein
Tumornachweis)
Rezidiv (R = Rezidiv)
Tumor vorhanden (T = Tumornachweis)
Unbekannt (x = unbekannt)
Metastase im Ovar*
fragliches Ergebnis (F = Fraglicher
Befund)
kein Nachweis des Tumors (K = Kein
Tumornachweis)
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Rezidiv (R = Rezidiv)
Tumor vorhanden (T = Tumornachweis)
Unbekannt (x = unbekannt)
Metastase im Knochenmark*
fragliches Ergebnis (F = Fraglicher
Befund)
kein Nachweis des Tumors (K = Kein
Tumornachweis)
Rezidiv (R = Rezidiv)
Tumor vorhanden (T = Tumornachweis)
Unbekannt (x = unbekannt)
Fernmestastase (andere Organe)*
fragliches Ergebnis (F = Fraglicher
Befund)
kein Nachweis des Tumors (K = Kein
Tumornachweis)
Rezidiv (R = Rezidiv)
Tumor vorhanden (T = Tumornachweis)
Unbekannt (x = unbekannt)
anderes Organ, welches?*
Datum der Arzt-Unterschrift*
Arzt-Unterschrift*
Datum der Dokumentar-Unterschrift*
Dokumentar-Unterschrift*
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quality management ADT-dataset breast
cancer breast cancer
ADT - specific dataset for breast cancer, add for base-
dataset, ODM derived from
http://www.tumorzentren.de/tl_files/dokumente/Module%20
zum%20Basisdatensatz/Anlage_2_Organspezifischer_DS_
Mamma_Aufnahme%20BIRADS_24.04.2012.pdf
All rights reserved. Please visit https://medical-data-
models.org/forms/4056
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Patient data
Patientennummer*
Krankenkasse*
Patienten-Telefonnummer*
Patienten-Nachname*
Geburtsname*
Patienten-Vorname*
Patienten-Geschlecht*
männlich (männlich)
weiblich (weiblich)
Patienten-Geburtsdatum*
Nationalität/Staatsangehörigkeit*
Patientenadresse
Straße*
Postleitzahl Patient*
Wohnort*
Brust
Tastbarer Mamma-Befund*
Ja (Ja)
Nein (Nein)
keine Angabe (Unbekannt)
Prä-Biopsie Drahtmarkierung*
Mammographie (Mammographie)
Kernspintomographie (MRT)
Sonographie (Sonographie)
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Intraoperatives Präparatröntgen*
Ja (Ja)
Nein (Nein)
keine Angabe (Unbekannt)
Tumorgröße*
Abstand vom Resektionsrand*
Abstand des Tumors vom nächstgelegenen
Rand*
Grading nach Elston und Ellis*
Hormonrezeptoren
Östrogen-Rezeptor*
negativ (negativ)
positiv (positiv)
Progesteron-Rezeptor*
negativ (negativ)
positiv (positiv)
MammaCa
Her-2/neu*
negativ (negativ)
positiv (positiv)
Ki-67 Antigen *
Tumorproteasen
Plasminogen Activator Inhibitor 1 *
Urokinase*
MammaCa
Menopausenstatus*
Prämenopause (1 = Prämenopausal)
Perimenopause (2 = Perimenopausal)
Postmenopause (3 = Postmenopausal)
unbekannter Menopausen-Status (4 =
Unbekannt)
Strahlentherapie - Technik*
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klinische Studie*
Ja
Nein
Revisionsoperation*
Ja
Nein
Psychoonkologie*
Ja
Nein
Sozialdienst*
Ja
Nein
Tumorkonferenz*
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quality management ADT-systemic therapy
cancer
base-dataset from ADT - systemic therapy, ODM derived
from
http://www.tumorzentren.de/tl_files/dokumente/adt_basis.p
df
All rights reserved. Please visit https://medical-data-
models.org/forms/4057
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Patient data
Patientennummer*
Krankenkasse*
Patienten-Telefonnummer*
Patienten-Nachname*
Geburtsname*
Patienten-Vorname*
Patienten-Geschlecht*
männlich (männlich)
weiblich (weiblich)
Patienten-Geburtsdatum*
Nationalität/Staatsangehörigkeit*
Patientenadresse
Straße*
Postleitzahl Patient*
Wohnort*
Therapieart
Chemotherapie*
Ja
Nein
Hormon- / endokrine Therapie*
Ja
Nein
Immuntherapie*
Ja
Nein
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Intention - Chemotherapie*
Adjuvant (adjuvant)
Kurativ (kurativ)
Neoadjuvant (neoadjuvant)
Palliativ (palliativ)
Intention - endokrine Therapie*
Adjuvant (adjuvant)
Kurativ (kurativ)
Neoadjuvant (neoadjuvant)
Palliativ (palliativ)
Intention - Immuntherapie*
Adjuvant (adjuvant)
Kurativ (kurativ)
Neoadjuvant (neoadjuvant)
Palliativ (palliativ)
Therapeutic procedure
Protokoll*
Zyklen geplant*
Zyklen durchgeführt*
Datum Therapiebeginn - Chemotherapie*
Datum Therapiebeginn - endokrine Therapie*
Datum Therapiebeginn - Immuntherapie*
Chemotherapie Substanz*
Dosislevel der Chemotherapie reduziert*
Ja
Nein
Einzeldosis*
kumulative Dosis*
Einheit*
Unterbrechung der Behandlung von*
Beginn Therapie nach Unterbrechung*
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Grund für Therapieunterbrechung*
Ende der systemischen Therapie
Therapieende Chemo*
Therapieende endokrine Therape*
Therapieende Immuntherapie*
Ende der systemischen Therapie*
Abbruch wegen Nebenwirkungen
(Abbruch wegen Nebenwirkung)
Verweigerung der Therapie (Patient
verweigert Therapie)
reguläres Ende der Therapie (reguläres
Ende)
sonstige Gründe*
Therapie-Erfolg
Tumorstatus*
stable disease (keine Änderung)
nicht beurteilbar (nicht beurteilbar)
Tumor Progression (Progression)
Teilremission (Teilremission)
unbekannt (unbekannt)
Vollremission (Vollremission)
Nebenwirkungen
Nebenwirkungen*
Ja
Nein
Hämoglobin*
keine Nebenwirkungen (0 = keine
Nebenwirkungen)
leichte Nebenwirkungen (1 = Geringe
Nebenwirkungen)
mäßige Nebenwirkungen (2 =
Allgemeinbefinden verschlechtert)
starke Nebenwirkungen (3 =
Unterbrechung notwendig)
lebensbedrohliche Nebenwirkungen (4 =
Stationäre Krankenhausbehandlung
notwendig)
Nebenwirkungen unbekannt (X =
Nebenwirkung unbekannt)
Aspartat-Transaminase*
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keine Nebenwirkungen (0 = keine
Nebenwirkungen)
leichte Nebenwirkungen (1 = Geringe
Nebenwirkungen)
mäßige Nebenwirkungen (2 =
Allgemeinbefinden verschlechtert)
starke Nebenwirkungen (3 =
Unterbrechung notwendig)
lebensbedrohliche Nebenwirkungen (4 =
Stationäre Krankenhausbehandlung
notwendig)
only in connection with GPT (only in
connection with GPT)
Nebenwirkungen unbekannt (X =
Nebenwirkung unbekannt)
Alanin-Transaminase*
keine Nebenwirkungen (0 = keine
Nebenwirkungen)
leichte Nebenwirkungen (1 = Geringe
Nebenwirkungen)
mäßige Nebenwirkungen (2 =
Allgemeinbefinden verschlechtert)
starke Nebenwirkungen (3 =
Unterbrechung notwendig)
lebensbedrohliche Nebenwirkungen (4 =
Stationäre Krankenhausbehandlung
notwendig)
only in connection with GPT (only in
connection with GPT)
Nebenwirkungen unbekannt (X =
Nebenwirkung unbekannt)
Creatinine*
keine Nebenwirkungen (0 = keine
Nebenwirkungen)
leichte Nebenwirkungen (1 = Geringe
Nebenwirkungen)
mäßige Nebenwirkungen (2 =
Allgemeinbefinden verschlechtert)
starke Nebenwirkungen (3 =
Unterbrechung notwendig)
lebensbedrohliche Nebenwirkungen (4 =
Stationäre Krankenhausbehandlung
notwendig)
Nebenwirkungen unbekannt (X =
Nebenwirkung unbekannt)
Haut*
keine Nebenwirkungen (0 = keine
Nebenwirkungen)
leichte Nebenwirkungen (1 = Geringe
Nebenwirkungen)
mäßige Nebenwirkungen (2 =
Allgemeinbefinden verschlechtert)
starke Nebenwirkungen (3 =
Unterbrechung notwendig)
lebensbedrohliche Nebenwirkungen (4 =
Stationäre Krankenhausbehandlung
notwendig)
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Nebenwirkungen unbekannt (X =
Nebenwirkung unbekannt)
Peripherer Nerv*
keine Nebenwirkungen (0 = keine
Nebenwirkungen)
leichte Nebenwirkungen (1 = Geringe
Nebenwirkungen)
mäßige Nebenwirkungen (2 =
Allgemeinbefinden verschlechtert)
starke Nebenwirkungen (3 =
Unterbrechung notwendig)
lebensbedrohliche Nebenwirkungen (4 =
Stationäre Krankenhausbehandlung
notwendig)
Nebenwirkungen unbekannt (X =
Nebenwirkung unbekannt)
Blutungen*
keine Nebenwirkungen (0 = keine
Nebenwirkungen)
leichte Nebenwirkungen (1 = Geringe
Nebenwirkungen)
mäßige Nebenwirkungen (2 =
Allgemeinbefinden verschlechtert)
starke Nebenwirkungen (3 =
Unterbrechung notwendig)
lebensbedrohliche Nebenwirkungen (4 =
Stationäre Krankenhausbehandlung
notwendig)
Nebenwirkungen unbekannt (X =
Nebenwirkung unbekannt)
Bilirubin*
keine Nebenwirkungen (0 = keine
Nebenwirkungen)
leichte Nebenwirkungen (1 = Geringe
Nebenwirkungen)
mäßige Nebenwirkungen (2 =
Allgemeinbefinden verschlechtert)
starke Nebenwirkungen (3 =
Unterbrechung notwendig)
lebensbedrohliche Nebenwirkungen (4 =
Stationäre Krankenhausbehandlung
notwendig)
Nebenwirkungen unbekannt (X =
Nebenwirkung unbekannt)
Leukozyten*
keine Nebenwirkungen (0 = keine
Nebenwirkungen)
leichte Nebenwirkungen (1 = Geringe
Nebenwirkungen)
mäßige Nebenwirkungen (2 =
Allgemeinbefinden verschlechtert)
starke Nebenwirkungen (3 =
Unterbrechung notwendig)
lebensbedrohliche Nebenwirkungen (4 =
Stationäre Krankenhausbehandlung
notwendig)
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Nebenwirkungen unbekannt (X =
Nebenwirkung unbekannt)
Alkalische Phosphatase*
keine Nebenwirkungen (0 = keine
Nebenwirkungen)
leichte Nebenwirkungen (1 = Geringe
Nebenwirkungen)
mäßige Nebenwirkungen (2 =
Allgemeinbefinden verschlechtert)
starke Nebenwirkungen (3 =
Unterbrechung notwendig)
lebensbedrohliche Nebenwirkungen (4 =
Stationäre Krankenhausbehandlung
notwendig)
Nebenwirkungen unbekannt (X =
Nebenwirkung unbekannt)
Proteinurie*
keine Nebenwirkungen (0 = keine
Nebenwirkungen)
leichte Nebenwirkungen (1 = Geringe
Nebenwirkungen)
mäßige Nebenwirkungen (2 =
Allgemeinbefinden verschlechtert)
starke Nebenwirkungen (3 =
Unterbrechung notwendig)
lebensbedrohliche Nebenwirkungen (4 =
Stationäre Krankenhausbehandlung
notwendig)
Nebenwirkungen unbekannt (X =
Nebenwirkung unbekannt)
Haar*
keine Nebenwirkungen (0 = keine
Nebenwirkungen)
leichte Nebenwirkungen (1 = Geringe
Nebenwirkungen)
mäßige Nebenwirkungen (2 =
Allgemeinbefinden verschlechtert)
starke Nebenwirkungen (3 =
Unterbrechung notwendig)
lebensbedrohliche Nebenwirkungen (4 =
Stationäre Krankenhausbehandlung
notwendig)
Nebenwirkungen unbekannt (X =
Nebenwirkung unbekannt)
Obstipation*
keine Nebenwirkungen (0 = keine
Nebenwirkungen)
leichte Nebenwirkungen (1 = Geringe
Nebenwirkungen)
mäßige Nebenwirkungen (2 =
Allgemeinbefinden verschlechtert)
starke Nebenwirkungen (3 =
Unterbrechung notwendig)
lebensbedrohliche Nebenwirkungen (4 =
Stationäre Krankenhausbehandlung
notwendig)
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Nebenwirkungen unbekannt (X =
Nebenwirkung unbekannt)
Diarrhoe*
keine Nebenwirkungen (0 = keine
Nebenwirkungen)
leichte Nebenwirkungen (1 = Geringe
Nebenwirkungen)
mäßige Nebenwirkungen (2 =
Allgemeinbefinden verschlechtert)
starke Nebenwirkungen (3 =
Unterbrechung notwendig)
lebensbedrohliche Nebenwirkungen (4 =
Stationäre Krankenhausbehandlung
notwendig)
Nebenwirkungen unbekannt (X =
Nebenwirkung unbekannt)
Harnstoff*
keine Nebenwirkungen (0 = keine
Nebenwirkungen)
leichte Nebenwirkungen (1 = Geringe
Nebenwirkungen)
mäßige Nebenwirkungen (2 =
Allgemeinbefinden verschlechtert)
starke Nebenwirkungen (3 =
Unterbrechung notwendig)
lebensbedrohliche Nebenwirkungen (4 =
Stationäre Krankenhausbehandlung
notwendig)
Nebenwirkungen unbekannt (X =
Nebenwirkung unbekannt)
Granulozyten*
keine Nebenwirkungen (0 = keine
Nebenwirkungen)
leichte Nebenwirkungen (1 = Geringe
Nebenwirkungen)
mäßige Nebenwirkungen (2 =
Allgemeinbefinden verschlechtert)
starke Nebenwirkungen (3 =
Unterbrechung notwendig)
lebensbedrohliche Nebenwirkungen (4 =
Stationäre Krankenhausbehandlung
notwendig)
Nebenwirkungen unbekannt (X =
Nebenwirkung unbekannt)
Schleimhaut*
keine Nebenwirkungen (0 = keine
Nebenwirkungen)
leichte Nebenwirkungen (1 = Geringe
Nebenwirkungen)
mäßige Nebenwirkungen (2 =
Allgemeinbefinden verschlechtert)
starke Nebenwirkungen (3 =
Unterbrechung notwendig)
lebensbedrohliche Nebenwirkungen (4 =
Stationäre Krankenhausbehandlung
notwendig)
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Nebenwirkungen unbekannt (X =
Nebenwirkung unbekannt)
Hämaturie*
keine Nebenwirkungen (0 = keine
Nebenwirkungen)
leichte Nebenwirkungen (1 = Geringe
Nebenwirkungen)
mäßige Nebenwirkungen (2 =
Allgemeinbefinden verschlechtert)
starke Nebenwirkungen (3 =
Unterbrechung notwendig)
lebensbedrohliche Nebenwirkungen (4 =
Stationäre Krankenhausbehandlung
notwendig)
Nebenwirkungen unbekannt (X =
Nebenwirkung unbekannt)
Infektion*
keine Nebenwirkungen (0 = keine
Nebenwirkungen)
leichte Nebenwirkungen (1 = Geringe
Nebenwirkungen)
mäßige Nebenwirkungen (2 =
Allgemeinbefinden verschlechtert)
starke Nebenwirkungen (3 =
Unterbrechung notwendig)
lebensbedrohliche Nebenwirkungen (4 =
Stationäre Krankenhausbehandlung
notwendig)
Nebenwirkungen unbekannt (X =
Nebenwirkung unbekannt)
Schmerzen*
keine Nebenwirkungen (0 = keine
Nebenwirkungen)
leichte Nebenwirkungen (1 = Geringe
Nebenwirkungen)
mäßige Nebenwirkungen (2 =
Allgemeinbefinden verschlechtert)
starke Nebenwirkungen (3 =
Unterbrechung notwendig)
lebensbedrohliche Nebenwirkungen (4 =
Stationäre Krankenhausbehandlung
notwendig)
Nebenwirkungen unbekannt (X =
Nebenwirkung unbekannt)
Fieber*
keine Nebenwirkungen (0 = keine
Nebenwirkungen)
leichte Nebenwirkungen (1 = Geringe
Nebenwirkungen)
mäßige Nebenwirkungen (2 =
Allgemeinbefinden verschlechtert)
starke Nebenwirkungen (3 =
Unterbrechung notwendig)
lebensbedrohliche Nebenwirkungen (4 =
Stationäre Krankenhausbehandlung
notwendig)
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Nebenwirkungen unbekannt (X =
Nebenwirkung unbekannt)
Allergie*
keine Nebenwirkungen (0 = keine
Nebenwirkungen)
leichte Nebenwirkungen (1 = Geringe
Nebenwirkungen)
mäßige Nebenwirkungen (2 =
Allgemeinbefinden verschlechtert)
starke Nebenwirkungen (3 =
Unterbrechung notwendig)
lebensbedrohliche Nebenwirkungen (4 =
Stationäre Krankenhausbehandlung
notwendig)
Nebenwirkungen unbekannt (X =
Nebenwirkung unbekannt)
Thrombozyten*
keine Nebenwirkungen (0 = keine
Nebenwirkungen)
leichte Nebenwirkungen (1 = Geringe
Nebenwirkungen)
mäßige Nebenwirkungen (2 =
Allgemeinbefinden verschlechtert)
starke Nebenwirkungen (3 =
Unterbrechung notwendig)
lebensbedrohliche Nebenwirkungen (4 =
Stationäre Krankenhausbehandlung
notwendig)
Nebenwirkungen unbekannt (X =
Nebenwirkung unbekannt)
Übelkeit*
keine Nebenwirkungen (0 = keine
Nebenwirkungen)
leichte Nebenwirkungen (1 = Geringe
Nebenwirkungen)
mäßige Nebenwirkungen (2 =
Allgemeinbefinden verschlechtert)
starke Nebenwirkungen (3 =
Unterbrechung notwendig)
lebensbedrohliche Nebenwirkungen (4 =
Stationäre Krankenhausbehandlung
notwendig)
Nebenwirkungen unbekannt (X =
Nebenwirkung unbekannt)
Lunge*
keine Nebenwirkungen (0 = keine
Nebenwirkungen)
leichte Nebenwirkungen (1 = Geringe
Nebenwirkungen)
mäßige Nebenwirkungen (2 =
Allgemeinbefinden verschlechtert)
starke Nebenwirkungen (3 =
Unterbrechung notwendig)
lebensbedrohliche Nebenwirkungen (4 =
Stationäre Krankenhausbehandlung
notwendig)
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Nebenwirkungen unbekannt (X =
Nebenwirkung unbekannt)
Herzrhythmus*
keine Nebenwirkungen (0 = keine
Nebenwirkungen)
leichte Nebenwirkungen (1 = Geringe
Nebenwirkungen)
mäßige Nebenwirkungen (2 =
Allgemeinbefinden verschlechtert)
starke Nebenwirkungen (3 =
Unterbrechung notwendig)
lebensbedrohliche Nebenwirkungen (4 =
Stationäre Krankenhausbehandlung
notwendig)
Nebenwirkungen unbekannt (X =
Nebenwirkung unbekannt)
Herzfunktion*
keine Nebenwirkungen (0 = keine
Nebenwirkungen)
leichte Nebenwirkungen (1 = Geringe
Nebenwirkungen)
mäßige Nebenwirkungen (2 =
Allgemeinbefinden verschlechtert)
starke Nebenwirkungen (3 =
Unterbrechung notwendig)
lebensbedrohliche Nebenwirkungen (4 =
Stationäre Krankenhausbehandlung
notwendig)
Nebenwirkungen unbekannt (X =
Nebenwirkung unbekannt)
Perikarditis*
keine Nebenwirkungen (0 = keine
Nebenwirkungen)
leichte Nebenwirkungen (1 = Geringe
Nebenwirkungen)
mäßige Nebenwirkungen (2 =
Allgemeinbefinden verschlechtert)
starke Nebenwirkungen (3 =
Unterbrechung notwendig)
lebensbedrohliche Nebenwirkungen (4 =
Stationäre Krankenhausbehandlung
notwendig)
Nebenwirkungen unbekannt (X =
Nebenwirkung unbekannt)
Bewusstsein*
keine Nebenwirkungen (0 = keine
Nebenwirkungen)
leichte Nebenwirkungen (1 = Geringe
Nebenwirkungen)
mäßige Nebenwirkungen (2 =
Allgemeinbefinden verschlechtert)
starke Nebenwirkungen (3 =
Unterbrechung notwendig)
lebensbedrohliche Nebenwirkungen (4 =
Stationäre Krankenhausbehandlung
notwendig)
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Nebenwirkungen unbekannt (X =
Nebenwirkung unbekannt)
Strahlentherapie*
Ja
Nein
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quality management ADT-diagnosisdata
cancer
base-dataset from ADT - diagnosisdata, ODM derived from
http://www.tumorzentren.de/tl_files/dokumente/adt_basis.p
df
All rights reserved. Please visit https://medical-data-
models.org/forms/4060
quality management
Meldung Krebsregister
Einwilligung zur Meldung an das Klinische und
Epidemiologische Krebsregister*
abgelehnt (Abgelehnt)
ist nicht verfügbar (Liegt nicht vor)
ist verfügbgar (Liegt vor)
Patient data
Patientennummer*
Krankenkasse*
Patienten-Telefonnummer*
Patienten-Nachname*
Geburtsname*
Patienten-Vorname*
Patienten-Geschlecht*
männlich (männlich)
weiblich (weiblich)
Patienten-Geburtsdatum*
Nationalität/Staatsangehörigkeit*
Patientenadresse
Straße*
Postleitzahl Patient*
Wohnort*
Diagnose
Tumordiagnose*
1 / 7
Datum der Diagnose*
Diagnosesicherheit*
Postmortem-Diagnose (a = autoptisch)
Histologischer Befund (h = histologisch)
klinische Diagnose (k = klinisch)
Zytologischer Befund (z = zytologisch)
Lokalisation Tumor
Lokalisation Primärtumor*
Nebenlokalisation*
Körperseite*
beidseits (B = beidseits)
links (L = links)
Mittellinie (M = Mittellinienzone)
rechts (R = rechts)
Systemerkrankung (S =
Systemerkrankung)
unbekannt (x = unbekannt)
Tumorvorgeschichte*
Ja (Ja)
Nein (Nein)
unbekannt (unbekannt)
Tumor-Vorerkrankung*
Diagnosedatum*
Grund des Arztbesuches *
nicht näher bezeichnete Untersuchung
(A = andere Untersuchungen)
Screening (C = Screening)
Krebs-Screeninguntersuchung (F =
Krebsfrüherkennung)
Nachsorge (L =
Langzeitbetreuung/Nachsorge)
Selbstuntersuchung (S =
Selbstuntersuchung)
Tumorsymptome (T = Tumorsymptome)
unbekannt (x = unbekannt)
Chemotherapie in der Anamnese*
Ja
Nein
Strahlentherapie in der Anamnese*
Ja
Nein
Komorbidität*
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Tumorhistologie
Pathologisches Institut*
Histologie-Identifikationsnummer*
Histopathologie
Datum der Histologie*
Histologie-Code ICD-0-3*
Histologisches Grading*
Histologische Diagnose Freitext*
Anzahl der untersuchten Lymphknoten*
Anzahl der beteiligten Lymphknoten *
Anzahl der untersuchten Sentinellymphknoten*
Anzahl der beteiligten Sentinellymphknoten *
Lymphgefäßinvasion*
L0 = keine Lymphgefäßinvasion (L0 =
keine Lymphgefäßinvasion)
L1 = Lymphgefäßinvasion (L1 =
Lymphgefäßinvasion)
LX = nicht beurteilbar (LX = nicht
beurteilbar)
Veneninvasion*
V0 = keine Veneninvasion (V0 = keine
Veneninvasion)
V1 = mikroskopische Veneninvasion (V1
= mikroskopische Veneninvasion)
V2 = makroskopische Veneninvasion (V2
= makroskopische Veneninvasion)
VX = nicht beurteilbar (VX = nicht
beurteilbar)
TNM
Tumorstaging-Symbole*
neoadjuvanter Therapie (y) (nach
Neoadjuvanter Therapie (y))
klinisches TNM-Staging
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klinisches TNM-Staging*
Ja
Nein
T-Stadium*
Grad der Diagnosesicherheit des T-Stadium*
N - Stadium der regionalen Lymphknoten*
Grad der Diagnosesicherheit des N-Stadium*
M- Stadium*
Grad der Diagnosesicherheit des M-Stadium*
Pathologischer TNM
Pathologischer TNM*
Ja
Nein
pathologisch ermitteltes T-Stadium*
Ja
Nein
T-Stadium*
pathologisch ermitteltes N-Stadium*
Ja
Nein
N - Stadium der regionalen Lymphknoten*
pathologisch ermitteltes M-Stadium*
Ja
Nein
M- Stadium*
Ann Arbor Klassifikation*
anderes Staging System*
Residualklassifikation
Lokales Residualtumor Stadium LR0*
Ja
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Nein
Residualklassifikation*
Residualtumor Stadium R0 (R0 = kein
Residualtumor)
Residualtumor Stadium R1 (R1 =
mikroskopischer Residualtumor)
Residualtumor Stadium R2 (R2 =
makroskopischer Residualtumor)
Residualtumor Stadium RX (RX = nicht
beurteilbar)
Fernmetastasen
Lokalisation Fernmetastase*
Datum der Diagnose*
Lokalisation Fernmetastase*
Metastase in der Nebenniere (ADR =
Nebenniere)
Metastase im Gehirn (BRA = Hirn)
Generalisiere Metastasierung (GEN =
Generalisiere Metastasierung)
Metastase in der Leber (HEP = Leber)
Metastase im Lymphknoten (LYM =
Lymphknoten)
Metastase im Knochenmark (MAR =
Knochenmark)
Metastase in den Knochen (OSS =
Knochen)
Fernmestastase (andere Organe) (OTH
= andere Organe)
Metastase im Peritoneum (PER =
Peritoneum)
Metastase in der Pleura (PLE = Pleura)
Metastase in der Lunge (PUL = Lunge)
Metastase in der Haut (SKI = Haut)
Leistungszustand
ECOG Leistungszustand*
Vorgesehene Maßnahmen
geplantes therapeutisches Vorgehen*
Ja
Nein
Operation*
Ja
Nein
Intention*
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Kurativ (K = kurativ)
Palliativ (P = palliativ)
Bestrahlung*
Ja
Nein
Intention*
Adjuvant (A = adjuvant)
Kurativ (K = kurativ)
Neoadjuvant (N = neoadjuvant)
Palliativ (P = palliativ)
Chemotherapie*
Ja
Nein
Intention*
Adjuvant (A = adjuvant)
Kurativ (K = kurativ)
Neoadjuvant (N = neoadjuvant)
Palliativ (P = palliativ)
Hormon- / endokrine Therapie*
Ja
Nein
Intention*
Adjuvant (A = adjuvant)
Kurativ (K = kurativ)
Neoadjuvant (N = neoadjuvant)
Palliativ (P = palliativ)
Knochenmarkstransplantation*
Ja
Nein
Intention*
Adjuvant (A = adjuvant)
Kurativ (K = kurativ)
Palliativ (P = palliativ)
Hämopoetische Stammzelltransplantation*
Ja
Nein
Intention*
Adjuvant (A = adjuvant)
Kurativ (K = kurativ)
Neoadjuvant (N = neoadjuvant)
Palliativ (P = palliativ)
Immuntherapie*
Ja
Nein
Intention*
Adjuvant (A = adjuvant)
Kurativ (K = kurativ)
Neoadjuvant (N = neoadjuvant)
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Palliativ (P = palliativ)
Schmerztherapie / Schmerzmanagement*
Ja
Nein
Intention*
Kurativ (K = kurativ)
Palliativ (P = palliativ)
onkologische Psychotherapie*
Ja
Nein
supportive Theapie*
Ja
Nein
Intention*
Adjuvant (A = adjuvant)
Kurativ (K = kurativ)
Neoadjuvant (N = neoadjuvant)
Palliativ (P = palliativ)
Welche Therapie*
Administrative Daten
Wiedervorstellung für onkologische Therapie*
Ort der Wiedervorstellung*
nicht_kodiert*
Datum der Arzt-Unterschrift*
Arzt-Unterschrift*
Datum der Dokumentar-Unterschrift*
Dokumentar-Unterschrift*
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quality management ADT-final data cancer
base-dataset from ADT - final data, ODM derived from
http://www.tumorzentren.de/tl_files/dokumente/adt_basis.p
df
All rights reserved. Please visit https://medical-data-
models.org/forms/4061
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Patient data
Patientennummer*
Krankenkasse*
Patienten-Telefonnummer*
Patienten-Nachname*
Geburtsname*
Patienten-Vorname*
Patienten-Geschlecht*
männlich (männlich)
weiblich (weiblich)
Patienten-Geburtsdatum*
Nationalität/Staatsangehörigkeit*
Patientenadresse
Straße*
Postleitzahl Patient*
Wohnort*
Nachsorge
Letzter Kontakt*
Nachsorge abgeschlossen*
Ja
Nein
Letzter Kontakt - Nachsorge abgeschlossen*
Nachsorge abgebrochen*
Ja
Nein
1 / 3
Letzter Kontakt - Nachsorge abgebrochen*
Nachsorge abgebrochen*
Ja
Nein
Nachsorge nicht gewünscht*
Ja
Nein
Patient nicht erschienen*
Ja
Nein
Tumorstatus
Tumorstatus*
nicht beurteilbar (Beurteilung nicht
möglich)
stable disease (no change)
Tumor Progression (Progression)
Teilremission (Teilremission)
kein Tumor (Tumorfrei)
komplette Remission (Vollremission)
Vitalstatus*
Patient verstorben
Patient verstorben*
Ja
Nein
Todesdatum*
Todesursache*
andere Todesursache (andere
Todesursache)
Todesursache tumorbedingt
(Todesursache tumorbedingt)
fraglich Patient verstorben*
Ja
Nein
unbekannt ob Patient verstorben*
Ja
Nein
Autopsie*
Ja (J = Ja)
Nein (N = Nein)
Unbekannt (X = Unbekannt)
Datum der Arzt-Unterschrift*
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Arzt-Unterschrift*
Datum der Dokumentar-Unterschrift*
Dokumentar-Unterschrift*
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quality management ADT-dataset prostate
cancer prostate cancer
ADT - specific dataset for prostate cancer, add for base-
dataset, ODM derived from
http://www.tumorzentren.de/tl_files/dokumente/Module%20
zum%20Basisdatensatz/Ergaenzungen_organspezifischer
_DS_Prostata_24.04.2012.pdf
All rights reserved. Please visit https://medical-data-
models.org/forms/4063
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Patient data
Patientennummer*
Krankenkasse*
Patienten-Telefonnummer*
Patienten-Nachname*
Geburtsname*
Patienten-Vorname*
Patienten-Geschlecht*
männlich (männlich)
weiblich (weiblich)
Patienten-Geburtsdatum*
Nationalität/Staatsangehörigkeit*
Patientenadresse
Straße*
Postleitzahl Patient*
Wohnort*
Prostata
Gleason-Score
vorangiges Gleason-Muster*
zweithäufigstes Gleason-Muster*
Gesamt-Gleason-Score*
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Perineurale Invasion*
keine perineurale Invasion (PN0 = keine
perineurale Invasion)
perineurale Invasion (Pn1 =  perineurale
Invasion)
nicht beurteilbar (PNx = nicht
beurteilbar)
Revisionsoperation*
Ja (1 = ja)
Nein (2 = nein)
keine Angabe (3 = keine Angabe)
Tumorkonferenz*
Fallbesprechung*
Ja (1 = ja)
Nein (2 = nein)
keine Angabe (3 = keine Angabe)
Lebensqualität*
keine Angabe (keine Angabe)
vorhanden (vorhanden)
Gesundheitszustand*
keine Angabe (keine Angabe)
vorhanden (vorhanden)
Internationaler Index für erektile Funktion*
ICIQ-Summenscore (SF 2004)*
Active surveillance *
Ja (1 = ja)
Nein (2 = nein)
keine Angabe (3 = keine Angabe)
Ja, von - bis (4 = Ja, wenn Ja Angabe
von - bis)
Beginn Active surveillance*
Ende Active surveillance*
Watchful Waiting*
Ja (1 = ja)
Nein (2 = nein)
keine Angabe (3 = keine Angabe)
Ja, von - bis (4 = Ja, wenn Ja Angabe
von - bis)
Beginn Watchful Waiting*
Ende Watchful Waiting*
Strahlentherapie - Technik*
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Interne Radiotherapie - permanente
Seeds (Permanente Seedimplantation)
Interne Radiotherapie - permanente Seeds*
Ja (1 = ja)
Nein (2 = nein)
keine Angabe (3 = keine Angabe)
D90 > 130 Gy erreicht?*
Ja (1 = ja)
Nein (2 = nein)
keine Angabe (3 = keine Angabe)
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quality management ADT-radiotherapy
cancer
base-dataset from ADT - radiotherapy, ODM derived from
http://www.tumorzentren.de/tl_files/dokumente/adt_basis.p
df
All rights reserved. Please visit https://medical-data-
models.org/forms/4064
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Patient data
Patientennummer*
Krankenkasse*
Patienten-Telefonnummer*
Patienten-Nachname*
Geburtsname*
Patienten-Vorname*
Patienten-Geschlecht*
männlich (männlich)
weiblich (weiblich)
Patienten-Geburtsdatum*
Nationalität/Staatsangehörigkeit*
Patientenadresse
Straße*
Postleitzahl Patient*
Wohnort*
Strahlentherapie
Zielorgane*
Strahlentherapie - Technik*
Afterloading (A = afterloading)
Interne Radiotherapie - permanente
Seeds (I = Interstitielle Kontakttherapie)
Intrakavitäre Radiotherapie (K =
endokavitäare Kontakttherapie)
Interne metabolische Therapie (M =
Metabolische Therapie (radionuclide))
Brachytherapy (P = Percutan
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(Brachytherapie))
Tele-Radiotherapie (P = Percutan
(Teletherapie))
Beginn Strahlentherapie*
Ende Strahlentherapie*
Gesamtdosis*
Intention*
Adjuvant (adjuvant)
Kurativ (kurativ)
Neoadjuvant (neoadjuvant)
Palliativ (palliativ)
Beendigung der Strahlentherapie*
Abbruch wegen Nebenwirkungen
(Abbruch wegen Nebenwirkungen)
Verweigerung der Therapie (Pat. verw.
Therapie)
reguläres Ende der Therapie (reguläres
Ende)
Nebenwirkungen nach CTC
Nebenwirkungen*
Ja
Nein
Laborwerte*
keine Nebenwirkungen (0 = keine)
leichte Nebenwirkungen (1 =
gering/leicht)
mäßige Nebenwirkungen (2 =
mäßig/deutlich)
starke Nebenwirkungen (3 =
stark/ausgeprägt)
lebensbedrohliche Nebenwirkungen (4 =
lebensbedrohlich)
Nebenwirkungen unbekannt (X =
Nebenwirkungen unbekannt)
Urogenital-System*
keine Nebenwirkungen (0 = keine)
leichte Nebenwirkungen (1 =
gering/leicht)
mäßige Nebenwirkungen (2 =
mäßig/deutlich)
starke Nebenwirkungen (3 =
stark/ausgeprägt)
lebensbedrohliche Nebenwirkungen (4 =
lebensbedrohlich)
Nebenwirkungen unbekannt (X =
Nebenwirkungen unbekannt)
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Haut*
keine Nebenwirkungen (0 = keine)
leichte Nebenwirkungen (1 =
gering/leicht)
mäßige Nebenwirkungen (2 =
mäßig/deutlich)
starke Nebenwirkungen (3 =
stark/ausgeprägt)
lebensbedrohliche Nebenwirkungen (4 =
lebensbedrohlich)
only in connection with Allergy (only in
connection with Allergy)
Nebenwirkungen unbekannt (X =
Nebenwirkungen unbekannt)
Allergie*
keine Nebenwirkungen (0 = keine)
leichte Nebenwirkungen (1 =
gering/leicht)
mäßige Nebenwirkungen (2 =
mäßig/deutlich)
starke Nebenwirkungen (3 =
stark/ausgeprägt)
lebensbedrohliche Nebenwirkungen (4 =
lebensbedrohlich)
only in connection with Skin (only in
connection with Skin)
Nebenwirkungen unbekannt (X =
Nebenwirkungen unbekannt)
Gastrointestinaltrakt*
keine Nebenwirkungen (0 = keine)
leichte Nebenwirkungen (1 =
gering/leicht)
mäßige Nebenwirkungen (2 =
mäßig/deutlich)
starke Nebenwirkungen (3 =
stark/ausgeprägt)
lebensbedrohliche Nebenwirkungen (4 =
lebensbedrohlich)
Nebenwirkungen unbekannt (X =
Nebenwirkungen unbekannt)
Nervensystem*
keine Nebenwirkungen (0 = keine)
leichte Nebenwirkungen (1 =
gering/leicht)
mäßige Nebenwirkungen (2 =
mäßig/deutlich)
starke Nebenwirkungen (3 =
stark/ausgeprägt)
lebensbedrohliche Nebenwirkungen (4 =
lebensbedrohlich)
Nebenwirkungen unbekannt (X =
Nebenwirkungen unbekannt)
Fieber*
keine Nebenwirkungen (0 = keine)
leichte Nebenwirkungen (1 =
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gering/leicht)
mäßige Nebenwirkungen (2 =
mäßig/deutlich)
starke Nebenwirkungen (3 =
stark/ausgeprägt)
lebensbedrohliche Nebenwirkungen (4 =
lebensbedrohlich)
only in connection with Infection (only in
connection with Infection)
Nebenwirkungen unbekannt (X =
Nebenwirkungen unbekannt)
Infektion*
keine Nebenwirkungen (0 = keine)
leichte Nebenwirkungen (1 =
gering/leicht)
mäßige Nebenwirkungen (2 =
mäßig/deutlich)
starke Nebenwirkungen (3 =
stark/ausgeprägt)
lebensbedrohliche Nebenwirkungen (4 =
lebensbedrohlich)
only in connection with fever (only in
connection with fever)
Nebenwirkungen unbekannt (X =
Nebenwirkungen unbekannt)
Systemischer Kreislauf*
keine Nebenwirkungen (0 = keine)
leichte Nebenwirkungen (1 =
gering/leicht)
mäßige Nebenwirkungen (2 =
mäßig/deutlich)
starke Nebenwirkungen (3 =
stark/ausgeprägt)
lebensbedrohliche Nebenwirkungen (4 =
lebensbedrohlich)
Nebenwirkungen unbekannt (X =
Nebenwirkungen unbekannt)
Sinnesorgane*
keine Nebenwirkungen (0 = keine)
leichte Nebenwirkungen (1 =
gering/leicht)
mäßige Nebenwirkungen (2 =
mäßig/deutlich)
starke Nebenwirkungen (3 =
stark/ausgeprägt)
lebensbedrohliche Nebenwirkungen (4 =
lebensbedrohlich)
Nebenwirkungen unbekannt (X =
Nebenwirkungen unbekannt)
Allgemeinsymptome*
keine Nebenwirkungen (0 = keine)
leichte Nebenwirkungen (1 =
gering/leicht)
mäßige Nebenwirkungen (2 =
mäßig/deutlich)
starke Nebenwirkungen (3 =
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stark/ausgeprägt)
lebensbedrohliche Nebenwirkungen (4 =
lebensbedrohlich)
Nebenwirkungen unbekannt (X =
Nebenwirkungen unbekannt)
Lunge/Kehlkopf*
keine Nebenwirkungen (0 = keine)
leichte Nebenwirkungen (1 =
gering/leicht)
mäßige Nebenwirkungen (2 =
mäßig/deutlich)
starke Nebenwirkungen (3 =
stark/ausgeprägt)
lebensbedrohliche Nebenwirkungen (4 =
lebensbedrohlich)
Nebenwirkungen unbekannt (X =
Nebenwirkungen unbekannt)
Endokrines System*
keine Nebenwirkungen (0 = keine)
leichte Nebenwirkungen (1 =
gering/leicht)
mäßige Nebenwirkungen (2 =
mäßig/deutlich)
starke Nebenwirkungen (3 =
stark/ausgeprägt)
lebensbedrohliche Nebenwirkungen (4 =
lebensbedrohlich)
Nebenwirkungen unbekannt (X =
Nebenwirkungen unbekannt)
Allgemeinzustand*
keine Nebenwirkungen (0 = keine)
leichte Nebenwirkungen (1 =
gering/leicht)
mäßige Nebenwirkungen (2 =
mäßig/deutlich)
starke Nebenwirkungen (3 =
stark/ausgeprägt)
lebensbedrohliche Nebenwirkungen (4 =
lebensbedrohlich)
Nebenwirkungen unbekannt (X =
Nebenwirkungen unbekannt)
andere Nebenwirkung*
keine Nebenwirkungen (0 = keine)
leichte Nebenwirkungen (1 =
gering/leicht)
mäßige Nebenwirkungen (2 =
mäßig/deutlich)
starke Nebenwirkungen (3 =
stark/ausgeprägt)
lebensbedrohliche Nebenwirkungen (4 =
lebensbedrohlich)
Nebenwirkungen unbekannt (X =
Nebenwirkungen unbekannt)
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base-dataset from ADT - surgery, ODM derived from
http://www.tumorzentren.de/tl_files/dokumente/adt_basis.p
df
All rights reserved. Please visit https://medical-data-
models.org/forms/4065
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Patient data
Patientennummer*
Krankenkasse*
Patienten-Telefonnummer*
Patienten-Nachname*
Geburtsname*
Patienten-Vorname*
Patienten-Geschlecht*
männlich (männlich)
weiblich (weiblich)
Patienten-Geburtsdatum*
Nationalität/Staatsangehörigkeit*
Patientenadresse
Straße*
Postleitzahl Patient*
Wohnort*
Sicherung der Tumordiagnose
Mikroskopische Sicherung vor Operation*
Ja
Nein
Diagnosesicherheit*
histologisch (H = Ja, Histologie)
keine Mikroskopische Sicherung (K =
Keine mikroskopische Sicherung der
Malignität)
unbekannt (X = unbekannt)
zytologisch (Z = Ja, Zytologie)
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Operationen
OP-Bezeichnung*
OP-Datum*
Intention*
diagnostisch (D = Diagnostisch)
Kurativ (K = Kurativ)
Palliativ (P = Palliativ)
Chirurgische und medizinische Prozeduren*
Erster Operateur*
intraoperative Komplikationen
intraoperative Komplikationen*
Ja
Nein
Welche intraoperative Komplikation*
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quality management AQUA breast surgery
breast cancer
quality management forms, with friendly permission,
(http://www.sqg.de/downloads/2013/SR3/Dokumentationsb
oegen/18-1.pdf) AQUA - Institut für angewandte
Qualitätsförderung
und Forschung im Gesundheitswesen GmbH
All rights reserved. Please visit https://medical-data-
models.org/forms/4066
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Mammachirurgie
Basis
Identifikationsnummer der Meldequelle*
nicht_sinnvoll_für_Untersuchung*
Institution*
Identifikationsnummer der Patientin*
Patienten-Geburtsdatum*
Patienten-Geschlecht*
männlich (1 = männlich)
weiblich (2 = weiblich)
Aufnahmedatum*
Aufnahmediagnose*
ASA*
ASA Status 1 (1)
ASA Status 2 (2)
ASA Status 3 (3)
ASA Status 4 (4)
ASA Status 5 (5)
Brust
Körperseite*
rechts (1 = rechts)
links (2 = links)
Stadium*
Primärtumor (1 = Primärerkrankung)
lokal-rezidiviert (2 = lokoregionäres
Rezidiv nach BET)
lokal-rezidiviert (3 = lokoregionäres
Rezidiv nach Mastektomie)
Erste Operation - Primärtumor*
Ja
Nein
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Tastbarer Mamma-Befund*
Ja
Nein
Grund des Arztbesuches *
Krebs-Screeninguntersuchung
(Früherkennung)
Ja (ja)
Screening (Mammografie-Screening)
Nachsorge (Nachsorge)
Nein (nein)
Selbstuntersuchung
(Selbstuntersuchung)
nicht näher bezeichnete Untersuchung
(sonstiges)
Tumorsymptome (Tumorsymptomatik)
prätherapeutischer histologischer Befund*
Ja
Nein
Histologie*
normales Brustgewebe (1 = nicht
verwertbar oder ausschließlich
Normalgewebe)
benigne (2 = benigne / entzündliche
Veränderung)
unklar ob benigne oder maligne (3 =
benigne, aber mit unsicherem
biologischem Potential)
Malignitätsverdacht (4 =
malignitätsverdächtig)
DCIS (B5a)
Invasive Karzinom (B5b)
Tumor Invasion kann nicht beurteilt
werden (B5c)
anderer Tumor (B5d)
Histologie-Code ICD-0-3*
Datum Pathologie Befund*
Tumorkonferenz*
prätherapeutisch (prätherapeutisch)
Datum der Konferenz*
präoperative Therapie*
Hormon- / endokrine Therapie
(endokrine Therapie)
sonstige Therapie (sonstige)
Immuntherapie (spezifische
Antikörpertherapie)
Bestrahlung (Strahlentherapie)
Chemotherapie (systemische
Chemotherapie)
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Operation
Anzahl Operationen*
Prä-Biopsie Drahtmarkierung*
Mammographie (Mammographie )
Kernspintomographie (MRT)
Sonographie (Sonographie)
Intraoperatives Präparatröntgen*
Ja
Nein
Datum der OP*
Chirurgische und medizinische Prozeduren*
Sentinel Lymphknoten Biopsie*
Ja
Nein
Antibiotikaprophylaxe*
Ja
Nein
Komplikation
postoperative Komplikationen mit operativer
Revision*
Ja
Nein
postoperative Wundinfektion*
Ja
Nein
Hämatom*
Ja
Nein
Serom*
Ja
Nein
Sonstiges*
Ja
Nein
Histologie*
normales Brustgewebe (ausschließlich
Normalgewebe)
Malignitätsverdacht (B4)
DCIS (B5a)
Invasive Karzinom (B5b)
Tumor Invasion kann nicht beurteilt
werden (B5c)
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anderer Tumor (B5d)
benigne (benigne / entzündliche
Veränderung)
unklar ob benigne oder maligne
(Risikoläsion)
Histologie-Code ICD-0-3*
abgeschlossene Primärtherapie*
Ja
Nein
andere Empfehlung*
Ja
Nein
Revisionsoperation*
Ja
Nein
Mastektomie*
Ja
Nein
Sentinel Lymphknoten Biopsie*
Ja
Nein
Axilladissektion*
Ja
Nein
Brusterhaltende Therapie*
Ja
Nein
pathologisches Stadium
pathologisches Stadium*
Ja
Nein
pT Stadium*
pN Stadium*
Anzahl der untersuchten Lymphknoten*
Anzahl der untersuchten Lymphknoten*
Ja
Nein
Histologisches Grading*
G1 (G1)
G2 (G2)
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G3 (G3)
X = Differenzierungsgrad kann nicht
bestimmt werden (GX)
Tumorgröße*
Östrogen-Rezeptor*
negativ (negativ)
only_in_connection_with_ER
(only_in_connection_with_ER)
positiv (positiv)
schwach positiv (schwach positiv)
unbekannt (unbekannt)
Progesteron-Rezeptor*
negativ (negativ)
only_in_connection_with_ER
(only_in_connection_with_ER)
positiv (positiv)
schwach positiv (schwach positiv)
unbekannt (unbekannt)
Her-2/neu*
negativ (0 = negativ)
positiv (1 = positiv)
unbekannt (9 = unbekannt)
multilokulär*
Ja
Nein
Abstand des Tumors vom nächstgelegenen
Rand*
Nein (0 = nein)
Ja (1 = ja)
Vollremission - neoadjuvante Therape (2
= Vollremission nach neoadjuvanter
Therapie)
Abstand des Tumors vom nächstgelegenen
Rand*
M Stadium*
Therapie
brusterhaltende Therapie (BET)*
Nein (0 = nein)
Ja (1 = ja)
Ja (2 = ja (auf Wunsch Patient(in) trotz
erfültter Kriterien BET))
Nein (2 = nein (auf Wunsch Patient(in)
trotz erfültter Kriterien BET))
Axilladissektion*
Ja
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Nein
Sentinel Lymphknoten Biopsie*
Ja
Nein
Markierung*
Farbmarkierung (Farbmarkierung)
Radionuklidmarkierung
(Radionuklidmarkierung)
Behandlungsverlauf Patient
postoperativ*
Ja
Nein
Tumorkonferenz*
postoperativ (postoperative)
Gespräch mit Patient über
Tumorkonferenzentscheidung*
Ja
Nein
datum Gespräch mit Patient über
Tumorkonferenzentscheidung*
Meldung Krebsregister*
Ja
Nein
Patienten Entlassung
Entlassungsdatum Krankenhaus*
Entlassungsdiagnose*
Grund für Entlassung*
nicht_sinnvoll_für_Untersuchung
(Behandlung aus sonstigen Gru ̈nden
beendet  )
reguläre Therapieende (Behandlung
regulär beendet )
nicht_sinnvoll_für_Untersuchung
(Behandlung regula ̈r beendet,
nachstationäre Behandlung vorgesehen
)
Autopsie*
Ja
Nein
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dataset CPCTR CDE Prostata Cancer
prostate cancer
with friendly permission, ODM derived from PDFs attached
to the paper:
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1236914/
All rights reserved. Please visit https://medical-data-
models.org/forms/4067
dataset
Demographie
Identifier Krankenhaus*
Patienten-Nachname*
Patienten-Vorname*
Fallnummer*
Rasse*
Afroamerikaner (African American)
Asiate (Asian)
Kaukasier (Caucasian)
Hispanoamerikaner (Hispanic)
amerikaner Ureinwohner (Native
American)
nicht verfügbar (Not available)
andere (Other)
Pazifikinsulaner (Pacific Islander)
Unbekannt (Unknown)
Kommentar andere Rasse*
Ethnische Gruppe*
Hispanoamerikanische Herkunft
(Hispanic Origin)
Unbekannt (Unknown)
Geburtstag*
Krankengeschichte
Prostatakarzinom in der Familienanamnese *
Nein (No)
Unbekannt (Unknown)
Ja (Yes)
Kommentar Familienanamnese*
Diagnosedatum / Datum des positiven Biopsie
Befunds*
Kommentar Demography*
1 / 11
Prostata-spezifisches-Antigen
Diagnostik PSA
Erhöhter PSA Wert*
Datum des erhöhten PSA Wertes*
PSA Matrix
PSA unterhalb Nachweisgrenze (<0.1)*
Ja
Nein
PSA Wert*
Datum des PSA Wert*
Kommentar zur PSA Matrix*
Histologischer Befund Prostatektomie
Datum der Prostatektomie*
Ist bei der Prostatektomie ein Residualtumor
vorhanden*
Spender (Donor)
nur High Grade PIN (HGPIN only)
Nein (No)
Unbekannt (Unknown)
Ja (Yes)
Lappen Lateralisation*
eine Seite, nur der linke Lappen (One -
left lobe only)
eine Seite, nur der rechte Lappen (One -
right lobe only)
eine Seite, nicht näher bezeichnet (One -
unspecified (laterality unknown))
zwei Seiten, bilaterale Beteiligung (Two -
bilateral involvement)
Histologischer Typ bei Prostatektomie*
Azinäres Adenokarzinom
(Adenocarcinoma NOS (aka acinar))
Basalzellkarzinom (Basal cell carcinoma)
Duktales Adenokarzinom (Ductal
adenocarcinoma)
Lymphom (Lymphoma)
Mesenchymaler Tumor (Mesenchymal
tumor (NOS))
azinär-muzinöses Prostata-
Adenokarzinom (Mucinous
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adenocarcinoma)
Neuroendokrines Karzinom
(Neuroendocrine carcinoma)
andere (Other (specify in comments))
nur PIN (PIN only)
sarkomatöses Karzinom (Sarcomatoid
carcinoma)
Siegelringzell-Karzinom (Signet ring
adenocarcinoma)
klein-zelliges anaplastisches Karzinom
(Small cell anaplastic carcinoma)
Plattenepitelkarzinom oder Adeno-
Plattenepithelkarzinom (Squamous or
adenosquamous carcinoma)
Transitional-Zell Karzinom der Prostata
(Transitional (not primary))
undifferenziertes Prostatakarzinom
(Undifferentiated non-small cell
carcinoma)
Unbekannt (Unknown)
Kommentar Histologischer Typ*
Prostatektomie: häufigstes Gleason-
Muster
häufigstes Gleason-Muster*
Gleason Muster 1 (1)
Gleason Muster 2 (2)
Gleason Muster 3 (3)
Gleason Muster 4 (4)
Gleason Muster 5 (5)
histologischer Typ*
kein Adenokarzinom (not
adenocarcinoma)
kein Primärtumor (not primary tumor)
nur PIN (PIN only)
Unbekannt (Unknown)
Prostatektomie: zweithäufigstes Gleason-
Muster
Prostatektomie: zweithäufigstes Gleason-Muster*
Gleason Muster 1 (1)
Gleason Muster 2 (2)
Gleason Muster 3 (3)
Gleason Muster 4 (4)
Gleason Muster 5 (5)
histologischer Typ*
kein Adenokarzinom (not
adenocarcinoma)
kein Primärtumor (not primary tumor)
nur PIN (PIN only)
Unbekannt (Unknown)
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Prostatektomie: Gesamt-Gleason-Score
Prostatektomie: Gesamt-Gleason-Score*
Gleason Score 10 (Gleason score 10)
Gleason Score 2 (Gleason score 2)
Gleason Score 3 (Gleason score 3)
Gleason Score 4 (Gleason score 4)
Gleason Score 5  (Gleason score 5)
Gleason Score 6  (Gleason score 6)
Gleason Score 7  (Gleason score 7)
Gleason Score 8  (Gleason score 8)
Gleason Score 9  (Gleason score 9)
histologischer Typ*
kein Adenokarzinom (not
adenocarcinoma)
kein Primärtumor (not primary tumor)
Unbekannt (Unknown)
Histological Characteristics of
Prostatectomy II
Anteil des Gleason-Musters 4/5*
Größe des vorherrschenden Tumor-Knotens*
Anteil der tumor-durchsetzten Prostata*
< 5% (< 5%)
größer als 25% (> 25%)
5 bis 25% (5 to 25%)
Unbekannt (Unknown)
multifokaler Tumor*
Nein (No)
Unbekannt (Unknown)
Ja (Yes)
High Grade Intraepitheliale Prostata Neoplasie*
nein (No)
Unbekannt (Unknown)
Ja - Anzahl der Foci unbekannt (Yes - #
of foci unknown)
nicht regionaler Focus (Yes - 1 or 2 foci
away from tumor)
regionaler Focus (Yes - 1 or 2 foci in
region of tumor)
multifokal (Yes - multifocal)
extraprostatische Ausdehnung des Tumors*
festgestellt (Established)
fokal (Focal)
multifokal (Multifocal)
keine (None)
Unbekannt (Unknown)
Infiltration der Schnittränder*
Alle Schnittränder frei von Tumor (All
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surgical margins free of tumor)
fokale Infiltration der Schnittränder
(Tumor focal at margin)
multifokal infiltrierte Schnittränder (Tumor
widespread at margin)
Unbekannt (Unknown)
Perineurale Invasion vorhanden*
Nein (No)
Unbekannt (Unknown)
Ja (Yes)
Infiltration der Samenblase vorhanden*
Nein (No)
Unbekannt (Unknown)
Ja (Yes)
Lymphatische Invasion des Tumors vorhanden*
Nein (No)
Unbekannt (Unknown)
Ja (Yes)
Kommentar Prostatektomie*
Status der regionären Lymphknoten
Datum der Lymphknoten-Exzision*
Anzahl der untersuchten Lymphknoten*
Anzahl der beteiligten Lymphknoten*
Kommentar Lymphknoten*
Extrakapsuläre Ausdehnung vorhanden?*
Nein (No)
Unbekannt (Unknown)
Ja (Yes)
Rezdivtumor
Biochemischer Rezidiv-Status*
Resttumor (Never Disease Free
(Residual tumor))
kein Rezidiv (No recurrence)
PSA Rezidiv (PSA recurrence)
Unbekannt (Unknown)
Rezidiv PSA Wert*
Datum des biochemischen Rezidivs*
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Status der Metastasierung
Ort des Fernmetastasen*
Metastase in der Harnblase (Bladder)
Circulierende Tumorzellen (Blood)
Metastase in den Knochen (Bone)
Metastase im Knochenmark (Bone
Marrow)
Metastase im Gehirn (Brain)
Lymphangitis carcinomatosa
(Carcinomatosis)
Metastase im zentralen Nervensystem
(CNS)
generalisiertes Tumorleiden
(Generalized)
Metastase in der Leber (Liver)
lokale Tumorausbreitung (Local
extension)
Metastase in der Lunge (Lung)
Metastase im Lymphknoten (Lymph
Nodes (Distant))
Metastase im Lymphknoten (Lymph
Nodes (Regional))
keine (None)
Fernmestastase (andere Organe) (Other
(NOS))
Metastase im Peritoneum (Peritoneum)
Metastase im Rektum (Rectum)
Metastase in der Haut (Skin)
Unbekannt (Unknown)
Diagnosedatum der Fernmetastase*
Kommentar Metastasierung und Rezidiv*
Staging
pathologisches Stadium
pathologisches Stadium*
Ja
Nein
pT Stadium*
pT0 (pT0)
pT1 (pT1)
pT1a (pT1a)
pT1b (pT1b)
pT1c (pT1c)
pT2 (pT2)
pT2a (pT2a)
pT2b (pT2b)
pT2c (pT2c)
pT3 (pT3)
pT3a (pT3a)
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pT3b (pT3b)
pT4 (pT4)
pTX (pTX)
pN Stadium*
pN0 (pN0)
pN1 (pN1)
pNX (pNX)
pM Stadium*
pM0 (pM0)
pM1 (pM1)
pM1a (pM1a)
pM1b (pM1b)
pM1c (pM1c)
pMX (pMX)
klinisches Stadium
klinisches Stadium*
Ja
Nein
cT Stadium*
T0 (T0)
T1 (T1)
T1a (T1a)
T1b (T1b)
T1c (T1c)
T2 (T2)
T2a (T2a)
T2b (T2b)
T2c (T2c)
T3 (T3)
T3a (T3a)
T3b (T3b)
T4 (T4)
TX (TX)
cN Stadium*
N0 (N0)
N1 (N1)
NX (NX)
cM Stadium*
M0 (M0)
M1 (M1)
M1a (M1a)
M1b (M1b)
M1c (M1c)
MX (MX)
Kommentar Staging*
Vital Status/Follow Up
Datum Vital Status*
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Todesdatum*
Vital Status*
lebend (Alive)
tot (Dead)
tot, warme Autopsie durchgeführt (Dead
with Warm Autopsy)
keine Nachuntersuchung erfolgt (Lost to
follow up)
Kommentare Vital Status*
Behandlungsverlauf Patient
Therapieart
Brachytherapy*
Ja
Nein
Chemotherapie*
Ja
Nein
Kryotherapie*
Ja
Nein
Watchful waiting*
Ja
Nein
externe Strahlentherapie*
Ja
Nein
Strahlentherapie*
Ja
Nein
Immuntherapie*
Ja
Nein
Hormon- / endokrine Therapie*
Ja
Nein
Hormonsuppressionstherapie*
Ja
Nein
alternative Therapien*
Ja
Nein
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Orchiektomie*
Ja
Nein
experimentell*
Ja
Nein
Therapie Startdatum*
Einhaltung des initialen Therapieplans*
Nein (No)
Unbekannt (Unknown)
Ja (Yes)
Kommentar Behandlungsverlauf*
Kommentar Therapie-Ansprechen*
Kommentar Therapie*
Nadelbiopsie
histologischer Typ*
Azinäres Adenokarzinom
(Adenocarcinoma NOS (aka acinar))
Basalzellkarzinom (Basal cell carcinoma)
Duktales Adenokarzinom (Ductal
adenocarcinoma)
Lymphom (Lymphoma)
Mesenchymaler Tumor (Mesenchymal
tumor (NOS))
azinär-muzinöses Prostata-
Adenokarzinom (Mucinous
adenocarcinoma)
Neuroendokrines Karzinom
(Neuroendocrine carcinoma)
andere (Other (specify in comments))
nur PIN (PIN only)
sarkomatöses Karzinom (Sacromatoid
carcinoma)
Siegelringzell-Karzinom (Signet ring
adenocarcinoma)
klein-zelliges anaplastisches Karzinom
(Small cell anaplastic carcinoma)
Plattenepitelkarzinom oder Adeno-
Plattenepithelkarzinom (Squamous or
adenosquamous carcinoma)
Transitional-Zell Karzinom der Prostata
(Transitional (not primary))
undifferenziertes Prostatakarzinom
(Undifferentiated non-small cell
carcinoma)
Unbekannt (Unknown)
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Biopsie:  häufigstes Gleason-Muster
häufigstes Gleason-Muster*
Gleason Muster 1 (1)
Gleason Muster 2 (2)
Gleason Muster 3 (3)
Gleason Muster 4 (4)
Gleason Muster 5 (5)
histologischer Typ*
kein Adenokarzinom (not
adenocarcinoma)
kein Primärtumor (not primary tumor)
nur PIN (PIN only)
Unbekannt (Unknown)
zweithäufigstes Gleason-Muster
zweithäufigstes Gleason-Muster*
Gleason Muster 1 (1)
Gleason Muster 2 (2)
Gleason Muster 3 (3)
Gleason Muster 4 (4)
Gleason Muster 5 (5)
histologischer Typ*
kein Adenokarzinom (not
adenocarcinoma)
kein Primärtumor (not primary tumor)
nur PIN (PIN only)
Unbekannt (Unknown)
Gesamt-Gleason-Score
Gesamt-Gleason-Score*
Gleason Score 10 (Gleason score 10)
Gleason Score 2 (Gleason score 2)
Gleason Score 3 (Gleason score 3)
Gleason Score 4 (Gleason score 4)
Gleason Score 5  (Gleason score 5)
Gleason Score 6  (Gleason score 6)
Gleason Score 7  (Gleason score 7)
Gleason Score 8  (Gleason score 8)
Gleason Score 9  (Gleason score 9)
histologischer Typ*
kein Adenokarzinom (not
adenocarcinoma)
kein Primärtumor (not primary tumor)
Unbekannt (Unknown)
Overall Needle Biopsy Attributes II
Anteil des Gleason-Musters 4/5*
Anteil der tumor-durchsetzten Prostata*
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< 5% (< 5%)
größer als 25% (> 25%)
5 bis 25% (5 to 25%)
Unbekannt (Unknown)
High Grade Intraepitheliale Prostata Neoplasie*
nein (No)
Unbekannt (Unknown)
Ja - Anzahl der Foci unbekannt (Yes - #
of foci unknown)
nicht regionaler Focus (Yes - 1 or 2 foci
away from tumor)
regionaler Focus (Yes - 1 or 2 foci in
region of tumor)
multifokal (Yes - multifocal)
folgende Prostatektomie*
Nein (No)
Unbekannt (Unknown)
Ja (Yes)
Kommentar folgende Prostatektomie*
Kommentar Biopsie*
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quality management Breast Center
requirements breast cancer
Breast Center requirements of the "Ärztekammer
Westfalen-Lippe" - Forms adapted from the requirement
definition cataloge for 2012 that were available at
http://www.aekwl.de/index.php?id=1788
All rights reserved. Please visit https://medical-data-
models.org/forms/4069
quality management
breast cancer
Wartezeit Sprechstunde*
Wartezeit Termin*
Zeitlicher Abstand zwischen Diagnose und
Operationsdatum*
Mikroskopische Sicherung vor Operation*
Ja
Nein
Tumor Befund*
Histologischer Befund (histologisch)
Excisionsbiopsie*
Sentinel Lymphknoten Biopsie*
Ja
Nein
Histologie*
DCIS (DCIS)
invasives lobuläre Karzinom (IL)
invasives Karzinom (invasiv)
Intraoperatives Präparatröntgen*
Ja
Nein
Brusterhaltende Therapie*
Ja
Nein
pT-Stadium*
Axilladissektion*
Ja
Nein
Anzahl der untersuchten Lymphknoten*
Residualklassifikation*
Residualtumor Stadium R0 (R0 = kein
Residualtumor)
Komplikationen*
Ja
Nein
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chirurgische Revision*
postoperative Wundinfektion*
Östrogen-Rezeptor*
negativ (negativ)
positiv (positiv)
Progesteron-Rezeptor*
negativ (negativ)
positiv (positiv)
Her-2/neu*
Abstand des Tumors vom nächstgelegenen
Rand*
Einverständniserklärung*
Bestrahlung*
Chemotherapie*
Ja
Nein
Hormon- / endokrine Therapie*
Ja
Nein
pN - Stadium der regionalen Lymphknoten*
Zustimmung Evaluation Patientenzufriedenheit*
hohe Patientenzufriedenheit*
Patienten-Geburtsdatum*
Histologie-Code ICD-0-3*
Chirurgische und medizinische Prozeduren*
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dataset minimal dataset DPKK prostate
cancer
with friendly permission, http://www.dpkk.de,
Minimaldatensatz des DPKK
All rights reserved. Please visit https://medical-data-
models.org/forms/4070
dataset
Datenelemente I
Patientenpseudonym*
Fallpseudonym*
klinische Studie*
klinisches N Stadium*
cT0 (cT0)
cT1 (cT1)
cT2 (cT2)
cT3 (cT3)
cT4 (cT4)
cTX (cTX)
klinisches M Stadium*
cM0 (cM0)
cM1 (cM1)
cMX (cMX)
Ortsangabe der Metastase(n) (klinisch)*
Intervall zwischen klinischen M Stadium und OP*
Topographie
Versionsnummer ICD*
Verschlüssselung nach ICD*
Codebeschreibung ICD-10*
Datenelemente II
digitale rektale Untersuchung*
nicht suspekt (DRU nicht suspekt)
suspekt (DRU suspekt)
unbekannt (unbekannt)
Prostatektomie: häufigstes Gleason-Muster*
Prostatektomie: zweithäufigstes Gleason-Muster*
Prostatektomie: Gesamt-Gleason-Score*
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Prostata-spezifisches Antigen
Prostata-spezifisches Antigen*
Ja
Nein
präoperativer Wert*
postoperativer Wert*
Intervall zwischen PSA Wert und OP*
Datenelemente III
Chemotherapie in der Anamnese*
Ja
Nein
präoperative Chemotherapie*
Ja (Ja)
Nein (Nein)
Unbekannt (unbekannt)
postoperative Chemotherapie*
Ja (Ja)
Nein (Nein)
Unbekannt (unbekannt)
Strahlentherapie in der Anamnese*
Ja
Nein
präoperative Strahlentherapie*
Ja (Ja)
Nein (Nein)
Unbekannt (unbekannt)
postoperative Strahlentheapie*
Ja (Ja)
Nein (Nein)
Unbekannt (unbekannt)
Zweitmalignom*
Ja (Ja)
Nein (Nein)
Unbekannt (unbekannt)
Szintigraphie in Anamnese*
Ja
Nein
präoperative Ganzkörperszintigraphie*
Ja (Ja)
Nein (Nein)
Unbekannt (unbekannt)
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Ganzkörperszintigramm suspekt*
nicht suspekt (Nicht suspekt)
suspekt (Suspekt)
unbekannt (unbekannt)
Datum der Biopsieentnahme*
Patientenalter bei Biopsie*
Operation
Chirurgische und medizinische Prozeduren -
Katalogversion*
Chirurgische und medizinische Prozeduren*
Chirurgische und medizinische Prozeduren -
Freitext*
Datenelemente IV
Anzahl der untersuchten Lymphknoten*
Anzahl der befallenen Lymphknoten *
Morphologie des Präparates
Version der Klassifikation*
Verschlüsselung nach ICD-O-3*
Codebeschreibung ICD-O-3*
Datenelemente V
Histologisches Grading*
G1 (G1)
G2 (G2)
G3 (G3)
0 = Grading nicht vorgesehen (O)
X = Differenzierungsgrad kann nicht
bestimmt werden (X)
pathologisches Stadium*
pT Stadium*
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pT0 (pT0)
pT1 (pT1)
pT1a (pT1a)
pT1b (pT1b)
pT1c (pT1c)
pT2 (pT2)
pT2a (pT2a)
pT2b (pT2b)
pT2c (pT2c)
pT3 (pT3)
pT3a (pT3a)
pT3b (pT3b)
pT4 (pT4)
pTX (pTX)
pN Stadium*
pN0 (pN0)
pN1 (pN1)
pN2 (pN2)
pN3 (pN3)
pNX (pNX)
pM Stadium*
pM0 (pM0)
pM1 (pM1)
pMX (pMX)
Ortsangabe der Metastase(n) (pathologisch)*
Intervall zwischen pathologischem M Status und
OP*
Residualklassifikation*
Residualtumor Stadium R0 (R0)
Residualtumor Stadium R1 (R1)
Residualtumor Stadium RX (RX)
Art der Probe*
Blutprobe (Blut/Serum/Plasma)
DNA aus Blutprobe (DNS aus Blut)
Gewebeprobe (Nativgewebe)
Paraffin-fixierte Probe (Paraffin)
Uri (Urin)
PSA Rezidiv*
Ja (Ja)
Nein (Nein)
Unbekannt (unbekannt)
Tumor in Gewebeprobe(n) enthalten*
Ja (Ja)
Nein (Nein)
Unbekannt (unbekannt)
4 / 4
dataset minimal dataset DPKK prostate cancer
register epidemiogical cancer registry
North-Rhine-Westphalia cancer
dataset epidemiogical cancer registry North-Rhine-
Westphalia. With friendly permission
All rights reserved. Please visit https://medical-data-
models.org/forms/4071
register
MeldungDaten
Idenität
Patienten-Nachname*
Patienten-Vorname*
Patienten-Titel*
Geburtsname*
anderer früherer Name, wenn verschieden von
Familiennahme und Geburtsname*
Patienten-Geschlecht*
männlich (M)
Unbekannt (U)
weiblich (W)
Patienten-Geburtsdatum*
Straße*
Hausnummer*
Postleitzahl Patient*
Wohnort*
Nationalität/Staatsangehörigkeit*
Informationsstatus nach §4, Abs. 4*
Ja (J)
Nein (N)
Unbekannt (U)
Widerspruchstatus nach $4, Abs. 4*
Ja (J)
Nein (N)
Unbekannt (U)
Referenz*
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Patienten-Tod
Sterbedatum*
Gemeindekennziffer des Sterbeortes*
Todesursache nach ICD-10*
Standesamt*
Sterbebuchnummer*
Diagnose
Datum der Diagnose*
Handelt es sich bei Diagnosedatum um ein
exaktes Datum*
Ja
Nein
Körperseite*
beidseits (B)
links (L)
multilokulär (M)
rechts (R)
systemisch (S)
nicht zutreffend (T)
unbekannt (U)
Histopathologisches Grading*
G1 gut differenziert (1)
G2 mäßig differenziert (2)
G3 schlecht differenziert (3)
G4 undifferenziert (4)
High Grade (G3-G4) (H)
Low Grade (G1-G2) (L)
Intermediate Grade (G2-G3) (M)
unbekannt (U)
nicht bestimmbar (X)
Histopathologisches Grading*
G1 gut differenziert (1)
G2 mäßig differenziert (2)
G3 schlecht differenziert (3)
G4 undifferenziert (4)
High Grade (G3-G4) (H)
Low Grade (G1-G2) (L)
Intermediate Grade (G2-G3) (M)
unbekannt (U)
nicht bestimmbar (X)
Zelltyp*
B-Zell-Lymphom (B)
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Natural-Killer-Zell-Lymphom (K)
Null-Zell-Lymphom (N)
Borderline (O)
T-Zell-Lymphom (T)
Grund des Arztbesuches *
Selbstuntersuchung (E)
(gesetzl.) Früherkennung (F)
Hautkrebsfrüherkennung (H)
Nachsorge (N)
sonstiges (S)
Tumorsymptomatik (T)
unbekannt (U)
(nicht gesetzl. Vorsorge) (V)
Wurde schon früher eine bösartige Neubildung
diagnostiziert*
Ja (J)
Nein (N)
unbekannt (U)
Sicherung der Tumordiagnose*
autoptisch (A)
histologisch (H)
klinisch (K)
sonstiges (S)
unbekannt (U)
zytologisch (Z)
TNM-Klassifikation
Organgruppe der TNM-Klassfikation*
Liegt zur bösartigen Neubildung eine TNM-
Klassifikation vor*
Ja
Nein
Tumorstaging-Symbole*
Tumorstaging Symbol y (YSymbol)
Handelt es sich es bei der T-Kategorie um ein
klinisches Stadium (c) *
Ja
Nein
Handelt es sich es bei der T-Kategorie um ein
pathologisches Stadium (p) *
Ja
Nein
Enthält die T-Kategorie ein m-Symbol*
Ja
Nein
T-Kategorie*
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Liegt zur bösartigen Erkrankung eine T-Kategorie
vor*
Ja
Nein
Handelt es sich es bei der N-Kategorie um ein
klinisches Stadium (c) *
Ja
Nein
Handelt es sich es bei der N-Kategorie um ein
pathologisches Stadium (p) *
Ja
Nein
Enthält die T-Kategorie ein sn-Symbol*
Ja
Nein
N-Kategorie*
Liegt zur bösartigen Erkrankung eine N-
Kategorie vor*
Ja
Nein
Handelt es sich es bei der M-Kategorie um ein
klinisches Stadium (c) *
Ja
Nein
Handelt es sich es bei der M-Kategorie um ein
pathologisches Stadium (p) *
Ja
Nein
M-Kategorie*
Liegt zur bösartigen Erkrankung eine M-
Kategorie vor*
Ja
Nein
Anzahl der befallenen Lymphknoten*
Anzahl der untersuchten Lymphknoten*
Andere Tumorklassifikationen
Identifikationsnummer der Klassifikation*
Stadium der Klassifikation*
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Tumormarker und Hormonrezeptoren
Identifikationsnummer des Tumormarkers bzw.
des Hormonrezeptors*
Gemessener Wert*
Angaben zur Primärtherapie
Mit welchem Ziel wurde die Therapie begonnen*
kurativ (K)
palliativ (P)
unbekannt (U)
Wurde eine Operation durchgeführt*
Ja (J)
Nein (N)
unbekannt (U)
Wurde eine Chemotherapie durchgeführt*
Ja (J)
Nein (N)
Unbekannt (U)
Wurde eine Strahlentherapie durchgeführt*
Ja (J)
Nein (N)
Unbekannt (U)
Wurde eine andere Therapie durchgeführt*
Ja (J)
Nein (N)
Unbekannt (U)
Verschlüsselungen der Tumordiagnosen
Verschlüssselung nach ICD*
Auflage des verwendeten ICD-Codes*
Verschlüsselung nach ICD-O-3*
Verschlüsselung nach ICD-O-3*
Daten von Pathologischen Instituten
Datum des histopathologischen Gutachtens*
Text des histopathologischenGutachtens*
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Einsender des Untersuchungsgutes im Klartext*
Identifikationsnummer der Meldequelle*
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HIS documentation cancer conference -
gynecology  breast cancer
HIS form from Soarian. "Frauenklinik Erlangen" with
friendly permission of the gynecology Erlangen (Prof.
Beckmann) and the medical informatics department
Erlangen (PD Dr. Bürkle)
All rights reserved. Please visit https://medical-data-
models.org/forms/4074
HIS
Admininstrative Daten
Patienten-Nachname*
Patienten-Vorname*
Patienten-Titel*
früherer Name*
Patienten-Geburtsdatum*
Alter des Patienten*
Nationalität/Staatsangehörigkeit*
Straße*
Postleitzahl Patient*
Wohnort*
Dokumentation TB Mamma
nicht_sinnvoll_für_Untersuchung*
Ja
Nein
vorgestellt von*
Datum der Diagnose*
Anamnese*
bisherige Tumortherapie*
Fragestellung*
klinisches TNM-Staging
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T-Stadium*
N - Stadium der regionalen Lymphknoten*
M- Stadium*
vorhandenes TNM
vorhandenes TNM*
Ja
Nein
pT-Stadium*
pN - Stadium der regionalen Lymphknoten*
pM- Stadium*
Pathologischer TNM
Pathologischer TNM*
Ja
Nein
pT-Stadium*
pN - Stadium der regionalen Lymphknoten*
pM- Stadium*
Residualklassifikation*
endgültiges TNM Stadium
T*
N*
M*
Residualklassifikation*
Änderung des TNM Stadiums*
Ja
Nein
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Kommentar TNM*
FIGO Stadium*
geplantes therapeutisches Vorgehen
Operation*
Ja
Nein
Intention*
Kurativ (Kura.)
Palliativ (Palli.)
Kommentar Operation*
Bestrahlung*
Ja
Nein
Intention*
Adjuvant (Adj.)
Kurativ (Kura.)
Neoadjuvant (Neoadj.)
Palliativ (Palli.)
Kommentar Strahlentherapie*
Chemotherapie*
Ja
Nein
Intention*
Adjuvant (Adj.)
Kurativ (Kura.)
Neoadjuvant (Neoadj.)
Palliativ (Palli.)
Name Chemotherapie*
Kommentar Chemotherapie*
Hormon- / endokrine Therapie*
Ja
Nein
Intention*
Adjuvant (Adj.)
Kurativ (Kura.)
Neoadjuvant (Neoadj.)
Palliativ (Palli.)
Name Hormontherapie*
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Kommentar endokrine Therapie*
Immuntherapie*
Ja
Nein
Intention*
Adjuvant (Adj.)
Kurativ (Kura.)
Neoadjuvant (Neoadj.)
Palliativ (Palli.)
Name Immuntherapie*
Kommentar Immuntherapie*
Interventionelle Radiologie*
Ja
Nein
Intention*
Adjuvant (Adj.)
Kurativ (Kura.)
Neoadjuvant (Neoadj.)
Palliativ (Palli.)
Kommentar interventionelle Radiologie*
Schmerztherapie / Schmerzmanagement*
Ja
Nein
Kommentar Schmerztherapie*
supportive Theapie*
Ja
Nein
Kommentar supportive Therapie*
Palliativmedizin*
Ja
Nein
Kommentar Palliativmedizin*
weitere Diagnostik*
Ja
Nein
Kommentar Diagnostik*
Watchful Waiting*
Ja
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Nein
keine Therapie*
Ja
Nein
onkologische Psychotherapie*
Ja
Nein
Target Therapie*
Ja
Nein
Name Target-Therapie*
Bemerkung Target Therapie*
medizinische Besonderheiten*
Ja
Nein
Bezeichung med. Besonderheiten*
Kommentar Besonderheiten*
Nachsorge*
Ja
Nein
Kommentar Nachsorge*
Wiedervorstellung*
Ja
Nein
Kommentar Wiedervorstellung*
Weiteres
Möglicher Studienpatient*
Ja
Nein
klinische Studie*
Kommentar klinische Studie*
Einhaltung der Leitlinen*
Ja (Ja)
keine Leitlinie (Keine Leitlinie vorhanden)
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Nein (Nein)
Kommentar Leitlinie*
Tumorboard Indikation*
Primärfall (Primärpatient (Erste Therapie
je Stadium))
nicht_kodiert (Verlaufstherapie (Weitere
Therapie je Stadium))
Zweitmeinung (Zweitmeinung/Externer
Patient)
Tumorboard Typ*
posttherapeutisch (Posttherapeutische
Konferenz)
prätherapeutisch (Prätherapeutische
Konferenz)
Teilnehmer*
Andere (Andere)
Gynäkologie (Frauenklinik (Vorsitz))
Radiologie (Gynäkologische Radiologie)
Intern. Onkologie (Medizin 5)
Palliativmedizin (Palliativmedizin)
Pathologie (Pathologie)
Strahlentherapie (Strahlentherapie)
Protokoll*
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HIS pathology documtation cancer
conference breast cancer
HIS form from Soarian. "Frauenklinik Erlangen" with
friendly permission of the gynecology Erlangen (Prof.
Beckmann) and the medical informatics department
Erlangen (PD Dr. Bürkle)
All rights reserved. Please visit https://medical-data-
models.org/forms/4075
HIS
Admininstrative Daten
Patienten-Nachname*
Patienten-Vorname*
Patienten-Titel*
früherer Name*
Patienten-Geburtsdatum*
Alter des Patienten*
Nationalität/Staatsangehörigkeit*
Straße*
Postleitzahl Patient*
Wohnort*
Pathologie-Dokumentation für FK
Tumorboard
Histologie-Identifikationsnummer*
Präparate*
Präparate mit pathologischem Befund*
Histopathologie*
Pathologischer TNM
Tumorstaging-Symbole*
Tumorstaging Symbol r (r)
Tumorstaging Symbol y (y)
pT-Stadium*
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pN - Stadium der regionalen Lymphknoten*
Anzahl der befallenen Lymphknoten *
Anzahl der untersuchten Lymphknoten *
Anzahl der beteiligten Sentinellymphknoten *
Anzahl der untersuchten Sentinellymphknoten*
pM- Stadium*
Lymphgefäßinvasion*
Veneninvasion*
Perineurale Invasion*
Histologisches Grading*
Residualklassifikation*
Sicherheitsabstand DCIS*
Östrogen-Rezeptor*
Progesteron-Rezeptor*
Ki-67 Antigen *
Her-2/neu*
CISH*
negativ (negativ)
positiv (positiv)
Histologie-Code*
Histologie-Code ICD-0-3*
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HIS Registration cancer conference -
gynecology  breast cancer
HIS form from Soarian. "Frauenklinik Erlangen" with
friendly permission of the gynecology Erlangen (Prof.
Beckmann) and the medical informatics department
Erlangen (PD Dr. Bürkle)
All rights reserved. Please visit https://medical-data-
models.org/forms/4076
HIS
Admininstrative Daten
Patienten-Nachname*
Patienten-Vorname*
Patienten-Titel*
früherer Name*
Patienten-Geburtsdatum*
Alter des Patienten*
Nationalität/Staatsangehörigkeit*
Straße*
Postleitzahl Patient*
Wohnort*
Anmeldung TB Mamma
Anamnese*
Tumorboard Indikation*
CIN (CIN)
Gynäkologische Tumore
(Gynäkologische Tumore)
Kurzvorstellung (Kurzvorstellung)
intern (Mamma intern)
Mamma Screenin Stadt (Mamma
Screenin Stadt)
Mamma Screening Land (Mamma
Screening Land)
gewünschte Präsentation*
Histologie (nur histologische Demo)
Radiologie (nur radiologische Demo)
Radiologie und Histologie (Radiologische
und histologische Demo)
bisherige Tumortherapie*
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Kreatinin*
Datum Kreatinin*
Tumormarker und Hormonrezeptoren*
AFP (AFP)
CA-125 (CA-125)
CA15-3 (CA15-3)
CEA (CEA)
HCG (HCG)
SCC (SCC)
Wert*
Datum Tumormarker*
Zytologie-Befunde
Pap Test*
HPV-High Risk *
Ja
Nein
FIGO Stadium*
Biospie*
Ja (ja)
Nein (nicht durchgeführt)
betroffenes Organ*
Datum der Biopsieentnahme*
Histopathologie*
Operation*
Ja (ja)
nicht durchgeführt (nicht durchgeführt)
Datum Operation*
OP-Bezeichnung*
Erster Operateur*
Staging*
Ja (ja)
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Nein (nein)
unbekannt (unbekannt)
Röntgen Thorax*
auffällig (auffällig)
nicht durchgeführt (nicht durchgeführt)
unauffällig (unauffällig)
Befund Röntgen Thorax*
Sonographie Abdomen*
auffällig (auffällig)
nicht durchgeführt (nicht durchgeführt)
unauffällig (unauffällig)
Befund Sonographie Abdomen*
Szinitgraphie*
auffällig (auffällig)
nicht durchgeführt (nicht durchgeführt)
unauffällig (unauffällig)
Befund Szinitgraphie*
Computertomographie*
auffällig (auffällig)
nicht durchgeführt (nicht durchgeführt)
unauffällig (unauffällig)
Befund Computertomographie*
Kernspintomographie*
auffällig (auffällig)
nicht durchgeführt (nicht durchgeführt)
unauffällig (unauffällig)
Befund MRT*
MRT-Mamma*
auffällig (auffällig)
nicht durchgeführt (nicht durchgeführt)
unauffällig (unauffällig)
Befund MRT-Mamma*
Spülzytologie*
auffällig (auffällig)
nicht durchgeführt (nicht durchgeführt)
unauffällig (unauffällig)
Befund Spülzytologie*
andere Untersuchung*
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auffällig (auffällig)
nicht durchgeführt (nicht durchgeführt)
unauffällig (unauffällig)
anderer Befund*
Fragestellung*
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HIS short medical history - cancer
conference breast cancer
HIS form from Soarian. "Frauenklinik Erlangen" with
friendly permission of the gynecology Erlangen (Prof.
Beckmann) and the medical informatics department
Erlangen (PD Dr. Bürkle)
All rights reserved. Please visit https://medical-data-
models.org/forms/4077
HIS
Admininstrative Daten
Patienten-Nachname*
Patienten-Vorname*
Patienten-Titel*
früherer Name*
Patienten-Geburtsdatum*
Alter des Patienten*
Nationalität/Staatsangehörigkeit*
Straße*
Postleitzahl Patient*
Wohnort*
Mini-Anamnese für Tumorkonferenz
Journalnummer*
Erstdiagnose*
Ja (Ja)
Nein (Nein)
Unbekannt (Unbekannt)
Datum der Diagnose*
Therapie Intention*
Adjuvant (adjuvant)
Neoadjuvant (neoadjuvant)
Stadium*
lokal-rezidiviert ((Lokal-)Rezidiv)
metastasiert (metastasiert)
anderes Stadium (sonstiges)
anderes Stadium*
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betroffenes Organ*
Corpus (Corpus)
Mamma (Mamma)
Ovar (Ovar)
anderes Organ (sonstiges)
Throphoblasttumore
(Throphoblasttumore)
Vulva (Vulva)
Zervix (Zervix)
anderes Organ - Freitext*
ECOG Leistungszustand*
FIGO Stadium*
klinisches TNM-Staging
klinisches TNM-Staging*
Ja
Nein
T-Stadium*
N - Stadium der regionalen Lymphknoten*
M- Stadium*
Pathologischer TNM
Pathologischer TNM*
Ja
Nein
pT-Stadium*
pathologisch ermitteltes N-Stadium*
pathologisch ermitteltes M-Stadium*
Anamnese
Anamnese - Freitext*
Menopausenstatus*
Perimenopause (perimenopausal)
Postmenopause (postmenopausal)
Prämenopause (prämenopausal)
Komorbidität*
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Ja (Ja)
Nein (Nein)
unbekannt (unbekannt)
Herzfunktion*
auffällig (auffällig)
unauffällig (unauffällig)
unbekannt (unbekannt)
Herzfunktion - Freitext*
Neuropathien*
auffällig (auffällig)
unauffällig (unauffällig)
unbekannt (unbekannt)
Neuropathien - Freitext*
anderes Malignom*
auffällig (auffällig)
unauffällig (unauffällig)
unbekannt (unbekannt)
anderes Malignom - Freitext*
andere Komorbidität*
auffällig (auffällig)
unauffällig (unauffällig)
unbekannt (unbekannt)
andere Komorbidität - Freitext*
Größe*
Körpergewicht*
Körbchengröße*
Familienanamnese*
negativ (negativ)
positiv (positiv)
unbekannt (unbekannt)
Familienanamnese - Freitext*
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HIS form ORBIS.  with friendly permission form gynecology
(Dr. Tio) and medical informatics department (Dr. Breil)
All rights reserved. Please visit https://medical-data-
models.org/forms/4078
HIS
Patientenaufkleber groß
Aufnahmedatum*
Patientenidentifikationsnummer*
Geschlecht Patient*
Patienten-Nachname*
Patienten-Vorname*
Patienten-Geburtsdatum*
Aufnahmezeit*
Einweisender Arzt*
Tumorkonferenz
Tumorboard Typ*
adjuvante Konferenz (interdisziplinäre
adjuvante Therapieempfehlung)
palliative Konferenz (interdisziplinäre
palliative Therapieempfehlung)
Datum der Konferenz*
Ort der Konferenz*
Verantwortliche Person für die Anmeldung*
Datum der Anmeldung*
Teilnehmer*
Nuklearmedizin (Nuklearmedizin)
Pathologie (Pathologie)
Radiologie (Radiologie)
Gynäkologie (Senologie)
Strahlentherapie (Strahlentherapie)
Patientendaten
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Status Patient*
Primärfall (Primärpatient)
Diagnose*
Karnofsky Index*
klinische Studie*
Krankheitsverlauf
Krankheitsverlauf*
Pathologie Befund
Kommentar zu den Pathologie Proben*
Frage
Frage*
Subformular
Tumorboardentscheidungen
Operation*
Ja
Nein
Intention*
Adjuvant (adjuvant)
Kurativ (kurativ)
Neoadjuvant (neoadjuvant)
Palliativ (palliativ)
sonstiges (sonstiges)
Chemotherapie*
Ja
Nein
Intention*
Adjuvant (adjuvant)
Kurativ (kurativ)
Neoadjuvant (neoadjuvant)
Palliativ (palliativ)
sonstiges (sonstiges)
Bestrahlung*
Ja
Nein
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Intention*
Adjuvant (adjuvant)
Kurativ (kurativ)
Neoadjuvant (neoadjuvant)
Palliativ (palliativ)
sonstiges (sonstiges)
Hormon- / endokrine Therapie*
Ja
Nein
Intention*
Adjuvant (adjuvant)
Kurativ (kurativ)
Neoadjuvant (neoadjuvant)
Palliativ (palliativ)
sonstiges (sonstiges)
Immuntherapie*
Ja
Nein
Intention*
Adjuvant (adjuvant)
Kurativ (kurativ)
Neoadjuvant (neoadjuvant)
Palliativ (palliativ)
sonstiges (sonstiges)
Studienprotokoll*
Ja
Nein
Studienprotokoll - Freitext*
Verlaufskontrolle*
Ja
Nein
Verlaufskontrolle - Freitext*
Analgetika*
Ja
Nein
Analgetika - Freitext*
andere Empfehlung*
Ja
Nein
andere Empfehlung - Freitext*
Re-Biopsie*
Ja
Nein
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Bisphosphonate*
Ja
Nein
Bisphosphonate - Freitext*
Radioiodtherapie*
Ja
Nein
Wiedervorstellung nach Diagnostik*
Ja
Nein
Active Surveillance*
Ja
Nein
Diagnostik notwendig*
Therapie Freitext*
Datum der Arzt-Unterschrift*
Arzt-Unterschrift*
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HIS Checklist - interdisciplinary breast team
breast cancer
documentation standard - breast cancer - gynecology, with
friendly permission (Dr. Tio)
- kooperatives Brustzentrum Münster, Bereich Senologie an
der Klinik und Poliklinik für Frauenheilkunde und
Geburtshilfe - Leitung: Dr. med. Joke Tio
All rights reserved. Please visit https://medical-data-
models.org/forms/4079
HIS
Patienteninformation
Patienten-Nachname*
Patienten-Vorname*
Patienten-Geburtsdatum*
Patientenidentifikationsnummer*
Zuweisender Arzt *
Anamnese
Alter Patientin*
Gewicht*
Größe*
Alter Menarche*
Menopausenstatus*
Nein (nein)
Postmenopause (Postmenopause)
Prämenopause (Prämenopause)
Senium (Senium)
Alter Menopause*
Hormonpräparat*
Ja (ja)
Nein (nein)
Hormonersatztherapie*
Ja
Nein
nicht_kodiert*
Ja
Nein
Dauer der Therapie*
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Parität*
Ja (ja)
Nein (nein)
Schwangerschaften*
Alter bei Erstparität*
Laktation*
Ja (ja)
Nein (nein)
Stillzeit (Monate)*
Mammakarzinom in der Familie*
Ja (ja, andere)
ja, Großmutter (mütterlicherseits) (ja,
Großmutter (mütterlicherseits))
ja, Mutter (ja, Mutter)
ja, Schwester (ja, Schwester)
Nein (nein)
Alter bei Erkrankungsbeginn*
Frühere andere maligne Tumore*
ja, in anderen Organen (ja, in anderen
Organen)
ja, Mamma, gegenseitig (ja, Mamma,
gegenseitig)
ja, Mamma, gleichseitig (ja, Mamma,
gleichseitig)
Nein (keine)
Pathologisches Institut*
Histologie-Identifikationsnummer*
Synchrone andere maligne Tumoren*
ja, in anderen Organen (ja, in anderen
Organen)
ja, Mamma der Gegenseite (ja, Mamma
der Gegenseite)
ja, Mamma Gegenseite und andere
Organe (ja, Mamma Gegenseite und
andere Organe)
Nein (keine)
Pathologisches Institut*
Histologie-Identifikationsnummer*
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Lokalbefund des Tumors
Seite finding*
links (links)
rechts (rechts)
Anzahl der Tumoren*
multiple (multiple)
solitär (solitär)
Anzahl *
Tastbefund*
Ja (ja)
Nein (kein)
klinisch unauffällig (klinisch nicht
suspekt)
klinisch suspekt (klinisch suspekt)
Topografie des Tastbefundes*
äußerer oberer Quadrant (äußerer
oberer Quadrant)
äußerer unterer Quadrant (äußerer
unterer Quadrant)
axillärer Anteil (axillärer Anteil)
innerer oberer Quadrant (innerer oberer
Quadrant)
innerer unterer Quadrant (innerer unterer
Quadrant)
Mamille (Mamille)
zentraler Anteil (zentraler Anteil)
Körbchengröße*
nicht_kodiert (A)
nicht_kodiert (B)
nicht_kodiert (C)
nicht_kodiert (D)
Ausdehnung auf Brustwand oder Haut*
Brustwand (Brustwand)
Brustwand, Hautödem, Ulzeration,
Hautsatelliten (Brustwand, Hautödem,
Ulzeration, Hautsatelliten)
entzündlich (inflammatorisches)
Karzinom (entzündlich
(inflammatorisches) Karzinom)
Hautödem / Ulzeration / Hautsatelliten
(Hautödem / Ulzeration / Hautsatelliten)
Nein (keine (im Sinne der TNM))
Haut*
Brustödem (Hautödem)
Hautmetastasen (Hautsatelliten)
Ulzeration der Brust (Ulzeration)
entzündlich (inflammatorisches) Karzinom*
Ja
Nein
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Axilläre Lymphknotenmetastasen*
fixiert (klinisch ja, fixiiert)
verschiebbar (klinisch ja, verschieblich)
keine (klinisch keine)
Fernmetastasen*
Ja (ja)
Nein (keine)
präoperativ keine Angabe (präoperativ
keine Angabe)
Lokalisation Fernmetastasen*
Untersuchung Fernmetastasen*
Histologie-Identifikationsnummer*
Bildgebende Diagnostik
Mammografie
Mammografie*
Ja
Nein
Herd*
Ja (ja)
Nein (nein)
nicht beurteilbar (nicht beurteilbar,
(Überlagerung))
seitendifferente Verdichtung
(seitendifferente Verdichtung bzw.
Gefügestörung)
Größe Läsion*
Begrenzung*
glatt (glatt)
nicht_kodiert (lobuliert)
nicht beurteilbar (nicht beurteilbar,
(Überlagerung))
sternförmige Gefügestörung
(sternförmige Gefügestörung)
strahlige Ausläufer (strahlige Ausläufer)
unregelmäßig (unregelmäßig)
Mikrokalk*
Ja (ja)
Nein (nein)
Durchmesser Mikrokalk*
Form des Mikrokalk*
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komplex (polymorph)
rund (rundlich)
linear (strichförmig)
oval (überwiegend rundlich)
Anordnung*
diffus (diffus)
gruppiert (gruppiert)
segmental (segmental)
nicht_kodiert (straßenförmig)
Größe der Verkalkungen*
fein (fein)
fein und grob (fein und grob)
grob (grob)
Verlauf*
keine Voruntersuchungen (keine
Voruntersuchungen)
neu (neu aufgetreten)
progredient (progredient)
unverändert (unverändert zu
Voruntersuchung)
BI-RADS Mammographie*
BI-RADS 0 = unauffällig (BI-RADS 0 =
unauffällig)
BI-RADS 1 = unauffällig (BI-RADS 1 =
unauffällig)
BI-RADS 2 = benigne (BI-RADS 2 =
benigne)
BI-RADS 3 = wahrscheinlich benigne
(BI-RADS 3 = wahrscheinlich benigne)
BI-RADS 4  = verdächtig (BI-RADS 4  =
verdächtig)
nicht_kodiert (BI-RADS 4A)
nicht_kodiert (BI-RADS 4B)
nicht_kodiert (BI-RADS 4C)
BI-RADS 5 = maligne (BI-RADS 5 =
maligne)
Sonografie
Sonografie*
Ja
Nein
Läsion*
nicht_kodiert (Areal mit
Schallauslöschung)
fraglich (fraglich)
Ja (ja)
Nein (nein)
Größe Läsion*
Begrenzung*
scharf (scharf begrenzt)
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unscharf (unscharf begrenzt)
BI-RADS Sonographie*
nicht_kodiert (BI-RADS 0)
nicht_kodiert (BI-RADS I = unauffällig)
nicht_kodiert (BI-RADS II = benigne)
nicht_kodiert (BI-RADS III =
wahrscheinlich benigne)
nicht_kodiert (BI-RADS IV = verdächtig)
nicht_kodiert (BI-RADS V = maligne)
MRT
Kernspintomographie Brust*
Ja
Nein
BI-RADS MRT*
nicht_kodiert (BI-RADS 0)
nicht_kodiert (BI-RADS I = unauffällig)
nicht_kodiert (BI-RADS II = benigne)
nicht_kodiert (BI-RADS III =
wahrscheinlich benigne)
nicht_kodiert (BI-RADS IV = verdächtig)
nicht_kodiert (BI-RADS V = maligne)
BI-RADS Klassifikation*
nicht_kodiert (AK I - retromamillär ohne
Befund)
nicht_kodiert (AK II - benigne)
nicht_kodiert (AK III - wahrscheinlich
benigne)
nicht_kodiert (AK IV - verdächtig)
nicht_kodiert (AK V - maligne
(invasiv/DCIS))
radiologische Verdachtsdiagnose*
Zeichnung*
Seite*
links (links)
rechts (rechts)
Topografie *
äußerer oberer Quadrant (äußerer
oberer Quadrant)
äußerer unterer Quadrant (äußerer
unterer Quadrant)
axillärer Anteil (axillärer Anteil)
innerer oberer Quadrant (innerer oberer
Quadrant)
innerer unterer Quadrant (innerer unterer
Quadrant)
Mamille (Mamille)
zentraler Drüsenkorper (zentraler
Drüsenkorper)
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Biopsie
keine Biopsie*
Ja
Nein
Biopsie bei Mammographie*
Ja
Nein
Ultraschallgestütze Biopsie*
Ja
Nein
Biopsie*
Ja
Nein
Mammotome*
Ja
Nein
Biospie Areal*
Biopsie Läsion (abklärungsbedüftige
Läsion)
mamillenwärts orientierte Biopsie
(mamillenwärts orientierte Biopsie)
behind nipple (Retromamillärregion)
Anzahl der Stanzen*
Distanz zwischen Biopsien*
Kalk in Mammotome*
Mikrokalk in Biopsie*
Ja (ja)
Nein (nein)
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HIS cancer conference after biopsy breast
cancer
HIS form ORBIS.  with friendly permission form gynecology
(Dr. Tio) and medical informatics department (Dr. Breil)
All rights reserved. Please visit https://medical-data-
models.org/forms/4080
HIS
Patientenaufkleber groß
Aufnahmedatum*
Patientenidentifikationsnummer*
Geschlecht Patient*
Patienten-Nachname*
Patienten-Vorname*
Patienten-Geburtsdatum*
Aufnahmezeit*
Einweisender Arzt*
Tumorkonferenz
Datum der Konferenz*
Ort der Konferenz*
Verantwortliche Person für die Anmeldung*
Datum der Anmeldung*
Teilnehmer*
Nuklearmedizin (Nuklearmedizin)
Pathologie (Pathologie)
Radiologie (Radiologie)
Gynäkologie (Senologie)
Strahlentherapie (Strahlentherapie)
Patientendaten
Status Patient*
Primärfall (Primärpatient)
Diagnose*
1 / 6
Karnofsky Index*
klinische Studie*
Krankheitsverlauf
Krankheitsverlauf*
Pathologie Befund
Kommentar zu den Pathologie Proben*
Frage
Frage*
Subformular
MDT (MIB)
Klinischer Befund vorhanden*
Ja
Nein
Mamma-Screening*
Ja
Nein
Ultraschall-gestütze Biopsie*
Ja
Nein
Vakuumsaugbiopsie - Sonographie*
Ja
Nein
Biopsie bei Mammographie*
Ja
Nein
Vakuumsaugbiopsie - Mammographie*
Ja
Nein
Vakuumsaugbiopsie - MRT*
Ja
Nein
Datum Pathologie Befund*
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Histologie Klassifikation (B)*
normales Brustgewebe (B1)
benigne (B2)
unklar ob benigne oder maligne (B3)
Malignitätsverdacht (B4)
DCIS (B5a)
Invasive Karzinom (B5b)
Tumor Invasion kann nicht beurteilt
werden (B5c)
anderer Tumor (B5d)
nicht_kodiert*
nicht_kodiert (K1 (sicher))
nicht_kodiert (K2 (sicher))
nicht_kodiert (K3a (unsicher, aber
wahrscheinlich))
nicht_kodiert (K3b (unsicher und
wahrscheinlich))
Aktion
Wiederholung der Biopsie*
Ja
Nein
regülare Vorsorge*
Ja
Nein
geplante Kontrolle*
Ja
Nein
Monate Check-Up*
Check-Up Mammographie*
Ja
Nein
Check-Up Sonographie*
Ja
Nein
Check-Up MRT*
Ja
Nein
zusätzliche Biopsie*
Ja
Nein
Excisionsbiopsie*
Ja
Nein
onkologische Operation*
Ja
Nein
3 / 6
HIS cancer conference after biopsy breast cancer
Audit*
Ja
Nein
Tumorboardentscheidungen
Operation*
Ja
Nein
Intention*
Adjuvant (adjuvant)
Kurativ (kurativ)
Neoadjuvant (neoadjuvant)
Palliativ (palliativ)
sonstiges (sonstiges)
Chemotherapie*
Ja
Nein
Intention*
Adjuvant (adjuvant)
Kurativ (kurativ)
Neoadjuvant (neoadjuvant)
Palliativ (palliativ)
sonstiges (sonstiges)
Bestrahlung*
Ja
Nein
Intention*
Adjuvant (adjuvant)
Kurativ (kurativ)
Neoadjuvant (neoadjuvant)
Palliativ (palliativ)
sonstiges (sonstiges)
Hormon- / endokrine Therapie*
Ja
Nein
Intention*
Adjuvant (adjuvant)
Kurativ (kurativ)
Neoadjuvant (neoadjuvant)
Palliativ (palliativ)
sonstiges (sonstiges)
Immuntherapie*
Ja
Nein
Intention*
Adjuvant (adjuvant)
Kurativ (kurativ)
Neoadjuvant (neoadjuvant)
Palliativ (palliativ)
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sonstiges (sonstiges)
Studienprotokoll*
Ja
Nein
Studienprotokoll - Freitext*
Verlaufskontrolle*
Ja
Nein
Verlaufskontrolle - Freitext*
Analgetika*
Ja
Nein
Analgetika - Freitext*
andere Empfehlung*
Ja
Nein
andere Empfehlung - Freitext*
Re-Biopsie*
Ja
Nein
Bisphosphonate*
Ja
Nein
Bisphosphonate - Freitext*
Radioiodtherapie*
Ja
Nein
Wiedervorstellung nach Diagnostik*
Ja
Nein
Active Surveillance*
Ja
Nein
Diagnostik notwendig*
Therapie Freitext*
Datum der Arzt-Unterschrift*
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Arzt-Unterschrift*
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HIS cancer conference after surgery breast
cancer
documentation standard - breast cancer - gynecology, with
friendly permission (Dr. Tio)
- kooperatives Brustzentrum Münster, Bereich Senologie an
der Klinik und Poliklinik für Frauenheilkunde und
Geburtshilfe - Leitung: Dr. med. Joke Tio
All rights reserved. Please visit https://medical-data-
models.org/forms/4081
HIS
Patientenaufkleber groß
Aufnahmedatum*
Patientenidentifikationsnummer*
Geschlecht Patient*
Patienten-Nachname*
Patienten-Vorname*
Patienten-Geburtsdatum*
Aufnahmezeit*
Einweisender Arzt*
Postoperative MDT
Datum der Konferenz*
Histologischer Typ*
lobuläres Carcinoma in situ (CLIS ext.
Type)
DCIS (DCIS)
invasives lobuläre Karzinom (IL)
nicht anders spezifiziert (NOS)
andere histologischer Typ (sonstige)
sonstige Histologie*
Tumorgröße*
DCIS Größe*
Histologisches Grading*
G1 (G1)
G2 (G2)
G3 (G3)
Kernmalignitätsgrad*
high (high)
intermediate (intermediate)
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low (low)
Östrogen-Rezeptor*
negativ (negativ)
positiv (positiv)
% positiv*
Progesteron-Rezeptor*
negativ (negativ)
positiv (positiv)
% positiv*
Her-2/neu*
negativ (0)
negativ (1+)
Borderline (2+)
positiv (3+)
Fluoreszenz-in-situ-Hybridisierung*
negativ (neg.)
positiv (pos.)
Sicherheitsabstände
Sicherheitsabstand*
caudal (caudal)
cranial (cranial)
dorsal (dorsal)
lateral (lateral)
mamillär (mamillär)
medial (medial)
peripher (peripher)
ventral (ventral)
Sicherheitsabstand invasives Karzinom*
Sicherheitsabstand DCIS*
Revisionsoperation*
Ja
Nein
Sentinel Lymphknoten
Anzahl der untersuchten Sentinellymphknoten*
Befund Sentinel Lymphknoten*
histologisch (erst in endgültiger
Histologie festgestellt)
intraoperativ (intraoperativ festgestellt)
Makrometastasen (Makrometastasen)
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Mikrometastasen (Micrometastasen)
kein Tumor (tumorfrei)
Axilladissektion
Axilladissektion*
Ja
Nein
Anzahl der untersuchten Lymphknoten*
Anzahl der befallenen Lymphknoten *
Tumorboardentscheidungen
Datum der Konferenz*
Operation*
Ja
Nein
sekundäre Lymphknotenentfernung*
Ja
Nein
Revisionsoperation*
Ja
Nein
sekundär totale Mastektomie*
Ja
Nein
pathologisches Stadium
pT Stadium*
pN Stadium*
Lymphgefäßinvasion*
Veneninvasion*
cM Stadium*
Histologisches Grading*
Unterschrift*
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HIS form ORBIS.  with friendly permission form gynecology
(Dr. Tio) and medical informatics department (Dr. Breil)
All rights reserved. Please visit https://medical-data-
models.org/forms/4082
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Patientenaufkleber groß
Aufnahmedatum*
Patientenidentifikationsnummer*
Geschlecht Patient*
Patienten-Nachname*
Patienten-Vorname*
Patienten-Geburtsdatum*
Aufnahmezeit*
Einweisender Arzt*
Tumorkonferenz
Datum der Konferenz*
Ort der Konferenz*
Verantwortliche Person für die Anmeldung*
Datum der Anmeldung*
Teilnehmer*
Nuklearmedizin (Nuklearmedizin)
Pathologie (Pathologie)
Radiologie (Radiologie)
Gynäkologie (Senologie)
Strahlentherapie (Strahlentherapie)
Patientendaten
Status Patient*
Primärfall (Primärpatient)
Diagnose*
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Karnofsky Index*
klinische Studie*
Krankheitsverlauf
Krankheitsverlauf*
Pathologie Befund
Kommentar zu den Pathologie Proben*
Frage
Frage*
Subformular
MDT (nur Bildgebung)
prätherapeutisch*
Befund Mammographie*
Ja
Nein
Befund MRT*
Ja
Nein
Befund Bildgebung*
Ja
Nein
Freitext*
Entscheidung Konferenz
Entscheidung Konferenz*
Ja
Nein
zusätzliche Bildgebung*
Ja
Nein
zusätzliche Bildgebung*
Kompression der Brust (Kompression)
radiologische Vergrößerung
(Vergrößerung)
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Mammographie*
Ja
Nein
MRT*
Ja
Nein
Sonographie*
Ja
Nein
Sonographie*
nicht_sinnvoll_für_Untersuchung (durch
Gyn)
nicht_sinnvoll_für_Untersuchung (durch
RAD)
Biopsie*
Ja
Nein
geplante Kontrolle*
Ja
Nein
Monate Check-Up*
Check-Up Mammographie*
Ja
Nein
Check-Up Sonographie*
Ja
Nein
Check-Up MRT*
Ja
Nein
Audit*
Ja
Nein
Tumorboardentscheidungen
Operation*
Ja
Nein
Intention*
Adjuvant (adjuvant)
Kurativ (kurativ)
Neoadjuvant (neoadjuvant)
Palliativ (palliativ)
sonstiges (sonstiges)
Chemotherapie*
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Ja
Nein
Intention*
Adjuvant (adjuvant)
Kurativ (kurativ)
Neoadjuvant (neoadjuvant)
Palliativ (palliativ)
sonstiges (sonstiges)
Bestrahlung*
Ja
Nein
Intention*
Adjuvant (adjuvant)
Kurativ (kurativ)
Neoadjuvant (neoadjuvant)
Palliativ (palliativ)
sonstiges (sonstiges)
Hormon- / endokrine Therapie*
Ja
Nein
Intention*
Adjuvant (adjuvant)
Kurativ (kurativ)
Neoadjuvant (neoadjuvant)
Palliativ (palliativ)
sonstiges (sonstiges)
Immuntherapie*
Ja
Nein
Intention*
Adjuvant (adjuvant)
Kurativ (kurativ)
Neoadjuvant (neoadjuvant)
Palliativ (palliativ)
sonstiges (sonstiges)
Studienprotokoll*
Ja
Nein
Studienprotokoll - Freitext*
Verlaufskontrolle*
Ja
Nein
Verlaufskontrolle - Freitext*
Analgetika*
Ja
Nein
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Analgetika - Freitext*
andere Empfehlung*
Ja
Nein
andere Empfehlung - Freitext*
Re-Biopsie*
Ja
Nein
Bisphosphonate*
Ja
Nein
Bisphosphonate - Freitext*
Radioiodtherapie*
Ja
Nein
Wiedervorstellung nach Diagnostik*
Ja
Nein
Active Surveillance*
Ja
Nein
Diagnostik notwendig*
Therapie Freitext*
Datum der Arzt-Unterschrift*
Arzt-Unterschrift*
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HIS course of treatment - tumortherapy
breast cancer
HIS form ORBIS.  with friendly permission form gynecology
(Dr. Tio) and medical informatics department (Dr. Breil)
All rights reserved. Please visit https://medical-data-
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Patientenaufkleber groß
Patientenidentifikationsnummer*
Geschlecht Patient*
Patienten-Nachname*
Patienten-Vorname*
Patienten-Geburtsdatum*
Tumorverlaufsbogen
Patientenname*
Geburtstag*
verantwortliche Person*
Datum der Erhebung*
Frauenfacharzt *
Hausarzt*
Chemotherapiezyklus*
Studie*
Ja
Nein
Diagnose*
Verlauf der Erkrankung*
Verlauf der Therapie*
Stadium*
lokal-fortgeschritten (lokal-
fortgeschritten)
lokal-rezidiviert (lokal-rezidiviert)
metastasiert (metastasiert)
Primärtumor (Primärtumor)
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Bemerkung metastasiert*
Tumorbiologie
Hormonrezeptoren
Östrogen-Rezeptor*
negativ (negativ)
nicht bestätigt (nicht best.)
only_in_connection with PR
(only_in_connection with PR)
positiv (positiv)
Progesteron-Rezeptor*
negativ (negativ)
nicht bestätigt (nicht best.)
only_in_connection with ER
(only_in_connection with ER)
positiv (positiv)
Her-2/neu*
negative (neg)
nicht bestätigt (nicht best.)
positive (pos)
Diagnostik
Echokardiographie*
unauffällig (ja)
auffällig (nein)
nicht indiziert (nicht indiziert)
Bemerkung Sonographie*
Staging*
Ja (ja)
Nein (nein)
nicht indiziert (nicht indiziert)
Bemerkung staging*
unauffällig Laborwerte*
Ja
Nein
auffällige Laborwerte*
Ja
Nein
Laboruntersuchung nicht indiziert*
Ja
Nein
Bemerkung Labor*
2 / 4
HIS course of treatment - tumortherapy breast cancer
Urinstick Test*
unauffällig (ja)
auffällig (nein)
nicht indiziert (nicht indiziert)
Bemerkung Urinuntersuchung*
Anamnese
Karnofsky Index*
ECOG Leistungszustand*
Beschwerden*
Ja
Nein
Beschwerden*
Menstuationsbeschwerden*
Ja
Nein
Symptome*
Grad der Beschwerden*
mild (1)
moderat (2)
schwer (3)
sehr schwer (4)
Therapie
intravenös via Port*
Ja
Nein
intravenös via PVK*
Ja
Nein
Chemotherapie*
Ja
Nein
Chemotherapie*
Bisphosphonate*
Ja
Nein
Bisphosphonate*
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Hormon- / endokrine Therapie*
Ja
Nein
Hormon- / endokrine Therapie*
Medikamente*
Rezepte
Antiemetika*
Aprepitant  (Aprepitant (mitgegeben))
Dexamethason (Dexamethason)
Ondansetron (Ondansetron)
Mukositis management *
Ampho-Moronal-Suspension (Ampho-
Moronal-Susp)
therapeutische Gurgellösung (Mucositis-
Gurgellösung (mitgegeben))
andere Medikamente*
Antibiotikaprophylaxe
(Antibiotikaprophylaxe)
Neulasta (primäre GCSF-Prophylaxe
(Neulasta))
sonstige (Sonstige)
nächster Chemotherapiezyklus
Datum nächster Chemotherapie Zyklus*
Bildgebung*
sonstiges*
Unterschrift*
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documentation standard - breast cancer - gynecology, with
friendly permission (Dr. Tio)
- kooperatives Brustzentrum Münster, Bereich Senologie an
der Klinik und Poliklinik für Frauenheilkunde und
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Patientenaufkleber groß
Aufnahmedatum*
Patientenidentifikationsnummer*
Geschlecht Patient*
Patienten-Nachname*
Patienten-Vorname*
Patienten-Geburtsdatum*
Aufnahmezeit*
Einweisender Arzt*
Anamnesebogen
Untersuchungsdatum*
Anamnese erhoben durch *
Zuweisender Arzt *
Frauenfacharzt *
Überweisungsgrund*
Grund des Arztbesuches *
Nachsorge (Nachsorge)
Screening (Screening)
Selbstuntersuchung
(Selbstuntersuchung)
Symptomatik (Symptomatik)
Vorsorge (Vorsorge)
Zufallsbefund (Zufallsbefund)
Anamnese *
Menopausenstatus*
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Perimenopause (peripausal)
Postmenopause (Postmenopause)
Prämenopause (Prämenopause)
unbekannter Menopausen-Status
(unbekannt)
Schwangerschaften*
Stillzeit (Monate)*
Medikamente*
Kontrazeptiva*
Ja
Nein
Hormonersatztherapie*
Ja
Nein
Aspirin*
Ja
Nein
Phenprocoumon *
Ja
Nein
Allergische Reaktion*
Tabak Rauchen*
Ja
Nein
Wie viele Zigaretten pro Tag*
Alkohol Konsum*
Ja
Nein
Details Trinkverhalten*
Vorerkrankungen
Vorerkrankungen*
Ja
Nein
Thrombose*
Ja
Nein
Vorerkrankunge*
2 / 8
HIS medical history breast cancer
Datum Vorerkrankungen*
Therapie*
Externe Befunde
Mammographie*
Ja
Nein
Datum Mammografie*
Seite finding*
links (links)
rechts (rechts)
BIRADS *
Sonografie*
Ja
Nein
Datum Sonografie*
BIRADSanalog *
Magnetresonanz-Mammografie*
Ja
Nein
Datum Magnetresonanz-Mammografie*
MR-BIRADS *
Histologie*
Ja
Nein
sonstiger Befund*
Ja
Nein
Familienanamnese
Familienanamnese*
Klinischer Befund
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Körbchengröße*
nicht_kodiert (> D)
nicht_kodiert (A)
nicht_kodiert (B)
nicht_kodiert (C)
nicht_kodiert (D)
Ptosis*
ausgeprägt (ausgeprägt)
keine (keine)
mittel (mittel)
Symmetrie*
Symmetrie der Brust (ja)
Asymmetrie der Brust (nein)
nein: li<re (nein: li<re)
nein: li>re (nein: li>re)
Absonderung*
Absonderung vorhanden (ja)
blutige Absonderung (ja: blutig)
milchige Absonderung (ja: milchig)
seröse Absonderung (ja: serös)
keine Absonderung (nein)
Haut*
Hauteinziehung (Einziehung)
Brustödem (Ödem)
Plateau (Plateau)
Ulzeration der Brust (Ulzeration)
unauffällig (unauffällig)
intradermale Knoten*
Ja
Nein
entzündlich (inflammatorisches) Karzinom*
Ja
Nein
Brustkonsistenz*
knotige Brustkonsistenz (knotig, schwer
beurteilbar)
normale Brustkonsistenz (weich, gut
beurteilbar)
Seite finding*
links (links)
rechts (rechts)
auffälliger Tastbefund *
multiple (multiple)
nein (nonpalpabel) (nein (nonpalpabel))
solitär (solitär)
Anzahl *
Uhr *
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Größe *
Suspekt *
Ja
Nein
Seite Lymphknoten*
links (links)
rechts (rechts)
Lymphknoten *
nicht tastbar (nicht tastbar)
suspekt (suspekt)
tastbar (tastbar)
Zeichnung*
Sonographie
Zeichnung Sonography*
Seite Sonographie*
links (links)
rechts (rechts)
Nr. *
Uhr *
Größe *
BI-Rads Ultraschall *
Lymphknoten *
pathologisch (pathologisch)
suspekt (suspekt)
unauffällig (unauffällig)
Nummer Herdbefund*
Seite Läsion*
links (links)
rechts (rechts)
Form*
komplex (komplex)
oval (oval)
rund (rund)
Achse*
horizontal (horizontal)
indifferent (indifferent)
vertikal (vertikal)
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Begrenzung*
echoreicher Saum (echoreicher Saum)
unregelmäßig (gezackt)
glatt (glatt)
scharf (scharf)
unscharf (unscharf)
Echogenität*
echoarm (echoarm)
echogleich (echogleich)
echoleer (echoleer)
echoreich (echoreich)
Echostruktur*
homogen (homogen)
heterogen (inhomogen)
dorsale Schallverstärkung*
Ja
Nein
Schallschatten*
Ja
Nein
unilat. Schallauslöschung*
Ja
Nein
bilaterale Schallauslöschung*
Ja
Nein
Destruktionsphänomen*
Umgebungsarchitektur verdrängt
(Umgebungsarchitektur verdrängt)
unterbrochen (unterbrochen)
komprimierbar*
fehlend (fehlend)
gering (gering)
gut (gut)
Gefäße*
im Tumor (im Tumor)
in Umgebung (in Umgebung)
keine Gefäße (keine Gefäße)
Biopsie*
Ja
Nein
Ultraschallgestütze Biopsie*
Ja
Nein
Zystenpunktion*
Ja
Nein
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Nummer Herdbefund*
Anzahl der Stanzen*
Herd nach Stanze*
kleiner (kleiner)
Nein (nein)
entfernt (weg)
Fotodokumentation*
Ja
Nein
Datum*
Unterschrift*
Prozeduren
weiterführende Bildgebung*
Ja
Nein
Mammographie*
Ja
Nein
Datum Mammographie*
Sonographie*
Ja
Nein
Datum Sonographie*
andere Bildgebung*
Ja
Nein
Datum andere Bildgebung*
Tumorkonferenz*
Ja
Nein
Datum Tumorkonferenz*
Nachsorge*
Ja
Nein
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Wiedervorstellung*
Ja
Nein
Datum Wiedervorstellung*
Freitext*
Datum*
Unterschrift*
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HIS surgery planning breast cancer
HIS form ORBIS.  with friendly permission form gynecology
(Dr. Tio) and medical informatics department (Dr. Breil)
All rights reserved. Please visit https://medical-data-
models.org/forms/4085
HIS
Patientenaufkleber
Aufnahmedatum*
Patientenidentifikationsnummer*
Geschlecht Patient*
Patienten-Nachname*
Patienten-Vorname*
Patienten-Geburtsdatum*
Aufnahmezeit*
Einweisender Arzt*
OP Planung
Körperseite*
beidseits (beidseits)
rechts (links)
links (rechts)
Histologie*
B3 (B3)
benigne (benigne)
DCIS (DCIS)
invasives lobuläre Karzinom (IL)
invasives Karzinom (invasiv)
nicht anders spezifiziert (NOS)
Histologisches Grading*
G1 (1)
G2 (2)
G3 (3)
DCIS Kerngrad*
low (1)
intermediate (2)
high (3)
Durchmesser Herd*
Kernspintomographie*
Ja
1 / 3
Nein
Befund MR*
zusätzlicher Herdbefund*
Ja
Nein
zusätzlicher Herdbefund - Freitext*
Architekturstörung Durchmesser*
Durchmesser Mikrokalk*
Körbchengröße*
nicht_kodiert (2D)
nicht_kodiert (A)
nicht_kodiert (B)
nicht_kodiert (C)
nicht_kodiert (D)
Operation
Mastektomie*
Ja
Nein
Brusterhaltende Therapie*
Ja
Nein
rekonstruktive brusterhaltende Therapie*
Ja
Nein
Excisionsbiopsie*
Ja
Nein
Nachresektion*
Ja
Nein
sekundäre  Mastektomie*
Ja
Nein
Segmentgröße*
Prä-Biopsie Drahtmarkierung*
sonographische Markierung (sonograf.
Markierung)
mammograpische Markierung (stereotakt
Markierung)
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Anzahl Markierungen*
Kommentar Markierungen*
Intraoperatives Präparatröntgen*
Ja
Nein
intraoperative makroskopische Begutachtung*
Ja
Nein
Röntgen der pathologischen Präparate*
Ja
Nein
Sentinel Lymphknoten Biopsie*
Ja
Nein
Axilladissektion*
Ja
Nein
Intraoperative Strahlentherapie*
Ja
Nein
klinische Studie*
Freitext*
Verantwortlicher Arzt*
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HIS Talk after conference breast cancer
documentation standard - breast cancer - gynecology, with
friendly permission (Dr. Tio)
- kooperatives Brustzentrum Münster, Bereich Senologie an
der Klinik und Poliklinik für Frauenheilkunde und
Geburtshilfe - Leitung: Dr. med. Joke Tio
All rights reserved. Please visit https://medical-data-
models.org/forms/4087
HIS
Patientenaufkleber groß
Aufnahmedatum*
Patientenidentifikationsnummer*
Geschlecht Patient*
Patienten-Nachname*
Patienten-Vorname*
Patienten-Geburtsdatum*
Aufnahmezeit*
Einweisender Arzt*
Gespräch nach Tumorkonferenz
Datum*
verantwortliche Person*
Einverstädnis für Entscheidung Tumorkonferenz
vorhanden*
Ja
Nein
Änderung der Entscheidung Tumorkonferenz*
geplante Prozeduren*
Ja (ja)
externe Therapie (nein, da weitere
Therapie extern)
nicht erforderlich (nicht erforderlich)
Patient informiert Systemtherapie*
Ja
Nein
Patient informiert endokrine Therapie*
Ja
Nein
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Patient informiert Chemotherapie*
Ja
Nein
Patient informiert Immuntherapie*
Ja
Nein
Rezept endokrine Therapie*
Ja
Nein
Information endokrine Therapie*
Ja
Nein
Portimplantation*
Ja
Nein
Termin Tagesklnik*
Ja
Nein
Termin Strahlentherapie*
Ja
Nein
Information DMP*
Ja
Nein
sonstiges*
Datum der Arzt-Unterschrift*
Unterschrift*
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HIS Talk after conference breast cancer
quality management Onkozert Prostate
prostate cancer
Items needed for Onkozert Cerfication for prostate cancer,
Definitions adapted from download
(http://www.onkozert.de/prostatakrebszentren.htm)
All rights reserved. Please visit https://medical-data-
models.org/forms/4098
quality management
prostate cancer
Primärfall*
Prostata-spezifisches-Antigen*
Gesamt-Gleason-Score*
T-Stadium*
Tumorboard Typ*
Morbiditätskonferenz
(Morbiditätskonferenz)
posttherapeutisch (posttherapeut.
Konferenz )
prätherapeutisch (prätherapeut.
Konferenz )
Teilnehmer*
Pathologie (Pathologie)
Strahlentherapie (Strahlentherapie)
Urologie (Urologie)
pT-Stadium*
pN - Stadium der regionalen Lymphknoten*
pM- Stadium*
Residualklassifikation*
Residualtumor Stadium R0 (R0 = kein
Residualtumor)
Residualtumor Stadium R1 (R1 =
mikroskopischer Residualtumor)
Aufnahmeanlass*
Fernmetastasen (M-Fernmetastase)
Primärtumor (P-Primärtumor)
Rezidiv (R-Rezidiv)
active surveillance*
Strahlentherapie - Technik*
Brachytherapy (Brachytherapie)
Tele-Radiotherapie (P-perkutane
Therapie (Tele- und Brachyth.))
Interne Radiotherapie - permanente
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Seeds (Permanente Seedimplantation)
Hormon- / endokrine Therapie*
Ja
Nein
onkologische Psychotherapie*
Ja
Nein
Sozialdienst*
Ja
Nein
Studienpatient*
Prostatektomie*
Komplikationen*
Ja
Nein
postoperative Wundinfektion*
chirurgische Revision*
Nachblutung mit Revision*
Ja
Nein
Lymphozele*
Ja
Nein
Harnfistel*
Ja
Nein
Sonstige Komplikation*
Ja
Nein
Nerverhalt*
Bestrahlung*
D90 > 130 Gy erreicht?*
Chirurgische und medizinische Prozeduren*
Patientgesundheits-Fragebogen*
Ja
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Nein
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HIS aftercare form - physician prostate
cancer
HIS form from Soarian. Urologie Erlangen" with friendly
permission of the urology Erlangen (Prof. Wullich) and the
medical informatics department Erlangen (PD Dr. Bürkle)
All rights reserved. Please visit https://medical-data-
models.org/forms/4099
HIS
Admininstrative Daten
Patienten-Nachname*
Patienten-Vorname*
Patienten-Titel*
früherer Name*
Patienten-Geburtsdatum*
Alter des Patienten*
Nationalität/Staatsangehörigkeit*
Straße*
Postleitzahl Patient*
Wohnort*
Fallnummer*
Tumordiagnose
Tumordiagnose*
Datum der Diagnose*
Nachsorge
Status Patient*
Primärfall (Primärpatient)
sonstiges (sonstiges)
nicht_kodiert (Wiederkehrer)
Untersuchungsdatum*
Tumorstatus*
Beurteilung nicht möglich (Beurteilung
1 / 7
nicht möglich)
Tumor Progression (Progression)
stable disease (stable disease)
Teilremission (Teilremission)
kein Tumor (Tumorfrei)
komplette Remission (Vollremission)
Grund für nicht mögliche Beurteilung*
ECOG Leistungszustand*
0 (0)
1 (1)
2 (2)
3 (3)
4 (4)
X (X)
Untersuchungen an der Prostata
digitale rektale Untersuchung*
nicht suspekt (nicht suspekt)
suspekt (suspekt)
unbekannt (unbekannt)
Datum DRU*
PSA unterhalb der Nachweisgrenze*
Ja
Nein
PSA*
Datum PSA*
Auffälligkeiten im Labor
Auffälligkeiten im Labor*
Ja
Nein
Datum Laborauffälligkeit*
Anämie*
Ja
Nein
Niereninsuffizienz*
Ja
Nein
Leukozytopenie*
Ja
Nein
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LDH*
Ja
Nein
CRP*
Ja
Nein
andere*
Ja
Nein
Thrombozytopenie*
Ja
Nein
Bildgebende Diagnostik
Bildgebende Diagnostik*
Ja
Nein
Computertomografie*
Ja (Ja)
Nein (Nein)
unbekannt (unbekannt)
Kernspintomographie*
Ja (Ja)
Nein (Nein)
unbekannt (unbekannt)
Szintigraphie*
Ja
Nein
Positronen-Emissions-Tomographie*
Ja
Nein
Tumorstatus
Tumor Progression*
Ja (ja)
Nein (nein)
unbekannt (unbekannt)
Primärtumor*
fragliches Ergebnis (F = fraglicher
Befund)
kein Nachweis des Tumors (K = kein
Tumornachweis)
Rezidiv (R = Rezidiv)
Tumor vorhanden (T = Tumornachweis)
unbekannt (unbekannt)
Medizinische Untersuchung*
Exploration (CH = Chirurg. Exploration)
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Computertomografie (CT =
Computertomographie)
Doppler-Ultraschall (DO = Doppler)
Endoskopie (EN = Endoskopie)
Histo-/Zytologie (HI = Histo-/Zytologie)
körperliche Untersuchung (KU =
Körperliche Untersuchung)
Labor (LA = Labor)
Kernspintomographie (NM =
Kernspintomographie)
Positronen-Emissions-Tomographie (PT
= Positronen-Emissions-Tomo)
Röntgen (RÖ = Röntgen)
Sonographie (SO = Sonographie)
Szintigraphie (SZ = Szintigraphie)
Metastase in regionären Lymphknoten*
fragliches Ergebnis (F = fraglicher
Befund)
kein Nachweis des Tumors (K = kein
Tumornachweis)
Rezidiv (R = Rezidiv)
Tumor vorhanden (T = Tumornachweis)
unbekannt (unbekannt)
Medizinische Untersuchung*
Exploration (CH = Chirurg. Exploration)
Computertomografie (CT =
Computertomographie)
Doppler-Ultraschall (DO = Doppler)
Endoskopie (EN = Endoskopie)
Histo-/Zytologie (HI = Histo-/Zytologie)
körperliche Untersuchung (KU =
Körperliche Untersuchung)
Labor (LA = Labor)
Kernspintomographie (NM =
Kernspintomographie)
Positronen-Emissions-Tomographie (PT
= Positronen-Emissions-Tomo)
Röntgen (RÖ = Röntgen)
Sonographie (SO = Sonographie)
Szintigraphie (SZ = Szintigraphie)
Metastase*
fragliches Ergebnis (F = fraglicher
Befund)
kein Nachweis des Tumors (K = kein
Tumornachweis)
Rezidiv (R = Rezidiv)
Tumor vorhanden (T = Tumornachweis)
unbekannt (unbekannt)
Tumorausbreitung
Lokalisation Fernmetastase*
Metastase in der Haut*
Ja
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Nein
Metastase im Gehirn*
Ja
Nein
Metastase in den Knochen*
Ja
Nein
Metastase im Knochenmark*
Ja
Nein
Metastase in der Leber*
Ja
Nein
Metastase in der Lunge*
Ja
Nein
Metastase im Lymphknoten*
Ja
Nein
Metastase in der Nebenniere*
Ja
Nein
Metastase im Peritoneum*
Ja
Nein
Metastase in der Pleura*
Ja
Nein
Generalisiere Metastasierung*
Ja
Nein
Fernmestastase (andere Organe)*
Ja
Nein
Medizinische Untersuchung*
Exploration (CH = Chirurg. Exploration)
Computertomografie (CT =
Computertomographie)
Doppler-Ultraschall (DO = Doppler)
Endoskopie (EN = Endoskopie)
Histo-/Zytologie (HI = Histo-/Zytologie)
körperliche Untersuchung (KU =
Körperliche Untersuchung)
Labor (LA = Labor)
Kernspintomographie (NM =
Kernspintomographie)
Positronen-Emissions-Tomographie (PT
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= Positronen-Emissions-Tomo)
Röntgen (RÖ = Röntgen)
Sonographie (SO = Sonographie)
Szintigraphie (SZ = Szintigraphie)
Datum der Diagnose*
Nebenwirkungen*
Ja
Nein
Spätnebenwirkung während der Beobachtung
des Patienten*
Ja (Ja)
Nein (Nein (allgemein Keine))
unbekannt (unbekannt)
SpätNebenwirkung in Zusammenhang nmit
urologischen Operation*
Harnstauungsnieren
(Harnstauungsnieren)
Hernie (Hernie)
Impotenz (Impotenz)
Urininkontinenz (Inkontinenz)
Lymphocele (Lymphocele)
unbekannt (unbekannt)
Wundheilungsstörungen
(Wundheilungsstörungen)
Spätnebenwirkung in Zusammenhang mit der
Strahlentherapie*
Darmblutung (Darmblutung)
eingeschränkte Blasenfunktion
(eingeschränkte Blasenfunktion)
Harnstauungsnieren
(Harnstauungsnieren)
Impotenz (Impotenz)
Urininkontinenz (Inkontinenz)
unbekannt (unbekannt)
andere Spätnebenwirkungen?*
Ja (Ja)
Nein (Nein)
unbekannt (unbekannt)
Therapie
Radical Prostatectomy*
Ja
Nein
Chemotherapie*
Ja
Nein
Bestrahlung*
Ja
Nein
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Antiandrogen Therapie*
Ja
Nein
Watchful Waiting*
Ja
Nein
Active surveillance *
Ja
Nein
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HIS autopsy form prostate cancer
HIS form from Soarian. Urologie Erlangen" with friendly
permission of the urology Erlangen (Prof. Wullich) and the
medical informatics department Erlangen (PD Dr. Bürkle)
All rights reserved. Please visit https://medical-data-
models.org/forms/4100
HIS
Admininstrative Daten
Patienten-Nachname*
Patienten-Vorname*
Patienten-Titel*
früherer Name*
Patienten-Geburtsdatum*
Alter des Patienten*
Nationalität/Staatsangehörigkeit*
Straße*
Postleitzahl Patient*
Wohnort*
Fallnummer*
Tumordiagnose
Tumordiagnose*
Datum der Diagnose*
Autopsiedaten
Datum der Autopsie*
Tumorausbreitung
Primärtumor*
fragliches Ergebnis (F = fraglicher
Befund)
kein Nachweis des Tumors (K = Kein
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Tumornachweis)
Rezidiv (R = Rezidiv)
Tumor vorhanden (T = Tumornachweis)
Unbekannt (X = unbekannt)
Metastase in regionären Lymphknoten*
fragliches Ergebnis (F = fraglicher
Befund)
kein Nachweis des Tumors (K = Kein
Tumornachweis)
Rezidiv (R = Rezidiv)
Tumor vorhanden (T = Tumornachweis)
Unbekannt (X = unbekannt)
Fernmetastasen
Metastase in Fern - Lymphknoten*
fragliches Ergebnis (F = fraglicher
Befund)
kein Nachweis des Tumors (K = Kein
Tumornachweis)
Rezidiv (R = Rezidiv)
Tumor vorhanden (T = Tumornachweis)
Unbekannt (X = unbekannt)
Metastase in der Lunge*
fragliches Ergebnis (F = fraglicher
Befund)
kein Nachweis des Tumors (K = Kein
Tumornachweis)
Rezidiv (R = Rezidiv)
Tumor vorhanden (T = Tumornachweis)
Unbekannt (X = unbekannt)
Metastase in der Leber*
fragliches Ergebnis (F = fraglicher
Befund)
kein Nachweis des Tumors (K = Kein
Tumornachweis)
Rezidiv (R = Rezidiv)
Tumor vorhanden (T = Tumornachweis)
Unbekannt (X = unbekannt)
Metastase im Gehirn*
fragliches Ergebnis (F = fraglicher
Befund)
kein Nachweis des Tumors (K = Kein
Tumornachweis)
Rezidiv (R = Rezidiv)
Tumor vorhanden (T = Tumornachweis)
Unbekannt (X = unbekannt)
Metastase in der Pleura*
fragliches Ergebnis (F = fraglicher
Befund)
kein Nachweis des Tumors (K = Kein
Tumornachweis)
Rezidiv (R = Rezidiv)
Tumor vorhanden (T = Tumornachweis)
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Unbekannt (X = unbekannt)
Metastase in der Haut*
fragliches Ergebnis (F = fraglicher
Befund)
kein Nachweis des Tumors (K = Kein
Tumornachweis)
Rezidiv (R = Rezidiv)
Tumor vorhanden (T = Tumornachweis)
Unbekannt (X = unbekannt)
Metastase in den Knochen*
fragliches Ergebnis (F = fraglicher
Befund)
kein Nachweis des Tumors (K = Kein
Tumornachweis)
Rezidiv (R = Rezidiv)
Tumor vorhanden (T = Tumornachweis)
Unbekannt (X = unbekannt)
Metastase in der Nebenniere*
fragliches Ergebnis (F = fraglicher
Befund)
kein Nachweis des Tumors (K = Kein
Tumornachweis)
Rezidiv (R = Rezidiv)
Tumor vorhanden (T = Tumornachweis)
Unbekannt (X = unbekannt)
Metastase im Peritoneum*
fragliches Ergebnis (F = fraglicher
Befund)
kein Nachweis des Tumors (K = Kein
Tumornachweis)
Rezidiv (R = Rezidiv)
Tumor vorhanden (T = Tumornachweis)
Unbekannt (X = unbekannt)
Metastase in der Milz*
fragliches Ergebnis (F = fraglicher
Befund)
kein Nachweis des Tumors (K = Kein
Tumornachweis)
Rezidiv (R = Rezidiv)
Tumor vorhanden (T = Tumornachweis)
Unbekannt (X = unbekannt)
Metastase im Ovar*
fragliches Ergebnis (F = fraglicher
Befund)
kein Nachweis des Tumors (K = Kein
Tumornachweis)
Rezidiv (R = Rezidiv)
Tumor vorhanden (T = Tumornachweis)
Unbekannt (X = unbekannt)
Metastase im Knochenmark*
fragliches Ergebnis (F = fraglicher
Befund)
kein Nachweis des Tumors (K = Kein
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Tumornachweis)
Rezidiv (R = Rezidiv)
Tumor vorhanden (T = Tumornachweis)
Unbekannt (X = unbekannt)
Fernmestastase (andere Organe)*
Tumor vorhanden*
Unbekannt (F = fraglicher Befund)
Rezidiv (K = Kein Tumornachweis)
fragliches Ergebnis (R = Rezidiv)
kein Nachweis des Tumors (T =
Tumornachweis)
anderes Organ, welches? (X =
unbekannt)
TNM-Klassifikation
Tumorstaging-Symbole*
rezidiv Stadium (r)  (r-Symbol)
neoadjuvanter Therapie (y) (Y-Symbol)
T-Stadium*
T0 (T0)
T1 (T1)
T2 (T2)
T3 (T3)
T4 (T4)
TX (TX)
Multple*
Ja
Nein
N - Stadium der regionalen Lymphknoten*
N0 (N0)
N1 (N1)
N2 Stadium (N2)
N3 Stadium (N3)
NX (NX)
M- Stadium*
M0 (M0)
M1 (M1)
MX (MX)
Tumorhistologie
Pathologisches Institut*
Datum Pathologie Befund*
Histologie-Code ICD-0-3*
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Histologisches Grading*
G1 (G1 = Gut differenziert)
G2 (G2 = Mäßig differenziert)
G3 (G3 = Schlecht differenziert)
High grade (High grade)
Low grade (Low grade)
Grading nicht vorgesehen (O = Grading
nicht vorgesehen)
X = Differenzierungsgrad kann nicht
bestimmt werden (X =
Differenzierungsgrad kann nicht
bestimmt werden)
Seite Lymphknoten*
links (links)
rechts (rechts)
Anzahl der untersuchten Lymphknoten *
Anzahl der befallenen Lymphknoten *
Gesamt-Gleason-Score*
häufigstes Gleason-Muster*
zweithäufigstes Gleason-Muster*
Lymphgefäßinvasion*
L0 = keine Lymphgefäßinvasion (L0)
L1 = Lymphgefäßinvasion (L1)
LX = nicht beurteilbar (LX)
Veneninvasion*
V0 = keine Veneninvasion (V0)
V1 = mikroskopische Veneninvasion (V1)
V2 = makroskopische Veneninvasion
(V2)
VX = nicht beurteilbar (VX)
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HIS systemic therapy - form prostate cancer
HIS form from Soarian. Urologie Erlangen" with friendly
permission of the urology Erlangen (Prof. Wullich) and the
medical informatics department Erlangen (PD Dr. Bürkle)
All rights reserved. Please visit https://medical-data-
models.org/forms/4102
HIS
Admininstrative Daten
Patienten-Nachname*
Patienten-Vorname*
Patienten-Titel*
früherer Name*
Patienten-Geburtsdatum*
Alter des Patienten*
Nationalität/Staatsangehörigkeit*
Straße*
Postleitzahl Patient*
Wohnort*
Fallnummer*
Tumordiagnose
Tumordiagnose*
Datum der Diagnose*
Systemische Therapie
Einhaltung der Leitlinen*
Ja
Nein
Grund für Einhaltung Leitlinien*
Therapieart
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Therapieart*
Ja
Nein
Chemotherapie*
Ja
Nein
Hormon- / endokrine Therapie*
Ja
Nein
Immuntherapie*
Ja
Nein
Antikörper Therapie*
Ja
Nein
Aufnahmestatus*
ambulant (ambulant)
stationär (stationär)
teilstationär (teilstationär)
Intention*
Ja
Nein
Intention - Chemotherapie*
Adjuvant (adjuvant)
Kurativ (kurativ)
Neoadjuvant (neoadjuvant)
Palliativ (palliativ)
Chemoradiotherapy *
Ja
Nein
Intention - endokrine Therapie*
Adjuvant (adjuvant)
Kurativ (kurativ)
Neoadjuvant (neoadjuvant)
Palliativ (palliativ)
Intention - Immuntherapie*
Adjuvant (adjuvant)
Kurativ (kurativ)
Neoadjuvant (neoadjuvant)
Palliativ (palliativ)
Intention - Antikörpertherapie*
Adjuvant (adjuvant)
Kurativ (kurativ)
Neoadjuvant (neoadjuvant)
Palliativ (palliativ)
Unterbrechung
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Unterbrechung*
Ja
Nein
Unterbrechung von*
Unterbrechung bis*
Grund für Unterbrecung*
Protokoll
Protokoll*
Chemotherapy cycle (procedure)
Chemotherapy cycle (procedure) *
Ja
Nein
Zyklen geplant*
aktueller Zyklus*
Datum Therapiebeginn - Chemotherapie*
Datum Therapiebeginn - endokrine Therapie*
Datum Therapiebeginn - Immuntherapie*
Voraussichtliche Beendigung*
pharmakologische Substanz
Chemotherapie Substanz*
Dosislevel der Chemotherapie reduziert*
Ja
Nein
Einzeldosis*
kumulative Dosis*
Einheit*
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Begleitmedikation
Begleitmedikation*
Ja
Nein
Antihomornelle Therapie*
LHRH (LHRH)
Orchiektomie*
Ja
Nein
Antiandrogen Therapie*
Ja
Nein
supportive Theapie*
sonstiges (andere)
Estramustin (Estramustin)
Prednison (Prednison)
Zoledronsäure (Zometa)
sonstiges*
Nebenwirkungen
Nebenwirkungen*
Ja
Nein
Leukozyten*
keine Nebenwirkungen (0 = keine
Nebenwirkungen)
leichte Nebenwirkungen (1 = milde
Nebenwirkungen)
mäßige Nebenwirkungen (2 = moderate
Nebenwirkungen)
starke Nebenwirkungen (3 = schwere
Nebenwirkungen)
lebensbedrohliche Nebenwirkungen (4 =
Lebensbedrohliche Nebenwirkungen)
letale Nebenwirkung (S = Tod)
Grad der Nebenwirkungen unbekannt (X
= Nebenwirkung unbekannt)
Hämoglobin*
keine Nebenwirkungen (0 = keine
Nebenwirkungen)
leichte Nebenwirkungen (1 = milde
Nebenwirkungen)
mäßige Nebenwirkungen (2 = moderate
Nebenwirkungen)
starke Nebenwirkungen (3 = schwere
Nebenwirkungen)
lebensbedrohliche Nebenwirkungen (4 =
Lebensbedrohliche Nebenwirkungen)
letale Nebenwirkung (S = Tod)
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Grad der Nebenwirkungen unbekannt (X
= Nebenwirkung unbekannt)
Granulozyten*
keine Nebenwirkungen (0 = keine
Nebenwirkungen)
leichte Nebenwirkungen (1 = milde
Nebenwirkungen)
mäßige Nebenwirkungen (2 = moderate
Nebenwirkungen)
starke Nebenwirkungen (3 = schwere
Nebenwirkungen)
lebensbedrohliche Nebenwirkungen (4 =
Lebensbedrohliche Nebenwirkungen)
letale Nebenwirkung (S = Tod)
Grad der Nebenwirkungen unbekannt (X
= Nebenwirkung unbekannt)
Thrombozyten*
keine Nebenwirkungen (0 = keine
Nebenwirkungen)
leichte Nebenwirkungen (1 = milde
Nebenwirkungen)
mäßige Nebenwirkungen (2 = moderate
Nebenwirkungen)
starke Nebenwirkungen (3 = schwere
Nebenwirkungen)
lebensbedrohliche Nebenwirkungen (4 =
Lebensbedrohliche Nebenwirkungen)
letale Nebenwirkung (S = Tod)
Grad der Nebenwirkungen unbekannt (X
= Nebenwirkung unbekannt)
Kreatinin*
keine Nebenwirkungen (0 = keine
Nebenwirkungen)
leichte Nebenwirkungen (1 = milde
Nebenwirkungen)
mäßige Nebenwirkungen (2 = moderate
Nebenwirkungen)
starke Nebenwirkungen (3 = schwere
Nebenwirkungen)
lebensbedrohliche Nebenwirkungen (4 =
Lebensbedrohliche Nebenwirkungen)
letale Nebenwirkung (S = Tod)
Grad der Nebenwirkungen unbekannt (X
= Nebenwirkung unbekannt)
Proteinurie*
keine Nebenwirkungen (0 = keine
Nebenwirkungen)
leichte Nebenwirkungen (1 = milde
Nebenwirkungen)
mäßige Nebenwirkungen (2 = moderate
Nebenwirkungen)
starke Nebenwirkungen (3 = schwere
Nebenwirkungen)
lebensbedrohliche Nebenwirkungen (4 =
Lebensbedrohliche Nebenwirkungen)
letale Nebenwirkung (S = Tod)
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Grad der Nebenwirkungen unbekannt (X
= Nebenwirkung unbekannt)
Harnstoff*
keine Nebenwirkungen (0 = keine
Nebenwirkungen)
leichte Nebenwirkungen (1 = milde
Nebenwirkungen)
mäßige Nebenwirkungen (2 = moderate
Nebenwirkungen)
starke Nebenwirkungen (3 = schwere
Nebenwirkungen)
lebensbedrohliche Nebenwirkungen (4 =
Lebensbedrohliche Nebenwirkungen)
letale Nebenwirkung (S = Tod)
Grad der Nebenwirkungen unbekannt (X
= Nebenwirkung unbekannt)
Bilirubin*
keine Nebenwirkungen (0 = keine
Nebenwirkungen)
leichte Nebenwirkungen (1 = milde
Nebenwirkungen)
mäßige Nebenwirkungen (2 = moderate
Nebenwirkungen)
starke Nebenwirkungen (3 = schwere
Nebenwirkungen)
lebensbedrohliche Nebenwirkungen (4 =
Lebensbedrohliche Nebenwirkungen)
letale Nebenwirkung (S = Tod)
Grad der Nebenwirkungen unbekannt (X
= Nebenwirkung unbekannt)
Alkalische Phosphatase*
keine Nebenwirkungen (0 = keine
Nebenwirkungen)
leichte Nebenwirkungen (1 = milde
Nebenwirkungen)
mäßige Nebenwirkungen (2 = moderate
Nebenwirkungen)
starke Nebenwirkungen (3 = schwere
Nebenwirkungen)
lebensbedrohliche Nebenwirkungen (4 =
Lebensbedrohliche Nebenwirkungen)
letale Nebenwirkung (S = Tod)
Grad der Nebenwirkungen unbekannt (X
= Nebenwirkung unbekannt)
Alanin-Transaminase*
keine Nebenwirkungen (0 = keine
Nebenwirkungen)
leichte Nebenwirkungen (1 = milde
Nebenwirkungen)
mäßige Nebenwirkungen (2 = moderate
Nebenwirkungen)
starke Nebenwirkungen (3 = schwere
Nebenwirkungen)
lebensbedrohliche Nebenwirkungen (4 =
Lebensbedrohliche Nebenwirkungen)
only_in_connection with GOT
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(only_in_connection with GOT)
letale Nebenwirkung (S = Tod)
Grad der Nebenwirkungen unbekannt (X
= Nebenwirkung unbekannt)
Aspartat-Transaminase*
keine Nebenwirkungen (0 = keine
Nebenwirkungen)
leichte Nebenwirkungen (1 = milde
Nebenwirkungen)
mäßige Nebenwirkungen (2 = moderate
Nebenwirkungen)
starke Nebenwirkungen (3 = schwere
Nebenwirkungen)
lebensbedrohliche Nebenwirkungen (4 =
Lebensbedrohliche Nebenwirkungen)
only_in_connection with GPT
(only_in_connection with GPT)
letale Nebenwirkung (S = Tod)
Grad der Nebenwirkungen unbekannt (X
= Nebenwirkung unbekannt)
Übelkeit*
keine Nebenwirkungen (0 = keine
Nebenwirkungen)
leichte Nebenwirkungen (1 = milde
Nebenwirkungen)
mäßige Nebenwirkungen (2 = moderate
Nebenwirkungen)
starke Nebenwirkungen (3 = schwere
Nebenwirkungen)
lebensbedrohliche Nebenwirkungen (4 =
Lebensbedrohliche Nebenwirkungen)
letale Nebenwirkung (S = Tod)
Grad der Nebenwirkungen unbekannt (X
= Nebenwirkung unbekannt)
Diarrhoe*
keine Nebenwirkungen (0 = keine
Nebenwirkungen)
leichte Nebenwirkungen (1 = milde
Nebenwirkungen)
mäßige Nebenwirkungen (2 = moderate
Nebenwirkungen)
starke Nebenwirkungen (3 = schwere
Nebenwirkungen)
lebensbedrohliche Nebenwirkungen (4 =
Lebensbedrohliche Nebenwirkungen)
letale Nebenwirkung (S = Tod)
Nebenwirkungen unbekannt (X =
Nebenwirkung unbekannt)
Schleimhaut*
keine Nebenwirkungen (0 = keine
Nebenwirkungen)
leichte Nebenwirkungen (1 = milde
Nebenwirkungen)
mäßige Nebenwirkungen (2 = moderate
Nebenwirkungen)
starke Nebenwirkungen (3 = schwere
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Nebenwirkungen)
lebensbedrohliche Nebenwirkungen (4 =
Lebensbedrohliche Nebenwirkungen)
letale Nebenwirkung (S = Tod)
Nebenwirkungen unbekannt (X =
Nebenwirkung unbekannt)
Vomiting*
keine Nebenwirkungen (0 = keine
Nebenwirkungen)
leichte Nebenwirkungen (1 = milde
Nebenwirkungen)
mäßige Nebenwirkungen (2 = moderate
Nebenwirkungen)
starke Nebenwirkungen (3 = schwere
Nebenwirkungen)
lebensbedrohliche Nebenwirkungen (4 =
Lebensbedrohliche Nebenwirkungen)
letale Nebenwirkung (S = Tod)
Nebenwirkungen unbekannt (X =
Nebenwirkung unbekannt)
Obstipation*
keine Nebenwirkungen (0 = keine
Nebenwirkungen)
leichte Nebenwirkungen (1 = milde
Nebenwirkungen)
mäßige Nebenwirkungen (2 = moderate
Nebenwirkungen)
starke Nebenwirkungen (3 = schwere
Nebenwirkungen)
lebensbedrohliche Nebenwirkungen (4 =
Lebensbedrohliche Nebenwirkungen)
letale Nebenwirkung (S = Tod)
Nebenwirkungen unbekannt (X =
Nebenwirkung unbekannt)
Peripherer Nerv*
keine Nebenwirkungen (0 = keine
Nebenwirkungen)
leichte Nebenwirkungen (1 = milde
Nebenwirkungen)
mäßige Nebenwirkungen (2 = moderate
Nebenwirkungen)
starke Nebenwirkungen (3 = schwere
Nebenwirkungen)
lebensbedrohliche Nebenwirkungen (4 =
Lebensbedrohliche Nebenwirkungen)
letale Nebenwirkung (S = Tod)
Nebenwirkungen unbekannt (X =
Nebenwirkung unbekannt)
Bewusstsein*
keine Nebenwirkungen (0 = keine
Nebenwirkungen)
leichte Nebenwirkungen (1 = milde
Nebenwirkungen)
mäßige Nebenwirkungen (2 = moderate
Nebenwirkungen)
starke Nebenwirkungen (3 = schwere
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Nebenwirkungen)
lebensbedrohliche Nebenwirkungen (4 =
Lebensbedrohliche Nebenwirkungen)
letale Nebenwirkung (S = Tod)
Nebenwirkungen unbekannt (X =
Nebenwirkung unbekannt)
Dyspnoe*
keine Nebenwirkungen (0 = keine
Nebenwirkungen)
leichte Nebenwirkungen (1 = milde
Nebenwirkungen)
mäßige Nebenwirkungen (2 = moderate
Nebenwirkungen)
starke Nebenwirkungen (3 = schwere
Nebenwirkungen)
lebensbedrohliche Nebenwirkungen (4 =
Lebensbedrohliche Nebenwirkungen)
letale Nebenwirkung (S = Tod)
Nebenwirkungen unbekannt (X =
Nebenwirkung unbekannt)
Infektion*
keine Nebenwirkungen (0 = keine
Nebenwirkungen)
leichte Nebenwirkungen (1 = milde
Nebenwirkungen)
mäßige Nebenwirkungen (2 = moderate
Nebenwirkungen)
starke Nebenwirkungen (3 = schwere
Nebenwirkungen)
lebensbedrohliche Nebenwirkungen (4 =
Lebensbedrohliche Nebenwirkungen)
letale Nebenwirkung (S = Tod)
Nebenwirkungen unbekannt (X =
Nebenwirkung unbekannt)
Herzrhythmus*
keine Nebenwirkungen (0 = keine
Nebenwirkungen)
leichte Nebenwirkungen (1 = milde
Nebenwirkungen)
mäßige Nebenwirkungen (2 = moderate
Nebenwirkungen)
starke Nebenwirkungen (3 = schwere
Nebenwirkungen)
lebensbedrohliche Nebenwirkungen (4 =
Lebensbedrohliche Nebenwirkungen)
letale Nebenwirkung (S = Tod)
Nebenwirkungen unbekannt (X =
Nebenwirkung unbekannt)
Herzfunktion*
keine Nebenwirkungen (0 = keine
Nebenwirkungen)
leichte Nebenwirkungen (1 = milde
Nebenwirkungen)
mäßige Nebenwirkungen (2 = moderate
Nebenwirkungen)
starke Nebenwirkungen (3 = schwere
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Nebenwirkungen)
lebensbedrohliche Nebenwirkungen (4 =
Lebensbedrohliche Nebenwirkungen)
letale Nebenwirkung (S = Tod)
Nebenwirkungen unbekannt (X =
Nebenwirkung unbekannt)
Perikarditis*
keine Nebenwirkungen (0 = keine
Nebenwirkungen)
leichte Nebenwirkungen (1 = milde
Nebenwirkungen)
mäßige Nebenwirkungen (2 = moderate
Nebenwirkungen)
starke Nebenwirkungen (3 = schwere
Nebenwirkungen)
lebensbedrohliche Nebenwirkungen (4 =
Lebensbedrohliche Nebenwirkungen)
letale Nebenwirkung (S = Tod)
Nebenwirkungen unbekannt (X =
Nebenwirkung unbekannt)
Fieber*
keine Nebenwirkungen (0 = keine
Nebenwirkungen)
leichte Nebenwirkungen (1 = milde
Nebenwirkungen)
mäßige Nebenwirkungen (2 = moderate
Nebenwirkungen)
starke Nebenwirkungen (3 = schwere
Nebenwirkungen)
lebensbedrohliche Nebenwirkungen (4 =
Lebensbedrohliche Nebenwirkungen)
letale Nebenwirkung (S = Tod)
Nebenwirkungen unbekannt (X =
Nebenwirkung unbekannt)
Allergie*
keine Nebenwirkungen (0 = keine
Nebenwirkungen)
leichte Nebenwirkungen (1 = milde
Nebenwirkungen)
mäßige Nebenwirkungen (2 = moderate
Nebenwirkungen)
starke Nebenwirkungen (3 = schwere
Nebenwirkungen)
lebensbedrohliche Nebenwirkungen (4 =
Lebensbedrohliche Nebenwirkungen)
letale Nebenwirkung (S = Tod)
Nebenwirkungen unbekannt (X =
Nebenwirkung unbekannt)
Schmerzen*
keine Nebenwirkungen (0 = keine
Nebenwirkungen)
leichte Nebenwirkungen (1 = milde
Nebenwirkungen)
mäßige Nebenwirkungen (2 = moderate
Nebenwirkungen)
starke Nebenwirkungen (3 = schwere
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Nebenwirkungen)
lebensbedrohliche Nebenwirkungen (4 =
Lebensbedrohliche Nebenwirkungen)
letale Nebenwirkung (S = Tod)
Nebenwirkungen unbekannt (X =
Nebenwirkung unbekannt)
Haut*
keine Nebenwirkungen (0 = keine
Nebenwirkungen)
leichte Nebenwirkungen (1 = milde
Nebenwirkungen)
mäßige Nebenwirkungen (2 = moderate
Nebenwirkungen)
starke Nebenwirkungen (3 = schwere
Nebenwirkungen)
lebensbedrohliche Nebenwirkungen (4 =
Lebensbedrohliche Nebenwirkungen)
letale Nebenwirkung (S = Tod)
Nebenwirkungen unbekannt (X =
Nebenwirkung unbekannt)
Zystitis*
keine Nebenwirkungen (0 = keine
Nebenwirkungen)
leichte Nebenwirkungen (1 = milde
Nebenwirkungen)
mäßige Nebenwirkungen (2 = moderate
Nebenwirkungen)
starke Nebenwirkungen (3 = schwere
Nebenwirkungen)
lebensbedrohliche Nebenwirkungen (4 =
Lebensbedrohliche Nebenwirkungen)
letale Nebenwirkung (S = Tod)
Nebenwirkungen unbekannt (X =
Nebenwirkung unbekannt)
Hämaturie*
keine Nebenwirkungen (0 = keine
Nebenwirkungen)
leichte Nebenwirkungen (1 = milde
Nebenwirkungen)
mäßige Nebenwirkungen (2 = moderate
Nebenwirkungen)
starke Nebenwirkungen (3 = schwere
Nebenwirkungen)
lebensbedrohliche Nebenwirkungen (4 =
Lebensbedrohliche Nebenwirkungen)
letale Nebenwirkung (S = Tod)
Nebenwirkungen unbekannt (X =
Nebenwirkung unbekannt)
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HIS surgery complication prostate cancer
HIS form from Soarian. Urologie Erlangen" with friendly
permission of the urology Erlangen (Prof. Wullich) and the
medical informatics department Erlangen (PD Dr. Bürkle)
All rights reserved. Please visit https://medical-data-
models.org/forms/4103
HIS
Admininstrative Daten
Patienten-Nachname*
Patienten-Vorname*
Patienten-Titel*
früherer Name*
Patienten-Geburtsdatum*
Alter des Patienten*
Nationalität/Staatsangehörigkeit*
Straße*
Postleitzahl Patient*
Wohnort*
Fallnummer*
Komplikationsbogen
Tumordiagnose*
Datum der Diagnose*
Datum der OP*
postoperative Wundinfektion
postoperative Wundinfektion*
Ja
Nein
Fallnummer*
1 / 2
Postoperative Revisionseingriffe
chirurgische Revision*
Ja
Nein
Welche Revisionsoperation*
Lymphozelendrainage - ambulant
(ambulante Lymphozelendrainage)
Blutung (Hämatom)
Lymphozelendrainage - operativ
(operativ:
Lymphozelendrainage/Lymphozelenfenst
er)
Sonstiges (Sonstiges)
Sonstiges*
nicht_kodiert
nicht_kodiert*
nicht_kodiert (Grad I - Abweichung vom
normalen postoperativen Verlauf ohne
die Notwendigkeit einer Intervention)
nicht_kodiert (Grad II - Leichte
Komplikationen, die einer
medikamentösen Intervention,
Bluttransfusion oder parenteralen
Ernährung bedürfen)
nicht_kodiert (Grad III - Komplikationen,
bei denen eine chirurgische,
endoskopische oder radiologische
Intervention notwendig ist)
nicht_kodiert (Grad IIIa - wie zuvor
jedoch ohne Vollnarkose)
nicht_kodiert (Grad IIIb - wie zuvor
jedoch  mit Vollnarkose)
nicht_kodiert (Grad IV -
Lebensbedrohliche Komplikation, die
eine intensivmedizinische Behandlung
verlangten)
nicht_kodiert (Grad IVa - Versagen eines
Organs)
nicht_kodiert (Grad IVb - Versagen
mehrerer Organe)
nicht_kodiert (Grad V - Tod durch
Komplikationen hervorgerufen)
nicht_kodiert*
nicht_kodiert (individuell)
nicht_kodiert (schicksalhaft =
unvermeidbar)
nicht_kodiert (systemisch)
nicht_kodiert (vermeidbar)
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HIS temporary and final report prostate
cancer
HIS form from Soarian. Urologie Erlangen" with friendly
permission of the urology Erlangen (Prof. Wullich) and the
medical informatics department Erlangen (PD Dr. Bürkle)
All rights reserved. Please visit https://medical-data-
models.org/forms/4104
HIS
Admininstrative Daten
Patienten-Nachname*
Patienten-Vorname*
Patienten-Titel*
früherer Name*
Patienten-Geburtsdatum*
Alter des Patienten*
Nationalität/Staatsangehörigkeit*
Straße*
Postleitzahl Patient*
Wohnort*
Fallnummer*
Tumordiagnose
Tumordiagnose*
Datum der Diagnose*
Zwischen- und Endbericht
Letzter Kontakt*
Letzter Kontakt - Nachsorge abgeschlossen*
Nachsorge*
Ja
Nein
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Letzter Kontakt*
Nachsorge abgebrochen*
Patient nicht erschienen (Patient ist nicht
mehr erschienen)
Nachsorge nicht gewünscht (Patient
wünscht keine weitere Nachsorge)
Letzter Kontakt*
Tumorangaben
Tumorstatus*
Beurteilung nicht möglich (Beurteilung
nicht möglich)
stable disease (no change)
Tumor Progression (Progression)
Teilremission (Teilremission)
kein Tumor (Tumorfrei)
komplette Remission (Vollremission)
Vitalstatus*
Datum Vitalstatus*
Patient verstorben*
Ja
Nein
Todesursache*
andere Todesursache (andere
Todesursache)
fraglich Patient verstorben (fraglich)
Todesursache tumorbedingt
(Todesursache Tumorbedingt)
unbekannt ob Patient verstorben
(unbekannt)
Todesdatum*
Autopsie*
Ja (J = Ja)
Nein (N = Nein)
Unbekannt (X = unbekannt)
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HIS medical history prostate cancer
HIS form from Soarian. Urologie Erlangen" with friendly
permission of the urology Erlangen (Prof. Wullich) and the
medical informatics department Erlangen (PD Dr. Bürkle)
All rights reserved. Please visit https://medical-data-
models.org/forms/4105
HIS
Admininstrative Daten
Patienten-Nachname*
Patienten-Vorname*
Patienten-Titel*
früherer Name*
Patienten-Geburtsdatum*
Alter des Patienten*
Nationalität/Staatsangehörigkeit*
Straße*
Postleitzahl Patient*
Wohnort*
Fallnummer*
Abteilung*
Nachsorgenummer*
Einverständniserklärung Krebsregister*
Ja
Nein
Studiendaten
klinische Studie*
Ja (ja)
Nein (nein)
unsicher (noch unklar)
Name der Studie*
Ein- und Ausschluss*
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Ausschluss (Ausschluss)
Einschluss (Einschluss)
Einschlussdatum*
Anamnese
Status Patient*
Primärfall (Primärpatient)
Sonstiges (sonstiges)
nicht_kodiert (Wiederkehrer)
Patienten-Geschlecht*
Nachkomme einer Mehrlingsschwangerschaft*
Ja (Ja)
Nein (Nein)
unbekannt (unbekannt)
letzte Beschäftigung*
Dauer der letzten Beschäftigung*
Längste Beschäftigung*
Dauer der längsten Beschäftigung*
Psychoonkologie*
Ja (Ja)
Nein (Nein)
unbekannt (unbekannt)
Sozialdienst*
Ja (Ja)
Nein (Nein)
unbekannt (unbekannt)
Tumorerkrankungen
Tumorvorgeschichte*
Ja (Ja)
Nein (Nein)
unbekannt (unbekannt)
Tumor-Vorerkrankung*
Tumor-Vorerkrankung*
Diagnosedatum*
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Tumordaten
Datum der ersten Diagnose*
Tumordiagnose*
Diagnosesicherheit*
Postmortem-Diagnose (a = autoptisch)
Histologischer Befund (h =
histologisch/Stanze)
klinische Diagnose (k = klinisch)
Sonstiges (s = sonstiges)
unbekannt (x = unbekannt)
Zytologischer Befund (z = zytologisch)
Datum der Diagnose*
Ort der Diagnose*
Grund des Arztbesuches *
nicht näher bezeichnete Untersuchung
(A = andere Untersuchungen)
Screening (C = Screening)
Krebs-Screeninguntersuchung (F =
Krebsfrüherkennung)
Nachsorge (L =
Langzeitbetreuung/Nachsorge)
Selbstuntersuchung (S =
Selbstuntersuchung)
Tumorsymptome (T = Tumorsymptome)
unbekannt (x = unbekannt)
Lokalisation Primärtumor*
Körperseite*
links (L = links)
Mittellinie (M = Mittellinienzone)
rechts (R = rechts)
beidseits (S = beidseits)
Systemerkrankung (S =
Systemerkrankung)
trifft nicht zu (t = trifft nicht zu)
unbekannt (x = unbekannt)
ECOG Leistungszustand*
0 (0)
1 (1)
2 (2)
3 (3)
4 (4)
X (X)
klinisches TNM-Staging
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klinisches TNM-Staging*
Ja
Nein
Tumorstaging-Symbole*
Tumorstaging Symbol r (r)
Tumorstaging Symbol y (y)
T-Stadium*
T0 Stadium (T0)
T1 Stadium  (T1)
T1a Stadium  (T1a)
T1b Stadium  (T1b)
T1c Stadium  (T1c)
T2 Stadium  (T2)
T2a Stadium  (T2a)
T2b Stadium  (T2b)
T2c Stadium  (T2c)
T3 Stadium (T3)
T3a Stadium (T3a)
T3b Stadium (T3b)
T4 Stadium   (T4)
Ta Stadium (Ta)
Tis Stadium (Tis)
TX Stadium (TX)
C-Faktor - Befundsicherung*
C-Faktor C1 (C1 = diagnostische
Standardmethoden)
C-Faktor C2 (C2 = bildgebende
Verfahren)
C-Faktor C3 (C3 = chirurgische
Exploration einschließlich Biopsie und
zytologischer Untersuchung)
N - Stadium der regionalen Lymphknoten*
N0 Stadium  (N0)
N1 Stadium  (N1)
N2 Stadium (N2)
N3 Stadium (N3)
NX Stadium  (NX)
C-Faktor - Befundsicherung*
C-Faktor C1 (C1 = diagnostische
Standardmethoden)
C-Faktor C2 (C2 = bildgebende
Verfahren)
C-Faktor C3 (C3 = chirurgische
Exploration einschließlich Biopsie und
zytologischer Untersuchung)
M- Stadium*
M0 Stadium  (M0)
M1 Stadium (M1)
M1a (M1a)
M1b (M1b)
M1c (M1c)
MX Stadium  (MX)
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C-Faktor - Befundsicherung*
C-Faktor C1 (C1 = diagnostische
Standardmethoden)
C-Faktor C2 (C2 = bildgebende
Verfahren)
C-Faktor C3 (C3 = chirurgische
Exploration einschließlich Biopsie und
zytologischer Untersuchung)
Freitext TNM*
Lokalisation Fernmetastase
Lokalisation Fernmetastase*
Ja
Nein
Metastase in der Haut*
Ja
Nein
Metastase im Gehirn*
Ja
Nein
Metastase in den Knochen*
Ja
Nein
Metastase im Knochenmark*
Ja
Nein
Metastase in der Leber*
Ja
Nein
Metastase in der Lunge*
Ja
Nein
Metastase im Lymphknoten*
Ja
Nein
Metastase in der Nebenniere*
Ja
Nein
Metastase im Peritoneum*
Ja
Nein
Metastase in der Pleura*
Ja
Nein
Generalisiere Metastasierung*
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Ja
Nein
Fernmestastase (andere Organe)*
Ja
Nein
Datum*
Freitext Lokalisation von Fernmetastasen*
Nebenlokalisation*
Anamnese Historie
Chemotherapie in der Anamnese*
Ja (Ja)
Nein (Nein)
unbekannt (unbekannt)
Strahlentherapie in der Anamnese*
Ja (Ja)
Nein (Nein)
unbekannt (unbekannt)
Komorbidität*
Zweitmalignom*
Ja (Ja)
Nein (Nein)
Unbekannt (unbekannt)
Zweitmalignom*
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HIS pathology report - biopsy prostate
cancer
HIS form from Soarian. Urologie Erlangen" with friendly
permission of the urology Erlangen (Prof. Wullich) and the
medical informatics department Erlangen (PD Dr. Bürkle)
All rights reserved. Please visit https://medical-data-
models.org/forms/4106
HIS
Admininstrative Daten
Patienten-Nachname*
Patienten-Vorname*
Patienten-Titel*
früherer Name*
Patienten-Geburtsdatum*
Alter des Patienten*
Nationalität/Staatsangehörigkeit*
Straße*
Postleitzahl Patient*
Wohnort*
Fallnummer*
Tumorhistologie
Pathologisches Institut*
Histologie-Identifikationsnummer*
Aufnahme-Information*
Histopathologie
Datum der Histologie*
Eingangszeit*
Histologie-Code ICD-0-3*
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Histopathologie*
Histologie-Code ICD-0-3*
Stanzen
Ort der Biopsie*
links apikal lateral (LAL)
links apikal medial (LAM)
links basal lateral (LBL)
links basal medial (LBM)
links mittig lateral (LML)
links mittig medial (LMM)
rechts apikal lateral (RAL)
rechts apikal medial (RAM)
rechts basal lateral (RBL)
rechts basal medial (RBM)
rechts mittig lateral (RML)
rechts mittig medial (RMM)
Zusatz (Zusatz)
Stanze
Biopsie*
durchgeführt*
kein Tumornachweis*
Ja
Nein
Gesamt-Gleason-Score*
vorangiges Gleason-Muster*
zweithäufigstes Gleason-Muster*
Tumor in % der Stanze*
Länge (in mm)*
sonstige nützliche Informationen*
atypische klein-azinäre Proliferation der Prostata*
Ja
Nein
PIN-High Grade*
Ja
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Nein
Prostatitis*
Ja
Nein
Nekrosen*
Ja
Nein
Samenblaseninfiltration*
Ja
Nein
extraprostatische Tumorausbreitung*
Ja
Nein
Perineurale Invasion*
Ja
Nein
p63 (negativ)*
Ja
Nein
Alpha-Methylacyl-CoA Racemase *
Ja
Nein
Lokalisation Fernmetastase
Lokalisation Fernmetastase*
Datum*
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HIS pathology report - biopsy prostate cancer
HIS pathology report - organ prostate
cancer
HIS form from Soarian. Urologie Erlangen" with friendly
permission of the urology Erlangen (Prof. Wullich) and the
medical informatics department Erlangen (PD Dr. Bürkle)
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HIS
Admininstrative Daten
Patienten-Nachname*
Patienten-Vorname*
Patienten-Titel*
früherer Name*
Patienten-Geburtsdatum*
Alter des Patienten*
Nationalität/Staatsangehörigkeit*
Straße*
Postleitzahl Patient*
Wohnort*
Fallnummer*
Tumordiagnose
Tumordiagnose*
Datum der Diagnose*
Tumorhistologie
Pathologisches Institut*
Histologie-Identifikationsnummer*
Aufnahme-Information*
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Histopathologie
Datum der Histologie*
Eingangszeit*
Histologie-Code ICD-0-3*
Histopathologie*
Histologie-Code ICD-0-3*
Histologisches Grading*
Grading nicht vorgesehen (0 = Grading
nicht vorgesehen)
G1 (G1 = Gut differenziert)
G2 (G2 = Mäßig differenziert)
G3 (G3 = Schlecht differenziert)
High grade (High grade)
Low grade (Low grade)
Differenzierungsgrad kann nicht
bestimmt werden (X =
Differenzierungsgrad kann nicht
bestimmt werden)
Gleason-Score
Gleason-Score*
vorhanden (Angaben vorhanden)
keine Gleason-Angabe (keine Angabe)
vorangiges Gleason-Muster*
zweithäufigstes Gleason-Muster*
Gesamt-Gleason-Score*
tertiäres Gleason-Muster*
Gleason Muster 1 (Gl1)
Gleason Muster 2 (Gl2)
Gleason Muster 3 (Gl3)
Gleason Muster 4 (Gl4)
Gleason Muster 5 (Gl5)
verschiedene Kriterien
Prostatitis*
Ja
Nein
Nekrosen*
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Ja
Nein
Samenblaseninfiltration*
Ja
Nein
Lokalisation Tumor*
Ja
Nein
extraprostatische Tumorausbreitung*
Ja
Nein
Tumorlokalisation Seite*
links (L)
multilokulär (multilokulär)
rechts (R)
unilokulär (unilokulär)
Transitionalzone*
Ja
Nein
Tumorlokalisation Höhe*
apikal (apikal)
basal (basal)
mittig (mittig)
Tumorvolumen (cm^3)*
Prostatagewicht*
sonstige nützliche Informationen*
Pathologischer TNM
Pathologischer TNM*
Ja
Nein
Tumorstaging-Symbole*
Tumorstaging Symbol r (r)
Tumorstaging Symbol y (y)
pT-Stadium*
pT1a (pT1a)
pT1b (pT1b)
pT1c (pT1c)
pT2a (pT2a)
pT2b (pT2b)
pT2c (pT2c)
pT3a (pT3a)
pT3b (pT3b)
pT0 Stadium (T0)
3 / 5
HIS pathology report - organ prostate cancer
pT1 Stadium  (T1)
pT2 Stadium (T2)
pT3 Stadium  (T3)
pT4 Stadium  (T4)
pTa Stadium (Ta)
pTis Stadium (Tis)
pTX Stadium (TX)
pN - Stadium der regionalen Lymphknoten*
pN0 Stadium (N0)
pN1 Stadium (N1)
pN2 Stadium (N2)
pN3 Stadium (N3)
pM- Stadium*
pM0 Stadium  (M0)
pM1 Stadium  (M1)
pMX Stadium (MX)
pM1a (pM1a)
pM1b (pM1b)
pM1c (pM1c)
Seite Lymphknoten*
links (links)
rechts (rechts)
Anzahl der untersuchten Lymphknoten *
Anzahl der befallenen Lymphknoten *
Lymphgefäßinvasion*
L0 = keine Lymphgefäßinvasion (L0 =
keine Lymphgefäßinvasion)
L1 = Lymphgefäßinvasion (L1)
LX = nicht beurteilbar (LX = nicht
beurteilbar)
Veneninvasion*
V0 = keine Veneninvasion (V0 = keine
Veneninvasion)
V1 = mikroskopische Veneninvasion (V1)
VX = nicht beurteilbar (VX = nicht
beurteilbar)
Residualklassifikation*
Residualtumor Stadium R0 (R0)
Residualtumor Stadium R1 (R1)
Residualtumor Stadium RX (RX = nicht
beurteilbar)
Gewebeprobe Anzahl
Gewebeprobe Anzahl*
Ja
Nein
Anzahl Gewebeproben ohne Tumor*
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Anzahl Gewebeproben mit Tumor*
Anzahl unbekannter Gewebeproben*
Größe der Gewebeprobe
Größe der Gewebeprobe*
Ja
Nein
Größe der Gewebeprobe, längste Abmessung*
Größe der Gewebeprobe, weitere Abmessung*
Schnellschnitt*
Ja
Nein
Verantwortliche Person für Gewebeproben-
Lagerung*
Lokalisation Fernmetastase
Lokalisation Fernmetastase*
Datum*
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HIS radiotherapy form prostate cancer
HIS form from Soarian. Urologie Erlangen" with friendly
permission of the urology Erlangen (Prof. Wullich) and the
medical informatics department Erlangen (PD Dr. Bürkle)
All rights reserved. Please visit https://medical-data-
models.org/forms/4108
HIS
Admininstrative Daten
Patienten-Nachname*
Patienten-Vorname*
Patienten-Titel*
früherer Name*
Patienten-Geburtsdatum*
Alter des Patienten*
Nationalität/Staatsangehörigkeit*
Straße*
Postleitzahl Patient*
Wohnort*
Fallnummer*
Tumordiagnose
Tumordiagnose*
Datum der Diagnose*
Bestrahlung
Einhaltung der Leitlinen*
Ja
Nein
Grund für Einhaltung Leitlinien*
Tumortherapie allgemein
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Intention*
Adjuvant (adjuvant)
Kurativ (kurativ)
Neoadjuvant (neoadjuvant)
Palliativ (palliativ)
Bestrahlung
Zielorgane*
Sonstiges (Other)
Prostata (Prostata)
nicht_sinnvoll_für_Untersuchung
(Prostata + LK kleines Becken)
nicht_sinnvoll_für_Untersuchung
(Prostata + pelvine paraaortale LK im
Bauchraum)
nicht_sinnvoll_für_Untersuchung
(Prostataloge)
nicht_sinnvoll_für_Untersuchung
(Prostataloge + LK kleines Becken)
nicht_sinnvoll_für_Untersuchung
(Prostataloge + pelvine paraaortale LK
im Bauchraum)
nicht_sinnvoll_für_Untersuchung
(sonstiges)
Strahlentherapie - Technik*
Brachytherapy (Brachytherapie)
HDR temporäre Brachytherapie (HDR
temporäre Brachytherapie)
PDR temporäre Brachytherapie (PDR
temporäre Brachytherapie)
Tele-Radiotherapie (percutane
Strahlentherapie)
Strahlenart*
Iridium-192 (IR-Iridium-192)
Jod-125 (J1-Jod-125)
Palladium Pd-103  (Palladium Pd-103 )
Beginn Strahlentherapie*
Ende Strahlentherapie*
Gesamtdosis*
Therapiebeurteilung
Beendigung der Strahlentherapie*
Abbruch wegen Nebenwirkungen
(Abbruch wegen Nebenwirkungen)
Verweigerung der Therapie (Patient
verweigert die Therapie)
reguläres Ende der Therapie (reguläres
Ende)
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ECOG Leistungszustand*
0 (0)
1 (1)
2 (2)
3 (3)
4 (4)
Nebenwirkungen nach CTC (Common
Toxicity Criteria)
Nebenwirkungen*
Ja
Nein
Urogenital-System*
keine Nebenwirkungen (0 = keine
Nebenwirkungen)
leichte Nebenwirkungen (1 =
geringe/leichte Nebenwirkungen)
mäßige Nebenwirkungen (2 = mäßige /
deutliche Nebenwirkungen)
starke Nebenwirkungen (3 = starke /
ausgeprägte Nebenwirkungen)
lebensbedrohliche Nebenwirkungen (4 =
lebensbedrohliche Nebenwirkungen)
Nebenwirkungen unbekannt (X = Grad
der Nebenwirkungen unbekannt)
Gastrointestinaltrakt*
keine Nebenwirkungen (0 = keine
Nebenwirkungen)
leichte Nebenwirkungen (1 =
geringe/leichte Nebenwirkungen)
mäßige Nebenwirkungen (2 = mäßige /
deutliche Nebenwirkungen)
starke Nebenwirkungen (3 = starke /
ausgeprägte Nebenwirkungen)
lebensbedrohliche Nebenwirkungen (4 =
lebensbedrohliche Nebenwirkungen)
Nebenwirkungen unbekannt (X = Grad
der Nebenwirkungen unbekannt)
Fieber*
keine Nebenwirkungen (0 = keine)
leichte Nebenwirkungen (1 =
gering/leicht)
mäßige Nebenwirkungen (2 =
mäßig/deutlich)
starke Nebenwirkungen (3 =
stark/ausgeprägt)
lebensbedrohliche Nebenwirkungen (4 =
lebensbedrohlich)
only in connection with Infection (only in
connection with Infection)
Nebenwirkungen unbekannt (X =
Nebenwirkungen unbekannt)
Infektion*
keine Nebenwirkungen (0 = keine)
3 / 4
HIS radiotherapy form prostate cancer
leichte Nebenwirkungen (1 =
gering/leicht)
mäßige Nebenwirkungen (2 =
mäßig/deutlich)
starke Nebenwirkungen (3 =
stark/ausgeprägt)
lebensbedrohliche Nebenwirkungen (4 =
lebensbedrohlich)
only in connection with fever (only in
connection with fever)
Nebenwirkungen unbekannt (X =
Nebenwirkungen unbekannt)
Laborwerte*
keine Nebenwirkungen (0 = keine
Nebenwirkungen)
leichte Nebenwirkungen (1 =
geringe/leichte Nebenwirkungen)
mäßige Nebenwirkungen (2 = mäßige /
deutliche Nebenwirkungen)
starke Nebenwirkungen (3 = starke /
ausgeprägte Nebenwirkungen)
lebensbedrohliche Nebenwirkungen (4 =
lebensbedrohliche Nebenwirkungen)
Nebenwirkungen unbekannt (X = Grad
der Nebenwirkungen unbekannt)
andere Nebenwirkung*
keine Nebenwirkungen (0 = keine
Nebenwirkungen)
leichte Nebenwirkungen (1 =
geringe/leichte Nebenwirkungen)
mäßige Nebenwirkungen (2 = mäßige /
deutliche Nebenwirkungen)
starke Nebenwirkungen (3 = starke /
ausgeprägte Nebenwirkungen)
lebensbedrohliche Nebenwirkungen (4 =
lebensbedrohliche Nebenwirkungen)
Nebenwirkungen unbekannt (X = Grad
der Nebenwirkungen unbekannt)
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cancer
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HIS
Admininstrative Daten
Patientenname*
früherer Name*
Patienten-Geburtsdatum*
Alter des Patienten*
Nationalität/Staatsangehörigkeit*
Straße*
Postleitzahl Patient*
Wohnort*
Fallnummer*
Abteilung*
Nachsorgenummer*
Organspezifisch Prostata
Tumordiagnose*
Datum der Diagnose*
Therapien*
Operation (Operation)
Sonstiges (Sonstiges)
Bestrahlung (Strahlentherapie)
Systemische Therapie (Systemische
Therapie)
Gewebebank Einwilligung
Einverständniserklärung für Gewebebank*
Ja
1 / 3
Nein
nicht_kodiert*
Ja
Nein
Einwolligung für Gewebebank*
Ja
Nein
Tumorspezifische Daten
Histologisches Grading*
G1 (G1)
G2 (G2)
G3 (G3)
High grade (High grade)
Low grade (Low grade)
0 = Grading nicht vorgesehen (O)
X = Differenzierungsgrad kann nicht
bestimmt werden (X)
Gleason-Score*
vorhanden (Angaben vorhanden)
keine Gleason-Angabe (keine Angabe)
vorangiges Gleason-Muster*
zweithäufigstes Gleason-Muster*
Gesamt-Gleason-Score*
digitale rektale Untersuchung*
nicht suspekt (nicht suspekt)
suspekt (suspekt)
unbekannt (unbekannt)
Prostata-spezifisches-Antigen*
Datum des PSA*
Szintigraphie*
Ja (Ja)
Nein (Nein)
unbekannt (unbekannt)
suspekt?*
Ja (Ja)
Nein (Nein)
unbekannt (unbekannt)
Lokalisation*
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Patientenbefragung
Vorerkrankungen in Familie*
Nein (keine Vorerkrankung in der
Familie)
unbekannt (unbekannt)
Ja (Vorerkrankung in der Familie)
Familienangehörige mit Tumorerkrankung*
Familienangehörige mit Prostatakarzinom*
Familienangehörige mit einer anderen
Tumorerkrankung*
Wunsch Nerve-Sparing Prostatektomie*
Ja
Nein
Score
Score IIEF*
Score ICIQ*
Score IPSS*
EORTC Fragen
(Kontinenzbogen Frage 4)*
(EQRTC QLQ-C30 Frage 29)*
(EQRTC QLQ-C30 Frage 30)*
3 / 3
HIS medical history - prostate prostate cancer
HIS surgery form prostate cancer
HIS form from Soarian. Urologie Erlangen" with friendly
permission of the urology Erlangen (Prof. Wullich) and the
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All rights reserved. Please visit https://medical-data-
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HIS
Admininstrative Daten
Patienten-Nachname*
Patienten-Vorname*
Patienten-Titel*
früherer Name*
Patienten-Geburtsdatum*
Alter des Patienten*
Nationalität/Staatsangehörigkeit*
Straße*
Postleitzahl Patient*
Wohnort*
Fallnummer*
OP-Bogen
Tumordiagnose*
Datum der Diagnose*
Datum der OP*
Einhaltung der Leitlinen*
Ja
Nein
Grund für Einhaltung Leitlinien*
ASA*
ASA Status 1 (ASA I: Normaler,
gesunder Patient)
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ASA Status 2 (ASA II: Patient mit leichter
Allgemeinerkrankung)
ASA Status 3 (ASA III: Patient mit
schwerer Allgemeinerkrankung)
ASA Status 4 (ASA IV: Patient mit
lebensbedrohlicher
Allgemeinerkrankung)
Operation
Chirurgische und medizinische Prozeduren*
Körperseite*
einiseitg (einiseitg)
zweiseitig (zweiseitig)
Intention*
diagnostisch (D = diagnostisch)
Kurativ (K = kurativ)
Palliativ (P = palliativ)
unbekannt (unbekannt)
Welche Operation*
Nerverhalt*
Ja
Nein
Körperseite*
beidseits (beidseits)
links (links)
rechts (rechts)
Erster Operateur*
Erste Assistenz*
weitere Operation*
Chirurgische und medizinische Prozeduren*
Körperseite*
einiseitg (einiseitg)
zweiseitig (zweiseitig)
Intention*
diagnostisch (D = diagnostisch)
Kurativ (K = kurativ)
Palliativ (P = palliativ)
unbekannt (unbekannt)
intraoperative Komplikationen*
Ja
Nein
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Welche intraoperative Komplikation*
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HIS trial form prostate cancer
HIS form from Soarian. Urologie Erlangen" with friendly
permission of the urology Erlangen (Prof. Wullich) and the
medical informatics department Erlangen (PD Dr. Bürkle)
All rights reserved. Please visit https://medical-data-
models.org/forms/4111
HIS
Admininstrative Daten
Patienten-Nachname*
Patienten-Vorname*
Patienten-Titel*
früherer Name*
Patienten-Geburtsdatum*
Alter des Patienten*
Nationalität/Staatsangehörigkeit*
Straße*
Postleitzahl Patient*
Wohnort*
Fallnummer*
Studienbogen
Name der Studie*
Intention der Therapie*
Adjuvant (adjuvant)
Neoadjuvant (neoadjuvant)
Palliativ (palliativ)
Einschlussdatum*
Zyklen geplant*
Zyklen durchgeführt*
letztes Follow-Up*
1 / 2
Vital Status*
Patient lebt (alive)
Patient verstorben (dead)
unbekannt (unknown)
Datum Staging*
Ergebnis Staging*
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HIS finding prostate biopsy prostate cancer
HIS form ORBIS.  with friendly permission form urology
(Prof. Semjonow) and medical informatics department (Dr.
Breil)
All rights reserved. Please visit https://medical-data-
models.org/forms/4113
HIS
Patientenaufkleber groß
Aufnahmedatum*
Patientenidentifikationsnummer*
Geschlecht Patient*
Patienten-Nachname*
Patienten-Vorname*
Patienten-Geburtsdatum*
Aufnahmezeit*
Einweisender Arzt*
Urologische Daten
Primärfall*
Ja
Nein
Datum Bericht*
Anzahl Seiten*
Fax-Nr.*
Hausarzt*
Datum der Biopsieentnahme*
Datum PSA*
Prostata-spezifisches-Antigen*
freies PSA *
Volumen Prostata*
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Volumen Übergangszone*
Prostatakarzinom in der Familienanamnese *
Ja (Ja)
keine Angabe (keine Angabe)
Nein (Nein)
Körpergewicht*
Größe*
BMI*
Tastbefund*
dubios einseitig (dubios einseitig)
dubios zweiseitig (dubios zweiseitig)
keine Angabe (keine Angabe)
Normal (Normal)
suspekt einseitig (suspekt einseitig)
suspekt zweiseitig (suspekt zweiseitig)
V.a. Organüberschreitung (V.a.
Organüberschreitung)
TRUS*
dubios (dubios)
keine Angabe (keine Angabe)
Normal (Normal)
suspekt (suspekt)
Untersucher*
Internationaler Prostata Symptom Score*
Lebensqualität*
Internationaler Index für erektile Funktion*
Pathologic findings
Ort der Biopsie*
Apex links (Apex links)
Apex rechts (Apex rechts)
links basal lateral (Basis links lateral)
rechts basal lateral (Basis rechts lateral)
links mittig lateral (Mitte links lateral)
links mittig medial (Mitte links medial)
rechts mittig lateral (Mitte rechts lateral)
rechts mittig medial (Mitte rechts medial)
Übergangszone links (Übergangszone
links)
Übergangszone rechts (Übergangszone
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rechts)
Zusatz links (Zusatz links)
Zusatz rechts (Zusatz rechts)
Länge der Probe*
Anteil des tumorbefallenen Gewebe *
vorangiges Gleason-Muster*
zweithäufigstes Gleason-Muster*
Gesamt-Gleason-Score*
Anzahl Biopsien*
Anzahl positiver Biopsien*
keine Malignität*
Ja
Nein
high grade PIN*
Ja
Nein
Adenokarzinom*
Ja
Nein
Lokalisation Adenokarzinom*
Gesamt-Gleason-Score*
nicht_kodiert*
nicht_kodiert (Ia)
nicht_kodiert (Ib)
nicht_kodiert (Iia)
nicht_kodiert (Iib)
nicht_kodiert (IIIa)
nicht_kodiert (IIIb)
keine Angabe (keine Angabe)
Perineurale Invasion*
Ja
Nein
Perineurale Invasion - Freitext*
Extrakapsuläre Wachstum*
Ja
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Nein
Extrakapsuläre Wachstum - Freitext*
Prostatitis*
chronisch (chronisch)
akute (floride)
keine (keine)
chronisch*
gering (gering)
mittel (mittel)
stark (stark)
akute*
gering (gering)
mittel (mittel)
stark (stark)
Kommentar zu den Pathologie Proben*
Datum Pathologie Befund*
Name Pathologe*
Klinik
Kommentar Urologe*
PSA Messungen*
Aufnahmedaten
onkologische Psychotherapie*
angeboten (angeboten)
angenommen (angenommen)
Sozialdienst*
angeboten (angeboten)
angenommen (angenommen)
Rehabilitationstherapie*
angeboten (angeboten)
angenommen (angenommen)
Interdisziplinäre Gespräche*
angeboten (angeboten)
angenommen (angenommen)
Zweitmeinung*
angeboten (angeboten)
angenommen (angenommen)
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Nerverhalt*
erwünscht (erwünscht)
nicht indiziert (nicht indiziert)
Beratung unter Einhaltung der Leitlinie*
Ja
Nein
Wunsch Telefongespräch mit Arzt*
Szintigraphie*
Ja
Nein
Datum Szintigramm*
Ergebnis Szintigramm*
fraglich (fraglich)
negativ (negativ)
positiv (positiv)
Ergebnis Szintigramm*
Vorbehandlung Hormon- / endokrine Therapie*
Ja
Nein
Beginn Vorbehandlung Hormon- / endokrine
Therapie*
5-Alpha-Reduktase Hemmer*
Ja
Nein
Alpha-Blocker*
Ja
Nein
Gerinnungshemmer*
Ja
Nein
Gerinnungshemmer*
Tastbefund*
cT1c (cT1c)
cT2 (cT2)
cT3 (cT3)
cT4 (cT4)
Entlassdatum*
Liegezeit*
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Partin Tabellen
Organbegrenzte Erkrankung (in %)*
Samenblasenbefall (in %)*
Kapseldurchbruch (in %)*
Lymphknotenbefall (in %)*
Vorerkrankungen
Vorerkrankungen*
Komorbiditätsindex*
Tumorkonferenz
Datum der Tumorkonferenz*
nicht_kodiert*
Ja
Nein
Daten komplett*
Ja
Nein
Untersucher*
Kommentar*
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HIS cancer conference urology prostate
cancer
HIS form ORBIS.  with friendly permission form urology
(Prof. Semjonow) and medical informatics department (Dr.
Breil)
All rights reserved. Please visit https://medical-data-
models.org/forms/4114
HIS
Patientenaufkleber groß
Aufnahmedatum*
Patientenidentifikationsnummer*
Geschlecht Patient*
Patienten-Nachname*
Patienten-Vorname*
Patienten-Geburtsdatum*
Aufnahmezeit*
Einweisender Arzt*
Tumorkonferenz
Tumorboard Typ*
Morbiditätskonferenz
(Morbiditätskonferenz)
posttherapeutisch (posttherapeut.
Konferenz )
prätherapeutisch (prätherapeut.
Konferenz )
posttherapeutisch*
Prostatektomie (Prostatektomie)
Bestrahlung (Radiatio)
Datum der Konferenz*
Ort der Konferenz*
Verantwortliche Person für die Anmeldung*
Datum der Anmeldung*
Teilnehmer*
Pathologie (Pathologie)
nicht_kodiert (Prostatazentrum)
Strahlentherapie (Strahlentherapie)
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Urologie (Urologie)
Patientendaten
Status Patient*
Primärfall (Primärpatient)
Primärfall*
echter Primärfall (echter Primärfall)
Zufallsbefund Adenom (Inzidendell
Adenom)
Zufallsbefund bei transurethraler
Prostataresektion (Inzidendell TURP)
andere (übriges)
Zystektomie (Zystektomie)
Diagnose*
Karnofsky Index*
klinische Studie*
Krankheitsverlauf
Krankheitsverlauf*
Pathologie Befund
Kommentar zu den Pathologie Proben*
Frage
Frage*
Subformular
Tumorboardentscheidungen
Operation*
Ja
Nein
Intention*
Adjuvant (adjuvant)
Kurativ (kurativ)
Neoadjuvant (neoadjuvant)
Palliativ (palliativ)
sonstiges (sonstiges)
Chemotherapie*
Ja
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Nein
Intention*
Adjuvant (adjuvant)
Kurativ (kurativ)
Neoadjuvant (neoadjuvant)
Palliativ (palliativ)
sonstiges (sonstiges)
Bestrahlung*
Ja
Nein
Intention*
Adjuvant (adjuvant)
Kurativ (kurativ)
Neoadjuvant (neoadjuvant)
Palliativ (palliativ)
sonstiges (sonstiges)
Hormon- / endokrine Therapie*
Ja
Nein
Intention*
Adjuvant (adjuvant)
Kurativ (kurativ)
Neoadjuvant (neoadjuvant)
Palliativ (palliativ)
sonstiges (sonstiges)
Immuntherapie*
Ja
Nein
Intention*
Adjuvant (adjuvant)
Kurativ (kurativ)
Neoadjuvant (neoadjuvant)
Palliativ (palliativ)
sonstiges (sonstiges)
Studienprotokoll*
Ja
Nein
Studienprotokoll - Freitext*
Verlaufskontrolle*
Ja
Nein
Verlaufskontrolle - Freitext*
Analgetika*
Ja
Nein
Analgetika - Freitext*
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andere Empfehlung*
Ja
Nein
andere Empfehlung - Freitext*
Re-Biopsie*
Ja
Nein
Bisphosphonate*
Ja
Nein
Bisphosphonate - Freitext*
Radioiodtherapie*
Ja
Nein
Wiedervorstellung nach Diagnostik*
Ja
Nein
Active Surveillance*
Ja
Nein
Diagnostik notwendig*
Therapie Freitext*
Datum der Arzt-Unterschrift*
Arzt-Unterschrift*
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Kopfzeile
Datum Bericht*
Arzt*
Patientendaten
Patientenname*
Patienten-Geburtsdatum*
Fallnummer*
Krankenhaus*
Aufnahmedatum*
Entlassungsdatum*
Aufnahmestatus*
Station*
OP-Personal
Anästhesist*
Operations Team*
Weitere Angaben für Urologie-Ops
Intraoperativ
Präparate*
Dauer der Operation*
Volumen Prostata*
1 / 2
Geschätzter Blutverlust*
Erythrozyten Transfusion*
Infusion*
Anastomose intakt*
Ja
Nein
nicht_kodiert*
Rektumläsion*
Ja
Nein
Nervus obturatorius Läsion*
Ja
Nein
intraoperative Komplikationen*
Ja
Nein
Arzt-Unterschrift*
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HIS surgery report prostate cancer
registry GEKID dataset cancer
report from doctor's offices and hospitals for the
epidemiological register - Gesellschaft der
epidemiologischen Krebsregister in Deutschland e.V.
(GEKID)
All rights reserved. Please visit https://medical-data-
models.org/forms/4152
registry
Meldestelle
Identifikationsnummer der Meldequelle*
Institution*
Name Arzt*
Arzt Adresse*
Arzt Postleitzahl*
Arzt Wohnort*
Meldedatum*
Idenität
Patienten-Titel*
Patienten-Vorname*
Patienten-Nachname*
Zusatz Patientenname*
früherer Name*
Geburtsname*
Patienten-Geschlecht*
männlich (M)
Unbekannt (U)
weiblich (W)
Patienten-Geburtsdatum*
Straße*
Hausnummer*
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Zusatz Hausnummer*
Postleitzahl Patient*
Wohnort*
Sterbedatum*
Einverständniserklärung Krebsregister*
Ja
Nein
Meldebegründung*
Widerspruch Kontaktaufnahme (Patientin
/ Patient hat einer Kontaktaufnahme
gemäß § 10(3) widersprochen)
Information pseudonymisierte Meldung
Krebsregister (Patientin / Patient wurde
über die pseudonymisierte Meldung an
das Krebsregister informiert)
Tumor Epidemiologie
Referenznummer*
Datum der Diagnose*
Verschlüssselung nach ICD*
Codebeschreibung ICD-10*
Verschlüsselung nach ICD-O-3*
Codebeschreibung ICD-O-3*
Verschlüsselung nach ICD-O-3*
Codebeschreibung ICD-O-3*
Tumorbiologie*
unsicher (1 = unsicher)
Ursprungsort (2 = in situ)
bösartige Neubildung (3 = bösartige
Neubildung)
Versionsnummer ICD*
Verschlüsselung nach ICD-O-3*
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registry GEKID dataset cancer
Version der Klassifikation*
Histopathologisches Grading*
G1 gut differenziert (1 = gut differenziert)
G2 mäßig differenziert (2 = mäßig
differenziert)
G3 schlecht differenziert (3 = schlecht
differenziert)
G4 undifferenziert (4 =
undifferenziert/annapl.)
High Grade (G3-G4) (H = high grade
(hochmaligne))
Low Grade (G1-G2) (L = low grade
(niedrigmaligne))
Intermediate Grade (G2-G3) (M =
intermediate (mittelgradig maligne))
unbekannt (U = unbekannt)
X = Differenzierungsgrad kann nicht
bestimmt werden (X = nicht bestimmbar)
Histopathologisches Grading*
G1 gut differenziert (1 = gut differenziert)
G2 mäßig differenziert (2 = mäßig
differenziert)
G3 schlecht differenziert (3 = schlecht
differenziert)
G4 undifferenziert (4 =
undifferenziert/annapl.)
High Grade (G3-G4) (H = high grade
(hochmaligne))
Low Grade (G1-G2) (L = low grade
(niedrigmaligne))
Intermediate Grade (G2-G3) (M =
intermediate (mittelgradig maligne))
unbekannt (U = unbekannt)
X = Differenzierungsgrad kann nicht
bestimmt werden (X = nicht bestimmbar)
Zelltyp*
B-Zell-Lymphom (B = B-Zell-Typ)
Natural-Killer-Zell-Lymphom (K =
Natural-Killer-Zell-Typ)
Null-Zell-Lymphom (N = Null-Zell-Typ)
T-Zell-Lymphom (T = T-Zell-Typ)
unbekannt (U = unbekannt)
nicht bestimmbar (X = nicht bestimmbar)
Sicherung der Tumordiagnose*
klinische Diagnose (1 = klinisch ohne
spez. Diagnostik)
klinische Diagnose mit spezieller
Diagnostik (2 = klinische Diagnostik)
spezielle Tumormarker (4 = spez.
Tumormarker)
Zytologischer Befund (5 = Zytologie)
Nachweis Histologie Metastase (6 =
Histologie Metastase)
Nachweis Histologie Primärtumor (7 =
Histologie Primärtumor)
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registry GEKID dataset cancer
Sonstiges (8 = Sonstige)
unbekannt (9 = Unbekannt)
Grund des Arztbesuches *
Anamnese (A = Anamnese)
Selbstuntersuchung (E =
Eigenuntersuchung
(Selbstuntersuchung))
(gesetzl.) Früherkennung (F = gesetzl.
Früherkennung)
Nachsorge (N = Nachsorge)
Tumorsymptome (T =
Tumorsymptomatik)
unbekannt (U = unbekannt)
(nicht gesetzl. Vorsorge) (V = nicht
gesetzl Vorsorge)
Körperseite*
beidseits (B = beidseits)
links (L = links)
rechts (R = rechts)
Not Applicable  (T = Trifft nicht zu)
unbekannt (U = unbekannt)
Stadium*
Fernmetastasen (F = Fernmetastasen)
Ursprungsort (I = in situ)
lokal (L = lokal)
regional (R = regional)
Systemerkrankung (S =
Systemerkrankung)
unbekannt (U = unbekannt)
TNM Klassifikation prätherapeutisch*
Ja
Nein
TNM Klassifikation nach der OP*
Ja
Nein
T Stadium*
N Stadium*
M Stadium*
TNM Auflage*
Operation*
Ja (J = Ja)
Nein (N = Nein)
Unbekannt (U = unbekannt)
Bestrahlung*
Ja (J = Ja)
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registry GEKID dataset cancer
Nein (N = Nein)
Unbekannt (U = unbekannt)
Chemotherapie*
Ja (J = Ja)
Nein (N = Nein)
Unbekannt (U = unbekannt)
Hormon- / endokrine Therapie*
Ja (J = Ja)
Nein (N = Nein)
Unbekannt (U = unbekannt)
Immuntherapie*
Ja (J = Ja)
Nein (N = Nein)
Unbekannt (U = unbekannt)
Knochenmarkstransplantation*
Ja (J = Ja)
Nein (N = Nein)
Unbekannt (U = unbekannt)
andere Therapie*
Ja (J = Ja)
Nein (N = Nein)
Unbekannt (U = unbekannt)
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registry GEKID dataset cancer
Eligibility NCT00051012 T-Cell Lymphoma
Study of ONTAK (Denileukin Diftitox) in Previously Treated
Cutaneous T-Cell Lymphoma Patients
Inclusion Criteria:
- Patient must have been previously enrolled in Protocol 93-
04-11 and randomized to the placebo arm; or the patient
met all eligibility criteria for protocol 93-04-11 other than the
expression of CD25 on CTCL tumor cells. 
- CTCL disease Stage Ia - III. 
- History of less than or equal to 3 previous therapies.
Repeated use of the same agent is considered to be 1
therapy unless it is part of a different combination regimen.
Only 1 prior combination cytotoxic chemotherapy regimen
is permitted. Topical or systemic steroids are not
considered a therapy. 
- Patient must have evaluable or measurable disease.
Lymph node involvement no greater than LN2. No CTCL
involvement of bone marrow. 
- No significant pulmonary or cardiac disease. No active
CNS, kidney, or liver disease. No systemic infections. 
- ECOG performance status of 0 or 1. 
Exclusion Criteria: 
- The 93-04-14 study is no longer open to subjects
previously enrolled in 93-04-10 or 92-04-01
All rights reserved. Please visit https://medical-data-
models.org/forms/4181
Eligibility
Inclusion criteria
Patient must have been previously enrolled in
Protocol 93-04-11 and randomized to the placebo
arm; or the patient met all eligibility criteria for
protocol 93-04-11 other than the expression of
CD25 on CTCL tumor cells.*
Yes
No
CTCL disease Stage Ia - III*
Yes
No
History of less than or equal to 3 previous
therapies. Repeated use of the same agent is
considered to be 1 therapy unless it is part of a
different combination regimen. Only 1 prior
combination cytotoxic chemotherapy regimen is
permitted. Topical or systemic steroids are not
considered a therapy*
Yes
No
Patient must have evaluable or measurable
disease. Lymph node involvement no greater
than LN2. No CTCL involvement of bone
marrow.*
Yes
No
No significant pulmonary or cardiac disease. No
active CNS, kidney, or liver disease. No systemic
infections. 
*
Yes
No
ECOG performance status of 0 or 1*
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Yes
No
Exclusion criteria
The 93-04-14 study is no longer open to subjects
previously enrolled in 93-04-10 or 92-04-01*
Yes
No
Medical Concepts
Enrollment*
Diagnosis*
Diagnostic Neoplasm Staging*
Therapeutic procedure*
Pharmaceutical Preparations*
ECOG performance status finding*
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Eligibility NCT00051012 T-Cell Lymphoma
Laborbefund_Nierentransplantationspatient S.0001
Laborbefund_Nierentransplantationspatient
Laborbefund für Patienten in der Nierentransplantation,
Quelle: Transplantationsnephrologie, Wartelistenbüro,
Univeritätsklinikum Münster
All rights reserved. Please visit https://medical-data-
models.org/forms/4215
Laborbefund_Nierentransplantations
patient
Identitätsdaten des Patienten
Nachname *
Vorname des Patienten*
Geburtsdatum *
Geburtsort *
Nationalitaet *
Anschrift *
Haus-Telefonnumber *
Mobilfunknummber *
Emailadresse *
Tel.Nr. eines Angehörigen *
Name des Versicherers*
Versichertennummer *
Anschrift der Versicherung*
Blutwerte
Datum der Laborwerte*
CRP (mg/dl)*
Hb (g/dl)*
Hkt (%)*
Erythrozyten (Millionen/µL)*
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Leukozyten(/µL)*
Thrombozyten(/µL)*
Glukose (mg/dL)*
HBA1C (%)*
Harnstoff (mg/dL)*
Kreatinin (mg/dL)*
Harnsäure (mg/dL)*
Quick (%)*
PTT (sec.)*
INR*
Natrium (mmol/L)*
Kalium (mmol/L)*
Kalzium (mmol/L)*
Phosphat (mg/dL)*
Ferrtin (µg/L)*
Transferrinsättigung (%)*
Alkalische Phosphatase  (U/L)*
Amylase  (U/L)*
GOT  (U/L)*
GPT  (U/L)*
Gamma-GT (U/L)*
PHCE (U/L)*
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Laborbefund_Nierentransplantationspatient S.0001
Laborbefund_Nierentransplantationspatient
LDH (U/L)*
Bilirubin (mg/dL)*
Cholesterin  (mg/dL)*
HDL (mg/dL)*
LDL (mg/dL)*
Triglyzeride  (mg/dL)*
CK (U/L)*
CK-MB (U/L)*
Intaktes PTH (pmol/L)*
PSH (ng/mL, nur wenn männlich, >40J.)*
TSH basal (µIUI/ml)*
FT3 (ng/dL)*
FT4 (ng/dL)*
CMV-IgG (negative, weakly positive, positive)*
CMV-IgM (negative, weakly positive, positive)*
EBV-IgG (negative, weakly positive, positive)*
EBV-IgM (negative, weakly positive, positive)*
HSV-IgG positiv?*
Ja
Nein
HSV-IgM positiv?*
Ja
Nein
VZV-IgG positiv?*
Ja
Nein
VZV-IgM positiv?*
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Laborbefund_Nierentransplantationspatient S.0001
Laborbefund_Nierentransplantationspatient
Ja
Nein
Urinuntersuchung und Hämoccult
Hämoccult positiv?*
Ja
Nein
PH-Wert*
Proteine (g/L)*
Glukose positiv?*
Ja
Nein
Erythrozyten (bitte Einheit mit angeben)*
Leukozyten (bitte Einheit mit angeben)*
Nitrit positiv?*
Ja
Nein
Erfolgte eine Mikroskopische Untersuchung des
Harns (Urikult)?*
Ja
Nein
Erreger aus Urikult*
Erreger aus Urikult ist empindlich auf*
Fakultativ: bei vorhandenem Diabetes
mellitus Typ 1
GAD Antikörper nachweisbar ?*
Ja
Nein
ICA-Antikörper nachweisbar ?*
Ja
Nein
IA-2 Antikörper nachweisbar?*
Ja
Nein
Insulin basal (mU/L)*
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Laborbefund_Nierentransplantationspatient S.0001
Laborbefund_Nierentransplantationspatient
C-Peptid basal (µg/L)*
Fakultativ: Bei vorhandener
Gerinnungsstörung
APC-Resistenz?*
Ja
Nein
Protein-C Aktivität (%)*
Protein-C Koncentration (%)*
Protein-S Koncentration gesamt(%)*
Freies Protein-S (%)*
Protein-S Aktivität (%)*
Fakultativ: Falls Autoimmunerkrankung
vorliegt
Ana Titer (1:X)*
c-ANCA Titer (1:X)*
p-ANCA Titer (1:X)*
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Laborbefund_Nierentransplantationspatient S.0001
Laborbefund_Nierentransplantationspatient
Befundbogen_NTX_ohneLabor S.0002
Befundbogen_NTX_ohneLabor
Befundbogen fuer die Aufnahme von  Patienten in der
Nierentrasplantransplantion, siehe
Laborbefund_Nierentransplantationspatient für den
entsprechenden Laborbefundbogen.
Quelle: Transplantationsnephrologie, Wartelistenbüro,
Univeritätsklinikum Münster
All rights reserved. Please visit https://medical-data-
models.org/forms/4218
Befundbogen_NTX_ohneLabor
Identitätsdaten des Patienten
Identifikationsnummer*
Anmeldedatum*
Nachname *
Vorname des Patienten*
Sex (m/w)*
Geburtsname*
Geburtsdatum *
Geburtsort *
Nationalitaet *
Anschrift *
Haus-Telefonnumber *
Mobilfunknummber *
Emailadresse *
Tel.Nr. eines Angehörigen *
Name des Versicherers*
Versichertennummer *
Anschrift der Versicherung*
Dialysezentrum
Anschrift *
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Tel Nr *
Haus-Tel. Nr.*
Fax Nr*
Betreunde Aerzte*
Mobilfunknummer*
Emailadresse *
Patientenimmunologie
Blutgruppe (AB)*
Rh-positiv?*
Ja
Nein
HLA-Klasse-1 *
HLA-Klasse-2 *
HLA Typisierung *
HLA-Antikörper*
Elisa Antigennachweis*
Tx-immunologische Besonderheiten*
Gespräche
Gruppengespraech*
Einzelgespraech*
Familienanamnese
Vaters*
Mutter*
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Befundbogen_NTX_ohneLabor S.0002 Befundbogen_NTX_ohneLabor
Geschwister*
Patientenanamnese
Beruf *
Familienstand*
Anzahl an Kindern *
Vorerkrankungen des Patienten*
vorhandene art. Hypertonie?*
Ja
Nein
vorhandener Diab. Mel.?*
Ja
Nein
vorhandener Nikotinabusus?*
Ja
Nein
Tabakkonsum in Packyears*
Frühere Operationen*
Kinderkrankheiten*
Schutzimpfungen*
Durchgemachte Tbc-Infektion*
Ja
Nein
Durchgemachte Hepatitis*
Ja
Nein
Anzahl der Schwangerschaften*
Renale Anamnese
Datum der Erstdiagnose der Nierenerkrankung*
Punktion und/oder Histologie der Niere*
Ja
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Nein
Harnwegsinfektionen*
Ja
Nein
NSAR-Medikation (Aspirin, Ibuproben,
Diclofenac, etc) *
Ja
Nein
Datum der Erstdiagnose der arteriellen
Hypertonie*
Fundus Hypertonicus*
Ja
Nein
Blutdruckeinstellung*
Ja
Nein
Datum der ersten Dialyse*
Restdiurese*
Dialyseart*
Dialysezugang*
liegt eine Ostepathie vor*
Ja
Nein
liegt eine Ostepathie vor*
Ja
Nein
Allergien*
Medikamente (Medikament, Dosierung,
Einnahmefrequenz)*
Ergebnisse obligater Untersuchungen
Koerpergroeße*
Urologisches Konsil (fuer Maenner
>40J+Messung von t-PSA, fuer Frauen mit
Harnrefluxerkrankung oder reyidivierenden
Harnwegsinfekten)*
Ja
Nein
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Befundbogen_NTX_ohneLabor S.0002 Befundbogen_NTX_ohneLabor
Harnvolumen (ml/24Std)*
Blasenkapazitaet (mit Angabe von Maßeinheit)*
Fuer Frauen: Gynaekologischen Untersuchung*
Fuer Frauen >40 J oder >35J mit pos.
Familienanamnese)*
Datum der Abdomen- und
Schilddruesensonographie*
Nierengroeße im Ultraschall (cm)*
Gallenblase und Gallenwege im
Ultraschall(Befund)*
Milz im Ultraschall (Befund)*
Pankreas im Ultraschall (Befund)*
Bauchgefaeße im Ultraschall (Befund)*
Schilddruese und Nebenschilddruese im
Ultraschall(Befund)*
Roentgen Thorax (Befund)*
Ekg (Befund, bitte Kopie des EKGs beifuegen)*
Echokardiographie unter Adenosin(Befund)*
Myokardszintigraphie (Befund)*
Stressechokardiographie unter
pharmakologischer Belastung*
Dopplersonographie der Hals-,Becken-
,Beingefaeße*
Ergebnisse fakultativer Untersuchungen
(nur bei Indikation)
Koronarangiographie (z.B. bei pathologischem
Stress-Echo)*
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Befundbogen_NTX_ohneLabor S.0002 Befundbogen_NTX_ohneLabor
Angiography der Becken- und Beingefaeße (z.B.
bei pAVK)*
Lungenfunktionstest (z.B. bei Nikotinabusus,
COPD, restriktive Lungenerkrankung)*
Gastroskopy (z.B. bei rezidivierenden Gastritiden
und GERD-Symptomen)*
24 Stunden Blutdruckmessung (z.B. bei schwer
einstellbarer arterieller Hypertonie)*
HNO Konsil (z.B. bei chronischerSinusitis)*
Roentgen der Nasennebenhoehlen (z.B. bei
chronischer Sinusitis)*
Ultraschall der Nasennebenhoehlen (z.B. bei
chronischer Sinusitis)*
Dermatologisches Konsil (z.B. bei multiplen
Naevi, Basaliom, aktinischer Keratose, Mykosen,
Z.n. vorheriger Ntx)*
MKG oder zahnaerztliches Konsil *
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Eligibility NCT00761787 Graft Rejection
ODM derived from
http://clinicaltrials.gov/show/NCT00761787
All rights reserved. Please visit https://medical-data-
models.org/forms/4266
Eligibility
Einschlusskriterien
Alter mindestens 18 Jahre*
Ja
Nein
Cardiac Allograft Rejection*
Ja
Nein
New and existing allograft recipients*
Ja
Nein
All patients (age >= 18 years) receiving post-
transplant care at the enrolling centers *
Ja
Nein
Ausschlusskriterien
Concurrent enrollment in a double-blind drug trial
(immunosuppressive drugs).*
Ja
Nein
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Eligibility NCT00759174 Optic Neuropathy,
Ischemic
ODM derived from
http://clinicaltrials.gov/show/NCT00759174
All rights reserved. Please visit https://medical-data-
models.org/forms/4268
Eligibility
Einschlusskriterien
Alter mindestens 45 Jahre*
Ja
Nein
Optic Neuropathy, Ischemic*
Ja
Nein
männlich*
Ja
Nein
Experienced abrupt visual change in only 1 eye *
Ja
Nein
Ausschlusskriterien
Pain determined by an ophthalmologist to be
consistent with an inflammatory/arteritic process
or optic neuritis*
Ja
Nein
History of NAION or optic neuritis.*
Ja
Nein
Participation in other studies within 60 days prior
to entry in the study.*
Ja
Nein
1 / 1
Eligibility NCT00754559 Rheumatoid
Arthritis
ODM derived from
http://clinicaltrials.gov/show/NCT00754559
All rights reserved. Please visit https://medical-data-
models.org/forms/4270
Eligibility
Einschlusskriterien
Alter mindestens 18 Jahre*
Ja
Nein
Erwachsener, erwachsen*
Ja
Nein
rheumatoid arthritis of >=6 months duration
diagnosed according to the revised 1987 ACR
criteria*
Ja
Nein
Disease activity score using 28 joint count*
Ja
Nein
At screening either ESR >=28 mm/h or CRP >=1
mg/dL*
Ja
Nein
Having received permitted DMARDs >= 1.
Current DMARD therapy must have been at a
stable dose for at least 8 weeks prior to baseline.
*
Ja
Nein
Ausschlusskriterien
major surgery (including joint surgery) within 8
weeks prior to screening or planned major
surgery within 6 months following screening*
Ja
Nein
functional class IV as identified by the ACR
classification of functional status in RA*
Ja
Nein
rheumatoid autoimmune disease other than RA*
Ja
Nein
prior history of or current inflammatory joint
disease other than RA.*
Ja
Nein
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Eligibility NCT00740831 Uterine Myomas
ODM derived from
http://clinicaltrials.gov/show/NCT00740831
All rights reserved. Please visit https://medical-data-
models.org/forms/4274
Eligibility
Einschlusskriterien
Alter 18 bis 50 Jahre*
Ja
Nein
Be a pre-menopausal woman between 18 and 50
years inclusive.*
Ja
Nein
Have excessive uterine bleeding due to myoma*
Ja
Nein
Have a myomatous uterus with at least one
myoma of >= 3 cm diameter in size*
Ja
Nein
Be eligible for one surgical procedure: e.g.
hysterectomy, myomectomy or others.*
Ja
Nein
If of childbearing potential the subject must be
practicing a non-hormonal method of
contraception.*
Ja
Nein
BMI >= 18 und <= 40*
Ja
Nein
Ausschlusskriterien
Has a history of or current uterine, cervical,
ovarian or breast cancer.*
Ja
Nein
Has a history of or current endometrium atypical
hyperplasia or adenocarcinoma.*
Ja
Nein
Has a known severe coagulation disorder.*
Ja
Nein
Has a history of or current treatment for myoma
with a Selective Progesterone Receptor
Modulator (SPRM) or a GnRH-agonist.*
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Ja
Nein
Has a history of or known current osteoporosis.*
Ja
Nein
Has abnormal hepatic function at study entry.*
Ja
Nein
Has a positive pregnancy test at baseline or is
nursing or planning a pregnancy during the
course of the study.*
Ja
Nein
Has a current (within twelve months) problem
with alcohol or drug abuse.*
Ja
Nein
Is currently enrolled in an investigational drug or
device study or has participated in such a study
within the last 30 days.*
Ja
Nein
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Eligibility NCT00740831 Uterine Myomas
Eligibility NCT00661609 Advanced Bladder
Cancer
The purpose of this Phase II study is to determine if
AZD4877, an experimental drug that is a novel anti-mitotic
agent (Eg5 or Kinesin Spindle Protein inhibitor that
interferes with tumor cell division leading to tumor growth),
can reduce tumor sizes in patients with bladder cancer
All rights reserved. Please visit https://medical-data-
models.org/forms/4282
Eligibility
Inclusion criteria
Confirmed urothelial cancer (cancer of the
bladder, renal pelvis, ureter, or urethra).*
Yes
No
Tumor, Node, Metastasis (TNM) Stage IV
urothelial cancer that can not be helped by
curative surgery and/or curative radiotherapy*
Yes
No
Must have had a maximum of 2 prior
chemotherapeutic regimens, one for unremovable
and/or metastasized disease, and the other in the
adjuvant or neo-adjuvant setting.*
Yes
No
Ambulatory and capable of all selfcare more than
50% of waking hours*
Yes
No
Exclusion criteria
Prior treatment with investigational or standard
anti-cancer agents, including radiotherapy, within
4 weeks prior to first dose of study medication; 6
weeks if prior systemic mitomycin, nitrosourea, or
suramin.*
Yes
No
Inadequate bone marrow reserve*
Yes
No
Inadequate liver function in the presence of liver
metastases*
Yes
No
Impaired renal function*
Yes
No
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Eligibility NCT00728351 Diabetes Mellitus,
Type 2
ODM derived from
http://clinicaltrials.gov/show/NCT00728351
All rights reserved. Please visit https://medical-data-
models.org/forms/4283
Eligibility
Einschlusskriterien
Alter 18 bis 78 Jahre*
Ja
Nein
History of T2DM treated with Metformin *
Ja
Nein
Ausschlusskriterien
Nüchternblutzucker im Plasma*
Ja
Nein
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Eligibility NCT01212991 Prostate Cancer
ODM derived from
http://clinicaltrials.gov/show/NCT01212991
All rights reserved. Please visit https://medical-data-
models.org/forms/4285
Eligibility
Einschlusskriterien
Alter mindestens 18 Jahre*
Ja
Nein
Histologically confirmed adenocarcinoma of the
prostate without neuroendocrine differentiation or
small cell features*
Ja
Nein
Ongoing androgen deprivation therapy with a
GnRH analogue or bilateral orchiectomy*
Ja
Nein
Progressive disease despite androgen
deprivation therapy as defined by rising PSA
levels or progressive soft tissue or bony disease*
Ja
Nein
No prior treatment with cytotoxic chemotherapy*
Ja
Nein
Asymptomatic or mildly symptomatic from
prostate cancer *
Ja
Nein
Ausschlusskriterien
Severe concurrent disease, infection, or co-
morbidity that, in the judgment of the Investigator,
would make the patient inappropriate for
enrollment*
Ja
Nein
Known or suspected brain metastasis or active
leptomeningeal disease*
Ja
Nein
History of another malignancy within the previous
5 years other than curatively treated non-
melanomatous skin cancer*
Ja
Nein
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Eligibility NCT00606723 Acute Myeloid
Leukemia (AML)
ODM derived from
http://clinicaltrials.gov/show/NCT00606723
All rights reserved. Please visit https://medical-data-
models.org/forms/4287
Eligibility
Einschlusskriterien
Alter bis zu 21 Jahre*
Ja
Nein
Children, adolescents and young adults aged 0-
21 years, male and female*
Ja
Nein
Patients suffering from refractory de novo AML*
Ja
Nein
Patients with relapsed AML*
Ja
Nein
sekundäre AML*
Ja
Nein
Ausschlusskriterien
Severely impaired functional performance*
Ja
Nein
Severe renal impairment*
Ja
Nein
Schwangerschaft*
Ja
Nein
Current participation in another clinical trial*
Ja
Nein
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Eligibility NCT01177033 Intermittent
Claudication
ODM derived from
http://clinicaltrials.gov/show/NCT01177033
All rights reserved. Please visit https://medical-data-
models.org/forms/4289
Eligibility
Einschlusskriterien
Alter 50 bis 85 Jahre*
Ja
Nein
Patient is able to verbally acknowledge and
understanding of the associated risks, benefits,
and treatment alternatives to therapeutic options
of this trial. The patients, by providing informed
consent, agree to these risks and benefits as
stated in the patient informed consent
document.*
Ja
Nein
Patients who are mentally and linguistically able
to understand the aim of the study and to show
sufficient compliance in following the study
protocol.*
Ja
Nein
Intermittent claudication (IC) class 2 or 3
(Rutherford) assessed by treadmill testing or 6-
Minute Walk Test.*
Ja
Nein
Lasting >3 months.*
Ja
Nein
Failed conservative therapy and the patient's
desire for further treatment.*
Ja
Nein
Atherosclerotic single or multiple stenoses
(>50%) or an occlusion of the Superficial Femoral
Artery (SFA) with a target lesion length of 10-20
cm without involvement of the common/deep
femoral artery and/or the popliteal artery
confirmed by duplex ultrasound and
angiography.*
Ja
Nein
At least one patent tibioperoneal artery with no
stenosis >50% in diameter. Technical and
morphological accessibility for both catheter
intervention and bypass surgery.*
Ja
Nein
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Absence of other disease that would limit
exercise (e.g. angina or chronic respiratory
disease). *
Ja
Nein
Ausschlusskriterien
>50% stenosis or occlusion of the iliac, the
common, the deep femoral or the popliteal
artery.*
Ja
Nein
Surgical reconstruction or catheter intervention
on the index leg within the last six months.*
Ja
Nein
Unsuitability of treadmill testing / Six-Minute Walk
Test. Chronic limb ischemia (intermittent
claudication class 2 to 6) on the contralateral
leg.*
Ja
Nein
Known allergy to contrast agents containing
iodine.*
Ja
Nein
Contraindication for antiplatelet agents or
anticoagulants.*
Ja
Nein
Clinically manifested heart insufficiency (NYHA
III, IV) and/or uncorrected hyperthyreosis.*
Ja
Nein
Serious general disease state with an estimated
life expectancy < 2 years (ASA IV, V).*
Ja
Nein
Schwangerschaft*
Ja
Nein
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Eligibility NCT01177033 Intermittent Claudication
Eligibility NCT01171417 Postmenopause
ODM derived from
http://clinicaltrials.gov/show/NCT01171417
All rights reserved. Please visit https://medical-data-
models.org/forms/4292
Eligibility
Einschlusskriterien
Alter mindestens 18 Jahre*
Ja
Nein
Signed written informed consent*
Ja
Nein
Female postmenopausal patient (or patient post-
ovarectomy) and age >=18 years
Postmenopause ist defined as*
Ja
Nein
Age >= 60 years and natural menopause with
menses > 1year ago or*
Ja
Nein
FSH and E2 levels in the postmenopausal range
or*
Ja
Nein
Patients who had bilateral ovariectomy (NCCN
V.I. 2009)*
Ja
Nein
Histologically confirmed ER+ locally advanced or
metastatic breast cancer*
Ja
Nein
Not eligible for curative therapy*
Ja
Nein
Prior treatment with tamoxifen*
Ja
Nein
Suitable to undergo endocrine treatment for ER+
ABC with SERD / sAI*
Ja
Nein
Patient is able to read and understand German *
Ja
Nein
Ausschlusskriterien
1 / 2
Known hypersensitivity to Faslodex or Exemestan
or any compounds of the drugs*
Ja
Nein
Prior treatment with Faslodex 500 mg or Faslodex
250 mg, for patients who receive treatment with
Faslodex 500 mg within this observational study.
Patients who are included in the exemestane arm
may have received prior Faslodex treatment.*
Ja
Nein
Prior treatment with Exemestan for patients who
receive treatment with Exemestan within this
observational study*
Ja
Nein
Acutely life threatening disease*
Ja
Nein
Treatment with Faslodex 250 mg/month
(previously approved dose)*
Ja
Nein
Prior palliative chemotherapy*
Ja
Nein
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Eligibility NCT01171417 Postmenopause
1 blood pressure any condition
ODM derived from http://www.openehr.org
All rights reserved. Please visit https://medical-data-
models.org/forms/4293
1
Blutdruck
Systolischer Blutdruck [mmHg]*
Diastolischer Blutdruck [mmHg]*
Position*
liegend (lying)
nach hinten lehnend (reclining)
sitzend (sitting)
stehend (standing)
Level der Belastung [J/min]*
Belastung*
in Ruhe (At_Rest)
während Belastung (During_exercise)
nach Belastung (Post_exercise)
Neigung [-90.0 - 90.0°]*
Zeitpunkt*
10 Minuten-Messung
(10_minute_reading)
5 Minuten-Messung (5_minute_reading)
any event (any_event)
Initialwert (baseline_reading)
posturale Änderung des Blutdrucks*
Variation des Blutdrucks bei Atmung*
Manschettengröße*
Erwachsene (Adult)
Neugeborene (Neonatal)
Kinder (Paediatric)
Oberschenkel (Thigh)
Erwachsene/extraweit (Wide_adult)
Messgerät*
Ort der Messung*
intra-arteriell (Intra-arterial)
linker Arm (Left_arm)
linkes Bein (Left_leg)
rechtes Bein (Right leg)
rechter Arm (Right_arm)
Korotkoff Töne*
5. Ton (Fifth_sound)
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4. Ton (Fourth_sound)
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1 blood pressure any condition
Eligibility NCT01159691 Idiopathic
Parkinson's Disease
ODM derived from
http://clinicaltrials.gov/show/NCT01159691
All rights reserved. Please visit https://medical-data-
models.org/forms/4295
Eligibility
Einschlusskriterien
Alter mindestens 18 Jahre*
Ja
Nein
The decision to prescribe Neupro must have
been made by the physician before and
independently of his/her decision to include the
patient in the study.*
Ja
Nein
The patient's treatment must be in accordance
with the terms of the local marketing
authorization (MA) for Neupro*
Ja
Nein
The patients must have a diagnosis of Idiopathic
Parkinson's disease.*
Ja
Nein
Only patients having signed the Consent form
regarding study information, data transfer and
use*
Ja
Nein
Patients suffering from gastrointestinal symptoms
whilst on a label compliant dose of anti-
Parkinson's medication *
Ja
Nein
Ausschlusskriterien
Patients not fulfilling the inclusion criteria *
Ja
Nein
And according to SmPC:*
Ja
Nein
Hypersensitivity to the active substance or to any
of the excipients*
Ja
Nein
Magnetic resonance tomography (MRT) or
cardioversion*
Ja
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Nein
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Eligibility NCT01159691 Idiopathic Parkinson's Disease
Eligibility NCT01152606 Breast Cancer
ODM derived from
http://clinicaltrials.gov/show/NCT01152606
All rights reserved. Please visit https://medical-data-
models.org/forms/4298
Eligibility
Einschlusskriterien
Alter mindestens 18 Jahre*
Ja
Nein
HER2 Positive Early Breast Cancer *
Ja
Nein
All patients who are considered candidates to
receive Herceptin for this indication *
Ja
Nein
Ausschlusskriterien
Patients for whom Herceptin is contraindicated*
Ja
Nein
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Eligibility NCT01134939 HIV Infections
ODM derived from
http://clinicaltrials.gov/show/NCT01207388
All rights reserved. Please visit https://medical-data-
models.org/forms/4302
Eligibility
Einschlusskriterien
Alter mindestens 18 Jahre*
Ja
Nein
Patients with B-precursor ALL in complete
hematological remission after at least 3 intense
chemotherapy blocks*
Ja
Nein
Presence of minimal residual disease at a level of
>=10-3*
Ja
Nein
Availability of bone marrow specimen from
primary diagnosis for clone-specific MRD
assessment*
Ja
Nein
Negative HIV test, negative hepatitis B (HbsAg)
test and hepatitis C virus (anti-HCV) test*
Ja
Nein
Negative pregnancy test in women of
childbearing potential*
Ja
Nein
ECOG performance status 0 or 1 *
Ja
Nein
Ausschlusskriterien
Presence of circulating blasts or current extra-
medullary involvement by ALL*
Ja
Nein
History of relevant CNS pathology or current CNS
pathology*
Ja
Nein
Prior allogeneic HSCT*
Ja
Nein
Eligibility for treatment with TKIs*
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Ja
Nein
Systemic cancer chemotherapy within 2 weeks
prior to study treatment*
Ja
Nein
Therapy with monoclonal antibodies (rituximab,
alemtuzumab) within 4 weeks prior to study
treatment*
Ja
Nein
Previous treatment with blinatumomab*
Ja
Nein
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Eligibility NCT01134939 HIV Infections
Eligibility NCT01203228 Myelodysplastic
Syndromes
ODM derived from
http://clinicaltrials.gov/show/NCT01200758
All rights reserved. Please visit https://medical-data-
models.org/forms/4305
Eligibility
Einschlusskriterien
Alter mindestens 18 Jahre*
Ja
Nein
Erwachsener, erwachsen*
Ja
Nein
CD20-positive, follicular Non-Hodgkin's
lymphoma grade 1, 2, 3a. A tumor biopsy must
have been performed within 6 months before
study entry with material available for central
review.*
Ja
Nein
No prior treatment*
Ja
Nein
ECOG performance status 0-2 *
Ja
Nein
Ausschlusskriterien
follikuläres Lymphom, Grad IIIb*
Ja
Nein
Transformation to high-grade lymphoma
secondary to follicular lymphoma*
Ja
Nein
Types of Non-Hodgkin's lymphoma other than
follicular lymphoma*
Ja
Nein
ZNS Erkrankung*
Ja
Nein
Corticoid therapy during the last 4 weeks, except
prednisone treatment <20 mg per day*
Ja
Nein
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Eligibility NCT01196091 Systemic Lupus
Erythematosus
ODM derived from
http://clinicaltrials.gov/show/NCT01196091
All rights reserved. Please visit https://medical-data-
models.org/forms/4308
Eligibility
Einschlusskriterien
Alter mindestens 18 Jahre*
Ja
Nein
Clinical diagnosis of SLE by American College of
Rheumatology (ACR) criteria*
Ja
Nein
ANA positiv*
Ja
Nein
Agree not to become pregnant throughout the
course of the trial*
Ja
Nein
Have the appropriate Safety of Estrogens in
Lupus Erythematosus National Assessment -
Systemic Lupus Erythematosus Disease Activity
Index (SELENA-SLEDAI)score at screening *
Ja
Nein
Ausschlusskriterien
Have active severe Lupus kidney disease*
Ja
Nein
Have active Central Nervous System or
peripheral neurologic disease*
Ja
Nein
Have received intravenous immunoglobulin (IVIg)
within 180 days of randomization*
Ja
Nein
Have active or recent infection within 30 days of
screening*
Ja
Nein
Have had a serious infection within 90 days of
randomization*
Ja
Nein
Have evidence or test positive for Hepatitis B*
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Ja
Nein
Hepatitis C*
Ja
Nein
HIV-positiv*
Ja
Nein
Have evidence of active or latent tuberculosis
(TB)*
Ja
Nein
Presence of significant laboratory abnormalities
at screening*
Ja
Nein
Have had a malignancy in the past 5 years,
except for cervical carcinoma in-situ or basal cell
or squamous epithelial skin cell that were
completely resected with no reoccurrence in the
3 yrs prior to randomization*
Ja
Nein
Have received > 40 mgs of prednisone or
equivalent in the past 30 days*
Ja
Nein
Have changed your dose of antimalarial drug in
the past 30 days*
Ja
Nein
Have changed your dose of immunosuppressive
drug in the past 90 days*
Ja
Nein
Have previously received rituximab*
Ja
Nein
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Eligibility NCT01196091 Systemic Lupus Erythematosus
Eligibility NCT01131585 Diabetic Macular
Edema
ODM derived from
http://clinicaltrials.gov/show/NCT01131585
All rights reserved. Please visit https://medical-data-
models.org/forms/4313
Eligibility
Einschlusskriterien
Alter mindestens 18 Jahre*
Ja
Nein
verminderte Sehschärfe*
Ja
Nein
Macular Edema in at least one eye*
Ja
Nein
Type 1 or Type 2 Diabetes Mellitus*
Ja
Nein
Stable medication of diabetes in past 3 month *
Ja
Nein
Ausschlusskriterien
Patients with uncontrolled systemic or ocular
diseases*
Ja
Nein
Laser photocoagulation in the study eye for the
last 3 months*
Ja
Nein
Any history of any intraocular surgery in the study
eye within the past 3 months*
Ja
Nein
Blutdruck*
Ja
Nein
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dataset Aftercare cancer
clinical cancer registry used in Münster
All rights reserved. Please visit https://medical-data-
models.org/forms/4314
dataset
Patient data
Patient title *
patient number*
Patient surname *
Patient forename*
Patient date of birth*
Patient sex*
Female (Female)
Male (Male)
Street Address*
Patient postal code*
City of residence *
Patient telephone number*
Attending physician *
not_useful_for_research*
Diagnosis*
Aftercare
Aftercare Diagnostic*
Date last aftercare*
current aftercare*
Cancer Diagnosis*
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Date case last changed *
Free Text*
Date of aftercare*
ECOG performance status grade *
0 (0)
1 (1)
2 (2)
3 (3)
4 (4)
no information (no information)
not_useful_for_research*
not_useful_for_research*
late adverse event*
No (No)
no information (no information)
Not Applicable  (Not Applicable )
Yes (Yes)
Collection*
complete (complete)
incomplete (incomplete)
Finding
Medical History
Appetite*
Appetite normal (Appetite normal)
Decrease in appetite (Decrease in
appetite)
Reluctance of meat (Reluctance of meat)
Complaints*
No (No)
Yes (Yes)
Defecation *
Add to Stool (Add to Stool)
alternating (alternating)
Constipation (Constipation)
Diarrhea  (Diarrhea )
irregular (irregular)
regular (regular)
Drugs*
No (No)
Yes (Yes)
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dataset Aftercare cancer
Medical Examination
Body Weight *
Surgical scar*
Hernia  (Hernia )
normal (normal)
Other (Other)
swelling (swelling)
Palpation of abdomen*
normal finding (normal finding)
Suspected (Suspected)
Medical Examination
X-Ray of Thorax*
Metastasis suspected (Metastasis
suspected)
normal finding (normal finding)
not executed (not executed)
other (other)
Relapse suspected (Relapse suspected)
Tumor suspected (Tumor suspected)
Ultrasonography of Abdomen*
Metastasis suspected (Metastasis
suspected)
normal finding (normal finding)
not executed (not executed)
other (other)
Relapse suspected (Relapse suspected)
Tumor suspected (Tumor suspected)
Esophagogastroduodenoscopy*
Metastasis suspected (Metastasis
suspected)
normal finding (normal finding)
not executed (not executed)
other (other)
Relapse suspected (Relapse suspected)
Tumor suspected (Tumor suspected)
Esophagogastroduodenoscopy (EGD) with
biopsy *
Yes
No
Screening procedure
Physical Examination Date *
Tumor Status
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dataset Aftercare cancer
Tumor Expansion
Primary Neoplasm *
No evidence of neoplasm  (No evidence
of neoplasm )
questionable Result (questionable
Result)
Recurrent Disease (Recurrent Disease)
Residual Disease  (Residual Disease )
Metastatic Malignant Neoplasm to the regional
Lymph Nodes*
No evidence of neoplasm  (No evidence
of neoplasm )
questionable Result (questionable
Result)
Recurrent Disease (Recurrent Disease)
Residual Disease  (Residual Disease )
Distant metastasis (other organs)*
No evidence of neoplasm  (No evidence
of neoplasm )
questionable Result (questionable
Result)
Recurrent Disease (Recurrent Disease)
Residual Disease  (Residual Disease )
Tumor Status*
- (-)
Assessment not possble (Assessment
not possble)
clinical improvement (clinical
improvement)
In complete remission  (In complete
remission )
no information (no information)
No neoplasm (qualifier value)  (No
neoplasm (qualifier value) )
not clarified (not clarified)
not_coded (not_coded)
partial response  (partial response )
Stable Disease (Stable Disease)
Tumor marker increase (Tumor marker
increase)
Tumor Progression (Tumor Progression)
planned therapeutic procedure
planned therapeutic procedure
Aftercare*
Yes
No
Operative Surgical Procedures *
Yes
No
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dataset Aftercare cancer
Chemotherapy Regimen*
Yes
No
Therapeutic radiology procedure *
Yes
No
Endocrine Therapy*
Yes
No
Immunotherapy *
Yes
No
Supportive Care*
Yes
No
Pain management *
Yes
No
Other therapy*
Yes
No
disease stage*
Yes
No
Consultation*
Yes
No
Hemopoietic stem cell transplant *
Yes
No
Bone Marrow Transplantation*
Yes
No
Prophylactic treatment *
Yes
No
Rehabilitation therapy *
Yes
No
Disease management program *
Yes
No
Prostate Questionaire*
Yes
No
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dataset Aftercare cancer
altered aftercare*
Yes
No
active surveillance*
Yes
No
Inquiry*
Yes
No
no activities*
Yes
No
place of presentation*
Appointment date*
last therapy*
last aftercare*
Number Medical-Examination*
Target Number Medical-Examination*
Chronic pain
Chronic pain *
No (No)
no information (no information)
Yes (Yes)
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dataset Aftercare cancer
Eligibility NCT01120301 Acute Ischemic
Stroke
ODM derived from
http://clinicaltrials.gov/show/NCT01120301
All rights reserved. Please visit https://medical-data-
models.org/forms/4317
Eligibility
Einschlusskriterien
Alter 40 bis 80 Jahre*
Ja
Nein
Clinical diagnosis of acute ischemic stroke*
Ja
Nein
Subject is not a candidate for treatment with
neurothrombectomy*
Ja
Nein
Initiation of the TLT procedure begins between
4.5 and 24 hours*
Ja
Nein
Baseline NIHSS score range: 7-17*
Ja
Nein
Full functional independence just prior to the
present stroke episode*
Ja
Nein
Negative pregnancy test in females of
childbearing potential*
Ja
Nein
Subject Informed Consent obtained prior to
enrollment into this study*
Ja
Nein
Ausschlusskriterien
Evidence of an intracranial, subdural, or
subarachnoid hemorrhage*
Ja
Nein
Acute ischemic strokes located exclusively in the
brainstem, or cerebellum, or small deep
infarctions, or massive hemispheric strokes*
Ja
Nein
Seizure at stroke onset or within the 7 days prior
to stroke onset*
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Ja
Nein
Sustained blood glucose >300 or <60 mg/dl*
Ja
Nein
Sustained hypertension (SBP >220 mmHg or
DBP >140 mmHg)*
Ja
Nein
Sustained hypotension (SBP <80 mmHg or DBP
<50 mmHg)*
Ja
Nein
A presumed and/or confirmed septic embolus*
Ja
Nein
History of CNS vascular disease (e.g. aneurysm,
AVM) or history of CNS disease or damage (e.g.
neoplasm or dementia) which may influence the
subject's outcome assessment.*
Ja
Nein
Head implant of any kind*
Ja
Nein
Significant skin condition of the scalp (eg.
psoriasis)*
Ja
Nein
Use of any intravenous or intra-arterial
thrombolytic medication*
Ja
Nein
Use of any diagnostic or therapeutic
interventional neurovascular procedure*
Ja
Nein
Female who is pregnant or lactating or who is of
childbearing potential and not using a medically
acceptable method of birth control.*
Ja
Nein
2 / 2
Eligibility NCT01120301 Acute Ischemic Stroke
Eligibility NCT01113710 Idiopathic Restless
Legs Syndrome
ODM derived from
http://clinicaltrials.gov/show/NCT01113710
All rights reserved. Please visit https://medical-data-
models.org/forms/4319
Eligibility
Einschlusskriterien
Alter mindestens 18 Jahre*
Ja
Nein
The patient's treatment must be in accordance
with the local marketing authorization (MA) for
Neupro*
Ja
Nein
The patient must have a diagnosis of moderate to
severe idiopathic RLS*
Ja
Nein
The patient is considered reliable and capable of
adhering to the visit schedule or medication
administration according to the judgment of the
investigator*
Ja
Nein
The decision to prescribe the drug has been
made by the physician independently of his/her
decision to include the patient in the study*
Ja
Nein
Subject is informed and given ample time and
opportunity to think about his/her participation in
the study and has given written informed data
consent *
Ja
Nein
Ausschlusskriterien
Hypersensitivity to the active substance or to any
of the excipients*
Ja
Nein
Magnetic resonance imaging or cardioversion
(see SmPC)*
Ja
Nein
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Eligibility NCT01103284 Type 1 Diabetes
Mellitus
ODM derived from
http://clinicaltrials.gov/show/NCT01103284
All rights reserved. Please visit https://medical-data-
models.org/forms/4321
Eligibility
Einschlusskriterien
Alter 20 bis 45 Jahre*
Ja
Nein
clinical diagnosis of type 1 diabetes within last 6
months*
Ja
Nein
fasting basal C-peptide >= 0.22nmol/L, <
0.8nmol/L*
Ja
Nein
BMI between 17 and 30 at screening *
Ja
Nein
Ausschlusskriterien
Significant disease or condition other than type 1
diabetes*
Ja
Nein
Diabetes-Komplikationen*
Ja
Nein
Ongoing treatment with immunosuppressive or
immunomodulating agents including chronic
corticosteroids*
Ja
Nein
1 / 1
Eligibility NCT01090089 Multiple Myeloma
ODM derived from
http://clinicaltrials.gov/show/NCT01090089
All rights reserved. Please visit https://medical-data-
models.org/forms/4325
Eligibility
Einschlusskriterien
Alter 60 bis 75 Jahre*
Ja
Nein
Understand and voluntarily sign an informed
consent form.*
Ja
Nein
Able to adhere to the study visit schedule and
other protocol requirements.*
Ja
Nein
Symptomatic MM requiring therapy.*
Ja
Nein
Measurable monoclonal protein in serum and/or
urine*
Ja
Nein
Monoclonal plasma cells in the bone marrow >/=
10% and/or biopsy-proven plasmacytoma*
Ja
Nein
Myeloma-related organ dysfunction, at least one
of   *
Ja
Nein
Serumkalzium erhöht*
Ja
Nein
[R] Renal insufficiency (creatinine > 173 μmol/l or
> 2 mg/dL)*
Ja
Nein
[A] Anemia (Hb < 10 g/dL or 2 g/dL < normal) *
Ja
Nein
[B] Bone lesions or general osteoporosis*
Ja
Nein
ECOG Status <= 2*
Ja
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Nein
Laboratory test results within these ranges within
1 week prior to randomization:*
Ja
Nein
Absolute Neutrophil Count*
Ja
Nein
Platelet count >/= 75 x 109/L or in case of bone
marrow infiltration with myeloma cells >/= 30 x
109/L.*
Ja
Nein
Gesamtbilirubin*
Ja
Nein
AST (SGOT) and ALT (SGPT) </= 3 x ULN. *
Ja
Nein
Female subjects of childbearing potential must:
*
Ja
Nein
o Understand the study drug is expected to have
a teratogenic risk*
Ja
Nein
o Agree to use, ..., effective contraception without
interruption,...*
Ja
Nein
o Understand that even if she has amenorrhea,
she must follow all the advice on effective
contraception.*
Ja
Nein
o She understands the potential consequences of
pregnancy and the need to rapidly consult if there
is a risk of pregnancy*
Ja
Nein
o Agree to have a medically supervised
pregnancy test ...*
Ja
Nein
Male subjects must *
Ja
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Eligibility NCT01090089 Multiple Myeloma
Nein
o Agree to use condoms throughout study drug
therapy, during any dose interruption and for one
week after cessation of study drug therapy ...*
Ja
Nein
Agree not to donate semen during study drug
therapy and for one week after end  of study drug
therapy.*
Ja
Nein
All subjects must*
Ja
Nein
Agree to abstain from donating blood while taking
study drug therapy and for one  week following
discontinuation of study drug therapy.*
Ja
Nein
Agree not to share study drug with another
person and to return all unused study  drug to the
investigator.  *
Ja
Nein
Disease free of prior malignancies for >/= 5 years
with exception of  currently treated basal cell,
squamous cell carcinoma of the skin, or
carcinoma  in situ of the cervix or breast.  *
Ja
Nein
Able to receive antithrombotic prophylaxis (...). *
Ja
Nein
Life-expectancy > 3  months. *
Ja
Nein
Ausschlusskriterien
Any serious medical condition, laboratory
abnormality, or psychiatric illness that would
prevent the subject from signing the ICF.*
Ja
Nein
Pregnant or lactating females*
Ja
Nein
Any condition, incl. the presence of laboratory
abnormalities, which places the subject at
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Eligibility NCT01090089 Multiple Myeloma
unacceptable risk if he/she were to participate in
the study or confounds the ability to interpret data
from the study.*
Ja
Nein
Patient currently is enrolled in another clinical
research study or has been enrolled ...within 4
weeks before randomization and/or is receiving
an investigational agent for any reason ...*
Ja
Nein
Known hypersensitivity to thalidomide,
dexamethasone, or melphalan.*
Ja
Nein
The development of erythema nodosum if
characterized by a desquamating rash while
taking thalidomide or similar drugs.*
Ja
Nein
Any prior use of lenalidomide.*
Ja
Nein
Concurrent use of other anti-cancer agents or
treatments.*
Ja
Nein
Known positive for HIV or active infectious
hepatitis, type A, B or C or treponema pallidum*
Ja
Nein
Prior treatment with dexamethasone discontinued
because of ≥ grade 3 dexamethasone-related
toxicity.*
Ja
Nein
Any prior chemotherapy with the exception of a
short course of dexamethasone > 4 weeks before
randomization.*
Ja
Nein
Immunotherapy or antibody therapy within 8
weeks before randomization.*
Ja
Nein
major surgery*
Ja
Nein
Renal failure requiring dialysis.*
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Eligibility NCT01090089 Multiple Myeloma
Ja
Nein
Myocardial infarction within 6 months before
randomization, NYHA Class III or IV heart failure,
uncontrolled angina, severe uncontrolled
ventricular arrhythmias, or electrocardiographic
evidence of acute ischemia or active conduction
system abnormalities.*
Ja
Nein
Severe pulmonary disease (diffusion capacity <
60% of normal).*
Ja
Nein
Treatment for cancer other than MM within 5
years before randomization, with the exception of
basal cell carcinoma or cervical cancer in situ.*
Ja
Nein
Senile cardiac amyloidosis, Cardiac amyloidosis,
AS transthyretin amyloidosis*
Ja
Nein
Poorly controlled hypertension, diabetes mellitus,
or other serious medical or psychiatric illness that
could potentially interfere with the completion of
treatment according to the protocol.*
Ja
Nein
Any systemic infection requiring treatment.*
Ja
Nein
Unability or unwillingness of the patient to receive
antithrombotic prophylaxis.*
Ja
Nein
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Eligibility NCT01090089 Multiple Myeloma
Eligibility NCT01081782 Multiple Sclerosis
ODM derived from
http://clinicaltrials.gov/show/NCT01081782
All rights reserved. Please visit https://medical-data-
models.org/forms/4327
Eligibility
Einschlusskriterien
Alter 18 bis 55 Jahre*
Ja
Nein
Adult male or female aged 18-55 years inclusive
at screening*
Ja
Nein
Patients who have a definite diagnosis of
relapsing-remitting Multiple Sclerosis *
Ja
Nein
Ausschlusskriterien
Multiple Sclerosis course other than relapsing-
remitting multiple sclerosis*
Ja
Nein
History of neoplastic disease*
Ja
Nein
History of clinically significant chronic disease of
the immune system (other than Multiple
Sclerosis)*
Ja
Nein
Inability to undergo Gd-enhanced MRI scans*
Ja
Nein
Diagnosis of diabetes mellitus (type I or type II)*
Ja
Nein
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Eligibility NCT01079182 Ankylosing
Spondylitis
ODM derived from
http://clinicaltrials.gov/show/NCT01079182
All rights reserved. Please visit https://medical-data-
models.org/forms/4328
Eligibility
Einschlusskriterien
Alter mindestens 18 Jahre*
Ja
Nein
Active, ankylosing spondylitis in adults with
insufficient response to conventional therapy. *
Ja
Nein
Ausschlusskriterien
Hypersensitivity against the drug or one of the
other ingredients*
Ja
Nein
Active tuberculosis or other severe infections (e.g.
sepsis and opportunistic infections)*
Ja
Nein
Moderate to severe cardiac insufficiency.*
Ja
Nein
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Eligibility NCT01069419 Rheumatoid
Arthritis
ODM derived from
http://clinicaltrials.gov/show/NCT01069419
All rights reserved. Please visit https://medical-data-
models.org/forms/4329
Eligibility
Einschlusskriterien
Alter mindestens 18 Jahre*
Ja
Nein
Rheumatoid Arthritis*
Ja
Nein
Patients eligible for treatment with Cimzia as
defined in EU approved SmPC *
Ja
Nein
Ausschlusskriterien
Patient previously treated with Cimzia. *
Ja
Nein
Patient with known hypersensitivity to any
component of Cimzia.*
Ja
Nein
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dataset Surgery cancer
clinical cancer registry used in Münster
All rights reserved. Please visit https://medical-data-
models.org/forms/4332
dataset
Patient data
Patient title *
patient number*
Patient surname *
Patient forename*
Patient date of birth*
Patient sex*
Female (Female)
Male (Male)
Street Address*
Patient postal code*
City of residence *
Patient telephone number*
Date of surgery*
Emergency operation*
Yes
No
ASA physical status*
ASA physical status 1 (ASA physical
status 1)
ASA physical status 2 (ASA physical
status 2)
ASA physical status 3 (ASA physical
status 3)
ASA physical status 4 (ASA physical
status 4)
ASA physical status 5 (ASA physical
status 5)
no information (no information)
Surgical and medical procedures *
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Technique Surgery*
Primary Neoplasm*
No (No)
no information (no information)
Yes (Yes)
Metastatic Malignant Neoplasm to the Lymph
Node*
No (No)
no information (no information)
Yes (Yes)
Distant metastasis (other organs)*
No (No)
no information (no information)
Yes (Yes)
Residual tumor stage*
no information (no information)
Not Applicable  (Not Applicable )
not_coded (not_coded)
not_coded (not_coded)
not_coded (not_coded)
not_coded (not_coded)
Residual tumor stage R0 (Residual
tumor stage R0)
Residual tumor stage R1  (Residual
tumor stage R1 )
Residual tumor stage R2  (Residual
tumor stage R2 )
Residual tumor stage RX (Residual
tumor stage RX)
Distance of tumor from closest margin*
primary surgeon*
first assistant surgeon *
Intraoperative Complication*
No (No)
no information (no information)
Yes (Yes)
Complication*
Yes
No
abscess *
Yes
No
Postoperative intra-abdominal abscess*
Yes
No
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subfascial abscess *
Yes
No
Kidney Failure *
Yes
No
Allergic disorder*
Yes
No
anaphylaxis *
Yes
No
Anastomotic Leak*
Yes
No
Apoplectic apoplexy*
Yes
No
Deep Vein Thrombosis *
Yes
No
Biliary Fistula *
Yes
No
Upper gastrointestinal hemorrhage *
Yes
No
not_useful_for_research*
Yes
No
not_useful_for_research*
Yes
No
Cholangitis *
Yes
No
Disseminated Intravascular Coagulation *
Yes
No
not_useful_for_research*
Yes
No
Pressure Ulcer *
Yes
No
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not_useful_for_research*
Yes
No
Gastrointestinal Fistula *
Yes
No
Blood Coagulation Disorders *
Yes
No
not_useful_for_research*
Yes
No
Hematuria *
Yes
No
Hemorrhagic Shock *
Yes
No
Urinary Tract Fistula*
Yes
No
Skin necrosis *
Yes
No
Heart failure *
Yes
No
Cardiac Arrhythmia *
Yes
No
Cranial nerve palsies*
Yes
No
Organic brain syndrome *
Yes
No
not_useful_for_research*
Yes
No
not_useful_for_research*
Yes
No
Ileofemoral deep vein thrombosis *
Yes
No
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Cardiogenic Shock *
Yes
No
not_useful_for_research*
Yes
No
Complication of implant *
Yes
No
Seizure*
Yes
No
not_useful_for_research*
Yes
No
not_useful_for_research*
Yes
No
Pulmonary Embolism *
Yes
No
Pulmonary Edema*
Yes
No
Lymph fistula *
Yes
No
Lymphocele *
Yes
No
not_useful_for_research*
Yes
No
Ileus*
Yes
No
not_useful_for_research*
Yes
No
Thrombosis of mesenteric vein or artery*
Yes
No
Myocardial Infarction *
Yes
No
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Postoperative Hemorrhage *
Yes
No
Postoperative Hemorrhage with revision
procedure*
Yes
No
stitch leakage *
Yes
No
not_useful_for_research*
Yes
No
not_useful_for_research*
Yes
No
not_useful_for_research*
Yes
No
peranal bleeding*
Yes
No
Peripheral paralysis *
Yes
No
Peripheral Arterial Occlusion  *
Yes
No
Peritonitis *
Yes
No
Abdominal wound dehiscence *
Yes
No
not_useful_for_research*
Yes
No
Pleural effusion  *
Yes
No
Pneumonia *
Yes
No
not_useful_for_research*
Yes
No
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Paralytic Ileus *
Yes
No
Pulmonary Embolism *
Yes
No
vocal cord paresis*
Yes
No
Pulmonary insufficiency *
Yes
No
septic complication of implant*
Yes
No
Septic Shock*
Yes
No
other complication*
Yes
No
stenosis*
Yes
No
not_useful_for_research*
Yes
No
Disorder of water electrolyte and/or acid-base
balance *
Yes
No
Thrombocytopenia *
Yes
No
Transient Ischemic Attack *
Yes
No
Transfusion Reaction*
Yes
No
Wound hematoma (finding) *
Yes
No
Wound Complication*
Yes
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No
Postoperative Wound Infection *
Yes
No
Surgical Revision*
No (No)
no information (no information)
Yes (Yes)
Collection*
complete (complete)
incomplete (incomplete)
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dataset radiotherapy cancer
clinical cancer registry used in Münster
All rights reserved. Please visit https://medical-data-
models.org/forms/4334
dataset
Patient data
Patient title *
patient number*
Patient surname *
Patient forename*
Patient date of birth*
Patient sex*
Female (Female)
Male (Male)
Street Address*
Patient postal code*
City of residence *
Patient telephone number*
Therapeutic radiology procedure
Start Radiotherapy*
End Radiotherapy*
Radiotherapy Technique*
Internal metabolic radiotherapy
(procedure) (Internal metabolic
radiotherapy (procedure))
Internal radiotherapy - permanent seeds
(Internal radiotherapy - permanent seeds
)
Intracavity Radiotherapy  (Intracavity
Radiotherapy )
Intraoperative Radiation Therapy
(Intraoperative Radiation Therapy )
no information (no information)
Teleradiotherapy procedure
(Teleradiotherapy procedure)
1 / 3
radiation dose *
Fractions*
Total boost radiation dose *
Total radiation dose *
Radioactivity*
Organ target(s) *
Organ target(s) *
Side *
Left (Left)
Midline (Midline)
Not Applicable  (Not Applicable )
Right (Right)
Unknown (Unknown)
Adverse event *
No (No)
no information (no information)
Yes (Yes)
Radiation*
Cesium Cs 137  (Cesium Cs 137 )
Cobalt Co-60 (Cobalt Co-60)
Electron Beam (Electron Beam)
Gold 198 (Gold 198)
Iodine 131  (Iodine 131 )
Iodine-125  (Iodine-125 )
Iridium 192 (Iridium 192)
Neutron Radiation  (Neutron Radiation )
no information (no information)
not_coded (not_coded)
other (other)
Phosphorus 32 (Phosphorus 32)
Proton + Electron Beam (Proton +
Electron Beam)
Proton beam (Proton beam)
PUVA local (PUVA local)
PUVA systemic (PUVA systemic)
Radium 226 (Radium 226)
Roentgen Rays  (Roentgen Rays )
Ruthenium-106 (Ruthenium-106)
Strontium Sr-90  (Strontium Sr-90 )
Strontium-89  (Strontium-89 )
Tantalum 182 (Tantalum 182)
Ultrahard X-rays  (Ultrahard X-rays )
Ultraviolet B Radiation  (Ultraviolet B
Radiation )
Yttrium Y-90 (Yttrium Y-90)
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electric potential*
electric energy*
Treatment modification *
No (No)
no information (no information)
Yes (Yes)
Application*
Interruption *
Device not ready  (Device not ready )
Interruption  (Interruption )
no information (no information)
no interruption (no interruption)
other reason (other reason)
Patient absent (Patient absent)
Unknown (Unknown)
planned therapeutic procedure*
Interruption  (Interruption )
no information (no information)
Previous treatment continue  (Previous
treatment continue )
Unknown (Unknown)
Termination of Radiotherapy*
Completion of therapy (Completion of
therapy)
Discontinue because of adverse effects
(Discontinue because of adverse effects)
Discontinue because of progression
(Discontinue because of progression)
Interruption  (Interruption )
no information (no information)
other reason for discontinue (other
reason for discontinue)
Refusal of Treatment (Refusal of
Treatment)
regular End of Therapy (regular End of
Therapy)
Unknown (Unknown)
Collection*
complete (complete)
incomplete (incomplete)
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Eligibility NCT01036763 Pulmonary
Disease, Chronic Obstructive
ODM derived from
http://clinicaltrials.gov/show/NCT01036763
All rights reserved. Please visit https://medical-data-
models.org/forms/4337
Eligibility
Einschlusskriterien
Alter mindestens 18 Jahre*
Ja
Nein
COPD patients requiring long-acting
bronchodilators according to approved Summary
of Product Characteristics (SPC) and guidelines *
Ja
Nein
Ausschlusskriterien
Patients cannot be recruited if any of the general
or specific contraindications listed in the Patient
information leaflet or the Summary of Product
Characteristics applies.*
Ja
Nein
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dataset finalreport and autopsy cancer
clinical cancer registry used in Münster
All rights reserved. Please visit https://medical-data-
models.org/forms/4338
dataset
Patient data
Patient title *
patient number*
Patient surname *
Patient forename*
Patient date of birth*
Patient sex*
Female (Female)
Male (Male)
Street Address*
Patient postal code*
City of residence *
Patient telephone number*
Attending physician *
Registration office/authority*
Diagnosis*
Date last contact*
Source of information *
Cancer Center  (Cancer Center )
Cancer Registry  (Cancer Registry )
Central Office (Central Office)
Hospitals (Hospitals)
Newspapers  (Newspapers )
Other (Other)
1 / 9
Primary Care Physician (Primary Care
Physician)
RegistrationCenter (RegistrationCenter)
Unknown (Unknown)
Collection Date *
reason for termination*
Aftercare completed (Aftercare
completed)
aftercare in other hospital (aftercare in
other hospital)
aftercare not designated (aftercare not
designated)
Aftercare not wanted (Aftercare not
wanted)
Age of Patient (Age of Patient)
no information (no information)
Patient absent (Patient absent)
Patient died (Patient died)
Patient moribund (Patient moribund)
patient moved elsewhere (patient moved
elsewhere)
Primary Care Physician unknowm
(Primary Care Physician unknowm)
uncooperative physician (uncooperative
physician)
Place of Aftercare*
Date of death*
Cause of death*
Death by neoplasm (Death by neoplasm)
Death by neoplasm uncertain (Death by
neoplasm uncertain)
no information (no information)
other cause of death (other cause of
death)
unknown (unknown)
Autopsy*
no information (no information)
not executed (not executed)
Yes (Yes)
Collection*
complete (complete)
incomplete (incomplete)
Autopsy
place of autopsy*
autopsy identifier*
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Date of Receipt*
Date of report*
Tumor Status
Tumor Expansion
Primary Neoplasm *
No evidence of neoplasm  (No evidence
of neoplasm )
questionable Result (questionable
Result)
Recurrent Disease (Recurrent Disease)
Residual Disease  (Residual Disease )
Metastatic Malignant Neoplasm to the regional
Lymph Nodes*
No evidence of neoplasm  (No evidence
of neoplasm )
questionable Result (questionable
Result)
Recurrent Disease (Recurrent Disease)
Residual Disease  (Residual Disease )
Distant metastasis (other organs)*
No evidence of neoplasm  (No evidence
of neoplasm )
questionable Result (questionable
Result)
Recurrent Disease (Recurrent Disease)
Residual Disease  (Residual Disease )
Tumor Status*
- (-)
Assessment not possble (Assessment
not possble)
clinical improvement (clinical
improvement)
Divergent event (Divergent event)
In complete remission  (In complete
remission )
no information (no information)
No neoplasm (qualifier value)  (No
neoplasm (qualifier value) )
not clarified (not clarified)
partial response  (partial response )
Stable Disease (Stable Disease)
Tumor marker increase (Tumor marker
increase)
Tumor Progression (Tumor Progression)
Histopathology
Histology ICD-O-3 *
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histologic diagnosis text*
Tumor site*
Site of primary tumor (Site of primary
tumor)
Subsite (Subsite)
Histologic Grade*
G1 grade  (G1 grade )
G2 grade (G2 grade)
G3 grade (G3 grade)
G4 Grade (G4 Grade)
Grade cannot be determined  (Grade
cannot be determined )
Grade not designated (Grade not
designated)
High grade (High grade)
Low grade (Low grade)
Neoplasm, Uncertain Whether Benign or
Malignant  (Neoplasm, Uncertain
Whether Benign or Malignant )
no information (no information)
cell type *
B-Cell Lymphomas  (B-Cell Lymphomas
)
Grade cannot be determined  (Grade
cannot be determined )
no information (no information)
Primary Cutaneous Anaplastic Large
Cell Lymphoma  (Primary Cutaneous
Anaplastic Large Cell Lymphoma )
T-Cell Lymphoma  (T-Cell Lymphoma )
Score *
Gleason-Score (Gleason-Score)
no information (no information)
Sarcoma by FNCLCC Grade  (Sarcoma
by FNCLCC Grade )
VNPI-Score (DCIS) (VNPI-Score (DCIS))
Primary Gleason Pattern *
Secondary Gleason Pattern *
Total Gleason Score for Prostate Cancer *
Staging*
Yes
No
Generic tumor staging descriptor *
Tumor staging descriptor r (Tumor
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staging descriptor r)
Tumor staging descriptor y (Tumor
staging descriptor y)
TNM Classification before any treatment*
Yes
No
TNM Classification after operation*
Yes
No
TNM Stage descriptor*
T Stage*
Degree of certainty of TNM classification
(observable entity) *
TNM Stage descriptor*
N Stage*
Degree of certainty of TNM classification
(observable entity) *
TNM Stage descriptor*
M Stage*
Degree of certainty of TNM classification
(observable entity) *
Number of sentinel lymph nodes involved*
Number of sentinel lymph nodes examined*
Number of lymph nodes involved by malignant
neoplasm *
Number of lymph nodes examined*
Lymph vessel invasion*
L0 Stage Finding (L0 Stage Finding)
L1 Stage Finding (L1 Stage Finding)
LX Stage Finding (LX Stage Finding)
Venous Invasion*
V0 Stage Finding (V0 Stage Finding)
V1 Stage Finding  (V1 Stage Finding )
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V2 Stage Finding (V2 Stage Finding)
VX Stage Finding (VX Stage Finding)
organ capsule infiltration*
No (No)
no information (no information)
Yes, breakthrough (Yes, breakthrough)
Yes, Infiltration (Yes, Infiltration)
Perineural Invasion*
No (No)
no information (no information)
Status of perineural invasion cannot be
assessed (Status of perineural invasion
cannot be assessed)
Yes (Yes)
Residual tumor stage*
no information (no information)
Not Applicable  (Not Applicable )
Residual tumor stage R0 (Residual
tumor stage R0)
Residual tumor stage R1  (Residual
tumor stage R1 )
Residual tumor stage R1  (Residual
tumor stage R1 )
Residual tumor stage R1  (Residual
tumor stage R1 )
Residual tumor stage R2 (Residual
tumor stage R2)
Residual tumor stage R2 (Residual
tumor stage R2)
Residual tumor stage R2 (Residual
tumor stage R2)
Residual tumor stage RX (Residual
tumor stage RX)
UICC-Classification*
available  (available )
no information (no information)
Ann Arbor Lymphoma Staging System *
Yes
No
other Staging System *
Yes
No
Description Staging System*
Stage*
Microsatellite Instability *
TME Grade*
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distant metastasis
Metastatic Malignant Neoplasm to the Lung*
Yes
No
C-factor status*
C1 certainty  (C1 certainty )
C2 certainty  (C2 certainty )
C3 certainty  (C3 certainty )
C4 certainty  (C4 certainty )
C5 certainty  (C5 certainty )
Metastatic Malignant Neoplasm to the Pleura*
Yes
No
C-factor status*
C1 certainty  (C1 certainty )
C2 certainty  (C2 certainty )
C3 certainty  (C3 certainty )
C4 certainty  (C4 certainty )
C5 certainty  (C5 certainty )
Metastatic Malignant Neoplasm to the Liver*
Yes
No
C-factor status*
C1 certainty  (C1 certainty )
C2 certainty  (C2 certainty )
C3 certainty  (C3 certainty )
C4 certainty  (C4 certainty )
C5 certainty  (C5 certainty )
Metastatic Malignant Neoplasm to the Spleen *
Yes
No
C-factor status*
C1 certainty  (C1 certainty )
C2 certainty  (C2 certainty )
C3 certainty  (C3 certainty )
C4 certainty  (C4 certainty )
C5 certainty  (C5 certainty )
Metastatic Malignant Neoplasm to the Ovary *
Yes
No
C-factor status*
C1 certainty  (C1 certainty )
C2 certainty  (C2 certainty )
C3 certainty  (C3 certainty )
C4 certainty  (C4 certainty )
C5 certainty  (C5 certainty )
Metastatic Malignant Neoplasm to the
Peritoneum *
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Yes
No
C-factor status*
C1 certainty  (C1 certainty )
C2 certainty  (C2 certainty )
C3 certainty  (C3 certainty )
C4 certainty  (C4 certainty )
C5 certainty  (C5 certainty )
Metastatic Malignat Neoplasm to the adrenal
gland*
Yes
No
C-factor status*
C1 certainty  (C1 certainty )
C2 certainty  (C2 certainty )
C3 certainty  (C3 certainty )
C4 certainty  (C4 certainty )
C5 certainty  (C5 certainty )
Metastatic Malignant Neoplasm to the Bone
Marrow*
Yes
No
C-factor status*
C1 certainty  (C1 certainty )
C2 certainty  (C2 certainty )
C3 certainty  (C3 certainty )
C4 certainty  (C4 certainty )
C5 certainty  (C5 certainty )
Metastatic Malignant Neoplasm to the Bone *
Yes
No
C-factor status*
C1 certainty  (C1 certainty )
C2 certainty  (C2 certainty )
C3 certainty  (C3 certainty )
C4 certainty  (C4 certainty )
C5 certainty  (C5 certainty )
Metastatic Malignant Neoplasm to the Lymph
Node *
Yes
No
C-factor status*
C1 certainty  (C1 certainty )
C2 certainty  (C2 certainty )
C3 certainty  (C3 certainty )
C4 certainty  (C4 certainty )
C5 certainty  (C5 certainty )
Secondary malignant neoplasm of skin *
Yes
No
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C-factor status*
C1 certainty  (C1 certainty )
C2 certainty  (C2 certainty )
C3 certainty  (C3 certainty )
C4 certainty  (C4 certainty )
C5 certainty  (C5 certainty )
Metastatic malignant neoplasm to brain*
Yes
No
C-factor status*
C1 certainty  (C1 certainty )
C2 certainty  (C2 certainty )
C3 certainty  (C3 certainty )
C4 certainty  (C4 certainty )
C5 certainty  (C5 certainty )
Metastatic Malignant Neoplasm to the Kidney *
Yes
No
C-factor status*
C1 certainty  (C1 certainty )
C2 certainty  (C2 certainty )
C3 certainty  (C3 certainty )
C4 certainty  (C4 certainty )
C5 certainty  (C5 certainty )
Distant metastasis (other organs)*
Yes
No
C-factor status*
C1 certainty  (C1 certainty )
C2 certainty  (C2 certainty )
C3 certainty  (C3 certainty )
C4 certainty  (C4 certainty )
C5 certainty  (C5 certainty )
Generalized cancer*
Yes
No
C-factor status*
C1 certainty  (C1 certainty )
C2 certainty  (C2 certainty )
C3 certainty  (C3 certainty )
C4 certainty  (C4 certainty )
C5 certainty  (C5 certainty )
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Eligibility NCT01021670 Sexual
Dysfunction, Physiological
ODM derived from
http://clinicaltrials.gov/show/NCT01021670
All rights reserved. Please visit https://medical-data-
models.org/forms/4342
Eligibility
Einschlusskriterien
Alter 18 bis 64 Jahre*
Ja
Nein
In accordance with the therapeutic indication
stated in the Summary of Product Characteristics
for dapoxetine hydrochloride, patients will be
candidates for enrollment if they have an
intravaginal ejaculatory latency time of < two
minutes*
Ja
Nein
Persistent or recurrent ejaculation with minimal
sexual stimulation before, on, or shortly after
penetration and before the patient wishes*
Ja
Nein
Marked personal distress or interpersonal
difficulty as a consequence of premature
ejaculation*
Ja
Nein
Poor control over ejaculation *
Ja
Nein
Ausschlusskriterien
In accordance with the contraindications, special
warnings and precautions for use as stated in the
Summary of Product Characteristics for
dapoxetine hydrochloride, patients will be
excluded from treatment if they have
hypersensitivity to dapoxetine hydrochloride or to
any of the excipients*
Ja
Nein
Significant pathological cardiac conditions such
as: heart failure (New York Heart Association
[NYHA] class II-IV), conduction abnormalities
(second or third degree atrioventicular (AV) block
or sick sinus syndrome) not treated with a
permanent pacemaker, significant ischemic heart
disease, or significant valvular disease*
Ja
Nein
Concomitant treatment with monoamine oxidase
1 / 2
inhibitors (MAOIs), or within 14 days of
discontinuing treatment with an MAOI*
Ja
Nein
Concomitant treatment with thioridazine,
concomitant treatment with serotonin reuptake
inhibitors (selective serotonin reuptake inhibitors
[SSRIs], serotonin-norepinephrine reuptake
inhibitors [SNRIs], tricyclic antidepressants
[TCAs)] or other medicinal/herbal products with
serotonergic effects (for example, L-tryptophan,
triptans, tramadol, linezolid, lithium, St. John's
Wort (Hypericum perforatum)*
Ja
Nein
Concomitant treatment of potent CYP3A4
inhibitors such as ketoconazole, itraconazole,
ritonavir, saquinavir, telithromycin, nefazadone,
nelfinavir, atazanavir, etc.*
Ja
Nein
Moderate and severe hepatic impairment*
Ja
Nein
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Eligibility NCT01019473 Huntington's
Disease
ODM derived from
http://clinicaltrials.gov/show/NCT01019473
All rights reserved. Please visit https://medical-data-
models.org/forms/4343
Eligibility
Einschlusskriterien
Alter 30 bis 85 Jahre*
Ja
Nein
Huntington's disease (based on DNA testing
polyQ >36) with a UHDRS maximal chorea score
of >10*
Ja
Nein
patient with concomitant Huntington's medication
(anti-depressants, neuroleptics,
benzodiazepines) are allowed but the total daily
dose and dosing regimen has to be stable for at
least one months prior to randomization*
Ja
Nein
female patients without childbearing potential
(post-menopausal or surgically sterilized), all
patients must using a double-barrier local
contraception *
Ja
Nein
Ausschlusskriterien
patients with marked cognitive impairment
(MMSE < 18), with presence of psychosis and/or
confusional states*
Ja
Nein
patients with a history or presence of renal
impairment and/or liver disease*
Ja
Nein
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Eligibility NCT01012973 Retinal Vein
Occlusion
ODM derived from
http://clinicaltrials.gov/show/NCT01012973
All rights reserved. Please visit https://medical-data-
models.org/forms/4347
Eligibility
Einschlusskriterien
Alter mindestens 18 Jahre*
Ja
Nein
Center-involved macular edema secondary to
central retinal vein occlusion (CRVO) for no
longer than 9 months with mean central subfield
thickness >= 250 microm on optical coherence
tomography (OCT)*
Ja
Nein
Erwachsener, erwachsen*
Ja
Nein
Early treatment diabetic retinopathy study
(ETDRS) best corrected visual acuity (BCVA) of
20/40 to 20/320 (73 to 24 letters) in the study eye
*
Ja
Nein
Ausschlusskriterien
Any prior treatment with anti-VEGF agents in the
study eye (Pegaptanib sodium, anecortave
acetate, bevacizumab, ranibizumab, etc.) or
previous administration of systemic anti-
angiogenic medications*
Ja
Nein
Prior panretinal laser photocoagulation or
macular laser photocoagulation in the study eye*
Ja
Nein
CRVO disease duration > 9 months from date of
diagnosis*
Ja
Nein
Previous use of intraocular corticosteroids in the
study eye or use of periocular corticosteroids in
the study eye within the 3 months prior to Day 1*
Ja
Nein
Iris neovascularization, vitreous hemorrhage,
traction retinal detachment, or preretinal fibrosis
involving the macula in either the study eye or
fellow eye*
1 / 2
Ja
Nein
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Eligibility NCT01011738 Hepatitis B,
Chronic
ODM derived from
http://clinicaltrials.gov/show/NCT01011738
All rights reserved. Please visit https://medical-data-
models.org/forms/4348
Eligibility
Einschlusskriterien
Alter mindestens 18 Jahre*
Ja
Nein
Erwachsener, erwachsen*
Ja
Nein
chronic hepatitis B*
Ja
Nein
treatment with peginterferon alfa-2A *
Ja
Nein
Ausschlusskriterien
coinfection with HAV, HCV and HIV *
Ja
Nein
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Eligibility NCT00997230 Newly Diagnosed
Locally Advanced or Metastatic NSCLC
ODM derived from
http://clinicaltrials.gov/show/NCT00997230
All rights reserved. Please visit https://medical-data-
models.org/forms/4350
Eligibility
Einschlusskriterien
Alter mindestens 18 Jahre*
Ja
Nein
Histologically confirmed locally advanced or
metastatic NSCLC (stage IIIB/IV). Mixed
histology of small cell and non-small cell lung
cancer*
Ja
Nein
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dataset cancer conference cancer
clinical cancer registry used in Münster
All rights reserved. Please visit https://medical-data-
models.org/forms/4352
dataset
Patient data
Patient title *
patient number*
Patient surname *
Patient forename*
Patient date of birth*
Patient sex*
Female (Female)
Male (Male)
Street Address*
Patient postal code*
City of residence *
Patient telephone number*
Attending physician *
not_useful_for_research*
Diagnosis*
Date of cancer conference*
Cancer conference type*
morbidity conference (morbidity
conference)
post-surgery (post-surgery)
post-therapeutic (post-therapeutic)
pre-therapeutic (pre-therapeutic)
Cancer conference Decision
1 / 3
Intention*
Adjuvant - intent (Adjuvant - intent)
Curative - procedure intent  (Curative -
procedure intent )
Neo-adjuvant - intent  (Neo-adjuvant -
intent )
no information (no information)
Not Applicable  (Not Applicable )
Palliative - procedure intent  (Palliative -
procedure intent )
treatment classification *
Diagnostic procedure (Diagnostic
procedure)
following therapy (following therapy)
Long-Term therapy (Long-Term therapy)
no information (no information)
primal therapy (primal therapy)
relapse treatment (relapse treatment)
therapy of metastasis (therapy of
metastasis)
Cancer conference Decision
Aftercare*
Yes
No
Operative Surgical Procedures *
Yes
No
Chemotherapy Regimen*
Yes
No
Therapeutic radiology procedure *
Yes
No
Endocrine Therapy*
Yes
No
Immunotherapy *
Yes
No
Supportive Care*
Yes
No
Pain management *
Yes
No
Other therapy*
Yes
No
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disease stage*
Yes
No
Consultation*
Yes
No
Hemopoietic stem cell transplant *
Yes
No
Bone Marrow Transplantation*
Yes
No
Prophylactic treatment *
Yes
No
Rehabilitation therapy *
Yes
No
active surveillance*
Yes
No
Inquiry*
Yes
No
no activities*
Yes
No
Free Text*
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Eligibility NCT00985712 Diabetes Mellitus,
Type 1
ODM derived from
http://clinicaltrials.gov/show/NCT00985712
All rights reserved. Please visit https://medical-data-
models.org/forms/4354
Eligibility
Einschlusskriterien
Alter mindestens 8 Jahre*
Ja
Nein
Type 1 diabetes mellitus*
Ja
Nein
receiving at least 3 prandial injections per day
with short-acting or analogue insulin *
Ja
Nein
Ausschlusskriterien
Insulin pump therapy*
Ja
Nein
receiving pre-mixed insulin preparations*
Ja
Nein
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dataset medical therapy cancer
clinical cancer registry used in Münster
All rights reserved. Please visit https://medical-data-
models.org/forms/4356
dataset
Patient data
Patient title *
patient number*
Patient surname *
Patient forename*
Patient date of birth*
Patient sex*
Female (Female)
Male (Male)
Street Address*
Patient postal code*
City of residence *
Patient telephone number*
Therapeutic procedure
Chemotherapy Regimen*
Yes
No
Endocrine Therapy*
Yes
No
Immunotherapy *
Yes
No
Pain management *
Yes
No
Date treatment started - chemotherapy*
1 / 4
Date treatment started - endocrine therapy*
Date treatment started - immunotherapy*
Date treatment started - Pain management*
Date treatment stopped - chemotherapy*
Date treatment stopped - endocrine therapy*
Date treatment stopped - immunotherapy*
Date treatment stopped - Pain management*
current cycle*
Chemotherapy Protocols, Antineoplastic *
Chemotherapeutic agent*
Single dose characteristic *
Unit type (qualifier value) *
Microgram (Microgram)
Milligram (Milligram)
Milliliter  (Milliliter )
not_coded (not_coded)
Application*
intraarterial (intraarterial)
intracavitary (intracavitary)
intramusculary (intramusculary)
intraperitoneal (intraperitoneal)
intrapleural (intrapleural)
intrathecal (intrathecal)
Intravenous  (Intravenous )
local (local)
long-term intravenous (long-term
intravenous)
no information (no information)
oral (oral)
percutaneous (percutaneous)
Regional Perfusion  (Regional Perfusion
)
subcutaneous (subcutaneous)
Topical (Topical)
Unknown (Unknown)
Time Interval *
Annual  (Annual )
Every Hour  (Every Hour )
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Every other year  (Every other year )
Every Three Days  (Every Three Days )
Every Three Months  (Every Three
Months )
Every Three Weeks  (Every Three
Weeks )
Every Two Weeks  (Every Two Weeks )
Monthly  (Monthly )
no information (no information)
Once daily (Once daily)
repeatedly Daily  (repeatedly Daily )
Weekly  (Weekly )
Number of days *
% Target*
Admission status*
inpatient  (inpatient )
outpatient (outpatient)
Adverse event *
No (No)
no information (no information)
Yes (Yes)
planned therapeutic procedure*
Interruption  (Interruption )
no information (no information)
treatment continue (treatment continue)
Unknown (Unknown)
Termination systemic therapy*
Completion of therapy (Completion of
therapy)
Discontinue because of adverse effects
(Discontinue because of adverse effects)
Discontinue because of progression
(Discontinue because of progression)
Interruption  (Interruption )
no information (no information)
other reason for discontinue (other
reason for discontinue)
Refusal of Treatment (Refusal of
Treatment)
regular End of Therapy (regular End of
Therapy)
Unknown (Unknown)
Treatment modification *
No (No)
no information (no information)
Yes (Yes)
Collection*
complete (complete)
incomplete (incomplete)
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Tumor Status
Tumor Expansion
Primary Neoplasm *
No evidence of neoplasm  (No evidence
of neoplasm )
questionable Result (questionable
Result)
Recurrent Disease (Recurrent Disease)
Residual Disease  (Residual Disease )
Metastatic Malignant Neoplasm to the regional
Lymph Nodes*
No evidence of neoplasm  (No evidence
of neoplasm )
questionable Result (questionable
Result)
Recurrent Disease (Recurrent Disease)
Residual Disease  (Residual Disease )
Distant metastasis (other organs)*
No evidence of neoplasm  (No evidence
of neoplasm )
questionable Result (questionable
Result)
Recurrent Disease (Recurrent Disease)
Residual Disease  (Residual Disease )
Tumor Status*
- (-)
Assessment not possble (Assessment
not possble)
clinical improvement (clinical
improvement)
In complete remission  (In complete
remission )
no information (no information)
No neoplasm (qualifier value)  (No
neoplasm (qualifier value) )
not clarified (not clarified)
not_coded (not_coded)
partial response  (partial response )
Stable Disease (Stable Disease)
Tumor marker increase (Tumor marker
increase)
Tumor Progression (Tumor Progression)
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dataset Patient and Diagnosis Data cancer
clinical cancer registry used in Münster
All rights reserved. Please visit https://medical-data-
models.org/forms/4357
dataset
Patient data
Patient title *
patient number*
Patient surname *
Patient forename*
Maiden Name *
Patient date of birth*
Ethnicity / related nationality data*
Patient sex*
Female (Female)
Male (Male)
Street Address*
Street Number*
Country Code *
Patient postal code*
City of residence *
Patient telephone number*
Health Insurance Number*
Institution*
Group Practice  (Group Practice )
Hospitals (Hospitals)
Physicians' Offices  (Physicians' Offices )
Hospitalists *
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Hospital*
Department*
Street Address*
Country*
Patient postal code*
City of residence *
Telephone Number*
Diagnosis
Date of diagnosis*
Source of information *
Cancer Center  (Cancer Center )
Cancer Registry  (Cancer Registry )
Central Office (Central Office)
Hospitals (Hospitals)
Newspapers  (Newspapers )
Other (Other)
Primary Care Physician (Primary Care
Physician)
RegistrationCenter (RegistrationCenter)
Unknown (Unknown)
Reason for patient visit*
Aftercare (Aftercare)
no information (no information)
Other  (Other )
Screening for cancer (Screening for
cancer)
Screening procedure (Screening
procedure)
Self-Examination  (Self-Examination )
Special Screening (Special Screening)
tumor symptoms (tumor symptoms)
Unknown (Unknown)
Admission date*
reason for admission*
Decision not possible (Decision not
possible)
Distant Metastasis (Distant Metastasis)
no information (no information)
Primary Neoplasm  (Primary Neoplasm )
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Recurrent Disease (Recurrent Disease)
Systemic Disease (Systemic Disease)
Current Tumor*
Multiple tumors (Multiple tumors)
no information (no information)
Primary Neoplasm (Primary Neoplasm)
Secondary Neoplasm (Secondary
Neoplasm)
Menopause Status*
no information (no information)
Perimenopause (Perimenopause)
Postmenopause (Postmenopause)
Premenopause (Premenopause)
ECOG performance status grade *
0 (0)
1 (1)
2 (2)
3 (3)
4 (4)
no information (no information)
Consent*
Consent obtained with permission for
contact (Consent obtained with
permission for contact)
Consent obtained without permission for
contact (Consent obtained without
permission for contact)
consent refused (consent refused)
not_useful_for_research*
not_useful_for_research
(not_useful_for_research)
not_useful_for_research
(not_useful_for_research)
Family Cancer History *
First Degree Relative  (First Degree
Relative )
no information (no information)
none (none)
Second Degree Relative  (Second
Degree Relative )
oncologic psychotherapy*
Yes
No
Social service*
Yes
No
Genetic Counseling *
Yes
No
Patient Health Questionnaire survey *
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Yes
No
Collection*
complete (complete)
incomplete (incomplete)
Tumor site
ICDO3 Topography Axis *
Localisation text*
Tumor site*
Site of primary tumor (Site of primary
tumor)
Subsite (Subsite)
Side *
Left (Left)
Midline (Midline)
multilocular (multilocular)
no information (no information)
Not Applicable  (Not Applicable )
Right (Right)
Systemic Disease (Systemic Disease)
Unknown (Unknown)
Histopathology
Histology ICD-O-3 *
histologic diagnosis text*
Tumor site*
Site of primary tumor (Site of primary
tumor)
Subsite (Subsite)
Histologic Grade*
G1 grade  (G1 grade )
G2 grade (G2 grade)
G3 grade (G3 grade)
G4 Grade (G4 Grade)
Grade cannot be determined  (Grade
cannot be determined )
Grade not designated (Grade not
designated)
High grade (High grade)
Low grade (Low grade)
Neoplasm, Uncertain Whether Benign or
Malignant  (Neoplasm, Uncertain
Whether Benign or Malignant )
no information (no information)
cell type *
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B-Cell Lymphomas  (B-Cell Lymphomas
)
Grade cannot be determined  (Grade
cannot be determined )
no information (no information)
Primary Cutaneous Anaplastic Large
Cell Lymphoma  (Primary Cutaneous
Anaplastic Large Cell Lymphoma )
T-Cell Lymphoma  (T-Cell Lymphoma )
Score *
Gleason-Score (Gleason-Score)
no information (no information)
Sarcoma by FNCLCC Grade  (Sarcoma
by FNCLCC Grade )
VNPI-Score (DCIS) (VNPI-Score (DCIS))
Primary Gleason Pattern *
Secondary Gleason Pattern *
Total Gleason Score for Prostate Cancer *
Diagnostic Accuracy
normal finding*
Clinical Diagnosis (Clinical Diagnosis)
Cytologic finding (Cytologic finding)
endoscopic (endoscopic)
Histological finding  (Histological finding )
Operative Surgical Procedures
(Operative Surgical Procedures )
Other (Other)
Radiographic imaging procedure
(Radiographic imaging procedure )
sonograpy (sonograpy)
X-Ray Computed Tomography  (X-Ray
Computed Tomography )
Tumor finding *
Clinical Diagnosis (Clinical Diagnosis)
Cytologic finding (Cytologic finding)
endoscopic (endoscopic)
Histological finding  (Histological finding )
Operative Surgical Procedures
(Operative Surgical Procedures )
Other (Other)
Radiographic imaging procedure
(Radiographic imaging procedure )
sonograpy (sonograpy)
X-Ray Computed Tomography  (X-Ray
Computed Tomography )
Other*
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Place of Diagnosis*
Histopathology-number*
Date of Receipt*
Date of pathology report*
Staging*
Yes
No
Generic tumor staging descriptor *
Tumor staging descriptor r (Tumor
staging descriptor r)
Tumor staging descriptor y (Tumor
staging descriptor y)
TNM Classification before any treatment*
Yes
No
TNM Classification after operation*
Yes
No
TNM Stage descriptor*
T Stage*
Degree of certainty of TNM classification
(observable entity) *
TNM Stage descriptor*
N Stage*
Degree of certainty of TNM classification
(observable entity) *
TNM Stage descriptor*
M Stage*
Degree of certainty of TNM classification
(observable entity) *
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Number of sentinel lymph nodes involved*
Number of sentinel lymph nodes examined*
Number of lymph nodes involved by malignant
neoplasm *
Number of lymph nodes examined*
Lymph vessel invasion*
L0 Stage Finding (L0 Stage Finding)
L1 Stage Finding (L1 Stage Finding)
LX Stage Finding (LX Stage Finding)
Venous Invasion*
V0 Stage Finding (V0 Stage Finding)
V1 Stage Finding  (V1 Stage Finding )
V2 Stage Finding (V2 Stage Finding)
VX Stage Finding (VX Stage Finding)
organ capsule infiltration*
No (No)
no information (no information)
Yes, breakthrough (Yes, breakthrough)
Yes, Infiltration (Yes, Infiltration)
Perineural Invasion*
No (No)
no information (no information)
Status of perineural invasion cannot be
assessed (Status of perineural invasion
cannot be assessed)
Yes (Yes)
Residual tumor stage*
no information (no information)
Not Applicable  (Not Applicable )
Residual tumor stage R0 (Residual
tumor stage R0)
Residual tumor stage R1  (Residual
tumor stage R1 )
Residual tumor stage R1  (Residual
tumor stage R1 )
Residual tumor stage R1  (Residual
tumor stage R1 )
Residual tumor stage R2 (Residual
tumor stage R2)
Residual tumor stage R2 (Residual
tumor stage R2)
Residual tumor stage R2 (Residual
tumor stage R2)
Residual tumor stage RX (Residual
tumor stage RX)
UICC-Classification*
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available  (available )
no information (no information)
Ann Arbor Lymphoma Staging System *
Yes
No
other Staging System *
Yes
No
Description Staging System*
Stage*
Microsatellite Instability *
TME Grade*
distant metastasis
Metastatic Malignant Neoplasm to the Lung*
Yes
No
C-factor status*
C1 certainty  (C1 certainty )
C2 certainty  (C2 certainty )
C3 certainty  (C3 certainty )
C4 certainty  (C4 certainty )
C5 certainty  (C5 certainty )
Metastatic Malignant Neoplasm to the Pleura*
Yes
No
C-factor status*
C1 certainty  (C1 certainty )
C2 certainty  (C2 certainty )
C3 certainty  (C3 certainty )
C4 certainty  (C4 certainty )
C5 certainty  (C5 certainty )
Metastatic Malignant Neoplasm to the Liver*
Yes
No
C-factor status*
C1 certainty  (C1 certainty )
C2 certainty  (C2 certainty )
C3 certainty  (C3 certainty )
C4 certainty  (C4 certainty )
C5 certainty  (C5 certainty )
Metastatic Malignant Neoplasm to the Spleen *
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Yes
No
C-factor status*
C1 certainty  (C1 certainty )
C2 certainty  (C2 certainty )
C3 certainty  (C3 certainty )
C4 certainty  (C4 certainty )
C5 certainty  (C5 certainty )
Metastatic Malignant Neoplasm to the Ovary *
Yes
No
C-factor status*
C1 certainty  (C1 certainty )
C2 certainty  (C2 certainty )
C3 certainty  (C3 certainty )
C4 certainty  (C4 certainty )
C5 certainty  (C5 certainty )
Metastatic Malignant Neoplasm to the
Peritoneum *
Yes
No
C-factor status*
C1 certainty  (C1 certainty )
C2 certainty  (C2 certainty )
C3 certainty  (C3 certainty )
C4 certainty  (C4 certainty )
C5 certainty  (C5 certainty )
Metastatic Malignat Neoplasm to the adrenal
gland*
Yes
No
C-factor status*
C1 certainty  (C1 certainty )
C2 certainty  (C2 certainty )
C3 certainty  (C3 certainty )
C4 certainty  (C4 certainty )
C5 certainty  (C5 certainty )
Metastatic Malignant Neoplasm to the Bone
Marrow*
Yes
No
C-factor status*
C1 certainty  (C1 certainty )
C2 certainty  (C2 certainty )
C3 certainty  (C3 certainty )
C4 certainty  (C4 certainty )
C5 certainty  (C5 certainty )
Metastatic Malignant Neoplasm to the Bone *
Yes
No
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C-factor status*
C1 certainty  (C1 certainty )
C2 certainty  (C2 certainty )
C3 certainty  (C3 certainty )
C4 certainty  (C4 certainty )
C5 certainty  (C5 certainty )
Metastatic Malignant Neoplasm to the Lymph
Node *
Yes
No
C-factor status*
C1 certainty  (C1 certainty )
C2 certainty  (C2 certainty )
C3 certainty  (C3 certainty )
C4 certainty  (C4 certainty )
C5 certainty  (C5 certainty )
Secondary malignant neoplasm of skin *
Yes
No
C-factor status*
C1 certainty  (C1 certainty )
C2 certainty  (C2 certainty )
C3 certainty  (C3 certainty )
C4 certainty  (C4 certainty )
C5 certainty  (C5 certainty )
Metastatic malignant neoplasm to brain*
Yes
No
C-factor status*
C1 certainty  (C1 certainty )
C2 certainty  (C2 certainty )
C3 certainty  (C3 certainty )
C4 certainty  (C4 certainty )
C5 certainty  (C5 certainty )
Metastatic Malignant Neoplasm to the Kidney *
Yes
No
C-factor status*
C1 certainty  (C1 certainty )
C2 certainty  (C2 certainty )
C3 certainty  (C3 certainty )
C4 certainty  (C4 certainty )
C5 certainty  (C5 certainty )
Distant metastasis (other organs)*
Yes
No
C-factor status*
C1 certainty  (C1 certainty )
C2 certainty  (C2 certainty )
10 / 15
dataset Patient and Diagnosis Data cancer
C3 certainty  (C3 certainty )
C4 certainty  (C4 certainty )
C5 certainty  (C5 certainty )
Generalized cancer*
Yes
No
C-factor status*
C1 certainty  (C1 certainty )
C2 certainty  (C2 certainty )
C3 certainty  (C3 certainty )
C4 certainty  (C4 certainty )
C5 certainty  (C5 certainty )
tumor marker
tumor marker*
BCM (Breast-Cancer-Mucin) (BCM
(Breast-Cancer-Mucin))
CA 125 (CA 125)
CA 15-3 (CA 15-3)
CA 549 (CA 549)
CEA (CEA)
CYFRA 21-1 (CYFRA 21-1)
free prostate specific antigen  (free
prostate specific antigen )
MCA (Mucin-like Antigen) (MCA (Mucin-
like Antigen))
not_useful_for_research
(not_useful_for_research)
not_useful_for_research
(not_useful_for_research)
not_useful_for_research
(not_useful_for_research)
not_useful_for_research
(not_useful_for_research)
not_useful_for_research
(not_useful_for_research)
not_useful_for_research
(not_useful_for_research)
not_useful_for_research
(not_useful_for_research)
not_useful_for_research
(not_useful_for_research)
not_useful_for_research
(not_useful_for_research)
not_useful_for_research
(not_useful_for_research)
not_useful_for_research
(not_useful_for_research)
not_useful_for_research
(not_useful_for_research)
not_useful_for_research
(not_useful_for_research)
not_useful_for_research
(not_useful_for_research)
not_useful_for_research
(not_useful_for_research)
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not_useful_for_research
(not_useful_for_research)
not_useful_for_research
(not_useful_for_research)
not_useful_for_research
(not_useful_for_research)
not_useful_for_research
(not_useful_for_research)
not_useful_for_research
(not_useful_for_research)
not_useful_for_research
(not_useful_for_research)
not_useful_for_research
(not_useful_for_research)
not_useful_for_research
(not_useful_for_research)
not_useful_for_research
(not_useful_for_research)
not_useful_for_research
(not_useful_for_research)
not_useful_for_research
(not_useful_for_research)
not_useful_for_research
(not_useful_for_research)
not_useful_for_research
(not_useful_for_research)
not_useful_for_research
(not_useful_for_research)
not_useful_for_research
(not_useful_for_research)
not_useful_for_research
(not_useful_for_research)
not_useful_for_research
(not_useful_for_research)
not_useful_for_research
(not_useful_for_research)
not_useful_for_research
(not_useful_for_research)
not_useful_for_research
(not_useful_for_research)
not_useful_for_research
(not_useful_for_research)
not_useful_for_research
(not_useful_for_research)
not_useful_for_research
(not_useful_for_research)
not_useful_for_research
(not_useful_for_research)
not_useful_for_research
(not_useful_for_research)
not_useful_for_research
(not_useful_for_research)
not_useful_for_research
(not_useful_for_research)
not_useful_for_research
(not_useful_for_research)
not_useful_for_research
(not_useful_for_research)
not_useful_for_research
(not_useful_for_research)
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not_useful_for_research
(not_useful_for_research)
not_useful_for_research
(not_useful_for_research)
not_useful_for_research
(not_useful_for_research)
not_useful_for_research
(not_useful_for_research)
not_useful_for_research
(not_useful_for_research)
not_useful_for_research
(not_useful_for_research)
Prostate-Specific Antigen (Prostate-
Specific Antigen)
prostatic-specific acid phosphatase
(prostatic-specific acid phosphatase)
Surface Antigens (Surface Antigens)
TAG 12 (TAG 12)
TPA (Tissue-Polypeptide-Antigen) (TPA
(Tissue-Polypeptide-Antigen))
TPS (Tissue-Polypeptide-specific-
Antigen) (TPS (Tissue-Polypeptide-
specific-Antigen))
Value*
Finding of serum tumor marker level*
Increase  (Increase )
no information (no information)
Normal  (Normal )
Reduced  (Reduced )
Unknown (Unknown)
planned therapeutic procedure
planned therapeutic procedure
Aftercare*
Yes
No
Operative Surgical Procedures *
Yes
No
Chemotherapy Regimen*
Yes
No
Therapeutic radiology procedure *
Yes
No
Endocrine Therapy*
Yes
No
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Immunotherapy *
Yes
No
Supportive Care*
Yes
No
Pain management *
Yes
No
Other therapy*
Yes
No
disease stage*
Yes
No
Consultation*
Yes
No
Hemopoietic stem cell transplant *
Yes
No
Bone Marrow Transplantation*
Yes
No
Prophylactic treatment *
Yes
No
Rehabilitation therapy *
Yes
No
Disease management program *
Yes
No
Prostate Questionaire*
Yes
No
altered aftercare*
Yes
No
active surveillance*
Yes
No
Inquiry*
Yes
No
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no activities*
Yes
No
place of presentation*
Appointment date*
last therapy*
last aftercare*
Number Medical-Examination*
Target Number Medical-Examination*
Quality of life scale*
available  (available )
no information (no information)
refused (refused)
health status*
available  (available )
no information (no information)
refused (refused)
incontinence questionnaire*
available  (available )
no information (no information)
refused (refused)
International index of erectile function score*
available  (available )
no information (no information)
refused (refused)
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Eligibility NCT01206803 Infertility,
Subfertility
ODM derived from
http://clinicaltrials.gov/show/NCT01206803
All rights reserved. Please visit https://medical-data-
models.org/forms/4358
Eligibility
Einschlusskriterien
Alter 18 bis 45 Jahre*
Ja
Nein
Infertility, Subfertility*
Ja
Nein
Female patients for who the treating physician
decides that treatment with long acting FSH
150microg in a GnRH-antagonist protocol is
indicated. *
Ja
Nein
Ausschlusskriterien
Contraindications for the use of gonadotropins
(e.g., tumors, pregnancy/lactation, undiagnosed
vaginal bleeding, hypersensitivity, ovarian cysts)
Use of hormonal preparations within one month
prior to inclusion*
Ja
Nein
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Eligibility NCT01122277 Patients in ICU
ODM derived from
http://clinicaltrials.gov/show/NCT01122277
All rights reserved. Please visit https://medical-data-
models.org/forms/4361
Eligibility
Einschlusskriterien
Alter mindestens 18 Jahre*
Ja
Nein
ICU patients with an indication for fluid/volume
therapy *
Ja
Nein
Ausschlusskriterien
Patients hospitalized by order of a court of law or
a government agency*
Ja
Nein
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Eligibility NCT01046448 Chronic Kidney
Disease
ODM derived from
http://clinicaltrials.gov/show/NCT01046448
All rights reserved. Please visit https://medical-data-
models.org/forms/4362
Eligibility
Einschlusskriterien
Alter 6 bis 17 Jahre*
Ja
Nein
*
Ja
Nein
Ausschlusskriterien
Active systemic vasculitis*
Ja
Nein
Diabetes mellitus*
Ja
Nein
Renal vascular anomalies*
Ja
Nein
Anomalies of the limbs preventing standardized
diagnostic procedures*
Ja
Nein
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Eligibility NCT00982111 Non Small Cell
Lung Cancer
ODM derived from
http://clinicaltrials.gov/show/NCT00982111
All rights reserved. Please visit https://medical-data-
models.org/forms/4367
Eligibility
Einschlusskriterien
Alter mindestens 18 Jahre*
Ja
Nein
Has histologically or cytologically confirmed
nonsquamous (adenocarcinoma/large cell or
other) non small cell lung cancer.*
Ja
Nein
Has Stage IV disease at the time of study entry.*
Ja
Nein
Measurable or nonmeasurable disease (as
defined by the Response Evaluation Criteria in
Solid Tumors RECIST 1.0) at the time of study
entry (patients with only truly nonmeasurable
disease are not eligible).*
Ja
Nein
Has resolution to Grade <= 1 of all clinically
significant toxic effects of prior chemotherapy,
surgery, radiotherapy, or hormonal therapy (with
the exception of alopecia).*
Ja
Nein
Has an Eastern Cooperative Oncology Group
performance status score of 0-2.*
Ja
Nein
Has adequate hepatic function*
Ja
Nein
Has adequate renal function*
Ja
Nein
Has adequate hematologic function*
Ja
Nein
If female, is surgically sterile, postmenopausal, or
compliant with a highly effective contraceptive
method during and for 6 months after the
treatment period (oral hormonal contraception
alone is not considered highly effective and must
be used in combination with a barrier method). If
male, the patients surgically sterile or compliant
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with a highly effective contraceptive regimen
during and for 6 months after the treatment
period.*
Ja
Nein
Female patients of childbearing potential must
have a negative serum *
Ja
Nein
Ausschlusskriterien
Has squamous non small cell lung cancer.*
Ja
Nein
Has received prior anticancer therapy with
monoclonal antibodies, signal transduction
inhibitors, or any therapies targeting the EGFR,
vascular endothelial growth factor (VEGF), or
VEGF receptor.*
Ja
Nein
Received previous chemotherapy for advanced
NSCLC (patients who have received adjuvant
chemotherapy are eligible if the last
administration of the prior adjuvant regimen
occurred at least 1 year prior to randomization).*
Ja
Nein
Undergone major surgery or received any
investigational therapy in the 4 weeks prior to
randomization.*
Ja
Nein
Undergone chest irradiation within 12 weeks prior
to randomization (except palliative irradiation of
bone lesions, which is allowed).*
Ja
Nein
Has brain metastases that are symptomatic or
require ongoing treatment with steroids or
anticonvulsants. Patients who have undergone
previous radiotherapy for brain metastases, who
are now nonsymptomatic and no longer require
treatment with steroids or anticonvulsants, are
eligible.*
Ja
Nein
Has superior vena cava syndrome
contraindicating hydration.*
Ja
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Nein
Has current clinically-relevant coronary artery
disease or uncontrolled congestive heart failure*
Ja
Nein
Has experienced myocardial infarction within 6
months prior to randomization.*
Ja
Nein
Has an ongoing or active infection (requiring
antibiotics), including active tuberculosis or
known infection with the human
immunodeficiency virus.*
Ja
Nein
Has a history of significant neurological or
psychiatric disorders, including dementia,
seizures, or bipolar disorder, potentially
precluding protocol compliance.*
Ja
Nein
Has Grade >= 2 peripheral neuropathy.*
Ja
Nein
Has significant third space fluid retention,
requiring repeated drainage.*
Ja
Nein
Has any other serious uncontrolled medical
disorders or psychological conditions that would,
in the opinion of the investigator, limit the patient's
ability to complete the study or sign an informed
consent document. *
Ja
Nein
The patient has a known allergy / history of
hypersensitivity reaction to any of the treatment
components, including any ingredient used in the
formulation of IMC-11F8, or any other
contraindication to one of the administered
treatments.*
Ja
Nein
Is pregnant or breastfeeding.*
Ja
Nein
History of substance abuse*
Ja
Nein
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Has a concurrent active malignancy other than
adequately-treated basal cell carcinoma of the
skin or preinvasive carcinoma of the cervix. A
patient with previous history of malignancy other
than NSCLC is eligible, provided that he/she has
been free of disease for >= 3 years.*
Ja
Nein
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Eligibility NCT00981058 Non Small Cell
Lung Cancer
ODM derived from
http://clinicaltrials.gov/show/NCT00981058
All rights reserved. Please visit https://medical-data-
models.org/forms/4368
Eligibility
Einschlusskriterien
Alter mindestens 18Jahre*
Ja
Nein
Has histologically or cytologically confirmed
squamous NSCLC.*
Ja
Nein
Has Stage IV disease at the time of study entry.*
Ja
Nein
Measurable or nonmeasurable disease at the
time of study entry as defined by the Response
Evaluation Criteria in Solid Tumors (RECIST 1.0)
(patients with only truly nonmeasurable disease
are not eligible).*
Ja
Nein
Has resolution to Grade <= 1 of all clinically
significant toxic effects of prior chemotherapy,
surgery, radiotherapy, or hormonal therapy (with
the exception of alopecia).*
Ja
Nein
Has adequate hepatic function*
Ja
Nein
Has adequate renal function*
Ja
Nein
Has adequate hematologic function*
Ja
Nein
If female, is surgically sterile, postmenopausal, or
compliant with a highly effective contraceptive
method (failure rate < 1%) during and for 6
months after the treatment period (oral hormonal
contraception alone is not considered highly
effective and must be used in combination with a
barrier method).*
Ja
Nein
If male, the patient is surgically sterile or
compliant with a highly effective contraceptive
regimen during and for 6 months after the
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treatment period.*
Ja
Nein
Female patients of childbearing potential must
have a negative serum pregnancy test within 7
days prior to randomization.*
Ja
Nein
Has archived tumor tissue available for analysis
of EGFR and KRAS mutation status (by PCR)
and EGFR gene copy number (by FISH).
Minimum of four slides, paraffin-embedded
tissue, required. *
Ja
Nein
Ausschlusskriterien
Has nonsquamous NSCLC
(adenocarcinoma/large cell or other).*
Ja
Nein
Has received prior anticancer therapy with
monoclonal antibodies, signal transduction
inhibitors, or any therapies targeting the EGFR,
vascular endothelial growth factor (VEGF), or
VEGF receptor.*
Ja
Nein
Has received previous chemotherapy for
advanced NSCLC (patients who have received
adjuvant chemotherapy are eligible if the last
administration of the prior adjuvant regimen
occurred at least 1 year prior to randomization).*
Ja
Nein
Has undergone major surgery or received any
investigational therapy in the 4 weeks prior to
randomization.*
Ja
Nein
Has undergone chest irradiation within 12 weeks
prior to randomization (except palliative
irradiation of bone lesions, which is allowed).*
Ja
Nein
Has brain metastases that are symptomatic or
require ongoing treatment with steroids or
anticonvulsants. Patients who have undergone
previous radiotherapy for brain metastases, who
are now nonsymptomatic and no longer require
treatment with steroids or anticonvulsants, are
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eligible.*
Ja
Nein
Has superior vena cava syndrome
contraindicating hydration.*
Ja
Nein
Has current clinically-relevant coronary artery
disease or uncontrolled congestive heart failure.*
Ja
Nein
Has experienced myocardial infarction within 6
months prior to randomization.*
Ja
Nein
Has an ongoing or active infection (requiring
antibiotics), including active tuberculosis or
known infection with the human
immunodeficiency virus.*
Ja
Nein
Has a history of significant neurological or
psychiatric disorders, including dementia,
seizures, or bipolar disorder.*
Ja
Nein
Has any NCI-CTCAE Version 3.0 Grade >= 2
peripheral neuropathy.*
Ja
Nein
Has significant third space fluid retention,
requiring repeated drainage.*
Ja
Nein
Has any other serious uncontrolled medical
disorders or psychological conditions that would,
in the opinion of the investigator, limit the patient's
ability to complete the study or sign an informed
consent document.*
Ja
Nein
Has a known allergy / history of hypersensitivity
reaction to any of the treatment components,
including any ingredient used in the formulation of
necitumumab (IMC-11F8), or any other
contraindication to one of the administered
treatments.*
Ja
Nein
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Eligibility NCT00981058 Non Small Cell Lung Cancer
Is pregnant or breastfeeding.*
Ja
Nein
History of substance abuse*
Ja
Nein
Has a concurrent active malignancy other than
adequately-treated basal cell carcinoma of the
skin or preinvasive carcinoma of the cervix. A
patient with previous history of malignancy other
than NSCLC is eligible, provided that he/she has
been free of disease for >= 3 years.*
Ja
Nein
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Eligibility NCT00981058 Non Small Cell Lung Cancer
Eligibility NCT00979420 HIV Infections
ODM derived from
http://clinicaltrials.gov/show/NCT00979420
All rights reserved. Please visit https://medical-data-
models.org/forms/4369
Eligibility
Einschlusskriterien
Alter mindestens 18 Jahre*
Ja
Nein
HIV Infections*
Ja
Nein
The inclusion criteria for treatment with Viramune
plus other antiretroviral combination drugs are to
be based on the current Information for
Healthcare Professionals/SPC (R08-0843).*
Ja
Nein
Ausschlusskriterien
The exclusion criteria for treatment with Viramune
plus other antiretroviral combination drugs are to
be based on the current Information for
Healthcare Professionals/SPC (R08-0843).*
Ja
Nein
1 / 1
Eligibility NCT00967330 Glioblastoma
Multiforme
ODM derived from
http://clinicaltrials.gov/show/NCT00967330
All rights reserved. Please visit https://medical-data-
models.org/forms/4373
Eligibility
Einschlusskriterien
Alter 18 bis 70 Jahre*
Ja
Nein
Erwachsener, erwachsen*
Ja
Nein
glioblastoma, confirmed histologically*
Ja
Nein
no previous chemotherapy or radiotherapy for
glioblastoma*
Ja
Nein
non-methylated MGMT promoter in the tumor. *
Ja
Nein
Ausschlusskriterien
prior systemic treatment for glioblastoma
multiforme*
Ja
Nein
prior treatment with Avastin*
Ja
Nein
significant cardiovascular disease*
Ja
Nein
other active malignant disease.*
Ja
Nein
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Eligibility NCT00960661 Type 2 Diabetes
Mellitus
ODM derived from
http://clinicaltrials.gov/show/NCT00960661
All rights reserved. Please visit https://medical-data-
models.org/forms/4376
Eligibility
Einschlusskriterien
Alter mindestens 18 Jahre*
Ja
Nein
Type 2 Diabetes Mellitus*
Ja
Nein
Have been taking a basal insulin Glargine, at
dose of >= 20 units/day, for at least 3 months
prior to study start.*
Ja
Nein
Have been taking basal insulin Glargine at dose
of >= 20 units/day, in combination with 1 of the
following oral antidiabetic medication (OAM)
regimens, for at least 3 months prior to study
start:*
Ja
Nein
*
Ja
Nein
Metformin or immediate-release metformin or
extended-release metformin at a  maximum
tolerated and stable dose with no < 500 mg/day
for at least 6  weeks prior to study start and
sulfonylurea at a stable dose for 6 weeks prior  to
study start.*
Ja
Nein
HbA1c*
Ja
Nein
BMI*
Ja
Nein
Ausschlusskriterien
Are currently taking OAM that is not described
above and not allowed with concurrent use of
insulin per local product label.*
Ja
Nein
Have taken more than 1 week within 1 month
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prior to the study start any glucose-lowering
medications not included above either alone or in
combination formulations, or have used a drug for
weight loss (for example, prescription drugs such
as orlistat, sibutramine, phenylpropanolamine,
rimonabant or similar over-the-counter
medications).*
Ja
Nein
Have taken any insulin other than Glargine within
the 3 months prior to study start for more than 1
week.*
Ja
Nein
Are receiving chronic (lasting longer than 2
weeks) systemic glucocorticoid therapy
(excluding topical, intraocular, and inhaled
preparations) within 4 weeks prior to the study
start.*
Ja
Nein
Are currently enrolled in, or discontinued within
the last 30 days from, a clinical trial involving an
off-label use of an investigational drug or device
(other than the study drug/device used in this
study), or concurrently enrolled in any other type
of medical research judged not to be scientifically
or medically compatible with this study.*
Ja
Nein
Have previously completed or been withdrawn
from this study after enrollment.*
Ja
Nein
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Eligibility NCT00960661 Type 2 Diabetes Mellitus
Eligibility NCT00925002 ATTR-PN
ODM derived from
http://clinicaltrials.gov/show/NCT00925002
All rights reserved. Please visit https://medical-data-
models.org/forms/4381
Eligibility
Einschlusskriterien
Alter 18 bis 75 Jahre*
Ja
Nein
ATTR-PN*
Ja
Nein
Patient has successfully completed either
Protocol Fx-006 or Fx1A-201.*
Ja
Nein
If female, patient is post-menopausal, surgically
sterilized, or willing to use two acceptable
methods of birth control (i.e., hormonal
contraceptive, intra-uterine device, diaphragm
with spermicide, condom with spermicide)
throughout the study and for 3 months from the
end of the study. (A condom alone is not
considered an acceptable method of birth
control.)*
Ja
Nein
Patient is, in the opinion of the investigator, willing
and able to comply with the investigational
product regimen and all other study
requirements. *
Ja
Nein
Ausschlusskriterien
Patient has not successfully completed either
Protocol Fx-006 or Fx1A-201.*
Ja
Nein
Chronic use of non-protocol approved non-
steroidal anti-inflammatory drugs (NSAIDs),
defined as > 3 to 4 times/month. The following
NSAIDs are allowed: acetylsalicylic acid,
etodolac, ibuprofen, indomethicin, ketoprofen,
nabumetone, naproxen, nimesulide, piroxicam,
and sulindac.*
Ja
Nein
If female, patient is pregnant or breast feeding.*
Ja
Nein
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Clinically significant medical condition that, in the
opinion of the investigator, would place the
patient at an increased risk to participate in the
study.*
Ja
Nein
The patient has received a liver or heart
transplant.*
Ja
Nein
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Eligibility NCT00925002 ATTR-PN
Eligibility NCT00944034 Meningococcal
Disease
ODM derived from
http://clinicaltrials.gov/show/NCT00944034
All rights reserved. Please visit https://medical-data-
models.org/forms/4384
Eligibility
Einschlusskriterien
Alter 12 bis 24 Monate*
Ja
Nein
Meningococcal Disease*
Ja
Nein
Follow-on participants of V72P12:*
Ja
Nein
Healthy toddlers who completed Study V72P12,
aged:*
Ja
Nein
12 months or older - Groups 1a, 2a, 3a, 4*
Ja
Nein
18 months (0/ +29 days window) - Groups 1b, 2b,
3b*
Ja
Nein
24 months (0/ +29 days window) - Groups 1c, 2c,
3c*
Ja
Nein
Naive subjects newly enrolled:*
Ja
Nein
Group 5: healthy 18-month-old toddlers (0/ +29
days window)*
Ja
Nein
Group 6: healthy 24-month-old toddlers (0/ +29
days window) *
Ja
Nein
Ausschlusskriterien
History of any meningococcal B vaccine
administration (only for groups 5 and 6)*
Ja
Nein
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Previous ascertained or suspected disease
caused by N. meningitidis*
Ja
Nein
History of severe allergic reaction after previous
vaccinations or hypersensitivity to any vaccine
component*
Ja
Nein
Significant acute or chronic infection within the
previous 7 days or axillary temperature >=38
degrees within the previous day*
Ja
Nein
Antibiotics within 6 days prior to enrollment*
Ja
Nein
Any serious chronic or progressive disease*
Ja
Nein
Known or suspected impairment or alteration of
the immune system*
Ja
Nein
Receipt of blood, blood products and/or plasma
derivatives or any parenteral immunoglobulin
preparation.*
Ja
Nein
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Eligibility NCT00944034 Meningococcal Disease
Eligibility NCT00895037 Hemophilia A
ODM derived from
http://clinicaltrials.gov/show/NCT00895037
All rights reserved. Please visit https://medical-data-
models.org/forms/4390
Eligibility
Einschlusskriterien
Patients with hemophilia A of any severity already
receiving or starting treatment with ReFacto AF *
Ja
Nein
Ausschlusskriterien
Patients with Hemophilia A treated with a product
other than Refacto AF*
Ja
Nein
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Eligibility NCT00885937 Healthy
ODM derived from
http://clinicaltrials.gov/show/NCT00885937
All rights reserved. Please visit https://medical-data-
models.org/forms/4393
Eligibility
Einschlusskriterien
Alter mindestens 18 Jahre*
Ja
Nein
Skin type I, II, or III according to Fitzpatrick*
Ja
Nein
Subjects of childbearing potential must use an
acceptable method of contraception. Hormonal or
oral contraceptive drugs, intra-uterine devices
(IUD) and abstinence are considered acceptable
methods of contraception. *
Ja
Nein
Ausschlusskriterien
Clinical history suggestive of intolerance,
allergies or idiosyncrasies to one of the products
or the ingredients of the products including the
patch.*
Ja
Nein
Allergie der Haut, kutane Hypersensitivität*
Ja
Nein
Dermatologic diseases that might interfere with
the evaluation of test site reaction.*
Ja
Nein
Other(s), considered as important by the
investigator (e.g. multiple birth marks in the test
area, important hair growth in the test area,
pigmented or extremely suntanned skin impairing
visual assessment, tattoos in the test area.*
Ja
Nein
Topical use of any cosmetic preparation on the
test areas within 5 days prior to Day 1 (Start of
Treatment) or during the trial*
Ja
Nein
Within 3 weeks prior to Day 1 and during the
entire trial. Any systemic or topical medication
likely to interfere with the trial purposes: e.g.
immune-modulating therapy (e.g. corticosteroids,
1 / 2
cytotoxics or immunosuppressants) and any
dermatological medication (drug or medical
device.*
Ja
Nein
Within 1 week prior to Day 1 and during the entire
trial any medication with common effects on the
perfusion of skin vessels (e.g. vasodilators or
vasoconstrictors, beta-receptor blocking drugs,
antihistamines) should not be used.*
Ja
Nein
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Eligibility NCT00885937 Healthy
Eligibility NCT00855218 Carcinoma,
Hepatocellular
ODM derived from
http://clinicaltrials.gov/show/NCT00855218
All rights reserved. Please visit https://medical-data-
models.org/forms/4407
Eligibility
Einschlusskriterien
Alter mindestens 18 Jahre*
Ja
Nein
Unresectable, multinodular asymptomatic tumor
without vascular invasion or extrahepatic spread*
Ja
Nein
Confirmed Diagnosis of HCC:*
Ja
Nein
Cirrhotic subjects: Clinical diagnosis by AASLD
criteria*
Ja
Nein
HCC can be defined in cirrhotic subjects by one
imaging technique (CT scan, MRI, or second
generation contrast ultrasound) showing a nodule
larger than 2 cm with contrast uptake in the
arterial phase and washout in venous or late
phases or two imaging techniques showing this
radiological behavior for nodules of 1-2 cm in
diameter.*
Ja
Nein
Cytohistological confirmation is required for
subjects who do not fulfill these eligibility criteria.*
Ja
Nein
Non-cirrhotic subjects: For subjects without
cirrhosis, histological or cytological confirmation
is mandatory*
Ja
Nein
Documentation of original biopsy for diagnosis is
acceptable*
Ja
Nein
Child Pugh class A without ascites*
Ja
Nein
Adequate bone marrow, liver and renal function
as assessed by central lab by means of the
following laboratory requirements from samples
within 7 days prior to randomization: *
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Ja
Nein
Ausschlusskriterien
Patients on a liver transplantation list or with
advanced liver disease as defined below:*
Ja
Nein
Child Pugh B and C*
Ja
Nein
Active gastrointestinal bleeding*
Ja
Nein
Enzephalopathie*
Ja
Nein
Aszites*
Ja
Nein
Lesions having previously been treated with local
therapy such as resection of HCC,
radiofrequency ablation (RFA), percutaneous
ethanol injection (PEI) or cryoablation can not be
selected as the target lesions.*
Ja
Nein
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Eligibility NCT00855218 Carcinoma, Hepatocellular
Eligibility NCT00852670 Plaque Psoriasis
ODM derived from
http://clinicaltrials.gov/show/NCT00852670
All rights reserved. Please visit https://medical-data-
models.org/forms/4408
Eligibility
Einschlusskriterien
Alter 18 bis 60 Jahre*
Ja
Nein
Adult males and females with moderate to severe
plaque psoriasis who require systemic treatment
and for whom participation in a placebo-
controlled study of an investigational drug is
justified. *
Ja
Nein
Ausschlusskriterien
Patients with other forms of psoriasis and
patients who are currently treated for
autoimmune disorders other than psoriasis.*
Ja
Nein
Systemic or topical treatments for psoriasis other
than emollients.*
Ja
Nein
Ongoing bacterial, viral or fungal infections.*
Ja
Nein
History or presence of malignancy.*
Ja
Nein
Additional inclusion and exclusion criteria apply
with respect to medical conditions and
concomitant treatments which could affect
patients' risk from participating in the study.*
Ja
Nein
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Eligibility NCT00851084 Colorectal
Neoplasms
ODM derived from
http://clinicaltrials.gov/show/NCT00851084
All rights reserved. Please visit https://medical-data-
models.org/forms/4409
Eligibility
Einschlusskriterien
Alter mindestens 18 Jahre*
Ja
Nein
Histologically proven adenocarcinoma of the
colon or the rectum*
Ja
Nein
Metastatic disease not amenable to potentially
curative treatment *
Ja
Nein
Ausschlusskriterien
Prior therapy for metastatic cancer of the colon or
the rectum*
Ja
Nein
Prior treatment with angiogenesis inhibitors *
Ja
Nein
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Eligibility NCT00844194 Diabetic
Neuropathies
ODM derived from
http://clinicaltrials.gov/show/NCT00844194
All rights reserved. Please visit https://medical-data-
models.org/forms/4410
Eligibility
Einschlusskriterien
Alter mindestens 18 Jahre*
Ja
Nein
Present with pain due to bilateral peripheral
neuropathy (according to International Statistical
Classification of Diseases and Related Health
Problems 10 (ICD 10).*
Ja
Nein
To qualify for the MDD+ cohort, patients need to
meet the ICD-10 criteria for MDD. Furthermore,
Hamilton rating scale for depression 17 (HAMD-
17) scores need to match with the ICD-10 criteria
for qualification of the MDD+ or MDD- groups.*
Ja
Nein
Male or female outpatients at least 18 years of
age.*
Ja
Nein
Females with child bearing potential must test
negative for a serum pregnancy test at Visit 1.
Females of child-bearing potential (not surgically
sterilized and between menarche and 1 year
post-menopause) must agree to utilize medically
acceptable and reliable means of birth control as
determined by the investigator during the study
and for 1 month following the last dose of the
study. Examples of reliable methods include use
of oral contraceptives or Depo-Clinovir
Contraceptive Injection (sterile
medroxyprogesterone acetate suspension,
Pharmacia), partner with vasectomy, diaphragms
with contraceptive jelly, cervical caps with
contraceptive jelly, condoms with contraceptive
foam, or intrauterine devices. Women who are
pregnant or breast-feeding may not participate in
the study.*
Ja
Nein
Educational level and degree of understanding
such that they can communicate intelligibly with
the investigator and study coordinator.*
Ja
Nein
Judged to be reliable and agrees to keep all
appointments for clinic visits, tests, and
procedures required by the protocol.*
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Ja
Nein
Ausschlusskriterien
Have already a diagnosis of Depression and are
currently treated with an antidepressant
medication for depression, when entering the
study.*
Ja
Nein
Suffer from pain that cannot be clearly
differentiated from or conditions that interfere with
the assessment of DPNPain.*
Ja
Nein
Had a historical exposure to drugs known to
cause neuropathy, that could have been
responsible for neuropathy.*
Ja
Nein
Have previously been treated with duloxetine (for
DPNP or MDD)*
Ja
Nein
Are judged to be at suicidal risk by the clinical
investigator or as defined by a score of >= 2 on
question 9 of the Beck Depression Inventory-II
(BDI-II).*
Ja
Nein
Had a history of substance abuse or dependence
within the past year, excluding nicotine and
caffeine.*
Ja
Nein
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Eligibility NCT00844194 Diabetic Neuropathies
Eligibility NCT00878293 Diabetic
Polyneuropathy
ODM derived from
http://clinicaltrials.gov/show/NCT00878293
All rights reserved. Please visit https://medical-data-
models.org/forms/4416
Eligibility
Einschlusskriterien
Alter 18 bis 75 Jahre*
Ja
Nein
Subjects with pain at least NRS >4 due to painful
diabetic polyneuropaty. *
Ja
Nein
Ausschlusskriterien
Contraindications to, or history of allergy or
hypersensitivity to morphine, fentanyl,
hydrocodone, acetaminophen, heparin,
polyethylene glycol 400 USP-NF or any
compound planned to be used during the
anesthesia, or their excipients.*
Ja
Nein
non Caucasian or Hispanic.*
Ja
Nein
Concomitant painful disease.*
Ja
Nein
Life-long history of seizure disorder or epilepsy.*
Ja
Nein
Subjects with clinical relevant cardiac and
vascular diseases.*
Ja
Nein
Nierendysfunktion, Nierenfunktionsstörung*
Ja
Nein
Leberdysfunktion, Leberfunktionsstörung*
Ja
Nein
Female subjects who are pregnant or
breastfeeding.*
Ja
Nein
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Eligibility NCT00798317 Symptomatic
Vitreomacular Adhesion
ODM derived from
http://clinicaltrials.gov/show/NCT00798317
All rights reserved. Please visit https://medical-data-
models.org/forms/4426
Eligibility
Einschlusskriterien
Alter mindestens 18 Jahre*
Ja
Nein
Presence of focal vitreomacular adhesion (i.e.,
central vitreal adhesion within 6 mm OCT field
surrounded by elevation of the posterior vitreous
cortex) that in the opinion of the Investigator is
related to decreased visual function (such as
metamorphopsia, decreased visual acuity, or
other visual complaint) *
Ja
Nein
Ausschlusskriterien
Any evidence of proliferative retinopathy
(including PDR or other ischemic retinopathies
involving vitreoretinal vascular proliferation) or
exudative AMD or retinal vein occlusion in the
study eye*
Ja
Nein
Subjects with any vitreous hemorrhage or any
other vitreous opacification which precludes
either of the following: visualization of the
posterior pole by visual inspection OR adequate
assessment of the macula by either OCT and/or
fluorescein angiogram in the study eye*
Ja
Nein
Subjects with macular hole diameter > 400 µm in
the study eye*
Ja
Nein
Aphakia in the study eye*
Ja
Nein
High myopia (> 8D) in study eye (unless prior
cataract extraction or refractive surgery that
makes refraction assessment unreliable for
myopia severity approximation, in which case
axial length >28 mm is an exclusion).*
Ja
Nein
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Eligibility NCT00796757 Renal Cell Cancer
ODM derived from
http://clinicaltrials.gov/show/NCT00796757
All rights reserved. Please visit https://medical-data-
models.org/forms/4427
Eligibility
Einschlusskriterien
Alter mindestens 18 Jahre*
Ja
Nein
adult patients, >=18 years of age*
Ja
Nein
metastatic RCC with majority (>50%) of
conventional clear-cell type*
Ja
Nein
prior total nephrectomy for primary RCC*
Ja
Nein
at least one measurable or non-measurable
lesions*
Ja
Nein
ECOG performance score of 0 or 2. *
Ja
Nein
Ausschlusskriterien
prior systemic treatment for metastatic RCC*
Ja
Nein
current or previously treated but non-stable CNS
metastases or spinal cord compression*
Ja
Nein
major surgery (including open biopsy) or radiation
therapy within 28 days prior to enrollment*
Ja
Nein
significant cardiovascular disease within 6
months prior to enrollment.*
Ja
Nein
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Eligibility NCT00791492 Familial Amyloid
Polyneuropathy
ODM derived from
http://clinicaltrials.gov/show/NCT00791492
All rights reserved. Please visit https://medical-data-
models.org/forms/4429
Eligibility
Einschlusskriterien
Alter 18 bis 75 Jahre*
Ja
Nein
Familial Amyloid Polyneuropathy*
Ja
Nein
Inclusion Criteria: Male and non-pregnant female
patients meeting all of the following criteria are
eligible for enrollment in this study:*
Ja
Nein
Patient has completed the Month 18 visit of Study
Fx-005.*
Ja
Nein
If female, patient is post-menopausal, surgically
sterilized, or willing to use an acceptable method
of birth control (i.e., a hormonal contraceptive,
intra-uterine device, diaphragm with spermicide,
condom with spermicide) throughout the study. (A
condom alone is not considered an acceptable
method of birth control.) If male with a female
partner of childbearing potential, willing to use an
acceptable method of birth control for the
duration of the study. For both females and
males, acceptable birth control must be used for
at least 3 months after the last dose of study
medication.*
Ja
Nein
Patient is, in the opinion of the investigator, willing
and able to comply with the study medication
regimen and all other study requirements.*
Ja
Nein
Patient agrees not to participate in another
investigational drug or device study while
participating in this open-label extension study. *
Ja
Nein
Ausschlusskriterien
Chronic use of non-steroidal anti-inflammatory
drugs (NSAIDs), defined as greater than 3-4
times/month (ibuprofen and nimesulide will be
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permitted).*
Ja
Nein
If female, patient is pregnant or breast feeding.*
Ja
Nein
Patient has liver function test abnormalities:
alanine transaminases (ALT) and/or aspartate
transaminases (AST) >2 times upper limit of
normal (ULN) that in the medical judgment of the
investigator are due to reduced liver function or
active liver disease.*
Ja
Nein
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Eligibility NCT00791492 Familial Amyloid Polyneuropathy
Eligibility NCT00786253 Erectile
Dysfunction
ODM derived from
http://clinicaltrials.gov/show/NCT00786253
All rights reserved. Please visit https://medical-data-
models.org/forms/4431
Eligibility
Einschlusskriterien
Alter 18 bis 64 Jahre*
Ja
Nein
männlich*
Ja
Nein
Mild or mild to moderate ED (defined as >15 and
<21 score points according to the Erectile
Function Domain Score from IIEF as assessed at
the randomisation visit)*
Ja
Nein
History of at least one of the following conditions:
Diabetes mellitus type 2, hypertension, peripheral
arterial occlusive disease*
Ja
Nein
Stable, heterosexual relationship for > 6 months *
Ja
Nein
Ausschlusskriterien
Primary hypoactive sexual desire*
Ja
Nein
History of myocardial infarction, stroke or life-
threatening arrhythmia within prior 6 months*
Ja
Nein
Nitrate therapy.*
Ja
Nein
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Eligibility NCT00785330 Non-Hodgkin's
Lymphoma
ODM derived from
http://clinicaltrials.gov/show/NCT00785330
All rights reserved. Please visit https://medical-data-
models.org/forms/4432
Eligibility
Einschlusskriterien
Alter 18 bis 65 Jahre*
Ja
Nein
histology proven aggressive non Hodgkin's
lymphoma and*
Ja
Nein
primary progressive disease or*
Ja
Nein
early relapse after < 12 months of remission
duration and at least one risk factor according to
the international prognostic index (IPI) or*
Ja
Nein
relapse or progression after high dose
chemotherapy and autologous transplantation or*
Ja
Nein
relapse or progression and lack of an autologous
stem cell product. *
Ja
Nein
Ausschlusskriterien
severe comorbidity or impaired organ function*
Ja
Nein
Documented hypersensitivity to administered
drug*
Ja
Nein
HIV-positiv*
Ja
Nein
active hepatitis*
Ja
Nein
other active malignant disease*
Ja
Nein
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Eligibility NCT00771927 Epilepsies, Partial
ODM derived from
http://clinicaltrials.gov/show/NCT00771927
All rights reserved. Please visit https://medical-data-
models.org/forms/4435
Eligibility
Einschlusskriterien
Alter mindestens 16 Jahre*
Ja
Nein
This study includes any subject 16 years or older
who has an epilepsy diagnosis with partial on-set
seizures, and whose seizure activity is
uncontrolled on current therapy*
Ja
Nein
Patients who are prescribed Vimpat or any other
add-on AED may be included in the study.*
Ja
Nein
The initiation of an add-on AED therapy can not
be more than 2 days before the patient's start of
the study. *
Ja
Nein
Ausschlusskriterien
No Information Available*
Ja
Nein
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Eligibility NCT00439725 Deep Vein
Thrombosis
This is a multicenter, randomized, double-blind, placebo-
controlled, event-driven, superiority study for efficacy.
Patients with confirmed symptomatic DVT or PE who
completed 6 or 12 months of treatment with rivaroxaban or
VKA are eligible for this trial (Einstein-Extension study).
All rights reserved. Please visit https://medical-data-
models.org/forms/4437
Eligibility
Inclusion criteria
18 Years and older*
Yes
No
Patients with confirmed symptomatic PE or DVT
who have been treated for 6 or 12 months with
VKA or rivaroxaban*
Yes
No
Exclusion criteria
Legal lower age limitations (country specific)*
Yes
No
Indication for VKA other than DVT and/or PE*
Yes
No
Patients in whom anticoagulant treatment for their
index PE or DVT should be continued*
Yes
No
Childbearing potential without proper
contraceptive measures,  pregnancy or breast
feeding. Proper contraceptive measures are
defined as a method of contraception with
a failure rate < 1 % during the course of the study
(including the observational
period). These methods of contraception
according to the note for guidance on
non-clinical safety studies for the conduct of
human trials for pharmaceuticals
(CPMP/ICH/286/95, modification) include
consistent and correct use of hormone
containing implants and injectables, combined
oral contraceptives, hormone containing
intrauterine devices, surgical sterilization, sexual
abstinence and vasectomy
*
Yes
No
Medical Concepts
Age*
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Pulmonary Embolism*
Deep Vein Thrombosis*
Vitamin K antagonist*
Rivaroxaban*
age restriction in context*
age subdivision of legal significance*
Anticoagulant therapy*
Contraceptive methods*
Patient currently pregnant*
Breast Feeding*
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Eligibility NCT00439725 Deep Vein Thrombosis
Eligibility NCT00539487 Hypertension
ODM derived from
http://clinicaltrials.gov/show/NCT00539487
All rights reserved. Please visit https://medical-data-
models.org/forms/4440
Eligibility
Einschlusskriterien
Alter mindestens 18 Jahre*
Ja
Nein
patients with essential hypertension aged >/= 18
years with one of the following risk factors: history
of coronary artery disease or stroke/TIA or
peripheral artery disease or diabetes mellitus. *
Ja
Nein
Ausschlusskriterien
according to SPC*
Ja
Nein
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Eligibility NCT00684619 T-ALL, T-NHL
(Lymphoblastic)
ODM derived from
http://clinicaltrials.gov/show/NCT00684619
All rights reserved. Please visit https://medical-data-
models.org/forms/4441
Eligibility
Einschlusskriterien
Alter mindestens 18 Jahre*
Ja
Nein
T-ALL, T-NHL*
Ja
Nein
cytological treatment failure / relapse*
Ja
Nein
molecular treatment failure / relapse*
Ja
Nein
no promising therapy alternatives with approved
medication available*
Ja
Nein
no CNS-manifestation, requiring intrathecal
therapy or CNS-radiation*
Ja
Nein
no convulsive disease or neurotoxicity > grade III
in patients history*
Ja
Nein
written informed consent*
Ja
Nein
no cytostatic therapy in the last 10 days*
Ja
Nein
no pregnancy or breastfeeding*
Ja
Nein
Kontrazeption*
Ja
Nein
recovery of toxicities of previous chemotherapy -
except leukemia-related changes like bone
marrow suppression or pathological
transaminases in liver manifestation*
Ja
Nein
1 / 2
Ausschlusskriterien
Severe psychiatric illness*
Ja
Nein
uncontrolled or severe cardiac disease or
infection*
Ja
Nein
active secondary neoplasms - except skin cancer
(no melanoma)*
Ja
Nein
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Eligibility NCT00684619 T-ALL, T-NHL (Lymphoblastic)
Eligibility NCT00700141 Hemorrhage
ODM derived from
http://clinicaltrials.gov/show/NCT00700141
All rights reserved. Please visit https://medical-data-
models.org/forms/4447
Eligibility
Einschlusskriterien
Alter mindestens 18 Jahre*
Ja
Nein
Hemorrhage*
Ja
Nein
Patients undergoing total or subtotal
thyroidectomy  *
Ja
Nein
Ausschlusskriterien
Contraindications, such as hypersensitivity to the
active pharmaceutical ingredient or to another
ingredient*
Ja
Nein
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Eligibility NCT00717366 Anemia
ODM derived from
http://clinicaltrials.gov/show/NCT00717366
All rights reserved. Please visit https://medical-data-
models.org/forms/4450
Eligibility
Einschlusskriterien
Alter 5 bis 17 Jahre*
Ja
Nein
children aged 5-17 years with clinically stable
chronic renal anemia*
Ja
Nein
hemodialysis for >=8 weeks*
Ja
Nein
intravenous stable maintenance epoetin alfa,
epoetin beta or darbepoetin alfa for >= 8 weeks
before screening*
Ja
Nein
stable maintenance epoetin alfa, epoetin beta or
darbepoetin alfa with no more than one dose
change <=25% during the 2 weeks of screening.
*
Ja
Nein
Ausschlusskriterien
overt gastrointestinal bleeding, or bleeding
episode necessitating transfusion within 8 weeks
before screening*
Ja
Nein
red blood cell transfusions within 8 weeks before
screening*
Ja
Nein
active malignant disease.*
Ja
Nein
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Eligibility NCT00574249 Chronic Plaque
Psoriasis
ODM derived from
http://clinicaltrials.gov/show/NCT00574249
All rights reserved. Please visit https://medical-data-
models.org/forms/4455
Eligibility
Einschlusskriterien
Alter mindestens 18 Jahre*
Ja
Nein
Subject had a clinical diagnosis of chronic plaque
psoriasis for at least 6 months, and has moderate
to severe plaque psoriasis*
Ja
Nein
Subject must have been treated and failed to
respond to, or has a contraindication to, or is
intolerant to at least two different systemic
therapies, one of which must be cyclosporine, or
methotrexate or oral PUVA*
Ja
Nein
Subject is judged to be in generally good health
as determined by the principal investigator *
Ja
Nein
Ausschlusskriterien
Subject has previous exposure to adalimumab*
Ja
Nein
Subject cannot discontinue systemic therapies
and/or topical therapies for the treatment of
psoriasis and cannot avoid UVB or PUVA
phototherapy*
Ja
Nein
Subject is taking or requires oral or injectible
corticosteroids*
Ja
Nein
Subject diagnosed with erythrodermic psoriasis,
pustular psoriasis, medication-induced or
medication-exacerbated psoriasis or new onset
guttate psoriasis*
Ja
Nein
Subject considered by the investigator, for any
reason, to be an unsuitable candidate*
Ja
Nein
1 / 2
Female subject who is pregnant or breast-feeding
or considering becoming pregnant*
Ja
Nein
Calcium Metabolism Disorders*
Ja
Nein
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Eligibility NCT00574249 Chronic Plaque Psoriasis
Eligibility NCT00391287 Pure Red-Cell
Aplasia
ODM derived from
http://clinicaltrials.gov/show/NCT00391287
All rights reserved. Please visit https://medical-data-
models.org/forms/4456
Eligibility
Einschlusskriterien
Alter mindestens 18 Jahre*
Ja
Nein
Patients with established CRF as an indication for
the treatment of anemia*
Ja
Nein
Patients who are receiving or are about to receive
(within 1 month) a marketed erythropoietin
product by the s.c. route of administration*
Ja
Nein
Patients who are likely to continue to receive s.c.
erythropoietin product(s) for at least 1 year *
Ja
Nein
Ausschlusskriterien
Patients with a history of pure red cell aplasia or
aplastic anemia*
Ja
Nein
Patients who are experiencing unexplained loss
or lack of effect to a recombinant erythropoietin
product ongoing at the time of enrollment*
Ja
Nein
Patients who have had prior recombinant
erythropoietin treatment whose anemia had never
responded (primary lack of efficacy)*
Ja
Nein
Patients with a history of EPO antibodies prior to
enrollment*
Ja
Nein
Subjects who are currently receiving
immunosuppressive medication (e.g.,
cyclosporine, tacrolimus, sirolimus, mycophenolic
mofetil, azathioprine, or monoclonal antibodies)
or corticosteroids at a dose corresponding to >15
mg/day prednisolone*
Ja
Nein
1 / 2
Subjects whose first s.c. exposure to any
erythropoietin product was >1 year prior to
enrollment*
Ja
Nein
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Eligibility NCT00391287 Pure Red-Cell Aplasia
Eligibility NCT00391872 Acute Coronary
Syndrome
ODM derived from
http://clinicaltrials.gov/show/NCT00391872
All rights reserved. Please visit https://medical-data-
models.org/forms/4457
Eligibility
Einschlusskriterien
Alter mindestens 18 Jahre*
Ja
Nein
Male or female 18 years or older who has been
hospitalised for chest pain and potential ACS*
Ja
Nein
Females of child-bearing potential must have a
negative pregnancy test at enrollment and be
willing to use 2 methods of reliable contraception
*
Ja
Nein
Ausschlusskriterien
Persons with moderate or severe liver disease*
Ja
Nein
Persons who have already been treated with an
invasive (angioplasty) procedure for the current
episode of ACS*
Ja
Nein
Persons who are being treated with blood clotting
agents that cannot be stopped*
Ja
Nein
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Eligibility NCT00133952 # Diabetes Mellitus
The purpose of the study is to test the hypothesis that oral
administration of ruboxistaurin
will reduce the occurence of sustained moderate visual loss
(SMVL) in patients with
clinically significant macular edema. SMVL is defined as a
15 letter or more decrease from
baseline in best-corrected Early Treatment Diabetic
Retinopathy Study (ETDRS) visual acuity
that is sustained for the patient's last 6 months of study
participation. The SMVL data from
this study will be combined with the SMVL data from Study
B7A-MC-MBDL for the purpose of
comparing ruboxistaurin to placebo.
All rights reserved. Please visit https://medical-data-
models.org/forms/4459
Eligibility
Inclusion criteria
No Healthy Volunteers*
Yes
No
Type 1 or 2 diabetes*
Yes
No
18 Years and older*
Yes
No
HbA1c less than or equal to 11%*
Yes
No
Mild to very severe non-proliferative diabetic
retinopathy in the study eye*
Yes
No
Clinically significant macular edema in the study
eye not within 100 microns of center of macula*
Yes
No
Exclusion criteria
Previous surgery or laser treatment (or need for
laser treatment within 3 months) in the study eye*
Yes
No
Glaucoma in the study eye*
Yes
No
Unstable cardiovascular disease*
Yes
No
Major surgery within past 3 months*
Yes
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No
Significantly impaired kidney or liver function, or
malignancy requiring chemotherapy or radiation
therapy.*
Yes
No
Medical Concepts
Age*
Healthy Subject*
Diabetes Mellitus*
Hemoglobin A1c/Hemoglobin.total:SFr:Pt:Bld:Qn*
Diabetic Retinopathy*
Macular retinal edema*
Ophthalmologic Surgical Procedures*
Eye laser surgery*
Glaucoma*
Cardiovascular Diseases*
major surgery*
Abnormal renal function*
Liver Dysfunction*
Malignant Neoplasms*
Chemotherapy Regimen*
Therapeutic radiology procedure*
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Eligibility NCT00133952 # Diabetes Mellitus
Eligibility NCT00404092 Invasive
Aspergillosis
ODM derived from
http://clinicaltrials.gov/show/NCT00404092
All rights reserved. Please visit https://medical-data-
models.org/forms/4463
Eligibility
Einschlusskriterien
Alter mindestens 18 Jahre*
Ja
Nein
Immunocompromised due to hematologic
malignancies, bone marrow failure syndromes,
hematopoietic stem cell transplantation, solid
organ transplantation, other conditions resulting
in severe neutropenia, HIV infection, prolonged
corticosteroid therapy, treatment with other
immunosuppressive medications, or other
immunocompromising conditions that place
patients at risk for invasive fungal infections.*
Ja
Nein
Evidence of proven or probable invasive
aspergillosis, by modified EORTC criteria *
Ja
Nein
Ausschlusskriterien
Concomitant other systemic antifungal agents are
not permitted on study.*
Ja
Nein
Chronic invasive fungal infection, defined as
signs/symptoms of invasive fungal infection
present for > 4 weeks preceding entry into study*
Ja
Nein
Prior systemic therapy of >= 4 days with any
polyene anti-fungal agent within 14 days of study
enrollment*
Ja
Nein
Prior systemic therapy of >= 4 days with non-
polyenes for the current, documented IFI.*
Ja
Nein
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Eligibility NCT00404482 Uveitis
ODM derived from
http://clinicaltrials.gov/show/NCT00404482
All rights reserved. Please visit https://medical-data-
models.org/forms/4464
Eligibility
Einschlusskriterien
Alter bis zu 16 Jahre*
Ja
Nein
Uveitis*
Ja
Nein
JIA*
Ja
Nein
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Eligibility NCT00408473 Atrial Fibrillation
ODM derived from
http://clinicaltrials.gov/show/NCT00408473
All rights reserved. Please visit https://medical-data-
models.org/forms/4469
Eligibility
Einschlusskriterien
Alter 18 bis 65 Jahre*
Ja
Nein
History of first symptomatic & documented
episode of AF*
Ja
Nein
LVEF > 40% and not on AAD and in sinus rhythm
at time of recruitment *
Ja
Nein
Ausschlusskriterien
History of more than 1 symptomatic documented
AF episode, persistent or permanent AF.*
Ja
Nein
History of ablation for previous AF*
Ja
Nein
Reversible cause for AF (e.g.thyroid, alcohol,
pulmonary embolism, surgery*
Ja
Nein
Severe symptoms during AF episode
(e.g.syncope, chest pain)*
Ja
Nein
All types of treated arrhythmias other than AF*
Ja
Nein
History of myocardial infarction (MI), coronary
artery disease (CAD), heart failure (I, II, III and IV
of New York Heart Association -NYHA-
classification) or valvular diseases*
Ja
Nein
LVEF - Left ventricular ejection fraction*
Ja
Nein
Bradycardia < 40 beats/min and all ECG
abnormalities: PR> 240ms or QRS> 120 ms or
1 / 3
QTc> 440 ms*
Ja
Nein
Brugada Syndrome (disorder)*
Ja
Nein
Conduction disturbances: complete bundle
branch block (LBBB) or (RBBB), bifascicular
block*
Ja
Nein
2nd or 3rd degree atrioventricular (AV) block*
Ja
Nein
Coronary sinus rhythm disorder*
Ja
Nein
Severe hypertension with:Systolic blood pressure
>= 180 mmHg, and / or Diastolic blood pressure
>= 100 mmHg*
Ja
Nein
Left ventricular hypertrophy (LVH) with septal
thickness > 14 mm on Echocardiogram*
Ja
Nein
Herzschrittmacher*
Ja
Nein
Heart surgery within the last 6 months, or non-
stable postoperative condition*
Ja
Nein
Renal failure: serum creatinine >= 150 µmol/l or
creatinine clearance <= 50 ml/min (Cockroft and
Gault formula*
Ja
Nein
Uncorrected electrolytic abnormalities*
Ja
Nein
Have used recently in the last 3 months prior to
the inclusion any of the following treatments: Oral
amiodarone, Treatments that lengthen QT interval
(e.g.Sultopride, Drugs causing torsades de pointe
(e.g.mizolastine, pentamidine, sparfloxacin,
moxifloxacin, Bupropion*
Ja
Nein
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Eligibility NCT00408473 Atrial Fibrillation
Anti-hypertensive drugs other than permitted in
the study: ACE-I, ARB (sartans) and DHP from
Calcium channel blockers (CCB*
Ja
Nein
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Eligibility NCT00408473 Atrial Fibrillation
Eligibility NCT00036543 Prostate Cancer
A Study of Atrasentan in Men With Metastatic, Hormone-
Refractory Prostate Cancer
Inclusion Criteria: 
- Diagnosis of prostate cancer. 
- Rising PSA while on hormonal therapy or following
surgical castration. 
- Documented evidence of metastatic disease. 
Exclusion Criteria: 
- Have received cytotoxic chemotherapy. 
- Have received opioid or narcotic medications (such as
codeine or morphine) or radiation for pain caused by your
prostate cancer in the last 6 months
All rights reserved. Please visit https://medical-data-
models.org/forms/4471
Eligibility
Inclusion criteria
Diagnosis of prostate cancer*
Yes
No
Rising PSA while on hormonal therapy or
following surgical castration*
Yes
No
Documented evidence of metastatic disease*
Yes
No
Exclusion criteria
Have received cytotoxic chemotherapy*
Yes
No
Have received opioid or narcotic medications
(such as codeine or morphine) or radiation for
pain caused by your prostate cancer in the last 6
months*
Yes
No
Medical Concepts
Diagnosis*
PSA*
Metastatic malignant disease*
Cancer chemotherapy*
Medication*
Radiotherapy*
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Eligibility NCT00409175 Familial Amyloid
Polyneuropathy
ODM derived from
http://clinicaltrials.gov/show/NCT00409175
All rights reserved. Please visit https://medical-data-
models.org/forms/4472
Eligibility
Einschlusskriterien
Alter 18 bis 75 Jahre*
Ja
Nein
Amyloid documented by biopsy.*
Ja
Nein
Documented V30M TTR mutation.*
Ja
Nein
Peripheral and/or autonomic neuropathy with a
Karnofsky Performance Status ≥50.*
Ja
Nein
If female, patient is post-menopausal, surgically
sterilized, or willing to use an acceptable method
of birth control. If male with a female partner of
childbearing potential, willing to use an
acceptable method of birth control for the
duration of the study. For both females and
males, birth control must be used for at least 3
months after the last dose of study medication.*
Ja
Nein
Patient is, in the opinion of the investigator, willing
and able to comply with the study medication
regimen and all other study requirements.*
Ja
Nein
Ausschlusskriterien
Chronic use of non-steroidal anti-inflammatory
drugs (NSAIDs).*
Ja
Nein
primäre Amyloidose*
Ja
Nein
If female, patient is pregnant or breast feeding.*
Ja
Nein
Prior liver transplantation.*
Ja
Nein
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No recordable sensory threshold for vibration
perception in both feet, as measured by CASE
IV.*
Ja
Nein
Positive results for hepatitis B surface antigen
(HBsAg), anti-hepatitis C virus (HCV), and/or
human immunodeficiency virus (HIV).*
Ja
Nein
Renal insufficiency or liver function test
abnormalities.*
Ja
Nein
New York Heart Association (NYHA) Functional
Classification ≥III.*
Ja
Nein
Other causes of sensorimotor neuropathy (B12
deficiency, Diabetes Mellitus, HIV treated with
retroviral medications, thyroid disorders, alcohol
abuse, and chronic inflammatory diseases).*
Ja
Nein
Co-morbidity anticipated to limit survival to < 18
months.*
Ja
Nein
Patient received an investigational drug/device
and/or participated in another clinical
investigational study within 60 days before
Baseline.*
Ja
Nein
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Eligibility NCT00409175 Familial Amyloid Polyneuropathy
Eligibility NCT00409799 Tibia Plateau
Fractures
ODM derived from
http://clinicaltrials.gov/show/NCT00409799
All rights reserved. Please visit https://medical-data-
models.org/forms/4473
Eligibility
Einschlusskriterien
Alter mindestens 18 Jahre*
Ja
Nein
Radiological evidence of a tibial plateau fracture
requiring grafting*
Ja
Nein
Females of child-bearing potential must be willing
to undergo a pregnancy test (urine) prior to
treatment start (at screening). *
Ja
Nein
Ausschlusskriterien
Concomitant ipsilateral fractures of the limb other
than the fracture of the tibial plateau.*
Ja
Nein
Active or past history of malignant tumor.*
Ja
Nein
Evidence of systemic or localized infection at time
of surgery.*
Ja
Nein
Pregnant or lactating females.*
Ja
Nein
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Eligibility NCT00420472 Kidney
Transplantation
ODM derived from
http://clinicaltrials.gov/show/NCT00420472
All rights reserved. Please visit https://medical-data-
models.org/forms/4476
Eligibility
Einschlusskriterien
Alter mindestens 18 Jahre*
Ja
Nein
Erwachsener, erwachsen*
Ja
Nein
first or second kidney transplant*
Ja
Nein
EC-MPS therapy for >=6 months, with a stable
dose for >=2 months*
Ja
Nein
lower than recommended dose of EC-MPS
(<1440g/day) due to gastrointestinal complaints. *
Ja
Nein
Ausschlusskriterien
patients who have participated in this study
before*
Ja
Nein
patients currently participating in another clinical
trial, or who participated in one during the last 30
days.*
Ja
Nein
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Eligibility NCT00683930 Pemphigus
Vulgaris (PV)
ODM derived from
http://clinicaltrials.gov/show/NCT00683930
All rights reserved. Please visit https://medical-data-
models.org/forms/4485
Eligibility
Einschlusskriterien
Alter 18 bis 70 Jahre*
Ja
Nein
Erwachsenenalter*
Ja
Nein
Diagnosis of mild to moderate pemphigus
vulgaris within the past 12 months, requiring high
dose corticosteroids *
Ja
Nein
Ausschlusskriterien
Female patients who are pregnant,
breastfeeding, or lactating*
Ja
Nein
Regularly scheduled plasma exchange (PE) or
intravenous immunoglobulin (IVIG) treatment, or
PE or IVIG treatment within 8 weeks prior to
randomization*
Ja
Nein
CellCept or other immunosuppressive therapy,
except corticosteroids, exceeding 2 weeks total
duration and within 8 weeks prior to
randomization*
Ja
Nein
Use of PV therapies other than those noted
above, within 4 weeks prior to randomization*
Ja
Nein
Use of topical corticosteroids within 2 weeks prior
to randomization*
Ja
Nein
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Eligibility NCT00679731 Psoriasis
ODM derived from
http://clinicaltrials.gov/show/NCT00679731
All rights reserved. Please visit https://medical-data-
models.org/forms/4487
Eligibility
Einschlusskriterien
Alter mindestens 18 Jahre*
Ja
Nein
Diagnosis of Psoriasis for 6 MO.. BSA 10%, PASI
>= 12, PGA >= 3 *
Ja
Nein
Ausschlusskriterien
Previous exposure to anti-IL 12*
Ja
Nein
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Eligibility NCT00679419 Coronary Artery
Disease Renal Failure
ODM derived from
http://clinicaltrials.gov/show/NCT00679419
All rights reserved. Please visit https://medical-data-
models.org/forms/4491
Eligibility
Einschlusskriterien
Alter mindestens 18 Jahre*
Ja
Nein
Women and men*
Ja
Nein
Patients with actually performed interventional
coronary angiography and there a documented
coronary heart disease, defined as at least one
documented stenosis >= 50 % in at least one
main coronary vessel (Main stem RCX, RIVA,
RCA)*
Ja
Nein
European/Caucasian descent
(European/Caucasian parents and
grandparents)*
Ja
Nein
Availability of an urine, serum- and EDTA blood
sample of the patient*
Ja
Nein
Documented consent of patients for handling of
personal medical data, including a genetic
analysis *
Ja
Nein
Ausschlusskriterien
Patients who have been already recruited into
this registry*
Ja
Nein
Patients with organ transplantations, apart from
kidney transplantations*
Ja
Nein
Immunosuppressive therapy, apart from
immunosuppressive therapy after kidney
transplantation*
Ja
Nein
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polyzystische Nierendegeneration,
Zystennierenleiden*
Ja
Nein
Pregnant and breastfeeding patients*
Ja
Nein
Known malignant tumor*
Ja
Nein
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Eligibility NCT00679419 Coronary Artery Disease Renal Failure
Eligibility NCT00663858 Benign Prostatic
Hypertrophy
ODM derived from
http://clinicaltrials.gov/show/NCT00663858
All rights reserved. Please visit https://medical-data-
models.org/forms/4495
Eligibility
Einschlusskriterien
Alter mindestens 50 Jahre*
Ja
Nein
Benign Prostatic Hyperplasia, based on medical
history*
Ja
Nein
Voiding symptoms *
Ja
Nein
Ausschlusskriterien
Urgent need for prostate surgery or prior surgical
treatment of the prostate or bladder*
Ja
Nein
Major organ dysfunction*
Ja
Nein
Eczema (atopic dermatitis) treated during the last
6 months*
Ja
Nein
Current or recent treatment with sexual hormone
drugs or 5 alpha reductase inhibitors or botulinum
toxin type a (Botox) within the last 6 months prior
randomization or with alpha blockers or saw
palmetto within the last 6 weeks prior to
randomization*
Ja
Nein
Urologic disorders including neurogenic bladder
dysfunction due to diabetes mellitus or
documented neurologic disorder, urethral
stricture disease or history of pelvic radiation
therapy*
Ja
Nein
History of acute obstructive, infectious, or
neurological disorders of the genitourinary tract
within the last 3 months*
Ja
Nein
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Eligibility NCT00655252 Metastatic Renal
Cell Cancer
ODM derived from
http://clinicaltrials.gov/show/NCT00655252
All rights reserved. Please visit https://medical-data-
models.org/forms/4497
Eligibility
Einschlusskriterien
Alter mindestens 18 Jahre*
Ja
Nein
metastatic renal cancer, intolerant of or failed
sunitinib and/or sorafenib*
Ja
Nein
Adequate bone marrow function, liver function,
renal function*
Ja
Nein
Adequate birth control *
Ja
Nein
Other protocol-defined inclusion criteria may
apply*
Ja
Nein
Ausschlusskriterien
Previously received RAD001 or other mTOR
inhibitors, known hypersensitivity to rapamycin,
chronic systemic treatment with corticosteroids or
immunosuppressive agents (prednisone <= 20
mg/day for adrenal insufficiency OK*
Ja
Nein
Topical or inhaled steroids OK)*
Ja
Nein
Active bleeding*
Ja
Nein
Uncontrolled angina, CHF, heart attack <= 6
months, uncontrolled diabetes *
Ja
Nein
Other protocol-defined exclusion criteria may
apply*
Ja
Nein
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Eligibility NCT00642941 Sarcoma
ODM derived from
http://clinicaltrials.gov/show/NCT00642941
All rights reserved. Please visit https://medical-data-
models.org/forms/4500
Eligibility
Einschlusskriterien
Alter mindestens 2 Jahre*
Ja
Nein
progressive, recurrent or refractory Ewing's
sarcoma, or recurrent or refractory
osteosarcoma, synovial sarcoma,
rhabdomyosarcoma, or other sarcomas of the
following sub-types: alveolar soft part sarcoma,
desmoplastic small round cell tumor, extraskeletal
myxoid chondrosarcoma, clear cell sarcoma and
myxoid liposarcoma. *
Ja
Nein
Ausschlusskriterien
clinically significant unrelated systemic illness
which would compromise the patient's ability to
tolerate the investigational agent, or interfere with
the study procedures or results*
Ja
Nein
known hypersensitivity to any of the components
of R1507 or prior hypersensitivity reactions to
monoclonal antibodies*
Ja
Nein
current or previous treatment (within last 6
months) with chronic pharmacological doses of
corticosteroids, immunosuppressive agents or
medications that inactivate or may interfere with
the pharmacological activity of R1507*
Ja
Nein
current or prior therapy with IGF inhibitor
(monoclonal or specific kinase inhibitor)*
Ja
Nein
history of solid organ transplant*
Ja
Nein
other malignant disease diagnosed within the
previous 5 years, excluding intra-epithelial
cervical neoplasia or non-melanoma skin
cancer.*
Ja
1 / 2
Nein
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Eligibility NCT00642941 Sarcoma
Eligibility NCT00130858 # Soft Tissue
Sarcoma
Phase II Study to evaluate the response on two blocks of
topotecan and carboplatin
All rights reserved. Please visit https://medical-data-
models.org/forms/4501
Eligibility
Inclusion criteria
Both*
Yes
No
age < 21*
Yes
No
Soft tissue sarcoma chemosensible, stage IV*
Yes
No
measurable tumor lesions*
Yes
No
Exclusion criteria
Lack of cooperation by the patient*
Yes
No
no willingness of follow-up examinations*
Yes
No
participation on another clinical trial at the same
time*
Yes
No
death due to the sickness within four weeks*
Yes
No
Medical Concepts
Age*
Gender*
Soft tissue sarcoma stage IV*
Tumor size finding*
Compliance behavior*
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Refusal of Treatment*
Subject Enrolled in Study*
Enrollment*
Life Expectancy*
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Eligibility NCT00130858 # Soft Tissue Sarcoma
Eligibility NCT00117650 # Intermittent
Claudication
The purpose of this Phase 2 clinical research study is to
examine the safety of an
experimental gene transfer agent, Ad2/HIF-1_/VP16, and
its ability to stimulate the growth
of new blood vessels from existing blood vessels (a process
called angiogenesis) in an
attempt to improve the flow of blood in the legs of patients
with peripheral arterial
disease (PAD).
Specifically, this study will enroll patients with severe
intermittent claudication (IC)
which is the stage of PAD in which a patient's walking ability
is severely limited, causing
pain in the legs upon exercise due to inadequate blood flow
to the muscles of the lower
limbs.
All rights reserved. Please visit https://medical-data-
models.org/forms/4502
Eligibility
Inclusion criteria
No Healthy Volunteers*
Yes
No
Males and females 40 to 80 years of age,
inclusive.*
Yes
No
Clinical diagnosis of PAD, secondary to
atherosclerosis, in both lower limbs,
confirmed by objective evidence: An ankle-
brachial index (ABI) of ≤ 0.90 at rest in
at least 1 lower limb (Note: The index limb must
be ≤ 0.90 at rest.); The ABI after
exercise must be reduced by ≥ 20% from the ABI
at rest in the index leg (the most
symptomatic leg during the treadmill testing).
The post-exercise ABI will also be
performed on the other leg if the resting ABI >
0.90.  
A patient may be eligible for the study with a
resting ABI in the non-index limb > 0.90 if: 
a. The post-exercise ABI in the non-index leg is
also reduced by greater than or equal to 20%
OR; 
b. A medically significant stenosis (defined as ≥
50%) of a femoropopliteal or
infrapopliteal artery is present, as documented
via an imaging study (such as MR,
conventional angiography, duplex ultrasound, or
CT); If the ABI cannot be measured in
either leg (due to non-compressible arteries),
then a toe-brachial index (TBI) of ≤
0.70 may be used in its place to confirm PAD.
*
Yes
No
1 / 13
Symptoms of severe intermittent claudication (IC)
in at least 1 lower limb persisting for ≥ 6 months*
Yes
No
Patients with a peak walking time (PWT) of 1 to
12 minutes (inclusive) using the
standardized exercise treadmill test at each of the
2 consecutive treadmill tests
performed at least a week apart during the
Screening period.
*
Yes
No
During Screening, patients must demonstrate
consistency of PWTs between 2
standardized exercise treadmill tests (Walk 1 and
Walk 2) performed at least 1 week
apart.
*
Yes
No
Consistency of the PWT between the 2 visits is
achieved if the difference between PWT
at Walk 1 and Walk 2 is ≤ 25% of the higher of
the 2 PWTs ([higher PWT - lower
PWT]/higher PWT).
*
Yes
No
If the difference between PWT at Walk 1 and
Walk 2 is > 25% of the higher of the 2
PWTs, a third treadmill test (Walk 3) may be
performed at the discretion of the
Principal Investigator between 7 and 14 days
following Walk 2.  The variability in
PWT warranting the performance of Walk 3 must
be secondary to circumstances that may
contribute to the observed variation (e.g., prior
exertion, inconsistent timing,
ingestion of a meal within 4 hours, etc).  To
qualify for the study, the difference
between PWT of either Walk 1 or Walk 2 as
compared with Walk 3 must be ≤ 25% of the
higher of the 2 PWTs ([higher PWT - lower
PWT]/higher PWT). The decision whether Walk
1 or Walk 2 will be used for comparison with Walk
3 will be made prospectively and
reviewed with the Sponsor.
*
Yes
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Eligibility NCT00117650 # Intermittent Claudication
No
An acceptable mean PWT must be achieved
within 4 weeks of treatment administration.*
Yes
No
Patients have been considered for other potential
treatment options including
exercise rehabilitation, smoking cessation, and
pharmacological therapy prior to
Enrollment.
*
Yes
No
Claudication severity, concomitant medications
for the treatment of CAD, PAD, and IC,
smoking status and exercise habits should be
clinically stable for 3 months prior to
Enrollment.
*
Yes
No
Patients who are committed to following the
protocol requirements as evidenced by
written informed consent.
*
Yes
No
Exclusion criteria
Patients with either current or any history of
Critical Limb Ischemia (CLI; that is,
patients classified as Rutherford Category 4
[ischemic rest pain], Rutherford
Category 5 [non-healing ischemic ulcers and
minor tissue loss], or Rutherford
Category 6 [non-healing ischemic ulcers and
major tissue loss]).
*
Yes
No
Patients in whom arterial insufficiency in the
lower extremity is the result of acute
limb ischemia or an immunological or
inflammatory non-atherosclerotic disorder (eg,
thromboangiitis obliterans [Buerger's Disease])
and systemic sclerosis [both limited
and diffuse forms]).
*
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Eligibility NCT00117650 # Intermittent Claudication
Yes
No
A PAD-specific surgical revascularization
procedure within 6 months of enrollment or
a PAD-specific percutaneous procedure within 3
months of enrollment, or patients
likely to require a PAD-specific revascularization
procedure within 6 months after
Enrollment.
*
Yes
No
Patients with aortoiliac disease that limits inflow
in either leg: 
a. Patients with concomitant aortoiliac disease
(i.e., patients with a significant component of
inflow
disease in the distal aorta, common or external
iliac, or proximal common femoral
artery) as assessed by an imaging modality (e.g.,
segmental limb pressures and
waveform analysis, duplex ultrasound scanning,
magnetic resonance angiography, or
radio-contrast arteriogram) performed within 1
year prior to Enrollment.  If subject
has had a bypass after the imaging study, then
documentation of graft patency is
required within 6 months prior to Enrollment; 
b. If it is suspected at Screening that a patient
has aortoiliac disease based on vascular
examination, an imaging modality
(e.g., segmental limb pressures and waveform
analysis, duplex ultrasound scanning,
magnetic resonance angiography, or radio-
contrast arteriogram) must be performed to
rule it out if there is not one available within the
times specified above. If there
is no suspicion of aortoiliac disease in the
Principal Investigator's judgment, an
imaging test at Screening is not required for study
purposes.
*
Yes
No
Patients in whom walking impairment due to pain
in the index leg is the result of
these nonatherosclerotic comorbid conditions:
venous claudication, chronic
compartment syndrome, peripheral nerve pain
(e.g., severe peripheral neuropathy),
pseudoclaudication caused by spinal cord
compression, or acute limb ischemia which,
in the Principal Investigator's judgment are
severe enough to confound the assessment
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of the patient's IC.
*
Yes
No
Conditions other than IC of significant severity
that could confound PWT on the
standardized exercise treadmill test causing
premature or inconsistent termination of
exercise (e.g., angina pectoris, heart failure [New
York Heart Association {NYHA}
Classes III and IV], respiratory disease [e.g.,
chronic obstructive pulmonary
disease], orthopedic disease, neurological
disorders, rheumatologic disorders [e.g.,
severe degenerative joint diseases], dyspnea,
fatigue, prior lower limb amputation,
including amputations proximal to the metatarsal
or phalangeal joints).
*
Yes
No
Presence or history of cancer within 5 years of
enrollment or not current with
recommended screening guidelines for
colorectal, lung, prostate, breast, cervical,
and uterine cancers, with the exception of low
grade and fully resolved non-melanoma
skin malignancy.
*
Yes
No
Patients with a well-defined clinical or genetic
disorder predisposing to malignancy
should be excluded (e.g., von Hippel Lindau,
familial polyposis coli, BRCA1, BRCA2,
etc).
*
Yes
No
Patients with a well-defined clinical or genetic
disorder predisposing to malignancy
should be excluded (e.g., von Hippel Lindau,
familial polyposis coli, BRCA1, BRCA2,
etc).
*
Yes
No
Patients with baseline funduscopic evidence of
active proliferative diabetic
retinopathy, preproliferative diabetic retinopathy,
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or wet AMD AND/OR Patients with a
history of treatment for active proliferative diabetic
retinopathy or wet AMD within
5 years of enrollment.
*
Yes
No
Diabetes type 1 (juvenile onset)*
Yes
No
Poorly controlled type 2 diabetes (ie, HbA1C
>10%) at Screening*
Yes
No
Active hepatitis defined as clinically significant
increase in liver enzymes (ie, 3
times the ULN) or other current infectious disease
*
Yes
No
Patients with symptoms of respiratory infection at
time of Screening and/or
randomization period and/or patients who have
been on systemic or oral antibiotics
for active infection within 2 weeks of study drug
administration.
*
Yes
No
Patients with clinically significant abnormal
hematology (eg, hematocrit < 30%, white
blood cell count > 14,000), blood chemistry, renal,
hepatic, or other laboratory
parameters that could be the result of an
underlying malignancy or systemic infection
(e.g., serum creatinine ≥ 2.5 mg/dL), as judged
by the investigator.
*
Yes
No
Patients with the following comorbidities who may
not be healthy enough to
successfully complete all protocol requirements
or in whom results may be
particularly difficult to assess: Concurrent severe
congestive heart failure (NYHA
Classes III and IV); Life-threatening ventricular
arrhythmias, unstable angina
(characterized by increasingly frequent episodes
6 / 13
Eligibility NCT00117650 # Intermittent Claudication
with modest exertion or at rest,
worsening severity, and prolonged duration),
and/or myocardial infarction within 4
weeks before enrollment; Coronary artery bypass
grafting or percutaneous coronary
intervention within 3 months before enrollment; A
renal and/or carotid
revascularization procedure within 1 month of
enrollment; Transient ischemic attack
within 3 months before enrollment; Deep vein
thrombosis within 3 months before
enrollment; Severe chronic obstructive pulmonary
disease (room air arterial PO2 < 60
mmHg or PCO2 > 50 mmHg, or abnormal
pulmonary function tests (FEV1 < 1.2 L/sec);
Thrombocytopenia (defined as platelet count <
100,000/mm3); Undergoing hemodialysis;
Patients with immunocompromised conditions,
organ transplant recipients and/or need
for immunosuppressive therapy; Neurological
dementia (i.e., Alzheimer's Disease);
Hemorrhagic stroke
*
Yes
No
Patients with a known allergy to the vehicle,
placebo control, or any other
medications or imaging agents required for
participation in this study.
*
Yes
No
Fertile women who are pregnant (as confirmed
by a serum pregnancy test at the
Screening Visit and a urine pregnancy test at Day
0 prior to study drug
administration), nursing, or using either no or an
inadequate form of contraception.
*
Yes
No
Fertile men and women who are not willing to use
barrier-type contraception for at
least 90 days post-treatment.
*
Yes
No
Patients with a recent history of alcoholism or
drug abuse, or severe emotional,
behavioral or psychiatric problems, who may not
be able to adequately comply with the
requirements of the study.
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*Yes
No
Patients receiving experimental medications or
participating in another study using
an experimental drug or experimental procedure
within 30 days of enrollment into this
study.
*
Yes
No
Patients previously enrolled in a prior angiogenic
gene therapy clinical study,
unless patient was a known placebo patient.
*
Yes
No
Medical Concepts
Healthy Subject*
Gender*
Age*
Peripheral Arterial Diseases*
Atherosclerosis*
Lower Extremity*
Ankle-Brachial Index*
Treadmill Tests*
Femoropopliteal stenosis*
Crural artery*
Stenosis*
Image Study*
Toe-Brachial Index*
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Intermittent Claudication*
Walking exercise test*
Investigator*
Patient notified*
treatment options*
Enrollment*
Severity*
Concomitant Medication Ongoing*
Coronary heart disease*
Smoking Status*
Exercise*
Stable status*
Informed Consent*
Critical limb ischaemia*
Lower limb ischemia*
Immune System Disorder*
Inflammatory Disorder*
Thromboangiitis Obliterans*
Systemic Scleroderma*
Revascularization of lower limb*
Aortoiliac atherosclerosis*
Bypass*
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Lameness*
Venous intermittent claudication*
Compartment syndrome of lower limb*
Peripheral Neuropathy*
Spinal claudication*
Angina Pectoris*
Heart failure*
New York Heart Association Class III*
New York Heart Association Class IV*
Respiration Disorders*
Disorder of skeletal system*
nervous system disorder*
Collagen Diseases*
Degenerative polyarthritis*
Dyspnea*
Fatigue*
Amputation of lower limb*
Amputation of ankle (procedure)*
Midfoot amputation*
Malignant Neoplasms*
Screening for cancer*
Screening for Colorectal Cancer*
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Screening for Lung Cancer*
Screening for Prostate Cancer*
Breast Cancer Screening*
Cervical Cancer Screening*
Screening for Endometrial Cancer*
Skin Neoplasms*
Non-Melanomatous Lesion*
Precancerous Conditions*
Von Hippel-Lindau Syndrome*
Adenomatous Polyposis Coli*
BRCA1 gene*
BRCA2 gene*
Ophthalmoscopy*
Diabetic Retinopathy*
Exudative age-related macular degeneration*
Diabetes Mellitus, Insulin-Dependent*
Diabetes Mellitus, Non-Insulin-Dependent*
Hemoglobin A1c/Hemoglobin.total:SFr:Pt:Bld:Qn*
Hepatitis*
Increased liver enzymes*
Respiratory Tract Infections*
Antibiotic Therapy*
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Abnormal Hematology Test Result*
Hematocrit:VFr:Pt:Bld:Qn:Automated count*
Leukocytes:NCnc:Pt:Bld:Qn:Automated count*
Abnormal Blood Chemistry and Hematology Test
Result*
Abnormal Laboratory Test Result*
Increased Creatinine*
Ventricular arrhythmia*
Angina, Unstable*
Myocardial Infarction*
Coronary Artery Bypass Surgery*
Percutaneous coronary intervention*
Revascularization - action*
Structure of renal artery*
Carotid Arteries*
Transient Ischemic Attack*
Deep Vein Thrombosis*
Chronic Obstructive Airway Disease*
Partial Pressure of Oxygen Measurement*
Partial Pressure of Carbon Dioxide
Measurement*
Lung function testing abnormal*
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Forced Expiratory Volume in 1 Second*
Thrombocytopenia*
Platelet # Bld Auto*
Hemodialysis*
Immunocompromised*
Transplant Recipients*
Therapeutic immunosuppression*
Dementia*
Alzheimer's Disease*
Brain hemorrhage*
Drug Allergy*
Contrast media allergy*
Negative Pregnancy Test*
Breastfeeding*
Contraceptive methods*
Contraception, Barrier*
Alcoholic Intoxication, Chronic*
Mental disorders*
Drug abuse*
Experimental drug*
Prior Gene Therapy*
Placebos*
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Eligibility NCT00053768 NHL
Combination Chemotherapy Followed By Radiation
Therapy in Treating Patients With Aggressive Non-
Hodgkin's Lymphoma
DISEASE CHARACTERISTICS: 
- Histologically confirmed aggressive non-Hodgkin's
lymphoma 
- Previously untreated disease 
- Favorable prognosis 
- International Prognostic Index score of 0-1 
- No more than 25% marrow involvement 
PATIENT CHARACTERISTICS: 
Age - 18 to 60 
Performance status - ECOG 0-3 OR - Karnofsky 40-100% 
Life expectancy - Not specified 
Hematopoietic - Platelet count at least 100,000/mm^3 -
WBC at least 2,500/mm^3 
Hepatic - No active hepatitis infection 
Renal - Not specified 
Other - HIV negative - Not pregnant or nursing - No
relevant accompanying disease - No other concurrent
malignancy - No contraindications to any study medications
- No prior noncompliance by patient 
PRIOR CONCURRENT THERAPY: 
Biologic therapy - Not specified 
Chemotherapy - No prior chemotherapy 
Endocrine therapy - Not specified 
Radiotherapy - No prior radiotherapy 
Surgery - Not specified 
Other - No other concurrent participation in another
treatment study
All rights reserved. Please visit https://medical-data-
models.org/forms/4506
Eligibility
Disease characteristics
Histologically confirmed aggressive non-
Hodgkin's lymphoma *
Yes
No
Previously untreated disease*
Yes
No
Favorable prognosis*
Yes
No
International Prognostic Index score of 0-1*
Yes
No
No more than 25% marrow involvement *
Yes
No
Patient characteristics and prior
concurrent therapy
Age 18 to 60*
Yes
No
ECOG 0-3 OR Karnofsky 40-100%*
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Yes
No
Platelet count at least  100,000/mm^3*
Yes
No
WBC at least 2,500/mm^3*
Yes
No
No active hepatitis infection*
Yes
No
HIV negative; Not pregnant or nursing; No
relevant accompanying disease; No other
concurrent malignancy; No contraindications to
any study medications; No prior noncompliance
by patient*
Yes
No
No prior chemotherapy*
Yes
No
No prior radiotherapy*
Yes
No
No other concurrent participation in another
treatment study*
Yes
No
Medical Concepts
Diagnosis*
Therapeutic procedure*
Medication*
International Prognostic Index*
Bone Marrow Involvement*
Age*
ECOG performance status*
Karnofsky performance status*
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Platelet count - finding*
White blood cell count*
Hepatitis*
HIV negative*
pregnant*
Breast feeding*
Contraindication to medical treatment*
Treatment noncompliance*
Cancer chemotherapy*
Radiotherapy*
Enrollment*
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Eligibility NCT00639483 Schizophrenia
ODM derived from
http://clinicaltrials.gov/show/NCT00639483
All rights reserved. Please visit https://medical-data-
models.org/forms/4507
Eligibility
Einschlusskriterien
Alter 18 bis 50 Jahre*
Ja
Nein
Diagnosis of schizophrenia (according to
Diagnostic and Statistical Manual of Mental
Disorders [DSM]-IV-TR criteria and made by a
specialist in psychiatry) and acute exacerbation
of schizophrenia requiring hospitalization*
Ja
Nein
Total PANSS score of ?60 at screening*
Ja
Nein
History of schizophrenia of ?10 years (from onset
of prodromal symptoms) *
Ja
Nein
Ausschlusskriterien
Axis-I DSM-IV-TR diagnosis other than
schizophrenia*
Ja
Nein
Less than a full cycle has lapsed at time of
screening following the last injection of a depot
antipsychotic*
Ja
Nein
Currently taking celecoxib or other selective
cyclo-oxygenase 2 inhibitors, or other
antiinflammatory medication*
Ja
Nein
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Eligibility NCT00635492 Type 2 Diabetes
Mellitus
ODM derived from
http://clinicaltrials.gov/show/NCT00635492
All rights reserved. Please visit https://medical-data-
models.org/forms/4510
Eligibility
Einschlusskriterien
Alter mindestens 18 Jahre*
Ja
Nein
diagnosed with type 2 diabetes*
Ja
Nein
have had a treatment decision made within the
normal course of care to initiate either insulin or
exenatide for the treatment of type 2 diabetes*
Ja
Nein
have not previously been treated with either
insulin or exenatide*
Ja
Nein
are not simultaneously participating in another
study which includes an investigational drug or
procedure at study entry*
Ja
Nein
have been fully informed and given their written
consent for use of their data*
Ja
Nein
have sufficient understanding of the primary
language of their country such that they will be
able to complete the questionnaires.*
Ja
Nein
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Satraplatin in Hormone Refractory Prostate Cancer
Patients Previously Treated With One Cytotoxic
Chemotherapy Regimen
Inclusion Criteria: 
- Stage D2 metastatic prostate cancer 
- Progression after one prior chemotherapy 
- ECOG Performance status equal / less than 2 
- Life expectancy > 3 months 
- Surgical or medical castration 
- Adequate bone marrow, hepatic and renal functions 
- Informed consent 
Exclusion Criteria: 
- More than one prior chemotherapy
- Prior platinum containing compounds 
- Prior malignancy 
- Prior significant RT/radionuclide therapy 
- Major GI surgery or GI disease affecting absorption 
- Disease with contraindication to steroids 
- Brain metastases
All rights reserved. Please visit https://medical-data-
models.org/forms/4511
Eligibility
Inclusion criteria
Stage D2 metastatic prostate cancer *
Yes
No
Progression after one prior chemotherapy *
Yes
No
ECOG Performance status equal / less than 2 *
Yes
No
Life expectancy > 3 months *
Yes
No
Surgical or medical castration*
Yes
No
Adequate bone marrow, hepatic and renal
functions *
Yes
No
Exclusion criteria
More than one prior chemotherapy*
Yes
No
Prior platinum containing compounds *
Yes
No
Prior malignancy*
Yes
No
Prior significant RT/radionuclide therapy*
Yes
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No
Major GI surgery or GI disease affecting
absorption*
Yes
No
Disease with contraindication to steroids *
Yes
No
Brain metastases*
Yes
No
Medical Concepts
Diagnosis*
Prostate cancer metastatic*
Diagnostic Neoplasm Staging*
Cancer chemotherapy*
Tumor progression*
ECOG performance status*
Life expectancy*
Male castration*
White blood cell count*
Platelet count - finding*
Hemoglobin*
Creatinine*
Bilirubin*
Platinum compound*
Radiotherapy*
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Malabsorption*
Contraindication to medical treatment*
Steroid*
Brain metastases*
Metastatic malignant disease*
Therapeutic procedure*
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Eligibility NCT00630864 Transthyretin-
associated Amyloidosis With Polyneuropathy
ODM derived from
http://clinicaltrials.gov/show/NCT00630864
All rights reserved. Please visit https://medical-data-
models.org/forms/4516
Eligibility
Einschlusskriterien
Alter 18 bis 75 Jahre*
Ja
Nein
Patient has amyloid documented by biopsy (in
accordance with institutional site standard of
care).*
Ja
Nein
Patient has documentation of one of the following
targeted TTR mutations: Ser77Tyr, Thr60Ala,
Tyr114Cys, Leu58His, Glu89Gln, Ser77Phe,
Thr49Ala, Ile107Val, Val30Ala, Gly47Ala,
Gly47Glu, Leu55Arg, Lys70Asn, Ile84Thr,
Ile107Met. Patients with mutations other than
those listed may be enrolled only after approval
by the Sponsor.*
Ja
Nein
Patient has peripheral and/or autonomic
neuropathy and/or cardiomyopathy with a
Karnofsky Performance Status >= 50.*
Ja
Nein
If female, patient is post-menopausal, surgically
sterilized, or willing to use two acceptable
methods of birth control (i.e., a hormonal
contraceptive, intra-uterine device, diaphragm
with spermicide, condom with spermicide)
throughout the study and for 3 months from the
end of the study. (A condom alone is not
considered an acceptable method of birth
control.) If male with a female partner of
childbearing potential, willing to use two
acceptable methods of birth control for the
duration of the study. For both females and
males, acceptable birth control must be used for
at least 3 months after the last dose of study
medication.*
Ja
Nein
Patient is, in the opinion of the investigator, willing
and able to comply with the study medication
regimen and all other study requirements. *
Ja
Nein
Ausschlusskriterien
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Chronic use of non-steroidal anti-inflammatory
drugs (NSAIDs), defined as > 3-4 times/month
(ibuprofen and nimesulide will be permitted).*
Ja
Nein
Patient has primary or secondary amyloidosis.*
Ja
Nein
Patient has TTR-associated amyloidosis with
V30M mutation.*
Ja
Nein
If female, patient is pregnant or breast feeding.*
Ja
Nein
Patient has received prior liver transplantation.*
Ja
Nein
Patient is expected to undergo liver
transplantation within 12 months after
enrollment.*
Ja
Nein
Patient with positive results for hepatitis B surface
antigen (HBsAg), anti-hepatitis C virus (HCV),
and/or human immunodeficiency virus (HIV).*
Ja
Nein
Patient has renal insufficiency (creatinine
clearance < 30 ml/min).*
Ja
Nein
Patient has liver function test abnormalities:
alanine transaminases (ALT) and/or aspartate
transaminases (AST) > 2 times upper limit of
normal (ULN) that in the medical judgment of the
investigator are due to reduced liver function or
active liver disease.*
Ja
Nein
Patient has a New York Heart Association
(NYHA) Functional Classification >=  III.*
Ja
Nein
Patient has other causes of sensorimotor
neuropathy (B12 deficiency, Diabetes Mellitus,
HIV treated with retroviral medications, thyroid
disorders, alcohol abuse, and chronic
inflammatory diseases).*
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Ja
Nein
Patient has prior non-amyloid cardiac disease
such as: myocardial infarction due to obstructive
coronary artery disease, active non-amyloid
cardiomyopathy (e.g., symptomatic left ventricular
dysfunction from any cause other than amyloid,
patients with a primary diagnosis of symptomatic
valvular heart disease)*
Ja
Nein
Patient has a co-morbidity anticipated to limit
survival to < 12 months.*
Ja
Nein
Patient has received an investigational
drug/device and/or participated in another clinical
investigational study within 60 days before
Baseline (Day 0).*
Ja
Nein
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Eligibility NCT00624338 Systemic Lupus
Erythematosus, SLE
ODM derived from
http://clinicaltrials.gov/show/NCT00624338
All rights reserved. Please visit https://medical-data-
models.org/forms/4517
Eligibility
Einschlusskriterien
Alter mindestens 16 Jahre*
Ja
Nein
Disease history of at least six months meeting at
least 4 ACR criteria for SLE*
Ja
Nein
BILAG flare A or B at screening requiring a
change in corticosteroids*
Ja
Nein
a positive ANA or anti-dsDNA at screening*
Ja
Nein
Female subjects must be willing to avoid
pregnancy *
Ja
Nein
Ausschlusskriterien
Active moderate to severe glomerulonephritis
(kidney impairment)*
Ja
Nein
Active central nervous system SLE deemed to be
severe/progressive*
Ja
Nein
Previous treatment with rituximab, abatacept, or
belimumab*
Ja
Nein
History of demyelinating disease or optic neuritis*
Ja
Nein
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Eligibility NCT00625898 Breast Cancer
ODM derived from
http://clinicaltrials.gov/show/NCT00625898
All rights reserved. Please visit https://medical-data-
models.org/forms/4518
Eligibility
Einschlusskriterien
Alter mindestens 18 Jahre*
Ja
Nein
Life expectancy of at least 10 years, excluding
their diagnosis of breast cancer.*
Ja
Nein
Women who have had breast reconstruction
utilizing tissue expanders must be in agreement
with delaying surgery to replace the tissue
expanders with permanent implants until 3
months following the last dose of bevacizumab*
Ja
Nein
Women of reproductive potential must agree to
use an effective non-hormonal method of
contraception (for example condoms, some
intrauterine devices, diaphragms, vasectomized
partner, or abstinence) during therapy and for at
least 6 months after the last dose of bevacizumab
and/or trastuzumab.*
Ja
Nein
Submission of tumor samples from the breast
surgery for central HER2 testing is required for all
patients prior to enrollment in the BETH Trial*
Ja
Nein
Signed and dated IRB/EC-approved consent*
Ja
Nein
ECOG Status <= 1*
Ja
Nein
The tumor must be unilateral invasive
adenocarcinoma of the breast on histologic
examination.*
Ja
Nein
The breast cancer must be HER2-positive based
on test results as follows: Local testing (if
available) should demonstrate that the tumor is
IHC 2+ or 3+ or is considered to be HER2-
positive for gene amplification by FISH, CISH, or
other in situ hybridization (ISH) method. If local
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ISH test results are considered equivocal, the
tumor can be submitted for central HER2 testing.
(If local testing is not possible, the tumor can be
submitted for central HER2 testing.) Central
testing (a requirement for ALL patients) must
demonstrate that the tumor is HER2-positive
which is defined as FISH-positive and/or IHC 3+.*
Ja
Nein
All of the following staging criteria (according to
the 6th edition of the AJCC Cancer Staging
Manual) must be met: By pathologic evaluation,
primary tumor must be pT1-3. By pathologic
evaluation, ipsilateral nodes must be pN0, pN1
(pN1mi, pN1a, pN1b, pN1c), pN2a, pN3a, or
pN3b. If pN0, at least one of the following criteria
must be met: Pathologic tumor size > 2.0 cm. ER
negative and PgR negative. Histologic and/or
nuclear grade 2 (intermediate) or 3 (high). Or Age
< 35 years.*
Ja
Nein
Patients must have undergone either a total
mastectomy or breast conserving surgery
(lumpectomy).*
Ja
Nein
For patients who undergo lumpectomy, the
margins of the resected specimen must be
histologically free of invasive tumor and ductal
carcinoma in situ (DCIS) as determined by the
local pathologist. If pathologic examination
demonstrates tumor at the line of resection,
additional operative procedures may be
performed to obtain clear margins. If tumor is still
present at the resected margin after re-
excision(s), the patient must undergo total
mastectomy to be eligible. (Patients with margins
positive for lobular carcinoma in situ [LCIS] are
eligible without additional resection.)*
Ja
Nein
For patients who undergo mastectomy, margins
must be free of gross residual tumor. Patients
with microscopic positive margins are eligible.*
Ja
Nein
Patients must have completed one of the
following procedures for evaluation of pathologic
nodal status: Sentinel lymphadenectomy followed
by removal of additional non-sentinel lymph
nodes if the sentinel node (SN) is positive.
Sentinel lymphadenectomy alone if pathologic
nodal staging based on sentinel
lymphadenectomy is pN0, pN1mi or pN1b. Or
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Axillary lymphadenectomy without SN isolation
procedure.*
Ja
Nein
The interval between the last surgery for breast
cancer (treatment or staging) and randomization
must be at least 28 days but no more than 84
days.*
Ja
Nein
Patients must have ER analysis performed on the
primary tumor prior to randomization. If ER
analysis is negative, then PgR analysis must also
be performed.*
Ja
Nein
The most recent postoperative blood counts,
performed within 6 weeks prior to randomization,
must meet the following criteria: ANC must be >=
1200/mm3. Platelet count must be >=
100,000/mm3. And Hemoglobin must be >= 10
g/dL.*
Ja
Nein
and AST must be less than or equal to 1.5 x ULN
for the lab. Alkaline phosphatase and AST may
not both be > the ULN.*
Ja
Nein
Patients with AST or alkaline phosphatase > ULN
are eligible for inclusion in the study if liver
imaging (CT, MRI, PET scan, or PET-CT scan
performed within 3 months prior to
randomization) does not demonstrate metastatic
disease and the requirements for evidence of
adequate hepatic function are met.*
Ja
Nein
Patients with alkaline phosphatase that is > ULN
but <= 2.5 x ULN are eligible for inclusion in the
study if a bone scan,PET scan, or PET-CT scan
(performed within 3 months prior to
randomization) does not demonstrate metastatic
disease.*
Ja
Nein
The following criteria for renal function must be
met based on the results of the most recent
postoperative tests performed within 6 weeks
prior to randomization: Serum creatinine must be
<= ULN for the lab. Measured or calculated
creatinine clearance must be > 60 mL/min.*
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Ja
Nein
A urine sample must be tested for protein by
determination of the urine protein/creatinine
(UPC) ratio or by urine dipstick. UPC ratio must
be < 1.0. Urine dipstick must indicate 0-1+
protein. If dipstick reading is >= 2+, determine the
UPC ratio, which must be < 1.0, or collect a 24-
hour urine specimen, which must demonstrate <
1.0 g of protein per 24 hours.*
Ja
Nein
LVEF assessment must be performed within 3
months prior to randomization. The LVEF must
be >= 55% regardless of the cardiac imaging
facility's lower limit of normal (LLN).*
Ja
Nein
and conduction abnormality requiring a
pacemaker. *
Ja
Nein
Ausschlusskriterien
Inflammatory Breast Carcinoma, Mastitis
carcinomatosa*
Ja
Nein
Definitive clinical or radiologic evidence of
metastatic disease. (Chest imaging [mandatory
for all patients] and other imaging [if required]
must have been performed within 3 months prior
to randomization.)*
Ja
Nein
Synchronous or previous contralateral invasive
breast cancer (Patients with synchronous or
previous contralateral DCIS or LCIS are eligible).*
Ja
Nein
History of ipsilateral invasive breast cancer
regardless of treatment or ipsilateral DCIS treated
with excision and RT. (Patients with history of
ipsilateral LCIS are eligible.)*
Ja
Nein
History of non-breast malignancies within the 5
years prior to study entry, except for the following:
carcinoma in situ of the cervix, carcinoma in situ
of the colon, melanoma in situ, and basal cell and
squamous cell carcinomas of the skin.*
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Ja
Nein
Previous therapy with anthracyclines, taxanes,
carboplatin, trastuzumab, or bevacizumab for any
malignancy.*
Ja
Nein
RT, chemotherapy, and/or targeted therapy,
administered for the currently diagnosed breast
cancer prior to randomization.*
Ja
Nein
Continued therapy with any hormonal agent such
as raloxifene or tamoxifen (or other SERM) or an
aromatase inhibitor. (Patients are eligible if these
medications are discontinued prior to
randomization.)*
Ja
Nein
Any sex hormonal therapy, e.g., birth control pills,
ovarian hormone replacement therapy, etc.
Patients are eligible if these medications are
discontinued prior to randomization.*
Ja
Nein
Cardiac disease (history of and/or active disease)
that would preclude the use of the drugs included
in the treatment regimens. This includes but is
not confined to: Active cardiac disease - angina
pectoris that requires the use of anti-anginal
medication. Ventricular arrhythmias except for
benign premature ventricular contractions.
Supraventricular and nodal arrhythmias requiring
a pacemaker or not controlled with medication.
Conduction abnormality requiring a pacemaker.
Valvular disease with documented compromise in
cardiac function. And symptomatic pericarditis.
History of cardiac disease - myocardial infarction
documented by elevated cardiac enzymes or
persistent regional wall abnormalities on
assessment of LV function. History of
documented CHF. And documented
cardiomyopathy.*
Ja
Nein
Uncontrolled hypertension defined as systolic
blood pressure (BP) > 150 mmHg or diastolic BP
> 90 mmHg, with or without anti-hypertensive
medication. (BP must be assessed within 28 days
prior to randomization.) Patients with initial BP
elevations are eligible if initiation or adjustment of
BP medication lowers pressure to meet entry
criteria.*
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Ja
Nein
History of hypertensive crisis or hypertensive
encephalopathy.*
Ja
Nein
History of TIA or CVA.*
Ja
Nein
History of any arterial thrombotic event within 12
months before randomization.*
Ja
Nein
Symptomatic peripheral vascular disease*
Ja
Nein
Intrinsic lung disease resulting in dyspnea*
Ja
Nein
labiler Diabetes mellitus Typ I*
Ja
Nein
Active infection or chronic infection requiring
chronic suppressive antibiotics.*
Ja
Nein
Any significant bleeding within 6 months before
randomization, exclusive of menorrhagia in
premenopausal women.*
Ja
Nein
Non-healing wound, skin ulcers, or incompletely
healed bone fracture.*
Ja
Nein
Major surgical procedure, open biopsy, or
significant traumatic injury within 28 days prior to
planned start of study therapy.*
Ja
Nein
Anticipation of need for major surgical procedures
during study therapy and for at least 3 months
following completion of bevacizumab.*
Ja
Nein
Gastroduodenal ulcer(s) documented by
endoscopy to be active within 6 months before
randomization.*
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Eligibility NCT00625898 Breast Cancer
Ja
Nein
History of GI perforation, abdominal fistulae, or
intra-abdominal abscess.*
Ja
Nein
Known bleeding diathesis or coagulopathy.*
Ja
Nein
Requirement for therapeutic doses of coumadin
or equivalent.*
Ja
Nein
Sensory/motor neuropathy >= grade 2, as
defined by the NCI CTCAE v3.0.*
Ja
Nein
Conditions that would prohibit administration of
corticosteroids.*
Ja
Nein
Chronic daily treatment with corticosteroids (dose
of > 10 mg/day methylprednisolone equivalent)
(excluding inhaled steroids).*
Ja
Nein
History of hypersensitivity reaction to drugs
formulated with polysorbate 80.*
Ja
Nein
Pregnancy or lactation at the time of study entry.
(Note: Pregnancy testing must be performed
within 14 days prior to randomization according to
institutional standards for women of child-bearing
potential.)*
Ja
Nein
Other non-malignant systemic disease that would
preclude the patient from receiving study
treatment or would prevent required follow-up.*
Ja
Nein
Psychiatric or addictive disorders or other
conditions that, in the opinion of the investigator,
would preclude the patient from meeting the
study requirements.*
Ja
Nein
Use of any investigational product within 4 weeks
7 / 8
Eligibility NCT00625898 Breast Cancer
prior to enrollment in the study.*
Ja
Nein
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Eligibility NCT00625898 Breast Cancer
Eligibility NCT00622700 Multiple Sclerosis
ODM derived from
http://clinicaltrials.gov/show/NCT00622700
All rights reserved. Please visit https://medical-data-
models.org/forms/4523
Eligibility
Einschlusskriterien
Alter 18 bis 55 Jahre*
Ja
Nein
First acute or subacute, well-defined neurological
event consistent with demyelination (i.e. optic
neuritis confirmed by an ophthalmologist, spinal
cord syndrome, brainstem/cerebellar
syndromes),*
Ja
Nein
Onset of MS symptoms occurring within 90 days
of randomization,*
Ja
Nein
A screening MRI scan with 2 or more T2 lesions
at least 3 mm in diameter that are characteristic
of MS. *
Ja
Nein
Ausschlusskriterien
Clinically relevant cardiovascular, hepatic,
neurological, endocrine or other major systemic
disease,*
Ja
Nein
Significantly impaired bone marrow function,*
Ja
Nein
Pregnancy or nursing,*
Ja
Nein
Alcohol or drug abuse,*
Ja
Nein
Use of cladribine, mitoxantrone, or other
immunosuppressant agents such as
azathioprine, cyclophosphamide, cyclosporin,
methotrexate or mycophenolate before
enrollment*
Ja
Nein
Any known condition or circumstance that would
prevent in the investigator's opinion compliance
1 / 2
or completion of the study. *
Ja
Nein
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Eligibility NCT00622700 Multiple Sclerosis
Eligibility NCT00598442 Chronic Renal
Failure
ODM derived from
http://clinicaltrials.gov/show/NCT00598442
All rights reserved. Please visit https://medical-data-
models.org/forms/4524
Eligibility
Einschlusskriterien
Alter mindestens 18 Jahre*
Ja
Nein
Chronic Renal Failure with an estimated
glomerular filtration rate < 60 mL/min/1.73m2 and
not expected to begin dialysis for at least 12
weeks. *
Ja
Nein
Two consecutive Hgb values >=8.0 g/dL and <
11.0 g/dL within 4 weeks prior to randomization. *
Ja
Nein
Ausschlusskriterien
Females who are pregnant or breast-feeding. *
Ja
Nein
Treatment with an ESA in the 12 weeks prior to
randomization.*
Ja
Nein
Known intolerance to any ESA, parenteral iron
supplementation, or PEGylated molecule.*
Ja
Nein
Prior chronic hemodialysis or chronic peritoneal
dialysis treatment.*
Ja
Nein
Known bleeding or coagulation disorder. *
Ja
Nein
Known hematologic disease or cause of anemia
other than renal disease.*
Ja
Nein
Poorly controlled hypertension.*
Ja
Nein
Evidence of active malignancy within one year
prior to randomization*
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Ja
Nein
A scheduled kidney transplant.*
Ja
Nein
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Eligibility NCT00598442 Chronic Renal Failure
Eligibility NCT00552019 Uveitis
ODM derived from
http://clinicaltrials.gov/show/NCT00552019
All rights reserved. Please visit https://medical-data-
models.org/forms/4525
Eligibility
Einschlusskriterien
Alter mindestens 18 Jahre*
Ja
Nein
active anterior or panuveitis with
keratoprecipitates *
Ja
Nein
Ausschlusskriterien
Hornhautendotheldystrophie*
Ja
Nein
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Eligibility NCT00556270 Severe, Chronic
Pain
ODM derived from
http://clinicaltrials.gov/show/NCT00556270
All rights reserved. Please visit https://medical-data-
models.org/forms/4527
Eligibility
Einschlusskriterien
Alter mindestens 18 Jahre*
Ja
Nein
Patients with severe, chronic pain *
Ja
Nein
Ausschlusskriterien
Hypersensitivity of fentanyl*
Ja
Nein
Co-administration of monoaminooxidase-
inhibitors*
Ja
Nein
Schwangerschaft*
Ja
Nein
Atemdepression*
Ja
Nein
COPD*
Ja
Nein
Drug abuse*
Ja
Nein
Impairment of CNS functions*
Ja
Nein
Other criteria as defined in the Summary of
Product Characteristics (Fachinformation Chapter
4.3)*
Ja
Nein
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Eligibility NCT00562094 Erosive
Gastroesophageal Reflux Disease
ODM derived from
http://clinicaltrials.gov/show/NCT00562094
All rights reserved. Please visit https://medical-data-
models.org/forms/4529
Eligibility
Einschlusskriterien
Alter mindestens 12 Jahre*
Ja
Nein
GERD*
Ja
Nein
Non-erosive reflux disease (NERD)*
Ja
Nein
Ausschlusskriterien
Criteria as defined in the Summary of Product
Characteristics*
Ja
Nein
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Eligibility NCT00560651 Keratoconus
ODM derived from
http://clinicaltrials.gov/show/NCT00560651
All rights reserved. Please visit https://medical-data-
models.org/forms/4532
Eligibility
Einschlusskriterien
Patients diagnosed with keratokonus and treated
with corneal cross Linking in Germany *
Ja
Nein
Ausschlusskriterien
Non-ectatic conditions*
Ja
Nein
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Eligibility NCT00528567 Breast Cancer
ODM derived from
http://clinicaltrials.gov/show/NCT00528567
All rights reserved. Please visit https://medical-data-
models.org/forms/4538
Eligibility
Einschlusskriterien
Alter mindestens 18 Jahre*
Ja
Nein
Erwachsenenalter*
Ja
Nein
operable primary invasive breast cancer*
Ja
Nein
completed definitive loco-regional surgery*
Ja
Nein
primary tumor centrally confirmed as triple
negative. *
Ja
Nein
Ausschlusskriterien
locally advanced breast cancers*
Ja
Nein
previous breast cancer history*
Ja
Nein
clinically significant cardiovascular disease.*
Ja
Nein
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Eligibility NCT00510406 Lower Urinary
Tract Symptoms
ODM derived from
http://clinicaltrials.gov/show/NCT00510406
All rights reserved. Please visit https://medical-data-
models.org/forms/4542
Eligibility
Einschlusskriterien
Alter mindestens 45 Jahre*
Ja
Nein
male patients with LUTS associated with BPH
diagnosed > 3 months*
Ja
Nein
International prostate symptom score > 13*
Ja
Nein
voiding and storage symptoms*
Ja
Nein
Maximal urinary flow rate*
Ja
Nein
Ausschlusskriterien
post void residual volume > 200 mL*
Ja
Nein
symptomatic urinary tract infection*
Ja
Nein
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Eligibility NCT00505570 Migraine
ODM derived from
http://clinicaltrials.gov/show/NCT00505570
All rights reserved. Please visit https://medical-data-
models.org/forms/4547
Eligibility
Einschlusskriterien
Alter 18 bis 65 Jahre*
Ja
Nein
Subjects who have migraine headaches with aura
diagnosed by a doctor*
Ja
Nein
Subjects who have not responded to or cannot
take common migraine preventive medications *
Ja
Nein
Ausschlusskriterien
Subjects with a clinical history of stroke*
Ja
Nein
Subjects who cannot take aspirin and clopidogrel
(Plavix)*
Ja
Nein
Subjects who are pregnant or desire to become
pregnant within the next year*
Ja
Nein
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Eligibility NCT00502840 Rheumatoid
Arthritis
ODM derived from
http://clinicaltrials.gov/show/NCT00502840
All rights reserved. Please visit https://medical-data-
models.org/forms/4548
Eligibility
Einschlusskriterien
Alter 18 bis 75 Jahre*
Ja
Nein
adult patients with rheumatoid arthritis who
participated in ML19070, and have completed the
week 24 visit*
Ja
Nein
eligible for re-treatment (DAS28 >2.6 after week
24, swollen joint count >=4, tender joint count
>=4). *
Ja
Nein
Ausschlusskriterien
patients who have withdrawn from treatment in
ML19070 pre-week 16*
Ja
Nein
patients with a previous response in DAS28 <0.6
to MabThera after week 16*
Ja
Nein
concurrent treatment with any DMARD except for
methotrexate, any TNF alpha inhibitor, or other
biologic or investigational agent.*
Ja
Nein
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Eligibility NCT00501059 Moderate Risk of
CVD
ODM derived from
http://clinicaltrials.gov/show/NCT00501059
All rights reserved. Please visit https://medical-data-
models.org/forms/4550
Eligibility
Einschlusskriterien
Alter mindestens 55 Jahre*
Ja
Nein
Males aged 55 years and above with 2 to 4 risk
factors. Male Risk Factors:*
Ja
Nein
Elevated cholesterol (Tchol>200 mg/dL or
LDL>130 mg/dL, as measured at  screening)
irrespective of current treatment*
Ja
Nein
Current smoking: defined as any cigarette
smoking in the past 12 months*
Ja
Nein
Low HDL cholesterol (HDL<40 mg/dL, as
measured at screening)*
Ja
Nein
Elevated blood pressure (SBP>140 mmHg, as
measured at screening)*
Ja
Nein
Currently on any medication to treat high blood
pressure*
Ja
Nein
Positive family history of early CHD (a first-
degree relative [father, mother,  brother, sister,
son, daughter] suffered a heart attack [myocardial
infarction]  before the age of 60 years)*
Ja
Nein
Females aged 60 and above with 3 or more risk
factors. Female Risk Factors:*
Ja
Nein
Elevated cholesterol (Tchol>240 mg/dL or
LDL>160 mg/dL, as measured at  screening)
irrespective of current treatment*
Ja
Nein
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Current smoking: defined as any cigarette
smoking in the past 12 months*
Ja
Nein
Low HDL cholesterol (HDL<40 mg/dL, as
measured at screening)*
Ja
Nein
Elevated blood pressure (SBP>140 mmHg, as
measured at screening)*
Ja
Nein
Currently on any medication to treat high blood
pressure*
Ja
Nein
Positive family history of early CHD (a first-
degree relative [father, mother,  brother, sister,
son, daughter] suffered a heart attack [myocardial
infarction]  before the age of 60 years)*
Ja
Nein
An understanding and willingness to comply with
trial procedures and has given written informed
consent to participate in the trial *
Ja
Nein
Ausschlusskriterien
History of a documented vascular event, such as
MI, stroke, coronary artery angioplasty or
stenting, coronary artery bypass graft, relevant
arrhythmias, or congestive heart failure or
vascular intervention*
Ja
Nein
Patients who are at higher than moderate risk on
the basis of their diabetes status, other factors
known to the investigator, or the currently used
national risk score*
Ja
Nein
Known contraindications to the study drug, e.g.
hypersensitivity to acetylsalicylic acid*
Ja
Nein
Recent (in the past year) history of
gastrointestinal or genitourinary bleeding or other
bleeding disorders*
Ja
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Eligibility NCT00501059 Moderate Risk of CVD
Nein
Active diagnosed and documented reflux
esophagitis*
Ja
Nein
Patients presenting with any medical condition, or
psychiatric or substance abuse disorder, that, in
the opinion of the investigator, is likely to affect
the patient's ability to complete the study or
precludes the patient's participation in the study*
Ja
Nein
Lactating women or women of childbearing
potential*
Ja
Nein
Severe liver disease or damage based on the
clinical judgment of the investigator*
Ja
Nein
Severe renal disease or damage based on the
clinical judgement of the investigator*
Ja
Nein
A definite indication for acetylsalicylic acid
therapy, other antiplatelet drug, or anticoagulant
in the opinion of the physician*
Ja
Nein
A history of asthma induced by administration of
salicylates or substances with a similar action,
notably NSAIDS*
Ja
Nein
Chronic, frequent (> 5 days/month) use of
NSAIDs (including aspirin, or aspirin containing
products), COX-2 inhibitors or metamizole*
Ja
Nein
Current participation in any other trials involving
investigational products within 30 days prior to
the Screening Visit*
Ja
Nein
Langzeitanwendung von Antikoagulanzien*
Ja
Nein
Sitting systolic blood pressure*
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Eligibility NCT00501059 Moderate Risk of CVD
Ja
Nein
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Eligibility NCT00501059 Moderate Risk of CVD
Eligibility NCT00479557 Alzheimer Disease
ODM derived from
http://clinicaltrials.gov/show/NCT00479557
All rights reserved. Please visit https://medical-data-
models.org/forms/4552
Eligibility
Einschlusskriterien
Alter 50 bis 85 Jahre*
Ja
Nein
Diagnosis of probable Alzheimer's Disease with
Mini-Mental State Examination (MMSE) score of
16-26 (except Germany: 21-26)*
Ja
Nein
Brain MRI consistent with Alzheimer Disease*
Ja
Nein
Concurrent use of Cholinesterase inhibitor or
memantine allowed if stable*
Ja
Nein
Other inclusion criteria apply *
Ja
Nein
Ausschlusskriterien
Significant Neurological Disease other than
Alzheimer's disease*
Ja
Nein
Major psychiatric disorder*
Ja
Nein
Contraindication to undergo brain MRI*
Ja
Nein
Clinically significant systemic illness*
Ja
Nein
Other exclusion criteria apply*
Ja
Nein
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Eligibility NCT00464204 Sepsis
ODM derived from
http://clinicaltrials.gov/show/NCT00464204
All rights reserved. Please visit https://medical-data-
models.org/forms/4554
Eligibility
Einschlusskriterien
age 18 Years to N/A*
Ja
Nein
Severe sepsis*
Ja
Nein
Requirement for fluid resuscitation *
Ja
Nein
Ausschlusskriterien
Kreatinin im Serum*
Ja
Nein
Kidney Failure, Chronic*
Ja
Nein
Anurie*
Ja
Nein
Requirement for renal support*
Ja
Nein
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Eligibility NCT00244465 Narcolepsy
ODM derived from
http://clinicaltrials.gov/show/NCT00244465
All rights reserved. Please visit https://medical-data-
models.org/forms/4555
Eligibility
Einschlusskriterien
Patients who received Xyrem on prescription*
Ja
Nein
Ausschlusskriterien
No limitations*
Ja
Nein
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Eligibility NCT00246974 Bladder Cancer
ODM derived from
http://clinicaltrials.gov/show/NCT00246974
All rights reserved. Please visit https://medical-data-
models.org/forms/4556
Eligibility
Einschlusskriterien
Alter 18 Jahre und älter*
Ja
Nein
Histologically or cytologically-confirmed
transitional cell carcinoma of the urothelium*
Ja
Nein
Locally advanced or metastatic disease*
Ja
Nein
At least one measurable lesion as defined by
RECIST*
Ja
Nein
Chemotherapy-naiv*
Ja
Nein
Ausschlusskriterien
Previous chemotherapy or other systemic
antitumour therapy*
Ja
Nein
Other co-existing malignancies or malignancies
diagnosed within the last 5 years with the
exception of basal cell carcinoma, cervical cancer
in situ or locally limited prostate cancer*
Ja
Nein
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Eligibility NCT00245765 Chronic Plaque
Psoriasis
ODM derived from
http://clinicaltrials.gov/show/NCT00245765
All rights reserved. Please visit https://medical-data-
models.org/forms/4557
Eligibility
Einschlusskriterien
Alter älter als 18 Jahre*
Ja
Nein
Chronic plaque psoriasis stable for at least 3
months and moderate to severe for at least 6
months*
Ja
Nein
PASI ≥ 12 and BSA ≥ 10%*
Ja
Nein
Candidates for systemic psoriasis therapy and/or
phototherapy and/or photochemotherapy*
Ja
Nein
Ausschlusskriterien
Erythrodermic, guttate, palmar or plantar,
generalized pustular form of psoriasis*
Ja
Nein
A history of chronic infection, recent serious or
life-threatening infection (within six months,
including herpes zoster), or any current sign or
symptom that may indicate an infection (e.g.
fever, cough)*
Ja
Nein
Leukozyten-Anzahl*
Ja
Nein
Suspected or diagnosed demyelinating disease
of the central nervous system (e.g. multiple
sclerosis or optic neuritis)*
Ja
Nein
systemischer Lupus erythematodes*
Ja
Nein
Non respect of adequate wash out periods for
treatments that might have an impact on the
disease*
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Ja
Nein
Any associated disease that could be impacted
by the study treatment intake*
Ja
Nein
Any other condition, which in the Investigator's
judgment would make the subject unsuitable for
inclusion in the study*
Ja
Nein
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Eligibility NCT00245765 Chronic Plaque Psoriasis
Eligibility NCT00242801 NSCLC
ODM derived from
http://clinicaltrials.gov/show/NCT00242801
All rights reserved. Please visit https://medical-data-
models.org/forms/4558
Eligibility
Einschlusskriterien
Alter 18 Jahre und älter*
Ja
Nein
Life expectancy of at least 8 weeks.
Histologically or cytologically confirmed non-small
cell bronchogenic carcinoma: adenocarcinoma
(including bronchoalveolar), squamous cell
carcinoma, large cell carcinoma or mixed
(adenocarcinoma and squamous) or
undifferentiated carcinoma.                           Not
suitable for chemotherapy.               WHO
Performance status <=3.  *
Ja
Nein
Ausschlusskriterien
Newly diagnosed CNS mets*
Ja
Nein
<1 week since completion of prior radiotherapy or
persistence of any radiotherapy related toxicity*
Ja
Nein
ALT/AST >5 x upper limit of normal*
Ja
Nein
ANC <1.0 x 109/L or platelets <100 x 109/L*
Ja
Nein
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Eligibility NCT00241540 GERD
ODM derived from
http://clinicaltrials.gov/show/NCT00241540
All rights reserved. Please visit https://medical-data-
models.org/forms/4560
Eligibility
Einschlusskriterien
Alter 18 Jahre oder älter*
Ja
Nein
Capable of completing the diary card*
Ja
Nein
Ability to complete the HRQL questionnaires*
Ja
Nein
A clinical diagnosis of a chronic condition (e.g.,
osteoarthritis or rheumatoid arthritis) that
requires continuous daily NSAID treatment for at
least 7 months.*
Ja
Nein
Daily NSAID treatment is defined as taking the
prescribed dose for at least 5 of 7 days in any
given week and can include COX-2 selective
NSAIDs, multiple NSAIDs, and high-dose aspirin
(>325 mg/day).*
Ja
Nein
Daily NSAID treatment dose and type: (Must
have been stable for at least 4 weeks prior to
baseline endoscopy and. Are expected to remain
stable for the duration of the study. and. Must be
administered orally for the duration of the study. If
more than one type of NSAID treatment is used,
at least one type must be given orally).*
Ja
Nein
Ausschlusskriterien
Current, or history of, gastric or duodenal ulcer*
Ja
Nein
Current, or history of, esophageal, gastric or
duodenal surgery.*
Ja
Nein
History of GERD, not associated with NSAID
use.*
Ja
Nein
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Pain, discomfort or burning in the upper abdomen
precipitated by exercise or relieved by
defecation.*
Ja
Nein
Pain, discomfort or burning in the upper abdomen
not associated with the use of NSAIDs, including
COX-2 selective NSAIDs, as judged by the
investigator.*
Ja
Nein
Endoscopic Barrett's esophagus(>3 cm) or
significant dysplastic changes in the esophagus*
Ja
Nein
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Eligibility NCT00241540 GERD
Eligibility NCT00241514 GERD
ODM derived from
http://clinicaltrials.gov/show/NCT00241514
All rights reserved. Please visit https://medical-data-
models.org/forms/4561
Eligibility
Einschlusskriterien
Alter 18 Jahre und älter*
Ja
Nein
Signed informed consent.*
Ja
Nein
Completed the SH-NEN-0001 study with relief of
upper GI symptom. Relief is defined as "last 7
days with a diary assessment of None or
Minimal, but allowing up to 2 days to be rated as
Mild during the 7-day period".*
Ja
Nein
A clinical diagnosis of a chronic condition (e.g.,
osteoarthritis or rheumatoid arthritis) that
requires continuous daily NSAID treatment for at
least 6 months. Daily NSAID treatment is defined
as taking the prescribed dose for at least 5 of 7
days in any given week and can include COX-2
selective NSAIDs, multiple NSAIDs, and high-
dose NSAIDs.*
Ja
Nein
Daily NSAID treatment dose and type: (Must
have been stable for at least 9 weeks prior to
inclusion and. Are expected to remain stable for
the duration of the study. and. Must be
administered orally. If more than one type of
NSAID treatment is used, at least one type must
be administered orally).*
Ja
Nein
Hp negative on Histology performed at baseline
endoscopy in the study SHNEN- 0001.*
Ja
Nein
Ausschlusskriterien
Discontinuation from study SH-NEN-0001*
Ja
Nein
Pain, discomfort or burning in the upper abdomen
precipitated by exercise or relieved by
defecation.*
Ja
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Nein
Pain, discomfort or burning in the upper abdomen
not associated with the use of NSAIDs, including
COX-2 selective NSAIDs.*
Ja
Nein
Pregnancy or lactation. Women of childbearing
potential must maintain effective contraception
during the study period as judged by the
investigator.*
Ja
Nein
Need for continuous concomitant therapy with:
(Anticoagulants, Corticosteroids at doses higher
than explained under inclusion criterion)*
Ja
Nein
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Eligibility NCT00241514 GERD
Eligibility NCT00240474 Hypertension
ODM derived from
http://clinicaltrials.gov/show/NCT00240474
All rights reserved. Please visit https://medical-data-
models.org/forms/4562
Eligibility
Einschlusskriterien
Alter 60 Jahre und älter*
Ja
Nein
mean SBP >140 mmHg and mean DBP <=95
mmHg*
Ja
Nein
24-hour mean ambulatory SBP >125 mmHg*
Ja
Nein
hypertensive patients not on current
antihypertensive therapy or able to stop their
current treatment for a period of up to eighteen
weeks*
Ja
Nein
willing and able to provide written informed
consent*
Ja
Nein
Ausschlusskriterien
women of child-bearing potential who are NOT
practicing acceptable means of birth control*
Ja
Nein
known or suspected secondary hypertension*
Ja
Nein
mean SBP >=200 mmHg*
Ja
Nein
hepatic and/or renal dysfunction as defined by
the following laboratory parameters:
Bilateral renal artery stenosis, renal artery
stenosis in a solitary kidney, patients post-renal
transplant or with only one functioning kidney.
Clinically relevant hypokalemia or hyperkalemia.
Uncorrected volume or sodium depletion.*
Ja
Nein
Primary aldosteronism, unspecified*
Ja
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Nein
Hereditary fructose intolerance syndrome*
Ja
Nein
biliärer Verschluss, Gallen(wegs)verschluss*
Ja
Nein
patients who have previously experienced
symptoms characteristic of angioedema during
treatment with ACE inhibitors or angiotensin-II
receptor antagonists*
Ja
Nein
history of drug or alcohol dependency within the
previous six months*
Ja
Nein
chronic administration of any medication known
to affect blood pressure, other than the trial
medication*
Ja
Nein
concurrent participation in another clinical trial or
any investigational therapy within thirty days prior
to signing the consent form.*
Ja
Nein
symptomatic congestive heart failure (New York
Heart Academy (NYHA) functional class CHF II-
IV)*
Ja
Nein
unstable angina pectoris, myocardial infarction,
percutaneous transluminal coronary angioplasty
(PTCA) or coronary artery bypass graft (CABG)
surgery <3 months prior to informed consent*
Ja
Nein
stroke <6 months prior to informed consent*
Ja
Nein
sustained ventricular tachycardia, atrial
fibrillation, atrial flutter or other clinically relevant
arrhythmias as determined by the investigator*
Ja
Nein
hypertrophic obstructive cardiomyopathy,
hemodynamically relevant stenosis of the aortic
or mitral valve*
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Eligibility NCT00240474 Hypertension
Ja
Nein
insulin-dependent diabetes mellitus whose
diabetes has not been stable and controlled for
the previous three months*
Ja
Nein
night-shift workers who routinely sleep during the
daytime and whose working hours include
midnight to 4:00 AM*
Ja
Nein
known allergic hypersensitivity to any component
of the formulations under investigation*
Ja
Nein
concomitant therapy with lithium, cholestyramine
or colestipol resins. non-compliance with study
medication (defined as  <80% or >120%) during
the run-in period*
Ja
Nein
current treatment with any antihypertensive
agent*
Ja
Nein
any other clinical condition which, in the opinion
of the investigator, would not allow safe
completion of the protocol and safe
administration of telmisartan, amlodipine or
hydrochlorothiazide*
Ja
Nein
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Eligibility NCT00240474 Hypertension
Eligibility NCT00332852 Breast Cancer
ODM derived from
http://clinicaltrials.gov/show/NCT00332852
All rights reserved. Please visit https://medical-data-
models.org/forms/4563
Eligibility
Einschlusskriterien
Alter 18 Jahre und älter, weiblich*
Ja
Nein
Compliant postmenopausal women with primary
operable breast cancer after complete surgery
and suitable for endocrine treatment*
Ja
Nein
Nodal status negative or positive*
Ja
Nein
Good Health status <=2 (Eastern Cooperative
Oncology Group)*
Ja
Nein
Estrogen- and/or progesterone-receptor positive*
Ja
Nein
Adequate marrow, kidney and liver function*
Ja
Nein
Ausschlusskriterien
Metastatic or inflammatory breast cancer*
Ja
Nein
Patients with previous or concomitant cancers
(not breast cancer) within the past 5 years
EXCEPT adequately treated basal or squamous
cell skin cancer or in situ cancer of the cervix.
Patients with other previous cancers must have
been disease-free for at least 5 years and
Patients with uncontrolled, non-malignant
systemic cardiovascular, kidney, and liver
diseases.*
Ja
Nein
Current/active dental problems including infection
of the teeth or jawbone, dental or fixture trauma,
or a current or prior diagnosis of osteonecrosis of
the jaw, of exposed bone in the mouth, or of slow
healing after dental procedures.*
Ja
Nein
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Recent (within 6 weeks) or planned dental or jaw
surgery*
Ja
Nein
Patients with primary overactive parathyroid*
Ja
Nein
Patients with a known hypersensitivity to
zoledronic acid or other bisphosphonates.*
Ja
Nein
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Eligibility NCT00332852 Breast Cancer
Eligibility NCT00385372 Urticaria
ODM derived from
http://clinicaltrials.gov/show/NCT00385372
All rights reserved. Please visit https://medical-data-
models.org/forms/4564
Eligibility
Einschlusskriterien
age 7 Years to 80 Years*
Ja
Nein
signed informed consent*
Ja
Nein
chronic urticaria (duration: at least 6 weeks)*
Ja
Nein
patients who suffered from urticaria and/or angio
oedema at least once a week for a duration of at
least 4 weeks)*
Ja
Nein
Males and females, age between 7 and 80 years*
Ja
Nein
inpatients and outpatients*
Ja
Nein
oral antihistamines and glucocorticosteroids are
allowed as concomitant medication (if needed) *
Ja
Nein
Ausschlusskriterien
pregnant or breastfeeding woman*
Ja
Nein
patients suffering from diabetes mellitus*
Ja
Nein
patients with cachexia*
Ja
Nein
known food allergies of food which will be
administrated within the elimination diet (e.g.
milk, cereals)*
Ja
Nein
isolated urticaria with known aetiology (e.g.
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physical urticaria, aquagene urticaria, urticaria
factitia, cholinergic urticaria), Urticaria
pigmentosa mastocytoses)*
Ja
Nein
patients, seemed to be uncompliant under
suspicion of the investigator*
Ja
Nein
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Eligibility NCT00385372 Urticaria
Eligibility NCT00384046 Hypoactive Sexual
Desire Disorder
ODM derived from
http://clinicaltrials.gov/show/NCT00384046
All rights reserved. Please visit https://medical-data-
models.org/forms/4566
Eligibility
Einschlusskriterien
age 40 Years to 70 Years*
Ja
Nein
Women will be screened for study participation
according to the following inclusion criteria at
Week -4. Eligible women must be a woman one
year post menopausal, 40-70 years old in general
good health on transdermal HRT and in a stable
monogamous sexual relationship with low sexual
desire causing distress. *
Ja
Nein
Ausschlusskriterien
Women will be screened for study participation
according to the following exclusion criteria at
Week -4 or as specified. Eligible women must not
have any medical, physical, psychological, or
pharmacological condition that could confound
safety or efficacy.*
Ja
Nein
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Eligibility NCT00329303 Psoriasis
ODM derived from
http://clinicaltrials.gov/show/NCT00329303
All rights reserved. Please visit https://medical-data-
models.org/forms/4568
Eligibility
Einschlusskriterien
Alter bis 18 Jahre *
Ja
Nein
Subject having responded to treatment in study
C87040 and having relapsed during the follow-up
period.*
Ja
Nein
Ausschlusskriterien
Erythrodermic, guttate, palmar or plantar,
generalized pustular form of psoriasis*
Ja
Nein
A history of chronic infection, recent serious or
life-threatening infection (within six months,
including herpes zoster), or any current sign or
symptom that may indicate an infection (e.g.
fever, cough)*
Ja
Nein
Leukozyten-Anzahl*
Ja
Nein
Suspected or diagnosed demyelinating disease
of the central nervous system (e.g. multiple
sclerosis or optic neuritis)*
Ja
Nein
systemischer Lupus erythematodes*
Ja
Nein
Non respect of adequate wash out periods for
treatments that might have an impact on the
disease*
Ja
Nein
Any associated disease that could be impacted
by the study treatment intake*
Ja
Nein
Any other condition, which in the Investigator's
judgment would make the subject unsuitable for
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inclusion in the study*
Ja
Nein
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Eligibility NCT00329303 Psoriasis
Eligibility NCT00376337 Invasive
Aspergillosis
ODM derived from
http://clinicaltrials.gov/show/NCT00376337
All rights reserved. Please visit https://medical-data-
models.org/forms/4569
Eligibility
Einschlusskriterien
age >=18 Years*
Ja
Nein
Adult patients with HSCT, acute leukaemia or
myelodysplastic syndrome, with proven (probable
only in case of pulmonary aspergillosis) invasive
aspergillosis and refractory or intolerant to
amphotericin B or voriconazole products *
Ja
Nein
Ausschlusskriterien
Patients with allergic bronchopulmonary
aspergillosis, chronic pulmonary aspergillosis,
aspergilloma, sinus aspergillosis or external
otitis*
Ja
Nein
patient with previous salvage therapy for the
current episode of fungal infection*
Ja
Nein
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Eligibility NCT00327379 Postoperative
Hemorrhage
ODM derived from
http://clinicaltrials.gov/show/NCT00327379
All rights reserved. Please visit https://medical-data-
models.org/forms/4570
Eligibility
Einschlusskriterien
Alter >=18 Jahre*
Ja
Nein
Subjects requiring elective spinal fusion surgery
involving 3 to 7 vertebral levels with
instrumentation. One vertebral level is defined as
encompassing two vertebral bodies and one
inter-vertebral disc space, so that a contiguous
spinal fusion involving 3 vertebral levels would
include 4 vertebral bodies and 3 inter-vertebral
disc spaces.*
Ja
Nein
Ausschlusskriterien
Subjects with previous exposure to aprotinin in
the last 6 months. If the subject has undergone
cardiac surgery in the last 6 months, all attempts
should be made to ascertain if aprotinin was
administered during cardiac surgery. If no records
are available, or if the subject received aprotinin,
the subject should be excluded.*
Ja
Nein
Subjects with a known or suspected allergy to
aprotinin.*
Ja
Nein
Subjects with sepsis or a known bone infection.*
Ja
Nein
Personal history of malignant neoplasm of bone*
Ja
Nein
Subjects with a creatinine clearance <30mL/min
as calculated by the Cockcroft-Gault formula.*
Ja
Nein
Subjects with a history of bleeding diathesis or
known coagulation factor deficiency.*
Ja
Nein
Subjects with failure of a major organ system or
any active significant medical illness that in the
opinion of the Investigator is likely to affect the
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subject's ability to complete the study or
precludes the subject's participation in the study.*
Ja
Nein
Subjects who refuse to receive allogenic blood
products for religious or other reasons.*
Ja
Nein
Subjects whose preoperative red blood cell
volume is so low that a blood transfusion would
be likely to be given perioperatively (preoperative
hematocrit or hemoglobin values <24% or <8
g/dl, respectively).*
Ja
Nein
Subjects who have participated in an
investigational drug study within the past 30
days.*
Ja
Nein
Subjects with a history of deep vein thrombosis
or pulmonary embolism.*
Ja
Nein
Subjects who are pregnant or breast feeding.*
Ja
Nein
Women of childbearing potential in whom the
possibility of pregnancy cannot be excluded by a
negative serum pregnancy test at screening.*
Ja
Nein
Women of childbearing potential who are not
using a reliable method of contraception.*
Ja
Nein
Antifibrinolytikum*
Ja
Nein
Subjects on chronic anticoagulant treatment with
Vit K antagonists that cannot be temporarily
discontinued for the surgical procedure (as per
local practices).*
Ja
Nein
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Eligibility NCT00327379 Postoperative Hemorrhage
Eligibility NCT00372229 Cytomegalovirus
Infections
ODM derived from
http://clinicaltrials.gov/show/NCT00372229
All rights reserved. Please visit https://medical-data-
models.org/forms/4572
Eligibility
Einschlusskriterien
Alter>=18 Jahre*
Ja
Nein
primary or secondary renal allograft within
preceding 14 days*
Ja
Nein
IgG seropositive for CMV*
Ja
Nein
receiving immunosuppressive therapy*
Ja
Nein
Ausschlusskriterien
active CMV infection*
Ja
Nein
current/history of malignancy*
Ja
Nein
acute steroid resistant rejection episode since
transplantation.*
Ja
Nein
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Eligibility NCT00144079 # Thyroid
Carcinoma
The trial examines the clinical benefit of adjuvant external
beam radiotherapy (RTx) for
locally invasive differentiated carcinoma (TNM stages pT4
pN0/1/x M0/x; 5th ed. 1997) of the
thyroid gland (DTC). Patients are treated with surgery
(thyroidectomy and lymphadenectomy),
radioiodine therapy (RIT) to ablate the thyroid remnant
tissue, and TSH-suppressive
L-thyroxine therapy with or without RTx after documented
elimination of cervical I-131
uptake.
All rights reserved. Please visit https://medical-data-
models.org/forms/4574
Eligibility
Inclusion criteria
18 Years to 69 Years*
Yes
No
No Healthy Volunteers*
Yes
No
papillary or follicular thyroid carcinoma pT4
pN0/1/x M0/x*
Yes
No
completion of primary surgical therapy with R0
(no tumor residues) or R1 (microscopic residues)
resection*
Yes
No
Karnofsky index > 70 %*
Yes
No
freedom from distant metastases at the time of
initial radioiodine therapy*
Yes
No
informed patient consent*
Yes
No
Exclusion criteria
secondary malignancy except basalioma*
Yes
No
pregnancy*
Yes
No
serious general disease*
Yes
No
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serious psychiatric disorder*
Yes
No
inability to give informed consent*
Yes
No
previous RTx*
Yes
No
recurrence of previous thyroid cancer*
Yes
No
Medical Concepts
Age*
Healthy Subject*
Papillary thyroid carcinoma*
Follicular thyroid carcinoma*
pT4 Stage Finding*
cancer surgery*
Karnofsky Performance Status*
Neoplasm Metastasis*
Thyroid tumor/metastasis irradiation*
Informed Consent*
Secondary malignancy, unspecified site*
Basal cell carcinoma*
Patient currently pregnant*
Disease*
Mental disorders*
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Eligibility NCT00144079 # Thyroid Carcinoma
Therapeutic radiology procedure*
Recurrent Thyroid Gland Carcinoma*
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Eligibility NCT00144079 # Thyroid Carcinoma
Eligibility NCT00144287 # HIV-1 Infection
This study evaluated the safety and tolerability of tipranavir
to improve treatment options
for HIV type 1-infected patients who have been previously
treated and whose treatment is no
longer effective.
All rights reserved. Please visit https://medical-data-
models.org/forms/4575
Eligibility
Inclusion criteria
No Healthy Volunteers*
Yes
No
Triple antiretroviral class experienced patients
with at least two previous PI-based
regimens, who had failed or are intolerant to
currently approved HIV-1 treatments
*
Yes
No
Age >= 18 years*
Yes
No
Patient is willing to use an effective barrier
method of contraception for the
duration of study participation and up to three
months thereafter
*
Yes
No
Patient voluntarily provides written informed
consent to participate, in compliance with local
law*
Yes
No
Exclusion criteria
Hypersensitivity to active ingredients or any of the
excipients in tipranavir or ritonavir*
Yes
No
Required use of restricted medications*
Yes
No
Female patients of childbearing potential who:
-  Have a positive pregnancy test at baseline or
-  Are breast feeding.
*
Yes
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No
Any medical condition(s) which, in the opinion of
the investigator, would interfere
with the patient´s ability to participate in or
adhere to the requirements of this
protocol.
*
Yes
No
Use of other investigational drugs, within 30 days
prior to TPV/r initiation and for
the duration of study participation.
*
Yes
No
Hepatic impairment(*) evidenced by the following
baseline laboratory findings:
-  AST or ALT >5X upper limit of normal (ULN) or
total bilirubin >3.5X ULN or
-  AST or ALT >2.5X ULN and total bilirubin >2X
ULN
(*) Patients with liver enzymes outside this range
will be restricted from participation
in this safety study until more data become
available from ongoing phase III clinical
studies.
*
Yes
No
Medical Concepts
Healthy Subject*
AIDS PATIENT*
Antiretroviral therapy*
Proteinase inhibitor*
Anti-HIV Therapy*
Age*
Contraceptive methods*
Informed Consent*
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Eligibility NCT00144287 # HIV-1 Infection
Drug Allergy*
Tipranavir*
Ritonavir*
Restriction*
Pharmaceutical Preparations*
Positive Pregnancy Test*
Breast Feeding*
Investigator*
Investigational New Drug*
Tipranavir+Ritonavir*
Liver Dysfunction*
Aspartate Transaminase*
Aspartate
aminotransferase:CCnc:Pt:Ser/Plas:Qn*
Alanine Transaminase*
Alanine aminotransferase:CCnc:Pt:Ser/Plas:Qn*
Blood bilirubin total*
Bilirubin:MCnc:Pt:Ser/Plas:Qn*
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Eligibility NCT00144287 # HIV-1 Infection
Eligibility NCT00148148 # Stem-Cell
Transplantation
The study compares the safety, efficacy and
pharmacokinetics of caspofungin, liposomal
amphotericin B or the combination of both in the antifungal
treatment of adult patients
after allogeneic haematopoietic stem-cell transplantation
with granulocytopenia and
persistent i.g. recurrent fever under adequate antibacterial
therapy.
All rights reserved. Please visit https://medical-data-
models.org/forms/4576
Eligibility
Inclusion criteria
18 Years and older*
Yes
No
Male*
Yes
No
No Healthy Volunteers*
Yes
No
Adults (> or = 18 years of age) with
granulocytopenia (absolute number of neutrophil
granulocytes [ANC]: < or = 500/µL) who have
undergone allogeneic haematopoeitic stem
cell transplantation and immunosuppression with
cyclosporin A*
Yes
No
Patients with persistent or recurrent fever (oral
temperature > or = 38.0°C) and
granulocytopenia (absolute neutrophil count < or
= 500/µL) and adequate antibacterial
therapy for > or = 36-48 hours, who need
empirical antimycotic therapy*
Yes
No
Already inserted at least double-lumen central
venous catheter for administration of drugs and
extraction of plasma samples*
Yes
No
Sufficient renal and hepatic function*
Yes
No
Availability of negative pregnancy test and
adequate contraceptive measures for female
patients of childbearing age*
Yes
No
Availability  of written informed consent from the
patient or respectively from the legal
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representative after prior information*
Yes
No
Exclusion criteria
Patients with active, possible or proven (MSG-
EORTC criteria) invasive fungal infection at time
of enrollment*
Yes
No
Patients with pathological functional renal or
hepatic parameters*
Yes
No
Patients with clinical or laboratory chemical
evidence of active veno-occlusive disease (VOD)*
Yes
No
Hemodynamically unstable patients with a life
expectancy of less than 5 days*
Yes
No
Patients undergoing co-medication with
rifampicin, phenytoin, carbamazepine,
phenobarbital, dexamethasone, efavirenz and
nevirapine*
Yes
No
Patients with prior known serious reaction to
echinocandin-antifungal formulation or
documented allergy to amphotericin B*
Yes
No
Patients with other condition or illness which, in
the estimation of the investigator, distorts the
study results or leads to an additional risk for the
patient*
Yes
No
Prior inclusion in the study*
Yes
No
Medical Concepts
Age*
Gender*
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Eligibility NCT00148148 # Stem-Cell Transplantation
Healthy Subject*
Neutropenia*
Absolute Neutrophil Count*
Low peripheral neutrophil counts (absolute
neutrophil count less than 500/microliter)*
Allogeneic Hematopoietic Stem Cell
Transplantation*
Immunosuppressive therapy for transplant*
Cyclosporine*
Fever*
Continuous fever*
Intermittent Pyrexia*
Systemic antibacterial therapy*
Catheterization, Central Venous*
Normal renal function*
Normal liver function*
Negative Pregnancy Test*
Contraceptive methods*
Informed Consent*
Invasive mycosis*
Abnormal renal function*
Liver Dysfunction*
Venoocclusive disease*
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Eligibility NCT00148148 # Stem-Cell Transplantation
Hemodynamic instability*
Life Expectancy*
Rifampin*
Phenytoin*
Carbamazepine*
Phenobarbital*
Dexamethasone*
Efavirenz*
Nevirapine*
Investigator*
Enrollment*
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Eligibility NCT00148148 # Stem-Cell Transplantation
Eligibility NCT00148161 # Stuttering
The goal of the study is to examine the cortical activity
during speech perception and
speech production in idiopathic stutterers compared to
fluent speakers. Therefore, the
noninvasive method of magnetoencephalography (MEG) is
used. A better understanding for the
complexity of speech perception and its pathology should
be developed.
Fundamental properties of stuttering are repetitions,
prolongations, and blocks. In most
cases stuttering emerges between 2 and 5 years of age.
The auditory feedback should become
less important during development, as soon as information
about mispronounced words does not
occur  anymore. During speech development this control
function should be adopted by other
systems. In stutterers the dominance of the acoustic control
should remain.
Brain imaging studies with positron emission tomography
(PET) or magnetic resonance imaging
(MRI) show defects in the network of motor system, in the
lateralization of speech areas,
and functions of the auditory cortex.
Magnetoencephalographic studies describe a similar
variety as cause of stuttering. There may be defects in the
auditory feedback, a
modification of the lateralization of speech areas, or an
alteration of co-action of motor
planning and auditory system.
The benefit of magnetoencephalography is a very good
temporal resolution in the range of
milliseconds combined with good spatial resolution.
Therefore, it is well suited to examine
the dynamics of cortical processing during stuttering. In this
study evoked components of
the auditory systems related to complex sounds, vocals,
consonant-vocal combinations, and
single words are analyzed. Differences of these
components in the auditory cortices of
stutterers and fluent speakers are hypothesized as well in
temporal structure as in
localization and lateralization.
All rights reserved. Please visit https://medical-data-
models.org/forms/4577
Eligibility
Inclusion criteria
18 Years and older*
Yes
No
Male*
Yes
No
Accepts Healthy Volunteers*
Yes
No
Subjects with idiopathic stuttering (for the group
of stutterers)*
Yes
No
Fluently speaking subjects (for the control group)*
Yes
No
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Right handed*
Yes
No
Normal hearing*
Yes
No
Exclusion criteria
Neurological diseases*
Yes
No
Psychiatric diseases*
Yes
No
Medication with neurological effective drugs*
Yes
No
Implants with magnetic impact*
Yes
No
Medical Concepts
Age*
Gender*
Healthy Subject*
stuttering*
Primary stuttering*
Right handed*
Hearing normal*
nervous system disorder*
Mental disorders*
Central Nervous System Agents*
Implant*
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Eligibility NCT00148161 # Stuttering
Eligibility NCT00071084 T-Cell Lymphoma
DEPRECATED old version
All rights reserved. Please visit https://medical-data-
models.org/forms/4579
Eligibility
Inclusion criteria
Medical diagnosis of CTCL, and positivity for the
CD4 receptor*
Yes
No
Late stage CTCL*
Yes
No
Have received at least one prior anti-cancer
therapy with inadequate effect*
Yes
No
WHO performance status 0,1 or 2*
Yes
No
Age 18 or older*
Yes
No
Exclusion criteria
Certain rare types of CTCL*
Yes
No
Previous treatment with other anti-CD4
medications*
Yes
No
More than two previous treatments with systemic
chemotherapy*
Yes
No
Certain anti-psoriasis or anti-cancer therapies
within the last 4 weeks before entering this trial*
Yes
No
Some types of steroid treatments less than two
weeks before entering the trial*
Yes
No
Prolonged exposure to sunlight or UV light during
the trial*
Yes
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No
Other cancer diseases, except certain skin
cancers or cervix cancer*
Yes
No
Chronic infectious disease requiring medication*
Yes
No
Certain serious medical conditions, including
kidney or liver disease, some psychiatric
illnesses, and stomach, lung, heart, hormonal,
nerve or blood diseases*
Yes
No
Certain laboratory values which are too high or
too low*
Yes
No
HIV positivity*
Yes
No
Pregnant or breast-feeding women*
Yes
No
Women of childbearing age who are unable or
unwilling to use an IUD or hormonal birth control
during the whole trial*
Yes
No
If you are participating in another trial with a
different new drug 4 weeks before you enter this
trial*
Yes
No
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Eligibility NCT00071084 T-Cell Lymphoma
Eligibility NCT00087646 Hepatitis C
A Randomized, Open-label Study of the Effect of
PEGASYS Combined With Ribavirin on Sustained Virologic
Response in Patients With Chronic Hepatitis C Who Did
Not Respond to Previous Pegintron/Ribavirin Combination
Therapy
Inclusion Criteria
- adult patients >=18 years of age
- CHC infection
- liver biopsy (in <24 calendar months of first dose), with
results consistent with CHC infection
- use of 2 forms of contraception during study and 6
months after the study in both men and women
- Lack of response to previous treatment with peginterferon
alfa-2b (12KD)/ribavirin combination therapy given for >=12
weeks
Exclusion Criteria
- women who are pregnant or breastfeeding
- male partners of women who are pregnant
- conditions associated with decompensated liver disease
- other forms of liver disease, including liver cancer
- human immunodeficiency virus infection
All rights reserved. Please visit https://medical-data-
models.org/forms/4580
Eligibility
Inclusion criteria
adult patients >=18 years of age*
Yes
No
CHC infection*
Yes
No
liver biopsy (in <24 calendar months of first
dose), with results consistent with CHC infection*
Yes
No
use of 2 forms of contraception during study and
6 months after the study in both men and
women*
Yes
No
Lack of response to previous treatment with
peginterferon alfa-2b (12KD)/ribavirin
combination therapy given for >=12 weeks*
Yes
No
Exclusion criteria
women who are pregnant or breastfeeding*
Yes
No
male partners of women who are pregnant*
Yes
No
conditions associated with decompensated liver
disease*
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Yes
No
other forms of liver disease, including liver
cancer*
Yes
No
human immunodeficiency virus infection*
Yes
No
Medical Concepts
Age*
Diagnosis*
Chronic hepatitis C*
Diagnostic procedure*
Contraception*
Medication*
pregnant*
Breast feeding*
Advanced chronic liver disease*
HIV negative*
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Eligibility NCT00087646 Hepatitis C
Eligibility NCT00078338 Multiple Sclerosis
Rebif(R) Versus Copaxone(R) in the Treatment of
Relapsing Remitting Multiple Sclerosis
https://clinicaltrials.gov/ct2/show/NCT00078338
All rights reserved. Please visit https://medical-data-
models.org/forms/4581
Eligibility
Inclusion criteria
Be between 18 and 60 years of age*
Yes
No
Have definite relapsing multiple sclerosis.
Have had one or more relapses within the prior
12 months*
Yes
No
Must be in a clinically stable or improving
neurological state during the four weeks prior to
Study Day 1*
Yes
No
EDSS score from 0 to 5.5, inclusive *
Yes
No
If female, she must either be post-menopausal or
surgically sterilized; or use a hormonal
contraceptive, intra uterine device, diaphragm
with spermicide, or condom with spermicide, for
the duration of the study; and be neither pregnant
nor breast-feeding. Confirmation that the subject
is not pregnant must be established by a negative
serum hCG pregnancy test within 7 days of Study
Day 1 and a negative urine pregnancy test on
Study Day 1. A pregnancy test is not required if
the subject is post-menopausal or surgically
sterilized*
Yes
No
Exclusion criteria
Have secondary progressive MS or primary
progressive MS*
Yes
No
Prior use of any interferon or glatiramer acetate*
Yes
No
Have had treatment with oral or systemic
corticosteroids or ACTH within 4 weeks of Study
Day 1 and within 7 days prior to the Day 1 MRI*
Yes
No
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Have a psychiatric disorder that is unstable or
would preclude safe participation in the study*
Yes
No
Have significant leukopenia (white blood cell
count < 0.5 times the lower limit of normal of the
central laboratory) within 7 days of Study Day 1*
Yes
No
Have elevated liver function tests (AST, ALT,
alkaline phosphatase > 2.0 times the upper limit
of normal (ULN) of the central laboratory, or total
bilirubin > 1.5 times the ULN of the central
laboratory) within 7 days of Study Day 1 or a
history of hepatitis (including infectious or drug-
induced)
*
Yes
No
Prior cytokine or anti-cytokine therapy within 3
months prior to Study Day 1
*
Yes
No
Prior use of immunomodulatory or
immunosuppressive therapy (including but not
limited to cyclophosphamide, cyclosporin,
methotrexate, azathioprine, linomide,
mitoxantrone) within the 12 months prior to Study
Day 1*
Yes
No
Prior use of cladribine or have received total
lymphoid irradiation*
Yes
No
Have allergy or hypersensitivity to human serum
albumin, mannitol, glatiramer acetate, natural or
recombinant interferon-β, or any other
components of the study drugs or gadolinium
DTPA*
Yes
No
Have taken intravenous immunoglobulin or any
other investigational drug or taken part in any
experimental procedure in the 6 months prior to
Study Day 1*
Yes
No
Presence of systemic disease that might interfere
with subject safety, compliance or evaluation of
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Eligibility NCT00078338 Multiple Sclerosis
the condition under study (e.g. insulin-dependent
diabetes, Lyme disease, clinically significant
cardiac disease, HIV, HTLV-1)*
Yes
No
Have had plasma exchange in 3 months prior to
Study Day 1*
Yes
No
Medical Concepts
Age*
Diagnosis*
Relapsing-remitting multiple sclerosis*
EDSS - Expanded disability status scale*
pregnant*
Breast feeding*
Serum HCG Measurement*
Progressive multiple sclerosis*
Medication*
Therapeutic Corticosteroid*
White blood cell count*
Aspartate Transaminase (AST) = Glutamate
oxaloacetate transaminase (GOT)*
Alanine Transaminase (ALT) = glutamate
pyruvate transaminase (GPT)*
Alkaline phosphatase (AP)*
Bilirubin*
Hepatitis*
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Eligibility NCT00078338 Multiple Sclerosis
Unerwünschtes Ereignis (AE) - Blatt Nr.: 1 EudraCT-Nr 2008-004583-
40 Akute myeloische Leukämie(AML) AML alle außer FAB M3
A randomized, multi-center phase II trial to assess the
efficacy of 5-azacytidine added to standard primary therapy
in elderly patients with newly diagnosed AML
All rights reserved. Please visit https://medical-data-
models.org/forms/4590
Unerwünschtes Ereignis (AE) - Blatt
Nr.: 1
Patientendaten
Pat.-Nr.:    -*
Unerwünschtes Ereignis (AE)
fortlaufende AE-Nr.*
Unerwünschtes Ereignis (AE)*
Beginn AE Datum (Tag Monat Jahr)*
Schwerwiegend 0-2*
Nein (0)
Ja - SAE gemeldet (1)
Ja - gemäß Protokoll 7.1 keine SAE-
Meldung erforderlich (2)
Maßnahmen bzgl. Prüfmedikation*
Keine (0)
Dosis geändert (1)
Medikament vorübergehend abgesetzt
(2)
Medikament endgültig abgesetzt (3)
AE führt zum Studienabbruch*
Ja
Nein
Zusammenhang mit Prüfmedikation*
Kein V. a. Zusammenhang mit
Prüfmedikation (0)
V. a. Zusammenhang mit Prüfmedikation
(1)
CTCAE-Grading 1-5*
CTCAE-Grad 1 (1)
CTCAE-Grad 2 (2)
CTCAE-Grad 3 (3)
CTCAE-Grad 4 (4)
CTCAE-Grad 5 (5)
Ende AE - Dokumentation der
Nachverfolgung:                - bis 30 Tage
nach Studienende/-abbruch           - bei
später neu aufgetretenen AEs nicht
erforderlich
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Ende Datum*
[oder] anhaltend (anhaltend bei Ende der
Dokum.-pflicht)*
Ausgang des AE 0-5*
Wiederhergestellt (0)
Gebessert (1)
Noch nicht gebessert (2)
Wiederhergestellt mit Defekt (3)
Unbekannt (4)
Tod (5)
Unterschrift
Datum:*
Name/Unterschrift Prüfarzt*
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Unerwünschtes Ereignis (AE) - Blatt Nr.: 1 EudraCT-Nr 2008-004583-40
Akute myeloische Leukämie(AML) AML alle außer FAB M3
Rezidiv / Tod EudraCT-Nr 2008-004583-40 Akute
myeloische Leukämie(AML) AML alle außer FAB M3
A randomized, multi-center phase II trial to assess the
efficacy of 5-azacytidine added to standard primary therapy
in elderly patients with newly diagnosed AML
All rights reserved. Please visit https://medical-data-
models.org/forms/4591
Rezidiv / Tod
Patientendaten
Pat.-Nr.:    -*
Datum der Rezidiv-Diagnose:*
Differentialblutbild
Falls bereits im CRF dokumentiert, bitte
Seitenzahl angeben (Erneute Dokumentation
nicht erforderlich):*
Datum:*
Haemoglobin*
Haemoglobin*
[g/dl] ([g/dl])
[mmol/l] ([mmol/l])
Leukozyten *
Leukozyten*
[/nl] ( [/nl])
[/µl] ( [/µl])
[10E3/µl] ([10E3/µl])
[GPt/l] ([GPt/l])
Prozentanteil Neutrophile *
Prozentanteil Stabkernige *
[oder] Prozentanteil Segmentkernige *
Prozentanteil Lymphozyten *
Prozentanteil Monozyten*
Prozentanteil Eosinophile *
Prozentanteil Basophile *
Prozentanteil Blasten*
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Prozentanteil Promyelozyten*
Prozentanteil Myelozyten*
Prozentanteil Metamyelozyten*
Prozentanteil sonstige Zellen*
Thrombozyten*
Thrombozyten*
[/nl] ([/nl])
[/µl] ([/µl])
[10E3/µl] ([10E3/µl])
[GPt/l] ([GPt/l])
Knochenmarkuntersuchung
Datum - Knochenmarkuntersuchung*
Falls bereits im CRF dokumentiert, bitte
Seitenzahl angeben (Erneute Dokumentation
nicht erforderlich):*
Obligater Materialversand (Knochenmark + Blut)
zur Bestimmung des Methylierungsstatus nach:*
Münster (1)
Dresden (2)
Frankfurt (3)
kein Versand weil (kein Versand weil)
kein Versand weil*
Zytologie
Blastenanteil*
<5% (1)
>=5% (2)
nicht beurteilbar (3)
wenn >=5%, dann bitte angeben [%]*
Zytogenetik:*
durchgeführt (Befundkopie bitte
mitschicken!) (1)
nicht durchgeführt (2)
Zytogenetische Aberration nachweisbar:*
nein (no)
ja, in      % Interphasen-FISH (yes, in
interphase FISH)
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Rezidiv / Tod EudraCT-Nr 2008-004583-40 Akute myeloische
Leukämie(AML) AML alle außer FAB M3
ja, in      /     Metaphasen (yes, in
metaphases)
Anzahl Metaphasen*
Gesamtzahl Metaphasen*
% Interphasen-FISH*
Neue Aberration nachweisbar:*
Ja
Nein
Molekulargenetik (Befundkopie bitte
mitschicken!)
AML1/ETO:*
ja (1)
nein (2)
nicht untersucht (3)
PML/RARa:*
ja (1)
nein (2)
nicht untersucht (3)
CBFbeta/MYH11:*
ja (1)
nein (2)
nicht untersucht (3)
C/EBPalpha:*
ja (1)
nein (2)
nicht untersucht (3)
NPM1-Mut:*
ja (1)
nicht untersucht (1)
nein (2)
nicht untersucht (3)
IDH-Mutation:*
ja (1)
nein (2)
nicht untersucht (3)
Flt3-Punktmutation:*
ja (1)
nein (2)
nicht untersucht (3)
Flt3-ITD:*
ja (1)
nein (2)
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Rezidiv / Tod EudraCT-Nr 2008-004583-40 Akute myeloische
Leukämie(AML) AML alle außer FAB M3
nicht untersucht (3)
Sonstige:*
Extramedulläre AML-Manifestation*
ja (1)
nein (2)
nicht bekannt (3)
wenn ja, Lokalisation:*
ZNS (1)
andere: (2)
andere:*
Wurde die extramedulläre AML-Manifestation
durch eine Biopsie / Punktion gesichert?*
ja (Befundkopie bitte mitschicken!): (ja)
nein (nein)
Datum der Biopsie / Punktion:*
Unterschrift
Datum:*
Name/Unterschrift Prüfarzt*
Patientendaten
Pat.-Nr.:    -*
Todesdatum:*
Falls der Tod bis einschließlich 42 Tage nach
letzter Gabe von 5-Azacytidin / Chemotherapie
eingetreten ist , bitte AE- und SAE-Bogen
ausfüllen!*
Todesursache:*
Infektion (1)
Blutung (2)
Andere Ursache (3)
Bitte spezifizieren:*
Remissionsstatus zum Todeszeitpunkt:*
CR oder morphologisch Leukämie-freier
Status (1)
Primäres Therapieversagen / Rezidiv (2)
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Rezidiv / Tod EudraCT-Nr 2008-004583-40 Akute myeloische
Leukämie(AML) AML alle außer FAB M3
unbekannt (3)
Obduktion durchgeführt?*
Ja
Nein
Wenn ja, bitte Obduktionsbericht schicken oder
nähere Angaben:*
Unterschrift
Datum:*
Name/Unterschrift Prüfarzt*
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Rezidiv / Tod EudraCT-Nr 2008-004583-40 Akute myeloische
Leukämie(AML) AML alle außer FAB M3
Monat 1 Erhaltungstherapie / Nachbeobachtung EudraCT-Nr.: 2008-
004583-40 Akute myeloische Leukämie(AML) AML alle außer FAB M3
A randomized, multi-center phase II trial to assess the
efficacy of 5-azacytidine added to standard primary therapy
in elderly patients with newly diagnosed AML
All rights reserved. Please visit https://medical-data-
models.org/forms/4595
Monat 1 Erhaltungstherapie /
Nachbeobachtung
Patientendaten
Pat.-Nr.:    -*
Therapie-Status
Anzahl der erhaltenen Konsolidierungstherapien:*
1 Konsolidierungstherapie-block (1)
2 Konsolidierungstherapie-blöcke (2)
keine Konsolidierungstherapie (3)
ECOG-Status
Datum:*
ECOG-Status*
ECOG-Status 0 (Normale
Leistungsfähigkeit) (0)
ECOG-Status 1 (Ambulante Betreuung,
leichte Arbeiten möglich) (1)
ECOG-Status 2 (Weniger als 50% am
Tage bettlägerig, Selbstversorgung
möglich, aber nicht arbeitsfähig) (2)
ECOG-Status 3 (Mehr als 50% am Tage
bettlägerig, begrenzte Selbstversorgung
noch möglich) (3)
ECOG-Status 4 (Ständig bettlägerig) (4)
Wieviel Transfusionen hat der Patient im Zeitraum
zwischen:                                 Tag 1 der letzten
Chemotherapie UND
Tag 1 des 1. Monats der Erhaltungstherapie /
Nachbeobachtung* erhalten?
*: Festlegung des 1. Tages des jeweiligen
Monats:                               Erhaltungstherapie
(Arm A):    Tag der 1. Gabe von 5-Azacytidin
Nachbeobachtung (Arm B):    Tag des
Differentialblutbildes    *
Anzahl transfundierter Erythrozyten-
Konzentrate:*
Anzahl transfundierter Thrombozyten-
Konzentrate:*
Wenn zwischenzeitlich AEs aufgetreten sind,
bitte diese auf den AE-Bögen dokumentieren!*
1 / 6
Differentialblutbild
Datum:*
Haemoglobin*
Haemoglobin*
[g/dl] ([g/dl])
[mmol/l] ([mmol/l])
Leukozyten *
Leukozyten*
[/nl] ( [/nl])
[/µl] ( [/µl])
[10E3/µl] ([10E3/µl])
[GPt/l] ([GPt/l])
Prozentanteil Neutrophile *
Prozentanteil Stabkernige *
[oder] Prozentanteil Segmentkernige *
Prozentanteil Lymphozyten *
Prozentanteil Monozyten*
Prozentanteil Eosinophile *
Prozentanteil Basophile *
Prozentanteil Blasten*
Prozentanteil Promyelozyten*
Prozentanteil Myelozyten*
Prozentanteil Metamyelozyten*
Prozentanteil sonstige Zellen*
Thrombozyten*
Thrombozyten*
[/nl] ([/nl])
[/µl] ([/µl])
[10E3/µl] ([10E3/µl])
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Monat 1 Erhaltungstherapie / Nachbeobachtung EudraCT-Nr.: 2008-
004583-40 Akute myeloische Leukämie(AML) AML alle außer FAB M3
[GPt/l] ([GPt/l])
Klinische Chemie
Natrium [mmol/l]*
Kalium [mmol/l]*
Gesamteiweiß*
Gesamteiweiß*
[g/dl] ([g/dl])
[g/l] ([g/l])
Harnsäure *
Harnsäure *
[mg/dl] ([mg/dl])
[µmol/l] ([µmol/l])
Harnstoff-N *
Harnstoff-N *
[mg/dl] ([mg/dl])
[mmol/l] ([mmol/l])
Harnstoff*
Harnstoff*
[mg/dl] ([mg/dl])
[mmol/l] ([mmol/l])
Kreatinin*
Kreatinin*
[mg/dl] ([mg/dl])
[µmol/l] ([µmol/l])
Bilirubin (gesamt)*
Bilirubin (gesamt)*
[mg/dl] ([mg/dl])
[µmol/l] ([µmol/l])
GOT/AST *
GOT/AST *
[U/l] ([U/l])
[µmol/s*l] ([µmol/s*l])
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Monat 1 Erhaltungstherapie / Nachbeobachtung EudraCT-Nr.: 2008-
004583-40 Akute myeloische Leukämie(AML) AML alle außer FAB M3
GPT/ALT*
GPT/ALT*
[U/l] ([U/l])
[µmol/s*l] ([µmol/s*l])
AP*
AP*
[U/l] ([U/l])
[µmol/s*l] ([µmol/s*l])
LDH*
LDH*
[U/l] ([U/l])
[µmol/s*l] ([µmol/s*l])
CRP*
CRP*
[mg/dl] ([mg/dl])
[mg/l] ([mg/l])
Quick-Wert (in Prozent)*
INR*
PTT [sek]*
Knochenmarkuntersuchung
Knochenmarkuntersuchung *
durchgeführt (durchgeführt)
nicht durchgeführt (nicht durchgeführt)
Datum - Knochenmarkuntersuchung*
Obligater Materialversand (Knochenmark + Blut)
zur Bestimmung des Methylierungsstatus nach:*
Münster (1)
Dresden (2)
Frankfurt (3)
kein Versand weil (kein Versand weil)
kein Versand weil*
Zytologie
Blastenanteil*
4 / 6
Monat 1 Erhaltungstherapie / Nachbeobachtung EudraCT-Nr.: 2008-
004583-40 Akute myeloische Leukämie(AML) AML alle außer FAB M3
<5% (1)
>=5% (2)
nicht beurteilbar (3)
wenn >=5%, dann bitte angeben [%]*
Zytogenetik:*
durchgeführt (Befundkopie bitte
mitschicken!) (1)
nicht durchgeführt (2)
Zytogenetische Aberration nachweisbar:*
nein (no)
ja, in      % Interphasen-FISH (yes, in
interphase FISH)
ja, in      /     Metaphasen (yes, in
metaphases)
Anzahl Metaphasen*
Gesamtzahl Metaphasen*
% Interphasen-FISH*
Neue Aberration nachweisbar:*
Ja
Nein
Molekulargenetik (Befundkopie bitte
mitschicken!)
AML1/ETO:*
ja (1)
nein (2)
nicht untersucht (3)
PML/RARa:*
ja (1)
nein (2)
nicht untersucht (3)
CBFbeta/MYH11:*
ja (1)
nein (2)
nicht untersucht (3)
C/EBPalpha:*
ja (1)
nein (2)
nicht untersucht (3)
NPM1-Mut:*
ja (1)
nicht untersucht (1)
nein (2)
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Monat 1 Erhaltungstherapie / Nachbeobachtung EudraCT-Nr.: 2008-
004583-40 Akute myeloische Leukämie(AML) AML alle außer FAB M3
nicht untersucht (3)
IDH-Mutation:*
ja (1)
nein (2)
nicht untersucht (3)
Flt3-Punktmutation:*
ja (1)
nein (2)
nicht untersucht (3)
Flt3-ITD:*
ja (1)
nein (2)
nicht untersucht (3)
Sonstige:*
Remissionsstatus *
Morphologisch Leukämie-freier Status
(ohne Erreichen peripherer CR-Kriterien)
(1)
Morphologisch komplette Remission
(CR) (2)
Rezidiv (Bitte Bogen "Rezidiv" Seite
83+84 und Bogen "Studienende/Stu-
dienabbruch" Seite 82 ausfüllen!) (3)
Bei regulärem Studienende (1 Jahr nach Beginn
der 1. Induktions-therapie) bitte Bogen
"Studienende/Stu-dienabbruch" Seite 82
ausfüllen!*
Unterschrift
Datum:*
Name/Unterschrift Prüfarzt*
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Monat 1 Erhaltungstherapie / Nachbeobachtung EudraCT-Nr.: 2008-
004583-40 Akute myeloische Leukämie(AML) AML alle außer FAB M3
Bogen 2 Verlaufsbogen Seite 1 von 2
TIGER Studie Version 23052012 Condition
NCT01657604
All rights reserved. Please visit https://medical-data-
models.org/forms/4604
Bogen 2 Verlaufsbogen Seite 1 von 2
Adiminstrative Daten I
Klinik-Nr.*
Patienten-Nr.*
Geburtsdatum
Geburtsmonat*
Geburtstag*
Adiminstrative Daten II
Beurteilungsdatum*
Nummer des Verlaufsbogen*
Geschlecht*
männlich (männlich)
weiblich (weiblich)
Therapiephase
Erreichen des Therapiezieles der
Induktionsphase (nach mindestens 24 Monaten
Behandlung) am:*
Absetzdatum von Nilotinib im Kombinationsarm
am:*
Erreichen der Hauptphase (nach mindestens 12
Monaten Behandlung) am:*
Absetzdatum der Hauptphasentherapie am:*
Bisherige Therapie im Intervall
Nilotinib 2*300mg
andere Dosis (mg)*
1 / 3
Beginn*
Ende*
Therapietage*
Gesamtdosis (mg)*
Absetzen*
A (A)
G (G)
ja (ja)
nein (nein)
S (S)
U (U)
Grund für Absetzen*
Nilotinib - Pause
Beginn*
Ende*
PEG-IFN
Beginn*
Ende*
Einzeldosis (μg)*
Intervall (Tage)*
Anzahl Injektionen*
Absetzen*
A (A)
G (G)
ja (ja)
nein (nein)
S (S)
U (U)
Grund für Absetzen*
PEG-IFN - Pause
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Bogen 2 Verlaufsbogen Seite 1 von 2 TIGER Studie Version 23052012
Condition
Beginn*
Ende*
weitere Medikation
Grund*
Medikament*
Dosis*
Einheit*
Beginn*
Ende*
Unterschrift
Kommentar*
Klinik*
Datum*
Unterschrift*
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Bogen 2 Verlaufsbogen Seite 1 von 2 TIGER Studie Version 23052012
Condition
Bogen 1  Einschluss Randomisierung
NCT01657604 Chronic Myeloid Leukemia
http://clinicaltrials.gov/ct2/show/NCT01657604
All rights reserved. Please visit https://medical-data-
models.org/forms/4606
Bogen 1  Einschluss
Randomisierung
Adiminstrative Daten I
Klinik-Nr.*
Patienten-Nr.*
Geburtsdatum
Geburtsmonat*
Geburtstag*
Adiminstrative Daten II
Beurteilungsdatum*
Diagnosedatum*
Geschlecht*
männlich (männlich)
weiblich (weiblich)
Randomisierung
Medikation*
Nilotinib + PEG-IFN (Nilotinib + PEG-
IFN)
Nilotinib 2*300mg (Nilotinib 2*300mg)
Datum der Randomisierung*
nicht randomisierbar*
Ja
Nein
Grund für nicht mögliche Randomisierung*
Laborwerte
Datum der Laborwerte*
Leukozyten (10^9/l)*
1 / 7
Blasten (%)*
Promyelozyten (%)*
Myelozyten, Metamyelozyten (%)*
Stabkernige (%)*
Segmentkernige (%)*
Eosinophile (%)*
Basophile (%)*
Monozyten (%)*
Lymphozyten (%)*
Normoblasten (%)*
Thrombozyten (10^9/L)*
Hämoglobin (mmol/L)*
Hämoglobin (g/dL)*
Hämatokrit (%)*
Harnstoff (mg/dL)*
Kreatinin (mg/dL)*
Harnsäure (mg/dL)*
Albumin (g/dL)*
Protein (g/dL)*
Bilirubin gesamt (μmol/L)*
Bilirubin gesamt (mg/dL)*
Bilirubin direkt (μmol/L)*
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Bogen 1  Einschluss Randomisierung NCT01657604 Chronic Myeloid
Leukemia
Bilirubin direkt (mg/dL)*
Bilirubin indirekt (μmol/L)*
Bilirubin indirekt (mg/dL)*
ALAT (SGPT) (U/L)*
ASAT (SGOT) (U/L)*
LDH (U/L)*
Natrium (mmol/L)*
Kalzium (mmol/L)*
Phosphat (mmol/L)*
Lipase (U/L)*
Amylase (U/L)*
Kalium (mmol/L)*
Magnesium (mmol/L)*
TSH (mU/L)*
Glukose (mg/dL)*
Glukose (mmol/L)*
Hämoglobin 1Ac (mmol/mol)*
Cholesterin (mg/dL)*
Cholesterin (mmol/L)*
Molekularbiologie
nicht durchgeführt*
Ja
Nein
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Bogen 1  Einschluss Randomisierung NCT01657604 Chronic Myeloid
Leukemia
Datum der Durchführung*
BCR-ABL-Transkripte
b2a2*
Ja
Nein
b3a2*
Ja
Nein
b2a3*
Ja
Nein
b3a3*
Ja
Nein
e1a2*
Ja
Nein
e6a2*
Ja
Nein
e19a2*
Ja
Nein
sonstige*
Ja
Nein
sonstige*
kein BCR-ABL-Transkript*
Ja
Nein
Untersucher/Ort*
Labor-Nr.*
Quality of Life
Fragebogen ausgefüllt*
Ja
Nein
klinischer Befund I
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Bogen 1  Einschluss Randomisierung NCT01657604 Chronic Myeloid
Leukemia
Datum klinischer Befund*
Körpergröße (cm)*
Gewicht (kg)*
Milzgröße (palpiert unter dem Rippenbogen)*
Milz in US, größter Durchmesser*
Blutdruck
Blutdruck systolisch*
Blutdruck diastolisch*
klinischer Befund II
Herzfrequenz (/min)*
Extramedulläre Manifestationen*
Ja
Nein
welche (z.B. LK, Haut, usw.)*
Vor- und Begleiterkrankungen
Vor- und Begleiterkrankung*
Medikamente
Medikament*
Dosis*
Einheit der Dosis*
Beginn Medikament*
Ende Medikament*
andauernde Medikation*
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Bogen 1  Einschluss Randomisierung NCT01657604 Chronic Myeloid
Leukemia
Ja
Nein
Knochenmarkanalyse
nich durchgeführt*
Ja
Nein
nicht vorliegend*
Ja
Nein
Datum der Durchführung*
Zellularität*
aplastisch (aplastisch)
hyperzellulär (hyperzellulär)
hypozellulär (hypozellulär)
normozellulär (normozellulär)
stark hyperzellulär (stark hyperzellulär)
Blasten (%)*
Promyelozyten (%)*
Basophile (%)*
Zytogenetik
ausgewertete Mitosen*
Normaler Karyotyp*
Normal, aber mit Zusatzaberrationen*
Philadelphia-Chromosom t(9;22)*
Philadelphia-Chromosom mit
Zusatzaberrationen*
Befunde nach ISCN:*
Nicht auswertbare Mitosen*
Untersucher/Ort*
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Bogen 1  Einschluss Randomisierung NCT01657604 Chronic Myeloid
Leukemia
Labor-Nr.*
Unterschrift
Kommentar*
Klinik*
Datum*
Unterschrift*
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Bogen 1  Einschluss Randomisierung NCT01657604 Chronic Myeloid
Leukemia
Bogen 2 Verlaufsbogen Seite 1 von 2
NCT01657604 Chronic Myeloid Leukemia
http://clinicaltrials.gov/ct2/show/NCT01657604
All rights reserved. Please visit https://medical-data-
models.org/forms/4607
Bogen 2 Verlaufsbogen Seite 1 von 2
Adiminstrative Daten I
Klinik-Nr.*
Patienten-Nr.*
Geburtsdatum
Geburtsmonat*
Geburtstag*
Adiminstrative Daten II
Beurteilungsdatum*
Nummer des Verlaufsbogen*
Geschlecht*
männlich (männlich)
weiblich (weiblich)
Therapiephase
Erreichen des Therapiezieles der
Induktionsphase (nach mindestens 24 Monaten
Behandlung) am:*
Absetzdatum von Nilotinib im Kombinationsarm
am:*
Erreichen der Hauptphase (nach mindestens 12
Monaten Behandlung) am:*
Absetzdatum der Hauptphasentherapie am:*
Bisherige Therapie im Intervall
Nilotinib 2*300mg
andere Dosis (mg)*
1 / 3
Beginn*
Ende*
Therapietage*
Gesamtdosis (mg)*
Absetzen*
ja (ja)
nein (nein)
Grund für Absetzen*
A=Ablehnung des Patienten (A)
G=Geplantes Absetzen gemäß dem
Therapieverlauf (G)
S=Sonstiges (S)
U=Unverträglichkeit (U)
Grund für Absetzen*
Nilotinib - Pause
Beginn*
Ende*
PEG-IFN
Beginn*
Ende*
Einzeldosis (μg)*
Intervall (Tage)*
Anzahl Injektionen*
Absetzen*
ja (ja)
nein (nein)
Grund für Absetzen*
A=Ablehnung des Patienten (A)
G=Geplantes Absetzen gemäß dem
Therapieverlauf (G)
S=Sonstiges (S)
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Bogen 2 Verlaufsbogen Seite 1 von 2 NCT01657604 Chronic Myeloid
Leukemia
U=Unverträglichkeit (U)
Grund für Absetzen*
PEG-IFN - Pause
Beginn*
Ende*
weitere Medikation
Grund*
Medikament*
Dosis*
Einheit*
Beginn*
Ende*
Unterschrift
Kommentar*
Klinik*
Datum*
Unterschrift*
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Bogen 2 Verlaufsbogen Seite 1 von 2 NCT01657604 Chronic Myeloid
Leukemia
Bogen 3 Molekulares Rezidiv Progression
NCT01657604 Chronic Myeloid Leukemia
http://clinicaltrials.gov/ct2/show/NCT01657604
All rights reserved. Please visit https://medical-data-
models.org/forms/4617
Bogen 3 Molekulares Rezidiv
Progression
Adiminstrative Daten I
Klinik-Nr.*
Patienten-Nr.*
Geburtsdatum
Geburtsmonat*
Geburtstag*
Adiminstrative Daten II
Beurteilungsdatum*
Diagnosedatum*
Geschlecht*
männlich (männlich)
weiblich (weiblich)
Transplantationspatient
allogen*
Ja
Nein
Datum der Stammzelltransplantation*
Transplantationszentrum*
Rezidiv
Molekulares Rezidiv*
Wiederaufnahme der Therapie*
Akzelerierte Phase*
Blastenphase*
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Patient verstorben
Patient verstorben*
Ja
Nein
Sterbedatum*
Todesursache CML*
Ja
Nein
Todesursache der CML*
Andere Ursachen (Andere Ursachen)
Blastenphase (Blastenphase)
Blutung (Blutung)
Infektion (Infektion)
Andere Ursachen*
CML-unabhängige Todesursache*
Ja
Nein
CML-unabhängige Todesursache*
Patient lebt
Patient lebt*
Ja
Nein
Datum*
Gründe für vorzeitiges Ausscheiden aus
der Studie
Datum vorzeitiges Ausscheiden aus der Studie*
Gründe für vorzeitiges Ausscheiden aus der
Studie*
Kein Patientenkontakt mehr (Loss to
follow up) (Kein Patientenkontakt mehr
(Loss to follow up))
keine CML (keine CML)
Patient zog Studieneinverständnis zurück
(Patient zog Studieneinverständnis
zurück)
Zweitmalignom (Zweitmalignom)
Zweitmalignom*
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Bogen 3 Molekulares Rezidiv Progression NCT01657604 Chronic
Myeloid Leukemia
Unterschrift
Bemerkungen*
Klinik*
Datum*
Unterschrift*
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Bogen 3 Molekulares Rezidiv Progression NCT01657604 Chronic
Myeloid Leukemia
MRT-Befund der Lendenwirbelsäule ELGA
ODM derived from http://www.elga.gv.at/
ELGA-Befund_bildgebende_Diagnostik_EIS-FullSupport
Magnetresonanztomographie-Befund LOINC 18755-9
Amadeus Spital
All rights reserved. Please visit https://medical-data-
models.org/forms/4618
MRT-Befund der Lendenwirbelsäule
ClinicalDocument
realmCode.code*
typeId.root*
typeId.extension*
templateId.root*
templateId.assigningAuthorityName*
templateId.root*
templateId.assigningAuthorityName*
id.root*
id.extension*
id.assigningAuthorityName*
code.code*
code.displayName*
code.codeSystem*
code.codeSystemName*
title*
effectiveTime.value*
confidentialityCode.code*
confidentialityCode.displayName*
confidentialityCode.codeSystem*
1 / 25
confidentialityCode.codeSystemName*
languageCode.code*
setId.root*
setId.extension*
setId.assigningAuthorityName*
versionNumber.value*
id.root*
id.extension*
id.assigningAuthorityName*
id.root*
id.extension*
id.assigningAuthorityName*
addr.use*
streetAddressLine*
postalCode*
city*
state*
country*
telecom.use*
telecom.value*
telecom.use*
telecom.value*
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MRT-Befund der Lendenwirbelsäule ELGA
telecom.value*
prefix.qualifier*
prefix*
prefix.qualifier*
prefix*
given*
given*
family*
family.qualifier*
family*
suffix.qualifier*
suffix*
suffix.qualifier*
suffix*
administrativeGenderCode.code*
administrativeGenderCode.displayName*
administrativeGenderCode.codeSystem*
administrativeGenderCode.codeSystemName*
birthTime.value*
maritalStatusCode.code*
maritalStatusCode.displayName*
maritalStatusCode.codeSystem*
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MRT-Befund der Lendenwirbelsäule ELGA
maritalStatusCode.codeSystemName*
religiousAffiliationCode.code*
religiousAffiliationCode.codeSystem*
religiousAffiliationCode.codeSystemName*
religiousAffiliationCode.displayName*
streetAddressLine*
postalCode*
city*
state*
country*
telecom.use*
telecom.value*
telecom.use*
telecom.value*
telecom.use*
telecom.value*
given*
family*
streetAddressLine*
postalCode*
city*
state*
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MRT-Befund der Lendenwirbelsäule ELGA
country*
functionCode.code*
functionCode.codeSystem*
functionCode.codeSystemName*
functionCode.displayName*
time.value*
id.root*
id.extension*
id.assigningAuthorityName*
code.code*
code.codeSystem*
code.codeSystemName*
code.displayName*
telecom.use*
telecom.value*
prefix*
family*
given*
id.root*
id.assigningAuthorityName*
telecom.value*
telecom.value*
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MRT-Befund der Lendenwirbelsäule ELGA
telecom.value*
telecom.value*
streetName*
houseNumber*
postalCode*
city*
state*
country*
time.value*
id.root*
id.extension*
id.assigningAuthorityName*
family*
given*
id.root*
id.assigningAuthorityName*
telecom.value*
streetName*
houseNumber*
postalCode*
city*
state*
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MRT-Befund der Lendenwirbelsäule ELGA
country*
informationRecipient.typeCode*
id.root*
id.assigningAuthorityName*
prefix.qualifier*
prefix*
given*
family*
id.root*
id.assigningAuthorityName*
telecom.value*
telecom.value*
telecom.value*
telecom.value*
telecom.value*
streetName*
houseNumber*
postalCode*
city*
country*
informationRecipient.typeCode*
id.root*
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MRT-Befund der Lendenwirbelsäule ELGA
id.assigningAuthorityName*
prefix.qualifier*
prefix*
given*
family*
id.root*
id.assigningAuthorityName*
telecom.value*
telecom.value*
telecom.value*
telecom.value*
telecom.value*
streetName*
houseNumber*
postalCode*
city*
country*
time.value*
signatureCode.code*
id.root*
id.extension*
id.assigningAuthorityName*
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MRT-Befund der Lendenwirbelsäule ELGA
telecom.use*
telecom.value*
prefix*
family*
given*
id.root*
id.assigningAuthorityName*
telecom.value*
telecom.value*
telecom.value*
telecom.value*
streetName*
houseNumber*
postalCode*
city*
state*
country*
time.value*
signatureCode.code*
id.root*
id.extension*
id.assigningAuthorityName*
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MRT-Befund der Lendenwirbelsäule ELGA
telecom.use*
telecom.value*
prefix*
family*
given*
id.root*
id.assigningAuthorityName*
telecom.value*
telecom.value*
telecom.value*
telecom.value*
streetName*
houseNumber*
postalCode*
city*
state*
country*
participant.typeCode*
templateId.root*
associatedEntity.classCode*
telecom.use*
telecom.value*
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15 / 138
Allgemeiner Laborbefund ELGA
id.extension*
id.root*
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title*
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code.displayName*
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targetSiteCode.code*
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id.root*
code.code*
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code.displayName*
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code.code*
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code.codeSystemName*
code.displayName*
effectiveTime.value*
targetSiteCode.code*
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id.root*
code.code*
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td*
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td*
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content.ID*
content*
content*
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act.classCode*
act.moodCode*
code.code*
code.codeSystem*
code.codeSystemName*
code.displayName*
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organizer.classCode*
organizer.moodCode*
templateId.root*
code.code*
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code.codeSystemName*
code.displayName*
statusCode.code*
component.typeCode*
observation.classCode*
observation.moodCode*
templateId.root*
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id.extension*
id.root*
code.code*
code.codeSystem*
code.codeSystemName*
code.displayName*
reference.value*
statusCode.code*
effectiveTime.value*
value.unit*
value.value*
value.type*
interpretationCode.code*
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interpretationCode.codeSystem*
interpretationCode.displayName*
interpretationCode.code*
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interpretationCode.codeSystem*
interpretationCode.displayName*
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text*
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interpretationCode.code*
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interpretationCode.displayName*
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id.root*
code.code*
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code.codeSystemName*
code.displayName*
reference.value*
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effectiveTime.value*
value.unit*
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value.type*
interpretationCode.code*
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interpretationCode.code*
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text*
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low.value*
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interpretationCode.codeSystemName*
interpretationCode.codeSystem*
interpretationCode.displayName*
component.typeCode*
observation.classCode*
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templateId.root*
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id.root*
code.code*
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code.displayName*
reference.value*
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interpretationCode.code*
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interpretationCode.displayName*
referenceRange.typeCode*
observationRange.classCode*
observationRange.moodCode*
text*
value.type*
low.value*
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high.value*
high.unit*
interpretationCode.code*
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interpretationCode.codeSystem*
interpretationCode.displayName*
component.typeCode*
observation.classCode*
observation.moodCode*
templateId.root*
id.extension*
id.root*
code.code*
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code.codeSystem*
code.codeSystemName*
code.displayName*
reference.value*
statusCode.code*
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value.unit*
value.value*
value.type*
interpretationCode.code*
interpretationCode.codeSystemName*
interpretationCode.codeSystem*
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referenceRange.typeCode*
observationRange.classCode*
observationRange.moodCode*
text*
value.type*
low.value*
low.unit*
high.value*
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interpretationCode.codeSystemName*
interpretationCode.codeSystem*
interpretationCode.displayName*
component.typeCode*
observation.classCode*
observation.moodCode*
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id.root*
code.code*
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code.codeSystemName*
code.displayName*
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value.unit*
value.value*
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interpretationCode.code*
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interpretationCode.codeSystem*
interpretationCode.displayName*
participant.typeCode*
templateId.root*
time.value*
id.extension*
id.root*
addr.nullFlavor*
telecom.value*
given*
family*
referenceRange.typeCode*
observationRange.classCode*
observationRange.moodCode*
text*
value.type*
low.value*
low.unit*
high.value*
high.unit*
interpretationCode.code*
interpretationCode.codeSystemName*
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interpretationCode.codeSystem*
interpretationCode.displayName*
component.typeCode*
observation.classCode*
observation.moodCode*
templateId.root*
id.extension*
id.root*
code.code*
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code.codeSystemName*
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reference.value*
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observationRange.classCode*
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text*
value.type*
low.value*
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high.value*
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observation.classCode*
observation.moodCode*
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id.root*
code.code*
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code.codeSystemName*
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effectiveTime.value*
value.unit*
value.value*
value.type*
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text*
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observationRange.classCode*
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text*
value.type*
low.value*
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interpretationCode.displayName*
component.typeCode*
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templateId.root*
templateId.root*
code.code*
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code.displayName*
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statusCode.code*
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organizer.classCode*
organizer.moodCode*
templateId.root*
code.code*
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code.displayName*
statusCode.code*
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code.code*
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reference.value*
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value.value*
value.type*
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referenceRange.typeCode*
observationRange.classCode*
observationRange.moodCode*
text*
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text*
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title*
paragraph.styleCode*
paragraph*
th*
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paragraph*
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code.code*
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code.codeSystemName*
code.displayName*
statusCode.code*
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code.code*
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code.displayName*
statusCode.code*
component.typeCode*
observation.classCode*
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id.extension*
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text*
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given*
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text*
value.type*
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templateId.root*
id.extension*
id.root*
code.code*
code.codeSystem*
code.codeSystemName*
code.displayName*
reference.value*
statusCode.code*
effectiveTime.value*
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value.unit*
value.value*
value.type*
interpretationCode.code*
interpretationCode.codeSystemName*
interpretationCode.codeSystem*
interpretationCode.displayName*
referenceRange.typeCode*
observationRange.classCode*
observationRange.moodCode*
text*
value.type*
low.value*
low.unit*
high.value*
high.unit*
interpretationCode.code*
interpretationCode.codeSystemName*
interpretationCode.codeSystem*
interpretationCode.displayName*
component.typeCode*
observation.classCode*
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observation.moodCode*
templateId.root*
id.extension*
id.root*
code.code*
code.codeSystem*
code.codeSystemName*
code.displayName*
reference.value*
statusCode.code*
effectiveTime.value*
value.unit*
value.value*
value.type*
interpretationCode.code*
interpretationCode.codeSystemName*
interpretationCode.codeSystem*
interpretationCode.displayName*
referenceRange.typeCode*
observationRange.classCode*
observationRange.moodCode*
text*
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value.type*
low.value*
low.unit*
high.value*
high.unit*
interpretationCode.code*
interpretationCode.codeSystemName*
interpretationCode.codeSystem*
interpretationCode.displayName*
component.typeCode*
observationMedia.classCode*
observationMedia.moodCode*
observationMedia.ID*
id.root*
value.mediaType*
value.representation*
value*
component.typeCode*
section.classCode*
templateId.root*
id.extension*
id.root*
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code.code*
code.codeSystem*
code.codeSystemName*
code.displayName*
title*
paragraph.styleCode*
paragraph*
table.border*
th*
th*
th*
th*
th*
tr.ID*
td*
td*
td*
td*
tr.ID*
tr.styleCode*
td*
td*
118 / 138
Allgemeiner Laborbefund ELGA
td*
td*
td*
tr.ID*
td*
td*
td*
td*
tr.ID*
td*
td*
td*
td*
tr.ID*
tr.styleCode*
td*
td*
td*
td*
td*
paragraph.styleCode*
paragraph*
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th*
th*
th*
th*
th*
tr.ID*
td*
td*
td*
td*
entry.typeCode*
templateId.root*
templateId.extension*
act.classCode*
act.moodCode*
code.code*
code.codeSystem*
code.codeSystemName*
code.displayName*
statusCode.code*
entryRelationship.typeCode*
organizer.classCode*
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organizer.moodCode*
templateId.root*
code.code*
code.codeSystem*
code.codeSystemName*
code.displayName*
statusCode.code*
component.typeCode*
observation.classCode*
observation.moodCode*
templateId.root*
id.extension*
id.root*
code.code*
code.codeSystem*
code.codeSystemName*
code.displayName*
reference.value*
statusCode.code*
effectiveTime.value*
value.unit*
value.value*
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value.type*
interpretationCode.code*
interpretationCode.codeSystemName*
interpretationCode.codeSystem*
interpretationCode.displayName*
referenceRange.typeCode*
observationRange.classCode*
observationRange.moodCode*
text*
value.type*
low.value*
low.unit*
high.value*
high.unit*
interpretationCode.code*
interpretationCode.codeSystemName*
interpretationCode.codeSystem*
interpretationCode.displayName*
component.typeCode*
observation.classCode*
observation.moodCode*
templateId.root*
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id.extension*
id.root*
code.code*
code.codeSystem*
code.codeSystemName*
code.displayName*
reference.value*
statusCode.code*
effectiveTime.value*
value.unit*
value.value*
value.type*
interpretationCode.code*
interpretationCode.codeSystemName*
interpretationCode.codeSystem*
interpretationCode.displayName*
referenceRange.typeCode*
observationRange.classCode*
observationRange.moodCode*
text*
value.type*
low.value*
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low.unit*
high.value*
high.unit*
interpretationCode.code*
interpretationCode.codeSystemName*
interpretationCode.codeSystem*
interpretationCode.displayName*
component.typeCode*
observation.classCode*
observation.moodCode*
templateId.root*
id.extension*
id.root*
code.code*
code.codeSystem*
code.codeSystemName*
code.displayName*
reference.value*
statusCode.code*
effectiveTime.value*
value.unit*
value.value*
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value.type*
interpretationCode.code*
interpretationCode.codeSystemName*
interpretationCode.codeSystem*
interpretationCode.displayName*
referenceRange.typeCode*
observationRange.classCode*
observationRange.moodCode*
text*
value.type*
low.value*
low.unit*
high.value*
high.unit*
interpretationCode.code*
interpretationCode.codeSystemName*
interpretationCode.codeSystem*
interpretationCode.displayName*
component.typeCode*
observation.classCode*
observation.moodCode*
templateId.root*
125 / 138
Allgemeiner Laborbefund ELGA
id.extension*
id.root*
code.code*
code.codeSystem*
code.codeSystemName*
code.displayName*
reference.value*
statusCode.code*
effectiveTime.value*
value.unit*
value.value*
value.type*
interpretationCode.code*
interpretationCode.codeSystemName*
interpretationCode.codeSystem*
interpretationCode.displayName*
referenceRange.typeCode*
observationRange.classCode*
observationRange.moodCode*
text*
value.type*
low.value*
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low.unit*
high.value*
high.unit*
interpretationCode.code*
interpretationCode.codeSystemName*
interpretationCode.codeSystem*
interpretationCode.displayName*
component.typeCode*
observation.classCode*
observation.moodCode*
templateId.root*
id.extension*
id.root*
code.code*
code.codeSystem*
code.codeSystemName*
code.displayName*
reference.value*
statusCode.code*
effectiveTime.value*
value.unit*
value.value*
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value.type*
interpretationCode.code*
interpretationCode.codeSystemName*
interpretationCode.codeSystem*
interpretationCode.displayName*
referenceRange.typeCode*
observationRange.classCode*
observationRange.moodCode*
text*
value.type*
low.value*
low.unit*
high.value*
high.unit*
interpretationCode.code*
interpretationCode.codeSystemName*
interpretationCode.codeSystem*
interpretationCode.displayName*
entryRelationship.typeCode*
organizer.classCode*
organizer.moodCode*
templateId.root*
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code.code*
code.codeSystem*
code.codeSystemName*
code.displayName*
statusCode.code*
component.typeCode*
observation.classCode*
observation.moodCode*
templateId.root*
id.extension*
id.root*
code.code*
code.codeSystem*
code.codeSystemName*
code.displayName*
reference.value*
statusCode.code*
effectiveTime.value*
value.unit*
value.value*
value.type*
interpretationCode.code*
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interpretationCode.codeSystemName*
interpretationCode.codeSystem*
interpretationCode.displayName*
referenceRange.typeCode*
observationRange.classCode*
observationRange.moodCode*
text*
value.type*
low.value*
low.unit*
high.value*
high.unit*
interpretationCode.code*
interpretationCode.codeSystemName*
interpretationCode.codeSystem*
interpretationCode.displayName*
component.typeCode*
section.classCode*
templateId.root*
id.extension*
id.root*
code.code*
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code.codeSystem*
code.codeSystemName*
code.displayName*
title*
paragraph.styleCode*
paragraph*
table.border*
th*
th*
th*
th*
th*
footnote.ID*
sup*
footnote*
tr.ID*
td*
td*
td*
td*
sup*
tr.ID*
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td*
td*
td*
td*
sup*
entry.typeCode*
templateId.root*
templateId.extension*
act.classCode*
act.moodCode*
code.code*
code.codeSystem*
code.codeSystemName*
code.displayName*
statusCode.code*
entryRelationship.typeCode*
organizer.classCode*
organizer.moodCode*
templateId.root*
code.code*
code.codeSystem*
code.codeSystemName*
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code.displayName*
statusCode.code*
component.typeCode*
observation.classCode*
observation.moodCode*
templateId.root*
id.extension*
id.root*
code.code*
code.codeSystem*
code.codeSystemName*
code.displayName*
reference.value*
statusCode.code*
effectiveTime.value*
value.unit*
value.value*
value.type*
interpretationCode.code*
interpretationCode.codeSystemName*
interpretationCode.codeSystem*
interpretationCode.displayName*
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entryRelationship.typeCode*
act.classCode*
act.moodCode*
templateId.root*
templateId.root*
code.code*
code.codeSystem*
code.codeSystemName*
code.displayName*
reference.value*
statusCode.code*
referenceRange.typeCode*
observationRange.classCode*
observationRange.moodCode*
text*
value.type*
low.value*
low.unit*
high.value*
high.unit*
interpretationCode.code*
interpretationCode.codeSystemName*
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interpretationCode.codeSystem*
interpretationCode.displayName*
component.typeCode*
observation.classCode*
observation.moodCode*
templateId.root*
id.extension*
id.root*
code.code*
code.codeSystem*
code.codeSystemName*
code.displayName*
reference.value*
statusCode.code*
effectiveTime.value*
value.unit*
value.value*
value.type*
interpretationCode.code*
interpretationCode.codeSystemName*
interpretationCode.codeSystem*
interpretationCode.displayName*
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entryRelationship.typeCode*
act.classCode*
act.moodCode*
templateId.root*
templateId.root*
code.code*
code.codeSystem*
code.codeSystemName*
code.displayName*
reference.value*
statusCode.code*
referenceRange.typeCode*
observationRange.classCode*
observationRange.moodCode*
text*
value.type*
low.value*
low.unit*
high.value*
high.unit*
interpretationCode.code*
interpretationCode.codeSystemName*
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interpretationCode.codeSystem*
interpretationCode.displayName*
component.typeCode*
section.classCode*
templateId.root*
code.code*
code.codeSystem*
code.displayName*
code.codeSystemName*
title*
th*
content.ID*
content*
entry.typeCode*
act.classCode*
act.moodCode*
templateId.root*
templateId.root*
code.code*
code.displayName*
code.codeSystem*
code.codeSystemName*
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reference.value*
statusCode.code*
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Einschlusskriterien NCT01657604 Chronic
Myeloid Leukemia
http://clinicaltrials.gov/ct2/show/NCT01657604
All rights reserved. Please visit https://medical-data-
models.org/forms/4629
Einschlusskriterien
Adiminstrative Daten I
Klinik-Nr.*
Patienten-Nr.*
Geburtsdatum
Geburtsmonat*
Geburtstag*
Adiminstrative Daten II
Beurteilungsdatum*
Diagnosedatum*
Geschlecht*
männlich (männlich)
weiblich (weiblich)
Einschlusskriterium
CML in chronischer Phase mit zytogenetischem
Nachweis des Philadelphia-Chromosoms oder
vatiante Translokation (BCR-ABL-positiv in
Multiplex-PCR)*
Ja
Nein
Datum der Diagnose nicht älter als sechs
Monate*
Ja
Nein
CML bislang unbehandelt (Ausnahme bis zu
sechs Monate Hydroxyurea und/oder bis zu
sechs Wochen Imatinib oder Nilotinib)*
Ja
Nein
Alter bei Studieneinschluss mindestens 18 Jahre*
Ja
Nein
Serum-Werte Kalium, Magnesium und Kalzium
größer oder gleich LLN (untere Normschranke)
1 / 2
bzw. innerhalb des Normbereichs unter
Supplementation*
Ja
Nein
ASAT und ALAT kleiner oder gleich 2.5 x UNL
(obere Normschranke) bzw. kleiner oder gleich 5
x ULN, falls durch die Leukämie induziert.*
Ja
Nein
Alkalische Phosphatase kleiner oder gleich 2.5 x
UNL, falls nicht durch die Leukämie induziert.*
Ja
Nein
Gesamt-Bilirubin kleiner oder gleich 1.5 x ULN,
sofern kein bekannter Morbus Gilbert
(Meulengracht)*
Ja
Nein
Serum-Lipase und Amylase kleiner oder gleich
1.5 ULN*
Ja
Nein
Serum-Kreatinin kleiner oder gleich 2 x ULN*
Ja
Nein
ECOG-Status im Bereich von 0 bis 2*
Ja
Nein
Schriftliche Einwilligungserklärung des
aufgeklärten Patienten vor jeglicher
Studienintervention erhalten*
Ja
Nein
Unterschrift
Klinik*
Datum*
Unterschrift*
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Ausschlusskriterien NCT01657604 Chronic
Myeloid Leukemia
http://clinicaltrials.gov/ct2/show/NCT01657604
All rights reserved. Please visit https://medical-data-
models.org/forms/4643
Ausschlusskriterien
Adiminstrative Daten I
Klinik-Nr.*
Patienten-Nr.*
Geburtsdatum
Geburtsmonat*
Geburtstag*
Adiminstrative Daten II
Beurteilungsdatum*
Diagnosedatum*
Geschlecht*
männlich (männlich)
weiblich (weiblich)
Ausschlusskriterium
Vorbestehende beeinträchtige kardiale Funktion:
LVEF kleiner als 45%, kongenitales Long-QT-
Syndrom, vormals oder aktuell bestehende
klinische relevante ventrikuläre oder atriale
Tachyarrhythmien*
Ja
Nein
Klinisch relevatne Ruhe-Bradykardie (weniger als
50 bpm)*
Ja
Nein
QTc größer als 450ms auf Screening-EKG*
Ja
Nein
Myokardinfarkt innerhalb der letzten 12 Monate
vor Therapiebeginn*
Ja
Nein
Andere klinisch relevante Herzerkrankungen
(z.Bsp. Instabile Angina pectoris, schwere
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Herinsuffzienz, nicht kontrollierter
Bluthochdruck)*
Ja
Nein
Innerhalb des letzten Jahres vor Therapiebeginn
bestehende akute oder chronische Pankreatitis*
Ja
Nein
Akute oder chronische Virus-Hepatitis mit
moderater oder schwerwiegender
Leberfunktionsstörung (Child-Pugh Score größer
als 6), auch falls unter Kontrolle*
Ja
Nein
Weitere vorliegende unkontrollierte Erkrankung
(z.Bsp. Unkontrollierter Diabetes mellitus,
bestehende oder nicht kontrollierte Infektionen,
akute oder chronische Leber- oder
Nierenerkrankungen), die nicht akzeptable
Sicherheitsrisiken darstellen oder die Protokoll-
Compliance beeinträchtigen könnten*
Ja
Nein
Beeinträchtigte gastrointestinale Funktionen oder
Krankheiten, die die Absorption der
Studienmedikamente beeinflussen könnten (z.
Bsp. Ulcera, unkontrollierte Übelkeit, Erbrechen
oder Diarrhoe, Malabsorptions-Syndrom,
Dünndarmresektion oder Magen-Bypass
Operation)*
Ja
Nein
Begleitmedikation mit potentieller QT –
Verlängerung*
Ja
Nein
Begleitmedikation mit nachgewiesenem
Induktions- oder Inhibitationseffekt auf das
CYP450 iso-Enzym CYP3A4*
Ja
Nein
Schwerwiegender chirurgischer Eingriff in den
letzten beiden Wochen vor Therapiebeginn, oder
bei länger zurückliegendem Eingriff, falls sich der
Patient noch nicht vollständig von diesem erholt
hat*
Ja
Nein
Schwangerschaft, Stillzeit oder Frauen im
gebärfähigen Alter, die keine effektiven
Verhütungsmaßnahmen vornehmen. Als post-
menopausaler Lebensabschnitt gilt, wenn bei
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Frauen im fortgeschrittenen Lebensalter die letzte
Regelblutung mindestens ein Jahr zurückliegt*
Ja
Nein
HIV-Positivität, Test hierauf jedoch nicht
obligatorisch*
Ja
Nein
Bestehende Autoimmunerkrankungen, inklusive
Autoimmunhepatitis*
Ja
Nein
Bekannte schwerwiegende Hypersensitivität-
Reaktionen auf  Peginterferon alfa-2b oder
Interferon alfa-2b oder dessen Arzneistoffträger*
Ja
Nein
Bekannte schwerwiegende Hypersensitivität-
Reaktionen auf Nilotinib*
Ja
Nein
Patienten mit anderen primären malignen
Erkrankungen, falls diese aktuell klinisch relevant
sind oder klinischer Interventionen bedürfen*
Ja
Nein
Patienten mit fehlender Bereitschaft oder
fehlendem Vermögen zur Protokoll-Compliance*
Ja
Nein
Unterschrift
Klinik*
Datum*
Unterschrift*
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register Finish Cancer Registry cancer
Data set from the Finish cancer registry, with friendly
permission
(http://www.cancer.fi/syoparekisteri/en/registration/forms-
and-instructions/)
All rights reserved. Please visit https://medical-data-
models.org/forms/4701
register
CancerRegistry
Patientennummer*
Patientenname*
Patienten-Geschlecht*
männlich (1)
weiblich (2)
Postleitzahl Patient*
Wohnort*
frühere Tumorerkrankung
frühere Tumorerkrankung*
Ja
Nein
Lokalisation Primärtumor*
Ort der Behadnlung*
Datum der Diagnose*
Aktueller Tumor
Lokalisation Primärtumor*
Datum der Diagnose*
Diagnosesicherheit*
unbekannt (0 = Unknown)
klinische Diagnose (1 = Clinical)
Operation (2 = Surgery)
Röntgen (3 = X-ray)
Zytologischer Befund (4 = Cytology)
Histologischer Befund (5 = Histology
from primary tumour)
Histologischer Befund (6 = Histology
from metastasis)
mikroskopische Autopsie (7 = Autopsy,
microscopial)
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Autopsie (8 = Autopsy, macroscopial)
spezielle Tumormarker (9 = Specific
tumour markers)
Morphologie Grad (PAD)*
Stadium*
Primärtumor (1 = Localised)
Metastasen in regionären Lymphknoten
(2 = Metastasis in regional lymph nodes
only)
Fernmetastasen (3 = Distant metastasis
or tumour invades adjacent tissue)
unbekannter Primärtumor (4 = non-
localised, NOS)
Unbekannt (5 = not known)
T-Stadium*
N - Stadium der regionalen Lymphknoten*
M- Stadium*
Therapie
keine Informationen zu Therapie*
Ja
Nein
Operation
Operation*
Ja
Nein
Intention*
kurativ (1 = Curative)
palliativ (2 = Palliative)
nicht spezifiziert (3 = Unspecified)
Krankenhaus*
Operationsdatum*
Bezeichnung der OP*
Strahlentherapie
Strahlentherapie*
Ja
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Nein
Intention*
kurativ (1 = Curative)
palliativ (2 = Palliative)
nicht spezifiziert (3 = Unspecified)
Krankenhaus*
Datum der ersten Strahlentherapie*
Strahlendosis*
Chemotherapie*
Ja
Nein
Krankenhaus*
Datum der ersten Chemotherapie*
Chemotherapie Substanz*
Endokrine Therapie*
Ja
Nein
Krankenhaus*
Datum der ersten endokrinen Therapie*
Behandlung endokrine Therapie*
andere Therapie*
Ja
Nein
Krankenhaus*
Datum der ersten Behandlung*
Behandlung - Freitext*
keine Therapie*
Ja
Nein
Begründung*
hohes Alter (1 = old age)
unheilbare Erkrankung (2 = incurable
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disease)
Verweigerung durch Patient (3 = Patient
refusal)
anderweitig überwiesen (4 = Referred
elsewhere (name institution))
anderer Status (5 = Other (state))
Name der Institution*
Status*
Todesdatum*
Todesursache*
Meldestelle*
Datum*
Kommentar*
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Breast Cancer NCT00053339 Treatment - CALGB: 49903 ADVANCED
TREATMENT SUMMARY FORM; All Patients - 2054479v3.0
CALGB: 49903 ADVANCED TREATMENT SUMMARY
FORM; All Patients
Trastuzumab With or Without Tamoxifen in Treating Women
With Progressive Stage IV Breast Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=A73D1CA4-
8ADF-4761-E034-0003BA0B1A09
All rights reserved. Please visit https://medical-data-
models.org/forms/4703
CALGB: 49903 CCRR ADVANCED
TREATMENT SUMMARY FORM - all
patients
Header
CALGB Form
CALGB Study No
CALGB Patient ID
First date protocol therapy was given
Last date protocol therapy was given (M)
Amended data?
Yes (Yes)
IDs
Patient's Name
Participating Group
Patient Hospital Number
Participating Group Protocol No.
Main Member Institution/Adjunct
Participating Group Patient No.
Treatment Cycle Information
Total Dose of Drugs for this Regimen [mg]
Agent Name
1 / 3
Reason Treatment Ended (mark one with an X)
Alternative Therapy (Alternative therapy)
Death On Study (Death on study)
Disease Progression, Relapse During
Active Treatment (Disease progression,
relapse during active treatment)
Patient Off-treatment For Other
Complicating Disease (Other
complicating disease)
Other (Other, specify)
Patient Withdrawal Or Refusal After
Beginning Protocol Therapy (Patient
withdrawal or refusal after beginning
protocol therapy)
Patient Withdrawal Or Refusal Prior To
Beginning Protocol Therapy (Patient
withdrawal or refusal prior to beginning
protocol therapy)
Toxicity/side Effects/complications
(Toxicity/side effects/complications)
Treatment Completed Per Protocol
Criteria (Treatment completed per
protocol criteria)
Other, specify (reason treatment ended)
Treatment Schedule - Systemic Therapy
Were there any dose modifications or additions/
omissions to protocol treatment? (mark one with
an X)
No (No)
Unknown (Unknown)
(i.e., The Treatment Was Changed
According To Protocol Guidelines) (Yes,
planned)
(i.e., The Treatment Change Was Not
Part Of Protocol Guidelines) (Yes,
unplanned)
Treatment Schedule - Other Therapy
Were any optional protocol therapies given?
No (No)
Yes (Yes)
optional protocol therapy name(s)
Was any concurrent non-protocol therapy given
during protocol treatment?
No (No)
Yes (Yes)
indicate below (concurrent non-protocol therapy
given during protocol treatment) (mark all that
apply with an X)
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Concurrent Non-protocol Biologic
Response Modifier Therapy (Concurrent
non-protocol biologic response modifier
therapy)
Concurrent Non-protocol Chemotherapy
(Concurrent non-protocol chemotherapy)
Concurrent Non-protocol High Dose
Chemotherapy/autologous Stem Cell
Transplant (Concurrent non-protocol high
dose chemotherapy/ autologous stem
cell transplant)
Concurrent Non-protocol Hormonal
Therapy (Concurrent non-protocol
hormonal therapy)
Concurrent Non-protocol Radiation
Therapy (Concurrent non-protocol
radiation therapy)
Comments
Comments
Signature
Completed By (Print or Type Name)
Date Completed
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TREATMENT SUMMARY FORM; All Patients - 2054479v3.0
Breast Cancer NCT00053339 Follow-Up - CALGB:
Secondary Malignancy Form - 2029264v3.0
CALGB: Secondary Malignancy Form
Trastuzumab With or Without Tamoxifen in Treating Women
With Progressive Stage IV Breast Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=A73D10AA-
19A6-4733-E034-0003BA0B1A09
All rights reserved. Please visit https://medical-data-
models.org/forms/4707
CALGB: Secondary Malignancy
Form
CALGB Form
CALGB Study No
CALGB Patient ID
Amended data?
Yes
No
Patient's Name
Participating Group
Patient Hospital Number
Participating Group Protocol No.
Main Member Institution/Adjunct
Participating Group Patient No.
Type of secondary malignancy (site, histology)
Date of first pathologic diagnosis of secondary
malignancy
Has FDA Form 3500 (MEDWATCH) or NCI/CTEP
Secondary AML/MDS Form been sent to Central
Office?
No (no)
Yes (yes)
1 / 2
If yes, specify date sent (MEDWATCH)
If no, specify reason not sent (MEDWATCH)
Comments
Completed by
Date completed
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Eligibility Criteria NCT00035451 AF
clinicaltrials.gov/ct2/show/NCT00035451
All rights reserved. Please visit https://medical-data-
models.org/forms/4709
Eligibility
Inclusion criteria
Documented (12-lead ECG) history of
symptomatic atrial fibrillation occurring between
48 hours and 6 months before screening*
Yes
No
procedure of cardioversion (electric shock to
correct abnormal rhythm)*
Yes
No
Patient anticoagulated according to the
recommendations of the Study Group on Atrial
Fibrillation of the European Society of Cardiology
guidelines*
Yes
No
Exclusion criteria
Previously unsuccessful electrical cardioversions*
Yes
No
Failed to respond to any Class III antiarrhythmic
drugs*
Yes
No
Qualifying arrhythmia due to acute reversible
illness, acute myocardial infarction, and/or
cardiac or thoracic surgery within one month prior
to randomization*
Yes
No
1 / 1
Eligibility Criteria NCT00044564
clinicaltrials.gov/ct2/show/NCT00044564
All rights reserved. Please visit https://medical-data-
models.org/forms/4710
Eligibility
Inclusion criteria
measurable disease as defined by the presence
of at least one measurable lesion*
Yes
No
prior immunotherapy (up to 2 regimens) or prior
radiotherapy is permitted but at least 4 weeks
must have elapsed prior to enter study*
Yes
No
life expectancy of at least 12 weeks*
Yes
No
adequate bone marrow, liver and kidney function*
Yes
No
Exclusion criteria
excluded medical conditions like: pre-existing
neuropathy, active heart diseases or ischemia,
serious infections, HIV infection, chronic hepatitis
B or C, brain metastasis, seizures,
hypersensitivity to taxanes, organ transplants,
some previous cancers*
Yes
No
excluded therapies and medications, previous
and concomitant such as: anticancer
chemotherapy or immunotherapy during the study
or within 4 weeks prior to study entry; more than
two prior anticancer chemotherapy regimens;
radiotherapy during study or within 4 weeks prior
to study entry; bone marrow transplant*
Yes
No
others: pregnant or breast-feeding patients; both
men and women enrolled in this trial must use
adequate barrier birth control measures during
the course of the trial; substance abuse, medical,
psychological or social conditions that may
interfere with the patient's participation*
Yes
No
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Eligibility NCT00048295 Crohns Disease
see http://clinicaltrials.gov/ct2/show/study/NCT00048295
ISIS 2302 is an antisense oligonucleotide drug that reduces
the production of a specific protein called intercellular
adhesion molecule (ICAM-1), a substance that plays a
significant role in the increase of inflammation. People with
Crohn’s disease have been shown to over-produce ICAM-1
in their gut tissues. Alicaforsen works by blocking ICAM-1
messenger RNA, the “instruction” molecule that is required
for the production of ICAM-1 protein. This trial will examine
effects of alicaforsen delivered by 2-hour intravenous
infusion over a four-week period, compared to a placebo.
Patients may remain on stable background 5-ASA,
antibiotic, or immunosuppressive drugs, and prednisone (or
equivalent) at </= 30 mg per day.
All rights reserved. Please visit https://medical-data-
models.org/forms/4712
Eligibility NCT00048295
Inclusion
Age at least 12 years*
Weight at least 36 kg*
Yes
No
CDAI score of 220 - 400*
Yes
No
Documentation of Crohns disease activity by
endoscopy, biopsy or imaging in the last 2 years*
Yes
No
No TNF-alpha inhibitor treatment for three
months prior to first study drug infusion*
Yes
No
Exclusion
Known severe, fixed, symptomatic stenosis of the
small or large intestine with significant dilation*
Yes
No
Extensive external fistulization (> 3 external
fistulae which are expressible with gentle
compression); colostomy or ileostomy*
Yes
No
Active infection, including infectious colitis, or
infection with HIV, Hepatitis B or Hepatitis C*
Yes
No
Malignancy within 3 years or poorly controlled
medical illness*
Yes
No
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Requires intravenous heparin therapy or with a
history of a bleeding problem*
Yes
No
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Eligibility NCT00048295 Crohns Disease
Eligibility Criteria NCT00044915
see http://clinicaltrials.gov/ct2/show/study/NCT00044915
All rights reserved. Please visit https://medical-data-
models.org/forms/4714
Eligibility NCT00044915
Inclusion criteria
Acute ischemic stroke of hemispheric localization
(exclude brainstem and cerebellum), of
suspected thromboembolic origin*
Yes
No
Males or females aged 18 years or over*
Yes
No
National Institute of Health Stroke Scale (NIH-SS)
total score 8 to 23 with a motor deficit >/= 2 (for
either one arm or leg) and level of consciousness
< 2 and at least one of the following: Visual field
deficit, neglect, or aphasia. If a patient receives t-
PA, NIH-SS must be performed prior to receiving
the study drug but after infusion of t-PA is
initiated*
Yes
No
Exclusion criteria
CT scan evidence of clearly defined areas of
hypodensity indicating infarction of >1/3 of the
MCA territory or evidence of significant mass
effect with shift of midline or major areas of sulcal
effacement associated with loss of cortical
definition (grey-white distinction). Minor early CT
changes are common in MCA strokes and
patients with early or subtle changes are eligible.*
Yes
No
CT scan evidence of a primary intra-cerebral
haemorrhage or any finding not consistent with
an acute ischemic stroke as the cause of
presenting symptoms*
Yes
No
Clinical evidence of acute stroke due to lacunar
infarct (pure motor hemiplegia; pure sensory
deficit, ataxia/clumsy hand syndromes)*
Yes
No
Neurological (other than the presenting stroke) or
psychiatric conditions that may affect the patient's
functional status and/or that may interfere with
the patient's assessment*
Yes
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No
Clinically relevant pre-existing neurological deficit
(Historical Rankin score >/= 2 regardless of
cause)*
Yes
No
Generalized seizures having developed since the
onset of stroke symptoms*
Yes
No
Systolic blood pressure >210 or <110 mmHg
(confirmed by up to three readings prior to
randomization)*
Yes
No
Diastolic blood pressure >110 or <60 mmHg
(confirmed by up to three readings prior to
randomization)*
Yes
No
Myocardial infarction within 3 months, unstable
angina within 3-5 days prior to starting infusion,
unstable supra-ventricular and/or ventricular
arrhythmia, severe conduction defect (AV block
grades 2 and 3), complete left or right Bundle
Branch Block, bradycardia (heart rate [HR] less
than 50 bpm), uncompensated heart failure*
Yes
No
History of myocarditis, cardiomyopathy or aortic
stenosis*
Yes
No
Patients known to have prolonged QTc intervals
(inherited and sporadic syndromes of QTc
prolongation or QTc interval >450 msec males
and 470 msec females on baseline ECG) or
using Class IA or Class III antiarrhythmic drugs
(e.g., quinidine, procainamide, amiodarone,
sotalol)*
Yes
No
Any patients that require initiation of new digoxin
therapy are excluded. Patients already on digoxin
therapy (for at least 1 month stable dose) at time
of enrollment will be allowed in the study.*
Yes
No
Electrolyte imbalance at baseline. Should the
results not be available before starting the study
drug infusion, the patients will be allowed in the
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Eligibility Criteria NCT00044915
study providing that the corrective therapy of any
abnormal electrolyte results is implemented
immediately upon availability of the laboratory
report.*
Yes
No
Any conditions predisposing to electrolyte
imbalances (e.g., chronic vomiting, anorexia
nervosa, bulimia nervosa) will also be excluded at
baseline.
*
Yes
No
Participation in a research protocol for
investigation of a pharmaceutical agent or
innovative invasive procedure (including intra-
arterial t-PA) within the past 30 days*
Yes
No
Previously in the BRAIN-Study or treated with
repinotan*
Yes
No
Life expectancy of less than 6 months due to
comorbid conditions*
Yes
No
Any other known clinically significant medical
disorder (e.g., cardiovascular, gastrointestinal,
hepatic, renal, endocrine, major uncompensated
metabolic disturbances, respiratory,
immunological, hematological or bleeding
disorder, cancer, AIDS)*
Yes
No
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Eligibility Criteria NCT00044915
Anal Cancer NCT00324415 Demographic - AMC-
045 Demographic Form (DEM) - 2937136v1.0
AMC-045 Demographic Form (DEM)
Cisplatin, Fluorouracil, Cetuximab, and Radiation Therapy
in Treating Patients With HIV and Stage I, Stage II, or
Stage III Anal Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=72857762-
35A6-7AF0-E040-BB89AD434241
All rights reserved. Please visit https://medical-data-
models.org/forms/4734
Demographic Form AMC-045
Demographics
Patient Initials (First, Last)
Patient's Date of Birth (mm/dd/yyyy)
Gender
Female (f)
Male (m)
Ethnicity
A Person Of Mexican, Puerto Rican,
Cuban, Central Or South American Or
Other Spanish Culture Or Origin,
Regardless Of Race. (Hispanic or Latino)
A Person Not Meeting The Definition For
Hispanic Or Latino. (Not Hispanic or
Latino)
Could Not Be Determined Or Unsure
(Unknown)
Patient Race (check all that apply)
A Person Having Origins In Any Of The
Original Peoples Of North And South
America (including Central America),
And Who Maintains Tribal Affiliation Or
Community Attachment. (American
Indian or Alaska Native)
A Person Having Origins In Any Of The
Original Peoples Of The Far East,
Southeast Asia, Or The Indian
Subcontinent Including, For Example,
Cambodia, China, India, Japan, Korea,
Malaysia, Pakistan, The Philippine
Islands, Thailand, And Vietnam. (Asian)
A Person Having Origins In Any Of The
Black Racial Groups Of Africa. Terms
Such As "haitian" Or "negro" Can Be
Used In Addition To "black Or African
American." (Black or African American)
A Person Having Origins In Any Of The
Original Peoples Of Hawaii, Guam,
Samoa, Or Other Pacific Islands. (Native
Hawaiian or other Pacific Islander)
Could Not Be Determined Or Unsure
(Unknown)
A Person Having Origins In Any Of The
Original Peoples Of Europe, The Middle
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East, Or North Africa. (White)
Patient Zip Code (xxxxx)
Patient Method of Payment
Medicaid (Medicaid)
Medicaid And Medicare (Medicaid and
Medicare)
Medicare (Medicare)
Medicare And Private Insurance
(Medicare and Private Insurance)
Military Or Veterans Sponsored Nos
(Military or Veterans Sponsored, Not
Otherwise Specified (NOS))
Military Sponsored (including Champus
& Tricare) (Military Sponsored (including
CHAMPUS & TRICARE))
No Means Of Payment (no Insurance)
(No means of payment (no insurance))
Other (Other)
Private Insurance (Private Insurance)
Self Pay (no Insurance) (Self Pay (No
Insurance))
Unknown (Unknown)
Veterans Sponsored (Veterans
Sponsored)
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Anal Cancer NCT00324415 Demographic - AMC-045 Demographic Form
(DEM) - 2937136v1.0
Breast Cancer NCT00684983 Demographic -
NCCTG N0733 Demography Form - 2842806v1.0
NCCTG N0733 Demography Form
Capecitabine and Lapatinib With or Without Cixutumumab
in Treating Patients With Previously Treated HER2-Positive
Stage IIIB, Stage IIIC, or Stage IV Breast Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=643B1D4E-
2802-CA4C-E040-BB89AD432C8F
All rights reserved. Please visit https://medical-data-
models.org/forms/4738
Demography Form NCCTG N0733
Standard Patient Identifier
Patient Initials LastName
Patient initials first name
Patient initials middle name
Patient SSN
Patient Medical Record Number
Standard Demographics
Ethnicity
A Person Of Mexican, Puerto Rican,
Cuban, Central Or South American Or
Other Spanish Culture Or Origin,
Regardless Of Race. (Hispanic or Latino)
A Person Not Meeting The Definition For
Hispanic Or Latino. (Not Hispanic or
Latino)
Not Provided Or Available (Not reported)
Could Not Be Determined Or Unsure
(Unknown)
Gender of a Person
Female Gender (Female Gender)
Male Gender (Male Gender)
Unknown (Unknown)
Unspecified (Unspecified)
Patient's Date of Birth
2000 Census Tract  Codes
Patient's Country of Residence
Patient's ZIP Code
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Race
Race Category
A Person Having Origins In Any Of The
Original Peoples Of North And South
America (including Central America),
And Who Maintains Tribal Affiliation Or
Community Attachment. (American
Indian or Alaska Native)
A Person Having Origins In Any Of The
Original Peoples Of The Far East,
Southeast Asia, Or The Indian
Subcontinent Including, For Example,
Cambodia, China, India, Japan, Korea,
Malaysia, Pakistan, The Philippine
Islands, Thailand, And Vietnam. (Asian)
A Person Having Origins In Any Of The
Black Racial Groups Of Africa. Terms
Such As "haitian" Or "negro" Can Be
Used In Addition To "black Or African
American." (Black or African American)
A Person Having Origins In Any Of The
Original Peoples Of Hawaii, Guam,
Samoa, Or Other Pacific Islands. (Native
Hawaiian or other Pacific Islander)
Not Provided Or Available (Not
Reported)
Could Not Be Determined Or Unsure
(Unknown)
A Person Having Origins In Any Of The
Original Peoples Of Europe, The Middle
East, Or North Africa. (White)
Method Of Payment
Method of Payment
Private Insurance (1)
Medicare (2)
Medicare And Private Insurance (3)
Medicaid (4)
Medicaid And Medicare (5)
Military Or Veterans Sponsored Nos (6)
Military Sponsored (including Champus
&tricare) (6a)
Veterans Sponsored (6b)
Self Pay (no Insurance) (7)
No Means Of Payment (no Insurance)
(8)
Other (98)
Unknown (99)
Optional Questions
CDC Race Code
CDC Ethnicity Code
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Breast Cancer NCT00684983 Demographic - NCCTG N0733
Demography Form - 2842806v1.0
Education Level
10th Grade (10th Grade)
11th Grade (11th Grade)
12th Grade (12th Grade No Diploma)
1st Grade (1st Grade)
2nd Grade (2nd Grade)
3rd Grade (3rd Grade)
4th Grade (4th Grade)
5th Grade (5th Grade)
6th Grade (6th Grade)
7th Grade (7th Grade)
8th Grade (8th Grade)
9th Grade (9th Grade)
Academic Doctorate Degree Completion
(Academic Doctorate Degree)
Associate Degree (Associate Degree)
Bachelor's Degree Completion (Bachelor
Degree)
Does Not Know (Don't Know)
General Equivalency Diploma (General
Equivalency Diploma)
High School Graduate (High School
Graduate)
Kindergarten Completion (Kindergarten)
Master's Degree Completion (Master's
Degree)
Never Attended (No Formal Schooling)
Preschool Completion (Preschool)
Professional Doctorate Degree
Completion (Professional Doctorate
Degree)
Refuse (Refused)
Some College (Some College, No
Degree)
Vocational Degree (VoTech Program)
Marital Status
Divorced: C51776 (Divorced)
Domestic Partner (Domestic Partnership)
Married: C51773 (Married)
Never Married (Never Married)
Separated (Separated)
Widowed (Widowed)
Place of Birth
3 / 3
Breast Cancer NCT00684983 Demographic - NCCTG N0733
Demography Form - 2842806v1.0
Eligibility NCT00153023 Type 2 diabetes
mellitus
1 Year Trial Telmisartan 80 mg Versus Valsartan 160 mg in
Hypertensive Type 2 Diabetic Patients With Overt
Nephropathy
see http://clinicaltrials.gov/ct2/show/study/NCT00153023
All rights reserved. Please visit https://medical-data-
models.org/forms/4740
Eligibility Hypertension and Diabetes
NCT00153023
Inclusion Criteria
30 to 80 Years*
Yes
No
Type 2 diabetes mellitus*
Yes
No
Hypertension at screening defined as: an
average cuff systolic blood pressure > 130 mmHg
and/or diastolic blood pressure >80 mmHg in
untreated patients OR
patients receiving antihypertensive therapy (i.e.,
medications specifically prescribed to treat
hypertension)*
Yes
No
Overt nephropathy defined by 24 hour proteinuria
>= 900 mg and by serum creatinine below 265
mol/l (3.0 mg/dl)*
Yes
No
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Eligibility NCT00079482  AML
Study of CEP-701 in Patients With Acute Myeloid Leukemia
(AML)
See http://clinicaltrials.gov/ct2/show/study/NCT00079482
All rights reserved. Please visit https://medical-data-
models.org/forms/4745
Eligibility AML NCT00079482
Inclusion criteria
cytological confirmation of AML*
Yes
No
relapsed disease following first CR of 1
month(30days) to 24 months(730days). The time
from first relapse to study entry (start of first
course of induction chemotherapy) must be no
longer than 30days*
Yes
No
confirmation of FLT-3 activating mutation positive
status after point of initial relapse*
Yes
No
aged 18 years or older*
Yes
No
no comorbid conditions that would limit life
expectancy to less than 3 months*
Yes
No
ECOG Performance Score of 0, 1,or 2*
Yes
No
women must be neither pregnant nor lactating,
and either of non-childbearing potential or using
adequate contraception with a negative
pregnancy test at study entry
*
Yes
No
Exclusion criteria
bilirubin > 2x ULN*
Yes
No
ALT/AST > 3x ULN
*
Yes
No
serum creatinine > 1.5 mg/dL*
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Yes
No
resting ejection fraction of left ventricle < 45%
(applies only to patients scheduled to receive
mitoxantrone, etoposide, and cytarabine (MEC))*
Yes
No
untreated or progressive infection*
Yes
No
any physical or psychiatric condition that may
compromise participation in the study*
Yes
No
known CNS involvement with AML*
Yes
No
any previous treatment with a FLT-3 inhibitor
*
Yes
No
requires current treatment for HIV with protease
inhibitors*
Yes
No
active GI ulceration or bleeding
*
Yes
No
use of an investigational drug that is not expected
to be cleared by the start of CEP-701 treatment*
Yes
No
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Eligibility NCT00079482  AML
Eligibility NCT00661609 Bladder Cancer
Phase II Study of AZD4877 (a Novel Anti-mitotic Agent)
See http://clinicaltrials.gov/ct2/show/record/NCT00661609
All rights reserved. Please visit https://medical-data-
models.org/forms/4755
Eligibility Advanced Bladder Cancer
NCT00661609
Inclusion criteria
Confirmed urothelial cancer (cancer of the
bladder, renal pelvis, ureter, or urethra)*
Yes
No
Tumor, Node, Metastasis (TNM) Stage IV
urothelial cancer that can not be helped by
curative surgery and/or curative radiotherapy*
Yes
No
Must have had a maximum of 2 prior
chemotherapeutic regimens, one for unremovable
and/or metastasized disease, and the other in the
adjuvant or neo-adjuvant setting*
Yes
No
Ambulatory and capable of all selfcare more than
50% of waking hours*
Yes
No
Exclusion criteria
Prior treatment with investigational or standard
anti-cancer agents, including radiotherapy, within
4 weeks prior to first dose of study medication, 6
weeks if prior systemic mitomycin, nitrosourea, or
suramin.*
Yes
No
Inadequate bone marrow reserve*
Yes
No
Inadequate liver function in the presence of liver
metastases*
Yes
No
Impaired renal function*
Yes
No
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Eligibility NCT00126087   Stroke
The investigators plan to improve the learning of motor
skills by pharmacological means (dopamine), and by
noninvasive brain stimulation. They will study both healthy
subjects and chronic stroke patients. In addition, they want
to study the mechanisms of enhanced learning, on the
molecular and the systems level.
Condition: Stroke
Intervention: drug dopamine
Phase 4
See http://clinicaltrials.gov/ct2/show/record/NCT00126087
All rights reserved. Please visit https://medical-data-
models.org/forms/4757
Eligibility Stroke NCT00126087
Inclusion healthy volunteers
18 Years  to 80 Years*
Yes
No
Normal neurological examination*
Yes
No
Mini Mental State Examination of more than 27*
Right Handedness*
Yes
No
Inclusion patients
Cortical or subcortical stroke with an initial severe
hemiparesis Medical Research Council (MRC)
scale less than 2 that has recovered to a degree
that patients are able to perform the proposed
task (in general more than MRC 4.5, with low
spasticity, work in progress on motor learning in
stroke patients)*
Yes
No
At least 1 year post-stroke*
Yes
No
Mini Mental State Examination more than 27*
Right Handedness*
Yes
No
Exclusion Criteria healthy volunteers and
stroke patients
No antipsychotic, antidepressant drugs, and
drugs affecting the dopaminergic system*
Yes
No
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Eligibility NCT00148213 Thyroid
Neoplasms
see http://clinicaltrials.gov/ct2/show/study/NCT00148213
All rights reserved. Please visit https://medical-data-
models.org/forms/4761
Eligibility Thyroid Carcinoma
NCT00148213
Inclusion Criteria
histological diagnosis of differentiated thyroid
carcinoma*
Yes
No
total or near total thyroidectomy*
Yes
No
informed consent*
Yes
No
Exclusion Criteria
no informed consent*
Yes
No
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A Phase II Study of AZD4877 (a Novel Anti-
mitotic
The purpose of this Phase II study is to determine if
AZD4877, an experimental drug that is a novel anti-mitotic
agent (Eg5 or Kinesin Spindle Protein inhibitor that
interferes with tumor cell division leading to tumor growth),
can reduce tumor sizes in patients with bladder cancer
see http://clinicaltrials.gov/ct2/show/study/NCT00661609
All rights reserved. Please visit https://medical-data-
models.org/forms/4762
Eligibility Bladder Cancer
NCT00661609
Inclusion criteria
Confirmed urothelial cancer (cancer of the
bladder, renal pelvis, ureter, or urethra).*
Yes
No
Tumor, Node, Metastasis (TNM) Stage IV
urothelial cancer that can not be helped by
curative surgery and/or curative radiotherapy*
Yes
No
Must have had a maximum of 2 prior
chemotherapeutic regimens, one for unremovable
and/or metastasized disease, and the other in the
adjuvant or neo-adjuvant setting.*
Yes
No
Ambulatory and capable of all selfcare more than
50% of waking hours*
Yes
No
Exclusion criteria
Prior treatment with investigational or standard
anti-cancer agents, including radiotherapy, within
4 weeks prior to first dose of study medication; 6
weeks if prior systemic mitomycin, nitrosourea, or
suramin.*
Yes
No
Inadequate bone marrow reserve*
Yes
No
Inadequate liver function in the presence of liver
metastases*
Yes
No
Impaired renal function*
Yes
No
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Eligibility NCT00824083 Sarcoma, Ewing's
Functional and Clinical Long-Term Outcome of Ewing
Sarcoma Treatment
see http://clinicaltrials.gov/show/NCT00824083
All rights reserved. Please visit https://medical-data-
models.org/forms/4763
Eligibility Ewing Sarcoma
NCT00824083
Einschlusskriterien
Alter 6 bis 60 Jahre*
Ja
Nein
CESS81/CESS86/EICESS92/EURO-
E.W.I.N.G.99 trials participants of the German
Society of Pediatric Hematology and Oncology
(GPOH) *
Ja
Nein
Ausschlusskriterien
no complete remission (CR)*
Ja
Nein
any kind of paralysis*
Ja
Nein
<5y after diagnosis*
Ja
Nein
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CDASH Adverse Event
translated and modified from
CDASH Adverse Event 2011-10-24
http://www.cdisc.org/
All rights reserved. Please visit https://medical-data-
models.org/forms/4775
Adverse Event
Generelle Information
Ist ein Adverse Event aufgetreten?*
Nein (N)
Ja (Y)
Details
Ist ein Adverse Event aufgetreten?*
Anfangsdatum*
Andauernd?*
Nein (N)
Ja (Y)
EndDatum*
Schweregrad*
leicht (MILD)
mittel (MODERATE)
schwer (SEVERE)
Schweres Adverse Event*
Nein (N)
Ja (Y)
Kongenitale Anomalie oder Geburtsfehler*
Nein (N)
Ja (Y)
Signifikante Behinderung*
Nein (N)
Ja (Y)
Tod*
Nein (N)
Ja (Y)
Krankenhausaufenthalt*
Nein (N)
Ja (Y)
Lebensbedrohlich*
Nein (N)
Ja (Y)
Anderes medizinisch wichtiges Ereignis*
Nein (N)
Ja (Y)
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Bezug zur Studienbehandlung*
kein Bezug (NOT RELATED)
möglicherweise Bezug (POSSIBLY)
Bezug (RELATED)
Bezug unwahrscheinlich (UNLIKELY)
Änderung der Studienbehandlung*
Dosiserhöhung (DOSE INCREASED)
Dosis unverändert (DOSE NOT
CHANGED)
Dosis reduziert (DOSE REDUCED)
Medikament unterbrochen (DRUG
INTERRUPTED)
Medikament abgesetzt (DRUG
WITHDRAWN)
nicht anwendbar (NOT APPLICABLE)
unbekannt (UNKNOWN)
Andere Maßnahmen*
Outcome*
fatal (FATAL)
nicht wiederhergestellt (NOT
RECOVERED/NOT RESOLVED)
wiederhergestellt
(RECOVERED/RESOLVED)
wiederhergestellt mit Sequelae
(RECOVERED/RESOLVED WITH
SEQUELAE)
in Remission
(RECOVERING/RESOLVING)
unbekannt (UNKNOWN)
Ursache für Ausscheiden aus der Studie*
Nein (N)
Ja (Y)
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CDASH Adverse Event
CDASH Concomitant Medication
translated and modified from
CDASH 2011-10-24
http://www.cdisc.org
All rights reserved. Please visit https://medical-data-
models.org/forms/4776
Concomitant medication
Generelle Information
Irgendwelche Medikamente?*
Nein (N)
Ja (Y)
Details
Medikation
or
Therapy*
Wurde es vor Studienbeginn eingenommen?*
Nein (N)
Ja (Y)
Startdatum*
Ongoing*
Nein (N)
Ja (Y)
Endedatum*
Dosis*
Häufigkeit*
zweimal täglich (BID)
bei Bedarf (PRN)
viermal täglich (QID)
monatlich (QM)
jeden zweiten Tag (QOD)
dreimal täglich (TID)
unbekannt (UNKNOWN)
Route*
intraläsional (INTRALESIONAL)
intramuskulär (INTRAMUSCULAR)
intraokular (INTRAOCULAR)
intraperitoneal (INTRAPERITONEAL)
nasal (NASAL)
oral (ORAL)
rektal (RECTAL)
Inhalation (RESPIRATORY
(INHALATION))
subkutan (SUBCUTANEOUS)
topisch (TOPICAL)
transdermal (TRANSDERMAL)
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vaginal (VAGINAL)
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CDASH Concomitant Medication
CDASH Drug accountability(1)
modified from http://www.cdisc.org
All rights reserved. Please visit https://medical-data-
models.org/forms/4779
Drug accountability (1)
General information
DA Performed?*
NO (N)
YES (Y)
Study Treatment – Returned Amount
Treatment label ID*
Amount*
Study Treatment – Dispensed Amount
Treatment label ID*
Amount*
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CDASH Drug accountability (2)
modified from http://www.cdisc.org
All rights reserved. Please visit https://medical-data-
models.org/forms/4780
Drug accountability (2)
Study Treatment – Returned
DA Performed?*
NO (N)
YES (Y)
Study Treatment – Returned Amount
Date*
Treatment label ID*
Amount*
Study Treatment – Dispensed
DA Performed?*
NO (N)
YES (Y)
Study Treatment – Dispensed Amount
Date*
Treatment label ID*
Amount*
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CDASH Drug accountability (3)
modified from http://www.cdisc.org
All rights reserved. Please visit https://medical-data-
models.org/forms/4781
Drug accountability (3)
General information
DA Performed?*
NO (N)
YES (Y)
Study Treatment
Date (dispensed or returned)*
Dispensed or returned*
DISPAMT (Dispensed Amount)
RETAMT (Returned Amount)
Treatment label ID*
Amount*
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CDASH End of Study
modified from http://www.cdisc.org
All rights reserved. Please visit https://medical-data-
models.org/forms/4784
End of Study
End of Study
Completion or Discontinuation Date*
Completion or Discontinuation Time*
Status*
ADVERSE EVENT (ADVERSE EVENT)
COMPLETED (COMPLETED)
DEATH (DEATH)
LOST TO FOLLOW-UP (LOST TO
FOLLOW-UP)
OTHER (OTHER)
PHYSICIAN DECISION (PHYSICIAN
DECISION)
PROTOCOL VIOLATION (PROTOCOL
VIOLATION)
STUDY TERMINATED BY SPONSOR
(STUDY TERMINATED BY SPONSOR)
WITHDRAWAL BY SUBJECT
(WITHDRAWAL BY SUBJECT)
Specify Status*
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CDASH Demographics
modified from http://www.cdisc.org
All rights reserved. Please visit https://medical-data-
models.org/forms/4785
Demographics
Demographische Daten
Geburtsdatum*
Geschlecht*
weiblich (F)
männlich (M)
Ethnische Gruppe*
lateinamerikanisch (HISPANIC OR
LATINO)
nicht lateinamerikanisch (NOT HISPANIC
OR LATINO)
nicht berichtet (NOT REPORTED)
unbekannt (UNKNOWN)
Indianischer Herkunft oder aus Alaska*
Ja
Nein
Asiatischer Herkunft*
Ja
Nein
Afroamerikanischer Herkunft*
Ja
Nein
Herkunft aus Hawaii oder Pazifische Inseln*
Ja
Nein
Europäischer Herkunft*
Ja
Nein
Andere ethnische Herkunft*
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CDASH Protocol Deviations
modified from http://www.cdisc.org
All rights reserved. Please visit https://medical-data-
models.org/forms/4787
Protocol Deviations
Generelle Information
Abweichung vom Studienprotokoll?*
nein (N)
ja (Y)
Details
Angaben zur Abweichung vom Studienprotokoll*
Datum und Uhrzeit des Beginns der Abweichung
vom Studienprotokoll*
Datum und Uhrzeit des Endes der Abweichung
vom Studienprotokoll*
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CDASH ECG - Scenario 1
modified from http://www.cdisc.org
All rights reserved. Please visit https://medical-data-
models.org/forms/4789
ECG – Scenario 1
General information
ECG Performed*
NO (N)
YES (Y)
ECG Information (Central processing)
ECG Reference ID*
ECG Method*
12 LEAD 1 LEAD MISSING (12 LEAD 1
LEAD MISSING)
12 LEAD CABRERA (12 LEAD
CABRERA)
12 LEAD EASI DOWER
TRANSFORMATION (12 LEAD EASI
DOWER TRANSFORMATION)
12 LEAD MASON LIKAR (12 LEAD
MASON LIKAR)
12 LEAD MODIFIED MASON LIKAR (12
LEAD MODIFIED MASON LIKAR)
12 LEAD NON-STANDARD (12 LEAD
NON-STANDARD)
12 LEAD SINGLE PAD (12 LEAD
SINGLE PAD)
12 LEAD STANDARD (12 LEAD
STANDARD)
12 LEAD UNSPECIFIED (12 LEAD
UNSPECIFIED)
BIPOLAR UNCORRECTED XYZ LEAD
SYSTEM (BIPOLAR UNCORRECTED
XYZ LEAD SYSTEM)
CUBE LEAD SYSTEM (CUBE LEAD
SYSTEM)
FRANK LEAD SYSTEM (FRANK LEAD
SYSTEM)
MCFEE-PARUNGAO LEAD SYSTEM
(MCFEE-PARUNGAO LEAD SYSTEM)
PSEUDO-ORTHOGONAL XYZ LEAD
SYSTEM (PSEUDO-ORTHOGONAL
XYZ LEAD SYSTEM)
STANDARD 12-LEAD AND CC5-CM5-
ML (STANDARD 12-LEAD AND CC5-
CM5-ML)
STANDARD 12-LEAD AND CM5-CC5-
CH5 (STANDARD 12-LEAD AND CM5-
CC5-CH5)
STANDARD 12-LEAD EXTENDED LEFT
(STANDARD 12-LEAD EXTENDED
LEFT)
STANDARD 12-LEAD EXTENDED
RIGHT (STANDARD 12-LEAD
EXTENDED RIGHT)
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STANDARD LEADS FOR BICYCLE
EXERCISE (STANDARD LEADS FOR
BICYCLE EXERCISE)
STANDARD LEADS ONE
INTERCOSTAL SPACE HIGHER
(STANDARD LEADS ONE
INTERCOSTAL SPACE HIGHER)
VECTORCARDIOGRAPH CORRECTED
(VECTORCARDIOGRAPH
CORRECTED)
VECTORCARDIOGRAPH
UNCORRECTED
(VECTORCARDIOGRAPH
UNCORRECTED)
ECG Subject Position*
SITTING (SITTING)
STANDING (STANDING)
SUPINE (SUPINE)
ECG Date and Time*
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CDASH ECG - Scenario 1
CDASH ECG – Scenario 3
modified from http://www.cdisc.org
All rights reserved. Please visit https://medical-data-
models.org/forms/4792
ECG – Scenario 3 (central
information processing)
General information
ECG Performed*
NO (N)
YES (Y)
ECG Information (Central processing)
Reference  ID*
Method*
12 LEAD 1 LEAD MISSING (12 LEAD 1
LEAD MISSING)
12 LEAD CABRERA (12 LEAD
CABRERA)
12 LEAD EASI DOWER
TRANSFORMATION (12 LEAD EASI
DOWER TRANSFORMATION)
12 LEAD MASON LIKAR (12 LEAD
MASON LIKAR)
12 LEAD MODIFIED MASON LIKAR (12
LEAD MODIFIED MASON LIKAR)
12 LEAD NON-STANDARD (12 LEAD
NON-STANDARD)
12 LEAD SINGLE PAD (12 LEAD
SINGLE PAD)
12 LEAD STANDARD (12 LEAD
STANDARD)
12 LEAD UNSPECIFIED (12 LEAD
UNSPECIFIED)
BIPOLAR UNCORRECTED XYZ LEAD
SYSTEM (BIPOLAR UNCORRECTED
XYZ LEAD SYSTEM)
CUBE LEAD SYSTEM (CUBE LEAD
SYSTEM)
FRANK LEAD SYSTEM (FRANK LEAD
SYSTEM)
MCFEE-PARUNGAO LEAD SYSTEM
(MCFEE-PARUNGAO LEAD SYSTEM)
PSEUDO-ORTHOGONAL XYZ LEAD
SYSTEM (PSEUDO-ORTHOGONAL
XYZ LEAD SYSTEM)
STANDARD 12-LEAD AND CC5-CM5-
ML (STANDARD 12-LEAD AND CC5-
CM5-ML)
STANDARD 12-LEAD AND CM5-CC5-
CH5 (STANDARD 12-LEAD AND CM5-
CC5-CH5)
STANDARD 12-LEAD EXTENDED LEFT
(STANDARD 12-LEAD EXTENDED
LEFT)
STANDARD 12-LEAD EXTENDED
RIGHT (STANDARD 12-LEAD
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EXTENDED RIGHT)
STANDARD LEADS FOR BICYCLE
EXERCISE (STANDARD LEADS FOR
BICYCLE EXERCISE)
STANDARD LEADS ONE
INTERCOSTAL SPACE HIGHER
(STANDARD LEADS ONE
INTERCOSTAL SPACE HIGHER)
VECTORCARDIOGRAPH CORRECTED
(VECTORCARDIOGRAPH
CORRECTED)
VECTORCARDIOGRAPH
UNCORRECTED
(VECTORCARDIOGRAPH
UNCORRECTED)
Subject Position*
SITTING (SITTING)
STANDING (STANDING)
SUPINE (SUPINE)
ECG Date and Time*
ECG Results
Summary (Mean) Ventricular Rate*
Summary (Mean) Ventricular Rate Clinically
Significant*
NO (N)
YES (Y)
PR*
PR Clinically Significant*
NO (N)
YES (Y)
QRS*
QRS Clinically Significant*
NO (N)
YES (Y)
QT*
QT Clinically Significant*
NO (N)
YES (Y)
QTc - Bazett's*
QTc - Bazett's  Clinically Significant*
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CDASH ECG – Scenario 3
NO (N)
YES (Y)
Interpretation*
Interpretation Clinically Significant*
NO (N)
YES (Y)
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CDASH ECG – Scenario 3
CDASH Exposure
modified from http://www.cdisc.org
All rights reserved. Please visit https://medical-data-
models.org/forms/4794
CDASH Exposure
Exposure
Start Date and Time*
End Date and Time*
Dose*
Lot Number*
Treatment Name*
Adjusted*
NO (N)
YES (Y)
Reason adjusted*
Frequency*
BID (BID)
PRN (PRN)
QID (QID)
QM (QM)
QOD (QOD)
TID (TID)
Route*
INTRAMUSCULAR (INTRAMUSCULAR)
INTRAOCULAR (INTRAOCULAR)
ORAL (ORAL)
SUBCUTANEOUS (SUBCUTANEOUS)
TOPICAL (TOPICAL)
TRANSDERMAL (TRANSDERMAL)
Interruption Duration*
Anatomical Location*
ARM (ARM)
HIP (HIP)
LEG (LEG)
SHOULDER (SHOULDER)
Total Amount*
Infusion Rate*
Completed treatment*
NO (N)
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YES (Y)
Planned Dose*
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CDASH Exposure
CDASH ECG – Scenario 2 (local
processing)
modified from http://www.cdisc.org
All rights reserved. Please visit https://medical-data-
models.org/forms/4795
ECG – Scenario 2 (local processing)
Generelle Information
Wurde ein EKG durchgeführt?*
nein (N)
ja (Y)
EKG Information (lokale Durchführung)
EKG-Verfahren*
12 Kanal 1 Ableitung fehlend (12 LEAD 1
LEAD MISSING)
12 Kanal CABRERA (12 LEAD
CABRERA)
12 Kanal EASI DOWER
TRANSFORMATION (12 LEAD EASI
DOWER TRANSFORMATION)
12 Kanal MASON LIKAR (12 LEAD
MASON LIKAR)
12 Kanal MASON LIKAR modifiziert (12
LEAD MODIFIED MASON LIKAR)
12 Kanal Non-Standard (12 LEAD NON-
STANDARD)
12 Kanal SINGLE PAD (12 LEAD
SINGLE PAD)
12 Kanal Standard (12 LEAD
STANDARD)
12 Kanal nicht spezifiziert (12 LEAD
UNSPECIFIED)
Bipolares unkorrigiertes XYZ
Ableitungssystem (BIPOLAR
UNCORRECTED XYZ LEAD SYSTEM)
Ableitung CUBE SYSTEM (CUBE LEAD
SYSTEM)
Ableitung FRANK LEAD (FRANK LEAD
SYSTEM)
Ableitung MCFEE-PARUNGAO (MCFEE-
PARUNGAO LEAD SYSTEM)
Pseudo-orthogonales XYZ
Ableitungssystem (PSEUDO-
ORTHOGONAL XYZ LEAD SYSTEM)
Standard 12 Kanal und CC5-CM5-ML
(STANDARD 12-LEAD AND CC5-CM5-
ML)
Standard 12 Kanal und CM5-CC5-CH5
(STANDARD 12-LEAD AND CM5-CC5-
CH5)
Standard 12 Kanal erweitert links
(STANDARD 12-LEAD EXTENDED
LEFT)
Standard 12 Kanal erweitert rechts
(STANDARD 12-LEAD EXTENDED
RIGHT)
Standardableitungen für
Fahrradergometer (STANDARD LEADS
FOR BICYCLE EXERCISE)
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Standardableitungen einen
Interkostalraum höher (STANDARD
LEADS ONE INTERCOSTAL SPACE
HIGHER)
Vektorkardiograph korrigiert
(VECTORCARDIOGRAPH
CORRECTED)
Vektorkardiograph unkorrigiert
(VECTORCARDIOGRAPH
UNCORRECTED)
EKG Position*
sitzend (SITTING)
stehend (STANDING)
Rückenlage (SUPINE)
Datum und Uhrzeit des EKG*
EKG Ergebnisse (lokale Durchführung)
Mittlere Herzkammerfrequenz*
EKG-Ergebnisse zur Herzkammerfrequenz
klinisch signifikant*
nein (N)
ja (Y)
PR Dauer*
PR Dauer klinisch signifikant*
nein (N)
ja (Y)
Mittlere QRS Dauer*
QRS-Dauer klinisch signifikant*
nein (N)
ja (Y)
Mittlere QT Dauer*
Mittlere QT Dauer klinisch signifikant*
nein (N)
ja (Y)
QTc Dauer (Bazett)*
QTc Dauer klinisch signifikant*
nein (N)
ja (Y)
Interpretation des EKG*
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CDASH ECG – Scenario 2 (local processing)
EKG klinisch signifikant*
nein (N)
ja (Y)
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CDASH ECG – Scenario 2 (local processing)
CDASH LAB Information (Scenario 3, Part
1)
modified from http://www.cdisc.org
All rights reserved. Please visit https://medical-data-
models.org/forms/4799
CDASH LAB Information (Scenario
3, Part 1)
LAB Information
Lab Status*
NO (N)
YES (Y)
Collection Date and Time*
Fasting ?*
NO (N)
YES (Y)
Accession Number*
Laboratory Name*
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CDASH Physical examination
modified from http://www.cdisc.org
All rights reserved. Please visit https://medical-data-
models.org/forms/4803
CDASH Physical examination
General information
Exam performed*
NO (N)
YES (Y)
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CDASH Substance use
modified from http://www.cdisc.org
All rights reserved. Please visit https://medical-data-
models.org/forms/4808
CDASH Substance use
Zigarettenkonsum
Zigarettenkonsum*
derzeit (CURRENT)
ehemalig (FORMER)
nie (NEVER)
Menge Zigaretten*
20 bis 60 pro Tag (20 TO 60 PER DAY)
weniger als 20 pro Tag (LESS THAN 20
PER DAY)
über 60 pro Tag (MORE THAN 60 PER
DAY)
Startdatum Zigarettenkonsum*
Enddatum Zigarettenkonsum*
Dauer des Zigarettenkonsums*
Zigarrenkonsum
Status Zigarrenkonsum*
derzeit (CURRENT)
ehemalig (FORMER)
nie (NEVER)
Anzahl Zigarren*
3 bis 10 pro Tag (3 TO 10 PER DAY)
weniger als 3 pro Tag (LESS THAN 3
PER DAY)
mehr als 10 pro Tag (MORE THAN 10
PER DAY)
Startdatum des Zigarrenkonsums*
Enddatum des Zigarrenkonsums*
Dauer des Zigarrenkonsums*
Alkoholkonsum
Status Alkoholkonsum*
derzeit (CURRENT)
ehemalig (FORMER)
nie (NEVER)
Menge an Bier*
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Häufigkeit Bierkonsum*
alle 24h (Q24H)
jeden Morgen (QM)
nach Bedarf (QS)
Menge Wein*
Häufigkeit Wein*
alle 24h (Q24H)
jeden Morgen (QM)
nach Bedarf (QS)
Menge Spirituosen*
Häufigkeit Spirituosen*
alle 24h (Q24H)
jeden Morgen (QM)
nach Bedarf (QS)
Startdatum Alkoholkonsum*
Enddatum Alkoholkonsum*
Dauer Alkoholkonsum*
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CDASH Subject Characteristics
modified from http://www.cdisc.org
All rights reserved. Please visit https://medical-data-
models.org/forms/4817
CDASH Subject Characteristics
Subject Characteristics
Gestationsalter*
Gebärfähiges Alter*
Nein (N)
Ja (Y)
Ausbildungslevel*
Hauttyp*
Hauttyp 1 (TYPE1)
Hauttyp 2 (TYPE2)
Hauttyp 3 (TYPE3)
Hauttyp 4 (TYPE4)
Hauttyp 5 (TYPE5)
Hauttyp 6 (TYPE6)
Familienstand*
annuliert (ANNULLED)
geschieden (DIVORCED)
Lebenspartner (DOMESTIC PARTNER)
getrennt lebend (INTERLOCUTORY)
gesetzlich getrennt (LEGALLY
SEPARATED)
verheiratet (MARRIED)
ledig (NEVER MARRIED)
polygam (POLYGAMOUS)
verwitwet (WIDOWED)
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Registry for Sickle Cell Diseases,
1.registration form
Registerzentrale: Dr. Dickerhoff / Dr. Potthoff, Klinik für
Kinder-Onkologie, -Hämatologie und Klinische
Immunologie, Universitätsklinikum Düsseldorf
All rights reserved. Please visit https://medical-data-
models.org/forms/4834
Sichel-Reg, 1. Meldebogen
Patientendaten
Nachname*
Vorname*
Geburtsdatum*
Geschlecht*
m (1)
w (2)
Meldedatum*
ID Nummer*
Straße*
PLZ (Patient)*
Stadt*
E-Mail des Patienten*
Telefon des Patienten*
Behandelnde Klinik
Klinik*
Ansprechpartner*
Straße*
PLZ (Klinik)*
Stadt (Klinik)*
E-Mail Klinik*
Telefon der Klinik*
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Fax der Klinik*
Hausarzt
Praxis*
Ansprechpartner*
Straße (Hausarzt)*
PLZ (Hausarzt)*
Stadt (Hausarzt)*
E-Mail (Hausarzt)*
Telefon (Hausarzt)*
Faxnummer des Hausarztes*
Patientencharakteristika
Diagnose (z.B. HbSS, HbSC...)*
Herkunftsland*
Familienstand*
ledig (1)
verheiratet (2)
geschieden (3)
verwitwet (4)
Beruflicher Werdegang
Schulform*
Schulabschluss*
Ausbildung/Studium/Beruf*
Aktuelle Tätigkeit*
Bemerkungen
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Registry for Sickle Cell Diseases, 1.registration form
Bemerkungen*
Unterschrift
Name des dokumentierenden Arztes*
Datum der Unterschrift*
Unterschrift*
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Registry for Sickle Cell Diseases, 1.registration form
Eligibility Criteria NCT00071084
ODM derived from
http://clinicaltrials.gov/ct2/show/record/NCT00071084
All rights reserved. Please visit https://medical-data-
models.org/forms/4844
Eligibility
Inclusion
Medical diagnosis of CTCL, and positivity for the
CD4 receptor. - Late stage CTCL*
Yes
No
Have received at least one prior anti-cancer
therapy with inadequate effect*
Yes
No
WHO performance status 0,1 or 2 - Male or
female, age 18 or older. - Signed informed
consent. *
Yes
No
Exclusion
Certain rare types of CTCL. *
Yes
No
Previous treatment with other anti-CD4
medications. - More than two previous treatments
with systemic chemotherapy. - Certain anti-
psoriasis or anti-cancer therapies within the last 4
weeks before entering this trial. - Some types of
steroid treatments less than two weeks before
entering the trial*
Yes
No
Prolonged exposure to sunlight or UV light during
the trial. - Other cancer diseases, except certain
skin cancers or cervix cancer. - Chronic infectious
disease requiring medication. - Certain serious
medical conditions, including kidney or liver
disease, some psychiatric illnesses, and
stomach, lung, heart, hormonal, nerve or blood
diseases. - Certain laboratory values which are
too high or too low. - HIV positivity*
Yes
No
Pregnant or breast-feeding women. - Women of
childbearing age who are unable or unwilling to
use an IUD or hormonal birth control during the
whole trial*
Yes
No
If you are participating in another trial with a
different new drug 4 weeks before you enter this
1 / 2
trial*
Yes
No
Medical concepts
Diagnosis*
Lymphoma, T-Cell, Cutaneous*
Diagnostic Neoplasm Staging*
Therapeutic procedure*
WHO performance status finding*
Age*
Medication*
Chemotherapy*
Exposure to sunlight*
Infection*
HIV negative*
pregnant*
Breast feeding*
Contraception*
Enrollment*
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Eligibility Criteria NCT00071084
Eligibility NCT00006045 AML
Combination Chemotherapy With or Without Monoclonal
Antibody Therapy in Treating Patients With Refractory or
Relapsed Acute Myelogenous Leukemia
see http://clinicaltrials.gov/ct2/show/record/NCT00006045
All rights reserved. Please visit https://medical-data-
models.org/forms/4846
Eligibility AML NCT00006045
Disease Characteristics
Histologically proven acute myelogenous
leukemia (AML) that may have been primary
AML, secondary AML, or preceded by
hematologic disorder*
Yes
No
All FAB subtypes except M3 Must meet one of
the following three criteria: 
- First relapse within 1 year after documentation
of a previous complete remission (CR) achieved
by chemotherapy 
- Refractory to prior chemotherapy comprised of
a minimum of 1 induction course, including
cytarabine at a minimum of 500 mg/m2 (e.g., 100
mg/m2/day for 5 days) plus an anthracycline 
- No high dose cytarabine (no cumulative dose
greater than 3 g/m2) 
*
Yes
No
First relapse from a previous CR with subsequent
autologous bone marrow transplantation (BMT),
only if all of the following criteria are met: 
- First BMT At least 100 days but less than 1 year
posttransplantation 
- At least 25% cellularity of the bone marrow 
- Previous BMT included full hematopoietic
recovery, defined by all of the following: 
-- Hemoglobin at least 10 g/dL (without
transfusion) 
-- Platelet count at least 100,000/mm3 (without
transfusion) 
-- Absolute neutrophil count at least 1,500/mm3 
*
Yes
No
No transplantation candidates*
Yes
No
Bone marrow blasts (leukemic cells) greater than
10% 
No chronic myelogenous leukemia in blast crisis*
Yes
No
No active CNS leukemia*
Yes
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No
Patient Characteristics
Age: 18 and over*
Yes
No
Karnofsky 50-100%*
Yes
No
Bilirubin less than 2.0 mg/dL (unless related to
Gilbert's disease or due to leukemic infiltration)*
Yes
No
SGOT or SGPT no greater than 4 times upper
limit of normal (unless related to AML) 
C1522609*
Yes
No
Creatinine less than 2.0 mg/dL (unless related to
AML) 
*
Yes
No
Left ventricular function normal 
No unstable cardiac arrhythmias, unstable angina
pectoris, or myocardial infarction within the past 6
months 
No New York Heart Association class III or IV
heart disease 
No electrocardiogram evidence of active
ischemia*
Yes
No
Not pregnant or nursing 
Negative pregnancy test 
Fertile patients must use effective contraception
during and for 1 month after study
negation*
Yes
No
HIV negative*
Yes
No
No other active malignancy requiring therapy 
No active serious infection that is uncontrolled by
antimicrobial therapy 
Medically stable 
No significant organ dysfunction*
Yes
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Eligibility NCT00006045 AML
No
Prior concurrent therapy
At least 30 days since prior experimental biologic
therapy (e.g., interleukin-2) 
No concurrent biologic therapy, including bone
marrow transplantation*
Yes
No
For first relapse AML with recent or prior
chemotherapy: Prior hydroxyurea given as a
short course (up to 48 hours) allowed, if needed,
to reduce the peripheral leukocyte count 
Hydroxyurea must be discontinued prior to study 
For refractory AML with recent or prior
chemotherapy: Greater than 2 weeks since prior
chemotherapy except hydroxyurea given as
above 
No other concurrent chemotherapy 
*
Yes
No
No concurrent radiotherapy 
*
Yes
No
No other concurrent experimental therapy 
Concurrent therapy for other preexisting diseases
allowed*
Yes
No
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Eligibility NCT00006045 AML
Eligibility NCT00048295 Crohns Disease
see http://clinicaltrials.gov/ct2/show/study/NCT00048295
ISIS 2302 is an antisense oligonucleotide drug that reduces
the production of a specific protein called intercellular
adhesion molecule (ICAM-1), a substance that plays a
significant role in the increase of inflammation. People with
Crohn’s disease have been shown to over-produce ICAM-1
in their gut tissues. Alicaforsen works by blocking ICAM-1
messenger RNA, the “instruction” molecule that is required
for the production of ICAM-1 protein. This trial will examine
effects of alicaforsen delivered by 2-hour intravenous
infusion over a four-week period, compared to a placebo.
Patients may remain on stable background 5-ASA,
antibiotic, or immunosuppressive drugs, and prednisone (or
equivalent) at </= 30 mg per day.
All rights reserved. Please visit https://medical-data-
models.org/forms/4848
Eligibility NCT00048295
Inclusion
Age at least 12 years*
Weight at least 36 kg*
Yes
No
CDAI score of 220 - 400*
Yes
No
Documentation of Crohns disease activity by
endoscopy, biopsy or imaging in the last 2 years*
Yes
No
No TNF-alpha inhibitor treatment for three
months prior to first study drug infusion*
Yes
No
Exclusion
Known severe, fixed, symptomatic stenosis of the
small or large intestine with significant dilation*
Yes
No
Extensive external fistulization (> 3 external
fistulae which are expressible with gentle
compression); colostomy or ileostomy*
Yes
No
Active infection, including infectious colitis, or
infection with HIV, Hepatitis B or Hepatitis C*
Yes
No
Malignancy within 3 years or poorly controlled
medical illness*
Yes
No
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Requires intravenous heparin therapy or with a
history of a bleeding problem*
Yes
No
2 / 2
Eligibility NCT00048295 Crohns Disease
Eligibility NCT00050999 T-Cell Lymphoma
ODM derived from
http://clinicaltrials.gov/ct2/show/record/NCT00050999
All rights reserved. Please visit https://medical-data-
models.org/forms/4849
Eligibility NCT00050999
Inclusion criteria
18 Years and older*
Yes
No
Histopathologically confirmed recurrent or
persistent CTCL as determined by reference
pathology lab*
Yes
No
Patient must have had 1 to 3 prior CTCL
therapies. Repeated use of the same agent is
considered to be 1 therapy unless it is part of a
different combination regimen. Only 1 prior
combination cytotoxic regimen is permitted.
Topical or systemic steroids are not considered a
therapy
*
Yes
No
Interleukin-2 receptor (IL-2R) expression on at
least 20% of tumor cells as determined by
immunohistochemistry*
Yes
No
Stage IA - III disease and unlikely to progress
during the first month on study. Life expectancy of
at least 12 months. Measurable or evaluable
disease. Lymph node involvement no greater
than LN2. No CTCL involvement of bone
marrow.*
Yes
No
No active CNS disease, kidney or liver disease,
significant pulmonary disease, or cardiac
disease. No systemic infections*
Yes
No
Willingness to be randomized to a placebo
treatment only arm*
Yes
No
ECOG performance status 0 or 1*
ECOG 0 (0)
ECOG 1 (1)
Exclusion criteria
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Patients must not have previously received
treatment with DAB389IL-2 or DAB486IL 2
(previous candidate compound evaluated in a
clinical setting).*
Yes
No
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Eligibility NCT00050999 T-Cell Lymphoma
Eligibility NCT00894387 Heart Failure
Six Months Efficacy and Safety of Aliskiren Therapy on Top
of Standard Therapy, on Morbidity and Mortality in Patients
With Acute Decompensated Heart Failure (ASTRONAUT)
See http://clinicaltrials.gov/ct2/show/record/NCT00894387
All rights reserved. Please visit https://medical-data-
models.org/forms/4850
Eligibility Heart failure NCT00894387
Inclusion criteria
primary diagnosis of worsening heart failure*
Yes
No
age >= 18 years*
Yes
No
acute heart failure symptoms (dyspnea or
fatigability - NYHA Class III-IV) and signs of fluid
overload (i.e., jugular venous distension, edema
or positive rales auscultation or pulmonary
congestion on chest x-ray) at the time of
hospitalization*
Yes
No
LVEF less than 40% (measured within the last 6
months)*
Yes
No
Hospitalization for ADHF and remain "stabilized"
for at least 6 hours (defined as SBP >= 110 mm
Hg after acute decompensated episode) and did
not receive IV vasodilators (other than nitrates)
and/or IV inotropic drugs at anytime from ADHF
presentation to time of randomization*
Yes
No
Elevated BNP at Visit 1 or at randomization (BNP
>= 400 pg/ml)*
Yes
No
Patients with a history of chronic heart failure on
standard therapy defined as requiring HF
treatment for at least 30 days before the current
hospitalization (NYHA Class II - IV).*
Yes
No
Exclusion criteria
Patients that required any use of IV vasodilators
(except nitrates), and/or any IV inotropic therapy
from the time of presentation for worsening HF to
randomization.*
Yes
No
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Concomitant use of ACEI and ARB at
randomization.*
Yes
No
Right heart failure due to pulmonary disease.*
Yes
No
Diagnosis of postpartum cardiomyopathy.*
Yes
No
Myocardial infarction or cardiac surgery, including
percutaneous transluminal coronary angioplasty
(PTCA), within past 3 months.*
Yes
No
Patients with a history of heart transplant or who
are on a transplant list.*
Yes
No
Unstable angina or coronary artery disease likely
to require coronary artery bypass graft (CABG) or
PTCA before randomization.*
Yes
No
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Eligibility NCT00151099 Dysgnathia
See http://clinicaltrials.gov/ct2/show/record/NCT00151099
All rights reserved. Please visit https://medical-data-
models.org/forms/4851
Eligibility Protein Drink
NCT00151099
Inclusion Criteria
18 Years to 40 Years*
Yes
No
Female*
Yes
No
Patients with surgery for dysgnathia*
Yes
No
Exclusion Criteria
Diabetes mellitus*
Yes
No
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Eligibility NCT00626548 Prostate Cancer
A Phase III Trial of ZD4054 (Zibotentan) (Endothelin A
Antagonist) in Non-metastatic Hormone Resistant Prostate
Cancer (ENTHUSE M0)
see http://clinicaltrials.gov/ct2/show/study/NCT00626548
All rights reserved. Please visit https://medical-data-
models.org/forms/4852
Eligibility NCT00626548
Inclusion criteria
18 Years and older*
Yes
No
Male*
Yes
No
Confirmed diagnosis of prostate cancer
(adenocarcinoma of the prostate) that has NOT
spread to the other parts of the body
(metastases). Patients with lymph node
involvement may be eligible if specified criteria is
met.*
Yes
No
Increasing Prostate Specific Antigen (PSA),
collected within one year of enrollment*
Yes
No
Currently receiving treatment with surgical or
medical castration*
Yes
No
Exclusion criteria
Currently using opiate based pain killers for
cancer related pain*
Yes
No
Previous treatment with chemotherapy
(paclitaxel, docetaxel, and mitoxantrone). Prior
targeted cancer therapies are permitted if
received during a previous clinical trial*
Yes
No
Suffering from heart failure or had a myocardial
infarction within last 6 months*
Yes
No
A history of epilepsy or seizures*
Yes
No
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Eligibility NCT00778388 Pseudomonas
Aeruginosa
ODM derived from
http://clinicaltrials.gov/ct2/show/record/NCT00778388
All rights reserved. Please visit https://medical-data-
models.org/forms/4853
Eligibility
Inclusion Criteria
written informed consent obtained prior to study
entry *
Yes
No
healthy adults aged between 18 and 65 years*
Yes
No
no clinically relevant pathological findings in any
of the investigations at the Screening visit. Minor
deviations of laboratory values from the normal
range may be accepted, if judged by the
investigator to have no clinical relevance *
Yes
No
In female subjects either childbearing potential
terminated by surgery or a negative serum
pregnancy test during screening and the
willingness not to become pregnant during the
entire study period by practicing reliable methods
of contraception *
Yes
No
Exclusion Criteria
History of autoimmune diseases and
malignancies *
Yes
No
Active or passive vaccination 4 weeks before and
during the entire study protocol*
Yes
No
Use of any other investigational or non-registered
drug or vaccine in addition to the study vaccine
during the study period or within 30 days
preceding the first dose of study vaccine *
Yes
No
History of severe hypersensitivity reactions and
anaphylaxis *
Yes
No
Known hypersensitivity or allergic reactions to
one of the components of the vaccine*
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Yes
No
Clinically significant diseases as judged by the
investigator *
Yes
No
Immunodeficiency due to immunosuppressive
therapy*
Yes
No
A family history of congenital or hereditary
immunodeficiency*
Yes
No
Medical Concepts
Informed Consent*
Age*
Healthy Subject*
pregnant*
Contraception*
Serum pregnancy test (B-HCG)*
Diagnosis*
Autoimmune Disease*
Malignant Neoplasms*
Vaccination*
Enrollment*
Hypersensitivity*
Immunomodulatory or immunosuppressive
therapy*
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Eligibility NCT00778388 Pseudomonas Aeruginosa
congenital immunodeficiency*
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Eligibility NCT00778388 Pseudomonas Aeruginosa
Eligibility NCT00157157 Hemophilia
ODM derived from
http://clinicaltrials.gov/show/NCT00157157
All rights reserved. Please visit https://medical-data-
models.org/forms/4855
Eligibility
Inclusion Criteria
The subject has severe or moderately severe
hemophilia A as defined by a baseline factor VIII
level <= 2% of normal, as documented at
screening
*
Yes
No
The subject is < 6 years of age*
Yes
No
The subject's legally authorized representative
has provided written informed consent*
Yes
No
Exclusion Criteria
The subject has a history of exposure to factor
VIII other than rAHF PFM or more than 3
infusions of commercially available rAHF PFM
(i.e., ADVATE) within 28 days prior to screening,
as determined by the subject's medical history.
Any infusion of factor VIII replacement products
prior to the 28-day period excludes the subject
from participation*
Yes
No
The subject has received more than 3 infusions
of rAHF PFM (commercially available and/or
study product) between screening and prior to
the initial recovery infusion*
Yes
No
The subject has a detectable inhibitor to factor
VIII, as measured in the screening sample by the
Nijmegen assay in the central laboratory*
Yes
No
The subject has a history of inhibitor to factor VIII
at any time prior to screening*
Yes
No
The subject has a known hypersensitivity to rAHF
PFM*
Yes
No
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The subject has any 1 of the following laboratory
abnormalities at the time of screening:
1) Platelet count < 100,000/mm^3
2) Hemoglobin concentration < 10 g/dL (100 g/L)
3) Serum creatinine > 1.5 times the upper limit of
normal (ULN) for age
4) Total bilirubin > 2 times the ULN for age*
Yes
No
The subject has an inherited or acquired
hemostatic defect other than hemophilia A (e.g.,
qualitative platelet defect or von Willebrand's
disease)*
Yes
No
The subject is known to be seropositive for
human immunodeficiency virus (HIV), hepatitis C
virus (HCV), or hepatitis B virus (HBV), as
determined by the subject's medical history*
Yes
No
At the time of enrollment, the subject has a
clinically significant chronic disease other than
hemophilia A*
Yes
No
The subject is currently participating in another
investigational drug study, or has participated in
any clinical study involving an investigational drug
within 120 days of the screening visit*
Yes
No
The subject (or the subject's legally authorized
representative) is identified by the investigator as
being unable or unwilling to cooperate with study
procedures*
Yes
No
The subject has received any blood product,
including packed red blood cells (RBC), platelets,
plasma, or cryoprecipitate*
Yes
No
Medical concepts
Diagnosis*
Hemophilia A*
Factor VIII Measurement*
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Eligibility NCT00157157 Hemophilia
Age*
Informed Consent*
Medication*
Factor VIII*
Factor VIII inhibitor screening test*
Hypersensitivity*
Platelet count - finding*
Hemoglobin*
Creatinine*
Bilirubin*
Coagulation Factor Deficiency*
HIV negative*
Hepatitis B, C*
Enrollment*
Compliance*
Blood product*
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Eligibility NCT00157157 Hemophilia
Eligibility NCT00160524 Crohns Disease
ODM derived from
http://clinicaltrials.gov/show/NCT00160524
All rights reserved. Please visit https://medical-data-
models.org/forms/4856
Eligibility
Inclusion Criteria
18 Years and older*
Yes
No
previously completed studies CDP870-031 or
CDP870-032
*
Yes
No
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Eligibility NCT00160706 Crohn's Disease
ODM derived from
http://clinicaltrials.gov/show/NCT00160706
All rights reserved. Please visit https://medical-data-
models.org/forms/4857
Eligibility
Inclusion Criteria
18 Years and older*
Yes
No
Previously withdrawn from study CDP870-031 or
CDP870-032 due to an exacerbation of Crohn's
disease*
Yes
No
Medical Concepts
Age*
Enrollment*
Diagnosis*
Crohn's Disease*
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Eligibility NCT00165828 Epilepsy
Efficacy and Safety of an add-on Treatment With
Zonisamide in Adults With Focal Epileptic Seizures With or
Without Secondary Generalization
see http://clinicaltrials.gov/show/NCT00165828
All rights reserved. Please visit https://medical-data-
models.org/forms/4859
Eligibility NCT00165828
Inclusion Criteria at screening
Adult aged between 18 years and 74 years*
Yes
No
Focal epileptic seizures with or without secondary
generalization
*
Yes
No
Present treatment with one or two antiepileptic
drugs (constant dosage during 8 weeks baseline
phase prior to initiation of treatment with
zonisamide). Stimulation of the vagus nerve is
permitted and will not be counted as antiepileptic
drug.*
Yes
No
For women of childbearing potential
(postmenopausal for more than 1 year): possible
pregnancy during the study can be excluded (by
hysterectomy, sterilization or simultaneous
application of two recognized methods of
contraception (no oral contraceptives only)*
Yes
No
For male patients with partners of childbearing
potential: a safe method of contraception is
practiced during their study participation*
Yes
No
Written consent to participate in the study*
Yes
No
Inclusion criteria for randomisation
At least 6 focal or clonicotonic seizures
documented completely in a seizure diary or the
patient chart during the 8 prospective or
retrospective weeks baseline phase.*
Yes
No
Exclusion criteria at screening
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Epileptic state during the past year*
Yes
No
Non-epileptic fits*
Yes
No
Generalized epilepsy*
Yes
No
More than 4 weeks of seizure freedom during
baseline phase*
Yes
No
Concomitant progressive CNS disease including
progressive myoclonus epilepsy*
Yes
No
Concomitant treatment with vigabatrine and / or
topiramate*
Yes
No
Hepatic and/or renal insufficiency (creatine >
2mg% or GPT > 2 times ULN)*
Yes
No
Body weight <= 40 kg*
Yes
No
(History of) kidney stones; erythrocyturia, family
history (in parents, children, brothers and sisters
or grandparents) of kidney stones*
Yes
No
(History of) drug and/or alcohol dependence*
Yes
No
Active psychosis*
Yes
No
Suicide attempt during the past 3 years*
Yes
No
Pre-treatment with zonisamide*
Yes
No
Known hypersensitivity to sulfonamides
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*Yes
No
Concomitant treatment with neuroleptic drugs
*
Yes
No
pregnant or breast feeding woman
*
Yes
No
participation in another therapy study within 3
months prior to or during this study*
Yes
No
blood donation planned during or within 4 weeks
after the participation in this study*
Yes
No
elective surgery planned during the participation
in this study*
Yes
No
patient is not willing or not capable to meet the
study demands*
Yes
No
patient does not agree to the forwarding of
his/her pseudonymous data*
Yes
No
patient without legal competence*
Yes
No
Exclusion criteria for randomisation
More than 4 consecutive weeks of freedom from
seizure during baseline phase*
Yes
No
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Eligibility NCT00175903 Epilepsy
ODM derived from
http://clinicaltrials.gov/show/NCT00175903
All rights reserved. Please visit https://medical-data-
models.org/forms/4861
Eligibility
Inclusion Criteria
16 Years and older*
Yes
No
Diagnosis of epilepsy (all types of seizures) was
made during the past year*
Yes
No
Subjects must have had at least two unprovoked
seizures in the past 2 years with at least one
during the last 6 months*
Yes
No
Female subjects without childbearing potential
are eligible. Female subjects with childbearing
potential are eligible if they use a medically
accepted contraceptive method.*
Yes
No
Exclusion Criteria
Subjects previously allocated to a trial treatment
(CBZ, VPA and LEV) used in this trial*
Yes
No
Participation in another clinical trial with an
investigational drug or device within 12 weeks of
the selection visit (V1), or at any time during this
trial*
Yes
No
Pregnant or lactating women*
Yes
No
Presence of known pseudoseizures within the
last year*
Yes
No
Uncountable seizures (clusters) or history of
convulsive status epilepticus*
Yes
No
Any disorder or condition that may interfere with
the absorption, distribution, metabolisation or
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excretion of drugs*
Yes
No
History of suicide attempt, current suicidal
ideation, or other serious psychiatric disorders
requiring or having required hospitalization or
medication within the previous five years*
Yes
No
Presence of progressive cerebral disease, any
other progressively degenerative neurological
disease, or any cerebral tumors*
Yes
No
Presence of a terminal illness or any medical
condition that might interfere with the subject's
trial participation*
Yes
No
Medical concepts
Age*
Diagnosis*
Epilepsia*
Convulsion*
pregnant*
Breast feeding, Nursing*
Contraception*
Enrollment*
Pseudoseizure (Hysterical fits, factitious
seizures)*
Epileptic state*
Malabsorption*
Renal Insufficiency*
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Eligibility NCT00175903 Epilepsy
Hepatic Insufficiency*
Attempted Suicide*
Psychosis (Psychotic disorder)*
Brain Neoplasms*
CNS disorder, Central Nervous System Disease*
Degenerative Neurologic Disease*
end stage disease*
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Eligibility NCT00185211 Multiple Sclerosis
ODM derived from http://clinicaltrials.gov/show/
All rights reserved. Please visit https://medical-data-
models.org/forms/4862
Eligibility
Inclusion Criteria
18 Years to 48 Years*
Yes
No
Patients who have reached scheduled end of
study in BENEFIT, either by developing CDMS or
by completing 24 months*
Yes
No
Exclusion Criteria
No participation in the initial BENEFIT study*
Yes
No
Medical Concepts
Age*
Enrollment*
Study End Date*
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Eligibility NCT00185250 Cardiomyopathies
Heart Dis
ODM derived from
http://clinicaltrials.gov/show/NCT00185250
All rights reserved. Please visit https://medical-data-
models.org/forms/4863
Eligibility
Inclusion Criteria
18 Years to 75 Years*
Yes
No
Unexplained heart with evidence of Adeno-,
Entero- and/or Parvoviruses which must be
identified directly in the heart tissue*
Yes
No
Being in a chronic (at least 6 month after the
onset of clinical symptoms) and stable phase of
the disease*
Yes
No
Impaired cardiac function*
Yes
No
Exclusion Criteria
Severe (decompensated) or acute heart failure*
Yes
No
Any other disease which could better explain the
patient's clinical symptoms*
Yes
No
Any other severe and/or malignant disease*
Yes
No
Suffering from convulsions, depression or suicidal
ideas judged by a physician*
Yes
No
Serious viral or bacterial infections during the last
weeks*
Yes
No
Pregnancy or lactation*
Yes
No
Medical concepts
Age*
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Diagnosis*
Cardiac disorder*
Heart failure*
Cardiomyopathy*
Viral cardiomyopathy*
Adenovirus*
Enterovirus*
Parvovirus*
Chronic disease*
Cardiac rate*
Cardiac ejection fraction*
Cardiac Arrhythmia*
Malignant Neoplasms*
disorder*
Convulsion*
Depression*
Infection*
Severe (Qualitative Concept)*
pregnant*
Breast feeding, Nursing*
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Eligibility NCT00190047 Stroke
ODM derived from
http://clinicaltrials.gov/show/NCT00190047
All rights reserved. Please visit https://medical-data-
models.org/forms/4864
Eligibility
Inclusion Criteria
18 Years to 85 Years*
Yes
No
Patients with ischemic stroke, (that is, stroke that
results from a blockage of blood flow to part of
the brain), which is accompanied by language
dysfunction (e.g. inability to understand speech),
visual field defect or inattention to one side of the
body or the space around the patient*
Yes
No
Patients in whom the study treatment can start no
less than 1 and not more than 9 hours after the
stroke's onset*
Yes
No
Patients with moderate-severe degree of
neurological deficit in the 9 hours after stroke
onset (defined as NIHSS score of 7 to 20)*
Yes
No
Patients that can understand the requirements of
the study and are willing to provide written
informed consent (If the subject is incapacitated,
informed consent will be sought from a legally
acceptable representative.)*
Yes
No
Exclusion Criteria
Patients with a brain (intracerebral or
subarachnoid) hemorrhage per screening
computed tomography scan *
Yes
No
candidates for thrombolytic therapy for the current
stroke *
Yes
No
patients having a mental impairment that renders
them incapable to understand the study's
requirements *
Yes
No
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patients with other diseases that in the
investigator's opinion may lead, independently of
the current stroke, to further deterioration in the
subject's neurological status during the trial
period, or may confuse the evaluation of the
present stroke*
Yes
No
Patients likely to undergo a procedure involving
cardiopulmonary bypass during the study period*
Yes
No
Patients with medical conditions that may not
enable them to complete the study (e.g life-
threatening diseases,)*
Yes
No
Patients whose condition improves already during
the screening period*
Yes
No
Patients who already have functional limitations
before the present study (retrospective Modified
Rankin Scale score of >3)*
Yes
No
Patients who suffered a stroke within the past 90
days that seems to have been in the same brain
region as the current acute stroke*
Yes
No
Patients with severe hypertension (systolic BP
>210 mm Hg or diastolic BP >120 mm Hg) or
hypotension (systolic BP <90 mm Hg), *
Yes
No
Patients with significant history of renal or liver
disease(s) (serum creatinine of > 2.0 mg/dL,
alanine aminotransferase, aspartate
aminotransferase, or gamma-glutamyl transferase
values of > threefold the upper normal limit)*
Yes
No
Patients with a platelet count of <100,000/mm3*
Yes
No
Female patients of childbearing potential who are
not using adequate and effective birth control
measures or who are pregnant or lactating (the
screening evaluation of female subjects of
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childbearing potential will include a serum
pregnancy test.)*
Yes
No
Patients who are users of addictive agents, or
alcoholics*
Yes
No
Patients who have received an investigational
drug within the 90 days before the present stroke
or such that are past recipients of DP-b99*
Yes
No
Medical concepts
Age*
Diagnosis*
Ischemic stroke*
Disorder of language*
Visual field defect*
Hemi-inattention*
Onset*
NIH-SS*
Neurologic deficit*
Informed Consent*
Compliance*
Brain hemorrhage*
Therapeutic procedure*
Medication*
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Eligibility NCT00190047 Stroke
Mental impairment disorders*
Cardiopulmonary bypass operation*
Life expectancy*
Rankin score*
Hypertensive disease*
Hypotension*
Creatinine*
GPT (Serum)*
GOT (Serum)*
Gamma Glutamyl Transpeptidase Measurement*
Platelet count - finding*
pregnant*
Breast feeding, Nursing*
Contraception*
Alcohol abuse*
Drug abuse*
Enrollment*
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Eligibility NCT00190047 Stroke
Eligibility NCT00204334
ODM derived from
http://clinicaltrials.gov/show/NCT00204334
All rights reserved. Please visit https://medical-data-
models.org/forms/4865
Eligibility
Inclusion Criteria
18 Years to 75 Years*
Yes
No
kidney transplant recipient stable kidney function*
Yes
No
Hb between 10mg/ml and 10.5mg/ml*
Yes
No
Exclusion Criteria
acute rejection*
Yes
No
Hb above 12.0mg/dl*
Yes
No
Medical concepts
Age*
Renal transplant*
kidney function*
Stability*
Hemoglobin*
Acute rejection of renal transplant*
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Eligibility NCT00214578 Schizophrenia
ODM derived from
http://clinicaltrials.gov/show/NCT00214578
All rights reserved. Please visit https://medical-data-
models.org/forms/4866
Eligibility
Inclusion Criteria
Alter 18 bis 65 Jahre*
Ja
Nein
In- or outpatients with schizophrenia, 18-65 years
old, requiring a change in treatment due to
insufficient efficacy or tolerability and giving
signed informed consent.*
Ja
Nein
Exclusion Criteria
Known diabetes mellitus, high HbA1c, fasting
plasma glucose and/or high 2h glucose-OGTT*
Ja
Nein
Previous use of atypicals (3 months) or other
medications that might influence glucose
metabolism*
Ja
Nein
Contraindications or non-responsiveness for any
of the treatments or other safety issues*
Ja
Nein
Expected non-compliance to treatment and/or
study procedures*
Ja
Nein
Medical Concepts
Alter*
Diagnose*
Schizophrenie*
Änderung der Therapie*
Effectiveness*
Einverständniserklärung*
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Diabetes mellitus*
HbA1c*
Oraler Glukose-Toleranztest*
Nüchternblutzucker im Plasma*
Medikation*
Treatment noncompliance*
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Eligibility NCT00214578 Schizophrenia
Eligibility NCT01435616 Diabetes Mellitus,
Type 2
ODM derived from
http://clinicaltrials.gov/show/NCT01435616
All rights reserved. Please visit https://medical-data-
models.org/forms/4867
Eligibility
Inclusion Criteria
Alter 18 Jahre und älter*
Ja
Nein
Have type 2 diabetes mellitus, not treated with
insulin, for at least one year prior to the study*
Ja
Nein
Have been receiving at least 2 oral
antihyperglycemic medication for at least 3
months before entering the study*
Ja
Nein
Have hemoglobin A1c value between 7.0% and
11.0%, inclusive, at screening*
Ja
Nein
Are capable of, and willing to inject insulin with a
vial and syringe and perform self blood glucose
monitoring*
Ja
Nein
Woman of Childbearing potential only: are not
breastfeeding, have a negative pregnancy test at
the time of screening and randomization and
intend to not become pregnant during the trial.
Have practiced a reliable method of birth control
for at least 6 weeks prior to screening and agree
to use a reliable method of birth control during
the study and until 2 weeks following the last
dose of study drug*
Ja
Nein
Exclusion Criteria
Have used insulin therapy (outside of pregnancy)
anytime in the past 2 years, except for short-term
treatment of acute conditions, and up to a
maximum of 4 continuous weeks*
Ja
Nein
Use of rosiglitazone, pramlintide, glucagon-like
peptide 1 (GLP-1) receptor agonist (for example,
exenatide, exenatide once weekly, or liraglutide)
concurrently or within 3 months prior to
screening*
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Ja
Nein
Are currently taking, or have taken within the 3
months preceding screening, medications to
promote weight loss*
Ja
Nein
Have had any episodes of severe hypoglycemia
within 6 months prior to screening*
Ja
Nein
Have had 1 or more episodes of ketoacidosis or
hyperosmolar state/coma in the 6 months prior to
the study*
Ja
Nein
Have cardiac disease with functional status that
is New York Heart Association Class III or IV (per
New York Heart Association [NYHA] Cardiac
Disease Classification)*
Ja
Nein
Have a history of renal transplantation, or are
currently receiving renal dialysis or have serum
creatinine greater or equal than 2 mg/dL*
Ja
Nein
Have obvious clinical signs or symptoms of liver
disease (excluding non- alcoholic fatty liver
disease [NAFLD]), acute or chronic hepatitis,
non-alcoholic steatohepatitis (NASH), or elevated
liver enzyme measurements at screening*
Ja
Nein
Have had a blood transfusion or severe blood
loss within 3 months prior to screening or have
known hemoglobinopathy, hemolytic anemia or
sickle cell anemia, or any other traits of
hemoglobin abnormalities known to interfere with
the measurement of hemoglobin A1c*
Ja
Nein
Have active or untreated malignancy, have been
in remission from clinically significant malignancy
for less than 5 years*
Ja
Nein
Have fasting or nonfasting triglycerides greater
than 400 mg/dL (greater than 4.5 mmol/L) at
screening*
Ja
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Eligibility NCT01435616 Diabetes Mellitus, Type 2
Nein
Are using lipid lowering medication at a dose that
has not been stable for 90 days prior to
screening*
Ja
Nein
Are using niacin preparations as a lipid lowering
medication and bile acid sequestrants within 90
days prior to screening*
Ja
Nein
Medical Concepts
Alter*
Diagnose*
Diabetes mellitus Typ II*
Anti-hyperglycemics*
HbA1c*
Self-monitoring of blood glucose*
Serum pregnancy test (B-HCG)*
Kontrazeption*
Breast feeding, Nursing*
Insulin*
Medikation*
rosiglitazone*
Pramlintide*
GLP-1 Receptor Agonist*
Weight-Loss Drugs*
Hypoglykämie*
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Eligibility NCT01435616 Diabetes Mellitus, Type 2
Ketoazidose*
Hyperosmolar coma associated with diabetes
mellitus*
Herzkrankheit*
NYHA*
Nierentransplantation*
Renal dialysis*
Liver diseases*
Bluttransfusion*
Malignant Neoplasms*
Triglyceride*
Lipid lowering drug*
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Eligibility NCT01435616 Diabetes Mellitus, Type 2
Eligibility NCT01442636 Peripheral Arterial
Disease
ODM derived from
http://clinicaltrials.gov/show/NCT01442636
All rights reserved. Please visit https://medical-data-
models.org/forms/4869
Eligibility
Inclusion Criteria
Alter >18 Jahre*
Ja
Nein
Patient presenting with rest pain or minor tissue
loss (Rutherford class 4 or 5)*
Ja
Nein
Patient is willing to comply with specified follow-
up evaluations at the specified times*
Ja
Nein
Patient understands the nature of the procedure
and provides written informed consent, prior to
enrolment in the study*
Ja
Nein
Life-expectancy of at least 12 months*
Ja
Nein
Eligibility for treatment with XIENCE PRIME stent
(Abbott Vascular)*
Ja
Nein
Male, infertile female, or female of child bearing
potential practicing an acceptable method of birth
control with a negative pregnancy test within 7
days prior to study procedure*
Ja
Nein
Angiographic Inclusion Criteria
De novo lesion or restenotic lesion after PTA in
the infrapopliteal arteries, suitable for
endovascular therapy*
Ja
Nein
Target lesion length minimally 30mm and
maximally 100mm*
Ja
Nein
Target vessel diameter >2.0mm and <3.5mm*
Ja
Nein
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Guidewire and delivery system successfully
traversed lesion*
Ja
Nein
Exclusion Criteria
Patient refusing treatment*
Ja
Nein
Reference segment diameter not suitable for
stent design*
Ja
Nein
Untreated flow-limiting inflow lesions*
Ja
Nein
Perioperative unsuccessful ipsilateral
percutaneous vascular procedure to treat inflow
disease just prior to enrollment*
Ja
Nein
Any previous surgery in the target vessel
(including prior ipsilateral crural bypass)*
Ja
Nein
Aneurysm in the target vessel*
Ja
Nein
Non-atherosclerotic disease resulting in occlusion
(e.g. embolism, Buerger's disease, vasculitis)*
Ja
Nein
Severe medical comorbidities (untreated
CAD/CHF, severe COPD, metastatic malignancy,
dementia, etc) or other medical condition that
would preclude compliance with the study
protocol or 1-year life expectancy*
Ja
Nein
Major distal amputation (above the
transmetatarsal) in the study limb or non-study
limb*
Ja
Nein
Septicemia or bacteremia*
Ja
Nein
Any previously known coagulation disorder,
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including hypercoagulability*
Ja
Nein
Contraindication to anticoagulation or antiplatelet
therapy *
Ja
Nein
Known allergies to stent or stent components;
Known allergy to contrast media that cannot be
adequately pre-medicated prior to the study
procedure*
Ja
Nein
Hypersensitivity to heparin, including patients
who have had a previous incidence of heparin-
induced thrombocytopenia (HIT) type II*
Ja
Nein
Currently participating in another clinical research
trial*
Ja
Nein
Angiographic evidence of intra-arterial thrombus
or atheroembolism from inflow treatment*
Ja
Nein
Target lesion access not performed by
transfemoral approach*
Ja
Nein
Medical Concepts
Alter*
Diagnose*
Ruheschmerz*
Compliance*
Einverständniserklärung*
Life expectancy*
Eligibility Determination*
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Eligibility NCT01442636 Peripheral Arterial Disease
Kontrazeption*
Serum pregnancy test (B-HCG)*
PTA*
Vessel lumen diameter*
Stent, device*
Therapeutic procedure*
Aneurysma*
Embolism*
Thromboangiitis Obliterans*
Vaskulitis*
Coronary Artery Disease*
Congestive heart failure*
COPD*
Malignant Neoplasms*
Demenz*
Amputation*
Septikämie  *
Bakteriämie*
Thrombophilie*
Contraindication to medical treatment*
Allergie*
Heparin*
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Eligibility NCT01442636 Peripheral Arterial Disease
Thrombocytopenia*
Thrombus*
Atheroembolism*
Enrollment*
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Eligibility NCT01442636 Peripheral Arterial Disease
Eligibility NCT00233662 Chronic Plaque
Psoriasis
ODM derived from
http://clinicaltrials.gov/show/NCT00233662
All rights reserved. Please visit https://medical-data-
models.org/forms/4874
Eligibility
Einschlusskriterien
16 Jahre und älter*
Ja
Nein
Written informed consent*
Ja
Nein
Diagnosed with chronic plaque psoriasis and
require systemic therapy*
Ja
Nein
CD4+ lymphocyte counts at or above the lower
limit of normal for Covance Central Laboratory
Services, Inc., unless on a stable dose of
prednisone (counts must be at or above 300
cells/mm3).*
Ja
Nein
Ausschlusskriterien
Unstable erthrodermic or pustular psoriasis*
Ja
Nein
Diagnosis of guttate psoriasis*
Ja
Nein
Serious local infection or systemic infection within
3 months prior to first dose of alefacept*
Ja
Nein
Positive for HIV antibody*
Ja
Nein
Known invasive malignancy within 5 years of
enrollment. Patients with a history of treated
squamous cell and/or basal cell carcinomas
limited to the skin are not excluded*
Ja
Nein
Evidence of active tuberculosis, Current
treatment for active tuberculosis or tuberculosis
prophylaxis*
Ja
Nein
1 / 3
Female patients unwilling to practice effective
contraception as defined by the investigator*
Ja
Nein
Female patients who are pregnant or breast-
feeding*
Ja
Nein
Current enrollment in any other investigational
drug study*
Ja
Nein
Previous participation in this study or previous
alefacept studies*
Ja
Nein
Medizinische Konzepte
Alter*
Einverständniserklärung*
Diagnose*
Psoriasis*
Systemische Therapie*
CD4+ Anzahl*
exfoliative psoriasis*
Psoriasis guttata*
pustular psoriasis*
Infektion*
HIV Infektion*
Krebs*
Medikation*
Tuberkulose*
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Kontrazeption*
schwanger*
Stillzeit*
Registrierung*
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Eligibility NCT00233662 Chronic Plaque Psoriasis
Eligibility NCT00333411 Psoriasis
ODM derived from
http://clinicaltrials.gov/show/NCT00333411
All rights reserved. Please visit https://medical-data-
models.org/forms/4875
Eligibility
Einschlusskriterien
18 Years to 75 Years*
Ja
Nein
Patients with stable moderate to severe plaque-
type psoriasis involving >10% body surface area,
with minimum disease severity PASI >10 and with
static PGA of at least moderate (score of at least
3) at screening visit*
Ja
Nein
Psoriasis disease duration of at least 6 months
prior to screening*
Ja
Nein
Patients must be candidates for systemic
psoriasis treatment or phototherapy*
Ja
Nein
Patient must give informed consent and sign an
approved consent form prior to any study
procedures, including wash out of prohibited
medications (Patients participating in the PK sub-
study will sign an additional consent form.
Refusal to participate in the sub-study will not
exclude from participation in the main trial)*
Ja
Nein
Ausschlusskriterien
Patients with primary guttatae, erythrodermic, or
pustular psoriasis*
Ja
Nein
Patients who have previously discontinued
efalizumab treatment due to lack of efficacy*
Ja
Nein
Patients using treatments that could interfere with
the primary endpoint of the study (cf. protocol
section 4.2.2.1)*
Ja
Nein
Patients on treatment with warfarin, paracetamol
(acetaminophen), some NSAIDs, some
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antidepressants, medications known to induce or
inhibit CYP3A4, or any other concomitant
medication where potential drug-drug interactions
with BIRT 2584 XX could either result in
decreased efficacy or an unacceptable benefit-
risk assessment, and where replacement of that
concomitant medication with a safe equivalent
drug is not possible (cf. protocol section 4.2.2.2
and the Investigator Site File).*
Ja
Nein
Patients with active liver disease or history of any
significant liver disease*
Ja
Nein
Any clinically significant illness or unstable
disease which according to investigator
judgement may either put the patient at risk
because of participation in the study or may
influence the results of the study or the patients
ability to participate*
Ja
Nein
Patient with serum creatinine and/or white blood
cell count >1.5 x ULN at screening (Repeat
laboratory is allowed once between screening
and randomisation prior to excluding the patient)*
Ja
Nein
Patients with ALT, AST and/or total bilirubin >
1.5xULN at screening (Repeat laboratory is
allowed once between screening and
randomisation prior to excluding the patient)*
Ja
Nein
Abnormal values of other laboratory parameters
at screening that would define a clinically
significant disease as described above (Repeat
laboratory is allowed once between screening
and randomisation prior to excluding the patient)*
Ja
Nein
Positive testing at screening, or history of HIV or
hepatitis B or hepatitis C, or any serious infection
(requiring hospitalisation or parenteral antibiotic
therapy) in the past 3 months prior to screening*
Ja
Nein
History of malignancy in the past 5 years or
suspicion of active malignant disease except
treated cutaneous squamous cell or basal cell
carcinoma*
Ja
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Nein
Patients with the following findings at the
screening visit that could interfere with cardiac
repolarisation:
marked baseline prolongation of QT/QTc interval
as measured on ECG (e.g. QTc interval
>450ms),
history of additional risk factors for Torsade de
pointe (e.g. heart failure, - hypokalemia, family
history of long QT syndrome),
use of concomitant medications that prolong the
QT/QTc interval*
Ja
Nein
History of drug or alcohol abuse within the past
two years*
Ja
Nein
Pre-menopausal (last menstruation 1 year prior
to screening) sexually active woman who:
is pregnant or nursing,
is of child bearing potential and not practicing
acceptable methods of birth control, or does not
plan to continue practising an acceptable method
throughout the study (acceptable methods of
birth control include surgical sterilisation,
intrauterine devices, double barrier, male partner
sterilisation, but not hormonal contraceptives) [A
negative serum pregnancy test at screening (Visit
1) and a negative urine test prior to
randomisation (Visit 2) are required]*
Ja
Nein
Patient not willing to avoid excess sun exposure
during the trial duration*
Ja
Nein
Patients who have taken an investigational drug,
within the last 4 weeks or 5 half lives (which ever
is greater) prior to randomisation [Patients who
have been treated with any investigational
antibody or fusion protein within the past 12
weeks before randomisation are excluded]*
Ja
Nein
Known allergy to BIRT 2584 XX or to the
excipients used for tablet formulation*
Ja
Nein
Body mass index > 34 kg/m2 at screening*
Ja
Nein
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Eligibility NCT00333411 Psoriasis
Medizinische Konzepte
Alter*
Psoriasis*
Systemische Therapie*
Phototherapie*
Einverständniserklärung*
Psoriasis guttata*
exfoliative psoriasis*
pustular psoriasis*
Medikation*
Lebererkrankung*
Kreatinin*
Leukozyten-Anzahl*
ALT*
AST*
Bilirubin*
HIV Infektion*
Hepatitis*
Sepsis*
Krebs*
Elektrokardiogramm (EKG)*
Drug abuse*
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Eligibility NCT00333411 Psoriasis
Alkohol-Abusus*
schwanger*
Stillzeit*
Kontrazeption*
Serum pregnancy test (B-HCG)*
Sonnenexposition*
Registrierung*
Allergie*
BMI*
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Eligibility NCT00333411 Psoriasis
Eligibility NCT00220779 Multiple sclerosis
ODM derived from
http://clinicaltrials.gov/ct2/show/NCT00220779?term=NCT0
0220779&rank=1
All rights reserved. Please visit https://medical-data-
models.org/forms/4876
Eligibility
Einschlusskriterien
Alter*
Ja
Nein
Symptoms consistent with Multiple Sclerosis up
to 5 years*
Ja
Nein
Symptome Multiple Sklerose*
Ja
Nein
Diagnose Multiple Sklerose*
Ja
Nein
Kurtzke Extended Disability Status Scale (EDSS)
< 5.0*
Ja
Nein
Kontrazeption*
Ja
Nein
Klinisch stabil*
Ja
Nein
Hyperintense Läsionen in den Basalganglien im
MRI*
Ja
Nein
Einverständniserklärung*
Ja
Nein
Ausschlusskriterien
Schwanger, stillen oder ohne ausreichende
Kontrazeption*
Ja
Nein
Immunsuppression*
Ja
Nein
Steroid Therapie*
Ja
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Nein
Interferon, Glatiramer Azetat oder IGIV Therapie*
Ja
Nein
Use of an investigational compound within 6
months prior to study entry*
Ja
Nein
Herzerkrankungen*
Ja
Nein
Niereninsuffizienz*
Ja
Nein
IgA Defizienz*
Ja
Nein
Conditions whose symptoms and effects could
alter protein catabolism and/or IgG utilization
(e.g., protein-losing enteropathies, nephrotic
syndrome)*
Ja
Nein
Medizinische Konzepte
Alter*
Diagnose*
Medikamente*
Multiple Sklerose*
Symptome*
schubförmig remittierende Multiple Sklerose*
Stabile Erkrankung*
Kontrazeption*
Hyperintense Läsionen in den Basalganglien im
MRI*
Einverständniserklärung*
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Eligibility NCT00220779 Multiple sclerosis
pregnant*
Stillen, Stillzeit*
Immunomodulatory or immunosuppressive
therapy*
Therapeutic Corticosteroid*
Steroide*
Interferone*
Immunglobuline, intravenös*
glatiramer acetate*
Kardiale Erkrankungen*
Niereninsuffizienz*
Immunglobulin A Defizienz*
regulation of protein catabolic process*
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Eligibility NCT00220779 Multiple sclerosis
Eligibility NCT00251901 Chest Pain
Gastroesophageal Reflux
ODM derived from
http://clinicaltrials.gov/show/NCT00251901
All rights reserved. Please visit https://medical-data-
models.org/forms/4878
Eligibility
Einschlusskriterien
Alter 18 Jahre bis 70 Jahre*
Ja
Nein
Pain or discomfort in the chest without any
identifiable cause and severe enough for the
patient to seek primary medical or similar care*
Ja
Nein
History of pain or discomfort in the chest for at
least the last two weeks prior to enrollment*
Ja
Nein
Ausschlusskriterien
Signs, symptoms or relevant investigations
suggestion present symptomatic coronary heart
disease*
Ja
Nein
Patients whose pain or discomfort in the chest
warrants urgent cardiac investigation*
Ja
Nein
Medizinische Konzepte
Alter*
Diagnose*
Brustschmerz*
Anamnese*
Medizinische Versorgung*
Registrierung*
Koronare Herzerkrankung*
Untersuchung*
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Cardiac*
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Eligibility NCT00251901 Chest Pain Gastroesophageal Reflux
Eligibility NCT00252863 Asthma
ODM derived from
http://clinicaltrials.gov/show/NCT00252863
All rights reserved. Please visit https://medical-data-
models.org/forms/4879
Eligibility
Einschlusskriterien
Alter 18 Jahre und älter*
Ja
Nein
Patients with asthma, either well-controlled on a
regular therapy with a combination of long-acting
beta-agonists and inhaled corticosteroids or
symptomatic on therapy with inhaled
corticosteroids alone*
Ja
Nein
Ausschlusskriterien
Any other significant lung disease other than
asthma*
Ja
Nein
Any disease that might put patients at risk if they
participate in the study*
Ja
Nein
Medizinische Konzepte
Alter*
Diagnose*
Asthma*
Therapie*
Beta-adrenoceptor agonist*
Corticosteroide*
Lungenerkrankung*
disease risk*
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Eligibility NCT00264056 Advanced Metastastic Malignant Melanoma  Refractory
to First-Line Chemotherapy Irresectable Progressive Soft Tissue Metastases
ODM derived from
http://clinicaltrials.gov/show/NCT00264056
All rights reserved. Please visit https://medical-data-
models.org/forms/4880
Eligibility
Einschlusskriterien
Alter zwischen 18 und 70*
Ja
Nein
histologically proven malignant melanoma with
advanced inoperable soft tissue metastases*
Ja
Nein
progressive disease upon systemic first-line
chemotherapy*
Ja
Nein
2 or more bidimensionally measurable soft tissue
lesions*
Ja
Nein
WHO performance status (ECOG) of 2 or more*
Ja
Nein
life expectancy of 8 weeks and more*
Ja
Nein
prior informed consent*
Ja
Nein
Ausschlusskriterien
participation in other therapy studies*
Ja
Nein
pregnancy or breast feeding*
Ja
Nein
concomitant clinically significant infection*
Ja
Nein
cardiac pacemaker or other medical implants, or
implants within the hyperthermia treated region
(including a safe distance of 5 cm)*
Ja
Nein
lack of physiological heat sensitivity within the
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hyperthermia treated region (including a safe
distance of 5 cm)*
Ja
Nein
Medizinische Konzepte
Alter*
Diagnose*
Malignes Melanom*
Secondary malignant neoplasm of soft tissues*
Progressive Disease*
Systemic Chemotherapy*
Soft tissue lesion*
ECOG Status*
ECOG performance status - grade 2*
Life expectancy*
Einverständniserklärung*
Pregnancy*
Stillzeit*
Infektion*
Artificial cardiac pacemaker*
Biomedical implant*
Hyperthermia Treatment*
Intolerant of heat*
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Eligibility NCT00264056 Advanced Metastastic Malignant Melanoma  Refractory
to First-Line Chemotherapy Irresectable Progressive Soft Tissue Metastases
Eligibility NCT00261352 Type 2 Diabetes
ODM derived from
http://clinicaltrials.gov/show/NCT00261352
All rights reserved. Please visit https://medical-data-
models.org/forms/4881
Eligibility
Einschlusskriterien
Alter 18 Jahre und älter*
Ja
Nein
Provision of a written informed consent*
Ja
Nein
Female patients: postmenopausal,
hysterectomized, or if of childbearing potential,
using a reliable method of birth control*
Ja
Nein
Diagnosed with type 2 diabetes*
Ja
Nein
Treated with diet alone or treatment with a single
oral antidiabetic agent or low doses of two oral
antidiabetic agents*
Ja
Nein
Ausschlusskriterien
Type 1 diabetes*
Ja
Nein
New York Heart Association heart failure Class III
or IV*
Ja
Nein
Treatment with chronic insulin*
Ja
Nein
History of hypersensitivity or intolerance to any
peroxisome proliferator-activated receptor agonist
(like Actos or Avandia), fenofibrate, metformin or
3-hydroxy-3-methylglutaryl coenzyme A
reductase inhibitor (statin)*
Ja
Nein
History of drug-induced myopathy or drug-
induced creatine kinase elevation, liver enzyme
elevations, neutropenia (low white blood cells)*
Ja
Nein
Creatinine levels above the normal range*
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Ja
Nein
Received any investigational product in other
clinical studies within 12 weeks*
Ja
Nein
Any clinically significant abnormality identified on
physical examination, laboratory tests or
electrocardiogram, which in the judgment of the
investigator would compromise the patient's
safety or successful participation in the clinical
study*
Ja
Nein
Medizinische Konzepte
Alter*
Diagnose*
Einverständniserklärung*
Postmenopause*
Hysterektomie*
Kontrazeption*
Diabetes mellitus Typ II*
Diät*
Antidiabetikum*
Diabetes Mellitus, Insulin-Dependent*
Heart failure*
New York Heart Association Class III*
New York Heart Association Class IV*
Therapeutic Insulin*
Insulin*
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Eligibility NCT00261352 Type 2 Diabetes
chronisch*
Allergie*
intolerance to substance*
Peroxisom*
Fenofibrate (substance)*
Metformin (substance)*
Pioglitazone hydrochloride*
Rosiglitazone maleate*
Hydroxymethylglutaryl-CoA Reductase Inhibitors*
Myopathie*
Abnormalities, Drug-Induced*
Kreatin(phospho)kinase, CPK*
Elevated liver enzyme levels*
Neutropenia*
Kreatinin abnormal*
klinische Studie*
Physical examination procedure*
Labortest*
Elektrokardiogramm (EKG)*
patient safety*
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Eligibility NCT00261352 Type 2 Diabetes
Eligibility NCT00343161 Gastroesophageal
Reflux Disease
ODM derived from
http://clinicaltrials.gov/ct2/show/NCT00343161?term=NCT0
0343161&rank=1
All rights reserved. Please visit https://medical-data-
models.org/forms/4882
Eligibility
Einschlusskriterien
Alter*
Ja
Nein
unterschriebene Einverständniserklärung*
Ja
Nein
Symptome der gastroösophagealen
Refluxkrankheit*
Ja
Nein
Ausschlusskriterien
Vorbehandlung/Vordiagnose*
Ja
Nein
Schwere Ösophagitis in der Vorgeschichte*
Ja
Nein
Vorgehende Antirefluxchirurgie*
Ja
Nein
Medikamenten-/Drogenmißbrauch in der
Vorgeschichte*
Ja
Nein
Schwangerschaft/Stillzeit*
Ja
Nein
Medizinische Konzepte
Alter*
Diagnose*
Medikamente*
gastroösophageale Refluxkrankheit*
Einverständniserklärung*
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Ösophagitis*
Antirefluxchirurgie*
schwanger*
treatment*
Drug abuse*
Stillzeit*
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Eligibility NCT00343161 Gastroesophageal Reflux Disease
Eligibility NCT00273338 Prostate Cancer
ODM derived from
http://clinicaltrials.gov/show/NCT00273338
All rights reserved. Please visit https://medical-data-
models.org/forms/4883
Eligibility
Einschlusskriterien
Alter >= 18 Jahre*
Ja
Nein
Histopathologically or cytologically proven
adenocarcinoma of the prostate*
Ja
Nein
Documented metastatic prostate
adenocarcinoma*
Ja
Nein
Documented progression while on androgen
ablation therapy detected by rising prostate
specific antigen (PSA) and/or imaging*
Ja
Nein
Eastern Cooperative Oncology Group (ECOG)
performance status <= 2*
Ja
Nein
Adequate hematologic, renal and hepatic
function*
Ja
Nein
Life expectancy >= 3 months*
Ja
Nein
Ausschlusskriterien
Prior chemotherapy, except estramustine*
Ja
Nein
Prior chemotherapy with docetaxel*
Ja
Nein
Prior isotope therapy (e.g., strontium-89,
samarium-153, etc.)*
Ja
Nein
One or more contraindications to the use of
corticosteroids*
Ja
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Nein
History of cancer-related hypercalcemia*
Ja
Nein
Medizinische Konzepte
Alter*
Diagnose*
Prostate Adenocarcinoma*
Metastatic prostate cancer*
Course of illness*
androgen ablation therapy*
Prostate-Specific Antigen*
Diagnostic Imaging*
ECOG performance status - grade 0*
ECOG performance status - grade 1*
ECOG performance status - grade 2*
Hematologic function*
kidney function*
Hepatic function*
Chemotherapie*
Estramustine (substance)*
Taxotere*
radioisotope therapy*
Strontium 89 therapy*
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Eligibility NCT00273338 Prostate Cancer
Samarium 153*
Contraindication to medical treatment*
Corticosteroide*
Hypercalcemia*
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Eligibility NCT00273338 Prostate Cancer
Eligibility NCT00296309 Kidney
Transplantation
ODM derived from
http://clinicaltrials.gov/show/NCT00296309
All rights reserved. Please visit https://medical-data-
models.org/forms/4885
Eligibility
Einschlusskriterien
Alter 60 Jahre und älter*
Ja
Nein
Patients with end stage kidney disease who are
suitable candidates for primary renal
transplantation or retransplantation are eligible for
the study. Patients receiving a kidney transplant,
from a cadaveric or living donor (not HLA
identical) with compatible ABO blood type can be
included.*
Ja
Nein
Ausschlusskriterien
Patient has an immunological high risk*
Ja
Nein
Cold ischemia time greater than 30 hours*
Ja
Nein
Patient has significant liver disease*
Ja
Nein
Patient is allergic or intolerant to study
medication*
Ja
Nein
Patient or donor is known to be HIV positive.*
Ja
Nein
Patient with malignancy or history of malignancy*
Ja
Nein
Patient has significant, uncontrolled concomitant
infections*
Ja
Nein
Medizinische Konzepte
Alter*
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disorder*
terminale Niereninsuffizienz*
Renal transplant*
retransplantation*
Nierentransplantat*
Live donor*
Donor person*
humanes Leukozytenantigen, HLA*
ABO Blutgruppensystem*
Immunological Risk Factors*
Cold Ischemic Time*
Lebererkrankung*
Drug intolerance*
HIV-positiv*
Krebs*
Infektion*
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Eligibility NCT00296309 Kidney Transplantation
Eligibility NCT00293943 Atrial Fibrillation
ODM derived from
http://clinicaltrials.gov/show/NCT00293943
All rights reserved. Please visit https://medical-data-
models.org/forms/4886
Eligibility
Einschlusskriterien
Alter 50 - 85 Jahre*
Ja
Nein
Idiopathic paroxysmal symptomatic atrial
fibrillation refractory to antiarrhythmic therapy*
Ja
Nein
Patient willing to participate in randomized trial
and an invasive follow-up at month 3 (-6)*
Ja
Nein
Structural normal heart*
Ja
Nein
Patient willing and able to participate in 12
months follow-up period*
Ja
Nein
ECG documentation of atrial fibrillation (ECG,
Holter, event recorders, etc) for at least one AF
event in the prior year (related to symptomatic or
asymptomatic episodes) with an average number
of one episode per month*
Ja
Nein
Written informed consent of the patient*
Ja
Nein
Ausschlusskriterien
Patients who have had previous pulmonary vein
ablation procedures. Patients with atrial fibrillation
secondary to a reversible cause*
Ja
Nein
Known presence of intracardiac or other thrombi*
Ja
Nein
Evidence of obstructive lung disease requiring
bronchodilator therapy*
Ja
Nein
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Pregnant females or those of child bearing
potential who have not had a negative pregnancy
test within 48 hours before treatment.*
Ja
Nein
Other medical illness (i.e. cancer, congestive
heart failure) that may cause the patient to be
non-compliant with the protocol, confound the
data interpretation or is associated with limited
life-expectancy (i.e., less than one year)*
Ja
Nein
History of bleeding diathesis or suspected pro-
coagulant state contraindication to
anticoagulation therapy*
Ja
Nein
Hyperthyroidism or hypothyroidism manifested
clinically and in laboratory tests (TSH, T3, T4)*
Ja
Nein
Participation in a clinical trial within the last 30
days. Simultaneous participation in a registry
(e.g. project AB1 of the AFNET) is permitted.*
Ja
Nein
Drug addiction or chronic alcohol abuse*
Ja
Nein
Legal incapacity, or other circumstances which
would prevent the patient from understanding the
aim, nature or extent of the clinical trial*
Ja
Nein
Evidence of an uncooperative attitude*
Ja
Nein
Medizinische Konzepte
Alter*
disorder*
Paroxysmal atrial fibrillation*
Antiarrhythmic drug*
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Eligibility NCT00293943 Atrial Fibrillation
Subject Participation Status in Clinical Study*
Randomized Clinical Trial*
Follow-up*
invasiv*
Herz*
Elektrokardiogramm (EKG)*
Dokumentation*
Vorhofflimmern*
Holter Electrocardiography*
EVENT RECORDER, CARDIAC
(IMPLANTABLE)*
Episode (qualifier value)*
Einverständniserklärung*
Pulmonalvene*
Ablation Therapy*
Intracardiac thrombus*
Thrombus*
obstruktive Lungenerkrankung*
Inhaled bronchodilator therapy*
negativer Schwangerschaftstest*
Schwangerschaftstest*
Krebs*
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Eligibility NCT00293943 Atrial Fibrillation
kongestive Herzinsuffizienz*
Life expectancy*
Blutungsneigung*
Kontraindikation*
Anticoagulation Therapy*
Hyperthyreose*
Hypothyreose*
Registry*
Drogenabhängigkeit*
chronischer Alkohol-Abusus*
Persistent or Significant Disability or Incapacity*
Disturbance of understanding*
nicht-kooperatives Verhalten*
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Eligibility NCT00293943 Atrial Fibrillation
Eligibility NCT00289978 Relapsing-
remitting Multiple Sclerosis
ODM derived from
http://clinicaltrials.gov/show/NCT00289978
All rights reserved. Please visit https://medical-data-
models.org/forms/4887
Eligibility
Einschlusskriterien
Alter 18 Jahre bis 55 Jahre*
Ja
Nein
Patients with a relapsing-remitting disease
course*
Ja
Nein
Patients with EDSS score of 0-5.5*
Ja
Nein
Ausschlusskriterien
Patients with other chronic disease of the
immune system, malignancies, acute pulmonary
disease, cardiac failure, etc.*
Ja
Nein
Pregnant or nursing women*
Ja
Nein
Medizinische Konzepte
Alter*
disorder*
Multiple Sklerose, MS*
Multiple Sclerosis, Relapsing-Remitting*
EDSS*
chronische Erkrankung des Immunsystems*
Krebs*
Lungenerkrankung*
akut*
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Heart failure*
schwanger*
Stillzeit*
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Eligibility NCT00289978 Relapsing-remitting Multiple Sclerosis
Eligibility NCT00296361 Kidney
Transplantation
ODM derived from
http://clinicaltrials.gov/show/NCT00296361
All rights reserved. Please visit https://medical-data-
models.org/forms/4888
Eligibility
Einschlusskriterien
Alter 18 bis 60 Jahre*
Ja
Nein
Patients having end stage kidney disease who
will undergo primary renal transplantation or
retransplantation are eligible for the study.
Patients receiving a kidney transplant, from a
cadaveric or living donor (not HLA identical) with
compatible AB0 blood type can be included.*
Ja
Nein
Ausschlusskriterien
Patient has a high immunological risk*
Ja
Nein
Cold ischemia time greater than 30 hours*
Ja
Nein
Patient has significant liver disease*
Ja
Nein
Patient has severe hyper-cholesterolaemia*
Ja
Nein
Patient is allergic or intolerant to study
medication*
Ja
Nein
Patient requires ongoing dosing with
corticosteroids.*
Ja
Nein
Patient or donor is known to be HIV positive*
Ja
Nein
Patient with malignancy or history of malignancy*
Ja
Nein
Medizinische Konzepte
Alter*
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Diagnose*
terminale Niereninsuffizienz*
Renal transplant*
retransplantation*
Nierentransplantat*
Live donor*
Donor person*
humanes Leukozytenantigen, HLA*
ABO Blutgruppensystem*
Immunological Risk Factors*
Cold Ischemic Time*
Lebererkrankung*
Hypercholesterinämie*
Drug intolerance*
Corticosteroide*
fortlaufend*
HIV-positiv*
Krebs*
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Eligibility NCT00296361 Kidney Transplantation
Eligibility NCT00357227 Atrial Fibrillation
ODM derived from
http://clinicaltrials.gov/show/NCT00357227
All rights reserved. Please visit https://medical-data-
models.org/forms/4889
Eligibility
Einschlusskriterien
Alter 50 bis 85 Jahre*
Ja
Nein
Klinische Diagnose von permanentem,
paroxysmalem oder episodischem
Vorhofflimmern in der Vergangenheit oder
Gegenwart*
Ja
Nein
Ausschlusskriterien
Herzschrittmacher*
Ja
Nein
Metallimplantate*
Ja
Nein
History of acute stroke*
Ja
Nein
Diagnosis of vascular or degenerative dementia*
Ja
Nein
History of brain tumors*
Ja
Nein
History of severe brain injury*
Ja
Nein
History of psychiatric disorders*
Ja
Nein
Schwangerschaft*
Ja
Nein
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Eligibility NCT00354627 HIV-1
ODM derived from
http://clinicaltrials.gov/show/NCT00354627
All rights reserved. Please visit https://medical-data-
models.org/forms/4891
Eligibility
Einschlusskriterien
Patient mindestens 18 Jahre alt*
Ja
Nein
Patient is at least 3-class experienced (3 classes
of licensed oral antiretrovirals: nucleoside/tide
reverse transcriptase inhibitors [N[t]RTI], protease
inhibitors [PI], non-nucleoside reverse
transcriptase inhibitors [NNRTI])*
Ja
Nein
Patients with primary NNRTI resistance can be
included if they are experienced with at least 2
classes of ARVs (PIs, N[t]RTIs) and meet all the
other inclusion criteria*
Ja
Nein
Patient has previously received 2 different PI-
based regimens*
Ja
Nein
Patient is unable to use currently approved
NNRTIs due to resistance (primary or acquired)
and/or intolerance*
Ja
Nein
Patient, if currently receiving an ARV regimen, is
not achieving adequate virologic suppression on
his/her current regimen. *
Ja
Nein
Ausschlusskriterien
Prior or current participation in DUET trials
(TMC125-C206 or TMC125-C216).*
Ja
Nein
Use of disallowed concomitant therapy, including
disallowed antiretrovirals (ARV)*
Ja
Nein
Use of investigational ARVs (with exceptions)*
Ja
Nein
Any active clinically significant disease (e.g.,
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cardiac dysfunction, pancreatitis, acute viral
infection) or findings during screening of medical
history or physical examination that is not either
resolved or stabilized for at least 30 days before
the Screening Phase*
Ja
Nein
Pregnant or breast-feeding female*
Ja
Nein
Female patient of childbearing potential not using
effective non-hormonal birth control methods*
Ja
Nein
Patients with specific laboratory abnormalities*
Ja
Nein
Patients with clinical or laboratory evidence of
significantly decreased hepatic function or
decompensation.*
Ja
Nein
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Eligibility NCT00354627 HIV-1
Eligibility NCT00306215 Crohn's Disease
ODM derived from
http://clinicaltrials.gov/show/NCT00306215
All rights reserved. Please visit https://medical-data-
models.org/forms/4892
Eligibility
Einschlusskriterien
Alter 18 Jahre und älter*
Ja
Nein
moderate to severe Crohn's Disease*
Ja
Nein
CDAI 250-450*
Ja
Nein
CRP >7.5*
Ja
Nein
signed written informed consent*
Ja
Nein
Ausschlusskriterien
> 100 cm of small bowel resected*
Ja
Nein
ileostomy, colostomy or rectal pouch*
Ja
Nein
diagnosis of ulcerative colitis or indeterminate
colitis*
Ja
Nein
evidence of short bowel syndrome requiring
enteral or parenteral supplementation or total
parenteral nutrition*
Ja
Nein
hepatitis B, C or HIV infection*
Ja
Nein
history of infection requiring IV antibiotics*
Ja
Nein
serious or GI infection in the previous 12 weeks*
Ja
Nein
1 / 3
Medizinische Konzepte
Alter*
Diagnose*
M. Crohn*
Crohn's disease activity index*
CRP*
Einverständniserklärung*
Dünndarmresektion*
Ileostomie*
Kolostomie*
Rectal pouch*
Colitis ulcerosa*
Colitis of Indeterminate Type*
Evidence of*
Syndrom des kurzen Darms*
enteral*
Nutritional Supplementation*
Parenteral Therapeutic Nutritional
Supplementation*
vollständig parenterale Ernährung*
Hepatitis B*
Hepatitis C*
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Eligibility NCT00306215 Crohn's Disease
HIV Infektion*
Infektion*
Antibiotika*
intravenös*
Serious (qualifier value)*
Magen-Darm-Infektion*
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Eligibility NCT00306215 Crohn's Disease
Eligibility NCT00309621 Hand Dermatoses
ODM derived from
http://clinicaltrials.gov/show/NCT00309621
All rights reserved. Please visit https://medical-data-
models.org/forms/4893
Eligibility
Einschlusskriterien
Alter 18 bis 75 Jahre*
Ja
Nein
Chronic hand dermatitis, rated as severe by
physicians global assessment, present for at
least 6 months, that has not responded to the
avoidance of allergens and irritants and the use
of topical steroids*
Ja
Nein
Ausschlusskriterien
female of childbearing potential, unless
participating in a pregnancy prevention program*
Ja
Nein
psoriasis*
Ja
Nein
active major psychiatric condition*
Ja
Nein
Medizinische Konzepte
Alter*
Diagnose*
Chronic hand dermatitis*
Arzt, Mediziner*
Untersuchung*
Allergen*
Irritans, Reizmittel*
Steroide*
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Topical Route of Drug Administration*
weiblich*
string*
Schwangerschaft*
prevention program*
Psoriasis*
Psychiatrische Erkrankung*
aktiv*
Major (qualifier value)*
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Eligibility NCT00309621 Hand Dermatoses
Eligibility NCT00312845 Non-Hodgkin's
Lymphoma
ODM derived from
http://clinicaltrials.gov/show/NCT00312845
All rights reserved. Please visit https://medical-data-
models.org/forms/4894
Eligibility
Einschlusskriterien
Alter >= 18 Jahre*
Ja
Nein
Diagnosis of follicular B-NHL of the following
subtypes (World Health Organization [WHO]
classification 1997): follicular lymphoma (FL)
(Grades 1 and 2).*
Ja
Nein
Documented relapse or progression following
prior antineoplastic treatment. New lesions or
objective evidence of progression of existing
lesions must document relapse or progression
following the previous therapy.*
Ja
Nein
If any prior regimen included rituximab, the
subject must have responded (complete
response [CR], unconfirmed complete response
[CRu], partial response [PR]), and the time to
progression (TTP) from the first dose of rituximab
must have been 6 months or more.*
Ja
Nein
At least 1 measurable tumor mass (greater than
1.5 cm in the longest dimension and greater than
1.0 cm in the short axis) that has not been
previously irradiated, or has grown since previous
irradiation*
Ja
Nein
In the opinion of the investigator the decision to
initiate treatment is justified to manage the
subject's lymphoma*
Ja
Nein
No active central nervous system lymphoma*
Ja
Nein
Eastern Cooperative Oncology Group [ECOG]
status ? 2*
Ja
Nein
Female subjects must be postmenopausal (for at
least 6 months), surgically sterile, abstinent, or, if
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sexually active, be practicing an effective method
of birth control (e.g., prescription oral
contraceptives, contraceptive injections,
intrauterine device, double-barrier method,
contraceptive patch, male partner sterilization)
before entry and throughout the study; and have
a negative serum beta-human chorionic
gonadotropin (?-hCG) pregnancy test at
screening.*
Ja
Nein
Subjects (or their legally acceptable
representatives) must have signed an informed
consent document indicating that they
understand the purpose of and procedures
required for the study and are willing to
participate in the study.*
Ja
Nein
In countries where health authorities have
approved the pharmacogenomic testing, subjects
or their legally acceptable representatives must
have signed a separate informed consent that
they agree to participate in the genetic part and
protein testing part of the study; participation in
the genetic and protein testing component is
mandatory for pharmacogenomics testing, but
optional for serum protein testing and future
testing.*
Ja
Nein
Ausschlusskriterien
Diagnosed or treated for a malignancy other than
NHL within 1 year of randomization, or who were
previously diagnosed with a malignancy other
than NHL and have any radiographic or
biochemical marker evidence of malignancy.
Subjects with completely resected basal cell
carcinoma, squamous cell carcinoma of the skin,
or in situ malignancy are not excluded.*
Ja
Nein
Clinical evidence of a transformation from
indolent NHL to a more aggressive form of NHL.*
Ja
Nein
Prior treatment with VELCADE; Antineoplastic
(including unconjugated therapeutic antibodies),
experimental, or radiation therapy within 3 weeks
before randomization;      Nitrosoureas within 6
weeks before randomization;
Radioimmunoconjugates or toxin
immunoconjugates within 10 weeks before
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randomization;                      Stem cell transplant
within 6 months before randomization;
Major surgery within 2 weeks before
randomization.*
Ja
Nein
Residual toxic effects of previous therapy or
surgery of Grade 3 or worse*
Ja
Nein
Peripheral neuropathy or neuropathic pain of
Grade 2 or worse*
Ja
Nein
Have received an experimental drug or used an
experimental medical device within 21 days
before the planned start of treatment.*
Ja
Nein
History of allergic reaction attributable to
compounds containing boron or mannitol*
Ja
Nein
Known anaphylaxis or immunoglobulin E (IgE)-
mediated hypersensitivity to murine proteins or to
any component of rituximab including polysorbate
80 and sodium citrate dihydrate*
Ja
Nein
Concurrent treatment with another investigational
agent*
Ja
Nein
Female subject who is pregnant or breast-
feeding*
Ja
Nein
Medizinische Konzepte
Alter*
Diagnose*
Mann*
Frau*
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Eligibility NCT00312845 Non-Hodgkin's Lymphoma
Lymphoma, Non-Hodgkin (Non-Hodgkins
lymphoma)*
Follicular low grade B-cell lymphoma, Follicular
non-Hodgkin lymphoma*
Follicular lymphoma grade I, unspecified site*
Follicular lymphoma grade II, unspecified site*
WHO-Klassifikation*
Rezidiv*
Documented (qualifier value)*
Krankheitsverlauf*
Antineoplastic Drug/Agent Therapy*
Therapie*
Previous (qualifier value)*
Läsion*
Evidence of*
Treatment Regimen*
Rituximab*
Complete Response (CR)*
partial response (partial remission)*
Time to Progression*
Mass of body structure,                       Mass
(morphologic abnormality), Tumor Mass*
Irradiation*
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Lymphom*
Central Nervous System Lymphoma*
aktiv*
ECOG Status*
weiblich*
Postmenopause*
Operative Surgical Procedures*
Steril*
Abstinent*
Kontrazeption*
orales Kontrazeptivum*
Prescription (procedure)*
Kontrazeptivum*
Injektion*
Intrauterine contraceptive device*
Barrier contraception method*
Double (qualifier value)*
Contraceptive Patch*
Male sterilization (procedure)*
Entry*
Studie*
Schwangerschaftstest (B-HCG im Serum)*
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negativer Schwangerschaftstest*
Screening*
Einverständniserklärung*
Pharmacogenomic Test*
Procurement of patient informed consent,
investigational study*
Subject Participation Status in Clinical Study*
Genetischer Test*
Serum/plasma protein test*
Testing*
Future*
Mandatory Testing*
Optional*
Krebs*
Random Allocation*
Biochemischer Marker*
Marker, Biomarker*
Radiographisch*
Basalzellenkarzinom*
Plattenepithelkarzinom*
In situ cancer*
klinisch*
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Eligibility NCT00312845 Non-Hodgkin's Lymphoma
Transformation*
Indolent Non-Hodgkin Lymphoma*
Aggressive Non-Hodgkin Lymphoma*
Velcade*
Immunotherapy, antineoplastic*
Antikörper*
nicht konjugiert*
Antikörpertherapie*
Therapies, Investigational*
Radiotherapie, Strahlentherapie*
Nitroharnstoff*
Radioimmunoconjugate*
Immunoconjugates*
Toxin*
stem cell transplantation*
operative procedures*
Major (qualifier value)*
Residual*
Toxisch*
poisonous effects*
Previous (qualifier value)*
Grade 3*
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Disorders of the peripheral nervous system*
Neuropathic Pain*
Grade 2*
Investigational New Drug*
Investigational Medical Device*
allergische Reaktion*
Bor*
Mannitol*
Anaphylaxie, anaphylaktischer Schock*
IgE-mediated hypersensitivity disorder*
Murine*
Protein, Eiweiß*
Polyoxethylenesorbitan oleate*
sodium citrate dihydrate*
kombinierte Therapie*
Investigational New Drug, Experimental Drug*
schwanger*
Stillzeit*
8 / 8
Eligibility NCT00312845 Non-Hodgkin's Lymphoma
Eligibility NCT00355849 Diabetes Mellitus,
Type 2
ODM derived from
http://clinicaltrials.gov/show/NCT00355849
All rights reserved. Please visit https://medical-data-
models.org/forms/4895
Eligibility
Einschlusskriterien
age >=18 Years*
Ja
Nein
Diabetes mellitus Typ II*
Ja
Nein
one or more oral antihyperglycemic medications*
Ja
Nein
once-daily insulin glargine*
Ja
Nein
HbA1c greater than or equal to 7.5 and less than
or equal to 10.5%*
Ja
Nein
Nichtraucher*
Ja
Nein
Ausschlusskriterien
taking a TZD dose greater than what is indicated*
Ja
Nein
more than two episodes of severe hypoglycemia
during the 6 months prior*
Ja
Nein
Have had a lower respiratory infection in the 3
months prior*
Ja
Nein
systemische Steroidtherapie*
Ja
Nein
klinische Zeichen oder Symptome einer
Lebererkrankung, akute oder chronische
Hepatitis*
Ja
Nein
history of renal transplantation*
1 / 2
Ja
Nein
aktives oder unbehandeltes Malignom*
Ja
Nein
Require more than 150 U/day of insulin glargine*
Ja
Nein
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Eligibility NCT00355849 Diabetes Mellitus, Type 2
Eligibility NCT00356109 Diabetes Mellitus,
Type 1
ODM derived from
http://clinicaltrials.gov/show/NCT00356109
All rights reserved. Please visit https://medical-data-
models.org/forms/4896
Eligibility
Einschlusskriterien
Alter >=18 Jahre*
Ja
Nein
Type 1 diabetes for at least 24 months*
Ja
Nein
Have an HbA1c less than or equal to 11%*
Ja
Nein
Patients who are on an insulin regimen involving
2 or 3 preprandial injections per day for at least 2
months*
Ja
Nein
Nichtraucher*
Ja
Nein
Ausschlusskriterien
Require a daily total insulin dosage greater than
150 U at screening*
Ja
Nein
Patients who have a current or past history of
asthma, chronic obstructive pulmonary disease,
other clinically relevant pulmonary disease*
Ja
Nein
systemische Steroidtherapie*
Ja
Nein
Clinical signs or symptoms of liver disease, acute
or chronic hepatitis*
Ja
Nein
History of lung transplantation and/or lung
cancer*
Ja
Nein
Diagnosed with pneumonia in the 3 months prior
to screening*
1 / 2
Ja
Nein
History of renal transplantation*
Ja
Nein
aktiver oder unbehandelter Tumor*
Ja
Nein
2 / 2
Eligibility NCT00356109 Diabetes Mellitus, Type 1
Eligibility NCT00321464 Bone Metastases
in Subjects With Advanced Breast Cancer
ODM derived from
http://clinicaltrials.gov/show/NCT00321464
All rights reserved. Please visit https://medical-data-
models.org/forms/4897
Eligibility
Einschlusskriterien
Alter 18 Jahre und älter*
Ja
Nein
Adults with histologically or cytologically
confirmed breast adenocarcinoma*
Ja
Nein
radiographic evidence of at least one bone mets*
Ja
Nein
ECOG Status*
Ja
Nein
adequate organ function*
Ja
Nein
Ausschlusskriterien
Current or prior IV bisphosphonate
administration*
Ja
Nein
current or prior oral bisphosphonates for bone
mets*
Ja
Nein
life expectancy <6 months*
Ja
Nein
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Eligibility NCT00324662 Tachyarrhythmia
ODM derived from
http://clinicaltrials.gov/show/NCT00321620
All rights reserved. Please visit https://medical-data-
models.org/forms/4899
Eligibility
Einschlusskriterien
Alter 18 Jahre und älter*
Ja
Nein
Men >/= 18 years of age with histologically
confirmed prostate cancer*
Ja
Nein
Radiographic evidence of at least one bone
metastasis*
Ja
Nein
Failure of at least one hormonal therapy as
evidenced by a rising PSA*
Ja
Nein
Serum testosterone level of <50 ng/dL*
Ja
Nein
ECOG Status*
Ja
Nein
Adequate organ function*
Ja
Nein
Ausschlusskriterien
Current or prior IV bisphosphonate
administration*
Ja
Nein
Current or prior oral bisphosphonates for bone
mets*
Ja
Nein
life expectancy <6 months*
Ja
Nein
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Eligibility NCT00326027 Gastroesophageal
Reflux
ODM derived from
http://clinicaltrials.gov/show/NCT00326027
All rights reserved. Please visit https://medical-data-
models.org/forms/4900
Eligibility
Einschlusskriterien
Alter 18 Jahre und älter*
Ja
Nein
Written informed consent*
Ja
Nein
Inpatients (hospitalization during the entire study
period is mandatory)*
Ja
Nein
Symptomatic (heartburn, acid regurgitation or
dysphagia for at least 1 day since admission to
the hospital) non-erosive reflux disease (NERD)
or erosive gastroesophageal reflux disease
(GERD, LA Grade A-D)*
Ja
Nein
Ausschlusskriterien
Known Zollinger-Ellison syndrome or other
gastric hypersecretory condition*
Ja
Nein
Previous acid-lowering surgery or other surgery
of the esophagus and/or upper gastrointestinal
tract (exception: polypectomy and
cholecystectomy)*
Ja
Nein
On initial endoscopy, presence of obstructive
esophageal strictures, Schatzki's ring,
esophageal diverticula, esophageal varices,
achalasia or Barrett's esophagus with known
high-grade dysplasia or longer than 3 cm*
Ja
Nein
Acute peptic ulcer and/or ulcer complications*
Ja
Nein
Pylorusstenose*
Ja
Nein
Known inflammatory bowel diseases*
1 / 2
Ja
Nein
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Eligibility NCT00326027 Gastroesophageal Reflux
Eligibility NCT00359762 Type 2 Diabetes
Mellitus
ODM derived from
http://clinicaltrials.gov/show/NCT00359762
All rights reserved. Please visit https://medical-data-
models.org/forms/4901
Eligibility
Einschlusskriterien
age 18 Years to 85 Years*
Ja
Nein
Diagnosed with type 2 diabetes mellitus.*
Ja
Nein
Treated with diet and exercise and a stable,
maximally tolerated dose of metformin for at least
3 months prior to screening.*
Ja
Nein
HbA1c >=6.5% und <=9.0%.*
Ja
Nein
Body Mass Index (BMI) >=25 kg/m2 und <40
kg/m2. *
Ja
Nein
Ausschlusskriterien
Participated in an interventional medical, surgical,
or pharmaceutical study within 30 days prior to
screening.*
Ja
Nein
Characteristics contraindicating metformin or
glimepiride use.*
Ja
Nein
Receiving drugs that directly affect
gastrointestinal motility.*
Ja
Nein
Receiving chronic (lasting longer than 2 weeks)
systemic glucocorticoid therapy.*
Ja
Nein
Have used any prescription drug to promote
weight loss within 3 months prior to screening.*
Ja
Nein
*
1 / 2
Ja
Nein
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Eligibility NCT00359762 Type 2 Diabetes Mellitus
Eligibility NCT00373373 Acute Myeloid
Leukemia
ODM derived from
http://clinicaltrials.gov/show/NCT00373373
All rights reserved. Please visit https://medical-data-
models.org/forms/4902
Eligibility
Einschlusskriterien
Alter >=61 Jahre*
Ja
Nein
Patients with newly diagnosed AML (except APL)
according to the FAB and WHO classification,
including AML evolving from MDS or other
hematologic diseases and AML after previous
cytotoxic therapy or radiation (secondary AML)*
Ja
Nein
Bone marrow aspirate or biopsy must contain >=
20% blasts of all nucleated cells, with the
exception of AML FAB M6, where >= 30% of non-
erythroid cells must be leukemic blasts*
Ja
Nein
Age >= 61 years*
Ja
Nein
Informed consent, personally signed and dated to
participate in the study*
Ja
Nein
Male patients enrolled in this trial must use
adequate barrier birth control measures during
the course of the Sorafenib treatment and for at
least 3 months after the last administration of
Sorafenib *
Ja
Nein
Ausschlusskriterien
Central nervous system manifestation of AML*
Ja
Nein
Cardiac Disease: Heart failure NYHA III or IV.
Active coronary artery disease (MI more than 6
months prior to study entry is permitted).  Serious
cardiac ventricular arrhythmias requiring anti-
arrhythmic therapy (beta blockers or digoxin are
permitted)*
Ja
Nein
Chronically impaired renal function (creatinin
1 / 3
clearance < 30 ml/min)*
Ja
Nein
Chronic pulmonary disease with relevant
hypoxia*
Ja
Nein
Inadequate liver function (ALT and AST >= 2.5 x
ULN)*
Ja
Nein
Total bilirubin >= 1.5 x ULN*
Ja
Nein
Resting blood pressure (BP) consistently higher
than systolic 160 mmHg and/or diastolic 95
mmHg*
Ja
Nein
Any severe concomitant condition which makes it
undesirable for the patient to participate in the
study or which could jeopardise compliance with
the protocol*
Ja
Nein
Uncontrolled active infection*
Ja
Nein
Concurrent malignancies other than AML*
Ja
Nein
Previous treatment of AML except hydroxyurea
and up to 2 days <= 100 mg/m2/d cytarabine*
Ja
Nein
Known HIV and/or hepatitis C infection*
Ja
Nein
Evidence or history of CNS disease, including
primary or metastatic brain tumors, seizure
disorders*
Ja
Nein
Thrombotic or embolic events such as
cerebrovascular accident or pulmonary embolism
within 1 year of study entry*
Ja
Nein
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Eligibility NCT00373373 Acute Myeloid Leukemia
Evidence or history of severe non-leukemia
associated bleeding diathesis or coagulopathy*
Ja
Nein
History of organ allograft*
Ja
Nein
Concomitant treatment with kinase inhibitors,
angiogenesis inhibitors and Myelotarg*
Ja
Nein
Patients with major surgery, open biopsy or
significant traumatic injury within 4 weeks of start
or first dose*
Ja
Nein
Serious, non-healing wound, ulcer or bone
fracture*
Ja
Nein
Allergy to study medication or excipients in study
medication*
Ja
Nein
Investigational drug therapy outside of this trial
during or within 4 weeks of study entry*
Ja
Nein
Patients who are not eligible for standard
chemotherapy*
Ja
Nein
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Eligibility NCT00373373 Acute Myeloid Leukemia
Eligibility NCT00373373 Acute Myeloid
Leukemia
ODM derived from
http://clinicaltrials.gov/show/NCT00373373
All rights reserved. Please visit https://medical-data-
models.org/forms/4903
Eligibility
Einschlusskriterien
Alter >=61 Jahre*
Ja
Nein
Patients with newly diagnosed AML (except APL)
according to the FAB and WHO classification,
including AML evolving from MDS or other
hematologic diseases and AML after previous
cytotoxic therapy or radiation (secondary AML)*
Ja
Nein
Bone marrow aspirate or biopsy must contain >=
20% blasts of all nucleated cells, with the
exception of AML FAB M6, where >= 30% of non-
erythroid cells must be leukemic blasts*
Ja
Nein
Age >= 61 years*
Ja
Nein
Informed consent, personally signed and dated to
participate in the study*
Ja
Nein
Male patients enrolled in this trial must use
adequate barrier birth control measures during
the course of the Sorafenib treatment and for at
least 3 months after the last administration of
Sorafenib *
Ja
Nein
Ausschlusskriterien
Central nervous system manifestation of AML*
Ja
Nein
Cardiac Disease: Heart failure NYHA III or IV.
Active coronary artery disease (MI more than 6
months prior to study entry is permitted).  Serious
cardiac ventricular arrhythmias requiring anti-
arrhythmic therapy (beta blockers or digoxin are
permitted)*
Ja
Nein
Chronically impaired renal function (creatinin
1 / 3
clearance < 30 ml/min)*
Ja
Nein
Chronic pulmonary disease with relevant
hypoxia*
Ja
Nein
Inadequate liver function (ALT and AST >= 2.5 x
ULN)*
Ja
Nein
Total bilirubin >= 1.5 x ULN*
Ja
Nein
Resting blood pressure (BP) consistently higher
than systolic 160 mmHg and/or diastolic 95
mmHg*
Ja
Nein
Any severe concomitant condition which makes it
undesirable for the patient to participate in the
study or which could jeopardise compliance with
the protocol*
Ja
Nein
Uncontrolled active infection*
Ja
Nein
Concurrent malignancies other than AML*
Ja
Nein
Previous treatment of AML except hydroxyurea
and up to 2 days <= 100 mg/m2/d cytarabine*
Ja
Nein
Known HIV and/or hepatitis C infection*
Ja
Nein
Evidence or history of CNS disease, including
primary or metastatic brain tumors, seizure
disorders*
Ja
Nein
Thrombotic or embolic events such as
cerebrovascular accident or pulmonary embolism
within 1 year of study entry*
Ja
Nein
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Eligibility NCT00373373 Acute Myeloid Leukemia
Evidence or history of severe non-leukemia
associated bleeding diathesis or coagulopathy*
Ja
Nein
History of organ allograft*
Ja
Nein
Concomitant treatment with kinase inhibitors,
angiogenesis inhibitors and Myelotarg*
Ja
Nein
Patients with major surgery, open biopsy or
significant traumatic injury within 4 weeks of start
or first dose*
Ja
Nein
Serious, non-healing wound, ulcer or bone
fracture*
Ja
Nein
Allergy to study medication or excipients in study
medication*
Ja
Nein
Investigational drug therapy outside of this trial
during or within 4 weeks of study entry*
Ja
Nein
Patients who are not eligible for standard
chemotherapy*
Ja
Nein
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Eligibility NCT00373373 Acute Myeloid Leukemia
Eligibility NCT00331890 Acute Stroke.
Cerebral Infarction.
ODM derived from
http://clinicaltrials.gov/show/NCT00331890
All rights reserved. Please visit https://medical-data-
models.org/forms/4904
Eligibility
Einschlusskriterien
Alter älter als 18 Jahre*
Ja
Nein
Patients must be treated within 24 hours of their
initial stroke symptoms onset.*
Ja
Nein
Patients with a measurable focal neurological
deficit lasting for a minimum of 60 minutes.*
Ja
Nein
Patients must have a CT scan and/or
conventional MRI compatible with the clinical
diagnosis of acute ischemic stroke prior to being
randomized.*
Ja
Nein
Patients must have an acute ischemic stroke
referable to the middle cerebral artery territory*
Ja
Nein
At inclusion, NIHSS score > 7, with at least 2 of
these points from sections 5 & 6 (motor)*
Ja
Nein
Immediately (i.e. minutes) pre-stroke, MRS < 2*
Ja
Nein
Women of childbearing potential must have a
negative pregnancy test prior to enrolment*
Ja
Nein
Signed informed consent*
Ja
Nein
Ausschlusskriterien
Patients in coma: patients having a score of >=2
in the items regarding the level of consciousness
in the NIHSS (1a)*
Ja
Nein
1 / 2
CT or conventional MRI evidence of brain tumor,
cerebral edema with a clinically significant mass
midline shift with compression of the ventricles,
brainstem or cerebellar infarction, subarachnoid
and/or intracerebral and/or intraventricular
hemorrhage*
Ja
Nein
History of ventricular dysrhythmias, acute
myocardial infarction within 72 hours prior to
enrolment, unstable angina, decompensated
congestive heart failure or any other acute,
severe, uncontrollable or sustained
cardiovascular condition that, in the Investigator's
opinion, may interfere with effective participation
in the study*
Ja
Nein
Previous disorders that may confound the
interpretation of the neurological scales*
Ja
Nein
Drug addiction-related disorders*
Ja
Nein
Pre existing dementia, when dementia implies a
disability, measured as an score of >=2 in the
previous MRS*
Ja
Nein
Pre existing medical condition that, in the
Investigator's opinion, may interfere with the
patient's suitability and participation in the study*
Ja
Nein
Patients participating in another clinical trial or
receiving a non-approved drug (clinical
investigational drug) <30 days prior to screening*
Ja
Nein
Patients under current treatment with citicoline*
Ja
Nein
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Eligibility NCT00332709 Osteoporosis.
Postmenopausal
ODM derived from
http://clinicaltrials.gov/show/NCT00332709
All rights reserved. Please visit https://medical-data-
models.org/forms/4905
Eligibility
Einschlusskriterien
Alter 18 Jahre und älter*
Ja
Nein
Compliant postmenopausal women with primary
operable breast cancer after 4 to 6 years of
therapy with tamoxifen (end of tamoxifen therapy
within last 6 months)*
Ja
Nein
ECOG Status*
Ja
Nein
Patients without severe osteoporosis at study
entry*
Ja
Nein
No evidence of relapse at the time of
randomization*
Ja
Nein
Adequate function of bone marrow, kidney, and
liver*
Ja
Nein
Ausschlusskriterien
Estrogen- and progesterone-receptor status
negative or unknown*
Ja
Nein
Completion of adjuvant tamoxifen therapy more
than 6 months prior to study start*
Ja
Nein
Inflammatory Breast Carcinoma, Mastitis
carcinomatosa*
Ja
Nein
Current/active dental problems including infection
of the teeth or jawbone, dental or fixture trauma,
or a current or prior diagnosis of osteonecrosis of
the jaw, of exposed bone in the mouth, or of slow
healing after dental procedures*
1 / 2
Ja
Nein
Recent (within 6 weeks) or planned dental or jaw
surgery*
Ja
Nein
History of diseases with influence on bone
metabolism such as Paget's disease and primary
overactive parathyroid*
Ja
Nein
Prior or concomitant therapies: chemotherapy
within the last 12 months, intravenous or oral
bisphosphonates, systemic corticosteroids,
anabolic steroids or growth hormones, Tibolone,
parathyroid hormone, systemic sodium fluoride or
any drugs known to affect the skeleton (such as
calcitonin, mithramycin, or gallium nitrate)*
Ja
Nein
Patients with previous or concomitant cancers
(not breast cancer) within the past 5 years
EXCEPT adequately treated basal or squamous
cell skin cancers or in situ cancer of the cervix.
Patients with previous other cancer(s) must have
been disease-free for at least 5 years.*
Ja
Nein
Patients currently receiving oral bisphosphonates
must discontinue these at least 3 weeks prior to
study start.*
Ja
Nein
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Eligibility NCT00240474 Hypertension
ODM derived from
http://clinicaltrials.gov/show/NCT00240474
All rights reserved. Please visit https://medical-data-
models.org/forms/4906
Eligibility
Einschlusskriterien
Alter 60 Jahre und älter*
Ja
Nein
mean SBP >140 mmHg and mean DBP <=95
mmHg*
Ja
Nein
24-hour mean ambulatory SBP >125 mmHg*
Ja
Nein
hypertensive patients not on current
antihypertensive therapy or able to stop their
current treatment for a period of up to eighteen
weeks*
Ja
Nein
willing and able to provide written informed
consent*
Ja
Nein
Ausschlusskriterien
women of child-bearing potential who are NOT
practicing acceptable means of birth control*
Ja
Nein
known or suspected secondary hypertension*
Ja
Nein
mean SBP >=200 mmHg*
Ja
Nein
hepatic and/or renal dysfunction as defined by
the following laboratory parameters:
Bilateral renal artery stenosis, renal artery
stenosis in a solitary kidney, patients post-renal
transplant or with only one functioning kidney.
Clinically relevant hypokalemia or hyperkalemia.
Uncorrected volume or sodium depletion.*
Ja
Nein
Primary aldosteronism, unspecified*
Ja
1 / 3
Nein
Hereditary fructose intolerance syndrome*
Ja
Nein
biliärer Verschluss, Gallen(wegs)verschluss*
Ja
Nein
patients who have previously experienced
symptoms characteristic of angioedema during
treatment with ACE inhibitors or angiotensin-II
receptor antagonists*
Ja
Nein
history of drug or alcohol dependency within the
previous six months*
Ja
Nein
chronic administration of any medication known
to affect blood pressure, other than the trial
medication*
Ja
Nein
concurrent participation in another clinical trial or
any investigational therapy within thirty days prior
to signing the consent form.*
Ja
Nein
symptomatic congestive heart failure (New York
Heart Academy (NYHA) functional class CHF II-
IV)*
Ja
Nein
unstable angina pectoris, myocardial infarction,
percutaneous transluminal coronary angioplasty
(PTCA) or coronary artery bypass graft (CABG)
surgery <3 months prior to informed consent*
Ja
Nein
stroke <6 months prior to informed consent*
Ja
Nein
sustained ventricular tachycardia, atrial
fibrillation, atrial flutter or other clinically relevant
arrhythmias as determined by the investigator*
Ja
Nein
hypertrophic obstructive cardiomyopathy,
hemodynamically relevant stenosis of the aortic
or mitral valve*
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Ja
Nein
insulin-dependent diabetes mellitus whose
diabetes has not been stable and controlled for
the previous three months*
Ja
Nein
night-shift workers who routinely sleep during the
daytime and whose working hours include
midnight to 4:00 AM*
Ja
Nein
known allergic hypersensitivity to any component
of the formulations under investigation*
Ja
Nein
concomitant therapy with lithium, cholestyramine
or colestipol resins. non-compliance with study
medication (defined as  <80% or >120%) during
the run-in period*
Ja
Nein
current treatment with any antihypertensive
agent*
Ja
Nein
any other clinical condition which, in the opinion
of the investigator, would not allow safe
completion of the protocol and safe
administration of telmisartan, amlodipine or
hydrochlorothiazide*
Ja
Nein
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Eligibility NCT00241514 GERD
ODM derived from
http://clinicaltrials.gov/show/NCT00241514
All rights reserved. Please visit https://medical-data-
models.org/forms/4907
Eligibility
Einschlusskriterien
Alter 18 Jahre und älter*
Ja
Nein
Signed informed consent.*
Ja
Nein
Completed the SH-NEN-0001 study with relief of
upper GI symptom. Relief is defined as "last 7
days with a diary assessment of None or
Minimal, but allowing up to 2 days to be rated as
Mild during the 7-day period".*
Ja
Nein
A clinical diagnosis of a chronic condition (e.g.,
osteoarthritis or rheumatoid arthritis) that
requires continuous daily NSAID treatment for at
least 6 months. Daily NSAID treatment is defined
as taking the prescribed dose for at least 5 of 7
days in any given week and can include COX-2
selective NSAIDs, multiple NSAIDs, and high-
dose NSAIDs.*
Ja
Nein
Daily NSAID treatment dose and type: (Must
have been stable for at least 9 weeks prior to
inclusion and. Are expected to remain stable for
the duration of the study. and. Must be
administered orally. If more than one type of
NSAID treatment is used, at least one type must
be administered orally).*
Ja
Nein
Hp negative on Histology performed at baseline
endoscopy in the study SHNEN- 0001.*
Ja
Nein
Ausschlusskriterien
Discontinuation from study SH-NEN-0001*
Ja
Nein
Pain, discomfort or burning in the upper abdomen
precipitated by exercise or relieved by
defecation.*
Ja
1 / 2
Nein
Pain, discomfort or burning in the upper abdomen
not associated with the use of NSAIDs, including
COX-2 selective NSAIDs.*
Ja
Nein
Pregnancy or lactation. Women of childbearing
potential must maintain effective contraception
during the study period as judged by the
investigator.*
Ja
Nein
Need for continuous concomitant therapy with:
(Anticoagulants, Corticosteroids at doses higher
than explained under inclusion criterion)*
Ja
Nein
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Eligibility NCT00241514 GERD
Eligibility NCT00242775 Asthma
ODM derived from
http://clinicaltrials.gov/show/NCT00242775
All rights reserved. Please visit https://medical-data-
models.org/forms/4908
Eligibility
Einschlusskriterien
Alter 12 Jahre und älter*
Ja
Nein
Diagnosed with asthma since at least 6 months
prior to first visit*
Ja
Nein
Prescribed daily use of glucocorticosteroids for at
least 3 months prior to first visit*
Ja
Nein
At least one asthma exacerbation >1 but <12
months prior to first visit*
Ja
Nein
Ausschlusskriterien
Respiratory infection affecting asthma within 30
days before first visit*
Ja
Nein
Use of oral, rectal, or parenteral
glucocorticosteroids for within 30 days before first
visit*
Ja
Nein
Any significant disease or disorder that may
jeopardize the safety of the patient*
Ja
Nein
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Eligibility NCT00478777 Relapsed or
Refractory Multiple Myeloma
ODM derived from
http://clinicaltrials.gov/show/NCT00478777
All rights reserved. Please visit https://medical-data-
models.org/forms/4909
Eligibility
Einschlusskriterien
Alter mindestens 18 Jahre*
Ja
Nein
Must understand and voluntarily sign an informed
consent form.*
Ja
Nein
Must be >=18 years of age at the time of signing
the informed consent form.*
Ja
Nein
Must be able to adhere to the study visit schedule
and other protocol requirements.*
Ja
Nein
Must be diagnosed with multiple myeloma that is
progressing after at least 2 cycles of anti-
myeloma treatment or that has relapsed with
progressive disease after treatment.*
Ja
Nein
Subjects may have been previously treated with
thalidomide and/or radiation therapy. In addition,
radiation therapy initiated prior to or at baseline
(Day 1) may be given concurrently with study
therapy, provided that all other eligibility criteria
are satisfied.*
Ja
Nein
Subjects must discontinue all anti-myeloma drug
or non-drug therapy prior to the first dose of study
drug with the exception of radiation therapy
initiated prior to or at baseline (Day 1).*
Ja
Nein
Measurable levels of myeloma paraprotein in
serum (>0.5 g/dL) or urine (>0.2 g excreted in a
24-hour collection sample).*
Ja
Nein
ECOG Status <= 2*
Ja
Nein
*
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Ja
Nein
Ausschlusskriterien
The presence of any of the following will exclude
a subject from study enrollment:*
Ja
Nein
Any serious medical condition, laboratory
abnormality, or psychiatric illness that would
prevent the subject from signing the informed
consent form.*
Ja
Nein
Pregnant or lactating females.*
Ja
Nein
Any condition, including the presence of
laboratory abnormalities, which places the
subject at unacceptable risk if he/she were to
participate in the study or confounds the ability to
interpret data from the study.*
Ja
Nein
Any of the following laboratory abnormalities:*
Ja
Nein
Absolute Neutrophil Count*
Ja
Nein
Platelet count <75,000/mm^3 (75 x 109/L) for
subjects in whom <50% of the bone  marrow
nucleated cells are plasma cells.*
Ja
Nein
Platelet count <30,000/mm^3 (30x10^9/L) for
subjects in whom >=50% of bone marrow
nucleated cells are plasma cells.*
Ja
Nein
Kreatinin im Serum*
Ja
Nein
Serum SGOT/AST or SGPT/ALT >3.0 x upper
limit of normal (ULN)*
Ja
Nein
Serum Total Bilirubin Measurement*
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Ja
Nein
Prior history of malignancies other than multiple
myeloma (except for basal cell or squamous cell
carcinoma of the skin or carcinoma in situ of the
cervix or breast) unless the subject has been free
of the disease for >=1 year.*
Ja
Nein
Prior history of stroke and/or thromboembolic
event*
Ja
Nein
Known hypersensitivity to thalidomide or
dexamethasone.*
Ja
Nein
Prior history of uncontrollable side effects to
dexamethasone therapy.*
Ja
Nein
The development of a desquamating rash while
taking thalidomide.*
Ja
Nein
Neuropathy >= Grade 2.*
Ja
Nein
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Eligibility NCT00478777 Relapsed or Refractory Multiple Myeloma
Eligibility NCT00486759 Lymphoma, B-Cell
ODM derived from
http://clinicaltrials.gov/show/NCT00486759
All rights reserved. Please visit https://medical-data-
models.org/forms/4910
Eligibility
Einschlusskriterien
Alter mindestens 18 Jahre*
Ja
Nein
CD20-positive diffuse large B-cell lymphoma*
Ja
Nein
low-intermediate, high-intermediate or high risk
disease and/or bulky tumor (.7.5 cm)*
Ja
Nein
ECOG Status <=2*
Ja
Nein
Ausschlusskriterien
prior treatment for diffuse large B-cell lymphoma*
Ja
Nein
types of non-Hodgkin's lymphoma other than
DLBCL*
Ja
Nein
CNS Lymphoma*
Ja
Nein
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Eligibility NCT00501059 Moderate Risk of
CVD
ODM derived from
http://clinicaltrials.gov/show/NCT00501059
All rights reserved. Please visit https://medical-data-
models.org/forms/4911
Eligibility
Einschlusskriterien
Alter mindestens 55 Jahre*
Ja
Nein
Males aged 55 years and above with 2 to 4 risk
factors. Male Risk Factors:*
Ja
Nein
Elevated cholesterol (Tchol>200 mg/dL or
LDL>130 mg/dL, as measured at  screening)
irrespective of current treatment*
Ja
Nein
Current smoking: defined as any cigarette
smoking in the past 12 months*
Ja
Nein
Low HDL cholesterol (HDL<40 mg/dL, as
measured at screening)*
Ja
Nein
Elevated blood pressure (SBP>140 mmHg, as
measured at screening)*
Ja
Nein
Currently on any medication to treat high blood
pressure*
Ja
Nein
Positive family history of early CHD (a first-
degree relative [father, mother,  brother, sister,
son, daughter] suffered a heart attack [myocardial
infarction]  before the age of 60 years)*
Ja
Nein
Females aged 60 and above with 3 or more risk
factors. Female Risk Factors:*
Ja
Nein
Elevated cholesterol (Tchol>240 mg/dL or
LDL>160 mg/dL, as measured at  screening)
irrespective of current treatment*
Ja
Nein
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Current smoking: defined as any cigarette
smoking in the past 12 months*
Ja
Nein
Low HDL cholesterol (HDL<40 mg/dL, as
measured at screening)*
Ja
Nein
Currently on any medication to treat high blood
pressure*
Ja
Nein
Positive family history of early CHD (a first-
degree relative [father, mother,  brother, sister,
son, daughter] suffered a heart attack [myocardial
infarction]  before the age of 60 years)*
Ja
Nein
An understanding and willingness to comply with
trial procedures and has given written informed
consent to participate in the trial *
Ja
Nein
Ausschlusskriterien
History of a documented vascular event, such as
MI, stroke, coronary artery angioplasty or
stenting, coronary artery bypass graft, relevant
arrhythmias, or congestive heart failure or
vascular intervention*
Ja
Nein
Patients who are at higher than moderate risk on
the basis of their diabetes status, other factors
known to the investigator, or the currently used
national risk score*
Ja
Nein
Known contraindications to the study drug, e.g.
hypersensitivity to acetylsalicylic acid*
Ja
Nein
Recent (in the past year) history of
gastrointestinal or genitourinary bleeding or other
bleeding disorders*
Ja
Nein
Active diagnosed and documented reflux
esophagitis*
Ja
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Nein
Patients presenting with any medical condition, or
psychiatric or substance abuse disorder, that, in
the opinion of the investigator, is likely to affect
the patient's ability to complete the study or
precludes the patient's participation in the study*
Ja
Nein
Lactating women or women of childbearing
potential*
Ja
Nein
Severe liver disease or damage based on the
clinical judgment of the investigator*
Ja
Nein
Severe renal disease or damage based on the
clinical judgement of the investigator*
Ja
Nein
A definite indication for acetylsalicylic acid
therapy, other antiplatelet drug, or anticoagulant
in the opinion of the physician*
Ja
Nein
A history of asthma induced by administration of
salicylates or substances with a similar action,
notably NSAIDS*
Ja
Nein
Chronic, frequent (> 5 days/month) use of
NSAIDs (including aspirin, or aspirin containing
products), COX-2 inhibitors or metamizole*
Ja
Nein
Current participation in any other trials involving
investigational products within 30 days prior to
the Screening Visit*
Ja
Nein
Langzeitanwendung von Antikoagulanzien*
Ja
Nein
Sitting systolic blood pressure*
Ja
Nein
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Eligibility NCT00501059 Moderate Risk of CVD
Eligibility NCT00505388 Bronchial Asthma
ODM derived from
http://clinicaltrials.gov/show/NCT00505388
All rights reserved. Please visit https://medical-data-
models.org/forms/4912
Eligibility
Einschlusskriterien
Alter mindestens 18 Jahre*
Ja
Nein
Asthma patients prescribed Symbicort as
maintenance and reliever therapy, according to
the label, before inclusion in this programme*
Ja
Nein
signed and dated informed consent(ICF)*
Ja
Nein
for patients under-age, signed and dated ICF
form from both the patient and the patient's
parent/legal guardian is required *
Ja
Nein
Ausschlusskriterien
Involvement in the planning and conduct of the
programme (applies to both AstraZeneca staff or
staff at the investigational site)*
Ja
Nein
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Eligibility NCT00505570 Migraine
ODM derived from
http://clinicaltrials.gov/show/NCT00505570
All rights reserved. Please visit https://medical-data-
models.org/forms/4913
Eligibility
Einschlusskriterien
Alter 18 bis 65 Jahre*
Ja
Nein
Subjects who have migraine headaches with aura
diagnosed by a doctor*
Ja
Nein
Subjects who have not responded to or cannot
take common migraine preventive medications *
Ja
Nein
Ausschlusskriterien
Subjects with a clinical history of stroke*
Ja
Nein
Subjects who cannot take aspirin and clopidogrel
(Plavix)*
Ja
Nein
Subjects who are pregnant or desire to become
pregnant within the next year*
Ja
Nein
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Eligibility NCT00506688 Cystic Fibrosis
ODM derived from
http://clinicaltrials.gov/show/NCT00506688
All rights reserved. Please visit https://medical-data-
models.org/forms/4914
Eligibility
Einschlusskriterien
Alter mindestens 8 Jahre*
Ja
Nein
Male or female patient, 8 years (pediatric 8 - 17
years inclusive, adult 18 years)*
Ja
Nein
Confirmed diagnosis of CF (positive sweat
chloride, 60 mEq/liter by pilocarpine
iontophoresis and/or a genotype with two
identifiable mutations consistent with CF
accompanied by one or more clinical features
with the CF phenotype)*
Ja
Nein
Patient is able to perform acceptable spirometric
maneuvers according to ATS standards*
Ja
Nein
FEV1 > 40% predicted and < 90% predicted*
Ja
Nein
The patient is clinically stable fulfilling the
following: No evidence of acute upper or lower
respiratory tract infection within 4 weeks of
screening. No pulmonary exacerbation requiring
an use of i.v./oral/inhaled antibiotics, or oral
corticosteroids within 4 weeks of screening.
FEV1 at Visit 2 is within a range of +10% and
-10% of FEV1 from the Visit 1. (If FEV1 at V2 is
not within that range, V2 may be re-scheduled
once within 7 days)*
Ja
Nein
Concomitant or chronic medication is planned to
be continued unchanged for the entire study
duration*
Ja
Nein
The patient or the patient's legally acceptable
representative is able to give informed consent in
accordance with ICH and GCP guidelines and
local legislation*
Ja
Nein
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Patient is able to comply with the study visit
schedule and willing and able to complete the
assessments specified in the protocol. *
Ja
Nein
Ausschlusskriterien
History of allergy/hypersensitivity (including
medication allergy) that is deemed relevant to the
trial by the investigator. Relevance in this context
refers to any increased risk of hypersensitivity
reaction to trial medication. (Specific concerns
currently identified with respect to the use of
inhaled glutathione in allergic patients per se are
not existing)*
Ja
Nein
Concomitant inhaled thiol-containing medications
(e.g., inhaled N-acetylcysteine). Such medication
had to be finished at least 2 weeks before the
screening visit. Oral N-acetylcysteine may be
continued.*
Ja
Nein
New oral or inhaled thiol-containing medications
(e.g., inhaled or oral N-acetylcysteine) throughout
the study period.*
Ja
Nein
Patient with a known relevant substance abuse,
including alcohol or drug abuse.*
Ja
Nein
Pregnant or lactating woman or female patient of
child bearing potential who is sexually active and
not using a medically approved form of
contraception such as oral or injectable
contraceptives, intrauterine devices, double-
barrier method, contraceptive patch, male partner
sterilization or condoms.*
Ja
Nein
Patient with a documented persistent colonization
with B. cepacia (defined as >1 positive culture
within the past year).*
Ja
Nein
Start of a new concomitant or chronic medication
for CF within 4 weeks of screening.*
Ja
Nein
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Existing cycling medication regimen without
completion of at least 3 cycles prior to the
screening visit or the drug cycles of other
therapies are not in accordance with the 4-week
time-schedule for the single visits of this study*
Ja
Nein
Clinically relevant diseases or medical conditions
other than CF or CF-related conditions that, in
the opinion of the investigator, would compromise
the safety of the patient or the quality of the data.
This includes, but is not limited to, significant
hematological, hepatic,renal, cardiovascular, and
neurological diseases (diabetic patients may
participate if their disease is under good control
prior to screening).*
Ja
Nein
Participation in another study with an
investigational drug within one month or 6
halflives(whichever is greater) preceding the
screening visit.*
Ja
Nein
The patient is an employee of the investigator or
the institution with direct involvement in the trial
or other trials under the direction of the
investigator or their members.*
Ja
Nein
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Eligibility NCT00506688 Cystic Fibrosis
Eligibility NCT00507832 Prurigo Nodularis
ODM derived from
http://clinicaltrials.gov/show/NCT00507832
All rights reserved. Please visit https://medical-data-
models.org/forms/4915
Eligibility
Einschlusskriterien
Alter 18 bis 70 Jahre*
Ja
Nein
Diagnosis: Prurigo nodularis*
Ja
Nein
Pruritus intensity >VAS 3 (Visual analoge scale 0
to 10)*
Ja
Nein
Nodules on arms and legs (target areas: arms)*
Ja
Nein
No effective current external or internal
antipruritic medication*
Ja
Nein
Signed informed consent *
Ja
Nein
Ausschlusskriterien
prurigo nodularis with massive excoriations
and/or local infections*
Ja
Nein
atopic dermatitis, predisposition for atopic
dermatitis*
Ja
Nein
Itch intensity <VAS 4 (visual analoge scale 0 to
10)*
Ja
Nein
Pregnant or nursing (lactating) women, where
pregnancy is defined as the state of a female
after conception and until the termination of
gestation, confirmed by a positive hCG test.
Pregnancy should be ruled out before stating the
study by a b-subunit HCG test.*
Ja
Nein
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Females of childbearing potential and not
practicing a medically approved, highly effective
(low failure rate) method of contraception during
and up to at least 4 weeks after the end of
treatment. 'Medically approved' contraception
may include implants, injectables, combined oral
contraceptives, some IUDs (e.g. intrauterine
device), sexual abstinence or if the woman has a
vasectomized partner.*
Ja
Nein
active psychosomatic and psychiatric diseases*
Ja
Nein
History of active malignancy of any organ
system*
Ja
Nein
actual diseases which need therapy and may
induce pruritus (e.g. deficiency of iron, zinc)*
Ja
Nein
Systemic immunosuppression*
Ja
Nein
Topical use of tacrolimus, pimecrolimus, steroids
or capsaicin within 2 weeks prior to study entry*
Ja
Nein
current and past (within 2 weeks prior to study
entry) systemic use of antihistamines, steroids,
cyclosporin A and other immunosuppressants,
paroxetin, fluvoxamine (selective serotonin
reuptake-inhibitors, study possible in case of
medication since 6 months due to depression
without having any Antipruritic effect) naltrexone
and UV-therapy.*
Ja
Nein
wound healing disturbances, disposition for
keloids, current medication which leads to
increased bleeding during procedure e.g.
acetylsalicylic acid (ASS), marcumar (no suction
blister possible)*
Ja
Nein
History of hypersensitivity to pimecrolimus 1%
cream or hydrocortisone 1% cream*
Ja
Nein
Participation in other clinical studies within the
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Eligibility NCT00507832 Prurigo Nodularis
last 4 weeks*
Ja
Nein
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Eligibility NCT00507832 Prurigo Nodularis
Eligibility NCT00508664 Squamous Cell
Carcinoma of the Hypopharynx
ODM derived from
http://clinicaltrials.gov/show/NCT00508664
All rights reserved. Please visit https://medical-data-
models.org/forms/4916
Eligibility
Einschlusskriterien
Alter 18 bis 75 Jahre*
Ja
Nein
Histologically confirmed, primary only with
laryngectomy respectable squamous-cell
carcinoma of the larynx or hypopharynx*
Ja
Nein
T3-T4a carcinoma of the glottis*
Ja
Nein
T2-T4a carcinoma of the supraglottic, only
controllable by laryngectomy and if applicable by
root of tongue segmental resection*
Ja
Nein
T2-T4a carcinoma of the hypopharynx only
controllable by laryngectomy (for example T2,
post cricoidal) and hypopharynx segmental
resection*
Ja
Nein
N-status: cervical metastases (N <=3) have to be
rehabilitate by surgical procedures*
Ja
Nein
Blood count: Leukocytes >3500/mm\3,
Neutrophils > 1500/ mm\3, Thrombocytes >
8000/ mm\3*
Ja
Nein
Clinical Chemistry Finding*
Ja
Nein
adequate renal function, defined by serum
creatinine and urea not >25% upper NL,
creatinine-clearance > 60 ml/min/1,72 m\2*
Ja
Nein
adequate hepatic function with SGOT, SGPT not
>50% and bilirubin not >upper NL*
Ja
Nein
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Electrolytes normal*
Ja
Nein
anesthetic risk normal or low-grade elevated*
Ja
Nein
Alter 18-75 Jahre*
Ja
Nein
written informed consent*
Ja
Nein
effective contraception after individual advice for
men and women if there is a  possibility of
reproductive potential (effective contraception
are: oral  contraception with estrogen and
gestagen (no minipill), vaginal ring,  contraception
patch, estrogen free ovulation suppressors,
hormone spiral with  progesterone, injection for
three month with depot gestagen, hormone
releasing  implantation (luteal hormone
containing rod), abstinence or sterilization
(vasectomy) of the male) *
Ja
Nein
Ausschlusskriterien
primary cancer treatable by operational larynx-
conserving procedures*
Ja
Nein
distant metastases (M1-Status)*
Ja
Nein
total tumor volume exceeding 80 ml or larynx
skeleton punctuated with infiltration of
surrounding soft tissues respectively the
esophageal aditus (exclusive cartilage infiltration
represents no exclusion criteria)*
Ja
Nein
tumor-specific prior chemo- or radiotherapy*
Ja
Nein
metachronous or synchronous malignant tumor
(exception basalioma) [in case of a controlled
tumor of different localization with a non-treated
interval over 5 years to the present therapy the
patient can be included after consultation with the
coordinating investigator]*
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Ja
Nein
Life expectancy*
Ja
Nein
Karnofsky performance status <70%*
Ja
Nein
serious cardiopulmonary concomitant disease
(cardiac insufficiency grade III and IV according
NYHA status, myocardial infarction, angina
pectoris, respiratory global insufficiency)*
Ja
Nein
Chronic diseases with permanent-therapy
(uncontrolled diabetes, active rheumatoid
arthritis)*
Ja
Nein
recurrent pneumonia, COPD GOLD stage <2,
chronic inflammation of intestine or any other
concomitant diseases, which disallow study
participation in the opinion of the responsible
physician*
Ja
Nein
Other circumstances (contra-indications), which
disallow treatment with Docetaxel, Cisplatin, 5-
FU, Cetuximab or radiotherapy*
Ja
Nein
Expected absent patient compliance*
Ja
Nein
Periodic follow-up not possible (for example
address outside germany)*
Ja
Nein
Pregnant or breast-feeding woman*
Ja
Nein
Absent or constricted legal capacity*
Ja
Nein
Participation to another clinical trial with any
investigational study within 30 days prior to study
screening*
Ja
Nein
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Eligibility NCT00508664 Squamous Cell Carcinoma of the Hypopharynx
Eligibility NCT00509184 Lymphoma,
Malignant
ODM derived from
http://clinicaltrials.gov/show/NCT00509184
All rights reserved. Please visit https://medical-data-
models.org/forms/4917
Eligibility
Einschlusskriterien
Alter 18 bis 75 Jahre*
Ja
Nein
verified follicular lymphoma grade 1 or 2*
Ja
Nein
only nodal involvement (incl. Waldeyer) clinical
stage I or II*
Ja
Nein
Tumorvolumen*
Ja
Nein
adequate bone marrow reserves *
Ja
Nein
Ausschlusskriterien
ECOG Status >2*
Ja
Nein
Follicular lymphoma grade III, unspecified*
Ja
Nein
Bulky Disease (>7cm)*
Ja
Nein
involvement of the spleen*
Ja
Nein
neoplasia in PMH (except: basalioma,
spinalioma)*
Ja
Nein
Immunodeficiency syndromes, viral hepatitis,
connective tissue disease*
Ja
Nein
severe psychiatric disease*
Ja
Nein
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pregnancy or breast feeding*
Ja
Nein
known allergies against foreign proteins*
Ja
Nein
2 / 2
Eligibility NCT00509184 Lymphoma, Malignant
Eligibility NCT00518895 Melanoma
ODM derived from
http://clinicaltrials.gov/show/NCT00518895
All rights reserved. Please visit https://medical-data-
models.org/forms/4918
Eligibility
Einschlusskriterien
Alter mindestens 18 Jahre*
Ja
Nein
Histologically confirmed diagnosis of melanoma*
Ja
Nein
Progressive disease that is not surgically
resectable, or metastatic Stage IV*
Ja
Nein
Low-normal LDH, defined as <= 0.8 times the
upper limit of normal*
Ja
Nein
No prior chemotherapy*
Ja
Nein
Measurable Disease*
Ja
Nein
ECOG Status <= 1*
Ja
Nein
At least 4 weeks and recovery from effects of
major prior surgery or other therapy, including
immunotherapy, radiation therapy, or cytokine,
biologic or vaccine therapy*
Ja
Nein
Prior immunotherapy allowed*
Ja
Nein
Adequate organ function *
Ja
Nein
Ausschlusskriterien
Prior cytotoxic chemotherapy, including regional
perfusion, or prior Genasense treatment*
Ja
Nein
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Primary ocular or mucosal melanoma*
Ja
Nein
Knochenmetastasierung*
Ja
Nein
History or presence of brain metastasis or
leptomeningeal disease*
Ja
Nein
Significant medical disease other than cancer*
Ja
Nein
Organ allograft*
Ja
Nein
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Eligibility NCT00522834 Melanoma
ODM derived from
http://clinicaltrials.gov/show/NCT00522834
All rights reserved. Please visit https://medical-data-
models.org/forms/4919
Eligibility
Einschlusskriterien
Alter mindestens 18 Jahre*
Ja
Nein
Histologically confirmed metastatic (Stage IV)
melanoma of cutaneous origin*
Ja
Nein
ECOG Status <=2*
Ja
Nein
Measurable disease according to modified
RECIST*
Ja
Nein
Life expectancy >12 weeks*
Ja
Nein
LDH <= 2.0 x ULN*
Ja
Nein
Clinical lab values within protocol parameters.*
Ja
Nein
At least 18 years old and able and willing to
provide informed consent to participate *
Ja
Nein
Ausschlusskriterien
Previous cytotoxic chemotherapy treatment for
melanoma*
Ja
Nein
Received more than one regimen of
immunotherapy, kinase inhibitor, biologic therapy,
vaccine or investigational non-chemotherapeutic
treatment for melanoma.*
Ja
Nein
Presence of brain metastases*
Ja
Nein
1 / 2
Presence or history (<= 5 years) of a second
malignancy other than nonmelanoma skin cancer
or cervical carcinoma in situ*
Ja
Nein
Female subjects who are pregnant or nursing*
Ja
Nein
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Eligibility NCT00522834 Melanoma
Eligibility NCT00525512 Pulmonary
Disease, Chronic Obstructive
ODM derived from
http://clinicaltrials.gov/show/NCT00525512
All rights reserved. Please visit https://medical-data-
models.org/forms/4920
Eligibility
Einschlusskriterien
Alter mindestens 40 Jahre*
Ja
Nein
All patients must sign an informed consent*
Ja
Nein
Diagnosis of COPD with specific spirometric
criteria (determined at study visits) *
Ja
Nein
Alter >= 40 Jahre *
Ja
Nein
Medical Research Council Dyspnea Scale >= 2*
Ja
Nein
Current or ex-smoker with a >= 10 pack-year
smoking history *
Ja
Nein
Ability to exercise on treadmill *
Ja
Nein
Ausschlusskriterien
Significant diseases other than COPD such as
history of life-threatening pulmonary obstruction,
thoracotomy with pulmonary resection, interstitial
lung disease, CF, pulmonary thromboembolic
disease, clinically evident bronchiectasis, active
tuberculosis, or known moderate to severe renal
impairment*
Ja
Nein
Clinical history of asthma*
Ja
Nein
Use of supplemental oxygen therapy*
Ja
Nein
Respiratory tract infection or COPD exacerbation
in the 6 weeks prior to Visit 1 or during the
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washout period prior to Visit 3 (may randomize 6
weeks after recovery)*
Ja
Nein
Recent history (<= 12 months) of myocardial
infarction*
Ja
Nein
Unstable or life-threatening cardiac arrhythmia*
Ja
Nein
Malignancy treated with radiation therapy or
chemotherapy in the last 5 years*
Ja
Nein
Pregnant or nursing women*
Ja
Nein
Known hypersensitivity to anticholinergic drugs or
any component of the study medications*
Ja
Nein
Participation in pulmonary or cardiac rehab
program within 13 weeks of Visit 1*
Ja
Nein
Estimated life expectancy < 2 years *
Ja
Nein
Symptomatic prostatic hyperplasia or bladder
neck obstruction *
Ja
Nein
Known narrow-angle glaucoma *
Ja
Nein
Any condition that is contraindicated for exercise*
Ja
Nein
Orthopaedic, muscular, neurological or cardiac
disease that would interfere with regular
participation in aerobic exercise or with exercise
testing *
Ja
Nein
Body mass index < 18 kg/m2 or >35 kg/m2 list
truncated for space*
Ja
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Nein
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Eligibility NCT00525512 Pulmonary Disease, Chronic Obstructive
Eligibility NCT00543803 HIV Infections
ODM derived from
http://clinicaltrials.gov/show/NCT00543803
All rights reserved. Please visit https://medical-data-
models.org/forms/4923
Eligibility
Einschlusskriterien
Alter mindestens 18 Jahre*
Ja
Nein
male and female adult HIV type 1 infected
patients, who have either not been treated
previously, whose previous combination
treatment with PIs has failed, or who have to
switch their previous treatment from protease
inhibitors (PI) or non-nucleoside reverse
transcriptase inhibitors (NNRT)I due to side
effects or intolerability after achieving
suppression of viral load below the limit of
detection.*
Ja
Nein
Viramune (nevirapine) is indicated as part of
combination therapy for the antiviral treatment of
HIV-1 infected patients with advanced or
progressive immunodeficiency.*
Ja
Nein
Truvada (tenofovir and emtricitabine) is indicated
in antiretroviral combination therapy for the
treatment of HIV-1 infected adults. *
Ja
Nein
Ausschlusskriterien
Alter < 18 Jahre*
Ja
Nein
Pregnant female patients*
Ja
Nein
Hypersensitivity to the active substance or to any
of the excipients of Viramune (nevirapine) or
Truvada (tenofovir and emtricitabine).*
Ja
Nein
Viramune (nevirapine) should not be
readministered to patients who have required
permanent discontinuation for severe rash, rash
accompanied by constitutional symptoms,
hypersensitivity reactions, or clinical hepatitis due
to nevirapine.*
Ja
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Nein
Viramune (nevirapine) should not be used in
patients with severe hepatic impairment (Child-
Pugh C) or pre-treatment aspartine transaminase
(ASAT) or alanine transaminase (ALAT) > 5 upper
limit normal (ULN) until baseline ASAT/ALAT are
stabilised < 5 ULN.*
Ja
Nein
Viramune (nevirapine) should not be
readministered in patients who previously had
ASAT or ALAT > 5 ULN during Viramune
(nevirapine) therapy and had recurrence of liver
function abnormalities upon readministration of
Viramune (nevirapine)*
Ja
Nein
Herbal preparations containing St Johns wort
(Hypericum perforatum) must not be used while
taking Viramune (nevirapine) due to the risk of
decreased plasma concentrations and reduced
clinical effects of nevirapine*
Ja
Nein
The available pharmacokinetic data suggest that
the concomitant use of rifampicin and Viramune
(nevirapine) is not recommended.*
Ja
Nein
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Eligibility NCT00534287 Severe Sepsis
ODM derived from
http://clinicaltrials.gov/show/NCT00534287
All rights reserved. Please visit https://medical-data-
models.org/forms/4924
Eligibility
Einschlusskriterien
Alter mindestens 18 Jahre*
Ja
Nein
Severe sepsis or septic shock according to
ACCP/SCCM criteria*
Ja
Nein
Onset of severe sepsis or septic shock <24 h*
Ja
Nein
Einverständniserklärung*
Ja
Nein
Effective contraception in fertile women *
Ja
Nein
Ausschlusskriterien
Alter <18 Jahre*
Ja
Nein
Schwangerschaft*
Ja
Nein
Stillzeit*
Ja
Nein
Pretreatment with meropenem, imipenem, or
ertapenem within the last 4 weeks (>1 daily
dosage)*
Ja
Nein
Pretreatment with moxifloxacin,ciprofloxacin, or
levofloxacin within the last 4 weeks (>1 daily
dosage)*
Ja
Nein
Pretreatment with a pseudomonas effective
cephalosporin (cefepime, ceftazidim, cefpirom) or
piperacillin within the last 48 hours (>1 daily
dosage).*
Ja
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Nein
Pretreatment with other chinolones within the last
4 weeks (>1 daily dosage)*
Ja
Nein
Presence of infection where guidelines
recommend another antimicrobial therapy than
the study medication (i.e. endocarditis)*
Ja
Nein
Evidence or strong clinical suspicion of a
microorganism where the study medication is
known to be ineffective (i.e. tuberculosis, MRSA-
or VRE-infection)*
Ja
Nein
Known allergy against meropenem or
moxifloxacin*
Ja
Nein
Tendon disease or injury due to past quinolone
therapy*
Ja
Nein
Congenital or acquired prolongation of QT-
interval*
Ja
Nein
Concomitant medication which prolongs the QT-
interval*
Ja
Nein
Electrolyte imbalance, especially uncorrected
hypokalemia*
Ja
Nein
Clinically relevant bradycardia*
Ja
Nein
Clinically relevant cardiac dysfunction with
reduced left-ventricular ejection fraction*
Ja
Nein
Symptomatic arrhythmias in the medical history*
Ja
Nein
Significant hepatic impairment (Child-Pugh C) or
elevation of liver enzymes >5x the upper normal
2 / 3
Eligibility NCT00534287 Severe Sepsis
range*
Ja
Nein
No commitment to full patient support (i.e. DNR
order)*
Ja
Nein
Patient's death is considered imminent due to
coexisting disease*
Ja
Nein
Concomitant participation in another study or
study participation within the last 30 days.*
Ja
Nein
Relationship of the patient to study team member
(i.e. colleague, relative)*
Ja
Nein
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Eligibility NCT00545077 Breast Cancer
ODM derived from
http://clinicaltrials.gov/show/NCT00545077
All rights reserved. Please visit https://medical-data-
models.org/forms/4925
Eligibility
Einschlusskriterien
Alter 18 bis 80 Jahre*
Ja
Nein
Before starting the specific protocol procedures,
the written informed consent must be obtained
and documented.*
Ja
Nein
Women >=18 years.*
Ja
Nein
Capacity to comply with all the protocol
requirements.*
Ja
Nein
Functional ECOG status  <= 1.*
Ja
Nein
Life expectancy >= 24 weeks.*
Ja
Nein
Histologically confirmed breast adenocarcinoma,
with measurable or non-measurable, locally
advanced or metastatic (stage IV) disease. In the
event that the patient only has locally advanced
disease, she will not be able to undergo curative
local treatment. Patients with metastasis confined
to the bone can be chosen, but the disease must
be confirmed by radiology, CT scan or NMR if
there is any doubt after a single bone scan.*
Ja
Nein
Patients with HER2-negative disease evaluated
by IHC and FISH/CISH (IHC 0 or 1+, or 2+ and
negative FISH). Patients with 3+ by IHC cannot
be chosen regardless of the FISH/CISH status
and those with positive FISH/CISH (> 2
amplifications) cannot be chosen either,
regardless of the IHC findings.*
Ja
Nein
Positive hormone receptors (estrogen receptor
[ER] and/or progesterone receptor [PgR])
evaluated by a local or central laboratory,
according to the criteria of the participating
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institution.*
Ja
Nein
Patients who are candidates for receiving first-line
treatment with letrozole.*
Ja
Nein
Patients may have received (neo)adjuvant
chemotherapy, provided that the last dose of the
latter was received at least 12 months before
randomization . Patients must be recovered from
toxicity.*
Ja
Nein
The patients are allowed to have received
adjuvant radiotherapy, provided that it was
completed at least 6 weeks before randomization
and the patient has recovered from the reversible
acute effects of the radiation. The previous
administration of radiotherapy to palliate the pain
of bone metastases is authorized, provided that:*
Ja
Nein
Not more than 30% of bone marrow has been
irradiated.*
Ja
Nein
The patient has recovered from the reversible
acute effects of the radiation.*
Ja
Nein
The patient has at least one metastatic location
which has not been irradiated  and which may be
evaluated for progression, or a clear progression
of the bone  disease has been objectified after
the end of the palliative radiotherapy. *
Ja
Nein
Ausschlusskriterien
Evolutionary disease requiring an immediate
treatment with cytotoxic chemotherapy according
to the investigator's judgment.*
Ja
Nein
Patients with locally advanced breast cancer who
are expected to undergo surgery or curative
radiotherapy.*
Ja
Nein
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Previous chemotherapy or hormonotherapy for
the metastatic disease. Patients may have
received neoadjuvant chemotherapy or
neoadjuvant hormonotherapy with curative
intention as a part or as an alternative to an
adjuvant treatment. For the previous neoadjuvant
hormonotherapy the same premises than for the
adjuvant hormonotherapy are valid.*
Ja
Nein
Previous therapy with anti-VEGF or VEGFR
tyrosine-kinase inhibitors.*
Ja
Nein
History of another pathology that may affect the
development of the protocol or the interpretation
of results. It is considered that patients who have
suffered from a skin carcinoma that is not
melanoma, cervical carcinoma in situ or another
neoplasia treated with a curative intention and
with a disease-free interval exceeding 5 years
can be chosen.*
Ja
Nein
Evidence of CNS metastasis. A CT scan or brain
NMR must be done within the 4 weeks before the
randomization in case of suspecting brain
metastasis.*
Ja
Nein
History or evidence in the physical or neurological
examination of CNS pathology unrelated to
cancer unless it is suitable treated with standard
therapy (e.g. uncontrolled convulsions). *
Ja
Nein
History of peripheral neuropathy NCI CTCAE
grade >2 at the time of randomization.*
Ja
Nein
Patients subjected to major surgical procedures,
open biopsies or those having significant trauma
injuries within the 28 days prior to randomization,
or patients who are expected to undergo a major
surgical procedure that must necessarily be
performed within the course of the study.*
Ja
Nein
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Eligibility NCT00560794 Acute
Lymphoblastic Leukemia
ODM derived from
http://clinicaltrials.gov/show/NCT00560794
All rights reserved. Please visit https://medical-data-
models.org/forms/4926
Eligibility
Einschlusskriterien
Alter mindestens 18 Jahre*
Ja
Nein
B-precursor ALL patients in complete
hematological remission with molecular failure or
molecular relapse starting at any time after
consolidation I of front-line therapy within GMALL
standards or at any time outside GMALL
standards.*
Ja
Nein
Patients must have a molecular marker for
evaluation of minimal residual disease which is
either Bcr/abl at any detection level or individual
rearrangements of immunoglobulin or TCR-genes
measured by an assay with a sensitivity of
minimum 10-4: At least one individual marker at a
quantitative level 10-4.*
Ja
Nein
ECOG Status < 2*
Ja
Nein
Ability to understand and willingness to sign a
written informed consent*
Ja
Nein
Signed and dated written informed consent is
available *
Ja
Nein
Ausschlusskriterien
Current extra medullar involvement*
Ja
Nein
History of or current relevant CNS pathology
(except migraine/headache and/or previous
infiltration of cerebrospinal fluid (CSF) by ALL)*
Ja
Nein
Current infiltration of cerebrospinal fluid by ALL*
Ja
Nein
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History of or current autoimmune disease*
Ja
Nein
Autologous stem cell transplantation within 6
weeks prior to study entry*
Ja
Nein
Any prior allogeneic stem cell transplantation*
Ja
Nein
Cancer chemotherapy within 4 weeks prior to
study treatment (except for intrathecal
prophylaxis and/or low dose maintenance therapy
such as vincalkaloids, mercaptopurine,
methotrexate, steroids)*
Ja
Nein
Radiotherapy within 4 weeks prior to study
treatment*
Ja
Nein
Therapy with monoclonal antibodies (Rituximab,
MabCampath) within 6 weeks prior to study
treatment*
Ja
Nein
Known hypersensitivity to immunoglobulins or to
any other component of the study drug
formulation*
Ja
Nein
Presence of human anti-murine antibodies
(HAMA)*
Ja
Nein
Abnormal bone marrow, renal or hepatic function*
Ja
Nein
Indication for a hypercoagulative state*
Ja
Nein
History of malignancy other than ALL within 5
years prior to study entry, with the exception of
basal cell carcinoma of the skin or cervix
carcinoma in situ*
Ja
Nein
Active severe infection, any other concurrent
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disease or medical condition that are deemed to
interfere with the conduct of the study as judged
by the investigator*
Ja
Nein
Known infection with human immunodeficiency
virus (HIV) or chronic infection with hepatitis B
virus (HbsAg positive) or hepatitis C virus (anti-
HCV positive*
Ja
Nein
Pregnant or nursing women*
Ja
Nein
Women of childbearing potential not willing to use
an effective form of contraception during
participation in the study and at least 3 months
thereafter or male patients not willing to ensure
effective contraception dur-ing participation in the
study and at least three months thereafter*
Ja
Nein
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Eligibility NCT00558584 Dilated
Cardiomyopathy
ODM derived from
http://clinicaltrials.gov/show/NCT00558584
All rights reserved. Please visit https://medical-data-
models.org/forms/4927
Eligibility
Einschlusskriterien
Alter 18 bis 65 Jahre*
Ja
Nein
Dilated cardiomyopathy*
Ja
Nein
LVEF <= 40% determined by contrast
echocardiography*
Ja
Nein
NYHA class II - IV*
Ja
Nein
Alter 18 - 65 *
Ja
Nein
Disease duration: symptomatic heart failure >1
year and <5 years prior to screening date*
Ja
Nein
Treatment with ACE inhibitors or angiotensin II
receptor blockers (ARB), beta-blockers, and
aldosterone antagonists (the latter at the
discretion of the attending physician), for at least
6 months and at stable doses for at least 2
months prior to screening date.*
Ja
Nein
Einverständniserklärung*
Ja
Nein
Ausschlusskriterien
NYHA class IV patients who are bed-ridden and
dependent upon parenteral medication*
Ja
Nein
Cardiac insufficiency resulting from another basic
disease (e.g. coronary artery disease, >= 50%
stenosis of major vessel as ascertained by
coronary angiography performed more recent
than three years before screening date,
hypertensive heart disease, or valvular defects
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>second degree*
Ja
Nein
History of - myocardial infarction*
Ja
Nein
Acute myocarditis according to Dallas criteria*
Ja
Nein
Endocrine disorder excluding insulin-dependent
diabetes mellitus*
Ja
Nein
Implanted cardiac defibrillator (ICD) <1 month
before screening date*
Ja
Nein
Cardiac resynchronization therapy (CRT) <6
months before screening date*
Ja
Nein
I.v. medication with inotropic drugs, vasodilators
or repeated (>1/day) i.v. administration of
diuretics.*
Ja
Nein
Active infectious disease, or signs of ongoing
infection with CRP >10mmol/L*
Ja
Nein
Impaired renal function (serum creatinine >220
µmol/L)*
Ja
Nein
Any disease requiring immunosuppressive drugs*
Ja
Nein
Anaemia (haemoglobin below 90 g/L) due to
other causes than CHF*
Ja
Nein
Pregnancy or lactation, or childbearing potential
without appropriate contraception*
Ja
Nein
Alcohol or drug abuse*
Ja
Nein
2 / 3
Eligibility NCT00558584 Dilated Cardiomyopathy
Presence of a malignant tumour, or remission of
malignancy < 5 years*
Ja
Nein
Suspected poor capability to follow instructions
and cooperate*
Ja
Nein
Another life-threatening disease with poor
prognosis (survival < 2 years)*
Ja
Nein
Participation in any other clinical study within <
30 days prior to screening date*
Ja
Nein
Previous treatments with IA or immunoglobulin*
Ja
Nein
Contraindications for application of
echocardiography contrast agent (Luminity(R)
according to Luminity(R) specifications, including
cardiac shunts, pulmonary vascular
compromise)*
Ja
Nein
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Eligibility NCT00561925 HIV Infections
ODM derived from
http://clinicaltrials.gov/show/NCT00561925
All rights reserved. Please visit https://medical-data-
models.org/forms/4929
Eligibility
Einschlusskriterien
Alter mindestens 18 Jahre*
Ja
Nein
Signed informed consent in accordance with
Good Clinical Practice and local regulatory
requirements prior to trial participation*
Ja
Nein
HIV-1 infected males or females >= 18 years of
age with positive serology (ELISA) confirmed by
Western blot*
Ja
Nein
No previous antiretroviral treatment *
Ja
Nein
Males with CD4+ counts >50 <400 cells/ml or
females with CD4+ counts >50-<250 cells/ml *
Ja
Nein
Adequate renal function defined as a calculated
creatinine clearance (CLCr) >= 50 mL/min
according to the Cockcroft-Gault formula as
follows: Male: (140 age in years) x (weight in kg)
divided by 72 x (serum creatinine in mg/dl) =
CLCr (mL/min). Female: (140 age in years) x
(weight in kg) divided by 72 x (serum creatinine in
mg/dl) x 0.85 = CLCr (mL/min).  *
Ja
Nein
Karnofsky performance status (assessment
scale)*
Ja
Nein
An HIV-1 viral load of 1,000 copies/mL*
Ja
Nein
Willingness to initiate CD4+ cell count-guided
chemoprophylaxis to prevent important
opportunistic infections as defined in Appendix
10.2*
Ja
Nein
Willingness to abstain from ingesting substances
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which may alter plasma study drug levels by
interaction with the cytochrome P450 system
(listed in Appendix 10.3) during the study.*
Ja
Nein
For centers participating in the PK substudy only:
Written informed consent in accordance with
GCP and local legislation for participation in the
PK substudy. Refusal to participate in the PK
substudy is not an exclusion criterion for
participation in the trial. Only study centers with
previous experience and equipped in handling PK
samples are eligible for participation in the
substudy. *
Ja
Nein
Ausschlusskriterien
Active drug abuse or chronic alcoholism at the
investigator's discretion*
Ja
Nein
Active hepatitis B or C disease, defined as
HBsAg-positive and HBV-DNA-positive or HCV-
RNA-positive*
Ja
Nein
Female patients of child-bearing potential who:
are pregnant at screening, are breast feeding, are
planning to become pregnant are not willing to
use a barrier method of contraception, or are not
willing to use methods of contraception other
than ethinyl estradiol containing oral
contraceptives. Note: During participation in this
study, females and males have to use barrier
methods of contraception in addition or instead of
ethinyl estradiol containing oral contraceptives.*
Ja
Nein
Laboratory parameters >DAIDS Grade 2*
Ja
Nein
ALT/AST > DAIDS Grade 1*
Ja
Nein
Hypersensitivity to any ingredients of the test
products*
Ja
Nein
Previous use of Viramune (nevirapine) or any
other antiretroviral agents (does not include use
2 / 3
Eligibility NCT00561925 HIV Infections
of single dose NVP for the prevention of mother
to child transmission)*
Ja
Nein
Resistance to NNRTIs or either one of the
components of Truvada (emtricitabine or tenofovir
disoproxil fumarate) or lamivudine (3TC) based
on HIV-1 genotypic resistance testing report
obtained at screening*
Ja
Nein
Patients who are receiving other concomitant
treatments which are not permitted, as described
in the prescribing information*
Ja
Nein
Use of investigational medications (any
experimental agent other than the study regimen)
within 30 days before study entry or during the
trial*
Ja
Nein
Use of immunomodulatory drugs within 30 days
before study entry or during the trial (e.g.,
interferon, cyclosporin, hydroxyurea, interleukin
2)*
Ja
Nein
Patients who have been diagnosed with
malignant disease*
Ja
Nein
Patients who in the opinion of the investigator are
not candidates for inclusion in the study*
Ja
Nein
Patient with Progressive Multifocal
Leukoencephalopathy (PML), Visceral Kaposi's
Sarcoma (KS), and/or any lymphoma*
Ja
Nein
Any AIDS defining illness that is unresolved,
symptomatic or not stable on treatment for at
least 12 weeks at screening visit*
Ja
Nein
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Eligibility NCT00556270 Severe, Chronic
Pain
ODM derived from
http://clinicaltrials.gov/show/NCT00556270
All rights reserved. Please visit https://medical-data-
models.org/forms/4931
Eligibility
Einschlusskriterien
Alter mindestens 18 Jahre*
Ja
Nein
Patients with severe, chronic pain *
Ja
Nein
Ausschlusskriterien
Hypersensitivity of fentanyl*
Ja
Nein
Co-administration of monoaminooxidase-
inhibitors*
Ja
Nein
Schwangerschaft*
Ja
Nein
Atemdepression*
Ja
Nein
COPD*
Ja
Nein
Drug abuse*
Ja
Nein
Impairment of CNS functions*
Ja
Nein
Other criteria as defined in the Summary of
Product Characteristics (Fachinformation Chapter
4.3)*
Ja
Nein
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Eligibility NCT00554502 IGA Nephropathy
ODM derived from
http://clinicaltrials.gov/show/NCT00554502
All rights reserved. Please visit https://medical-data-
models.org/forms/4933
Eligibility
Einschlusskriterien
Alter 18 bis 70 Jahre*
Ja
Nein
Male or female patients from 18-70 years with
histologically proven primary IgAN with typical
mesangioproliferative features. Diagnosis has to
be made by a neuropathologist.*
Ja
Nein
Proteinuria above 0.75 g/day within 12 weeks
prior to or at the first visit in the run-in phase
(month -6)and presence of at least one further
risk factor for the development of end stage renal
disease  1. arterial hypertension, defined as
ambulatory blood pressure >140/90 mm Hg or
the  use of antihypertensive medication or  2.
impaired renal function, defined as creatinine
clearance or estimated GFR <90  ml/min. *
Ja
Nein
Ausschlusskriterien
Known allergy or intolerance to study medication
(except in case of ACE-inhibitor, in which case a
change to an angiotensin receptor blocker is
possible).*
Ja
Nein
Women who are pregnant or breastfeeding and
women without sufficient contraception.*
Ja
Nein
Any prior immunosuppressive therapy.*
Ja
Nein
Variants of primary IgAN (e.g. rapidly progressive
IgAN with crescents in >50% of glomeruli or
minimal change GN with glomerular IgA
deposits).*
Ja
Nein
Significant liver dysfunction (more than three fold
increased GPT compared to norm)*
Ja
Nein
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Contraindication for immunosuppressive therapy,
like*
Ja
Nein
acute or chronic infectious disease incl. hepatitis
and HIV positive patients*
Ja
Nein
Krebs*
Ja
Nein
leukocytopenia, thrombocytopenia or known
allergy against prednisolone,  cyclophosphamide
or azathioprine*
Ja
Nein
active intestinal bleeding, active gastric or
duodenal ulcer*
Ja
Nein
Need of permanent immunosuppression, (e.g.
transplanted patients,  steroid-dependent
inflammatory diseases)*
Ja
Nein
Secondary IgAN or diseases associated with
glomerular deposits of IgA.*
Ja
Nein
Additional other chronic renal disease.*
Ja
Nein
Creatinine clearance below 30 ml/min (mean of 3
measurements).*
Ja
Nein
Alcohol or drug abuse*
Ja
Nein
Mental condition rendering the subject unable to
understand the nature, scope, and possible
consequences of the study*
Ja
Nein
Subject unlikely to comply with protocol, e.g.,
uncooperative attitude, inability to return for
follow-up visits, and unlikelihood of completing
the study*
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Ja
Nein
Participation in a parallel clinical trial or
participation in another clinical trial within the last
3 months.*
Ja
Nein
Subjects who are in any state of dependency to
the sponsor or the investigators.*
Ja
Nein
Employees of the sponsor or the investigators.*
Ja
Nein
Subjects who have been committed to an
institution by legal or regulatory order.*
Ja
Nein
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Eligibility NCT00617214 Schizophrenia
ODM derived from
http://clinicaltrials.gov/show/NCT00617214
All rights reserved. Please visit https://medical-data-
models.org/forms/4937
Eligibility
Einschlusskriterien
Alter 18 bis 65 Jahre*
Ja
Nein
Outpatients suffering from schizophrenia,
schizoaffective disorder, schizophreni-form
disorder, delusional disorder or psychotic
disorder not otherwise specified*
Ja
Nein
Current stable treatment with Seroquel according
to SmPC since at least 2 months*
Ja
Nein
Given consent to take part in an integrated care
program prior to study start. Written informed
consent to take part in this NIS *
Ja
Nein
Ausschlusskriterien
Presence of any contraindication as described in
the SmPC*
Ja
Nein
Cancellation of participation in the integrated care
program*
Ja
Nein
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Eligibility NCT00606723 Acute Myeloid
Leukemia (AML)
ODM derived from
http://clinicaltrials.gov/show/NCT00606723
All rights reserved. Please visit https://medical-data-
models.org/forms/4938
Eligibility
Einschlusskriterien
Alter bis zu 21 Jahre*
Ja
Nein
Children, adolescents and young adults aged 0-
21 years, male and female*
Ja
Nein
Patients suffering from refractory de novo AML*
Ja
Nein
Patients with relapsed AML*
Ja
Nein
sekundäre AML*
Ja
Nein
Ausschlusskriterien
Severely impaired functional performance*
Ja
Nein
Severe renal impairment*
Ja
Nein
Schwangerschaft*
Ja
Nein
Current participation in another clinical trial*
Ja
Nein
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Eligibility NCT00606450 Psoriasis
ODM derived from
http://clinicaltrials.gov/show/NCT00606450
All rights reserved. Please visit https://medical-data-
models.org/forms/4939
Eligibility
Einschlusskriterien
Alter mindestens 18 Jahre*
Ja
Nein
Must understand and voluntarily sign an informed
consent form*
Ja
Nein
Must be in good health as judged by the
investigator*
Ja
Nein
Must be able to adhere to the study visit schedule
and other protocol requirements*
Ja
Nein
Must have a >= 6 month history of moderate-to-
severe plaque-type psoriasis*
Ja
Nein
Must have a PASI score >=10 and BSA >=10%*
Ja
Nein
Must meet specific laboratory criteria*
Ja
Nein
Must be a candidate for photo/systemic therapy*
Ja
Nein
Women of childbearing potential must have a
negative pregnancy test *
Ja
Nein
Ausschlusskriterien
Must not have clinically significant underlying
disease processes*
Ja
Nein
Must not be pregnant or lactating females*
Ja
Nein
Must not have any condition, including lab
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abnormalities, which places the subject at
unacceptable risk if the subject were to
participate in the study or confounds the ability to
interpret data from the study*
Ja
Nein
Must not have a history of active mycobacterium
tuberculosis infection within 3 years prior to the
screening visit*
Ja
Nein
Must not have a history of incompletely treated
active of latent mycobacterium tuberculosis
infection*
Ja
Nein
Must not have a known history of exposure to an
infectious case of mycobacterium tuberculosis
within 2 years prior to the screening visit*
Ja
Nein
Must not be an immigrant from a high-incidence
country for mycobacterium tuberculosis disease
within 2 years prior to the screening visit*
Ja
Nein
Must not have current erythrodermic, guttate, or
pustular psoriasis*
Ja
Nein
Must not have a clinical history of failure to
adequately respond to treatment in the
investigator's opinion to one or more treatment
courses of cyclosporine or the following biologic
therapies: alefacept, etanercept, efalizumab,
infliximab or adalimumab*
Ja
Nein
Must not use topical therapy within 14 days of
randomization*
Ja
Nein
Must not use systemic therapy for psoriasis within
28 days of randomization*
Ja
Nein
Must not use phototherapy within 28 days of
randomization*
Ja
Nein
2 / 5
Eligibility NCT00606450 Psoriasis
Must not use adalimumab or infliximab within 3
months of randomization*
Ja
Nein
Must not use etanercept or efalizumab within 56
days of randomization*
Ja
Nein
Must not use alefacept within 6 months of
randomization*
Ja
Nein
Einschlusskriterien
Alter mindestens 18 Jahre*
Ja
Nein
Must understand and voluntarily sign an informed
consent form*
Ja
Nein
Must be in good health as judged by the
investigator*
Ja
Nein
Must be able to adhere to the study visit schedule
and other protocol requirements*
Ja
Nein
Must have a >= 6 month history of moderate-to-
severe plaque-type psoriasis*
Ja
Nein
Must have a PASI score >=10 and BSA >=10%*
Ja
Nein
Must meet specific laboratory criteria*
Ja
Nein
Must be a candidate for photo/systemic therapy*
Ja
Nein
Women of childbearing potential must have a
negative pregnancy test *
Ja
Nein
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Ausschlusskriterien
Must not have clinically significant underlying
disease processes*
Ja
Nein
Must not be pregnant or lactating females*
Ja
Nein
Must not have any condition, including lab
abnormalities, which places the subject at
unacceptable risk if the subject were to
participate in the study or confounds the ability to
interpret data from the study*
Ja
Nein
Must not have a history of active mycobacterium
tuberculosis infection within 3 years prior to the
screening visit*
Ja
Nein
Must not have a history of incompletely treated
active of latent mycobacterium tuberculosis
infection*
Ja
Nein
Must not have a known history of exposure to an
infectious case of mycobacterium tuberculosis
within 2 years prior to the screening visit*
Ja
Nein
Must not be an immigrant from a high-incidence
country for mycobacterium tuberculosis disease
within 2 years prior to the screening visit*
Ja
Nein
Must not have current erythrodermic, guttate, or
pustular psoriasis*
Ja
Nein
Must not have a clinical history of failure to
adequately respond to treatment in the
investigator's opinion to one or more treatment
courses of cyclosporine or the following biologic
therapies: alefacept, etanercept, efalizumab,
infliximab or adalimumab*
Ja
Nein
Must not use topical therapy within 14 days of
randomization*
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Ja
Nein
Must not use systemic therapy for psoriasis within
28 days of randomization*
Ja
Nein
Must not use phototherapy within 28 days of
randomization*
Ja
Nein
Must not use adalimumab or infliximab within 3
months of randomization*
Ja
Nein
Must not use etanercept or efalizumab within 56
days of randomization*
Ja
Nein
Must not use alefacept within 6 months of
randomization*
Ja
Nein
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Eligibility NCT00623727 Hemophilia A
ODM derived from
http://clinicaltrials.gov/show/NCT00623727
All rights reserved. Please visit https://medical-data-
models.org/forms/4940
Eligibility
Einschlusskriterien
Alter 12 bis 70 Jahre*
Ja
Nein
männlich*
Ja
Nein
Subjects with severe hemophilia A (< 1% factor
VIII [FVIII]:C)*
Ja
Nein
Subjects with >= 150 exposure days (EDs) with
any FVIII in total*
Ja
Nein
Subjects who have been on-demand treatment
with a minimum of 1 relevant bleed per month or
have been on secondary prophylaxis treatment
with not more than a 3x/week schedule*
Ja
Nein
Subjects with bleeding events and/or treatments
during the last 6 months prior to study entry
which are documented in the subjects medical
records*
Ja
Nein
Subjects with no measurable inhibitor activity*
Ja
Nein
Subjects with no history of FVIII inhibitor antibody
formation*
Ja
Nein
Written informed consent by subject and parent /
legal representative, if < 18 years *
Ja
Nein
Ausschlusskriterien
Subjects who are receiving primary prophylaxis*
Ja
Nein
1 / 2
Subjects on prophylaxis with documented
requirements of > 75 IU/kg/week*
Ja
Nein
Subjects with any other bleeding disease beside
hemophilia A (i.e., von Willebrand disease)*
Ja
Nein
Nierendysfunktion, Nierenfunktionsstörung*
Ja
Nein
Elevated hepatic transaminases*
Ja
Nein
Subjects on treatment with immunomodulatory
agents within the last 3 months prior to study
entry or during the study*
Ja
Nein
Subjects with known hypersensitivity to the active
substance, mouse or hamster protein, liposomes
or polyethyleneglycol (PEG)*
Ja
Nein
Subjects who require any pre-medication for FVIII
injections*
Ja
Nein
2 / 2
Eligibility NCT00623727 Hemophilia A
Eligibility NCT00625898 Breast Cancer
ODM derived from
http://clinicaltrials.gov/show/NCT00625898
All rights reserved. Please visit https://medical-data-
models.org/forms/4941
Eligibility
Einschlusskriterien
Alter mindestens 18 Jahre*
Ja
Nein
Life expectancy of at least 10 years, excluding
their diagnosis of breast cancer.*
Ja
Nein
Women who have had breast reconstruction
utilizing tissue expanders must be in agreement
with delaying surgery to replace the tissue
expanders with permanent implants until 3
months following the last dose of bevacizumab*
Ja
Nein
Women of reproductive potential must agree to
use an effective non-hormonal method of
contraception (for example condoms, some
intrauterine devices, diaphragms, vasectomized
partner, or abstinence) during therapy and for at
least 6 months after the last dose of bevacizumab
and/or trastuzumab.*
Ja
Nein
Submission of tumor samples from the breast
surgery for central HER2 testing is required for all
patients prior to enrollment in the BETH Trial*
Ja
Nein
Signed and dated IRB/EC-approved consent*
Ja
Nein
ECOG Status <= 1*
Ja
Nein
The tumor must be unilateral invasive
adenocarcinoma of the breast on histologic
examination.*
Ja
Nein
The breast cancer must be HER2-positive based
on test results as follows: Local testing (if
available) should demonstrate that the tumor is
IHC 2+ or 3+ or is considered to be HER2-
positive for gene amplification by FISH, CISH, or
other in situ hybridization (ISH) method. If local
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ISH test results are considered equivocal, the
tumor can be submitted for central HER2 testing.
(If local testing is not possible, the tumor can be
submitted for central HER2 testing.) Central
testing (a requirement for ALL patients) must
demonstrate that the tumor is HER2-positive
which is defined as FISH-positive and/or IHC 3+.*
Ja
Nein
All of the following staging criteria (according to
the 6th edition of the AJCC Cancer Staging
Manual) must be met: By pathologic evaluation,
primary tumor must be pT1-3. By pathologic
evaluation, ipsilateral nodes must be pN0, pN1
(pN1mi, pN1a, pN1b, pN1c), pN2a, pN3a, or
pN3b. If pN0, at least one of the following criteria
must be met: Pathologic tumor size > 2.0 cm. ER
negative and PgR negative. Histologic and/or
nuclear grade 2 (intermediate) or 3 (high). Or Age
< 35 years.*
Ja
Nein
Patients must have undergone either a total
mastectomy or breast conserving surgery
(lumpectomy).*
Ja
Nein
For patients who undergo lumpectomy, the
margins of the resected specimen must be
histologically free of invasive tumor and ductal
carcinoma in situ (DCIS) as determined by the
local pathologist. If pathologic examination
demonstrates tumor at the line of resection,
additional operative procedures may be
performed to obtain clear margins. If tumor is still
present at the resected margin after re-
excision(s), the patient must undergo total
mastectomy to be eligible. (Patients with margins
positive for lobular carcinoma in situ [LCIS] are
eligible without additional resection.)*
Ja
Nein
For patients who undergo mastectomy, margins
must be free of gross residual tumor. Patients
with microscopic positive margins are eligible.*
Ja
Nein
Patients must have completed one of the
following procedures for evaluation of pathologic
nodal status: Sentinel lymphadenectomy followed
by removal of additional non-sentinel lymph
nodes if the sentinel node (SN) is positive.
Sentinel lymphadenectomy alone if pathologic
nodal staging based on sentinel
lymphadenectomy is pN0, pN1mi or pN1b. Or
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Axillary lymphadenectomy without SN isolation
procedure.*
Ja
Nein
The interval between the last surgery for breast
cancer (treatment or staging) and randomization
must be at least 28 days but no more than 84
days.*
Ja
Nein
Patients must have ER analysis performed on the
primary tumor prior to randomization. If ER
analysis is negative, then PgR analysis must also
be performed.*
Ja
Nein
The most recent postoperative blood counts,
performed within 6 weeks prior to randomization,
must meet the following criteria: ANC must be >=
1200/mm3. Platelet count must be >=
100,000/mm3. And Hemoglobin must be >= 10
g/dL.*
Ja
Nein
and AST must be less than or equal to 1.5 x ULN
for the lab. Alkaline phosphatase and AST may
not both be > the ULN.*
Ja
Nein
Patients with AST or alkaline phosphatase > ULN
are eligible for inclusion in the study if liver
imaging (CT, MRI, PET scan, or PET-CT scan
performed within 3 months prior to
randomization) does not demonstrate metastatic
disease and the requirements for evidence of
adequate hepatic function are met.*
Ja
Nein
Patients with alkaline phosphatase that is > ULN
but <= 2.5 x ULN are eligible for inclusion in the
study if a bone scan,PET scan, or PET-CT scan
(performed within 3 months prior to
randomization) does not demonstrate metastatic
disease.*
Ja
Nein
The following criteria for renal function must be
met based on the results of the most recent
postoperative tests performed within 6 weeks
prior to randomization: Serum creatinine must be
<= ULN for the lab. Measured or calculated
creatinine clearance must be > 60 mL/min.*
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Ja
Nein
A urine sample must be tested for protein by
determination of the urine protein/creatinine
(UPC) ratio or by urine dipstick. UPC ratio must
be < 1.0. Urine dipstick must indicate 0-1+
protein. If dipstick reading is >= 2+, determine the
UPC ratio, which must be < 1.0, or collect a 24-
hour urine specimen, which must demonstrate <
1.0 g of protein per 24 hours.*
Ja
Nein
LVEF assessment must be performed within 3
months prior to randomization. The LVEF must
be >= 55% regardless of the cardiac imaging
facility's lower limit of normal (LLN).*
Ja
Nein
and conduction abnormality requiring a
pacemaker. *
Ja
Nein
Ausschlusskriterien
Inflammatory Breast Carcinoma, Mastitis
carcinomatosa*
Ja
Nein
Definitive clinical or radiologic evidence of
metastatic disease. (Chest imaging [mandatory
for all patients] and other imaging [if required]
must have been performed within 3 months prior
to randomization.)*
Ja
Nein
Synchronous or previous contralateral invasive
breast cancer (Patients with synchronous or
previous contralateral DCIS or LCIS are eligible).*
Ja
Nein
History of ipsilateral invasive breast cancer
regardless of treatment or ipsilateral DCIS treated
with excision and RT. (Patients with history of
ipsilateral LCIS are eligible.)*
Ja
Nein
History of non-breast malignancies within the 5
years prior to study entry, except for the following:
carcinoma in situ of the cervix, carcinoma in situ
of the colon, melanoma in situ, and basal cell and
squamous cell carcinomas of the skin.*
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Ja
Nein
Previous therapy with anthracyclines, taxanes,
carboplatin, trastuzumab, or bevacizumab for any
malignancy.*
Ja
Nein
RT, chemotherapy, and/or targeted therapy,
administered for the currently diagnosed breast
cancer prior to randomization.*
Ja
Nein
Continued therapy with any hormonal agent such
as raloxifene or tamoxifen (or other SERM) or an
aromatase inhibitor. (Patients are eligible if these
medications are discontinued prior to
randomization.)*
Ja
Nein
Any sex hormonal therapy, e.g., birth control pills,
ovarian hormone replacement therapy, etc.
Patients are eligible if these medications are
discontinued prior to randomization.*
Ja
Nein
Cardiac disease (history of and/or active disease)
that would preclude the use of the drugs included
in the treatment regimens. This includes but is
not confined to: Active cardiac disease - angina
pectoris that requires the use of anti-anginal
medication. Ventricular arrhythmias except for
benign premature ventricular contractions.
Supraventricular and nodal arrhythmias requiring
a pacemaker or not controlled with medication.
Conduction abnormality requiring a pacemaker.
Valvular disease with documented compromise in
cardiac function. And symptomatic pericarditis.
History of cardiac disease - myocardial infarction
documented by elevated cardiac enzymes or
persistent regional wall abnormalities on
assessment of LV function. History of
documented CHF. And documented
cardiomyopathy.*
Ja
Nein
Uncontrolled hypertension defined as systolic
blood pressure (BP) > 150 mmHg or diastolic BP
> 90 mmHg, with or without anti-hypertensive
medication. (BP must be assessed within 28 days
prior to randomization.) Patients with initial BP
elevations are eligible if initiation or adjustment of
BP medication lowers pressure to meet entry
criteria.*
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Ja
Nein
History of hypertensive crisis or hypertensive
encephalopathy.*
Ja
Nein
History of TIA or CVA.*
Ja
Nein
History of any arterial thrombotic event within 12
months before randomization.*
Ja
Nein
Symptomatic peripheral vascular disease*
Ja
Nein
Intrinsic lung disease resulting in dyspnea*
Ja
Nein
labiler Diabetes mellitus Typ I*
Ja
Nein
Active infection or chronic infection requiring
chronic suppressive antibiotics.*
Ja
Nein
Any significant bleeding within 6 months before
randomization, exclusive of menorrhagia in
premenopausal women.*
Ja
Nein
Non-healing wound, skin ulcers, or incompletely
healed bone fracture.*
Ja
Nein
Major surgical procedure, open biopsy, or
significant traumatic injury within 28 days prior to
planned start of study therapy.*
Ja
Nein
Anticipation of need for major surgical procedures
during study therapy and for at least 3 months
following completion of bevacizumab.*
Ja
Nein
Gastroduodenal ulcer(s) documented by
endoscopy to be active within 6 months before
randomization.*
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Ja
Nein
History of GI perforation, abdominal fistulae, or
intra-abdominal abscess.*
Ja
Nein
Known bleeding diathesis or coagulopathy.*
Ja
Nein
Requirement for therapeutic doses of coumadin
or equivalent.*
Ja
Nein
Sensory/motor neuropathy >= grade 2, as
defined by the NCI CTCAE v3.0.*
Ja
Nein
Conditions that would prohibit administration of
corticosteroids.*
Ja
Nein
Chronic daily treatment with corticosteroids (dose
of > 10 mg/day methylprednisolone equivalent)
(excluding inhaled steroids).*
Ja
Nein
History of hypersensitivity reaction to drugs
formulated with polysorbate 80.*
Ja
Nein
Pregnancy or lactation at the time of study entry.
(Note: Pregnancy testing must be performed
within 14 days prior to randomization according to
institutional standards for women of child-bearing
potential.)*
Ja
Nein
Other non-malignant systemic disease that would
preclude the patient from receiving study
treatment or would prevent required follow-up.*
Ja
Nein
Psychiatric or addictive disorders or other
conditions that, in the opinion of the investigator,
would preclude the patient from meeting the
study requirements.*
Ja
Nein
Use of any investigational product within 4 weeks
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prior to enrollment in the study.*
Ja
Nein
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Eligibility NCT00628745 Transthyretin
Mutations
ODM derived from
http://clinicaltrials.gov/show/NCT00628745
All rights reserved. Please visit https://medical-data-
models.org/forms/4942
Eligibility
Einschlusskriterien
Alter mindestens 18 Jahre*
Ja
Nein
Written informed consent.*
Ja
Nein
Patient has confirmed: genotyped TTR mutation
with or without a diagnosis of TTR-associated
amyloidosis (e.g., ATTR-PN, ATTR-CM), or Wild-
type TTR-associated amyloidosis with
cardiomyopathy (wild-type ATTR-CM).*
Ja
Nein
*
Ja
Nein
A. Presence of amyloid in cardiac biopsy tissue
confirmed as TTR amyloid by
immunohistochemistry and genotyped
confirmation that patient does not possess a
known mutation in TTR gene (i.e., is a carrier of
wild-type allele only) via genetic testing*
Ja
Nein
B. Evidence of cardiac involvement by
echocardiogram as defined by mean left ventricle
wall thickness of > 12 mm, and presence of
amyloid in non-cardiac tissue confirmed as TTR
amyloid by immunohistochemistry, and
genotyped confirmation that patient does not
possess a known mutation in TTR gene (i.e., is a
carrier of wild-type allele only) via genetic testing.
*
Ja
Nein
Ausschlusskriterien
Patient has primary or secondary amyloidosis.*
Ja
Nein
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Eligibility NCT00632749 Leukemia,
Myeloid, Acute
ODM derived from
http://clinicaltrials.gov/show/NCT00632749
All rights reserved. Please visit https://medical-data-
models.org/forms/4943
Eligibility
Einschlusskriterien
Alter mindestens 18 Jahre*
Ja
Nein
Male or female adult with previously untreated
acute myeloid leukaemia (AML)*
Ja
Nein
Confirmed diagnosis of AML according to the
WHO definition (except for acute promyelocytic
leukaemia, APL)*
Ja
Nein
Patient is considered ineligible for intensive
treatment*
Ja
Nein
Patient is eligible for low-dose cytarabine (LD-
Ara-C) treatment*
Ja
Nein
Life expectancy > 3 months*
Ja
Nein
Eastern co-operative oncology group (ECOG,
R01-0787) performance score <=2 at screening*
Ja
Nein
Signed written informed consent consistent with
international conference on harmonisation good
clinical practice (ICH-GCP) and local legislation *
Ja
Nein
Ausschlusskriterien
Patient with APL (AML subtype M3 according to
the French-American-British (FAB)
classification).*
Ja
Nein
Relapsed or treatment refractory AML.*
Ja
Nein
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Hypersensitivity to one of the trial drugs or the
excipients.*
Ja
Nein
Other malignancy requiring treatment.*
Ja
Nein
Known central nervous system involvement.*
Ja
Nein
Aspartate amino transferase (AST) or alanine
amino transferase (ALT) > 2.5 times the upper
limit of normal (ULN).*
Ja
Nein
INR > 1.5 x ULN for subjects not on therapeutic
vitamin K antagonists (phenprocoumon,
warfarin).*
Ja
Nein
Bilirubin*
Ja
Nein
Kreatinin im Serum*
Ja
Nein
LVEF (Left ventricular ejection fraction) < 50% in
echocardiography or clinical congestive heart
failure New York Heart Association (NYHA) grade
III or IV.*
Ja
Nein
Concomitant intercurrent illness, which would
compromise the evaluation of efficacy or safety of
the trial drug, e.g. active severe infection,
unstable angina pectoris or cardiac arrhythmia.*
Ja
Nein
Psychiatric illness or social situation that would
limit compliance with trial requirements.*
Ja
Nein
Concomitant therapy, which is considered
relevant for the evaluation of the efficacy or safety
of the trial drug (i.e. other chemo- or
immunotherapy, see also section 4.2.2).*
Ja
Nein
Contraindications for cytarabine treatment
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according to the summary of product
characteristics (SPC).*
Ja
Nein
Patients who are sexually active and unwilling to
use a medically acceptable method of
contraception during the trial (hormonal
contraception, intrauterine device, condom with
spermicide, etc.).*
Ja
Nein
Pregnant or nursing female patients.*
Ja
Nein
Patient unable to comply with the protocol.*
Ja
Nein
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Eligibility NCT00637377 Macular
Degeneration
ODM derived from
http://clinicaltrials.gov/show/NCT00637377
All rights reserved. Please visit https://medical-data-
models.org/forms/4944
Eligibility
Inclusion Criteria
age at least 50 Years*
Yes
No
Signed informed consent.*
Yes
No
Men and women >/=50 years of age.*
Yes
No
Active primary or recurrent subfoveal CNV
lesions secondary to AMD, including juxtafoveal
lesions that affect the fovea as evidenced by FA
in the study eye.*
Yes
No
ETDRS best-corrected visual acuity of: 20/40 to
20/320 (letter score of 73 to 25) in the study eye
at 4 meters.*
Yes
No
Willing, committed, and able to return for ALL
clinic visits and complete all study-related
procedures.*
Yes
No
informed consent*
Yes
No
Exclusion Criteria
Any prior ocular (in the study eye) or systemic
treatment or surgery for neovascular AMD, except
dietary supplements or vitamins.*
Yes
No
Any prior or concomitant therapy with another
investigational agent to treat neovascular AMD in
the study eye.*
Yes
No
Any prior treatment with anti-VEGF agents in the
study eye.*
Yes
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No
Total lesion size >12 disc areas (30.5 mm,
including blood, scars and neovascularization) as
assessed by FA in the study eye.*
Yes
No
Subretinal hemorrhages that is either 50% or
more of the total lesion area, or if the blood is
under the fovea and is 1 or more disc areas in
size in the study eye (if the blood is under the
fovea, then the fovea must be surrounded by 270
degrees by visible CNV).*
Yes
No
Scar or fibrosis making up >50% of the total
lesion in the study eye.*
Yes
No
Scar, fibrosis, or atrophy involving the center of
the fovea in the study eye.*
Yes
No
Presence of retinal pigment epithelial tears or rips
involving the macula in the study eye.*
Yes
No
History of any vitreous hemorrhage within 4
weeks prior to Visit 1 in the study eye.*
Yes
No
Presence of other causes of CNV in the study
eye.*
Yes
No
Prior vitrectomy in the study eye.*
Yes
No
History of retinal detachment or treatment or
surgery for retinal detachment in the study eye.*
Yes
No
Any history of macular hole of stage 2 and above
in the study eye.*
Yes
No
Any intraocular or periocular surgery within 3
months of Day 1 on the study eye, except lid
surgery, which may not have taken place within 1
month of Day 1, as long as it is unlikely to
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interfere with the injection.*
Yes
No
History or clinical evidence of diabetic
retinopathy, diabetic macular edema or any
retinal vascular disease other than AMD in either
eye.*
Yes
No
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Eligibility NCT00643565 Sarcoma
ODM derived from
http://clinicaltrials.gov/show/NCT00643565
All rights reserved. Please visit https://medical-data-
models.org/forms/4945
Eligibility
Einschlusskriterien
Alter 6 Monate bis 18 Jahre*
Ja
Nein
childhood and adolescent patients*
Ja
Nein
metastatic rhabdomyosarcoma or non-
rhabdomyosarcoma soft tissue sarcoma*
Ja
Nein
adequate bone marrow function*
Ja
Nein
adequate renal and liver function*
Ja
Nein
adequate blood clotting *
Ja
Nein
Ausschlusskriterien
previous malignant tumors*
Ja
Nein
tumor invading major blood vessels*
Ja
Nein
prior systemic anti-tumor treatment*
Ja
Nein
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Eligibility NCT00641056 Type 2 Diabetes
Mellitus
ODM derived from
http://clinicaltrials.gov/show/NCT00641056
All rights reserved. Please visit https://medical-data-
models.org/forms/4946
Eligibility
Einschlusskriterien
Alter mindestens 18 Jahre*
Ja
Nein
Has type 2 diabetes and at least 18 years of age
at screening.*
Ja
Nein
Hemoglobin A1c (HbA1c) of 7.1% to 11.0%,
inclusive, at screening.*
Ja
Nein
Body mass index (BMI) of 25 kg/m2 to 45 kg/m2,
inclusive, at screening.*
Ja
Nein
Have a history of stable body weight (not varying
by >5% for at least 3 months prior to screening).*
Ja
Nein
Have been treated with metformin(Met) for at
least 3 months and have been taking a stable
dose for at least 8 weeks prior to screening OR*
Ja
Nein
Have been treated with metformin(Met) for at
least 3 months and have been taking a stable
dose for at least 8 weeks prior to screening and
have been treated with SU for at least 3 months
and have been taking a stable dose of at least an
optimally effective dose of brand of SU for 8
weeks prior to screening. *
Ja
Nein
Ausschlusskriterien
Have had a clinically significant history of cardiac
disease or presence of active cardiac disease
within the year prior to inclusion in the study,
including myocardial infarction, clinically
significant arrhythmia, unstable angina, moderate
to severe congestive heart failure, coronary
artery bypass surgery, or angioplasty. or is
expected to require coronary artery bypass
surgery or angioplasty during the course of the
study.*
Ja
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Nein
Have clinical signs or symptoms of liver disease,
acute or chronic hepatitis.*
Ja
Nein
Have a history of renal transplantation or are
currently receiving renal dialysis.*
Ja
Nein
Have active or untreated malignancy, or have
been in remission from clinically significant
malignancy (other than basal cell or squamous
cell skin cancer, in situ carcinomas of the cervix,
or in situ prostate cancer) for less than 5 years.*
Ja
Nein
Have had > 3 episodes of major hypoglycemia
within 6 months prior to screening.*
Ja
Nein
Have any contraindication for the oral antidiabetic
agent which they use.*
Ja
Nein
Have a known allergy or hypersensitivity to insulin
glargine, exenatide once weekly, or excipients
contained in these agents.*
Ja
Nein
Are known to have active proliferative
retinopathy.*
Ja
Nein
Have been treated with drugs that promote
weight loss (e.g., Xenical [orlistat], Meridia
[sibutramine], Acomplia [rimonabant], Acutrim
[phenylpropanolamine], or similar over-the-
counter medications) within 3 months of
screening.*
Ja
Nein
Have been treated for longer than 2 weeks with
any of the following excluded medications within
3 months prior to screening:*
Ja
Nein
Insulin*
Ja
Nein
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Thiazolidinediones (e.g., Actos [pioglitazone] or
Avandia [rosiglitazone])*
Ja
Nein
Alpha-glucosidase inhibitors (e.g., Glyset
[miglitol] or Precose [acarbose])*
Ja
Nein
Meglitinides (e.g., Prandin [repaglinide] or Starlix
[nateglinide]).*
Ja
Nein
Byetta (exenatide BID formulation)*
Ja
Nein
Dipeptidyl peptidase (DPP)-4 inhibitors (e.g.,
Januvia [sitagliptin], Galvus  [vildagliptin])*
Ja
Nein
Symlin, Pramlintidacetat*
Ja
Nein
Organtransplantation*
Ja
Nein
Have donated blood within 30 days of screening.*
Ja
Nein
Have previously completed or withdrawn from this
study or any other study investigating exenatide
once weekly.*
Ja
Nein
Have received treatment within the last 30 days
with a drug that has not received regulatory
approval for any indication at the time of study
entry.*
Ja
Nein
Are currently enrolled in any other clinical study.*
Ja
Nein
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Eligibility NCT00662714 Cystic Fibrosis
ODM derived from
http://clinicaltrials.gov/show/NCT00662714
All rights reserved. Please visit https://medical-data-
models.org/forms/4947
Eligibility
Einschlusskriterien
Alter mindestens 10 Jahre*
Ja
Nein
Diagnosed cystic fibrosis*
Ja
Nein
Newly diagnosed Diabetes mellitus in the
screening *
Ja
Nein
Ausschlusskriterien
Diabetic keto-acidosis (blood glucose > 350 mg/dl
and arterial pH < 7.25)*
Ja
Nein
Already treated Diabetes mellitus by oral
antidiabetic medication or insulin *
Ja
Nein
Systemic steroid therapy during the last 3
months*
Ja
Nein
Transplantation (status post TX or on the waiting
list for TX)*
Ja
Nein
Beginning pulmonary insufficiency, FEV1 < 35%
at pulmonary function test in stable condition*
Ja
Nein
Schwangerschaft*
Ja
Nein
Already diagnosed and treated diabetes mellitus*
Ja
Nein
Patients with diabetic keto-acidosis (blood
glucose > 350 mg/dl and arterial pH < 7.25) with
or without diabetic coma*
Ja
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Nein
Severe liver insufficiency (chronic hepatitis B,
AST or ALT twice the upper limit of normal,
Quick's value < 70% which is a contraindication
to use Repaglinide)*
Ja
Nein
Treatment with an indispensable important drug
which contraindicates Repaglinide*
Ja
Nein
PEG/ gastric tube/ total parenteral alimentation
for more than 4 weeks during the study*
Ja
Nein
CF-patients with type 1 diabetes*
Ja
Nein
Not patient's consent to randomisation and
therapeutic trial*
Ja
Nein
Participation on other medical trial*
Ja
Nein
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Eligibility NCT00669708 Compensate the
Roughness of the Skin
ODM derived from
http://clinicaltrials.gov/show/NCT00669708
All rights reserved. Please visit https://medical-data-
models.org/forms/4948
Eligibility
Einschlusskriterien
Alter mindestens 18 Jahre*
Ja
Nein
itch over VAS 3 *
Ja
Nein
Ausschlusskriterien
pregnancy, lactating women*
Ja
Nein
Drug abuse*
Ja
Nein
active psychosomatic and psychiatric disease*
Ja
Nein
active cancer*
Ja
Nein
topical application of tacrolimus, pimecrolimus,
corticosteroids or capsaicin two weeks before
study start*
Ja
Nein
intake of antihistamines, corticosteroids,
cyclosporine A and other immunosuppressants,
naltrexone, UV-therapy two weeks before study
start*
Ja
Nein
participation in any other research study during
the previous 4 weeks*
Ja
Nein
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Eligibility NCT00663364 Eczema
ODM derived from
http://clinicaltrials.gov/show/NCT00663364
All rights reserved. Please visit https://medical-data-
models.org/forms/4949
Eligibility
Einschlusskriterien
Alter mindestens 18 Jahre*
Ja
Nein
Eczema*
Ja
Nein
Willing to apply skin care for 2 to 4 weeks, twice
daily *
Ja
Nein
Willing to fulfill questionnaires / home diaries:
self-perception of roughness of the skin,
desquamation of the skin, lack of skin brightness,
feelings of tension and itching *
Ja
Nein
Ausschlusskriterien
Participation in any other research study during
the previous 4 weeks. *
Ja
Nein
Previous participation in this study.*
Ja
Nein
Concurrent participation in any other research
study involving an investigational product.*
Ja
Nein
Current need for the use of topical steroids.*
Ja
Nein
History of skin disease or allergy likely to interfere
with the study or known sensitivity to the test
product or its ingredients.*
Ja
Nein
Subjects considered unable or unlikely to fulfill
diaries.*
Ja
Nein
Employees of (CRO) or Stiefel Laboratories, or
an immediate family member (partner, offspring,
1 / 2
parents, siblings or sibling's offspring) of an
employee.*
Ja
Nein
History of neoplastic disease*
Ja
Nein
Recent immunization (< 10 days prior to the use
of the test product).*
Ja
Nein
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Eligibility NCT00662922 Critical Illness
ODM derived from
http://clinicaltrials.gov/show/NCT00662922
All rights reserved. Please visit https://medical-data-
models.org/forms/4950
Eligibility
Einschlusskriterien
Alter 18 bis 80 Jahre*
Ja
Nein
Ausschlusskriterien
clinical diagnosis of diabetes mellitus*
Ja
Nein
brain injury of any kind prior to or upon ICU-
admission*
Ja
Nein
pre-existing mental or psychiatric disorder*
Ja
Nein
terminal kidney or liver failure prior admission*
Ja
Nein
Drug abuse*
Ja
Nein
CPR > 5 min*
Ja
Nein
HIV-Virus*
Ja
Nein
Lues, Syphilis*
Ja
Nein
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Eligibility NCT00673647 Cannabis Use
Disorders
ODM derived from
http://clinicaltrials.gov/show/NCT00673647
All rights reserved. Please visit https://medical-data-
models.org/forms/4951
Eligibility
Einschlusskriterien
Alter mindestens 16 Jahre*
Ja
Nein
Cannabis Use Disorders*
Ja
Nein
motivation to change cannabis use*
Ja
Nein
current (12 mth) regular cannabis use (at least 2
days a week)*
Ja
Nein
informed consent to the study procedures and
assessments *
Ja
Nein
Ausschlusskriterien
current alcohol or any illicit drug dependence
syndrome according to DSM-IV other than due to
cannabis*
Ja
Nein
lifetime history of any psychotic disorder*
Ja
Nein
current severe episode of Major depression*
Ja
Nein
current panic-agoraphobic disorder (severe)*
Ja
Nein
severe learning disability, brain damage or
pervasive developmental disorder*
Ja
Nein
currently acute suicidality*
Ja
Nein
not fluent in german language*
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Ja
Nein
any other current treatment for cannabis use
disorders*
Ja
Nein
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Eligibility NCT00680550 Atrial Fibrillation
ODM derived from
http://clinicaltrials.gov/show/NCT00680550
All rights reserved. Please visit https://medical-data-
models.org/forms/4952
Eligibility
Einschlusskriterien
Alter mindestens 18 Jahre*
Ja
Nein
Patient implanted or scheduled for an implant
with a Reveal XT Insertable Cardiac Monitor
System for arrhythmia diagnosis or monitoring*
Ja
Nein
Patient must be willing to sign a Patient Data
Release Form (or Informed Consent where
applicable) *
Ja
Nein
Ausschlusskriterien
Enrollment outside a 30-day window from the
planned/performed Reveal XT implant procedure
(from 15 days pre-implant until 15 days post
implant)*
Ja
Nein
Patient is implanted with a pacemaker, ICD, CRT-
device or an implantable hemodynamic
monitoring system*
Ja
Nein
Unwillingness or inability to cooperate or give
written informed consent or, if the patient is a
minor and the legal guardian refuses to give
consent*
Ja
Nein
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Eligibility NCT00682396 Myelodysplastic
Syndrome
ODM derived from
http://clinicaltrials.gov/show/NCT00682396
All rights reserved. Please visit https://medical-data-
models.org/forms/4953
Eligibility
Einschlusskriterien
Alter 18 bis 65 Jahre*
Ja
Nein
Disease: cytologically proven*
Ja
Nein
primary or therapy related myelodysplastic
syndrome (MDS) either as*
Ja
Nein
refractory anaemia (RA) according FAB or RA
with or without dysplasia  according WHO*
Ja
Nein
refractory anaemia with ringsideroblasts (RARS)
according FAB or RARS with  or without
dysplasia according WHO*
Ja
Nein
refractory anaemia with excess of blasts (RAEB)
according FAB or RAEB I or  RAEB II according
WHO*
Ja
Nein
refractory anaemia with excess of blast in
transformation (RAEB-T)  according FAB*
Ja
Nein
CMML (dysplastic type) according WHO*
Ja
Nein
sekundäre akute myeloische Leukämie*
Ja
Nein
Blast count <20 percent in bone marrow with or
without chemotherapy at time of transplantation*
Ja
Nein
Patient eligible for standard and dose-reduced
conditioning as per local guideline*
Ja
Nein
Patient age 18-60 years if donor is a HLA-
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matched UNRELATED donor (HLA-A, HLA-B,
HLA-DRB1 and HLA-DQB1) (one mismatch
allowed)*
Ja
Nein
Patient age 18-65 years if donor is a HLA-
matched RELATED donor (HLA-A, HLA-B, HLA-
DRB1 and HLA-DQB1)(one antigen-mismatch
allowed)*
Ja
Nein
no major organ dysfunction*
Ja
Nein
written informed consent of the patient *
Ja
Nein
Ausschlusskriterien
Blasts >20% in bone marrow at time of
transplantation*
Ja
Nein
no written informed consent*
Ja
Nein
Zentralnervensystembeteiligung, Status*
Ja
Nein
Severe irreversible renal, hepatic, pulmonary or
cardiac disease, such as*
Ja
Nein
total bilirubin, SGPT or SGOT > 2 times upper
the normal level*
Ja
Nein
LVEF - Left ventricular ejection fraction*
Ja
Nein
Kreatinin-Clearance*
Ja
Nein
DLCO <35% and/or receiving supplementary
continuous oxygen*
Ja
Nein
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Eligibility NCT00682396 Myelodysplastic Syndrome
Positive serology for HIV*
Ja
Nein
pregnant or lactating women*
Ja
Nein
patients with a life-expectancy of < 6 months
because of another debilitating disease*
Ja
Nein
serious psychiatric or psychological disorders*
Ja
Nein
invasive fungal infection at time of registration*
Ja
Nein
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Eligibility NCT00682396 Myelodysplastic Syndrome
Eligibility NCT00459667 Multiple Sclerosis,
Relapsing-Remitting
ODM derived from
http://clinicaltrials.gov/show/NCT00459667
All rights reserved. Please visit https://medical-data-
models.org/forms/4954
Eligibility
Einschlusskriterien
Alter 18 bis 55 Jahre*
Ja
Nein
Completion of the BEYOND study 306440 as
scheduled*
Ja
Nein
Relapsing multiple sclerosis*
Ja
Nein
Medical assessment by the investigator that there
is no objection to the patient's participation in this
trial considering the medical experience from
study 306440. Special attention should be given
to laboratory abnormalities and clinically relevant
liver, renal and bone-marrow dysfunction.*
Ja
Nein
Females of child-bearing potential:*
Ja
Nein
Agreement to practice adequate contraception
methods and*
Ja
Nein
negativer Schwangerschaftstest*
Ja
Nein
No lactation*
Ja
Nein
Written informed consent *
Ja
Nein
Ausschlusskriterien
Serious or acute heart diseases*
Ja
Nein
History of severe depression or suicide attempt*
Ja
Nein
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Epilepsy not adequately controlled by treatment*
Ja
Nein
Known allergy to IFNs, to human albumin or to
mannitol*
Ja
Nein
Medical, psychiatric or other conditions that
compromise the patient's ability to understand the
patient information, to give informed consent, to
comply with the trial protocol, or to complete the
study*
Ja
Nein
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Eligibility NCT00459667 Multiple Sclerosis, Relapsing-Remitting
Eligibility NCT00456092 Psoriatic Arthritis
ODM derived from
http://clinicaltrials.gov/show/NCT00456092
All rights reserved. Please visit https://medical-data-
models.org/forms/4955
Eligibility
Einschlusskriterien
Alter mindestens 18 Jahre*
Ja
Nein
diagnosis of psoriatic arthritis (Moll and Wright
criteria) including symmetrical or asymmetrical
peripheral joint involvement for at least 6 months*
Ja
Nein
active psoriatic arthritis defined as at least 3
tender and at least 3 swollen joints*
Ja
Nein
Rheumafaktor negativ*
Ja
Nein
if on MTX, must be on for at least 24 weeks and
on stable dose at least 56 days before screening*
Ja
Nein
if on oral steroids, must be on stable dose of
prednisone <=10mg/day or equivalent for 28
days*
Ja
Nein
if on NSAID, must be on a stable dose at least 14
days prior to screening*
Ja
Nein
Lab criteria: Hb >9g/dL, HCT >27%, WBC
>3000/uL and <20000/uL, neut >1500/uL,
platelets >100,000/uL, creatinine <1.5mg/dL, total
bilirubin <2.0mg/dL, AST and ALT < 1.5 ULN*
Ja
Nein
FCBP must have negative pregnancy tests and
be on two forms of contraception throughout the
study*
Ja
Nein
Males must use barrier contraception with FCBP
partner *
Ja
Nein
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Ausschlusskriterien
clinically significant diseases*
Ja
Nein
any condition placing subject at risk*
Ja
Nein
pregnant or lactating females*
Ja
Nein
history of TB infection within 3 years*
Ja
Nein
history of incompletely treated latent TB*
Ja
Nein
clinically significant abnormality on CXR at
screening*
Ja
Nein
current erythrodermic, guttate or pustular
psoriasis*
Ja
Nein
history of infected joint prosthesis within 5 years*
Ja
Nein
systemic therapy including sulphasalazine,
leflunomide, chloroquine, hydroxychloroquine,
gold, parenteral steroids, penicillamine,
cyclosporine, oral retinoids, mycophenolate
mofetil, thioguanine, hydroxyurea, sirolimus,
tacrolimus, azathioprine and fumaric acid esters
within 28 days of randomization*
Ja
Nein
topical therapy for treatment of psoriasis within 14
days of randomization (except mild or moderate
steroids and non medicated emollients)*
Ja
Nein
phototherapy within 28 days randomization*
Ja
Nein
etanercept within 56 days randomization*
Ja
Nein
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Eligibility NCT00456092 Psoriatic Arthritis
Adalimumab, efalizumab, or infliximab within 84
days randomization*
Ja
Nein
alefacept within 24 weeks randomization*
Ja
Nein
use of any intra-articular steroids within 28 days
randomization*
Ja
Nein
use of any investigational medication within 28
days randomization or 5 half-lives whichever is
longer*
Ja
Nein
clinically significant abnormality on ECG at
screening*
Ja
Nein
high risk factors for HIV or hepatitis B or C*
Ja
Nein
history of malignancy within 5 years (except basal
cell skin carcinomas and/or fewer than 3 treated
squamous cell skin carcinomas*
Ja
Nein
evidence of skin conditions at screening that
would interfere with evaluations of psoriasis*
Ja
Nein
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Eligibility NCT00456092 Psoriatic Arthritis
Eligibility NCT00450684 Congenital Heart
Defects
ODM derived from
http://clinicaltrials.gov/show/NCT00450684
All rights reserved. Please visit https://medical-data-
models.org/forms/4956
Eligibility
Einschlusskriterien
congenital heart defect*
Ja
Nein
morphologic heart failure of the right or left
system ventricle with an ejection fraction of
absolute <= 40%*
Ja
Nein
NYHA II - IV*
Ja
Nein
optimal drug therapy for heart failure according to
the ESC guidelines*
Ja
Nein
QRS-interval >= 120 ms (according to at least
two ECG)*
Ja
Nein
chronic stimulation of the subpulmonary ventricle
by a 1- or 2-ventricle pacemaker, which also
meets the above mentioned criteria*
Ja
Nein
morphologically right ventricle in system position
and significant insufficiency of the systemic AV
valve, which also meets the above mentioned
criteria*
Ja
Nein
electromechanic dyssynchrony as defined in
study protocol *
Ja
Nein
Ausschlusskriterien
PTCA, cardiomyoplasty, myocardium infarction,
instable angina pectoris or cerebral insult within 6
weeks before the planned cardiac
resynchronization therapy*
Ja
Nein
pulmonary hypertension/Eisenmenger syndrome*
Ja
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Nein
univentricular heart without Fontan procedure*
Ja
Nein
life expectancy less than 1 year due to a non-
cardiac disease*
Ja
Nein
expected poor compliance of the patient, e.g.
Trisomic 21 or other mental retardation*
Ja
Nein
ergospirometry cannot be performed*
Ja
Nein
Schwangerschaft*
Ja
Nein
participation in a clinical trial within the last 4
weeks or current participation in a clinical trial
(except studies of the Competence Network for
Congenital Heart Defects)*
Ja
Nein
diseases or functional disorders that exclude
participation according to physician's
convenience*
Ja
Nein
nicht-kooperatives Verhalten*
Ja
Nein
known or continuous drug or alcohol abuse*
Ja
Nein
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Eligibility NCT00450684 Congenital Heart Defects
Eligibility NCT00447772 Cervical Dystonia
ODM derived from
http://clinicaltrials.gov/show/NCT00447772
All rights reserved. Please visit https://medical-data-
models.org/forms/4957
Eligibility
Einschlusskriterien
Alter mindestens 18 Jahre*
Ja
Nein
De novo patients with cervical dystonia*
Ja
Nein
ambulanter Patient*
Ja
Nein
Written informed consent to participate in the
study *
Ja
Nein
Ausschlusskriterien
Pre-treatment of cervical dystonia with botulinum
toxin*
Ja
Nein
Pre-treatment with botulinum toxin for any
indication other than cervical dystonia within the
past 12 months*
Ja
Nein
Pure retro- or antecollis*
Ja
Nein
Neurological or other diseases which may affect
head and neck motor function or neuromuscular
transmission, e.g. polyneuropathy with pareses,
myasthenia, myopathy, motor neurone diseases,
Bekhterev's disease*
Ja
Nein
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Eligibility NCT00445081 Atopic Dermatitis
ODM derived from
http://clinicaltrials.gov/show/NCT00445081
All rights reserved. Please visit https://medical-data-
models.org/forms/4958
Eligibility
Inclusion Criteria
Age >= 18 and < 55*
Yes
No
Body weight (observable entity)*
Yes
No
confirmed diagnosis of AE (UK working party
criteria)*
Yes
No
objective SCORAD > 40*
Yes
No
DLQI > 10*
Yes
No
resistancy against topical treatment options
including steroids and calcineurin-inhibitors *
Yes
No
Exclusion Criteria
participation to another clinical trial within the last
4 weeks before baseline*
Yes
No
pregnant or breastfeeding*
Yes
No
women of childbearing potential without adequate
contraception*
Yes
No
allergy against prednisolone or Ciclosporine A*
Yes
No
acute bacterial or viral infection*
Yes
No
History of neoplastic disease*
Yes
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No
Diabetes mellitus*
Yes
No
Hypertensive disease, High Blood Pressure*
Yes
No
Glaucoma*
Yes
No
Peptic Ulcer*
Yes
No
Severe osteoporosis*
Yes
No
Personal history of tuberculosis*
Yes
No
Ulcerative colitis (UC), Colitis ulcerative*
Yes
No
Diverticulitis*
Yes
No
concurrent treatment with chloroquin, Mefloquin,
Statins, Warafin*
Yes
No
Creatinine clearance (CrCl)  measurement*
Yes
No
UV treatment within 8 weeks before inclusion*
Yes
No
ongoing systemic immunosuppressive treatment*
Yes
No
planned vaccination within 8 weeks before study
entry, during study and 2 weeks after end of
study*
Yes
No
POLIOMYELITIS*
Yes
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No
Lymphadenitis after BCG vaccination*
Yes
No
Hyperuricemia*
Yes
No
Chronic liver disease*
Yes
No
Xeroderma pigmentosum, Cockaye-Syndrome,
Bloom Syndrome*
Yes
No
Psychiatric co-morbidity*
Yes
No
drug or alcohol abuse*
Yes
No
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Eligibility NCT00445081 Atopic Dermatitis
Eligibility NCT00442065 Abdominal Aortic
Aneurysm
ODM derived from
http://clinicaltrials.gov/show/NCT00442065
All rights reserved. Please visit https://medical-data-
models.org/forms/4959
Eligibility
Einschlusskriterien
Alter mindestens 19 Jahre*
Ja
Nein
Diagnosis of abdominal aortic aneurysm 50 mm
or larger in diameter, 40 mm or larger in diameter
if symptomatic (i.e. pain, embolisation), or
documented AAA growth of more than 5 mm
within the previous 6 months, and/or including
extension into common iliac artery(ies), or any
saccular aneurysm.*
Ja
Nein
Infrarenal neck with a minimum length of 15 mm
and a neck angulation between 60° and 90°, as
assessed in 3 dimensions.*
Ja
Nein
The iliac artery diameter must be of appropriate
diameter (1 mm smaller than the device
diameter), with an appropriate distal landing
length. The tortuosity of the common or external
iliac arteries or femoral arteries must be low to
medium (refer to operations manual).*
Ja
Nein
Patient provides written informed consent.*
Ja
Nein
Patients >18 years who are suitable for
endovascular repair.*
Ja
Nein
Patient fit for endovascular surgery, with a
diameter at the access sites of 7mm or larger
bilaterally.*
Ja
Nein
Patient has a life expectancy longer than the
duration of the study. *
Ja
Nein
Ausschlusskriterien
rupturiertes Aneurysma*
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Ja
Nein
Patient has insufficient length of proximal
aneurysm neck (<15mm from aneurysm to lowest
renal artery and <20 mm from the aneurysm to
the SMA).*
Ja
Nein
Aneurysm extends above renal arteries.*
Ja
Nein
Proximal neck of aneurysm has significant loose
thrombus associated with it, or significant
circumferential calcifications.*
Ja
Nein
Pregnant or nursing patients.*
Ja
Nein
Patient unfit for bail-out surgery and appropriate
anaesthesia.*
Ja
Nein
Patient with an acute or chronic aortic dissection
or mycotic aneurysm (defined by localised
asymmetric aneurysm sac).*
Ja
Nein
Patient has current non-localised infection.*
Ja
Nein
Patient has known allergy to graft materials,
Nitinol, or contrast media.*
Ja
Nein
Patient's where imaging is problematic. An
example is an obese patient.*
Ja
Nein
Patient has co-morbidities that deny vascular
access, including small / tortuous access
vessels.*
Ja
Nein
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Eligibility NCT00442065 Abdominal Aortic Aneurysm
Eligibility NCT00427024 Kidney
Transplantation
ODM derived from
http://clinicaltrials.gov/show/NCT00427024
All rights reserved. Please visit https://medical-data-
models.org/forms/4960
Eligibility
Einschlusskriterien
Alter mindestens 18 Jahre*
Ja
Nein
individuals transplanted with a donor kidney*
Ja
Nein
akute Transplantatabstoßung*
Ja
Nein
Ausschlusskriterien
Schwangerschaft*
Ja
Nein
Krebs*
Ja
Nein
HIV Infektion*
Ja
Nein
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Eligibility NCT00420212 Relapsing-
remitting Multiple Sclerosis
ODM derived from
http://clinicaltrials.gov/show/NCT00420212
All rights reserved. Please visit https://medical-data-
models.org/forms/4961
Eligibility
Einschlusskriterien
Alter 18 bis 55 Jahre*
Ja
Nein
Unless otherwise specified, to be eligible to
participate in this study, candidates must meet
the following eligibility criteria at the time of the
randomization:*
Ja
Nein
Aged 18 to 55 years old, inclusive, at the time of
informed consent.*
Ja
Nein
Must have a confirmed diagnosis of RRMS
according to McDonald criteria #1-4.*
Ja
Nein
Must have a baseline EDSS <= 5.0, inclusive.*
Ja
Nein
Must have relapsing-remitting disease course. *
Ja
Nein
Ausschlusskriterien
Unless otherwise specified, candidates will be
excluded from study entry if any of the following
exclusion criteria exist at randomization:*
Ja
Nein
Other chronic disease of the immune system,
malignancies, acute urologic, pulmonary,
gastrointestinal disease.*
Ja
Nein
Pregnant or nursing women.*
Ja
Nein
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Eligibility NCT00419705 Ischemic Stroke
ODM derived from
http://clinicaltrials.gov/show/NCT00419705
All rights reserved. Please visit https://medical-data-
models.org/forms/4962
Eligibility
Einschlusskriterien
Alter 40 bis 90 Jahre*
Ja
Nein
Diagnosis of Acute Ischemic Stroke within 24
hours*
Ja
Nein
Clinical diagnosis of Acute Ischemic Stroke after
exclusion of hemorrhage by a CT scan or
susceptibility weighted MRI sequences*
Ja
Nein
NIHSS ≥7 - ≤22*
Ja
Nein
Ausschlusskriterien
>24hours from symptom onset to time of
treatment*
Ja
Nein
Evidence of intracranial, subdural, or
subarachnoid hemorrhage*
Ja
Nein
Clinical presentation of intracranial hemorrhage*
Ja
Nein
Pre stroke ≥3 mRS*
Ja
Nein
The presence of a brainstem or cerebellar stroke*
Ja
Nein
Transitorische ischämische Attacke*
Ja
Nein
Seizure at stroke onset*
Ja
Nein
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Blutzuckerspiegel*
Ja
Nein
Sustained systolic BP >220mmHG < 80mmHG or
diastolic >140mmHG <50mmHG*
Ja
Nein
septischer Embolus, bakterieller Embolus*
Ja
Nein
CNS tumor (except asymptomatic meningioma)*
Ja
Nein
Dermatologic condition of the scalp (e.g.
Psoriasis)*
Ja
Nein
thrombolytische Therapie*
Ja
Nein
Head implant (e.g. Clipped aneurysm, Hakim
valve)*
Ja
Nein
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Eligibility NCT00419705 Ischemic Stroke
Eligibility NCT00408746 Premature Birth
ODM derived from
http://clinicaltrials.gov/show/NCT00408746
All rights reserved. Please visit https://medical-data-
models.org/forms/4963
Eligibility
Einschlusskriterien
Alter bis zu 5 Jahre*
Ja
Nein
Premature Birth*
Ja
Nein
infants of the tertiary care level University
Hospital of Münster*
Ja
Nein
delivery between May 1999 and December 2008*
Ja
Nein
caucasian origin*
Ja
Nein
written informed consent by both parents *
Ja
Nein
Ausschlusskriterien
history of orotracheal intubation / orogastric tube
feeding*
Ja
Nein
Hydrocephalus*
Ja
Nein
palatal cleft, congenital syndrome, head / neck
malformation*
Ja
Nein
congenital metabolic disease beyond osteopenia
of prematurity*
Ja
Nein
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Eligibility NCT00408187 Psoriasis
ODM derived from
http://clinicaltrials.gov/show/NCT00408187
All rights reserved. Please visit https://medical-data-
models.org/forms/4964
Eligibility
Einschlusskriterien
Alter mindestens 18 Jahre*
Ja
Nein
Aged >= 18 years of age inclusive at time of
screening.*
Ja
Nein
Diagnosed with plaque psoriasis >= 6 months
prior to screening.*
Ja
Nein
Diagnosis of stable, plaque psoriasis, i.e.
psoriasis must not be spontaneously improving or
worsening in the 4 weeks prior to the screening
visit.*
Ja
Nein
Psoriasis failing at least one systemic treatment
regimen or where other systemic therapies are
contraindicated or where tolerability is an issue.*
Ja
Nein
Plaque psoriasis involving >= 10% of the body
surface area and a SPGA score >= 3 at
screening and prior to randomization at the day 0
visit.*
Ja
Nein
Not pregnant or nursing.*
Ja
Nein
Sexually active women of childbearing potential
or <1 year post-menopausal and sexually active
men who are not surgically sterile must use a
reliable form of birth control during study
treatment and for at least 3 months after the last
dose of study drug. Surgically sterile females are
not considered to be of childbearing potential.
Reliable forms of birth control include oral or
depot contraceptives, and double-barrier
methods.*
Ja
Nein
Written informed consent prior to washout and
screening procedures.*
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Ja
Nein
Able to keep study appointments and cooperate
with all study requirements, in the opinion of the
Investigator. *
Ja
Nein
Ausschlusskriterien
Has generalized erythrodermic, guttate, or
pustular psoriasis.*
Ja
Nein
Have other dermatoses that would interfere with
the evaluation of psoriasis, at the discretion of the
Investigator.*
Ja
Nein
A current malignancy or history of malignancy
within 5 years or a history of lymphoma at any
time. Subjects can be enrolled with a history of
squamous or basal cell carcinoma that has been
surgically excised or removed with curettage and
electrodesiccation.*
Ja
Nein
Has a current, uncontrolled bacterial, viral, or
fungal infection that requires intravenous
antibiotics or antifungals or has had such
infections within 60 days prior to screening.*
Ja
Nein
Personal history of tuberculosis*
Ja
Nein
Serologic evidence or known latent HIV, HBV or
HCV virus.*
Ja
Nein
Uncontrolled hypertension of systolic blood
pressure >= 160 mmHg or diastolic blood
pressure >= 90 mmHg.*
Ja
Nein
MDRD GFR < 60 mL/min.*
Ja
Nein
Variation between the screening and Visit 1 SCr
>= 30%.*
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Eligibility NCT00408187 Psoriasis
Ja
Nein
ALT, AST, GGT >= 2x upper limit of normal
(ULN).*
Ja
Nein
Leukozyten-Anzahl*
Ja
Nein
Requires the following prohibited medications or
treatments during the washout or treatment
period: drugs potentiating the nephrotoxicity of
voclosporin, drugs interfering with its
pharmacokinetics, drugs considered to contribute
to psoriasis flare. Or, systemic and topical
psoriasis medication that may interfere with
assessment of study drug efficacy.*
Ja
Nein
Has used any investigational drug or device
within 30 days or 10 half lives (whichever is
longer) prior to the screening visit.*
Ja
Nein
Current participation in another clinical trial of any
drug or biological agent.*
Ja
Nein
Has taken biological agent(s), except flu shots,
tetanus shots, or boosters, within 3 months of
randomization. Biological agents include any
virus, live vaccine, therapeutic serum, toxin,
antitoxin, monoclonal antibodies or analogous
product applicable to the prevention, treatment, or
cure of diseases or injuries of man.*
Ja
Nein
Previous exposure to voclosporin.*
Ja
Nein
A history of clinically defined allergy to
ciclosporin, constituents of Neoral or any of the
constituents of the ISA247 formulation.*
Ja
Nein
A history of alcoholism or drug addiction.*
Ja
Nein
Körpergewicht*
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Ja
Nein
A history of disease, including mental/emotional
disorder that would interfere with the subject's
participation in the study, in the evaluation of
his/her response or that might cause the
administration of voclosporin to pose a significant
risk to the subject, in the opinion of the
Investigator.*
Ja
Nein
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Eligibility NCT00408187 Psoriasis
Eligibility NCT00405743 Hematologic
Malignancies
ODM derived from
http://clinicaltrials.gov/show/NCT00405743
All rights reserved. Please visit https://medical-data-
models.org/forms/4965
Eligibility
Einschlusskriterien
Alter mindestens 18 Jahre*
Ja
Nein
ARM A and B: Phase I CP-4055 single agent *
Ja
Nein
Patients must have relapsed/refractory leukemias
for which no standard therapies are anticipated to
result in a durable response or have failed
potentially curative therapy, or have refused or
are considered unsuitable for standard therapy*
Ja
Nein
ARM C: CP-4055 in combination with idarubicin*
Ja
Nein
Patients with relapsed/refractory AML for which
no standard therapies are anticipated to result in
a durable response or who have failed potentially
curative therapy, or who refuse or are considered
unsuitable for standard therapy*
Ja
Nein
ARM A, B, C: CP-4055 as single agent and/or in
combination with idarubicin*
Ja
Nein
ECOG Status <= 2*
Ja
Nein
Women of child-bearing potential (i.e., women
who are pre-menopausal or not surgically sterile)
must have a negative serum or urine pregnancy
test within 2 weeks prior to beginning treatment
on this study. Nursing patients are excluded.*
Ja
Nein
Male and female patients must use acceptable
contraceptive methods for the duration of time on
study, and males also for 3 months after the last
CP-4055 dose*
Ja
Nein
Patients must be capable of understanding and
1 / 3
complying with parameters as outlined in the
protocol, and able and willing to sign a written
informed consent form*
Ja
Nein
In the absence of rapidly progressing disease,
the interval from prior treatment to time of study
drug administration should be at least 2 weeks for
cytotoxic agents, or at least 5 half-lives for
noncytotoxic agents.*
Ja
Nein
Patients must have the following clinical
laboratory values:*
Ja
Nein
Serum creatinine <= 1.5 x the institutional upper
limit of normal (ULN)*
Ja
Nein
Total bilirubin <= 1.5 x the ULN unless
considered due to Gilbert's syndrome*
Ja
Nein
Alanine aminotransferase (ALT) (SGPT), or
aspartate aminotransferase (AST) (SGOT) <= 2.5
x the ULN unless considered due to organ
leukemic involvement*
Ja
Nein
Patients with a confirmed diagnosis of AML who
have received cytotoxic chemotherapy*
Ja
Nein
Ausschlusskriterien
A history of allergic reactions or sensitivity
attributed to compounds of similar chemical or
biologic composition to CP-4055, i.e., ara-C
and/or egg*
Ja
Nein
Known positive status for human
immunodeficiency virus (HIV) or hepatitis B or C*
Ja
Nein
Pregnant and nursing patients are excluded*
Ja
Nein
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Uncontrolled intercurrent illness*
Ja
Nein
Active heart disease*
Ja
Nein
Patients receiving any other standard or
investigational cytotoxic treatment for their
hematologic malignancy other than a maximum
of 5 g of hydroxyurea to a maximum of 5 days in
cycle 1 of therapy*
Ja
Nein
Any medical condition which in the opinion of the
investigator places the patient at an unacceptably
high risk for toxicities*
Ja
Nein
Ausschlusskriterium*
Ja
Nein
Patients with hypersensitivity to idarubicin or any
other component of the product, and/or other
anthracyclines or anthracenediones*
Ja
Nein
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Eligibility NCT00404885 Uveitis, Anterior
ODM derived from
http://clinicaltrials.gov/show/NCT00404885
All rights reserved. Please visit https://medical-data-
models.org/forms/4966
Eligibility
Einschlusskriterien
Alter mindestens 13 Jahre*
Ja
Nein
Documented history of non-infectious anterior,
anterior and intermediate- or panuveitis*
Ja
Nein
Currently uncontrolled uveitis for a minimum of 2
weeks despite use of oral and/or topical
corticosteroid,or subjects who are intolerant of
local corticosteroid therapy due to the
development of an ocular hypertensive response
or subjects for whom oral corticosteroid is
contraindicated.*
Ja
Nein
Grade of >= 2+ for anterior chamber cells at time
of enrollment*
Ja
Nein
Considered by the investigator to require
corticosteroid-sparing therapy.*
Ja
Nein
Subjects not planning to undergo elective ocular
surgery during the study *
Ja
Nein
Ausschlusskriterien
Uveitis of infectious etiology*
Ja
Nein
Presence of an ocular toxoplasmosis scar*
Ja
Nein
An immune suppression regimen that includes an
alkylating agent within the previous 90 days*
Ja
Nein
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Eligibility NCT00402727 Abscess
ODM derived from
http://clinicaltrials.gov/show/NCT00402727
All rights reserved. Please visit https://medical-data-
models.org/forms/4967
Eligibility
Einschlusskriterien
Alter mindestens 18 Jahre*
Ja
Nein
Written informed consent*
Ja
Nein
Men or women of 18 years and above with a
diagnosis of bacterial skin and skin structure
infection that requires*
Ja
Nein
Inpatient care (regime/therapy)*
Ja
Nein
Initial parenteral therapy for at least 48 hours
and*
Ja
Nein
Meets at least one of the following criteria:*
Ja
Nein
Involvement of deep soft tissue (e.g. fascial,
muscle layers)*
Ja
Nein
Requirement for a significant surgical intervention
including surgical  drainage, drainage procedure
guided by imaging and/or debridement*
Ja
Nein
Association with a significant underlying disease
that may complicate  response to treatment. An
underlying disease is considered significant if  it
includes any of the following conditions that are
present at the time of  presentation: cancer
(except basal- or squamous-cell cancer of the
skin),  cardiac (i.e., congestive heart disease),
diabetes mellitus, hepatic (i.e.,  cirrhosis or
another form of chronic liver disease),
immunologic, renal  disease, respiratory,
transplantation or vascular disease*
Ja
Nein
Duration of infection < 21 days*
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Ja
Nein
Diagnosis of one of the following skin and skin
structure infections that requires hospitalization
and initial parenteral antibiotic therapy for at least
48 hours:*
Ja
Nein
Major abscess(es) associated with extensive
cellulitis, which requires  antibiotic therapy in
addition to surgical incision and drainage*
Ja
Nein
Diabetic foot infection of mild to severe intensity
(perfusion, extent/size,  depth/tissue loss,
infection and sensation (PEDIS) grade 2-4) in the
presence or  absence of osteomyelitis. Subjects
with osteomyelitis may only be enrolled if  the
infected bone is completely removed by surgery
and if residual infection  requiring antibiotics is
still present following surgery*
Ja
Nein
Wound infection including: post surgical (surgical
incision), post-traumatic,  human bite/clenched
fist and animal bite wound and wound associated
with  injection drug abuse:*
Ja
Nein
Infections must have occurred within 30 days of a
surgical procedure,  trauma, animal bite, or
human bite, and involve the skin and skin
structures at the site of the incision, trauma, or
bite*
Ja
Nein
In addition, post-surgical/trauma wound infections
must meet the following  criteria:*
Ja
Nein
Involvement of deep soft tissues (e.g. fascial and
muscle layers) of  the incision/trauma*
Ja
Nein
At least one of the following criteria:*
Ja
Nein
Purulent drainage from the deep incision/trauma*
Ja
Nein
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Identification of an infecting organism from an
aseptically   obtained culture of fluid or tissue
from incision/trauma*
Ja
Nein
At least one of the following signs and
symptoms:*
Ja
Nein
Localized pain or tenderness*
Ja
Nein
Fever (see below) AND the incision (in case of
post-surgical   wound infections) is deliberately
opened by a surgeon, unless the   culture is
negative*
Ja
Nein
Abscess or other evidence of infection involving
the deep   incision/trauma, found on direct
examination, during   reoperation/operation (in
case of trauma), or by histologic or   radiologic
examination*
Ja
Nein
Diagnosis of a deep incisional/post-trauma Skin
Structure Infections  (SSI) by a surgeon or
attending physician*
Ja
Nein
Bite wounds/clenched fist infections and wounds
associated with  injection drug abuse must meet
the criteria defining a Complicated  Skin and Skin
Structure Infections (cSSSI)*
Ja
Nein
Infected ischemic ulcers with at least one of the
following conditions:*
Ja
Nein
periphere Gefäßkrankheit*
Ja
Nein
Conditions pre-disposing to pressure sores such
as paraplegia, peripheral  neuropathy*
Ja
Nein
Presence of at least 3 of the following signs or
symptoms:*
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Ja
Nein
Purulent drainage or discharge*
Ja
Nein
Erythema extending > 1 cm from the wound
edge*
Ja
Nein
Fluctuance*
Ja
Nein
Pain or tenderness to palpation*
Ja
Nein
Swelling or induration*
Ja
Nein
Fever, defined as body temperature*
Ja
Nein
> 37.5°C (axillary)*
Ja
Nein
> 38°C (orally)*
Ja
Nein
> 38.5°C (tympanically) or*
Ja
Nein
> 39°C (rectally)*
Ja
Nein
oder*
Ja
Nein
Elevated total peripheral white blood cell (WBC)
count >   12,000/mm3 or*
Ja
Nein
>15 % immature neutrophils (bands) regardless
of total peripheral   WBC count*
Ja
Nein
CRP*
Ja
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Nein
Specimen obtained for culture from infected area
by needle aspiration of obviously purulent
material or by tissue biopsy or by curettage of the
surface of ulcer within 48 hours prior to the
initiation of study drug therapy*
Ja
Nein
Duration of treatment of the skin/skin structure
infection is anticipated to be at least 7 days.*
Ja
Nein
Surgical drainage or debridement of infected
wounds or abscesses, if necessary, have to have
been completed <= 48 hours after the initiation of
study drug therapy *
Ja
Nein
Ausschlusskriterien
Women, who are pregnant or lactating, or in
whom pregnancy can not be excluded (Note: a
urine pregnancy test has to be performed for all
women of childbearing potential before
randomization to the study drug)*
Ja
Nein
The following skin and skin structure infections:*
Ja
Nein
Necrotizing fasciitis including Fourniers
gangrene, ecthyma gangrenosum,  streptococcal
necrotizing fasciitis and clostridial necrotizing
fasciitis*
Ja
Nein
Burn wound infections*
Ja
Nein
Secondary infections of a chronic skin disease
(e.g. atopic dermatitis)*
Ja
Nein
Infection of prosthetic materials (e.g.
subcutaneous tissue infection related to  a central
venous catheter or permanent cardiac
pacemaker battery pack). Subjects  with removal
of a prosthetic device involved in an infection
should not be  included*
Ja
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Nein
Infections where a surgical procedure alone is
definitive therapy*
Ja
Nein
Subjects with uncomplicated skin and skin
structure infections including  folliculitis and
furunculosis, carbunculosis, simple abscesses
and superficial  cellulitis*
Ja
Nein
Known hypersensitivity to quinolones and/or any
type of beta-lactam antibiotic drugs or any of the
excipients*
Ja
Nein
Previous history of cholestatic jaundice/hepatic
dysfunction associated with amoxicillin-clavulanic
acid*
Ja
Nein
Severe, life threatening disease with a life
expectancy of < 2 months*
Ja
Nein
Immunosuppression including:*
Ja
Nein
Known neutropenia (neutrophil count < 1000/µL)*
Ja
Nein
Known lymphopenia with absolute CD4+ T cell
count < 200/mm3*
Ja
Nein
Acquired immunodeficiency syndrome (AIDS)-
defining event and/or concomitant  therapy with
Highly Active Antiretroviral Therapy (HAART)*
Ja
Nein
Chronic treatment (>/= 2 weeks) with known
immunosuppressant therapy (including  treatment
with > 15 mg/day of systemic prednisone or
equivalent)*
Ja
Nein
Any other congenital or acquired immune defect
or immunosuppression*
Ja
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Nein
Known severe hepatic insufficiency (Child Pugh
C) or transaminases increase > 5 fold upper limit
of normal (ULN)*
Ja
Nein
Known renal impairment with a baseline
measured or calculated serum creatinine
clearance < 40 mL/min*
Ja
Nein
Known prolongation of the QT interval or
concomitant use of drugs reported to increase
the QT interval (e.g. Class IA or Class III
antiarrhythmics [eg., quinidine, procainamide,
amiodarone, sotalol], neuroleptics [e.g.
haloperidol], tricyclic antidepressive agents,
certain antimicrobials [e.g. pentamidine,
halofantrine], certain antihistaminics [e.g.
terfenadine], and other [cisapride, vincamine IV,
depridil, diphemanil])*
Ja
Nein
Uncorrected hypokalemia*
Ja
Nein
Clinically relevant bradycardia*
Ja
Nein
Clinically relevant heart failure with reduced left
ventricular ejection fraction (i.e., below 40%)*
Ja
Nein
Previous history of symptomatic arrhythmias*
Ja
Nein
Previous history of tendon disease/disorder with
quinolones*
Ja
Nein
Known or suspected concomitant bacterial
infection requiring additional systemic
antibacterial treatment, e.g. underlying septic
arthritis*
Ja
Nein
Requiring therapy with probenecid*
Ja
Nein
Treatment with a systemic or topical antibacterial
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agent for > 24 hours in the previous 7 days
preceding study entry unless the subject showed
no response or had worsening of clinical signs
and symptoms despite 3 or more days of prior
therapy and a culture obtained at the time of
subject enrollment showed persistence of a
pathogen which is susceptible to the study drugs.
The prior antimicrobial therapy must not have
been a fluoroquinolone or a beta lactam/beta
lactamase combination*
Ja
Nein
Infection known to be due to a Methicillin-
Resistant Staphylococcus Aureus (MRSA),
Methicillin-Resistant Staphylococcus Epidermidis
(MRSE) or Vancomycin Resistant Enterococcus
(VRE) as the single isolated pathogen*
Ja
Nein
Previous enrolment in this study*
Ja
Nein
Participation in any clinical investigational drug
study within 4 weeks of screening*
Ja
Nein
Previous history of seizure disorders*
Ja
Nein
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Eligibility NCT00395070 Metastatic
Melanoma
ODM derived from
http://clinicaltrials.gov/show/NCT00395070
All rights reserved. Please visit https://medical-data-
models.org/forms/4968
Eligibility
Einschlusskriterien
Alter mindestens 18 Jahre*
Ja
Nein
Confirmed Stage 3 or Stage 4 melanoma that
may have had previous treatment via surgery,
radiation or biologic drugs (typically Interferon
Alpha or Interleukin-2)*
Ja
Nein
At least 1 melanoma tumor that is 1cm x 1cm or
greater in size (about the size of a dime) and can
be injected*
Ja
Nein
Normal blood chemistries and blood cell counts*
Ja
Nein
At least 18 years old and able and willing to
provide informed consent to participate*
Ja
Nein
Ausschlusskriterien
Previous chemotherapy treatment for melanoma*
Ja
Nein
Melanoma lesions in the brain or liver (however,
lesions in the lungs are allowed)*
Ja
Nein
If surgical removal of all lesions would be
possible and could be curative*
Ja
Nein
Any melanoma tumors   >10cm x 10cm in size*
Ja
Nein
Known condition resulting in a suppressed
immune system*
Ja
Nein
Female subjects who are pregnant*
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Ja
Nein
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Eligibility NCT00393692 Age-related
Macular Degeneration
ODM derived from
http://clinicaltrials.gov/show/NCT00393692
All rights reserved. Please visit https://medical-data-
models.org/forms/4969
Eligibility
Einschlusskriterien
Alter mindestens 50 Jahre*
Ja
Nein
Must be considered reliable, willing and able to
give informed consent.*
Ja
Nein
Must have age-related macular degeneration in
at least one eye*
Ja
Nein
Clear media to allow imaging *
Ja
Nein
Ausschlusskriterien
any history of retinal surgery, including laser
treatment, photodynamic therapy, radiation or
intravitreal injections*
Ja
Nein
history of retinal vascular occlusions*
Ja
Nein
any concurrent intraocular condition that, in the
opinion of the investigator, could exclude the
patient from the medical or ethical point of view*
Ja
Nein
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Eligibility NCT00722566 Multiple Myeloma
ODM derived from
http://clinicaltrials.gov/show/NCT00722566
All rights reserved. Please visit https://medical-data-
models.org/forms/4970
Eligibility
Einschlusskriterien
Alter mindestens 18 Jahre*
Ja
Nein
Diagnosis of multiple myeloma*
Ja
Nein
Measurable, secretory multiple myeloma defined
as serum monoclonal IgG of ≥10 g/L, serum
monoclonal IgA or IgE ≥5 g/L, or serum
monoclonal IgD ≥0.5g/L; or urine M-protein of
≥200 mg/24 hr*
Ja
Nein
Ausschlusskriterien
Previous treatment with VELCADE*
Ja
Nein
More than 3 previous lines of therapy (separate
lines of therapy are defined as single or
combination therapies that are either separated
by disease progression or by a greater than 6
month treatment-free interval)*
Ja
Nein
Peripheral neuropathy or neuropathic pain of NCI
CTCAE Grade ≥2*
Ja
Nein
Any of the following within 3 weeks prior to
randomization:*
Ja
Nein
antineoplastic or experimental therapy,
corticosteroid use above 10mg a day (prednisone
or equivalent), or plasmapheresis*
Ja
Nein
Any of the following within 2 weeks prior to
randomization:*
Ja
Nein
radiation therapy, major surgery (kyphoplasty is
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not considered major surgery)*
Ja
Nein
Prior malignancy other than multiple myeloma
diagnosed or treated within the last 2 years, with
the exception of completely resected carcinoma
in situ or basal/squamous carcinoma of the skin*
Ja
Nein
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Eligibility NCT00717470 Kidney
Transplantation
ODM derived from
http://clinicaltrials.gov/show/NCT00717470
All rights reserved. Please visit https://medical-data-
models.org/forms/4971
Eligibility
Einschlusskriterien
Alter mindestens 18 Jahre*
Ja
Nein
End stage kidney disease and a suitable
candidate for primary renal transplantation or re-
transplantation (unless the graft was lost from
rejection within 12 months)*
Ja
Nein
Receiving a kidney transplant from a cadaveric or
living (non HLA identical) donor with compatible
ABO blood type*
Ja
Nein
Female subject of childbearing potential must
have a negative serum pregnancy test at
enrollment and must agree to maintain effective
birth control during the study *
Ja
Nein
Ausschlusskriterien
Receiving or having previously received an organ
transplant other than a kidney*
Ja
Nein
Cold ischemia time of the donor kidney > 30
hours*
Ja
Nein
Receiving a graft from a non-heart-beating donor
other than of Maastricht category 3 (withdrawn of
support awaiting cardiac arrest)*
Ja
Nein
Significant liver disease, defined as having
continuously elevated SGPT/ALT and/or
SGOT/AST and/or total bilirubin levels >= 2 times
the upper value of the normal range of the
investigational site or is receiving a graft from a
hepatitis C or B positive donor*
Ja
Nein
Requiring initial sequential or parallel therapy with
immunosuppressive antibody preparation(s)*
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Ja
Nein
Requiring ongoing dosing with a systemic
immunosuppressive drug prior to
transplantation.*
Ja
Nein
Significant, uncontrolled concomitant infections
and/or severe diarrhea, vomiting, active upper
gastro-intestinal tract malabsorption or active
peptic ulcer*
Ja
Nein
Pregnant woman or breast-feeding mother*
Ja
Nein
Subject or donor known to be HIV positive*
Ja
Nein
Known allergy or intolerance to tacrolimus,
macrolide antibiotics, corticosteroids, basiliximab
or mycophenolate mofetil or any of the product
excipients*
Ja
Nein
Diagnosis of new-onset malignancy prior to
transplantation, with the exception of basocellular
or squamous cell carcinoma of the skin which
had been treated successfully*
Ja
Nein
Currently participating in another clinical trial,
and/or has taken an investigational drug within 28
days prior to enrollment*
Ja
Nein
Any form of substance abuse, psychiatric
disorder or condition which, in the opinion of the
investigator, may complicate communication with
the investigator*
Ja
Nein
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Eligibility NCT00717457 Diabetes Mellitus,
Type 2
ODM derived from
http://clinicaltrials.gov/show/NCT00717457
All rights reserved. Please visit https://medical-data-
models.org/forms/4972
Eligibility
Einschlusskriterien
Alter 18 bis 75 Jahre*
Ja
Nein
Erwachsener, erwachsen*
Ja
Nein
type 2 diabetes receiving metformin and/or
pioglitazone or rosiglitazone for at least 12
weeks*
Ja
Nein
HbA1c >=7.0% and <=10% at screening*
Ja
Nein
BMI >=25kg/m2 (>23kg/m2 for Asians) and
<=45kg/m2 at screening*
Ja
Nein
stable weight +/- 5% for at least 12 weeks prior to
screening. *
Ja
Nein
Ausschlusskriterien
history of type 1 diabetes, diabetes resulting from
pancreatic injury or secondary forms of diabetes*
Ja
Nein
history of acute metabolic diabetic complications
within the previous 6 months*
Ja
Nein
evidence of clinically significant diabetic
complications*
Ja
Nein
Proliferative diabetic retinopathy*
Ja
Nein
myocardial infarction (MI), coronary artery bypass
surgery, post-transplantation cardiomyopathy
(PTCM) or stroke within the past 6 months*
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Ja
Nein
any abnormality in clinical laboratory test or ECG,
which precludes safe involvement in the study as
judged by the investigator*
Ja
Nein
known hemoglobinopathy or chronic anemia*
Ja
Nein
clinically significant gastrointestinal disease.*
Ja
Nein
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Eligibility NCT00717366 Anemia
ODM derived from
http://clinicaltrials.gov/show/NCT00717366
All rights reserved. Please visit https://medical-data-
models.org/forms/4973
Eligibility
Einschlusskriterien
Alter 5 bis 17 Jahre*
Ja
Nein
children aged 5-17 years with clinically stable
chronic renal anemia*
Ja
Nein
hemodialysis for >=8 weeks*
Ja
Nein
intravenous stable maintenance epoetin alfa,
epoetin beta or darbepoetin alfa for >= 8 weeks
before screening*
Ja
Nein
stable maintenance epoetin alfa, epoetin beta or
darbepoetin alfa with no more than one dose
change <=25% during the 2 weeks of screening.
*
Ja
Nein
Ausschlusskriterien
overt gastrointestinal bleeding, or bleeding
episode necessitating transfusion within 8 weeks
before screening*
Ja
Nein
red blood cell transfusions within 8 weeks before
screening*
Ja
Nein
active malignant disease.*
Ja
Nein
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Eligibility NCT00701766 Leukemia,
Myeloid, Acute
ODM derived from
http://clinicaltrials.gov/show/NCT00701766
All rights reserved. Please visit https://medical-data-
models.org/forms/4975
Eligibility
Einschlusskriterien
Alter über 60 Jahre*
Ja
Nein
Patient with confirmed AML (except for APL)
according to the WHO definition who relapsed
after or are refractory to prior chemotherapy*
Ja
Nein
Leukozyten-Anzahl*
Ja
Nein
Patient not eligible for intensive treatment
options*
Ja
Nein
Life expectancy >= 2 months*
Ja
Nein
ECOG Status <= 2*
Ja
Nein
Signed written informed consent consistent with
international conference on harmonisation - good
clinical practice (ICH-GCP) and local legislation *
Ja
Nein
Ausschlusskriterien
Patient with acute promyelocytic leukaemia (APL,
AML of the French-American-British (FAB)
classification subtype M3)*
Ja
Nein
Hypersensitivity to the trial drug or the excipients*
Ja
Nein
Secondary malignancy requiring therapy*
Ja
Nein
Zentralnervensystembeteiligung, Status*
Ja
Nein
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Aspartate amino transferase (AST) or alanine
amino transferase (ALT) > 2.5 times the upper
limit of normal, or AST or ALT > 5 times the upper
limit of normal in case of known liver involvement*
Ja
Nein
Bilirubin > 1.5 mg/dl (> 26 mcmol/l, SI unit
equivalent)*
Ja
Nein
Kreatinin im Serum*
Ja
Nein
Concomitant intercurrent illness, which would
compromise the evaluation of efficacy or safety of
the trial drug, e.g. active severe infection,
unstable angina pectoris or cardiac arrhythmia*
Ja
Nein
Psychiatric illness or social situation that would
limit compliance with trial requirements*
Ja
Nein
Concomitant therapy, which is considered
relevant for the evaluation of the efficacy or safety
of the trial drug*
Ja
Nein
Chemotherapy (except hydroxyurea) or
immunotherapy or treatment with any other
investigational drug within the past four weeks
prior to treatment with the trial drug*
Ja
Nein
Persistence of toxicities of prior anti-leukaemia
therapies which are deemed to be clinically
relevant*
Ja
Nein
Patients who are sexually active and unwilling to
use a medically acceptable method of
contraception during the trial (hormonal
contraception, intrauterine device, condom with
spermicide, etc.)*
Ja
Nein
Patient unable to comply with the protocol*
Ja
Nein
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Eligibility NCT00701714 Anemia
ODM derived from
http://clinicaltrials.gov/show/NCT00701714
All rights reserved. Please visit https://medical-data-
models.org/forms/4976
Eligibility
Einschlusskriterien
Alter mindestens 18 Jahre*
Ja
Nein
Known chronic renal insufficiency of at least 4
weeks duration. CKD stage at least 3 or higher*
Ja
Nein
Patients who are naive to ESA treatment or
previously ESA treated after 3 months of ESA-
free period (i.v. or s.c.)*
Ja
Nein
Patients with symptomatic anemia, defined as Hb
level below 11.0 g/dL and not lower than or equal
to 7.5 g/dL on at least 2 visits during the
screening period*
Ja
Nein
Adequate iron status, serum ferritin >= 100 µg/L
or transferrin saturation >= 20%*
Ja
Nein
Ability to follow study instructions and likely to
complete all required visits and compliant with
subcutaneous administration*
Ja
Nein
Written informed consent of the patient. *
Ja
Nein
Ausschlusskriterien
Anemia of non-renal causes*
Ja
Nein
Therapy with immunosuppressants (other than
corticosteroids for chronic treatment) within 3
months before screening and during the study for
patients with renal allograft in place or other
chronic conditions (e.g. lupus erythematosus,
rheumatic arthritis)*
Ja
Nein
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Patients previously treated with chronic dialysis
within the last 6 months (exception: one session
of acute dialysis)*
Ja
Nein
Patients with acute deterioration of renal function
during the screening phase according to the
investigator's judgment*
Ja
Nein
Patients receiving any RBC/whole blood
transfusion during the screening period*
Ja
Nein
Primary hematological disorder (e.g. myeloma,
myelodysplastic syndrome, sickle cell anemia,
hematological malignancy, hemolytic anemia)*
Ja
Nein
Evidence of uncontrolled diabetes mellitus
(HbA1c > 10 % at visit -2)*
Ja
Nein
Evidence of severe hepatic dysfunction (e.g. ALT
and/or AST above 2x upper limit of normal range.
Or gamma-GT above 3x upper limit of normal
range)*
Ja
Nein
Clinical evidence of current uncontrolled or
symptomatic hyperparathyroidism, defined as
parathyroid hormone > 500 ng/L at visit -2.*
Ja
Nein
Uncontrolled hypertension, defined as a systolic
blood pressure of >= 160 mmHg and a diastolic
blood pressure measurement >= 100 mmHg
(average of two values with at least one day
between measurements)*
Ja
Nein
Congestive heart failure and/or angina pectoris
[New York Heart Association (NYHA) class III and
IV]*
Ja
Nein
History of stroke or myocardial infarction during
the last 6 months prior to visit -2*
Ja
Nein
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Ongoing treatment with phenprocoumon or other
cumarin derivates*
Ja
Nein
Thrombocytopenia (platelet count <100.000/µL)
or leucopenia (white blood cell count < 2.000/µL)*
Ja
Nein
Gastrointestinal bleeding within the last 6 months
prior to visit -2 or hemolysis*
Ja
Nein
Evidence of acute or chronic infection by a C-
reactive protein value of > 30 mg/L*
Ja
Nein
Suspicion or known PRCA (pure red cell aplasia)*
Ja
Nein
Previously diagnosed HIV or acute hepatitis
infection*
Ja
Nein
History of epilepsy or epileptic seizures or
treatment for epilepsy within the past 6 months
prior to screening*
Ja
Nein
Planned major surgery (with expected high blood
loss) during the next 3 months or major surgery
within the previous 3 months (except laser
photocoagulation, access surgery)*
Ja
Nein
Clinical evidence of active malignant diseases
within the last 5 years (except non-melanoma
skin cancer)*
Ja
Nein
Pregnancy, breastfeeding women or women not
using a highly effective birth control method (e.g.
implants, injectables, combined oral
contraceptives, IUD, sexual abstinence,
vasectomised partner)*
Ja
Nein
Known history of severe drug related allergies
(e.g. anaphylactic shock)*
Ja
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Nein
Known allergy to one of the ingredients of the test
product or hypersensitivity to mammalian-derived
products*
Ja
Nein
Known or suspicion of any non-compliance with
respect to subcutaneous treatment*
Ja
Nein
Simultaneous participation in another clinical
study or participation in a study in the month
preceding visit-2 or previously randomized in this
study*
Ja
Nein
Participation in another ESA study in the 3
months preceding visit -2*
Ja
Nein
Any other condition which at the investigator's
discretion may put the patient at risk or which
may confound the study results.*
Ja
Nein
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Eligibility NCT00700102 Colorectal Cancer
ODM derived from
http://clinicaltrials.gov/show/NCT00700102
All rights reserved. Please visit https://medical-data-
models.org/forms/4977
Eligibility
Einschlusskriterien
Alter mindestens 18 Jahre*
Ja
Nein
Erwachsener, erwachsen*
Ja
Nein
metastatic colorectal cancer and disease
progression*
Ja
Nein
previously treated with first-line chemotherapy
plus Avastin*
Ja
Nein
ECOG Status <=2*
Ja
Nein
Ausschlusskriterien
Diagnosis of progression of disease more than 3
months after last Avastin administration*
Ja
Nein
first line patients with progression-free survival in
first line of <3 months*
Ja
Nein
Patients receiving less than 3 consecutive
months of Avastin in first-line therapy*
Ja
Nein
Past or current history (within the last 2 years
prior to treatment start) of other malignancies,
except for curatively treated basal and squamous
cell cancer of the skin or in situ cancer of the
cervix*
Ja
Nein
clinically significant cardiovascular disease within
6 months prior to start of study treatment*
Ja
Nein
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Known CNS disease, except for treated CNS
metastases as defined by protocol*
Ja
Nein
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Eligibility NCT00700102 Colorectal Cancer
Eligibility NCT00699335 Severe Chronic
Pain
ODM derived from
http://clinicaltrials.gov/show/NCT00699335
All rights reserved. Please visit https://medical-data-
models.org/forms/4978
Eligibility
Einschlusskriterien
Alter mindestens 18 Jahre*
Ja
Nein
Outpatients with severe, chronic pain *
Ja
Nein
Ausschlusskriterien
Hypersensitivity to fentanyl*
Ja
Nein
Co-administration of monoamineoxidase-
inhibitors*
Ja
Nein
Schwangerschaft*
Ja
Nein
Atemdepression*
Ja
Nein
COPD*
Ja
Nein
Drug abuse*
Ja
Nein
Impairment of CNS functions*
Ja
Nein
Other criteria as defined in the Summary of
Product Characteristics (Chapter 4.3)*
Ja
Nein
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Eligibility NCT00699283 Epilepsy
ODM derived from
http://clinicaltrials.gov/show/NCT00699283
All rights reserved. Please visit https://medical-data-
models.org/forms/4979
Eligibility
Einschlusskriterien
Alter 16 bis 75 Jahre*
Ja
Nein
Alter zwischen 16 und 75 Jahren*
Ja
Nein
Well-characterized focal epilepsy or epileptic
syndrome.*
Ja
Nein
Subjects having at least 2 but not exceeding 40
partial onset seizures, whether or not secondarily
generalized per 4 weeks during the 8-week
Baseline Period.*
Ja
Nein
Subjects on a stable dose of at least 1 but no
more than 2 concomitant AEDs with the second
AED <= 50% of the minimum recommended
maintenance dose. *
Ja
Nein
Ausschlusskriterien
Seizure type IA non-motor as only seizure type.*
Ja
Nein
History or presence of seizures occurring too
frequently or indistinctly separated to be reliably
counted during the 6 months preceding Visit 1 or
during Baseline.*
Ja
Nein
Other serious uncontrolled disease.*
Ja
Nein
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Eligibility NCT00689936 Multiple Myeloma
ODM derived from
http://clinicaltrials.gov/show/NCT00689936
All rights reserved. Please visit https://medical-data-
models.org/forms/4980
Eligibility
Einschlusskriterien
Must understand and voluntarily sign informed
consent form*
Ja
Nein
Age ≥ 18 years at the time of signing consent*
Ja
Nein
Previously untreated, symptomatic multiple
myeloma as defined by the 3 criteria below:*
Ja
Nein
MM diagnostic criteria (all 3 required)*
Ja
Nein
Monoclonal plasma cells in the bone marrow
≥10% and/or presence of a biopsy-proven
plasmacytoma*
Ja
Nein
Monoclonal protein present in the serum and/or
urine*
Ja
Nein
Myeloma-related organ dysfunction (at least one
of the following) [C] Calcium elevation in the
blood (serum calcium >10.5 mg/dl or upper limit
of normal) [R] Renal insufficiency (serum
creatinine >2 mg/dl) [A] Anemia (hemoglobin <10
g/dl or 2 g < laboratory normal) [B] Lytic bone
lesions or osteoporosis*
Ja
Nein
AND have measurable disease by protein
electrophoresis analyses as defined by the
following*
Ja
Nein
IgG multiple myeloma: Serum monoclonal
paraprotein (M-protein) level ≥ 1.0 g/dl or urine
M-protein level ≥ 200 mg/24 hours*
Ja
Nein
IgA multiple myeloma: Serum M-protein level ≥
0.5 g/dl or urine M-protein level ≥ 200 mg/24
1 / 5
hours*
Ja
Nein
IgM multiple myeloma (IgM M-protein plus lytic
bone disease documented by skeletal survey
plain films): Serum M-protein level ≥ 1.0 g/dl or
urine M-protein level ≥ 200mg/24hours*
Ja
Nein
IgD multiple myeloma: Serum M-protein level ≥
0.05 g/dl or urine M-protein level ≥ 200 mg/24
hours*
Ja
Nein
Light chain multiple myeloma: Serum M-protein
level ≥ 1.0 g/dl or urine M-protein level ≥ 200
mg/24 hours*
Ja
Nein
AND are at least 65 years of age or older or, if
younger than 65 years of age, are not candidates
for stem cell transplantation because*
Ja
Nein
The patient declines to undergo stem cell
transplantation or*
Ja
Nein
Stem cell transplantation is not available to the
patient due to cost or other reasons*
Ja
Nein
ECOG Status <= 2*
Ja
Nein
Able to adhere to the study visit schedule and
other protocol requirements*
Ja
Nein
Females of child-bearing potential (FCBP)^2*
Ja
Nein
Must agree to undergo two medically supervised
pregnancy tests prior to starting study therapy
with either Rd or MPT. The first pregnancy test
will be performed within 10-14 days prior to the
start of Rd or MPT and the second pregnancy
test will be performed within 24 hours prior to the
start of Rd or MPT. She must also agree to
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ongoing pregnancy testing during the course of
the study and after the end of study therapy. This
applies even if the patient practices complete and
continued sexual abstinence.*
Ja
Nein
Must commit to either continued abstinence from
heterosexual intercourse (which must be
reviewed on a monthly basis) or agree to use and
be able to comply with effective contraception
without interruption, 28 days prior to starting
study drug, during the study therapy (including
during periods of dose interruptions), and for 28
days after discontinuation of study therapy.*
Ja
Nein
männlich*
Ja
Nein
Must agree to use a condom during sexual
contact with a FCBP, even if they have had a
vasectomy, throughout study drug therapy, during
any dose interruption and after cessation of study
therapy.*
Ja
Nein
Must agree to not donate semen during study
drug therapy and for a period after end of study
drug therapy*
Ja
Nein
All patients must*
Ja
Nein
Have an understanding that the study drug could
have a potential teratogenic risk*
Ja
Nein
Agree to abstain from donating blood while taking
study drug therapy and following discontinuation
of study drug therapy.*
Ja
Nein
Agree not to share study medication with another
person. All FCBP and male patients must be
counseled about pregnancy precautions and
risks of fetal exposure*
Ja
Nein
Ausschlusskriterien
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Previous treatment with anti-myeloma therapy
(does not include radiotherapy, bisphosphonates,
or a single short course of steroid [i.e., <= the
equivalent of dexamethasone 40 mg/day for 4
days; such a short course of steroid treatment
must not have been given within 14 days of
randomization]).*
Ja
Nein
Any serious medical condition that places the
patient at an unacceptable risk if he or she
participates in this study. Examples of such a
medical condition are, but are not limited to,
patient with unstable cardiac disease as defined
by: Cardiac events such as MI within the past 6
months, NYHA heart failure class III-IV,
uncontrolled atrial fibrillation or hypertension;
patients with conditions requiring chronic steroid
or immunosuppressive treatment, such as
rheumatoid arthritis, multiple sclerosis and lupus,
that likely need additional steroid or
immunosuppressive treatments in addition to the
study treatment.*
Ja
Nein
Pregnant or lactating females*
Ja
Nein
Any of the following laboratory abnormalities*
Ja
Nein
Absolute Neutrophil Count*
Ja
Nein
Untransfused platelet count < 50,000 cells/µL (50
x 10^9/L)*
Ja
Nein
Serum SGOT/AST or SGPT/ALT > 3.0 x upper
limit of normal (ULN)*
Ja
Nein
Renal failure requiring hemodialysis or peritoneal
dialysis.*
Ja
Nein
Prior history of malignancies, other than multiple
myeloma, unless the patient has been free of the
disease for ≥ 3 years. Exceptions include the
following:*
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Ja
Nein
Basalzellenkarzinom*
Ja
Nein
Plattenepithelkarzinom*
Ja
Nein
Carcinoma in situ of uterine cervix*
Ja
Nein
Stage 0 Breast Carcinoma*
Ja
Nein
Incidental histological finding of prostate cancer
(TNM stage of T1a or T1b)*
Ja
Nein
Patients who are unable or unwilling to undergo
antithrombotic therapy.*
Ja
Nein
Peripheral neuropathy of > grade 2 severity.*
Ja
Nein
Known HIV positivity or active infectious hepatitis,
type A, B, or C. Primary AL (immunoglobulin light
chain) amyloidosis and myeloma complicated by
amyloidosis.*
Ja
Nein
A variety of other types of end organ dysfunctions
can occasionally occur and lead to a need for
therapy. Such dysfunction is sufficient to support
classification as myeloma if proven to be
myeloma-related.*
Ja
Nein
A FCBP is a sexually mature woman who: 1) has
not undergone a hysterectomy or bilateral
oophorectomy or 2) has not been naturally
postmenopausal (i.e., amenorrhea following
cancer therapy does not rule out childbearing
potential) for at least 24 consecutive months (i.e.,
has had menses at any time in the preceding 24
consecutive months).*
Ja
Nein
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Eligibility NCT00688753 Carcinoma
ODM derived from
http://clinicaltrials.gov/show/NCT00688753
All rights reserved. Please visit https://medical-data-
models.org/forms/4982
Eligibility
Einschlusskriterien
Alter mindestens 18 Jahre*
Ja
Nein
Patients with metastatic papillary renal cell
carcinoma, type I or II*
Ja
Nein
Patients with at least one measurable lesion*
Ja
Nein
ECOG Status <= 1*
Ja
Nein
Adequate bone marrow function*
Ja
Nein
Adequate liver function*
Ja
Nein
Adequate renal function*
Ja
Nein
Adequate lipid profile*
Ja
Nein
Ausschlusskriterien
Patients who had radiation therapy within 28 days
prior to start of study.*
Ja
Nein
Patients who have received prior systemic
treatment for their metastatic RCC.*
Ja
Nein
Patients who received prior therapy with VEGF
pathway inhibitor.*
Ja
Nein
Patients who have previously received systemic
mTOR inhibitors.*
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Ja
Nein
Patients with a known hypersensitivity everolimus
or other rapamycins or to its excipients.*
Ja
Nein
Patients with uncontrolled central nervous system
(CNS) metastases.*
Ja
Nein
Patients receiving chronic systemic treatment
with corticosteroids or another
immunosuppressive agent.*
Ja
Nein
Patients with a known history of HIV
seropositivity.*
Ja
Nein
Autoimmune Hepatitis*
Ja
Nein
Patients with an active, bleeding diathesis.*
Ja
Nein
Patients who have any severe and/or
uncontrolled medical conditions or other
conditions that could affect their participation in
the study.*
Ja
Nein
Patients who have a history of another primary
malignancy and off treatment ≤ 3 years, with the
exception of non-melanoma skin cancer and
carcinoma in situ of the uterine cervix.*
Ja
Nein
Female patients who are pregnant or breast
feeding, or adults of reproductive potential who
are not using effective birth control methods.*
Ja
Nein
Patients who are using other investigational
agents or who had received investigational drugs
≤ 4 weeks prior to study treatment start.*
Ja
Nein
Patients unwilling to or unable to comply with the
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protocol.*
Ja
Nein
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Eligibility NCT00349076 Rectal Neoplasms
ODM derived from
http://clinicaltrials.gov/show/NCT00349076
All rights reserved. Please visit https://medical-data-
models.org/forms/4983
Eligibility
Einschlusskriterien
Alter mindestens 18 Jahre*
Ja
Nein
Histologically proven, advanced primary
carcinoma of the rectum (tumor ? 12cm from the
anal verge, with clinically staged T3/4 or any
node-positive disease*
Ja
Nein
No prior therapy except a diverting stoma*
Ja
Nein
ECOG Status <= 2*
Ja
Nein
Adequate bone marrow function: Leukocytes >
3,5 x 10^9/L Absolute neutrophil count > 1,5 x
10^9/L Platelet count > 100 x 10^9/L Hemoglobin
> 10 g/dl*
Ja
Nein
Adequate hepatic function: Total bilirubin < 2,0
mg/dl ALAT, ASAT, alkaline phosphatase,
gamma-GT < 3 x ULN 7. Serum creatinine < 1,5
mg/dl, creatinine-clearance > 50 ml/min*
Ja
Nein
Written informed consent before randomization *
Ja
Nein
Ausschlusskriterien
Pregnant or breast feeding women*
Ja
Nein
Fertile patients without adequate contraception
during therapy*
Ja
Nein
Past or ongoing drug abuse or alcoholic excess*
Ja
Nein
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frühere Chemotherapie*
Ja
Nein
Prior radiotherapy to the pelvis*
Ja
Nein
Prior (within 4 weeks) or concurrent treatment
with any other investigational agent*
Ja
Nein
Psychological, familial, sociological or
geographical condition potentially hampering
compliance with the study protocol and follow-up
schedule*
Ja
Nein
History of severe somatic or psychological
diseases: - instable cardiac disease not well
controlled with medication, myocardial infarction
within the last 6 months:* Central nervous system
disorders or psychiatric disability including
dementia or epileptic disease. * active
uncontrolled intercurrent infections or sepsis*
Ja
Nein
Peripheral neuropathy > 2 (NCI CTC AE
grading)*
Ja
Nein
Previous or concurrent malignancies, with the
exception of adequately treated basal cell
carcinoma of the skin or in situ carcinoma of the
cervix. The inclusion of patients with other
adequately treated tumors within the last 5 years
has to be discussed with the principal
investigator*
Ja
Nein
Chronic diarrhea (> NCI CTC AE-Grad 1)*
Ja
Nein
Known allergy to substances containing platinum
compounds*
Ja
Nein
Concurrent use of the antiviral agent sorivudine
or chemically related analogues*
Ja
Nein
Known deficiency of
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dehydropyrimidindehydrogenase (DPD)*
Ja
Nein
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Eligibility NCT00724022 Renal
Transplantation
ODM derived from
http://clinicaltrials.gov/show/NCT00724022
All rights reserved. Please visit https://medical-data-
models.org/forms/4984
Eligibility
Einschlusskriterien
Alter 18 bis 75 Jahre*
Ja
Nein
Post mortal kidney donation or living donation*
Ja
Nein
Primary and secondary renal transplantation,
unless the graft was lost due to severe rejection
within the first year*
Ja
Nein
PRA level <= 20%.*
Ja
Nein
AB0-compatible*
Ja
Nein
Negative crossmatch*
Ja
Nein
Patient's Signature on Informed Consent Form*
Ja
Nein
Women of child-bearing age must agree to an
efficient contraception *
Ja
Nein
Ausschlusskriterien
Third or multiple transplantation*
Ja
Nein
Transplantation per a non-heart beating donor*
Ja
Nein
HLA-identical living donation*
Ja
Nein
Incompatibility to study medication (allergy,
intolerance, hypersensitivity)*
Ja
1 / 3
Nein
Patients with existing malignant underlying
disease or tumour anamnesis < 5 years.
Exception: basaloma or squamous cell
carcinoma of the skin after successful therapy*
Ja
Nein
Female patients who do not use a safe method of
contraception*
Ja
Nein
Patients with clinically significant, uncontrolled
infectious diseases (incl. HIV) and/or severe
diarrhoea, emesis, active malabsorption of the
upper gastrointestinal tract or active peptic ulcer*
Ja
Nein
Patients currently, resp. within the last 30 days,
participating in other studies*
Ja
Nein
Primary focal-sclerosing glomerulonephritis and
membranoproliferative glomerulonephritis as an
underlying disease*
Ja
Nein
Autoimmune disease as underlying disease
(collagen diseases, colitis, HUS, SLE) which
might require chronic cortisone therapy*
Ja
Nein
Additional disease requiring temporary or chronic
cortisone therapy (including inhalation medicine)*
Ja
Nein
Chronic hepatitis B and hepatitis C infection*
Ja
Nein
Thrombopenia < 70.000/mm3 or leukopenia <
2.500/mm3 or neutropenia < 1500/ mm3.*
Ja
Nein
Patients with hepatocirrhosis Child B or C or
another severe disease of the liver*
Ja
Nein
Patients with symptoms of a significant somatic
or psychiatric / mental illness. Patients who are
not able to realize nature, relevance and
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consequences of the clinical trial and who are not
able to comply, to cooperate and communicate
adequately and to follow the instructions of the
study or even to give their informed consent
(according to § 40 article 4 and § 41 article 2 and
3 AMG).*
Ja
Nein
Patients who possibly depend on the sponsor or
the trial physician*
Ja
Nein
Patients with signs of drug abuse or alcohol
abuse*
Ja
Nein
Patients taking additional medicines with known
interactions with the immune suppressive
substances (MMF and tacrolimus) that preclude
an adequate control of the immunosuppression*
Ja
Nein
Cold ischemia time of donor kidney > 30 hours*
Ja
Nein
Schwanger oder Stillend*
Ja
Nein
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Eligibility NCT00729235 Biventricular
Tachycardias
ODM derived from
http://clinicaltrials.gov/show/NCT00729235
All rights reserved. Please visit https://medical-data-
models.org/forms/4985
Eligibility
Einschlusskriterien
Alter mindestens 18 Jahre*
Ja
Nein
Biventricular Tachycardias*
Ja
Nein
Patient has been prescribed the implantation or
replacement of a CRT-ICD system accordingly to
the relevant currently-approved ACC/AHA15
(August 2005, Appendix §  M.10) or ESC 16
(Update 2005, Appendix § M.11) guidelines or
any relevant currently-approved local guidelines
for the implantation or replacement of CRT-ICD.*
Ja
Nein
Patient's Signature on Informed Consent Form*
Ja
Nein
Ausschlusskriterien
Clinical history of symptomatic or not
symptomatic slow VT*
Ja
Nein
permanentes Vorhofflimmern*
Ja
Nein
Any contraindication to the implant or
replacement of CRT-ICD*
Ja
Nein
Pt is unable to attend the scheduled f-up visits at
the implanting Centre*
Ja
Nein
Pt is already included in another ongoing clinical
study*
Ja
Nein
Pt is unable to understand the objectives of the
ITAC04 study*
Ja
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Nein
Pt refuses to cooperate*
Ja
Nein
Pt is unable or refuses to provide informed
consent*
Ja
Nein
Minderjähriger*
Ja
Nein
Pt has life expectancy of less than 1 year*
Ja
Nein
Pt is pregnant.*
Ja
Nein
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Eligibility NCT00729703 Tachycardia
ODM derived from
http://clinicaltrials.gov/show/NCT00729703
All rights reserved. Please visit https://medical-data-
models.org/forms/4986
Eligibility
Einschlusskriterien
Alter mindestens 18 Jahre*
Ja
Nein
Patient has been prescribed the implantation for
an ICD system accordingly to the relevant
currently-approved ACC/AHA guidelines 1 or
ESC guidelines 35 or any relevant currently-
approved local guidelines for the implantation of
an ICD-system*
Ja
Nein
Impaired left ventricular function demonstrated by
a left-ventricular ejection fraction (LVEF) <= 40 %,
measured by angio-scintigraphy,
echocardiography, or contrast ventriculogram.*
Ja
Nein
An optimal (as determined by the enrolling
physician) medical regimen.*
Ja
Nein
Patient's Signature on Informed Consent Form*
Ja
Nein
Ausschlusskriterien
Any generally accepted indication for standard
cardiac pacing, or any contraindication for
standard cardiac pacing.*
Ja
Nein
Any indication for CRT accordingly to the relevant
currently-approved ACC/AHA1 or ESC35
guidelines for the implantation of a CRT system.*
Ja
Nein
Any contraindication for ICD therapy and the
implant of a dual chamber ICD.*
Ja
Nein
ICD replacement*
Ja
Nein
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Chronic atrial arrhythmias or cardioversion for
atrial fibrillation within the past month.*
Ja
Nein
A PR interval > 250 ms or AR interval > 300 ms
measured at implant.*
Ja
Nein
hypertrophe obstruktive Kardiomyopathie,
HOCM, idiopathische hypertrophe
Subaortenstenose*
Ja
Nein
akute Myokarditis, akute Herzmuskelentzündung*
Ja
Nein
Unstable coronary symptoms or myocardial
infarction within the last month.*
Ja
Nein
Recent (within the last month) or planned cardiac
revascularization or coronary angioplasty.*
Ja
Nein
Recently performed (in the last month) or
planned cardiac surgery*
Ja
Nein
Already included in another clinical study.*
Ja
Nein
Life expectancy less than 24 months.*
Ja
Nein
Inability to understand the purpose of the study or
refusal to cooperate.*
Ja
Nein
Inability or refusal to provide informed consent
and, if not part of the informed consent, a Health
Insurance Portability and Accountability Act
(HIPAA) authorization.*
Ja
Nein
Unavailability for scheduled follow-up at the
implanting or cooperating center.*
Ja
Nein
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Alter < 18 Jahre *
Ja
Nein
Schwangerschaft*
Ja
Nein
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Eligibility NCT00731289 Osteoarthritis
ODM derived from
http://clinicaltrials.gov/show/NCT00731289
All rights reserved. Please visit https://medical-data-
models.org/forms/4987
Eligibility
Einschlusskriterien
Alter 35 bis 80 Jahre*
Ja
Nein
radiographically verified degenerative
osteoarthritis of the knee (grade II or III according
to the Kellgren and Lawrence classification)*
Ja
Nein
pain of at least 40 mm on a 100 mm visual
analogue scale (VAS) at initial examination*
Ja
Nein
persisting pain for at least 6 months*
Ja
Nein
Lequesne index - knee (assessment scale)*
Ja
Nein
good physical and mental status*
Ja
Nein
good compliance and agreement to participate in
this study *
Ja
Nein
Ausschlusskriterien
non-degeneratively induced osteoarthritis*
Ja
Nein
Rheumatoide Arthritis*
Ja
Nein
ligamentous instability or complete resection of
the meniscus*
Ja
Nein
Sudeck'sche Knochenatrophie*
Ja
Nein
operations of the affected knee within the last
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three months*
Ja
Nein
varus or valgus deformity of > 15 degrees*
Ja
Nein
patellofemoral arthritis*
Ja
Nein
intraarticular therapy of the affected joint within
the last 6 months with hyaluronan and three
months with glucocorticoids*
Ja
Nein
severe systemic diseases (tumor, exacerbated
diabetes mellitus, hyperthyroidism)*
Ja
Nein
anti-thrombotic medication or regular medication
with NSAID/psychiatric pharmaceuticals*
Ja
Nein
Infektionskrankheit, übertragbare Krankheit*
Ja
Nein
Alkohol-Abusus*
Ja
Nein
Drug abuse*
Ja
Nein
psychiatric diseases or suicidal tendencies*
Ja
Nein
involvement in another study*
Ja
Nein
Non-Compliance*
Ja
Nein
acute hemarthrosis or joint effusion*
Ja
Nein
allergic predisposition*
Ja
Nein
2 / 3
Eligibility NCT00731289 Osteoarthritis
skin infections or skin diseases around the knee*
Ja
Nein
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Eligibility NCT00733343 Heart Failure
ODM derived from
http://clinicaltrials.gov/show/NCT00733343
All rights reserved. Please visit https://medical-data-
models.org/forms/4988
Eligibility
Einschlusskriterien
Alter mindestens 22 Jahre*
Ja
Nein
Chronic heart failure (at least 12 weeks since
diagnosis) according to the current applicable
guidelines (ESC, ACC/AHA)*
Ja
Nein
Left ventricular systolic dysfunction (LVEF <=
45% by imaging method such as
echocardiography, radionuclide angiography, left
ventriculography, or cardiac magnetic resonance
imaging) documented less than 12 weeks before
randomisation*
Ja
Nein
NYHA class III or IV at the time of inclusion or
NYHA class II with at least one hospitalisation for
HF in the last 24 months*
Ja
Nein
No hospitalisation for heart failure for at least 4
weeks prior to inclusion*
Ja
Nein
Optimised medical treatment according to
applicable guidelines with no new class of
disease modifying drug for more than 4 weeks
prior to randomisation. In case of no beta
blockers or ACE inhibitors/ ARB antagonists the
reasons must be documented*
Ja
Nein
SDB (AHI > 15/h with >= 50% central events and
a central AHI >= 10/h, derived from polygraphy or
polysomnography (based on total recording time
(TRT)), documented less than 4 weeks before
randomisation. Flow measurement has to be
performed with nasal cannula*
Ja
Nein
Patients for whom the use of AutoSet CS2/VPAP
Adapt may be contra-indicated because of
symptomatic hypotension or significant
intravascular volume depletion or pneumothorax
or pneumomediastinum*
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Ja
Nein
Patient is able to fully understand study
information and signed informed consent *
Ja
Nein
Ausschlusskriterien
Significant COPD with Forced Expiratory Volume
within one second (FEV1) <50% (European
Respiratory Society criteria) in the last four weeks
before randomisation*
Ja
Nein
Oxygen saturation at rest during the day <= 90%
at inclusion*
Ja
Nein
Current use of Positive Airway Pressure (PAP) -
therapy*
Ja
Nein
Life expectancy < 1 year for diseases unrelated to
chronic HF*
Ja
Nein
Cardiac surgery, Percutaneous coronary
intervention (PCI), Myocardial Infarction (MI) or
unstable angina within 6 months prior to
randomisation*
Ja
Nein
CRT-implantation or ICD-implantation scheduled
or within 6 months prior to randomisation*
Ja
Nein
Transient ischemic attack (TIA) or Stroke within 3
months prior to randomisation*
Ja
Nein
Primary hemodynamically significant uncorrected
valvular heart disease, obstructive or regurgitant,
or any valvular disease expected to lead to
surgery during the trial*
Ja
Nein
Acute myocarditis/pericarditis within 6 months
prior to randomisation*
Ja
2 / 3
Eligibility NCT00733343 Heart Failure
Nein
Untreated or therapy refractory Restless legs-
Syndrome (RLS) according to criteria listed in
Appendix IX at the time of study entry*
Ja
Nein
Schwangerschaft*
Ja
Nein
3 / 3
Eligibility NCT00733343 Heart Failure
Eligibility NCT00739986 Crohn's Disease
ODM derived from
http://clinicaltrials.gov/show/NCT00408746
All rights reserved. Please visit https://medical-data-
models.org/forms/4989
Eligibility
Einschlusskriterien
Alter bis zu 5 Jahre*
Ja
Nein
Premature Birth*
Ja
Nein
infants of the tertiary care level University
Hospital of Münster*
Ja
Nein
delivery between May 1999 and December 2008*
Ja
Nein
caucasian origin*
Ja
Nein
written informed consent by both parents *
Ja
Nein
Ausschlusskriterien
history of orotracheal intubation / orogastric tube
feeding*
Ja
Nein
Hydrocephalus*
Ja
Nein
palatal cleft, congenital syndrome, head / neck
malformation*
Ja
Nein
congenital metabolic disease beyond osteopenia
of prematurity*
Ja
Nein
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ODM derived from
http://clinicaltrials.gov/show/NCT00740103
All rights reserved. Please visit https://medical-data-
models.org/forms/4990
Eligibility
Einschlusskriterien
Alter mindestens 18 Jahre*
Ja
Nein
Crohn's Disease*
Ja
Nein
Patients satisfactorily completing study CNI-
1493-04 were eligible for participation in this
study. Satisfactory completion was defined as
follows:*
Ja
Nein
The patient met all eligibility criteria for
participation in study CNI-1493-04 or was
granted an exemption by the medical monitor for
factors indicating ineligibility*
Ja
Nein
The patient received at least 2 of the 3 planned
doses of study medication.*
Ja
Nein
The patient had no adverse event >grade 2 felt to
be possibly, probably or definitely related to study
medication.*
Ja
Nein
The patient underwent all required evaluations,
both for safety and efficacy, at baseline and day
29 and, for patients enrolling between days 43
and 57 of study CNI-1493-CD-04, at least one full
later evaluation, ie the procedures required at day
43 and/or 57.*
Ja
Nein
At baseline for study CNI-1493-CD-05, patients
were to meet the same concomitant medication
criteria as for study CNI-1493-CD-04:*
Ja
Nein
Patients receiving medications for CD were to be
on each medication for at least 8 weeks prior to
screening and on stable doses of each for at
least 2 weeks prior to baseline assessments, with
the following exceptions:*
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Ja
Nein
those on methotrexate were to be on a stable
dose for at least 4 weeks and  must not be
receiving > 25mg/week*
Ja
Nein
those on azathioprine or 6-mercaptopurine on a
stable dose for at least 10  weeks*
Ja
Nein
those on corticosteroids were to have been on
them for at least 2 weeks and  on a stable for
those 2 weeks. They were not to be receiving >
20  mg/day prednisone (or equivalent).*
Ja
Nein
those on mesazaline were to have been on for at
least 6 weeks and on a  stable dose for at least 2
weeks*
Ja
Nein
those on antibiotics for CD were to have been on
for at least 2 weeks and  on a stable dose for
those 2 weeks  *
Ja
Nein
Patients who were not using other CD
medications were to have stopped any previous
use of these agents at least 4 weeks prior to
baseline assessment for study CNI-1493-CD-05.*
Ja
Nein
Patients were required to sign informed consent
specifically for this study, in addition to the
consent for study CNI-1493-CD-04.*
Ja
Nein
Men and women of childbearing potential were to
be using a barrier method (diaphragm or
condom) of contraception and continue doing so
for at least 3 months after last study medication.
It was strongly recommended that two forms be
used.*
Ja
Nein
Patients were to be able to adhere to the study
visit schedule and/or protocol requirements.*
Ja
Nein
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Ausschlusskriterien
Only patients completing CD04 were eligible and
must not have met any of the exclusion criteria for
that study.*
Ja
Nein
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Eligibility NCT00749723 Recurrent Brain
Tumors
ODM derived from
http://clinicaltrials.gov/show/NCT00749723
All rights reserved. Please visit https://medical-data-
models.org/forms/4991
Eligibility
Einschlusskriterien
Alter 3 Monate bis 30 Jahre*
Ja
Nein
Histologically confirmed Medulloblastoma,
cerebral PNET or Ependymoma*
Ja
Nein
Refractory or relapsed disease*
Ja
Nein
Measurable disease by MRI or detection of tumor
cells in cerebrospinal fluid*
Ja
Nein
Performance status ECOG >= 3 or Karnofsky
Status >= 40%*
Ja
Nein
Life expectancy  >= 8 weeks*
Ja
Nein
Absolute leukocyte count >= 2.0 x 10^9 /l*
Ja
Nein
Hämoglobin, Hb*
Ja
Nein
Thrombozyten*
Ja
Nein
Creatinine no greater than 1.5 times UNL*
Ja
Nein
No overt renal disease *
Ja
Nein
Bilirubin < 2.5 times UNL*
Ja
Nein
AST and ALT < 5 times UNL*
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Ja
Nein
No overt hepatic disease *
Ja
Nein
No overt pulmonary disease*
Ja
Nein
No overt cardiovascular disease*
Ja
Nein
Not pregnant or nursing*
Ja
Nein
negativer Schwangerschaftstest*
Ja
Nein
Fertile patients must use effective contraception*
Ja
Nein
No uncontrolled infection prior concurrent
therapy*
Ja
Nein
> 2 weeks since prior systemic chemotherapy*
Ja
Nein
> 4 weeks since prior radiotherapy*
Ja
Nein
No other concurrent anticancer or experimental
drugs*
Ja
Nein
Examination of lumbar CSF*
Ja
Nein
Cranial and spinal MRI within 14 days prior to
start of treatment*
Ja
Nein
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Eligibility NCT00750282 Alzheimer Disease
ODM derived from
http://clinicaltrials.gov/show/NCT00750282
All rights reserved. Please visit https://medical-data-
models.org/forms/4992
Eligibility
Einschlusskriterien
Alter mindestens 55 Jahre*
Ja
Nein
Is a man or woman and is > 55 of age, whereby
females must be without  childbearing potential
(confirmed by either: age >/= 60. Or history of
hysterectomy, or last spontaneous bleeding at
least 2 years prior to the study  start)*
Ja
Nein
Has at least 6 years of education*
Ja
Nein
Is able to provide informed consent, understand
the information provided on the  purpose and
conduct of the trial and to comply with study
procedures*
Ja
Nein
Possesses a general health that permits
adequate compliance with all study  procedures*
Ja
Nein
The subject, or the subject and caregiver (for
probable AD patients) will be  compliant and have
a high probability of completing the study*
Ja
Nein
Informed consent has been signed and dated
(with time) by the subject and/or the  subject's
caregiver (for probable AD patients)*
Ja
Nein
Healthy Subject*
Ja
Nein
Has no evidence of cognitive impairment*
Ja
Nein
Has MRI brain scan that has been judged as
normal (age-appropriate)*
Ja
Nein
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Alzheimer'sche Krankheit, präsenile Demenz*
Ja
Nein
Presents with positive assessment for dementia
of Alzheimer's type*
Ja
Nein
Does not fulfill the criteria DLB or VaD*
Ja
Nein
MRI brain scan findings that do not reveal
changes indicative of stroke and/or  generalized
cerebrovascular disease*
Ja
Nein
Has a caregiver that is willing and able to attend
all study visits and perform  the psychometric
tests requiring the presence of a caregiver *
Ja
Nein
Ausschlusskriterien
Has any contraindication to MRI examination
scan*
Ja
Nein
Is scheduled for surgery and/or another invasive
procedure within the time period of up to 24
hours following IMP application*
Ja
Nein
Is allergic to the IMP or any of its constituents
and/or has a history of severe allergic reactions
to drugs or allergens (e.g. patients / volunteers
with allergic asthma)*
Ja
Nein
is critically ill and/or medically unstable and
whose clinical course during the observation
period is unpredictable*
Ja
Nein
Has a history of exposure to any radiation >15
mSv/year (e.g. occupational or radiation therapy)*
Ja
Nein
Is receiving drug therapy or other treatment that
is known to lead to greatly fluctuating values of
the hematological or chemical laboratory
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parameters or to severe side effects (e.g.
chemotherapy)*
Ja
Nein
Has been previously enrolled in this study or
participated in a clinical study involving an
investigational pharmaceutical product within 30
days prior to screening, and/or any
radiopharmaceutical*
Ja
Nein
Has a brain tumor or other intracranial lesion, a
disturbance of CSF circulation (e.g., normal
pressure hydrocephalus) and/or a history of head
trauma or brain surgery*
Ja
Nein
Has an inflammatory or infectious CNS disease,
e.g. multiple sclerosis, HIV, syphilis, or
Creutzfeldt-Jacob disease*
Ja
Nein
Has a history, physical, laboratory or imaging
findings indicative of a neurological or psychiatric
illness*
Ja
Nein
Has another disease that can cause disturbance
of brain function (e.g. vitamin B12 or folic acid
deficiency, disturbed thyroid function)*
Ja
Nein
Has a history of alcohol or drug abuse*
Ja
Nein
Has history of severe persistent depression*
Ja
Nein
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Eligibility NCT00750282 Alzheimer Disease
Eligibility NCT00752388 Parkinson Disease
ODM derived from
http://clinicaltrials.gov/show/NCT00752388
All rights reserved. Please visit https://medical-data-
models.org/forms/4993
Eligibility
Einschlusskriterien
Alter mindestens 30 Jahre*
Ja
Nein
PD patients attending one of the participating
neurologist practices during 2 fixed weeks in
November 2008*
Ja
Nein
Idiopathic PD with or without fluctuations*
Ja
Nein
Male or female PD patients aged at least 30*
Ja
Nein
Ability to reliably complete self-rating scales
(WHO-5, MDI) ), according to the physician's
judgement.*
Ja
Nein
Written informed consent by the patient for study
participation.*
Ja
Nein
Ausschlusskriterien
PD Patients who only attend the practice to get a
prescription and are not seen by the doctor on
that day*
Ja
Nein
Patients who are not able to understand the
questionnaires (e.g. due to mental impairment or
language problems).*
Ja
Nein
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Eligibility NCT00757523 Acne Vulgaris
ODM derived from
http://clinicaltrials.gov/show/NCT00757523
All rights reserved. Please visit https://medical-data-
models.org/forms/4994
Eligibility
Einschlusskriterien
Alter 12 bis 45 Jahre*
Ja
Nein
Males or females 12 to 45 years of age, inclusive,
in good general health.*
Ja
Nein
Clinical diagnosis of acne vulgaris*
Ja
Nein
Capable of understanding and willing to provide
signed and dated written voluntary informed
consent*
Ja
Nein
Female subjects of childbearing potential must
have a negative pregnancy test at baseline.
Sexually active women of childbearing potential
participating in the study must use a medically
acceptable form of contraception*
Ja
Nein
Subjects who have been treated with estrogens,
androgens, or anti-androgenic agents for more
than 12 consecutive weeks prior to the first dose
of study product are allowed to enroll as long as
they do not expect to change dose, drug, or
discontinue use during the study.*
Ja
Nein
The ability and willingness to follow all study
procedures, attend all scheduled visits, and
successfully complete the study. *
Ja
Nein
Ausschlusskriterien
Female subjects who are pregnant, trying to
become pregnant, or who are lactating.*
Ja
Nein
Any clinically relevant finding at their baseline
physical examination or medical history such as
severe systemic diseases or diseases of the
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facial skin other than acne vulgaris.*
Ja
Nein
Facial hair that may obscure the accurate
assessment of acne grade.*
Ja
Nein
History or presence of regional enteritis or
inflammatory bowel disease (eg, ulcerative colitis,
pseudomembranous colitis, chronic diarrhea, or a
history of antibiotic-associated colitis) or similar
symptoms.*
Ja
Nein
Used topical antibiotics on the face or systemic
antibiotics within the past 2 and 4 weeks,
respectively.*
Ja
Nein
Used topical corticosteroids on the face or
systemic corticosteroids within the past 4 weeks.
Use of inhaled, intra articular or intra-lesional
(other than for facial acne lesions) steroids is
acceptable.*
Ja
Nein
Used systemic retinoids within the past 6
months.*
Ja
Nein
Using drugs known to be photosensitizers (eg,
thiazides, tetracyclines, fluoroquinolones,
phenothiazines, sulfonamides) because of the
possibility of increased phototoxicity.*
Ja
Nein
Using neuromuscular blocking agents.
Clindamycin has neuromuscular blocking
activities, which may enhance the action of other
neuromuscular blocking agents.*
Ja
Nein
Used topical anti-acne medications (eg, BPO,
retinoids, azelaic acid, resorcinol, salicylates,
sulfacetamide sodium and derivatives, glycolic
acid) within the past 2 weeks.*
Ja
Nein
Used any investigational therapy within 4 weeks
of study day 1.*
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Eligibility NCT00757523 Acne Vulgaris
Ja
Nein
Using the following types of facial products:
astringents, toners, abradants, facials, peels
containing glycolic or other acids, masks, washes
or soaps containing BPO, sulfacetamide sodium
or salicylic acid, non-mild facial cleansers, or
moisturizers that contain retinol, salicylic acid, or
alpha- or beta-hydroxy acids.*
Ja
Nein
Using medications that are reported to
exacerbate acne (eg, mega-doses of certain
vitamins such as vitamin D, vitamin A, and
vitamins B2, B6, and B12, haloperidol, halogens
such as iodide and bromide, lithium, hydantoin,
and phenobarbital) as these may impact efficacy
assessments*
Ja
Nein
Have had a facial procedure (chemical or laser
peel, microdermabrasion, artificial ultraviolet [UV]
therapy) performed by an esthetician, beautician,
physician, nurse, or other practitioner, within the
past 4 weeks.*
Ja
Nein
Have a known hypersensitivity or previous allergic
reaction to any of the active components,
lincomycin, adapalene, clindamycin, BPO, or
excipients of the study medication.*
Ja
Nein
Employees of a clinical research organization
involved in the study, or Stiefel Laboratories, or
an immediate family member (partner, offspring,
parents, siblings, or sibling's offspring) of an
employee.*
Ja
Nein
Have a member of the same household in this
trial.*
Ja
Nein
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Eligibility NCT00757523 Acne Vulgaris
Eligibility NCT00761280 Anaplastic
Astrocytoma
ODM derived from
http://clinicaltrials.gov/show/NCT00761280
All rights reserved. Please visit https://medical-data-
models.org/forms/4995
Eligibility
Einschlusskriterien
Alter 18 bis 70 Jahre*
Ja
Nein
The patient has provided written informed
consent prior to any study-related procedure.*
Ja
Nein
The patient has a present diagnosis of AA or
secondary GBM.*
Ja
Nein
The patient has a measurable lesion (> 1 ccm in
volume, central MRI review).*
Ja
Nein
The lesion (or sum of lesions) does not exceed
50 ccm in volume (central MRI review).*
Ja
Nein
The tumor is localized supratentorially (central
MRI review).*
Ja
Nein
All patients have recurrent or refractory disease,
i.e. disease has progressed after prior surgery
and radiotherapy at any time of the disease
course or stage. Secondary GBM patients have
progressed after a previous diagnosis of A and/or
AA.*
Ja
Nein
The patient has not received more than one
chemotherapy regimen. Radiation with
concomitant chemotherapy, followed by adjuvant
chemotherapy, is considered as one
chemotherapy regimen.*
Ja
Nein
The patient is eligible for chemotherapy.*
Ja
Nein
The patient is on a maximum dose of 4 mg/day
dexamethasone or equivalent doses for other
corticosteroids, which has been stable or
decreasing for at least 3 weeks prior to
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Screening.*
Ja
Nein
The patient is male or a non-pregnant, non-
lactating female.*
Ja
Nein
Females of childbearing potential must have a
negative beta-HCG pregnancy test at Screening.*
Ja
Nein
Females of childbearing potential and males must
practice strict birth control.*
Ja
Nein
The patient must have recovered from acute
toxicity caused by any previous therapy.*
Ja
Nein
The patient has a life expectancy of at least 3
months.*
Ja
Nein
Karnofsky performance status (assessment
scale)*
Ja
Nein
The patient shows adequate organ functions as
assessed by the following screening laboratory
values: *
Ja
Nein
Adequate renal function determined by serum
creatinine and urea < 2 times the upper limit of
normal*
Ja
Nein
Adequate liver function with ALT, AST and AP < 3
times the upper limit of normal, and bilirubin < 2.5
mg/dL*
Ja
Nein
INR < 1.5 and aPTT < 1.5 x ULN*
Ja
Nein
Hämoglobin*
Ja
Nein
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Eligibility NCT00761280 Anaplastic Astrocytoma
Thrombozyten*
Ja
Nein
Leukozyten-Anzahl*
Ja
Nein
ANC > 1.5 x 10E9/L (or WBC > 3.0 x 10E9/L)*
Ja
Nein
Ausschlusskriterien
Patient unable or not willing to comply with the
protocol regulations.*
Ja
Nein
The investigator deems it necessary to surgically
(re-)resect the present tumor (NOTE: the patient
might still be eligible for randomization at a later
timepoint).*
Ja
Nein
Tumor surgery, tumor debulking, or other
neurosurgery within 3 months prior to
randomization. If a <=48-hour routine post-
surgery MRI (in accordance with study
specifications) qualifies the patient for study
participation, the patient can be randomized 30 ±
7 days post-surgery.*
Ja
Nein
Radiotherapy or stereotactic (gamma knife)
radiosurgery within 3 months prior to
randomization.*
Ja
Nein
Prior interstitial brachytherapy of the brain with
permanent implants. Prior interstitial
brachytherapy of the brain with removable
implants within 3 months prior to randomization.*
Ja
Nein
Chemotherapy, hormone therapy, or any other
therapy with established or suggested anti-tumor
effects within 4 weeks (nitrosoureas: 6 weeks)
prior to randomization.*
Ja
Nein
Prior anti-TGF-beta 2 targeted therapy.*
Ja
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Eligibility NCT00761280 Anaplastic Astrocytoma
Nein
Screening MRI shows a mass effect caused by
the tumor defined as significant compression of
the ventricular system and/or a midline shift (>= 3
mm, central MRI review). Compression of the
ventricular system and/or a midline shift >= 3 mm
only due to the presence of (a) cyst(s) or scarring
processes does not exclude an individual from
the study.*
Ja
Nein
Participation in another clinical study with another
investigational medicinal product within 30 days
prior to randomization.*
Ja
Nein
History of a second independent malignant
disorder within 5 years, except for carcinoma in
situ of the cervix and basal cell carcinoma.*
Ja
Nein
Seizures, poorly controlled*
Ja
Nein
Clinically relevant cardiovascular abnormalities
such as uncontrolled hypertension, congestive
heart failure, unstable angina, or poorly controlled
arrhythmia. Myocardial infarction within 6 months
prior to randomization.*
Ja
Nein
Known HIV, HBV or HCV infection.*
Ja
Nein
Acute viral, bacterial, or fungal infection.*
Ja
Nein
Acute medical problems that may be considered
to become an unacceptable risk, or any
conditions, which might be contraindications for
starting study treatment.*
Ja
Nein
Presence of high risk for pulmonary toxicities,
defined as:*
Ja
Nein
Lung function: vital capacity ≤ 70%*
Ja
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Eligibility NCT00761280 Anaplastic Astrocytoma
Nein
Status following sequential or concomitant
thoracic irradiation*
Ja
Nein
Increased risk for a pulmonary toxicity induced by
BCNU (Carmustine) or CCNU (Lomustine). Risk
factors include smoking, presence of a
respiratory condition, pre-existing radiographic
pulmonary abnormalities, exposure to agents that
cause lung damage.*
Ja
Nein
History of allergies to reagents used in this
study.*
Ja
Nein
Drug abuse or extensive use of alcohol.*
Ja
Nein
Clinically relevant psychiatric disorders / legal
incapacity or a limited legal capacity.*
Ja
Nein
Concomitant treatment with yellow fever vaccine.*
Ja
Nein
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Eligibility NCT00761280 Anaplastic Astrocytoma
Eligibility NCT00766779 Acute Myeloid
Leukemia
ODM derived from
http://clinicaltrials.gov/show/NCT00766779
All rights reserved. Please visit https://medical-data-
models.org/forms/4996
Eligibility
Einschlusskriterien
Alter 60 bis 75 Jahre*
Ja
Nein
primary or secondary AML as defined by WHO or
refractory anemia with excess of blasts (RAEB)*
Ja
Nein
First complete remission following one or two
cycles of induction chemotherapy*
Ja
Nein
Chemotherapy was administered according to
current participating cooperative group protocols*
Ja
Nein
Karnofsky performance status (assessment
scale)*
Ja
Nein
Written informed consent *
Ja
Nein
Ausschlusskriterien
AML FAB M3*
Ja
Nein
HIV-positiv*
Ja
Nein
Participation in another clinical trial without prior
consent of the coordinating investigator, patients
may exceptionally take part in a further study only
if*
Ja
Nein
The second study exclusively concerns induction
therapy*
Ja
Nein
Consolidation cycle one and two are given
according to the accredited study  group policy*
Ja
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Nein
No investigational drugs are used post
registration for the HCT vs CT in elderly  AML
study.*
Ja
Nein
Documentation for the HCT vs CT in elderly AML
study is not compromised. Second  hand data
from foreign study is not accepted*
Ja
Nein
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Eligibility NCT00766779 Acute Myeloid Leukemia
Eligibility NCT00770445 Diabetes Mellitus
ODM derived from
http://clinicaltrials.gov/show/NCT00770445
All rights reserved. Please visit https://medical-data-
models.org/forms/4997
Eligibility
Einschlusskriterien
Alter 30 bis 75 Jahre*
Ja
Nein
Has Diabetes Mellitus type 2.*
Ja
Nein
glykosyliertes Hämoglobin*
Ja
Nein
Treatment with the following insulins with or
without Oral Antidiabetic Therapy since 3
months:*
Ja
Nein
Long acting basal insulin analogs*
Ja
Nein
NPH-Insulin*
Ja
Nein
Combination insulin with 1-2 daily doses except
intensified insulin therapies.*
Ja
Nein
BMI*
Ja
Nein
Females of childbearing potential who are
sexually active must agree to use adequate
contraception, and can neither be pregnant nor
lactating from Screening throughout the duration
of the study. *
Ja
Nein
Ausschlusskriterien
Has a history of type 1 diabetes mellitus.*
Ja
Nein
Has uncontrolled hypertension (systolic blood
pressure > 160mmHg and/or diastolic blood
pressure > 95mmHg) or change of
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antihypertensive treatment within the last 2
weeks.*
Ja
Nein
Acute infection*
Ja
Nein
Has anamnestic history of hypersensitivity to the
study drugs or to drugs with similar chemical
structure.*
Ja
Nein
Has a history of severe or multiple allergies.*
Ja
Nein
History of drug or alcohol abuse in the past 5
years*
Ja
Nein
A history of significant cardiovascular (New York
Heart Association stage I - IV), respiratory,
gastrointestinal, hepatic (Alanine
Aminotransferase and/or Aspartate
Aminotransferase > 2.5 times the upper limit of
the normal reference range), renal (serum
creatinine > 1.2 mg/dL in women and > 1.5
mg/dL in men, Glomerular Filtration Rate < 60
ml/min as estimated by the Cockroft-Gault
formula), neurological, psychiatric and/or
hematological disease as judged by the
investigator*
Ja
Nein
History of macular edema.*
Ja
Nein
State after kidney transplantation.*
Ja
Nein
Serumkalium*
Ja
Nein
History of primary hyperaldosteronism.*
Ja
Nein
Acute myocardial infarction, open heart surgery
or cerebral event (stroke/ Transitory Ischemic
Attack) within the previous 12 months.*
Ja
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Eligibility NCT00770445 Diabetes Mellitus
Nein
Is required to take or intends to continue taking
any disallowed medication, any prescription
medication, herbal treatment or over-the counter
medication that may interfere with evaluation of
the study medication, including:*
Ja
Nein
Pre-treatment with gemfibrozil within the last 12
weeks.*
Ja
Nein
Pre-treatment with rifampicin within the last 12
weeks.*
Ja
Nein
Treatment with thiazolidinediones within the past
3 months.*
Ja
Nein
If statin therapy applicable: Change of medication
within the last 4 weeks.*
Ja
Nein
Has used non-steroidal anti-inflammatory agents
including low dose ASA or  Cox-2-inhibitors if
therapy has been initiated within the last 4
weeks.*
Ja
Nein
Treatment with any other investigational drug
within 4 weeks before trial entry.*
Ja
Nein
Any elective surgery during study participation.*
Ja
Nein
Have had more than one unexplained episode of
severe hypoglycemia (defined as requiring
assistance of another person due to disabling
hypoglycemia) within 6 months prior to screening
visit.*
Ja
Nein
History of dehydration, precoma diabeticorum or
shock or diabetic ketoacidosis within the past
year prior to screening visit.*
Ja
Nein
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Eligibility NCT00770445 Diabetes Mellitus
Acute or scheduled investigation with iodine
containing radiopaque material.*
Ja
Nein
Uncontrolled unstable angina pectoris.*
Ja
Nein
Medical history of acute and clinically relevant
pericarditis, myocarditis, endocarditis, recent
pulmonary embolism, hemodynamic relevant
aortic stenosis, aortic aneurysm.*
Ja
Nein
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Eligibility NCT00770445 Diabetes Mellitus
Eligibility NCT00770653 Diabetes Mellitus
ODM derived from
http://clinicaltrials.gov/show/NCT00770653
All rights reserved. Please visit https://medical-data-
models.org/forms/4998
Eligibility
Einschlusskriterien
Alter 18 bis 75 Jahre*
Ja
Nein
Type 2 diabetes according to the American
Diabetes Association Criteria.*
Ja
Nein
Treatment with individual maximal tolerated dose
of metformin (850 - 2000 mg) as monotherapy
within the last 12 weeks*
Ja
Nein
glykosyliertes Hämoglobin*
Ja
Nein
Dyslipidemia defined as high-density lipoprotein
cholesterol <= 1.03 mmol/l (40 mg/dL) and/or
triglycerides >= 1.7 mmol/l (150 mg/dL).*
Ja
Nein
Females of childbearing potential who are
sexually active must agree to use adequate
contraception, and can neither be pregnant nor
lactating from Screening throughout the duration
of the study. *
Ja
Nein
Ausschlusskriterien
Diabetes mellitus Typ 1*
Ja
Nein
insulinpflichtiger Diabetes mellitus Typ 2*
Ja
Nein
Treatment or history of treatment with any insulin
formulation other than emergency for more than 2
weeks.*
Ja
Nein
Treatment with other oral antidiabetic drugs in
addition to metformin within the last 12 weeks.*
Ja
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Nein
Anamnestic history of hypersensitivity to the
study drugs or to drugs with similar chemical
structures.*
Ja
Nein
Is required to take or intends to continue taking
any disallowed medication, any prescription
medication, herbal treatment or over-the counter
medication that may interfere with evaluation of
the study medication, including:*
Ja
Nein
Heparin (and heparin-like drugs)*
Ja
Nein
Cumarin, Kumarin*
Ja
Nein
Phenprocoumon*
Ja
Nein
Hirudin*
Ja
Nein
Protein C*
Ja
Nein
Fondaparinux*
Ja
Nein
Antithrombin III*
Ja
Nein
Peroxisome Proliferation Activating Receptor
(gamma) agonists*
Ja
Nein
Treatment within the last 12 weeks with:*
Ja
Nein
Fibrate*
Ja
Nein
Gemfibrozil*
Ja
Nein
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Eligibility NCT00770653 Diabetes Mellitus
Niacin, Niazin, Nicotinsäure*
Ja
Nein
Rifampicin*
Ja
Nein
Changes in dosage of any statin treatment to
lower low-density lipoprotein  within 2 weeks
before study entry and during study participation
interval.*
Ja
Nein
Changes in dosage of any anticoagulant
treatment with acetyl salicylic acid  and/or
clopidogrel within 2 weeks before study entry and
during study  participation interval.*
Ja
Nein
Start of statin and/or anticoagulant treatment
during study participation  interval.*
Ja
Nein
History of severe or multiple allergies and/ or
acute severe infections.*
Ja
Nein
Have had more than one unexplained episode of
severe hypoglycemia (defined as requiring
assistance of another person due to disabling
hypoglycemia) within 6 months prior to screening
visit.*
Ja
Nein
Progressive fatal disease.*
Ja
Nein
Any elective surgery during study participation.*
Ja
Nein
History of drug or alcohol abuse within the last 5
years.*
Ja
Nein
A history of significant cardiovascular (New York
Heart Association stage I - IV), respiratory,
gastrointestinal, hepatic (alanine
aminotransferase and/or aspartate
aminotransferase greater than 2.5 times the
upper limit of the normal reference range), renal
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(serum creatinine > 1.2 mg/dL in women and >
1.5 mg/dL in men, glomerular filtration rate < 60
ml/min as estimated by the Cockroft-Gault
formula), neurological, psychiatric and/or
hematological disease as judged by the
investigator, history of macular edema.*
Ja
Nein
Blood donation within the last 30 days.*
Ja
Nein
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Eligibility NCT00770653 Diabetes Mellitus
Eligibility NCT00777127 Actinic Keratosis
ODM derived from
http://clinicaltrials.gov/show/NCT00777127
All rights reserved. Please visit https://medical-data-
models.org/forms/4999
Eligibility
Einschlusskriterien
Alter mindestens 18 Jahre*
Ja
Nein
immunkompetent*
Ja
Nein
A study treatment area must be identifiable:
Minimum of 5 and maximum of 10 typical visible
AKs in one contiguous area of up to 50 cm2 on
the face or scalp. The eyelids, the inside of the
nostrils or ears, or the lip area inside the
vermilion border must not be part of this area.*
Ja
Nein
A positive histological finding for AK grade I or II
(see Section 7.1.1.2). This will be determined
from the most suspicious lesion in the STA and
there from the most pathological area biopsied
during screening visit. This analysis will be done
by the central histopathological laboratory.*
Ja
Nein
Willingness to comply with the obligations of the
study. *
Ja
Nein
Ausschlusskriterien
History of allergic reaction to imiquimod,
diclofenac, acetyl salicylic acid, other non
steroidal anti-inflammatory drugs (NSAID),
hyaluronic acid, or relevant excipients.*
Ja
Nein
Pregnancy, breast-feeding or planned pregnancy
during the study. Women of child bearing
potential not using a highly effective method of
birth control defined as those which result in a
low failure rate (i.e. <1% per year) when used
consistently and correctly such as implants,
injectables, combined oral contraceptives,
hormonal IUDs, tubal ligation or vasectomised
partner.*
Ja
Nein
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Presence of AK lesions in the STA with clinically
marked hyperkeratosis or hypertrophy as seen in
cutaneous horns.*
Ja
Nein
Any topical AK treatment including imiquimod or
diclofenac, or any systemic AK treatment such as
systemic retinoids, or any surgical AK treatment
at the STA within the last 2 months prior to
randomisation.*
Ja
Nein
Persisting AK lesion at screening visit following
topical treatment with imiquimod or diclofenac in
the STA.*
Ja
Nein
Topical treatment with imiquimod or diclofenac
anywhere else on the body within the last 2
months prior to randomisation.*
Ja
Nein
Presence of any histologically confirmed skin
tumour in the STA: in situ SCC including Bowen's
disease, invasive SCC, basal cell carcinoma, or
other malignant tumours.*
Ja
Nein
Any dermatological disease or condition that may
exacerbate by treatment with imiquimod or
diclofenac (e.g. rosacea, psoriasis, atopic
dermatitis).*
Ja
Nein
Any dermatological disease or condition in the
STA that causes difficulty with examination (e.g.
eczema).*
Ja
Nein
Systemic immunomodulatory treatment such as
interferon, azathioprine, cyclosporine, retinoids,
any oral or injectable corticosteroids, or inhaled
or nasal corticosteroids with dosages of >1200
µg/day beclomethasone or equivalent within 4
weeks before start of study treatment.*
Ja
Nein
History of any malignant tumour with high tumour
burden or any systemic antitumour treatment
(incl. radiotherapy).*
Ja
Nein
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History of any malignant skin tumour having
metastasised or where metastasis could be
expected.*
Ja
Nein
History of severe cardiovascular, pulmonary,
hepatic, renal, gastrointestinal, haematological,
endocrine, metabolic, mental, neurological, or
other disease within the last two years.*
Ja
Nein
geistig behindert*
Ja
Nein
Present or history of drug or alcohol abuse within
the last 3 years.*
Ja
Nein
Exposure to an investigational product within the
last 3 months.*
Ja
Nein
Lack of ability or willingness to give informed
consent.*
Ja
Nein
Alter unter 18 Jahre*
Ja
Nein
Lack of willingness to have personal study related
data collected, archived or transmitted according
to protocol.*
Ja
Nein
Anticipated non-availability for study
visits/procedures.*
Ja
Nein
Vulnerable subjects (such as persons kept in
detention).*
Ja
Nein
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Eligibility NCT00777998 Multiple Myeloma
ODM derived from
http://clinicaltrials.gov/show/NCT00408746
All rights reserved. Please visit https://medical-data-
models.org/forms/5000
Eligibility
Einschlusskriterien
Alter bis zu 5 Jahre*
Ja
Nein
Premature Birth*
Ja
Nein
infants of the tertiary care level University
Hospital of Münster*
Ja
Nein
delivery between May 1999 and December 2008*
Ja
Nein
caucasian origin*
Ja
Nein
written informed consent by both parents *
Ja
Nein
Ausschlusskriterien
history of orotracheal intubation / orogastric tube
feeding*
Ja
Nein
Hydrocephalus*
Ja
Nein
palatal cleft, congenital syndrome, head / neck
malformation*
Ja
Nein
congenital metabolic disease beyond osteopenia
of prematurity*
Ja
Nein
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Eligibility NCT00787683 Ventricular
Arrhythmia
ODM derived from
http://clinicaltrials.gov/show/NCT00787683
All rights reserved. Please visit https://medical-data-
models.org/forms/5001
Eligibility
Einschlusskriterien
Alter 18 bis 80 Jahre*
Ja
Nein
Ventricular Arrhythmia*
Ja
Nein
The patient is willing/able to undergo the study
protocol appointments and
procedures/questionnaires*
Ja
Nein
Indication for implantation of single chamber ICD
or dual chamber ICD according to European
guidelines *
Ja
Nein
Ausschlusskriterien
Alter < 18 und > 80 Jahre*
Ja
Nein
Expected non-compliance*
Ja
Nein
Known drug or alcohol abuse*
Ja
Nein
Life expectancy < 1 year*
Ja
Nein
New York Heart Association Class IV*
Ja
Nein
Participation in another clinical study*
Ja
Nein
Participation in another telemonitoring concept*
Ja
Nein
Pregnant or breast-feeding woman*
Ja
Nein
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Uncontrolled hypertension*
Ja
Nein
No mobile phone use possible in patient
residence*
Ja
Nein
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Eligibility NCT00787683 Ventricular Arrhythmia
Eligibility NCT00796354 Constipation
ODM derived from
http://clinicaltrials.gov/show/NCT00796354
All rights reserved. Please visit https://medical-data-
models.org/forms/5002
Eligibility
Einschlusskriterien
Alter 18 bis 80 Jahre*
Ja
Nein
Written informed consent obtained.*
Ja
Nein
Females of child-bearing potential must employ
an adequate method of contraception and must
undergo a pregnancy test at Randomisation
Visit.*
Ja
Nein
Willing, able and competent to complete the
entire study and comply with study instructions.*
Ja
Nein
Patients > 50 years old have to have undergone a
colonoscopy or computerised tomography (CT)
after the onset of their IBS-C symptoms or within
the last 5 years.*
Ja
Nein
Patient has diagnosed IBS-C using Rome III
criteria for the last 3 months, with symptom onset
at least 6 months prior to diagnosis. *
Ja
Nein
Ausschlusskriterien
History or evidence of organic disease in the
large bowel, intestinal perforation or obstruction
due to structural or functional disorder of the gut
wall, ileus, severe inflammatory conditions of the
intestinal tract such as Crohn's disease,
complicated diverticulitis, ulcerative colitis, toxic
megacolon and occlusive or subocclusive
syndrome.*
Ja
Nein
Abdominal pain of unknown cause, not related to
IBS.*
Ja
Nein
History of - major abdominal surgery*
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Ja
Nein
IBS subtype other than IBS-C.*
Ja
Nein
Known allergy to polyethylene glycol (PEG) 3350
or known hypersensitivity to any of the active
substances.*
Ja
Nein
Laxative, drug or alcohol abuse (recent history or
within previous 12 months).*
Ja
Nein
Pregnant or lactating females.*
Ja
Nein
Severe or acute disease within 2 weeks prior to
the start of the study.*
Ja
Nein
Patients with type I or II diabetes.*
Ja
Nein
Use of other investigational drugs, prescribed or
OTC medications affecting gastrointestinal
function such as anticholinergics, prokinetics,
drugs affecting motility, anthraquinones,
opioids,ondansetron or other 5-HT3 antagonists.*
Ja
Nein
Incomplete Patient Diary Card during the run-in
period.*
Ja
Nein
The occurrence of diarrhoea during the run-in
period.*
Ja
Nein
Patients with abnormal laboratory tests,
proctoscopy /abdominal ultrasound, colonoscopy,
sigmoidoscopy or CT that requires further
investigation.*
Ja
Nein
Patients with any condition, which, in the
Investigator's may put the patient at significant
risk, may confound the study results, or may
interfere significantly with the results of the
study.*
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Eligibility NCT00796354 Constipation
Ja
Nein
Participation in another clinical study of drugs or
devices parallel to or less than 1 month before
study entry, or previous participation in this
study.*
Ja
Nein
Employees of the Investigator or study site with
direct involvement in the proposed study or other
studies under the direction of that Investigator or
study site, as well as family members of the
employees or the Investigator.*
Ja
Nein
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Eligibility NCT00796354 Constipation
Eligibility NCT00803309 Hepatitis C,
Chronic
Chronic Hepatitis C: Optimization of Treatment for Patients
infected With HCV-genotype 2 or 3: 12 vs. 24 Weeks of
Treatment Extension for Patients Without Rapid Virological
Response
see http://clinicaltrials.gov/show/NCT00803309
All rights reserved. Please visit https://medical-data-
models.org/forms/5003
Eligibility Hepatitis C NCT00803309
Einschlusskriterien
Alter mindestens 18 Jahre*
Ja
Nein
Male and female patients with HCV-genotype 2/3
chronic hepatitis C documented by detectable
plasma HCV RNA (> 15 IU/mL) and positivity of
anti-HCV antibodies*
Ja
Nein
Compensated liver disease (Child-Pugh Grade A
clinical classification)*
Ja
Nein
Negative urine or blood pregnancy test (one of
the both, for women of childbearing potential)
documented within the 24-hour period prior to the
first dose of study drug. Additionally, all fertile
males and females must be using two forms of
effective contraception during treatment and
during the 7 months after treatment end. This
includes using birth control pills (no interaction
with investigational drugs), IUDs, condoms,
diaphragms, or implants, being surgically
sterilized, or being in a post-menopausal state. At
least one contraception method must be of
barrier method*
Ja
Nein
Ongoing treatment with 1.5 µg/kg Peg-Interferon
alpha-2b (PegIntron) and > 10.6 mg/kg ribavirin
(Rebetol)*
Ja
Nein
No rapid virological response (HCV-RNA positive
after week 4 of the ongoing therapy)*
Ja
Nein
Willingness to give written informed consent and
willingness to participate to and to comply with
the study protocol *
Ja
Nein
Ausschlusskriterien
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Women with ongoing pregnancy or breast
feeding*
Ja
Nein
Male partners of women who are pregnant*
Ja
Nein
Positive tests at screening for anti-HAV IgM Ab,
HBsAg, anti-HBc IgM Ab, HBeAg, anti-HIV, HIV-
RNA*
Ja
Nein
History or other evidence of a medical condition
associated with chronic liver disease other than
HCV associated (e.g., hemochromatosis,
autoimmune hepatitis, alcoholic liver disease,
toxin exposures)*
Ja
Nein
History or other evidence of bleeding from
esophageal varices or other conditions consistent
with decompensated liver disease*
Ja
Nein
Patients with liver cirrhosis with a lesion
suspicious for hepatic malignancy on the
screening*
Ja
Nein
Absolute neutrophil count (ANC) <750 cells/mm3
at screening*
Ja
Nein
Platelet count <50,000 cells/mm3 at screening*
Ja
Nein
Hb <10 g/dl at screening*
Ja
Nein
Dose modification of Peg-Interferon alpha-2b
(PegIntron) or ribavirin (Rebetol) during the first 4
weeks of the ongoing therapy*
Ja
Nein
Interferon alpha or ribavirin therapy at any time
point before the actual ongoing treatment*
Ja
Nein
< 80% adherence to treatment of the ongoing
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treatment until randomization (week 20-22 of
ongoing treatment)*
Ja
Nein
Serum creatinine level >1.5 times the upper limit
of normal at screening*
Ja
Nein
History of severe psychiatric disease, especially
depression (ICD 10 codes F30-F33). Severe
psychiatric disease is defined as treatment with
an antidepressant medication or a major
tranquilizer at therapeutic doses for major
depression or psychosis, respectively, for at least
3 months at any previous time. Patients are
excluded if any history of suicidal attempts is
evident. If hospitalization for psychiatric disease,
or a period of disability due to a psychiatric
disease are documented, psychiatric consultation
is mandatory. Patients with a mild or moderate
psychiatric disease (ICD 10 codes F32.0, F32.1,
F33.0, F33.1) are only allowed to be included into
the trial if a regular monitoring by a psychiatrist is
performed during the trial*
Ja
Nein
History of a severe seizure disorder or current
anticonvulsant use*
Ja
Nein
History of immunologically mediated disease
(e.g., inflammatory bowel disease, idiopathic
thrombocytopenic purpura, lupus erythematosus,
autoimmune hemolytic anemia, scleroderma,
severe psoriasis, rheumatoid arthritis)*
Ja
Nein
History or any other evidence of autoimmune
diseases*
Ja
Nein
History or other evidence of chronic pulmonary
disease associated with functional limitation*
Ja
Nein
History of significant cardiac disease that could
be worsened by acute anemia (e.g. NYHA
Functional Class III or IV, myocardial infarction
within 6 months prior to treatment with Peg-
Interferon/ribavirin therapy, ventricular
tachyarrhythmias requiring ongoing treatment,
unstable angina)*
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Ja
Nein
Evidence of thyroid disease that is poorly
controlled on prescribed medications*
Ja
Nein
Evidence of severe retinopathy (e.g. CMV
retinitis, macular degeneration)*
Ja
Nein
History of major organ transplantation with an
existing functional graft*
Ja
Nein
History or other evidence of severe illness,
malignancy or any other conditions which would
make the patient, in the opinion of the
investigator, unsuitable for the study*
Ja
Nein
History of any systemic anti-neoplastic or
immunomodulatory treatment (including
supraphysiologic doses of steroids and radiation)
6 months prior to the first dose of study drug or
the expectation that such treatment will be
needed at any time during the study*
Ja
Nein
Patients with evidence for tuberculosis*
Ja
Nein
Drug abuse within 6 months prior to the first dose
of study drug and excessive alcohol
consumption. Patients on
methadone/polamidone/buprenorphine programs
are not excluded*
Ja
Nein
Any investigational drug and/or participation in
another clinical study prior 6 months to the actual
ongoing antiviral treatment*
Ja
Nein
Limited contractual capability*
Ja
Nein
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Eligibility NCT00804856 Leukemia,
Myeloid, Acute
ODM derived from
http://clinicaltrials.gov/show/NCT00804856
All rights reserved. Please visit https://medical-data-
models.org/forms/5004
Eligibility
Einschlusskriterien
Alter mindestens 18 Jahre*
Ja
Nein
Male or female adult with relapsed/refractory
AML ineligible for intensive treatment (phase I
part only)  *
Ja
Nein
Male or female adult with previously untreated
AML ineligible for intensive treatment (phase IIa
part only)*
Ja
Nein
Confirmed diagnosis of AML according to the
WHO definition (except for acute promyelocytic
leukaemia, APL)*
Ja
Nein
Patient is eligible for LD-Ara-C treatment*
Ja
Nein
Life expectancy > 3 months*
Ja
Nein
Eastern co-operative oncology group (ECOG,
R01-0787) performance score <=2 at screening*
Ja
Nein
Signed written informed consent consistent with
international conference on harmonisation, good
clinical practice (ICH-GCP) and local legislation*
Ja
Nein
Ausschlusskriterien
Previously untreated AML (phase I part only)*
Ja
Nein
Relapsed or treatment refractory AML (phase IIa
part only)*
Ja
Nein
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Patient with APL (AML subtype M3 according to
the French-American-British (FAB) classification)*
Ja
Nein
Hypersensitivity to one of the trial drugs or the
excipients*
Ja
Nein
Other malignancy requiring treatment*
Ja
Nein
Symptomatic central nervous system
involvement*
Ja
Nein
Clinically relevant QT prolongation (e.g. long QT
syndrome, QTcF>470 ms)*
Ja
Nein
Aspartate amino transferase (AST) or alanine
amino transferase (ALT) > 2.5 times the upper
limit of normal (ULN), or AST or ALT > 5 times
the ULN in case of known leukaemia liver
involvement*
Ja
Nein
Prothrombin time (PT) > 1.5 x ULN for subjects
not on therapeutic vitamin K antagonists
(phenprocoumon, warfarin)*
Ja
Nein
Bilirubin*
Ja
Nein
Kreatinin im Serum*
Ja
Nein
Concomitant intercurrent illness, which would
compromise the evaluation of efficacy or safety of
the trial drug, e.g. active severe infection,
unstable angina pectoris, cardiac arrhythmia or
severe heart failure/cardiac insufficiency.*
Ja
Nein
Psychiatric illness or social situation that would
limit compliance with trial requirements*
Ja
Nein
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Concomitant therapy, which is considered
relevant for the evaluation of the efficacy or safety
of the trial drug*
Ja
Nein
Contraindications for cytarabine treatment
according to the SPC*
Ja
Nein
Female patients of childbearing potential who are
sexually active and unwilling to use a medically
acceptable method of contraception during the
trial, i.e. combination of two forms of effective
contraception (hormonal contraception,
intrauterine device, condom with spermicide,
etc.).*
Ja
Nein
Male patients with partners of childbearing
potential who are unwilling to use condoms in
combination with a second medically acceptable
method of contraception during the trial*
Ja
Nein
Pregnant or nursing female patients*
Ja
Nein
Patient unable to comply with the protocol*
Ja
Nein
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Eligibility NCT00812799 Allergic
Rhinoconjunctivitis
ODM derived from
http://clinicaltrials.gov/show/NCT00804856
All rights reserved. Please visit https://medical-data-
models.org/forms/5005
Eligibility
Einschlusskriterien
Alter mindestens 18 Jahre*
Ja
Nein
Male or female adult with relapsed/refractory
AML ineligible for intensive treatment (phase I
part only)  *
Ja
Nein
Male or female adult with previously untreated
AML ineligible for intensive treatment (phase IIa
part only)*
Ja
Nein
Confirmed diagnosis of AML according to the
WHO definition (except for acute promyelocytic
leukaemia, APL)*
Ja
Nein
Patient is eligible for LD-Ara-C treatment*
Ja
Nein
Life expectancy > 3 months*
Ja
Nein
Eastern co-operative oncology group (ECOG,
R01-0787) performance score <=2 at screening*
Ja
Nein
Signed written informed consent consistent with
international conference on harmonisation, good
clinical practice (ICH-GCP) and local legislation*
Ja
Nein
Ausschlusskriterien
Previously untreated AML (phase I part only)*
Ja
Nein
Relapsed or treatment refractory AML (phase IIa
part only)*
Ja
Nein
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Patient with APL (AML subtype M3 according to
the French-American-British (FAB) classification)*
Ja
Nein
Hypersensitivity to one of the trial drugs or the
excipients*
Ja
Nein
Other malignancy requiring treatment*
Ja
Nein
Symptomatic central nervous system
involvement*
Ja
Nein
Clinically relevant QT prolongation (e.g. long QT
syndrome, QTcF>470 ms)*
Ja
Nein
Aspartate amino transferase (AST) or alanine
amino transferase (ALT) > 2.5 times the upper
limit of normal (ULN), or AST or ALT > 5 times
the ULN in case of known leukaemia liver
involvement*
Ja
Nein
Prothrombin time (PT) > 1.5 x ULN for subjects
not on therapeutic vitamin K antagonists
(phenprocoumon, warfarin)*
Ja
Nein
Bilirubin*
Ja
Nein
Kreatinin im Serum*
Ja
Nein
Concomitant intercurrent illness, which would
compromise the evaluation of efficacy or safety of
the trial drug, e.g. active severe infection,
unstable angina pectoris, cardiac arrhythmia or
severe heart failure/cardiac insufficiency.*
Ja
Nein
Psychiatric illness or social situation that would
limit compliance with trial requirements*
Ja
Nein
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Concomitant therapy, which is considered
relevant for the evaluation of the efficacy or safety
of the trial drug*
Ja
Nein
Contraindications for cytarabine treatment
according to the SPC*
Ja
Nein
Female patients of childbearing potential who are
sexually active and unwilling to use a medically
acceptable method of contraception during the
trial, i.e. combination of two forms of effective
contraception (hormonal contraception,
intrauterine device, condom with spermicide,
etc.).*
Ja
Nein
Male patients with partners of childbearing
potential who are unwilling to use condoms in
combination with a second medically acceptable
method of contraception during the trial*
Ja
Nein
Pregnant or nursing female patients*
Ja
Nein
Patient unable to comply with the protocol*
Ja
Nein
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Eligibility NCT00816660 Von Willebrand
Disease
ODM derived from
http://clinicaltrials.gov/show/NCT00816660
All rights reserved. Please visit https://medical-data-
models.org/forms/5007
Eligibility
Einschlusskriterien
Alter 18 bis 60 Jahre*
Ja
Nein
Subject has voluntarily given written informed
consent (before conduct of any study-related
procedures)*
Ja
Nein
The subject has hereditary type 3 VWD (<= 3
IU/dL VWF:Ag)or severe type 1 or type 2A VWD
(VWF:RCo <= 10% and FVIII:C <20%)*
Ja
Nein
The subject has a medical history of at least 25
exposure days to VWF/FVIII coagulation factor
concentrates*
Ja
Nein
Karnofsky performance status (assessment
scale)*
Ja
Nein
NOT APPLICABLE IN ITALY: Female subjects of
child-bearing potential must have a negative
pregnancy test and agree to practice
contraception using a method of proven reliability
from the day of screening until the study
completion visit*
Ja
Nein
APPLICABLE ONLY IN ITALY: Female subjects of
child-bearing potential must have a negative
pregnancy test and agree to practice non-
hormonal-based contraception using a method of
proven reliability (IUD acceptable) from the day of
screening until 96 hours after the last
investigational drug infusion*
Ja
Nein
NOT APPLICABLE IN ITALY: The subject must
agree not to be on any therapy (hormone-based
contraception acceptable) interfering with
coagulation factor pharmacokinetics until 96
hours after the last investigational drug infusion*
Ja
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Nein
APPLICABLE ONLY IN ITALY: The subject must
agree not to be on any therapy interfering with
coagulation factor pharmacokinetics until 96
hours after the last investigational drug infusion *
Ja
Nein
Ausschlusskriterien
The subject has been diagnosed with a
hereditary or acquired coagulation disorder other
than VWD (including qualitative and quantitative
platelet disorders and/or an international
normalized ratio (INR) > 1.4)*
Ja
Nein
The subject has been diagnosed with an
ADAMTS13 deficiency with < 10% ADAMTS13
activity*
Ja
Nein
von-Willebrand-Faktor-Inhibitor*
Ja
Nein
The subject has a history or presence of FVIII
inhibitor with a titer >= 0.4 BU (by Nijmegen
assay) or >= 0.6 BU (by Bethesda assay)*
Ja
Nein
The subject has a known hypersensitivity to
mouse or hamster proteins*
Ja
Nein
The subject has a medical history of
immunological disorders, excluding seasonal
allergic rhinitis/conjunctivitis, food allergies or
animal allergies*
Ja
Nein
The subject has a medical history of a
thromboembolic event*
Ja
Nein
The subject is HIV positive with an absolute CD4
count < 200/mm3*
Ja
Nein
The subject has been diagnosed with
cardiovascular disease (New York Heart
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Association (NYHA) classes 1-4)*
Ja
Nein
The subject has been diagnosed with insulin-
dependent diabetes mellitus*
Ja
Nein
The subject has an acute illness (e.g. influenza,
flu-like syndrome, allergic rhinitis/conjunctivitis)*
Ja
Nein
The subject has been diagnosed with liver
disease, as evidenced by, but not limited to, any
of the following: serum ALT three times the upper
limit of normal, hypoalbuminemia, portal vein
hypertension (e.g. presence of otherwise
unexplained splenomegaly, history of esophageal
varices)*
Ja
Nein
The subject has been diagnosed with renal
disease, with a serum creatinine level >= 2
mg/dL*
Ja
Nein
In the judgment of the investigator, the subject
has another clinically significant concomitant
disease (e.g. uncontrolled hypertension, diabetes
type II) that may pose additional risks for the
subject*
Ja
Nein
The subject has been treated with an
immunomodulatory drug, excluding topical
treatment (e.g. ointments, nasal sprays) within 30
days before enrollment*
Ja
Nein
The subject has been treated with drugs known
to induce thrombotic thrombocytopenic purpura
(TTP) (e.g. Adenosine diphosphate (ADP)
receptor inhibitors (Clopidogrel, Ticlopidine))
within 60 days before enrollment*
Ja
Nein
The subject is receiving or anticipates receiving
another investigational and/or interventional drug
within 30 days before enrollment*
Ja
Nein
The subject is a lactating female*
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Ja
Nein
The subject has a history of drug or alcohol
abuse within the last 5 years*
Ja
Nein
The subject has a progressive fatal disease
and/or life expectancy of < 3 months*
Ja
Nein
The subject is identified by the investigator as
being unable or unwilling to cooperate with study
procedures*
Ja
Nein
The subject suffers from a mental condition
rendering him/her unable to understand the
nature, scope and possible consequences of the
study and/or evidence of an uncooperative
attitude*
Ja
Nein
Subject is in prison or compulsory detention by
regulatory and/or juridical order*
Ja
Nein
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Eligibility NCT00820105 Migraine
ODM derived from
http://clinicaltrials.gov/show/NCT00820105
All rights reserved. Please visit https://medical-data-
models.org/forms/5009
Eligibility
Einschlusskriterien
Alter zwischen 18 und 65 Jahrens*
Ja
Nein
History of migraine*
Ja
Nein
Aged <= 50 years at onset of migraine history *
Ja
Nein
Ausschlusskriterien
Cluster headache or chronic migraine
headaches*
Ja
Nein
Currently uses, or within 3 months of Screening,
has used: sodium valproate or topiramate and
any other drugs used specifically for migraine
prophylaxis, for example beta-blockers, calcium
channel blockers, tricyclic antidepressants,
selective serotonin reuptake inhibitors*
Ja
Nein
Unable to distinguish migraine headache from
tension and other types of headache*
Ja
Nein
Current history of psychiatric disorder requiring
regular medication*
Ja
Nein
History of alcohol abuse*
Ja
Nein
Known clinically significant allergy or known
hypersensitivity to drugs*
Ja
Nein
History of a significant medical condition that may
affect the safety of the patient or preclude
adequate participation in the study*
Ja
Nein
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Pregnant or breast-feeding*
Ja
Nein
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Eligibility NCT00820365 Inflammatory
Bowel Disease (IBD)
ODM derived from
http://clinicaltrials.gov/show/NCT00820365
All rights reserved. Please visit https://medical-data-
models.org/forms/5010
Eligibility
Einschlusskriterien
Alter 18 bis 70 Jahre*
Ja
Nein
Established diagnosis of CD, confirmed by
standard criteria (e.g. endoscopy, ultrasound, X-
ray)*
Ja
Nein
Patients must be in clinical remission (Crohn's
Disease Activity Index [CDAI] <150 points) on
steroid therapy for at least 2 weeks*
Ja
Nein
Confirmed steroid-dependency of CD: patients
who are either *
Ja
Nein
unable to taper steroids completely within 3
months of starting steroids,  without recurrent
active disease, or*
Ja
Nein
who have a relapse within 2 months of stopping
steroids*
Ja
Nein
Individual threshold dose of previous relapses
should be <= 20 mg/day Prednisolone or
equivalent steroid dose*
Ja
Nein
Patients with stable glucocorticosteroid therapy
between 20 and 40 mg/day Prednisolone or
equivalent steroid dose for the previous week *
Ja
Nein
Established diagnosis of UC, confirmed by
standard criteria (e.g. endoscopy, ultrasound, X-
ray)*
Ja
Nein
Patients must be in clinical remission (Clinical
Activity Index [CAI] <4 points) on steroid therapy
for at least 2 weeks*
1 / 5
Ja
Nein
Individual threshold dose of previous relapses
should be <= 20 mg/day Prednisolone or
equivalent steroid dose*
Ja
Nein
Patients with stable glucocorticosteroid therapy
between 20 and 40 mg/day Prednisolone or
equivalent steroid dose for the previous week (*
The threshold dose is that dose at which the
patient experienced the relapses)*
Ja
Nein
Written informed consent*
Ja
Nein
Negative pregnancy test at screening in females
of child-bearing potential*
Ja
Nein
Males willing to use condoms or to be sexually
abstinent*
Ja
Nein
Use of appropriate contraceptive methods for
females of childbearing potential one month
before, throughout the course of the study and
one month after study termination. This must be
a combination of the following:  *
Ja
Nein
a highly effective method of first choice = a
method with a low failure rate  (i.e. < 1% per
year) like sexual abstinence, combined oral
contraceptives, implants, injectables, some Intra
Uterine Devices (IUDs),  vasectomized partner
together with*
Ja
Nein
a method of second choice like condom,
diaphragm, or cup pessary *
Ja
Nein
Ausschlusskriterien
Syndrom des kurzen Darms*
Ja
Nein
Ileostomy, colostomy or rectal pouch*
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Ja
Nein
Relapse during screening *
Ja
Nein
History of or existence of active tuberculosis*
Ja
Nein
History of or existence of urolithiasis*
Ja
Nein
History of or existence of human immune
deficiency virus (HIV), Hepatitis B or C*
Ja
Nein
History of malignancy within the past five years
(excluding basal cell carcinoma of the skin)*
Ja
Nein
Previous opportunistic infection*
Ja
Nein
History of serious drug sensitivity *
Ja
Nein
Significant cardiac arrhythmia, bradycardia or
tachycardia or any other significant finding in the
electrocardiogram (ECG)*
Ja
Nein
kongestive Herzinsuffizienz*
Ja
Nein
Uncontrolled hypertension*
Ja
Nein
Uncontrolled asthma*
Ja
Nein
Nierenerkrankung*
Ja
Nein
Renal insufficiency defined as glomerular
filtration rate (GRF) <50 ml/min/1.73 m
(estimated GRF according to Cockcroft-Gault)*
Ja
Nein
3 / 5
Eligibility NCT00820365 Inflammatory Bowel Disease (IBD)
Psychiatrische Erkrankung*
Ja
Nein
Known or suspected immunodeficiency*
Ja
Nein
Laboratory abnormalities: hemoglobin <8.5 g/dl,
white blood cell count <3500/mm, platelet count
<125 000/mm, clinically relevant elevation of liver
enzymes, serum creatinine level >=1.4 mg/dl,
hematuria (>=10 erythrocytes/field on dipsticks) *
Ja
Nein
Pregnancy, lactation*
Ja
Nein
History of alcohol and/or drug dependence*
Ja
Nein
starker Raucher (mehr als 20 pro Tag)*
Ja
Nein
Use of prohibited drugs or treatments*
Ja
Nein
Patient not able or not willing to follow study
procedures due to physical or psychological
limitations or language problems*
Ja
Nein
Participation in another investigational drug or
vaccine trial within the last three months or
concurrently with this study*
Ja
Nein
Vaccination with life attenuated viruses within 4
weeks prior to study start*
Ja
Nein
Patient with any medical condition which, in the
opinion of the investigator or his designee, could
jeopardize or compromise the ability of the
patient to participate in the trial*
Ja
Nein
Patients possibly dependent on the investigator
or the sponsor*
Ja
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Nein
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Eligibility NCT00822159 Femoral Fractures
ODM derived from
http://clinicaltrials.gov/show/NCT00822159
All rights reserved. Please visit https://medical-data-
models.org/forms/5011
Eligibility
Einschlusskriterien
Alter mindestens 50 Jahre*
Ja
Nein
Patients with trochanteric or femoral neck
fractures, classified as: AO 31-A1, AO 31-A2, AO
31-A3, AO 31-B1, AO 31-B2, AO 31-B3*
Ja
Nein
Patients undergoing fixation with DHS (135°
aiming device, anti-rotational K-wire)*
Ja
Nein
Patients willing to participate in the study
according to the clinical investigation plan*
Ja
Nein
Patients able to understand and read country
national language at an elementary level*
Ja
Nein
Signed written informed consent by the patient or
legal guardian *
Ja
Nein
Ausschlusskriterien
Bilateral hip fractures (at present or in the past)*
Ja
Nein
Open hip fracture*
Ja
Nein
Any previous surgical procedures of the hip
(ipsilateral / contralateral)*
Ja
Nein
More than 7 days between injury and surgery*
Ja
Nein
Polytrauma (multiple injuries, whereof one or the
combination of several injuries is life-threatening)*
Ja
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Nein
Patients being pregnant or breast-feeding*
Ja
Nein
pathologische Fraktur, Spontanfraktur*
Ja
Nein
Active malignancy*
Ja
Nein
Psychiatric disorders that would preclude reliable
assessment (e.g. severe depression)*
Ja
Nein
Drug or alcohol abuse*
Ja
Nein
Patients having participated in any other device
or drug related clinical trial within the previous
month*
Ja
Nein
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Eligibility NCT00822393 Acute Myeloid
Leukemia
ODM derived from
http://clinicaltrials.gov/show/NCT00822393
All rights reserved. Please visit https://medical-data-
models.org/forms/5012
Eligibility
Einschlusskriterien
Alter 18 bis 70 Jahre*
Ja
Nein
Patients with acute myeloid leukaemia acc. to
WHO, 2001 (AML in complete remission at
transplant, i.e. blast counts < 5 % in bone
marrow) or myelodysplastic syndrome acc. to
WHO, 2001 (MDS with blast counts < 20 % in
bone marrow during disease history) indicated for
allogeneic haematopoietic progenitor cell
transplantation but considered to be at increased
risk for standard conditioning therapies according
to the following criteria:*
Ja
Nein
patients aged >= 50 years at transplant and / or*
Ja
Nein
patients with a HCT-CI score > 2 [acc. to Sorror
et al., 2005] *
Ja
Nein
Availability of an HLA-identical sibling donor
(MRD) or HLA-identical unrelated donor (MUD).
Donor selection is based on molecular high
resolution typing (4 digits) of class II alleles of the
DRB1 and DQB1 gene loci and molecular (at
least) low resolution typing (2 digits) of class I
alleles (i.e., antigens) of the HLA-A, B, and C
gene loci. In case, no class I and class II
completely identical donor (10 out of 10 gene
loci) can be identified, one antigen disparity
(class I) and/or one allele disparity (class II)
between patient and donor are acceptable.
Conversely, disparity of two antigens (irrespective
of the involved gene loci) cannot be accepted.
These definitions for the required degree of
histocompatibility apply to the selection of related
as well as of unrelated donors.*
Ja
Nein
Adult patients of both gender, age 18 - 70 years*
Ja
Nein
Karnofsky performance status (assessment
scale)*
Ja
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Nein
Written informed consent *
Ja
Nein
Men capable of reproduction and women of
childbearing potential must be willing to consent
to using a highly effective method of birth control
such as condoms, implants, injectables,
combined oral contraceptives, IUDs, sexual
abstinence or vasectomised partner while on
treatment and for at least 6 months thereafter *
Ja
Nein
Ausschlusskriterien
Patients with acute promyelocytic leukaemia with
t(15,17)(q22,q12) and in CR1*
Ja
Nein
Patients considered contra-indicated for
allogeneic HSCT due to severe concomitant
illness (within three weeks prior to scheduled day
-6):*
Ja
Nein
patients with severe renal impairment like
patients on dialysis or prior  renal transplantation
or S-creatinine > 3.0 x ULN or calculated
creatinine-clearance < 60 ml/min*
Ja
Nein
patients with severe pulmonary impairment,
DLCO/or FEV1 < 50 % or severe  dyspnoea at
rest or requiring oxygen supply*
Ja
Nein
patients with severe cardiac impairment
diagnosed by echocardiography and  LVEF < 40
%*
Ja
Nein
patients with severe hepatic impairment indicated
by hyperbilirubinaemia > 3  x ULN or ALT / AST >
5 x ULN  *
Ja
Nein
Active malignant involvement of the CNS*
Ja
Nein
HIV-positivity, active non-controlled infectious
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disease under treatment (no decrease of CRP or
PCT) including active viral liver infection*
Ja
Nein
Previous allogeneic HSCT*
Ja
Nein
Pleural effusion or ascites > 1.0 L *
Ja
Nein
Pregnancy or lactation*
Ja
Nein
Known hypersensitivity to treosulfan, busulfan
and/or related ingredients *
Ja
Nein
Participation in another experimental drug trial
within 4 weeks prior to day -6 of the protocol *
Ja
Nein
Non-cooperative behaviour or non-compliance*
Ja
Nein
Psychiatric diseases or conditions that might
compromise the ability to give informed consent*
Ja
Nein
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Eligibility NCT00823173 Anterior Uveitis
ODM derived from
http://clinicaltrials.gov/show/NCT00823173
All rights reserved. Please visit https://medical-data-
models.org/forms/5013
Eligibility
Einschlusskriterien
Alter mindestens 18 Jahre*
Ja
Nein
Signed and dated informed consent.*
Ja
Nein
Patients with the typical presentation of HLA-B27
positive AAU (unilateral, painful anterior uveitis of
sudden onset).*
Ja
Nein
2+ anterior chamber cells according to the SUN
Working Group criteria, as assessed by slit lamp
biomicroscopy.*
Ja
Nein
Start of the typical first symptoms of the current
attack, defined as the point in time when the
patient felt the first sensation of the attack, within
the last 72 hours before initiation of treatment
with the study medication.*
Ja
Nein
Negative pregnancy test for females of
childbearing potential (pre menopausal, <2 years
post-menopausal, not surgically sterile).*
Ja
Nein
Patients with a negative QuantiFERON TB Gold
test result.*
Ja
Nein
Patients who currently have no clinically apparent
symptoms of an HLA B27 associated acute
extraocular disorder requiring systemic
immunosuppressive therapy.*
Ja
Nein
Patients who are willing and able to cooperate
with study requirements. *
Ja
Nein
Ausschlusskriterien
1 / 3
IOP elevation requiring therapy.*
Ja
Nein
Uncontrolled diabetes mellitus and diabetic
retinopathy.*
Ja
Nein
Patients with a single eye or a pinhole Snellen
visual acuity 20/200 or worse in the non study
eye.*
Ja
Nein
Zellen in der Augenvorderkammer <= 1+*
Ja
Nein
Patients with 3+ or 4+ anterior chamber cells or
hypopyon.*
Ja
Nein
Patients in whom the time of the beginning of the
current attack can not be determined.*
Ja
Nein
Patients exhibiting corneal ulceration or a history
of recurrent herpetic keratitis or clinical evidence
of herpetic dermatitis.*
Ja
Nein
Patients currently treated with topical
corticosteroids.*
Ja
Nein
Patients treated with systemic
immunosuppressive therapy within the last 2
months.*
Ja
Nein
Patients treated with a systemically administered
TNF-alpha inhibitor within the last 2 months.*
Ja
Nein
Pregnant or breast-feeding women or women of
childbearing potential, who with their partners
refuse to use 2 reliable methods of contraception
(including 1 barrier method) during the study.*
Ja
Nein
Male patients with a female partner who could
become pregnant and who refuse, with their
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partner, to use 2 reliable methods of
contraception (including 1 barrier method) during
the study.*
Ja
Nein
Patients whose clinical presentation is suggestive
for an active bacterial, viral or fungal infection
anywhere in the body.*
Ja
Nein
Patients with history of recurrent infections, or a
clinical presentation suggestive of a chronic
infection requiring antimicrobial therapy (e.g.
syphilis) including active episodes of serious viral
infections by, e.g. herpes simplex, herpes zoster,
cytomegalic or hepatitis viruses or clinical signs
of fungal infections, such as histoplasmosis,
aspergillosis or coccidiomycosis.*
Ja
Nein
Patients presenting with higher intraocular
pressure in the uveitic eye than in the
contralateral eye.*
Ja
Nein
Patients with known carrier status of human
immunodeficiency virus, hepatitis B or hepatitis
C.*
Ja
Nein
Patients with a history of demyelinating disease
(multiple sclerosis) or optic neuritis.*
Ja
Nein
Patients with positive or unclear QuantiFERON
TB Gold test result or history of high risk
exposure to Mycobacterium tuberculosis.*
Ja
Nein
Patients with known coexisting malignancy.*
Ja
Nein
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Eligibility NCT00823992 Diabetes Mellitus,
Type 2
ODM derived from
http://clinicaltrials.gov/show/NCT00823992
All rights reserved. Please visit https://medical-data-
models.org/forms/5014
Eligibility
Einschlusskriterien
Alter 18 bis 75 Jahre*
Ja
Nein
Erwachsener, erwachsen*
Ja
Nein
type 2 diabetes mellitus, receiving metformin at a
stable dose of >=1500mg/day for at least 12
weeks*
Ja
Nein
HbA1c >=6.5% and <=9.5% at screening*
Ja
Nein
BMI >=30 and <=50 kg/m2 at screening*
Ja
Nein
stable weight +/-5% for at least 12 weeks prior to
screening. *
Ja
Nein
Ausschlusskriterien
history of type 1 diabetes or acute metabolic
diabetic complications such as ketoacidosis or
hyperosmolar coma within the past 6 months*
Ja
Nein
evidence of clinically significant diabetic
complications*
Ja
Nein
myocardial infarction, coronary artery bypass
surgery, post-transplantation cardiomyopathy or
stroke within the past 6 months.*
Ja
Nein
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Eligibility NCT00826059 Acute Ischemic
Stroke
ODM derived from
http://clinicaltrials.gov/show/NCT00826059
All rights reserved. Please visit https://medical-data-
models.org/forms/5015
Eligibility
Einschlusskriterien
Alter 40 bis 85 Jahre*
Ja
Nein
Age: Between 40 years and 80 years for male
and 85 for female subjects*
Ja
Nein
Clinical diagnosis of an acute ischemic stroke in
the Carotid, Middle or Anterior Cerebral Artery
territories*
Ja
Nein
Imaging findings demonstrating signs of ischemia
in the anterior circulation, consistent with the
clinical diagnosis*
Ja
Nein
Baseline NIHSS ≥ 7 and ≤ 18 within 2 hours prior
to implantation.*
Ja
Nein
Ability to initiate treatment within 8- 24 hours from
stroke onset*
Ja
Nein
Signed informed consent from patient him/herself
or legally authorized representative if applicable*
Ja
Nein
Ausschlusskriterien
Intracranial hemorrhage or hemorrhagic
transformation*
Ja
Nein
Massive stroke*
Ja
Nein
Acute ischemic stroke in the posterior circulation*
Ja
Nein
Minor stroke*
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Ja
Nein
Treated with IV-tPA ,IA-tPA or
neurothrombectomy devices for the current
stroke*
Ja
Nein
Previous stroke in the last 6 months or pre-
existing disability*
Ja
Nein
Patients with bleeding propensity or any condition
in the oral cavity that prevents implantation*
Ja
Nein
Clinical signs and symptoms or imaging evidence
of bilateral stroke.*
Ja
Nein
Known cerebral arteriovenous malformation,
cerebral aneurysm.*
Ja
Nein
Clinical suspicion of septic embolus.*
Ja
Nein
Uncontrolled hypertension (systolic >185 mmHg
and/or diastolic >110 mmHg)*
Ja
Nein
Serious systemic infection.*
Ja
Nein
Women known to be pregnant or having a
positive or indeterminate pregnancy test.*
Ja
Nein
Patients with other implanted neural stimulator/
electronic devices (pacemakers).*
Ja
Nein
Life expectancy < 1 year from causes other than
stroke.*
Ja
Nein
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Eligibility NCT00832039 Severe Sepsis
ODM derived from
http://clinicaltrials.gov/show/NCT00832039
All rights reserved. Please visit https://medical-data-
models.org/forms/5016
Eligibility
Einschlusskriterien
Alter mindestens 18 Jahre*
Ja
Nein
Severe sepsis or septic shock according to
ACCP/SCCM criteria*
Ja
Nein
Onset of severe sepsis or septic shock <24 h*
Ja
Nein
Einverständniserklärung*
Ja
Nein
Ausschlusskriterien
Pregnant or breast-feeding women*
Ja
Nein
Fertile female women without effective
contraception*
Ja
Nein
Participation in interventional clinical trial within
the last 30 days*
Ja
Nein
Current participation in any study*
Ja
Nein
Former participation in this trial*
Ja
Nein
Selenium intoxication*
Ja
Nein
No commitment to full patient support (i.e. DNR
order)*
Ja
Nein
Patient's death is considered imminent due to
coexisting disease*
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Ja
Nein
Relationship of the patient to study team member
(i.e. colleague, relative)*
Ja
Nein
Infection where guidelines recommend a longer
duration of antimicrobial therapy (i.e.
endocarditis, tuberculosis, malaria etc)*
Ja
Nein
immungeschwächt, (immun)abwehrgeschwächt*
Ja
Nein
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Eligibility NCT00833924 Abdominal Aortic
Aneurysms
ODM derived from
http://clinicaltrials.gov/show/NCT00833924
All rights reserved. Please visit https://medical-data-
models.org/forms/5017
Eligibility
Einschlusskriterien
Alter mindestens 18 Jahre*
Ja
Nein
Abdominal aortic, aortoiliac, and iliac aneurysms
of appropriate size*
Ja
Nein
Vessels suitable for endovascular access and
aneurysm repair *
Ja
Nein
Ausschlusskriterien
Alter unter 18 Jahre*
Ja
Nein
Inability or refusal to give informed consent*
Ja
Nein
Disease considerations that would compromise
patient safety or study outcomes*
Ja
Nein
Unsuitable arterial anatomy*
Ja
Nein
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Eligibility NCT00844064 Pancreatic
Neoplasms, Melanoma, Colorectal Neoplasms
ODM derived from
http://clinicaltrials.gov/show/NCT00844064
All rights reserved. Please visit https://medical-data-
models.org/forms/5018
Eligibility
Einschlusskriterien
Alter 18 bis 75 Jahre*
Ja
Nein
Written informed consent.*
Ja
Nein
Male or non-pregnant, non-lactating female.*
Ja
Nein
Pancreatic cancer: Histologically or cytologically
confirmed diagnosis, stage IVA or IVB (AJCC,
1997).*
Ja
Nein
Melanoma: Histologically or cytologically
confirmed diagnosis, stage III or IV (AJCC,
UICC)*
Ja
Nein
Colorectal cancer: Histologically or cytologically
confirmed diagnosis, stage III or IV (AJCC,
UICC), excluded from the last cohort.*
Ja
Nein
Patient is not or no longer amenable to
established forms of therapy.*
Ja
Nein
At least one measurable lesion.*
Ja
Nein
Karnofsky performance status of at least 80%.*
Ja
Nein
Recovery from acute toxicity caused by any
previous therapy.*
Ja
Nein
Adequate organ function as assessed by the
following laboratory values:*
Ja
Nein
Serum creatinine and urea < 2 times the upper
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limit of normal (ULN).*
Ja
Nein
ALT and AST < 3 ULN (in case of a liver
metastasis: < 5x ULN); alkaline phosphatase < 3
ULN; and bilirubin < 2.5 mg/dL.*
Ja
Nein
Prothrombin time < 1.5 INR and PTT < 1.5 times
the upper limit of normal.*
Ja
Nein
Hämoglobin*
Ja
Nein
Blutplättchen, Thrombozyt*
Ja
Nein
Leukozyten-Anzahl*
Ja
Nein
Absolute Neutrophil Count, ANC*
Ja
Nein
Ausschlusskriterien
Patient unable to comply with the protocol
regulations.*
Ja
Nein
Pregnant or lactating female.*
Ja
Nein
Antitumor radiation therapy within 12 weeks,
tumor surgery within 4 weeks or any other
therapy with established antitumor effects within 2
weeks prior to study entry.*
Ja
Nein
The patient takes or is likely to need other
prohibited concomitant medication.
Administration of corticosteroids should be strictly
avoided during the course of the study.*
Ja
Nein
Patient's participation in another clinical trial with
investigational medication within 30 days prior to
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study entry.*
Ja
Nein
History of brain metastases. In the case of
suspected brain metastases a CT scan of the
skull will be performed (not mandatory in
asymptomatic patients).*
Ja
Nein
Clinically significant cardiovascular abnormalities
such as refractory hypertension, congestive heart
failure, unstable angina, or poorly controlled
arrhythmia, or a myocardial infarction within 6
months prior to treatment.*
Ja
Nein
Gastric or duodenal ulcers within 6 months before
study entry or is at risk of gastrointestinal
ulceration due to high consumption of NSAIDs.*
Ja
Nein
An active infection with HIV, HBV, or HCV.*
Ja
Nein
Clinically significant acute viral, bacterial, or
fungal infection.*
Ja
Nein
Acute medical problems that may be considered
to become an unacceptable risk, or any
conditions that might be contraindications for
starting study treatment.*
Ja
Nein
History of allergies to reagents used in this
study.*
Ja
Nein
Drug abuse or extensive use of alcohol.*
Ja
Nein
Significant psychiatric disorders/ legal incapacity
or limited legal capacity.*
Ja
Nein
History of Long QT Syndrome or QTc time ≥ 480
msec in screening/baseline ECGs. The average
QTc time is to be calculated from three separate
ECGs performed prior to start of infusion: two
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ECGs performed at Screening/Baseline (with a
minimum 1-hour interval in between) and one
performed within 1 hour prior to start of infusion.*
Ja
Nein
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Eligibility NCT00856284 Type 2 Diabetes
Mellitus
ODM derived from
http://clinicaltrials.gov/show/NCT00856284
All rights reserved. Please visit https://medical-data-
models.org/forms/5019
Eligibility
Einschlusskriterien
Alter 18 bis 80 Jahre*
Ja
Nein
Has a diagnosis of type 2 diabetes mellitus.*
Ja
Nein
Must meet one of the following:*
Ja
Nein
Has been inadequately controlled on a stable
daily dose of >= 1500 mg (or  documented
maximum tolerated dose) of metformin for at
least 2 months prior to  Screening.*
Ja
Nein
Has been inadequately controlled (as defined by
a glycosylated hemoglobin 7.5  10%, inclusive)
on metformin <1500 mg without documented
maximum tolerated dose.*
Ja
Nein
No treatment with antidiabetic agents other than
metformin within 2 months prior to Screening (for
Schedule A)/Pre-Screening (for Schedule B).*
Ja
Nein
Has body mass index within 23kg/m2 and
45kg/m2 unless the subject is Asian or of Asian
descent, for whom the allowable body mass index
will be >= 20 kg/m2 and <= 35 kg/m2, inclusive.*
Ja
Nein
Has fasting C-peptide concentration at least 0.8
ng.*
Ja
Nein
If regularly using non-excluded medications, must
be on a stable dose at least 4 wks prior to
Screening/Pre-screening.*
Ja
Nein
Females of childbearing potential who are
sexually active must agree to use adequate
contraception, and can neither be pregnant,
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lactating or intends to donate ova from Screening
throughout the duration of the study.*
Ja
Nein
Must be able and willing to monitor their blood
glucose concentrations with a home monitor, and
comply with protocol requirements including
scheduled clinic appointments. *
Ja
Nein
Ausschlusskriterien
Systolic blood pressure >= 150 mmHg and/or
diastolic pressure >= 90.*
Ja
Nein
Hemoglobin <= 12 g/dL for males and <= 10 g/dL
for females at Screening Visit.*
Ja
Nein
Alanine aminotransferase >= 2.5 times the upper
limit of normal at Screening Visit.*
Ja
Nein
Serum creatinine >= 1.5 mg/dL for males and 1.4
for females, or calculated creatinine clearance <
60 L/min.*
Ja
Nein
Males intending to impregnate others or donate
sperm before, during or within 1 month after
participating in the study.*
Ja
Nein
A history of cancer other than squamous or basal
cell carcinoma of the skin that has not been in full
remission for at least 5 yrs.*
Ja
Nein
A history of laser treatment for diabetic
retinopathy within 6 months of screening.*
Ja
Nein
Treated for diabetic gastric paresis, gastric
banding, or gastric bypass.*
Ja
Nein
New York Heart Association Class III or IV heart
failure.*
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Ja
Nein
History of coronary angioplasty, coronary stent
placement, coronary bypass surgery, myocardial
infarction, stroke or transient ischemic attack
within 3 months prior to screening.*
Ja
Nein
Known history of human immunodeficiency virus,
hepatitis B or C.*
Ja
Nein
Alcohol or substance abuse within 2 years prior
to screening.*
Ja
Nein
Is required to take or intends to continue taking
any disallowed medication, any prescription
medication, herbal treatment or over-the counter
medication that may interfere with evaluation of
the study medication, including:*
Ja
Nein
Any investigational drug within 30 days*
Ja
Nein
Any investigational diabetic drug within 3 months*
Ja
Nein
Any antidiabetic drug in the dipeptidyl peptidase-
4 inhibitors or glucagon-like  peptide-1 mimetics
classes within 90 days prior to Screening other
than  metformin*
Ja
Nein
Prior treatment with alogliptin.*
Ja
Nein
Weight-Loss Agents*
Ja
Nein
Investigational antidiabetics*
Ja
Nein
Oral or systemically injected glucocorticoids*
Ja
Nein
A hypersensitivity allergy or anaphylactic reaction
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to any dipeptidyl peptidase-4 drug, metformin or
glipizide.*
Ja
Nein
Has a documented history or concurrent signs of
significant thyroid disease (eg, autoimmune
thyroid diseases such as Graves disease and
Hashimoto thyroiditis or active thyroid nodules).*
Ja
Nein
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Eligibility NCT00856622 Ocular
Hypertension
ODM derived from
http://clinicaltrials.gov/show/NCT00856622
All rights reserved. Please visit https://medical-data-
models.org/forms/5020
Eligibility
Einschlusskriterien
Alter mindestens 18 Jahre*
Ja
Nein
Unilateral or bilateral primary open angle
glaucoma, capsular glaucoma, pigmentary
glaucoma or ocular hypertension.*
Ja
Nein
Patients currently on IOP reducing therapy: IOP
>= 25mmHg (two IOP determinations at pre-
study separated by at least one hour) OR
Patients without IOP reducing therapy: IOP >=
30mmHg (two IOP determinations at pre-study
separated by at least one hour). *
Ja
Nein
Ausschlusskriterien
History of acute angle closure or closed/barely
open anterior chamber angle.*
Ja
Nein
Current use of contact lenses.*
Ja
Nein
Ocular surgery or argon laser trabeculoplasty
(ALT) within three months prior to pre-study visit.*
Ja
Nein
Ocular inflammation/infection occurring within
three months prior to pre-study visit.*
Ja
Nein
Hypersensitivity to benzalkonium chloride or to
any other component of the study drug solutions.*
Ja
Nein
Other abnormal ocular condition or symptom
preventing the patient from entering the study,
according to the investigator's judgement.*
Ja
Nein
Cardiac failure, sinus bradycardia, second and
third degree of atrioventricular block. (The
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routines for prescribing topical B-blocking agents
will be followed.*
Ja
Nein
Bronchial asthma, history of bronchial asthma or
chronic obstructive pulmonary disease. (The
routines for prescribing topical B-blocking agents
will be followed).*
Ja
Nein
Schwangerschaft*
Ja
Nein
Women of childbearing potential who has not
used adequate contraceptive methods during the
last three months.*
Ja
Nein
Inability to adhere to treatment/visit plan.*
Ja
Nein
Have participated in any other clinical study
within one month prior to pre-study visit.*
Ja
Nein
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Eligibility NCT00858364 Non-Small Cell
Lung Cancer
ODM derived from
http://clinicaltrials.gov/show/NCT00858364
All rights reserved. Please visit https://medical-data-
models.org/forms/5021
Eligibility
Einschlusskriterien
Alter mindestens 18 Jahre*
Ja
Nein
Subjects with stage IV NSCLC (not recurrent or
re-staged).*
Ja
Nein
Expected to receive at least 2 additional cycles
(at least 6 total weeks) of first line
myelosuppressive cyclic chemotherapy after
randomization. Subjects should not be expected
to receive only maintenance chemotherapy.*
Ja
Nein
Eastern Cooperative Oncology Group
performance status of 0 or 1 as assessed within
21 days prior to randomization.*
Ja
Nein
Life expectancy > 6 months based on the
judgment of the investigator and documented
during screening.*
Ja
Nein
Hemoglobin level <= 11.0 g/dL as assessed by
the local laboratory, sample obtained within 7
days prior to randomization (retest in screening is
acceptable).*
Ja
Nein
Adequate serum folate (>= 2 ng/mL) and vitamin
B12 (>= 200 pg/mL) levels assessed by central
laboratory (supplementation and retest
acceptable) during screening.*
Ja
Nein
Subjects must have had a baseline scan (CT,
MRI, or PET/CT) of the chest to assess disease
burden before starting on first line chemotherapy
for NSCLC and those images must have been
reviewed by the investigator prior to
randomization. If the scan was performed more
than 28 days prior to randomization, an additional
scan must be performed and reviewed by the
investigator to confirm that the patient has not
progressed before randomization.*
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Ja
Nein
Before any study-specific procedure, the
appropriate written informed consent must be
obtained from the subject or a legally accepted
representative . *
Ja
Nein
Ausschlusskriterien
Known primary benign or malignant hematologic
disorder which can cause anemia.*
Ja
Nein
History of, or current active cancer other than
NSCLC, with the exception of curatively resected
non-melanomatous skin cancer, curatively treated
cervical carcinoma in situ, or other primary solid
tumors curatively treated with no known active
disease present and no curative treatment
administered for the last 3 years.*
Ja
Nein
Received any prior adjuvant or neoadjuvant
therapy for NSCLC.*
Ja
Nein
Subjects with a history of brain metastasis .*
Ja
Nein
Uncontrolled hypertension (systolic BP > 160
mmHg or diastolic BP > 100 mmHg), or as
determined by the investigator during screening.*
Ja
Nein
History of neutralizing antibody activity to
rHuEPO or darbepoetin alfa.*
Ja
Nein
Uncontrolled angina, uncontrolled heart failure, or
uncontrolled cardiac arrhythmia as determined by
the investigator at screening. Subjects with
known myocardial infarction within 6 months prior
to randomization.*
Ja
Nein
Subjects with a history of seizure disorder taking
anti-seizure medication within 30 days prior to
randomization.*
Ja
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Nein
Clinically significant systemic infection or
uncontrolled chronic inflammatory disease (eg,
rheumatoid arthritis, inflammatory bowel disease)
as determined by the investigator during
screening.*
Ja
Nein
Known seropositivity for HIV or diagnosis of
AIDS, positive for hepatitis B surface antigen, or
seropositive for hepatitis C virus*
Ja
Nein
History of pure red cell aplasia*
Ja
Nein
History of deep venous thrombosis or embolic
event (eg, pulmonary embolism) within 6 months
prior to randomization.*
Ja
Nein
Transferrin saturation < 20% and ferritin < 50
ng/mL as assessed by the central laboratory
during screening. Subjects must have both to be
excluded (supplementation and retest
acceptable).*
Ja
Nein
Abnormal renal function (serum creatinine level >
2X ULN) as assessed by the central laboratory
during screening.*
Ja
Nein
Abnormal liver function (total bilirubin > 2X ULN
or liver enzymes ALT or AST > 2.5X ULN for
subjects without liver metastasis or >= 5X ULN
for subjects with liver metastasis) as assessed by
the central laboratory during screening. Subjects
with documented Gilbert's Disease may be
eligible.*
Ja
Nein
Erythrocyte Transfusion*
Ja
Nein
Plan to receive any RBC transfusion between
randomization and study day 1.*
Ja
Nein
Known previous treatment failure to ESAs (eg,
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rHuEPO, darbepoetin alfa).*
Ja
Nein
ESA therapy within the 28 days prior to
randomization.*
Ja
Nein
Known hypersensitivity to recombinant ESAs or
the excipients contained within the investigational
product.*
Ja
Nein
< 30 days since receipt of any investigational
product or device. Investigational use/receipt of a
medicinal product or device that has been
approved by the country's local regulatory
authority for any indication is permitted.*
Ja
Nein
Subjects of reproductive potential who are
pregnant, breast feeding or not willing to use
effective contraceptive precautions during the
study and for at least one month after the last
dose of investigational product in the judgment of
the investigator (including females of childbearing
potential who are partners of male subjects).*
Ja
Nein
Previously randomized to this study.*
Ja
Nein
Investigator has concerns regarding the ability of
the subject to give written informed consent
and/or to comply with study procedures (including
availability for follow up visits.*
Ja
Nein
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Eligibility NCT00866684 Kidney
Transplantation
ODM derived from
http://clinicaltrials.gov/show/NCT00866684
All rights reserved. Please visit https://medical-data-
models.org/forms/5022
Eligibility
Einschlusskriterien
Alter mindestens 18 Jahre*
Ja
Nein
Recipients of renal allograft with current actinic
keratosis I or II or successfully treated actinic
keratosis III (inclusion possible immediately after
completed wound healing from surgical excision),
invasive squamous cell carcinoma (SCC), basal
cell carcinoma and/or premalignant neoplastic
skin lesions*
Ja
Nein
Minimum period of 6 month after renal
transplantation*
Ja
Nein
Stable renal function and a calculated creatinine
clearance of at least 40 ml/min*
Ja
Nein
Written informed consent*
Ja
Nein
Proteinuria <= 800 mg/d at time of enrolment*
Ja
Nein
Successfully treated solid tumor (no recurrence
or metastasis in the last 2 years) *
Ja
Nein
Ausschlusskriterien
Current Sirolimus- or Everolimus-intake*
Ja
Nein
Instable graft function (creatinine clearance < 40
ml/min)*
Ja
Nein
Transplantatabstoßung*
Ja
Nein
Proteinuria*
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Ja
Nein
Non-controlled hyperlipidemia (Cholesterol >7,8
mmol/l, Triglycerides > 4)*
Ja
Nein
Leuko(zyto)penie, Leukozytenmangel*
Ja
Nein
Thrombocytopenia*
Ja
Nein
Pregnancy or breastfeeding*
Ja
Nein
Women of childbearing age without highly
effective contraception (= defined as those which
result in a low failure rate (i.e. less than 1 % per
year))*
Ja
Nein
Known allergy to macrolides*
Ja
Nein
Current participation in other studies*
Ja
Nein
Refusal to sign informed consent form*
Ja
Nein
Neoplasm other than defined as inclusion
criteria*
Ja
Nein
All contraindications to SRL (see package insert,
appendix)*
Ja
Nein
Persons who are detained officially or legally to
an official institute*
Ja
Nein
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Eligibility NCT00867672 Acute Myeloid
Leukemia
ODM derived from
http://clinicaltrials.gov/show/NCT00867672
All rights reserved. Please visit https://medical-data-
models.org/forms/5023
Eligibility
Einschlusskriterien
Alter mindestens 60 Jahre*
Ja
Nein
Patients older than 60 years with acute myeloid
leukemia according to FAB (> 30 % bone marrow
blasts) not qualifying for, or not consenting to,
standard induction chemotherapy or immediate
allografting*
Ja
Nein
Life expectancy > 3 months with successful
treatment*
Ja
Nein
Performance status ECOG 0, 1, 2*
Ja
Nein
Age-adjusted normal cardiac, kidney, liver
function (creatinine < 1.5 mg/dl unless leukemia-
related, total bilirubin < 2.0 of upper normal
limits)*
Ja
Nein
Patients with >50 000 leukocytes/µl in whom
initial cytoreduction according to protocol is
effective*
Ja
Nein
Written informed consent *
Ja
Nein
Ausschlusskriterien
AML of FAB subtype M3*
Ja
Nein
Previous induction-type chemotherapy for MDS
or AML*
Ja
Nein
Previous treatment with DAC, 5-azacytidine, VPA
or another HDAC inhibitor, or ATRA*
Ja
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Nein
low-dose chemotherapy (e.g.hydroxyurea,
cytosine arabinoside, melphalan) within 8 weeks
prior to DAC treatment, except for cytoreduction
of leukocytosis >50 000/µl according to protocol*
Ja
Nein
Patients with > 50 000 leukocytes/µl in whom
initial cytoreduction according to protocol is
ineffective*
Ja
Nein
Treatment with cytokines within previous 4
weeks*
Ja
Nein
Concomitant use of any other investigational
drug*
Ja
Nein
Other malignancy that is not in remission
(previous chemotherapy for other malignancies is
not an exclusion criteria)*
Ja
Nein
Cardiac insufficiency NYHA IV*
Ja
Nein
HIV Infektion*
Ja
Nein
Other uncontrolled active infection*
Ja
Nein
Psychiatric disorder that interferes with
treatment*
Ja
Nein
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Eligibility NCT00875667 Mantle Cell
Lymphoma
ODM derived from
http://clinicaltrials.gov/show/NCT00875667
All rights reserved. Please visit https://medical-data-
models.org/forms/5024
Eligibility
Einschlusskriterien
Alter mindestens 18 Jahre*
Ja
Nein
Biopsy proven mantle cell lymphoma*
Ja
Nein
Patients who have progressed or relapsed after
or are refractory to at least one, and up to three
prior chemotherapy regimens, and who have
documented progressive disease.*
Ja
Nein
ECOG performance score 0,1, or 2*
Ja
Nein
Willing to follow pregnancy precaution *
Ja
Nein
Ausschlusskriterien
abnormale Laborbefunde*
Ja
Nein
Absolute Neutrophil Count, ANC*
Ja
Nein
Thrombozyten*
Ja
Nein
Serum aspartate transaminase (AST/SGOT) or
alanine transaminase (ALT/SGPT) >3.0 x upper
limit or normal (ULN), except patients with
documented liver involvement by lymphoma*
Ja
Nein
Serum total bilirubin > 1.5 x ULN, except in case
of Gilbert's Syndrome and documented liver
involvement by lymphoma.*
Ja
Nein
Estimation of creatinine clearance by Cockcroft-
Gault formula (procedure)*
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Ja
Nein
History of active CNS lymphoma within the
previous 3 months*
Ja
Nein
Subjects not willing to take DVT prophylaxis*
Ja
Nein
Known seropositive for or active viral infection
with human immunodeficiency virus (HIV),
hepatitis B virus (HBV) or hepatitis C virus (HCV).
Patients who are sero-positive because of
hepatitis B virus vaccine are eligible*
Ja
Nein
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Eligibility NCT00876733 HIV Infections
ODM derived from
http://clinicaltrials.gov/show/NCT00876733
All rights reserved. Please visit https://medical-data-
models.org/forms/5026
Eligibility
Einschlusskriterien
Alter mindestens 18 Jahre*
Ja
Nein
To construct a treatment option with Viramune
(nevirapine) and antiretroviral, e.g. Combivir
(fixed dose combination of Zidovudine and
Lamivudine), Kivexa (fixed dose combination of
Abacavir and Lamivudine) or Truvada (fixed dose
combination of tenofovir and emtricitabine) in
male and female adult HIV type 1 infected
patients*
Ja
Nein
HIV type 1 infected patients, who have either not
been treated previously*
Ja
Nein
HIV type 1 infected patients, whose previous
combination treatment with protease inhibitors
has failed*
Ja
Nein
HIV type 1 infected patients, who have to switch
their previous treatment from protease inhibitor or
nucleosidaI reverse transcriptase inhibitor due to
side effects or intolerability after achieving
suppression of viral load below the limit of
detection.*
Ja
Nein
Viramune (nevirapine) is indicated as part of
combination therapy for the antiviral treatment of
HIV-1 infected patients with advanced or
progressive immunodeficiency.*
Ja
Nein
Ausschlusskriterien
Alter unter 18 Jahre*
Ja
Nein
Pregnant female patients*
Ja
Nein
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Hypersensitivity to the active substance or to any
of the excipients of Viramune (nevirapine) or
antiretroviral in combination with Viramune, e.g.
Combivir (Zidovudine and Lamivudine), Kivexa
(Abacavir and Lamivudine) or Truvada (tenofovir
and emtricitabine).*
Ja
Nein
Viramune (nevirapine) should not be
readministered to patients who have required
permanent discontinuation for severe rash, rash
accompanied by constitutional symptoms,
hypersensitivity reactions, or clinical hepatitis due
to nevirapine.*
Ja
Nein
Viramune (nevirapine) should not be used in
patients with severe hepatic impairment (Child-
Pugh C) or pre-treatment GOT (Glutamic
Oxaloacetic Transaminase) or GPT (Glutamic
Pyruvate Transaminase) > 5 upper limit of normal
until baseline GOT/GPT are stabilised < 5 upper
limit of normal.*
Ja
Nein
Viramune (nevirapine) should not be
readministered in patients who previously had
GOT or GPT (Liver enzymes) > 5 ULN (upper
limit of normal) during Viramune (nevirapine)
therapy and had recurrence of liver function
abnormalities upon readministration of Viramune
(nevirapine)*
Ja
Nein
Herbal preparations containing St Johns wort
(Hypericum perforatum) must not be used while
taking Viramune (nevirapine) due to the risk of
decreased plasma concentrations and reduced
clinical effects of nevirapine*
Ja
Nein
The available pharmacokinetic data suggest that
the concomitant use of rifampicin and Viramune
(nevirapine) is not recommended.*
Ja
Nein
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Eligibility NCT00876733 HIV Infections
Eligibility NCT00879658 Relapsing-
remitting Multiple Sclerosis
ODM derived from
http://clinicaltrials.gov/show/NCT00879658
All rights reserved. Please visit https://medical-data-
models.org/forms/5027
Eligibility
Einschlusskriterien
Alter 18 bis 55 Jahre*
Ja
Nein
Diagnosis of Multiple Sclerosis (MS) as defined
by revised McDonald criteria.*
Ja
Nein
A relapsing-remitting course of disease with at
least 1 documented relapse during the previous
year, or 2 documented relapses during the
previous 2 years, or a positive gadolinium (Gd)-
enhanced MRI scan at screening (in case the first
MRI scan obtained at screening is negative, a
second scan may be obtained 1 month later.)*
Ja
Nein
An Expanded Disability Status Scale (EDSS)
score of 0-5.0 inclusive at randomization.*
Ja
Nein
Neurologically stable with no evidence of relapse
or corticosteroid treatment within 30 days prior to
randomization.*
Ja
Nein
Patients who decline initiation or continuation of
treatment with available disease modifying drugs
for MS, for whatever reason, after having been
informed about their respective benefits and
possible adverse events by the investigator. *
Ja
Nein
Ausschlusskriterien
A manifestation of another type of MS than
RRMS*
Ja
Nein
History of chronic disease of the immune system
other than MS*
Ja
Nein
Malignancies, diabetes, significant
cardiovascular, pulmonary and hepatic diseases
and conditions*
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Ja
Nein
Active infections*
Ja
Nein
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Eligibility NCT00882245 Atopic Dermatitis
ODM derived from
http://clinicaltrials.gov/show/NCT00882245
All rights reserved. Please visit https://medical-data-
models.org/forms/5028
Eligibility
Einschlusskriterien
Alter mindestens 18 Jahre*
Ja
Nein
Subjects with a history of AD*
Ja
Nein
Written and dated informed consent*
Ja
Nein
Satisfactory medical assessment with no clinical
relevant abnormalities. *
Ja
Nein
Ausschlusskriterien
Subjects with current or recurrent disease (except
AD) that could affect the site of application, the
action, absorption or disposition of the
investigational product, or clinical or laboratory
assessments.*
Ja
Nein
Subjects who have medical or psychiatric
condition or laboratory abnormality that may
increase the risk associated with trial
participation or investigational product
administration or may interfere with the
interpretation of trial results and, in the
judgement of the investigator, would make the
subject inappropriate for entry into this trial.*
Ja
Nein
Subjects with any skin tattoo, scar, cuts, bruises,
or other skin damage, including excessive UV
exposure, at the possible drug application sites
which could impact the application of the test
agent or confound the local assessments during
this study.*
Ja
Nein
Subjects with clinically significant renal and liver
parameters, as defined as > 1.5 x creatinine and
3 x AST ULN (upper limit of normal) respectively.*
Ja
Nein
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Eligibility NCT00876031 Soft Tissue
Sarcoma
ODM derived from
http://clinicaltrials.gov/show/NCT00876031
All rights reserved. Please visit https://medical-data-
models.org/forms/5035
Eligibility
Einschlusskriterien
Alter 6 Monate bis 21 Jahre*
Ja
Nein
written informed consent for registration,
randomisation, data collection/transfer, and
tumour material asservation available*
Ja
Nein
pathologically (including molecular pathology)
proven diagnosis of rhabdomyosarcoma (RMS)
or RMS-like soft tissue sarcoma (STS) and
tumour material available for pathology review*
Ja
Nein
Rhabdomyosarcoma of the High Risk Group,
i.e.:*
Ja
Nein
RME, N0, M0, IRS II&III, >5 cm or >10 years in
EXT, HN-PM, OTH, UG-BP*
Ja
Nein
RME, N1, M0, any IRS-group, any size or age*
Ja
Nein
RMA, NO, M0, any IRS-group, any size or age
(exception: paratesticular RMA are not eligible)
or*
Ja
Nein
Rhabdomyosarcoma of the Very High Risk
Group, i.e.:*
Ja
Nein
RMA, N1, MO, IRS II&III, any size or age or*
Ja
Nein
localised high-risk RMS-like Soft Tissue
Sarcoma, i.e.:*
Ja
Nein
EES, pPNET, UDS: any N, M0, any IRS-group,
any size or age*
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Ja
Nein
Synovial(is)sarkom*
Ja
Nein
no pre-existing illness preventing treatment (esp.
those listed in the medicinal product information,
e.g. cardiac, hepatic, metabolic, or renal
dysfunction, hypersensitivity)*
Ja
Nein
no previous malignant tumours*
Ja
Nein
available for long term follow up through the
treating centre*
Ja
Nein
in remission (according to the CWS-2007-HR
definition (see X7.1.8X)) at the time of
randomisation after standard multimodal therapy
e.g. according to the CWS-guidance *
Ja
Nein
Ausschlusskriterien
pregnant or lactating women*
Ja
Nein
other medical condition precluding treatment with
protocol therapy (e.g. HIV, psychiatric disorder,
etc.)*
Ja
Nein
for sexually active females and males in Arm B
(O-TIE treatment): refusal to use effective
contraception (e.g. oral, IUD)*
Ja
Nein
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Eligibility NCT00876031 Soft Tissue Sarcoma
Eligibility NCT00883051 Migraine Disorders
ODM derived from
http://clinicaltrials.gov/show/NCT00883051
All rights reserved. Please visit https://medical-data-
models.org/forms/5036
Eligibility
Einschlusskriterien
Alter 18 bis 65 Jahre*
Ja
Nein
Patients with migraine with or without aura
fulfilling the IHS diagnostic criteria 1.1 and 1.2.1
(2004)*
Ja
Nein
History of migraine of at least 1 year*
Ja
Nein
Migraine onset before the age of 50 years*
Ja
Nein
History of 1 - 8 migraine attacks per month*
Ja
Nein
Female patients of child-bearing potential must
be using a highly effective form of contraception
(e.g., combined oral contraceptive, IUD,
abstinence, vasectomized partner)*
Ja
Nein
Able and willing to give written informed consent*
Ja
Nein
Able and willing to complete a migraine diary card
to record details of the attack treated with study
medication *
Ja
Nein
Ausschlusskriterien
History of life threatening or intolerable adverse
reaction to any triptan*
Ja
Nein
Use of prescription migraine prophylactic drugs
within 15 days (30 days for flunarizine) prior to
Screening Visit and during study participation*
Ja
Nein
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Using herbal preparations (e.g., feverfew,
butterbur) for migraine prophylaxis*
Ja
Nein
Using 5-HT reuptake inhibitors*
Ja
Nein
Using drugs known to inhibit CYP450 enzymes
(see Appendix 2 for details)*
Ja
Nein
Pregnant or breast-feeding women*
Ja
Nein
Women of child-bearing potential not using highly
effective contraception*
Ja
Nein
History or evidence of coronary artery disease,
ischemic or hemorrhagic stroke, epilepsy or any
other condition placing the patient at increased
risk of seizures*
Ja
Nein
History of hypertension (controlled or
uncontrolled)*
Ja
Nein
History of orthostatic hypotension*
Ja
Nein
Current use of hemodynamically active
cardiovascular drugs*
Ja
Nein
History within the previous 3 years or current
evidence of abuse of any drug, prescription or
illicit, or alcohol*
Ja
Nein
Significant renal or hepatic impairment*
Ja
Nein
Previous participation in this clinical trial*
Ja
Nein
Participation in any clinical trial of an
experimental drug or device in the previous 30
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Eligibility NCT00883051 Migraine Disorders
days*
Ja
Nein
Any medical condition or laboratory test which in
the judgment of the investigator makes the
patient unsuitable for the study*
Ja
Nein
Known Hepatitis B or C or HIV infection*
Ja
Nein
Patients who are employees of the sponsor*
Ja
Nein
Relatives of, or staff directly reporting to, the
investigator*
Ja
Nein
Patients with known hypersensitivity to COL-144,
other 5HT1F receptor agonists or to any excipient
of COL-144 drug product*
Ja
Nein
Patients who were treated with study medication
in the COL MIG-201 study (Patients screened but
not treated under that protocol are not excluded)*
Ja
Nein
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Eligibility NCT00883051 Migraine Disorders
Eligibility NCT00883337 Multiple Sclerosis
ODM derived from
http://clinicaltrials.gov/show/NCT00883337
All rights reserved. Please visit https://medical-data-
models.org/forms/5037
Eligibility
Einschlusskriterien
Alter mindestens 18 Jahre*
Ja
Nein
Patients with relapsing forms of multiple sclerosis
meeting McDonald's criteria for MS diagnosis at
time of screening visit, and EDSS score <=5.5 at
screening visit*
Ja
Nein
Provided informed consent with signature on
informed consent form *
Ja
Nein
Ausschlusskriterien
Patients with significantly impaired bone marrow
function or significant anemia, leukopenia, or
thrombocytopenia*
Ja
Nein
Persistent significant or severe infection*
Ja
Nein
Liver function impairment or known history of
hepatitis*
Ja
Nein
Use of adrenocorticotrophic hormone (ACTH) or
systemic corticosteroids for 2 weeks prior to
randomization*
Ja
Nein
HIV-positiv*
Ja
Nein
Prior use of Rebif, or prior or concomitant use of
other interferons in the 3 months prior to
randomization*
Ja
Nein
Prior or concomitant use of cladribine,
mitoxantrone, or other immunosuppressant
agents such as azathioprine, cyclophosphamide,
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cyclosporin, methotrexate, mycophenolate, or
natalizumab*
Ja
Nein
Pregnant or breast-feeding women*
Ja
Nein
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Eligibility NCT00883337 Multiple Sclerosis
Eligibility NCT00887198 Prostate Cancer
ODM derived from
http://clinicaltrials.gov/show/NCT00887198
All rights reserved. Please visit https://medical-data-
models.org/forms/5038
Eligibility
Einschlusskriterien
Alter mindestens 18 Jahre*
Ja
Nein
Metastatic castration-resistant prostate cancer*
Ja
Nein
Previous anti-androgen therapy and progression
after withdrawal*
Ja
Nein
ECOG performance status of either 0 or 1*
Ja
Nein
Medical or surgical castration with testosterone <
50 ng/dL*
Ja
Nein
Able to provide written informed consent *
Ja
Nein
Ausschlusskriterien
Prior cytotoxic chemotherapy or biologic therapy
for CRPC*
Ja
Nein
Prior ketoconazole for prostate cancer*
Ja
Nein
Known brain metastasis or visceral organ
metastasis*
Ja
Nein
Use of opiate analgesics for cancer-related pain,
including codeine and dextropropoxyphene,
currently or anytime within 4 weeks of Cycle 1
Day 1*
Ja
Nein
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Eligibility NCT00906399 Relapsing Multiple
Sclerosis
ODM derived from
http://clinicaltrials.gov/show/NCT00906399
All rights reserved. Please visit https://medical-data-
models.org/forms/5040
Eligibility
Einschlusskriterien
Alter 18 bis 65 Jahre*
Ja
Nein
Einverständniserklärung*
Ja
Nein
Must have a confirmed diagnosis of relapsing
MS, as defined by McDonald criteria #1-4*
Ja
Nein
EDSS - Expanded disability status scale <= 5.0*
Ja
Nein
Must have experienced at least 2 relapses that
have been medically documented within the last
3 years with one occurring in the last 12 months *
Ja
Nein
Ausschlusskriterien
Other chronic disease of immune system,
malignancies, urologic, pulmonary,
gastrointestinal disease*
Ja
Nein
Pregnant or nursing women *
Ja
Nein
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Eligibility NCT00909597 Diabetes Mellitus,
Type 2
ODM derived from
http://clinicaltrials.gov/show/NCT00909597
All rights reserved. Please visit https://medical-data-
models.org/forms/5042
Eligibility
Einschlusskriterien
Alter 18 bis 75 Jahre*
Ja
Nein
type 2 diabetes mellitus*
Ja
Nein
treated with stable sulfonylurea monotherapy or
metformin + sulfonylurea for >=12 weeks prior to
screening*
Ja
Nein
HbA1c >=7.0% and <=10% at screening*
Ja
Nein
stable weight +/-5% for >=12 weeks prior to
screening. *
Ja
Nein
Ausschlusskriterien
type 1 diabetes, diabetes resulting from
pancreatic injury, or secondary forms of diabetes*
Ja
Nein
clinically significant diabetic complications*
Ja
Nein
clinically symptomatic gastrointestinal disease*
Ja
Nein
>3 episodes of severe hypoglycemia within 6
months before screening.*
Ja
Nein
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Eligibility NCT00915252 Acute Myeloid
Leukemia
ODM derived from
http://clinicaltrials.gov/show/NCT00915252
All rights reserved. Please visit https://medical-data-
models.org/forms/5043
Eligibility
Einschlusskriterien
Alter mindestens 61 Jahre*
Ja
Nein
Patients with newly diagnosed AML (except APL)
according to the FAB or WHO classification,
including AML evolving from MDS or other
hematological diseases and AML after previous
cytotoxic therapy or radiation (secondary AML).*
Ja
Nein
Bone marrow aspirate or biopsy must contain >=
20% blasts of all nucleated cells or differential
blood count must contain >= 20% blasts. In AML
FAB M6 >= 30% of non-erythroid cells in the
bone marrow must be leukemic blasts. In AML
defined by cytogenetic aberrations the proportion
of blasts may be < 20%.*
Ja
Nein
Informed consent, personally signed and dated to
participate in the study*
Ja
Nein
Male patients enrolled in this trial must use
adequate barrier birth control measures during
the course of the 5-azacytidine treatment and for
at least 3 months after the last administration of
5-azacytidine. *
Ja
Nein
Ausschlusskriterien
Patients who are not eligible for standard
chemotherapy as described in chapter 5.2 and
5.3*
Ja
Nein
Hyperleukocytosis (leukocytes >
20,000/microliter) at study entry. These patients
should be treated with hydroxyurea or receive
leukocytapheresis treatment (if leukocytes >
100,000/microliter) according to routine practice
and entered into the study when leukocyte counts
below 20,000/microliter are reached. This applies
only for the controlled part of the study.*
Ja
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Nein
Patients with initial hyperleukocytosis above
20,000/microliter can only be enrolled into the
controlled part of the study, but not in the run-in
dose finding part.*
Ja
Nein
Known central nervous system manifestation of
AML*
Ja
Nein
Cardiac Disease: Heart failure NYHA class 3 or
4. Unstable coronary artery disease (MI more
than 6 months prior to study entry is permitted).
Serious cardiac ventricular arrhythmias requiring
anti-arrhythmic therapy (beta blockers or digoxin
are permitted)*
Ja
Nein
Chronically impaired renal function (creatinin
clearance < 30 ml / min)*
Ja
Nein
Inadequate liver function (ALT and AST >= 2.5 x
ULN) if not caused by leukemic infiltration*
Ja
Nein
Total bilirubin  >= 1.5 x ULN if not caused by
leukemic infiltration*
Ja
Nein
Known HIV and/or hepatitis C infection*
Ja
Nein
Evidence or history of severe non-leukemia
associated bleeding diathesis or coagulopathy*
Ja
Nein
Evidence or recent history of CNS disease,
including primary or metastatic brain tumors,
seizure disorders*
Ja
Nein
Uncontrolled active infection*
Ja
Nein
Concurrent malignancies other than AML with an
estimated life expectancy of < 2 years*
Ja
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Eligibility NCT00915252 Acute Myeloid Leukemia
Nein
History of organ allograft*
Ja
Nein
Hypersensitivity to cytarabine (not including drug
fever or exanthema), daunorubicin, azacytidine or
mannitol*
Ja
Nein
Previous treatment of AML except hydroxyurea
and up to 2 days of <=100 mg/m2/d cytarabine*
Ja
Nein
Previous therapy with 5-azacytidine (i.e. for an
antecedent myelodysplastic syndrome)*
Ja
Nein
Patients with investigational drug therapy outside
of this trial during or within 4 weeks of study entry
should be discussed with the study office whether
study participation is possible*
Ja
Nein
Any severe concomitant condition, which makes it
undesirable for the patient to participate in the
study or which could jeopardize compliance with
the protocol*
Ja
Nein
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Eligibility NCT00915252 Acute Myeloid Leukemia
Eligibility NCT00919373 Ventricular
Tachycardia
ODM derived from
http://clinicaltrials.gov/show/NCT00919373
All rights reserved. Please visit https://medical-data-
models.org/forms/5045
Eligibility
Einschlusskriterien
Alter 18 bis 80 Jahre*
Ja
Nein
Coronary artery disease For the purpose of this
study, coronary artery disease will be defined as
the presence of a 50 % or more diameter
stenosis of the left main coronary artery, or 75 %
or more diameter stenosis of the left anterior
descending, circumflex or right coronary arteries*
Ja
Nein
coronary artery disease will be defined as the
history of a surgical or percutaneous
revascularization procedure, or history of
successful thrombolysis, or a history of prior
myocardial infarction (e.g.: documented by Q-
wave, R-reduction, aneurysm)*
Ja
Nein
Left ventricular ejection fraction <= 50 % as
estimated by echocardiography or contrast
ventriculography within the previous 30 days and
evidence for old myocardial infarction (ECG,
echocardiographic or venticulographic).*
Ja
Nein
One episode of documented stable clinical VT
without any reversible causes*
Ja
Nein
Written informed consent *
Ja
Nein
Ausschlusskriterien
Alter < 18 Jahre oder > 80 Jahre *
Ja
Nein
Protruding LV thrombus on pre-ablation
echocardiogram*
Ja
Nein
Akuter Myokardinfarkt*
Ja
1 / 3
Nein
Class IV NYHA heart failure*
Ja
Nein
Valvular heart disease or mechanical heart valve
precluding access to the left ventricle*
Ja
Nein
instabile Angina, Crescendo-Angina*
Ja
Nein
Cardiac surgery involving cardiotomy (not CABG)
within the past 2 months*
Ja
Nein
Kreatinin im Serum*
Ja
Nein
Thrombocytopenia or coagulopathy*
Ja
Nein
Contraindication to heparin*
Ja
Nein
Schwangerschaft*
Ja
Nein
Acute illness or active systemic infection*
Ja
Nein
Other disease process likely to limit survival to
<12 months*
Ja
Nein
Significant medical problem that in the opinion of
the principal investigator would preclude
enrollment in the study*
Ja
Nein
Participation in another investigational study*
Ja
Nein
Unwillingness to participate or lack of availability
for follow-up*
Ja
Nein
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Incessant VT or electrical storm*
Ja
Nein
Bundle branch reentry tachycardia as the
presenting VT*
Ja
Nein
Preexisting ICD*
Ja
Nein
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Eligibility NCT00919373 Ventricular Tachycardia
Eligibility NCT00949650 Carcinoma, Non-
Small-Cell Lung
ODM derived from
http://clinicaltrials.gov/show/NCT00949650
All rights reserved. Please visit https://medical-data-
models.org/forms/5046
Eligibility
Einschlusskriterien
Alter mindestens 18 Jahre*
Ja
Nein
Pathologically confirmed diagnosis of Stage IIIB
(with cytologically proven pleural effusion or
pericardial effusion) or Stage IV adenocarcinoma
of the lung. Patients with mixed histology are
eligible if adenocarcinoma is the predominant
histology.*
Ja
Nein
Epidermal Growth Factor Receptor mutation
detected by central laboratory analysis of tumour
biopsy material.*
Ja
Nein
Measurable disease according to RECIST 1.1.*
Ja
Nein
Eastern Cooperative Oncology Group score of 0
or 1.*
Ja
Nein
Life expectancy of at least three months.*
Ja
Nein
Written informed consent that is consistent with
ICH-GCP guidelines. *
Ja
Nein
Ausschlusskriterien
Prior chemotherapy for relapsed and/or
metastatic NSCLC. Neoadjuvant/adjuvant
chemotherapy is permitted if at least 12 months
has elapsed between the end of chemotherapy
and randomisation.*
Ja
Nein
Prior treatment with Epidermal Growth Factor
Receptor targeting small molecules or
antibodies.*
Ja
Nein
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Radiotherapy or surgery (other than biopsy)
within 4 weeks prior to randomisation.*
Ja
Nein
Active brain metastases*
Ja
Nein
Any other current malignancy or malignancy
diagnosed within the past five years*
Ja
Nein
Known pre-existing interstitial lung disease.*
Ja
Nein
Significant or recent acute gastrointestinal
disorders with diarrhoea as a major symptom.*
Ja
Nein
History or presence of clinically relevant
cardiovascular abnormalities.*
Ja
Nein
Any other concomitant serious illness or organ
system dysfunction.*
Ja
Nein
Adequate absolute neutrophil count and platelet
count*
Ja
Nein
Adequate liver and kidney function*
Ja
Nein
Active hepatitis B infection, active hepatitis C
infection or known HIV carrier.*
Ja
Nein
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Eligibility NCT00949650 Carcinoma, Non-Small-Cell Lung
Eligibility NCT00923754 Descending
Thoracic Aortic Aneurysm
ODM derived from
http://clinicaltrials.gov/show/NCT00923754
All rights reserved. Please visit https://medical-data-
models.org/forms/5047
Eligibility
Einschlusskriterien
Alter mindestens 18 Jahre*
Ja
Nein
Descending thoracic aortic aneurysm with
diameter >= 5.0 cm, or*
Ja
Nein
Descending thoracic aortic aneurysm with a
history of growth >= 0.5 cm within the previous 12
months, or*
Ja
Nein
Descending thoracic aortic degenerative or
atherosclerotic ulcers >= 10 mm in depth and 20
mm in diameter *
Ja
Nein
Ausschlusskriterien
Alter < 18 Jahre*
Ja
Nein
Other medical condition that may cause the
patient to be non-compliant with the protocol,
confound the results, or is associated with limited
life expectancy (i.e., < 2 years)*
Ja
Nein
Pregnant, breast-feeding, or planning on
becoming pregnant within 24 months*
Ja
Nein
Unwilling or unable to comply with the follow-up
schedule*
Ja
Nein
Inability or refusal to give informed consent*
Ja
Nein
< 30 days beyond primary endpoint in another
investigative device or drug study*
Ja
Nein
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Eligibility NCT00932724 Metastatic
Colorectal Cancer
ODM derived from
http://clinicaltrials.gov/show/NCT00932724
All rights reserved. Please visit https://medical-data-
models.org/forms/5048
Eligibility
Einschlusskriterien
Alter mindestens 18 Jahre*
Ja
Nein
Patients are eligible with diagnosis of measurable
metastatic colorectal carcinoma and radiologic
documentation of disease progression during or
with 3 months after termination of standard
chemotherapy (fluoropyrimidine-based therapy
with oxaliplatin and irinotecan). Patients who had
to interrupt the 1st or 1nd line therapy due to
intolerance or who were refractory or intolerant to
the standard treatment regimens are eligible, too.
Bevacizumab can, but does not need to be
administered at discretion of treating physician.
Patients with K-RAS wild-type can be treated with
cetuximab or panitumumab before they enter the
study.*
Ja
Nein
No chemotherapy within 4 weeks before
treatment start*
Ja
Nein
No residual significant toxicity (> NCI grade 1), in
case of peripheral neuropathy: no symptoms of
peripheral neuropathy of NCI CTC grade 4 within
4 weeks before treatment start.*
Ja
Nein
No previous treatment with experimental
therapies after standard therapies is allowed.*
Ja
Nein
Patients must use effective contraception if of
reproductive potential. Females must not be
pregnant or lactating*
Ja
Nein
Eastern Cooperative Oncology Group (ECOG)
Performance status of 0 - 2*
Ja
Nein
WBC >= 3,000/mm3, absolute neutrophil count
(ANC) >= 1,500/mm3, platelet count
>=100,000/mm3*
Ja
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Nein
Bilirubin <= 2.0 mg/dL (40 micromol/L) (unless
due to Gilbert's syndrome in which case the
bilirubin should be <=3.5 mg/dL (59.86
micromol/L)), aspartate transaminase
(AST)/alanine transaminase (ALT) <= 5 x upper
limit of normal (ULN). Hepatic alkaline
phosphatase <= 3.0 x ULN (in case of liver
metastases higher levels do not hinder inclusion
of patients)*
Ja
Nein
Serum creatinine <= 2.0 mg/dL (180
micromol/L)or creatinine clearance >= 50 ml/min.
, proteinuria < 2.0 g/24 hr urine collection in
patients with a positive urine dipstick for protein*
Ja
Nein
Written informed consent according to ICH-GCP
and national laws and regulations prior to receipt
of any trial medication or beginning trial
procedures *
Ja
Nein
Ausschlusskriterien
Evidence of any other malignant disease (with
the exception of tumors operatively cured >= 5
years prior to the trial)*
Ja
Nein
Hirnmetastasen*
Ja
Nein
Uncontrolled pleural effusions*
Ja
Nein
Interstitial pneumonitis or pulmonary fibrosis*
Ja
Nein
Severe/ unstable systemic disease or infection
and circumstances not permitting trial
participation (e.g., alcoholism or substance
abuse)*
Ja
Nein
Unstable cardiac disease in the last 6 months*
Ja
Nein
Use of conventional mistletoe preparations, any
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Eligibility NCT00932724 Metastatic Colorectal Cancer
immunostimulating substances and/or
monoclonal antibodies within four weeks prior to
and during the trial - ongoing therapy with
steroids is permitted if the dose is not > 20 mg of
prednisone-equivalent at the time of inclusion and
during this clinical trial*
Ja
Nein
Any evidence or history (elicited by the
investigator) of symptomatic cerebrovascular
events (i.e., stroke or transient ischemic attack)
within 6 months prior to randomization*
Ja
Nein
Any history or evidence of pulmonary embolism
or thrombophlebitis (including deep vein
thrombosis) requiring anticoagulant therapy (e.g.,
marcumar or heparin)*
Ja
Nein
History of hypersensitivity to mistletoe*
Ja
Nein
History of primary immunodeficiency*
Ja
Nein
Known human immunodeficiency virus (HIV) or
known active viral hepatic infections*
Ja
Nein
Prior treatment with CY-503*
Ja
Nein
A general medical or psychological condition or
behaviour, including substance dependence or
abuse that, in the opinion of the investigator,
might not permit the patient to complete the trial
or sign the informed consent*
Ja
Nein
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Eligibility NCT00932724 Metastatic Colorectal Cancer
Eligibility NCT00927667 Hemophilia A
ODM derived from
http://clinicaltrials.gov/show/NCT00927667
All rights reserved. Please visit https://medical-data-
models.org/forms/5049
Eligibility
Einschlusskriterien
Alter 12 bis 35 Jahre*
Ja
Nein
männlich*
Ja
Nein
Severe hemophilia A ( < 1 % FVIII:C)*
Ja
Nein
No history of Factor VIII inhibitory antibody*
Ja
Nein
For prophylaxis groups, having received at least
two prophylactic infusions per week for 45 weeks
per year for the prevention of bleeding without
relevant interruption and continuing until the
present.*
Ja
Nein
Complete documentation of joints bleeds and
their locations prior to start of prophylaxis,*
Ja
Nein
Bleeding history and/or treatments received
during the last 5 years documented in the
subjects medical records.*
Ja
Nein
For the on-demand subjects > 12 bleeds/year in
the last 5 years.*
Ja
Nein
Written informed consent by subject and
parent/legal representative, if < 18 years *
Ja
Nein
Ausschlusskriterien
Individuals with other coagulopathies (e.g., von
Willebrand disease)*
Ja
Nein
HIV-positiv*
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Ja
Nein
Individuals for whom the most clinically severe
joint is not one of the 4 index joints (ankle, knee)*
Ja
Nein
HCV seropositive individuals who underwent
interferon therapy during the last 12 months*
Ja
Nein
Gelenkersatz, Arthroplastik*
Ja
Nein
For the on-demand treatment group, any period >
8 consecutive months having received >/= 50 IU
per kg per week Factor VIII for the prevention of
bleeding*
Ja
Nein
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Eligibility NCT00927667 Hemophilia A
Eligibility NCT00927836 Acute Ischemic
Stroke
ODM derived from
http://clinicaltrials.gov/show/NCT00927836
All rights reserved. Please visit https://medical-data-
models.org/forms/5050
Eligibility
Einschlusskriterien
Alter 18 bis 85 Jahre*
Ja
Nein
diagnosis of acute ischemic stroke with an onset
within 9 hours prior to start of study agent
administration*
Ja
Nein
ischemic stroke in the MCA territory confirmed by
MRI (diffusion)*
Ja
Nein
lesion size on DWI >=15 ccm*
Ja
Nein
written informed consent *
Ja
Nein
Ausschlusskriterien
prior to current stroke: inability to walk or to lead
an independent life*
Ja
Nein
life expectancy <= 6 months*
Ja
Nein
stupor or coma*
Ja
Nein
Lacunar infarction*
Ja
Nein
Intracerebral hemorrhage (ICH)*
Ja
Nein
maligner Hypertonus*
Ja
Nein
presence of history of active malignancies*
Ja
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Nein
platelet count <100/nl at randomization*
Ja
Nein
leukocyte count >20/nl at randomization*
Ja
Nein
kongenitale Neutro(zyto)penie*
Ja
Nein
pregnant or lactating women*
Ja
Nein
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Eligibility NCT00927836 Acute Ischemic Stroke
Eligibility NCT00930319 Androgen Ablative Therapy of
Advanced Hormone-dependent Prostate Carcinoma
ODM derived from
http://clinicaltrials.gov/show/NCT00930319
All rights reserved. Please visit https://medical-data-
models.org/forms/5051
Eligibility
Einschlusskriterien
Alter mindestens 18 Jahre*
Ja
Nein
Advanced Hormone-dependent Prostate
Carcinoma*
Ja
Nein
therapeutic need according to SPC*
Ja
Nein
written informed consent *
Ja
Nein
Ausschlusskriterien
contraindications according to SPC*
Ja
Nein
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Eligibility NCT00955565 Hip Fracture
ODM derived from
http://clinicaltrials.gov/show/NCT00955565
All rights reserved. Please visit https://medical-data-
models.org/forms/5052
Eligibility
Einschlusskriterien
Alter mindestens 18 Jahre*
Ja
Nein
Radiologically confirmed sacroiliac dislocation or
sacroiliac fracture*
Ja
Nein
sakroiliakale Arthritis*
Ja
Nein
Written informed consent by patient or his/her
legal representative *
Ja
Nein
Ausschlusskriterien
Poor life expectancy (<3 months)*
Ja
Nein
Fracture of pathologic origin*
Ja
Nein
History of substance abuse (recreational drugs,
alcohol)within 12 months prior to screening*
Ja
Nein
Häftling, Gefangene(r)*
Ja
Nein
Currently involved in another study that precludes
or complicates participation*
Ja
Nein
Disease or condition that would preclude
accurate evaluation (e.g., significant psychiatric
disease)*
Ja
Nein
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Eligibility NCT00980629 Atopic Dermatitis
ODM derived from
http://clinicaltrials.gov/show/NCT00980629
All rights reserved. Please visit https://medical-data-
models.org/forms/5054
Eligibility
Einschlusskriterien
Alter 18 bis 65 Jahre*
Ja
Nein
Male or female patients (aged 18-65 years) with a
diagnosis of AD.*
Ja
Nein
Female patients of child bearing potential must
be using a medically acceptable form of
contraception.*
Ja
Nein
Patients who are able and willing to give signed
informed consent.*
Ja
Nein
Patients who have pruritus exceed the reference
range.*
Ja
Nein
Ausschlusskriterien
Patients who have a history of allergy to
hydrocortisone.*
Ja
Nein
Patients who have a history of relevant drug
hypersensitivity.*
Ja
Nein
Patients who have a history of contact dermatitis
induced by a topical steroid.*
Ja
Nein
Patients who are taking, and who are unwilling
not to take, any medications or therapy prohibited
by the protocol for the complete duration of the
study.*
Ja
Nein
Krebs*
Ja
Nein
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Patients who have any renal or liver insufficiency,
or clinically significant cardiac, renal or hepatic
disease.*
Ja
Nein
Patients who, in the opinion of the investigator,
are not deemed eligible as determined by
medical history, physical examination or clinical
laboratory safety tests.*
Ja
Nein
Patients who have pruritus associated with
conditions other than AD.*
Ja
Nein
Patients who have pruritus only on the face and
head.*
Ja
Nein
Patients who, in the opinion of the investigator,
have clinically relevant history or presence of any
disease, or surgical history other than AD which
is likely to affect the conduct of the study.*
Ja
Nein
Patients who have used M5161(active ingredient
of M516102).*
Ja
Nein
Patients who cannot communicate reliably with
the investigator.*
Ja
Nein
Patients who are pregnant or lactating.*
Ja
Nein
Patients who have used any IMP and/or
participated in any clinical trial within 3 months.*
Ja
Nein
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Eligibility NCT00980629 Atopic Dermatitis
Eligibility NCT00964977 Oropharyngeal
Cancer
ODM derived from
http://clinicaltrials.gov/show/NCT00964977
All rights reserved. Please visit https://medical-data-
models.org/forms/5055
Eligibility
Einschlusskriterien
Alter mindestens 18 Jahre*
Ja
Nein
histological diagnosis of a primary squamous cell
carcinoma of the oral cavity or the oropharynx*
Ja
Nein
maximum tumor diameter < 4 cm in the
pathohistological specimen irrespective of
histological grading (pT1 or pT2)*
Ja
Nein
concomitant histological verification of a singular
ipsilateral lymph node metastasis < 3cm in
diameter (pN1) without penetration of the lymph
node´s capsule and without presence of invasion
of lymphatic vessels (lymphangiosis
carcinomatosa)*
Ja
Nein
radical resection of the tumor within adequate
resection margins (R0)*
Ja
Nein
written informed consent from the patient*
Ja
Nein
adequate performance status ECOG Index <= 2 *
Ja
Nein
Ausschlusskriterien
Alter < 18 Jahre*
Ja
Nein
pregnant women*
Ja
Nein
reported drug addiction*
Ja
Nein
intake of remedies with potential influence on
compliance or impaired judgment*
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Ja
Nein
patients with mental disorders or conceivable
physical, familial or job related embarrassments
which may preclude the patient to realize the
study schedule*
Ja
Nein
inadequate performance status ECOG Index > 2*
Ja
Nein
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Eligibility NCT00964977 Oropharyngeal Cancer
Eligibility NCT00968708 Diabetes Mellitus,
Type 2
ODM derived from
http://clinicaltrials.gov/show/NCT00968708
All rights reserved. Please visit https://medical-data-
models.org/forms/5056
Eligibility
Einschlusskriterien
Alter mindestens 18 Jahre*
Ja
Nein
Diagnosis of type 2 diabetes mellitus*
Ja
Nein
Subject is receiving monotherapy or combination
antidiabetic therapy with a glycosylated
hemoglobin level between 6.5% and 11.0%,
inclusive, at Screening (between 7.0 and 11.0%,
inclusive, if the subject's antidiabetic regimen
includes insulin)*
Ja
Nein
Diagnosis of acute coronary syndrome within 15
to 90 days prior to randomization *
Ja
Nein
Ausschlusskriterien
Signs of type 1 diabetes mellitus*
Ja
Nein
Currently receiving a glucagon-like peptide-1
analogue for glycemic control of type 2 diabetes
mellitus at Screening*
Ja
Nein
Received a dipeptidyl peptidase-4 inhibitor for
either more than 14 days total or within the 3
months prior to Screening*
Ja
Nein
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Eligibility NCT00974311 Castration-
Resistant Prostate Cancer
ODM derived from
http://clinicaltrials.gov/show/NCT00974311
All rights reserved. Please visit https://medical-data-
models.org/forms/5057
Eligibility
Einschlusskriterien
Alter mindestens 18 Jahre*
Ja
Nein
Progressive prostate cancer*
Ja
Nein
Medical or surgical castration with testosterone <
50 ng/dl*
Ja
Nein
One or two prior chemotherapy regimens. At
least one chemotherapy regimen must have
contained docetaxel*
Ja
Nein
ECOG performance status 0-2*
Ja
Nein
Adequate bone marrow, hepatic, and renal
function*
Ja
Nein
Able to swallow the study drug and comply with
study requirements*
Ja
Nein
Einverständniserklärung*
Ja
Nein
Ausschlusskriterien
Metastases in the brain or active epidural
disease*
Ja
Nein
Another malignancy within the previous 5 years*
Ja
Nein
Clinically significant cardiovascular disease*
Ja
Nein
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GI disorder affecting absorption*
Ja
Nein
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Eligibility NCT00974311 Castration-Resistant Prostate Cancer
Eligibility NCT00974740 Type 1 Diabetes
ODM derived from
http://clinicaltrials.gov/show/NCT00974740
All rights reserved. Please visit https://medical-data-
models.org/forms/5058
Eligibility
Einschlusskriterien
Alter 18 bis 39 Jahre*
Ja
Nein
Insulin treated patients with a newly diagnosed
type 1 diabetes mellitus as defined by the ADA
criteria at least two weeks but not later than 3
months after start of insulin treatment*
Ja
Nein
Male patient or female patient using adequate
contraceptive methods*
Ja
Nein
Tested positive for at least one of the three islet
autoantibodies GAD65, IA2 or ICA *
Ja
Nein
Ausschlusskriterien
History of neoplastic disease*
Ja
Nein
Presence of a clinically significant hepatic or
renal disease, as indicated, but not limited to a
serum creatinine elevated > ten percent above
the upper limit of normal, elevation of AST or ALT
> 3 times the upper limit of normal*
Ja
Nein
Any other acute or chronic condition that may
affect the patient's response to treatment or might
be associated with an increased risk for the
patient to participate, as judged by the
investigator*
Ja
Nein
Current use of anti-inflammatory or
immunomodulatory drugs, antihypertensive, lipid-
lowering, or antidiabetic drugs other than insulin*
Ja
Nein
Pregnant or nursing women or women intending
to become pregnant*
Ja
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Nein
Known or suspected allergy to atorvastatin or any
component of the trial product*
Ja
Nein
Known myopathy, myalgia or myositis with a
serum-CPK > 3 times the upper limit of normal*
Ja
Nein
Patients who had a severe blood loss (>= 400
mL, e.g. blood donation) within 2 months prior to
visit 2*
Ja
Nein
Any significant laboratory abnormality*
Ja
Nein
A serum LDL-cholesterol > 150 mg/dL at time of
screening*
Ja
Nein
Unwillingness to comply with study procedures*
Ja
Nein
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Eligibility NCT00974740 Type 1 Diabetes
Eligibility NCT00983138 Acute Lymphoid
Leukemia
ODM derived from
http://clinicaltrials.gov/show/NCT00983138
All rights reserved. Please visit https://medical-data-
models.org/forms/5060
Eligibility
Einschlusskriterien
Alter bis zu 364 Tage*
Ja
Nein
Previously untreated T-lineage or precursor B-
lineage ALL or biphenotypic leukaemia according
to EGIL criteria.*
Ja
Nein
Morphological verification of the diagnosis,
confirmed with cyto-chemistry and
immunophenotyping.*
Ja
Nein
Written informed consent of the parents or other
legally authorised guardian of the patient.*
Ja
Nein
Treatment according to protocol INTERFANT 06 *
Ja
Nein
Ausschlusskriterien
Mature B-lineage ALL, defined by the
immunophenotypical presence of surface
immunoglobulins or t(8;14) and breakpoint as in
B-ALL.*
Ja
Nein
The presence of the t(9;22)(q34;q11) or bcr-abl
fusion in the leukaemic cells.*
Ja
Nein
Systemic use of corticosteroids < 4 weeks before
diagnosis. Patients who received corticosteroids
by aerosol are eligible.*
Ja
Nein
Known allergy to any ASNase preparation.*
Ja
Nein
Pre-existing known coagulopathy (e.g.
haemophilia).*
Ja
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Nein
Pre-existing pancreatitis.*
Ja
Nein
Liver insufficiency (bilirubin > 50 micromol/L,
SGOT/SGPT > 10 x the upper limit of normal).*
Ja
Nein
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Eligibility NCT00983138 Acute Lymphoid Leukemia
Eligibility NCT00984867 Type 2 Diabetes
ODM derived from
http://clinicaltrials.gov/show/NCT00984867
All rights reserved. Please visit https://medical-data-
models.org/forms/5061
Eligibility
Einschlusskriterien
Alter mindestens 18 Jahre*
Ja
Nein
Patients with type 2 diabetes*
Ja
Nein
Patients who are not receiving treatment , or
those who currently receive metformin, sitagliptin
or vildagliptin or the combination of these*
Ja
Nein
Patients will be screened by a blood test and only
those who need additional therapy can be
enrolled *
Ja
Nein
Ausschlusskriterien
Diabetes mellitus Typ 1*
Ja
Nein
Diabetes mellitus poor control*
Ja
Nein
Any clinically significant illness, which in the
judgement of the investigator would compromise
the patient's safety or successful participation in
the clinical study*
Ja
Nein
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Eligibility NCT00987636 Ewing's Sarcoma
ODM derived from
http://clinicaltrials.gov/show/NCT00987636
All rights reserved. Please visit https://medical-data-
models.org/forms/5062
Eligibility
Einschlusskriterien
Alter 48 Monate bis 50 Jahre*
Ja
Nein
Diagnosis: Histologically confirmed Ewing
sarcoma of bone or soft tissue.*
Ja
Nein
Age and sex: Either sex, age >48 months (for
GPOH patients) and <50 years at the date of
diagnostic biopsy. Younger or elderly patients
may be reported to the appropriate office (see
section 1.4) but are not included in this study.*
Ja
Nein
Registration: <= 45 days after diagnostic
biopsy/surgery.*
Ja
Nein
Start of chemotherapy: <= 45 days after
diagnostic biopsy/surgery.*
Ja
Nein
Informed consent: Must be signed prior to study
entry.*
Ja
Nein
Performance status: Lansky or Karnofsky score >
50%, may be modified for handicapped patients.*
Ja
Nein
Haematological parameters:*
Ja
Nein
Haemoglobin > 8 g/dl (transfusion allowed),*
Ja
Nein
Platelets > 80.000/nicrol (transfusion allowed),*
Ja
Nein
Leukozyt, weiße Blutzelle, weißes
Blutkörperchen*
Ja
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Nein
Cardiac values: LVEF > 40%, SF > 28%. *
Ja
Nein
Ausschlusskriterien
> one cycle of other chemotherapy prior to
registration*
Ja
Nein
Neoplasms, Second Primary*
Ja
Nein
Pregnancy and lactation*
Ja
Nein
Concurrent treatment within any other clinical
trial, except trials with different endpoints that due
to the nature of their endpoints must run parallel
to EWING 2008 e.g. trials on antiemetics,
antimycotics, antibiotics, strategies for
psychosocial support, etc...*
Ja
Nein
Any other medical, psychiatric, or social condition
incompatible with protocol treatment*
Ja
Nein
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Eligibility NCT00987636 Ewing's Sarcoma
Eligibility NCT00989261 Acute Myeloid
Leukemia
Phase 2 Open-Label, AC220 Monotherapy Efficacy (ACE)
Study in Patients With Acute Myeloid Leukemia (AML) With
and Without FLT3-ITD Activating Mutations
see http://clinicaltrials.gov/show/NCT00989261
All rights reserved. Please visit https://medical-data-
models.org/forms/5063
Eligibility AML NCT00989261
Einschlusskriterien
Alter 18 bis 85 Jahre*
Ja
Nein
Males and females age ≥18 years in second
relapse or refractory.*
Ja
Nein
Males and females age ≥60 years in first relapse
or refractory.*
Ja
Nein
Must have baseline bone marrow sample taken.*
Ja
Nein
Morphologically documented primary AML or
AML secondary to myelodysplastic syndrome
(MDS with ≥20% bone marrow or peripheral
blasts), as defined by the World Health
Organization (WHO) criteria, confirmed by
pathology review at treating institution.*
Ja
Nein
Able to swallow the liquid study drug.*
Ja
Nein
ECOG performance status of 0 to 2*
Ja
Nein
In the absence of rapidly progressing disease,
the interval from prior treatment to time of AC220
administration will be at least 2 weeks for
cytotoxic agents or at least 5 half-lives for
noncytotoxic agents. The use of
chemotherapeutic or antileukemic agents other
than hydroxyurea is not permitted during the
study with the possible exception of intrathecal
(IT) therapy at the discretion of the Investigator
and with the agreement of the Sponsor.*
Ja
Nein
Persistent chronic clinically significant non-
hematological toxicities from prior treatment must
be ≤ Grade 1.*
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Ja
Nein
Prior therapy with FLT3 inhibitors is permitted,
except previous treatment with AC220.*
Ja
Nein
Serum creatinine ≤1.5 × ULN and glomerular
filtration rate (GFR) > 30 mL/min*
Ja
Nein
Serum potassium, magnesium, and calcium
levels should be at least within institutional
normal limits.*
Ja
Nein
Total serum bilirubin ≤1.5 × ULN*
Ja
Nein
Serum aspartate transaminase (AST) and/or
alanine transaminase (ALT) ≤2.5 × ULN*
Ja
Nein
Females of childbearing potential must have a
negative pregnancy test (urine β-hCG).*
Ja
Nein
Females of childbearing potential and sexually
mature males must agree to use a medically
accepted method of contraception throughout the
study.*
Ja
Nein
Procurement of patient informed consent,
investigational study*
Ja
Nein
Ausschlusskriterien
Alter >85 Jahre*
Ja
Nein
Diagnosis of acute promyelocytic leukemia*
Ja
Nein
Diagnosis of chronic myelogenous leukemia
(CML) in blast crisis*
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Eligibility NCT00989261 Acute Myeloid Leukemia
Ja
Nein
AML in relapse or refractory after 3 or more
previous lines of chemotherapy (and/or HSCT)
treatment*
Ja
Nein
AML or antecedent MDS secondary to prior
chemotherapy*
Ja
Nein
Persistent clinically significant non-hematological
toxicity that is Grade >1 by NCI CTCAE v4 from
prior chemotherapy*
Ja
Nein
Patients who have had HSCT and are within 100
days of transplant and/or are still taking
immunosuppressive drugs and/or have clinically
significant graft-versus-host disease requiring
treatment and/or have >Grade 1 persistent non
hematological toxicity related to the transplant*
Ja
Nein
ZNS-Leukämie*
Ja
Nein
Patients who have previously received AC220*
Ja
Nein
Disseminated intravascular coagulation (DIC)
(diagnosis by laboratory or clinical assessment)*
Ja
Nein
Major surgery within 4 weeks prior to enrollment
in the study*
Ja
Nein
Radiation therapy within 4 weeks prior to, or
concurrent with study*
Ja
Nein
Use of concomitant drugs that prolong QT/QTc
interval and/or are CYP3A4 inhibitors are
prohibited with the exception of antibiotics,
antifungals, and other antimicrobials that are
used as standard of care to prevent or treat
infections and other such drugs that are
considered absolutely essential for the care of the
patient.*
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Eligibility NCT00989261 Acute Myeloid Leukemia
Ja
Nein
Uncontrolled or significant cardiovascular
disease*
Ja
Nein
Women who are pregnant, lactating, or unwilling
to use contraception if of childbearing potential*
Ja
Nein
Men who are unwilling to use contraception if
their partners are of childbearing potential*
Ja
Nein
Active, uncontrolled infection*
Ja
Nein
HIV-positiv*
Ja
Nein
Active hepatitis B or C or other active liver
disease*
Ja
Nein
History of cancer, except Stage 1 cervix or
nonmelanotic skin cancer, with the possible
exception of patients in complete remission*
Ja
Nein
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Eligibility NCT00989261 Acute Myeloid Leukemia
Eligibility NCT00993473 Type 1 Diabetes
Mellitus
ODM derived from
http://clinicaltrials.gov/show/NCT00993473
All rights reserved. Please visit https://medical-data-
models.org/forms/5064
Eligibility
Einschlusskriterien
Alter 1 Jahr bis 6 Jahre*
Ja
Nein
Pediatric patients with type 1 diabetes mellitus
aged >= one year to < 6 years at screening, for
whom signed written informed consent has been
obtained from parent or legal guardian to
participate in the study *
Ja
Nein
Ausschlusskriterien
Diagnosis of type 1 diabetes for < one year*
Ja
Nein
HbA1c at screening >12% or <6%*
Ja
Nein
Diabetes other than type 1 diabetes*
Ja
Nein
Parents and patients not willing to undergo all
study assessments and treatments, including
home blood glucose monitoring, Continuous
Glucose Monitoring System (CGMS) sensor
placement and maintenance both at the site and
at home, multiple daily insulin injections, and
visits, as dictated by the protocol (if a telephone
is not available patients may undergo all visits in
person)*
Ja
Nein
Patients and families for whom 6 days in total (not
necessarily continuous) of useable CGMS data
cannot be obtained (either by home sensor
replacement, or by sensor replacement at the site
at additional screening visits if needed) during the
screening CGMS evaluations between Visit 2 and
the randomization visit*
Ja
Nein
Patients treated with insulin pump therapy during
the two months prior to screening*
Ja
Nein
1 / 2
History of primary seizure disorder*
Ja
Nein
History of severe hypoglycemic episode
accompanied by seizure and/or coma, or diabetic
ketoacidosis leading to hospitalization or to care
in the emergency ward, in the 2 months prior to
the screening visit*
Ja
Nein
Need for chronic treatment with acetaminophen
(paracetamol)-containing medications*
Ja
Nein
Serum creatinine > 2.0mg/dL at screening*
Ja
Nein
Serum ALT or AST > 3x upper limit of normal for
the patient's age and gender, at screening*
Ja
Nein
Hemoglobin < 10g/dL, or platelet count <
100,000/cu mm, at screening*
Ja
Nein
Treatment with any pharmacologic anti-
hyperglycemic oral agent for > 3 months at any
time*
Ja
Nein
Treatment with any non-insulin antihyperglycemic
medication (eg, Symlin) for the 3 months prior to
screening*
Ja
Nein
Treatment with systemic glucocorticoids within
the month prior to screening*
Ja
Nein
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Eligibility NCT00993473 Type 1 Diabetes Mellitus
Eligibility NCT01011205 Liver
Transplantation
ODM derived from
http://clinicaltrials.gov/show/NCT01011205
All rights reserved. Please visit https://medical-data-
models.org/forms/5065
Eligibility
Einschlusskriterien
Alter mindestens 18 Jahre*
Ja
Nein
Undergoing orthotopic liver or split liver allograft
transplantation*
Ja
Nein
Female subject of childbearing potential must
have a negative serum or urine pregnancy test at
enrollment and must agree to maintain effective
birth control during the study *
Ja
Nein
Ausschlusskriterien
Receiving a multi-organ transplant or having
previous received an organ transplant (including
liver re-transplantation)*
Ja
Nein
Receiving an auxiliary graft or in whom a bio-
artificial liver (cell system) has been used*
Ja
Nein
Receiving ABO incompatible graft or a graft from
a non heart beating donor*
Ja
Nein
Ongoing dosing with systemic corticosteroids*
Ja
Nein
Subjects with systemic infection requiring
treatment except viral hepatitis*
Ja
Nein
Diagnosis of new-onset malignancy prior to
transplantation, with the exception of basocellular
or squamous cell carcinoma of the skin which
had been treated successfully. However, subjects
with primary liver carcinoma can be included if
they meet the following criteria:*
Ja
Nein
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< 3 nodes*
Ja
Nein
no node larger than 5 cm*
Ja
Nein
No metastases (tumor staging)*
Ja
Nein
Vascular invasion by tumor absent*
Ja
Nein
Significant, uncontrolled concomitant infections
and/or severe diarrhea, vomiting, active upper
gastro-intestinal tract malabsorption or active
peptic ulcer*
Ja
Nein
Subject or donor known to be HIV positive*
Ja
Nein
Known allergy or intolerance to tacrolimus,
macrolide antibiotics, corticosteroids, basiliximab
or mycophenolate mofetil or any of the product
excipients*
Ja
Nein
Pregnant woman or breast-feeding mother*
Ja
Nein
Currently participating in another clinical trial,
and/or has taken an investigational drug within 28
days prior to enrollment*
Ja
Nein
Unlikely to comply with the Visits scheduled in the
protocol*
Ja
Nein
Any unstable medical condition that could
interfere with the study objectives in the opinion
of the Investigator*
Ja
Nein
Receiving prohibited concomitant therapy, or
received prohibited concomitant therapy within 28
days prior to enrollment*
Ja
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Eligibility NCT01011205 Liver Transplantation
Nein
Any form of substance abuse, psychiatric
disorder or condition which, in the opinion of the
Investigator, may complicate communication with
the Investigator*
Ja
Nein
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Eligibility NCT01011205 Liver Transplantation
Eligibility NCT01016275 Iliac Lesions
ODM derived from
http://clinicaltrials.gov/show/NCT01016275
All rights reserved. Please visit https://medical-data-
models.org/forms/5066
Eligibility
Einschlusskriterien
Alter mindestens 18 Jahre*
Ja
Nein
Patient presenting with a stenotic or occlusive
lesion at the iliac arteries suitable for stenting (on
indication for primary stenting, based on the
discretion of the investigator)*
Ja
Nein
Patient presenting a score from 2 to 5 following
Rutherford classification*
Ja
Nein
Patient is willing to comply with specified follow-
up evaluations at the specified times for the
duration of the study*
Ja
Nein
Patient (or their legal representative) understands
the nature of the procedure and provides written
informed consent, prior to enrolment in the study*
Ja
Nein
Patient is eligible for treatment with the Misago
(Terumo)*
Ja
Nein
The target lesion is either a modified TASC-II
class A or B lesion with one of the listed
specifications:*
Ja
Nein
Type A lesions*
Ja
Nein
Unilateral or bilateral stenoses of the Common
Iliac Artery*
Ja
Nein
Unilateral or bilateral single short (<=3 cm)
stenosis of the External Iliac  Artery*
Ja
Nein
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Type B lesions*
Ja
Nein
Unilateral Common Iliac Artery occlusion*
Ja
Nein
Single or multiple stenosis totaling 3-10 cm
involving the External Iliac  Artery not extending
into the Common Femoral Artery*
Ja
Nein
Unilateral External Iliac Artery occlusion not
involving the origins of  Internal Iliac Artery or
Common Iliac Artery*
Ja
Nein
The target lesion has angiographic evidence of
stenosis or restenosis > 50% or occlusion which
can be passed with standard guidewire
manipulation*
Ja
Nein
There is angiographic evidence of a patent
Common an Deep Femoral Artery *
Ja
Nein
Ausschlusskriterien
The target lesion is either a modified TASC-II
class B lesion with aortic lesion involvement:*
Ja
Nein
Short (<=3 cm) stenosis of infrarenal aorta*
Ja
Nein
The target lesion is either a modified TASC-II
class C or D lesion with aortic lesion
involvement:*
Ja
Nein
Presence of aneurysm at the level of the iliac
arteries*
Ja
Nein
Previously implanted stent(s) at the same lesion
site*
Ja
Nein
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Eligibility NCT01016275 Iliac Lesions
Reference segment diameter is not suitable for
available stent design*
Ja
Nein
Untreatable lesion located at the distal outflow
arteries*
Ja
Nein
Use of alternative therapy (e.g. atherectomy,
cutting balloon, laser, radiation therapy) as part of
the index procedure*
Ja
Nein
Therapieablehnung, Behandlungsverweigerung*
Ja
Nein
Patients for whom antiplatelet therapy,
anticoagulants or thrombolytic drugs are
contraindicated*
Ja
Nein
Patients who exhibit persistent acute intraluminal
thrombus of the proposed lesion site*
Ja
Nein
Perforation at the angioplasty site evidenced by
extravasation of contrast medium*
Ja
Nein
Patients with a history of prior life-threatening
contrast medium reaction*
Ja
Nein
Patients with known hypersensitivity to nickel-
titanium*
Ja
Nein
Patients with uncorrected bleeding disorders*
Ja
Nein
Female patient with child bearing potential not
taking adequate contraceptives or currently
breastfeeding*
Ja
Nein
Life expectancy of < twelve months*
Ja
Nein
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Eligibility NCT01016275 Iliac Lesions
Any planned surgical intervention/procedure
within 30 days of the study procedure*
Ja
Nein
Any patient considered to be hemodynamically
unstable at onset of procedure*
Ja
Nein
Patient is currently participating in another
investigational drug or device study that has not
completed the entire follow up period.*
Ja
Nein
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Eligibility NCT01016275 Iliac Lesions
Eligibility NCT01018069 Leukemia
ODM derived from
http://clinicaltrials.gov/show/NCT01018069
All rights reserved. Please visit https://medical-data-
models.org/forms/5067
Eligibility
Einschlusskriterien
Alter mindestens 18 Jahre*
Ja
Nein
Patients with AML, except those with APL (acute
promyelocytic leukemia), failing a single standard
dose cytarabine based frontline induction
regimen. The diagnosis of refractory AML is
based on the presence of either > 10% blasts in
marrow or blood or 5-10% blasts in either site
together with cytopenia (Hb < 10 g/dL, or
platelets < 100 x 109/L, or neutrophil count < 1.0
x 109/L).*
Ja
Nein
ECOG Status <=2*
Ja
Nein
Male, or female patients who are post-
menopausal (amenorrheic for at least 12
months), or surgically or biologically sterile.*
Ja
Nein
Patients must have adequate organ and immune
function as indicated by the following laboratory
values:*
Ja
Nein
Parameter Laboratory Values Serum creatinine;
≤2.0 mg/dL (≤ 177 μmol/L Total Bilirubin ≤2.0
mg/dL (≤ 34 μmol/L) AST (SGOT) and ALT
(SGPT) ≤3 X ULN*
Ja
Nein
The patient must understand, be able and willing
and likely to fully comply with study procedures,
including scheduled follow-up, and restrictions. *
Ja
Nein
Ausschlusskriterien
Clinical evidence of ongoing grade 3 or 4 non-
hematological toxicities from the initial standard
dose cytarabine-based induction chemotherapy*
Ja
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Nein
Patients with a prior history of peripheral
neuropathy of grade >= 2.*
Ja
Nein
Clinical evidence of active CNS leukemic
involvement.*
Ja
Nein
Active and uncontrolled infection. Patients with an
infection who are under active treatment with
antibiotics and whose infections are controlled
may be entered to the study.*
Ja
Nein
Current evidence of invasive fungal infection
(blood or tissue culture).*
Ja
Nein
Current evidence of an active second malignancy
except for non-melanoma skin cancer.*
Ja
Nein
Uncontrolled medical problems, unrelated to the
malignancy, or of sufficient severity that in the
opinion of the investigator, impair a patient's
ability to give informed consent or unacceptably
reduce the safety of the proposed treatment.*
Ja
Nein
Neurological or psychiatric disorders that would
interfere with consent or study follow-up.*
Ja
Nein
Known or suspected intolerance or
hypersensitivity to the study drugs [or closely
related compounds] or any of their stated
ingredients. Study drugs being the antisense,
cytarabine and idarubicin.*
Ja
Nein
History of alcohol or other substance abuse
within the last year.*
Ja
Nein
Use of another investigational agent within the
last 14 days prior to enrolment. Patients who
have received a previous antisense agent in the
last 90 days will be excluded.*
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Ja
Nein
Female patients who are pregnant, lactating, or
with a positive pregnancy test at screening must
be excluded.*
Ja
Nein
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Eligibility NCT01019174 Multiple Myeloma
ODM derived from
http://clinicaltrials.gov/show/NCT01019174
All rights reserved. Please visit https://medical-data-
models.org/forms/5068
Eligibility
Einschlusskriterien
Alter mindestens 18 Jahre*
Ja
Nein
Understand and voluntarily sign an informed
consent form.*
Ja
Nein
Able to adhere to the study visit schedule and
other protocol requirements.*
Ja
Nein
Previously diagnosed with multiple myeloma
based on standard criteria and requires therapy
for primary refractory disease or 1st - 3rd relapse
because of progressive disease (PD), defined as
a 25% increase in M-protein, development of new
or worsening of existing lytic bone lesions or soft
tissue plasmacytoma, or hypercalcemia (serum
calcium > 11.3 mg/dL), or clinical relapse from
CR.*
Ja
Nein
At least one measurable disease manifestation
defined as follows:*
Ja
Nein
For secretory multiple myeloma, measurable
disease is defined as any  quantifiable serum
monoclonal protein value (generally, but not
exclusively, >  1g/dL IgG M-protein or > 0.5 g/dL
IgA) and, where applicable, urine light-chain
excretion of >= 200 mg/24 h.*
Ja
Nein
For oligo- or non-secretory multiple myeloma,
measurable disease is defined by the presence of
soft tissue (not bone) plasmacytomas as
determined by clinical examination or applicable
radiographs (i.e. MRI, CT-Scan) or a quantifiable
plasma cell infiltration of the bone marrow as
determined by bone marrow biopsy.*
Ja
Nein
ECOG performance status <= 2 at time of
randomization/registration (see Appendix I).*
Ja
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Nein
Laboratory test results within these ranges within
1 week prior to randomization/registration:*
Ja
Nein
Absolute neutrophil count >= 1.5 x 109/L without
the use of colony stimulating  factors within 14
days before the laboratory test.*
Ja
Nein
Platelet count >= 75 x 109/L without transfusion
support within 14 days before  the laboratory
test.*
Ja
Nein
Hemoglobin >= 7.5 g/dL (regardless of
transfusion support or prior medication  with
erythropoietin).*
Ja
Nein
Calculated creatinine clearance >= 50
mL/minute.*
Ja
Nein
Gesamtbilirubin*
Ja
Nein
AST (SGOT) and ALT (SGPT) <= 2,5 x ULN.*
Ja
Nein
korrigiertes Serumkalzium*
Ja
Nein
Female subjects of childbearing potential must:*
Ja
Nein
Understand that the study medication could have
a potential teratogenic risk*
Ja
Nein
Agree to use, and be able to comply with,
effective contraception without  interruption, 4
weeks before starting study drug, throughout
study drug therapy  (including dose interruptions)
and for 4 weeks after the end of study drug
therapy, even if she has amenorrhoea. This
applies unless the subject commits to  absolute
and continued abstinence confirmed on a
monthly basis. The following  are effective
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methods of contraception:*
Ja
Nein
Contraceptive Implant*
Ja
Nein
INSERTION OF LEVONORGESTREL-
RELEASING INTRAUTERINE SYSTEM*
Ja
Nein
Medroxyprogesterone acetate depot*
Ja
Nein
Tubensterilisation, Eileiterunterbindung*
Ja
Nein
Sexual intercourse with a vasectomised male
partner only. Vasectomy must be  confirmed by
two negative semen analyses*
Ja
Nein
Ovulation inhibitory progesterone-only pills (i.e.,
desogestrel).*
Ja
Nein
Combined oral contraceptive pills are not
recommended. If a subject was using combined
oral contraception, she must switch to one of the
methods above. The increased risk of VTE
continues for 4 to 6 weeks after stopping
combined oral contraception*
Ja
Nein
Prophylactic antibiotics should be considered at
the time of insertion particularly in patients with
neutropenia due to risk of infection*
Ja
Nein
Agree to have a medically supervised pregnancy
test with a minimum sensitivity  of 25 mIU/ml not
more than 3 days from the start of study
medication once the  subject has been on
effective contraception for at least 4 weeks. This
requirement also applies to women of
childbearing potential who practice  complete and
continued abstinence.*
Ja
Nein
Agree to have a medically supervised pregnancy
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test every 4 weeks including 4  weeks after the
end of study treatment, except in the case of
confirmed tubal  sterilization. These tests should
be performed not more than 3 days before the
start of next treatment. This requirement also
applies to women of childbearing  potential who
practice complete and continued abstinence *
Ja
Nein
Male subjects must*
Ja
Nein
Agree to use condoms throughout study drug
therapy, during any dose interruption  and for one
week after cessation of study therapy if their
partner is of  childbearing potential and has no
contraception.*
Ja
Nein
Agree not to donate semen during study drug
therapy and for one week after end  of study drug
therapy. *
Ja
Nein
All subjects must*
Ja
Nein
Agree to abstain from donating blood while taking
study drug therapy and for one  week following
discontinuation of study drug therapy.*
Ja
Nein
Agree not to share study medication with another
person and to return all unused  study drug to the
investigator.*
Ja
Nein
Disease free of prior malignancies for ≥ 5 years
with exception of currently treated basal cell,
squamous cell carcinoma of the skin, or
carcinoma "in situ" of the cervix or breast*
Ja
Nein
Able and willing to take heparin (usually low-
molecular weight - LMWH) or low acetylsalicylic
acid (100 mg) daily as prophylactic
anticoagulation.*
Ja
Nein
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Life-expectancy > 3 months.*
Ja
Nein
Ausschlusskriterien
Any serious medical condition, laboratory
abnormality, or psychiatric illness that would
prevent the subject from signing the informed
consent form.*
Ja
Nein
Females, who are pregnant, calculate to get
pregnant or are breast feeding (Lactating females
must agree not to breast feed while taking
lenalidomide).*
Ja
Nein
Any condition, including the presence of
laboratory abnormalities, which places the
subject at an unacceptable risk if he/she were to
participate in the study or confounds the ability to
interpret data from the study.*
Ja
Nein
Patient currently is enrolled in another clinical
research study or has been enrolled in such a
study within 4 weeks before
randomization/registration and/or is receiving an
investigational agent for any reason or has
received such an agent within 4 weeks before
randomization/registration.*
Ja
Nein
Known hypersensitivity to thalidomide,
dexamethasone, or cyclophosphamide or similar
drugs.*
Ja
Nein
Any prior use of lenalidomide.*
Ja
Nein
Concurrent use of other anti-cancer agents or
treatments.*
Ja
Nein
Known positive for HIV or infectious hepatitis,
type A, B or C.*
Ja
Nein
Any other chemotherapy or high-dose
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dexamethasone within 4 weeks before
randomization/registration.*
Ja
Nein
Immunotherapy or antibody therapy within 8
weeks before randomization/registration.*
Ja
Nein
major surgery*
Ja
Nein
Myocardial infarction within 6 months before
randomization/registration, New York Heart
Association Class III or IV heart failure,
uncontrolled angina, severe uncontrolled
ventricular arrhythmias, or electrocardiographic
evidence of acute ischemia or active conduction
system abnormalities.*
Ja
Nein
Senile cardiac amyloidosis, Cardiac amyloidosis,
AS transthyretin amyloidosis*
Ja
Nein
Poorly controlled hypertension, diabetes mellitus,
or other serious medical or psychiatric illness that
could potentially interfere with the completion of
treatment according to the protocol.*
Ja
Nein
Any systemic infection requiring treatment.*
Ja
Nein
Zystitis*
Ja
Nein
Disturbance of urinary flow.*
Ja
Nein
Unable or unwilling to take heparin (usually low-
molecular weight - LMWH) or low acetylsalicylic
acid (100 mg) daily as prophylactic
anticoagulation.*
Ja
Nein
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Eligibility NCT01026142 Breast Cancer
ODM derived from
http://clinicaltrials.gov/show/NCT01026142
All rights reserved. Please visit https://medical-data-
models.org/forms/5069
Eligibility
Einschlusskriterien
Alter mindestens 18 Jahre*
Ja
Nein
Erwachsener, erwachsen*
Ja
Nein
Metastatic HER2 positive breast cancer*
Ja
Nein
ECOG performance status 0 or 1*
Ja
Nein
Disease progression during or following
trastuzumab-based therapy for 1st line metastatic
breast cancer (trastuzumab must have been part
of the last prior treatment regimen)*
Ja
Nein
Prior treatment with taxane-containing regimen*
Ja
Nein
LVEF - Left ventricular ejection fraction*
Ja
Nein
For women of childbearing potential agreement to
use highly effective non-hormonal form of
contraception or two effective forms of non-
hormonal contraception by patient and/or partner.
Contraception must continue for duration of study
treatment and for at least 6 months after last
dose of study drug treatment *
Ja
Nein
Ausschlusskriterien
Prior treatment with pertuzumab or capecitabine*
Ja
Nein
Concurrent treatment with other experimental
drug*
Ja
Nein
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Concurrent immunotherapy or anticancer
hormonal therapy*
Ja
Nein
Serious concurrent disease (e.g. active infection,
uncontrolled hypertension, cardiovascular
disease)*
Ja
Nein
CNS metastases, which are not well controlled*
Ja
Nein
History of exposure to anthracycline cumulative
dose equivalent to 360mg/m2 doxorubicin*
Ja
Nein
History of congestive heart failure of any New
York Heart Association criteria, or serious cardiac
arrhythmia requiring treatment*
Ja
Nein
Past history of myocardial infarction*
Ja
Nein
History of LVEF decline to below 50% during or
after prior trastuzumab therapy or other cardiac
toxicity during previous trastuzumab treatment
that necessitated discontinuation of trastuzumab*
Ja
Nein
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Eligibility NCT01031680 Type 2 Diabetes
Mellitus
ODM derived from
http://clinicaltrials.gov/show/NCT01031680
All rights reserved. Please visit https://medical-data-
models.org/forms/5070
Eligibility
Einschlusskriterien
Alter mindestens 45 Jahre*
Ja
Nein
Type 2 diabetes mellitus.*
Ja
Nein
Kardiovaskuläre Erkrankung*
Ja
Nein
Hypertonie*
Ja
Nein
Ausschlusskriterien
Patients with type 1 diabetes or diabetes
insipidus*
Ja
Nein
Patients with 3 or more oral anti-hyperglycaemic
drugs with or without insulin and/or poorly
controlled diabetes*
Ja
Nein
Any clinically significant illness, which would
compromise the patient's safety and their
participation in the study*
Ja
Nein
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Eligibility NCT01033097 Atopic Dermatitis
ODM derived from
http://clinicaltrials.gov/show/NCT01033097
All rights reserved. Please visit https://medical-data-
models.org/forms/5071
Eligibility
Einschlusskriterien
Alter 18 bis 45 Jahre*
Ja
Nein
Male and female atopic dermatitis patients,18 to
45 years of age inclusive, who fulfill the following
criteria:*
Ja
Nein
Requirement of systemic therapy*
Ja
Nein
Itch VAS score > 50 mm*
Ja
Nein
EASI score > 8 *
Ja
Nein
Ausschlusskriterien
Pregnant or breastfeeding women. Women of
child-bearing potential or men who are not willing
to follow the restrictions in inclusion criteria 3 and
4, respectively, are not allowed in the study.*
Ja
Nein
Any systemic immunosuppressive treatment
and/or phototherapy within 4 weeks prior to the
first dosing.*
Ja
Nein
Any topical or oral treatment for atopic dermatitis
within 2 weeks prior to the first dosing. Use of any
topical or systemic treatment for atopic dermatitis
(with the exception of emollients prescribed by
the Investigator) will not be allowed during the
study period.*
Ja
Nein
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Eligibility NCT01035502 Acute Myeloid
Leukemia
ODM derived from
http://clinicaltrials.gov/show/NCT01035502
All rights reserved. Please visit https://medical-data-
models.org/forms/5072
Eligibility
Einschlusskriterien
Alter mindestens 18 Jahre*
Ja
Nein
Patients with a confirmed diagnosis of AML
according to WHO classification (excluding acute
promyelocytic leukaemia)*
Ja
Nein
Patients who have received one previous
standard dose ara-C-containing regimen aiming
at induction of complete remission (CR) and who
have > 5 % remaining blast cells in bone marrow
following the first course of remission-induction or
by other means documented residual disease
(i.e. circulating blasts, persistent chloromas, other
evident disease from day 12 on).*
Ja
Nein
Patients from whom samples for determination of
hENT1 status on leukemic blast cells can be
taken and prepared at diagnosis and/or at
baseline*
Ja
Nein
Patients must have ECOG performance status
(PS) of 0 - 2*
Ja
Nein
Left ventricular ejection fraction (LVEF) must be
>= 45 % as measured by MUGA scan or 2D
ECHO within 14 days prior to start of therapy.*
Ja
Nein
Women of child-bearing potential (i.e., women
who are pre-menopausal or not surgically sterile)
must have a negative serum or urine pregnancy
test within 2 weeks prior to beginning treatment
on this study*
Ja
Nein
Male and female patients must use acceptable
contraceptive methods for the duration of time on
study, and males also for 3 months after the last
elacytarabine dose*
Ja
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Nein
Patients must be capable of understanding and
complying with parameters as outlined in the
protocol, and able and willing to sign a written
informed consent form*
Ja
Nein
Patients must have the following clinical
laboratory values:*
Ja
Nein
Serum creatinine <= 1.5 x the institutional upper
limit of normal (ULN)*
Ja
Nein
Total bilirubin <= 1.5 x the ULN according to
national prescribing information  unless
considered due to Gilbert's syndrome*
Ja
Nein
Alanine aminotransferase (ALT) (SGPT), or
aspartate aminotransferase (AST)  (SGOT) <=
2.5 x the ULN unless considered due to organ
leukemic involvement *
Ja
Nein
Patients must be eligible for administration of
idarubicin according to current national
prescribing information for idarubicin *
Ja
Nein
Ausschlusskriterien
A history of allergic reactions to egg, idarubicin
and/or other anthracyclines or other components
of the products. A history of allergic reactions to
ara-C of CTCAE grade 3 or 4*
Ja
Nein
Persistent clinically significant and relevant
toxicities from the previous course of
chemotherapy*
Ja
Nein
A cancer history, that according to the
investigator might confound the assessment of
the study endpoints*
Ja
Nein
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Patients with prior treatment with a cumulative
dose of doxorubicin or equivalent exceeding 300
mg/m2 according to the following calculation
index: X/300 + Y/160 < 1 where X is the
doxorubicin or equivalent dose in mg/m2 and Y is
the mitoxantrone dose in mg/m2. These
calculations are to be used as guidance as there
is no maximum cumulative dose defined in the
summary of product characteristics (SPC) for
idarubicin. The patient should tolerate minimum
one course of combination therapy*
Ja
Nein
Active heart disease including myocardial
infarction within the previous 3 months,
symptomatic coronary disease, arrhythmias not
controlled by medication, or uncontrolled
congestive heart failure. Any NYHA grade 3 or 4*
Ja
Nein
HIV-positiv*
Ja
Nein
Pregnant and nursing patients are excluded
because the effects of elacytarabine on a fetus or
a nursing child are unknown*
Ja
Nein
Uncontrolled intercurrent illness including, but not
limited to uncontrolled infection, or psychiatric
illness/social situations that may reduce
compliance with study requirements*
Ja
Nein
Patients receiving hydroxyurea within the last 12
hours prior to treatment on this protocol or any
other investigational or standard cytotoxic
treatment within the last 14 days, except the first
remission-induction course*
Ja
Nein
Any medical condition, which in the opinion of the
investigator places the patient at an unacceptably
high risk for toxicities*
Ja
Nein
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Eligibility NCT01042769 Diabetes Mellitus,
Type 2
ODM derived from
http://clinicaltrials.gov/show/NCT01042769
All rights reserved. Please visit https://medical-data-
models.org/forms/5073
Eligibility
Einschlusskriterien
Alter mindestens 18 Jahre*
Ja
Nein
Erwachsener, erwachsen*
Ja
Nein
Type 2 diabetes mellitus*
Ja
Nein
Hospitalization for ACS event and randomization
2-6 weeks after day of hospitalization *
Ja
Nein
Ausschlusskriterien
Estimated glomerular filtration rate
<45mL/min/1.73m2*
Ja
Nein
Concomitant treatment with a thiazolidinedione
and/or fibrate*
Ja
Nein
Triglycerid, Triglyzerid*
Ja
Nein
Anämie*
Ja
Nein
Symptomatic congestive heart failure classified
as NYHA class II-IV*
Ja
Nein
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Eligibility NCT01042977 Type 2 Diabetes
Mellitus
ODM derived from
http://clinicaltrials.gov/show/NCT01042977
All rights reserved. Please visit https://medical-data-
models.org/forms/5074
Eligibility
Einschlusskriterien
Alter mindestens 45 Jahre*
Ja
Nein
Type 2 diabetes mellitus.*
Ja
Nein
kardiovaskuläre Erkrankung*
Ja
Nein
Uninterrupted anti-diabetic treatment for at least 8
weeks before enrolment *
Ja
Nein
Ausschlusskriterien
Patients with type 1 diabetes or diabetes
insipidus*
Ja
Nein
Patients with >= 3 oral anti-hyperglycaemic drugs
with or without insulin and/or poorly controlled
diabetes*
Ja
Nein
Any clinically significant illness, which would
compromise the patient's safety and their
participation in the study*
Ja
Nein
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Eligibility NCT01043029 Diabetes Mellitus,
Type 2
ODM derived from
http://clinicaltrials.gov/show/NCT01043029
All rights reserved. Please visit https://medical-data-
models.org/forms/5075
Eligibility
Einschlusskriterien
Alter mindestens 18 Jahre*
Ja
Nein
Erwachsener, erwachsen*
Ja
Nein
Diabetes mellitus, Type 2*
Ja
Nein
Moderately impaired kidney function*
Ja
Nein
Drug naive or up to 2 antihyperglycemic
medications at stable dose for over 1 month at
screening*
Ja
Nein
BMI*
Ja
Nein
Ausschlusskriterien
Current or previous treatment with a
thiazolidinedione*
Ja
Nein
Current or previous treatment with insulin*
Ja
Nein
Treatment with fibrates <3 months prior to
screening*
Ja
Nein
History of renal disease other than diabetic
nephropathy*
Ja
Nein
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Eligibility NCT01064401 Relapsing
Remitting Multiple Sclerosis
ODM derived from
http://clinicaltrials.gov/show/NCT01064401
All rights reserved. Please visit https://medical-data-
models.org/forms/5076
Eligibility
Einschlusskriterien
Alter 18 bis 55 Jahre*
Ja
Nein
Einverständniserklärung*
Ja
Nein
Must have a confirmed diagnosis of RRMS, and a
cranial MRI demonstrating lesion(s) consistent
with MS*
Ja
Nein
Must have a baseline EDSS between 0.0 and
5.0, inclusive*
Ja
Nein
Male subjects and female subjects of
childbearing potential must be willing to practice
effective contraception during the study and be
willing and able to continue contraception for 4
months after their last dose of study treatment *
Ja
Nein
Ausschlusskriterien
Known intolerance, contraindication to, or history
of non compliance with Avonex 30 mcg*
Ja
Nein
History of treatment with Dac HYP*
Ja
Nein
History of neoplastic disease*
Ja
Nein
History of severe allergic or anaphylactic
reactions*
Ja
Nein
Known hypersensitivity to study drugs or their
excipients*
Ja
Nein
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History of abnormal laboratory results indicative
of any significant disease*
Ja
Nein
History of human immunodeficiency virus (HIV)
or other immunodeficient conditions*
Ja
Nein
History of drug or alcohol abuse (as defined by
the Investigator) within the 2 years prior to
randomization*
Ja
Nein
History of seizure disorder or unexplained
blackouts OR history of a seizure within 6 months
prior to Baseline*
Ja
Nein
History of suicidal ideation or an episode of
clinically severe depression (as determined by
the Investigator) within 3 months prior to Day 1*
Ja
Nein
An MS relapse that has occurred within the 50
days prior to randomization AND/OR the subject
has not stabilized from a previous relapse prior to
randomization*
Ja
Nein
Known history of, or positive screening test result
for hepatitis C virus or hepatitis B virus*
Ja
Nein
Varicella or herpes zoster virus infection or any
severe viral infection within 6 weeks before
screening*
Ja
Nein
Exposure to varicella zoster virus within 21 days
before screening*
Ja
Nein
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Eligibility NCT01066208 Wegener's
Granulomatosis
ODM derived from
http://clinicaltrials.gov/show/NCT01066208
All rights reserved. Please visit https://medical-data-
models.org/forms/5077
Eligibility
Einschlusskriterien
Alter mindestens 18 Jahre*
Ja
Nein
Ability to give informed consent. If the patient is
unable to give informed consent as a result of
death or physical incapacity, then informed
assent from next of kin.*
Ja
Nein
Inclusion Criteria for Classification criteria:*
Ja
Nein
Presumed diagnosis of a primary systemic
vasculitis.*
Ja
Nein
diagnostic criteria*
Ja
Nein
Suspected diagnosis of a primary systemic
vasculitis*
Ja
Nein
Inclusion criteria for controls group for diagnostic
criteria:*
Ja
Nein
Patients presenting to secondary care with one of
the following clinical presentations: *
Ja
Nein
Multi-system disease. Presentation of disease
with at least 2 organs involved.*
Ja
Nein
Pulmonary-renal syndrome. Defined as
haemoptysis / pulmonary haemorrhage with
acute renal impairment.*
Ja
Nein
akutes Nierenversagen *
Ja
Nein
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akute Atemnot*
Ja
Nein
Chronic upper airways symptoms and signs.*
Ja
Nein
Polyarthritis*
Ja
Nein
Fieber unbekannten Ursprungs, Pyrexie
unbekannten Ursprungs*
Ja
Nein
Acute or chronic abdominal pain*
Ja
Nein
Hypertonie*
Ja
Nein
Referred to secondary care with suspicion of
vasculitis but confirmed not to have vasculitis.*
Ja
Nein
New onset headache*
Ja
Nein
Jaw or tongue pain*
Ja
Nein
plötzlicher Visusverlust*
Ja
Nein
Limb claudication*
Ja
Nein
Aortenaneurysma*
Ja
Nein
Ausschlusskriterien
Alter < 18 Jahre*
Ja
Nein
Exclusion criteria for classification criteria:*
Ja
Nein
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Inability to provide informed consent.*
Ja
Nein
Hepatitis B or C*
Ja
Nein
Co-morbidities that explain the clinical symptoms
and signs on which the diagnosis of vasculitis is
made. E.g. infection, tumour, other inflammatory
condition, etc.*
Ja
Nein
diagnostic criteria*
Ja
Nein
Patient or next of kin unable or unwilling to
provide informed consent or assent.*
Ja
Nein
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Eligibility NCT01085136 Carcinoma, Non-
Small-Cell Lung
ODM derived from
http://clinicaltrials.gov/show/NCT01085136
All rights reserved. Please visit https://medical-data-
models.org/forms/5078
Eligibility
Einschlusskriterien
Alter mindestens 18 Jahre*
Ja
Nein
Patients with pathologically confirmed diagnosis
of NSCLC Stage IIIB (with cytologically proven
pleural effusion or pericardial effusion) or Stage
IV who have failed treatment with erlotinib
(Tarceva) or gefitinib (Iressa).*
Ja
Nein
Patients should have received and failed at least
one line of cytotoxic chemotherapy including a
platinum-based regimen in patients eligible for
platinum-based therapy and pemetrexed in
pemetrexed eligible patients (unless pemetrexed
is not considered a regulatory or clinical standard
of care e.g. no label indication, no availability or
no coverage by 3rd party payer(s)) for advanced
or metastatic disease and have progressive
disease following at least 12 weeks of treatment
with erlotinib or gefitinib*
Ja
Nein
Patients pretreated with taxane-based
chemotherapy for advanced or metastatic
disease must have experienced stable disease,
partial or complete response as best response*
Ja
Nein
Eastern Cooperative Oncology Group
performance Score 0 or 1.*
Ja
Nein
Patients with at least one tumor lesion that can
accurately be measured by magnetic resonance
imaging (MRI), or computed tomography (CT) in
at least one dimension with longest diameter to
be recorded as 20 mm or greater using
conventional techniques or10 mm or greater with
spiral CT scan according to RESIST 1.1.*
Ja
Nein
Life expectancy of >= three (3) months.*
Ja
Nein
Written informed consent that is consistent with
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ICH-GCP guidelines. Part B 1) Clinical benefit
(disease stabilization or antitumor response) of
12 weeks duration in Part A of the trial
determined on the second tumour assessment.*
Ja
Nein
Ausschlusskriterien
Chemo-, hormone- (other than megestrol
acetate, steroids required for maintenance non-
cancer therapy or as premedication before
chemotherapy) or immunotherapy within the past
4 weeks; except for TKI pretreatment (2 weeks
only)*
Ja
Nein
Active brain metastases (stable <4 weeks,
symptomatic, requiring treatment with
anticonvulsants, or leptomeningeal disease).
Dexamethasone therapy will be allowed if
administered as a stable dose for at least one
month before randomization.*
Ja
Nein
Significant or recent acute gastrointestinal
disorders with diarrhea as a major symptom e.g.,
Crohn's disease, mal-absorption, or CTCAE
Grade >2 diarrhea of any etiology at baseline*
Ja
Nein
Patients who have any other life-threatening
illness or organ system dysfunction, which in the
opinion of the Investigator, would either
compromise patient safety or interfere with the
evaluation of the safety of the test drug*
Ja
Nein
Other malignancies diagnosed within the past five
(5) years (other than non-melanomatous skin
cancer and in situ cervical cancer)*
Ja
Nein
Radiotherapy within the past 2 weeks prior to
treatment with the trial drug*
Ja
Nein
History of clinically significant or uncontrolled
cardiac disease, including congestive heart
failure, angina, myocardial infarction, arrhythmia,
including New York Heart Association (NYHA)
functional classification of 3*
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Ja
Nein
Cardiac left ventricular function with resting
ejection fraction of < 50% measured by
multigated blood pool imaging of the heart
(MUGA scan) or echocardiogram*
Ja
Nein
QTc-Intervall*
Ja
Nein
Prior treatment with anthracyclines with a
cumulative dose of doxorubicin (or equivalent) at
or > 400 mg/m2*
Ja
Nein
Absolute Neutrophil Count*
Ja
Nein
Thrombozyten*
Ja
Nein
Bilirubin at or > 1.5 mg / dL (>26 mol / L, SI unit
equivalent)*
Ja
Nein
Aspartate amino transferase (AST) or alanine
amino transferase (ALT) at or > three times the
upper limit of normal (if related to liver
metastases at or > five times the upper limit of
normal)*
Ja
Nein
Serum creatinine at or > 1.5 times the upper
normal limit or calculated/measured creatinine
clearance at or < 60 mL/min*
Ja
Nein
Women of child-bearing potential or men who are
able to father a child unwilling to use a medically
acceptable method of contraception during the
trial*
Ja
Nein
Pregnancy or breast feeding*
Ja
Nein
Patients unable to comply with the protocol*
Ja
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Eligibility NCT01085136 Carcinoma, Non-Small-Cell Lung
Nein
Patients with any serious active infection
including known human immunodeficiency virus
(HIV), active hepatitis B or active hepatitis C*
Ja
Nein
Known or suspected active drug or alcohol
abuse*
Ja
Nein
interstitielle Lungenerkrankung*
Ja
Nein
Peripheral polyneuropathy Grade >= 2*
Ja
Nein
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Eligibility NCT01085136 Carcinoma, Non-Small-Cell Lung
Eligibility NCT01092533 Non-infectious
Intermediate Uveitis
ODM derived from
http://clinicaltrials.gov/show/NCT01092533
All rights reserved. Please visit https://medical-data-
models.org/forms/5080
Eligibility
Einschlusskriterien
Alter 18 bis 80 Jahre*
Ja
Nein
Subjects with a documented at least 6 months
history of unilateral or bilateral intermediate
uveitis either idiopathic or due to non-infectious
systemic disease (e.g. sarcoidosis, multiple
sclerosis)*
Ja
Nein
Uveitis has to be considered to be active at the
timepoint of enrolment according to at least one
of the following criteria:*
Ja
Nein
Grade 2+ or higher for vitreous haze*
Ja
Nein
Grade 2+ or higher for anterior chamber cells*
Ja
Nein
Presence of cystoid macular edema in OCT*
Ja
Nein
Presence of retinal vessel leakage in FA*
Ja
Nein
Considered by the investigator to require
systemic treatment.*
Ja
Nein
Not planning to undergo elective ocular surgery
during the study*
Ja
Nein
Capable of understanding the purposes and risks
of the study, able to give informed consent and to
comply with the study requirements*
Ja
Nein
Subjects of both gender with reproductive
potential who are sexually active agree to use
contraception throughout the course of the study
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and for at least 3 months after completion of their
study participation.*
Ja
Nein
Women of childbearing potential have to use a
highly effective method of birth control defined as
one which results in a low failure rate (i.e. < 1%
per year) when used consistently and correctly,
such as implants, injectables, combined oral
contraceptives, hormonal IUDs combined with
barrier methods (e.g. condom, diaphragm or
spermicide), sexual abstinence or vasectomised
partner.*
Ja
Nein
Women of childbearing age must have a negative
urine pregnancy test (UPT) within 48 hours prior
to starting study drug and must not be lactating.
*
Ja
Nein
Female subjects of non-childbearing potential
must meet at least one of the following criteria:*
Ja
Nein
Postmenopausal females, defined as:  *
Ja
Nein
Females over the age of 60 years.*
Ja
Nein
Females who are 45 to 60 years of age must be
amenorrheic for at least 2 years.*
Ja
Nein
Females who had a hysterectomy and/or bilateral
oophorectomy.*
Ja
Nein
Ausschlusskriterien
Uveitis of infectious etiology*
Ja
Nein
Signs of tuberculosis in chest x-ray during the
past 12 months before study entry*
Ja
Nein
Clinically suspected or confirmed central nervous
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Eligibility NCT01092533 Non-infectious Intermediate Uveitis
system or ocular lymphoma*
Ja
Nein
Primary diagnosis of anterior or posterior uveitis*
Ja
Nein
Uncontrolled glaucoma or known steroid
response*
Ja
Nein
Subjects who received treatment with a systemic
immunosuppressive drug, a monoclonal antibody
or any other biologic therapy within 90 days prior
study entry*
Ja
Nein
Treatment with mycophenolate mofetil or
mycophenolate sodium in the past*
Ja
Nein
Treatment with a periocular steroid injection
within 6 weeks prior to study entry*
Ja
Nein
Presence of absolute contraindications for
Decortin H and/or Myfortic as mentioned in the
product informations (Appendix 1 and 2)*
Ja
Nein
Presence of relative contraindications for
Decortin H and/or Myfortic as mentioned in the
product information (Appendix 1 and 2) if the
disorder leading to the relative contraindication
can not sufficiently managed by concomitant
medication.*
Ja
Nein
Recipients of a solid organ transplant*
Ja
Nein
Subjects with lens opacities or obscured ocular
media upon enrolment making unable evaluation
of the posterior eye segment*
Ja
Nein
Subjects with a history of herpes zoster or
varicella infection within 3 months before
enrollment*
Ja
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Eligibility NCT01092533 Non-infectious Intermediate Uveitis
Nein
Active, extraocular infection requiring the
prolonged or chronic use of antimicrobial agents
or the history/presence of active hepatitis A, B or
C*
Ja
Nein
HIV-positiv*
Ja
Nein
Alanine transaminase (ALT), aspartate
transaminase (AST), or gamma-glutamyl
transferase (GGT) >= 2x upper limit of normal
(ULN)*
Ja
Nein
Severe anemia (hemoglobin < 8 g/dL),
leukopenia (white blood cell count [WBC] < 2500
mm3), thrombocytopenia (platelet count < 80,000
mm3)*
Ja
Nein
Krebs*
Ja
Nein
Pregnant or lactating women*
Ja
Nein
Known allergy for fluorescein natrium*
Ja
Nein
Currently participating in another clinical trial with
an investigational agent in the 30 days prior to
study participation and/or has not recovered from
any reversible effects or side effects of prior
investigational agent*
Ja
Nein
Subjects with non-ocular, medically significant co-
morbid conditions that impair normal activities,
require systemic corticosteroids or
immunosuppressives, or any medical condition
that would likely have an impact on the
participant´s ability to comply with the study visit
schedule*
Ja
Nein
Any current or history of substance abuse,
psychiatric disorder or a condition that, in the
opinion of the investigator, may invalidate
communication*
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Eligibility NCT01092533 Non-infectious Intermediate Uveitis
Ja
Nein
Einschlusskriterien
Alter 18 bis 80 Jahre*
Ja
Nein
Subjects with a documented at least 6 months
history of unilateral or bilateral intermediate
uveitis either idiopathic or due to non-infectious
systemic disease (e.g. sarcoidosis, multiple
sclerosis)*
Ja
Nein
Uveitis has to be considered to be active at the
timepoint of enrolment according to at least one
of the following criteria:*
Ja
Nein
Grade 2+ or higher for vitreous haze*
Ja
Nein
Grade 2+ or higher for anterior chamber cells*
Ja
Nein
Presence of cystoid macular edema in OCT*
Ja
Nein
Presence of retinal vessel leakage in FA*
Ja
Nein
Considered by the investigator to require
systemic treatment.*
Ja
Nein
Not planning to undergo elective ocular surgery
during the study*
Ja
Nein
Capable of understanding the purposes and risks
of the study, able to give informed consent and to
comply with the study requirements*
Ja
Nein
Subjects of both gender with reproductive
potential who are sexually active agree to use
contraception throughout the course of the study
and for at least 3 months after completion of their
5 / 9
Eligibility NCT01092533 Non-infectious Intermediate Uveitis
study participation.*
Ja
Nein
Women of childbearing potential have to use a
highly effective method of birth control defined as
one which results in a low failure rate (i.e. < 1%
per year) when used consistently and correctly,
such as implants, injectables, combined oral
contraceptives, hormonal IUDs combined with
barrier methods (e.g. condom, diaphragm or
spermicide), sexual abstinence or vasectomised
partner.*
Ja
Nein
Women of childbearing age must have a negative
urine pregnancy test (UPT) within 48 hours prior
to starting study drug and must not be lactating.
*
Ja
Nein
Female subjects of non-childbearing potential
must meet at least one of the following criteria:*
Ja
Nein
Postmenopausal females, defined as:  *
Ja
Nein
Females over the age of 60 years.*
Ja
Nein
Females who are 45 to 60 years of age must be
amenorrheic for at least 2 years.*
Ja
Nein
Females who had a hysterectomy and/or bilateral
oophorectomy.*
Ja
Nein
Ausschlusskriterien
Uveitis of infectious etiology*
Ja
Nein
Signs of tuberculosis in chest x-ray during the
past 12 months before study entry*
Ja
Nein
Clinically suspected or confirmed central nervous
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Eligibility NCT01092533 Non-infectious Intermediate Uveitis
system or ocular lymphoma*
Ja
Nein
Primary diagnosis of anterior or posterior uveitis*
Ja
Nein
Uncontrolled glaucoma or known steroid
response*
Ja
Nein
Subjects who received treatment with a systemic
immunosuppressive drug, a monoclonal antibody
or any other biologic therapy within 90 days prior
study entry*
Ja
Nein
Treatment with mycophenolate mofetil or
mycophenolate sodium in the past*
Ja
Nein
Treatment with a periocular steroid injection
within 6 weeks prior to study entry*
Ja
Nein
Presence of absolute contraindications for
Decortin H and/or Myfortic as mentioned in the
product informations (Appendix 1 and 2)*
Ja
Nein
Presence of relative contraindications for
Decortin H and/or Myfortic as mentioned in the
product information (Appendix 1 and 2) if the
disorder leading to the relative contraindication
can not sufficiently managed by concomitant
medication.*
Ja
Nein
Recipients of a solid organ transplant*
Ja
Nein
Subjects with lens opacities or obscured ocular
media upon enrolment making unable evaluation
of the posterior eye segment*
Ja
Nein
Subjects with a history of herpes zoster or
varicella infection within 3 months before
enrollment*
Ja
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Eligibility NCT01092533 Non-infectious Intermediate Uveitis
Nein
Active, extraocular infection requiring the
prolonged or chronic use of antimicrobial agents
or the history/presence of active hepatitis A, B or
C*
Ja
Nein
HIV-positiv*
Ja
Nein
Alanine transaminase (ALT), aspartate
transaminase (AST), or gamma-glutamyl
transferase (GGT) >= 2x upper limit of normal
(ULN)*
Ja
Nein
Severe anemia (hemoglobin < 8 g/dL),
leukopenia (white blood cell count [WBC] < 2500
mm3), thrombocytopenia (platelet count < 80,000
mm3)*
Ja
Nein
Krebs*
Ja
Nein
Pregnant or lactating women*
Ja
Nein
Known allergy for fluorescein natrium*
Ja
Nein
Currently participating in another clinical trial with
an investigational agent in the 30 days prior to
study participation and/or has not recovered from
any reversible effects or side effects of prior
investigational agent*
Ja
Nein
Subjects with non-ocular, medically significant co-
morbid conditions that impair normal activities,
require systemic corticosteroids or
immunosuppressives, or any medical condition
that would likely have an impact on the
participant´s ability to comply with the study visit
schedule*
Ja
Nein
Any current or history of substance abuse,
psychiatric disorder or a condition that, in the
opinion of the investigator, may invalidate
communication*
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Eligibility NCT01092533 Non-infectious Intermediate Uveitis
Ja
Nein
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Eligibility NCT01092533 Non-infectious Intermediate Uveitis
Eligibility NCT01094678 Peripheral Arterial
Disease
ODM derived from
http://clinicaltrials.gov/show/NCT01094678
All rights reserved. Please visit https://medical-data-
models.org/forms/5081
Eligibility
Einschlusskriterien
Alter mindestens 18 Jahre*
Ja
Nein
stenosis of the above-the-knee femoropopliteal
artery*
Ja
Nein
appropriate size and location of the lesion *
Ja
Nein
Ausschlusskriterien
pregnant or breast feeding*
Ja
Nein
failure or inability to give informed consent*
Ja
Nein
simultaneously participating in another drug or
device study*
Ja
Nein
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Eligibility NCT01095926 Wilms Tumor
ODM derived from
http://clinicaltrials.gov/show/NCT01095926
All rights reserved. Please visit https://medical-data-
models.org/forms/5082
Eligibility
Einschlusskriterien
Alter bis zu 17 Jahre*
Ja
Nein
plan to receive at least two cycles of doxorubicin*
Ja
Nein
must be enrolled in a national or European
protocol for treatment of Wilms Tumours,
Neuroblastoma, Soft tissue sarcoma, Ewing
Sarcoma or Acute lymphoblastic leukaemia and
must be treated with doxorubicin according to
that protocol Or Patients < 3 years enrolled or
listed in any national or European study protocol
for any paediatric malignancy. Treatment with
doxorubicin has to be according to that protocol.*
Ja
Nein
Parents or legal representative(s) must provide
written informed consent to participate in the trial
according to national regulations. Patients that
are able to understand should provide assent to
participate in the trial.*
Ja
Nein
Life expectancy of at least 3 month*
Ja
Nein
Karnofsky*
Ja
Nein
Additional blood withdrawal is acceptable for the
patient. The decision is left to the investigator *
Ja
Nein
Ausschlusskriterien
prior cardiac problems*
Ja
Nein
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Eligibility NCT01107886 Type 2 Diabetes
Mellitus
ODM derived from
http://clinicaltrials.gov/show/NCT01107886
All rights reserved. Please visit https://medical-data-
models.org/forms/5083
Eligibility
Einschlusskriterien
Alter mindestens 40 Jahre*
Ja
Nein
Patients with type 2 diabetes mellitus*
Ja
Nein
HbA1c >=6.5%. (based on the last measured and
documented laboratory measurement within 6
months)*
Ja
Nein
High risk for CV events -Established
cardiovascular disease and/or multiple risk
factors *
Ja
Nein
Ausschlusskriterien
Current or previous (within 6 months) treatment
with DPP4 inhibitors and/or GLP-1 mimetics*
Ja
Nein
Acute vascular event <2months prior to
randomisation*
Ja
Nein
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Eligibility NCT01117441 Leukemia
ODM derived from
http://clinicaltrials.gov/show/NCT01117441
All rights reserved. Please visit https://medical-data-
models.org/forms/5084
Eligibility
Einschlusskriterien
Alter 1 Jahr bis 18 Jahre*
Ja
Nein
newly diagnosed acute lymphoblastic leukemia*
Ja
Nein
no Ph+ (BCR/ABL or t(9;22)-positive) ALL*
Ja
Nein
no evidence of pregnancy or lactation period*
Ja
Nein
no participation in another clinical study*
Ja
Nein
patient enrolled in a participating center*
Ja
Nein
written informed consent *
Ja
Nein
Ausschlusskriterien
pre-treatment with cytostatic drugs*
Ja
Nein
steroid pre-treatment with >= 1 mg/kg/d for > two
weeks during the last month before diagnosis*
Ja
Nein
treatment started according to another protocol*
Ja
Nein
underlying diseases that prohibit treatment
according to the protocol*
Ja
Nein
ALL diagnosed as second malignancy steroid
pre-treatment with >= 1 mg/kg/d for more than
two weeks during the last month before
diagnosis*
Ja
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Nein
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Eligibility NCT01117441 Leukemia
Eligibility NCT01120301 Acute Ischemic
Stroke
ODM derived from
http://clinicaltrials.gov/show/NCT01120301
All rights reserved. Please visit https://medical-data-
models.org/forms/5085
Eligibility
Einschlusskriterien
Alter 40 bis 80 Jahre*
Ja
Nein
Clinical diagnosis of acute ischemic stroke*
Ja
Nein
Subject is not a candidate for treatment with
neurothrombectomy*
Ja
Nein
Initiation of the TLT procedure begins between
4.5 and 24 hours*
Ja
Nein
Baseline NIHSS score range: 7-17*
Ja
Nein
Full functional independence just prior to the
present stroke episode*
Ja
Nein
Negative pregnancy test in females of
childbearing potential*
Ja
Nein
Subject Informed Consent obtained prior to
enrollment into this study*
Ja
Nein
Ausschlusskriterien
Evidence of an intracranial, subdural, or
subarachnoid hemorrhage*
Ja
Nein
Acute ischemic strokes located exclusively in the
brainstem, or cerebellum, or small deep
infarctions, or massive hemispheric strokes*
Ja
Nein
Seizure at stroke onset or within the 7 days prior
to stroke onset*
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Ja
Nein
Sustained blood glucose >300 or <60 mg/dl*
Ja
Nein
Sustained hypertension (SBP >220 mmHg or
DBP >140 mmHg)*
Ja
Nein
Sustained hypotension (SBP <80 mmHg or DBP
<50 mmHg)*
Ja
Nein
A presumed and/or confirmed septic embolus*
Ja
Nein
History of CNS vascular disease (e.g. aneurysm,
AVM) or history of CNS disease or damage (e.g.
neoplasm or dementia) which may influence the
subject's outcome assessment.*
Ja
Nein
Head implant of any kind*
Ja
Nein
Significant skin condition of the scalp (eg.
psoriasis)*
Ja
Nein
Use of any intravenous or intra-arterial
thrombolytic medication*
Ja
Nein
Use of any diagnostic or therapeutic
interventional neurovascular procedure*
Ja
Nein
Female who is pregnant or lactating or who is of
childbearing potential and not using a medically
acceptable method of birth control.*
Ja
Nein
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Eligibility NCT01120301 Acute Ischemic Stroke
Eligibility NCT01126580 Diabetes Mellitus,
Type 2
ODM derived from
http://clinicaltrials.gov/show/NCT01126580
All rights reserved. Please visit https://medical-data-
models.org/forms/5086
Eligibility
Einschlusskriterien
Alter mindestens 18 Jahre*
Ja
Nein
Have type 2 diabetes for >= 3 months and <= 5
years based on the disease diagnostic criteria
(refer to the World Health Organization's
[WHO]Classification of Diabetes).*
Ja
Nein
Are treatment-naive, not optimally controlled with
diet and exercise alone, or are taking 1 oral
antihyperglycemic medication (OAM) as
monotherapy (excluding thiazolidinediones).*
Ja
Nein
Are able and willing to tolerate a minimum dose
of 1500 mg/day or up to 2000 mg/day of
metformin.*
Ja
Nein
HbA1c*
Ja
Nein
*
Ja
Nein
a)test negative for pregnancy at screening based
on a serum pregnancy test, and*
Ja
Nein
b)agree to use a reliable method of birth control
during the study and for 1 month following the
last dose of study drug, or *
Ja
Nein
Not Lactating*
Ja
Nein
Have a stable weight (plus or minus 5%) >=  3
months prior to screening.*
Ja
Nein
BMI*
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Ja
Nein
Are well-motivated, capable, and willing to:  *
Ja
Nein
a)perform SMBG testing *
Ja
Nein
b)learn how to self-inject treatment (LY2189265
or placebo)and*
Ja
Nein
c)maintain a study diary. *
Ja
Nein
Ausschlusskriterien
Diabetes mellitus Typ 1*
Ja
Nein
You are being or have been treated with any of
the following medications:     *
Ja
Nein
a)chronically treated with insulin for the treatment
of diabetes in the past,  however, a short-term
use of > 3 months prior to screening is
allowable,*
Ja
Nein
b)GLP-1 analogs within 3 months prior to this
screening,*
Ja
Nein
c)drugs to cause weight loss within 3 months
prior to screening, *
Ja
Nein
d)thiazolidinediones (TZDs)within 3 months prior
to screening,*
Ja
Nein
e)chronically treated(>= 14 days) an oral
glucocorticoid or have received this type of
therapy within 4 weeks prior to screening,or*
Ja
Nein
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Eligibility NCT01126580 Diabetes Mellitus, Type 2
illegales Arzneimittel, verbotenes Medikament*
Ja
Nein
You have had 1 or more cases of uncontrolled
diabetes which required hospitalization in the 6
months prior to screening,*
Ja
Nein
You have a problem with your stomach or have
chronically taken medication to increase
movement in your digestive tract or slow down
the emptying of your digestive tract or you have
had gastric bypass (bariatric) surgery.*
Ja
Nein
You have had problems with your heart or brain in
the past 2 months prior to screening, such as a
heart attack, chest pain, heart failure, heart
bypass operation, angioplasty or stent insertion,a
heart rhythm problem, or a stroke.*
Ja
Nein
You have a serum creatinine result which shows
a >= 1.5 mg/dL for men or >= 1.4 mg/dL for
women.*
Ja
Nein
You have a problem with your liver or pancreas.*
Ja
Nein
You have creatinine clearance result which shows
< 60 mL/minute, evidence of a significant active,
uncontrolled endocrine (hormone) or active
autoimmune abnormality.*
Ja
Nein
You have a serum calcitonin test and it shows a
>= 20 pcg/mL at the time of screening.*
Ja
Nein
You have or have a family history of medullary C-
cell hyperplasia or endocrine neoplasia type 2A
or type 2B.*
Ja
Nein
You have cancer (except for skin cancer) or have
been in remission from cancer for < 5 years.*
Ja
Nein
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Eligibility NCT01126580 Diabetes Mellitus, Type 2
You have had an organ transplant except for
corneal transplant.*
Ja
Nein
You have received treatment within the last 30
days with a drug which has not been regulatory
approved.*
Ja
Nein
You have participated in a medical, surgical, or
pharmaceutical study where these types of
procedures were performed on you within 30
days prior to screening.*
Ja
Nein
You have any condition that is a contraindication
to or would interfere with medications provided for
this study to treat your diabetes.*
Ja
Nein
You have a blood disorder that would interfere
with us drawing blood glucose measurement or
lab samples.*
Ja
Nein
You have previously participated or signed an
informed consent document for this same type of
study and study drug.*
Ja
Nein
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Eligibility NCT01126580 Diabetes Mellitus, Type 2
Eligibility NCT01134107 Diabetes Mellitus,
Type 1
ODM derived from
http://clinicaltrials.gov/show/NCT01134107
All rights reserved. Please visit https://medical-data-
models.org/forms/5087
Eligibility
Einschlusskriterien
Alter mindestens 13 Jahre*
Ja
Nein
Diagnosed with type 1 diabetes (World Health
Organization criteria) for at least 24 months*
Ja
Nein
Treated with continuous subcutaneous insulin
infusion (CSII) therapy for the previous 6 months*
Ja
Nein
Mean total daily insulin dose for 3 days prior to
screening <= 46 units/day if using a 300-Unit
reservoir or <= 26 units/day if using a 180 unit
reservoir*
Ja
Nein
Baseline body mass index (BMI) <= 35.0 kg/m2*
Ja
Nein
Baseline HbA1c 5% to 9% *
Ja
Nein
Ausschlusskriterien
Currently using continuous glucose monitoring
(CGM), unless patients agree to not use their
personal CGM during the study*
Ja
Nein
Impaired renal function (serum creatinine >= 2.0
mg/dl)*
Ja
Nein
gesetzliche Blindheit*
Ja
Nein
Have had any episode in the 12 months prior to
screening of hypoglycemic coma, seizures, or
disorientation*
Ja
Nein
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Have had hypoglycemia unawareness (routinely
asymptomatic at BG < 45 mg/dl) in the 12 months
prior to screening.*
Ja
Nein
Have had any emergency room visits or
hospitalizations due to poor glucose control in the
12 months prior to screening.*
Ja
Nein
Have had a pump-related infusion site abscess in
the 12 months prior to screening.*
Ja
Nein
Have had multiple, clinically significant occlusions
as judged by the investigator.*
Ja
Nein
Staphylococcus aureus-Infektion*
Ja
Nein
Have one of the following concomitant diseases:
presence of clinically significant hematologic,
oncologic, renal, cardiac, hepatic, or
gastrointestinal disease, or any other serious
disease considered by the investigator to be
exclusionary.*
Ja
Nein
Patients with malignancy other than basal cell or
squamous cell skin cancer who have not yet
been treated, are currently being treated, or who
were diagnosed less than 5 years ago.*
Ja
Nein
Have had a blood transfusion or severe blood
loss within the 3 months prior to screening or
have known hemoglobinopathy, hemolytic or
sickle cell anemia, or any other traits of
hemoglobin abnormalities known to interfere with
HbA1c methodology.*
Ja
Nein
Are receiving chronic systemic glucocorticoid
therapy, or have received such therapy within the
4 weeks preceding screening.*
Ja
Nein
irregulärer Schlaf-Wach-Rhythmus*
Ja
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Eligibility NCT01134107 Diabetes Mellitus, Type 1
Nein
Have a known hypersensitivity or allergy to any of
the study insulins or their excipients*
Ja
Nein
Are breastfeeding or pregnant, or intend to
become pregnant during the course of the study,
or are sexually active women of childbearing
potential not actively practicing birth control by a
method determined by the investigator to be
medically acceptable.*
Ja
Nein
Are currently enrolled in, or discontinued within
the last 30 days from a clinical trial involving off-
label use of an investigational drug or device, or
currently enrolled in any other type of medical
research not to be scientifically or medically
compatible with this study.*
Ja
Nein
Are unwilling or unable to comply with the use of
a data collection device to directly record data
from the patient.*
Ja
Nein
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Eligibility NCT01134107 Diabetes Mellitus, Type 1
Eligibility NCT01144338 Type 2 Diabetes
Mellitus
ODM derived from
http://clinicaltrials.gov/show/NCT01144338
All rights reserved. Please visit https://medical-data-
models.org/forms/5088
Eligibility
Einschlusskriterien
Alter mindestens 18 Jahre*
Ja
Nein
Patient has type 2 diabetes mellitus*
Ja
Nein
Patient has an HbA1c of >= 7.0 % and <= 10.0%
on stable doses of up to three oral
antihyperglycemic agents for at least 3 months
(i.e. no oral antihyperglycemic agent adjustments
in the past 3 months)*
Ja
Nein
Female patients must not be breast feeding and
agree to use an effective method of contraception
or must not otherwise be at risk of becoming
pregnant. *
Ja
Nein
Ausschlusskriterien
Patient has a diagnosis of type 1 diabetes
mellitus, or a history of ketoacidosis.*
Ja
Nein
Patient has taken insulin within 2 weeks of
screening visit or for > 1 week within 3 months of
screening visit.*
Ja
Nein
Patient has ever been treated with an approved
or investigational GLP-1 receptor agonist e.g.
BYETTA (exenatide), Exenatide Once Weekly,
VICTOZA (liraglutide), or taspoglutide.*
Ja
Nein
Patient is enrolled in another experimental
protocol which involves the use of an
investigational drug or device, or an intervention
that would interfere with the conduct of the trial.*
Ja
Nein
Patient has a planned or anticipated
revascularization procedure.*
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Ja
Nein
Pregnancy or planned pregnancy during the trial
period.*
Ja
Nein
Patient has previously been enrolled in EXenatide
Study of Cardiovascular Event Lowering
(EXSCEL).*
Ja
Nein
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Eligibility NCT01144338 Type 2 Diabetes Mellitus
Eligibility NCT01146444 Cutaneous Lupus
Erythematosus
ODM derived from
http://clinicaltrials.gov/show/NCT01146444
All rights reserved. Please visit https://medical-data-
models.org/forms/5089
Eligibility
Einschlusskriterien
Alter 18 bis 85 Jahre*
Ja
Nein
Patients with subacute cutaneous lupus
erythematosus (SCLE), discoid lupus
erythematosus (DLE), or lupus erythematosus
tumidus (LET) according to the Düsseldorf
Classification 2004 (Kuhn and Ruzicka 2004)
confirmed by histological analysis.*
Ja
Nein
Women of childbearing potential with a negative
pregnancy test at screening (urine test) and using
a medically accepted contraceptive regimen
(intra-uterine device, partner's vasectomy, >3
months previous hormonal contraception
(oestrogen plus gestagen pill, depot injections, or
subcutaneous depot) combined with a barrier
method (preservative, vaginal diaphragm,
cervical cap, spermicide) during the study and for
8 weeks after the last UV exposure.*
Ja
Nein
Women clinically sterile (post-menopausal,
undergone hysterectomy or tubal ligation).*
Ja
Nein
Actively cooperating to participate in the study, to
follow the instructions of the investigator and to
attend the centre at the agreed times.*
Ja
Nein
Development of skin lesions any time under
current systemic treatment if patient is receiving
systemic medication for the treatment of CLE.*
Ja
Nein
Signed informed consent form after the nature of
the study has been fully explained. *
Ja
Nein
Ausschlusskriterien
Pregnancy or lactation and women with positive
pregnancy test.*
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Ja
Nein
Known hypersensitivity or allergic contact
reactions to components of the study agents.*
Ja
Nein
Treatment with photosensitizing drugs.*
Ja
Nein
Exposure to direct natural (sunlight) or artificial
UV radiation on the back within 4 weeks prior to
entering the study.*
Ja
Nein
History of another photodermatosis, except
polymorph light eruption (PLE).*
Ja
Nein
Any current known skin malignancy or any history
of skin malignancy within the previous 5 years or
Xeroderma pigmentosum.*
Ja
Nein
Initiation or change in the dose of any current
systemic medication for the treatment of CLE
within 8 weeks prior to standardized
photoprovocation.*
Ja
Nein
Local therapy for the treatment of CLE within two
weeks prior to standardized photoprovocation at
the back of the patient*
Ja
Nein
Acute exacerbation of CLE skin disease within 2
weeks prior to entering the study.*
Ja
Nein
Acute illness within 7 days prior to phototesting or
major illness including infection or hospitalization
within 1 month of study entry.*
Ja
Nein
Anti-dsDNA (RIA) > 7 U/ml and/or at least one of
the following criteria:*
Ja
Nein
Serositis: pleuritis or pericarditis documented by
electrocardiogram or rub or evidence of
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Eligibility NCT01146444 Cutaneous Lupus Erythematosus
pericardial effusion*
Ja
Nein
Renal disorder: proteinuria > 0.5 g/d or > 3+, or
cellular casts*
Ja
Nein
Neurologic disorder: seizures or psychosis
without other cause.*
Ja
Nein
Patients with a documented HIV and/or hepatitis
B or C infection.*
Ja
Nein
Any medical condition, which would place the
subject at undue risk of, or make it unlikely that
follow-up-measurements could be obtained*
Ja
Nein
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Eligibility NCT01146444 Cutaneous Lupus Erythematosus
Eligibility NCT01154751 Superficial
Femoral Artery Stenosis
ODM derived from
http://clinicaltrials.gov/show/NCT01154751
All rights reserved. Please visit https://medical-data-
models.org/forms/5090
Eligibility
Einschlusskriterien
Alter mindestens 18 Jahre*
Ja
Nein
Patient or legal guardian understands registry
procedures and has voluntarily signed an
informed consent in accordance with institutional
and local regulatory policies. (Note: Retrospective
data may be collected and entered into the EDC
system after a fully executed informed consent
has been provided).*
Ja
Nein
Rutherford-Becker classification 2 through 5 only*
Ja
Nein
Patient is at least 18 years of age and of legal
age of consent.*
Ja
Nein
Patient must be willing to participate in the
registry for at least 5 years.*
Ja
Nein
Target lesion is a single de novo or restenotic
(outside a stent) SFA or Popliteal artery lesion >=
1 cm from origin of another stent.  Additional
lesions may be present, but there is only one
target lesion.*
Ja
Nein
All SFA target lesions are to be located with the
proximal point at least 2 cm below the origin of
the profunda femoris artery.*
Ja
Nein
All Popliteal Artery target lesions are to be
located with the most distal point at least 1 cm
proximal to the bifurcation of the anterior tibial
artery and the tibioperoneal trunk.*
Ja
Nein
Target lesion length 1-20 cm (visual estimate)*
Ja
Nein
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Target lesion stenosis >=50% (visual estimate)*
Ja
Nein
Popliteal artery patent if the lesion is in the SFA*
Ja
Nein
SFA patent if the lesion is in the popliteal artery*
Ja
Nein
At least one widely patent (< 50% stenosis)
infrapopliteal artery (for distal run-off) *
Ja
Nein
Ausschlusskriterien
Evidence of heparin induced thrombocytopenia
(HIT), or intravenous tPA, Plavix, Ticlid, or aspirin
therapy sensitivities*
Ja
Nein
Patient is participating in a clinical study that
could confound results*
Ja
Nein
Patient is pregnant/breastfeeding at time
enrollment or plans to become pregnant during
the course of participation in the registry.*
Ja
Nein
Target lesion length > 20 cm*
Ja
Nein
Instent restenotic / reoccluded target lesion*
Ja
Nein
Acute (<= 4 weeks) thrombotic occlusion*
Ja
Nein
Untreated ipsilateral pelvic stenosis*
Ja
Nein
2 / 2
Eligibility NCT01154751 Superficial Femoral Artery Stenosis
Eligibility NCT01157871 Peripheral Arterial
Occlusive Disease
ODM derived from
http://clinicaltrials.gov/show/NCT01157871
All rights reserved. Please visit https://medical-data-
models.org/forms/5091
Eligibility
Einschlusskriterien
Alter mindestens 40 Jahre*
Ja
Nein
History of typical intermittent claudication lasting
for at least 3 months, showing no improvement
and consistent with treadmill test findings*
Ja
Nein
Objective evidence of Peripheral Arterial
Occlusive Disease. After 10 minutes of rest,
either by Ankle brachial index measure (ABI) <0.8
or Systolic ankle pressure (AP) < 50 mmHg or
Systolic toe pressure <50 mmHg*
Ja
Nein
Patent femoral inflow above the level of injections
recently (<2 weeks) documented either with
Doppler ultrasonography or Magnetic Resonance
Angiography or Angiography *
Ja
Nein
Ausschlusskriterien
Evidence of other causes for leg pain other than
intermittent claudication.*
Ja
Nein
Illnesses limiting subject exercise capacity
(angina pectoris, heart failure, respiratory
disease, orthopaedic disease, neurological
disorders)*
Ja
Nein
Ruheschmerz*
Ja
Nein
Bürger'sche Krankheit, Thrombangitis obliterans*
Ja
Nein
Positive serology for HIV 1 or 2, positive serology
hepatitis B or C.*
Ja
Nein
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Subjects with serum creatinine > 2 mg/dl (176
micromol/l) and subjects on dialysis.*
Ja
Nein
Active proliferative retinopathy defined by the
presence of new vessel formation and scarring.*
Ja
Nein
Subjects who had a stroke or neurologic deficit
presumed to be due to stroke within 3 months
prior to the first administration of study treatment*
Ja
Nein
Previous treatment with any angiogenic growth
factor*
Ja
Nein
Pregnant or breast feeding women or who
disagree to practice a medically accepted method
of birth control. Men and women who do not
agree to use condoms as the only accepted
protection barrier, for the entire study period*
Ja
Nein
Serious concomitant medical conditions not
adequately controlled.*
Ja
Nein
Current alcohol or drug abuse*
Ja
Nein
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Eligibility NCT01157871 Peripheral Arterial Occlusive Disease
Eligibility NCT01164592 Heart Failure
ODM derived from
http://clinicaltrials.gov/show/NCT01164592
All rights reserved. Please visit https://medical-data-
models.org/forms/5092
Eligibility
Einschlusskriterien
Alter mindestens 22 Jahre*
Ja
Nein
Severe Chronic Heart Failure (CHF) with NYHA
class III-IV or NYHA class II with at least one
hospitalisation for HF within the last 24 months*
Ja
Nein
Left ventricular ejection fraction (LVEF) <= 45%
by means of echocardiography, radionucleotide
angiography, left ventriculography or cardiac MRI
documented < 12 weeks before randomisation*
Ja
Nein
Diagnosis of sleep disordered breathing (SDB)
with an apnoea-hypopnoea-index (AHI) of >15/hr
with at least 50% central events and a central AHI
of at least 10/hr*
Ja
Nein
Clinically stable with no change in medication and
no unplanned hospitalisation for heart failure in
preceding month*
Ja
Nein
Optimised medical treatment according to the
applicable guidelines*
Ja
Nein
Able to provide informed consent *
Ja
Nein
Predominant central sleep apnoea (apnoea
hypopnoea index > 15/hour with ≥ 50% central
events and a central AHI ≥10/hour, derived from
full polysomnography (based on total sleep time),
documented < 4 weeks before randomization.
Flow measurements have to be performed with
nasal cannula*
Ja
Nein
Ausschlusskriterien
Significant chronic obstructive pulmonary disease
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(COPD) with Forced Expiratory Volume within
one second (FEV1)<50% predicted*
Ja
Nein
Oxygen saturation at rest during the day 90% at
the time of inclusion*
Ja
Nein
Current use of Positive Airway Pressure (PAP)
therapy*
Ja
Nein
Life expectancy < 1 year for diseases unrelated to
chronic heart failure*
Ja
Nein
Cardiac surgery, Percutaneous coronary
intervention (PCI), Myocardial Infarction (MI) or
unstable angina within 6 months prior to
randomisation*
Ja
Nein
Implantation of ICD (implanted cardiodefibrillator)
or CRT (cardiac resynchronisation therapy)
scheduled or within 6 months prior to
randomisation*
Ja
Nein
Transient ischemic attack (TIA) or Stroke within 3
months prior to randomisation*
Ja
Nein
Primary hemodynamically significant uncorrected
valvular heart disease, obstructive or regurgitant,
or any valvular disease expected to lead to
surgery during the trial*
Ja
Nein
Acute myocarditis/pericarditis within 6 months
prior to randomisation*
Ja
Nein
Untreated or therapy refractory Restless legs
Syndrome (RLS)*
Ja
Nein
Schwangerschaft*
Ja
Nein
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Eligibility NCT01164592 Heart Failure
Amyloidosis, hypertrophic obstructive
cardiomyopathy or arteriovenous fistulas*
Ja
Nein
Dosage changes of diuretics more than doubled
within the last 4 weeks prior to randomisation*
Ja
Nein
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Eligibility NCT01164592 Heart Failure
Eligibility NCT01174446 Hemophilia B
ODM derived from
http://clinicaltrials.gov/show/NCT01174446
All rights reserved. Please visit https://medical-data-
models.org/forms/5093
Eligibility
Einschlusskriterien
Alter 12 bis 65 Jahre*
Ja
Nein
Subject is 12 to 65 years old at the time of
screening*
Ja
Nein
Subject and/or legal representative has/have
provided signed informed consent*
Ja
Nein
Subject has severe (factor IX (FIX) level < 1%) or
moderately severe (FIX level <= 2%) hemophilia
B (based on the one stage activated partial
thromboplastin time [aPTT] assay), as tested at
screening at the central laboratory*
Ja
Nein
Subject is previously treated with plasma-derived
or recombinant FIX concentrate(s) for a minimum
of 150 exposure days (EDs)(based on the
subject's medical records)*
Ja
Nein
Subject has no evidence of a history of FIX
inhibitors (based on the subject's medical
records). If a verifiable, documented history is
unavailable, the subject can be enrolled if s/he
has participated in Study 050901 for at least 50
EDs to Immunine prior to enrollment.  *
Ja
Nein
Ausschlusskriterien
The subject has a history of FIX inhibitors with a
titer >= 0.6 Bethesda Units (BU) (as determined
by the Nijmegen modification of the Bethesda
assay or the assay employed in the respective
local laboratory) at any time prior to screening*
Ja
Nein
The subject has a detectable FIX inhibitor at
screening, with a titer >= 0.6 BU as determined
by the Nijmegen modification of the Bethesda
assay in the central laboratory*
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Ja
Nein
Gewicht anomal*
Ja
Nein
The subject has a history of allergic reaction, eg,
anaphylaxis, following exposure to FIX
concentrate(s)*
Ja
Nein
The subject has a known hypersensitivity to
hamster proteins or rFurin*
Ja
Nein
The subject has ongoing or recent evidence of a
thrombotic disease, fibrinolysis or DIC*
Ja
Nein
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Eligibility NCT01174446 Hemophilia B
Eligibility NCT01177033 Intermittent
Claudication
ODM derived from
http://clinicaltrials.gov/show/NCT01177033
All rights reserved. Please visit https://medical-data-
models.org/forms/5094
Eligibility
Einschlusskriterien
Alter 50 bis 85 Jahre*
Ja
Nein
Patient is able to verbally acknowledge and
understanding of the associated risks, benefits,
and treatment alternatives to therapeutic options
of this trial. The patients, by providing informed
consent, agree to these risks and benefits as
stated in the patient informed consent
document.*
Ja
Nein
Patients who are mentally and linguistically able
to understand the aim of the study and to show
sufficient compliance in following the study
protocol.*
Ja
Nein
Intermittent claudication (IC) class 2 or 3
(Rutherford) assessed by treadmill testing or 6-
Minute Walk Test.*
Ja
Nein
Lasting >3 months.*
Ja
Nein
Failed conservative therapy and the patient's
desire for further treatment.*
Ja
Nein
Atherosclerotic single or multiple stenoses
(>50%) or an occlusion of the Superficial Femoral
Artery (SFA) with a target lesion length of 10-20
cm without involvement of the common/deep
femoral artery and/or the popliteal artery
confirmed by duplex ultrasound and
angiography.*
Ja
Nein
At least one patent tibioperoneal artery with no
stenosis >50% in diameter. Technical and
morphological accessibility for both catheter
intervention and bypass surgery.*
Ja
Nein
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Absence of other disease that would limit
exercise (e.g. angina or chronic respiratory
disease). *
Ja
Nein
Ausschlusskriterien
>50% stenosis or occlusion of the iliac, the
common, the deep femoral or the popliteal
artery.*
Ja
Nein
Surgical reconstruction or catheter intervention
on the index leg within the last six months.*
Ja
Nein
Unsuitability of treadmill testing / Six-Minute Walk
Test. Chronic limb ischemia (intermittent
claudication class 2 to 6) on the contralateral
leg.*
Ja
Nein
Known allergy to contrast agents containing
iodine.*
Ja
Nein
Contraindication for antiplatelet agents or
anticoagulants.*
Ja
Nein
Clinically manifested heart insufficiency (NYHA
III, IV) and/or uncorrected hyperthyreosis.*
Ja
Nein
Serious general disease state with an estimated
life expectancy < 2 years (ASA IV, V).*
Ja
Nein
Schwangerschaft*
Ja
Nein
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Eligibility NCT01177033 Intermittent Claudication
Eligibility NCT01179984 Peripheral
Vascular Disease
ODM derived from
http://clinicaltrials.gov/show/NCT01179984
All rights reserved. Please visit https://medical-data-
models.org/forms/5095
Eligibility
Einschlusskriterien
Alter mindestens 21 Jahre*
Ja
Nein
The subject or legal representative has been
informed of the nature of the evaluation, agrees
to its provisions, and has signed the informed
consent form (ICF).*
Ja
Nein
Subject agrees to comply with the protocol-
mandated follow-up procedures and visits.*
Ja
Nein
Female subjects of childbearing potential must
have a negative urine or serum pregnancy test
within seven days prior to index procedure.
Female subjects who are surgically sterile or
post-menopausal are exempt from having a
pregnancy test.*
Ja
Nein
The subject has lifestyle-limiting claudication or
ischemic rest pain defined as: Rutherford
Category1 2-4 (moderate claudication to
ischemic rest pain).*
Ja
Nein
The target lesion(s) has angiographic evidence of
stenosis or restenosis ≥50% or occlusion (by
visual estimate) and is amenable to PTA and
stenting.*
Ja
Nein
The total treated segment(s) must be ≤ 240 mm.*
Ja
Nein
The target vessel reference diameter is ≥4.0 mm
and ≤6.5 mm (by visual estimate) and therefore
appropriate for treatment with available stent
diameters of 6.0 mm and 7.0 mm.*
Ja
Nein
There is angiographic evidence of at least one
vessel runoff to the foot (at the level of the
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malleolus).*
Ja
Nein
Ausschlusskriterien
The subject is unable or unwilling to provide
informed consent or is unable or unwilling to
comply with the study follow-up procedure and
visits.*
Ja
Nein
The subject has claudication or critical limb
ischemia described as Rutherford Category1 1
(mild claudication), 5 (minor tissue loss) or 6
(major tissue loss).*
Ja
Nein
The subject has a known contraindication
(including allergic reaction) or sensitivity to
antiplatelet/anticoagulant medications, nickel,
titanium or tantalum.*
Ja
Nein
The subject has a known sensitivity to contrast
media that is not amenable to pretreatment with
steroids or/and antihistamines.*
Ja
Nein
The subject has a history of bleeding diatheses
or coagulopathy.*
Ja
Nein
The subject has concomitant renal failure with a
creatinine of >2.5 mg/dL.*
Ja
Nein
The subject has concomitant hepatic
insufficiency, thrombophlebitis, uremia, systemic
lupus erythematosus (SLE), or deep vein
thrombosis (DVT) at the time of the study
procedure.*
Ja
Nein
The subject is receiving dialysis or
immunosuppressive therapy.*
Ja
Nein
The subject is participating in an investigational
drug or another investigational device study.*
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Eligibility NCT01179984 Peripheral Vascular Disease
Ja
Nein
The subject has another medical condition,
which, in the opinion of the investigator, may
cause him/her to be non-compliant with the
protocol, confound the data interpretation, or is
associated with limited life expectancy of < two
years.*
Ja
Nein
The subject has extensive peripheral vascular
disease, which, in the opinion of the investigator,
precludes safe insertion of an introducer sheath.*
Ja
Nein
The target lesion(s) is located within an
aneurysm or associated with an aneurysm in the
vessel segment either proximal or distal to the
target lesion(s).*
Ja
Nein
The subject has angiographic evidence of poor
inflow, which would be deemed inadequate to
support a vascular bypass graft.*
Ja
Nein
The subject is diagnosed with septicemia at the
time of the study procedure.*
Ja
Nein
Patients with a stent previously implanted into the
target vessel.*
Ja
Nein
Bilateral disease in the native SFA and/or
proximal popliteal artery where both limbs meet
the inclusion/exclusion criteria and it is planned to
treat both limbs within 30 days. Note: One limb
may be enrolled in the study, but only if the
second limb is planned to be treated after the 30-
day follow-up visit has taken place. The limb that
may be enrolled has to be the limb with the more
severe lesion and the reasons for treating this
specific limb will need to be stated in the CRF.*
Ja
Nein
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Eligibility NCT01179984 Peripheral Vascular Disease
Eligibility NCT01200758 Non-Hodgkin's
Lymphoma
ODM derived from
http://clinicaltrials.gov/show/NCT01200758
All rights reserved. Please visit https://medical-data-
models.org/forms/5097
Eligibility
Einschlusskriterien
Alter mindestens 18 Jahre*
Ja
Nein
Erwachsener, erwachsen*
Ja
Nein
CD20-positive, follicular Non-Hodgkin's
lymphoma grade 1, 2, 3a. A tumor biopsy must
have been performed within 6 months before
study entry with material available for central
review.*
Ja
Nein
No prior treatment*
Ja
Nein
ECOG performance status 0-2 *
Ja
Nein
Ausschlusskriterien
follikuläres Lymphom, Grad IIIb*
Ja
Nein
Transformation to high-grade lymphoma
secondary to follicular lymphoma*
Ja
Nein
Types of Non-Hodgkin's lymphoma other than
follicular lymphoma*
Ja
Nein
ZNS Erkrankung*
Ja
Nein
Corticoid therapy during the last 4 weeks, except
prednisone treatment <20 mg per day*
Ja
Nein
1 / 1
Eligibility NCT01204710 Prostate Cancer
ODM derived from
http://clinicaltrials.gov/show/NCT01204710
All rights reserved. Please visit https://medical-data-
models.org/forms/5098
Eligibility
Einschlusskriterien
Alter mindestens 18 Jahre*
Ja
Nein
histologically-confirmed adenocarcinoma of the
prostate*
Ja
Nein
radiographic evidence of metastatic prostate
cancer (stage M1 or D2)*
Ja
Nein
has prostate cancer unresponsive or refractory to
medical or surgical castration with a serum
testosterone level of < 50 ng/mL*
Ja
Nein
has had disease progression or intolerance on
docetaxel-based therapy*
Ja
Nein
PSA, prostataspezifisches Antigen*
Ja
Nein
all clinically significant toxic effects of prior
surgery, radiotherapy, chemotherapy or hormonal
therapy have resolved to <= Grade 1, based on
NCI CTCAE v 4.02*
Ja
Nein
patient has an ECOG Performance Status 0-2*
Ja
Nein
adequate hematologic function*
Ja
Nein
adequate hepatic function*
Ja
Nein
adequate renal function*
Ja
Nein
urinary protein is <= 1 on dipstick or routine
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analysis*
Ja
Nein
life expectancy of > 3 months*
Ja
Nein
fertile man with partners that are women of
childbearing potential must use an adequate
method of contraception during the study*
Ja
Nein
signed Informed Consent document *
Ja
Nein
Ausschlusskriterien
concurrent active malignancy other than
adequately treated nonmelanomatous skin
cancer or other noninvasive or in situ neoplasms*
Ja
Nein
The patient has received more than 1 prior
cytotoxic chemotherapy regimen for metastatic
disease*
Ja
Nein
prior therapy with mitoxantrone for advanced
prostate cancer*
Ja
Nein
The patient has a history of symptomatic
congestive heart failure or has a pre study
echocardiogram or multigated acquisition scan
with left ventricular ejection fraction that is >=
10% below the lower limit of normal institutional
range*
Ja
Nein
history of prior treatment with other agents that
directly inhibit PDGF or platelet-derived growth
factor receptors*
Ja
Nein
known allergy to any of the treatment
components: IMC 3G3, mitoxantrone, and/or
prednisone*
Ja
Nein
radiotherapy within 21 days prior to first dose of
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Eligibility NCT01204710 Prostate Cancer
IMC-3G3*
Ja
Nein
any investigational therapy within 30 days of
randomization*
Ja
Nein
is receiving corticosteroids at a dose > 5 mg
prednisone orally (PO) 2 times per day (BID) or
equivalent*
Ja
Nein
received prior strontium-89, rhenium-186,
rhenium-188, or samarium-153 radionucleotide
therapy and has either ongoing evidence of bone
marrow dysfunction or poorly controlled bone
pain*
Ja
Nein
has any ongoing or active infection, symptomatic
congestive heart failure, unstable angina pectoris,
serious cardiac arrhythmia, psychiatric illness,
active bleeding or pathological condition that
carries a high risk of bleeding, or any other
serious uncontrolled medical disorders*
Ja
Nein
known or suspected brain or leptomeningeal
metastases*
Ja
Nein
known human immunodeficiency virus infection
or acquired immunodeficiency syndrome-related
illness*
Ja
Nein
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Eligibility NCT01204710 Prostate Cancer
Eligibility NCT01206647 Diabetes Mellitus,
Type 2
ODM derived from
http://clinicaltrials.gov/show/NCT01206647
All rights reserved. Please visit https://medical-data-
models.org/forms/5099
Eligibility
Einschlusskriterien
Alter 18 bis 80 Jahre*
Ja
Nein
Diabetes Mellitus, Type 2*
Ja
Nein
Combination of OAD and basal insulin treatment
(BOT) or intensified conventional therapy (ICT, >
2 injections of basal and prandial) or conventional
insulin therapy (CIT, 1 or 2 injections of basal or
biphasic)*
Ja
Nein
HbA1c*
Ja
Nein
History of - insulin therapy*
Ja
Nein
Insulin dose < 120 IU/day*
Ja
Nein
Fasting C-peptide > 0.6 ng/l*
Ja
Nein
erhöhte Nüchternglukose*
Ja
Nein
Full legal, mental and physical ability to give
informed consent*
Ja
Nein
Patient consent that the general physician will be
informed of trail participation*
Ja
Nein
Experience in self measurement of blood glucose
> 1 year *
Ja
Nein
Ausschlusskriterien
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Diabetes mellitus Typ 1*
Ja
Nein
History of drug or alcohol abuse within the last
five years prior to screening*
Ja
Nein
History of severe or multiple allergies*
Ja
Nein
Progressive fatal disease*
Ja
Nein
History of significant cardiovascular, respiratory,
gastrointestinal, hepatic (ALAT and/or ASAT > 3
times the normal reference range), neurological,
psychiatric and/or haematological disease as
judged by the investigator*
Ja
Nein
Renal insufficiency or history of significant renal
diseases (creatinine clearance < 60 ml/min
determined using the Cockroft-Goult equation).*
Ja
Nein
Contra-indications for study drugs including
contraindications for the rescue drugs*
Ja
Nein
Anamnestic history of hypersensitivity to the
study drugs or to drugs with similar chemical
structures*
Ja
Nein
Pregnancy or breast feeding*
Ja
Nein
Sexually active women of childbearing potential
not consistently and correctly practicing birth
control by implants, injectables, combined oral
contraceptives, hormonal intrauterine devices
(IUDs), sexual abstinence or vasectomised
partner*
Ja
Nein
Treatment with any other investigational drug
within 3 months prior to screening*
Ja
Nein
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Eligibility NCT01206647 Diabetes Mellitus, Type 2
Lack of compliance or other similar reason, that
according to investigator, precludes satisfactory
participation in the study*
Ja
Nein
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Eligibility NCT01206647 Diabetes Mellitus, Type 2
Eligibility NCT01207388 B-ALL
ODM derived from
http://clinicaltrials.gov/show/NCT01207388
All rights reserved. Please visit https://medical-data-
models.org/forms/5100
Eligibility
Einschlusskriterien
Alter mindestens 18 Jahre*
Ja
Nein
Patients with B-precursor ALL in complete
hematological remission after at least 3 intense
chemotherapy blocks*
Ja
Nein
Presence of minimal residual disease at a level of
>=10-3*
Ja
Nein
Availability of bone marrow specimen from
primary diagnosis for clone-specific MRD
assessment*
Ja
Nein
Negative HIV test, negative hepatitis B (HbsAg)
test and hepatitis C virus (anti-HCV) test*
Ja
Nein
Negative pregnancy test in women of
childbearing potential*
Ja
Nein
ECOG performance status 0 or 1 *
Ja
Nein
Ausschlusskriterien
Presence of circulating blasts or current extra-
medullary involvement by ALL*
Ja
Nein
History of relevant CNS pathology or current CNS
pathology*
Ja
Nein
Prior allogeneic HSCT*
Ja
Nein
Eligibility for treatment with TKIs*
1 / 2
Ja
Nein
Systemic cancer chemotherapy within 2 weeks
prior to study treatment*
Ja
Nein
Therapy with monoclonal antibodies (rituximab,
alemtuzumab) within 4 weeks prior to study
treatment*
Ja
Nein
Previous treatment with blinatumomab*
Ja
Nein
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Eligibility NCT01207388 B-ALL
Eligibility NCT01209286 B-ALL
ODM derived from
http://clinicaltrials.gov/show/NCT01209286
All rights reserved. Please visit https://medical-data-
models.org/forms/5101
Eligibility
Einschlusskriterien
Alter mindestens 18 Jahre*
Ja
Nein
Patients with B-precursor ALL relapsed after at
least induction and consolidation or having
refractory disease*
Ja
Nein
More than 5% blasts in bone marrow*
Ja
Nein
ECOG Status <= 2*
Ja
Nein
Life expectancy of >= 12 weeks *
Ja
Nein
Ausschlusskriterien
History or presence of clinically relevant CNS
pathology*
Ja
Nein
Infiltration of cerebrospinal fluid (CSF) by ALL*
Ja
Nein
Autologous/allogeneic HSCT within six
weeks/three months prior to start of
blinatumomab treatment*
Ja
Nein
Active Graft-versus-Host Disease (GvHD)*
Ja
Nein
Patients with Ph+ ALL eligible for treatment with
dasatinib or imatinib*
Ja
Nein
Cancer chemotherapy within two weeks prior to
start of blinatumomab treatment*
Ja
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Nein
Immunotherapy (e.g. rituximab) within four weeks
prior to start of blinatumomab treatment*
Ja
Nein
Infection with HIV or hepatitis B (HBsAg positive)
or hepatitis C virus (anti-HCV positive)*
Ja
Nein
Pregnant or nursing women*
Ja
Nein
Previous treatment with blinatumomab*
Ja
Nein
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Eligibility NCT01209286 B-ALL
Eligibility NCT01217528 Cardiac Death
ODM derived from
http://clinicaltrials.gov/show/NCT01217528
All rights reserved. Please visit https://medical-data-
models.org/forms/5102
Eligibility
Einschlusskriterien
Alter mindestens 18 Jahre*
Ja
Nein
Approved indication for new ICD implantation for
primary prevention of sudden cardiac death*
Ja
Nein
Written informed consent *
Ja
Nein
Ausschlusskriterien
ICD indication for secondary prevention reasons*
Ja
Nein
ICD indication for electrical disorders (i.e.
long/short QT syndrome, Brugada syndrome
etc...)*
Ja
Nein
ICD change or upgrade*
Ja
Nein
Schwangerschaft*
Ja
Nein
Nonage*
Ja
Nein
Patient is already participating to another study
with active therapy arm*
Ja
Nein
Patient will most likely not be able to participate
to the routine follow ups in the study center.*
Ja
Nein
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Eligibility NCT01229215 Geographic
Atrophy
ODM derived from
http://clinicaltrials.gov/show/NCT01229215
All rights reserved. Please visit https://medical-data-
models.org/forms/5103
Eligibility
Einschlusskriterien
Alter 60 bis 89 Jahre*
Ja
Nein
Willingness and ability to provide signed Informed
Consent. In addition, at U.S. sites, Health
Insurance Portability and Accountability Act
(HIPAA) authorization, in other countries, as
applicable according to national laws*
Ja
Nein
Well-demarcated area of GA secondary to age-
related macular degeneration (AMD) in the
absence of choroidal neovascularization (CNV) *
Ja
Nein
Ausschlusskriterien
History of vitrectomy surgery, submacular
surgery, or other surgical intervention for AMD in
the study eye*
Ja
Nein
Previous subfoveal focal laser photocoagulation
in the study eye*
Ja
Nein
Laser photocoagulation in the study eye*
Ja
Nein
Prior treatment with Visudyne, external-beam
radiation therapy, or transpupillary thermotherapy
in the study eye*
Ja
Nein
GA in either eye due to causes other than AMD*
Ja
Nein
Diabetic retinopathy in either eye*
Ja
Nein
Active or history of wet AMD in either eye*
Ja
Nein
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History of other disease, metabolic dysfunction,
physical examination finding, or clinical laboratory
finding giving reasonable suspicion of a disease
or condition that contraindicates the use an
investigational drug or that might affect
interpretation of the results of the study or that
renders the patient at high risk for treatment
complications*
Ja
Nein
Active malignancy or history of malignancy within
the past 5 years*
Ja
Nein
Previous participation in any studies of
investigational drugs within 3 months preceding
Day 0*
Ja
Nein
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Eligibility NCT01229215 Geographic Atrophy
Eligibility NCT01232452 Non-Small-Cell
Lung Carcinoma
ODM derived from
http://clinicaltrials.gov/show/NCT01232452
All rights reserved. Please visit https://medical-data-
models.org/forms/5104
Eligibility
Einschlusskriterien
Alter mindestens 18 Jahre*
Ja
Nein
The patient has histologically or cytologically
confirmed, nonsquamous (adenocarcinoma/large
cell or other) NSCLC.*
Ja
Nein
The patient has Stage IV disease at the time of
study entry.*
Ja
Nein
Patients with treated brain metastases are eligible
if they are clinically stable with regard to
neurologic function, off steroids after cranial
irradiation (whole brain radiation therapy, focal
radiation therapy, and stereotactic radiosurgery)
ending at least 2 weeks prior to randomization, or
after surgical resection performed at least 28
days prior to randomization. The patient may
have no evidence of Grade 1 (or greater) Central
Nervous System (CNS) hemorrhage based on
pretreatment scans(performed within 21 days
before randomization).*
Ja
Nein
The patient has measurable or nonmeasurable
disease according to Response Evaluation
Criteria In Solid Tumors (RECIST) Version 1.1
guidelines.*
Ja
Nein
The patient has an Eastern Cooperative
Oncology Group (ECOG) Performance Status
(PS) of 0 or 1.*
Ja
Nein
If prior adjuvant chemotherapy, the last dose of
adjuvant treatment was administered at least 6
months prior to randomization.*
Ja
Nein
The patient has adequate bone marrow reserve,
and renal and hepatic function*
Ja
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Nein
The patient has fasting serum glucose <= 100
mg/dL, and hemoglobin A1C <= 6%.*
Ja
Nein
Females with reproductive potential: Must have a
negative serum or urine pregnancy test within 7
days prior to the first dose of any study drug.*
Ja
Nein
Males and females with reproductive potential:
Must agree to use medically approved
contraceptive precautions during the study and
for 6 months following the last dose of any study
drug.*
Ja
Nein
The patient has the ability to understand and the
willingness to sign a written informed consent
form.*
Ja
Nein
Previous radiation therapy is allowed to < 25% of
the bone marrow, but should have been limited
and must not have included whole pelvis
radiation.*
Ja
Nein
The patient has archived tumor tissue available
for analysis (can be either primary tumor or
metastases).*
Ja
Nein
The patient has an estimated life expectancy of at
least 12 weeks. *
Ja
Nein
Ausschlusskriterien
Are currently enrolled in, or discontinued within
the last 30 days from, a clinical trial involving an
investigational drug or device or off-label use of a
drug or device, or concurrently enrolled in any
other type of medical research judged not to be
scientifically or medically compatible with this
study.*
Ja
Nein
Patients who have squamous histology.*
Ja
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Nein
The patient's tumor fully or partially contains
Small Cell Lung Cancer (SCLC).*
Ja
Nein
Leptomeningeal disease*
Ja
Nein
The patient is currently or has previously received
chemotherapy for advanced (Stage IV) NSCLC.
Patients who have received adjuvant
chemotherapy are eligible if the last
administration of the prior adjuvant regimen
occurred at least 6 months prior to
randomization*
Ja
Nein
The patient has a history of treatment with other
agents targeting the Insulin-like or Epidermal
Growth factor receptors.*
Ja
Nein
Patients who have received prior Pemetrexed
treatment.*
Ja
Nein
The patient has a known allergy/history of
hypersensitivity reaction to any of the treatment
components.*
Ja
Nein
Diabetes mellitus*
Ja
Nein
The patient has an uncontrolled intercurrent
illness including, but not limited to, ongoing or
active infection requiring parenteral antibiotics,
symptomatic congestive heart failure,
uncontrolled hypertension, clinically significant
cardiac arrhythmia,or psychiatric/social situations
that would limit compliance with study
requirements.*
Ja
Nein
The patient has an ongoing or active infection
requiring parenteral antibiotic, antifungal, or
antiviral therapy.*
Ja
Nein
The patient has undergone major surgery within
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28 days prior to randomization.*
Ja
Nein
The patient has received a prior autologous or
allogeneic organ or tissue transplantation.*
Ja
Nein
The patient is pregnant or lactating.*
Ja
Nein
The patient has a history of another primary
cancer, with the exception of the following:
curatively resected nonmelanomatous skin
cancer, curatively treated carcinoma in situ, or
other primary solid tumor treated with curative
intent and no known active disease present and
no treatment administered during the last 5
years.*
Ja
Nein
The patient has superior vena cava syndrome
contraindicating hydration.*
Ja
Nein
The patient has current clinically-relevant
coronary artery disease (New York Heart
Association III or IV) or uncontrolled congestive
heart failure.*
Ja
Nein
The patient has any Grade 2 (or greater)
peripheral neuropathy.*
Ja
Nein
The patient has clinically significant third-space
fluid collections, for example, ascites or pleural
effusions that cannot be controlled by drainage or
other procedures prior to study entry.*
Ja
Nein
The patient is unable to interrupt aspirin or other
nonsteroidal anti-inflammatory agents, other than
an aspirin dose <= 1.3 grams per day, for a 5-day
period (8-day period for long-acting agents, such
as piroxicam).*
Ja
Nein
The patient is unwilling or unable to take
premedications (folic acid, vitamin B12, or
corticosteroids) required by the pemetrexed
label.*
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Ja
Nein
The patient has received a recent (within 30 days
of enrollment) or is receiving concurrent yellow
fever vaccination.*
Ja
Nein
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Eligibility NCT01233440 Hemophilia B
ODM derived from
http://clinicaltrials.gov/show/NCT01233440
All rights reserved. Please visit https://medical-data-
models.org/forms/5105
Eligibility
Einschlusskriterien
Alter 12 bis 65 Jahre*
Ja
Nein
Male, 12 - 65 years, with body weight >= 30 kg
and <= 120 kg*
Ja
Nein
Documented severe Hemophilia B (FIX activity of
<= 2%) or tested by the central laboratory at
screening*
Ja
Nein
Subjects who have received FIX products for >
150 exposure days (EDs) (estimated)*
Ja
Nein
No confirmed prior history of FIX inhibitor (history
of positive FIX inhibitor defined as two
consecutive positive tests - a confirmatory test on
a second, separately drawn sample shortly after
the previous positive test) and confirmed no
detectable FIX inhibitors (negative FIX inhibitor
defined as < 0.6 Bethesda Units [BU] by the
central laboratory at screening*
Ja
Nein
Subjects can be treated on-demand or under
prophylactic therapy*
Ja
Nein
Signed Informed Consent/Assent *
Ja
Nein
Ausschlusskriterien
Known hypersensitivity (allergic reaction or
anaphylaxis) to any FIX product or hamster
protein*
Ja
Nein
Any known congenital or acquired coagulation
disorder other than congenital FIX deficiency*
Ja
Nein
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Thrombozyten*
Ja
Nein
Immunocompromised (CD4 count < 200/mm3),
(HIV positive subjects may participate in the
study and protease inhibitors and antiviral
therapy are permitted, at the discretion of the
Investigator)*
Ja
Nein
Currently receiving IV immunomodulating agents
such as immunoglobulin or chronic systemic
corticosteroid treatment*
Ja
Nein
Serum aspartate aminotransferase (AST) or
serum alanine aminotransferase (ALT)
concentration > 5 times (x) the upper limit of
normal (ULN)*
Ja
Nein
Serum creatinine > 2 x ULN*
Ja
Nein
Evidence of thrombosis, including deep vein
thrombosis, stroke, pulmonary embolism,
myocardial infarction and arterial embolus within
3 months prior to enrollment*
Ja
Nein
Use of an Investigational Medicinal Product (IMP)
within 30 days prior to the first rIX-FP
administration*
Ja
Nein
Experienced life-threatening bleeding episode or
had major surgery or an orthopedic surgical
procedure during the 3 months prior to study
entry*
Ja
Nein
Subject currently on a dose and/or regimen of
FIX that would preclude participation in the study
due to possible increased risk of bleeding
because of the requirement to withhold treatment
during the PK sampling period*
Ja
Nein
Suspected inability (e.g., language problem or
mental condition) or unwillingness to comply with
study procedures or history of noncompliance*
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Ja
Nein
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Eligibility NCT01234311 Prostate Cancer
ODM derived from
http://clinicaltrials.gov/show/NCT01234311
All rights reserved. Please visit https://medical-data-
models.org/forms/5106
Eligibility
Einschlusskriterien
Alter mindestens 18 Jahre*
Ja
Nein
Age at least 18 years at the time of signing the
informed consent form. For patients in Taiwan the
minimum age is 20 years.*
Ja
Nein
Histologically confirmed diagnosis of
adenocarcinoma of the prostate.*
Ja
Nein
Evidence of bone metastatic disease on
radiographic examination, whether from bone
scan or other imaging modality.*
Ja
Nein
Castrate levels of serum testosterone (≤50 ng/dL
or 1.7 nmol/L).*
Ja
Nein
Evidence of progressive disease.*
Ja
Nein
Karnofsky*
Ja
Nein
Meet screening laboratory values as specified in
the protocol.*
Ja
Nein
If sexually active with partner of childbearing
potential, patient will agree to use adequate
contraceptive methods (barrier contraceptive with
spermicide or vasectomy) while on study drug.
The adequate contraceptive method should be
continued for 14 days after the patient stops
taking study drug.*
Ja
Nein
No evidence (within 5 years) of prior
malignancies (except successfully treated basal
cell or squamous cell carcinoma of the skin).*
Ja
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Nein
Able to swallow and retain oral medication.*
Ja
Nein
Able to adhere to the study visit schedule and
other protocol requirements.*
Ja
Nein
Ability to comprehend the full nature and purpose
of the study, including possible risks and side
effects; ability to cooperate with the investigator
and to comply with the requirements of the entire
study.*
Ja
Nein
Able (or patient's legal guardian, if applicable) to
sign and date the written informed consent after
being informed of the full nature and purpose of
the study, including possible risks and side
effects, and given ample time and opportunity to
read and understand this information.*
Ja
Nein
Ausschlusskriterien
Prior cytotoxic chemotherapy for the treatment of
prostate ca within 2 years or within 4 weeks for
Estracyt (estramustine) prior to study treatment.*
Ja
Nein
Previous anticancer therapy using radiation,
biologics or vaccines, including abiraterone, TAK-
700 (Orteronel), or MDV3100 within 4 weeks prior
or sipuleucel-T (Provenge) within 2 weeks prior to
the start of study treatment. If radiation therapy is
applied after baseline scan, a new baseline scan
needs to be done at least 4 weeks after the
radiation therapy.*
Ja
Nein
Previous therapy with antiandrogens within 4
weeks (within 6 weeks for bicalutamide eg,
Casodex) prior to study treatment.*
Ja
Nein
Concurrent use of other anticancer agents or
treatments, with the following exceptions:*
Ja
Nein
Ongoing treatment with luteinizing hormone-
releasing hormone agonists or antagonists,
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denosumab (Prolia) or bisphosphonate (eg,
zoledronic acid) is allowed. Ongoing treatment
should be kept at a stable schedule; however, if
medically required, a change of dose, compound,
or both is allowed.*
Ja
Nein
Any treatment modalities involving major surgery
within 4 weeks prior to the start of study
treatment.*
Ja
Nein
Prostate ca pain that requires ongoing treatment
with narcotic analgesics or warrants the initiation
of radio- or chemotherapy.*
Ja
Nein
Ongoing treatment with warfarin unless the
international normalized ratio (INR) is well
controlled and below 4 (Section 4.6.8.1).*
Ja
Nein
Maintenance treatment with corticosteroids
corresponding to a prednisolone or prednisone
dose above 10 mg/day. The dose must have
been stable for at least 5 days.*
Ja
Nein
Systemic exposure to ketoconazole or other
strong cytochrome P450 (CYP) 3A4 isozyme
inhibitors or inducers within 14 days prior to the
start of study treatment. Systemic exposure to
amiodarone is not allowed within 1 year prior to
the start of study treatment.*
Ja
Nein
Ongoing treatment with sensitive CYP1A2
substrate or CYP1A2 substrate with narrow
therapeutic range at the start of study treatment.*
Ja
Nein
Ongoing treatment with CYP3A4 substrate with
narrow therapeutic range at the start of study
treatment.*
Ja
Nein
Simultaneous participation in any other study
involving treatment with investigational drugs or
having received treatment with investigational
drugs < 4 weeks prior to the start of study
treatment.*
Ja
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Nein
Myocardial infarction, percutaneous coronary
intervention, acute coronary syndrome, coronary
artery bypass graft, class III/IV congestive heart
failure, cerebrovascular accident, transient
ischemic attack, or limb claudication at rest,
within 6 months prior to start of study treatment
and ongoing symptomatic dysrhythmias, unstable
angina, uncontrolled hypertension, and
uncontrolled atrial or ventricular arrhythmias.*
Ja
Nein
History of pancreatitis.*
Ja
Nein
Known brain or epidural metastases.*
Ja
Nein
Known positive serology for HIV (patients with
known history of HIV will be excluded because of
potential for unforeseen toxicity and morbidity in
an immunocompromised host).*
Ja
Nein
Chronic hepatitis with advanced, decompensated
hepatic disease or cirrhosis of the liver or history
of a chronic viral hepatitis or known viral hepatitis
carrier (patients who have recovered from
hepatitis will be allowed to enter the study).*
Ja
Nein
Patients with active tuberculosis (TB), or with
known, untreated latent TB. (Country-specific TB
therapy should have been given for at least 30
days prior to the start of study treatment and the
patient should intend to complete the entire
course of that therapy.)*
Ja
Nein
Any condition, including other active or latent
infections, medical or psychiatric conditions, or
the presence of laboratory abnormalities, which
could confound the ability to interpret data from
the study or places the patient at unacceptable
risk if he participates in the study.*
Ja
Nein
Any patient who in the opinion of the investigator
should not participate*
Ja
Nein
4 / 4
Eligibility NCT01234311 Prostate Cancer
Eligibility NCT01234727 Diabetes Mellitus
ODM derived from
http://clinicaltrials.gov/show/NCT01234727
All rights reserved. Please visit https://medical-data-
models.org/forms/5107
Eligibility
Einschlusskriterien
Alter 18 bis 75 Jahre*
Ja
Nein
Subjects diagnosed with type 1 or type 2
diabetes mellitus*
Ja
Nein
Patients with stable blood glucose in judgment of
the investigator.*
Ja
Nein
Subjects receive intensive insulin therapy
(Multiple Daily Injection defined as at least two
insulin injections per day)*
Ja
Nein
Patients perform blood glucose self
measurements on a routine basis*
Ja
Nein
Patients must have experience in self
measurement blood glucose for at least 6
months. *
Ja
Nein
Ausschlusskriterien
Patients with unstable blood glucose in judgment
of the investigator.*
Ja
Nein
Patient has been diagnosed with progressive /
serious diseases that in judgment of the
investigator preclude successful completion of
the observational period.*
Ja
Nein
Lack of compliance or other justifications that, in
the discretion of the investigator, precludes
satisfactory participation in the study.*
Ja
Nein
Subject without legal capacity.*
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Ja
Nein
Blood donation within the last 30 days.*
Ja
Nein
Schwangerschaft*
Ja
Nein
Subject has already participated in the study.*
Ja
Nein
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Eligibility NCT01238029 Metastatic Breast
Cancer
ODM derived from
http://clinicaltrials.gov/show/NCT01238029
All rights reserved. Please visit https://medical-data-
models.org/forms/5108
Eligibility
Einschlusskriterien
Alter mindestens 18 Jahre*
Ja
Nein
Written informed consent*
Ja
Nein
Able to comply with the protocol*
Ja
Nein
ECOG performance status 0-1*
Ja
Nein
Adequate contraception*
Ja
Nein
Confirmed Her2/neu-positive, adenocarcinoma of
the breast*
Ja
Nein
At least one measurable lesion according to
RECIST 1.1 criteria*
Ja
Nein
First or second chemotherapy after diagnosis of
metastasis*
Ja
Nein
Lapatinib treatment indicated (adjuvant
trastuzumab treatment <12 months ago or
progressive disease with trastuzumab treatment)*
Ja
Nein
No signs and symptoms of CHF (chronic heart
failure), LVEF (left ventricular ejection fraction) at
study start at least 55%*
Ja
Nein
Adequate hepatic and renal function value*
Ja
Nein
Adequate hematologic function values *
Ja
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Nein
Ausschlusskriterien
Pregnant or lactating women*
Ja
Nein
Concurrent participation in another clinical trial.
Prior participation is allowed if the last study
medication was administered more than 4 weeks
prior to randomization*
Ja
Nein
Asymptomatic with regards to tumor illness*
Ja
Nein
Previous treatment with lapatinib, capecitabine or
vinorelbine*
Ja
Nein
Necessity of planned treatment with other
chemotherapeutics oder anti-hormone therapy*
Ja
Nein
Major surgical procedure, open biopsy or
significant traumatic injury within 28 days prior to
randomization, or anticipation of the need for
major surgery during the course of the study*
Ja
Nein
Evidence of cardiovascular disease, e.g.
myocardial infection, unstable angina pectoris or
arrhythmia*
Ja
Nein
History of vascular or cardiovascular disease
within the past 6 months*
Ja
Nein
All illnesses that result in malabsorption of oral
medication or inability to take oral medication*
Ja
Nein
Concurrent treatment with anti-viral drugs based
on sorivudine or with aminoglycosides*
Ja
Nein
Concurrent treatment with any drug interfering
with study medication, especially, those that
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induce CYP3A*
Ja
Nein
Concurrent treatment with allopurinol*
Ja
Nein
Other malignancies (except for basal cell
carcinoma of the skin and cervical carcinoma in
situ). Patient can be included in the study if no
recurrent disease has been observed for at least
5 years*
Ja
Nein
Concurrent illnesses or other circumstances that
could interfere with trial participation, efficacy or
safety of the patient*
Ja
Nein
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Eligibility NCT01241448 Diabetes Mellitus,
Type 2
ODM derived from
http://clinicaltrials.gov/show/NCT01241448
All rights reserved. Please visit https://medical-data-
models.org/forms/5110
Eligibility
Einschlusskriterien
Alter 18 bis 70 Jahre*
Ja
Nein
Have a diagnosis of Type 2 diabetes mellitus
according to the World Health Organization
(WHO) diagnostic criteria*
Ja
Nein
Are women not of child-bearing potential due to
surgical sterilization (hysterectomy or bilateral
oophorectomy or tubal ligation) or menopause.*
Ja
Nein
Are male patients using a reliable method of birth
control during the study and until 3 months after
the last dose of study medication.*
Ja
Nein
Are being treated with either diet and exercise
alone, or with diet and exercise in combination
with metformin. Metformin therapy must have
been stable and unchanged for at least 3 months
prior to screening and at a dose of at least 1000
mg/day.*
Ja
Nein
Have an HbA1c value of 7.0% to 10.5% ,
inclusive.*
Ja
Nein
BMI*
Ja
Nein
In the opinion of the investigator, are capable and
willing to:*
Ja
Nein
Perform self-monitoring of blood glucose*
Ja
Nein
Complete a study diary as required for this
protocol*
Ja
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Nein
Maintain consistent dietary, physical activity, and
sleeping patterns throughout the duration of the
study*
Ja
Nein
Comply with treatment regimens*
Ja
Nein
Have given written informed consent to
participate in this study in accordance with local
regulations and the Ethical Review Board (ERB)
governing the study site. *
Ja
Nein
Ausschlusskriterien
Have > 1 episode of severe hypoglycemia
(defined as an event during which the patient
requires the assistance of another person to
actively administer carbohydrate, glucagon, or
other resuscitative actions) within 6 months prior
to screening, or have a current diagnosis of
hypoglycemia unawareness.*
Ja
Nein
Have had two or more emergency room visits or
hospitalizations due to poor glucose control in the
6 months prior to screening.*
Ja
Nein
Have gastrointestinal disease that may
significantly impact gastric emptying or motility or
have undergone gastric bypass or gastric
banding surgery.*
Ja
Nein
Have had a previous diagnosis of pancreatitis.*
Ja
Nein
Have New York Heart Association (NYHA) class
II, III, or IV symptoms of heart failure*
Ja
Nein
Have a history of myocardial infarction, unstable
angina, or a coronary revascularization procedure
within 6 months of screening.*
Ja
Nein
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Have a history of supraventricular tachycardia,
ventricular tachycardia, or other cardiac
arrhythmia.*
Ja
Nein
Have a history of transient ischemic attack (TIA)
or stroke within 6 months of screening.*
Ja
Nein
Have poorly controlled hypertension (systolic
blood pressure >= 150 mm Hg or diastolic blood
pressure >= 90 mm Hg) as determined by the
mean of three separate measurements.*
Ja
Nein
Show evidence of labile blood pressure, including
symptomatic postural hypotension.*
Ja
Nein
Have any abnormality of the ECG that would
impact patient safety or data interpretation.*
Ja
Nein
Show clinical signs or symptoms of liver disease,
or liver function tests (LFTs, aspartate
aminotransferase [AST] or alanine
aminotransferase [ALT]) > 2.5 times upper limit of
normal (ULN) as determined by the central
laboratory at screening.*
Ja
Nein
Have a current or previous diagnosis of Gilbert's
disease.*
Ja
Nein
Have previous or current diagnosis of Hepatitis B
or C*
Ja
Nein
Have a serum creatinine >2 mg/dL or, in patients
being treated with metformin, a serum creatinine
above (or creatinine clearance below) what is
approved in the metformin product labeling in the
respective country.*
Ja
Nein
Show evidence of uncorrected hypothyroidism or
hyperthyroidism based on clinical evaluation
and/or an abnormal thyroid stimulating hormone
result as determined by the central laboratory at
screening. Patients receiving dose-stable thyroid
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replacement therapy for at least 3 months prior to
screening will be allowed to participate in the
study.*
Ja
Nein
Have any other abnormal laboratory value that, in
the opinion of the investigator, precludes the
patient from participation in the study. Laboratory
abnormalities consistent with type 2 diabetes
mellitus and all other eligibility criteria are
acceptable: for example, abnormalities of blood
glucose, hemoglobin A1C (HbA1c), urinary
glucose, and urinary protein (with a range of
trace to 1+ on dipstick).*
Ja
Nein
Have a currently suspected or treated
malignancy, or are in remission from a clinically
significant malignancy (other than basal or
squamous cell skin cancer, in situ carcinomas of
the cervix, or in situ prostate cancer) for less than
5 years.*
Ja
Nein
Have a personal or family history of pancreatic
neoplasia.*
Ja
Nein
Have non-fasting triglycerides >600 mg/dL.*
Ja
Nein
Use or have used insulin or GLP-1 agonists (for
more than 1 week within the 3-month period prior
to screening), or any oral antihyperglycemic
medication (OAM) other than metformin within
the 3-month period prior to screening.*
Ja
Nein
Currently use or intend to use prescription or
over-the-counter medications, including herbal
supplements, to promote weight loss or to
regulate blood glucose.*
Ja
Nein
Have current chronic (>2 weeks) systemic
glucocorticoid therapy (excluding ocular topical,
other topical, inhaled preparations)or have
received such therapy within 8 weeks prior to
screening.*
Ja
Nein
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Currently use hyperglycemia-causing agents,
hypoglycemia-causing agents (other than
metformin), class II and III antiarrythmic agents,
agents that reduce gastrointestinal motility,central
nervous system stimulants (with the exception of
caffeinated beverages), fibrates, and niacin >= 1
gm/day.*
Ja
Nein
Have an average weekly alcohol intake that
exceeds 2 units per day for males and 1 unit per
day for females (1 unit = 12 oz or 360 mL of beer,
5 oz or 150 mL of wine, 1.5 oz or 45 mL of
distilled spirits).*
Ja
Nein
Currently use drugs that are known to prolong the
QT interval.*
Ja
Nein
Currently use or intend to use potent inhibitors of
CYP3A, which include but are not limited to
atazanavir, indinavir, nelfinavir, ritonavir,
clarithromycin, itraconazole, ketoconazole,
nefazodone, saquinavir, and telithromycin.*
Ja
Nein
Have previously completed or withdrawn from this
study or any other study investigating
LY2409021.*
Ja
Nein
Have known allergies to LY2409021 or related
compounds.*
Ja
Nein
Are currently enrolled in, or discontinued within
the last 30 days from, a clinical trial involving an
investigational product or unapproved use of a
drug or device, or concurrently enrolled in any
other type of medical research judged not to be
scientifically or medically compatible with this
study*
Ja
Nein
Have any other condition such as alcohol abuse,
drug abuse, or psychiatric disorder that may
affect the ability to participate in the trial.*
Ja
Nein
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Eligibility NCT01243424 Diabetes Mellitus,
Type 2
ODM derived from
http://clinicaltrials.gov/show/NCT01243424
All rights reserved. Please visit https://medical-data-
models.org/forms/5111
Eligibility
Einschlusskriterien
Alter 40 bis 85 Jahre*
Ja
Nein
Type 2 diabetes*
Ja
Nein
Elevated glycosylated heamoglobin (HbA1c): 6.5
- 8.5%, inclusive, if treatment naïve or mono-/dual
therapy with metformin and/or an alpha-
glucosidase inhibitor; 6.5 - 7.5%, inclusive, if
treatment with sulphonylurea/glinide in mono- or
dual (with metformin OR an alpha-glucosidase
inhibitor) therapy)*
Ja
Nein
Pre-existing cardiovascular disease OR specified
diabetes end-organ damage OR age => 70 years
OR two or more specified cardiovascular risk
factor*
Ja
Nein
Ausschlusskriterien
Diabetes mellitus Typ 1*
Ja
Nein
Treatment with other antidiabetic drugs (e.g.
rosiglitazone, pioglitazone, Glucagon-like peptide
1 (GLP-1) analogue/agonists, Dipeptidyl-
peptidase IV (DPP-IV) inhibitors or any insulin)
prior to informed consent (previous short term
use of insulin (up to two weeks) is allowed if
taken at least 8 weeks prior informed consent)*
Ja
Nein
Inappropriateness of glimepiride treatment for
renal safety issues according to local prescribing
information*
Ja
Nein
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ODM derived from
http://clinicaltrials.gov/show/NCT01246986
All rights reserved. Please visit https://medical-data-
models.org/forms/5112
Eligibility
Einschlusskriterien
Alter mindestens 18 Jahre*
Ja
Nein
Have histological evidence of a diagnosis of HCC
not amenable to curative surgery*
Ja
Nein
Serum alpha fetoprotein >= 1.5 Upper Limits of
Normal*
Ja
Nein
Child-Pugh Stage A*
Ja
Nein
Have the presence of measurable disease as
defined by the Response Evaluation Criteria in
Solid Tumors (RECIST 1.1). A lesion that has
been previously treated by local therapy will
qualify as a measurable or evaluable lesion if
there was demonstrable progression following
locoregional therapy*
Ja
Nein
Have given written informed consent prior to any
study-specific procedures*
Ja
Nein
Have adequate hematologic, hepatic and renal
function*
Ja
Nein
ECOG Status <= 1*
Ja
Nein
Have received sorafenib and have progressed or
were intolerant to sorafenib or are ineligible for
sorafenib treatment*
Ja
Nein
Are reliable and willing to make themselves
available for the duration of the study and are
willing to follow study procedures*
Ja
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Nein
Males and females with reproductive potential
must agree to use medically approved
contraceptive precautions during the trial and for
3 months following the last dose of study drug*
Ja
Nein
Females with childbearing potential must have
had a negative serum pregnancy test <= 7 days
prior to the first dose of study drug*
Ja
Nein
Are able to swallow capsules or tablets *
Ja
Nein
Ausschlusskriterien
Are currently enrolled in, or discontinued within
the last 28 days from a clinical trial involving an
investigational drug or device or not approved
use of a drug or device (other than the study drug
used in this study), or concurrently enrolled in any
other type of medical research judged not to be
scientifically or medically compatible with this
study*
Ja
Nein
Known HCC with fibro-lamellar or mixed
histology*
Ja
Nein
Presence of clinically relevant ascitis*
Ja
Nein
History of liver transplant*
Ja
Nein
Have received > 1 line of systemic treatment*
Ja
Nein
Have moderate or severe cardiac disease:        *
Ja
Nein
Have the presence of cardiac disease, including
a myocardial infarction within 6  months prior to
study entry, unstable angina pectoris, New York
Heart  Association (NYHA) Class III/IV
congestive heart failure, or uncontrolled
hypertension*
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Ja
Nein
Have documented major electrocardiogram
(ECG) abnormalities at the  investigator's
discretion*
Ja
Nein
Have major abnormalities documented by
echocardiography with Doppler. For  additional
details*
Ja
Nein
Have predisposing conditions that are consistent
with development of aneurysms  of the ascending
aorta or aortic stress*
Ja
Nein
Have serious preexisting medical conditions that,
in the opinion of the investigator, that cannot be
adequately controlled with appropriate therapy or
would preclude participation in this study*
Ja
Nein
Females who are pregnant or lactating*
Ja
Nein
Have a history of any other cancer (except non-
melanoma skin cancer or carcinoma in-situ of the
cervix) unless in complete remission and off all
therapy for that disease for a minimum of 3 years*
Ja
Nein
Have active infection that would interfere with the
study objectives or influence study compliance*
Ja
Nein
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Eligibility NCT01250379 Breast Cancer
ODM derived from
http://clinicaltrials.gov/show/NCT01250379
All rights reserved. Please visit https://medical-data-
models.org/forms/5113
Eligibility
Einschlusskriterien
Alter mindestens 18 Jahre*
Ja
Nein
weiblich*
Ja
Nein
Histologically confirmed HER2-negative breast
cancer*
Ja
Nein
Disease progression during or following first-line
treatment with Avastin and chemotherapy for
locally recurrent or metastatic breast cancer*
Ja
Nein
Avastin treatment in first-line setting must have
been a minimum of 4 cycles (15 mg/kg) or 6
cycles (10 mg/kg) in combination with
chemotherapy*
Ja
Nein
ECOG performance status 0-2*
Ja
Nein
At least 28 days since prior radiation therapy or
surgery and recovery from treatment *
Ja
Nein
Ausschlusskriterien
Anti-angiogenic therapy or anti-vascular
endothelial growth factors other than Avastin for
first-line treatment*
Ja
Nein
Active malignancy other than superficial basal
cell and superficial squamous cell carcinoma of
the skin, or in situ carcinoma of the cervix or
breast within the last 5 years*
Ja
Nein
Inadequate renal function*
Ja
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Nein
Clinically relevant cardio-vascular disease*
Ja
Nein
Known CNS disease except for treated brain
metastases*
Ja
Nein
Chronic daily treatment with high-dose aspirin
(>325 mg/day) or clopidogrel (>75 mg/day)*
Ja
Nein
Pregnant or lactating women*
Ja
Nein
2 / 2
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Eligibility NCT01271699 Multiple Sclerosis
ODM derived from
http://clinicaltrials.gov/show/NCT01271699
All rights reserved. Please visit https://medical-data-
models.org/forms/5114
Eligibility
Einschlusskriterien
Alter 18 bis 50 Jahre*
Ja
Nein
Patients at age 18-50 years old with a confirmed
or probably diagnosis of Multiple Sclerosis
according to the McDonald diagnostic criteria for
MS*
Ja
Nein
Patients with confirmed diagnosis of Multiple
Sclerosis according to the McDonald diagnostic
criteria but without confirmation of oligoclonal IgG
in the CSF*
Ja
Nein
Patients with present oligoclonal IgG in the CSF
but without proof of dissemination of spinal
inflammatory processes in the MRI*
Ja
Nein
Signed informed consent *
Ja
Nein
Ausschlusskriterien
Patients being younger than 18 years or older
than 50 years*
Ja
Nein
Patients without performed MRI of the brain and
spinoaxis*
Ja
Nein
Patients with a structural change in the brain that
is not caused by a chronic inflammatory disease
of the CNS*
Ja
Nein
Missing signed informed consent*
Ja
Nein
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Eligibility NCT01272232 Obesity
ODM derived from
http://clinicaltrials.gov/show/NCT01272232
All rights reserved. Please visit https://medical-data-
models.org/forms/5115
Eligibility
Einschlusskriterien
Alter mindestens 18 Jahre*
Ja
Nein
Procurement of patient informed consent,
investigational study*
Ja
Nein
Subjects diagnosed with type 2 diabetes and
treated with either diet and exercise alone,
metformin, SU, glitazone as single agent therapy
or any combination of the previously mentioned
compounds (metformin+SU, metformin+glitazone,
SU+glitazone, metformin+SU+glitazone)*
Ja
Nein
HbA1c*
Ja
Nein
BMI*
Ja
Nein
Stable body weight*
Ja
Nein
Preceding failed dietary effort *
Ja
Nein
Ausschlusskriterien
Treatment with glucagon-like peptide-1 (GLP-1)
receptor agonists, dipeptidyl peptidase-4 (DPP-4)
inhibitors or insulin within the last 3 months*
Ja
Nein
Known proliferative retinopathy or maculopathy*
Ja
Nein
History of acute or chronic pancreatitis*
Ja
Nein
Obesity induced by drug treatment*
Ja
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Nein
Use of approved weight lowering
pharmacotherapy*
Ja
Nein
Previous surgical treatment of obesity*
Ja
Nein
History of major depressive disorder or suicide
attempt*
Ja
Nein
Uncontrolled hypertension (systolic blood
pressure of 160 mmHg or above and/or diastolic
blood pressure of 100 mmHg or above)*
Ja
Nein
Screening calcitonin of 50 ng/L or above*
Ja
Nein
Familial or personal history of multiple endocrine
neoplasia type 2 (MEN2) or familial medullary
thyroid carcinoma (FMTC)*
Ja
Nein
Personal history of non-familial medullary thyroid
carcinoma*
Ja
Nein
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Eligibility NCT01282294 Tibial Fractures
ODM derived from
http://clinicaltrials.gov/show/NCT01282294
All rights reserved. Please visit https://medical-data-
models.org/forms/5116
Eligibility
Einschlusskriterien
Alter mindestens 18 Jahre*
Ja
Nein
Erwachsener, erwachsen*
Ja
Nein
Open or closed tibia fracture according to the
surgical technique *
Ja
Nein
Ausschlusskriterien
Women who are pregnant or breast-feeding or
are planning to become pregnant during the
study*
Ja
Nein
Patients with consumptive/ malignant primary
disease and a life expectancy of < 3 months*
Ja
Nein
Patients with a known allergy to
aminoglycosides*
Ja
Nein
Physical or mental incapacity, which makes it
impossible to obtain informed consent*
Ja
Nein
History of drug and alcohol abuse*
Ja
Nein
Patient unlikely to cooperate*
Ja
Nein
Legal incompetence*
Ja
Nein
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Eligibility NCT01282645 E04.525.190
ODM derived from
http://clinicaltrials.gov/show/NCT01282645
All rights reserved. Please visit https://medical-data-
models.org/forms/5117
Eligibility
Einschlusskriterien
Alter mindestens 18 Jahre*
Ja
Nein
Cranial Defects*
Ja
Nein
Received a Synthes PSI made of PEEK intended
for replacement of bony voids in the
cranial/craniofacial skeleton at least 24 months
before inclusion in the study*
Ja
Nein
Ability to obtain written informed consent from the
recipient or the recipient's legal guardian*
Ja
Nein
Ability to comply with the procedures described in
the protocol, including responding to simple
questionnaires either by the recipient in person or
by a next relative (spouse, parent) who lives with
the recipient *
Ja
Nein
Ausschlusskriterien
Patient was contraindicated to receive a PSI
made of PEEK at the time of implantation*
Ja
Nein
1 / 1
Eligibility NCT01285401 Relapsing-
Remitting Multiple Sclerosis
ODM derived from
http://clinicaltrials.gov/show/NCT01285401
All rights reserved. Please visit https://medical-data-
models.org/forms/5118
Eligibility
Einschlusskriterien
Alter 18 bis 50 Jahre*
Ja
Nein
Diagnosis of a relapsing-remitting form of MS*
Ja
Nein
Brain and/or spinal MRI with findings typical of
MS*
Ja
Nein
A first clinical event prior to Screening.*
Ja
Nein
Active disease diagnosis*
Ja
Nein
EDSS score of <= 4.0 at Screening.*
Ja
Nein
Currently treated with interferon-beta-1a (tiw) sc*
Ja
Nein
Willingness and ability to comply with the
protocol*
Ja
Nein
Written informed consent *
Ja
Nein
Ausschlusskriterien
Pregnancy and lactation period*
Ja
Nein
Any disease other than MS that could better
explain signs and symptoms.*
Ja
Nein
Complete transverse myelitis or bilateral optic
neuritis.*
Ja
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Nein
Currently receiving or use at any time of
monoclonal antibodies, mitoxantrone, cytotoxic or
immunosuppressive therapy (excluding systemic
steroids and adrenocorticotrophic hormone
[ACTH]), B cell modulating therapies (e.g.
RituxiMab or BelimuMab), total lymphoid
irradiation or bone marrow transplantation.*
Ja
Nein
Use of any cytokine or anti-cytokine therapy,
intravenous immunoglobulin, plasmapheresis, or
any investigational drug or experimental
procedure*
Ja
Nein
Use of oral or systemic corticosteroids or ACTH*
Ja
Nein
Have abnormalities of Vitamin D related
hormonal system other than low dietary intake or
decreased sun exposure, i.e. primary
hyperparathyroidism or granulomatous
disorders.*
Ja
Nein
Have an urine calcium/creatinine (mmol/mmol)
ratio > 1.0 or hypercalcaemia*
Ja
Nein
Are taking medications that influence Vitamin D
metabolism other than corticosteroids, e.g.,
phenytoin, barbiturates, thiazide diuretics and
cardiac glycosides.*
Ja
Nein
Are taking > 400 IU (10 microg) of Vitamin D
supplement daily.*
Ja
Nein
Have conditions with increased susceptibility to
hypercalcaemia, e.g., known arrhythmia or heart
disease, treatment with Digitalis, or
Hydrochlorothiazide and those who suffer from
nephrolithiasis.*
Ja
Nein
Have inadequate liver function*
Ja
Nein
Moderate to severe renal impairment*
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Eligibility NCT01285401 Relapsing-Remitting Multiple Sclerosis
Ja
Nein
Inadequate bone marrow reserve*
Ja
Nein
History or presence of serious or acute heart
disease such as uncontrolled cardiac
dysrhythmia or arrhythmia, uncontrolled angina
pectoris, cardiomyopathy, or uncontrolled
congestive heart failure (NYHA class 3 or 4).*
Ja
Nein
History or presence of severe depression, history
of suicide attempt, or current suicidal ideation.*
Ja
Nein
Epilepsy or seizures not adequately controlled by
treatment.*
Ja
Nein
Current or past alcohol or drug abuse.*
Ja
Nein
Any major medical or psychiatric illness (such as
psychosis, bipolar disorder) that in the opinion of
the Investigator could create undue risk to the
subject or could affect adherence with the trial
protocol.*
Ja
Nein
Known contra-indication to treatment with vitamin
D*
Ja
Nein
Known hypersensitivity to interferon or its
excipient(s)*
Ja
Nein
Known hypersensitivity to gadolinium.*
Ja
Nein
Any other condition that would prevent the
subject from undergoing an MRI scan.*
Ja
Nein
Signs and symptoms suggestive of transmissible
spongiform encephalopathy, or family members
who suffer(ed) from such.*
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Eligibility NCT01285401 Relapsing-Remitting Multiple Sclerosis
Ja
Nein
Positive HIV, hepatitis C, or hepatitis B (HBsAg
and HBc antibody) serology (test performed at
screening).*
Ja
Nein
Legal incapacity or limited legal capacity.*
Ja
Nein
Another current autoimmune disease, except
diabetes.*
Ja
Nein
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Eligibility NCT01285401 Relapsing-Remitting Multiple Sclerosis
Eligibility NCT01291810 Crohn's Disease
ODM derived from
http://clinicaltrials.gov/show/NCT01291810
All rights reserved. Please visit https://medical-data-
models.org/forms/5119
Eligibility
Einschlusskriterien
Alter 18 bis 65 Jahre*
Ja
Nein
Have had a diagnosis of Crohn's disease for at
least 6 months.*
Ja
Nein
Moderate to severe active Crohn's disease
defined as a Crohn's Disease Activity Index
(CDAI) score ≥ 220 and ≤ 450, and presence of
colonic mucosal ulcerations in at least 2
segments, or ulcerations on ≥ 10% of the
mucosal surface if only one segment is involved.*
Ja
Nein
Have developed secondary resistance to anti-
TNFα therapy.*
Ja
Nein
Ausschlusskriterien
Primary non-response to a previously received
treatment directed against TNFα Or Intolerance
related to the primary pharmacological effect of
anti-TNFα such as for instance, but not limited to,
severe or opportunistic infections and
demyelinating or autoimmune diseases.*
Ja
Nein
History of severe systemic bacterial, fungal, viral,
or parasitic infections within the 3 months prior to
screening; or the occurrence of any acute
infection within 2 weeks of the first administration
of study drug.*
Ja
Nein
Treatment with immunosuppressive or
immunomodulatory drugs*
Ja
Nein
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Eligibility NCT01185821 Relapsing
Remitting Multiple Sclerosis
ODM derived from
http://clinicaltrials.gov/show/NCT01185821
All rights reserved. Please visit https://medical-data-
models.org/forms/5120
Eligibility
Einschlusskriterien
Alter 18 bis 56 Jahre*
Ja
Nein
Relapsing Remitting Multiple Sclerosis*
Ja
Nein
Patients completed the core study
BAF312A2201*
Ja
Nein
Written informed consent provided before any
assessment of the extension study*
Ja
Nein
Female patients at risk of becoming pregnant
must have a negative pregnancy test and use
simultaneously two forms of effective
contraception *
Ja
Nein
Ausschlusskriterien
Newly diagnosed systemic disease other than
MS (which may require immunosuppressive
treatment)*
Ja
Nein
Malignancies, diabetes, significant cardiovascular
and pulmonary diseases and conditions*
Ja
Nein
Active infections*
Ja
Nein
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Eligibility NCT01194219 Plaque Psoriasis
ODM derived from
http://clinicaltrials.gov/show/NCT01194219
All rights reserved. Please visit https://medical-data-
models.org/forms/5121
Eligibility
Einschlusskriterien
Alter mindestens 18 Jahre*
Ja
Nein
Males or females, ≥ 18 years of age at the time of
signing the informed consent document*
Ja
Nein
Diagnosis of chronic plaque psoriasis for at least
12 months prior to Screening*
Ja
Nein
Have moderate to severe plaque psoriasis at
Screening and Baseline*
Ja
Nein
Must meet all laboratory criteria*
Ja
Nein
Females of childbearing potential (FCBP) must
have a negative pregnancy test at Screening and
Baseline. FCBP who engage in activity in which
conception is possible must use 2 forms of
contraception as described by the Study Doctor
while on study medication and for at least 28
days after taking the last dose of study
medication*
Ja
Nein
Male subjects (including those who have had a
vasectomy) who engage in activity in which
conception is possible must use barrier
contraception (latex condom or any nonlatex
condom NOT made out of natural [animal]
membrane [eg, polyurethane]) while on study
medication and for a least 28 days after the last
dose of study medication.*
Ja
Nein
Ausschlusskriterien
Other than psoriasis, history of any clinically
significant (as determined by the Investigator) or
other major uncontrolled disease.*
Ja
Nein
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Pregnant or breast feeding*
Ja
Nein
History of allergy to any component of the study
drug*
Ja
Nein
Hepatitis B surface antigen positive at Screening*
Ja
Nein
Anti-hepatitis C antibody positive at Screening*
Ja
Nein
Active tuberculosis (TB) or a history of
incompletely treated TB*
Ja
Nein
Clinically significant abnormality on 12-Lead ECG
at Screening*
Ja
Nein
Clinically significant abnormal chest x-ray*
Ja
Nein
History of positive human immunodeficiency virus
(HIV), or have congenital or acquired
immunodeficiency*
Ja
Nein
Active substance abuse or a history of substance
abuse within 6 months prior to Screening*
Ja
Nein
Bacterial infections requiring treatment with oral
or injectable antibiotics, or significant viral or
fungal infections, within 4 weeks of Screening*
Ja
Nein
Malignancy or history of malignancy (except for
treated [ie, cured] basal cell or squamous cell in
situ skin carcinomas and treated [ie, cured]
cervical intraepithelial neoplasia [CIN] or
carcinoma in situ of the cervix with no evidence
of recurrence within the previous 5 years)*
Ja
Nein
Psoriasis flare or rebound within 4 weeks prior to
Screening*
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Eligibility NCT01194219 Plaque Psoriasis
Ja
Nein
Evidence of skin conditions that would interfere
with clinical assessments*
Ja
Nein
Topical therapy within 2 weeks of randomization*
Ja
Nein
Systemic therapy for psoriasis within 4 weeks
prior to randomization*
Ja
Nein
Use of phototherapy within 4 weeks prior to
randomization (ie, UVB, PUVA)*
Ja
Nein
Adalimumab, etanercept, infliximab, or
certolizumab pegol within 12 weeks prior to
randomization*
Ja
Nein
Alefacept, briakinumab, or ustekinumab within 24
weeks prior to randomization*
Ja
Nein
Use of any investigational drug within 4 weeks
prior to randomization*
Ja
Nein
Prolonged sun exposure or use of tanning booths
or other ultraviolet (UV) light sources*
Ja
Nein
Prior treatment with apremilast*
Ja
Nein
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Eligibility NCT01194219 Plaque Psoriasis
Eligibility NCT01195480 Acute
Lymphoblastic Leukemia
ODM derived from
http://clinicaltrials.gov/show/NCT01195480
All rights reserved. Please visit https://medical-data-
models.org/forms/5122
Eligibility
Einschlusskriterien
Alter bis 18 Jahre*
Ja
Nein
Pre-emptive arm*
Ja
Nein
Children (18 years or younger) with CD19+
precursor B cell ALL fulfilling one of the following
criteria who are undergoing an allogeneic stem
cell transplant from an EBV-seropositive donor: *
Ja
Nein
In first remission, if at least one of the following
criteria are met:*
Ja
Nein
t(9;22) and prednisone poor response or not in
molecular remission (BCR-ABL/ABL ratio >
0.02%) pre-HSCT or*
Ja
Nein
Infant ALL age < 6 months at diagnosis with MLL
gene rearrangement and either presenting wcc
>300 x 109/L or poor steroid early response (i.e
circulating blast count >1x109/L following 7 day
steroid pre-phase of Interfant 06) or*
Ja
Nein
Resistant disease (> 30% blasts at end of
induction treatment day 28-33) in subsequent
morphological CR or*
Ja
Nein
High level bone marrow MRD (> 1 in 1000) at
week 12 ALL-BFM 2000/AIEOP BFM ALL
2009/EORTC 58951 protocols, week 12-15 of
FRALLE A or at week 14 of UKALL2010 *
Ja
Nein
Relapsed patients if at least one of the following
criteria are met:*
Ja
Nein
Very early (< 18 months from diagnosis) bone
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marrow or extramedullary relapse in second CR
or*
Ja
Nein
Early (within 6 months of finishing therapy)
isolated bone marrow relapse with bone marrow
MRD > 1 in 100 at day 35 of reinduction in
second CR or*
Ja
Nein
Early (within 6 months of finishing therapy) bone
marrow or combined relapse with high level bone
marrow MRD (> 1 in 1000) at the end of
consolidation therapy (week 12-13 UKALL
R3/INTREALL and COOPRALL protocols, prior
to protocol M in BFM relapse protocol (ALL-REZ
BFM 2002) and after Protocol II-IDA in AIEOP
LLA Rec 2003) These patients have a high (>
50%) risk of relapse and will be monitored for
evidence of MRD in bone marrow aspirates
(monthly for months 1-6, 6 weekly months 7.5-12
post HSCT) for the first year post-transplant.
Patients who become MRD +ve in the marrow at
a level minimum 5 x 10-4 but are in
morphological remission (<5% blasts in BM) will
be eligible to be treated pre-emptively with
CD19zeta transduced CTL *
Ja
Nein
Prophylaxis arm*
Ja
Nein
Additionally, any patient (≤ 18 years) with ALL
relapsing in the bone marrow (isolated or
combined) after myeloablative allogeneic HSCT
who achieves morphological remission after re-
induction and who is a candidate for second
HSCT at one of the participating centres is
eligible to receive CD19zeta transduced CTL
prophylactically*
Ja
Nein
Stem cell donors must be EBV sero-positive and
HLA-matched (10/10) or a single antigenic/allelic
(9/10) mismatch with the recipient*
Ja
Nein
A life expectancy of at least 8 weeks*
Ja
Nein
Karnofsky score of >60% if >10 years old or
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Lansky performance score of > 60 if <= 10 years
old*
Ja
Nein
Patients must have transduced donor-derived
EBV-specific CTLs with 15% or higher expression
of CD19zeta determined by flow-cytometry which
meet the specified release criteria*
Ja
Nein
Informed written consent indicating that patients
are aware this is a research study and have been
told of its possible benefits and toxic side effects*
Ja
Nein
Ausschlusskriterien
EBV seronegative or > single antigenic/allelic
HLA-mismatched donor*
Ja
Nein
Active acute GVHD overall Grade 2 or higher or
significant chronic GVHD requiring systemic
steroids at the time of scheduled infusion of
transduced CTL will be excluded until the patient
is GVHD-free and off steroids*
Ja
Nein
Pre-existing severe lung disease (FEV1 or FVC <
50% predicted) pre-HSCT or an oxygen
requirement of >28% O2 supplementation or
active pulmonary infiltrates on chest X-ray at the
time scheduled for transduced CTL infusion*
Ja
Nein
Serum bilirubin >3 times the upper limit of normal
or an AST or ALT > 5 times the upper limit of
normal*
Ja
Nein
Serum creatinine >3 times upper limit of normal*
Ja
Nein
Active severe intercurrent infection at the time of
transduced CTL infusion (if present consult with
Chief investigator).*
Ja
Nein
Patients in whom transduced donor-derived EBV-
specific CTLs don't meet release criteria*
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Ja
Nein
Serologically positive for Hepatitis B, C or HIV
pre-HSCT*
Ja
Nein
Females of childbearing age with a positive
pregnancy test*
Ja
Nein
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Eligibility NCT01195480 Acute Lymphoblastic Leukemia
Eligibility NCT01295307 Acute Myeloid
Leukemia
ODM derived from
http://clinicaltrials.gov/show/NCT01295307
All rights reserved. Please visit https://medical-data-
models.org/forms/5123
Eligibility
Einschlusskriterien
Alter mindestens 40 Jahre*
Ja
Nein
Diagnosis of AML according to WHO criteria.*
Ja
Nein
Untreated relapse or refractory disease after a
minimum of one standard induction therapy.
Treatment of relapse with leukocyte-apheresis or
up to 5 days with low dose cytarabine or
hydroxyurea is allowed.*
Ja
Nein
Refractory disease is defined as >=5% blasts
after the second cycle of induction  therapy or no
reduction in marrow blasts at early treatment
assessment (day +15)  after the first cycle of
induction therapy.*
Ja
Nein
Relapse is defined as an increase in bone
marrow blast count >=5%, re-appearance  of
blasts in the peripheral blood or extramedullary
disease.*
Ja
Nein
Have adequate renal and hepatic functions as
indicated by the following laboratory values:*
Ja
Nein
Serum creatinine <=1.0 mg/dL. If serum
creatinine >1.0 mg/dL, then the estimated
glomerular filtration rate (GFR) must be >60
mL/min/1.73 m2 (see reference  below*)*
Ja
Nein
Serum bilirubin <=1.5 x upper limit of normal
(ULN)*
Ja
Nein
Aspartate transaminase (AST)/alanine
transaminase (ALT) <=2.5 x ULN*
Ja
Nein
Alkaline phosphatase <=2.5 x ULN*
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Ja
Nein
Eligibility for intensive chemotherapy*
Ja
Nein
Patient needs to be capable to understand the
clinical trial as an investigational approach to
bridge the time to potential allogeneic HCT,
potential risks and benefits of the study.*
Ja
Nein
Signed written informed consent.*
Ja
Nein
Female patients of childbearing potential must
have a negative serum*
Ja
Nein
Male and female patients must use an effective
contraceptive method during the study and for a
minimum of 6 months after study treatment. *
Ja
Nein
Ausschlusskriterien
For refractory disease, more than two prior
induction chemotherapies or more than one prior
salvage chemotherapy containing high-dose
cytarabine (cumulative dose of cytarabine >= 5
g/m2).*
Ja
Nein
Second or higher relapse. Patients who received
hypomethylating agents like azacytidine or
decitabine as a treatment of first relapse, respond
and relapse later on may be included.*
Ja
Nein
Acute promyelocytic leukemia with
t(15;17)(q22;q12) molecular detection or
(PML/RARalpha).*
Ja
Nein
Central nervous system involvement (i.e. WBC
>= 5/microL in cerebrospinal fluid with blasts
present on cytospin).*
Ja
Nein
Prior allogeneic HCT*
2 / 3
Eligibility NCT01295307 Acute Myeloid Leukemia
Ja
Nein
Autologous transplantation within 100 days prior
to start of study treatment*
Ja
Nein
Use of investigational agents or anticancer
therapy within 10 days before study entry with the
exception of hydroxyurea or low-dose
cytarabine.*
Ja
Nein
Have any other severe concurrent disease, or
have a history of serious organ dysfunction or
disease involving the heart, kidney, liver, or other
organ system that may place the patient at undue
risk to undergo transplantation.*
Ja
Nein
Patients with known refractoriness to platelet
support.*
Ja
Nein
Patients with a systemic fungal, bacterial, viral, or
other infection not controlled (defined as
exhibiting ongoing signs/symptoms related to the
infection and without improvement, despite
appropriate antibiotics or other treatment).*
Ja
Nein
Pregnant or lactating patients.*
Ja
Nein
Any significant concurrent disease, illness, or
psychiatric disorder that would compromise
patient safety or compliance, interfere with
consent, study participation, follow up, or
interpretation of study results.*
Ja
Nein
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Eligibility NCT01303302 Diabetes Mellitus,
Type 2
ODM derived from
http://clinicaltrials.gov/show/NCT01303302
All rights reserved. Please visit https://medical-data-
models.org/forms/5124
Eligibility
Einschlusskriterien
Alter 18 bis 70 Jahre*
Ja
Nein
BMI*
Ja
Nein
Type 2 diabetes duration more than 6 month*
Ja
Nein
Type 2 diabetic sublecys treated with oral anti-
diabetic agents*
Ja
Nein
Stable anti-diabetic medication for at least 3
month prior to enrollment*
Ja
Nein
HbA1c >=7.5% and <=9.5% on visit 1. Subjects
with T2DM duration .10 years should have
<=9.0% at visit 1*
Ja
Nein
Stable HbA1c, defined as no significant change
(variation <=0.5%)between a historical value
recorded in the subject's medical record with in 3
month prior to enrollment and the HbA1c
gathered at visit 1*
Ja
Nein
Fasting blood glucose >120 and < 240 mg/dl on
visit 1. Subjects with T2DM duration > 10 yaers
should have .120 ans<=180 mg/dl at visit 1*
Ja
Nein
Women with child bearing potential (i.e, not post
menopausal or surgically sterilized) must agree to
use adequate birth control methods*
Ja
Nein
Stable weight, defined as no significant weight
change (variation <5%)within three months prior
to enrollment*
Ja
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Nein
If taking these medication, stable anti-
hepertensive and lipid-lowering medication for at
least one month prior to enrollment*
Ja
Nein
If subject is under anti-depressant medication the
treatment needs to be stable for at least six
month prior to enrollment*
Ja
Nein
Willingness to refrain from using prescription,
over the counter or herbal weight loss product for
the duration of the trial*
Ja
Nein
Ability and willingliness to perform required study
and data collection procedures and adhere to
operating requirements of the TANTALUS II
System*
Ja
Nein
Alert, mentally competant, and able to
understand and willing to comply with the
requirements of the clinical trial, and personally
motivated to abide by the requirements and
restrictions of the clinical trial*
Ja
Nein
Able to provide voluntary informed consent *
Ja
Nein
Ausschlusskriterien
Insulin therapy*
Ja
Nein
Taking GLP-1 analogue, such as exenatide
(Byette) in the last 3 month before enrollment
Taking medication known to affect gastric mobility
such as narcotics (chronic use) and
anticholinergics/antispasmodics*
Ja
Nein
Use of prescription, over the counter or herbal
weight loss product or obesity drugs during the
past two month*
Ja
Nein
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Experiencing severe and progressing diabetic
complications (i.e retinopathy not stabilized,
nephropathy with macroalbuminuria)*
Ja
Nein
Prior wound healing problems*
Ja
Nein
Diagnosed with past or present psychiatric
condition that may impair his or her ability to
comply with the study procedure*
Ja
Nein
Use of anti-psychotic medication*
Ja
Nein
Diagnosed with an eating disorder such as
bulimia or binge eating*
Ja
Nein
Obesity due to endocrinopathy (e.g.Cushing
disease, Hypothyroidism)*
Ja
Nein
Hiatal hernia requiring surgical repair or
paraesophageal hernia*
Ja
Nein
Pregnant or lactating*
Ja
Nein
Diagnosed with impaired liver function (liver
enzymes 3 times graeted than normal)*
Ja
Nein
Any prior bariatric surgery*
Ja
Nein
Any history of pancreatitis *
Ja
Nein
Personal history of peptic ulcer disease*
Ja
Nein
Diagnosed with gastroparesis or GI motility
disorder *
Ja
3 / 4
Eligibility NCT01303302 Diabetes Mellitus, Type 2
Nein
Use of active medical device (either implantable
or external) such as ICD, pacemaker, drug
infusion device, or neurostimulator (either
implantable or worn)*
Ja
Nein
Subjects using an external active device who are
able and willing to avoid use of the device during
the study may be enrolled.*
Ja
Nein
Cardiac history that physician feels should
exclude the subject from the study.*
Ja
Nein
Use of another investigational device agent in the
30 days prior to enrollment*
Ja
Nein
A history of life threatening disease within 5 years
of enrollment*
Ja
Nein
Change in diabetic medication from between visit
1 and visit 3*
Ja
Nein
Any additional condition(S) that in the
investigator's opinion would warrant exclusion
from the study or prevent the subject from
completing the study*
Ja
Nein
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Eligibility NCT01303315 Diabetes Mellitus,
Type 2
ODM derived from
http://clinicaltrials.gov/show/NCT01303315
All rights reserved. Please visit https://medical-data-
models.org/forms/5125
Eligibility
Einschlusskriterien
Alter 21 bis 70 Jahre*
Ja
Nein
Type 2 diabetes duration > 6 months and < 10
years*
Ja
Nein
7.8% < HbA1c < 10.5% if T2DM duration<= 5
years*
Ja
Nein
7.8% < HbA1c < 10.0% if T2DM duration > 5
years*
Ja
Nein
BMI*
Ja
Nein
Taking at least one oral anti-diabetic medication*
Ja
Nein
Patients treated with GLP-1 receptor agonist with
at least one oral anti-diabetic medication may be
included under the following conditions:*
Ja
Nein
a. The HbA1c, before GLP-1 receptor agonist
therapy was administered, was: i. 7.8% < HbA1c
< 10.5% if T2DM duration < 5 years ii. 7.8% <
HbA1c < 10.0% if T2DM duration > 5 years*
Ja
Nein
b. The patient was on GLP-1 receptor agonist
therapy for no more than 12 weeks*
Ja
Nein
Women with childbearing potential (i.e., not post-
menopausal or surgically sterilized) must agree to
use adequate birth control methods*
Ja
Nein
If subject is taking lipid-lowering medication, the
treatment must be stable for at least one month
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prior to enrollment*
Ja
Nein
If subject is taking anti-hypertensive medication,
the treatment must be stable for at least one
month prior to enrollment*
Ja
Nein
If subject is taking anti-depressant medication,
the treatment must be stable for at least one
month prior to enrollment*
Ja
Nein
Willingness to refrain from using prescription,
over the counter, or herbal weight loss products
for the duration of the trial*
Ja
Nein
Ability and willingness to perform required study
and data collection procedures and adhere to
operating requirements of the TANTALUS®
System*
Ja
Nein
Alert, mentally competent, and able to
understand and willing to comply with the
requirements of the clinical trial, and personally
motivated to abide by the requirements and
restrictions of the clinical trial*
Ja
Nein
Able to provide voluntary informed consent*
Ja
Nein
Ausschlusskriterien
Insulin therapy within the last 3 months*
Ja
Nein
GLP-1 receptor agonist therapy longer than 3
months*
Ja
Nein
Diagnosed with renal dysfunction or history of
renal dysfunction*
Ja
Nein
Taking medications known to affect gastric
motility*
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Ja
Nein
Use of prescription, over the counter or herbal
weight loss products or obesity drugs during the
past two months*
Ja
Nein
Experiencing severe and progressing diabetic
complications*
Ja
Nein
Prior wound healing problems*
Ja
Nein
Diagnosed with past or current psychiatric
condition that may impair his or her ability to
comply with the study procedures*
Ja
Nein
Use of anti-psychotic medications*
Ja
Nein
Diagnosed with eating disorder such as bulimia
or binge eating*
Ja
Nein
Obesity due to an endocrinopathy*
Ja
Nein
Hiatal hernia requiring surgical repair or a
paraesophageal hernia*
Ja
Nein
Pregnant or lactating*
Ja
Nein
Diagnosed with impaired liver function*
Ja
Nein
Any prior bariatric surgery*
Ja
Nein
Any history of pancreatitis*
Ja
Nein
Personal history of peptic ulcer disease*
Ja
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Nein
Diagnosed with Gastroparesis or other GI motility
disorder*
Ja
Nein
Use of active medical devices (either implantable
or external) such as ICD, drug infusion device, or
neurostimulator (either implanted or worn).*
Ja
Nein
Subjects using an external active device who are
able and willing to avoid use of the device during
the study may be enrolled.*
Ja
Nein
Cardiac history that physician feels should
exclude the subject from the study.*
Ja
Nein
Use of another investigational device or agent in
the 30 days prior to enrollment*
Ja
Nein
A history of life-threatening disease within 5 years
of enrollment*
Ja
Nein
Any additional condition(s) that in the
Investigator's opinion would warrant exclusion
from the study or prevent the subject from
completing the study*
Ja
Nein
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Eligibility NCT01307397 Malignant
Melanoma
ODM derived from
http://clinicaltrials.gov/show/NCT01307397
All rights reserved. Please visit https://medical-data-
models.org/forms/5126
Eligibility
Einschlusskriterien
Alter mindestens 18 Jahre*
Ja
Nein
Erwachsener, erwachsen*
Ja
Nein
Histologically confirmed metastatic melanoma
with BRAF V600 mutation determined by Cobas
4800 BRAF Mutation Test*
Ja
Nein
Disease Progression after at least one prior
systemic treatment for metastatic melanoma*
Ja
Nein
Eastern Cooperative Oncology Group (ECOG)
performance status 0-2*
Ja
Nein
Adequate hematologic, renal and liver function *
Ja
Nein
Ausschlusskriterien
Evidence of symptomatic CNS lesions*
Ja
Nein
Previous malignancy (other than melanoma)
within the past 2 years, except for treated and
controlled basal or squamous cell carcinoma of
the skin or carcinoma in-situ of the cervix*
Ja
Nein
Concurrent administration of any anti-cancer
therapies other than those administered in the
study*
Ja
Nein
Clinically significant cardiovascular disease or
event within the 6 months prior to first
administration of study drug*
Ja
Nein
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Refractory nausea or vomiting, external biliary
shunt, or significant bowel resection that would
preclude adequate absorption*
Ja
Nein
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Eligibility NCT01311687 Multiple Myeloma
ODM derived from
http://clinicaltrials.gov/show/NCT01311687
All rights reserved. Please visit https://medical-data-
models.org/forms/5127
Eligibility
Einschlusskriterien
Alter mindestens 18 Jahre*
Ja
Nein
Subjects must have documented diagnosis of
multiple myeloma and have measurable disease*
Ja
Nein
Subjects must have undergone prior treatment
with >= 2 treatment lines of anti-myeloma
therapy*
Ja
Nein
Subjects must have either refractory or relapsed
and refractory disease defined as documented
disease progression during or within 60 days of
completing their last myeloma therapy*
Ja
Nein
All subjects must have received at least 2
consecutive cycles of prior treatment that
included lenalidomide and bortezomib*
Ja
Nein
All subjects must have failed treatment with both
lenalidomide and bortezomib in one of the
following ways:*
Ja
Nein
1) Documented progressive disease on or within
60 days of completing treatment with
lenalidomide and/or bortezomib, or*
Ja
Nein
2) In case of prior response [>= partial response
(PR)] to lenalidomide or bortezomib, subjects
must have relapsed within 6 months after
stopping treatment with lenalidomide and/or
bortezomib-containing regimens, or*
Ja
Nein
3) Subjects who have not had a >= minimal
response (MR) and have developed
intolerance/toxicity after a minimum of two cycles
of lenalidomide*
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Ja
Nein
Patients must have received adequate prior
alkylator therapy*
Ja
Nein
Eastern Cooperative Oncology Group (ECOG)
performance status score of 0, 1, or 2*
Ja
Nein
Females of childbearing potential (FCBP) must
not become pregnant for 28 days prior to initiation
of study drug, during the study, and for 28 days
after discontinuation*
Ja
Nein
Females must agree to abstain from
breastfeeding during study participation and 28
days after study drug discontinuation*
Ja
Nein
Males must agree to use a latex condom during
any sexual during the study and for 28 days
following discontinuation from this study*
Ja
Nein
Males must also agree to refrain from donating
semen or sperm while on pomalidomide and for
28 days after discontinuation from this study *
Ja
Nein
Ausschlusskriterien
Any of the following laboratory abnormalities:*
Ja
Nein
Absolute Neutrophil Count*
Ja
Nein
Platelet count < 75,000/microL for subjects in
whom < 50% of bone marrow nucleated  cells are
plasma cells*
Ja
Nein
Kreatinin-Clearance*
Ja
Nein
korrigiertes Serumkalzium*
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Ja
Nein
Hämoglobin*
Ja
Nein
Serum glutamic oxaloacetic transaminase
(SGOT)/ aspartate aminotransferase (AST)  or
Transaminase, serum glutamic pyruvic (SGPT)/
alanine aminotransferase (ALT) >  3.0 x upper
limit of normal (ULN)*
Ja
Nein
Serum Total Bilirubin Measurement*
Ja
Nein
Previous therapy with Pomalidomide*
Ja
Nein
Hypersensitivity to thalidomide, lenalidomide, or
dexamethasone*
Ja
Nein
Resistance to high-dose dexamethasone used in
the last line of therapy*
Ja
Nein
Peripheral neuropathy >= Grade 2*
Ja
Nein
Subjects who received an allogeneic bone
marrow or allogeneic peripheral blood stem cell
transplant*
Ja
Nein
Subjects who are planning for or who are eligible
for stem cell transplant*
Ja
Nein
Subjects with any one of the following: 1)
Congestive heart failure, 2) Myocardial infarction
within 12 months prior to starting study treatment,
3) Unstable or poorly controlled angina pectoris,
including Prinzmetal variant angina pectoris*
Ja
Nein
Subjects who received any of the following within
the last 14 days of initiation of study treatment: 1)
Plasmapheresis, 2) Major surgery, 3) Radiation
therapy, 4) Use of any anti-myeloma drug
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therapy*
Ja
Nein
Use of any investigational agents within 28 days
or 5 half-lives (whichever is longer) of treatment*
Ja
Nein
Subjects with conditions requiring chronic steroid
or immunosuppressive treatment*
Ja
Nein
Any condition including the presence of
laboratory abnormalities, which places the
subject at unacceptable risk if he/she were to
participate in the study*
Ja
Nein
Incidence of gastrointestinal disease that may
significantly alter the absorption of
pomalidomide*
Ja
Nein
Subjects unable or unwilling to undergo
antithrombotic prophylactic treatment*
Ja
Nein
Any serious medical condition, laboratory
abnormality, or psychiatric illness that would
prevent the subjects from signing the informed
consent form*
Ja
Nein
Pregnant or breastfeeding females*
Ja
Nein
Known Human Immunodeficiency Virus (HIV)
positivity or active infectious hepatitis A, B or C*
Ja
Nein
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Eligibility NCT01319487 Diabetic Macular
Edema
ODM derived from
http://clinicaltrials.gov/show/NCT01319487
All rights reserved. Please visit https://medical-data-
models.org/forms/5128
Eligibility
Einschlusskriterien
Alter mindestens 18 Jahre*
Ja
Nein
Diagnosis of diabetes mellitus*
Ja
Nein
Patient must be able to self administer study
drug.*
Ja
Nein
Clinically significant diabetic macular edema in at
least one eye ("study eye") involving the center of
the macula:*
Ja
Nein
Mild to severe non proliferative diabetic
retinopathy (Early Treatment Diabetic
Retinopathy Study [ETDRS] grade between 20
and 53).*
Ja
Nein
BCVA score ≥ 34 letters and < 80 letters in the
study eye.*
Ja
Nein
Women of childbearing potential must have a
negative urine pregnancy test at Screening and
be using two highly effective methods of
contraception throughout the study.*
Ja
Nein
Male patients with partners of childbearing
potential must agree to use at least one highly
effective method of contraception throughout the
study.*
Ja
Nein
Ausschlusskriterien
Any ocular condition in the study eye that in the
opinion of the investigator would prevent
improvement in visual acuity.*
Ja
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Nein
Proliferative diabetic retinopathy in the study
eye.*
Ja
Nein
History of panretinal scatter
photocoagulation(PRP)in the study eye within 4
months prior to screening, and/or anticipated
need for PRP in the 3 months following
randomization.*
Ja
Nein
Active optic disc or retinal neovascularization,
rubeosis iridis, active or history of choroidal
neovascularization in the study eye.*
Ja
Nein
History of pars plana vitrectomy at any time,
intraocular surgery in the study eye within 90
days prior to screening.*
Ja
Nein
History of use of intravitreal injectable or
periocular depots corticosteroids (other than
triamcinolone acetonide)within 3 months prior to
the screening visit in the study eye.*
Ja
Nein
Patients who have previously received
triamcinolone acetonide in the study eye:*
Ja
Nein
The intended dose for each triamcinolone
acetonide injection was > 4 mg.*
Ja
Nein
The most recent dose was < 3 months prior to
the screening visit.*
Ja
Nein
Any treatment-related adverse event that was
seen, and in the opinion of the investigator, has
the potential to worsen or reoccur with study
treatment.*
Ja
Nein
Patients who have previously received anti-VEGF
therapy within 3 months prior to the screening
visit in the study eye.*
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Ja
Nein
Uncontrolled glaucoma or glaucoma treated by 2
or more medications.*
Ja
Nein
Aphakia or intraocular lens placement in the
anterior chamber of the study eye.*
Ja
Nein
Any active ocular infection; any history of
recurrent or chronic infection or inflammation in
the study eye.*
Ja
Nein
History of herpetic infection in either eye.*
Ja
Nein
History of corneal pathology/surgery*
Ja
Nein
Contact lens use at any time during the study.*
Ja
Nein
Uncontrolled systemic disease.*
Ja
Nein
Diabetes mellitus poor control*
Ja
Nein
Impaired renal function*
Ja
Nein
Poorly controlled arterial hypertension*
Ja
Nein
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Eligibility NCT01332019 Relapsing Multiple
Sclerosis
ODM derived from
http://clinicaltrials.gov/show/NCT01332019
All rights reserved. Please visit https://medical-data-
models.org/forms/5129
Eligibility
Einschlusskriterien
Alter 18 bis 70 Jahre*
Ja
Nein
Relapsing Multiple Sclerosis*
Ja
Nein
Must have completed the study treatment and
visit schedule through Week 96 in Study
105MS301. *
Ja
Nein
Ausschlusskriterien
Subjects exceeding more than 6 weeks since
completion of the Week 96 visit of Study
105MS301.*
Ja
Nein
Subjects with any clinically significant lab
abnormalities, malignancies, cardiac,
endocrinologic, hematologic, hepatic,
immunologic, metabolic, urologic, pulmonary,
neurologic, dermatologic, psychiatric, renal, or
other major disease*
Ja
Nein
Pregnant or nursing women.*
Ja
Nein
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Eligibility NCT01332968 Non-Hodgkin's
Lymphoma
ODM derived from
http://clinicaltrials.gov/show/NCT01332968
All rights reserved. Please visit https://medical-data-
models.org/forms/5130
Eligibility
Einschlusskriterien
Alter mindestens 18 Jahre*
Ja
Nein
Erwachsener, erwachsen*
Ja
Nein
CD20-positive indolent B-cell non-Hodgkin's
lymphoma (follicular lymphoma or splenic, nodal
or extranodal marginal zone lymphoma)*
Ja
Nein
Stage III or IV disease, or Stage II bulky disease,
requiring treatment*
Ja
Nein
At least one bi-dimensionally measurable lesion
(>2 cm in its largest dimension by CT scan or
MRI)*
Ja
Nein
Eastern Cooperative Oncology Group (ECOG)
performance status 0, 1 or 2*
Ja
Nein
Adequate hematologic function *
Ja
Nein
Ausschlusskriterien
Central nervous system lymphoma,
leptomeningeal lymphoma, or histological
evidence of transformation to a high-grade or
diffuse large B-cell lymphoma*
Ja
Nein
Grade 3b follicular lymphoma, small lymphocytic
lymphoma or Waldenström's
macroglobulinaemia*
Ja
Nein
Ann Arbor Stage I disease*
Ja
Nein
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History of severe allergic or anaphylactic
reactions to monoclonal antibody therapy, known
hypersensitivity to any of the study drugs or
sensitivity to murine products, or history of
sensitivity to mannitol*
Ja
Nein
For patients with follicular lymphoma: prior
treatment for non-Hodgkin's lymphoma with
chemotherapy, immunotherapy, or radiotherapy*
Ja
Nein
For patients with non-follicular lymphoma: prior
treatment with chemotherapy or immunotherapy*
Ja
Nein
History of prior malignancy with the exception of
curatively treated basal or squamous cell
carcinoma of the skin and low-grade in situ
carcinoma of the cervix*
Ja
Nein
Known active infection, or major episode of
infection within 4 week prior to the start of Cycle
1*
Ja
Nein
Positive for HIV, HTLV1, hepatitis C or chronic
hepatitis B*
Ja
Nein
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Eligibility NCT01335477 Pulmonary
Fibrosis
ODM derived from
http://clinicaltrials.gov/show/NCT01335477
All rights reserved. Please visit https://medical-data-
models.org/forms/5131
Eligibility
Einschlusskriterien
Alter mindestens 40 Jahre*
Ja
Nein
IPF diagnosed, according to most recent
American Thoracic Society (ATS), European
Respiratory Society (ERS), Japanese Respiratory
Society (JRS), Latin American Thoracic
Association (ALAT) IPF guideline for diagnosis
and management, within 5 years*
Ja
Nein
Combination of High Resolution Computerized
Tomography (HRCT) pattern, and if available
surgical lung biopsy pattern, as assessed by
central reviewers, are consistent with diagnosis of
IPF*
Ja
Nein
Dlco (corrected for Hb): 30%-79% predicted of
normal*
Ja
Nein
forcierte Vitalkapazität, FVC*
Ja
Nein
Ausschlusskriterien
Aspartate Aminotransferase (AST), Alanine
Aminotransferase (ALT) > 1.5 x Upper Limit of
Normal (ULN) *
Ja
Nein
Bilirubin > 1.5 x ULN*
Ja
Nein
Relevant airways obstruction (i.e. pre-
bronchodilator FEV1/FVC < 0.7)*
Ja
Nein
Patient likely to have lung transplantation during
study (being on transplantation list is acceptable
for participation)*
Ja
Nein
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Myocardial infarction within 6 months*
Ja
Nein
Unstable angina within 1 month*
Ja
Nein
Bleeding risk (genetic predisposition; fibrinolysis
or full-dose therapeutic anticoagulation or high
dose antiplatelet therapy; history of hemorrhagic
CNS event within 12 months; haemoptysis or
haematuria or active gastro-intestinal bleeding or
ulcers or major injury or surgery within 3
months);*
Ja
Nein
Thrombotic risk (inherited predisposition; history
of thrombotic event (including stroke and
transient ischemic attacks) within 12 months;*
Ja
Nein
International normalised ratio (INR) > 2,
prolongation of prothrombin time (PT) and partial
thromboplastin time (PTT) by > 50% of
institutional ULN)*
Ja
Nein
N-ACetyl Cystein, prednisone > 15mg/day or
equivalent received within 2 weeks of visit 1*
Ja
Nein
Pirfenidone, azathioprine, cyclophosphamide,
cyclosporine A received within 8 weeks of visit 1*
Ja
Nein
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Eligibility NCT01347671 Pain
ODM derived from
http://clinicaltrials.gov/show/NCT01347671
All rights reserved. Please visit https://medical-data-
models.org/forms/5132
Eligibility
Einschlusskriterien
Alter 18 bis 75 Jahre*
Ja
Nein
Type 1 or type 2 diabetes.*
Ja
Nein
Painful DPN symptoms and signs for at least 3
months.*
Ja
Nein
Blood glucose controlled with medication.*
Ja
Nein
Glycosylated hemoglobin <= 9.5 or 11%, country
dependent.*
Ja
Nein
Prior analgesic medication.*
Ja
Nein
Average score of >= 4 on the 11 point NRS
during the last 3 days prior to randomization. *
Ja
Nein
Ausschlusskriterien
Impaired liver, cardiac or renal function.*
Ja
Nein
Breastfeeding and pregnancy.*
Ja
Nein
History of substance abuse, alcohol or
medication.*
Ja
Nein
Chronic gastrointestinal disease.*
Ja
Nein
History of seizures and or epilepsy.*
Ja
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Nein
Krebs*
Ja
Nein
Presence of painful medical conditions that are
not due to diabetic neuropathy, e.g. rheumatoid
arthritis.*
Ja
Nein
Allergies to opioids, acetaminophen or excipients
of the medications.*
Ja
Nein
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Eligibility NCT01355120 Advanced Ocular
Melanoma
ODM derived from
http://clinicaltrials.gov/show/NCT01355120
All rights reserved. Please visit https://medical-data-
models.org/forms/5133
Eligibility
Einschlusskriterien
Alter mindestens 18 Jahre*
Ja
Nein
Histologically proven ocular melanoma*
Ja
Nein
Measurable disease according to RECIST in
unresectable stage III-IV*
Ja
Nein
Able and willing to give valid written inform
consent*
Ja
Nein
Patients with or without prior systemic treatment
for advanced malignant melanoma are eligible .*
Ja
Nein
In case of systemic pre-treatment, an interval of
at least 28 days since treatment with
chemotherapy, biochemotherapy, surgery,
radiation, or immunotherapy is mandatory as well
as recovery from any clinically significant toxicity
experienced during treatment is recommended.
Prior treatment must be completed by the time of
ipilimumab administration. Palliative radiation
therapy outside of the brain or therapeutic
radiation to the brain after the patient's condition
is stabilized and systemic steroids required for
the management of symptoms due to brain
metastases is decreased to the lowest fixed dose
possible and does not require the 28-day waiting
period. Patient must have recovered from any
acute toxicity associated with prior therapy.*
Ja
Nein
Expected survival of at least six months*
Ja
Nein
ECOG Performance Status 0, 1 or 2.*
Ja
Nein
Within the last 2 weeks prior to study day 1 the
following laboratory parameters, which should be
within the ranges specified:*
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Ja
Nein
Lab Parameter Range White blood cells (WBC)
>= 2500/mm3 (≥ 1 2.5 x 109/L) Absolute
neutrophil count (ANC) >= 1000/mm3 (≥ 1.0 x
109/L) Platelets ≥75.000/mm3 (≥ 75 x 109/L)
Hemoglobin ≥ 9 g/dL (≥ 90 g/L; may be
transfused) Creatinine <= 2.0 x ULN Bilirubin
total <= 2.0 x ULN (excepted patients with
Gilbert's Syndrome, who must have a total
bilirubin < 3.0 mg/dL) <= 5 x ULN for patients with
liver metastases*
Ja
Nein
No childbearing potential or negative pregnancy
test of women of childbearing potential performed
within 7 days prior to the start of treatment.*
Ja
Nein
Women of childbearing potential (WOCP) must
be using an effective method of contraception
(Pearl-Index < 1, e.g. oral contraceptives, other
hormonal contraceptives [vaginal products, skin
patches, or implanted or injectable products], or
mechanical products such as an intrauterine
device or barrier methods [diaphragm,
spermicides]) throughout the study and for up to
26 weeks after the last dose of investigational
product, in such a manner that the risk of
pregnancy is minimized.*
Ja
Nein
No men of fathering potential or men of fathering
potential must be using an effective method of
contraception to avoid conception throughout the
study and for up to 26 weeks after the last dose
of investigational product, in such a manner that
the risk of pregnancy is minimized.*
Ja
Nein
WOCBP include any female who has
experienced menarche and who has not
undergone successful surgical sterilization
(hysterectomy, bilateral tubal ligation, or bilateral
oophorectomy) or is not post-menopausal.*
Ja
Nein
Post-menopause is defined as:*
Ja
Nein
Amenorrhea >= 12 consecutive months without
another cause, or*
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Ja
Nein
For women with irregular menstrual periods and
taking hormone replacement therapy (HRT), a
documented serum follicle stimulating hormone
(FSH) level >=35 mIU/mL.*
Ja
Nein
Women who are using oral contraceptives, other
hormonal contraceptives (vaginal products, skin
patches, or implanted or injectable products), or
mechanical products such as an intrauterine
device or barrier methods (diaphragm, condoms,
spermicides) to prevent pregnancy, or are
practicing abstinence or where their partner is
sterile (eg, vasectomy) should be considered to
be of childbearing potential. *
Ja
Nein
WOCBP must have a negative serum or urine
pregnancy test (minimum sensitivity 25 IU/L or
equivalent units of HCG) at Baseline within 7
days before the start of ipilimumab and at week
12. *
Ja
Nein
Ausschlusskriterien
The patient requires concomitant therapy with
any of the following: IL 2, interferon, or other non-
study immunotherapy regimens; cytotoxic
chemotherapy; immunosuppressive agents; other
investigation therapies; any other systemic
therapy for cancer including any other
experimental treatment.*
Ja
Nein
The patient requires chronic use of systemic
corticosteroids. Systemic steroids for
management of symptoms due to brain mets
should be avoided if possible or subject should
be stable on the lowest clinically effective dose.
Topical or inhalational steroids are permitted.*
Ja
Nein
Use of any investigational or non-registered
product (drug or vaccine) other than the study
treatment.*
Ja
Nein
Active autoimmune disease: Patients with a
history of inflammatory bowel disease, including
ulcerative colitis and Crohn's Disease, are
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excluded from this study, as are patients with a
history of symptomatic disease (eg, rheumatoid
arthritis, systemic progressive sclerosis
[scleroderma], systemic lupus erythematosus,
autoimmune vasculitis [eg, Wegener's
Granulomatosis]); motor neuropathy considered
of autoimmune origin (e.g. Guillain-Barre
Syndrome and Myasthenia Gravis).*
Ja
Nein
Symptomatic CNS metastases (Remark:
Asymptomatic stable, untreated or pretreated
central nervous system (CNS) metastasis are
allowed)*
Ja
Nein
Family history of congenital or hereditary
immunodeficiency.*
Ja
Nein
The patient is known to be positive for Human
Immunodeficiency Virus (HIV) or other chronic
infections (HBV, HCV) or has another confirmed
or suspected immunosuppressive or
immunodeficient condition.*
Ja
Nein
The patient has psychiatric or addictive disorders
that may compromise his/her ability to give
informed consent or to comply with the trial
procedures.*
Ja
Nein
Lack of availability for clinical follow-up
assessments.*
Ja
Nein
The patient has concurrent severe medical
problems, unrelated to the malignancy, that would
significantly limit full compliance with the study or
expose the patient to unacceptable risk.*
Ja
Nein
Other serious illnesses, e.g., serious infections
requiring antibiotics or bleeding disorders.*
Ja
Nein
Patients with serious intercurrent illness, requiring
hospitalization.*
Ja
Nein
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For female patients: the patient is pregnant or
lactating. Women of childbearing potential:
Refusal or inability to use effective means of
contraception*
Ja
Nein
Any underlying medical or psychiatric condition,
which in the opinion of the investigator will make
the administration of ipilimumab hazardous or
obscure the interpretation of AEs, such as a
condition associated with frequent diarrhea.*
Ja
Nein
Subjects with melanoma who have another
active, concurrent, malignant disease are not
eligible for this trial, with the exception of
adequately treated basal or squamous cell skin
cancer, superficial bladder cancer, or carcinoma
in situ of the cervix.*
Ja
Nein
Previous treatment with ipilimumab*
Ja
Nein
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Eligibility NCT01358877 Breast Cancer
ODM derived from
http://clinicaltrials.gov/show/NCT01358877
All rights reserved. Please visit https://medical-data-
models.org/forms/5134
Eligibility
Einschlusskriterien
Alter mindestens 18 Jahre*
Ja
Nein
Erwachsener, erwachsen*
Ja
Nein
Non-metastatic primary invasive HER2-positive
carcinoma of the breast that is adequately
excised, and that is either node-positive (except
T0) or node-negative but with presence of at least
one risk factor as defined by the protocol*
Ja
Nein
ECOG Status <= 1*
Ja
Nein
The interval between definitive surgery for breast
cancer and randomization must be at least 3
weeks but no more than 7 weeks and the patient
must be willing and able to start treatment within
1 week of randomization*
Ja
Nein
Known hormone receptor status (estrogen
receptor and progesterone receptor)*
Ja
Nein
Baseline LVEF >/= 55%*
Ja
Nein
Women of childbearing potential and male
participants with partners of childbearing
potential must agree to use effective
contraception (as defined by the protocol) by the
patient and/or partner for the duration of the
study treatment and for at least 6 months after
the last dose of study drug *
Ja
Nein
Ausschlusskriterien
History of any prior (ipsi- and/or contralateral)
invasive breast cancer*
Ja
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Nein
History of non-breast malignancies within the 5
years prior to study entry, except for carcinoma in
situ of the cervix, carcinoma in situ of the colon,
melanoma in situ, and basal cell and squamous
cell carcinomas of the skin*
Ja
Nein
Any clinical T4 tumor as defined by TNM,
including inflammatory breast cancer*
Ja
Nein
Any previous systemic chemotherapy for cancer
or radiotherapy for cancer*
Ja
Nein
Prior use of anti-HER2 therapy for any reason or
other prior biologic or immunotherapy for cancer*
Ja
Nein
Concurrent anti-cancer treatment in another
investigational trial*
Ja
Nein
Serious cardiac or cardiovascular disease or
condition*
Ja
Nein
Pregnant or lactating women*
Ja
Nein
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Eligibility NCT01360008 Arrhythmia
ODM derived from
http://clinicaltrials.gov/show/NCT01360008
All rights reserved. Please visit https://medical-data-
models.org/forms/5135
Eligibility
Einschlusskriterien
Alter mindestens 18 Jahre*
Ja
Nein
Documented paroxysmal AF (2 episodes of PAF
within the last 3 months) or Persistent AF (lasting
< 1 year)*
Ja
Nein
First ablation of AF*
Ja
Nein
Documented inefficacy of at least 1 AAD not
including beta-blockers*
Ja
Nein
Written informed consent *
Ja
Nein
Ausschlusskriterien
Longstanding persistent AF lasting > 1 year*
Ja
Nein
ACS - Acute coronary syndrome*
Ja
Nein
Heart failure NYHA IV*
Ja
Nein
Thrombocytosis, thrombocytopenia*
Ja
Nein
Any condition contraindicating chronic
anticoagulation*
Ja
Nein
Stroke or TIA within 6 months prior to ablation*
Ja
Nein
Uncontrolled hyperthyroidism*
Ja
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Nein
Schwangerschaft*
Ja
Nein
Life expectancy < 1 year*
Ja
Nein
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Eligibility NCT01360008 Arrhythmia
Eligibility NCT01363427 Crohn's Disease
ODM derived from
http://clinicaltrials.gov/show/NCT01363427
All rights reserved. Please visit https://medical-data-
models.org/forms/5136
Eligibility
Einschlusskriterien
Alter mindestens 18 Jahre*
Ja
Nein
Crohn's Disease*
Ja
Nein
therapeutic need according to SPC*
Ja
Nein
written informed consent*
Ja
Nein
1 / 1
Eligibility NCT01363453 Ulcerative Colitis
ODM derived from
http://clinicaltrials.gov/show/NCT01363453
All rights reserved. Please visit https://medical-data-
models.org/forms/5137
Eligibility
Einschlusskriterien
Alter mindestens 18 Jahre*
Ja
Nein
Ulcerative Colitis*
Ja
Nein
therapeutic need according to SPC*
Ja
Nein
written informed consent *
Ja
Nein
Ausschlusskriterien
contraindications according to SPC*
Ja
Nein
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Eligibility NCT01363752 Kidney
Transplantation
ODM derived from
http://clinicaltrials.gov/show/NCT01363752
All rights reserved. Please visit https://medical-data-
models.org/forms/5138
Eligibility
Einschlusskriterien
Alter mindestens 18 Jahre*
Ja
Nein
End stage kidney disease and a suitable
candidate for primary renal transplantation or re-
transplantation (unless the graft was lost from
rejection within 6 months)*
Ja
Nein
Receiving a kidney transplant from a deceased or
living (non Human Leukocyte Antigen [HLA]
identical) donor with compatible ABO blood type*
Ja
Nein
Female subject of childbearing potential has a
negative serum or urine pregnancy test at
enrollment*
Ja
Nein
Female and male subjects agree to maintain
highly effective birth control during the study and
for 90 days after discontinuation of dosing with
study drugs. A highly effective method of birth
control is defined as those which result in a low
failure rate (CPMP/ ICH/ 286/ 95 modified) of <
1% per year when used consistently and correctly
such as implants, injectables, combined oral
contraceptives, some Intrauterine Devises (IUDs),
sexual abstinence or vasectomized partner *
Ja
Nein
Ausschlusskriterien
Receiving or having previously received an organ
transplant other than a kidney*
Ja
Nein
Cold ischemia time of the donor kidney > 30
hours*
Ja
Nein
Panel-reactive antibody*
Ja
Nein
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Receiving a graft from a non-heart-beating donor
other than of Maastricht category 3 (withdrawal of
support awaiting cardiac arrest)*
Ja
Nein
Significant liver disease, defined as having
continuously elevated SGPT/ ALT and/ or SGOT/
AST and/ or total bilirubin levels >= 2 times the
upper value of the normal range of the
investigational site or is receiving a graft from a
hepatitis C or B positive donor*
Ja
Nein
Requiring initial sequential or parallel therapy with
immunosuppressive antibody preparation(s)*
Ja
Nein
Requiring ongoing dosing with a systemic
immunosuppressive drug prior to transplantation
(other than minimal levels of immunosuppression
following failure of previous transplantation
without nephrectomy)*
Ja
Nein
Significant, uncontrolled concomitant infections
and/ or severe diarrhea, vomiting, active upper
gastro-intestinal tract malabsorption or active
peptic ulcer*
Ja
Nein
Pregnant woman or breast-feeding mother*
Ja
Nein
Subject or donor known to be HIV positive*
Ja
Nein
Known allergy or intolerance to tacrolimus,
macrolide antibiotics, corticosteroids, sirolimus,
MMF or any of the product excipients or iodine*
Ja
Nein
Evidence of malignant disease within the last 5
years, not including non-malignant skin cancers*
Ja
Nein
Currently participating in another clinical trial,
and/ or has taken an investigational drug within
28 days prior to enrollment*
Ja
Nein
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Eligibility NCT01363752 Kidney Transplantation
Unlikely to comply with the visits scheduled in the
protocol*
Ja
Nein
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Eligibility NCT01363752 Kidney Transplantation
Eligibility NCT01365351 Growth Hormone
Deficiency
ODM derived from
http://clinicaltrials.gov/show/NCT01365351
All rights reserved. Please visit https://medical-data-
models.org/forms/5139
Eligibility
Einschlusskriterien
Children With Growth Hormone Deficiency*
Ja
Nein
therapeutic need according to SPC*
Ja
Nein
written informed consent *
Ja
Nein
Ausschlusskriterien
contraindications according to SPC*
Ja
Nein
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Eligibility NCT01374789 Urinary Bladder
Cancer
ODM derived from
http://clinicaltrials.gov/show/NCT01374789
All rights reserved. Please visit https://medical-data-
models.org/forms/5140
Eligibility
Einschlusskriterien
Alter mindestens 18 Jahre*
Ja
Nein
Histologically or cytologically confirmed,
unresectable urothelial carcinoma of the bladder
or the upper urinary tract*
Ja
Nein
Wild-type HRAS*
Ja
Nein
General condition ECOG 0-1*
Ja
Nein
Life expectancy at least 12 weeks*
Ja
Nein
Women of child-bearing potential: negative
pregnancy test and use of effective
contraception(oral contraceptive, coil). Men: use
of adequate male contraception (condom) for up
to 3 months after discontinuation of panitumumab
therapy*
Ja
Nein
Locally advanced or metastatic disease (T3b,T4
and/or N+ and/or M+)*
Ja
Nein
At least one unidimensionally measurable lesion
detectable in CT or MRI corresponding to the
RECIST criteria*
Ja
Nein
Adequate haematological, hepatic, renal and
metabolic function parameters:*
Ja
Nein
Leukocytes > 3000/mm³, ANC >= 1500/mm³,
platelets >= 100,000/mm³, hemoglobin > 9 g/dl
Creatinine clearance >= 50 ml/min and serum
creatinine <= 1.5 x upper limit of normal Bilirubin
<= 1.5 x upper limit of normal, GOT-GPT <= 2.5 x
upper limit of normal in absence of liver
1 / 4
metastases, or <= 5 x upper limit of normal in
presence of liver metastases, AP <= 5 x upper
limit of normal Magnesium >= lower limit of
normal. Calcium >= lower limit of normal INR and
PTT < 1.5 x the upper limit of the normal
reference range *
Ja
Nein
Ausschlusskriterien
HRAS mutation*
Ja
Nein
Absence of any of the above-listed inclusion
criteria*
Ja
Nein
Dialysis-dependence following nephrectomy*
Ja
Nein
Patients with cerebral tumours and/or cerebral
metastases*
Ja
Nein
Clinically significant cardiovascular disease in
(incl. myocardial infarction, unstable angina,
symptomatic congestive heart failure, serious
uncontrolled cardiac arrhythmia) <= 1 year before
enrolment.*
Ja
Nein
Patients with uncontrolled hypertension. Systolic
blood pressure > 150 mmHg or diastolic blood
pressure > 90 mmHg despite optimal medical
treatment*
Ja
Nein
History of interstitial lung disease, e.g.
pneumonitis or pulmonary fibrosis or evidence of
interstitial lung disease on baseline chest CT
scan.*
Ja
Nein
Patients with thrombotic or embolic events, such
as stroke or pulmonary embolism*
Ja
Nein
Patients with recent or known history of
haemorrhagic diathesis*
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Eligibility NCT01374789 Urinary Bladder Cancer
Ja
Nein
Known significant neurological or psychiatric
disorders, including dementia and epileptic
seizures*
Ja
Nein
Serious inflammatory eye conditions, hearing
impairment*
Ja
Nein
Pulmonary (pO2 < 60 mmHg), haemopoietic (e.g.
serious bone marrow aplasia), hepatic or renal
disorders*
Ja
Nein
Diabetes mellitus poor control*
Ja
Nein
Serious bacterial or fungal infections (>grade 2
NCI CTC Version 3)*
Ja
Nein
Chronic hepatitis B or C. HIV infection*
Ja
Nein
Autoimmunerkrankung*
Ja
Nein
Allergic reaction to one of the medications to be
used*
Ja
Nein
Status post organ transplantation*
Ja
Nein
Status post autologous bone marrow
transplantation or stem cell transplantation in the
4 months prior to study commencement*
Ja
Nein
Manifest secondary malignancy or other form of
cancer in the previous 5 years (excluding
basalioma, in situ cervical cancer, incidental
prostatic cancer)*
Ja
Nein
Subject pregnant or breast feeding, or planning to
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Eligibility NCT01374789 Urinary Bladder Cancer
become pregnant within 6 months after the end
of treatment*
Ja
Nein
Subject (male or female) is not willing to use
highly effective methods of contraception (per
institutional standard) during treatment and for 3
months (male or female) after the end of
treatment (adequate: oral contraceptives,
intrauterine device or barrier method in
conjunction with spermicidal jelly).*
Ja
Nein
Active participation in other clinical studies in the
previous 4 weeks*
Ja
Nein
Prior systemic therapy with cytostatics or
immunotherapeutic agents*
Ja
Nein
Concurrent use of other anticancer treatments
after study commencement*
Ja
Nein
intravesikale Chemotherapie*
Ja
Nein
Radiotherapie, Strahlentherapie*
Ja
Nein
Previous radiotherapy in which all lesions to be
used for the evaluation of tumour response were
irradiated*
Ja
Nein
Patients in a closed institution according to an
authority or court decision*
Ja
Nein
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Eligibility NCT01374789 Urinary Bladder Cancer
Eligibility NCT01376908 Phenylketonuria
(PKU)
ODM derived from
http://clinicaltrials.gov/show/NCT01376908
All rights reserved. Please visit https://medical-data-
models.org/forms/5141
Eligibility
Einschlusskriterien
Alter bis 4 Jahre*
Ja
Nein
Male or female PKU infants and young children
<4 years of age at the scheduled Day 1 visit of
the 26-week Study Period (taking into
consideration the maximum of 21 days in the
Screening Period).*
Ja
Nein
Confirmed clinical and biochemical PKU,
including at least two previous blood Phe levels ≥
400 micromol/L obtained on 2 separate
occasions.*
Ja
Nein
Previously responded, as assessed by the
Investigator, to a BH4 test, if all 3 of the following
criteria are satisfied:*
Ja
Nein
The BH4 dose was 20 mg/kg/day.*
Ja
Nein
The duration of the test was at least for 24
hours.*
Ja
Nein
A 30% decrease in blood Phe levels.*
Ja
Nein
Defined level of dietary Phe tolerance consistent
with the diagnosis of PKU;*
Ja
Nein
Good adherence to dietary treatment, including
prescribed dietary Phe restriction and prescribed
amounts of Phe-free protein supplements and
low-Phe foods.*
Ja
Nein
Maintenance of blood Phe levels within the
therapeutic target range of 120-360 micromol/L
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(defined as ≥120 to < 360 micromol/L) over a 1-
month period prior to Screening, as assessed by
the Investigator.*
Ja
Nein
Parent(s) and/or guardian(s) willing to comply
with all study procedures, maintain strict
adherence to the diet, and willing and able to
provide written, signed informed consent after the
nature of the study has been explained and prior
to any study procedures.*
Ja
Nein
Ausschlusskriterien
Use of Kuvan, Biopten, or any unregistered
preparation of tetrahydrobiopterin within the
previous 30 days, unless for the purposes of a
BH4 responsiveness test.*
Ja
Nein
Previous exposure to Kuvan, Biopten, or any
unregistered preparation of tetrahydrobiopterin
for >30 days.*
Ja
Nein
Known hypersensitivity to Kuvan or its
excipients.*
Ja
Nein
Known hypersensitivity to other approved or non-
approved formulations of tetrahydrobiopterin.*
Ja
Nein
Previous diagnosis of BH4 deficiency.*
Ja
Nein
Current use of methotrexate, trimethoprim, or
other dihydrofolate reductase inhibitors.*
Ja
Nein
Current use of medications that are known to
affect nitric oxide synthesis, metabolism or
action.*
Ja
Nein
Current use of levodopa.*
Ja
Nein
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Eligibility NCT01376908 Phenylketonuria (PKU)
Current use of experimental/other investigational
or unregistered drugs that may affect the study
outcomes.*
Ja
Nein
Inability to comply with study procedures.*
Ja
Nein
Inability to tolerate oral intake.*
Ja
Nein
History of organ transplantation.*
Ja
Nein
Concurrent disease or condition that would
interfere with study participation or increase the
risk for adverse events, including seizure
disorders, corticosteroid administration, active
malignancy, diabetes mellitus, severe congenital
heart disease, renal or hepatic failure.*
Ja
Nein
Other significant disease that in the Investigator's
opinion would exclude the subject from the trial.*
Ja
Nein
Any condition that, in the view of the Principal
Investigator renders the subject at high risk for
failure to comply with treatment or to complete
the study.*
Ja
Nein
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Eligibility NCT01376908 Phenylketonuria (PKU)
Eligibility NCT01377090 Systemic Sclerosis
ODM derived from
http://clinicaltrials.gov/show/NCT01377090
All rights reserved. Please visit https://medical-data-
models.org/forms/5143
Eligibility
Einschlusskriterien
Alter mindestens 18 Jahre*
Ja
Nein
Signed informed consent prior to enrollment*
Ja
Nein
Diagnosis of systemic sclerosis (SSc) according
to the American College of Rheumatology and/or
limited cutaneous SSc or diffuse cutaneous SSc
according to LeRoy criteria *
Ja
Nein
For patients with no history of digital ulcers (DU)
and no DU at enrollment only:*
Ja
Nein
Enrollment must be within 2 years of the first
physician-documented non-Raynaud clinical
feature *
Ja
Nein
Ausschlusskriterien
systemische Sklerose ohne Sklerodermie*
Ja
Nein
Patients who underwent stem cell
transplantation*
Ja
Nein
Participation in interventional clinical trials within
3 months prior to enrollment and/or during the
study*
Ja
Nein
Inability to undergo Nailfold Videocapillaroscopy
(NVC) assessment (e.g., inability to extend
fingers sufficiently)*
Ja
Nein
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Eligibility NCT01385657 Atopic Dermatitis
ODM derived from
http://clinicaltrials.gov/show/NCT01385657
All rights reserved. Please visit https://medical-data-
models.org/forms/5144
Eligibility
Einschlusskriterien
Alter mindestens 18 Jahre*
Ja
Nein
Chronic AD diagnosed by the Eichenfield revised
criteria of Hannifin and Rajka that has been
present for at least 3 years before the screening
visit*
Ja
Nein
Eczema Area and Severity Index (EASI) score
>/= 12 at the screening and baseline visits*
Ja
Nein
Investigator's Global Assessment (IGA) score >/=
3 at the screening and baseline visits*
Ja
Nein
>/= 10% body surface area (BSA) of AD
involvement at the screening and baseline visits*
Ja
Nein
History of inadequate response to a stable (>/= 1
month) regimen of topical corticosteroids or
calcineurin inhibitors as treatment for AD within 3
months before the screening visit*
Ja
Nein
Ausschlusskriterien
Positive Hepatitis B surface antigen, and/or
positive Hepatitis C antibody at the screening
visit*
Ja
Nein
Treatment with an investigational drug within 8
weeks or within 5 half-lives, if known, whichever
is longer, before the baseline visit*
Ja
Nein
Treatment with leukotriene inhibitors within 4
weeks before the baseline visit*
Ja
Nein
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Treatment with systemic corticosteroids within 4
weeks before the baseline visit*
Ja
Nein
Treatment with topical corticosteroids, tacrolimus,
and/or pimecrolimus within 1 week before the
baseline visit*
Ja
Nein
Systemic treatment for AD with an
immunosuppressive/immunomodulating
substance within 4 weeks before the baseline
visit*
Ja
Nein
Chronic or acute infection requiring treatment
with oral or IV antibiotics, antivirals, or antifungals
within 4 weeks before the screening visit or
superficial skin infections within 1 week before
the screening visit*
Ja
Nein
Known history of human immunodeficiency virus
(HIV) infection*
Ja
Nein
History of clinical parasite infection, other than
treated trichomoniasis*
Ja
Nein
History of malignancy within 5 years before the
baseline visit, with the following exceptions:
patients with a history of completely treated
carcinoma in situ of cervix, and non-metastatic
squamous or basal cell carcinoma of the skin are
allowed*
Ja
Nein
Any medical or psychiatric condition which, in the
opinion of the investigator or the sponsor's
medical monitor, would place the patient at risk,
interfere with participation in the study, or
interfere with the interpretation of study results*
Ja
Nein
Pregnant or breast-feeding women*
Ja
Nein
Unwilling to use adequate birth control, if of
reproductive potential and sexually active*
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Eligibility NCT01385657 Atopic Dermatitis
Ja
Nein
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Eligibility NCT01385657 Atopic Dermatitis
Eligibility NCT01403376 Multiple Sclerosis
ODM derived from
http://clinicaltrials.gov/show/NCT01403376
All rights reserved. Please visit https://medical-data-
models.org/forms/5145
Eligibility
Einschlusskriterien
Alter 18 bis 59 Jahre*
Ja
Nein
Male or female patients <60 years old with
relapsing multiple sclerosis*
Ja
Nein
treated for at least 6 months with 7 or 14 mg
teriflunomide in one of the  studies LTS6048 or
LTS6050 or*
Ja
Nein
treated with a stable dose of IFN-beta-1 for at
least 6 months*
Ja
Nein
Patient's Signature on Informed Consent Form*
Ja
Nein
Ausschlusskriterien
Having concomitant infectious pathology at the
time of vaccination*
Ja
Nein
MS relapse within 1 month before vaccination*
Ja
Nein
Systemic corticosteroids within 1 month before
the vaccination*
Ja
Nein
Any contraindication to influenza vaccine*
Ja
Nein
Any vaccination within the last 6 months.*
Ja
Nein
Prior use of any investigational drug or
participation to a clinical trial within 1 year (only
for patients under interferon Beta-1) *
Ja
Nein
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Prior or concomitant use (for a minimum of 1 year
before study entry) of cladribine, mitoxantrone, or
other immunosuppressant agents such as
azathioprine, cyclophosphamide, cyclosporin,
methotrexate, mycophenolate, natalizumab
(Tysabri), leflunomide or fingolimod or other
immunomodulator/immunosuppressant in
development*
Ja
Nein
Prior or concomitant use of Glatiramer acetate
within 1 year before study entry*
Ja
Nein
Prior or concomitant use of intravenous
immunoglobulins within 3 months before study
entry*
Ja
Nein
Pregnant or breast feeding women*
Ja
Nein
Women of childbearing potential without
adequate contraception.*
Ja
Nein
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Eligibility NCT01403376 Multiple Sclerosis
Eligibility NCT01404741 Myelodysplastic
Syndrome
ODM derived from
http://clinicaltrials.gov/show/NCT01404741
All rights reserved. Please visit https://medical-data-
models.org/forms/5146
Eligibility
Einschlusskriterien
Alter 55 bis 70 Jahre*
Ja
Nein
Patients with proven de novo or therapy-related
MDS / CMML (WBC <13 GPT/l)according to FAB
and risk profile according to IPSS: intermediate
II- risk or high-risk or intermediate I with high-risk
cytogenetic (according to IPSS, taking into
account that IPSS, however, was not validated for
t- MDS), patients with secondary AML (according
to WHO) and blasts <= 30 % (= RAEB-t
according to FAB)*
Ja
Nein
Previously untreated or maximal 1 cycle of 5-
azacytidine (Vidaza)*
Ja
Nein
Understand and voluntarily sign an informed
consent form*
Ja
Nein
ECOG Status <= 2*
Ja
Nein
Adequate renal and liver function: creatinine and
bilirubin < 3 x the upper limit of normal*
Ja
Nein
Sufficient cardiac function (ejection fraction > 30
%) *
Ja
Nein
Ausschlusskriterien
Blasts > 30 % in bone marrow at time of
diagnosis*
Ja
Nein
Zentralnervensystembeteiligung, Status*
Ja
Nein
Severe irreversible renal, hepatic, pulmonary or
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cardiac disease, such as*
Ja
Nein
Total bilirubin, SGPT or SGOT >= 3 times upper
the normal level*
Ja
Nein
LVEF - Left ventricular ejection fraction*
Ja
Nein
Kreatinin-Clearance*
Ja
Nein
DLCO < 35 % and/or receiving supplementary
continuous oxygen*
Ja
Nein
Pregnant or breastfeeding female subject*
Ja
Nein
Patients with a life-expectancy of < six months
because of another debilitating disease*
Ja
Nein
Serious psychiatric or psychological disorders*
Ja
Nein
Uncontrolled invasive fungal infection at time of
registration*
Ja
Nein
Known positive for HIV or acute infectious
hepatitis, type A, B or C*
Ja
Nein
Participation in another study with ongoing use of
unlicensed investigational product from 28 days
before study enrollment until the end of the study*
Ja
Nein
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Eligibility NCT01404741 Myelodysplastic Syndrome
Eligibility NCT01408095 Diabetes Mellitus,
Type 2
ODM derived from
http://clinicaltrials.gov/show/NCT01408095
All rights reserved. Please visit https://medical-data-
models.org/forms/5147
Eligibility
Einschlusskriterien
Alter 18 bis 70 Jahre*
Ja
Nein
Clinical diagnosis of type 2 diabetes mellitus prior
to entering the trial*
Ja
Nein
May be treated with: *
Ja
Nein
1. Diet and exercise alone or *
Ja
Nein
2. Diet and exercise in combination with a stable
dose of metformin for at least 3  months before
Screening or*
Ja
Nein
3. Diet and exercise in combination with a stable
dose of sulfonylurea or  meglitinide (repaglinide,
nateglinide) for at least 3 months before
Screening or *
Ja
Nein
4. Diet and exercise in combination with stable
doses of metformin and sulfonylurea  or
metformin and meglitinides for at least 3 months
before Screening and have  had diabetes for at
least 6 years*
Ja
Nein
Must have an Hemoglobin A1c value between 7%
and 10%*
Ja
Nein
BMI*
Ja
Nein
Must have stable weight during the 3 months
prior to Screening (weight change not to exceed
5 kg (11 lb))*
Ja
Nein
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If female, you must not be able to get pregnant*
Ja
Nein
Must be well motivated, capable, and willing to
complete study required glucose monitoring and
instruction *
Ja
Nein
Ausschlusskriterien
Use of insulin or any antidiabetic agent other than
metformin or sulfonylurea or meglitinide during
the 3 months prior to Screening*
Ja
Nein
Have a gastrointestinal disease that significantly
impacts gastric emptying or motility or have
undergone gastric bypass or gastric banding
surgery*
Ja
Nein
Have had more than one episode of severe
hypoglycemia within 6 months prior to entry into
the study, or are currently diagnosed as having
hypoglycemia unawareness or have had 2 or
more emergency room visits or hospitalizations
due to poor glucose control in the past 6 months*
Ja
Nein
Are currently taking or have taken within the last
2 months, prescription or over-the counter
medications which affect body weight*
Ja
Nein
Have cardiac disease with functional status that
is New York Heart Association [NYHA] Class II,
III, or IV or a history of myocardial infarction,
unstable angina, or decompensated congestive
heart failure in the past 6 months.*
Ja
Nein
Have poorly controlled hypertension, history of
malignant hypertension, evidence of renal artery
stenosis and/or evidence of labile blood pressure
including symptomatic postural hypotension.
Doses of antihypertensive medications must be
stable for 30 days before randomization*
Ja
Nein
Have a QTcB (Bazett's-corrected QT interval)
interval > 450 msec for men or > 470 for women
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Eligibility NCT01408095 Diabetes Mellitus, Type 2
at Screening or any personal history of
ventricular tachycardia or unexplained syncope*
Ja
Nein
Have obvious clinical signs or symptoms of liver
disease, acute or chronic hepatitis, or significantly
elevated liver blood tests*
Ja
Nein
Are currently receiving renal dialysis, have a
serum creatinine > 2.0 mg/dL (177 micromol/L) or
a calculated creatinine clearance of < 60 ml/min
or in patients being treated with metformin, have
other known contradictions to metformin use
including, but not limited to, a serum creatinine
above (or creatinine clearance below) what is
approved in the metformin product label*
Ja
Nein
Have fasting state hypertriglyceridemia (defined
as > 5.65 mmol/L, 500 mg/dl) at Screening. If
taking lipid-lowering agents, doses of these
medications must be stable for 30 days prior to
randomization.*
Ja
Nein
Are receiving chronic (for > 2 weeks) systemic
glucocorticoid therapy (excluding topical or
inhaled preparations) or have received such
therapy within 4 weeks immediately prior to
Randomization*
Ja
Nein
Have an active or untreated malignancy or have
been in remission from a clinically significant
malignancy (other than basal or squamous cell
skin cancer, in situ carcinomas of the cervix, or in
situ prostate cancer) for < 5 years*
Ja
Nein
Have a history of seizure disorder*
Ja
Nein
Are currently using or intend to use inhibitors of
Cytochrome P450 family 3A (CYP3A4)*
Ja
Nein
Currently taking a medication that is a sensitive
substrate of the CYP3A4 pathway with a narrow
therapeutic index*
Ja
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Eligibility NCT01408095 Diabetes Mellitus, Type 2
Nein
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Eligibility NCT01408095 Diabetes Mellitus, Type 2
Eligibility NCT01410916 Shiga-like Toxin-
producing Escherichia Coli
ODM derived from
http://clinicaltrials.gov/show/NCT01410916
All rights reserved. Please visit https://medical-data-
models.org/forms/5148
Eligibility
Einschlusskriterien
Alter mindestens 2 Monate*
Ja
Nein
Patient must be willing and able to give written
informed consent/Assent. *
Ja
Nein
Adults, adolescents, or pediatric (>=2 months and
>=5kg) patients*
Ja
Nein
Patient has been diagnosed with Escherichia Coli
Hemolytic-Uremic Syndrome (STEC-HUS) *
Ja
Nein
Ausschlusskriterien
Known complement regulatory mutation or family
history of complement regulatory mutation*
Ja
Nein
Unresolved systemic meningococcal disease*
Ja
Nein
Hypersensitivity to eculizumab, to murine proteins
or to one of the excipients*
Ja
Nein
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Eligibility NCT01413139 Peripheral
Vascular Disease
ODM derived from
http://clinicaltrials.gov/show/NCT01413139
All rights reserved. Please visit https://medical-data-
models.org/forms/5149
Eligibility
Einschlusskriterien
Alter mindestens 18 Jahre*
Ja
Nein
De novo, restenotic or reoccluded lesion located
in the femoropopliteal arteries suitable for
endovascular treatment*
Ja
Nein
Patient presenting with a score from 2 to 4
according to the Rutherford classification*
Ja
Nein
Patient is willing to comply with specified follow-
up evaluations at the predefined time intervals
times*
Ja
Nein
Patient understands the nature of the procedure
and provides written informed consent, prior to
enrollment in the study*
Ja
Nein
Prior to enrollment, the target lesion was crossed
with standard guidewire manipulation*
Ja
Nein
Patient is eligible for treatment with 4F compatible
devices*
Ja
Nein
The target lesions are located within the native
superficial femoral artery: Distal point 3 cm above
knee joint and 1 cm below the origin of the
profunda femoralis.*
Ja
Nein
The target lesion has angiographic evidence of
stenosis or restenosis > 50% or occlusion*
Ja
Nein
Length of the target lesion is =20 cm by visual
estimation and can be covered with one stent*
Ja
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Nein
Target vessel diameter visually estimated is =4
mm and =6.5 mm*
Ja
Nein
There is angiographic evidence of at least one-
vessel-runoff to the foot *
Ja
Nein
Ausschlusskriterien
Presence of another stent in the target vessel
that was placed during a previous procedure*
Ja
Nein
Presence of an aortic thrombosis or significant
common femoral ipsilateral stenosis*
Ja
Nein
Previous bypass surgery in the same limb*
Ja
Nein
Patients contraindicated for antiplatelet therapy,
anticoagulants or thrombolytics*
Ja
Nein
Patients who exhibit persistent acute intraluminal
thrombus at the target lesion site*
Ja
Nein
Perforation at the angioplasty site evidenced by
extravasation of contrast medium*
Ja
Nein
Patients with known hypersensitivity to nickel-
titanium*
Ja
Nein
Patients with uncorrected bleeding disorders*
Ja
Nein
Female patient with child bearing potential not
taking adequate contraceptives or currently
breastfeeding*
Ja
Nein
Life expectancy of < 12 months*
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Eligibility NCT01413139 Peripheral Vascular Disease
Ja
Nein
Ipsilateral iliac artery treatment before target
lesion treatment with a residual stenosis > 30%*
Ja
Nein
Use of thrombectomy, atherectomy or laser
devices during procedure*
Ja
Nein
Any planned surgical intervention/procedure 30
days after the study procedure*
Ja
Nein
Any patient considered to be hemodynamically
unstable at onset of procedure*
Ja
Nein
Patient is currently participating in another
investigational drug or device study that has not
reached the primary endpoint*
Ja
Nein
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Eligibility NCT01423747 Lymphoblastic
Leukemia, Acute, Childhood
ODM derived from
http://clinicaltrials.gov/show/NCT01423747
All rights reserved. Please visit https://medical-data-
models.org/forms/5150
Eligibility
Einschlusskriterien
Alter 3 Monate bis 18 Jahre*
Ja
Nein
Lymphoblastic Leukemia, Acute, Childhood*
Ja
Nein
age at time of initial diagnosis or relapse
diagnosis, respectively under or equal 18 years*
Ja
Nein
indication for allogeneic HSCT*
Ja
Nein
complete remission before HSCT*
Ja
Nein
written consent of the parents (legal guardian)
and, if necessary, the minor patient via Informed
Consent Form*
Ja
Nein
nicht schwanger*
Ja
Nein
no secondary malignancy*
Ja
Nein
no previous HSCT*
Ja
Nein
HSCT is performed in a study participating
centre. *
Ja
Nein
Ausschlusskriterien
age at time of initial diagnosis or relapse
diagnosis, respectively above 18 years*
Ja
Nein
no indication for allogeneic HSCT*
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Ja
Nein
no complete remission before SCT*
Ja
Nein
no written consent of the parents (legal guardian)
and, if necessary, the minor patient via Informed
Consent Form*
Ja
Nein
Schwangerschaft*
Ja
Nein
Secondary malignant neoplastic disease*
Ja
Nein
previous HSCT*
Ja
Nein
HSCT is not performed in a study participating
centre.*
Ja
Nein
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Eligibility NCT01423747 Lymphoblastic Leukemia, Acute, Childhood
Eligibility NCT01147939 Acute Myeloid
Leukemia (AML)
ODM derived from
http://clinicaltrials.gov/show/NCT01147939
All rights reserved. Please visit https://medical-data-
models.org/forms/5151
Eligibility
Einschlusskriterien
Alter mindestens 18 Jahre*
Ja
Nein
confirmed diagnosis of AML according to WHO
classification (excluding acute promyelocytic
leukaemia) who have received two or three
previous induction/re-induction regimens or
patients of age >= 65 with adverse cytogenetics
who have received 1-3 previous induction/re-
induction regimens. One of the (re-)induction
regimens could be stem cell transplantation
(SCT) for achievement of remission. Maintenance
and consolidation (including SCT) may have been
given, but are not counted as previous regimens.*
Ja
Nein
bone marrow aspirates and/or biopsies must
contain > 5 % leukaemic blast cells or patient
must have biopsy-proven extramedullary AML, or
patient's peripheral blood shows occurrence of
leukaemic blast cells*
Ja
Nein
Bedürfnis, Notwendigkeit*
Ja
Nein
have never attained CR or CRi (primary
refractory), or*
Ja
Nein
have failed initial induction therapy, and have
attained CR or CRi after salvage  therapy(ies),
and then relapsed within < 6 months, or*
Ja
Nein
have attained CR or CRi after initial induction
therapy and relapsed within <12  months, and
failed to respond to salvage therapy(ies), or*
Ja
Nein
have relapsed after the latest CR or CRi within <
6 months*
Ja
Nein
Patients younger than 65 years should have
1 / 4
received previous treatment with cytarabine*
Ja
Nein
Patients must have recovered from previous bone
marrow and/or stem cell transplantation to a
stage that the patient can tolerate the study
treatment. There is no restriction on number of
regimens or type of treatment administered for
maintenance or consolidation during previous
stages of the disease*
Ja
Nein
ECOG performance status (PS) of 0 - 2*
Ja
Nein
Women of child-bearing potential must have a
negative serum or urine pregnancy test within 2
weeks prior to treatment start*
Ja
Nein
Male and female patients must use acceptable
contraceptive methods for the duration of time on
study, and males also for 3 months after the last
elacytarabine dose*
Ja
Nein
capable of understanding and complying with
protocol requirements, and must be able and
willing to sign a written informed consent form *
Ja
Nein
Ausschlusskriterien
A history of allergic reactions to egg. A history of
allergic reactions of CTCAE grade 3 or 4 to
cytarabine*
Ja
Nein
Persistent clinically significant toxicities from
previous chemotherapy*
Ja
Nein
A cancer history that, according to the
investigator, might confound the assessment of
the study endpoints*
Ja
Nein
HIV-positiv*
Ja
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Nein
Pregnant and nursing patients*
Ja
Nein
Uncontrolled intercurrent illness including, but not
limited to, uncontrolled infection, or psychiatric
illness/social situations that would limit
compliance with study requirements*
Ja
Nein
Impairment of hepatic or renal function to such an
extent that the patient, in the opinion of the
investigator, will be exposed to an excessive risk
if entered into this clinical study*
Ja
Nein
Active heart disease including myocardial
infarction within previous 3 months, symptomatic
coronary artery disease, arrhythmias not
controlled by medication, or uncontrolled
congestive heart failure. Any New York Heart
Association (NYHA) functional classification
grade 3 or 4*
Ja
Nein
Applicable only for patients for whom an
anthracycline is part of the selected control
treatment: Left ventricular ejection fraction (LVEF)
must be >= 45 % as measured by MUGA scan or
2D ECHO within 14 days prior to start of therapy.
Either method is acceptable for measuring LVEF*
Ja
Nein
Applicable only for patients for whom an
anthracycline is part of the selected control
treatment: The patient should tolerate minimum
one course of combination therapy*
Ja
Nein
any anti-leukaemic agents within the last 3
weeks. Hydroxyurea,however, is allowed for up to
12 hours prior to study treatment*
Ja
Nein
any investigational treatment within the last 14
days*
Ja
Nein
Any medical condition which in the opinion of the
investigator places the patient at an unacceptably
high risk for toxicities*
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Eligibility NCT01147939 Acute Myeloid Leukemia (AML)
Ja
Nein
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Eligibility NCT01147939 Acute Myeloid Leukemia (AML)
Eligibility NCT01179620 Renal Dialysis
ODM derived from
http://clinicaltrials.gov/show/NCT01179620
All rights reserved. Please visit https://medical-data-
models.org/forms/5152
Eligibility
Einschlusskriterien
Alter mindestens 18 Jahre*
Ja
Nein
Patients requiring hemodialysis*
Ja
Nein
Patients requiring anticoagulation therapy during
hemodialysis*
Ja
Nein
Written informed consent *
Ja
Nein
Ausschlusskriterien
Hypersensitivity to study medication*
Ja
Nein
Genetic abnormality or disease of clotting
system*
Ja
Nein
Prior major surgery or bleeding*
Ja
Nein
Other protocol-defined inclusion/exclusion criteria
may apply*
Ja
Nein
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Eligibility NCT01324947 Multiple Myeloma
ODM derived from
http://clinicaltrials.gov/show/NCT01324947
All rights reserved. Please visit https://medical-data-
models.org/forms/5153
Eligibility
Einschlusskriterien
Alter mindestens 18 Jahre*
Ja
Nein
Subjects with refractory or relapsed and
refractory multiple myeloma who were enrolled in
Study CC-4047-MM-003 and discontinued study
therapy with dexamethasone alone after disease
progression.*
Ja
Nein
Subjects must have documented diagnosis of
multiple myeloma and have measurable disease*
Ja
Nein
Eastern Cooperative Oncology Group (ECOG)
performance status score of 0, 1, or 2.*
Ja
Nein
Females of childbearing potential (FCBP) must
not become pregnant for 28 days prior to initiation
of study drug, during the study, and for 28 days
after discontinuation*
Ja
Nein
Females must agree to abstain from
breastfeeding during study participation and 28
days after study discontinuation.*
Ja
Nein
Males must agree to use a latex condom during
any sexual contact during the study and for 28
days following discontinuation from this study*
Ja
Nein
Males must also agree to refrain from donating
semen or sperm while on pomalidomide and for
28 days after discontinuation from this study.*
Ja
Nein
Ausschlusskriterien
Subjects with multiple myeloma who were not
treated as a part of Study CC-4047-MM-003
(high dose dexamethasone).*
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Ja
Nein
Subjects who received any treatments (steroids,
anti-myeloma, or anti-cancer therapy) within the
last 14 days before initiation of study treatment.*
Ja
Nein
Subjects who discontinued CC-4047-MM-003
study ≥120 days.*
Ja
Nein
Subjects who initiate another anti-myeloma
therapy from the time of disease progression on
study CC-4047-MM-003 to the time of treatment
initiation in the companion study.*
Ja
Nein
abnormale Laborbefunde*
Ja
Nein
Absolute Neutrophil Count*
Ja
Nein
Platelet count < 75,000/μL for subjects in whom <
50% of bone marrow nucleated cells are plasma
cells, or a platelet count < 30,000/uL for subjects
in whom >= 50% of bone marrow nucleated cells
are plasma cells*
Ja
Nein
Kreatinin-Clearance*
Ja
Nein
Corrected serum calcium > 14 mg/dL
Hemoglobin ≤ 8 g/dL*
Ja
Nein
SGOT/AST or SGPT/ALT > 3.0 x upper limit of
normal (ULN)*
Ja
Nein
Prior history of malignancies, other than MM,
unless the subject has been free of the disease
for ≥ 3 years.*
Ja
Nein
Hypersensitivity to thalidomide or lenalidomide*
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Ja
Nein
Peripheral neuropathy ≥ Grade 2.*
Ja
Nein
Subjects who received an allogeneic bone
marrow or allogeneic peripheral blood stem cell
transplant.*
Ja
Nein
Subjects who are planning for or who are eligible
for stem cell transplant.*
Ja
Nein
Subjects with any one of the following: 1)
Congestive heart failure, 2) Myocardial infarction
within 12 months prior to starting study treatment,
3) Unstable or poorly controlled angina pectoris,
including Prinzmetal variant angina pectoris*
Ja
Nein
Subjects who received any of the following within
the last 14 days of initiation of study treatment:1)
Plasmapheresis, 2) Major surgery, 3) Radiation
therapy*
Ja
Nein
Use of any investigational agents within 28 days
or 5 half-lives (whichever is longer) of treatment.*
Ja
Nein
Subjects with chronic conditions such as
rheumatoid arthritis, multiple sclerosis and
lupus.*
Ja
Nein
Any condition including the presence of
laboratory abnormalities, which places the
subject at unacceptable risk if he/she were to
participate in the study.*
Ja
Nein
Incidence of gastrointestinal disease that may
significantly alter the absorption of
pomalidomide.*
Ja
Nein
Subjects unable or unwilling to undergo
antithrombotic prophylactic treatment.*
Ja
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Nein
Any serious medical condition, laboratory
abnormality, or psychiatric illness that would
prevent the subject from signing the informed
consent form.*
Ja
Nein
Pregnant or breastfeeding females.*
Ja
Nein
Known Human Immunodeficiency Virus (HIV)
positivity or active infectious hepatitis A, B or C.*
Ja
Nein
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Eligibility NCT01324947 Multiple Myeloma
Eligibility NCT00321620 Bone Metastases
ODM derived from
http://clinicaltrials.gov/show/NCT00321620
All rights reserved. Please visit https://medical-data-
models.org/forms/5155
Eligibility
Einschlusskriterien
Alter 18 Jahre und älter*
Ja
Nein
Men >/= 18 years of age with histologically
confirmed prostate cancer*
Ja
Nein
Radiographic evidence of at least one bone
metastasis*
Ja
Nein
Failure of at least one hormonal therapy as
evidenced by a rising PSA*
Ja
Nein
Serum testosterone level of <50 ng/dL*
Ja
Nein
ECOG Status*
Ja
Nein
Adequate organ function*
Ja
Nein
Ausschlusskriterien
Current or prior IV bisphosphonate
administration*
Ja
Nein
Current or prior oral bisphosphonates for bone
mets*
Ja
Nein
life expectancy <6 months*
Ja
Nein
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HIS Review of Systems
Form from HIS OpenVistA
All rights reserved. Please visit https://medical-data-
models.org/forms/5215
HIS
GENERAL
Positive for*
Negative for*
NARRATIVE*
Denies change in appetite or weight. Denies
fever, chills, dizziness*
Ja
Nein
Appetite change*
Ja
Nein
Gewichtszunahme*
Ja
Nein
Gewichtsabnahme*
Ja
Nein
Fieber*
Ja
Nein
Schüttelfrost*
Ja
Nein
Schwindel*
Ja
Nein
Additional comments*
EYE
Auge*
Denies change in vision*
Ja
Nein
Denies diplopia, itchy/dry eyes, photophobia or
eye pain*
Ja
Nein
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unscharfes Sehen*
Ja
Nein
Doppeltsehen*
Jucken des Auges*
Xerophthalmie*
Sehstörung*
Sehverlust*
Brille*
Farbenblindheit*
Lichtempfindlichkeit*
Schmerz*
EAR
Ohr*
Denies earache,deafness,tinnitus,vertigo,or
discharge*
Ja
Nein
Ohrenschmerzen*
Taubheit*
Tinnitus*
Vertigo*
Ausfluss*
NOSE
Nase*
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Denies rhinorrhea, epistaxis, sneezing, or sinus
pain/tenderness*
Ja
Nein
Rhinorrhoe*
Epistaxis*
Niesen*
schmerzhafte Nasennebenhöhlen*
MOUTH
Mund*
Denies toothache, mouth sores, dysphagia,
odynophagia*
Ja
Nein
Zahnschmerzen*
Dysphagie*
Schluckschmerz*
Aphthe*
RESPIRATORY
Pulmonal*
Denies chest pain, shortness of breath, or cough*
Ja
Nein
Dyspnoe, Atemnot*
Belastungsdyspnoe*
Orthopnoe*
Husten*
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Sputum*
Hämoptyse*
Schmerz*
CARDIOVASCULAR
Kardiovaskuläres System*
Denies chest pain or palpitations*
Ja
Nein
Brustschmerzen*
Ort*
Ausstrahlung*
TYPE*
Schweregrad der Erkrankung*
Pain exacerbating factors*
Symptom relieving factors*
Timing*
Palpitationen*
Orthopnoe*
Paroxysmale nächtliche Dyspnoe*
Beinödeme*
GASTROINTESTINAL
Gastrointestinales System*
Denies heartburn, abdominal pain, nausea,
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vomiting, blood in stool,diarrhea, or constipation.*
Ja
Nein
Sodbrennen*
Bauchschmerzen*
Übelkeit*
Erbrechen*
Inkontinenz*
Hämatemesis*
Diarrhö*
Verstopfung*
bright red blood in stool*
Blut im Stuhl*
Teerstuhl*
GENITOURINARY
Urogenitales System*
Denies dysuria, hematuria*
Ja
Nein
Dysurie*
Hämaturie*
Impotenz*
vaginale Blutung*
Vaginaler Ausfluss*
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Dyspareunie*
MUSCULOSKELETAL
Muskuloskeletales System*
Denies muscle or joint pain or swelling.*
Ja
Nein
Myalgie*
Rückenschmerzen*
Steifheit*
Arthralgie*
Gelenksschwellung*
NEUROLOGIC
Nervensystem*
Denies headache, dizziness, weakness or
paresthesias*
Ja
Nein
Schwindel*
Kopfschmerz*
Schwäche*
Parästhesie*
PAIN
Schmerz*
Stärke des Schmerzes*
Ort*
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Ausstrahlung*
EXACERBATING FACTORS*
RELIEVING FACTORS*
GERIATRIC
geriatrisch*
Stürze*
Ja
Nein
Inkontinenz*
Ja
Nein
Gedächtnisverlust*
Ja
Nein
Wandering, Wandering around*
Ja
Nein
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Entlassungsbrief ELGA
Test CDA2ODM
Discharge summarization note (physician) LOINC 11490-0
Amadeus Spital
All rights reserved. Please visit https://medical-data-
models.org/forms/5217
Entlassungsbrief
ClinicalDocument
realmCode.code*
typeId.root*
typeId.extension*
templateId.root*
templateId.assigningAuthorityName*
templateId.root*
templateId.assigningAuthorityName*
templateId.root*
templateId.assigningAuthorityName*
id.root*
id.extension*
id.assigningAuthorityName*
code.code*
code.displayName*
code.codeSystem*
code.codeSystemName*
title*
effectiveTime.value*
confidentialityCode.code*
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confidentialityCode.displayName*
confidentialityCode.codeSystem*
confidentialityCode.codeSystemName*
languageCode.code*
setId.root*
setId.extension*
setId.assigningAuthorityName*
versionNumber.value*
id.root*
id.extension*
id.assigningAuthorityName*
id.root*
id.extension*
id.assigningAuthorityName*
addr.use*
streetAddressLine*
postalCode*
city*
state*
country*
telecom.use*
telecom.value*
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Entlassungsbrief ELGA
telecom.use*
telecom.value*
telecom.value*
prefix.qualifier*
prefix*
prefix.qualifier*
prefix*
given*
given*
family*
family.qualifier*
family*
suffix.qualifier*
suffix*
suffix.qualifier*
suffix*
administrativeGenderCode.code*
administrativeGenderCode.displayName*
administrativeGenderCode.codeSystem*
administrativeGenderCode.codeSystemName*
birthTime.value*
maritalStatusCode.code*
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Entlassungsbrief ELGA
maritalStatusCode.displayName*
maritalStatusCode.codeSystem*
maritalStatusCode.codeSystemName*
religiousAffiliationCode.code*
religiousAffiliationCode.displayName*
religiousAffiliationCode.codeSystem*
religiousAffiliationCode.codeSystemName*
streetAddressLine*
postalCode*
city*
state*
country*
telecom.use*
telecom.value*
telecom.use*
telecom.value*
telecom.use*
telecom.value*
given*
family*
addr*
functionCode.code*
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Entlassungsbrief ELGA
functionCode.displayName*
functionCode.codeSystem*
functionCode.codeSystemName*
time.value*
id.root*
id.extension*
id.assigningAuthorityName*
code.code*
code.displayName*
code.codeSystem*
code.codeSystemName*
telecom.use*
telecom.value*
prefix*
given*
family*
id.root*
id.assigningAuthorityName*
telecom.value*
telecom.value*
telecom.value*
telecom.value*
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Entlassungsbrief ELGA
streetName*
houseNumber*
postalCode*
city*
state*
country*
time.value*
id.nullFlavor*
given*
family*
id.root*
id.assigningAuthorityName*
telecom.value*
streetName*
houseNumber*
postalCode*
city*
state*
country*
informationRecipient.typeCode*
id.nullFlavor*
prefix.qualifier*
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Entlassungsbrief ELGA
prefix*
given*
family*
id.nullFlavor*
telecom.value*
telecom.value*
telecom.value*
telecom.value*
telecom.value*
streetName*
houseNumber*
postalCode*
city*
country*
informationRecipient.typeCode*
id.nullFlavor*
prefix.qualifier*
prefix*
given*
family*
id.nullFlavor*
telecom.value*
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Entlassungsbrief ELGA
telecom.value*
telecom.value*
telecom.value*
telecom.value*
streetName*
houseNumber*
postalCode*
city*
country*
time.value*
signatureCode.code*
id.root*
id.extension*
id.assigningAuthorityName*
telecom.use*
telecom.value*
prefix*
given*
family*
id.root*
id.assigningAuthorityName*
telecom.value*
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Entlassungsbrief ELGA
telecom.value*
telecom.value*
telecom.value*
streetName*
houseNumber*
postalCode*
city*
state*
country*
time.value*
signatureCode.code*
id.root*
id.extension*
id.assigningAuthorityName*
telecom.use*
telecom.value*
prefix*
given*
family*
id.root*
id.assigningAuthorityName*
telecom.value*
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Entlassungsbrief ELGA
telecom.value*
telecom.value*
telecom.value*
streetName*
houseNumber*
postalCode*
city*
state*
country*
participant.typeCode*
templateId.root*
associatedEntity.classCode*
telecom.use*
telecom.value*
prefix*
given*
family*
id.root*
id.assigningAuthorityName*
telecom.value*
telecom.value*
telecom.value*
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Entlassungsbrief ELGA
telecom.value*
streetName*
houseNumber*
postalCode*
city*
state*
country*
participant.typeCode*
templateId.root*
associatedEntity.classCode*
id.nullFlavor*
prefix.qualifier*
prefix*
given*
family*
id.nullFlavor*
telecom.value*
telecom.value*
telecom.value*
telecom.value*
telecom.value*
streetName*
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Entlassungsbrief ELGA
houseNumber*
postalCode*
city*
country*
participant.typeCode*
templateId.root*
functionCode.code*
functionCode.displayName*
functionCode.codeSystem*
functionCode.codeSystemName*
associatedEntity.classCode*
id.nullFlavor*
prefix.qualifier*
prefix*
given*
family*
id.nullFlavor*
telecom.value*
telecom.value*
telecom.value*
telecom.value*
telecom.value*
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Entlassungsbrief ELGA
streetName*
houseNumber*
postalCode*
city*
country*
participant.typeCode*
templateId.root*
associatedEntity.classCode*
code.code*
code.displayName*
code.codeSystem*
code.codeSystemName*
addr*
telecom.use*
telecom.value*
participant.typeCode*
templateId.root*
associatedEntity.classCode*
code.code*
code.displayName*
code.codeSystem*
code.codeSystemName*
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Entlassungsbrief ELGA
addr*
telecom.use*
telecom.value*
participant.typeCode*
templateId.root*
low.value*
high.value*
associatedEntity.classCode*
id.root*
id.extension*
id.assigningAuthorityName*
code.code*
code.displayName*
code.codeSystem*
code.codeSystemName*
telecom.value*
telecom.value*
telecom.value*
streetName*
houseNumber*
postalCode*
city*
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Entlassungsbrief ELGA
state*
country*
participant.typeCode*
templateId.root*
associatedEntity.classCode*
id.nullFlavor*
telecom.value*
telecom.value*
telecom.value*
telecom.value*
streetName*
houseNumber*
postalCode*
city*
state*
country*
code.code*
code.displayName*
code.codeSystem*
code.codeSystemName*
low.value*
high.value*
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Entlassungsbrief ELGA
id.root*
id.extension*
id.assigningAuthorityName*
code.code*
code.displayName*
code.codeSystem*
code.codeSystemName*
low.value*
high.value*
id.root*
id.extension*
id.assigningAuthorityName*
telecom.use*
telecom.value*
prefix*
given*
family*
id.root*
id.assigningAuthorityName*
telecom.value*
telecom.value*
telecom.value*
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Entlassungsbrief ELGA
telecom.value*
streetName*
houseNumber*
postalCode*
city*
state*
country*
text.mediaType*
text.representation*
text*
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Entlassungsbrief ELGA
CDASH LAB (Scenario 2)
modified from http://www.cdisc.org
All rights reserved. Please visit https://medical-data-
models.org/forms/5218
CDASH LAB (Scenario 2)
LAB Information
Lab Status*
NO (N)
YES (Y)
Collection Date and Time*
Fasting ?*
NO (N)
YES (Y)
Accession Number*
Laboratory Name*
CBC LAB Results - Ery. Mean
Corpuscular HB Concentration
Result*
Units*
mmol/L (mmol/L)
Low Normal*
High Normal*
Abnormal*
HIGH (HIGH)
LOW (LOW)
NORMAL (NORMAL)
Clinically Significant*
NO (N)
YES (Y)
CBC LAB Results - Ery. Mean
Corpuscular Hemoglobin
Result*
Units*
fmol (fmol)
Low Normal*
1 / 7
High Normal*
Abnormal*
HIGH (HIGH)
LOW (LOW)
NORMAL (NORMAL)
Clinically Significant*
NO (N)
YES (Y)
CBC LAB Results - Mean Platelet Volume
Result*
Units*
fL (fL)
Low Normal*
High Normal*
Abnormal*
HIGH (HIGH)
LOW (LOW)
NORMAL (NORMAL)
Clinically Significant*
NO (N)
YES (Y)
CBC LAB Results - Ery. Mean
Corpuscular Volume
Result*
Units*
fL (fL)
Low Normal*
High Normal*
Abnormal*
HIGH (HIGH)
LOW (LOW)
NORMAL (NORMAL)
Clinically Significant*
NO (N)
YES (Y)
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CBC LAB Results - Platelet Count
Result*
Units*
x10E9/L (x10E9/L)
Low Normal*
High Normal*
Abnormal*
HIGH (HIGH)
LOW (LOW)
NORMAL (NORMAL)
Clinically Significant*
NO (N)
YES (Y)
CBC LAB Results – Hematocrit
Result*
Units*
% (%)
Low Normal*
High Normal*
Abnormal*
HIGH (HIGH)
LOW (LOW)
NORMAL (NORMAL)
Clinically Significant*
NO (N)
YES (Y)
CBC LAB Results – Hemoglobin
Result*
Units*
mmol/L (mmol/L)
Low Normal*
High Normal*
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Abnormal*
HIGH (HIGH)
LOW (LOW)
NORMAL (NORMAL)
Clinically Significant*
NO (N)
YES (Y)
CBC LAB Results – Erythrocytes
Result*
Units*
x10E12/L (x10E12/L)
Low Normal*
High Normal*
Abnormal*
HIGH (HIGH)
LOW (LOW)
NORMAL (NORMAL)
Clinically Significant*
NO (N)
YES (Y)
CBC LAB Results – Basophils
Result*
Units*
x10E9/L (x10E9/L)
Low Normal*
High Normal*
Abnormal*
HIGH (HIGH)
LOW (LOW)
NORMAL (NORMAL)
Clinically Significant*
NO (N)
YES (Y)
CBC LAB Results – Eosinophils
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Result*
Units*
x10E9/L (x10E9/L)
Low Normal*
High Normal*
Abnormal*
HIGH (HIGH)
LOW (LOW)
NORMAL (NORMAL)
Clinically Significant*
NO (N)
YES (Y)
CBC LAB Results – Monocytes
Result*
Units*
x10E9/L (x10E9/L)
Low Normal*
High Normal*
Abnormal*
HIGH (HIGH)
LOW (LOW)
NORMAL (NORMAL)
Clinically Significant*
NO (N)
YES (Y)
CBC LAB Results – Lymphocytes
Result*
Units*
x10E9/L (x10E9/L)
Low Normal*
High Normal*
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Abnormal*
HIGH (HIGH)
LOW (LOW)
NORMAL (NORMAL)
Clinically Significant*
NO (N)
YES (Y)
CBC LAB Results – Neutrophils
Result*
Units*
nmol/L (nmol/L)
Low Normal*
High Normal*
Abnormal*
HIGH (HIGH)
LOW (LOW)
NORMAL (NORMAL)
Clinically Significant*
NO (N)
YES (Y)
CBC LAB Results – Leukocytes
Result*
Units*
x10E9/L (x10E9/L)
Low Normal*
High Normal*
Abnormal*
HIGH (HIGH)
LOW (LOW)
NORMAL (NORMAL)
Clinically Significant*
NO (N)
YES (Y)
CBC LAB Results - Erythrocytes
Distribution Width
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Result*
Units*
% (%)
Low Normal*
High Normal*
Abnormal*
HIGH (HIGH)
LOW (LOW)
NORMAL (NORMAL)
Clinically Significant*
NO (N)
YES (Y)
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Ewing Study Demographie
EWING 2008, EudraCT 2008-003658-13,
http://clinicaltrials.gov/ct2/show/NCT00824083
Prof. Dr. Heribert Jürgens, Prof. Dr. Uta Dirksen
All rights reserved. Please visit https://medical-data-
models.org/forms/5250
Demographie
Personal data
Vorname*
Nachname*
Geburtsname
Geburtsdatum*
Geschlecht*
Männlich (1)
Weiblich (2)
Identification numbers
GPOH-PID
MaligID DKKR
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Ewing Study Death of patient
EWING 2008, EudraCT 2008-003658-13,
http://clinicaltrials.gov/ct2/show/NCT00824083
All rights reserved. Please visit https://medical-data-
models.org/forms/5251
Death of patient
Show identification of patient
Patient
Patient deceased
Todesdatum*
Todesursache*
Malignombedingt (DOD) (1)
Therapiebedingt (DOC) (2)
Sekundärmalignom (3)
Sonstige Ursache (4)
Unbekannt (5)
Bitte nÃ¤here Angaben zum Tod*
1 / 1
Ewing Study Lokaler histopathologischer
Befund
EWING 2008, EudraCT 2008-003658-13,
http://clinicaltrials.gov/ct2/show/NCT00824083
All rights reserved. Please visit https://medical-data-
models.org/forms/5252
Lokaler histopathologischer Befund
Show identification of patient
Patient
Histopathologie durchgeführt?
DurchgefÃ¼hrt?*
Nein (0)
Ja (1)
Histopathogische Diagnose
Datum der Biopsie*
Pathologe*
Journal Nr.*
Probe-Entnahme*
Resektionsbiopsie/OP-Präparat (1)
Stanze (2)
Feinnadelaspirat (3)
Gefriermaterial verfÃ¼gbar?*
Nein (0)
Ja (1)
Histopathologische Diagnose*
Undifferenziertes Ewing-Sarkom (1)
Neurodifferenziertes Ewing-Sarkom (z.B.
PNET) (2)
Großzelliges Ewing-Sarkom (3)
Andere Variante des Ewings-Sarkoms
(4)
Andere Erkrankung (5)
Bitte spezifizieren*
Tumor-Marker
PAS*
Negativ (0)
Positiv (1)
Vimentin*
Negativ (0)
Positiv (1)
1 / 2
MIC2 (CD99)*
Negativ (0)
Positiv (1)
S100*
Negativ (0)
Positiv (1)
NSE*
Negativ (0)
Positiv (1)
Desmin*
Negativ (0)
Positiv (1)
CD45*
Negativ (0)
Positiv (1)
2 / 2
Ewing Study Lokaler histopathologischer Befund
Ewing Study Untersuchungen bei Diagnose
EWING 2008, EudraCT 2008-003658-13,
http://clinicaltrials.gov/ct2/show/NCT00824083
All rights reserved. Please visit https://medical-data-
models.org/forms/5254
Untersuchungen bei Diagnose
Show identification of patient
Patient
Untersuchungen Primärtumor
CT*
Nein (0)
Ja (1)
MRI*
Nein (0)
Ja (1)
RÃ¶ntgen*
Nein (0)
Ja (1)
Staging-Untersuchungen
Thorax RÃ¶ntgen*
Nein (0)
Ja (1)
Thorax CT*
Nein (0)
Ja (1)
Tc-Knochenzintigraphie*
Nein (0)
Ja (1)
PET-Scan*
Nein (0)
Ja (1)
SUV (Maximum) PrimÃ¤rtumor*
SUV (Mittelwert) Leber*
PET-CT*
Nein (0)
Ja (1)
SUV (Maximum) PrimÃ¤rtumor*
SUV (Mittelwert) Leber*
Knochemark-Aspirat
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Knochenmark-Aspirat*
Nein (0)
Ja (1)
Anzahl untersuchter Stellen*
Anzahl positiver Stellen*
Knochenmarkstanze
Knochenmarkstanze*
Nein (0)
Ja (1)
Anzahl untersuchter Stellen*
Anzahl positiver Stellen*
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Ewing Study Untersuchungen bei Diagnose
Ewing Study Regionale Tumorausdehnung
EWING 2008, EudraCT 2008-003658-13,
http://clinicaltrials.gov/ct2/show/NCT00824083
All rights reserved. Please visit https://medical-data-
models.org/forms/5256
Regionale Tumorausdehnung
Show identification of patient
Patient
Regionale Tumorausdehnung
Pleuraerguss (PrimÃ¤rtumor Thoraxwand)*
Nein (0)
Ja (1)
Zytologie*
Negativ (0)
Positiv (1)
Peritonealerguss*
Nein (0)
Ja (1)
Zytologie*
Negativ (0)
Positiv (1)
Intraspinaler Befall*
Nein (0)
Ja (1)
Skip-LÃ¤sion(en) im tumortragenden
Kompartiment*
Nein (0)
Ja (1)
Befall benachbarter Lymphknoten*
Nein (0)
Ja (1)
Sonstiges*
Nein (0)
Ja (1)
wenn ja, bitte Angaben*
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Ewing Study Metastasen bei Diagnose
EWING 2008, EudraCT 2008-003658-13,
http://clinicaltrials.gov/ct2/show/NCT00824083
All rights reserved. Please visit https://medical-data-
models.org/forms/5257
Metastasen bei Diagnose
Show identification of patient
Patient
Metastasen bei Diagnose
Metastase(n) vorhanden?*
Nein (0)
Ja (1)
Lungenmetastasen
Lungenmetastase(n) vorhanden?*
Nein (0)
Ja (1)
rechts*
Keine (0)
1 Herd (1)
2-5 Herde (2)
>5 Herde (3)
links*
Keine (0)
1 Herd (1)
2-5 Herde (2)
>5 Herde (3)
GrÃ¶ÃŸter Herd*
< 0.5 cm (1)
0.5 - 1.0 cm (2)
>1.0 - 5.0 cm (3)
> 5.0 cm (4)
Biopsie?*
Nein (0)
Ja (1)
Pleuraerguss (PrimÃ¤rtumor nicht Thoraxwand)*
Nein (0)
Ja (1)
Zytologie*
Negativ (0)
Positiv (1)
Knochenmetastasen
Knochenmetastase(n) vorhanden?*
Nein (0)
Ja (1)
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Anzahl LÃ¤sionen*
1 Metastase (1)
2-5 Metastasen (2)
> 5 Metastasen (3)
Knochenmarksmetastasen
Knochenmarkmetastase(n) vorhanden?*
Nein (0)
Ja (1)
ZNS-Metastasen
ZNS-Metastase(n) vorhanden?*
Nein (0)
Ja (1)
Leber-Metastase(n)
Leber-Metastase(n) vorhanden?*
Nein (0)
Ja (1)
Lymphknotenmetastasen
Lymphknotenmetastase(n) vorhanden? (nur
Fernmetastasen)*
Nein (0)
Ja (1)
Sonstige Metastasen
Sonstige Metastase(n) vorhanden?*
Nein (0)
Ja (1)
Sonstige Metastasenlokalisation
Lokalisation*
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Ewing Study Metastasen bei Diagnose
Ewing Study OP Primaertumor
EWING 2008, EudraCT 2008-003658-13,
http://clinicaltrials.gov/ct2/show/NCT00824083
All rights reserved. Please visit https://medical-data-
models.org/forms/5259
OP Primaertumor
Show identification of patient
Patient
Therapie
DurchgefÃ¼hrt?*
Nein (0)
Ja (1)
Art der OP
Datum der OP*
Chirurgische Klinik*
OP Art*
Endoprothese (11)
Autograft (12)
Allograft (13)
Auto-plus Allograft (14)
Sonstige (15)
Amputation- durch den betroffenen
Knochen (21)
Amputation- Exartikulation (22)
Amputation- oberhalb des betroffenen
Knochens (23)
Umkehrplastik (30)
Knochen-Resektion ohne Rekonstruktion
(zB. Rippe, Fibula) (40)
Resektion eines Weichteiltumors (50)
Lediglich Re-Biopsie (60)
OP-bedingte Komplikationen*
Nein (0)
Ja (1)
Welche?*
OP Bericht zugesandt*
Nein (0)
Ja (1)
Histologischer Bericht zugesandt*
Nein (0)
Ja (1)
Histologischer Befund
1 / 2
RadikalitÃ¤t der OP*
radikal/weit (1)
marginal (2)
intraläsional (3)
Histologisches Ansprechen (% vitale
Tumorzellen)*
Histologisches Ansprechen (Klassifikation)*
Keine vitalen Tumorzellen (1)
<1% vitale Tumorzellen (2)
1-4% vitale Tumorzellen (3)
5-9% vitale Tumorzellen (4)
10-29% vitale Tumorzellen (5)
30-49% vitale Tumorzellen (6)
>=50% vitale Tumorzellen (7)
Histologisches Ansprechen (gut/schlecht)*
Gut (1)
Schlecht (2)
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Ewing Study OP Primaertumor
Ewing Study OP Lungenmetastasen
EWING 2008, EudraCT 2008-003658-13,
http://clinicaltrials.gov/ct2/show/NCT00824083
All rights reserved. Please visit https://medical-data-
models.org/forms/5260
OP Lungenmetastasen
Show identification of patient
Patient
Therapie
DurchgefÃ¼hrt?*
Nein (0)
Ja (1)
Art der OP
Datum der OP*
Chirurgische Klinik*
Pneumektomie*
Nein (0)
Rechts (1)
Links (2)
Lobektomie*
Nein (0)
Rechts (1)
Links (2)
Beidseits (3)
Keilexzision(en), Metastasektomie*
Nein (0)
Rechts (1)
Links (2)
Beidseits (3)
Makroskopisch: vollstÃ¤ndige Entfernung*
Nein (0)
Ja (1)
Anzahl der entfernten Metastasen*
OP-bedingte Komplikationen*
Nein (0)
Ja (1)
Welche?*
OP Bericht zugesandt*
Nein (0)
Ja (1)
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Histologischer Bericht zugesandt*
Nein (0)
Ja (1)
Histologischer Befund
RadikalitÃ¤t der OP*
radikal/weit (1)
marginal (2)
intraläsional (3)
Histologisches Ansprechen (% vitale
Tumorzellen)*
Histologisches Ansprechen (Klassifikation)*
Keine vitalen Tumorzellen (1)
<1% vitale Tumorzellen (2)
1-4% vitale Tumorzellen (3)
5-9% vitale Tumorzellen (4)
10-29% vitale Tumorzellen (5)
30-49% vitale Tumorzellen (6)
>=50% vitale Tumorzellen (7)
Histologisches Ansprechen (gut/schlecht)*
Gut (1)
Schlecht (2)
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Ewing Study OP Lungenmetastasen
Ewing Study Referenzhistopathologie
EWING 2008, EudraCT 2008-003658-13,
http://clinicaltrials.gov/ct2/show/NCT00824083
All rights reserved. Please visit https://medical-data-
models.org/forms/5262
Referenzhistopathologie
Show identification of patient
Patient
Histopathologie durchgeführt?
DurchgefÃ¼hrt?*
Nein (0)
Ja (1)
Histopathogische Diagnose
Datum der Biopsie*
Pathologe*
Prof.G.Köhler (Münster) (1)
Prof.C.Poremba (Düsseldorf) (2)
Prof.I.Leuschner (Kiel) (3)
Prof.S.Lang (Wien) (4)
Prof.P.Hogendoorn (Leiden) (5)
andere (9)
Name des Referenzhistopathologen*
Journal Nr.*
Probe-Entnahme*
Resektionsbiopsie/OP-Präparat (1)
Stanze (2)
Feinnadelaspirat (3)
Gefriermaterial verfÃ¼gbar?*
Nein (0)
Ja (1)
Histopathologische Diagnose*
Undifferenziertes Ewing-Sarkom (1)
Neurodifferenziertes Ewing-Sarkom (z.B.
PNET) (2)
Großzelliges Ewing-Sarkom (3)
Andere Variante des Ewings-Sarkoms
(4)
Andere Erkrankung (5)
Bitte spezifizieren*
Tumor-Marker
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PAS*
Negativ (0)
Positiv (1)
Vimentin*
Negativ (0)
Positiv (1)
MIC2 (CD99)*
Negativ (0)
Positiv (1)
S100*
Negativ (0)
Positiv (1)
NSE*
Negativ (0)
Positiv (1)
Desmin*
Negativ (0)
Positiv (1)
CD45*
Negativ (0)
Positiv (1)
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Ewing Study Referenzhistopathologie
Ewing Study Referenzmolekularbiologie
EWING 2008, EudraCT 2008-003658-13,
http://clinicaltrials.gov/ct2/show/NCT00824083
All rights reserved. Please visit https://medical-data-
models.org/forms/5263
Referenzmolekularbiologie
Show identification of patient
Patient
Zytogenetik
Zytogenetik durchgefÃ¼hrt?*
Nein (0)
Ja (1)
Datum der Probe-Entnahme*
Translokation t(11;22)*
Nein (0)
Ja (1)
Variante*
Nein (0)
Ja (1)
Welche Variante?*
Molekularbiologie
Molekularbiologie durchgefÃ¼hrt?*
Nein (0)
Ja (1)
Warum nicht?*
Technische Gründe (1)
Kein Material verfügbar (2)
Sonstige Gründe (3)
Datum der Probe-Entnahme*
Name des Molekularbiologen*
Prof.G.Köhler (Münster) (1)
Prof.C.Poremba (Düsseldorf) (2)
-- gelöscht -- (3)
Prof.H.Kovar (Wien) (4)
Prof.P.Hogendoorn (Leiden) (5)
andere (9)
Name des Referenzmolekularbiologen*
Rearrangement von Chromosom 22*
Nein (0)
Ja (1)
Angabe des Transkripts*
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EWS-FLI1 Type 1 (1)
EWS-FLI1 Type 2 (2)
EWS-ERG (3)
andere (4)
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Ewing Study Referenzmolekularbiologie
Ewing Study Disease status prior to high
dose chemo
EWING 2008, EudraCT 2008-003658-13,
http://clinicaltrials.gov/ct2/show/NCT00824083
All rights reserved. Please visit https://medical-data-
models.org/forms/5264
Disease status prior to high dose
chemo
Show identification of patient
Patient
Disease status gobal and primary prior
highdose chemo
Datum der Statusevaluation*
Globalstatus (schlechtester Befund) (RECIST
Richtlinien)*
Komplette Remission (CR) (1)
Teilremission (PR) (2)
Stable disease (SD) (3)
Progress (PD) (4)
Status PrimÃ¤rtumor (RECIST Richtlinien)*
Komplette Remission (CR) (1)
Teilremission (PR) (2)
Stable disease (SD) (3)
Progress (PD) (4)
Status Lungen-/Pleurametastasen (RECIST
Richtlinien)*
Komplette Remission (CR) (1)
Teilremission (PR) (2)
Stable disease (SD) (3)
Progress (PD) (4)
Status Knochenmetastasen (RECIST
Richtlinien)*
Komplette Remission (CR) (1)
Teilremission (PR) (2)
Stable disease (SD) (3)
Progress (PD) (4)
Status Knochenmarkmetastasen (RECIST
Richtlinien)*
Komplette Remission (CR) (1)
Teilremission (PR) (2)
Stable disease (SD) (3)
Progress (PD) (4)
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Ewing Study Performance status prior to
high dose chemo
EWING 2008, EudraCT 2008-003658-13,
http://clinicaltrials.gov/ct2/show/NCT00824083
All rights reserved. Please visit https://medical-data-
models.org/forms/5265
Performance status prior to high
dose chemo
Show identification of patient
Patient
Performance status prior to high-dose
chemotherapy
Allgemeinzustand evaluiert nach*
Lansky (1)
Karnofsky (2)
GPOH-Score (3)
Allgemeinzustand (GPOH-Score)*
Normale Aktivität, keine
Beeinträchtigung (1)
Geringe Beeinträchtigung, jedoch keine
zusätzliche Hilfe erforderlich (2)
Altersentsprechende Aktivität stark
eingeschränkt, z.B. kein regelmäßiger
Kindergarten- bzw. Schulbesuch möglich
(3)
Bettlägrig, pflegebedürftig (4)
Intensive Behandlung notwendig,
schwerstkrank, moribund (5)
Karnofsky*
10%: Moribund, Krankheit schreitet
schnell fort (10)
100%: Normalzustand, keine
Beschwerden, keine manifeste
Erkrankung (100)
20%: Krankenhauspflege und supportive
Maßnahmen erforderlich (20)
30%: Schwerkrank, Krankenhauspflege
notwendig (30)
40%: Bettlägrig, spezielle Pflege
erforderlich (40)
50%: Krankenpflegerische und ärztliche
Hilfe, nicht dauernd bettlägrig (50)
60%: Gelegentliche fremde Hilfe (60)
70%: Eingeschränkte Leistungsfähigkeit,
arbeitsunfähig, kann sich alleine
versorgen (70)
80%: Normale Leistungsfähigkeit mit
Anstrengung (80)
90%: Minimale Krankheitssymptome (90)
Lansky*
10%: Kein Teilnahme an Spiel, dauerhaft
bettlägerig (10)
100%: Normale Aktivität (100)
20%: Oft schläfrig, Spiel auf passive
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Teilnahme beschränkt (20)
30%: Bettlägerig, benötigt Unterstützung
selbst bei ruhigem Spiel (30)
40%: Zumeist im Bett, nimmt an ruhigen
Aktivitäten teil (40)
50%: Zieht sich selbst an, kein aktives
Spiel, fähig zur Teilnahme an ruhigem
Spiel und allen Aktivitäten (50)
60%: Minimales aktives Spiel,
vorzugsweise ruhige Aktivitäten (60)
70%: Sowohl größere Einschränkungen
als auch geringere Ausdauer im Spiel
(70)
80%: Aktiv, aber ermüdet leichter (80)
90%: Geringe Einschränkungen;
normale körperliche Aktivität (90)
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Ewing Study Performance status prior to high dose chemo
Ewing Study Organ function prior to high
dose chemo
EWING 2008, EudraCT 2008-003658-13,
http://clinicaltrials.gov/ct2/show/NCT00824083
All rights reserved. Please visit https://medical-data-
models.org/forms/5266
Organ function prior to high dose
chemo
Show identification of patient
Patient
Cardiac function
Evaluationsmethode*
Echokardiographisch untersucht (1)
Szintigraphisch untersucht (2)
% Shortening Fraction (LV-SF)*
% Ejektionsfraktion (EF)*
Glomerular filtration
Evaluationsmethode*
Ermittelt per Kreatinin-Clearance (1)
Ermittelt per EDTA (2)
Ergebnis*
Tubular function
Ermittelt*
Nein (0)
Ja (1)
TP/CCrea oder TmP/GFR*
HCO3*
Liver function
SGOT*
Oberer SGOT-Grenzwert des Labors*
Lung function
Ergebnis*
Normal (1)
Eingeschränkt (2)
1 / 2
Lungenfunktion (Compliance) (% der Norm)*
CO-Diffusion (% der Norm)*
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Ewing Study Organ function prior to high dose chemo
Ewing Study Viral status prior to high dose
chemo
EWING 2008, EudraCT 2008-003658-13,
http://clinicaltrials.gov/ct2/show/NCT00824083
All rights reserved. Please visit https://medical-data-
models.org/forms/5267
Viral status prior to high dose chemo
Show identification of patient
Patient
Viral status
CMV*
Negativ (0)
Positiv (1)
HBV*
Negativ (0)
Positiv (1)
HCV*
Negativ (0)
Positiv (1)
HIV*
Negativ (0)
Positiv (1)
Blood group and rhesus factor
AB0-Gruppe*
0 (1)
A (2)
B (3)
AB (4)
Rhesusfaktor*
Negativ (0)
Positiv (1)
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Ewing Study Stem cell rescue
EWING 2008, EudraCT 2008-003658-13,
http://clinicaltrials.gov/ct2/show/NCT00824083
All rights reserved. Please visit https://medical-data-
models.org/forms/5269
Stem cell rescue
Show identification of patient
Patient
Stem cell rescue
Datum der Stammzellinfusion (Tag 0)*
Anzahl infundierter CD34+ Zellen*
Anzahl infundierter ANC*
Anzahl infundierter CD3+ Zellen*
HÃ¤matologische Wachstumsfaktoren (HGF)*
Keine (0)
G-CSF (1)
GM-CSF (2)
Andere (3)
Andere HGF*
Dosis HGF*
Erster Tag der HGF-Gabe*
Letzter Tag der HGF-Gabe*
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Ewing Study Engraftment
EWING 2008, EudraCT 2008-003658-13,
http://clinicaltrials.gov/ct2/show/NCT00824083
All rights reserved. Please visit https://medical-data-
models.org/forms/5270
Engraftment
Show identification of patient
Patient
Engraftment
Leukozytennadir*
Datum Leukozyten > 1,0 x 10E9/l*
Datum ANC > 0,5 x 10E9/l*
Thrombozytennadir*
Datum Thrombozyten > 20 x 10E9/l*
Datum Thrombozyten > 50 x 10E9/l*
Anzahl Tage mit Thrombozytentransfusion*
Niedrigster gemessener Hb-Wert*
Anzahl Tage mit Erythrozytentransfusion*
Graft failure*
Nein (0)
Ja (1)
Secondary graft failure
Datum Graft failure*
Therapie des Engraftmentversagens*
Therapie mit Zytokinen (1)
Erneute Transplantation (2)
Keine spezifische Therapie (3)
Art der erneuten Transplantation*
Autologe PBPC (1)
Syngene PBPC (2)
Allogene PBPC (3)
Autologes KM (4)
Syngenes KM (5)
Allogenes KM (6)
Andere (7)
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Andere Transplantation, bitte angeben*
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Ewing Study Engraftment
Ewing Study Disease status after high dose
chemo
EWING 2008, EudraCT 2008-003658-13,
http://clinicaltrials.gov/ct2/show/NCT00824083
All rights reserved. Please visit https://medical-data-
models.org/forms/5271
Disease status after high dose
chemo
Show identification of patient
Patient
Disease status after highdose chemo
Datum der Statusevaluation*
Status PrimÃ¤rtumor (RECIST Richtlinien)*
Komplette Remission (CR) (1)
Teilremission (PR) (2)
Stable disease (SD) (3)
Progress (PD) (4)
Status Lungen-/Pleurametastasen (RECIST
Richtlinien)*
Komplette Remission (CR) (1)
Teilremission (PR) (2)
Stable disease (SD) (3)
Progress (PD) (4)
Status Knochenmetastasen (RECIST
Richtlinien)*
Komplette Remission (CR) (1)
Teilremission (PR) (2)
Stable disease (SD) (3)
Progress (PD) (4)
Status Knochenmarkmetastasen (RECIST
Richtlinien)*
Komplette Remission (CR) (1)
Teilremission (PR) (2)
Stable disease (SD) (3)
Progress (PD) (4)
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Ewing Study Further treatment after high
dose chemo
EWING 2008, EudraCT 2008-003658-13,
http://clinicaltrials.gov/ct2/show/NCT00824083
All rights reserved. Please visit https://medical-data-
models.org/forms/5272
Further treatment after high dose
chemo
Show identification of patient
Patient
Further treatment after high dose chemo
Weiterbehandlung*
Therapieende (1)
OP (2)
Radiotherapie (3)
OP + Radiotherapie (4)
Radiotherapie + OP (5)
Andere (6)
Beschreibung der anderen Weiterbehandlung*
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Ewing Study Basic registration data
EWING 2008, EudraCT 2008-003658-13,
http://clinicaltrials.gov/ct2/show/NCT00824083
All rights reserved. Please visit https://medical-data-
models.org/forms/5273
Basic registration data
Registration
Datum der Dokumentation*
Teilnahme*
Einwilligung zur Weitergabe der Daten gegeben*
Nein (1)
Ja (2)
Bemerkungen
Patient transfer
Studien-ID*
Aktuelle Transfer-ID
Marvin-ID*
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Ewing Study Studienstatus
EWING 2008, EudraCT 2008-003658-13,
http://clinicaltrials.gov/ct2/show/NCT00824083
All rights reserved. Please visit https://medical-data-
models.org/forms/5274
Studienstatus
Show identification of patient
Patient
Einschlusskriterien
Histologische Diagnose Ewing-Sarkom oder
PNET?*
Nein (0)
Ja (1)
Allgemeinzustand: Lansky oder Karnofsky score
> 50%?*
Nein (0)
Ja (1)
Herzfunktion: LVEF > 40% SF >28%?*
Nein (0)
Ja (1)
HÃ¤matologische Parameter: HÃ¤moglobin >
8g/dl (Transfusion erlaubt),
Thrombozyten>80.000/Âµl (Transfusion erlaubt),
WBC > 2000/Âµl?*
Nein (0)
Ja (1)
Diagnosealter >=4Jahre <50 Jahre?*
Nein (0)
Ja (1)
VIDE 1 Datum <=45 Tage ab Diagnose?*
Nein (0)
Ja (1)
Registrierung in MARVIN <=45 Tage ab
Diagnose?*
Nein (0)
Ja (1)
Ausschlusskriterien
Mehr als 1 Zyklus an Chemotherapie vor
Registrierung?*
Nein (0)
Ja (1)
Maligne Vorerkrankung?*
Nein (0)
Ja (1)
Welche?*
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Schwangerschaft oder Stillzeit?*
Nein (0)
Ja (1)
Gleichzeitige Behandlung?*
Nein (0)
Ja (1)
Welche?*
Medizinische Kontraindikatoren?*
Nein (0)
Ja (1)
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Ewing Study Studienstatus
Ewing Study OP extrapulmonaler
Metastasen
EWING 2008, EudraCT 2008-003658-13,
http://clinicaltrials.gov/ct2/show/NCT00824083
All rights reserved. Please visit https://medical-data-
models.org/forms/5276
OP extrapulmonaler Metastasen
Show identification of patient
Patient
Therapie
Durchgeführt?*
Nein (0)
Ja (1)
OP
Datum der OP*
Chirurgische Klinik*
Lokalisation der Metastase*
Becken: sonstige (10)
Becken-ossär: Os ilium (11)
Becken-ossär: Ischiopubis (12)
Becken-ossär: Acetabulum (13)
Becken-ossär: Os sacrum (14)
Becken-Weichteil: Beckenweichgewebe
(15)
Becken-Weichteil: Gesäß (16)
Becken-Weichteil: Hüfte/Inguinalregion
(17)
Becken-Weichteil: Perineum (18)
Abdomen-Weichteil: sonstige (20)
Abdomen-Weichteil: Intra-abdominell
(21)
Abdomen-Weichteil: Retroperitoneal (22)
Abdomen-Weichteil: Abdominalwand
(23)
Abdomen-Weichteil: Niere (24)
WS-ossär: HWK (31)
WS-ossär: BWK (32)
WS-ossär: LWK (33)
WS-Weichteil: Cervikal intraspinal (34)
WS-Weichteil: Dorsal intraspinal (35)
WS-Weichteil: Lumbal intraspinal (36)
Thorax: sonstige (40)
Thorax-ossär: Scapula (41)
Thorax-ossär: Clavicula (42)
Thorax-ossär: Rippe (43)
Thorax-ossär: Sternum (44)
Thorax-Weichteil: Schulter (45)
Thorax-Weichteil: Axilla (46)
Thorax-Weichteil: Thoraxwand (47)
Kopf/Hals: sonstige (50)
Kopf/Hals-ossär: Schädel (51)
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Kopf/Hals-ossär: Mandibula (52)
Kopf/Hals-ossär: Maxilla (53)
Kopf/Hals-Weichteil: Kopfhaut (54)
Kopf/Hals-Weichteil: Hals (55)
Kopf/Hals-Weichteil: Gesicht (56)
Obere Extremitäten: sonstige (60)
Obere Extremitäten-ossär: Humerus (61)
Obere Extremitäten-ossär: Ulna
(Cubitus) (62)
Obere Extremitäten-ossär: Radius (63)
Obere Extremitäten-ossär: Carpus (64)
Obere Extremitäten-ossär: Metacarpus
(65)
Obere Extremitäten-ossär: Finger (66)
Obere Extremitäten-Weichteil: Oberarm
(67)
Obere Extremitäten-Weichteil: Ellbogen
(68)
Obere Extremitäten-Weichteil: Unterarm
(69)
Obere Extremitäten-Weichteil:
Handgelenk (70)
Obere Extremitäten-Weichteil: Hand (71)
Untere Extremitäten: sonstige (80)
Untere Extremitäten-ossär: Femur (81)
Untere Extremitäten-ossär: Tibia (82)
Untere Extremitäten-ossär: Fibula (83)
Untere Extremitäten-ossär: Calcanaeum
(84)
Untere Extremitäten-ossär: Talus (85)
Untere Extremitäten-ossär: Metatarsus
(86)
Untere Extremitäten-ossär: Zehe (87)
Untere Extremitäten-Weichteil:
Oberschenkel (88)
Untere Extremitäten-Weichteil: Knie (89)
Untere Extremitäten-Weichteil:
Unterschenkel (90)
Untere Extremitäten-Weichteil: Knöchel
(91)
Untere Extremitäten-Weichteil: Fuß (92)
OP Art*
Endoprothese (11)
Autograft (12)
Allograft (13)
Auto-plus Allograft (14)
Sonstige (15)
Amputation- durch den betroffenen
Knochen (21)
Amputation- Exartikulation (22)
Amputation- oberhalb des betroffenen
Knochens (23)
Umkehrplastik (30)
Knochen-Resektion ohne Rekonstruktion
(zB. Rippe, Fibula) (40)
Resektion eines Weichteiltumors (50)
Lediglich Re-Biopsie (60)
OP-bedingte Komplikationen*
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Ewing Study OP extrapulmonaler Metastasen
Nein (0)
Ja (1)
Welche?*
OP Bericht zugesandt*
Nein (0)
Ja (1)
Histologischer Bericht zugesandt*
Nein (0)
Ja (1)
Histologischer Befund
Radikalität der OP*
radikal/weit (1)
marginal (2)
intraläsional (3)
Histologisches Ansprechen (% vitale
Tumorzellen)*
Histologisches Ansprechen (Klassifikation)*
Keine vitalen Tumorzellen (1)
<1% vitale Tumorzellen (2)
1-4% vitale Tumorzellen (3)
5-9% vitale Tumorzellen (4)
10-29% vitale Tumorzellen (5)
30-49% vitale Tumorzellen (6)
>=50% vitale Tumorzellen (7)
Histologisches Ansprechen (gut/schlecht)*
Gut (1)
Schlecht (2)
3 / 3
Ewing Study OP extrapulmonaler Metastasen
Ewing Study Statuserhebung
EWING 2008, EudraCT 2008-003658-13,
http://clinicaltrials.gov/ct2/show/NCT00824083
All rights reserved. Please visit https://medical-data-
models.org/forms/5277
Statuserhebung
Show identification of patient
Patient
Patientenstatus
Datum der letzten Untersuchung*
Tumorstatus des Patienten*
CR (1)
Zweite oder weitere CR (2)
Patient lebt mit Erkrankung (3)
Progress (4)
Sekundärmalignom (5)
Laufende Rezidivtherapie (6)
1 / 1
Ewing Study RT der Lunge
EWING 2008, EudraCT 2008-003658-13,
http://clinicaltrials.gov/ct2/show/NCT00824083
All rights reserved. Please visit https://medical-data-
models.org/forms/5278
RT der Lunge
Show identification of patient
Patient
Therapie
DurchgefÃ¼hrt?*
Nein (0)
Ja (1)
Durchführung der Lungenbestrahlung
Beginn der Strahlentherapie*
Abschluss der Strahlentherapie*
Gleichzeitige Chemotherapie*
Nein (0)
Ja (1)
Gesamtdosis*
Lungenkorrekturfaktor*
Nein (0)
Ja (1)
Gesamtdosis inkl. Boost*
Dosis per Fraktion*
Hyperfraktionierung*
Nein (0)
Ja (1)
Technische Daten und Zielvolumen
Ganzlunge*
Rechts (1)
Links (2)
Beidseits (3)
Teillunge (inkl. Boost)*
Nein (0)
Ja (1)
Teilchen und Energie*
Kobalt 60 (1)
Hochvolt-Rö-Strahlung (2)
1 / 2
Energie 1*
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Ewing Study RT der Lunge
Ewing Study RT des Primaertumors
EWING 2008, EudraCT 2008-003658-13,
http://clinicaltrials.gov/ct2/show/NCT00824083
All rights reserved. Please visit https://medical-data-
models.org/forms/5279
RT des Primaertumors
Show identification of patient
Patient
Therapie
DurchgefÃ¼hrt?*
Nein (0)
Ja (1)
Durchführung der Primätumor-
Bestrahlung
Beginn der Strahlentherapie*
Abschluss der Strahlentherapie*
Gleichzeitige Chemotherapie*
Nein (0)
Ja (1)
Bestrahlungszeitpunkt*
Frühe Strahlentherapie (während
Induktion) (1)
Späte Strahlentherapie (nach Induktion)
(2)
Grund fÃ¼r Bestrahlungszeitpunkt*
Marginale Resektion (wahrscheinlich) (1)
Tumor nicht resezierbar (2)
Schlechtes klinisches Ansprechen auf
Chemotherapie (3)
Histologisch schlechtes Ansprechen auf
Chemotherapie (4)
Nachweis vitaler Tumorzellen am
Resektatrand (5)
Resttumor (6)
Andere (7)
Zielvolumen*
Initiales Tumorvolumen (1)
Resttumor nach Chemotherapie (2)
Pleurahöhle (3)
Sonstiges (4)
Gesamtdosis*
Gesamtdosis inkl. Boost*
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Dosis per Fraktion*
Unterbrechung der Strahlentherapie*
Nein (0)
Ja, Abbruch (1)
Ja, zeitweise Unterbrechung (2)
Hyperfraktionierung*
Nein (0)
Ja (1)
Chirurgische Verlagerung innerer Organe*
Nein (0)
Ja, Ovarien (1)
Ja, andere (2)
Technische Daten
Spezielle Technik*
Nein (0)
Ja: Brachytherapie (1)
Ja: non-koplanar konformational (2)
Sonstige (3)
Teilchen und Energie*
Kobalt 60 (1)
Hochvolt-Rö-Strahlung (2)
Elektronen (3)
Neutronen (4)
Protonen (5)
Sonstige (6)
Energie*
Energie 1*
Energie 2*
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Ewing Study RT des Primaertumors
Ewing Study RT von Metastase(n)
EWING 2008, EudraCT 2008-003658-13,
http://clinicaltrials.gov/ct2/show/NCT00824083
All rights reserved. Please visit https://medical-data-
models.org/forms/5280
RT von Metastase(n)
Show identification of patient
Patient
Therapie
DurchgefÃ¼hrt?*
Nein (0)
Ja (1)
Durchführung der Bestrahlung
extrapulmonaler Metastasen
Beginn der Strahlentherapie*
Abschluss der Strahlentherapie*
Gleichzeitige Chemotherapie*
Nein (0)
Ja (1)
Lokalisation der Metastase*
Becken: sonstige (10)
Becken-ossär: Os ilium (11)
Becken-ossär: Ischiopubis (12)
Becken-ossär: Acetabulum (13)
Becken-ossär: Os sacrum (14)
Becken-Weichteil: Beckenweichgewebe
(15)
Becken-Weichteil: Gesäß (16)
Becken-Weichteil: Hüfte/Inguinalregion
(17)
Becken-Weichteil: Perineum (18)
Abdomen-Weichteil: sonstige (20)
Abdomen-Weichteil: Intra-abdominell
(21)
Abdomen-Weichteil: Retroperitoneal (22)
Abdomen-Weichteil: Abdominalwand
(23)
Abdomen-Weichteil: Niere (24)
WS-ossär: HWK (31)
WS-ossär: BWK (32)
WS-ossär: LWK (33)
WS-Weichteil: Cervikal intraspinal (34)
WS-Weichteil: Dorsal intraspinal (35)
WS-Weichteil: Lumbal intraspinal (36)
Thorax: sonstige (40)
Thorax-ossär: Scapula (41)
Thorax-ossär: Clavicula (42)
Thorax-ossär: Rippe (43)
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Thorax-ossär: Sternum (44)
Thorax-Weichteil: Schulter (45)
Thorax-Weichteil: Axilla (46)
Thorax-Weichteil: Thoraxwand (47)
Kopf/Hals: sonstige (50)
Kopf/Hals-ossär: Schädel (51)
Kopf/Hals-ossär: Mandibula (52)
Kopf/Hals-ossär: Maxilla (53)
Kopf/Hals-Weichteil: Kopfhaut (54)
Kopf/Hals-Weichteil: Hals (55)
Kopf/Hals-Weichteil: Gesicht (56)
Obere Extremitäten: sonstige (60)
Obere Extremitäten-ossär: Humerus (61)
Obere Extremitäten-ossär: Ulna
(Cubitus) (62)
Obere Extremitäten-ossär: Radius (63)
Obere Extremitäten-ossär: Carpus (64)
Obere Extremitäten-ossär: Metacarpus
(65)
Obere Extremitäten-ossär: Finger (66)
Obere Extremitäten-Weichteil: Oberarm
(67)
Obere Extremitäten-Weichteil: Ellbogen
(68)
Obere Extremitäten-Weichteil: Unterarm
(69)
Obere Extremitäten-Weichteil:
Handgelenk (70)
Obere Extremitäten-Weichteil: Hand (71)
Untere Extremitäten: sonstige (80)
Untere Extremitäten-ossär: Femur (81)
Untere Extremitäten-ossär: Tibia (82)
Untere Extremitäten-ossär: Fibula (83)
Untere Extremitäten-ossär: Calcanaeum
(84)
Untere Extremitäten-ossär: Talus (85)
Untere Extremitäten-ossär: Metatarsus
(86)
Untere Extremitäten-ossär: Zehe (87)
Untere Extremitäten-Weichteil:
Oberschenkel (88)
Untere Extremitäten-Weichteil: Knie (89)
Untere Extremitäten-Weichteil:
Unterschenkel (90)
Untere Extremitäten-Weichteil: Knöchel
(91)
Untere Extremitäten-Weichteil: Fuß (92)
Gesamtdosis*
Gesamtdosis inkl. Boost*
Hyperfraktionierung*
Nein (0)
Ja (1)
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Ewing Study RT von Metastase(n)
Ewing Study Wichtige Studiendaten
EWING 2008, EudraCT 2008-003658-13,
http://clinicaltrials.gov/ct2/show/NCT00824083
All rights reserved. Please visit https://medical-data-
models.org/forms/5281
Wichtige Studiendaten
Show identification of patient
Patient
Daten zur Kontrolle des Studienstatus
Datum der diagnostischen Biopsie oder initialen
OP*
Tag 1 von VIDE 1*
Datum der MARVIN-Registrierung*
1 / 1
Ewing Study Rezidiv und Progress
EWING 2008, EudraCT 2008-003658-13,
http://clinicaltrials.gov/ct2/show/NCT00824083
All rights reserved. Please visit https://medical-data-
models.org/forms/5282
Rezidiv und Progress
Show identification of patient
Patient
Event
Datum des Events (Diagnose)*
Art des Events*
a. Lokalrezidiv/Lokaler Progress (1)
b. Sekundäre
Metatasierung/Metatasenprogress (2)
Kombiniertes(r) Rezidiv/Progress (a+b)
(3)
Lokalrezidiv/lokaler Progress
Ausdehnung des Lokalrezidivs/lokalen
Progresses*
Lokalisiert (1)
Regional (2)
Lokal+regional (3)
Rezidiv nach Strahlentherapie*
Nein (0)
Ja (1)
wenn ja, wo*
Im Strahlenfeld (1)
Marginal (2)
Außerhalb des Strahlenfeldes (3)
Sekundäre Metastasierung/
Metastasenprogress
Lungenmetastase(n)*
Nein (0)
Einseitig (1)
Beidseits (2)
Knochenmetastase(n)*
Nein (0)
Eine (1)
Mehrere (2)
Knochenmarkmetastase(n)*
Nein (0)
Ja (1)
ZNS-Metastase(n)*
Nein (0)
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Ja (1)
Leber-Metastase(n)*
Nein (0)
Ja (1)
Lymphknotenmetastase(n)*
Nein (0)
Ja (1)
Sonstige Metastase(n)*
Nein (0)
Ja (1)
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Ewing Study Rezidiv und Progress
Ewing Study Sekundaermalignom
EWING 2008, EudraCT 2008-003658-13,
http://clinicaltrials.gov/ct2/show/NCT00824083
All rights reserved. Please visit https://medical-data-
models.org/forms/5283
Sekundaermalignom
Show identification of patient
Patient
Event
Datum des Events (Diagnose)*
Art des Zweitmailgnoms*
Systemisch (1)
Lokalisiert (2)
Bitte nÃ¤here Angaben zur Art und zur
Lokalisation*
SekundÃ¤rmalignom im Strahlenfeld*
Nein (0)
Ja (1)
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Ewing Study Therapieabschluss
EWING 2008, EudraCT 2008-003658-13,
http://clinicaltrials.gov/ct2/show/NCT00824083
All rights reserved. Please visit https://medical-data-
models.org/forms/5284
Therapieabschluss
Show identification of patient
Patient
Therapiedaten
Beginn der Therapie*
Therapieende*
Therapiearm*
R1 (1)
R2loc (2)
R2pulm (3)
R3 (4)
Status (RECIST Richtlinien)*
Komplette Remission (CR) (1)
Teilremission (PR) (2)
Stable disease (SD) (3)
Progress (PD) (4)
Grund fÃ¼r Therapieabschluss*
Protokollgemäß (1)
Toxizität (2)
Progress (3)
Entscheidung des Patienten (4)
Entscheidung des Arztes (5)
Tod (6)
Lost to follow-up (7)
Diagnoseänderung (8)
Besondere Bemerkungen zur Therapie/ zum
Patienten
Erhaltene Therapie
Anzahl VIDE-Kurse*
Anzahl VAI-Kurse*
Anzahl VAC-Kurse*
Anzahl andere Chemotherapiekurse*
Hochdosischemotherapie*
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Keine (0)
Bu-Mel (1)
Treo-Mel (2)
Bu-Mel + andere (3)
Andere (4)
Anzahl R1 Add-on Kurse*
Stammzellapharese*
Nein (0)
Ja (1)
Nicht erfolgreich (2)
OP PrimÃ¤rtumor*
Nein (0)
Ja (1)
RT PrimÃ¤rtumor*
Nein (0)
Ja (1)
OP Lungen-/Pleura-Metastase(n)*
Nein (0)
Ja (1)
RT Lunge*
Nein (0)
Ja (1)
OP extrapulmonaler Metastasen*
Nein (0)
Ja (1)
RT extrapulmonaler Metastasen*
Nein (0)
Ja (1)
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Ewing Study Therapieabschluss
Ewing Study Protokollabweichungen
EWING 2008, EudraCT 2008-003658-13,
http://clinicaltrials.gov/ct2/show/NCT00824083
All rights reserved. Please visit https://medical-data-
models.org/forms/5285
Protokollabweichungen
Show identification of patient
Patient
Protokollabweichungen
Induktionschemotherapie (VIDE)*
Keine Abweichung (0)
Toxizität (1)
Entscheidung des Patienten (2)
Entscheidung des Arztes (3)
Progress (4)
Lost to follow-up (5)
Sonstige Gründe (6)
Konsolidierungschemotherapie (VAI/VAC)*
Keine Abweichung (0)
Toxizität (1)
Entscheidung des Patienten (2)
Entscheidung des Arztes (3)
Progress (4)
Lost to follow-up (5)
Sonstige Gründe (6)
Hochdosischemotherapie*
Keine Abweichung (0)
Toxizität (1)
Entscheidung des Patienten (2)
Entscheidung des Arztes (3)
Progress (4)
Lost to follow-up (5)
Sonstige Gründe (6)
Operation*
Keine Abweichung (0)
Toxizität (1)
Entscheidung des Patienten (2)
Entscheidung des Arztes (3)
Progress (4)
Lost to follow-up (5)
Sonstige Gründe (6)
Radiotherapie*
Keine Abweichung (0)
Toxizität (1)
Entscheidung des Patienten (2)
Entscheidung des Arztes (3)
Progress (4)
Lost to follow-up (5)
Sonstige Gründe (6)
R1 Add-on Therapie*
Keine Abweichung (0)
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Toxizität (1)
Entscheidung des Patienten (2)
Entscheidung des Arztes (3)
Progress (4)
Lost to follow-up (5)
Sonstige Gründe (6)
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Ewing Study Protokollabweichungen
Ewing Study Randomisierung
EWING 2008, EudraCT 2008-003658-13,
http://clinicaltrials.gov/ct2/show/NCT00824083
All rights reserved. Please visit https://medical-data-
models.org/forms/5286
Randomisierung
Show identification of patient
Patient
Anforderung/Risikogruppe
Soll der Patient randomisiert werden?*
Nein (0)
Ja (1)
Therapiearm*
R1 (1)
R2loc (2)
R2pulm (3)
R3 (4)
Grund fÃ¼r Nichtrandomisierung*
Progress (1)
Medizinische Kontraindikation/Toxizität
(2)
Verweigerung Patient/Eltern (3)
Entscheidung des Arztes (4)
Organisatorische Gründe (5)
Sonstige (6)
R1
Rearrangement von Chromosom 22*
Kein positiver Nachweis oder Nachweis
fehlend! (0)
Positiver Nachweis liegt vor (1)
MIC2 positiv (CD99)*
Kein positiver Nachweis oder Nachweis
fehlend! (0)
Positiver Nachweis liegt vor (1)
PrimÃ¤re Metastasierung (muss nein sein!)*
Nein (0)
Ja (1)
Klinisches Ansprechen des PrimÃ¤rtumors auf
Induktionschemotherapie (RECIST Richtlinien)*
CR oder PR (1)
SD (2)
PD (3)
Lokaltherapie (geplant oder durchgefÃ¼hrt)*
Andere (0)
OP nach alleiniger Chemotherapie: jedes
Tumorvolumen und histologisch gutes
Ansprechen (1)
OP nach Chemotherapie und früher
Radiotherapie: Tumorvolumen bei
1 / 6
Diagnose <200ml und histologisch gutes
Ansprechen (2)
Initiale OP: Tumorvolumen bei Diagnose
<200ml (3)
Alleinige Radiotherapie (Tumor nicht
reszierbar): Tumorvolumen bei Diagnose
<200ml und mind. partielles klinisches
Ansprechen, kein Progress (4)
Bitte genaue Angaben*
Anzahl bislang verabreichter VIDE-Kurse*
Medizinische Kontraindikationen gegen die
geplante Chemotherapie*
Nein (0)
Ja (1)
Welche?*
EinwilligungserklÃ¤rung zur Randomisierung
unterzeichnet*
Nein (0)
Ja (1)
Material an Referenzpathologen versandt*
Nein (0)
Ja (1)
R2loc
Rearrangement von Chromosom 22*
Kein positiver Nachweis oder Nachweis
fehlend! (0)
Positiver Nachweis liegt vor (1)
MIC2 positiv (CD99)*
Kein positiver Nachweis oder Nachweis
fehlend! (0)
Positiver Nachweis liegt vor (1)
PrimÃ¤re Metastasierung (muss nein sein!)*
Nein (0)
Ja (1)
Kriterien fÃ¼r R1? (muss nein sein!)*
Nein (0)
Ja (1)
Klinisches Ansprechen des PrimÃ¤rtumors auf
Induktionschemotherapie (RECIST Richtlinien)*
CR oder PR (1)
SD (2)
PD (3)
Lokaltherapie (geplant oder durchgefÃ¼hrt)*
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Ewing Study Randomisierung
Andere (0)
OP nach alleiniger Chemotherapie: jedes
Tumorvolumen und histologisch
schlechtes Ansprechen (1)
OP nach Chemotherapie und früher RT:
Tumorsitz Extremitäten + Tumorvolumen
bei Diagnose >=200ml + histologisch
schlechtes Ansprechen (2)
Initiale OP: Tumorvolumen bei Diagnose
>=200ml (3)
Alleinige frühe RT (Tumor nicht
reszierbar): Tumorsitz Extremitäten und
jedes Tumorvolumen + klinisch
schlechtes Ansprechen und kein
Progress (4)
Alleinige späte Radiotherapie:
Tumorvolumen bei Diagnose >=200ml
und kein Progress (5)
Alleinige späte Radiotherapie (Tumor
nicht reszierbar): Tumorvolumen bei
Diagnose <200ml, klinisch schlechtes
Ansprechen und kein Progress (6)
Bitte genaue Angaben*
Anzahl bislang verabreichter VIDE-Kurse*
Medizinische Kontraindikationen gegen die
geplante Chemotherapie*
Nein (0)
Ja (1)
Welche?*
EinwilligungserklÃ¤rung zur Randomisierung
unterzeichnet*
Nein (0)
Ja (1)
Material an Referenzpathologen versandt*
Nein (0)
Ja (1)
R2pulm
Rearrangement von Chromosom 22*
Kein positiver Nachweis oder Nachweis
fehlend! (0)
Positiver Nachweis liegt vor (1)
MIC2 positiv (CD99)*
Kein positiver Nachweis oder Nachweis
fehlend! (0)
Positiver Nachweis liegt vor (1)
PrimÃ¤re Lungenmetastasen (muss ja sein!)*
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Ewing Study Randomisierung
Nein (0)
Ja (1)
PrimÃ¤re extrapulmonale Metastasen (muss nein
sein!)*
Nein (0)
Ja (1)
Klinisches Ansprechen des PrimÃ¤rtumors auf
Induktionschemotherapie (RECIST Richtlinien)*
CR oder PR (1)
SD (2)
PD (3)
Klinisches Ansprechen der Lungenmetastasen
auf Induktionschemotherapie (RECIST
Richtlinien)*
CR oder PR (1)
SD (2)
PD (3)
Lokaltherapie (geplant oder durchgefÃ¼hrt)*
Andere (0)
OP nach alleiniger Chemotherapie +/-
späte Radiotherapie (1)
Frühe Radiotherapie und OP, Tumorsitz
Extremitäten (2)
Initiale OP (3)
Alleinige frühe Radiotherapie (Tumorsitz
nicht resezierbar) (4)
Alleinige späte Radiotherapie (Tumorsitz
nicht resezierbar) (5)
Bitte genaue Angaben*
Anzahl bislang verabreichter VIDE-Kurse*
Medizinische Kontraindikationen gegen die
geplante Chemotherapie*
Nein (0)
Ja (1)
Welche?*
EinwilligungserklÃ¤rung zur Randomisierung
unterzeichnet*
Nein (0)
Ja (1)
Material an Referenzpathologen versandt*
Nein (0)
Ja (1)
R3
Rearrangement von Chromosom 22*
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Ewing Study Randomisierung
Kein positiver Nachweis oder Nachweis
fehlend! (0)
Positiver Nachweis liegt vor (1)
MIC2 positiv (CD99)*
Kein positiver Nachweis oder Nachweis
fehlend! (0)
Positiver Nachweis liegt vor (1)
PrimÃ¤re extrapulmonale Metastasen (muss ja
sein!)*
Nein (0)
Ja (1)
Klinisches Ansprechen des PrimÃ¤rtumors auf
Induktionschemotherapie (RECIST Richtlinien)*
CR oder PR (1)
SD (2)
PD (3)
Klinisches Ansprechen der Metastasen
(schlechteste Bewertung) auf
Induktionschemotherapie (RECIST Richtlinien)*
CR oder PR (1)
SD (2)
PD (3)
Lokaltherapie (geplant oder durchgefÃ¼hrt)*
Andere (0)
OP nach alleiniger Chemotherapie +/-
späte Radiotherapie (1)
Frühe Radiotherapie und OP, Tumorsitz
Extremitäten (2)
Initiale OP (3)
Alleinige frühe Radiotherapie (Tumorsitz
nicht resezierbar) (4)
Alleinige späte Radiotherapie (Tumorsitz
nicht resezierbar) (5)
Bitte genaue Angaben*
Anzahl bislang verabreichter VIDE-Kurse*
Medizinische Kontraindikationen gegen die
geplante Chemotherapie*
Nein (0)
Ja (1)
Welche?*
EinwilligungserklÃ¤rung zur Randomisierung
unterzeichnet*
Nein (0)
Ja (1)
Material an Referenzpathologen versandt*
Nein (0)
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Ewing Study Randomisierung
Ja (1)
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Ewing Study Randomisierung
Ewing Study Rando ergebnis
EWING 2008, EudraCT 2008-003658-13,
http://clinicaltrials.gov/ct2/show/NCT00824083
All rights reserved. Please visit https://medical-data-
models.org/forms/5287
Rando ergebnis
Show identification of patient
Patient
Ergebnis
Randomisierungsdatum*
Randomisierung*
R1: Add-on (Zoledronsäure) (1)
R1: kein Add-on (keine Zoledronsäure)
(2)
R2loc: VAI (3)
R2loc: Bu-Mel (4)
R2pulm: VAI + LuRAD (5)
R2pulm: Bu-Mel (6)
R3: VAC (7)
R3: Treo-Mel (8)
1 / 1
Ewing Study Toxicity
EWING 2008, EudraCT 2008-003658-13,
http://clinicaltrials.gov/ct2/show/NCT00824083
All rights reserved. Please visit https://medical-data-
models.org/forms/5288
Toxicity
Show identification of patient
Patient
General condition ctc scale
Allgemeinzustand*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Toxicity hematology
HÃ¤moglobin*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Leukozyten*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Granulozyten*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Thrombozyten*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Toxicity infection
Infektion*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
1 / 4
Fieber*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Toxicity gut
Stomatitis*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Erbrechen*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Diarrhoe*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Toxicity skin
HautverÃ¤nderungen*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Toxicity renal
Kreatinin*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Proteinurie*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
HÃ¤maturie*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
2 / 4
Ewing Study Toxicity
Grad 3 (3)
Grad 4 (4)
GlomerulÃ¤re Filtrationsrate (GFR)*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
TubulÃ¤re Phosphatreabsorption*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Toxicity liver
Bilirubin*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
S-GOT/S-GPT*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
VOD aufgetreten*
Nein (0)
Ja (1)
LeberfunktionsstÃ¶rung nach Bearman*
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Toxicity cardiac
Herzfunktion*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
ECHO: LV-SF*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
3 / 4
Ewing Study Toxicity
Toxicity neurological
Zentrale NeurotoxizitÃ¤t*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
KrampfanfÃ¤lle*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Periphere NeurotoxizitÃ¤t*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Toxicity other
Andere ToxizitÃ¤t aufgetreten*
Nein (0)
Ja (1)
Toxicity other
Beschreibung andere ToxizitÃ¤t*
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Ewing Study Toxicity
Ewing Study Toxicity
EWING 2008, EudraCT 2008-003658-13,
http://clinicaltrials.gov/ct2/show/NCT00824083
All rights reserved. Please visit https://medical-data-
models.org/forms/5289
Toxicity
Show identification of patient
Patient
General condition ctc scale
Allgemeinzustand*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Toxicity hematology
HÃ¤moglobin*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Leukozyten*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Granulozyten*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Thrombozyten*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Toxicity infection
Infektion*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
1 / 5
Fieber*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Toxicity gut
Stomatitis*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Erbrechen*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Diarrhoe*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Parenterale Analgesie erforderlich*
Nein (0)
Ja (1)
Dauer der parenteralen Analgesie*
Parenterale ErnÃ¤hrung erforderlich*
Nein (0)
Ja (1)
Dauer der parenteralen ErnÃ¤hrung*
Parenterale Antibiose erforderlich*
Nein (0)
Ja (1)
Dauer der parenterale Antibiose*
Toxicity skin
HautverÃ¤nderungen*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
2 / 5
Ewing Study Toxicity
Toxicity renal
Kreatinin*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Proteinurie*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
HÃ¤maturie*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
GlomerulÃ¤re Filtrationsrate (GFR)*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
TubulÃ¤re Phosphatreabsorption*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Toxicity liver
Bilirubin*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
S-GOT/S-GPT*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
VOD-PrÃ¤vention durchgefÃ¼hrt*
Nein (0)
Ja (1)
VOD-PrÃ¤vention mit Ursodiol*
Nein (0)
3 / 5
Ewing Study Toxicity
Ja (1)
VOD-PrÃ¤vention mit Heparin*
Nein (0)
Ja (1)
VOD aufgetreten*
Nein (0)
Ja (1)
LeberfunktionsstÃ¶rung nach Bearman*
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Toxicity lungs
Pulmonale ToxizitÃ¤t aufgetreten*
Nein (0)
Ja (1)
Pneumonitis*
Nein (0)
Radiologisch Veränderungen, keine
Steroide erforderlich (1)
Steroide erforderlich (2)
Sauerstoffgabe erforderlich (3)
Beatmung erforderlich (4)
Andere pulmonale ToxizitÃ¤t*
Nein (0)
Ja (1)
Beschreibung andere pulmonale ToxizitÃ¤t*
Toxicity cardiac
Herzfunktion*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
ECHO: LV-SF*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Toxicity neurological
Zentrale NeurotoxizitÃ¤t*
Grad 0 (0)
Grad 1 (1)
4 / 5
Ewing Study Toxicity
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
KrampfanfÃ¤lle*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Periphere NeurotoxizitÃ¤t*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Toxicity other
Andere ToxizitÃ¤t aufgetreten*
Nein (0)
Ja (1)
Toxicity other
Beschreibung andere ToxizitÃ¤t*
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Ewing Study Toxicity
Ewing Study Toxicity of primary tumour
radiotherapy
EWING 2008, EudraCT 2008-003658-13,
http://clinicaltrials.gov/ct2/show/NCT00824083
All rights reserved. Please visit https://medical-data-
models.org/forms/5292
Toxicity of primary tumour
radiotherapy
General condition ctc scale
Allgemeinzustand*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Toxicity skin
HautverÃ¤nderungen*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Visceral/Gastrointestinal toxicity
Stomatitis*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
SchleimhÃ¤ute*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
SpeicheldrÃ¼sen*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Pharynx und SpeiserÃ¶hre*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Kehlkopf*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
1 / 3
Grad 3 (3)
Grad 4 (4)
Oberer GI-Trakt*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Erbrechen*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Unterer GI-Trakt: Dick- und Enddarm mit
Beckenregion*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Diarrhoe*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Toxicity renal and lower urinary tract
Harnleiter und Blase*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Toxicity cardiac and pulmonary
Herzfunktion*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
ECHO: LV-SF*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Lunge*
2 / 3
Ewing Study Toxicity of primary tumour radiotherapy
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Toxicity neurological
Periphere NeurotoxizitÃ¤t*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Kopfschmerzen*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Toxicity other
Andere ToxizitÃ¤t aufgetreten*
Nein (0)
Ja (1)
Toxicity other
Beschreibung andere ToxizitÃ¤t*
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Ewing Study Toxicity of primary tumour radiotherapy
Ewing Study Toxicity of lung radiotherapy
EWING 2008, EudraCT 2008-003658-13,
http://clinicaltrials.gov/ct2/show/NCT00824083
All rights reserved. Please visit https://medical-data-
models.org/forms/5293
Toxicity of lung radiotherapy
General condition ctc scale
Allgemeinzustand*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Toxicity skin
HautverÃ¤nderungen*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Visceral/Gastrointestinal toxicity
Stomatitis*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
SchleimhÃ¤ute*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Pharynx und SpeiserÃ¶hre*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Kehlkopf*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Oberer GI-Trakt*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
1 / 2
Erbrechen*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Toxicity cardiac and pulmonary
Herzfunktion*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
ECHO: LV-SF*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Lunge*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Toxicity neurological
Periphere NeurotoxizitÃ¤t*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Kopfschmerzen*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Toxicity other
Andere ToxizitÃ¤t aufgetreten*
Nein (0)
Ja (1)
Toxicity other
Beschreibung andere ToxizitÃ¤t*
2 / 2
Ewing Study Toxicity of lung radiotherapy
Ewing Study Toxicity of metastasis
radiotherapy
EWING 2008, EudraCT 2008-003658-13,
http://clinicaltrials.gov/ct2/show/NCT00824083
All rights reserved. Please visit https://medical-data-
models.org/forms/5295
Toxicity of metastasis radiotherapy
General condition ctc scale
Allgemeinzustand*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Toxicity skin
HautverÃ¤nderungen*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Visceral/Gastrointestinal toxicity
Stomatitis*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
SchleimhÃ¤ute*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
SpeicheldrÃ¼sen*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Pharynx und SpeiserÃ¶hre*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Kehlkopf*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
1 / 3
Oberer GI-Trakt*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Erbrechen*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Unterer GI-Trakt: Dick- und Enddarm mit
Beckenregion*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Diarrhoe*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Toxicity renal and lower urinary tract
Harnleiter und Blase*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Toxicity cardiac and pulmonary
Herzfunktion*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
ECHO: LV-SF*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Lunge*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
2 / 3
Ewing Study Toxicity of metastasis radiotherapy
Grad 3 (3)
Grad 4 (4)
Toxicity neurological
Periphere NeurotoxizitÃ¤t*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Kopfschmerzen*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Toxicity other
Andere ToxizitÃ¤t aufgetreten*
Nein (0)
Ja (1)
Toxicity other
Beschreibung andere ToxizitÃ¤t*
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Ewing Study Toxicity of metastasis radiotherapy
Ewing Study SAE
EWING 2008, EudraCT 2008-003658-13,
http://clinicaltrials.gov/ct2/show/NCT00824083
All rights reserved. Please visit https://medical-data-
models.org/forms/5296
SAE
Show identification of patient
Patient
SAE
Datum des SAE*
Beschreibung des SAE*
SAE-Nr.*
1 / 1
Ewing Study Stammzellenapherese_-
sammlung
EWING 2008, EudraCT 2008-003658-13,
http://clinicaltrials.gov/ct2/show/NCT00824083
All rights reserved. Please visit https://medical-data-
models.org/forms/5297
Stammzellenapherese/-sammlung
Show identification of patient
Patient
Apherese und Sammlung
Datum der 1. Stammzellapherese/-sammlung*
Anzahl der Apheresen*
KÃ¶rpergewicht*
Progenitorzellen*
Autolog, peripheres Blut (1)
Autolog, Knochenmark (2)
Sonstige (3)
Mobilisation*
Chemotherapie+HGF (1)
Steady state+HGF (2)
Nur Chemotherapie (3)
Sonstige (4)
HÃ¤matologische Wachstumsfaktoren*
Keine (0)
G-CSF (1)
GM-CSF (2)
Sonstige (3)
Chemotherapie vor Mobilisation*
VIDE (1)
VAI (2)
VAC (3)
Sonstige (4)
Mobilisation nach EWING 2008 Chemotherapie
Kurs Nr.*
Tag 1 des Mobilisations-Chemotherapiekurses*
Purging*
Kein Purging (0)
CD34+ Selektion (1)
Sonstiges (2)
Anzahl gesammelter Stammzellen vor Einfrieren:
CD34+*
1 / 2
Anzahl gesammelter Stammzellen vor Einfrieren:
ANC*
Anzahl gesammelter Stammzellen vor Einfrieren:
CD3+*
Wurden Stammzellen zur molekularbiologischen
Untersuchung geschickt?*
Nein (0)
Ja (1)
2 / 2
Ewing Study Stammzellenapherese_-sammlung
Ewing Study Herzfunktion
EWING 2008, EudraCT 2008-003658-13,
http://clinicaltrials.gov/ct2/show/NCT00824083
All rights reserved. Please visit https://medical-data-
models.org/forms/5298
Herzfunktion
Show identification of patient
Patient
Untersuchung der Herzfunktion
Datum*
Anzeichen einer kardiovaskulÃ¤ren Erkrankung*
Nein (0)
Ja (1)
Bitte spezifizieren:*
Funktionelle Untersuchungen*
Echokardiographie (1)
Szintigraphie (2)
Methode*
Fractional shortening (LV-SF) (1)
Ejection fraction (EF) (2)
Medikation*
Nein (0)
Ja (1)
Bitte spezifizieren:*
1 / 1
Ewing Study Nierenfunktion
EWING 2008, EudraCT 2008-003658-13,
http://clinicaltrials.gov/ct2/show/NCT00824083
All rights reserved. Please visit https://medical-data-
models.org/forms/5299
Nierenfunktion
Show identification of patient
Patient
Untersuchung der Nierenfunktion
Datum*
GlomerulÃ¤re Filtration*
Untersucht mit Kreatinin-Clearance (1)
Untersucht mit EDTA (2)
GlomerulÃ¤re Filtrationsrate (GFR)*
Kreatinin*
Normal (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
TubulÃ¤re Funktion*
Nein (0)
Ja (1)
TRP*
HCO3*
Medikation*
Nein (0)
Ja (1)
Bitte spezifizieren:*
1 / 1
Ewing Study Geschlechtsdruesenfunktion
EWING 2008, EudraCT 2008-003658-13,
http://clinicaltrials.gov/ct2/show/NCT00824083
All rights reserved. Please visit https://medical-data-
models.org/forms/5300
Geschlechtsdruesenfunktion
Show identification of patient
Patient
Untersuchung der
Geschlechtsdrüsenfunktion
Datum*
Klinische Symptome
Hodenvolumen*
Spontaner PubertÃ¤tsbeginn?*
Nein (0)
Ja (1)
Menstruation*
normal (0)
abnormal (1)
Anzahl der Schwangerschaften/Vaterschaften
seit Ende der Behandlung*
Anzahl der Lebendgeburten*
Anzahl Totgeburten/Aborte*
Anzahl der therapeutischen Totgeburten/Aborte*
Anzahl der spontanen Totgeburten/Aborte*
Hormons
Hormonkonzentrationen untersucht?*
Nein (0)
Ja (1)
FSH*
Normal Range FSH*
LH*
1 / 2
Normal Range LH*
Ã–stradiol*
Testosteron*
Spermaanalyse*
Normal (1)
Oligospermie (2)
Azoospermie (3)
Nicht relevant (9)
Wenn Oligosperma, bitte spezifizieren:*
Medikamentöse Behandlung
FertilitÃ¤tstherapie*
Nein (0)
Ja (1)
Nicht relevant (2)
Hormonsubstitution (auÃŸerhalb einer
FertilitÃ¤tstherapie)*
Nein (0)
Ja (1)
Nicht relevant (2)
Bitte spezifizieren:*
2 / 2
Ewing Study Geschlechtsdruesenfunktion
Ewing Study Lungenfunktion
EWING 2008, EudraCT 2008-003658-13,
http://clinicaltrials.gov/ct2/show/NCT00824083
All rights reserved. Please visit https://medical-data-
models.org/forms/5301
Lungenfunktion
Show identification of patient
Patient
Untersuchung der Lungenfunktion
Datum*
Anzeichen/Symptome einer Lungenerkrankung*
Nein (0)
Ja (1)
Bitte spezifizieren:*
Funktionelle Untersuchungen*
Normal (1)
Reduziert (2)
Lungenfunktion (Compliance) (% der Norm)*
CO-Diffusion (% der Norm)*
Behandlung*
Nein (0)
Ja (1)
Bitte spezifizieren:*
1 / 1
Ewing Study Nachsorgezyklus
EWING 2008, EudraCT 2008-003658-13,
http://clinicaltrials.gov/ct2/show/NCT00824083
All rights reserved. Please visit https://medical-data-
models.org/forms/5302
Nachsorgezyklus
Show identification of patient
Patient
Zeitpunkt der Untersuchung
Wie viele Jahre nach Diagnose wurde die
Untersuchung durchgefÃ¼hrt?*
Untersuchung von
Herzfunktion (mindestens klinisch)*
Nein (0)
Ja (1)
Nierenfunktion*
Nein (0)
Ja (1)
GeschlechtsdrÃ¼senfunktion (mindestens
klinisch) (Kontrolle erst nach der PubertÃ¤t)*
Nein (0)
Ja (1)
Lungenfunktion (mindestens klinisch)*
Nein (0)
Ja (1)
1 / 1
Ewing Study Studienstatus
EWING 2008, EudraCT 2008-003658-13,
http://clinicaltrials.gov/ct2/show/NCT00824083
All rights reserved. Please visit https://medical-data-
models.org/forms/5303
Studienstatus
Show identification of patient
Patient
Protokoll- oder Beobachtungspatient?
Studien- oder Beobachtungspatient?*
Beobachtungspatient (Patient wird
dokumentiert, aber nicht zur
Randomisation zugelassen) (0)
Studienpatient (für Randomisation
zugelassen) (1)
Datum der frÃ¼hesten Meldung an die
Studienzentrale*
Studiennummer*
1 / 1
Ewing Study Toxicity
EWING 2008, EudraCT 2008-003658-13,
http://clinicaltrials.gov/ct2/show/NCT00824083
All rights reserved. Please visit https://medical-data-
models.org/forms/5304
Toxicity
Show identification of patient
Patient
General condition ctc scale
Allgemeinzustand*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Toxicity hematology
HÃ¤moglobin*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Leukozyten*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Granulozyten*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Thrombozyten*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Toxicity infection
Infektion*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
1 / 4
Fieber*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Toxicity gut
Stomatitis*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Erbrechen*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Diarrhoe*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Toxicity skin
HautverÃ¤nderungen*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Toxicity renal
Kreatinin*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Proteinurie*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
HÃ¤maturie*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
2 / 4
Ewing Study Toxicity
Grad 3 (3)
Grad 4 (4)
GlomerulÃ¤re Filtrationsrate (GFR)*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
TubulÃ¤re Phosphatreabsorption*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Toxicity liver
Bilirubin*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
S-GOT/S-GPT*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Toxicity cardiac
Herzfunktion*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
ECHO: LV-SF*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Toxicity neurological
Zentrale NeurotoxizitÃ¤t*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
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Ewing Study Toxicity
KrampfanfÃ¤lle*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Periphere NeurotoxizitÃ¤t*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Toxicity other
Andere ToxizitÃ¤t aufgetreten*
Nein (0)
Ja (1)
Toxicity other
Beschreibung andere ToxizitÃ¤t*
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Ewing Study Toxicity
Ewing Study Toxicity
EWING 2008, EudraCT 2008-003658-13,
http://clinicaltrials.gov/ct2/show/NCT00824083
All rights reserved. Please visit https://medical-data-
models.org/forms/5305
Toxicity
Show identification of patient
Patient
General condition ctc scale
Allgemeinzustand*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Toxicity hematology
HÃ¤moglobin*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Leukozyten*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Granulozyten*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Thrombozyten*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Toxicity infection
Infektion*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
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Fieber*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Toxicity gut
Stomatitis*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Erbrechen*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Diarrhoe*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Toxicity skin
HautverÃ¤nderungen*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Toxicity renal
Kreatinin*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Proteinurie*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
HÃ¤maturie*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
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Ewing Study Toxicity
Grad 3 (3)
Grad 4 (4)
GlomerulÃ¤re Filtrationsrate (GFR)*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
TubulÃ¤re Phosphatreabsorption*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Toxicity liver
Bilirubin*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
S-GOT/S-GPT*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Toxicity cardiac
Herzfunktion*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
ECHO: LV-SF*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Toxicity neurological
Zentrale NeurotoxizitÃ¤t*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
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Ewing Study Toxicity
KrampfanfÃ¤lle*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Periphere NeurotoxizitÃ¤t*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Toxicity other
Andere ToxizitÃ¤t aufgetreten*
Nein (0)
Ja (1)
Toxicity other
Beschreibung andere ToxizitÃ¤t*
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Ewing Study Event date
EWING 2008, EudraCT 2008-003658-13,
http://clinicaltrials.gov/ct2/show/NCT00824083
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Event date
Event date
Event-Datum*
Datum der Dokumentation*
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Syndromes(MDS) and Juvenile Myelomonocytic Leukemia
(JMML) in childhood. PI: Prof. Dr. Charlotte Niemeyer
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Basic registration data
Study participation
Datum der Dokumentation*
Teilnahme*
Einwilligung gegeben*
Nein (1)
Ja (2)
Bemerkungen
Patient transfer
Studien-ID neu
Studien-ID
Marvin-ID*
Identification numbers
GPOH PID
UPN*
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EWOG MDS 2006 MDS clinical features at
diagnosis
Prospective non–randomized multi_center study for
epidemiology and characterization of Myelodysplastic
Syndromes(MDS) and Juvenile Myelomonocytic Leukemia
(JMML) in childhood. PI: Prof. Dr. Charlotte Niemeyer
http://clinicaltrials.gov/ct2/show/NCT00662090
http://www.ewog-mds.org/
All rights reserved. Please visit https://medical-data-
models.org/forms/5309
MDS clinical features at diagnosis
Show identification of patient
Dummy
Clinical features
Fatigue*
Nein (1)
Ja (2)
Fieber > 38°C*
Nein (1)
Ja (2)
Aktive Infektion*
Nein (1)
Ja (2)
Respiratorische Symptome*
Nein (1)
Ja (2)
Blutung*
Nein (1)
Ja (2)
Hautausschlag*
Nein (1)
Ja (2)
Lymphknoten > 1,5cm*
Nein (1)
Ja (2)
VergrÃ¶ÃŸerte Tonsillen*
Nein (1)
Ja (2)
Chlorom*
Nein (1)
Ja (2)
Diabetes insipidus*
Nein (1)
Ja (2)
Blasten im Liquor*
Nein (1)
Ja (2)
Andere Symptome*
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Nein (1)
Ja (2)
Hepatomegalie*
Nein (1)
Ja (2)
Splenomegalie*
Nein (1)
Ja (2)
Bleeding site
Lokalisation der Blutung*
Schleimhautblutung (1)
Intrakraniell (2)
Beides (Schleimhautblutung und
Intrakraniell) (3)
Hautblutung (Petechien und Hämatome)
(4)
Andere (99)
Sonstige Lokalisation der Blutung*
Skin rash site
Lokalisation des Hautausschlags*
Chloroma site
Lokalisation des Chloroms*
Number of blasts
Anzahl der Blasten*
Type of other symptoms
Art der anderen Symptome*
Liver size below costal margin
Tastbare LebergrÃ¶ÃŸe unter Rippenbogen (in
cm)*
Spleen size below costal margin
Tastbare MilzgrÃ¶ÃŸe unter Rippenbogen (in
cm)*
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Prospective non–randomized multi_center study for
epidemiology and characterization of Myelodysplastic
Syndromes(MDS) and Juvenile Myelomonocytic Leukemia
(JMML) in childhood. PI: Prof. Dr. Charlotte Niemeyer
http://clinicaltrials.gov/ct2/show/NCT00662090
http://www.ewog-mds.org/
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MDS basic data
Personal data
Vorname*
Nachname*
Geburtsname
Initialen*
Geburtsdatum*
Geschlecht*
Männlich (1)
Weiblich (2)
Dokumentierendes Zentrum
Date of diagnosis
Diagnosedatum*
MDS basic data
Grund der Vorstellung*
Krankheitssymptome (1)
Vorsorgeuntersuchung (2)
Zufallsfund (3)
Datum der ersten Symptome*
MDS diagnosis
MDS Diagnose*
MDR-AML (40)
RC (41)
RARS (42)
RAEB (43)
RAEB-T (44)
JMML (45)
CMML (46)
Noonan Syn. + JMML ähnliches Bild (47)
Hypereosinophiles Syndrom (50)
Myelofibrotisches MDS (60)
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MDS, nicht klassifiziert (99)
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EWOG MDS 2006 Previous history
Prospective non–randomized multi_center study for
epidemiology and characterization of Myelodysplastic
Syndromes(MDS) and Juvenile Myelomonocytic Leukemia
(JMML) in childhood. PI: Prof. Dr. Charlotte Niemeyer
http://clinicaltrials.gov/ct2/show/NCT00662090
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Previous history
Show identification of patient
Dummy
Previous history
Xanthom*
Nein (1)
Ja (2)
Café-au-lait-Flecken*
Nein (1)
Ja (2)
Andere NF1 Symptome*
Nein (1)
Ja (2)
Verwandte 1. Grades mit NF1*
Nein (1)
Ja (2)
Vorhergehendes angeborenes
Knochenmarkversagen*
Nein (1)
Ja (2)
Vorhergehendes erworbenes
Knochenmarkversagen*
Nein (1)
Ja (2)
Maligne Vorerkrankung*
Nein (1)
Ja (2)
Vorhergehende Chemo-Strahlentherapie*
Nein (1)
Ja (2)
Mentale Retardierung*
Nein (1)
Ja (2)
Geburtsgewicht < dritte Perzentile*
Nein (1)
Ja (2)
Größe < dritte Perzentile (bei Diagnose)*
Nein (1)
Ja (2)
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Gewicht < dritte Perzentile (bei Diagnose)*
Nein (1)
Ja (2)
Kopfumfang < dritte Perzentile (bei Diagnose)*
Nein (1)
Ja (2)
Klinische Zeichen für PNH*
Nein (1)
Ja (2)
Hepatitis/Hepatopathie*
Nein (1)
Ja (2)
Patient ist Zwilling*
Nein (1)
Ja (2)
Angeborene Auffälligkeiten*
Nein (1)
Ja (2)
Sonstige Auffälligkeiten*
Nein (1)
Ja (2)
Anzahl der Café-au-lait-Flecken
Anzahl der Café-au-lait-Flecken*
1 (1)
> (10)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
7 (7)
8 (8)
9 (9)
Type of other NF1 Symptoms
Neurofibrom jeglicher Art*
Nein (1)
Ja (2)
Plexiformes Neurofibrom*
Nein (1)
Ja (2)
Freckling im Achsel- oder Leistenbereich*
Nein (1)
Ja (2)
Optikusgliom*
Nein (1)
Ja (2)
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>= 2 Lisch-Knötchen*
Nein (1)
Ja (2)
Knochenläsionen in Verbindung mit NF1*
Nein (1)
Ja (2)
Degree of relationship of NF1 relatives
Mutter*
Nein (1)
Ja (2)
Vater*
Nein (1)
Ja (2)
Schwester*
Nein (1)
Ja (2)
Bruder*
Nein (1)
Ja (2)
Sonstige Verwandte*
Nein (1)
Ja (2)
Type of previous cBMF
Art des vorhergehenden angeborenen
Knochenmarkversagens*
Shwachman Diamond Syndrom (1)
Schwere kongenitale Neutropenie (2)
Diamond Blackfan Anämie (DBA) (3)
Angeborene sideroblastische Anämie (4)
Fanconi Anämie (5)
Dyskeratosis congenita (6)
Andere (99)
Andere Art des angeborenen
Knochenmarkversagens*
Date and type of acquired BMF
Datum des vorhergehenden erworbenen
Knochenmarkversagens*
Art des vorhergehenden angeborenen
Knochenmarkversagens*
SAA (1)
Andere (99)
Andere Art des vorhergehenden angeborenen
Knochenmarkversagens*
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Date and type of previous malignancy
Datum der malignen Vorerkrankung*
Typ der malignen Vorerkrankung*
ALL (1)
AML (2)
NHL (3)
Ewing Sarkom (4)
Medulloblastom (5)
Neuroblastom (6)
Sonstige (99)
Andere Art der vorhergehenden malignen
Erkrankung*
Type of previous chemo therapy
Art der Chemotherapie*
Art der Strahlentherapie*
Art der angeborenen Auffälligkeit
Art der angeborenen Auffälligkeit*
Art der sonstigen Auffälligkeiten
Art der sonstigen Auffälligkeiten*
Type of twin
Art des Zwillings*
Eineiig (1)
Zweieiig (2)
Family history
Eltern sind konsanguin*
Nein (1)
Ja (2)
Maligne Erkrankungen in der Familie (Verwandte
ersten Grades)*
Nein (1)
Ja (2)
Hämato-/immunologische Erkrankungen*
Nein (1)
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Ja (2)
Weitere mögliche relevante Erkrankungen*
Nein (1)
Ja (2)
Family history of malignancies
Mutter*
Nein (1)
Ja (2)
Vater*
Nein (1)
Ja (2)
Schwester*
Nein (1)
Ja (2)
Bruder*
Nein (1)
Ja (2)
Mother affected
Erkrankung der Mutter*
Father affected
Erkrankung des Vaters*
Sister affected
Erkrankung der Schwester*
Brother affected
Erkrankung des Bruders*
Hemato/Immunological diseases in the
family
Typ der hämato-/immunologischen Erkrankung*
Type of other diseases in the family
Art der anderen möglicherweise relevanten
Erkrankungen*
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Prospective non–randomized multi_center study for
epidemiology and characterization of Myelodysplastic
Syndromes(MDS) and Juvenile Myelomonocytic Leukemia
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Laboratory data
Show identification of patient
Dummy
Chemistry
HbA2 Wert*
HbF Wert*
IgA Wert*
IgM Wert*
IgG Wert*
Ferritin Wert*
Coombs test
Direkt*
Negativ (1)
Positiv (2)
Indirekt*
Negativ (1)
Positiv (2)
LDH erhÃ¶ht*
Nein (1)
Ja (2)
HarnsÃ¤ure erhÃ¶ht*
Nein (1)
Ja (2)
HLA Type
HLA-A Allel 1*
HLA-A Allel 2*
HLA-B Allel 1*
1 / 4
HLA-B Allel 2*
HLA-C Allel 1*
HLA-C Allel 2*
HLA-DRB1 Allel 1*
HLA-DRB1 Allel 2*
HLA-DQB1 Allel 1*
HLA-DQB1 Allel 2*
HLA-DPB1 Allel 1*
HLA-DPB1 Allel 2*
Analysis to exclude Shwachman Diamond
Syndrome
Trypsinogen im Serum*
Normal (1)
Abormal (2)
Isoamylase im Serum*
Normal (1)
Abormal (2)
Mutation im SBDS-Gen*
Nein (1)
Ja (2)
Elastase im Stuhl*
Normal (1)
Abormal (2)
Wert*
Einheit*
Markers of infection
EBV-VCA IgG*
Negativ (1)
Positiv (2)
EBV-VCA IgM*
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Negativ (1)
Positiv (2)
EBV-EA IgG*
Negativ (1)
Positiv (2)
EBV EBNA IgG*
Negativ (1)
Positiv (2)
EBV PCR*
Negativ (1)
Positiv (2)
HSV IgG*
Negativ (1)
Positiv (2)
HSV IgM*
Negativ (1)
Positiv (2)
Anti HBs*
Negativ (1)
Positiv (2)
Anti HBc*
Negativ (1)
Positiv (2)
HBs Ag*
Negativ (1)
Positiv (2)
HIV IgG*
Negativ (1)
Positiv (2)
HIV PCR*
Negativ (1)
Positiv (2)
CMV IgG*
Negativ (1)
Positiv (2)
CMV IgM*
Negativ (1)
Positiv (2)
CMV PCR*
Negativ (1)
Positiv (2)
HHV6 IgG*
Negativ (1)
Positiv (2)
HHV6 IgM*
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Negativ (1)
Positiv (2)
HHV6 PCR*
Negativ (1)
Positiv (2)
Parvovirus B 19 IgG*
Negativ (1)
Positiv (2)
Parvovirus B 19 IgM*
Negativ (1)
Positiv (2)
Parvovirus B 19 PCR*
Negativ (1)
Positiv (2)
HCV IgG*
Negativ (1)
Positiv (2)
HCV IgM*
Negativ (1)
Positiv (2)
HCV PCR*
Negativ (1)
Positiv (2)
Fanconi anemia
Analyse-Ergebnis*
Negativ (1)
Positiv (2)
Ausstehend (3)
4 / 4
EWOG MDS 2006 Laboratory data
EWOG MDS 2006 Therapy for MDS prior to
diagnosis of MDS
Prospective non–randomized multi_center study for
epidemiology and characterization of Myelodysplastic
Syndromes(MDS) and Juvenile Myelomonocytic Leukemia
(JMML) in childhood. PI: Prof. Dr. Charlotte Niemeyer
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Therapy for MDS prior to diagnosis
of MDS
Show identification of patient
Dummy
Therapy for MDS prior to diagnosis of
MDS
Vorhergehende Therapie*
Nein (1)
Ja (2)
Art der Therapie*
Chemo vor Diagnose (1)
Steroid (2)
G-CSF (3)
Erythropoietin (4)
Andere hämatopoetische
Wachstumsfaktoren (5)
IVIG (6)
Andere (99)
Sonstige Art der Therapie*
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EWOG MDS 2006 Study centre specific
variables
Prospective non–randomized multi_center study for
epidemiology and characterization of Myelodysplastic
Syndromes(MDS) and Juvenile Myelomonocytic Leukemia
(JMML) in childhood. PI: Prof. Dr. Charlotte Niemeyer
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Study centre specific variables
Show identification of patient
Dummy
Study centre specific variables
FamiliÃ¤re Erkrankung*
Nein (1)
Ja (2)
MDS Diagnose*
MDR-AML (40)
RC (41)
RARS (42)
RAEB (43)
RAEB-T (44)
JMML (45)
CMML (46)
Noonan Syn. + JMML ähnliches Bild (47)
Hypereosinophiles Syndrom (50)
Myelofibrotisches MDS (60)
MDS, nicht klassifiziert (99)
CSC ZellularitÃ¤t*
Ohne (1)
Vermindert (2)
Normal (3)
Erhöht (4)
Kommentar
SekundÃ¤r*
Nein (1)
Ja (2)
Status in der Studie*
EWOG MDS retrospektiv (1)
Studienpatient 98 (2)
Protokollpatient 98 (3)
Patient eines nicht-EWOG Landes (4)
Studienpatient 06 (5)
Protokollpatient 06 (6)
Zusammenfassender Kary-Code Datum*
Zusammenfassender Kary-Code 1*
Kein Ergebnis (0)
Normal bzgl. Metaphasen Zytogenetik
(1)
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Normal für 7+8 by FISH (40)
-7 by FISH (41)
+8 by FISH (42)
Other abn by FISH (43)
-7 alone (51)
-7 +add (52)
7q- alone (53)
7q- +add (54)
-7 unclear (55)
+8 alone (57)
+8 +add (58)
Random aberration (99)
Zusammenfassender Kary-Code 2
komplex 3 oder 4 Abberationen (35)
komplex>4 Abberationen (36)
EWOG komplex (37)
Chemotherapie/ATG vor HSCT*
Nein (1)
Ja (2)
GM-CSF HypersensitivitÃ¤t*
Nein (1)
Ja (2)
Secondary class
Klasse*
Chemo/Bestrahlungstherapie (1)
Erworbene AA (aplastische Anämie) (2)
Angeborenes KM Versagen (3)
Konstitutionelle +21 (4)
Andere konst. chromosomale Aberration
(5)
Autoimmunerkrankung (6)
Andere vorhergehende Erkrankung (99)
Weitere*
Chemo therapy/atg prior HSCT
Datum*
Typ*
CTX (1)
ATG (2)
GM-CSF hypersensitivity
Labor*
Resultat*
Negativ (1)
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Positiv (2)
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EWOG MDS 2006 Registration Form for
BM Histology
Prospective non–randomized multi_center study for
epidemiology and characterization of Myelodysplastic
Syndromes(MDS) and Juvenile Myelomonocytic Leukemia
(JMML) in childhood. PI: Prof. Dr. Charlotte Niemeyer
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Registration Form for BM Histology
Show identification of patient
Dummy
Bone marrow biopsy basic data
Reportnummer*
Datum der Knochenmarkbiopsie*
Referenzzentrum*
Referenzpathologie, nicht weiter
spezifiziert (1)
Kerndrup (Vejle) (10)
Hernandez (Valencia) (11)
Simonitsch-Klupp (Wien) (2)
De Paepe (Ghent) (3)
Campr (Prag) (4)
Baumann (Böblingen) (5)
Schwarz-Furlan (Kaufbeuren) (6)
O´Sullivan (Dublin) (7)
Devito (Rom) (8)
Leguit (Utrecht) (9)
Anderes (99)
MaÃŸ der Knochenmarkbiopsie 1*
MaÃŸ der Knochenmarkbiopsie 2*
Fixierung*
Nein (1)
Ja (2)
Dekalzifizierung*
EDTA (1)
Methansäure (2)
QualitÃ¤t der Knochenmarkbiopsie*
OK (1)
Ungenügend (2)
Nicht auswertbar (3)
Other center
Sonstiges Zentrum*
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Type of fixation
Art der Fixierung*
Formaldehyd 4-5% (1)
Andere (99)
Andere Art der Fixierung*
Cellularity
Gesamt*
Ohne (1)
Vermindert (2)
Normal (3)
Erhöht (4)
Granulopoese*
Ohne (1)
Vermindert (2)
Normal (3)
Erhöht (4)
Erythropoese*
Ohne (1)
Vermindert (2)
Normal (3)
Erhöht (4)
Megakaryopoese*
Ohne (1)
Vermindert (2)
Normal (3)
Erhöht (4)
Megakaryopoese immunohystochemisch
nachgewiesen*
Nein (1)
Ja (2)
FleckfÃ¶rmige Stellen - Erythropoese*
Nein (1)
Ja (2)
FleckfÃ¶rmige Stellen - Granulopoese*
Nein (1)
Ja (2)
Fettgewebe von*
Fettgewebe bis*
Fe*
Keins (1)
Niedrig (2)
Normal (3)
Hoch (4)
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Maturation defects
Erythropoese - ausreifend*
Nein (1)
Ja (2)
Erythropoese - linksverschoben*
Nein (1)
Ja (2)
Erythropoese - vermehrte Mitosen*
Nein (1)
Ja (2)
Granulopoese - ausreifend*
Nein (1)
Ja (2)
Granulopoese - linksverschoben*
Nein (1)
Ja (2)
Megakaryopoese - Mikromegakaryozyten*
Nein (1)
Ja (2)
Megakaryopoese - Andere Dysplasien*
Nein (1)
Ja (2)
Myelofibrosis
Myelofibrose*
Nein (1)
Ja (2)
Art der Myelofibrose*
Schwach (1)
Moderat (2)
Schwerwiegend (3)
Fleckige Myelofibrose*
Nein (1)
Ja (2)
Blasts
Prozent an Blasten*
< 5% (1)
5-9% (2)
10-19% (3)
20-29% (4)
30-50% (5)
> 50% (6)
Blastenverteilung*
Fokal (1)
Diffus (2)
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Immunophenotyp der Blasten*
Nein (1)
Ja (2)
Immunophenotyp angeben*
Negativ (1)
CD 34 pos. (2)
Anderer (99)
Anderer Immunophenotyp*
Diagnosis
Diagnose*
Aplasie (20)
MDR-AML (40)
RC (41)
RARS (42)
RAEB (43)
RAEB-t (44)
JMML (45)
Myelofibrotisches MDS (60)
Andere (99)
Andere Diagnose*
Other features of diagnosis
PB Blutausstrich fÃ¼r ÃœberprÃ¼fung der
Biopsy vorhanden*
Nein (1)
Ja (2)
Knochenmarkaspirat fÃ¼r ÃœberprÃ¼fung der
Biopsy vorhanden*
Nein (1)
Ja (2)
Kommentar
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PNH
Show identification of patient
Dummy
PNH sample
Datum der PNH*
Labor*
Rotterdam (1)
Ulm (2)
Freiburg (3)
Anderes (99)
Anderes PNH Labor angeben*
Art der Probe*
PB (1)
KM (2)
Anderes (99)
Andere Art der Probe angeben*
PNH results (flow cytometry)
Granulozyten total*
Granulozyten unterhalb der Messgrenze*
Nein (1)
Ja (2)
Monozyten total*
Monozyten unterhalb der Messgrenze*
Nein (1)
Ja (2)
Erythrozyten total*
Erythrozyten unterhalb der Messgrenze*
Nein (1)
Ja (2)
Kommentar
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MDS Morphology
Show identification of patient
Dummy
Peripheral blood
Abnahmedatum des peripheren Bluts*
Anisopoikiliozytose*
Nein (1)
Ja (2)
Schistozyten*
Nein (1)
Ja (2)
TrÃ¤nenformen*
Nein (1)
Ja (2)
Makrozytose*
Nein (1)
Ja (2)
Pseudo-Pelger Zellen*
Nein (1)
Ja (2)
Riesenthrombozyten*
Nein (1)
Ja (2)
Bone marrow
Datum der KM Aspiration*
Histozyten > 1%*
Nein (1)
Ja (2)
Erythropoieses
Erythropoese fehlend*
Nein (1)
Ja (2)
1 / 3
Erythropoieses detail
Dyserythropoese*
Ausbleibend (<1%) (1)
Leicht (1-10%) (2)
Mittelgradig (11-50%) (3)
Schwer (>50%) (4)
KernbrÃ¼cken*
Nein (1)
Ja (2)
Kernlobulierung*
Nein (1)
Ja (2)
Mehrkernigkeit*
Nein (1)
Ja (2)
Zytoplasmatische Granula*
Nein (1)
Ja (2)
Megaloblastische VerÃ¤nderungen*
Nein (1)
Ja (2)
Myelopoiesis
Myelopoese fehlend*
Nein (1)
Ja (2)
Myelopoiesis detail
Dysmyelopoese*
Ausbleibend (<1%) (1)
Leicht (1-10%) (2)
Mittelgradig (11-50%) (3)
Schwer (>50%) (4)
Hypo-agranulÃ¤re Zellen*
Nein (1)
Ja (2)
N/C AsynchronitÃ¤t*
Nein (1)
Ja (2)
Abnormale Granula*
Nein (1)
Ja (2)
Pseudo-Pelger Zellen*
Nein (1)
Ja (2)
Chromatinverklumpung*
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Nein (1)
Ja (2)
MPO Defizit*
Nein (1)
Ja (2)
Megakaryopoiesis
Megakaryopoese fehlend*
Nein (1)
Ja (2)
Megakaryopoiesis detail
Dysmegakaryopoese*
Ausbleibend (<1%) (1)
Leicht (1-10%) (2)
Mittelgradig (11-50%) (3)
Schwer (>50%) (4)
Separierte einzelne Kerne*
Nein (1)
Ja (2)
Micromegakaryozyten*
Nein (1)
Ja (2)
Kleine zweikernige Kerne*
Nein (1)
Ja (2)
Runde, nicht lobulierte Zellen*
Nein (1)
Ja (2)
3 / 3
EWOG MDS 2006 MDS Morphology
EWOG MDS 2006 Basic data
Prospective non–randomized multi_center study for
epidemiology and characterization of Myelodysplastic
Syndromes(MDS) and Juvenile Myelomonocytic Leukemia
(JMML) in childhood. PI: Prof. Dr. Charlotte Niemeyer
http://clinicaltrials.gov/ct2/show/NCT00662090
http://www.ewog-mds.org/
All rights reserved. Please visit https://medical-data-
models.org/forms/5321
Basic data
Show identification of patient
Dummy
Molecular genetics basic data
Interne Labornummer*
Datum der Materialentnahme*
Analysezentrum*
Freiburg (1)
Pavia (2)
Anderes (99)
Anderes Analysezentrum*
Ausgewertetes Gewebe*
PB (1)
KM (2)
Anderes (99)
PTPN11-Mutation*
Nein (1)
Ja (2)
RAS-Mutation*
Nein (1)
Ja (2)
CBL-Mutation*
Nein (1)
Ja (2)
Other type of tissue
Andere Gewebeart*
Examined cells and nucleic acid
Ausgewertete NukleinsÃ¤ure*
RNA (1)
DNA (2)
Ausgewertete Zellen*
1 / 6
MNC (1)
Ficollrest (2)
unfraktioniert (3)
Anderes (99)
Sonstige ausgewertete Zellen*
PTPN11
Exon 3 Resultat*
Negativ (1)
Positiv (2)
Exon 13 Resultat*
Negativ (1)
Positiv (2)
Andere PTPN11-Mutation*
Nein (1)
Ja (2)
PTPN11-Mutation*
Keimbahnmutation*
Negativ (1)
Positiv (2)
Benutztes Material zum Nachweis einer
Keimbahnmutation*
Mundschleimhautabstrich (1)
Fibroblasten (2)
Haar (3)
Fingernagel (4)
Anderes (99)
Sonstiges Material*
PTPN11 exon 3 details
DNA Mutation im Exon 3*
Protein 1 im Exon 3*
Protein 2 im Exon 3*
Protein 3 im Exon 3*
PTPN11 Exon 13 details
DNA Mutation im Exon 13*
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Protein 1 im Exon 13*
Protein 2 im Exon 13*
Protein 3 im Exon 13*
RAS
KRAS Mutation im Exon 1*
Negativ (1)
Positiv (2)
KRAS Mutation im Exon 2*
Negativ (1)
Positiv (2)
NRAS Mutation im Exon 1*
Negativ (1)
Positiv (2)
NRAS Mutation im Exon 2*
Negativ (1)
Positiv (2)
Keimbahnmutation*
Negativ (1)
Positiv (2)
Benutztes Material zum Nachweis einer
Keimbahnmutation*
Mundschleimhautabstrich (1)
Fibroblasten (2)
Haar (3)
Fingernagel (4)
Anderes (99)
Sonstiges Material*
KRAS exon 1
DNA Mutation im KRAS Exon 1*
Protein 1 im KRAS Exon 1*
Protein 2 im KRAS Exon 1*
Protein 3 im KRAS Exon 1*
KRAS exon 2
3 / 6
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DNA Mutation im KRAS Exon 2*
Protein 1 im KRAS Exon 2*
Protein 2 im KRAS Exon 2*
Protein 3 im KRAS Exon 2*
NRAS exon 1
DNA Mutation im NRAS Exon 1*
Protein 1 im NRAS Exon 1*
Protein 2 im NRAS Exon 1*
Protein 3 im NRAS Exon 1*
NRAS exon 2
DNA Mutation im NRAS Exon 2*
Protein 1 im NRAS Exon 2*
Protein 2 im NRAS Exon 2*
Protein 3 im NRAS Exon 2*
CBL
CBL Mutation im Exon 8*
Negativ (1)
Positiv (2)
CBL Mutation im Exon 9*
Negativ (1)
Positiv (2)
Keimbahnmutation*
Negativ (1)
Positiv (2)
Benutztes Material zum Nachweis einer
Keimbahnmutation*
Mundschleimhautabstrich (1)
Fibroblasten (2)
Haar (3)
Fingernagel (4)
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Anderes (99)
Sonstiges Material*
CBL exon 8 details
Erste DNA Mutation im Exon 8*
Zweite DNA Mutation im Exon 8*
Protein 1 im CBL Exon 8*
Protein 2 im CBL Exon 8*
Protein 3 im CBL Exon 8*
CBL exon 9 details
Erste DNA Mutation im Exon 9*
Zweite DNA Mutation im Exon 9*
Protein 1 im CBL Exon 9*
Protein 2 im CBL Exon 9*
Protein 3 im CBL Exon 9*
Study centre specific data
DHPLC*
Negativ (1)
Positiv (2)
PTPN11 mehrdeutiger Spitzenwert*
Normaler Klon (1)
Kleiner Klon (2)
RAS mehrdeutiger Spitzenwert*
Normaler Klon (1)
Kleiner Klon (2)
CBL mehrdeutiger Spitzenwert*
Normaler Klon (1)
Kleiner Klon (2)
PTP Zygotie*
Homozygot (1)
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Heterozygot (2)
RAS Zygotie*
Homozygot (1)
Heterozygot (2)
CBL Zygotie*
Homozygot (1)
Heterozygot (2)
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Karyotype
Show identification of patient
Dummy
Basic data
Datum der Materialentnahme*
Knochenmark Metaphasen Zytogenetik
untersucht?*
Nein (1)
Ja (2)
Peripheres Blut Metaphasen Zytogenetik
untersucht?*
Nein (1)
Ja (2)
FISH untersucht?*
Nein (1)
Ja (2)
Referenzlabor*
Schlegelberger (Hannover) (1)
Cervera (Valencia) (10)
Schaefer (Zürich) (11)
Kroemer (Wien) (2)
Van Roy (Ghent) (3)
Michalova (Prag) (4)
Betts (Dublin) (6)
Sainati (Padova) (7)
Beverloo (Rotterdam) (8)
Kerndrup (Vejle) (9)
Anderes (99)
Anderes Labor*
Bonemarrow
ISCN Code*
Peripheral blood
ISCN Code*
1 / 3
FISH
ISCN Code*
Study centre specific variables
Kary Code 1*
Kein Ergebnis (0)
Normal bzgl. Metaphasen Zytogenetik
(1)
Normal für 7+8 by FISH (40)
-7 by FISH (41)
+8 by FISH (42)
Other abn by FISH (43)
-7 alone (51)
-7 +add (52)
7q- alone (53)
7q- +add (54)
-7 unclear (55)
+8 alone (57)
+8 +add (58)
Random aberration (99)
Kary Code 2
komplex 3 oder 4 Abberationen (35)
komplex>4 Abberationen (36)
EWOG komplex (37)
Gesamtanzahl der analysierten Metaphasen*
Gesamtanzahl der abnormalen Metaphasen*
UnabhÃ¤ngige Klone*
Nein (1)
Ja (2)
Ausgeglichen oder unausgeglichen*
Balanced (1)
Unbalanced (2)
Klonale Evolution*
Nein (1)
Ja (2)
FISH Code 1*
Kein Ergebnis (0)
Normal für 7 und 8 (40)
-7 (41)
+8 (42)
Anderer (99)
FISH Code 2
Kein Ergebnis (0)
Normal für 7 und 8 (40)
-7 (41)
+8 (42)
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Anderer (99)
Kommentar
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Syndromes(MDS) and Juvenile Myelomonocytic Leukemia
(JMML) in childhood. PI: Prof. Dr. Charlotte Niemeyer
http://clinicaltrials.gov/ct2/show/NCT00662090
http://www.ewog-mds.org/
All rights reserved. Please visit https://medical-data-
models.org/forms/5323
Therapy
Show identification of patient
Dummy
Therapy
Art der Therapie*
Nur Beobachtung (1)
AML Therapie (2)
Chemotherapie (nicht AML / IST) (3)
Splenektomie (4)
Andere (99)
Beginn*
Ende*
Type of protocol
Protokoll*
Anderes Protokoll*
Single drugs
Einzelne Medikamente*
5 Azacyticline (VIDAZA) (201)
6-MP (202)
alpha-Interferon (203)
ARA-C (204)
Busulfan (205)
Cyclosporin A (206)
Daunoxome (207)
Dexamethason (208)
Hydroxyurea (209)
Idarubicin (210)
Mitoxantron (211)
Rituximab (213)
Roacutan (214)
Steroids (215)
Thioguanin (216)
VP-16 (217)
Andere (99)
Andere Medikamente*
1 / 2
Dosis + Einheit / Tag*
Type of steroids
Art der Steroide*
Dexamethason (1)
Prednison (2)
Anderes (99)
Anderes Steroid*
Other type of therapy
Andere Art der Therapie angeben*
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EWOG MDS 2006 Follow-up
Prospective non–randomized multi_center study for
epidemiology and characterization of Myelodysplastic
Syndromes(MDS) and Juvenile Myelomonocytic Leukemia
(JMML) in childhood. PI: Prof. Dr. Charlotte Niemeyer
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Follow-up
Show identification of patient
Dummy
Follow-up
Datum des letzten Besuchs/der letzten
Untersuchung*
Krankheitsstatus*
Komplette Remission (1)
Am Leben mit Krankheit (2)
Genereller Status*
Gut (1)
Schlecht (2)
Ã„nderung des verantwortlichen Zentrums*
Nein (1)
Ja (2)
Verantwortliches Zentrum*
1 / 1
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Patient deceased
Show identification of patient
Dummy
Patient deceased
Todesdatum*
Todesursache*
Grunderkrankung: Rezidiv, Progression
oder Persistenz (1)
HSZT-bezogene Ursache (2)
Anderer Grund (99)
Andere Todesursache*
HSCT related cause(s) of death
GvHD*
Nein (1)
Ja (2)
Transplantatversagen*
Nein (1)
Ja (2)
Pulmonale ToxizitÃ¤t*
Nein (1)
Ja (2)
Kardiologische ToxizitÃ¤t*
Nein (1)
Ja (2)
Infektion*
Nein (1)
Ja (2)
VOD*
Nein (1)
Ja (2)
Lymphoproliferative Erkrankung (PTLD)*
Nein (1)
Ja (2)
Andere HSZT-bezogene Ursache*
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Nein (1)
Ja (2)
HSZT-bezogene Ursache*
MDS specific
Todesursache (MDS spezifisch)*
Rezidiv (1)
Progress der Erkrankung (2)
Vorerkrankung (vor MDS/JMML) (3)
Sekundärmalignom nach MDS/JMML (4)
Anderes (99)
Andere Todesursache (MDS spezifisch)*
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Lost to follow-up
Show identification of patient
Dummy
Lost to follow-up
Grund fÃ¼r lost to follow-up*
Datum lost to follow-up*
1 / 1
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Secondary malignancy
Show identification of patient
Dummy
Secondary malignancy
Diagnosedatum*
Beschreibung/Diagnose*
1 / 1
EWOG MDS 2006 BM Histology (regional
coordinator)
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Syndromes(MDS) and Juvenile Myelomonocytic Leukemia
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BM Histology (regional coordinator)
Show identification of patient
Dummy
Bone marrow biopsy basic data
Datum der Knochenmarkbiopsie*
Befundendes Labor*
Referenzpathologie, nicht weiter
spezifiziert (1)
Kerndrup (Vejle) (10)
Hernandez (Valencia) (11)
Simonitsch-Klupp (Wien) (2)
De Paepe (Ghent) (3)
Campr (Prag) (4)
Baumann (Boeblingen) (5)
Schwarz-Furlan (Kaufbeuren) (6)
O´Sullivan (Dublin) (7)
Devito (Rom) (8)
Leguit (Utrecht) (9)
Anderes (99)
Anderes Labor*
Quality
QualitÃ¤t der Knochenmarkbiopsie*
OK (1)
Ungenügend (2)
Nicht auswertbar (3)
Cellularity
Gesamt*
Ohne (1)
Vermindert (2)
Normal (3)
Erhöht (4)
Myelofibrosis
Myelofibrose*
Nein (1)
Ja (2)
1 / 2
Art der Myelofibrose*
Schwach (1)
Moderat (2)
Schwerwiegend (3)
Blasts
Prozent an Blasten*
< 5% (1)
5-9% (2)
10-19% (3)
20-29% (4)
30-50% (5)
> 50% (6)
Diagnosis
Diagnose*
Aplasie (20)
MDR-AML (40)
RC (41)
RARS (42)
RAEB (43)
RAEB-t (44)
JMML (45)
Myelofibrotisches MDS (60)
Andere (99)
Andere Diagnose*
2 / 2
EWOG MDS 2006 BM Histology (regional coordinator)
EWOG MDS 2006 Blood count before start
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Blood count before start of IST
Show identification of patient
Dummy
Blood Count
RegelmÃ¤ÃŸige Erythrozytentransfusionen
notwendig*
Nein (1)
Ja (2)
RegelmÃ¤ÃŸige Thrombozytentransfusionen
notwendig*
Nein (1)
Ja (2)
Granulozytentransfusion notwendig*
Nein (1)
Ja (2)
Leukozyten*
Neutrophile*
Hb Wert*
Erythrozyten*
MCV*
Retikulozyten*
Thrombozyten*
Niedrigstes ANC vor Beginn der IST*
1 / 1
EWOG MDS 2006 Immunosuppressive
Therapy
Prospective non–randomized multi_center study for
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Immunosuppressive Therapy
Show identification of patient
Dummy
Type of ATG
Art des ATG*
Thymoglobulin (Genzyme) (1)
ATG rabbit (Fresenius) (2)
ATGAM horse (Merieux) (3)
ATGAM horse (Pfizer) (4)
Andere (99)
Andere Art der ATG*
Day 1 to 8
Datum Tag 1*
Absolute Dosis Tag 1*
Dosis Tag 1*
Datum Tag 2*
Absolute Dosis Tag 2*
Dosis Tag 2*
Datum Tag 3*
Absolute Dosis Tag 3*
Dosis Tag 3*
Datum Tag 4*
Absolute Dosis Tag 4*
Dosis Tag 4*
1 / 3
Datum Tag 5*
Absolute Dosis Tag 5*
Dosis Tag 5*
Datum Tag 6
Absolute Dosis Tag 6
Dosis Tag 6
Datum Tag 7
Absolute Dosis Tag 7
Dosis Tag 7
Datum Tag 8
Absolute Dosis Tag 8
Dosis Tag 8
Steroids
Steroide*
Nein (1)
Ja (2)
Datum der ersten Dosis*
Datum der letzten Dosis*
Cyclosporin A
Datum der ersten Dosis*
G-CSF
G-CSF*
Nein (1)
Ja (2)
Datum der ersten Dosis*
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Maximale Dosis*
Ausschleichen*
Nein (1)
Ja (2)
Datum der ersten Reduktion*
Datum der letzten Dosis*
Gesamtdosis Tag 0-30*
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Status Day 30
Show identification of patient
Dummy
Complications - Infection
Infektion*
Nein (1)
Ja (2)
Bakteriell > CTCAE Grad 2*
Nein (1)
CTCAE Grad 3 (3)
CTCAE Grad 4 (4)
Bakterieller Organismus*
Fungal > CTCAE Grad 2*
Nein (1)
CTCAE Grad 3 (3)
CTCAE Grad 4 (4)
Fungaler Organismus*
ParasitÃ¤r > CTCAE Grad 2*
Nein (1)
CTCAE Grad 3 (3)
CTCAE Grad 4 (4)
ParasitÃ¤rer Organismus*
Viral > CTCAE Grad 2*
Nein (1)
CTCAE Grad 3 (3)
CTCAE Grad 4 (4)
Virus*
Unbekannt > CTCAE Grad 2*
Nein (1)
CTCAE Grad 3 (3)
CTCAE Grad 4 (4)
Organismus der unbekannten Infektion*
1 / 5
Complications - EBV PCR
EBV PCR durchgefÃ¼hrt*
Nein (1)
Ja (2)
EBV PCR Datum*
EBV PCR Wert*
Complications - EBV LPD
EBV LPD*
Nein (1)
Ja (2)
Complications - EBV LPD symptoms
Fieber*
Nein (1)
Ja (2)
Malaise*
Nein (1)
Ja (2)
Gewichtsverlust*
Nein (1)
Ja (2)
Complications - EBV LPD site
Mediastinale Lymphknoten*
Nein (1)
Ja (2)
Abdominale Lymphknoten*
Nein (1)
Ja (2)
Inguinale Lymphknoten*
Nein (1)
Ja (2)
AxilÃ¤re Lymphknoten*
Nein (1)
Ja (2)
Zervikale Lymphknoten*
Nein (1)
Ja (2)
Darm*
Nein (1)
Ja (2)
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Lunge*
Nein (1)
Ja (2)
Tonsillen*
Nein (1)
Ja (2)
Andere*
Nein (1)
Ja (2)
Andere Lokalisation*
Complications - EBV LPD treatment
Anti CD20 AntikÃ¶rper*
Nein (1)
Ja (2)
Virustatische Therapie*
Nein (1)
Ja (2)
Chemotherapie*
Nein (1)
Ja (2)
Steroide*
Nein (1)
Ja (2)
Reduktion der IST*
Nein (1)
Ja (2)
Ende der IST*
Nein (1)
Ja (2)
Andere*
Nein (1)
Ja (2)
Andere Art der Behandlung*
Complications - Hemorrhage
Blutung > CTCAE Grad 2*
Nein (1)
CTCAE Grad 3 (3)
CTCAE Grad 4 (4)
Complications - Renal/Metabolic Lab.,
Creatinine
3 / 5
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Niere/Stoffwechsel, Kreatinin > CTCAE Grad 2*
Nein (1)
CTCAE Grad 3 (3)
CTCAE Grad 4 (4)
HÃ¤modialyse oder HÃ¤mofiltration*
Nein (1)
Ja (2)
Fanconi-Syndrom*
Nein (1)
Ja (2)
Nephrotisches Syndrom*
Nein (1)
Ja (2)
Complications - Other type of complication
Andere Komplikation > CTCAE Grad 2*
Nein (1)
CTCAE Grad 3 (3)
CTCAE Grad 4 (4)
Art*
Transfusions
Weiterhin regelmÃ¤ÃŸige
Thrombozytentransfusionen notwendig*
Nein (1)
Ja (2)
Weiterhin regelmÃ¤ÃŸige
Erythrozytentransfusionen notwendig*
Nein (1)
Ja (2)
Transfusion PLT
Datum der letzten Transfusion*
Transfusion RBC
Datum der letzten Transfusion*
Complete blood count
Abnahmedatum des peripheren Bluts*
Erythrozyten*
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MCV*
Hb Wert*
Retikulozyten*
Leukozyten*
Absolute Neutrophilenanzahl (in /mmÂ³)*
Thrombozyten*
Study centre specific variables
CSC*
Komplette Remission Def.A (1)
Komplette Remission Def.B (2)
Gute Teilremission (3)
Schlechte Teilremission (4)
keine Remission (5)
Clonal evolution (6)
Rezidiv (7)
PNH Erkrankung (8)
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EWOG MDS 2006 IST FUP {0}
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IST FUP {0}
Show identification of patient
Dummy
IST FUP
Intervall*
Tag 31-60 (2)
Tag 61-90 (3)
Tag 91-120 (4)
Tag 121-180 (5)
Tag 181-240 (6)
Tag 241-270 (7)
Tag 271-360 (8)
Halbjährlich nach Jahr 1 (9)
HalbjÃ¤hrlich (Anzahl der Monate)*
Immunosuppressive Therapy - Steroids in
given interval
Steroide*
Nein (1)
Ja (2)
Indikation fÃ¼r Steroide*
Datum der letzten Dosis*
Immunosuppressive Therapy -
Cyclosporin A
Cyclosporin A fortlaufend*
Nein (1)
Ja (2)
Grund fÃ¼r das Absetzen von CSA*
CR (1)
NR (2)
Toxizität (3)
Anderer Grund (99)
Anderer Grund*
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Immunosuppressive Therapy -
Cyclosporin A
Cyclosporin A fortlaufend*
Nein (1)
Ja (2)
Cyclosporin A ausschleichend*
Nein (1)
Ja (2)
Datum der ersten Reduktion*
Cyclosporin A gestoppt*
Nein (1)
Ja (2)
Datum der letzten Dosis*
Grund fÃ¼r das Absetzen von CSA*
CR (1)
NR (2)
Toxizität (3)
Anderer Grund (99)
Anderer Grund*
Cyclosporin A erneut gestartet*
Nein (1)
Ja (2)
Datum des erneuten Starts*
Indikation fÃ¼r erneuten Start von CSA*
Immunosuppressive Therapy - G-CSF
G-CSF*
Nein (1)
Ja (2)
Ausschleichen*
Nein (1)
Ja (2)
Datum der ersten Reduktion*
Datum der letzten Dosis*
Gesamtdosis seit Tag 31*
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Complications - Infection
Infektion*
Nein (1)
Ja (2)
Bakteriell > CTCAE Grad 2*
Nein (1)
CTCAE Grad 3 (3)
CTCAE Grad 4 (4)
Bakterieller Organismus*
Fungal > CTCAE Grad 2*
Nein (1)
CTCAE Grad 3 (3)
CTCAE Grad 4 (4)
Fungaler Organismus*
ParasitÃ¤r > CTCAE Grad 2*
Nein (1)
CTCAE Grad 3 (3)
CTCAE Grad 4 (4)
ParasitÃ¤rer Organismus*
Viral > CTCAE Grad 2*
Nein (1)
CTCAE Grad 3 (3)
CTCAE Grad 4 (4)
Virus*
Unbekannt > CTCAE Grad 2*
Nein (1)
CTCAE Grad 3 (3)
CTCAE Grad 4 (4)
Organismus der unbekannten Infektion*
Complications - EBV PCR
EBV PCR durchgefÃ¼hrt*
Nein (1)
Ja (2)
EBV PCR Datum*
EBV PCR Wert*
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Complications - EBV LPD
EBV LPD*
Nein (1)
Ja (2)
Complications - EBV LPD symptoms
Fieber*
Nein (1)
Ja (2)
Malaise*
Nein (1)
Ja (2)
Gewichtsverlust*
Nein (1)
Ja (2)
Complications - EBV LPD site
Mediastinale Lymphknoten*
Nein (1)
Ja (2)
Abdominale Lymphknoten*
Nein (1)
Ja (2)
Inguinale Lymphknoten*
Nein (1)
Ja (2)
AxilÃ¤re Lymphknoten*
Nein (1)
Ja (2)
Zervikale Lymphknoten*
Nein (1)
Ja (2)
Darm*
Nein (1)
Ja (2)
Lunge*
Nein (1)
Ja (2)
Tonsillen*
Nein (1)
Ja (2)
Andere*
Nein (1)
Ja (2)
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Andere Lokalisation*
Complications - EBV LPD treatment
Anti CD20 AntikÃ¶rper*
Nein (1)
Ja (2)
Virustatische Therapie*
Nein (1)
Ja (2)
Chemotherapie*
Nein (1)
Ja (2)
Steroide*
Nein (1)
Ja (2)
Reduktion der IST*
Nein (1)
Ja (2)
Ende der IST*
Nein (1)
Ja (2)
Andere*
Nein (1)
Ja (2)
Andere Art der Behandlung*
Complications - Hemorrhage
Blutung > CTCAE Grad 2*
Nein (1)
CTCAE Grad 3 (3)
CTCAE Grad 4 (4)
Complications - Renal/Metabolic Lab.,
Creatinine
Niere/Stoffwechsel, Kreatinin > CTCAE Grad 2*
Nein (1)
CTCAE Grad 3 (3)
CTCAE Grad 4 (4)
HÃ¤modialyse oder HÃ¤mofiltration*
Nein (1)
Ja (2)
Fanconi-Syndrom*
Nein (1)
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Ja (2)
Nephrotisches Syndrom*
Nein (1)
Ja (2)
Complications - Other type of complication
Andere Komplikation > CTCAE Grad 2*
Nein (1)
CTCAE Grad 3 (3)
CTCAE Grad 4 (4)
Art*
Response - Transfusions
Weiterhin regelmÃ¤ÃŸige
Thrombozytentransfusionen notwendig*
Nein (1)
Ja (2)
Weiterhin regelmÃ¤ÃŸige
Erythrozytentransfusionen notwendig*
Nein (1)
Ja (2)
Response - Transfusion PLT
Datum der letzten Transfusion*
Response - Transfusion RBC
Datum der letzten Transfusion*
Response - Complete blood count
Abnahmedatum des peripheren Bluts*
Erythrozyten*
MCV*
Hb Wert*
Retikulozyten*
Leukozyten*
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Absolute Neutrophilenanzahl (in /mmÂ³)*
Thrombozyten*
Response
Ansprechen*
Vollständiges Ansprechen (1)
Teilweises Ansprechen (3)
Kein Ansprechen (4)
Klonale Evolution (5)
Rezidiv (6)
PNH Erkrankung (7)
Datum*
Study centre specific variables
CSC*
Komplette Remission Def.A (1)
Komplette Remission Def.B (2)
Gute Teilremission (3)
Schlechte Teilremission (4)
keine Remission (5)
Clonal evolution (6)
Rezidiv (7)
PNH Erkrankung (8)
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EWOG MDS 2006 Study centre specific
variables
Prospective non–randomized multi_center study for
epidemiology and characterization of Myelodysplastic
Syndromes(MDS) and Juvenile Myelomonocytic Leukemia
(JMML) in childhood. PI: Prof. Dr. Charlotte Niemeyer
http://clinicaltrials.gov/ct2/show/NCT00662090
http://www.ewog-mds.org/
All rights reserved. Please visit https://medical-data-
models.org/forms/5333
Study centre specific variables
Show identification of patient
Dummy
Study centre specific variables
CSC*
Komplette Remission Def.A (1)
Komplette Remission Def.B (2)
Gute Teilremission (3)
Schlechte Teilremission (4)
keine Remission (5)
Clonal evolution (6)
Rezidiv (7)
PNH Erkrankung (8)
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EWOG MDS 2006 Chimerism
Prospective non–randomized multi_center study for
epidemiology and characterization of Myelodysplastic
Syndromes(MDS) and Juvenile Myelomonocytic Leukemia
(JMML) in childhood. PI: Prof. Dr. Charlotte Niemeyer
http://clinicaltrials.gov/ct2/show/NCT00662090
http://www.ewog-mds.org/
All rights reserved. Please visit https://medical-data-
models.org/forms/5335
Chimerism
Show identification of patient
Dummy
Best chimerism
Materialart*
Peripheres Blut (1)
Knochenmark (3)
Datum der Materialentnahme*
ChimÃ¤rismus Methode*
STR (Short Tandem Repeats) (1)
Andere Methode (99)
% Spender-Zellen*
Further chimerism
Materialart*
Peripheres Blut (1)
Knochenmark (3)
Datum der Materialentnahme*
ChimÃ¤rismus Methode*
STR (Short Tandem Repeats) (1)
Andere Methode (99)
% Spender-Zellen*
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Prospective non–randomized multi_center study for
epidemiology and characterization of Myelodysplastic
Syndromes(MDS) and Juvenile Myelomonocytic Leukemia
(JMML) in childhood. PI: Prof. Dr. Charlotte Niemeyer
http://clinicaltrials.gov/ct2/show/NCT00662090
http://www.ewog-mds.org/
All rights reserved. Please visit https://medical-data-
models.org/forms/5336
Data on HSCT patient
Show identification of patient
Dummy
Informed consents for participation in
HSCT registries
Einwilligung PRST*
Nein (1)
Ja (2)
Einwilligung DRST*
Nein (1)
Ja (2)
Einwilligung EBMT*
Nein (1)
Ja (2)
Einwilligung CIBMTR*
Nein (1)
Ja (2)
Diagnosis according to EBMT
classification
Diagnosedatum*
Diagnose: EBMT-Klassifikation*
Acute leukemia (1000000)
Autoimmune disorder (10000000)
Haemoglobinopathy (11000000)
Chronic leukemia (2000000)
Lymphoma (3000000)
Plasma cell disorder (4000000)
Solid tumour (5000000)
Myelodysplastic / Myeloproliferative
syndrome (6000000)
Bone marrow failure including aplastic
anaemia (7000000)
Inherited disorder (8000000)
Histiocytic disorder (9000000)
Klassifizierung der akuten LeukÃ¤mie*
AML (1001000)
ALL (1002000)
Klassifizierung der chronischen LeukÃ¤mie*
CML (2001000)
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CLL (2002000)
PPL (2003000)
Klassifizierung Lymphom*
NHL (3001000)
Hodgkin (3002000)
Classification of plasma cell disorder*
Multiple myeloma (4001000)
Plasma cell leukemia (4002001)
Solitary plasmacytoma (4003001)
Primary amyloidosis (4004001)
Klassifizierung solide Tumoren*
Bone sarcoma (excluding EWING/PNET)
(5010001)
Osteosarcoma (5011001)
Chondrosarcoma (5012001)
Astrocytoma (5021001)
Oligodendroglioma (5022001)
Glioblastoma (5023001)
Ependymoma (5024001)
Other glioma (5025001)
PNET (5030001)
Ewing sarcoma (5031001)
Medulloblastoma (5032001)
Neuroblastoma (5033001)
Central nervous system (including CNS
PNET) (5034001)
Retinoblastoma (5036001)
Ewing sarcoma/PNET, extra-skeletal
(5037001)
Ewing sarcoma/PNET, skeletal
(5038001)
Germ cell tumour (5040001)
Seminoma (5041001)
Embryonal carcinoma (5042001)
Teratocarcinoma (yolk sac tumour)
(5043001)
Testicular (5044001)
Germ cell tumour, extragonadal
(5045001)
Choriocarcinoma (5046001)
Mixed tumour without seminoma
(5047001)
Mixed tumour with seminoma (5048001)
Ovarian (5049001)
Skin tumour (5050001)
Melanoma (5051001)
Lung, unspecified (5053001)
Small cell lung cancer (SCLC) (5054001)
Non-small cell lung cancer (NSCLC)
(5057001)
Soft tissue sarcoma (5060001)
Myxoma (5061001)
Mesenchymoma (5062001)
Leiomyiosarcoma (5063001)
Rhabdomyiosarcoma (5064001)
Liposarcoma (5065001)
Fibrosarcoma (5066001)
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Synovial sarcoma (5067001)
Angiosarcoma (5068001)
Haemangiosarcoma (5069001)
Lymphangiosarcoma (5070001)
Neurogenic sarcoma (5071001)
Hepatobiliary (5072001)
Pancreas (5074001)
Prostate (5075001)
Breast (5080000)
Undifferentiated carcinoma (5090001)
Thymoma (5091001)
Gastric carcinoma + adenocarcinoma
(5092001)
Adenocarcinoma origin X (5093001)
Colon adenocarcinoma (5096001)
Granulocytic sarcoma (5097001)
Wilms tumour (5098001)
Other kidney tumour (5099001)
Other solid tumour (5777001)
Unknown solid tumour (5999001)
Klassifizierung MDS*
MDS (6001000)
MPS (6002000)
MDS und MPS kombiniert (6003000)
Anderes myelodysplatisches Syndrom
(6004001)
Klassifizierung AnÃ¤mie*
Non constitutional (7001000)
Fanconi (congenital) (7002001)
Pure red cell aplasia (non congenital
PRCA) (7003000)
Diamond-Blackfan (congenital PRCA)
(7004001)
Paroxysmal nocturnal haemoglobinuria
(PNH) (7005000)
Amegakariocytic thrombocytopaenia (not
congenital) (7006000)
Schwachman-Diamond (congenital)
(7007001)
Classification of Inherited disorder*
Primaryimmune deficiency (8001000)
Disorders of metabolism (8002000)
Other inherited disorder (8003000)
Classification of histiocytic disorder*
Familial erythro/hemophagocytic
lymphohistiocytosis (9001001)
Langerhans cell histiocytosis
(Histiocytosis-X) (9002001)
Hemophagocytosis (reactive or viral
associated) (9003001)
Malignant histiocytosis (9004001)
Other histiocytic disorder (9077001)
Unknown histiocytic disorder (9099001)
Classification of autoimmune disorder*
Connective tissue disease (10001000)
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Vasculitis (10002000)
Arthristis (10003000)
Multiple sclerosis (10004001)
Other neurological (10005000)
Haematological (10006000)
Bowel disease (10007000)
Other autoimmune disorder (10077001)
Classification of haemoglobinopathy*
Thalassaemia (11001001)
Sickle cell anaemia/Drepanocytosis
(11002001)
Compound heterozygous state
(11003001)
Other haemoglobinopathy (11004001)
Unknown haemoglobinopathy
(11005001)
EMBT diagnosis subclassification
Subklassifizierung der ALL*
Precursor B-cell ALL (1002001)
t(9;22)(a34;q11) BCR/ABL (1002002)
t(v;11q23) MLL rearranged (1002003)
t(1;19)(q23;p13) E2A/PBX1 (1002004)
t(12;21)(p12;q22) ETV/CBF-alpha
(1002005)
Precursor T-cell ALL (1002011)
ALL not otherwise specified or other
(1002077)
Unknown ALL (1002099)
Subklassifizierung der AML*
AML w t(8;21)(q22;q22), (AML1/ETO)
(1001001)
AML w abnormal BM eosinophils und
inv(16)(p13;q22) (1001002)
AML w t(15;17)(q22;q12),
(PML/RARalpha) [M3] (1001003)
AML w 11q23, (MLL) abnormalities
(1001004)
AML w multilineage dysplasia (w/o MDS
or MP/MDS) (1001005)
AML not otherwise categorised
(1001009)
AML mimimally differentiated [M0]
(1001010)
AML wo maturation [M1] (1001011)
AML w maturation [M2] (1001012)
Acute myelomonocytic leukemia [M4]
(1001014)
Acute monoblastic/monocytic leukemia
[M5] (1001015)
Acute erythroid leukemia [M6] (1001016)
Acute megakaryoblastic leukemia [M7]
(1001017)
Acute basophilic leukemia (1001018)
Acute panmyelosis with myelofibrosis
(1001019)
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Myeloid sarcoma (1001020)
AML not otherwise specified or other
(1001777)
Unknown AML (1001999)
Subklassifizierung CML*
(t9) (2001001)
(t9;22) positive (2001002)
Other chromosome abnormality
(2001003)
Other CML (2001077)
Unknown CML (2001099)
Subclassification of CLL*
CLL B-cell/Small lymphocytic lymphoma
(2002001)
CLL T-cell (2002002)
Hairy cell leukaemia (2002003)
Atypic hairy cell leukaemia (2002004)
Richters syndrome (2002005)
Other leukemia (2002077)
Unknown leukaemia (2002099)
Subklassifizierung PPL*
PPL B-cell (2003001)
PPL T-cell (2003002)
Other PPL (2003077)
Unknown PPL (2003099)
Subklassifizierung NHL*
NHL unspecified (3001001)
B-cell NHL unspecified (3001005)
Follicular (3001010)
Mantle cell (3001020)
Extranodal marginal zone B-cell of MALT
type (3001030)
Diffuse large B-cell (3001040)
Centroblastic (3001041)
Immunoblastic (3001042)
Anaplastic large B-cell (3001043)
Intravascular large cell lymphoma
(3001045)
Mediastinal large cell lymphoma
(3001046)
Primary effusion large cell lymphoma
(3001047)
Burkitts lymphoma/Burkitt cell leukaemia
(3001050)
High grade B-cell lymphoma, Burkitt-like
(prov.) (3001051)
Precursor B-cell lymphoblastic
(3001060)
Lymphoplasmcytic lymphoma including
Waldenstrom (3001070)
Lymphoplasmcytic lymphoma (3001071)
Waldenstrom macroglobulinaemia
(3001072)
Splenic marginal zone (3001080)
Nodal marginal zone (3001090)
Primary CNS lymphoma (3001096)
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T-cell NHL unspecified (3001105)
Angioimmunoblastic T-cell (AILD)
(3001110)
Peripheral T-cell (3001120)
Anaplastic large T-cell (3001130)
Anaplastic large-cell, T/null-cell, primary
cuta (3001131)
Anaplastic large-cell T/null-cell, primary
syste (3001132)
PreT lymphoblastic (3001140)
Blast NK cell (3001145)
Extranodal NK/T-cell (3001150)
Enteropathy type T-cell (3001160)
Hepatosplenic gamma-delta T-cell
(3001170)
Subcutaneous panniculitis-like T-cell
(3001180)
Adult T-cell lymphoma/leukaemia
(3001181)
Aggressive NK-cell leukaemia (3001182)
Large T-cell granular lymphocytic
leukaemia (3001183)
Mycosis fungoides (3001190)
Sezary syndrome (3001195)
Post-transplant lymphoproliferative
disease (PTL (3001300)
Other NHL (3001800)
Unknown NHL (3001999)
Subclassification of HD*
Nodular lymphocyte predominant
(3002001)
Lymphocyte rich (3002002)
Nodular sclerosis (3002003)
Mixed cellularity (3002004)
Lymphoma depleted (3002005)
Other Hodgkin lymphoma (3002077)
Unknown Hodgkin lymphoma (3002099)
Subclassification of multiple myeloma*
Multiple myeloma light chain (4001001)
Multiple myeloma light chain kappa
(4001002)
Multiple myeloma light chain lambda
(4001003)
Multiple myeloma light chain both
(4001004)
Multiple myeloma light chain unknown
(4001005)
Multiple myeloma non secretory
(4001006)
Multiple myeloma non secretory stage I
(4001007)
Multiple myeloma non secretory stage II
(4001008)
Multiple myeloma non secretory stage III
(4001009)
Multiple myeloma not evaluated
(4001010)
Multiple myeloma unknown (4001011)
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Multiple myeloma common type IgG
(4001012)
Multiple myeloma common type IgA
(4001013)
Multiple myeloma common type IgD
(4001014)
Multiple myeloma common type IgE
(4001015)
Multiple myeloma common type IgM
(4001016)
Multiple myeloma common type
unknown (4001017)
Subclassification of breast cancer*
Breast cancer M0 (No distant
metastasis) (5080010)
Breast cancer M1 (With distant
metastasis) (5080011)
Breast cancer MX (Distant metastasis
not evaluable) (5080015)
Breast cancer not evaluated (5080088)
Breast cancer unknown (5080099)
Subclassification of MDS*
MDS RA (6001001)
MDS RARS (6001002)
MDS RAEB-1 (6001003)
MDS RAEB-2 (6001004)
MDS Refractory cytopenia with
multilineage dysplasia (6001005)
MDS RCMD-RS (6001006)
MDS associated with isolated del(5q)
(6001007)
MDS Transformed to AML (6001008)
MDS Unclassifiable (MDS-U) or other
(6001077)
MDS unknown (6001099)
Subklassifizierung MPS*
MPS Chronic idiopathic myelofibrosis
(primary) (6002001)
MPS Polycythemia vera (6002002)
MPS Essential or primary
thrombocythemia (6002003)
MPS Hyper eosinophilic syndrome
(HES) (6002004)
MPS Chronic eosinophilic leukaemia
(CEL) (6002005)
MPS Chronic neutrophilic leukaemia
(6002006)
MPS Stem cell leuk-lymphoma
syndrome (8p11 syndr) (6002007)
MPS Secondary myelofibrosis (6002008)
MPS Transformed to AML (6002009)
MPS Systemic mastocytosis (6002010)
MPS not otherwise specified or other
(6002077)
MPS unknown (6002099)
Subclassification of 'MDS and MPS combined'*
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Chronic myelomonocytic leukaemia
(6003001)
Juvenile myelomonocytic leukaemia
(6003002)
Atypical CML (t(9;22) and bcr-abl
negative (6003003)
MDS and MPS combined other
(6003077)
MDS and MPS combined unknown
(6003099)
Subclassification of non constitutional anaemia*
Non constitutional anaemia idiopathic
(7001010)
Non constitutional anaemia congenital
(7001020)
Non constitutional anaemia post-hepatic
(7001030)
Non constitutional anaemia post-hepat A
(7001031)
Non constitutional anaemia post-hepat B
(7001032)
Non constitutional anaemia postHep
noAB (7001033)
Non constitutional anaemia drug related
(7001040)
Non constitutional anaemia toxic
(7001050)
Non constitutional anaemia other viral
(7001060)
Non constitutional anaemia other
(7001077)
Non constitutional anaemia unknown
(7001099)
Subclassification of PRCA*
PRCA idiopathic (7003010)
PRCA congenital (7003020)
PRCA post-hepatic (7003030)
PRCA post-hepat A (7003031)
PRCA post-hepat B (7003032)
PRCA postHep noAB (7003033)
PRCA drug related (7003040)
PRCA toxic (7003050)
PRCA other viral (7003060)
PRCA other (7003077)
PRCA unknown (7003099)
Subclassification of PNH*
PNH idiopathic (7005010)
PNH congenital (7005020)
PNH post-hepatic (7005030)
PNH post-hepat A (7005031)
PNH post-hepat B (7005032)
PNH postHep noAB (7005033)
PNH drug related (7005040)
PNH toxic (7005050)
PNH other viral (7005060)
PNH other (7005077)
PNH unknown (7005099)
8 / 12
EWOG MDS 2006 Data on HSCT patient
Subclassification of amegakariocytic
thrombocytopaenia (not congenital)*
Amegakariocytic thrombocytopaenia (not
congenital) Idiopathic (7006010)
Amegakariocytic thrombocytopaenia (not
congenital) Congenital (7006020)
Amegakariocytic thrombocytopaenia (not
congenital) Post-hepatic (7006030)
Amegakariocytic thrombocytopaenia (not
congenital) Post-hepat A (7006031)
Amegakariocytic thrombocytopaenia (not
congenital) Post-hepat B (7006032)
Amegakariocytic thrombocytopaenia (not
congenital) PostHep noAB (7006033)
Amegakariocytic thrombocytopaenia (not
congenital) Drug related (7006040)
Amegakariocytic thrombocytopaenia (not
congenital) Toxic (7006050)
Amegakariocytic thrombocytopaenia (not
congenital) Other viral (7006060)
Amegakariocytic thrombocytopaenia (not
congenital) Other (7006077)
Amegakariocytic thrombocytopaenia (not
congenital) unknown (7006099)
Subclassification of primaryimmune deficiency*
Absence of T and B cells SCID
(8001010)
Artemis (8001011)
Ligase IV (8001012)
Rag-1 or Rag-2 (8001013)
Other T- B- cells SCID (8001017)
Absence of T, normal B cell SCID
(8001020)
Gamma c deficiency (8001021)
JAK 3 deficiency (8001022)
IL-7R alpha deficiency (8001023)
Other T- B+ cells SCID (8001027)
ADA deficiency (Adenosine deaminase
deficiency) (8001031)
Purine nucleoside phosphorylase
deficiency (PNP- (8001032)
Reticular dysgenesis (AR) (8001033)
Other SCID (8001037)
Combined immune deficiency (CID),
unspecified (8001050)
Omenn syndrome (8001051)
Neutrophil actin deficiency (8001052)
Other CID (8001057)
Wiskott Aldrich syndrome (8001131)
Familial lymphohistiocytosis (8001132)
Interferon g deficiency (8001133)
X-linked lymphoproliferative (Purtilo)
(8001134)
Ataxia telangiectasia (8001135)
Di George syndrome (8001136)
CD40 ligand deficiency (Hyper IgM/Ig
deficienc) (8001137)
Cartilage hair hypoplasia (Dyskeratosis
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congen) (8001138)
Bare lymphocyte/MHC class II/HLA-antig
xp def (8001139)
Griscelli syndrome (8001140)
IPEX syndrome (8001141)
Chediak-Higashi syndrome (8001151)
Chronic granulomatous disease
(8001152)
Agranulocytosis (Kostmann) (8001153)
Leukocyte adhesion deficiency (LAD)
(8001154)
Other primaryimmune deficiency
(8001777)
Unknown primaryimmune deficiency
(8001999)
Subclassification of disorders of metabolism*
Mucopolysaccharidoses, unspecified
(8002010)
Hurler (8002011)
Scheie (8002012)
Hurler/Scheie (8002013)
Hunter (8002014)
Sanfilippo A (8002015)
Sanfilippo B (8002016)
Sanfilippo C (8002017)
Sanfilippo D (8002018)
Morquio (IV) (8002019)
Mucopolis V (8002021)
Maroteaux-Lamy (8002022)
B-glucuronidase deficiency/Type VII / Sly
(8002023)
Sphingolipidoses, unspecified (8002030)
Metachromatic leucodystrophy
(8002031)
Multiple sulphatidosis (8002032)
Fabry / alpha-D-galactosidase (8002033)
GM1 ganglios (8002034)
GM2 gangl T1 (8002035)
GM3 gangl T2 (8002036)
NiemPick AB (8002037)
NiemPick CDE (8002038)
Gaucher (8002039)
Neuronal ceriod-lipofuscinosis (Batten
disease) (8002040)
Krabbe (8002041)
Mucolipidose (8002050)
Mucolipid I (8002051)
I-cell disea (8002052)
MucolipidIII (8002053)
Fucosidosis (8002054)
Mannosidosis (8002055)
Aspartyl
glucosaminuria/glucosaminidase
(8002061)
B-d-mannosid (8002062)
N-acetyl-alpha-D-galactosaminase
deficiency (8002063)
Wolman disease/acid lipase (8002064)
Adrenoleukodistrophy (8002070)
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Glucose storage disease (8002071)
Lesch-Nyhan (8002072)
Erythropoietic porphyria/Gunther`s
(8002080)
Disorders of metabolism Other
(8002777)
Disorders of metabolism unknown
(8002999)
Subclassification of other inherited disorder*
Platelet defect, unspecified (8003020)
Glanzmann (8003021)
Congenital
amegakaryocytosis/thrombocytopaenia
(8003022)
Osteoclast defect, unspecified (8003040)
Osteopetrosis (8003041)
Other inherited disorders (8003077)
Other unknown inherited disorders
(8003099)
Subclassification of connective tissue disease*
Systemic sclerosis (10001001)
Systemic lupus erythematosus
(10001002)
Polymyositis-dermatomyositis
(10001003)
Sjogren syndrome (10001004)
Antiphospholipid syndrome (10001005)
Connective tissue disease Other
(10001077)
Connective tissue disease unknown
(10001099)
Subclassification of vasculitis*
Wegener granulomatosis (10002001)
Classical polyarteritis nodosa
(10002002)
Microscopic polyarteritis nodosa
(10002003)
Churg-Strauss (10002004)
Necrotising arteritis (10002005)
Giant cell arteritis (10002006)
Takayasu (10002007)
Behcets syndrome (10002008)
Vasculitis Other (10002077)
Vasculitis unknown (10002099)
Subclassification of arthritis*
Rheumatoid arthritis (10003001)
Psoriatic arthritis/psoriasis (10003002)
Juvenile idiopathic arthritis: Systemic
(Stills) (10003003)
Juvenile idiopathic arthritis: Polyarticular
(10003004)
Juvenile idiopathic arthritis: Other
(10003005)
Arthristis other (10003077)
Arthristis unknown (10003099)
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Subclassification of other neurological*
Myasthenia gravis (10005001)
Other neurological (10005077)
Unknown other neurological (10005099)
Subclassification of haematological*
Idiopathic thrombocytopenic purpura
(ITP) (10006001)
Idiopathic haemolytic anaemia
(10006002)
Pure red cell (acquired PRCA)
(10006003)
Pure white cell (10006004)
Evan syndrome/combine (10006005)
Other haematological (10006077)
Unknown haematological (10006099)
Subclassification of bowel disease*
Crohns disease (10007001)
Ulcerative colitis (10007002)
Other bowel disease (10007077)
Unknown bowel disease (10007099)
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EWOG MDS 2006 Allogeneic donor
Prospective non–randomized multi_center study for
epidemiology and characterization of Myelodysplastic
Syndromes(MDS) and Juvenile Myelomonocytic Leukemia
(JMML) in childhood. PI: Prof. Dr. Charlotte Niemeyer
http://clinicaltrials.gov/ct2/show/NCT00662090
http://www.ewog-mds.org/
All rights reserved. Please visit https://medical-data-
models.org/forms/5337
Allogeneic donor
Show identification of patient
Dummy
Basic data on donor
Alter des Spenders*
Spender Geschlecht*
Männlich (1)
Weiblich (2)
VerwandtschaftsverhÃ¤ltnis*
Nicht verwandt (1)
Eineiiger Zwilling (2)
Andere Geschwister (3)
Andere Verwandschaften (4)
Interner Spender Identifikator*
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
Externer Spender Identifikator (Spenderregister)*
WMDA-Code*
Spenderregister oder CB-Bank*
Blood group of donor
Datum der Materialentnahme*
Spender Blutgruppe*
A (1)
B (2)
AB (3)
0 (4)
Spender Rhesusfaktor*
Negativ (1)
Positiv (2)
1 / 4
HLA typing of donor
Datum der Materialentnahme*
Methode Klasse 1-Typisierung*
molekularbiologisch (1)
serologisch (2)
Methode Klasse 2-Typisierung*
molekularbiologisch (1)
serologisch (2)
HLA-A Allel 1*
HLA-A Allel 2*
HLA-B Allel 1*
HLA-B Allel 2*
HLA-C Allel 1*
HLA-C Allel 2*
HLA-DRB1 Allel 1*
HLA-DRB1 Allel 2*
HLA-DQB1 Allel 1*
HLA-DQB1 Allel 2*
HLA-DPB1 Allel 1*
HLA-DPB1 Allel 2*
HLA matching
Anzahl untersuchter Loci*
Anzahl Mismatch Antigen*
Loci Antigen Mismatch*
Anzahl Mismatch Allel*
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Loci Allel Mismatch*
Markers of infection of donor
Spender CMV IgG*
Negativ (1)
Positiv (2)
Spender CMV IgM*
Negativ (1)
Positiv (2)
Spender EBV IgG*
Negativ (1)
Positiv (2)
Spender EBV IgM*
Negativ (1)
Positiv (2)
Spender Anti Hbc*
Negativ (1)
Positiv (2)
Spender HBs Ag*
Negativ (1)
Positiv (2)
Spender Anti Hbs*
Negativ (1)
Positiv (2)
Spender HCV IgG*
Negativ (1)
Positiv (2)
Spender HIV IgG*
Negativ (1)
Positiv (2)
Spender HSV IgG*
Negativ (1)
Positiv (2)
Spender HTLV IgG*
Negativ (1)
Positiv (2)
Spender Toxoplasma IgG*
Negativ (1)
Positiv (2)
Spender VZV IgG*
Negativ (1)
Positiv (2)
Spender HCV PCR*
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Negativ (1)
Positiv (2)
Spender HIV PCR*
Negativ (1)
Positiv (2)
Spender HTLV PCR*
Negativ (1)
Positiv (2)
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EWOG MDS 2006 HSCT {0}
Prospective non–randomized multi_center study for
epidemiology and characterization of Myelodysplastic
Syndromes(MDS) and Juvenile Myelomonocytic Leukemia
(JMML) in childhood. PI: Prof. Dr. Charlotte Niemeyer
http://clinicaltrials.gov/ct2/show/NCT00662090
http://www.ewog-mds.org/
All rights reserved. Please visit https://medical-data-
models.org/forms/5338
HSCT {0}
Show identification of patient
Dummy
General HSCT data
Dokumentierte HSZT*
1. (1)
2. (2)
3. (3)
4. (4)
5. (5)
Transplantationsdatum*
Art der HSZT*
Autolog (1)
Allogen (2)
Dokumentierendes Zentrum
Event center LocationOID
1 / 1
EWOG MDS 2006 Blood group and HLA
typing
Prospective non–randomized multi_center study for
epidemiology and characterization of Myelodysplastic
Syndromes(MDS) and Juvenile Myelomonocytic Leukemia
(JMML) in childhood. PI: Prof. Dr. Charlotte Niemeyer
http://clinicaltrials.gov/ct2/show/NCT00662090
http://www.ewog-mds.org/
All rights reserved. Please visit https://medical-data-
models.org/forms/5339
Blood group and HLA typing
Show identification of patient
Dummy
Blood group (patient)
Datum der Materialentnahme*
Blutgruppe*
A (1)
B (2)
AB (3)
0 (4)
Rhesusfaktor*
Negativ (1)
Positiv (2)
HLA typing (patient)
Datum der Materialentnahme*
Methode Klasse 1-Typisierung*
molekularbiologisch (1)
serologisch (2)
Methode Klasse 2-Typisierung*
molekularbiologisch (1)
serologisch (2)
HLA-A Allel 1*
HLA-A Allel 2*
HLA-B Allel 1*
HLA-B Allel 2*
HLA-C Allel 1*
HLA-C Allel 2*
HLA-DRB1 Allel 1*
1 / 2
HLA-DRB1 Allel 2*
HLA-DQB1 Allel 1*
HLA-DQB1 Allel 2*
HLA-DPB1 Allel 1*
HLA-DPB1 Allel 2*
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EWOG MDS 2006 Marker of infection prior
to HSCT
Prospective non–randomized multi_center study for
epidemiology and characterization of Myelodysplastic
Syndromes(MDS) and Juvenile Myelomonocytic Leukemia
(JMML) in childhood. PI: Prof. Dr. Charlotte Niemeyer
http://clinicaltrials.gov/ct2/show/NCT00662090
http://www.ewog-mds.org/
All rights reserved. Please visit https://medical-data-
models.org/forms/5340
Marker of infection prior to HSCT
Show identification of patient
Dummy
Markers of infection
CMV IgG*
Negativ (1)
Positiv (2)
CMV IgM*
Negativ (1)
Positiv (2)
EBV-VCA IgG*
Negativ (1)
Positiv (2)
EBV-VCA IgM*
Negativ (1)
Positiv (2)
Anti HBc*
Negativ (1)
Positiv (2)
HBs Ag*
Negativ (1)
Positiv (2)
Anti HBs*
Negativ (1)
Positiv (2)
HCV IgG*
Negativ (1)
Positiv (2)
HIV IgG*
Negativ (1)
Positiv (2)
HSV IgG*
Negativ (1)
Positiv (2)
HTLV IgG*
Negativ (1)
Positiv (2)
Toxoplasma IgG*
1 / 2
Negativ (1)
Positiv (2)
VZV IgG*
Negativ (1)
Positiv (2)
HCV PCR*
Negativ (1)
Positiv (2)
HIV PCR*
Negativ (1)
Positiv (2)
HTLV PCR*
Negativ (1)
Positiv (2)
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EWOG MDS 2006 Status at HSCT
Prospective non–randomized multi_center study for
epidemiology and characterization of Myelodysplastic
Syndromes(MDS) and Juvenile Myelomonocytic Leukemia
(JMML) in childhood. PI: Prof. Dr. Charlotte Niemeyer
http://clinicaltrials.gov/ct2/show/NCT00662090
http://www.ewog-mds.org/
All rights reserved. Please visit https://medical-data-
models.org/forms/5341
Status at HSCT
Show identification of patient
Dummy
Body measurements
KÃ¶rpergrÃ¶ÃŸe*
KÃ¶rpergewicht*
KÃ¶rperoberflÃ¤che (KOF)*
KOF berechnet*
Performance status (Karnofsky/Lansky)
Datum Bewertung*
Score Karnofsky/Lansky*
10% (10)
100% (100)
20% (20)
30% (30)
40% (40)
50% (50)
60% (60)
70% (70)
80% (80)
90% (90)
Clinical data at HSCT (MDS specific)
Splenomegalie*
Nein (1)
Ja (2)
Tastbare MilzgrÃ¶ÃŸe unter Rippenbogen (in
cm)*
Bestrahlung der Milz*
Nein (1)
Ja (2)
Dosis der Betrahlung*
1 / 4
Splenektomie vor HSZT*
Nein (1)
Ja (2)
Hepatomegalie*
Nein (1)
Ja (2)
Tastbare LebergrÃ¶ÃŸe unter Rippenbogen (in
cm)*
Lymphknoten > 1,5cm*
Nein (1)
Ja (2)
Interstitielle Pneumonie*
Nein (1)
Ja (2)
Erguss*
Nein (1)
Ja (2)
Pleuraerguss*
Nein (1)
Ja (2)
Perikarderguss*
Nein (1)
Ja (2)
Aszites*
Nein (1)
Ja (2)
Andere ErgÃ¼sse*
Nein (1)
Ja (2)
Andere Effusion*
Arthritis*
Nein (1)
Ja (2)
HautlÃ¤sion (auÃŸer Naevi, HÃ¤matomen)*
Nein (1)
Ja (2)
Xanthom*
Nein (1)
Ja (2)
CafÃ©-au-lait-Flecken*
Nein (1)
Ja (2)
Anzahl der CafÃ©-au-lait-Flecken*
2 / 4
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1 (1)
>=10 (10)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
7 (7)
8 (8)
9 (9)
Abmessung des grÃ¶ÃŸten Flecks*
NF1*
Nein (1)
Ja (2)
CSF cytology (MDS specific)
Blut im Liquor (sichtbar)*
Nein (1)
Ja (2)
Datum der Bewertung*
Erythrozyten im Liquor*
Leukozyten im Liquor*
Gesamtzahl der Blasten Zytospin*
BM/PB blasts (MDS specific)
KM Blasten (zeitnahester Wert zu Beginn der
Konditionierung)*
Datum des KM Ausstriches*
PB Blasten (zeitnahester Wert zu Beginn der
Konditionierung)*
Datum des PB*
WBC*
Disease status at HSCT
Erkrankungsstatus bei HSZT*
Komplette Remission (CR) (1)
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Partielle Remission (PR) (2)
Refraktäre Erkrankung / Non-response /
Nie in Remission (3)
Rezidiv/Progression (4)
Unbehandelt (5)
Chronolog. Nr. dieser kompletten Remission*
Chronolog. Nr. dieser Teilremission*
SekundÃ¤rmalignom*
Nein (1)
Ja (2)
SC specific data
Zusammenfassender Kary-Code 1*
Kein Ergebnis (0)
Normal bzgl. Metaphasen Zytogenetik
(1)
Normal für 7+8 by FISH (40)
-7 by FISH (41)
+8 by FISH (42)
Other abn by FISH (43)
-7 alone (51)
-7 +add (52)
7q- alone (53)
7q- +add (54)
-7 unclear (55)
+8 alone (57)
+8 +add (58)
Random aberration (99)
Zusammenfassender Kary-Code 2*
komplex 3 oder 4 Abberationen (35)
komplex>4 Abberationen (36)
EWOG komplex (37)
MDS Diagnose*
MDR-AML (40)
RC (41)
RARS (42)
RAEB (43)
RAEB-T (44)
JMML (45)
CMML (46)
Noonan Syn. + JMML ähnliches Bild (47)
Hypereosinophiles Syndrom (50)
Myelofibrotisches MDS (60)
MDS, nicht klassifiziert (99)
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EWOG MDS 2006 Conditioning chemo
therapy
Prospective non–randomized multi_center study for
epidemiology and characterization of Myelodysplastic
Syndromes(MDS) and Juvenile Myelomonocytic Leukemia
(JMML) in childhood. PI: Prof. Dr. Charlotte Niemeyer
http://clinicaltrials.gov/ct2/show/NCT00662090
http://www.ewog-mds.org/
All rights reserved. Please visit https://medical-data-
models.org/forms/5342
Conditioning chemo therapy
Show identification of patient
Dummy
Conditioning chemo therapy generic
Generischer Wirkstoffname*
Falls anderes Generikum, Name*
ATG-PrÃ¤parat (Handelsname)*
Anderes ATG-PrÃ¤parat (Handelsname)*
Applikationsart*
p.o. (1)
i.v. (2)
p.i. (3)
i.th. (4)
i.vent. (5)
i.m. (6)
s.c. (7)
lokal (8)
supp (9)
Verordnete Tagesdosis*
Dosismodifikation*
Nein (1)
Ja (2)
Indikation fÃ¼r die Dosisabweichung*
Day of administration
Verabreicht an Tag*
-1 (1)
-10 (10)
-11 (11)
-12 (12)
-13 (13)
-14 (14)
-15 (15)
-2 (2)
1 / 2
-3 (3)
-4 (4)
-5 (5)
-6 (6)
-7 (7)
-8 (8)
-9 (9)
Further administration (outside range of -1
to -15)
Anderer Verabreichungstag*
2 / 2
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EWOG MDS 2006 Conditioning
radiotherapy
Prospective non–randomized multi_center study for
epidemiology and characterization of Myelodysplastic
Syndromes(MDS) and Juvenile Myelomonocytic Leukemia
(JMML) in childhood. PI: Prof. Dr. Charlotte Niemeyer
http://clinicaltrials.gov/ct2/show/NCT00662090
http://www.ewog-mds.org/
All rights reserved. Please visit https://medical-data-
models.org/forms/5343
Conditioning radiotherapy
Show identification of patient
Dummy
radiotherapy given
Radiotherapie in der Konditionierung*
Nein (1)
Ja (2)
Conditioning radiotherapy admistration
Bestrahlungsart*
Ganzkörperbestrahlung (1)
TLI (Total lymph.) (2)
Schädel Boost (3)
Hoden Boost (4)
TAI (Total abdominal) (5)
TNI (Total nodal irradiation) (6)
Anzahl Fraktionen pro Tag*
Dosis pro Fraktion*
Radionuclide therapy
Substanz*
MIBG (1)
Samarium (2)
Yttrium (3)
Dosis*
Beginn der Therapie*
Day of administration
Verabreicht an Tag*
-1 (1)
-10 (10)
-11 (11)
-12 (12)
-13 (13)
-14 (14)
1 / 2
-15 (15)
-2 (2)
-3 (3)
-4 (4)
-5 (5)
-6 (6)
-7 (7)
-8 (8)
-9 (9)
Further administration (outside range of -1
to -15)
Anderer Verabreichungstag*
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EWOG MDS 2006 Graft
Prospective non–randomized multi_center study for
epidemiology and characterization of Myelodysplastic
Syndromes(MDS) and Juvenile Myelomonocytic Leukemia
(JMML) in childhood. PI: Prof. Dr. Charlotte Niemeyer
http://clinicaltrials.gov/ct2/show/NCT00662090
http://www.ewog-mds.org/
All rights reserved. Please visit https://medical-data-
models.org/forms/5344
Graft
Show identification of patient
Dummy
Graft
Interner Spender Identifikator*
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
Datum der Stammzellgewinnung*
Quelle der Stammzellen*
Knochenmark (1)
Nabelschnurblut (2)
Peripheres Blut (3)
Manipulation des Transplantats*
Nein (1)
Ja (2)
CD34-positiv Selektion*
Nein (1)
Ja (2)
CD3/CD19 Depletion*
Nein (1)
Ja (2)
Andere Manipulation durchgefÃ¼hrt*
Nein (1)
Ja (2)
Falls andere Manipulation, Beschreibung*
Anzahl infundierter kernhaltige Zellen*
Anzahl infundierter CD34+ Zellen*
Anzahl infundierter CD3+ Zellen*
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EWOG MDS 2006 Cytokines immediate
after HSCT
Prospective non–randomized multi_center study for
epidemiology and characterization of Myelodysplastic
Syndromes(MDS) and Juvenile Myelomonocytic Leukemia
(JMML) in childhood. PI: Prof. Dr. Charlotte Niemeyer
http://clinicaltrials.gov/ct2/show/NCT00662090
http://www.ewog-mds.org/
All rights reserved. Please visit https://medical-data-
models.org/forms/5345
Cytokines immediate after HSCT
Show identification of patient
Dummy
G-CSF immediate after HSCT
G-CSF verabreicht*
Nein (1)
Ja (2)
Datum der ersten G-CSF-Gabe*
Datum der letzten G-CSF-Gabe*
Anderes Cytokin*
Nein (1)
Ja (2)
Other cytokine immediate after HSCT
Cytokin Name*
Datum der ersten Gabe*
Datum der letzten Gabe*
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EWOG MDS 2006 GvHD prophylaxis
Prospective non–randomized multi_center study for
epidemiology and characterization of Myelodysplastic
Syndromes(MDS) and Juvenile Myelomonocytic Leukemia
(JMML) in childhood. PI: Prof. Dr. Charlotte Niemeyer
http://clinicaltrials.gov/ct2/show/NCT00662090
http://www.ewog-mds.org/
All rights reserved. Please visit https://medical-data-
models.org/forms/5346
GvHD prophylaxis
Show identification of patient
Dummy
GvHD prophylaxis CSA
CSA verabreicht*
Nein (1)
Ja (2)
GvHD prophylaxis CSA application
Datum der ersten CSA-Gabe*
Anfangsdosis i.v. CSA*
Beendet*
Nein (1)
Ja (2)
Datum der letzten CSA-Gabe*
GvHD prophylaxis MTX
MTX verabreicht*
Nein (1)
Ja (2)
GvHD prophylaxis MTX application
Anzahl MTX-Applikationstage*
LCV-Rescue*
Nein (1)
Ja (2)
Other drug for GvHD prophylaxis
Anderes Medikament verabreicht*
Nein (1)
Ja (2)
1 / 2
Other drug application for GvHD
prophylaxis
Falls anderes Generikum, Name*
Neu begonnen / fortgesetzt*
Fortgesetzt (1)
Neu begonnen (2)
Datum der ersten Gabe*
Beendet*
Nein (1)
Ja (2)
Datum der letzten Gabe*
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EWOG MDS 2006 Day +100
Prospective non–randomized multi_center study for
epidemiology and characterization of Myelodysplastic
Syndromes(MDS) and Juvenile Myelomonocytic Leukemia
(JMML) in childhood. PI: Prof. Dr. Charlotte Niemeyer
http://clinicaltrials.gov/ct2/show/NCT00662090
http://www.ewog-mds.org/
All rights reserved. Please visit https://medical-data-
models.org/forms/5347
Day +100
Show identification of patient
Dummy
Data about day +100
Datum Tag +100*
1 / 1
EWOG MDS 2006 Engraftment
Prospective non–randomized multi_center study for
epidemiology and characterization of Myelodysplastic
Syndromes(MDS) and Juvenile Myelomonocytic Leukemia
(JMML) in childhood. PI: Prof. Dr. Charlotte Niemeyer
http://clinicaltrials.gov/ct2/show/NCT00662090
http://www.ewog-mds.org/
All rights reserved. Please visit https://medical-data-
models.org/forms/5348
Engraftment
Show identification of patient
Dummy
Engraftment
Leukozyten-Engraftment*
Nein (1)
Ja (2)
Lagen niemals unter diesem Wert (3)
Datum Leukozyten-Engraftment*
Neutrophilen Engraftment*
Nein (1)
Ja (2)
Lagen niemals unter diesem Wert (3)
Datum Neutrophilen Engraftment*
Thrombozyten > 20 x 10E9/l*
Nein (1)
Ja (2)
Lagen niemals unter diesem Wert (3)
Datum Thrombozyten > 20 x 10E9/l*
Thrombozyten > 50 x 10E9/l*
Nein (1)
Ja (2)
Lagen niemals unter diesem Wert (3)
Datum Thrombozyten > 50 x 10E9/l*
Erythrozytentransfusion erforderlich > Tag 100*
Nein (1)
Ja (2)
Graft failure
Transplantatversagen aufgetreten*
Nein (1)
Ja (2)
Art des Transplantatversagens*
Abstoßung (1)
Spätes Transplantatversagen (2)
1 / 2
Datum des Transplantatversagens*
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EWOG MDS 2006 GvHD occurred
Prospective non–randomized multi_center study for
epidemiology and characterization of Myelodysplastic
Syndromes(MDS) and Juvenile Myelomonocytic Leukemia
(JMML) in childhood. PI: Prof. Dr. Charlotte Niemeyer
http://clinicaltrials.gov/ct2/show/NCT00662090
http://www.ewog-mds.org/
All rights reserved. Please visit https://medical-data-
models.org/forms/5349
GvHD occurred
Show identification of patient
Dummy
GvHD occurred
GvHD aufgetreten*
Nein (1)
Ja (2)
1 / 1
EWOG MDS 2006 Severe complications till
day +100
Prospective non–randomized multi_center study for
epidemiology and characterization of Myelodysplastic
Syndromes(MDS) and Juvenile Myelomonocytic Leukemia
(JMML) in childhood. PI: Prof. Dr. Charlotte Niemeyer
http://clinicaltrials.gov/ct2/show/NCT00662090
http://www.ewog-mds.org/
All rights reserved. Please visit https://medical-data-
models.org/forms/5350
Severe complications till day +100
Show identification of patient
Dummy
Severe infection occurred
Infektion*
Nein (1)
Ja (2)
Severe pulmonary complications
Radiologische VerÃ¤nderungen und/oder
Sauerstoffbedarf*
Nein (1)
Ja (2)
KÃ¼nstliche Beatmung*
Nein (1)
Ja (2)
Severe cardio-vascular complications
Shortening Fraction < 25 %*
Nein (1)
Ja (2)
Katechecholaminbedarf*
Nein (1)
Ja (2)
TherapiebedÃ¼rftige Arrhythmien*
Nein (1)
Ja (2)
Severe renal complications
Relevante Kreatinin ErhÃ¶hung > CTCAE Grad
2*
Nein (1)
CTCAE Grad 3 (3)
CTCAE Grad 4 (4)
HÃ¤modialyse oder HÃ¤mofiltration*
Nein (1)
Ja (2)
Fanconi-Syndrom*
Nein (1)
1 / 2
Ja (2)
Nephrotisches Syndrom*
Nein (1)
Ja (2)
Severe hepatic complications
Relevante Bilirubin ErhÃ¶hung > CTCAE Grad 2*
Nein (1)
CTCAE Grad 3 (3)
CTCAE Grad 4 (4)
VOD
VOD*
Nein (1)
Ja (2)
Severe neurological complications
Leukenzephalopathie*
Nein (1)
Ja (2)
ZNS-Blutung*
Nein (1)
Ja (2)
KrampfanfÃ¤lle*
Nein (1)
Ja (2)
Severe gastrointestinal complications
Ileus*
Nein (1)
Ja (2)
Gastrointestinale Blutung*
Nein (1)
Ja (2)
Other severe complications
Andere schwere Komplikation(en)*
Nein (1)
Ja (2)
Beschreibung der anderen schweren
Komplikation(en)*
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EWOG MDS 2006 Treatment after HSCT
Prospective non–randomized multi_center study for
epidemiology and characterization of Myelodysplastic
Syndromes(MDS) and Juvenile Myelomonocytic Leukemia
(JMML) in childhood. PI: Prof. Dr. Charlotte Niemeyer
http://clinicaltrials.gov/ct2/show/NCT00662090
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All rights reserved. Please visit https://medical-data-
models.org/forms/5351
Treatment after HSCT
Show identification of patient
Dummy
Treatment after HSCT
Art der Therapie*
Chemotherapie (1)
Weitere HSZT (2)
Zelltherapie (3)
Reason for therapy
Indikation fÃ¼r die Zelltherapie*
Rezidiv (1)
Nicht erreichte Remission (2)
Gemischter Chimerismus (3)
Transplantatversagen (4)
GvHD (5)
Virusinfektion (6)
EBV assoziierte Lymphproliferation (7)
Prophylaktischer Einsatz (8)
Anderer (99)
Anderer Grund*
Reason for therapy
Indikation fÃ¼r weitere HSZT*
Rezidiv (1)
Nicht erreichte Remission (2)
Gemischter Chimerismus (3)
Transplantatversagen (4)
Anderer (99)
Anderer Grund*
Reason for therapy
Indikation fÃ¼r die Chemotherapie*
Rezidiv (1)
Nicht erreichte Remission (2)
EBV assoziierte Lymphproliferation (7)
Prophylaktischer Einsatz (8)
Anderer (99)
1 / 2
Anderer Grund*
Infusions
Art des Spenders*
Autolog (1)
Allogen (2)
Art der Infusion*
MNC-Zellen (1)
CD34+ Zellen (2)
CD3+ Zellen (3)
Dentritische Zellen (4)
Mesenchymale Stammzellen (5)
NK-Zellen (6)
Antigenspezifische T-Zellen (7)
Fibroblasten (8)
Art der Infusion (2)
MNC-Zellen (1)
CD34+ Zellen (2)
CD3+ Zellen (3)
Dentritische Zellen (4)
Mesenchymale Stammzellen (5)
NK-Zellen (6)
Antigenspezifische T-Zellen (7)
Fibroblasten (8)
Art der Infusion (3)
MNC-Zellen (1)
CD34+ Zellen (2)
CD3+ Zellen (3)
Dentritische Zellen (4)
Mesenchymale Stammzellen (5)
NK-Zellen (6)
Antigenspezifische T-Zellen (7)
Fibroblasten (8)
Anzahl an Infusionen dieser Art*
Datum der (ersten) Zellinfusion
Bemerkung
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EWOG MDS 2006 Treatment after HSCT
EWOG MDS 2006 Status after HSCT till
day +100
Prospective non–randomized multi_center study for
epidemiology and characterization of Myelodysplastic
Syndromes(MDS) and Juvenile Myelomonocytic Leukemia
(JMML) in childhood. PI: Prof. Dr. Charlotte Niemeyer
http://clinicaltrials.gov/ct2/show/NCT00662090
http://www.ewog-mds.org/
All rights reserved. Please visit https://medical-data-
models.org/forms/5352
Status after HSCT till day +100
Show identification of patient
Dummy
Disease status till day +100
Autologe Rekonstitution*
Nein (1)
Ja (2)
SekundÃ¤rmalignom*
Nein (1)
Ja (2)
Rezidiv oder Progress aufgetreten*
Nein (1)
Ja (2)
Bester Erkrankungsstatus*
Komplette Remission (CR) (1)
Partielle Remission (PR) (2)
Keine Remission bzw. nie in Remission
gewesen (3)
Chronolog. Nr. dieser kompletten Remission*
Chronolog. Nr. dieser Teilremission*
Survival status
Ãœberlebensstatus*
Verstorben (1)
Lebt (2)
Lost to follow-up (9)
Score Karnofsky/Lansky*
10% (10)
100% (100)
20% (20)
30% (30)
40% (40)
50% (50)
60% (60)
70% (70)
80% (80)
90% (90)
Datum Bewertung*
1 / 1
EWOG MDS 2006 GvHD
Prospective non–randomized multi_center study for
epidemiology and characterization of Myelodysplastic
Syndromes(MDS) and Juvenile Myelomonocytic Leukemia
(JMML) in childhood. PI: Prof. Dr. Charlotte Niemeyer
http://clinicaltrials.gov/ct2/show/NCT00662090
http://www.ewog-mds.org/
All rights reserved. Please visit https://medical-data-
models.org/forms/5353
GvHD
Show identification of patient
Dummy
Type of GvHD
Art der GvHD*
Akut (1)
Chronisch (2)
Datum der Erstmanifestation*
Acute GvHD
Histologisch bestÃ¤tigt*
Nein (1)
Ja (2)
Stadium der Haut*
Keine (0)
Stage 1 (1)
Stage 2 (2)
Stage 3 (3)
Stage 4 (4)
Stadium der Leber*
Keine (0)
Stage 1 (1)
Stage 2 (2)
Stage 3 (3)
Stage 4 (4)
Stadium des Gastrointestinaltraktes*
Keine (0)
Stage 1 (1)
Stage 2 (2)
Stage 3 (3)
Stage 4 (4)
Grad der akuten GvHD*
Grad I (1)
Grad II (2)
Grad III (3)
Grad IV (4)
Chronic GvHD
Klassische chronische GvHD*
1 / 3
Nein (1)
Ja (2)
Ãœberlappungssyndrom der akuten/chronischen
GvHD*
Nein (1)
Ja (2)
Staging according to NIH consensus
GvHD Score Lansky/Karnofski*
Score 0 (0)
Score 1 (1)
Score 2 (2)
Score 3 (3)
GvHD Score Haut*
Score 0 (0)
Score 1 (1)
Score 2 (2)
Score 3 (3)
GvHD Score Mund*
Score 0 (0)
Score 1 (1)
Score 2 (2)
Score 3 (3)
GvHD Score Augen*
Score 0 (0)
Score 1 (1)
Score 2 (2)
Score 3 (3)
GvHD Score Gastrointestinaltrakt*
Score 0 (0)
Score 1 (1)
Score 2 (2)
Score 3 (3)
GvHD Score Lungen*
Score 0 (0)
Score 1 (1)
Score 2 (2)
Score 3 (3)
GvHD Score Leber*
Score 0 (0)
Score 1 (1)
Score 2 (2)
Score 3 (3)
GvHD Score Gelenke und Faszia*
Score 0 (0)
Score 1 (1)
Score 2 (2)
Score 3 (3)
GvHD Score Urogenitaltrakt*
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EWOG MDS 2006 GvHD
Score 0 (0)
Score 1 (1)
Score 2 (2)
Score 3 (3)
Maximaler Gesamtgrad GvHD*
Mild (1)
Moderat (2)
Schwer (3)
Staging according to classical definition
AusprÃ¤gung der chron. GvHD*
Limited (1)
Extended (2)
Resolution of GvHD in same period of
documentation
Ãœberwindung der GvHD*
Nein (1)
Ja (2)
Datum der Ãœberwindung der GvHD*
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EWOG MDS 2006 GvHD
EWOG MDS 2006 GvHD treatment
Prospective non–randomized multi_center study for
epidemiology and characterization of Myelodysplastic
Syndromes(MDS) and Juvenile Myelomonocytic Leukemia
(JMML) in childhood. PI: Prof. Dr. Charlotte Niemeyer
http://clinicaltrials.gov/ct2/show/NCT00662090
http://www.ewog-mds.org/
All rights reserved. Please visit https://medical-data-
models.org/forms/5354
GvHD treatment
Show identification of patient
Dummy
Treatment of GvHD
CSA verabreicht*
Nein (1)
Ja (2)
Prednison verabreicht*
Nein (1)
Ja (2)
MMF verabreicht*
Nein (1)
Ja (2)
Anderes Medikament verabreicht*
Nein (1)
Ja (2)
ECP durchgefÃ¼hrt*
Nein (1)
Ja (2)
CSA in GvHD treatment
Neu begonnen / fortgesetzt*
Fortgesetzt (1)
Neu begonnen (2)
Datum der ersten CSA-Gabe*
Beendet*
Nein (1)
Ja (2)
Datum der letzten CSA-Gabe*
Prednison in GvHD treatment
Neu begonnen / fortgesetzt*
Fortgesetzt (1)
Neu begonnen (2)
Datum der ersten Prednisonanwendung*
1 / 2
Beendet*
Nein (1)
Ja (2)
Datum der letzten Prednisonanwendung*
MMF in GvHD treatment
Neu begonnen / fortgesetzt*
Fortgesetzt (1)
Neu begonnen (2)
Datum der ersten MMF Dosis*
Beendet*
Nein (1)
Ja (2)
Datum der letzten MMF Dosis*
Other drug in GvHD treatment
Falls anderes Generikum, Name*
Neu begonnen / fortgesetzt*
Fortgesetzt (1)
Neu begonnen (2)
Datum der ersten Gabe*
Beendet*
Nein (1)
Ja (2)
Datum der letzten Gabe*
ECP in GvHD treatment
Neu begonnen / fortgesetzt*
Fortgesetzt (1)
Neu begonnen (2)
Datum erste ECP-Applikation*
Beendet*
Nein (1)
Ja (2)
Datum letzte ECP-Applikation*
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EWOG MDS 2006 GvHD treatment
EWOG MDS 2006 Infection
Prospective non–randomized multi_center study for
epidemiology and characterization of Myelodysplastic
Syndromes(MDS) and Juvenile Myelomonocytic Leukemia
(JMML) in childhood. PI: Prof. Dr. Charlotte Niemeyer
http://clinicaltrials.gov/ct2/show/NCT00662090
http://www.ewog-mds.org/
All rights reserved. Please visit https://medical-data-
models.org/forms/5355
Infection
Show identification of patient
Dummy
Infection
Datum*
Infektionsart, klinisch*
Viral (1)
Bakteriell (2)
Fungal (3)
Parasitisch (4)
AusprÃ¤gung der Lokalisation*
Systemisch (1)
Lokalisiert (2)
Lokalisation*
Respiratorisches System (1)
Gastrointestinaltrakt (2)
ZNS (3)
Urogenitaltrakt (4)
Andere Lokalisation (99)
Andere Lokalisation*
Infection pathogen
Erreger identifiziert*
Nein (1)
Ja (2)
Viral infection
Virus*
CMV (1)
EBV (2)
Adenovirus (3)
Anderer (99)
Anderer Erreger*
CMV infection
1 / 2
Status CMV-Infektion*
CMV-Reaktivierung (1)
CMV-Erkrankung (2)
EBV infection
Status EBV-Infektion*
Infektion (1)
PTLD (2)
Fungal infection
Pilz*
Aspergillus (1)
Candida (2)
Anderer (99)
Anderer Erreger*
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EWOG MDS 2006 Infection
EWOG MDS 2006 Jahres-Follow-up (Jahr
{0})
Prospective non–randomized multi_center study for
epidemiology and characterization of Myelodysplastic
Syndromes(MDS) and Juvenile Myelomonocytic Leukemia
(JMML) in childhood. PI: Prof. Dr. Charlotte Niemeyer
http://clinicaltrials.gov/ct2/show/NCT00662090
http://www.ewog-mds.org/
All rights reserved. Please visit https://medical-data-
models.org/forms/5356
Jahres-Follow-up (Jahr {0})
Show identification of patient
Dummy
Covered period and date of
documentation
Ende des Beobachtungszeitraumes*
Anzahl Jahre seit HSZT*
1 / 1
EWOG MDS 2006 Severe complications
after day 100
Prospective non–randomized multi_center study for
epidemiology and characterization of Myelodysplastic
Syndromes(MDS) and Juvenile Myelomonocytic Leukemia
(JMML) in childhood. PI: Prof. Dr. Charlotte Niemeyer
http://clinicaltrials.gov/ct2/show/NCT00662090
http://www.ewog-mds.org/
All rights reserved. Please visit https://medical-data-
models.org/forms/5357
Severe complications after day 100
Show identification of patient
Dummy
Severe infection occurred
Infektion*
Nein (1)
Ja (2)
Severe pulmonary complications
Radiologische VerÃ¤nderungen und/oder
Sauerstoffbedarf*
Nein (1)
Ja (2)
KÃ¼nstliche Beatmung*
Nein (1)
Ja (2)
Severe cardio-vascular complications
Shortening Fraction < 25 %*
Nein (1)
Ja (2)
Katechecholaminbedarf*
Nein (1)
Ja (2)
TherapiebedÃ¼rftige Arrhythmien*
Nein (1)
Ja (2)
Severe renal complications
Relevante Kreatinin ErhÃ¶hung > CTCAE Grad
2*
Nein (1)
CTCAE Grad 3 (3)
CTCAE Grad 4 (4)
HÃ¤modialyse oder HÃ¤mofiltration*
Nein (1)
Ja (2)
Fanconi-Syndrom*
Nein (1)
1 / 3
Ja (2)
Nephrotisches Syndrom*
Nein (1)
Ja (2)
Severe hepatic complications
Relevante Bilirubin ErhÃ¶hung > CTCAE Grad 2*
Nein (1)
CTCAE Grad 3 (3)
CTCAE Grad 4 (4)
Severe neurological complications
Leukenzephalopathie*
Nein (1)
Ja (2)
ZNS-Blutung*
Nein (1)
Ja (2)
KrampfanfÃ¤lle*
Nein (1)
Ja (2)
Severe gastrointestinal complications
Ileus*
Nein (1)
Ja (2)
Gastrointestinale Blutung*
Nein (1)
Ja (2)
Severe endocrinologic complications
Hypothyreose*
Nein (1)
Ja (2)
Hypogonadismus*
Nein (1)
Ja (2)
WachstumsverzÃ¶gerung*
Nein (1)
Ja (2)
Severe sceletal complications
TherapiebedÃ¼rftige Osteopenie*
Nein (1)
2 / 3
EWOG MDS 2006 Severe complications after day 100
Ja (2)
Gelenkersatz*
Nein (1)
Ja (2)
Other severe complications
Andere schwere Komplikation(en)*
Nein (1)
Ja (2)
Beschreibung der anderen schweren
Komplikation(en)*
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EWOG MDS 2006 Severe complications after day 100
EWOG MDS 2006 Graft failure
Prospective non–randomized multi_center study for
epidemiology and characterization of Myelodysplastic
Syndromes(MDS) and Juvenile Myelomonocytic Leukemia
(JMML) in childhood. PI: Prof. Dr. Charlotte Niemeyer
http://clinicaltrials.gov/ct2/show/NCT00662090
http://www.ewog-mds.org/
All rights reserved. Please visit https://medical-data-
models.org/forms/5358
Graft failure
Show identification of patient
Dummy
Graft failure
Transplantatversagen aufgetreten*
Nein (1)
Ja (2)
Art des Transplantatversagens*
Abstoßung (1)
Spätes Transplantatversagen (2)
Datum des Transplantatversagens*
1 / 1
EWOG MDS 2006 Status annually after
HSCT
Prospective non–randomized multi_center study for
epidemiology and characterization of Myelodysplastic
Syndromes(MDS) and Juvenile Myelomonocytic Leukemia
(JMML) in childhood. PI: Prof. Dr. Charlotte Niemeyer
http://clinicaltrials.gov/ct2/show/NCT00662090
http://www.ewog-mds.org/
All rights reserved. Please visit https://medical-data-
models.org/forms/5359
Status annually after HSCT
Show identification of patient
Dummy
Disease status annually after HSCT
Autologe Rekonstitution*
Nein (1)
Ja (2)
SekundÃ¤rmalignom*
Nein (1)
Ja (2)
Rezidiv oder Progress aufgetreten*
Nein (1)
Ja (2)
Bester Erkrankungsstatus*
Komplette Remission (CR) (1)
Partielle Remission (PR) (2)
Keine Remission bzw. nie in Remission
gewesen (3)
Chronolog. Nr. dieser kompletten Remission*
Chronolog. Nr. dieser Teilremission*
Survival status
Ãœberlebensstatus*
Verstorben (1)
Lebt (2)
Lost to follow-up (9)
Score Karnofsky/Lansky*
10% (10)
100% (100)
20% (20)
30% (30)
40% (40)
50% (50)
60% (60)
70% (70)
80% (80)
90% (90)
Datum Bewertung*
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EWOG MDS 2006 Relapse or progression
Prospective non–randomized multi_center study for
epidemiology and characterization of Myelodysplastic
Syndromes(MDS) and Juvenile Myelomonocytic Leukemia
(JMML) in childhood. PI: Prof. Dr. Charlotte Niemeyer
http://clinicaltrials.gov/ct2/show/NCT00662090
http://www.ewog-mds.org/
All rights reserved. Please visit https://medical-data-
models.org/forms/5360
Relapse or progression
Show identification of patient
Dummy
Relapse or progression
Datum Rezidiv/Progress*
Chronologische Nr. dieses Rezidivs/Progress*
Lokalisation Knochenmark*
Nein (1)
Ja (2)
Lokalisation ZNS*
Nein (1)
Ja (2)
Lokalisation Hoden*
Nein (1)
Ja (2)
Andere Lokalisation*
Nein (1)
Ja (2)
Bitte die andere Lokalisation spezifizieren*
Relapse dates (MDS specific)
Datum des Rezidivs (HÃ¤matologie)*
Datum des Rezidivs (Zytogenetik)*
Datum des Rezidivs (Molekulargenetik)*
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EWOG MDS 2006 Follow up (year {0})
Prospective non–randomized multi_center study for
epidemiology and characterization of Myelodysplastic
Syndromes(MDS) and Juvenile Myelomonocytic Leukemia
(JMML) in childhood. PI: Prof. Dr. Charlotte Niemeyer
http://clinicaltrials.gov/ct2/show/NCT00662090
http://www.ewog-mds.org/
All rights reserved. Please visit https://medical-data-
models.org/forms/5361
Follow up (year {0})
Show identification of patient
Dummy
Follow up
Anzahl Jahre seit HSZT*
Ãœberwindung der GvHD*
Nein (1)
Ja (2)
Datum der Ãœberwindung der GvHD*
1 / 1
EWOG MDS 2006 GvHD occurred
Prospective non–randomized multi_center study for
epidemiology and characterization of Myelodysplastic
Syndromes(MDS) and Juvenile Myelomonocytic Leukemia
(JMML) in childhood. PI: Prof. Dr. Charlotte Niemeyer
http://clinicaltrials.gov/ct2/show/NCT00662090
http://www.ewog-mds.org/
All rights reserved. Please visit https://medical-data-
models.org/forms/5362
GvHD occurred
Show identification of patient
Dummy
GvHD occurred
GvHD aufgetreten*
Nein (1)
Ja, noch nicht dokumentiert
(Neuauftreten) (2)
Ja, in vorheriger Periode bereits
dokumentiert (3)
1 / 1
EWOG MDS 2006 First complete response
(CR)
Prospective non–randomized multi_center study for
epidemiology and characterization of Myelodysplastic
Syndromes(MDS) and Juvenile Myelomonocytic Leukemia
(JMML) in childhood. PI: Prof. Dr. Charlotte Niemeyer
http://clinicaltrials.gov/ct2/show/NCT00662090
http://www.ewog-mds.org/
All rights reserved. Please visit https://medical-data-
models.org/forms/5363
First complete response (CR)
First complete response (CR)
Datum*
1 / 1
EWOG MDS 2006 First partial response
(PR)
Prospective non–randomized multi_center study for
epidemiology and characterization of Myelodysplastic
Syndromes(MDS) and Juvenile Myelomonocytic Leukemia
(JMML) in childhood. PI: Prof. Dr. Charlotte Niemeyer
http://clinicaltrials.gov/ct2/show/NCT00662090
http://www.ewog-mds.org/
All rights reserved. Please visit https://medical-data-
models.org/forms/5364
First partial response (PR)
First partial response (PR)
Datum*
1 / 1
EWOG MDS 2006 MDS participation
Prospective non–randomized multi_center study for
epidemiology and characterization of Myelodysplastic
Syndromes(MDS) and Juvenile Myelomonocytic Leukemia
(JMML) in childhood. PI: Prof. Dr. Charlotte Niemeyer
http://clinicaltrials.gov/ct2/show/NCT00662090
http://www.ewog-mds.org/
All rights reserved. Please visit https://medical-data-
models.org/forms/5365
MDS participation
Redirect
Einwilligung gegeben*
Nein (1)
Ja (2)
Datum der Einwilligung*
Studien-ID in dieser Studie
furtherstudyid
Teilnahme*
1 / 1
EWOG MDS 2006 Progress
Prospective non–randomized multi_center study for
epidemiology and characterization of Myelodysplastic
Syndromes(MDS) and Juvenile Myelomonocytic Leukemia
(JMML) in childhood. PI: Prof. Dr. Charlotte Niemeyer
http://clinicaltrials.gov/ct2/show/NCT00662090
http://www.ewog-mds.org/
All rights reserved. Please visit https://medical-data-
models.org/forms/5366
Progress
Show identification of patient
Dummy
Progress
Progress WHO*
MDR-AML (40)
RAEB (43)
RAEB-T (44)
MDS myelofibrotisch (60)
Unbekannt (99)
Progress-Datum*
1 / 1
EWOG SAA Medical history
Genetische und immunologische Charakterisierung der
schweren aplastischen Anaemie (SAA) bei Kindern und
Jugendlichen (EWOG-SAA) http://ewog-mds.org/
All rights reserved. Please visit https://medical-data-
models.org/forms/5398
Medical history
Show identification of patient
Dummy
Previous history
Mentale Retardierung*
Nein (1)
Ja (2)
Geburtsgewicht < dritte Perzentile
Nein (1)
Ja (2)
GrÃ¶ÃŸe < dritte Perzentile (bei Diagnose)
Nein (1)
Ja (2)
Gewicht < dritte Perzentile (bei Diagnose)
Nein (1)
Ja (2)
Kopfumfang < dritte Perzentile (bei Diagnose)*
Nein (1)
Ja (2)
Klinische Zeichen fÃ¼r PNH*
Nein (1)
Ja (2)
Sonstige AuffÃ¤lligkeiten*
Nein (1)
Ja (2)
Type of other abnormalties
Art der sonstigen AuffÃ¤lligkeiten*
Family history
Eltern sind konsanguin*
Nein (1)
Ja (2)
Maligne Erkrankungen in der Familie (Verwandte
ersten Grades)*
Nein (1)
Ja (2)
HÃ¤mato-/immunologische Erkrankungen*
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Nein (1)
Ja (2)
Weitere mÃ¶gliche relevante Erkrankungen*
Nein (1)
Ja (2)
Family history of malignancies
Mutter*
Nein (1)
Ja (2)
Vater*
Nein (1)
Ja (2)
Schwester*
Nein (1)
Ja (2)
Bruder*
Nein (1)
Ja (2)
Mother affected
Erkrankung der Mutter*
Father affected
Erkrankung des Vaters*
Sister affected
Erkrankung der Schwester*
Brother affected
Erkrankung des Bruders*
Hemato/Immunological diseases in the
family
Typ der hÃ¤mato-/immunologischen Erkrankung*
Type of other diseases in the family
Art der anderen mÃ¶glicherweise relevanten
Erkrankungen*
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EWOG SAA Medical history
EWOG SAA Jahres-Follow-up (Jahr {0})
Genetische und immunologische Charakterisierung der
schweren aplastischen Anaemie (SAA) bei Kindern und
Jugendlichen (EWOG-SAA) http://ewog-mds.org/
All rights reserved. Please visit https://medical-data-
models.org/forms/5399
Jahres-Follow-up (Jahr {0})
Show identification of patient
Dummy
Covered period and date of
documentation
Ende des Beobachtungszeitraumes*
Anzahl Jahre seit HSZT*
1 / 1
EWOG SAA BM Histology (regional
coordinator)
Genetische und immunologische Charakterisierung der
schweren aplastischen Anaemie (SAA) bei Kindern und
Jugendlichen (EWOG-SAA) http://ewog-mds.org/
All rights reserved. Please visit https://medical-data-
models.org/forms/5400
BM Histology (regional coordinator)
Show identification of patient
Dummy
Bone marrow biopsy basic data
Datum der Knochenmarkbiopsie*
Befundendes Labor*
Kerndrup (Vejle) (10)
Hernandez (Valencia) (11)
Simonitsch-Klupp (Wien) (2)
De Paepe (Ghent) (3)
Campr (Prag) (4)
Baumann (Boeblingen) (5)
Schwarz-Furlan (Kaufbeuren) (6)
O´Sullivan (Dublin) (7)
Devito (Rom) (8)
Leguit (Utrecht) (9)
Anderes (99)
Anderes Labor*
Quality
QualitÃ¤t der Knochenmarkbiopsie*
OK (1)
Ungenügend (2)
Nicht auswertbar (3)
Cellularity
Gesamt*
Komplette Aplasie (1)
Vermindert (2)
Normal (3)
Erhöht (4)
Myelofibrosis
Myelofibrose*
Nein (1)
Ja (2)
Art der Myelofibrose*
Schwach (1)
Moderat (2)
Schwerwiegend (3)
Blasts
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Prozent an Blasten*
< 5% (1)
5-9% (2)
10-19% (3)
20-29% (4)
30-50% (5)
> 50% (6)
Diagnosis
Diagnose*
Aplastische Anämie (21)
Hypoplastische Panmyelopathie (22)
Refraktäre Zytopenie (41)
Regeneration unter/nach Therapie (90)
Andere (99)
Andere Diagnose*
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EWOG SAA BM Histology (regional coordinator)
EWOG SAA Blood group and HLA typing
Genetische und immunologische Charakterisierung der
schweren aplastischen Anaemie (SAA) bei Kindern und
Jugendlichen (EWOG-SAA) http://ewog-mds.org/
All rights reserved. Please visit https://medical-data-
models.org/forms/5401
Blood group and HLA typing
Show identification of patient
Dummy
Blood group (patient)
Datum der Materialentnahme*
Blutgruppe*
A (1)
B (2)
AB (3)
0 (4)
Rhesusfaktor*
Negativ (1)
Positiv (2)
HLA typing (patient)
Datum der Materialentnahme*
Methode Klasse 1-Typisierung*
molekularbiologisch (1)
serologisch (2)
Methode Klasse 2-Typisierung*
molekularbiologisch (1)
serologisch (2)
HLA-A Allel 1*
HLA-A Allel 2*
HLA-B Allel 1*
HLA-B Allel 2*
HLA-C Allel 1*
HLA-C Allel 2*
HLA-DRB1 Allel 1*
HLA-DRB1 Allel 2*
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HLA-DQB1 Allel 1*
HLA-DQB1 Allel 2*
HLA-DPB1 Allel 1*
HLA-DPB1 Allel 2*
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EWOG SAA Blood group and HLA typing
EWOG SAA Haematological data on
PB_BM
Genetische und immunologische Charakterisierung der
schweren aplastischen Anaemie (SAA) bei Kindern und
Jugendlichen (EWOG-SAA) http://ewog-mds.org/
All rights reserved. Please visit https://medical-data-
models.org/forms/5402
Haematological data on PB/BM
Show identification of patient
Dummy
Basic data
Datum der KM Aspiration*
Befund Referenzmorphologie*
Prof. Niemeyer (Freiburg) (1)
Schmugge (Zürich) (10)
Dworzak (Wien) (2)
Philippe (Ghent) (3)
Stary (Prag) (4)
Smith (Dublin) (5)
Fenu (Rom) (6)
De Haas (Den Haag) (7)
Kerndrup (Vejle) (8)
Camos (Barcelona) (9)
Anderes (99)
Anderes Labor*
PB basic data
Erythrozytentransfusion in den letzten 4 Wochen*
Nein (1)
Ja (2)
Thrombozytentransfusion in den letzten 4
Wochen*
Nein (1)
Ja (2)
Hb Wert*
MCV*
Thrombozyten*
Leukozyten*
Retikulozyten*
Erythrozyten*
Differential count
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Blasten*
Promyelozyten*
Myelozyten*
Metamyelozyten*
Stabkernige*
Segmentkernige*
Eosinophile*
Basophile*
Lymphozyten*
Monozyten*
Erythroblasten*
BM basic data
Zellgehalt*
Aplastisch (1)
Hypozellulär (2)
Normozellulär (3)
Hyperzellular (4)
Nicht beurteilbar (5)
Megakaryozyten*
Keine (1)
Vermindert (2)
Normal (3)
Erhöht (4)
Differential count
Blasten*
Promyelozyten*
Myelozyten*
Metamyelozyten*
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EWOG SAA Haematological data on PB_BM
Stabkernige*
Segmentkernige*
Eosinophile*
Basophile*
Lymphozyten*
Monozyten*
Erythroblasten*
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EWOG SAA Haematological data on PB_BM
EWOG SAA Chimerism
Genetische und immunologische Charakterisierung der
schweren aplastischen Anaemie (SAA) bei Kindern und
Jugendlichen (EWOG-SAA) http://ewog-mds.org/
All rights reserved. Please visit https://medical-data-
models.org/forms/5404
Chimerism
Show identification of patient
Dummy
Best chimerism
Materialart*
Peripheres Blut (1)
Knochenmark (3)
Datum der Materialentnahme*
ChimÃ¤rismus Methode*
STR (Short Tandem Repeats) (1)
Andere Methode (99)
% Spender-Zellen*
Further chimerism
Materialart*
Peripheres Blut (1)
Knochenmark (3)
Datum der Materialentnahme*
ChimÃ¤rismus Methode*
STR (Short Tandem Repeats) (1)
Andere Methode (99)
% Spender-Zellen*
1 / 1
EWOG SAA Severe complications till day
+100
Genetische und immunologische Charakterisierung der
schweren aplastischen Anaemie (SAA) bei Kindern und
Jugendlichen (EWOG-SAA) http://ewog-mds.org/
All rights reserved. Please visit https://medical-data-
models.org/forms/5405
Severe complications till day +100
Show identification of patient
Dummy
Severe infection occurred
Infektion*
Nein (1)
Ja (2)
Severe pulmonary complications
Radiologische VerÃ¤nderungen und/oder
Sauerstoffbedarf*
Nein (1)
Ja (2)
KÃ¼nstliche Beatmung*
Nein (1)
Ja (2)
Severe cardio-vascular complications
Shortening Fraction < 25 %*
Nein (1)
Ja (2)
Katechecholaminbedarf*
Nein (1)
Ja (2)
TherapiebedÃ¼rftige Arrhythmien*
Nein (1)
Ja (2)
Severe renal complications
Relevante Kreatinin ErhÃ¶hung > CTCAE Grad
2*
Nein (1)
CTCAE Grad 3 (3)
CTCAE Grad 4 (4)
HÃ¤modialyse oder HÃ¤mofiltration*
Nein (1)
Ja (2)
Fanconi-Syndrom*
Nein (1)
1 / 2
Ja (2)
Nephrotisches Syndrom*
Nein (1)
Ja (2)
Severe hepatic complications
Relevante Bilirubin ErhÃ¶hung > CTCAE Grad 2*
Nein (1)
CTCAE Grad 3 (3)
CTCAE Grad 4 (4)
VOD
VOD*
Nein (1)
Ja (2)
Severe neurological complications
Leukenzephalopathie*
Nein (1)
Ja (2)
ZNS-Blutung*
Nein (1)
Ja (2)
KrampfanfÃ¤lle*
Nein (1)
Ja (2)
Severe gastrointestinal complications
Ileus*
Nein (1)
Ja (2)
Gastrointestinale Blutung*
Nein (1)
Ja (2)
Other severe complications
Andere schwere Komplikation(en)*
Nein (1)
Ja (2)
Beschreibung der anderen schweren
Komplikation(en)*
2 / 2
EWOG SAA Severe complications till day +100
EWOG SAA Infection
Genetische und immunologische Charakterisierung der
schweren aplastischen Anaemie (SAA) bei Kindern und
Jugendlichen (EWOG-SAA) http://ewog-mds.org/
All rights reserved. Please visit https://medical-data-
models.org/forms/5406
Infection
Show identification of patient
Dummy
Infection
Datum*
Infektionsart, klinisch*
Viral (1)
Bakteriell (2)
Fungal (3)
Parasitisch (4)
AusprÃ¤gung der Lokalisation*
Systemisch (1)
Lokalisiert (2)
Lokalisation*
Respiratorisches System (1)
Gastrointestinaltrakt (2)
ZNS (3)
Urogenitaltrakt (4)
Andere Lokalisation (99)
Andere Lokalisation*
Infection pathogen
Erreger identifiziert*
Nein (1)
Ja (2)
Viral infection
Virus*
CMV (1)
EBV (2)
Adenovirus (3)
Anderer (99)
Anderer Erreger*
CMV infection
Status CMV-Infektion*
CMV-Reaktivierung (1)
1 / 2
CMV-Erkrankung (2)
EBV infection
Status EBV-Infektion*
Infektion (1)
PTLD (2)
Fungal infection
Pilz*
Aspergillus (1)
Candida (2)
Anderer (99)
Anderer Erreger*
2 / 2
EWOG SAA Infection
EWOG SAA Severe complications after day
100
Genetische und immunologische Charakterisierung der
schweren aplastischen Anaemie (SAA) bei Kindern und
Jugendlichen (EWOG-SAA) http://ewog-mds.org/
All rights reserved. Please visit https://medical-data-
models.org/forms/5407
Severe complications after day 100
Show identification of patient
Dummy
Severe infection occurred
Infektion*
Nein (1)
Ja (2)
Severe pulmonary complications
Radiologische VerÃ¤nderungen und/oder
Sauerstoffbedarf*
Nein (1)
Ja (2)
KÃ¼nstliche Beatmung*
Nein (1)
Ja (2)
Severe cardio-vascular complications
Shortening Fraction < 25 %*
Nein (1)
Ja (2)
Katechecholaminbedarf*
Nein (1)
Ja (2)
TherapiebedÃ¼rftige Arrhythmien*
Nein (1)
Ja (2)
Severe renal complications
Relevante Kreatinin ErhÃ¶hung > CTCAE Grad
2*
Nein (1)
CTCAE Grad 3 (3)
CTCAE Grad 4 (4)
HÃ¤modialyse oder HÃ¤mofiltration*
Nein (1)
Ja (2)
Fanconi-Syndrom*
Nein (1)
1 / 3
Ja (2)
Nephrotisches Syndrom*
Nein (1)
Ja (2)
Severe hepatic complications
Relevante Bilirubin ErhÃ¶hung > CTCAE Grad 2*
Nein (1)
CTCAE Grad 3 (3)
CTCAE Grad 4 (4)
Severe neurological complications
Leukenzephalopathie*
Nein (1)
Ja (2)
ZNS-Blutung*
Nein (1)
Ja (2)
KrampfanfÃ¤lle*
Nein (1)
Ja (2)
Severe gastrointestinal complications
Ileus*
Nein (1)
Ja (2)
Gastrointestinale Blutung*
Nein (1)
Ja (2)
Severe endocrinologic complications
Hypothyreose*
Nein (1)
Ja (2)
Hypogonadismus*
Nein (1)
Ja (2)
WachstumsverzÃ¶gerung*
Nein (1)
Ja (2)
Severe sceletal complications
TherapiebedÃ¼rftige Osteopenie*
Nein (1)
2 / 3
EWOG SAA Severe complications after day 100
Ja (2)
Gelenkersatz*
Nein (1)
Ja (2)
3 / 3
EWOG SAA Severe complications after day 100
EWOG SAA Graft failure
Genetische und immunologische Charakterisierung der
schweren aplastischen Anaemie (SAA) bei Kindern und
Jugendlichen (EWOG-SAA) http://ewog-mds.org/
All rights reserved. Please visit https://medical-data-
models.org/forms/5411
Graft failure
Show identification of patient
Dummy
Graft failure
Transplantatversagen aufgetreten*
Nein (1)
Ja (2)
Art des Transplantatversagens*
Abstoßung (1)
Spätes Transplantatversagen (2)
Datum des Transplantatversagens*
1 / 1
EWOG SAA Day +100
Genetische und immunologische Charakterisierung der
schweren aplastischen Anaemie (SAA) bei Kindern und
Jugendlichen (EWOG-SAA) http://ewog-mds.org/
All rights reserved. Please visit https://medical-data-
models.org/forms/5412
Day +100
Show identification of patient
Dummy
Data about day +100
Datum Tag +100*
1 / 1
EWOG SAA Patient deceased
Genetische und immunologische Charakterisierung der
schweren aplastischen Anaemie (SAA) bei Kindern und
Jugendlichen (EWOG-SAA) http://ewog-mds.org/
All rights reserved. Please visit https://medical-data-
models.org/forms/5415
Patient deceased
Show identification of patient
Dummy
Patient deceased
Todesdatum*
Todesursache*
Grunderkrankung: Rezidiv, Progression
oder Persistenz (1)
HSZT-bezogene Ursache (2)
Anderer Grund (99)
Andere Todesursache*
HSCT related cause(s) of death
GvHD*
Nein (1)
Ja (2)
Transplantatversagen*
Nein (1)
Ja (2)
Pulmonale ToxizitÃ¤t*
Nein (1)
Ja (2)
Kardiologische ToxizitÃ¤t*
Nein (1)
Ja (2)
Infektion*
Nein (1)
Ja (2)
VOD*
Nein (1)
Ja (2)
Lymphoproliferative Erkrankung (PTLD)*
Nein (1)
Ja (2)
Andere HSZT-bezogene Ursache*
Nein (1)
Ja (2)
1 / 2
HSZT-bezogene Ursache*
2 / 2
EWOG SAA Patient deceased
EWOG SAA Allogeneic donor
Genetische und immunologische Charakterisierung der
schweren aplastischen Anaemie (SAA) bei Kindern und
Jugendlichen (EWOG-SAA) http://ewog-mds.org/
All rights reserved. Please visit https://medical-data-
models.org/forms/5418
Allogeneic donor
Show identification of patient
Dummy
Basic data on donor
Alter des Spenders*
Spender Geschlecht*
Männlich (1)
Weiblich (2)
VerwandtschaftsverhÃ¤ltnis*
Nicht verwandt (1)
Eineiiger Zwilling (2)
Andere Geschwister (3)
Andere Verwandschaften (4)
Interner Spender Identifikator*
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
Externer Spender Identifikator (Spenderregister)*
WMDA-Code*
Spenderregister oder CB-Bank*
Blood group of donor
Datum der Materialentnahme*
Spender Blutgruppe*
A (1)
B (2)
AB (3)
0 (4)
Spender Rhesusfaktor*
Negativ (1)
Positiv (2)
HLA typing of donor
1 / 4
Datum der Materialentnahme*
Methode Klasse 1-Typisierung*
molekularbiologisch (1)
serologisch (2)
Methode Klasse 2-Typisierung*
molekularbiologisch (1)
serologisch (2)
HLA-A Allel 1*
HLA-A Allel 2*
HLA-B Allel 1*
HLA-B Allel 2*
HLA-C Allel 1*
HLA-C Allel 2*
HLA-DRB1 Allel 1*
HLA-DRB1 Allel 2*
HLA-DQB1 Allel 1*
HLA-DQB1 Allel 2*
HLA-DPB1 Allel 1*
HLA-DPB1 Allel 2*
HLA matching
Anzahl untersuchter Loci*
Anzahl Mismatch Antigen*
Loci Antigen Mismatch*
Anzahl Mismatch Allel*
Loci Allel Mismatch*
2 / 4
EWOG SAA Allogeneic donor
Markers of infection of donor
Spender CMV IgG*
Negativ (1)
Positiv (2)
Spender CMV IgM*
Negativ (1)
Positiv (2)
Spender EBV IgG*
Negativ (1)
Positiv (2)
Spender EBV IgM*
Negativ (1)
Positiv (2)
Spender Anti Hbc*
Negativ (1)
Positiv (2)
Spender HBs Ag*
Negativ (1)
Positiv (2)
Spender Anti Hbs*
Negativ (1)
Positiv (2)
Spender HCV IgG*
Negativ (1)
Positiv (2)
Spender HIV IgG*
Negativ (1)
Positiv (2)
Spender HSV IgG*
Negativ (1)
Positiv (2)
Spender HTLV IgG*
Negativ (1)
Positiv (2)
Spender Toxoplasma IgG*
Negativ (1)
Positiv (2)
Spender VZV IgG*
Negativ (1)
Positiv (2)
Spender HCV PCR*
Negativ (1)
Positiv (2)
Spender HIV PCR*
3 / 4
EWOG SAA Allogeneic donor
Negativ (1)
Positiv (2)
Spender HTLV PCR*
Negativ (1)
Positiv (2)
4 / 4
EWOG SAA Allogeneic donor
EWOG SAA Engraftment
Genetische und immunologische Charakterisierung der
schweren aplastischen Anaemie (SAA) bei Kindern und
Jugendlichen (EWOG-SAA) http://ewog-mds.org/
All rights reserved. Please visit https://medical-data-
models.org/forms/5420
Engraftment
Show identification of patient
Dummy
Engraftment
Leukozyten-Engraftment*
Nein (1)
Ja (2)
Lagen niemals unter diesem Wert (3)
Datum Leukozyten-Engraftment*
Neutrophilen Engraftment*
Nein (1)
Ja (2)
Lagen niemals unter diesem Wert (3)
Datum Neutrophilen Engraftment*
Thrombozyten > 20 x 10E9/l*
Nein (1)
Ja (2)
Lagen niemals unter diesem Wert (3)
Datum Thrombozyten > 20 x 10E9/l*
Thrombozyten > 50 x 10E9/l*
Nein (1)
Ja (2)
Lagen niemals unter diesem Wert (3)
Datum Thrombozyten > 50 x 10E9/l*
Erythrozytentransfusion erforderlich > Tag 100*
Nein (1)
Ja (2)
Graft failure
Transplantatversagen aufgetreten*
Nein (1)
Ja (2)
Art des Transplantatversagens*
Abstoßung (1)
Spätes Transplantatversagen (2)
1 / 2
Datum des Transplantatversagens*
2 / 2
EWOG SAA Engraftment
EWOG SAA GvHD
Genetische und immunologische Charakterisierung der
schweren aplastischen Anaemie (SAA) bei Kindern und
Jugendlichen (EWOG-SAA) http://ewog-mds.org/
All rights reserved. Please visit https://medical-data-
models.org/forms/5421
GvHD
Show identification of patient
Dummy
Type of GvHD
Art der GvHD*
Akut (1)
Chronisch (2)
Datum der Erstmanifestation*
Acute GvHD
Histologisch bestÃ¤tigt*
Nein (1)
Ja (2)
Stadium der Haut*
Keine (0)
Stage 1 (1)
Stage 2 (2)
Stage 3 (3)
Stage 4 (4)
Stadium der Leber*
Keine (0)
Stage 1 (1)
Stage 2 (2)
Stage 3 (3)
Stage 4 (4)
Stadium des Gastrointestinaltraktes*
Keine (0)
Stage 1 (1)
Stage 2 (2)
Stage 3 (3)
Stage 4 (4)
Grad der akuten GvHD*
Grad I (1)
Grad II (2)
Grad III (3)
Grad IV (4)
Chronic GvHD
Klassische chronische GvHD*
Nein (1)
Ja (2)
1 / 3
Ãœberlappungssyndrom der akuten/chronischen
GvHD*
Nein (1)
Ja (2)
Staging according to NIH consensus
GvHD Score Lansky/Karnofski*
Score 0 (0)
Score 1 (1)
Score 2 (2)
Score 3 (3)
GvHD Score Haut*
Score 0 (0)
Score 1 (1)
Score 2 (2)
Score 3 (3)
GvHD Score Mund*
Score 0 (0)
Score 1 (1)
Score 2 (2)
Score 3 (3)
GvHD Score Augen*
Score 0 (0)
Score 1 (1)
Score 2 (2)
Score 3 (3)
GvHD Score Gastrointestinaltrakt*
Score 0 (0)
Score 1 (1)
Score 2 (2)
Score 3 (3)
GvHD Score Lungen*
Score 0 (0)
Score 1 (1)
Score 2 (2)
Score 3 (3)
GvHD Score Leber*
Score 0 (0)
Score 1 (1)
Score 2 (2)
Score 3 (3)
GvHD Score Gelenke und Faszia*
Score 0 (0)
Score 1 (1)
Score 2 (2)
Score 3 (3)
GvHD Score Urogenitaltrakt*
Score 0 (0)
Score 1 (1)
Score 2 (2)
2 / 3
EWOG SAA GvHD
Score 3 (3)
Maximaler Gesamtgrad GvHD*
Mild (1)
Moderat (2)
Schwer (3)
Staging according to classical definition
AusprÃ¤gung der chron. GvHD*
Limited (1)
Extended (2)
Resolution of GvHD in same period of
documentation
Ãœberwindung der GvHD*
Nein (1)
Ja (2)
Datum der Ãœberwindung der GvHD*
3 / 3
EWOG SAA GvHD
EWOG SAA Follow up (year {0})
Genetische und immunologische Charakterisierung der
schweren aplastischen Anaemie (SAA) bei Kindern und
Jugendlichen (EWOG-SAA) http://ewog-mds.org/
All rights reserved. Please visit https://medical-data-
models.org/forms/5422
Follow up (year {0})
Show identification of patient
Dummy
Follow up
Anzahl Jahre seit HSZT*
Ãœberwindung der GvHD*
Nein (1)
Ja (2)
Datum der Ãœberwindung der GvHD*
1 / 1
EWOG SAA GvHD occurred
Genetische und immunologische Charakterisierung der
schweren aplastischen Anaemie (SAA) bei Kindern und
Jugendlichen (EWOG-SAA) http://ewog-mds.org/
All rights reserved. Please visit https://medical-data-
models.org/forms/5423
GvHD occurred
Show identification of patient
Dummy
GvHD occurred
GvHD aufgetreten*
Nein (1)
Ja, noch nicht dokumentiert
(Neuauftreten) (2)
Ja, in vorheriger Periode bereits
dokumentiert (3)
1 / 1
EWOG SAA GvHD treatment
Genetische und immunologische Charakterisierung der
schweren aplastischen Anaemie (SAA) bei Kindern und
Jugendlichen (EWOG-SAA) http://ewog-mds.org/
All rights reserved. Please visit https://medical-data-
models.org/forms/5424
GvHD treatment
Show identification of patient
Dummy
Treatment of GvHD
CSA verabreicht*
Nein (1)
Ja (2)
Prednison verabreicht*
Nein (1)
Ja (2)
MMF verabreicht*
Nein (1)
Ja (2)
Anderes Medikament verabreicht*
Nein (1)
Ja (2)
ECP durchgefÃ¼hrt*
Nein (1)
Ja (2)
CSA in GvHD treatment
Neu begonnen / fortgesetzt*
Fortgesetzt (1)
Neu begonnen (2)
Datum der ersten CSA-Gabe*
Beendet*
Nein (1)
Ja (2)
Datum der letzten CSA-Gabe*
Prednison in GvHD treatment
Neu begonnen / fortgesetzt*
Fortgesetzt (1)
Neu begonnen (2)
Datum der ersten Prednisonanwendung*
1 / 2
Beendet*
Nein (1)
Ja (2)
Datum der letzten Prednisonanwendung*
MMF in GvHD treatment
Neu begonnen / fortgesetzt*
Fortgesetzt (1)
Neu begonnen (2)
Datum der ersten MMF Dosis*
Beendet*
Nein (1)
Ja (2)
Datum der letzten MMF Dosis*
Other drug in GvHD treatment
Falls anderes Generikum, Name*
Neu begonnen / fortgesetzt*
Fortgesetzt (1)
Neu begonnen (2)
Datum der ersten Gabe*
Beendet*
Nein (1)
Ja (2)
Datum der letzten Gabe*
ECP in GvHD treatment
Neu begonnen / fortgesetzt*
Fortgesetzt (1)
Neu begonnen (2)
Datum erste ECP-Applikation*
Beendet*
Nein (1)
Ja (2)
Datum letzte ECP-Applikation*
2 / 2
EWOG SAA GvHD treatment
EWOG SAA GvHD occurred
Genetische und immunologische Charakterisierung der
schweren aplastischen Anaemie (SAA) bei Kindern und
Jugendlichen (EWOG-SAA) http://ewog-mds.org/
All rights reserved. Please visit https://medical-data-
models.org/forms/5425
GvHD occurred
Show identification of patient
Dummy
GvHD occurred
GvHD aufgetreten*
Nein (1)
Ja (2)
1 / 1
EWOG SAA GvHD prophylaxis
Genetische und immunologische Charakterisierung der
schweren aplastischen Anaemie (SAA) bei Kindern und
Jugendlichen (EWOG-SAA) http://ewog-mds.org/
All rights reserved. Please visit https://medical-data-
models.org/forms/5426
GvHD prophylaxis
Show identification of patient
Dummy
GvHD prophylaxis CSA
CSA verabreicht*
Nein (1)
Ja (2)
GvHD prophylaxis CSA application
Datum der ersten CSA-Gabe*
Anfangsdosis i.v. CSA*
Beendet*
Nein (1)
Ja (2)
Datum der letzten CSA-Gabe*
GvHD prophylaxis MTX
MTX verabreicht*
Nein (1)
Ja (2)
GvHD prophylaxis MTX application
Anzahl MTX-Applikationstage*
LCV-Rescue*
Nein (1)
Ja (2)
Other drug for GvHD prophylaxis
Anderes Medikament verabreicht*
Nein (1)
Ja (2)
Other drug application for GvHD
prophylaxis
1 / 2
Falls anderes Generikum, Name*
Neu begonnen / fortgesetzt*
Fortgesetzt (1)
Neu begonnen (2)
Datum der ersten Gabe*
Beendet*
Nein (1)
Ja (2)
Datum der letzten Gabe*
2 / 2
EWOG SAA GvHD prophylaxis
EWOG SAA HSCT {0}
Genetische und immunologische Charakterisierung der
schweren aplastischen Anaemie (SAA) bei Kindern und
Jugendlichen (EWOG-SAA) http://ewog-mds.org/
All rights reserved. Please visit https://medical-data-
models.org/forms/5427
HSCT {0}
Show identification of patient
Dummy
General HSCT data
Dokumentierte HSZT*
1. (1)
2. (2)
3. (3)
4. (4)
5. (5)
Transplantationsdatum*
Art der HSZT*
Autolog (1)
Allogen (2)
Dokumentierendes Zentrum
Event center LocationOID
1 / 1
EWOG SAA Conditioning chemo therapy
Genetische und immunologische Charakterisierung der
schweren aplastischen Anaemie (SAA) bei Kindern und
Jugendlichen (EWOG-SAA) http://ewog-mds.org/
All rights reserved. Please visit https://medical-data-
models.org/forms/5428
Conditioning chemo therapy
Show identification of patient
Dummy
Conditioning chemo therapy generic
Generischer Wirkstoffname*
Falls anderes Generikum, Name*
ATG-PrÃ¤parat (Handelsname)*
Anderes ATG-PrÃ¤parat (Handelsname)*
Applikationsart*
p.o. (1)
i.v. (2)
p.i. (3)
i.th. (4)
i.vent. (5)
i.m. (6)
s.c. (7)
lokal (8)
supp (9)
Verordnete Tagesdosis*
Dosismodifikation*
Nein (1)
Ja (2)
Indikation fÃ¼r die Dosisabweichung*
Day of administration
Verabreicht an Tag*
-1 (1)
-10 (10)
-11 (11)
-12 (12)
-13 (13)
-14 (14)
-15 (15)
-2 (2)
-3 (3)
-4 (4)
-5 (5)
1 / 2
-6 (6)
-7 (7)
-8 (8)
-9 (9)
Further administration (outside range of -1
to -15)
Anderer Verabreichungstag*
2 / 2
EWOG SAA Conditioning chemo therapy
EWOG SAA Conditioning radiotherapy
Genetische und immunologische Charakterisierung der
schweren aplastischen Anaemie (SAA) bei Kindern und
Jugendlichen (EWOG-SAA) http://ewog-mds.org/
All rights reserved. Please visit https://medical-data-
models.org/forms/5429
Conditioning radiotherapy
Show identification of patient
Dummy
radiotherapy given
Radiotherapie in der Konditionierung*
Nein (1)
Ja (2)
Conditioning radiotherapy admistration
Bestrahlungsart*
Ganzkörperbestrahlung (1)
TLI (Total lymph.) (2)
Schädel Boost (3)
Hoden Boost (4)
TAI (Total abdominal) (5)
TNI (Total nodal irradiation) (6)
Anzahl Fraktionen pro Tag*
Dosis pro Fraktion*
Radionuclide therapy
Substanz*
MIBG (1)
Samarium (2)
Yttrium (3)
Dosis*
Beginn der Therapie*
Day of administration
Verabreicht an Tag*
-1 (1)
-10 (10)
-11 (11)
-12 (12)
-13 (13)
-14 (14)
-15 (15)
-2 (2)
-3 (3)
1 / 2
-4 (4)
-5 (5)
-6 (6)
-7 (7)
-8 (8)
-9 (9)
Further administration (outside range of -1
to -15)
Anderer Verabreichungstag*
2 / 2
EWOG SAA Conditioning radiotherapy
EWOG SAA Graft
Genetische und immunologische Charakterisierung der
schweren aplastischen Anaemie (SAA) bei Kindern und
Jugendlichen (EWOG-SAA) http://ewog-mds.org/
All rights reserved. Please visit https://medical-data-
models.org/forms/5430
Graft
Show identification of patient
Dummy
Graft
Interner Spender Identifikator*
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
Datum der Stammzellgewinnung*
Quelle der Stammzellen*
Knochenmark (1)
Nabelschnurblut (2)
Peripheres Blut (3)
Manipulation des Transplantats*
Nein (1)
Ja (2)
CD34-positiv Selektion*
Nein (1)
Ja (2)
CD3/CD19 Depletion*
Nein (1)
Ja (2)
Andere Manipulation durchgefÃ¼hrt*
Nein (1)
Ja (2)
Falls andere Manipulation, Beschreibung*
Anzahl infundierter kernhaltige Zellen*
Anzahl infundierter CD34+ Zellen*
Anzahl infundierter CD3+ Zellen*
1 / 1
EWOG SAA Cytokines immediate after
HSCT
Genetische und immunologische Charakterisierung der
schweren aplastischen Anaemie (SAA) bei Kindern und
Jugendlichen (EWOG-SAA) http://ewog-mds.org/
All rights reserved. Please visit https://medical-data-
models.org/forms/5431
Cytokines immediate after HSCT
Show identification of patient
Dummy
G-CSF immediate after HSCT
G-CSF verabreicht*
Nein (1)
Ja (2)
Datum der ersten G-CSF-Gabe*
Datum der letzten G-CSF-Gabe*
Anderes Cytokin*
Nein (1)
Ja (2)
Other cytokine immediate after HSCT
Cytokin Name*
Datum der ersten Gabe*
Datum der letzten Gabe*
1 / 1
EWOG SAA Clinical features at diagnosis
Genetische und immunologische Charakterisierung der
schweren aplastischen Anaemie (SAA) bei Kindern und
Jugendlichen (EWOG-SAA) http://ewog-mds.org/
All rights reserved. Please visit https://medical-data-
models.org/forms/5432
Clinical features at diagnosis
Show identification of patient
Dummy
Clinical features
Gewicht bei Diagnose*
GrÃ¶ÃŸe bei Diagnose*
Kopfumfang bei Diagnose*
Aktive Infektion*
Nein (1)
Ja (2)
Hepatitis*
Nein (1)
Ja (2)
Zustand nach Lebertransplantation*
Nein (1)
Ja (2)
Datum der Lebertransplantation*
Respiratorische Symptome*
Nein (1)
Ja (2)
Blutung*
Nein (1)
Ja (2)
Andere Symptome*
Nein (1)
Ja (2)
Hepatitis
Datum der Hepatitisdiagnose*
Virus*
A (1)
B (2)
C (3)
Anderes (99)
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Anderes Virus*
Respiratory symptoms
Respiratorische Symptome*
Nein (1)
Ja (2)
Bleeding site
Lokalisation der Blutung*
Schleimhautblutung (1)
Intrakraniell (2)
Beides (Schleimhautblutung und
Intrakraniell) (3)
Hautblutung (Petechien und Hämatome)
(4)
Andere (99)
Sonstige Lokalisation der Blutung*
Type of other symptoms
Art der anderen Symptome*
Organ dysfunction
Skelett*
Nein (1)
Ja (2)
Art*
CTCAE Grad*
CTCAE Grad 1 (1)
CTCAE Grad 2 (2)
CTCAE Grad 3 (3)
CTCAE Grad 4 (4)
Schwerwiegende Herzkreislauf-Komplikationen*
Nein (1)
Ja (2)
Art*
CTCAE Grad*
CTCAE Grad 1 (1)
CTCAE Grad 2 (2)
CTCAE Grad 3 (3)
CTCAE Grad 4 (4)
Gastrointestinal*
Nein (1)
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Ja (2)
Art*
CTCAE Grad*
CTCAE Grad 1 (1)
CTCAE Grad 2 (2)
CTCAE Grad 3 (3)
CTCAE Grad 4 (4)
Hepatisch*
Nein (1)
Ja (2)
Art*
CTCAE Grad*
CTCAE Grad 1 (1)
CTCAE Grad 2 (2)
CTCAE Grad 3 (3)
CTCAE Grad 4 (4)
Metabolisch*
Nein (1)
Ja (2)
Art*
CTCAE Grad*
CTCAE Grad 1 (1)
CTCAE Grad 2 (2)
CTCAE Grad 3 (3)
CTCAE Grad 4 (4)
ZNS*
Nein (1)
Ja (2)
Art*
CTCAE Grad*
CTCAE Grad 1 (1)
CTCAE Grad 2 (2)
CTCAE Grad 3 (3)
CTCAE Grad 4 (4)
Urogenitaltrakt*
Nein (1)
Ja (2)
Art*
CTCAE Grad*
CTCAE Grad 1 (1)
CTCAE Grad 2 (2)
CTCAE Grad 3 (3)
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CTCAE Grad 4 (4)
Haut*
Nein (1)
Ja (2)
Art*
CTCAE Grad*
CTCAE Grad 1 (1)
CTCAE Grad 2 (2)
CTCAE Grad 3 (3)
CTCAE Grad 4 (4)
Andere Dysfunktion*
Nein (1)
Ja (2)
Art*
CTCAE Grad*
CTCAE Grad 1 (1)
CTCAE Grad 2 (2)
CTCAE Grad 3 (3)
CTCAE Grad 4 (4)
4 / 4
EWOG SAA Clinical features at diagnosis
EWOG SAA Laboratory data
Genetische und immunologische Charakterisierung der
schweren aplastischen Anaemie (SAA) bei Kindern und
Jugendlichen (EWOG-SAA) http://ewog-mds.org/
All rights reserved. Please visit https://medical-data-
models.org/forms/5433
Laboratory data
Show identification of patient
Dummy
Chemistry
HbA2 Wert*
HbF Wert*
IgA Wert*
IgM Wert*
IgG Wert*
HLA Type
HLA-A Allel 1*
HLA-A Allel 2*
HLA-B Allel 1*
HLA-B Allel 2*
HLA-C Allel 1*
HLA-C Allel 2*
HLA-DRB1 Allel 1*
HLA-DRB1 Allel 2*
HLA-DQB1 Allel 1*
HLA-DQB1 Allel 2*
HLA-DPB1 Allel 1*
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HLA-DPB1 Allel 2*
HLA identes Geschwisterkind*
Nein (1)
Ja (2)
Initiale HSZT geplant*
Nein (1)
Ja (2)
Grund fÃ¼r Protokollabweichung*
Markers of infection
EBV-VCA IgG*
Negativ (1)
Positiv (2)
EBV-VCA IgM*
Negativ (1)
Positiv (2)
EBV-EA IgG*
Negativ (1)
Positiv (2)
EBV EBNA IgG*
Negativ (1)
Positiv (2)
EBV PCR*
Negativ (1)
Positiv (2)
HSV IgG*
Negativ (1)
Positiv (2)
HSV IgM*
Negativ (1)
Positiv (2)
Anti HBs*
Negativ (1)
Positiv (2)
Anti HBc*
Negativ (1)
Positiv (2)
HBs Ag*
Negativ (1)
Positiv (2)
HIV IgG*
Negativ (1)
Positiv (2)
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HCV PCR*
Negativ (1)
Positiv (2)
CMV IgG*
Negativ (1)
Positiv (2)
CMV IgM*
Negativ (1)
Positiv (2)
CMV PCR*
Negativ (1)
Positiv (2)
HHV6 IgG*
Negativ (1)
Positiv (2)
HHV6 IgM*
Negativ (1)
Positiv (2)
HHV6 PCR*
Negativ (1)
Positiv (2)
Parvovirus B 19 IgG*
Negativ (1)
Positiv (2)
Parvovirus B 19 IgM*
Negativ (1)
Positiv (2)
Parvovirus B 19 PCR*
Negativ (1)
Positiv (2)
HCV IgG*
Negativ (1)
Positiv (2)
HCV IgM*
Negativ (1)
Positiv (2)
Fanconi anemia
Analyse-Ergebnis*
Negativ (1)
Positiv (2)
Ausstehend (3)
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EWOG SAA Laboratory data
EWOG SAA SAA basic data
Genetische und immunologische Charakterisierung der
schweren aplastischen Anaemie (SAA) bei Kindern und
Jugendlichen (EWOG-SAA) http://ewog-mds.org/
All rights reserved. Please visit https://medical-data-
models.org/forms/5434
SAA basic data
Personal data
Vorname*
Nachname*
Geburtsname
Initialen*
Geburtsdatum*
Geschlecht*
Männlich (1)
Weiblich (2)
Dokumentierendes Zentrum
SAA basic data
Grund der Vorstellung*
Krankheitssymptome (1)
Vorsorgeuntersuchung (2)
Zufallsfund (3)
Datum der ersten Symptome*
Date of diagnosis
Diagnosedatum*
SAA diagnosis
Diagnose idiopathisch*
Nein (1)
Ja (2)
Diagnose Hepatitis assoziiert*
Nein (1)
Ja (2)
Diagnose medikamentenassoziiert*
Nein (1)
Ja (2)
Art des Medikaments*
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Antikonvulsiva (1)
Antibiotoka (2)
Gold (3)
Analgetika (4)
Cimetidin (5)
Anderes (99)
Anderes Medikament*
MÃ¶gliche andere Ursache*
Nein (1)
Ja (2)
Andere Ursache*
Severity of disease
Klassifikation entsprechend der Morphologie*
VSAA (1)
SAA (2)
NSAA (3)
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EWOG SAA SAA basic data
EWOG SAA Therapy for SAA prior to
diagnosis of SAA
Genetische und immunologische Charakterisierung der
schweren aplastischen Anaemie (SAA) bei Kindern und
Jugendlichen (EWOG-SAA) http://ewog-mds.org/
All rights reserved. Please visit https://medical-data-
models.org/forms/5435
Therapy for SAA prior to diagnosis of
SAA
Show identification of patient
Dummy
Therapy for SAA prior to diagnosis of SAA
Vorhergehende Therapie*
Nein (1)
Ja (2)
Art der Therapie*
Steroid (2)
G-CSF (3)
Erythropoietin (4)
Andere hämatopoetische
Wachstumsfaktoren (5)
IVIG (6)
Andere (99)
Sonstige Art der Therapie*
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EWOG SAA Blood count before start of IST
Genetische und immunologische Charakterisierung der
schweren aplastischen Anaemie (SAA) bei Kindern und
Jugendlichen (EWOG-SAA) http://ewog-mds.org/
All rights reserved. Please visit https://medical-data-
models.org/forms/5436
Blood count before start of IST
Show identification of patient
Dummy
Blood count before start of IST
RegelmÃ¤ÃŸige Erythrozytentransfusionen
notwendig*
Nein (1)
Ja (2)
RegelmÃ¤ÃŸige Thrombozytentransfusionen
notwendig*
Nein (1)
Ja (2)
Granulozytentransfusion notwendig*
Nein (1)
Ja (2)
Leukozyten*
Neutrophile*
Hb Wert*
Erythrozyten*
MCV*
Retikulozyten*
Thrombozyten*
Niedrigstes ANC vor Beginn der IST*
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EWOG SAA Status Day 30
Genetische und immunologische Charakterisierung der
schweren aplastischen Anaemie (SAA) bei Kindern und
Jugendlichen (EWOG-SAA) http://ewog-mds.org/
All rights reserved. Please visit https://medical-data-
models.org/forms/5437
Status Day 30
Show identification of patient
Dummy
Complications - Infection
Infektion*
Nein (1)
Ja (2)
Bakteriell > CTCAE Grad 2*
Nein (1)
CTCAE Grad 3 (3)
CTCAE Grad 4 (4)
Bakterieller Organismus*
Fungal > CTCAE Grad 2*
Nein (1)
CTCAE Grad 3 (3)
CTCAE Grad 4 (4)
Fungaler Organismus*
ParasitÃ¤r > CTCAE Grad 2*
Nein (1)
CTCAE Grad 3 (3)
CTCAE Grad 4 (4)
ParasitÃ¤rer Organismus*
Viral > CTCAE Grad 2*
Nein (1)
CTCAE Grad 3 (3)
CTCAE Grad 4 (4)
Virus*
Unbekannt > CTCAE Grad 2*
Nein (1)
CTCAE Grad 3 (3)
CTCAE Grad 4 (4)
Organismus der unbekannten Infektion*
Complications - EBV PCR
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EBV PCR durchgefÃ¼hrt*
Nein (1)
Ja (2)
EBV PCR Datum*
EBV PCR Wert*
Complications - EBV LPD
EBV LPD*
Nein (1)
Ja (2)
Complications - EBV LPD symptoms
Fieber*
Nein (1)
Ja (2)
Malaise*
Nein (1)
Ja (2)
Gewichtsverlust*
Nein (1)
Ja (2)
Complications - EBV LPD stie
Mediastinale Lymphknoten*
Nein (1)
Ja (2)
Abdominale Lymphknoten*
Nein (1)
Ja (2)
Inguinale Lymphknoten*
Nein (1)
Ja (2)
AxilÃ¤re Lymphknoten*
Nein (1)
Ja (2)
Zervikale Lymphknoten*
Nein (1)
Ja (2)
Darm*
Nein (1)
Ja (2)
Lunge*
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Nein (1)
Ja (2)
Tonsillen*
Nein (1)
Ja (2)
Andere*
Nein (1)
Ja (2)
Andere Lokalisation*
Complications - EBV PCR
Anti CD20 AntikÃ¶rper*
Nein (1)
Ja (2)
Virustatische Therapie*
Nein (1)
Ja (2)
Chemotherapie*
Nein (1)
Ja (2)
Steroide*
Nein (1)
Ja (2)
Reduktion der IST*
Nein (1)
Ja (2)
Ende der IST*
Nein (1)
Ja (2)
Andere*
Nein (1)
Ja (2)
Andere Art der Behandlung*
Complications - Hemorrhage
Blutung > CTCAE Grad 2*
Nein (1)
CTCAE Grad 3 (3)
CTCAE Grad 4 (4)
Severe renal complications
Relevante Kreatinin ErhÃ¶hung > CTCAE Grad
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2*
Nein (1)
CTCAE Grad 3 (3)
CTCAE Grad 4 (4)
HÃ¤modialyse oder HÃ¤mofiltration*
Nein (1)
Ja (2)
Fanconi-Syndrom*
Nein (1)
Ja (2)
Nephrotisches Syndrom*
Nein (1)
Ja (2)
Complications - Other type of complication
Andere Komplikation > CTCAE Grad 2*
Nein (1)
CTCAE Grad 3 (3)
CTCAE Grad 4 (4)
Art*
Transfusions
Weiterhin regelmÃ¤ÃŸige
Thrombozytentransfusionen notwendig*
Nein (1)
Ja (2)
Weiterhin regelmÃ¤ÃŸige
Erythrozytentransfusionen notwendig*
Nein (1)
Ja (2)
Transfusion PLT
Datum der letzten Transfusion*
Transfusion RBC
Datum der letzten Transfusion*
Hemtological data
Abnahmedatum des peripheren Bluts*
Erythrozyten*
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MCV*
Hb Wert*
Retikulozyten*
Leukozyten*
Absolute Neutrophilenanzahl*
Thrombozyten*
Response
CSC*
Komplette Remission (CR) (1)
Gute Teilremission (GPR) (3)
Schlechte Teilremission (PPR) (4)
keine Remission (NR) (5)
Rezidiv (7)
PNH Erkrankung (8)
Progression (9)
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EWOG SAA Status Day 30
EWOG SAA First complete response (CR)
Genetische und immunologische Charakterisierung der
schweren aplastischen Anaemie (SAA) bei Kindern und
Jugendlichen (EWOG-SAA) http://ewog-mds.org/
All rights reserved. Please visit https://medical-data-
models.org/forms/5438
First complete response (CR)
First complete response (CR)
Datum*
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EWOG SAA First partial response (PR)
Genetische und immunologische Charakterisierung der
schweren aplastischen Anaemie (SAA) bei Kindern und
Jugendlichen (EWOG-SAA) http://ewog-mds.org/
All rights reserved. Please visit https://medical-data-
models.org/forms/5439
First partial response (PR)
First partial response (PR)
Datum*
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EWOG SAA IST FUP {0}
Genetische und immunologische Charakterisierung der
schweren aplastischen Anaemie (SAA) bei Kindern und
Jugendlichen (EWOG-SAA) http://ewog-mds.org/
All rights reserved. Please visit https://medical-data-
models.org/forms/5440
IST FUP {0}
Show identification of patient
Dummy
IST FUP
Intervall*
Tag 31-60 (2)
Tag 61-90 (3)
Tag 91-120 (4)
Tag 121-180 (5)
Tag 181-240 (6)
Tag 241-270 (7)
Tag 271-360 (8)
Halbjährlich nach Jahr 1 (9)
HalbjÃ¤hrlich (Anzahl der Monate)*
Immunosuppressive Therapy - Steroids in
given interval
Steroide*
Nein (1)
Ja (2)
Indikation fÃ¼r Steroide*
Datum der letzten Dosis*
Immunosuppressive Therapy -
Cyclosporin A
Cyclosporin A fortlaufend*
Nein (1)
Ja (2)
Grund fÃ¼r das Absetzen von CSA*
CR (1)
NR (2)
Toxizität (3)
Anderer Grund (99)
Anderer Grund*
Immunosuppressive Therapy -
Cyclosporin A
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Cyclosporin A fortlaufend*
Nein (1)
Ja (2)
Cyclosporin A ausschleichend*
Nein (1)
Ja (2)
Datum der ersten Reduktion*
Cyclosporin A gestoppt*
Nein (1)
Ja (2)
Datum der letzten Dosis*
Grund fÃ¼r das Absetzen von CSA*
CR (1)
NR (2)
Toxizität (3)
Anderer Grund (99)
Anderer Grund*
Cyclosporin A erneut gestartet*
Nein (1)
Ja (2)
Datum des erneuten Starts*
Indikation fÃ¼r erneuten Start von CSA*
Rezidiv (1)
Drohendes Rezidiv (2)
Andere Indikation (99)
Andere Indikation fÃ¼r erneuten Start von CSA*
Immunosuppressive Therapy - G-CSF
G-CSF*
Nein (1)
Ja (2)
Ausschleichen*
Nein (1)
Ja (2)
Datum der ersten Reduktion*
Datum der letzten Dosis*
Gesamtdosis seit Tag 31*
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Complications - Infection
Infektion*
Nein (1)
Ja (2)
Bakteriell > CTCAE Grad 2*
Nein (1)
CTCAE Grad 3 (3)
CTCAE Grad 4 (4)
Bakterieller Organismus*
Fungal > CTCAE Grad 2*
Nein (1)
CTCAE Grad 3 (3)
CTCAE Grad 4 (4)
Fungaler Organismus*
ParasitÃ¤r > CTCAE Grad 2*
Nein (1)
CTCAE Grad 3 (3)
CTCAE Grad 4 (4)
ParasitÃ¤rer Organismus*
Viral > CTCAE Grad 2*
Nein (1)
CTCAE Grad 3 (3)
CTCAE Grad 4 (4)
Virus*
Unbekannt > CTCAE Grad 2*
Nein (1)
CTCAE Grad 3 (3)
CTCAE Grad 4 (4)
Organismus der unbekannten Infektion*
Complications - EBV PCR
EBV PCR durchgefÃ¼hrt*
Nein (1)
Ja (2)
EBV PCR Datum*
EBV PCR Wert*
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Complications - EBV LPD
EBV LPD*
Nein (1)
Ja (2)
Complications - EBV LPD symptoms
Fieber*
Nein (1)
Ja (2)
Malaise*
Nein (1)
Ja (2)
Gewichtsverlust*
Nein (1)
Ja (2)
Complications - EBV LPD site
Mediastinale Lymphknoten*
Nein (1)
Ja (2)
Abdominale Lymphknoten*
Nein (1)
Ja (2)
Inguinale Lymphknoten*
Nein (1)
Ja (2)
AxilÃ¤re Lymphknoten*
Nein (1)
Ja (2)
Zervikale Lymphknoten*
Nein (1)
Ja (2)
Darm*
Nein (1)
Ja (2)
Lunge*
Nein (1)
Ja (2)
Tonsillen*
Nein (1)
Ja (2)
Andere*
Nein (1)
Ja (2)
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Andere Lokalisation*
Complications - EBV LPD treatment
Anti CD20 AntikÃ¶rper*
Nein (1)
Ja (2)
Virustatische Therapie*
Nein (1)
Ja (2)
Chemotherapie*
Nein (1)
Ja (2)
Steroide*
Nein (1)
Ja (2)
Reduktion der IST*
Nein (1)
Ja (2)
Ende der IST*
Nein (1)
Ja (2)
Andere*
Nein (1)
Ja (2)
Andere Art der Behandlung*
Complications - Hemorrhage
Blutung > CTCAE Grad 2*
Nein (1)
CTCAE Grad 3 (3)
CTCAE Grad 4 (4)
Complications - Renal/Metabolic Lab.,
Creatinine
Niere/Stoffwechsel, Kreatinin > CTCAE Grad 2*
Nein (1)
CTCAE Grad 3 (3)
CTCAE Grad 4 (4)
Complications - Other type of complication
Andere Komplikation > CTCAE Grad 2*
Nein (1)
CTCAE Grad 3 (3)
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CTCAE Grad 4 (4)
Art*
Response - Transfusions
Weiterhin regelmÃ¤ÃŸige
Thrombozytentransfusionen notwendig*
Nein (1)
Ja (2)
Weiterhin regelmÃ¤ÃŸige
Erythrozytentransfusionen notwendig*
Nein (1)
Ja (2)
Response - Transfusion PLT
Datum der letzten Transfusion*
Response - Transfusion RBC
Datum der letzten Transfusion*
Response - Complete blood count
Abnahmedatum des peripheren Bluts*
Erythrozyten*
MCV*
Hb Wert*
Retikulozyten*
Leukozyten*
Absolute Neutrophilenanzahl*
Thrombozyten*
Response
Ansprechen*
Vollständiges Ansprechen (1)
6 / 7
EWOG SAA IST FUP {0}
Teilweises Ansprechen (3)
Kein Ansprechen (4)
Klonale Evolution (5)
Rezidiv (6)
PNH Erkrankung (7)
Study centre specific variables
CSC*
Komplette Remission Def.A (1)
Komplette Remission Def.B (2)
Gute Teilremission (3)
Schlechte Teilremission (4)
keine Remission (5)
Clonal evolution (6)
Rezidiv (7)
PNH Erkrankung (8)
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EWOG SAA IST FUP {0}
EWOG SAA Immunosuppressive Therapy
Genetische und immunologische Charakterisierung der
schweren aplastischen Anaemie (SAA) bei Kindern und
Jugendlichen (EWOG-SAA) http://ewog-mds.org/
All rights reserved. Please visit https://medical-data-
models.org/forms/5441
Immunosuppressive Therapy
Show identification of patient
Dummy
Type of ATG
Art des ATG*
Thymoglobulin (Genzyme) (1)
ATG rabbit (Fresenius) (2)
ATGAM horse (Merieux) (3)
ATGAM horse (Pfizer) (4)
Andere (99)
Andere Art der ATG*
Day 1 to 8
Datum Tag 1*
Absolute Dosis Tag 1*
Dosis Tag 1*
Datum Tag 2*
Absolute Dosis Tag 2*
Dosis Tag 2*
Datum Tag 3*
Absolute Dosis Tag 3*
Dosis Tag 3*
Datum Tag 4*
Absolute Dosis Tag 4*
Dosis Tag 4*
Datum Tag 5*
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Absolute Dosis Tag 5*
Dosis Tag 5*
Datum Tag 6
Absolute Dosis Tag 6
Dosis Tag 6
Datum Tag 7
Absolute Dosis Tag 7
Dosis Tag 7
Datum Tag 8
Absolute Dosis Tag 8
Dosis Tag 8
Steroids
Steroide*
Nein (1)
Ja (2)
Datum der ersten Dosis*
Datum der letzten Dosis*
Cyclosporin A
Datum der ersten Dosis*
G-CSF
G-CSF*
Nein (1)
Ja (2)
Datum der ersten Dosis*
Maximale Dosis*
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EWOG SAA Immunosuppressive Therapy
Ausschleichen*
Nein (1)
Ja (2)
Datum der ersten Reduktion*
Datum der letzten Dosis*
Gesamtdosis Tag 0-30*
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EWOG SAA Immunosuppressive Therapy
EWOG SAA Karyotype
Genetische und immunologische Charakterisierung der
schweren aplastischen Anaemie (SAA) bei Kindern und
Jugendlichen (EWOG-SAA) http://ewog-mds.org/
All rights reserved. Please visit https://medical-data-
models.org/forms/5442
Karyotype
Show identification of patient
Dummy
Basic data
Datum der Materialentnahme*
Knochenmark Metaphasen Zytogenetik
untersucht?*
Nein (1)
Ja (2)
Peripheres Blut Metaphasen Zytogenetik
untersucht?*
Nein (1)
Ja (2)
FISH untersucht?*
Nein (1)
Ja (2)
Referenzlabor*
Schlegelberger (Hannover) (1)
Cervera (Valencia) (10)
Schaefer (Zürich) (11)
Kroemer (Wien) (2)
Van Roy (Ghent) (3)
Michalova (Prag) (4)
Betts (Dublin) (6)
Sainati (Padova) (7)
Beverloo (Rotterdam) (8)
Kerndrup (Vejle) (9)
Anderes (99)
Anderes Labor*
Bonemarrow
ISCN Code*
Peripheral blood
ISCN Code*
FISH
1 / 2
ISCN Code*
Study centre specific variables
Kary Code 1*
Kein Ergebnis (0)
Normal bzgl. Metaphasen Zytogenetik
(1)
Normal für 7+8 by FISH (40)
-7 by FISH (41)
+8 by FISH (42)
Other abn by FISH (43)
-7 alone (51)
-7 +add (52)
7q- alone (53)
7q- +add (54)
-7 unclear (55)
+8 alone (57)
+8 +add (58)
Random aberration (99)
Gesamtanzahl der analysierten Metaphasen*
Gesamtanzahl der abnormalen Metaphasen*
UnabhÃ¤ngige Klone*
Nein (1)
Ja (2)
Ausgeglichen oder unausgeglichen*
Balanced (1)
Unbalanced (2)
Klonale Evolution*
Nein (1)
Ja (2)
FISH Code 1*
Kein Ergebnis (0)
Normal für 7 und 8 (40)
-7 (41)
+8 (42)
Anderer (99)
Kommentar
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EWOG SAA Lost to follow-up
Genetische und immunologische Charakterisierung der
schweren aplastischen Anaemie (SAA) bei Kindern und
Jugendlichen (EWOG-SAA) http://ewog-mds.org/
All rights reserved. Please visit https://medical-data-
models.org/forms/5444
Lost to follow-up
Show identification of patient
Dummy
Lost to follow-up
Grund fÃ¼r lost to follow-up*
Datum lost to follow-up*
1 / 1
EWOG SAA PNH
Genetische und immunologische Charakterisierung der
schweren aplastischen Anaemie (SAA) bei Kindern und
Jugendlichen (EWOG-SAA) http://ewog-mds.org/
All rights reserved. Please visit https://medical-data-
models.org/forms/5445
PNH
Show identification of patient
Dummy
PNH sample
Datum der PNH*
Labor*
Rotterdam (1)
Ulm (2)
Freiburg (3)
Anderes (99)
Anderes PNH Labor angeben*
Art der Probe*
PB (1)
KM (2)
Anderes (99)
Andere Art der Probe angeben*
PNH results (flow cytometry)
PNH Resultate*
Negativ (1)
Positiv (2)
Erythrozyten total*
Erythrozyten Typ II*
Erythrozyten Typ III*
Granulozyten total*
Granulozyten Typ II*
Granulozyten Typ III*
Monozyten total*
1 / 2
Kommentar
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EWOG SAA PNH
EWOG SAA Data on HSCT patient
Genetische und immunologische Charakterisierung der
schweren aplastischen Anaemie (SAA) bei Kindern und
Jugendlichen (EWOG-SAA) http://ewog-mds.org/
All rights reserved. Please visit https://medical-data-
models.org/forms/5446
Data on HSCT patient
Show identification of patient
Dummy
Informed consents for participation in
HSCT registries
Einwilligung PRST*
Nein (1)
Ja (2)
Einwilligung DRST*
Nein (1)
Ja (2)
Einwilligung EBMT*
Nein (1)
Ja (2)
Einwilligung CIBMTR*
Nein (1)
Ja (2)
Diagnosis according to EBMT
classification
Diagnosedatum*
Diagnose: EBMT-Klassifikation*
Acute leukemia (1000000)
Autoimmune disorder (10000000)
Haemoglobinopathy (11000000)
Chronic leukemia (2000000)
Lymphoma (3000000)
Plasma cell disorder (4000000)
Solid tumour (5000000)
Myelodysplastic / Myeloproliferative
syndrome (6000000)
Bone marrow failure including aplastic
anaemia (7000000)
Inherited disorder (8000000)
Histiocytic disorder (9000000)
Klassifizierung der akuten LeukÃ¤mie*
AML (1001000)
ALL (1002000)
Klassifizierung der chronischen LeukÃ¤mie*
CML (2001000)
CLL (2002000)
PPL (2003000)
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Klassifizierung Lymphom*
NHL (3001000)
Hodgkin (3002000)
Classification of plasma cell disorder*
Multiple myeloma (4001000)
Plasma cell leukemia (4002001)
Solitary plasmacytoma (4003001)
Primary amyloidosis (4004001)
Klassifizierung solide Tumoren*
Bone sarcoma (excluding EWING/PNET)
(5010001)
Osteosarcoma (5011001)
Chondrosarcoma (5012001)
Astrocytoma (5021001)
Oligodendroglioma (5022001)
Glioblastoma (5023001)
Ependymoma (5024001)
Other glioma (5025001)
PNET (5030001)
Ewing sarcoma (5031001)
Medulloblastoma (5032001)
Neuroblastoma (5033001)
Central nervous system (including CNS
PNET) (5034001)
Retinoblastoma (5036001)
Ewing sarcoma/PNET, extra-skeletal
(5037001)
Ewing sarcoma/PNET, skeletal
(5038001)
Germ cell tumour (5040001)
Seminoma (5041001)
Embryonal carcinoma (5042001)
Teratocarcinoma (yolk sac tumour)
(5043001)
Testicular (5044001)
Germ cell tumour, extragonadal
(5045001)
Choriocarcinoma (5046001)
Mixed tumour without seminoma
(5047001)
Mixed tumour with seminoma (5048001)
Ovarian (5049001)
Skin tumour (5050001)
Melanoma (5051001)
Lung, unspecified (5053001)
Small cell lung cancer (SCLC) (5054001)
Non-small cell lung cancer (NSCLC)
(5057001)
Soft tissue sarcoma (5060001)
Myxoma (5061001)
Mesenchymoma (5062001)
Leiomyiosarcoma (5063001)
Rhabdomyiosarcoma (5064001)
Liposarcoma (5065001)
Fibrosarcoma (5066001)
Synovial sarcoma (5067001)
Angiosarcoma (5068001)
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Haemangiosarcoma (5069001)
Lymphangiosarcoma (5070001)
Neurogenic sarcoma (5071001)
Hepatobiliary (5072001)
Pancreas (5074001)
Prostate (5075001)
Breast (5080000)
Undifferentiated carcinoma (5090001)
Thymoma (5091001)
Gastric carcinoma + adenocarcinoma
(5092001)
Adenocarcinoma origin X (5093001)
Colon adenocarcinoma (5096001)
Granulocytic sarcoma (5097001)
Wilms tumour (5098001)
Other kidney tumour (5099001)
Other solid tumour (5777001)
Unknown solid tumour (5999001)
Klassifizierung MDS*
MDS (6001000)
MPS (6002000)
MDS und MPS kombiniert (6003000)
Anderes myelodysplatisches Syndrom
(6004001)
Klassifizierung AnÃ¤mie*
Non constitutional (7001000)
Fanconi (congenital) (7002001)
Pure red cell aplasia (non congenital
PRCA) (7003000)
Diamond-Blackfan (congenital PRCA)
(7004001)
Paroxysmal nocturnal haemoglobinuria
(PNH) (7005000)
Amegakariocytic thrombocytopaenia (not
congenital) (7006000)
Schwachman-Diamond (congenital)
(7007001)
Classification of Inherited disorder*
Primaryimmune deficiency (8001000)
Disorders of metabolism (8002000)
Other inherited disorder (8003000)
Classification of histiocytic disorder*
Familial erythro/hemophagocytic
lymphohistiocytosis (9001001)
Langerhans cell histiocytosis
(Histiocytosis-X) (9002001)
Hemophagocytosis (reactive or viral
associated) (9003001)
Malignant histiocytosis (9004001)
Other histiocytic disorder (9077001)
Unknown histiocytic disorder (9099001)
Classification of autoimmune disorder*
Connective tissue disease (10001000)
Vasculitis (10002000)
Arthristis (10003000)
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Multiple sclerosis (10004001)
Other neurological (10005000)
Haematological (10006000)
Bowel disease (10007000)
Other autoimmune disorder (10077001)
Classification of haemoglobinopathy*
Thalassaemia (11001001)
Sickle cell anaemia/Drepanocytosis
(11002001)
Compound heterozygous state
(11003001)
Other haemoglobinopathy (11004001)
Unknown haemoglobinopathy
(11005001)
EMBT diagnosis subclassification
Subklassifizierung der ALL*
Precursor B-cell ALL (1002001)
t(9;22)(a34;q11) BCR/ABL (1002002)
t(v;11q23) MLL rearranged (1002003)
t(1;19)(q23;p13) E2A/PBX1 (1002004)
t(12;21)(p12;q22) ETV/CBF-alpha
(1002005)
Precursor T-cell ALL (1002011)
ALL not otherwise specified or other
(1002077)
Unknown ALL (1002099)
Subklassifizierung der AML*
AML w t(8;21)(q22;q22), (AML1/ETO)
(1001001)
AML w abnormal BM eosinophils und
inv(16)(p13;q22) (1001002)
AML w t(15;17)(q22;q12),
(PML/RARalpha) [M3] (1001003)
AML w 11q23, (MLL) abnormalities
(1001004)
AML w multilineage dysplasia (w/o MDS
or MP/MDS) (1001005)
AML not otherwise categorised
(1001009)
AML mimimally differentiated [M0]
(1001010)
AML wo maturation [M1] (1001011)
AML w maturation [M2] (1001012)
Acute myelomonocytic leukemia [M4]
(1001014)
Acute monoblastic/monocytic leukemia
[M5] (1001015)
Acute erythroid leukemia [M6] (1001016)
Acute megakaryoblastic leukemia [M7]
(1001017)
Acute basophilic leukemia (1001018)
Acute panmyelosis with myelofibrosis
(1001019)
Myeloid sarcoma (1001020)
AML not otherwise specified or other
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(1001777)
Unknown AML (1001999)
Subklassifizierung CML*
(t9) (2001001)
(t9;22) positive (2001002)
Other chromosome abnormality
(2001003)
Other CML (2001077)
Unknown CML (2001099)
Subclassification of CLL*
CLL B-cell/Small lymphocytic lymphoma
(2002001)
CLL T-cell (2002002)
Hairy cell leukaemia (2002003)
Atypic hairy cell leukaemia (2002004)
Richters syndrome (2002005)
Other leukemia (2002077)
Unknown leukaemia (2002099)
Subklassifizierung PPL*
PPL B-cell (2003001)
PPL T-cell (2003002)
Other PPL (2003077)
Unknown PPL (2003099)
Subklassifizierung NHL*
NHL unspecified (3001001)
B-cell NHL unspecified (3001005)
Follicular (3001010)
Mantle cell (3001020)
Extranodal marginal zone B-cell of MALT
type (3001030)
Diffuse large B-cell (3001040)
Centroblastic (3001041)
Immunoblastic (3001042)
Anaplastic large B-cell (3001043)
Intravascular large cell lymphoma
(3001045)
Mediastinal large cell lymphoma
(3001046)
Primary effusion large cell lymphoma
(3001047)
Burkitts lymphoma/Burkitt cell leukaemia
(3001050)
High grade B-cell lymphoma, Burkitt-like
(prov.) (3001051)
Precursor B-cell lymphoblastic
(3001060)
Lymphoplasmcytic lymphoma including
Waldenstrom (3001070)
Lymphoplasmcytic lymphoma (3001071)
Waldenstrom macroglobulinaemia
(3001072)
Splenic marginal zone (3001080)
Nodal marginal zone (3001090)
Primary CNS lymphoma (3001096)
T-cell NHL unspecified (3001105)
Angioimmunoblastic T-cell (AILD)
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(3001110)
Peripheral T-cell (3001120)
Anaplastic large T-cell (3001130)
Anaplastic large-cell, T/null-cell, primary
cuta (3001131)
Anaplastic large-cell T/null-cell, primary
syste (3001132)
PreT lymphoblastic (3001140)
Blast NK cell (3001145)
Extranodal NK/T-cell (3001150)
Enteropathy type T-cell (3001160)
Hepatosplenic gamma-delta T-cell
(3001170)
Subcutaneous panniculitis-like T-cell
(3001180)
Adult T-cell lymphoma/leukaemia
(3001181)
Aggressive NK-cell leukaemia (3001182)
Large T-cell granular lymphocytic
leukaemia (3001183)
Mycosis fungoides (3001190)
Sezary syndrome (3001195)
Post-transplant lymphoproliferative
disease (PTL (3001300)
Other NHL (3001800)
Unknown NHL (3001999)
Subclassification of HD*
Nodular lymphocyte predominant
(3002001)
Lymphocyte rich (3002002)
Nodular sclerosis (3002003)
Mixed cellularity (3002004)
Lymphoma depleted (3002005)
Other Hodgkin lymphoma (3002077)
Unknown Hodgkin lymphoma (3002099)
Subclassification of multiple myeloma*
Multiple myeloma light chain (4001001)
Multiple myeloma light chain kappa
(4001002)
Multiple myeloma light chain lambda
(4001003)
Multiple myeloma light chain both
(4001004)
Multiple myeloma light chain unknown
(4001005)
Multiple myeloma non secretory
(4001006)
Multiple myeloma non secretory stage I
(4001007)
Multiple myeloma non secretory stage II
(4001008)
Multiple myeloma non secretory stage III
(4001009)
Multiple myeloma not evaluated
(4001010)
Multiple myeloma unknown (4001011)
Multiple myeloma common type IgG
(4001012)
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Multiple myeloma common type IgA
(4001013)
Multiple myeloma common type IgD
(4001014)
Multiple myeloma common type IgE
(4001015)
Multiple myeloma common type IgM
(4001016)
Multiple myeloma common type
unknown (4001017)
Subclassification of breast cancer*
Breast cancer M0 (No distant
metastasis) (5080010)
Breast cancer M1 (With distant
metastasis) (5080011)
Breast cancer MX (Distant metastasis
not evaluable) (5080015)
Breast cancer not evaluated (5080088)
Breast cancer unknown (5080099)
Subclassification of MDS*
MDS RA (6001001)
MDS RARS (6001002)
MDS RAEB-1 (6001003)
MDS RAEB-2 (6001004)
MDS Refractory cytopenia with
multilineage dysplasia (6001005)
MDS RCMD-RS (6001006)
MDS associated with isolated del(5q)
(6001007)
MDS Transformed to AML (6001008)
MDS Unclassifiable (MDS-U) or other
(6001077)
MDS unknown (6001099)
Subklassifizierung MPS*
MPS Chronic idiopathic myelofibrosis
(primary) (6002001)
MPS Polycythemia vera (6002002)
MPS Essential or primary
thrombocythemia (6002003)
MPS Hyper eosinophilic syndrome
(HES) (6002004)
MPS Chronic eosinophilic leukaemia
(CEL) (6002005)
MPS Chronic neutrophilic leukaemia
(6002006)
MPS Stem cell leuk-lymphoma
syndrome (8p11 syndr) (6002007)
MPS Secondary myelofibrosis (6002008)
MPS Transformed to AML (6002009)
MPS Systemic mastocytosis (6002010)
MPS not otherwise specified or other
(6002077)
MPS unknown (6002099)
Subclassification of 'MDS and MPS combined'*
Chronic myelomonocytic leukaemia
(6003001)
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Juvenile myelomonocytic leukaemia
(6003002)
Atypical CML (t(9;22) and bcr-abl
negative (6003003)
MDS and MPS combined other
(6003077)
MDS and MPS combined unknown
(6003099)
Subclassification of non constitutional anaemia*
Non constitutional anaemia idiopathic
(7001010)
Non constitutional anaemia congenital
(7001020)
Non constitutional anaemia post-hepatic
(7001030)
Non constitutional anaemia post-hepat A
(7001031)
Non constitutional anaemia post-hepat B
(7001032)
Non constitutional anaemia postHep
noAB (7001033)
Non constitutional anaemia drug related
(7001040)
Non constitutional anaemia toxic
(7001050)
Non constitutional anaemia other viral
(7001060)
Non constitutional anaemia other
(7001077)
Non constitutional anaemia unknown
(7001099)
Subclassification of PRCA*
PRCA idiopathic (7003010)
PRCA congenital (7003020)
PRCA post-hepatic (7003030)
PRCA post-hepat A (7003031)
PRCA post-hepat B (7003032)
PRCA postHep noAB (7003033)
PRCA drug related (7003040)
PRCA toxic (7003050)
PRCA other viral (7003060)
PRCA other (7003077)
PRCA unknown (7003099)
Subclassification of PNH*
PNH idiopathic (7005010)
PNH congenital (7005020)
PNH post-hepatic (7005030)
PNH post-hepat A (7005031)
PNH post-hepat B (7005032)
PNH postHep noAB (7005033)
PNH drug related (7005040)
PNH toxic (7005050)
PNH other viral (7005060)
PNH other (7005077)
PNH unknown (7005099)
Subclassification of amegakariocytic
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thrombocytopaenia (not congenital)*
Amegakariocytic thrombocytopaenia (not
congenital) Idiopathic (7006010)
Amegakariocytic thrombocytopaenia (not
congenital) Congenital (7006020)
Amegakariocytic thrombocytopaenia (not
congenital) Post-hepatic (7006030)
Amegakariocytic thrombocytopaenia (not
congenital) Post-hepat A (7006031)
Amegakariocytic thrombocytopaenia (not
congenital) Post-hepat B (7006032)
Amegakariocytic thrombocytopaenia (not
congenital) PostHep noAB (7006033)
Amegakariocytic thrombocytopaenia (not
congenital) Drug related (7006040)
Amegakariocytic thrombocytopaenia (not
congenital) Toxic (7006050)
Amegakariocytic thrombocytopaenia (not
congenital) Other viral (7006060)
Amegakariocytic thrombocytopaenia (not
congenital) Other (7006077)
Amegakariocytic thrombocytopaenia (not
congenital) unknown (7006099)
Subclassification of primaryimmune deficiency*
Absence of T and B cells SCID
(8001010)
Artemis (8001011)
Ligase IV (8001012)
Rag-1 or Rag-2 (8001013)
Other T- B- cells SCID (8001017)
Absence of T, normal B cell SCID
(8001020)
Gamma c deficiency (8001021)
JAK 3 deficiency (8001022)
IL-7R alpha deficiency (8001023)
Other T- B+ cells SCID (8001027)
ADA deficiency (Adenosine deaminase
deficiency) (8001031)
Purine nucleoside phosphorylase
deficiency (PNP- (8001032)
Reticular dysgenesis (AR) (8001033)
Other SCID (8001037)
Combined immune deficiency (CID),
unspecified (8001050)
Omenn syndrome (8001051)
Neutrophil actin deficiency (8001052)
Other CID (8001057)
Wiskott Aldrich syndrome (8001131)
Familial lymphohistiocytosis (8001132)
Interferon g deficiency (8001133)
X-linked lymphoproliferative (Purtilo)
(8001134)
Ataxia telangiectasia (8001135)
Di George syndrome (8001136)
CD40 ligand deficiency (Hyper IgM/Ig
deficienc) (8001137)
Cartilage hair hypoplasia (Dyskeratosis
congen) (8001138)
9 / 12
EWOG SAA Data on HSCT patient
Bare lymphocyte/MHC class II/HLA-antig
xp def (8001139)
Griscelli syndrome (8001140)
IPEX syndrome (8001141)
Chediak-Higashi syndrome (8001151)
Chronic granulomatous disease
(8001152)
Agranulocytosis (Kostmann) (8001153)
Leukocyte adhesion deficiency (LAD)
(8001154)
Other primaryimmune deficiency
(8001777)
Unknown primaryimmune deficiency
(8001999)
Subclassification of disorders of metabolism*
Mucopolysaccharidoses, unspecified
(8002010)
Hurler (8002011)
Scheie (8002012)
Hurler/Scheie (8002013)
Hunter (8002014)
Sanfilippo A (8002015)
Sanfilippo B (8002016)
Sanfilippo C (8002017)
Sanfilippo D (8002018)
Morquio (IV) (8002019)
Mucopolis V (8002021)
Maroteaux-Lamy (8002022)
B-glucuronidase deficiency/Type VII / Sly
(8002023)
Sphingolipidoses, unspecified (8002030)
Metachromatic leucodystrophy
(8002031)
Multiple sulphatidosis (8002032)
Fabry / alpha-D-galactosidase (8002033)
GM1 ganglios (8002034)
GM2 gangl T1 (8002035)
GM3 gangl T2 (8002036)
NiemPick AB (8002037)
NiemPick CDE (8002038)
Gaucher (8002039)
Neuronal ceriod-lipofuscinosis (Batten
disease) (8002040)
Krabbe (8002041)
Mucolipidose (8002050)
Mucolipid I (8002051)
I-cell disea (8002052)
MucolipidIII (8002053)
Fucosidosis (8002054)
Mannosidosis (8002055)
Aspartyl
glucosaminuria/glucosaminidase
(8002061)
B-d-mannosid (8002062)
N-acetyl-alpha-D-galactosaminase
deficiency (8002063)
Wolman disease/acid lipase (8002064)
Adrenoleukodistrophy (8002070)
Glucose storage disease (8002071)
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Lesch-Nyhan (8002072)
Erythropoietic porphyria/Gunther`s
(8002080)
Disorders of metabolism Other
(8002777)
Disorders of metabolism unknown
(8002999)
Subclassification of other inherited disorder*
Platelet defect, unspecified (8003020)
Glanzmann (8003021)
Congenital
amegakaryocytosis/thrombocytopaenia
(8003022)
Osteoclast defect, unspecified (8003040)
Osteopetrosis (8003041)
Other inherited disorders (8003077)
Other unknown inherited disorders
(8003099)
Subclassification of connective tissue disease*
Systemic sclerosis (10001001)
Systemic lupus erythematosus
(10001002)
Polymyositis-dermatomyositis
(10001003)
Sjogren syndrome (10001004)
Antiphospholipid syndrome (10001005)
Connective tissue disease Other
(10001077)
Connective tissue disease unknown
(10001099)
Subclassification of vasculitis*
Wegener granulomatosis (10002001)
Classical polyarteritis nodosa
(10002002)
Microscopic polyarteritis nodosa
(10002003)
Churg-Strauss (10002004)
Necrotising arteritis (10002005)
Giant cell arteritis (10002006)
Takayasu (10002007)
Behcets syndrome (10002008)
Vasculitis Other (10002077)
Vasculitis unknown (10002099)
Subclassification of arthritis*
Rheumatoid arthritis (10003001)
Psoriatic arthritis/psoriasis (10003002)
Juvenile idiopathic arthritis: Systemic
(Stills) (10003003)
Juvenile idiopathic arthritis: Polyarticular
(10003004)
Juvenile idiopathic arthritis: Other
(10003005)
Arthristis other (10003077)
Arthristis unknown (10003099)
Subclassification of other neurological*
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Myasthenia gravis (10005001)
Other neurological (10005077)
Unknown other neurological (10005099)
Subclassification of haematological*
Idiopathic thrombocytopenic purpura
(ITP) (10006001)
Idiopathic haemolytic anaemia
(10006002)
Pure red cell (acquired PRCA)
(10006003)
Pure white cell (10006004)
Evan syndrome/combine (10006005)
Other haematological (10006077)
Unknown haematological (10006099)
Subclassification of bowel disease*
Crohns disease (10007001)
Ulcerative colitis (10007002)
Other bowel disease (10007077)
Unknown bowel disease (10007099)
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EWOG SAA Relapse or progression
Genetische und immunologische Charakterisierung der
schweren aplastischen Anaemie (SAA) bei Kindern und
Jugendlichen (EWOG-SAA) http://ewog-mds.org/
All rights reserved. Please visit https://medical-data-
models.org/forms/5447
Relapse or progression
Show identification of patient
Dummy
Relapse or progression
Datum Rezidiv/Progress*
Chronologische Nr. dieses Rezidivs/Progress*
Lokalisation Knochenmark*
Nein (1)
Ja (2)
Lokalisation ZNS*
Nein (1)
Ja (2)
Lokalisation Hoden*
Nein (1)
Ja (2)
Andere Lokalisation*
Nein (1)
Ja (2)
Bitte die andere Lokalisation spezifizieren*
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EWOG SAA Secondary malignancy
Genetische und immunologische Charakterisierung der
schweren aplastischen Anaemie (SAA) bei Kindern und
Jugendlichen (EWOG-SAA) http://ewog-mds.org/
All rights reserved. Please visit https://medical-data-
models.org/forms/5448
Secondary malignancy
Show identification of patient
Dummy
Secondary malignancy
Diagnosedatum*
Beschreibung/Diagnose*
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EWOG SAA Status annually after HSCT
Genetische und immunologische Charakterisierung der
schweren aplastischen Anaemie (SAA) bei Kindern und
Jugendlichen (EWOG-SAA) http://ewog-mds.org/
All rights reserved. Please visit https://medical-data-
models.org/forms/5449
Status annually after HSCT
Show identification of patient
Dummy
Disease status annually after HSCT
Autologe Rekonstitution*
Nein (1)
Ja (2)
SekundÃ¤rmalignom*
Nein (1)
Ja (2)
Rezidiv oder Progress aufgetreten*
Nein (1)
Ja (2)
Bester Erkrankungsstatus*
Komplette Remission (CR) (1)
Partielle Remission (PR) (2)
Keine Remission bzw. nie in Remission
gewesen (3)
Chronolog. Nr. dieser kompletten Remission*
Chronolog. Nr. dieser Teilremission*
Survival status
Ãœberlebensstatus*
Verstorben (1)
Lebt (2)
Lost to follow-up (9)
Score Karnofsky/Lansky*
10% (10)
100% (100)
20% (20)
30% (30)
40% (40)
50% (50)
60% (60)
70% (70)
80% (80)
90% (90)
Datum Bewertung*
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EWOG SAA Status at HSCT
Genetische und immunologische Charakterisierung der
schweren aplastischen Anaemie (SAA) bei Kindern und
Jugendlichen (EWOG-SAA) http://ewog-mds.org/
All rights reserved. Please visit https://medical-data-
models.org/forms/5450
Status at HSCT
Show identification of patient
Dummy
Body measurements
KÃ¶rpergrÃ¶ÃŸe*
KÃ¶rpergewicht*
KÃ¶rperoberflÃ¤che (KOF)*
KOF berechnet*
Performance status (Karnofsky/Lansky)
Datum Bewertung*
Score Karnofsky/Lansky*
10% (10)
100% (100)
20% (20)
30% (30)
40% (40)
50% (50)
60% (60)
70% (70)
80% (80)
90% (90)
Therapy (SAA specific)
Cyclosporin A*
Nicht verabreicht (1)
Fortlaufend (2)
Gestoppt (3)
Datum der letzten Dosis*
Andere immunosuppressive Therapie*
Nein (1)
Ja (2)
Art der anderen Therapie*
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Clinical data at HSCT (SAA specific)
Infektion*
Nein (1)
Ja (2)
Bakteriell > CTCAE Grad 2*
Nein (1)
CTCAE Grad 3 (3)
CTCAE Grad 4 (4)
Bakterieller Organismus*
Fungal > CTCAE Grad 2*
Nein (1)
CTCAE Grad 3 (3)
CTCAE Grad 4 (4)
Fungaler Organismus*
ParasitÃ¤r > CTCAE Grad 2*
Nein (1)
CTCAE Grad 3 (3)
CTCAE Grad 4 (4)
ParasitÃ¤rer Organismus*
Viral > CTCAE Grad 2*
Nein (1)
CTCAE Grad 3 (3)
CTCAE Grad 4 (4)
Virus*
Unbekannt > CTCAE Grad 2*
Nein (1)
CTCAE Grad 3 (3)
CTCAE Grad 4 (4)
Organismus der unbekannten Infektion*
Clinical data at HSCT (SAA specific) -
Organ dysfunction
Schwerwiegende Herzkreislauf-Komplikationen*
Nein (1)
Ja (2)
Shortening Fraction < 25 %*
Nein (1)
Ja (2)
Katechecholaminbedarf*
Nein (1)
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Ja (2)
TherapiebedÃ¼rftige Arrhythmien*
Nein (1)
Ja (2)
Schwerwiegende hepatische Komplikationen*
Nein (1)
Ja (2)
Art*
CTCAE Grad*
CTCAE Grad 1 (1)
CTCAE Grad 2 (2)
CTCAE Grad 3 (3)
CTCAE Grad 4 (4)
Relevante BilirubinerhÃ¶hung > CTCAE Grad 2*
Nein (1)
Ja (2)
S-GOT/S-GPT-ErhÃ¶hung*
Nein (1)
Ja (2)
Leukenzephalopathie*
Nein (1)
Ja (2)
ZNS-Blutung*
Nein (1)
Ja (2)
KrampfanfÃ¤lle*
Nein (1)
Ja (2)
Relevante Kreatinin ErhÃ¶hung > CTCAE Grad
2*
Nein (1)
CTCAE Grad 3 (3)
CTCAE Grad 4 (4)
HÃ¤modialyse oder HÃ¤mofiltration*
Nein (1)
Ja (2)
Fanconi-Syndrom*
Nein (1)
Ja (2)
Nephrotisches Syndrom*
Nein (1)
Ja (2)
Andere Dysfunktion*
Nein (1)
Ja (2)
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Art*
CTCAE Grad*
CTCAE Grad 1 (1)
CTCAE Grad 2 (2)
CTCAE Grad 3 (3)
CTCAE Grad 4 (4)
Hematology (SAA specific)
RegelmÃ¤ÃŸige Erythrozytentransfusionen
notwendig*
Nein (1)
Ja (2)
RegelmÃ¤ÃŸige Thrombozytentransfusionen
notwendig*
Nein (1)
Ja (2)
Granulozytentransfusion*
Nein (1)
Ja (2)
Abnahmedatum des peripheren Bluts*
Hb Wert*
MCV*
Thrombozyten*
Leukozyten*
Neutrophile*
Erythrozyten*
Retikulozyten*
Niedrigster ANC vor HSZT (nur bei primÃ¤rer
HSZT)*
Disease status at HSCT
Erkrankungsstatus bei HSZT*
Komplette Remission (CR) (1)
Partielle Remission (PR) (2)
Refraktäre Erkrankung / Non-response /
Nie in Remission (3)
Rezidiv/Progression (4)
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Unbehandelt (5)
Chronolog. Nr. dieser kompletten Remission*
Chronolog. Nr. dieser Teilremission*
SekundÃ¤rmalignom*
Nein (1)
Ja (2)
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EWOG SAA Status at HSCT
EWOG SAA Status after HSCT till day +100
Genetische und immunologische Charakterisierung der
schweren aplastischen Anaemie (SAA) bei Kindern und
Jugendlichen (EWOG-SAA) http://ewog-mds.org/
All rights reserved. Please visit https://medical-data-
models.org/forms/5451
Status after HSCT till day +100
Show identification of patient
Dummy
Disease status till day +100
Autologe Rekonstitution*
Nein (1)
Ja (2)
SekundÃ¤rmalignom*
Nein (1)
Ja (2)
Rezidiv oder Progress aufgetreten*
Nein (1)
Ja (2)
Bester Erkrankungsstatus*
Komplette Remission (CR) (1)
Partielle Remission (PR) (2)
Keine Remission bzw. nie in Remission
gewesen (3)
Chronolog. Nr. dieser kompletten Remission*
Chronolog. Nr. dieser Teilremission*
Survival status
Ãœberlebensstatus*
Verstorben (1)
Lebt (2)
Lost to follow-up (9)
Score Karnofsky/Lansky*
10% (10)
100% (100)
20% (20)
30% (30)
40% (40)
50% (50)
60% (60)
70% (70)
80% (80)
90% (90)
Datum Bewertung*
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EWOG SAA Therapy
Genetische und immunologische Charakterisierung der
schweren aplastischen Anaemie (SAA) bei Kindern und
Jugendlichen (EWOG-SAA) http://ewog-mds.org/
All rights reserved. Please visit https://medical-data-
models.org/forms/5452
Therapy
Show identification of patient
Dummy
Therapy
Art der Therapie*
Nur Beobachtung (1)
Andere spezielle Therapie als IST/HSZT
(99)
Beginn*
Ende*
Andere Art der Therapie angeben*
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EWOG SAA Treatment after HSCT
Genetische und immunologische Charakterisierung der
schweren aplastischen Anaemie (SAA) bei Kindern und
Jugendlichen (EWOG-SAA) http://ewog-mds.org/
All rights reserved. Please visit https://medical-data-
models.org/forms/5453
Treatment after HSCT
Show identification of patient
Dummy
Treatment after HSCT
Art der Therapie*
Chemotherapie (1)
Weitere HSZT (2)
Zelltherapie (3)
Reason for therapy
Indikation fÃ¼r die Zelltherapie*
Rezidiv (1)
Nicht erreichte Remission (2)
Gemischter Chimerismus (3)
Transplantatversagen (4)
GvHD (5)
Virusinfektion (6)
EBV assoziierte Lymphproliferation (7)
Prophylaktischer Einsatz (8)
Anderer (99)
Anderer Grund*
Reason for therapy
Indikation fÃ¼r weitere HSZT*
Rezidiv (1)
Nicht erreichte Remission (2)
Gemischter Chimerismus (3)
Transplantatversagen (4)
Anderer (99)
Anderer Grund*
Reason for therapy
Indikation fÃ¼r die Chemotherapie*
Rezidiv (1)
Nicht erreichte Remission (2)
EBV assoziierte Lymphproliferation (7)
Prophylaktischer Einsatz (8)
Anderer (99)
Anderer Grund*
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Infusions
Art des Spenders*
Autolog (1)
Allogen (2)
Art der Infusion*
MNC-Zellen (1)
CD34+ Zellen (2)
CD3+ Zellen (3)
Dentritische Zellen (4)
Mesenchymale Stammzellen (5)
NK-Zellen (6)
Antigenspezifische T-Zellen (7)
Fibroblasten (8)
Art der Infusion (2)
MNC-Zellen (1)
CD34+ Zellen (2)
CD3+ Zellen (3)
Dentritische Zellen (4)
Mesenchymale Stammzellen (5)
NK-Zellen (6)
Antigenspezifische T-Zellen (7)
Fibroblasten (8)
Art der Infusion (3)
MNC-Zellen (1)
CD34+ Zellen (2)
CD3+ Zellen (3)
Dentritische Zellen (4)
Mesenchymale Stammzellen (5)
NK-Zellen (6)
Antigenspezifische T-Zellen (7)
Fibroblasten (8)
Anzahl an Infusionen dieser Art*
Datum der (ersten) Zellinfusion
Bemerkung
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EWOG SAA Treatment after HSCT
EWOG SAA Marker of infection prior to
HSCT
Genetische und immunologische Charakterisierung der
schweren aplastischen Anaemie (SAA) bei Kindern und
Jugendlichen (EWOG-SAA) http://ewog-mds.org/
All rights reserved. Please visit https://medical-data-
models.org/forms/5454
Marker of infection prior to HSCT
Show identification of patient
Dummy
Markers of infection
CMV IgG*
Negativ (1)
Positiv (2)
CMV IgM*
Negativ (1)
Positiv (2)
EBV-VCA IgG*
Negativ (1)
Positiv (2)
EBV-VCA IgM*
Negativ (1)
Positiv (2)
Anti HBc*
Negativ (1)
Positiv (2)
HBs Ag*
Negativ (1)
Positiv (2)
Anti HBs*
Negativ (1)
Positiv (2)
HCV IgG*
Negativ (1)
Positiv (2)
HIV IgG*
Negativ (1)
Positiv (2)
HSV IgG*
Negativ (1)
Positiv (2)
HTLV IgG*
Negativ (1)
Positiv (2)
Toxoplasma IgG*
Negativ (1)
Positiv (2)
1 / 2
VZV IgG*
Negativ (1)
Positiv (2)
HCV PCR*
Negativ (1)
Positiv (2)
HIV PCR*
Negativ (1)
Positiv (2)
HTLV PCR*
Negativ (1)
Positiv (2)
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EWOG SAA Marker of infection prior to HSCT
EWOG SAA SAA participation
Genetische und immunologische Charakterisierung der
schweren aplastischen Anaemie (SAA) bei Kindern und
Jugendlichen (EWOG-SAA) http://ewog-mds.org/
All rights reserved. Please visit https://medical-data-
models.org/forms/5455
SAA participation
Redirect
Einwilligung gegeben*
Nein (1)
Ja (2)
Datum der Einwilligung*
Studien-ID in dieser Studie
furtherstudyid
Teilnahme*
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EWOG SAA Chimerism
Genetische und immunologische Charakterisierung der
schweren aplastischen Anaemie (SAA) bei Kindern und
Jugendlichen (EWOG-SAA) http://ewog-mds.org/
All rights reserved. Please visit https://medical-data-
models.org/forms/5456
Chimerism
Show identification of patient
Dummy
Best chimerism
Materialart*
Peripheres Blut (1)
Knochenmark (3)
Datum der Materialentnahme*
ChimÃ¤rismus Methode*
STR (Short Tandem Repeats) (1)
Andere Methode (99)
% Spender-Zellen*
Further chimerism
Materialart*
Peripheres Blut (1)
Knochenmark (3)
Datum der Materialentnahme*
ChimÃ¤rismus Methode*
STR (Short Tandem Repeats) (1)
Andere Methode (99)
% Spender-Zellen*
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EWOG SAA GvHD occurred
Genetische und immunologische Charakterisierung der
schweren aplastischen Anaemie (SAA) bei Kindern und
Jugendlichen (EWOG-SAA) http://ewog-mds.org/
All rights reserved. Please visit https://medical-data-
models.org/forms/5457
GvHD occurred
Show identification of patient
Dummy
GvHD occurred
GvHD aufgetreten*
Nein (1)
Ja, noch nicht dokumentiert
(Neuauftreten) (2)
Ja, in vorheriger Periode bereits
dokumentiert (3)
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EWOG SAA Severe complications after day
100
Genetische und immunologische Charakterisierung der
schweren aplastischen Anaemie (SAA) bei Kindern und
Jugendlichen (EWOG-SAA) http://ewog-mds.org/
All rights reserved. Please visit https://medical-data-
models.org/forms/5458
Severe complications after day 100
Show identification of patient
Dummy
Severe infection occurred
Infektion*
Nein (1)
Ja (2)
Severe pulmonary complications
Radiologische VerÃ¤nderungen und/oder
Sauerstoffbedarf*
Nein (1)
Ja (2)
KÃ¼nstliche Beatmung*
Nein (1)
Ja (2)
Severe cardio-vascular complications
Shortening Fraction < 25 %*
Nein (1)
Ja (2)
Katechecholaminbedarf*
Nein (1)
Ja (2)
TherapiebedÃ¼rftige Arrhythmien*
Nein (1)
Ja (2)
Severe renal complications
Relevante Kreatinin ErhÃ¶hung > CTCAE Grad
2*
Nein (1)
CTCAE Grad 3 (3)
CTCAE Grad 4 (4)
HÃ¤modialyse oder HÃ¤mofiltration*
Nein (1)
Ja (2)
Fanconi-Syndrom*
Nein (1)
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Ja (2)
Nephrotisches Syndrom*
Nein (1)
Ja (2)
Severe hepatic complications
Relevante Bilirubin ErhÃ¶hung > CTCAE Grad 2*
Nein (1)
CTCAE Grad 3 (3)
CTCAE Grad 4 (4)
Severe neurological complications
Leukenzephalopathie*
Nein (1)
Ja (2)
ZNS-Blutung*
Nein (1)
Ja (2)
KrampfanfÃ¤lle*
Nein (1)
Ja (2)
Severe gastrointestinal complications
Ileus*
Nein (1)
Ja (2)
Gastrointestinale Blutung*
Nein (1)
Ja (2)
Severe endocrinologic complications
Hypothyreose*
Nein (1)
Ja (2)
Hypogonadismus*
Nein (1)
Ja (2)
WachstumsverzÃ¶gerung*
Nein (1)
Ja (2)
Severe sceletal complications
TherapiebedÃ¼rftige Osteopenie*
Nein (1)
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EWOG SAA Severe complications after day 100
Ja (2)
Gelenkersatz*
Nein (1)
Ja (2)
Other severe complications
Andere schwere Komplikation(en)*
Nein (1)
Ja (2)
Beschreibung der anderen schweren
Komplikation(en)*
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EWOG SAA Severe complications after day 100
EWOG SAA Graft failure
Genetische und immunologische Charakterisierung der
schweren aplastischen Anaemie (SAA) bei Kindern und
Jugendlichen (EWOG-SAA) http://ewog-mds.org/
All rights reserved. Please visit https://medical-data-
models.org/forms/5459
Graft failure
Show identification of patient
Dummy
Graft failure
Transplantatversagen aufgetreten*
Nein (1)
Ja (2)
Art des Transplantatversagens*
Abstoßung (1)
Spätes Transplantatversagen (2)
Datum des Transplantatversagens*
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EWOG SAA Status annually after HSCT
Genetische und immunologische Charakterisierung der
schweren aplastischen Anaemie (SAA) bei Kindern und
Jugendlichen (EWOG-SAA) http://ewog-mds.org/
All rights reserved. Please visit https://medical-data-
models.org/forms/5460
Status annually after HSCT
Show identification of patient
Dummy
Disease status annually after HSCT
Autologe Rekonstitution*
Nein (1)
Ja (2)
SekundÃ¤rmalignom*
Nein (1)
Ja (2)
Rezidiv oder Progress aufgetreten*
Nein (1)
Ja (2)
Bester Erkrankungsstatus*
Komplette Remission (CR) (1)
Partielle Remission (PR) (2)
Keine Remission bzw. nie in Remission
gewesen (3)
Chronolog. Nr. dieser kompletten Remission*
Chronolog. Nr. dieser Teilremission*
Survival status
Ãœberlebensstatus*
Verstorben (1)
Lebt (2)
Lost to follow-up (9)
Score Karnofsky/Lansky*
10% (10)
100% (100)
20% (20)
30% (30)
40% (40)
50% (50)
60% (60)
70% (70)
80% (80)
90% (90)
Datum Bewertung*
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CWS-2007-HR B3 - Primaere
Standardtherapie
CWS-2007-HR: A randomised phase-_III trial of the
Cooperative Soft-_Tissue-_Study-_Group for localised
high-_risk rhabdomyosarcoma and localised
Rhabdomyosarcoma-_like Soft Tissue Sarcoma in children,
adolescents, and young adults
http://clinicaltrials.gov/show/NCT00876031
http://www.cws.olgahospital-stuttgart.de
All rights reserved. Please visit https://medical-data-
models.org/forms/5462
B3 - Primaere Standardtherapie
Anzeige Namen auf Formular
Patient
Primäre Chemotherapie
Therapie nach*
CWS-guidance (1)
andere (2)
sonstige
Chemotherapie mit*
I2VA (1)
VAIA III (2)
andere (3)
anderes Therapieschema*
Chemotherapie-Beginn*
Chemotherapie-Ende*
Primäre Radiotherapie
Radiotherapie erhalten*
ja (1)
nein (2)
Radiotherapie-Beginn*
Radiotherapie-Ende*
Anzahl der Fraktionierungen/Tag*
Einzeldosis [Gy] / Tag*
Gesamtdosis [Gy]*
Sekundäre Resektion
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SekundÃ¤re Operation durchgefÃ¼hrt?*
ja (1)
nein (2)
Datum der Operation*
Operationsart*
Biopsie (1)
Resektion ohne Organentfernung (2)
Resektion mit Organentfernung (3)
Welches Organ wurde entfernt?*
Operationsergebnis*
R0 Tumor makro- u.mikroskopisch
vollständig entfernt (0)
R1 Tumor makroskopisch entfernt,
mikroskopisch noch Reste vorhanden (1)
R2 Tum.inkomplett
reseziert,makroskopisch noch Reste
vorhanden oder nur Biopsie (2)
Remissionsstatus
Datum der ersten Vollremission*
Remissionsstatus bei Therapieende*
Komplette Remission (1)
Reststruktur in der Bildgebung
vorhanden (2)
Bemerkungen
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CWS-2007-HR B3 - Primaere Standardtherapie
CWS-2007-HR B3 - Primaertumor
CWS-2007-HR: A randomised phase-_III trial of the
Cooperative Soft-_Tissue-_Study-_Group for localised
high-_risk rhabdomyosarcoma and localised
Rhabdomyosarcoma-_like Soft Tissue Sarcoma in children,
adolescents, and young adults
http://clinicaltrials.gov/show/NCT00876031
http://www.cws.olgahospital-stuttgart.de
All rights reserved. Please visit https://medical-data-
models.org/forms/5463
B3 - Primaertumor
Anzeige Namen auf Formular
Patient
Lokalisation Tumor
KÃ¶rperseite*
rechts (1)
links (2)
beidseitig (3)
Mittellinie (4)
Lokalisation*
Orbita (ohne knöcherne Arrosion) (10)
HN-PM Kopf/Hals-parameningeal,
Sonstige (20)
HN-PM Nasennebenhöhle (21)
HN-PM Mittelohr/Mastoid (22)
HN-PM Fossa pterygopalatina (23)
HN-PM Epipharynx (24)
HN-PM Nasopharynx (25)
HN-PM Schädelbasis (26)
HN-PM Cerebrum (27)
HN-PM Orbita (mit knöcherner Arrosion)
(28)
HN-nPM Kopf/Hals-NICHT-
parameningeal, Sonstige (30)
HN-nPM Nase (31)
HN-nPM Wange (32)
HN-nPM Zunge (33)
HN-nPM Lippe (34)
HN-nPM Halsweichteile (35)
UG-BP Urogenital-Blase/Prostata unklar
(40)
UG-BP Blase (41)
UG-BP Prostata (42)
UG-nBP Urogenital-NICHT-
Blase/Prostata, Sonstige (50)
UG-nBP Paratestikulär (51)
UG-nBP Uterus (52)
UG-nBP Vagina (53)
UG-nBP Vulva (54)
EXT Extremitäten, Sonstige (60)
EXT Schultergürtel (61)
EXT Oberarm (62)
EXT Unterarm (63)
EXT Hand (64)
EXT Leiste/Gesäß (65)
EXT Oberschenkel (66)
EXT Unterschenkel (67)
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EXT Fuß (68)
OTH Andere, Sonstiges (70)
OTH Intraabdominal (71)
OTH Retroperitoneal (72)
OTH Kleines Becken (73)
OTH Stamm (74)
OTH Intrathorakal (75)
OTH Mediastinal (76)
Lokalisation im Volltext
TNM-Klassifikation bei Primärdiagnostik
Tumor*
T1 Tumor aufs Ausgangsorgan/-gewebe
beschränkt (1)
T2 Tumor nicht aufs Ausgangsorgan
beschränkt (2)
TX Unzureichende Information (9)
Lymphknoten*
N0 Kein Anhalt für Befall der regionären
Lymphknoten (0)
N1 Befall regionaler Lymphknoten (1)
welche*
Metastasen*
M0 Kein Anhalt für Fernmetastasen (0)
TumorgrÃ¶ÃŸe*
Ta, < 3 cm (1)
Ta, 3 bis 5 cm (2)
Tb, >5 bis < 10 cm (3)
Tb, 10 cm und größer (4)
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CWS-2007-HR B3 - Primaertumor
CWS-2007-HR B3 - Primaere Diagnostik
CWS-2007-HR: A randomised phase-_III trial of the
Cooperative Soft-_Tissue-_Study-_Group for localised
high-_risk rhabdomyosarcoma and localised
Rhabdomyosarcoma-_like Soft Tissue Sarcoma in children,
adolescents, and young adults
http://clinicaltrials.gov/show/NCT00876031
http://www.cws.olgahospital-stuttgart.de
All rights reserved. Please visit https://medical-data-
models.org/forms/5464
B3 - Primaere Diagnostik
Anzeige Namen auf Formular
Patient
Primäres chirurgisches Vorgehen
Biopsie am*
Resektion am*
Nachresektion am*
Ergebnis der Resektion(en)*
organerhaltend (1)
nicht organerhaltend (2)
pTNM Klassifikation
Tumor*
pT1 Tumor auf Ausgangsorgan oder
-Gewebe beschränkt (1)
pT2 Tumor mit Invasion
jenseits..,Exzision komplett (2)
pT3 Tumor mit oder ohne Invasion
jenseits Ausgangsorgan (3)
pT3a Mikroskopischer Residualtumor (4)
pT3b Makroskopischer Resttumor oder
nur Biopsie (5)
pTX Unzureichende Information (9)
Lymphknoten*
pN0 Kein Tumornachweis bei
hist.Untersuchung reg. Lymphknoten (0)
pN1 Befall regionärer Lymphknoten (1)
pN1a komplett reseziert (2)
pN1b inkomplett reseziert oder nur
biopsiert (3)
pNX Unzureichende Information (9)
welche*
Metastasen*
pM0 Keine Fernmetastasen (0)
Histologische Untersuchung
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Referenzhistologische Untersuchung
durchgefÃ¼hrt in*
Kiel (1)
andere (2)
Ort des Labors
Tumorregister-Nr.
Datum der definitiven Diagnosestellung*
Alter bei Diagnosestellung grÃ¶ÃŸer oder gleich
10 Jahre*
ja (1)
nein (2)
Diagnose*
RMS-Rhabdomyosarkom o.n.A. (1)
pPNET-periph.primitiver
neuroektodermaler Tumor (10)
EES-Ewingsarkom extrao. o.n.A. (11)
EES-Ewingsarkom extraossär (12)
UDS-undifferenziertes Weichteilsarkom
(13)
STET-Soft tissue Ewing Tumor (14)
RMA-Rhabdomyosarkom alveolär o.n.A.
(2)
RMA-Rhabdomyosarkom alveolär, solide
(3)
RME-Rhabdomyosarkom embryonal
o.n.A. (4)
RME-Rhabdomyosarkom embryonal
botryoid (5)
RME-Rhabdomyosarkom embryonal
spindelzellig (6)
SySa-Synovialsarkom o.n.A. (7)
SySa-Synovialsarkom monophasisch (8)
SySa-Synovialsarkom biphasisch (9)
Molekulargenetische Untersuchungen am
Referenzlabor Stuttgart durchgefÃ¼hrt?*
ja (1)
nein (2)
Molekulargenetische Untersuchungen in
CWS
PAX3-FOXO1*
Positiv (1)
Negativ (2)
fraglich (3)
PAX7-FOXO1*
Positiv (1)
Negativ (2)
fraglich (3)
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CWS-2007-HR B3 - Primaere Diagnostik
ews-fli1*
Positiv (1)
Negativ (2)
fraglich (3)
ews-erg*
Positiv (1)
Negativ (2)
fraglich (3)
ews-etv1*
Positiv (1)
Negativ (2)
fraglich (3)
ews-eaf1*
Positiv (1)
Negativ (2)
fraglich (3)
ews-wt1*
Positiv (1)
Negativ (2)
fraglich (3)
ews-chop*
Positiv (1)
Negativ (2)
fraglich (3)
ews-nor1*
Positiv (1)
Negativ (2)
fraglich (3)
syt-ssx1*
Positiv (1)
Negativ (2)
fraglich (3)
syt-ssx2*
Positiv (1)
Negativ (2)
fraglich (3)
weitere postive Ergebnisse*
ja (1)
nein (2)
Bezeichnung positiver Genorte*
IRS-Stadium und Risikogruppe bei
Diagnosestellung
IRS-Stadium*
Stadium I-Tumor komplett entfernt und
reg. Lymphknoten nicht befallen (1)
Stadium II- Tumor makroskopisch
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CWS-2007-HR B3 - Primaere Diagnostik
entfernt, mikroskopische Tumorreste
vorhanden (2)
Stadium III- Tumor inkomplett entfernt
oder nur Biopsie (3)
Stadium I*
Ia-Tumor auf Ausgangsorgan oder
-gewebe beschränkt (1)
Ib-Tumor nicht auf Ausgangsorgan oder
-gewebe beschränkt (2)
Stadium II*
IIa- reg. LK nicht befallen (1)
IIb- reg.LK befallen und komplett entfernt
(2)
IIc- reg.LK befallen, makr.entfernt,
mikroskopische Tumorreste (3)
Stadium III*
IIIa- nur Biopsie (1)
IIIb- Tumor inkomplett entfernt,
makroskopische Tumorreste (2)
Risikogruppe*
RMS high (1)
RMS very high (2)
RMS-like: extraossäre Ewing-und undif.
Sarkome (3)
RMS-like: Synovialsarkom (4)
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CWS-2007-HR B4 - O-TIE modifications
CWS-2007-HR: A randomised phase-_III trial of the
Cooperative Soft-_Tissue-_Study-_Group for localised
high-_risk rhabdomyosarcoma and localised
Rhabdomyosarcoma-_like Soft Tissue Sarcoma in children,
adolescents, and young adults
http://clinicaltrials.gov/show/NCT00876031
http://www.cws.olgahospital-stuttgart.de
All rights reserved. Please visit https://medical-data-
models.org/forms/5471
B4 - O-TIE modifications
O-TIE modification
Gesamte Therapie (Block 1-8) erhalten wie
vorgesehen*
ja, Therapie protokollgemäß (1)
nein, Abweichungen im Zeitplan (2)
nein, Abweichungen der Dosisvorgabe
(3)
nein, Reihenfolge der Blöcke verändert
(4)
nein, nicht alle Blöcke erhalten (5)
nein, andere Abweichung (6)
Genaue Beschreibung der Abweichung*
Grund fÃ¼r die Abweichung*
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CWS-2007-HR Identifizierende Daten der
CWS Studie
CWS-2007-HR: A randomised phase-_III trial of the
Cooperative Soft-_Tissue-_Study-_Group for localised
high-_risk rhabdomyosarcoma and localised
Rhabdomyosarcoma-_like Soft Tissue Sarcoma in children,
adolescents, and young adults
http://clinicaltrials.gov/show/NCT00876031
http://www.cws.olgahospital-stuttgart.de
All rights reserved. Please visit https://medical-data-
models.org/forms/5472
Identifizierende Daten der CWS
Studie
Demograpische Daten
Geburtsmonat*
Januar (1)
Oktober (10)
November (11)
Dezember (12)
Februar (2)
März (3)
April (4)
Mai (5)
Juni (6)
Juli (7)
August (8)
September (9)
Geburtsjahr*
Geschlecht*
Männlich (1)
Weiblich (2)
Vorname
Nachname
GPOH-PID
LÃ¤nder-Code*
Standardtherapie beendet am*
Ablauf der Randomisierungsfrist*
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CWS-2007-HR Randomisierung
CWS-2007-HR: A randomised phase-_III trial of the
Cooperative Soft-_Tissue-_Study-_Group for localised
high-_risk rhabdomyosarcoma and localised
Rhabdomyosarcoma-_like Soft Tissue Sarcoma in children,
adolescents, and young adults
http://clinicaltrials.gov/show/NCT00876031
http://www.cws.olgahospital-stuttgart.de
All rights reserved. Please visit https://medical-data-
models.org/forms/5473
Randomisierung
Anzeige Namen auf Formular
Patient
Randomisierung
Stratum*
Stratum 1 - low risk (1)
Stratum 2 - high risk (2)
Randomisierungsergebnis*
Arm A - keine Erhaltungstherapie (1)
Arm B - Erhaltungstherapie O-TIE (2)
Datum der Randomisierung*
Studiennummer*
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CWS-2007-HR B5 -
Therapieabschlussbogen
CWS-2007-HR: A randomised phase-_III trial of the
Cooperative Soft-_Tissue-_Study-_Group for localised
high-_risk rhabdomyosarcoma and localised
Rhabdomyosarcoma-_like Soft Tissue Sarcoma in children,
adolescents, and young adults
http://clinicaltrials.gov/show/NCT00876031
http://www.cws.olgahospital-stuttgart.de
All rights reserved. Please visit https://medical-data-
models.org/forms/5474
B5 - Therapieabschlussbogen
Anzeige Namen auf Formular
Patient
I. Arm A - keine Erhaltungstherapie
Ende Beobachtungszeitraum bei
protokollgerechtem Ablauf (berechneter
Richtwert)*
Therapie(Arm B) bzw. Beobachtungszeitraum
(Arm A) beendet am*
CWS-2007-HR protokollkonform beendet?*
ja, Ende protokollkonform (1)
nein, Abbruch wg. Toxizität (2)
nein, Abbruch wg. Rezidiv (3)
nein, Abbruch auf Wunsch des Patienten
(4)
nein, Patient verstorben (5)
nein, Randomisierungsergebnis nicht
akzeptiert (6)
nein, anderer Grund (7)
NÃ¤here Beschreibung
Sonstige Events in Beobachtungsarm A*
ja (1)
nein (2)
Ae's für  Arm A
Beschreibung des Events/ToxizitÃ¤t*
ToxizitÃ¤t Grad*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Grad 5 (5)
Beginn AE*
1 / 3
Ende AE*
Outcome AE*
noch anhaltend, nicht wiederhergestellt
(1)
in Genesung (z.Zt. Nachw. noch unklar)
(2)
Genesung mit Nachwirkungen (3)
Genesung ohne Nachwirkungen (4)
Tod durch SAE (5)
Tod, nicht in Verbindung SAE (6)
unbekannt (7)
ggf. Bemerkungen
II. Arm B - Erhaltungstherapie O-TIE
Therapie(Arm B) bzw. Beobachtungszeitraum
(Arm A) beendet am*
CWS-2007-HR protokollkonform beendet?*
ja, Ende protokollkonform (1)
nein, Abbruch wg. Toxizität (2)
nein, Abbruch wg. Rezidiv (3)
nein, Abbruch auf Wunsch des Patienten
(4)
nein, Patient verstorben (5)
nein, Randomisierungsergebnis nicht
akzeptiert (6)
nein, anderer Grund (7)
NÃ¤here Beschreibung
III. Zusätzliche Therapie während CWS-
2007-HR
Wurde eine zusÃ¤tzliche Therapie wÃ¤hrend
CWS-2007-HR durchgefÃ¼hrt?*
ja (1)
nein (2)
Operation*
ja (1)
nein (2)
Radiotherapie*
ja (1)
nein (2)
Sonstige Therapie wÃ¤hrend CWS-2007-HR*
ja (1)
nein (2)
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CWS-2007-HR B5 - Therapieabschlussbogen
weitere Operation
Datum der OP*
Art der OP*
Probeexcision (PE, Biopsie) (1)
Resektion des Tumors (2)
Resektion der Lymphknoten (3)
Resektion der Metastasen (4)
Sonstige OP (5)
Sonstige OP*
weitere Radiotherapie
Radiotherapie-Beginn*
Radiotherapie-Ende*
Einzeldosis [Gy] / Tag*
Anzahl der Fraktionierungen/Tag*
Gesamtdosis [Gy]*
Art der sonstigen Therapie
Art sonstige Therapie wÃ¤hrend CWS-2007-HR*
Patient's status at the end of therapy
Status*
Remission (1)
Progression (3)
Rezidiv (4)
verstorben (5)
Datum der letzten Untersuchung*
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CWS-2007-HR B5 - Therapieabschlussbogen
CWS-2007-HR Studienzentralen interne
Informationen
CWS-2007-HR: A randomised phase-_III trial of the
Cooperative Soft-_Tissue-_Study-_Group for localised
high-_risk rhabdomyosarcoma and localised
Rhabdomyosarcoma-_like Soft Tissue Sarcoma in children,
adolescents, and young adults
http://clinicaltrials.gov/show/NCT00876031
http://www.cws.olgahospital-stuttgart.de
All rights reserved. Please visit https://medical-data-
models.org/forms/5475
Studienzentralen interne
Informationen
Anzeige Namen auf Formular
Patient
Studienzentrale intern
Kodierung fÃ¼r Abweichung
Bemerkungen
VollstÃ¤ndigkeit der Dokumentation*
unvollständig (0)
vollständig bis Therapieende (1)
vollständig mit min. 1 FUP (2)
vollständig mit min. 2 FUP (3)
vollständig mit min. 3 FUP (4)
vollständig mit min. 4 FUP (5)
vollständig mit min. 5 FUP (6)
vollständig mit allen FUP (7)
anderer Dokumentationsstatus (8)
Dokupauschale bezahlt*
nur Studiendokumentation bezahlt (1)
studiendoku + FUP bezahlt (2)
nicht bezahlt (3)
anderes (4)
Bemerkungen zur Bezahlung
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CWS-2007-HR B7 - Ereignis Rezidiv
CWS-2007-HR: A randomised phase-_III trial of the
Cooperative Soft-_Tissue-_Study-_Group for localised
high-_risk rhabdomyosarcoma and localised
Rhabdomyosarcoma-_like Soft Tissue Sarcoma in children,
adolescents, and young adults
http://clinicaltrials.gov/show/NCT00876031
http://www.cws.olgahospital-stuttgart.de
All rights reserved. Please visit https://medical-data-
models.org/forms/5476
B7 - Ereignis Rezidiv
Anzeige Namen auf Formular
Patient
Angaben zum Rezidiv
Rezidiv-Datum*
Lokalrezidiv*
ja (1)
nein (2)
Lymphknotenrezidiv*
ja (1)
nein (2)
welche*
Metastasen*
ja (1)
nein (2)
Lungenmetastasen*
ja (1)
nein (2)
Knochenmetastasen*
ja (1)
nein (2)
Knochenmarkmetastasen*
ja (1)
nein (2)
Weichteilmetastasen*
ja (1)
nein (2)
Lebermetastatasen*
ja (1)
nein (2)
ZNS Metastasen*
ja (1)
nein (2)
Sonstige Metastasen*
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CWS-2007-HR B7 - Status nach Rezidiv
CWS-2007-HR: A randomised phase-_III trial of the
Cooperative Soft-_Tissue-_Study-_Group for localised
high-_risk rhabdomyosarcoma and localised
Rhabdomyosarcoma-_like Soft Tissue Sarcoma in children,
adolescents, and young adults
http://clinicaltrials.gov/show/NCT00876031
http://www.cws.olgahospital-stuttgart.de
All rights reserved. Please visit https://medical-data-
models.org/forms/5477
B7 - Status nach Rezidiv
Anzeige Namen auf Formular
Patient
Patientenstatus
Aktueller Status des Patienten*
Vollremission (1)
Teilremission (2)
Progression (3)
Rezidiv (4)
Lost to follow up (6)
Status seit*
Datum der letzten Untersuchung*
Bemerkungen
1 / 1
CWS-2007-HR B7 - Ereignis Tod
CWS-2007-HR: A randomised phase-_III trial of the
Cooperative Soft-_Tissue-_Study-_Group for localised
high-_risk rhabdomyosarcoma and localised
Rhabdomyosarcoma-_like Soft Tissue Sarcoma in children,
adolescents, and young adults
http://clinicaltrials.gov/show/NCT00876031
http://www.cws.olgahospital-stuttgart.de
All rights reserved. Please visit https://medical-data-
models.org/forms/5478
B7 - Ereignis Tod
Anzeige Namen auf Formular
Patient
Angaben zum Tod
Tod bedingt durch*
Tumorbedingt (1)
Tumorabhängigkeit nicht entscheidbar
(2)
Therapiebedingt (3)
Zweitmalignom (4)
andere Ursachen (5)
Andere Ursache*
Patient verstorben am*
Bemerkungen
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CWS-2007-HR B7 - Zweitmalignom
CWS-2007-HR: A randomised phase-_III trial of the
Cooperative Soft-_Tissue-_Study-_Group for localised
high-_risk rhabdomyosarcoma and localised
Rhabdomyosarcoma-_like Soft Tissue Sarcoma in children,
adolescents, and young adults
http://clinicaltrials.gov/show/NCT00876031
http://www.cws.olgahospital-stuttgart.de
All rights reserved. Please visit https://medical-data-
models.org/forms/5479
B7 - Zweitmalignom
Anzeige Namen auf Formular
Patient
Angaben zum Zweitmalingnom
Datum des Auftretens*
Diagnose*
1 / 1
CWS-2007-HR Statuserhebung
CWS-2007-HR: A randomised phase-_III trial of the
Cooperative Soft-_Tissue-_Study-_Group for localised
high-_risk rhabdomyosarcoma and localised
Rhabdomyosarcoma-_like Soft Tissue Sarcoma in children,
adolescents, and young adults
http://clinicaltrials.gov/show/NCT00876031
http://www.cws.olgahospital-stuttgart.de
All rights reserved. Please visit https://medical-data-
models.org/forms/5480
Statuserhebung
Anzeige Namen auf Formular
Patient
Patientenstatus
Aktueller Status des Patienten*
Vollremission (1)
Teilremission (2)
Progression (3)
Rezidiv (4)
Lost to follow up (6)
Status seit*
Datum der letzten Untersuchung*
Bemerkungen
1 / 1
CWS-2007-HR B1 - Ein-
_Ausschlusskriterien
CWS-2007-HR: A randomised phase-_III trial of the
Cooperative Soft-_Tissue-_Study-_Group for localised
high-_risk rhabdomyosarcoma and localised
Rhabdomyosarcoma-_like Soft Tissue Sarcoma in children,
adolescents, and young adults
http://clinicaltrials.gov/show/NCT00876031
http://www.cws.olgahospital-stuttgart.de
All rights reserved. Please visit https://medical-data-
models.org/forms/5481
B1 - Ein-/Ausschlusskriterien
Anzeige Namen auf Formular
Patient
Einschlusskriterien
Schriftliches EinverstÃ¤ndnis liegt vor*
ja (1)
nein (2)
RMS oder -like Weichteiltumor nachgewiesen*
ja (1)
nein (2)
Alter > 6 Monate und < 21 Jahre bei
Randomisierung*
ja (1)
nein (2)
Stratifizierung High-Risk, Very High-Risk oder
RMS-"like"*
ja (1)
nein (2)
Keine Kontraindikation Chemotherapie*
ja (1)
nein (2)
Tumor ist kein Zweittumor*
ja (1)
nein (2)
Standardtherapie protokollgerecht beendet*
ja (1)
nein (2)
Patient ist in Remission*
ja (1)
nein (2)
Langzeit Follow -up mÃ¶glich*
ja (1)
nein (2)
Datum der EinverstÃ¤ndniserklÃ¤rung fÃ¼r
CWS-07-HR*
Ausschlusskriterien
1 / 2
Besteht eine Schwangerschaft / Stillzeit*
ja (1)
nein (2)
Erkrankungen, die Studientherapie verhindern*
ja (1)
nein (2)
Weigerung der Anwendung effektiver
Kontrazeption*
ja (1)
nein (2)
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CWS-2007-HR B1 - Ein-_Ausschlusskriterien
CWS-2007-HR Status after second
malingancy
CWS-2007-HR: A randomised phase-_III trial of the
Cooperative Soft-_Tissue-_Study-_Group for localised
high-_risk rhabdomyosarcoma and localised
Rhabdomyosarcoma-_like Soft Tissue Sarcoma in children,
adolescents, and young adults
http://clinicaltrials.gov/show/NCT00876031
http://www.cws.olgahospital-stuttgart.de
All rights reserved. Please visit https://medical-data-
models.org/forms/5482
Status after second malingancy
Anzeige Namen auf Formular
Patient
Patientenstatus
Aktueller Status des Patienten*
Vollremission (1)
Teilremission (2)
Progression (3)
Rezidiv (4)
Lost to follow up (6)
Status seit*
Datum der letzten Untersuchung*
Bemerkungen
1 / 1
CWS-2007-HR SAE Kurzbericht
CWS-2007-HR: A randomised phase-_III trial of the
Cooperative Soft-_Tissue-_Study-_Group for localised
high-_risk rhabdomyosarcoma and localised
Rhabdomyosarcoma-_like Soft Tissue Sarcoma in children,
adolescents, and young adults
http://clinicaltrials.gov/show/NCT00876031
http://www.cws.olgahospital-stuttgart.de
All rights reserved. Please visit https://medical-data-
models.org/forms/5483
SAE Kurzbericht
Anzeige Namen auf Formular
Patient
SAE in CWS
Datum des SAE*
Beschreibung des SAE*
SAE Nr. neu*
SAE Nr.
1 / 1
CWS-2007-HR Studienzentrale
CWS-2007-HR: A randomised phase-_III trial of the
Cooperative Soft-_Tissue-_Study-_Group for localised
high-_risk rhabdomyosarcoma and localised
Rhabdomyosarcoma-_like Soft Tissue Sarcoma in children,
adolescents, and young adults
http://clinicaltrials.gov/show/NCT00876031
http://www.cws.olgahospital-stuttgart.de
All rights reserved. Please visit https://medical-data-
models.org/forms/5485
Studienzentrale
Organisatorische Daten
Kodierung fÃ¼r Analyse
PP (1)
ITT (2)
noch nicht beurteilbar (3)
Safety
ja (1)
nein (2)
VollstÃ¤ndigkeit der Dokumentation
unvollständig (0)
vollständig bis Therapieende (1)
vollständig mit min. 1 FUP (2)
vollständig mit min. 2 FUP (3)
vollständig mit min. 3 FUP (4)
vollständig mit min. 4 FUP (5)
vollständig mit min. 5 FUP (6)
vollständig mit allen FUP (7)
anderer Dokumentationsstatus (8)
Dokumentationspauschale bezahlt
Studiendoku + FUP bezahlt (2)
nicht bezahlt (3)
anderes (4)
Bemerkungen zur Bezahlung
Allgemeines Bemerkungsfeld*
Abweichungen vom Protokoll
Kodierung fÃ¼r Abweichung
Bemerkungen
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dataset treatment cancer
clinical cancer registry used in Münster
All rights reserved. Please visit https://medical-data-
models.org/forms/5517
dataset
Patient data
Patient title *
patient number*
Patient surname *
Patient forename*
Patient date of birth*
Patient sex*
Female (Female)
Male (Male)
Street Address*
Patient postal code*
City of residence *
Patient telephone number*
Treatment
Date of Treatment*
Source of information *
Cancer Center  (Cancer Center )
Cancer Registry  (Cancer Registry )
Central Office (Central Office)
Hospitals (Hospitals)
Newspapers  (Newspapers )
Other (Other)
Primary Care Physician (Primary Care
Physician)
RegistrationCenter (RegistrationCenter)
Unknown (Unknown)
Timepoint *
no information (no information)
Not Applicable  (Not Applicable )
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therapy complete (therapy complete)
treatment changed (treatment changed)
treatment continue (treatment continue)
treatment started  (treatment started )
Unknown (Unknown)
treatment classification *
Diagnostic procedure (Diagnostic
procedure)
Follow-up therapy (Follow-up therapy)
long-term treatment (long-term
treatment)
no information (no information)
primal therapy (primal therapy)
relapse treatment (relapse treatment)
therapy of metastasis (therapy of
metastasis)
Intention*
Adjuvant - intent (Adjuvant - intent)
Curative - procedure intent  (Curative -
procedure intent )
Neo-adjuvant - intent  (Neo-adjuvant -
intent )
no information (no information)
Not Applicable  (Not Applicable )
Palliative - procedure intent  (Palliative -
procedure intent )
Admission date*
Admission status*
inpatient  (inpatient )
outpatient (outpatient)
Pre-hospital care (Pre-hospital care)
Status post hospitalization (Status post
hospitalization)
Clinical Trial Subject*
No (No)
no information (no information)
Yes (Yes)
Clinical Trials *
Collection*
complete (complete)
incomplete (incomplete)
Cancer conference type*
morbidity conference (morbidity
conference)
No (No)
no information (no information)
post-therapeutic (post-therapeutic)
pre- and post-therapeutic (pre- and post-
therapeutic)
pre-therapeutic (pre-therapeutic)
ECOG performance status grade *
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0 (0)
1 (1)
2 (2)
3 (3)
4 (4)
no information (no information)
executed therapeutic procedure
Operative Surgical Procedures *
executed (executed)
refused (refused)
Chemotherapy Regimen*
executed (executed)
refused (refused)
Therapeutic radiology procedure *
executed (executed)
refused (refused)
Endocrine Therapy*
executed (executed)
refused (refused)
Immunotherapy *
executed (executed)
refused (refused)
disease stage*
executed (executed)
refused (refused)
Consultation*
executed (executed)
refused (refused)
Hemopoietic stem cell transplant *
executed (executed)
refused (refused)
Bone Marrow Transplantation*
executed (executed)
refused (refused)
Prophylactic treatment *
executed (executed)
refused (refused)
Rehabilitation therapy *
executed (executed)
refused (refused)
Targeted Therapy*
executed (executed)
refused (refused)
active surveillance*
3 / 16
dataset treatment cancer
executed (executed)
refused (refused)
Inquiry*
executed (executed)
refused (refused)
local destructive therapy*
executed (executed)
refused (refused)
Compassionate Treatment*
executed (executed)
refused (refused)
no activities*
executed (executed)
refused (refused)
Reason for Refusal of Treatmend*
Death (Death)
Medical contraindication  (Medical
contraindication )
Multimorbidity (Multimorbidity)
no information (no information)
Patient desire (Patient desire)
Secondary diseases
Secondary disease*
No (No)
no information (no information)
Yes (Yes)
diagnosis code*
diagnosis text*
Tumor site
ICDO3 Topography Axis *
Localisation text*
Tumor site*
Site of primary tumor (Site of primary
tumor)
Subsite (Subsite)
Side *
Left (Left)
Midline (Midline)
multilocular (multilocular)
no information (no information)
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Not Applicable  (Not Applicable )
Right (Right)
Systemic Disease (Systemic Disease)
Unknown (Unknown)
Histopathology
Histology ICD-O-3 *
histologic diagnosis text*
Tumor site*
Site of primary tumor (Site of primary
tumor)
Subsite (Subsite)
Histologic Grade*
G1 grade  (G1 grade )
G2 grade (G2 grade)
G3 grade (G3 grade)
G4 Grade (G4 Grade)
Grade cannot be determined  (Grade
cannot be determined )
Grade not designated (Grade not
designated)
High grade (High grade)
Low grade (Low grade)
Neoplasm, Uncertain Whether Benign or
Malignant  (Neoplasm, Uncertain
Whether Benign or Malignant )
no information (no information)
cell type *
B-Cell Lymphomas  (B-Cell Lymphomas
)
Grade cannot be determined  (Grade
cannot be determined )
no information (no information)
Primary Cutaneous Anaplastic Large
Cell Lymphoma  (Primary Cutaneous
Anaplastic Large Cell Lymphoma )
T-Cell Lymphoma  (T-Cell Lymphoma )
Score *
Gleason-Score (Gleason-Score)
no information (no information)
Sarcoma by FNCLCC Grade  (Sarcoma
by FNCLCC Grade )
VNPI-Score (DCIS) (VNPI-Score (DCIS))
Primary Gleason Pattern *
Secondary Gleason Pattern *
Total Gleason Score for Prostate Cancer *
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dataset treatment cancer
Diagnostic Accuracy
normal finding*
Clinical Diagnosis (Clinical Diagnosis)
Cytologic finding (Cytologic finding)
endoscopic (endoscopic)
Histological finding  (Histological finding )
Operative Surgical Procedures
(Operative Surgical Procedures )
Other (Other)
Radiographic imaging procedure
(Radiographic imaging procedure )
sonograpy (sonograpy)
X-Ray Computed Tomography  (X-Ray
Computed Tomography )
Tumor finding *
Clinical Diagnosis (Clinical Diagnosis)
Cytologic finding (Cytologic finding)
endoscopic (endoscopic)
Histological finding  (Histological finding )
Operative Surgical Procedures
(Operative Surgical Procedures )
Other (Other)
Radiographic imaging procedure
(Radiographic imaging procedure )
sonograpy (sonograpy)
X-Ray Computed Tomography  (X-Ray
Computed Tomography )
Other*
Place of Diagnosis*
Histopathology-number*
Date of Receipt*
Date of pathology report*
Staging*
Yes
No
Generic tumor staging descriptor *
Tumor staging descriptor r (Tumor
staging descriptor r)
Tumor staging descriptor y (Tumor
staging descriptor y)
TNM Classification before any treatment*
Yes
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No
TNM Classification after operation*
Yes
No
TNM Stage descriptor*
T Stage*
Degree of certainty of TNM classification
(observable entity) *
TNM Stage descriptor*
N Stage*
Degree of certainty of TNM classification
(observable entity) *
TNM Stage descriptor*
M Stage*
Degree of certainty of TNM classification
(observable entity) *
Number of sentinel lymph nodes involved*
Number of sentinel lymph nodes examined*
Number of lymph nodes involved by malignant
neoplasm *
Number of lymph nodes examined*
Lymph vessel invasion*
L0 Stage Finding (L0 Stage Finding)
L1 Stage Finding (L1 Stage Finding)
LX Stage Finding (LX Stage Finding)
Venous Invasion*
V0 Stage Finding (V0 Stage Finding)
V1 Stage Finding  (V1 Stage Finding )
V2 Stage Finding (V2 Stage Finding)
VX Stage Finding (VX Stage Finding)
organ capsule infiltration*
No (No)
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no information (no information)
Yes, breakthrough (Yes, breakthrough)
Yes, Infiltration (Yes, Infiltration)
Perineural Invasion*
No (No)
no information (no information)
Status of perineural invasion cannot be
assessed (Status of perineural invasion
cannot be assessed)
Yes (Yes)
Residual tumor stage*
no information (no information)
Not Applicable  (Not Applicable )
Residual tumor stage R0 (Residual
tumor stage R0)
Residual tumor stage R1  (Residual
tumor stage R1 )
Residual tumor stage R1  (Residual
tumor stage R1 )
Residual tumor stage R1  (Residual
tumor stage R1 )
Residual tumor stage R2 (Residual
tumor stage R2)
Residual tumor stage R2 (Residual
tumor stage R2)
Residual tumor stage R2 (Residual
tumor stage R2)
Residual tumor stage RX (Residual
tumor stage RX)
UICC-Classification*
available  (available )
no information (no information)
Ann Arbor Lymphoma Staging System *
Yes
No
other Staging System *
Yes
No
Description Staging System*
Stage*
Microsatellite Instability *
TME Grade*
distant metastasis
Metastatic Malignant Neoplasm to the Lung*
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Yes
No
C-factor status*
C1 certainty  (C1 certainty )
C2 certainty  (C2 certainty )
C3 certainty  (C3 certainty )
C4 certainty  (C4 certainty )
C5 certainty  (C5 certainty )
Metastatic Malignant Neoplasm to the Pleura*
Yes
No
C-factor status*
C1 certainty  (C1 certainty )
C2 certainty  (C2 certainty )
C3 certainty  (C3 certainty )
C4 certainty  (C4 certainty )
C5 certainty  (C5 certainty )
Metastatic Malignant Neoplasm to the Liver*
Yes
No
C-factor status*
C1 certainty  (C1 certainty )
C2 certainty  (C2 certainty )
C3 certainty  (C3 certainty )
C4 certainty  (C4 certainty )
C5 certainty  (C5 certainty )
Metastatic Malignant Neoplasm to the Spleen *
Yes
No
C-factor status*
C1 certainty  (C1 certainty )
C2 certainty  (C2 certainty )
C3 certainty  (C3 certainty )
C4 certainty  (C4 certainty )
C5 certainty  (C5 certainty )
Metastatic Malignant Neoplasm to the Ovary *
Yes
No
C-factor status*
C1 certainty  (C1 certainty )
C2 certainty  (C2 certainty )
C3 certainty  (C3 certainty )
C4 certainty  (C4 certainty )
C5 certainty  (C5 certainty )
Metastatic Malignant Neoplasm to the
Peritoneum *
Yes
No
C-factor status*
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dataset treatment cancer
C1 certainty  (C1 certainty )
C2 certainty  (C2 certainty )
C3 certainty  (C3 certainty )
C4 certainty  (C4 certainty )
C5 certainty  (C5 certainty )
Metastatic Malignat Neoplasm to the adrenal
gland*
Yes
No
C-factor status*
C1 certainty  (C1 certainty )
C2 certainty  (C2 certainty )
C3 certainty  (C3 certainty )
C4 certainty  (C4 certainty )
C5 certainty  (C5 certainty )
Metastatic Malignant Neoplasm to the Bone
Marrow*
Yes
No
C-factor status*
C1 certainty  (C1 certainty )
C2 certainty  (C2 certainty )
C3 certainty  (C3 certainty )
C4 certainty  (C4 certainty )
C5 certainty  (C5 certainty )
Metastatic Malignant Neoplasm to the Bone *
Yes
No
C-factor status*
C1 certainty  (C1 certainty )
C2 certainty  (C2 certainty )
C3 certainty  (C3 certainty )
C4 certainty  (C4 certainty )
C5 certainty  (C5 certainty )
Metastatic Malignant Neoplasm to the Lymph
Node *
Yes
No
C-factor status*
C1 certainty  (C1 certainty )
C2 certainty  (C2 certainty )
C3 certainty  (C3 certainty )
C4 certainty  (C4 certainty )
C5 certainty  (C5 certainty )
Secondary malignant neoplasm of skin *
Yes
No
C-factor status*
C1 certainty  (C1 certainty )
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C2 certainty  (C2 certainty )
C3 certainty  (C3 certainty )
C4 certainty  (C4 certainty )
C5 certainty  (C5 certainty )
Metastatic malignant neoplasm to brain*
Yes
No
C-factor status*
C1 certainty  (C1 certainty )
C2 certainty  (C2 certainty )
C3 certainty  (C3 certainty )
C4 certainty  (C4 certainty )
C5 certainty  (C5 certainty )
Metastatic Malignant Neoplasm to the Kidney *
Yes
No
C-factor status*
C1 certainty  (C1 certainty )
C2 certainty  (C2 certainty )
C3 certainty  (C3 certainty )
C4 certainty  (C4 certainty )
C5 certainty  (C5 certainty )
Distant metastasis (other organs)*
Yes
No
C-factor status*
C1 certainty  (C1 certainty )
C2 certainty  (C2 certainty )
C3 certainty  (C3 certainty )
C4 certainty  (C4 certainty )
C5 certainty  (C5 certainty )
Generalized cancer*
Yes
No
C-factor status*
C1 certainty  (C1 certainty )
C2 certainty  (C2 certainty )
C3 certainty  (C3 certainty )
C4 certainty  (C4 certainty )
C5 certainty  (C5 certainty )
Tumor Status
Tumor Expansion
Tumor Expansion *
Yes
No
Primary Neoplasm *
No evidence of neoplasm  (No evidence
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of neoplasm )
questionable Result (questionable
Result)
Recurrent Disease (Recurrent Disease)
Residual Disease  (Residual Disease )
Metastatic Malignant Neoplasm to the regional
Lymph Nodes*
No evidence of neoplasm  (No evidence
of neoplasm )
questionable Result (questionable
Result)
Recurrent Disease (Recurrent Disease)
Residual Disease  (Residual Disease )
Distant metastasis (other organs)*
No evidence of neoplasm  (No evidence
of neoplasm )
questionable Result (questionable
Result)
Recurrent Disease (Recurrent Disease)
Residual Disease  (Residual Disease )
Tumor Status*
- (-)
Assessment not possble (Assessment
not possble)
clinical improvement (clinical
improvement)
Divergent event (Divergent event)
In complete remission  (In complete
remission )
no information (no information)
No neoplasm (No neoplasm)
not clarified (not clarified)
partial response  (partial response )
Stable Disease (Stable Disease)
Tumor marker increase (Tumor marker
increase)
Tumor Progression (Tumor Progression)
Tumor Expansion
Tumor Expansion *
Yes
No
Primary Neoplasm *
No evidence of neoplasm  (No evidence
of neoplasm )
questionable Result (questionable
Result)
Recurrent Disease (Recurrent Disease)
Residual Disease  (Residual Disease )
Metastatic Malignant Neoplasm to the regional
Lymph Nodes*
No evidence of neoplasm  (No evidence
of neoplasm )
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questionable Result (questionable
Result)
Recurrent Disease (Recurrent Disease)
Residual Disease  (Residual Disease )
Distant metastasis (other organs)*
No evidence of neoplasm  (No evidence
of neoplasm )
questionable Result (questionable
Result)
Recurrent Disease (Recurrent Disease)
Residual Disease  (Residual Disease )
Tumor Status*
- (-)
Assessment not possble (Assessment
not possble)
clinical improvement (clinical
improvement)
Divergent event (Divergent event)
In complete remission  (In complete
remission )
no information (no information)
No neoplasm (No neoplasm)
not clarified (not clarified)
partial response  (partial response )
Stable Disease (Stable Disease)
Tumor marker increase (Tumor marker
increase)
Tumor Progression (Tumor Progression)
Hormone Receptor
Hormone Receptor
FisH-Test*
Yes
No
Her-2/neu*
Yes
No
Estrogen Receptor*
Yes
No
progesterone receptor*
Yes
No
Value*
Finding of serum tumor marker level*
negative (negative)
no information (no information)
postive (postive)
Reduced  (Reduced )
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planned therapeutic procedure
planned therapeutic procedure
Aftercare*
Yes
No
Operative Surgical Procedures *
Yes
No
Chemotherapy Regimen*
Yes
No
Therapeutic radiology procedure *
Yes
No
Endocrine Therapy*
Yes
No
Immunotherapy *
Yes
No
Supportive Care*
Yes
No
Pain management *
Yes
No
Other therapy*
Yes
No
disease stage*
Yes
No
Consultation*
Yes
No
Hemopoietic stem cell transplant *
Yes
No
Bone Marrow Transplantation*
Yes
No
Prophylactic treatment *
Yes
No
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dataset treatment cancer
Rehabilitation therapy *
Yes
No
Disease management program *
Yes
No
Prostate Questionaire*
Yes
No
altered aftercare*
Yes
No
active surveillance*
Yes
No
Inquiry*
Yes
No
no activities*
Yes
No
place of presentation*
Appointment date*
last therapy*
last aftercare*
Chronic pain
Chronic pain *
No (No)
no information (no information)
Yes (Yes)
Prostate
Site of involved surgical margin*
Apex of Prostate (Apex of Prostate)
others (others)
Urinary Bladder (Urinary Bladder)
Length of surgical margin involved by tumor*
Size Prostate*
Yes
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No
Length Prostate*
Width Prostate*
Height Prostate*
Weight of prostate*
Quality of life scale*
available  (available )
no information (no information)
refused (refused)
health status*
available  (available )
no information (no information)
refused (refused)
incontinence questionnaire*
available  (available )
no information (no information)
refused (refused)
International index of erectile function score*
available  (available )
no information (no information)
refused (refused)
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dataset treatment cancer
EHR4CR data inventory
Doods J, Botteri F, Dugas M, Fritz F; EHR4CR WP7. A
European inventory of
common electronic health record data elements for clinical
trial feasibility.
Trials. 2014 Jan 10;15:18
http://www.ncbi.nlm.nih.gov/pubmed/24410735
All rights reserved. Please visit https://medical-data-
models.org/forms/5518
EHR4CR data inventory
Patientendaten
Geburtsdatum*
Geschlecht*
Aufnahmedatum*
Entlassungsdatum*
Fallstatus*
Anamnese
zur Zeit schwanger*
Ja
Nein
Gravidität (Anzahl gehabter Schwangerschaften)*
Menauposaler Status*
Allergien oder Hypersensibilitätsreaktionen *
Diät*
Raucher Status*
Alkohol Abusus*
Substanz Abusus*
Diagnose
Diagnosetext*
Diagnosedatum*
Diagnose Code*
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Histologisch gesicherte Diagnose*
Prozeduren
Prozedur Text*
Prozedur Code*
Prozedur Datum*
Untersuchungsergebnisse
Datum / Zeit der Ergebnisse*
Körpergewicht*
Körpergröße*
Temperatur*
Puls*
Blutdruck systolisch*
Blutdruck diastolisch*
Laborergebnisse
HER2 status*
Ja
Nein
Zeit, Datum der
Laborergebnisse/untersuchungen*
Gesamt Cholesterol im Serum *
HDL im serum *
LDL im serum *
Triglyzeride*
Harnstoff im Serum*
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Calcium im Serum *
Kreatinin im Serum *
Glucose im Serum *
Kalikum im serum *
Natrium im Serum *
GFR *
Albumin*
Alkalische Phosphatase*
SGOT (AST)*
SGPT (ALT)*
Gesamt Bilirubin im Serum*
Direktes Bilirubin im Serum*
Gesamt Protein im Serum*
HbA1c*
CRP *
PTT *
INR *
Haemoglobin*
Haematocrit *
Thrombozyten *
Erythrozyten *
Leukozyten*
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Neutrophile*
Lymphozytes*
Eosinophile*
TSH *
Beta HCG im Serum *
Cardiales Troponin T *
NTproBNP*
biPTH*
BNP*
Ca x P*
GGT*
PSA*
Medikation
Wortgetreuer  Handelsname des Arzneimittels*
Medikationscode*
Dosierung*
Verabreichungsart*
Beginndatum Medikation*
Enddatum Medikation*
Wirkstoffgruppe*
4 / 4
EHR4CR data inventory
HIS ENDOSCOPY PROCEDURE
RECORD
Form from HIS OpenVistA
All rights reserved. Please visit https://medical-data-
models.org/forms/5521
HIS
SCOPE INSTRUMENT USED
COLONOSCOPE*
EGD SCOPE*
FLEX SIGMOID SCOPE*
ERCP SCOPE*
ENTEROSCOPE*
DB CHANNEL SCOPE*
LOANER SCOPE*
VIDEO CAMERA*
General Info
HISTORY & PHYSICAL COMPLETED? *
Ja
Nein
IV START*
IV PUNCTURE SITE*
IV GAUGE*
IV FLUID*
AMOUNT*
IV RATE [ml/hr]*
TIME STARTED*
IV INSERTED BY*
NOTES*
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ENDOSCOPY START*
ENDOSCOPY ROOM*
TIME OUT TAKEN FOR PROCEDURE
VERIFICATION*
Ja
Nein
VERIFICATION PROCESS*
Finding of American Society of Anesthesiologists
physical status classification*
OXYGEN DELIVERY METHOD*
PROCEDURE*
PROCEDURE START*
PROCEDURE STOP*
ANESTHESIA START*
ANESTHESIA STOP*
Vitalzeichen*
IV MEDICATIONS*
COMMENTS*
COLD BIOPSY*
HOT BIOPSY*
SNARE POLYPECTOMY*
CYTOLOGY BRUSHINGS*
POST CASE*
PATIENT TOLERATED PROCEDURE WELL*
Ja
Nein
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POST-OP CONDITION*
Postoperative Diagnose*
OTHER*
ERCP OMNIPAQUE CONTRAST MEDIUM [ml]*
FLUOROSCOPY TIME [minutes]*
ESU*
SETTINGS*
PLACEMENT OF GROUNDING PAD*
TEXT*
SKIN CLEAR & INTACT BENEATH SITE OF
GROUNDING PAD*
DISCHARGE*
IV DISCONTINUED*
AMOUNT OF SOLUTION GIVEN [ml]*
CONDITION AT DISCHARGE*
Discharge disposition*
ACCOMPANIED BY*
DISCHARGE INSTRUCTIONS GIVEN TO*
TIME OF DISCHARGE*
PROCEDURE REPORT GIVEN TO STAFF
NURSE*
Patient able to *
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ALDRETE  SCORE
ACTIVITY (2= all 4 extremities move voluntarily
or on command, 1= 2 extremities move
voluntarily or on command, 0= cannot move
extremities)*
RESPIRATORY (2= able to deep breath, cough
freely, 1= dyspnea or limited breathing, 0= apnea
or SAO2 <90%)*
BLOOD PRESSURE (2= BP +/- 20% of pre-
procedure level, 1= BP +/- 21-49% pre-procedure
level, 0= BP +/- 50% pre-procedure level)*
Bewusstseinslage*
EVALUATION OF SKIN CONDITION AND
COLOR (2=Skin is pink-warm- dry, 1= Skin is
pale-dusky-blotchy- jaundice, 0= Patient is
cyanotic)*
ALDRETE TOTAL SCORE*
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CDASH Vital Signs (fine 1)
modified from http://www.cdisc.org
All rights reserved. Please visit https://medical-data-
models.org/forms/5523
CDASH Vital Signs (fine 1)
Height
Height collected?*
NO (N)
YES (Y)
Height*
Clinically Significant*
NO (N)
YES (Y)
Weight
Weight collected?*
NO (N)
YES (Y)
Weight*
Clinically Significant*
NO (N)
YES (Y)
Blood pressure
BP collected?*
NO (N)
YES (Y)
Time of blood pressure measurement*
Diastolic*
Systolic*
BP Location*
ANKLE (ANKLE)
BRACHIAL ARTERY (BRACHIAL
ARTERY)
BP Position*
PRONE (PRONE)
SITTING (SITTING)
STANDING (STANDING)
SUPINE (SUPINE)
BP Clinically Significant*
NO (N)
YES (Y)
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Pulse
Pulse collected?*
NO (N)
YES (Y)
Pulse*
Pulse Location*
BRACHIAL ARTERY (BRACHIAL
ARTERY)
CAROTID ARTERY (CAROTID
ARTERY)
RADIAL ARTERY (RADIAL ARTERY)
Pulse Position*
PRONE (PRONE)
SITTING (SITTING)
STANDING (STANDING)
SUPINE (SUPINE)
Clinically Significant*
NO (N)
YES (Y)
Temperature
Temperature collected?*
NO (N)
YES (Y)
Temperature*
Temperature Location*
AXILLA (AXILLA)
EAR (EAR)
Clinically Significant*
NO (N)
YES (Y)
Body Frame Size
Frame Size collected?*
NO (N)
YES (Y)
Frame Size*
LARGE (LARGE)
MEDIUM (MEDIUM)
SMALL (SMALL)
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Vital Signs - 3281249v1.0
Record the patient's Vital Signs while on study. Please note
that if Vital Signs are taken as a part of protocol specific
Physical Exam, record those Vital Signs on the Physical
Exam eCRF.
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=AD24E1F2-
5206-264F-E040-BB89AD430ED7
All rights reserved. Please visit https://medical-data-
models.org/forms/5571
Vital Signs
Vital Signs
Visit Date
Course #
Day in Course (Cycle)
Date (Enter the date the vital signs were taken.)
Time (Enter the time the vital signs were taken.)
Notes (If necessary, enter some brief notes.)
Performance Status (Karnofsky) (Select a value
from the Karnofsky performance status scale.)
Dead (0)
Moribund, Fatal Processes Progressing
Rapidly (10)
Normal, No Complaints, No Evidence Of
Disease (100)
Very Sick, Hospitalization Indicated.
Death Not Imminent (20)
Severely Disabled, Hospitalization
Indicated. Death Not Imminent (30)
Disabled, Requires Special Care And
Assistance (40)
Requires Considerable Assistance And
Frequent Medical Care (50)
Requires Occasional Assistance, But Is
Able To Care For Most Of His/her Needs
(60)
Cares For Self, Unable To Carry On
Normal Activity Or To Do Active Work
(70)
Normal Activity With Effort; Some Signs
Or Symptoms Of Disease (80)
Able To Carry On Normal Activity; Minor
Signs Or Symptoms Of Disease (90)
Performance Status (Zubrod) (Select a value
from the Zubrod/ECOG performance status
scale.)
Normal Activity (0)
Symptoms, But Nearly Fully Ambulatory
(1)
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Some Bed Time, But Needs To Be In
Bed <50% Of Normal Daytime (2)
Needs To Be In Bed > 50% Of Normal
Daytime (3)
Unable To Get Out Of Bed (4)
Performance Status (Lansky) (Select a value
from the Lansky performance status scale.)
Unresponsive (0)
No Play; Does Not Get Out Of Bed. (10)
Fully Active, Normal (100)
Often Sleeping; Play Entirely Limited To
Very Passive Activities. (20)
In Bed; Needs Assistance Even For
Quiet Play. (30)
Mostly In Bed; Participates In Quiet
Activities. (40)
Gets Dressed, But Lies Around Much Of
The Day; No Active Play, Able To
Participate In All Quiet Play And
Activities. (50)
Up And Around, But Minimal Active Play;
Keeps Busy With Quieter Activities. (60)
Both Greater Restriction Of And Less
Time Spent In Play Activity (70)
Active, But Tires More Quickly (80)
Minor Restrictions In Physically
Strenuous Activity (90)
Body Weight (Enter the patient's weight only in
kilograms. Use decimal places only for patients
under 10kg.)
Height (Enter the patient's height only in
centimeters, to one decimal place.)
BSA (Enter the patient's body surface area in m2
to two decimal places if needed for the
calculation of study medication dose level.)
Temperature (Enter the patient's temperature
only in Celsius, to one decimal place.)
Pulse (Enter the patient's pulse rate.)
Respiration Rate (Enter the patient's respiration
rate.)
Systolic BP (Enter the patient's systolic blood
pressure.)
Diastolic BP (Enter the patient's diastolic blood
pressure.)
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Pulse Ox (Enter the patient's pulse oximetry
reading.)
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HIS Occupational Therapy Consult Results
Form from HIS OpenVistA
All rights reserved. Please visit https://medical-data-
models.org/forms/5584
HIS
General Info
Allergie*
Diagnose*
Vitalzeichen*
Größe*
Gewicht*
Occupational Therapy (OT) order*
Frühere Operationen*
Vorsichtsmaßnahmen*
Medical History / Onset*
Functional Status before Onset*
Subjective
Conversation content*
Orientation - Person
(Alert|Oriented|Comatose|Disoriented)*
Orientation - Place (Alert| Oriented| Comatose|
Disoriented)*
Orientation - Situation (Alert|Oriented|Comatose|
Disoriented)*
Orientation - Time (Alert|Oriented|Comatose|
Disoriented)*
Schmerz*
Objective
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Objective observation*
Assessment
Occupational therapy assessment*
Plan
Occupational Therapy treatment plan*
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Eligibility NCT00206167 COPD
ODM derived from
http://clinicaltrials.gov/ct2/show/NCT00206167?term=NCT0
0206167&rank=1
All rights reserved. Please visit https://medical-data-
models.org/forms/5590
Eligibility
Inclusion Criteria
40 Years and older*
Yes
No
both*
Yes
No
A clinical diagnosis of COPD with symptoms for
more than 2 years*
Yes
No
Smoking history of 10 or more pack years*
Yes
No
COPD exacerbation within 1-12 months before
first visit*
Yes
No
Exclusion criteria
A history of asthma*
Yes
No
Patients taking oral steroids*
Yes
No
Any significant disease or disorder that may
jeopardize the safety of the patient*
Yes
No
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Eligibility NCT00334295 Metastatic
Endometrial Carcinoma
ODM derived from
http://clinicaltrials.gov/ct2/show/NCT00334295?term=NCT0
0334295&rank=1
All rights reserved. Please visit https://medical-data-
models.org/forms/5591
Eligibility
Inclusion Criteria
18 Years and older*
Yes
No
Female Gender*
Yes
No
Histologically confirmed, recurrent or metastatic
endometrial carcinoma*
Yes
No
Postmenopausal*
Yes
No
Hormonreceptor positive tumor*
Yes
No
Exclusion criteria
Pre-treatment with Fulvestrant*
Yes
No
Previous endocrine therapy of the endometrial
carcinoma*
Yes
No
Previous malignancy less than 3 years ago other
than in situ carcinoma of the cervix, basal cell
carcinoma or squamous carcinoma of the skin*
Yes
No
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Eligibility NCT00168051 Hemophilia A
ODM derived from
http://clinicaltrials.gov/show/NCT00168051
All rights reserved. Please visit https://medical-data-
models.org/forms/5592
Eligibility
Inclusion Criteria
18 Years to 64 Years*
Yes
No
Male*
Yes
No
Severe hemophilia A*
Yes
No
Previously treated patients with at least 150
exposure days to any Factor VIII product*
Yes
No
Exclusion Criteria
Hypersensitivity to any recombinant Factor VIII
product*
Yes
No
History of or current Factor VIII inhibitor*
Yes
No
Bleeding episode or other reason requiring Factor
VIII treatment within 3 days of study*
Yes
No
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Eligibility NCT00617669 Prostate Cancer
see http://clinicaltrials.gov/ct2/show/record/NCT00617669
Phase III Trial of ZD4054 (Zibotentan) (Endothelin A
Antagonist) and Docetaxel in Metastatic Hormone
Resistant Prostate Cancer
All rights reserved. Please visit https://medical-data-
models.org/forms/5593
Eligibility NCT00617669
Inclusion Criteria
18 Years and older*
male*
Yes
No
Confirmed diagnosis of prostate cancer
(adenocarcinoma of the prostate) that has spread
to the bone (bone metastasis)
*
Yes
No
Increasing Prostate Specific Antigen (PSA),
collected within one year of enrollment*
Yes
No
Currently receiving treatment with surgical or
medical castration*
Yes
No
Exclusion Criteria
Previous treatment with chemotherapy
(paclitaxel, docetaxel, and mitoxantrone). Prior
targeted cancer therapies are permitted if
received during a previous clinical trial*
Yes
No
Suffering from heart failure or had a myocardial
infarction within last 6 months*
Yes
No
A history of epilepsy or seizures
*
Yes
No
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Anal Cancer NCT00324415 Quality of Life - AMC-
045 Quality of Life Instruments (QLQ)_2937315v1_0
AMC-045 Quality of Life Instruments (QLQ)
Phase II Trial Of Combined Modality Therapy Plus
Cetuximab in HIV-Associated Anal Carcinoma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=7288A090-
8102-4969-E040-BB89AD433657
All rights reserved. Please visit https://medical-data-
models.org/forms/5594
AMC-045 Quality of Life Instruments
(QLQ)
Unnamed1
Visit number
Date Questionnaire Completed (mm/dd/yyyy)
EORTC QLQ-C30 (version 3)
Do you have any trouble doing strenuous
activities, like carrying a heavy shopping bag or a
suitcase
A Little (A little)
1 (Not at all)
4 (Quite a bit)
5 (Very much)
Do you have any trouble taking a long walk
A Little (A little)
1 (Not at all)
4 (Quite a bit)
5 (Very much)
Do you have any trouble taking a short walk
outside of the house
A Little (A little)
1 (Not at all)
4 (Quite a bit)
5 (Very much)
Do you need to stay in bed or a chair during the
day
A Little (A little)
1 (Not at all)
4 (Quite a bit)
5 (Very much)
Do you need help with eating, dressing, washing
yourself or using the toilet
A Little (A little)
1 (Not at all)
4 (Quite a bit)
5 (Very much)
Eortc1
Were you limited in doing either your work or
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other daily activities?
A Little (A little)
1 (Not at all)
4 (Quite a bit)
5 (Very much)
Were you limited in pursuing your hobbies or
other leisure time activities?
A Little (A little)
1 (Not at all)
4 (Quite a bit)
5 (Very much)
Were you short of breath
A Little (A little)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Very Much (Very much)
Have you had pain
A Little (A little)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Very Much (Very much)
Did you need to rest
A Little (A little)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Very Much (Very much)
Eortc2
Have you had trouble sleeping
A Little (A little)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Very Much (Very much)
Have you felt weak
A Little (A little)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Very Much (Very much)
Have you lacked appetite
A Little (A little)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Very Much (Very much)
Have you felt nauseated
A Little (A little)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Very Much (Very much)
Have you vomited
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A Little (A little)
1 (Not at all)
4 (Quite a bit)
5 (Very much)
Eortc3
Have you been constipated
A Little (A little)
1 (Not at all)
4 (Quite a bit)
5 (Very much)
Have you had diarrhea
A Little (A little)
1 (Not at all)
4 (Quite a bit)
5 (Very much)
Were you tired
A Little (A little)
1 (Not at all)
4 (Quite a bit)
5 (Very much)
Did pain interfere with your daily activities
A Little (A little)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Very Much (Very much)
Have you had difficulty in concentrating on things,
like reading a newspaper or watching television
A Little (A little)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Very Much (Very much)
Eortc4
Did you feel tense
A Little (A little)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Very Much (Very much)
Did you worry
A Little (A little)
1 (Not at all)
4 (Quite a bit)
5 (Very much)
Did you feel irritable
A Little (A little)
1 (Not at all)
4 (Quite a bit)
5 (Very much)
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Did you feel depressed
A Little (A little)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Very Much (Very much)
Have you had difficulty remembering things
A Little (A little)
1 (Not at all)
4 (Quite a bit)
5 (Very much)
Eortc5
Has your physical condition or medical treatment
interfered with your family life
A Little (A little)
1 (Not at all)
4 (Quite a bit)
5 (Very much)
Has your physical condition or medical treatment
interfered with your social activities
A Little (A little)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Very Much (Very much)
Has your physical condition or medical treatment
caused you financial difficulties
A Little (A little)
1 (Not at all)
4 (Quite a bit)
5 (Very much)
How would you rate your overall health during the
past week? (For the following questions please
circle the number between 1 and 7 that best
applies to you)
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
7 (7)
How would you rate your overall quality of life
during the past week? (For the following
questions please circle the number between 1
and 7 that best applies to you)
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
7 (7)
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Additional Concerns
Did you urinate frequently during the day
A Little (A little)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Very Much (Very much)
Did you urinate frequently during the night?
A Little (A little)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Very Much (Very much)
Did you have pain when you urinated?
A Little (A little)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Very Much (Very much)
Did you have a bloated feeling in your abdomen
A Little (A little)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Very Much (Very much)
Did you have abdominal pain?
A Little (A little)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Very Much (Very much)
Did you have pain in your buttocks?
A Little (A little)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Very Much (Very much)
Were you bothered by gas (flatulence)?
A Little (A little)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Very Much (Very much)
Did you belch?
A Little (A little)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Very Much (Very much)
Have you lost weight?
A Little (A little)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Very Much (Very much)
Did you have a dry mouth?
A Little (A little)
Not At All (Not at all)
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Quite A Bit (Quite a bit)
Very Much (Very much)
Have you had thin or lifeless hair as a result of
your disease or treatment
A Little (A little)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Very Much (Very much)
Did food and drink taste different from usual?
A Little (A little)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Very Much (Very much)
Have you felt physically less attractive as a result
of your disease or treatment?
A Little (A little)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Very Much (Very much)
Have you been feeling less feminine/masculine
as a result of your disease or treatment?
A Little (A little)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Very Much (Very much)
Have you been dissatisfied with your body?
A Little (A little)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Very Much (Very much)
Were you worried about your health in the future?
A Little (A little)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Very Much (Very much)
During The Past Four Weeks:
To what extent were you interested in sex?
Not At All (0)
A Little (1)
Quite A Bit (2)
Very Much (3)
To what extent were you sexually active (with or
without intercourse)?
Not At All (0)
A Little (1)
Quite A Bit (2)
Very Much (3)
To what extent was sex enjoyable for you?
(Answer this question only if you have been
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sexually active)
A Little (A little)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Very Much (Very much)
Did you have difficulty getting or maintaining an
erection? (For men only)
A Little (A little)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Very Much (Very much)
Did you have problems with ejaculation (e.g., so-
called 'dry ejaculation')? (For men only)
A Little (A little)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Very Much (Very much)
Did you have a dry vagina during intercourse?
(Only for women who have had intercourse)
A Little (A little)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Very Much (Very much)
Did you have pain during intercourse? (Only for
women who have had intercourse)
A Little (A little)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Very Much (Very much)
Stoma
Do you have a stoma (colostomy bag)?
No (No)
Yes (Yes)
Only For Patients Without A Stoma
(colostomy Bag):
Did you have frequent bowel movements during
the day?
A Little (A little)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Very Much (Very much)
Did you have frequent bowel movements during
the night?
A Little (A little)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Very Much (Very much)
7 / 9
Anal Cancer NCT00324415 Quality of Life - AMC-045 Quality of Life
Instruments (QLQ)_2937315v1_0
Did you feel the urge to move your bowels without
actually producing any stools
A Little (A little)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Very Much (Very much)
Have you had any unintentional release of stools
A Little (A little)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Very Much (Very much)
Have you had blood with your stools
A Little (A little)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Very Much (Very much)
Have you had difficulty in moving your bowels
A Little (A little)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Very Much (Very much)
Have your bowel movements been painful?
A Little (A little)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Very Much (Very much)
Unnamed 4
Were you afraid that other people would be able
to hear your stoma
A Little (A little)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Very Much (Very much)
Were you afraid that other people would be able
to smell your stools
A Little (A little)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Very Much (Very much)
Were you worried about possible leakage from
the stoma bag?
A Little (A little)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Very Much (Very much)
Did you have problems with caring for your stoma
A Little (A little)
Not At All (Not at all)
Quite A Bit (Quite a bit)
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Very Much (Very much)
Was your skin around the stoma irritated
A Little (A little)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Very Much (Very much)
Did you feel embarassed because of your stoma
A Little (A little)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Very Much (Very much)
Did you feel less complete because of your stoma
A Little (A little)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Very Much (Very much)
Supplemental Quality Of Life Questions
How satisfied are you with your current degree of
anal or anal/rectal function (on a scale of 1-10
with 1 being totally dissatisfied to 10 totally
satisfied)
0 (0)
1 (1)
10 (10)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
7 (7)
8 (8)
9 (9)
How well does your anus function (MEMORIAL
SLOAN KETTERING ANAL FUNCTION SCALE)
Excellent; Typically 1-2 Bowel
Movements Per Day And No Soilage
(Excellent; Typically 1-2 bowel
movements per day and no soilage)
Fair; >4 Bowel Movements A Day At
Least At Times And/or Moderate Soilage
(Fair; >4 bowel movements a day at least
at times and/or moderate soilage)
Good; Typically 3-4 Bowel Movements
Per Day And/or Mild Soilage (Good;
Typically 3-4 bowel movements per day
and/or mild soilage)
Poor; Incontinence (Poor; Incontinence)
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GOG-0240 Quality of  Life (QOL) Form
Paclitaxel and Cisplatin or Topotecan With or Without
Bevacizumab in Treating Patients With Stage IVB,
Recurrent, or Persistent Cervical Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=4C9230B2-
FA5F-0653-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/5598
GOG-0240 Quality of  Life (QOL)
Form
Physical Well-being
I have a lack of energy.
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have nausea.
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
Because of my physical condition, I have trouble
meeting the needs of my family.
2 (A little bit)
1 (Not at all)
4 (Quite a bit)
3 (Somewhat)
5 (Very much)
I have pain.
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am bothered by side effects of treatment.
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I feel ill
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am forced to spend time in bed
A Little Bit (A little bit)
Not At All (Not at all)
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Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
Functional Wellbeing
I am able to work (include work at home)
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
My work (include work at home) is fulfilling
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am able to enjoy life.
2 (A little bit)
1 (Not at all)
4 (Quite a bit)
3 (Somewhat)
5 (Very much)
I have accepted my illness
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am sleeping well
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am enjoying the things I usually do for fun
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am content with the quality of my life right now
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
Additional Concerns
I am bothered by discharge or bleeding from my
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vagina
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am bothered by odor coming from my vagina
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am afraid to have sex
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I feel sexually attractive.
2 (A little bit)
1 (Not at all)
4 (Quite a bit)
3 (Somewhat)
5 (Very much)
My vagina feels too narrow or short
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have concerns about my ability to have children
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am afraid the treatment may harm my body
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am interested in having sex
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I like the appearance of my body
2 (A little bit)
1 (Not at all)
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4 (Quite a bit)
3 (Somewhat)
5 (Very much)
I am bothered by constipation
2 (A little bit)
1 (Not at all)
4 (Quite a bit)
3 (Somewhat)
5 (Very much)
I have a good appetite
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have trouble controlling my urine
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
It burns when I urinate
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have discomfort when I urinate
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am able to eat the foods that I like
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
Ntx4 Subscale
I have numbness or tingling in my hands
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have numbness or tingling in my feet
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
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Somewhat (Somewhat)
Very Much (Very much)
I feel discomfort in my hands
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I feel discomfort in my feet
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
Brief Pain Invertory
Please rate your pain by selecting the one
number that best describes your pain at its
WORST in the past 24 hours.
Whole Number (0)
Whole Number (1)
Whole Number (10)
Whole Number (2)
Whole Number (3)
Whole Number (4)
Whole Number (5)
Whole Number (6)
Whole Number (7)
Whole Number (8)
Whole Number (9)
5 / 5
Cervical Cancer NCT00803062 Quality of Life - GOG-0240 Quality of
Life (QOL) Form - 2746943v1.0
Anal Cancer NCT00324415 Quality of Life - AMC-
045 Quality of Life Instruments (QLQ) - 2937315v1.0
AMC-045 Quality of Life Instruments (QLQ)
Cisplatin, Fluorouracil, Cetuximab, and Radiation Therapy
in Treating Patients With HIV and Stage I, Stage II, or
Stage III Anal Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=7288A090-
8102-4969-E040-BB89AD433657
All rights reserved. Please visit https://medical-data-
models.org/forms/5606
AMC-045 Quality of Life Instruments
(QLQ)
Unnamed1
Visit number
Date Questionnaire Completed (mm/dd/yyyy)
Eortc
Do you have any trouble doing strenuous
activities, like carrying a heavy shopping bag or a
suitcase
A Little (A little)
1 (Not at all)
4 (Quite a bit)
5 (Very much)
Do you have any trouble taking a long walk
A Little (A little)
1 (Not at all)
4 (Quite a bit)
5 (Very much)
Do you have any trouble taking a short walk
outside of the house
A Little (A little)
1 (Not at all)
4 (Quite a bit)
5 (Very much)
Do you need to stay in bed or a chair during the
day
A Little (A little)
1 (Not at all)
4 (Quite a bit)
5 (Very much)
Do you need help with eating, dressing, washing
yourself or using the toilet
A Little (A little)
1 (Not at all)
4 (Quite a bit)
5 (Very much)
Eortc1
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Were you limited in doing either your work or
other daily activities?
A Little (A little)
1 (Not at all)
4 (Quite a bit)
5 (Very much)
Were you limited in pursuing your hobbies or
other leisure time activities?
A Little (A little)
1 (Not at all)
4 (Quite a bit)
5 (Very much)
Were you short of breath
A Little (A little)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Very Much (Very much)
Have you had pain
A Little (A little)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Very Much (Very much)
Did you need to rest
A Little (A little)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Very Much (Very much)
Eortc2
Have you had trouble sleeping
A Little (A little)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Very Much (Very much)
Have you felt weak
A Little (A little)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Very Much (Very much)
Have you lacked appetite
A Little (A little)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Very Much (Very much)
Have you felt nauseated
A Little (A little)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Very Much (Very much)
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Have you vomited
A Little (A little)
1 (Not at all)
4 (Quite a bit)
5 (Very much)
Eortc3
Have you been constipated
A Little (A little)
1 (Not at all)
4 (Quite a bit)
5 (Very much)
Have you had diarrhea
A Little (A little)
1 (Not at all)
4 (Quite a bit)
5 (Very much)
Were you tired
A Little (A little)
1 (Not at all)
4 (Quite a bit)
5 (Very much)
Did pain interfere with your daily activities
A Little (A little)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Very Much (Very much)
Have you had difficulty in concentrating on things,
like reading a newspaper or watching television
A Little (A little)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Very Much (Very much)
Eortc4
Did you feel tense
A Little (A little)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Very Much (Very much)
Did you worry
A Little (A little)
1 (Not at all)
4 (Quite a bit)
5 (Very much)
Did you feel irritable
A Little (A little)
1 (Not at all)
4 (Quite a bit)
5 (Very much)
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Did you feel depressed
A Little (A little)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Very Much (Very much)
Have you had difficulty remembering things
A Little (A little)
1 (Not at all)
4 (Quite a bit)
5 (Very much)
Eortc5
Has your physical condition or medical treatment
interfered with your family life
A Little (A little)
1 (Not at all)
4 (Quite a bit)
5 (Very much)
Has your physical condition or medical treatment
interfered with your social activities
A Little (A little)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Very Much (Very much)
Has your physical condition or medical treatment
caused you financial difficulties
A Little (A little)
1 (Not at all)
4 (Quite a bit)
5 (Very much)
How would you rate your overall health during the
past week? (For the following questions please
circle the number between 1 and 7 that best
applies to you)
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
7 (7)
How would you rate your overall quality of life
during the past week? (For the following
questions please circle the number between 1
and 7 that best applies to you)
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
7 (7)
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Additional Concerns
Did you urinate frequently during the day
A Little (A little)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Very Much (Very much)
Did you urinate frequently during the night?
A Little (A little)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Very Much (Very much)
Did you have pain when you urinated?
A Little (A little)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Very Much (Very much)
Did you have a bloated feeling in your abdomen
A Little (A little)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Very Much (Very much)
Did you have abdominal pain?
A Little (A little)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Very Much (Very much)
Did you have pain in your buttocks?
A Little (A little)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Very Much (Very much)
Were you bothered by gas (flatulence)?
A Little (A little)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Very Much (Very much)
Did you belch?
A Little (A little)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Very Much (Very much)
Have you lost weight?
A Little (A little)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Very Much (Very much)
Did you have a dry mouth?
A Little (A little)
Not At All (Not at all)
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Quite A Bit (Quite a bit)
Very Much (Very much)
Have you had thin or lifeless hair as a result of
your disease or treatment
A Little (A little)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Very Much (Very much)
Did food and drink taste different from usual?
A Little (A little)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Very Much (Very much)
Have you felt physically less attractive as a result
of your disease or treatment?
A Little (A little)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Very Much (Very much)
Have you been feeling less feminine/masculine
as a result of your disease or treatment?
A Little (A little)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Very Much (Very much)
Have you been dissatisfied with your body?
A Little (A little)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Very Much (Very much)
Were you worried about your health in the future?
A Little (A little)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Very Much (Very much)
During The Past Four Weeks:
To what extent were you interested in sex?
A Little (A little)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Very Much (Very much)
To what extent were you sexually active (with or
without intercourse)?
A Little (A little)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Very Much (Very much)
To what extent was sex enjoyable for you?
(Answer this question only if you have been
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sexually active)
A Little (A little)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Very Much (Very much)
Did you have difficulty getting or maintaining an
erection? (For men only)
A Little (A little)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Very Much (Very much)
Did you have problems with ejaculation (e.g., so-
called 'dry ejaculation')? (For men only)
A Little (A little)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Very Much (Very much)
Did you have a dry vagina during intercourse?
(Only for women who have had intercourse)
A Little (A little)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Very Much (Very much)
Did you have pain during intercourse? (Only for
women who have had intercourse)
A Little (A little)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Very Much (Very much)
Stoma
Do you have a stoma (colostomy bag)?
No (No)
Yes (Yes)
Only For Patients Without A Stoma
(colostomy Bag):
Did you have frequent bowel movements during
the day?
A Little (A little)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Very Much (Very much)
Did you have frequent bowel movements during
the night?
A Little (A little)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Very Much (Very much)
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Did you feel the urge to move your bowels without
actually producing any stools
A Little (A little)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Very Much (Very much)
Have you had any unintentional release of stools
A Little (A little)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Very Much (Very much)
Have you had blood with your stools
A Little (A little)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Very Much (Very much)
Have you had difficulty in moving your bowels
A Little (A little)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Very Much (Very much)
Have your bowel movements been painful?
A Little (A little)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Very Much (Very much)
Unnamed 4
Were you afraid that other people would be able
to hear your stoma
A Little (A little)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Very Much (Very much)
Were you afraid that other people would be able
to smell your stools
A Little (A little)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Very Much (Very much)
Were you worried about possible leakage from
the stoma bag?
A Little (A little)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Very Much (Very much)
Did you have problems with caring for your stoma
A Little (A little)
Not At All (Not at all)
Quite A Bit (Quite a bit)
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Very Much (Very much)
Was your skin around the stoma irritated
A Little (A little)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Very Much (Very much)
Did you feel embarassed because of your stoma
A Little (A little)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Very Much (Very much)
Did you feel less complete because of your stoma
A Little (A little)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Very Much (Very much)
Supplemental Quality Of Life Questions
How satisfied are you with your current degree of
anal or anal/rectal function (on a scale of 1-10
with 1 being totally dissatisfied to 10 totally
satisfied)
0 (0)
1 (1)
10 (10)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
7 (7)
8 (8)
9 (9)
How well does your anus function (MEMORIAL
SLOAN KETTERING ANAL FUNCTION SCALE)
Excellent; Typically 1-2 Bowel
Movements Per Day And No Soilage
(Excellent; Typically 1-2 bowel
movements per day and no soilage)
Fair; >4 Bowel Movements A Day At
Least At Times And/or Moderate Soilage
(Fair; >4 bowel movements a day at least
at times and/or moderate soilage)
Good; Typically 3-4 Bowel Movements
Per Day And/or Mild Soilage (Good;
Typically 3-4 bowel movements per day
and/or mild soilage)
Poor; Incontinence (Poor; Incontinence)
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Eligibility NCT00274573 Pulmonary
Disease, Chronic Obstructive
ODM derived from
http://clinicaltrials.gov/show/NCT00274573
All rights reserved. Please visit https://medical-data-
models.org/forms/5610
Eligibility
Inclusion Criteria
Male or female patients 40 years of age or older*
Yes
No
All patients must have a diagnosis of chronic
obstructive pulmonary disease and must meet
the following spirometric criteria: Patients must
have relatively stable, mild to severe airway
obstruction with an FEV1 =<70% of predicted
normal and an FEV1/FVC < 70 %. Predicted
normal values will be taken from the print-outs of
the spirometers. Spirometers have to calibrated
according to ECCS.*
Yes
No
Patients must be current or ex-smokers with a
smoking history of 10 or more than 10 pack-
years. Pack Years = Number of cigarettes/day :
20 x years of smoking (Patients who have never
smoked cigarettes must not be included)*
Yes
No
Patients must be able to perform all study related
tests, acceptable pulmonary function tests,
including Peak Expiratory Flow Rate (PEFR)
measurements, and must be able to maintain
diary cards during the study period as required in
the protocol*
Yes
No
Patients must be able to inhale medication from
the HandiHaler*
Yes
No
All patients must sign an Informed Consent Form
prior to participation in the trial i.e. prior to pre-
study washout of their usual pulmonary
medications*
Yes
No
Exclusion Criteria
Patients with significant diseases other than
COPD will be excluded. A significant disease is
defined as a disease which in the opinion of the
investigator may either put the patient at risk
because of participation in the study or a disease
which may influence the results of the study or
1 / 6
the patient's ability to participate in the study.*
Yes
No
Patients with a recent history (i.e., one year or
less) of myocardial infarction.*
Yes
No
Patients with any cardiac arrhythmia requiring
drug therapy or who have been hospitalised for
heart failure within the past three years.*
Yes
No
Patients who regularly use daytime oxygen
therapy for more than 1 hour per day and in the
investigator's opinion will be unable to abstain
from the use of oxygen therapy.*
Yes
No
Patients with known active tuberculosis.*
Yes
No
Patients with a history of cancer within the last
five years. Patients with treated basal cell
carcinoma are allowed.*
Yes
No
Patients with a history of life-threatening
pulmonary obstruction, or a history of cystic
fibrosis or bronchiectasis.*
Yes
No
Patients who have undergone thoracotomy with
pulmonary resection. Patients with a history of
thoracotomy for other reasons should be
evaluated as per exclusion 1.*
Yes
No
Patients with any respiratory infection in the past
six weeks prior to the Screening Visit (Visit 1) or
during the run-in period.*
Yes
No
Patients who are currently in a pulmonary
rehabilitation programme or who have completed
a pulmonary rehabilitation programme in the six
week prior to the Screening Visit (Visit 1).*
Yes
No
Patients with known hypersensitivity to
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anticholinergic drugs, lactose or any other
components of the inhalation capsule delivery
system.*
Yes
No
Patients with known symptomatic prostate
hypertrophy or bladder neck obstruction.*
Yes
No
Patients with known narrow-angle glaucoma.*
Yes
No
Patients using oral corticosteroid medication at
unstable doses (i.e., less than four weeks on a
stable dose before Visit 1) or at doses in excess
of the equivalent of 10 mg of prednisolone per
day or 20 mg every other day.*
Yes
No
Pregnant or nursing women or women of
childbearing potential not using a medically
approved means of contraception (i.e. oral
contraceptives, intrauterine devices, diaphragm
or subdermal implants).*
Yes
No
Patients with a history of asthma, allergic rhinitis
or atopy.*
Yes
No
Patients with a history of and/or active significant
alcohol or drug abuse.*
Yes
No
Patients who have taken an investigational drug
within one month prior to Screening Visit (Visit 1).
A log of all subjects screened, and reasons for
exclusion for those not randomised will be
maintained.*
Yes
No
Medical Concepts
Age*
disorder*
Chronic Obstructive Pulmonary Disease*
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Spirometry*
Respiratory obstruction*
Forced expired volume in one second/vital
capacity ratio*
European Coal and Steel Community*
Pack years (assessment scale)*
Test*
Lung function tests*
Peak expiratory flow rate measurement*
Peak expiratory flow rate monitoring using diary*
Home Medications*
Informed Consent*
Subject Participation Status in Clinical Study*
disease risk*
Heart infarction*
Cardiac Arrhythmia*
Drug Therapy*
Heart failure*
Warburg Therapy*
Active tuberculosis*
Malignant Neoplasms*
Basal cell carcinoma*
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Lung structure*
Obstruction*
Mucoviscidosis*
Bronchiectasis*
Opening of chest*
Pulmonary resection*
Respiratory Tract Infections*
Screening*
Pulmonary rehabilitation programme completed*
Anticholinergic allergy*
Lactose malabsorption*
Inhaled drug administration*
adenofibromatous hypertrophy of prostate*
Bladder neck obstruction*
Chronic narrow angle glaucoma*
Therapeutic Corticosteroid*
prednisolone (substance)*
pregnant*
Breast feeding, Nursing*
Contraception, Birth control*
Oral contraceptive preparation*
Intrauterine contraceptive device*
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Subdermal implantation of progesterone*
Implant, device*
Subcutaneous route*
Vaginal contraceptive diaphragm (device)*
Asthma*
Allergic rhinitis due to allergen*
Atopic Allergy*
Alcohol abuse*
Drug abuse*
Investigational New Drug*
Screening*
patient encounter*
Random Allocation*
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Eligibility NCT00153062 Stroke
ODM derived from
http://clinicaltrials.gov/ct2/show/record/NCT00153062
All rights reserved. Please visit https://medical-data-
models.org/forms/5712
Eligibility
Inclusion Criteria
50 Years and older*
Yes
No
Male or female subjects 55 year or older who
have suffered an ischemic stroke within the past
90 days and who meet all other inclusion criteria.
Include also patients of ages 50 - 54 years and/or
90 to 120 days after the qualifying stroke
provided the patient has at least two of the
following additional risk factors: Diabetes mellitus,
Hypertension (systolic blood pressure (BP)>=140
millimeters of Mercury (mmHg) or diastolic
BP>=90mmHg), Smoker at time of qualifying
stroke, 
Obesity (Body mass index (BMI)>30, BMI=weight
in kilograms (kg)/[height in meters (m)]2),
Previous vascular disease (stroke, MI, or
peripheral arterial disease prior to qualifying
stroke), End-organ-damage (retinopathy, left
ventricular hypertrophy (LVH), or
microalbuminuria),
Hyperlipidemia*
Yes
No
Exclusion Criteria
hemorrhagic stroke (must be ruled out by
imaging)*
Yes
No
unable to give informed consent*
Yes
No
known brain tumor, severe renal or hepatic
insufficiency, current active peptic ulcer disease,
severe coronary artery disease including
unstable angina pectoris or an MI within the
previous 3 months,or history of a hemostatic
disorder or systemic bleeding*
Yes
No
hyperkalemia, uncorrected volume or sodium
depletion*
Yes
No
pre-stroke history of dementia, modified Rankin
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score greater than 4*
Yes
No
qualifying stroke induced by surgical or
cardiovascular procedure*
Yes
No
uncontrolled hypertension at entry above 180/110
mmHg (goal blood pressures are lower)*
Yes
No
Systolic blood pressure (SBP) 120 mmHg or less
for hospitalized patients. Currently taking an
Angiotensin II receptor blocker (ARB) and not
able or willing to switch to alternative. Required or
planned continuing treatment with
antithrombotics or anticoagulants including
heparin or warfarin or non-study platelet
inhibitors*
Yes
No
syndrome of asthma, rhinitis and nasal polyps*
Yes
No
scheduled for major surgery, carotid
endarterectomy, or carotid angioplasty (4 weeks
post surgery is allowed)*
Yes
No
unlikely to be released from hospital following the
qualifying stroke or presence of a severe
disability likely to lead to being bedridden or
demented or a non-vascular disease or condition
which makes it unlikely that the patient will
survive to the end of the trial*
Yes
No
history of thrombocytopenia or neutropenia*
Yes
No
Medical concepts
Age*
Ischemic stroke*
Diabetes mellitus*
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Hypertensive disease*
Smoking Status*
Obesity*
Body mass index*
Diagnosis*
Stroke*
Acute myocardial infarction*
Peripheral Arterial Diseases*
Retinopathy*
Left Ventricular Hypertrophy*
Microalbuminuria*
Hyperlipidemia*
Brain hemorrhage*
Brain Neoplasms*
Renal Insufficiency*
Hepatic Insufficiency*
Peptic Ulcer*
Coronary artery disease (CAD)*
Bleeding tendency*
hyperkalemia*
Dementia*
Rankin score*
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Complication of surgical and medical care,
unspecified*
Systolic Blood Pressure*
Medication*
Angiotensin II receptor antagonist*
Anticoagulant treatment*
Antithrombic Drugs*
Heparin*
Warfarin*
Therapeutic procedure*
Asthma*
Life expectancy*
Platelet count - finding*
White Blood Cells*
Neutropenia*
Thrombocytopenia*
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Eligibility NCT00322621 Diabetic
Neuropathies
ODM derived from
http://clinicaltrials.gov/show/NCT00322621
All rights reserved. Please visit https://medical-data-
models.org/forms/5721
Eligibility
Einschlusskriterien
Alter 18 Jahre und älter*
Ja
Nein
Have pain due to bilateral peripheral neuropathy
caused by Type I or Type II diabetes with the pain
beginning in the feet and present for at least 6
months.*
Ja
Nein
May not be pregnant and agree to utilize
medically acceptable and reliable means of birth
control during participation in the study.*
Ja
Nein
Score of 4 or greater on the Brief Pain Inventory
on the 24-hour average pain item.*
Ja
Nein
Ausschlusskriterien
History of substance abuse or dependence within
the past year, excluding nicotine and caffeine.*
Ja
Nein
Serious or unstable cardiovascular, hepatic
(acute liver injury such as hepatitis or severe
cirrhosis),kidney, respiratory, or blood disorder,
seizure disorder, problems with peripheral
vascular disease, or other medical conditions or
psychiatric conditions that would hinder your
participation or be likely to lead to hospitalization
during the course of the study.*
Ja
Nein
Taking monoamine oxidase inhibitor (MAOI)
within 14 days of starting the study or the
potential need to take during or within 5 days
after discontinuation from the study.*
Ja
Nein
Fluoxetin*
Ja
Nein
Unstable blood sugar control and uncontrolled or
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poorly controlled hypertension.*
Ja
Nein
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Eligibility NCT00564993 Tetralogy of Fallot
ODM derived from
http://clinicaltrials.gov/show/NCT00564993
All rights reserved. Please visit https://medical-data-
models.org/forms/5722
Eligibility
Einschlusskriterien
Alter mindestens 14 Jahre*
Ja
Nein
Written informed consent of the patient or
patient's legal representatives*
Ja
Nein
No participation in another AMG driven study
within the past 4 weeks or during the whole
duration of this study*
Ja
Nein
Patients with Tetralogy of Fallot after corrective
surgery*
Ja
Nein
group A (n=45): Adolescents >= 14 years or
adults with Tetralogy of Fallot after  corrective
surgery and necessary re-intervention
(pulmonary valve replacement  because of
pulmonary insufficiency*
Ja
Nein
group B (n=35): Adolescents >= 14 years or
adults with Tetralogy of Fallot after  corrective
surgery and good result of repair and good right
ventricular function *
Ja
Nein
Ausschlusskriterien
pregnancy or lactation*
Ja
Nein
women of child-bearing age who are sexually
active without practising highly effective methods
of contraception (a urine/serum pregnancy test
may be requested at the discretion of the
investigator)*
Ja
Nein
any diseases or impairment that, in the opinion of
the investigator, would justify to exclude a subject
from participation*
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Ja
Nein
substance abuse (alcohol, medicines, drugs)*
Ja
Nein
other medical, psychological or social
circumstances that would adversely affect a
patient's ability to participate reliably in the study
or increase the risk to themselves or others if
they participated*
Ja
Nein
insufficient compliance*
Ja
Nein
disagreement with storage & transfer of
anonymized disease data within this study.*
Ja
Nein
Persons who are detained officially or legally to
an official institution*
Ja
Nein
contraindication against pharmacological stress
testing (ventricular tachycardia or severe
arrhythmia, profound pulmonary stenosis and
hypertension of the pulmonary artery)*
Ja
Nein
Koronare Herzerkrankung*
Ja
Nein
atrial fibrillation or flutter*
Ja
Nein
DORV (if there is another VSD than subaortic)*
Ja
Nein
associated severe heart defects*
Ja
Nein
associated other severe (=hemodynamic
significantly) valvular defects except for
pulmonary insufficiency*
Ja
Nein
Other clinically relevant diseases, such as
malignant tumour or florid diseases (as
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considered by the investigating physician)*
Ja
Nein
MRI contraindication, e.g. cardiac pacemaker,
implanted neurostimulators and other
magnetisable foreign bodies*
Ja
Nein
Patient is not able to perform spiroergometry
(bicycle/treadmill) or existing contraindications*
Ja
Nein
Patients with Type I or II diabetes*
Ja
Nein
prohibited concomitant medication: MAO-
inhibitors*
Ja
Nein
Treatment with beta- or alpha-blocker*
Ja
Nein
Treatment with high doses of ACE-inhibitors or
inhibitors of the AT-receptor and permanent
treatment with nitrates (in the investigating
physician's risk assessment)*
Ja
Nein
Anticoagulation treatment (risk-benefit decision
by the investigating physician, as there may be
additional inhibition of platelet aggregation with
dobutamine)*
Ja
Nein
Treatment with diuretics (risk-benefit decision by
the investigating physician, as there may be
enhancement of the hypokalemia by
administration of dobutamine). If necessary
verification of the serum K+ -level before
exposure to dobutamine*
Ja
Nein
all contraindications against the study medication
described in the SMPC*
Ja
Nein
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Eligibility NCT00586794 Pulmonary Arterial
Hypertension (PAH)
ODM derived from
http://clinicaltrials.gov/show/NCT00586794
All rights reserved. Please visit https://medical-data-
models.org/forms/5723
Eligibility
Einschlusskriterien
Alter mindestens 14 Jahre*
Ja
Nein
Written informed consent obtained*
Ja
Nein
No participation in another AMG driven study
attendancing this treatment protocol*
Ja
Nein
Presence of cyanosis with < 93 % arterial oxygen
saturation (measured by transcutaneous pulse
oximetry)*
Ja
Nein
Clinical indication for the invasive diagnostic
procedures planned for the study is given. This is
evaluated on the basis of observation before,
during and after medicinal therapy)*
Ja
Nein
Presence of PAH as diagnosed by invasive
methods with Rp:Rs > 0.5 measured at rest,
before testing of pulmonary vasodilatory reserve*
Ja
Nein
Diagnose*
Ja
Nein
non-corrected large congenital shunting defect at
atrial, ventricular or  arterial level:*
Ja
Nein
Partial anomalous pulmonary venous drainage,
Partial Anomalous Pulmonary Venous Return*
Ja
Nein
Vorhofseptumdefekt, ASD*
Ja
Nein
Atrial Septal Defect Sinus Venosus, Sinus
venosus atrial septal defect *
Ja
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Nein
Ventrikelseptumdefekt, VSD,
Herzkammerscheidewanddefekt*
Ja
Nein
Atrioventricular septal defect, Atrioventricular
septal defect and common atrioventricular
junction*
Ja
Nein
TAC*
Ja
Nein
Aortopulmonary window, Aortopulmonary septal
defect*
Ja
Nein
Ductus arteriosus apertus persistens*
Ja
Nein
combinations thereof *
Ja
Nein
Surgically corrected shunting defect (diagnoses
as above) with significant  residual defect*
Ja
Nein
Other diagnoses with univentricular physiology/
hemodynamics. *
Ja
Nein
Ausschlusskriterien
pregnancy or lactation*
Ja
Nein
women of child-bearing age who are sexually
active without practising highly effective methods
of contraception*
Ja
Nein
any diseases or impairment that, in the opinion of
the investigator exclude a subject from
participation*
Ja
Nein
substance abuse (alcohol, medicines, drugs)*
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Ja
Nein
other medical, psychological or social
circumstances that would adversely affect a
patient's ability to participate reliably in the study
or increase the risk to themselves or others if
they participated*
Ja
Nein
insufficient compliance*
Ja
Nein
missing willingness to storaging and transferring
pseudonymous disease data within this study.*
Ja
Nein
subjects who are not able to perform Cardio-
Pulmonary Exercise Testing (CPX).*
Ja
Nein
pulmonary hypertension secondary to any
etiology other than those specified in the
inclusion criteria*
Ja
Nein
subjects with known intolerance of NO and
iloprost or their constituents*
Ja
Nein
acute decompensated heart failure within the 7
days before the invasive diagnostic procedure*
Ja
Nein
clinically significant haemoptysis within the last 6
months*
Ja
Nein
hemodynamic instability which would represent
an unjustifiable risk during testing of pulmonary
arterial vasoreagibility*
Ja
Nein
arterial hypotension (as defined by age-specific
values)*
Ja
Nein
Anämie*
Ja
Nein
3 / 7
Eligibility NCT00586794 Pulmonary Arterial Hypertension (PAH)
decompensated symptomatic policythemia;
(details: 4.2.2. exclusion criteria)*
Ja
Nein
Thrombocytopenia*
Ja
Nein
secondary impairment of organic function:*
Ja
Nein
impairment of renal function (GFR < 30
ml/min/1,73 m2 BSA)*
Ja
Nein
impairment of hepatic function (ALT and/or AST >
3 x ULN and bilirubin ≥ 2 mg/dl)*
Ja
Nein
other sources of pulmonary blood flow which
prohibit measurement of the blood flow into the
lungs and therefore of the pulmonary vascular
resistance:*
Ja
Nein
Glenn shunt, Anastomosis of superior vena cava
to pulmonary artery*
Ja
Nein
BT - Blalock-Taussig shunt, Subclavian to
pulmonary artery shunt operation*
Ja
Nein
significant number of MAPCAs; (details: 4.2.2.
exclusion criteria)*
Ja
Nein
Obstruction of pulmonary outflow tract*
Ja
Nein
obstruction of pulmonary venous return*
Ja
Nein
mitral valve dysfunction*
Ja
Nein
Left heart diseases:*
Ja
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Nein
aortic or mitral valve disease (more severe than
"mild")*
Ja
Nein
restrictive or congestive cardiomyopathy*
Ja
Nein
PCWP/LVEDP > 15 mmHg*
Ja
Nein
symptomatic coronary artery disease*
Ja
Nein
Significant valvular diseases other than tricuspid
or pulmonary regurgitation (these are not
exclusion criteria; details: 4.2.2. exclusion
criteria).*
Ja
Nein
PERICARDIAL CONSTRICTION*
Ja
Nein
History of stroke, myocardial infarction or life-
threatening arrhythmia within the 6 months before
screening*
Ja
Nein
Bronchopulmonary dysplasia (BPD) and other
chronic lung diseases*
Ja
Nein
History of significant pulmonary embolism*
Ja
Nein
Other relevant diseases (e.g. HIV, diabetes
mellitus requiring medical treatment)*
Ja
Nein
Subjects with trisomy 21 (reproducibility of 6-
MWT and CPX doubtful; communication as to
side effects and subjective quality of life
doubtful)*
Ja
Nein
all contraindications against the study medication
(see also "4.2.3 concomitant medication")*
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Ja
Nein
hypersensitivity against the active ingredients as
well as supplementaries*
Ja
Nein
patients who lost vision on one eye due to a non
arteriitic anterior ischaemic neuropathy of the
opticus (NAION).*
Ja
Nein
Prohibited concomitant medication:*
Ja
Nein
Any medication listed below which has not been
discontinued at least 30 days prior to screening.
Specific pulmonary vasodilators during cardiac
catheterization are allowed.*
Ja
Nein
Unspecified concomitant medication*
Ja
Nein
Other significant medication (a.o. chronic intake
of systemic immunosuppression as e.g. systemic
glucocorticoids, cytostatic drugs, ciclosporin)*
Ja
Nein
Instable medication (details: 4.2.5 prohibited
concomitant medication):*
Ja
Nein
begin of a new medication regimen within the last
30 days before screening*
Ja
Nein
change in the dosage of existing medication
within the last 7 days before cardiac
catheterization*
Ja
Nein
Existing anti-pulmonary hypertensive medication
(in any form) with:*
Ja
Nein
PDE-5 antagonists (e.g. sildenafil)*
Ja
Nein
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prostanoids (e.g. iloprost, prostacyclin, beraprost)
In case the patient is stable and on Bosentan
therapy at least for 6 months. Bosentan (Tracleer)
is unprohibited as concomitant medication.*
Ja
Nein
Other medication with vascular action:*
Ja
Nein
Alpha-Blocker*
Ja
Nein
L-arginin (acts through NO axis)*
Ja
Nein
ritonavir, nicorandil (act through K+ channels)*
Ja
Nein
Medication that is not compatible with sildenafil or
interferes with the metabolism:*
Ja
Nein
cytochrome P450-CYP2C9 and CYP3A4
inhibitors (e.g.
erythromycin/ketoconazole/itraconazole/protease
inhibitors)*
Ja
Nein
any existing medication that, in the opinion of the
investigator, may interfere with sildenafil
treatment.*
Ja
Nein
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Cardiac - 3273436v1.0
The patient's cardiac ejection fraction.
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=ACEBB4B0-
67EC-0DE7-E040-BB89AD4329A6
All rights reserved. Please visit https://medical-data-
models.org/forms/5738
Cardiac
Cardiac
Visit Date (Enter the start date of the first course
in this field.)
Course (Cycle) #
Day in Course (Cycle)
Evaluation Date (Enter the date the procedure
was performed.)
Evaluation Time (Enter the time the procedure
was performed.)
Procedure
Cardiac Catheterization (Cardiac
Catheterization)
Echocardiogram (Echocardiogram)
Magnetic Resonance Imaging (MRI)
Multi-gated Acquisition Scan (MUGA)
Nuclear Stress Test (Nuclear stress test)
Pre-Ejection Period (Enter the Pre-Ejection
Period.)
LV Ejection Time (Enter the Left Ventricular
Ejection Time.)
LV Ejection Fraction (Enter the Left Ventricular
Fraction percentage.)
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Lab - Procedures (Literal Laboratory) -
3291321v1.0
Record the results of the procedures that are performed as
part of the protocol. All laboratory results are to be
recorded on the appropriate lab CRF.
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=AEA73056-
4694-EA34-E040-BB89AD4309A0
All rights reserved. Please visit https://medical-data-
models.org/forms/5739
Procedures (Literal Laboratory)
Procedures
Visit Date
Course # (Indicates the course number the
procedure is related to based on their date and
time.)
Day in Course (Cycle) (Indicates the day since
the beginning of course the procedure is related
to based on their date and time.)
Date (Enter the date that the procedure was
done.)
Time (Enter the time the procedure was done.)
Procedure (Select the procedure from the pick
list.)
Alpha-lipoic Acid (Alpha-Lipoic Acid)
Apheresis (Apheresis)
Arteriogram (Arteriogram)
Arthroscopy (Arthroscopy)
Aspirate, Bone Marrow (Aspirate, Bone
Marrow)
Aspirate, Ultrasound Guided (Aspirate,
Us Guided)
Audiogram (Audiogram)
Barium Enema (Barium Enema)
Barium Swallow (Barium Swallow)
Biopsy (Biopsy)
Biopsy, Core Needle (Biopsy, Core
Needle)
Biopsy, Image Guided (Biopsy, Image
Guided)
Blister Induction (Blister Induction)
Bone Marrow Cellularity (BM Cellularity)
Biopsy, Bone Marrow (Bone Marrow
Biopsy)
Bone Mineral Density (Bone Mineral
Density)
Bone Scan (Bone Scan)
Bone Spectometry (Bone Spectometry)
Bronchoalveolar Lavage
(Bronchoalveolar Lavage)
Bronchogram (Bronchogram)
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Bronchoscopy (Bronchoscopy)
Bronchoscopy/lavage
(Bronchoscopy/Lavage)
Cardiac Catheterization (Cardiac
Catheterization)
Computerized Axial Tomography (CAT
(CT))
Cathetergram (Cathetergram)
Cauterization (Cautery, AgNO3 (Silver
nitrate))
Central Line Insertion (Central Line
Insertion)
Colonoscopy (Colonoscopy)
Craniotomy (Craniotomy)
Culture Procedure (Culture)
Curative Surgery (Curative Surgery)
X-ray, Chest (CXR)
Cystectomy (Cystectomy)
Cystogram (Cystogram)
Cystoscopy (Cystoscopy)
Cytology (Cytology)
Debridement Of Wound Of Skin
(Debridement)
Dental Examination (Dental
Examination)
Dental Procedure (Dental Procedure)
Dissection (Dissection)
Doppler Study (Doppler)
Electrocardiogram (ECG)
Echocardiogram (Echocardiogram)
Electroencephalogram (EEG)
Upper Endoscopy
Esophagogastroduodenoscopy (EGD)
Electrocardiogram (EKG)
Electromyography (EMG)
Endoscopy (Endoscopy)
Esophageal Dilation (Esophageal
dilation)
Esophagoscopy (Esophagoscopy)
Examination Under Anesthesia (EUA)
Excision (Excision)
Exercise Thallium (Exercise Thallium)
Eye Exam (Eye Exam)
Aspirate, Fine Needle (Fine Needle
Aspiration)
Flexible Fiberoptic Sigmoidoscopy
(Flexible Fiberoptic Sigmoidoscopy)
Fluoroscopy (Fluoroscopy)
Flow Cytometry (Flw Cyt)
Flow Cytometry, Blood (Flw Cyt Bld)
Flow Cytometry, Bone Marrow (Flw Cyt
BM)
Holter Monitor (Holter Monitor)
Hyperbaric Treatment(s) (Hyperbaric
Treatment(s))
Hyperthermia (Hyperthermia)
Hysterosonogram (Hysterosonogram)
Incision & Drainage (I&D)
Ice Application (Ice Application)
Laser Doppler Imaging (Imaging, Laser
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Doppler)
Multispectral Imaging (Imaging,
Multispectral)
Near Infrared Imaging (Imaging, Near
Infrared)
Immunohistochemical Detection/staining
(Immunohistochemical Detection)
Infrared (Infrared)
Irrigation (Irrigation)
Intravenous Pyelogram (IVP)
X-ray, Abdominal (KUB)
Lymphangiogram (LAG)
Laparoscopy (Laparoscopy)
Laryngoscopy (Laryngoscopy)
Leukapheresis (Leukopheresis)
Lower Gastrointestinal Series (Lower GI)
Lumbar Puncture (LP)
Lumpectomy (Lumpectomy)
Lymphadenectomy (Lymphadenectomy)
Lymphocyte Harvest (Lymphocyte
Harvest)
Lymphocyte Infusion (Lymphocyte
Infusion)
Lymphopheresis With Scda Solution
(Lymphopheresis w/SCDA)
Mammogram (Mammogram)
Mammogram, Birad (Mammogram,
BIRAD)
Mammogram, Digitized (Mammogram,
DIGITIZED)
Mammogram, Wolfe (Mammogram,
WOLFE)
Mastectomy (Mastectomy)
Magnetic Resonance Imaging (MRI)
Magnetic Resonance Spectroscopy
(MRS)
Multi-gated Acquisition Scan (MUGA)
Nasopharyngeal Laryngoscopy
(Nasopharyngeal Laryngoscopy)
Nasopharyngoscopy
(Nasopharyngoscopy)
Nipple Suction Aspirate (Nipple Suction
Aspirate)
Nuclear Stress Test (Nuclear stress test)
In 111 Pentetreotide (Octreoscan)
Ommaya Resevoir Tap (Ommaya
Resevoir Tap)
Papanicolaou Test (PAP)
Paracentesis (Paracentesis)
Physical Examination (PE)
Pelvic Exam (Pelvic Exam)
Peritoneoscopy (Peritoneoscopy)
Positron Emission Tomography (PET)
Positron Emission Tomography
Computerized Tomography (PET CT)
Positron Emission Tomography With
Sestamibi (PET w/Sestamibi)
Pet, Dlop (PET, dLop)
Positron Emission Tomography With Fdg
(PET, FDG)
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Positron Emission Tomography With O-
15 Water (h2o15) (PET, H2O15)
Pulmonary Function Test Interpretation
(PFT Interpretation)
Pulmonary Function Test/carbon
Monoxide Diffusing Capability
(PFT/DLCO)
Pulmonary Function Test/forced
Expiratory Volume 1 (PFT/FEV1)
Pulmonary Function Test/ Inspired
Oxygen Fraction (PFT/FIO2)
Pulmonary Function Test/forced Vital
Capacity (fvc) (PFT/FVC)
Photography (Photography)
Pleurodesis (Pleurodesis)
Portacath Placement (Portacath
Placement)
Percutaneous Transluminal Coronary
Angioplasty (PTCA)
Pulse Oximetry (Pulse Oximetry)
Renogram (Renogram)
Resection (Resection)
Radiofrequency Ablation (RFA)
Imaging Scan (Scan)
Scan, Blood Oxygenated Level
Dependant (bold) (Scan, BOLD)
Bone Scan (Scan, Bone)
Scan, Dynamic Contrast-enhanced
Magnetic Resonance Imaging (Scan,
DCE MRI)
Scan, Dual-energy X-ray Absorpitometry
(Scan, DEXA)
Scan, Dynamic Optical Breast Imaging
(Scan, Dynamic Optical Breast Imaging)
Scan, Gallium (Scan, Gallium)
Scan, Iodine 123 Uptake (Scan, I 123
Uptake)
Scan, I 131 Uptake (Scan, I 131 Uptake)
Scan, Indium (Scan, Indium WBC)
Scan, Lung Perfusion (Scan, Lung
Perfusion)
Scan, Single Photon Emission
Computed Tomography (Scan, PET CT)
Scan, Sestamibi (Scan, Sestamibi)
Scan, Spiral Ct (Scan, Spiral CT)
Ventilation-perfusion Scan (Scan, VQ)
Scraping (Scraping)
Sigmoidoscopy (Sigmoidoscopy)
Skeletal Survey (Skeletal Survey)
Skin Test (Skin Test)
Splenectomy (Splenectomy)
Stress Thallium Test (Stress Thallium
Test)
Swallow Evaluation (Swallow Evaluation)
Thoracentesis (Thoracentesis)
Tomogram (Tomogram)
Transrectal Ultrasound (Transrect US)
Transurethral Resection Bladder
Neoplasm (TURBT)
Upper Gastrointestinal Series (UGI)
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Upper Gastrointestinal Series W/small
Bowel Follow Through (UGI/w sm bowel
f/t)
Ultrasound (Ultrasound)
Urine Casts (Urine Casts)
Vascular Access Device Placement (VAD
Placement)
Vaginogram (Vaginogram)
Venacavagrm (Venacavagrm)
Venogram (Venogram)
Video Recording (Videography)
X-ray (X-Ray)
Body Site (Select the body site from the pick list.)
Abdomen (Abdomen)
Abdomen/pelvis (Abdomen/Pelvis)
Abdominal Wall (Abdominal wall)
Acetabulum (Acetabulum)
Pharyngeal Tonsil (Adenoid)
Adipose Tissue (Adipose)
Adrenal Gland (Adrenal gland)
Alveolar Ridge (Alveolar Ridge)
Amniotic Fluid (Amniotic Fluid)
Ampulla Of Vater (Ampulla of Vater)
Anal Canal (Anal canal)
Anal Sphincter (Anal sphincter)
Ankle (Ankle)
Anorectum (Anorectum)
Antecubital Fossa (Antecubital fossa)
Antrum Pylori (Antrum)
Anus (Anus)
Aorta (Aorta)
Aortic Body (Aortic Body)
Appendix (Appendix)
Aqueous Fluid (Aqueous Fluid)
Arm (Arm)
Artery (Artery)
Ascending Colon (Ascending colon)
Ascending Colon Hepatic Flexure
(Ascending Colon Hepatic Flexure)
Auditory Canal (Auditory canal)
Autonomic Nervous System (Autonomic
nervous system)
Axilla (Axilla)
Back (Back)
Bile Duct (Bile duct)
Bladder (Bladder)
Blood (Blood)
Blood Vessel (Blood vessel)
Bone (Bone)
Bone Marrow (Bone marrow)
Bowel (Bowel)
Brain (Brain)
Brain Stem (Brain stem)
Breast (Breast)
Broad Ligament (Broad ligament)
Bronchiole (Bronchiole)
Bronchus (Bronchus)
Bronchus And Lung (Bronchus and
Lung)
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Brow (Brow)
Buccal Cavity (Buccal cavity)
Buccal Mucosa (Buccal mucosa)
Buttock (Buttock)
Calf (Calf)
Capillary (Capillary)
Gastric Cardia (Cardia)
Carina (Carina)
Carotid Artery (Carotid artery)
Carotid Body (Carotid body)
Cartilage (Cartilage)
Cecum (Cecum)
Central Line Catheter (Central Line
Catheter)
Central Nervous System (Central
nervous system)
Cerebellum (Cerebellum)
Cerebral Cortex (Cerebral cortex)
Cerebrospinal Fluid (Cerebrospinal fluid)
Cerebrum (Cerebrum)
Cervical Spine (Cervical spine)
Cervical/thoracic/lumbar Spine
(Cervical/Thoracic/Lumbar spine)
Cervix (Cervix)
Chest (Chest)
Chest Wall (Chest wall)
Chest/abdomen/pelvis
(Chest/Abdomen/Pelvis)
Chest/pelvis (Chest/Pelvis)
Chin (Chin)
Clavicle (Clavicle)
Clitoris (Clitoris)
Colon (Colon)
Colon And Rectum (Colon and rectum)
Colon Mucosa (Colon, mucosa only)
Common Duct (Common duct)
Conjunctiva (Conjunctiva)
Connective Tissue (Connective tissue)
Descending Colon (Descending colon)
Diaphragm (Diaphragm)
Duodenum (Duodenum)
Ear (Ear)
Ear Canal (Ear canal)
External Ear (Ear, Pinna (External))
Effusion (Effusion)
Elbow (Elbow)
Endocrine Gland (Endocrine gland)
Epididymis (Epididymis)
Epidural Spinal Canal Space (Epidural
space)
Esophagogastric Junction
(Esophagogastric junction)
Esophagus (Esophagus)
Esophageal Mucosa (Esophagus,
Mucosa only)
Extremities (Extremities)
Eye (Eye)
Fallopian Tube (Fallopian tube)
Femur (Femur)
Fibula (Fibula)
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Finger (Finger)
Floor Of Mouth (Floor of Mouth)
Body Fluid Or Substance (Fluid)
Foot (Foot)
Forearm (Forearm)
Forehead (Forehead)
Foreskin (Foreskin)
Frontal Lobe (Frontal lobe)
Fundus Of Stomach (Fundus of
stomach)
Gallbladder (Gallbladder)
Ganglion (Ganglia)
Gastroesophageal Junction
(Gastroesophageal Junction)
Gastrointestinal Tract (Gastrointestinal
tract)
Genitourinary (Genitourinary)
Groin (Groin)
Gum (Gum)
Hand (Hand)
Hard Palate (Hard palate)
Head - Face Or Neck, Nos (Head - face
or neck, NOS)
Head/neck (Head/Neck)
Head/neck/chest/adb/pelvis
(Head/Neck/Chest/Adb/Pelvis)
Heart (Heart)
Hepatic Duct (Hepatic duct)
Hip (Hip)
Humerus (Humerus)
Hypopharynx (Hypopharynx)
Ileum (Ileum)
Ilium (Ilium)
Intestine (Intestine)
Ischium (Ischium)
Jaw (Jaw)
Jejunum (Jejunum)
Joints (Joints)
Kidney (Kidney)
Knee (Knee)
Lacrimal Gland (Lacrimal Gland)
Large Bowel (Large bowel)
Laryngopharynx (Laryngopharynx)
Larynx (Larynx)
Leg (Leg)
Ligament (Ligament)
Lip (Lip)
Liver (Liver)
Liver And Intrahepatic Duct (Liver and
intrahepatic duct)
Liver/spleen (Liver/Spleen)
Lumbar Spine (Lumbar spine)
Lung (Lung)
Lymph Node (Lymph node)
Lymph Node(s) Axilla (Lymph Node(s)
Axilla)
Lymph Node(s) Cervical (Lymph Node(s)
Cervical)
Distant Lymph Node (Lymph node(s)
Distant)
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Lymph Node(s) Hilar (Lymph Node(s)
Hilar)
Lymph Node(s) Inguinal (Lymph Node(s)
Inguinal)
Lymph Node(s) Int Mammary (Lymph
Node(s) Int Mammary)
Lymph Node(s) Mammary (Lymph
Node(s) Mammary)
Paraaortic Region Lymph Node (Lymph
node(s) Para aortic)
Lymph Node(s) Pelvic (Lymph Node(s)
Pelvic)
Regional Lymph Node (Lymph node(s)
Regional)
Scalene Lymph Node (Lymph node(s)
Scalene)
Lymph Node(s) Subclavicular (Lymph
Node(s) Subclavicular)
Lymph Node(s) Supraclav (Lymph
Node(s) Supraclav)
Lymph Nodes (Lymph nodes)
Mediastinal Lymph Node (Lymph
nodes(s) Mediastinal)
Lymphoma (Lymphoma)
Mammary Gland (Mammary Gland)
Mandible (Mandible)
Maxilla (Maxilla)
Mediastinum (Mediastinum)
Mesentery (Mesentery)
Mesothelium (Mesothelium)
Mini Mantle (Mini Mantle)
Mouth (Mouth)
Muscle (Muscle)
Nail (Nails)
Nasal Cavity (Nasal Cavity)
Nasopharynx (Nasopharynx)
Neck (Neck)
Neck Chest (Neck/Chest)
Neck/chest/abdomen/pelvis
(Neck/Chest/Abdomen/Pelvis)
Nerve (Nerve)
Cranial Nerve (Nerve(s) Cranial)
Not Applicable (Not Applicable)
Ocular Orbits (Ocular Orbits)
Omentum (Omentum)
Oral Cavity (Oral cavity)
Oral Cavity Mucosa (Oral Cavity, Mucosa
only)
Oropharynx (Oropharynx)
Other (Other)
Ovary (Ovary)
Posterior Anterior/lateral (PA/Lat)
Palate (Palate)
Pancreas (Pancreas)
Paraspinal Ganglion (Paraspinal
Ganglion)
Parathyroid Gland (Parathyroid)
Parotid Gland (Parotid gland)
Patella (Patella)
Pelvis (Pelvis)
8 / 10
Lab - Procedures (Literal Laboratory) - 3291321v1.0
Penis (Penis)
Perianus (Perianus)
Pericardium (Pericardium)
Peritoneal Cavity (Peritoneal cavity)
Peritoneum (Peritoneum)
Pharynx (Pharynx)
Pineal Gland (Pineal Gland)
Pituitary Gland (Pituitary gland)
Placenta (Placenta)
Pleura (Pleura)
Popliteal Fossa (Popliteal fossa)
Prostate (Prostate)
Pylorus (Pylorus)
Rectosigmoid Junction (Rectosigmoid
Junction)
Rectum (Rectum)
Retina (Retina)
Retro-orbital Area (Retro-orbital Area)
Retroperitoneum (Retroperitoneum)
Ribs (Ribs)
Round Ligament (Round ligament)
Sacrum (Sacrum)
Salivary Gland (Salivary gland)
Scalp (Scalp)
Scapula (Scapula)
Scrotum (Scrotum)
Shoulder Joint (Shoulder)
Sigmoid Colon (Sigmoid colon)
Sinus(es) (Sinus(es))
Sinus(es), Maxillary (Sinus(es),
Maxillary)
Skeletal Muscle Tissue (Skeletal Muscle)
Skin (Skin)
Skull (Skull)
Small Bowel Mucosa (Small Bowel,
Mucosa only)
Small Intestine (Small intestine)
Soft Tissue (Soft Tissue)
Spinal Cord (Spinal Cord)
Spine (Spine)
Spine/femur (Spine/Femur)
Spine/femur/radius
(Spine/Femur/Radius)
Spleen (Spleen)
Splenic Flexure (Splenic Flexure)
Sternum (Sternum)
Stomach (Stomach)
Stomach Mucosa (Stomach, Mucosa
only)
Subcutaneous Tissue (Subcutaneous
tissue)
Synovial Membrane (Synovium)
Tendon (Tendon)
Testicle (Testicle)
Testis (Testicle)
Thigh (Thigh)
Thoracic Spine (Thoracic spine)
Thoracic/lumbar Spine (Thoracic/Lumbar
spine)
Thorax (Thorax)
9 / 10
Lab - Procedures (Literal Laboratory) - 3291321v1.0
Throat (Throat)
Thymus (Thymus)
Thyroid Gland (Thyroid gland)
Tibia (Tibia)
Tongue (Tongue)
Tongue, Base Of Tongue (Tongue, Base
of tongue)
Tonsil (Tonsil)
Pharyngeal Tonsil (Tonsil, Pharyngeal)
Trachea (Trachea)
Trachea Main Bronchus (Trachea/Major
Bronchi)
Transverse Colon (Transverse Colon)
Trunk (Trunk)
Superficial Trunk (Trunk, Superficial)
Umbilical Cord (Umbilical Cord)
Upper Extremity (Upper extremity)
Ureter (Ureter)
Urethra (Urethra)
Urinary Tract (Urinary tract)
Uterus (Uterus)
Uvula (Uvula)
Vagina (Vagina)
Vas Deferens (Vas Deferens)
Vein (Vein)
Vena Cava (Vena Cava,
Inferior/Superior)
Vertebra (Vertebra)
Vertebral Column (Vertebral column)
Vulva (Vulva)
Whole Body (Whole body)
Wrist (Wrist)
Abnormal Result? (Select whether the finding
results for the particular procedure / body site.)
Abnormal (A)
Normal (N)
Findings (If abnormal, enter as summary of the
abnormal findings.)
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Chimerism form for C3D 3.12 Adopters
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=014D938F-
EE58-0A7A-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/5740
CHIMERISM
Chimerism
Transplant Received Date
Research Comments Text
Course Day Number
Course Day Number
Evaluation Date
Lab Collection Time
Transplant Received Day Number
Procedure
Apheresis (Apheresis)
Arteriogram (Arteriogram)
Arthroscopy (Arthroscopy)
Aspirate, Bone Marrow (Aspirate, Bone
Marrow)
Aspirate, Ultrasound Guided (Aspirate,
Us Guided)
Audiogram (Audiogram)
Barium Enema (Barium Enema)
Barium Swallow (Barium Swallow)
Biopsy (Biopsy)
Biopsy, Core Needle (Biopsy, Core
Needle)
Biopsy, Image Guided (Biopsy, Image
Guided)
Bone Marrow Cellularity (BM Cellularity)
Biopsy, Bone Marrow (Bone Marrow
Biopsy)
Bone Mineral Density (Bone Mineral
Density)
Bone Scan (Bone Scan)
Bone Spectometry (Bone Spectometry)
Bronchoalveolar Lavage
(Bronchoalveolar Lavage)
Bronchogram (Bronchogram)
Bronchoscopy (Bronchoscopy)
Bronchoscopy/lavage
(Bronchoscopy/Lavage)
Cardiac Catheterization (Cardiac
Catheterization)
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Computerized Axial Tomography (CAT
(CT))
Cathetergram (Cathetergram)
Central Line Insertion (Central Line
Insertion)
Colonoscopy (Colonoscopy)
Culture Procedure (Culture)
Curative Surgery (Curative Surgery)
X-ray, Chest (CXR)
Cystogram (Cystogram)
Cystoscopy (Cystoscopy)
Cytology (Cytology)
Dental Examination (Dental
Examination)
Dental Procedure (Dental Procedure)
Dissection (Dissection)
Doppler Study (Doppler)
Electrocardiogram (ECG)
Echocardiogram (Echocardiogram)
Electroencephalogram (EEG)
Upper Endoscopy
Esophagogastroduodenoscopy (EGD)
Electrocardiogram (EKG)
Electromyography (EMG)
Endoscopy (Endoscopy)
Esophageal Dilation (Esophageal
dilation)
Esophagoscopy (Esophagoscopy)
Examination Under Anesthesia (EUA)
Excision (Excision)
Exercise Thallium (Exercise Thallium)
Eye Exam (Eye Exam)
Aspirate, Fine Needle (Fine Needle
Aspiration)
Flexible Fiberoptic Sigmoidoscopy
(Flexible Fiberoptic Sigmoidoscopy)
Fluoroscopy (Fluoroscopy)
Flow Cytometry (Flw Cyt)
Flow Cytometry, Blood (Flw Cyt Bld)
Flow Cytometry, Bone Marrow (Flw Cyt
BM)
Holter Monitor (Holter Monitor)
Hyperbaric Treatment(s) (Hyperbaric
Treatment(s))
Hyperthermia (Hyperthermia)
Hysterosonogram (Hysterosonogram)
Incision & Drainage (I&D)
Laser Doppler Imaging (Imaging, Laser
Doppler)
Multispectral Imaging (Imaging,
Multispectral)
Near Infrared Imaging (Imaging, Near
Infrared)
Immunohistochemical Detection/staining
(Immunohistochemical Detection)
Infrared (Infrared)
Irrigation (Irrigation)
Intravenous Pyelogram (IVP)
X-ray, Abdominal (KUB)
Lymphangiogram (LAG)
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Laparoscopy (Laparoscopy)
Laryngoscopy (Laryngoscopy)
Leukapheresis (Leukopheresis)
Lower Gastrointestinal Series (Lower GI)
Lumbar Puncture (LP)
Lumpectomy (Lumpectomy)
Lymphadenectomy (Lymphadenectomy)
Lymphocyte Harvest (Lymphocyte
Harvest)
Lymphocyte Infusion (Lymphocyte
Infusion)
Lymphopheresis With Scda Solution
(Lymphopheresis w/SCDA)
Mammogram (Mammogram)
Mammogram, Birad (Mammogram,
BIRAD)
Mammogram, Digitized (Mammogram,
DIGITIZED)
Mammogram, Wolfe (Mammogram,
WOLFE)
Mastectomy (Mastectomy)
Magnetic Resonance Imaging (MRI)
Magnetic Resonance Spectroscopy
(MRS)
Multi-gated Acquisition Scan (MUGA)
Nasopharyngeal Laryngoscopy
(Nasopharyngeal Laryngoscopy)
Nasopharyngoscopy
(Nasopharyngoscopy)
Nipple Suction Aspirate (Nipple Suction
Aspirate)
Ommaya Resevoir Tap (Ommaya
Resevoir Tap)
Papanicolaou Test (PAP)
Paracentesis (Paracentesis)
Physical Examination (PE)
Pelvic Exam (Pelvic Exam)
Peritoneoscopy (Peritoneoscopy)
Positron Emission Tomography (PET)
Positron Emission Tomography
Computerized Tomography (PET CT)
Positron Emission Tomography With Fdg
(PET, FDG)
Positron Emission Tomography With O-
15 Water (h2o15) (PET, H2O15)
Pulmonary Function Test Interpretation
(PFT Interpretation)
Pulmonary Function Test/carbon
Monoxide Diffusing Capability
(PFT/DLCO)
Pulmonary Function Test/forced
Expiratory Volume 1 (PFT/FEV1)
Pulmonary Function Test/ Inspired
Oxygen Fraction (PFT/FIO2)
Photography (Photography)
Pleurodesis (Pleurodesis)
Portacath Placement (Portacath
Placement)
Percutaneous Transluminal Coronary
Angioplasty (PTCA)
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Pulse Oximetry (Pulse Oximetry)
Renogram (Renogram)
Resection (Resection)
Radiofrequency Ablation (RFA)
Imaging Scan (Scan)
Scan, Blood Oxygenated Level
Dependant (bold) (Scan, BOLD)
Scan, Dynamic Contrast-enhanced
Magnetic Resonance Imaging (Scan,
DCE MRI)
Scan, Dual-energy X-ray Absorpitometry
(Scan, DEXA)
Scan, Gallium (Scan, Gallium)
Scan, Iodine 123 Uptake (Scan, I 123
Uptake)
Scan, I 131 Uptake (Scan, I 131 Uptake)
Scan, Indium (Scan, Indium WBC)
Scan, Lung Perfusion (Scan, Lung
Perfusion)
Scan, Sestamibi (Scan, Sestamibi)
Scan, Spiral Ct (Scan, Spiral CT)
Ventilation-perfusion Scan (Scan, VQ)
Scraping (Scraping)
Sigmoidoscopy (Sigmoidoscopy)
Skeletal Survey (Skeletal Survey)
Skin Test (Skin Test)
Splenectomy (Splenectomy)
Stress Thallium Test (Stress Thallium
Test)
Swallow Evaluation (Swallow Evaluation)
Thoracentesis (Thoracentesis)
Tomogram (Tomogram)
Transrectal Ultrasound (Transrect US)
Upper Gastrointestinal Series (UGI)
Upper Gastrointestinal Series W/small
Bowel Follow Through (UGI/w sm bowel
f/t)
Ultrasound (Ultrasound)
Urine Casts (Urine Casts)
Vascular Access Device Placement (VAD
Placement)
Vaginogram (Vaginogram)
Venacavagrm (Venacavagrm)
Venogram (Venogram)
X-ray (X-Ray)
Result
Comments
Note Date
Research Comments Text
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Toxicity - INFECTION EPISODE -
2406136v1.0
Infection Episode form for C3D 3.12 Adopters
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=0149546E-
768C-1694-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/5741
INFECTION EPISODE
Infection Episode
Course Number
Course Day Number
Adverse Event Onset Date
Resolved Date
Infection Type
Bacterial Infection (Bacterial)
Fungal Infection (Fungal)
Microbacterial Infection (Microbacterial)
No Isolated Organism (No Isolated
Organism)
Parasitic Infection (Parasitic)
Pneumonia (Pneumonia)
Protozoal Infection (Protozoal)
Unknown Infection Type (Unknown)
Upper Respiratory Infection (URI)
Urinary Tract Infection (UTI)
Viral Infection (Viral)
Primary Site of Disease Name
Adrenal Gland (Adrenal Gland)
Anus (Anus)
Appendix (Appendix)
Back (Back)
Bile Duct (Bile Duct)
Bladder (Bladder)
Bone Marrow (Bone Marrow)
Brainstem (Brainstem)
Breast (Breast)
Cerebellum (Cerebellum)
Cerebrum (Cerebrum)
Cervix (Cervix)
Chest (Chest)
Colon (Colon)
Cerebrospinal Fluid (CSF)
Duodenum (Duodenum)
Ear, External (Ear, External)
Ear, Inner (Ear, Inner)
Ear, Mid (Ear, Mid)
Esophagus (Esophagus)
Eye, Globe (Eye, Globe)
Eye, Orbit (Eye, Orbit)
Fallopian Tube (Fallopian Tube)
Feet (Feet)
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Femur (Femur)
Fibula (Fibula)
Hands (Hands)
Hilum, Thoracic (Hilum)
Humerus (Humerus)
Ileum (Ileum)
Iliac Bone (Iliac)
Jejunum (Jejunum)
Kidney (Kidney)
Liver (Liver)
Lymph Node (LN)
Lymph Node, Axilla (LN, Axilla)
Lymph Node, Brachial (LN, Brachial)
Lymph Node, Cervical (LN, Cervical)
Lymph Node, Epitrochlear (LN,
Epitrochlear)
Lymph Node, Femoral (LN, Femoral)
Lymph Node, Hilar (LN, Hilar)
Lymph Node, Iliac (LN, Iliac)
Lymph Node, Inguinal (LN, Inguinal)
Lymph Node, Internal Mammary (LN,
Internal Mammary)
Lymph Node, Mediastinal (LN,
Mediastinal)
Lymph Node, Mesenteric (LN,
Mesenteric)
Lymph Node, Mid-pelvis (LN, Mid Pelvis)
Lymph Node, Neck (LN, Neck)
Lymph Node, Occipital (LN, Occipital)
Lymph Node, Paraaortic (LN, Paraaortic)
Lymph Node, Pelvis (LN, Pelvis)
Lymph Node, Periauricular (LN,
Periauricular)
Lymph Node, Popliteal (LN, Popliteal)
Lymph Node, Retroperitoneal (LN,
Retroperitoneal)
Lymph Node(s), Subclavian (LN,
Subclavian)
Lymph Node, Submental (LN,
Submental)
Lymph Node, Supraclavicular (LN,
Supraclavicular)
Lung (Lung)
Lung, Anterior Left Lower Lobe (Lung,
Ant-LLL)
Lung, Anterior Left Upper Lobe (Lung,
Ant-LUL)
Lung, Anterior Right Lower Lobe (Lung,
Ant-RLL)
Lung, Anterior Right Middle Lobe (Lung,
Ant-RML)
Lung, Anterior Right Upper Lobe (Lung,
Ant-RUL)
Lung, Posterior Left Lower Lobe (Lung,
Post-LLL)
Lung, Posterior Left Upper Lobe (Lung,
Post-LUL)
Lung, Posterior Right Lower Lobe (Lung,
Post-RLL)
Lung, Posterior Right Middle Lobe (Lung,
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Post-RML)
Lung, Posterior Right Upper Lobe (Lung,
Post-RUL)
Mandible (Mandible)
Mediastinum (Mediastinum)
Mouth (Mouth)
Muscle, Lower Extremity Distal (Muscle,
LE DIstal)
Muscle, Lower Extremity Proximal
(Muscle, LE Proximal)
Muscle, Upper Extremity Distal (Muscle,
UE Distal)
Muscle, Upper Extremity Proximal
(Muscle, UE Proximal)
Nasopharynx (Nasopharynx)
Nose (Nose)
Other Site (Other Site)
Ovary (Ovary)
Pancreas (Pancreas)
Pelvis (Pelvis)
Penis (Penis)
Pericardium (Pericardium)
Peripheral Blood (Peripheral Blood)
Pharynx (Pharynx)
Pleura (Pleura)
Prostate (Prostate)
Radius (Radius)
Rectum (Rectum)
Ribs (Ribs)
Sigmoid Colon (Sigmoid Colon)
Sinuses (Sinuses)
Skin (Skin)
Skull (Skull)
Spine, Cervical (Spine-C)
Spine, Lumbar (Spine-L)
Spine, Sacral (Spine-S)
Spine, Thoracic (Spine-T)
Spleen (Spleen)
Sternum (Sternum)
Stomach (Stomach)
Testicle (Testicle)
Throat (Throat)
Thyroid (Thyroid)
Tibia (Tibia)
Ulna (Ulna)
Ureter (Ureter)
Uterus (Uterus)
Vagina (Vagina)
Procedure
Apheresis (Apheresis)
Arteriogram (Arteriogram)
Arthroscopy (Arthroscopy)
Aspirate, Bone Marrow (Aspirate, Bone
Marrow)
Aspirate, Ultrasound Guided (Aspirate,
Us Guided)
Audiogram (Audiogram)
Barium Enema (Barium Enema)
Barium Swallow (Barium Swallow)
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Biopsy (Biopsy)
Biopsy, Core Needle (Biopsy, Core
Needle)
Biopsy, Image Guided (Biopsy, Image
Guided)
Bone Marrow Cellularity (BM Cellularity)
Biopsy, Bone Marrow (Bone Marrow
Biopsy)
Bone Mineral Density (Bone Mineral
Density)
Bone Scan (Bone Scan)
Bone Spectometry (Bone Spectometry)
Bronchoalveolar Lavage
(Bronchoalveolar Lavage)
Bronchogram (Bronchogram)
Bronchoscopy (Bronchoscopy)
Bronchoscopy/lavage
(Bronchoscopy/Lavage)
Cardiac Catheterization (Cardiac
Catheterization)
Computerized Axial Tomography (CAT
(CT))
Cathetergram (Cathetergram)
Central Line Insertion (Central Line
Insertion)
Colonoscopy (Colonoscopy)
Culture Procedure (Culture)
Curative Surgery (Curative Surgery)
X-ray, Chest (CXR)
Cystogram (Cystogram)
Cystoscopy (Cystoscopy)
Cytology (Cytology)
Dental Examination (Dental
Examination)
Dental Procedure (Dental Procedure)
Dissection (Dissection)
Doppler Study (Doppler)
Electrocardiogram (ECG)
Echocardiogram (Echocardiogram)
Electroencephalogram (EEG)
Upper Endoscopy
Esophagogastroduodenoscopy (EGD)
Electrocardiogram (EKG)
Electromyography (EMG)
Endoscopy (Endoscopy)
Esophageal Dilation (Esophageal
dilation)
Esophagoscopy (Esophagoscopy)
Examination Under Anesthesia (EUA)
Excision (Excision)
Exercise Thallium (Exercise Thallium)
Eye Exam (Eye Exam)
Aspirate, Fine Needle (Fine Needle
Aspiration)
Flexible Fiberoptic Sigmoidoscopy
(Flexible Fiberoptic Sigmoidoscopy)
Fluoroscopy (Fluoroscopy)
Flow Cytometry (Flw Cyt)
Flow Cytometry, Blood (Flw Cyt Bld)
Flow Cytometry, Bone Marrow (Flw Cyt
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BM)
Holter Monitor (Holter Monitor)
Hyperbaric Treatment(s) (Hyperbaric
Treatment(s))
Hyperthermia (Hyperthermia)
Hysterosonogram (Hysterosonogram)
Incision & Drainage (I&D)
Laser Doppler Imaging (Imaging, Laser
Doppler)
Multispectral Imaging (Imaging,
Multispectral)
Near Infrared Imaging (Imaging, Near
Infrared)
Immunohistochemical Detection/staining
(Immunohistochemical Detection)
Infrared (Infrared)
Irrigation (Irrigation)
Intravenous Pyelogram (IVP)
X-ray, Abdominal (KUB)
Lymphangiogram (LAG)
Laparoscopy (Laparoscopy)
Laryngoscopy (Laryngoscopy)
Leukapheresis (Leukopheresis)
Lower Gastrointestinal Series (Lower GI)
Lumbar Puncture (LP)
Lumpectomy (Lumpectomy)
Lymphadenectomy (Lymphadenectomy)
Lymphocyte Harvest (Lymphocyte
Harvest)
Lymphocyte Infusion (Lymphocyte
Infusion)
Lymphopheresis With Scda Solution
(Lymphopheresis w/SCDA)
Mammogram (Mammogram)
Mammogram, Birad (Mammogram,
BIRAD)
Mammogram, Digitized (Mammogram,
DIGITIZED)
Mammogram, Wolfe (Mammogram,
WOLFE)
Mastectomy (Mastectomy)
Magnetic Resonance Imaging (MRI)
Magnetic Resonance Spectroscopy
(MRS)
Multi-gated Acquisition Scan (MUGA)
Nasopharyngeal Laryngoscopy
(Nasopharyngeal Laryngoscopy)
Nasopharyngoscopy
(Nasopharyngoscopy)
Nipple Suction Aspirate (Nipple Suction
Aspirate)
Ommaya Resevoir Tap (Ommaya
Resevoir Tap)
Papanicolaou Test (PAP)
Paracentesis (Paracentesis)
Physical Examination (PE)
Pelvic Exam (Pelvic Exam)
Peritoneoscopy (Peritoneoscopy)
Positron Emission Tomography (PET)
Positron Emission Tomography
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Computerized Tomography (PET CT)
Positron Emission Tomography With Fdg
(PET, FDG)
Positron Emission Tomography With O-
15 Water (h2o15) (PET, H2O15)
Pulmonary Function Test Interpretation
(PFT Interpretation)
Pulmonary Function Test/carbon
Monoxide Diffusing Capability
(PFT/DLCO)
Pulmonary Function Test/forced
Expiratory Volume 1 (PFT/FEV1)
Pulmonary Function Test/ Inspired
Oxygen Fraction (PFT/FIO2)
Photography (Photography)
Pleurodesis (Pleurodesis)
Portacath Placement (Portacath
Placement)
Percutaneous Transluminal Coronary
Angioplasty (PTCA)
Pulse Oximetry (Pulse Oximetry)
Renogram (Renogram)
Resection (Resection)
Radiofrequency Ablation (RFA)
Imaging Scan (Scan)
Scan, Blood Oxygenated Level
Dependant (bold) (Scan, BOLD)
Scan, Dynamic Contrast-enhanced
Magnetic Resonance Imaging (Scan,
DCE MRI)
Scan, Dual-energy X-ray Absorpitometry
(Scan, DEXA)
Scan, Gallium (Scan, Gallium)
Scan, Iodine 123 Uptake (Scan, I 123
Uptake)
Scan, I 131 Uptake (Scan, I 131 Uptake)
Scan, Indium (Scan, Indium WBC)
Scan, Lung Perfusion (Scan, Lung
Perfusion)
Scan, Sestamibi (Scan, Sestamibi)
Scan, Spiral Ct (Scan, Spiral CT)
Ventilation-perfusion Scan (Scan, VQ)
Scraping (Scraping)
Sigmoidoscopy (Sigmoidoscopy)
Skeletal Survey (Skeletal Survey)
Skin Test (Skin Test)
Splenectomy (Splenectomy)
Stress Thallium Test (Stress Thallium
Test)
Swallow Evaluation (Swallow Evaluation)
Thoracentesis (Thoracentesis)
Tomogram (Tomogram)
Transrectal Ultrasound (Transrect US)
Upper Gastrointestinal Series (UGI)
Upper Gastrointestinal Series W/small
Bowel Follow Through (UGI/w sm bowel
f/t)
Ultrasound (Ultrasound)
Urine Casts (Urine Casts)
Vascular Access Device Placement (VAD
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Placement)
Vaginogram (Vaginogram)
Venacavagrm (Venacavagrm)
Venogram (Venogram)
X-ray (X-Ray)
Procedure
Apheresis (Apheresis)
Arteriogram (Arteriogram)
Arthroscopy (Arthroscopy)
Aspirate, Bone Marrow (Aspirate, Bone
Marrow)
Aspirate, Ultrasound Guided (Aspirate,
Us Guided)
Audiogram (Audiogram)
Barium Enema (Barium Enema)
Barium Swallow (Barium Swallow)
Biopsy (Biopsy)
Biopsy, Core Needle (Biopsy, Core
Needle)
Biopsy, Image Guided (Biopsy, Image
Guided)
Bone Marrow Cellularity (BM Cellularity)
Biopsy, Bone Marrow (Bone Marrow
Biopsy)
Bone Mineral Density (Bone Mineral
Density)
Bone Scan (Bone Scan)
Bone Spectometry (Bone Spectometry)
Bronchoalveolar Lavage
(Bronchoalveolar Lavage)
Bronchogram (Bronchogram)
Bronchoscopy (Bronchoscopy)
Bronchoscopy/lavage
(Bronchoscopy/Lavage)
Cardiac Catheterization (Cardiac
Catheterization)
Computerized Axial Tomography (CAT
(CT))
Cathetergram (Cathetergram)
Central Line Insertion (Central Line
Insertion)
Colonoscopy (Colonoscopy)
Culture Procedure (Culture)
Curative Surgery (Curative Surgery)
X-ray, Chest (CXR)
Cystogram (Cystogram)
Cystoscopy (Cystoscopy)
Cytology (Cytology)
Dental Examination (Dental
Examination)
Dental Procedure (Dental Procedure)
Dissection (Dissection)
Doppler Study (Doppler)
Electrocardiogram (ECG)
Echocardiogram (Echocardiogram)
Electroencephalogram (EEG)
Upper Endoscopy
Esophagogastroduodenoscopy (EGD)
Electrocardiogram (EKG)
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Electromyography (EMG)
Endoscopy (Endoscopy)
Esophageal Dilation (Esophageal
dilation)
Esophagoscopy (Esophagoscopy)
Examination Under Anesthesia (EUA)
Excision (Excision)
Exercise Thallium (Exercise Thallium)
Eye Exam (Eye Exam)
Aspirate, Fine Needle (Fine Needle
Aspiration)
Flexible Fiberoptic Sigmoidoscopy
(Flexible Fiberoptic Sigmoidoscopy)
Fluoroscopy (Fluoroscopy)
Flow Cytometry (Flw Cyt)
Flow Cytometry, Blood (Flw Cyt Bld)
Flow Cytometry, Bone Marrow (Flw Cyt
BM)
Holter Monitor (Holter Monitor)
Hyperbaric Treatment(s) (Hyperbaric
Treatment(s))
Hyperthermia (Hyperthermia)
Hysterosonogram (Hysterosonogram)
Incision & Drainage (I&D)
Laser Doppler Imaging (Imaging, Laser
Doppler)
Multispectral Imaging (Imaging,
Multispectral)
Near Infrared Imaging (Imaging, Near
Infrared)
Immunohistochemical Detection/staining
(Immunohistochemical Detection)
Infrared (Infrared)
Irrigation (Irrigation)
Intravenous Pyelogram (IVP)
X-ray, Abdominal (KUB)
Lymphangiogram (LAG)
Laparoscopy (Laparoscopy)
Laryngoscopy (Laryngoscopy)
Leukapheresis (Leukopheresis)
Lower Gastrointestinal Series (Lower GI)
Lumbar Puncture (LP)
Lumpectomy (Lumpectomy)
Lymphadenectomy (Lymphadenectomy)
Lymphocyte Harvest (Lymphocyte
Harvest)
Lymphocyte Infusion (Lymphocyte
Infusion)
Lymphopheresis With Scda Solution
(Lymphopheresis w/SCDA)
Mammogram (Mammogram)
Mammogram, Birad (Mammogram,
BIRAD)
Mammogram, Digitized (Mammogram,
DIGITIZED)
Mammogram, Wolfe (Mammogram,
WOLFE)
Mastectomy (Mastectomy)
Magnetic Resonance Imaging (MRI)
Magnetic Resonance Spectroscopy
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(MRS)
Multi-gated Acquisition Scan (MUGA)
Nasopharyngeal Laryngoscopy
(Nasopharyngeal Laryngoscopy)
Nasopharyngoscopy
(Nasopharyngoscopy)
Nipple Suction Aspirate (Nipple Suction
Aspirate)
Ommaya Resevoir Tap (Ommaya
Resevoir Tap)
Papanicolaou Test (PAP)
Paracentesis (Paracentesis)
Physical Examination (PE)
Pelvic Exam (Pelvic Exam)
Peritoneoscopy (Peritoneoscopy)
Positron Emission Tomography (PET)
Positron Emission Tomography
Computerized Tomography (PET CT)
Positron Emission Tomography With Fdg
(PET, FDG)
Positron Emission Tomography With O-
15 Water (h2o15) (PET, H2O15)
Pulmonary Function Test Interpretation
(PFT Interpretation)
Pulmonary Function Test/carbon
Monoxide Diffusing Capability
(PFT/DLCO)
Pulmonary Function Test/forced
Expiratory Volume 1 (PFT/FEV1)
Pulmonary Function Test/ Inspired
Oxygen Fraction (PFT/FIO2)
Photography (Photography)
Pleurodesis (Pleurodesis)
Portacath Placement (Portacath
Placement)
Percutaneous Transluminal Coronary
Angioplasty (PTCA)
Pulse Oximetry (Pulse Oximetry)
Renogram (Renogram)
Resection (Resection)
Radiofrequency Ablation (RFA)
Imaging Scan (Scan)
Scan, Blood Oxygenated Level
Dependant (bold) (Scan, BOLD)
Scan, Dynamic Contrast-enhanced
Magnetic Resonance Imaging (Scan,
DCE MRI)
Scan, Dual-energy X-ray Absorpitometry
(Scan, DEXA)
Scan, Gallium (Scan, Gallium)
Scan, Iodine 123 Uptake (Scan, I 123
Uptake)
Scan, I 131 Uptake (Scan, I 131 Uptake)
Scan, Indium (Scan, Indium WBC)
Scan, Lung Perfusion (Scan, Lung
Perfusion)
Scan, Sestamibi (Scan, Sestamibi)
Scan, Spiral Ct (Scan, Spiral CT)
Ventilation-perfusion Scan (Scan, VQ)
Scraping (Scraping)
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Sigmoidoscopy (Sigmoidoscopy)
Skeletal Survey (Skeletal Survey)
Skin Test (Skin Test)
Splenectomy (Splenectomy)
Stress Thallium Test (Stress Thallium
Test)
Swallow Evaluation (Swallow Evaluation)
Thoracentesis (Thoracentesis)
Tomogram (Tomogram)
Transrectal Ultrasound (Transrect US)
Upper Gastrointestinal Series (UGI)
Upper Gastrointestinal Series W/small
Bowel Follow Through (UGI/w sm bowel
f/t)
Ultrasound (Ultrasound)
Urine Casts (Urine Casts)
Vascular Access Device Placement (VAD
Placement)
Vaginogram (Vaginogram)
Venacavagrm (Venacavagrm)
Venogram (Venogram)
X-ray (X-Ray)
Infectious Agent Name
Acinetobacter (Acinetobacter)
Adenovirus (Adenovirus)
Agrobacterium (Agrobacterium)
Alcaligenes (Alcaligenes)
Aspergillus Flavus (Aspergillus flavus)
Aspergillus Fumigatus (Aspergillus
fumigatus)
Aspergillus Niger (Aspergillus niger)
Aspergillus Terreus (Aspergillus terreus)
Aspergillus, Not Otherwise Specified
(Aspergillus, NOS)
Bacillus (Bacillus)
Bacteria (Bacterium)
Bacteroides (Bacteroides)
Bk Virus (BK Virus)
Bordetella Pertussis Bacterium
(Bordetella pertussis Bacterium)
Borrelia (Borrelia)
Branhamella Catarrhalis (Branhamella
catarrhalis)
Burkholderia Cepacia (Burkholderia
cepacia)
Campylobacter (Campylobacter)
Candida Albicans (Candida albicans)
Candida Krusei (Candida krusei)
Candida Lusitaniae (Candida lusitaniae)
Candida Parapsilosis (Candida
parapsilosis)
Candida Tropicalis (Candida tropicalis)
Candida, Not Otherwise Specified
(Candida, NOS)
Capnocytophaga (Capnocytophaga)
Chlamydia (Chlamydia)
Citrobacter (Citrobacter)
Clavispora Lusitaniae (Clavispora
lusitaniae)
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Clostridium Difficile (Clostridium difficile)
Clostridium Non-difficile (Clostridium
non-difficile)
Condyloma/warts (Condyloma/Warts)
Corynebacterium (Corynebacterium)
Coxiella (Coxiella)
Cryptococcosis (Cryptococcosis)
Cryptosporidium (Cryptosporidium)
Cytomegalovirus (Cytomegalovirus)
Dactylaria (Dactylaria)
Enterobacter (Enterobacter)
Enterococcus (Enterococcus)
Enterovirus (Enterovirus)
Epstein-barr Virus (Epstein-Barr Virus)
Escherichia Coli (Escherichia coli)
Exserohilum Species (Exserohilum
Species)
Fungi, Filamentous (Filamentous fungus,
NOS)
Flavimonas Flavimonas Flavimonas
(Flavimonas)
Flavobacterium (Flavobacterium)
Fusarium (Fusarium)
Fusobacteria (Fusobacterium)
Giardia (Giardia)
Gonorrhea (Gonorrhea)
Gram Negative Cocci (Gram negative
cocci)
Gram Negative Diplococci (Gram
negative diplococci)
Gram Negative Rod (Gram negative rod)
Gram Positive Bacillus (Gram positive
bacillus)
Gram Positive Cocci (Gram positive
cocci)
Haemophilus Influenzae (Haemophilus
influenzae)
Helicobacter Pylori (Helicobacter pylori)
Hepatitis A (Hepatitis A)
Hepatitis B Virus (Hepatitis B Virus)
Hepatitis C (Hepatitis C)
Hepatitis G (hepatitis G)
Hepatitis, Not Otherwise Specified
(Hepatitis, NOS)
Herpes Simplex (Herpes Simplex)
Herpes Zoster (Herpes Zoster)
Histoplasma (Histoplasma)
Human Immunodeficiency Virus (Human
Immunodeficiency Virus)
Hyphae (Hyphae)
Influenza (Influenza)
Klebsiella (Klebsiella)
Lactobacillus (Lactobacillus)
Legionella (Legionella)
Leptospira (Leptospira)
Leptotrichia (Leptotrichia)
Leuconostoc (Leuconostoc)
Listeria (Listeria)
Maltophilia (Maltophilia)
Methylobacterium (Methylobacterium)
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Micrococcus (Micrococcus)
Microsporidia (Microsporidia)
Moraxella (Moraxella)
Moraxella (branhamella) Catarrhalis
(Moraxella (Branhamella) catarrhalis)
Morganella Morganii (Morganella
morganii)
Mucor Species Mucor Species (Mucor
Species)
Mycobacterium Infection
(Mycobacterium)
Mycoplasma (Mycoplasma)
Neisseria Gonorrhoeae (Neisseria
gonorrhoeae)
Neisseria Meningitidis (Neisseria
meningitidis)
No Growth (No growth)
Nocardia (Nocardia)
Other Microorganism, Specify (Other)
Papillomavirus (Papillomavirus)
Parainfluenza (Parainfluenza)
Parvovirus B19, Human (Parvovirus B19,
Human)
Pneumocystis Carinii (Pneumocystis
carinii)
Polyomavirus (Polyomavirus)
Propionibacterium (Propionibacterium)
Proteus Mirabilis (Proteus mirabilis)
Protozoa, Not Otherwise Specified
(Protozoa, NOS)
Pseudomonas (Pseudomonas)
Pseudomonas Aeruginosa
(Pseudomonas aeruginosa)
Respiratory Syncytial Virus (Respiratory
Syncytial Virus)
Rhodococcus (Rhodococcus)
Rhodotorula Mucilaginosa (Rhodotorula
mucilaginosa)
Rickettsia (Rickettsia)
Rotavirus (Rotavirus)
Salmonella (Salmonella)
Scabies (Scabies)
Septate Hyphae (Septate hyphae)
Serratia (Serratia)
Shigella (Shigella)
Staphylococcus (Staphylococcus)
Staphylococcus Aureus (Staphylococcus
aureus)
Staphylococcus Coag Negative
(Staphylococcus coag negative)
Staphylococcus Epidermidis
(Staphylococcus epidermidis)
Staphylococcus Haemolyticus
Staphylococcus Haemolyticus
(Staphylococcus haemolyticus)
Staphylococcus Hominus
(Staphylococcus hominus)
Staphylococcus Hyphae
(Staphylococcus hyphae)
Staphylococcus Intermedius
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(Staphylococcus intermedius)
Staphylococcus Maltophilia
(Staphylococcus maltophilia)
Staphylococcus Warneri
(Staphylococcus warneri)
Stenotrophomonas Maltophilia
(Stenotrophomonas maltophilia)
Stomatococcus Mucilaginosis
(Stomatococcus mucilaginosis)
Strep Alpha Hemolytic (Streptococcul
alpha hemolytic)
Streptococcus (Streptococcus)
Streptococcus Mitis (Streptococcus
mitis)
Streptococcus Pneumoniae
(Streptococcus pneumoniae)
Streptococcus Pyogenes (Streptococcus
pyogenes)
Streptococcus Salivarius (Streptococcus
salivarius)
Streptococcus Viridans (Streptococcus
viridans)
Toxoplasma (Toxoplasma)
Treponema (Treponema)
Trichomonas (Trichomonas)
Tuberculosis, Not Otherwise Specified
(Tuberculosis, NOS)
Varicella (Varicella)
Vibrio (Vibrio)
Xanthomonas (Xanthomonas)
Yeast (Yeast)
Zygomycetes (Zygomycetes)
Treatment
3tc (lamivudine) (3TC)
Abacavir (Abacavir)
Acyclovir (Acyclovir)
Adefovir (Adefovir)
Amantadine Hydrochloride (Amantadine
HCL)
Amikacin (Amikacin)
Amoxicillin (Amoxicillin)
Amoxicillin-clavulanate Potassium
(Amoxicillin/Clavulanate Potassium)
Amphotercin B (Amphotericin B)
Amphotericin B Liposomal (Amphotericin
B Liposomal)
Ampicillin (Ampicillin)
Ampicillin Sodium/sulbactam Sodium
(Ampicillin Sodium/Sulbactam Sodium)
Amprenavir (Amprenavir)
Anidulafungin (Anidulafungin)
Atovoquone (Atovoquone)
Azithromycin (Azithromycin)
Aztreonam (Aztreonam)
Bacitracin (Bacitracin)
Bacitracin Zinc (Bacitracin Zinc)
Benzylpenicillin Sodium (Benzylpenicillin
Sodium)
Caspofungin (Caspofungin)
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Cefaclor (Cefaclor)
Cefadroxil (Cefadroxil)
Cefazolin (Cefazolin)
Cefdinir (Cefdinir)
Cefepime (Cefepime HCL)
Cefotaxime Sodium (Cefotaxime
Sodium)
Cefoxitin Sodium (Cefoxitin Sodium)
Cefpodoxime (Cefpodoxime)
Cefprozil (Cefprozil)
Ceftazidime (Ceftazidime)
Ceftriaxone (Ceftriaxone)
Cefuroxime Axetil (Cefuroxime Axetil)
Cephalexin (Cephalexin)
Cidofovir (Cidofovir)
Ciprofloxacin (Ciprofloxacin)
Clarithromycin (Clarithromycin)
Clindamycin (Clindamycin)
Clotrimazole (Clotrimazole)
Colistimethate (Colistimethate)
Lamivudine/zidovudine (Combivir)
Trimethoprim-sulfamethoxazole
(Cotrimoxazole)
Dapsone (Dapsone)
Daptomycin (Daptomycin)
Zalcitabine (ddC)
Didanosine (ddI)
Double Pharmaceutical Strength
Didanosine (ddi DS)
Delavirdine Mesylate (Delavirdine
Mesylate)
Demeclocycline (Demeclocycline HCL)
Dicloxacillin (Dicloxacillin)
Extended Release Dosage Form
Didanosine (Didanosine EC)
Doxycycline Calcium (Doxycycline
Calcium)
Doxycycline Monohydrate (Doxycycline
Chloride)
Doxycycline Hyclate (Doxycycline
Hyclate)
Doxycycline Monohydrate (Doxycycline
Monohydrate)
Efavirenz (Efavirenz)
Erythromycin (Erythromycin)
Ethambutol (Ethambutol HCL)
Famciclovir (Famciclovir)
Fluconazole (Fluconazole)
Foscarnet Sodium (Foscarnet Sodium)
Ganciclovir (Ganciclovir)
Gatifloxacin (Gatifloxacin)
Gentamicin (Gentamicin)
Imipenem (Imipenem)
Imipenem-cilastatin Sodium
(Imipenem/Cilastatin)
Indinavir Sulfate (Indinavir)
Isoniazid (Isoniazid)
Itraconazole (Itraconazole)
Ivermectin (Ivermectin)
Ketoconazole (Ketoconazole)
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Levofloxacin (Levofloxacin)
Linezolid (Linezolid)
Lopinavir (Lopinavir)
Lopinavir/ritonavir (Lopinavir/Ritonavir)
Meropenem (Meropenem)
Metronidazole (Metronidazole)
Micafungin (Micafungin Sodium)
Miconazole (Miconazole)
Moxifloxacin (Moxifloxacin HCL)
Mupirocin (Mupirocin)
Nafcillin (Nafcillin)
Nelfinavir (Nelfinavir)
Neosporin Cream (Neosporin)
Nevirapine (Nevirapine)
Nitrofurantoin (Nitrofurantoin)
Nystatin (Nystatin)
Ofloxacin (Ofloxacin)
Oseltamivir (Oseltamivir)
Oxacillin Sodium (Oxacillin Sodium)
Penicillin V (Penicillin V)
Pentamidine (Pentamidine Isethionate)
Permethrin (Permethrin)
Penicillin V (Phenoxymethylpenicillin)
Piperacillin Sodium (Piperacillin)
Piperacillin-tazobactam (Piperacillin
Sodium/Tazobactam Sodium)
Pyrimethamine (Pyrimethamine)
Ribavirin (Ribavirin)
Rifabutin (Rifabutin)
Rifampin (Rifampin)
Ritonavir (Ritonavir)
Saquinavir (Saquinavir)
Sulfacetamide (Sulfacetamide)
Sulfadiazine (Sulfadiazine)
Trimethoprim-sulfamethoxazole
(Sulfamethoxazole/Trimethoprim)
Double Pharmaceutical Strength
Trimethoprim-sulfamethoxazole
(Sulfamethoxazole/Trimethoprim
(Bactrim) DS)
Tenofovir (Tenofovir)
Terbinafine (Terbinafine HCL)
Terconazole (Terconazole)
Tetracycline (Tetracycline HCL)
Ticarcillin Disodium (Ticarcillin Disodium)
Tobramycin (Tobramycin)
Undecylenic Acid (Undecyclenic Acid)
Urised (Urised)
Valacyclovir (Valacyclovir HCL)
Valganciclovir (Valganciclovir)
Vancomycin (Vancomycin)
Voriconazole (Voriconazole)
Adverse Event Outcome
Recovered (1)
Still Under Treatment/ Observation (2)
Alive With Sequelae (3)
Died (4)
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Pre-Study - PRIOR SURGERY
SUPPLEMENT - 2398212v1.0
Prior Surgery form for C3D 3.12 Adopters
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=FF2F7B22-
5065-707B-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/5742
PRIOR SURGERY SUPPLEMENT
Prior Surgery Supplement
Surgery Date
Procedure
Apheresis (Apheresis)
Arteriogram (Arteriogram)
Arthroscopy (Arthroscopy)
Aspirate, Bone Marrow (Aspirate, Bone
Marrow)
Aspirate, Ultrasound Guided (Aspirate,
Us Guided)
Audiogram (Audiogram)
Barium Enema (Barium Enema)
Barium Swallow (Barium Swallow)
Biopsy (Biopsy)
Biopsy, Core Needle (Biopsy, Core
Needle)
Biopsy, Image Guided (Biopsy, Image
Guided)
Bone Marrow Cellularity (BM Cellularity)
Biopsy, Bone Marrow (Bone Marrow
Biopsy)
Bone Mineral Density (Bone Mineral
Density)
Bone Scan (Bone Scan)
Bone Spectometry (Bone Spectometry)
Bronchoalveolar Lavage
(Bronchoalveolar Lavage)
Bronchogram (Bronchogram)
Bronchoscopy (Bronchoscopy)
Bronchoscopy/lavage
(Bronchoscopy/Lavage)
Cardiac Catheterization (Cardiac
Catheterization)
Computerized Axial Tomography (CAT
(CT))
Cathetergram (Cathetergram)
Central Line Insertion (Central Line
Insertion)
Colonoscopy (Colonoscopy)
Culture Procedure (Culture)
Curative Surgery (Curative Surgery)
X-ray, Chest (CXR)
Cystogram (Cystogram)
Cystoscopy (Cystoscopy)
Cytology (Cytology)
Dental Examination (Dental
Examination)
Dental Procedure (Dental Procedure)
Dissection (Dissection)
Doppler Study (Doppler)
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Electrocardiogram (ECG)
Echocardiogram (Echocardiogram)
Electroencephalogram (EEG)
Upper Endoscopy
Esophagogastroduodenoscopy (EGD)
Electrocardiogram (EKG)
Electromyography (EMG)
Endoscopy (Endoscopy)
Esophageal Dilation (Esophageal
dilation)
Esophagoscopy (Esophagoscopy)
Examination Under Anesthesia (EUA)
Excision (Excision)
Exercise Thallium (Exercise Thallium)
Eye Exam (Eye Exam)
Aspirate, Fine Needle (Fine Needle
Aspiration)
Flexible Fiberoptic Sigmoidoscopy
(Flexible Fiberoptic Sigmoidoscopy)
Fluoroscopy (Fluoroscopy)
Flow Cytometry (Flw Cyt)
Flow Cytometry, Blood (Flw Cyt Bld)
Flow Cytometry, Bone Marrow (Flw Cyt
BM)
Holter Monitor (Holter Monitor)
Hyperbaric Treatment(s) (Hyperbaric
Treatment(s))
Hyperthermia (Hyperthermia)
Hysterosonogram (Hysterosonogram)
Incision & Drainage (I&D)
Laser Doppler Imaging (Imaging, Laser
Doppler)
Multispectral Imaging (Imaging,
Multispectral)
Near Infrared Imaging (Imaging, Near
Infrared)
Immunohistochemical Detection/staining
(Immunohistochemical Detection)
Infrared (Infrared)
Irrigation (Irrigation)
Intravenous Pyelogram (IVP)
X-ray, Abdominal (KUB)
Lymphangiogram (LAG)
Laparoscopy (Laparoscopy)
Laryngoscopy (Laryngoscopy)
Leukapheresis (Leukopheresis)
Lower Gastrointestinal Series (Lower GI)
Lumbar Puncture (LP)
Lumpectomy (Lumpectomy)
Lymphadenectomy (Lymphadenectomy)
Lymphocyte Harvest (Lymphocyte
Harvest)
Lymphocyte Infusion (Lymphocyte
Infusion)
Lymphopheresis With Scda Solution
(Lymphopheresis w/SCDA)
Mammogram (Mammogram)
Mammogram, Birad (Mammogram,
BIRAD)
Mammogram, Digitized (Mammogram,
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DIGITIZED)
Mammogram, Wolfe (Mammogram,
WOLFE)
Mastectomy (Mastectomy)
Magnetic Resonance Imaging (MRI)
Magnetic Resonance Spectroscopy
(MRS)
Multi-gated Acquisition Scan (MUGA)
Nasopharyngeal Laryngoscopy
(Nasopharyngeal Laryngoscopy)
Nasopharyngoscopy
(Nasopharyngoscopy)
Nipple Suction Aspirate (Nipple Suction
Aspirate)
Ommaya Resevoir Tap (Ommaya
Resevoir Tap)
Papanicolaou Test (PAP)
Paracentesis (Paracentesis)
Physical Examination (PE)
Pelvic Exam (Pelvic Exam)
Peritoneoscopy (Peritoneoscopy)
Positron Emission Tomography (PET)
Positron Emission Tomography
Computerized Tomography (PET CT)
Positron Emission Tomography With Fdg
(PET, FDG)
Positron Emission Tomography With O-
15 Water (h2o15) (PET, H2O15)
Pulmonary Function Test Interpretation
(PFT Interpretation)
Pulmonary Function Test/carbon
Monoxide Diffusing Capability
(PFT/DLCO)
Pulmonary Function Test/forced
Expiratory Volume 1 (PFT/FEV1)
Pulmonary Function Test/ Inspired
Oxygen Fraction (PFT/FIO2)
Photography (Photography)
Pleurodesis (Pleurodesis)
Portacath Placement (Portacath
Placement)
Percutaneous Transluminal Coronary
Angioplasty (PTCA)
Pulse Oximetry (Pulse Oximetry)
Renogram (Renogram)
Resection (Resection)
Radiofrequency Ablation (RFA)
Imaging Scan (Scan)
Scan, Blood Oxygenated Level
Dependant (bold) (Scan, BOLD)
Scan, Dynamic Contrast-enhanced
Magnetic Resonance Imaging (Scan,
DCE MRI)
Scan, Dual-energy X-ray Absorpitometry
(Scan, DEXA)
Scan, Gallium (Scan, Gallium)
Scan, Iodine 123 Uptake (Scan, I 123
Uptake)
Scan, I 131 Uptake (Scan, I 131 Uptake)
Scan, Indium (Scan, Indium WBC)
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Scan, Lung Perfusion (Scan, Lung
Perfusion)
Scan, Sestamibi (Scan, Sestamibi)
Scan, Spiral Ct (Scan, Spiral CT)
Ventilation-perfusion Scan (Scan, VQ)
Scraping (Scraping)
Sigmoidoscopy (Sigmoidoscopy)
Skeletal Survey (Skeletal Survey)
Skin Test (Skin Test)
Splenectomy (Splenectomy)
Stress Thallium Test (Stress Thallium
Test)
Swallow Evaluation (Swallow Evaluation)
Thoracentesis (Thoracentesis)
Tomogram (Tomogram)
Transrectal Ultrasound (Transrect US)
Upper Gastrointestinal Series (UGI)
Upper Gastrointestinal Series W/small
Bowel Follow Through (UGI/w sm bowel
f/t)
Ultrasound (Ultrasound)
Urine Casts (Urine Casts)
Vascular Access Device Placement (VAD
Placement)
Vaginogram (Vaginogram)
Venacavagrm (Venacavagrm)
Venogram (Venogram)
X-ray (X-Ray)
Site
Abdomen (Abdomen)
Abdomen/pelvis (Abdomen/Pelvis)
Abdominal Wall (Abdominal wall)
Acetabulum (Acetabulum)
Adrenal Gland (Adrenal gland)
Anal Canal (Anal canal)
Anal Sphincter (Anal sphincter)
Ankle (Ankle)
Anorectum (Anorectum)
Antecubital Fossa (Antecubital fossa)
Anus (Anus)
Aorta (Aorta)
Appendix (Appendix)
Aqueous Fluid (Aqueous Fluid)
Arm (Arm)
Artery (Artery)
Ascending Colon (Ascending colon)
Auditory Canal (Auditory canal)
Autonomic Nervous System (Autonomic
nervous system)
Axilla (Axilla)
Back (Back)
Bile Duct (Bile duct)
Bladder (Bladder)
Blood (Blood)
Blood Vessel (Blood vessel)
Bone (Bone)
Bone Marrow (Bone marrow)
Bowel (Bowel)
Brain (Brain)
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Brain Stem (Brain stem)
Breast (Breast)
Broad Ligament (Broad ligament)
Bronchiole (Bronchiole)
Bronchus (Bronchus)
Bronchus And Lung (Bronchus and
Lung)
Brow (Brow)
Buccal Cavity (Buccal cavity)
Buccal Mucosa (Buccal mucosa)
Buttock (Buttock)
Calf (Calf)
Carina (Carina)
Carotid Artery (Carotid artery)
Cecum (Cecum)
Central Line Catheter (Central Line
Catheter)
Central Nervous System (Central
nervous system)
Cerebellum (Cerebellum)
Cerebral Cortex (Cerebral cortex)
Cerebrospinal Fluid (Cerebrospinal fluid)
Cerebrum (Cerebrum)
Cervical Spine (Cervical spine)
Cervical/thoracic/lumbar Spine
(Cervical/Thoracic/Lumbar spine)
Cervix (Cervix)
Chest (Chest)
Chest Wall (Chest wall)
Chest/abdomen/pelvis
(Chest/Abdomen/Pelvis)
Chest/pelvis (Chest/Pelvis)
Chin (Chin)
Clavicle (Clavicle)
Colon (Colon)
Colon And Rectum (Colon and rectum)
Common Duct (Common duct)
Conjunctiva (Conjunctiva)
Connective Tissue (Connective tissue)
Descending Colon (Descending colon)
Diaphragm (Diaphragm)
Duodenum (Duodenum)
Ear (Ear)
Ear Canal (Ear canal)
External Ear (Ear, Pinna (External))
Elbow (Elbow)
Endocrine Gland (Endocrine gland)
Epididymis (Epididymis)
Esophagogastric Junction
(Esophagogastric junction)
Esophagus (Esophagus)
Eye (Eye)
Fallopian Tube (Fallopian tube)
Femur (Femur)
Fibula (Fibula)
Finger (Finger)
Foot (Foot)
Forearm (Forearm)
Forehead (Forehead)
Frontal Lobe (Frontal lobe)
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Fundus Of Stomach (Fundus of
stomach)
Gallbladder (Gallbladder)
Gastrointestinal Tract (Gastrointestinal
tract)
Genitourinary (Genitourinary)
Groin (Groin)
Gum (Gum)
Hand (Hand)
Hard Palate (Hard palate)
Head - Face Or Neck, Nos (Head - face
or neck, NOS)
Head/neck (Head/Neck)
Head/neck/chest/adb/pelvis
(Head/Neck/Chest/Adb/Pelvis)
Heart (Heart)
Hepatic Duct (Hepatic duct)
Hip (Hip)
Humerus (Humerus)
Hypopharynx (Hypopharynx)
Ileum (Ileum)
Ilium (Ilium)
Intestine (Intestine)
Ischium (Ischium)
Jaw (Jaw)
Jejunum (Jejunum)
Joints (Joints)
Kidney (Kidney)
Knee (Knee)
Large Bowel (Large bowel)
Laryngopharynx (Laryngopharynx)
Larynx (Larynx)
Leg (Leg)
Lip (Lip)
Liver (Liver)
Liver And Intrahepatic Duct (Liver and
intrahepatic duct)
Liver/spleen (Liver/Spleen)
Lumbar Spine (Lumbar spine)
Lung (Lung)
Lymph Node (Lymph node)
Lymph Node(s) Axilla (Lymph Node(s)
Axilla)
Lymph Node(s) Cervical (Lymph Node(s)
Cervical)
Lymph Node(s) Hilar (Lymph Node(s)
Hilar)
Lymph Node(s) Inguinal (Lymph Node(s)
Inguinal)
Lymph Node(s) Int Mammary (Lymph
Node(s) Int Mammary)
Lymph Node(s) Mammary (Lymph
Node(s) Mammary)
Lymph Node(s) Pelvic (Lymph Node(s)
Pelvic)
Lymph Node(s) Supraclav (Lymph
Node(s) Supraclav)
Lymph Nodes (Lymph nodes)
Lymphoma (Lymphoma)
Mammary Gland (Mammary Gland)
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Mandible (Mandible)
Maxilla (Maxilla)
Mediastinum (Mediastinum)
Mesentery (Mesentery)
Mini Mantle (Mini Mantle)
Mouth (Mouth)
Muscle (Muscle)
Nasal Cavity (Nasal Cavity)
Nasopharynx (Nasopharynx)
Neck (Neck)
Neck/chest/abdomen/pelvis
(Neck/Chest/Abdomen/Pelvis)
Nerve (Nerve)
Ocular Orbits (Ocular Orbits)
Omentum (Omentum)
Oral Cavity (Oral cavity)
Ovary (Ovary)
Posterior Anterior/lateral (PA/Lat)
Palate (Palate)
Pancreas (Pancreas)
Parotid Gland (Parotid gland)
Patella (Patella)
Pelvis (Pelvis)
Penis (Penis)
Perianus (Perianus)
Pericardium (Pericardium)
Peritoneal Cavity (Peritoneal cavity)
Pharynx (Pharynx)
Pituitary Gland (Pituitary gland)
Pleura (Pleura)
Popliteal Fossa (Popliteal fossa)
Prostate (Prostate)
Pylorus (Pylorus)
Rectum (Rectum)
Retina (Retina)
Retroperitoneum (Retroperitoneum)
Ribs (Ribs)
Round Ligament (Round ligament)
Sacrum (Sacrum)
Salivary Gland (Salivary gland)
Scalp (Scalp)
Scapula (Scapula)
Scrotum (Scrotum)
Shoulder (Shoulder)
Sigmoid Colon (Sigmoid colon)
Sinus(es) (Sinus(es))
Sinus(es), Maxillary (Sinus(es),
Maxillary)
Skin (Skin)
Skull (Skull)
Small Intestine (Small intestine)
Soft Tissue (Soft Tissue)
Spine (Spine)
Spine/femur (Spine/Femur)
Spine/femur/radius
(Spine/Femur/Radius)
Spleen (Spleen)
Sternum (Sternum)
Stomach (Stomach)
Subcutaneous Tissue (Subcutaneous
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tissue)
Testicle (Testicle)
Thigh (Thigh)
Thoracic Spine (Thoracic spine)
Thoracic/lumbar Spine (Thoracic/Lumbar
spine)
Thorax (Thorax)
Throat (Throat)
Thymus (Thymus)
Thyroid Gland (Thyroid gland)
Tibia (Tibia)
Tongue (Tongue)
Tongue, Base Of Tongue (Tongue, Base
of tongue)
Tonsil (Tonsil)
Trachea (Trachea)
Trunk (Trunk)
Ureter (Ureter)
Urinary Tract (Urinary tract)
Uterus (Uterus)
Uvula (Uvula)
Vagina (Vagina)
Vertebra (Vertebra)
Vertebral Column (Vertebral column)
Vulva (Vulva)
Whole Body (Whole body)
Wrist (Wrist)
Findings
Residual Disease Extent
Therapeutic Intent Indicator
No (N)
Yes (Y)
Comments
Note Date
Research Comments Text
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On-Study - CARDIAC - 2406850v1.0
Cardiac form for C3D 3.12 Adopters
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=014B7099-
D329-3E1B-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/5743
CARDIAC
Cardiac
Course Number
Course Day Number
Evaluation Date
Lab Collection Time
Procedure
Apheresis (Apheresis)
Arteriogram (Arteriogram)
Arthroscopy (Arthroscopy)
Aspirate, Bone Marrow (Aspirate, Bone
Marrow)
Aspirate, Ultrasound Guided (Aspirate,
Us Guided)
Audiogram (Audiogram)
Barium Enema (Barium Enema)
Barium Swallow (Barium Swallow)
Biopsy (Biopsy)
Biopsy, Core Needle (Biopsy, Core
Needle)
Biopsy, Image Guided (Biopsy, Image
Guided)
Bone Marrow Cellularity (BM Cellularity)
Biopsy, Bone Marrow (Bone Marrow
Biopsy)
Bone Mineral Density (Bone Mineral
Density)
Bone Scan (Bone Scan)
Bone Spectometry (Bone Spectometry)
Bronchoalveolar Lavage
(Bronchoalveolar Lavage)
Bronchogram (Bronchogram)
Bronchoscopy (Bronchoscopy)
Bronchoscopy/lavage
(Bronchoscopy/Lavage)
Cardiac Catheterization (Cardiac
Catheterization)
Computerized Axial Tomography (CAT
(CT))
Cathetergram (Cathetergram)
Central Line Insertion (Central Line
Insertion)
Colonoscopy (Colonoscopy)
Culture Procedure (Culture)
Curative Surgery (Curative Surgery)
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X-ray, Chest (CXR)
Cystogram (Cystogram)
Cystoscopy (Cystoscopy)
Cytology (Cytology)
Dental Examination (Dental
Examination)
Dental Procedure (Dental Procedure)
Dissection (Dissection)
Doppler Study (Doppler)
Electrocardiogram (ECG)
Echocardiogram (Echocardiogram)
Electroencephalogram (EEG)
Upper Endoscopy
Esophagogastroduodenoscopy (EGD)
Electrocardiogram (EKG)
Electromyography (EMG)
Endoscopy (Endoscopy)
Esophageal Dilation (Esophageal
dilation)
Esophagoscopy (Esophagoscopy)
Examination Under Anesthesia (EUA)
Excision (Excision)
Exercise Thallium (Exercise Thallium)
Eye Exam (Eye Exam)
Aspirate, Fine Needle (Fine Needle
Aspiration)
Flexible Fiberoptic Sigmoidoscopy
(Flexible Fiberoptic Sigmoidoscopy)
Fluoroscopy (Fluoroscopy)
Flow Cytometry (Flw Cyt)
Flow Cytometry, Blood (Flw Cyt Bld)
Flow Cytometry, Bone Marrow (Flw Cyt
BM)
Holter Monitor (Holter Monitor)
Hyperbaric Treatment(s) (Hyperbaric
Treatment(s))
Hyperthermia (Hyperthermia)
Hysterosonogram (Hysterosonogram)
Incision & Drainage (I&D)
Laser Doppler Imaging (Imaging, Laser
Doppler)
Multispectral Imaging (Imaging,
Multispectral)
Near Infrared Imaging (Imaging, Near
Infrared)
Immunohistochemical Detection/staining
(Immunohistochemical Detection)
Infrared (Infrared)
Irrigation (Irrigation)
Intravenous Pyelogram (IVP)
X-ray, Abdominal (KUB)
Lymphangiogram (LAG)
Laparoscopy (Laparoscopy)
Laryngoscopy (Laryngoscopy)
Leukapheresis (Leukopheresis)
Lower Gastrointestinal Series (Lower GI)
Lumbar Puncture (LP)
Lumpectomy (Lumpectomy)
Lymphadenectomy (Lymphadenectomy)
Lymphocyte Harvest (Lymphocyte
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Harvest)
Lymphocyte Infusion (Lymphocyte
Infusion)
Lymphopheresis With Scda Solution
(Lymphopheresis w/SCDA)
Mammogram (Mammogram)
Mammogram, Birad (Mammogram,
BIRAD)
Mammogram, Digitized (Mammogram,
DIGITIZED)
Mammogram, Wolfe (Mammogram,
WOLFE)
Mastectomy (Mastectomy)
Magnetic Resonance Imaging (MRI)
Magnetic Resonance Spectroscopy
(MRS)
Multi-gated Acquisition Scan (MUGA)
Nasopharyngeal Laryngoscopy
(Nasopharyngeal Laryngoscopy)
Nasopharyngoscopy
(Nasopharyngoscopy)
Nipple Suction Aspirate (Nipple Suction
Aspirate)
Ommaya Resevoir Tap (Ommaya
Resevoir Tap)
Papanicolaou Test (PAP)
Paracentesis (Paracentesis)
Physical Examination (PE)
Pelvic Exam (Pelvic Exam)
Peritoneoscopy (Peritoneoscopy)
Positron Emission Tomography (PET)
Positron Emission Tomography
Computerized Tomography (PET CT)
Positron Emission Tomography With Fdg
(PET, FDG)
Positron Emission Tomography With O-
15 Water (h2o15) (PET, H2O15)
Pulmonary Function Test Interpretation
(PFT Interpretation)
Pulmonary Function Test/carbon
Monoxide Diffusing Capability
(PFT/DLCO)
Pulmonary Function Test/forced
Expiratory Volume 1 (PFT/FEV1)
Pulmonary Function Test/ Inspired
Oxygen Fraction (PFT/FIO2)
Photography (Photography)
Pleurodesis (Pleurodesis)
Portacath Placement (Portacath
Placement)
Percutaneous Transluminal Coronary
Angioplasty (PTCA)
Pulse Oximetry (Pulse Oximetry)
Renogram (Renogram)
Resection (Resection)
Radiofrequency Ablation (RFA)
Imaging Scan (Scan)
Scan, Blood Oxygenated Level
Dependant (bold) (Scan, BOLD)
Scan, Dynamic Contrast-enhanced
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Magnetic Resonance Imaging (Scan,
DCE MRI)
Scan, Dual-energy X-ray Absorpitometry
(Scan, DEXA)
Scan, Gallium (Scan, Gallium)
Scan, Iodine 123 Uptake (Scan, I 123
Uptake)
Scan, I 131 Uptake (Scan, I 131 Uptake)
Scan, Indium (Scan, Indium WBC)
Scan, Lung Perfusion (Scan, Lung
Perfusion)
Scan, Sestamibi (Scan, Sestamibi)
Scan, Spiral Ct (Scan, Spiral CT)
Ventilation-perfusion Scan (Scan, VQ)
Scraping (Scraping)
Sigmoidoscopy (Sigmoidoscopy)
Skeletal Survey (Skeletal Survey)
Skin Test (Skin Test)
Splenectomy (Splenectomy)
Stress Thallium Test (Stress Thallium
Test)
Swallow Evaluation (Swallow Evaluation)
Thoracentesis (Thoracentesis)
Tomogram (Tomogram)
Transrectal Ultrasound (Transrect US)
Upper Gastrointestinal Series (UGI)
Upper Gastrointestinal Series W/small
Bowel Follow Through (UGI/w sm bowel
f/t)
Ultrasound (Ultrasound)
Urine Casts (Urine Casts)
Vascular Access Device Placement (VAD
Placement)
Vaginogram (Vaginogram)
Venacavagrm (Venacavagrm)
Venogram (Venogram)
X-ray (X-Ray)
Cardiac Preejection Period Percentage
LV Ejection Fraction
LV Ejection Time
Comments
Note Date
Research Comments Text
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On-Study - PROCEDURES - 2406656v1.0
Procedures form for C3D 3.12 Adopters
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=014A5424-
E723-5F82-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/5744
PROCEDURES
Procedures
Course Number
Course Day Number
Evaluation Date
Lab Collection Time
Procedure
Apheresis (Apheresis)
Arteriogram (Arteriogram)
Arthroscopy (Arthroscopy)
Aspirate, Bone Marrow (Aspirate, Bone
Marrow)
Aspirate, Ultrasound Guided (Aspirate,
Us Guided)
Audiogram (Audiogram)
Barium Enema (Barium Enema)
Barium Swallow (Barium Swallow)
Biopsy (Biopsy)
Biopsy, Core Needle (Biopsy, Core
Needle)
Biopsy, Image Guided (Biopsy, Image
Guided)
Bone Marrow Cellularity (BM Cellularity)
Biopsy, Bone Marrow (Bone Marrow
Biopsy)
Bone Mineral Density (Bone Mineral
Density)
Bone Scan (Bone Scan)
Bone Spectometry (Bone Spectometry)
Bronchoalveolar Lavage
(Bronchoalveolar Lavage)
Bronchogram (Bronchogram)
Bronchoscopy (Bronchoscopy)
Bronchoscopy/lavage
(Bronchoscopy/Lavage)
Cardiac Catheterization (Cardiac
Catheterization)
Computerized Axial Tomography (CAT
(CT))
Cathetergram (Cathetergram)
Central Line Insertion (Central Line
Insertion)
Colonoscopy (Colonoscopy)
Culture Procedure (Culture)
Curative Surgery (Curative Surgery)
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X-ray, Chest (CXR)
Cystogram (Cystogram)
Cystoscopy (Cystoscopy)
Cytology (Cytology)
Dental Examination (Dental
Examination)
Dental Procedure (Dental Procedure)
Dissection (Dissection)
Doppler Study (Doppler)
Electrocardiogram (ECG)
Echocardiogram (Echocardiogram)
Electroencephalogram (EEG)
Upper Endoscopy
Esophagogastroduodenoscopy (EGD)
Electrocardiogram (EKG)
Electromyography (EMG)
Endoscopy (Endoscopy)
Esophageal Dilation (Esophageal
dilation)
Esophagoscopy (Esophagoscopy)
Examination Under Anesthesia (EUA)
Excision (Excision)
Exercise Thallium (Exercise Thallium)
Eye Exam (Eye Exam)
Aspirate, Fine Needle (Fine Needle
Aspiration)
Flexible Fiberoptic Sigmoidoscopy
(Flexible Fiberoptic Sigmoidoscopy)
Fluoroscopy (Fluoroscopy)
Flow Cytometry (Flw Cyt)
Flow Cytometry, Blood (Flw Cyt Bld)
Flow Cytometry, Bone Marrow (Flw Cyt
BM)
Holter Monitor (Holter Monitor)
Hyperbaric Treatment(s) (Hyperbaric
Treatment(s))
Hyperthermia (Hyperthermia)
Hysterosonogram (Hysterosonogram)
Incision & Drainage (I&D)
Laser Doppler Imaging (Imaging, Laser
Doppler)
Multispectral Imaging (Imaging,
Multispectral)
Near Infrared Imaging (Imaging, Near
Infrared)
Immunohistochemical Detection/staining
(Immunohistochemical Detection)
Infrared (Infrared)
Irrigation (Irrigation)
Intravenous Pyelogram (IVP)
X-ray, Abdominal (KUB)
Lymphangiogram (LAG)
Laparoscopy (Laparoscopy)
Laryngoscopy (Laryngoscopy)
Leukapheresis (Leukopheresis)
Lower Gastrointestinal Series (Lower GI)
Lumbar Puncture (LP)
Lumpectomy (Lumpectomy)
Lymphadenectomy (Lymphadenectomy)
Lymphocyte Harvest (Lymphocyte
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Harvest)
Lymphocyte Infusion (Lymphocyte
Infusion)
Lymphopheresis With Scda Solution
(Lymphopheresis w/SCDA)
Mammogram (Mammogram)
Mammogram, Birad (Mammogram,
BIRAD)
Mammogram, Digitized (Mammogram,
DIGITIZED)
Mammogram, Wolfe (Mammogram,
WOLFE)
Mastectomy (Mastectomy)
Magnetic Resonance Imaging (MRI)
Magnetic Resonance Spectroscopy
(MRS)
Multi-gated Acquisition Scan (MUGA)
Nasopharyngeal Laryngoscopy
(Nasopharyngeal Laryngoscopy)
Nasopharyngoscopy
(Nasopharyngoscopy)
Nipple Suction Aspirate (Nipple Suction
Aspirate)
Ommaya Resevoir Tap (Ommaya
Resevoir Tap)
Papanicolaou Test (PAP)
Paracentesis (Paracentesis)
Physical Examination (PE)
Pelvic Exam (Pelvic Exam)
Peritoneoscopy (Peritoneoscopy)
Positron Emission Tomography (PET)
Positron Emission Tomography
Computerized Tomography (PET CT)
Positron Emission Tomography With Fdg
(PET, FDG)
Positron Emission Tomography With O-
15 Water (h2o15) (PET, H2O15)
Pulmonary Function Test Interpretation
(PFT Interpretation)
Pulmonary Function Test/carbon
Monoxide Diffusing Capability
(PFT/DLCO)
Pulmonary Function Test/forced
Expiratory Volume 1 (PFT/FEV1)
Pulmonary Function Test/ Inspired
Oxygen Fraction (PFT/FIO2)
Photography (Photography)
Pleurodesis (Pleurodesis)
Portacath Placement (Portacath
Placement)
Percutaneous Transluminal Coronary
Angioplasty (PTCA)
Pulse Oximetry (Pulse Oximetry)
Renogram (Renogram)
Resection (Resection)
Radiofrequency Ablation (RFA)
Imaging Scan (Scan)
Scan, Blood Oxygenated Level
Dependant (bold) (Scan, BOLD)
Scan, Dynamic Contrast-enhanced
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Magnetic Resonance Imaging (Scan,
DCE MRI)
Scan, Dual-energy X-ray Absorpitometry
(Scan, DEXA)
Scan, Gallium (Scan, Gallium)
Scan, Iodine 123 Uptake (Scan, I 123
Uptake)
Scan, I 131 Uptake (Scan, I 131 Uptake)
Scan, Indium (Scan, Indium WBC)
Scan, Lung Perfusion (Scan, Lung
Perfusion)
Scan, Sestamibi (Scan, Sestamibi)
Scan, Spiral Ct (Scan, Spiral CT)
Ventilation-perfusion Scan (Scan, VQ)
Scraping (Scraping)
Sigmoidoscopy (Sigmoidoscopy)
Skeletal Survey (Skeletal Survey)
Skin Test (Skin Test)
Splenectomy (Splenectomy)
Stress Thallium Test (Stress Thallium
Test)
Swallow Evaluation (Swallow Evaluation)
Thoracentesis (Thoracentesis)
Tomogram (Tomogram)
Transrectal Ultrasound (Transrect US)
Upper Gastrointestinal Series (UGI)
Upper Gastrointestinal Series W/small
Bowel Follow Through (UGI/w sm bowel
f/t)
Ultrasound (Ultrasound)
Urine Casts (Urine Casts)
Vascular Access Device Placement (VAD
Placement)
Vaginogram (Vaginogram)
Venacavagrm (Venacavagrm)
Venogram (Venogram)
X-ray (X-Ray)
Site
Abdomen (Abdomen)
Abdomen/pelvis (Abdomen/Pelvis)
Abdominal Wall (Abdominal wall)
Acetabulum (Acetabulum)
Adrenal Gland (Adrenal gland)
Anal Canal (Anal canal)
Anal Sphincter (Anal sphincter)
Ankle (Ankle)
Anorectum (Anorectum)
Antecubital Fossa (Antecubital fossa)
Anus (Anus)
Aorta (Aorta)
Appendix (Appendix)
Aqueous Fluid (Aqueous Fluid)
Arm (Arm)
Artery (Artery)
Ascending Colon (Ascending colon)
Auditory Canal (Auditory canal)
Autonomic Nervous System (Autonomic
nervous system)
Axilla (Axilla)
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Back (Back)
Bile Duct (Bile duct)
Bladder (Bladder)
Blood (Blood)
Blood Vessel (Blood vessel)
Bone (Bone)
Bone Marrow (Bone marrow)
Bowel (Bowel)
Brain (Brain)
Brain Stem (Brain stem)
Breast (Breast)
Broad Ligament (Broad ligament)
Bronchiole (Bronchiole)
Bronchus (Bronchus)
Bronchus And Lung (Bronchus and
Lung)
Brow (Brow)
Buccal Cavity (Buccal cavity)
Buccal Mucosa (Buccal mucosa)
Buttock (Buttock)
Calf (Calf)
Carina (Carina)
Carotid Artery (Carotid artery)
Cecum (Cecum)
Central Line Catheter (Central Line
Catheter)
Central Nervous System (Central
nervous system)
Cerebellum (Cerebellum)
Cerebral Cortex (Cerebral cortex)
Cerebrospinal Fluid (Cerebrospinal fluid)
Cerebrum (Cerebrum)
Cervical Spine (Cervical spine)
Cervical/thoracic/lumbar Spine
(Cervical/Thoracic/Lumbar spine)
Cervix (Cervix)
Chest (Chest)
Chest Wall (Chest wall)
Chest/abdomen/pelvis
(Chest/Abdomen/Pelvis)
Chest/pelvis (Chest/Pelvis)
Chin (Chin)
Clavicle (Clavicle)
Colon (Colon)
Colon And Rectum (Colon and rectum)
Common Duct (Common duct)
Conjunctiva (Conjunctiva)
Connective Tissue (Connective tissue)
Descending Colon (Descending colon)
Diaphragm (Diaphragm)
Duodenum (Duodenum)
Ear (Ear)
Ear Canal (Ear canal)
External Ear (Ear, Pinna (External))
Elbow (Elbow)
Endocrine Gland (Endocrine gland)
Epididymis (Epididymis)
Esophagogastric Junction
(Esophagogastric junction)
Esophagus (Esophagus)
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Eye (Eye)
Fallopian Tube (Fallopian tube)
Femur (Femur)
Fibula (Fibula)
Finger (Finger)
Foot (Foot)
Forearm (Forearm)
Forehead (Forehead)
Frontal Lobe (Frontal lobe)
Fundus Of Stomach (Fundus of
stomach)
Gallbladder (Gallbladder)
Gastrointestinal Tract (Gastrointestinal
tract)
Genitourinary (Genitourinary)
Groin (Groin)
Gum (Gum)
Hand (Hand)
Hard Palate (Hard palate)
Head - Face Or Neck, Nos (Head - face
or neck, NOS)
Head/neck (Head/Neck)
Head/neck/chest/adb/pelvis
(Head/Neck/Chest/Adb/Pelvis)
Heart (Heart)
Hepatic Duct (Hepatic duct)
Hip (Hip)
Humerus (Humerus)
Hypopharynx (Hypopharynx)
Ileum (Ileum)
Ilium (Ilium)
Intestine (Intestine)
Ischium (Ischium)
Jaw (Jaw)
Jejunum (Jejunum)
Joints (Joints)
Kidney (Kidney)
Knee (Knee)
Large Bowel (Large bowel)
Laryngopharynx (Laryngopharynx)
Larynx (Larynx)
Leg (Leg)
Lip (Lip)
Liver (Liver)
Liver And Intrahepatic Duct (Liver and
intrahepatic duct)
Liver/spleen (Liver/Spleen)
Lumbar Spine (Lumbar spine)
Lung (Lung)
Lymph Node (Lymph node)
Lymph Node(s) Axilla (Lymph Node(s)
Axilla)
Lymph Node(s) Cervical (Lymph Node(s)
Cervical)
Lymph Node(s) Hilar (Lymph Node(s)
Hilar)
Lymph Node(s) Inguinal (Lymph Node(s)
Inguinal)
Lymph Node(s) Int Mammary (Lymph
Node(s) Int Mammary)
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Lymph Node(s) Mammary (Lymph
Node(s) Mammary)
Lymph Node(s) Pelvic (Lymph Node(s)
Pelvic)
Lymph Node(s) Supraclav (Lymph
Node(s) Supraclav)
Lymph Nodes (Lymph nodes)
Lymphoma (Lymphoma)
Mammary Gland (Mammary Gland)
Mandible (Mandible)
Maxilla (Maxilla)
Mediastinum (Mediastinum)
Mesentery (Mesentery)
Mini Mantle (Mini Mantle)
Mouth (Mouth)
Muscle (Muscle)
Nasal Cavity (Nasal Cavity)
Nasopharynx (Nasopharynx)
Neck (Neck)
Neck/chest/abdomen/pelvis
(Neck/Chest/Abdomen/Pelvis)
Nerve (Nerve)
Ocular Orbits (Ocular Orbits)
Omentum (Omentum)
Oral Cavity (Oral cavity)
Ovary (Ovary)
Posterior Anterior/lateral (PA/Lat)
Palate (Palate)
Pancreas (Pancreas)
Parotid Gland (Parotid gland)
Patella (Patella)
Pelvis (Pelvis)
Penis (Penis)
Perianus (Perianus)
Pericardium (Pericardium)
Peritoneal Cavity (Peritoneal cavity)
Pharynx (Pharynx)
Pituitary Gland (Pituitary gland)
Pleura (Pleura)
Popliteal Fossa (Popliteal fossa)
Prostate (Prostate)
Pylorus (Pylorus)
Rectum (Rectum)
Retina (Retina)
Retroperitoneum (Retroperitoneum)
Ribs (Ribs)
Round Ligament (Round ligament)
Sacrum (Sacrum)
Salivary Gland (Salivary gland)
Scalp (Scalp)
Scapula (Scapula)
Scrotum (Scrotum)
Shoulder (Shoulder)
Sigmoid Colon (Sigmoid colon)
Sinus(es) (Sinus(es))
Sinus(es), Maxillary (Sinus(es),
Maxillary)
Skin (Skin)
Skull (Skull)
Small Intestine (Small intestine)
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Soft Tissue (Soft Tissue)
Spine (Spine)
Spine/femur (Spine/Femur)
Spine/femur/radius
(Spine/Femur/Radius)
Spleen (Spleen)
Sternum (Sternum)
Stomach (Stomach)
Subcutaneous Tissue (Subcutaneous
tissue)
Testicle (Testicle)
Thigh (Thigh)
Thoracic Spine (Thoracic spine)
Thoracic/lumbar Spine (Thoracic/Lumbar
spine)
Thorax (Thorax)
Throat (Throat)
Thymus (Thymus)
Thyroid Gland (Thyroid gland)
Tibia (Tibia)
Tongue (Tongue)
Tongue, Base Of Tongue (Tongue, Base
of tongue)
Tonsil (Tonsil)
Trachea (Trachea)
Trunk (Trunk)
Ureter (Ureter)
Urinary Tract (Urinary tract)
Uterus (Uterus)
Uvula (Uvula)
Vagina (Vagina)
Vertebra (Vertebra)
Vertebral Column (Vertebral column)
Vulva (Vulva)
Whole Body (Whole body)
Wrist (Wrist)
Finding Results Indicator
Abnormal (A)
No Change (C)
Equivocal (E)
Negative (G)
Improving (I)
Not Applicable (L)
Normal (N)
No Source Data (O)
Positive (P)
Stable (S)
Unstable (U)
Not Evaluable (V)
Worse (W)
Not Examined (X)
Findings
Comments
Note Date
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SIOP CNS GCT II Basic registration data
SIOP CNS GCT II: Prospective Trial for the Diagnosis and
Treatment of Children, Adolescents and Young Adults With
Intracranial Germ Cell Tumors. Principal Investigator
Gabriele Calaminus, MD.
http://clinicaltrials.gov/show/NCT01424839
All rights reserved. Please visit https://medical-data-
models.org/forms/5749
Basic registration data
Study participation
Datum der Dokumentation*
Teilnahme*
Einwilligung gegeben*
Nein (1)
Ja (2)
Bemerkungen
Patient transfer
Studien-ID neu
Studien-ID
Marvin-ID*
Identification numbers
GPOH PID
UPN*
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SIOP CNS GCT II Admission for diagnosis
SIOP CNS GCT II: Prospective Trial for the Diagnosis and
Treatment of Children, Adolescents and Young Adults With
Intracranial Germ Cell Tumors. Principal Investigator
Gabriele Calaminus, MD.
http://clinicaltrials.gov/show/NCT01424839
All rights reserved. Please visit https://medical-data-
models.org/forms/5751
Admission for diagnosis
Show identification of patient
Dummy
Admission for diagnosis
Datum der klinischen Untersuchung*
Grund der Einweisung*
Symptome aufgetreten (1)
Asymptomatisch, aus anderen Gründen
festgestellt (2)
Tumor festgestellt bei folgender Untersuchung*
First clinical symptom
Zeit seit dem ersten klinischen Symptom*
Welches war das erste klinische Symptom*
Allgemeinbefinden gesunken (1)
Ataxie des Stammes (10)
Extremitätensteifheit oder -lähmung (11)
Aufmerksamkeits- und
Gedächtnisstörungen (12)
Andere neurologische Symptome oder
Anzeichen (13)
Diabetes insipidus (14)
DI mit starkem Durstgefühl (15)
ACTH Auffälligkeiten (16)
TSH Auffälligkeiten (17)
HGH Auffälligkeiten (18)
FSH Auffälligkeiten (19)
Erhöhter intrakranialer Druck (2)
LH Auffälligkeiten (20)
Prolactin Auffälligkeiten (21)
Anderes Symptom (22)
Bewusstseinsstörungen (3)
Krämpfe (4)
Sehstörungen (5)
Einschränkung der Hirnnerven III, IV, VI
(6)
Gesichtslähmung (7)
Einschränkung der Hirnnerven IX, X, XI
(8)
Ataxie der Arme (9)
Anderes Symptom*
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Admission preoperatively - 1
Datum der klinischen Untersuchung*
Allgemeinbefinden nach Lansky/Karnofsky*
Tod (0)
10% (10)
100% (100)
20% (20)
30% (30)
40% (40)
50% (50)
60% (60)
70% (70)
80% (80)
90% (90)
ErhÃ¶hter intrakranialer Druck*
Nein (1)
Ja (2)
BewusstseinsstÃ¶rungen*
Nein (1)
Schläfrigkeit (2)
Koma (3)
Trat ein Krampfanfall auf*
Nein (1)
Ja (2)
Traten SehstÃ¶rungen auf*
Nein (1)
Ja (2)
Admission preoperatively - 2
SehstÃ¶rung*
Parinaud´s Syndrom (2)
Diplopia (3)
Gesichtsfeldeinschränkungen (4)
Admission preoperatively - 3
Trat ein Ausfall der Nerven III, IV, VI auf*
Nein (1)
Ja (2)
Trat eine LÃ¤hmung des Gesichts auf*
Nein (1)
Ja (2)
Trat ein Ausfall der Nerven IX, X, XI auf*
Nein (1)
Ja (2)
Trat eine Ataxie der Arme auf*
Nein (1)
Ja (2)
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SIOP CNS GCT II Admission for diagnosis
Trat eine Ataxie des Stamms auf*
Nein (1)
Ja (2)
Trat eine Steifheit oder LÃ¤hmung der
ExtremitÃ¤ten auf*
Nein (1)
Ja (2)
Traten Aufmerksamkeits- oder
GedÃ¤chtnisstÃ¶rungen auf*
Nein (1)
Ja (2)
Traten andere neurologische Symptome oder
Anzeichen auf*
Nein (1)
Ja (2)
Welche andere neurologische Symptome oder
Anzeichen traten auf*
Trat Diabetes insipidus auf*
Nein (1)
Ja (2)
Trat der Diabetes insipidus mit starkem
DurstgefÃ¼hl auf*
Nein (1)
Ja (2)
ACTH*
Normal (1)
Erhöht (2)
Erniedrigt (3)
TSH*
Normal (1)
Erhöht (2)
Erniedrigt (3)
HGH*
Normal (1)
Erhöht (2)
Erniedrigt (3)
FSH*
Normal (1)
Erhöht (2)
Erniedrigt (3)
LH*
Normal (1)
Erhöht (2)
Erniedrigt (3)
Prolactin*
Normal (1)
Erhöht (2)
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SIOP CNS GCT II Admission for diagnosis
Erniedrigt (3)
Traten andere Symptome oder Anzeichen auf*
Nein (1)
Ja (2)
Anderes Symptom, das bisher nicht aufgefÃ¼hrt
wurde*
Admission postoperatively/pretreatment -
1
Datum der klinischen Untersuchung*
Allgemeinbefinden nach Lansky/Karnofsky*
Tod (0)
10% (10)
100% (100)
20% (20)
30% (30)
40% (40)
50% (50)
60% (60)
70% (70)
80% (80)
90% (90)
ErhÃ¶hter intrakranialer Druck*
Nein (1)
Ja (2)
BewusstseinsstÃ¶rungen*
Nein (1)
Schläfrigkeit (2)
Koma (3)
Trat ein Krampfanfall auf*
Nein (1)
Ja (2)
Traten SehstÃ¶rungen auf*
Nein (1)
Ja (2)
Admission postoperatively/pretreatment -
2
SehstÃ¶rung*
Parinaud´s Syndrom (2)
Diplopia (3)
Gesichtsfeldeinschränkungen (4)
Admission postoperatively/pretreatment -
3
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SIOP CNS GCT II Admission for diagnosis
Trat ein Ausfall der Nerven III, IV, VI auf*
Nein (1)
Ja (2)
Trat eine LÃ¤hmung des Gesichts auf*
Nein (1)
Ja (2)
Trat ein Ausfall der Nerven IX, X, XI auf*
Nein (1)
Ja (2)
Trat eine Ataxie der Arme auf*
Nein (1)
Ja (2)
Trat eine Ataxie des Stamms auf*
Nein (1)
Ja (2)
Trat eine Steifheit oder LÃ¤hmung der
ExtremitÃ¤ten auf*
Nein (1)
Ja (2)
Traten Aufmerksamkeits- oder
GedÃ¤chtnisstÃ¶rungen auf*
Nein (1)
Ja (2)
Traten andere neurologische Symptome oder
Anzeichen auf*
Nein (1)
Ja (2)
Welche andere neurologische Symptome oder
Anzeichen traten auf*
Trat Diabetes insipidus auf*
Nein (1)
Ja (2)
Trat der Diabetes insipidus mit starkem
DurstgefÃ¼hl auf*
Nein (1)
Ja (2)
ACTH*
Normal (1)
Erhöht (2)
Erniedrigt (3)
TSH*
Normal (1)
Erhöht (2)
Erniedrigt (3)
HGH*
Normal (1)
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SIOP CNS GCT II Admission for diagnosis
Erhöht (2)
Erniedrigt (3)
FSH*
Normal (1)
Erhöht (2)
Erniedrigt (3)
LH*
Normal (1)
Erhöht (2)
Erniedrigt (3)
Prolactin*
Normal (1)
Erhöht (2)
Erniedrigt (3)
Traten andere Symptome oder Anzeichen auf*
Nein (1)
Ja (2)
Anderes Symptom, das bisher nicht aufgefÃ¼hrt
wurde*
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SIOP CNS GCT II Admission for diagnosis
SIOP CNS GCT II Medical history
SIOP CNS GCT II: Prospective Trial for the Diagnosis and
Treatment of Children, Adolescents and Young Adults With
Intracranial Germ Cell Tumors. Principal Investigator
Gabriele Calaminus, MD.
http://clinicaltrials.gov/show/NCT01424839
All rights reserved. Please visit https://medical-data-
models.org/forms/5752
Medical history
Show identification of patient
Dummy
Patient’s anamnesis
Trisomie 21*
Nein (1)
Ja (2)
Anderes Syndrom*
Nein (1)
Ja (2)
Pineale Zyste*
Nein (1)
Ja (2)
Andere Fehlbildungen*
Nein (1)
Ja (2)
LymphozytÃ¤re Infiltration der Hypophyse*
Nein (1)
Ja (2)
Seit wann besteht diese LymphozytÃ¤re
Hypophyseninfiltration*
Langerhans-Zellhistiozytose*
Nein (1)
Ja (2)
Seit wann besteht diese Langerhans-
Zellhistiozytose*
Andere intrakraniale Erkrankung*
Nein (1)
Ja (2)
Welche andere intrakraniale Erkrankung*
Seit wann besteht diese andere intrakraniale
Erkrankung*
Patient’s previous Treatment
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FrÃ¼here offene Operation*
Nein (1)
Ja (2)
Datum der frÃ¼heren OP*
FrÃ¼here Chemotherapie*
Nein (1)
Ja (2)
Welche frÃ¼here Chemotherapie*
Beginn der frÃ¼heren Chemotherapie*
Ende der frÃ¼heren Chemotherapie*
FrÃ¼here Bestrahlungstherapie*
Nein (1)
Ja (2)
Welche frÃ¼here Bestrahlungstherapie*
Beginn der frÃ¼heren Radiotherapie*
Ende der frÃ¼heren Radiotherapie*
FrÃ¼here andere Tumortherapie*
Nein (1)
Ja (2)
Welche frÃ¼here Tumortherapie*
Beginn der frÃ¼heren Tumortherapie*
Ende der frÃ¼heren Tumortherapie*
Family´s medical history
Sind Tumore (inklusive benigne Keimzelltumoren)
oder maligne Erkrankungen in der biologischen
Familie des Patienten bekannt?*
Nein (1)
Ja (2)
Disease in the family
Erkrankung*
Teratom (1)
Germinom (2)
Sez. KZT (3)
Andere Histologie/Erkrankung (4)
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SIOP CNS GCT II Medical history
Verwandtschaftsgrad*
Vater (1)
Mutter (2)
Geschwister (3)
Großeltern (4)
Onkel/Tante (5)
Cousin/Cousine (6)
Andere Blutsverwandte (7)
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SIOP CNS GCT II Medical history
SIOP CNS GCT II Response evaluation
SIOP CNS GCT II: Prospective Trial for the Diagnosis and
Treatment of Children, Adolescents and Young Adults With
Intracranial Germ Cell Tumors. Principal Investigator
Gabriele Calaminus, MD.
http://clinicaltrials.gov/show/NCT01424839
All rights reserved. Please visit https://medical-data-
models.org/forms/5754
Response evaluation
Show identification of patient
Dummy
Response
Zeitpunkt*
Nach 1. Kurs Chemotherapie (1)
Nach 2. Kurs Chemotherapie (2)
Nach 3. Kurs Chemotherapie (3)
Nach 4. Kurs Chemotherapie (4)
Nach Radiotherapie (5)
Anderer Zeitpunkt (6)
Anderer Zeitpunkt*
Response evaluation: Cranial imaging
Bildgebung durchgefÃ¼hrt*
Nein (1)
Ja (2)
Datum*
Technik*
MRT (1)
Andere (2)
Andere Technik, welche*
Response evaluation: Tumour site pineal
Tumor gefunden*
Nein (1)
Ja (2)
TumorlÃ¤nge*
Tumorbreite*
TumorhÃ¶he*
Tumorvolumen*
1 / 3
Response evaluation: Tumour site supra-
/intrasellar
Tumor gefunden*
Nein (1)
Ja (2)
TumorlÃ¤nge*
Tumorbreite*
TumorhÃ¶he*
Tumorvolumen*
Response evaluation: Other tumour site
Tumor gefunden*
Nein (1)
Ja (2)
Wo ist die andere Lokalisation*
TumorlÃ¤nge*
Tumorbreite*
TumorhÃ¶he*
Tumorvolumen*
Response evaluation: Tumour volume
Volumen*
Befund im Vergleich zu frÃ¼herer Bildgebung*
Kein Tumorgewebe sichtbar (CR) (1)
> 50% Volumenreduktion (PR) (2)
< 50% Volumenreduktion (SD) (3)
> 25% Größenzunahme einer
messbaren Läsion und/oder Auftreten
einer neuen Läsion (PD) (4)
Response evaluation: Cranial imaging
Bildgebung durchgefÃ¼hrt*
Nein (1)
Ja (2)
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SIOP CNS GCT II Response evaluation
Datum*
Technik*
MRT (1)
Andere (2)
Andere Technik, welche*
Befund im Vergleich zu frÃ¼herer Bildgebung*
Kein Tumorgewebe sichtbar (CR) (1)
> 50% Volumenreduktion (PR) (2)
< 50% Volumenreduktion (SD) (3)
> 25% Größenzunahme einer
messbaren Läsion und/oder Auftreten
einer neuen Läsion (PD) (4)
CSF cytology
Liquor-Zytologie durchgefÃ¼hrt*
Nein (1)
Ja (2)
Datum der Liquor-Zytologie*
Tumorzellen im Liquor*
Nein (1)
Ja (2)
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SIOP CNS GCT II Response evaluation
SIOP CNS GCT II Death of patient
SIOP CNS GCT II: Prospective Trial for the Diagnosis and
Treatment of Children, Adolescents and Young Adults With
Intracranial Germ Cell Tumors. Principal Investigator
Gabriele Calaminus, MD.
http://clinicaltrials.gov/show/NCT01424839
All rights reserved. Please visit https://medical-data-
models.org/forms/5756
Death of patient
Show identification of patient
Dummy
Death of patient
Patient verstorben am*
Todesursache*
Tod bedingt durch*
Primärtumor (Ersterkrankung) (1)
Zweitmalignom (2)
Therapie (3)
Anderer Grund (4)
Unklar (5)
Autopsie durchgefÃ¼hrt*
Nein (1)
Ja (2)
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SIOP CNS GCT II Date of diagnosis and
start of therapy
SIOP CNS GCT II: Prospective Trial for the Diagnosis and
Treatment of Children, Adolescents and Young Adults With
Intracranial Germ Cell Tumors. Principal Investigator
Gabriele Calaminus, MD.
http://clinicaltrials.gov/show/NCT01424839
All rights reserved. Please visit https://medical-data-
models.org/forms/5757
Date of diagnosis and start of
therapy
Show identification of patient
Dummy
Date of diagnosis and start of therapy
Diagnosedatum*
Alter bei Diagnose*
Wurde bereits mit der Therapie begonnen*
Nein (1)
Ja (2)
Therapiestart am*
Womit wurde/wird die Therapie begonnen*
CarboPEI (Germinom, nicht
metastasiert) (1)
PEI (NGGCT) (2)
Radiotherapie (Germinom, metastasiert)
(3)
Resektion (4)
Individuelle Therapie (Teratom) (5)
Anderer Therapiestart (6)
Andere Starttherapie*
Andere Chemotherapie (1)
Andere Radiotherapie (2)
Beschreibung sonstige Starttherapie*
Status of patient and therapy
recommendation
Protpat
Protokollpatient (1)
OP zu spät (10)
OP nicht nach Protokoll-Richtlinien
durchgeführt (11)
Diagnostik nicht vollständig (12)
Diagnoseänderung, nicht KZT (13)
Nicht genug Information (14)
Weitere histologische Komponente (nicht
KZT) (15)
Andere Chemotherapie (2)
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Zu wenig Chemotherapie (3)
Zu viel Chemotherapie (4)
Andere Bestrahlung (5)
Zu wenig Bestrahlung (6)
Zu viel Bestrahlung (7)
Operation nicht indiziert (8)
OP zu früh (9)
Welche Therapieempfehlung wurde geschickt
Lokalisierte Germinome (1)
Metastasierte Germinome (2)
Lokalisierte NGGCT Standardrisiko (3)
Lokalisierte NGGCT Hochrisiko (4)
Metastasierte NGGCT Standardrisiko (5)
Metastasierte NGGCT Hochrisiko (6)
Teratom (7)
Andere/individuell (8)
Patient verstorben*
Nein (1)
Ja (2)
2 / 2
SIOP CNS GCT II Date of diagnosis and start of therapy
SIOP CNS GCT II Summary of therapy
SIOP CNS GCT II: Prospective Trial for the Diagnosis and
Treatment of Children, Adolescents and Young Adults With
Intracranial Germ Cell Tumors. Principal Investigator
Gabriele Calaminus, MD.
http://clinicaltrials.gov/show/NCT01424839
All rights reserved. Please visit https://medical-data-
models.org/forms/5758
Summary of therapy
Show identification of patient
Dummy
Summary chemotherapy
Chemotherapiestart
Chemotherapieende
Chemotherapie protokollgemÃ¤ÃŸ verabreicht*
Nein (1)
Ja (2)
Warum war die Chemotherapie nicht
protokollgerecht*
Therapie angepasst wegen Toxizitäten
(1)
Therapie angepasst wegen klinischem
Status (2)
Therapie musste aus med. Gründen
abgebrochen/unterbrochen werden (3)
Patient hatte Progress/Rezidiv (4)
Therapie wegen 2. Tumor verändert (5)
Patient unter Therapie verstorben (6)
Kein rechtfertigender Grund -->
Beobachtungspatient (9)
Summary radiotherapy
Radiotherapiestart
Radiotherapieende
Radiotherapie protokollgemÃ¤ÃŸ verabreicht*
Nein (1)
Ja (2)
Warum war die Radiotherapie nicht
protokollgerecht*
Therapie angepasst wegen Toxizitäten
(1)
Therapie angepasst wegen klinischem
Status (2)
Therapie musste aus med. Gründen
abgebrochen/unterbrochen werden (3)
Patient hatte Progress/Rezidiv (4)
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Therapie wegen 2. Tumor verändert (5)
Patient unter Therapie verstorben (6)
Kein rechtfertigender Grund -->
Beobachtungspatient (9)
Summary surgery
Anzahl Tumoroperationen*
Summary other therapy
Wurde noch weitere Therapie durchgefÃ¼hrt*
Nein (1)
Hyperthermie (2)
Knochenmarktransplantation (3)
Stammzellsupport (4)
Andere (5)
Welche andere Therapie*
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SIOP CNS GCT II Summary of therapy
SIOP CNS GCT II Patient condition at
therapy end
SIOP CNS GCT II: Prospective Trial for the Diagnosis and
Treatment of Children, Adolescents and Young Adults With
Intracranial Germ Cell Tumors. Principal Investigator
Gabriele Calaminus, MD.
http://clinicaltrials.gov/show/NCT01424839
All rights reserved. Please visit https://medical-data-
models.org/forms/5759
Patient condition at therapy end
Show identification of patient
Dummy
Patient´s condition at therapy end
Status des Patienten*
Komplette Remission (CR) (1)
Partielle Remission (PR) (2)
Progress (PD) (3)
Rezidiv (4)
2. Tumor (5)
An Tumorerkrankung verstorben (DOD)
(6)
An Komplikationen verstorben (DOC) (7)
Verstorben, sonstiger Grund (8)
Lost to Follow-up (LFU) (9)
Protpat
Protokollpatient (1)
OP zu spät (10)
OP nicht nach Protokoll-Richtlinien
durchgeführt (11)
Diagnostik nicht vollständig (12)
Diagnoseänderung, nicht KZT (13)
Nicht genug Information (14)
Weitere histologische Komponente (nicht
KZT) (15)
Andere Chemotherapie (2)
Zu wenig Chemotherapie (3)
Zu viel Chemotherapie (4)
Andere Bestrahlung (5)
Zu wenig Bestrahlung (6)
Zu viel Bestrahlung (7)
Operation nicht indiziert (8)
OP zu früh (9)
1 / 1
SIOP CNS GCT II Event date
SIOP CNS GCT II: Prospective Trial for the Diagnosis and
Treatment of Children, Adolescents and Young Adults With
Intracranial Germ Cell Tumors. Principal Investigator
Gabriele Calaminus, MD.
http://clinicaltrials.gov/show/NCT01424839
All rights reserved. Please visit https://medical-data-
models.org/forms/5760
Event date
Event date
Event-Datum*
Datum der Dokumentation*
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SIOP CNS GCT II SIOP CNS GCT II
participation
SIOP CNS GCT II: Prospective Trial for the Diagnosis and
Treatment of Children, Adolescents and Young Adults With
Intracranial Germ Cell Tumors. Principal Investigator
Gabriele Calaminus, MD.
http://clinicaltrials.gov/show/NCT01424839
All rights reserved. Please visit https://medical-data-
models.org/forms/5763
SIOP CNS GCT II participation
Redirect
Einwilligung gegeben*
Nein (1)
Ja (2)
Datum der Einwilligung*
Studien-ID in dieser Studie
furtherstudyid
Teilnahme*
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SIOP CNS GCT II Tumour markers
SIOP CNS GCT II: Prospective Trial for the Diagnosis and
Treatment of Children, Adolescents and Young Adults With
Intracranial Germ Cell Tumors. Principal Investigator
Gabriele Calaminus, MD.
http://clinicaltrials.gov/show/NCT01424839
All rights reserved. Please visit https://medical-data-
models.org/forms/5764
Tumour markers
Show identification of patient
Dummy
Measurement
Zeitpunkt der Messung*
Während Therapie (1)
Im Follow-up (2)
Tumormarker im Serum gemessen*
Nein (1)
Ja (2)
Tumormarker im Liquor gemessen*
Nein (1)
Ja (2)
Tumour markers in serum
Datum der Blutabnahme*
AFP*
AFP in ng/ml*
HCG*
Tumour markers in CSF
Datum der Liquorentnahme*
AFP*
AFP in ng/ml*
HCG*
Default.ItemGroup.503
Formular-Datum*
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SIOP CNS GCT II Initial tumour markers
SIOP CNS GCT II: Prospective Trial for the Diagnosis and
Treatment of Children, Adolescents and Young Adults With
Intracranial Germ Cell Tumors. Principal Investigator
Gabriele Calaminus, MD.
http://clinicaltrials.gov/show/NCT01424839
All rights reserved. Please visit https://medical-data-
models.org/forms/5765
Initial tumour markers
Show identification of patient
Dummy
Tumour markers in serum at diagnosis
Tumormarker im Serum bei Diagnose bestimmt*
Nein (1)
Ja (2)
Datum der Blutabnahme*
Zuordnung der Tumormarker zum zeitlichen
Ablauf der Therapie*
Präoperativ (falls OP erfolgt/geplant) (1)
Postoperativ (falls OP erfolgt) (2)
Prätherapeutisch (falls OP nach Chemo
bzw. Bestrahlung geplant) (3)
Erster AFP-Wert*
Erster AFP-Wert in ng/ml*
Erster HCG-Wert*
AFP-Wert erhÃ¶ht*
Normal (1)
Erhöht, aber physiologisch, weil Patient <
730 Tage alt (2)
Erhöht, Dottersacktumor (3)
HCG-Wert erhÃ¶ht*
Normal (1)
Erhöht, aber physiologisch, weil Patient
<= 6 Monate alt (2)
Erhöht, Choriocarcinom (3)
Tumour markers in CSF at diagnosis
Tumormarker im Liquor bei Diagnose bestimmt*
Nein (1)
Ja (2)
Datum der Liquorentnahme*
Zuordnung der Tumormarker zum zeitlichen
Ablauf der Therapie*
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Präoperativ (falls OP erfolgt/geplant) (1)
Postoperativ (falls OP erfolgt) (2)
Prätherapeutisch (falls OP nach Chemo
bzw. Bestrahlung geplant) (3)
Erster AFP-Wert*
Erster AFP-Wert in ng/ml*
Erster HCG-Wert*
AFP-Wert erhÃ¶ht*
Normal (1)
Erhöht, aber physiologisch, weil Patient <
730 Tage alt (2)
Erhöht, Dottersacktumor (3)
HCG-Wert erhÃ¶ht*
Normal (1)
Erhöht, aber physiologisch, weil Patient
<= 6 Monate alt (2)
Erhöht, Choriocarcinom (3)
2 / 2
SIOP CNS GCT II Initial tumour markers
SIOP CNS GCT II Local pathology
SIOP CNS GCT II: Prospective Trial for the Diagnosis and
Treatment of Children, Adolescents and Young Adults With
Intracranial Germ Cell Tumors. Principal Investigator
Gabriele Calaminus, MD.
http://clinicaltrials.gov/show/NCT01424839
All rights reserved. Please visit https://medical-data-
models.org/forms/5766
Local pathology
Show identification of patient
Dummy
Local pathology report
Nummer des Histologiebefundes*
Wurde der lokale Histologiebericht an die
Studienzentrale versandt*
Nein (1)
Ja (2)
Warum wurde der lokale Histologiebericht nicht
an die Studienzentrale versandt*
Noch nicht verfügbar, wird nachgereicht
(1)
Nicht verfügbar, da OP in anderer Klinik
(2)
Wann wurde der lokale Histologiebericht an die
Studienzentrale versandt*
Lokalen Histologiebericht in Studienzentrale
erhalten*
Nein (1)
Ja (2)
Findings of local pathology
Matures Teratom*
Nein (1)
Ja (2)
Immatures Teratom Gr 1*
Nein (1)
Ja (2)
Immatures Teratom Gr 2*
Nein (1)
Ja (2)
Immatures Teratom Gr 3*
Nein (1)
Ja (2)
Wurden bei der histologischen Beurteilung
maligne Microfoci gefunden*
Nein (1)
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Ja (2)
Germinom*
Nein (1)
Ja (2)
Embryonales Karzinom (EC)*
Nein (1)
Ja (2)
Dottersacktumor (YST)*
Nein (1)
Ja (2)
Choriokarzinom (ChC)*
Nein (1)
Ja (2)
Andere Tumorkomponente*
Nein (1)
Ja (2)
Welche andere Tumorkomponente*
Konnte noch Frischmaterial fÃ¼r die "Tumorbox"
gesammelt/versandt werden*
Nein (1)
Ja (2)
2 / 2
SIOP CNS GCT II Local pathology
SIOP CNS GCT II Reference pathology
SIOP CNS GCT II: Prospective Trial for the Diagnosis and
Treatment of Children, Adolescents and Young Adults With
Intracranial Germ Cell Tumors. Principal Investigator
Gabriele Calaminus, MD.
http://clinicaltrials.gov/show/NCT01424839
All rights reserved. Please visit https://medical-data-
models.org/forms/5767
Reference pathology
Show identification of patient
Dummy
Reference pathology and report
Ist die referenzpathologische Untersuchung
durchgefÃ¼hrt worden*
Nein (1)
Ja, nationales Referenzzentrum (2)
Ja, anderes Zentrum (3)
Welches andere Zentrum*
Nummer des Histologiebefundes*
Findings of reference pathology
Matures Teratom*
Nein (1)
Ja (2)
Immatures Teratom Gr 1*
Nein (1)
Ja (2)
Immatures Teratom Gr 2*
Nein (1)
Ja (2)
Immatures Teratom Gr 3*
Nein (1)
Ja (2)
Wurden bei der histologischen Beurteilung
maligne Microfoci gefunden*
Nein (1)
Ja (2)
Germinom*
Nein (1)
Ja (2)
Embryonales Karzinom (EC)*
Nein (1)
Ja (2)
Dottersacktumor (YST)*
Nein (1)
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Ja (2)
Choriokarzinom (ChC)*
Nein (1)
Ja (2)
Andere Tumorkomponente*
Nein (1)
Ja (2)
Welche andere Tumorkomponente*
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SIOP CNS GCT II Reference pathology
SIOP CNS GCT II Basic data on
radiotherapy
SIOP CNS GCT II: Prospective Trial for the Diagnosis and
Treatment of Children, Adolescents and Young Adults With
Intracranial Germ Cell Tumors. Principal Investigator
Gabriele Calaminus, MD.
http://clinicaltrials.gov/show/NCT01424839
All rights reserved. Please visit https://medical-data-
models.org/forms/5769
Basic data on radiotherapy
Show identification of patient
Dummy
Basic data on radiotherapy
Behandelnde Radiologie*
Radiotherapiestart*
Radiotherapieende*
Bestrahlungsoption*
Fokale Bestrahlung (1)
Ventrikuläre Bestrahlung (2)
Kranio-spinale Bestrahlung (3)
Whole brain
Gesamtdosis*
Dosis/Fraktion*
Fraktionen/Woche*
Photonenenergie*
Protonen*
Unterbrechungen*
Behandlungszeitraum*
Spinal canal
Gesamtdosis*
Dosis/Fraktion*
Fraktionen/Woche*
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Photonenenergie*
Protonen*
Unterbrechungen*
Behandlungszeitraum*
Ventricles
Gesamtdosis*
Dosis/Fraktion*
Fraktionen/Woche*
Photonenenergie*
Protonen*
Unterbrechungen*
Behandlungszeitraum*
Boost tumour site
Gesamtdosis*
Dosis/Fraktion*
Fraktionen/Woche*
Photonenenergie*
Protonen*
Unterbrechungen*
Behandlungszeitraum*
Tumour site only
Gesamtdosis*
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SIOP CNS GCT II Basic data on radiotherapy
Dosis/Fraktion*
Fraktionen/Woche*
Photonenenergie*
Protonen*
Unterbrechungen*
Behandlungszeitraum*
Boost sites of metastatic disease
Gesamtdosis*
Dosis/Fraktion*
Fraktionen/Woche*
Photonenenergie*
Protonen*
Unterbrechungen*
Behandlungszeitraum*
Tumour, cumulative dose
Gesamtdosis*
Dosis/Fraktion*
Fraktionen/Woche*
Photonenenergie*
Protonen*
Unterbrechungen*
Behandlungszeitraum*
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SIOP CNS GCT II Treatment technique
SIOP CNS GCT II: Prospective Trial for the Diagnosis and
Treatment of Children, Adolescents and Young Adults With
Intracranial Germ Cell Tumors. Principal Investigator
Gabriele Calaminus, MD.
http://clinicaltrials.gov/show/NCT01424839
All rights reserved. Please visit https://medical-data-
models.org/forms/5770
Treatment technique
Show identification of patient
Dummy
Technique whole brain
3D-Planung*
Nein (1)
Ja (2)
Fusionierung der Bildgebung (MR/CT)*
Nein (1)
Ja (2)
Bestrahlung von seitlich und
gegenÃ¼berliegenden Feldern*
Nein (1)
Ja (2)
Mehrfeldertechnik*
Nein (1)
Ja (2)
IMRT*
Nein (1)
Ja (2)
Protonen*
Nein (1)
Ja (2)
Maximale Dosis*
Minimale Dosis*
Dosis "hot spot"*
Mittlere Dosis*
Technique spinal axis
3D-Planung*
Nein (1)
Ja (2)
Fusionierung der Bildgebung (MR/CT)*
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Nein (1)
Ja (2)
Bestrahlung von seitlich und
gegenÃ¼berliegenden Feldern*
Nein (1)
Ja (2)
Mehrfeldertechnik*
Nein (1)
Ja (2)
IMRT*
Nein (1)
Ja (2)
Protonen*
Nein (1)
Ja (2)
Maximale Dosis*
Minimale Dosis*
Dosis "hot spot"*
Mittlere Dosis*
Technique ventricular system
3D-Planung*
Nein (1)
Ja (2)
Fusionierung der Bildgebung (MR/CT)*
Nein (1)
Ja (2)
Bestrahlung von seitlich und
gegenÃ¼berliegenden Feldern*
Nein (1)
Ja (2)
Mehrfeldertechnik*
Nein (1)
Ja (2)
IMRT*
Nein (1)
Ja (2)
Protonen*
Nein (1)
Ja (2)
Maximale Dosis*
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SIOP CNS GCT II Treatment technique
Minimale Dosis*
Dosis "hot spot"*
Mittlere Dosis*
Technique boost to tumour bed or TR to
Tumour site only
3D-Planung*
Nein (1)
Ja (2)
Fusionierung der Bildgebung (MR/CT)*
Nein (1)
Ja (2)
Bestrahlung von seitlich und
gegenÃ¼berliegenden Feldern*
Nein (1)
Ja (2)
Mehrfeldertechnik*
Nein (1)
Ja (2)
IMRT*
Nein (1)
Ja (2)
Protonen*
Nein (1)
Ja (2)
Maximale Dosis*
Minimale Dosis*
Dosis "hot spot"*
Mittlere Dosis*
Technique boost to sites of metastatic
disease
3D-Planung*
Nein (1)
Ja (2)
Fusionierung der Bildgebung (MR/CT)*
Nein (1)
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Ja (2)
Bestrahlung von seitlich und
gegenÃ¼berliegenden Feldern*
Nein (1)
Ja (2)
Mehrfeldertechnik*
Nein (1)
Ja (2)
IMRT*
Nein (1)
Ja (2)
Protonen*
Nein (1)
Ja (2)
Maximale Dosis*
Minimale Dosis*
Dosis "hot spot"*
Mittlere Dosis*
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SIOP CNS GCT II Treatment technique
SIOP CNS GCT II Toxicity during
radiotherapy
SIOP CNS GCT II: Prospective Trial for the Diagnosis and
Treatment of Children, Adolescents and Young Adults With
Intracranial Germ Cell Tumors. Principal Investigator
Gabriele Calaminus, MD.
http://clinicaltrials.gov/show/NCT01424839
All rights reserved. Please visit https://medical-data-
models.org/forms/5771
Toxicity during radiotherapy
Show identification of patient
Dummy
Toxicity hematology
HÃ¤moglobin*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Leukozyten*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Neutrophile*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Thrombozyten*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Blutung*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Toxicity neurological
Kopfschmerzen*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
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KrampfanfÃ¤lle*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Zentrale NeurotoxizitÃ¤t*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Periphere NeurotoxizitÃ¤t*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Epilepsie*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Toxicity infection
Infektion*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Fieber*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Toxicity gastrointestinal
Ãœbelkeit*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Erbrechen*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
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Mukosa (CTC-Version 2)*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Toxicity skin
Alopezie*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
HautverÃ¤nderungen*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Erythema multiforme*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Ohr/Haut*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Toxicity other
Andere ToxizitÃ¤t aufgetreten*
Nein (1)
Ja (2)
Grad andere ToxizitÃ¤t*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Beschreibung andere ToxizitÃ¤t*
Further data on radiotherapy toxicity
War wÃ¤hrend der Radiotherapie ein
Krankenhausaufenthalt erforderlich*
Nein (1)
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Ja (2)
Kommentar zum Krankenhausaufenthalt
4 / 4
SIOP CNS GCT II Toxicity during radiotherapy
SIOP CNS GCT II Registration data SIOP
CNS GCT II
SIOP CNS GCT II: Prospective Trial for the Diagnosis and
Treatment of Children, Adolescents and Young Adults With
Intracranial Germ Cell Tumors. Principal Investigator
Gabriele Calaminus, MD.
http://clinicaltrials.gov/show/NCT01424839
All rights reserved. Please visit https://medical-data-
models.org/forms/5772
Registration data SIOP CNS GCT II
Show identification of patient
Dummy
Registration data SIOP CNS GCT II
Datum der EinwilligungserklÃ¤rung*
Inclusion criteria
Hauptwohnsitz in einem der teilnehmenden
LÃ¤nder*
Nein (1)
Ja (2)
Intrakranialer Keimzelltumor als Hauptdiagnose*
Nein (1)
Ja (2)
Demographic data
Nation
Deutschland (1)
Finnland (10)
Österreich (11)
Schweiz (12)
Tschechien (13)
Belgien (14)
Niederlande (2)
Frankreich (3)
Italien (4)
United Kingdom (5)
Norwegen (6)
Dänemark (7)
Schweden (8)
Spanien (9)
Nationale Pat.-Nr.
Vorname
Nachname
Geburtsname
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Geburtsdatum*
Geschlecht*
Männlich (1)
Weiblich (2)
Exclusion criteria
Teilnahme in einer anderen klinischen Studie*
Nein (1)
Ja (2)
Welche Studie*
FrÃ¼here Tumorerkrankung oder
Tumorbehandlung (inkl. Dermoidzyste oder
Teratom)*
Nein (1)
Ja (2)
Welche Tumorerkrankung oder
Tumorbehandlung*
Klassierung durch Studienzentrale*
Teratom früher (1)
Dermoidzyste früher (2)
Anderer gutartiger Tumor früherer (3)
Andere maligne Erkrankung früher (4)
Ist eine andere Therapie als nach SIOP CNS
GCT II geplant*
Nein (1)
Ja (2)
Gibt es eine klinische Indikation, die eine
Modifikation der Therapie zur Folge hat*
Nein (1)
Ja (2)
Welche klinische Indikation*
Schwangerschaft/Stillzeit (1)
Gehörschädigung (2)
Nierenschädigung (3)
Andere Indikation (4)
Andere klinische Indikation*
Liegt eine Schwangerschaft oder Stillzeit vor*
Nein (1)
Ja (2)
Erhielt der Patient vor Registrierung eine
Therapie, die nicht mit SIOP CNS GCT II konform
ist*
Nein (1)
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Ja (2)
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SIOP CNS GCT II Diagnosis of relapse
(local relapse or metastasis)
SIOP CNS GCT II: Prospective Trial for the Diagnosis and
Treatment of Children, Adolescents and Young Adults With
Intracranial Germ Cell Tumors. Principal Investigator
Gabriele Calaminus, MD.
http://clinicaltrials.gov/show/NCT01424839
All rights reserved. Please visit https://medical-data-
models.org/forms/5773
Diagnosis of relapse (local relapse or
metastasis)
Show identification of patient
Dummy
Type and date of event
Auftreten eines Lokalrezidivs/Metastase*
Lokalrezidiv (1)
Metastase(n) (2)
Lokalrezidiv + Metastase(n) (3)
Diagnosedatum des Lokalrezidivs*
Diagnosedatum der Metastase(n)*
Localisation of relapse
Lokalisation*
Steißbein (1)
Magen (10)
Abdomen (11)
Lymphknoten (12)
Andere Lokalisation (13)
Hoden (15)
Ovar (2)
Retroperitoneum (3)
Mediastinum (4)
ZNS (5)
Urogenitalbereich (6)
Skelett (7)
Lunge (8)
Leber (9)
Liegt die Lokalisation innerhalb des
Bestrahlungsfeldes*
Nein (1)
Ja (2)
Welche Lokalisation im ZNS*
Welche andere Lokalisation*
Diagnostics - Tumour components
Diagnose gestellt anhand*
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Bildgebung (CT/MRT/Ultraschall) (1)
Tumormarker (Serum/CSF) (2)
Bildgebung + Tumormarker (3)
Matures Teratom*
Histologisch gesichert (1)
Durch Bildgebung diagnostiziert (4)
Vermutet (5)
Nicht vorhanden (6)
Immatures Teratom Gr 1*
Histologisch gesichert (1)
Durch Bildgebung diagnostiziert (4)
Vermutet (5)
Nicht vorhanden (6)
Immatures Teratom Gr 2*
Histologisch gesichert (1)
Durch Bildgebung diagnostiziert (4)
Vermutet (5)
Nicht vorhanden (6)
Immatures Teratom Gr 3*
Histologisch gesichert (1)
Durch Bildgebung diagnostiziert (4)
Vermutet (5)
Nicht vorhanden (6)
Wurden bei der histologischen Beurteilung
maligne Microfoci gefunden*
Nein (1)
Ja (2)
Germinom*
Histologisch gesichert (1)
Durch Bildgebung diagnostiziert (4)
Vermutet (5)
Nicht vorhanden (6)
Embryonales Karzinom (EC)*
Histologisch gesichert (1)
Durch Bildgebung diagnostiziert (4)
Vermutet (5)
Nicht vorhanden (6)
Dottersacktumor (YST)*
Histologisch gesichert (1)
Durch Tumormarker gesichert (2)
Histologisch und durch Tumormarker
gesichert (3)
Durch Bildgebung diagnostiziert (4)
Vermutet (5)
Nicht vorhanden (6)
Choriokarzinom (ChC)*
Histologisch gesichert (1)
Durch Tumormarker gesichert (2)
Histologisch und durch Tumormarker
gesichert (3)
Durch Bildgebung diagnostiziert (4)
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Vermutet (5)
Nicht vorhanden (6)
Andere Tumorkomponente*
Nein (1)
Ja (2)
Welche andere Tumorkomponente*
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SIOP CNS GCT II Relapse biopsy_surgery
and treatment
SIOP CNS GCT II: Prospective Trial for the Diagnosis and
Treatment of Children, Adolescents and Young Adults With
Intracranial Germ Cell Tumors. Principal Investigator
Gabriele Calaminus, MD.
http://clinicaltrials.gov/show/NCT01424839
All rights reserved. Please visit https://medical-data-
models.org/forms/5774
Relapse biopsy/surgery and
treatment
Show identification of patient
Dummy
Relapse biopsy/surgery
Biopsie durchgefÃ¼hrt*
Nein (1)
Ja (2)
Datum der Biopsie*
Offene Resektion durchgefÃ¼hrt*
Nein (1)
Ja (2)
Datum der offenen Resektion*
AusmaÃŸ der Resektion*
Komplette Resektion (1)
Inkomplette Resektion > 50% (2)
Teilweise Resektion < 50% (3)
Nur Biopsie möglich während der
offenen Resektion (4)
Chemotherapy of relapse
Chemotherapie geplant*
Nein, keine Chemotherapie (1)
Ja, HIT-Rez-Protokoll (2)
Ja, HD-Chemo nach De Giorgi (3)
Ja, Tremodal (4)
Ja, VP16/Trofosphamid (5)
Ja, VP16/Trofosphamid/Vinblastin (6)
Ja, andere Chemo (7)
Welche Chemotherapie*
Relapse radiotherapy
Radiotherapie geplant*
Nein (1)
Ja (2)
Welche Radiotherapie*
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Other relapse therapy
Andere Therapie geplant*
Nein (1)
Ja (2)
Welche andere Therapie*
2 / 2
SIOP CNS GCT II Relapse biopsy_surgery and treatment
SIOP CNS GCT II SAE
SIOP CNS GCT II: Prospective Trial for the Diagnosis and
Treatment of Children, Adolescents and Young Adults With
Intracranial Germ Cell Tumors. Principal Investigator
Gabriele Calaminus, MD.
http://clinicaltrials.gov/show/NCT01424839
All rights reserved. Please visit https://medical-data-
models.org/forms/5775
SAE
Show identification of patient
Dummy
SAE
Fallnr. beim Sponsor*
Beginn des Ereignisses*
Kurzbeschreibung*
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SIOP CNS GCT II Study centre
SIOP CNS GCT II: Prospective Trial for the Diagnosis and
Treatment of Children, Adolescents and Young Adults With
Intracranial Germ Cell Tumors. Principal Investigator
Gabriele Calaminus, MD.
http://clinicaltrials.gov/show/NCT01424839
All rights reserved. Please visit https://medical-data-
models.org/forms/5776
Study centre
Show identification of patient
Dummy
Study centre data on registration
EinwilligungserklÃ¤rung*
Nein (1)
Ja (2)
Datum der EinwilligungserklÃ¤rung*
Registrierung/RegistrierungsbestÃ¤tigung*
Nein (1)
Ja (2)
Datum Registrierung oder
RegistrierungsbestÃ¤tigung*
Therapieempfehlung verschickt*
Nein (1)
Ja (2)
Datum Therapieempfehlung*
Ersterhebung vollstÃ¤ndig*
Nein (1)
Ja (2)
Datum Ersterhebung vollstÃ¤ndig*
Study centre data on chemotherapy
Chemodokumentation vollstÃ¤ndig*
Nein (1)
Ja (2)
Datum Chemodokumentation vollstÃ¤ndig*
Study centre data on radiotherapy
Radiotherapiedokumentation vollstÃ¤ndig*
Nein (1)
Ja (2)
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Datum Radiotherapiedokumentation
vollstÃ¤ndig*
Study centre data on end of therapy
Therapieabschluss-Dokumentation vollstÃ¤ndig*
Nein (1)
Ja (2)
Datum Therapieabschluss-Dokumentation
vollstÃ¤ndig*
Study centre data on surgery
OP-Dokumentation vollstÃ¤ndig*
Nein (1)
Ja (2)
Datum OP-Dokumentation vollstÃ¤ndig*
Alle OP-Berichte erhalten*
Nein (1)
Ja (2)
Datum alle OP-Berichte erhalten*
Study centre data on histology
Alle lokalen Histologiebefunde erhalten*
Nein (1)
Ja (2)
Datum alle lokalen Histologiebefunde erhalten*
Alle Referenzhistologiebefunde erhalten*
Nein (1)
Ja (2)
Datum alle Referenzhistologiebefunde erhalten*
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SIOP CNS GCT II Study centre
SIOP CNS GCT II Second malignancy
biopsy_surgery and treatment
SIOP CNS GCT II: Prospective Trial for the Diagnosis and
Treatment of Children, Adolescents and Young Adults With
Intracranial Germ Cell Tumors. Principal Investigator
Gabriele Calaminus, MD.
http://clinicaltrials.gov/show/NCT01424839
All rights reserved. Please visit https://medical-data-
models.org/forms/5777
Second malignancy biopsy/surgery
and treatment
Show identification of patient
Dummy
Second malignancy biopsy/surgery
Biopsie durchgefÃ¼hrt*
Nein (1)
Ja (2)
Datum der Biopsie*
Offene Resektion durchgefÃ¼hrt*
Nein (1)
Ja (2)
Datum der offenen Resektion*
AusmaÃŸ der Resektion*
Komplette Resektion (1)
Inkomplette Resektion > 50% (2)
Teilweise Resektion < 50% (3)
Nur Biopsie möglich während der
offenen Resektion (4)
Chemotherapy of second malignancy
Chemotherapie geplant*
Nein, keine Chemotherapie (1)
Ja, HIT-Rez-Protokoll (2)
Ja, HD-Chemo nach De Giorgi (3)
Ja, Tremodal (4)
Ja, VP16/Trofosphamid (5)
Ja, VP16/Trofosphamid/Vinblastin (6)
Ja, andere Chemo (7)
Welche Chemotherapie*
Second malignancy radiotherapy
Radiotherapie geplant*
Nein (1)
Ja (2)
Welche Radiotherapie*
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Other therapy of second malignancy
Andere Therapie geplant*
Nein (1)
Ja (2)
Welche andere Therapie*
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SIOP CNS GCT II Secondary malignancy
SIOP CNS GCT II: Prospective Trial for the Diagnosis and
Treatment of Children, Adolescents and Young Adults With
Intracranial Germ Cell Tumors. Principal Investigator
Gabriele Calaminus, MD.
http://clinicaltrials.gov/show/NCT01424839
All rights reserved. Please visit https://medical-data-
models.org/forms/5778
Secondary malignancy
Show identification of patient
Dummy
Diagnosis of secondary malignancy
Diagnosedatum*
Diagnose*
Localisation of second malignancy
Lokalisation*
Steißbein (1)
Magen (10)
Abdomen (11)
Lymphknoten (12)
Andere Lokalisation (13)
Systemisch (14)
Hoden (15)
Ovar (2)
Retroperitoneum (3)
Mediastinum (4)
ZNS (5)
Urogenitalbereich (6)
Skelett (7)
Lunge (8)
Leber (9)
Liegt die Lokalisation innerhalb des
Bestrahlungsfeldes*
Nein (1)
Ja (2)
Welche Lokalisation im ZNS*
Welche andere Lokalisation*
1 / 1
SIOP CNS GCT II Staging postoperative
SIOP CNS GCT II: Prospective Trial for the Diagnosis and
Treatment of Children, Adolescents and Young Adults With
Intracranial Germ Cell Tumors. Principal Investigator
Gabriele Calaminus, MD.
http://clinicaltrials.gov/show/NCT01424839
All rights reserved. Please visit https://medical-data-
models.org/forms/5779
Staging postoperative
Show identification of patient
Dummy
Cranial imaging postoperative
Datum*
Technik*
MRT (1)
CT (2)
Szintigraphie (3)
SPECT (4)
PET (5)
Andere (6)
Andere Technik, welche*
Resttumor im Vergleich zur prÃ¤operativen
Bildgebung*
Kein Tumorrest (CR) (1)
> 50 % Rückgang des Tumorvolumens
(PR) (2)
< 50% Verringerung des Tumorvolumens
(SD) (3)
> 25% Tumorrest in irgendeiner
messbaren Tumorläsion und/oder
Auftreten neuer Läsionen (PD) (4)
Vergleich nicht möglich, da präoperative
Bilder fehlen/nicht auswertbar (5)
Vergleich nicht möglich, da postoperative
Bilder fehlen/nicht auswertbar (6)
Tumour site pineal postoperative
TumorlÃ¤nge*
Tumorbreite*
TumorhÃ¶he*
Tumorvolumen*
Tumour site supra-/intrasellar
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postoperative
TumorlÃ¤nge*
Tumorbreite*
TumorhÃ¶he*
Tumorvolumen*
Other tumour site postoperative
TumorlÃ¤nge*
Tumorbreite*
TumorhÃ¶he*
Tumorvolumen*
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SIOP CNS GCT II Staging preoperative
SIOP CNS GCT II: Prospective Trial for the Diagnosis and
Treatment of Children, Adolescents and Young Adults With
Intracranial Germ Cell Tumors. Principal Investigator
Gabriele Calaminus, MD.
http://clinicaltrials.gov/show/NCT01424839
All rights reserved. Please visit https://medical-data-
models.org/forms/5780
Staging preoperative
Show identification of patient
Dummy
Cranial imaging preoperative
Datum*
Technik*
MRT (1)
CT (2)
Szintigraphie (3)
SPECT (4)
PET (5)
Andere (6)
Andere Technik, welche*
Tumour site pineal preoperative
Tumor gefunden*
Nein (1)
Ja (2)
TumorlÃ¤nge*
Tumorbreite*
TumorhÃ¶he*
Tumorvolumen*
Tumour site supra-/intrasellar preoperative
Tumor gefunden*
Nein (1)
Ja (2)
TumorlÃ¤nge*
Tumorbreite*
TumorhÃ¶he*
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Tumorvolumen*
Other tumour site preoperative
Tumor gefunden*
Nein (1)
Ja (2)
Wo ist die andere Lokalisation*
TumorlÃ¤nge*
Tumorbreite*
TumorhÃ¶he*
Tumorvolumen*
Tumour volume preoperative
Volumen*
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SIOP CNS GCT II Tumour components
SIOP CNS GCT II: Prospective Trial for the Diagnosis and
Treatment of Children, Adolescents and Young Adults With
Intracranial Germ Cell Tumors. Principal Investigator
Gabriele Calaminus, MD.
http://clinicaltrials.gov/show/NCT01424839
All rights reserved. Please visit https://medical-data-
models.org/forms/5781
Tumour components
Show identification of patient
Dummy
Tumour components at registration
Matures Teratom*
Histologisch gesichert (1)
Durch Bildgebung diagnostiziert (4)
Vermutet (5)
Nicht vorhanden (6)
Immatures Teratom Gr 1*
Histologisch gesichert (1)
Durch Bildgebung diagnostiziert (4)
Vermutet (5)
Nicht vorhanden (6)
Immatures Teratom Gr 2*
Histologisch gesichert (1)
Durch Bildgebung diagnostiziert (4)
Vermutet (5)
Nicht vorhanden (6)
Immatures Teratom Gr 3*
Histologisch gesichert (1)
Durch Bildgebung diagnostiziert (4)
Vermutet (5)
Nicht vorhanden (6)
Wurden bei der histologischen Beurteilung
maligne Microfoci gefunden*
Nein (1)
Ja (2)
Germinom*
Histologisch gesichert (1)
Durch Bildgebung diagnostiziert (4)
Vermutet (5)
Nicht vorhanden (6)
Embryonales Karzinom (EC)*
Histologisch gesichert (1)
Durch Bildgebung diagnostiziert (4)
Vermutet (5)
Nicht vorhanden (6)
Dottersacktumor (YST)*
Histologisch gesichert (1)
Durch Tumormarker gesichert (2)
Histologisch und durch Tumormarker
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gesichert (3)
Durch Bildgebung diagnostiziert (4)
Vermutet (5)
Nicht vorhanden (6)
Choriokarzinom (ChC)*
Histologisch gesichert (1)
Durch Tumormarker gesichert (2)
Histologisch und durch Tumormarker
gesichert (3)
Durch Bildgebung diagnostiziert (4)
Vermutet (5)
Nicht vorhanden (6)
Andere Tumorkomponente*
Nein (1)
Ja (2)
Welche andere Tumorkomponente*
Tumour diagnosis group
Diagnosegruppe (berechnet)
Mal. Non-Germinoma (1)
Germinom (2)
Teratom (3)
Kein KZT (4)
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SIOP CNS GCT II Sites of tumour and
metastases
SIOP CNS GCT II: Prospective Trial for the Diagnosis and
Treatment of Children, Adolescents and Young Adults With
Intracranial Germ Cell Tumors. Principal Investigator
Gabriele Calaminus, MD.
http://clinicaltrials.gov/show/NCT01424839
All rights reserved. Please visit https://medical-data-
models.org/forms/5782
Sites of tumour and metastases
Show identification of patient
Dummy
Primary tumour at registration
PrimÃ¤re Tumorlokalisation*
Pineal (1)
Suprasellär (2)
Andere Lokalisation (3)
Bifokal (pineal + suprasellär) (4)
Welche andere primÃ¤re Tumorlokalisation*
Fand eine primÃ¤re Tumorresektion (nicht
Biopsie) statt*
Nein (1)
Ja (2)
Datum der Tumorresektion*
Metastases at registration
Intrakraniale Metastasen*
Nein (1)
Ja (2)
Wo sind die intrakranialen Metastasen*
Spinale Metastasen*
Nein (1)
Ja (2)
Wo sind die spinalen Metastasen*
Datum der Liquor-Zytologie*
Wo wurde Liquor abgenommen*
Lumbal (1)
Ventrikulär (2)
Lumbal und ventrikulär (3)
Konnte nicht gewonnen werden (4)
Tumorzellen im lumbal gewonnenen Liquor*
Nein, keine Tumorzellen im lumbalen
Liquor (1)
Ja, Tumorzellen im lumbalen Liquor (2)
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Tumorzellen im ventrikulÃ¤r gewonnenen Liquor*
Nein, keine Tumorzellen im ventrikulären
Liquor (1)
Ja, Tumorzellen im ventrikulären Liquor
(2)
Tumorzellen im Liquor
Nein (1)
Ja (2)
Metastasen auÃŸerhalb des ZNS*
Nein (1)
Ja (2)
Wo sind die extrakranialen Metastasen*
Site of tumour summarised
Metastasen bei Diagnose
Nein (1)
Ja (2)
Anzahl Tumorlokalisationen*
Unifokal (1)
Bifokal (2)
Multifokal (metastatisch) (3)
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SIOP CNS GCT II Sites of tumour and metastases
SIOP CNS GCT II Time point and surgery
base data
SIOP CNS GCT II: Prospective Trial for the Diagnosis and
Treatment of Children, Adolescents and Young Adults With
Intracranial Germ Cell Tumors. Principal Investigator
Gabriele Calaminus, MD.
http://clinicaltrials.gov/show/NCT01424839
All rights reserved. Please visit https://medical-data-
models.org/forms/5783
Time point and surgery base data
Show identification of patient
Dummy
Surgery documentation
In welcher Klinik wurde operiert*
Neurosurgery-Bogen versandt*
Nein (1)
Ja, an Neurochirurgie (2)
Ja, an Studienzentrale/in Marvin
eingetragen (3)
OP-Bericht an die Studienzentrale versandt*
Nein (1)
Ja (2)
Warum wurde der OP-Bericht nicht an die
Studienzentrale versandt*
Noch nicht verfügbar, wird nachgereicht
(1)
Nicht verfügbar, da OP in anderer Klinik
(2)
Wann wurde der OP-Bericht an die
Studienzentrale versandt*
OP-Bericht in Studienzentrale erhalten*
Nein (1)
Ja (2)
Surgery
Der wievielte neurochirurgische Eingriff wird hier
dokumentiert*
Zeitpunkt der Operation*
Primär, bei Diagnose (1)
Nach Chemotherapie (2)
Nach Radiotherapie (3)
2. Operation ohne vorherige Therapie (4)
Anderer Zeitpunkt (5)
Primär, bei Diagnose (nur Shunt/Biopsie)
(6)
Welcher andere Zeitpunkt*
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Dringlichkeit*
Notfall (1)
Geplant (2)
Preoperative information about tumour
site(s)
Pineal*
Nein (1)
Ja (2)
Hypothalamus/Hypophyse*
Nein (1)
Ja (2)
SellÃ¤r*
Nein (1)
Ja (2)
SuprasellÃ¤r*
Nein (1)
Ja (2)
Hypophysenstiel*
Nein (1)
Ja (2)
3. Ventrikel*
Nein (1)
Ja (2)
Andere Lokalisation(en)*
Nein (1)
Ja (2)
Welche andere(n) Lokalisation(en)*
Hydrocephalus*
Nein (1)
Ja (2)
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SIOP CNS GCT II Time point and surgery base data
SIOP CNS GCT II Peri- or postoperative
complications
SIOP CNS GCT II: Prospective Trial for the Diagnosis and
Treatment of Children, Adolescents and Young Adults With
Intracranial Germ Cell Tumors. Principal Investigator
Gabriele Calaminus, MD.
http://clinicaltrials.gov/show/NCT01424839
All rights reserved. Please visit https://medical-data-
models.org/forms/5784
Peri- or postoperative complications
Show identification of patient
Dummy
Peri-/postoperative complications
Peri-/postoperative Komplikationen*
Nein (1)
Ja (2)
Subdurales HÃ¤matom*
Nein (1)
Ja (2)
Bluttransfusion notwendig*
Nein (1)
Ja (2)
Apoplexie*
Nein (1)
Ja (2)
Schwerwiegende Elektrolyt- und
Wasserhaushaltentgleisung*
Nein (1)
Ja (2)
Peri-/postoperative infection
Infektion*
Nein (1)
Ja (2)
WundoberflÃ¤che*
Nein (1)
Ja (2)
Meningitis/Ventriculitis*
Nein (1)
Ja (2)
CSF-Fistel/-Infektion*
Nein (1)
Ja (2)
Andere Infektion*
Nein (1)
Ja (2)
Welche andere Infektion*
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Reoperation
Reoperation*
Nein (1)
Ja (2)
Datum der Reoperation*
Indikation*
Art der Operation*
PrÃ¤operative Zeichen/Symptome*
Status of patient
Patient verstorben*
Nein (1)
Ja (2)
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SIOP CNS GCT II Peri- or postoperative complications
SIOP CNS GCT II Intraoperative events
SIOP CNS GCT II: Prospective Trial for the Diagnosis and
Treatment of Children, Adolescents and Young Adults With
Intracranial Germ Cell Tumors. Principal Investigator
Gabriele Calaminus, MD.
http://clinicaltrials.gov/show/NCT01424839
All rights reserved. Please visit https://medical-data-
models.org/forms/5785
Intraoperative events
Show identification of patient
Dummy
Intraoperative events
Fand eine intraoperative Histologie statt*
Nein (1)
Ja (2)
Ergebnis der intraoperativen Histologie*
Hypophysenstiel*
Angeschnitten (1)
Erhalten (2)
Nicht identifiziert (3)
Hypothalamusinfiltration*
Nein (1)
Ja (2)
Ablauf der Operation*
Ereignislos (1)
Abgebrochen (2)
Aus welchem Grund wurde die OP abgebrochen*
Histologische Information (1)
Tumorbeschaffenheit (2)
Adhäsion mit vasculären Strukturen (3)
Infiltration von Hirnparenchym (4)
Blutung (5)
Anderer Grund (6)
Welcher andere Grund*
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SIOP CNS GCT II Type of surgery
SIOP CNS GCT II: Prospective Trial for the Diagnosis and
Treatment of Children, Adolescents and Young Adults With
Intracranial Germ Cell Tumors. Principal Investigator
Gabriele Calaminus, MD.
http://clinicaltrials.gov/show/NCT01424839
All rights reserved. Please visit https://medical-data-
models.org/forms/5786
Type of surgery
Show identification of patient
Dummy
Shunt/drainage
Shunt/Drainage*
Nein (1)
Ja (2)
Datum der OP*
Art des Shunts/der Drainage*
Ventriculo-atrial (VA) (1)
Ventriculo-peritoneal (VP) (2)
Extern (3)
Ventriculoscopic (endoscopic)
Ventrikuloskopische (endoskopische) OP*
Nein (1)
Ja (2)
Datum der OP*
Art der OP*
Ventriculostomie (1)
Ventriculostomie + Biopsie (2)
Nur Biopsie (3)
Inspektion/ependymale VerÃ¤nderung (bzgl.
Tumoraussaat)*
Nein (1)
Ja (2)
Lokalisation(en)*
Intraoperative Liquorentnahme (Zytologie und
Tumormarker)*
Nein (1)
Ja (2)
Zeitpunkt der Liquorentnahme*
Vor Ventriculostomie und Biopsie (1)
Nach Ventriculostomie und vor Biopsie
(2)
Nach Biopsie (3)
1 / 2
Stereotactic biopsy
Stereotaktische Biopsie*
Nein (1)
Ja (2)
Datum der stereotaktischen Biopsie*
Open/transcranial surgery
Offene/transkraniale OP*
Nein (1)
Ja (2)
Datum der OP*
Vorgesehene operative Strategie*
Biopsie (1)
Debulking (partielle Resektion) (2)
Radikale Resektion (3)
AusmaÃŸ der Resektion (Eindruck des
Chirurgen)*
Biopsie (1)
Partielle Resektion (2)
Totale Resektion (3)
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Registry for Sickle Cell Diseases, 2.initial
assessment
Registerzentrale: Dr. Dickerhoff / Dr. Potthoff, Klinik für
Kinder-Onkologie, -Hämatologie und Klinische
Immunologie, Universitätsklinikum Düsseldorf
All rights reserved. Please visit https://medical-data-
models.org/forms/5788
Sichel-Reg, 2. Ersterhebung
Patientendaten
Nachname*
Vorname*
Geburtsdatum*
ID Nummer*
Familienanamnese
Herkunftsland Vater*
Herkunftsland Mutter*
Geburtsjahr Vater*
Geburtsjahr Mutter*
HbS-Status (Vater)*
HbS-Status (Mutter)*
Registerpatient (Vater)*
Ja
Nein
Registerpatient (Mutter)*
Ja
Nein
Geburtsjahr Geschwister*
Geschlecht des Geschwisters*
m (1)
w (2)
HbS-Status (Geschwister)*
Registerpatient (Geschwister)*
Ja
Nein
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Geburtsjahr (Kind)*
Geschlecht (Kind)*
m (1)
w (2)
HbS-Status (Kind)*
Registerpatient (Kind)*
Ja
Nein
Diagnose
Datum Hb Analyse*
Labor Hb-Analyse*
HbA*
HbF*
HbC*
HbA2*
HbS*
HbD*
Andere Hb*
Welche andere Hb*
alpha-Thalassämie*
nein (1)
ja (2)
molekulargenetisch gesichert (3)
Datum Blutbild*
Hämoglobin*
Erythrozyten*
MCV*
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Leukozyten*
Retikulozyten*
Thrombozyten*
Ferritin*
Hat nach der Diagnosestellung eine genetische
Beratung stattgefunden?*
Ja
Nein
Wird/ wurde für folgende Schwangerschaften
eine pränatale Diagnostik gewünscht?*
Ja
Nein
Sind Vorerkrankungen bekannt?*
Ja
Nein
Vorerkrankungen*
Besondere Ereignisse wie Operationen, Unfälle
usw.*
Ja
Nein
Besondere Ereignisse wie Operationen, Unfälle
usw.*
Ereignisse vor Meldung
Aplastische Krise*
Milzsequestration*
Splenektomie*
Grund für Splenektomie*
Zerebraler Infarkt*
Aseptische Knochennekrosen*
Akutes Thoraxsyndrom*
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Schmerzkrise*
nein (0)
bis zu 3 pro Jahr (1)
mehr als 3 pro Jahr (2)
Hand-Fuß-Syndrom*
Priapismus*
Impfstatus
Hepatitis B Impfung*
Prevenar Impfung (Pneumokokken)*
Pneumovax Impfung*
Hämophilus Influenza Impfung*
Medikamente
Penicillin Prophylaxe (Empfehlung bis zum 5.
Geburtstag)*
Ja
Nein
wenn Prophylaxe >5. Geburtstag Grund*
Hydroxycarbamid (Litalir, Siklos, Syrea) seit*
ACE Hemmer seit*
Andere Medikamente*
Klinische Untersuchung
Untersuchungsdatum*
Körpergewicht*
Perzentile des Körpergewichts*
Körperlänge*
Perzentile der Körperlänge*
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Pubertäre Entwicklung altersgerecht*
Ja
Nein
Systolischer Blutdruck*
Diastolischer Blutdruck*
Labor
Datum der Laborwerte*
Bilirubin gesamt*
Kreatinin*
U-Stix Protein positiv*
Ja
Nein
Sonografie Abdomen
Untersuchungsdatum*
Vergrößerung der Leber über Altersnorm*
Ja
Nein
Strukturauffälligkeiten der Leber*
Ja
Nein
Länge der Leber in der vorderen Axillarlinie*
Gallenblase*
leer (1)
Gries (2)
Steine (3)
Z.n. Cholezystektomie (4)
Milz*
keine Vergrößerung (1)
Vergrößerung über Altersnorm (2)
Z.n. Splenektomie (3)
Kardiologische Befunde
Untersuchungsdatum*
EKG*
nicht durchgeführt (0)
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normal (1)
pathologisch (2)
EKG Rhythmusstörungen*
Ja
Nein
EKG Hypertrophiezeichen*
Ja
Nein
EKG weitere Auffälligkeiten*
Echokardiografie*
nicht durchgeführt (0)
normal (1)
pathologisch (2)
Myokardiale Kontraktilitätsverminderung*
Ja
Nein
V.a. pulmonale Hypertonie*
Ja
Nein
Echokardiografie weitere Auffälligkeiten*
Augenuntersuchung
Untersuchungsdatum*
Funduskopie*
nicht durchgeführt (0)
normal (1)
pathologisch (2)
Retinaablösung*
Ja
Nein
Proliferative Retinopathie*
Ja
Nein
Glaskörperblutung*
Ja
Nein
Abnormale Fundoskopie*
Intervention*
Visusprüfung*
nicht durchgeführt (0)
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normal (1)
pathologisch (2)
Visusprüfung*
Bemerkungen
Zu welchen speziellen Problemen wünschen Sie
Informationen?*
Bemerkungen*
Unterschrift
Name des dokumentierenden Arztes*
Datum der Unterschrift*
Unterschrift*
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Registry for Sickle Cell Diseases, 2.initial assessment
Physician discharge letter UKM
Template for physician discharge letter at University
Hospital of Münster, Germany
All rights reserved. Please visit https://medical-data-
models.org/forms/5792
EHR discharge letter UKM
Briefkopf
Absender*
Empfänger*
Datum*
Anrede*
Brieftext
Text des Entlassungsbriefes*
Medikation*
Unterschrift
Arzt*
Oberarzt*
Direktor*
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Registry for Sickle Cell Diseases, 5.info
sheet age 10-15
Registerzentrale: Dr. Dickerhoff / Dr. Potthoff, Klinik für
Kinder-Onkologie, -Hämatologie und Klinische
Immunologie, Universitätsklinikum Düsseldorf
All rights reserved. Please visit https://medical-data-
models.org/forms/5794
Sichel-Reg, 5. Informationsblatt für
Kinder von 10 bis 15 Jahren
Patienteninformation
Nachname*
Vorname*
Geburtsdatum*
Aufklärungsgespräch am:*
Aufklärender Arzt*
Patienteninformation*
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Registry for Sickle Cell Diseases, 4.info
sheet
Registerzentrale: Dr. Dickerhoff / Dr. Potthoff, Klinik für
Kinder-Onkologie, -Hämatologie und Klinische
Immunologie, Universitätsklinikum Düsseldorf
All rights reserved. Please visit https://medical-data-
models.org/forms/5795
Sichel-Reg, 4. Informationsblatt für
Patienten, Eltern / Sorgeberechtigte
und Jugendliche ab 16 Jahren
Patienteninformation
Nachname*
Vorname*
Geburtsdatum*
Aufklärungsgespräch am:*
Aufklärender Arzt*
Patienteninformation*
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Registry for Sickle Cell Diseases, 6.consent
Registerzentrale: Dr. Dickerhoff / Dr. Potthoff, Klinik für
Kinder-Onkologie, -Hämatologie und Klinische
Immunologie, Universitätsklinikum Düsseldorf
All rights reserved. Please visit https://medical-data-
models.org/forms/5796
Sichel-Reg, 6.
Einverständniserklärung zur
Aufnahme in das Register für
Sichelzellerkrankungen
Einverständniserklärung
Einverständnisformular*
Nachname*
Vorname*
Geburtsdatum*
Aufklärungsgespräch am:*
Ort und Datum*
Unterschrift*
Patient aufgrund seines Alters nicht
einwilligungsfähig*
Ja
Nein
Name des Sorgeberechtigten*
Ort und Datum*
Unterschrift*
Name des Sorgeberechtigten*
Ort und Datum*
Unterschrift*
Aufklärender Arzt*
Ort und Datum*
Unterschrift*
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Registry for Sickle Cell Diseases, 7.consent
blood samples
Registerzentrale: Dr. Dickerhoff / Dr. Potthoff, Klinik für
Kinder-Onkologie, -Hämatologie und Klinische
Immunologie, Universitätsklinikum Düsseldorf
All rights reserved. Please visit https://medical-data-
models.org/forms/5797
Sichel-Reg, 7.
Einverständniserklärung zur
Asservierung einer Blutprobe und
Durchführung molekulargenetischer
Untersuchungen
Einverständniserklärung
Einverständnisformular*
Nachname*
Vorname*
Geburtsdatum*
Aufklärungsgespräch am:*
Ort und Datum*
Unterschrift*
Patient aufgrund seines Alters nicht
einwilligungsfähig*
Ja
Nein
Name des Sorgeberechtigten*
Ort und Datum*
Unterschrift*
Name des Sorgeberechtigten*
Ort und Datum*
Unterschrift*
Aufklärender Arzt*
Ort und Datum*
Unterschrift*
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Operating Room case record form (EuSOS)
European Surgical Outcomes Study (EuSOS)
http://clinicaltrials.gov/show/NCT01203605
All rights reserved. Please visit https://medical-data-
models.org/forms/5829
Operating Room case record form
(EuSOS)
Operating Room case record form
EuSOS unique patient ID*
Age*
Gender*
M (1)
F (2)
Current smoker*
Yes
No
ASA score*
I (1)
II (2)
III (3)
IV (4)
V (5)
Black ethnicity*
Yes
No
Coronary artery disease*
Yes
No
Congestive heart failure*
Yes
No
Diabetes mellitus with insulin therapy*
Yes
No
Cirrhosis*
Yes
No
Metastatic cancer*
Yes
No
Diabetes mellitus (no insulin)*
Yes
No
Stroke or Transient ischaemic attack*
Yes
No
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COPD / Asthma*
Yes
No
Haemoglobin*
Leukocytes (no more than 28 days before
surgery)*
Sodium (no more than 28 days before surgery)*
Urea/BUN (no more than 28 days before
surgery)*
Creatinine (no more than 28 days before
surgery)*
Anaesthesia induction time (24h) and date*
General anaesthesia*
Yes
No
Spinal anaesthesia*
Yes
No
Epidural anaesthesia*
Yes
No
Sedation*
Yes
No
Local anaesthesia*
Yes
No
Other regional anaesthesia*
Yes
No
Surgical Procedure*
Orthopaedic (1)
Plastics / Cutaneous (10)
Kidney (11)
Other (12)
Gynaecological (2)
Upper gastro-intestinal (3)
Hepato-biliary (4)
Urological (5)
Head and neck (6)
Breast (7)
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Vascular (8)
Lower gastro-intestinal (9)
Surgical checklist used*
Yes
No
Most senior anaesthetist present in operating
room*
Attending (1)
Middle Grade (2)
Junior (less than 3 years in anaesthesia)
(3)
Most senior surgeon present in operating room*
Attending (1)
Middle Grade (2)
Junior (less than 3 years in surgery) (3)
Intra-abdominal surgery*
Yes
No
Intra-thoracic surgery*
Yes
No
Laparoscopic surgery*
Yes
No
Laparoscopic assisted surgery*
Yes
No
Central venous catheter inserted?*
Yes
No
Cardiac output monitoring during surgery?*
Doppler ultrasound (1)
Pulmonary artery catheter (2)
Arterial wave form analysis (3)
Other (4)
None (5)
Urgency of surgery*
elective (1)
urgent (2)
Emergency (3)
Severity of surgery*
minor (1)
major (2)
intermediate (3)
Blood loss during surgery*
End of surgery (24 hr clock) and date*
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Post-operative follow-up (EuSOS)
European Surgical Outcomes Study (EuSOS)
http://clinicaltrials.gov/show/NCT01203605
All rights reserved. Please visit https://medical-data-
models.org/forms/5830
Post-operative follow-up (EuSOS)
Post-operative Follow Up
Duration of post-anaesthetic recovery stay*
Invasive ventilation within 24 hrs of surgery*
Yes
No
Non-invasive ventilation within 24 hrs of surgery*
Yes
No
Inotrope / vasopressor infusion within 24 hrs of
surgery*
Yes
No
Survival to hospital discharge?*
Yes
No
Date of hospital discharge (or death)*
Critical care admission any time during hospital
stay?*
Yes
No
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EHR General report
EHR General report
All rights reserved. Please visit https://medical-data-
models.org/forms/5831
General report
Allgemeiner Bericht
Erstelldatum*
Medizinisches Datum*
Dringlichkeit*
Status des Berichts*
Empfänger*
Zusammenfassung*
Anlage*
Bewusstsein*
Psyche*
Allgemeinzustand*
Ernährungszustand*
Dyspnoe*
Zyanose*
Einflussstauung*
Turgor*
Ikterus*
Ödeme*
Dekubitus*
Leberhautzeichen*
Nägel*
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Beweglichkeit der Gelenke*
Deformierungen des Bewegungsapparates*
Muskulatur*
Bewegung Sonstiges*
Deformierungen der Wirbelsäule*
Gelenke*
Schmerz der Wirbelsäule*
Beweglichkeit der Wirbelsäule*
Kalotte*
Nervenaustrittspunkte*
Zunge*
Rachen*
Tonsillen*
Schleimhäute Sonstiges*
Schilddrüse*
Lymphknoten auffällig*
Ja
Nein
KopfSonstiges*
Lymphknoten Sonstige Rechts*
Lymphknoten Sonstige Links*
Beinumfänge*
Periphere Pulse*
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Varizen*
Thrombophlebitis*
Mammae*
Klopfschall*
Blutdruck Systole Rechts*
Blutdruck Diastole Rechts*
Blutdruck Systole links*
Herzrhythmus*
Herzspitzenstoss*
Herzgeräusche*
Herztöne*
Carotiden*
Aorta*
Bauchdecke*
Hernien*
Peristaltik (Darm)*
Äußeres Genitale*
Rektaler Befund*
Wunden oder Narben*
Meteorismus*
Druckschmerz*
Resistenzen*
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Aszites*
Leber*
Gallenblase*
Milz*
Nierenlager*
Vigilanz*
Nackensteifigkeit*
Pupillen*
KonvReaktion*
Pupillenreaktion*
FNV*
KHV*
Tremor*
Muskeltonus*
Grobe Kraft*
Sensibilität*
Motorik*
Diadochokinese*
Sprache*
Lagesinn*
BSR*
TSR*
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RPR*
PSR*
ASR*
Babinski*
Neurologischer Status Sonstiges*
Klinik*
Aufnahmedatum*
Entlassdatum*
Erstellerkürzel*
Unterschrift*
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AHB Report MS
Report for insurance (G0260)
All rights reserved. Please visit https://medical-data-
models.org/forms/5832
AHB Diagnosis Report MS
Generelle Information
Versicherungsnummer*
Kennzeichen (soweit bekannt)*
Anschrift der AHB-Einrichtung*
Anschrift des Krankenhauses*
Ansprechpartnerin / Ansprechpartner mit Telefon-
und Faxnummer*
Art des Verfahrens*
Direkteinweisung (1)
Einweisung nach Prüfung bei RV-Träger
(2)
Vorgeschlagene Rehabilitationsform*
outpatient (1)
inpatient (2)
Personalien der Patientin / des Patienten
Name*
Vorname*
Geburtsdatum*
Adresse*
Krankenhaus
Aufnahmetag im Krankenhaus*
AHB-begründendes Ereignis*
Operation (1)
sonstiges Akut-Ereignis (2)
letzte Bestrahlung (3)
letzte antineoplastische Therapie (4)
entfällt (5)
Datum des AHB-begründenden Ereignisses*
Arbeitsunfall, Berufskrankheit*
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Ja
Nein
ASR-Revisionseingriff*
Ja
Nein
mögliche Schädigung durch Dritte*
Voraussichtlicher Entlassungstag*
Datum der vorgesehenen Verlegung in die AHB-
Einrichtung*
Diagnose
Diagnose für die Anschlussrehabilitation*
Diagnose nach ICD-10-GM*
DRG-Fallgruppe*
Krankheitsverlauf
Krankheitsverlauf, Komplikationen,
Risikofaktoren*
Derzeitige Therapie, Ergebnisse (bei
onkologischen Erkrankungen Remissionsstatus)*
Weitere erforderliche therapeutische oder
diagnostische Maßnahmen (z.B. Chemotherapie-
Zyklus, Radiatio, postoperative
Belastungsvorgaben bei Z.n. TEP)*
Weitere Krankheiten oder Behinderungen
Weitere behandlungsrelevante Krankheiten,
Behinderungen, Funktionseinschränkungen,
Schweregrade (z.B. NYHA-Stadien, Paresen,
kognitive / mnestische Störungen). Mit ICD-10-
GM Kodes.*
Klinische und medizinisch-technische
Befunde
Klinische und medizinisch-technische Befunde
(u.a. Histologie bei Malignomen, Ejektionsfraktion
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bei kardiologischer Erkrankung,
Lungenfunktionsparameter bei pneumologischer
Erkrankung oder Ähnliches)*
Patienteneigenschaften (pflegerisch /
sozial)
Kann die Patientin / der Patient ohne fremde Hilfe
essen?*
Ja
Nein
Kann die Patientin / der Patient sich alleine
waschen und anziehen?*
Ja
Nein
Kann die Patientin / der Patient sich alleine auf
der Station bewegen?*
Ja
Nein
Wunde reizlos / geschlossen ?*
Ja
Nein
Ist eine Infektion / Besiedelung mit
multiresistenten Keimen bekannt? Wenn ja,
welche?*
Besteht Harninkontinenz?*
Ja
Nein
Liegen Katheter / Drainagen / Sonden? Wenn ja,
welche?*
Besteht Stuhlinkontinenz?*
Ja
Nein
Rollstuhlfahrer*
Ja
Nein
Ist die Patientin / der Patient situativ / örtlich /
zeitlich orientiert?*
Für die Anreise ist möglich*
öffentliches Verkehrsmittel (1)
Kraftfahrzeug (2)
Ist eine Begleitperson erforderlich?*
Ja
Nein
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Taxi erforderlich*
Ja
Nein
Krankentransport erforderlich?*
Ja
Nein
Bemerkungen (z.B. Ergänzungen zu vorigem
Absatz, geringe Kenntnisse der deutschen
Sprache, Vorliegen einer stoffgebundenen
Abhängigkeitserkrankung, Stand der
Prothesenanpassung)*
Die Patientin / der Patient ist frühmobilisiert und
körperlich und geistig fähig, aktiv an der
medizinischen Rehabilitation teilzunehmen*
Ja
Nein
Unterschrift
Datum*
Unterschrift der Ärztin / des Arztes*
Arztstempel*
Telefonnummer*
4 / 4
AHB Report MS
Critical Care case record form (EuSOS)
European Surgical Outcomes Study (EuSOS)
http://clinicaltrials.gov/show/NCT01203605
All rights reserved. Please visit https://medical-data-
models.org/forms/5835
Critical Care case record form
(EuSOS)
Data describing first hour of admission to
critical care
Age*
Gender*
M (1)
F (2)
Height*
Weight*
Time (24h) & date of hospital admission*
Time (24h) & date of Critical care admit*
Location before critical care admission (or
surgery if admitted directly after procedure)*
Emergency Department (1)
General Ward (2)
Critical Care (3)
Other (4)
Critical care admission*
Planned (1)
Unplanned (2)
Non-haematological malignancy (chronic co-
morbid disease)*
Yes
No
Haematological malignancy*
Yes
No
Hypertension (chronic co-morbid disease)*
Yes
No
Chronic renal failure (chronic co-morbid disease)*
Yes
No
Chronic excessive alcohol intake (chronic co-
morbid disease)*
Yes
No
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Intra-venous drug user (chronic co-morbid
disease)*
Yes
No
HIV/AIDS (chronic co-morbid disease)*
Yes
No
Cirrhosis (chronic co-morbid disease)*
Yes
No
Chronic respiratory failure (chronic co-morbid
disease)*
Yes
No
Steroid therapy (chronic co-morbid disease)*
Yes
No
Radiotherapy (chronic co-morbid disease)*
Yes
No
Chemotherapy (chronic co-morbid disease)*
Yes
No
Coma/delirium (reason for critical care
admission)*
Yes
No
Acute abdomen (reason for critical care
admission)*
Yes
No
Severe pancreatitis (reason for critical care
admission)*
Yes
No
Liver failure (reason for critical care admission)*
Yes
No
Arrhythmia (reason for critical care admission)*
Yes
No
Hypovolaemic shock (reason for critical care
admission)*
Yes
No
Septic shock (reason for critical care admission)*
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Yes
No
Routine care (reason for critical care admission)*
Yes
No
Respiratory arrest in 24 hours prior to critical care
admission*
Yes
No
Cardiac arrest in 24 hours prior to critical care
admission*
Yes
No
Airway at end of first hour in critical care*
Own (1)
Endotracheal tube (2)
Tracheostomy (3)
Other (4)
Ventilation at end of first hour in critical care*
Invasive (via tracheal tube or
tracheostomy) (1)
Non-invasive (2)
None (3)
Plan made at critical care admission for renal
replacement therapy*
Yes
No
Confirmed / strongly suspected infection at
critical care admission*
Yes
No
If yes, was this a nosocomial (hospital acquired)
infection*
Yes
No
Site of infection*
Wound (1)
Lung (2)
Urinary (3)
Abdominal (4)
Other (5)
Heart rate (highest value)*
Systolic arterial pressure (lowest value)*
Mean arterial pressure (lowest value)*
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Lowest GCS (even if sedated)*
Core temperature (highest value)*
Arterial PaO2 (lowest value)*
FiO2 at the time of this PaO2*
Serum pH (lowest value)*
Serum bicarbonate (lowest value)*
Leucocytes (highest value)*
Platelets (lowest value)*
Bilirubin (highest value)*
Creatinine (highest value)*
Surgical site
Lower gastro-intestinal surgery*
Yes
No
Upper gastro-intestinal surgery*
Yes
No
Biliary tract surgery*
Yes
No
Liver surgery*
Yes
No
Pancreas surgery*
Yes
No
Head and Neck Surgery*
Yes
No
Gynaecological surgery*
Yes
No
4 / 6
Critical Care case record form (EuSOS)
Endocrine surgery*
Yes
No
Upper limb surgery*
Yes
No
Hip and lower limb surgery*
Yes
No
Kidney surgery*
Yes
No
Other urology surgery*
Yes
No
Spine surgery*
Yes
No
Lung surgery*
Yes
No
Transplant surgery*
Yes
No
Cutaneous and burns surgery*
Yes
No
Trauma surgery*
Yes
No
Breast surgery*
Yes
No
Pneumonectomy*
Yes
No
Lobectomy*
Yes
No
Pleural surgery*
Yes
No
Other thoracic surgery*
Yes
No
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Aortic surgery*
Yes
No
Carotid endarterectomy*
Yes
No
Peripheral vascular surgery*
Yes
No
Other vascular surgery*
Yes
No
All other procedures*
Yes
No
Highest vasoactive drug dose in the first
hour following admission
Dobutamine (highest dose in first hour following
admission)*
Dopamine (highest dose in first hour following
admission)*
Norepinephrine*
Epinephrine*
Dopexamine*
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Physiological data following 24 hours in
critical care (EuSOS)
European Surgical Outcomes Study (EuSOS)
http://clinicaltrials.gov/show/NCT01203605
All rights reserved. Please visit https://medical-data-
models.org/forms/5836
Physiological data following 24 hours
in critical care (EuSOS)
Physiological data following 24 hours in
critical care (Enter most severe
physiological data / highest drug dose in
previous 24 hours)
Arterial PaO2 (lowest value)*
FiO2 at the time of this PaO2*
Actual Glasgow coma score (lowest value)*
Serum Creatinine (highest value)*
Serum Bilirubin (highest value)*
Platelets (lowest value)*
Mean arterial pressure (lowest value)*
Dobutamine*
Dopamine*
Norepinephrine*
Epinephrine*
Dopexamine*
Airway*
Own (1)
Endotracheal tube (2)
Tracheostomy (3)
Other (4)
Ventilation*
Invasive ventilation (1)
Non-invasive ventilation (2)
None (3)
Renal replacement therapy*
Yes
No
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Physiological data following 48 hours in
critical care (EuSOS)
European Surgical Outcomes Study (EuSOS)
http://clinicaltrials.gov/show/NCT01203605
All rights reserved. Please visit https://medical-data-
models.org/forms/5837
Physiological data following 48 hours
in critical care (EuSOS)
Physiological data following 48 hours in
critical care (Enter most severe
physiological data / highest drug dose in
previous 24 hours)
Arterial PaO2 (lowest value)*
FiO2 at the time of this PaO2*
Actual Glasgow coma score (lowest value)*
Serum Creatinine (highest value)*
Serum Bilirubin (highest value)*
Platelets (lowest value)*
Mean arterial pressure (lowest value)*
Dobutamine*
Dopamine*
Norepinephrine*
Epinephrine*
Dopexamine*
Airway*
Own (1)
Endotracheal tube (2)
Tracheostomy (3)
Other (4)
Ventilation*
Invasive ventilation (1)
Non-invasive ventilation (2)
None (3)
Renal replacement therapy*
Yes
No
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European Surgical Outcomes Study (EuSOS)
http://clinicaltrials.gov/show/NCT01203605
All rights reserved. Please visit https://medical-data-
models.org/forms/5838
Critical care discharge data (EuSOS)
Critical care discharge data
Time of Critical care discharge (or death)*
Date of Critical care discharge (or death)*
Critical care discharge Planned*
Yes
No
Major therapeutic limitation during critical care
stay?*
Yes
No
Status at critical care discharge*
Alive (1)
Dead (2)
Status at Hospital discharge*
Alive (1)
Dead (2)
Still in hospital 60 days after surgery?*
Yes
No
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Diagnostic Imaging Report 
LOINC 18748-4
converted from CDA template
All rights reserved. Please visit https://medical-data-
models.org/forms/5840
Diagnostic Imaging Report (CDA)
ClinicalDocument
Title of Report*
Given name*
Family name
(recordTarget.patientRole.patient.name.family)*
Patient gender*
Date of Birth
(recordTarget.patientRole.patient.birthTime.value
)*
Documentation time (author.time.value)*
Document author given name
(author.assignedAuthor.assignedPerson.name.gi
ven)*
Document author family name
(author.assignedAuthor.assignedPerson.name.fa
mily)*
Information recipient given name
(informationRecipient.intendedRecipient.informati
onRecipient.name.given)*
Information recipient family name
(informationRecipient.intendedRecipient.informati
onRecipient.name.family)*
Service event code*
Service event name
(documentationOf.serviceEvent.code.attributes.di
splayName), e.g. Magnetic resonance
angiography, head; without contrast material(s)*
Date and time of service event
(documentationOf.serviceEvent.effectiveTime.low
.value)*
Performing entity code
(documentationOf.serviceEvent.performer.assign
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edEntity.code.attributes.code)*
Performing entity name
(documentationOf.serviceEvent.performer.assign
edEntity.code.displayName), e.g. Diagnostic
Radiology*
Performer given name
(documentationOf.serviceEvent.performer.assign
edEntity.assignedPerson.name.given)*
Performer family name
(documentationOf.serviceEvent.performer.assign
edEntity.assignedPerson.name.family)*
Modality code
(component.structuredBody.component.section.e
ntry.act.entryRelationship.act.code.qualifier.value
.attributes.code), e.g. CR*
Modality name
(component.structuredBody.component.section.e
ntry.act.entryRelationship.act.code.qualifier.value
.attributes.displayName), e.g. Computed
Radiography*
Storage System Code
(component.structuredBody.component.section.e
ntry.act.entryRelationship.act.entryRelationship.o
bservation.code.codeSystemName), e.g.
DCMUID*
Storage System Name
(component.structuredBody.component.section.e
ntry.act.entryRelationship.act.entryRelationship.o
bservation.code.attributes.displayName), e.g.
Computed Radiography Image Storage*
Reference to image
(component.structuredBody.component.section.e
ntry.act.entryRelationship.act.entryRelationship.o
bservation.text.reference.attributes.value)*
Indications for procedure
(component.structuredBody.component.section.t
ext)*
Medical history
(component.structuredBody.component.section.t
ext.paragraph.content)*
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Findings
(component.structuredBody.component.section.t
ext.paragraph.content)*
Finding ID
(component.structuredBody.component.section.t
ext.paragraph.content.attributes.ID)*
Finding value
(component.structuredBody.component.section.t
ext.paragraph.content)*
Source of Measurement
(component.structuredBody.component.section.t
ext.paragraph.content.linkHtml.href), Link to
source*
Impression
(component.structuredBody.component.section.t
ext.paragraph.content)*
3 / 3
Diagnostic Imaging Report (CDA)
First registration (DKKR)
German Pediatric Oncology Registry
http://www.kinderkrebsregister.de
All rights reserved. Please visit https://medical-data-
models.org/forms/5842
First registration (DKKR)
Administrative Angaben
MaligID(DKKR)*
Adresse der Klinik*
Telefonnummer der Klinik*
Nachname des Patienten*
Vorname des Patienten*
Geburtsdatum*
Geschlecht*
männl. (1)
weibl. (2)
Zum Zeitpunkt der Erkrankung Hauptwohnsitz in
Deutschland*
Ja
Nein
Adresse des Patienten*
Geburtsort (falls im Ausland Geburtsland)*
GPOH-PID*
Diagnose*
Lokalisation*
Stadium*
Malignitätsgrad*
Diagnosedatum*
Sicherung der Diagnose durch*
Klinik (inkl.bildgeb.Verfahren) (1)
Spezifische Diagnostik
(z.B.biochem./immunol.Tests) (2)
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Zytologie (3)
Histologie (4)
Autopsie (5)
unbekannt (6)
Seite*
rechts (1)
links (2)
beidseitig (3)
Mittellinie (4)
Systemerkrankung (5)
unbekannt (6)
Studienteilnahme*
Schriftliche Einwilligung zur Datenübermittlung an
das DKKR*
liegt vom Patienten vor (zwingend bei
mind. 16-Jährigen) (1)
liegt vom Sorgeberechtigen vor (2)
wurde verweigert (3)
wird baldmöglichst nachgereicht (4)
Die Informationsunterlagen des DKKR wurden
ausgehändigt*
Ja
Nein
Name des dokumentierenden Arztes*
Datum*
Unterschrift*
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Patient status (DKKR)
German Pediatric Oncology Registry
http://www.kinderkrebsregister.de
All rights reserved. Please visit https://medical-data-
models.org/forms/5843
Patient status (DKKR)
Administrative Angaben
Nachname des Patienten*
Vorname des Patienten*
Geburtsdatum*
Geschlecht*
männl. (1)
weibl. (2)
Pat.-Nr. (Studie)*
GPOH-PID*
MaligID(DKKR)*
Kliniknr. (DKKR)*
PatID (DKKR)*
Datum letzter Patientenkontakt*
Datum letzte Untersuchung*
Erste Vollremission erreicht*
Ja
Nein
Datum 1. Vollremission*
Auftreten eines ersten Ereignisses (Rezidiv,
Metastase, Lymphknotenbefall)*
Ja
Nein
Datum des Auftretens eines ersten Ereignisses
(Rezidiv, Metastase, Lymphknotenbefall)*
Auftreten einer Zweitneoplasie*
Ja
Nein
Zweitneoplasie Datum*
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Diagnose Zweitneoplasie*
Patient steht weiterhin in Kontakt mit unserer
Klinik*
Ja
Nein
Grund für keinen Kontakt*
Todesdatum*
Todesursache*
Erstneoplasie (1)
Rezidiv/Metastase (o.n.A.) (2)
Rezidiv/Metastase (Erstneoplasie) (3)
Tumorabhängigkeit nicht entscheidbar
(4)
Zweitneoplasie (5)
Therapie (6)
Rezidiv/Metastase (Zweitneoplasie) (7)
andere Todesurasche (8)
Sonstiges (9)
Todesursache Text*
Autopsie*
Ja
Nein
Name des dokumentierenden Arztes*
Datum*
Unterschrift*
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Radiology order form MS
EHR Radiology order form MS converted to ODM format
All rights reserved. Please visit https://medical-data-
models.org/forms/5853
Radiology order form MS
Radiologische Anforderung MS
Auftragsnummer*
Anforderungsdatum*
Art der Anforderung*
Dringlichkeit*
Status des Auftrags*
Name Patienten*
Behandelnder Arzt*
Telefon Behandelnder Arzt*
Anfordernde Klinik*
Anfordernde Station*
Telefon Anfordernde Station*
Name der Zielstelle*
Ergänzungsinfo*
Wunschtermin*
Transport*
Schwangerschaft*
Allergie*
Versicherung*
Voruntersuchungen*
Hinweis*
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TSH*
Kreatinin*
GFR*
fT3*
fT4*
Infektionsart*
Narkose*
Behindert*
Ja
Nein
Aktenzeichen*
Studienpatient*
Ja
Nein
Studienbezeichnung*
Fragestellung*
Klinischer Befund*
Bemerkungen*
Unterschrift*
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Hospital Anxiety and Depression Scale
(HADS)
Hospital Anxiety and Depression Scale (HADS) was
originally developed by [Zigmond, AS; Snaith, RP (1983).
"The hospital anxiety and depression scale". Acta
Psychiatrica Scandinavica 67 (6): 361–370] and is
commonly used by doctors to determine the levels of
anxiety and depression that a patient is experiencing.
see
http://en.wikipedia.org/wiki/Hospital_Anxiety_and_Depressi
on_Scale
All rights reserved. Please visit https://medical-data-
models.org/forms/5854
Hospital Anxiety and Depression
Scale (HADS)
Tick the box beside the reply that is
closest to how you have been feeling in
the past week. Don’t take too long over
you replies: your immediate is best.
I feel tense or 'wound up':*
Not at all (0)
From time to time, occasionally (1)
A lot of the time (2)
Most of the time (3)
I still enjoy the things I used to enjoy:*
Definitely as much (0)
Not quite so much (1)
Only a little (2)
Hardly at all (3)
I get a sort of frightened feeling as if something
awful is about to happen:*
Not at all (0)
A little, but it doesn't worry me (1)
Yes, but not too badly (2)
Very definitely and quite badly (3)
I can laugh and see the funny side of things:*
As much as I always could (0)
Not quite so much now (1)
Definitely not so much now (2)
Not at all (3)
Worrying thoughts go through my mind:*
Only occasionally (0)
From time to time, but not too often (1)
A lot of the time (2)
A great deal of the time (3)
I feel cheerful:*
Most of the time (0)
Sometimes (1)
Not often (2)
Not at all (3)
I can sit at ease and feel relaxed:*
Definitely (0)
Usually (1)
Not Often (2)
Not at all (3)
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I feel as if I am slowed down:*
Not at all (0)
Sometimes (1)
Very often (2)
Nearly all the time (3)
I get a sort of frightened feeling like 'butterflies' in
the stomach:*
Not at all (0)
Occasionally (1)
Quite Often (2)
Very Often (3)
I have lost interest in my appearance:*
I take just as much care as ever (0)
I may not take quite as much care (1)
I don't take as much care as I should (2)
Definitely (3)
I feel restless as I have to be on the move:*
Not at all (0)
Not very much (1)
Quite a lot (2)
Very much indeed (3)
I look forward with enjoyment to things:*
As much as I ever did (0)
Rather less than I used to (1)
Definitely less than I used to (2)
Hardly at all (3)
I get sudden feelings of panic:*
Not at all (0)
Not very often (1)
Quite often (2)
Very often indeed (3)
I can enjoy a good book or radio or TV program:*
Often (0)
Sometimes (1)
Not often (2)
Very seldom (3)
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SF-36 (RAND)
SF-36 (Short Form 36) Health Survey is a patient-reported
survey of patient health. 
Original SF-36 is based on Medical Outcome Study done
by RAND Corporation.
RAND 36-Item Health Survey 1.0 Questionnaire Items
http://www.rand.org/health/surveys_tools/mos/mos_core_3
6item_survey.html
http://en.wikipedia.org/wiki/SF-36
All rights reserved. Please visit https://medical-data-
models.org/forms/5855
SF-36 (RAND)
General Info
1. In general, would you say your health is:*
Excellent (1)
Very good (2)
Good (3)
Fair (4)
Poor (5)
2. Compared to one year ago, how would your
rate your health in general now?*
Much better now than one year ago (1)
Somewhat better now than one year ago
(2)
About the same (3)
Somewhat worse now than one year ago
(4)
Much worse now than one year ago (5)
The following items are about activities
you might do during a typical day. Does
your health now limit you in these
activities? If so, how much?
3. Vigorous activities, such as running, lifting
heavy objects, participating in strenuous sports*
Yes, Limited a Lot (1)
Yes, Limited a Little (2)
No, Not limited at All (3)
4. Moderate activities, such as moving a table,
pushing a vacuum cleaner, bowling, or playing
golf*
Yes, Limited a Lot (1)
Yes, Limited a Little (2)
No, Not limited at All (3)
5. Lifting or carrying groceries*
Yes, Limited a Lot (1)
Yes, Limited a Little (2)
No, Not limited at All (3)
6. Climbing several flights of stairs*
Yes, Limited a Lot (1)
Yes, Limited a Little (2)
No, Not limited at All (3)
7. Climbing one flight of stairs*
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Yes, Limited a Lot (1)
Yes, Limited a Little (2)
No, Not limited at All (3)
8. Bending, kneeling, or stooping*
Yes, Limited a Lot (1)
Yes, Limited a Little (2)
No, Not limited at All (3)
9. Walking more than a mile*
Yes, Limited a Lot (1)
Yes, Limited a Little (2)
No, Not limited at All (3)
10. Walking several blocks*
Yes, Limited a Lot (1)
Yes, Limited a Little (2)
No, Not limited at All (3)
11. Walking one block*
Yes, Limited a Lot (1)
Yes, Limited a Little (2)
No, Not limited at All (3)
12. Bathing or dressing yourself*
Yes, Limited a Lot (1)
Yes, Limited a Little (2)
No, Not limited at All (3)
During the past 4 weeks, have you had
any of the following problems with your
work or other regular daily activities as a
result of your physical health?
13. Cut down the amount of time you spent on
work or other activities*
Yes
No
14. Accomplished less than you would like*
Yes
No
15. Were limited in the kind of work or other
activities*
Yes
No
16. Had difficulty performing the work or other
activities (for example, it took extra effort)*
Yes
No
During the past 4 weeks, have you had
any of the following problems with your
work or other regular daily activities as a
result of any emotional problems (such as
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feeling depressed or anxious)?
17. Cut down the amount of time you spent on
work or other activities*
Yes
No
18. Accomplished less than you would like*
Yes
No
19. Didn't do work or other activities as carefully
as usual*
Yes
No
Past 4 weeks
During the past 4 weeks, to what extent has your
physical health or emotional problems interfered
with your normal social activities with family,
friends, neighbors, or groups?*
Not at all (1)
Slightly (2)
Moderately (3)
Quite a bit (4)
Extremely (5)
21. How much bodily pain have you had during
the past 4 weeks?*
None (1)
Very mild (2)
Mild (3)
Moderate (4)
Severe (5)
Very severe (6)
22. During the past 4 weeks, how much did pain
interfere with your normal work (including both
work outside the home and housework)?*
Not at all (1)
A little bit (2)
Moderately (3)
Quite a bit (4)
Extremely (5)
How much of the time during the past 4 weeks . .
.
23. Did you feel full of pep?*
All of the Time (1)
Most of the Time (2)
A Good Bit of the Time (3)
Some of the Time (4)
A Little of the Time (5)
None of the Time (6)
How much of the time during the past 4 weeks . .
.
24. Have you been a very nervous person?*
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All of the Time (1)
Most of the Time (2)
A Good Bit of the Time (3)
Some of the Time (4)
A Little of the Time (5)
None of the Time (6)
How much of the time during the past 4 weeks . .
.
25. Have you felt so down in the dumps that
nothing could cheer you up?*
All of the Time (1)
Most of the Time (2)
A Good Bit of the Time (3)
Some of the Time (4)
A Little of the Time (5)
None of the Time (6)
How much of the time during the past 4 weeks . .
.
26. Have you felt calm and peaceful?*
All of the Time (1)
Most of the Time (2)
A Good Bit of the Time (3)
Some of the Time (4)
A Little of the Time (5)
None of the Time (6)
How much of the time during the past 4 weeks . .
.
27. Did you have a lot of energy?*
All of the Time (1)
Most of the Time (2)
A Good Bit of the Time (3)
Some of the Time (4)
A Little of the Time (5)
None of the Time (6)
How much of the time during the past 4 weeks . .
.
28. Have you felt downhearted and blue?*
All of the Time (1)
Most of the Time (2)
A Good Bit of the Time (3)
Some of the Time (4)
A Little of the Time (5)
None of the Time (6)
How much of the time during the past 4 weeks . .
.
29. Did you feel worn out?*
All of the Time (1)
Most of the Time (2)
A Good Bit of the Time (3)
Some of the Time (4)
A Little of the Time (5)
None of the Time (6)
How much of the time during the past 4 weeks . .
.
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30. Have you been a happy person?*
All of the Time (1)
Most of the Time (2)
A Good Bit of the Time (3)
Some of the Time (4)
A Little of the Time (5)
None of the Time (6)
How much of the time during the past 4 weeks . .
.
31. Did you feel tired?*
All of the Time (1)
Most of the Time (2)
A Good Bit of the Time (3)
Some of the Time (4)
A Little of the Time (5)
None of the Time (6)
32. During the past 4 weeks, how much of the
time has your physical health or emotional
problems interfered with your social activities (like
visiting with friends, relatives, etc.)?*
All of the time (1)
Most of the time (2)
Some of the time (3)
A little of the time (4)
None of the time (5)
General statements
33. I seem to get sick a little easier than other
people*
Definitely True (1)
Mostly True (2)
Don't Know (3)
Mostly False (4)
Definitely False (5)
34. I am as healthy as anybody I know*
Definitely True (1)
Mostly True (2)
Don't Know (3)
Mostly False (4)
Definitely False (5)
35. I expect my health to get worse*
Definitely True (1)
Mostly True (2)
Don't Know (3)
Mostly False (4)
Definitely False (5)
36. My health is excellent*
Definitely True (1)
Mostly True (2)
Don't Know (3)
Mostly False (4)
Definitely False (5)
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Peripheral Atherosclerotic Disease (PAD) -
Lower Extremity data elements
2012 ACCF / AHA Data Standard
Peripheral Atherosclerotic Disease (PAD)
Lower Extremity data elements
see
http://www.ncbi.nlm.nih.gov/pubmed/22144570
All rights reserved. Please visit https://medical-data-
models.org/forms/5873
Peripheral Atherosclerotic Disease
(PAD) - Lower Extremity data
elements
Patient assessment: Signs and Symptoms
Asymptomatic*
Yes
No
Claudication characteristics*
Claudication description*
Claudication location*
Claudication: walking*
Claudication: Date of onset*
Claudication: Duration of symptoms*
Claudication: stability of symptoms*
Improved (1)
Stabilized (2)
Worsened (3)
Atypical symptoms*
Ischemic rest pain*
Tissue loss*
Acute Limb Ischemia*
Patient Assessment: Physical evaluation
Pulses*
Bruits*
Elevation pallor*
Yes
1 / 5
No
Reperfusion delay*
Yes
No
Dependent rubor*
Yes
No
Acute limb ischemia*
Tissue loss: characteristics*
Tissue loss: affected limb*
Left (1)
Right (2)
Bilateral (3)
Tissue loss: location*
Tissue loss: wound area*
Tissue loss: infection*
Yes
No
Tissue loss: type*
Minor: nonhealing ulcer, focal gangrene
with diffuse pedal ischemia (1)
Major: extending above transmetatarsal
level; functional foot no longer
salvageable (2)
Tissue loss: depth/Wagner grade*
Pre- or postulcerative lesion (Grade 0)
Partial/full thickness ulcer (Grade 1)
Probing to tendon or capsule (Grade 2)
Deep with osteitis (Grade 3)
Partial foot gangrene (Grade 4)
Whole foot gangrene (Grade 5)
Diagnostic Testing: Noninvasive
Procedures
Ankle Brachial Index/Toe Brachial Index*
Treadmill Exercise*
Segmental Pressure Examination*
Pulse Volume Recording*
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elements
Transcutaneous Oxygen Pressure*
Duplex Ultrasound*
Peak systolic velocity*
Category of stenosis*
Bypass graft*
Peak systolic velocity of bypass graft*
Ratios of peak systolic velocities along bypass
graft*
Category of bypass graft stenosis*
0%–49% (1)
50%–99% (2)
Occluded (3)
Magnetic Resonance Angiography*
CT Angiography*
Diagnostic Testing: Invasive procedures
Catheter Angiography*
Pharmacological Therapy for Symptoms of
Claudication
Cilostazol*
Pentoxifylline*
Exercise Rehabilitation for Intermittent
Claudication
Exercise Program Assessment*
Exercise Prescription*
Therapeutic Procedures: Endovascular
and Open Surgical Revascularization
Endovascular Revascularization*
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elements
Open Surgery*
Outcomes of Endovascular/Open Surgery
Procedures
Time point of outcome*
Periprocedure (24 h) (1)
Procedure related (30 d) (2)
3 mo (3)
6 mo (4)
1 y (5)
Serious adverse event*
No (0)
Hospitalization/prolonged hospitalization
(1)
Loss of limb or function of organ system
(2)
Persistent or significant disability or
incapacity (3)
Death (4)
Complications of endovascular procedure*
Pseudoaneurysm (1)
Infection (10)
Requirement of intervention to prevent
permanent impairment/damage (11)
AV fistula (2)
Hematoma (3)
Dissection (4)
Vessel thrombosis (5)
Vessel perforation (6)
Atheromatous embolization (7)
Contrast nephropathy (8)
Contrast hypersensitivity (9)
Complications of open surgery*
no complication (0)
Minor complication (specify) (1)
Thrombosis (10)
Compartment syndrome (11)
Acute graft failure (12)
Death (2)
Shock (cardiogenic or septic) (3)
MI (4)
Stroke (ischemic, hemorrhagic, unknown
type) (5)
Renal failure (6)
Prolonged hospitalization (7)
Infection (8)
Coagulopathy (9)
Clinical Outcomes: Limb-Related
Outcomes
Time point of outcome*
1 mo (1)
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3 mo (2)
6 mo (3)
1 y (4)
Symptoms (limb)*
Limb-related outcomes: functional capacity*
Noninvasive assessment of outcome*
Patency*
Primary (1)
Assisted (2)
Secondary (3)
Wound healing characteristics*
Cardiovascular outcomes
New cardiovascular ischemic event*
Angina (1)
MI (2)
Coronary artery revascularization (3)
CHF (4)
TIA (5)
Stroke (ischemic, hemorrhagic, unknown
type) (6)
Carotid artery revascularization (7)
Death (8)
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Abdominal Aortic Aneurysm (AAA)
data elements
Anamnese (Aortenaneurysma)
Jetzige Anamnese (Aortenaneurysma)*
No symptoms (0)
Abdominal pain (1)
Back pain (2)
Groin pain (3)
Leg pain (4)
Frühere Anamnese (Aortenaneurysma)*
Aneurysms or dissection (Indicate
location(s) and extent) (1)
Prior aneurysm surgery (2)
Marfan syndrome (3)
Ehlers-Danlos syndrome (4)
Aortic surgery or endovascular repair
(Indicate location(s), type, and extent of
repair) (5)
Aortitis (6)
Other inflammatory or infectious
disorders (Giant cell arteritis, Takayasu’s
arteritis, Behc¸et’s syndrome, Infection)
(7)
Familienanamnese (Aortenaneurysma)*
Aneurysms or dissections (Indicate
location(s)) (1)
Marfan syndrome (2)
Ehlers-Danlos syndrome (3)
Loeys-Dietz syndrome (4)
Other (5)
Körperliche Untersuchung
Body habitus*
Thin (1)
Normal (2)
Obese (3)
Aortic pulsations*
Ja
Nein
Aortic pulsation characteristics*
Normal (1)
Expansile (2)
Aortic diameter*
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Abdominal bruit*
Ja
Nein
Abdominal aortic area tenderness*
Ja
Nein
Abdominal tenderness*
Ja
Nein
Abdominal tenderness location*
Lumbar spinal tenderness*
Ja
Nein
Arterial pulse quality*
Diagnostik, nicht-invasiv
Ultraschall*
Magnetic Resonance Imaging*
Computed Tomography*
Diagnostics, invasive
Catheter Angiography*
Therapeutic Procedures
Open AAA Repair*
Endovascular AAA Repair*
Blood loss*
Blood products*
Auto transfused blood (specify volume)
(1)
Packed RBCs (2)
Fresh frozen plasma (3)
Platelets (4)
Other (specify) (5)
OP-Zeit*
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Time to extubation*
Immediate (0)
Postoperative day (specify day number)
(1)
Oral intake*
Length of stay in ICU*
Length of stay in step-down unit*
Postoperative complications*
None (0)
Bleeding (1)
Cardiac (2)
Infections (3)
Pulmonary (4)
Renal (5)
Neurological (6)
Reoperation (7)
Other (specify) (8)
Length of stay, total*
Discharge status*
Discharged to home or self-care (1)
Discharged/transferred to short-term
general hospital for inpatient care (2)
Discharged/transferred to SNF with
Medicare certification in anticipation of
skilled care (3)
Discharged/transferred to ICF (4)
Discharged/transferred to standard
rehabilitation facility (5)
Discharged/transferred to ventilator
rehabilitation facility (6)
Discharged/transferred to another type of
healthcare institution other than the
above (7)
Patient died (8)
Patient counseling education
Medication instruction*
Recognition of new or worsening symptoms*
Diet counseling*
Sodium restriction (1)
Fluid restriction (2)
Referral to dietitian for weight
management and/or advanced nutritional
instruction (3)
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Other (specify) (4)
Smoking cessation*
Counseling (may be basic or advanced)
(1)
Written materials (2)
Referral to smoking cessation program
(3)
Drugs to help with smoking cessation (4)
Activity counseling*
Follow-Up
Follow-Up Open repair*
Follow-up Endovascular/hybrid approach*
Outcomes of Open AAA and
Endovascular Repair
Time point of outcome*
Periprocedure (24 h) (0)
Procedure related (30 d) (1)
3 mo (2)
6 mo (3)
1 y (4)
Other (5)
Serious adverse event*
Ja
Nein
Complications of endovascular repair*
Complications of open repair*
Graft or endograft-related outcomes*
Cardiovascular outcomes*
Arterial pulse quality*
Ankle Brachial Index (ABI)*
Open AAA repair: long-term outcomes*
no complication (0)
Infection (1)
Aortoenteric fistulae (2)
Second aneurysm formation (remote
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from open AAA repair) (3)
Paragraft aneurysm formation (close or
near old aneurysm repair) (4)
Need for secondary procedure (5)
Endovascular AAA repair: long-term outcomes*
no complication (0)
Infection (1)
Aortoenteric fistulae (2)
Secondary aneurysm formation (remote
from open AAA repair) (3)
Paragraft aneurysm formation (close or
near old aneurysm repair) (4)
Endoleak (5)
Need for secondary procedure (6)
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Renal Artery Disease data elements
Anamnese
Hoher Blutdruck mit Verdacht auf
Nierenarterienerkrankung*
New-onset hypertension in those <30 or
>55 years of age (1)
Accelerated hypertension (2)
Refractory hypertension (3)
Hypertension and concomitant
atherosclerotic disease in other vascular
territories (4)
Hypertension urgency/emergency (5)
Akute Niereninsuffizienz in der Anamnese*
Chronische Nierenerkrankung*
No known kidney disease (Stage 0)
Kidney damage with normal or high
GFR: > (Stage 1)
Kidney damage with mildly decreased
GFR: 60–89 mL/min/1.73 m2 (Stage 2)
Moderately decreased GFR: 30–59
mL/min/1.73 m2 (Stage 3)
Severely decreased GFR: 15–29
mL/min/1.73 m2 (Stage 4)
Kidney failure: GFR <15 mL/min/1.73 m2
or on dialysis (Stage 5)
Ursache der chronischen Nierenerkrankung*
Glomerular disease (1)
Tubular/interstitial disease (2)
Obstructive uropathy (3)
Polycystic kidney disease (4)
Other (specify) (5)
Unknown (6)
Andere Nierenerkrankung*
Single kidney (1)
Cancer (2)
Nephrectomy (3)
Past trauma (4)
Other (5)
Recurrent flash pulmonary edema*
Other cardiovascular disease*
Diagnostics, noninvasive
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Duplex Ultrasound*
Magnetic Resonance Angiography*
Computed Tomographic Angiography*
Diagnostics, invasive
Catheter-Based Angiography*
Medication
Antihypertensive therapy*
Lipid-lowering therapy*
Antiplatelet therapy*
Therapy, invasive
Angioplasty renal artery/Stenting*
Procedure Indications and Anatomic Variables*
Lesions*
Device*
Renal Artery Surgical Revascularization*
Outcomes of Endovascular/Open Surgical
Procedures
Time point of outcome*
Periprocedure (24 h) (0)
Procedure related (30 d) (1)
3 mo (2)
6 mo (3)
1 y (4)
Complications of endovascular procedure*
none (0)
Pseudoaneurysm (1)
Requirement of intervention to prevent
permanent impairment/damage (10)
Other (specify) (11)
AV fistula (2)
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Hematoma (3)
Dissection (4)
Vessel thrombosis (5)
Vessel perforation (6)
Atheromatous embolization (7)
Contrast nephropathy (8)
Contrast hypersensitivity (9)
Complications of open surgery*
Total length of stay*
Discharge status*
Patient education/Counseling
Medication instruction*
Recognition of new or worsening symptoms*
Diet counseling*
Smoking cessation counseling*
Activity counseling*
Follow-up
Follow-Up Open repair*
Follow-Up Endovascular*
Outcome assessment
Outcome Time points*
1 mo (1)
3 mo (2)
6 mo (3)
1 y (4)
Blood pressure*
Renal function*
Improvement: Change of at least 1 stage
for the better (eg, going from stage 3 to
stage 2) (1)
Stable: No change in stage (2)
Decline: Change for the worse of at least
3 / 4
Renal Artery Disease data elements
1 stage (eg, going from stage 3 to stage
4) (3)
Morbidity*
Myocardial Infarction (MI) (1)
Congestive Heart Failure (CHF) (2)
Stroke (3)
Other adverse cardiovascular event (4)
Hospitalization/prolonged hospitalization
(5)
Loss of function of organ system (6)
Persistent or significant disability or
incapacity (7)
Death (indicate causes) (8)
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Erhebungsbogen Neuropsychologie
SHT-Register
Erhebungsdatum
Datum der Erhebung*
Unfalldatum*
Aufmerksamkeit
Alertness, tonisch (in %)*
Alertness, mit Ton (in %)*
Alertness, phasisch (in %)*
Selektive Aufmerksamkeit, Reaktionszeit (in %)*
Selektive Aufmerksamkeit, falsch Positive (in %)*
Selektive Aufmerksamkeit, Auslassungsfehler (in
%)*
Geteilte Aufmerksamkeit (auditiv), Reaktionszeit
(in %)*
Geteilte Aufmerksamkeit (visuell), Reaktionszeit
(in %)*
Geteilte Aufmerksamkeit, falsch Positive (in %)*
Geteilte Aufmerksamkeit, Auslassungsfehler (in
%)*
Lernen / Gedächtnis
VLMT, 1. Durchgang (in %)*
VLMT, Summe 1.-5. Durchgang (in %)*
VLMT, Ablenkungsliste (in %)*
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VLMT, Interferenz (in %)*
VLMT, verzögerter Abruf (in %)*
VLMT, Wiedererkennen (in %)*
Exekutive
Mosaiktest (in Wertpunkten)*
Rechnerisches Denken (in Wertpunkten)*
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Frühreha Verlaufsassessment
Erhebungsdatum
Datum der Erhebung*
Unfalldatum*
Vigilanz
Bewusstsein / Aufmerksamkeit*
nicht beurteilbar (0)
schwer eingeschränkt (1)
leicht eingeschränkt (2)
normale altersgerechte Funktion (3)
Orientierung: Zeit*
nicht beurteilbar (0)
schwer eingeschränkt (1)
leicht eingeschränkt (2)
normale altersgerechte Funktion (3)
Energie und Antrieb*
nicht beurteilbar (0)
schwer eingeschränkt (1)
leicht eingeschränkt (2)
normale altersgerechte Funktion (3)
Einschlafen*
nicht beurteilbar (0)
schwer eingeschränkt (1)
leicht eingeschränkt (2)
normale altersgerechte Funktion (3)
Durchschlafen*
nicht beurteilbar (0)
schwer eingeschränkt (1)
leicht eingeschränkt (2)
normale altersgerechte Funktion (3)
Körperfunktionen
Atmungsstabilität*
nicht beurteilbar (0)
schwer eingeschränkt (1)
leicht eingeschränkt (2)
normale altersgerechte Funktion (3)
Herzfrequenzstabilität*
nicht beurteilbar (0)
schwer eingeschränkt (1)
leicht eingeschränkt (2)
normale altersgerechte Funktion (3)
Blutdruckstabilität*
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nicht beurteilbar (0)
schwer eingeschränkt (1)
leicht eingeschränkt (2)
normale altersgerechte Funktion (3)
Tracheostoma*
Ja (0)
Nein (3)
Maschinelle Beatmung*
Ja (0)
Nein (3)
PEG-Sonde*
Ja (0)
Nein (3)
Lippenbewegungen*
nicht beurteilbar (0)
schwer eingeschränkt (1)
leicht eingeschränkt (2)
normale altersgerechte Funktion (3)
Zungenbewegungen*
nicht beurteilbar (0)
schwer eingeschränkt (1)
leicht eingeschränkt (2)
normale altersgerechte Funktion (3)
Kauen*
nicht beurteilbar (0)
schwer eingeschränkt (1)
leicht eingeschränkt (2)
normale altersgerechte Funktion (3)
Schlucken*
nicht beurteilbar (0)
schwer eingeschränkt (1)
leicht eingeschränkt (2)
normale altersgerechte Funktion (3)
Essen*
nicht beurteilbar (0)
schwer eingeschränkt (1)
leicht eingeschränkt (2)
normale altersgerechte Funktion (3)
Trinken*
nicht beurteilbar (0)
schwer eingeschränkt (1)
leicht eingeschränkt (2)
normale altersgerechte Funktion (3)
Mastdarmkontrolle*
nicht beurteilbar (0)
schwer eingeschränkt (1)
leicht eingeschränkt (2)
normale altersgerechte Funktion (3)
Blasenkontrolle*
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nicht beurteilbar (0)
schwer eingeschränkt (1)
leicht eingeschränkt (2)
normale altersgerechte Funktion (3)
Miktionsverhalt*
nicht beurteilbar (0)
schwer eingeschränkt (1)
leicht eingeschränkt (2)
normale altersgerechte Funktion (3)
Motorik
Gelenkbeweglichkeit*
nicht beurteilbar (0)
schwer eingeschränkt (1)
leicht eingeschränkt (2)
normale altersgerechte Funktion (3)
Muskelkraft*
nicht beurteilbar (0)
schwer eingeschränkt (1)
leicht eingeschränkt (2)
normale altersgerechte Funktion (3)
Muskeltonus *
nicht beurteilbar (0)
schwer eingeschränkt (1)
leicht eingeschränkt (2)
normale altersgerechte Funktion (3)
Spastik*
nicht beurteilbar (0)
schwer eingeschränkt (1)
leicht eingeschränkt (2)
normale altersgerechte Funktion (3)
Kontrakturen*
nicht beurteilbar (0)
schwer eingeschränkt (1)
leicht eingeschränkt (2)
normale altersgerechte Funktion (3)
Motorische Reflexe*
nicht beurteilbar (0)
schwer eingeschränkt (1)
leicht eingeschränkt (2)
normale altersgerechte Funktion (3)
Auge-Hand-Koordination*
nicht beurteilbar (0)
schwer eingeschränkt (1)
leicht eingeschränkt (2)
normale altersgerechte Funktion (3)
Kopfkontrolle*
nicht beurteilbar (0)
schwer eingeschränkt (1)
leicht eingeschränkt (2)
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normale altersgerechte Funktion (3)
Rumpfkontrolle*
nicht beurteilbar (0)
schwer eingeschränkt (1)
leicht eingeschränkt (2)
normale altersgerechte Funktion (3)
Spontanbewegungen*
nicht beurteilbar (0)
schwer eingeschränkt (1)
leicht eingeschränkt (2)
normale altersgerechte Funktion (3)
Feinmotorik der Hand*
nicht beurteilbar (0)
schwer eingeschränkt (1)
leicht eingeschränkt (2)
normale altersgerechte Funktion (3)
Zielmotorik*
nicht beurteilbar (0)
schwer eingeschränkt (1)
leicht eingeschränkt (2)
normale altersgerechte Funktion (3)
Drehen im Liegen*
nicht beurteilbar (0)
schwer eingeschränkt (1)
leicht eingeschränkt (2)
normale altersgerechte Funktion (3)
Sitzen*
nicht beurteilbar (0)
schwer eingeschränkt (1)
leicht eingeschränkt (2)
normale altersgerechte Funktion (3)
Stehen*
nicht beurteilbar (0)
schwer eingeschränkt (1)
leicht eingeschränkt (2)
normale altersgerechte Funktion (3)
Gehen*
nicht beurteilbar (0)
schwer eingeschränkt (1)
leicht eingeschränkt (2)
normale altersgerechte Funktion (3)
Treppensteigen*
nicht beurteilbar (0)
schwer eingeschränkt (1)
leicht eingeschränkt (2)
normale altersgerechte Funktion (3)
Fortbewegung mit Gerät (Rollstuhl)*
nicht beurteilbar (0)
schwer eingeschränkt (1)
leicht eingeschränkt (2)
4 / 9
Frühreha Verlaufsassessment SHT-Register
normale altersgerechte Funktion (3)
Unwillkürliche Bewegungen
Rigor*
nicht beurteilbar (0)
schwer eingeschränkt (1)
leicht eingeschränkt (2)
normale altersgerechte Funktion (3)
Dystonie*
nicht beurteilbar (0)
schwer eingeschränkt (1)
leicht eingeschränkt (2)
normale altersgerechte Funktion (3)
Athetose*
nicht beurteilbar (0)
schwer eingeschränkt (1)
leicht eingeschränkt (2)
normale altersgerechte Funktion (3)
Chorea*
nicht beurteilbar (0)
schwer eingeschränkt (1)
leicht eingeschränkt (2)
normale altersgerechte Funktion (3)
Myoklonien*
nicht beurteilbar (0)
schwer eingeschränkt (1)
leicht eingeschränkt (2)
normale altersgerechte Funktion (3)
Tremor*
nicht beurteilbar (0)
schwer eingeschränkt (1)
leicht eingeschränkt (2)
normale altersgerechte Funktion (3)
Tics*
nicht beurteilbar (0)
schwer eingeschränkt (1)
leicht eingeschränkt (2)
normale altersgerechte Funktion (3)
Epilepsie
Fokal*
nicht beurteilbar (0)
schwer eingeschränkt (1)
leicht eingeschränkt (2)
normale altersgerechte Funktion (3)
Generalisiert*
nicht beurteilbar (0)
schwer eingeschränkt (1)
leicht eingeschränkt (2)
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normale altersgerechte Funktion (3)
Tonisch*
nicht beurteilbar (0)
schwer eingeschränkt (1)
leicht eingeschränkt (2)
normale altersgerechte Funktion (3)
Klonisch*
nicht beurteilbar (0)
schwer eingeschränkt (1)
leicht eingeschränkt (2)
normale altersgerechte Funktion (3)
Sensorik / Wahrnehmung /
Hirnnervenfunktionen
Fühlen*
nicht beurteilbar (0)
schwer eingeschränkt (1)
leicht eingeschränkt (2)
normale altersgerechte Funktion (3)
Schmecken*
nicht beurteilbar (0)
schwer eingeschränkt (1)
leicht eingeschränkt (2)
normale altersgerechte Funktion (3)
Schmerz*
nicht beurteilbar (0)
schwer eingeschränkt (1)
leicht eingeschränkt (2)
normale altersgerechte Funktion (3)
Reaktion auf akustischen Reiz*
nicht beurteilbar (0)
schwer eingeschränkt (1)
leicht eingeschränkt (2)
normale altersgerechte Funktion (3)
Verstehen von Sprache*
nicht beurteilbar (0)
schwer eingeschränkt (1)
leicht eingeschränkt (2)
normale altersgerechte Funktion (3)
VEP*
nicht beurteilbar (0)
schwer eingeschränkt (1)
leicht eingeschränkt (2)
normale altersgerechte Funktion (3)
Visuelle Wahrnehmung*
nicht beurteilbar (0)
schwer eingeschränkt (1)
leicht eingeschränkt (2)
normale altersgerechte Funktion (3)
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Lesen*
nicht beurteilbar (0)
schwer eingeschränkt (1)
leicht eingeschränkt (2)
normale altersgerechte Funktion (3)
Strabismus*
nicht beurteilbar (0)
schwer eingeschränkt (1)
leicht eingeschränkt (2)
normale altersgerechte Funktion (3)
Nystagmus*
nicht beurteilbar (0)
schwer eingeschränkt (1)
leicht eingeschränkt (2)
normale altersgerechte Funktion (3)
Stimme / Sprache
Laute*
nicht beurteilbar (0)
schwer eingeschränkt (1)
leicht eingeschränkt (2)
normale altersgerechte Funktion (3)
Lautstärke*
nicht beurteilbar (0)
schwer eingeschränkt (1)
leicht eingeschränkt (2)
normale altersgerechte Funktion (3)
Motorisch (Aphasie)*
nicht beurteilbar (0)
schwer eingeschränkt (1)
leicht eingeschränkt (2)
normale altersgerechte Funktion (3)
Sensorisch (Aphasie)*
nicht beurteilbar (0)
schwer eingeschränkt (1)
leicht eingeschränkt (2)
normale altersgerechte Funktion (3)
Aktivität / Partizipation / Kommunikation /
Neuropsychologie
Aufmerksamkeit fokussieren*
nicht beurteilbar (0)
schwer eingeschränkt (1)
leicht eingeschränkt (2)
normale altersgerechte Funktion (3)
Kommunikationsgeräte nutzen*
nicht beurteilbar (0)
schwer eingeschränkt (1)
leicht eingeschränkt (2)
normale altersgerechte Funktion (3)
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Lesen*
nicht beurteilbar (0)
schwer eingeschränkt (1)
leicht eingeschränkt (2)
normale altersgerechte Funktion (3)
Schreiben*
nicht beurteilbar (0)
schwer eingeschränkt (1)
leicht eingeschränkt (2)
normale altersgerechte Funktion (3)
Rechnen*
nicht beurteilbar (0)
schwer eingeschränkt (1)
leicht eingeschränkt (2)
normale altersgerechte Funktion (3)
Gedächtnis*
nicht beurteilbar (0)
schwer eingeschränkt (1)
leicht eingeschränkt (2)
normale altersgerechte Funktion (3)
Freude*
nicht beurteilbar (0)
schwer eingeschränkt (1)
leicht eingeschränkt (2)
normale altersgerechte Funktion (3)
Ärger*
nicht beurteilbar (0)
schwer eingeschränkt (1)
leicht eingeschränkt (2)
normale altersgerechte Funktion (3)
Mimik*
nicht beurteilbar (0)
schwer eingeschränkt (1)
leicht eingeschränkt (2)
normale altersgerechte Funktion (3)
Selbstversorgung / Hygiene
Mundhygiene*
nicht beurteilbar (0)
schwer eingeschränkt (1)
leicht eingeschränkt (2)
normale altersgerechte Funktion (3)
Sich selbst waschen*
nicht beurteilbar (0)
schwer eingeschränkt (1)
leicht eingeschränkt (2)
normale altersgerechte Funktion (3)
Zur Toilette gehen*
nicht beurteilbar (0)
schwer eingeschränkt (1)
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leicht eingeschränkt (2)
normale altersgerechte Funktion (3)
An-/Auskleiden*
nicht beurteilbar (0)
schwer eingeschränkt (1)
leicht eingeschränkt (2)
normale altersgerechte Funktion (3)
Transfer Bett-(Roll)Stuhl*
nicht beurteilbar (0)
schwer eingeschränkt (1)
leicht eingeschränkt (2)
normale altersgerechte Funktion (3)
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NP-Score
Erhebungsdatum
Datum der Erhebung*
Unfalldatum*
Hattinger Kognitions Score (NP-Score
(Hattingen)) SHT-Register
Gedächtnis (anterograd)*
sehr gutes Gedächtnis und Lernen (1)
durchschnittliche Lernleistung (2)
leichte Auffälligkeiten im Lernen (3)
vergisst Informationen über einen Tag (4)
behält Informationen innerhalb einer TE
(5)
schwerstgradiges amnestisches
Syndrom d.h. Sekundengedächtnis (6)
Aufmerksamkeit*
gute geteilte Aufmerksamkeit (1)
gute selektive Aufmerksamkeit aber
Defizite in der geteilten Aufmerksamkeit
(2)
gute Alertness; aber Defizite in der
selektiven und geteilten Aufmerksamkeit
(3)
Verlangsamung in der Alertness, leichte
Ablenkbarkeit (4)
starke Verlangsamung in der Alertness;
vermehrte Ablenkbarkeit (5)
massive Ablenkbarkeit; kann Aufgaben
nur kurzfristig bearbeiten (6)
Exekutive*
schnelles und sicheres Planen mit
vorausschauendem Denken (1)
Planen mit vorausschauendem Denken;
leicht unsicher (2)
leichte Unsicherheiten im Planen mit
vorausschauendem Denken, Arbeitsstil
leicht auffällig (3)
impulsiver Stil; leichte
Arbeitsgedächtnisdefizite
Regelverletzungen (4)
stark impulsiver Stil, deutliche
Regelverletzungen (5)
kein vorausschauendes Denken etc.
möglich, fast ausschließlich impulsiver
Stil und Regelverletzungen (6)
Verhalten*
völlig alters- und bildungsgemäß; sozial
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adäquat und unauffällig (1)
leichte Abweichung, gelegentlich
auffälliges Verhalten (2)
leichte Auffälligkeiten in Stress (3)
leichte Distanzminderung etc.;
Auffälligkeiten werden wöchentlich
deutlich (4)
deutliche Distanzminderung etc.; tägliche
Auffälligkeiten (5)
massive Distanzminderung; massive,
tägliche Auffälligkeiten (6)
Wahrnehmung / Visuokonstruktion*
kann komplexe Muster (auch 3-D) sicher
und schnell bearbeiten (1)
Mosaik knapp durchschnittlich (2)
Kopie der ROF und Mosaiktest leicht
auffällig d.h. unterer Durchschnitt;
Simultanextinktion unauffällig (3)
Simultanextinktion; Exploration unsicher;
Lesen unsicher (4)
schweres Neglectsyndrom (Exploration
bis zur Mitte) (5)
schwerstes Neglectsyndrom (Exploration
nur rechts) (6)
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Outcome
Allgemeines
Datum der Outcome-Abfrage*
Unfalldatum*
Behandlungsphase*
Akutbehandlung auf Intensiv- oder
Normalstation Phase A (1)
Frührehabilitation Phase B (Barthel-
Index 0–30 Punkte) (2)
Weiterführende Rehabilitation Phase C
(Barthel-Index 35–65 Punkte) (3)
AHB – Anschlussheilbehandlung Phase
D (Barthel-Index ab 70 Punkte) (4)
Ambulante Rehabilitation Phase E (5)
Zustandserhaltende Pflege Phase F (6)
Kostenträger*
Gesetzliche Krankenkasse (1)
Private Krankenkasse (2)
Haftpflichtversicherung (3)
Berufsgenossenschaft (4)
Unfallkasse (5)
Rente (6)
Glasgow Outcome Scale*
1: Tod (1)
2: persistierender vegetativer Status (2)
3: schwere Behinderung (3)
4: mäßige Behinderung (4)
5: geringe Behinderung (5)
6: keine erkennbaren Spätfolgen (6)
Gross Motor Function Level*
I: Fortbewegung nicht eingeschränkt,
Gehstrecke normal (1)
II: Fortbewegung oder Gehstrecke
eingeschränkt selbstständig (2)
III: Fortbewegung mit Gehstützen oder
im Rollstuhl selbständig (3)
IV: Fortbewegung im Rollstuhl, ohne
Rollstuhl nur mit Begleitperson (4)
V: Fortbewegung im Rollstuhl mit
Begleitperson (5)
Therapien
Therapieeinheiten pro Woche*
Krankengymnastik*
Ja
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Nein
Ergotherapie*
Ja
Nein
Logopädie*
Ja
Nein
Neuropsychologie*
Ja
Nein
Psychotherapie*
Ja
Nein
sonstige Kassenfinanzierte Therapie*
sonstige nicht Kassenfinanzierte Therapie*
Neurologisches Outcome
Epilepsie*
keine (1)
fokal (2)
generalisiert (3)
antiepileptische Medikation*
Ja
Nein
Anfälle*
Frühestanfälle (0)
Frühanfälle (1)
Spätanfälle (2)
EEG-Auffälligkeit
EEG-Auffälligkeit*
Verlangsamung (0)
Anfallsbereitschaft (1)
keine (2)
EEG-Parameter*
keine (1)
fokal (2)
generalisiert (3)
sensorisches Defizit*
Ja
Nein
sensorisches Defizit Freitext*
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Arbeit
Return to Work*
Ja
Nein
Rechtliche / finanzielle Absicherung*
KG (1)
ALG I/II (2)
EM-Rente (3)
Grundsicherung (4)
Stufenweise berufliche Wiedereingliederung*
Ja
Nein
Dauer der beruflichen Wiedereingliederung (in
Monaten)*
Arbeitgeberwechsel*
Ja
Nein
Jobcoaching*
Ja
Nein
Fortsetzung Schule / Studium*
Ja
Nein
Schule
Schulwechsel / Zurückstufung*
Zurück in die Ursprungsklasse (1)
Zurück in die Ursprungsschule (2)
Schulwechsel (3)
Werkstatt für Behinderte*
Ja
Nein
Berufliche Reha*
Ja
Nein
Selbstständigkeit
Wiedererlangung Fahrtauglichkeit*
Ja (1)
Nein (2)
Nicht zutreffend (3)
Pflegebedürftigkeit*
Ja
Nein
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Pflegestufe*
Altersgemäßer vermehrter Betreuungsbedarf*
Ja
Nein
Schwerbehindertenausweis GdB*
Ja
Nein
Schwerbehindertenausweis GdB Merkzeichen*
aG: Außergewöhnliche Gehbehinderung
(aG)
B: Berechtigung zur Mitnahme einer
Begleitperson bei der Benutzung
öffentlicher Verkehrsmittel (B)
BI: Blind (BI)
G: Erhebliche Beeinträchtigung der
Bewegungsfähigkeit im Straßenverkehr
(G)
GI: Gehörlos (GI)
H: Hilflos im Sinne des
Einkommensteuergesetzes, nicht im
Sinne des SGB XII (H)
RF:Ermäßigung des Rundfunkbeitrags
um 2/3 auf Antrag (RF)
Selbstständigkeit (Erwachsene)
Gesetzliche Betreuung*
Ja
Nein
Selbständiges Wohnen / Leben*
ja (1)
nein (2)
mit Einschränkungen (3)
Partnerschaft / Ehe*
besteht weiter (1)
beendet (2)
neu (3)
Soziales Umfeld
Familienbegleitende Dienste*
Ja
Nein
Fahrdienst*
Ja
Nein
Sozialpädagogische Familienhilfe*
Ja
Nein
Integrationshelfer*
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Ja
Nein
Soziales Netzwerk / Freundeskreis*
besteht weiter (1)
mit Einschränkungen (2)
neu (3)
Teilhabescore
Schulisch / berufliche Tätigkeit*
Förderschule mit vollst. Unterstützung (0)
Förderschule (1)
Integrationsklasse mit viel Hilfen (2)
Integrationsklasse mit geringer
Unterstützung (3)
Regelschule mit
Hausaufgabenbetreuung (4)
Regelschule (5)
Altersgerechte Freizeitgestaltung*
vollst. Abhängigkeit von Fremdhilfe (0)
mit prof. Kontakthilfe (KH) möglich (1)
mit Laien-KH möglich (2)
selbständig mit Supervision (3)
Selbständig mit Hilfsmittel (HiMi) (4)
selbständig ohne Hilfsmittel (5)
Altersgerechte Geld- & Finanzverwaltung*
nicht möglich (0)
nur einfache Mithilfe möglich (1)
nur mäßige Mithilfe möglich (2)
nur unter strenger Supervision (3)
mit leichter Supervision (4)
altersgerecht (5)
Altersgerechte Lebensführung /
Selbstversorgung Essen / Anziehen / Hygiene*
vollst. Abhängigkeit von Fremdhilfe (0)
mit prof. Kontakthilfe (KH) möglich (1)
mit Laien-KH möglich (2)
selbständig mit Supervision (3)
Selbständig mit Hilfsmittel (HiMi) (4)
selbständig ohne Hilfsmittel (5)
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Selbstständkeitsindex Kinder und
Jugendliche (3-5 Jahre) SHT-
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Erhebungsdatum
Datum der Erhebung*
Unfalldatum*
Pflege
Altersgemäßes Essen / Trinken*
PEG u/o vollst. Abhängigkeit von
Fremdhilfe (0)
PEG & FOT o. sicheres Schlucken in der
Therapie mit prof. Kontakthilfe (1)
sicheres Schlucken angepasster
Nahrung außerhalb Therapie; ggf mit
KH; (2)
PEG für Flüssigkeit Pat. mit PEG
selbständig ggf. teiloral oder volloral mit
Supervision (3)
mit HiMi; ggf. verlangsamt; aber
selbständig (4)
selbständig ohne HiMi nutzt Löffel oder
Gabel (5)
Altersgemäßes Anziehen / Ausziehen*
vollst. Abhängigkeit von Fremdhilfe (0)
erste Mithilfe bei Oberkörper (OK) mit
prof. KH (z.B. Körperverlagerung) (1)
selbständig bei OK; Unterkörper mit
Laienhilfe möglich (2)
SV und Vorbereitung; ggf. KH bei
Schuhen, Verschlüssen, Strümpfen (3)
selbständig mit HiMi; ggf. Orthesenhilfe,
Hilfe bei Knöpfen etc. (4)
selbständig ohne HiMi nutzt
Reißverschluss und Knöpfe (5)
Altersgemäße Persönliche Pflege (Gesicht
waschen, Kämmen, Zähneputzen etc.)*
vollst. Abhängigkeit von Fremdhilfe (0)
erste Mithilfe bei prof. KH; Festhalten
bzw. Führen des Lappens... (1)
Geringe KH bei einer Region,
Verschlüssen, Wasserhähnen ... (2)
SV und Vorbereitung; Hilfe bei
Zahnprothese (3)
selbständig mit HiMi; z.B.
Sitzgelegenheit, Adaptations-HiMi (4)
selbständig ohne HiMi (5)
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Altersgemäßes Waschen, Baden, Duschen*
vollst. Abhängigkeit von Fremdhilfe (0)
erste Mithilfe (Gesicht / OK vorn) bei
prof. KH (1)
Pat wäscht mind. die Hälfte ohne KH (2)
SV und Vorbereitung bei
Ganzkörperwaschung (3)
selbständig mit HiMi; erhöhter Zeitbedarf
(4)
selbständig ohne HiMi (5)
Altersgemäße Stuhlkontrolle*
vollst. Abhängigkeit von Fremdhilfe (0)
Mithilfe bei Benutzung von HiMi; meldet
sich inkonstant (1)
Zwischenfälle (ZF) max. 5x pro Woche;
meldet sich immer; geringe KH bei HiMi
(2)
ZF max. 2 Woche SV & Vorbereitung bei
HiMi & Entsorgung;  (3)
selbständig mit HiMi; seltene
Zwischenfälle (4)
keine Zwischenfälle (5)
Altersgemäße Harnkontrolle*
vollst. Abhängigkeit von Fremdhilfe (0)
Zwischenfälle täglich; Mithilfe bei HiMi
(1)
Zwischenfälle (ZF) max. 5x pro Woche;
geringe KH bei HiMi (2)
SV & Vorbereitung Hi-Mi; ZF 2x-
4x/Woche (3)
SV & Vorbereitung Hi-Mi; ZF 1x/Woche
(4)
selbständig ohne HiMi (5)
Toilettenbenutzung*
vollst. Abhängigkeit von Fremdhilfe (0)
Mithilfe bei Prof. KH (1 Helfer), Laie
überfordert (1)
Leichte KH nötig, d.h. mit Kindkontakt (2)
SV und Vorbereitung; in der Regel
Utensilien anreichen (3)
selbständig, Supervision nur verbale
Hilfen (4)
selbständig ohne HiMi, oft ohne
Supervision (5)
Physio
Altersgemäßer Transfer (Bett - Stuhl / Rollstuhl)*
vollst. Abhängigkeit von Fremdhilfe (0)
erste Mithilfe (Körpergewicht verlagern /
abstützen); prof. KH nötig (1)
nur geringe Hebehilfe; aktive
Unterstützung des Aufhebens (2)
SV und Vorbereitung wegen
Sicherheitsbedenken; Vorbereitung HiMi
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(3)
selbständig mit HiMi (4)
selbständig ohne HiMi (5)
Lagewechsel / Liegen-Sitzen*
vollständige Abhängigkeit von Fremdhilfe
(0)
Beginnende Mithilfe; Geführte
Bewegungen (1)
adäquate Mithilfe (2)
Supervision und verbale Anleitung (3)
Lagewechsel selbständig mit
Kompensationsstrategien
(Pflegebettfunktionen) (4)
selbständig (5)
Altersgemäße Rollstuhlnutzung*
vollst. Abhängigkeit von Fremdhilfe (0)
erste Mithilfe bei Strecken bis 5m (1)
KH bei Autofahren, Strcken über 20m o.
Richtungsänderungen (2)
SV und Vorbereitung bei Strecken über
50m (3)
fährt alleine über 300m o. 100m ohne
Pause (4)
selbständig ohne HiMi (5)
Altersgemäßes Gehen*
gehunfähig (0)
wenige Schritte mit prof. KH (1-2 Pers.) &
HiMi (1)
Gehen > 20m mit KH; ggf. mit HiMi (2)
SV wegen Sicherheitsbedenken; Gehen
> 50m; ggf. HiMi (3)
allein. Gehen > 200m ggf. mit HiMi (4)
selbständig ohne HiMi (5)
Altersgemäßes Treppensteigen*
vollst. Abhängigkeit von Fremdhilfe (0)
max 5 Stufen mit prof. KH (1-2 Pers.) (1)
15 Stufen mit Laien-KH (1 Pers.) (2)
SV und Vorbereitung bei > 15 Stufen
ohne KH (3)
selbständig mit HiMi für mind. 1 Etage
incl. Geländer (4)
selbständig ohne HiMi (5)
Logo
Altersgemäßes Hörverstehen (Kommunizieren
als Empfänger von Mitteilungen)*
keinerlei Verständnis verbaler /
nonverbaler Mitteilungen (0)
erstes Hörverstehen erkennbar bei
Namen, Objekten (1)
Hörverstehen möglich bei einfachen
Aufforderungen (2)
Hörverstehen für komplexe Sätze &
Aufforderungen, die nicht nur die eigene
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Person betreffen (3)
Hörverstehen noch etwas verlangsamt
bei komplexen Sätzen und
Themenwechsel (4)
Hörverstehen ungestört (5)
Altersgemäßes Sprechen (Kommunizieren als
Sender von Mitteilungen)*
keinerlei sprachliche Äußerungen (0)
einzelne Wörter / Gesten für basale
Bedürfnisse (1)
spricht kurze Phrasen, Kontakthilfe durch
Nachfragen, 2 Wortsätze (2)
spricht ganze Sätze; Sinn nicht entstellt;
aber noch häufige Fehler (3)
kommuniziert komplexe Sachverhalte;
selten Fehler (4)
sprachliche Kommunikation ungestört
(Mehr-Wort-Sätze) (5)
Malen/Schreiben (motorisch)*
Zeigen, Malen oder Schreiben nicht
möglich (0)
beginnend Sprachcomputer; unsicheres
Zeigen (1)
sicher Sprachcomputer sicheres Zeigen
(2)
Nutzen von Mal- und  Schreibhilfen
(Verdickung) (3)
noch Veränderungen des Mal- oder
Schriftbildes (4)
Malen oder Schreiben ungestört (5)
Psycho
Altersgemäße Orientierung (O) & Gedächtnis
(G)*
vollständig desorientiert & massivste
Gedächtnisstörungen (0)
Rückkehr basaler Gedächtnisinhalte;
zumeist nur in Therapie nutzbar (1)
hochfrequente Erinnerungen auch
außerhalb der Therapie nutzbar (2)
wesentliche Erinnerungen vorhanden;
nur noch Supervision erforderlich (3)
nur noch leichte Unsicherheiten: Pat.
nutzt Gedächtnishilfen selbständig (4)
Orientierung & Gedächtnis unauffällig (5)
Altersgemäße Konzentrative Belastbarkeit (KB)*
KB < 5 Min. (0)
5-10 Min. stabil, Ablenkbarkeit noch
hoch (1)
10-20 Min. stabil; z.B. bei Therapie; max.
1 kurze Pause (2)
20-30 Min. stabil; ohne Pause & ohne
Ablenkbarkeit (3)
20-30 Min. stabil; ohne Pause & ohne
Ablenkbarkeit (4)
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20-30 Min. stabil; ohne Pause & ohne
Ablenkbarkeit (5)
Altersgemäße Planungsfähigkeit und
Problemlösen*
Keinerlei Handlungsübernahme möglich
(0)
mit KH Übernahme einzelner
Handlungsschritte (1)
nach Aufforderung Übernahme einer
Handlungseinheit (2)
Alltagshandlungen (AH) werden
selbständig allein fehlerarm erbracht (3)
fehlerfrei; neue Anforderungen
verlangsamt; wenige Hinweise (4)
Planungsfähigkeit ungestört (5)
Altersgemäßes soziales Verhalten
Selbstregulation*
Keinerlei Kontaktaufnahme; nicht
altersgemäße Daueraufsicht erforderlich
(0)
beginnende Kontaktaufnahme im
therapeutisch geschützen Raum (1)
befolgt Laienhinweise im alltäglichen
sozialen Kontakt (2)
Hinweise nur in Stresssituationen nötig;
hinreichende Einsichtsfähigkeit (3)
Hinweise nur in Stresssituationen nötig;
hinreichende Einsichtsfähigkeit (4)
Hinweise nur in Stresssituationen nötig;
hinreichende Einsichtsfähigkeit (5)
Ergo
Altersgemäße Aufgabenübernahme (Einkaufen,
Essen zubereiten, Spielen, Hausaufgaben etc.)*
vollständig von Fremdhilfe abhängig (0)
übernimmt einzelne simple
Handlunggschritte (1)
übernimmt mehrere aufeinanderfolgende
Schritte (2)
übernimmt sicher komplexe
Handlungsschritte (3)
übernimmt sicher komplexe
Handlungsschritte (4)
übernimmt sicher komplexe
Handlungsschritte (5)
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Erhebungsdatum
Datum der Erhebung*
Unfalldatum*
Pflege
Altersgemäßes Essen / Trinken*
PEG u/o vollst. Abhängigkeit von
Fremdhilfe (0)
PEG & FOT o. sicheres Schlucken in der
Therapie mit prof. Kontakthilfe (1)
sicheres Schlucken angepasster
Nahrung außerhalb Therapie; ggf mit
KH; (2)
PEG für Flüssigkeit Pat. mit PEG
selbständig ggf. teiloral oder volloral mit
Supervision (3)
mit HiMi; ggf. verlangsamt; aber
selbständig (4)
selbständig ohne HiMi nutzt Löffel oder
Gabel (5)
Altersgemäßes Anziehen / Ausziehen*
vollst. Abhängigkeit von Fremdhilfe (0)
erste Mithilfe bei Oberkörper (OK) mit
prof. KH (z.B. Körperverlagerung) (1)
selbständig bei OK; Unterkörper mit
Laienhilfe möglich (2)
SV und Vorbereitung; ggf. KH bei
Schuhen, Verschlüssen, Strümpfen (3)
selbständig mit HiMi; ggf. Orthesenhilfe,
Hilfe bei Knöpfen etc. (4)
selbständig ohne HiMi nutzt
Reißverschluss und Knöpfe (5)
Altersgemäße Persönliche Pflege (Gesicht
waschen, Kämmen, Zähneputzen etc.)*
vollst. Abhängigkeit von Fremdhilfe (0)
erste Mithilfe bei prof. KH; Festhalten
bzw. Führen des Lappens... (1)
Geringe KH bei einer Region,
Verschlüssen, Wasserhähnen ... (2)
SV und Vorbereitung; Hilfe bei
Zahnprothese (3)
selbständig mit HiMi; z.B.
Sitzgelegenheit, Adaptations-HiMi (4)
selbständig ohne HiMi (5)
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Altersgemäßes Waschen, Baden, Duschen*
vollst. Abhängigkeit von Fremdhilfe (0)
erste Mithilfe (Gesicht / OK vorn) bei
prof. KH (1)
Pat wäscht mind. die Hälfte ohne KH (2)
SV und Vorbereitung bei
Ganzkörperwaschung (3)
selbständig mit HiMi; erhöhter Zeitbedarf
(4)
selbständig ohne HiMi (5)
Altersgemäße Stuhlkontrolle*
vollst. Abhängigkeit von Fremdhilfe (0)
Mithilfe bei Benutzung von HiMi; meldet
sich inkonstant (1)
Zwischenfälle (ZF) max. 2x pro Woche;
meldet sich immer; geringe KH bei HiMi
(2)
SV & Vorbereitung bei HiMi &
Entsorgung; Zeitplankontrolle; (3)
selbständig mit HiMi; seltene
Zwischenfälle (4)
keine Zwischenfälle (5)
Altersgemäße Harnkontrolle*
vollst. Abhängigkeit von Fremdhilfe (0)
Zwischenfälle täglich; Mithilfe bei HiMi
(1)
Zwischenfälle (ZF) max. 3x pro Woche;
geringe KH bei HiMi (2)
SV & Vorbereitung Hi-Mi; ZF 1x/Woche
(3)
SV & Vorbereitung Hi-Mi; ZF weniger als
1x/Woche (4)
selbständig ohne HiMi (5)
Toilettenbenutzung*
vollst. Abhängigkeit von Fremdhilfe (0)
Mithilfe bei Prof. KH (1-2 Helfer) (1)
Leichte KH nötig (2)
SV und Vorbereitung; ggf. Utensilien
anreichen (3)
selbständig mit HiMi; (4)
selbständig ohne HiMi (5)
Physio
Altersgemäßer Transfer (Bett - Stuhl / Rollstuhl)*
vollst. Abhängigkeit von Fremdhilfe (0)
erste Mithilfe (Körpergewicht verlagern /
abstützen); prof. KH nötig (1)
nur geringe Hebehilfe; aktive
Unterstützung des Aufhebens (2)
SV und Vorbereitung wegen
Sicherheitsbedenken; Vorbereitung HiMi
(3)
selbständig mit HiMi (4)
selbständig ohne HiMi (5)
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Lagewechsel / Liegen-Sitzen*
vollständige Abhängigkeit von Fremdhilfe
(0)
Beginnende Mithilfe; Geführte
Bewegungen (1)
adäquate Mithilfe (2)
Supervision und verbale Anleitung (3)
Lagewechsel selbständig mit
Kompensationsstrategien
(Pflegebettfunktionen) (4)
selbständig (5)
Altersgemäße Rollstuhlnutzung*
vollst. Abhängigkeit von Fremdhilfe (0)
erste Mithilfe bei Strecken bis 5m (1)
KH bei Autofahren, Strcken über 20m o.
Richtungsänderungen (2)
SV und Vorbereitung bei Strecken über
50m (3)
fährt alleine über 300m o. 100m ohne
Pause (4)
selbständig ohne HiMi (5)
Altersgemäßes Gehen*
gehunfähig (0)
wenige Schritte mit prof. KH (1-2 Pers.) &
HiMi (1)
Gehen > 20m mit KH; ggf. mit HiMi (2)
SV wegen Sicherheitsbedenken; Gehen
> 50m; ggf. HiMi (3)
allein. Gehen > 200m ggf. mit HiMi (4)
selbständig ohne HiMi (5)
Altersgemäßes Treppensteigen*
vollst. Abhängigkeit von Fremdhilfe (0)
max 5 Stufen mit prof. KH (1-2 Pers.) (1)
15 Stufen mit Laien-KH (1 Pers.) (2)
SV und Vorbereitung bei > 15 Stufen
ohne KH (3)
selbständig mit HiMi für mind. 1 Etage
incl. Geländer (4)
selbständig ohne HiMi (5)
Logo
Altersgemäßes Hörverstehen (Kommunizieren
als Empfänger von Mitteilungen)*
keinerlei Verständnis verbaler /
nonverbaler Mitteilungen (0)
erstes Hörverstehen erkennbar bei
Namen, Objekten (1)
Hörverstehen möglich bei einfachen
Aufforderungen (2)
Hörverstehen für komplexe Sätze &
Aufforderungen, die nicht nur die eigene
Person betreffen (3)
Hörverstehen noch etwas verlangsamt
bei komplexen Sätzen und
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Themenwechsel (4)
Hörverstehen ungestört (5)
Altersgemäßes Sprechen (Kommunizieren als
Sender von Mitteilungen)*
keinerlei sprachliche Äußerungen (0)
einzelne Wörter / Gesten für basale
Bedürfnisse (1)
spricht kurze Phrasen, Kontakthilfe durch
Nachfragen, 2 Wortsätze (2)
spricht ganze Sätze; Sinn nicht entstellt;
aber noch häufige Fehler (3)
kommuniziert komplexe Sachverhalte;
selten Fehler (4)
sprachliche Kommunikation ungestört
(Mehr-Wort-Sätze) (5)
Altersgemäßes Lesen und Verstehen*
erkennt Symbole (2)
erkennt wenige Schlüsselwörter (3)
Liest Schlüsselwörter & wenige Worte
(4)
Lesen & Verstehen sicher (5)
Altersgemäßes Schreiben*
schreibt Namen nicht immer korrekt (3)
schreibt Namen sicher Ansonsten nicht
immer korrekt (4)
Schreiben ungestört (5)
Schreiben (motorisch)*
Schreiben nicht möglich (0)
beginnend Sprachcomputer (1)
sicher Sprachcomputer (2)
Nutzen von Schreibhilfen (Verdickung)
(3)
noch Veränderungen des Schriftbildes
(4)
Schreiben ungestört (5)
Psycho
Altersgemäße Orientierung (O) & Gedächtnis
(G)*
vollständig desorientiert & massivste
Gedächtnisstörungen (0)
Rückkehr basaler Gedächtnisinhalte;
zumeist nur in Therapie nutzbar (1)
hochfrequente Erinnerungen auch
außerhalb der Therapie nutzbar (2)
wesentliche Erinnerungen vorhanden;
nur noch Supervision erforderlich (3)
nur noch leichte Unsicherheiten: Pat.
nutzt Gedächtnishilfen selbständig (4)
Orientierung & Gedächtnis unauffällig (5)
Altersgemäße Konzentrative Belastbarkeit (KB)*
KB < 5 Min. (0)
5-10 Min. stabil, Ablenkbarkeit noch
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hoch (1)
10-20 Min. stabil; z.B. bei Therapie; max.
1 kurze Pause (2)
20-30 Min. stabil; ohne Pause & ohne
Ablenkbarkeit (3)
> 30 Min. stabil; mit Pause & mit leichter
Ablenkbarkeit (4)
> 30 Min. stabil; mit Pause & ohne
Ablenkbarkeit (5)
Altersgemäße Planungsfähigkeit und
Problemlösen*
Keinerlei Handlungsübernahme möglich
(0)
mit KH Übernahme einzelner
Handlungsschritte (1)
nach Aufforderung Übernahme einer
Handlungseinheit, einfaches Sortieren
(2)
Alltagshandlungen (AH) werden
selbständig allein fehlerarm erbracht (3)
fehlerfrei; neue Anforderungen
verlangsamt; wenige Hinweise (4)
Planungsfähigkeit ungestört (5)
Altersgemäßes soziales Verhalten
Selbstregulation*
Keinerlei Kontaktaufnahme; nicht
altersgemäße Daueraufsicht erforderlich
(0)
beginnende Kontaktaufnahme im
therapeutisch geschützen Raum (1)
befolgt nicht immer Laienhinweise im
alltäglichen sozialen Kontakt (2)
Hält sich oft an Regeln; befolgt immer
Laienhinweise im alltäglichen sozialen
Kontakt (3)
Hält sich immer an Regeln; Hinweise nur
in Stresssituationen nötig; hinreichende
Einsichtsfähigkeit (4)
Hält sich immer an Regeln; Hinweise nur
in Stresssituationen nötig; hinreichende
Einsichtsfähigkeit (5)
Ergo
Altersgemäße Aufgabenübernahme (Einkaufen,
Essen zubereiten, Spielen, Hausaufgaben etc.)*
vollständig von Fremdhilfe abhängig (0)
übernimmt einzelne simple
Handlunggschritte (1)
übernimmt mehrere aufeinanderfolgende
Schritte (2)
übernimmt sicher komplexe
Handlungsschritte spielt 10-20 Min. allein
(3)
übernimmt sicher komplexe
Handlungsschritte spielt über 20 Min.
allein (4)
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übernimmt sicher komplexe
Handlungsschritte spielt über 30 Min.
allein & kreativ (5)
6 / 6
Selbstständigkeitsindex Kinder und Jugendliche (5-7 Jahre) SHT-
Register
Selbstständigkeitsindex Kinder und
Jugendliche (7-12 Jahre) SHT-Register
Selbstständigkeitsindex Kinder und Jugendliche (7-12
Jahre) SHT-Register
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models.org/forms/5898
Selbstständigkeitsindex Kinder und
Jugendliche (7-12 Jahre) SHT-
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Erhebungsdatum
Datum der Erhebung*
Unfalldatum*
Pflege
Altersgemäßes Essen / Trinken*
PEG u/o vollst. Abhängigkeit von
Fremdhilfe (0)
PEG & FOT o. sicheres Schlucken in der
Therapie mit prof. Kontakthilfe (1)
sicheres Schlucken angepasster
Nahrung außerhalb Therapie; ggf mit
KH; (2)
PEG für Flüssigkeit Pat. mit PEG
selbständig ggf. teiloral oder volloral mit
Supervision (3)
mit HiMi; ggf. verlangsamt; aber
selbständig (4)
selbständig ohne HiMi (5)
Altersgemäßes Anziehen / Ausziehen*
vollst. Abhängigkeit von Fremdhilfe (0)
erste Mithilfe bei Oberkörper (OK) mit
prof. KH (z.B. Körperverlagerung) (1)
selbständig bei OK; Unterkörper mit
Laienhilfe möglich (2)
SV und Vorbereitung; ggf. KH bei
Schuhen, Verschlüssen, Strümpfen (3)
selbständig mit HiMi; ggf. Orthesenhilfe
(4)
selbständig ohne HiMi (5)
Altersgemäße Persönliche Pflege (Gesicht
waschen, Kämmen, Zähneputzen etc.)*
vollst. Abhängigkeit von Fremdhilfe (0)
erste Mithilfe bei prof. KH; Festhalten
bzw. Führen des Lappens... (1)
Geringe KH bei einer Region,
Verschlüssen, Wasserhähnen ... (2)
SV und Vorbereitung; Hilfe bei
Zahnprothese (3)
selbständig mit HiMi; z.B.
Sitzgelegenheit, Adaptations-HiMi (4)
selbständig ohne HiMi (5)
Altersgemäßes Waschen, Baden, Duschen*
vollst. Abhängigkeit von Fremdhilfe (0)
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erste Mithilfe (Gesicht / OK vorn) bei
prof. KH (1)
Pat wäscht mind. die Hälfte ohne KH (2)
SV und Vorbereitung bei
Ganzkörperwaschung (3)
selbständig mit HiMi; erhöhter Zeitbedarf
(4)
selbständig ohne HiMi (5)
Altersgemäße Stuhlkontrolle*
vollst. Abhängigkeit von Fremdhilfe (0)
Mithilfe bei Benutzung von HiMi; meldet
sich inkonstant (1)
Zwischenfälle (ZF) max. 2x pro Woche;
meldet sich immer; geringe KH bei HiMi
(2)
SV & Vorbereitung bei HiMi &
Entsorgung; Zeitplankontrolle; ZF
seltene Ausnahme (3)
selbständig mit HiMi; keine Zwischenfälle
(4)
selbstständig ohne HiMi (5)
Altersgemäße Harnkontrolle*
vollst. Abhängigkeit von Fremdhilfe (0)
Zwischenfälle täglich; Mithilfe bei HiMi
(1)
Zwischenfälle (ZF) max. 3x pro Woche;
geringe KH bei HiMi (2)
SV & Vorbereitung Hi-Mi; ZF weniger
1x/Woche (3)
selbständig mit HiMi (4)
selbständig ohne HiMi (5)
Toilettenbenutzung*
vollst. Abhängigkeit von Fremdhilfe (0)
Mithilfe bei Prof. KH (1-2 Helfer) (1)
Leichte KH nötig (2)
SV und Vorbereitung; ggf. Utensilien
anreichen (3)
selbständig mit HiMi; (4)
selbständig ohne HiMi (5)
Physio
Altersgemäßer Transfer (Bett - Stuhl / Rollstuhl)*
vollst. Abhängigkeit von Fremdhilfe (0)
erste Mithilfe (Körpergewicht verlagern /
abstützen); prof. KH nötig (1)
nur geringe Hebehilfe; aktive
Unterstützung des Aufhebens (2)
SV und Vorbereitung wegen
Sicherheitsbedenken; Vorbereitung HiMi
(3)
selbständig mit HiMi (4)
selbständig ohne HiMi (5)
Lagewechsel / Liegen-Sitzen*
vollständige Abhängigkeit von Fremdhilfe
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(0)
Beginnende Mithilfe; Geführte
Bewegungen (1)
adäquate Mithilfe (2)
Supervision und verbale Anleitung (3)
Lagewechsel selbständig mit
Kompensationsstrategien
(Pflegebettfunktionen) (4)
selbständig (5)
Altersgemäße Rollstuhlnutzung*
vollst. Abhängigkeit von Fremdhilfe (0)
erste Mithilfe bei Strecken bis 5m (1)
KH bei Autofahren, Strcken über 20m o.
Richtungsänderungen (2)
SV und Vorbereitung bei Strecken über
50m (3)
fährt alleine über 300m o. 100m ohne
Pause (4)
selbständig ohne HiMi (5)
Altersgemäßes Gehen*
gehunfähig (0)
wenige Schritte mit prof. KH (1-2 Pers.) &
HiMi (1)
Gehen > 20m mit KH; ggf. mit HiMi (2)
SV wegen Sicherheitsbedenken; Gehen
> 50m; ggf. HiMi (3)
allein. Gehen > 200m ggf. mit HiMi (4)
selbständig ohne HiMi (5)
Altersgemäßes Treppensteigen*
vollst. Abhängigkeit von Fremdhilfe (0)
max 5 Stufen mit prof. KH (1-2 Pers.) (1)
15 Stufen mit Laien-KH (1 Pers.) (2)
SV und Vorbereitung bei > 15 Stufen
ohne KH (3)
selbständig mit HiMi für mind. 1 Etage
incl. Geländer (4)
selbständig ohne HiMi (5)
Logo
Altersgemäßes Hörverstehen (Kommunizieren
als Empfänger von Mitteilungen)*
keinerlei Verständnis verbaler /
nonverbaler Mitteilungen (0)
erstes Hörverstehen erkennbar bei
Namen, Objekten (1)
Hörverstehen möglich bei einfachen
Aufforderungen (2)
Hörverstehen für komplexe Sätze &
Aufforderungen, die nicht nur die eigene
Person betreffen (3)
Hörverstehen noch etwas verlangsamt
bei komplexen Sätzen und
Themenwechsel (4)
Hörverstehen ungestört (5)
Altersgemäßes Sprechen (Kommunizieren als
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Sender von Mitteilungen)*
keinerlei sprachliche Äußerungen (0)
einzelne Wörter / Gesten für basale
Bedürfnisse (1)
spricht kurze Phrasen, Kontakthilfe durch
Nachfragen (2)
spricht ganze Sätze; Sinn nicht entstellt;
aber noch häufige Fehler (3)
kommuniziert komplexe Sachverhalte;
selten Fehler (4)
sprachliche Kommunikation ungestört (5)
Altersgemäßes Lesen und Verstehen*
Lesen nicht möglich (0)
Erfassen der Bedeutung von einzelnen
Wörtern (1)
Erfassen verschiedener Wortarten /
Phrasen (2)
Kann einfache Sätze lesen & verstehen
(3)
selbständiger Umgang mit schriftl.
Informationen (kurze Texte) (4)
Lesen & Verstehen ungestört (5)
Altersgemäßes Schreiben*
Schreiben nicht möglich (0)
schreibt bzw. kopiert Namen (1)
schreibt einfache Wörter (nach Diktat,
Fehler möglich) (2)
schreibt einfache Sätze ohne
Sinnentstellung (3)
schreibt kurze Texte selbst.; Aussage
immer erfassbar (4)
Schreiben ungestört (5)
Schreiben (motorisch)*
Schreiben nicht möglich (0)
beginnend Sprachcomputer (1)
sicher Sprachcomputer (2)
Nutzen von Schreibhilfen (Verdickung)
(3)
noch Veränderungen des Schriftbildes
(4)
Schreiben ungestört (5)
Psycho
Altersgemäße Orientierung (O) & Gedächtnis
(G)*
vollständig desorientiert & massivste
Gedächtnisstörungen (0)
Rückkehr basaler Gedächtnisinhalte;
zumeist nur in Therapie nutzbar (1)
hochfrequente Erinnerungen auch
außerhalb der Therapie nutzbar (2)
wesentliche Erinnerungen vorhanden;
nur noch Supervision erforderlich (3)
nur noch leichte Unsicherheiten: Pat.
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nutzt Gedächtnishilfen selbständig (4)
Orientierung & Gedächtnis unauffällig (5)
Altersgemäße Konzentrative Belastbarkeit (KB)*
KB < 10 Min. (0)
10-20 Min. stabil, Ablenkbarkeit noch
hoch (1)
30 Min. stabil; z.B. bei Therapie; max. 1
kurze Pause (2)
30-60 Min. stabil; ohne Pause & ohne
Ablenkbarkeit (3)
> 60 Min. stabil; Pausen; nicht den
ganzen tag (4)
Konzentration ungestört altersgemäß (5)
Altersgemäße Planungsfähigkeit und
Problemlösen*
Keinerlei Handlungsübernahme möglich
(0)
mit KH Übernahme einzelner
Handlungsschritte (1)
nach Aufforderung Übernahme einer
Handlungseinheit (2)
Alltagshandlungen (AH) werden
selbständig allein fehlerarm erbracht (3)
fehlerfrei; neue Anforderungen
verlangsamt; wenige Hinweise (4)
Planungsfähigkeit ungestört (5)
Altersgemäßes soziales Verhalten
Selbstregulation*
Keinerlei Kontaktaufnahme; nicht
altersgemäße Daueraufsicht erforderlich
(0)
beginnende Kontaktaufnahme im
therapeutisch geschützen Raum (1)
befolgt Laienhinweise im alltäglichen
sozialen Kontakt (2)
Hinweise nur in Stresssituationen nötig;
hinreichende Einsichtsfähigkeit (3)
selten inadäquat; korrigiert sich selbst
(4)
soz. Verhalten unauffällig altersgemäß
(5)
Ergo
Altersgemäße Aufgabenübernahme (Einkaufen,
Essen zubereiten, Spielen, Hausaufgaben etc.)*
vollständig von Fremdhilfe abhängig (0)
benötigt prof. Anleitung Laien benötigen
Anleitung (1)
konkrete Laienhilfe häufige Erinnerung
und Anleitung (2)
Supervision & leichte Erinnerung
Laienhilfe reicht (3)
Im Alltag voll selbständig. Liest und
befolgt T-Plan (4)
Im Alltag voll selbständig. Liest und hat
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den T-Plan präsent (5)
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Singer Score
Erhebungsdatum
Datum der Erhebung*
Unfalldatum*
Pflege
Essen / Trinken*
PEG u/o vollst. Abhängigkeit von
Fremdhilfe (0)
PEG & FOT o. sicheres Schlucken in der
Therapie mit prof. Kontakthilfe (1)
sicheres Schlucken angepasster
Nahrung außerhalb Therapie; ggf mit
KH; PEG für Flüssigkeit (2)
Pat. mit PEG selbständig ggf. teiloral
oder volloral mit Supervision (3)
mit HiMi; ggf. verlangsamt; aber
selbständig (4)
selbständig ohne HiMi (5)
Anziehen / Ausziehen*
vollst. Abhängigkeit von Fremdhilfe (0)
erste Mithilfe bei Oberkörper (OK) mit
prof. KH (z.B. Körperverlagerung) (1)
selbständig bei OK; Unterkörper mit
Laienhilfe möglich (2)
SV und Vorbereitung; ggf. KH bei
Schuhen, Verschlüssen, Strümpfen (3)
selbständig mit HiMi; ggf. Orthesenhilfe
(4)
selbständig ohne HiMi (5)
Persönliche Pflege (Gesicht waschen, Kämmen,
Zähneputzen etc.)*
vollst. Abhängigkeit von Fremdhilfe (0)
erste Mithilfe bei prof. KH; Festhalten
bzw. Führen des Lappens... (1)
Geringe KH bei einer Region,
Verschlüssen, Wasserhähnen ... (2)
SV und Vorbereitung; Hilfe bei
Zahnprothese (3)
selbständig mit HiMi; z.B.
Sitzgelegenheit, Adaptations-HiMi (4)
selbständig ohne HiMi (5)
Waschen, Baden, Duschen*
vollst. Abhängigkeit von Fremdhilfe (0)
erste Mithilfe (Gesicht / OK vorn) bei
prof. KH (1)
Pat wäscht mind. die Hälfte ohne KH (2)
SV und Vorbereitung bei
Ganzkörperwaschung (3)
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selbständig mit HiMi; erhöhter Zeitbedarf
(4)
selbständig ohne HiMi (5)
Stuhlkontrolle*
vollst. Abhängigkeit von Fremdhilfe (0)
Mithilfe bei Benutzung von HiMi; meldet
sich inkonstant (1)
Zwischenfälle (ZF) max. 2x pro Woche;
meldet sich immer; geringe KH bei HiMi
(2)
SV und Vorbereitung bei HiMi und
Entsorgung; Zeitplankontrolle; ZF
seltene Ausnahme (3)
selbständig mit HiMi; keine Zwischenfälle
(4)
selbständig ohne HiMi (5)
Harnkontrolle*
vollst. Abhängigkeit von Fremdhilfe (0)
Zwischenfälle täglich; Mithilfe bei HiMi
(1)
Zwischenfälle (ZF) max. 3x pro Woche;
geringe KH bei HiMi (2)
SV und Vorbereitung HiMi; ZF weniger
als 1x pro Woche (3)
selbständig mit HiMi (4)
selbständig ohne HiMi (5)
Toilettenbenutzung*
vollst. Abhängigkeit von Fremdhilfe (0)
Mithilfe bei Prof. KH (1-2 Helfer) (1)
Leichte KH nötig (2)
SV und Vorbereitung; ggf. Utensilien
anreichen (3)
selbständig mit HiMi (4)
selbständig ohne HiMi (5)
Physio
Transfer (Bett - Stuhl / Rollstuhl)*
vollst. Abhängigkeit von Fremdhilfe (0)
erste Mithilfe (Körpergewicht verlagern /
abstützen); prof. KH nötig (1)
nur geringe Hebehilfe; aktive
Unterstützung des Aufhebens (2)
SV und Vorbereitung wegen
Sicherheitsbedenken; Vorbereitung HiMi
(3)
selbständig mit HiMi (4)
selbständig ohne HiMi (5)
Rollstuhlnutzung*
vollst. Abhängigkeit von Fremdhilfe (0)
erste Mithilfe bei Strecken bis 5m (1)
KH bei Autofahren, Strecken über 20m o.
Richtungsänderungen (2)
SV und Vorbereitung bei Strecken über
50m (3)
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fährt alleine über 300m o. 100m ohne
Pause (4)
selbständig ohne HiMi (5)
Gehen*
gehunfähig (0)
wenige Schritte mit prof. KH (1-2 Pers.) &
HiMi (1)
Gehen > 20m mit KH; ggf. mit HiMi (2)
SV wegen Sicherheitsbedenken; Gehen
> 50m; ggf. HiMi (3)
allein. Gehen > 200m ggf. mit HiMi (4)
selbständig ohne HiMi (5)
Treppensteigen*
vollst. Abhängigkeit von Fremdhilfe (0)
max 5 Stufen mit prof. KH (1-2 Pers.) (1)
15 Stufen mit Laien-KH (1 Pers.) (2)
SV und Vorbereitung bei > 15 Stufen
ohne KH (3)
selbständig mit HiMi für mind. 1 Etage
incl. Geländer (4)
selbständig ohne HiMi (5)
Logo
Hörverstehen (Kommunizieren als Empfänger
von Mitteilungen)*
keinerlei Verständnis verbaler /
nonverbaler Mitteilungen (0)
erstes Hörverstehen erkennbar bei
Namen, Objekten (1)
Hörverstehen möglich bei einfachen
Aufforderungen (2)
Hörverstehen für komplexe Sätze &
Aufforderungen, die nicht nur die eigene
Person betreffen (3)
Hörverstehen noch etwas verlangsamt
bei komplexen Sätzen und
Themenwechsel (4)
Hörverstehen ungestört (5)
Sprechen (Kommunizieren als Sender von
Mitteilungen)*
keinerlei sprachliche Äußerungen (0)
einzelne Wörter / Gesten für basale
Bedürfnisse (1)
spricht kurze Phrasen, Kontakthilfe durch
Nachfragen (2)
spricht ganze Sätze; Sinn nicht entstellt;
aber noch häufige Fehler (3)
kommuniziert komplexe Sachverhalte;
selten Fehler (4)
sprachliche Kommunikation ungestört (5)
Lesen und Verstehen*
Lesen nicht möglich (0)
Erfassen der Bedeutung von einzelnen
Wörtern (1)
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Erfassen verschiedener Wortarten /
Phrasen (2)
Kann einfache Sätze lesen & verstehen
(3)
selbständiger Umgang mit schriftl.
Informationen (kurze Texte) (4)
Lesen & Verstehen ungestört (5)
Schreiben*
Schreiben nicht möglich (0)
schreibt bzw. kopiert Namen (1)
schreibt einfache Wörter (nach Diktat,
Fehler möglich) (2)
schreibt einfache Sätze ohne
Sinnentstellung (3)
schreibt kurze Texte selbst.; Aussage
immer erfassbar (4)
Schreiben ungestört (5)
Psycho
Orientierung (O) & Gedächtnis (G)*
vollständig desorientiert & massivste
Gedächtnisstörungen (0)
Rückkehr basaler Gedächtnisinhalte;
zumeist nur in Therapie nutzbar (1)
hochfrequente Erinnerungen auch
außerhalb der Therapie nutzbar (2)
wesentliche Erinnerungen vorhanden;
nur noch Supervision erforderlich (3)
nur noch leichte Unsicherheiten: Pat.
nutzt Gedächtnishilfen selbständig (4)
Orientierung & Gedächtnis unauffällig (5)
Konzentrative Belastbarkeit (KB)*
KB < 10 Min. (0)
10-20 Min. stabil, Ablenkbarkeit noch
hoch (1)
30 Min. stabil; z.B. bei Therapie; max. 1
kurze Pause (2)
30-60 Min. stabil; ohne Pause & ohne
Ablenkbarkeit (3)
mehrere Stunden, nicht den ganzen Tag
(4)
Konzentration ungestört (5)
Planungsfähigkeit und Problemlösen*
Keinerlei Handlungsübernahme möglich
(0)
mit KH Übernahme einzelner
Handlungsschritte (1)
nach Aufforderung Übernahme einer
Handlungseinheit (2)
Alltagshandlungen (AH) werden
selbständig allein fehlerarm erbracht (3)
fehlerfrei; neue Anforderungen
verlangsamt; wenige Hinweise (4)
Planungsfähigkeit ungestört (5)
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soziales Verhalten*
Keinerlei Kontaktaufnahme;
Daueraufsicht erforderlich (0)
beginnende Kontaktaufnahme im
therapeutisch geschützen Raum (1)
befolgt Laienhinweise im alltäglichen
sozialen Kontakt (2)
Hinweise nur in Stresssituationen nötig;
hinreichende Einsichtsfähigkeit (3)
selten inadäquat; korrigiert sich selbst
(4)
soz. Verhalten unauffällig (5)
Ergo
Haushaltsführung (Einkaufen, Essen zubereiten,
Wohnungen reinigen)*
vollständig von Fremdhilfe abhängig (0)
Tägl. Haushaltshilfe erforderlich, Pat. so
weit zur Mithilfe fähig, dass keine
Unfallgefahr (1)
Pat. könnte warme Mahlzeiten
zubereiten; aber täglich Supervision
erforderlich (2)
Mit externer Hilfe 1x pro Woche kann
Pat. den Haushalt versorgen (3)
Wenn auch mit Mühe, könnte Pat. den
Haushalt alleine versorgen (4)
Im Haushalt voll selbständig (5)
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Chronic Mesenteric Artery Disease
data elements
Anamnese
Risikofaktoren Atherosklerose*
Symptoms suggestive of mesenteric ischemia*
Abdominal pain, postprandial*
Ja
Nein
Fear of eating*
Ja
Nein
Weight loss*
Malnutrition*
Ja
Nein
Malabsorption*
Ja
Nein
Körperliche Untersuchung
Habitus*
Thin (1)
Normal (2)
Obese (3)
Aortic diameter*
Abdominal bruit*
Ja
Nein
Digital rectal examination*
Stool testing for occult blood*
Ja
Nein
Laboratory Testing
Amylase*
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Lipase*
Stool fat content*
Fecal occult blood*
Ja
Nein
Diagnosis, Noninvasive
Mesenteric Artery Duplex Ultrasound*
Computed Tomographic Angiography*
Magnetic Resonance Angiography*
Diagnostics, invasive
Catheter-Based Angiography*
Therapeutic Procedures
Mesenteric Artery Angioplasty Stenting*
Revascularization*
Outcomes
Outcome Time point*
Periprocedure (24 h) (1)
Procedure related (30 d) (2)
3 mo (3)
6 mo (4)
1 y (5)
Complications of endovascular procedure*
Complications of open surgery*
Total length of stay*
Discharge status*
Patient education
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Medication instruction*
Recognition of new or worsening symptoms*
Diet counseling*
Smoking cessation counseling*
Activity counseling*
Follow-up
Follow-Up Open repair*
Follow-Up Endovascular*
Outcomes
Time point of outcome*
Patient assessment*
Adverse events*
Recurrent bowel ischemia/infarction (1)
Repeat revascularization (2)
Bowel resection (3)
MI (4)
Stroke (ischemic, hemorrhagic, unknown
type) (5)
Other adverse event (6)
Death (7)
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Extracranial Carotid and Vertebral Artery
Disease data elements
2012 ACCF / AHA Data Standard
Extracranial Carotid and Vertebral Artery Disease data
elements
see
http://www.ncbi.nlm.nih.gov/pubmed/22144570
All rights reserved. Please visit https://medical-data-
models.org/forms/5914
Extracranial Carotid and Vertebral
Artery Disease data elements
Anamnese
Asymptomatisch*
Ja
Nein
Symptomatisch*
Früherer Schlaganfall*
History of TIA*
ASA grade*
Grade I: Normal, healthy (1)
Grade II: Mild systemic disease that
does not limit activity (2)
Grade III: Severe systemic disease that
limits activity but is not incapacitating (3)
Grade IV: Incapacitating systemic
disease that is constantly life threatening
(4)
Grade V: Moribund; not expected to
survive 24 h with or without surgery (5)
History of dementia*
History of epilepsy*
Ja
Nein
Hemorrhage*
Cause of carotid/vertebral stenosis*
Anatomic High-Risk Conditions
Previous neck radiation*
Ja
Nein
Previous neck surgery*
Ja
Nein
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Previous carotid intervention*
Previous vertebral intervention*
Previous ipsilateral CEA*
Ja
Nein
Tracheostomy*
Ja
Nein
Cranial nerve palsy*
Comorbitiy, cardiopulmonary
History of chronic lung disease*
Home oxygen*
NYHA class III or IV in last 6 wk*
Patient assessment
Carotid bruits*
Supraclavicular bruits*
NIH Stroke Scale score*
Modified Rankin Scale*
No symptoms at all (0)
No significant disability despite
symptoms; able to carry out all usual
duties and activities (1)
Slight disability; unable to carry out all
previous activities but able to look after
own affairs without assistance (2)
Moderate disability; requiring some help
but able to walk without assistance (3)
Moderately severe disability; unable to
walk without assistance and unable to
attend to own bodily needs without
assistance (4)
Severe disability; bedridden, incontinent,
and requiring constant nursing care and
attention (5)
Death (6)
Barthel index*
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Specific neurologic findings*
Diagnostic Procedures
Carotid Duplex Ultrasound*
CT Angiography*
Magnetic Resonance Angiography*
Therapeutic Procedures, invasive
Carotid and Vertebral Artery Stenting*
Carotid Endarterectomy*
Outcomes
Intraoperative Complications*
Results*
Acute arterial occlusion*
Ja
Nein
Residual stenosis*
Stenosis, right side*
Stenosis, left side*
Stent migration/deformation*
Distal embolization*
Postoperative Complications*
Patient education
Medication instruction*
Recognition of new or worsening symptoms*
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Diet counseling*
Referral to dietician for diet counseling*
Activity counseling*
Smoking cessation counseling*
Plan for follow-up care*
Patient referral*
Discharge status*
Outcomes
Outcome time point*
Follow-up visit*
Repeat duplex ultrasound performed*
Repeat Hospitalization*
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IKDC Subjective Knee Evaluation Form
IKDC 2000 Score
modified from http://www.orthopaedicscores.com
All rights reserved. Please visit https://medical-data-
models.org/forms/5940
IKDC Subjective Knee Evaluation
Form
Allgemeine Informationen
Name des Patienten*
Geburtsdatum*
Klinische Diagnose*
Art der Operation*
Operationsdatum*
Symptome
Was ist die höchste Aktivitätsstufe, die Sie ohne
erhebliche Schmerzen im Knie ausüben
können?*
Ich kann aufgrund meiner Schmerzen im
Knie keine der oben genannten
Aktivitäten ausführen. (0)
Leichte Aktivitäten wie Gehen, Haus-
oder Gartenarbeit (1)
Mäßig anstrengende Aktivitäten wie
mäßige körperliche Arbeit, Laufen oder
Joggen (2)
Anstrengende Aktivitäten wie schwere
körperliche Arbeit, Skilaufen oder Tennis
(3)
Sehr anstrengende Aktivitäten wie
Springen oder Drehbewegungen bei
einseitiger Fußbelastung (Basketball
oder Fußball) (4)
Wie oft hatten Sie in den vergangenen 4 Wochen
oder seit dem Auftreten Ihrer Verletzung
Schmerzen?*
Nie (0)
1 (1)
Ständig Schmerzen (10)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
7 (7)
8 (8)
9 (9)
Wie stark sind Ihre Schmerzen?*
1 / 5
Keine Schmerzen (0)
1 (1)
Unerträgliche Schmerzen (10)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
7 (7)
8 (8)
9 (9)
Wie steif oder geschwollen war Ihr Knie während
der vergangenen 4 Wochen oder seit dem
Auftreten Ihrer Verletzung?*
überhaupt nicht (0)
etwas (1)
ziemlich (2)
sehr (3)
extrem (4)
Was ist das höchste Aktivitätsstufe, die Sie ohne
erhebliches Anschwellen des Knies ausüben
können?*
Ich kann aufgrund meiner Schmerzen im
Knie keine der oben genannten
Aktivitäten ausführen. (0)
Leichte Aktivitäten wie Gehen, Haus-
oder Gartenarbeit (1)
Mäßig anstrengende Aktivitäten wie
mäßige körperliche Arbeit, Laufen oder
Joggen (2)
Anstrengende Aktivitäten wie schwere
körperliche Arbeit, Skilaufen oder Tennis
(3)
Sehr anstrengende Aktivitäten wie
Springen oder Drehbewegungen bei
einseitiger Fußbelastung (Basketball
oder Fußball) (4)
Hatten Sie in den vergangenen 4 Wochen oder
seit dem Auftreten Ihrer Verletzung ein
gesperrtes Knie oder ist Ihr Knie aus- und wieder
eingeschnappt?*
Ja
Nein
Was ist die höchste Aktivitätsstufe, die Sie ohne
erhebliche durch Knieschwäche verursachte
Gangunsicherheit einhalten können?*
Ich kann aufgrund meiner Schmerzen im
Knie keine der oben genannten
Aktivitäten ausführen. (0)
Leichte Aktivitäten wie Gehen, Haus-
oder Gartenarbeit (1)
Mäßig anstrengende Aktivitäten wie
mäßige körperliche Arbeit, Laufen oder
Joggen (2)
Anstrengende Aktivitäten wie schwere
körperliche Arbeit, Skilaufen oder Tennis
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(3)
Sehr anstrengende Aktivitäten wie
Springen oder Drehbewegungen bei
einseitiger Fußbelastung (Basketball
oder Fußball) (4)
Sportliche Betätigung
Was ist die höchste Aktivitätsstufe, an der Sie
regelmäßig teilnehmen können?*
Ich kann aufgrund meiner Schmerzen im
Knie keine der oben genannten
Aktivitäten ausführen. (0)
Leichte Aktivitäten wie Gehen, Haus-
oder Gartenarbeit (1)
Mäßig anstrengende Aktivitäten wie
mäßige körperliche Arbeit, Laufen oder
Joggen (2)
Anstrengende Aktivitäten wie schwere
körperliche Arbeit, Skilaufen oder Tennis
(3)
Sehr anstrengende Aktivitäten wie
Springen oder Drehbewegungen bei
einseitiger Fußbelastung (Basketball
oder Fußball) (4)
Treppensteigen: Wie schwierig ist dies aufgrund
Ihres Knies?*
unmöglich (0)
extrem schwierig (1)
ziemlich schwierig (2)
minimal schwierig (3)
überhaupt nicht schwierig (4)
Treppe hinuntergehen: Wie schwierig ist dies
aufgrund Ihres Knies?*
unmöglich (0)
extrem schwierig (1)
ziemlich schwierig (2)
minimal schwierig (3)
überhaupt nicht schwierig (4)
Auf dem vorderen Knie knien: Wie schwierig ist
dies aufgrund Ihres Knies?*
unmöglich (0)
extrem schwierig (1)
ziemlich schwierig (2)
minimal schwierig (3)
überhaupt nicht schwierig (4)
Hockstellung: Wie schwierig ist dies aufgrund
Ihres Knies?*
unmöglich (0)
extrem schwierig (1)
ziemlich schwierig (2)
minimal schwierig (3)
überhaupt nicht schwierig (4)
Normal sitzen: Wie schwierig ist dies aufgrund
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Ihres Knies?*
unmöglich (0)
extrem schwierig (1)
ziemlich schwierig (2)
minimal schwierig (3)
überhaupt nicht schwierig (4)
Vom Stuhl aufstehen: Wie schwierig ist dies
aufgrund Ihres Knies?*
unmöglich (0)
extrem schwierig (1)
ziemlich schwierig (2)
minimal schwierig (3)
überhaupt nicht schwierig (4)
Geradeaus laufen: Wie schwierig ist dies
aufgrund Ihres Knies?*
unmöglich (0)
extrem schwierig (1)
ziemlich schwierig (2)
minimal schwierig (3)
überhaupt nicht schwierig (4)
Hochspringen und auf dem betroffenen Bein
landen: Wie schwierig ist dies aufgrund Ihres
Knies?*
unmöglich (0)
extrem schwierig (1)
ziemlich schwierig (2)
minimal schwierig (3)
überhaupt nicht schwierig (4)
Beim Gehen (bzw. Laufen, wenn Sie Sportler/in
sind) schnell anhalten und starten: Wie schwierig
ist dies aufgrund Ihres Knies?*
unmöglich (0)
extrem schwierig (1)
ziemlich schwierig (2)
minimal schwierig (3)
überhaupt nicht schwierig (4)
Aktivitäten des täglichen Lebens
Funktionsfähigkeit vor der Knieverletzung?*
Kann keine täglichen Aktivitäten
ausführen (0)
1 (1)
Keine Einschränkung der täglichen
Aktivitäten (10)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
7 (7)
8 (8)
9 (9)
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Derzeitige Funktionsfähigkeit Ihres Knies?*
Kann keine täglichen Aktivitäten
ausführen (0)
1 (1)
Keine Einschränkung der täglichen
Aktivitäten (10)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
7 (7)
8 (8)
9 (9)
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Shoulder Pain and Disability Index (SPADI)
derived from:
Roach KE, Budiman-Mak E, Songsiridej N, Lertratanakul Y.
Development of a shoulder pain and disability index.
Arthritis Care Res. 1991 Dec;4(4):143-9.
All rights reserved. Please visit https://medical-data-
models.org/forms/5942
Shoulder Pain and Disability Index
(SPADI)
Schmerzskala
Wie stark sind Ihre Schmerzen, wenn sie am
stärksten sind?*
keine Schmerzen (0)
1 (1)
schlimmste Schmerzen (10)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
7 (7)
8 (8)
9 (9)
Wie stark sind Ihre Schmerzen, wenn Sie auf der
betroffenen Seite liegen?*
keine Schmerzen (0)
1 (1)
schlimmste Schmerzen (10)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
7 (7)
8 (8)
9 (9)
Wie stark sind Ihre Schmerzen, wenn Sie nach
etwas auf einem hohen Regal greifen?*
keine Schmerzen (0)
1 (1)
schlimmste Schmerzen (10)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
7 (7)
8 (8)
9 (9)
Wie stark sind Ihre Schmerzen, wenn Sie Ihren
Nacken berühren?*
keine Schmerzen (0)
1 (1)
schlimmste Schmerzen (10)
2 (2)
3 (3)
4 (4)
5 (5)
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6 (6)
7 (7)
8 (8)
9 (9)
Wie stark sind Ihre Schmerzen, wenn Sie mit
dem betroffenen Arm etwas wegstoßen/gegen
etwas drücken?*
keine Schmerzen (0)
1 (1)
schlimmste Schmerzen (10)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
7 (7)
8 (8)
9 (9)
Behinderungsskala
Wie große Schwierigkeiten haben Sie, wenn Sie
sich die Haare waschen?*
ohne Schwierigkeiten durchführbar (0)
1 (1)
Tätigkeit nicht ausführbar (10)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
7 (7)
8 (8)
9 (9)
Wie große Schwierigkeiten haben Sie, wenn Sie
sich Ihren Rücken waschen?*
ohne Schwierigkeiten durchführbar (0)
1 (1)
Tätigkeit nicht ausführbar (10)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
7 (7)
8 (8)
9 (9)
Wie große Schwierigkeiten haben Sie, wenn Sie
sich einen Pullover anziehen?*
ohne Schwierigkeiten durchführbar (0)
1 (1)
Tätigkeit nicht ausführbar (10)
2 (2)
3 (3)
4 (4)
5 (5)
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6 (6)
7 (7)
8 (8)
9 (9)
Wie große Schwierigkeiten haben Sie, wenn Sie
ein Hemd/eine Bluse anziehen, das/die vorne
zugeknöpft werden muss?*
ohne Schwierigkeiten durchführbar (0)
1 (1)
Tätigkeit nicht ausführbar (10)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
7 (7)
8 (8)
9 (9)
Wie große Schwierigkeiten haben Sie, wenn Sie
Ihre Hose anziehen?*
ohne Schwierigkeiten durchführbar (0)
1 (1)
Tätigkeit nicht ausführbar (10)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
7 (7)
8 (8)
9 (9)
Wie große Schwierigkeiten haben Sie, wenn Sie
einen Gegenstand auf ein hohes Regal legen?*
ohne Schwierigkeiten durchführbar (0)
1 (1)
Tätigkeit nicht ausführbar (10)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
7 (7)
8 (8)
9 (9)
Wie große Schwierigkeiten haben Sie, wenn Sie
einen Gegenstand von etwa 5 kg tragen?*
ohne Schwierigkeiten durchführbar (0)
1 (1)
Tätigkeit nicht ausführbar (10)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
7 (7)
8 (8)
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9 (9)
Wie große Schwierigkeiten haben Sie, wenn Sie
etwas aus Ihrer hinteren Hosentasche nehmen?*
ohne Schwierigkeiten durchführbar (0)
1 (1)
Tätigkeit nicht ausführbar (10)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
7 (7)
8 (8)
9 (9)
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Consultation report (EHR)
EHR Konsilbericht converted to ODM format
All rights reserved. Please visit https://medical-data-
models.org/forms/5945
Consultation report (EHR)
Administrative Angaben
Konsiliarabteilung*
Konsilnummer*
Konsildatum*
Uhrzeit Beginn*
Uhrzeit Ende*
Konsildauer*
Konsiliararzt*
Erfassungszeitpunkt*
Benutzer*
Anfordernde Abteilung*
Anforderungsdatum*
Anfordernder Arzt*
Unterschrift*
Klinische Angaben
Fragestellung*
Befund*
Bericht*
Therapievorschlag*
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Documentation form for quality assurance in German
Health Care by the institute forapplied quality Improvement
and Research in Health Care (Aqua), https://www.aqua-
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Allgemeine Patientendaten
Behandlungsfall muss gemeldet werden*
nein (0)
ja (1)
Geburtsdatum (TT.MM.JJJJ)
Ort
PLZ
Hausnummer
Straße
frühere(r) Name(n)
Geburtsname
Vorname
Name
Titel
Identifikationsnummer des Patienten
eGK-Versichertennummer
Geschlecht
männlich (1)
weiblich (2)
Behandelnde Institution
Stationäre Aufnahme
nein (0)
ja (1)
Krankenhaus
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Institutionskennzeichen
Betriebsstätten-Nummer
Fachabteilung (§ 301-Vereinbarung)
Innere Medizin (0100)
Innere Medizin/Schwerpunkt Geriatrie
(0102)
Innere Medizin/Schwerpunkt Kardiologie
(0103)
Innere Medizin/Schwerpunkt
Nephrologie (0104)
Innere Medizin/Schwerpunkt
Hämatologie und internistische
Onkologie (0105)
Innere Medizin/Schwerpunkt
Endokrinologie (0106)
Innere Medizin/Schwerpunkt
Gastroenterologie (0107)
Innere Medizin/Schwerpunkt
Pneumologie (0108)
Innere Medizin/Schwerpunkt
Rheumatologie (0109)
Innere Medizin/Schwerpunkt Lungen-
und Bronchialheilkunde (0114)
Innere Medizin/Tumorforschung (0150)
Innere Medizin/Schwerpunkt
Coloproktologie (0151)
Innere Medizin/Schwerpunkt
Infektionskrankheiten (0152)
Innere Medizin/Schwerpunkt Diabetes
(0153)
Innere Medizin/Schwerpunkt
Naturheilkunde (0154)
Innere Medizin/Schwerpunkt
Schlaganfallpatienten (Stroke units,
Artikel 7 § 1 Abs. 3GKV-SolG) (0156)
Innere Medizin (0190)
Geriatrie (0200)
Geriatrie/Schwerpunkt Frauenheilkunde
(0224)
Geriatrie/Tagesklinik (für teilstationäre
Pflegesätze) (0260)
Geriatrie/Nachtklinik (für teilstationäre
Pflegesätze) (0261)
Geriatrie (0290)
Kardiologie (0300)
Nephrologie (0400)
Nephrologie/Schwerpunkt Pädiatrie
(0410)
Nephrologie/Intensivmedizin (0436)
Nephrologie (0490)
Hämatologie und internistische
Onkologie (0500)
Hämatologie und internistische
Onkologie/Schwerpunkt Pädiatrie (0510)
Hämatologie und internistische
Onkologie/Schwerpunkt Frauenheilkunde
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(0524)
Hämatologie und internistische
Onkologie/Schwerpunkt
Strahlenheilkunde (0533)
Hämatologie und internistische
Onkologie (0590)
Endokrinologie (0600)
Endokrinologie/Schwerpunkt
Gastroenterologie (0607)
Endokrinologie/Schwerpunkt Pädiatrie
(0610)
Endokrinologie (0690)
Gastroenterologie (0700)
Gastroenterologie/Schwerpunkt
Endokrinologie (0706)
Gastroenterologie/Schwerpunkt Pädiatrie
(0710)
Gastroenterologie (0790)
Pneumologie (0800)
Rheumatologie (0900)
Rheumatologie/Schwerpunkt Pädiatrie
(0910)
Rheumatologie (0990)
Pädiatrie (1000)
Pädiatrie/Schwerpunkt Nephrologie
(1004)
Pädiatrie/Schwerpunkt Hämatologie und
internistische Onkologie (1005)
Pädiatrie/Schwerpunkt Endokrinologie
(1006)
Pädiatrie/Schwerpunkt Gastroenterologie
(1007)
Pädiatrie/Schwerpunkt Rheumatologie
(1009)
Pädiatrie/Schwerpunkt Kinderkardiologie
(1011)
Pädiatrie/Schwerpunkt Neonatologie
(1012)
Pädiatrie/Schwerpunkt Lungen- und
Bronchialheilkunde (1014)
Pädiatrie/Schwerpunkt Kinderneurologie
(1028)
Pädiatrie/Schwerpunkt Perinatalmedizin
(1050)
Langzeitbereich Kinder (1051)
Pädiatrie (1090)
Kinderkardiologie (1100)
Kinderkardiologie/Schwerpunkt
Intensivmedizin (1136)
Kinderkardiologie (1190)
Neonatologie (1200)
Kinderchirurgie (1300)
Lungen- und Bronchialheilkunde (1400)
Lungen- und
Bronchialheilkunde/Schwerpunkt
Pädiatrie (1410)
Lungen- und Bronchialheilkunde (1490)
Allgemeine Chirurgie (1500)
Allgemeine Chirurgie/Schwerpunkt
Kinderchirurgie (1513)
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Allgemeine Chirurgie/Schwerpunkt
Unfallchirurgie (1516)
Allgemeine Chirurgie/Schwerpunkt
Gefäßchirurgie (1518)
Allgemeine Chirurgie/Schwerpunkt
Plastische Chirurgie (1519)
Allgemeine Chirurgie/Schwerpunkt
Thoraxchirurgie (1520)
Chirurgie/Schwerpunkt Orthopädie
(1523)
Allgemeine Chirurgie/Intensivmedizin (§
13 Abs. 2 Satz 3, 2. Halbsatz BPflV in
der am 31.12.2003 geltenden Fassung)
(1536)
Allgemeine Chirurgie/Schwerpunkt
Abdominal- und Gefäßchirurgie (1550)
Allgemeine Chirurgie/Schwerpunkt
Handchirurgie (1551)
Allgemeine Chirurgie (1590)
Unfallchirurgie (1600)
Neurochirurgie (1700)
Gefäßchirurgie (1800)
Plastische Chirurgie (1900)
Thoraxchirurgie (2000)
Thoraxchirurgie/Schwerpunkt
Herzchirurgie (2021)
Thoraxchirurgie/Intensivmedizin (2036)
Thoraxchirurgie/Schwerpunkt
Herzchirurgie Intensivmedizin (2050)
Thoraxchirurgie (2090)
Herzchirurgie (2100)
Herzchirurgie/Schwerpunkt
Gefäßchirurgie (2118)
Herzchirurgie/Schwerpunkt
Thoraxchirurgie (2120)
Herzchirurgie/Intensivmedizin (§ 13 Abs.
2 Satz 3 2. Halbsatz BPflV in der am
31.12.2003 geltenden Fassung) (2136)
Herzchirurgie/Schwerpunkt
Thoraxchirurgie Intensivmedizin (2150)
Herzchirurgie (2190)
Urologie (2200)
Orthopädie (2300)
Orthopädie/Schwerpunkt Rheumatologie
(2309)
Orthopädie/Schwerpunkt Chirurgie
(2315)
Orthopädie und Unfallchirurgie (2316)
Orthopädie (2390)
Frauenheilkunde und Geburtshilfe (2400)
Frauenheilkunde/Schwerpunkt Geriatrie
(2402)
Frauenheilkunde/Schwerpunkt
Hämatologie und internistische
Onkologie (2405)
Frauenheilkunde/Schwerpunkt
Endokrinologie (2406)
Frauenheilkunde (2425)
Frauenheilkunde und Geburtshilfe (2490)
Geburtshilfe (2500)
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Hals-, Nasen-, Ohrenheilkunde (2600)
Augenheilkunde (2700)
Neurologie (2800)
Neurologie/Schwerpunkt Pädiatrie
(2810)
Neurologie/Schwerpunkt
Schlaganfallpatienten (Stroke units,
Artikel 7 § 1 Abs. 3 GKV-SolG) (2856)
Neurologie (2890)
Allgemeine Psychiatrie (2900)
Allgemeine Psychiatrie/Schwerpunkt
Neurologie (2928)
Allgemeine Psychiatrie/Schwerpunkt
Kinder- und Jugendpsychiatrie (2930)
Allgemeine Psychiatrie/Schwerpunkt
Psychosomatik/Psychotherapie (2931)
Allgemeine Psychiatrie/Schwerpunkt
Suchtbehandlung (2950)
Allgemeine Psychiatrie/Schwerpunkt
Gerontopsychiatrie (2951)
Allgemeine Psychiatrie/Schwerpunkt
Forensische Behandlung (2952)
Allgemeine Psychiatrie/Schwerpunkt
Suchtbehandlung, Tagesklinik (2953)
Allgemeine Psychiatrie/Schwerpunkt
Suchtbehandlung, Nachtklinik (2954)
Allgemeine Psychiatrie/Schwerpunkt
Gerontopsychiatrie, Tagesklinik (2955)
Allgemeine Psychiatrie/Schwerpunkt
Gerontopsychiatrie, Nachtklinik (2956)
Allgemeine Psychiatrie/Tagesklinik (für
teilstationäre Pflegesätze) (2960)
Allgemeine Psychiatrie/Nachtklinik (für
teilstationäre Pflegesätze) (2961)
Allgemeine Psychiatrie (2990)
Kinder- und Jugendpsychiatrie (3000)
Kinder- und
Jugendpsychiatrie/Tagesklinik (für
teilstationäre Pflegesätze) (3060)
Kinder- und
Jugendpsychiatrie/Nachtklinik (für
teilstationäre Pflegesätze) (3061)
Kinder- und Jugendpsychiatrie (3090)
Psychosomatik/Psychotherapie (3100)
Psychosomatik/Psychotherapie/Schwerp
unkt Kinder- und Jugendpsychosomatik
(3110)
Psychosomatik/Psychotherapie/Tageskli
nik (für teilstationäre Pflegesätze) (3160)
Psychosomatik/Psychotherapie/Nachtkli
nik (für teilstationäre Pflegesätze) (3161)
Psychosomatik/Psychotherapie (3190)
Nuklearmedizin (3200)
Nuklearmedizin/Schwerpunkt
Strahlenheilkunde (3233)
Nuklearmedizin (3290)
Strahlenheilkunde (3300)
Strahlenheilkunde/Schwerpunkt
Hämatologie und internistische
Onkologie (3305)
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Strahlenheilkunde/Schwerpunkt
Radiologie (3350)
Strahlenheilkunde (3390)
Dermatologie (3400)
Dermatologie/Tagesklinik (für
teilstationäre Pflegesätze) (3460)
Dermatologie (3490)
Zahn- und Kieferheilkunde, Mund- und
Kieferchirurgie (3500)
Intensivmedizin (3600)
Intensivmedizin/Schwerpunkt Innere
Medizin (3601)
Intensivmedizin/Schwerpunkt Kardiologie
(3603)
Intensivmedizin/Schwerpunkt Pädiatrie
(3610)
Intensivmedizin/Schwerpunkt
Neurochirurgie (3617)
Intensivmedizin/Schwerpunkt Chirurgie
(3618)
Intensivmedizin/Herzchirurgie (3621)
Intensivmedizin/Schwerpunkt Urologie
(3622)
Intensivmedizin/Schwerpunkt
Frauenheilkunde und Geburtshilfe (3624)
Intensivmedizin/Schwerpunkt Hals-,
Nasen-, Ohrenheilkunde (3626)
Intensivmedizin/Schwerpunkt Neurologie
(3628)
Operative Intensivmedizin/Schwerpunkt
Chirurgie (3650)
Intensivmedizin/Thorax-Herzchirurgie
(3651)
Intensivmedizin/Herz-Thoraxchirurgie
(3652)
Intensivmedizin (3690)
sonstige Fachabteilung (3700)
Angiologie (3750)
Radiologie (3751)
Palliativmedizin (3752)
Schmerztherapie (3753)
Heiltherapeutische Abteilung (3754)
Wirbelsäulenchirurgie (3755)
Suchtmedizin (3756)
Visceralchirurgie (3757)
Sonstige Fachabteilung (3790)
Praxis/ambulante Einrichtung
KV-Nummer Arzt
Angaben zur Institution
Meldender Arzt
Name der Institution
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Straße
Hausnummer
PLZ
Ort
Bundesland
Schleswig-Holstein (1)
Saarland (10)
Berlin (11)
Brandenburg (12)
Mecklenburg-Vorpommern (13)
Sachsen (14)
Sachsen-Anhalt (15)
Thüringen (16)
Hamburg (2)
Niedersachsen (3)
Bremen (4)
Nordrhein-Westfalen (5)
Hessen (6)
Rheinland-Pfalz (7)
Baden-Württemberg (8)
Bayern (9)
Landesgesetzliche Vorgaben-Angaben bei
Meldungen aus Schleswig-Holstein
Patient(in) ist gemäß §4 (4) LKRG über die
Meldung unterrichtet
nein (0)
ja (1)
Patient(in) hat gemäß §4 (4) LKRG der
Mitwirkung an Forschungsvorhaben zugestimmt
nein (0)
ja (1)
Angaben bei Meldungen Hamburg
Patient(in) hat gemäß §2 (1) HmbKrebsRG in die
Meldung eingewilligt
nein (0)
ja (1)
Angaben bei Meldungen aus
Niedersachsen
Patient(in) hat gemäß §3 (2) GEKN in die
Meldung eingewilligt
nein (0)
ja (1)
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Patient(in) fällt unter die Ausnahmeregelung
gemäß §3 (2) GEKN
nein (0)
ja (1)
Angaben bei Meldungen aus Bremen
Patient(in) ist gemäß §2 (2) BremKRG über die
Meldung informiert
nein (0)
ja (1)
Patient(in) hat gemäß §2 (2) BremKRG der
Meldung widersprochen
nein (0)
ja (1)
Patient(in) wurde über Erkrankung unterrichtet
nein (0)
ja (1)
Angaben bei Meldungen aus Nordrhein-
Westfalen
Patient(in) ist gemäß §4 (4) EKR-NRW über die
Meldung informiert
nein (0)
ja (1)
Patient(in) hat gemäß §10 (3) EKR-NRW einer
Kontaktaufnahme widersprochen
nein (0)
ja (1)
Angaben bei Meldungen aus Hessen
Patient(in) ist gemäß §4 (2) HKRG über die
Meldung unterrichtet
nein (0)
ja (1)
Patient(in) hat gemäß §4 (2) HKRG der Meldung
widersprochen
nein (0)
ja (1)
Angaben bei Meldungen aus Rheinland-
Pfalz
Patient(in) ist gemäß §4 (2) LKRG über die
Meldung unterrichtet
nein (0)
ja (1)
Patient(in) hat gemäß §4 (2) LKRG der Meldung
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widersprochen
nein (0)
ja (1)
Angaben bei Meldungen aus Baden
Württemberg
Patient(in) ist gemäß §4 (2) LKrebsRG über die
Meldung unterrichtet
nein (0)
ja (1)
nein, Patient verstorben (2)
nein, medizinische Kontraindikation (3)
nein, Pathologe ohne Patientenkontakt
(4)
Patient(in) hat gemäß §4 (2) LKrebsRG der
Meldung widersprochen
nein (0)
ja (1)
Angaben bei Meldungen aus Bayern
Patient(in) ist gemäß §5 (2) BayKRG über die
Meldung unterrichtet
nein (0)
ja (1)
Patient(in) hat gemäß §5 (2) BayKRG der
Meldung widersprochen
nein (0)
ja (1)
Angaben bei Meldungen aus dem
Saarland
Patient(in) ist gemäß (§5 (2) SKRG) über die
Meldung unterrichtet
nein (0)
ja (1)
Patient(in) hat gemäß (§5 (2) SKRG) der
Meldung widersprochen
nein (0)
ja (1)
Angaben bei Meldungen aus Berlin
Patient(in) ist gemäß §1 (2) Gesetz zur
Einführung einer Meldepflicht für
Krebserkrankungen unterrichtet
nein (0)
ja (1)
Angaben bei Meldungen aus Brandenburg
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Patient(in) ist gemäß §1 (2) Gesetz zur
Einführung einer Meldepflicht für
Krebserkrankungen unterrichtet
nein (0)
ja (1)
Patient(in) hat gemäß (§3 (2) KRG) der Meldung
widersprochen
nein (0)
ja (1)
Angaben bei Meldungen aus
Mecklenburg-Vorpommern
Patient(in) ist gemäß §2 (1) Gesetz zur
Ausführung des Krebsregistergesetzes
(Krebsregisterausführungsgesetz – KrebsRAG
M-V) unterrichtet
nein (0)
ja (1)
Angaben bei Meldungen aus Sachsen
Patient(in) ist gemäß §3 (5) Sächsisches
Ausführungsgesetz zum Krebsregistergesetz
(Sächsisches Krebsregisterausführungsgesetz –
SächsKRGAG) unterrichtet
nein (0)
ja (1)
Angaben bei Meldungen aus Sachsen-
Anhalt
Patient(in) ist gemäß §3 (2) Gesetz über
Krebsregister (Krebsregistergesetz-KRG)
unterrichtet
nein (0)
ja (1)
Patient(in) hat gemäß (§3 (2) KRG) der Meldung
widersprochen
nein (0)
ja (1)
Angaben bei Meldungen aus Thüringen
Patient(in) ist gemäß §3 (2) Gesetz über
Krebsregister (Krebsregistergesetz-KRG)
unterrichtet
nein (0)
ja (1)
Stationäre Aufnahme
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Aufnahmedatum Krankenhaus (TT.MM.JJJJ)
Entlassung aus dem Krankenhaus
Entlassungsdatum Krankenhaus (TT.MM.JJJJ)
Entlassungsgrund  (§ 301-Vereinbarung)
Behandlung regulär beendet (1)
Entlassung in eine Pflegeeinrichtung (10)
Entlassung in ein Hospiz (11)
interne Verlegung (12)
externe Verlegung zur psychiatrischen
Behandlung (13)
Behandlung aus sonstigen Gründen
beendet, nachstationäre Behandlung
vorgesehen (14)
Behandlung gegen ärztlichen Rat
beendet, nachstationäre Behandlung
vorgesehen (15)
interne Verlegung mit Wechsel zwischen
den Entgeltbereichen der DRG-
Fallpauschalen, nach der BPflV oder für
besondere Einrichtungen nach § 17b
Abs. 1 Satz 15 KHG (16)
Rückverlegung (18)
Entlassung vor Wiederaufnahme mit
Neueinstufung (19)
Behandlung regulär beendet,
nachstationäre Behandlung vorgesehen
(2)
Entlassung vor Wiederaufnahme mit
Neueinstufung wegen Komplikation (20)
Entlassung oder Verlegung mit
nachfolgender Wiederaufnahme (21)
Fallabschluss (interne Verlegung) bei
Wechsel zwischen voll- und
teilstationärer Behandlung (22)
Beginn eines externen Aufenthalts mit
Abwesenheit über Mitternacht (BPflV-
Bereich - für verlegende Fachabteilung)
(23)
Beendigung eines externen Aufenthalts
mit Abwesenheit über Mitternacht
(BPflV-Bereich - für Pseudo-
Fachabteilung 0003) (24)
Entlassung zum Jahresende bei
Aufnahme im Vorjahr (für Zwecke der
Abrechnung - PEPP, § 4 PEPPV 2013)
(25)
Behandlung aus sonstigen Gründen
beendet (3)
Behandlung gegen ärztlichen Rat
beendet (4)
Zuständigkeitswechsel des
Kostenträgers (5)
Verlegung in ein anderes Krankenhaus
(6)
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Tod (7)
Verlegung in ein anderes Krankenhaus
im Rahmen einer Zusammenarbeit (§ 14
Abs. 5 Satz 2 BPflV in der am
31.12.2003 geltenden Fassung) (8)
Entlassung in eine
Rehabilitationseinrichtung (9)
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Angaben zur aktuellen Tumordiagnose
Laufende Nummer des Tumors
Diagnose des aktuellen Tumors
Tumordiagnose
klinisches Diagnosedatum (TT.MM.JJJJ)
Diagnose einschl. Topographie und Morphologie
Anlass der Diagnosestellung
Anamnese (A)
Eigenuntersuchung
(Selbstuntersuchung) (E)
gesetzl. Früherkennung (F)
Nachsorge (N)
Tumorsymptomatik (T)
unbekannt (U)
nicht gesetzl. Vorsorge (V)
Seitenlokalisation des Primärtumors
rechts (1)
links (2)
beidseits (3)
systemisch (4)
Mittellinienzone (5)
trifft nicht zu (6)
unbekannt (88)
Sicherheit der Diagnose
Todesbescheinigung ohne Autopsie (1)
klinisch (2)
klinisch/apparative Diagnostik (3)
spezifische Tumor-Marker (4)
Zytologie (5)
Histologie Metastase (6)
Histologie Primärtumor (7)
Autopsie (8)
Datum des histopathologischen Erstbefundes
(TT.MM.JJJJ)
Tumorlokalisation des Primärtumors
Äußere Oberlippe (C00.0)
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Äußere Unterlippe (C00.1)
Äußere Lippe o.n.A. (C00.2)
Schleimhaut der Oberlippe (C00.3)
Schleimhaut der Unterlippe (C00.4)
Lippenschleimhaut o.n.A. (C00.5)
Lippenkommissur (C00.6)
Lippe, mehrere Teilbereiche überlappend
(C00.8)
Lippe o.n.A. (C00.9)
Zungengrund o.n.A. (C01.9)
Dorsale Oberfläche der Zunge (C02.0)
Zungenrand (C02.1)
Ventrale Oberfläche der Zunge o.n.A.
(C02.2)
Vordere 2/3 der Zunge (C02.3)
Zungentonsille (C02.4)
Zunge, mehrere Bereiche überlappend
(C02.8)
Zunge o.n.A. (C02.9)
Oberkieferzahnfleisch (C03.0)
Unterkieferzahnfleisch (C03.1)
Zahnfleisch o.n.A. (C03.9)
Vorderer Teil des Mundbodens (C04.0)
Seitlicher Teil des Mundbodens (C04.1)
Mundboden, mehrere Teilbereiche
überlappend (C04.8)
Mundboden o.n.A. (C04.9)
Harter Gaumen (C05.0)
Weicher Gaumen o.n.A. (C05.1)
Uvula (C05.2)
Gaumen, mehrere Teilbereiche
überlappend (C05.8)
Gaumen o.n.A. (C05.9)
Wangenschleimhaut (C06.0)
Vestibulum oris (C06.1)
Retromolarregion (C06.2)
Sonstige und nicht näher bezeichnete
Teile des Mundes, mehrere Teilbereiche
überlappend (C06.8)
Mund o.n.A. (C06.9)
Parotis (C07.9)
Glandula submandibularis (C08.0)
Glandula sublingualis (C08.1)
Große Speicheldrüsen, mehrere
Bereiche überlappend (C08.8)
Große Speicheldrüsen o.n.A. (C08.9)
Fossa tonsillaris (C09.0)
Gaumenbogen (C09.1)
Tonsille, mehrere Teilbereiche
überlappend (C09.8)
Tonsille o.n.A. (C09.9)
Vallecula epiglottica (C10.0)
Vorderfläche der Epiglottis (C10.1)
Seitenwand des Oropharynx (C10.2)
Hinterwand des Oropharynx (C10.3)
Kiemengang (C10.4)
Oropharynx, mehrere Teilbereiche
überlappend (C10.8)
Oropharynx o.n.A. (C10.9)
Obere Wand des Nasopharynx (C11.0)
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Hinterwand des Nasopharynx (C11.1)
Seitenwand des Nasopharynx (C11.2)
Vorderwand des Nasopharynx (C11.3)
Nasopharynx, mehrere Teilbereiche
überlappend (C11.8)
Nasopharynx o.n.A. (C11.9)
Sinus piriformis (C12.9)
Regio postcricoidea (C13.0)
Plica aryepiglottica, hypopharyngeale
Seite (C13.1)
Hinterwand des Hypopharynx (C13.2)
Hypopharynx, mehrere Teilbereiche
überlappend (C13.8)
Hypopharynx o.n.A. (C13.9)
Pharynx o.n.A. (C14.0)
Waldeyer-Ring (C14.2)
Lippe, Mundhöhle und Pharynx, mehrere
Bereiche überlappend (C14.8)
Ösophagus, Pars cervicalis (C15.0)
Ösophagus, Pars thoracalis (C15.1)
Ösophagus, Pars abdominalis (C15.2)
Ösophagus, oberes Drittel (C15.3)
Ösophagus, mittleres Drittel (C15.4)
Ösophagus, unteres intrathorakales
Drittel (C15.5)
Ösophagus, mehrere Teilbereiche
überlappend (C15.8)
Ösophagus o.n.A. (C15.9)
Kardia o.n.A. (C16.0)
Fundus ventriculi (C16.1)
Corpus ventriculi (C16.2)
Antrum ventriculi (C16.3)
Pylorus (C16.4)
Kleine Kurvatur o.n.A (C16.5)
Große Kurvatur o.n.A (C16.6)
Magen, mehrere Teilbereiche
überlappend (C16.8)
Magen o.n.A. (C16.9)
Duodenum (C17.0)
Jejunum (C17.1)
Ileum (C17.2)
Meckel-Divertikel (C17.3)
Dünndarm, mehrere Teilbereiche
überlappend (C17.8)
Dünndarm o.n.A. (C17.9)
Zökum (C18.0)
Appendix vermiformis (C18.1)
Colon ascendens (C18.2)
Flexura hepatica (C18.3)
Colon transversum (C18.4)
Flexura lienalis coli (C18.5)
Colon descendens (C18.6)
Colon sigmoideum (C18.7)
Kolon, mehrere Teilbereiche
überlappend (C18.8)
Colon (C18.9)
Rektosigmoidaler Übergang (C19.9)
Rektum o.n.A. (C20.9)
Anus o.n.A. (C21.0)
Analkanal (C21.1)
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Kloakenregion (C21.2)
Rektum, Anus und Analkanal, mehrere
Bereiche überlappend (C21.8)
Leber (C22.0)
Intrahepatische Gallengänge (C22.1)
Gallenblase (C23.9)
Extrahepatischer Gallengang (C24.0)
Ampulla Vateri (C24.1)
Gallenwege, mehrere Bereiche
überlappend (C24.8)
Gallenwege o.n.A. (C24.9)
Pankreaskopf (C25.0)
Pankreaskörper (C25.1)
Pankreasschwanz (C25.2)
Ductus pancreaticus (C25.3)
Pankreas-Inselzellen (C25.4)
Sonstige näher bezeichnete Teile des
Pankreas (C25.7)
Pankreas, mehrere Teilbereiche
überlappend (C25.8)
Pankreas o.n.A. (C25.9)
Intestinaltrakt o.n.A. (C26.0)
Verdauungssystem, mehrere Bereiche
überlappend (C26.8)
Gastrointestinaltrakt o.n.A. (C26.9)
Nasenhöhle (C30.0)
Mittelohr (C30.1)
Sinus maxillaris (C31.0)
Sinus ethmoidalis (C31.1)
Sinus frontalis (C31.2)
Sinus sphenoidalis (C31.3)
Nasennebenhöhlen, mehrere
Teilbereiche überlappend (C31.8)
Nasennebenhöhlen o.n.A. (C31.9)
Glottis (C32.0)
Supraglottis (C32.1)
Subglottis (C32.2)
Larynxknorpel (C32.3)
Larynx, mehrere Teilbereiche
überlappend (C32.8)
Kehlkopf o.n.A. (C32.9)
Trachea (C33.9)
Hauptbronchus (C34.0)
Lungenoberlappen (C34.1)
Lungenmittellappen (C34.2)
Lungenunterlappen (C34.3)
Lunge, mehrere Teilbereiche
überlappend (C34.8)
Lunge o.n.A. (C34.9)
Thymus (C37.9)
Herz (C38.0)
Vorderes Mediastinum (C38.1)
Hinteres Mediastinum (C38.2)
Mediastinum o.n.A. (C38.3)
Pleura o.n.A. (C38.4)
Herz, Mediastinum und Pleura, mehrere
Teilbereiche überlappend (C38.8)
Obere Atemwege o.n.A. (C39.0)
Atemwege [Respirationstrakt] und
intrathorakale Organe, mehrere Bereiche
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überlappend (C39.8)
Mangelhaft bezeichneter Sitz innerhalb
der Atmungsorgane (C39.9)
Lange Knochen von Arm und Schulter
und zugehörige Gelenke (C40.0)
Kurze Knochen der oberen Extremitäten
und zugehörige Gelenke (C40.1)
Lange Knochen der unteren
Extremitäten und zugehörige Gelenke
(C40.2)
Kurze Knochen der unteren Extremitäten
und zugehörige Gelenke (C40.3)
Knochen, Gelenke und Gelenkknorpel
der Extremitäten, mehrere Teilbereiche
überlappend (C40.8)
Knochen einer Extremität o.n.A. (C40.9)
Knochen des Hirn- und
Gesichtsschädels und zugehörige
Gelenke (C41.0)
Mandibula (C41.1)
Wirbelsäule (C41.2)
Rippen, Sternum, Klavikula und
zugehörige Gelenke (C41.3)
Beckenknochen, Kreuzbein, Steißbein
und zugehörige Gelenke (C41.4)
Knochen, Gelenke und Gelenkknorpel,
mehrere Bereiche überlappend (C41.8)
Knochen o.n.A. (C41.9)
Blut (C42.0)
Knochenmark (C42.1)
Milz (C42.2)
Retikuloendotheliales System o.n.A.
(C42.3)
Hämatopoetisches System o.n.A.
(C42.4)
Lippenhaut o.n.A. (C44.0)
Augenlid (C44.1)
Äußeres Ohr (C44.2)
Haut sonstiger und nicht näher
bezeichneter Teile des Gesichtes
(C44.3)
Behaarte Kopfhaut und Haut am Hals
(C44.4)
Haut am Stamm (C44.5)
Haut der oberen Extremitäten und der
Schulter (C44.6)
Haut der unteren Extremität und der
Hüfte (C44.7)
Haut, mehrere Teilbereiche überlappend
(C44.8)
Haut o.n.A. (C44.9)
Periphere Nerven und autonomes
Nervensystem des Kopfes, des
Gesichtes und des Halses (C47.0)
Periphere Nerven und autonomes
Nervensystem der oberen Extremität und
der Schulter (C47.1)
Periphere Nerven und autonomes
Nervensystem der unteren Extremität
und der Hüfte (C47.2)
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Periphere Nerven und autonomes
Nervensystem des Thorax (C47.3)
Periphere Nerven und autonomes
Nervensystem des Abdomens (C47.4)
Periphere Nerven und autonomes
Nervensystem des Beckens (C47.5)
Periphere Nerven und autonomes
Nervensystem des Stammes (C47.6)
Periphere Nerven und autonomes
Nervensystem, mehrere Teilbereiche
überlappend (C47.8)
Autonomes Nervensystem o.n.A. (C47.9)
Retroperitoneum (C48.0)
Näher bezeichnete Teile des
Peritoneums (C48.1)
Peritoneum o.n.A. (C48.2)
Retroperitoneum und Peritoneum,
mehrere Teilbereiche überlappend
(C48.8)
Bindegewebe, Subkutangewebe und
sonstige Weichteile des Kopfes, des
Gesichtes und des Halses (C49.0)
Bindegewebe, Subkutangewebe und
sonstige Weichteile der oberen
Extremität und der Schulter (C49.1)
Bindegewebe, Subkutangewebe und
sonstige Weichteile der unteren
Extremität und der Hüfte (C49.2)
Bindegewebe, Subkutangewebe und
sonstige Weichteile des Thorax (C49.3)
Bindegewebe, Subkutangewebe und
sonstige Weichteilgewebe des Abdomen
(C49.4)
Bindegewebe, Subkutangewebe und
sonstige Weichteile des Beckens (C49.5)
Bindegewebe, Subkutangewebe und
sonstige Weichteile des Stammes o.n.A.
(C49.6)
Bindegewebe, Subkutangewebe und
sonstige Weichteile, mehrere Bereiche
überlappend (C49.8)
Bindegewebe, Subkutangewebe und
sonstige Weichteile o.n.A. (C49.9)
Mamille (C50.0)
Zentraler Drüsenkörper der Brust
(C50.1)
Oberer innerer Quadrant der Brust
(C50.2)
Unterer innerer Quadrant der Brust
(C50.3)
Oberer äußerer Quadrant der Brust
(C50.4)
Unterer äußerer Quadrant der Brust
(C50.5)
Recessus axillaris der Brust (C50.6)
Brust, mehrere Teilbereiche überlappend
(C50.8)
Brust o.n.A. (C50.9)
Labium majus (C51.0)
Labium minus (C51.1)
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Klitoris (C51.2)
Vulva, mehrere Teilbereiche überlappend
(C51.8)
Vulva o.n.A. (C51.9)
Vagina o.n.A. (C52.9)
Endozervix (C53.0)
Ektozervix (C53.1)
Cervix uteri, mehrere Teilbereiche
überlappend (C53.8)
Cervix uteri (C53.9)
Isthmus uteri (C54.0)
Endometrium (C54.1)
Myometrium (C54.2)
Fundus uteri (C54.3)
Corpus uteri, mehrere Teilbereiche
überlappend (C54.8)
Corpus uteri (C54.9)
Uterus o.n.A. (C55.9)
Ovar (C56.9)
Eileiter (C57.0)
Ligamentum latum uteri (C57.1)
Ligamentum rotundum (C57.2)
Parametrium (C57.3)
Weibliche Adnexe (C57.4)
Sonstige näher bezeichnete Teile der
weiblichen Geschlechtsorgane (C57.7)
Weibliche Geschlechtsorgane, mehrere
Bereiche überlappend (C57.8)
Weibliche Geschlechtsorgane o.n.A.
(C57.9)
Plazenta (C58.9)
Präputium (C60.0)
Glans penis (C60.1)
Penisschaft (C60.2)
Penis, mehrere Teilbereiche überlappend
(C60.8)
Penis o.n.A. (C60.9)
Prostata (C61.9)
Kryptorchider Hoden (C62.0)
Deszendierter Hoden (C62.1)
Testis o.n.A. (C62.9)
Nebenhoden (C63.0)
Samenstrang (C63.1)
Skrotum o.n.A. (C63.2)
Sonstige näher bezeichnete Teile der
männlichen Geschlechtsorgane (C63.7)
Männliche Geschlechtsorgane, mehrere
Bereiche überlappend (C63.8)
Männliche Geschlechtsorgane o.n.A.
(C63.9)
Niere o.n.A. (C64.9)
Nierenbecken (C65.9)
Ureter (C66.9)
Trigonum vesicae (C67.0)
Blasendach (C67.1)
Laterale Harnblasenwand (C67.2)
Vordere Harnblasenwand (C67.3)
Hintere Harnblasenwand (C67.4)
Harnblasenhals (C67.5)
Ostium ureteris (C67.6)
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Urachus (C67.7)
Harnblase, mehrere Teilbereiche
überlappend (C67.8)
Blase o.n.A. (C67.9)
Urethra (C68.0)
Paraurethrale Drüse (C68.1)
Harntrakt, mehrere Bereiche
überlappend (C68.8)
Harntrakt o.n.A. (C68.9)
Konjunktiva (C69.0)
Kornea o.n.A. (C69.1)
Retina (C69.2)
Chorioidea (C69.3)
Bulbus oculi (C69.4)
Tränendrüse (C69.5)
Orbita o.n.A. (C69.6)
Auge und Augenanhangsgebilde,
mehrere Teilbereiche überlappend
(C69.8)
Auge o.n.A. (C69.9)
Hirnhäute (C70.0)
Rückenmarkhäute (C70.1)
Meningen o.n.A. (C70.9)
Cerebrum (C71.0)
Frontallappen (C71.1)
Temporallappen (C71.2)
Parietallappen (C71.3)
Okzipitallappen (C71.4)
Ventrikel o.n.A. (C71.5)
Kleinhirn o.n.A. (C71.6)
Hirnstamm (C71.7)
Gehirn, mehrere Teilbereiche
überlappend (C71.8)
Gehirn o.n.A. (C71.9)
Rückenmark (C72.0)
Cauda equina (C72.1)
N. olfactorius (C72.2)
N. opticus (C72.3)
N. acusticus (C72.4)
Hirnnerven o.n.A. (C72.5)
Gehirn und andere Teile des
Zentralnervensystems, mehrere
Bereiche überlappend (C72.8)
Nervensystem (C72.9)
Schilddrüse (C73.9)
Nebennierenrinde (C74.0)
Nebennierenmark (C74.1)
Nebenniere o.n.A. (C74.9)
Nebenschilddrüse (C75.0)
Hirnanhangsdrüse (C75.1)
Ductus craniopharyngealis (C75.2)
Glandula pinealis (C75.3)
Glomus caroticum (C75.4)
Glomus aorticum und sonstige
Paraganglien (C75.5)
Endokrine Drüsen und verwandte
Strukturen, mehrere Teilbereiche
überlappend (C75.8)
Endokrine Drüse o.n.A. (C75.9)
Kopf, Gesicht oder Hals o.n.A. (C76.0)
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Thorax o.n.A. (C76.1)
Abdomen o.n.A. (C76.2)
Becken o.n.A. (C76.3)
Obere Extremität o.n.A. (C76.4)
Untere Extremität o.n.A. (C76.5)
Sonstiger mangelhaft bezeichneter Sitz
(C76.7)
Mangelhaft bezeichneter Sitz, mehrere
Teilbereiche überlappend (C76.8)
Lymphknoten des Kopfes, des Gesichtes
und des Halses (C77.0)
Intrathorakaler Lymphknoten (C77.1)
Intraabdominaler Lymphknoten (C77.2)
Lymphknoten der Achseln und Arme
(C77.3)
Lymphknoten der Inguinalregion und des
Beines (C77.4)
Beckenlymphknoten (C77.5)
Lymphknoten mehrerer Regionen
(C77.8)
Lymphknoten o.n.A. (C77.9)
Unbekannte Primärlokalisation (C80.9)
Tumormorphologie
Benigne Neoplasie o.n.A. (8000/0)
Neoplasie fraglicher Dignität (8000/1)
Maligne Neoplasie (8000/3)
Neoplasie, Metastase (8000/6)
Maligne Neoplasie, unsicher ob
Primärtumor oder Metastase (8000/9)
Benigne Tumorzellen (8001/0)
Tumorzellen fraglicher Dignität (8001/1)
Maligne Tumorzellen (8001/3)
Kleinzelliger maligner Tumor (8002/3)
Riesenzelliger maligner Tumor (8003/3)
Spindelzelliger maligner Tumor (8004/3)
Klarzelliger Tumor o.n.A. (8005/0)
Klarzelliger maligner Tumor (8005/3)
Benigne epitheliale Neoplasie (8010/0)
Carcinoma in situ o.n.A. (8010/2)
Karzinom o.n.A. (8010/3)
Karzinom-Metastase o.n.A. (8010/6)
Karzinomatose (8010/9)
Benignes Epitheliom (8011/0)
Malignes Epitheliom (8011/3)
Großzelliges Karzinom o.n.A. (8012/3)
Großzelliges neuroendokrines Karzinom
(8013/3)
Großzelliges neuroendokrines Karzinom,
Metastase (8013/6)
Großzelliges neuroendokrines Karzinom,
unbestimmt ob Primärtumor oder
Metastase (8013/9)
Großzelliges Karzinom mit rhabdoidem
Phänotyp (8014/3)
Glaszellkarzinom (8015/3)
Undifferenziertes Karzinom o.n.A.
(8020/3)
Anaplastisches Karzinom o.n.A. (8021/3)
Pleomorphes Karzinom (8022/3)
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Pleomorphes Karzinom, Metastase
(8022/6)
Pleomorphes Karzinom, unbestimmt ob
Primärtumor oder Metastase (8022/9)
Riesenzell- und Spindelzellkarzinom
(8030/3)
Riesenzellkarzinom (8031/3)
Spindelzellkarzinom o.n.A. (8032/3)
Pseudosarkomatöses Karzinom (8033/3)
Polygonalzelliges Karzinom (8034/3)
Karzinom mit osteoklastenähnlichen
Riesenzellen (8035/3)
Karzinom mit osteoklastenähnlichen
Riesenzellen, Metastase (8035/6)
Karzinom mit osteoklastenähnlichen
Riesenzellen, unbestimmt ob
Primärtumor oder Metastase (8035/9)
Benignes Tumorlet (8040/0)
Tumorlet o.n.A. (8040/1)
Kleinzelliges Karzinom o.n.A. (8041/3)
Kleinzelliges Karzinom o.n.A., Metastase
(8041/6)
Kleinzelliges Karzinom o.n.A.,
unbestimmt ob Primärtumor oder
Metastase (8041/9)
Haferzell-Karzinom (8042/3)
Kleinzelliges spindelzelliges Karzinom
(8043/3)
Kleinzelliges Karzinom vom
Intermediärtyp (8044/3)
Kombiniertes kleinzelliges Karzinom
(8045/3)
Nichtkleinzelliges Karzinom (8046/3)
Papillom o.n.A. (8050/0)
Papilläres Carcinoma in situ (8050/2)
Papilläres Karzinom o.n.A. (8050/3)
Verruköses Papillom (8051/0)
Verruköses Karzinom o.n.A. (8051/3)
Plattenepithelpapillom o.n.A. (8052/0)
Nichtinvasives papilläres
Plattenepithelkarzinom (8052/2)
Papilläres Plattenepithelkarzinom
(8052/3)
Invertiertes Plattenepithel-Papillom
(8053/0)
Plattenepithel-Papillomatose (8060/0)
Plattenepithel-Carcinoma in situ o.n.A.
(8070/2)
Plattenepithelkarzinom o.n.A. (8070/3)
Plattenepithelkarzinom-Metastase o.n.A.
(8070/6)
Plattenepithelkarzinom o.n.A.,
unbestimmt ob Primärtumor oder
Metastase (8070/9)
Verhornendes Plattenepithelkarzinom
o.n.A. (8071/3)
Großzelliges nichtverhornendes
Plattenepithelkarzinom o.n.A. (8072/3)
Kleinzelliges nichtverhornendes
Plattenepithelkarzinom (8073/3)
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Spindelzelliges Plattenepithelkarzinom
(8074/3)
Adenoides Plattenepithelkarzinom
(8075/3)
Plattenepithel-Carcinoma in situ mit
fraglicher Stromainvasion (8076/2)
Mikroinvasives Plattenepithelkarzinom
(8076/3)
Intraepitheliale Neoplasie Grad 3
(8077/2)
Plattenepithelkarzinom mit Hornbildung
(8078/3)
Erythroplasie Queyrat (8080/2)
M. Bowen (8081/2)
Lymphoepitheliales Karzinom (8082/3)
Basaloides Plattenepithelkarzinom
(8083/3)
Klarzelliges Plattenepithelkarzinom
(8084/3)
Basalzelltumor (8090/1)
Basalzellkarzinom o.n.A. (8090/3)
Multifokales oberflächliches
Basalzellkarzinom (8091/3)
Infiltrierendes Basalzellkarzinom o.n.A.
(8092/3)
Fibroepitheliales Basalzellkarzinom
(8093/3)
Basosquamöses Karzinom (8094/3)
Metatypisches Karzinom (8095/3)
Intraepidermales Epitheliom Typ Borst-
Jadassohn (8096/0)
Noduläres Basalzellkarzinom (8097/3)
Adenoides Basalzellkarzinom (8098/3)
Trichoepitheliom (8100/0)
Trichofollikulom (8101/0)
Tricholemmom (8102/0)
Tricholemmkarzinom (8102/3)
Pilartumor (8103/0)
Pilomatrixom o.n.A. (8110/0)
Pilomatrix-Karzinom (8110/3)
Benignes Übergangszellpapillom
(8120/0)
Urothelpapillom o.n.A. (8120/1)
Übergangszell-Carcinoma in situ
(8120/2)
Übergangszellkarzinom o.n.A. (8120/3)
Schneider-Papillom o.n.A. (8121/0)
Invertiertes Übergangszellpapillom o.n.A.
(8121/1)
Schneider-Karzinom (8121/3)
Spindelzelliges Übergangszellkarzinom
(8122/3)
Basaloidkarzinom (8123/3)
Kloakogenes Karzinom (8124/3)
Papilläre Neoplasie der Übergangszellen
mit niedrigem Malignitätspotential
(8130/1)
Nichtinvasives papilläres
Übergangszellkarzinom (8130/2)
Papilläres Übergangszellkarzinom
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(8130/3)
Mikropapilläres Übergangszellkarzinom
(8131/3)
Adenom o.n.A. (8140/0)
Atypisches Adenom (8140/1)
Adenocarcinoma in situ o.n.A. (8140/2)
Adenokarzinom o.n.A. (8140/3)
Adenokarzinom-Metastase o.n.A.
(8140/6)
Adenokarzinom o.n.A., unbestimmt ob
Primärtumor oder Metastase (8140/9)
Szirrhöses Adenokarzinom (8141/3)
Linitis plastica (8142/3)
Oberflächlich spreitendes
Adenokarzinom (8143/3)
Adenokarzinom vom intestinalen Typ
(8144/3)
Diffuses Karzinom (8145/3)
Monomorphes Adenom (8146/0)
Basalzelladenom (8147/0)
Basalzell-Adenokarzinom (8147/3)
Glanduläre intraepitheliale Neoplasie
Grad 3 (8148/2)
Intrakanalikuläres Adenom (8149/0)
Inselzelladenom (8150/0)
Inselzelltumor o.n.A. (8150/1)
Inselzellkarzinom (8150/3)
Insulinom o.n.A. (8151/0)
Malignes Insulinom (8151/3)
Glukagonom o.n.A. (8152/1)
Malignes Glukagonom (8152/3)
Gastrinom o.n.A. (8153/1)
Malignes Gastrinom (8153/3)
Gemischtes Inselzell- und exokrines
Adenokarzinom (8154/3)
Vipom o.n.A. (8155/1)
Malignes Vipom (8155/3)
Somatostatinom o.n.A. (8156/1)
Malignes Somatostatinom (8156/3)
Enteroglukagonom o.n.A. (8157/1)
Malignes Enteroglukagonom (8157/3)
Gallengangsadenom (8160/0)
Intrahepatisches Cholangiokarzinom
(8160/3)
Gallengangs-Zystadenom (8161/0)
Gallengangs-Zystadenokarzinom
(8161/3)
Klatskin-Tumor (8162/3)
Leberzelladenom (8170/0)
Hepatozelluläres Karzinom o.n.A.
(8170/3)
Fibrolamelläres Leberzellkarzinom
(8171/3)
Szirrhöses hepatozelluläres Karzinom
(8172/3)
Spindelzelliges hepatozelluläres
Karzinom (8173/3)
Klarzelliges hepatozelluläres Karzinom
(8174/3)
Pleomorphes hepatozelluläres Karzinom
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(8175/3)
Kombiniertes hepatozelluläres Karzinom
und Cholangiokarzinom (8180/3)
Trabekuläres Adenom (8190/0)
Trabekuläres Adenokarzinom (8190/3)
Embryonales Adenom (8191/0)
Ekkrines dermales Zylindrom (8200/0)
Adenoid-zystisches Karzinom (8200/3)
Adenoid-zystisches Karzinom,
Metastase (8200/6)
Adenoid-zystisches Karzinom,
unbestimmt ob Primärtumor oder
Metastase (8200/9)
Kribriformes Carcinoma in situ (8201/2)
Kribriformes Karzinom o.n.A. (8201/3)
Kribriformes Karzinom o.n.A., Metastase
(8201/6)
Kribriformes Karzinom o.n.A.,
unbestimmt ob Primärtumor oder
Metastase (8201/9)
Mikrozystisches Adenom (8202/0)
Laktierendes Adenom (8204/0)
Adenomatöser Polyp o.n.A. (8210/0)
Adenocarcinoma in situ in
adenomatösem Polypen (8210/2)
Adenokarzinom in adenomatösem
Polypen (8210/3)
Tubuläres Adenom o.n.A. (8211/0)
Tubuläres Adenokarzinom (8211/3)
Tubuläres Adenokarzinom, Metastase
(8211/6)
Tubuläres Adenokarzinom, unbestimmt
ob Primärtumor oder Metastase (8211/9)
Flaches Adenom (8212/0)
Serrated adenoma (8213/0)
Parietalzellkarzinom (8214/3)
Adenokarzinom der Analdrüsen (8215/3)
Familiäre adenomatöse Polypose [FAP]
(8220/0)
Adenokarzinom in familiärer
adenomatöser Polypose [FAP] (8220/3)
Multiple adenomatöse Polypen (8221/0)
Adenokarzinom in multiplen
adenomatösen Polypen (8221/3)
Solides duktales Carcinoma in situ
(8230/2)
Solides Karzinom o.n.A. (8230/3)
Carcinoma simplex (8231/3)
Karzinoidtumor fraglicher Dignität
(8240/1)
Karzinoidtumor o.n.A. (8240/3)
Enterochromaffinzell-Karzinoid (8241/3)
Enterochromaffin-like-cell-Karzinoid
(8242/1)
Maligner Enterochromaffin-like-cell-
Tumor (8242/3)
Becherzellkarzinoid (8243/3)
Kombiniertes Karzinoid (8244/3)
Tubuläres Karzinoid (8245/1)
Adenokarzinoidtumor (8245/3)
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Neuroendokrines Karzinom o.n.A.
(8246/3)
Merkel-Zell-Karzinom (8247/3)
Apudom (8248/1)
Atypischer Karzinoidtumor (8249/3)
Atypischer Karzinoidtumor, Metastase
(8249/6)
Atypischer Karzinoidtumor, unbestimmt
ob Primärtumor oder Metastase (8249/9)
Lungenadenomatose (8250/1)
Bronchiolo-alveoläres Adenokarzinom
o.n.A. (8250/3)
Alveoläres Adenom (8251/0)
Alveoläres Adenokarzinom (8251/3)
Nichtmuzinöses bronchiolo-alveoläres
Karzinom (8252/3)
Muzinöses bronchiolo-alveoläres
Karzinom (8253/3)
Gemischtes muzinöses und
nichtmuzinöses bronchiolo-alveoläres
Karzinom (8254/3)
Adenokarzinom mit gemischten
Subtypen (8255/3)
Papilläres Adenom o.n.A. (8260/0)
Papilläres Adenokarzinom o.n.A.
(8260/3)
Villöses Adenom o.n.A. (8261/0)
Adenocarcinoma in situ in villösem
Adenom (8261/2)
Adenokarzinom in villösem Adenom
(8261/3)
Villöses Adenokarzinom (8262/3)
Tubulovillöses Adenom o.n.A. (8263/0)
Adenocarcinoma in situ in tubulovillösem
Adenom (8263/2)
Adenokarzinom in tubulovillösem
Adenom (8263/3)
Glanduläre Papillomatose (8264/0)
Chromophobes Adenom (8270/0)
Chromophobes Karzinom (8270/3)
Prolaktinom (8271/0)
Hypophysenadenom o.n.A. (8272/0)
Hypophysenkarzinom o.n.A. (8272/3)
Azidophiles Adenom (8280/0)
Azidophiles Karzinom (8280/3)
Gemischtzelliges azidophil-basophiles
Adenom (8281/0)
Gemischtzelliges azidophil-basophiles
Karzinom (8281/3)
Oxyphiles Adenom (8290/0)
Onkozytäres Karzinom (8290/3)
Onkozytäres Karzinom, Metastase
(8290/6)
Onkozytäres Karzinom, unklar ob
Primärtumor oder Metastase (8290/9)
Basophiles Adenom (8300/0)
Basophiles Karzinom (8300/3)
Klarzelliges Adenom (8310/0)
Klarzelliges Adenokarzinom o.n.A.
(8310/3)
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Hypernephroider Tumor (8311/1)
Nierenzellkarzinom o.n.A. (8312/3)
Klarzelliges Adenofibrom (8313/0)
Klarzelliges Adenofibrom mit Borderline-
Malignität (8313/1)
Klarzelliges Adenokarzinofibrom
(8313/3)
Lipidreiches Karzinom (8314/3)
Lipidreiches Karzinom, Metastase
(8314/6)
Lipidreiches Karzinom, unbestimmt ob
Primärtumor oder Metastase (8314/9)
Glykogenreiches Klarzellkarzinom
(8315/3)
Glykogenreiches Klarzellkarzinom,
Metastase (8315/6)
Glykogenreiches Klarzellkarzinom,
unklar ob Primärtumor oder Metastase
(8315/9)
Zystenassoziiertes Nierenzellkarzinom
(8316/3)
Nierenzellkarzinom vom chromophoben
Zelltyp (8317/3)
Sarkomatoides Nierenzellkarzinom
(8318/3)
Sammelrohrkarzinom (8319/3)
Granularzellkarzinom (8320/3)
Hauptzelladenom (8321/0)
Wasserklares Adenom (8322/0)
Wasserklares Adenokarzinom (8322/3)
Gemischtzelliges Adenom (8323/0)
Gemischtzelliges Adenokarzinom
(8323/3)
Lipoadenom (8324/0)
Nachnieren-Adenom (8325/0)
Follikuläres Adenom (8330/0)
Atypisches follikuläres Adenom (8330/1)
Follikuläres Adenokarzinom o.n.A.
(8330/3)
Gut differenziertes follikuläres
Adenokarzinom (8331/3)
Trabekuläres follikuläres Adenokarzinom
(8332/3)
Mikrofollikuläres Adenom (8333/0)
Fetales Adenokarzinom (8333/3)
Makrofollikuläres Adenom (8334/0)
Minimal-invasives follikuläres Karzinom
(8335/3)
Hyalinisiertes trabekuläres Adenom
(8336/0)
Insuläres Karzinom (8337/3)
Papilläres Karzinom, follikuläre Variante
(8340/3)
Papilläres Mikrokarzinom (8341/3)
Oxyphiles papilläres Karzinom (8342/3)
Abgekapseltes papilläres Karzinom
(8343/3)
Zylinderzelliges papilläres
Schilddrüsenkarzinom (8344/3)
Medulläres Karzinom mit amyloidem
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Stroma (8345/3)
Gemischtzelliges medullär-follikuläres
Karzinom (8346/3)
Medulläres Karzinom mit papillärer
Komponente (8347/3)
Nichtabgekapseltes sklerosierendes
Karzinom (8350/3)
Multiple endokrine Adenome (8360/1)
Juxtaglomerulärer Tumor (8361/0)
Nebennierenrindenadenom o.n.A.
(8370/0)
Nebennierenrindenkarzinom (8370/3)
Nebennierenrindenadenom vom
Kompaktzelltyp (8371/0)
Stark pigmentiertes
Nebennierenrindenadenom (8372/0)
Klarzelliges Nebennierenrindenadenom
(8373/0)
Glomerulosazelliges
Nebennierenrindenadenom (8374/0)
Gemischtzelliges
Nebennierenrindenadenom (8375/0)
Endometrioides Adenom o.n.A. (8380/0)
Endometrioides Adenom mit Borderline-
Malignität (8380/1)
Endometrioides Adenokarzinom o.n.A.
(8380/3)
Endometrioides Adenofibrom o.n.A.
(8381/0)
Endometrioides Adenofibrom mit
Borderline-Malignität (8381/1)
Malignes endometrioides Adenofibrom
(8381/3)
Endometrioides Adenokarzinom,
sekretorische Variante (8382/3)
Endometrioides Adenokarzinom,
Flimmerepithel-Variante (8383/3)
Endozervikales Adenokarzinom (8384/3)
Adenom der Hautanhangsgebilde
(8390/0)
Karzinom der Hautanhangsgebilde
(8390/3)
Follikuläres Fibrom (8391/0)
Syringofibroadenom (8392/0)
Schweißdrüsenadenom (8400/0)
Schweißdrüsentumor o.n.A. (8400/1)
Schweißdrüsenadenokarzinom (8400/3)
Apokrines Adenom (8401/0)
Apokrines Adenokarzinom (8401/3)
Apokrines Adenokarzinom, Metastase
(8401/6)
Apokrines Adenokarzinom, unbestimmt
ob Primärtumor oder Metastase (8401/9)
Noduläres Hidradenom (8402/0)
Malignes noduläres Hidradenom
(8402/3)
Ekkrines Spiradenom (8403/0)
Malignes ekkrines Spiradenom (8403/3)
Hidrozystom (8404/0)
Papilläres Hidradenom (8405/0)
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Papilläres Syringadenom (8406/0)
Syringom o.n.A. (8407/0)
Sklerosierendes Karzinom der
Schweißdrüsenausführungsgänge
(8407/3)
Ekkrines papilläres Adenom (8408/0)
Aggressives digitales papilläres Adenom
(8408/1)
Ekkrines papilläres Adenokarzinom
(8408/3)
Ekkrines Porom (8409/0)
Malignes ekkrines Porom (8409/3)
Talgdrüsenadenom (8410/0)
Talgdrüsenadenokarzinom (8410/3)
Talgdrüsenadenokarzinom, Metastase
(8410/6)
Talgdrüsenadenokarzinom, unbestimmt
ob Primärtumor oder Metastase (8410/9)
Ekkrines Adenokarzinom (8413/3)
Zeruminaladenom (8420/0)
Zeruminaladenokarzinom (8420/3)
Mukoepidermoidtumor (8430/1)
Mukoepidermoid-Karzinom (8430/3)
Mukoepidermoid-Karzinom, Metastase
(8430/6)
Mukoepidermoid-Karzinom, unbestimmt
ob Primärtumor oder Metastase (8430/9)
Zystadenom o.n.A (8440/0)
Zystadenokarzinom o.n.A. (8440/3)
Seröses Zystadenom o.n.A. (8441/0)
Seröses Zystadenokarzinom o.n.A.
(8441/3)
Seröses Zystadenom mit Borderline-
Malignität (8442/1)
Klarzelliges Zystadenom (8443/0)
Klarzelliger zystischer Tumor mit
Borderline-Malignität (8444/1)
Papilläres Zystadenom o.n.A. (8450/0)
Papilläres Zystadenokarzinom o.n.A.
(8450/3)
Papilläres Zystadenom mit Borderline-
Malignität (8451/1)
Solid-pseudopapillärer Tumor (8452/1)
Solid-pseudopapilläres Karzinom
(8452/3)
Intraduktales papillär-muzinöses
Adenom (8453/0)
Intraduktaler papillär-muzinöser Tumor
mit mäßiger Dysplasie (8453/1)
Nichtinvasives intraduktales papillär-
muzinöses Karzinom (8453/2)
Invasives intraduktales papillär-
muzinöses Adenokarzinom (8453/3)
Zystischer Tumor des atrioventrikulären
Knotens (8454/0)
Seröses papilläres Zystadenom (8460/0)
Seröses papilläres Zystadenokarzinom
(8460/3)
Seröses Oberflächenpapillom o.n.A.
(8461/0)
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Seröses papilläres Oberflächenkarzinom
(8461/3)
Serös-papillärer zystischer Tumor mit
Borderline-Malignität (8462/1)
Serös-papillärer Oberflächentumor mit
Borderline-Malignität (8463/1)
Muzinöses Zystadenom o.n.A. (8470/0)
Muzinöser zystischer Tumor mit mäßiger
Dysplasie (8470/1)
Nichtinvasives muzinöses Zystadenom
(8470/2)
Muzinöses Zystadenokarzinom o.n.A.
(8470/3)
Muzinöses papilläres Zystadenom o.n.A.
(8471/0)
Muzinöses papilläres
Zystadenokarzinom (8471/3)
Muzinöser zystischer Tumor mit
Borderline-Malignität (8472/1)
Muzinöses papilläres Zystadenom mit
Borderline-Malignität (8473/1)
Muzinöses Adenom (8480/0)
Muzinöses Adenokarzinom (8480/3)
Pseudomyxoma peritonei (8480/6)
Muzinöses Adenokarzinom, unbestimmt
ob Primärtumor oder Metastase (8480/9)
Schleimbildendes Adenokarzinom
(8481/3)
Endozervikales muzinöses
Adenokarzinom (8482/3)
Siegelringzellkarzinom (8490/3)
Metastase eines
Siegelringzellkarzinomes (8490/6)
Siegelringzellkarzinom, unbestimmt ob
Primärtumor oder Metastase (8490/9)
Duktales Carcinoma in situ (DCIS)
(8500/2)
Invasives duktales Karzinom o.n.A.
(8500/3)
Invasives duktales Karzinom o.n.A.,
Metastase (8500/6)
Invasives duktales Karzinom o.n.A.,
unbestimmt ob Primärtumor oder
Metastase (8500/9)
Nichtinvasives Komedokarzinom
(8501/2)
Komedokarzinom o.n.A. (8501/3)
Sekretorisches Mammakarzinom
(8502/3)
Sekretorisches Mammakarzinom,
Metastase (8502/6)
Sekretorisches Mammakarzinom,
unbestimmt ob Primärtumor oder
Metastase (8502/9)
Intraduktales Papillom (8503/0)
Intraduktales papilläres Karzinom
(8503/2)
Invasives papilläres Karzinom (8503/3)
Invasives papilläres Karzinom,
Metastase (8503/6)
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Invasives papilläres Karzinom, unklar ob
Primärtumor oder Metastase (8503/9)
Intrazystisches papilläres Adenom
(8504/0)
Intrazystisches papilläres Karzinom
(8504/2)
Intrazystisches Karzinom o.n.A. (8504/3)
Intraduktale Papillomatose o.n.A.
(8505/0)
Brustwarzen-Adenom (8506/0)
Intraduktales mikropapilläres Karzinom
(8507/2)
Invasives mikropapilläres Karzinom
(8507/3)
Invasives mikropapilläres Karzinom,
Metastase (8507/6)
Invasives mikropapilläres Karzinom,
unklar ob Primärtumor oder Metastase
(8507/9)
Zystisch-hypersekretorisches Karzinom
(8508/3)
Medulläres Karzinom o.n.A. (8510/3)
Medulläres Karzinom o.n.A., Metastase
(8510/6)
Medulläres Karzinom o.n.A., unbestimmt
ob Primärtumor oder Metastase (8510/9)
Medulläres Karzinom mit lymphoidem
Stroma (8512/3)
Atypisches medulläres Karzinom
(8513/3)
Desmoplastisches duktales Karzinom
(8514/3)
Lobuläres Carcinoma in situ o.n.A.
(8520/2)
Lobuläres Karzinom o.n.A. (8520/3)
Lobuläres Karzinom o.n.A., Metastase
(8520/6)
Lobuläres Karzinom o.n.A., unbestimmt
ob Primärtumor oder Metastase (8520/9)
Invasives duktuläres Karzinom (8521/3)
Intraduktales Karzinom und lobuläres
Carcinoma in situ (8522/2)
Invasives duktales und lobuläres
Karzinom (8522/3)
Invasives duktales und lobuläres
Karzinom, Metastase (8522/6)
Invasives duktales und lobuläres
Karzinom, unbestimmt ob Primärtumor
oder Metastase (8522/9)
Invasives duktales Karzinom gemischt
mit anderen Karzinom-Typen (8523/3)
invasives duktales Karzinom gemischt
mit anderen Karzinom-Typen, Metastase
(8523/6)
invasives duktales Karzinom gemischt
mit anderen Karzinom-Typen,
unbestimmt ob Primärtumor oder
Metastase (8523/9)
Invasives lobuläres Karzinom gemischt
mit anderen Karzinom-Typen (8524/3)
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invasives lobuläres Karzinom gemischt
mit anderen Karzinom-Typen, Metastase
(8524/6)
invasives lobuläres Karzinom gemischt
mit anderen Karzinom-Typen,
unbestimmt ob Primärtumor oder
Metastase (8524/9)
Polymorphes Low-grade-Adenokarzinom
(8525/3)
Inflammatorisches Karzinom (8530/3)
Inflammatorisches Karzinom, Metastase
(8530/6)
Inflammatorisches Karzinom,
unbestimmt ob Primärtumor oder
Metastase (8530/9)
M. Paget der Brustwarzenhaut (8540/3)
Invasives duktales Karzinom mit M.
Paget (8541/3)
Invasives duktales Karzinom mit M.
Paget, Metastase (8541/6)
Invasives duktales Karzinom mit M.
Paget, unklar ob Primärtumor oder
Metastase (8541/9)
Extramammärer M. Paget (8542/3)
Duktales Carcinoma in situ (DCIS) mit M.
Paget (8543/3)
Azinarzelladenom (8550/0)
Azinarzelltumor (8550/1)
Azinuszellkarzinom (8550/3)
Azinuszellkarzinom, Metastase (8550/6)
Azinuszellkarzinom, unbestimmt ob
Primärtumor oder Metastase (8550/9)
Azinuszell-Zystadenokarzinom (8551/3)
Gemischtes squamös-glanduläres
Papillom (8560/0)
Adenosquamöses Karzinom (8560/3)
Adenosquamöses Karzinom, Metastase
(8560/6)
Adenosquamöses Karzinom, unbestimmt
ob Primärtumor oder Metastase (8560/9)
Adenolymphom (8561/0)
Epithelial-myoepitheliales Karzinom
(8562/3)
Adenokarzinom mit
Plattenepithelmetaplasie (8570/3)
Adenokarzinom mit Knorpel- und
Knochenmetaplasie (8571/3)
Adenokarzinom mit
Spindelzellmetaplasie (8572/3)
Adenokarzinom mit
Spindelzellmetaplasie, Metastase
(8572/6)
Adenokarzinom mit
Spindelzellmetaplasie, unbestimmt ob
Primärtumor oder Metastase (8572/9)
Adenokarzinom mit apokriner Metaplasie
(8573/3)
Adenokarzinom mit neuroendokriner
Differenzierung (8574/3)
Metaplastisches Karzinom o.n.A.
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(8575/3)
Metaplastisches Karzinom o.n.A.,
Metastase (8575/6)
Metaplastisches Karzinom o.n.A.,
unbestimmt ob Primärtumor oder
Metastase (8575/9)
Hepatoides Adenokarzinom (8576/3)
Benignes Thymom (8580/0)
Thymom o.n.A. (8580/1)
Malignes Thymom o.n.A. (8580/3)
Thymom vom Typ A o.n.A. (8581/1)
Malignes Thymom vom Typ A (8581/3)
Thymom vom Typ AB o.n.A. (8582/1)
Malignes Thymom vom Typ AB (8582/3)
Thymom vom Typ B1 o.n.A. (8583/1)
Malignes Thymom vom Typ B1 (8583/3)
Thymom vom Typ B2 o.n.A. (8584/1)
Malignes Thymom vom Typ B2 (8584/3)
Thymom vom Typ B3 o.n.A. (8585/1)
Malignes Thymom vom Typ B3 (8585/3)
Thymuskarzinom o.n.A. (8586/3)
Ektope hamartomatöse Thymome
(8587/0)
Spindelzellig-epithelialer Tumor mit
thymusähnlichen Anteilen (8588/3)
Karzinome mit thymusähnlichen Anteilen
(8589/3)
Keimstrang-Stromatumor o. n. A.
(8590/1)
Inkomplett differenzierter Keimstrang-
Stromatumor (8591/1)
Keimstrang-Stromatumor, Mischtypen
(8592/1)
Stromatumor mit geringeren
Keimstranganteilen (8593/1)
Thekom o.n.A. (8600/0)
Malignes Thekom (8600/3)
Luteinisiertes Thekom (8601/0)
Sklerosierender Stromatumor (8602/0)
Luteom o.n.A. (8610/0)
Adulter Granulosazelltumor (8620/1)
Maligner Granulosazelltumor (8620/3)
Granulosa-Thekazelltumor (8621/1)
Juveniler Granulosazelltumor (8622/1)
Keimstrangtumor mit anulären Tubuli
(8623/1)
Benignes Androblastom (8630/0)
Androblastom o.n.A. (8630/1)
Malignes Androblastom (8630/3)
Gut differenzierter Sertoli-Leydig-Zell-
Tumor (8631/0)
Intermediär differenzierter Sertoli-Leydig-
Zell-Tumor (8631/1)
Schlecht differenzierter Sertoli-Leydig-
Zell-Tumor (8631/3)
Gynandroblastom (8632/1)
Retiformer Sertoli-Leydig-Zell-Tumor
(8633/1)
Intermediär differenzierter Sertoli-Leydig-
Zell-Tumor mit heterologen Elementen
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(8634/1)
Schlecht differenzierter Sertoli-Leydig-
Zell-Tumor mit heterologen Elementen
(8634/3)
Sertoli-Zell-Tumor o.n.A. (8640/1)
Sertoli-Zell-Karzinom (8640/3)
Lipidspeichernder Sertoli-Zell-Tumor
(8641/0)
Großzelliger verkalkender Sertoli-Zell-
Tumor (8642/1)
Benigner Leydig-Zell-Tumor (8650/0)
Leydig-Zell-Tumor o.n.A. (8650/1)
Maligner Leydig-Zell-Tumor (8650/3)
Hiluszelltumor (8660/0)
Lipidzelliger Ovarialtumor (8670/0)
Maligner Steroidzelltumor (8670/3)
Nebennierenresttumor (8671/0)
Benignes Paragangliom (8680/0)
Paragangliom o.n.A. (8680/1)
Malignes Paragangliom (8680/3)
Sympathisches Paragangliom (8681/1)
Parasympathisches Paragangliom
(8682/1)
Ganglienzell-Paragangliom (8683/0)
Glomus-jugulare-Tumor o.n.A. (8690/1)
Glomus-aorticum-Tumor (8691/1)
Glomus-caroticum-Tumor (8692/1)
Extraadrenales Paragangliom o.n.A.
(8693/1)
Malignes extraadrenales Paragangliom
(8693/3)
Phäochromozytom o.n.A. (8700/0)
Malignes Phäochromozytom (8700/3)
Glomangiosarkom (8710/3)
Glomustumor o.n.A. (8711/0)
Maligner Glomustumor (8711/3)
Glomangiom (8712/0)
Glomangiomyom (8713/0)
Pigmentierter Nävus o.n.A. (8720/0)
Melanoma in situ (8720/2)
Malignes Melanom o.n.A. (8720/3)
Noduläres malignes Melanom (NM)
(8721/3)
Ballonzellnävus (8722/0)
Ballonzellmelanom (8722/3)
Halonävus (8723/0)
Malignes Melanom in Regression
(8723/3)
Neuronävus (8725/0)
Großzelliger Nävus (8726/0)
Dysplastischer Nävus (8727/0)
Diffuse Melanozytose (8728/0)
Meningeales Melanozytom (8728/1)
Meningeale Melanomatose (8728/3)
Nichtpigmentierter Nävus (8730/0)
Amelanotisches malignes Melanom
(8730/3)
Junktionaler Nävus o.n.A. (8740/0)
Malignes Melanom in Junktions-Nävus
(8740/3)
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Prämaligne Melanose o.n.A. (8741/2)
Malignes Melanom in prämaligner
Melanose (8741/3)
Lentigo maligna (8742/2)
Lentigo-maligna-Melanom (8742/3)
Oberflächlich spreitendes Melanom
(8743/3)
Akral-lentiginöses malignes Melanom
(8744/3)
Desmoplastisches malignes Melanom
(8745/3)
Mukosal-lentiginöses malignes Melanom
(8746/3)
Intradermaler Nävus (8750/0)
Compound-Nävus (8760/0)
Kleiner kongenitaler Nävus (8761/0)
Pigmentierter Riesennävus o.n.A.
(8761/1)
Malignes Melanom in pigmentiertem
Riesennävus (8761/3)
Proliferative dermale Läsion in
kongenitalem Nävus (8762/1)
Epitheloid- und Spindelzellnävus
(8770/0)
Gemischtes Epitheloid- und
Spindelzellmelanom (8770/3)
Epitheloidzellnävus (8771/0)
Epitheloidzellmelanom (8771/3)
Spindelzellnävus o.n.A. (8772/0)
Spindelzellmelanom o.n.A. (8772/3)
Spindelzellmelanom Typ A (8773/3)
Spindelzellmelanom Typ B (8774/3)
Blauer Nävus o.n.A. (8780/0)
Maligner blauer Nävus (8780/3)
Zellreicher blauer Nävus (8790/0)
Benigner Weichteiltumor (8800/0)
Sarkom o.n.A. (8800/3)
Sarkom o.n.A., Metastase (8800/6)
Sarkomatose o.n.A. (8800/9)
Spindelzellsarkom (8801/3)
Riesenzellsarkom (8802/3)
Kleinzelliges Sarkom (8803/3)
Epitheloidsarkom (8804/3)
Undifferenziertes Sarkom (8805/3)
Desmoplastischer kleinzelliger Tumor
(8806/3)
Fibrom o.n.A. (8810/0)
Zellreiches Fibrom (8810/1)
Fibrosarkom o.n.A. (8810/3)
Fibromyxom (8811/0)
Fibromyxosarkom (8811/3)
Periostales Fibrom (8812/0)
Periostales Fibrosarkom (8812/3)
Faszienfibrom (8813/0)
Faszienfibrosarkom (8813/3)
Infantiles Fibrosarkom (8814/3)
Solitärer fibröser Tumor (8815/0)
Maligner solitärer fibröser Tumor
(8815/3)
Elastofibrom (8820/0)
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Aggressive Fibromatose (8821/1)
Abdominale Fibromatose (8822/1)
Desmoplastisches Fibrom (8823/0)
Myofibrom (8824/0)
Myofibromatose (8824/1)
Myofibroblastom (8825/0)
Myofibroblastentumor o.n.A. (8825/1)
Angiomyofibroblastom (8826/0)
Peribronchialer Myofibroblastentumor
(8827/1)
Fibröses Histiozytom (8830/0)
Atypisches fibröses Histiozytom (8830/1)
Malignes fibröses Histiozytom (8830/3)
Histiozytom o.n.A. (8831/0)
Dermatofibrom o.n.A. (8832/0)
Dermatofibrosarkom o.n.A. (8832/3)
Pigmentiertes Dermatofibrosarcoma
protuberans (8833/3)
Riesenzellfibroblastom (8834/1)
Plexiformer fibrohistiozytärer Tumor
(8835/1)
Angiomatoides fibröses Histiozytom
(8836/1)
Myxom o.n.A. (8840/0)
Myxosarkom (8840/3)
Angiomyxom (8841/1)
Ossifizierender fibromyxoider
Weichteiltumor (8842/0)
Lipom o.n.A. (8850/0)
Atypisches Lipom (8850/1)
Liposarkom o.n.A. (8850/3)
Liposarkom o.n.A., Metastase (8850/6)
Liposarkom o.n.A., unbestimmt ob
Primärtumor oder Metastase (8850/9)
Fibrolipom (8851/0)
Gut differenziertes Liposarkom (8851/3)
Fibromyxolipom (8852/0)
Myxoides Liposarkom (8852/3)
Rundzelliges Liposarkom (8853/3)
Pleomorphes Lipom (8854/0)
Pleomorphes Liposarkom (8854/3)
Gemischtzelliges Liposarkom (8855/3)
Intramuskuläres Lipom (8856/0)
Spindelzell-Lipom (8857/0)
Fibroblastisches Liposarkom (8857/3)
Entdifferenziertes Liposarkom (8858/3)
Angiomyolipom (8860/0)
Angiolipom o.n.A. (8861/0)
Chondroides Lipom (8862/0)
Myelolipom (8870/0)
Hibernom (8880/0)
Lipoblastomatose (8881/0)
Leiomyom o.n.A. (8890/0)
Leiomyomatose o.n.A. (8890/1)
Leiomyosarkom o.n.A. (8890/3)
Leiomyosarkom o.n.A., Metastase
(8890/6)
Leiomyosarkom o.n.A., unbestimmt ob
Primärtumor oder Metastase (8890/9)
Epitheloides Leiomyom (8891/0)
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Epitheloides Leiomyosarkom (8891/3)
Zellreiches Leiomyom (8892/0)
Bizarres Leiomyom (8893/0)
Angiomyom (8894/0)
Angiomyosarkom (8894/3)
Myom (8895/0)
Angaben zur aktuellen Tumordiagnose
Laufende Nummer des Tumors
Diagnose des aktuellen Tumors
Tumordiagnose
klinisches Diagnosedatum (TT.MM.JJJJ)
Diagnose einschl. Topographie und Morphologie
Anlass der Diagnosestellung
Anamnese (A)
Eigenuntersuchung
(Selbstuntersuchung) (E)
gesetzl. Früherkennung (F)
Nachsorge (N)
Tumorsymptomatik (T)
unbekannt (U)
nicht gesetzl. Vorsorge (V)
Seitenlokalisation des Primärtumors
rechts (1)
links (2)
beidseits (3)
systemisch (4)
Mittellinienzone (5)
trifft nicht zu (6)
unbekannt (88)
Sicherheit der Diagnose
Todesbescheinigung ohne Autopsie (1)
klinisch (2)
klinisch/apparative Diagnostik (3)
spezifische Tumor-Marker (4)
Zytologie (5)
Histologie Metastase (6)
Histologie Primärtumor (7)
Autopsie (8)
Datum des histopathologischen Erstbefundes
(TT.MM.JJJJ)
Tumorlokalisation des Primärtumors
Äußere Oberlippe (C00.0)
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Äußere Unterlippe (C00.1)
Äußere Lippe o.n.A. (C00.2)
Schleimhaut der Oberlippe (C00.3)
Schleimhaut der Unterlippe (C00.4)
Lippenschleimhaut o.n.A. (C00.5)
Lippenkommissur (C00.6)
Lippe, mehrere Teilbereiche überlappend
(C00.8)
Lippe o.n.A. (C00.9)
Zungengrund o.n.A. (C01.9)
Dorsale Oberfläche der Zunge (C02.0)
Zungenrand (C02.1)
Ventrale Oberfläche der Zunge o.n.A.
(C02.2)
Vordere 2/3 der Zunge (C02.3)
Zungentonsille (C02.4)
Zunge, mehrere Bereiche überlappend
(C02.8)
Zunge o.n.A. (C02.9)
Oberkieferzahnfleisch (C03.0)
Unterkieferzahnfleisch (C03.1)
Zahnfleisch o.n.A. (C03.9)
Vorderer Teil des Mundbodens (C04.0)
Seitlicher Teil des Mundbodens (C04.1)
Mundboden, mehrere Teilbereiche
überlappend (C04.8)
Mundboden o.n.A. (C04.9)
Harter Gaumen (C05.0)
Weicher Gaumen o.n.A. (C05.1)
Uvula (C05.2)
Gaumen, mehrere Teilbereiche
überlappend (C05.8)
Gaumen o.n.A. (C05.9)
Wangenschleimhaut (C06.0)
Vestibulum oris (C06.1)
Retromolarregion (C06.2)
Sonstige und nicht näher bezeichnete
Teile des Mundes, mehrere Teilbereiche
überlappend (C06.8)
Mund o.n.A. (C06.9)
Parotis (C07.9)
Glandula submandibularis (C08.0)
Glandula sublingualis (C08.1)
Große Speicheldrüsen, mehrere
Bereiche überlappend (C08.8)
Große Speicheldrüsen o.n.A. (C08.9)
Fossa tonsillaris (C09.0)
Gaumenbogen (C09.1)
Tonsille, mehrere Teilbereiche
überlappend (C09.8)
Tonsille o.n.A. (C09.9)
Vallecula epiglottica (C10.0)
Vorderfläche der Epiglottis (C10.1)
Seitenwand des Oropharynx (C10.2)
Hinterwand des Oropharynx (C10.3)
Kiemengang (C10.4)
Oropharynx, mehrere Teilbereiche
überlappend (C10.8)
Oropharynx o.n.A. (C10.9)
Obere Wand des Nasopharynx (C11.0)
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Hinterwand des Nasopharynx (C11.1)
Seitenwand des Nasopharynx (C11.2)
Vorderwand des Nasopharynx (C11.3)
Nasopharynx, mehrere Teilbereiche
überlappend (C11.8)
Nasopharynx o.n.A. (C11.9)
Sinus piriformis (C12.9)
Regio postcricoidea (C13.0)
Plica aryepiglottica, hypopharyngeale
Seite (C13.1)
Hinterwand des Hypopharynx (C13.2)
Hypopharynx, mehrere Teilbereiche
überlappend (C13.8)
Hypopharynx o.n.A. (C13.9)
Pharynx o.n.A. (C14.0)
Waldeyer-Ring (C14.2)
Lippe, Mundhöhle und Pharynx, mehrere
Bereiche überlappend (C14.8)
Ösophagus, Pars cervicalis (C15.0)
Ösophagus, Pars thoracalis (C15.1)
Ösophagus, Pars abdominalis (C15.2)
Ösophagus, oberes Drittel (C15.3)
Ösophagus, mittleres Drittel (C15.4)
Ösophagus, unteres intrathorakales
Drittel (C15.5)
Ösophagus, mehrere Teilbereiche
überlappend (C15.8)
Ösophagus o.n.A. (C15.9)
Kardia o.n.A. (C16.0)
Fundus ventriculi (C16.1)
Corpus ventriculi (C16.2)
Antrum ventriculi (C16.3)
Pylorus (C16.4)
Kleine Kurvatur o.n.A (C16.5)
Große Kurvatur o.n.A (C16.6)
Magen, mehrere Teilbereiche
überlappend (C16.8)
Magen o.n.A. (C16.9)
Duodenum (C17.0)
Jejunum (C17.1)
Ileum (C17.2)
Meckel-Divertikel (C17.3)
Dünndarm, mehrere Teilbereiche
überlappend (C17.8)
Dünndarm o.n.A. (C17.9)
Zökum (C18.0)
Appendix vermiformis (C18.1)
Colon ascendens (C18.2)
Flexura hepatica (C18.3)
Colon transversum (C18.4)
Flexura lienalis coli (C18.5)
Colon descendens (C18.6)
Colon sigmoideum (C18.7)
Kolon, mehrere Teilbereiche
überlappend (C18.8)
Colon (C18.9)
Rektosigmoidaler Übergang (C19.9)
Rektum o.n.A. (C20.9)
Anus o.n.A. (C21.0)
Analkanal (C21.1)
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Kloakenregion (C21.2)
Rektum, Anus und Analkanal, mehrere
Bereiche überlappend (C21.8)
Leber (C22.0)
Intrahepatische Gallengänge (C22.1)
Gallenblase (C23.9)
Extrahepatischer Gallengang (C24.0)
Ampulla Vateri (C24.1)
Gallenwege, mehrere Bereiche
überlappend (C24.8)
Gallenwege o.n.A. (C24.9)
Pankreaskopf (C25.0)
Pankreaskörper (C25.1)
Pankreasschwanz (C25.2)
Ductus pancreaticus (C25.3)
Pankreas-Inselzellen (C25.4)
Sonstige näher bezeichnete Teile des
Pankreas (C25.7)
Pankreas, mehrere Teilbereiche
überlappend (C25.8)
Pankreas o.n.A. (C25.9)
Intestinaltrakt o.n.A. (C26.0)
Verdauungssystem, mehrere Bereiche
überlappend (C26.8)
Gastrointestinaltrakt o.n.A. (C26.9)
Nasenhöhle (C30.0)
Mittelohr (C30.1)
Sinus maxillaris (C31.0)
Sinus ethmoidalis (C31.1)
Sinus frontalis (C31.2)
Sinus sphenoidalis (C31.3)
Nasennebenhöhlen, mehrere
Teilbereiche überlappend (C31.8)
Nasennebenhöhlen o.n.A. (C31.9)
Glottis (C32.0)
Supraglottis (C32.1)
Subglottis (C32.2)
Larynxknorpel (C32.3)
Larynx, mehrere Teilbereiche
überlappend (C32.8)
Kehlkopf o.n.A. (C32.9)
Trachea (C33.9)
Hauptbronchus (C34.0)
Lungenoberlappen (C34.1)
Lungenmittellappen (C34.2)
Lungenunterlappen (C34.3)
Lunge, mehrere Teilbereiche
überlappend (C34.8)
Lunge o.n.A. (C34.9)
Thymus (C37.9)
Herz (C38.0)
Vorderes Mediastinum (C38.1)
Hinteres Mediastinum (C38.2)
Mediastinum o.n.A. (C38.3)
Pleura o.n.A. (C38.4)
Herz, Mediastinum und Pleura, mehrere
Teilbereiche überlappend (C38.8)
Obere Atemwege o.n.A. (C39.0)
Atemwege [Respirationstrakt] und
intrathorakale Organe, mehrere Bereiche
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überlappend (C39.8)
Mangelhaft bezeichneter Sitz innerhalb
der Atmungsorgane (C39.9)
Lange Knochen von Arm und Schulter
und zugehörige Gelenke (C40.0)
Kurze Knochen der oberen Extremitäten
und zugehörige Gelenke (C40.1)
Lange Knochen der unteren
Extremitäten und zugehörige Gelenke
(C40.2)
Kurze Knochen der unteren Extremitäten
und zugehörige Gelenke (C40.3)
Knochen, Gelenke und Gelenkknorpel
der Extremitäten, mehrere Teilbereiche
überlappend (C40.8)
Knochen einer Extremität o.n.A. (C40.9)
Knochen des Hirn- und
Gesichtsschädels und zugehörige
Gelenke (C41.0)
Mandibula (C41.1)
Wirbelsäule (C41.2)
Rippen, Sternum, Klavikula und
zugehörige Gelenke (C41.3)
Beckenknochen, Kreuzbein, Steißbein
und zugehörige Gelenke (C41.4)
Knochen, Gelenke und Gelenkknorpel,
mehrere Bereiche überlappend (C41.8)
Knochen o.n.A. (C41.9)
Blut (C42.0)
Knochenmark (C42.1)
Milz (C42.2)
Retikuloendotheliales System o.n.A.
(C42.3)
Hämatopoetisches System o.n.A.
(C42.4)
Lippenhaut o.n.A. (C44.0)
Augenlid (C44.1)
Äußeres Ohr (C44.2)
Haut sonstiger und nicht näher
bezeichneter Teile des Gesichtes
(C44.3)
Behaarte Kopfhaut und Haut am Hals
(C44.4)
Haut am Stamm (C44.5)
Haut der oberen Extremitäten und der
Schulter (C44.6)
Haut der unteren Extremität und der
Hüfte (C44.7)
Haut, mehrere Teilbereiche überlappend
(C44.8)
Haut o.n.A. (C44.9)
Periphere Nerven und autonomes
Nervensystem des Kopfes, des
Gesichtes und des Halses (C47.0)
Periphere Nerven und autonomes
Nervensystem der oberen Extremität und
der Schulter (C47.1)
Periphere Nerven und autonomes
Nervensystem der unteren Extremität
und der Hüfte (C47.2)
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Periphere Nerven und autonomes
Nervensystem des Thorax (C47.3)
Periphere Nerven und autonomes
Nervensystem des Abdomens (C47.4)
Periphere Nerven und autonomes
Nervensystem des Beckens (C47.5)
Periphere Nerven und autonomes
Nervensystem des Stammes (C47.6)
Periphere Nerven und autonomes
Nervensystem, mehrere Teilbereiche
überlappend (C47.8)
Autonomes Nervensystem o.n.A. (C47.9)
Retroperitoneum (C48.0)
Näher bezeichnete Teile des
Peritoneums (C48.1)
Peritoneum o.n.A. (C48.2)
Retroperitoneum und Peritoneum,
mehrere Teilbereiche überlappend
(C48.8)
Bindegewebe, Subkutangewebe und
sonstige Weichteile des Kopfes, des
Gesichtes und des Halses (C49.0)
Bindegewebe, Subkutangewebe und
sonstige Weichteile der oberen
Extremität und der Schulter (C49.1)
Bindegewebe, Subkutangewebe und
sonstige Weichteile der unteren
Extremität und der Hüfte (C49.2)
Bindegewebe, Subkutangewebe und
sonstige Weichteile des Thorax (C49.3)
Bindegewebe, Subkutangewebe und
sonstige Weichteilgewebe des Abdomen
(C49.4)
Bindegewebe, Subkutangewebe und
sonstige Weichteile des Beckens (C49.5)
Bindegewebe, Subkutangewebe und
sonstige Weichteile des Stammes o.n.A.
(C49.6)
Bindegewebe, Subkutangewebe und
sonstige Weichteile, mehrere Bereiche
überlappend (C49.8)
Bindegewebe, Subkutangewebe und
sonstige Weichteile o.n.A. (C49.9)
Mamille (C50.0)
Zentraler Drüsenkörper der Brust
(C50.1)
Oberer innerer Quadrant der Brust
(C50.2)
Unterer innerer Quadrant der Brust
(C50.3)
Oberer äußerer Quadrant der Brust
(C50.4)
Unterer äußerer Quadrant der Brust
(C50.5)
Recessus axillaris der Brust (C50.6)
Brust, mehrere Teilbereiche überlappend
(C50.8)
Brust o.n.A. (C50.9)
Labium majus (C51.0)
Labium minus (C51.1)
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Klitoris (C51.2)
Vulva, mehrere Teilbereiche überlappend
(C51.8)
Vulva o.n.A. (C51.9)
Vagina o.n.A. (C52.9)
Endozervix (C53.0)
Ektozervix (C53.1)
Cervix uteri, mehrere Teilbereiche
überlappend (C53.8)
Cervix uteri (C53.9)
Isthmus uteri (C54.0)
Endometrium (C54.1)
Myometrium (C54.2)
Fundus uteri (C54.3)
Corpus uteri, mehrere Teilbereiche
überlappend (C54.8)
Corpus uteri (C54.9)
Uterus o.n.A. (C55.9)
Ovar (C56.9)
Eileiter (C57.0)
Ligamentum latum uteri (C57.1)
Ligamentum rotundum (C57.2)
Parametrium (C57.3)
Weibliche Adnexe (C57.4)
Sonstige näher bezeichnete Teile der
weiblichen Geschlechtsorgane (C57.7)
Weibliche Geschlechtsorgane, mehrere
Bereiche überlappend (C57.8)
Weibliche Geschlechtsorgane o.n.A.
(C57.9)
Plazenta (C58.9)
Präputium (C60.0)
Glans penis (C60.1)
Penisschaft (C60.2)
Penis, mehrere Teilbereiche überlappend
(C60.8)
Penis o.n.A. (C60.9)
Prostata (C61.9)
Kryptorchider Hoden (C62.0)
Deszendierter Hoden (C62.1)
Testis o.n.A. (C62.9)
Nebenhoden (C63.0)
Samenstrang (C63.1)
Skrotum o.n.A. (C63.2)
Sonstige näher bezeichnete Teile der
männlichen Geschlechtsorgane (C63.7)
Männliche Geschlechtsorgane, mehrere
Bereiche überlappend (C63.8)
Männliche Geschlechtsorgane o.n.A.
(C63.9)
Niere o.n.A. (C64.9)
Nierenbecken (C65.9)
Ureter (C66.9)
Trigonum vesicae (C67.0)
Blasendach (C67.1)
Laterale Harnblasenwand (C67.2)
Vordere Harnblasenwand (C67.3)
Hintere Harnblasenwand (C67.4)
Harnblasenhals (C67.5)
Ostium ureteris (C67.6)
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Urachus (C67.7)
Harnblase, mehrere Teilbereiche
überlappend (C67.8)
Blase o.n.A. (C67.9)
Urethra (C68.0)
Paraurethrale Drüse (C68.1)
Harntrakt, mehrere Bereiche
überlappend (C68.8)
Harntrakt o.n.A. (C68.9)
Konjunktiva (C69.0)
Kornea o.n.A. (C69.1)
Retina (C69.2)
Chorioidea (C69.3)
Bulbus oculi (C69.4)
Tränendrüse (C69.5)
Orbita o.n.A. (C69.6)
Auge und Augenanhangsgebilde,
mehrere Teilbereiche überlappend
(C69.8)
Auge o.n.A. (C69.9)
Hirnhäute (C70.0)
Rückenmarkhäute (C70.1)
Meningen o.n.A. (C70.9)
Cerebrum (C71.0)
Frontallappen (C71.1)
Temporallappen (C71.2)
Parietallappen (C71.3)
Okzipitallappen (C71.4)
Ventrikel o.n.A. (C71.5)
Kleinhirn o.n.A. (C71.6)
Hirnstamm (C71.7)
Gehirn, mehrere Teilbereiche
überlappend (C71.8)
Gehirn o.n.A. (C71.9)
Rückenmark (C72.0)
Cauda equina (C72.1)
N. olfactorius (C72.2)
N. opticus (C72.3)
N. acusticus (C72.4)
Hirnnerven o.n.A. (C72.5)
Gehirn und andere Teile des
Zentralnervensystems, mehrere
Bereiche überlappend (C72.8)
Nervensystem (C72.9)
Schilddrüse (C73.9)
Nebennierenrinde (C74.0)
Nebennierenmark (C74.1)
Nebenniere o.n.A. (C74.9)
Nebenschilddrüse (C75.0)
Hirnanhangsdrüse (C75.1)
Ductus craniopharyngealis (C75.2)
Glandula pinealis (C75.3)
Glomus caroticum (C75.4)
Glomus aorticum und sonstige
Paraganglien (C75.5)
Endokrine Drüsen und verwandte
Strukturen, mehrere Teilbereiche
überlappend (C75.8)
Endokrine Drüse o.n.A. (C75.9)
Kopf, Gesicht oder Hals o.n.A. (C76.0)
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Thorax o.n.A. (C76.1)
Abdomen o.n.A. (C76.2)
Becken o.n.A. (C76.3)
Obere Extremität o.n.A. (C76.4)
Untere Extremität o.n.A. (C76.5)
Sonstiger mangelhaft bezeichneter Sitz
(C76.7)
Mangelhaft bezeichneter Sitz, mehrere
Teilbereiche überlappend (C76.8)
Lymphknoten des Kopfes, des Gesichtes
und des Halses (C77.0)
Intrathorakaler Lymphknoten (C77.1)
Intraabdominaler Lymphknoten (C77.2)
Lymphknoten der Achseln und Arme
(C77.3)
Lymphknoten der Inguinalregion und des
Beines (C77.4)
Beckenlymphknoten (C77.5)
Lymphknoten mehrerer Regionen
(C77.8)
Lymphknoten o.n.A. (C77.9)
Unbekannte Primärlokalisation (C80.9)
Tumormorphologie
Benigne Neoplasie o.n.A. (8000/0)
Neoplasie fraglicher Dignität (8000/1)
Maligne Neoplasie (8000/3)
Neoplasie, Metastase (8000/6)
Maligne Neoplasie, unsicher ob
Primärtumor oder Metastase (8000/9)
Benigne Tumorzellen (8001/0)
Tumorzellen fraglicher Dignität (8001/1)
Maligne Tumorzellen (8001/3)
Kleinzelliger maligner Tumor (8002/3)
Riesenzelliger maligner Tumor (8003/3)
Spindelzelliger maligner Tumor (8004/3)
Klarzelliger Tumor o.n.A. (8005/0)
Klarzelliger maligner Tumor (8005/3)
Benigne epitheliale Neoplasie (8010/0)
Carcinoma in situ o.n.A. (8010/2)
Karzinom o.n.A. (8010/3)
Karzinom-Metastase o.n.A. (8010/6)
Karzinomatose (8010/9)
Benignes Epitheliom (8011/0)
Malignes Epitheliom (8011/3)
Großzelliges Karzinom o.n.A. (8012/3)
Großzelliges neuroendokrines Karzinom
(8013/3)
Großzelliges neuroendokrines Karzinom,
Metastase (8013/6)
Großzelliges neuroendokrines Karzinom,
unbestimmt ob Primärtumor oder
Metastase (8013/9)
Großzelliges Karzinom mit rhabdoidem
Phänotyp (8014/3)
Glaszellkarzinom (8015/3)
Undifferenziertes Karzinom o.n.A.
(8020/3)
Anaplastisches Karzinom o.n.A. (8021/3)
Pleomorphes Karzinom (8022/3)
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Pleomorphes Karzinom, Metastase
(8022/6)
Pleomorphes Karzinom, unbestimmt ob
Primärtumor oder Metastase (8022/9)
Riesenzell- und Spindelzellkarzinom
(8030/3)
Riesenzellkarzinom (8031/3)
Spindelzellkarzinom o.n.A. (8032/3)
Pseudosarkomatöses Karzinom (8033/3)
Polygonalzelliges Karzinom (8034/3)
Karzinom mit osteoklastenähnlichen
Riesenzellen (8035/3)
Karzinom mit osteoklastenähnlichen
Riesenzellen, Metastase (8035/6)
Karzinom mit osteoklastenähnlichen
Riesenzellen, unbestimmt ob
Primärtumor oder Metastase (8035/9)
Benignes Tumorlet (8040/0)
Tumorlet o.n.A. (8040/1)
Kleinzelliges Karzinom o.n.A. (8041/3)
Kleinzelliges Karzinom o.n.A., Metastase
(8041/6)
Kleinzelliges Karzinom o.n.A.,
unbestimmt ob Primärtumor oder
Metastase (8041/9)
Haferzell-Karzinom (8042/3)
Kleinzelliges spindelzelliges Karzinom
(8043/3)
Kleinzelliges Karzinom vom
Intermediärtyp (8044/3)
Kombiniertes kleinzelliges Karzinom
(8045/3)
Nichtkleinzelliges Karzinom (8046/3)
Papillom o.n.A. (8050/0)
Papilläres Carcinoma in situ (8050/2)
Papilläres Karzinom o.n.A. (8050/3)
Verruköses Papillom (8051/0)
Verruköses Karzinom o.n.A. (8051/3)
Plattenepithelpapillom o.n.A. (8052/0)
Nichtinvasives papilläres
Plattenepithelkarzinom (8052/2)
Papilläres Plattenepithelkarzinom
(8052/3)
Invertiertes Plattenepithel-Papillom
(8053/0)
Plattenepithel-Papillomatose (8060/0)
Plattenepithel-Carcinoma in situ o.n.A.
(8070/2)
Plattenepithelkarzinom o.n.A. (8070/3)
Plattenepithelkarzinom-Metastase o.n.A.
(8070/6)
Plattenepithelkarzinom o.n.A.,
unbestimmt ob Primärtumor oder
Metastase (8070/9)
Verhornendes Plattenepithelkarzinom
o.n.A. (8071/3)
Großzelliges nichtverhornendes
Plattenepithelkarzinom o.n.A. (8072/3)
Kleinzelliges nichtverhornendes
Plattenepithelkarzinom (8073/3)
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Spindelzelliges Plattenepithelkarzinom
(8074/3)
Adenoides Plattenepithelkarzinom
(8075/3)
Plattenepithel-Carcinoma in situ mit
fraglicher Stromainvasion (8076/2)
Mikroinvasives Plattenepithelkarzinom
(8076/3)
Intraepitheliale Neoplasie Grad 3
(8077/2)
Plattenepithelkarzinom mit Hornbildung
(8078/3)
Erythroplasie Queyrat (8080/2)
M. Bowen (8081/2)
Lymphoepitheliales Karzinom (8082/3)
Basaloides Plattenepithelkarzinom
(8083/3)
Klarzelliges Plattenepithelkarzinom
(8084/3)
Basalzelltumor (8090/1)
Basalzellkarzinom o.n.A. (8090/3)
Multifokales oberflächliches
Basalzellkarzinom (8091/3)
Infiltrierendes Basalzellkarzinom o.n.A.
(8092/3)
Fibroepitheliales Basalzellkarzinom
(8093/3)
Basosquamöses Karzinom (8094/3)
Metatypisches Karzinom (8095/3)
Intraepidermales Epitheliom Typ Borst-
Jadassohn (8096/0)
Noduläres Basalzellkarzinom (8097/3)
Adenoides Basalzellkarzinom (8098/3)
Trichoepitheliom (8100/0)
Trichofollikulom (8101/0)
Tricholemmom (8102/0)
Tricholemmkarzinom (8102/3)
Pilartumor (8103/0)
Pilomatrixom o.n.A. (8110/0)
Pilomatrix-Karzinom (8110/3)
Benignes Übergangszellpapillom
(8120/0)
Urothelpapillom o.n.A. (8120/1)
Übergangszell-Carcinoma in situ
(8120/2)
Übergangszellkarzinom o.n.A. (8120/3)
Schneider-Papillom o.n.A. (8121/0)
Invertiertes Übergangszellpapillom o.n.A.
(8121/1)
Schneider-Karzinom (8121/3)
Spindelzelliges Übergangszellkarzinom
(8122/3)
Basaloidkarzinom (8123/3)
Kloakogenes Karzinom (8124/3)
Papilläre Neoplasie der Übergangszellen
mit niedrigem Malignitätspotential
(8130/1)
Nichtinvasives papilläres
Übergangszellkarzinom (8130/2)
Papilläres Übergangszellkarzinom
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(8130/3)
Mikropapilläres Übergangszellkarzinom
(8131/3)
Adenom o.n.A. (8140/0)
Atypisches Adenom (8140/1)
Adenocarcinoma in situ o.n.A. (8140/2)
Adenokarzinom o.n.A. (8140/3)
Adenokarzinom-Metastase o.n.A.
(8140/6)
Adenokarzinom o.n.A., unbestimmt ob
Primärtumor oder Metastase (8140/9)
Szirrhöses Adenokarzinom (8141/3)
Linitis plastica (8142/3)
Oberflächlich spreitendes
Adenokarzinom (8143/3)
Adenokarzinom vom intestinalen Typ
(8144/3)
Diffuses Karzinom (8145/3)
Monomorphes Adenom (8146/0)
Basalzelladenom (8147/0)
Basalzell-Adenokarzinom (8147/3)
Glanduläre intraepitheliale Neoplasie
Grad 3 (8148/2)
Intrakanalikuläres Adenom (8149/0)
Inselzelladenom (8150/0)
Inselzelltumor o.n.A. (8150/1)
Inselzellkarzinom (8150/3)
Insulinom o.n.A. (8151/0)
Malignes Insulinom (8151/3)
Glukagonom o.n.A. (8152/1)
Malignes Glukagonom (8152/3)
Gastrinom o.n.A. (8153/1)
Malignes Gastrinom (8153/3)
Gemischtes Inselzell- und exokrines
Adenokarzinom (8154/3)
Vipom o.n.A. (8155/1)
Malignes Vipom (8155/3)
Somatostatinom o.n.A. (8156/1)
Malignes Somatostatinom (8156/3)
Enteroglukagonom o.n.A. (8157/1)
Malignes Enteroglukagonom (8157/3)
Gallengangsadenom (8160/0)
Intrahepatisches Cholangiokarzinom
(8160/3)
Gallengangs-Zystadenom (8161/0)
Gallengangs-Zystadenokarzinom
(8161/3)
Klatskin-Tumor (8162/3)
Leberzelladenom (8170/0)
Hepatozelluläres Karzinom o.n.A.
(8170/3)
Fibrolamelläres Leberzellkarzinom
(8171/3)
Szirrhöses hepatozelluläres Karzinom
(8172/3)
Spindelzelliges hepatozelluläres
Karzinom (8173/3)
Klarzelliges hepatozelluläres Karzinom
(8174/3)
Pleomorphes hepatozelluläres Karzinom
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(8175/3)
Kombiniertes hepatozelluläres Karzinom
und Cholangiokarzinom (8180/3)
Trabekuläres Adenom (8190/0)
Trabekuläres Adenokarzinom (8190/3)
Embryonales Adenom (8191/0)
Ekkrines dermales Zylindrom (8200/0)
Adenoid-zystisches Karzinom (8200/3)
Adenoid-zystisches Karzinom,
Metastase (8200/6)
Adenoid-zystisches Karzinom,
unbestimmt ob Primärtumor oder
Metastase (8200/9)
Kribriformes Carcinoma in situ (8201/2)
Kribriformes Karzinom o.n.A. (8201/3)
Kribriformes Karzinom o.n.A., Metastase
(8201/6)
Kribriformes Karzinom o.n.A.,
unbestimmt ob Primärtumor oder
Metastase (8201/9)
Mikrozystisches Adenom (8202/0)
Laktierendes Adenom (8204/0)
Adenomatöser Polyp o.n.A. (8210/0)
Adenocarcinoma in situ in
adenomatösem Polypen (8210/2)
Adenokarzinom in adenomatösem
Polypen (8210/3)
Tubuläres Adenom o.n.A. (8211/0)
Tubuläres Adenokarzinom (8211/3)
Tubuläres Adenokarzinom, Metastase
(8211/6)
Tubuläres Adenokarzinom, unbestimmt
ob Primärtumor oder Metastase (8211/9)
Flaches Adenom (8212/0)
Serrated adenoma (8213/0)
Parietalzellkarzinom (8214/3)
Adenokarzinom der Analdrüsen (8215/3)
Familiäre adenomatöse Polypose [FAP]
(8220/0)
Adenokarzinom in familiärer
adenomatöser Polypose [FAP] (8220/3)
Multiple adenomatöse Polypen (8221/0)
Adenokarzinom in multiplen
adenomatösen Polypen (8221/3)
Solides duktales Carcinoma in situ
(8230/2)
Solides Karzinom o.n.A. (8230/3)
Carcinoma simplex (8231/3)
Karzinoidtumor fraglicher Dignität
(8240/1)
Karzinoidtumor o.n.A. (8240/3)
Enterochromaffinzell-Karzinoid (8241/3)
Enterochromaffin-like-cell-Karzinoid
(8242/1)
Maligner Enterochromaffin-like-cell-
Tumor (8242/3)
Becherzellkarzinoid (8243/3)
Kombiniertes Karzinoid (8244/3)
Tubuläres Karzinoid (8245/1)
Adenokarzinoidtumor (8245/3)
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Neuroendokrines Karzinom o.n.A.
(8246/3)
Merkel-Zell-Karzinom (8247/3)
Apudom (8248/1)
Atypischer Karzinoidtumor (8249/3)
Atypischer Karzinoidtumor, Metastase
(8249/6)
Atypischer Karzinoidtumor, unbestimmt
ob Primärtumor oder Metastase (8249/9)
Lungenadenomatose (8250/1)
Bronchiolo-alveoläres Adenokarzinom
o.n.A. (8250/3)
Alveoläres Adenom (8251/0)
Alveoläres Adenokarzinom (8251/3)
Nichtmuzinöses bronchiolo-alveoläres
Karzinom (8252/3)
Muzinöses bronchiolo-alveoläres
Karzinom (8253/3)
Gemischtes muzinöses und
nichtmuzinöses bronchiolo-alveoläres
Karzinom (8254/3)
Adenokarzinom mit gemischten
Subtypen (8255/3)
Papilläres Adenom o.n.A. (8260/0)
Papilläres Adenokarzinom o.n.A.
(8260/3)
Villöses Adenom o.n.A. (8261/0)
Adenocarcinoma in situ in villösem
Adenom (8261/2)
Adenokarzinom in villösem Adenom
(8261/3)
Villöses Adenokarzinom (8262/3)
Tubulovillöses Adenom o.n.A. (8263/0)
Adenocarcinoma in situ in tubulovillösem
Adenom (8263/2)
Adenokarzinom in tubulovillösem
Adenom (8263/3)
Glanduläre Papillomatose (8264/0)
Chromophobes Adenom (8270/0)
Chromophobes Karzinom (8270/3)
Prolaktinom (8271/0)
Hypophysenadenom o.n.A. (8272/0)
Hypophysenkarzinom o.n.A. (8272/3)
Azidophiles Adenom (8280/0)
Azidophiles Karzinom (8280/3)
Gemischtzelliges azidophil-basophiles
Adenom (8281/0)
Gemischtzelliges azidophil-basophiles
Karzinom (8281/3)
Oxyphiles Adenom (8290/0)
Onkozytäres Karzinom (8290/3)
Onkozytäres Karzinom, Metastase
(8290/6)
Onkozytäres Karzinom, unklar ob
Primärtumor oder Metastase (8290/9)
Basophiles Adenom (8300/0)
Basophiles Karzinom (8300/3)
Klarzelliges Adenom (8310/0)
Klarzelliges Adenokarzinom o.n.A.
(8310/3)
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Hypernephroider Tumor (8311/1)
Nierenzellkarzinom o.n.A. (8312/3)
Klarzelliges Adenofibrom (8313/0)
Klarzelliges Adenofibrom mit Borderline-
Malignität (8313/1)
Klarzelliges Adenokarzinofibrom
(8313/3)
Lipidreiches Karzinom (8314/3)
Lipidreiches Karzinom, Metastase
(8314/6)
Lipidreiches Karzinom, unbestimmt ob
Primärtumor oder Metastase (8314/9)
Glykogenreiches Klarzellkarzinom
(8315/3)
Glykogenreiches Klarzellkarzinom,
Metastase (8315/6)
Glykogenreiches Klarzellkarzinom,
unklar ob Primärtumor oder Metastase
(8315/9)
Zystenassoziiertes Nierenzellkarzinom
(8316/3)
Nierenzellkarzinom vom chromophoben
Zelltyp (8317/3)
Sarkomatoides Nierenzellkarzinom
(8318/3)
Sammelrohrkarzinom (8319/3)
Granularzellkarzinom (8320/3)
Hauptzelladenom (8321/0)
Wasserklares Adenom (8322/0)
Wasserklares Adenokarzinom (8322/3)
Gemischtzelliges Adenom (8323/0)
Gemischtzelliges Adenokarzinom
(8323/3)
Lipoadenom (8324/0)
Nachnieren-Adenom (8325/0)
Follikuläres Adenom (8330/0)
Atypisches follikuläres Adenom (8330/1)
Follikuläres Adenokarzinom o.n.A.
(8330/3)
Gut differenziertes follikuläres
Adenokarzinom (8331/3)
Trabekuläres follikuläres Adenokarzinom
(8332/3)
Mikrofollikuläres Adenom (8333/0)
Fetales Adenokarzinom (8333/3)
Makrofollikuläres Adenom (8334/0)
Minimal-invasives follikuläres Karzinom
(8335/3)
Hyalinisiertes trabekuläres Adenom
(8336/0)
Insuläres Karzinom (8337/3)
Papilläres Karzinom, follikuläre Variante
(8340/3)
Papilläres Mikrokarzinom (8341/3)
Oxyphiles papilläres Karzinom (8342/3)
Abgekapseltes papilläres Karzinom
(8343/3)
Zylinderzelliges papilläres
Schilddrüsenkarzinom (8344/3)
Medulläres Karzinom mit amyloidem
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Stroma (8345/3)
Gemischtzelliges medullär-follikuläres
Karzinom (8346/3)
Medulläres Karzinom mit papillärer
Komponente (8347/3)
Nichtabgekapseltes sklerosierendes
Karzinom (8350/3)
Multiple endokrine Adenome (8360/1)
Juxtaglomerulärer Tumor (8361/0)
Nebennierenrindenadenom o.n.A.
(8370/0)
Nebennierenrindenkarzinom (8370/3)
Nebennierenrindenadenom vom
Kompaktzelltyp (8371/0)
Stark pigmentiertes
Nebennierenrindenadenom (8372/0)
Klarzelliges Nebennierenrindenadenom
(8373/0)
Glomerulosazelliges
Nebennierenrindenadenom (8374/0)
Gemischtzelliges
Nebennierenrindenadenom (8375/0)
Endometrioides Adenom o.n.A. (8380/0)
Endometrioides Adenom mit Borderline-
Malignität (8380/1)
Endometrioides Adenokarzinom o.n.A.
(8380/3)
Endometrioides Adenofibrom o.n.A.
(8381/0)
Endometrioides Adenofibrom mit
Borderline-Malignität (8381/1)
Malignes endometrioides Adenofibrom
(8381/3)
Endometrioides Adenokarzinom,
sekretorische Variante (8382/3)
Endometrioides Adenokarzinom,
Flimmerepithel-Variante (8383/3)
Endozervikales Adenokarzinom (8384/3)
Adenom der Hautanhangsgebilde
(8390/0)
Karzinom der Hautanhangsgebilde
(8390/3)
Follikuläres Fibrom (8391/0)
Syringofibroadenom (8392/0)
Schweißdrüsenadenom (8400/0)
Schweißdrüsentumor o.n.A. (8400/1)
Schweißdrüsenadenokarzinom (8400/3)
Apokrines Adenom (8401/0)
Apokrines Adenokarzinom (8401/3)
Apokrines Adenokarzinom, Metastase
(8401/6)
Apokrines Adenokarzinom, unbestimmt
ob Primärtumor oder Metastase (8401/9)
Noduläres Hidradenom (8402/0)
Malignes noduläres Hidradenom
(8402/3)
Ekkrines Spiradenom (8403/0)
Malignes ekkrines Spiradenom (8403/3)
Hidrozystom (8404/0)
Papilläres Hidradenom (8405/0)
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Papilläres Syringadenom (8406/0)
Syringom o.n.A. (8407/0)
Sklerosierendes Karzinom der
Schweißdrüsenausführungsgänge
(8407/3)
Ekkrines papilläres Adenom (8408/0)
Aggressives digitales papilläres Adenom
(8408/1)
Ekkrines papilläres Adenokarzinom
(8408/3)
Ekkrines Porom (8409/0)
Malignes ekkrines Porom (8409/3)
Talgdrüsenadenom (8410/0)
Talgdrüsenadenokarzinom (8410/3)
Talgdrüsenadenokarzinom, Metastase
(8410/6)
Talgdrüsenadenokarzinom, unbestimmt
ob Primärtumor oder Metastase (8410/9)
Ekkrines Adenokarzinom (8413/3)
Zeruminaladenom (8420/0)
Zeruminaladenokarzinom (8420/3)
Mukoepidermoidtumor (8430/1)
Mukoepidermoid-Karzinom (8430/3)
Mukoepidermoid-Karzinom, Metastase
(8430/6)
Mukoepidermoid-Karzinom, unbestimmt
ob Primärtumor oder Metastase (8430/9)
Zystadenom o.n.A (8440/0)
Zystadenokarzinom o.n.A. (8440/3)
Seröses Zystadenom o.n.A. (8441/0)
Seröses Zystadenokarzinom o.n.A.
(8441/3)
Seröses Zystadenom mit Borderline-
Malignität (8442/1)
Klarzelliges Zystadenom (8443/0)
Klarzelliger zystischer Tumor mit
Borderline-Malignität (8444/1)
Papilläres Zystadenom o.n.A. (8450/0)
Papilläres Zystadenokarzinom o.n.A.
(8450/3)
Papilläres Zystadenom mit Borderline-
Malignität (8451/1)
Solid-pseudopapillärer Tumor (8452/1)
Solid-pseudopapilläres Karzinom
(8452/3)
Intraduktales papillär-muzinöses
Adenom (8453/0)
Intraduktaler papillär-muzinöser Tumor
mit mäßiger Dysplasie (8453/1)
Nichtinvasives intraduktales papillär-
muzinöses Karzinom (8453/2)
Invasives intraduktales papillär-
muzinöses Adenokarzinom (8453/3)
Zystischer Tumor des atrioventrikulären
Knotens (8454/0)
Seröses papilläres Zystadenom (8460/0)
Seröses papilläres Zystadenokarzinom
(8460/3)
Seröses Oberflächenpapillom o.n.A.
(8461/0)
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Seröses papilläres Oberflächenkarzinom
(8461/3)
Serös-papillärer zystischer Tumor mit
Borderline-Malignität (8462/1)
Serös-papillärer Oberflächentumor mit
Borderline-Malignität (8463/1)
Muzinöses Zystadenom o.n.A. (8470/0)
Muzinöser zystischer Tumor mit mäßiger
Dysplasie (8470/1)
Nichtinvasives muzinöses Zystadenom
(8470/2)
Muzinöses Zystadenokarzinom o.n.A.
(8470/3)
Muzinöses papilläres Zystadenom o.n.A.
(8471/0)
Muzinöses papilläres
Zystadenokarzinom (8471/3)
Muzinöser zystischer Tumor mit
Borderline-Malignität (8472/1)
Muzinöses papilläres Zystadenom mit
Borderline-Malignität (8473/1)
Muzinöses Adenom (8480/0)
Muzinöses Adenokarzinom (8480/3)
Pseudomyxoma peritonei (8480/6)
Muzinöses Adenokarzinom, unbestimmt
ob Primärtumor oder Metastase (8480/9)
Schleimbildendes Adenokarzinom
(8481/3)
Endozervikales muzinöses
Adenokarzinom (8482/3)
Siegelringzellkarzinom (8490/3)
Metastase eines
Siegelringzellkarzinomes (8490/6)
Siegelringzellkarzinom, unbestimmt ob
Primärtumor oder Metastase (8490/9)
Duktales Carcinoma in situ (DCIS)
(8500/2)
Invasives duktales Karzinom o.n.A.
(8500/3)
Invasives duktales Karzinom o.n.A.,
Metastase (8500/6)
Invasives duktales Karzinom o.n.A.,
unbestimmt ob Primärtumor oder
Metastase (8500/9)
Nichtinvasives Komedokarzinom
(8501/2)
Komedokarzinom o.n.A. (8501/3)
Sekretorisches Mammakarzinom
(8502/3)
Sekretorisches Mammakarzinom,
Metastase (8502/6)
Sekretorisches Mammakarzinom,
unbestimmt ob Primärtumor oder
Metastase (8502/9)
Intraduktales Papillom (8503/0)
Intraduktales papilläres Karzinom
(8503/2)
Invasives papilläres Karzinom (8503/3)
Invasives papilläres Karzinom,
Metastase (8503/6)
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Invasives papilläres Karzinom, unklar ob
Primärtumor oder Metastase (8503/9)
Intrazystisches papilläres Adenom
(8504/0)
Intrazystisches papilläres Karzinom
(8504/2)
Intrazystisches Karzinom o.n.A. (8504/3)
Intraduktale Papillomatose o.n.A.
(8505/0)
Brustwarzen-Adenom (8506/0)
Intraduktales mikropapilläres Karzinom
(8507/2)
Invasives mikropapilläres Karzinom
(8507/3)
Invasives mikropapilläres Karzinom,
Metastase (8507/6)
Invasives mikropapilläres Karzinom,
unklar ob Primärtumor oder Metastase
(8507/9)
Zystisch-hypersekretorisches Karzinom
(8508/3)
Medulläres Karzinom o.n.A. (8510/3)
Medulläres Karzinom o.n.A., Metastase
(8510/6)
Medulläres Karzinom o.n.A., unbestimmt
ob Primärtumor oder Metastase (8510/9)
Medulläres Karzinom mit lymphoidem
Stroma (8512/3)
Atypisches medulläres Karzinom
(8513/3)
Desmoplastisches duktales Karzinom
(8514/3)
Lobuläres Carcinoma in situ o.n.A.
(8520/2)
Lobuläres Karzinom o.n.A. (8520/3)
Lobuläres Karzinom o.n.A., Metastase
(8520/6)
Lobuläres Karzinom o.n.A., unbestimmt
ob Primärtumor oder Metastase (8520/9)
Invasives duktuläres Karzinom (8521/3)
Intraduktales Karzinom und lobuläres
Carcinoma in situ (8522/2)
Invasives duktales und lobuläres
Karzinom (8522/3)
Invasives duktales und lobuläres
Karzinom, Metastase (8522/6)
Invasives duktales und lobuläres
Karzinom, unbestimmt ob Primärtumor
oder Metastase (8522/9)
Invasives duktales Karzinom gemischt
mit anderen Karzinom-Typen (8523/3)
invasives duktales Karzinom gemischt
mit anderen Karzinom-Typen, Metastase
(8523/6)
invasives duktales Karzinom gemischt
mit anderen Karzinom-Typen,
unbestimmt ob Primärtumor oder
Metastase (8523/9)
Invasives lobuläres Karzinom gemischt
mit anderen Karzinom-Typen (8524/3)
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invasives lobuläres Karzinom gemischt
mit anderen Karzinom-Typen, Metastase
(8524/6)
invasives lobuläres Karzinom gemischt
mit anderen Karzinom-Typen,
unbestimmt ob Primärtumor oder
Metastase (8524/9)
Polymorphes Low-grade-Adenokarzinom
(8525/3)
Inflammatorisches Karzinom (8530/3)
Inflammatorisches Karzinom, Metastase
(8530/6)
Inflammatorisches Karzinom,
unbestimmt ob Primärtumor oder
Metastase (8530/9)
M. Paget der Brustwarzenhaut (8540/3)
Invasives duktales Karzinom mit M.
Paget (8541/3)
Invasives duktales Karzinom mit M.
Paget, Metastase (8541/6)
Invasives duktales Karzinom mit M.
Paget, unklar ob Primärtumor oder
Metastase (8541/9)
Extramammärer M. Paget (8542/3)
Duktales Carcinoma in situ (DCIS) mit M.
Paget (8543/3)
Azinarzelladenom (8550/0)
Azinarzelltumor (8550/1)
Azinuszellkarzinom (8550/3)
Azinuszellkarzinom, Metastase (8550/6)
Azinuszellkarzinom, unbestimmt ob
Primärtumor oder Metastase (8550/9)
Azinuszell-Zystadenokarzinom (8551/3)
Gemischtes squamös-glanduläres
Papillom (8560/0)
Adenosquamöses Karzinom (8560/3)
Adenosquamöses Karzinom, Metastase
(8560/6)
Adenosquamöses Karzinom, unbestimmt
ob Primärtumor oder Metastase (8560/9)
Adenolymphom (8561/0)
Epithelial-myoepitheliales Karzinom
(8562/3)
Adenokarzinom mit
Plattenepithelmetaplasie (8570/3)
Adenokarzinom mit Knorpel- und
Knochenmetaplasie (8571/3)
Adenokarzinom mit
Spindelzellmetaplasie (8572/3)
Adenokarzinom mit
Spindelzellmetaplasie, Metastase
(8572/6)
Adenokarzinom mit
Spindelzellmetaplasie, unbestimmt ob
Primärtumor oder Metastase (8572/9)
Adenokarzinom mit apokriner Metaplasie
(8573/3)
Adenokarzinom mit neuroendokriner
Differenzierung (8574/3)
Metaplastisches Karzinom o.n.A.
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(8575/3)
Metaplastisches Karzinom o.n.A.,
Metastase (8575/6)
Metaplastisches Karzinom o.n.A.,
unbestimmt ob Primärtumor oder
Metastase (8575/9)
Hepatoides Adenokarzinom (8576/3)
Benignes Thymom (8580/0)
Thymom o.n.A. (8580/1)
Malignes Thymom o.n.A. (8580/3)
Thymom vom Typ A o.n.A. (8581/1)
Malignes Thymom vom Typ A (8581/3)
Thymom vom Typ AB o.n.A. (8582/1)
Malignes Thymom vom Typ AB (8582/3)
Thymom vom Typ B1 o.n.A. (8583/1)
Malignes Thymom vom Typ B1 (8583/3)
Thymom vom Typ B2 o.n.A. (8584/1)
Malignes Thymom vom Typ B2 (8584/3)
Thymom vom Typ B3 o.n.A. (8585/1)
Malignes Thymom vom Typ B3 (8585/3)
Thymuskarzinom o.n.A. (8586/3)
Ektope hamartomatöse Thymome
(8587/0)
Spindelzellig-epithelialer Tumor mit
thymusähnlichen Anteilen (8588/3)
Karzinome mit thymusähnlichen Anteilen
(8589/3)
Keimstrang-Stromatumor o. n. A.
(8590/1)
Inkomplett differenzierter Keimstrang-
Stromatumor (8591/1)
Keimstrang-Stromatumor, Mischtypen
(8592/1)
Stromatumor mit geringeren
Keimstranganteilen (8593/1)
Thekom o.n.A. (8600/0)
Malignes Thekom (8600/3)
Luteinisiertes Thekom (8601/0)
Sklerosierender Stromatumor (8602/0)
Luteom o.n.A. (8610/0)
Adulter Granulosazelltumor (8620/1)
Maligner Granulosazelltumor (8620/3)
Granulosa-Thekazelltumor (8621/1)
Juveniler Granulosazelltumor (8622/1)
Keimstrangtumor mit anulären Tubuli
(8623/1)
Benignes Androblastom (8630/0)
Androblastom o.n.A. (8630/1)
Malignes Androblastom (8630/3)
Gut differenzierter Sertoli-Leydig-Zell-
Tumor (8631/0)
Intermediär differenzierter Sertoli-Leydig-
Zell-Tumor (8631/1)
Schlecht differenzierter Sertoli-Leydig-
Zell-Tumor (8631/3)
Gynandroblastom (8632/1)
Retiformer Sertoli-Leydig-Zell-Tumor
(8633/1)
Intermediär differenzierter Sertoli-Leydig-
Zell-Tumor mit heterologen Elementen
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(8634/1)
Schlecht differenzierter Sertoli-Leydig-
Zell-Tumor mit heterologen Elementen
(8634/3)
Sertoli-Zell-Tumor o.n.A. (8640/1)
Sertoli-Zell-Karzinom (8640/3)
Lipidspeichernder Sertoli-Zell-Tumor
(8641/0)
Großzelliger verkalkender Sertoli-Zell-
Tumor (8642/1)
Benigner Leydig-Zell-Tumor (8650/0)
Leydig-Zell-Tumor o.n.A. (8650/1)
Maligner Leydig-Zell-Tumor (8650/3)
Hiluszelltumor (8660/0)
Lipidzelliger Ovarialtumor (8670/0)
Maligner Steroidzelltumor (8670/3)
Nebennierenresttumor (8671/0)
Benignes Paragangliom (8680/0)
Paragangliom o.n.A. (8680/1)
Malignes Paragangliom (8680/3)
Sympathisches Paragangliom (8681/1)
Parasympathisches Paragangliom
(8682/1)
Ganglienzell-Paragangliom (8683/0)
Glomus-jugulare-Tumor o.n.A. (8690/1)
Glomus-aorticum-Tumor (8691/1)
Glomus-caroticum-Tumor (8692/1)
Extraadrenales Paragangliom o.n.A.
(8693/1)
Malignes extraadrenales Paragangliom
(8693/3)
Phäochromozytom o.n.A. (8700/0)
Malignes Phäochromozytom (8700/3)
Glomangiosarkom (8710/3)
Glomustumor o.n.A. (8711/0)
Maligner Glomustumor (8711/3)
Glomangiom (8712/0)
Glomangiomyom (8713/0)
Pigmentierter Nävus o.n.A. (8720/0)
Melanoma in situ (8720/2)
Malignes Melanom o.n.A. (8720/3)
Noduläres malignes Melanom (NM)
(8721/3)
Ballonzellnävus (8722/0)
Ballonzellmelanom (8722/3)
Halonävus (8723/0)
Malignes Melanom in Regression
(8723/3)
Neuronävus (8725/0)
Großzelliger Nävus (8726/0)
Dysplastischer Nävus (8727/0)
Diffuse Melanozytose (8728/0)
Meningeales Melanozytom (8728/1)
Meningeale Melanomatose (8728/3)
Nichtpigmentierter Nävus (8730/0)
Amelanotisches malignes Melanom
(8730/3)
Junktionaler Nävus o.n.A. (8740/0)
Malignes Melanom in Junktions-Nävus
(8740/3)
46 / 49
Quality assurance GEKID Tumor Documentation - Tumor-specific  Basic
Documentation (AQUA)
Prämaligne Melanose o.n.A. (8741/2)
Malignes Melanom in prämaligner
Melanose (8741/3)
Lentigo maligna (8742/2)
Lentigo-maligna-Melanom (8742/3)
Oberflächlich spreitendes Melanom
(8743/3)
Akral-lentiginöses malignes Melanom
(8744/3)
Desmoplastisches malignes Melanom
(8745/3)
Mukosal-lentiginöses malignes Melanom
(8746/3)
Intradermaler Nävus (8750/0)
Compound-Nävus (8760/0)
Kleiner kongenitaler Nävus (8761/0)
Pigmentierter Riesennävus o.n.A.
(8761/1)
Malignes Melanom in pigmentiertem
Riesennävus (8761/3)
Proliferative dermale Läsion in
kongenitalem Nävus (8762/1)
Epitheloid- und Spindelzellnävus
(8770/0)
Gemischtes Epitheloid- und
Spindelzellmelanom (8770/3)
Epitheloidzellnävus (8771/0)
Epitheloidzellmelanom (8771/3)
Spindelzellnävus o.n.A. (8772/0)
Spindelzellmelanom o.n.A. (8772/3)
Spindelzellmelanom Typ A (8773/3)
Spindelzellmelanom Typ B (8774/3)
Blauer Nävus o.n.A. (8780/0)
Maligner blauer Nävus (8780/3)
Zellreicher blauer Nävus (8790/0)
Benigner Weichteiltumor (8800/0)
Sarkom o.n.A. (8800/3)
Sarkom o.n.A., Metastase (8800/6)
Sarkomatose o.n.A. (8800/9)
Spindelzellsarkom (8801/3)
Riesenzellsarkom (8802/3)
Kleinzelliges Sarkom (8803/3)
Epitheloidsarkom (8804/3)
Undifferenziertes Sarkom (8805/3)
Desmoplastischer kleinzelliger Tumor
(8806/3)
Fibrom o.n.A. (8810/0)
Zellreiches Fibrom (8810/1)
Fibrosarkom o.n.A. (8810/3)
Fibromyxom (8811/0)
Fibromyxosarkom (8811/3)
Periostales Fibrom (8812/0)
Periostales Fibrosarkom (8812/3)
Faszienfibrom (8813/0)
Faszienfibrosarkom (8813/3)
Infantiles Fibrosarkom (8814/3)
Solitärer fibröser Tumor (8815/0)
Maligner solitärer fibröser Tumor
(8815/3)
Elastofibrom (8820/0)
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Aggressive Fibromatose (8821/1)
Abdominale Fibromatose (8822/1)
Desmoplastisches Fibrom (8823/0)
Myofibrom (8824/0)
Myofibromatose (8824/1)
Myofibroblastom (8825/0)
Myofibroblastentumor o.n.A. (8825/1)
Angiomyofibroblastom (8826/0)
Peribronchialer Myofibroblastentumor
(8827/1)
Fibröses Histiozytom (8830/0)
Atypisches fibröses Histiozytom (8830/1)
Malignes fibröses Histiozytom (8830/3)
Histiozytom o.n.A. (8831/0)
Dermatofibrom o.n.A. (8832/0)
Dermatofibrosarkom o.n.A. (8832/3)
Pigmentiertes Dermatofibrosarcoma
protuberans (8833/3)
Riesenzellfibroblastom (8834/1)
Plexiformer fibrohistiozytärer Tumor
(8835/1)
Angiomatoides fibröses Histiozytom
(8836/1)
Myxom o.n.A. (8840/0)
Myxosarkom (8840/3)
Angiomyxom (8841/1)
Ossifizierender fibromyxoider
Weichteiltumor (8842/0)
Lipom o.n.A. (8850/0)
Atypisches Lipom (8850/1)
Liposarkom o.n.A. (8850/3)
Liposarkom o.n.A., Metastase (8850/6)
Liposarkom o.n.A., unbestimmt ob
Primärtumor oder Metastase (8850/9)
Fibrolipom (8851/0)
Gut differenziertes Liposarkom (8851/3)
Fibromyxolipom (8852/0)
Myxoides Liposarkom (8852/3)
Rundzelliges Liposarkom (8853/3)
Pleomorphes Lipom (8854/0)
Pleomorphes Liposarkom (8854/3)
Gemischtzelliges Liposarkom (8855/3)
Intramuskuläres Lipom (8856/0)
Spindelzell-Lipom (8857/0)
Fibroblastisches Liposarkom (8857/3)
Entdifferenziertes Liposarkom (8858/3)
Angiomyolipom (8860/0)
Angiolipom o.n.A. (8861/0)
Chondroides Lipom (8862/0)
Myelolipom (8870/0)
Hibernom (8880/0)
Lipoblastomatose (8881/0)
Leiomyom o.n.A. (8890/0)
Leiomyomatose o.n.A. (8890/1)
Leiomyosarkom o.n.A. (8890/3)
Leiomyosarkom o.n.A., Metastase
(8890/6)
Leiomyosarkom o.n.A., unbestimmt ob
Primärtumor oder Metastase (8890/9)
Epitheloides Leiomyom (8891/0)
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Epitheloides Leiomyosarkom (8891/3)
Zellreiches Leiomyom (8892/0)
Bizarres Leiomyom (8893/0)
Angiomyom (8894/0)
Angiomyosarkom (8894/3)
Myom (8895/0)
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Quality assurance Minimum Dataset
external Quality Assurace (AQUA)
Documentation form for quality assurance in German
Health Care by the institute forapplied quality Improvement
and Research in Health Care (Aqua), https://www.aqua-
institut.de/en/home. Internal Aqua form version: MDS
Specification 2015 V02
All rights reserved. Please visit https://medical-data-
models.org/forms/6013
Quality assurance Minimum Dataset
external Quality Assurace (AQUA)
Basisdokumentation
zugehöriges QS-Modul*
Dekompression bei
Karpaltunnelsyndrom (01/1)
Dekompression bei Sulcus-ulnaris-
Syndrom (01/2)
Kataraktoperation (03/1)
Nasenscheidewandkorrektur (05/1)
Tonsillektomie (07/1)
Herzschrittmacher-Implantation (09/1)
Herzschrittmacher-Aggregatwechsel
(09/2)
Herzschrittmacher-Revision/-
Systemwechsel/-Explantation (09/3)
Implantierbare Defibrillatoren-
Implantation (09/4)
Implantierbare Defibrillatoren-
Aggregatwechsel (09/5)
Implantierbare Defibrillatoren-Revision/-
Systemwechsel/-Explantation (09/6)
Varizenchirurgie (10/1)
Karotis-Rekonstruktion (10/2)
Cholezystektomie (12/1)
Appendektomie (12/2)
Leistenhernie (12/3)
Prostataresektion (14/1)
Gynäkologische Operationen (15/1)
Geburtshilfe (16/1)
Hüftgelenknahe Femurfraktur (17/1)
Knie-Schlittenprothesen-Erstimplantation
(17/6)
Mammachirurgie (18/1)
Koronarangiographie und Perkutane
Koronarintervention (PCI) (21/3)
Dekubitusprophylaxe (DEK)
Herzchirurgie (HCH)
Hüftendoprothesenversorgung (HEP)
Herztransplantation,
Herzunterstützungssysteme/Kunstherzen
(HTXM)
Knieendoprothesenversorgung (KEP)
Neonatologie (NEO)
Endonasale Nasennebenhöhleneingriffe
(NNH)
Ambulant erworbene Pneumonie
(PNEU)
Schlaganfall-Frührehabilitation (nur
Hessen) (SA_FRUEHREHA_HE)
Schlaganfall-Akutbehandlung (nur
Hessen) (SA_HE)
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Entlassungsdiagnose(n)*
Operation
Aufnahmedatum Krankenhaus (TT.MM.JJJJ)*
Geschlecht*
männlich (1)
weiblich (2)
Geburtsdatum (TT.MM.JJJJ)*
Identifikationsnummer des Patienten*
Fachabteilung (§ 301-Vereinbarung)*
Innere Medizin (0100)
Innere Medizin/Schwerpunkt Geriatrie
(0102)
Innere Medizin/Schwerpunkt Kardiologie
(0103)
Innere Medizin/Schwerpunkt
Nephrologie (0104)
Innere Medizin/Schwerpunkt
Hämatologie und internistische
Onkologie (0105)
Innere Medizin/Schwerpunkt
Endokrinologie (0106)
Innere Medizin/Schwerpunkt
Gastroenterologie (0107)
Innere Medizin/Schwerpunkt
Pneumologie (0108)
Innere Medizin/Schwerpunkt
Rheumatologie (0109)
Innere Medizin/Schwerpunkt Lungen-
und Bronchialheilkunde (0114)
Innere Medizin/Tumorforschung (0150)
Innere Medizin/Schwerpunkt
Coloproktologie (0151)
Innere Medizin/Schwerpunkt
Infektionskrankheiten (0152)
Innere Medizin/Schwerpunkt Diabetes
(0153)
Innere Medizin/Schwerpunkt
Naturheilkunde (0154)
Innere Medizin/Schwerpunkt
Schlaganfallpatienten (Stroke units,
Artikel 7 § 1 Abs. 3GKV-SolG) (0156)
Innere Medizin (0190)
Geriatrie (0200)
Geriatrie/Schwerpunkt Frauenheilkunde
(0224)
Geriatrie/Tagesklinik (für teilstationäre
Pflegesätze) (0260)
Geriatrie/Nachtklinik (für teilstationäre
Pflegesätze) (0261)
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Geriatrie (0290)
Kardiologie (0300)
Nephrologie (0400)
Nephrologie/Schwerpunkt Pädiatrie
(0410)
Nephrologie/Intensivmedizin (0436)
Nephrologie (0490)
Hämatologie und internistische
Onkologie (0500)
Hämatologie und internistische
Onkologie/Schwerpunkt Pädiatrie (0510)
Hämatologie und internistische
Onkologie/Schwerpunkt Frauenheilkunde
(0524)
Hämatologie und internistische
Onkologie/Schwerpunkt
Strahlenheilkunde (0533)
Hämatologie und internistische
Onkologie (0590)
Endokrinologie (0600)
Endokrinologie/Schwerpunkt
Gastroenterologie (0607)
Endokrinologie/Schwerpunkt Pädiatrie
(0610)
Endokrinologie (0690)
Gastroenterologie (0700)
Gastroenterologie/Schwerpunkt
Endokrinologie (0706)
Gastroenterologie/Schwerpunkt Pädiatrie
(0710)
Gastroenterologie (0790)
Pneumologie (0800)
Rheumatologie (0900)
Rheumatologie/Schwerpunkt Pädiatrie
(0910)
Rheumatologie (0990)
Pädiatrie (1000)
Pädiatrie/Schwerpunkt Nephrologie
(1004)
Pädiatrie/Schwerpunkt Hämatologie und
internistische Onkologie (1005)
Pädiatrie/Schwerpunkt Endokrinologie
(1006)
Pädiatrie/Schwerpunkt Gastroenterologie
(1007)
Pädiatrie/Schwerpunkt Rheumatologie
(1009)
Pädiatrie/Schwerpunkt Kinderkardiologie
(1011)
Pädiatrie/Schwerpunkt Neonatologie
(1012)
Pädiatrie/Schwerpunkt Lungen- und
Bronchialheilkunde (1014)
Pädiatrie/Schwerpunkt Kinderneurologie
(1028)
Pädiatrie/Schwerpunkt Perinatalmedizin
(1050)
Langzeitbereich Kinder (1051)
Pädiatrie (1090)
Kinderkardiologie (1100)
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Kinderkardiologie/Schwerpunkt
Intensivmedizin (1136)
Kinderkardiologie (1190)
Neonatologie (1200)
Kinderchirurgie (1300)
Lungen- und Bronchialheilkunde (1400)
Lungen- und
Bronchialheilkunde/Schwerpunkt
Pädiatrie (1410)
Lungen- und Bronchialheilkunde (1490)
Allgemeine Chirurgie (1500)
Allgemeine Chirurgie/Schwerpunkt
Kinderchirurgie (1513)
Allgemeine Chirurgie/Schwerpunkt
Unfallchirurgie (1516)
Allgemeine Chirurgie/Schwerpunkt
Gefäßchirurgie (1518)
Allgemeine Chirurgie/Schwerpunkt
Plastische Chirurgie (1519)
Allgemeine Chirurgie/Schwerpunkt
Thoraxchirurgie (1520)
Chirurgie/Schwerpunkt Orthopädie
(1523)
Allgemeine Chirurgie/Intensivmedizin (§
13 Abs. 2 Satz 3, 2. Halbsatz BPflV in
der am 31.12.2003 geltenden Fassung)
(1536)
Allgemeine Chirurgie/Schwerpunkt
Abdominal- und Gefäßchirurgie (1550)
Allgemeine Chirurgie/Schwerpunkt
Handchirurgie (1551)
Allgemeine Chirurgie (1590)
Unfallchirurgie (1600)
Neurochirurgie (1700)
Gefäßchirurgie (1800)
Plastische Chirurgie (1900)
Thoraxchirurgie (2000)
Thoraxchirurgie/Schwerpunkt
Herzchirurgie (2021)
Thoraxchirurgie/Intensivmedizin (2036)
Thoraxchirurgie/Schwerpunkt
Herzchirurgie Intensivmedizin (2050)
Thoraxchirurgie (2090)
Herzchirurgie (2100)
Herzchirurgie/Schwerpunkt
Gefäßchirurgie (2118)
Herzchirurgie/Schwerpunkt
Thoraxchirurgie (2120)
Herzchirurgie/Intensivmedizin (§ 13 Abs.
2 Satz 3 2. Halbsatz BPflV in der am
31.12.2003 geltenden Fassung) (2136)
Herzchirurgie/Schwerpunkt
Thoraxchirurgie Intensivmedizin (2150)
Herzchirurgie (2190)
Urologie (2200)
Orthopädie (2300)
Orthopädie/Schwerpunkt Rheumatologie
(2309)
Orthopädie/Schwerpunkt Chirurgie
(2315)
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Orthopädie und Unfallchirurgie (2316)
Orthopädie (2390)
Frauenheilkunde und Geburtshilfe (2400)
Frauenheilkunde/Schwerpunkt Geriatrie
(2402)
Frauenheilkunde/Schwerpunkt
Hämatologie und internistische
Onkologie (2405)
Frauenheilkunde/Schwerpunkt
Endokrinologie (2406)
Frauenheilkunde (2425)
Frauenheilkunde und Geburtshilfe (2490)
Geburtshilfe (2500)
Hals-, Nasen-, Ohrenheilkunde (2600)
Augenheilkunde (2700)
Neurologie (2800)
Neurologie/Schwerpunkt Pädiatrie
(2810)
Neurologie/Schwerpunkt
Schlaganfallpatienten (Stroke units,
Artikel 7 § 1 Abs. 3 GKV-SolG) (2856)
Neurologie (2890)
Allgemeine Psychiatrie (2900)
Allgemeine Psychiatrie/Schwerpunkt
Neurologie (2928)
Allgemeine Psychiatrie/Schwerpunkt
Kinder- und Jugendpsychiatrie (2930)
Allgemeine Psychiatrie/Schwerpunkt
Psychosomatik/Psychotherapie (2931)
Allgemeine Psychiatrie/Schwerpunkt
Suchtbehandlung (2950)
Allgemeine Psychiatrie/Schwerpunkt
Gerontopsychiatrie (2951)
Allgemeine Psychiatrie/Schwerpunkt
Forensische Behandlung (2952)
Allgemeine Psychiatrie/Schwerpunkt
Suchtbehandlung, Tagesklinik (2953)
Allgemeine Psychiatrie/Schwerpunkt
Suchtbehandlung, Nachtklinik (2954)
Allgemeine Psychiatrie/Schwerpunkt
Gerontopsychiatrie, Tagesklinik (2955)
Allgemeine Psychiatrie/Schwerpunkt
Gerontopsychiatrie, Nachtklinik (2956)
Allgemeine Psychiatrie/Tagesklinik (für
teilstationäre Pflegesätze) (2960)
Allgemeine Psychiatrie/Nachtklinik (für
teilstationäre Pflegesätze) (2961)
Allgemeine Psychiatrie (2990)
Kinder- und Jugendpsychiatrie (3000)
Kinder- und
Jugendpsychiatrie/Tagesklinik (für
teilstationäre Pflegesätze) (3060)
Kinder- und
Jugendpsychiatrie/Nachtklinik (für
teilstationäre Pflegesätze) (3061)
Kinder- und Jugendpsychiatrie (3090)
Psychosomatik/Psychotherapie (3100)
Psychosomatik/Psychotherapie/Schwerp
unkt Kinder- und Jugendpsychosomatik
(3110)
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Psychosomatik/Psychotherapie/Tageskli
nik (für teilstationäre Pflegesätze) (3160)
Psychosomatik/Psychotherapie/Nachtkli
nik (für teilstationäre Pflegesätze) (3161)
Psychosomatik/Psychotherapie (3190)
Nuklearmedizin (3200)
Nuklearmedizin/Schwerpunkt
Strahlenheilkunde (3233)
Nuklearmedizin (3290)
Strahlenheilkunde (3300)
Strahlenheilkunde/Schwerpunkt
Hämatologie und internistische
Onkologie (3305)
Strahlenheilkunde/Schwerpunkt
Radiologie (3350)
Strahlenheilkunde (3390)
Dermatologie (3400)
Dermatologie/Tagesklinik (für
teilstationäre Pflegesätze) (3460)
Dermatologie (3490)
Zahn- und Kieferheilkunde, Mund- und
Kieferchirurgie (3500)
Intensivmedizin (3600)
Intensivmedizin/Schwerpunkt Innere
Medizin (3601)
Intensivmedizin/Schwerpunkt Kardiologie
(3603)
Intensivmedizin/Schwerpunkt Pädiatrie
(3610)
Intensivmedizin/Schwerpunkt
Neurochirurgie (3617)
Intensivmedizin/Schwerpunkt Chirurgie
(3618)
Intensivmedizin/Herzchirurgie (3621)
Intensivmedizin/Schwerpunkt Urologie
(3622)
Intensivmedizin/Schwerpunkt
Frauenheilkunde und Geburtshilfe (3624)
Intensivmedizin/Schwerpunkt Hals-,
Nasen-, Ohrenheilkunde (3626)
Intensivmedizin/Schwerpunkt Neurologie
(3628)
Operative Intensivmedizin/Schwerpunkt
Chirurgie (3650)
Intensivmedizin/Thorax-Herzchirurgie
(3651)
Intensivmedizin/Herz-Thoraxchirurgie
(3652)
Intensivmedizin (3690)
sonstige Fachabteilung (3700)
Angiologie (3750)
Radiologie (3751)
Palliativmedizin (3752)
Schmerztherapie (3753)
Heiltherapeutische Abteilung (3754)
Wirbelsäulenchirurgie (3755)
Suchtmedizin (3756)
Visceralchirurgie (3757)
Sonstige Fachabteilung (3790)
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Betriebsstätten-Nummer
Entlassender Standort ([0-9]{2})*
Institutionskennzeichen*
Entlassungsdatum Krankenhaus (TT.MM.JJJJ)*
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Multiple Sclerosis - Past treatment
(REGIMS)
Frühere verlaufsmodifizierende MS-Therapie (bitte alle
Therapien der Vergangenheit aufführen)
http://epi.uni-muenster.de
All rights reserved. Please visit https://medical-data-
models.org/forms/6056
Multiple Sclerosis - Past treatment
(REGIMS)
Frühere MS-Therapie
Bisher keine verlaufsmodifizierende MS-
Therapie*
Ja
Nein
Medikation*
Interferon beta-1a Injectable Solution
(Avonex) (1)
Cyclophosphamid (10)
Rituximab (11)
Immunglobuline (12)
Medikation aus einer MS-Studie (13)
Alemtuzumab (Lemtrada) (14)
Teriflunomide (Aubagio) (15)
Fumarat (BG-12) (Tecfidera) (16)
Andere (17)
Interferon beta-1a SC (Rebif 22μg, Rebif
44 μg) (2)
Interferon beta-1b SC (Betaferon,
Extavia) (3)
Glatirameracetat (Copaxone) (4)
Natalizumab (Tysabri) (5)
Fingolimod (Gilenya) (6)
Azathioprin (7)
Methotrexat (8)
Mitoxantron (9)
Andere Medikation*
Medikation Beginn Monat /Jahr*
Medikation Ende Monat /Jahr*
Grund für Therapieende (Bitte ALLE Gründe
ankreuzen)*
unbekannt (0)
Unverträglichkeit, z.B. Haut- / allergische
Reaktion (1)
Leberwertveränderungen, andere
Laborauffälligkeiten (10)
anderer Grund (11)
Nebenwirkungen, z.B. Übelkeit,
Zunahme der Spastik (2)
Medikation vergessen / aus
Patientensicht nicht erforderlich oder
möglich (3)
Fehlende Wirksamkeit / Schübe unter
Therapie / Progression (4)
1 / 2
Eskalationstherapie wurde eingeleitet (5)
Schwangerschaft (6)
Entwicklung neutralisierender Antikörper
gegen das Medikament (7)
PML-Verdacht (8)
Andere Erkrankung stellt
Kontraindikation dar (Hepatitis etc.) (9)
wenn anderer Grund, bitte angeben*
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Multiple Sclerosis - Past treatment (REGIMS)
Anal Cancer NCT00324415 Toxicity - AMC-045 Type
III Adverse Event Reporting Form (TAE) - 2516535v1.0
AMC-045 Type III Adverse Event Reporting Form (TAE)
Cisplatin, Fluorouracil, Cetuximab, and Radiation Therapy
in Treating Patients With HIV and Stage I, Stage II, or
Stage III Anal Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=1C146B28-
823F-583B-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/6057
AMC-045 Type III Adverse Event
Reporting Form (TAE)
Header module
Visit number
Type III Adverse Events
Has the patient experienced a Type III adverse
event
Yes
No
Was RT interrupted for more than one week?
Yes
No
Days Treatment Was Interrupted
Has the subject failed to receive 6 courses of
cetuximab and 2 cycles of cisplatin and 5-FU due
to toxicity
Yes
No
Has the subject failed to complete the prescribed
course of irradiation due to toxicity
Yes
No
Comments
Comments
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Multiple Sclerosis Registry - Inclusion
(DMSG)
Datensatz des MS-Registers auf Grundlage des
gemeinsamen Datensatz von DMSG und KKNMS v 1.1
http://www.dmsg.de/msregister/
All rights reserved. Please visit https://medical-data-
models.org/forms/6061
Multiple Sclerosis Registry -
Inclusion (DMSG)
Administrative Angaben
Datum der Registeraufnahme*
Dokumentierende Person*
Zentrum*
Pseudonym*
Patienteneinwilligung
Datum der Einwilligungserklärung*
Version(en) der aktuell eingeholten
Einwilligung(en)*
MS-Register Ver. 1.0  (1)
MS-Register Ver. 1.0 & PRO Ver. 0.3 (2)
MS-Register Ver. 1.0 & PRO Ver. 0.4 (3)
MS-Register Ver. 1.0.1 (4)
MS-Register Ver. 1.0.1 & PRO Ver. 0.3
(5)
MS-Register Ver. 1.0.1 & PRO Ver. 0.4
(6)
Der Patient stimmt der Teilnahme am MS-
Register zu.*
Ja
Nein
Der Patient stimmt der Teilnahme an weiteren
Forschungsvorhaben zu.*
Ja
Nein
Der Patient stimmt der Möglichkeit einer
Kontaktaufnahme zu.*
Ja
Nein
Ein- und Ausschlusskriterien
KIS, RRMS, SPMS oder PPMS*
Ja
Nein
Nicht bestimmbare MS Verlaufsform*
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Ja
Nein
Stammdaten
geb.*
Geschlecht*
männlich (1)
weiblich (2)
Diagnosekriterien nach McDonald – Revison
2010*
keine Angabe (-1)
Kriterien nicht zutreffend (0)
McDonald-Kriterien 1 (1)
McDonald-Kriterien 2 (2)
McDonald-Kriterien 3 (3)
McDonald-Kriterien 4 (4)
McDonald-Kriterien 5 (5)
Diagnosekriterien nach McDonald – Revison
2005*
keine Angabe (-1)
Kriterien nicht zutreffend (0)
McDonald-Kriterien 1 (1)
McDonald-Kriterien 2 (2)
McDonald-Kriterien 3 (3)
McDonald-Kriterien 4 (4)
McDonald-Kriterien 5 (5)
Diagnosekriterien nach Poser*
Ja
Nein
Liegt nach diesen Kriterien eine MS vor?*
Ja
Nein
Anamnese
Beginn der Erkrankung*
Zeitpunkt der Diagnose*
Erstsymptomatik
Visusstörung*
Ja
Nein
Störung Hirnstammfunktionen*
Ja
Nein
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Motorische Störungen*
Ja
Nein
Kleinhirnstörung*
Ja
Nein
Sensibilitätsstörungen*
Ja
Nein
Blasenfunktionsstörung*
Ja
Nein
Darmfunktionsstörung*
Ja
Nein
Sexuelle Störungen*
Ja
Nein
Depression, Euphorie, Konzentrations- und
Gedächtnisstörungen, Erschöpfbarkeit*
Ja
Nein
Andere Symptome*
Ja
Nein
Andere Symptome (Beschreibung)*
Expanded Disability Status Scale
EDSS vor 12 Monaten*
EDSS vor 24 Monaten*
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Multiple Sclerosis Registry - Consultation
(DMSG)
Datensatz des MS-Registers auf Grundlage des
gemeinsamen Datensatz von DMSG und KKNMS v 1.1
http://www.dmsg.de/msregister/
All rights reserved. Please visit https://medical-data-
models.org/forms/6062
Multiple Sclerosis Registry -
Consultation  (DMSG)
Administrative Angaben
Datum der Konsultation*
Dokumentierende Person*
Zentrum*
Pseudonym*
Soziodemografische Daten
Höchster allgemeinbildender Schulabschluss*
keine Angabe (-1)
Kein Schulabschluss (0)
Hauptschulabschluss (1)
Realschulabschluss  (2)
Abschluss der Polytechnischen
Oberschule 10. Klasse (vor 1965: 8.
Klasse) (3)
Fachhochschulreife (4)
Hochschulreife (Abitur) (5)
Höchste berufliche Ausbildung*
keine Angabe (-1)
Keine abgeschlossene Ausbildung (0)
Abgeschlossene berufliche Ausbildung
(oder Vergleichbares) (1)
Abgeschlossene Hochschulausbildung
(oder Vergleichbares) (2)
Aktuelle Tätigkeit*
keine Angabe (0)
Ausbildung / Weiterbildung / Umschulung
(1)
Berufstätig (Vollzeit) (2)
Teilzeitbeschäftigt (3)
Vorzeitige Berentung (Erwerbs- /
Berufsunfähigkeit) (4)
Altersrente / Pension (5)
Arbeitslos (6)
Hausfrau / Hausmann (7)
Gibt es durch die MS bedingte Einschränkungen
der aktuellen Tätigkeit?*
Ja
Nein
Wenn ja, in welchem Ausmaß?*
1 / 13
keine Angabe (0)
Reduktion der Tätigkeit (1)
Aufgabe / Unterbrechung der Tätigkeit
(2)
Familiäre Situation*
keine Angabe (0)
Allein lebend  (1)
Lebensgemeinschaft (2)
Häusliche Unterstützung*
keine Angabe (0)
ja, Unterstützung durch Familie,
Freunde, Partnerschaft (1)
nein, Patient ist auf sich allein gestellt (2)
Verlaufsdaten
MS-Verlaufsform*
Klinisch isoliertes Syndrom (KIS) (1)
Schubförmige MS (relapsing-remitting,
RRMS) (2)
Sekundär progrediente MS (SPMS) (3)
Primär progrediente MS (PPMS) (4)
EDSS Score*
Monat und Jahr der Bestimmung des EDSS
Scores*
Multiple Sclerosis Functional Composite
Wurde der Strecke-Zeit-Test durchgeführt?*
Ja
Nein
1. Versuch Zeit in Sekunden*
1. Versuch abgebrochen*
Ja
Nein
Begründung*
Wurde ein zweiter Versuch durchgeführt?*
Ja
Nein
2. Versuch Zeit in Sekunden*
2. Versuch abgebrochen*
Ja
Nein
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Begründung*
Gehstrecke auf Zeit - Hilfsmittel
Beinschiene/ Sprunggelenkstütze*
Ja
Nein
Stock/Stöcke als Hilfsmittel*
keine Angabe (-1)
nein (0)
einseitig (1)
beidseitig (2)
Unterarm-Gehstütze(n)*
keine Angabe (-1)
nein (0)
einseitig (1)
beidseitig (2)
Rollator*
Ja
Nein
Mehr als zwei Versuche*
Ja
Nein
Wenn ja, bitte begründen*
Steckbrett-Test (9-Hole-Peg-Test)
Wurde der Steckbrett-Test durchgeführt?*
Ja
Nein
Dominante Hand*
rechts (1)
links (2)
Zeit in Sekunden*
Durchgang 1 abgebrochen*
Ja
Nein
Wenn Durchgang 1 abgebrochen, bitte
begründen*
Wurde ein zweiter Versuch durchgeführt?*
Ja
Nein
Zeit in Sekunden*
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Durchgang 2 abgebrochen*
Ja
Nein
Wenn Durchgang 2 abgebrochen, bitte
begründen*
Der Patient benötigte mehr als 2 Versuche für 2
Ergebnisse*
Ja
Nein
Wenn ja, bitte begründen*
Zeit in Sekunden*
Durchgang 1 abgebrochen*
Ja
Nein
Wenn Durchgang 1 abgebrochen, bitte
begründen*
Wurde ein zweiter Versuch durchgeführt?*
Ja
Nein
Zeit in Sekunden*
Durchgang 2 abgebrochen*
Ja
Nein
Wenn Durchgang 2 abgebrochen, bitte
begründen*
Der Patient benötigte mehr als 2 Versuche für 2
Ergebnisse*
Ja
Nein
Wenn ja, bitte begründen*
Paced Auditory Serial Addition Test
Wurde der PASAT 3 durchgeführt?*
Ja
Nein
Durchgang 1 - korrekte Antworten*
Versuch abgebrochen*
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Ja
Nein
Wenn ja, bitte begründen*
Wurde ein zweiter Versuch durchgeführt?*
Ja
Nein
Durchgang 2 - korrekte Antworten*
Versuch abgebrochen*
Ja
Nein
Wenn ja, bitte begründen*
Eingeschränktes Gehvermögen
Eingeschränktes Gehvermögen*
Ja
Nein
Therapie*
unbekannt (-1)
unbehandelt (0)
medikamentös (1)
nicht-medikamentös (2)
medikamentös und nicht-medikamentös
(3)
Ergotherapie*
Ja
Nein
Physiotherapie*
Ja
Nein
Psychotherapie*
Ja
Nein
Versorgung mit Hilfsmitteln*
Ja
Nein
Spastik
Spastik*
Ja
Nein
Therapie*
unbekannt (-1)
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unbehandelt (0)
medikamentös (1)
nicht-medikamentös (2)
medikamentös und nicht-medikamentös
(3)
Ergotherapie*
Ja
Nein
Physiotherapie*
Ja
Nein
Versorgung mit Hilfsmitteln*
Ja
Nein
Ataxie / Tremor
Ataxie / Tremor*
Ja
Nein
Therapie*
unbekannt (-1)
unbehandelt (0)
medikamentös (1)
nicht-medikamentös (2)
medikamentös und nicht-medikamentös
(3)
Ergotherapie*
Ja
Nein
Physiotherapie*
Ja
Nein
Versorgung mit Hilfsmitteln*
Ja
Nein
Müdigkeit
Müdigkeit*
Ja
Nein
Therapie*
unbekannt (-1)
unbehandelt (0)
medikamentös (1)
nicht-medikamentös (2)
medikamentös und nicht-medikamentös
(3)
6 / 13
Multiple Sclerosis Registry - Consultation  (DMSG)
Ergotherapie*
Ja
Nein
Physiotherapie*
Ja
Nein
Psychotherapie*
Ja
Nein
Versorgung mit Hilfsmitteln*
Ja
Nein
Schmerzen
Schmerzen*
Ja
Nein
Therapie*
unbekannt (-1)
unbehandelt (0)
medikamentös (1)
nicht-medikamentös (2)
medikamentös und nicht-medikamentös
(3)
Ergotherapie*
Ja
Nein
Physiotherapie*
Ja
Nein
Psychotherapie*
Ja
Nein
Versorgung mit Hilfsmitteln*
Ja
Nein
Miktion gestört
Miktion gestört*
Ja
Nein
Therapie*
unbekannt (-1)
unbehandelt (0)
medikamentös (1)
nicht-medikamentös (2)
medikamentös und nicht-medikamentös
(3)
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Physiotherapie*
Ja
Nein
Psychotherapie*
Ja
Nein
Versorgung mit Hilfsmitteln*
Ja
Nein
Defäkation gestört
Defäkation gestört*
Ja
Nein
Therapie*
unbekannt (-1)
unbehandelt (0)
medikamentös (1)
nicht-medikamentös (2)
medikamentös und nicht-medikamentös
(3)
Physiotherapie*
Ja
Nein
Psychotherapie*
Ja
Nein
Versorgung mit Hilfsmitteln*
Ja
Nein
Sexuelle Störungen
Sexuelle Störungen*
Ja
Nein
Therapie*
unbekannt (-1)
unbehandelt (0)
medikamentös (1)
nicht-medikamentös (2)
medikamentös und nicht-medikamentös
(3)
Physiotherapie*
Ja
Nein
Psychotherapie*
Ja
Nein
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Versorgung mit Hilfsmitteln*
Ja
Nein
Kognitive Störungen
Kognitive Störungen*
Ja
Nein
Therapie*
unbekannt (-1)
unbehandelt (0)
medikamentös (1)
nicht-medikamentös (2)
medikamentös und nicht-medikamentös
(3)
Ergotherapie*
Ja
Nein
Logopädie*
Ja
Nein
Physiotherapie*
Ja
Nein
Psychotherapie*
Ja
Nein
Versorgung mit Hilfsmitteln*
Ja
Nein
Depression
Depression*
Ja
Nein
Therapie*
unbekannt (-1)
unbehandelt (0)
medikamentös (1)
nicht-medikamentös (2)
medikamentös und nicht-medikamentös
(3)
Ergotherapie*
Ja
Nein
Physiotherapie*
Ja
Nein
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Psychotherapie*
Ja
Nein
Versorgung mit Hilfsmitteln*
Ja
Nein
Okulomotorische Störungen
Okulomotorische Störungen*
Ja
Nein
Therapie*
unbekannt (-1)
unbehandelt (0)
medikamentös (1)
nicht-medikamentös (2)
medikamentös und nicht-medikamentös
(3)
Ergotherapie*
Ja
Nein
Logopädie*
Ja
Nein
Physiotherapie*
Ja
Nein
Versorgung mit Hilfsmitteln*
Ja
Nein
Dysarthie/ Dysphonie
Dysarthie/ Dysphonie*
Ja
Nein
Therapie*
unbekannt (-1)
unbehandelt (0)
medikamentös (1)
nicht-medikamentös (2)
medikamentös und nicht-medikamentös
(3)
Ergotherapie*
Ja
Nein
Logopädie*
Ja
Nein
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Physiotherapie*
Ja
Nein
Versorgung mit Hilfsmitteln*
Ja
Nein
Dysphagie
Dysphagie*
Ja
Nein
Therapie*
unbekannt (-1)
unbehandelt (0)
medikamentös (1)
nicht-medikamentös (2)
medikamentös und nicht-medikamentös
(3)
Ergotherapie*
Ja
Nein
Logopädie*
Ja
Nein
Versorgung mit Hilfsmitteln*
Ja
Nein
Epileptische Anfälle
Epileptische Anfälle*
Ja
Nein
Therapie*
unbekannt (-1)
unbehandelt (0)
medikamentös (1)
nicht-medikamentös (2)
medikamentös und nicht-medikamentös
(3)
Physiotherapie*
Ja
Nein
Psychotherapie*
Ja
Nein
Versorgung mit Hilfsmitteln*
Ja
Nein
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Sonstige Paroxysmen
Sonstige Paroxysmen*
Ja
Nein
Therapie*
unbekannt (-1)
unbehandelt (0)
medikamentös (1)
nicht-medikamentös (2)
medikamentös und nicht-medikamentös
(3)
Ergotherapie*
Ja
Nein
Logopädie*
Ja
Nein
Physiotherapie*
Ja
Nein
Psychotherapie*
Ja
Nein
Versorgung mit Hilfsmitteln*
Ja
Nein
Immunmodulation / kausale Therapie
Wird eine immunmodulatorische / kausale
Therapie aktuell angewendet?*
Ja
Nein
Welche der folgenden Pflegearten nimmt
der Patient zurzeit in Anspruch?
Familiäre Pflege*
Ja
Nein
Ambulante Pflege*
Ja
Nein
Tagespflege*
Ja
Nein
Kurzzeitpflege*
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Ja
Nein
Vollstationäre Pflege*
Ja
Nein
Welche medizinischen Hilfsmittel werden
zurzeit benutzt?
Gehhilfe*
Ja
Nein
Wannenhilfe*
Ja
Nein
Rollstuhl*
Ja
Nein
Rollator*
Ja
Nein
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Anal Cancer NCT00324415 Treatment - AMC-045
Concomitant Medication Form (MED) - 2936871v1.0
AMC-045 Concomitant Medication Form (MED)
Cisplatin, Fluorouracil, Cetuximab, and Radiation Therapy
in Treating Patients With HIV and Stage I, Stage II, or
Stage III Anal Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=72844558-
61F6-0B0B-E040-BB89AD4314AD
All rights reserved. Please visit https://medical-data-
models.org/forms/6067
AMC-045 Concomitant Medication
Form (MED)
Ccrr Module For Concomitant
Antiretroviral Medications - Rf08
Agent Name
Dose Level Start Date
Total Daily Dose of Agent (or Drug)
Units
Capsules (Caps)
Drops (Dr)
International Unit (IU)
Milligram (mg)
Milliliter (ml)
Other (Other)
Tablets (Tabl)
Unit (U)
Microgram (µg)
Other, specify
Frequency
>4x/day (>4X/day)
As Needed (p.r.n) (as needed (P.R.N))
At Bedtime Or Hour Of Sleep (h.s.) (at
bedtime or hour of sleep (H.S.))
Every 12 Hours (q12hr) (every 12 hours
(Q12hr))
Every 4 Hours (q4hr) (every 4 hours
(Q4hr))
Every 6 Hours (q6hr) (every 6 hours
(Q6hr))
Every 8 Hours (q8hr) (every 8 hours
(Q8hr))
Every Other Day (q.o.d.) (every other day
(Q.O.D.))
Four Times A Day (q.i.d) (four times a
day (Q.I.D))
Monthly (Monthly)
Once A Day (q.d.) (Once a day (Q.D.))
Other (Other)
Three Times A Day (t.i.d) (three times a
day (T.I.D))
Twice A Day (b.i.d) (twice a day (B.I.D))
1 / 2
Weekly (Weekly)
Other, specify
Is this an antiretroviral agent
Yes
No
Please provide indication (If "no")
Is use of this agent ongoing
Yes
No
Date last taken (If "no" mm/dd/yyyy)
Comments
Comments
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Bladder Cancer NCT00014534 Treatment - NCI Cooperative
Group Treatment by Cycle Form-CALGB-90104 - 2056083v3.0
NCI Cooperative Group Treatment by Cycle Form-CALGB-
90104
Combination Chemotherapy in Treating Patients With
Bladder Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=A9C01F91-
F376-264F-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/6068
NCI Cooperative Group Treatment by
Cycle Form-CALGB-90104
Mskcc 00-138; Calgb-90104; Ecog
Coordinating Group Protocol Number
Coordinating Group Code
Protocol Title
Patient Study ID, Coordinating Group
Patient Study ID, Participating Group
Participating Group Code
Institution Name
Affiliate
Patient Last Name (initials acceptable)
Patient First Name (initials acceptable)
Patient Middle Name (initials acceptable)
Form Administration
Person Completing Form, Last Name
Person Completing Form, First Name
Are data amended?
Yes
No
Treatment Cycles
1 / 2
Current Cycle Number
Cycle Start Date
Chemotherapy Agent Name
Agent Start Date
Agent End Date
Agent Admin Route
Agent Total Dose (per day)
Agent Dose Level
Agent Dose Units
Ccrr Module For Nci Cooperative Group
Treatment By Cycle Form-calgb-90104
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Multiple Sclerosis - Patient Questionnaire
(REGIMS)
Patientenfragebogen Multiple Sklerose REGIMS
http://epi.uni-muenster.de
All rights reserved. Please visit https://medical-data-
models.org/forms/6158
Multiple Sclerosis - Patient
Questionnaire (REGIMS)
Allgemeine Informationen
In welchem Jahr sind Sie geboren?*
Wie alt waren Sie bei den ersten MS-
Symptomen?*
Wie alt waren Sie als die Diagnose MS gestellt
wurde?*
Wer hat die Diagnose gestellt?*
Neurologie/Nervenheilkunde (1)
Augenheilkunde (2)
Kinderheilkunde (3)
Hausarzt/Allgemeinmedizin (4)
Andere (5)
Diagnosestellung: anderes Fachgebiet*
Erstsymptome
Welche Erstsymptome sind bei Ihnen
aufgetreten?*
Doppelbilder (1)
Erschöpfbarkeit, verminderte
Belastbarkeit (10)
Euphorische/gesteigerte Stimmung (11)
Gedrückte Stimmung, vermehrte
Traurigkeit (12)
Zittern/Zeigeunsicherheit von
Händen/Armen (13)
Blasenfunktionsstörungen
(vermehrt/verminderter
Harndrang/Inkontinenz) (14)
Darmentleerungsstörung
(Verstopfung/Durchfall/Inkontinenz) (15)
Sexuelle Störungen (16)
Andere (Wenn ja bitte nennen) (17)
Andere Sehstörungen,
Verschwommensehen (2)
Gefühlsstörung des Gesichts (3)
Andere Gefühlsstörungen (4)
Gesichtslähmungen (5)
Andere motorische Störungen
(Schwäche/Lähmungen in
Armen/Beinen) (6)
Hörminderung/Sprach-/Schluckstörung
(7)
Koordinations- oder
Feinmotorikstörungen (8)
1 / 14
Konzentrations- oder
Gedächtnisstörungen (9)
Erstsymptome: Andere*
Wurde in den letzten 12 Monaten eine
oder mehrere der diagnostischen
Maßnahmen unternommen?
Kernspintomographie Gehirn*
Ja
Nein
Kernspintomographie Rückenmark*
Ja
Nein
Computertomographie Aufnahme Gehirn*
Ja
Nein
Nervenwasseruntersuchung*
Ja
Nein
Ultraschall vom Herzen*
Ja
Nein
Elektrokardiogram (EKG)*
Ja
Nein
Wie schnell sind Sie aufgrund lhrer MS-
Erkrankung erschöpft?
Körperliche Betätigung verursacht bei mir rasch
Erschöpfung*
trifft überhaupt nicht zu (1)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
trifft vollständig zu (7)
Erschöpfung beeinträchtigt mich bei der Arbeit im
familiären und sozialen Leben*
trifft überhaupt nicht zu (1)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
trifft vollständig zu (7)
Geistige Tätigkeiten erschöpfen mich rasch*
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trifft überhaupt nicht zu (1)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
trifft vollständig zu (7)
Course
Wie oft sind Sie bisher wegen Ihrer MS stationär
in einem Krankenhaus behandelt worden?*
Wie oft waren Sie in den letzten 12 Monaten aus
anderen Gründen als der MS stationär in einem
Krankenhaus?*
Wie oft sind Sie in den letzten 12 Monaten
ambulant in einem Krankenhaus behandelt
worden ohne dort über Nacht zu bleiben?*
Wieviele Tage sind Sie in den letzten 12 Monaten
zu einer stationären Rehabilitation gewesen?*
Haben Sie in der Vergangenheit wegen
lhrer MS eines oder mehrere der
folgenden Hilfsmittel gekauft oder
erhalten?
Stock, Unterarmgehstütze*
Ja
Nein
Gehwagen*
Ja
Nein
Bauliche Änderungen der Wohnung*
Ja
Nein
Änderungen am Auto*
Ja
Nein
Fußhebemanschette*
Ja
Nein
(Elektrischer) Rollstuhl*
Ja
Nein
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Bettenlift*
Ja
Nein
Treppenlift, Rampe*
Ja
Nein
Neue Brille*
Ja
Nein
Inkontinenzeinlagen*
Ja
Nein
Andere*
Medizinische Leistungen
Medizinische Leistungen*
Krankengymnastik/Physiotherapie (1)
Massagen (2)
Ergo-/Arbeitstherapie (3)
Sprech- oder Sprachtherapie (4)
Sport- oder Bewegungstherapie (5)
Betreuung durch ambulanten
Pflegedienst (6)
Leistung komplett selbst bezahlt*
Ja
Nein
Haben Sie in den vergangenen 12
Monaten eine der folgenden Leistungen
erhalten?
Besuch einer MS Schwester/Pfleger zu Hause*
Ja
Nein
Häusliche Hilfe*
Ja
Nein
Transport durch Krankenwagen*
Ja
Nein
Transport durch Taxi*
Ja
Nein
Sozialberatung*
Ja
Nein
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Sind Sie im vergangenen Jahr von lhrer
Krankenkasse wegen Überschreitung der
Belastungsgrenze von der Zuzahlung von
Medikamenten und Behandlungen befreit
worden?*
Ich weiß nicht (-1)
Nein (0)
Ja (1)
Zufriedenheit mit der Therapie
Wie zufrieden sind Sie mit dem Erfolg lhrer
derzeitigen MS-Therapie?*
Sehr zufrieden (1)
Eher zufrieden (2)
Eher unzufrieden (3)
Sehr unzufrieden (4)
Wie zufrieden sind Sie mit der Verträglichkeit
ihrer derzeitigen MS-Therapie?*
Sehr zufrieden (1)
Eher zufrieden (2)
Eher unzufrieden (3)
Sehr unzufrieden (4)
Familienanamnese
Gibt es in lhrer Familie Personen, die unter MS
leiden?*
Mutter (1)
Vater (2)
Tochter (3)
Sohn (4)
Schwester (5)
Bruder (6)
Tante (7)
Onkel (8)
Andere (9)
Andere Familienmitglieder: bitte aufschreiben*
Beschwerden in den letzten 12 Monaten
Beschwerden*
Atemnot bzw. Schwierigkeiten beim
Atmen, Kurzatmigkeit (1)
Juckender oder brennender
Hautausschlag (10)
Lustlosigkeit, depressive Verstimmung
(11)
Unregelmäßiger Herzschlag (12)
Pilzinfektion (13)
Schwindel (14)
Andere (15)
Augenentzundungen, Nachlass der
Sehkraft, Augenschmerzen (2)
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Übelkeit, Erbrechen (3)
Durchfall (4)
Blasenentleerungsstörungen (5)
Bläschenbildung, Brennen, Juckreiz in
Mund- oder Genitalbereich (6)
Fieber mind. 38°C (7)
Halsentzündung (8)
Gelenk- oder Gliederschmerzen (9)
Glauben Sie, dass lhre Beschwerden durch ein
MS-Medikament bedingt ist? Wenn ja, welches?*
Andere Beschwerden*
Medication within last 7 days
Name des Medikaments*
Dosierung*
Tägliche Einnahme*
Ja
Nein
Wie oft pro Tag?*
1x (1)
2x (2)
3x oder mehr (3)
Komplett selbst bezahlt?*
Ja
Nein
Demographics
Welches ist Ihr höchster allgemeinbildender
Schulabschluss?*
Kein Schulabschluss (0)
Hauptschule/Volksschule (1)
Mittlere Reife/Realschule (2)
Fachhochschul-/Hochschulreife (3)
Sonstiger Abschluss (4)
Welches ist Ihr höchster berufsbildender
Abschluss?*
Kein berufsbildender Abschluss (0)
Lehre/Berufsschulabschluss (1)
Techniker-/Meisterschule (2)
Ingenieurschule/Polytechnikum (3)
Fachhochschul-/Universitätsabschluss
(4)
Sonstiger Abschluss (5)
Sind Sie zurzeit berufstätig?*
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Ja, regelmäßig vollzeitbeschäftigt (> (1)
Ja, regelmäßig teilzeitbeschäftigt (> (2)
Ja, geringfügig oder unregelmäßig
teilzeitbeschäftigt (<15 Std./Woche) (3)
Nein (4)
Wieviele Tage sind Sie in den letzten 12 Monaten
aufgrund einer Erkrankung krankgeschrieben
worden?*
Wie viele Tage davon aufgrund Ihrer MS-
Erkrankung?*
Sind Sie zurzeit ...*
... in der Ausbildung oder Umschulung?
(1)
... Hausfrau/Hausmann? (2)
... in Mutterschutz/Erziehungsurlaub,
Altersteilzeit oder sonstige Beurlaubung?
(3)
... arbeitslos? (4)
... Rentner/Pensionär/im Vorruhestand?
(5)
Wie alt waren Sie, als Sie in Pension oder Rente
gingen?*
Wurden Sie aufgrund Ihrer MS-Erkrankung
berentet?*
Ja
Nein
Ihr Geschlecht ?*
Weiblich (1)
Männlich (2)
Welchen Familienstand haben Sie?*
Ledig (1)
Verheiratet (2)
Geschieden (3)
Verwitwet (4)
Leben Sie mit einem/einer Ehepartner/in bzw.
einem/einer Partner/in zusammen? Gemeint ist
ein gemeinsamer Haushalt.*
Ja
Nein
Sind Sie im Gebiet des heutigen Deutschland
geboren?*
Ja
Nein
Seit wann leben Sie im heutigen Deutschland?*
In welchem Land sind Sie geboren? Gemeint ist
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die heutige Bezeichnung des Landes.*
Rauchen Sie zurzeit Zigaretten, Pfeife, Zigarren
oder Zigarillos? Wenn ja, was rauchen Sie? Bitte
ankreuzen, was auf Sie zutrifft.*
Nein, ich habe nie geraucht (1)
Nein, aber früher habe ich regelmäßig
geraucht (2)
Ja, ich rauche gelegentlich d.h. < 1
Zigarette/Tag (3)
Ja, ich rauche zurzeit d.h. > 1
Zigarette/Tag (4)
Wieviele Zigaretten pro Tag*
Wieviele Pfeifen pro Tag*
Wieviele Zigarren/Zigarillos pro Tag*
Seit wie vielen Jahren rauchen Sie?*
Wie alt waren Sie, als Sie mit dem Rauchen
aufgehört haben?*
Wie viele Jahre haben Sie geraucht?*
Arztbesuch
Bitte geben Sie an, welche der folgenden Ärzte
oder Ärztinnen Sie innerhalb der letzten 12
Monate aufgesucht haben.*
Allgemeinmediziner oder praktischer Arzt
(1)
Schmerzspezialist (10)
Heilpraktiker (11)
Sonstige Ärzte (12)
Internist (2)
Frauenarzt (3)
Urologe (4)
Augenarzt (5)
Orthopäde (6)
Neurologe/Nervenarzt (7)
Zahnarzt/Kieferchirurg (8)
Psychotherapeut/Psychiater (9)
Sonstiger Arzt*
Wie oft haben Sie diesen Arzt in den letzten 12
Monaten aufgesucht?*
Lebensqualität
Wir möchten Sie nun bitten, zu kennzeichnen,
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wie gut oder schlecht Ihrer Ansicht nach Ihr
persönlicher Gesundheitszustand heute ist.
(0=Schlechtester denkbarer Gesundheitszustand,
100=Bester denkbarer Gesundheitszustand)*
Besitzen Sie einen Schwerbehindertenausweis?*
Ja
Nein
Bitte geben Sie den Schweregrad Ihrer
Behinderung an*
<50 (1)
50 (2)
60 (3)
70 (4)
80 (5)
90 (6)
100 (7)
Haben Sie jemals Leistungen aus der deutschen
Pflegeversicherung beantragt?*
Ja
Nein
Wenn ja, war der Antrag auf Leistungen der
Pflegeversicherung erfolgreich?*
Nein (0)
Ja (1)
Noch nicht entschieden (2)
Wenn ja, in welche Pflegestufe wurden Sie
eingestuft?*
Pflegestufe 1 (1)
Pflegestufe 2 (2)
Pflegestufe 3 (3)
Ab wann haben Sie Leistungen aus der
Pflegeversicherung erhalten?*
Welche Hauptleistung bekommen Sie momentan
aus der Pflegeversicherung?*
Geldleistungen (1)
Sachleistungen (z.B. durch ambulanten
Pflegedienst) (2)
Kombination aus beidem (Sach- und
Geldleistungen) (3)
Keine mehr (4)
Wie würden Sie Ihren Gesundheitszustand im
Allgemeinen beschreiben?*
Ausgezeichnet (1)
Sehr gut (2)
Gut (3)
Weniger gut (4)
Schlecht (5)
Im Vergleich zum letzten Jahr, wie würden Sie
Ihren derzeitigen Gesundheitszustand
beschreiben?*
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Derzeit viel besser als vor einem Jahr (1)
Derzeit etwas besser als vor einem Jahr
(2)
Etwa wie vor einem Jahr (3)
Derzeit etwas schlechter als vor einem
Jahr (4)
Derzeit viel schlechter als vor einem Jahr
(5)
Wie oft waren Sie in den vergangenen vier
Wochen voller Schwung?*
Immer (1)
Meistens (2)
Ziemlich oft (3)
Manchmal (4)
Selten (5)
Nie (6)
Wie oft waren Sie in den vergangenen vier
Wochen sehr nervös?*
Immer (1)
Meistens (2)
Ziemlich oft (3)
Manchmal (4)
Selten (5)
Nie (6)
Wie oft waren Sie in den vergangenen vier
Wochen so niedergeschlagen, dass Sie nichts
aufheitern konnte?*
Immer (1)
Meistens (2)
Ziemlich oft (3)
Manchmal (4)
Selten (5)
Nie (6)
Wie oft waren Sie in den vergangenen vier
Wochen ruhig und gelassen?*
Immer (1)
Meistens (2)
Ziemlich oft (3)
Manchmal (4)
Selten (5)
Nie (6)
Wie oft waren Sie in den vergangenen vier
Wochen voller Energie?*
Immer (1)
Meistens (2)
Ziemlich oft (3)
Manchmal (4)
Selten (5)
Nie (6)
Wie oft waren Sie in den vergangenen vier
Wochen entmutigt und traurig?*
Immer (1)
Meistens (2)
Ziemlich oft (3)
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Manchmal (4)
Selten (5)
Nie (6)
Wie oft waren Sie in den vergangenen vier
Wochen erschöpft?*
Immer (1)
Meistens (2)
Ziemlich oft (3)
Manchmal (4)
Selten (5)
Nie (6)
Wie oft waren Sie in den vergangenen vier
Wochen glücklich?*
Immer (1)
Meistens (2)
Ziemlich oft (3)
Manchmal (4)
Selten (5)
Nie (6)
Wie oft waren Sie in den vergangenen vier
Wochen müde?*
Immer (1)
Meistens (2)
Ziemlich oft (3)
Manchmal (4)
Selten (5)
Nie (6)
Sind Sie durch Ihren derzeitigen
Gesundheitszustand bei anstrengenden
Tätigkeiten (z.B. schnell laufen, schwere
Gegenstände heben, anstrengenden Sport
treiben) eingeschränkt? Wenn ja, wie stark?*
Nein, überhaupt nicht eingeschränkt (0)
Ja, etwas eingeschränkt (1)
Ja, stark eingeschränkt (2)
Sind Sie durch Ihren derzeitigen
Gesundheitszustand bei mittelschweren
Tätigkeiten (z.B. einen Tisch verschieben,
staubsaugen, kegeln, Golf spielen)
eingeschränkt? Wenn ja, wie stark?*
Nein, überhaupt nicht eingeschränkt (0)
Ja, etwas eingeschränkt (1)
Ja, stark eingeschränkt (2)
Sind Sie durch Ihren derzeitigen
Gesundheitszustand eingeschränkt
Einkaufstaschen zu heben und zu tragen? Wenn
ja, wie stark?*
Nein, überhaupt nicht eingeschränkt (0)
Ja, etwas eingeschränkt (1)
Ja, stark eingeschränkt (2)
Sind Sie durch Ihren derzeitigen
Gesundheitszustand eingeschränkt mehrere
Treppenabsätze zu steigen? Wenn ja, wie stark?*
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Nein, überhaupt nicht eingeschränkt (0)
Ja, etwas eingeschränkt (1)
Ja, stark eingeschränkt (2)
Sind Sie durch Ihren derzeitigen
Gesundheitszustand eingeschränkt einen
Treppenabsatz zu steigen? Wenn ja, wie stark?*
Nein, überhaupt nicht eingeschränkt (0)
Ja, etwas eingeschränkt (1)
Ja, stark eingeschränkt (2)
Sind Sie durch Ihren derzeitigen
Gesundheitszustand eingeschränkt sich zu
beugen, knien oder zu bücken? Wenn ja, wie
stark?*
Nein, überhaupt nicht eingeschränkt (0)
Ja, etwas eingeschränkt (1)
Ja, stark eingeschränkt (2)
Sind Sie durch Ihren derzeitigen
Gesundheitszustand eingeschränkt mehr als 1
km zu Fuß gehen? Wenn ja, wie stark?*
Nein, überhaupt nicht eingeschränkt (0)
Ja, etwas eingeschränkt (1)
Ja, stark eingeschränkt (2)
Sind Sie durch Ihren derzeitigen
Gesundheitszustand eingeschränkt mehrere
Straßenkreuzungen weit zu Fuß zu gehen?
Wenn ja, wie stark?*
Nein, überhaupt nicht eingeschränkt (0)
Ja, etwas eingeschränkt (1)
Ja, stark eingeschränkt (2)
Sind Sie durch Ihren derzeitigen
Gesundheitszustand eingeschränkt eine
Straßenkreuzung weit zu Fuß zu gehen? Wenn
ja, wie stark?*
Nein, überhaupt nicht eingeschränkt (0)
Ja, etwas eingeschränkt (1)
Ja, stark eingeschränkt (2)
Sind Sie durch Ihren derzeitigen
Gesundheitszustand eingeschränkt sich zu
baden oder anzuziehen? Wenn ja, wie stark?*
Nein, überhaupt nicht eingeschränkt (0)
Ja, etwas eingeschränkt (1)
Ja, stark eingeschränkt (2)
Konnten Sie in den vergangenen vier Wochen
aufgrund Ihrer körperlichen Gesundheit bei der
Arbeit oder anderen alltäglichen Tätigkeiten zu
Hause nicht so lange wie üblich tätig sein?*
Ja
Nein
Haben Sie in den vergangenen vier Wochen
aufgrund Ihrer körperlichen Gesundheit bei der
Arbeit oder anderen alltäglichen Tätigkeiten zu
Hause weniger geschafft als Sie wollten?*
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Ja
Nein
Konnten Sie in den vergangenen vier Wochen
aufgrund Ihrer körperlichen Gesundheit bei der
Arbeit oder anderen alltäglichen Tätigkeiten zu
Hause nur bestimmte Dinge tun?*
Ja
Nein
Hatten Sie in den vergangenen vier Wochen
aufgrund Ihrer körperlichen Gesundheit bei der
Arbeit oder anderen alltäglichen Tätigkeiten zu
Hause Schwierigkeiten bei der Ausführung (z.B.
ich musste mich besonders anstrengen)?*
Ja
Nein
Konnten Sie in den vergangenen vier Wochen
aufgrund seelischer Probleme nicht so lange wie
üblich tätig sein?*
Ja
Nein
Haben Sie in den vergangenen vier Wochen
aufgrund seelischer Probleme weniger geschafft
als Sie wollten?*
Ja
Nein
Konnten Sie in den vergangenen vier Wochen
aufgrund seelischer Probleme nicht so sorgfältig
wie üblich arbeiten?*
Ja
Nein
Wie sehr haben Ihre körperliche Gesundheit oder
seelische Probleme in den vergangenen vier
Wochen Ihre normalen Kontakte zu
Familienangehörigen, Freunden, Nachbarn oder
zum
Bekanntenkreis beeinträchtigt?*
Überhaupt nicht  (0)
Etwas (1)
Mäßig (2)
Ziemlich (3)
Sehr (4)
Wie stark waren Ihre Schmerzen in den
vergangenen vier Wochen?*
Ich hatte keine Schmerzen (0)
Sehr leicht (1)
Leicht (2)
Mäßig (3)
Stark (4)
Sehr stark (5)
Inwieweit haben die Schmerzen Sie in den
vergangenen vier Wochen bei der Ausübung
Ihrer
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Alltagstätigkeiten zu Hause und im Beruf
behindert?*
Überhaupt nicht (1)
Etwas (2)
Mäßig (3)
Ziemlich (4)
Sehr (5)
Wie häufig haben Ihre körperliche Gesundheit
oder seelische Probleme in den vergangenen
vier Wochen Ihre Kontakte zu anderen Menschen
(Besuche bei Freunden, Verwandten usw.)
beeinträchtigt?*
Nie (0)
Selten (1)
Manchmal (2)
Meistens (3)
Immer (4)
Ich scheine etwas leichter als andere krank zu
werden. Inwieweit trifft diese Aussage zu?*
Trifft weitgehend nicht zu (-1)
Trifft überhaupt nicht zu (-2)
Weiß nicht (0)
Trifft weitgehend zu (1)
Trifft ganz zu (2)
Ich bin genauso gesund wie alle anderen, die ich
kenne. Inwieweit trifft diese Aussage zu?*
Trifft weitgehend nicht zu (-1)
Trifft überhaupt nicht zu (-2)
Weiß nicht (0)
Trifft weitgehend zu (1)
Trifft ganz zu (2)
Ich erwarte, dass meine Gesundheit nachlässt.
Inwieweit trifft diese Aussage zu?*
Trifft weitgehend nicht zu (-1)
Trifft überhaupt nicht zu (-2)
Weiß nicht (0)
Trifft weitgehend zu (1)
Trifft ganz zu (2)
Ich erfreue mich ausgezeichneter Gesundheit.
Inwieweit trifft diese Aussage zu?*
Trifft weitgehend nicht zu (-1)
Trifft überhaupt nicht zu (-2)
Weiß nicht (0)
Trifft weitgehend zu (1)
Trifft ganz zu (2)
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Multiple Sclerosis - In-/Exclusion Criteria
(REGIMS)
REGIMS Multiple Sklerose-Register
http://epi.uni-muenster.de
All rights reserved. Please visit https://medical-data-
models.org/forms/6161
Multiple Sclerosis - In-/Exclusion
Criteria (REGIMS)
Einschlusskriterien
Gesicherte Diagnose der Multiplen Sklerose nach
rev. McDonald-Kriterien (2005)*
Ja
Nein
Patienten, die zum ersten Mal mit einer
Immuntherapie behandelt werden.*
Ja
Nein
Patienten, die mit Natalizumab, Fingolimod,
Mitoxantron, Alemtuzumab, Dimethylfumarat
(BG-12),
Teriflunomid oder einem zukünftig neu
zugelassenem Immuntherapeutikum behandelt
werden, unabhängig von der Therapiedauer.*
Ja
Nein
Patienten, die seit max. 36 Monaten eine der
folgenden Immuntherapien erhalten:
- Interferon-beta 1a i.m./s.c. oder 1b s.c.
- Glatirameracetat
- Azathioprin*
Ja
Nein
Ausschlusskriterien
Patienten ohne gesicherte MS-Diagnose mit
Ausnahme von Kis-Patienten*
Ja
Nein
Patienten, die seit mehr als drei Jahren mit der
gleichen MS-Therapie behandelt werden, mit
Ausnahme von der Behandlung mit Natalizumab,
Fingolimod.*
Ja
Nein
Patienten, die mit Tysabri behandelt werden und
bereits an der Anwendungsbeobachtung "TOP"
von Biogen teilgenommen haben.*
Ja
Nein
Bemerkungen
Falls Sie eine Patientin / einen Patienten
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einschließen wollen, bei der / dem nicht alle Ein-
und Ausschlusskriterien erfüllt sind, begründen
Sie dies bitte hier:*
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Breast Cancer NCT00024102 Quality of Life - CALGB: Y-ME
COUNSELOR TELEPHONE CONTACT FORM - 2044777v3.0
CALGB: Y-ME COUNSELOR TELEPHONE CONTACT
FORM
Comparison of Combination Chemotherapy Regimens in
Treating Older Women Who Have Undergone Surgery for
Breast Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=A50CF1AD-
5DEE-3887-E034-080020C9C0E0
All rights reserved. Please visit https://medical-data-
models.org/forms/6162
CALGB: Y-ME COUNSELOR
TELEPHONE CONTACT FORM
General Information
CALGB Form*
CALGB Form*
Y-ME Patient ID (DMC USE ONLY)*
Y-ME Patient ID (DMC USE ONLY)*
Patient enrolled in 49907 (1.)*
No (No)
Yes (Yes)
Counselor's Name (2.)*
Date of session (M)*
Time session began ([hour/minute])*
Time session ended ([hour/minute])*
Session with (mark one with an X)*
Family Member Or Friend (Family
member or friend)
Patient (Patient)
Topics Discussed (mark all that apply with an X)*
Consent Form (Consent Form)
Described Experience Of Being On A
Clinical Trial/research Study: How It
Differs From Just Being Treated 'off-
protocol' (Described experience of being
on a clinical trial/research study: How it
differs from just being treated 'off-
protocol')
Other Topics Discussed, Specify Below
(Other Topics Discussed, specify below)
Patient Asked The Following About This
Clinical Trial (Patient asked the following
about this clinical trial)
Specific Protocol-related Issues (Specific
protocol-related issues)
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Patient asked the following about this clinical trial
(mark all that apply with an X)*
Medical Tests Required (Medical tests
required)
Objectives; Significance Of Study
(Objectives; Significance of study)
Other, Specify (Other, specify)
Randomization Issues (Randomization
issues)
Side Effects (Side effects)
Specific Treatment (Specific treatment)
What Patient Is Required To Do (What
patient is required to do)
Other, specify (patient asked about this clinical
trial) (C.)*
Consent Form (mark all that apply with an X)*
Interpreted/explained Language Used In
Consent Form (Interpreted/explained
language used in consent form)
Patient Can Leave Study At Any Time
Without Repercussions (Patient can
leave study at any time without
repercussions)
The Right Of The Patient To Contact A
Person In The Hospital If She Feels Her
Rights Have Not Been Protected (The
right of the patient to contact a person in
the hospital if she feels her rights have
not been protected)
Specific protocol-related issues (mark all that
apply with an X)*
Confidentiality Of Data (Confidentiality of
data)
Other, Specify (Other, specify)
Transportation To/from Hospital
(Transportation to/from hospital)
Whether Costs Of Participation In Study
Would Be Covered By Insurance
(Whether costs of participation in study
would be covered by insurance)
Other, specify (specific protocol-related issues)
(E.)*
Other Topics Discussed, specify below*
CALGB Form*
CALGB Form*
Y-ME Patient ID (DMC USE ONLY)*
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Y-ME Patient ID (DMC USE ONLY)*
Telephone Interview
What were the patient's concerns about
participating in this clinical trial? (mark all that
apply)*
Didn't Understand The Study (a)
Treatment Side Effects (b)
Fear That Treatment Was Life-
threatening (c)
The Trial Was Not Asking An Important
Question (d)
Patient Felt That She Could Get Good
Care Without Needing To Be On A
Clinical Trial (e)
Randomization; Wanted To Be On A
Specific Arm Of The Trial (f)
Didn't Understand The Consent Form (g)
Was Frightened By The Consent Form
(h)
Transportation Not Available Or Too
Expensive (i)
Distance Need To Travel To Hospital Was
Too Far (j)
Costs Of Treatment That Would Not Be
Covered By Insurance (k)
Confidentiality Of Medical Records (l)
Afraid Of Oncologist's Reaction If She
Decided Not To Participate In Trial (m)
Fears Of Family Members Or Friends
Disapproving Of Her Decision About
Participating In This Trial (n)
Afraid Of Being A 'guinea Pig'; Treated
By An Unproven Experimental Therapy
(o)
Insufficient Support At Home From
Friends And Family To Help Patient
While Being Treated (p)
Other, Specify (q)
Don't Know (r)
Other, specify (patient's concerns about
participating in this clinical trial)*
Most Important (patient's concerns about
participating in this trial)*
Didn't Understand The Study (a)
Treatment Side Effects (b)
Fear That Treatment Was Life-
threatening (c)
The Trial Was Not Asking An Important
Question (d)
Patient Felt That She Could Get Good
Care Without Needing To Be On A
Clinical Trial (e)
Randomization; Wanted To Be On A
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Specific Arm Of The Trial (f)
Didn't Understand The Consent Form (g)
Was Frightened By The Consent Form
(h)
Transportation Not Available Or Too
Expensive (i)
Distance Need To Travel To Hospital Was
Too Far (j)
Costs Of Treatment That Would Not Be
Covered By Insurance (k)
Confidentiality Of Medical Records (l)
Afraid Of Oncologist's Reaction If She
Decided Not To Participate In Trial (m)
Fears Of Family Members Or Friends
Disapproving Of Her Decision About
Participating In This Trial (n)
Afraid Of Being A 'guinea Pig'; Treated
By An Unproven Experimental Therapy
(o)
Insufficient Support At Home From
Friends And Family To Help Patient
While Being Treated (p)
Other, Specify (q)
Don't Know (r)
2nd Most Important (patient's concerns about
participating in this trial)*
Didn't Understand The Study (a)
Treatment Side Effects (b)
Fear That Treatment Was Life-
threatening (c)
The Trial Was Not Asking An Important
Question (d)
Patient Felt That She Could Get Good
Care Without Needing To Be On A
Clinical Trial (e)
Randomization; Wanted To Be On A
Specific Arm Of The Trial (f)
Didn't Understand The Consent Form (g)
Was Frightened By The Consent Form
(h)
Transportation Not Available Or Too
Expensive (i)
Distance Need To Travel To Hospital Was
Too Far (j)
Costs Of Treatment That Would Not Be
Covered By Insurance (k)
Confidentiality Of Medical Records (l)
Afraid Of Oncologist's Reaction If She
Decided Not To Participate In Trial (m)
Fears Of Family Members Or Friends
Disapproving Of Her Decision About
Participating In This Trial (n)
Afraid Of Being A 'guinea Pig'; Treated
By An Unproven Experimental Therapy
(o)
Insufficient Support At Home From
Friends And Family To Help Patient
While Being Treated (p)
Other, Specify (q)
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Don't Know (r)
3rd Most Important (patient's concerns about
participating in this trial)*
Didn't Understand The Study (a)
Treatment Side Effects (b)
Fear That Treatment Was Life-
threatening (c)
The Trial Was Not Asking An Important
Question (d)
Patient Felt That She Could Get Good
Care Without Needing To Be On A
Clinical Trial (e)
Randomization; Wanted To Be On A
Specific Arm Of The Trial (f)
Didn't Understand The Consent Form (g)
Was Frightened By The Consent Form
(h)
Transportation Not Available Or Too
Expensive (i)
Distance Need To Travel To Hospital Was
Too Far (j)
Costs Of Treatment That Would Not Be
Covered By Insurance (k)
Confidentiality Of Medical Records (l)
Afraid Of Oncologist's Reaction If She
Decided Not To Participate In Trial (m)
Fears Of Family Members Or Friends
Disapproving Of Her Decision About
Participating In This Trial (n)
Afraid Of Being A 'guinea Pig'; Treated
By An Unproven Experimental Therapy
(o)
Insufficient Support At Home From
Friends And Family To Help Patient
While Being Treated (p)
Other, Specify (q)
Don't Know (r)
What was the outcome at the end of the call?
(mark all that apply with an X)*
Arranged To Speak Again To The Patient
(Arranged to speak again to the patient)
Other, Specify (Other, specify)
Patient Decided Not To Participate
(Patient decided not to participate)
Patient Decided To Participate In Trial
(Patient decided to participate in trial)
Patient Would Continue To Think About
Whether To Participate (Patient would
continue to think about whether to
participate)
Referred Patient To Another
Agency/professional Concerning Matters
Other Than Their Participation In This
Clinical Trial (Referred patient to another
agency/professional concerning matters
other than their participation in this
clinical trial)
Sent Some Information Brochures To
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The Patient [specify Which:] (Sent some
information brochures to the patient
[specify which:])
Suggested Patient Speak With A
Member Of Their Medical Team Where
She Is Being Treated (Suggested patient
speak with a member of their medical
team where she is being treated)
Sent some information brochures to the patient
[specify which:]*
Other, specify (outcome at the end of the call)*
Completed By (Print or Type Name)*
Date Completed*
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COUNSELOR TELEPHONE CONTACT FORM - 2044777v3.0
Breast Cancer NCT00090974 On-Study - FORM 1 - ELIGIBILITY
CHECK LIST AND INITIAL EVALUATION MA.27 - 2067101v3.0
FORM 1 - ELIGIBILITY CHECK LIST AND INITIAL
EVALUATION MA.27
Quality Of Life Companion Study For JMA27 (NCIC-
MA.27): A Randomized Phase III Trial Of Exemestane
Versus Anastrozole With Or Without Celecoxib In
Postmenopausal Women With Receptor Positive Primary
Breast Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=ABF84340-
BD14-67AC-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/6165
FORM 1 - ELIGIBILITY CHECK LIST
AND INITIAL EVALUATION MA.27
Patient Information
Patient Medical Record Number
Investigator Name
Institution Name
Registered Investigator (NCI Investigator #)
Patient's Date of Birth (yyyy mmm dd)
Patient Gender
Female (Female)
Male (Male)
Patient Race (check all that apply Patient is
encouraged to self designate: Race Categories
and Definitions definitions given with each value)
Native_american_cdus (American Indian
or Alaska Native)
Asian_cdus (Asian)
Black_cdus (Black or African American)
Pacific_islander_cdus (Native Hawaiian
or other Pacific Islander)
Unknown (Unknown)
White_cdus (White)
Patient Ethnicity (check one only Ethnicity
Categories and Definitions definition given with
value value)
Hispanic_or_latino (Hispanic or Latino)
Non_hispanic (Non-Hispanic)
Unknown (Unknown)
Payment method (check one USA only)
Medicaid (Medicaid)
Medicaid And Medicare (Medicaid and
Medicare)
Medicare (Medicare)
Medicare And Private Insurance
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(Medicare and Private Insurance)
Military Or Veterans Sponsored Nos
(Military or Veterans Sponsored NOS)
Military Sponsored (including Champus
& Tricare) (Military sponsored (including
CHAMPUS and TRICARE))
No Means Of Payment (no Insurance)
(No means of payment (no insurance))
Other (Other)
Private Insurance (Private Insurance)
Self Pay (no Insurance) (Self pay (no
insurance))
Unknown (Unknown)
Veterans Sponsored (Veterans
Sponsored)
IRB/REB Approval Date ([initial approval or
annual renewal] yyyy mmm dd)
Projected Start Date of Treatment ([within 10
working days of randomization] yyyy mmm dd)
Eligibility Checklist
Patient has completely resected and
histologically confirmed invasive breast
carcinoma.
Yes
No
Date prior adjuvant chemotherapy ended (yyyy
mmm dd)
Pathological TNM classification is (check one)
T1 (T1)
T2 (T2)
T3 (T3)
Pathological TNM classification is (check one)
T1 (T1)
T2 (T2)
T3 (T3)
Pathological TNM classification is (check one)
T1 (T1)
T2 (T2)
T3 (T3)
Primary tumour is receptor positive i.e. ER and/or
PgR positive (defined as receptor content of >=
10fmol/mg protein or receptor positive by ERICA
or PgRICA).
Yes
No
If patient has bilateral breast cancer, both were
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diagnosed at the same time and at least one of
the bilateral cancers is receptor positive (as
defined above)
Yes
No
Patient is post-menopausal according to one of
these three criteria
Bilateral Oophorectomy (bilateral
oophorectomy)
greater than (>) 55 years of age with no
spontaneous menses for at least 12
months; (greater than (>) 55 years of age
with no spontaneous menses for at least
12 months;)
less or equal to (<=) 55 years of age with
no spontaneous menses within the past
12 months (i.e. spontaneous cessation
or secondary to hysterectomy) AND with
and FSH level in the postmenopausal
range according to
institutional/laboratory standards (less or
equal to (<=) 55 years of age with no
spontaneous menses within the past 12
months (i.e. spontaneous cessation or
secondary to hysterectomy) AND with
and FSH level in the postmenopausal
range according to
institutional/laboratory standards)
FSH value
Date (FSH value) (yyyy mmm dd)
Radiologic investigations have been completed
within 4 weeks prior to surgical resection of
primary tumour and are negative for metastases
Yes
No
Radiologic investigations have been completed
(To specify investigations)
Bone Scan (1)
Abdominal Ultrasound Or Ct Abdomen
(2)
Chest X-ray (3)
bone scan (required only if alkaline phosphatase
is >= 2 x UNL and/or there are symptoms of
metastatic disease a confirmatory x-ray or other
imaging study such as CT or MRI is required if
the results from the bone scan are questionable)
Not Applicable (Not Applicable)
abdominal ultrasound or CT abdomen (required
only if the AST/ALT or alkaline phosphatase is >
2 x UNL unless the elevation is in the bone
fraction)
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Not Applicable (Not Applicable)
Date of chest x-ray (yyyy mmm dd)
Patient has had a bilateral mammogram within 10
months prior to randomization.
Yes
No
Date of bilateral mammogram (yyyy mmm dd)
If patient has received prior adjuvant
chemotherapy, no less than 3 weeks and no more
than 3 months have elapsed since completion of
chemotherapy (planned radiotherapy may be
given concurrently with protocol therapy).
Yes
No
Patient has a minimum life expectancy of 5 years.
Yes
No
Performance Status (ECOG) is (circle one see
Appendix II)
0 (0)
1 (1)
2 (2)
Patient is able to swallow the study medication
and have adequate unassisted oral intake to
maintain a reasonable state of nutrition.
Yes
No
Patient is able and willing to comply with
scheduled study visits at the participating centre.
Yes
No
Informed consent has been signed and dated by
patient.
Yes
No
Date informed consent signed (yyyy mmm dd)
Stratification
Axillary Nodes
No Regional Lymph Node Metastasis
(N0)
Metastasis To Movable Ipsilateral Axillary
Lymph Node(s) (N1)
Regional Lymph Nodes Cannot Be
Assessed (e.g., Previously Removed)
(NX)
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Prior adjuvant chemotherapy?
No (No)
Yes (Yes)
Chronic low dose prophylactic aspirin use
No (No)
Yes (Yes)
Eligibility Checklist Continued
Required hematologic investigations done within
4 weeks prior to randomization and are within the
required parameters for eligibility.
Yes
No
Required biochemistry investigations done within
4 weeks prior to randomization and are within the
required parameters for eligibility unless imaging
examinations have ruled out metastatic disease.
Yes
No
Initiation of protocol therapy will begin within 10
working days of randomization.
Patient has no history of other malignancies
except adequately treated non-melanoma skin
cancer, curatively treated in-situ cancer of the
cervix or other solid tumours curatively treated
with no evidence of disease for >= 5 years from
randomization.
Yes
No
Patient is not receiving concurrent hormonal
therapy with estrogens, progesterones,
androgens or any selective estrogen receptor
modulator (SERM). (previous use of Raloxifene,
specifically, is permitted provided this is
discontinued at least 3 weeks prior to
randomization; intermittent use, i.e. maximum of
2 x per week, of vaginal estrogens is permitted
on protocol if other local [trunc. see form])
Yes
No
No prior treatment with a recognized aromatase
inhibitor.
Yes
No
No known or incompletely treated peptic ulcer
disease.
Yes
No
Patient is not receiving concurrent NSAID therapy
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or Cox-2 Inhibitor therapy e.g. Vioxx. (chronic low
dose, i.e. <= 81 mg/day, prophylactic aspirin will
be allowed)
Yes
No
No known allergy to sulphonamides.
No history of asthma, urticaria or allergic type
reactions after taking aspirin or other NSAIDs.
Yes
No
No co-existing medical or psychiatric condition
that is likely to interfere with study procedures or
results.
Yes
No
If patient has participated in another trial for
breast cancer (e.g. adjuvant chemotherapeutic
trial), permission has been obtained, from the
sponsors of that trial for the patients to participate
in MA.27.
Yes
No
Randomization Date (yyyy mmm dd)
Certificate Of Eligibility
In the opinion of the investigator is the patient
eligible?
No (No)
Yes (Yes)
Investigator Signature
Date of Investigator Signature (yyyy mmm dd)
Person Completing Form, Last Name
Person Completing Form, First Name
Date Form Originally Completed (yyyy mmm dd)
History And Physical Exam
Date of evaluation (yyyy mmm dd)
Performance Status (check one see protocol
Appendix II)
2 (Ambulatory and capable of all self-
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care but unable to carry out any work
activities (K 50 - 60))
3 (Capable of only limited self-care,
confined to bed or chair more than 50%
of waking hours (K 30-40))
4 (Completely disabled. Cannot carry on
any self-care. Totally confined to bed or
chair (K 10-20))
0 (Fully active, able to carry on all pre-
disease performance without restriction
(Karnofsky 90 - 100))
1 (Restricted in physically strenuous
activity but ambulatory (K 70 - 80))
Patient Height (cm)
Patient Weight (kg)
Patient is post-menopausal according to one of
these three criteria
Bilateral Oophorectomy (bilateral
oophorectomy)
greater than (>) 55 years of age with no
spontaneous menses for at least 12
months; (greater than (>) 55 years of age
with no spontaneous menses for at least
12 months;)
less or equal to (<=) 55 years of age with
no spontaneous menses within the past
12 months (i.e. spontaneous cessation
or secondary to hysterectomy) AND with
and FSH level in the postmenopausal
range according to
institutional/laboratory standards (less or
equal to (<=) 55 years of age with no
spontaneous menses within the past 12
months (i.e. spontaneous cessation or
secondary to hysterectomy) AND with
and FSH level in the postmenopausal
range according to
institutional/laboratory standards)
FSH value
Date (FSH value) (yyyy mmm dd)
Investigations
Imaging Site
Abdomen (Abdomen)
Bone (Bone)
Chest (Chest)
Date of evaluation (yyyy mmm dd)
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Method of Evaluation
Bilateral Mammogram (Bilateral
Mammogram)
Bone Scan (Bone Scan)
Chest X-ray (Chest X-ray)
Ct Scan (CT Scan)
Mri (MRI (NMR))
Not Evaluated (Not Evaluated)
Ultrasound (Ultrasound)
Investigations Continued Baseline
Hematology/biochemistry Values
Date Hematology (Blood) Sample Obtained (yyyy
mmm dd)
Hemoglobin (Value)
Peripheral Platelet Count (Value)
Peripheral WBC Count  (Value)
Lab Unit of Measure (circle unit used)
G/dl (g/dl)
G/l (g/L)
Lab Unit of Measure (circle unit used)
G/dl (g/dl)
G/l (g/L)
Lab Unit of Measure (circle unit used)
G/dl (g/dl)
G/l (g/L)
Lab Unit of Measure (circle unit used)
G/dl (g/dl)
G/l (g/L)
Lab Unit of Measure (circle unit used)
G/dl (g/dl)
G/l (g/L)
Lab Unit of Measure (circle unit used)
G/dl (g/dl)
G/l (g/L)
Lab Unit of Measure (circle unit used)
G/dl (g/dl)
G/l (g/L)
Lab Unit of Measure (circle unit used)
G/dl (g/dl)
G/l (g/L)
Lab Unit of Measure (circle unit used)
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G/dl (g/dl)
G/l (g/L)
Lab Unit of Measure (circle unit used)
G/dl (g/dl)
G/l (g/L)
Peripheral Neutrophils (granulocytes) (Value)
Specimen Collection Date (Biochemistry yyyy
mmm dd)
SGOT (AST) (Value; Must be < 2 x ULN unless
imaging examinations have ruled out metastatic
disease.)
SGOT (AST) ULN
SGPT (ALT) (Value; Must be < 2 x ULN unless
imaging examinations have ruled out metastatic
disease.)
SGPT (ALT) ULN
Alkaline Phosphatase (Value; Must be < 2 x ULN
unless imaging examinations have ruled out
metastatic disease.)
Alkaline Phosphatase ULN
Creatinine (Value)
Creatinine ULN
Calcium (Ca) (Value)
Calcium LLN
Calcium ULN
Follicle Stimulating Hormone (FSH) (Value; **
Required only if necessary to confirm
postmenopausal status.)
Postmenopausal LLN
Postmenopausal ULN
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Disease History/prior Treatment/adverse
Events
First Positive Biopsy Date (date of initial
pathologic diagnosis yyyy mmm dd)
Most Extensive Primary Surgery Date (if
required, use last re-excision date yyyy mmm dd)
Most extensive primary surgery
Mastectomy, Nos (mastectomy, NOS)
Partial
Mastectomy/lumpectomy/excisional
Biopsy (partial
mastectomy/lumpectomy/excisional
biopsy)
Was axillary dissection performed?
No (No)
Yes (Yes)
Axillary Dissection Date (yyyy mmm dd)
Number of lymph nodes examined
Number of positive lymph nodes examined
Disease History... Continued
Tumour Laterality (check one)
Bilateral (Bilateral)
Left (Left)
Right (Right)
Receptor Status, ER (If measure in fmols/mg,
cytosl protein >= 10 is postive. If other measures
are used, apply institutional standards; borderline
results should be reported as positive)
Negative (Negative)
Positive (Positive)
Receptor Status, PgR (If measure in fmols/mg,
cytosl protein >= 10 is postive. If other measures
are used, apply institutional standards; borderline
results should be reported as positive)
Negative (Negative)
Positive (Positive)
T Stage, Pathologic (check one)
Refer To Figo And/or Ajcc Staging
Guidelines Per Protocol (T1)
Refer To Figo And/or Ajcc Staging
Guidelines Per Protocol (T2)
Refer To Figo And/or Ajcc Staging
Guidelines Per Protocol (T3)
Refer To Figo And/or Ajcc Staging
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Guidelines Per Protocol (TX)
N Stage, Pathologic (check one)
N0, According To Ajcc Criteria (N0)
N1, According To Ajcc Criteria (N1)
Nx, According To Ajcc Criteria (NX)
M Stage, Pathologic (check one)
No Distant Metastasis (M0)
Prior Treatment For Cancer
Prior adjuvant chemotherapy?
No (No)
Yes (Yes)
Agent Name
Date prior adjuvant chemotherapy ended (yyyy
mmm dd)
Total Number of Cycles Given
Prior raloxifene therapy?
Yes
No
Date Prior Raloxifene Therapy Ended (yyyy mmm
dd)
Prior adjuvant RT?
No (No)
Unknown (Unknown)
Yes (Yes)
Date Adjuvant Radiation Therapy Started (yyyy
mmm dd)
Total dose of Radiation Therapy (cGy)
Date Adjuvant Radiation Therapy Ended (yyyy
mmm dd)
Is concurrent RT planned for this patient?
No (No)
Yes (Yes)
Planned Concurrent RT Start Date (yyyy mmm
dd)
Disease History... Continued; Bone
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Fractures
Has the patient experienced a bone fracture in
the last 10 years?
Yes
No
Bone Fracture Site, Spinal (Check)
No (No)
Unknown (Unknown)
Yes (Yes)
Bone Fracture Site, Wrist (Check)
No (No)
Unknown (Unknown)
Yes (Yes)
Bone Fracture Site, Pelvis (Check)
No (No)
Unknown (Unknown)
Yes (Yes)
Bone Fracture Site, Hip (Check)
No (No)
Unknown (Unknown)
Yes (Yes)
Bone Fracture Site, Femur (Check)
No (No)
Unknown (Unknown)
Yes (Yes)
Bone Fracture Site, Tibia (Check)
No (No)
Unknown (Unknown)
Yes (Yes)
Bone Fracture Site, Ankle (Check)
No (No)
Unknown (Unknown)
Yes (Yes)
Bone Fracture Site, Other (specify) (Check)
No (No)
Unknown (Unknown)
Yes (Yes)
If sites other than specified, indicated site (bone
fracture site)
Date of Bone Fracture (yyyy-mmm-dd)
Osteoporosis
Has the patient had a diagnosis of osteoporosis?
Yes
12 / 15
Breast Cancer NCT00090974 On-Study - FORM 1 - ELIGIBILITY
CHECK LIST AND INITIAL EVALUATION MA.27 - 2067101v3.0
No
Date of diagnosis of osteoporosis (yyyy mmm dd)
Cardiovascular Morbidity
Has the patient suffered cardiovascular disease?
No (No)
Yes (Yes)
Cardiovascular Event
Myocardial infarction
Yes
No
Stroke/transient ischemic attack (TIA)
Yes
No
On-going angina (no surgical intervention)
No (No)
Unknown (Unknown)
Yes (Yes)
Angina requiring percutaneous transluminal
coronary angioplasty (PTCA)
Yes
No
Thromboembolic event
Yes
No
Other (specify), Cardiovascular Event
No (No)
Unknown (Unknown)
Yes (Yes)
please describe event (cardiovascular event) (If
other specified,)
Baseline Symptoms - Toxicity Status
CTC Adverse Event Term (Code/grade according
to NCI Common Toxicity Criteria, Version 2.0)
abdominal pain or cramping (abdominal
pain or cramping)
anorexia (anorexia)
arthralgia (joint pain) (arthralgia (joint
pain))
constipation (constipation)
cough (cough)
diarrhea (patients without colostomy)
(diarrhea (patients without colostomy))
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dizziness/lightheadedness
(dizziness/lightheadedness)
dyspepsia/heartburn
(dyspepsia/heartburn)
dyspnea (shortness of breath) (dyspnea
(shortness of breath))
edema (edema)
fatigue (lethary/malaise/asthenia)
(fatigue (lethary/malaise/asthenia))
flatulence (flatulence)
headache (headache)
hot flashes/flushes (hot flashes/flushes)
hypercholesterolemia
(hypercholesterolemia)
infection (without neutropenia) (infection
(without neutropenia))
nausea (nausea)
other (other)
rash/desquamation (rash/desquamation)
sweating (diaphoresis) (sweating
(diaphoresis))
vaginal bleeding (vaginal bleeding)
vomiting (vomiting)
CTC Adverse Event Term, Other (specify; other
CTC adverse event term)
CTC Adverse Event Category (Code/grade
according to NCI Common Toxicity Criteria,
Version 2.0)
cardiovascular (cardiovascular)
constitutional symptoms (constitutional
symptoms)
dermatology/skin (dermatology/skin)
endocrine (endocrine)
gastrointestinal (gastrointestinal)
hemorrhage (hemorrhage)
infection (infection)
metabolic (metabolic)
neurology (neurology)
pain (pain)
pulmonary (pulmonary)
CTC Adverse Event Grade (Code/grade
according to NCI Common Toxicity Criteria,
Version 2.0 0=None NA=Not Assessed)
Comments (Include all symptoms/findings
including disease related symptoms present at
baseline. All symptoms listed here must be
reported on subsequent forms.)
Concomitant Medications
Is the patient taking any medication?
Yes
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No
Agent Name (generic or trade name)
Aspirin (Aspirin)
Bisphosphonate (Bisphosphonate)
Calcium (Calcium)
Cardiovascular Medication
(Cardiovascular Medication)
Lipid Lowering Drug (Lipid Lowering
Drug)
Other Specify (Other (specify))
Agent Name
Indication (chronic low dose, prophylactic)
Continuing
No (No)
Unknown (Unknown)
Yes (Yes)
Other Major Medical Problems
Have there been any major medical problems?
Yes
No
Major Medical Problem (e.g. hypertension,
diabetes, previous cancers)
Comments
Comments (Include all symptoms/findings
including disease related symptoms present at
baseline. All symptoms listed here must be
reported on subsequent forms.)
Investigator Signature
Investigator Signature
Person Completing Form, Last Name
Person Completing Form, First Name
Date Form Originally Completed (yyyy mmm dd)
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Leukemia, Myelocytic, Acute null - - CTEP
Transplant CDEs - 2444533v1.0
CTEP Transplant CDEs
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=0B976B1B-
4AB1-64EE-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/6170
CTEP Transplant CDEs
Transplantation
Number of CD3-positive cells infused
Number of B cells (CD19) infused
Date of Admission for Transplant
Did acute Graft vs. Host Disease occur
No (no)
Not Evaluable (not evaluable)
Unknown (unknown)
Yes (yes)
Date of Resolution of Acute GVHD
Date of Onset of Acute GVHD
Number of T cells (CD3) infused
Did the patient receive protocol transplant?
Yes
No
Prior Transplant Thrombocytopenia Observed
Ind-3
No (No)
Unknown (Unknown)
Yes (Yes)
Prior Transplant Neutropenia Observed Ind-3
No (No)
Unknown (Unknown)
Yes (Yes)
Prior Transplant Lymphopenia Observed Ind-3
Yes
No
Prior Transplant Lymphocyte Infusion Last Date
Prior Transplant Lymphocyte Infusion Ind-2
No (No)
Yes (Yes)
Prior Transplant Last Date
Prior Transplant Date
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Prior Transplant Allogenic Administered Type
Mini (non-myeloablative) (mini (non-
myeloablative))
Myeloablative (myeloablative)
Unknown (unknown)
Prior Transplant Administered Type
Allogeneic (allogeneic)
Autologous (autologous)
Prior HDC/ASCT Adjuvant Administered Ind-3
No (No)
Unknown (Unknown)
Yes (Yes)
Prior BMSCT Administered Indicator
No (No)
Yes (Yes)
Prior BMSCT Administered Ind-3
No (No)
Unknown (Unknown)
Yes (Yes)
Prevention Treatment Transplant Graft Versus
Host Disease Text
Peripheral Blood Stem Cell Transplant Infusion
Date
Non-Protocol Transplant Administered Specify
Non-Protocol Therapy Concurrent Administered
HDC-ASCT Ind-3
No (No)
Unknown (Unknown)
Yes (Yes)
Non-Protocol BMT Performed Ind-3
No (No)
Unknown (Unknown)
Yes (Yes)
Lymphocyte Transplant Dendritic Infusion Dose
HLA-DrB1 Transplant Compatible Ind-3
No (No)
Unknown (Unknown)
Yes (Yes)
HLA-DQB1 Transplant Compatible Ind-3
No (No)
Unknown (Unknown)
Yes (Yes)
HLA-C Antigens Transplant Compatible Ind-3
No (No)
Unknown (Unknown)
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Yes (Yes)
HLA-B Antigen Transplant Compatible Ind-3
No (No)
Unknown (Unknown)
Yes (Yes)
HLA-A Antigen Transplant Compatible Ind-3
No (No)
Unknown (Unknown)
Yes (Yes)
Disease Stage Based on Bone Marrow Biopsy
Text Name
Cr On Bone Marrow Biopsy (CR on BM
Bx)
Minimal Disease On Bone Marrow
Biopsy (Minimal Disease on BM Bx)
Persistent Disease On Bone Marrow
Biopsy (Persistent Disease on BM Bx)
Recurrent Disease On Bone Marrow
Biopsy (Recurrent Disease on BM Bx)
Diagnosis Lymphoproliferative Present Transplant
Ind-3
No (No)
Unknown (Unknown)
Yes (Yes)
Chronic GVHD Transplant Treatment Ind-3
No (No)
Unknown (Unknown)
Yes (Yes)
Chronic Graft Versus Host Disease Transplant
Outcome Grade
Extensive (extensive)
Limited (limited)
Not Evaluated (not evaluated)
Unknown (unknown)
BMSCT Type
Bone Marrow Stem Cells Used For
Transplant Obtained From Recipient
Him/herself (Autologous bone marrow)
Peripheral Blood Stem Cells Used For
Transplant Obtained From Recipient
Him/herself (Autologous PBSC)
Bone Marrow Stem Cells Used For
Transplant Obtained From Antigen-
matched Sibling Or Family Member Of
Recipient (Bone marrow from matched
sibling or family member)
Bone Marrow Stem Cells Used For
Transplant Obtained From Antigen-
matched Individual Unrelated To
Recipient (Bone marrow from matched
unrelated donor)
Other Specify (Other, specify)
Peripheral Blood Stem Cells Used For
3 / 12
Leukemia, Myelocytic, Acute null - - CTEP Transplant CDEs -
2444533v1.0
Transplant Obtained From Antigen-
matched Sibling Or Family Member Of
Recipient (PBSC from matched sibling or
family member)
Peripheral Blood Stem Cells Used For
Transplant Obtained From Antigen-
matched Individual Unrelated To
Recipient (PBSC from matched
unrelated donor)
Autologous Transplant Prior Administered Count
Allogenic Transplant Prior Administered Count
Acute Graft Versus Host DIsease Transplant
Treatment Text
Acute Graft Versus Host Disease Transplant
Assessed Grade
0 (0)
1 (1)
2 (2)
3 (3)
4 (4)
Unknown (unknown)
Treatment to Transplant Time UOM
Days (days)
Months (months)
Weeks (weeks)
Treatment To Transplant Time Interval
Transplant T-Lymphocytesl Removed Type
Cd34 Selection (column) (CD34
selection (column))
Centrifugal Elutriation (centrifugal
elutriation)
Immunomagnetic Beads
(immunomagnetic beads)
Immunotoxin (immunotoxin)
Lectin Depletion (lectin depletion)
Monoclonal Antibody (monoclonal
antibody)
Other (other)
Transplant T-Lymphocyte Removed Specify
Transplant Symptomatic GVHD End Date
Transplant Received Ind-2
No (No)
Yes (Yes)
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Transplant Received Day Number
Transplant Received Date
Transplant Procedure Type
Allogeneic (allogeneic)
Autologous (autologous)
Cord Blood (cord blood)
Nonmyeloablative (nonmyeloablative)
Other (other)
Syngeneic (syngeneic)
Tandem (tandem)
Transplant Procedure Specify
Transplant Platelet Lab Declining Ind-3
No (No)
Unknown (Unknown)
Yes (Yes)
Transplant Platelet Engraftment Ind-3
No (No)
Unknown (Unknown)
Yes (Yes)
Transplant Platelet Engraftment Date
Transplant Peripheral Blood Mononuclear Cell
Infusion Dose
Transplant Patient Human Immunodeficiency
VirusAntibody Ind-3
No (No)
Unknown (Unknown)
Yes (Yes)
Transplant Patient Herpes Simplex Virus
Antibody Ind-3
No (No)
Unknown (Unknown)
Yes (Yes)
Transplant Patient Hepatitis C Virus Antibody Ind-
3
No (No)
Unknown (Unknown)
Yes (Yes)
Transplant Patient Hepatitis B Virus Antibody Ind-
3
No (No)
Unknown (Unknown)
Yes (Yes)
Transplant Patient Hepatitis B Surface Antigens
Ind-3
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No (No)
Unknown (Unknown)
Yes (Yes)
Transplant Patient Cytomegalovirus Antibody Ind-
3
No (No)
Unknown (Unknown)
Yes (Yes)
Transplant Patient Antibody Epstein-Barr Virus
Ind-3
No (No)
Unknown (Unknown)
Yes (Yes)
Transplant Neutrophil Lab Declining Ind-3
No (No)
Unknown (Unknown)
Yes (Yes)
Transplant Neutrophil Engraftment Ind-3
No (No)
Unknown (Unknown)
Yes (Yes)
Transplant Neutrophil Engraftment Date
Transplant Matching Method Type
Dna (DNA)
Other (other)
Serology (serology)
Transplant Matching Method Specify
Transplant Lymphocyte Lab Declining Ind-3
No (No)
Unknown (Unknown)
Yes (Yes)
Transplant Lymphocyte Infusion Total Dose
Transplant Lymphocyte Infusion Date
Transplant Lymphocyte Infusion Count
Transplant Lymphocyte Engraftment Ind-3
No (No)
Unknown (Unknown)
Yes (Yes)
Transplant Lymphocyte Engraftment Date
Transplant HLA Match Category
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Hla Match Of 10/10 (Match 10/10)
Hla Match Of 12/12 (Match 12/12)
Hla Match Of 6/6 (Match 6/6)
Hla Mismatch (Mismatch)
Transplant GVHD Severity Chronic Grade
Extensive (extensive)
Limited (limited)
Not Evaluated (not evaluated)
Unknown (unknown)
Transplant GVHD Severity Acute Grade
0 (0)
1 (1)
2 (2)
3 (3)
4 (4)
Unknown (unknown)
Transplant GVHD Involvement Acute Specify
Transplant Graft Versus Host Disease
Involvement Chronic Specify
Transplant Graft Versus Host Disease
Involvement Chronic Site
Constitutional (constitutional)
Esophagus (esophagus)
Eyes (eyes)
Hematologic (hematologic)
Intestinal (intestinal)
Kidney (kidney)
Liver (liver)
Lung (lung)
Mouth (mouth)
Musculoskeletal (musculoskeletal)
Other (other)
Skin (skin)
Spleen (spleen)
Vagina (vagina)
Transplant Graft Versus Host Disease
Involvement Acute Site
Constitutional (Constitutional)
Esophagus (Esophagus)
Eyes (Eyes)
Gastrointestinal Tract (gastrointestinal
tract)
Hematologic (Hematologic)
Intestinal (Intestinal)
Kidney (Kidney)
Liver (liver)
Lung (Lung)
Mouth (Mouth)
Musculoskeletal (Musculoskeletal)
Other (other)
Skin (Skin)
Spleen (Spleen)
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Vagina (Vagina)
Transplant Donor Significant Personal Medical
History Ind-3
No (No)
Unknown (Unknown)
Yes (Yes)
Transplant Donor Significant Diagnosis Date
Transplant Donor Rh Type
Negative (negative)
Positive (positive)
Transplant Donor Related Specify
Transplant Donor Recipient Relationship Type
Other Family Member (other family
member)
Related By Blood. (Related)
Sibling (sibling)
Unrelated (unrelated)
Transplant Donor Patient Relationship Type
Child (child)
Fraternal Twin (or Multiple) (fraternal twin
(or multiple))
Identical Twin (or Multiple) (identical twin
(or multiple))
Not Related (not related)
Other (other)
Parent (parent)
Sibling (sibling)
Unknown (unknown)
Transplant Donor Matching Type
Matched Sibling Or Family Member
(matched sibling or family member)
Matched Unrelated Donor (matched
unrelated donor)
Mismatched Sibling Or Family Member
(mismatched sibling or family member)
Mismatched Unrelated Donor
(mismatched unrelated donor)
Other (other)
Transplant Donor Matching Specify
Transplant Donor Lymphocyte Administered
Specify
Transplant Donor Lymphocyte Administered
Reason
Due To Relapse (due to relapse)
Other (other)
Planned Per Protocol (planned per
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protocol)
Transplant Donor Human Immunodeficiency Virus
Antibody Ind-3
No (No)
Unknown (Unknown)
Yes (Yes)
Transplant Donor Herpes Simplex Virus Antibody
Ind-3
No (No)
Unknown (Unknown)
Yes (Yes)
Transplant Donor Hepatitis C Virus Antibody Ind-
3
No (No)
Unknown (Unknown)
Yes (Yes)
Transplant Donor Hepatitis B Virus Antibody Ind-
3
No (No)
Unknown (Unknown)
Yes (Yes)
Transplant Donor Hepatitis B Surface Antigen
Ind-3
No (No)
Unknown (Unknown)
Yes (Yes)
Transplant Donor Gender Type
Female (female)
Male (male)
Unknown (unknown)
Transplant Donor Epstein-Barr Virus Antibody
Ind-3
No (No)
Unknown (Unknown)
Yes (Yes)
Transplant Donor Diagnostic History Type
Transplant Donor Cytomegalovirus Antibody Ind-
3
No (No)
Unknown (Unknown)
Yes (Yes)
Transplant Donor Birth Date
Transplant Donor Antibody Hepatitis B Surface
Antigen Ind-3
No (No)
Unknown (Unknown)
Yes (Yes)
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Transplant Donor ABO Status Blood Type
A (A)
Ab (AB)
B (B)
O (O)
Transplant Discharge Date
Transplant Delayed Failure Ind-3
No (No)
Unknown (Unknown)
Yes (Yes)
Transplant Delayed Failure Date
Transplant CTR Approval Ind
Transplant Conditioning Regimen Text Type
Myeloablative Conditioning
(Myeloablative)
Total Body Irradiation Based
Conditioning (TBI-Based)
Transplant Conditioning Regimen Indicator
No (No)
Yes (Yes)
Transplant Compatible Matching Specify
Transplant Compatible Match Type
Matched 1 Of 6 (matched 1 of 6)
Matched 2 Of 6 (matched 2 of 6)
Matched 3 Of 6 (matched 3 of 6)
Matched 4 Of 6 (matched 4 of 6)
Matched 5 Of 6 (matched 5 of 6)
Matched 6 Of 6 (matched 6 of 6)
Other (other)
Unknown (unknown)
Transplant Chronic GVHD Occurrence Ind
No (no)
Not Evaluable (not evaluable)
Unknown (unknown)
Yes (yes)
Transplant Chronic GVHD End Type
No (no)
No Symptoms But Patient Still Receiving
Therapy (no symptoms but patient still
receiving therapy)
Unknown (unknown)
Yes Off Medications For Cgvhd (yes off
medications for cGVHD)
Transplant Chronic GVHD End Date
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Transplant Chronic GVHD Begin Date
Transplant Child Donor Ind-3
No (No)
Unknown (Unknown)
Yes (Yes)
Transplant Cell Source Type
Bone Marrow (bone marrow)
Bone Marrow And Pbsc (bone marrow
and PBSC)
Cord Blood (cord blood)
Other (other)
Peripheral Blood Stem Cells (peripheral
blood stem cells)
Transplant Cell Source Specify
Transplant Cell Preparation Type
Cd34 Positive Selection To Purge
Malignant Cells (CD34 positive selection
to purge malignant cells)
Cryopreservation (cryopreservation)
Direct Purging Of Malignant Cells (not By
Cd34+ Selection) (direct purging of
malignant cells (not by CD34+ selection))
Other (other)
Plasma Depletion (plasma depletion)
Red Cell Depletion (red cell depletion)
T-cell Depletion (T-cell depletion)
Transplant Cell Preparation Specify
Transplant CD34+ Cell Infusion Dose
Stem Cell Transplant Received Ind-2
No (No)
Yes (Yes)
Stem Cell Transplant Engraftment Result Ind-3
No (No)
Unknown (Unknown)
Yes (Yes)
Stem Cell Transplant Aministered Ind-3
No (No)
Unknown (Unknown)
Yes (Yes)
Prior BMSCT Administered Count
Number of post-transplant RBC transfusions
Number of post-transplant platelet transfusions
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Non-Protocol HDC/ASCT Ind
No (NO)
Unknown (UNKNOWN)
Yes (YES)
Non-protocol Chemotherapy Transplant
Administered Ind-3
No (No)
Unknown (Unknown)
Yes (Yes)
Have you ever received a kidney transplantation?
Yes
No
Bone marrow transplant
Autologous Transplant Prior Administered Ind-3
Yes
No
Allogeneic Transplant Prior Administered Ind-3
Yes
No
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Lung Cancer null Follow-Up - E4599 Long-
Term Follow-up Form - 2036056v3.0
E4599 Long-Term Follow-up Form
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=A13401E7-
87EA-64C7-E034-080020C9C0E0
All rights reserved. Please visit https://medical-data-
models.org/forms/6171
E4599 Long-Term Follow-up Form
Follow-Up
Date of data transfer
Transfer Method
Specify other transfer method
Amended Data
Step No.
Patient Name
Particip. Group Protocol Number
Patient Study ID, Participating Group
Institution Name
Affiliate Name
Interval Report From Date
Interval Report To Date
Patient's Vital Status
Death Reason
Death Date/Last Contact Date
Death Reason, Specify
Cancer Follow-up Status Ind
Cancer Follow-up Status Date
Progression Ind
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Progression Date
Formal Progressive Disease Diagnosis
Progression Site
New Primary Cancer Ind
New Primary Site
Late Adverse Event Ind
Non protocol therapy prior to first progression
Second line therapy
Type of Second Line Therapy
Type of Second Line Chemotherapy
Comments
Comments2
New Primary Cancer Date
Non-Protocol Therapy Date, First
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Breast Cancer NCT00408408 Treatment - NSABP Protocol
B-40 - Treatment Form for Hormonal Therapy - 2511670v1.0
NSABP Protocol B-40 - Treatment Form for Hormonal
Therapy
A Randomized Phase III Trial of Neoadjuvant Therapy in
Patients With Palpable and Operable Breast Cancer
Evaluating the Effect on Pathologic Complete Response
(pCR) of Adding Capecitabine or Gemcitabine to Docetaxel
When Administered Before AC With or Without
Bevacizumab and Correlative Science Studies Attempting
to Identify Predictors of High Likelihood for pCR With Each
of the Regimens
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=1B7E215E-
B69B-0BD3-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/6174
NSABP Protocol B-40 - Treatment
Form for Hormonal Therapy
General information
Patient Initials (Last First Middle)*
NSABP Patient ID*
Institution/Affiliate*
Person Completing Form, Last Name*
Person Completing Form, First Name*
Person Completing Form, Phone*
Are data amended*
Yes
No
Date form completed*
Reason form completed*
Patient Will Not Begin Hormonal Therapy
(1)
Patient Received Less Than 5 Years Of
Hormonal Therapy, And Hormonal
Treatment Has Ended (2)
Patient Received 5 Years Of Hormonal
Therapy, And Hormonal Treatment Has
Ended (3)
Patient Received 5 Years Of Hormonal
Therapy, And Hormonal Treatment Will
Continue (4)
Hormone therapy
Agent Name*
Tamoxifen (1)
Aromatase Inhibitor (2)
Other (specify) (3)
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Other hormone therapy, specify*
Was agent administered*
Yes
No
Agent Start Date*
Agent End Date (Leave date boxes blank if agent
will continue beyond 5 years.)*
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Treatment Form for Hormonal Therapy - 2511670v1.0
Breast Cancer NCT00659373 Quality of Life - Quality of
Life Module for Trial 24-02 (Form 24-QLM) - 2073726v3.0
Quality of Life Module for Trial 24-02 (Form 24-QLM)
Brain Function in Premenopausal Women Receiving
Tamoxifen With or Without Ovarian Function Suppression
for Early-Stage Breast Cancer on Clinical Trial IBCSG-2402
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=B0EA5B57-
DF0D-6356-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/6175
Quality of Life Module for Trial 24-02
(Form 24-QLM)
Within The Last Two Weeks, How Severe
Have The Following Problems Been?
Being irritable
None (0)
Severe (1)
Sweats (including night sweats including night)
None (0)
Severe (1)
Vaginal discharge
None (0)
Severe (1)
Vaginal dryness
None (0)
Severe (1)
Vaginal itching / irritation
None (0)
Severe (1)
Sleep disturbance
None (0)
Severe (1)
Feeling dizzy
None (0)
Severe (1)
Headaches
None (0)
Severe (1)
Bone or joint pain
None (0)
Severe (1)
Troubled by weight gain
None (0)
Severe (1)
Loss of sexual interest
None (0)
Severe (1)
Overall, how much are you bothered by any
treatment related difficulties?
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Not At All (0)
Severely (1)
Have you been sexually active during the past six
months?
Yes
No
Did you have difficulties in becoming aroused?
None (0)
Severe (1)
Ccrr Module For Quality Of Life Module
For Trial 24-02 (form 24-qlm)
Patient ID Number (Study No.)
Patient Initials (f m fl sl)
Patient's Date of Birth (day)
Participating Center/Affiliate
Center Code
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Breast Cancer Pathology - ECOG MATERIAL
SUBMISSION FORM (E2100) - 2068992v3.0
ECOG MATERIAL SUBMISSION FORM (E2100)
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=AC221735-
7106-1535-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/6178
ECOG MATERIAL SUBMISSION
FORM (E2100)
General information
Patient's Name
ECOG Patient ID
ECOG Patient ID
ECOG Protocol No.
ECOG Protocol No.
Registration Step
Participating Group Protocol No.
Participating Group Patient ID
Institution/Affiliate
Part A
Date Material(s) collected (M D Y)
Date Material(s) sent to lab (M D Y)
Unnamed Question (Sample)
Sample Type #1 (Sample type #1)
Sample Type #2 (Sample type #2)
Sample Type #3 (Sample type #3)
Sample Type #4 (Sample type #4)
Tissue/material type
Bone Marrow Aspirate (bone marrow
aspirate)
Bone Marrow Biopsy (bone marrow
biopsy)
Karyotypes (karyotypes)
Other, Specify In Comments (other,
specify in Comments)
Peripheral Blood (peripheral blood)
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Plasma (plasma)
Serum (serum)
Skin Punch Biopsy (skin punch biopsy)
Sputum (sputum)
Urine (urine)
other, specify in Comments (tissue/material type)
Type of collection/stain/process
Blue (sodium Citrate) (blue (sodium
citrate))
Green Top (heparinized) (green top
(heparinized))
Other, Specify In Comments (other,
specify in Comments)
Pcli (PCLI)
Purple Top (edta) (purple top (EDTA))
Red Top (red top)
Rpmi (RPMI)
Slides/air Dried Smear (slides/air dried
smear)
Slides/fixed, Specify In Comments
(slides/fixed, specify in Comments)
Slides/h & E (slides/H & E)
Slides/unstained (slides/unstained)
Slides/wright Stain (slides/Wright stain)
Yellow Top (acd) (yellow top (ACD))
slides/fixed, specify in Comments (type of
collection/stain/process)
other, specify in Comments (type of
collection/stain/process)
Timing of material collection
Complete Remission/response
(complete remission/response)
Other, Specify In Comments (other,
specify in Comments)
Partial Remission/response (partial
remission/response)
Pre-study/baseline (pre-study/baseline)
Progression (progression)
Relapse (relapse)
other, specify in Comments (timing of material
collection)
Number of specimens (tubes, slides, etc.)
submitted (FOR LEUKEMIA STUDIES ONLY)
Diagnosis
acute lymphocytic leukemia (acute
lymphocytic leukemia)
acute myeloid leukemia (acute myeloid
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leukemia)
chronic lymphocytic leukemia (chronic
lymphocytic leukemia)
CML - blast cells (CML - blast cells)
CML - chronic phase (CML - chronic
phase)
MDS - myelodysplastic syndrome (MDS -
myelodysplastic syndrome)
other, specify in Comments (other,
specify in Comments)
unknown (unknown)
other, specify in Comments (diagnosis)
Absolute Blast count
Insititution contact name
Contact Phone Number (International)
Contact FAX Number (International)
Part B
Central Laboratory Name
Central Laboratory Contact Name
Unnamed Question (Sample)
Sample Type #1 (Sample type #1)
Sample Type #2 (Sample type #2)
Sample Type #3 (Sample type #3)
Sample Type #4 (Sample type #4)
Date Material(s) received at central lab (M D Y)
Condition of Material(s)
Not Usable As Received (not usable as
received)
Usable As Received (usable as received)
Lab Specimen ID Numbers
Aliquots of sample made
Yes
No
Contact Phone Number (International)
Contact FAX Number (International)
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Comments
Comments
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Eligibility AZD1152 and LDAC in AML
ODM derived from
http://clinicaltrials.gov/ct2/show/record/NCT00952588
All rights reserved. Please visit https://medical-data-
models.org/forms/6181
Eligibility AZD1152 and LDAC in
AML
Inclusion criteria
Provision of written informed consent*
Yes
No
Newly diagnosed male or female patients aged
60 and over*
Yes
No
De Novo or Secondary AML*
Yes
No
Not eligible for intensive induction with
anthracycline-based combination chemotherapy
as a result of at least one of the following: Age
>=75 years; Adverse cytogenetics, e.g., as
defined by the MRC Prognostic Groupings; WHO
performance status >2; Organ dysfunction arising
from significant co-morbidities not directly linked
to leukaemia*
Yes
No
Exclusion criteria
Participation in another clinical study in which an
investigational product was received within 14
days before the first dose in this study, or at any
time if the patient has not recovered from side-
effects associated with that investigational
product*
Yes
No
Administration of LDAC is clinically
contraindicated*
Yes
No
Patients with AML of FAB M3 classification Acute
Promyelocytic Leukaemia (APL)*
Yes
No
Patients with blast crisis of chronic myeloid
leukaemia*
Yes
No
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Breast Cancer NCT00016276 Pathology - CALGB
SPECIMEN ROUTING FORM PLASMA 2032060_v3_0
CALGB: SPECIMEN ROUTING FORM PLASMA
Combination Chemotherapy, Surgery, and Radiation
Therapy With or Without Dexrazoxane and Trastuzumab in
Treating Women With Stage III or Stage IV Breast Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=9E35395C-
82EA-227A-E034-080020C9C0E0
All rights reserved. Please visit https://medical-data-
models.org/forms/6182
CALGB: SPECIMEN ROUTING
FORM PLASMA
General information
CALGB Form*
CALGB Study No*
CALGB Patient ID*
Amended data?*
Yes
No
Patient's Name*
Participating Group*
Patient Hospital Number*
Participating Group Protocol No.*
Main Member Institution/Adjunct*
Participating Group Patient No.*
To Be Completed By Submitting Institution
Blood Sample (plasma)*
Date plasma specimen collected*
CALGB Treatment Study*
Does specimen accompany this form? (If yes,
complete the remainder of this form.)*
Yes
No
If no, specify reason*
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Number of tubes submitted*
Date sample sent*
Time Period Specimen Collected (mark one with
an X)*
At Relapse/progression (At
Relapse/Progression)
During Follow-up, No. Therapy (During
Follow-Up, No. Therapy)
During Initial Treatment (During Initial
Treatment)
Pre-treatment (Pre-treatment)
Responsible treating physician*
Phone Number to be used in event of sample
problems*
Completed By*
Date Completed*
To Be Completed By Receiving
Institution/laboratory
Date sample received*
Sample Condition (mark one with an X)*
Missing (0)
Okay (1)
Damaged (2)
Insufficient Amount (3)
Damaged But Stored (4)
Thawed But Stored (5)
Improperly Stored (6)
Sample ID no.*
Number of Aliquots*
Average aliquot volume (cc)*
Sample received by*
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ROUTING FORM PLASMA 2032060_v3_0
Breast Cancer NCT00024102 Transmittal - CALGB 49907
CAPECITABINE DRUG SUPPLY RECORD FORM 2044684_v3_0
CALGB: 49907 CAPECITABINE DRUG SUPPLY RECORD
FORM
Comparison of Combination Chemotherapy Regimens in
Treating Older Women Who Have Undergone Surgery for
Breast Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=A50CE624-
6F5F-37E3-E034-080020C9C0E0
All rights reserved. Please visit https://medical-data-
models.org/forms/6183
CALGB: 49907 CAPECITABINE
DRUG SUPPLY RECORD FORM
Unbenannt1
CALGB Formular*
CALGB Studiennummer*
CALGB Patienten-ID*
Letzter Tag des Reporting-Zyklus (M)*
Geändert Daten?*
ja (Yes)
Name des Patienten*
Teilnehmende Gruppe*
Krankenhaus-Nummer des Patienten*
Teilnehmende Gruppen Protokoll Nr.*
Hauptmitglieds Institution*
Teilnehmende Patientengruppen Nr.*
Unbenannt3
Täglich Capecitabin-Dosis (mg)*
Anzahl der verschrieben 500 mg-Tabletten, die
jeden Tag genommen werden*
Anzahl der ausgegeben 500 mg-Tabletten*
Datum und Uhrzeit, an dem das elektronische
Gerät an die Ampulle platziert wurde (
Verwenden Sie ein Militär-24 Stunden-Uhr)*
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Name der Person, die die Ampulle füllte (
Verwenden Sie ein militärischer -24 Stunden-
Uhr)*
Datum und Uhrzeit der Tabletten Zählung*
Wie viele Tabletten zu 500 mg gingen zurück
(exakte Tablettenanzahl)*
Datum und Uhrzeit, der Entfernung des
elektronischen Geräts von der Ampulle ( mit
einem militärischen -24 Stunden-Uhr)*
Name der Person, die die Tablettenrückgabe
gezählt hat*
Ausgefüllt von (Drucken oder schreiben des
Namens)*
Abschlussdatum (M)*
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Eligibility NCT00857012 Breast Cancer
Anastrozole Therapy (COMPACT)
Arimidex: Compliance and Arthralgias in Clinical Therapy
(COMPACT): An in Practice Assessment of Arthralgias and
Related Costs as Well as Compliance in the First Year of
Anastrozole Therapy
ODM derived from
http://clinicaltrials.gov/show/NCT00857012
All rights reserved. Please visit https://medical-data-
models.org/forms/6185
Eligibility NCT00857012 Breast
Cancer Anastrozole Therapy
(COMPACT)
Inclusion Criteria
age at least 18 Years*
Yes
No
Postmenopausal women aged 18 years or older.
Postmenopause is defined as Natural
menopause with menses >1 year ago or Serum
FSH (> 20 IU/ l), and E2 levels in the
postmenopausal range or patients who had
bilateral oophorectomy*
Yes
No
Histologically / cytologically confirmed primary
diagnosis of early breast cancer (M0) with
hormone sensitive tumour (ER+ve and/or
PgR+ve)*
Yes
No
Patients, who underwent breast cancer surgery
and, if appl. radiation therapy and/or neo/adjuvant
chemotherapy and have taken adjuvant
endocrine treatment with anastrozole (upfront or
following two to three years of tamoxifen) min 3
max 6 months*
Yes
No
In case of a previous therapy with tamoxifen
(switch-therapy), duration of tamoxifen treatment
for at least two and up to three years.*
Yes
No
Exclusion Criteria
Patients with severe renal function disorders
(Creatinine clearance < 20 ml/min or Patients
with moderate or severe disorders of hepatic
function*
Yes
No
Concomitant treatment with drugs known to affect
sex hormonal status and tamoxifen*
Yes
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No
Patients with ductal carcinoma in situ (DCIS)
without primary diagnosis of early breast cancer
(M0)*
Yes
No
Evidence of any significant clinical disorder or
laboratory finding which in the opinion of the
investigator, makes it undesirable for the patient
to participate in the program*
Yes
No
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Lung cancer Nontarget Lesions
Supplemental Form (ECOG 4599)
ECOG 4599 Nontarget Lesions Supplemental Form
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=A13424B4-
AED3-672E-E034-080020C9C0E0
All rights reserved. Please visit https://medical-data-
models.org/forms/6186
Lung cancer Nontarget Lesions
Supplemental Form (ECOG 4599)
General information
Date of data transfer*
Transfer Method*
Amended Data Ind*
Amended Data Ind*
Patient Name*
Particip. Group Protocol Number*
Patient Study ID, Participating Group*
Institution Name*
Affiliate Name*
Cycle*
Amended Data Ind*
Amended Data Ind*
Comments*
Lesion
Lesion Number*
Lesion Site*
Lesion Site Code*
Lesion Evaluation Method*
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Lesion Evaluation Date*
Follow Up Status of Lesions*
Cytology Result*
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Lung Cancer null Treatment - ECOG Non-
Protocol Therapy Form - 2036091v3.0
ECOG Non-Protocol Therapy Form
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=A134152B-
EFC9-660E-E034-080020C9C0E0
All rights reserved. Please visit https://medical-data-
models.org/forms/6187
ECOG Non-Protocol Therapy Form
General information
Date of data transfer
Transfer Method
Specify other transfer method
Patient Name
Particip. Group Protocol Number
Patient Study ID, Participating Group
Step Number
Institution Name
Affiliate Name
Amended Data Ind
Amended Data Ind
Non-Protocol Chemotherapy Ind
Non-Protocol HDC/ASCT Ind
Non-Protocol Hormonal Therapy Ind
Non-Protocol Therapy Date, First
Non-Protocol RT Ind
Other Non-Protocol Therapy Name
Non-Protocol Immunotherapy Ind
Other Non-Protocol Therapy Ind
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Step No.
Comments
Comments
Non-Protocol Surgery performed
Yes
No
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Lung Cancer null On-Study - E4599 On-
Study Form - 2036140v3.0
E4599 On-Study Form
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=A1346A5B-
91C6-6A0E-E034-080020C9C0E0
All rights reserved. Please visit https://medical-data-
models.org/forms/6188
E4599 On-Study Form
On-study form
Date of data transfer
Transfer Method
Specify other transfer method
Patient Name
Particip. Group Protocol Number
Patient Study ID, Participating Group
Institution Name
Affiliate Name
Patient Height
Body Surface Area
Patient Weight
Performance Status
Urine dipstick result
Date of urine dipstick
Date of 24 hour urine for protein
Weight Loss Prior Six Months
Protein in urine (mg/24hr)
Stage Grouping
Histologic Type
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Histologic Type, Other Name
Disease Assessment, Measurable Ind
Disease Assessment, Non-measurable Ind
Metastatic Site
Metastatic Site Indicator
Pleural Effusion Ind
Pleural Effusion, Malignant Ind
Lab Unit Type
Assessment Type, Target
Lab, Chemistry, Albumin
Date Albumin Obtained
LDH LLN
Lab, Chemistry, Lactate Dehydrogenase
Date LDH Obtained
Prior Surgery Ind
Prior Chemotherapy Ind
Prior RT Ind
Prior other systemic therapy
Yes
No
Prior RT End Date
Other systemic therapy, specify
Date of last dose
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Comments
Comments2
Patient Race/Ethnicity
Payment Method
Amended Data Ind
Step Number
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AIDS and Cancer Specimen Resource (ACSR)
Procurement Form (F37) 3369057v1.0
AIDS and Cancer Specimen Resource (ACSR)
Procurement Form (F37)
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=
All rights reserved. Please visit https://medical-data-
models.org/forms/6198
FP.0000
Header Module
Visit number*
Specimen Procurement
Date Specimen Obtained (mm/dd/yyyy)*
Specimen(s) obtained for donation to ACSR*
Yes
No
Specimen Type (check all that apply)*
Peripheral Blood (Blood)
Other (Other)
Pbmc (peripheral Blood Mononuclear
Cells) (PBMC)
Plasma (Plasma)
Serum (Serum)
Tissue (Tissue)
Other specify*
ACSR site the specimen(s) shipped to*
Gwu (GWU)
Jhu (JHU)
Other (Other)
Ucsf (UCSF)
Other, specify*
If specimens were not obtained for ACSR, please
indicate reason*
Other (Other)
Patient Had Previously Donated
Specimen To Acsr (Patient had
previously donated specimen to ACSR)
Patient Refused To Give Informed
Consent For Acsr Specimen Donation
(Patient refused to give informed consent
for ACSR specimen donation)
Patient Was Not Asked To Consider Acsr
Specimen Donation (Patient was not
asked to consider ACSR specimen
donation)
Other, specify*
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Date Specimen Obtained (mm/dd/yyyy)*
Study Coordinator
Study Coordinator's name*
E-mail*
Phone Number (xxx-xxx-xxxx)*
Comments
Comments*
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AIDS and Cancer Specimen Resource (ACSR) Procurement Form (F37)
3369057v1.0
AMC-078 HIV T-Cell Laboratory Values
Form (CD4) - 3369124v1.0
AMC-078 HIV T-Cell Laboratory Values Form (CD4)
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=
All rights reserved. Please visit https://medical-data-
models.org/forms/6202
HIV T-Cell Laboratory Values Form
CD4 (AMC-078)
Header Module
Visit number*
Sequence number*
Date of Evaluation (mm/dd/yyyy)*
T-cell Laboratory Values
T-Helper CD4+ %*
T-Helper CD4+ absolute count*
T-Suppressor CD8+ %*
T-Suppressor CD8+ absolute count*
Other, specify*
Percent Positive Lymphocytes*
Absolute Count*
Comments
Comments*
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ON-STUDY FORM (CALGB 49907)
CALGB: 49907 ON-STUDY FORM
Comparison of Combination Chemotherapy Regimens in
Treating Older Women Who Have Undergone Surgery for
Breast Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=A50D7D2E-
A557-3317-E034-080020C9C0E0
All rights reserved. Please visit https://medical-data-
models.org/forms/6211
ON-STUDY FORM (CALGB 49907)
Header
CALGB Form*
CALGB Study No*
CALGB Patient ID*
Amended data?*
Yes (Yes)
Patient's Name*
Participating Group*
Patient Hospital Number*
Participating Group Protocol No.*
Main Member Institution/Adjunct*
Participating Group Patient No.*
Surgical Procedures
First positive biopsy date (M)*
Most extensive primary surgery (mark one with
an X)*
Mastectomy, Nos (Mastectomy, NOS)
Partial
Mastectomy/lumpectomy/excisional
Biopsy (Partial
mastectomy/lumpectomy/excisional
biopsy)
Date of most extensive primary surgery (if
required, used date of last re-excision)*
Sentinel node biopsy?*
No (No)
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Yes (Yes)
Sentinel node biopsy date (M)*
Sentinel node biopsy results (per protocol)*
Negative (Negative)
Positive (Positive)
Was axillary dissection performed?*
No (No)
Yes (Yes)
Date of axillary dissection (M)*
Total number of lymph nodes examined (if
sentinel node biopsy and axillary node dissection
were performed, enter the total number of nodes
examined)*
Laboratory
Granulocytes*
Total bilirubin (mg/dl)*
Creatinine (mg/dl)*
Platelet count*
Bilirubin upper limit of institutional laboratory
normal (mg/dl)*
Calculated creatinine clearance (mL/min)*
% LVEF*
% Lower limit of institutional normal LVEF*
Pathology
Tumor laterality (mark one with an X)*
Bilateral (Bilateral)
Left (Left)
Right (Right)
Receptor status, ER (If measured in fmols/mg
cytosol protein >=10 is positive.  If other
measures are used apply institutional standards;
borderline results should be reported as
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positive)*
Negative (Negative)
Positive (Positive)
Receptor status, PgR*
Negative (Negative)
Positive (Positive)
Pathologic primary tumor size (cm)*
Histologic grade (combined histologic grade is
used according to SRE/Elston classification)*
Poorly Differentiated (High)
Moderately Differentiated (Intermediate)
Well Differentiated (Low)
Total number of positive lymph nodes (If sentinel
node biopsy and axillary node dissection were
performed, enter the sum of positive nodes)*
T (TNM classification)*
N (TNM classification)*
M (TNM classification) (Prior Systemic Therapy)*
Prior breast cancer prevention therapy?*
No (No)
Yes (Yes)
If Yes, what type (prior breast cancer prevention
therapy) (mark all that apply with an X)*
Other, Specify (Other, specify)
Raloxifene (Raloxifene)
Tamoxifen (Tamoxifen)
Other, specify (prior breast cancer therapy)*
Completed By (Print or Type Name)*
Date Completed*
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Cognitive/Functional Effects NCT01372774 Eligibility - N107C Pre-
Registration (Step 1) Form and Eligibility Checklist - 3226376v1.0
N107C Pre-Registration (Step 1) Form and Eligibility
Checklist
Stereotactic Radiosurgery or Whole-Brain Radiation
Therapy in Treating Patients With Brain Metastases That
Have Been Removed By Surgery
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=A06D80B4-
4143-B9BC-E040-BB89AD437EB8
All rights reserved. Please visit https://medical-data-
models.org/forms/6234
N107C Pre-Registration (Step 1)
Form and Eligibility Checklist
Required Characteristics
Four or fewer brain metastases (as defined on
the preoperative MRI brain scan) and status post
resection of one of the lesions
No (No)
Yes (Yes)
Pathology from the resected brain metastasis
must be consistent with a non-central nervous
system primary site (NOTE: Patients with or
without active disease outside the nervous
system are eligible including patients with
unknown primaries, as long as the pathology
from the brain is consistent with a non-central
nervous system primary site.)
No (No)
Yes (Yes)
Any unresected lesions must measure <=3.0 cm
in maximal extent on the contrasted preoperative
treatment MRI brain scan obtained <=35 days
prior to pre-registration (see Magnetic
Resonance Imaging Guidelines, Section 11.2).
The unresected lesions will be treated with SRS
as outlined in the treatment section (Section 7.0)
of the protocol. (NOTE: The metastases size
restriction does not apply to the resected brain
metastasis; with resected brain metastasis only
surgical cavity size determines eligibility see
3.114)
No (No)
Yes (Yes)
Resection cavity must measure <5.0 cm in
maximal extent on the postoperative MRI (or CT)
brain scan obtained <=35 days prior to pre-
registration (NOTE: It is permissible for the
resection of a dominant brain metastasis to
include a smaller "satellite" metastasis as long as
the single resection cavity is less than the
maximum size requirements.)
No (No)
Yes (Yes)
All standard tumor-staging procedures necessary
to define baseline extracranial disease status
completed <=42 days prior to pre-registration
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No (No)
Yes (Yes)
Ability to be treated with either a gamma knife or
a linear accelerator-based radiosurgery system
No (No)
Yes (Yes)
Age >= 18 years
No (No)
Yes (Yes)
Age (=)
Willing and able to complete neurocognitive
examination without assistance
No (No)
Yes (Yes)
Willing and able to complete QOL by themselves
or with assistance (see Section 4.0)
No (No)
Yes (Yes)
ECOG performance status (PS) 0, 1, or 2
No (No)
Yes (Yes)
ECOG Performance Status (=)
Fully Active, Able To Carry On All Pre-
disease Performance Without
Restriction. (0)
Restricted In Physically Strenuous
Activity But Ambulatory And Able To
Carry Out Work Of A Light Or Sedentary
Nature, E.g., Light Housework, Office
Work. (1)
Ambulatory And Capable Of All Selfcare
But Unable To Carry Out Any Work
Activities. Up And About More Than 50%
Of Waking Hours. (2)
SRS facility is Radiological Physics Center (RPC)
approved (see Section 6.24)
No (No)
Yes (Yes)
The Neurocognitive Testing examiner must have
credentialing confirming completion of the
neurocognitive testing training (see Section 6.25)
No (No)
Yes (Yes)
Provide informed written consent
No (No)
Yes (Yes)
Willing to provide blood and urine samples for
correlative research purposes (see Sections 6.0
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No (No)
Yes (Yes)
Pre-registration Exclusion Criteria
Any of the following: Pregnant women Nursing
women Men or women of childbearing potential
who are unwilling to employ adequate
contraception throughout the study and for men
for up to 3 months after completing treatment
No (No)
Yes (Yes)
Prior cranial RT (radiation therapy)
No (No)
Yes (Yes)
Inability to complete an MRI with contrast of the
head
No (No)
Yes (Yes)
Known allergy to gadolinium
No (No)
Yes (Yes)
Planned cytotoxic chemotherapy during the SRS
and WBRT
No (No)
Yes (Yes)
Primary germ cell tumor, small cell carcinoma, or
lymphoma
No (No)
Yes (Yes)
Widespread definitive leptomeningeal metastasis
No (No)
Yes (Yes)
A brain metastasis that is located <=5 mm of the
optic chiasm or within the brainstem
No (No)
Yes (Yes)
Pre-registration Check
Consent form signed and dated
No (No)
Yes (Yes)
Date Informed Consent Signed (mm/dd/yyyy)
Authorization for use and disclosure of protected
health information signed and dated (Non-USA
institution only check NA)
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Not Applicable (NA)
No (No)
Yes (Yes)
Date of authorization (mm/dd/yyyy)
A mandatory correlative research component for
blood and urine is part of this study; the patient
will be automatically registered onto this
component (see Sections 3.119f and 14.0)
No (No)
Yes (Yes)
Pre-registration tests/procedures must be
completed <=14 days prior to pre-registration
(see Section 4.0)
No (No)
Yes (Yes)
Earliest pre-registration test date (mm/dd/yyyy
NOTE:  The earliest pre-registration test date
must be less than or equal to the latest pre-
registration test date.  The above dates DO NOT
include footnote 9 of the test schedule that reads
"All standard tumor-staging procedures
necessary to define baseline extracranial status
as deemed appropriate by the treating oncology
physician completed <=42 days prior to pre-
registration.")
Latest pre-registration test date (mm/dd/yyyy)
All required baseline symptoms (see Section
10.3) must be documented and graded
No (No)
Yes (Yes)
A radiation oncologist has seen the patient and
confirms the patient is a suitable candidate for
this study
No (No)
Yes (Yes)
Blood/urine kits available on site
No (No)
Yes (Yes)
Patient Questionnaire Booklet-Quality of Life
(QOL) and Patient and Examiner Questionnaire
Booklet-Neurocognitive Evaluations are available
on site; copies are not acceptable for this
submission
No (No)
Yes (Yes)
Ran
Patient has given permission to store and use
4 / 5
Cognitive/Functional Effects NCT01372774 Eligibility - N107C Pre-
Registration (Step 1) Form and Eligibility Checklist - 3226376v1.0
his/her blood samples for use in future research
to learn about, prevent, or treat cancer
No: C49487 (No)
Yes: C49488 (Yes)
Patient has given permission to store and use
his/her blood samples for use in future research
to learn about, prevent, or treat other health
problems (for example: diabetes, Alzheimer's
disease, or heart disease.)
No (No)
Yes (Yes)
Patient has given permission for NCCTG to give
his/her stored blood samples for use in future
research to outside researchers
No (No)
Yes (Yes)
Patient has given permission to store and use
his/her urine samples for use in future research to
learn about, prevent, or treat cancer
No (No)
Yes (Yes)
Patient has given permission to store and use
his/her urine samples for use in future research to
learn about, prevent, or treat other health
problems (for example: diabetes, Alzheimer's
disease, or heart disease.)
No (No)
Yes (Yes)
Patient has given permission for NCCTG to give
his/her stored urine samples for use in future
research to outside researchers
No (No)
Yes (Yes)
Patient has given permission to store and use
his/her tissue samples for use in future research
to learn about, prevent, or treat cancer
No (No)
Yes (Yes)
Patient has given permission to store and use
his/her tissue samples for use in future research
to learn about, prevent, or treat other health
problems (for example: diabetes, Alzheimer's
disease, or heart disease.)
No (No)
Yes (Yes)
Patient has given permission for NCCTG to give
his/her stored tissue samples for use in future
research to outside researchers
No (No)
Yes (Yes)
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Cognitive/Functional Effects NCT01279681 Eligibility - N0949
Registration Form and Eligibility Checklist - 3143440v1.0
N0949 Registration Form and Eligibility Checklist
Combination Chemotherapy Plus Bevacizumab With or
Without Oxaliplatin in Treating Older Patients With
Metastatic Colorectal Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=9156A820-
0337-BDA0-E040-BB89AD435144
All rights reserved. Please visit https://medical-data-
models.org/forms/6236
N0949 Registration Form and
Eligibility Checklist
Required Characteristics
Age >= 70 years (age 70-74 years limited to no
greater than 25% of the whole study population
and eligibility will be modified at the time this
benchmark is reached)
No (no)
Yes (yes)
Patients must have metastatic colorectal cancer
that has been histologically or cytologically
confirmed. Confirmation may be from either the
primary tumor or a metastasis
No (No)
Yes (Yes)
Eastern Cooperative Oncology Group
Performance Status (ECOG PS) 0, 1 or 2
No (No)
Yes (Yes)
ECOG Performance Status
Fully Active, Able To Carry On All Pre-
disease Performance Without
Restriction. (0)
Restricted In Physically Strenuous
Activity But Ambulatory And Able To
Carry Out Work Of A Light Or Sedentary
Nature, E.g., Light Housework, Office
Work. (1)
Ambulatory And Capable Of All Selfcare
But Unable To Carry Out Any Work
Activities. Up And About More Than 50%
Of Waking Hours. (2)
The following laboratory values obtained <=14
days prior to randomization
No (No)
Yes (Yes)
Earliest laboratory test date
Latest laboratory test date
Absolute neutrophil count (ANC) >=1,500/mm^3
No (No)
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Yes (Yes)
Absolute neutrophil count (>=1500)
Peripheral platelet count (PLT) >=100,000/mm^3
No (no)
Yes (yes)
Peripheral Platelet Count (>=100000)
Hemoglobin >9.0 g/dL (HgB)
No (No)
Yes (Yes)
Hemoglobin (>9.0)
Total bilirubin <=1.5 x upper limit of normal (ULN)
No (no)
Yes (yes)
Total Bilirubin (<=1.5 x ULN - )
Total Bilirubin ULN
Aspartate transaminase (AST) <=2.5 x ULN (<=5
x ULN for patients with liver involvement)
No (no)
Yes (yes)
Aspartate transaminase (If Yes, <=5 x ULN - If
No, <=2.5 x ULN)
Aspartate transaminase ULN
Alkaline phosphatase <=3 x upper limit of normal
(ULN)  (<=5 x ULN for patients with liver
involvement)
No (no)
Yes (yes)
Is there liver involvement (This question can be
answered yes or no.)
No (No)
Yes (Yes)
Is there liver involvement (This question can be
answered yes or no.)
No (No)
Yes (Yes)
Alkaline Phosphatase (If yes, <=5 x ULN - If no,
<=3 x ULN)
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Alkaline Phosphatase ULN
Creatinine <= 1.5 x ULN
No (No)
Yes (Yes)
Creatinine (<=1.5 x ULN)
Creatinine ULN
INR <1.5 x upper limit of normal (ULN) unless
patients are receiving anti-coagulation therapy.
Patients receiving prophylactic anti-coagulation
therapy with an agent such as warfarin or heparin
are allowed to participate if INR <=3.0
No (no)
Yes (yes)
Patient receiving anti-coagulation therapy (This
question may be answered yes or no.)
No (No)
Yes (Yes)
INR (If yes, <= 3.0 x ULN - If no, <1.5 x ULN)
INR ULN
UPC ratio <1 or urine dipstick <2+ (NOTE: Urine
protein must be screen by urine analysis for Urine
Protein Creatinine UPC ratio or by dipstick. For
UPC ratio >=1.0 or urine dipstick >=2+, 24-hour
urine protein must be obtained and the level
should be <1000 mg)
No (No)
Yes (Yes)
Life expectancy >=3 months
No (No)
Yes (Yes)
Ability to complete questionnaire(s) by
themselves or with assistance
No (No)
Yes (Yes)
Provide informed written consent
No (No)
Yes (Yes)
Willing to provide mandatory blood samples for
correlative research purposes (see Sections 6.0
and 14.0)
No (No)
Yes (Yes)
Exclusion Criteria - All Responses In
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Section Below Must Be "no."
The following because this study involves agents
whose genotoxic, mutagenic and teratogenic
effects on the developing fetus and newborn are
unknown:  Men of childbearing potential who are
unwilling to employ adequate contraception
No (No)
Yes (Yes)
Co-morbid systemic illnesses or other severe
concurrent disease which, in the judgment of the
investigator, would make the patient inappropriate
for entry into this study or interfere significantly
with the proper assessment of the safety and
adverse events of the prescribed regimens
No (No)
Yes (Yes)
Immunocompromised patients (other than that
related to the use of corticosteroids) including
patients known to be HIV positive with CD4<100
cells/uL
No (No)
Yes (Yes)
Uncontrolled intercurrent illness including, but not
limited to, ongoing or active infection,
symptomatic congestive heart failure, unstable
angina pectoris, cardiac arrhythmia, or psychiatric
illness/social situations that would limit
compliance with study requirements
No (No)
Yes (Yes)
Receiving any other investigational agent which
would be considered as a treatment for the
primary neoplasm
No (No)
Yes (Yes)
Other active malignancy <=3 years prior to
randomization. EXCEPTIONS: Non-melanotic.
Skin cancer or carcinoma-in-situ of the cervix.
(NOTE: If there is a history of prior malignancy,
patient must not be receiving other specific
treatment other than hormonal therapy for this
prior cancer.)
No (No)
Yes (Yes)
Prior chemotherapy, radiation therapy,
immunotherapy, or biologic therapy for recurrent
or metastatic colorectal cancer (NOTE: Prior
chemotherapy or radiotherapy is permitted if they
had been administered as adjuvant or
neoadjuvant therapy and a complete surgical
resection of the original colorectal cancer had
been achieved.)
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No (No)
Yes (Yes)
Progressive disease <=12 months of completing
oxaliplatin-containing adjuvant therapy
No (No)
Yes (Yes)
Prior radiation to >30% of the bone marrow at
any time
No (No)
Yes (Yes)
Calculated creatinine clearance >=60 mL/minute
(NOTE: If calculated creatinine clearance does
not meet eligibility requirement, a 24-hour urine
can be collected for a creatinine clearance, and
the patient can be enrolled if measured creatinine
clearance >=60 mL/minute.)
No (No)
Yes (Yes)
Known central nervous system or brain
metastasis that are either symptomatic or
untreated (Note: If a patient has a resection of
the metastasis and is no longer symptomatic, the
patient is eligible for the study.  NOTE: Patients
with neurological symptoms must undergo a CT
scan/MRI of the brain to exclude brain
metastasis.)
No (No)
Yes (Yes)
New York Heart Association (NYHA)
classification III or IV congestive heart failure
No (No)
Yes (Yes)
Inadequately controlled hypertension (systolic
blood pressure of >150 mmHg or diastolic
pressure >100 mmHg on anti-hypertensive
medication)
No (No)
Yes (Yes)
Core biopsy or other minor surgical procedures
<=7 days prior to randomization
No (No)
Yes (Yes)
Active or recent Hemoptysis  (>=1/2 teaspoon of
bright red blood per episode) <=30 days prior to
randomization
No (No)
Yes (Yes)
History of abdominal fistula, gastrointestinal
perforation, or intra-abdominal abscess <=6
months prior to randomization
No (No)
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Yes (Yes)
Serious, non-healing wound, active ulcer, or
untreated bone fracture (NOTE: Patients with
fractures secondary to metastatic disease are
eligible after appropriate radiotherapy.)
No (No)
Yes (Yes)
History of hypertensive crisis or hypertensive
encephalopathy
No (No)
Yes (Yes)
Major surgical procedures, open biopsy or
significant traumatic injury <=28 days prior to
randomization or anticipation of need for elective
or planned major surgical procedure during the
course of the study
No (No)
Yes (Yes)
Patient has experienced any arterial
thromboembolic events, included but not limited
to myocardial infarction, stroke, transient
ischemic attack (TIA), cerebrovascular accident,
or unstable angina <=6 months prior to
randomization or congestive heart failure
requiring use of ongoing maintenance therapy for
life-threatening ventricular arrhythmias
No (No)
Yes (Yes)
Significant vascular disease (e.g., aortic
aneurysm, aortic dissection) or recent peripheral
arterial thrombosis <=6 months prior to
randomization
No (No)
Yes (Yes)
Evidence or history of bleeding diathesis (greater
than normal risk of bleeding) or coagulopathy (in
the absence of therapeutic anticoagulation), any
hemorrhage/bleeding event >Grade 3 <=4 weeks
prior to randomization. Patients with full-dose
anticoagulants are eligible provided the patient
has been on a stable dose, at least 2 weeks, of
low molecular weight heparin or warfarin and has
an INR range 2-3. Aspirin doses >325 daily are
not allowed.
No (No)
Yes (Yes)
Known hypersensitivity to any of the components
of 5-fluorouracil/leucovorin, capecitabine,
oxaliplatin, or bevacizumab
No (No)
Yes (Yes)
Clinically significant peripheral neuropathy at the
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time of randomization (defined in the NCI
COmmon Terminology Criteria for Adverse Event
[CTCAE} v4.0 as >=2 neurosensory or
neuromotor toxicity)
No (No)
Yes (Yes)
Pre-registration Check
Consent form signed and dated
No (No)
Yes (Yes)
Date Informed Consent Signed
Authorization for use and disclosure of protected
health information signed and dated (If not a USA
institution check NA)
Not Applicable (NA)
No (No)
Yes (Yes)
Date of authorization (If a USA institution)
A mandatory correlative research component for
blood is part of this study, the patient will be
automatically registered onto this component
(see Sections 3.18 and 14.0)
No (No)
Yes (Yes)
Treatment on this protocol must commence at the
accruing membership under the supervision of a
CTSU, NCCTG, or CALGB member physician
No (No)
Yes (Yes)
Treatment cannot begin prior to randomization
and must begin <=14 days and after submission
of Physician Fluoropyrimidine Treatment Decision
Form (NOTE: The Physician Fluoropyrimidine
Treatment Decision Form must be submitted <=7
days after patient randomization.)
No (No)
Yes (Yes)
Pretreatment tests/procedures (see Section 4.0)
must be completed <=14 days prior to
randomization (see Section 4.0)
No (No)
Yes (Yes)
Earliest pretreatment test/procedure date
Latest pretreatment test/procedure date
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All required baseline symptoms (see Section
10.3) must be documented and graded
No (No)
Yes (Yes)
Blood draw kit is available on site
No (No)
Yes (Yes)
Patient Questionnaire Booklets and Research
Team Questionnaire Booklets are available on
site; copies are not acceptable for this
submission
No (No)
Yes (Yes)
Ran
Patient has given permission to give his/her
tissue sample(s) to NCCTG for research testing
planned as part of this study
No (No)
Yes (Yes)
Patient has given permission to store and use
his/her sample(s) for use in future research to
learn about, prevent, or treat cancer (At the time
of randomization, the following will also be
recorded:)
No (No)
Yes (Yes)
Patient has given permission to store and use
his/her sample(s) for use in future research to
learn about, prevent, or treat other health
problems (for example: diabetes, Alzheimer's
disease, or heart disease)
No (No)
Yes (Yes)
Patient has given NCCTG permission to give
his/her stored sample(s) for use in future
research to outside researchers
No (No)
Yes (Yes)
Stratification Factors (used Fo
Randomization To Arms A-b)
Age (years)
>=85 (>=85)
70-74 (70-74)
75-79 (75-79)
80-84 (80-84)
ECOG Performance status (PS)
0-1 (0-1)
2 (2)
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Number of metastatic sites
>1 (>1)
1 (1)
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Dental Caries Pre-Study - PRL0501- Deep
Caries in Your Practice - 2444305v1.0
PRL0501- Deep Caries in Your Practice
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=0B58C210-
4908-3FE2-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/6248
PRL0501- Deep Caries in Your
Practice
Deep Caries In Your Practice
On average over the past year, how often each
week do you feel you treat lesions that are close
to the pulp
1-2 Times (1-2 times)
2-4 Times (2-4 times)
5 Times Or Greater (5 times or greater)
Less Than Once (Less than once)
On average over the past year how often each
week have you had to make a decision as to
whether to continue removing caries or expose
the pulp
1-2 Times (1-2 times)
2-4 Times (2-4 times)
5 Times Or Greater (5 times or greater)
Less Than Once (Less than once)
In a patient with deep caries (occlusal) & a
possible mild pulpitis on a posterior tooth where
the caries does not radiographically appear to be
close to the pulp, what % of the time do you find
that the caries, upon excavation, may involve the
pulp
About 10% Of The Time (About 10% of
the time)
About 15% Of The Time (About 15% of
the time)
About 20% Of The Time (About 20% of
the time)
About 5% Of The Time (About 5% of the
time)
Almost Never (Almost never)
In pt w/ deep caries assoc. w/ an existing Class I
resin-based comp rest & evidence of a possible
mild pulpitis but radiographically the caries
doesn¿t appear to be close to pulp, what % time
do you find that caries, upon excavation may
involve pulp (In a patient with deep caries
associated with an existing Class I resin-based
composite restoration and evidence of a possible
mild pulpitis but radiographically the caries does
not appear to be close to the pulp)
About 10% Of The Time (About 10% of
the time)
About 15% Of The Time (About 15% of
the time)
About 20% Of The Time (About 20% of
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the time)
About 5% Of The Time (About 5% of the
time)
Almost Never (Almost never)
If the restoration in question 4 was dental
amalgam, would your experience of caries
involving the pulp
Decrease In Percentage (Decrease in
percentage)
Increase In Percentage (Increase in
percentage)
Remain The Same (Remain the same)
In the situation presenting in question 3 where
you believe the caries extends to the pulp, what
percentage of the time do you stop before
removing all caries and perform an indirect pulp
cap (the percentages for 6-A through 6-C must
add to 100%)
In the situation presenting in question 3 where
you believe the caries extends to the pulp, what
percentage of the time do you remove all caries
and proceed with a direct pulp cap (the
percentages for 6-A through 6-C must add to
100%)
In the situation presenting in question 3 where
you believe the caries extends to the pulp, what
percentage of the time do you remove all caries
and proceed with endodontic related procedures
(the percentages for 6-A through 6-C must add to
100%)
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Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=
All rights reserved. Please visit https://medical-data-
models.org/forms/6251
FP.0000
Stratification
AALL08B1 Stratum (Select appropriate stratum)
Down Syndrome Patient (Down
Syndrome Patient)
Non-down Syndrome Patient (Non-Down
Syndrome Patient)
Projected Treatment Start Date of systemic
chemotherapy drug/treatment delivery
(MM/DD/CCYY Study enrollment must take place
within five 5 days of beginning protocol therapy.  If
enrollment takes place before starting therapy,
the date protocol therapy is projected to start
must be no later than five 5 calendar days after
enrollment. Do not report intrathecal IT
cytarabine as start date for Induction therapy,
however, systemic drug/treatment delivery must
begin within 72 hours of administering this IT
therapy)
AALL08B1 Treatment
Arm A: Post Induction Therapy For Mll-g
(sr (Arm A:  Post Induction)
Arm B: Post Induction Therapy Without
Lestaurtinib For Mll-r (ir/hr) (Arm B:  Post
Induction)
Arm C: Post Induction Therapy With
Lestaurtinib For Mll-r (ir/hr) (Arm C:  Post
Induction)
Induction Therapy - Weeks 1 - 5
(Induction)
Inclusion Criteria
Is the patient enrolled on study AALL08B1 (To be
eligible, patients must be enrolled on COG
AALL08B1 before treatment on AALL0932 begins
with the exception of the first dose of intrathecal
chemotherapy.)
No (No)
Yes (Yes)
Does the patient have newly diagnosed B-
precursor ALL (To be eligible, patient must be
newly diagnosed with NCI Standard Risk B-
precursor acute lymphoblastic leukemia ALL.)
No (No)
Yes (Yes)
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Exclusion Criteria
Has the patient received Prior Treatment with
cytotoxic chemotherapy for the current diagnosis
of ALL or any cancer diagnosed previously (with
exception of intrathecal cytarabine [Section 3.2.4]
or steroids [Section 3.3.2] for the current ALL
diagnosis)
No (No)
Yes (Yes)
Does patient have CNS 3 involvement (CNS
status must be known prior to enrollment as
patients with CNS3 involvement are not eligible
for this study. See Section 3.2.4 for details)
No (No)
Yes (Yes)
Does the patient have testicular disease (Patient
is not eligible if he has testicular disease)
N/a, Female (N/A, female)
No (No)
Yes (Yes)
Regulatory Information
Have all institutional, FDA, and NCI requirements
for human studies been met?
No (No)
Yes (Yes)
Date Informed Consent Signed (MM/DD/CCYY
Date entered is the date last authorized signature
is obtained)
Comments Module
Comments
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PRL0501 - Path EX (Pulp exposure
anticipated)
Deep Caries Patient Scenario
Path Ne (no Pulp Exposure Anticipated)
[Patient Edwards is a 25 year-old male... ]  Upon
opening the tooth and during the excavation of
the caries you realize that the lesion is deeper
than anticipated and may involve the mesial
buccal pulp horn.  You would usually (NE1)
Continue And Remove All The Decay
(Continue and remove all the decay)
Stop Removing Decay Near The Pulp
Horn And Remove It Elsewhere (Stop
removing decay near the pulp horn and
remove it elsewhere)
Temporize And Refer The Tooth For
Endodontics (Temporize and refer the
tooth for endodontics)
Path Ne-a -- Remove All Decay
You continue to remove the caries and have hard
dentin remaining but the preparation is close to
the pulp.  You would usually (NE-A1)
Other (Other)
Place A Caoh Material (Place a CaOH
material)
Place A Glass Ionomer Liner (Place a
glass ionomer liner)
Place A Resin Modified Glass Ionomer
Liner (Place a resin modified glass
ionomer liner)
Proceed With Placement Of A Dentin
Bonding Agent (Proceed with placement
of a dentin bonding agent)
Use An Antimicrobial Solution (Use an
antimicrobial solution)
Specify (If other,)
After use of an antimicrobial solution you would
usually (NE-A1-2)
Other (Other)
Place A Caoh Material (Place a CaOH
material)
Place A Glass Ionomer Liner (Place a
glass ionomer liner)
Place A Resin Modified Glass Ionomer
Liner (Place a resin modified glass
ionomer liner)
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Proceed With Placement Of A Dentin
Bonding Agent (Proceed with placement
of a dentin bonding agent)
Specify (If other,)
Upon caries removal and the treatment selected
in EX-A1 you would usually (NE-A2)
Place An Interim Restoration Of Another
Material (Place an interim restoration of
another material)
Place An Interim Restoration Of Zoe
Material (Place an interim restoration of
ZOE material)
Place Another Type Of Final Restoration
(Place another type of final restoration)
Place The Final Restoration Using
Composite And Dentin Bonding Agent If
Not Already Applied (Place the final
restoration using composite and dentin
bonding agent if not already applied)
Place The Final Restoration Using
Dental Amalgam (Place the final
restoration using dental amalgam)
Given the above sequence of treatment how
often do you feel this leads to transient (less than
one week duration) post-operative
hypersensitivity (NE-A3)
< 1% (< 1%)
>20% (>20%)
1-5% (1-5%)
11-20% (11-20%)
6-10% (6-10%)
Given the above sequence of treatment how
often in your experience in your practice will the
patient over the next 3-5 years require endodontic
treatment for this tooth (EX-A4)
< 1% (< 1%)
>20% (>20%)
1-5% (1-5%)
11-20% (11-20%)
6-10% (6-10%)
You are attempting to remove all the decay and
just as you are finishing the pulp horn starts to
bleed.  You are able to control the bleeding.  You
would usually (EX-A5)
Immediately Perform An Endodontic
Procedure (Immediately perform an
endodontic procedure)
Other (Other)
Perform A Pulpectomy And Schedule
The Patient For Endodontics (Perform a
pulpectomy and schedule the patient for
endodontics)
Place A Direct Pulp Cap (Place a direct
pulp cap)
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Specify (If other,)
If you would place a direct pulp cap for the above
situation (with the bleeding controlled) the
procedure would usually (EX-A6)
Other (Other)
Place A Caoh Material (Place a CaOH
material)
Place A Glass Ionomer Liner (Place a
glass ionomer liner)
Place A Resin Modified Glass Ionomer
Liner (Place a resin modified glass
ionomer liner)
Proceed With Placement Of A Dentin
Bonding Agent (Proceed with placement
of a dentin bonding agent)
Use An Antimicrobial Solution (Use an
antimicrobial solution)
Specify (If other,)
After use of an antimicrobial solution you would
then (EX-A6-2)
Other (Other)
Place A Caoh Material (Place a CaOH
material)
Place A Glass Ionomer Liner (Place a
glass ionomer liner)
Place A Resin Modified Glass Ionomer
Liner (Place a resin modified glass
ionomer liner)
Proceed With Placement Of A Dentin
Bonding Agent (Proceed with placement
of a dentin bonding agent)
Specify (If other,)
Given the above sequence of treatment with a
direct pulp capping procedure how often in your
experience in your practice will the patient over
the next 3-5 years require endodontic treatment
for this tooth (EX-A7)
< 1% (< 1%)
>20% (>20%)
1-5% (1-5%)
11-20% (11-20%)
6-10% (6-10%)
If the answer to EX-A5 was an endodontic
outcome, how often in your experience in your
practice will the patient over the next 3-5 years
require endodontic retreatment for this tooth (EX-
A8)
< 1% (< 1%)
>20% (>20%)
1-5% (1-5%)
11-20% (11-20%)
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6-10% (6-10%)
In the EX1 question of the survey would your
response have been different if the age of the
patient was 15 (NE-A9-A)
No (No)
Yes (Yes)
The path you would choose is (If yes,)
Ex-b (EX-B)
Ex-c (EX-C)
In the EX1 question of the survey would your
response have been different if the age of the
patient was 50 (NE-A9-B)
No (No)
Yes (Yes)
The path you would choose is (If yes,)
Ex-b (EX-B)
Ex-c (EX-C)
In the EX1 question of the survey would your
response have been different if the age of the
patient was 70 (NE-A9-C)
No (No)
Yes (Yes)
The path you would choose is (If yes,)
Ex-b (EX-B)
Ex-c (EX-C)
In the EX1 question of the survey would your
response have been different if the tooth involved
was a premolar (NE-A9-D)
No (No)
Yes (Yes)
The path you would choose is (If yes,)
Ex-b (EX-B)
Ex-c (EX-C)
In the EX1 question of the survey would your
response have been different if the lesion was
visible at the margin of an existing Class I
composite restoration and verified by the
radiograph to extend beneath the restoration (NE-
A9-E)
No (No)
Yes (Yes)
The path you would choose is (If yes,)
Ex-b (EX-B)
Ex-c (EX-C)
In the EX1 question of the survey would your
response have been different if the tooth was vital
with no lingering pain on testing (NE-A9-F)
No (No)
Yes (Yes)
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The path you would choose is (If yes,)
Ex-b (EX-B)
Ex-c (EX-C)
In the EX1 question of the survey would your
response have been different if the patient had a
large number of new lesions on radiographic
examination, (# 30 being the most advanced)
(NE-A9-G)
No (No)
Yes (Yes)
The path you would choose is (If yes,)
Ex-b (EX-B)
Ex-c (EX-C)
Ne-b Path--do Not Remove All Decay
You are near the pulp horn in tooth #30 and
caries remains that is still soft and moist in
appearance.  In this instance you would usually
(NE-B1)
Continue To Remove The Caries Until It
Is Slightly Soft And Stained Or There Is
A Pulp Exposure (Continue to remove
the caries until it is slightly soft and
stained or there is a pulp exposure)
Proceed With An Indirect Pulp Capping
Procedure (Proceed with an indirect pulp
capping procedure)
Temporize And Refer The Tooth For
Endodontics (Temporize and refer the
tooth for endodontics)
The indirect pulp capping procedure for the soft
moist caries you would usually (NE-B2)
Other (Other)
Place A Caoh Material (Place a CaOH
material)
Place A Glass Ionomer Liner (Place a
glass ionomer liner)
Place A Resin Modified Glass Ionomer
Liner (Place a resin modified glass
ionomer liner)
Proceed With Placement Of A Dentin
Bonding Agent (Proceed with placement
of a dentin bonding agent)
Use An Antimicrobial Solution (Use an
antimicrobial solution)
Specify (If other,)
After use of an antimicrobial solution you would
usually (NE-B2-2)
Other (Other)
Place A Caoh Material (Place a CaOH
material)
Place A Glass Ionomer Liner (Place a
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glass ionomer liner)
Place A Resin Modified Glass Ionomer
Liner (Place a resin modified glass
ionomer liner)
Proceed With Placement Of A Dentin
Bonding Agent (Proceed with placement
of a dentin bonding agent)
Specify (If other,)
Upon caries partial removal and the above
indirect pulp capping procedure your usual
treatment would be to (NE-B3)
Place An Interim Restoration Of Another
Material (Place an interim restoration of
another material)
Place An Interim Restoration Of Zoe
Material (Place an interim restoration of
ZOE material)
Place Another Type Of Final Restoration
(Place another type of final restoration)
Place The Final Restoration Using
Dental Amalgam (Place the final
restoration using dental amalgam)
Place The Final Restoration Using
Resin-based Composite And Dentin
Bonding Agent If Not Already Applied
(Place the final restoration using resin-
based composite and dentin bonding
agent if not already applied)
Given the above sequence of treatment how
often do you feel this leads to transient (less than
one week duration) post-operative
hypersensitivity (NE-B4)
< 1% (< 1%)
>20% (>20%)
1-5% (1-5%)
11-20% (11-20%)
6-10% (6-10%)
Given the above sequence of treatment how
often in your experience in your practice will the
patient over the next 3-5 years require endodontic
treatment for this tooth (NE-B5)
< 1% (< 1%)
>20% (>20%)
1-5% (1-5%)
11-20% (11-20%)
6-10% (6-10%)
You are removing caries near the mesial-buccal
pulp horn in tooth # 30 and some slightly soft and
stained caries remains.  In this instance you
proceed with an indirect pulp capping procedure
where you usually (NE-B6)
Other (Other)
Place A Caoh Material (Place a CaOH
material)
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Place A Glass Ionomer Liner (Place a
glass ionomer liner)
Place A Resin Modified Glass Ionomer
Liner (Place a resin modified glass
ionomer liner)
Proceed With Placement Of A Dentin
Bonding Agent (Proceed with placement
of a dentin bonding agent)
Use An Antimicrobial Solution (Use an
antimicrobial solution)
Specify (If other,)
After use of an antimicrobial solution you would
usually (NE-B6-2)
Other (Other)
Place A Caoh Material (Place a CaOH
material)
Place A Glass Ionomer Liner (Place a
glass ionomer liner)
Place A Resin Modified Glass Ionomer
Liner (Place a resin modified glass
ionomer liner)
Proceed With Placement Of A Dentin
Bonding Agent (Proceed with placement
of a dentin bonding agent)
Specify (If other,)
Upon caries partial removal and the above
indirect pulp capping procedure your treatment
would be to: (NE-B7)
Place An Interim Restoration Of Another
Material (Place an interim restoration of
another material)
Place An Interim Restoration Of Zoe
Material (Place an interim restoration of
ZOE material)
Place Another Type Of Final Restoration
(Place another type of final restoration)
Place The Final Restoration Using
Composite And Dentin Bonding Agent If
Not Already Applied (Place the final
restoration using composite and dentin
bonding agent if not already applied)
Place The Final Restoration Using
Dental Amalgam (Place the final
restoration using dental amalgam)
Given the above sequence of treatment how
often do you feel this leads to transient (less than
one week duration) post-operative
hypersensitivity (NE-B8)
< 1% (< 1%)
>20% (>20%)
1-5% (1-5%)
11-20% (11-20%)
6-10% (6-10%)
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Given the above sequence of treatment how
often in your experience in your practice will the
patient over the next 3-5 years require endodontic
treatment for this tooth (NE-B9)
< 1% (< 1%)
>20% (>20%)
1-5% (1-5%)
11-20% (11-20%)
6-10% (6-10%)
In the EX1 question of the survey would your
response have been different if the age of the
patient was 15 (NE-A9-A)
No (No)
Yes (Yes)
The path you would choose is (If yes,)
Ex-b (EX-B)
Ex-c (EX-C)
In the EX1 question of the survey would your
response have been different if the age of the
patient was 50 (NE-A9-B)
No (No)
Yes (Yes)
The path you would choose is (If yes,)
Ex-b (EX-B)
Ex-c (EX-C)
In the EX1 question of the survey would your
response have been different if the age of the
patient was 70 (NE-A9-C)
No (No)
Yes (Yes)
The path you would choose is (If yes,)
Ex-b (EX-B)
Ex-c (EX-C)
In the EX1 question of the survey would your
response have been different if the tooth involved
was a premolar (NE-A9-D)
No (No)
Yes (Yes)
The path you would choose is (If yes,)
Ex-b (EX-B)
Ex-c (EX-C)
In the EX1 question of the survey would your
response have been different if the lesion was
visible at the margin of an existing Class I
composite restoration and verified by the
radiograph to extend beneath the restoration (NE-
A9-E)
No (No)
Yes (Yes)
The path you would choose is (If yes,)
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Ex-b (EX-B)
Ex-c (EX-C)
In the EX1 question of the survey would your
response have been different if the tooth was vital
with no lingering pain on testing (NE-A9-F)
No (No)
Yes (Yes)
The path you would choose is (If yes,)
Ex-b (EX-B)
Ex-c (EX-C)
In the EX1 question of the survey would your
response have been different if the patient had a
large number of new lesions on radiographic
examination, (# 30 being the most advanced)
(NE-A9-G)
No (No)
Yes (Yes)
The path you would choose is (If yes,)
Ex-b (EX-B)
Ex-c (EX-C)
Path Ne-c -- Refer For Endodontic
Treatment
Given the referral for endodontic treatment how
often in your experience in your practice will the
patient over the next 3-5 years require endodontic
retreatment for this tooth
< 1% (< 1%)
>20% (>20%)
1-5% (1-5%)
11-20% (11-20%)
6-10% (6-10%)
In the EX1 question of the survey would your
response have been different if the age of the
patient was 15 (NE-A9-A)
No (No)
Yes (Yes)
The path you would choose is (If yes,)
Ex-b (EX-B)
Ex-c (EX-C)
In the EX1 question of the survey would your
response have been different if the age of the
patient was 50 (NE-A9-B)
No (No)
Yes (Yes)
The path you would choose is (If yes,)
Ex-b (EX-B)
Ex-c (EX-C)
In the EX1 question of the survey would your
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response have been different if the age of the
patient was 70 (NE-A9-C)
No (No)
Yes (Yes)
The path you would choose is (If yes,)
Ex-b (EX-B)
Ex-c (EX-C)
In the EX1 question of the survey would your
response have been different if the tooth involved
was a premolar (NE-A9-D)
No (No)
Yes (Yes)
The path you would choose is (If yes,)
Ex-b (EX-B)
Ex-c (EX-C)
In the EX1 question of the survey would your
response have been different if the lesion was
visible at the margin of an existing Class I
composite restoration and verified by the
radiograph to extend beneath the restoration (NE-
A9-E)
No (No)
Yes (Yes)
The path you would choose is (If yes,)
Ex-b (EX-B)
Ex-c (EX-C)
In the EX1 question of the survey would your
response have been different if the tooth was vital
with no lingering pain on testing (NE-A9-F)
No (No)
Yes (Yes)
The path you would choose is (If yes,)
Ex-b (EX-B)
Ex-c (EX-C)
In the EX1 question of the survey would your
response have been different if the patient had a
large number of new lesions on radiographic
examination, (# 30 being the most advanced)
(NE-A9-G)
No (No)
Yes (Yes)
The path you would choose is (If yes,)
Ex-b (EX-B)
Ex-c (EX-C)
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MetLife - Dental Survey 01
Contact Information
First Name
Last Name
Practice Name
Street Address
City/Town
State
ZIP Code
Email Address
Practice Phone Number
Fax Number
A. Post Operative Hypersensitivity With
Composite Resin Restorations
Is the frequency of composite resin
hypersensitivity a concern in your practice
No (No)
No Response (No Response)
Yes (Yes)
What is your estimate of the percentage of Class
I restorations with this problem
1-3% (1-3%)
3-5% (3-5%)
5-10% (5-10%)
Greater Than 10% (Greater than 10%)
Less Than 1% (Less than 1%)
No Response (No Response)
How frequently have you noticed hypersensitivity
in two or more restorations for a number of
patients
Never (Never)
No Response (No Response)
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Occasionally (Occasionally)
Often (Often)
Do you routinely use a self-etching dentin
bonding system for composite restorations
No (No)
No Response (No Response)
Yes (Yes)
Do you routinely use a resin modified glass
ionomer liner for composite restorations
No (No)
No Response (No Response)
Yes (Yes)
B. Dental Care For Pregnant Women
Do you provide comprehensive dental care for
pregnant women in your practice
No (No)
No Response (No Response)
Yes (Yes)
Do you limit treatment of pregnant women to
emergency care
No (No)
No Response (No Response)
Yes (Yes)
About how many individual pregnant women
present for care in your dental practice
About One A Month (About one a month)
About One Every Three Months (About
one every three months)
About Two A Month (About two a month)
Less Than One Every Six Months (Less
than one every six months)
More Than Two A Month (More than two
a month)
No Response (No Response)
Does your state have guidelines for treatment of
pregnant women
No (No)
No Response (No Response)
Unknown (Unknown)
Yes (Yes)
C. Porcelain Repair
How often is porcelain repair employed in your
practice on a per month basis
Less Than Once (Less than once)
More Than Four Times (More than four
times)
No Response (No Response)
One Or Two Times (One or two times)
Three Or Four Times (Three or four
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times)
How often do these repairs fail
26 - 50% Of The Time (26 - 50% of the
time)
51 - 75% Of The Time (51 - 75% of the
time)
Greater Than 75% Of The Time (Greater
than 75% of the time)
Less Than Or Equal To 25% Of The
Time (Less than or equal to 25% of the
time)
No Response (No Response)
Do you use hydrofluoric acid etching of porcelain
during the repair
No (No)
No Response (No Response)
Yes (Yes)
Do you use "micro etching" (sandblasting) during
a porcelain repair
No (No)
No Response (No Response)
Yes (Yes)
Do you use both "micro etching" and hyrofluorid
acid etching
No (No)
No Response (No Response)
Yes (Yes)
C. Porcelain Repair
In mildly symptomatic teeth do you selectively
leave caries in deep preparations to avoid pulpal
exposure
No (No)
No Response (No Response)
Yes (Yes)
If yes to the above, what method of indirect pulp
capping procedure do you follow
Apply A Caoh Product (Apply a CaOH
product)
Apply A Resin Modified Glass Ionomer
(Apply a resin modified glass ionomer)
Apply A Self-etching Dentin Bonding
Agent (Apply a self-etching dentin
bonding agent)
Apply A Zinc Oxide Eugenol Product
(Apply a zinc oxide eugenol product)
No Response (No Response)
None Of The Above (None of the above)
If no to the above, do you usually
No Response (No Response)
Remove All Carious Dentin And Perform
A Direct Pulp Cap (Remove all carious
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dentin and perform a direct pulp cap)
Remove All Carious Dentin And Perform
Endodontic Therapy (Remove all carious
dentin and perform endodontic therapy)
If you must perform a direct pulp cap which
procedure do you follow after stopping the
bleeding
Apply A Caoh Product (Apply a CaOH
product)
Apply A Resin Modified Glass Ionomer
(Apply a resin modified glass ionomer)
Apply A Self-etching Dentin Bonding
Agent (Apply a self-etching dentin
bonding agent)
Apply A Zinc Oxide Eugenol Product
(Apply a zinc oxide eugenol product)
No Response (No Response)
None Of The Above (None of the above)
E. Smoking Cessation
Do you have a smoking cessation program in
your practice
No (No)
No Response (No Response)
Yes (Yes)
If yes, what percentage of the patients
approached concerning this program participates
<5% (<5%)
>30% (>30%)
10-20% (10-20%)
20-30% (20-30%)
5-10% (5-10%)
No Response (No Response)
If no, would you consider incorporation of a
program if it were reimbursed for each patient
enrolled
No (No)
No Response (No Response)
Yes (Yes)
Is a course on smoking cessation required for a
dental license in your state
No (No)
No Response (No Response)
Unknown (Unknown)
Yes (Yes)
F. Visual Classification Of Caries
Are you aware of visual classification systems for
the progress of caries
No (No)
No Response (No Response)
Yes (Yes)
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Do you routinely employ a caries risk assessment
of patients in your practice that is part of the
patient chart
No (No)
No Response (No Response)
Yes (Yes)
Do you place any of your patients on a caries
management program with the intent of
promoting remineralization of early lesions
No (No)
No Response (No Response)
Yes (Yes)
G. Cracked Tooth
How often in a month do you diagnose and treat
a patient for one or more cracked posterior teeth
Four (Four)
Less Than Once (Less than once)
More Than Four (once A Week Or More)
(More than four (once a week or more))
No Response (No Response)
Once (Once)
Two Or Three (Two or three)
Do you feel the diagnosis of a cracked tooth is a
routine procedure
No (No)
No Response (No Response)
Yes (Yes)
What method besides visualization and
radiographs do you primarily use to assist with
diagnosis
Biting On A Wooden "stick" For A Period
Of Time (Biting on a wooden "stick" for a
period of time)
Desiccation With Air Syringe
(Desiccation with air syringe)
No Response (No Response)
Use Of A "tooth Sleuth" (Use of a "tooth
sleuth")
H. Leaking Sealant Detection
Do you routinely apply sealants to children's teeth
in your practice
No (No)
No Response (No Response)
Yes (Yes)
Do you routinely apply sealants to young adults
(16-30 years of age) teeth in your practice
No (No)
No Response (No Response)
Yes (Yes)
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Would a dye with good sensitivity for detection of
a leaking sealant be useful in your practice
No (No)
No Response (No Response)
Yes (Yes)
If detection of leaking sealant was possible would
this change and/or increase your use of sealants
in your practice
No (No)
No Response (No Response)
Yes (Yes)
Ii. Professional Information
Dental school
Year graduated
Degree
Years in practice
General Practice or Specialist
Generalist (Generalist)
Specialist (Specialist)
If Specialist, which
Endodontics (Endodontics)
Oral Surgery (Oral Surgery)
Orthodontics (Orthodontics)
Pediatric Dentistry (Pediatric Dentistry)
Periodontics (Periodontics)
Number of years at current practice location
Date of Birth (mm/dd/yyyy)
Gender
Female (Female)
Male (Male)
Ethnicity
A Person Of Mexican, Puerto Rican,
Cuban, Central Or South American Or
Other Spanish Culture Or Origin,
Regardless Of Race. (HISPANIC OR
LATINO)
A Person Not Meeting The Definition For
Hispanic Or Latino. (NOT HISPANIC OR
LATINO)
If Hispanic or Latino, specify
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Central American (Central American)
Cuban (Cuban)
Mexican (Mexican)
Nos (NOS)
Other (Other)
Puerto Rican (Puerto Rican)
Specify (If other,)
Race
Asian Indian (Asian Indian)
Black Or African American (Black or
African American)
Chinese (Chinese)
Filipino (Filipino)
Japanese (Japanese)
Korean (Korean)
Native American Or Alaskan Native
(Native American or Alaskan Native)
Native Hawaiian Or Other Pacific
Islander (Native Hawaiian or Other
Pacific Islander)
Other (Other)
Other Asian (Other Asian)
Vietnamese (Vietnamese)
White (White)
Specify (If other,)
Iii. Description Of Your Practice
What is your approximate active patient chart
count
Males (Estimate the percentage of your patients
that are - Percentage should add up to 100% )
Females (Estimate the percentage of your
patients that are - Percentage should add up to
100% )
Not Hispanic or Latino (Estimate the percentage
of your patients that are - Ethnicity)
Hispanic or Latino (Estimate the percentage of
your patients that are - Ethnicity)
White (Estimate the percentage of your patients
that are - Race)
Black or African American (Estimate the
percentage of your patients that are - Race)
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Native American or Alaskan Native (Estimate the
percentage of your patients that are - Race)
Native Hawaiian or Other Pacific Islander
(Estimate the percentage of your patients that are
- Race)
Asian (Estimate the percentage of your patients
that are - Race)
Other (Estimate the percentage of your patients
that are - Race)
Specify (If other,)
How would you characterize your practice
Rural (Rural)
Suburban (Suburban)
Urban (Urban)
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Lab - 2004 - Infectious Disease Markers -
2630454v6.0
Infectious Disease Markers
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=62093463-
23EF-B53C-E040-BB89AD434539
All rights reserved. Please visit https://medical-data-
models.org/forms/6275
2004 - Infectious Disease Markers
Registry Use Only
Sequence number:
Date received:
Identification Data
CIBMTR Center Number:
CIBMTR Recipient ID:
Identification Data
Non-NMDP donor ID:
Donor Gender
Female (female)
Male (male)
Donor date of birth:
Identification Data
Non-NMDP Cord Blood Unit (CBU) ID:
Identification Data
Today's date:
Date of Hematopoietic Stem Cell Transplantation
(HSCT) for which this form is being completed:
Hsct Type
What source was used for the hematopoietic
stem cell transplantation?
Related Allogenic (Allogeneic, related)
Unrelated Allogenic (Allogeneic,
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unrelated)
Syngeneic (Syngeneic (identical twin))
Was a particular hematopoietic stem cell source
used?
No (No)
Yes (Yes)
Product Type
What type of hematopoietic stem cell transplant
was used?
Umbilical Cord Blood (Cord blood)
Bone Marrow (Marrow)
Other (Other)
Peripheral Blood Stem Cell (PBSC)
Was a particular hematopoietic stem cell
transplant type used?
No (No)
Yes (Yes)
Specify the other hematopoietic stem cell
transplant type: (Answer only if the value for
2730912 is "Other". )
Source Information
Who is being tested for IDMs?
Disease Marker Umbilical Cord Blood
(Cord Blood Unit (IDM))
Disease Marker Donor (Donor IDM
(Marrow or PBSC))
Umbilical Cord Blood Disease Marker
Mother (Maternal IDM (Cord Blood))
Infectious Disease Marker
Test results of infectious disease marker for
hepatitis B virus (HBV)  surface antigen(HBsAG)
Not Reaction (Non-reactive)
Not Done: C49484 (Not Done)
Reaction (Reactive)
Date that the test for hepatitis B surface antigen
(HBsAG) was performed:
Test results of infectious disease marker for
hepatitis B virus (HBV) core antibody (Anti HBc)
(No confirmatory test available)
Not Reaction (Non-reactive)
Not Done: C49484 (Not Done)
Reaction (Reactive)
Date that the test for hepatitis B virus core
antibody (Anti HBc) was performed:
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Hepatitis C Virus (hcv)
Test results of infectious disease marker for
hepatitis C virus (HCV) antibody (Anti-HCV)
Not Reaction (Non-reactive)
Not Done: C49484 (Not Done)
Reaction (Reactive)
Date that the test for hepatitis C virus antibody
(Anti-HCV) was performed:
Human T-lymphotropic Virus
Test results of infectious disease marker for
human T-Lymphotropic virus antibody(Anti-HTLV
I/II):
Not Reaction (Non-reactive)
Not Done: C49484 (Not Done)
Reaction (Reactive)
Date that the test for human T-Lymphotropic virus
antibody (Anti-HTLV I/II) was performed:
Human Immunodeficiency Virus (hiv)
Test results of infectious disease marker for
human immunodeficiency virus(HIV)-1 p24
antigen:
Not Reaction (Non-reactive)
Human Immunodeficiency Virus Nucleic
Acid Amplification Test Performed (Not
performed; HIV NAT testing performed)
Not Report (Not reported)
Reaction (Reactive)
Date that the test for HIV-1 p24 antigen was
performed:
Was FDA licensed nucleic acid amplification test
(NAT)for human immunodeficiency virus(HIV)-1
or hepatitis C virus performed?
No (No)
Yes (Yes)
If FDA licensed nucleic acid amplification test
(NAT)for human immunodeficiency virus(HIV)-1
performed; specify results
Negative Finding (Negative)
Not Report (Not reported)
Positive Finding (Positive)
Date that the FDA licensed nucleic acid
amplification test (NAT) for human
immunodeficiency virus (HIV-1) was performed:
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Was FDA licensed nucleic acid amplification test
(NAT)for hepatitis C virus performed; specify
results
Negative Finding (Negative)
Positive Finding (Positive)
Date that the FDA licensed nucleic acid
amplification test (NAT) for hepatitis C virus was
performed:
Test results of infectious disease marker for Anti-
HIV 1 and anti-HIV 2 (antibodies to Human
Immunodeficiency Viruses): (Testing for both HIV
antibodies is required. This testing may be
performed as separate tests or done using a
combined assay.)
Not Reaction (Non-reactive)
Not Done: C49484 (Not Done)
Not Report (Not reported)
Reaction (Reactive)
Date that the test for Anti-HIV 1 and anti-HIV 2
(antibodies to Human Immunodeficiency Viruses)
was performed:
Syphilis
Test results of infectious disease marker for
syphilis using serologic testing for syphilis(STS)
Not Reaction (Non-reactive)
Not Done: C49484 (Not Done)
Reaction (Reactive)
Date that the the serologic test for syphilis (STS)
was performed:
Cytomegalovirus (cmv)
Test results of infectious disease marker for
cytomegalovirus(CMV) antibody (IgG or total):
Not Reaction (Non-reactive)
Not Done: C49484 (Not Done)
Previous Report Reaction (Previously
reported reactive, not tested)
Reaction (Reactive)
Date that the test for cytomegalovirus (CMV)
antibody (IgG or total) was performed:
West Nile Virus (wnv)
Test results of infectious disease marker for west
nile virus(WNV) using nucleic acid amplification
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test (NAT)
Negative Finding (Negative)
Not Applicable (Not applicable)
Not Done: C49484 (Not Done)
Positive Finding (Positive)
Date that the nucleic acid amplification test (NAT)
for West Nile Viruse (WNV) was performed:
Other Infectious Disease Marker
Other infectious disease marker?
No (NO)
Yes (YES)
Date test performed on other infectious disease
marker:
Specify test and method for test performed on
other infectious disease marker:
Specify test results for  test performed on other
infectious disease marker
Author Information
First Name
Last Name
Telephone number:
Fax number:
EMail Address
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Leukemia null Treatment - S0100 POST-
PBSCT TREATMENT FORM - 2071416v3.0
S0100 POST- PBSCT TREATMENT FORM
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=AEB3F489-
0AF8-434B-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/6287
S0100 POST- PBSCT TREATMENT
FORM
Physical
Weight (kg)
BSA (M2)
Gvhd Prophylaxis
Start Date
End Date
Growth Factor
G-csf (G-CSF)
Gm-csf (GM-CSF)
Other, Specify (Other, specify)
Other, specify (growth factor)
Gvhd Treatment
Did the patient develop acute GVHD? (If yes)
No (No)
Yes (Yes)
Start Date
Date of onset
End Date
Grade
1 (1)
2 (2)
3 (3)
4 (4)
Dose Modifications
Were there any dose modifications or
additions/omissions to protocol treatment? (check
1 / 2
one)
No (No)
(i.e., The Treatment Was Changed
According To Protocol Guidelines) (Yes,
planned (i.e., the treatment was changed
according to protocol guidelines))
(i.e., The Treatment Change Was Not
Part Of Protocol Guidelines) (Yes,
unplanned (i.e., the treatment change
was not part of protocol guidelines))
Yes, unplanned, specify change
Chronic Gvhd
Did the patient develop chronic GVHD? (If yes,)
No (No)
Yes (Yes)
date of onset
Extent (** Explain modifications to dose and/or
course and reasons for modification)
Extensive (Extensive)
Limited (Limited)
Comments
Ccrr Module For S0100 Post- Pbsct
Treatment Form
SWOG Patient ID
SWOG Study No.
Registration Step
Patient Initials (L, F, M)
Institution/Affiliate
Physician
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Leukemia null Treatment - S0100 CONSOLIDATION
TREATMENT FORM - 2070989v3.0
S0100 CONSOLIDATION TREATMENT FORM
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=AEB45C27-
2314-425F-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/6291
S0100 CONSOLIDATION
TREATMENT FORM
Physical
Weight (kg)
BSA (M2)
Chemotherapy
Consolidation Regimen (check only one:)
Cyclophosphamide/ara-c/6-mp/mtx
(Cyclophosphamide/Ara-C/6-MP/MTX)
Mtx/prednisone/vincristine
(MTX/Prednisone/Vincristine)
Treatment (*Treatment Codes:)
6-Mercaptopurine (6-Mercaptopurine)
Ara-C (Ara-C)
Bactrim (for dose given, record total
number of tablets given) (Bactrim (for
dose given, record total number of
tablets given))
Cyclophosphamide (Cyclophosphamide)
Methotrexate (Methotrexate)
Other, specify (Other, specify)
Prednisone (Prednisone)
Vincristone (Vincristone)
Treatment (*Treatment Codes:)
6-Mercaptopurine (6-Mercaptopurine)
Ara-C (Ara-C)
Bactrim (for dose given, record total
number of tablets given) (Bactrim (for
dose given, record total number of
tablets given))
Cyclophosphamide (Cyclophosphamide)
Methotrexate (Methotrexate)
Other, specify (Other, specify)
Prednisone (Prednisone)
Vincristone (Vincristone)
Start Date
Stop Date
Total dose given
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Chemotherapy Dose Modifications
Were there any dose modifications or
additions/omissions to protocol treatment? (check
one)
No (No)
(i.e., The Treatment Was Changed
According To Protocol Guidelines) (Yes,
planned (i.e., the treatment was changed
according to protocol guidelines))
(i.e., The Treatment Change Was Not
Part Of Protocol Guidelines) (Yes,
unplanned (i.e., the treatment change
was not part of protocol guidelines))
Cranial Irradiation For Cns Leukemia
Did the patient require cranial irradiation
according to the protocol? (check one)
No (No)
Yes, For Cns Prophylaxis In A Patient
Not Expected To Receive Allogeneic
Pbsct (Yes, for CNS prophylaxis in a
patient not expected to receive
allogeneic PBSCT)
Yes, For Treatment Of Cns Involvement
(Yes, for treatment of CNS involvement)
Did this patient receive protocol cranial
irradiation?
No (No)
Yes (Yes)
Start Date (RT)
Stop Date (RT)
Total dose given (RT)
Cranial Irradiation Dose Modifications
Were there any dose modifications or
additions/omissions to protocol treatment? (check
one)
No (No)
(i.e., The Treatment Was Changed
According To Protocol Guidelines) (Yes,
planned (i.e., the treatment was changed
according to protocol guidelines))
(i.e., The Treatment Change Was Not
Part Of Protocol Guidelines) (Yes,
unplanned (i.e., the treatment change
was not part of protocol guidelines))
Comments
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Ccrr Module For S0100 Consolidation
Treatment Form
SWOG Patient ID
SWOG Study No.
Registration Step
Patient Initials (L, F, M)
Institution/Affiliate
Physician
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Leukemia null Treatment - S0100 INDUCTION
TREATMENT FORM - 2070861v3.0
S0100 INDUCTION TREATMENT FORM
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=AEB42946-
1315-41FD-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/6296
S0100 INDUCTION TREATMENT
FORM
Physical
Weight (kg)
BSA (2 m)
Treatment
Induction Regimen (check only one)
Daunorubicin/vincristine/prednisone/l-
asparaginase
(Daunorubicin/Vincristine/Prednisone/L-
asparaginase)
High Dose Ara-c/mitoxantrone (High
dose Ara-C/Mitoxantrone)
Treatment (*Treatment Codes:)
Allopurinol (Allopurinol)
Ara-C (Ara-C)
Bactrim (for dose given, record total
number of tablets) (Bactrim (for dose
given, record total number of tablets))
Daunorubicin (Daunorubicin)
Dexamethasone (Dexamethasone)
G-CSF (G-CSF)
GM-CSF (GM-CSF)
L-asparaginase (L-asparaginase)
Methotrexate (Methotrexate)
Mitoxantrone (Mitoxantrone)
Other growth factor, specify (Other
growth factor, specify)
Prednisone (Prednisone)
Vincristine (Vincristine)
Treatment (*Treatment Codes:)
Allopurinol (Allopurinol)
Ara-C (Ara-C)
Bactrim (for dose given, record total
number of tablets) (Bactrim (for dose
given, record total number of tablets))
Daunorubicin (Daunorubicin)
Dexamethasone (Dexamethasone)
G-CSF (G-CSF)
GM-CSF (GM-CSF)
L-asparaginase (L-asparaginase)
Methotrexate (Methotrexate)
Mitoxantrone (Mitoxantrone)
Other growth factor, specify (Other
growth factor, specify)
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Prednisone (Prednisone)
Vincristine (Vincristine)
Treatment (*Treatment Codes:)
Allopurinol (Allopurinol)
Ara-C (Ara-C)
Bactrim (for dose given, record total
number of tablets) (Bactrim (for dose
given, record total number of tablets))
Daunorubicin (Daunorubicin)
Dexamethasone (Dexamethasone)
G-CSF (G-CSF)
GM-CSF (GM-CSF)
L-asparaginase (L-asparaginase)
Methotrexate (Methotrexate)
Mitoxantrone (Mitoxantrone)
Other growth factor, specify (Other
growth factor, specify)
Prednisone (Prednisone)
Vincristine (Vincristine)
Start Date
Stop Date
Total dose given
Dose Modifications
Were there any dose modifications or
additions/omissions to protocol treatment? (check
one)
No (No)
(i.e., The Treatment Was Changed
According To Protocol Guidelines) (Yes,
planned (i.e., the treatment was changed
according to protocol guidelines))
(i.e., The Treatment Change Was Not
Part Of Protocol Guidelines) (Yes,
unplanned (i.e., the treatment change
was not part of protocol guidelines))
Yes, unplanned, specify change
Comments
Ccrr Module For S0100 Induction
Treatment Form
SWOG Patient ID
SWOG Study No.
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2070861v3.0
Registration Step
Patient Initials (L, F, M)
Institution/Affiliate
Physician
Cycle
Current Phase Of Leukemia Treatment
For Patient Is Crossover (Cross-over
Induction)
Current Phase Of Leukemia Treatment
For Patient Is Induction (First Induction)
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Leukemia null Treatment - S0100 ALLOGENEIC
PBSCT TREATMENT FORM - 2071283v3.0
S0100 ALLOGENEIC PBSCT TREATMENT FORM
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=AEB397EC-
8B44-42D5-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
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S0100 ALLOGENEIC PBSCT
TREATMENT FORM
Physical
Weight (kg)
BSA (2 m)
TREATMENT
Allopurinol (Allopurinol)
TBI (TBI)
Testicular Boost (Testicular Boost)
VP-16 (VP-16)
Start Date
Stop Date
Total dose given (mg)
Number of fractions
Dose Modifications
Were there any dose modifications or
additions/omissions to protocol treatment? (check
one)
No (No)
(i.e., The Treatment Was Changed
According To Protocol Guidelines) (Yes,
planned (i.e., the treatment was changed
according to protocol guidelines))
(i.e., The Treatment Change Was Not
Part Of Protocol Guidelines) (Yes,
unplanned (i.e., the treatment change
was not part of protocol guidelines))
Stem Cell Infusion
Were stem cells infused? (if yes,)
No (No)
Yes (Yes)
date of infusion
CD34 cells infused (6 X 10 cells/kg)
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Donor ABO type
A (A)
Ab (AB)
B (B)
O (O)
Patient ABO type (** Explain modifications to
dose and/or course and reasons for modification)
A (A)
Ab (AB)
B (B)
O (O)
Comments
Ccrr Module For S0100 Allogeneic Pbsct
Treatment Form
SWOG Patient ID
SWOG Study No.
Registration Step
Patient Initials (L, F, M)
Institution/Affiliate
Physician
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Leukemia null Treatment - S0100 MAINTENANCE
TREATMENT FORM - 2071555v3.0
S0100 MAINTENANCE TREATMENT FORM
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=AEB50F10-
EF45-43A0-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/6298
S0100 MAINTENANCE
TREATMENT FORM
Physical
Weight (kg)
BSA (M2)
Treatment
Treatment (*Treatment Codes:)
6- Mercaptopurine (6- Mercaptopurine)
6-Thioguanine (6-Thioguanine)
Adriamycin (Adriamycin)
Ara-C (Ara-C)
Cyclophosphamide (Cyclophosphamide)
Dexamethasone (Dexamethasone)
G-CSF (G-CSF)
GM-CSF (GM-CSF)
Methotrexate (Methotrexate)
Other growth factor, specify (Other
growth factor, specify)
Vincristine (Vincristine)
Treatment (*Treatment Codes:)
6- Mercaptopurine (6- Mercaptopurine)
6-Thioguanine (6-Thioguanine)
Adriamycin (Adriamycin)
Ara-C (Ara-C)
Cyclophosphamide (Cyclophosphamide)
Dexamethasone (Dexamethasone)
G-CSF (G-CSF)
GM-CSF (GM-CSF)
Methotrexate (Methotrexate)
Other growth factor, specify (Other
growth factor, specify)
Vincristine (Vincristine)
Start Date
Stop Date
Total dose given
Dose Modifications
Were there any dose modifications or
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additions/omissions to protocol treatment? (check
one)
No (No)
(i.e., The Treatment Was Changed
According To Protocol Guidelines) (Yes,
planned (i.e., the treatment was changed
according to protocol guidelines))
(i.e., The Treatment Change Was Not
Part Of Protocol Guidelines) (Yes,
unplanned (i.e., the treatment change
was not part of protocol guidelines))
Yes, Unplanned, specify change (** Explain
modifications to dose and/or course and reasons
for modification)
Comments
Ccrr Module For S0100 Maintenance
Treatment Form
SWOG Patient ID
SWOG Study No.
Registration Step
Patient Initials (L, F, M)
Institution/Affiliate
Physician
Cycle (check only one)
1 (1)
2 (2)
3 (3)
4 (4)
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S0100 CNS LEUKEMIA TREATMENT FORM
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=AEB47F23-
BC3D-4283-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/6300
S0100 CNS LEUKEMIA
TREATMENT FORM
Physical
Weight (kg)
BSA (2 m)
Chemotherapy For Cns Leukemia Before
Elimination Of Blasts From Spinal Fluid
Did the patient receive chemotherapy for CNS
leukemia?
No (No)
Yes (Yes)
Methotrexate
Start Date (agent)
Date of last dose before blasts were eliminated
Total dose given: (mg)
Route(s) of administration (check all that apply:)
Intrathecal (Intrathecal)
Intravenous Administration Of Drug
(Intraventricular)
Leucovorin:
Start Date (agent)
Date of last dose before blasts were eliminated:
Total dose given: (mg)
Chemotherapy For Cns Leukemia After
Elimination Of Blasts From Spinal Fluid
Did the patient have an LP that was negative for
CNS involvement of ALL? (If yes)
No (No)
1 / 3
Yes (Yes)
date of LP negative for CNS involvement of ALL
Did the patient receive protocol chemotherapy for
CNS leukemia after elimination of blasts from
spinal fluid?
No (No)
Yes (Yes)
(specify reason)
Methotrexate
Date of 1st dose after blasts were eliminated
Total dose given: (mg)
Stop Date
Route(s) of administration (check all that apply:)
Intrathecal (Intrathecal)
Intravenous Administration Of Drug
(Intraventricular)
Dose Modifications
Were there any dose/fractionation modifications
or additions/omissions to protocol treatment?
(check one)
No (No)
(i.e., The Treatment Was Changed
According To Protocol Guidelines) (Yes,
planned (i.e., the treatment was changed
according to protocol guidelines))
(i.e., The Treatment Change Was Not
Part Of Protocol Guidelines) (Yes,
unplanned (i.e., the treatment change
was not part of protocol guidelines))
Comments
Ccrr Module For S0100 Cns Leukemia
Treatment Form
SWOG Patient ID
SWOG Study No.
Registration Step
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Patient Initials (L, F, M)
Institution/Affiliate
Physician
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Dental Caries Treatment - PRL0501 - Path NE
(No pulp exposure anticipated) - 2444306v1.0
PRL0501 - Path NE (No pulp exposure anticipated)
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=0B58CA14-
D33D-40B8-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/6320
PRL0501 - Path NE (No pulp
exposure anticipated)
Deep Caries Patient Scenario
Path Ne (no Pulp Exposure Anticipated)
[Patient Edwards is a 25 year-old male... ]  Upon
opening the tooth and during the excavation of
the caries you realize that the lesion is deeper
than anticipated and may involve the mesial
buccal pulp horn.  You would usually (NE1)
Continue And Remove All The Decay
(Continue and remove all the decay)
Stop Removing Decay Near The Pulp
Horn And Remove It Elsewhere (Stop
removing decay near the pulp horn and
remove it elsewhere)
Temporize And Refer The Tooth For
Endodontics (Temporize and refer the
tooth for endodontics)
Path Ne-a -- Remove All Decay
You continue to remove the caries and have hard
dentin remaining but the preparation is close to
the pulp.  You would usually (NE-A1)
Other (Other)
Place A Caoh Material (Place a CaOH
material)
Place A Glass Ionomer Liner (Place a
glass ionomer liner)
Place A Resin Modified Glass Ionomer
Liner (Place a resin modified glass
ionomer liner)
Proceed With Placement Of A Dentin
Bonding Agent (Proceed with placement
of a dentin bonding agent)
Use An Antimicrobial Solution (Use an
antimicrobial solution)
Specify (If other,)
After use of an antimicrobial solution you would
usually (NE-A1-2)
Place A Caoh Material (1)
Proceed With Placement Of A Dentin
Bonding Agent (2)
Place A Resin Modified Glass Ionomer
Liner (3)
Place A Glass Ionomer Liner (4)
Other (5)
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Specify (If other,)
Upon caries removal and the treatment selected
in NE-A1 you would usually (NE-A2)
Place An Interim Restoration Of Another
Material (Place an interim restoration of
another material)
Place An Interim Restoration Of Zoe
Material (Place an interim restoration of
ZOE material)
Place Another Type Of Final Restoration
(Place another type of final restoration)
Place The Final Restoration Using
Composite And Dentin Bonding Agent If
Not Already Applied (Place the final
restoration using composite and dentin
bonding agent if not already applied)
Place The Final Restoration Using
Dental Amalgam (Place the final
restoration using dental amalgam)
Given the above sequence of treatment how
often do you feel this leads to transient (less than
one week duration) post-operative
hypersensitivity (NE-A3)
< 1% (< 1%)
>20% (>20%)
1-5% (1-5%)
11-20% (11-20%)
6-10% (6-10%)
Given the above sequence of treatment how
often in your experience in your practice will the
patient over the next 3-5 years require endodontic
treatment for this tooth (NE-A4)
< 1% (< 1%)
>20% (>20%)
1-5% (1-5%)
11-20% (11-20%)
6-10% (6-10%)
You are attempting to remove all the decay, and
just as you are finishing, the pulp horn starts to
bleed.  You are able to control the bleeding.  You
would usually (NE-A5)
Immediately Perform An Endodontic
Procedure (Immediately perform an
endodontic procedure)
Perform A Pulpectomy And Schedule
The Patient For Endodontics (Perform a
pulpectomy and schedule the patient for
endodontics)
Place A Direct Pulp Cap (Place a direct
pulp cap)
If you place a direct pulp cap (answer B to NE-
A5), after you controlled the bleeding, you would
usually (NE-A6)
Other (Other)
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Place A Caoh Material (Place a CaOH
material)
Place A Glass Ionomer Liner (Place a
glass ionomer liner)
Place A Resin Modified Glass Ionomer
Liner (Place a resin modified glass
ionomer liner)
Proceed With Placement Of A Dentin
Bonding Agent (Proceed with placement
of a dentin bonding agent)
Use An Antimicrobial Solution (Use an
antimicrobial solution)
Specify (If other,)
After use of an antimicrobial solution you would
usually (NE-A6-2)
Other (Other)
Place A Caoh Material (Place a CaOH
material)
Place A Glass Ionomer Liner (Place a
glass ionomer liner)
Place A Resin Modified Glass Ionomer
Liner (Place a resin modified glass
ionomer liner)
Proceed With Placement Of A Dentin
Bonding Agent (Proceed with placement
of a dentin bonding agent)
Specify (If other,)
Given the above sequence of treatment with a
direct pulp capping procedure how often in your
experience in your practice will the patient over
the next 3-5 years require endodontic treatment
for this tooth (NE-A7)
< 1% (< 1%)
>20% (>20%)
1-5% (1-5%)
11-20% (11-20%)
6-10% (6-10%)
If the answer to NE-A5 above was an endodontic
outcome, how often in your experience in your
practice will the patient over the next 3-5 years
require endodontic retreatment for this tooth (NE-
A8)
< 1% (< 1%)
>20% (>20%)
1-5% (1-5%)
11-20% (11-20%)
6-10% (6-10%)
In the NE1 question of the survey would your
response have been different if the age of the
patient was 15 (NE-A9-A)
No (No)
Yes (Yes)
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The path you would choose is (If yes,)
Ne-b (NE-B)
Ne-c (NE-C)
In the NE1 question of the survey would your
response have been different if the age of the
patient was 50 (NE-A9-B)
No (No)
Yes (Yes)
The path you would choose is (If yes,)
Ne-b (NE-B)
Ne-c (NE-C)
In the NE1 question of the survey would your
response have been different if the age of the
patient was 70 (NE-A9-C)
No (No)
Yes (Yes)
The path you would choose is (If yes,)
Ne-b (NE-B)
Ne-c (NE-C)
In the NE1 question of the survey would your
response have been different if the tooth involved
was a premolar (NE-A9-D)
No (No)
Yes (Yes)
The path you would choose is (If yes,)
Ne-b (NE-B)
Ne-c (NE-C)
In the NE1 question of the survey would your
response have been different if the lesion was
visible at the margin of an existing Class I
composite restoration and verified by the
radiograph to extend beneath the restoration (NE-
A9-E)
No (No)
Yes (Yes)
The path you would choose is (If yes,)
Ne-b (NE-B)
Ne-c (NE-C)
In the NE1 question of the survey would your
response have been different if the tooth was vital
with no lingering pain on testing (NE-A9-F)
No (No)
Yes (Yes)
The path you would choose is (If yes,)
Ne-b (NE-B)
Ne-c (NE-C)
In the NE1 question of the survey would your
response have been different if the patient had a
large number of new lesions on radiographic
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examination, (# 30 being the most advanced)
(NE-A9-G)
No (No)
Yes (Yes)
The path you would choose is (If yes,)
Ne-b (NE-B)
Ne-c (NE-C)
Ne-b Path--do Not Remove All Decay
You are near the pulp horn in tooth #30 and
caries remains that is still soft and moist in
appearance.  In this instance you would usually
(NE-B1)
Proceed With An Indirect Pulp Capping
Procedure (1)
Continue To Remove The Caries Until It
Is Slightly Soft And Stained Or There Is
A Pulp Exposure (2)
Temporize And Refer The Tooth For
Endodontics (3)
The indirect pulp capping procedure for the soft
moist caries you would usually (NE-B2)
Use An Antimicrobial Solution (1)
Place A Caoh Material (2)
Proceed With Placement Of A Dentin
Bonding Agent (3)
Place A Resin Modified Glass Ionomer
Liner (4)
Place A Glass Ionomer Liner (5)
Other (6)
Specify (If other,)
After use of an antimicrobial solution you would
usually (NE-B2-2)
Other (Other)
Place A Caoh Material (Place a CaOH
material)
Place A Glass Ionomer Liner (Place a
glass ionomer liner)
Place A Resin Modified Glass Ionomer
Liner (Place a resin modified glass
ionomer liner)
Proceed With Placement Of A Dentin
Bonding Agent (Proceed with placement
of a dentin bonding agent)
Specify (If other,)
Upon caries partial removal and the above
indirect pulp capping procedure your usual
treatment would be to (NE-B3)
Place The Final Restoration Using
Dental Amalgam (1)
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Place The Final Restoration Using
Resin-based Composite And Dentin
Bonding Agent If Not Already Applied (2)
Place An Interim Restoration Of Zoe
Material (3)
Place An Interim Restoration Of Another
Material (4)
Place Another Type Of Final Restoration
(5)
Given the above sequence of treatment how
often do you feel this leads to transient (less than
one week duration) post-operative
hypersensitivity (NE-B4)
< 1% (< 1%)
>20% (>20%)
1-5% (1-5%)
11-20% (11-20%)
6-10% (6-10%)
Given the above sequence of treatment how
often in your experience in your practice will the
patient over the next 3-5 years require endodontic
treatment for this tooth (NE-B5)
< 1% (< 1%)
>20% (>20%)
1-5% (1-5%)
11-20% (11-20%)
6-10% (6-10%)
You are removing caries near the mesial-buccal
pulp horn in tooth # 30 and some slightly soft and
stained caries remains.  In this instance you
proceed with an indirect pulp capping procedure
where you usually (NE-B6)
Other (Other)
Place A Caoh Material (Place a CaOH
material)
Place A Glass Ionomer Liner (Place a
glass ionomer liner)
Place A Resin Modified Glass Ionomer
Liner (Place a resin modified glass
ionomer liner)
Proceed With Placement Of A Dentin
Bonding Agent (Proceed with placement
of a dentin bonding agent)
Use An Antimicrobial Solution (Use an
antimicrobial solution)
Specify (If other,)
After use of an antimicrobial solution you would
usually (NE-B6-2)
Place A Caoh Material (1)
Proceed With Placement Of A Dentin
Bonding Agent (2)
Place A Resin Modified Glass Ionomer
Liner (3)
Place A Glass Ionomer Liner (4)
6 / 10
Dental Caries Treatment - PRL0501 - Path NE (No pulp exposure
anticipated) - 2444306v1.0
Other (5)
Specify (If other,)
Upon caries partial removal and the above
indirect pulp capping procedure your treatment
would be to: (NE-B7)
Place The Final Restoration Using
Dental Amalgam (1)
Place The Final Restoration Using
Composite And Dentin Bonding Agent If
Not Already Applied (2)
Place An Interim Restoration Of Zoe
Material (3)
Place An Interim Restoration Of Another
Material (4)
Place Another Type Of Final Restoration
(5)
Given the above sequence of treatment how
often do you feel this leads to transient (less than
one week duration) post-operative
hypersensitivity (NE-B8)
< 1% (< 1%)
>20% (>20%)
1-5% (1-5%)
11-20% (11-20%)
6-10% (6-10%)
Given the above sequence of treatment how
often in your experience in your practice will the
patient over the next 3-5 years require endodontic
treatment for this tooth (NE-B9)
< 1% (< 1%)
>20% (>20%)
1-5% (1-5%)
11-20% (11-20%)
6-10% (6-10%)
In the NE1 question of the survey would your
response have been different if the age of the
patient was 15 (NE-A9-A)
No (No)
Yes (Yes)
The path you would choose is (If yes,)
Ne-b (NE-B)
Ne-c (NE-C)
In the NE1 question of the survey would your
response have been different if the age of the
patient was 50 (NE-A9-B)
No (No)
Yes (Yes)
The path you would choose is (If yes,)
Ne-b (NE-B)
Ne-c (NE-C)
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In the NE1 question of the survey would your
response have been different if the age of the
patient was 70 (NE-A9-C)
No (No)
Yes (Yes)
The path you would choose is (If yes,)
Ne-b (NE-B)
Ne-c (NE-C)
In the NE1 question of the survey would your
response have been different if the tooth involved
was a premolar (NE-A9-D)
No (No)
Yes (Yes)
The path you would choose is (If yes,)
Ne-b (NE-B)
Ne-c (NE-C)
In the NE1 question of the survey would your
response have been different if the lesion was
visible at the margin of an existing Class I
composite restoration and verified by the
radiograph to extend beneath the restoration (NE-
A9-E)
No (No)
Yes (Yes)
The path you would choose is (If yes,)
Ne-b (NE-B)
Ne-c (NE-C)
In the NE1 question of the survey would your
response have been different if the tooth was vital
with no lingering pain on testing (NE-A9-F)
No (No)
Yes (Yes)
The path you would choose is (If yes,)
Ne-b (NE-B)
Ne-c (NE-C)
In the NE1 question of the survey would your
response have been different if the patient had a
large number of new lesions on radiographic
examination, (# 30 being the most advanced)
(NE-A9-G)
No (No)
Yes (Yes)
The path you would choose is (If yes,)
Ne-b (NE-B)
Ne-c (NE-C)
Path Ne-c -- Refer For Endodontic
Treatment
Given the above sequence of treatment how
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often do you feel this leads to transient (less than
one week duration) post-operative
hypersensitivity (NE-A3)
< 1% (< 1%)
>20% (>20%)
1-5% (1-5%)
11-20% (11-20%)
6-10% (6-10%)
In the NE1 question of the survey would your
response have been different if the age of the
patient was 15 (NE-A9-A)
No (No)
Yes (Yes)
The path you would choose is (If yes,)
Ne-b (NE-B)
Ne-c (NE-C)
In the NE1 question of the survey would your
response have been different if the age of the
patient was 50 (NE-A9-B)
No (No)
Yes (Yes)
The path you would choose is (If yes,)
Ne-b (NE-B)
Ne-c (NE-C)
In the NE1 question of the survey would your
response have been different if the age of the
patient was 70 (NE-A9-C)
No (No)
Yes (Yes)
The path you would choose is (If yes,)
Ne-b (NE-B)
Ne-c (NE-C)
In the NE1 question of the survey would your
response have been different if the tooth involved
was a premolar (NE-A9-D)
No (No)
Yes (Yes)
The path you would choose is (If yes,)
Ne-b (NE-B)
Ne-c (NE-C)
In the NE1 question of the survey would your
response have been different if the lesion was
visible at the margin of an existing Class I
composite restoration and verified by the
radiograph to extend beneath the restoration (NE-
A9-E)
No (No)
Yes (Yes)
The path you would choose is (If yes,)
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Ne-b (NE-B)
Ne-c (NE-C)
In the NE1 question of the survey would your
response have been different if the tooth was vital
with no lingering pain on testing (NE-A9-F)
No (No)
Yes (Yes)
The path you would choose is (If yes,)
Ne-b (NE-B)
Ne-c (NE-C)
In the NE1 question of the survey would your
response have been different if the patient had a
large number of new lesions on radiographic
examination, (# 30 being the most advanced)
(NE-A9-G)
No (No)
Yes (Yes)
The path you would choose is (If yes,)
Ne-b (NE-B)
Ne-c (NE-C)
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Treatment - Hematopoietic Stem Cell Transplant (HSCT)
Infusion ISO Date Format Version 1 - 2894050v2.0
Hematopoietic Stem Cell Transplant (HSCT) Infusion ISO
Date Format Version 1
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=
All rights reserved. Please visit https://medical-data-
models.org/forms/6372
FP.0000
Registry Use Only
Sequence number:
Date received:
Identification Data
CIBMTR Center Number:
CIBMTR Recipient ID:
Donor ID:
NMDP Cord Blood Unit ID:
Non-NMDP Cord Blood Unit :
Yes (Yes)
Today's date:
Date of hematopoietic stem cell transplantation
(HSCT) for which this form is being completed:
Hsct Type
What source was used for the hematopoietic
stem cell transplantation?
Related Allogenic (Allogeneic, related)
Unrelated Allogenic (Allogeneic,
unrelated)
Autologous (Autologous)
Syngeneic (Syngeneic (identical twin))
Was a particular hematopoietic stem cell source
used?
Yes (Yes)
Product Type
What type of hematopoietic stem cell transplant
was used?
Umbilical Cord Blood (Cord blood)
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Bone Marrow (Marrow)
Multiple Umbilical Cord Blood (Multiple
cord blood units infused)
Other (Other)
Peripheral Blood Stem Cell (PBSC)
Was a particular hematopoietic stem cell
transplant type used?
Yes (Yes)
Specify the other hematopoietic stem cell
transplant type: (Answer only if the value for
2730912 is "Other". )
Pre-collection Therapy
Did the donor receive treatment, prior to any stem
cell harvest, to enhance the product collection for
this HSCT?
Umbilical Cord Blood Unit (Cord blood
unit)
National Marrow Donor Program Donor
(NMDP donor)
No (No)
Yes (Yes)
Other treatment
No (No)
Yes (Yes)
Specify (Answer only if the value for 2772114 is
"Yes")
Other growth factor(s)
No (No)
Yes (Yes)
GM-CSF
No (No)
Yes (Yes)
G-CSF
No (No)
Yes (Yes)
Growth factor(s)
No (No)
Yes (Yes)
Anti-CD20(rituximab,Rituxan) (autologous only)
No (No)
Yes (Yes)
Chemotherapy (autologous only)
No (No)
Yes (Yes)
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Specify treatment: (Answer only if the value for
2773751 is "Yes")
Product Collection
Date of product collection:
Was more than one collection required for this
HSCT?
No (No)
Yes (Yes)
Specify the number of subsequent days of
collection in this episode: (Complete a separate
product form for each subsequent collection that
was not part of this mobilization.)
Were anticoagulants added to the product during
collection?
No (No)
Yes (Yes)
Product Collection
What anticoagulants were added to the product
during collection?
Acid-citrate-dextrose (Acid-Citrate-
Dextrose (ACD))
Citrate Phosphate Dextrose (Citrate
Phosphate Dextrose (CPD))
Heparin (Heparin)
Other (Other)
Were particular anticoagulants added to the
product during collection?
No (No)
Yes (Yes)
Specify the other anticoagulants (Answer only if
the value for 2741578 is "Other")
Product Transport And Receipt
Was this product collected off-site and shipped to
your facility?
No (No)
Yes (Yes)
Temperature during storage:
Specify the storage method used for the cord
blood unit:
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Electricity Freezing (Electric Freezer)
Liquid Nitrogen (Liquid Nitrogen)
Vapor Phase Cooling (Vapor Phase)
Was the cord blood unit stored at your center
prior to thawing? (Cord blood product only)
No (No)
Yes (Yes)
Was the cord blood unit completely frozen when it
arrived at your center? (Cord blood product only)
No (No)
Yes (Yes)
Were the secondary containers (e.g., insulated
shipping containers and unit cassette) intact
when they arrived at your center? (Cord blood
product only)
No (No)
Yes (Yes)
Specify shipping environment:
Specify the shipping environment of the
product(s):
Freezing Umbilical Cord Blood Storage
Unit (Frozen Cord Blood Unit (s))
Freezing Gel Pack (Frozen Gel Pack)
Other Temperature (Other Temperature)
Ambient Temperature (Room
Temperature per Transplant Center
Request)
Is time of receipt of product standard time or
daylight savings time?
Daylight Savings Time (Daylight Savings
Time)
Standard Time (Standard time)
Time of receipt of product: (24-hour clock)
Date of receipt of product at your facility:
Date storage started:
Product Processing / Manipulation
Was a fresh product received, then
cryopreserved at your facility prior to infusion?
No (No)
Not Applicable (Not Applicable)
Yes (Yes)
Specify other thaw method: (Answer only if the
value for 2789998 is "Other method")
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What method was used to thaw the product?
Dimethyl Sulfoxide Dilute (DMSO dilution
- thawed in lab (added dextran and
albumin), then infused)
No Cell Wash (no wash - thawed at
bedside,then infused)
Other Method (other method)
Cell Wash (washed - thawed in lab
(added dextran and albumin),spun and
reconstituted in dextran albumin,then
infused)
Was the primary container (e.g.,cord blood unit
bag) intact upon thawing?
No (No)
Yes (Yes)
Is the thawing end time standard time or daylight
savings time?
Daylight Savings Time (Daylight Savings
Time)
Standard Time (Standard time)
Time at completion of thaw : (24-hour clock)
Is the thawing begin time standard time or
daylight savings time?
Daylight Savings Time (Daylight Savings
Time)
Standard Time (Standard time)
Time at initiation of thaw: (24-hour clock)
Date thawing process initiated:
Specify number of bags thawed:
Were there multiple product bags?
No (No)
Yes (Yes)
Was a compartment of the bag thawed?
No (No)
Yes (Yes)
Was the entire product thawed?
No (No)
Yes (Yes)
Was the product thawed from a cryopreserved
state prior to infusion?
No (No)
Yes (Yes)
Did any adverse events or incidents occur while
thawing the product?
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No (No)
Yes (Yes)
Product Processing / Manipulation - Part 2
Specify: (Answer only if the value for 2746486 is
"Yes" )
anti CD6
No (No)
Yes (Yes)
anti CD5
No (No)
Yes (Yes)
anti CD4
No (No)
Yes (Yes)
anti CD3
No (No)
Yes (Yes)
anti CD2
No (No)
Yes (Yes)
Were antibodies used during product
manipulation?
No (No)
Yes (Yes)
Specify: (Answer only if the value for 2744934 is
"Yes" )
Other manipulation
No (No)
Yes (Yes)
Specify: (Answer only if the value for 2774740 is
"Yes" )
Other (Other T-cell depletion)
No (No)
Yes (Yes)
anti CD7
No (No)
Yes (Yes)
anti CD8
No (No)
Yes (Yes)
other antibody
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No (No)
Yes (Yes)
campath-1H
No (No)
Yes (Yes)
campath-1G
No (No)
Yes (Yes)
campath-NOS
No (No)
Yes (Yes)
anti CD52
No (No)
Yes (Yes)
Specify (Answer only if the value for 2746342 is
"Yes" )
other CD3
No (No)
Yes (Yes)
OKT-3
No (No)
Yes (Yes)
anti TCR alpha / beta (T10-B9)
No (No)
Yes (Yes)
anti CD34
No (No)
Yes (Yes)
CD34 affinity column plus sheep red blood cell
rosetting
No (No)
Yes (Yes)
elutriation
No (No)
Yes (Yes)
Ex-vivo expansion
No (No)
Yes (Yes)
Specify: (Answer only if the value for 2774524 is
"Yes" )
Other
No (No)
Yes (Yes)
Sedimentation (i.e., hetastarch)
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No (No)
Yes (Yes)
Plasma removal
No (No)
Yes (Yes)
Density gradient separation (i.e., Ficoll)
No (No)
Yes (Yes)
Cell separator (i.e., COBE Spectra)
No (No)
Yes (Yes)
Buffy coat preparation
No (No)
Yes (Yes)
ABO incompatibility (RBC depletion)
No (No)
Yes (Yes)
Specify portion manipulated:
Entire Hematopoietic Stem Cell
Collection (Entire product)
Part Hematopoietic Stem Cell Collection
(Portion of product)
Genetic manipulation (gene transfer /
transduction)
No (No)
Yes (Yes)
Volume reduction
No (No)
Yes (Yes)
immunomagnetic beads
No (No)
Yes (Yes)
antibody and toxin
No (No)
Yes (Yes)
antibody and complement
No (No)
Yes (Yes)
antibody coated plates and soybean lectin
No (No)
Yes (Yes)
antibody coated plates
No (No)
Yes (Yes)
antibody affinity column
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No (No)
Yes (Yes)
T-cell depletion
No (No)
Yes (Yes)
Specify system: (Answer only if the value for
2786700 is "Other" )
Specify cell selection system used:
Clinimax Cell Selection System
(CliniMACS / CliniMax)
Isolex Cell Selection System (Isolex)
Other (Other)
CD34+ selection
No (No)
Yes (Yes)
Was the product manipulated prior to infusion?
No (No)
Yes (Yes)
Autologous Products Only - Part 1 / 2
Were tumor cells detected in the recipient or
autologous product prior to HSCT?
No (No)
Yes (Yes)
Autologous Products Only
What tumor cell detection method was used ?
Cell Culture Techniques (Cell culture
technique)
Ihc, Immunohistochemistry
(Immunohistochemistry)
Other (Other)
Other Molecular Techniques (Other
molecular technique)
Pcr, Polymerase Chain Reaction
(Polymerase chain reaction(PCR))
Histopathology (Routine histopathology)
Were particular tumor cell detection method used
prior to HSCT?
No (No)
Yes (Yes)
Were tumor cells detected in circulating blood
cells prior to HSCT?
No (No)
Not Done: C49484 (Not Done)
Yes (Yes)
Were tumor cells detected in bone marrow, in the
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interval between last systemic therapy and
collection prior to HSCT?
No (No)
Not Done: C49484 (Not Done)
Yes (Yes)
Were tumor cells detected in collected cells,
before purging prior to HSCT?
No (No)
Not Done: C49484 (Not Done)
Yes (Yes)
Specify method (Answer only if the value for
2775544 is "Other molecular technique" OR
"Other technique"  )
Autologous Products Only - Part 3 / 5
Was the product treated to remove malignant
cells (purged) ? (autologous product only)
No (No)
Yes (Yes)
Autologous Products Only - 3 / 4
What malignant cell removal method was used to
treat the product?
Perfosfamide (4-
hydroperoxycyclophosphamide(4HC))
Elutriative Centrifugation (Elutriation)
Immunomagnetic Column
(Immunomagnetic column)
Mafosfamide (Mafosfamide)
Monoclonal Antibody (Monoclonal
antibody)
Other Medication (Other drug)
Other Method (Other method)
Hematopoietic Stem Cell Positive
Selection (Positive stem cell
selection(other than preparation of
mononuclear fraction))
Toxin (Toxin)
Was a particular malignant cell removal method
used for product treatment?
No (No)
Yes (Yes)
Specify the other malignant cell removal method:
(Answer only if the value for 2748795 is
"Monoclonal antibody","Other drug",
"Toxin","Positive stem cell selection" or "Other
method".)
Autologous Products Only Part 4 / 4
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What kind of method was used to detect tumor
cells after purging?
Cell Culture Techniques (Cell culture
technique)
Ihc, Immunohistochemistry
(Immunohistochemistry)
Other (Other)
Other Molecular Techniques (Other
molecular technique)
Pcr, Polymerase Chain Reaction
(Polymerase chain reaction(PCR))
Histopathology (Routine histopathology)
Was a particular tumor cell detection method
used after purging?
No (No)
Not Done: C49484 (Not Done)
Yes (Yes)
Specify the other tumor cells detection method
(Answer only if the value for 2778929 is "Other")
Product Analysis (all Products)
If codes 198, 209, 219, or 259, specify organism:
(Answer only if the value for 2784429,
2784431,2784433,2784435,2784437 and
2784439 is "Other bacteria, specify","Other
Candida, specify",Other Aspergillus, specify" or
"Other fungus, specify".)
Total colonies per product: (One decimal place
with exponent "x10E5")
Was there growth?
No (No)
Yes (Yes)
Were the colony-forming units (CFU) assessed
after thawing? (cord blood product only)
No (No)
Yes (Yes)
Specify other method: (Answer only if the value
for 2760530 is "Other method")
Method of testing cell viability:
7-aminoactinomycin D (7-AAD)
Other Method (Other method)
Propidium Iodide (Propidium iodide)
Trypan Blue (Trypan blue)
Not tested (The cell viability not tested)
Negation Test (Not tested)
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Viability of cells
Not tested (Not tested for CD8+ cells)
Negation Test (Not tested)
CD8+  cells exponent value:
Unknown (Total colonies per productunknown )
Unknown Not Applicable (Unknown/not
applicable)
Total CFU-GM: (One decimal place with exponent
"x10E5")
Specify organism names: (6th Organism Name)
Acinetobacter (Acinetobacter)
Actinomyces (Actinomyces)
Aspergillus Flavus (Aspergillus flavus)
Aspergillus Fumigatus (Aspergillus
fumigatus)
Aspergillus Niger (Aspergillus niger)
Aspergillus Not Otherwise Specified
(Aspergillus, NOS)
Bacillus (Bacillus)
Bacteroides (Bacteroides (gracillis,
uniformis, vulgaris, other species))
Bordetella Pertussis (Bordetella
pertussis (whooping cough))
Borrelia Burgdorferi (Borrelia (lyme
disease))
Moraxella Catarrhalis (Branhamella or
Moraxella catarrhalis (other species))
Campylobacter (Campylobacter (all
species))
Candida Glabrata (Candida (Torulopsis)
glabrata)
Candida Albicans (Candida albicans)
Pichia Guilliermondii (Candida
guillermondi)
Issatchenkia Orientalis (Candida krusei)
Clavispora Lusitaniae (Candida
lusitaniae)
Candida Parapsilosis (Candida
parapsilosis)
Candida Tropicalis (Candida tropicalis)
Candida Not Otherwise Specified
(Candida, NOS)
Capnocytophaga (Capnocytophaga)
Chlamydophila Pneumoniae (Chlamydia
(pneumoniae))
Chlamydia Not Otherwise Specified
(Chlamydia, NOS)
Citrobacter (Citrobacter (freundii, other
species))
Clostridium (Clostridium (all species
except difficile))
Clostridium Difficile (Clostridium difficile)
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Corynebacterium (Corynebacterium (all
non-diptheria species))
Corynebacterium Jeikeium
(Corynebacterium (jeikeium))
Coxiella (Coxiella)
Cryptococcosis (Cryptococcosus
species)
Enterobacter (Enterobacter)
Enterococcus (Enterococcus (all
species))
Vancomycin Resistant Enterococcus
(Enterococcus, vancomycin resistant
(VRE))
Escherichia Coli (Escherichia (also E.
coli))
Pseudomonas Oryzihabitans
(Flavimonas oryzihabitans)
Flavobacterium (Flavobacterium)
Fusarium (Fusarium species)
Fusobacterium (Fusobacterium)
Haemophilus (Haemophilus (all species,
including influenzae))
Helicobacter Pylori (Helicobacter pylori)
Histoplasmosis (Histoplasmosis)
Klebsiella (Klebsiella)
Lactobacillus (Lactobacillus (bulgaricus,
acidophilus, other species))
Legionella (Legionella)
Leptospira (Leptospira)
C76356 (Leptotrichia buccalis)
Leuconostoc (Leuconostoc (all species))
Listeria (Listeria)
Methylobacterium (Methylobacterium)
Micrococcus Not Otherwise Specified
(Micrococcus, NOS)
Zygomycosis (Mucormycosis)
Multiple Bacteria (Multiple bacteria at a
single site)
Mycobacterium Avium Complex
(Mycobacterium avium - intracellulare
(MAC, MAI))
Mycobacterium Species (Mycobacterium
species (cheloneae, fortuitum,
haemophilum, kansasii, mucogenicum))
Mycobacterium Tuberculosis
(Mycobacterium tuberculosis
(tuberculosis, Koch bacillus))
Mycobacterium Not Otherwise Specified
(Mycobacterium, NOS)
Mycoplasma (Mycoplasma)
Neisseria (Neisseria (gonorrhoeae,
meningitidis, other species))
Nocardia (Nocardia)
Other Aspergillus (Other Aspergillus)
Other Bacteria (Other bacteria)
Other Candida (Other Candida)
Other Chlamydia (Other chlamydia)
Other Fungi (Other fungus)
Other Mycobacterium (Other
mycobacterium)
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Pasteurella Multocida (Pasteurella
multocida)
Pneumocystis Pneumonia
(Pneumocystis (PCP / PJP))
Propionibacterium Acnes
(Propionibacterium (acnes, avidum,
granulosum, other species))
Proteus (Proteus)
Pseudomonas (Pseudomonas (all
species except cepacia & maltophilia))
Burkholderia Cepacia (Pseudomonas or
Burkholder cepacia)
Stenotrophomonas Maltophilia
(Pseudomonas or Stenotrophomonas or
Xanthomonas maltophilia)
Rhizopus (Rhizopus)
Rhodococcus (Rhodococcus)
Rickettsia (Rickettsia)
Salmonella (Salmonella (all species))
Serratia Marcescens (Serratia
marcescens)
Shigella (Shigella)
Staphylococcus Aureus (Staphylococcus
aureus)
Staphylococcus Coag Negative
(Staphylococcus, coagulase negative)
Streptococcus Not Otherwise Specified
(Staphylococcus, NOS)
Rothia Mucilaginosa (Stomatococcus
mucilaginosis)
Streptococcus (Streptococcus (all
species except Enterococcus))
Streptococcus Pneumoniae
(Streptococcus pneumoniae)
Suspected Atypical Bacteria Infection
(Suspected atypical bacterial infection)
Suspected Bacteria Infection (Suspected
bacterial infection)
Suspected Fungal Infection (Suspected
fungal infection)
Treponema (Treponema (syphilis))
Vibrio (Vibrio (all species))
Yeast Not Otherwise Specified (Yeast,
NOS)
Zygomycota Not Otherwise Specified
(Zygomycetes, NOS)
Specify organism names: (5th Organism Name)
Acinetobacter (Acinetobacter)
Actinomyces (Actinomyces)
Aspergillus Flavus (Aspergillus flavus)
Aspergillus Fumigatus (Aspergillus
fumigatus)
Aspergillus Niger (Aspergillus niger)
Aspergillus Not Otherwise Specified
(Aspergillus, NOS)
Bacillus (Bacillus)
Bacteroides (Bacteroides (gracillis,
uniformis, vulgaris, other species))
Bordetella Pertussis (Bordetella
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pertussis (whooping cough))
Borrelia Burgdorferi (Borrelia (lyme
disease))
Moraxella Catarrhalis (Branhamella or
Moraxella catarrhalis (other species))
Campylobacter (Campylobacter (all
species))
Candida Glabrata (Candida (Torulopsis)
glabrata)
Candida Albicans (Candida albicans)
Pichia Guilliermondii (Candida
guillermondi)
Issatchenkia Orientalis (Candida krusei)
Clavispora Lusitaniae (Candida
lusitaniae)
Candida Parapsilosis (Candida
parapsilosis)
Candida Tropicalis (Candida tropicalis)
Candida Not Otherwise Specified
(Candida, NOS)
Capnocytophaga (Capnocytophaga)
Chlamydophila Pneumoniae (Chlamydia
(pneumoniae))
Chlamydia Not Otherwise Specified
(Chlamydia, NOS)
Citrobacter (Citrobacter (freundii, other
species))
Clostridium (Clostridium (all species
except difficile))
Clostridium Difficile (Clostridium difficile)
Corynebacterium (Corynebacterium (all
non-diptheria species))
Corynebacterium Jeikeium
(Corynebacterium (jeikeium))
Coxiella (Coxiella)
Cryptococcosis (Cryptococcosus
species)
Enterobacter (Enterobacter)
Enterococcus (Enterococcus (all
species))
Vancomycin Resistant Enterococcus
(Enterococcus, vancomycin resistant
(VRE))
Escherichia Coli (Escherichia (also E.
coli))
Pseudomonas Oryzihabitans
(Flavimonas oryzihabitans)
Flavobacterium (Flavobacterium)
Fusarium (Fusarium species)
Fusobacterium (Fusobacterium)
Haemophilus (Haemophilus (all species,
including influenzae))
Helicobacter Pylori (Helicobacter pylori)
Histoplasmosis (Histoplasmosis)
Klebsiella (Klebsiella)
Lactobacillus (Lactobacillus (bulgaricus,
acidophilus, other species))
Legionella (Legionella)
Leptospira (Leptospira)
C76356 (Leptotrichia buccalis)
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Leuconostoc (Leuconostoc (all species))
Listeria (Listeria)
Methylobacterium (Methylobacterium)
Micrococcus Not Otherwise Specified
(Micrococcus, NOS)
Zygomycosis (Mucormycosis)
Multiple Bacteria (Multiple bacteria at a
single site)
Mycobacterium Avium Complex
(Mycobacterium avium - intracellulare
(MAC, MAI))
Mycobacterium Species (Mycobacterium
species (cheloneae, fortuitum,
haemophilum, kansasii, mucogenicum))
Mycobacterium Tuberculosis
(Mycobacterium tuberculosis
(tuberculosis, Koch bacillus))
Mycobacterium Not Otherwise Specified
(Mycobacterium, NOS)
Mycoplasma (Mycoplasma)
Neisseria (Neisseria (gonorrhoeae,
meningitidis, other species))
Nocardia (Nocardia)
Other Aspergillus (Other Aspergillus)
Other Bacteria (Other bacteria)
Other Candida (Other Candida)
Other Chlamydia (Other chlamydia)
Other Fungi (Other fungus)
Other Mycobacterium (Other
mycobacterium)
Pasteurella Multocida (Pasteurella
multocida)
Pneumocystis Pneumonia
(Pneumocystis (PCP / PJP))
Propionibacterium Acnes
(Propionibacterium (acnes, avidum,
granulosum, other species))
Proteus (Proteus)
Pseudomonas (Pseudomonas (all
species except cepacia & maltophilia))
Burkholderia Cepacia (Pseudomonas or
Burkholder cepacia)
Stenotrophomonas Maltophilia
(Pseudomonas or Stenotrophomonas or
Xanthomonas maltophilia)
Rhizopus (Rhizopus)
Rhodococcus (Rhodococcus)
Rickettsia (Rickettsia)
Salmonella (Salmonella (all species))
Serratia Marcescens (Serratia
marcescens)
Shigella (Shigella)
Staphylococcus Aureus (Staphylococcus
aureus)
Staphylococcus Coag Negative
(Staphylococcus, coagulase negative)
Streptococcus Not Otherwise Specified
(Staphylococcus, NOS)
Rothia Mucilaginosa (Stomatococcus
mucilaginosis)
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Streptococcus (Streptococcus (all
species except Enterococcus))
Streptococcus Pneumoniae
(Streptococcus pneumoniae)
Suspected Atypical Bacteria Infection
(Suspected atypical bacterial infection)
Suspected Bacteria Infection (Suspected
bacterial infection)
Suspected Fungal Infection (Suspected
fungal infection)
Treponema (Treponema (syphilis))
Vibrio (Vibrio (all species))
Yeast Not Otherwise Specified (Yeast,
NOS)
Zygomycota Not Otherwise Specified
(Zygomycetes, NOS)
Specify organism names: (4th Organism Name)
Acinetobacter (Acinetobacter)
Actinomyces (Actinomyces)
Aspergillus Flavus (Aspergillus flavus)
Aspergillus Fumigatus (Aspergillus
fumigatus)
Aspergillus Niger (Aspergillus niger)
Aspergillus Not Otherwise Specified
(Aspergillus, NOS)
Bacillus (Bacillus)
Bacteroides (Bacteroides (gracillis,
uniformis, vulgaris, other species))
Bordetella Pertussis (Bordetella
pertussis (whooping cough))
Borrelia Burgdorferi (Borrelia (lyme
disease))
Moraxella Catarrhalis (Branhamella or
Moraxella catarrhalis (other species))
Campylobacter (Campylobacter (all
species))
Candida Glabrata (Candida (Torulopsis)
glabrata)
Candida Albicans (Candida albicans)
Pichia Guilliermondii (Candida
guillermondi)
Issatchenkia Orientalis (Candida krusei)
Clavispora Lusitaniae (Candida
lusitaniae)
Candida Parapsilosis (Candida
parapsilosis)
Candida Tropicalis (Candida tropicalis)
Candida Not Otherwise Specified
(Candida, NOS)
Capnocytophaga (Capnocytophaga)
Chlamydophila Pneumoniae (Chlamydia
(pneumoniae))
Chlamydia Not Otherwise Specified
(Chlamydia, NOS)
Citrobacter (Citrobacter (freundii, other
species))
Clostridium (Clostridium (all species
except difficile))
Clostridium Difficile (Clostridium difficile)
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Corynebacterium (Corynebacterium (all
non-diptheria species))
Corynebacterium Jeikeium
(Corynebacterium (jeikeium))
Coxiella (Coxiella)
Cryptococcosis (Cryptococcosus
species)
Enterobacter (Enterobacter)
Enterococcus (Enterococcus (all
species))
Vancomycin Resistant Enterococcus
(Enterococcus, vancomycin resistant
(VRE))
Escherichia Coli (Escherichia (also E.
coli))
Pseudomonas Oryzihabitans
(Flavimonas oryzihabitans)
Flavobacterium (Flavobacterium)
Fusarium (Fusarium species)
Fusobacterium (Fusobacterium)
Haemophilus (Haemophilus (all species,
including influenzae))
Helicobacter Pylori (Helicobacter pylori)
Histoplasmosis (Histoplasmosis)
Klebsiella (Klebsiella)
Lactobacillus (Lactobacillus (bulgaricus,
acidophilus, other species))
Legionella (Legionella)
Leptospira (Leptospira)
C76356 (Leptotrichia buccalis)
Leuconostoc (Leuconostoc (all species))
Listeria (Listeria)
Methylobacterium (Methylobacterium)
Micrococcus Not Otherwise Specified
(Micrococcus, NOS)
Zygomycosis (Mucormycosis)
Multiple Bacteria (Multiple bacteria at a
single site)
Mycobacterium Avium Complex
(Mycobacterium avium - intracellulare
(MAC, MAI))
Mycobacterium Species (Mycobacterium
species (cheloneae, fortuitum,
haemophilum, kansasii, mucogenicum))
Mycobacterium Tuberculosis
(Mycobacterium tuberculosis
(tuberculosis, Koch bacillus))
Mycobacterium Not Otherwise Specified
(Mycobacterium, NOS)
Mycoplasma (Mycoplasma)
Neisseria (Neisseria (gonorrhoeae,
meningitidis, other species))
Nocardia (Nocardia)
Other Aspergillus (Other Aspergillus)
Other Bacteria (Other bacteria)
Other Candida (Other Candida)
Other Chlamydia (Other chlamydia)
Other Fungi (Other fungus)
Other Mycobacterium (Other
mycobacterium)
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Pasteurella Multocida (Pasteurella
multocida)
Pneumocystis Pneumonia
(Pneumocystis (PCP / PJP))
Propionibacterium Acnes
(Propionibacterium (acnes, avidum,
granulosum, other species))
Proteus (Proteus)
Pseudomonas (Pseudomonas (all
species except cepacia & maltophilia))
Burkholderia Cepacia (Pseudomonas or
Burkholder cepacia)
Stenotrophomonas Maltophilia
(Pseudomonas or Stenotrophomonas or
Xanthomonas maltophilia)
Rhizopus (Rhizopus)
Rhodococcus (Rhodococcus)
Rickettsia (Rickettsia)
Salmonella (Salmonella (all species))
Serratia Marcescens (Serratia
marcescens)
Shigella (Shigella)
Staphylococcus Aureus (Staphylococcus
aureus)
Staphylococcus Coag Negative
(Staphylococcus, coagulase negative)
Streptococcus Not Otherwise Specified
(Staphylococcus, NOS)
Rothia Mucilaginosa (Stomatococcus
mucilaginosis)
Streptococcus (Streptococcus (all
species except Enterococcus))
Streptococcus Pneumoniae
(Streptococcus pneumoniae)
Suspected Atypical Bacteria Infection
(Suspected atypical bacterial infection)
Suspected Bacteria Infection (Suspected
bacterial infection)
Suspected Fungal Infection (Suspected
fungal infection)
Treponema (Treponema (syphilis))
Vibrio (Vibrio (all species))
Yeast Not Otherwise Specified (Yeast,
NOS)
Zygomycota Not Otherwise Specified
(Zygomycetes, NOS)
Specify organism names: (3rd Organism Name)
Acinetobacter (Acinetobacter)
Actinomyces (Actinomyces)
Aspergillus Flavus (Aspergillus flavus)
Aspergillus Fumigatus (Aspergillus
fumigatus)
Aspergillus Niger (Aspergillus niger)
Aspergillus Not Otherwise Specified
(Aspergillus, NOS)
Bacillus (Bacillus)
Bacteroides (Bacteroides (gracillis,
uniformis, vulgaris, other species))
Bordetella Pertussis (Bordetella
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pertussis (whooping cough))
Borrelia Burgdorferi (Borrelia (lyme
disease))
Moraxella Catarrhalis (Branhamella or
Moraxella catarrhalis (other species))
Campylobacter (Campylobacter (all
species))
Candida Glabrata (Candida (Torulopsis)
glabrata)
Candida Albicans (Candida albicans)
Pichia Guilliermondii (Candida
guillermondi)
Issatchenkia Orientalis (Candida krusei)
Clavispora Lusitaniae (Candida
lusitaniae)
Candida Parapsilosis (Candida
parapsilosis)
Candida Tropicalis (Candida tropicalis)
Candida Not Otherwise Specified
(Candida, NOS)
Capnocytophaga (Capnocytophaga)
Chlamydophila Pneumoniae (Chlamydia
(pneumoniae))
Chlamydia Not Otherwise Specified
(Chlamydia, NOS)
Citrobacter (Citrobacter (freundii, other
species))
Clostridium (Clostridium (all species
except difficile))
Clostridium Difficile (Clostridium difficile)
Corynebacterium (Corynebacterium (all
non-diptheria species))
Corynebacterium Jeikeium
(Corynebacterium (jeikeium))
Coxiella (Coxiella)
Cryptococcosis (Cryptococcosus
species)
Enterobacter (Enterobacter)
Enterococcus (Enterococcus (all
species))
Vancomycin Resistant Enterococcus
(Enterococcus, vancomycin resistant
(VRE))
Escherichia Coli (Escherichia (also E.
coli))
Pseudomonas Oryzihabitans
(Flavimonas oryzihabitans)
Flavobacterium (Flavobacterium)
Fusarium (Fusarium species)
Fusobacterium (Fusobacterium)
Haemophilus (Haemophilus (all species,
including influenzae))
Helicobacter Pylori (Helicobacter pylori)
Histoplasmosis (Histoplasmosis)
Klebsiella (Klebsiella)
Lactobacillus (Lactobacillus (bulgaricus,
acidophilus, other species))
Legionella (Legionella)
Leptospira (Leptospira)
C76356 (Leptotrichia buccalis)
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Leuconostoc (Leuconostoc (all species))
Listeria (Listeria)
Methylobacterium (Methylobacterium)
Micrococcus Not Otherwise Specified
(Micrococcus, NOS)
Zygomycosis (Mucormycosis)
Multiple Bacteria (Multiple bacteria at a
single site)
Mycobacterium Avium Complex
(Mycobacterium avium - intracellulare
(MAC, MAI))
Mycobacterium Species (Mycobacterium
species (cheloneae, fortuitum,
haemophilum, kansasii, mucogenicum))
Mycobacterium Tuberculosis
(Mycobacterium tuberculosis
(tuberculosis, Koch bacillus))
Mycobacterium Not Otherwise Specified
(Mycobacterium, NOS)
Mycoplasma (Mycoplasma)
Neisseria (Neisseria (gonorrhoeae,
meningitidis, other species))
Nocardia (Nocardia)
Other Aspergillus (Other Aspergillus)
Other Bacteria (Other bacteria)
Other Candida (Other Candida)
Other Chlamydia (Other chlamydia)
Other Fungi (Other fungus)
Other Mycobacterium (Other
mycobacterium)
Pasteurella Multocida (Pasteurella
multocida)
Pneumocystis Pneumonia
(Pneumocystis (PCP / PJP))
Propionibacterium Acnes
(Propionibacterium (acnes, avidum,
granulosum, other species))
Proteus (Proteus)
Pseudomonas (Pseudomonas (all
species except cepacia & maltophilia))
Burkholderia Cepacia (Pseudomonas or
Burkholder cepacia)
Stenotrophomonas Maltophilia
(Pseudomonas or Stenotrophomonas or
Xanthomonas maltophilia)
Rhizopus (Rhizopus)
Rhodococcus (Rhodococcus)
Rickettsia (Rickettsia)
Salmonella (Salmonella (all species))
Serratia Marcescens (Serratia
marcescens)
Shigella (Shigella)
Staphylococcus Aureus (Staphylococcus
aureus)
Staphylococcus Coag Negative
(Staphylococcus, coagulase negative)
Streptococcus Not Otherwise Specified
(Staphylococcus, NOS)
Rothia Mucilaginosa (Stomatococcus
mucilaginosis)
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Streptococcus (Streptococcus (all
species except Enterococcus))
Streptococcus Pneumoniae
(Streptococcus pneumoniae)
Suspected Atypical Bacteria Infection
(Suspected atypical bacterial infection)
Suspected Bacteria Infection (Suspected
bacterial infection)
Suspected Fungal Infection (Suspected
fungal infection)
Treponema (Treponema (syphilis))
Vibrio (Vibrio (all species))
Yeast Not Otherwise Specified (Yeast,
NOS)
Zygomycota Not Otherwise Specified
(Zygomycetes, NOS)
Specify organism names: (2nd Organism Name)
Acinetobacter (Acinetobacter)
Actinomyces (Actinomyces)
Aspergillus Flavus (Aspergillus flavus)
Aspergillus Fumigatus (Aspergillus
fumigatus)
Aspergillus Niger (Aspergillus niger)
Aspergillus Not Otherwise Specified
(Aspergillus, NOS)
Bacillus (Bacillus)
Bacteroides (Bacteroides (gracillis,
uniformis, vulgaris, other species))
Bordetella Pertussis (Bordetella
pertussis (whooping cough))
Borrelia Burgdorferi (Borrelia (lyme
disease))
Moraxella Catarrhalis (Branhamella or
Moraxella catarrhalis (other species))
Campylobacter (Campylobacter (all
species))
Candida Glabrata (Candida (Torulopsis)
glabrata)
Candida Albicans (Candida albicans)
Pichia Guilliermondii (Candida
guillermondi)
Issatchenkia Orientalis (Candida krusei)
Clavispora Lusitaniae (Candida
lusitaniae)
Candida Parapsilosis (Candida
parapsilosis)
Candida Tropicalis (Candida tropicalis)
Candida Not Otherwise Specified
(Candida, NOS)
Capnocytophaga (Capnocytophaga)
Chlamydophila Pneumoniae (Chlamydia
(pneumoniae))
Chlamydia Not Otherwise Specified
(Chlamydia, NOS)
Citrobacter (Citrobacter (freundii, other
species))
Clostridium (Clostridium (all species
except difficile))
Clostridium Difficile (Clostridium difficile)
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Corynebacterium (Corynebacterium (all
non-diptheria species))
Corynebacterium Jeikeium
(Corynebacterium (jeikeium))
Coxiella (Coxiella)
Cryptococcosis (Cryptococcosus
species)
Enterobacter (Enterobacter)
Enterococcus (Enterococcus (all
species))
Vancomycin Resistant Enterococcus
(Enterococcus, vancomycin resistant
(VRE))
Escherichia Coli (Escherichia (also E.
coli))
Pseudomonas Oryzihabitans
(Flavimonas oryzihabitans)
Flavobacterium (Flavobacterium)
Fusarium (Fusarium species)
Fusobacterium (Fusobacterium)
Haemophilus (Haemophilus (all species,
including influenzae))
Helicobacter Pylori (Helicobacter pylori)
Histoplasmosis (Histoplasmosis)
Klebsiella (Klebsiella)
Lactobacillus (Lactobacillus (bulgaricus,
acidophilus, other species))
Legionella (Legionella)
Leptospira (Leptospira)
C76356 (Leptotrichia buccalis)
Leuconostoc (Leuconostoc (all species))
Listeria (Listeria)
Methylobacterium (Methylobacterium)
Micrococcus Not Otherwise Specified
(Micrococcus, NOS)
Zygomycosis (Mucormycosis)
Multiple Bacteria (Multiple bacteria at a
single site)
Mycobacterium Avium Complex
(Mycobacterium avium - intracellulare
(MAC, MAI))
Mycobacterium Species (Mycobacterium
species (cheloneae, fortuitum,
haemophilum, kansasii, mucogenicum))
Mycobacterium Tuberculosis
(Mycobacterium tuberculosis
(tuberculosis, Koch bacillus))
Mycobacterium Not Otherwise Specified
(Mycobacterium, NOS)
Mycoplasma (Mycoplasma)
Neisseria (Neisseria (gonorrhoeae,
meningitidis, other species))
Nocardia (Nocardia)
Other Aspergillus (Other Aspergillus)
Other Bacteria (Other bacteria)
Other Candida (Other Candida)
Other Chlamydia (Other chlamydia)
Other Fungi (Other fungus)
Other Mycobacterium (Other
mycobacterium)
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Pasteurella Multocida (Pasteurella
multocida)
Pneumocystis Pneumonia
(Pneumocystis (PCP / PJP))
Propionibacterium Acnes
(Propionibacterium (acnes, avidum,
granulosum, other species))
Proteus (Proteus)
Pseudomonas (Pseudomonas (all
species except cepacia & maltophilia))
Burkholderia Cepacia (Pseudomonas or
Burkholder cepacia)
Stenotrophomonas Maltophilia
(Pseudomonas or Stenotrophomonas or
Xanthomonas maltophilia)
Rhizopus (Rhizopus)
Rhodococcus (Rhodococcus)
Rickettsia (Rickettsia)
Salmonella (Salmonella (all species))
Serratia Marcescens (Serratia
marcescens)
Shigella (Shigella)
Staphylococcus Aureus (Staphylococcus
aureus)
Staphylococcus Coag Negative
(Staphylococcus, coagulase negative)
Streptococcus Not Otherwise Specified
(Staphylococcus, NOS)
Rothia Mucilaginosa (Stomatococcus
mucilaginosis)
Streptococcus (Streptococcus (all
species except Enterococcus))
Streptococcus Pneumoniae
(Streptococcus pneumoniae)
Suspected Atypical Bacteria Infection
(Suspected atypical bacterial infection)
Suspected Bacteria Infection (Suspected
bacterial infection)
Suspected Fungal Infection (Suspected
fungal infection)
Treponema (Treponema (syphilis))
Vibrio (Vibrio (all species))
Yeast Not Otherwise Specified (Yeast,
NOS)
Zygomycota Not Otherwise Specified
(Zygomycetes, NOS)
Specify organism names: (1st Organism Name)
Acinetobacter (Acinetobacter)
Actinomyces (Actinomyces)
Aspergillus Flavus (Aspergillus flavus)
Aspergillus Fumigatus (Aspergillus
fumigatus)
Aspergillus Niger (Aspergillus niger)
Aspergillus Not Otherwise Specified
(Aspergillus, NOS)
Bacillus (Bacillus)
Bacteroides (Bacteroides (gracillis,
uniformis, vulgaris, other species))
Bordetella Pertussis (Bordetella
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pertussis (whooping cough))
Borrelia Burgdorferi (Borrelia (lyme
disease))
Moraxella Catarrhalis (Branhamella or
Moraxella catarrhalis (other species))
Campylobacter (Campylobacter (all
species))
Candida Glabrata (Candida (Torulopsis)
glabrata)
Candida Albicans (Candida albicans)
Pichia Guilliermondii (Candida
guillermondi)
Issatchenkia Orientalis (Candida krusei)
Clavispora Lusitaniae (Candida
lusitaniae)
Candida Parapsilosis (Candida
parapsilosis)
Candida Tropicalis (Candida tropicalis)
Candida Not Otherwise Specified
(Candida, NOS)
Capnocytophaga (Capnocytophaga)
Chlamydophila Pneumoniae (Chlamydia
(pneumoniae))
Chlamydia Not Otherwise Specified
(Chlamydia, NOS)
Citrobacter (Citrobacter (freundii, other
species))
Clostridium (Clostridium (all species
except difficile))
Clostridium Difficile (Clostridium difficile)
Corynebacterium (Corynebacterium (all
non-diptheria species))
Corynebacterium Jeikeium
(Corynebacterium (jeikeium))
Coxiella (Coxiella)
Cryptococcosis (Cryptococcosus
species)
Enterobacter (Enterobacter)
Enterococcus (Enterococcus (all
species))
Vancomycin Resistant Enterococcus
(Enterococcus, vancomycin resistant
(VRE))
Escherichia Coli (Escherichia (also E.
coli))
Pseudomonas Oryzihabitans
(Flavimonas oryzihabitans)
Flavobacterium (Flavobacterium)
Fusarium (Fusarium species)
Fusobacterium (Fusobacterium)
Haemophilus (Haemophilus (all species,
including influenzae))
Helicobacter Pylori (Helicobacter pylori)
Histoplasmosis (Histoplasmosis)
Klebsiella (Klebsiella)
Lactobacillus (Lactobacillus (bulgaricus,
acidophilus, other species))
Legionella (Legionella)
Leptospira (Leptospira)
C76356 (Leptotrichia buccalis)
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Leuconostoc (Leuconostoc (all species))
Listeria (Listeria)
Methylobacterium (Methylobacterium)
Micrococcus Not Otherwise Specified
(Micrococcus, NOS)
Zygomycosis (Mucormycosis)
Multiple Bacteria (Multiple bacteria at a
single site)
Mycobacterium Avium Complex
(Mycobacterium avium - intracellulare
(MAC, MAI))
Mycobacterium Species (Mycobacterium
species (cheloneae, fortuitum,
haemophilum, kansasii, mucogenicum))
Mycobacterium Tuberculosis
(Mycobacterium tuberculosis
(tuberculosis, Koch bacillus))
Mycobacterium Not Otherwise Specified
(Mycobacterium, NOS)
Mycoplasma (Mycoplasma)
Neisseria (Neisseria (gonorrhoeae,
meningitidis, other species))
Nocardia (Nocardia)
Other Aspergillus (Other Aspergillus)
Other Bacteria (Other bacteria)
Other Candida (Other Candida)
Other Chlamydia (Other chlamydia)
Other Fungi (Other fungus)
Other Mycobacterium (Other
mycobacterium)
Pasteurella Multocida (Pasteurella
multocida)
Pneumocystis Pneumonia
(Pneumocystis (PCP / PJP))
Propionibacterium Acnes
(Propionibacterium (acnes, avidum,
granulosum, other species))
Proteus (Proteus)
Pseudomonas (Pseudomonas (all
species except cepacia & maltophilia))
Burkholderia Cepacia (Pseudomonas or
Burkholder cepacia)
Stenotrophomonas Maltophilia
(Pseudomonas or Stenotrophomonas or
Xanthomonas maltophilia)
Rhizopus (Rhizopus)
Rhodococcus (Rhodococcus)
Rickettsia (Rickettsia)
Salmonella (Salmonella (all species))
Serratia Marcescens (Serratia
marcescens)
Shigella (Shigella)
Staphylococcus Aureus (Staphylococcus
aureus)
Staphylococcus Coag Negative
(Staphylococcus, coagulase negative)
Streptococcus Not Otherwise Specified
(Staphylococcus, NOS)
Rothia Mucilaginosa (Stomatococcus
mucilaginosis)
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Streptococcus (Streptococcus (all
species except Enterococcus))
Streptococcus Pneumoniae
(Streptococcus pneumoniae)
Suspected Atypical Bacteria Infection
(Suspected atypical bacterial infection)
Suspected Bacteria Infection (Suspected
bacterial infection)
Suspected Fungal Infection (Suspected
fungal infection)
Treponema (Treponema (syphilis))
Vibrio (Vibrio (all species))
Yeast Not Otherwise Specified (Yeast,
NOS)
Zygomycota Not Otherwise Specified
(Zygomycetes, NOS)
Specify results:
Negative Finding (Negative)
Positive Finding (Positive)
Unknown (Unknown)
Were cultures performed before infusion to test
the product(s) for bacterial or fungal infection?
(complete for all cell products)
No (No)
Yes (Yes)
Unknown (Total CFU-GMUnknown  )
Unknown Not Applicable (Unknown/not
applicable)
CD8+ cells: (Report the total number of cells not
cells per kilogram)
Not tested (Not tested for CD4+ cells)
Negation Test (Not tested)
Not tested (Not tested for mononucleated cells)
Negation Test (Not tested)
Mononucleated cells exponent value:
Mononucleated cells: (Report the total number of
cells not cells per kilogram)
Not tested (Not tested for nucleated cells)
Negation Test (Not tested)
Nucleated cells exponent value:
Nucleated cells: (Report the total number of cells
not cells per kilogram)
What was the unit of measure for the total volume
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of the product being analyzed?
Gram (g)
Milliliter (mL)
Total volume of product: (one decimal place)
Date of product analysis:
Nucleated red blood cells: (Report the total
number of cells not cells per kilogram)
Nucleated red blood cells exponent value:
CD4+  cells exponent value:
CD4+ cells: (Report the total number of cells not
cells per kilogram)
Not tested (Not tested for CD3+ cells)
Negation Test (Not tested)
CD3+  cells exponent value:
CD3+ cells: (Report the total number of cells not
cells per kilogram)
Not tested (Not tested for CD34+ cells)
Negation Test (Not tested)
CD34+  cells exponent value:
CD34+ cells: (Report the total number of cells not
cells per kilogram)
Not tested (Not tested for nucleated red blood
cells)
Negation Test (Not tested)
Specify the time point in the product preparation
that the product was analyzed:
Infusion Timepoint (At infusion (final
quantity infused))
Post Manipulation (Post-manipulation)
Post Processing Prior Cryopreservation
Prior Manipulation (Post-processing, pre-
cryopreservation / manipulation)
Post Thaw (Post-thaw)
Arrival (Product arrival)
Product Infusion
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Was more than one product infused? (e.g.,
marrow and PBSC,PBSC and cord blood, two
different cords, etc.)
No (No)
Yes (Yes)
Specify route of infusion:
Specify the route of product infusion:
Intramedullary Route Of Administration
(Intramedullary)
Intraperitoneal Route Of Administration
(Intraperitoneal)
Intravenous Route Of Administration
(Intravenous)
Other Route Of Administration (Other
route of infusion)
Total volume of product plus additives infused:
(One decimal place with Unit of Measure "ml")
Is it the standard time or daylight savings time?
Daylight Savings Time (Daylight Savings
Time)
Standard Time (Standard time)
Time product infusion completed (24-hour clock):
Is it the standard time or daylight savings time?
Daylight Savings Time (Daylight Savings
Time)
Standard Time (Standard time)
Time product infusion initiated (24-hour clock):
Date of this product infusion:
Was the product infusion described on this insert
intended to produce hematopoietic engraftment?
No (No)
Yes (Yes)
Did the volume of infused product include any
added agents?
No (No)
Yes (Yes)
Product Infusion - Part 2 / 3
What kind of additives are included in volume of
infused product?
Acid-citrate-dextrose (Acid-Citrate-
Dextrose (ACD))
Albumin (Albumin)
Antibiotic (Antibiotic)
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Dextran Sulfate Sodium (Dextran)
Heparin (Heparin)
Other (Other)
Were particular additives included in volume of
infused product?
No (No)
Yes (Yes)
Specify agent: (Answer only if the value for
2740356 is "Other")
Product Infusion
Was the entire volume of product infused?
No (No)
Yes (Yes)
Specify what happened to the reserved portion:
Cryopreservation (Cryopreserved for
future use)
Destruction (Discarded)
Other Endpoints (Other fate)
Specify: (Answer only if the value for 2769592 is
"Other fate")
Were there any adverse events or incidents
associated with the stem cell infusion? (The
question refers to all stem cell products except for
autologous marrow or autologous PBSC
products.)
No (No)
Yes (Yes)
Product Infusion
What type of Adverse Events associated with the
stem cell infusion?
Bradycardia (Brachycardia)
Chest Pain (Chest tightness/pain)
At Infusion Time Chills (Chills at time of
infusion)
Fever > 103 F Within 24 Hours Of
Infusion (Fever greater than 103 F within
24 hours of infusion)
Fever <= 103 F Within 24 Hours Of
Infusion (Fever less than or equal to 103
F within 24 hours of infusion)
Whole Hemoglobinuria (Gross
hemoglobinuria)
Headache (Headache)
Urticaria (Hives)
Hypertension (Hypertension)
Hypotension (Hypotension)
Required Oxygen Hypoxia (Hypoxia
30 / 36
Treatment - Hematopoietic Stem Cell Transplant (HSCT) Infusion ISO
Date Format Version 1 - 2894050v2.0
requiring oxygen(O2) support)
Nausea (Nausea)
Other Expected Adverse Event (Other
expected AE)
Other Unexpected Adverse Event (Other
unexpected AE)
Ctcae Grade 1 Rigors And Chills (Rigors,
mild)
Ctcae Grade 3 Rigors And Chills (Rigors,
severe)
Dyspnea (Shortness of breath(SOB))
Tachycardia (Tachycardia)
Vomiting (Vomiting)
Did a particular stem cell infusion associated
adverse event occur?
No (No)
Yes (Yes)
Did particular adverse events require medical
intervention?
No (No)
Yes (Yes)
Were particular adverse events resolved?
No (No)
Yes (Yes)
Specify (Answer only if the value for 2739534 is
"Other expected AE" or "Other unexpected AE")
Product Infusion
In the Medical Director's judgement, was the
adverse event a direct result of the infusion?
No (No)
Yes (Yes)
Specify the most likely cause of the adverse
event :
Medication Reaction (Drug reaction)
Other Diseases And Disorders (Other
illness)
Other Reason (Other reason)
Hematopoietic Stem Cell Transplant
Reaction (Product reaction)
Relationship Regimen (Regimen related)
Specify illness: (Answer only if the value for
2769598 is "Other illness")
Specify reason: (Answer only if the value for
2769598 is "Other reason")
Donor Demographic Information
Donor date of birth:
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Specify site: (Answer only if the value for
2769666 is "Other site")
Specify the site of the central line placement:
Femoral Vein (Femoral)
Internal Jugular Vein (Internal jugular)
Other Anatomic Site (Other site)
Subclavian Vein (Subclavian)
Did this donor have a central line placed?
No (No)
Not Applicable (Not Applicable)
Yes (Yes)
Donor's blood type and Rh factor:
Blood Group A Rh Negative Blood Group
(A negative)
Blood Group A Rh Positive Blood Group
(A positive)
Blood Group Ab Rh Negative Blood
Group (AB negative)
Blood Group Ab Rh Positive Blood
Group (AB positive)
Blood Group B Rh Negative Blood Group
(B negative)
Blood Group B Rh Positive Blood Group
(B positive)
Blood Group O Rh Negative Blood
Group (O negative)
Blood Group O Rh Positive Blood Group
(O positive)
Unknown (unknown)
What is the reason for the missing number of
pregnancies?
Unknown Not Applicable (Unknown/not
applicable)
Specify number of pregnancies:
Was the donor ever pregnant?
No (No)
Not Applicable (Not Applicable)
Unknown (Unknown)
Yes (Yes)
Donor Gender
Female (female)
Male (male)
Name of cord blood bank providing CBU: (Cord
blood unit only)
Is the CBU ID number also the ICCBBA ISBT 128
number? (Cord blood unit only)
No (No)
Yes (Yes)
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Non-NMDP Cord Blood Unit (CBU) ID: (Cord
blood unit only)
What is the reason for the mother's missing age?
(Cord blood unit only)
Unknown Not Applicable (Unknown/not
applicable)
Age of mother (approximate): (Cord blood unit
only)
Date unknown
Date Unknown (date unknown)
Donor's ethnicity:
A Person Of Mexican, Puerto Rican,
Cuban, Central Or South American Or
Other Spanish Culture Or Origin,
Regardless Of Race. (Hispanic or Latino)
A Person Not Meeting The Definition For
Hispanic Or Latino. (Not Hispanic or
Latino)
Could Not Be Determined Or Unsure
(Unknown)
Donor Demographic Information Part 2 / 2
Donor's race (Mark the groups in which the donor
is a member. Check all that apply )
African (African (both parents born in
Africa))
African American (African American)
Alaska Native (Alaskan Native or Aleut)
South Or Central American Indian
(American Indian, South or Central
America)
African Caribbean (Black Caribbean)
Black South Or Central American (Black
South or Central American)
Caribbean Indian (Caribbean Indian)
Chinese (Chinese)
Response Declined (Declines to provide
race)
Eastern European (Eastern European)
Filipino (Filipino (Pilipino))
Guamanian (Guamanian)
Hawaiian (Hawaiian)
Japanese (Japanese)
Korean (Korean)
Mediterranean (Mediterranean)
Middle Eastern (Middle Eastern)
North American (North American)
American Indian (North American Indian)
North Coast Of Africa (North Coast of
Africa)
Northern European (Northern European)
33 / 36
Treatment - Hematopoietic Stem Cell Transplant (HSCT) Infusion ISO
Date Format Version 1 - 2894050v2.0
Other Native Hawaiian Or Other Pacific
Islander (Other Pacific Islander)
Other South Asian (Other Southeast
Asian)
Other White (Other White)
Unknown (Race unknown)
Samoan (Samoan)
South Asian (South Asian)
Vietnamese (Vietnamese)
Western European (Western European)
White Caribbean (White Caribbean)
White South Or Central American (White
South or Central American)
Donor Demographic Information
What is the relationship of the donor to the
recipient?
Other Relative (Other relative)
Recipient Child (Recipient's child)
Sibling (Sibling)
Unrelated (Unrelated)
Was the blood transfusion product autologous?
(Question applies only to allogeneic non-NMDP
donors )
No (No)
Yes (Yes)
Specify number of units: (For the autologous
blood transfusion)
Was the blood transfusion product allogeneic
(homologous)? (Question applies only to
allogeneic non-NMDP donors)
No (No)
Yes (Yes)
Specify number of units: (For the autologous
blood transfusion)
Did the donor die as a result of the collection?
(Question applies only to allogeneic non-NMDP
donors)
No (No)
Yes (Yes)
Specify cause of death: (Question applies only to
allogeneic non-NMDP donors)
Did the recipient submit a research sample?
(Related donors only)
No (No)
Yes (Yes)
Research sample recipient ID:
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Did the donor submit a research sample?
(Related donors only)
No (No)
Yes (Yes)
Did the donor receive blood transfusions as a
result of the collection? (Question applies only to
allogeneic non-NMDP donors)
No (No)
Yes (Yes)
Specify complications: (Question applies only to
allogeneic non-NMDP donors. Answer only if the
value of CDE 2728986 is "Yes".)
Specify the relationship of the donor to the
recipient: (Answer only if the value for 2784447 is
"Other relative")
Aunt (Aunt)
Cousin (Cousin)
Other Relative (Other relative)
Parent (Parent)
Uncle (Uncle)
Specify relationship: (Answer only if the value for
2728852 is "Other relative")
Was the donor / product tested for potentially
transplantable genetic diseases?
No (No)
Unknown (Unknown)
Yes (Yes)
Sickle cell anemia
No (No)
Yes (Yes)
Thalassemia
No (No)
Yes (Yes)
Other
No (No)
Yes (Yes)
Specify genetic disease: (Answer only if the value
for 2772022 is "Yes")
Was the donor hospitalized (inpatient) during or
after the collection? (Question applies only to
allogeneic non-NMDP donors)
No (No)
Yes (Yes)
Did the donor experience any life-threatening
complications during or after the collection?
(Question applies only to allogeneic non-NMDP
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donors)
No (No)
Yes (Yes)
Research sample donor ID: (Related donors
only)
Author Information
First Name
Last Name
Telephone number:
Fax number:
E-mail address:
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Treatment - Study Medication
Administration - 3280117v1.0
Record study medication administration.
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=AD24494B-
49FC-235C-E040-BB89AD4305F5
All rights reserved. Please visit https://medical-data-
models.org/forms/6375
Study Medication Administration
Study Medication Administration
Visit Date (Enter the date the course started.)
Planned Schedule (Select the schedule of
medication administration as indicated in the
protocol.)
Twice A Week (2 times/week)
Twice A Week As Needed (2 times/week
PRN)
Three Times A Week (3 times/week)
Three Times A Week As Needed (3
times/week PRN)
Five Times Per Day (5 times/day)
Five Times A Day As Needed (5
times/day PRN)
Six Times A Day As Needed (6
times/day PRN)
Six Times Per Day (6 times/day)
Seven Times Per Day (7 times/day)
Seven Times A Day As Needed (7
times/day PRN)
Eight Times Per Day (8 times/day)
Eight Times A Day As Needed (8
times/day PRN)
Before Meals (ac)
Before Meals As Needed (ac PRN)
Twice A Day (BID)
Two Times A Day As Needed (bid PRN)
Two Times A Day Every Monday,
Tuesday And Wednesday (bid qMTW)
Two Times A Day Every Monday,
Wednesday And Thursday (bid qMWTh)
Two Times A Day, Every Other Day, For
3 Days (bid qod x3 days)
Two Times A Day, Every Other Day, For
6 Doses (bid qod x6 doses)
Twice A Week (BIW)
Continuous (Continuous)
Continuous As Needed (Continuous
PRN)
At Bedtime (hs)
At Bedtime As Needed (hs PRN)
After Meals (pc)
After Meals As Needed (pc PRN)
As Needed (PRN)
Every 1 To 2 Hours As Needed (q1-2h
PRN)
Every Ten Days (q10d)
Every 10 Days As Needed (q10d PRN)
1 / 11
Every Ten Hours (q10h)
Every 10 Hours As Needed (q10h PRN)
Every Eleven Hours (q11h)
Every 11 Hours As Needed (q11h PRN)
Every Twelve Hours (q12h)
Every 12 Hours As Needed (q12h PRN)
Every 12 Months (q12month)
Every Thirteen Hours (q13h)
Every 13 Hours As Needed (q13h PRN)
Every 14 Days (q14d)
Every Fourteen Hours (q14h)
Every 14 Hours As Needed (q14h PRN)
Every Fifteen Hours (q15h)
Every 15 Hours As Needed (q15h PRN)
Every Sixteen Hours (q16h)
Every 16 Hours As Needed (q16h PRN)
Every Seventeen Hours (q17h)
Every 17 Hours As Needed (q17h PRN)
Every Eighteen Hours (q18h)
Every 18 Hours As Needed (q18h PRN)
Every Nineteen Hours (q19h)
Every 19 Hours As Needed (q19h PRN)
Every One Hour (q1h)
Every One Hour As Needed (q1h PRN)
Every 2 To 3 Hours As Needed (q2-3h
PRN)
Every 2 To 4 Hours As Needed (q2-4h
PRN)
Every Twenty Hours (q20h)
Every 20 Hours As Needed (q20h PRN)
Every Twenty-one Hours (q21h)
Every 21 Hours As Needed (q21h PRN)
Every Twenty-two Hours (q22h)
Every 22 Hours As Needed (q22h PRN)
Every Twenty-three Hours (q23h)
Every 23 Hours As Needed (q23h PRN)
Every Twenty Four Hours (q24h)
Every 24 Hours As Needed (q24h PRN)
Every Two Days (q2d)
Every 2 Days As Needed (q2d PRN)
Every Two Hours (q2h)
Every 2 Hours As Needed (q2h PRN)
Every Two Months (q2month)
Every 2 Months As Needed (q2month
PRN)
Every Two Weeks (q2wk)
Every 2 Weeks As Needed (q2wk PRN)
Every 3-4 Hours As Needed (q3-4h
PRN)
Every Thirty Six Hours (q36h)
Every 36 Hours As Needed (q36h PRN)
Every Three Days (q3d)
Every 3 Days As Needed (q3d PRN)
Every Two Hours (q3h)
Every 3 Hours As Needed (q3h PRN)
Every Three Months (q3month)
Every 3 Months As Needed (q3month
PRN)
Every Three Weeks (q3wk)
Every Three Weeks As Needed (q3wk
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PRN)
Every 4 To 6 Hours (q4-6h)
Every 4 To 6 Hours As Needed (q4-6h
PRN)
Every Forty Eight Hours (q48h)
Every 48 Hours As Needed (q48h PRN)
Every Four Days (q4d)
Every 4 Days As Needed (q4d PRN)
Every 4 Hours As Needed (q4h PRN)
Every 4 Hours Every Other Day, For 3
Days (q4h qod x3 days)
Every 4 Hours (Q4HR)
Every Four Months (q4month)
Every 4 Months As Needed (q4month
PRN)
Every Four Weeks (q4wk)
Every 4 Weeks As Needed (q4wk PRN)
Every Five Days (q5d)
Every 5 Days As Needed (q5d PRN)
Every Five Hours (q5h)
Every 5 Hours As Needed (q5h PRN)
Every Five Months (q5month)
Every 5 Months As Needed (q5month
PRN)
Every Five Weeks (q5wk)
Every 5 Weeks As Needed (q5wk PRN)
Every 6 To 8 Hours As Needed (q6-8h
PRN)
Every Six Days (q6d)
Every 6 Days As Needed (q6d PRN)
Every 6 Hours As Needed (q6h PRN)
Every 6 Hours Every Other Day, For 3
Days (q6h qod x3 days)
Every 6 Hours (Q6HR)
Every Six Months (q6month)
Every 6 Months As Needed (q6month
PRN)
Every Six Weeks (q6wk)
Every 6 Weeks As Needed (q6wk PRN)
Every Seven Days (q7d)
Every 7 Days As Needed (q7d PRN)
Every Seven Hours (q7h)
Every 7 Hours As Needed (q7h PRN)
Every Seven Weeks (q7wk)
Every 7 Weeks As Needed (q7wk PRN)
Every 8 Days (q8d)
Every 8 Days As Needed (q8d PRN)
Every 8 Hours As Needed (q8h PRN)
Every 8 Hours (Q8HR)
Every 8 Weeks (q8wk)
Every 8 Weeks As Needed (q8wk PRN)
Every 9 Days (q9d)
Every 9 Days As Needed (q9d PRN)
Every 9 Hours (q9h)
Every 9 Hours As Needed (q9h PRN)
Every Morning (qam)
Every Morning As Needed (qam PRN)
Every Day (qd)
One Time A Day As Needed (qd PRN)
Once A Day For 3 Days (qd x3)
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Every Day For 4 Days (qd x4)
Once A Day For 5 Days (qd x5)
Once A Day For 7 Days (qd x7)
Every Night (qhs)
Every Night As Needed (qhs PRN)
Four Times A Day (qid)
Four Times A Day As Needed (qid PRN)
Monthly (qmonth)
Every Month As Needed (qmonth PRN)
Every Monday, Tuesday And Wednesday
(qMTW)
Every Monday, Wednesday And Friday
(qMWF)
Every Other Day (QOD)
Every Other Day As Needed (qod PRN)
Every Other Day For 3 Days (qod x3
days)
Weekly (qwk)
Every Week As Needed (qwk PRN)
Every Week For 4 Weeks (qwk x4)
Every Week For 8 Courses (cycles) (qwk
x8 courses)
Tapering Doses (Tapering Doses)
Three Times A Day (tid)
Three Times A Day As Needed (tid PRN)
Three Times In A Day, Every Other Day
(tid qod)
Three Times A Week (TIW)
Unknown (Unknown)
One Time (x1)
For 1 Course (cycle) (x1 Course)
One Time As Needed (x1 PRN)
For 12 Courses (cycles) (x12 Courses)
Two Times (x2)
For 2 Courses (cycles) (x2 Courses)
Two Times As Needed (x2 PRN)
Three Times (x3)
For 3 Courses (cycles) (x3 Courses)
Three Times As Needed (x3 PRN)
Four Times (x4)
For 4 Courses (cycles) (x4 Courses)
Four Times As Needed (x4 PRN)
Five Times (x5)
For 5 Courses (cycles) (x5 Courses)
Five Times As Needed (x5 PRN)
For 6 Courses (cycles) (x6 Courses)
For 8 Courses (cycles) (x8 Courses)
For 8 Days (x8 days)
Day in Course (Cycle)
Start Date (Enter the date the medication was
administered.)
Start Time (For IV infusions only: Enter the start
time of the infusion.)
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Stop Date (Enter the date the medication was
discontinued.)
Stop Time (For IV infusions only: Enter the stop
time of the infusion.)
Medication (Select a medication from the list.)
Planned Dose Level (Enter the amount of
medication a number that was planned to be
given for the dose level.)
Planned UOM (Select the Planned Dose Level
unit of measurement.)
Percent (%)
10e10 Cells (10E10 Cells)
10e3 Cells (10E3 Cells)
10e4 Cells Per Kilogram (10E4 Cell/kg)
10e4 Cells (10E4 Cells)
10e5 Cells Per Kilogram (10E5 Cell/kg)
10e5 Cells (10E5 Cells)
10e6 Cells Per Kilogram (10E6 Cell/kg)
10e6 Cells (10E6 Cells)
10e7 Cells Per Kilogram (10E7 Cell/kg)
10e7 Cells (10E7 Cells)
10e7 Plaque Forming Units (10E7 PFU)
10e8 Cells (10E8 Cells)
10e8 Plaque Forming Units (10E8 PFU)
10e9 Cells (10E9 Cells)
10e9 Plaque Forming Units (10E9 PFU)
Ampule (Ampule)
Application (Applcatn)
Atomic Unit (au)
Area Under The Curve (AUC)
Billion Pfu (bill PFU)
Bottle (Bottle)
Breaths Per Minute (BPM)
Capful (Capful)
Caplet (Caplet)
Capsule (Capsule)
Cells (Cells)
Cells Per Kilogram (Cells/kg)
Centigray (cGy)
Curie (Ci)
Course (Course)
Cycle (Course)
Deciliter (dL)
Dose (Dose)
Equivalent (Eq)
Grams (g) (g)
Gram Per M2 (g/m2)
Gallon (Gallon)
Drops (gtts)
Gray (Gy)
Hertz (Hz)
Inch (Inch)
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Inhalation (Inhalatn)
Iu Vitamin A (IU Vit A)
International Unit Per Milligram (IU/mg)
International Units Or Milligram Alpha
Tocopherol (IU/mg A-TE)
International Unit (IUnit)
International Unit Per Kilogram (IUnit/kg)
International Unit Per Liter (IUnit/L)
Intravenous Bag (IV Bag)
Infectious Viral Replicon Particles (IVRP)
Joules Per Centimeter Squared (Jcm2)
Kib-electron Volt (KeV)
Kilograms (kg)
Kilohertz (kHz)
Kilopascal (kPa)
Kilounit (kU)
Kilounit Per Kilogram (kU/kg)
Kilounit Per Liter (kU/L)
Liter (L)
Liters Per Minute (L/min)
Megabecquerel (MBq)
Millibecquerel (mBq)
Microgram (mcg)
Microgram Per Centimeter Squared
(mcg/cm2)
Microgram Per Hour (mcg/hr)
Microgram Per Kilogram (mcg/kg)
Microgram Per Meter Squared (mcg/m2)
Millicurie (mCi)
Measure (Measure)
Milliequivalent (mEq)
Milliequivalents Per 24 Hours (mEq/24hr)
Milliequivalent Per Deciliter (mEq/dL)
Milliequivalent Per Hour (mEq/hr)
Milliequivalent Per Liter (mEq/L)
Million Electron Volt (MeV)
Milligram (mg)
Milligram Per 24 Hours (mg/24hr)
Milligram Per Deciliter (mg/dL)
Milligram Per Hour (mg/hr)
Milligram Per Inhalation (mg/inh)
Milligram Per Kilogram (mg/kg)
Milligram Per Kilogram Per Day
(mg/kg/day)
Milligram Per Meter Squared (mg/m2)
Milligram Per Milliliter (mg/mL)
Milligram Per Week (mg/wk)
Megahertz (MHz)
Microcurie (microCi)
Microliter (microL)
Micromole (micromol)
Million Plaque Forming Units (mill PFU)
Million (Million)
Milliunit (millunit)
Milliinternational Unit (miu)
Milliinternational Units Per Meter
Squared (miu/m2)
Milliliter (mL)
Cubic Centimeter (cc) (mL)
Milliliter Per Hour (mL/hr)
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Milliliter Per Kilogram (mL/kg)
Millimoles Per Liter (mM/L)
Millimole (mmol)
Mole (Mole)
Milliosmole (mosmol)
Megarad (Mrad)
Million Units (MU)
Millivolt (mV)
Million Viral Particles (MVP)
Nanocurie (nCi)
Nanogram (ng)
Nanogram Per Kilogram (ng/kg)
Nanogram Per Liter (ng/L)
Nanograms Per Milliliter (ng/mL)
Nanometer Of Light (nm light)
Nanomole (nmol)
No Source Data (No Srce)
Osmolality (osmol)
Ounce (oz)
Pascal (Pa)
Packet (packet)
Patch (Patch)
Plaque Forming Units (PFU)
Picograms (pg)
Pounds Per Square Inch (psi)
Puff (puff)
Radiation Absorbed Dose (Rad)
Vitamin A Retinol (RAE)
Retinol Equivalents (RE)
Seed (Seed)
Session (Session)
Spray (Spray)
Suppository (Suppstry)
Tablets (Tablet)
Tablespoon (Tbsp)
Tissue Culture Infection Dose (TCID)
Thousand (Thousand)
Troche (Troche)
Teaspoon (tsp)
Unit (Unit)
Unit Per Gram (Unit/g)
Unit Per Kilogram (Unit/kg)
Unit Per Meter Squared (Unit/m2)
Unit Per Milliliter (Unit/mL)
Unknown (Unknown)
Viral Particles (VP)
Yeast Units (YU)
Planned Route (Select the route from the list.)
Continuous Intravenous Infusion (CIV)
Endotracheal Route Of Administration
(ENDOTR)
Gastrostomy Tube (G Tube)
Intra-arterial (IA)
Intradermal (ID)
Intrahepatic (IH)
Intrahepatic Infusion (IHI)
Intramuscular (IM)
Inhalation (Inhalatn)
Interstitial Route Of Administration
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(Interstl)
Intraventricular Route Of Administration
(Intraventricular)
Intravesical (Intravesical)
Intratumoral (INTUM)
Intraperitoneal (IP)
Intrathecal (IT)
Intravenous Bolus (IV)
Intravenous Infusion (IVI)
Nasal (NASAL)
Nasogastric (NG)
Ophthalmic, Each Eye (Oph Each)
Ophthalmic, Left Eye (Oph Left)
Ophthalmic, Right Eye (Oph Rt)
Auricular Route Of Administration (Otic)
Oral (PO)
Rectal (PR)
Radiation (RT)
Subcutaneous (SC)
Sublingual (Sublingual)
Swish & Spit (SWSP)
Swish & Swallow (SWSW)
Topical (TOP)
Transdermal (Transdermal)
Transmucosal Route (Transmucosal)
Unknown Route Of Administration
(Unknown)
Vaginal Route (Vaginal)
Actual Total Dose (Enter the total actual dose
given for the medication name entered above for
the time period encompassed by the duration.
See Actual UOM below for the units of measure
of the actual dose.)
Actual Dose UOM (Select the Actual Dose Level
unit of measurement.)
Percent (%)
10e10 Cells (10E10 Cells)
10e3 Cells (10E3 Cells)
10e4 Cells Per Kilogram (10E4 Cell/kg)
10e4 Cells (10E4 Cells)
10e5 Cells Per Kilogram (10E5 Cell/kg)
10e5 Cells (10E5 Cells)
10e6 Cells Per Kilogram (10E6 Cell/kg)
10e6 Cells (10E6 Cells)
10e7 Cells Per Kilogram (10E7 Cell/kg)
10e7 Cells (10E7 Cells)
10e7 Plaque Forming Units (10E7 PFU)
10e8 Cells (10E8 Cells)
10e8 Plaque Forming Units (10E8 PFU)
10e9 Cells (10E9 Cells)
10e9 Plaque Forming Units (10E9 PFU)
Ampule (Ampule)
Application (Applcatn)
Atomic Unit (au)
Area Under The Curve (AUC)
Billion Pfu (bill PFU)
Bottle (Bottle)
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Treatment - Study Medication Administration - 3280117v1.0
Breaths Per Minute (BPM)
Capful (Capful)
Caplet (Caplet)
Capsule (Capsule)
Cells (Cells)
Cells Per Kilogram (Cells/kg)
Centigray (cGy)
Curie (Ci)
Course (Course)
Cycle (Course)
Deciliter (dL)
Dose (Dose)
Equivalent (Eq)
Grams (g) (g)
Gram Per M2 (g/m2)
Gallon (Gallon)
Drops (gtts)
Gray (Gy)
Hertz (Hz)
Inch (Inch)
Inhalation (Inhalatn)
Iu Vitamin A (IU Vit A)
International Unit Per Milligram (IU/mg)
International Units Or Milligram Alpha
Tocopherol (IU/mg A-TE)
International Unit (IUnit)
International Unit Per Kilogram (IUnit/kg)
International Unit Per Liter (IUnit/L)
Intravenous Bag (IV Bag)
Infectious Viral Replicon Particles (IVRP)
Joules Per Centimeter Squared (Jcm2)
Kib-electron Volt (KeV)
Kilograms (kg)
Kilohertz (kHz)
Kilopascal (kPa)
Kilounit (kU)
Kilounit Per Kilogram (kU/kg)
Kilounit Per Liter (kU/L)
Liter (L)
Liters Per Minute (L/min)
Megabecquerel (MBq)
Millibecquerel (mBq)
Microgram (mcg)
Microgram Per Centimeter Squared
(mcg/cm2)
Microgram Per Hour (mcg/hr)
Microgram Per Kilogram (mcg/kg)
Microgram Per Meter Squared (mcg/m2)
Millicurie (mCi)
Measure (Measure)
Milliequivalent (mEq)
Milliequivalents Per 24 Hours (mEq/24hr)
Milliequivalent Per Deciliter (mEq/dL)
Milliequivalent Per Hour (mEq/hr)
Milliequivalent Per Liter (mEq/L)
Million Electron Volt (MeV)
Milligram (mg)
Milligram Per 24 Hours (mg/24hr)
Milligram Per Deciliter (mg/dL)
Milligram Per Hour (mg/hr)
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Milligram Per Inhalation (mg/inh)
Milligram Per Kilogram (mg/kg)
Milligram Per Kilogram Per Day
(mg/kg/day)
Milligram Per Meter Squared (mg/m2)
Milligram Per Milliliter (mg/mL)
Milligram Per Week (mg/wk)
Megahertz (MHz)
Microcurie (microCi)
Microliter (microL)
Micromole (micromol)
Million Plaque Forming Units (mill PFU)
Million (Million)
Milliunit (millunit)
Milliinternational Unit (miu)
Milliinternational Units Per Meter
Squared (miu/m2)
Milliliter (mL)
Cubic Centimeter (cc) (mL)
Milliliter Per Hour (mL/hr)
Milliliter Per Kilogram (mL/kg)
Millimoles Per Liter (mM/L)
Millimole (mmol)
Mole (Mole)
Milliosmole (mosmol)
Megarad (Mrad)
Million Units (MU)
Millivolt (mV)
Million Viral Particles (MVP)
Nanocurie (nCi)
Nanogram (ng)
Nanogram Per Kilogram (ng/kg)
Nanogram Per Liter (ng/L)
Nanograms Per Milliliter (ng/mL)
Nanometer Of Light (nm light)
Nanomole (nmol)
No Source Data (No Srce)
Osmolality (osmol)
Ounce (oz)
Pascal (Pa)
Packet (packet)
Patch (Patch)
Plaque Forming Units (PFU)
Picograms (pg)
Pounds Per Square Inch (psi)
Puff (puff)
Radiation Absorbed Dose (Rad)
Vitamin A Retinol (RAE)
Retinol Equivalents (RE)
Seed (Seed)
Session (Session)
Spray (Spray)
Suppository (Suppstry)
Tablets (Tablet)
Tablespoon (Tbsp)
Tissue Culture Infection Dose (TCID)
Thousand (Thousand)
Troche (Troche)
Teaspoon (tsp)
Unit (Unit)
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Unit Per Gram (Unit/g)
Unit Per Kilogram (Unit/kg)
Unit Per Meter Squared (Unit/m2)
Unit Per Milliliter (Unit/mL)
Unknown (Unknown)
Viral Particles (VP)
Yeast Units (YU)
lot # (Enter the Lot Number for the medication
supply.)
Duration (Enter the duration calculated from the
start date/time and stop date/time.)
Duration UOM (Select the units of measurement
so that the duration can be derived.)
Days (DY)
Hours (HR)
Minutes (MN)
Month (MO)
Weeks (WK)
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1. Induktionstherapieblock EudraCT-Nr 2008-004583-40
Akute myeloische Leukämie(AML) AML alle außer FAB M3
A randomized, multi-center phase II trial to assess the
efficacy of 5-azacytidine added to standard primary therapy
in elderly patients with newly diagnosed AML
All rights reserved. Please visit https://medical-data-
models.org/forms/6415
1. Induktionstherapieblock
Patientendaten
Pat.-Nr.:    -*
Randomisierung des Patienten in Studienarm:*
A (5-Azacytidin) (1)
B (Dokumentation weiter Seite 11) (2)
5-Azacytidin - Gabe-Nr. 1
Datum*
Dosis absolut/Tag (mg)*
Verabreichungsart
Kurzinf. (1)
nicht i.v. (2)
Grund für nicht i.v.*
5-Azacytidin - Gabe-Nr. 2
Datum*
Dosis absolut/Tag (mg)*
Verabreichungsart*
Kurzinf. (1)
nicht i.v. (2)
Grund für nicht i.v.*
5-Azacytidin - Gabe-Nr. 3
Datum*
Dosis absolut/Tag (mg)*
Verabreichungsart*
Kurzinf. (1)
nicht i.v. (2)
Grund für nicht i.v.*
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5-Azacytidin - Gabe-Nr. 4
Datum*
Dosis absolut/Tag (mg)*
Verabreichungsart*
Kurzinf. (1)
nicht i.v. (2)
Grund für nicht i.v.*
5-Azacytidin - Gabe-Nr. 5
Datum*
Dosis absolut/Tag (mg)*
Verabreichungsart*
Kurzinf. (1)
nicht i.v. (2)
Grund für nicht i.v.*
5-Azacytidin-Dosisreduktion
5-Azacytidin-Dosisreduktion*
Ja
Nein
ja, weil:*
AE(s) (1)
Auftreten einer Leukozytose > 50.000
/microl (2)
Therapiefehler (3)
Sonstiges (4)
Sonstiges:*
AE-Nr:*
Differentialblutbild
Datum:*
Haemoglobin*
Haemoglobin*
[g/dl] ([g/dl])
2 / 5
1. Induktionstherapieblock EudraCT-Nr 2008-004583-40 Akute
myeloische Leukämie(AML) AML alle außer FAB M3
[mmol/l] ([mmol/l])
Leukozyten *
Leukozyten*
[/nl] ( [/nl])
[/µl] ( [/µl])
[10E3/µl] ([10E3/µl])
[GPt/l] ([GPt/l])
Prozentanteil Neutrophile *
Prozentanteil Stabkernige *
[oder] Prozentanteil Segmentkernige *
Prozentanteil Lymphozyten *
Prozentanteil Monozyten*
Prozentanteil Eosinophile *
Prozentanteil Basophile *
Prozentanteil Blasten*
Prozentanteil Promyelozyten*
Prozentanteil Myelozyten*
Prozentanteil Metamyelozyten*
Prozentanteil sonstige Zellen*
Thrombozyten*
Thrombozyten*
[/nl] ([/nl])
[/µl] ([/µl])
[10E3/µl] ([10E3/µl])
[GPt/l] ([GPt/l])
Obligater Materialversand (Blut) zur Bestimmung
des Methylierungsstatus nach:*
Münster (1)
Dresden (2)
Frankfurt (3)
kein Versand weil (kein Versand weil)
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1. Induktionstherapieblock EudraCT-Nr 2008-004583-40 Akute
myeloische Leukämie(AML) AML alle außer FAB M3
kein Versand weil*
Chemotherapie
Tag 1:*
Ara-C (100mg/qm über 24h i.v. Tag 1-7)
Ara-C - Dosisreduktion*
Ja
Nein
(wenn ja:) a) Grund:*
(wenn ja:) b) Gesamtdosis absolut in diesem
Therapieblock (mg):*
Daunorubicin (60mg/qm über 1-2h i.v. Tag
3-5)
Daunorubicin (60mg/qm über 1-2h i.v. Tag 3-5) -
Dosisreduktion*
Ja
Nein
(wenn ja:) a) Grund:*
(wenn ja:) b) Gesamtdosis absolut in diesem
Therapieblock (mg):*
G-CSF-Gabe
Patient hat G-CSF erhalten: *
Ja
Nein
(wenn ja:) Beginn:*
(wenn ja:) Ende:*
(wenn ja:) Präparat:*
Neulasta (1)
Neupogen (2)
Granocyte (3)
Sonstiges (4)
Zytopeniedauer
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1. Induktionstherapieblock EudraCT-Nr 2008-004583-40 Akute
myeloische Leukämie(AML) AML alle außer FAB M3
Leukozyten <1,0 GPt/l bzw. <1000 /ul
Beginn (Leukozyten <1,0 GPt/l bzw. <1000 /ul)*
Ende (Leukozyten >=1,0 GPt/l or >=1000 /ul)*
(oder) Zytopenie andauernd [Leukozyten <1,0
GPt/l bzw. <1000 /ul] am:*
Neutrophile <0,5 GPt/l bzw. <500 /ul
Beginn (Neutrophile <0,5 GPt/l bzw. <500 /ul)*
Ende (Neutrophile >=0,5 GPt/l bzw. >=500 /ul)*
(oder) Zytopenie andauernd [Neutrophile <0,5
GPt/l bzw. <500 /ul] am:*
Beginn (Thrombozyten <25 GPt/l bzw.
<25000 /ul)
Beginn (Thrombozyten <25 GPt/l bzw. <25000
/ul)*
Ende (Thrombozyten >=25 GPt/l bzw. >=25000
/ul - ansteigend, unabhängig von Thrombozyten-
substitution)*
(oder) Zytopenie andauernd [Thrombozyten <25
GPt/l bzw. <25000 /ul] am:*
Unterschrift
Datum:*
Name/Unterschrift Prüfarzt*
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1. Induktionstherapieblock EudraCT-Nr 2008-004583-40 Akute
myeloische Leukämie(AML) AML alle außer FAB M3
Eligibility NCT00052936 NHL
Combination Chemotherapy With or Without Rituximab in
Treating Older Patients With Non-Hodgkin's Lymphoma
https://clinicaltrials.gov/show/NCT00052936
All rights reserved. Please visit https://medical-data-
models.org/forms/6416
Eligibility
Disease characteristics
Histologically confirmed aggressive non-
Hodgkin's lymphoma (NHL) by an excisional
biopsy of a lymph node or an extensive biopsy of
an extranodal involvement (if there is no lymph
node involvement); 
CD20+ B-cell lymphoma or CD20- B-cell and T-
cell lymphoma allowed*
Yes
No
B-cell NHL including the following: Stage III
follicular lymphoma; Stage III follicular lymphoma
and diffuse B-cell lymphoma; Lymphoblastic
precursor B-cell lymphoma; Diffuse large cell B-
cell lymphoma; Centroblastic; Immunoblastic;
Plasmablastic;  Anaplastic large cell; T-cell-rich
B-cell lymphoma; Primary effusion lymphoma;
Intravasal B-cell lymphoma; Primary mediastinal
B-cell lymphoma;  Mantle zone lymphoma,
blastoid; Burkitt's lymphoma; Burkitt-like
lymphoma; Aggressive marginal zone lymphoma
(monocytoid)*
Yes
No
T-cell NHL including the following: Lymphoblastic
precursor T-cell lymphoma; Peripheral T-cell
lymphoma (PTCL) not otherwise specified (NOS);
Lennert's lymphoma; T-zone lymphoma; T-cell
lymphoma of the angioimmunoblastic
lymphadenopathy with dysproteinemia (AILD)
type; Anaplastic large cell lymphoma; ALK^+ -
ALK^-; Extranodal NK/T-cell lymphoma, nasal
type; Intestinal T/NK-cell lymphoma (with or
without enteropathy); Hepatosplenic gamma-
delta lymphoma; Subcutaneous panniculitis-like
PTCL; Aggressive T/NK PTCL; Anaplastic large-
cell NHL, NOS*
Yes
No
Bone marrow involvement no more than 25%*
Yes
No
No lymphoma that is clearly restricted to the CNS
or originating from the gastrointestinal tract*
Yes
No
Patient characteristics and prior
concurrent therapy
1 / 2
Age 61 to 80*
Yes
No
ECOG 0-2 OR - Karnofsky 60-100%*
Yes
No
WBC at least 2,500/mm^3*
Platelet count at least 100,000/mm^3*
Bilirubin no greater than 2 times upper limit of
normal (ULN)*
Yes
No
No active hepatitis infection*
Yes
No
Creatinine no greater than 2 times ULN*
Yes
No
No Canadian Cardiovascular Society class III or
IV angina pectoris; 
No New York Heart Association class III or IV
cardiac failure; Ejection fraction at least 50%;
Fractional shortenings at least 25% by
echocardiography or nuclear medicine
examination*
Yes
No
FEV1 at least 50%*
Yes
No
Diffusion capacity at least 50%*
Yes
No
No uncontrolled diabetes mellitus; No known
hypersensitivity to any study medications; No
other concurrent malignancy; HIV negative*
Yes
No
No prior chemotherapy; No prior radiotherapy;
Must not have already initiated lymphoma therapy
(except for the prephase treatment specified for
this study); No other concurrent lymphoma
therapy; No concurrent participation in another
treatment study*
Yes
No
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Eligibility
ODM derived from http://clinicaltrials.gov/show/
All rights reserved. Please visit https://medical-data-
models.org/forms/6419
Eligibility
Inclusion Criteria Multiple Sclerosis
Age 18 Years to 55 Years*
Yes
No
Patients who meet the diagnosis criteria for
RRMS*
Yes
No
clinical disability measured by EDSS score
between 0 and 5.0*
Yes
No
Exclusion Criteria
Patients with medical conditions such as
diabetes, hypotension, insulinoma,
hyperuricemia, or other conditions (drug abuse,
inability to consent or to perform all the
procedures of the clinical trial)*
Yes
No
Patients who had received or are candidates for
liver transplantation*
Yes
No
Relapse in the 30 days period before baseline
visit*
Yes
No
Patients with corticosteroid therapy in the last
month, interferon-beta or glatiramer acetate in the
last 3 months, or natalizumab in the last 6
months*
Yes
No
Patients treated with chemotherapy*
Yes
No
Positive pregnancy test, breast feeding women or
childbearing potential*
Yes
No
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Eligibility NCT01197729 Myocardial
Infarction
ODM derived from
http://clinicaltrials.gov/show/NCT01197729
All rights reserved. Please visit https://medical-data-
models.org/forms/6420
Eligibility NCT01197729 Myocardial
Infarction
Einschlusskriterien
Alter bis zu 1 Tag*
Ja
Nein
all patients admitted to hospital with an acute ST-
Elevation myocardial infarction or with an acute
Non-ST-Elevation myocardial infarction, both not
older than 24 h *
Ja
Nein
Ausschlusskriterien
missing informed consent*
Ja
Nein
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Tag 35 nach Beginn der letzten
Induktionstherapie
A randomized, multi-center phase II trial to assess the
efficacy of 5-azacytidine added to standard primary therapy
in elderly patients with newly diagnosed AML
All rights reserved. Please visit https://medical-data-
models.org/forms/6421
Tag 35 nach Beginn der letzten
Induktionstherapie
Regeneration of blood cell count
Pat. No.:    -*
Hematologic regeneration on day 35 after begin
of the last induction therapy:         (Neutrophils >=
1000/µl, platelets >= 70.000/µl)*
Yes
No
Date:*
Name/Signature study physician*
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Studienende / Studienabbruch EudraCT  2008-004583-40
Akute myeloische Leukämie(AML) AML alle außer FAB M3
A randomized, multi-center phase II trial to assess the
efficacy of 5-azacytidine added to standard primary therapy
in elderly patients with newly diagnosed AML
All rights reserved. Please visit https://medical-data-
models.org/forms/6422
Studienende / Studienabbruch
Studienende
Pat.-Nr.:    -*
Reguläres Studienende am:*
Sofern 5-Azacytidin verabreicht wurde, bitte
Datum der letzten Gabe angeben:*
Vorzeitiger Studienabbruch
Vorzeitiger Studienabbruch am:*
Grund:*
Unerwünschte(s) Ereignis(se) (Bitte AE-
und ggf. SAE-Bogen ausfüllen!)
(Adverse event(s))
Einverständnis entzogen (Consent
withdrawn)
Tod (Bitte Bogen "Tod" Seite 85
ausfüllen!) (Death)
Einschlusskriterium nicht erfüllt (Did not
meet inclusion criterion)
Ausschlusskriterium liegt vor (Exclusion
Criterion)
Anderer Grund: (Other reason)
Primäres Therapieversagen (Primary
therapy failure)
Rezidiv (Bitte Bogen "Rezidiv" Seite
83+84 ausfüllen!) (Relapse)
Anderer Grund:*
AE-Nr:*
Remissionsstatus zum Zeitpunkt des
Studienabbruchs:*
CR oder morphologisch Leukämie-freier
Status (1)
Primäres Therapieversagen / Rezidiv (2)
unbekannt (3)
Unterschrift
Datum:*
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Name/Unterschrift Prüfarzt*
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Studienende / Studienabbruch EudraCT  2008-004583-40 Akute
myeloische Leukämie(AML) AML alle außer FAB M3
1. Konsolidierungstherapieblock  EudraCT-Nr 2008-004583-40
Akute myeloische Leukämie(AML) AML alle außer FAB M3
A randomized, multi-center phase II trial to assess the
efficacy of 5-azacytidine added to standard primary therapy
in elderly patients with newly diagnosed AML
All rights reserved. Please visit https://medical-data-
models.org/forms/6423
1. Konsolidierungstherapieblock
Clinical finding
Pat. No.*
Physical Examination Date:*
ECOG performance status finding:*
ECOG 0 (Normal physical fitness) (0)
ECOG 1 (Outpatient care, easy work
possible) (1)
ECOG 2 (Less than half day bed-ridden,
self-sufficiency possible, but not able to
work) (2)
ECOG 3 (More than half day bed-ridden,
limited self-sufficiency possible) (3)
ECOG 4 (Permanent bed-ridden) (4)
Weight*
Body Surface Area*
Differential blood count
Date:*
Hemoglobin*
Hemoglobin*
[g/dl] ([g/dl])
[mmol/l] ([mmol/l])
Leukocytes*
Leukocytes*
[/nl] ( [/nl])
[/µl] ( [/µl])
[10E3/µl] ([10E3/µl])
[GPt/l] ([GPt/l])
Neutrophil percentage
Band neutrophil percentage*
[or] Segmented neutrophil percentage*
Lymphocyte percentage*
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Monocyte percentage*
Eosinophil percentage*
Basophil percentage*
Blast cell percentage*
Promyelocyte percentage*
Myelocyte percentage*
Metamyelocyte percentage*
Percentage of other cells*
Platelets*
Platelets*
[/nl] ([/nl])
[/µl] ([/µl])
[10E3/µl] ([10E3/µl])
[GPt/l] ([GPt/l])
Clinical Chemistry
Sodium [mmol/L]*
Potassium [mmol/L]*
Total protein*
Total protein*
[g/dl] ([g/dl])
[g/l] ([g/l])
Uric acid*
Uric acid*
[mg/dl] ([mg/dl])
[µmol/L] ([µmol/l])
Blood Urea Nitrogen*
Blood Urea Nitrogen*
[mg/dl] ([mg/dl])
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1. Konsolidierungstherapieblock  EudraCT-Nr 2008-004583-40 Akute
myeloische Leukämie(AML) AML alle außer FAB M3
[mmol/l] ([mmol/l])
Urea*
Urea*
[mg/dl] ([mg/dl])
[mmol/l] ([mmol/l])
Creatinine*
Creatinine*
[mg/dl] ([mg/dl])
[µmol/l] ([µmol/l])
Bilirubin total*
Bilirubin total*
[mg/dl] ([mg/dl])
[µmol/l] ([µmol/l])
GOT/AST *
GOT/AST *
[U/l] ([U/l])
[µmol/s*l] ([µmol/s*l])
GPT/ALT*
GPT/ALT*
[U/l] ([U/l])
[µmol/s*l] ([µmol/s*l])
AP*
AP*
[U/l] ([U/l])
[µmol/s*l] ([µmol/s*l])
LDH*
LDH*
[U/l] ([U/l])
[µmol/s*l] ([µmol/s*l])
CRP*
CRP*
[mg/dl] ([mg/dl])
[mg/l] ([mg/l])
Quick's value (in percent)*
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1. Konsolidierungstherapieblock  EudraCT-Nr 2008-004583-40 Akute
myeloische Leukämie(AML) AML alle außer FAB M3
INR*
PTT [sec]*
Patient randomization in study arm:*
A (5-Azacytidine) (1)
B (Documentation continued on page 24)
(2)
5-Azacytidine
5-Azacytidine dose:*
DL 0: 18 mg/m2 (0)
DL 1: 37,5 mg/m2 (1)
DL 2: 75 mg/m2 (2)
5-Azacytidine - Dose (Dose 1 - 5)
Date*
Dose absolute/day*
Route of administration*
subcutaneous (1)
Reason for not subcutaneous*
5-Azacytidine dose reduction
5-Azacytidine dose reduction*
Yes
No
yes, reason:*
AE(s) in actual therapy block (1)
AE(s) in a previous therapy block (2)
treatment error (3)
Miscellaneous (4)
Miscellaneous:*
AE-No:*
AE-No:*
Transfusions
How many transfusions did the patient receive in
the period between                   day 1 of the last
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myeloische Leukämie(AML) AML alle außer FAB M3
induction chemotherapy AND           day 1 of the
1st consolidation chemotherapy?*
Number of transfused erythrocyte concentrates:*
Number of transfused platelet concentrates:*
Chemotherapy
Day 1:*
Ara-C (2 x 1g/sqm over 3 hrs intravenous
day 1,3,5)
Ara-C - dose reduction*
Yes
No
(if yes:) a) Reason:*
(if yes:) b) Absolute total dose in this therapy
block (mg):*
G-CSF dose
Patient did receive G-CSF: *
Yes
No
(if yes:) Start date:*
(if yes:) End date:*
(if yes:) Pharmaceutical Preparations:*
Neulasta (1)
Neupogen (2)
Granocyte (3)
other (4)
Cytopenia duration
leucocytes <1,0 GPt/l or <1000 /ul
Start date (leucocytes <1,0 GPt/l or <1000 /ul)*
End date (leucocytes >=1,0 GPt/l or >=1000 /ul)*
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1. Konsolidierungstherapieblock  EudraCT-Nr 2008-004583-40 Akute
myeloische Leukämie(AML) AML alle außer FAB M3
(or) cytopenia ongoing [leucocytes <1,0 GPt/l or
<1000 /ul] on:*
neutrophils <0,5 GPt/l or <500 /ul
Start date (neutrophils <0,5 GPt/l or <500 /ul)*
End date (neutrophils >=0,5 GPt/l or >=500 /ul)*
(or) cytopenia ongoing [neutrophils <0,5 GPt/l or
<500 /ul] on:*
Thrombopenia (platelets <25 GPt/l or
<25000 /ul)
Start date (platelets <25 GPt/l or <25000 /ul)*
End date (platelets >=25 GPt/l or >=25000 /ul -
increasing, independent of substitution of
platelets)*
(or) cytopenia ongoing [platelets <25 GPt/l or
<25000 /ul] on:*
Signature
Date:*
Name/Signature study physician*
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1. Konsolidierungstherapieblock  EudraCT-Nr 2008-004583-40 Akute
myeloische Leukämie(AML) AML alle außer FAB M3
Quality assurance Heart Surgery - Follow-
up (AQUA)
Documentation form for quality assurance in German
Health Care by the Institute for Applied Quality
Improvement and Research in Health Care (Aqua),
https://www.aqua-institut.de/en/home. Internal Aqua form
version: HCH-FU Specification 2015 V02
All rights reserved. Please visit https://medical-data-
models.org/forms/6439
Quality assurance Heart Surgery -
Follow-up (AQUA)
Nachbeobachtungen / Follow-up
Erhebungsdatum (TT.MM.JJJJ)*
Status des Patienten am 30. postoperativen Tag
- nach der ersten OP*
Patient ist verstorben (0)
Patient lebt (1)
Falldokumentation vor dem 30. Tag
postoperativ abgeschlossen / Follow-up
Information liegt noch nicht vor, wird
nachgeschickt (8)
Situation des Patienten ist unbekannt (9)
Todesdatum (TT.MM.JJJJ)
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Quality assurance Heart Surgery - Surgery
(AQUA)
Documentation form for quality assurance in German
Health Care by the Institute for Applied Quality
Improvement and Research in Health Care (Aqua),
https://www.aqua-institut.de/en/home. Internal Aqua form
version: HCH-O Specification 2015 V02
All rights reserved. Please visit https://medical-data-
models.org/forms/6458
Quality assurance Heart Surgery -
Surgery (AQUA)
Operation - Basic documentation
Number of surgical procedure at this stay?*
Operation Date (DD.MM.YY)*
Procedure codes *
Categories of applied procedures
Coronary artery bypass surgery*
CodelistItem 342487 (0)
CodelistItem 342488 (1)
Aortic clamp time (in minutes)
bypass time unknown
CodelistItem 342517 (1)
Cardiopulmonary bypass time(in Minuten)
Procedure Duration (in minutes)*
Surgical access way*
CodelistItem 342515 (1)
CodelistItem 342516 (9)
Surgical approach (w/o Heart Lung Machine)*
CodelistItem 342512 (1)
CodelistItem 342513 (2)
CodelistItem 342514 (3)
Wound contamination classifcation of  procedure
(according to CDC definition)*
CodelistItem 342508 (1)
CodelistItem 342509 (2)
CodelistItem 342510 (3)
CodelistItem 342511 (4)
(preoperative) Mechanical circulatory support*
CodelistItem 342505 (0)
CodelistItem 342506 (1)
CodelistItem 342507 (2)
Inotropic agent applied (preoperative) - i. v.*
CodelistItem 342503 (0)
CodelistItem 342504 (1)
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Troponin positive (preoperative)*
CodelistItem 342501 (0)
CodelistItem 342502 (1)
Nitrates (preoperative) - i. v.*
CodelistItem 342499 (0)
CodelistItem 342500 (1)
Urgency type of that procedure*
CodelistItem 342495 (1)
CodelistItem 342496 (2)
CodelistItem 342497 (3)
CodelistItem 342498 (4)
Leading procedure code of other operation
other Operation*
CodelistItem 342493 (0)
CodelistItem 342494 (1)
Aortic valve surgery*
CodelistItem 342489 (0)
CodelistItem 342490 (1)
CodelistItem 342491 (2)
CodelistItem 342492 (3)
Aortic clamp time unknown
CodelistItem 342518 (1)
Coronary Surgery
Number of grafts
Type of graft
Vein graft
CodelistItem 342519 (1)
Left internal thoracic artery
CodelistItem 342520 (1)
Left internal thoracic artery
CodelistItem 342521 (1)
Radial artery
CodelistItem 342522 (1)
other Grafts
CodelistItem 342523 (1)
(Number of) central coronal anastomosis
(Number of) peripheral  anastomosis, using
arterial graft
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(Number of) peripheral  anastomosis, using vein
graft
Treated coronary arteries
LAD and/or branches
CodelistItem 342524 (1)
RCA and/or branches
CodelistItem 342525 (1)
RCX and/or branches
CodelistItem 342526 (1)
Aortic valve surgery
Aortic stenosis
CodelistItem 342527 (0)
CodelistItem 342528 (1)
Cardiac Arrhythmia
CodelistItem 342564 (1)
Aortic Valve Insufficiency (>= 2. degree)
CodelistItem 342563 (1)
Cerebral embolism
CodelistItem 342562 (1)
Left ventricular decompensation
CodelistItem 342561 (1)
Pericardial tamponade
CodelistItem 342560 (1)
Rupture of fibrous ring of heart
CodelistItem 342559 (1)
Aortic dissection
CodelistItem 342558 (1)
Coronary ostium stenosis
CodelistItem 342557 (1)
Device micplacement
CodelistItem 342556 (1)
intraprocedural complications
CodelistItem 342554 (0)
CodelistItem 342555 (1)
Diameter of artificial valve (in mm)
Type of valve prosthesis
CodelistItem 342534 (1103)
CodelistItem 342535 (1104)
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CodelistItem 342536 (1105)
CodelistItem 342537 (1106)
CodelistItem 342538 (1188)
CodelistItem 342539 (1201)
CodelistItem 342540 (1202)
CodelistItem 342541 (1203)
CodelistItem 342542 (1204)
CodelistItem 342543 (1205)
CodelistItem 342544 (1206)
CodelistItem 342545 (1207)
CodelistItem 342546 (1208)
CodelistItem 342547 (1209)
CodelistItem 342548 (1210)
CodelistItem 342549 (1211)
CodelistItem 342550 (1212)
CodelistItem 342551 (1213)
CodelistItem 342552 (1288)
CodelistItem 342553 (1388)
Procedure on heart valve
CodelistItem 342531 (1)
CodelistItem 342532 (2)
CodelistItem 342533 (9)
Aortic valve insufficiency
CodelistItem 342529 (0)
CodelistItem 342530 (1)
Device-Embolization
CodelistItem 342565 (1)
Reason for catheteral intervention (instead
of open coronary surgery)
Age
Yes
No
Conversion of procedure
CodelistItem 342567 (0)
CodelistItem 342568 (1)
CodelistItem 342569 (2)
CodelistItem 342570 (3)
X-ray contrast media dose (in ml)
unknown dose area product
CodelistItem 342566 (1)
Dose Area product (cGy)* cm²)
X-Ray Exposure Time (in minutes)
other
Yes
No
Malignant tumor (without curative treatment )
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Yes
No
Porcelain aorta
Yes
No
Patient's wish
Yes
No
Prognosis-limiting comorbidity
Yes
No
High risk
Yes
No
Frailty
Yes
No
Vascular complication
CodelistItem 342571 (1)
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EHR breast cancer
Documentation standard - breast cancer - gynecology, with
friendly permission (Dr. Tio)
- kooperatives Brustzentrum Münster, Bereich Senologie an
der Klinik und Poliklinik für Frauenheilkunde und
Geburtshilfe - Leitung: Dr. med. Joke Tio
All rights reserved. Please visit https://medical-data-
models.org/forms/6459
EHR breast cancer
Administrative Angaben
Aufnahmedatum*
Patientenidentifikationsnummer*
Geschlecht Patient
Patienten-Nachname*
Patienten-Vorname*
Patienten-Geburtsdatum*
Aufnahmezeit
Einweisender Arzt
Untersuchungsdatum
Anamnese
Anamnese erhoben durch *
Zuweisender Arzt *
Frauenfacharzt *
Überweisungsgrund*
Grund des Arztbesuches *
Nachsorge (Nachsorge)
Screening (Screening)
Selbstuntersuchung
(Selbstuntersuchung)
Symptomatik (Symptomatik)
Vorsorge (Vorsorge)
Zufallsbefund (Zufallsbefund)
Anamnese *
Menopausenstatus*
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Perimenopause (peripausal)
Postmenopause (Postmenopause)
Prämenopause (Prämenopause)
unbekannter Menopausen-Status
(unbekannt)
Schwangerschaften*
Stillzeit (Monate)*
Medikamente*
Kontrazeptiva*
Ja
Nein
Hormonersatztherapie*
Ja
Nein
Aspirin*
Ja
Nein
Phenprocoumon *
Ja
Nein
Allergische Reaktion*
Tabak Rauchen*
Ja
Nein
Wie viele Zigaretten pro Tag*
Alkohol Konsum*
Ja
Nein
Details Trinkverhalten*
Familienanamnese
Vorerkrankungen
Vorerkrankungen*
Ja
Nein
Thrombose*
Ja
Nein
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Vorerkrankunge*
Datum Vorerkrankungen*
Therapie*
Externe Befunde
Mammographie*
Ja
Nein
Datum Mammografie*
Seite finding*
links (links)
rechts (rechts)
BIRADS *
Sonografie*
Ja
Nein
Datum Sonografie*
BIRADSanalog *
Magnetresonanz-Mammografie*
Ja
Nein
Datum Magnetresonanz-Mammografie*
MR-BIRADS *
Histologie*
Ja
Nein
sonstiger Befund*
Ja
Nein
Klinischer Befund
Körbchengröße*
nicht_kodiert (> D)
nicht_kodiert (A)
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nicht_kodiert (B)
nicht_kodiert (C)
nicht_kodiert (D)
Ptosis*
ausgeprägt (ausgeprägt)
keine (keine)
mittel (mittel)
Symmetrie*
Symmetrie der Brust (ja)
Asymmetrie der Brust (nein)
nein: li<re (nein: li<re)
nein: li>re (nein: li>re)
Absonderung*
Absonderung vorhanden (ja)
blutige Absonderung (ja: blutig)
milchige Absonderung (ja: milchig)
seröse Absonderung (ja: serös)
keine Absonderung (nein)
Haut*
Hauteinziehung (Einziehung)
Brustödem (Ödem)
Plateau (Plateau)
Ulzeration der Brust (Ulzeration)
unauffällig (unauffällig)
intradermale Knoten*
Ja
Nein
entzündlich (inflammatorisches) Karzinom*
Ja
Nein
Brustkonsistenz*
knotige Brustkonsistenz (knotig, schwer
beurteilbar)
normale Brustkonsistenz (weich, gut
beurteilbar)
Seite finding*
links (links)
rechts (rechts)
auffälliger Tastbefund *
multiple (multiple)
nein (nonpalpabel) (nein (nonpalpabel))
solitär (solitär)
Anzahl *
Uhr *
Größe *
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Suspekt *
Ja
Nein
Seite Lymphknoten*
links (links)
rechts (rechts)
Lymphknoten *
nicht tastbar (nicht tastbar)
suspekt (suspekt)
tastbar (tastbar)
Zeichnung*
Sonographie
Zeichnung Sonography*
Seite Sonographie*
links (links)
rechts (rechts)
Nr. *
Uhr *
Größe *
BI-Rads Ultraschall *
Lymphknoten *
pathologisch (pathologisch)
suspekt (suspekt)
unauffällig (unauffällig)
Nummer Herdbefund*
Seite Läsion*
links (links)
rechts (rechts)
Form*
komplex (komplex)
oval (oval)
rund (rund)
Achse*
horizontal (horizontal)
indifferent (indifferent)
vertikal (vertikal)
Begrenzung*
echoreicher Saum (echoreicher Saum)
5 / 8
EHR breast cancer
unregelmäßig (gezackt)
glatt (glatt)
scharf (scharf)
unscharf (unscharf)
Echogenität*
echoarm (echoarm)
echogleich (echogleich)
echoleer (echoleer)
echoreich (echoreich)
Echostruktur*
homogen (homogen)
heterogen (inhomogen)
dorsale Schallverstärkung*
Ja
Nein
Schallschatten*
Ja
Nein
unilat. Schallauslöschung*
Ja
Nein
bilaterale Schallauslöschung*
Ja
Nein
nicht_kodiert*
nicht_kodiert (Umgebungsarchitektur
verdrängt)
nicht_kodiert (unterbrochen)
nicht_kodiert*
nicht_kodiert (fehlend)
nicht_kodiert (gering)
nicht_kodiert (gut)
Gefäße*
im Tumor (im Tumor)
in Umgebung (in Umgebung)
keine Gefäße (keine Gefäße)
Biopsie*
Ja
Nein
Ultraschallgestütze Biopsie*
Ja
Nein
Zystenpunktion*
Ja
Nein
Nummer Herdbefund*
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Anzahl der Stanzen*
nicht_kodiert*
nicht_kodiert (kleiner)
nicht_kodiert (nein)
nicht_kodiert (weg)
Fotodokumentation*
Ja
Nein
Datum*
Unterschrift*
Prozeduren
weiterführende Bildgebung*
Ja
Nein
Mammographie*
Ja
Nein
Datum Mammographie*
Sonographie*
Ja
Nein
Datum Sonographie*
andere Bildgebung*
Ja
Nein
Datum andere Bildgebung*
Tumorkonferenz*
Ja
Nein
Datum Tumorkonferenz*
Nachsorge*
Ja
Nein
Wiedervorstellung*
Ja
Nein
Datum Wiedervorstellung*
7 / 8
EHR breast cancer
Freitext*
Datum*
Unterschrift*
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Anamnese und klinische Untersuchung
OPAL-Studie NCT01619124 ALL
Osteonekrosen bei pädiatrischen Patienten mit ALL
All rights reserved. Please visit https://medical-data-
models.org/forms/6465
Anamnese und klinische
Untersuchung OPAL-Studie
Allgemeine Angaben
Name*
Vorname*
Geburtsdatum*
Untersuchungsdatum*
Körpergewicht*
Körperlänge*
Tannerstadium*
I (1)
II (2)
III (3)
IV (4)
V (5)
Tägliche Aktivitäten
Treppenlaufen*
ohne Probleme hoch und runter (1)
runter mit Hilfe des Treppengeländers (2)
hoch und runter mit Geländer (3)
runter nicht möglich (4)
Treppensteigen unmöglich (5)
Bequemes Sitzen*
für ca. 60 min möglich (1)
für ca. 30 min möglich (2)
nicht möglich (3)
Anziehen von Schuhen und Socken*
leicht möglich (1)
schwierig möglich (2)
An- und Ausziehen unmöglich (3)
Gehen
Max. mögliche Gehstrecke (ohne Pause)*
nicht eingeschränkt (1)
längere Gehstrecken (über 1000 m)  (2)
mittlere Gehstrecken (500 - 1000 m)  (3)
nur kurze Gehstrecken (< 500 m)  (4)
an das Haus gebunden (5)
Gehen unmöglich (6)
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Unterstützung beim Gehen*
Keine (1)
einseitige Gehhilfe für längere Strecken
(2)
einseitige Gehhilfe fast immer nötig (3)
beidseitige Gehhilfen (4)
2 Unterarmgehhilfen (Krücken) nötig (5)
Rollstuhl (6)
Visuelle Analogskala (durchschnittliche
Schmerzen in den vergangenen 2 Wochen)*
Schmerzen*
Keine Schmerzen (1)
gelegentliche (geringe) Schmerzen bei
Belastung, keine
Belastungseinschränkung, alle
Aktivitäten möglich (2)
gelegentliche (mäßige) Schmerzen bei
sportlicher bzw. unüblicher Betätigung,
gelegentliche Einnahme eines
Analgetikums (WHO 1) (3)
mäßige (erträgliche) Schmerzen, die die
Alltagsbelastung einschränken können,
gelegentliche Einnahme stärkerer
Analgetika (> WHO 1) (4)
starke Schmerzen, deutl. Einschränkung
der Alltagsaktivität, nur geringste
Belastungen möglich, regelmäßig
stärkere Analgetika (>= WHO 2) nötig (5)
Bewegung nur unter starken
Schmerzen/Ruheschmerz, keine
Belastung mögl. (6)
Gelenkinspektion
Hüftgelenk Schwellung*
Keine (1)
re (2)
li (3)
re + li (4)
Hüftgelenk Erguss*
Kein (1)
re (2)
li (3)
re + li (4)
Hüftgelenk Schonhaltung*
Keine (1)
re (2)
li (3)
re + li (4)
Hüftgelenk Fehlstellung*
Keine (1)
re (2)
li (3)
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re + li (4)
Kniegelenk Schwellung*
Keine (1)
re (2)
li (3)
re + li (4)
Kniegelenk Erguss*
Kein (1)
re (2)
li (3)
re + li (4)
Kniegelenk Schonhaltung*
Keine (1)
re (2)
li (3)
re + li (4)
Kniegelenk Fehlstellung*
Keine (1)
re (2)
li (3)
re + li (4)
Sprunggelenk Schwellung*
Keine (1)
re (2)
li (3)
re + li (4)
Sprunggelenk Erguss*
Kein (1)
re (2)
li (3)
re + li (4)
Sprunggelenk Schonhaltung*
Keine (1)
re (2)
li (3)
re + li (4)
Sprunggelenk Fehlstellung*
Keine (1)
re (2)
li (3)
re + li (4)
Falls ja bitte Spezifizierung*
Bewegungsumfang (in °) Hüftgelenk
Flexion rechts*
Flexion links*
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Außenrotation rechts*
Außenrotation links*
Innenrotation rechts*
Innenrotation links*
Bewegungsumfang (in °) Kniegelenk
Flexion rechts*
Flexion links*
Extension rechts*
Extension links*
Bewegungsumfang (in °) Sprunggelenk
Plantarflexion rechts*
Plantarflexion links*
Vorfußpronation rechts*
Vorfußpronation links*
Zehenstand rechts*
Zehenstand links*
Muskelbefund
Reduzierter Tonus re.*
Ja
Nein
Reduzierter Tonus li.*
Ja
Nein
Atrophie re*
Ja
Nein
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Atrophie (Beinumfang in cm) re.*
Atrophie li*
Ja
Nein
Atrophie (Beinumfang in cm) li.*
Muskelbefund Unterschenkel
Reduzierter Tonus re.*
Ja
Nein
Reduzierter Tonus li.*
Ja
Nein
Atrophie re*
Ja
Nein
Atrophie (Beinumfang in cm) re.*
Atrophie li*
Ja
Nein
Atrophie (Beinumfang in cm) li.*
Gangbild*
Kein Hinken beim Gehen (1)
Leichtes Hinken beim Gehen (2)
Mäßiges Hinken beim Gehen (3)
Deutliches Hinken / Gehunfähigkeit (4)
Wachstumsstörung / Beinlängendifferenz*
Ja
Nein
Wachstumsstörung / Beinlängendifferenz*
Therapiekomplikationen
Septischer Schock*
Ja
Nein
Schwere MTX-Ausscheidungsstörung*
Ja
Nein
Thrombose / Embolie*
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Ja
Nein
Begleitmedikation
Gerinnungsaktive Substanzen (inkl. LMW-
Heparin) *
Ja
Nein
Hormone (inkl. GRH-Analoga)*
Ja
Nein
Sonstige*
Ja
Nein
Falls ja, bitte Spezifizierung:*
Spez. Intervention gegen Osteonekrosen
Pharmakologisch*
Ja
Nein
Orthopädisch-konservative*
Ja
Nein
Orthopädisch-operative*
Ja
Nein
Falls ja, bitte Spezifizierung:*
Bemerkungen
Name des dokumentierenden Arztes (Stempel)*
Datum*
Unterschrift*
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Concomitant Medications Form (CALGB
10603)
CALGB: 10603 Concomitant Medications Form
Daunorubicin, Cytarabine, and Midostaurin in Treating
Patients With Newly Diagnosed Acute Myeloid Leukemia
NCT00651261
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=742F65D1-
34F2-9883-E040-BB89AD437120
All rights reserved. Please visit https://medical-data-
models.org/forms/6469
Concomitant Medications Form
(CALGB 10603)
Administrative documentation
CALGB Form*
CALGB Study No*
CALGB Patient ID*
Treatment Reporting Period Start Date*
Treatment Reporting Period End Date*
Are data amended*
Yes
No
Patient Initials (Last, First Middle)*
Patient Hospital No.*
Institution/Affiliate*
Participating Group*
Participating Group Study No*
Participating Group Patient ID*
Page (___ of ___)*
Concomitant medication
Concomitant Medication*
Medication Category*
Antibiotic/antiviral/antifungal (1)
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Antiemetic (2)
Antihistamine (3)
Corticosteroid (4)
Diuretic/antihypertensive (5)
Growth Factor (6)
Nsaid/opioid (7)
Proton Pump Inhibitor/h2 Antagonist (8)
Other (9)
CYP3A4 inhibitor/inducer*
Yes
No
Agent Total Dose (per day)*
Units*
Start date*
Stop date (or)*
Ongoing*
Yes
No
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Treatment - PHASE II LUNG CANCER ¿ TREATMENT
BY CYCLE SUMMARY FORM - 2400140v1.0
Phase II Consortium - PHASE II LUNG CANCER -
TREATMENT BY CYCLE SUMMARY FORM
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=FF93BE54-
D125-5058-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/6471
Treatment by cycle summary form
(Lung Cancer)
CRF Header
Coordinating Group Protocol No.
Coordinating Group Code
Protocol Title*
Patient Study ID*
Registering Group Code
Patient Medical Record Number
Other Patient ID
Institution/Affiliate
Registering Institution Code
Physician of Record
Person Completing Form
Date Form Completed
Are data amended (If data are amended, please
circle in red when using paper form)
Yes
No
Treatment Plan
Cycle Number
Body Surface Area (m^2)
First Date (any modality of) protocol therapy was
given (for this cycle)
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Last Date (any modality of) protocol therapy was
given (for this cycle)
Agent Delayed
Yes
No
Reason Cycle was Delayed
Concomitant Medications
Were concomitant medications used during this
cycle? (including alternative medicines)
Yes
No
Reason for Administration
Concomitant Agent Name*
Was growth factor administered?
Yes
No
Specify growth factor
Radiation Therapy
Has the patient received radiation therapy?
Yes
No
Specify reason
Radiation Therapy Start Date
Radiation Therapy End Date
RT Administered Type
Adjuvant (Adjuvant RT)
Brachytherapy (Brachytherapy)
External Beam Radiation (External beam
radiation)
Neoadjuvant (Neoadjuvant RT)
Other (Other specify)
Other, specify
Radiation Therapy Site
RT Total Dose
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SUMMARY FORM - 2400140v1.0
Were there any unscheduled interruptions in
radiation therapy?
No (No)
Unknown (Unknown)
Yes, Due To Toxicity (Yes, due to toxicity)
Yes, For Other Reasons, Specify (Yes,
for other reasons, specify)
Specify RT interruption reason
Systemic Therapy
No. of Prior Regimens
Type of Systemic Therapy (check all that apply)
Chemotherapy (Chemotherapy)
Immunotherapy (Immunotherapy)
Other Specify (Other)
Other specify
Concomitant Agent Name*
Agent Start Date
Agent End Date
Agent Total Dose
Units
Overall Response Duration (weeks)
Were there any dose modifications or
additions/omissions to protocol treatment? (check
one)
No (No)
Unknown (Unknown)
Yes, Planned (i.e., The Treatment Was
Changed According To Protocol
Guidelines) (Yes, planned)
Yes, Unplanned (i.e., The Treatment
Change Was Not Part Of Protocol
Guidelines) (Yes, unplanned)
Name of Therapy (If yes,)
Reason for Therapy Modification
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Comments
Comments
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On-Study Form Lung Cancer - SCLC
Phase II Consortium - Phase II Lung Cancer - SCLC On-
Study Form
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=005B53D3-
2C60-14E5-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/6473
On-Study Form Lung Cancer - SCLC
CRF Header
Coordinating Group Protocol No.
Coordinating Group Code
Protocol Title
Patient Study ID
Registering Group Code
Patient Medical Record Number
Other Patient ID
Institution/Affiliate
Registering Institution Code
Physician of Record
Person Completing Form
Date Form Completed (MM DD YYYY)
Are data amended (If data are amended, please
circle in red when using paper form)
Yes
No
Lung: Pre-treatment Characteristics
Patient Weight (kg)
Weight Loss in Previous Six Months
Unknown (0)
<5% Of Body Weight (1)
5 To <10% Of Body Weight (2)
10 To <20% Of Body Weight (3)
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> Or  (4)
Weight loss in previous 6 months
Smoking History
Cigarette Smoker <20 Pack-years
(Cigarette smoker, <20 pack-years)
Cigarette Smoker >40 Pack-years
(Cigarette smoker, >40 pack-years)
Cigarette Smoker 20-40 Pack-years
(Cigarette smoker, 20-40 pack-years)
Never Smoked (Never smoked)
Pipe Or Cigar Smoker Only (Pipe or
cigar smoker only)
Unknown (Unknown)
Does the patient currently smoke
Yes
No
Number of Cigarettes per day (If yes,)
10 To 20 Cigarettes (10 to 20 cigarettes)
Fewer Than 10 Cigarettes (Fewer than
10 cigarettes)
More Than 20 Cigarettes (More than 20
cigarettes)
Not Applicable (Not applicable)
Time since last cigarette (If no,)
1 Month To <6 Months (1 month to <6
months)
1 Year To <5 Years (1 year to <5 years)
5 Years To <10 Years (5 years to <10
years)
6 Months To <1 Year (6 months to <1
year)
Less Than 1 Month (Less than 1 month)
More Than 10 Years (More than 10
years)
Not Applicable (Not applicable)
Lung: Disease Description Stage I-III
Extent of disease
Extensive (Extensive)
Limited (Limited)
Recurrent (Recurrent)
Has the patient been diagnosed with first local-
regional recurrence
Yes
No
Time since diagnosis (If yes,)
Less Than 3 Months (< 3 months)
Greater Than Or Equal To 3 Months (>=
3 months)
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Mixed histology?
Yes
No
Histologic Type (If yes check all apply)
Adenocarcinoma (Adenocarcinoma)
Large Cell Undifferentiated (Large cell
undifferentiated)
Large Cell With Neuroendocrine
Features (Large cell with neuroendocrine
features)
Non-small Cell Lung Cancer (nsclc), Nos
(Non-small cell lung cancer NOS)
Other (Other)
Squamous Cell Carcinoma (Squamous
cell carcinoma)
Specify Other Histologic Type
Is measurable disease present? (only applicable
in studies where there is disease at baseline)
Yes
No
Is non-measurable disease present? (only
applicable in studies where there is disease at
baseline)
Yes
No
Metastatic Sites (check all that apply)
Adrenal Gland (Adrenal(s))
Bone (Bone)
Bone Marrow (Bone marrow)
Brain (Brain)
Hilar Nodes (Hilar nodes)
Liver (Liver)
Mediastinal Nodes (Mediastinal nodes)
Other (Other)
Pleura (Pleura)
Skin (Skin)
Supraclavicular Or Scalene Nodes
(Supraclavicular/scalene nodes)
Other specify
Is Pleural Effusion present?
Yes
No
Is it Malignant? (If yes)
No (No)
Unknown (Unknown (not tapped))
Yes (Yes)
Lesion Site (Primary)
MedDRA Code (for Primary Disease Site)
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Paraneoplastic syndrome
Yes
No
Specify (If yes)
Lung: Prior Treatment (CDUS Module)
Prior therapy type (per CDUS reporting
guidelines check all that apply)
Agents Administered To Control The
Replication And/or Spread Of Viruses
(Anti-retroviral therapy)
Treatment With An Agent That Prevents
Or Impairs The Translation Of The
Genetic Message For Production Of A
Specific Protein (Antisense)
High Dose Chemotherapy Combined
With Transplantation Of Bone Marrow
Cells (Bone marrow transplant)
Non-systemic Chemotherapy Treatment
Or Chemotherapy Not Described By
Chemotherapy Single Agent Systemic Or
Multi-agent Systemic (Chemotherapy
(NOS))
Systemic Chemotherapy With A
Regimen Containing Multiple Agents
(Chemotherapy multiple agents
systemic)
Prior Therapy With Agents That Are Not
Known To Cause Damage To Cycling
Cells (Chemotherapy non-cytotoxic)
Systemic Chemotherapy With A Single
Agent Regimen (Chemotherapy single
agent systemic)
Drug And/or Immunotherapy (Drug
and/or Immunotherapy)
Treatment Of Human Disease By Gene
Transfer (Gene transfer)
Cancer Therapy Which Incorporates
Hormonal Manipulation (Hormonal
therapy)
No Previous Exposure To Drug (nos) (No
prior therapy)
Anticancer Treatment With A Live,
Replication-competent Virus (Oncolytic
virotherapy)
Prior Therapy (nos) (Prior therapy NOS)
Targeted Ionizing Radiation Therapy
Utilizing Radioactive Implants Or Seeds
(Radiation therapy)
Surgical Procedure, Or Operation, With
Therapeutic Intent (Surgery)
Therapy Nos (Therapy (NOS))
Substance Or Group Of Substances
Administered To Induce The Immune
System To Recognize And Destroy
Tumors Or Microorganisms (Vaccine)
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Number of prior therapy regimens (For example,
planned treatment of chemotherapy + RT = 1
regimen)
MedDRA Code (for Primary Disease Site)
Prior Systemic Therapy - SCLC
Prior systemic therapy
Yes
No
Number of prior therapy regimens (For example,
planned treatment of chemotherapy + RT = 1
regimen)
Agent Name
Agent Start Date (MM DD YYYY)
Agent End Date (MM DD YYYY)
Agent Total Cumulative Dose
Units
Overall Response Duration (weeks)
Prior Surgery SCLC
Prior Surgery
Yes
No
Surgical Approach
Thoracoscopy / Video-assisted (vats)
(Thoracoscopy / Video-assisted (VATS))
Thoracoscopy / Video-assisted (vats),
With Conversion To Thoracotomy
(Thoracoscopy / Video-assisted (VATS),
with conversion to Thoracotomy)
Thoracotomy (thoracotomy)
Primary Surgery Type
Bilobectomy (Bilobectomy)
Exploration, No Resection (Exploration,
No Resection)
Lobectomy (Lobectomy)
Pneumonectomy (Pneumonectomy)
Segmentectomy (Segmentectomy)
Wedge Resection (Wedge Resection)
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Surgery Date (MM DD YYYY)
Prior Radiation Therapy SCLC
Prior Radiation Therapy
Yes
No
Total Dose to Lung (cGy)
Radiation Therapy End Date (MM DD YYYY)
Did the patient receive prophylactic cranial
irradiation?
Yes
No
RT Daily Dose per Field (If yes)
RT Total Dose
Units
Grays (Gy)
Microcurie (mcCi)
Was radiation therapy hyperfractionated?
Yes
No
Units
Grays (Gy)
Microcurie (mcCi)
Radiation Therapy Site
RT Dose per Fraction
Units
Grays (Gy)
Microcurie (mcCi)
Total Number of Fractions
Units
Grays (Gy)
Microcurie (mcCi)
Were there any unscheduled interruptions in
radiation therapy?
No (No)
Yes, Due To Other Reason (Yes, due to
other reasons)
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Yes, Due To Toxicity (Yes, due to toxicity)
RT Interruptions Reason (Specify)
Comments
Comments
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On-Study - Phase II Lung Cancer - NSCLC
Advanced On-Study Form - 2398811v1.0
Phase II Consortium - Phase II Lung Cancer - NSCLC
Advanced On-Study Form
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=FF7A9F25-
B26C-5224-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/6474
Phase II Lung Cancer - NSCLC
Advanced On-Study Form
CRF Header
Coordinating Group Protocol No.
Coordinating Group Code
Protocol Title
Patient Study ID
Registering Group Code
Patient Medical Record Number
Other Patient ID
Institution/Affiliate
Registering Institution Code
Physician of Record
Person Completing Form
Date Form Completed (MM DD YYYY)
Are data amended (If data are amended, please
circle in red when using paper form)
Yes
No
Lung: Pre-treatment Characteristics
Patient Weight
Weight Loss in Previous Six Months
(Approximate check one)
<5% Of Body Weight (< 5% of body
weight)
> Or = 20% Of Body Weight (> or = 20%
1 / 6
of body weight)
10 To <20% Of Body Weight (10 to <20%
of body weight)
5 To <10% Of Body Weight (5 to < 10%
of body weight)
Unknown (Unknown)
Weight loss in previous 6 months (Approximate
kg)
Smoking History
Cigarette Smoker <20 Pack-years
(Cigarette smoker, <20 pack-years)
Cigarette Smoker >40 Pack-years
(Cigarette smoker, >40 pack-years)
Cigarette Smoker 20-40 Pack-years
(Cigarette smoker, 20-40 pack-years)
Never Smoked (Never smoked)
Pipe Or Cigar Smoker Only (Pipe or
cigar smoker only)
Unknown (Unknown)
Does the patient currently smoke
Yes
No
Number of Cigarettes per day (If yes,)
10 To 20 Cigarettes (10 to 20 cigarettes)
Fewer Than 10 Cigarettes (Fewer than
10 cigarettes)
More Than 20 Cigarettes (More than 20
cigarettes)
Not Applicable (Not applicable)
Time since last cigarette (If no,)
1 Month To <6 Months (1 month to <6
months)
1 Year To <5 Years (1 year to <5 years)
5 Years To <10 Years (5 years to <10
years)
6 Months To <1 Year (6 months to <1
year)
Less Than 1 Month (Less than 1 month)
More Than 10 Years (More than 10
years)
Not Applicable (Not applicable)
Lung: Disease Description NSCLC Stage
I-III
Tumor Stage
Recurrent (Recurrent)
IIIB (not recurrent) (Stage IIIb)
IV (not recurrent) (Stage IV)
Histologic Type
Adenocarcinoma (Adenocarcinoma)
Adenocarcinoma With Bac Features
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(Adenocarcinoma with BAC features)
Bronchoalveolar (bac) (Bronchoalveolar
carcinoma (BAC))
Large Cell Undifferentiated (Large cell
undifferentiated)
Large Cell With Neuroendocrine
Features (Large cell with neuroendocrine
features)
Non-small Cell Lung Cancer (nsclc), Nos
(Non-small cell lung cancer NOS)
Other (Other specify)
Squamous Cell Carcinoma (Squamous
cell carcinoma)
Specify Other Histologic Type
Is measurable disease present? (only applicable
in studies where there is disease at baseline)
Yes
No
Is non-measurable disease present? (only
applicable in studies where there is disease at
baseline)
Yes
No
Metastatic Sites (check all that apply)
Adrenal Gland (Adrenal(s))
Bone (Bone)
Brain (Brain)
Contralateral Lung (Contralateral lung)
Hilar Nodes (Hilar nodes)
Ipsilateral Lung (Ipsilateral lung)
Liver (Liver)
Mediastinal Nodes (Mediastinal nodes)
Other (Other)
Pleura (Pleura)
Skin (Skin)
Supraclavicular Or Scalene Nodes
(Supraclavicular/scalene nodes)
Other specify
Lung: Prior Treatment (CDUS Module)
NSCLC Stage I-III
Prior therapy type (per CDUS reporting
guidelines check all that apply)
Agents Administered To Control The
Replication And/or Spread Of Viruses
(Anti-retroviral therapy)
Treatment With An Agent That Prevents
Or Impairs The Translation Of The
Genetic Message For Production Of A
Specific Protein (Antisense)
High Dose Chemotherapy Combined
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With Transplantation Of Bone Marrow
Cells (Bone marrow transplant)
Non-systemic Chemotherapy Treatment
Or Chemotherapy Not Described By
Chemotherapy Single Agent Systemic Or
Multi-agent Systemic (Chemotherapy
(NOS))
Systemic Chemotherapy With A
Regimen Containing Multiple Agents
(Chemotherapy multiple agents
systemic)
Prior Therapy With Agents That Are Not
Known To Cause Damage To Cycling
Cells (Chemotherapy non-cytotoxic)
Systemic Chemotherapy With A Single
Agent Regimen (Chemotherapy single
agent systemic)
Drug And/or Immunotherapy (Drug
and/or Immunotherapy)
Treatment Of Human Disease By Gene
Transfer (Gene transfer)
Cancer Therapy Which Incorporates
Hormonal Manipulation (Hormonal
therapy)
No Previous Exposure To Drug (nos) (No
prior therapy)
Anticancer Treatment With A Live,
Replication-competent Virus (Oncolytic
virotherapy)
Prior Therapy (nos) (Prior therapy NOS)
Targeted Ionizing Radiation Therapy
Utilizing Radioactive Implants Or Seeds
(Radiation therapy)
Surgical Procedure, Or Operation, With
Therapeutic Intent (Surgery)
Therapy Nos (Therapy (NOS))
Substance Or Group Of Substances
Administered To Induce The Immune
System To Recognize And Destroy
Tumors Or Microorganisms (Vaccine)
Number of prior therapy regimens (For example,
planned treatment of chemotherapy + RT = 1
regimen)
MedDRA Code (for Primary Disease Site)
Lung: Prior Systemic Therapy NSCLC
Advanced
Prior systemic therapy
Yes
No
Number of prior therapy regimens (For example,
planned treatment of chemotherapy + RT = 1
regimen)
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Agent Name
Agent Start Date (MM DD YYYY)
Agent End Date (MM DD YYYY)
Agent Total Cumulative Dose
Units
Overall Response Duration (weeks)
Procedure Description
Prior Surgery
Yes
No
Surgical Approach
Thoracoscopy / Video-assisted (vats)
(Thoracoscopy / Video-assisted (VATS))
Thoracoscopy / Video-assisted (vats),
With Conversion To Thoracotomy
(Thoracoscopy / Video-assisted (VATS),
with conversion to Thoracotomy)
Thoracotomy (thoracotomy)
Primary Surgery Type
Bilobectomy (Bilobectomy)
Exploration, No Resection (Exploration,
No Resection)
Lobectomy (Lobectomy)
Pneumonectomy (Pneumonectomy)
Segmentectomy (Segmentectomy)
Wedge Resection (Wedge Resection)
Surgery Date (MM DD YYYY)
Lung: Prior Radiation Therapy NSCLC
Advanced
Prior Radiation Therapy
Yes
No
Total Dose to Lung (cGy)
Radiation Therapy End Date (MM DD YYYY)
Type of Radiation Therapy Administered
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External Beam Radiation (External beam
radiation)
Other (Other)
Other specify
Radiation Therapy Site
RT Dose per Fraction
Units
Grays (Gy)
Millicurie (mCi)
Total Number of Fractions
RT Total Dose
Were there any unscheduled interruptions in
radiation therapy?
No (No)
Yes, Due To Other Reason (Yes, due to
other reasons)
Yes, Due To Toxicity (Yes, due to toxicity)
RT Interruptions Reason (Specify)
Comments
Comments
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On-Study Form NSCLC Stage I-III
Phase II Consortium - Phase II Lung Cancer - NSCLC
Stage I-III On-Study Form (for Adjuvant Studies and
Inoperable Stage III)
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=FF3F2FE3-
D320-46AD-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/6475
On-Study Form NSCLC Stage I-III
CRF Header
Coordinating Group Protocol No.
Coordinating Group Code
Protocol Title
Patient Study ID
Registering Group Code
Patient Medical Record Number
Other Patient ID
Institution/Affiliate
Registering Institution Code
Physician of Record
Person Completing Form
Date Form Completed (MM DD YYYY)
Are data amended (If data are amended, please
circle in red when using paper form)
Yes
No
Lung: Pre-treatment Characteristics
Patient Weight
Weight Loss in Previous Six Months
(Approximate check one)
<5% Of Body Weight (< 5% of body
weight)
> Or = 20% Of Body Weight (> or = 20%
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of body weight)
10 To <20% Of Body Weight (10 to <20%
of body weight)
5 To <10% Of Body Weight (5 to < 10%
of body weight)
Unknown (Unknown)
Weight loss in previous 6 months (Approximate
kg)
Smoking History
Cigarette Smoker <20 Pack-years
(Cigarette smoker, <20 pack-years)
Cigarette Smoker >40 Pack-years
(Cigarette smoker, >40 pack-years)
Cigarette Smoker 20-40 Pack-years
(Cigarette smoker, 20-40 pack-years)
Never Smoked (Never smoked)
Pipe Or Cigar Smoker Only (Pipe or
cigar smoker only)
Unknown (Unknown)
Does the patient currently smoke
Yes
No
Number of Cigarettes per day (If yes,)
10 To 20 Cigarettes (10 to 20 cigarettes)
Fewer Than 10 Cigarettes (Fewer than
10 cigarettes)
More Than 20 Cigarettes (More than 20
cigarettes)
Not Applicable (Not applicable)
Time since last cigarette (If no,)
1 Month To <6 Months (1 month to <6
months)
1 Year To <5 Years (1 year to <5 years)
5 Years To <10 Years (5 years to <10
years)
6 Months To <1 Year (6 months to <1
year)
Less Than 1 Month (Less than 1 month)
More Than 10 Years (More than 10
years)
Not Applicable (Not applicable)
Lung: Disease Description Stage I-III
T Stage clinical, Clinical (leave blank if not done)
N Stage, Clinical  (leave blank if not done)
M Stage, Clinical  (leave blank if not done)
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T Stage, Pathologic (leave blank if not done)
N Stage, Pathologic (leave blank if not done)
M Stage, Pathologic (leave blank if not done)
MedDRA Code (for Primary Disease Site)
Lesion Site (Primary at diagnosis)
Longest Diameter of Lesion(s)
Pathologic Stage based on Mediastinoscopy?
Yes
No
Pathologic Stage based on Bronchoscopy?
Yes
No
Pathologic Stage based on
Thoracotomy/Sternotomy?
Yes
No
Histologic Type
Adenocarcinoma (Adenocarcinoma)
Adenocarcinoma With Bac Features
(Adenocarcinoma with BAC features)
Bronchoalveolar (bac) (Bronchoalveolar
carcinoma (BAC))
Large Cell Undifferentiated (Large cell
undifferentiated)
Large Cell With Neuroendocrine
Features (Large cell with neuroendocrine
features)
Non-small Cell Lung Cancer (nsclc), Nos
(Non-small cell lung cancer NOS)
Other (Other)
Squamous Cell Carcinoma (Squamous
cell carcinoma)
Specify Other Histologic Type
Was resection attempted?
Yes
No
Status of Primary Tumor (If resected,)
Recurrent (Recurrent)
Not Recurrent, Resected, No Residual
Tumor (Resected, no residual tumor)
Not Recurrent, Resected, Residual
Tumor (Resected, residual tumor)
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Unresected (Unresected)
Has the patient been diagnosed with first local-
regional recurrence
Yes
No
Does the tumor involve the surgical margin
Yes
No
Was all gross tumor removed
Yes
No
Is measurable disease present? (only applicable
in studies where there is disease at baseline)
Yes
No
Is non-measurable disease present? (only
applicable in studies where there is disease at
baseline)
Yes
No
Lung: Prior Treatment (CDUS Module)
NSCLC Stage I-III
Prior therapy type (per CDUS reporting
guidelines check all that apply)
Agents Administered To Control The
Replication And/or Spread Of Viruses
(Anti-retroviral therapy)
Treatment With An Agent That Prevents
Or Impairs The Translation Of The
Genetic Message For Production Of A
Specific Protein (Antisense)
High Dose Chemotherapy Combined
With Transplantation Of Bone Marrow
Cells (Bone marrow transplant)
Non-systemic Chemotherapy Treatment
Or Chemotherapy Not Described By
Chemotherapy Single Agent Systemic Or
Multi-agent Systemic (Chemotherapy
(NOS))
Systemic Chemotherapy With A
Regimen Containing Multiple Agents
(Chemotherapy multiple agents
systemic)
Prior Therapy With Agents That Are Not
Known To Cause Damage To Cycling
Cells (Chemotherapy non-cytotoxic)
Systemic Chemotherapy With A Single
Agent Regimen (Chemotherapy single
agent systemic)
Drug And/or Immunotherapy (Drug
and/or Immunotherapy)
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Treatment Of Human Disease By Gene
Transfer (Gene transfer)
Cancer Therapy Which Incorporates
Hormonal Manipulation (Hormonal
therapy)
No Previous Exposure To Drug (nos) (No
prior therapy)
Anticancer Treatment With A Live,
Replication-competent Virus (Oncolytic
virotherapy)
Prior Therapy (nos) (Prior therapy NOS)
Targeted Ionizing Radiation Therapy
Utilizing Radioactive Implants Or Seeds
(Radiation therapy)
Surgical Procedure, Or Operation, With
Therapeutic Intent (Surgery)
Therapy Nos (Therapy (NOS))
Substance Or Group Of Substances
Administered To Induce The Immune
System To Recognize And Destroy
Tumors Or Microorganisms (Vaccine)
Number of prior therapy regimens (For example,
planned treatment of chemotherapy + RT = 1
regimen)
MedDRA Code (for Primary Disease Site)
Lung: Prior Systemic Therapy NSCLC
Advanced
Prior systemic therapy
Yes
No
Number of prior therapy regimens (For example,
planned treatment of chemotherapy + RT = 1
regimen)
Agent Name
Agent Start Date (MM DD YYYY)
Agent End Date (MM DD YYYY)
Agent Total Cumulative Dose
Units
Overall Response Duration (weeks)
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Procedure Description
Prior Surgery
Yes
No
Surgical Approach
Thoracoscopy / Video-assisted (vats)
(Thoracoscopy / Video-assisted (VATS))
Thoracoscopy / Video-assisted (vats),
With Conversion To Thoracotomy
(Thoracoscopy / Video-assisted (VATS),
with conversion to Thoracotomy)
Thoracotomy (thoracotomy)
Primary Surgery Type
Bilobectomy (Bilobectomy)
Exploration, No Resection (Exploration,
No Resection)
Lobectomy (Lobectomy)
Pneumonectomy (Pneumonectomy)
Segmentectomy (Segmentectomy)
Wedge Resection (Wedge Resection)
Surgery Details
Bronchial Sleeve Resection (Bronchial
sleeve resection)
Chest Wall Resection, No
Reconstruction (Chest wall resection, no
reconstruction)
Chest Wall Resection, With
Reconstruction (Chest wall resection,
with reconstruction)
Intrapericardial Reconstruction
(Intrapericardial reconstruction)
Major Vascular Resection, No
Reconstruction (Major vascular
resection, no reconstruction)
Other, Specify (Other, specify)
Vascular Sleeve Resection (Vascular
sleeve resection)
Other, specify
Surgery Date (MM DD YYYY)
Duration of Surgery (enter hours and minutes
elapsed)
Lung: Prior Radiation Therapy NSCLC
Advanced
Prior Radiation Therapy
Yes
No
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Total Dose to Lung (cGy)
Radiation Therapy End Date (MM DD YYYY)
Were there any unscheduled interruptions in
radiation therapy?
No (No)
Yes, Due To Other Reason (Yes, due to
other reasons)
Yes, Due To Toxicity (Yes, due to toxicity)
RT Interruptions Reason (Specify)
Comments
Comments
7 / 7
On-Study Form NSCLC Stage I-III
Treatment Form Multiple Myeloma
Maintenance  E1A06
E1A06 Maintenance Treatment Form
Melphalan, Prednisone, and Thalidomide or Lenalidomide
in Treating Patients With Newly Diagnosed Multiple
Myeloma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=4066DEFA-
0353-324B-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/6476
Treatment Form Multiple Myeloma
Maintenance  E1A06
Header section
Patient Initials (Last, First)
ECOG Protocol Number
Participating Group Protocol Number
Institution/Affiliate
ECOG Patient ID
Participating Group Patient ID
DCI Name
Registration Step
Please mark an 'X' if data have been amended.
(Please circle amended items in red)
Date data amended
On Treatment
On Treatment Report Period (Maintenance
Therapy: Begins with Cycle 13)
> Cycle 34 (> Cycle 34)
Cycle 14 (Cycle 14)
Cycle 16 (Cycle 16)
Cycle 18 (Cycle 18)
Cycle 20 (Cycle 20)
Cycle 22 (Cycle 22)
Cycle 24 (Cycle 24)
Cycle 26 (Cycle 26)
Cycle 28 (Cycle 28)
Cycle 30 (Cycle 30)
Cycle 32 (Cycle 32)
Cycle 34 (Cycle 34)
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Specify Cycle
Reporting Period Start Date (mm/dd/yyyy)
Reporting Period End Date (mm/dd/yyyy)
Vital Status
Patient's Vital Status
Alive (Alive)
Dead (Dead)
Date of last contact or death
Primary Cause of Death
Due To Other Cause (Due to other
cause)
Due To Protocol Treatment (Due to
protocol treatment)
Due To This Disease (Due to this
disease)
Unknown (Unknown)
Describe cause of death
Patient Characteristics
Weight (Day 1 of this reporting period cycle)
Body Surface Area (BSA Day 1 of this reporting
period cycle)
Therapy Administered - Section I
Agent Name (Complete base on completed
Patient Pill Diary)
Was the agent administered during this reporting
period? (Lenalidomide)
Yes
No
Agent Start Date
Total Dose of Agents/Drugs for this Cycle (mg -
this report period)
Were there any dose modifications or
additions/omissions to Thalidomide protocol
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treatment
Yes
No
Was treatment modification to Thalidomide
planned (per protocol)?
Yes
No
Dose Modification Start Date
Dose Modification End Date
Total Modified Dose
Dose modification
Dose Delayed (Dose delayed)
Dose Escalated (Dose escalated)
Dose Held (Dose held)
Dose Missed (Dose missed)
Dose Reduced (Dose reduced)
Drug Discontinued (Drug discontinued)
No Dose Modification (No dose
modification)
Dose Modification Reason
Adverse Event (Adverse event)
Alternative Therapy For Other Reason
(Alternative therapy for other reason)
Dosing Error (Dosing error)
Other (Other)
Patient Refusal/noncompliance (Patient
refusal/noncompliance)
Scheduling (Scheduling)
Second Primary Cancer (Second
primary)
Other, specify
Therapy Administered - Section I
Agent Name (Complete base on completed
Patient Pill Diary)
Was the agent administered during this reporting
period? (Lenalidomide)
Yes
No
Agent Start Date
Total Dose of Agents/Drugs for this Cycle (mg -
this report period)
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Were there any dose modifications or
additions/omissions to Lenalidomide protocol
treatment
Yes
No
Was treatment modification to Lenalidomide
planned (per protocol)? (If yes,)
Yes
No
Start Date of Dose Modification
End Date of Dose Modification
Total Modified Dose
Dose modification
Dose Delayed (Dose delayed)
Dose Escalated (Dose escalated)
Dose Held (Dose held)
Dose Missed (Dose missed)
Dose Reduced (Dose reduced)
Drug Discontinued (Drug discontinued)
No Dose Modification (No dose
modification)
Dose Modification Reason
Adverse Event (Adverse event)
Alternative Therapy For Other Reason
(Alternative therapy for other reason)
Dosing Error (Dosing error)
Other (Other)
Patient Refusal/noncompliance (Patient
refusal/noncompliance)
Scheduling (Scheduling)
Second Primary Cancer (Second
primary)
Other, specify
Therapy Administered - Prophylaxis
Treatment
Did patient recieve DVT prophylaxis (this report
period)
Yes
No
Start date of first (prophylactic) treatment
Date of most recent (prophylactic) treatment
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Aspirin (81 mg) (Were any of the following given?
answer no 1 or yes 2 for each of the following)
Yes
No
Aspirin (325 mg)
Yes
No
Aspirin (other dose)
Yes
No
If other dose of Aspirin given, specify dose
Low molecular weight heparin
Yes
No
Warfarin
Yes
No
If Coumadin given, specify dose
Other, specify
Has the patient received erythropoietin-type
agents (e.g., Epogen, Procrit or Aranesp) (this
report period)
Yes
No
Section E: Non-protocol Therapy
Was any non-protocol therapy given during
protocol treatment (not previously reported)?
Yes
No
Comments
Comments
Investigator Signature
Investigator Signature Date
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Treatment Form Multiple Myeloma E3A06
Arm A
E3A06 Treatment Form (Arm A)
Lenalidomide or Observation in Treating Patients With
Asymptomatic High-Risk Smoldering Multiple Myeloma
NCT01169337
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=86D1B322-
221A-3014-E040-BB89AD432E00
All rights reserved. Please visit https://medical-data-
models.org/forms/6477
Treatment Form Multiple Myeloma
E3A06 Arm A
Header Module
ECOG Protocol Number
ECOG Patient ID
DCI Name
Registration Step (Place ID Label Here)
Patient Initials (Last, First)
Participating Group Protocol Number
Participating Group Patient ID
Institution/Affiliate
Please mark an 'X' if data have been amended.
(Please circle amended items in red)
Date data amended
Investigator Signature
Investigator Signature Date
On Treatment
On Treatment Report Period
> Cycle 19 (> Cycle 19)
Cycle 1 (Cycle 1)
Cycle 10 (Cycle 10)
Cycle 11 (Cycle 11)
Cycle 12 (Cycle 12)
Cycle 13 (Cycle 13)
Cycle 14 (Cycle 14)
Cycle 15 (Cycle 15)
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Cycle 16 (Cycle 16)
Cycle 17 (Cycle 17)
Cycle 18 (Cycle 18)
Cycle 19 (Cycle 19)
Cycle 2 (Cycle 2)
Cycle 3 (Cycle 3)
Cycle 4 (cycle 4)
Cycle 5 (Cycle 5)
Cycle 6 (Cycle 6)
Cycle 7 (Cycle 7)
Cycle 8 (cycle 8)
Cycle 9 (Cycle 9)
Specify Cycle
Reporting Period Start Date
Reporting Period End Date
Vital Status
Patient's Vital Status
Alive (Alive)
Dead (Dead)
Date of Last Contact or Death (M D Y)
Primary Cause of Death (if applicable)
Due To Other Cause (Due to other
cause)
Due To Protocol Treatment (Due to
protocol treatment)
Due To This Disease (Due to this
disease)
Unknown (Unknown)
Describe cause of death
Patient Characteristics
Weight (kg Day 1 of this treatment)
Therapy Administered
Agent Name (Lenalidomide)
Was the agent administered during this reporting
period? (Lenalidomidecycle)
Yes
No
Did the patient complete Patient Pill Diary
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Yes
No
Agent Start Date
Agent Total Dose (this report period)
Were there any dose modifications or
additions/omissions to Lenalidomide protocol
treatment
Yes
No
Was treatment modification to Lenalidomide
planned (per protocol)?
Yes
No
Start Date of Dose Modification
End Date of Dose Modification
Total Modified Dose (daily mg)
Dose modification
Dose Delayed (Dose delayed)
Dose Delayed And Reduced (Dose
delayed and reduced)
Dose Escalated (Dose escalated)
Dose Held (Dose held)
Dose Missed (Dose missed)
Dose Reduced (Dose reduced)
Drug Discontinued (Drug discontinued)
Dose Modification Reason
Adverse Event (Adverse event)
Alternative Therapy For Other Reason
(Alternative therapy for other reason)
Dosing Error (Dosing error)
Other (Other)
Patient Refusal/noncompliance (Patient
refusal/noncompliance)
Scheduling (Scheduling)
Second Primary Cancer (Second
primary)
Other, specify
Did patient receive thrombosis prophylaxis
Yes
No
DVT prophylaxis Daily dose prescribed (If yes)
325mg (aspirin) (325mg)
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Aspirin (other Dose) (Aspirin (Other
Dose))
Warfarin Sodium (Coumadin)
Levonox 40mg (Levonox 40mg)
Specify dose (if Aspirin given)
if Coumadin, specify (International Normal Ratio
INR at the end of report period - choose one)
<1.5 (<1.5)
>2.5 (>2.5)
1.5-2.5 (1.5-2.5)
Was the next cycle of treatment delayed
Yes
No
Non-protocol Therapy
Was any non-protocol therapy given during
protocol treatment? (not previously reported )
Yes
No
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Treatment Form Multiple Myeloma (Form
2860)
E1A05 Treatment Form - Form 2860
Bortezomib and Dexamethasone With or Without
Lenalidomide in Treating Patients With Multiple Myeloma
Previously Treated With Dexamethasone
NCT00522392
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=32B65860-
B480-5012-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/6478
Treatment Form Multiple Myeloma
(Form 2860)
Header section
Patient Initials (Last, First)
ECOG Protocol Number
Participating Group Protocol Number
Institution/Affiliate
ECOG Patient ID
Participating Group Patient ID
DCI Name
Reporting Period
Cycle 1 (Cycle 1)
Cycle 2 (Cycle 2)
Cycle 3 (Cycle 3)
Cycle 4 (Cycle 4)
Cycle 5 (Cycle 5)
Cycle 6 (Cycle 6)
Cycle 7 (Cycle 7)
Cycle 8 (Cycle 8)
Please mark an 'X' if data have been amended.
(Please circle amended items in red)
Date data amended (s - mm/dd/yyyy)
Reporting Period Start Date (mm/dd/yyyy)
Reporting Period End Date (mm/dd/yyyy)
Vital Status
Patient's Vital Status
1 / 6
Alive (Alive)
Dead (Dead)
Date of last contact or death (mm/dd/yyyy)
Primary Cause of Death
Due To Other Cause (Due to other
cause)
Due To Protocol Treatment (Due to
protocol treatment)
Due To This Disease (Due to this
disease)
Unknown (Unknown)
Describe cause of death
Patient Characteristics
Weight (Day 1 of this reporting period cycle)
Body Surface Area (BSA Day 1 of this reporting
period cycle)
Therapy Administered - Section I
Agent Name (Complete base on completed
Patient Pill Diary)
Was the agent administered during this reporting
period? (Bortezomib)
Yes
No
Date Agent Administered
Total Dose of Agents/Drugs for this Cycle
Were there any dose modifications or
additions/omissions to protocol treatment?
(Bortezomib this report period)
No (No)
Yes, Planned (i.e., The Treatment Was
Changed According To Protocol
Guidelines) (Yes, planned)
Yes, Unplanned (i.e., The Treatment
Change Was Not Part Of Protocol
Guidelines) (Yes, unplanned)
Dose modification
Dose Delayed (Dose delayed)
Dose Escalated (Dose escalated)
Dose Held (Dose held)
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Dose Missed (Dose missed)
Dose Reduced (Dose reduced)
Drug Discontinued (Drug discontinued)
No Dose Modification (No dose
modification)
Dose Modification Reason
Adverse Event (Adverse event)
Alternative Therapy For Other Reason
(Alternative therapy for other reason)
Dosing Error (Dosing error)
Other (Other)
Patient Refusal/noncompliance (Patient
refusal/noncompliance)
Scheduling (Scheduling)
Second Primary Cancer (Second
primary)
Other, specify
Therapy Administered - Section I
Agent Name (Complete base on completed
Patient Pill Diary)
Did the patient complete the Patient Pill Calendar
this cycle (Diary)
Yes
No
Was the agent administered during this reporting
period? (Bortezomib)
Yes
No
Date Agent Administered
Total Dose of Agents/Drugs for this Cycle
Were there any dose modifications or
additions/omissions to protocol treatment?
(Bortezomib this report period)
No (No)
Yes, Planned (i.e., The Treatment Was
Changed According To Protocol
Guidelines) (Yes, planned)
Yes, Unplanned (i.e., The Treatment
Change Was Not Part Of Protocol
Guidelines) (Yes, unplanned)
Dose modification
Dose Delayed (Dose delayed)
Dose Escalated (Dose escalated)
Dose Held (Dose held)
Dose Missed (Dose missed)
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Dose Reduced (Dose reduced)
Drug Discontinued (Drug discontinued)
No Dose Modification (No dose
modification)
Dose Modification Reason
Adverse Event (Adverse event)
Alternative Therapy For Other Reason
(Alternative therapy for other reason)
Dosing Error (Dosing error)
Other (Other)
Patient Refusal/noncompliance (Patient
refusal/noncompliance)
Scheduling (Scheduling)
Second Primary Cancer (Second
primary)
Other, specify
Therapy Administered - Section I
Agent Name (Complete base on completed
Patient Pill Diary)
Did the patient complete the Patient Pill Calendar
this cycle (Diary)
Yes
No
Was the agent administered during this reporting
period? (Bortezomib)
Yes
No
Number of days agent was taken
Total Dose of Agents/Drugs for this Cycle
Were there any dose modifications or
additions/omissions to Lenalidomide protocol
treatment
Yes
No
Was treatment modification to Lenalidomide
planned (per protocol)? (If yes,)
Yes
No
Start Date of Dose Modification
End Date of Dose Modification
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Total Modified Dose
Dose modification
Dose Delayed (Dose delayed)
Dose Escalated (Dose escalated)
Dose Held (Dose held)
Dose Missed (Dose missed)
Dose Reduced (Dose reduced)
Drug Discontinued (Drug discontinued)
No Dose Modification (No dose
modification)
Dose Modification Reason
Adverse Event (Adverse event)
Alternative Therapy For Other Reason
(Alternative therapy for other reason)
Dosing Error (Dosing error)
Other (Other)
Patient Refusal/noncompliance (Patient
refusal/noncompliance)
Scheduling (Scheduling)
Second Primary Cancer (Second
primary)
Other, specify
Other Therapy Administered - Section IV
Has the patient received bisphosphonates (this
report period)
Yes
No
Bisphosphonate type(s) received
Both Pamidronate And Zoledronic Acid
(both pamidronate and zoledronic acid)
Other (Other)
Pamidronate (pamidronate)
Zoledronic Acid (zoledronic acid)
Bisphosphonates, specify
Was patient on anti-coagulation therapy daily
(this report period)
Yes
No
Anti-Coagulant Drugs (Specify)
Aspirin 325mg (Aspirin 325mg)
Aspirin, Other (Aspirin, other)
Coumadin (Coumadin)
Low Molecular Weight Heparin (Low
Molecular Weight Heparin)
Other (Other)
Other, specify
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International Normalization Ratio (INR) (Specify
at the end of report period)
Section E: Non-protocol Therapy
Was any non-protocol therapy given during
protocol treatment (not previously reported)?
Yes
No
Comments
Comments
Investigator Signature
Investigator Signature Date
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Induction Treatment Form Multiple Myeloma
(E1A06)
E1A06 Induction Treatment Form
Melphalan, Prednisone, and Thalidomide or Lenalidomide
in Treating Patients With Newly Diagnosed Multiple
Myeloma
NCT00602641
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=402A1AE1-
FA70-56B0-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/6479
Induction Treatment Form Multiple
Myeloma (E1A06)
Header section
Patient Initials (Last, First)
ECOG Protocol Number
Participating Group Protocol Number
Institution/Affiliate
ECOG Patient ID
Participating Group Patient ID
DCI Name
Registration Step
Please mark an 'X' if data have been amended.
(Please circle amended items in red)
Date data amended (s - mm/dd/yyyy)
On Treatment Report Period (Induction Therapy:
Cycles 1 - 12)
Cycle 1 (Cycle 1)
Cycle 10 (Cycle 10)
Cycle 11 (Cycle 11)
Cycle 12 (Cycle 12)
Cycle 2 (Cycle 2)
Cycle 3 (Cycle 3)
Cycle 4 (cycle 4)
Cycle 5 (Cycle 5)
Cycle 6 (Cycle 6)
Cycle 7 (Cycle 7)
Cycle 8 (cycle 8)
Cycle 9 (Cycle 9)
Reporting Period Start Date (mm/dd/yyyy)
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Reporting Period End Date (mm/dd/yyyy)
Vital Status
Patient's Vital Status
Alive (Alive)
Dead (Dead)
Date of last contact or death (mm/dd/yyyy)
Primary Cause of Death
Due To Other Cause (Due to other
cause)
Due To Protocol Treatment (Due to
protocol treatment)
Due To This Disease (Due to this
disease)
Unknown (Unknown)
Describe cause of death
Patient Characteristics
Weight (Day 1 of this reporting period cycle)
Body Surface Area (BSA Day 1 of this reporting
period cycle)
Therapy Administered - Section I
Agent Name (Complete base on completed
Patient Pill Diary)
Was the agent administered during this reporting
period? (Lenalidomide)
Yes
No
Agent Start Date
Total Dose of Agents/Drugs for this Cycle (mg -
this report period)
Were there any dose modifications or
additions/omissions to Melphalan protocol
treatment
Yes
No
Was treatment modification to Melphalan planned
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(per protocol)? (If yes,)
Yes
No
Dose Modification Start Date
Dose Modification End Date
Total Modified Dose (mg)
Dose modification
Dose Delayed (Dose delayed)
Dose Escalated (Dose escalated)
Dose Held (Dose held)
Dose Missed (Dose missed)
Dose Reduced (Dose reduced)
Drug Discontinued (Drug discontinued)
No Dose Modification (No dose
modification)
Dose Modification Reason
Adverse Event (Adverse event)
Alternative Therapy For Other Reason
(Alternative therapy for other reason)
Dosing Error (Dosing error)
Other (Other)
Patient Refusal/noncompliance (Patient
refusal/noncompliance)
Scheduling (Scheduling)
Second Primary Cancer (Second
primary)
Other, specify
Therapy Administered - Section I
Agent Name (Complete base on completed
Patient Pill Diary)
Was the agent administered during this reporting
period? (Lenalidomide)
Yes
No
Agent Start Date
Total Dose of Agents/Drugs for this Cycle (mg -
this report period)
Were there any dose modifications or
additions/omissions to Prednisone protocol
treatment
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Yes
No
Was treatment modification to Prednisone
planned (per protocol)?
Yes
No
Dose Modification Start Date
Dose Modification End Date
Total Modified Dose (mg)
Dose modification
Dose Delayed (Dose delayed)
Dose Escalated (Dose escalated)
Dose Held (Dose held)
Dose Missed (Dose missed)
Dose Reduced (Dose reduced)
Drug Discontinued (Drug discontinued)
No Dose Modification (No dose
modification)
Dose Modification Reason
Adverse Event (Adverse event)
Alternative Therapy For Other Reason
(Alternative therapy for other reason)
Dosing Error (Dosing error)
Other (Other)
Patient Refusal/noncompliance (Patient
refusal/noncompliance)
Scheduling (Scheduling)
Second Primary Cancer (Second
primary)
Other, specify
Therapy Administered - Section I
Agent Name (Complete base on completed
Patient Pill Diary)
Was the agent administered during this reporting
period? (Lenalidomide)
Yes
No
Agent Start Date
Total Dose of Agents/Drugs for this Cycle (mg -
this report period)
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Were there any dose modifications or
additions/omissions to Thalidomide protocol
treatment
Yes
No
Was treatment modification to Thalidomide
planned (per protocol)?
Yes
No
Dose Modification Start Date
Dose Modification End Date
Total Modified Dose (mg)
Dose modification
Dose Delayed (Dose delayed)
Dose Escalated (Dose escalated)
Dose Held (Dose held)
Dose Missed (Dose missed)
Dose Reduced (Dose reduced)
Drug Discontinued (Drug discontinued)
No Dose Modification (No dose
modification)
Dose Modification Reason
Adverse Event (Adverse event)
Alternative Therapy For Other Reason
(Alternative therapy for other reason)
Dosing Error (Dosing error)
Other (Other)
Patient Refusal/noncompliance (Patient
refusal/noncompliance)
Scheduling (Scheduling)
Second Primary Cancer (Second
primary)
Other, specify
Therapy Administered - Prophylaxis
Treatment
Did patient receive protocol-specified prophylaxis
treatment without
delay/modification/discontinuation this report
period?
Yes
No
Agent
Aspirin 325mg (Aspirin 325mg)
Aspirin 81mg (Aspirin 81 mg)
Aspirin, Other (Aspirin, other)
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Coumadin (prophylactic Dose)
(Coumadin)
Low Molecular Weight Heparin
(prophylactic Dose) (Low Molecular
Weight Heparin)
Not Applicable (Not applicable)
Therapy Modification Type
Agent Changed (Agent changed)
Agent Discontinued (Agent discontinued)
Dose Delayed (Dose delay)
Dose Missed (Dose missed)
Dose Or Inr Modfication (Dose or INR
modfication)
Agent Start Date
Dose Modification Reason
Adverse Event (Adverse event)
Alternative Therapy For Other Reason
(Alternative therapy for other reason)
Dosing Error (Dosing error)
Other (Other)
Patient Refusal/noncompliance (Patient
refusal/noncompliance)
Scheduling (Scheduling)
Second Primary Cancer (Second
primary)
Other, specify
Has the patient received erythropoietin-type
agents (e.g., Epogen, Procrit or Aranesp) (this
report period)
Yes
No
Therapy Administered - Section I
Agent Name (Complete base on completed
Patient Pill Diary)
Was the agent administered during this reporting
period? (Lenalidomide)
Yes
No
Agent Start Date
Total Dose of Agents/Drugs for this Cycle (mg -
this report period)
Were there any dose modifications or
additions/omissions to Lenalidomide protocol
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treatment
Yes
No
Was treatment modification to Lenalidomide
planned (per protocol)? (If yes,)
Yes
No
Start Date of Dose Modification
End Date of Dose Modification
Total Modified Dose (mg)
Dose modification
Dose Delayed (Dose delayed)
Dose Escalated (Dose escalated)
Dose Held (Dose held)
Dose Missed (Dose missed)
Dose Reduced (Dose reduced)
Drug Discontinued (Drug discontinued)
No Dose Modification (No dose
modification)
Dose Modification Reason
Adverse Event (Adverse event)
Alternative Therapy For Other Reason
(Alternative therapy for other reason)
Dosing Error (Dosing error)
Other (Other)
Patient Refusal/noncompliance (Patient
refusal/noncompliance)
Scheduling (Scheduling)
Second Primary Cancer (Second
primary)
Other, specify
Section E: Non-protocol Therapy
Was any non-protocol therapy given during
protocol treatment (not previously reported)?
Yes
No
Comments
Comments
Investigator Signature
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Investigator Signature Date
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Brain and Central Nervous System Tumors NCT00978458 Treatment -
E3F05 Chemotherapy Form - Arm B Only - 2904374v1.0
E3F05 Chemotherapy Form - Arm B Only
Radiation Therapy With or Without Temozolomide in
Treating Patients With Low-Grade Glioma
NCT00978458
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=6D055B43-
63F1-A6F7-E040-BB89AD436A92
All rights reserved. Please visit https://medical-data-
models.org/forms/6480
Chemotherapy Form Glioma  (Arm
B, E3F05)
Header Module
ECOG Protocol Number
ECOG Patient ID
DCI Name
Registration Step (Place ID Label Here)
Patient Initials (Last, First)
Participating Group Protocol Number
Participating Group Patient ID
Institution/Affiliate
Please mark an 'X' if data have been amended.
(Please circle amended items in red)
Date data amended (s M D Y)
On Treatment Report Period (Choose one)
Cycle 1 (Cycle 1)
Cycle 2 (Cycle 2)
Cycle 3 (Cycle 3)
Cycles 10 - 12 (Cycles 10 - 12)
Cycles 4 - 6 (Cycles 4 - 6)
Cycles 7 - 9 (Cycles 7 - 9)
End Of Chemoradiation (End of
Chemoradiation)
Reporting Period Start Date (M D Y)
Reporting Period End Date (M D Y)
Investigator Signature
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Investigator Signature Date (MM DD YYYY)
Vital Status
Patient's Vital Status
Alive (Alive)
Dead (Dead)
Date of Last Contact or Death (m d y)
Primary Cause of Death (if applicable)
Due To Other Cause (Due to other
cause)
Due To Protocol Treatment (Due to
protocol treatment)
Due To This Disease (Due to this
disease)
Unknown (Unknown)
Describe cause of death
Patient Characteristics
Weight (Day 1 of this report period kg [Note: code
weight loss/gain per CTCAE on E3F05 Adverse
Event Form])
Body Surface Area (Patient Measurement BSA
Day 1 of this report period m^2)
Therapy Administered
Agent Name
Was the agent administered during this reporting
period? (Temozolomide)
Yes
No
Prescribed dose (Temozolomide Day 1 this report
period mg)
Dose level administered this report period
100mg/m^2 (100mg/m^2)
150mg/m^2 (150mg/m^2)
200mg/m^2 (200mg/m^2)
Number of days agent was taken (Temozolomide
this reporting perod)
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Agent Total Dose (Temozolomide this report
period mg)
Did the patient complete Patient Pill Diary (if yes,
please submit this form to ECOG with E3F05
Source Document Tracking Coversheet)
Yes
No
Why were doses missed (Check all that apply)
Logistical Difficulty (logistical difficulty)
Other (Other)
Patient Error (patient error)
Patient Withdrawal From Study (patient
withdrawal from study)
Toxicity (Toxicity)
Other, specify
Non-protocol Therapy
Was any non-protocol therapy given during
protocol treatment? (not previously reported )
Yes
No
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Treatment Form Liver Cancer CALGB
80802
CALGB: 80802 Treatment Form
Sorafenib Tosylate With or Without Doxorubicin
Hydrochloride in Treating Patients With Locally Advanced
or Metastatic Liver Cancer
NCT01015833
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=741A6270-
CE1B-C531-E040-BB89AD431F2C
All rights reserved. Please visit https://medical-data-
models.org/forms/6485
Treatment Form Liver Cancer
CALGB 80802
Header Module
CALGB Form
CALGB Study No.
CALGB Patient ID
Date of First dose for this reporting period
Cycle end date
Are data amended
Yes
No
Patient Initials (Last, First Middle)
Patient Hospital No.
Institution/Affiliate
Participating Group
Participating Group Study No.
Participating Group Patient ID
Completed by
Date Form Originally Completed
Treatment Data
Cycle Number
1 / 3
BSA
Total doxorubicin dose received this cycle (mg)
Dose level received on reporting period start date
400 Mg Every 12 Hrs (400 mg every 12
hrs)
400 Mg Every Day (400 mg every day)
400 Mg Every Other Day (400 mg every
other day)
Not Received (Not received)
Method of administration
Bolus Injection (Bolus injection)
Infusion (Infusion)
Was the doxorubicin dose reduced this cycle
No (No)
Yes, Planned Per Protocol (Yes, planned
per protocol)
Yes, Unplanned Per Protocol (Yes,
unplanned per protocol)
Total sorafenib dose received this cycle
Was the sorafenib dose reduced during this cycle
No (No)
Yes, Planned Per Protocol (Yes, planned
per protocol)
Yes, Unplanned Per Protocol (Yes,
unplanned per protocol)
Were any doses of sorafenib missed this cycle
No (No)
Yes, Planned Per Protocol (Yes, planned
per protocol)
Yes, Unplanned Per Protocol (Yes,
unplanned per protocol)
Number of missed Sorafenib doses
Did patient receive G-CSF or GM-CSF per
protocol
Yes
No
Date of first dose of G-CSF/GM-CSF during this
reporting period
Specify deviation (If no,)
Did the patient receive any additional supportive
care during this reporting period
No (No)
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Unknown (Unknown)
Yes (Yes)
Yes specify
Off Treatment Reason (only applicable if protocol
therapy has been discontinued permanently Mark
one with an X.)
Adverse Event/side Effects/complications
(Adverse Event/Side
Effects/Complications)
Alternative Therapy (Alternative therapy)
Death On Study (Death on study)
Disease Progression, Relapse During
Active Treatment (Disease progression,
relapse during active treatment)
Other (Other)
Patient Off-treatment For Other
Complicating Disease (Patient off-
treatment for other complicating disease)
Patient Withdrawal Or Refusal After
Beginning Protocol Therapy (Patient
withdrawal/refusal after beginning
protocol therapy)
Patient Withdrawal Or Refusal Before
Beginning Protocol Therapy (Patient
withdrawal/refusal prior to beginning
protocol therapy)
Other specify
Alternative therapy, specify
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Treatment and Response Form Lung
Cancer (CALGB 30607)
CALGB: 30607 Treatment and Response Form
Sunitinib as Maintenance Therapy in Treating Patients With
Stage III or Stage IV Non-Small Cell Lung Cancer
Previously Treated With Combination Chemotherapy
NCT00693992
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=35681A7B-
54DB-54F0-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/6486
Treatment and Response Form Lung
Cancer (CALGB 30607)
Header Section
Patient Initials (Last, First Middle)
Patient Hospital No
Institution/Affiliate
Participating Group
Participating Group Study No.
Participating Group Patient ID
CALGB Form
CALGB Study No
CALGB Patient ID
Date of Last dose for this reporting period
Reporting Period Start Date
Reporting Period End Date
Are data amended
Yes
No
Survival Status
Vital Status
Alive (Alive)
Dead (Dead)
Primary Cause of Death
Due To Other Cause (Due to other
1 / 3
cause)
Due To Protocol Treatment (Due to
protocol treatment)
Due To This Disease (Due to this
disease)
Due to other cause, specify
Treatment data
Dose level received on reporting period start date
25 Mg (25 mg)
25 Mg For 4 Of 6 Weeks (25 mg for 4 of
6 weeks)
37.5 Mg (37.5 mg)
Total dose of sunitinib/ placebo received during
this reporting period
Were there any dose modifications or
additions/omissions to protocol treatment?
(during this reporting period)
No (No)
Yes, Planned (i.e., The Treatment Was
Changed According To Protocol
Guidelines) (Yes, planned)
Yes, Unplanned (i.e., The Treatment
Change Was Not Part Of Protocol
Guidelines) (Yes, unplanned)
Date of Last dose for this reporting period
Off treatment reason (if applicable Mark one with
an X.)
Adverse Event/side Effects/complications
(Adverse event/side
effects/complications)
Alternative Therapy (Alternative therapy)
Death On Study (Death on study)
Disease Progression, Relapse During
Active Treatment (Disease progression,
relapse during active treatment)
Other (Other)
Patient Off-treatment For Other
Complicating Disease (Patient off-
treatment for other complicating disease)
Patient Withdrawal Or Refusal After
Beginning Protocol Therapy (Patient
withdrawal or refusal after beginning
protocol therapy)
Patient Withdrawal Or Refusal Before
Beginning Protocol Therapy (Patient
withdrawal or refusal prior to beginning
protocol therapy)
Other specify
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Alternative therapy, specify
Removed To Undergo Surgical
Resection (1)
Removed To Receive Non-protocol
Chemotherapy And/or Biologic Therapy
(2)
Disease Response
Date of Last Clinical Assessment
Best Overall Response to date
Complete Response (CR)
Not An Approved Recist Value (NED)
Progressive Disease (PD)
Partial Response (PR)
Stable Disease (SD)
Complete Response (CR) First Observed Date
Partial Response (PR) First Observed Date
Progressive Disease (PD) Observed Date
Sites of progression
Bone (Bone)
Central Nervous System (Central
Nervous System)
Distant Lymph Nodes (Distant lymph
nodes)
Liver (Liver)
Lung, Nos (Lung)
Contralateral Lung (Opposite lung)
Other (Other)
Pleura (Pleura)
Regional Lymph Nodes (Regional lymph
nodes)
Other specify
Completed by
Date form originally completed
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Sarcoma NCT01016730 Treatment - AMC-063
Velcade Administration Form (DA2) - 3021247v1.0
AMC-063 Velcade Administration Form (DA2)
Bortezomib in Treating Patients With Relapsed or
Refractory AIDS-Related Kaposi Sarcoma
NCT01016730
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=817724CA-
1778-200C-E040-BB89AD434BB8
All rights reserved. Please visit https://medical-data-
models.org/forms/6487
Velcade Administration Form
Sarcoma (AMC-063, DA2)
Header Module
Visit number
Comments
Dose Escalation
Was the participant's dose increased at this cycle
from the dose level which was assigned at
Baseline
Yes
No
Dose administered
0.75 Mg/m^2 (0.75 mg/m^2)
1.00 Mg/m^2 (1.00 mg/m^2)
1.30 Mg/m^2 (1.30 mg/m^2)
1.60 Mg/m^2 (1.60 mg/m^2)
BSA (m^2)
Day 1
Dose modification
Dose Delayed (Dose delayed)
Dose Delayed And Reduced (Dose
delayed and reduced)
Dose Escalated (Dose escalated)
Dose Reduced (Dose reduced)
Drug Discontinued (Drug discontinued)
No Dose Modification (No dose
modification)
Dose administered
0.75 Mg/m^2 (0.75 mg/m^2)
1.00 Mg/m^2 (1.00 mg/m^2)
1.30 Mg/m^2 (1.30 mg/m^2)
1.60 Mg/m^2 (1.60 mg/m^2)
Dose administered date (mm/dd/yyyy)
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Agent Total Dose (mg)
Duration Delay (days)
Dose Modification Reason (delay)
Adverse Event (Adverse event)
Other (Other)
Patient Forgot (Patient forgot)
Patient Request (Patient request)
Scheduling (Scheduling)
Other, specify
Day 8
Dose modification
Dose Delayed (Dose delayed)
Dose Delayed And Reduced (Dose
delayed and reduced)
Dose Escalated (Dose escalated)
Dose Reduced (Dose reduced)
Drug Discontinued (Drug discontinued)
No Dose Modification (No dose
modification)
Dose administered
0.75 Mg/m^2 (0.75 mg/m^2)
1.00 Mg/m^2 (1.00 mg/m^2)
1.30 Mg/m^2 (1.30 mg/m^2)
1.60 Mg/m^2 (1.60 mg/m^2)
Dose administered date (mm/dd/yyyy)
Agent Total Dose (mg)
Duration Delay (days)
Dose Modification Reason (delay)
Adverse Event (Adverse event)
Other (Other)
Patient Forgot (Patient forgot)
Patient Request (Patient request)
Scheduling (Scheduling)
Other, specify
Day 15
Dose modification
Dose Delayed (Dose delayed)
Dose Delayed And Reduced (Dose
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delayed and reduced)
Dose Escalated (Dose escalated)
Dose Reduced (Dose reduced)
Drug Discontinued (Drug discontinued)
No Dose Modification (No dose
modification)
Dose administered
0.75 Mg/m^2 (0.75 mg/m^2)
1.00 Mg/m^2 (1.00 mg/m^2)
1.30 Mg/m^2 (1.30 mg/m^2)
1.60 Mg/m^2 (1.60 mg/m^2)
Dose administered date (mm/dd/yyyy)
Agent Total Dose (mg)
Duration Delay (days)
Dose Modification Reason (delay)
Adverse Event (Adverse event)
Other (Other)
Patient Forgot (Patient forgot)
Patient Request (Patient request)
Scheduling (Scheduling)
Other, specify
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Treatment Form Breast Cancer Adriamycin,
Cyclophosphamide (NCT00087178)
NSABP PROTOCOL B-36 Treatment Form for Adriamycin,
Cyclophosphamide (AC)
Comparison of Two Combination Chemotherapy Regimens
in Treating Women With Breast Cancer
NCT00087178
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=C87B5EFD-
2DE6-59DF-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/6490
Treatment Form Breast Cancer
Adriamycin, Cyclophosphamide
(NCT00087178)
Header Section
Patient Initials (Last, First Middle)
NSABP Patient ID
Institution Name
Affiliate Name
Person Completing Form (Last Name)
Person Completing Form (First Name)
Person Completing Form (Phone)
Are data amended?
Yes
No
Comments
Summary Of Adriamycin,
Cyclophosphamide
Treatment Begin Date
Treatment End Date
Cycle #
1 (1)
2 (2)
3 (3)
4 (4)
Date Administered
Agent name
1 / 2
ADRIA (ADRIA)
CYCLO (CYCLO)
Protocol Dose
Was this cycle delayed for toxicity?
Yes
No
Was growth factor support employed?
Yes
No
Reason Treatment Ended
Treatment Completed Per Protocol
Criteria (1)
Adverse Event/side Effects/complications
(2)
Patient Off-treatment For Other
Complicating Disease (3)
Patient Withdrawal Or Refusal After
Beginning Protocol Therapy (4)
Disease Progression, Relapse During
Active Treatment (5)
Death On Study (6)
Alternative Therapy (7)
Other (8)
Patient Withdrawal Or Refusal Before
Beginning Protocol Therapy (9)
Other (specify)
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(NCT00087178)
Quality assurance Cardiac Pacemaker
Replacement (AQUA)
Documentation form for quality assurance in German
Health Care by the Institute for Applied Quality
Improvement and Research in Health Care (Aqua),
https://www.aqua-institut.de/en/home. Internal Aqua form
version: 09-2 Specification 2015 V02
All rights reserved. Please visit https://medical-data-
models.org/forms/6495
Quality assurance Cardiac
Pacemaker Replacement (AQUA)
Type of insurance
Health Insurance Identifier
Patient identifying data
Patient insurance ID
Basic documentation
Healthcare Facility Identifier *
Zip Code of Discharge*
Facility's Section Identifier
Medical specialty*
internal medicine (0100)
internal medicine: geriatrics (0102)
internal medicine: cardiology (0103)
internal medicine: nephrology (0104)
internal medicine: hematology and
internal oncology  (0105)
internal medicine: endocrinology (0106)
internal medicine: gastroenterology
(0107)
internal medicine: pneumonology (0108)
internal medicine: rheumatology (0109)
internal medicine: pulmonology (0114)
internal medicine: tumor research (0150)
internal medicine: coloproctology (0151)
internal medicine: infectiology (0152)
internal medicine: diabetes (0153)
internal medicine: naturopathy (0154)
internal medicine: stroke unit (0156)
internal medicine (0190)
geriatry (0200)
geriatry: gynecology  (0224)
geriatry: day unit (for semi-residential
care)   (0260)
geriaty: night unit (for semi-residential
care) (0261)
geriatry (0290)
cardiology (0300)
nephrology (0400)
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nephrology: pediatrics (0410)
nephrology: intensive care (0436)
nephrology (0490)
hematology and internal oncology
(0500)
hematology and internal oncology:
pediatrics (0510)
hematology and internal oncology:
gynacology (0524)
hematology and internal oncology:
radiation therapy (0533)
hematology and internal oncology
(0590)
endocrinology (0600)
endicrinology: gastroenterology (0607)
endocrinology: pediatrics (0610)
endocrinology (0690)
gastroenterology (0700)
gastroenterology: endocrinology (0706)
gastroenterology: pediatrics (0710)
gastroenterology (0790)
pneumology (0800)
rheumatology (0900)
rheumatology: pediatrics (0910)
rheumatology (0990)
pediatrics (1000)
pediatrics: nephrology (1004)
pediatrics: hematology and internal
oncology  (1005)
pediatrics: endocrinology (1006)
pediatrics: gastroenterology (1007)
pediatrics: rheumatology (1009)
pediatrics: pediatric cardiology (1011)
pediatrics: nephrology (1012)
pediatrics: pulmonology (1014)
pediatrics: pediatric neurology (1028)
pediatrics: perinatal medicine (1050)
continuing care for children (1051)
pediatrics (1090)
pediatric cardiology (1100)
pediatric cardiology: intensive care
(1136)
pediatric cardiology (1190)
neonatology (1200)
pediatric surgery (1300)
pulmonology (1400)
pulmonology: pediatrics (1410)
pulmonology (1490)
general surgery (1500)
general surgery: pediatric surgery (1513)
general surgery: trauma surgery (1516)
general surgery: vascular surgery (1518)
general surgery: plastic surgery (1519)
general surgery: thoracic surgery (1520)
general surgery: orthopedics (1523)
general surgery: intensive care (1536)
general surgery: abdominal- and
vascular surgery (1550)
Allgemeine Chirurgie: hand surgery
(1551)
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general surgery (1590)
trauma surgery (1600)
neurosurgery (1700)
vascular surgery (1800)
plastic surgery (1900)
thoracic surgery (2000)
thoracic surgery: cardiac surgery (2021)
thoracic surgery: intensive care (2036)
thoracic surgery: cardiac surgery
intensive care (2050)
thoracic surgery (2090)
cardiac surgery (2100)
cardiac surgery: vascular surgery (2118)
cardiac surgery: thoracic surgery (2120)
cardiac surgery: intensive care (2136)
cardiac surgery: thoracic surgery and
intensive care (2150)
cardiac surgery (2190)
urology (2200)
orthopedics (2300)
orthopedics: rheumatology (2309)
orthopedics: surgery (2315)
orthopedics and trauma surgery (2316)
orthopedics (2390)
gynecology and obstetrics (2400)
gynecology: geriatry (2402)
gynecology: hematology and internal
oncology  (2405)
gynecology: endocrinology (2406)
gynecology (2425)
gynecology and obstetrics (2490)
obstetrics (2500)
otolaryngology (2600)
ophthalmology (2700)
neurology: (2800)
neurology: pediatrics (2810)
neurology: stroke units (2856)
neurology (2890)
general psychiatry: (2900)
general psychiatry: neurology (2928)
general psychiatry: child and adolescent
psychiatry (2930)
general psychiatry: psychosomatics and
psychotherapy (2931)
general psychiatry: addiction treatment
(2950)
general psychiatry: geropsychiatry
(2951)
general psychiatry: forensic treatment
(2952)
general psychiatry: addiction treatment
(day unit) (2953)
general psychiatry: addiction treatment
(night unit) (2954)
general psychiatry: geropsychiatry (day
unit) (2955)
general psychiatry: geropsychiatry (night
unit) (2956)
general psychiatry: day unit (for semi-
residential care) (2960)
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general psychiatry: night unit (for semi-
residential care) (2961)
general psychiatry (2990)
child and adolescent psychiatry (3000)
child and adolescent psychiatry: day unit
(for semi-residential care) (3060)
child and adolescent psychiatry: night
unit (for semi-residential care) (3061)
child and adolescent psychiatry (3090)
psychosomatic/psychotherapy (3100)
psychosomatic/psychotherapy: child and
adolescent psychiatry (3110)
psychosomatic/psychotherapy: day unit
(for semi-residential care) (3160)
psychosomatic/psychotherapy: night unit
(for semi-residential care) (3161)
psychosomatic/psychotherapy (3190)
nuclear medicine (3200)
nuclear medicine: radiation therapy
(3233)
nuclear medicine (3290)
radiation therapy (3300)
radiation therapy: hematology and
internal oncology  (3305)
radiation therapy: radiology (3350)
radiation therapy (3390)
dermatology (3400)
dermatology: day unit (for semi-
residential care) (3460)
dermatology (3490)
dentistry, orthodontics, maxillofacial
surgery (3500)
intensive-care medicine (3600)
intensive-care medicine: internal
medicine (3601)
intensive-care medicine: cardiology
(3603)
intensive-care medicine: pediatrics
(3610)
intensive-care medicine: neurosurgery
(3617)
intensive-care medicine: surgery (3618)
intensive-care medicine: cardiac surgery
(3621)
intensive-care medicine: urology (3622)
intensive-care medicine: gynecology and
obstetrics (3624)
intensive-care medicine: otolaryngology
(3626)
intensive-care medicine: neurology
(3628)
operative intensive-care medicine:
surgery (3650)
intensive-care medicine: thorax-heart
surgery (3651)
intensive-care medicine: heart-thorax
surgery (3652)
intensive-care medicine (3690)
other medical specialty (3700)
angiology (3750)
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radiology (3751)
palliative care (3752)
pain therapy (3753)
section for alternative health practice
(3754)
spinal surgery (3755)
addiction medicine (3756)
visceral surgery (3757)
other medical specialty (3790)
Patient identification number*
Date of Birth (DD.MM.YYYY)*
Gender*
male (1)
female (2)
Hospital admission date (DD.MM.YYYY)*
Preoperative Clinical Examination
ASA classification*
A normal healthy patient (1)
A patient with mild systemic disease (2)
A patient with severe systemic disease
(3)
A patient with severe systemic disease
that is a constant threat to life (4)
A moribund patient who is not expected
to survive without the operation (5)
Need of pacemaker stimulation (in %)*
more than 95% (1)
40% to  95% (2)
less than 40% (3)
Medical Indication of Pulse generator
replacement
Indication for aggregate (pulse generator)
change*
regular battery depletion (1)
early battery depletion (2)
assumed pacemaker dysfunction  (3)
proven pacemaker dysfunction (4)
pacemaker dysfunction with return call
(5)
other indication (9)
Place of last pacemaker operation*
in-patient, own institution (1)
in-patient, other institution (2)
outpatient, own institution (3)
outpatient, other institution (4)
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Operation
Operation date (DD.MM.YY)*
Procedure codes *
Procedure Duration (in minutes)*
Functionally active parts of Pacemaker-
Implanted Pacemaker System
Pacemaker system*
VVI (1)
AAI (2)
DDD (3)
VDD (4)
CRT-System with atrial electrode (5)
CRT-System without atrial electrode (6)
other (9)
Implanted pulse generator
Manufacturer Name*
Biotronik (1)
Vitatron (11)
St. Jude Medical (18)
Boston
Scientific/CPI/Guidant/Intermedics (3)
Medtronic (7)
Osypka (8)
unknown (89)
Sorin Biomedica/ELA Medical (9)
other (99)
Left Pacemaker Electrode - Atrium
Sensing threshold (in V)
Reasons for not having measured
because of atrial fibrillation (1)
pther reasons (9)
P wave height
Reasons for not having measured
because of atrial fibrillation (1)
missing own atrial rhythm (2)
other reasons (9)
Ventricle
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Sensing Threshold (in V)
not measured
yes (1)
R wave height
Reasons for not having measured
no own rhythm (1)
other reasons (9)
Ventricle (2. Electrode)
Sensing threshold (in V)
not measured
yes (1)
R wave height
Reasons for not having measured
no own rhythm (1)
other reasons (9)
Functionally non-active parts of
Pacemaker-Explanted Pacemaker System
System*
VVI (1)
AAI (2)
DDD (3)
VDD (4)
CRT-System with atrial electrode (5)
CRT-System without atrial electrode (6)
other (9)
Year of implantation (YYYY)
unknown
yes (1)
Manufacturer Name*
Biotronik (1)
Vitatron (11)
St. Jude Medical (18)
Boston
Scientific/CPI/Guidant/Intermedics (3)
Medtronic (7)
Osypka (8)
unknown (89)
Sorin Biomedica/ELA Medical (9)
other (99)
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Peri/Postoperative Complications
peri- or postoperative complikation(s)*
no (0)
yes (1)
Asystolia
yes (1)
Ventricular fibrillation
yes (1)
Hematoma due to pacemaker, requiring action
yes (1)
postoperative wound infection
yes (1)
CDC classification (if postoperative wound
infection existing)
A1 (Superficial incisional surgical site
infections) (1)
A2 (Deep incisional surgical site
infections) (2)
A3 (Organ/Space surgical site infections)
(3)
other complications complication, requiring
action(if peri/operative complications existing)
yes (1)
Patient Discharge
Hostpital discharge date  (DD.MM.YYYY)*
Reason of Discharge*
treatment finished as planned (1)
transferral to nursing facility (10)
discharge to hospice (11)
external transferral to psychiatric
treatment (13)
treatment finished because of other
reasons, postdischarge treatment is
planned (14)
treatment aborted against medical
advice, postdischarge treatment is
planned (15)
internal transferral with change of DRG
payment areas (17)
treatment finished as planned,
postdischarge treatment is planned (2)
case termination (internal transferral)
with change between full- and partial
stationary  care (22)
discharge at the end of the year with
admission in previous year (25)
treatment finished because of other
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reasons (3)
treatment aborted against medical
advice (4)
change of jurisdiction of insurer or other
payer (5)
transferral to another hospital (6)
death (7)
transferral to another hospital within
cooperative and governmental policies
(8)
transferral to rehabilitation facility (9)
Discharge diagnosis according to ICD-10-GM*
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Quality assurance Implantable
Defibrillator: Implantation (AQUA)
Type of insurance
Health Insurance Identifier
Patient identifying data
Patient insurance ID
Basic documentation
Healthcare Facility Identifier *
Zip Code of Discharge*
Facility's Section Identifier
Medical specialty*
internal medicine (0100)
internal medicine: geriatrics (0102)
internal medicine: cardiology (0103)
internal medicine: nephrology (0104)
internal medicine: hematology and
internal oncology  (0105)
internal medicine: endocrinology (0106)
internal medicine: gastroenterology
(0107)
internal medicine: pneumonology (0108)
internal medicine: rheumatology (0109)
internal medicine: pulmonology (0114)
internal medicine: tumor research (0150)
internal medicine: coloproctology (0151)
internal medicine: infectiology (0152)
internal medicine: diabetes (0153)
internal medicine: naturopathy (0154)
internal medicine: stroke unit (0156)
internal medicine (0190)
geriatry (0200)
geriatry: gynecology  (0224)
geriatry: day unit (for semi-residential
care)   (0260)
geriaty: night unit (for semi-residential
care) (0261)
geriatry (0290)
cardiology (0300)
nephrology (0400)
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nephrology: pediatrics (0410)
nephrology: intensive care (0436)
nephrology (0490)
hematology and internal oncology
(0500)
hematology and internal oncology:
pediatrics (0510)
hematology and internal oncology:
gynacology (0524)
hematology and internal oncology:
radiation therapy (0533)
hematology and internal oncology
(0590)
endocrinology (0600)
endicrinology: gastroenterology (0607)
endocrinology: pediatrics (0610)
endocrinology (0690)
gastroenterology (0700)
gastroenterology: endocrinology (0706)
gastroenterology: pediatrics (0710)
gastroenterology (0790)
pneumology (0800)
rheumatology (0900)
rheumatology: pediatrics (0910)
rheumatology (0990)
pediatrics (1000)
pediatrics: nephrology (1004)
pediatrics: hematology and internal
oncology  (1005)
pediatrics: endocrinology (1006)
pediatrics: gastroenterology (1007)
pediatrics: rheumatology (1009)
pediatrics: pediatric cardiology (1011)
pediatrics: nephrology (1012)
pediatrics: pulmonology (1014)
pediatrics: pediatric neurology (1028)
pediatrics: perinatal medicine (1050)
continuing care for children (1051)
pediatrics (1090)
pediatric cardiology (1100)
pediatric cardiology: intensive care
(1136)
pediatric cardiology (1190)
neonatology (1200)
pediatric surgery (1300)
pulmonology (1400)
pulmonology: pediatrics (1410)
pulmonology (1490)
general surgery (1500)
general surgery: pediatric surgery (1513)
general surgery: trauma surgery (1516)
general surgery: vascular surgery (1518)
general surgery: plastic surgery (1519)
general surgery: thoracic surgery (1520)
general surgery: orthopedics (1523)
general surgery: intensive care (1536)
general surgery: abdominal- and
vascular surgery (1550)
Allgemeine Chirurgie: hand surgery
(1551)
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general surgery (1590)
trauma surgery (1600)
neurosurgery (1700)
vascular surgery (1800)
plastic surgery (1900)
thoracic surgery (2000)
thoracic surgery: cardiac surgery (2021)
thoracic surgery: intensive care (2036)
thoracic surgery: cardiac surgery
intensive care (2050)
thoracic surgery (2090)
cardiac surgery (2100)
cardiac surgery: vascular surgery (2118)
cardiac surgery: thoracic surgery (2120)
cardiac surgery: intensive care (2136)
cardiac surgery: thoracic surgery and
intensive care (2150)
cardiac surgery (2190)
urology (2200)
orthopedics (2300)
orthopedics: rheumatology (2309)
orthopedics: surgery (2315)
orthopedics and trauma surgery (2316)
orthopedics (2390)
gynecology and obstetrics (2400)
gynecology: geriatry (2402)
gynecology: hematology and internal
oncology  (2405)
gynecology: endocrinology (2406)
gynecology (2425)
gynecology and obstetrics (2490)
obstetrics (2500)
otolaryngology (2600)
ophthalmology (2700)
neurology: (2800)
neurology: pediatrics (2810)
neurology: stroke units (2856)
neurology (2890)
general psychiatry: (2900)
general psychiatry: neurology (2928)
general psychiatry: child and adolescent
psychiatry (2930)
general psychiatry: psychosomatics and
psychotherapy (2931)
general psychiatry: addiction treatment
(2950)
general psychiatry: geropsychiatry
(2951)
general psychiatry: forensic treatment
(2952)
general psychiatry: addiction treatment
(day unit) (2953)
general psychiatry: addiction treatment
(night unit) (2954)
general psychiatry: geropsychiatry (day
unit) (2955)
general psychiatry: geropsychiatry (night
unit) (2956)
general psychiatry: day unit (for semi-
residential care) (2960)
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general psychiatry: night unit (for semi-
residential care) (2961)
general psychiatry (2990)
child and adolescent psychiatry (3000)
child and adolescent psychiatry: day unit
(for semi-residential care) (3060)
child and adolescent psychiatry: night
unit (for semi-residential care) (3061)
child and adolescent psychiatry (3090)
psychosomatic/psychotherapy (3100)
psychosomatic/psychotherapy: child and
adolescent psychiatry (3110)
psychosomatic/psychotherapy: day unit
(for semi-residential care) (3160)
psychosomatic/psychotherapy: night unit
(for semi-residential care) (3161)
psychosomatic/psychotherapy (3190)
nuclear medicine (3200)
nuclear medicine: radiation therapy
(3233)
nuclear medicine (3290)
radiation therapy (3300)
radiation therapy: hematology and
internal oncology  (3305)
radiation therapy: radiology (3350)
radiation therapy (3390)
dermatology (3400)
dermatology: day unit (for semi-
residential care) (3460)
dermatology (3490)
dentistry, orthodontics, maxillofacial
surgery (3500)
intensive-care medicine (3600)
intensive-care medicine: internal
medicine (3601)
intensive-care medicine: cardiology
(3603)
intensive-care medicine: pediatrics
(3610)
intensive-care medicine: neurosurgery
(3617)
intensive-care medicine: surgery (3618)
intensive-care medicine: cardiac surgery
(3621)
intensive-care medicine: urology (3622)
intensive-care medicine: gynecology and
obstetrics (3624)
intensive-care medicine: otolaryngology
(3626)
intensive-care medicine: neurology
(3628)
operative intensive-care medicine:
surgery (3650)
intensive-care medicine: thorax-heart
surgery (3651)
intensive-care medicine: heart-thorax
surgery (3652)
intensive-care medicine (3690)
other medical specialty (3700)
angiology (3750)
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radiology (3751)
palliative care (3752)
pain therapy (3753)
section for alternative health practice
(3754)
spinal surgery (3755)
addiction medicine (3756)
visceral surgery (3757)
other medical specialty (3790)
Patient identification number*
Date of Birth (DD.MM.YYYY)*
Gender*
male (1)
female (2)
Hospital admission date (DD.MM.YYYY)*
Clinical Examination
ASA classification*
A normal healthy patient (1)
A patient with mild systemic disease (2)
A patient with severe systemic disease
(3)
A patient with severe systemic disease
that is a constant threat to life (4)
A moribund patient who is not expected
to survive without the operation (5)
Wound contamination classifcation of procedure
(according to CDC definition)*
aseptic procedure (1)
partially aseptic procedure (2)
procedure with contamination (3)
septic procedure (4)
Medical indication for
revision/explantation
Aggregate problem (pulse generator)
regular battery depletion (1)
early battery depletion (2)
assumed pacemaker dysfunction  (3)
proven pacemaker dysfunction (4)
pacemaker dysfunction with return call
(5)
other indication (9)
Problems of pacemaker pocket
Pocket hematoma (1)
perforation by pulse generator (2)
infection (3)
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other problem (9)
Problems of electrodes
yes (1)
[If item 15 =1 ] Special indication for
Revision/Explantation of electrodes
Atrium
dislocation (1)
electrode defect/insulation problem (2)
dysfunctional connection (3)
diaphracmatic or pectoral flutter (4)
inhibition through other muscular action
potentials/ oversensing (5)
sensing defect/Undersensing (6)
stimulation deficit/increase of sensing
threshold (7)
infection (8)
myocardial perforation (9)
other (99)
First ventricular electrode
dislocation (1)
electrode defect/insulation problem (2)
dysfunctional connection (3)
diaphracmatic or pectoral flutter (4)
inhibition through other muscular action
potentials/ oversensing (5)
sensing defect/Undersensing (6)
stimulation deficit/increase of sensing
threshold (7)
infection (8)
myocardial perforation (9)
other (99)
Second ventricular electrode
dislocation (1)
electrode defect/insulation problem (2)
dysfunctional connection (3)
diaphracmatic or pectoral flutter (4)
inhibition through other muscular action
potentials/ oversensing (5)
sensing defect/Undersensing (6)
stimulation deficit/increase of sensing
threshold (7)
infection (8)
myocardial perforation (9)
other (99)
Operation
Operation Date (DD.MM.YY)*
Place of last pacemaker operation before this
procedure*
in-patient, own institution (1)
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in-patient, other institution (2)
outpatient, own institution (3)
outpatient, other institution (4)
Procedure codes *
Procedure Duration (in minutes)*
Dose Area product (cGy)* cm²)
unknown dose area product
yes (1)
Functionally active parts of Pacemaker-
Pacemaker System
existing postoperative functionally active
Pacemaker system*
no, because this is an explantation (0)
yes (1)
Pacemaker system
VVI (1)
AAI (2)
DDD (3)
VDD (4)
CRT-System with atrial electrode (5)
CRT-System without atrial electrode (6)
other (9)
Pacemaker aggregate (pulse generator)
Kind of procedure
no intervention on pulse generator (0)
new implantation (1)
new placement/positioning (2)
other (9)
Year of implantation (YYYY)
Year of implantation (YYYY) unknown
yes (1)
Manufacturer Name
Biotronik (1)
Vitatron (11)
St. Jude Medical (18)
Boston
Scientific/CPI/Guidant/Intermedics (3)
Medtronic (7)
Osypka (8)
unknown (89)
Sorin Biomedica/ELA Medical (9)
other (99)
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Atrial pacemaker electrodes
Kind of procedure
no intervention on electrode (0)
new implantation (1)
new placement/positioning (2)
repair (4)
other (9)
P wave height
Reason for not having measured sensing
threshold,  intraoperative for 0,5 ms
because of atrial fibrillation (1)
other reasons (9)
Sensing threshold (in V)
Manufacturer Name
Biotronik (1)
Vitatron (11)
St. Jude Medical (18)
Boston
Scientific/CPI/Guidant/Intermedics (3)
Medtronic (7)
Osypka (8)
unknown (89)
Sorin Biomedica/ELA Medical (9)
other (99)
unknown - NBL-Code
yes (1)
NBL-Code second digit
no fixation (0)
active fixation, e.g. bolted electrode (A)
passive fixation, e.g. hooked electrode
(P)
NBL-Code first digit
bipolar (B)
multipolar (M)
unipolar (U)
Time intervall to implantation of this electrode
less than or equal to 1 year (1)
more than 1 year (2)
unknown (9)
Reasons for not having measured (P wave
height)
because of atrial fibrillation (1)
missing own atrial rhythm (2)
other reasons (9)
Ventricular pacemaker electrodes
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Kind of procedure
no intervention on electrode (0)
new implantation (1)
new placement/positioning (2)
repair (4)
other (9)
R wave height
sensing threshold not measured  (intraoperative
for 0,5 ms)
yes (1)
Sensing threshold (in V)
Manufacturer Name
Biotronik (1)
Vitatron (11)
St. Jude Medical (18)
Boston
Scientific/CPI/Guidant/Intermedics (3)
Medtronic (7)
Osypka (8)
unknown (89)
Sorin Biomedica/ELA Medical (9)
other (99)
unknown - NBL-Code
CodelistItem 345620 (1)
NBL-Code second digit
no fixation (0)
active fixation, e.g. bolted electrode (A)
passive fixation, e.g. hooked electrode
(P)
NBL-Code first digit
bipolar (B)
multipolar (M)
unipolar (U)
Time interval to implantation of this electrode
less than or equal to 1 year (1)
more than 1 year (2)
unknown (9)
Reasons for not having measured R-Wave
Height, intraoperative
no own rhythm (1)
other reasons (9)
Second ventricular eletrode
Kind of procedure
no intervention on electrode (0)
new implantation (1)
new placement/positioning (2)
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repair (4)
other (9)
R wave height
sensing threshold not measured  (intraoperative
for 0,5 ms)
yes (1)
Sensing threshold (in V)
Manufacturer Name
Biotronik (1)
Vitatron (11)
St. Jude Medical (18)
Boston
Scientific/CPI/Guidant/Intermedics (3)
Medtronic (7)
Osypka (8)
unknown (89)
Sorin Biomedica/ELA Medical (9)
other (99)
unknown - NBL-Code
yes (1)
NBL-Code second digit
no fixation (0)
active fixation, e.g. bolted electrode (A)
passive fixation, e.g. hooked electrode
(P)
NBL-Code first digit
bipolar (B)
multipolar (M)
unipolar (U)
Time intervall to implantation of this electrode
less than or equal to 1 year (1)
more than 1 year (2)
unknown (9)
Reasons for not having measured R-Wave
Height, intraoperative
no own rhythm (1)
because of other reasons (9)
Functionally non-active parts of
pacemaker - pacemaker system
Pacemaker system
VVI (1)
AAI (2)
DDD (3)
VDD (4)
CRT-System with atrial electrode (5)
CRT-System without atrial electrode (6)
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other (9)
Pacemaker aggregate (pulse generator)
Kind of procedure
explantation (1)
deactivation (2)
other (9)
Year of implantation (YYYY)
unknown year of implantation
yes (1)
Manufacturer Name
Biotronik (1)
Vitatron (11)
St. Jude Medical (18)
Boston
Scientific/CPI/Guidant/Intermedics (3)
Medtronic (7)
Osypka (8)
unknown (89)
Sorin Biomedica/ELA Medical (9)
other (99)
Atrial pacemaker eletrodes
Kind of procedure
explantation (1)
deactivation (2)
other (9)
Time intervall to implantation of this electrode
less than or equal to 1 year (1)
more than 1 year (2)
unknown (9)
NBL-Code first digit
bipolar (B)
multipolar (M)
unipolar (U)
NBL-Code second digit
no fixation (0)
active fixation, e.g. bolted electrode (A)
passive fixation, e.g. hooked electrode
(P)
unknown - NBL-Code
yes (1)
Manufacturer Name
CodelistItem 345693 (1)
CodelistItem 345694 (11)
CodelistItem 345695 (18)
CodelistItem 345696 (3)
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CodelistItem 345697 (7)
CodelistItem 345698 (8)
CodelistItem 345699 (89)
CodelistItem 345700 (9)
CodelistItem 345701 (99)
Ventricular pacemaker electrode
Kind of procedure
explantation (1)
deactivation (2)
other (9)
Time intervall to implantation of this electrode
less than or equal to 1 year (1)
> more than 1 year (2)
unknown (9)
NBL-Code first digit
bipolar (B)
multipolar (M)
unipolar (U)
NBL-Code second digit
no fixation (0)
active fixation, e.g. bolted electrode (A)
passive fixation, e.g. hooked electrode
(P)
unknown - NBL-Code
yes (1)
Manufacturer Name
Biotronik (1)
Vitatron (11)
St. Jude Medical (18)
Boston
Scientific/CPI/Guidant/Intermedics (3)
Medtronic (7)
Osypka (8)
unknown (89)
Sorin Biomedica/ELA Medical (9)
other (99)
second ventricular eletrode
Kind of procedure
explantation (1)
deactivation (2)
other (9)
Time intervall to implantation of this electrode
less than or equal to 1 year (1)
> more than 1 year (2)
unknown (9)
NBL-Code first digit
bipolar (B)
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multipolar (M)
unipolar (U)
NBL-Code second digit
no fixation (0)
active fixation, e.g. bolted electrode (A)
passive fixation, e.g. hooked electrode
(P)
unknownNBL-Code
CodelistItem 345736 (1)
Manufacturer Name
CodelistItem 345737 (1)
CodelistItem 345738 (11)
CodelistItem 345739 (18)
CodelistItem 345740 (3)
CodelistItem 345741 (7)
CodelistItem 345742 (8)
CodelistItem 345743 (89)
CodelistItem 345744 (9)
CodelistItem 345745 (99)
Peri/Postoperative Compliactions
peri- or postoperative complikation(s)*
Yes
No
Asystolia
yes (1)
Ventricular fibrillation
yes (1)
Pneumothorax, requiring action
yes (1)
Hemathorax, requiring actionx
yes (1)
Pericardial effusion, requiring action
yes (1)
Hematoma due to pacemaker, requiring action
yes (1)
Electrode displacement
yes (1)
Location of electrode displacement
Atrium
yes (1)
Ventricle
1. ventricular electrode (1)
2. ventricular electrode (2)
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both (3)
Electrode dysfunction
yes (1)
Location of electrode dysfunction
Atrium
yes (1)
Ventricle
1. ventricular electrode (1)
2. ventricular electrode (2)
both (3)
postoperative wound infection - according to
definition of CDC classification
yes (1)
CDC classification
A1 (Superficial incisional surgical site
infections ) (1)
A2 (Deep incisional surgical site
infections) (2)
A3 (Organ/Space surgical site infections)
(3)
other complications complication, requiring action
yes (1)
Discharge
Hostpital discharge date  (DD.MM.YYYY)*
Reason for Discharge*
treatment finished as planned (1)
transferral to nursing facility (10)
discharge to hospice (11)
external transferral to psychiatric
treatment (13)
treatment finished because of other
reasons, postdischarge treatment is
planned (14)
treatment aborted against medical
advice, postdischarge treatment is
planned (15)
internal transferral with change of DRG
payment areas (17)
treatment finished as planned,
postdischarge treatment is planned (2)
case termination (internal transferral)
with change between full- and partial
stationary  care (22)
discharge at the end of the year with
admission in previous year (25)
treatment finished because of other
reasons (3)
treatment aborted against medical
advice (4)
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change of jurisdiction of insurer or other
payer (5)
transferral to another hospital (6)
death (7)
transferral to another hospital within
cooperative and governmental policies
(8)
transferral to rehabilitation facility (9)
Discharge diagnoses - ICD codes*
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Breast Cancer NCT00433511 Off Treatment -
E5103 ECOG Off-Treatment Form - 2544731v1.0
E5103 ECOG Off-Treatment Form
Doxorubicin, Cyclophosphamide, and Paclitaxel With or
Without Bevacizumab in Treating Patients With Lymph
Node-Positive or High-Risk, Lymph Node-Negative Breast
Cancer
NCT00433511 
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=22B14F38-
F180-6454-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/6498
Off-Treatment Form Breast Cancer
ECOG
Header
ECOG Protocol Number
ECOG Patient ID
DCI Name
Registration Step
Reporting Period
End Treatment Step 1 (End treatment
Step 1)
End Treatment Step 2 (End treatment
step 2)
Patient Initials
Participating Group Protocol Number
Participating Group Patient ID
Institution/Affiliate
Please mark an 'X' if data have been amended.
(Please circle amended items in red)
Date data amended (s m/d/y)
Investigator Signature
Investigator Signature Date
Vital Status
1 / 3
Patient's Vital Status
Alive (Alive)
Dead (Dead)
Date of Last Contact or Death (m/d/y)
Primary Cause of Death (if applicable)
Due To Other Cause (Due to other
cause)
Due To Protocol Treatment (Due to
protocol treatment)
Due To This Disease (Due to this
disease)
Unknown (Unknown)
Describe cause of death
Treatment
Did patient receive protocol therapy?
Yes
No
Last date protocol therapy was given (Report last
date of any protocol therapy -
Bevacizumab/placebo or chemotherapy given this
step.)
Last date Bevacizumab/placebo was given
(Complete at End of Step 1 ONLY)
Reason Treatment Ended
Adverse Event/side Effects/complications
(Adverse Event/Side
Effects/Complications)
Alternative Therapy (Alternative therapy)
Death On Study (Death on study)
Disease Progression, Relapse During
Active Treatment (Disease progression,
relapse during active treatment)
Other (Other)
Patient Off-treatment For Other
Complicating Disease (Patient off-
treatment for other complicating disease)
Patient Withdrawal Or Refusal After
Beginning Protocol Therapy (Patient
withdrawal/refusal after beginning
protocol therapy)
Treatment Completed Per Protocol
Criteria (Treatment completed per
protocol criteria)
Other Complicating Disease specify
Other specify
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Reason treatment never started
Adverse Event/side Effects/complications
(Adverse events/side
effects/complications)
Death Before Beginning Protocol
Therapy (Death before beginning
protocol therapy)
Disease Progression, Relapse Prior To
Beginning Protocol Therapy (Disease
progression, relapse before protocol
treatment)
Medical Decision (Medical decision)
No Treatment, Per Protocol Criteria (No
treatment assigned per protocol)
Other (Other)
Patient_ineligible (Patient ineligible)
Patient Withdrawal/refusal Before
Beginning Protocol Therapy (Patient
withdrawal/refusal before beginning
protocol therapy)
Other specify
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Quality assurance Implantable Defibrillator:
Implantation (AQUA)
Documentation form for quality assurance in German
Health Care by the institute forapplied quality Improvement
and Research in Health Care (Aqua), https://www.aqua-
institut.de/en/home. Internal Aqua form version: 09-4
Specification 2015 V02
All rights reserved. Please visit https://medical-data-
models.org/forms/6500
Quality assurance Implantable
Defibrillator: Implantation (AQUA)
Basic documentation
Healthcare Facility Identifier *
Zip Code of Discharge*
Facility's Section Identifier
Medical specialty*
internal medicine (0100)
internal medicine: geriatrics (0102)
internal medicine: cardiology (0103)
internal medicine: nephrology (0104)
internal medicine: hematology and
internal oncology  (0105)
internal medicine: endocrinology (0106)
internal medicine: gastroenterology
(0107)
internal medicine: pneumonology (0108)
internal medicine: rheumatology (0109)
internal medicine: pulmonology (0114)
internal medicine: tumor research (0150)
internal medicine: coloproctology (0151)
internal medicine: infectiology (0152)
internal medicine: diabetes (0153)
internal medicine: naturopathy (0154)
internal medicine: stroke unit (0156)
internal medicine (0190)
geriatry (0200)
geriatry: gynecology  (0224)
geriatry: day unit (for semi-residential
care)   (0260)
geriaty: night unit (for semi-residential
care) (0261)
geriatry (0290)
cardiology (0300)
nephrology (0400)
nephrology: pediatrics (0410)
nephrology: intensive care (0436)
nephrology (0490)
hematology and internal oncology
(0500)
hematology and internal oncology:
pediatrics (0510)
hematology and internal oncology:
gynacology (0524)
hematology and internal oncology:
radiation therapy (0533)
hematology and internal oncology
(0590)
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endocrinology (0600)
endicrinology: gastroenterology (0607)
endocrinology: pediatrics (0610)
endocrinology (0690)
gastroenterology (0700)
gastroenterology: endocrinology (0706)
gastroenterology: pediatrics (0710)
gastroenterology (0790)
pneumology (0800)
rheumatology (0900)
rheumatology: pediatrics (0910)
rheumatology (0990)
pediatrics (1000)
pediatrics: nephrology (1004)
pediatrics: hematology and internal
oncology  (1005)
pediatrics: endocrinology (1006)
pediatrics: gastroenterology (1007)
pediatrics: rheumatology (1009)
pediatrics: pediatric cardiology (1011)
pediatrics: nephrology (1012)
pediatrics: pulmonology (1014)
pediatrics: pediatric neurology (1028)
pediatrics: perinatal medicine (1050)
continuing care for children (1051)
pediatrics (1090)
pediatric cardiology (1100)
pediatric cardiology: intensive care
(1136)
pediatric cardiology (1190)
neonatology (1200)
pediatric surgery (1300)
pulmonology (1400)
pulmonology: pediatrics (1410)
pulmonology (1490)
general surgery (1500)
general surgery: pediatric surgery (1513)
general surgery: trauma surgery (1516)
general surgery: vascular surgery (1518)
general surgery: plastic surgery (1519)
general surgery: thoracic surgery (1520)
general surgery: orthopedics (1523)
general surgery: intensive care (1536)
general surgery: abdominal- and
vascular surgery (1550)
Allgemeine Chirurgie: hand surgery
(1551)
general surgery (1590)
trauma surgery (1600)
neurosurgery (1700)
vascular surgery (1800)
plastic surgery (1900)
thoracic surgery (2000)
thoracic surgery: cardiac surgery (2021)
thoracic surgery: intensive care (2036)
thoracic surgery: cardiac surgery
intensive care (2050)
thoracic surgery (2090)
cardiac surgery (2100)
cardiac surgery: vascular surgery (2118)
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cardiac surgery: thoracic surgery (2120)
cardiac surgery: intensive care (2136)
cardiac surgery: thoracic surgery and
intensive care (2150)
cardiac surgery (2190)
urology (2200)
orthopedics (2300)
orthopedics: rheumatology (2309)
orthopedics: surgery (2315)
orthopedics and trauma surgery (2316)
orthopedics (2390)
gynecology and obstetrics (2400)
gynecology: geriatry (2402)
gynecology: hematology and internal
oncology  (2405)
gynecology: endocrinology (2406)
gynecology (2425)
gynecology and obstetrics (2490)
obstetrics (2500)
otolaryngology (2600)
ophthalmology (2700)
neurology: (2800)
neurology: pediatrics (2810)
neurology: stroke units (2856)
neurology (2890)
general psychiatry: (2900)
general psychiatry: neurology (2928)
general psychiatry: child and adolescent
psychiatry (2930)
general psychiatry: psychosomatics and
psychotherapy (2931)
general psychiatry: addiction treatment
(2950)
general psychiatry: geropsychiatry
(2951)
general psychiatry: forensic treatment
(2952)
general psychiatry: addiction treatment
(day unit) (2953)
general psychiatry: addiction treatment
(night unit) (2954)
general psychiatry: geropsychiatry (day
unit) (2955)
general psychiatry: geropsychiatry (night
unit) (2956)
general psychiatry: day unit (for semi-
residential care) (2960)
general psychiatry: night unit (for semi-
residential care) (2961)
general psychiatry (2990)
child and adolescent psychiatry (3000)
child and adolescent psychiatry: day unit
(for semi-residential care) (3060)
child and adolescent psychiatry: night
unit (for semi-residential care) (3061)
child and adolescent psychiatry (3090)
psychosomatic/psychotherapy (3100)
psychosomatic/psychotherapy: child and
adolescent psychiatry (3110)
psychosomatic/psychotherapy: day unit
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(for semi-residential care) (3160)
psychosomatic/psychotherapy: night unit
(for semi-residential care) (3161)
psychosomatic/psychotherapy (3190)
nuclear medicine (3200)
nuclear medicine: radiation therapy
(3233)
nuclear medicine (3290)
radiation therapy (3300)
radiation therapy: hematology and
internal oncology  (3305)
radiation therapy: radiology (3350)
radiation therapy (3390)
dermatology (3400)
dermatology: day unit (for semi-
residential care) (3460)
dermatology (3490)
dentistry, orthodontics, maxillofacial
surgery (3500)
intensive-care medicine (3600)
intensive-care medicine: internal
medicine (3601)
intensive-care medicine: cardiology
(3603)
intensive-care medicine: pediatrics
(3610)
intensive-care medicine: neurosurgery
(3617)
intensive-care medicine: surgery (3618)
intensive-care medicine: cardiac surgery
(3621)
intensive-care medicine: urology (3622)
intensive-care medicine: gynecology and
obstetrics (3624)
intensive-care medicine: otolaryngology
(3626)
intensive-care medicine: neurology
(3628)
operative intensive-care medicine:
surgery (3650)
intensive-care medicine: thorax-heart
surgery (3651)
intensive-care medicine: heart-thorax
surgery (3652)
intensive-care medicine (3690)
other medical specialty (3700)
angiology (3750)
radiology (3751)
palliative care (3752)
pain therapy (3753)
section for alternative health practice
(3754)
spinal surgery (3755)
addiction medicine (3756)
visceral surgery (3757)
other medical specialty (3790)
Patient identification number*
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Date of Birth (DD.MM.YYYY)*
Gender*
male (1)
female (2)
Hospital admission date (DD.MM.YYYY)*
Preoperative Clinical Examination
Heart failure (according to NYHA classification)*
no (0)
NYHA I (1)
NYHA II (2)
NYHA III (3)
NYHA IV (4)
ASA classification*
A normal healthy patient (1)
A patient with mild systemic disease (2)
A patient with severe systemic disease
(3)
A patient with severe systemic disease
that is a constant threat to life (4)
A moribund patient who is not expected
to survive without the operation (5)
Left ventricular ejection fraction (in %)
unknown LVEF
yes (1)
Diabetes mellitus*
no (0)
yes, not insulin-dependent (1)
yes, insulin-dependent (2)
Renal function /Serum Creatinine*
less than or equal to 1,5 mg/dl (133
μmol/l) (1)
> 1,5 mg/dl (> 133 µmol/l) to < (2)
> 2,5 mg/dl (> 221 µmol/l), NOT dialysis-
dependent (3)
> 2,5 mg/dl (> 221 µmol/l), dialysis-
dependent (4)
unknown (8)
Part ICD (Implantable cardioverter
defibrillator)
Leading indication of ICD-Implantation*
primary prevention (1)
secondary prevention (2)
Medical conditions as an indication for ICD-
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implantation*
ventricular fibrillation (1)
ventricular tachycardia, continuing (> 30
sec) (2)
ventricular tachycardia, not continuing (<
(3)
syncope without  ECG-documentation
(4)
no clinical event existing as an indication
(primary prevention) (5)
Leading symptoms (of Arrhythmia)
none (0)
cardiac arrest (resuscitated patient) (1)
cardiogenic shock (2)
pulmonary edema (3)
syncope (4)
near syncope (5)
sehr niedriger Blutdruck (z.B. unter 80
mmHg systolisch) (6)
Angina pectoris (7)
sonstige (9)
Existing indication of cardial resynchronization
therapy (CRT)*
no (0)
yes (1)
Medical history
Coronary Heart Disease (CHD)*
no (0)
yes, without myocardial infarction (1)
yes, with myocardial infarction (2)
reversible or avoidable risk factors of ventricular
tachycardia
no (0)
yes (1)
unknown (9)
WPW-Syndrome
no (0)
yes (1)
unknown (9)
significant right-ventricular dysplasia or left-
ventricular affection
no (0)
yes (1)
unknown (9)
Thickness of  septum >= 30 mm
no (0)
yes (1)
unknown (9)
abnormal stress response pressure  (blood
pressure increase of more than 20 mmHg)
6 / 15
Quality assurance Implantable Defibrillator: Implantation (AQUA)
no (0)
yes (1)
unknown (9)
sudden deaths of relatives
no (0)
yes (1)
unknown (9)
Heart Disease*
no (0)
ischemic cardiomyopathy (1)
arrhythmogenic right ventricular
cardiomyopathy (ARVC) (10)
dilated Kardiomyopathie DCM (2)
hypertensive cardiac disease (3)
acquired valvular defects (4)
congenital heart defects (5)
Brugada-syndrome (6)
short QT-Syndrom (7)
long QT-Syndrom (8)
hypertrophic cardiomyopathy (HCM) (9)
other cardiac disease (99)
Medical condition or event as an indication for
ICD-implantation within 48 hours after myocardial
infarction
Yes
No
Time interval Myokardinfarkt – Implantation ICD
< 28 days (1)
> 28 days - < 40 days (2)
> 40 days (3)
treatable idiopathic ventricular tachycardia
no (0)
yes (1)
unknown (9)
Further characteristics
inducible ventricular tachycardia
no (1)
yes (2)
programmed ventricular stimulation not
applied (3)
Heart failure medication (at the time of
diagnosis)*
Yes
No
Beta-blocker
yes (1)
AT-Rezeptor-Blockers / ACE-Inhibitors
yes (1)
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Diuretics
yes (1)
Aldosterone antagonists
yes (1)
Cardiac glycosides
yes (1)
Part Cardiac pacemaker
expected amount of ventricular stimulation*
> 95% (1)
> 40% to < 95% (2)
< 40% (3)
ECG findings
Atrial rhythm*
regular sinus rhythm (1)
sinus bradycardia / SA-blocks (2)
paroxysmal/ persisting atrial
fibrillation/flutter (3)
permanent atrial fribrillation (4)
Change between sinus bradycardia and
atrial fibrillation (5)
other (9)
AV Block*
regular sinus rhythm (1)
sinus bradycardia / SA-blocks (2)
paroxysmal/ persisting atrial
fibrillation/flutter (3)
permanent atrial fribrillation (4)
Change between sinus bradycardia and
atrial fibrillation (5)
other (9)
intraventricular conduction defect*
none (0)
right bundle branch block (RBBB) (1)
left anterior fascicular block (2)
left posterior fascicular block + RBBB (3)
left bundle branch block (LBBB) (4)
alternating bundle branch block (5)
other (9)
QRS-Komplex*
< 120 ms (1)
120 to < 150 ms (2)
> 150 ms (3)
Operation
Operation Date (DD.MM.YY)*
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Procedure codes *
Access point of implanted system
Vena cephalica
yes (1)
Vena subclavia
yes (1)
other
yes (1)
Procedure Duration (in minutes)*
Dose Area Product (cGy)* cm²)
unknown Dose Area Product
yes (1)
intraoperative test of defibrillation*
yes (1)
no, because of intracardiac clots (2)
no, because of hemodynamic
instability(need of catecholamines or
pulmonary edema) (3)
no, because of other reasons (4)
Safety margin for Defibrillation Test >= 10 J under
pulese generator-specific maximum engery
Yes
No
ICD: ICD-System
ICD-System*
VVI (1)
DDD (2)
VDD (3)
CRT-System with an atrial electrode (4)
CRT-System without atrial electrode (5)
subcutaneous ICD (6)
sonstiges (9)
ICD aggregate
Manufacturer*
Biotronik (1)
St. Jude Medical (18)
Nayamed (19)
Boston
Scientific/CPI/Guidant/Intermedics (3)
Medtronic (7)
unknown (89)
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Sorin Biomedica/ELA Medical (9)
other (99)
Position of aggregate (pulse generator)*
infraclavicular subcutaneous (1)
infraclavicular subfascial (2)
infraclavicular submuscular (3)
abdominal (4)
other (9)
Electrodes: Atrium (atriale Pace/Sense-
electrode)-
Manufacturer
Biotronik (1)
St. Jude Medical (18)
Nayamed (19)
Boston
Scientific/CPI/Guidant/Intermedics (3)
Medtronic (7)
unknown (89)
Sorin Biomedica/ELA Medical (9)
other (99)
Sensing threshold (in V)
reason for not having measured
because of atrial fibrillation (1)
other reasons (9)
P wave height
reason for not having measured
because of atrial fibrillation (1)
missing own atrial rhythm (2)
other reasons (9)
Electrodes: Ventricle
Number of applied ventricular electrodes
one (1)
two (2)
three (3)
First ventricular/defibrillation electrode
Manufacturer
Biotronik (1)
St. Jude Medical (18)
Nayamed (19)
Boston
Scientific/CPI/Guidant/Intermedics (3)
Medtronic (7)
unknown (89)
Sorin Biomedica/ELA Medical (9)
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other (99)
Defibrillation electrodes
Single Coil (1)
Dual Coil (2)
other (9)
Position
right-ventricular Apex (1)
right-ventricular Septum (2)
other (9)
Sensing threshold(in V)
reason for not having measured
separate pace/sense electrode (1)
other reasons (9)
R wave height
reasons for not having measured
separate pace/sense electrode (1)
no own rhythm (2)
other reasons (9)
Second ventricular electrode
Manufacturer
Biotronik (1)
St. Jude Medical (18)
Nayamed (19)
Boston
Scientific/CPI/Guidant/Intermedics (3)
Medtronic (7)
unknown (89)
Sorin Biomedica/ELA Medical (9)
other (99)
Position
right-ventricular apex (1)
right-ventricular septum (2)
coronary vein, anterior (3)
coronary vein, lateral, posterolateral (4)
coronary vein, posterior (5)
epimyocardial left-ventricular (6)
other (9)
Sensing threshold(in V)
not measured
yes (1)
R wave height
reason for not having measured
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missing own rhythm (1)
other reasons (9)
Third ventricular electrode
Manufacturer
Biotronik (1)
St. Jude Medical (18)
Nayamed (19)
Boston
Scientific/CPI/Guidant/Intermedics (3)
Medtronic (7)
unknown (89)
Sorin Biomedica/ELA Medical (9)
other (99)
Position
right-ventricular apex (1)
right-ventricular septum (2)
coronary vein, anterior (3)
coronary vein, lateral, posterolateral (4)
coronary vein, posterior (5)
epimyocardial left-ventricular (6)
other (9)
Sensing threshold (in V)
not measured
CodelistItem 346388 (1)
R wave height
reasons for not having measured
missing own rhythm (1)
other reasons (9)
Other defibrillator electrodes
Manufacturer
Biotronik (1)
St. Jude Medical (18)
Nayamed (19)
Boston
Scientific/CPI/Guidant/Intermedics (3)
Medtronic (7)
unknown (89)
Sorin Biomedica/ELA Medical (9)
other (99)
Position
superior vena cava (1)
subclavian vein (2)
right atrium (3)
subcutaneous (sub-Q-Array) (4)
subcutaneous (S-ICD) (5)
epimyocardial (Patch-Elektrode) (6)
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multiple (7)
other (9)
Perioperative complications
perioperative complications*
Yes
No
Cardiopulmonary Resuscitation
yes (1)
Pneumothorax, requiring action
yes (1)
Hemathorax, requiring actionx
yes (1)
Pericardial effusion, requiring action
yes (1)
Hematoma due to pacemaker, requiring action
yes (1)
Electrode displacement, requiring action
yes (1)
Location of electrode dislocation
Atrium
yes (1)
First ventricular electrode /defibrillation electrode
yes (1)
Second ventricular electrode
yes (1)
Third ventricular electrode
yes (1)
other defibrillation electrode
yes (1)
Electrode dysfunction, requiring action
yes (1)
Location of electrode dysfunction
Atrium
yes (1)
First ventricular electrode /defibrillation electrode
yes (1)
Second ventricular electrode
yes (1)
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Third ventricular electrode
yes (1)
other defibrillation electrode
yes (1)
postoperative wound infection - according to
definition of CDC classification
yes (1)
CDC classification
A1 (Superficial incisional surgical site
infections) (1)
A2 (Deep incisional surgical site
infections) (2)
A3 (Organ/Space surgical site infections)
(3)
other complications complication, requiring
action(if peri/operative complications existing)
yes (1)
Discharge
Hospital discharge date  (DD.MM.YYYY)*
Reason for Discharge*
treatment finished as planned (1)
transferral to nursing facility (10)
discharge to hospice (11)
external transferral to psychiatric
treatment (13)
treatment finished because of other
reasons, postdischarge treatment is
planned (14)
treatment aborted against medical
advice, postdischarge treatment is
planned (15)
internal transferral with change of DRG
payment areas (17)
treatment finished as planned,
postdischarge treatment is planned (2)
case termination (internal transferral)
with change between full- and partial
stationary  care (22)
discharge at the end of the year with
admission in previous year (25)
treatment finished because of other
reasons (3)
treatment aborted against medical
advice (4)
change of jurisdiction of insurer or other
payer (5)
transferral to another hospital (6)
death (7)
transferral to another hospital within
cooperative and governmental policies
(8)
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transferral to rehabilitation facility (9)
Discharge diagnoses - ICD codes*
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Colorectal Cancer NCT00303628 Off Treatment
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E5204 Off-Treatment Form
Combination Chemotherapy With or Without Bevacizumab
in Treating Patients Who Have Had Surgery for Stage II or
Stage III Rectal Cancer
NCT00303628
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=089B45A3-
26F5-38F3-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/6503
Off-Treatment Form Colorectal
Cancer E5204
Header
ECOG Protocol Number
ECOG Patient ID
DCI Name
Registration Step
Reporting Period
End Of Treatment (End of treatment)
Patient Initials (Last, First)
Participating Group Protocol Number
Institution/Affiliate
Participating Group Patient ID
Please mark if data have been amended
Yes
No
Date data amended (s - mm/dd/yyyy)
Investigator Signature
Investigator Signature Date
Vital Status
Patient Vital Status
Alive (Alive)
Dead (Dead)
Date of Last Contact or Death (mm/dd/yyyy)
1 / 3
Primary Cause of Death (if applicable)
Due To Other Cause (Due to other
cause)
Due To Protocol Treatment (Due to
protocol treatment)
Due To This Disease (Due to this
disease)
Unknown (Unknown)
Describe cause of death
Treatment
Did patient receive protocol therapy?
Yes
No
Reason Treatment Ended
Adverse Event/side Effects/complications
(Adverse Event/Side
Effects/Complications)
Alternative Therapy (Alternative therapy)
Death On Study (Death on study)
Disease Progression, Relapse During
Active Treatment (Disease progression,
relapse during active treatment)
Other (Other)
Patient Off-treatment For Other
Complicating Disease (Patient off-
treatment for other complicating disease)
Patient Withdrawal Or Refusal After
Beginning Protocol Therapy (Patient
withdrawal/refusal after beginning
protocol therapy)
Treatment Completed Per Protocol
Criteria (Treatment completed per
protocol criteria)
Other Complicating Disease specify (specify)
Other specify
Last date protocol therapy was given
(mm/dd/yyyy)
Reason treatment never started
Adverse Event/side Effects/complications
(Adverse events/side
effects/complications)
Death Before Beginning Protocol
Therapy (Death before beginning
protocol therapy)
Disease Progression, Relapse Prior To
Beginning Protocol Therapy (Disease
progression, relapse before protocol
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treatment)
Medical Decision (Medical decision)
No Treatment, Per Protocol Criteria (No
treatment assigned per protocol)
Other (Other)
Patient_ineligible (Patient ineligible)
Patient Withdrawal Or Refusal Before
Beginning Protocol Therapy (Patient
withdrawal or refusal before beginning
protocol therapy)
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Head and Neck Cancer NCT00588770 Off Treatment
- ECOG Off-Treatment Form - 2502331v1.0
ECOG Off-Treatment Form
Chemotherapy With or Without Bevacizumab in Treating
Patients With Recurrent or Metastatic Head and Neck
Cancer
NCT00588770
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=1A096316-
A5E7-28A3-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/6504
Off-Treatment Form Head and Neck
Cancer ECOG (NCT00588770)
Header
ECOG Protocol Number
ECOG Patient ID
DCI Name
Registration Step
Reporting Period
End Of Treatment (End of treatment)
Patient Initials (Last, First)
Participating Group Protocol Number
Participating Group Patient ID
Institution/Affiliate
Please mark an 'X' if data have been amended.
(Please circle amended items in red)
Date data amended
Investigator Signature
Investigator Signature Date
Vital Status
Vital Status
Alive (Alive)
Dead (Dead)
Date of Last Contact or Death
1 / 3
Primary Cause of Death (if applicable)
Due To Other Cause (Due to other
cause)
Due To Protocol Treatment (Due to
protocol treatment)
Due To This Disease (Due to this
disease)
Unknown (Unknown)
Describe cause of death
Treatment
Did patient receive protocol therapy?
Yes
No
Reason Treatment Ended
Adverse Event/side Effects/complications
(Adverse Event/Side
Effects/Complications)
Alternative Therapy (Alternative therapy)
Death On Study (Death on study)
Disease Progression, Relapse During
Active Treatment (Disease progression,
relapse during active treatment)
Other (Other)
Patient Off-treatment For Other
Complicating Disease (Patient off-
treatment for other complicating disease)
Patient Withdrawal Or Refusal After
Beginning Protocol Therapy (Patient
withdrawal/refusal after beginning
protocol therapy)
Treatment Completed Per Protocol
Criteria (Treatment completed per
protocol criteria)
Other Complicating Disease specify
Other specify
Last date protocol therapy was given
Reason treatment never started
Adverse Event/side Effects/complications
(Adverse events/side
effects/complications)
Death Before Beginning Protocol
Therapy (Death before beginning
protocol therapy)
Disease Progression, Relapse Prior To
Beginning Protocol Therapy (Disease
progression, relapse before protocol
treatment)
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Treatment Form - 2502331v1.0
Medical Decision (Medical decision)
No Treatment, Per Protocol Criteria (No
treatment assigned per protocol)
Other (Other)
Patient_ineligible (Patient ineligible)
Patient Withdrawal/refusal Before
Beginning Protocol Therapy (Patient
withdrawal/refusal before beginning
protocol therapy)
Other specify
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Head and Neck Cancer NCT00588770 Off Treatment - ECOG Off-
Treatment Form - 2502331v1.0
Off-Treatment Form Kidney Cancer
(NCT00326898)
E2805 Off-Treatment Form
Sunitinib or Sorafenib in Treating Patients With Kidney
Cancer That Was Removed By Surgery
NCT00326898
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=054AD4FB-
BA76-2822-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/6505
Off-Treatment Form Kidney Cancer
(NCT00326898)
Header
ECOG Protocol Number
ECOG Patient ID
DCI Name
Registration Step
Reporting Period
End Of Treatment (End of treatment)
Patient Initials
Participating Group Protocol Number
Institution/Affiliate
Participating Group Patient ID
Please mark an 'X' if data have been amended.
Date data amended
Investigator Signature
Investigator Signature Date
Vital Status
Patient's Vital Status
Alive (Alive)
Dead (Dead)
Date of Last Contact or Death
1 / 3
Primary Cause of Death (if applicable)
Due To Other Cause (Due to other
cause)
Due To Protocol Treatment (Due to
protocol treatment)
Due To This Disease (Due to this
disease)
Unknown (Unknown)
Describe cause of death
Treatment
Did patient receive protocol therapy
Yes
No
Reason Treatment Ended
Adverse Event/side Effects/complications
(Adverse Event/Side
Effects/Complications)
Alternative Therapy (Alternative therapy)
Death On Study (Death on study)
Disease Progression, Relapse During
Active Treatment (Disease progression,
relapse during active treatment)
Other (Other)
Patient Off-treatment For Other
Complicating Disease (Patient off-
treatment for other complicating disease)
Patient Withdrawal Or Refusal After
Beginning Protocol Therapy (Patient
withdrawal/refusal after beginning
protocol therapy)
Treatment Completed Per Protocol
Criteria (Treatment completed per
protocol criteria)
Complicating Disease
Other specify
Last date protocol therapy was given
Reason treatment never started
Adverse Event/side Effects/complications
(Adverse events/side
effects/complications)
Death Before Beginning Protocol
Therapy (Death before beginning
protocol therapy)
Disease Progression, Relapse Prior To
Beginning Protocol Therapy (Disease
progression, relapse before protocol
treatment)
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Medical Decision (Medical decision)
No Treatment, Per Protocol Criteria (No
treatment assigned per protocol)
Other (Other)
Patient_ineligible (Patient ineligible)
Patient Withdrawal Or Refusal Before
Beginning Protocol Therapy (Patient
withdrawal or refusal before beginning
protocol therapy)
Other specify
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Off-Treatment Form MDS (NCT00843882)
E2905 Off-Treatment Form
Lenalidomide With or Without Epoetin Alfa in Treating
Patients With Myelodysplastic Syndrome and Anemia
NCT00843882
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=0EAAB591-
EE7E-6F0E-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/6507
Off-Treatment Form MDS
(NCT00843882)
Header
ECOG Protocol Number
ECOG Patient ID
DCI Name
Registration Step
Reporting Period
End Of Treatment (End of treatment)
Patient Initials (Last, First)
Participating Group Protocol Number
Participating Group Patient ID
Institution/Affiliate
Please mark an 'X' if data have been amended.
(Please circle amended items in red)
Date data amended (MM/DD/YYYY)
Investigator Signature
Investigator Signature Date
Vital Status
Patient's Vital Status
Alive (Alive)
Dead (Dead)
Date of Last Contact or Death (MM/DD/YYYY)
1 / 3
Primary Cause of Death (if applicable)
Due To Other Cause (Due to other
cause)
Due To Protocol Treatment (Due to
protocol treatment)
Due To This Disease (Due to this
disease)
Unknown (Unknown)
Describe cause of death
Treatment
Did patient receive protocol therapy?
Yes
No
Reason Treatment Ended
Adverse Event/side Effects/complications
(Adverse Event/Side
Effects/Complications)
Alternative Therapy (Alternative therapy)
Death On Study (Death on study)
Disease Progression, Relapse During
Active Treatment (Disease progression,
relapse during active treatment)
Other (Other)
Patient Off-treatment For Other
Complicating Disease (Patient off-
treatment for other complicating disease)
Patient Withdrawal Or Refusal After
Beginning Protocol Therapy (Patient
withdrawal/refusal after beginning
protocol therapy)
Treatment Completed Per Protocol
Criteria (Treatment completed per
protocol criteria)
Other Complicating Disease specify
Other specify
Last date protocol therapy was given
(MM/DD/YYYY)
Did patient discontinue treatment due to failure to
achieve erythroid response
Yes
No
Reason treatment never started
Adverse Event/side Effects/complications
(Adverse events/side
effects/complications)
Death Before Beginning Protocol
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Therapy (Death before beginning
protocol therapy)
Disease Progression, Relapse Prior To
Beginning Protocol Therapy (Disease
progression, relapse before protocol
treatment)
Medical Decision (Medical decision)
No Treatment, Per Protocol Criteria (No
treatment assigned per protocol)
Other (Other)
Patient_ineligible (Patient ineligible)
Patient Withdrawal/refusal Before
Beginning Protocol Therapy (Patient
withdrawal/refusal before beginning
protocol therapy)
Other specify
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Off-Treatment Form Lung Cancer
(NCT00324805)
ECOG-E1505 Off-Treatment Form
Chemotherapy With or Without Bevacizumab in Treating
Patients With Stage IB, Stage II, or Stage IIIA Non-Small
Lung Cancer That Was Removed By Surgery
NCT00324805 
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=07459D41-
1B93-4F16-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/6508
Off-Treatment Form Lung Cancer
(NCT00324805)
Header
ECOG Protocol Number
ECOG Patient ID
DCI Name
Registration Step
Reporting Period
End Of Treatment (End of treatment)
Patient Initials (Last, First)
Participating Group Protocol Number
Institution/Affiliate
Participating Group Patient ID
Please mark if data have been amended
Yes
No
Date data amended (M D Y)
Investigator Signature
Investigator Signature Date
Vital Status
Patient's Vital Status
Alive (Alive)
Dead (Dead)
Date of Last Contact or Death
1 / 3
Primary Cause of Death (if applicable)
Due To Other Cause (Due to other
cause)
Due To Protocol Treatment (Due to
protocol treatment)
Due To This Disease (Due to this
disease)
Unknown (Unknown)
Describe cause of death
Treatment
Did patient receive protocol therapy (This form is
required regardless of whether patient started
protocol treatment.)
Yes
No
Reason Treatment Ended
Adverse Event/side Effects/complications
(Adverse Event/Side
Effects/Complications)
Alternative Therapy (Alternative therapy)
Death On Study (Death on study)
Disease Progression, Relapse During
Active Treatment (Disease progression,
relapse during active treatment)
Other (Other)
Patient Off-treatment For Other
Complicating Disease (Patient off-
treatment for other complicating disease)
Patient Withdrawal Or Refusal After
Beginning Protocol Therapy (Patient
withdrawal/refusal after beginning
protocol therapy)
Treatment Completed Per Protocol
Criteria (Treatment completed per
protocol criteria)
Complicating Disease
Other specify
Last date protocol therapy was given
Reason treatment never started
Adverse Event/side Effects/complications
(Adverse events/side
effects/complications)
Death Before Beginning Protocol
Therapy (Death before beginning
protocol therapy)
Disease Progression, Relapse Prior To
Beginning Protocol Therapy (Disease
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progression, relapse before protocol
treatment)
Medical Decision (Medical decision)
No Treatment, Per Protocol Criteria (No
treatment assigned per protocol)
Other (Other)
Patient_ineligible (Patient ineligible)
Patient Withdrawal/refusal Before
Beginning Protocol Therapy (Patient
withdrawal/refusal before beginning
protocol therapy)
Other specify
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Multiple Myeloma and Plasma Cell Neoplasm NCT00522392 Off
Treatment - E1A05 Off-Treatment Form - Form 2866 - 2653886v1.0
E1A05 Off-Treatment Form - Form 2866
Bortezomib and Dexamethasone With or Without
Lenalidomide in Treating Patients With Multiple Myeloma
Previously Treated With Dexamethasone
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=32BBD908-
FCE8-6EDB-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/6509
E1A05 Off-Treatment Form - Form
2866
Header
ECOG Protocol Number
ECOG Patient ID
DCI Name
Registration Step
Reporting Period
End Of Treatment (End of treatment)
Patient Initials (Last, First)
Participating Group Protocol Number
Institution/Affiliate
Participating Group Patient ID
Please mark an 'X' if data have been amended.
(Please circle amended items in red)
Date data amended (s - mm/dd/yyyy)
Investigator Signature
Investigator Signature Date
Vital Status
Patient Vital Status
Alive (Alive)
Dead (Dead)
Date of Last Contact or Death (mm/dd/yyyy)
1 / 3
Primary Cause of Death (if applicable)
Due To Other Cause (Due to other
cause)
Due To Protocol Treatment (Due to
protocol treatment)
Due To This Disease (Due to this
disease)
Unknown (Unknown)
Describe cause of death
Treatment
Did patient receive protocol therapy?
Yes
No
Reason Treatment Ended
Adverse Event/side Effects/complications
(Adverse Event/Side
Effects/Complications)
Alternative Therapy (Alternative therapy)
Death On Study (Death on study)
Disease Progression, Relapse During
Active Treatment (Disease progression,
relapse during active treatment)
Other (Other)
Patient Off-treatment For Other
Complicating Disease (Patient off-
treatment for other complicating disease)
Patient Withdrawal Or Refusal After
Beginning Protocol Therapy (Patient
withdrawal/refusal after beginning
protocol therapy)
Treatment Completed Per Protocol
Criteria (Treatment completed per
protocol criteria)
Other Complicating Disease specify (specify)
Other specify
Last date protocol therapy was given
(mm/dd/yyyy)
Reason treatment never started
Adverse Event/side Effects/complications
(Adverse events/side
effects/complications)
Death Before Beginning Protocol
Therapy (Death before beginning
protocol therapy)
Disease Progression, Relapse Prior To
Beginning Protocol Therapy (Disease
progression, relapse before protocol
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Multiple Myeloma and Plasma Cell Neoplasm NCT00522392 Off
Treatment - E1A05 Off-Treatment Form - Form 2866 - 2653886v1.0
treatment)
Medical Decision (Medical decision)
No Treatment, Per Protocol Criteria (No
treatment assigned per protocol)
Other (Other)
Patient Withdrawal/refusal Before
Beginning Protocol Therapy (Patient
withdrawal/refusal before beginning
protocol therapy)
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Multiple Myeloma and Plasma Cell Neoplasm NCT00522392 Off
Treatment - E1A05 Off-Treatment Form - Form 2866 - 2653886v1.0
Off-Treatment Form Prostate Cancer
(NCT00309985)
E3805 Off-Treatment Form
Androgen Ablation Therapy With or Without Chemotherapy
in Treating Patients With Metastatic Prostate Cancer
NCT00309985
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=F9C0F192-
5ECF-6996-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/6510
Off-Treatment Form Prostate Cancer
(NCT00309985)
Header
ECOG Protocol Number
ECOG Patient ID
DCI Name
Registration Step
Reporting Evaluation Period Type
End Of Treatment (End of treatment)
Patient Initials
Participating Group Protocol Number
Institution/Affiliate
Participating Group Patient ID
Please mark an 'X' if data have been amended.
Date data amended
Comments
Investigator Signature
Investigator Signature Date
Vital Status
Vital Status
Alive (Alive)
Dead (Dead)
1 / 3
Date of Last Contact or Death
Primary Cause of Death
Due To Other Cause (Due to other
cause)
Due To Protocol Treatment (Due to
protocol treatment)
Due To This Disease (Due to this
disease)
Unknown (Unknown)
Describe cause of death
Treatment
Did patient receive protocol therapy?
Yes
No
Reason Treatment Ended
Adverse Event/side Effects/complications
(Adverse Event/Side
Effects/Complications)
Alternative Therapy (Alternative therapy)
Death On Study (Death on study)
Disease Progression, Relapse During
Active Treatment (Disease progression,
relapse during active treatment)
Other (Other)
Patient Off-treatment For Other
Complicating Disease (Patient off-
treatment for other complicating disease)
Patient Withdrawal Or Refusal After
Beginning Protocol Therapy (Patient
withdrawal/refusal after beginning
protocol therapy)
Treatment Completed Per Protocol
Criteria (Treatment completed per
protocol criteria)
Off-treatment Complicating Reason Specify
Off-treatment Reason Specify
Last date protocol therapy was given
Reason treatment never started
Adverse Event/side Effects/complications
(Adverse events/side
effects/complications)
Death Before Beginning Protocol
Therapy (Death before beginning
protocol therapy)
Disease Progression, Relapse Prior To
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Beginning Protocol Therapy (Disease
progression, relapse before protocol
treatment)
Medical Decision (Medical decision)
No Treatment, Per Protocol Criteria (No
treatment assigned per protocol)
Other (Other)
Patient_ineligible (Patient ineligible)
Patient Withdrawal Or Refusal Before
Beginning Protocol Therapy (Patient
withdrawal or refusal before beginning
protocol therapy)
Other specify
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Initial Follow-up Form Prostate Cancer
(NCT00288080)
RTOG 0521 FO: Radiation Therapy Oncology Group Phase
III Randomized Study of Localized, High-Risk Prostate
Cancer Initial Follow-up Form
Hormone Therapy and Radiation Therapy or Hormone
Therapy and Radiation Therapy Followed by Docetaxel and
Prednisone in Treating Patients With Localized Prostate
Cancer
NCT00288080
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=0CB07BEA-
FAB7-6032-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/6511
Initial Follow-up Form Prostate
Cancer (NCT00288080)
Unnamed2
RTOG Study No.
Institution Name
Institution No.
Patient Initials
RTOG Patient ID
Amended Data
Yes
No
Comments
Signature of Person Completing This Form
Date Form Originally Completed
Vital Status
Patient's Vital Status
Alive (Alive)
Dead (Dead)
Date of Last Contact or Death
Primary Cause of Death
Due To Other Cause (Due to other
cause)
Due To Protocol Treatment (Due to
protocol treatment)
Due To This Disease (Due to this
disease)
1 / 7
Not Applicable (Not applicable)
Unknown (Unknown)
Due to other cause, specify
Has the patient had a documented clinical
assessment for this cancer (SINCE
SUBMISSION OF THE PREVIOUS FOLLOW-UP
FORM)
No (No)
Unknown (Unknown)
Yes (Yes)
Date
Performance Status
Fully Active, Able To Carry On All Pre-
disease Performance Without
Restriction. (0)
Restricted In Physically Strenuous
Activity But Ambulatory And Able To
Carry Out Work Of A Light Or Sedentary
Nature, E.g., Light Housework, Office
Work. (1)
Ambulatory And Capable Of All Selfcare
But Unable To Carry Out Any Work
Activities. Up And About More Than 50%
Of Waking Hours. (2)
Capable Of Only Limited Selfcare,
Confined To Bed Or Chair More Than
50% Of Waking Hours. (3)
Completely Disabled. Cannot Carry On
Any Selfcare. Totally Confined To Bed Or
Chair. (4)
Dead (5)
Has the patient has a prostate biospy (SINCE
SUBMISSION OF THE LAST FOLLOW-UP
FORM)
No (No)
Unknown (Unknown)
Yes, Negative (Yes, negative)
Yes, Positive (Yes, positive)
Yes, Results Unknown (Yes, results
unknown)
Biopsy Date
Was the tumor palpable
Equivocal (Equivocal)
No (No)
Not Evaluated (Not evaluated)
Unknown (Unknown)
Yes (Yes)
New or continuing adverse events (IF PATIENT
EXPERIENCED ANY TREATMENT RELATED
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ADVERSE EVENTS DURING THIS REPORT
PERIOD, SUBMIT ADVERSE EVENT FORM AE)
No (No)
Unknown (Unknown)
Yes (Yes)
Tumor progression
Primary Disease Site
Has the patient been diagnosed with biochemical
recurrence since submission of the last follow-up
form
No (NO)
Unknown (Unknown)
Yes (YES)
Has the patient been diagnosed with a first local
recurrence (SINCE SUBMISSION OF LAST
FOLLOW-UP FORM See Protocol Section 11)
No (NO)
Unknown (Unknown)
Yes (YES)
Date
Method of Evaluation (LOCAL PROGRESSION)
Mri (MRI (NMR))
Not Applicable (Not applicable)
Other (Other)
Pathologic (Pathologic)
Physical Exam (Physical exam)
Radiographic (Radiographic)
Other Specify
Has the patient been diagnosed with first distant
progression (SINCE SUBMISSION OF THE
LAST FOLLOW-UP FORM)
No (No)
Unknown (Unknown)
Yes (Yes)
Date
Sites of Progression (First distant)
Method of Evaluation (DISTAL PROGRESSION)
Mri (MRI (NMR))
Not Applicable (Not applicable)
Other (Other)
Pathologic (Pathologic)
Physical Exam (Physical exam)
Radiographic (Radiographic)
3 / 7
Initial Follow-up Form Prostate Cancer (NCT00288080)
Evaluation method, specify
Has a new primary cancer or MDS been
diagnosed that has not been previously reported
No (No)
Unknown (Unknown)
Yes (Yes)
Second Primary Tumor Site
Aml/mds (AML/MDS)
Bcc (BCC)
Bladder Is The Site Of Second Primary
Or Recurrent Tumor (bladder)
Brain Is The Site Of Second Primary Or
Recurrent Tumor (brain)
Colorectal (Colorectal)
Esophageal (Esophageal)
Gastric (Gastric)
Liver Is The Site Of Second Primary Or
Recurrent Tumor (liver)
Lung Is The Site Of Second Primary Or
Recurrent Tumor (lung)
Melanoma (Melanoma)
Nhl (NHL)
Other Hematologic (Other hematologic)
Other Solid (Other solid)
Pancreatic (Pancreatic)
Renal (Renal)
Squamous-skin (Squamous-skin)
Unknown Primary (Unknown primary)
Second Primary Cancer Date
PROSTATE: PSA MEASUREMENTS
PSA Date
PSA Value
Units of Measure
Nanograms Per Deciliter (ng/dL)
Nanograms Per Milliliter (ng/mL)
Nanomoles Per Liter (nmol/l)
Not Otherwise Specified (NOS)
Testosterone
Testosterone
Abnormal (Abnormal)
Normal (Normal)
Not Done (Not done)
Unknown (Unknown)
Testosterone Lower Limit Normal
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Testosterone Upper Limit Normal
Units Testosteron
Nanograms Per Deciliter (ng/dL)
Nanograms Per Milliliter (ng/mL)
Nanomoles Per Liter (nmol/l)
Not Otherwise Specified (NOS)
Treatment Schedule (LHRH Agonist)
Is patient on protocol hormone (ORAL
ANTIANDROGEN)
Yes
No
LHRH agonist
Eligard (Eligard)
Lupron (Lupron)
Other (Other)
Viadur (Viadur)
Zoladex (Zoladex)
Other, specify
LHRH agonist start date (IF STARTED IN THIS
FOLLOW-UP PERIOD)
LHRH agonist end date (IF TERMINATED IN
THIS FOLLOW-UP PERIOD)
Reason Treatment Ended
Adverse Event/side Effects/complications
(Adverse Event/Side
Effects/Complications)
Alternative Therapy (Alternative therapy)
Death On Study (Death on study)
Disease Progression, Relapse During
Active Treatment (Disease progression,
relapse during active treatment)
Other (Other)
Patient Off-treatment For Other
Complicating Disease (Patient off-
treatment for other complicating disease)
Patient Withdrawal Or Refusal After
Beginning Protocol Therapy (Patient
withdrawal/refusal after beginning
protocol therapy)
Patient Withdrawal Or Refusal Before
Beginning Protocol Therapy (Patient
withdrawal/refusal prior to beginning
protocol therapy)
Treatment Completed Per Protocol
Criteria (Treatment completed per
protocol criteria)
Alternative Therapy, Specify
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Patient off-treatment for other complicating
disease, specify
Other specify
Total Dose (TO DATE)
Treatment Schedule (oral Antiandrogen)
Is patient on protocol hormone (ORAL
ANTIANDROGEN)
Yes
No
Oral antiandrogen taken
Casodex (Casodex)
Eulexin (Eulexin)
Other (Other)
Other, specify
Oral Antiandrogen Start Date (IF STARTED IN
THIS FOLLOW-UP PERIOD)
Oral Antiandrogen End Date (IF TERMINATED IN
THIS FOLLOW-UP PERIOD)
Reason Treatment Ended
Adverse Event/side Effects/complications
(Adverse Event/Side
Effects/Complications)
Alternative Therapy (Alternative therapy)
Death On Study (Death on study)
Disease Progression, Relapse During
Active Treatment (Disease progression,
relapse during active treatment)
Other (Other)
Patient Off-treatment For Other
Complicating Disease (Patient off-
treatment for other complicating disease)
Patient Withdrawal Or Refusal After
Beginning Protocol Therapy (Patient
withdrawal/refusal after beginning
protocol therapy)
Patient Withdrawal Or Refusal Before
Beginning Protocol Therapy (Patient
withdrawal/refusal prior to beginning
protocol therapy)
Treatment Completed Per Protocol
Criteria (Treatment completed per
protocol criteria)
Alternative Therapy, Specify
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Patient off-treatment for other complicating
disease, specify
Other specify
Total Dose (TO DATE)
Non-protocol Therapy
Is the patient receiving any non-protocol cancer
therapy not previously reported (PROSTATE If
yes, enter therapy type and date for each therapy
delivered during the follow-up period.)
No (No)
Unknown (Unknown)
Yes (Yes)
Non-Protocol Therapy Type
Chemotherapy (Chemotherapy)
Hormones (Hormones)
None (None)
Other Specify (Other, specify)
Radiation To Other Sites, Specify
(Radiation to other sites, specify)
Radiation To Pelvis (Radiation to pelvis)
Surgery (Surgery)
Date of First Non-Protocol Therapy
Specify
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Quality assurance Implantable Defibrillator:
Replacement (AQUA)
Documentation form for quality assurance in German
Health Care by the institute forapplied quality Improvement
and Research in Health Care (Aqua), https://www.aqua-
institut.de/en/home. Internal Aqua form version: 09-5
Specification 2015 V02
All rights reserved. Please visit https://medical-data-
models.org/forms/6512
Quality assurance Implantable
Defibrillator: Replacement (AQUA)
Basic documentation
Healthcare Facility Identifier *
Zip Code of Discharge*
Facility's Section Identifier
Medical specialty*
internal medicine (0100)
internal medicine: geriatrics (0102)
internal medicine: cardiology (0103)
internal medicine: nephrology (0104)
internal medicine: hematology and
internal oncology  (0105)
internal medicine: endocrinology (0106)
internal medicine: gastroenterology
(0107)
internal medicine: pneumonology (0108)
internal medicine: rheumatology (0109)
internal medicine: pulmonology (0114)
internal medicine: tumor research (0150)
internal medicine: coloproctology (0151)
internal medicine: infectiology (0152)
internal medicine: diabetes (0153)
internal medicine: naturopathy (0154)
internal medicine: stroke unit (0156)
internal medicine (0190)
geriatry (0200)
geriatry: gynecology  (0224)
geriatry: day unit (for semi-residential
care)   (0260)
geriaty: night unit (for semi-residential
care) (0261)
geriatry (0290)
cardiology (0300)
nephrology (0400)
nephrology: pediatrics (0410)
nephrology: intensive care (0436)
nephrology (0490)
hematology and internal oncology
(0500)
hematology and internal oncology:
pediatrics (0510)
hematology and internal oncology:
gynacology (0524)
hematology and internal oncology:
radiation therapy (0533)
hematology and internal oncology
(0590)
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endocrinology (0600)
endicrinology: gastroenterology (0607)
endocrinology: pediatrics (0610)
endocrinology (0690)
gastroenterology (0700)
gastroenterology: endocrinology (0706)
gastroenterology: pediatrics (0710)
gastroenterology (0790)
pneumology (0800)
rheumatology (0900)
rheumatology: pediatrics (0910)
rheumatology (0990)
pediatrics (1000)
pediatrics: nephrology (1004)
pediatrics: hematology and internal
oncology  (1005)
pediatrics: endocrinology (1006)
pediatrics: gastroenterology (1007)
pediatrics: rheumatology (1009)
pediatrics: pediatric cardiology (1011)
pediatrics: nephrology (1012)
pediatrics: pulmonology (1014)
pediatrics: pediatric neurology (1028)
pediatrics: perinatal medicine (1050)
continuing care for children (1051)
pediatrics (1090)
pediatric cardiology (1100)
pediatric cardiology: intensive care
(1136)
pediatric cardiology (1190)
neonatology (1200)
pediatric surgery (1300)
pulmonology (1400)
pulmonology: pediatrics (1410)
pulmonology (1490)
general surgery (1500)
general surgery: pediatric surgery (1513)
general surgery: trauma surgery (1516)
general surgery: vascular surgery (1518)
general surgery: plastic surgery (1519)
general surgery: thoracic surgery (1520)
general surgery: orthopedics (1523)
general surgery: intensive care (1536)
general surgery: abdominal- and
vascular surgery (1550)
Allgemeine Chirurgie: hand surgery
(1551)
general surgery (1590)
trauma surgery (1600)
neurosurgery (1700)
vascular surgery (1800)
plastic surgery (1900)
thoracic surgery (2000)
thoracic surgery: cardiac surgery (2021)
thoracic surgery: intensive care (2036)
thoracic surgery: cardiac surgery
intensive care (2050)
thoracic surgery (2090)
cardiac surgery (2100)
cardiac surgery: vascular surgery (2118)
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cardiac surgery: thoracic surgery (2120)
cardiac surgery: intensive care (2136)
cardiac surgery: thoracic surgery and
intensive care (2150)
cardiac surgery (2190)
urology (2200)
orthopedics (2300)
orthopedics: rheumatology (2309)
orthopedics: surgery (2315)
orthopedics and trauma surgery (2316)
orthopedics (2390)
gynecology and obstetrics (2400)
gynecology: geriatry (2402)
gynecology: hematology and internal
oncology  (2405)
gynecology: endocrinology (2406)
gynecology (2425)
gynecology and obstetrics (2490)
obstetrics (2500)
otolaryngology (2600)
ophthalmology (2700)
neurology: (2800)
neurology: pediatrics (2810)
neurology: stroke units (2856)
neurology (2890)
general psychiatry: (2900)
general psychiatry: neurology (2928)
general psychiatry: child and adolescent
psychiatry (2930)
general psychiatry: psychosomatics and
psychotherapy (2931)
general psychiatry: addiction treatment
(2950)
general psychiatry: geropsychiatry
(2951)
general psychiatry: forensic treatment
(2952)
general psychiatry: addiction treatment
(day unit) (2953)
general psychiatry: addiction treatment
(night unit) (2954)
general psychiatry: geropsychiatry (day
unit) (2955)
general psychiatry: geropsychiatry (night
unit) (2956)
general psychiatry: day unit (for semi-
residential care) (2960)
general psychiatry: night unit (for semi-
residential care) (2961)
general psychiatry (2990)
child and adolescent psychiatry (3000)
child and adolescent psychiatry: day unit
(for semi-residential care) (3060)
child and adolescent psychiatry: night
unit (for semi-residential care) (3061)
child and adolescent psychiatry (3090)
psychosomatic/psychotherapy (3100)
psychosomatic/psychotherapy: child and
adolescent psychiatry (3110)
psychosomatic/psychotherapy: day unit
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(for semi-residential care) (3160)
psychosomatic/psychotherapy: night unit
(for semi-residential care) (3161)
psychosomatic/psychotherapy (3190)
nuclear medicine (3200)
nuclear medicine: radiation therapy
(3233)
nuclear medicine (3290)
radiation therapy (3300)
radiation therapy: hematology and
internal oncology  (3305)
radiation therapy: radiology (3350)
radiation therapy (3390)
dermatology (3400)
dermatology: day unit (for semi-
residential care) (3460)
dermatology (3490)
dentistry, orthodontics, maxillofacial
surgery (3500)
intensive-care medicine (3600)
intensive-care medicine: internal
medicine (3601)
intensive-care medicine: cardiology
(3603)
intensive-care medicine: pediatrics
(3610)
intensive-care medicine: neurosurgery
(3617)
intensive-care medicine: surgery (3618)
intensive-care medicine: cardiac surgery
(3621)
intensive-care medicine: urology (3622)
intensive-care medicine: gynecology and
obstetrics (3624)
intensive-care medicine: otolaryngology
(3626)
intensive-care medicine: neurology
(3628)
operative intensive-care medicine:
surgery (3650)
intensive-care medicine: thorax-heart
surgery (3651)
intensive-care medicine: heart-thorax
surgery (3652)
intensive-care medicine (3690)
other medical specialty (3700)
angiology (3750)
radiology (3751)
palliative care (3752)
pain therapy (3753)
section for alternative health practice
(3754)
spinal surgery (3755)
addiction medicine (3756)
visceral surgery (3757)
other medical specialty (3790)
Patient identification number*
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Date of Birth (DD.MM.YYYY)*
Gender*
male (1)
female (2)
Hospital admission date (DD.MM.YYYY)*
Preoperative Clinical Examination
ASA classification*
A normal healthy patient (1)
A patient with mild systemic disease (2)
A patient with severe systemic disease
(3)
A patient with severe systemic disease
that is a constant threat to life (4)
A moribund patient who is not expected
to survive without the operation (5)
Indication of aggregate replacement
Indikation of aggregate (pulse generator)
replacement*
regular battery depletion (1)
dysfunction / return call (2)
other indication (9)
Place of last ICD-(or pacemaker-)Operation
before this procedure*
in-patient, own institution (1)
in-patient, other institution (2)
outpatient, own institution (3)
outpatient, other institution (4)
Applied therapeutical shockings*
no (0)
adequate (1)
inadequate (2)
both (3)
Operation
Operation Date (DD.MM.YY)*
Procedure codes *
Procedure Duration (in minutes)*
intraoperative test of defibrillation*
yes (1)
no, because of intracardiac clots (2)
5 / 9
Quality assurance Implantable Defibrillator: Replacement (AQUA)
no, because of hemodynamic
instability(need of catecholamines or
pulmonary edema) (3)
no, because of other reasons (4)
Safety margin for Defibrillation Test >= 10 J under
aggregate-specific maximum engery
Yes
No
ICD: Implanted ICD-System
ICD-System*
VVI (1)
DDD (2)
VDD (3)
CRT-System with an atrial electrode (4)
CRT-System without atrial electrode (5)
subcutaneous ICD (6)
other (9)
Implanted ICD-Aggregate
Manufacturer*
Biotronik (1)
St. Jude Medical (18)
Nayamed (19)
Boston
Scientific/CPI/Guidant/Intermedics (3)
Medtronic (7)
unknown (89)
Sorin Biomedica/ELA Medical (9)
other (99)
Explanted ICD-System
ICD-System*
VVI (1)
DDD (2)
VDD (3)
CRT-System with an atrial electrode (4)
CRT-System without atrial electrode (5)
subcutaneous ICD (6)
other (9)
Explanted ICD-Aggregate
Year of implantation (YYYY)
unknown
yes (1)
Manufacturer
Biotronik (1)
St. Jude Medical (18)
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Nayamed (19)
Boston
Scientific/CPI/Guidant/Intermedics (3)
Medtronic (7)
unknown (89)
Sorin Biomedica/ELA Medical (9)
other (99)
Left ICD electrodes - Atrium
Sensing threshold (in V)
reason for not having measured
because of atrial fibrillation (1)
other reasons (9)
P wave height
reasons for not having measured
because of atrial fibrillation (1)
missing own atrial rhythm (2)
other reasons (9)
Ventricle
Number of existing ventricular electrodes
one (1)
two (2)
three (3)
First ventricular electrode /defibrillation
electrode
Position
right-ventricular Apex (1)
right-ventricular Septum (2)
other (9)
Sensing threshold(in V)
reason for not having measured
separate pace/sense electrode (1)
other reasons (9)
R wave height
reason for not having measured
separate pace/sense electrode (1)
no own rhythm (2)
other reasons (9)
Second ventricular electrode
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Position
right-ventricular apex (1)
right-ventricular septum (2)
coronary vein, anterior (3)
coronary vein, lateral, posterolateral (4)
coronary vein, posterior (5)
epimyocardial left-ventricular (6)
other (9)
Sensing threshold(in V)
not measured
yes (1)
R wave height
reason for not having measured
missing own rhythm (1)
other reasons (9)
Third ventricular electrode
Position
right-ventricular apex (1)
right-ventricular septum (2)
coronary vein, anterior (3)
coronary vein, lateral, posterolateral (4)
coronary vein, posterior (5)
epimyocardial left-ventricular (6)
other (9)
Sensing threshold (in V)
not measured
yes (1)
R wave height
reason for not having measured
missing own rhythm (1)
other reasons (9)
Perioperative Complications
perioperative complications*
Yes
No
Cardiopulmonary Resuscitation
yes (1)
Hematoma due to pacemaker, requiring action
yes (1)
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postoperative wound infection - according to
definition of CDC classification
yes (1)
CDC classification
A1 (Superficial incisional surgical site
infections) (1)
A2 (Deep incisional surgical site
infections) (2)
A3 (Organ/Space surgical site infections)
(3)
other complications complication, requiring
action(if peri/operative complications existing)
yes (1)
Discharge
Hostpital discharge date  (DD.MM.YYYY)*
Reason for Discharge*
treatment finished as planned (1)
transferral to nursing facility (10)
discharge to hospice (11)
external transferral to psychiatric
treatment (13)
treatment finished because of other
reasons, postdischarge treatment is
planned (14)
treatment aborted against medical
advice, postdischarge treatment is
planned (15)
internal transferral with change of DRG
payment areas (17)
treatment finished as planned,
postdischarge treatment is planned (2)
case termination (internal transferral)
with change between full- and partial
stationary  care (22)
discharge at the end of the year with
admission in previous year (25)
treatment finished because of other
reasons (3)
treatment aborted against medical
advice (4)
change of jurisdiction of insurer or other
payer (5)
transferral to another hospital (6)
death (7)
transferral to another hospital within
cooperative and governmental policies
(8)
transferral to rehabilitation facility (9)
Discharge diagnoses - ICD codes*
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TREATMENT FORM Breast Cancer
(NCT00770809)
CALGB 40601 TREATMENT FORM
Paclitaxel and Trastuzumab With or Without Lapatinib in
Treating Patients With Stage II or Stage III Breast Cancer
That Can Be Removed by Surgery
NCT00770809 
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=3A0519D7-
D7F7-3073-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/6514
TREATMENT FORM Breast Cancer
(NCT00770809)
Header
CALGB Form
CALGB Study No
CALGB Patient ID
Reporting Period Start Date (MM DD YYYY)
Reporting Period End Date (MM DD YYYY)
Patient Initials (Last, First Middle)
Patient Hospital No.
Institution/Affiliate
Participating Group
Participating Group Study No.
Participating Group Patient ID
Are data amended
Yes
No
Comments
Completed by (Last name, First name)
Date form completed (MM DD YYYY)
Bevacizumab/placebo
1 / 3
Assigned Treatment Arm
Arm 1 (Arm 1)
Arm 2 (Arm 2)
Arm 3 (Arm 3)
On Treatment Report Period
Weeks 1-4 (Weeks 1-4)
Weeks 13-16 (Weeks 13-16)
Weeks 5-8 (Weeks 5-8)
Weeks 9-12 (Weeks 9-12)
Bevacizumab/placebo
Agent
Prescribed dose (mg/kg)
Total actual dose of agent/drugs (for this period
mg/kg)
Were there any delays in dose administration
Yes
No
Days Treatment Was Interrupted
Reason dose was delayed
Was treatment discontinued during this period?
Yes
No
Date treatment was discontinued (MM DD YYYY)
Bevacizumab/placebo
Agent
Prescribed dose (mg/kg)
Total actual dose of agent/drugs (for this period
mg/kg)
Were there any delays in dose administration
Yes
No
Days Treatment Was Interrupted
Reason dose was delayed
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Was treatment discontinued during this period?
Yes
No
Specify (Yes)
Date treatment was discontinued (MM DD YYYY)
Bevacizumab/placebo
Agent
Dose used
Total actual dose of agent/drugs (for this period
mg/kg)
Were there any delays in dose administration
Yes
No
Days Treatment Was Interrupted
Reason dose was delayed
Was treatment discontinued during this period?
Yes
No
Date treatment was discontinued (MM DD YYYY)
Muga Results
Time point (Mark one with an X.)
Baseline (baseline)
Other (Other)
Week 8 (Week 8)
Other specify
LVEF (%)
LVEF Institutional Lower Limit of Normal (%)
Has the patient experienced a drop of at least 15
percentage points in the current LVEF compared
with the baseline value
Not Available (NA)
No (No)
Yes (Yes)
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Treatment Form Kidney Cancer
(NCT01198158)
CALGB 90802 Treatment Form
Everolimus With or Without Bevacizumab in Treating
Patients With Advanced Kidney Cancer That Progressed
After First-Line Therapy
NCT01198158
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=87963E33-
F0BE-4A17-E040-BB89AD433B67
All rights reserved. Please visit https://medical-data-
models.org/forms/6517
Treatment Form Kidney Cancer
(NCT01198158)
Header
CALGB Form
CALGB Study No
CALGB Patient ID
Cycle Start Date (MM DD YYYY)
Cycle end date (MM DD YYYY)
Are data amended
Yes
No
Patient Initials (Last, First Middle)
Patient Hospital No.
Institution/Affiliate
Participating Group
Participating Group Study No.
Participating Group Patient ID
Comments
Completed by (Last name, First name)
Date form completed (MM DD YYYY)
Header
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Current Cycle Number
Height (cm)
Weight (kg)
BSA (m^2)
Blood Pressure, Systolic (mm Hg)
Blood pressure, Diastolic (mm Hg)
If the patient is registered to CALGB 580902
were MRIs submitted to the Central Imaging Core
laboratory for
Week 2 (Week 2)
Specify (If no)
Urinalysis
Day of cycle
Day 15 (Day 15)
Urine Protein (OR)
0 (0)
1+ (1+)
2+ (2+)
3+ (3+)
4+ (4+)
Protein from 24 hour Urine Collection (g of
protein/24 hours AND)
Urine Protein/Creatinine Ratio (UPC)
Urinalysis
Gemcitabine
Agent Name
Administered
Yes
No
Specify (If no)
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Agent Total Dose (this cycle mg)
Dose modification
Dose Delayed (Dose delayed)
Dose Delayed And Reduced (Dose
delayed and reduced)
Dose Held (Dose held)
Dose Reduced (Dose reduced)
Drug Discontinued (Drug discontinued)
No Dose Modification (No dose
modification)
Dose Modification Reason
Cardiotoxicity (Cardiotoxicity)
Change In Bsa (Change in BSA)
Cns Toxicity (CNS toxicity)
Dosing Error (Dosing error)
Gi Toxicity (GI toxicity)
Hematologic Toxicity (Hematologic
toxicity)
Hepatic Dysfunction (Hepatic
dysfunction)
Hypersensitivity (Hypersensitivity)
Hypertension (Hypertension)
Infection/fever (Infection/fever)
Other (Other)
Patient Refusal/noncompliance (Patient
refusal/noncompliance)
Pns Toxicity (PNS toxicity)
Pulmonary Toxicity (Pulmonary toxicity)
Renal Toxicity (Renal toxicity)
Scheduling (Scheduling)
If dose modification reason = 99, specify
Unnamed2
Was treatment permanently discontinued during
this cycle (Everolimus)
Yes
No
Reason Treatment Ended (Everolimus)
Adverse Event/side Effects/complications
(Adverse Event/Side
Effects/Complications)
Alternative Therapy (Alternative therapy)
Death On Study (Death on study)
Disease Progression, Relapse During
Active Treatment (Disease progression,
relapse during active treatment)
Other (Other)
Patient Off-treatment For Other
Complicating Disease (Patient off-
treatment for other complicating disease)
Patient Withdrawal Or Refusal After
Beginning Protocol Therapy (Patient
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withdrawal/refusal after beginning
protocol therapy)
Patient Withdrawal Or Refusal Before
Beginning Protocol Therapy (Patient
withdrawal/refusal prior to beginning
protocol therapy)
Treatment Completed Per Protocol
Criteria (Treatment completed per
protocol criteria)
Specify
Total number of cycles completed (Everolimus)
Last dose date (Everolimus MM DD YYYY)
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Rapid Toxicity Reporting Form ANHL01P1
(NCT00057811)
ANHL01P1: Rapid Toxicity Reporting Form
Rituximab, Rasburicase, and Combination Chemotherapy
in Treating Young Patients With Newly Diagnosed
Advanced B-Cell Leukemia or Lymphoma
NCT00057811
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=B9F50C5F-
ABA8-2543-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/6521
Rapid Toxicity Reporting Form
ANHL01P1 (NCT00057811)
Header
Institution
Institution Personnel
Institution Patient Identifier
Today's date
Date worksheet entered into RDE
Clinical Data
Treatment Assignment (Required field)
Consolidation, 1st course (CYM-RM1)
(Consolidation, 1st course (CYM-RM1))
Consolidation, other than CYM-RM1
(Consolidation, other than CYM-RM1)
Induction, 1st Cycle (Induction, 1st
Cycle)
Induction, 2nd cycle (Induction, 2nd
cycle)
Maintenance, Course 1 (Maintenance,
Course 1)
Maintenance, Course 2 (Maintenance,
Course 2)
Maintenance, Course 3 (Maintenance,
Course 3)
Maintenance, Course 4 (Maintenance,
Course 4)
Reduction Phase (Reduction Phase)
Tumor Reduction (Please choose one)
greater than or equal to (>=) 20% tumor
reduction by the end of Reduction
(greater than or equal to (>=) 20% tumor
reduction by the end of Reduction)
less than (<) 20% tumor reduction by the
end of Reduction (less than (<) 20%
tumor reduction by the end of Reduction)
No (no)
Unknown (unknown)
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Yes (yes)
Did patient have residual disease following 1st
cycle (CYM-RM1) of consolidation? (Required for
Consolidation 1st Cycle CYM-RM1 only of Group
B Sub-Pilot or Group B Pilot)
Yes
No
Did patient experience Stevens-Johnson
Syndrome (SJS)? (Required field)
Yes
No
Did patient experience Toxic Epidermal Necrosis
(TEN)? (Required field)
Yes
No
If patient experienced stomatitis, grade?
(Required if stomatitis question is yes.)
Did patient experience delayed recovery?
(Required field)
Yes
No
Number of days of delayed recovery (Required
only if above question is answered yes.)
Toxic Death (Required field)
Adverse Event Has Improved (improved)
No (No)
Adverse Event Is Ongoing (ongoing)
Adverse Event Is Resolved (resolved)
Adverse Event Is Resolved With
Sequelae (resolved with sequelae)
Adverse Event Is Unchanged
(unchanged)
Adverse Event Is Worse (worsened)
Adverse Event Was Fatal (Yes)
COMMENTS
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TREATMENT AND RESPONSE SUMMARY
FORM Breast Cancer (NCT00390455)
CALGB 40302 TREATMENT AND RESPONSE SUMMARY
FORM (SUBSET OF PATIENTS)
Fulvestrant With or Without Lapatinib in Treating
Postmenopausal Women With Stage III or Stage IV Breast
Cancer That is Hormone Receptor-Positive
NCT00390455
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=F5BC1727-
9755-553F-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/6527
TREATMENT AND RESPONSE
SUMMARY FORM Breast Cancer
(NCT00390455)
Header
CALGB Form
CALGB Study No
CALGB Patient ID
Last date of reporting period
Patient Initials
Patient Hospital No
Institution/Affiliate
Participating Group
Participating Group Protocol No
Participating Group Patient ID
Date of last clinical assessment
Are data amended
Yes
No
Lapatinib/placebo
Current cycle number
Cycle start date
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Cycle end date
Number of tablets issued
Prescribed dose
Number of tablets remaining
Actual Dose
Dose Modification (Change)
No (No)
Yes, Planned (i.e., The Treatment Was
Changed According To Protocol
Guidelines) (Yes)
Yes, Unplanned (i.e., The Treatment
Change Was Not Part Of Protocol
Guidelines) (Yes, unplanned)
Modified Dose
Specify reason for modification
Were there any delays in dose administration
Yes
No
Number of days delayed
Specify reason for delay
Fluvestrant
Dose day 1
Dose day 15 cycle 1 (cycle 1 only)
Specify reason for delay
Laboratory Values
Heart LVEF Test Percentage Value (%)
Lab, Hematology, INR
Peripheral Granulocytes Count
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Peripheral Platelet Count
Creatinine
Bilirubin
Lab, Hepatic, SGOT
Lab, Hepatic, SGPT
Response Assessment
Has the patient achieved a response?
Yes
No
Partial response first observed date (PR)
Complete response first observed date (CR)
Has the patient been diagnosed with a new
progression (during this reporting period not
previously reported?)
Yes
No
No, specify
Date response last documented
Yes, specify
Progressive disease first observed date (PD)
Progressive disease documentation (Mark one
with an X.)
Progressive Disease Defined By New
Lesions (Appearance of one or more
new lesions)
Nontarget Lesions (unequivocal
Progression Of Existing Nontarget
Lesions) (Nontarget lesions)
Other, Specify (Other)
Target Lesions (at Least A 20% Increase
In The Sum Of Longest Diameters Of
Target Lesions, Taking As Reference The
Smallest Sum Recorded Since The
Treatment Started) (Target lesions)
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Other, specify
Completed by (Last name, First name)
Date form completed
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Quality assurance Implantable Defibrillator:
Revision/System-Change/Explantation (AQUA)
Documentation form for quality assurance in German
Health Care by the Institute for Applied Quality
Improvement and Research in Health Care (Aqua),
https://www.aqua-institut.de/en/home. Internal Aqua form
version: 09-6 Specification 2015 V02
All rights reserved. Please visit https://medical-data-
models.org/forms/6529
Quality assurance Implantable
Defibrillator: Revision/System-
Change/Explantation (AQUA)
Basic documentation
Healthcare Facility Identifier *
Zip Code of Discharge*
Facility's Section Identifier
Medical specialty*
internal medicine (0100)
internal medicine: geriatrics (0102)
internal medicine: cardiology (0103)
internal medicine: nephrology (0104)
internal medicine: hematology and
internal oncology  (0105)
internal medicine: endocrinology (0106)
internal medicine: gastroenterology
(0107)
internal medicine: pneumonology (0108)
internal medicine: rheumatology (0109)
internal medicine: pulmonology (0114)
internal medicine: tumor research (0150)
internal medicine: coloproctology (0151)
internal medicine: infectiology (0152)
internal medicine: diabetes (0153)
internal medicine: naturopathy (0154)
internal medicine: stroke unit (0156)
internal medicine (0190)
geriatry (0200)
geriatry: gynecology  (0224)
geriatry: day unit (for semi-residential
care)   (0260)
geriaty: night unit (for semi-residential
care) (0261)
geriatry (0290)
cardiology (0300)
nephrology (0400)
nephrology: pediatrics (0410)
nephrology: intensive care (0436)
nephrology (0490)
hematology and internal oncology
(0500)
hematology and internal oncology:
pediatrics (0510)
hematology and internal oncology:
gynacology (0524)
hematology and internal oncology:
radiation therapy (0533)
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hematology and internal oncology
(0590)
endocrinology (0600)
endicrinology: gastroenterology (0607)
endocrinology: pediatrics (0610)
endocrinology (0690)
gastroenterology (0700)
gastroenterology: endocrinology (0706)
gastroenterology: pediatrics (0710)
gastroenterology (0790)
pneumology (0800)
rheumatology (0900)
rheumatology: pediatrics (0910)
rheumatology (0990)
pediatrics (1000)
pediatrics: nephrology (1004)
pediatrics: hematology and internal
oncology  (1005)
pediatrics: endocrinology (1006)
pediatrics: gastroenterology (1007)
pediatrics: rheumatology (1009)
pediatrics: pediatric cardiology (1011)
pediatrics: nephrology (1012)
pediatrics: pulmonology (1014)
pediatrics: pediatric neurology (1028)
pediatrics: perinatal medicine (1050)
continuing care for children (1051)
pediatrics (1090)
pediatric cardiology (1100)
pediatric cardiology: intensive care
(1136)
pediatric cardiology (1190)
neonatology (1200)
pediatric surgery (1300)
pulmonology (1400)
pulmonology: pediatrics (1410)
pulmonology (1490)
general surgery (1500)
general surgery: pediatric surgery (1513)
general surgery: trauma surgery (1516)
general surgery: vascular surgery (1518)
general surgery: plastic surgery (1519)
general surgery: thoracic surgery (1520)
general surgery: orthopedics (1523)
general surgery: intensive care (1536)
general surgery: abdominal- and
vascular surgery (1550)
Allgemeine Chirurgie: hand surgery
(1551)
general surgery (1590)
trauma surgery (1600)
neurosurgery (1700)
vascular surgery (1800)
plastic surgery (1900)
thoracic surgery (2000)
thoracic surgery: cardiac surgery (2021)
thoracic surgery: intensive care (2036)
thoracic surgery: cardiac surgery
intensive care (2050)
thoracic surgery (2090)
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cardiac surgery (2100)
cardiac surgery: vascular surgery (2118)
cardiac surgery: thoracic surgery (2120)
cardiac surgery: intensive care (2136)
cardiac surgery: thoracic surgery and
intensive care (2150)
cardiac surgery (2190)
urology (2200)
orthopedics (2300)
orthopedics: rheumatology (2309)
orthopedics: surgery (2315)
orthopedics and trauma surgery (2316)
orthopedics (2390)
gynecology and obstetrics (2400)
gynecology: geriatry (2402)
gynecology: hematology and internal
oncology  (2405)
gynecology: endocrinology (2406)
gynecology (2425)
gynecology and obstetrics (2490)
obstetrics (2500)
otolaryngology (2600)
ophthalmology (2700)
neurology: (2800)
neurology: pediatrics (2810)
neurology: stroke units (2856)
neurology (2890)
general psychiatry: (2900)
general psychiatry: neurology (2928)
general psychiatry: child and adolescent
psychiatry (2930)
general psychiatry: psychosomatics and
psychotherapy (2931)
general psychiatry: addiction treatment
(2950)
general psychiatry: geropsychiatry
(2951)
general psychiatry: forensic treatment
(2952)
general psychiatry: addiction treatment
(day unit) (2953)
general psychiatry: addiction treatment
(night unit) (2954)
general psychiatry: geropsychiatry (day
unit) (2955)
general psychiatry: geropsychiatry (night
unit) (2956)
general psychiatry: day unit (for semi-
residential care) (2960)
general psychiatry: night unit (for semi-
residential care) (2961)
general psychiatry (2990)
child and adolescent psychiatry (3000)
child and adolescent psychiatry: day unit
(for semi-residential care) (3060)
child and adolescent psychiatry: night
unit (for semi-residential care) (3061)
child and adolescent psychiatry (3090)
psychosomatic/psychotherapy (3100)
psychosomatic/psychotherapy: child and
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adolescent psychiatry (3110)
psychosomatic/psychotherapy: day unit
(for semi-residential care) (3160)
psychosomatic/psychotherapy: night unit
(for semi-residential care) (3161)
psychosomatic/psychotherapy (3190)
nuclear medicine (3200)
nuclear medicine: radiation therapy
(3233)
nuclear medicine (3290)
radiation therapy (3300)
radiation therapy: hematology and
internal oncology  (3305)
radiation therapy: radiology (3350)
radiation therapy (3390)
dermatology (3400)
dermatology: day unit (for semi-
residential care) (3460)
dermatology (3490)
dentistry, orthodontics, maxillofacial
surgery (3500)
intensive-care medicine (3600)
intensive-care medicine: internal
medicine (3601)
intensive-care medicine: cardiology
(3603)
intensive-care medicine: pediatrics
(3610)
intensive-care medicine: neurosurgery
(3617)
intensive-care medicine: surgery (3618)
intensive-care medicine: cardiac surgery
(3621)
intensive-care medicine: urology (3622)
intensive-care medicine: gynecology and
obstetrics (3624)
intensive-care medicine: otolaryngology
(3626)
intensive-care medicine: neurology
(3628)
operative intensive-care medicine:
surgery (3650)
intensive-care medicine: thorax-heart
surgery (3651)
intensive-care medicine: heart-thorax
surgery (3652)
intensive-care medicine (3690)
other medical specialty (3700)
angiology (3750)
radiology (3751)
palliative care (3752)
pain therapy (3753)
section for alternative health practice
(3754)
spinal surgery (3755)
addiction medicine (3756)
visceral surgery (3757)
other medical specialty (3790)
Patient identification number*
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Quality assurance Implantable Defibrillator: Revision/System-
Change/Explantation (AQUA)
Date of Birth (DD.MM.YYYY)*
Gender*
male (1)
female (2)
Hospital admission date (DD.MM.YYYY)*
Preoperative Clinical Examination
ASA classification*
A normal healthy patient (1)
A patient with mild systemic disease (2)
A patient with severe systemic disease
(3)
A patient with severe systemic disease
that is a constant threat to life (4)
A moribund patient who is not expected
to survive without the operation (5)
Wound contamination classifcation of  procedure
(according to CDC definition)*
CodelistItem 347793 (1)
CodelistItem 347794 (2)
CodelistItem 347795 (3)
CodelistItem 347796 (4)
Indication of Revision/System change/
Explantation
Aggregate problem
CodelistItem 347797 (1)
CodelistItem 347798 (2)
CodelistItem 347799 (3)
CodelistItem 347800 (4)
CodelistItem 347801 (9)
Problems of pacemaker pocket
Pocket hematoma (1)
perforation by pulse generator (2)
infection (3)
other problem (9)
Problems of electrodes
yes (1)
ineffektive defibrillation
yes (1)
Applied therapeutical shockings*
no (0)
adequate (1)
inadequate (2)
both (3)
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Change/Explantation (AQUA)
Operation
Operation Date (DD.MM.YY)*
Place of last ICD-(or pacemaker-)Operation
before this procedure*
in-patient, own institution (1)
in-patient, other institution (2)
outpatient, own institution (3)
outpatient, other institution (4)
Procedure codes *
Procedure Duration (in minutes)*
Dose Area product (cGy)* cm²)
unknown Dose Area Product
yes (1)
intraoperative test of defibrillation*
CodelistItem 347817 (1)
CodelistItem 347818 (2)
CodelistItem 347819 (3)
CodelistItem 347820 (4)
Safety margin for Defibrillation Test >= 10 J under
aggregate-specific maximum engery
Yes
No
ICD -ICD-System
active System (after applied procedure)*
none (explantation or deactivation) (0)
VVI (1)
DDD (2)
VDD (3)
CRT-System with atrial electrode (4)
CRT-System without atrial electrode (5)
subcutaneous ICD (6)
other (9)
ICD-Aggregat
Kind of procedure*
aggregate (pulse generator) not existing
(0)
no intervention on aggregate (1)
replacement (2)
aggregate-explantation and implantation
of new aggregate contralaterally (3)
aggregate repositioning (4)
explantation (5)
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Change/Explantation (AQUA)
sonstiges (9)
Manufacturer of active aggregate (after applied
procedure)
Biotronik (1)
St. Jude Medical (18)
Nayamed (19)
Boston
Scientific/CPI/Guidant/Intermedics (3)
Medtronic (7)
unknown (89)
Sorin Biomedica/ELA Medical (9)
other (99)
Aggregate position
infraclavicular subcutaneous (1)
infraclavicular subfascial (2)
infraclavicular submuscular (3)
abdominal (4)
other (9)
explanted system
VVI (1)
DDD (2)
VDD (3)
CRT-System with an atrial electrode (4)
CRT-System without atrial electrode (5)
subcutaneous ICD (6)
other (9)
Year of implantation (YYYY)
unknown
yes (1)
Manufacturer of explanted Aggregate
Biotronik (1)
St. Jude Medical (18)
Nayamed (19)
Boston
Scientific/CPI/Guidant/Intermedics (3)
Medtronic (7)
unknown (89)
Sorin Biomedica/ELA Medical (9)
other (99)
ICD electrodes - Atrium
Kind of procedure
no intervention on electrode (0)
new implantation and deactivation of old
electrode (1)
new implantation and removal of old
electrode (replacement) (2)
new further implantation (3)
respositioning of electrode (4)
repair (5)
explantation (6)
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Change/Explantation (AQUA)
deactivation of whole electrode (7)
other (99)
Problem
dislocation (1)
electrode defect/insulation problem (2)
dysfunctional connection (3)
diaphracmatic or pectoral flutter (4)
inhibition through other muscular action
potentials/ oversensing (5)
sensing defect/Undersensing (6)
stimulation deficit/increase of sensing
threshold (7)
infection (8)
myocardial perforation (9)
other (99)
Time interval to implantation of revised or
explanted pace/sensing eletrode respectively
< 1 year (1)
> 1 year (2)
unknown (9)
Manufacturer of resived or explanted
Pace/Sense-Sonde respectively
Biotronik (1)
St. Jude Medical (18)
Nayamed (19)
Boston
Scientific/CPI/Guidant/Intermedics (3)
Medtronic (7)
unknown (89)
Sorin Biomedica/ELA Medical (9)
other (99)
Sensing threshold(in V)
reason for not having measured
because of atrial fibrillation (1)
other reasons (9)
P wave height
reason for not having measured
because of atrial fibrillation (1)
missing own atrial rhythm (2)
other reasons (9)
First ventricular electrode /defibrillation
electrode
Kind of procedure
no intervention on electrode (0)
new implantation and deactivation of old
electrode (1)
new implantation and removal of old
electrode (replacement) (2)
8 / 15
Quality assurance Implantable Defibrillator: Revision/System-
Change/Explantation (AQUA)
new further implantation (3)
respositioning of electrode (4)
repair (5)
Explantation (6)
deactivation of whole electrode (7)
other (99)
R wave height
not having measured
separate pace/sense electrode (1)
other reasons (9)
Sensing threshold(in V)
Position
right-ventricular Apex (1)
right-ventricular Septum (2)
other (9)
Defibrillation electrodes
Single Coil (1)
Dual Coil (2)
other (9)
Manufacturer of revised/explanted (respectively)
first ventricular/defibrillation electrode
Biotronik (1)
St. Jude Medical (18)
Nayamed (19)
Boston
Scientific/CPI/Guidant/Intermedics (3)
Medtronic (7)
unknown (89)
Sorin Biomedica/ELA Medical (9)
other (99)
Timeinterval to Implantation of revised/explanted
(respectively)  first ventricular/defibrillation
electrode
< 1 year (1)
> 1 year (2)
unknown (9)
Problem
system change (0)
dislocation (1)
ineffective defibrillation (10)
electrode damage or insulation defect (2)
connection defect (3)
diaphragm or pectoralis flutter (4)
oversensing (5)
undersensing (6)
decrease of stimulation or increase of
sensing threshold (7)
infektion (8)
myocardial perforation (9)
other (99)
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Change/Explantation (AQUA)
not measured
separate pace/sense electrode (1)
no own atrial rhythm  (2)
other reasons (9)
Second ventricular electrode
Kind of procedure
no intervention on electrode (0)
new implantation and deactivation of old
electrode (1)
new implantation and removal of old
electrode (replacement) (2)
new further implantation (3)
respositioning of electrode (4)
repair (5)
Explantation (6)
deactivation of whole electrode (7)
other (99)
Problem
system change (0)
dislocation (1)
ineffective defibrillation (10)
electrode damage or insulation defect (2)
connection defect (3)
diaphragm or pectoralis flutter (4)
oversensing (5)
undersensing (6)
decrease of stimulation or increase of
sensing threshold (7)
infektion (8)
myocardial perforation (9)
other (99)
Timeinterval to Implantation of revised/explanted
(respectively)  second ventricular/defibrillation
electrode
< 1 year (1)
> 1 year (2)
unknown (9)
Manufacturer of revised/explanted (respectively)
second ventricular/defibrillation electrode
Biotronik (1)
St. Jude Medical (18)
Nayamed (19)
Boston
Scientific/CPI/Guidant/Intermedics (3)
Medtronic (7)
unknown (89)
Sorin Biomedica/ELA Medical (9)
other (99)
Position
right-ventricular apex (1)
right-ventricular septum (2)
coronary vein, anterior (3)
coronary vein, lateral, posterolateral (4)
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Change/Explantation (AQUA)
coronary vein, posterior (5)
epimyocardial left-ventricular (6)
other (9)
Sensing threshold (in V)
not measured
yes (1)
R wave height
not gemessen
no own rhythm (1)
other reasons (9)
Third ventricular electrode
Kind of procedure
no intervention on electrode (0)
new implantation and deactivation of old
electrode (1)
new implantation and removal of old
electrode (replacement) (2)
new further implantation (3)
respositioning of electrode (4)
repair (5)
Explantation (6)
deactivation of whole electrode (7)
other (99)
Problem
system change (0)
dislocation (1)
ineffective defibrillation (10)
electrode damage or insulation defect (2)
connection defect (3)
diaphragm or pectoralis flutter (4)
oversensing (5)
undersensing (6)
decrease of stimulation or increase of
sensing threshold (7)
infektion (8)
myocardial perforation (9)
other (99)
Timeinterval to Implantation of revised/explanted
(respectively)  third ventricular/defibrillation
electrode
< 1 year (1)
> 1 year (2)
unknown (9)
Manufacturer of revised/explanted (respectively)
third ventricular/defibrillation electrode
Biotronik (1)
St. Jude Medical (18)
Nayamed (19)
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Change/Explantation (AQUA)
Boston
Scientific/CPI/Guidant/Intermedics (3)
Medtronic (7)
unknown (89)
Sorin Biomedica/ELA Medical (9)
other (99)
Position
CodelistItem 348017 (1)
CodelistItem 348018 (2)
CodelistItem 348019 (3)
CodelistItem 348020 (4)
CodelistItem 348021 (5)
CodelistItem 348022 (6)
CodelistItem 348023 (9)
Sensing threshold(in V)
not measured
yes (1)
R wave height
reason for not having measured
no own rhythm (1)
other reasons (9)
Other defibrillator electrodes
Kind of procedure
no intervention on electrode (0)
new implantation and deactivation of old
electrode (1)
new implantation and removal of old
electrode (replacement) (2)
new further implantation (3)
respositioning of electrode (4)
repair (5)
explantation (6)
deactivation of whole electrode (7)
other (99)
Problem
system change (0)
dislocation (1)
electrode damage or insulation defect (2)
connection defect (3)
infection (4)
myocardial perforation (5)
ineffektive Defibrillation (6)
other (9)
Timeinterval to Implantation of revised/explanted
(respectively)  other defibrillation electrodes
< 1 year (1)
> 1 year (2)
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Change/Explantation (AQUA)
unknown (9)
Manufacturer of revised/explanted (respectively)
other ventricular/defibrillation electrode
Biotronik (1)
St. Jude Medical (18)
Nayamed (19)
Boston
Scientific/CPI/Guidant/Intermedics (3)
Medtronic (7)
unknown (89)
Sorin Biomedica/ELA Medical (9)
other (99)
Position
superior vena cava (1)
subclavian vein (2)
right atrium (3)
subcutaneous (sub-Q-Array) (4)
subcutaneous (S-ICD) (5)
epimyocardial (Patch-Elektrode) (6)
multiple (7)
other (9)
Further inactive or explanted electrodes
further inactive/deactivated electrodes*
Yes
No
further explanted electrodes*
Yes
No
Perioperative Complications
perioperative complications*
Yes
No
Cardiopulmonary Resuscitation
yes (1)
Pneumothorax, requiring action
yes (1)
Hemathorax, requiring actionx
yes (1)
Pericardial effusion, requiring action
yes (1)
Hematoma due to pacemaker, requiring action
yes (1)
Electrode displacement, requiring action
yes (1)
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Change/Explantation (AQUA)
Location of electrode dislocation
Atrium
yes (1)
First ventricular electrode/ defibrillation electrode
yes (1)
Second ventricular electrode
yes (1)
Third ventricular electrode
yes (1)
Other defibrillation electrode
yes (1)
further inactive/deactivated electrode
yes (1)
Electrode dysfunction, requiring action
yes (1)
Location of electrode dysfunction
Atrium
yes (1)
First ventricular electrode /defibrillation electrode
yes (1)
Second ventricular electrode
yes (1)
Third ventricular electrode
yes (1)
Other defibrillation electrode
yes (1)
postoperative wound infection - according to
definition of CDC classification
yes (1)
CDC classification
A1 (Superficial incisional surgical site
infections) (1)
A2 (Deep incisional surgical site
infections) (2)
A3 (Organ/Space surgical site infections)
(3)
other complications complication, requiring
action(if peri/operative complications existing)
yes (1)
Discharge
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Quality assurance Implantable Defibrillator: Revision/System-
Change/Explantation (AQUA)
Hostpital discharge date  (DD.MM.YYYY)*
Reason for Discharge*
treatment finished as planned (1)
transferral to nursing facility (10)
discharge to hospice (11)
external transferral to psychiatric
treatment (13)
treatment finished because of other
reasons, postdischarge treatment is
planned (14)
treatment aborted against medical
advice, postdischarge treatment is
planned (15)
internal transferral with change of DRG
payment areas (17)
treatment finished as planned,
postdischarge treatment is planned (2)
case termination (internal transferral)
with change between full- and partial
stationary  care (22)
discharge at the end of the year with
admission in previous year (25)
treatment finished because of other
reasons (3)
treatment aborted against medical
advice (4)
change of jurisdiction of insurer or other
payer (5)
transferral to another hospital (6)
death (7)
transferral to another hospital within
cooperative and governmental policies
(8)
transferral to rehabilitation facility (9)
Discharge diagnoses - ICD codes*
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Erhebungsbogen Nachuntersuchung
Neuropsychologie SHT-Register
Erhebungsdatum
Datum der Erhebung*
Unfalldatum*
Aufmerksamkeit
D2 RW (Rohwert)*
D2 RW (in %)*
D2 RW-F (Rohwert)*
D2 RW-F (in %)*
D2 F% (Rohwert)*
D2 F% (in %)*
Wechsler-Batterie Zahlen-Symbol-Test (bearb.
Items) (Rohwert)*
Wechsler-Batterie Zahlen-Symbol-Test (bearb.
Items) (in Wertpunkten)*
Wechsler-Batterie Trail-Making-A (Zeit)
(Rohwert)*
Wechsler-Batterie Trail-Making-A (Zeit) (in %)*
Wechsler-Batterie Trail-Making-B (Zeit)
(Rohwert)*
Wechsler-Batterie Trail-Making-B (Zeit) (in %)*
Lernen / Gedächtnis
VLMT, 1. Durchgang (Rohwert)*
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VLMT, 1. Durchgang (in %)*
VLMT, Summe 1.-5. Durchgang (Rohwert)*
VLMT, Summe 1.-5. Durchgang (in %)*
VLMT, Ablenkungsliste (Rohwert)*
VLMT, Ablenkungsliste (in %)*
VLMT, Interferenz (Rohwert)*
VLMT, Interferenz (in %)*
VLMT, verzögerter Abruf (Rohwert)*
VLMT, verzögerter Abruf (in %)*
VLMT, Wiedererkennen (Rohwert)*
VLMT, Wiedererkennen (in %)*
Wechsler-Batterie Zahlennachsprechen (vorw.;
max. Anzahl) (Rohwert)*
Wechsler-Batterie Zahlennachsprechen (vorw.;
max. Anzahl) (in Wertpunkten)*
Wechsler-Batterie Zahlennachsprechen (rückw.;
max. Anzahl) (Rohwert)*
Wechsler-Batterie Zahlennachsprechen (rückw.;
max. Anzahl) (in Wertpunkten)*
Wechsler-Batterie Zahlennachsprechen
(Gesamtwert) (Rohwert)*
Wechsler-Batterie Zahlennachsprechen
(Gesamtwert) (in Wertpunkten)*
Verzögerte Kopie der Rey-Osterrieth-Figur
(Rohwert)*
Verzögerte Kopie der Rey-Osterrieth-Figur (Z-
Wert)*
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Exekutive
Kopie der Rey-Osterrieth-Figur (Score)
(Rohwert)*
Kopie der Rey-Osterrieth-Figur (Score) (Z-Wert)*
Wort-Fluency (alternierend Sportarten-Tiere; jew.
1 Min.) ab 8. Lj. (Rohwert)*
Wort-Fluency (alternierend Sportarten-Tiere; jew.
1 Min.) ab 8. Lj. (in %)*
BUEVA II
Nonverbale Intelligenz (Rohwert)*
Nonverbale Intelligenz (T-Wert)*
Verbale Intelligenz (Rohwert)*
Verbale Intelligenz (T-Wert)*
Visuomotorik - fakultativ- (Rohwert)*
Visuomotorik - fakultativ- (T-Wert)*
Artikulation - fakultativ- (Rohwert)*
Artikulation - fakultativ- (T-Wert)*
Expressive Sprache (Rohwert)*
Expressive Sprache (T-Wert)*
Aufmerksamkeit, Richtige (Rohwert)*
Aufmerksamkeit, Richtige (T-Wert)*
Aufmerksamkeit, Verwechslungsfehler (Rohwert)*
Aufmerksamkeit, Verwechslungsfehler: kritischer
Wert erreicht?*
Ja
Nein
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Arbeitsgedächtnis (Rohwert)*
Arbeitsgedächtnis (T-Wert)*
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Stammdaten und Anamnese
Stammdaten
Erfassungsdatum*
Lebensalter (Jahren und Monaten als
Dezimalzahl)*
Geschlecht*
männlich (1)
weiblich (2)
Todeszeitpunkt*
Kostenträger
Kostenträger*
Gesetzliche Krankenkasse (1)
Private Krankenkasse (2)
Haftpflichtversicherung (3)
Berufsgenossenschaft (4)
Unfallkasse (5)
Rente (6)
Kostenträgerwechsel*
Ja
Nein
Wann fand der Kostenträgerwechsel statt?*
Zu welchem Kostenträger wurde gewechselt?*
Gesetzliche Krankenkasse (1)
Private Krankenkasse (2)
Haftpflichtversicherung (3)
Berufsgenossenschaft (4)
Unfallkasse (5)
Rente (6)
Schulbildung des Patienten
Aktuelle Schulklasse*
Schulbildung*
Kindergarten (1)
Grundschule (2)
Förderschule für Kinder mit geistiger
Behinderung (3)
Förderschule für Kinder mit körperlicher
Behinderung (4)
Volksschule / Hauptschule (5)
Realschule (6)
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Gymnasium (7)
Gesamtschule (8)
Berufsschule (9)
Höchster erreichter Schulabschluss*
kein Abschluss (1)
Sonderschulabschluss (2)
Hauptschul-/Volksschulabschluss (3)
Realschulabschluss (4)
(Fach-)Abitur (5)
(Fach-)Abitur und Berufsschule (6)
Hochschulabschluss (7)
anderer Schulabschluss (8)
unbekannt (9)
Sprachkenntnisse des Patienten
Muttersprache*
Deutschkenntnisse*
schlecht (1)
mittel (2)
wie Muttersprache (3)
unbekannt (4)
Migrationshintergrund*
Ja
Nein
Eltern
Familienstand (Eltern)*
ledig (1)
verheiratet oder eingetragene
Lebensgemeinschaft (2)
zusammenlebend (3)
geschieden (4)
verwitwet (5)
unbekannt (6)
Muttersprache (Mutter)*
Muttersprache (Vater)*
Deutschkenntnisse (Mutter)*
schlecht (1)
mittel (2)
wie Muttersprache (3)
unbekannt (4)
Deutschkenntnisse (Vater)*
schlecht (1)
mittel (2)
wie Muttersprache (3)
unbekannt (4)
Berufstätigkeit (Mutter)*
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Anlern (1)
Lehre (2)
Fachschule (3)
Hochschule (4)
Hausfrau (5)
arbeitslos (6)
nicht anwendbar (7)
unbekannt (8)
Berufstätigkeit (Vater)*
Anlern (1)
Lehre (2)
Fachschule (3)
Hochschule (4)
Hausfrau (5)
arbeitslos (6)
nicht anwendbar (7)
unbekannt (8)
Erwachsene Patienten
Familienstand*
ledig (1)
verheiratet oder eingetragene
Lebensgemeinschaft (2)
zusammenlebend (3)
geschieden (4)
verwitwet (5)
unbekannt (6)
Berufstätigkeit*
Anlern (1)
Lehre (2)
Fachschule (3)
Hochschule (4)
Hausfrau (5)
arbeitslos (6)
nicht anwendbar (7)
unbekannt (8)
Ruhestand / Berentung*
nein (1)
altersgemäß (2)
vorzeitig (3)
unbekannt (4)
Vorerkrankungen
Vorerkrankungen nach ICD*
Medikamente / Genussmittel
Medikation*
Alkohol*
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Nikotin*
Andere Substanzen*
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Erhebungsbogen Akutversorgung
und Hospitalphase
Unfallzeitpunkt und Einweisungsart
Datum des Unfalls*
Uhrzeit des Unfalls in hh:mm*
Pubertätsstatus beim Unfall*
präpubertär (1)
postpubertär (2)
Einweisungsart*
RTW (1)
NAW (2)
Hubschrauber (3)
Hausarzt (4)
selbst (5)
Unfallort
Unfallort: *
Straße (1)
Öffentlicher Ort, z. B.
Bahnhof/Bushaltestelle (2)
Häusliche Umgebung (3)
Arbeit/Schule (4)
Sport/Freizeitaktivitäten (5)
Sonstige: Freitext*
Unfallursache
Verkehrsunfall*
Ja
Nein
Sturz*
Fallhöhe aus dem Stand/Lauf (1)
Fallhöhe > 1 m (2)
Sturz von …: Freitext*
Sonstiger Unfall*
Ja
Nein
Gewalt/körperlicher Angriff*
Ja
Nein
1 / 13
Kindsmisshandlung*
Ja
Nein
Schütteltrauma*
Ja
Nein
sonstige Gewalteinwirkung als Freitext*
Selbstmordversuch*
Ja
Nein
Unfallmechanismus
Akzeleration/Dezeleration*
Ja
Nein
Direkte Krafteinwirkung auf den Kopf*
Ja
Nein
Direkte Krafteinwirkung: Kopf gegen Objekt*
Ja
Nein
Einklemmung/crush*
Ja
Nein
Fall*
Ja
Nein
Bei Verkehrsunfall
Patient*
Autofahrer (1)
Autoinsasse (2)
Motorrad (3)
Moped (4)
Fußgänger (5)
Radfahrer (6)
sonstige*
Gegnerische Partei*
LKW (1)
PKW (2)
Fußgänger (3)
Radfahrer (4)
Motorrad (5)
Moped (6)
sonstiges Hindernis (7)
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keine andere Partei (8)
sonstige (Freitext)*
Sicherheitsvorkehrungen
Helm*
Ja
Nein
Airbag*
Ja
Nein
Sicherheitsgurt*
Ja
Nein
Sicherheitskleidung*
ja (1)
nein (2)
nicht anwendbar (3)
unklar (4)
Zeitlicher Verlauf
Uhrzeit Eintreffen NAW in hh:mm*
Uhrzeit Eintreffen im ersten Krankenhaus in
hh:mm (daraus Berechnung der "time to
hospital"*
Uhrzeit Eintreffen im Maximalversorger in hh:mm*
Spätvorstellung *
ja (1)
nein (2)
unklar (3)
Zeit nach Ereignis in hh:mm*
Strukturqualität des erstversorgenden
Krankenhauses
NCh*
Ja
Nein
Kinderintensivstation*
Ja
Nein
Unfallchirurgie*
Ja
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Nein
Maximalversorger*
Ja
Nein
GCS (Notarzt)
Augen öffnen (Notarzt)*
keine Reaktion (1)
auf Schmerzreiz (2)
auf Ansprache (3)
spontan (4)
Sprache (Notarzt)*
keine Antwort (1)
unverständlich (2)
inadäquat (3)
desorientiert (4)
orientiert (5)
Motorik (Notarzt)*
keine Reaktion (1)
Streckreaktion (2)
Beugereaktion (3)
ungezielte Schmerzabwehr (4)
gezielte Schmerzabwehr (5)
befolgt Aufforderungen (6)
Glasgow Coma Scale (Notarzt)*
Pupillenreaktion
Lichtreaktion links*
positiv (1)
negativ (2)
zweifelhaft (3)
nicht beurteilbar (4)
Lichtreaktion rechts*
positiv (1)
negativ (2)
zweifelhaft (3)
nicht beurteilbar (4)
Vitalparameter Notarzt
HF pro Minute: min-1*
Minim. RR: mmHg*
Minim. SO2: %*
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BZ: mg/dl*
Körpertemperatur: °C*
Reanimation
Reanimation*
Ja
Nein
Reanimation: Dauer (in Minuten)*
Beatmung
Intubation*
Ja
Nein
Datum der Intubation*
Uhrzeit der Intubation in hh:mm*
Beatmung*
Ja
Nein
Beatmungsdauer in dd:hh:mm*
Hyperventilation*
Ja
Nein
Kreislauftherapie
Volumensubst.*
ja (1)
nein (2)
unklar (3)
Katecholamine*
ja (1)
nein (2)
unklar (3)
Schweregrad des Schädelhirntraumas
Time of assessment (CDE Modul)*
Unfallort (1)
Aufnahme im Krankenhaus (2)
post Stabilisierung (3)
5 / 13
Erhebungsbogen Akutversorgung – Prähospitalphase SHT Register
Conditions of assessment (CDE Modul)*
vor Sedierung (1)
nach Sedierung (2)
Bewusstlosigkeit*
Ja
Nein
Bewusstlosigkeit / Dauer in dd:hh:mm*
Art des Schädelhirntrauma*
offen (1)
geschlossen (2)
penetrierend (3)
Polytrauma
Polytrauma*
ja (1)
nein (2)
unklar (3)
Körperregionen nach abbreviated injury
score/AIS (1-6)
Externa/Haut*
keine, keine Behandlung notwendig (0)
minimal, keine Behandlung notwendig
(1)
mittelgradig, lediglich ambulante
Behandlung notwendig (2)
ernst, stationäre nicht-intensive
Behandlung notwendig (3)
schwer, intensivmedizinische
Überwachung (4)
kritisch, erfordert Intubation & Beatmung
oder Kreislaufunterstützung (5)
maximal, ohne Überlebensmöglichkeit
(6)
Kopf/Hals*
keine, keine Behandlung notwendig (0)
minimal, keine Behandlung notwendig
(1)
mittelgradig, lediglich ambulante
Behandlung notwendig (2)
ernst, stationäre nicht-intensive
Behandlung notwendig (3)
schwer, intensivmedizinische
Überwachung (4)
kritisch, erfordert Intubation & Beatmung
oder Kreislaufunterstützung (5)
maximal, ohne Überlebensmöglichkeit
(6)
Gesicht*
keine, keine Behandlung notwendig (0)
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minimal, keine Behandlung notwendig
(1)
mittelgradig, lediglich ambulante
Behandlung notwendig (2)
ernst, stationäre nicht-intensive
Behandlung notwendig (3)
schwer, intensivmedizinische
Überwachung (4)
kritisch, erfordert Intubation & Beatmung
oder Kreislaufunterstützung (5)
maximal, ohne Überlebensmöglichkeit
(6)
Brustkorb/Rücken*
keine, keine Behandlung notwendig (0)
minimal, keine Behandlung notwendig
(1)
mittelgradig, lediglich ambulante
Behandlung notwendig (2)
ernst, stationäre nicht-intensive
Behandlung notwendig (3)
schwer, intensivmedizinische
Überwachung (4)
kritisch, erfordert Intubation & Beatmung
oder Kreislaufunterstützung (5)
maximal, ohne Überlebensmöglichkeit
(6)
Abdomen/Beckenorgane*
keine, keine Behandlung notwendig (0)
minimal, keine Behandlung notwendig
(1)
mittelgradig, lediglich ambulante
Behandlung notwendig (2)
ernst, stationäre nicht-intensive
Behandlung notwendig (3)
schwer, intensivmedizinische
Überwachung (4)
kritisch, erfordert Intubation & Beatmung
oder Kreislaufunterstützung (5)
maximal, ohne Überlebensmöglichkeit
(6)
Extremitäten/Beckengürtel*
keine, keine Behandlung notwendig (0)
minimal, keine Behandlung notwendig
(1)
mittelgradig, lediglich ambulante
Behandlung notwendig (2)
ernst, stationäre nicht-intensive
Behandlung notwendig (3)
schwer, intensivmedizinische
Überwachung (4)
kritisch, erfordert Intubation & Beatmung
oder Kreislaufunterstützung (5)
maximal, ohne Überlebensmöglichkeit
(6)
Rückenmarkverletzung
7 / 13
Erhebungsbogen Akutversorgung – Prähospitalphase SHT Register
Halsmark*
ja (1)
nein (2)
unklar (3)
Thorakalmark*
ja (1)
nein (2)
unklar (3)
Lumbosakralmark*
ja (1)
nein (2)
unklar (3)
Extremitätenbewegungen
rechts oben*
normal (1)
leicht vermindert (2)
stark vermindert (3)
nicht geprüft (4)
links oben*
normal (1)
leicht vermindert (2)
stark vermindert (3)
nicht geprüft (4)
rechts unten*
normal (1)
leicht vermindert (2)
stark vermindert (3)
nicht geprüft (4)
links unten*
normal (1)
leicht vermindert (2)
stark vermindert (3)
nicht geprüft (4)
Verlauf und second insults
Augen öffnen (Krankenhaus)*
keine Reaktion (1)
auf Schmerzreiz (2)
auf Ansprache (3)
spontan (4)
Sprache (Krankenhaus)*
keine Antwort (1)
unverständlich (2)
inadäquat (3)
desorientiert (4)
orientiert (5)
Motorik (Krankenhaus)*
keine Reaktion (1)
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Streckreaktion (2)
Beugereaktion (3)
ungezielte Schmerzabwehr (4)
gezielte Schmerzabwehr (5)
befolgt Aufforderungen (6)
Glasgow Coma Scale (Krankenhaus)*
Eintrübung*
ja (1)
nein (2)
unklar (3)
Anfälle*
keine (1)
sofort (2)
>1 min nach Trauma (3)
Amnesie für das Ereignis*
ja (1)
nein (2)
unklar (3)
Dauer Amnesie in dd:hh:mm*
Amnesie*
retrograd (1)
anterograd (2)
retrograd & anterograd (3)
Erbrechen*
ja (1)
nein (2)
unklar (3)
Otoliquorrhoe und Rhinoliquorrhoe*
ja (1)
nein (2)
unklar (3)
Fieber unter Intensivtherapie*
ja (1)
nein (2)
unklar (3)
Höhe des Fiebers unter Intensivtherapie*
EEG-Auffälligkeiten*
Ja
Nein
Dauer der EEG-Auffälligkeiten (in Tagen nach
SHT)*
EEG-Auffälligkeit: Anfallsbereitschaft*
Ja
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Nein
EEG-Auffälligkeit: Verlangsamung*
Ja
Nein
Kopfschmerzen im Verlauf*
Ja
Nein
Prozeduren
Hemikraniektomie, links*
Reimplantation nach Hemikraniektomie, links*
Hemikraniektomie, rechts*
Reimplantation nach Hemikraniektomie, rechts*
Hemikraniektomie, total*
Reimplantation nach Hemikraniektomie, total*
Trepanation*
Kraniotomie*
Hirndrucksonde*
Hirndruck ICP in cmH2O*
ICP: cut off in Ruhe > 20cmH2O über 5 Minuten*
Ja
Nein
ICP: rasch steigend*
Ja
Nein
Hirndruck CCP in cmH2O*
Ventrikel Drainage*
Ja
Nein
Dauer der Ventrikel Drainage (in Tagen)*
Anlage eines VP/VA-shunts*
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Ja
Nein
Hyperosmolare Therapie*
Ja
Nein
Hypothermie*
Ja
Nein
Dauer der Hypothermie in dd:hh:mm*
Hochdosisbarbiturattherapie*
Ja
Nein
Dauer der Hochdosisbarbiturattherapie in
dd:hh:mm*
Laborwerte - Blutbild
Thrombozyten (1000/µl)*
Leukozyten (1000/µl)*
Hämoglobin (g/dl)*
Laborwerte - Elektrolyte
Natrium (mmol/l)*
Kalium (mmol/l)*
Calcium (mmol/l)*
Phosphat (mg/dl)*
Magnesium (mmol/l)*
Glukose max innerhalb der ersten 24 h (mg/dl)*
Glukose min innerhalb der ersten 24 h (mg/dl)*
Laborwerte - BGA
Art*
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kapillär (1)
arteriell (2)
venös (3)
erster pH-Wert*
schlechtester pH-Wert*
pO2 (mmHG)*
minimal pCO2 (mmHG)*
maximal pCO2 (mmHG)*
BE (mmol/l)*
HCO3 (mmol/l)*
Laktat (mmol/l)*
Sonstige Laborparameter
CK U/I*
LDH U/I*
GFAP*
MBP*
S100*
Neuronenspezifische Enolase (NSE)*
Substanzabusus
Alkoholkonsum des Patienten*
kein (1)
wahrscheinlich (2)
sicher (Promille) (3)
unklar (4)
Drogenkonsum des Patienten*
kein (1)
wahrscheinlich (2)
sicher (3)
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unklar (4)
Alkoholkonsum der gegnerischen Partei*
kein (1)
wahrscheinlich (2)
sicher (Promille) (3)
unklar (4)
Drogenkonsum der gegnerischen Partei*
kein (1)
wahrscheinlich (2)
sicher (3)
unklar (4)
Krankenhausaufenthalt
Dauer des Krankenhausaufenthalts (in Tagen)*
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Death Form (F04) Sarcoma
(NCT00450320)
AMC-051 Death Form (F04)
Sirolimus in Treating Patients With HIV-Related Kaposi's
Sarcoma
NCT00450320
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=2FDFA89A-
06DD-6018-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/6536
Death Form (F04) Sarcoma
(NCT00450320)
CCRR Modul für Todes-Formular - Rf04
Datum des letzten Kontaktes oder Todes
Behandlungsstatus (zum Zeitpunkt des Todes)
Off-Studie (Off study)
In Studie, Off-Protokoll Behandlung (On
study, off protocol treatment)
In Studie, In-Protokoll Behandlung (On
study, on protocol treatment)
Letztes Datum (jede Modalität), an dem die
Therapie durchgeführt wurde
Primäre Ursache des Todes
Aufgrund von nicht-malignen
Komplikationen der HIV-Erkrankung
(Due to Non-malignancy complications of
HIV disease)
Aufgrund anderer Ursache, angeben
(Due to other cause)
Aufgrund der Protokoll-Behandlung (Due
to protocol treatment)
Aufgrund zweiter primärer oder anderer
Krebserkrankungen (Due to second
primary or other malignancy)
Aufgrund dieser Krankheit (Due to this
disease)
Mitursache des Todes
Aufgrund von nicht-malignen
Komplikationen der HIV-Erkrankung
(Due to Non-malignancy complications of
HIV disease)
Aufgrund anderer Ursache, angeben
(Due to other cause)
Aufgrund der Protokoll-Behandlung (Due
to protocol treatment)
Aufgrund zweiter primärer oder anderer
Krebserkrankungen (Due to second
primary or other malignancy)
Aufgrund dieser Krankheit (Due to this
disease)
angeben
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Todesursache beschreiben
Informationen zur Quelle des Todes
Autopsy (Autopsy)
Klinische Evidenz war die
Informationsquelle des Patiententodes
(Clinical evidence)
Kontakt mit dem Arzt (Contact with
physician)
Totenschein war die Informationsquelle
des Patiententodes (Death certificate)
Die histologische Beweis war die
Informationsquelle des Patiententodes
(Histological evidence)
Informationen von Freunden und
Verwandten (Information from friends
and relatives)
andere (Other)
Andere, angeben
Kommentare
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Breast Cancer NCT01275677 On-Study - NSABP-B-
47 Cardiac Report Form (Form CR) - 3162764v1.0
NSABP-B-47 Cardiac Report Form (Form CR)
A Randomized Phase III Trial of Adjuvant Therapy
Comparing Chemotherapy Alone (Six Cycles of Docetaxel
Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus
Cyclophosphamide Followed by Weekly Paclitaxel) to
Chemotherapy Plus Trastuzumab in Women With Node-
Positive or High-Risk Node-Negative HER2-Low Invasive
Breast Cancer
NCT01275677
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=95D01C7E-
6AB6-38AE-E040-BB89AD4351B3
All rights reserved. Please visit https://medical-data-
models.org/forms/6537
Cardiac Report Form Breast Cancer
(NCT01275677)
Header
Patient Initials (Last First Middle)
NSABP Patient ID
Treatment Status Of Patient At Onset Of
Cardiac Event
Treatment Status (Mark the item that corresponds
to the patient's treatment status at the time of the
cardiac event)
After Study Therapy Has Ended (After
study therapy has ended)
During Chemotherapy (During
chemotherapy)
Post-chemotherapy Trastuzumab (Post-
chemotherapy trastuzumab)
Was therapy for recurrence or second primary
cancer initiated before the onset of this cardiac
event
Yes
No
Did the patient experience any of the following
cardiac events at the specified time point (Mark
all that apply to this report.)
Definite Or Probable Cardiac Death
(Definite or probable cardiac death)
Symptoms Suggestive Of Chf
(Symptoms suggestive of CHF)
Section 1 - Symptoms Suggestive Of
Congestive Heart Failure, Even If Chf Was
Not Subsequently Confirmed
Date of Onset of Symptoms (Month Day Year)
Type of Confirmatory Assessment
1 / 2
2-d Echocardiogram (2-D
Echocardiogram)
Muga Scan (MUGA scan)
Date of Confirmatory Assessment (The report for
the confirmatory MUGA scan and/or
echocardiogram must be submitted along with
any other pertinent documentation e.g., chest x-
ray report, cardiology consult note, medical
oncologist's progress note, discharge summary.
Enter Form LVA online for each confirmatory
MUGA scan or echocardiogram.)
Diagnosis (Group 2B only - If the diagnosis of
CHF is confirmed during AC, the initiation of
trastuzumab is prohibited Protocol Section 9.6.1)
Congestive Heart Failure Confirmed
(Congestive heart failure confirmed)
Congestive Heart Failure Not Confirmed
(Congestive heart failure not confirmed)
Specify
Section 2 - Definite Or Probable Cardiac
Death
Nature of Cardiac Death
Definite Cardiac (Definite cardiac)
Probable Cardiac (Probable cardiac)
Footer
Comments
Person Completing Form
Date Form Completed
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Follow-Up Form Colorectal Cancer
(NCT01150045)
CALGB 80702 Follow-Up Form
Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or
Without Celecoxib in Treating Patients With Stage III Colon
Cancer Previously Treated With Surgery
NCT01150045
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=7ADB9225-
BF4C-FA4C-E040-BB89AD4369EB
All rights reserved. Please visit https://medical-data-
models.org/forms/6538
Follow-Up Form Colorectal Cancer
(NCT01150045)
Header Module
CALGB Form
CALGB Study No.
CALGB Patient ID
Reporting Period Start Date (MM DD YYYY)
Reporting Period End Date (MM DD YYYY)
Are data amended
Yes
No
Patient Initials (Last, First Middle)
Patient Hospital No.
Institution/Affiliate
Participating Group
Participating Group Study No.
Participating Group Patient ID
Completed by (Last name, First name)
Date Form Originally Completed
Vital Status
Treatment type (Mark one with an X.)
Follow-up (Follow-up)
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On Treatment (On treatment)
Vital Status (Mark one with an X.)
Alive (Alive)
Dead (Dead)
Primary Cause of Death (Mark one with an X.)
Due To Other Cause (Due to other
cause)
Due To Protocol Treatment (Due to
protocol treatment)
Due To This Disease (Due to this
disease)
Describe cause of death
Disease Status
CEA Value (ng/mL)
Date CEA obtained (MM DD YYYY)
Has the patient had a documented clinical
assessment for this cancer?
Yes
No
Date of Most Recent Clinical Assessment (MM
DD YYYY)
Current disease status (Mark one with an X.)
Died With No Evidence Of Relapse (Died
with no evidence of relapse)
No Evidence Of Disease (No evidence of
disease)
Relapse/recurrence
(Relapse/Recurrence)
Sites Of Relapse
Date of Recurrence (MM DD YYYY)
Site of relapse/progression (Mark all that apply
with an X.)
Bone (Bone)
Colon (Colon)
Liver (Liver)
Lung (Lung)
Other (Other)
Specify
2 / 4
Follow-Up Form Colorectal Cancer (NCT01150045)
Colonoscopy Information
Has the patient had a colonoscopy assessment
for this cancer since submission of the previous
follow-up form?
Yes
No
Date of last colonoscopy (MM DD YYYY)
Were any samples sent to pathology
Yes
No
Colonoscopy findings (Mark all that apply with an
X.)
Adenomatous Polyps (Adenomatous
polyps)
New Primary Colon Cancer (New
primary colon cancer)
Normal (Normal)
Other Types Of Polyps (Other types of
polyps)
Recurrence Of Original Primary
Cancer/local Recurrence (Recurrence of
original primary cancer/local recurrence)
Neuropathy
CTC Adverse Event Peripheral Sensory
Neuropathy Grade
Absent Adverse Event (0)
Mild Adverse Event (1)
Moderate Adverse Event (2)
Severe Adverse Event (3)
Life Threatening Adverse Event (4)
Non-protocol Treatment
Has the patient received any non-protocol cancer
therapy during this reporting period?
Yes
No
Specify
Start Date of Non-protocol Therapy  (MM DD
YYYY)
New Primary Data
Has a new primary cancer or MDS been
diagnosed that has not been previously reported?
Yes
No
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Date of diagnosis (MM DD YYYY)
Site of new primary (Mark one with an X.)
Breast (Breast)
Lung (Lung)
Other (Other)
Prostate (Prostate)
Skin (Skin)
Specify
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Death Form (F04) Infection (NCT00513526)
AMC-052 Death Form (F04)
Human Papillomavirus Vaccine Therapy in Treating Men
With HIV-1 Infection
NCT00513526
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=39541C37-
41DD-4020-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/6539
Death Form (F04) Infection
(NCT00513526)
Death
Date of Last Contact or Death
Treatment Status (at time of death)
Off Study (Off study)
On Study, Off Protocol Treatment (On
study, off protocol treatment)
On Study, On Protocol Treatment (On
study, on protocol treatment)
Last Date (any modality of) protocol therapy was
given
Primary cause of death
Due To Non-malignancy Complications
Of Hiv Disease (Due to Non-malignancy
complications of HIV disease)
Due To Other Cause, Specify (Due to
other cause)
Due To Protocol Treatment (Due to
protocol treatment)
Due To Second Primary Or Other
Malignancy (Due to second primary or
other malignancy)
Due To This Disease (Due to this
disease)
Contributing cause of death
Due To Non-malignancy Complications
Of Hiv Disease (Due to Non-malignancy
complications of HIV disease)
Due To Other Cause, Specify (Due to
other cause)
Due To Protocol Treatment (Due to
protocol treatment)
Due To Second Primary Or Other
Malignancy (Due to second primary or
other malignancy)
Due To This Disease (Due to this
disease)
Specify
Describe cause of death
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Source of death information
Autopsy (Autopsy)
Clinical Evidence Was The Source Of
Information On The Patient's Death
(Clinical evidence)
Contact With Physician (Contact with
physician)
Death Certificate Was The Source Of
Information On The Patient's Death
(Death certificate)
Histological Evidence Was The Source
Of Information On The Patient's Death
(Histological evidence)
Information From Friends And Relatives
(Information from friends and relatives)
Other (Other)
Other, specify
Comments
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Death Form (F04) Lymphoma
(NCT00981097)
AMC-064 Death Form (F04)
Study of Blood and Tissue Samples From Patients With
Aggressive Non-Hodgkin B-Cell Lymphoma or Hodgkin
Lymphoma
NCT00981097
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=7C993962-
28E0-EDFE-E040-BB89AD43562B
All rights reserved. Please visit https://medical-data-
models.org/forms/6541
Death Form (F04) Lymphoma
(NCT00981097)
Death Information
Date of Death (mm/dd/yyyy)
Treatment Status (at time of death)
Off Study (Off study)
On Study, Off Protocol Treatment (On
study, off protocol treatment)
On Study, On Protocol Treatment (On
study, on protocol treatment)
Last Date (any modality of) protocol therapy was
given (mm/dd/yyyy)
Primary cause of death
Due To Non-malignancy Complications
Of Hiv Disease (Due to Non-malignancy
complications of HIV disease)
Due To Other Cause, Specify (Due to
other cause)
Due To Protocol Treatment (Due to
protocol treatment)
Due To Second Primary Or Other
Malignancy (Due to second primary or
other malignancy)
Due To This Disease (Due to this
disease)
Contributing cause of death
Due To Non-malignancy Complications
Of Hiv Disease (Due to Non-malignancy
complications of HIV disease)
Due To Other Cause, Specify (Due to
other cause)
Due To Protocol Treatment (Due to
protocol treatment)
Due To Second Primary Or Other
Malignancy (Due to second primary or
other malignancy)
Due To This Disease (Due to this
disease)
Specify
Describe cause of death
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Source of death information
Autopsy (Autopsy)
Clinical Evidence Was The Source Of
Information On The Patient's Death
(Clinical evidence)
Contact With Physician (Contact with
physician)
Death Certificate Was The Source Of
Information On The Patient's Death
(Death certificate)
Histological Evidence Was The Source
Of Information On The Patient's Death
(Histological evidence)
Information From Friends And Relatives
(Information from friends and relatives)
Other (Other)
Other, specify
Comments
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Death Form (F04) Lymphoma (NCT00981097)
Death Form (F04) Lymphoma
(NCT00392834)
AMC-048 Death Form (F04)
Rituximab and Combination Chemotherapy in Treating
Patients With Newly Diagnosed, HIV-Associated Burkitt's
Lymphoma
NCT00392834
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=32E18FA2-
3312-4AF2-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/6542
Death Form (F04) Lymphoma
(NCT00392834)
Death Information
Date of Last Contact or Death
Treatment Status (at time of death)
Off Study (Off study)
On Study, Off Protocol Treatment (On
study, off protocol treatment)
On Study, On Protocol Treatment (On
study, on protocol treatment)
Last Date (any modality of) protocol therapy was
given
Primary cause of death
Due To Non-malignancy Complications
Of Hiv Disease (Due to Non-malignancy
complications of HIV disease)
Due To Other Cause, Specify (Due to
other cause)
Due To Protocol Treatment (Due to
protocol treatment)
Due To Second Primary Or Other
Malignancy (Due to second primary or
other malignancy)
Due To This Disease (Due to this
disease)
Contributing cause of death
Due To Non-malignancy Complications
Of Hiv Disease (Due to Non-malignancy
complications of HIV disease)
Due To Other Cause, Specify (Due to
other cause)
Due To Protocol Treatment (Due to
protocol treatment)
Due To Second Primary Or Other
Malignancy (Due to second primary or
other malignancy)
Due To This Disease (Due to this
disease)
Specify
Describe cause of death
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Source of death information
Autopsy (Autopsy)
Clinical Evidence Was The Source Of
Information On The Patient's Death
(Clinical evidence)
Contact With Physician (Contact with
physician)
Death Certificate Was The Source Of
Information On The Patient's Death
(Death certificate)
Histological Evidence Was The Source
Of Information On The Patient's Death
(Histological evidence)
Information From Friends And Relatives
(Information from friends and relatives)
Other (Other)
Other, specify
Comments
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Death Form (F04) Lymphoma (NCT00392834)
Death Form (F04) Lymphoma
(NCT00598169)
AMC-053 Death Form (F04)
Bortezomib, Ifosfamide, Carboplatin, and Etoposide, With
or Without Rituximab, in Treating Patients With Relapsed or
Refractory AIDS-Related Non-Hodgkin Lymphoma
NCT00598169
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=8B708D70-
6800-F9DE-E040-BB89AD43114E
All rights reserved. Please visit https://medical-data-
models.org/forms/6544
Death Form (F04) Lymphoma
(NCT00598169)
Death Information
Date of Death (mm/dd/yyyy)
Treatment Status (at time of death)
Off Study (Off study)
On Study, Off Protocol Treatment (On
study, off protocol treatment)
On Study, On Protocol Treatment (On
study, on protocol treatment)
Last Date (any modality of) protocol therapy was
given (mm/dd/yyyy)
Primary cause of death
Due To Non-malignancy Complications
Of Hiv Disease (Due to Non-malignancy
complications of HIV disease)
Due To Other Cause, Specify (Due to
other cause)
Due To Protocol Treatment (Due to
protocol treatment)
Due To Second Primary Or Other
Malignancy (Due to second primary or
other malignancy)
Due To This Disease (Due to this
disease)
Contributing cause of death
Due To Non-malignancy Complications
Of Hiv Disease (Due to Non-malignancy
complications of HIV disease)
Due To Other Cause, Specify (Due to
other cause)
Due To Protocol Treatment (Due to
protocol treatment)
Due To Second Primary Or Other
Malignancy (Due to second primary or
other malignancy)
Due To This Disease (Due to this
disease)
Specify
Describe cause of death
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Source of death information
Autopsy (Autopsy)
Clinical Evidence Was The Source Of
Information On The Patient's Death
(Clinical evidence)
Contact With Physician (Contact with
physician)
Death Certificate Was The Source Of
Information On The Patient's Death
(Death certificate)
Histological Evidence Was The Source
Of Information On The Patient's Death
(Histological evidence)
Information From Friends And Relatives
(Information from friends and relatives)
Other (Other)
Other, specify
Comments
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Death Form (F04) Lymphoma
(NCT00389818)
AMC-047 Death Form (F04)
Combination Chemotherapy and Rituximab in Treating
Patients With Newly Diagnosed AIDS-Related B-Cell Non-
Hodgkin's Lymphoma
NCT00389818
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=1E9A5647-
9521-64E7-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/6545
Death Form (F04) Lymphoma
(NCT00389818)
Death Information
Date of Death (mm/dd/yyyy)
Treatment Status (at time of death)
Off Study (Off study)
On Study, Off Protocol Treatment (On
study, off protocol treatment)
On Study, On Protocol Treatment (On
study, on protocol treatment)
Last Date (any modality of) protocol therapy was
given (mm/dd/yyyy)
Primary cause of death
Due To Non-malignancy Complications
Of Hiv Disease (Due to Non-malignancy
complications of HIV disease)
Due To Other Cause, Specify (Due to
other cause)
Due To Protocol Treatment (Due to
protocol treatment)
Due To Second Primary Or Other
Malignancy (Due to second primary or
other malignancy)
Due To This Disease (Due to this
disease)
Contributing cause of death
Due To Non-malignancy Complications
Of Hiv Disease (Due to Non-malignancy
complications of HIV disease)
Due To Other Cause, Specify (Due to
other cause)
Due To Protocol Treatment (Due to
protocol treatment)
Due To Second Primary Or Other
Malignancy (Due to second primary or
other malignancy)
Due To This Disease (Due to this
disease)
Specify
Describe cause of death
1 / 2
Source of death information
Autopsy (Autopsy)
Clinical Evidence Was The Source Of
Information On The Patient's Death
(Clinical evidence)
Contact With Physician (Contact with
physician)
Death Certificate Was The Source Of
Information On The Patient's Death
(Death certificate)
Histological Evidence Was The Source
Of Information On The Patient's Death
(Histological evidence)
Information From Friends And Relatives
(Information from friends and relatives)
Other (Other)
Other, specify
Comments
2 / 2
Death Form (F04) Lymphoma (NCT00389818)
Death Form (F04) Brain and Central
Nervous System Tumors (NCT00890747)
AMC-061 Death Form (F04)
Sunitinib Malate in Treating HIV-Positive Patients With
Cancer Undergoing Highly Active Antiretroviral Therapy
NCT00890747
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=71988CF7-
F80D-68F0-E040-BB89AD4358A1
All rights reserved. Please visit https://medical-data-
models.org/forms/6546
Death Form (F04) Brain and Central
Nervous System Tumors
(NCT00890747)
Death Information
Date of Death (mm/dd/yyyy)
Treatment Status (at time of death)
Off Study (Off study)
On Study, Off Protocol Treatment (On
study, off protocol treatment)
On Study, On Protocol Treatment (On
study, on protocol treatment)
Last Date (any modality of) protocol therapy was
given (mm/dd/yyyy)
Primary cause of death
Due To Non-malignancy Complications
Of Hiv Disease (Due to Non-malignancy
complications of HIV disease)
Due To Other Cause, Specify (Due to
other cause)
Due To Protocol Treatment (Due to
protocol treatment)
Due To Second Primary Or Other
Malignancy (Due to second primary or
other malignancy)
Due To This Disease (Due to this
disease)
Contributing cause of death
Due To Non-malignancy Complications
Of Hiv Disease (Due to Non-malignancy
complications of HIV disease)
Due To Other Cause, Specify (Due to
other cause)
Due To Protocol Treatment (Due to
protocol treatment)
Due To Second Primary Or Other
Malignancy (Due to second primary or
other malignancy)
Due To This Disease (Due to this
disease)
Specify
Describe cause of death
1 / 2
Source of death information
Autopsy (Autopsy)
Clinical Evidence Was The Source Of
Information On The Patient's Death
(Clinical evidence)
Contact With Physician (Contact with
physician)
Death Certificate Was The Source Of
Information On The Patient's Death
(Death certificate)
Histological Evidence Was The Source
Of Information On The Patient's Death
(Histological evidence)
Information From Friends And Relatives
(Information from friends and relatives)
Other (Other)
Other, specify
Comments
2 / 2
Death Form (F04) Brain and Central Nervous System Tumors
(NCT00890747)
Radiology Review Form (SR) Glioblastoma
(NCT00884741)
RTOG 0825 Phase III GBM Radiology Review Form (SR)
Temozolomide and Radiation Therapy With or Without
Bevacizumab in Treating Patients With Newly Diagnosed
Glioblastoma
NCT00884741
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=5A7BE879-
E0E2-3571-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/6547
Radiology Review Form (SR)
Glioblastoma (NCT00884741)
Module 1
RTOG Study No.
Case #
Institution Name
Institution No.
Patient Initials
RTOG Patient ID
Amended Data (INSTRUCTIONS: Complete form
on web to unblind the protocol treatment arm)
Yes
No
Comments
Signature of Person Completing This Form
Form Completion Date, Original (MM DD YYYY)
Module 1
Treatment type
Protocol Therapy (Protocol therapy)
Salvage (Salvage therapy)
Image set
Other (Other)
Pre-cycle 1 (Pre-cycle 1)
Pre-cycle 10 (Pre-cycle 10)
Pre-cycle 4 (Pre-cycle 4)
Pre-cycle 7 (Pre-cycle 7)
Date of Assessment (MM DD YYYY)
1 / 2
Method of Evaluation
Ct Scan (CT scan)
Mri Scan (MRI scan)
Other (Other)
Other Specify
Overall Response (Disease response status)
Complete Response (CR)
Insufficient Evaluation To Determine
Response Status (insufficient evaluation
to determine response status)
Minor Response (MR)
Progressive Disease (PD)
Partial Response (PR)
Stable Disease (SD)
Radiologist's Signature
Review Date (MM DD YYYY)
Progression time point
Not Applicable (Not applicable)
Protocol Treatment Progression
(Protocol treatment progression)
Salvage Treatment Progression (Salvage
treatment progression)
Is patient going into salvage treatment
Yes
No
2 / 2
Radiology Review Form (SR) Glioblastoma (NCT00884741)
Death Form (F04) Anal Cancer
(NCT00324415)
AMC-045 Death Form (F04)
Cisplatin, Fluorouracil, Cetuximab, and Radiation Therapy
in Treating Patients With HIV and Stage I, Stage II, or
Stage III Anal Cancer
NCT00324415
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=72844558-
61AB-0B0B-E040-BB89AD4314AD
All rights reserved. Please visit https://medical-data-
models.org/forms/6548
Death Form (F04) Anal Cancer
(NCT00324415)
Date of Death (mm/dd/yyyy)
Treatment Status (at time of death)
Off Study (Off study)
On Study, Off Protocol Treatment (On
study, off protocol treatment)
On Study, On Protocol Treatment (On
study, on protocol treatment)
Last Date (any modality of) protocol therapy was
given (mm/dd/yyyy)
Primary cause of death
Due To Non-malignancy Complications
Of Hiv Disease (Due to Non-malignancy
complications of HIV disease)
Due To Other Cause, Specify (Due to
other cause)
Due To Protocol Treatment (Due to
protocol treatment)
Due To Second Primary Or Other
Malignancy (Due to second primary or
other malignancy)
Due To This Disease (Due to this
disease)
Contributing cause of death
Due To Non-malignancy Complications
Of Hiv Disease (Due to Non-malignancy
complications of HIV disease)
Due To Other Cause, Specify (Due to
other cause)
Due To Protocol Treatment (Due to
protocol treatment)
Due To Second Primary Or Other
Malignancy (Due to second primary or
other malignancy)
Due To This Disease (Due to this
disease)
Specify
Describe cause of death
1 / 2
Source of death information
Autopsy (Autopsy)
Clinical Evidence Was The Source Of
Information On The Patient's Death
(Clinical evidence)
Contact With Physician (Contact with
physician)
Death Certificate Was The Source Of
Information On The Patient's Death
(Death certificate)
Histological Evidence Was The Source
Of Information On The Patient's Death
(Histological evidence)
Information From Friends And Relatives
(Information from friends and relatives)
Other (Other)
Other, specify
Comments
2 / 2
Death Form (F04) Anal Cancer (NCT00324415)
Death Form (F04) Anal Cancer
(NCT00550589)
AMC-046 Death Form (F04)
Cidofovir in Treating HIV-Infected Patients With High-Grade
Squamous Intraepithelial Lesions of the Skin Near the Anus
NCT00550589
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=7D8985E5-
2EC8-08A5-E040-BB89AD434A3B
All rights reserved. Please visit https://medical-data-
models.org/forms/6549
Death Form (F04) Anal Cancer
(NCT00550589)
Date of Death (mm/dd/yyyy)
Treatment Status (at time of death)
Off Study (Off study)
On Study, Off Protocol Treatment (On
study, off protocol treatment)
On Study, On Protocol Treatment (On
study, on protocol treatment)
Last Date (any modality of) protocol therapy was
given (mm/dd/yyyy)
Primary cause of death
Due To Non-malignancy Complications
Of Hiv Disease (Due to Non-malignancy
complications of HIV disease)
Due To Other Cause, Specify (Due to
other cause)
Due To Protocol Treatment (Due to
protocol treatment)
Due To Second Primary Or Other
Malignancy (Due to second primary or
other malignancy)
Due To This Disease (Due to this
disease)
Contributing cause of death
Due To Non-malignancy Complications
Of Hiv Disease (Due to Non-malignancy
complications of HIV disease)
Due To Other Cause, Specify (Due to
other cause)
Due To Protocol Treatment (Due to
protocol treatment)
Due To Second Primary Or Other
Malignancy (Due to second primary or
other malignancy)
Due To This Disease (Due to this
disease)
Specify
Describe cause of death
1 / 2
Source of death information
Autopsy (Autopsy)
Clinical Evidence Was The Source Of
Information On The Patient's Death
(Clinical evidence)
Contact With Physician (Contact with
physician)
Death Certificate Was The Source Of
Information On The Patient's Death
(Death certificate)
Histological Evidence Was The Source
Of Information On The Patient's Death
(Histological evidence)
Information From Friends And Relatives
(Information from friends and relatives)
Other (Other)
Other, specify
Comments
2 / 2
Death Form (F04) Anal Cancer (NCT00550589)
Follow-Up Form Bladder Cancer
(NCT00942331)
CALGB 90601: Follow-Up Form
Gemcitabine Hydrochloride and Cisplatin With or Without
Bevacizumab in Treating Patients With Advanced Urinary
Tract Cancer
NCT00942331
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=6591C082-
D8C1-EC1C-E040-BB89AD43479B
All rights reserved. Please visit https://medical-data-
models.org/forms/6550
Follow-Up Form Bladder Cancer
(NCT00942331)
CALGB Form (C-1767)
CALGB Study No.
CALGB Patient ID
Reporting Period Start Date
Date of Last Contact or Death
Are data amended
Yes
No
Patient Initials
Patient Hospital No.
Institution/Affiliate
Participating Group
Participating Group Study No.
Participating Group Patient ID
Comments
Completed by
Date Form Completed
Vital Status
1 / 4
Patient's Vital Status
Alive (Alive)
Dead (Dead)
Primary Cause of Death
Due To Other Cause (Due to other
cause)
Due To Protocol Treatment (Due to
protocol treatment)
Due To This Disease (Due to this
disease)
Describe cause of death
Performance Status
Fully Active, Able To Carry On All Pre-
disease Performance Without
Restriction. (0)
Restricted In Physically Strenuous
Activity But Ambulatory And Able To
Carry Out Work Of A Light Or Sedentary
Nature, E.g., Light Housework, Office
Work. (1)
Ambulatory And Capable Of All Selfcare
But Unable To Carry Out Any Work
Activities. Up And About More Than 50%
Of Waking Hours. (2)
Capable Of Only Limited Selfcare,
Confined To Bed Or Chair More Than
50% Of Waking Hours. (3)
Completely Disabled. Cannot Carry On
Any Selfcare. Totally Confined To Bed Or
Chair. (4)
Patient Weight (kg)
Treatment Status
Treatment Status (Mark one with an X)
Follow-up, Off Protocol Therapy (Follow-
up, off protocol therapy)
On Study, On Protocol Treatment (On
study, on protocol treatment)
Other (Other)
Other, specify
Disease Follow-up Status
Has the patient had a documented clinical
assessment for this cancer? (since submission of
the previous follow-up form)
Yes
No
2 / 4
Follow-Up Form Bladder Cancer (NCT00942331)
Date of most recent physical exam
Measurable Disease Response
Response Status at This Assessment
Complete Response (CR)
Insufficient Evaluation (Insufficient
evaluation to determine response status)
Partial Response (PR)
Stable Disease (SD)
Complete Response (CR) First Observed Date
Partial Response (PR) First Observed Date
Progressive Disease First Observed Date
Sites of Progression
Bladder (Bladder)
Bone (Bone)
Central Nervous System/brain
(CNS/Brain)
Liver (Liver)
Lung, Nos (Lung)
Lymph Nodes, Specify (Lymph nodes)
Other (Other)
Pleura (Pleura)
Urothelial Tract (Urothelial Tract)
Other specify
Notice Of New Primary
Has a new primary cancer or MDS been
diagnosed that has not been previously reported?
Yes
No
New Primary Cancer Date
Site of New Primary
New Primary, Histologic type
Long-term Toxicity
Has the patient experienced post diagnosis of
progression or new primary, any severe (Grade >
3), long-term toxicity that has not been previously
3 / 4
Follow-Up Form Bladder Cancer (NCT00942331)
reported
Yes
No
Non-protocol Therapy
Has the patient received any non-protocol cancer
therapy during this reporting period?
Yes
No
Specify (If yes,)
Chemotherapy (Chemotherapy)
Hormonal Therapy (Hormonal Therapy)
Other Non-protocol Therapy (Other non-
protocol therapy)
Radiation Therapy (Radiation therapy)
Surgery (Surgery)
Specify (hormonal therapy)
Specify (radiation therapy)
Specify (chemotherapy)
Specify
Specify
Non-protocol Therapy Start Date (or date
performed)
Non-protocol Therapy End Date
4 / 4
Follow-Up Form Bladder Cancer (NCT00942331)
Anal Cancer NCT00550589 Off Treatment - AMC-046 Off-
Protocol Treatment Summary Form (F05) - 2989512v1.0
AMC-046 Off-Protocol Treatment Summary Form (F05)
Cidofovir in Treating HIV-Infected Patients With High-Grade
Squamous Intraepithelial Lesions of the Skin Near the Anus
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=7D8985E5-
2F13-08A5-E040-BB89AD434A3B
All rights reserved. Please visit https://medical-data-
models.org/forms/6551
AMC-046 Off-Protocol Treatment
Summary Form (F05)
Ccrr Module For Off Protocol Treatment
Summary - Rf05b
Last Date (any modality of) protocol therapy was
given (mm/dd/yyyy)
Reason Treatment Ended (select the primary
reason)
Adverse Event/side Effects/complications
(Adverse Event/Side
Effects/Complications)
Alternative Therapy (Alternative therapy)
Cytogenetic Resistance (Cytogenetic
Resistance)
Death On Study (Death on study)
Disease Progression Before Active
Treatment (Disease Progression before
active treatment)
Disease Progression, Relapse During
Active Treatment (Disease progression,
relapse during active treatment)
Lost To Follow-up (Lost to follow-up)
No Treatment, Per Protocol Criteria (No
treatment, per protocol criteria)
Other (Other)
Patient Off-treatment For Other
Complicating Disease (Patient off-
treatment for other complicating disease)
Patient Withdrawal Or Refusal After
Beginning Protocol Therapy (Patient
withdrawal/refusal after beginning
protocol therapy)
Patient Withdrawal Or Refusal Before
Beginning Protocol Therapy (Patient
withdrawal/refusal prior to beginning
protocol therapy)
Treatment Completed Per Protocol
Criteria (Treatment completed per
protocol criteria)
Other, specify
Comments
1 / 1
Anal Cancer NCT00324415 Off Treatment - AMC-045 Off
Protocol Treatment Summary Form (F05) - 2936946v1.0
AMC-045 Off Protocol Treatment Summary Form (F05)
Cisplatin, Fluorouracil, Cetuximab, and Radiation Therapy
in Treating Patients With HIV and Stage I, Stage II, or
Stage III Anal Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=7284A0F2-
BE44-FDEC-E040-BB89AD43537B
All rights reserved. Please visit https://medical-data-
models.org/forms/6552
AMC-045 Off Protocol Treatment
Summary Form (F05)
Ccrr Module For Off Protocol Treatment
Summary - Rf05b
Last Date (any modality of) protocol therapy was
given (mm/dd/yyyy)
Reason Treatment Ended (select the primary
reason)
Adverse Event/side Effects/complications
(Adverse Event/Side
Effects/Complications)
Alternative Therapy (Alternative therapy)
Cytogenetic Resistance (Cytogenetic
Resistance)
Death On Study (Death on study)
Disease Progression Before Active
Treatment (Disease Progression before
active treatment)
Disease Progression, Relapse During
Active Treatment (Disease progression,
relapse during active treatment)
Lost To Follow-up (Lost to follow-up)
No Treatment, Per Protocol Criteria (No
treatment, per protocol criteria)
Other (Other)
Patient Off-treatment For Other
Complicating Disease (Patient off-
treatment for other complicating disease)
Patient Withdrawal Or Refusal After
Beginning Protocol Therapy (Patient
withdrawal/refusal after beginning
protocol therapy)
Patient Withdrawal Or Refusal Before
Beginning Protocol Therapy (Patient
withdrawal/refusal prior to beginning
protocol therapy)
Treatment Completed Per Protocol
Criteria (Treatment completed per
protocol criteria)
Other, specify
Comments
1 / 1
Brain and Central Nervous System Tumors NCT00890747 Off Treatment
- AMC-061 Off Protocol Treatment Summary Form (F05) - 2934968v1.0
AMC-061 Off Protocol Treatment Summary Form (F05)
Sunitinib Malate in Treating HIV-Positive Patients With
Cancer Undergoing Highly Active Antiretroviral Therapy
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=71988CF7-
F855-68F0-E040-BB89AD4358A1
All rights reserved. Please visit https://medical-data-
models.org/forms/6555
AMC-061 Off Protocol Treatment
Summary Form (F05)
Ccrr Module For Off Protocol Treatment
Summary - Rf05b
Last Date (any modality of) protocol therapy was
given (mm/dd/yyyy)
Reason Treatment Ended (select the primary
reason)
Adverse Event/side Effects/complications
(Adverse Event/Side
Effects/Complications)
Alternative Therapy (Alternative therapy)
Cytogenetic Resistance (Cytogenetic
Resistance)
Death On Study (Death on study)
Disease Progression Before Active
Treatment (Disease Progression before
active treatment)
Disease Progression, Relapse During
Active Treatment (Disease progression,
relapse during active treatment)
Lost To Follow-up (Lost to follow-up)
No Treatment, Per Protocol Criteria (No
treatment, per protocol criteria)
Other (Other)
Patient Off-treatment For Other
Complicating Disease (Patient off-
treatment for other complicating disease)
Patient Withdrawal Or Refusal After
Beginning Protocol Therapy (Patient
withdrawal/refusal after beginning
protocol therapy)
Patient Withdrawal Or Refusal Before
Beginning Protocol Therapy (Patient
withdrawal/refusal prior to beginning
protocol therapy)
Treatment Completed Per Protocol
Criteria (Treatment completed per
protocol criteria)
Other, specify
Comments
1 / 1
Off Treatment - Phase II Breast Cancer - End
of Treatment Summary Form - 2583167v1.0
Phase II Breast Cancer - End of Treatment Summary Form
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=2588598D-
D8D0-1B66-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/6559
Phase II Breast Cancer - End of
Treatment Summary Form
Crf Header
Coordinating Group Protocol No.
Coordinating Group Code
Protocol Title
Patient Study ID
Registering Group Code
Institution/Affiliate
Registering Institution Code
Patient Initials
Lung: Adverse Events
Person Completing Form
Are data amended (If data are amended, please
circle in red when using paper form)
Yes
No
Lung: Treatment Plan
First Date (any modality of) protocol therapy was
given
Last Date (any modality of) protocol therapy was
given
Reason Treatment Ended
Adverse Event/side Effects/complications
(Adverse Event/Side
Effects/Complications)
Alternative Therapy (Alternative therapy)
1 / 3
Cytogenetic Resistance (Cytogenetic
Resistance)
Death On Study (Death on study)
Disease Progression Before Active
Treatment (Disease Progression before
active treatment)
Disease Progression, Relapse During
Active Treatment (Disease progression,
relapse during active treatment)
Lost To Follow-up (Lost to follow-up)
No Treatment, Per Protocol Criteria (No
treatment, per protocol criteria)
Other (Other)
Patient Off-treatment For Other
Complicating Disease (Patient off-
treatment for other complicating disease)
Patient Withdrawal Or Refusal After
Beginning Protocol Therapy (Patient
withdrawal/refusal after beginning
protocol therapy)
Patient Withdrawal Or Refusal Before
Beginning Protocol Therapy (Patient
withdrawal/refusal prior to beginning
protocol therapy)
Treatment Completed Per Protocol
Criteria (Treatment completed per
protocol criteria)
Alternative Therapy (Specify)
Complicating Disease (Specify)
Other specify
Lung: Treatment Schedule ¿ Radiation
Therapy
Total Number of Cycles given
Were there any dose modifications or
additions/omissions to protocol treatment?
No (No)
Yes, Planned (i.e., The Treatment Was
Changed According To Protocol
Guidelines) (Yes, planned)
Yes, Unplanned (i.e., The Treatment
Change Was Not Part Of Protocol
Guidelines) (Yes, unplanned)
Lung: Treatment Schedule ¿ Radiation
Therapy
Total Dose to Lung (cGy)
2 / 3
Off Treatment - Phase II Breast Cancer - End of Treatment Summary
Form - 2583167v1.0
Were there any unscheduled interruptions in
radiation therapy?
No (No)
Yes, Due To Toxicity (Yes, due to toxicity)
Yes, For Other Reasons, Specify (Yes,
for other reasons, specify)
Specify RT interruption reason
Lung: Off-study Follow-up
Is the patient currently being followed for study
endpoints? (whether on or off treatment)
Yes
No
Off Study Reason (If no,)
Death (Death)
Other (Other)
Lost To Follow-up (Patient lost to follow-
up)
Patient Refused Follow-up (Patient
refused follow-up)
Protocol-defined Follow-up Completed
(Protocol-defined follow-up completed)
Off Study Date
Other specify
Comments
Comments
3 / 3
Off Treatment - Phase II Breast Cancer - End of Treatment Summary
Form - 2583167v1.0
Treatment - Phase II Breast Cancer - Adjuvant
Treatment Summary Form - All Patients - 2583736v1.0
Phase II Breast Cancer - Adjuvant Treatment Summary
Form - All Patients
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=25A33C64-
E547-43BB-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/6560
Phase II Breast Cancer - Adjuvant
Treatment Summary Form - All
Patients
Crf Header
Coordinating Group Protocol No.
Coordinating Group Code
Protocol Title
Patient Study ID
Institution/Affiliate
Registering Group Code
Registering Institution Code
Patient Initials
Breast: Form Administration
Person Completing Form
Are data amended? (If data are amended, please
circle in red when using paper form)
Yes
No
Breast: Treatment Plan
First Date (any modality of) Protocol Therapy
Was Given
Initial Dose (of Cycle 1 use protocol specified
units)
Units
1 / 3
Agent Name (protocol specific Some groups may
pre-print protocol agents with appropriate units.)
Last Date (any modality of) protocol therapy was
given
Reason Treatment Ended
Adverse Event/side Effects/complications
(Adverse Event/Side
Effects/Complications)
Alternative Therapy (Alternative therapy)
Death On Study (Death on study)
Disease Progression, Relapse During
Active Treatment (Disease progression,
relapse during active treatment)
Other (Other)
Patient Off-treatment For Other
Complicating Disease (Patient off-
treatment for other complicating disease)
Patient Withdrawal Or Refusal After
Beginning Protocol Therapy (Patient
withdrawal/refusal after beginning
protocol therapy)
Patient Withdrawal Or Refusal Before
Beginning Protocol Therapy (Patient
withdrawal/refusal prior to beginning
protocol therapy)
Treatment Completed Per Protocol
Criteria (Treatment completed per
protocol criteria)
Breast: Treatment Schedule - Systemic
Therapy
Were there any dose modifications or
additions/omissions to protocol treatment? (check
one)
No (No)
Unknown (Unknown)
Yes, Planned (i.e., The Treatment Was
Changed According To Protocol
Guidelines) (Yes, planned)
Yes, Unplanned (i.e., The Treatment
Change Was Not Part Of Protocol
Guidelines) (Yes, unplanned)
Breast: Treatment Schedule - Other
Therapy
Were any optional therapies given?
Yes
No
Optional Protocol Therapy Name (If yes,)
2 / 3
Treatment - Phase II Breast Cancer - Adjuvant Treatment Summary Form
- All Patients - 2583736v1.0
Was any non-protocol therapy given during
protocol treatment?
Yes
No
Concurrent Non-Protocol Chemotherapy? (If yes,)
Yes
No
Concurrent Non-Protocol Hormonal Therapy?
Yes
No
Concurrent Non-Protocol Biologic Response
Modifier Therapy?
Yes
No
Concurrent Non-Protocol Radiation Therapy?
Yes
No
Concurrent Non-Protocol High Dose
Chemotherapy/Autologous Stem Cell Transplant?
Yes
No
Comments
Comments
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Treatment - Phase II Breast Cancer - Adjuvant Treatment Summary Form
- All Patients - 2583736v1.0
Off Treatment - Phase II Lung Cancer - End
of Treatment Summary Form - 2404726v1.0
Phase II Consortium - Phase II Lung Cancer - End of
Treatment Summary Form
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=00974A58-
3367-1106-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/6561
Phase II Lung Cancer - End of
Treatment Summary Form
Crf Header
Coordinating Group Protocol No.
Coordinating Group Code
Protocol Title
Patient Study ID
Registering Group Code
Patient Medical Record Number
Other Patient ID
Institution/Affiliate
Registering Institution Code
Physician of Record
Lung: Adverse Events
Person Completing Form
Date Form Completed (MM DD YYYY)
Are data amended (If data are amended, please
circle in red when using paper form)
Yes
No
Lung: Treatment Plan
Is the patient currently receiving protocol
treatment on-study?
1 / 3
Yes
No
First Date (any modality of) protocol therapy was
given (MM DD YYYY)
Last Date (any modality of) protocol therapy was
given (MM DD YYYY)
Reason Treatment Ended
Adverse Event/side Effects/complications
(Adverse Event/Side
Effects/Complications)
Alternative Therapy (Alternative therapy)
Cytogenetic Resistance (Cytogenetic
Resistance)
Death On Study (Death on study)
Disease Progression Before Active
Treatment (Disease Progression before
active treatment)
Disease Progression, Relapse During
Active Treatment (Disease progression,
relapse during active treatment)
Lost To Follow-up (Lost to follow-up)
No Treatment, Per Protocol Criteria (No
treatment, per protocol criteria)
Other (Other)
Patient Off-treatment For Other
Complicating Disease (Patient off-
treatment for other complicating disease)
Patient Withdrawal Or Refusal After
Beginning Protocol Therapy (Patient
withdrawal/refusal after beginning
protocol therapy)
Patient Withdrawal Or Refusal Before
Beginning Protocol Therapy (Patient
withdrawal/refusal prior to beginning
protocol therapy)
Treatment Completed Per Protocol
Criteria (Treatment completed per
protocol criteria)
Alternative Therapy (Specify)
Complicating Disease (Specify)
Other specify
Lung: Treatment Schedule ¿ Radiation
Therapy
Total Number of Cycles given
2 / 3
Off Treatment - Phase II Lung Cancer - End of Treatment Summary Form
- 2404726v1.0
Were there any dose modifications or
additions/omissions to protocol treatment?
No (No)
Yes, Planned (i.e., The Treatment Was
Changed According To Protocol
Guidelines) (Yes, planned)
Yes, Unplanned (i.e., The Treatment
Change Was Not Part Of Protocol
Guidelines) (Yes, unplanned)
Lung: Treatment Schedule ¿ Radiation
Therapy
Total Dose to Lung (cGy)
Were there any unscheduled interruptions in
radiation therapy?
No (No)
Yes, Due To Toxicity (Yes, due to toxicity)
Yes, For Other Reasons, Specify (Yes,
for other reasons, specify)
Specify RT interruption reason
Lung: Off-study Follow-up
Is the patient currently being followed for study
endpoints? (whether on or off treatment)
Yes
No
Off Study Reason (If no,)
Death (Death)
Other (Other)
Lost To Follow-up (Patient lost to follow-
up)
Patient Refused Follow-up (Patient
refused follow-up)
Protocol-defined Follow-up Completed
(Protocol-defined follow-up completed)
Off Study Date (MM DD YYYY)
Other specify
Comments
Comments
3 / 3
Off Treatment - Phase II Lung Cancer - End of Treatment Summary Form
- 2404726v1.0
Treatment - Head and Neck Cancers -
Treatment Summary Form - 2268818v3.0
Head and Neck Cancers - Treatment Summary Form
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=D496F3F7-
A64E-62CE-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/6565
Head and Neck Cancers - Treatment
Summary Form
Crf Header
Coordinating Group Protocol No.
Coordinating Group Code
Protocol Title
Patient Study ID
Institution/Affiliate
Other Patient ID
Participating Group Code
Patient Initials
Head & Neck: Patient Assessment
Patient Weight (kg)
Body Surface Area (m^2)
Performance Status (check one)
Fully Active, Able To Carry On All Pre-
disease Performance Without
Restriction. (0)
Restricted In Physically Strenuous
Activity But Ambulatory And Able To
Carry Out Work Of A Light Or Sedentary
Nature, E.g., Light Housework, Office
Work. (1)
Ambulatory And Capable Of All Selfcare
But Unable To Carry Out Any Work
Activities. Up And About More Than 50%
Of Waking Hours. (2)
Capable Of Only Limited Selfcare,
Confined To Bed Or Chair More Than
50% Of Waking Hours. (3)
Completely Disabled. Cannot Carry On
Any Selfcare. Totally Confined To Bed Or
1 / 9
Chair. (4)
Head & Neck: Treatment Plan
First Date (any modality of) protocol therapy was
given (mm dd yyyy)
Last Date (any modality of) protocol therapy was
given (mm dd yyyy)
Reason Treatment Ended (check one)
Adverse Event/side Effects/complications
(Adverse Event/Side
Effects/Complications)
Alternative Therapy (Alternative therapy)
Death On Study (Death on study)
Disease Progression Before Active
Treatment (Disease Progression before
active treatment)
Disease Progression, Relapse During
Active Treatment (Disease progression,
relapse during active treatment)
Lost To Follow-up (Lost to follow-up)
Other (Other)
Patient Off-treatment For Other
Complicating Disease (Patient off-
treatment for other complicating disease)
Patient Withdrawal Or Refusal After
Beginning Protocol Therapy (Patient
withdrawal/refusal after beginning
protocol therapy)
Patient Withdrawal Or Refusal Before
Beginning Protocol Therapy (Patient
withdrawal/refusal prior to beginning
protocol therapy)
Treatment Completed Per Protocol
Criteria (Treatment completed per
protocol criteria)
Other specify
Head & Neck: Surgical Treatment
Did the patient have surgery as part of protocol
treatment?
Yes
No
Protocol Surgery Date (mm dd yyyy)
Protocol Surgery Modality
Lymph Node Biopsy (Lymph node
biopsy)
Neck Dissection (Neck dissection)
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2268818v3.0
Primary Resection (Primary resection)
Salvage (Salvage)
Protocol Surgery Intent
Diagnostic (Diagnostic)
Palliative (Palliative)
Therapeutic (Therapeutic)
Protocol Surgery Type (Note: Include only
Head/Neck surgery.  Do not include feeding tube
procedures.)
Biopsy (Biopsy)
Complete Resection Of All Gross Tumor
(Complete resection of all gross tumor)
Incomplete/partial Resection Of Gross
Tumor (Incomplete/Partial Resection of
gross tumor)
Neck Dissection Diagnostic (Neck
Dissection, Diagnostic)
Neck Dissection Therapeutic (Neck
Dissection, Therapeutic)
Other (Other)
Sentinel Node Biopsy - Complete Sn
Removal (Sentinel Node biopsy -
complete SN removal)
Sentinel Node Biopsy - Incomplete Sn
Removal (Sentinel Node biopsy -
Incomplete SN removal)
Other specify
Lymph node levels removed, Right
I (I)
Ia (IA)
Ib (IB)
Ii (II)
Iia (IIA)
Iib (IIB)
Iii (III)
Iv (IV)
Other (Other)
V (V)
Vi (VI)
Vii (VII)
Other specify
Lymph node levels removed, Left
Level I - Submental, Subdigastric,
Submaxillary (I)
Ia (IA)
Ib (IB)
Level Ii - Upper Jugular (II)
Iia (IIA)
Iib (IIB)
Level Iii - Mid Jugular (III)
Level Iv - Lower Jugular (IV)
Other (Other)
Level V - Posterior Cervical (V)
Level Vi - Central (VI)
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2268818v3.0
Level Vii - Mediastinal (VII)
Other specify
Other Structures Removed
None (none)
Other (Other)
Other specify
Margin Status
Involved (<=5 Mm) (Involved (<= 5 mm))
Uninvolved (>5 Mm) (Uninvolved (> 5
mm))
Distance to Closest Margin
<=5 Mm (<= 5 mm)
>5 Mm (> 5 mm)
Unable To Interpret (Unable to interpret)
Distance to Deep Margin
<=5 Mm (<= 5 mm)
>5 Mm (> 5 mm)
Unable To Interpret (Unable to interpret)
Do surgery results qualify patient for further
protocol therapy
Not Applicable (N/A)
No (No)
Yes (Yes)
Head & Neck: Treatment Summary -
Radiation Therapy
Radiation Therapy Start Date (MM/DD/YYYY)
Radiation Therapy End Date (MM/DD/YYYY)
Radiation Therapy Intent (check all that apply)
Definitive (Definitive)
Other (Other)
Palliative (Palliative)
Post-operative (Post-operative)
Pre-operative (Pre-operative)
Other specify
Radiation Therapy Modality (check all that apply)
Brachytherapy (Brachytherapy)
External Beam Radiation (External beam
radiation)
Imrt (intensity Modulated Rt) (IMRT
(Intensity Modulated RT))
Other (Other)
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2268818v3.0
Other specify
Radiation Therapy Site (s protocol specific)
RT Total Dose Planned (Gy)
RT Total Dose Delivered (Gy)
Total Number of Fractions Planned
Total Number of Fractions Delivered
Were there any unscheduled interruptions in
radiation therapy?
No (No)
Unknown (Unknown)
Yes Due To Local-regional Toxicity (Yes,
due to local-regional toxicity)
Yes Due To Systemic Toxicity (Yes, due
to systemic toxicity)
Yes, For Other Reasons, Specify (Yes,
for other reasons, specify)
RT Interruptions Reason (If other Reason,
specify)
Duration of all unscheduled interruption (If yes,)
Units (specify units)
Days (Days)
Hours (Hours)
Weeks (Weeks)
Head & Neck: Treatment Summary -
Chemotherapy Concurrent With Radiation
Therapy
Type of Systemic Therapy (check all that apply)
Adjuvant Chemotherapy (Adjuvant
chemotherapy)
Immunotherapy (Immunotherapy)
Neoadjuvant Chemotherapy
(Neoadjuvant chemotherapy)
Other Specify (Other)
Other specify
Start Date of First Dose of First Cycle
(MM/DD/YYYY)
Start Date of First Dose of Last Cycle
(MM/DD/YYYY)
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Treatment - Head and Neck Cancers - Treatment Summary Form -
2268818v3.0
Total Number of Cycles given
Agent Name (protocol specific Some groups may
pre-print protocol agents with appropriate units.)
Total Agent Dose for Cycle 1
Units (Some groups may pre-print protocol
agents with appropriate units.)
Were there any dose modifications or
additions/omissions to protocol treatment? (check
one)
No (No)
Unknown (Unknown)
Yes, Planned (i.e., The Treatment Was
Changed According To Protocol
Guidelines) (Yes, planned)
Yes, Unplanned (i.e., The Treatment
Change Was Not Part Of Protocol
Guidelines) (Yes, unplanned)
Were there any delays in dose administration
No (No)
Unknown (Unknown)
Yes (Yes)
Name of Therapy (If yes to any modification or
delay, being modified)
Reason for Therapy Modification
Head & Neck: Treatment Summary -
Systemic Therapy
Type of Systemic Therapy (check all that apply)
Adjuvant Chemotherapy (Adjuvant
chemotherapy)
Immunotherapy (Immunotherapy)
Neoadjuvant Chemotherapy
(Neoadjuvant chemotherapy)
Other Specify (Other)
Other specify
Start Date of First Dose of First Cycle
(MM/DD/YYYY)
Start Date of First Dose of Last Cycle
(MM/DD/YYYY)
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2268818v3.0
Total Number of Cycles given
Agent Name (protocol specific Some groups may
pre-print protocol agents with appropriate units.)
Total Agent Dose for Cycle 1
Units (Some groups may pre-print protocol
agents with appropriate units.)
Were there any dose modifications or
additions/omissions to protocol treatment? (check
one)
No (No)
Unknown (Unknown)
Yes, Planned (i.e., The Treatment Was
Changed According To Protocol
Guidelines) (Yes, planned)
Yes, Unplanned (i.e., The Treatment
Change Was Not Part Of Protocol
Guidelines) (Yes, unplanned)
Were there any delays in dose administration
No (No)
Unknown (Unknown)
Yes (Yes)
Name of Therapy (If yes to any modification or
delay, being modified)
Reason for Therapy Modification
Head & Neck: Supportive Care
Assessment
Was supportive therapy given to patient as
permitted by protocol
No (no)
Unknown (Unknown)
Yes (Yes)
Type of Supportive Care Given (If yes,)
Amifostine (Amifostine)
Growth Factors (Growth factors)
Other (Other)
Other specify
Does the patient have swallowing problems
following treatment
No (No)
Unknown (Unknown)
Yes (Yes)
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2268818v3.0
Does the patient currently require tube feeding
No (No)
Unknown (Unknown)
Yes (Yes)
Is patient dependent on tube feeding for >50% of
nutritional support (If yes,)
No (No)
Unknown (Unknown)
Yes (Yes)
Was a feeding tube inserted during this reporting
period (including CTC event dysphagia >= grade
3)
No (No)
Unknown (Unknown)
Yes (Yes)
Was a feeding tube discontinued during this
reporting period
No (No)
Unknown (Unknown)
Yes (Yes)
Date Feeding Tube Discontinued (If yes,)
Was a tracheostomy performed during this
reporting period (e.g., for breathing difficulty)
No (No)
Unknown (Unknown)
Yes (Yes)
Was use of a tracheostomy discontinued during
this reporting period
No (No)
Not Applicable (Not applicable)
Yes (Yes)
Date Tracheostomy was closed (If yes,)
Head & Neck: Treatment Schedule - Non-
protocol Cancer Therapy
Was any non-protocol therapy given during
protocol treatment?
Yes
No
Non-Protocol Supportive Therapy
Yes
No
Yes specify
Non-Protocol Growth Factor Agents
Yes
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No
Yes specify
Non-Protocol Chemotherapy
Yes
No
Yes specify
Non-Protocol Radiation Therapy?
Yes
No
Yes specify
Non-Protocol Surgery?
Yes
No
Yes specify
Other Non-Protocol Therapy
Yes
No
Name of Other Non-Protocol Therapy (If yes,)
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Treatment - Head and Neck Cancers - Treatment Summary Form -
2268818v3.0
Breast Cancer NCT00513292 Treatment - Z1041:
End of Intervention Period Form - 2533589v1.0
Z1041: End of Intervention Period Form
Combination Chemotherapy and Paclitaxel Plus
Trastuzumab in Treating Women With Palpable Breast
Cancer That Can Be Removed by Surgery
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=211D4CFE-
8742-4C95-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/6579
Z1041: End of Intervention Period
Form
Header Module
Visit
Surgery (Surgery)
Unscheduled (Unscheduled)
Date
Patient ID (Patient ID issued during registration or
previously issued Patient ID.)
Patient Initials (F M L)
Institution No.
Institution Name
Header
Reason Treatment Ended (Mark "X" in only one
box)
Adverse Event/side Effects/complications
(Adverse Event/Side
Effects/Complications)
Alternative Therapy (Alternative therapy)
Death On Study (Death on study)
Disease Progression, Relapse During
Active Treatment (Disease progression,
relapse during active treatment)
Other (Other)
Patient Off-treatment For Other
Complicating Disease (Patient off-
treatment for other complicating disease)
Patient Withdrawal Or Refusal After
Beginning Protocol Therapy (Patient
withdrawal/refusal after beginning
protocol therapy)
Treatment Completed Per Protocol
Criteria (Treatment completed per
protocol criteria)
Other, specify
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If death, mark type
Definite Cardiac (Definite cardiac)
Other (Other)
Probable Cardiac (Probable cardiac)
Other specify
Treatment End Date (Intervention)
Footer Module
Completed by
Date Form Completed
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Breast Cancer NCT00513292 Treatment - Z1041: End of Intervention
Period Form - 2533589v1.0
Cervical Cancer NCT01101451 Off Treatment - GOG-0263:
Treatment Completion Form (Form Q0) - 2933678v1.0
GOG-0263: Treatment Completion Form (Form Q0)
Radiation Therapy With or Without Chemotherapy in
Patients With Stage I or Stage II Cervical Cancer Who
Previously Underwent Surgery
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=7170934C-
5E1C-20E2-E040-BB89AD434964
All rights reserved. Please visit https://medical-data-
models.org/forms/6582
GOG-0263: Treatment Completion
Form (Form Q0)
Header Module
Date form originally completed (m d y)
Date form amended (m d y)
Person amending form, last name
Patient Initials (First, Middle, Last)
Patient Study ID
Person Completing Form, Last Name
Treatment Schedule
Total number of cycles given
Last date (any modality of) protocol therapy was
given (m d y)
Off-treatment Reason
Reason Treatment Ended
Adverse Event/side Effects/complications
(Adverse event/side
effects/complications)
Death On Study (Death on study)
Disease Progression, Relapse During
Active Treatment (Disease progression,
relapse during active treatment)
Other (Other)
Patient Off-treatment For Other
Complicating Disease (Patient off-
treatment for other complicating disease)
Patient Withdrawal Or Refusal For
Reason Other Than Toxicity (Patient
withdrawal/refusal for reason other than
toxicity)
Treatment Completed Per Protocol
Criteria (Treatment completed per
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protocol criteria)
Adverse event/side effects/complications specify
(specify)
Patient withdrawal/Refusal for reason other than
toxicity, specify
Patient off-treatment for other complicating
disease, specify
Other specify
Will patient receive further treatment?
Yes
No
Yes specify (below)
Best Tumor Response
Biologic Progression (Biologic
progression)
Complete Response (Complete
Response)
Increasing Disease (Increasing Disease)
N.a., Non-measurable Disease At
Baseline (N.A., Non-measurable disease
at baseline)
Not Evaluated This Course (Not
evaluated this course)
Partial Response (Partial Response)
Stable Disease (Stable Disease)
Symptomatic Deterioration (Symptomatic
Deterioration)
Comments
COMMENTS
2 / 2
Cervical Cancer NCT01101451 Off Treatment - GOG-0263: Treatment
Completion Form (Form Q0) - 2933678v1.0
Cervical Cancer NCT00262821 Off Treatment - Treatment
Completion Form, Form Q0, GOG-0219 - 2302649v3.0
Treatment Completion Form, Form Q0, GOG-0219
Cisplatin and Radiation Therapy With or Without
Tirapazamine in Treating Patients With Cervical Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=EF89A84E-
7B15-0E3D-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/6583
Treatment Completion Form, Form
Q0, GOG-0219
Header Module
Date form originally completed (m d y)
Date form amended (m d y)
Person amending form, last name
Patient Initials (First, Middle, Last)
Patient Study ID
Person Completing Form, Last Name
Treatment Schedule
Total number of cycles given
Last date (any modality of) protocol therapy was
given (m d y)
Off-treatment Reason
Reason treatment ended (check only one)
Death Of Patient Occurred After The
Patient Began Protocol Therapy (Death
after beginning protocol therapy)
Disease Progression, Relapse During
Active Treatment (Disease progression,
relapse during active treatment)
Other (Other)
Patient Off-treatment For Other
Complicating Disease (Patient off-
treatment for other complicating disease)
Patient Withdrawal Or Refusal For
Reason Other Than Toxicity (Patient
withdrawal or refusal for reason other
than toxicity)
Routine Completion Of Planned Protocol
Treatment (Routine completion of
planned protocol treatment)
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Adverse Event/side Effects/complications
(Toxicity/side effects/complications)
Toxicity/side effects/complications (specify)
Patient withdrawal or refusal for reason other
than toxicity (specify)
complicating disease (specify)
Other (specify)
Will patient receive further treatment?
Yes
No
Yes specify (below)
Comments
COMMENTS
Footer Module
Participating Group Code
Participating Group Protocol Number
Participating Group Patient ID
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Cervical Cancer NCT00262821 Off Treatment - Treatment Completion
Form, Form Q0, GOG-0219 - 2302649v3.0
Cervical Cancer NCT00803062 Off Treatment - GOG-0240
Treatment Completion Form (Form Q0) - 2727945v1.0
GOG-0240 Treatment Completion Form (Form Q0)
Paclitaxel and Cisplatin or Topotecan With or Without
Bevacizumab in Treating Patients With Stage IVB,
Recurrent, or Persistent Cervical Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=4580B20A-
F9FA-2748-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/6584
GOG-0240 Treatment Completion
Form (Form Q0)
Header Module
Date form originally completed (m d y)
Date form amended (m d y)
Person amending form, last name
Patient Initials (First, Middle, Last)
Patient Study ID
Person Completing Form, Last Name
Treatment Schedule
Total number of cycles given
Last date (any modality of) protocol therapy was
given (m d y)
Off-treatment Reason
Reason Treatment Ended
Adverse Event/side Effects/complications
(Adverse event/side
effects/complications)
Death On Study (Death on study)
Disease Progression, Relapse During
Active Treatment (Disease progression,
relapse during active treatment)
Other (Other)
Patient Off-treatment For Other
Complicating Disease (Patient off-
treatment for other complicating disease)
Patient Withdrawal Or Refusal For
Reason Other Than Toxicity (Patient
withdrawal/refusal for reason other than
toxicity)
Treatment Completed Per Protocol
Criteria (Treatment completed per
1 / 2
protocol criteria)
Adverse event/side effects/complications specify
(specify)
Patient withdrawal/Refusal for reason other than
toxicity, specify
Patient off-treatment for other complicating
disease, specify
Other specify
Will patient receive further treatment?
Yes
No
Yes specify (below)
Best Tumor Response
Biologic Progression (Biologic
progression)
Complete Response (Complete
Response)
Increasing Disease (Increasing Disease)
N.a., Non-measurable Disease At
Baseline (N.A., Non-measurable disease
at baseline)
Not Evaluated This Course (Not
evaluated this course)
Partial Response (Partial Response)
Stable Disease (Stable Disease)
Symptomatic Deterioration (Symptomatic
Deterioration)
Comments
COMMENTS
2 / 2
Cervical Cancer NCT00803062 Off Treatment - GOG-0240 Treatment
Completion Form (Form Q0) - 2727945v1.0
Colorectal Cancer NCT00499369 Treatment - SOUTHWEST ONCOLOGY
GROUP S0600 CONCOMITANT MEDICATION FORM - 2582968v1.0
SOUTHWEST ONCOLOGY GROUP S0600
CONCOMITANT MEDICATION FORM
Irinotecan and Cetuximab With or Without Bevacizumab in
Treating Patients With Metastatic Colorectal Cancer That
Progressed During First-Line Therapy
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=258561E9-
CE1C-6F0C-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/6592
SOUTHWEST ONCOLOGY GROUP
S0600 CONCOMITANT
MEDICATION FORM
Header
SWOG Patient ID
SWOG Study No.
Registration Step
Patient Initials (L, F M)
Reporting Period Start Date
Institution/Affiliate
Physician
Participating Group Name
Participating Study No.
Participating Patient ID
Unnamed Module 2
Is patient on anti-hypertensive therapy
Yes
No
Agent Name (or procedure)
Treatment begin date
Treatment end date
Unnamed Module 2
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Is the patient on anticoagulant therapy
Yes
No
Anti-Coagulant Drugs
Aspirin > 325mg (Aspirin > 325mg)
Aspirin >81mg And <325mg (Aspirin
>81mg and <325mg)
Aspirin 81mg (Aspirin 81mg)
Coumadin (prophylactic Dose)
(Coumadin (prophylactic dose))
Coumadin (therapeutic Dose) (Coumadin
(therapeutic dose))
Low Molecular Weight Heparin
(prophylactic Dose) (Low Molecular
Weight Heparin (prophylactic dose))
Low Molecular Weight Heparin
(therapeutic Dose) (Low Molecular
Weight Heparin (therapeutic dose))
Other (Other)
Agent Name (or procedure)
Other, specify
Treatment begin date
Treatment end date
Unnamed Module 2
Is the patient on magnesium supplements
Yes
No
Agent Name (or procedure)
Treatment begin date
Route of Administration
Intravenous Administration Of Drug (IV)
Oral Administration Of Drug (oral)
Treatment end date
Comments
Comments
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Colorectal Cancer NCT00499369 Treatment - SOUTHWEST ONCOLOGY
GROUP S0600 CONCOMITANT MEDICATION FORM - 2582968v1.0
Colorectal Cancer NCT00726622 Off Treatment -
Z6051 End of Intervention Period - 2718001v1.0
Z6051 End of Intervention Period
Laparoscopic-Assisted Resection or Open Resection in
Treating Patients With Stage IIA, Stage IIIA, or Stage IIIB
Rectal Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=42C2602B-
8FA6-68E2-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/6594
Z6051 End of Intervention Period
Header Module
Visit
1-2 Weeks Post-surgery (1-2 weeks
post-surgery)
Patient ID (Patient ID issued during registration or
previously issued Patient ID.)
Patient Initials
Institution Name
Institution No.
Header
Reason Treatment Ended (mark only one)
Alternative Therapy (Alternative therapy)
Other (Other)
Patient Withdrawal Or Refusal After
Beginning Protocol Therapy (Patient
withdrawal/refusal after beginning
protocol therapy)
Treatment Completed Per Protocol
Criteria (Treatment completed per
protocol criteria)
Other, specify
Treatment End Date (when the above occurred)
Footer Module
Completed by
Date Form Completed
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Endometrial Cancer NCT00265759 Treatment - Z1031:
End of Intervention Period Form - 2316498v3.0
Z1031: End of Intervention Period Form
Exemestane, Letrozole, or Anastrozole in Treating
Postmenopausal Women Who Are Undergoing Surgery for
Stage II or Stage III Breast Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=FAD707A2-
CB43-0A2D-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/6595
Z1031: End of Intervention Period
Form
Header Module
Visit
Surgery (Surgery)
Patient ID (Patient ID issued during registration or
previously issued Patient ID.)
Institution No.
Patient Initials (F M L)
Institution Name
Header
Reason Treatment Ended
Adverse Event/side Effects/complications
(Adverse Event/Side
Effects/Complications)
Alternative Therapy (Alternative therapy)
Disease Progression, Relapse During
Active Treatment (Disease progression,
relapse during active treatment)
Other (Other)
Patient Off-treatment For Other
Complicating Disease (Patient off-
treatment for other complicating disease)
Patient Withdrawal Or Refusal After
Beginning Protocol Therapy (Patient
withdrawal/refusal after beginning
protocol therapy)
Treatment Completed Per Protocol
Criteria (Treatment completed per
protocol criteria)
Other, specify
Treatment End Date (Intervention)
Footer Module
1 / 2
Completed by
Date Form Completed
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Endometrial Cancer NCT00265759 Treatment - Z1031: End of
Intervention Period Form - 2316498v3.0
Fallopian Tube Cancer NCT00108745 Treatment - Treatment
Completion Form, GOG-0212, Form Q0 - 2296418v3.0
Treatment Completion Form, GOG-0212, Form Q0
Paclitaxel or Polyglutamate Paclitaxel or Observation in
Treating Patients With Stage III or Stage IV Ovarian
Epithelial or Peritoneal Cancer or Fallopian Tube Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=E7489B50-
2644-4BC6-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/6596
Treatment Completion Form, GOG-
0212, Form Q0
Header Module
Date form originally completed (m d y)
Date form amended (m d y)
Person amending form, last name
Patient Initials (First, Middle, Last)
Patient Study ID
Person Completing Form, Last Name
Treatment Schedule
Total number of cycles given
Last date (any modality of) protocol therapy was
given (m d y)
Off-treatment Reason
Reason treatment ended (check only one)
Death After Beginning Protocol Therapy
(Death after beginning protocol therapy)
Disease Progression, Relapse During
Active Treatment (Disease progression,
relapse during active treatment)
Other (Other)
Patient Off-treatment For Other
Complicating Disease (Patient off-
treatment for other complicating disease)
Patient Withdrawal Or Refusal (Patient
withdrawal or refusal for reason other
than toxicity)
Routine Completion Of Planned Protocol
Treatment (Routine completion of
planned protocol treatment)
Toxicity/side Effects/complications
(Toxicity/side effects/complications)
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Toxicity/side effects/complications (specify)
Patient withdrawal or refusal for reason other
than toxicity (specify)
complicating disease (specify)
Other (specify)
Will patient receive further treatment?
Yes
No
Yes specify (below)
Comments
COMMENTS
Footer Module
Participating Group Code
Participating Group Protocol Number
Participating Group Patient ID
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Fallopian Tube Cancer NCT00108745 Treatment - Treatment Completion
Form, GOG-0212, Form Q0 - 2296418v3.0
Fallopian Tube Cancer NCT01081262 Off Treatment - GOG-
0241 Treatment Completion Form (Q0) - 3127331v1.0
GOG-0241 Treatment Completion Form (Q0)
Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine,
With or Without Bevacizumab, as First-Line Therapy in
Treating Patients With Newly Diagnosed Stage II, Stage III,
Stage IV, or Recurrent Stage I Epithelial Ovarian Cancer or
Fallopian Tube Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=8D1826DA-
E893-F792-E040-BB89AD433BF7
All rights reserved. Please visit https://medical-data-
models.org/forms/6597
GOG-0241 Treatment Completion
Form (Q0)
Header Module
Date form originally completed (m d y)
Date form amended (m d y)
Person amending form, last name
Patient Initials (First, Middle, Last)
Patient Study ID
Person Completing Form, Last Name
Treatment Schedule
Total number of cycles given
Last date (any modality of) protocol therapy was
given (m d y)
Off-treatment Reason
Reason Treatment Ended (check only one)
Adverse Event/side Effects/complications
(Adverse event/side
effects/complications)
Death On Study (Death on study)
Disease Progression, Relapse During
Active Treatment (Disease progression,
relapse during active treatment)
Other (Other)
Patient Off-treatment For Other
Complicating Disease (Patient off-
treatment for other complicating disease)
Patient Withdrawal Or Refusal For
Reason Other Than Toxicity (Patient
withdrawal/refusal for reason other than
toxicity)
Treatment Completed Per Protocol
Criteria (Treatment completed per
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protocol criteria)
Adverse event/side effects/complications specify
Patient withdrawal/Refusal for reason other than
toxicity, specify
Patient off-treatment for other complicating
disease, specify
Other specify
Will patient receive further treatment?
Yes
No
Yes specify
Best Tumor Response
Biologic Progression (Biologic
progression)
Complete Response (Complete
Response)
Increasing Disease (Increasing Disease)
N.a., Non-measurable Disease At
Baseline (N.A., Non-measurable disease
at baseline)
Not Evaluated This Course (Not
evaluated this course)
Partial Response (Partial Response)
Stable Disease (Stable Disease)
Symptomatic Deterioration (Symptomatic
Deterioration)
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Fallopian Tube Cancer NCT01081262 Off Treatment - GOG-0241
Treatment Completion Form (Q0) - 3127331v1.0
Fallopian Tube Cancer NCT00951496 Off Treatment - Gynecologic
Oncology Group Treatment Completion Form (Form Q0) - 2758589v1.0
Gynecologic Oncology Group Treatment Completion Form
(Form Q0)
Bevacizumab and Intravenous or Intraperitoneal
Chemotherapy in Treating Patients With Stage II, Stage III,
or Stage IV Ovarian Epithelial Cancer, Fallopian Tube
Cancer, or Primary Peritoneal Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=4F550492-
CD41-047C-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/6598
Gynecologic Oncology Group
Treatment Completion Form (Form
Q0)
Header Module
Date form originally completed (m d y)
Date form amended (m d y)
Person amending form, last name
Patient Initials (First, Middle, Last)
Patient Study ID
Person Completing Form, Last Name
Treatment Schedule
Total number of cycles given
Last date (any modality of) protocol therapy was
given (m d y)
Off-treatment Reason
Reason Treatment Ended
Adverse Event/side Effects/complications
(Adverse event/side
effects/complications)
Death On Study (Death on study)
Disease Progression, Relapse During
Active Treatment (Disease progression,
relapse during active treatment)
Other (Other)
Patient Off-treatment For Other
Complicating Disease (Patient off-
treatment for other complicating disease)
Patient Withdrawal Or Refusal For
Reason Other Than Toxicity (Patient
1 / 2
withdrawal/refusal for reason other than
toxicity)
Treatment Completed Per Protocol
Criteria (Treatment completed per
protocol criteria)
Adverse event/side effects/complications specify
Patient withdrawal/Refusal for reason other than
toxicity, specify
Patient off-treatment for other complicating
disease, specify
Other specify
Will patient receive further treatment?
Yes
No
Yes specify
Best Tumor Response
Biologic Progression (Biologic
progression)
Complete Response (Complete
Response)
Increasing Disease (Increasing Disease)
N.a., Non-measurable Disease At
Baseline (N.A., Non-measurable disease
at baseline)
Not Evaluated This Course (Not
evaluated this course)
Partial Response (Partial Response)
Stable Disease (Stable Disease)
Symptomatic Deterioration (Symptomatic
Deterioration)
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Fallopian Tube Cancer NCT00951496 Off Treatment - Gynecologic
Oncology Group Treatment Completion Form (Form Q0) - 2758589v1.0
Fallopian Tube Cancer NCT00262847 Off Treatment -
GOG-0218 Treatment Completion Form - 2303917v3.0
GOG-0218 Treatment Completion Form
Carboplatin and Paclitaxel With or Without Bevacizumab in
Treating Patients With Stage III or Stage IV Ovarian
Epithelial, Primary Peritoneal Cancer, or Fallopian Tube
Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=F0E25E00-
7729-11AE-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/6600
GOG-0218 Treatment Completion
Form
Header Module
Date form originally completed
Date form amended
Person amending form, last name
Patient Initials
Patient Study ID
Person Completing Form, Last Name
Treatment Schedule
Total number of cycles given
Last date protocol therapy was given (any
modality of)
Off-treatment Reason
Reason treatment ended (check only one)
Death Of Patient Occurred After The
Patient Began Protocol Therapy (Death
after beginning protocol therapy)
Disease Progression, Relapse During
Active Treatment (Disease progression,
relapse during active treatment)
Other (Other)
Patient Off-treatment For Other
Complicating Disease (Patient off-
treatment for other complicating disease)
Patient Withdrawal Or Refusal For
Reason Other Than Toxicity (Patient
withdrawal or refusal for reason other
than toxicity)
Routine Completion Of Planned Protocol
Treatment (Routine completion of
planned protocol treatment)
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Adverse Event/side Effects/complications
(Toxicity/side effects/complications)
Toxicity/side effects/complications, specify
Patient withdrawal or refusal for reason other
than toxicity, specify
Patient off-treatment for other complicating
disease, specify
Other, specify
Will patient receive further treatment?
Yes
No
Yes specify (below)
Best Tumor Response
Biologic Progression (Biologic
progression)
Complete Response (Complete
Response)
Increasing Disease (Increasing Disease)
N.a., Non-measurable Disease At
Baseline (N.A., Non-measurable disease
at baseline)
Not Evaluated This Course (Not
evaluated this course)
Partial Response (Partial Response)
Stable Disease (Stable Disease)
Symptomatic Deterioration (Symptomatic
Deterioration)
Comments
COMMENTS
Footer Module
Participating Group Code
Participating Group Protocol Number
Participating Group Patient ID
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Fallopian Tube Cancer NCT00262847 Off Treatment - GOG-0218
Treatment Completion Form - 2303917v3.0
Infection NCT00513526 Off Treatment - AMC-052 Off
Protocol Treatment Summary Form (F05) - 2676943v1.0
AMC-052 Off Protocol Treatment Summary Form (F05)
Human Papillomavirus Vaccine Therapy in Treating Men
With HIV-1 Infection
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=395422A0-
6033-42B3-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/6601
AMC-052 Off Protocol Treatment
Summary Form (F05)
Ccrr Module For Off Protocol Treatment
Summary - Rf05b
Last Date (any modality of) protocol therapy was
given
Reason Treatment Ended (select the primary
reason)
Adverse Event/side Effects/complications
(Adverse Event/Side
Effects/Complications)
Alternative Therapy (Alternative therapy)
Cytogenetic Resistance (Cytogenetic
Resistance)
Death On Study (Death on study)
Disease Progression Before Active
Treatment (Disease Progression before
active treatment)
Disease Progression, Relapse During
Active Treatment (Disease progression,
relapse during active treatment)
Lost To Follow-up (Lost to follow-up)
No Treatment, Per Protocol Criteria (No
treatment, per protocol criteria)
Other (Other)
Patient Off-treatment For Other
Complicating Disease (Patient off-
treatment for other complicating disease)
Patient Withdrawal Or Refusal After
Beginning Protocol Therapy (Patient
withdrawal/refusal after beginning
protocol therapy)
Patient Withdrawal Or Refusal Before
Beginning Protocol Therapy (Patient
withdrawal/refusal prior to beginning
protocol therapy)
Treatment Completed Per Protocol
Criteria (Treatment completed per
protocol criteria)
Other, specify
Comments
1 / 1
Leukemia NCT01041703 Treatment - E2906
Allogeneic Transplant Form - Arm G - 2951703v1.0
E2906 Allogeneic Transplant Form - Arm G
Clofarabine or Daunorubicin Hydrochloride and Cytarabine
Followed By Decitabine or Observation in Treating Older
Patients With Newly Diagnosed Acute Myeloid Leukemia
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=758373C9-
BE14-F79E-E040-BB89AD433D62
All rights reserved. Please visit https://medical-data-
models.org/forms/6605
E2906 Allogeneic Transplant Form -
Arm G
Header
DCI Name
Registration Step (Place ID Label Here)
Patient Initials (Last, First)
ECOG Protocol Number
ECOG Protocol Number
ECOG Patient ID
ECOG Patient ID
Participating Group Protocol Number
Participating Group Patient ID
Institution/Affiliate
On Treatment
On Treatment Reporting Period
At Transplant (At Transplant)
Unnamed2
Please mark an 'X' if data have been amended.
(Please circle amended items in red)
Date data amended (s M D Y)
Vital Status
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Patient's Vital Status
Alive (Alive)
Dead (Dead)
Weight (kg Day 1 of this treatment)
Date of Last Contact or Death (M D Y)
Primary Cause of Death (if applicable)
Due To Other Cause (Due to other
cause)
Due To Protocol Treatment (Due to
protocol treatment)
Due To This Disease (Due to this
disease)
Unknown (Unknown)
Describe cause of death
Section Ii - Reporting Period
Treatment Start Date (M D Y)
Treatment End Date (M D Y)
Therapy Administered
Agent Name
Agent Total Dose (mg)
Dose modification
Dose Delayed (Dose delayed)
Dose Delayed And Reduced (Dose
delayed and reduced)
Dose Held (Dose held)
Dose Reduced (Dose reduced)
No Dose Modification (No dose
modification)
Dose Modification Reason
Adverse Event (Adverse event)
Change In Bsa (Change in BSA)
Dosing Error (Dosing error)
Patient Refusal/noncompliance (Patient
refusal/noncompliance)
Scheduling (Scheduling)
Donor Information
Donor's Relationship to recipient
Not Related (not related)
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Leukemia NCT01041703 Treatment - E2906 Allogeneic Transplant Form
- Arm G - 2951703v1.0
Other Family Member (Other family
member)
Sibling (sibling)
Donor Birth Date (M D Y if known)
Donor Gender
Female (female)
Male (male)
CMV status (Patient)
Negative (negative)
Positive (positive)
Unknown (unknown)
EBV status
Negative (negative)
Positive (positive)
Unknown (unknown)
Are patient and donor matched at HLA-A
No (No)
Unknown (Unknown)
Yes (Yes)
Are patient and donor matched at HLA-B
No (No)
Unknown (Unknown)
Yes (Yes)
Are patient and donor matched at HLA-C
No (No)
Unknown (Unknown)
Yes (Yes)
Are patient and donor matched at HLA-DR
No (No)
Unknown (Unknown)
Yes (Yes)
Are patient and donor matched at HLA-DQ
No (No)
Unknown (Unknown)
Yes (Yes)
Are patient and donor matched at HLA-DP
No (No)
Unknown (Unknown)
Yes (Yes)
Allogeneic Transplant
Did the patient receive protocol transplant?
Yes
No
Source of Stem Cells (If yes)
Bone Marrow (bone marrow)
Peripheral Blood (Peripheral Blood)
3 / 4
Leukemia NCT01041703 Treatment - E2906 Allogeneic Transplant Form
- Arm G - 2951703v1.0
CMV status (Patient)
Negative (negative)
Positive (positive)
Unknown (unknown)
Date of Peripheral Blood Stem Cell Infusion (M D
Y last PBSC If patient completed transplant
therapy this date should correspond with the
"Last Date Protocol Therapy Was Given" date on
the Step 2 Off-Treatment Form)
Number of CD34-positive cells infused (Total X
10^6 cells per kg of body weight)
Number of T cells (CD3) infused (X 10^6 cells per
kg of body weight)
Comments
Investigator Signature
Investigator Signature Date (MM DD YYYY)
4 / 4
Leukemia NCT01041703 Treatment - E2906 Allogeneic Transplant Form
- Arm G - 2951703v1.0
Lung Cancer NCT00107172 Off Treatment -
Z4032 End of Intervention Period - 2306382v3.0
Z4032 End of Intervention Period
Surgery With or Without Internal Radiation Therapy in
Treating Patients With Stage I Non-Small Cell Lung Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=F20E8F7F-
CB09-6BD0-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/6606
Z4032 End of Intervention Period
Header Module
Visit
Month 1 (Month 1)
Patient ID (Patient ID issued during registration or
previously issued Patient ID.)
Institution ID
Patient Initials
Institution
Header
Reason for end of intervention period (mark only
one)
Death On Study (Death)
Treatment Completed Per Protocol
Criteria (Intervention completed per
protocol specifications)
Other (Other)
Patient Withdrawal Or Refusal After
Beginning Protocol Therapy (Patient
withdrawal or refusal after beginning
protocol intervention)
Other, specify
Date of Intervention Period End (when the above
occurred)
Footer Module
Completed by
Date Form Completed
1 / 1
Lymphoma NCT00598169 Off Treatment - AMC-053 Off-
Protocol Treatment Summary Form (F05) - 3122199v1.0
AMC-053 Off-Protocol Treatment Summary Form (F05)
Bortezomib, Ifosfamide, Carboplatin, and Etoposide, With
or Without Rituximab, in Treating Patients With Relapsed or
Refractory AIDS-Related Non-Hodgkin Lymphoma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=8B708D70-
672A-F9DE-E040-BB89AD43114E
All rights reserved. Please visit https://medical-data-
models.org/forms/6615
AMC-053 Off-Protocol Treatment
Summary Form (F05)
Ccrr Module For Off Protocol Treatment
Summary - Rf05b
Last Date (any modality of) protocol therapy was
given (mm/dd/yyyy)
Reason Treatment Ended (select the primary
reason)
Adverse Event/side Effects/complications
(Adverse Event/Side
Effects/Complications)
Alternative Therapy (Alternative therapy)
Cytogenetic Resistance (Cytogenetic
Resistance)
Death On Study (Death on study)
Disease Progression Before Active
Treatment (Disease Progression before
active treatment)
Disease Progression, Relapse During
Active Treatment (Disease progression,
relapse during active treatment)
Lost To Follow-up (Lost to follow-up)
No Treatment, Per Protocol Criteria (No
treatment, per protocol criteria)
Other (Other)
Patient Off-treatment For Other
Complicating Disease (Patient off-
treatment for other complicating disease)
Patient Withdrawal Or Refusal After
Beginning Protocol Therapy (Patient
withdrawal/refusal after beginning
protocol therapy)
Patient Withdrawal Or Refusal Before
Beginning Protocol Therapy (Patient
withdrawal/refusal prior to beginning
protocol therapy)
Treatment Completed Per Protocol
Criteria (Treatment completed per
protocol criteria)
Other, specify
Comments
1 / 1
Lymphoma NCT00389818 Off Treatment - AMC-047 Off-
Protocol Treatment Summary Form (F05) - 2524249v1.0
AMC-047 Off-Protocol Treatment Summary Form (F05)
Combination Chemotherapy and Rituximab in Treating
Patients With Newly Diagnosed AIDS-Related B-Cell Non-
Hodgkin's Lymphoma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=1E9A6324-
AFFC-66EE-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/6616
AMC-047 Off-Protocol Treatment
Summary Form (F05)
Ccrr Module For Off Protocol Treatment
Summary - Rf05b
Last Date (any modality of) protocol therapy was
given (mm/dd/yyyy)
Reason Treatment Ended (select the primary
reason)
Adverse Event/side Effects/complications
(Adverse Event/Side
Effects/Complications)
Alternative Therapy (Alternative therapy)
Cytogenetic Resistance (Cytogenetic
Resistance)
Death On Study (Death on study)
Disease Progression Before Active
Treatment (Disease Progression before
active treatment)
Disease Progression, Relapse During
Active Treatment (Disease progression,
relapse during active treatment)
Lost To Follow-up (Lost to follow-up)
No Treatment, Per Protocol Criteria (No
treatment, per protocol criteria)
Other (Other)
Patient Off-treatment For Other
Complicating Disease (Patient off-
treatment for other complicating disease)
Patient Withdrawal Or Refusal After
Beginning Protocol Therapy (Patient
withdrawal/refusal after beginning
protocol therapy)
Patient Withdrawal Or Refusal Before
Beginning Protocol Therapy (Patient
withdrawal/refusal prior to beginning
protocol therapy)
Treatment Completed Per Protocol
Criteria (Treatment completed per
protocol criteria)
Other, specify
Comments
1 / 1
Lymphoma NCT00392834 Off Treatment - AMC-048
Off Protocol Treatment Summary (F05) - 2655565v1.0
AMC-048 Off Protocol Treatment Summary (F05)
Rituximab and Combination Chemotherapy in Treating
Patients With Newly Diagnosed, HIV-Associated Burkitt's
Lymphoma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=32E1BD21-
3EF8-538C-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/6617
AMC-048 Off Protocol Treatment
Summary (F05)
Ccrr Module For Off Protocol Treatment
Summary - Rf05b
Last Date (any modality of) protocol therapy was
given
Reason Treatment Ended (select the primary
reason)
Adverse Event/side Effects/complications
(Adverse Event/Side
Effects/Complications)
Alternative Therapy (Alternative therapy)
Cytogenetic Resistance (Cytogenetic
Resistance)
Death On Study (Death on study)
Disease Progression Before Active
Treatment (Disease Progression before
active treatment)
Disease Progression, Relapse During
Active Treatment (Disease progression,
relapse during active treatment)
Lost To Follow-up (Lost to follow-up)
No Treatment, Per Protocol Criteria (No
treatment, per protocol criteria)
Other (Other)
Patient Off-treatment For Other
Complicating Disease (Patient off-
treatment for other complicating disease)
Patient Withdrawal Or Refusal After
Beginning Protocol Therapy (Patient
withdrawal/refusal after beginning
protocol therapy)
Patient Withdrawal Or Refusal Before
Beginning Protocol Therapy (Patient
withdrawal/refusal prior to beginning
protocol therapy)
Treatment Completed Per Protocol
Criteria (Treatment completed per
protocol criteria)
Other, specify
Comments
1 / 1
Treatment - E2906 Leukemia Treatment
Form - Observation (Arm C) - 2949093v1.0
E2906 Treatment Form - Observation (Arm C)Not longer
part of CRF set 4/13/10 version
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=74CEC72C-
CCC3-2C0E-E040-BB89AD4367D1
All rights reserved. Please visit https://medical-data-
models.org/forms/6619
E2906 Leukemia Treatment Form -
Observation (Arm C)
Header
DCI Name
Registration Step (Place ID Label Here)
Patient Initials (Last, First)
ECOG Protocol Number
ECOG Protocol Number
ECOG Patient ID
ECOG Patient ID
Participating Group Protocol Number
Participating Group Patient ID
Institution/Affiliate
On Treatment
Reporting Period
Cycle 1- Observation (Cycle 1-
Observation)
Cycle 10 - Observation (Cycle 10 -
Observation)
Cycle 11 - Observation (Cycle 11 -
Observation)
Cycle 12 - Observation (Cycle 12 -
Observation)
Cycle 2 - Observation (Cycle 2 -
Observation)
Cycle 3 - Observation (Cycle 3 -
Observation)
Cycle 4 - Observation (Cycle 4 -
Observation)
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Cycle 5 - Observation (Cycle 5 -
Observation)
Cycle 6 - Observation (Cycle 6 -
Observation)
Cycle 7 - Observation (Cycle 7 -
Observation)
Cycle 8 - Observation (Cycle 8 -
Observation)
Cycle 9 - Observation (Cycle 9 -
Observation)
Unnamed2
Please mark an 'X' if data have been amended.
(Please circle amended items in red)
Date data amended (s M D Y)
Section Ii - Reporting Period
Treatment Start Date (M D Y)
Treatment End Date (M D Y)
Vital Status
Patient's Vital Status
Alive (Alive)
Dead (Dead)
Date of Last Contact or Death (M D Y)
Primary Cause of Death (if applicable)
Due To Other Cause (Due to other
cause)
Due To Protocol Treatment (Due to
protocol treatment)
Due To This Disease (Due to this
disease)
Unknown (Unknown)
Describe cause of death
Patient Characteristics
Weight (kg Day 1 of this treatment)
Body Surface Area (m^2 Patient Measurement
BSA Day 1 of this treatment)
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Treatment - E2906 Leukemia Treatment Form - Observation (Arm C) -
2949093v1.0
Non-protocol Therapy
Was any non-protocol therapy given during
protocol treatment? (not previously reported )
Yes
No
Comments
Investigator Signature
Investigator Signature Date (MM DD YYYY)
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Treatment - E2906 Leukemia Treatment Form - Observation (Arm C) -
2949093v1.0
Sarcoma NCT01533207 Off Treatment -
Treatment Completion Form (Q0) - 2843448v1.0
Treatment Completion Form (Q0)
Gemcitabine Hydrochloride and Docetaxel Followed by
Doxorubicin Hydrochloride or Observation in Treating
Patients With High-Risk Uterine Leiomyosarcoma
Previously Removed by Surgery
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=644E86D7-
D585-D7C8-E040-BB89AD4321CC
All rights reserved. Please visit https://medical-data-
models.org/forms/6623
Treatment Completion Form (Q0)
Header Module
Date form originally completed (m d y)
Date form amended (m d y)
Person amending form, last name
Patient Initials (First, Middle, Last)
Patient Study ID
Person Completing Form, Last Name
Treatment Schedule
Total number of cycles given
Last date (any modality of) protocol therapy was
given (m d y)
Off-treatment Reason
Reason Treatment Ended (Check only one)
Adverse Event/side Effects/complications
(Adverse event/side
effects/complications)
Death On Study (Death on study)
Disease Progression, Relapse During
Active Treatment (Disease progression,
relapse during active treatment)
Other (Other)
Patient Off-treatment For Other
Complicating Disease (Patient off-
treatment for other complicating disease)
Patient Withdrawal Or Refusal For
Reason Other Than Toxicity (Patient
withdrawal/refusal for reason other than
toxicity)
Treatment Completed Per Protocol
Criteria (Treatment completed per
1 / 2
protocol criteria)
Adverse event/side effects/complications specify
(specify)
Patient withdrawal/Refusal for reason other than
toxicity, specify
Patient off-treatment for other complicating
disease, specify
Other specify
Will patient receive further treatment?
Yes
No
Yes specify (below)
Best Tumor Response
Biologic Progression (Biologic
progression)
Complete Response (Complete
Response)
Increasing Disease (Increasing Disease)
N.a., Non-measurable Disease At
Baseline (N.A., Non-measurable disease
at baseline)
Not Evaluated This Course (Not
evaluated this course)
Partial Response (Partial Response)
Stable Disease (Stable Disease)
Symptomatic Deterioration (Symptomatic
Deterioration)
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Sarcoma NCT01533207 Off Treatment - Treatment Completion Form
(Q0) - 2843448v1.0
Off Treatment - Off Treatment -
3278673v1.0
Information concerning the patient's off treatment date,
reason and best response to treatment.
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=AD006CC7-
CD06-B0A3-E040-BB89AD437A16
All rights reserved. Please visit https://medical-data-
models.org/forms/6626
Off Treatment
Off Treatment
Visit Date (Enter the date the form is being
completed.)
Date Off Treatment (Enter the date when all
courses have been completed including the
normal observation period or discontinued and no
further treatment courses are planned.)
Reason Off Treatment (Select an off treatment
reason from one of the following reason groups:)
Alternative Treatment (A)
Disease Progression Before Treatment
(B)
Study Complete (C)
Death On Study (D)
Cytogenetic Resistance (G)
Ineligible (I)
Pi Discretion (N)
Other (O)
Disease Progression (P)
Treatment Period Completed (Q)
Refused Further Treatment (R)
Complicating Disease (S)
Toxicity (T)
Not Treated - Other Reasons (U)
Protocol Violation (V)
Declined To Participate (X)
No Treatment, Per Protocol Criteria (Z)
Explain 'Other' Reason Off Treatment (Enter an
explanation for selecting "Other" for a Reason Off
Treatment.)
Patient Began Protocol Specified Follow-up
(Indicate whether or not the patient began the
protocol-specified follow-up period.)
Yes
No
Date of Last Medication Administration
Best Response to Treatment (Select the best
overall response to treatment while on protocol.)
Complete Response (CR)
Complete Response Unconfirmed (CRU)
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Disease Unchanged (DU)
Less Than Partial Response (MR)
Not Assessed (NA)
Not Evauable (NE)
Non-cr/non-pd (Non-CR/Non-PD)
Not Applicable Per Protocol (NP)
Progressive Disease (PD)
Partial Response (PR)
Stable Disease (SD)
Too Early (TE)
Date of Best Response (Enter the date that a
Best Response of Treatment response of CR,
PR, or MR was first observed, or that an SD
response began.)
Date of Disease Progression (Enter the date that
progression or relapse was first observed i.e.:
date of scan.)
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Off Treatment - Off Treatment - 3278673v1.0
Sarcoma, Kaposi xxx Treatment - Concomitant
Antiretroviral Medications - RF08 - 2266224v3.0
Concomitant Antiretroviral Medications - RF08
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=CCE1D5AB-
D35E-42F6-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/6627
Concomitant Antiretroviral
Medications - RF08
Ccrr Module For Concomitant
Antiretroviral Medications - Rf08
ACTG Drug Code
Started prior to study?
Yes
No
Frequency (per day)
During this cycle, has the subject started or
stopped any antiretroviral medications?
Yes
No
Patient Initials
Study#
Site#
ID#
Cycle #
First day of cycle
Medication (Generic Name Only)
Amount
Units
Date Started
Date Stopped
Date Stopped
1 / 1
Sarcoma NCT00450320 Off Treatment - AMC-051 Off
Protocol Treatment Summary Form (F05) - 2636160v1.0
AMC-051 Off Protocol Treatment Summary Form (F05)
Sirolimus in Treating Patients With HIV-Related Kaposi's
Sarcoma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=2FDFA89A-
0872-6018-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/6628
AMC-051 Off Protocol Treatment
Summary Form (F05)
Ccrr Module For Off Protocol Treatment
Summary - Rf05b
Last Date (any modality of) protocol therapy was
given
Reason Treatment Ended (select the primary
reason)
Adverse Event/side Effects/complications
(Adverse Event/Side
Effects/Complications)
Alternative Therapy (Alternative therapy)
Cytogenetic Resistance (Cytogenetic
Resistance)
Death On Study (Death on study)
Disease Progression Before Active
Treatment (Disease Progression before
active treatment)
Disease Progression, Relapse During
Active Treatment (Disease progression,
relapse during active treatment)
Lost To Follow-up (Lost to follow-up)
No Treatment, Per Protocol Criteria (No
treatment, per protocol criteria)
Other (Other)
Patient Off-treatment For Other
Complicating Disease (Patient off-
treatment for other complicating disease)
Patient Withdrawal Or Refusal After
Beginning Protocol Therapy (Patient
withdrawal/refusal after beginning
protocol therapy)
Patient Withdrawal Or Refusal Before
Beginning Protocol Therapy (Patient
withdrawal/refusal prior to beginning
protocol therapy)
Treatment Completed Per Protocol
Criteria (Treatment completed per
protocol criteria)
Other, specify
Comments
1 / 1
Sarcoma, Kaposi xxx Off Treatment - Off Protocol
Treatment Summary - RF05B - 2266924v3.0
Off Protocol Treatment Summary - RF05B
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=CCE2A45C-
D0F7-48EE-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/6629
Off Protocol Treatment Summary -
RF05B
Ccrr Module For Off Protocol Treatment
Summary - Rf05b
Patient Initials
Study#
Site#
ID#
Date of Visit
Date of last dose of therapy
Reason patient for discontinuation of study drug
therapy
Adverse Event/side Effects/complications
(Adverse event)
Cytogenetic Resistance (Cytogenetic
resistance)
Death On Study (Death on Study)
Disease Progression Before Active
Treatment (Disease progression before
active treatment)
Disease Progression, Relapse During
Active Treatment (Disease progression,
relapse during active treatment)
Lost To Follow-up (Lost to follow-up)
Other (Other)
Patient Off-treatment For Other
Complicating Disease (Patient off-
treatment for other complicating disease)
Patient Withdrawal Or Refusal After
Beginning Protocol Therapy (Patient
withdrawal or refusal after beginning
protocol treatment)
Patient Withdrawal Or Refusal Before
Beginning Protocol Therapy (Patient
withdrawal or refusal before beginning
protocol treatment)
Other (Physician decision)
Other (Study discontinued)
Treatment Completed Per Protocol
Criteria (Treatment completed per
1 / 2
protocol)
Other, specify
2 / 2
Sarcoma, Kaposi xxx Off Treatment - Off Protocol Treatment Summary -
RF05B - 2266924v3.0
Sarcoma NCT01016730 Off Treatment -
AMC-063 Death Form (F04) - 3020173v1.0
AMC-063 Death Form (F04)
Bortezomib in Treating Patients With Relapsed or
Refractory AIDS-Related Kaposi Sarcoma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=815F9798-
A005-E20D-E040-BB89AD435094
All rights reserved. Please visit https://medical-data-
models.org/forms/6631
AMC-063 Death Form (F04)
Ccrr Module For Death Form - Rf04
Date of Death (mm/dd/yyyy)
Treatment Status (at time of death)
Off Study (Off study)
On Study, Off Protocol Treatment (On
study, off protocol treatment)
On Study, On Protocol Treatment (On
study, on protocol treatment)
Last Date (any modality of) protocol therapy was
given (mm/dd/yyyy)
Primary cause of death
Due To Non-malignancy Complications
Of Hiv Disease (Due to Non-malignancy
complications of HIV disease)
Due To Other Cause, Specify (Due to
other cause)
Due To Protocol Treatment (Due to
protocol treatment)
Due To Second Primary Or Other
Malignancy (Due to second primary or
other malignancy)
Due To This Disease (Due to this
disease)
Contributing cause of death
Due To Non-malignancy Complications
Of Hiv Disease (Due to Non-malignancy
complications of HIV disease)
Due To Other Cause, Specify (Due to
other cause)
Due To Protocol Treatment (Due to
protocol treatment)
Due To Second Primary Or Other
Malignancy (Due to second primary or
other malignancy)
Due To This Disease (Due to this
disease)
Specify
Describe cause of death
Source of death information
1 / 2
Autopsy (Autopsy)
Clinical Evidence Was The Source Of
Information On The Patient's Death
(Clinical evidence)
Contact With Physician (Contact with
physician)
Death Certificate Was The Source Of
Information On The Patient's Death
(Death certificate)
Histological Evidence Was The Source
Of Information On The Patient's Death
(Histological evidence)
Information From Friends And Relatives
(Information from friends and relatives)
Other (Other)
Other, specify
Comments
Comments
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Sarcoma NCT01016730 Off Treatment - AMC-063 Death Form (F04) -
3020173v1.0
Nonneoplastic Condition NCT01057121 Off Treatment - AMC-
070 Off-Protocol Treatment Summary Form (F05) - 3147099v1.0
AMC-070 Off-Protocol Treatment Summary Form (F05)
Lenalidomide in Treating Patients With AIDS-Related
Kaposi Sarcoma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=91E448E8-
A157-E89F-E040-BB89AD433766
All rights reserved. Please visit https://medical-data-
models.org/forms/6632
AMC-070 Off-Protocol Treatment
Summary Form (F05)
Ccrr Module For Off Protocol Treatment
Summary - Rf05b
Last Date (any modality of) protocol therapy was
given (mm/dd/yyyy)
Reason Treatment Ended (select the primary
reason)
Adverse Event/side Effects/complications
(Adverse Event/Side
Effects/Complications)
Alternative Therapy (Alternative therapy)
Cytogenetic Resistance (Cytogenetic
Resistance)
Death On Study (Death on study)
Disease Progression Before Active
Treatment (Disease Progression before
active treatment)
Disease Progression, Relapse During
Active Treatment (Disease progression,
relapse during active treatment)
Lost To Follow-up (Lost to follow-up)
No Treatment, Per Protocol Criteria (No
treatment, per protocol criteria)
Other (Other)
Patient Off-treatment For Other
Complicating Disease (Patient off-
treatment for other complicating disease)
Patient Withdrawal Or Refusal After
Beginning Protocol Therapy (Patient
withdrawal/refusal after beginning
protocol therapy)
Patient Withdrawal Or Refusal Before
Beginning Protocol Therapy (Patient
withdrawal/refusal prior to beginning
protocol therapy)
Treatment Completed Per Protocol
Criteria (Treatment completed per
protocol criteria)
Other, specify
Comments
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Sarcoma NCT00450320 Follow-Up - AMC-
051 Death Form (F04) - 2635976v1.0
AMC-051 Death Form (F04)
Sirolimus in Treating Patients With HIV-Related Kaposi's
Sarcoma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=2FDFA89A-
06DD-6018-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/6634
AMC-051 Death Form (F04)
Ccrr Module For Death Form - Rf04
Date of Last Contact or Death
Treatment Status (at time of death)
Off Study (Off study)
On Study, Off Protocol Treatment (On
study, off protocol treatment)
On Study, On Protocol Treatment (On
study, on protocol treatment)
Last Date (any modality of) protocol therapy was
given
Primary cause of death
Due To Non-malignancy Complications
Of Hiv Disease (Due to Non-malignancy
complications of HIV disease)
Due To Other Cause, Specify (Due to
other cause)
Due To Protocol Treatment (Due to
protocol treatment)
Due To Second Primary Or Other
Malignancy (Due to second primary or
other malignancy)
Due To This Disease (Due to this
disease)
Contributing cause of death
Due To Non-malignancy Complications
Of Hiv Disease (Due to Non-malignancy
complications of HIV disease)
Due To Other Cause, Specify (Due to
other cause)
Due To Protocol Treatment (Due to
protocol treatment)
Due To Second Primary Or Other
Malignancy (Due to second primary or
other malignancy)
Due To This Disease (Due to this
disease)
Specify
Describe cause of death
Source of death information
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Autopsy (Autopsy)
Clinical Evidence Was The Source Of
Information On The Patient's Death
(Clinical evidence)
Contact With Physician (Contact with
physician)
Death Certificate Was The Source Of
Information On The Patient's Death
(Death certificate)
Histological Evidence Was The Source
Of Information On The Patient's Death
(Histological evidence)
Information From Friends And Relatives
(Information from friends and relatives)
Other (Other)
Other, specify
Comments
Comments
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Sarcoma NCT00450320 Follow-Up - AMC-051 Death Form (F04) -
2635976v1.0
Sarcoma NCT01016730 Off Treatment - AMC-063 Off-
Protocol Treatment Summary Form (F05) - 3019646v1.0
AMC-063 Off-Protocol Treatment Summary Form (F05)
Bortezomib in Treating Patients With Relapsed or
Refractory AIDS-Related Kaposi Sarcoma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=8100CE37-
23B4-8765-E040-BB89AD431777
All rights reserved. Please visit https://medical-data-
models.org/forms/6636
AMC-063 Off-Protocol Treatment
Summary Form (F05)
Ccrr Module For Off Protocol Treatment
Summary - Rf05b
Last Date (any modality of) protocol therapy was
given (mm/dd/yyyy)
Reason Treatment Ended (select the primary
reason)
Adverse Event/side Effects/complications
(Adverse Event/Side
Effects/Complications)
Alternative Therapy (Alternative therapy)
Cytogenetic Resistance (Cytogenetic
Resistance)
Death On Study (Death on study)
Disease Progression Before Active
Treatment (Disease Progression before
active treatment)
Disease Progression, Relapse During
Active Treatment (Disease progression,
relapse during active treatment)
Lost To Follow-up (Lost to follow-up)
No Treatment, Per Protocol Criteria (No
treatment, per protocol criteria)
Other (Other)
Patient Off-treatment For Other
Complicating Disease (Patient off-
treatment for other complicating disease)
Patient Withdrawal Or Refusal After
Beginning Protocol Therapy (Patient
withdrawal/refusal after beginning
protocol therapy)
Patient Withdrawal Or Refusal Before
Beginning Protocol Therapy (Patient
withdrawal/refusal prior to beginning
protocol therapy)
Treatment Completed Per Protocol
Criteria (Treatment completed per
protocol criteria)
Other, specify
Comments
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Nonneoplastic Condition NCT01057121 Off Treatment
- AMC-070 Death Form (F04) - 3146384v1.0
AMC-070 Death Form (F04)
Lenalidomide in Treating Patients With AIDS-Related
Kaposi Sarcoma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=91E333A1-
42A6-701C-E040-BB89AD433C30
All rights reserved. Please visit https://medical-data-
models.org/forms/6639
AMC-070 Death Form (F04)
Ccrr Module For Death Form - Rf04
Date of Death (mm/dd/yyyy)
Treatment Status (at time of death)
Off Study (Off study)
On Study, Off Protocol Treatment (On
study, off protocol treatment)
On Study, On Protocol Treatment (On
study, on protocol treatment)
Last Date (any modality of) protocol therapy was
given (mm/dd/yyyy)
Primary cause of death
Due To Non-malignancy Complications
Of Hiv Disease (Due to Non-malignancy
complications of HIV disease)
Due To Other Cause, Specify (Due to
other cause)
Due To Protocol Treatment (Due to
protocol treatment)
Due To Second Primary Or Other
Malignancy (Due to second primary or
other malignancy)
Due To This Disease (Due to this
disease)
Contributing cause of death
Due To Non-malignancy Complications
Of Hiv Disease (Due to Non-malignancy
complications of HIV disease)
Due To Other Cause, Specify (Due to
other cause)
Due To Protocol Treatment (Due to
protocol treatment)
Due To Second Primary Or Other
Malignancy (Due to second primary or
other malignancy)
Due To This Disease (Due to this
disease)
Specify
Describe cause of death
Source of death information
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Autopsy (Autopsy)
Clinical Evidence Was The Source Of
Information On The Patient's Death
(Clinical evidence)
Contact With Physician (Contact with
physician)
Death Certificate Was The Source Of
Information On The Patient's Death
(Death certificate)
Histological Evidence Was The Source
Of Information On The Patient's Death
(Histological evidence)
Information From Friends And Relatives
(Information from friends and relatives)
Other (Other)
Other, specify
Comments
Comments
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Nonneoplastic Condition NCT01057121 Off Treatment - AMC-070 Death
Form (F04) - 3146384v1.0
Breast Cancer NCT00087178 Treatment - NSABP PROTOCOL B-36 Treatment
Form for 5-FU, Epirubicin, Cyclophosphamide (FEC) - 2174958v3.0
NSABP PROTOCOL B-36 Treatment Form for 5-FU,
Epirubicin, Cyclophosphamide (FEC)
Comparison of Two Combination Chemotherapy Regimens
in Treating Women With Breast Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=C87B6D74-
9381-59FA-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/6641
NSABP PROTOCOL B-36 Treatment
Form for 5-FU, Epirubicin,
Cyclophosphamide (FEC)
General information
Patient Initials (Last, First Middle)*
NSABP Patient ID*
NSABP Patient ID*
Institution Name*
Affiliate Name*
Person Completing Form (Phone)*
Person Completing Form (Phone)*
Person Completing Form (Phone)*
Person Completing Form (Phone)*
Person Completing Form (Phone)*
Person Completing Form (Phone)*
Person Completing Form (Phone)*
Person Completing Form (Phone)*
Person Completing Form (Phone)*
Are data amended?*
Yes
No
NSABP Patient ID*
1 / 3
NSABP Patient ID*
Summary Of 5-fu, Epirubicin,
Cyclophosphamide
Treatment Begin Date (0=not begun)*
Treatment End Date (0=not begun)*
Cycle #*
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
Date Administered (0=not administered)*
Unnamed question [agent name]*
5-FU (5-FU)
CYCLO (CYCLO)
EPI (EPI)
Protocol Dose (mg/m^2)*
Was this cycle delayed for toxicity? (Circle Y or N
for Yes, No)*
N (N)
Y (Y)
Was growth factor support employed? (Circle Y
or N for Yes, No)*
No (N)
Yes (Y)
Summary Of 5-fu, Epirubicin,
Cyclophosphamide (continued)
Reason Treatment Ended (Select the reason that
best explains why FEC has ended, or why the
patient did not begin FEC.)*
Alternative Therapy (Alternative therapy)
Death On Study (Death)
Disease Progression, Relapse During
Active Treatment (Disease progression,
relapse during active treatment)
Other (Other (specify))
Patient Off-treatment For Other
Complicating Disease (Patient off-
treatment for other complicating disease)
Patient Withdrawal Or Refusal After
Beginning Protocol Therapy (Patient
withdrawal or refusal)
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Breast Cancer NCT00087178 Treatment - NSABP PROTOCOL B-36 Treatment
Form for 5-FU, Epirubicin, Cyclophosphamide (FEC) - 2174958v3.0
Adverse Event/side Effects/complications
(Toxicity/Side effects/Complications)
Treatment Completed Per Protocol
Criteria (Treatment completed per
protocol criteria)
Other (specify)*
Comments*
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Breast Cancer NCT00087178 Treatment - NSABP PROTOCOL B-36 Treatment
Form for 5-FU, Epirubicin, Cyclophosphamide (FEC) - 2174958v3.0
Breast Cancer NCT00382070 Treatment - NSABP Protocol B-
42 - Off Form Worksheet for Letrozole/Placebo - 2494251v1.0
NSABP Protocol B-42 - Off Form Worksheet for
Letrozole/Placebo
Letrozole in Treating Postmenopausal Women Who Have
Received Hormone Therapy for Hormone Receptor-Positive
Breast Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=17AF5771-
2C3C-429B-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/6650
NSABP Protocol B-42 - Off Form
Worksheet for Letrozole/Placebo
Header
NSABP Patient ID
Patient Initials (Last First Middle)
Summary Of Letrozole/placebo
Administration
Did the patient begin Letrozole/Placebo
Yes
No
Treatment Start Date (If not begun, leave blank.)
Treatment End Date (If not begun, leave blank.)
Why did treatment end or not begin (Select the
reason that best explains why treatment has
ended or why the patient did not begin
treatment.)
Alternative Therapy (Alternative therapy)
Death (Death)
Declining Bone Density/osteoporotic
Bone Fracture (Declining Bone
Density/Osteoporotic Bone Fracture)
Disease Progression Or Relapse
(Disease progression or relapse)
Other (Other)
Other Adverse Event/side
Effects/complications (Other Adverse
Event/Side Effects/Complications)
Patient Off-treatment For Other
Complicating Disease (Patient off-
treatment for other complicating disease)
Patient Withdrawal Or Refusal (Patient
withdrawal or refusal)
Treatment Completed Per Protocol
Criteria (Treatment completed per
protocol criteria)
Specify
1 / 2
Footer Module
Completed by
Date
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Breast Cancer NCT00382070 Treatment - NSABP Protocol B-42 - Off
Form Worksheet for Letrozole/Placebo - 2494251v1.0
Breast Cancer NCT00382070 Treatment - NSABP Protocol B-42 - Off Form
Worksheet for Optional Letrozole Registration Program - 2494268v1.0
NSABP Protocol B-42 - Off Form Worksheet for Optional
Letrozole Registration Program
Letrozole in Treating Postmenopausal Women Who Have
Received Hormone Therapy for Hormone Receptor-Positive
Breast Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=17AF6A8E-
5354-44C8-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/6653
NSABP Protocol B-42 - Off Form
Worksheet for Optional Letrozole
Registration Program
Header
Patient Registration Number
Patient Initials (Last First Middle)
Summary Of Letrozole/placebo
Administration
Did the patient begin Letrozole
Yes
No
Treatment Start Date (If not begun, leave blank.)
Treatment End Date (If not begun, leave blank.)
Why did treatment end or not begin (Select the
reason that best explains why treatment has
ended or why the patient did not begin treatment.
)
Adverse Event/side Effects/complications
(Adverse event/side
effects/complications)
Alternative Therapy (Alternative therapy)
Death (Death)
Disease Progression Or Relapse
(Disease progression or relapse)
Other (Other)
Patient Withdrawal Or Refusal (Patient
withdrawal or refusal)
Treatment Completed Per Registration
Program (Treatment Completed per
Registration Program)
Specify
Footer Module
Completed by
1 / 2
Date
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Breast Cancer NCT00382070 Treatment - NSABP Protocol B-42 - Off Form
Worksheet for Optional Letrozole Registration Program - 2494268v1.0
TREATMENT SUMMARY FORM Breast
Cancer (NCT00601900)
CALGB 40503 TREATMENT SUMMARY FORM (ALL
PATIENTS)
Tamoxifen or Letrozole With or Without Bevacizumab in
Treating Women With Stage III or Stage IV Breast Cancer
NCT00601900
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=24078F1C-
5787-05D7-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/6656
TREATMENT SUMMARY FORM
Breast Cancer (NCT00601900)
Header
CALGB Form
CALGB Study No
CALGB Patient ID
Reporting period start date (MM DD YYYY)
Reporting period end date (MM DD YYYY)
Are data amended
Yes
No
Patient Initials (Last, First Middle)
Patient Hospital No.
Institution/Affiliate
Participating Group
Participating Group Study No.
Participating Group Patient ID
COMMENTS
Completed by (Last name, First name)
Date form completed (MM DD YYYY)
Treatment Plan
1 / 3
Total Number of Cycles given
Treatment End Date (MM DD YYYY)
Reason Treatment Ended (mark one with an X)
Adverse Event/side Effects/complications
(Adverse Event/Side
Effects/Complications)
Alternative Therapy (Alternative therapy)
Death On Study (Death on study)
Disease Progression, Relapse During
Active Treatment (Disease progression,
relapse during active treatment)
Other (Other)
Patient Off-treatment For Other
Complicating Disease (Patient off-
treatment for other complicating disease)
Patient Withdrawal Or Refusal After
Beginning Protocol Therapy (Patient
withdrawal/refusal after beginning
protocol therapy)
Patient Withdrawal Or Refusal Before
Beginning Protocol Therapy (Patient
withdrawal/refusal prior to beginning
protocol therapy)
Other specify
Was any non-protocol therapy given during
protocol treatment?
Yes
No
specify (If Yes)
Concurrent Non-protocol Biologic
Response Modifier Therapy (Concurrent
non-protocol biologic response modifier
therapy)
Concurrent Non-protocol Chemotherapy
(Concurrent non-protocol chemotherapy)
Concurrent Non-protocol High Dose
Chemotherapy/autologous Stem Cell
Transplant (Concurrent non-protocol high
dose chemotherapy/autologous stem cell
transplant)
Concurrent Non-protocol Hormonal
Therapy (Concurrent non-protocol
hormonal therapy)
Concurrent Non-protocol Radiation
Therapy (Concurrent non-protocol
radiation therapy)
Non-protocol Therapy Start Date
Were supporting agents given at any point during
protocol treatment
Aspirin (Aspirin)
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TREATMENT SUMMARY FORM Breast Cancer (NCT00601900)
Bisphosphonates (Bisphosphonates)
Blood Or Blood Products (Blood or blood
products)
Heparin (Heparin)
Low Molecular Weight Heparin (Low
Molecular Weight Heparin)
Nsaid (NSAIDS)
Other (Other)
Warfarin (Warfarin)
Bisphosphonates, specify
Other, specify
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TREATMENT SUMMARY FORM Breast Cancer (NCT00601900)
Breast Cancer NCT00601900 Toxicity - CALGB 40503
Supplemental Adverse Event (AE) Form - 2823361v1.0
CALGB 40503 Supplemental Adverse Event (AE) Form
Tamoxifen or Letrozole With or Without Bevacizumab in
Treating Women With Stage III or Stage IV Breast Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=604DB84A-
54BF-38D2-E040-BB89AD43495E
All rights reserved. Please visit https://medical-data-
models.org/forms/6661
CALGB 40503 Supplemental
Adverse Event (AE) Form
Header
CALGB Form
CALGB Study No
CALGB Patient ID
Reporting Period Start Date (MM DD YYYY)
Reporting Period End Date (MM DD YYYY)
Are data amended
Yes
No
Unnamed2
Patient Initials
Patient Hospital No.
Institution/Affiliate
Participating Group (Country name for
International sites)
Participating Group Study No.
Participating Group Patient ID
Expected Adverse Events
MedDRA Code
MedDRA Code
CTC adverse event term
1 / 2
CTC adverse event term
CTC AE grade (^1)
CTC AE grade (^1)
Duration (in days of highest grade during
assessment period)
Duration (in days of highest grade during
assessment period)
Attributable to which medication (Mark all that
apply)
Placebo Bevacizumab
(Bevacizumab/Placebo)
Tamoxifen Letrozole
(Letrozole/Tamoxifen)
Attributable to which medication (Mark all that
apply)
Placebo Bevacizumab
(Bevacizumab/Placebo)
Tamoxifen Letrozole
(Letrozole/Tamoxifen)
Completed by (Last name, First name)
Date form completed (MM DD YYYY)
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Breast Cancer NCT00601900 Toxicity - CALGB 40503 Supplemental
Adverse Event (AE) Form - 2823361v1.0
Breast Cancer NCT00601900 Follow-Up - CALGB
40503 FOLLOW-UP FORM - 2551098v1.0
CALGB 40503 FOLLOW-UP FORM
Tamoxifen or Letrozole With or Without Bevacizumab in
Treating Women With Stage III or Stage IV Breast Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=2403F6CA-
49D5-5F41-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/6663
CALGB 40503 FOLLOW-UP FORM
Header
CALGB Form
CALGB Study No
CALGB Patient ID
Reporting Period Start Date (MM DD YYYY)
Reporting Period End Date (MM DD YYYY date
of last contact or death)
Are data amended
Yes
No
Unnamed2
Patient Initials
Patient Hospital No.
Institution/Affiliate
Participating Group
Participating Group Study No.
Participating Group Patient ID
Vital Status
Patient's vital status (Mark one with an X.)
Alive (Alive)
Dead (Dead)
Lost To Follow-up (Lost to follow-up)
Primary cause of death (Mark one with an X.)
Due To Other Cause (Due to other
cause)
1 / 3
Due To Protocol Treatment (Due to
protocol treatment)
Due To This Disease (Due to this
disease)
Unknown (Unknown)
Describe cause of death
Has the patient had a documented clinical
assessment for this cancer (since submission of
last follow-up form)
Yes
No
Date of Last Clinical Assessment
Was patient restaged during this time period (If
Yes, complete the following questions and submit
C-817 Follow-Up Solid Tumor Measurement
Form)
Yes
No
Overall Tumor Response
Complete Response (CR)
Partial Response (PR)
CR First Observed Date (MM DD YYYY)
PR First Observed Date (MM DD YYYY)
Non-protocol Therapy
Has the patient received any non-protocol cancer
therapy prior to first progression (If yes, specify
the therapy given)
Yes
No
Agent
Total Dose
Units
Agent Start Date (MM DD YYYY)
Agent End Date (MM DD YYYY)
Notice Of Progression
Has the patient developed a first progression (or
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Breast Cancer NCT00601900 Follow-Up - CALGB 40503 FOLLOW-UP
FORM - 2551098v1.0
relapse) that has not been previously reported?
(or relapse)
No (No)
Unknown (Unknown)
Yes (Yes)
Date of progression (MM DD YYYY)
Has a new primary cancer or MDS been
diagnosed that has not been previously reported?
(myelodysplastic syndrome)
Yes
No
Date of diagnosis (MM DD YYYY)
Site of new primary (s)
Skeletal Related Events
Did patient experience any skeletal related
event?
Yes
No
Type of skeletal related event (Mark all that apply
with an X.)
Fracture (fracture)
Hypercalcemia (Hypercalcemia)
Palliative Radiotherapy (Palliative
radiation for bone metastasis)
Spinal Cord Compression (spinal cord
compression)
Date of event (MM DD YYYY)
Comments
COMMENTS
Completed by (Last name, First name)
Date form completed (MM DD YYYY)
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Breast Cancer NCT00601900 Follow-Up - CALGB 40503 FOLLOW-UP
FORM - 2551098v1.0
Breast Cancer NCT00659373 Treatment -
Tamoxifen/Exemestane Form (Form 24-TE) - 2080772v3.0
Tamoxifen/Exemestane Form (Form 24-TE)
Brain Function in Premenopausal Women Receiving
Tamoxifen With or Without Ovarian Function Suppression
for Early-Stage Breast Cancer on Clinical Trial IBCSG-2402
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=B70B84C2-
ED22-2268-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/6666
Tamoxifen/Exemestane Form (Form
24-TE)
Ccrr Module For Tamoxifen/exemestane
Form - Revised (form 24-te)
Patient ID No.
Patient Initials (f m fl sl)
Patient's Date of Birth (day)
Participating Center/Affiliate
Center Code
Reporting Period Start Date (if this is the first
follow-up period, enter date started)
Reporting Period End Date (day month year)
Is this the first follow-up period during which the
patient has taken Tamoxifen or Exemestane
Yes
No
Date started
Tamoxifen
Did patient receive Tamoxifen during this follow-
up period (select all that apply)
No, Not Randomized To Tamoxifen (No,
not randomized to Tamoxifen)
No, Will Never Start (No, will never start)
No, Will Start Later, Submit Another
Form 24-te With Next 24-e Follow-up
Form (No, will start later, submit another
Form 24-TE with next 24-E Follow-Up
Form)
Yes, But At Non-protocol Dose Or
Interrupted For At Least One Month (Yes,
but at non-protocol dose or interrupted
1 / 7
for at least one month)
Yes, But Stopped Early (Yes, but stopped
early)
Yes, Completed 5 Years After
Randomization (Yes, completed 5 years
after randomization)
Yes, Continuing As Per Protocol (Yes,
continuing as per protocol)
Yes, Took Tamoxifen But Randomized To
Exemestane, Check Reason (Yes, took
Tamoxifen but randomized to
Exemestane, check reason)
Yes, took Tamoxifen but randomized to
Exemestane, check reason (select one) (select
one)
Adverse Event(s) Report On Form 24-ae
(Adverse Event(s) Report on Form 24-
AE)
Medical Decision (Medical decision)
Other, Specify (Other, specify)
Patient Refusal (Patient refusal)
Other, specify (took Tamoxifen but randomized to
Exemestane)
Compliance Code
Interrupted For At Least One Month
(Interrupted for at least one month)
Not Taken At All (Not taken at all)
Other, Specify (Other, specify)
Taken As Per Protocol (Taken as per
protocol)
Other, specify (compliance code)
Reason not taken code
Adverse Event, Specify (Adverse event,
specify)
Other, Specify (Other, specify)
Patient Refusal (Patient refusal)
Recurrence/relapse
(Recurrence/relapse)
Adverse event, specify
Adverse event, specify
Adverse event, specify
Other, specify (reason not taken)
If non-protocol dose was used during this follow-
up period, what dosage was given
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Breast Cancer NCT00659373 Treatment - Tamoxifen/Exemestane Form
(Form 24-TE) - 2080772v3.0
Date of first dose for this reporting period
End date of non-protocol dose
Reason non-protocol dose used
Adverse Event (Adverse event)
Medical Decision (Medical decision)
Other, Specify (Other, specify)
Patient Refusal (Patient refusal)
Adverse event, specify (reason non-protocol dose
used)
Medical decision, specify (reason non-protocol
dose used)
Other, specify (reason non-protocol dose used)
Drug Stop Date
Drug Resume Date
Reason for Interruption Code
Adverse Event, Specify (Adverse event,
specify)
Other, Specify (Other, specify)
Patient Refusal (Patient refusal)
Recurrence/relapse
(Recurrence/relapse)
Other, specify (reason for interruption)
If patient permanently discontinued Tamoxifen
during this follow-up period give date of last dose
(or prior follow-up period if not previously
reported,)
If Tamoxifen stopped early or never started,
reason (select one)
Adverse Event, Specify (Adverse event,
specify)
Death On Study (Death on study)
Error (Error)
Medical Decision, Specify (Medical
decision, specify)
Other, Specify (Other, specify)
Patient Refusal (Patient refusal)
Recurrence (Recurrence)
Medical decision, specify
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Breast Cancer NCT00659373 Treatment - Tamoxifen/Exemestane Form
(Form 24-TE) - 2080772v3.0
Other, specify
If Tamoxifen will start later, reason
Adverse Event, Specify (Adverse event,
specify)
Error (Error)
Medical Decision, Specify (Medical
decision, specify)
Other, Specify (Other, specify)
Patient Refusal (Patient refusal)
Adverse event, specify (if Tamoxifen will start
later, reason)
Medical decision, specify  (if Tamoxifen will start
later, reason)
Other, specify  (if Tamoxifen will start later,
reason)
Exemestane
Did patient receive Exemestane during this
follow-up period (select all that apply)
No, Not Randomized To Exemestane
(No, not randomized to Exemestane)
No, Will Never Start (No, will never start)
No, Will Start Later, Submit Another
Form 24-te With Next 24-e Follow-up
Form (No, will start later, submit another
Form 24-TE with next 24-E Follow-Up
Form)
Yes, But Interrupted For At Least One
Month (Yes, but interrupted for at least
one month)
Yes, But Stopped Early (Yes, but stopped
early)
Yes, Completed 5 Years After
Randomization (Yes, completed 5 years
after randomization)
Yes, Continuing As Per Protocol (Yes,
continuing as per protocol)
Yes, Took Exemestane But Randomized
To Tamoxifen, Check Reason (select
One) (Yes, took Exemestane but
randomized to Tamoxifen, check reason
(select one))
Yes, took Exemestane but randomized to
Tamoxifen, check reason  (select one)
Adverse Event(s) Report On Form 24-ae
(Adverse Event(s) Report on Form 24-
AE)
Medical Decision (Medical decision)
Other, Specify (Other, specify)
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Breast Cancer NCT00659373 Treatment - Tamoxifen/Exemestane Form
(Form 24-TE) - 2080772v3.0
Patient Refusal (Patient refusal)
Other, specify (specify)
Compliance Code
Interrupted For At Least One Month
(Interrupted for at least one month)
Not Taken At All (Not taken at all)
Other, Specify (Other, specify)
Taken As Per Protocol (Taken as per
protocol)
Dose
Number of tablets dispensed
Other, specify (compliance code)
Reason not taken code
Adverse Event, Specify (Adverse event,
specify)
Other, Specify (Other, specify)
Patient Refusal (Patient refusal)
Recurrence/relapse
(Recurrence/relapse)
Batch Number
Adverse event, specify
Adverse event, specify
Date tablets dispensed
Adverse event, specify
Other, specify (reason not taken)
Tablets dispensed by (initials)
If non-protocol dose was used during this follow-
up period, what dosage was given
Number of tablets returned
Date tablets returned
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End date of non-protocol dose
Reason non-protocol dose used
Adverse Event (Adverse event)
Medical Decision (Medical decision)
Other, Specify (Other, specify)
Patient Refusal (Patient refusal)
Adverse event, specify (reason non-protocol dose
used)
Medical decision, specify (reason non-protocol
dose used)
Other, specify (reason non-protocol dose used)
Drug Stop Date
Date of First dose for this reporting period
Drug Resume Date
Reason for Interruption Code
Adverse Event, Specify (Adverse event,
specify)
Other, Specify (Other, specify)
Patient Refusal (Patient refusal)
Recurrence/relapse
(Recurrence/relapse)
Other, specify (reason for interruption)
Medical decision, specify
Other, specify
If patient permanently discontinued Exemestane
during this follow-up period give date of last dose
(or prior follow-up period if not previously
reported,)
If Exemestane stopped early or never started,
reason (select one)
Adverse Event, Specify (Adverse event,
specify)
Death On Study (Death on study)
Error (Error)
Gnrh Stopped Early And Patient
Remained Premenopausal (GnRH
stopped early and patient remained
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premenopausal)
Medical Decision, Specify (Medical
decision, specify)
Other, Specify (Other, specify)
Patient Refusal (Patient refusal)
Recurrence (Recurrence)
If Exemestane will start later, reason
Adverse Event, Specify (Adverse event,
specify)
Error (Error)
Medical Decision, Specify (Medical
decision, specify)
Other, Specify (Other, specify)
Patient Refusal (Patient refusal)
Adverse event, specify (if Exemestane will start
later, reason)
Medical decision, specify  (if Exemestane will
start later, reason)
Other, specify  (if Exemestane will start later,
reason)
Investigator Signature (Designee)
Date
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Breast Cancer NCT01275677 Toxicity - NSABP-B-47 Protocol
Treatment and Adverse Event Form (Form TRTAE) - 3161483v1.0
NSABP-B-47 Protocol Treatment and Adverse Event Form
(Form TRTAE)
A Randomized Phase III Trial of Adjuvant Therapy
Comparing Chemotherapy Alone (Six Cycles of Docetaxel
Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus
Cyclophosphamide Followed by Weekly Paclitaxel) to
Chemotherapy Plus Trastuzumab in Women With Node-
Positive or High-Risk Node-Negative HER2-Low Invasive
Breast Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=9556EA2E-
762A-EB5C-E040-BB89AD4324DE
All rights reserved. Please visit https://medical-data-
models.org/forms/6667
NSABP-B-47 Protocol Treatment and
Adverse Event Form (Form TRTAE)
Header
Patient Initials (Last First Middle)
NSABP Patient ID
Arm 1
Reporting Period (for Groups 1B, 2B)
1 (1)
2 (2)
3 (3)
4 (4)
Pc 1-3 (PC 1-3)
Pc 10-12 (PC 10-12)
Pc 13-15 (PC 13-15)
Pc 16-17 (PC 16-17)
Pc 4-6 (PC 4-6)
Pc 7-9 (PC 7-9)
Wp 1-3 (WP 1-3)
Wp 10-12 (WP 10-12)
Wp 4-6 (WP 4-6)
Wp 7-9 (WP 7-9)
Arm 2
Reporting Period (for Groups 1B, 2B)
1 (1)
2 (2)
3 (3)
4 (4)
Pc 1-3 (PC 1-3)
Pc 10-12 (PC 10-12)
Pc 13-15 (PC 13-15)
Pc 16-17 (PC 16-17)
Pc 4-6 (PC 4-6)
Pc 7-9 (PC 7-9)
Wp 1-3 (WP 1-3)
Wp 10-12 (WP 10-12)
Wp 4-6 (WP 4-6)
Wp 7-9 (WP 7-9)
1 / 4
Header
Reporting Period Start Date (Month Day Year)
Reporting Period End Date (Month Day Year)
Section 1
Agent Name
Dose
2 Mg/kg (2 mg/kg)
4 Mg/kg (4 mg/kg)
45 Mg/m^2 (45 mg/m^2)
60 Mg/m^2 (60 mg/m^2)
80 Mg/m^2 (80 mg/m^2)
Not Given (Not given)
Other (Other)
Other, specify
Section 1
Agent Name
Agent Dose Number (in Reporting Period First
dose Second dose Third dose)
Dose
2 Mg/kg (2 mg/kg)
4 Mg/kg (4 mg/kg)
45 Mg/m^2 (45 mg/m^2)
60 Mg/m^2 (60 mg/m^2)
80 Mg/m^2 (80 mg/m^2)
Not Given (Not given)
Other (Other)
Other, specify
Number of Trastuzumab doses (in this Reporting
Period)
1 (1)
2 (2)
3 (3)
Other (Other)
Other, specify
Section 1b - Post-chemotherapy
Trastuzumab
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Agent Dose Number (in Reporting Period First
dose Second dose Third dose)
Did the patient receive trastuzumab during this
treatment period
Yes
No
Selected Surgical Complications
Was the patient hospitalized with an adverse
event (Hospitalization associated with an adverse
event is defined as any hospitalization lasting >=
24 hours or prolongation of an existing
hospitalization.)
Yes
No
Adverse Event
Allergic Reaction (Allergic reaction)
Dyspnea (Dyspnea)
Infusion Related Reaction (Infusion
related reaction)
Pulmonary Fibrosis (Pulmonary fibrosis)
Grade
Mild Adverse Event (1)
Selected Surgical Complications
Adverse Event
Allergic Reaction (Allergic reaction)
Dyspnea (Dyspnea)
Infusion Related Reaction (Infusion
related reaction)
Pulmonary Fibrosis (Pulmonary fibrosis)
Grade
Mild Adverse Event (1)
Selected Surgical Complications
Adverse Event
Allergic Reaction (Allergic reaction)
Dyspnea (Dyspnea)
Infusion Related Reaction (Infusion
related reaction)
Pulmonary Fibrosis (Pulmonary fibrosis)
Grade
Mild Adverse Event (1)
Footer Module
Comments (optional)
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Person Completing Form, Last Name
Person Completing Form, First Name
Person Completing Form, Phone
E-mail
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Breast Cancer NCT01242800 Follow-Up -
E2108 Step 2 Follow-up Form - 3130846v1.0
E2108 Step 2 Follow-up Form
Early Surgery or Standard Palliative Therapy in Treating
Patients With Stage IV Breast Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=8E30083E-
7422-9EAD-E040-BB89AD430E1D
All rights reserved. Please visit https://medical-data-
models.org/forms/6669
E2108 Step 2 Follow-up Form
Header
ECOG Protocol Number
DCI Name
Registration Step
ECOG Patient ID
Unnamed2
Patient Initials (Last, First)
ECOG Protocol Number
Participating Group Protocol Number
Institution/Affiliate
ECOG Patient ID
Participating Group Patient ID
Unnamed4
Please mark an 'X' if data have been amended.
(Please circle amended items in red)
Date data amended (s M D Y)
On Treatment Report Period
Report Period (Choose one)
12 Months Post Randomization (12
Months Post Randomization)
15 Months Post Randomization (15
Months Post Randomization)
21 Months Post Randomization (21
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Months Post Randomization)
24 Months Post Randomization (24
Months Post Randomization)
3 Months Post Randomization (3 Months
Post Randomization)
30 Months Post Randomization (30
Months Post Randomization)
36 Months Post Randomization (36
Months Post Randomization)
42 Months Post Randomization (42
Months Post Randomization)
48 Months Post Randomization (48
Months Post Randomization)
54 Months Post Randomization (54
Months Post Randomization)
6 Months Post Randomization (6 Months
Post Randomization)
60 Months Post Randomization (60
Months Post Randomization)
9 Months Post Randomization (9 Months
Post Randomization)
At Decision For Local Therapy (At
Decision for Local Therapy)
Baseline Step 2 (Baseline Step 2)
Vital Status
Patient's Vital Status
Alive (Alive)
Dead (Dead)
Date of last contact or death (M D Y)
Primary Cause of Death (if applicable)
Due To Other Cause (Due to other
cause)
Due To Protocol Treatment (Due to
protocol treatment)
Due To This Disease (Due to this
disease)
Unknown (Unknown)
Describe cause of death
Section Ii - Reporting Period
Reporting Period Start Date (M D Y)
Reporting Period End Date (M D Y NOTE: The
remainder of the questions on this form should be
answered with respect to the report period dates
above. Any known events other than survival
status and date that occurred outside of these
dates should be reported on the form for the
appropriate report period)
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Has the patient been diagnosed with first local-
regional recurrence (since submission of last
follow-up form)
No (NO)
Unknown (Unknown)
Yes (YES)
Basis of Diagnosis
Clinical (Clinical)
Histology (Histology)
Other (Other)
Radiologic (Radiologic)
Radiologic And Histologic (Radiologic
and Histologic)
Date of First Local-Regional Recurrence (If yes M
D Y)
Other Specify
Iib - Local-regional Recurrence
Axillary Node(s) and/or Soft Tissue
Yes
No
Infraclavicular Node(s)
Yes
No
Skin of breast
Yes
No
Internal mammary node
Yes
No
Ipsilateral Breast
Yes
No
Supraclavicular Node(s)
Yes
No
Skin of the chest wall
Yes
No
Chest Wall
Skin nodules present?
Yes
No
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Sum of longest diameter of largest five nodules
Ulceration present?
Yes
No
Area of Ulceration
Area of Ulceration
Is direct invasion of tumor into skin present?
Yes
No
Longest dimension of skin invasion
Status Of Local-regional Disease
Skin nodules present?
Yes
No
Sum of longest diameter of largest five nodules (If
yes,)
Ulceration present?
Yes
No
Area of Ulceration (If yes,)
Area of Ulceration
Tumor Mobility
Attached To Fascia (Attached to fascia)
Chest Wall Fixation (Chest wall fixation)
Free (Free)
Is direct invasion of tumor into skin present?
Yes
No
Longest dimension of skin invasion (If yes,)
Asymptomatic tumor in the intact breast present?
Yes
No
Sum of longest diameter of largest five tumors (If
yes,)
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Disease Description
Has the patient been diagnosed with first distant
progression? (since submission of last follow-up
form)
No (No)
Unknown (Unknown)
Yes (Yes)
Date of First Distant Progression
Basis of Diagnosis
Clinical (Clinical)
Histology (Histology)
Other (Other)
Radiologic (Radiologic)
Radiologic And Histologic (Radiologic
and Histologic)
Opposite Breast
No (NO)
Unknown (UNKNOWN)
Yes (YES)
Distant Lymph Nodes
No (NO)
Unknown (UNKNOWN)
Yes (YES)
Distant Skin/subcutaneous Tissue
No (No)
Unknown (Unknown)
Yes (Yes)
Bone
No (NO)
Unknown (UNKNOWN)
Yes (YES)
Bone Marrow
No (No)
Unknown (Unknown)
Yes (Yes)
Lung
No (NO)
Unknown (UNKNOWN)
Yes (YES)
Liver
No (NO)
Unknown (UNKNOWN)
Yes (YES)
Pleura
No (NO)
Unknown (UNKNOWN)
Yes (YES)
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Brain
No (NO)
Unknown (UNKNOWN)
Yes (YES)
Other CNS
No (NO)
Unknown (UNKNOWN)
Yes (YES)
Other
No (NO)
Unknown (UNKNOWN)
Yes (YES)
Other specify
Overall Response Per Recist Criteria -
Target, Nontarget And New Lesions
Were circulating tumor cells (CTCs) assessed
Yes
No
Date of Enumeration
CTC Count (#CTC/mL)
Comments
Investigator Signature
Investigator Signature Date
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Breast Cancer Follow-Up - IBCSG Long Term
Follow-Up Form (18-LTF) - 3108506v1.0
IBCSG Long Term Follow-Up Form (18-LTF)
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=889C3F60-
2C47-8540-E040-BB89AD4303DD
All rights reserved. Please visit https://medical-data-
models.org/forms/6675
IBCSG Long Term Follow-Up Form
(18-LTF)
Header Module
Visit number
IBCSG Patient ID
IBCSG Study No.
Randomization No.
Institution Code Number
Institution Name
Long Term Follow-up
Reporting Period Start Date (day month year
From day following date of previous report)
Reporting Period End Date (day month year To
date of examination for this report or patient
contact)
Source of patient information for this report
Documentation Of Hospital Or Clinic Visit
(Documentation of hospital or clinic visit)
Family Member (Family member)
Contact With Physician (General
physician)
Lost To Follow-up (Lost to follow-up)
Other (Other)
Phone Contact To Patient (Phone
contact to patient)
Central Registry (Registry)
Other, specify
Specify (Lost to follow-up, specify reason)
Performance Status
Fully Active, Able To Carry On All Pre-
disease Performance Without
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Restriction. (0)
Restricted In Physically Strenuous
Activity But Ambulatory And Able To
Carry Out Work Of A Light Or Sedentary
Nature, E.g., Light Housework, Office
Work. (1)
Ambulatory And Capable Of All Selfcare
But Unable To Carry Out Any Work
Activities. Up And About More Than 50%
Of Waking Hours. (2)
Capable Of Only Limited Selfcare,
Confined To Bed Or Chair More Than
50% Of Waking Hours. (3)
Completely Disabled. Cannot Carry On
Any Selfcare. Totally Confined To Bed Or
Chair. (4)
Dead (5)
Weight (kg if patient seen for clinic visit. -1 if not
seen)
Select all that apply to this follow-up period and
submit the specified forms
Not Able To Obtain Any Additional
Information (Not able to obtain any
additional information)
Not Applicable (Not Applicable)
Patient Died (Patient died)
Patient Experienced An Arthralgia (grade
2 Or Higher), Myalgia (grade 2 Or
Higher), Osteopenia/osteoporosis, Bone
Fracture Or Cardiovascular Event
(Patient experienced an arthralgia (grade
2 or higher), myalgia (grade 2 or higher),
osteopenia/osteoporosis, bone fracture
or cardiovascular event)
Patient Had A Proven
Recurrence/metastasis Or Contralateral
Invasive Breast Cancer (Patient had a
proven recurrence/metastasis or
contralateral invasive breast cancer)
Patient Had A Proven Second (non-
breast) Malignancy (Patient had a proven
second (non-breast) malignancy)
Patient Received Bone Active Medication
(e.g., Bisphosphonates),
Glucocorticosteroids, Continuous
Nonsteroidal Anti-inflammatory Drug,
Extended Adjuvant Endocrine Therapy
(Patient received bone active medication
(e.g., bisphosphonates),
glucocorticosteroids, continuous
nonsteroidal anti-inflammatory drug,
extended adjuvant endocrine therapy)
Footer Module
Investigator/Designee Signature
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Date (day month year)
3 / 3
Breast Cancer Follow-Up - IBCSG Long Term Follow-Up Form (18-LTF) -
3108506v1.0
Brain and Central Nervous System Tumors NCT00978458
Follow-Up - E3F05 Long-Term Follow-up Form - 2900961v1.0
E3F05 Long-Term Follow-up Form
Radiation Therapy With or Without Temozolomide in
Treating Patients With Low-Grade Glioma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=6C1889F9-
D142-5474-E040-BB89AD431A23
All rights reserved. Please visit https://medical-data-
models.org/forms/6676
E3F05 Long-Term Follow-up Form
Header
ECOG Protocol Number
ECOG Protocol Number
ECOG Patient ID
ECOG Patient ID
DCI Name
Registration Step (Place ID Label Here)
Patient Initials (Last, First)
Participating Group Protocol Number
Participating Group Patient ID
Institution/Affiliate
Off Treatment Report Period (since registration
choose one)
9 Years (108 months post registration)
12 Months (12 Months Post Registration)
10 Years (120 months post registration)
11 Years Post Registration (132 Months
Post Registration)
12 Years Post Registration (144 Months
Post Registration)
15 Months (15 Months Post Registration)
13 Years Post Registration (156 Months
Post Registration)
14 Years Post Registration (168 Months
Post Registration)
18 Months (18 Months Post Registration)
15 Years Post Registration (180 Months
Post Registration)
21 Months Post Registration (21 Months
Post Registration)
2 Years (24 Months Post Registration)
3 Months (3 Months Post Registration)
1 / 4
30 Months (30 Months Post Registration)
3 Years (36 Months Post Registration)
42 Months (42 Months Post Registration)
4 Years (48 Months Post Registration)
54 Months (54 Months Post Registration)
6 Months (6 Months Post Registration)
5 Years (60 Months Post Registration)
6 Years (72 Months Post Registration)
84 Months Post Registration (84 Months
Post Registration)
9 Months (9 Months Post Registration)
8 Years (96 months post registration)
Unnamed2
Please mark an 'X' if data have been amended.
(Please circle amended items in red)
Date data amended (s M D Y)
Vital Status
Patient's Vital Status
Alive (Alive)
Dead (Dead)
Date of Last Contact or Death (m d y)
Primary Cause of Death (if applicable)
Due To Other Cause (Due to other
cause)
Due To Protocol Treatment (Due to
protocol treatment)
Due To This Disease (Due to this
disease)
Unknown (Unknown)
Describe cause of death
Section Ii - Reporting Period
Reporting Period Start Date (M D Y)
Reporting Period End Date (M D Y)
Section Iv - Notice Of New Primary
Has a new primary cancer or MDS been
diagnosed that has not been previously reported?
No (No)
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Unknown (Unknown)
Yes (Yes)
Site of new primary (s If new primary site is
AML/MDS/ALL, submit NCI AML/MDS/ALL form
If new primary site is other than AML/MDS/ALL,
submit ECOG Second Primary Form)
Section Iii - Disease Follow-up Status
Has the patient had a documented clinical
assessment for this cancer (this reporting period)
No (No)
Unknown (Unknown)
Yes (Yes)
If unknown, please explain
Date of last clinical assessment (If yes M D Y
Submit E3F05 Primary Brain Tumor Follow-up
Disease Evaluation Form)
Has the patient developed a first progression that
has not been previously reported? (CNS or
relapse)
No (No)
Unknown (Unknown)
Yes (Yes)
If unknown, please explain
Date of progression (If yes, CNS relapse M D Y
Submit E3F05 Primary Brain Tumor Follow-up
Disease Evaluation Form)
Site(s) of progression (CNS)
Did a physician make a formal diagnosis of
progressive disease? (CNS)
No (No)
Unknown (Unknown)
Yes (Yes)
Specify basis of progression (If no or unknown
CNS)
Section V - Adverse Events
Has the patient experienced any severe (Grade =
3) long term toxicity that has not been previously
reported? (prior to diagnosis of CNS
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progression/relapse NOTE: Do not report
adverse events occurring after start of non-
protocol therapy.)
No (No)
Unknown (Unknown)
Yes (Yes)
Section Vi - Non-protocol Therapy Prior To
Progression
Has the patient received any non-protocol cancer
therapy prior to first progression (CNS not
previously reported)
No (No)
Unknown (Unknown)
Yes (Yes)
Comments
Investigator Signature
Investigator Signature Date (M D Y)
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Breast Cancer NCT01272037 Treatment -
S1007 Treatment Form (TX1007) - 3140038v1.0
S1007 Treatment Form (TX1007)
Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane
With or Without Chemotherapy in Treating Patients With
Invasive RxPONDER Breast Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=90CA1C57-
43D2-A228-E040-BB89AD43458D
All rights reserved. Please visit https://medical-data-
models.org/forms/6689
S1007 Treatment Form (TX1007)
Header
SWOG Patient ID
SWOG Study No.
Registration Step
Patient Initials (L, F M)
Reporting Period
12 Months (12 months)
18 Months (18 months)
24 Months (24 months)
30 Months (30 months)
36 Months (36 months)
48 Months (48 months)
6 Months (6 months)
60 Months (60 months)
Institution/Affiliate
Physician
Participating Group Name
Participating Group Study No.
Participating Group Patient ID
Status
Vital Status
Alive (Alive)
Dead (Dead)
Date of Last Contact or Death (MM DD YYYY)
Has the patient progressed per the definition in
Section 10.0 of the protocol
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Yes
No
Treatment For This Cycle
Assigned Treatment Arm
Arm 1: Chemotherapy + Endocrine
Therapy (Arm 1: Chemotherapy +
endocrine therapy)
Arm 2: Endocrine Therapy Only (Arm 2:
Endocrine therapy only)
Was the patient treated on the assigned arm
during this reporting period
Yes
No
Reporting Period Start Date (MM DD YYYY)
Reporting Period End Date (MM DD YYYY)
Weight (kg)
Has the patient received any chemotherapy
during this reporting period?
No (No)
Yes, Chemotherapy Completed (Yes,
chemotherapy completed)
Yes, Chemotherapy Continuing (Yes,
chemotherapy continuing)
Section Iv - Treatment
Has the patient received any endocrine therapy
during this reporting period
Yes
No
Did patient switch type of endocrine therapy
during this reporting period
Yes
No
Specify reason for switch in endocrine therapy (If
yes)
Adverse Events From Prior Endocrine
Therapy (Adverse events from prior
endocrine therapy)
Both Planned Switch For Therapeutic
Reason And For Adverse Events From
Prior Hormonal Therapy (Both)
Other (Other)
Planned Switch For Therapeutic Reason
(Planned switch for therapeutic reason)
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Other, specify
Start date of new endocrine therapy (MM DD
YYYY)
Specify new type of endocrine therapy given
Aromatase Inhibitor (Aromatase
Inhibitor)
Other (Other)
Tamoxifen (Tamoxifen)
Other, specify
Specify which Aromatase Inhibitor was given (If
Aromatase Inhibitor)
Anastrozole (ANASTROZOLE)
Exemestane (EXEMESTANE)
Letrozole (LETROZOLE)
Other (Other)
Other, specify
Tamoxifen (If no, Answer Yes or No for each of
the following therapies the patient consistently
took during this reporting period)
Yes
No
Aromatase Inhibitor (If no, Answer Yes or No for
each of the following therapies the patient
consistently took during this reporting period)
Yes
No
Specify which Aromatase Inhibitor was given
Anastrozole (ANASTROZOLE)
Exemestane (EXEMESTANE)
Letrozole (LETROZOLE)
Other (Other)
Specify
Other
Yes
No
Specify (If yes,)
If the patient was premenopausal at registration,
is she currently having regular menstrual periods
Yes
No
Did patient receive Ovarian Function Suppression
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(OFS) during this reporting period
No (No)
Unknown (Unknown)
Yes (Yes)
Ovarian Function Suppression Type (If yes)
Medical Suppression Of Ovarian
Function (Medical suppression)
Bilateral Surgical Oophorectomy
(Oophorectomy)
Other (Other)
Radiation Therapy (Ovarian radiation)
Other, specify
Was all endocrine therapy discontinued this
reporting period
Yes
No
Date any endocrine therapy last given (If yes MM
DD YYYY)
Concurrent Medications/clinical Trials
Did the patient receive bisphosphonates during
this reporting period (select all that apply)
Bisphosphonates For Breast Cancer
Treatment (Bisphosphonates for breast
cancer treatment)
Bisphosphonates For Prevention Of
Bone Loss (Bisphosphonates for
prevention of bone loss)
Is the patient currently co-enrolled on another
CTEP or NCI-sponsored clinical trial for breast
cancer
Yes
No
Specify
Date of enrollment (MM DD YYYY)
Comments
Comments
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Follow-Up - Chronic Myelogenous Leukemia
(CML) - Follow-Up Form - 2019375v3.0
Chronic Myelogenous Leukemia (CML) - Follow-Up Form
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=1AB0C43D-
1393-07D0-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/6716
Chronic Myelogenous Leukemia
(CML) - Follow-Up Form
Crf Header
Coordinating Group Protocol No.
Coordinating Group Code
Protocol Title
Patient Study ID
Institution/Affiliate
Other Patient ID
Participating Group Code
Patient Initials
Registration Type
Leukemia/mds: Form Administration
Person Completing Form
Are data amended (If data are amended, please
circle in red when using paper form)
Yes
No
Reporting Period Start Date (mm dd yyyy)
Reporting Period End Date (mm dd yyyy)
Aml/all/apl: Vital Status
Patient's Vital Status
Alive (Alive)
Dead (Dead)
Primary Cause of Death (if dead check one)
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Due To Other Cause (Due to other
cause)
Due To Protocol Treatment (Due to
protocol treatment)
Due To This Disease (Due to this
disease)
Unknown (Unknown)
Describe cause of death
Date of Last Contact or Death (mm dd yyyy)
Aml/all/apl: Disease Follow-up Status
Has the patient had a documented clinical
assessment for this cancer? (during this reporting
period)
No (No)
Unknown (Unknown)
Yes (Yes)
Date of Last Clinical Assessment (mm dd yyyy
only provide date if assessment during this
reporting period)
Did the patient achieve a complete response
according to clinical/ hematologic criteria (during
this reporting period)
No (NO)
Unknown (Unknown)
Yes (YES)
Date of Complete Response (If yes, indicate  mm
dd yyyy  only provide date if CR was achieved
during this reporting period)
Cml:disease Follow-up Status-
cytogenetic/molecular
Has the patient had a documented cytogenetic or
molecular assessment (including Philadelphia
chromosome karotype or BCR-abl) (during this
reporting period)
No (No)
Unknown (Unknown)
Yes (Yes)
Date of Last Cytogenetic or Molecular
Assessment (mm dd yyyy)
Did the patient achieve a complete response
according to cytogenetic or molecular criteria
(during this reporting period)
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No (NO)
Unknown (Unknown)
Yes (YES)
Date of Complete Response (If yes, indicate  mm
dd yyyy  only provide date if CR was achieved
during this reporting period)
Was cytogenetic analysis successful? (If yes,
indicate the results of cytogenetic or molecular
assessment.)
Yes
No
Karyotypic Philadelphia Chromosome Positive
The Karyotype Assessment For The
Philadelphia Chromosome Was
Indeterminate (Indeterminate)
No, The Philadelphia Chromosome
Karyotype Assessment Is Not Positive
(No)
A Karyotype Assessment For The
Philadelphia Chromosome Was Not
Done (Not done)
Yes, The Philadelphia Chromosome
Karyotype Assessment Is Positive (Yes)
Were FISH studies performed
Yes
No
FISH probe(s) specify (If yes,)
Specific Abnormalities Detected by FISH
Other Specify (Other)
T(9;22)(q34;q11.2); Bcr/abl
(t(9;22)(q34;q11.2); BCR/ABL)
Other specify
Result of FISH
Indeterminate (Indeterminate)
Negative (Negative)
Positive (Positive)
RT-PCR Marker Type
Bcr-abl1 Fusion Protein Expression
(BCR/ABL)
Other Specify (Other)
Other specify
Result of RT-PCR for Chimeric Genes
(Polymerase Chain Reaction)
Indeterminate (Indeterminate)
Negative (Negative)
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Not Done (Not done)
Positive (Positive)
Cml: Notice Of Progression -
Clinical/hematologic
Has the patient developed clinical or hematologic
evidence of progression or relapse (during this
reporting period)
No (NO)
Unknown (Unknown)
Yes (YES)
Date of Clinical/Hematologic Progression (mm dd
yyyy only provide date if progression occurred
during this reporting period)
Indicate the CML classification at the time of
clinical/ hematologic progression (If yes,)
Blast Count In The Marrow Or Blood
Increasing Over Period Of Time, But
Currently Less Than 30% (CML
accelerating phase)
Blast Count In The Marrow Or Blood
Greater Than 30% (CML blast crisis)
Blast Count In The Marrow Or Blood
Steady Or Constant Level Less Than
30% Over Period Of Time (CML chronic
phase)
Other Specify (Other)
Unknown (Unknown)
Other specify
Cml:disease Follow-up Status-
cytogenetic/molecular
Has the patient developed cytogenetic or
molecular evidence of progression or relapse
(during this reporting period)
No (NO)
Unknown (Unknown)
Yes (YES)
Date of Progression by Cytogenetic or  Molecular
Assessment (mm dd yyyy only provide date if
progression occurred during this reporting period)
Was cytogenetic analysis successful? (If yes,
indicate the results of cytogenetic or molecular
assessment.)
Yes
No
Karyotypic Philadelphia Chromosome Positive
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The Karyotype Assessment For The
Philadelphia Chromosome Was
Indeterminate (Indeterminate)
No, The Philadelphia Chromosome
Karyotype Assessment Is Not Positive
(No)
A Karyotype Assessment For The
Philadelphia Chromosome Was Not
Done (Not done)
Yes, The Philadelphia Chromosome
Karyotype Assessment Is Positive (Yes)
Were FISH studies performed
Yes
No
FISH probe(s) specify (If yes,)
Specific Abnormalities Detected by FISH
Other Specify (Other)
T(9;22)(q34;q11.2); Bcr/abl
(t(9;22)(q34;q11.2); BCR/ABL)
Other specify
Result of FISH
Indeterminate (Indeterminate)
Negative (Negative)
Positive (Positive)
RT-PCR Marker Type
Bcr-abl1 Fusion Protein Expression
(BCR/ABL)
Other Specify (Other)
Other specify
Result of RT-PCR for Chimeric Genes
(Polymerase Chain Reaction)
Indeterminate (Indeterminate)
Negative (Negative)
Not Done (Not done)
Positive (Positive)
Allows Documentation Of Any Additional
Cooments
Comments
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Follow-Up - Chronic Myelogenous Leukemia (CML) - Follow-Up Form -
2019375v3.0
Follow-Up - Acute Leukemia (AML/ALL/APL)
- Follow-Up Form - 2019373v3.0
Acute Leukemia (AML/ALL/APL) - Follow-Up Form
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=1AB0D69C-
1E03-0A07-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/6717
Acute Leukemia (AML/ALL/APL) -
Follow-Up Form
Crf Header
Coordinating Group Protocol No.
Coordinating Group Code
Protocol Title
Patient Study ID
Institution/Affiliate
Other Patient ID
Participating Group Code
Patient Initials
Registration Type
Leukemia/mds: Form Administration
Person Completing Form
Are data amended (If data are amended, please
circle in red when using paper form)
Yes
No
Reporting Period Start Date (mm dd yyyy)
Reporting Period End Date (mm dd yyyy)
Aml/all/apl: Vital Status
Patient's Vital Status
Alive (Alive)
Dead (Dead)
Primary Cause of Death (if dead check one)
1 / 2
Due To Other Cause (Due to other
cause)
Due To Protocol Treatment (Due to
protocol treatment)
Due To This Disease (Due to this
disease)
Unknown (Unknown)
Describe cause of death
Date of Last Contact or Death (mm dd yyyy)
Aml/all/apl: Disease Follow-up Status
Has the patient had a documented clinical
assessment for this cancer? (during this reporting
period)
No (No)
Unknown (Unknown)
Yes (Yes)
Date of Last Clinical Assessment (mm dd yyyy
only provide date if assessment during this
reporting period)
Did the patient achieve a complete response
according to clinical/ hematologic criteria (during
this reporting period)
No (NO)
Unknown (Unknown)
Yes (YES)
Date of Complete Response (If yes, indicate mm
dd yyyy only provide date if CR was achieved
during this reporting period)
Aml/all/apl: Notice Of Progression
Has the patient developed a first progression (or
relapse) that has not been previously reported?
No (No)
Unknown (Unknown)
Yes (Yes)
Date of Progression (mm dd yyyy only provide
date if progression occurred during this reporting
period)
Allows Documentation Of Any Additional
Cooments
Comments
2 / 2
Follow-Up - Acute Leukemia (AML/ALL/APL) - Follow-Up Form -
2019373v3.0
Follow-Up - Hairy Cell Leukemia (HCL) -
Follow-Up Form - 2019377v3.0
Hairy Cell Leukemia (HCL) - Follow-Up Form
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=1AADC1DC-
7623-1FD6-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/6719
Hairy Cell Leukemia (HCL) - Follow-
Up Form
Crf Header
Coordinating Group Protocol No.
Coordinating Group Code
Protocol Title
Patient Study ID
Institution/Affiliate
Other Patient ID
Participating Group Code
Patient Initials
Registration Type
Leukemia/mds: Form Administration
Person Completing Form
Are data amended (If data are amended, please
circle in red when using paper form)
Yes
No
Reporting Period Start Date (mm dd yyyy)
Reporting Period End Date (mm dd yyyy)
Aml/all/apl: Vital Status
Patient's Vital Status
Alive (Alive)
Dead (Dead)
Primary Cause of Death (if dead check one)
1 / 3
Due To Other Cause (Due to other
cause)
Due To Protocol Treatment (Due to
protocol treatment)
Due To This Disease (Due to this
disease)
Unknown (Unknown)
Describe cause of death
Date of Last Contact or Death (mm dd yyyy)
Aml/all/apl: Disease Follow-up Status
Has the patient had a documented clinical
assessment for this cancer? (during this reporting
period)
No (No)
Unknown (Unknown)
Yes (Yes)
Date of Last Clinical Assessment (mm dd yyyy
only provide date if assessment during this
reporting period)
Did the patient achieve a complete response
according to clinical/ hematologic criteria (during
this reporting period)
No (NO)
Unknown (Unknown)
Yes (YES)
Date of Complete Response (If yes, indicate mm
dd yyyy only provide date if CR was achieved
during this reporting period)
Cll: Notice Of Progression
Has the patient developed a first progression (or
relapse) that has not been previously reported?
(If assessed,)
No (No)
Unknown (Unknown)
Yes (Yes)
Liver Assessment (If yes, indicate all evidence of
progression from the following: refer to protocol
criteria for guidelines on organ assessment)
No (NO)
Unknown (Unknown)
Yes (YES)
Spleen Assessment
No (NO)
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Unknown (Unknown)
Yes (YES)
Lymph Node Assessment
No (NO)
Unknown (Unknown)
Yes (YES)
Hemoglobin
No (NO)
Unknown (Unknown)
Yes (YES)
Platelet Count
No (NO)
Unknown (Unknown)
Yes (YES)
Lymphocytes
No (NO)
Unknown (Unknown)
Yes (YES)
Neutrophils
No (NO)
Unknown (Unknown)
Yes (YES)
Hairy Cells
No (NO)
Unknown (Unknown)
Yes (YES)
Date of Progression (If yes, Earliest  mm dd yyyy
only provide date if progression occurred during
this reporting period)
Allows Documentation Of Any Additional
Cooments
Comments
3 / 3
Follow-Up - Hairy Cell Leukemia (HCL) - Follow-Up Form - 2019377v3.0
Follow-Up - Myelodysplastic Syndrome
(MDS) - Follow-Up Form - 2019374v3.0
Myelodysplastic Syndrome (MDS) - Follow-Up Form
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=1AADB4F0-
41BA-1ED3-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/6722
Myelodysplastic Syndrome (MDS) -
Follow-Up Form
Crf Header
Coordinating Group Protocol No.
Coordinating Group Code
Protocol Title
Patient Study ID
Institution/Affiliate
Other Patient ID
Participating Group Code
Patient Initials
Registration Type
Leukemia/mds: Form Administration
Person Completing Form
Are data amended (If data are amended, please
circle in red when using paper form)
Yes
No
Reporting Period Start Date (mm dd yyyy)
Reporting Period End Date (mm dd yyyy)
Aml/all/apl: Vital Status
Patient's Vital Status
Alive (Alive)
Dead (Dead)
Primary Cause of Death (if dead check one)
1 / 3
Due To Other Cause (Due to other
cause)
Due To Protocol Treatment (Due to
protocol treatment)
Due To This Disease (Due to this
disease)
Unknown (Unknown)
Describe cause of death
Date of Last Contact or Death (mm dd yyyy)
Aml/all/apl: Disease Follow-up Status
Has the patient had a documented clinical
assessment for this cancer? (during this reporting
period)
No (No)
Unknown (Unknown)
Yes (Yes)
Date of Last Clinical Assessment (mm dd yyyy
only provide date if assessment during this
reporting period)
Did the patient achieve a complete response
according to clinical/ hematologic criteria (during
this reporting period)
No (NO)
Unknown (Unknown)
Yes (YES)
Date of Complete Response (If yes, indicate mm
dd yyyy only provide date if CR was achieved
during this reporting period)
Aml/all/apl: Notice Of Progression
Has the patient developed a first progression (or
relapse) that has not been previously reported?
No (No)
Unknown (Unknown)
Yes (Yes)
Date of Progression (mm dd yyyy only provide
date if progression occurred during this reporting
period)
Has the patient developed progression of MDS to
Acute Myelogenous Leukemia (AML)
Yes
No
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2019374v3.0
Allows Documentation Of Any Additional
Cooments
Comments
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Follow-Up - Myelodysplastic Syndrome (MDS) - Follow-Up Form -
2019374v3.0
Follow-Up - Chronic Lymphocytic Leukemia
(CLL) - Follow-Up Form - 2019376v3.0
Chronic Lymphocytic Leukemia (CLL) - Follow-Up Form
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=1AB0CFAE-
6B41-0894-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/6723
Chronic Lymphocytic Leukemia
(CLL) - Follow-Up Form
Crf Header
Coordinating Group Protocol No.
Coordinating Group Code
Protocol Title
Patient Study ID
Institution/Affiliate
Other Patient ID
Participating Group Code
Patient Initials
Registration Type
Leukemia/mds: Form Administration
Person Completing Form
Are data amended (If data are amended, please
circle in red when using paper form)
Yes
No
Reporting Period Start Date (mm dd yyyy)
Reporting Period End Date (mm dd yyyy)
Aml/all/apl: Vital Status
Patient's Vital Status
Alive (Alive)
Dead (Dead)
Primary Cause of Death (if dead check one)
1 / 3
Due To Other Cause (Due to other
cause)
Due To Protocol Treatment (Due to
protocol treatment)
Due To This Disease (Due to this
disease)
Unknown (Unknown)
Describe cause of death
Date of Last Contact or Death (mm dd yyyy)
Aml/all/apl: Disease Follow-up Status
Has the patient had a documented clinical
assessment for this cancer? (during this reporting
period)
No (No)
Unknown (Unknown)
Yes (Yes)
Date of Last Clinical Assessment (mm dd yyyy
only provide date if assessment during this
reporting period)
Did the patient achieve a complete response
according to clinical/ hematologic criteria (during
this reporting period)
No (NO)
Unknown (Unknown)
Yes (YES)
Date of Complete Response (If yes, indicate mm
dd yyyy only provide date if CR was achieved
during this reporting period)
Cll: Notice Of Progression
Has the patient developed a first progression (or
relapse) that has not been previously reported?
No (No)
Unknown (Unknown)
Yes (Yes)
Liver Assessment (If yes, indicate all evidence of
progression from the following: refer to protocol
criteria for guidelines on organ assessment)
No (NO)
Unknown (Unknown)
Yes (YES)
Spleen Assessment
No (NO)
Unknown (Unknown)
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Yes (YES)
Lymph Node Assessment
No (NO)
Unknown (Unknown)
Yes (YES)
Lymphocytes (> or = 50% increase in absolute
number of circulating lymphocytes to at least
5000/mcL)
No (NO)
Unknown (Unknown)
Yes (YES)
Date of Progression (If yes, Earliest  mm dd yyyy
only provide date if progression occurred during
this reporting period)
Allows Documentation Of Any Additional
Cooments
Comments
3 / 3
Follow-Up - Chronic Lymphocytic Leukemia (CLL) - Follow-Up Form -
2019376v3.0
Leukemia NCT00492856 Treatment - SOUTHWEST ONCOLOGY GROUP Post-
Consolidation Treatment Summary Form: Maintenance Chemotherapy (S0521) -
2416411v1.0
SOUTHWEST ONCOLOGY GROUP Post-Consolidation
Treatment Summary Form:Maintenance Chemotherapy
(S0521)
Combination Chemotherapy With or Without Gemtuzumab
Followed By Tretinoin, Mercaptopurine, and Methotrexate
or Observation in Treating Patients With Acute
Promyelocytic Leukemia
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=02DF9FE4-
284E-05F8-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/6731
SOUTHWEST ONCOLOGY GROUP
Post-Consolidation Treatment
Summary Form: Maintenance
Chemotherapy (S0521)
Header
SWOG Patient ID
SWOG Study No.
Registration Step
Reporting Period Start Date
Reporting Period End Date
Patient Initials (L, F M)
Institution/Affiliate
Physician (Participating Group:)
Participating Group Name
American College Of Surgeons
Oncology Group (ACOSOG)
American College Of Radiology
Oncologic Imaging Network (ACRIN)
Aids-associated Malignancies Clinical
Trials Consortium (AMC)
Cancer And Leukemia Group B (CALGB)
Children's Oncology Group (COG)
Eastern Cooperative Oncology Group
(ECOG)
European Organization For Research
And Treatment Of Cancer (EORTC)
Gynecologic Oncology Group (GOG)
International Breast Cancer Study Group
(IBCSG)
North American Brain Tumor Consortium
(NABTC)
Nabtt Brain Tumor Consortium (NABTT)
North Central Cancer Treatment Group
(NCCTG)
1 / 4
National Cancer Institute Of Canada
Clinical Trials Group (NCIC)
National Surgical Adjuvant Breast And
Bowel Project (NSABP)
Radiation Therapy Oncology Group
(RTOG)
Southwest Oncology Group (SWOG)
Participating Group Study No.
Participating Group Patient ID (Instructions: All
dates are MONTH, DAY, YEAR. Explain any
blank fields or blank dates in the Comments
section. Place an X in appropriate boxes. Circle
AMENDED items in red and write AMENDED
across the top of the form.)
Patient And Disease Description
Date of Last Contact or Death
Vital Status
Alive (Alive)
Dead (Dead)
Physical
Weight
BSA
Treatment: Atra
Did the patient receive ATRA during this reporting
period?
Yes
No
Total dose of ATRA in this reporting period? (If
yes, - mg)
Start date of ATRA during this reporting period?
End date of ATRA during this reporting period?
Treatment: 6-mp
Did the patient receive 6-MP during this reporting
period?
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Yes
No
Total dose of 6-MP in this reporting period? (If
yes, - mg)
Start date of 6-MP during this reporting period?
End date of 6-MP during this reporting period?
Treatment: Methotrexate
Did the patient receive methotrexate during this
reporting period?
Yes
No
Total dose of methotrexate in this reporting
period? (If yes, - mg)
Start date of methotrexate during this reporting
period?
End date of methotrexate during this reporting
period?
Treatment: Growth Factors
If yes,
Granulocyte-macrophage Colony-
stimulating Factor (G-CSF)
Other (Other)
Recombinant Granulocyte-macrophage
Colony-stimulating Factor (rhGM_CSF)
Other, specify
Total dose of growth factor in this reporting
period? (mcg)
Start date of growth factor during this reporting
period?
End date of growth factor during this reporting
period?
Was growth factor permanently discontined
during this reporting period?
Yes
No
Was growth factor permanently discontined
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during this reporting period?
Yes
No
Date of discontinuation (If yes,)
Treatment: Other Therapy
Did the patient receive other therapy during this
reporting period? (If yes, give start and end dates
and describe the other therapy in the Comments
section.)
Yes
No
Specify agent
Dose Modifications
Were there any dose modifications or
additions/omissions to protocol treatment?
No (No)
Yes, Planned (i.e., The Treatment Was
Changed According To Protocol
Guidelines) (Yes, planned)
Yes, Unplanned (i.e., The Treatment
Change Was Not Part Of Protocol
Guidelines) (Yes, unplanned)
Comments
Comments
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Leukemia NCT00492856 Treatment - SOUTHWEST ONCOLOGY GROUP Post-
Consolidation Treatment Summary Form: Maintenance Chemotherapy (S0521) -
2416411v1.0
Leukemia NCT00492856 Treatment - SOUTHWEST ONCOLOGY GROUP Post-
Consolidation Treatment Summary Form: Gemtuzumab Ozogamicin (S0521) -
2466403v1.0
SOUTHWEST ONCOLOGY GROUP Post-Consolidation
Treatment Summary Form: Gemtuzumab Ozogamicin
(S0521)
Combination Chemotherapy With or Without Gemtuzumab
Followed By Tretinoin, Mercaptopurine, and Methotrexate
or Observation in Treating Patients With Acute
Promyelocytic Leukemia
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=1024CCDD-
8EF2-4085-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/6732
SOUTHWEST ONCOLOGY GROUP
Post-Consolidation Treatment
Summary Form: Gemtuzumab
Ozogamicin (S0521)
Header
SWOG Patient ID
SWOG Study No.
Registration Step
Reporting Period Start Date
Reporting Period End Date
Patient Initials (L, F M)
Institution/Affiliate
Physician (Participating Group:)
Participating Group Name
American College Of Surgeons
Oncology Group (ACOSOG)
American College Of Radiology
Oncologic Imaging Network (ACRIN)
Aids-associated Malignancies Clinical
Trials Consortium (AMC)
Cancer And Leukemia Group B (CALGB)
Children's Oncology Group (COG)
Eastern Cooperative Oncology Group
(ECOG)
European Organization For Research
And Treatment Of Cancer (EORTC)
Gynecologic Oncology Group (GOG)
International Breast Cancer Study Group
(IBCSG)
North American Brain Tumor Consortium
(NABTC)
Nabtt Brain Tumor Consortium (NABTT)
North Central Cancer Treatment Group
(NCCTG)
1 / 4
National Cancer Institute Of Canada
Clinical Trials Group (NCIC)
National Surgical Adjuvant Breast And
Bowel Project (NSABP)
Radiation Therapy Oncology Group
(RTOG)
Southwest Oncology Group (SWOG)
Participating Group Study No.
Participating Group Patient ID (Instructions: All
dates are MONTH, DAY, YEAR. Explain any
blank fields or blank dates in the Comments
section. Place an X in appropriate boxes. Circle
AMENDED items in red and write AMENDED
across the top of the form.)
Patient And Disease Description
Date of Last Contact or Death
Vital Status
Alive (Alive)
Dead (Dead)
Physical
Weight
BSA
Gemtuzumab Ozogamicin
Was first dose of Gemtuzumab Ozogamicin given
Yes
No
Date of first dose (If yes,)
Dose given (mg)
Was second dose of Gemtuzumab Ozogamicin
given
Yes
No
Date of second dose (If yes,)
Dose given (mg)
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Was third dose of Gemtuzumab Ozogamicin
given
Yes
No
Date of third dose (If yes,)
Dose given (mg)
Was fourth dose of Gemtuzumab Ozogamicin
given
Yes
No
Date of fourth dose (If yes,)
Dose given (mg)
Was fifth dose of Gemtuzumab Ozogamicin given
Yes
No
Date of fifth dose (If yes,)
Dose given (mg)
Was sixth dose of Gemtuzumab Ozogamicin
given
Yes
No
Date of sixth dose (If yes,)
Dose given (mg)
Treatment: Growth Factors
If yes,
Granulocyte-macrophage Colony-
stimulating Factor (G-CSF)
Other (Other)
Recombinant Granulocyte-macrophage
Colony-stimulating Factor (rhGM_CSF)
Other, specify
Total dose of growth factor in this reporting
period? (mcg)
Start date of growth factor during this reporting
period?
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End date of growth factor during this reporting
period?
Was growth factor permanently discontined
during this reporting period?
Yes
No
Was growth factor permanently discontined
during this reporting period?
Yes
No
Date of discontinuation (If yes,)
Treatment: Other Therapy
Did the patient receive other therapy during this
reporting period? (If yes, give start and end dates
and describe the other therapy in the Comments
section.)
Yes
No
Specify agent
Dose Modifications
Were there any dose modifications or
additions/omissions to protocol treatment?
No (No)
Yes, Planned (i.e., The Treatment Was
Changed According To Protocol
Guidelines) (Yes, planned)
Yes, Unplanned (i.e., The Treatment
Change Was Not Part Of Protocol
Guidelines) (Yes, unplanned)
Comments
Comments
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Leukemia NCT00492856 Treatment - SOUTHWEST ONCOLOGY GROUP Post-
Consolidation Treatment Summary Form: Gemtuzumab Ozogamicin (S0521) -
2466403v1.0
Kidney Cancer NCT01198158 Toxicity - CALGB 90802 Supplemental
Adverse Event Form (Thromboembolic Events) - 3103388v1.0
CALGB 90802 Supplemental Adverse Event Form
(Thromboembolic Events)
Everolimus With or Without Bevacizumab in Treating
Patients With Advanced Kidney Cancer That Progressed
After First-Line Therapy
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=8785C648-
8EAC-0F46-E040-BB89AD432B73
All rights reserved. Please visit https://medical-data-
models.org/forms/6737
CALGB 90802 Supplemental
Adverse Event Form
(Thromboembolic Events)
Header
CALGB Form
CALGB Study No.
CALGB Patient ID
Reporting period start date (MM DD YYYY)
Reporting period end date (MM DD YYYY)
Are data amended
Yes
No
Unnamed2
Patient Initials (Last, First Middle)
Patient Hospital No.
Institution/Affiliate
Participating Group
Participating Group Study No.
Participating Group Patient ID
Unnamed 3
Cycle number
Medications received during this reporting period
1 / 3
(Mark all that apply with an X.)
Anti-platelet (Anti-platelet)
Anticoagulant (Anticoagulant)
Aspirin (Aspirin)
Bp Or Cardiac Medication (BP or cardiac
medication)
None (None)
Nsaid (NSAID)
Statin (Statin)
NSAID, specify
Anti-platelet, specify
Statin, specify
BP or cardiac medication, specify
Anticoagulant, specify
Medications received during this reporting period
Prophylactic (Prophylactic)
Therapeutic (Therapeutic)
Which of the following arterial thrombotic events
(ATEs) occurred during this reporting period?
(Mark all that apply with an X.)
Angina (Angina)
Cva - Hemorrhagic (CVA - hemorrhagic)
Cva - Thrombotic (CVA - thrombotic)
Myocardial Infarction (Myocardial
infarction)
None (None)
Other Arterial Event (Other arterial
event)
Transient Ischemic Attack (Transient
ischemic attack)
Other arterial event, specify
Treatment for ATE (Mark all that apply with an X.)
Emergency Room (Emergency room)
Hospitalization (Hospitalization)
Outpatient Management Only
(Outpatient management only)
Outcome of ATE
Not Resolved (Not resolved)
Resolved (Resolved)
Resulted In Death (Resulted in death)
Which of the following venous thrombotic events
(VTEs) occurred during this reporting period?
(Mark all that apply with an X.)
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Adverse Event Form (Thromboembolic Events) - 3103388v1.0
Catheter Related (Catheter related)
Dvt (DVT)
None (None)
Other Venous Thrombotic Event (Other
venous thrombotic event)
Pulmonary Embolism (Pulmonary
embolism)
Specify status
Asymptomatic (asymptomatic)
Symptomatic (symptomatic)
Other venous thrombotic event, specify
Treatment for VTE (Mark all that apply with an X.)
Emergency Room (Emergency room)
Hospitalization (Hospitalization)
Outpatient Management Only
(Outpatient management only)
Thrombolysis (Thrombolysis)
Outcome of VTE
Not Resolved (Not resolved)
Resolved (Resolved)
Resulted In Death (Resulted in death)
Completed by (Last name, First name)
Date form completed (MM DD YYYY)
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Kidney Cancer NCT01198158 Toxicity - CALGB 90802 Supplemental
Adverse Event Form (Thromboembolic Events) - 3103388v1.0
Leukemia NCT00492856 Treatment - SOUTHWEST ONCOLOGY
GROUP Induction Treatment Summary Form (S0521) - 2415093v1.0
SOUTHWEST ONCOLOGY GROUP Induction Treatment
Summary Form (S0521)
Combination Chemotherapy With or Without Gemtuzumab
Followed By Tretinoin, Mercaptopurine, and Methotrexate
or Observation in Treating Patients With Acute
Promyelocytic Leukemia
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=02C67B15-
4677-0783-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/6741
SOUTHWEST ONCOLOGY GROUP
Induction Treatment Summary Form
(S0521)
Header
SWOG Patient ID
SWOG Study No.
Registration Step
Patient Initials (L, F M)
Reporting Period Start Date
Reporting Period End Date
Institution/Affiliate
Physician (Participating Group:)
Participating Group Name
American College Of Surgeons
Oncology Group (ACOSOG)
American College Of Radiology
Oncologic Imaging Network (ACRIN)
Aids-associated Malignancies Clinical
Trials Consortium (AMC)
Cancer And Leukemia Group B (CALGB)
Children's Oncology Group (COG)
Eastern Cooperative Oncology Group
(ECOG)
European Organization For Research
And Treatment Of Cancer (EORTC)
Gynecologic Oncology Group (GOG)
International Breast Cancer Study Group
(IBCSG)
North American Brain Tumor Consortium
(NABTC)
Nabtt Brain Tumor Consortium (NABTT)
North Central Cancer Treatment Group
(NCCTG)
1 / 4
National Cancer Institute Of Canada
Clinical Trials Group (NCIC)
National Surgical Adjuvant Breast And
Bowel Project (NSABP)
Radiation Therapy Oncology Group
(RTOG)
Southwest Oncology Group (SWOG)
Participating Group Study No.
Participating Group Patient ID (Instructions: All
dates are MONTH, DAY, YEAR. Explain any
blank fields or blank dates in the Comments
section. Place an X in appropriate boxes. Circle
AMENDED items in red and write AMENDED
across the top of the form.)
Patient And Disease Description
Date of Last Contact or Death
Vital Status
Alive (Alive)
Dead (Dead)
Physical
Weight
BSA
Treatment: Atra
Did the patient receive ATRA during this reporting
period?
Yes
No
Total dose of ATRA in this reporting period? (If
yes, - mg)
Start date of ATRA during this reporting period?
End date of ATRA during this reporting period?
Treatment: Cytosine Arabinoside (ara-c)
Did the patient receive daunorubicin during this
reporting period?
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Leukemia NCT00492856 Treatment - SOUTHWEST ONCOLOGY
GROUP Induction Treatment Summary Form (S0521) - 2415093v1.0
Yes
No
Total dose of daunorubicin in this reporting
period? (If yes, - mg)
Start date of daunorubicin during this reporting
period?
End date of daunorubicin during this reporting
period?
Treatment: Daunorubicin
Did the patient receive Ara-C during this reporting
period?
Yes
No
Total dose of Ara-C in this reporting period? (If
yes, - mg)
Start date of Ara-C during this reporting period?
End date of Ara-C during this reporting period?
Treatment: Growth Factors
If yes,
Granulocyte-macrophage Colony-
stimulating Factor (G-CSF)
Other (Other)
Recombinant Granulocyte-macrophage
Colony-stimulating Factor (rhGM_CSF)
Other, specify
Total dose of growth factor in this reporting
period? (mcg)
Start date of growth factor during this reporting
period?
End date of growth factor during this reporting
period?
Was growth factor permanently discontined
during this reporting period?
Yes
No
Was growth factor permanently discontined
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Leukemia NCT00492856 Treatment - SOUTHWEST ONCOLOGY
GROUP Induction Treatment Summary Form (S0521) - 2415093v1.0
during this reporting period?
Yes
No
Date of discontinuation (If yes,)
Treatment: Other Therapy
Did the patient receive other therapy during this
reporting period? (If yes, give start and end dates
and describe the other therapy in the Comments
section.)
Yes
No
Specify agent
Dose Modifications
Were there any dose modifications or
additions/omissions to protocol treatment?
No (No)
Yes, Planned (i.e., The Treatment Was
Changed According To Protocol
Guidelines) (Yes, planned)
Yes, Unplanned (i.e., The Treatment
Change Was Not Part Of Protocol
Guidelines) (Yes, unplanned)
Comments
Comments
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Leukemia NCT00492856 Treatment - SOUTHWEST ONCOLOGY
GROUP Induction Treatment Summary Form (S0521) - 2415093v1.0
Kidney Cancer NCT01120249 Treatment - Southwest Oncology
Group S0931 Treatment Form (Form #44488) - 2992372v1.0
Southwest Oncology Group S0931 Treatment Form (Form
#44488)
Everolimus in Treating Patients With Kidney Cancer Who
Have Undergone Surgery
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=7E001FA4-
EC45-AE5A-E040-BB89AD432C94
All rights reserved. Please visit https://medical-data-
models.org/forms/6742
Southwest Oncology Group S0931
Treatment Form (Form #44488)
Header
SWOG Patient ID
SWOG Study No.
Registration Step
Cycle Number
Patient Initials (L, F M)
Institution/Affiliate
Physician
Participating Group Name
Participating Study No.
Participating Patient ID
Status
Vital Status
Alive (Alive)
Dead (Dead)
Date of Last Contact or Death (MM DD YYYY)
Has the patient progressed per the definition in
Section 10.0 of the protocol?
Yes
No
Treatment For This Cycle
Reporting Period Start Date
1 / 3
Reporting Period End Date (Day 1 of next cycle.
If final cycle, date of last treatment.)
Treatment Start Date
Date of Last Treatment
Performance Status (first day this cycle)
Weight (kg)
Did the patient have radiographic evidence of
pneumonitis?
No (No)
Not Assessed (Not assessed)
Yes (Yes)
Were there any dose modifications or
additions/omissions to protocol treatment?
No (No)
Yes, Planned (i.e., The Treatment Was
Changed According To Protocol
Guidelines) (Yes, planned)
Yes, Unplanned (i.e., The Treatment
Change Was Not Part Of Protocol
Guidelines) (Yes, unplanned)
Treatment
Agent Name
Dose planned at cycle start (mg/day)
Dose delivered at cycle end (mg/day)
Total Dose
Agent dose modification
Dose Delayed (Dose delayed)
Dose Delayed And Reduced (Dose
delayed and reduced)
Dose Held (Dose held)
Dose Reduced (Dose reduced)
Drug Discontinued (Drug discontinued)
No Dose Modification (No dose
modification)
Dose Modification Reason
Adverse Event (Adverse event)
Alternative Therapy For Other Reason
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Kidney Cancer NCT01120249 Treatment - Southwest Oncology Group
S0931 Treatment Form (Form #44488) - 2992372v1.0
(Alternative therapy for other reason)
Death (Death)
Disease Progression (Disease
progression)
Dosing Error (Dosing error)
Other (Other)
Patient Refusal/noncompliance (Patient
refusal/noncompliance)
Scheduling (Scheduling)
Other, specify
Number of days delayed (if applicable)
Modification due to Adverse Event
Allergy/immunology
(Allergy/immunology)
Blood/bone Marrow (Blood/Bone
Marrow)
Cardiac (Cardiac)
Coagulation (Coagulation)
Gastrointestinal (Gastrointestinal)
Hepatobiliary/pancreas
(Hepatobiliary/Pancreas)
Infection (Infection)
Metabolic/laboratory
(Metabolic/Laboratory)
Neurology (Neurology)
Other (Other)
Pain (Pain)
Pulmonary/upper Respiratory
(Pulmonary/Upper Respiratory)
Renal/genitourinary
(Renal/Genitourinary)
Vascular (Vascular)
Other, specify
Comments
Comments
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Kidney Cancer NCT01120249 Treatment - Southwest Oncology Group
S0931 Treatment Form (Form #44488) - 2992372v1.0
Leukemia NCT01041703 Follow-Up - E2906
Long-Term Follow-up Form - 2947429v1.0
E2906 Long-Term Follow-up Form
Clofarabine or Daunorubicin Hydrochloride and Cytarabine
Followed By Decitabine or Observation in Treating Older
Patients With Newly Diagnosed Acute Myeloid Leukemia
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=74BCE806-
5598-4D7A-E040-BB89AD437934
All rights reserved. Please visit https://medical-data-
models.org/forms/6744
E2906 Long-Term Follow-up Form
Header
ECOG Protocol Number
ECOG Protocol Number
ECOG Patient ID
ECOG Patient ID
DCI Name
Registration Step (Place ID Label Here)
Patient Initials (Last, First)
Participating Group Protocol Number
Participating Group Patient ID
Institution/Affiliate
Off Treatment Report Period (since registration
Choose one)
12 Months (12 Months Post Registration)
15 Months (15 Months Post Registration)
18 Months (18 Months Post Registration)
21 Months Post Registration (21 Months
Post Registration)
2 Years (24 Months Post Registration)
3 Months (3 Months Post Registration)
30 Months (30 Months Post Registration)
3 Years (36 Months Post Registration)
42 Months (42 Months Post Registration)
4 Years (48 Months Post Registration)
54 Months (54 Months Post Registration)
6 Months (6 Months Post Registration)
5 Years (60 Months Post Registration)
9 Months (9 Months Post Registration)
Unnamed2
1 / 3
Please mark an 'X' if data have been amended.
(Please circle amended items in red)
Date data amended (s M D Y)
Vital Status
Patient's Vital Status
Alive (Alive)
Dead (Dead)
Date of Last Contact or Death (M D Y)
Primary Cause of Death
Due To Other Cause (Due to other
cause)
Due To Protocol Treatment (Due to
protocol treatment)
Due To This Disease (Due to this
disease)
Unknown (Unknown)
Describe cause of death
Section Ii - Reporting Period
Reporting Period Start Date (M D Y)
Reporting Period End Date (M D Y)
Section Iv - Notice Of New Primary
Has a new primary cancer or MDS been
diagnosed that has not been previously reported?
No (No)
Unknown (Unknown)
Yes (Yes)
Site of new primary (s)
Section Iii - Disease Follow-up Status
Has the patient had a documented clinical
assessment for this cancer (this reporting period)
No (No)
Unknown (Unknown)
Yes (Yes)
If unknown, please explain
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Leukemia NCT01041703 Follow-Up - E2906 Long-Term Follow-up Form -
2947429v1.0
Date of last clinical assessment (If yes M D Y
Submit E2906 Acute Leukemia Disease
Assessment Form)
Has the patient developed a first progression (or
relapse) that has not been previously reported?
(or relapse)
No (No)
Unknown (Unknown)
Yes (Yes)
If unknown, please explain
Date of progression (If yes, relapse M D Y Submit
E2906 Acute Leukemia Disease Assessment
Form)
Site(s) of progression
Did a physician make a formal diagnosis of
progressive disease?
No (No)
Unknown (Unknown)
Yes (Yes)
Specify basis of progression (If no or unknown)
Section V - Adverse Events
Has the patient experienced (prior to diagnosis of
progression/relapse) any reportable long term
toxicity that has not been previously reported?
No (No)
Unknown (Unknown)
Yes (Yes)
Section Vi - Non-protocol Therapy Prior To
Progression
Has the patient received any non-protocol cancer
therapy prior to first progression (not previously
reported)
No (No)
Unknown (Unknown)
Yes (Yes)
Comments
Investigator Signature
Investigator Signature Date (M D Y)
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Leukemia NCT01041703 Follow-Up - E2906 Long-Term Follow-up Form -
2947429v1.0
Leukemia NCT01041703 Treatment - E2906 Treatment
Form - INDUCTION - Arm A - Step 1 - 2948839v1.0
E2906 Treatment Form - INDUCTION - Arm A - Step 1
Clofarabine or Daunorubicin Hydrochloride and Cytarabine
Followed By Decitabine or Observation in Treating Older
Patients With Newly Diagnosed Acute Myeloid Leukemia
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=74CE8E4B-
E13E-C2ED-E040-BB89AD436D94
All rights reserved. Please visit https://medical-data-
models.org/forms/6745
E2906 Treatment Form -
INDUCTION - Arm A - Step 1
Header
DCI Name
Registration Step (Place ID Label Here)
Patient Initials (Last, First)
ECOG Protocol Number
ECOG Protocol Number
ECOG Patient ID
ECOG Patient ID
Participating Group Protocol Number
Participating Group Patient ID
Institution/Affiliate
On Treatment
Reporting Period
Cycle 1 - Induction (Cycle 1 - Induction)
Cycle 2 - Induction (Cycle 2 - Induction)
Unnamed2
Please mark an 'X' if data have been amended.
(Please circle amended items in red)
Date data amended (s M D Y)
Section Ii - Reporting Period
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Reporting Period Start Date (M D Y)
Reporting Period End Date (M D Y)
Vital Status
Patient's Vital Status
Alive (Alive)
Dead (Dead)
Date of Last Contact or Death (M D Y)
Primary Cause of Death (if applicable)
Due To Other Cause (Due to other
cause)
Due To Protocol Treatment (Due to
protocol treatment)
Due To This Disease (Due to this
disease)
Unknown (Unknown)
Describe cause of death
Patient Characteristics
Weight (kg Day 1 of this treatment)
Body Surface Area (m^2 Patient Measurement
BSA Day 1 of this treatment)
Therapy Administered
Agent Name
Was the agent administered during this reporting
period? (cycle)
Yes
No
Date of First dose for this reporting period (M D
Y)
Date of Last dose for this reporting period (M D
Y)
Agent Total Dose (mg/m^2 this report period)
Therapy Administered
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Leukemia NCT01041703 Treatment - E2906 Treatment Form -
INDUCTION - Arm A - Step 1 - 2948839v1.0
Agent Name
Was the agent administered during this reporting
period? (cycle)
Yes
No
Date of First dose for this reporting period (M D
Y)
Date of Last dose for this reporting period (M D
Y)
Agent Total Dose (mg/m^2 this report period)
Other Therapy Administered
Agent Name
Did patient receive Dexamethasone this reporting
period (as an anti-emetic cycle)
Yes
No
Non-protocol Therapy
Was any non-protocol therapy given during
protocol treatment? (not previously reported )
Yes
No
Comments
Investigator Signature
Investigator Signature Date (MM DD YYYY)
3 / 3
Leukemia NCT01041703 Treatment - E2906 Treatment Form -
INDUCTION - Arm A - Step 1 - 2948839v1.0
Leukemia NCT01041703 Treatment - E2906 Treatment
Form - CONSOLIDATION - Arm C - Step 2 - 2949165v1.0
E2906 Treatment Form - CONSOLIDATION - Arm C - Step
2
Clofarabine or Daunorubicin Hydrochloride and Cytarabine
Followed By Decitabine or Observation in Treating Older
Patients With Newly Diagnosed Acute Myeloid Leukemia
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=74CEC72C-
CD53-2C0E-E040-BB89AD4367D1
All rights reserved. Please visit https://medical-data-
models.org/forms/6746
E2906 Treatment Form -
CONSOLIDATION - Arm C - Step 2
Header
DCI Name
Registration Step (Place ID Label Here)
Patient Initials (Last, First)
ECOG Protocol Number
ECOG Protocol Number
ECOG Patient ID
ECOG Patient ID
Participating Group Protocol Number
Participating Group Patient ID
Institution/Affiliate
On Treatment
Reporting Period
Cycle 1 - Consolidation (Cycle 1 -
Consolidation)
Cycle 2 - Consolidation (Cycle 2 -
Consolidation)
Unnamed2
Please mark an 'X' if data have been amended.
(Please circle amended items in red)
Date data amended (s M D Y)
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Section Ii - Reporting Period
Reporting Period Start Date (M D Y)
Reporting Period End Date (M D Y)
Vital Status
Patient's Vital Status
Alive (Alive)
Dead (Dead)
Date of Last Contact or Death (M D Y)
Primary Cause of Death (if applicable)
Due To Other Cause (Due to other
cause)
Due To Protocol Treatment (Due to
protocol treatment)
Due To This Disease (Due to this
disease)
Unknown (Unknown)
Describe cause of death
Patient Characteristics
Weight (kg Day 1 of this treatment [Note: code
weight loss/gain >= grade 1 per CTCAE on
E2906 Adverse Event Form])
Body Surface Area (m^2 Patient Measurement
BSA Day 1 of this treatment)
Age group
Age >=70 Years Of Age (Age >=70 years
of age)
Age 60-69 Years Of Age (Age 60-69
years of age)
Therapy Administered
Agent Name
Was the agent administered during this reporting
period? (Cytarabinecycle)
Yes
No
Date of First dose for this reporting period (M D
Y)
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Leukemia NCT01041703 Treatment - E2906 Treatment Form -
CONSOLIDATION - Arm C - Step 2 - 2949165v1.0
Date of Last dose for this reporting period (M D
Y)
Agent Total Dose (mg/m^2 this report period)
Dose modification
Dose Delayed (Dose delayed)
Dose Delayed And Reduced (Dose
delayed and reduced)
Dose Held (Dose held)
Dose Reduced (Dose reduced)
No Dose Modification (No dose
modification)
Dose Modification Reason
Adverse Event (Adverse event)
Change In Bsa (Change in BSA)
Dosing Error (Dosing error)
Patient Refusal/noncompliance (Patient
refusal/noncompliance)
Scheduling (Scheduling)
On which dose schedule was agent administered
(Cytarabine)
Iv Every 12 Hours (IV every 12 hours)
Iv Once Daily (IV once daily)
Other Therapy Administered
Agent Name
Did patient receive Dexamethasone this reporting
period (as an anti-emetic cycle)
Yes
No
Non-protocol Therapy
Was any non-protocol therapy given during
protocol treatment? (not previously reported )
Yes
No
Comments
Investigator Signature
Investigator Signature Date (MM DD YYYY)
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Leukemia NCT01041703 Treatment - E2906 Treatment Form -
CONSOLIDATION - Arm C - Step 2 - 2949165v1.0
Leukemia NCT01041703 Treatment - E2906 Treatment
Form - INDUCTION - Arm B - Step 1 - 2949013v1.0
E2906 Treatment Form - INDUCTION - Arm B - Step 1
Clofarabine or Daunorubicin Hydrochloride and Cytarabine
Followed By Decitabine or Observation in Treating Older
Patients With Newly Diagnosed Acute Myeloid Leukemia
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=74CEC72C-
CC23-2C0E-E040-BB89AD4367D1
All rights reserved. Please visit https://medical-data-
models.org/forms/6747
E2906 Treatment Form -
INDUCTION - Arm B - Step 1
Header
DCI Name
Registration Step (Place ID Label Here)
Patient Initials (Last, First)
ECOG Protocol Number
ECOG Protocol Number
ECOG Patient ID
ECOG Patient ID
Participating Group Protocol Number
Participating Group Patient ID
Institution/Affiliate
On Treatment
Reporting Period
Cycle 1 - Induction (Cycle 1 - Induction)
Cycle 2 - Induction (Cycle 2 - Induction)
Unnamed2
Please mark an 'X' if data have been amended.
(Please circle amended items in red)
Date data amended (s M D Y)
Section Ii - Reporting Period
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Reporting Period Start Date (M D Y)
Reporting Period End Date (M D Y)
Vital Status
Patient's Vital Status
Alive (Alive)
Dead (Dead)
Date of Last Contact or Death (M D Y)
Primary Cause of Death (if applicable)
Due To Other Cause (Due to other
cause)
Due To Protocol Treatment (Due to
protocol treatment)
Due To This Disease (Due to this
disease)
Unknown (Unknown)
Describe cause of death
Patient Characteristics
Weight (kg Day 1 of this treatment [Note: code
weight loss/gain >= grade 1 per CTCAE on
E2906 Adverse Event Form])
Body Surface Area (m^2 Patient Measurement
BSA Day 1 of this treatment)
Therapy Administered
Agent Name
Was the agent administered during this reporting
period? (cycle)
Yes
No
Date of First dose for this reporting period (M D
Y)
Date of Last dose for this reporting period (M D
Y)
Agent Total Dose (mg/m^2 this report period)
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Leukemia NCT01041703 Treatment - E2906 Treatment Form -
INDUCTION - Arm B - Step 1 - 2949013v1.0
Other Therapy Administered
Agent Name
Did patient receive Dexamethasone this reporting
period (as an anti-emetic cycle)
Yes
No
Non-protocol Therapy
Was any non-protocol therapy given during
protocol treatment? (not previously reported )
Yes
No
Comments
Investigator Signature
Investigator Signature Date (MM DD YYYY)
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Leukemia NCT01041703 Treatment - E2906 Treatment Form -
INDUCTION - Arm B - Step 1 - 2949013v1.0
Leukemia NCT01041703 Treatment - E2906 Treatment
Form - CONSOLIDATION - Arm D - Step 2 - 2949249v1.0
E2906 Treatment Form - CONSOLIDATION - Arm D - Step
2
Clofarabine or Daunorubicin Hydrochloride and Cytarabine
Followed By Decitabine or Observation in Treating Older
Patients With Newly Diagnosed Acute Myeloid Leukemia
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=74CEC72C-
CDF5-2C0E-E040-BB89AD4367D1
All rights reserved. Please visit https://medical-data-
models.org/forms/6748
E2906 Treatment Form -
CONSOLIDATION - Arm D - Step 2
Header
DCI Name
Registration Step (Place ID Label Here)
Patient Initials (Last, First)
ECOG Protocol Number
ECOG Protocol Number
ECOG Patient ID
ECOG Patient ID
Participating Group Protocol Number
Participating Group Patient ID
Institution/Affiliate
On Treatment
Reporting Period
Cycle 1 - Consolidation (Cycle 1 -
Consolidation)
Cycle 2 - Consolidation (Cycle 2 -
Consolidation)
Unnamed2
Please mark an 'X' if data have been amended.
(Please circle amended items in red)
Date data amended (s M D Y)
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Section Ii - Reporting Period
Reporting Period Start Date (M D Y)
Reporting Period End Date (M D Y)
Vital Status
Patient's Vital Status
Alive (Alive)
Dead (Dead)
Date of Last Contact or Death (M D Y)
Primary Cause of Death (if applicable)
Due To Other Cause (Due to other
cause)
Due To Protocol Treatment (Due to
protocol treatment)
Due To This Disease (Due to this
disease)
Unknown (Unknown)
Describe cause of death
Patient Characteristics
Weight (kg Day 1 of this treatment [Note: code
weight loss/gain >= grade 1 per CTCAE on
E2906 Adverse Event Form])
Body Surface Area (m^2 Patient Measurement
BSA Day 1 of this treatment)
Age group
Age >=70 Years Of Age (Age >=70 years
of age)
Age 60-69 Years Of Age (Age 60-69
years of age)
Therapy Administered
Agent Name
Was the agent administered during this reporting
period? (cycle)
Yes
No
Date of First dose for this reporting period (M D
Y)
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Leukemia NCT01041703 Treatment - E2906 Treatment Form -
CONSOLIDATION - Arm D - Step 2 - 2949249v1.0
Date of Last dose for this reporting period (M D
Y)
Agent Total Dose (mg/m^2 this report period)
Dose modification
Dose Delayed (Dose delayed)
Dose Delayed And Reduced (Dose
delayed and reduced)
Dose Held (Dose held)
Dose Reduced (Dose reduced)
No Dose Modification (No dose
modification)
Dose Modification Reason
Adverse Event (Adverse event)
Change In Bsa (Change in BSA)
Dosing Error (Dosing error)
Patient Refusal/noncompliance (Patient
refusal/noncompliance)
Scheduling (Scheduling)
Other Therapy Administered
Agent Name
Did patient receive Dexamethasone this reporting
period (as an anti-emetic cycle)
Yes
No
Non-protocol Therapy
Was any non-protocol therapy given during
protocol treatment? (not previously reported )
Yes
No
Comments
Investigator Signature
Investigator Signature Date (MM DD YYYY)
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Leukemia NCT01041703 Treatment - E2906 Treatment Form -
CONSOLIDATION - Arm D - Step 2 - 2949249v1.0
Liver Cancer NCT01004978 Follow-Up - E1208
Long-Term Follow-up Form - 2926924v1.0
E1208 Long-Term Follow-up Form
Chemoembolization With or Without Sorafenib Tosylate in
Treating Patients With Liver Cancer That Cannot Be
Removed By Surgery
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=705708B9-
0164-E0FE-E040-BB89AD435F94
All rights reserved. Please visit https://medical-data-
models.org/forms/6749
E1208 Long-Term Follow-up Form
Header
ECOG Protocol Number
ECOG Protocol Number
ECOG Patient ID
ECOG Patient ID
DCI Name
Registration Step (Place ID Label Here)
Patient Initials (Last, First)
Participating Group Protocol Number
Participating Group Patient ID
Institution/Affiliate
Off Treatment Report Period (since registration
choose one)
12 Months (12 Months Post Registration)
15 Months (15 Months Post Registration)
18 Months (18 Months Post Registration)
21 Months Post Registration (21 Months
Post Registration)
2 Years (24 Months Post Registration)
3 Months (3 Months Post Registration)
30 Months (30 Months Post Registration)
3 Years (36 Months Post Registration)
42 Months (42 Months Post Registration)
4 Years (48 Months Post Registration)
6 Months (6 Months Post Registration)
9 Months (9 Months Post Registration)
Unnamed2
Please mark an 'X' if data have been amended.
(Please circle amended items in red)
1 / 3
Date data amended (s M D Y)
Vital Status
Patient's Vital Status
Alive (Alive)
Dead (Dead)
Date of Last Contact or Death (m d y)
Primary Cause of Death (if applicable)
Due To Other Cause (Due to other
cause)
Due To Protocol Treatment (Due to
protocol treatment)
Due To This Disease (Due to this
disease)
Unknown (Unknown)
Describe cause of death
Section Ii - Reporting Period
Reporting Period Start Date (M D Y)
Reporting Period End Date (M D Y)
Section Iv - Notice Of New Primary
Has a new primary cancer or MDS been
diagnosed that has not been previously reported?
No (No)
Unknown (Unknown)
Yes (Yes)
Site of new primary (s If new primary site is
AML/MDS/ALL, submit NCI AML/MDS/ALL form
If new primary site is other than AML/MDS/ALL,
submit ECOG Second Primary Form)
Section Iii - Disease Follow-up Status
Has the patient had a documented imaging
assessment for this cancer
No (No)
Unknown (Unknown)
Yes (Yes)
If unknown, please explain
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Liver Cancer NCT01004978 Follow-Up - E1208 Long-Term Follow-up
Form - 2926924v1.0
Date of last clinical assessment (If yes M D Y
Submit Follow-up Disease Evaluation Form
RECIST)
Has the patient developed a first progression that
has not been previously reported? (or relapse)
No (No)
Unknown (Unknown)
Yes (Yes)
If unknown, please explain
Date of progression (relapse Submit Follow-up
Disease Evaluation Form RECIST)
Site(s) of progression
Did a physician make a formal diagnosis of
progressive disease?
No (No)
Unknown (Unknown)
Yes (Yes)
Specify basis of progression (If no or unknown )
Section V - Adverse Events
Has the patient experienced any severe (Grade =
3) long term toxicity that has not been previously
reported? (prior to diagnosis of
progression/relapse Grade >=3NOTE: Do not
report adverse events occurring after start of non-
protocol therapy.)
No (No)
Unknown (Unknown)
Yes (Yes)
Section Vi - Non-protocol Therapy Prior To
Progression
Has the patient received any non-protocol cancer
therapy prior to first progression
No (No)
Unknown (Unknown)
Yes (Yes)
Comments
Investigator Signature
Investigator Signature Date (M D Y)
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Liver Cancer NCT01004978 Follow-Up - E1208 Long-Term Follow-up
Form - 2926924v1.0
Liver Cancer NCT01015833 Response - CALGB:
80802 Follow-Up and Response Form - 2943577v1.0
CALGB: 80802 Follow-Up and Response Form
Sorafenib Tosylate With or Without Doxorubicin
Hydrochloride in Treating Patients With Locally Advanced
or Metastatic Liver Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=741A9174-
BCA1-70FC-E040-BB89AD436A0F
All rights reserved. Please visit https://medical-data-
models.org/forms/6750
CALGB: 80802 Follow-Up and
Response Form
Header
CALGB Form
CALGB Study No
CALGB Patient ID
Reporting period start date (MM DD YYYY)
Date of Last Contact or Death
Reporting Period End Date (MM DD YYYY)
Are data amended
Yes
No
Unnamed2
Patient Initials
Patient Hospital No.
Institution/Affiliate
Participating Group
Participating Group Study No.
Participating Group Patient ID
Unnamed Module 3
Vital status (Mark one with an X.)
Alive (Alive)
Dead (Dead)
1 / 3
Primary Cause of Death (Mark one with an X.)
Due To Other Cause (Due to other
cause)
Due To Protocol Treatment (Due to
protocol treatment)
Due To This Disease (Due to this
disease)
Due to other cause, specify
Response Data
Date of Last Clinical Assessment (MM DD YYYY)
Best response since beginning protocol therapy
(Mark one with an X.)
Complete Response (Complete
Response)
Not Assessed (Not assessed)
Partial Response (Partial Response)
Progressive Disease (Progressive
disease)
Stable Disease (Stable Disease)
Complete Response (CR) First Observed Date (If
yes MM DD YYYY)
Partial Response (PR) First Observed Date (If
yes MM DD YYYY)
Progressive Disease Observed Date (MM DD
YYYY)
Sites of Progression (Mark all that apply with an
X.)
Bone (Bone)
Intra-abdominal (Intra-abdominal)
Local-regional (including Ipsilateral
Breast; Chest Wall; Axillary, Internal
Mammary, And Infraclavicular Nodes;
Local-regional Skin And Subcutaneous
Tissue) (Local-regional)
Lung, Nos (Lung)
Other (Other)
Other specify
Is the patient receiving any non-protocol cancer
therapy not previously reported?
Yes
No
Specify
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Liver Cancer NCT01015833 Response - CALGB: 80802 Follow-Up and
Response Form - 2943577v1.0
Start Date of Non-protocol Therapy
Footer
Completed by (Last name, First name)
Date Form Originally Completed
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Liver Cancer NCT01015833 Response - CALGB: 80802 Follow-Up and
Response Form - 2943577v1.0
Leukemia NCT01041703 Treatment - E2906 Arm E/F
Observation/Maintenance Form - Step 3 - 3060491v1.0
E2906 Arm E/F Observation/Maintenance Form - Step 3
Clofarabine or Daunorubicin Hydrochloride and Cytarabine
Followed By Decitabine or Observation in Treating Older
Patients With Newly Diagnosed Acute Myeloid Leukemia
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=842E6463-
29A6-D18F-E040-BB89AD431F47
All rights reserved. Please visit https://medical-data-
models.org/forms/6756
E2906 Arm E/F
Observation/Maintenance Form -
Step 3
Header
DCI Name
Registration Step (Place ID Label Here)
Patient Initials (Last, First)
ECOG Protocol Number
ECOG Protocol Number
ECOG Patient ID
ECOG Patient ID
Participating Group Protocol Number
Participating Group Patient ID
Institution/Affiliate
On Treatment
Reporting Period
Cycle 1 - Step 3 (Cycle 1 - Step 3)
Cycle 10 - Step 3 (Cycle 10 - Step 3)
Cycle 11 - Step 3 (Cycle 11 - Step 3)
Cycle 12 - Step 3 (Cycle 12 - Step 3)
Cycle 13 - Step 3 (Cycle 13 - Step 3)
Cycle 2 - Step 3 (Cycle 2 - Step 3)
Cycle 3 - Step 3 (Cycle 3 - Step 3)
Cycle 4 - Step 3 (Cycle 4 - Step 3)
Cycle 5 - Step 3 (Cycle 5 - Step 3)
Cycle 6 - Step 3 (Cycle 6 - Step 3)
Cycle 7 - Step 3 (Cycle 7 - Step 3)
Cycle 8 - Step 3 (Cycle 8 - Step 3)
Cycle 9 - Step 3 (Cycle 9 - Step 3)
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On Treatment
Reporting Period
Cycle 1 - Step 3 (Cycle 1 - Step 3)
Cycle 10 - Step 3 (Cycle 10 - Step 3)
Cycle 11 - Step 3 (Cycle 11 - Step 3)
Cycle 12 - Step 3 (Cycle 12 - Step 3)
Cycle 13 - Step 3 (Cycle 13 - Step 3)
Cycle 2 - Step 3 (Cycle 2 - Step 3)
Cycle 3 - Step 3 (Cycle 3 - Step 3)
Cycle 4 - Step 3 (Cycle 4 - Step 3)
Cycle 5 - Step 3 (Cycle 5 - Step 3)
Cycle 6 - Step 3 (Cycle 6 - Step 3)
Cycle 7 - Step 3 (Cycle 7 - Step 3)
Cycle 8 - Step 3 (Cycle 8 - Step 3)
Cycle 9 - Step 3 (Cycle 9 - Step 3)
Unnamed2
Please mark an 'X' if data have been amended.
(Please circle amended items in red)
Date data amended (s M D Y)
Section Ii - Reporting Period
Reporting Period Start Date (M D Y)
Reporting Period End Date (M D Y)
Vital Status
Patient's Vital Status
Alive (Alive)
Dead (Dead)
Date of Last Contact or Death (M D Y)
Primary Cause of Death (if applicable)
Due To Other Cause (Due to other
cause)
Due To Protocol Treatment (Due to
protocol treatment)
Due To This Disease (Due to this
disease)
Unknown (Unknown)
Describe cause of death
Patient Characteristics
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Leukemia NCT01041703 Treatment - E2906 Arm E/F
Observation/Maintenance Form - Step 3 - 3060491v1.0
Weight (kg Day 1 of this treatment)
Body Surface Area (m^2 BSA Day 1 of this
treatment)
Age group
Age >=70 Years Of Age (Age >=70 years
of age)
Age 60-69 Years Of Age (Age 60-69
years of age)
Therapy Administered
Agent Name
Was the agent administered during this reporting
period? (Decitabinecycle)
Yes
No
Date of First dose for this reporting period (If yes:
M D Y)
Date of Last dose for this reporting period (M D
Y)
Agent Total Dose (mg this report period)
Dose modification
Dose Delayed (Dose delayed)
Dose Delayed And Reduced (Dose
delayed and reduced)
Dose Held (Dose held)
Dose Reduced (Dose reduced)
No Dose Modification (No dose
modification)
Dose Modification Reason
Adverse Event (Adverse event)
Change In Bsa (Change in BSA)
Dosing Error (Dosing error)
Patient Refusal/noncompliance (Patient
refusal/noncompliance)
Scheduling (Scheduling)
Non-protocol Therapy
Was any non-protocol therapy given during
protocol treatment? (not previously reported )
Yes
No
Comments
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Leukemia NCT01041703 Treatment - E2906 Arm E/F
Observation/Maintenance Form - Step 3 - 3060491v1.0
Investigator Signature
Investigator Signature Date (MM DD YYYY)
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Leukemia NCT01041703 Treatment - E2906 Arm E/F
Observation/Maintenance Form - Step 3 - 3060491v1.0
Lung Cancer NCT00632853 Treatment - CALGB:
30610 Treatment and Response Form - 2688627v1.0
CALGB: 30610 Treatment and Response Form
Three Different Radiation Therapy Regimens in Treating
Patients With Limited-Stage Small Cell Lung Cancer
Receiving Cisplatin and Etoposide
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=3C3834F7-
372A-2795-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/6762
CALGB: 30610 Treatment and
Response Form
Ccrr Module For Calgb 90202: Skeletal
Survey Form
CALGB Form (C-1244)
CALGB Study No.
CALGB Patient ID
Reporting Period Start Date
Reporting Period End Date
Are data amended
Yes
No
Patient Initials (Last, First Middle)
Patient Hospital No.
Institution/Affiliate
Participating Group
Participating Group Study No.
Participating Group Patient ID
Survival Date
Vital Status (Mark one with an X.)
Alive (Alive)
Dead (Dead)
Date of Last Contact or Death
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Treatment Data
Reporting Period
Cycles 1 & 2 (Cycles 1 & 2)
Cycles 3 & 4 (Cycles 3 & 4)
BSA
Number of cycles given (this reporting period)
Total dose of cisplatin administered this reporting
period (mg)
Total dose of etoposide administered this
reporting period (mg)
Total dose of radiation therapy administered
during this reporting period
Were there any dose modifications or
additions/omissions to protocol treatment?
(Radiation therapy)
No (No)
Yes, Planned (i.e., The Treatment Was
Changed According To Protocol
Guidelines) (Yes, planned)
Yes, Unplanned (i.e., The Treatment
Change Was Not Part Of Protocol
Guidelines) (Yes, unplanned)
Were there any dose modifications or
additions/omissions to protocol treatment?
(Radiation therapy)
No (No)
Yes, Planned (i.e., The Treatment Was
Changed According To Protocol
Guidelines) (Yes, planned)
Yes, Unplanned (i.e., The Treatment
Change Was Not Part Of Protocol
Guidelines) (Yes, unplanned)
Reason Treatment Ended
Adverse Event/side Effects/complications
(Adverse Event/Side
Effects/Complications)
Alternative Therapy (Alternative therapy)
Death On Study (Death on study)
Disease Progression, Relapse During
Active Treatment (Disease progression,
relapse during active treatment)
Other (Other)
Patient Off-treatment For Other
Complicating Disease (Patient off-
treatment for other complicating disease)
Patient Withdrawal Or Refusal After
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Lung Cancer NCT00632853 Treatment - CALGB: 30610 Treatment and
Response Form - 2688627v1.0
Beginning Protocol Therapy (Patient
withdrawal/refusal after beginning
protocol therapy)
Patient Withdrawal Or Refusal Before
Beginning Protocol Therapy (Patient
withdrawal/refusal prior to beginning
protocol therapy)
Alternative Therapy
Other specify
Response Data
Date of Last Clinical Assessment
Best Overall Response to date
Complete Response (CR)
Insufficient Evaluation (Insufficient
evaluation to determine response status)
Progressive Disease (PD)
Partial Response (PR)
Stable Disease (SD)
Complete Response (CR) First Observed Date
Partial Response (PR) First Observed Date
Progressive Disease (PD) Observed Date
Sites of Progression
Bone (Bone)
Brain (Brain)
Hilar Lymph Node (Hilar lymph nodes)
Liver (Liver)
Lung, Nos (Lung)
Mediastinal Lymph Node (Mediastinal
lymph nodes)
Contralateral Lung (Opposite lung)
Other (Other)
Pleura (Pleura)
Other specify
Site of progression with regard to RT fields
Outside The Rt Field And Outside The
Initial (pre-chemotherapy) Tumor Volume
(Outside the RT field and outside the
initial (pre-chemotherapy) tumor volume)
Outside The Rt Field And Within The
Initial (pre-chemotherapy) Tumor Volume
(Outside the RT field and within the initial
(pre-chemotherapy) tumor volume)
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Response Form - 2688627v1.0
Within Delivered/intended Low Dose
Volume (Within delivered/intended low
dose volume)
Within The Delivered/intended High
Dose Volume (Within the
delivered/intended high dose volume)
Footer
Completed by (Last name, First name)
Date Form Originally Completed
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Lung Cancer NCT00632853 Treatment - CALGB: 30610 Treatment and
Response Form - 2688627v1.0
Lung Cancer NCT00632853 Follow-Up - CALGB:
30610 Follow-Up and Response Form - 2688976v1.0
CALGB: 30610 Follow-Up and Response Form
Three Different Radiation Therapy Regimens in Treating
Patients With Limited-Stage Small Cell Lung Cancer
Receiving Cisplatin and Etoposide
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=3C4C812C-
0751-322F-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/6764
CALGB: 30610 Follow-Up and
Response Form
Ccrr Module For Calgb 90202: Skeletal
Survey Form
CALGB Form (C-1244)
CALGB Study No.
CALGB Patient ID
Reporting Period Start Date
Reporting Period End Date
Are data amended
Yes
No
Patient Initials (Last, First Middle)
Patient Hospital No.
Institution/Affiliate
Participating Group
Participating Group Study No.
Participating Group Patient ID
Survival Date
Vital Status (Mark one with an X.)
Alive (Alive)
Dead (Dead)
Date of Last Contact or Death
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Response Data
Date of Last Clinical Assessment
Best Overall Response to date
Complete Response (CR)
Insufficient Evaluation (Insufficient
evaluation to determine response status)
Progressive Disease (PD)
Partial Response (PR)
Stable Disease (SD)
Complete Response (CR) First Observed Date
Partial Response (PR) First Observed Date
Progressive Disease (PD) Observed Date
Sites of Progression
Bone (Bone)
Brain (Brain)
Hilar Lymph Node (Hilar lymph nodes)
Liver (Liver)
Lung, Nos (Lung)
Mediastinal Lymph Node (Mediastinal
lymph nodes)
Contralateral Lung (Opposite lung)
Other (Other)
Pleura (Pleura)
Other specify
Site of progression with regard to RT fields
Outside The Rt Field And Outside The
Initial (pre-chemotherapy) Tumor Volume
(Outside the RT field and outside the
initial (pre-chemotherapy) tumor volume)
Outside The Rt Field And Within The
Initial (pre-chemotherapy) Tumor Volume
(Outside the RT field and within the initial
(pre-chemotherapy) tumor volume)
Within Delivered/intended Low Dose
Volume (Within delivered/intended low
dose volume)
Within The Delivered/intended High
Dose Volume (Within the
delivered/intended high dose volume)
Cranial Irradiation
Did the patient receive prophylactic cranial
irradiation? (during this reporting period)
Yes
No
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Lung Cancer NCT00632853 Follow-Up - CALGB: 30610 Follow-Up and
Response Form - 2688976v1.0
Footer
Completed by (Last name, First name)
Date Form Originally Completed
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Lung Cancer NCT00632853 Follow-Up - CALGB: 30610 Follow-Up and
Response Form - 2688976v1.0
Lung Cancer NCT00020709 Toxicity - SOUTHWEST ONCOLOGY
GROUP S0023 ADVERSE EVENT FORM - 2291195v3.0
SOUTHWEST ONCOLOGY GROUP S0023 ADVERSE
EVENT FORM
S0023: Combination Chemo Plus RT With or Without
Gefitinib in Treating Patients With Unresectable Stage III
NSCLC
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=E1C4BD05-
F022-4833-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/6766
SOUTHWEST ONCOLOGY GROUP
S0023 ADVERSE EVENT FORM
Header
SWOG Patient ID
SWOG Study No.
Registration Step
Patient Initials
Institution/Affiliate
Physician
Treatment Segment
Consolidation Chemo (Consolidation
Chemo)
Induction Chemo/rt (Induction
Chemo/RT)
Other (Other)
Zd1839/placebo Week 12
(ZD1839/Placebo week 12)
Zd1839/placebo Week 4
(ZD1839/Placebo week 4)
Zd1839/placebo Week 8
(ZD1839/Placebo week 8)
Participating Group Name
Participating Group Study No.
Participating Group Patient ID
Toxicity
Reporting period start date (Day 1 of this Cycle)
Reporting period end date (Day 1 of next cycle. If
final cycle, date of first visit or contact after
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resolution of acute adverse events.)
Were adverse events assessed during this time
period?
No (No)
Yes (Yes)
Yes, And Reportable Adverse Events
Occurred (Yes, and reportable adverse
events occurred)
Yes, But No Reportable Adverse Events
Occurred (Yes, but no reportable adverse
events occurred)
Select box if adverse events were assessed but
none were seen. (Otherwise complete
information below.)
CTC Code 2.0
Ca51 (CA51)
Ca52 (CA52)
Ca53 (CA53)
Ea20 (EA20)
Ey02_2005347 (EY02)
Ey30_2005348 (EY30)
Ey42 (EY42)
Ey992005350 (EY99)
Fl01 (FL01)
Fl10 (FL10)
Fl40_2005351 (FL40)
Fl51 (FL51)
Gi00_2005354 (GI00)
Gi10_2005356 (GI10)
Gi20_2005357 (GI20)
Gi23 (GI23)
Gi30 (GI30)
Gi43 (GI43)
Gi51 (GI51)
Gi60 (GI60)
Gi61 (GI61)
Gir60 (GIR60)
Gir69 (GIR69)
Gu50_2005358 (GU50)
He002005359 (HE00)
He102005360 (HE10)
He202005361 (HE20)
He21 (HE21)
He302005362 (HE30)
Im00_2005363 (IM00)
In002005364 (IN00)
In01 (IN01)
In05_2005365 (IN05)
In06 (IN06)
In30_2005366 (IN30)
Li00_2005352 (LI00)
Li11 (LI11)
Li12_2005353 (LI12)
Li20 (LI20)
Lu50 (LU50)
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GROUP S0023 ADVERSE EVENT FORM - 2291195v3.0
Nr50 (NR50)
Nr60 (NR60)
Pa21 (PA21)
Pa22 (PA22)
Pa30 (PA30)
Sk00 (SK00)
Sk16 (SK16)
Skr72 (SKR72)
Toxicity
Abdominal Pain (Abdominal pain)
Alkaline Phosphatase Increase (Alkaline
phosphatase increase)
Allergyhypersensitivity2005386
(Allergy/hypertension)
Anemia_2005384 (Anemia)
Arthralgia (Arthralgia)
Bilirubin_increase_2005375 (Bilirubin
increase)
Blurred Vision (Blurred vision)
Constipation (Constipation)
Creatinine_increase_2005381
(Creatinine increase)
Dehydration (Dehydration)
Diarrhea_2005380 (Diarrhea)
Edema (Edema)
Esophagitis (Esophagitis)
Eye_other2005373 (eye - other)
Fatigue_2005374
(Fatigue/malaise/lethargy)
Febrile_neutropenia_2005389 (Febrile
neutropenia)
Fever Without Neutropenia (Fever
without neutropenia)
Gastritis (Gastritis)
Hearing Loss (Hearing loss)
Hypotension (Hypotension)
Infection Without 3-4 Neutropenia
(Infection without 3-4 neutropenia)
Keratitis_2005370 (Keratitis)
Leukopenia2005382 (Leukopenia)
Local/injection Site Reaction
(Local/injection site reaction)
Motor Neuropathy (Motor neuropathy)
Myalgia (Myalgia)
Nausea_2005377 (Nausea)
Neutropeniagranulocytop2005385
(Neutropenia/granulocytopenia)
Paresthesia (Paresthesia)
Phlebitis (Phlebitis)
Pneumonitis (Pneumonitis)
Prbc Transfusion (pRBC transfusion)
Pruritis (Pruritis)
Radiation Dermatitis (Radiation
dermatitis)
Rashdesquamation2005368
(Rash/desquamation)
Respiratory Infection With Neutropenia
(Respiratory infection with neutropenia)
Rigors/chills (Rigors/chills)
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GROUP S0023 ADVERSE EVENT FORM - 2291195v3.0
Rt-dysphasia (RT-dysphasia)
Rt-esophagitis (RT-esophagitis)
Rt-mucositis (RT-mucositis)
Sgot Increase (SGOT increase)
Sgpt_increase_2005376 (SGPT
increase)
Stomatitis/pharyngitis
(Stomatitis/pharyngitis)
Taste Disturbance (Taste disturbance)
Tearing_2005371 (Tearing)
Thrombocytopenia_2005383
(Thrombocytopenia)
Thrombosis/embolism
(Thrombosis/embolism)
Vomiting_2005379 (Vomiting)
Weight Loss (Weight loss)
Other toxicities (specify)
Grade (1 - 5)
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
Treatment relation (*)
Definite_2005397 (definite)
Possible_2005395 (possible)
Probable_2005396 (probable)
Unlikely_2005394 (unlikely)
Unrelated_2005393 (unrelated)
Comments
Comments
4 / 4
Lung Cancer NCT00020709 Toxicity - SOUTHWEST ONCOLOGY
GROUP S0023 ADVERSE EVENT FORM - 2291195v3.0
Lung Cancer NCT00499330 Follow-Up -
CALGB: 140503 Follow-Up Form - 2538338v1.0
CALGB: 140503 Follow-Up Form
Comparison of Different Types of Surgery in Treating
Patients With Stage IA Non-Small Cell Lung Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=219730B6-
29AE-6C8D-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/6769
CALGB: 140503 Follow-Up Form
Ccrr Module For Calgb 90202: Skeletal
Survey Form
CALGB Form
CALGB Study No.
CALGB Patient ID
Reporting Period Start Date (mm/dd/yyyy)
Reporting Period End Date (mm/dd/yyyy)
Are data amended
Yes
No
Patient Initials (Last, First Middle)
Patient Hospital No.
Institution/Affiliate
Participating Group
Participating Group Protocol Number
Participating Group Patient ID
Vital Status
Patient Vital Status (Mark one with an X.)
Alive (Alive)
Dead (Dead)
Lost To Follow-up (Lost to follow-up)
Primary Cause of Death (Mark one with an X.)
Complications Of Protocol Surgery
(Complications of protocol surgery)
Due To Other Cause (Due to other
cause)
1 / 4
Due To This Disease (Due to this
disease)
Describe cause of death
Disease Status
Date of Most Recent Clinical Assessment
Current disease status (Mark one with an X.)
Died With No Evidence Of Relapse (Died
with no evidence of relapse)
No Evidence Of Disease (No evidence of
disease)
Relapse/recurrence
(Relapse/Recurrence)
Progression/relapse Data
Date of Recurrence
Is an additional resection planned (If disease has
recurred,)
Yes
No
Type(s) of relapse (Mark all that apply)
Distant (Distant)
Local (Local)
Regional (Regional)
Sites Of Relapse
Sites of relapse
Adrenal Gland (Adrenal(s))
Bone (Bone)
Bone Marrow (Bone Marrow)
Contralateral Lung (Contralateral lung)
Hilar Lymph Node (Hilar nodes)
Liver (Liver)
Mediastinal Lymph Node (Mediastinal
nodes)
Other (Other)
Pleura (Pleura)
Primary Lung (Primary lung)
Supraclavicular Lymph Node
(Supraclavicular/scalene nodes)
Specify
Pulmonary Function Tests
Pulmonary function tests performed?
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Lung Cancer NCT00499330 Follow-Up - CALGB: 140503 Follow-Up
Form - 2538338v1.0
Yes
No
Date of Pulmonary Function Test
Forced Expiratory Volume 1 (%Predicted FEV1)
Forced Vital Capacity (% predicted) (FVC)
Forced Expiratory Volume 1 (FEV1) (Observed
FEV1)
Forced Vital Capacity (FVC) (Observed FVC)
Post-surgical Treatment
Has the patient had adjuvant chemotherapy,
including target therapy, for this cancer during the
time covered by this form
Yes
No
Agent Name
Agent Start Date
Has the patient had radiotherapy for this cancer
during the time perior covered by this form
Yes
No
Date Adjuvant Radiation Therapy Started
Has the patient had additional surgery for this
cancer during the time period covered by this
form
Yes
No
Surgery Date
Procedure Type
Extent of resection (Mark one)
Complete (Complete)
Incomplete (Incomplete)
New Primary Data
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Lung Cancer NCT00499330 Follow-Up - CALGB: 140503 Follow-Up
Form - 2538338v1.0
Has a new primary cancer or MDS been
diagnosed that has not been previously reported?
Yes
No
Date of diagnosis
Site of new primary (Mark one)
Breast (Breast)
Lung (Lung)
Other (Other)
Prostate (Prostate)
Skin (Skin)
Other, specify
Footer
Completed by (Last name, First name)
Date Form Originally Completed
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Lung Cancer NCT00499330 Follow-Up - CALGB: 140503 Follow-Up
Form - 2538338v1.0
Lung Cancer NCT01107626 Follow-Up - E5508
Long-Term Follow-up Form - 2905089v1.0
E5508 Long-Term Follow-up Form
Bevacizumab or Pemetrexed Disodium Alone or In
Combination After Induction Therapy in Treating Patients
With Advanced Non-Squamous Non-Small Cell Lung
Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=6D41D0A3-
AEE4-13D4-E040-BB89AD430599
All rights reserved. Please visit https://medical-data-
models.org/forms/6770
E5508 Long-Term Follow-up Form
Header
ECOG Protocol Number
ECOG Protocol Number
ECOG Patient ID
ECOG Patient ID
DCI Name
Registration Step (Place ID Label Here)
Patient Initials (Last, First)
Participating Group Protocol Number
Participating Group Patient ID
Institution/Affiliate
Off Treatment Report Period (since registration
Choose one)
12 Months (12 Months Post Registration)
15 Months (15 Months Post Registration)
18 Months (18 Months Post Registration)
21 Months Post Registration (21 Months
Post Registration)
2 Years (24 Months Post Registration)
3 Months (3 Months Post Registration)
30 Months (30 Months Post Registration)
3 Years (36 Months Post Registration)
42 Months (42 Months Post Registration)
4 Years (48 Months Post Registration)
54 Months (54 Months Post Registration)
6 Months (6 Months Post Registration)
5 Years (60 Months Post Registration)
9 Months (9 Months Post Registration)
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Unnamed2
Please mark an 'X' if data have been amended.
(Please circle amended items in red)
Date data amended (s M D Y)
Vital Status
Patient's Vital Status
Alive (Alive)
Dead (Dead)
Date of Last Contact or Death (M D Y)
Primary Cause of Death
Due To Other Cause (Due to other
cause)
Due To Protocol Treatment (Due to
protocol treatment)
Due To This Disease (Due to this
disease)
Unknown (Unknown)
Describe cause of death
Section Ii - Reporting Period
Reporting Period Start Date (M D Y)
Reporting Period End Date (M D Y)
Section Iv - Notice Of New Primary
Has a new primary cancer or MDS been
diagnosed that has not been previously reported?
No (No)
Unknown (Unknown)
Yes (Yes)
Site of new primary (s)
Section Iii - Disease Follow-up Status
Has the patient had a documented clinical
assessment for this cancer (this reporting period)
No (No)
Unknown (Unknown)
Yes (Yes)
If unknown, please explain
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Lung Cancer NCT01107626 Follow-Up - E5508 Long-Term Follow-up
Form - 2905089v1.0
Date of last clinical assessment (If yes M D Y
Submit E5508 Follow-up Disease Evaluation
Form RECIST)
Has the patient developed a first progression that
has not been previously reported? (or relapse)
No (No)
Unknown (Unknown)
Yes (Yes)
If unknown, please explain
Date of progression (If yes, relapse M D Y Submit
E5508 Follow-up Disease Evaluation Form
RECIST)
Site(s) of progression
Did a physician make a formal diagnosis of
progressive disease?
No (No)
Unknown (Unknown)
Yes (Yes)
Specify basis of progression (If no or unknown)
Section V - Adverse Events
Has the patient experienced any severe (Grade =
3) long term toxicity that has not been previously
reported? (prior to diagnosis of
progression/relapse)
No (No)
Unknown (Unknown)
Yes (Yes)
Section Vi - Non-protocol Therapy Prior To
Progression
Has the patient received any non-protocol cancer
therapy prior to first recurrence (not previously
reported)
No (No)
Unknown (Unknown)
Yes (Yes)
Comments
Investigator Signature
Investigator Signature Date (M D Y)
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Lung Cancer NCT01107626 Follow-Up - E5508 Long-Term Follow-up
Form - 2905089v1.0
Multiple Myeloma and Plasma Cell Neoplasm NCT01169337
Treatment - E3A06 Observation Form (Arm B) - 3088885v1.0
E3A06 Observation Form (Arm B)
Lenalidomide or Observation in Treating Patients With
Asymptomatic High-Risk Smoldering Multiple Myeloma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=86F8804D-
3BC0-A474-E040-BB89AD435240
All rights reserved. Please visit https://medical-data-
models.org/forms/6772
E3A06 Observation Form (Arm B)
Header
DCI Name
Registration Step (Place ID Label Here)
Patient Initials (Last, First)
ECOG Protocol Number
ECOG Protocol Number
ECOG Patient ID
ECOG Patient ID
Participating Group Protocol Number
Participating Group Patient ID
Institution/Affiliate
On Treatment
On Observation Report Period
> Cycle 19 (> Cycle 19)
Cycle 1 (Cycle 1)
Cycle 10 (Cycle 10)
Cycle 11 (Cycle 11)
Cycle 12 (Cycle 12)
Cycle 13 (Cycle 13)
Cycle 14 (Cycle 14)
Cycle 15 (Cycle 15)
Cycle 16 (Cycle 16)
Cycle 17 (Cycle 17)
Cycle 18 (Cycle 18)
Cycle 19 (Cycle 19)
Cycle 2 (Cycle 2)
Cycle 3 (Cycle 3)
Cycle 4 (cycle 4)
Cycle 5 (Cycle 5)
Cycle 6 (Cycle 6)
1 / 3
Cycle 7 (Cycle 7)
Cycle 8 (cycle 8)
Cycle 9 (Cycle 9)
Specify Cycle
Section Ii - Reporting Period
Report Period Start Date (M D Y)
Report Period End Date (M D Y)
Unnamed2
Please mark an 'X' if data have been amended.
(Please circle amended items in red)
Date data amended (s M D Y)
Vital Status
Patient's Vital Status
Alive (Alive)
Dead (Dead)
Date of Last Contact or Death (M D Y)
Primary Cause of Death (if applicable)
Due To Other Cause (Due to other
cause)
Due To Protocol Treatment (Due to
protocol treatment)
Due To This Disease (Due to this
disease)
Unknown (Unknown)
Describe cause of death
Non-protocol Therapy
Was any non-protocol therapy given during
protocol treatment? (not previously reported )
Yes
No
Comments
Investigator Signature
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E3A06 Observation Form (Arm B) - 3088885v1.0
Investigator Signature Date (MM DD YYYY)
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Multiple Myeloma and Plasma Cell Neoplasm NCT01169337 Treatment -
E3A06 Observation Form (Arm B) - 3088885v1.0
Melanoma (Skin) NCT01274338 Follow-Up -
E1609 Long-Term Follow-up Form - 3173517v1.0
E1609 Long-Term Follow-up Form
Ipilimumab or High-Dose Interferon Alfa-2b in Treating
Patients With High-Risk Stage III or Stage IV Melanoma
That Has Been Removed by Surgery
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=97EE23A9-
7DEA-11D3-E040-BB89AD437097
All rights reserved. Please visit https://medical-data-
models.org/forms/6782
E1609 Long-Term Follow-up Form
Header
DCI Name
Registration Step (Place ID Label Here)
Patient Initials (Last, First)
ECOG Protocol Number
ECOG Protocol Number
ECOG Patient ID
ECOG Patient ID
Participating Group Protocol Number
Participating Group Patient ID
Institution/Affiliate
Off Treatment
Off Treatment Report Period (Choose one)
9 Years (108 months post registration)
12 Months (12 Months Post Registration)
10 Years (120 months post registration)
11 Years Post Registration (132 Months
Post Registration)
12 Years Post Registration (144 Months
Post Registration)
15 Months (15 Months Post Registration)
13 Years Post Registration (156 Months
Post Registration)
14 Years Post Registration (168 Months
Post Registration)
18 Months (18 Months Post Registration)
15 Years Post Registration (180 Months
Post Registration)
16 Years Post Registration (192 Months
Post Registration)
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17 Years Post Registration (204 Months
Post Registration)
21 Months Post Registration (21 Months
Post Registration)
18 Years Post Registration (216 Months
Post Registration)
19 Years Post Registration (228 Months
Post Registration)
2 Years (24 Months Post Registration)
20 Years Post Registration (240 Months
Post Registration)
3 Months (3 Months Post Registration)
30 Months (30 Months Post Registration)
3 Years (36 Months Post Registration)
42 Months (42 Months Post Registration)
4 Years (48 Months Post Registration)
54 Months (54 Months Post Registration)
6 Months (6 Months Post Registration)
5 Years (60 Months Post Registration)
6 Years (72 Months Post Registration)
84 Months Post Registration (84 Months
Post Registration)
9 Months (9 Months Post Registration)
8 Years (96 months post registration)
Unnamed2
Please mark an 'X' if data have been amended.
(Please circle amended items in red)
Date data amended (s M D Y)
Ecog Performance Status
ECOG Performance Status
Fully Active, Able To Carry On All Pre-
disease Performance Without
Restriction. (0)
Restricted In Physically Strenuous
Activity But Ambulatory And Able To
Carry Out Work Of A Light Or Sedentary
Nature, E.g., Light Housework, Office
Work. (1)
Ambulatory And Capable Of All Selfcare
But Unable To Carry Out Any Work
Activities. Up And About More Than 50%
Of Waking Hours. (2)
Capable Of Only Limited Selfcare,
Confined To Bed Or Chair More Than
50% Of Waking Hours. (3)
Completely Disabled. Cannot Carry On
Any Selfcare. Totally Confined To Bed Or
Chair. (4)
Dead (5)
Vital Status
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Melanoma (Skin) NCT01274338 Follow-Up - E1609 Long-Term Follow-up
Form - 3173517v1.0
Patient's Vital Status
Alive (Alive)
Dead (Dead)
Date of Last Contact or Death (m d y)
Primary Cause of Death (if applicable)
Due To Other Cause (Due to other
cause)
Due To Protocol Treatment (Due to
protocol treatment)
Due To This Disease (Due to this
disease)
Unknown (Unknown)
Describe cause of death
Section Ii - Reporting Period
Reporting Period Start Date (M D Y)
Reporting Period End Date (M D Y)
Section Iv - Notice Of New Primary
Has a new primary cancer or MDS been
diagnosed that has not been previously reported?
No (No)
Unknown (Unknown)
Yes (Yes)
Site of new primary (s If new primary site is
AML/MDS/ALL, submit NCI AML/MDS/ALL form
If new primary site is other than AML/MDS/ALL,
submit ECOG Second Primary Form)
Section Iii - Disease Follow-up Status
Has the patient had a documented clinical
assessment for this cancer?
No (No)
Unknown (Unknown)
Yes (Yes)
If unknown, please explain
Date of last clinical assessment (If yes M D Y
Submit Follow-up Disease Evaluation Form
RECIST)
Has the patient developed a first progression that
3 / 5
Melanoma (Skin) NCT01274338 Follow-Up - E1609 Long-Term Follow-up
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has not been previously reported? (or relapse)
No (No)
Unknown (Unknown)
Yes (Yes)
If unknown, please explain
Date of progression (relapse Submit Follow-up
Disease Evaluation Form RECIST)
Site(s) of progression
Did a physician make a formal diagnosis of
progressive disease?
No (No)
Unknown (Unknown)
Yes (Yes)
Specify basis of progression (If no or unknown )
Section V - Salvage Therapy
Has the patient received any salvage therapy
after recurrence
Yes
No
Type of Salvage Therapy
Anti-pd1 Antibody (Anti-PD1 antibody)
Anti-pd-l1 Antibody (Anti-PDL1 antibody)
Chemotherapy (Chemotherapy)
Immunotherapy (Immunotherapy)
Radiation Therapy (Radiation Therapy)
Surgery (Surgery)
Anti-PD1 antibody, specify
Anti-PDL1 antibody, specify
Date of salvage therapy (if applicable)
Did the patient receive any of the following as
part of salvage therapy
Braf Inhibitor Gsk2118436
(GSK2118436)
Interferon Alpha (Interferon-alpha)
Ipilimumab (Ipilimumab)
Other (Other)
Plx4032 (rg7204; Ro5185426) (PLX4032
(RG7204; RO5185426))
Raf265 (RAF265)
Tremelimumab (Tremelimumab)
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Specify
Date of any other non-protocol systemic
treatment
Unnamed3
Was BRAF Gene Analysis performed (If yes,
submit E1609 Source Document Tracking
Coversheet)
Yes
No
BRAF Mutation Result (If Yes:)
Other (Other)
Unknown (Unknown)
V600e (V600E)
V600k (V600K)
Wild Type (Wild Type)
Specify
Date of Test (BRAF Mutation)
Section V - Adverse Events
Has the patient experienced any reportable long
term toxicity that has not been previously
reported (prior to diagnosis of
progression/relapse)
No (No)
Unknown (Unknown)
Yes (Yes)
Section Vi - Non-protocol Therapy Prior To
Progression
Has the patient received any non-protocol cancer
therapy prior to first progression (If yes, submit
ECOG Non-Protocol Therapy Form - Note:  Only
the first occurrence of non-protocol therapy
should be reported.)
No (No)
Unknown (Unknown)
Yes (Yes)
Comments
Investigator Signature
Investigator Signature Date (M D Y)
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Form - 3173517v1.0
Lung Cancer NCT00863512 Follow-Up -
CALGB 30506 Follow-Up Form - 2817823v1.0
CALGB 30506 Follow-Up Form
Chemotherapy or Observation in Treating Patients With
Early Stage Non-Small Cell Lung Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=5EA3ECF9-
4D34-6727-E040-BB89AD437448
All rights reserved. Please visit https://medical-data-
models.org/forms/6784
CALGB 30506 Follow-Up Form
Ccrr Module For Calgb 90202: Skeletal
Survey Form
CALGB Form
CALGB Study No.
CALGB Patient ID
Reporting Period Start Date (mm/dd/yyyy)
Reporting Period End Date (mm/dd/yyyy)
Are data amended
Yes
No
Patient Initials (Last, First Middle)
Patient Hospital No.
Institution/Affiliate
Participating Group
Participating Group Protocol Number
Participating Group Patient ID
Vital Status
Vital Status (Mark one with an X.)
Alive (Alive)
Dead (Dead)
Date of Death (specify)
Primary Cause of Death (Mark one with an X.)
Due To Other Cause (Due to other
cause)
1 / 3
Due To Protocol Treatment (Due to
protocol treatment)
Due To This Disease (Due to this
disease)
Describe cause of death
Did the patient have a CXR or chest CT during
this reporting period
Yes
No
Date of Chest X-Ray or CT scan (specify MM DD
YYYY)
Disease Status
Current disease status (Mark one with an X.)
Died With No Evidence Of Relapse (Died
with no evidence of relapse)
No Evidence Of Disease (No evidence of
disease)
Relapse/recurrence
(Relapse/Recurrence)
Progression/relapse Data
Date of Recurrence (MM DD YYYY)
Sites Of Relapse
Sites of relapse
Adrenal Gland (Adrenal(s))
Bone (Bone)
Bone Marrow (Bone Marrow)
Contralateral Lung (Contralateral lung)
Hilar Lymph Node (Hilar nodes)
Liver (Liver)
Mediastinal Lymph Node (Mediastinal
nodes)
Other (Other)
Pleura (Pleura)
Primary Lung (Primary lung)
Supraclavicular Lymph Node
(Supraclavicular/scalene nodes)
Specify
Non-protocol Treatment
Has the patient received any non-protocol cancer
therapy during this reporting period?
Yes
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No
Start Date of Non-protocol Therapy  (MM DD
YYYY)
Footer
Completed by (Last name, First name)
Date Form Originally Completed
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Lung Cancer NCT01041781 Response - CALGB:
30801 Follow-Up and Response Form - 2891478v1.0
CALGB: 30801 Follow-Up and Response Form
Gemcitabine Hydrochloride or Pemetrexed Disodium and
Carboplatin With or Without Celecoxib in Treating Patients
With Advanced Non-Small Cell Lung Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=6AF26CA3-
DEA5-EEE0-E040-BB89AD436D54
All rights reserved. Please visit https://medical-data-
models.org/forms/6787
CALGB: 30801 Follow-Up and
Response Form
Header
CALGB Form
CALGB Study No
CALGB Patient ID
Reporting period start date (MM DD YYYY)
Reporting Period End Date (MM DD YYYY)
Are data amended
Yes
No
Unnamed2
Patient Initials
Patient Hospital No.
Institution/Affiliate
Participating Group
Participating Group Study No.
Participating Group Patient ID
Unnamed Module 3
Vital status (Mark one with an X.)
Alive (Alive)
Dead (Dead)
Primary Cause of Death (Mark one with an X.)
1 / 3
Due To Other Cause (Due to other
cause)
Due To Protocol Treatment (Due to
protocol treatment)
Due To This Disease (Due to this
disease)
Due to other cause, specify
Response Data
Date of Last Clinical Assessment (MM DD YYYY)
Is complete response first observed
Yes
No
Complete Response (CR) First Observed Date (If
yes MM DD YYYY)
Other specify
Is partial response first observed
Yes
No
Partial Response (PR) First Observed Date (If
yes MM DD YYYY)
Has the patient developed a progression or
relapse that has not been previously reported?
Yes
No
Progressive Disease Observed Date (MM DD
YYYY)
Sites of Progression (Mark all that apply with an
X.)
Bone (Bone)
Central Nervous System (Central
Nervous System)
Distant Lymph Nodes (Distant lymph
nodes)
Liver (Liver)
Lung, Nos (Lung)
Contralateral Lung (Opposite lung)
Other (Other)
Pleura (Pleura)
Regional Lymph Nodes (Regional lymph
nodes)
Best response since beginning protocol therapy
(Mark one with an X.)
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Response Form - 2891478v1.0
Complete Response (Complete
Response)
Not Assessed (Not assessed)
Partial Response (Partial Response)
Progressive Disease (Progressive
disease)
Stable Disease (Stable Disease)
Non-protocol Treatment
Is the patient receiving any non-protocol cancer
therapy not previously reported?
Yes
No
Specify
Date of First Non-Protocol Therapy (if during this
reporting period MM DD YYYY)
New Primary Data
Has a new primary cancer or MDS been
diagnosed that has not been previously reported?
Yes
No
Site of new primary (Mark one with an X.)
Breast (Breast)
Lung (Lung)
Other (Other)
Prostate (Prostate)
Skin (Skin)
Other specify
Completed by
Date form originally completed (MM DD YYYY)
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Response Form - 2891478v1.0
Prostate Cancer NCT00430183 Follow-Up -
CALGB 90203: Follow-Up Form - 2525712v1.0
CALGB 90203: Follow-Up Form  [Form C-1244 v 1
11/08/2006]
Surgery With or Without Docetaxel and Leuprolide or
Goserelin in Treating Patients With High-Risk Localized
Prostate Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=1F18671A-
961D-6EE4-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/6790
CALGB 90203: Follow-Up Form
Ccrr Module For Calgb 90202: Skeletal
Survey Form
CALGB Form (C-1244)
CALGB Study No.
CALGB Patient ID
Reporting Period Start Date (mm/dd/yyyy)
Reporting Period End Date (mm/dd/yyyy)
Are data amended
Yes
No
Patient Initials (Last, First Middle)
Patient Hospital No.
Institution/Affiliate
Participating Group
Participating Group Study No.
Participating Group Patient ID
Vital Status
Patient Vital Status (Mark one with an X.)
Alive (Alive)
Dead (Dead)
Lost To Follow-up (Lost to follow-up)
Primary Cause of Death (Mark one with an X.)
Due To Other Cause (Due to other
cause)
1 / 7
Due To Protocol Treatment (Due to
protocol treatment)
Due To This Disease (Due to this
disease)
Describe cause of death
Date of Last Contact or Death (mm dd yyyy)
ECOG Performance Status (Mark one with an X.)
Fully Active, Able To Carry On All Pre-
disease Performance Without
Restriction. (0)
Restricted In Physically Strenuous
Activity But Ambulatory And Able To
Carry Out Work Of A Light Or Sedentary
Nature, E.g., Light Housework, Office
Work. (1)
Ambulatory And Capable Of All Selfcare
But Unable To Carry Out Any Work
Activities. Up And About More Than 50%
Of Waking Hours. (2)
Capable Of Only Limited Selfcare,
Confined To Bed Or Chair More Than
50% Of Waking Hours. (3)
Completely Disabled. Cannot Carry On
Any Selfcare. Totally Confined To Bed Or
Chair. (4)
Disease Follow-up Status
Has the patient had a documented clinical
assessment for this cancer? (since submission of
the previous follow-up form)
Yes
No
Method of Evaluation (s Mark all that apply with
an X.)
Digital Rectal Examination (Digital rectal
exam)
Pathologic (Pathologic)
Radiographic (Radiographic)
Other Specify
Date of examination (Recommeded Term to
replace CRF Text "date" - specify  mm dd yyyy)
Date of Assessment (specify  mm dd yyyy)
Date of PSA Assessment (Recommended Term
to replace CRF Text "date" - specify  mm dd yyyy)
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Form - 2525712v1.0
Notice Of Progression
Has the patient been diagnosed with a first
biochemical progression? (PSA)
Yes
No
Date of First Biochemical Progression (PSA)
Method of Evaluation (s Mark all that apply with
an X.)
Digital Rectal Examination (Digital rectal
exam)
Pathologic (Pathologic)
Radiographic (Radiographic)
PSA Value at Progression (Recommended Term
for CRF Text "PSA Value at first Progression" -
ng/mL)
Biochemical progression confirmed date
(Recommended Term for CRF Text "Biochemical
progression confirmation date" - mm dd yyyy)
Has the patient been diagnosed with a first local
recurrence (e.g., prostate bed)
Yes
No
Date of first local recurrence (mm dd yyyy)
Has patient been diagnosed with first bone
progression
Yes
No
Date of first bone progression (per bone scan mm
dd yyyy)
Has the patient been diagnosed with first distant
recurrence/progression? (Recommended Term
for CRF Text "Has patient been diagnosed with
first distant non-bone progression")
Yes
No
Date of First Distant Progression (non-bone
recurrence/ - mm dd yyyy)
Site of First Distant Progression (Specify Mark all
that apply with an X. - Recommended Term for
CRF Text "Sites of first distant non-bone
progression")
Central Nervous System/brain (Central
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nervous system/Brain)
Liver (Liver)
Lung (Lung)
Lymph Nodes (Lymph nodes)
Other Specify (Other)
Pleura (Pleura)
Lymph Nodes Specify
Other specify
Treatment Status
Did patient start adjuvant postoperative
radiotherapy?
Yes
No
When was adjuvant radiotherapy initiated
More Than 6 Months After Surgery
(More than 6 months after surgery)
Within 6 Months After Surgery (Within 6
months after surgery)
Postoperative Radiation Therapy Start Date
(Recommended Term for CRF Text "Prostate
EBRT external beam radiation therapy start date"
mm dd yyyy)
Postoperative Radiation Therapy End Date
(Recommended Term for CRF Text "Prostate
EBRT external beam radiation therapy end date"
mm dd yyyy)
Total dose administered (cGy)
Radiation Therapy Site (Recommended Term for
CRF Text "Sites irradiated")
Other Specify (Other)
Pelvic Region (Pelvis)
Other specify
Did patient receive androgen deprivation
therapy?
Yes
No
LHRH agonist therapy (Recommended Term for
CRF Text "Postoperative LHRH Agonist Type" -
Mark one with an X.)
Goserelin (Goserelin (Zoladex))
Leuprolide Acetate (Leuprolide (Eligard))
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Leuprolide Acetate (Leuprolide (Lupron))
Other (Other)
Other specify
LHRH agonist start date (Recommended Term
for CRF Text "Postoperative LHRH agonist start
date" mm dd yyyy)
LHRH agonist last administered date
(Recommended Term for CRF Text
"Postoperative LHRH agonist end date" mm dd
yyyy)
LHRH Agonist Total Dose (Recommended Term
for CRF Text "Postoperative LHRH agonist total
dose to date" mg)
Date of orchiectomy (specify if applicable mm dd
yyyy)
Oral antiandrogen therapy (Recommended Term
for CRF Text "Postoperative oral antiandrogen
type" Mark one with an X.)
Bicalutamide (Bicalutamide (Casodex))
Flutamide (Flutamide (Eulexin))
Nilutamide (Nilutamide (Nilandron))
Other (Other)
Other specify
Oral Antiandrogen Start Date (Recommended
Term for CRF Text "Postoperative oral
antiandrogen start date" mm dd yyyy)
Oral antiandrogen last administered date
(Recommended Term for CRF Text
"Postoperative oral antiandrogen start date" mm
dd yyyy)
Oral antiandrogen Total Daily Dose
(Recommended Term for CRF Text
"Postoperative Oral antiandrogen dose to date"
mg)
Postoperative Therapy (continued)
Is the patient receiving any non-protocol cancer
therapy not previously reported?
Yes
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No
Non-Protocol Therapy Type (*Non-protocol
therapy type: 1=Radiation to pelvis; 2=Radiation
to other sites, specify; 3=Surgery;
4=Chemotherapy; 5=Hormone; 6=Other, specify)
Chemotherapy (Chemotherapy)
Hormones (Hormones)
Other Specify (Other)
Radiation To Other Sites, Specify
(Radiation to other sites)
Radiation To Pelvis (Radiation to pelvis)
Surgery (Surgery)
Start Date of Non-protocol Therapy  (mm dd
yyyy)
Specify
Notice Of New Primary
Has a new primary cancer or MDS been
diagnosed that has not been previously reported?
Yes
No
MedDRA disease code (New Primary Tumor Site
* MedDRA Disease Code=Disease Site table
10000884=AML; 1004146=BCC;
10018192=Bladder; 10007959=Brain;
10010029=Colorectal; ... 10018864=Other -
hematologic, specify; 10029000=Other - solid,
specify; 99999999=Unknown)
New Primary Cancer Date
Specify disease site (If code=10018664 or
10029000, - below Recommended Term to
replace CRF Text "specify")
Long-term Toxicity
Has the patient experienced (prior to diagnosis of
recurrence or second primary) any severe (Grade
>=3), long term toxicity that has not been
previously reported (*Long-term toxicity is any
toxicity that lasts 30 days or longer)
Yes
No
Specify type and/or site (If non-AML/MDS
secondary malignancy occurs,)
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Footer
Completed by (Last name, First name)
Date Form Completed (mm dd yyyy)
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Treatment - Phase II Breast Cancer - Advanced
Treatment Summary Form - All Patients - 2583264v1.0
Phase II Breast Cancer - Advanced Treatment Summary
Form - All Patients
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=2587F53B-
B69F-4967-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/6796
Phase II Breast Cancer - Advanced
Treatment Summary Form - All
Patients
Crf Header
Coordinating Group Protocol No.
Coordinating Group Code
Protocol Title
Patient Study ID
Institution/Affiliate
Registering Group Code
Registering Institution Code
Patient Initials
Breast: Form Administration
Person Completing Form
Are data amended? (If data are amended, please
circle in red when using paper form)
Yes
No
Breast: Treatment Reporting Interval
Reporting Period Start Date
Reporting Period End Date
Breast: Advanced Treatment Plan
Date of First Dose for This Reporting Period
1 / 3
Date of Last Dose for This Reporting Period
Initial Dose (of Cycle 1 use protocol specified
units)
Units
Agent Name (protocol specific Some groups may
pre-print protocol agents with appropriate units.)
Reason Treatment Ended
Adverse Event/side Effects/complications
(Adverse Event/Side
Effects/Complications)
Alternative Therapy (Alternative therapy)
Death On Study (Death on study)
Disease Progression, Relapse During
Active Treatment (Disease progression,
relapse during active treatment)
Other (Other)
Patient Off-treatment For Other
Complicating Disease (Patient off-
treatment for other complicating disease)
Patient Withdrawal Or Refusal After
Beginning Protocol Therapy (Patient
withdrawal/refusal after beginning
protocol therapy)
Patient Withdrawal Or Refusal Before
Beginning Protocol Therapy (Patient
withdrawal/refusal prior to beginning
protocol therapy)
Treatment Completed Per Protocol
Criteria (Treatment completed per
protocol criteria)
Were there any dose modifications or
additions/omissions to protocol treatment? (check
one)
No (No)
Unknown (Unknown)
Yes, Planned (i.e., The Treatment Was
Changed According To Protocol
Guidelines) (Yes, planned)
Yes, Unplanned (i.e., The Treatment
Change Was Not Part Of Protocol
Guidelines) (Yes, unplanned)
Were any optional therapies given?
Yes
No
Optional Protocol Therapy Name (If yes,)
Was any non-protocol therapy given during
protocol treatment?
2 / 3
Treatment - Phase II Breast Cancer - Advanced Treatment Summary
Form - All Patients - 2583264v1.0
Yes
No
Concurrent Non-Protocol Chemotherapy? (If yes,)
Yes
No
Concurrent Non-Protocol Hormonal Therapy?
Yes
No
Concurrent Non-Protocol Biologic Response
Modifier Therapy?
Yes
No
Concurrent Non-Protocol Radiation Therapy?
Yes
No
Concurrent Non-Protocol High Dose
Chemotherapy/Autologous Stem Cell Transplant?
Yes
No
Comments
Comments
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Form - All Patients - 2583264v1.0
Response - Summary Response/Progression
Form for Solid Tumors - 2278235v3.0
Summary Response/Progression Form for Solid Tumors
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=D8883549-
3CBC-0049-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/6800
Summary Response/Progression
Form for Solid Tumors
Crf Header
Coordinating Group Protocol No.
Coordinating Group Code
Protocol Title
Patient Study ID
Institution/Affiliate
Other Patient ID
Participating Group Code
Patient Initials
Form Administration
Reporting Period Start Date (mm dd yyyy)
Reporting Period End Date (mm dd yyyy)
Date of Last Clinical Assessment (mm dd yyyy)
Response Assessment
Has the patient achieved a response?
Yes
No
Partial Response (PR) First Observed Date (mm
dd yyyy)
Complete Response (CR) First Observed Date
(mm dd yyyy)
Has the patient been diagnosed with a new
1 / 2
progression? (during this reporting period not
previously reported)
Yes
No
Progressive Disease (PD) Observed Date (mm
dd yyyy)
Progressive Disease Documentation (Note:
Record all anatomic sites of progression on the
Follow-Up form for the specific disease being
treated.)
Progressive Disease Defined By New
Lesions (Appearance of one or more
new lesions)
Nontarget Lesions (unequivocal
Progression Of Existing Nontarget
Lesions) (Nontarget Lesions)
Other, Specify (Other)
Target Lesions (at Least A 20% Increase
In The Sum Of Longest Diameters Of
Target Lesions, Taking As Reference The
Smallest Sum Recorded Since The
Treatment Started) (Target Lesions)
Other specify
Date Response Last Documented (mm dd yyyy)
Comments
Comments
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Response - Summary Response/Progression Form for Solid Tumors -
2278235v3.0
Response - Phase II Breast Cancer - Summary
Response/Progression Form for Solid Tumors - 2582834v1.0
Phase II Breast Cancer - Summary Response/Progression
Form for Solid Tumors
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=25794336-
1BEF-04E8-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/6803
Phase II Breast Cancer - Summary
Response/Progression Form for
Solid Tumors
Crf Header
Coordinating Group Protocol No.
Coordinating Group Code
Protocol Title
Patient Study ID
Registering Group Code
Patient Medical Record Number
Other Patient ID
Institution/Affiliate
Registering Institution Code
Physician of Record
Form Administration
Person Completing Form
Date Form Completed
Are data amended (If data are amended, please
circle in red when using paper form.)
Yes
No
Reporting Period Start Date (mm dd yyyy)
Reporting Period End Date (mm dd yyyy)
1 / 2
Date of Last Clinical Assessment (mm dd yyyy)
Response Assessment
Has the patient achieved a response?
Yes
No
Partial Response (PR) First Observed Date (mm
dd yyyy)
Complete Response (CR) First Observed Date
(mm dd yyyy)
Has the patient been diagnosed with a new
progression? (during this reporting period not
previously reported)
Yes
No
Progressive Disease (PD) Observed Date (mm
dd yyyy)
Progressive Disease Documentation (Note:
Record all anatomic sites of progression on the
Follow-Up form for the specific disease being
treated.)
Progressive Disease Defined By New
Lesions (Appearance of one or more
new lesions)
Nontarget Lesions (unequivocal
Progression Of Existing Nontarget
Lesions) (Nontarget Lesions)
Other, Specify (Other)
Target Lesions (at Least A 20% Increase
In The Sum Of Longest Diameters Of
Target Lesions, Taking As Reference The
Smallest Sum Recorded Since The
Treatment Started) (Target Lesions)
Other specify
Date Response Last Documented (mm dd yyyy)
Comments
Comments
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Response - Phase II Breast Cancer - Summary Response/Progression
Form for Solid Tumors - 2582834v1.0
Response - Follow-Up Solid Tumor
Evaluation Form - 2264083v3.0
Follow-Up Solid Tumor Evaluation Form
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=D8887F28-
3F68-039E-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/6812
Follow-Up Solid Tumor Evaluation
Form
Crf Header
Coordinating Group Protocol No.
Coordinating Group Code
Protocol Title
Patient Study ID
Institution/Affiliate
Other Patient ID
Participating Group Code
Patient Initials
Form Administration
Reporting Period Start Date (mm dd yyyy)
Reporting Period End Date (mm dd yyyy)
Date of Last Clinical Assessment (mm dd yyyy)
Target Lesion(s) Follow-up Evaluation
Are there any target lesions?
Yes
No
Lesion Number
Target Lesion Site
Date of Evaluation (mm dd yyyy)
1 / 4
Method of Evaluation (* use code below Methods
of Evaluation)
Bone Scan (Bone scan)
Chest X-ray (Chest X-ray)
Clinical Examination (pe) (Clinical
examination)
Ct Scan (CT Scan)
Cytology (Cytology)
Mri (MRI (NMR))
Other (Other)
Spiral Ct Scan (Spiral CT Scan)
Ultrasound (Ultrasound)
Other specify (If)
Longest Diameter of Lesion(s) (cm)
Sum of Longest Diameters of All Target Lesions
(cm)
Response Status at This Assessment (mark one)
Complete Response (CR)
Incomplete Response Or Stable
Disesase (Incomplete response/SD)
Insufficient Evaluation (Insufficient
evaluation to determine response status)
Progressive Disease (PD)
Nontarget Lesion(s) Follow-up Evaluation
Are there any nontarget lesions?
Yes
No
Lesion Number
Nontarget Lesion Site
Date of Evaluation (mm dd yyyy)
Method of Evaluation (* use code below Methods
of Evaluation)
Bone Scan (Bone scan)
Chest X-ray (Chest X-ray)
Clinical Examination (pe) (Clinical
examination)
Ct Scan (CT Scan)
Cytology (Cytology)
Mri (MRI (NMR))
Other (Other)
Spiral Ct Scan (Spiral CT Scan)
Ultrasound (Ultrasound)
Other specify (If)
2 / 4
Response - Follow-Up Solid Tumor Evaluation Form - 2264083v3.0
Follow-up Status of Lesion (s ?  Follow-up Status
of Lesions)
Complete Response (CR)
Progressive Disease (PD)
Stable Disease Or Unchanged (Stable)
Response Status at This Assessment (mark one)
Complete Response (CR)
Incomplete Response Or Stable
Disesase (Incomplete response/SD)
Insufficient Evaluation (Insufficient
evaluation to determine response status)
Progressive Disease (PD)
New Lesion(s) At Follow-up Evaluation
Is there Symptomatic Deterioration of the
patient's health status requiring discontinuation of
treatment?
Yes
No
Yes specify
Lesion Number
Was the appearance of any new lesions
documented (since the baseline evaluation)
Yes
No
Date of Evaluation (mm dd yyyy)
New Lesion Site
Method of Evaluation (* use code below Methods
of Evaluation)
Bone Scan (Bone scan)
Chest X-ray (Chest X-ray)
Clinical Examination (pe) (Clinical
examination)
Ct Scan (CT Scan)
Cytology (Cytology)
Mri (MRI (NMR))
Other (Other)
Spiral Ct Scan (Spiral CT Scan)
Ultrasound (Ultrasound)
Other specify (If)
Evaluation Summary
Overall Response Status at This Assessment
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(mark one)
Complete Response (CR)
Death Prior To Completion Of Protocol
Criteria (Early death)
Insufficient Evaluation (Insufficient
evaluation to determine response status)
Progressive Disease (PD)
Partial Response (PR)
Stable Disease (SD)
Comments
Comments
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Treatment - Leukemia/Myelodysplastic Syndrome
(MDS) - Treatment Form - 2019361v3.0
Leukemia/Myelodysplastic Syndrome (MDS) - Treatment
Form
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=1A9B0A01-
FA23-1E8E-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/6816
Leukemia/Myelodysplastic Syndrome
(MDS) - Treatment Form
Crf Header
Coordinating Group Protocol No.
Coordinating Group Code
Protocol Title
Patient Study ID
Institution/Affiliate
Other Patient ID
Participating Group Code
Patient Initials
Registration Type
Leukemia/mds: Form Administration
Person Completing Form
Are data amended (If data are amended, please
circle in red when using paper form)
Yes
No
Reporting Period Start Date (mm dd yyyy)
Reporting Period End Date (mm dd yyyy)
Leukemia/mds: Treatment Phase
Information
Treatment Phase (*Note: Indicate number of
1 / 3
Courses or Cycles given this reporting period for
treatment phases that include multiple cycles.)
Consolidation (Consolidation)
Current Phase Of Leukemia Treatment
For Patient Is Crossover (Crossover)
Current Phase Of Leukemia Treatment
For Patient Is Follow-up, Or Patient Is Off
Therapy (Follow-up/Off Therapy)
Induction (Induction)
Current Phase Of Leukemia Treatment
For Patient Is Intensification
(Intensification)
Maintenance (Maintenance)
Other Specify (Other)
Current Phase Of Leukemia Treatment
For Patient Is Post-induction (Post-
Induction)
Current Phase Of Leukemia Treatment
For Patient Is Post-remission (Post-
Remission)
Other specify
Leukemia/mds: Treatment Plan
Did the patient receive any protocol treatment?
Yes
No
Date of First dose for this reporting period (mm
dd yyyy)
Date of Last dose for this reporting period (mm
dd yyyy)
No. of Courses given this reporting period (or
Cycles refer to treatment plan in protocol)
Agent Name (protocol specific)
Initial Dose (of Current Course)
Units (use protocol specified units)
Reason Treatment Ended (If treatment ended this
period, or not given check one)
Adverse Event/side Effects/complications
(Adverse Event/Side
Effects/Complications)
Alternative Therapy (Alternative therapy)
Death On Study (Death on study)
Disease Progression Before Active
Treatment (Disease Progression before
active treatment)
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Form - 2019361v3.0
Disease Progression, Relapse During
Active Treatment (Disease progression,
relapse during active treatment)
Other (Other)
Patient Off-treatment For Other
Complicating Disease (Patient off-
treatment for other complicating disease)
Patient Withdrawal Or Refusal After
Beginning Protocol Therapy (Patient
withdrawal/refusal after beginning
protocol therapy)
Patient Withdrawal Or Refusal Before
Beginning Protocol Therapy (Patient
withdrawal/refusal prior to beginning
protocol therapy)
Treatment Completed Per Protocol
Criteria (Treatment completed per
protocol criteria)
Other specify
Were there any dose modifications or
additions/omissions to protocol treatment? (check
one)
No (No)
Yes, Planned (i.e., The Treatment Was
Changed According To Protocol
Guidelines) (Yes, planned)
Yes, Unplanned (i.e., The Treatment
Change Was Not Part Of Protocol
Guidelines) (Yes, unplanned)
If yes, unplanned, Specify change
Allows Documentation Of Any Additional
Cooments
Comments
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Treatment - Head and Neck Cancers -
Treatment by Cycle Form - 2268199v3.0
Head and Neck Cancers - Treatment by Cycle Form
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=D4971610-
643B-5B05-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/6819
Head and Neck Cancers - Treatment
by Cycle Form
Crf Header
Coordinating Group Protocol No.
Coordinating Group Code
Protocol Title
Patient Study ID
Institution/Affiliate
Other Patient ID
Participating Group Code
Patient Initials
Head & Neck: Patient Assessment
Patient Weight (kg)
Body Surface Area (m^2)
Performance Status (check one)
Fully Active, Able To Carry On All Pre-
disease Performance Without
Restriction. (0)
Restricted In Physically Strenuous
Activity But Ambulatory And Able To
Carry Out Work Of A Light Or Sedentary
Nature, E.g., Light Housework, Office
Work. (1)
Ambulatory And Capable Of All Selfcare
But Unable To Carry Out Any Work
Activities. Up And About More Than 50%
Of Waking Hours. (2)
Capable Of Only Limited Selfcare,
Confined To Bed Or Chair More Than
50% Of Waking Hours. (3)
Completely Disabled. Cannot Carry On
Any Selfcare. Totally Confined To Bed Or
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Chair. (4)
Head & Neck: Treatment Reporting
Interval
Reporting Period Start Date (MM/DD/YYYY)
Reporting Period End Date (MM/DD/YYYY)
Head & Neck: Treatment Cycle
Information - Systemic Therapy
Type of Systemic Therapy (check all that apply)
Chemotherapy (Chemotherapy)
Immunotherapy (Immunotherapy)
Other Specify (Other)
Other specify
Is this Systemic Therapy concurrent with
Radiation Therapy?
No (No)
Unknown (Unknown)
Yes (Yes)
Cycle Start Date (MM/DD/YYYY)
Current Cycle Number
Agent Name (use protocol specified agents and
units)
Total Dose of Agents/Drugs for this Cycle
Units (Some groups may pre-print protocol
agents and units.)
Were there any dose modifications or
additions/omissions to protocol treatment? (check
one)
No (No)
Unknown (Unknown)
Yes, Planned (i.e., The Treatment Was
Changed According To Protocol
Guidelines) (Yes, planned)
Yes, Unplanned (i.e., The Treatment
Change Was Not Part Of Protocol
Guidelines) (Yes, unplanned)
Were there any delays in dose administration?
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No (No)
Unknown (Unknown)
Yes (Yes)
Name of Therapy (If yes to any modification or
delay, being modified)
Reason for Therapy Modification
Head & Neck: Treatment Summary -
Radiation Therapy
Radiation Therapy Start Date (MM/DD/YYYY)
Radiation Therapy End Date (MM/DD/YYYY)
Radiation Therapy Intent (check all that apply)
Definitive (Definitive)
Other (Other)
Palliative (Palliative)
Post-operative (Post-operative)
Pre-operative (Pre-operative)
Other specify
Radiation Therapy Modality (check all that apply)
Brachytherapy (Brachytherapy)
External Beam Radiation (External beam
radiation)
Imrt (intensity Modulated Rt) (IMRT
(Intensity Modulated RT))
Other (Other)
Other specify
Radiation Therapy Site (s protocol specific)
RT Total Dose Planned (Gy)
RT Total Dose Delivered (Gy)
Total Number of Fractions Planned
Total Number of Fractions Delivered
Were there any unscheduled interruptions in
radiation therapy?
No (No)
Unknown (Unknown)
Yes Due To Local-regional Toxicity (Yes,
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due to local-regional toxicity)
Yes Due To Systemic Toxicity (Yes, due
to systemic toxicity)
Yes, For Other Reasons, Specify (Yes,
for other reasons, specify)
RT Interruptions Reason (If other Reason,
specify)
Duration of all unscheduled interruption (If yes,)
Units (specify units)
Days (Days)
Hours (Hours)
Weeks (Weeks)
Comments
Comments
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Leukemia NCT00492856 Treatment - SOUTHWEST ONCOLOGY GROUP
Consolidation #1 And #2 Treatment Summary Form (S0521) - 2415788v1.0
SOUTHWEST ONCOLOGY GROUP Consolidation #1 And
#2 Treatment Summary Form (S0521)
Combination Chemotherapy With or Without Gemtuzumab
Followed By Tretinoin, Mercaptopurine, and Methotrexate
or Observation in Treating Patients With Acute
Promyelocytic Leukemia
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=02DB2B73-
5A1C-5C81-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/6831
SOUTHWEST ONCOLOGY GROUP
Consolidation #1 And #2 Treatment
Summary Form (S0521)
Header
SWOG Patient ID
SWOG Study No.
Registration Step
Cycle completed
First Arsenic Consolidation (First arsenic
consolidation)
Second Arsenic Consolidation (Second
arsenic consolidation)
Patient Initials (L, F M)
Institution/Affiliate
Physician (Participating Group:)
Participating Group Name
American College Of Surgeons
Oncology Group (ACOSOG)
American College Of Radiology
Oncologic Imaging Network (ACRIN)
Aids-associated Malignancies Clinical
Trials Consortium (AMC)
Cancer And Leukemia Group B (CALGB)
Children's Oncology Group (COG)
Eastern Cooperative Oncology Group
(ECOG)
European Organization For Research
And Treatment Of Cancer (EORTC)
Gynecologic Oncology Group (GOG)
International Breast Cancer Study Group
(IBCSG)
North American Brain Tumor Consortium
(NABTC)
Nabtt Brain Tumor Consortium (NABTT)
North Central Cancer Treatment Group
(NCCTG)
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National Cancer Institute Of Canada
Clinical Trials Group (NCIC)
National Surgical Adjuvant Breast And
Bowel Project (NSABP)
Radiation Therapy Oncology Group
(RTOG)
Southwest Oncology Group (SWOG)
Participating Group Study No.
Participating Group Patient ID
Reporting Period
Reporting Period Start Date
Reporting Period End Date
Patient And Disease Description
Date of Last Contact or Death
Vital Status
Alive (Alive)
Dead (Dead)
Physical
Weight
BSA (Note: Enter values used to calculate
doses.)
Treatment: Atra
Did the patient receive arsenic trioxide during this
reporting period?
Yes
No
Total dose of arsenic trioxide in this reporting
period? (If yes, - mg)
Start date of arsenic trioxide during this reporting
period?
End date of arsenic trioxide during this reporting
period?
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Consolidation #1 And #2 Treatment Summary Form (S0521) - 2415788v1.0
Treatment: Growth Factors
If yes,
Granulocyte-macrophage Colony-
stimulating Factor (G-CSF)
Other (Other)
Recombinant Granulocyte-macrophage
Colony-stimulating Factor (rhGM_CSF)
Other, specify
Total dose of growth factor in this reporting
period? (mcg)
Start date of growth factor during this reporting
period?
End date of growth factor during this reporting
period?
Was growth factor permanently discontined
during this reporting period?
Yes
No
Was growth factor permanently discontined
during this reporting period?
Yes
No
Date of discontinuation (If yes,)
Treatment: Other Therapy
Did the patient receive other therapy during this
reporting period? (If yes, give start and end dates
and describe the other therapy in the Comments
section.)
Yes
No
Specify agent
Dose Modifications
Were there any dose modifications or
additions/omissions to protocol treatment?
No (No)
Yes, Planned (i.e., The Treatment Was
Changed According To Protocol
Guidelines) (Yes, planned)
Yes, Unplanned (i.e., The Treatment
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Change Was Not Part Of Protocol
Guidelines) (Yes, unplanned)
Plans For Consildation #3 And #4
Is this patient expected to receive consolidation
#3 and #4? (see NOTE in protocol section 7.3)
Yes
No
Ejection fraction
Echocardiogram (Echocardiogram)
Radionuclide Ventriculogram Scan
(Multiple Gated Acquisition (MUGA))
LVEF
Collection Date
Other evidence of inadequate LV function
Other reason, specify
Comments
Comments
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Leukemia NCT00492856 Treatment - SOUTHWEST ONCOLOGY GROUP
Consolidation #3 and #4 Treatment Summary Form (S0521) - 2416094v1.0
SOUTHWEST ONCOLOGY GROUP Consolidation #3 and
#4 Treatment Summary Form (S0521)
Combination Chemotherapy With or Without Gemtuzumab
Followed By Tretinoin, Mercaptopurine, and Methotrexate
or Observation in Treating Patients With Acute
Promyelocytic Leukemia
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=02DDF771-
2EEC-49BA-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/6832
SOUTHWEST ONCOLOGY GROUP
Consolidation #3 and #4 Treatment
Summary Form (S0521)
Header
SWOG Patient ID
SWOG Study No.
Registration Step
Cycle completed
First Atra/daunorubicin Consolidation
(First ATRA/daunorubicin consolidation)
Second Atra/daunorubicin Consolidation
(Second ATRA/daunorubicin
consolidation)
Patient Initials (L, F M)
Institution/Affiliate
Physician (Participating Group:)
Participating Group Name
American College Of Surgeons
Oncology Group (ACOSOG)
American College Of Radiology
Oncologic Imaging Network (ACRIN)
Aids-associated Malignancies Clinical
Trials Consortium (AMC)
Cancer And Leukemia Group B (CALGB)
Children's Oncology Group (COG)
Eastern Cooperative Oncology Group
(ECOG)
European Organization For Research
And Treatment Of Cancer (EORTC)
Gynecologic Oncology Group (GOG)
International Breast Cancer Study Group
(IBCSG)
North American Brain Tumor Consortium
(NABTC)
Nabtt Brain Tumor Consortium (NABTT)
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North Central Cancer Treatment Group
(NCCTG)
National Cancer Institute Of Canada
Clinical Trials Group (NCIC)
National Surgical Adjuvant Breast And
Bowel Project (NSABP)
Radiation Therapy Oncology Group
(RTOG)
Southwest Oncology Group (SWOG)
Participating Group Study No.
Participating Group Patient ID (Instructions: All
dates are MONTH, DAY, YEAR. Explain any
blank fields or blank dates in the Comments
section. Place an X in appropriate boxes. Circle
AMENDED items in red and write AMENDED
across the top of the form.)
Reporting Period
Reporting Period Start Date
Reporting Period End Date
Patient And Disease Description
Date of Last Contact or Death
Vital Status
Alive (Alive)
Dead (Dead)
Physical
Weight
BSA
Treatment: Atra
Did the patient receive ATRA during this reporting
period?
Yes
No
Total dose of ATRA in this reporting period? (If
yes, - mg)
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Consolidation #3 and #4 Treatment Summary Form (S0521) - 2416094v1.0
Start date of ATRA during this reporting period?
End date of ATRA during this reporting period?
Treatment: Cytosine Arabinoside (ara-c)
Did the patient receive daunorubicin during this
reporting period?
Yes
No
Total dose of daunorubicin in this reporting
period? (If yes, - mg)
Start date of daunorubicin during this reporting
period?
End date of daunorubicin during this reporting
period?
Treatment: Growth Factors
If yes,
Granulocyte-macrophage Colony-
stimulating Factor (G-CSF)
Other (Other)
Recombinant Granulocyte-macrophage
Colony-stimulating Factor (rhGM_CSF)
Other, specify
Total dose of growth factor in this reporting
period? (mcg)
Start date of growth factor during this reporting
period?
End date of growth factor during this reporting
period?
Was growth factor permanently discontined
during this reporting period?
Yes
No
Was growth factor permanently discontined
during this reporting period?
Yes
No
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Consolidation #3 and #4 Treatment Summary Form (S0521) - 2416094v1.0
Date of discontinuation (If yes,)
Treatment: Other Therapy
Did the patient receive other therapy during this
reporting period? (If yes, give start and end dates
and describe the other therapy in the Comments
section.)
Yes
No
Specify agent
Dose Modifications
Were there any dose modifications or
additions/omissions to protocol treatment?
No (No)
Yes, Planned (i.e., The Treatment Was
Changed According To Protocol
Guidelines) (Yes, planned)
Yes, Unplanned (i.e., The Treatment
Change Was Not Part Of Protocol
Guidelines) (Yes, unplanned)
Comments
Comments
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Prostate Cancer NCT00079001 Follow-Up -
CALGB 90202: Follow-Up Form - 2427399v1.0
CALGB 90202: Follow-Up Form
Zoledronate in Preventing Skeletal (Bone)-Related Events
in Patients Who Are Receiving Androgen Deprivation
Therapy For Prostate Cancer and Bone Metastases
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=05291069-
4AD0-383B-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/6843
CALGB 90202: Follow-Up Form
Ccrr Module For Calgb 90202: Skeletal
Survey Form
CALGB Form
CALGB Study No.
CALGB Patient ID
Reporting Period Start Date
Reporting Period End Date
Are data amended
Yes
No
Patient Initials
Patient Medical Record No.
Institution/Affiliate
Participating Group
Participating Group Protocol Number
Participating Group Patient ID
Vital Status
Patient Vital Status
Alive (Alive)
Dead (Dead)
Lost To Follow-up (Lost to follow-up)
Primary Cause of Death
Due To Other Cause (Due to other
cause)
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Due To Protocol Treatment (Due to
protocol treatment)
Due To This Disease (Due to this
disease)
Unknown (Unknown)
Describe cause of death
Date of Last Contact or Death
Treatment Status
Treatment Status (Mark one with an X)
Double-blinded (Double-blinded)
Follow-up, Off Protocol Therapy (Follow-
up, off protocol therapy)
Open Label (Open label)
Other (Other)
Other, specify
Did patient receive androgen deprivation
therapy? (during this report period)
Yes
No
Type of Androgen Deprivation (If yes, - Mark one
with an X)
Continuous (Continuous)
Intermittent (Intermittent)
Start date of Androgen Deprivation (if not
previously reported)
End date of Androgen Deprivation (if not
previously reported)
Current Supplements
Calcium
Yes
No
Vitamin D
Yes
No
Total Daily Dose of Agent (or Drug) (If yes,)
Average number of pills per week
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Notice Of Skeletal Related Event
Did patient experience any skeletal related
event? (during this reporting period)
Yes
No
Type of skeletal related event (Mark all that apply
with an X)
Clinical Fracture (Clinical fracture)
Death Due To Prostate Cancer (Death
due to prostate cancer)
Radiation To Bone (radiation to bone)
Spinal Cord Compression (spinal cord
compression)
Surgery To Bone (surgery to bone)
Date of event
Clinical fracture (Mark all that apply with an X)
Clinical Vertebral Fractures (Clinical
vertebral fractures)
Hip Fractures (Hip fractures)
Nonvertebral Fractures (Nonvertebral
fractures)
Wrist Fractures (Wrist fractures)
Clinical vertebral fractures (Select one:)
Pathological (Pathological)
Traumatic (Traumatic)
Nonvertebral fractures (Select one:)
Pathological (Pathological)
Traumatic (Traumatic)
Hip fractures (Select one:)
Pathological (Pathological)
Traumatic (Traumatic)
Wrist fractures (Select one:)
Pathological (Pathological)
Traumatic (Traumatic)
Disease Follow-up Status
Has the patient had a documented clinical
assessment for this cancer? (since submission of
the previous follow-up form)
Yes
No
Date of Last Clinical Assessment
Notice Of Progression
Has the patient developed new bone metastases,
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a first biochemical progression, or developed an
indication for radiation therapy to the bone that
has not been previously reported? (NOTE: Three
consecutive PSA rises must be documented on
Form C-714 before switch to Open Label is
initiated.)
Yes
No
Date of First Biochemical Progression (PSA)
PSA Value at Progression
Date of Bone Progression
Notice Of New Primary
Has a new primary cancer or MDS been
diagnosed that has not been previously reported?
Yes
No
Date of diagnosis
Site of New Primary
New Primary, Histologic type
Non-protocol Therapy
Has the patient received any non-protocol cancer
therapy during this reporting period?
Yes
No
Non-Protocol Therapy Type (If yes,)
Biphosphonate (Bisphosphonate)
Chemotherapy (Chemotherapy)
Other Non-protocol Therapy (Other non-
protocol therapy)
Non-protocol bisphosphonate therapy, specify
Specify agents, dose, schedule
Other non-protocol therapy, specify
Non-protocol Therapy Start Date
Non-protocol Therapy Start Date
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Non-protocol Therapy Start Date
Non-protocol Therapy End Date
Non-protocol Therapy End Date
Non-protocol Therapy End Date
Footer
Completed by
Date Form Originally Completed
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Leukemia NCT01041703 Treatment - E2906
Engraftment Form - Arm G - 2951586v1.0
E2906 Engraftment Form - Arm G
Clofarabine or Daunorubicin Hydrochloride and Cytarabine
Followed By Decitabine or Observation in Treating Older
Patients With Newly Diagnosed Acute Myeloid Leukemia
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=7583518B-
5574-8F0A-E040-BB89AD437B26
All rights reserved. Please visit https://medical-data-
models.org/forms/6861
E2906 Engraftment Form - Arm G
Header
DCI Name
Registration Step (Place ID Label Here)
Patient Initials (Last, First)
ECOG Protocol Number
ECOG Protocol Number
ECOG Patient ID
ECOG Patient ID
Participating Group Protocol Number
Participating Group Patient ID
Institution/Affiliate
On Treatment
On Treatment Reporting Period
100 Days Post Transplant (100 Days
Post Transplant)
30 Days Post Transplant (30 Days Post
Transplant)
Unnamed2
Please mark an 'X' if data have been amended.
(Please circle amended items in red)
Date data amended (s M D Y)
Vital Status
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Patient's Vital Status
Alive (Alive)
Dead (Dead)
Date of Last Contact or Death (M D Y)
Primary Cause of Death (if applicable)
Due To Other Cause (Due to other
cause)
Due To Protocol Treatment (Due to
protocol treatment)
Due To This Disease (Due to this
disease)
Unknown (Unknown)
Describe cause of death
Engraftment
Did patient engraft neutrophils (ANC >= 500 x 2
consecutive days)
Yes
No
Neutrophil Engraftment Date (M D Y Date of first
of 2 days)
Did patient reconstitute platelets where the
patient did not receive platelet transfusion for the
next 7 days (PLT >= 20K x 2 consecutive days)
Yes
No
Platelet Engraftment Date (M D Y Date of first of
2 days)
Did patient achieve PLT >= 100K without
transfusion
Yes
No
Date Achieved (M D Y)
Donor Chimerism percentage (%)
Laboratory Procedure (eg. FISH, STR PCR, etc)
Date Obtained (M D Y)
Comments
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Investigator Signature
Investigator Signature Date (MM DD YYYY)
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Leukemia NCT01041703 Treatment - E2906
Transfusion Form - Arm G - 2951660v1.0
E2906 Transfusion Form - Arm G
Clofarabine or Daunorubicin Hydrochloride and Cytarabine
Followed By Decitabine or Observation in Treating Older
Patients With Newly Diagnosed Acute Myeloid Leukemia
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=758373C9-
BDBE-F79E-E040-BB89AD433D62
All rights reserved. Please visit https://medical-data-
models.org/forms/6862
E2906 Transfusion Form - Arm G
Header
ECOG Patient ID
ECOG Patient ID
DCI Name
Registration Step (Place ID Label Here)
Patient Initials (Last, First)
ECOG Protocol Number
ECOG Protocol Number
Participating Group Protocol Number
Participating Group Patient ID
Institution/Affiliate
On Treatment
On Treatment Reporting Period
100 Days Post Transplant (100 Days
Post Transplant)
30 Days Post Transplant (30 Days Post
Transplant)
Unnamed2
Please mark an 'X' if data have been amended.
(Please circle amended items in red)
Date data amended (s M D Y)
Vital Status
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Patient's Vital Status
Alive (Alive)
Dead (Dead)
Date of Last Contact or Death (M D Y)
Primary Cause of Death (if applicable)
Due To Other Cause (Due to other
cause)
Due To Protocol Treatment (Due to
protocol treatment)
Due To This Disease (Due to this
disease)
Unknown (Unknown)
Describe cause of death
Transfusions
Number of post-transplant platelet transfusions
(to date)
Date of most recent platelet transfusion (M D Y)
Number of post-transplant RBC transfusions (to
date)
Date of most recent RBC transfusion (M DY)
Is patient transfusion-dependent
No (No)
Unknown (Unknown)
Yes (Yes)
Comments
Investigator Signature
Investigator Signature Date (MM DD YYYY)
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Follow-Up - Melanoma-Follow-up Form -
2020198v2.31
Melanoma-Follow-up Form
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=99CD59C5-
A99C-3FA4-E034-080020C9C0E0
All rights reserved. Please visit https://medical-data-
models.org/forms/6864
Melanoma-Follow-up Form
Crf Header
Coordinating Group Protocol Number
Coordinating Group Code
Protocol Title
Patient Study ID, Coordinating Group
Patient Study ID, Participating Group
Participating Group Code
Institution Name
Affiliate Name
Patient Name, Last
Patient Name, First
Patient Name, Middle
Melanoma: Vital Status
Patient's Vital Status
Alive (Alive)
Dead (Dead)
Death Reason
Due To Other Cause, Specify (Due to
other cause, specify)
Due To Protocol Treatment (Due to
protocol treatment)
Due To This Disease (Due to this
disease)
Unknown (Unknown)
Death Reason, Specify
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Death Date/Last Contact Date
Melanoma: Disease Follow-up Status
Cancer Follow-up Status Ind
No (NO)
Unknown (UNKNOWN)
Yes (YES)
Cancer Follow-up Status Date
Melanoma: Notice Of Progression
Progression Ind
No (NO)
Unknown (UNKNOWN)
Yes (YES)
Progression Date
Progression Site
Bone (Bone)
Brain (Brain)
Distant Lymph Nodes (Distant lymph
nodes)
Distant Skin/subcutaneous Tissue,
Including Soft Tissue Metastases
(Distant skin/subcutaneous tissue)
Intransit Recurrence (everything In
Between The Local And Regional
Recurrence) (Intransit recurrence)
Liver (Liver)
Local Recurrence (within 2 Cm Of The
Primary) (Local recurrence)
Any Local-regional Recurrence (use This
Value In Place Of Local Recurrence,
Regional Recurrence, And Intransit
Recurrence) (Local-regional recurrence)
Lung (Lung)
Other Cns (Other CNS)
Other Non-visceral, Specify (Other non-
visceral, specify)
Other Visceral, Specify (Other visceral,
specify)
Regional Recurrence (the Regional
Lymph Nodes Or In The Regional Nodal
Basin) (Regional recurrence)
Progression Site, Other Visceral
Progression Site, Other Non-visceral
RT Recurrence Site Ind
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Yes
No
Melanoma: Non-protocol Therapy
Non-Protocol Therapy Ind
No (NO)
Unknown (UNKNOWN)
Yes (YES)
Other Therapy Type
Non-Protocol Therapy Date, First
Melanoma: Notice Of New Primary
New Primary Cancer Ind
No (NO)
Unknown (UNKNOWN)
Yes (YES)
New Primary Cancer Date
New Primary Site
Melanoma: Long-term Toxicity
Late Adverse Event Ind
No (NO)
Unknown (UNKNOWN)
Yes (YES)
Late Adverse Event Term
Use Rtog/eortc Grading System ( See
Ctc Version 2.0.
Http://ctep.info.nih.gov/ctc3/ctc.htm).
(Use RTOG/EORTC grading system (
See CTC version 2.0.
http://ctep.info.nih.gov/CTC3/ctc.htm).)
Late Adverse Event Grade
Allows Documentation Of Any Additional
Cooments
Comments
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Follow-Up - Superficial Bladder Cancer -
Follow-Up Form - 2019332v2.31
Superficial Bladder Cancer - Follow-Up Form
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=99CD59C5-
A95F-3FA4-E034-080020C9C0E0
All rights reserved. Please visit https://medical-data-
models.org/forms/6866
Superficial Bladder Cancer - Follow-
Up Form
Crf Header
Coordinating Group Protocol Number
Coordinating Group Code
Protocol Title
Patient Study ID, Coordinating Group
Patient Study ID, Participating Group
Participating Group Code
Institution Name
Affiliate Name
Patient Name, Last
Patient Name, First
Patient Name, Middle
Bladder: Form Administration
Person Completing Form, Last Name
Person Completing Form, First Name
Amended Data Ind
No (NO)
Unknown (UNKNOWN)
Yes (YES)
Bladder: Vital Status
Patient's Vital Status
Alive (Alive)
1 / 5
Dead (Dead)
Death Reason
Due To Other Cause (Due to other
cause)
Due To Protocol Treatment (Due to
protocol treatment)
Due To This Disease (Due to this
disease)
Unknown (Unknown)
Death Reason, Specify
Death Date/Last Contact Date
Bladder: Disease Follow-up Status
Cancer Follow-up Status Ind
No (NO)
Unknown (UNKNOWN)
Yes (YES)
Cancer Follow-up Status Date
Bladder: Superficial Disease Follow-up
Assessment
Cytology Date
Cytology Result
Inflammatory Changes With Or Without
Dyscariosis (Inflammatory changes with
or without dyscariosis)
Moderate Dysplasia Or Papillary
Clusters (suspect) (Moderate dysplasia
or papillary clusters (suspect))
Negative (Negative)
Normal Tissue (Normal exfoliated cells)
Not Done (Not done)
Numerous Atypical And Malignant Cells
(Numerous atypical and malignant cells)
Other (Other, specify)
Positive (Positive)
Severe Dysplasia (Severe dysplasia)
Cytology Result, Other
Cystoscopy Date
Cystoscopy, Lesions Identified Ind
No (No)
Unknown (unknown)
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Yes (Yes)
Cystoscopy, Papillary Tumors Present Ind
No (No)
Unknown (unknown)
Yes (Yes)
T Stage, Papillary Tumor
T0 (T0)
T1 (T1)
T2 (T2)
T3 (T3)
T4 (T4)
Ta (Ta)
Tx (Tx)
Histologic Grade
Tumor Grade Cannot Be Assessed
(grade cannot be assessed (GX))
Moderately Differentiated (moderately
differentiated (G2))
Poorly Differentiated (poorly
differentiated (G3))
Well Differentiated (well differentiated
(G1))
CIS Ind
No (No)
Unknown (unknown)
Yes (Yes)
Progression, Superficial Bladder, Treatment
Applied
Intravesical Chemotherapy Was Used To
Treat Superficial Bladder Cancer Prior To
Progression Or Diagnosis Of More
Advanced Disease (intravesical
chemotherapy)
Intravesical Immunotherapy Was Used
To Treat Superficial Bladder Cancer Prior
To Progression Or Diagnosis Of More
Advanced Disease (intravesical
immunotherapy)
No Treatment Was Given Prior To
Progression Or Diagnosis Of More
Advanced Disease (none)
Another Treatment Was Used To Treat
Superficial Bladder Cancer Prior To
Progression Or Diagnosis Of More
Advanced Disease (other, specify)
Cystectomy Was Used To Treat
Superficial Bladder Cancer Prior To
Progression Or Diagnosis Of More
Advanced Disease (surgery-cystectomy)
Other Surgery Was Used To Treat
Superficial Bladder Cancer Prior To
Progression Or Diagnosis Of More
Advanced Disease (surgery-other,
specify)
Progression, Superficial Bladder, Other Surgery
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Progression, Superficial Bladder, Other Treatment
Bladder: Notice Of Progression
Progression Ind, Superficial Bladder
No (No)
Unknown (unknown)
Yes (Yes)
Progression Date, First Local
Progression Site, First Local
Local Progression To The Abdominal
Wall (abdominal wall)
Progression To Another Site, Specify
Site (other, specify)
Local Progression To The Pelvic Wall
(pelvic wall)
Local Spread To Peritoneal Tissue
(peritoneum)
Local Spread To The Prostate (prostate)
Spread Of Cancer To Skin Or
Subcutaneous Tissue Near To The
Bladder (skin)
Local Spread To The Ureter (ureter)
Local Spread To The Urethra (urethra)
Local Spread To The Uterus (uterus)
Local Spread To The Vagina (vagina)
Progression Site, First Local, Other
Progression, T Category Increase
T2 (T2)
T3 (T3)
T4 (T4)
T Stage Of Tumor Cannot Be Assessed
(Tx)
Progression Ind, Distant Metastatic
No (No)
Unknown (unknown)
Yes (Yes)
Progression Date, First Distant
Progression Site, First Distant
Bone (bone)
Central Nervous System Or Brain
(central nervous system/brain)
Distant Lymph Nodes (distant nodes)
Liver (liver)
Lung (lung)
Other, Specify (other)
Peritoneum (peritoneum)
Pleura (pleura)
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Skin (skin)
Lymph Nodes, Distant Location
Progression Site, Other
Bladder: Notice Of New Primary
New Primary Cancer Ind
No (NO)
Unknown (UNKNOWN)
Yes (YES)
New Primary Cancer Date
New Primary Site
Bladder: Long-term Toxicity
Late Adverse Event Ind
No (NO)
Unknown (UNKNOWN)
Yes (YES)
Late Adverse Event Term
Use Rtog/eortc Grading System (see Ctc
Version 2.0.
Http://ctep.info.nih.gov/ctc3/ctc.htm).
(Use RTOG/EORTC grading system
(See CTC version 2.0.
http://ctep.info.nih.gov/CTC3/ctc.htm).)
Late Adverse Event Grade
Late Adverse Event Onset Date
Allows Documentation Of Any Additional
Cooments
Comments
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Follow-Up - Upper Gastrointestinal Cancers
- Follow Up Form - 2020208v2.31
Upper Gastrointestinal Cancers - Follow Up Form
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=99CD59C5-
A9B0-3FA4-E034-080020C9C0E0
All rights reserved. Please visit https://medical-data-
models.org/forms/6868
Upper Gastrointestinal Cancers -
Follow Up Form
Crf Header
Cytogenetics Ind
Coordinating Group Protocol Number
Coordinating Group Code
Protocol Title
Patient Study ID, Coordinating Group
Patient Study ID, Participating Group
Participating Group Code
Http://ctep.info.nih.gov.
(http://ctep.info.nih.gov.)
Institution Name
Affiliate Name
Patient Name, Last
Patient Name, First
Patient Name, Middle
Gi: Vital Status
Patient's Vital Status
Alive (Alive)
Dead (Dead)
Death Reason
Due To Other Cause, Specify (Due to
other cause, specify)
Due To Protocol Treatment (Due to
protocol treatment)
1 / 3
Due To This Disease (Due to this
disease)
Unknown (Unknown)
Death Date/Last Contact Date
Gi: Disease Follow-up Status
Cancer Follow-up Status Ind
No (NO)
Unknown (UNKNOWN)
Yes (YES)
Cancer Follow-up Status Date
Gi: Notice Of Progression
Progression Ind
No (NO)
Unknown (UNKNOWN)
Yes (YES)
Progression Date
Progression Site
Bone (Bone)
Cns/brain (CNS/Brain)
Distant Lymph Nodes (Distant lymph
nodes)
Liver (Liver)
Lung (Lung)
Other, Specify (Other, specify)
Regional Lymph Nodes (Regional lymph
nodes)
Progression Site, Other
Gi: Notice Of New Primary
New Primary Cancer Ind
No (NO)
Unknown (UNKNOWN)
Yes (YES)
New Primary Cancer Date
New Primary Site
Allows Documentation Of Any Additional
Cooments
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Comments
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Leukemia NCT01041703 Quality of Life - E2906 Quality
of Life Assessment Form - FACT - 2952035v1.0
E2906 Quality of Life Assessment Form - FACT
Clofarabine or Daunorubicin Hydrochloride and Cytarabine
Followed By Decitabine or Observation in Treating Older
Patients With Newly Diagnosed Acute Myeloid Leukemia
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=7586A704-
3004-A522-E040-BB89AD4359F8
All rights reserved. Please visit https://medical-data-
models.org/forms/6869
E2906 Quality of Life Assessment
Form - FACT
Header
DCI Name
Registration Step (Place ID Label Here)
Patient Initials (Last, First)
ECOG Protocol Number
ECOG Protocol Number
ECOG Patient ID
ECOG Patient ID
Participating Group Protocol Number
Participating Group Patient ID
Institution/Affiliate
On Treatment
On Treatment Report Period (Choose one)
100 Days Post Transplant (100 Days
Post Transplant)
At Transplant (At Transplant)
Baseline Step 1 (Baseline Step 1)
Cycle 1 - Consolidation (Cycle 1 -
Consolidation)
Cycle 1 - Induction (Cycle 1 - Induction)
Cycle 2 - Consolidation (Cycle 2 -
Consolidation)
Cycle 2 - Induction (Cycle 2 - Induction)
Header
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Date of Assessment
Physical Well-being
I have a lack of energy
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have nausea
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
Because of my physical condition, I have trouble
meeting the needs of my family
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have pain
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am bothered by side effects of treatment
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I feel ill
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am forced to spend time in bed
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
Functional Well-being
I am able to work (include work at home)
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2 (A little bit)
1 (Not at all)
4 (Quite a bit)
3 (Somewhat)
5 (Very much)
My work is fulfilling (include work at home)
2 (A little bit)
1 (Not at all)
4 (Quite a bit)
3 (Somewhat)
5 (Very much)
I am able to enjoy life
2 (A little bit)
1 (Not at all)
4 (Quite a bit)
3 (Somewhat)
5 (Very much)
I have accepted my illness
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am sleeping well
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am enjoying the things I usually do for fun
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am content with the quality of my life right now
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
Social/family Well-being
I feel close to my friends
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I get emotional support from my family
A Little Bit (A little bit)
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Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I get support from my friends
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
My family has accepted my illness
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am satisfied with family communication about
my illness
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I feel close to my partner (or the person who is
my main support)
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am satisfied with my sex life
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
Emotional Well-being
I am satisfied with how I am coping with my
illness
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am losing hope in the fight against my illness
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
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I feel nervous
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I worry about dying
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I worry that my condition will get worse
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I feel isolated from others because of my illness
or treatment
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
Additional Concerns
I am bothered by fevers (episodes of high body
temperature)
2 (A little bit)
1 (Not at all)
4 (Quite a bit)
3 (Somewhat)
5 (Very much)
I have certain parts of my body where I
experience pain
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am bothered by the chills
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have night sweats
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
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Somewhat (Somewhat)
Very Much (Very much)
I am bothered by lumps or swelling in certain
parts of my body (e.g., neck, armpits, or groin)
2 (A little bit)
1 (Not at all)
4 (Quite a bit)
3 (Somewhat)
5 (Very much)
I bleed easily
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I bruise easily
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I feel fatigued
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am losing weight
2 (A little bit)
1 (Not at all)
4 (Quite a bit)
3 (Somewhat)
5 (Very much)
I have a good appetite
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am able to do my usual activities
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I worry about getting infections
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
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I feel uncertain about my future health
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I worry that I might get new symptoms of my
illness
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have emotional ups and downs
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I feel isolated from others because of my illness
or treatment
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
Additional Concerns
I feel weak all over
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I feel listless ("washed out")
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I feel tired
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have trouble starting things because I am tired
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
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I have trouble finishing things because I am tired
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have energy
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I feel fatigued
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I need to sleep during the day
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am too tired to eat
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am able to do my usual activities
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I need help doing my usual activities
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am frustrated by being too tired to do the things
I want to do
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have to limit my social activity because I am
tired
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A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
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Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getForm
Details&formIdSeq=99CD59C5-A982-3FA4-E034-080020C9C0E0
Ovarian Cancer - Pathology Form
All rights reserved. Please visit https://medical-data-
models.org/forms/6870
Ovarian Cancer - Pathology Form
Crf Header
Coordinating Group Protocol Number
Coordinating Group Code
Protocol Title
Patient Study ID, Coordinating Group
Patient Study ID, Participating Group
Participating Group Code
Institution Name
Affiliate Name
Patient Name, Last
Patient Name, First
Patient Name, Middle
Ovarian Pathology: Form Administration
Person Completing Form, Last Name
Person Completing Form, First Name
Pathologist Name, Reviewing
Amended Data Ind
No (NO)
Unknown (UNKNOWN)
Yes (YES)
Ovarian Pathology: Disease Assessment
Primary Site
Cervix (Cervix)
Endometrium (Endometrium)
Fallopian Tube (Fallopian tube)
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Omentum (Omentum)
Other, Specify (Other, specify)
Ovary (Ovary)
Peritoneum (Peritoneal)
Uterine Sarcoma (Uterine Sarcoma)
Uterus (Uterus)
Vagina (Vagina)
Primary Site, Other
Primary Tumor Laterality
Bilateral (Bilateral)
Both (Both)
Left (Left)
Not A Paired Site (Not a Paired site)
Right (Right)
Unilateral, Side Not Specified (Unilateral,
side not specified)
Unknown (Unknown)
Assessment Type
Biopsy (Biopsy)
Biopsy, Not Otherwise Specified (Biopsy,
other)
Bone Scan (Bone scan)
Chest X-ray (Chest X-Ray)
Clinical Examination (Clinical
examination)
Ct Scan (CT Scan)
Cytology (Cytology)
Histology (Histology)
Laparoscopy (Laparoscopy)
Laparotomy (Laparotomy)
Mri (MRI (NMR))
Not Applicable (Not applicable)
Not Evaluated (Not evaluated)
Other (Other)
Other, Specify (Other, specify)
Pathologic (Pathologic)
Physical Exam (Physical exam)
Radiograph (Radiograph)
Spiral Ct Scan (Spiral CT scan)
Tumor Markers (Tumor Markers)
Ultrasound (Ultrasound)
Assessment Type, Cytology Site
Assessment Type, Specify
Assessment Type, Diagnostic
Biopsy, Other Site (Biopsy, other site)
Cytology, Effusion Evaluation, Specify
Site (Cytology, effusion evaluation)
Fine Needle Aspiration (Fine needle
aspiration)
Laparoscopy (Laparoscopy)
Laparotomy (Laparotomy)
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Other, Specify (Other)
Ultrasound Guided Biopsy Or Fine
Needle Aspiration (Ultrasound guided
biopsy/Fine needle aspiration)
Assessment Type, Diagnostic Cytology Site
Assessment Type, Other Diagnostic
Primary Surgery Type
Bilateral Salpingo-oophorectomy
(bilateral salpingo-oophorectomy)
Cervical Conization (cervical conization)
Omentectal Biopsy (Omentectal biopsy)
Omentectomy (omentectomy)
Other, Specify (other, specify)
Para-aortic Node Sampling/dissection
(para-aortic node sampling/dissection)
Partial Hysterectomy (partial
hysterectomy)
Pelvic Lymphadenectomy (pelvic
lymphadenectomy)
Pelvic Node Sampling/dissection (pelvic
node sampling/dissection)
Peritoneal Sampling (Peritoneal
sampling)
Radical Hysterectomy (radical
hysterectomy)
Radical Trachelectomy (radical
trachelectomy)
Total Hysterectomy (total hysterectomy)
Unilateral Salpingo-oophorectomy
(unilateral salpingo-oophorectomy)
Primary Surgery Other Type
Peritoneal Sample Count
Peritoneal Sample Site
Bladder Peritoneum (Bladder
peritoneum)
Cul-de-sac (Cul-de-sac)
Diaphragm (Diaphragm)
Other, Specify (Other, specify)
Paracolic Gutter Left (Paracolic gutter
left)
Paracolic Gutter Right (Paracolic gutter
right)
Pelvic Wall Left (Pelvic wall left)
Pelvic Wall Right (Pelvic wall right)
Peritoneal Sample Other Site
Specimen Site
Bladder Peritoneum (Bladder
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peritoneum)
Bowel Peritoneum/serosa (Bowel
peritoneum/serosa)
Cervix (Cervix)
Corpus (Corpus)
Cul-de-sac (Cul-de-sac)
Diaphragm (Diaphragm)
Endometrium (Endometrium)
Fallopian Tube (Fallopian tube)
Lymph Node(s) (Lymph node(s))
Metastatic Site (Metastatic site)
Omentum (Omentum)
Other (Other)
Ovary (Ovary)
Paracolic Gutter Left (Paracolic gutter
left)
Paracolic Gutter Right (Paracolic gutter
right)
Pelvic Wall Left (Pelvic wall left)
Pelvic Wall Right (Pelvic wall right)
Peritoneum/uterine Serosa
(Peritoneum/uterine serosa)
Vagina (Vagina)
Specimen Site, Lymph Node
Specimen Site, Metastatic
Specimen Site, Other
Lymph Nodes Type
Inguinal (inguinal)
Other, Specify (other, specify)
Para-aortic (para-aortic)
Pelvic (pelvic)
Scalene (scalene)
Lymph Nodes Other Type
Tumor Nodule Ind, 2 cm
No (No)
Unknown (Unknown)
Yes (Yes)
Tumor Nodule Ind, 1 cm
No (No)
Unknown (Unknown)
Yes (Yes)
Histologic Components, Mixed Epithelial
Histologic Type
Adenocarcinoma With Squamous
Differentiation (Adenocarcinoma with
Squamous Differentiation)
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Adenocarcinoma, Unspecified
(Adenocarcinoma, unspecified)
Adenofibroma (Adenofibroma)
Adenosarcoma (Adenosarcoma)
Adenosquamous (Adenosquamous)
Brenner Tumor (benign) (Brenner tumor
(benign))
Brenner Tumor (malignant) (Brenner
tumor (malignant))
Brenner Tumor Of Low Malignant
Potential (Brenner tumor of LMP)
Cancer With Dermoid Cyst, Specify
Types (Cancer with dermoid cyst)
Carcinosarcoma/mesodermal (mullerian)
Mixed Tumor
(Carcinosarcoma/Mesodermal
(Mullerian) mixed tumor)
Choriocarcinoma (Choriocarcinoma)
Clear Cell Carcinoma (Clear cell
carcinoma)
Clear Cell Cystadenofibroma (benign)
(Clear cell cystadenofibroma (benign))
Clear Cell Cystadenoma (benign) (Clear
cell cystadenoma (benign))
Clear Cell Tumor Of Low Malignant
Potential (Clear cell tumor of LMP)
Dysgerminoma (Dysgerminoma)
Embryonal Carcinoma (Embryonal
carcinoma)
Endodermal Sinus Tumor (yolk Sac
Tumor) (Endodermal sinus tumor)
Endometrial Stromal Sarcoma
(Endometrial stromal sarcoma)
Endometrioid Adenocarcinoma
(Endometrioid adenocarcinoma)
Endometrioid Cystadenofibroma (benign)
(Endometrioid cystadenofibroma
(benign))
Endometrioid Cystadenoma (benign)
(Endometrioid cystadenoma (benign))
Endometrioid Tumor Of Low Malignant
Potential (Endometrioid tumor of LMP)
Fibroma (Fibroma)
Germ Cell Tumor, Mixed (Germ cell
tumor, mixed)
Gestational Trophoblastic Disease
(Gestational trophoblastic disease)
Granulosa Cell Tumor (Granulosa cell
tumor)
Gynandroblastoma (Gynandroblastoma)
Mixed Epithelial Carcinoma, Specify
Components (Mixed epithelial
carcinoma)
Mixed Malignant Germ Cell Tumor,
Specify Components (Mixed malignant
germ cell tumor)
Mucinous Adenocarcinoma (Mucinous
adenocarcinoma)
Mucinous Cystadenofibroma (benign)
(Mucinous cystadenofibroma (benign))
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Mucinous Cystadenoma (benign)
(Mucinous cystadenoma (benign))
Mucinous Tumor Of Low Malignant
Potential (Mucinous tumor of LMP)
Other, Specify (Other, specify)
Ovarian Endometriosis (Ovarian
endometriosis)
Physiologic Cyst (corpus Luteum)
(Physiologic cyst (corpus luteum))
Physiologic Cyst (follicle) (Physiologic
cyst (follicle))
Polyembryoma (Polyembryoma)
Serous Adenocarcinoma (Serous
adenocarcinoma)
Serous Cystadenofibroma (benign)
(Serous cystadenofibroma (benign))
Serous Cystadenoma (benign) (Serous
cystadenoma (benign))
Serous Tumor Of Low Malignant
Potential (Serous tumor of LMP)
Sertoli-leydig Cell (androblastoma)
(Sertoli-Leydig cell (Androblastoma))
Sex-cord/stromal, Unclassified (Sex-
cord/stromal, unclassified)
Simple Cyst (Simple cyst)
Squamous Cell Carcinoma (Squamous
cell carcinoma)
Steroid/lipid Cell Tumor (Steroid/Lipid cell
tumor)
Teratoma, Immature, Specify
Components (Teratoma, immature)
Teratoma, Mature (Teratoma, mature)
Transitional Cell Carcinoma, Including
Brenner Tumor (Transitional cell
carcinoma (including Brenner))
Undifferentiated Carcinoma
(Undifferentiated carcinoma)
Histologic Type
Adenocarcinoma With Squamous
Differentiation (Adenocarcinoma with
Squamous Differentiation)
Adenocarcinoma, Unspecified
(Adenocarcinoma, unspecified)
Adenofibroma (Adenofibroma)
Adenosarcoma (Adenosarcoma)
Adenosquamous (Adenosquamous)
Brenner Tumor (benign) (Brenner tumor
(benign))
Brenner Tumor (malignant) (Brenner
tumor (malignant))
Brenner Tumor Of Low Malignant
Potential (Brenner tumor of LMP)
Cancer With Dermoid Cyst, Specify
Types (Cancer with dermoid cyst)
Carcinosarcoma/mesodermal (mullerian)
Mixed Tumor
(Carcinosarcoma/Mesodermal
(Mullerian) mixed tumor)
Choriocarcinoma (Choriocarcinoma)
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Clear Cell Carcinoma (Clear cell
carcinoma)
Clear Cell Cystadenofibroma (benign)
(Clear cell cystadenofibroma (benign))
Clear Cell Cystadenoma (benign) (Clear
cell cystadenoma (benign))
Clear Cell Tumor Of Low Malignant
Potential (Clear cell tumor of LMP)
Dysgerminoma (Dysgerminoma)
Embryonal Carcinoma (Embryonal
carcinoma)
Endodermal Sinus Tumor (yolk Sac
Tumor) (Endodermal sinus tumor)
Endometrial Stromal Sarcoma
(Endometrial stromal sarcoma)
Endometrioid Adenocarcinoma
(Endometrioid adenocarcinoma)
Endometrioid Cystadenofibroma (benign)
(Endometrioid cystadenofibroma
(benign))
Endometrioid Cystadenoma (benign)
(Endometrioid cystadenoma (benign))
Endometrioid Tumor Of Low Malignant
Potential (Endometrioid tumor of LMP)
Fibroma (Fibroma)
Germ Cell Tumor, Mixed (Germ cell
tumor, mixed)
Gestational Trophoblastic Disease
(Gestational trophoblastic disease)
Granulosa Cell Tumor (Granulosa cell
tumor)
Gynandroblastoma (Gynandroblastoma)
Mixed Epithelial Carcinoma, Specify
Components (Mixed epithelial
carcinoma)
Mixed Malignant Germ Cell Tumor,
Specify Components (Mixed malignant
germ cell tumor)
Mucinous Adenocarcinoma (Mucinous
adenocarcinoma)
Mucinous Cystadenofibroma (benign)
(Mucinous cystadenofibroma (benign))
Mucinous Cystadenoma (benign)
(Mucinous cystadenoma (benign))
Mucinous Tumor Of Low Malignant
Potential (Mucinous tumor of LMP)
Other, Specify (Other, specify)
Ovarian Endometriosis (Ovarian
endometriosis)
Physiologic Cyst (corpus Luteum)
(Physiologic cyst (corpus luteum))
Physiologic Cyst (follicle) (Physiologic
cyst (follicle))
Polyembryoma (Polyembryoma)
Serous Adenocarcinoma (Serous
adenocarcinoma)
Serous Cystadenofibroma (benign)
(Serous cystadenofibroma (benign))
Serous Cystadenoma (benign) (Serous
cystadenoma (benign))
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Serous Tumor Of Low Malignant
Potential (Serous tumor of LMP)
Sertoli-leydig Cell (androblastoma)
(Sertoli-Leydig cell (Androblastoma))
Sex-cord/stromal, Unclassified (Sex-
cord/stromal, unclassified)
Simple Cyst (Simple cyst)
Squamous Cell Carcinoma (Squamous
cell carcinoma)
Steroid/lipid Cell Tumor (Steroid/Lipid cell
tumor)
Teratoma, Immature, Specify
Components (Teratoma, immature)
Teratoma, Mature (Teratoma, mature)
Transitional Cell Carcinoma, Including
Brenner Tumor (Transitional cell
carcinoma (including Brenner))
Undifferentiated Carcinoma
(Undifferentiated carcinoma)
Histologic Type
Adenocarcinoma With Squamous
Differentiation (Adenocarcinoma with
Squamous Differentiation)
Adenocarcinoma, Unspecified
(Adenocarcinoma, unspecified)
Adenofibroma (Adenofibroma)
Adenosarcoma (Adenosarcoma)
Adenosquamous (Adenosquamous)
Brenner Tumor (benign) (Brenner tumor
(benign))
Brenner Tumor (malignant) (Brenner
tumor (malignant))
Brenner Tumor Of Low Malignant
Potential (Brenner tumor of LMP)
Cancer With Dermoid Cyst, Specify
Types (Cancer with dermoid cyst)
Carcinosarcoma/mesodermal (mullerian)
Mixed Tumor
(Carcinosarcoma/Mesodermal
(Mullerian) mixed tumor)
Choriocarcinoma (Choriocarcinoma)
Clear Cell Carcinoma (Clear cell
carcinoma)
Clear Cell Cystadenofibroma (benign)
(Clear cell cystadenofibroma (benign))
Clear Cell Cystadenoma (benign) (Clear
cell cystadenoma (benign))
Clear Cell Tumor Of Low Malignant
Potential (Clear cell tumor of LMP)
Dysgerminoma (Dysgerminoma)
Embryonal Carcinoma (Embryonal
carcinoma)
Endodermal Sinus Tumor (yolk Sac
Tumor) (Endodermal sinus tumor)
Endometrial Stromal Sarcoma
(Endometrial stromal sarcoma)
Endometrioid Adenocarcinoma
(Endometrioid adenocarcinoma)
Endometrioid Cystadenofibroma (benign)
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(Endometrioid cystadenofibroma
(benign))
Endometrioid Cystadenoma (benign)
(Endometrioid cystadenoma (benign))
Endometrioid Tumor Of Low Malignant
Potential (Endometrioid tumor of LMP)
Fibroma (Fibroma)
Germ Cell Tumor, Mixed (Germ cell
tumor, mixed)
Gestational Trophoblastic Disease
(Gestational trophoblastic disease)
Granulosa Cell Tumor (Granulosa cell
tumor)
Gynandroblastoma (Gynandroblastoma)
Mixed Epithelial Carcinoma, Specify
Components (Mixed epithelial
carcinoma)
Mixed Malignant Germ Cell Tumor,
Specify Components (Mixed malignant
germ cell tumor)
Mucinous Adenocarcinoma (Mucinous
adenocarcinoma)
Mucinous Cystadenofibroma (benign)
(Mucinous cystadenofibroma (benign))
Mucinous Cystadenoma (benign)
(Mucinous cystadenoma (benign))
Mucinous Tumor Of Low Malignant
Potential (Mucinous tumor of LMP)
Other, Specify (Other, specify)
Ovarian Endometriosis (Ovarian
endometriosis)
Physiologic Cyst (corpus Luteum)
(Physiologic cyst (corpus luteum))
Physiologic Cyst (follicle) (Physiologic
cyst (follicle))
Polyembryoma (Polyembryoma)
Serous Adenocarcinoma (Serous
adenocarcinoma)
Serous Cystadenofibroma (benign)
(Serous cystadenofibroma (benign))
Serous Cystadenoma (benign) (Serous
cystadenoma (benign))
Serous Tumor Of Low Malignant
Potential (Serous tumor of LMP)
Sertoli-leydig Cell (androblastoma)
(Sertoli-Leydig cell (Androblastoma))
Sex-cord/stromal, Unclassified (Sex-
cord/stromal, unclassified)
Simple Cyst (Simple cyst)
Squamous Cell Carcinoma (Squamous
cell carcinoma)
Steroid/lipid Cell Tumor (Steroid/Lipid cell
tumor)
Teratoma, Immature, Specify
Components (Teratoma, immature)
Teratoma, Mature (Teratoma, mature)
Transitional Cell Carcinoma, Including
Brenner Tumor (Transitional cell
carcinoma (including Brenner))
Undifferentiated Carcinoma
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(Undifferentiated carcinoma)
Histologic Components, Immature Teratoma
Histologic Components, Mixed Germ Cell
Histologic Type, Dermoid Cyst
Histologic Type, Other Name
Histologic Type, Other Name
Histologic Type, Other Name
Histologic Grade
Grade 1-well Differentiated (1)
Grade 2-moderately Differentiated (2)
Grade 3-poorly Differentiated (3)
Indeterminate (Indeterminate)
Not Applicable (Not applicable)
Grade Unknown (Unknown)
Tumor Extension
Confined To Ovary (Confined to ovary)
Extension Beyond Pelvic Region
(Extension beyond pelvic region)
Extension To Pelvic Tissue Other Than
Uterus And/or Tubes (Extension to pelvic
tissue other than uterus and/or tubes)
Extension To Uterus And/or Tubes
(Extension to uterus and/or tubes)
Lymph Node(s) Examined Number
Lymph Node(s) Positive Number
Ascites Ind
No (No)
Unknown (unknown)
Yes (Yes)
Ascites/Aspiration Status
Negative (Negative)
Positive (Positive)
Unknown (Unknown)
Pleural Effusion Ind
No (No)
Unknown (Unknown)
Yes (Yes)
Residual Disease
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Ovary, Right Examination Ind
No (No)
Unknown (Unknown)
Yes (Yes)
Ovary, Left Examination Ind
No (No)
Unknown (Unknown)
Yes (Yes)
Ovary, Right Surface Involved Ind
No (No)
Unknown (Unknown)
Yes (Yes)
Ovary, Left Surface Involved Ind
No (No)
Unknown (Unknown)
Yes (Yes)
Ovary, Right Capsule Prior Rupture Ind
No (No)
Unknown (Unknown)
Yes (Yes)
Ovary, Left Capsule Prior Rupture Ind
No (No)
Unknown (Unknown)
Yes (Yes)
Ovary, Right Capsule Surgery Rupture Ind
No (No)
Unknown (Unknown)
Yes (Yes)
Ovary, Left Capsule Surgery Rupture Ind
No (No)
Unknown (Unknown)
Yes (Yes)
T Stage, Pathologic
Refer To Figo And/or Ajcc Staging
Guidelines Per Protocol (T0)
Refer To Figo And/or Ajcc Staging
Guidelines Per Protocol (T1, NOS)
Refer To Figo And/or Ajcc Staging
Guidelines Per Protocol (T1a)
Refer To Figo And/or Ajcc Staging
Guidelines Per Protocol (T1b)
Refer To Figo And/or Ajcc Staging
Guidelines Per Protocol (T1c)
Refer To Figo And/or Ajcc Staging
Guidelines Per Protocol (T2, NOS)
Refer To Figo And/or Ajcc Staging
Guidelines Per Protocol (T2a)
Refer To Figo And/or Ajcc Staging
Guidelines Per Protocol (T2b)
Refer To Figo And/or Ajcc Staging
Guidelines Per Protocol (T3, NOS)
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Refer To Figo And/or Ajcc Staging
Guidelines Per Protocol (T3a)
Refer To Figo And/or Ajcc Staging
Guidelines Per Protocol (T3b)
Refer To Figo And/or Ajcc Staging
Guidelines Per Protocol (T4, NOS)
Refer To Figo And/or Ajcc Staging
Guidelines Per Protocol (TX)
N Stage, Pathologic
No Positive Lymph Nodes Present (n0)
(N0)
Positive Lymph Nodes Present - See
Figo And Ajcc Staging For Complete
Details (N1)
Positive Lymph Nodes Present - See
Figo And Ajcc Staging For Complete
Details (N2)
Lymph Nodes Cannot Be Assessed (nx)
(NX)
M Stage, Pathologic
No Metastases Present (m0) (M0)
Metastases Present - See Figo And Ajcc
Staging For Complete Details (M1)
Metastases Cannot Be Assessed (mx)
(MX)
Stage Grouping
Refer To Figo Staging For Specific
Gynecologic Cancer (I)
Refer To Figo Staging For Specific
Gynecologic Cancer (IA)
Refer To Figo Staging For Specific
Gynecologic Cancer (IA1)
Refer To Figo Staging For Specific
Gynecologic Cancer (IA2)
Refer To Figo Staging For Specific
Gynecologic Cancer (IB)
Refer To Figo Staging For Specific
Gynecologic Cancer (IB1)
Refer To Figo Staging For Specific
Gynecologic Cancer (IB2)
Refer To Figo Staging For Specific
Gynecologic Cancer (IC)
Refer To Figo Staging For Specific
Gynecologic Cancer (II)
Refer To Figo Staging For Specific
Gynecologic Cancer (IIA)
Refer To Figo Staging For Specific
Gynecologic Cancer (IIB)
Refer To Figo Staging For Specific
Gynecologic Cancer (IIC)
Refer To Figo Staging For Specific
Gynecologic Cancer (III)
Refer To Figo Staging For Specific
Gynecologic Cancer (IIIA)
Refer To Figo Staging For Specific
Gynecologic Cancer (IIIB)
Refer To Figo Staging For Specific
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Gynecologic Cancer (IIIC)
Refer To Figo Staging For Specific
Gynecologic Cancer (IV)
Refer To Figo Staging For Specific
Gynecologic Cancer (IVA)
Refer To Figo Staging For Specific
Gynecologic Cancer (IVB)
Stage Grouping Cannot Be Assessed (X)
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Bladder/Urothelial Cancer - Toxicity Form
All rights reserved. Please visit https://medical-data-
models.org/forms/6872
Bladder/Urothelial Cancer - Toxicity
Form
Crf Header
Coordinating Group Protocol Number
Coordinating Group Code
Protocol Title
Patient Study ID, Coordinating Group
Patient Study ID, Participating Group
Participating Group Code
Institution Name
Affiliate Name
Patient Name, Last
Patient Name, First
Patient Name, Middle
Bladder/urothelial: Form Administration
Person Completing Form, Last Name
Person Completing Form, First Name
Amended Data Ind
No (NO)
Unknown (UNKNOWN)
Yes (YES)
Bladder/urothelial: Adverse Events
CTC Adverse Event Report Begin Date
Course Identification
1 / 2
CTC Adverse Event Report End Date
CTC Adverse Event Term
Ctep.info.nih.gov/ctc3/ctc.htm
(http://ctep.info.nih.gov/CTC3/ctc.htm)
CTC Adverse Event Grade
Ctep.info.nih.gov/ctc3/ctc.htm
(http://ctep.info.nih.gov/CTC3/ctc.htm)
CTC Adverse Event Attribution Code
Definitely (Definitely)
Possibly (Possibly)
Probably (Probably)
Unlikely (Unlikely)
Unrelated (Unrelated)
CTC Adverse Event Term, Other
Allows Documentation Of Any Additional
Cooments
Comments
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Treatment - Melanoma-Treatment Summary
Form - 2020200v2.31
Melanoma-Treatment Summary Form
Source Form: NCI FormBuilder:
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models.org/forms/6873
Melanoma-Treatment Summary
Form
Crf Header
Coordinating Group Protocol Number
Coordinating Group Code
Protocol Title
Patient Study ID, Coordinating Group
Patient Study ID, Participating Group
Participating Group Code
Institution Name
Affiliate Name
Patient Name, Last
Patient Name, First
Patient Name, Middle
Melanoma: Treatment Schedule-surgery
Protocol Surgery Ind
No (No)
Unknown (unknown)
Yes (Yes)
Protocol Surgery Date
Protocol Surgery Type
Surgical Treatment Completed
No, Surgical Treatment Was Modified
From Protocol Specification (specify) (no,
surgical treatment was modified from
protocol specification (specify))
1 / 6
No, Surgical Treatment Was Not Done
(specify) (no, surgical treatment was not
done (specify))
Yes, Surgical Treatment Was Completed
As Per Protocol (Yes)
Surgical Treatment Completed, Specify
Radial Margin Distance
Melanoma: Treatment Schedule-systemic
Therapy
Treatment Begin Date
Agent Count Courses Administered
Treatment End Date
Agent Total Dose
Agent Dose Units
Curie (Ci)
Centimeter (cm)
Deciliter (dL)
Decimeter (dm)
Gram-equivalent Weight (Eq)
Gram (g)
Gravity (in Centrifugation) (gravity)
Hertz (Hz)
International Unit (IU)
Joules Per Centimeter Square (JCM2)
Kilo-electron Volt (keV)
Kilogram (kg)
Kilohertz (kHz)
Kilopascal (kPa)
Liter (L)
Meter (m)
Microcurie (mcCi)
Microgram (mcg)
Millicurie (mCi)
Microliter (mcL)
Micrometer (mcm)
Milliequivalent (mEq)
Million Electron Volts (MeV)
Milligram (mg)
Megahertz (MHz)
Milliunit (milliunit)
Milliliter (mL)
Millimeter (mm)
Milligrams Per Milliliter Per Minute
(MMM)
Millimole (mmol)
Gram-molecular Weight (mole) (mol)
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Milliosmole (mOsmol)
Megarad (Mrad)
Million Unit (mU)
Millivolt (mV)
Not Applicable (N/A)
Nanocurie (nCi)
Nanogram (ng)
Nanometer (nm)
Nanometers Of Light (nm light)
Osmole (Osmol)
Pascal (Pa)
Plaque Forming Unit (pfu)
Picogram (pg)
Pounds Per Square Inch (psi)
Unit (unit)
Viral Particles (VP)
Agent Name
Melanoma: Treatment Schedule-vaccine
Therapy
Vaccine Date, First
Vaccine Date, Last
Vaccine Site
Left Lower Extremity (left lower
extremity)
Left Upper Extremity (left upper
extremity)
Other, Specify (other, specify)
Right Lower Extremity (right lower
extremity)
Right Upper Extremity (right upper
extremity)
Trunk (trunk)
Vaccine Site, Other
Agent Total Dose
Agent Dose Units
Curie (Ci)
Centimeter (cm)
Deciliter (dL)
Decimeter (dm)
Gram-equivalent Weight (Eq)
Gram (g)
Gravity (in Centrifugation) (gravity)
Hertz (Hz)
International Unit (IU)
Joules Per Centimeter Square (JCM2)
Kilo-electron Volt (keV)
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Kilogram (kg)
Kilohertz (kHz)
Kilopascal (kPa)
Liter (L)
Meter (m)
Microcurie (mcCi)
Microgram (mcg)
Millicurie (mCi)
Microliter (mcL)
Micrometer (mcm)
Milliequivalent (mEq)
Million Electron Volts (MeV)
Milligram (mg)
Megahertz (MHz)
Milliunit (milliunit)
Milliliter (mL)
Millimeter (mm)
Milligrams Per Milliliter Per Minute
(MMM)
Millimole (mmol)
Gram-molecular Weight (mole) (mol)
Milliosmole (mOsmol)
Megarad (Mrad)
Million Unit (mU)
Millivolt (mV)
Not Applicable (N/A)
Nanocurie (nCi)
Nanogram (ng)
Nanometer (nm)
Nanometers Of Light (nm light)
Osmole (Osmol)
Pascal (Pa)
Plaque Forming Unit (pfu)
Picogram (pg)
Pounds Per Square Inch (psi)
Unit (unit)
Viral Particles (VP)
Agent Name
Melanoma: Treatment Schedule
Summary-radiation Therapy
RT Begin Date
RT End Date
RT Site
Bone (Bone)
Brain (Brain)
Head And Neck (Head and Neck)
Lymph Nodes (soft Tissue) (Lymph
nodes (soft tissue))
Other, Specify (Other, specify)
RT Site, Other
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RT Total Dose
RT Interruptions Ind
No (No)
Unknown (Unknown)
Yes, Due To Toxicity (Yes, due to toxicity)
Yes, For Other Reasons, Specify (Yes,
for other reasons, specify)
RT Interruptions Reason
Melanoma: Treatment Modifications
Dose Modification (Change)
No (No)
Unknown (Unknown)
(i.e., The Treatment Was Changed
According To Protocol Guidelines) (Yes,
planned)
(i.e., The Treatment Change Was Not
Part Of Protocol Guidelines) (Yes,
unplanned)
Dose Modification Reason
Melanoma: Off-treatment
Off Treatment Reason
Alternative Therapy (Alternative therapy)
Death After Beginning Protocol Therapy
(Death after beginning protocol therapy)
Death On Study (Death on study)
Death Prior To Beginning Protocol
Therapy (Death prior to beginning
protocol therapy)
Disease Progression, Relapse During
Active Treatment (Disease progression,
relapse during active treatment)
Disease Progression, Relapse Prior To
Beginning Protocol Therapy (Disease
progression, relapse prior to beginning
protocol therapy)
New Primary (New primary)
Other (Other)
Patient Off-treatment For Other
Complicating Disease (Patient off-
treatment for other complicating disease)
Patient Withdrawal Or Refusal After
Beginning Protocol Therapy (Patient
withdrawal or refusal after beginning
protocol therapy)
Patient Withdrawal Or Refusal Prior To
Beginning Protocol Therapy (Patient
withdrawal or refusal prior to beginning
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protocol therapy)
Toxicity/side Effects/complications
(Toxicity/Side effects/Complications)
Treatment Completed Per Protocol
Criteria (Treatment completed per
protocol criteria)
Off Treatment Reason, Toxicity
Off Treatment Reason, Other
Melanoma: Treatment Schedule-non-
protocol Therapy
Non-Protocol Therapy Ind
No (NO)
Unknown (UNKNOWN)
Yes (YES)
Other Therapy Type
Non-Protocol Therapy Date, First
Allows Documentation Of Any Additional
Cooments
Comments
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Treatment - Upper Gastrointestinal Cancers - Treatment
Form (for Periodic Reporting) - 2020209v2.31
Upper Gastrointestinal Cancers - Treatment Form (for
Periodic Reporting)
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=99CD59C5-
A9B2-3FA4-E034-080020C9C0E0
All rights reserved. Please visit https://medical-data-
models.org/forms/6875
Upper Gastrointestinal Cancers -
Treatment Form (for Periodic
Reporting)
Crf Header
Coordinating Group Protocol Number
Coordinating Group Code
Protocol Title
Patient Study ID, Coordinating Group
Patient Study ID, Participating Group
Participating Group Code
Http://ctep.info.nih.gov.
(http://ctep.info.nih.gov.)
Institution Name
Affiliate Name
Patient Name, Last
Patient Name, First
Patient Name, Middle
Gi: Treatment Reporting Interval
Interval Report From Date
Interval Report To Date
Gi: Treatment Schedule - Radiation
Therapy
Protocol Treatment, RT Ind
1 / 4
No (No)
Unknown (Unknown)
Yes (Yes)
RT Begin Date
RT End Date
RT Type
Adjuvant Radiation Therapy (Adjuvant
RT)
Brachytherapy (Brachytherapy)
External Beam Radiation (External beam
radiation)
Neoadjuvant Radiation Therapy
(Neoadjuvant RT)
Other, Specify (Other, specify)
Palliative Radiation Therapy (Palliative
RT)
RT Type, Other
RT Site
RT Total Dose
RT Interruptions Ind
No (No)
Unknown (Unknown)
Yes, Due To Toxicity (Yes, due to toxicity)
Yes, For Other Reasons, Specify (Yes,
for other reasons, specify)
RT Interruptions Reason
Gi: Treatment Cycle Information -
Systemic Therapy
Protocol Treatment, Systemic Therapy Ind
No (No)
Unknown (Unknown)
Yes (Yes)
Total Course Number
First Treatment Start Date
Last Treatment Date
Systemic Therapy Type
Chemotherapy (Chemotherapy)
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Immunotherapy (Immunotherapy)
Other Specify (Other, specify)
Systemic Therapy Type, Other
Agent Name
Agent Total Dose (per course)
Agent Dose Units
Curie (Ci)
Centimeter (cm)
Deciliter (dL)
Decimeter (dm)
Gram-equivalent Weight (Eq)
Gram (g)
Gravity (in Centrifugation) (gravity)
Hertz (Hz)
International Unit (IU)
Joules Per Centimeter Square (JCM2)
Kilo-electron Volt (keV)
Kilogram (kg)
Kilohertz (kHz)
Kilopascal (kPa)
Liter (L)
Meter (m)
Microcurie (mcCi)
Microgram (mcg)
Millicurie (mCi)
Microliter (mcL)
Micrometer (mcm)
Milliequivalent (mEq)
Million Electron Volts (MeV)
Milligram (mg)
Megahertz (MHz)
Milliunit (milliunit)
Milliliter (mL)
Millimeter (mm)
Milligrams Per Milliliter Per Minute
(MMM)
Millimole (mmol)
Gram-molecular Weight (mole) (mol)
Milliosmole (mOsmol)
Megarad (Mrad)
Million Unit (mU)
Millivolt (mV)
Not Applicable (N/A)
Nanocurie (nCi)
Nanogram (ng)
Nanometer (nm)
Nanometers Of Light (nm light)
Osmole (Osmol)
Pascal (Pa)
Plaque Forming Unit (pfu)
Picogram (pg)
Pounds Per Square Inch (psi)
Unit (unit)
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Viral Particles (VP)
Dose Modification (Change)
No (No)
Unknown (Unknown)
(i.e., The Treatment Was Changed
According To Protocol Guidelines) (Yes,
planned)
(i.e., The Treatment Change Was Not
Part Of Protocol Guidelines) (Yes,
unplanned)
Therapy Modification Name
Therapy Modification Reason
Allows Documentation Of Any Additional
Cooments
Comments
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On-Study - Gastric Cancer - Advanced On-
Study Form - 2020204v2.31
Gastric Cancer - Advanced On-Study Form
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=99CD59C5-
A9A8-3FA4-E034-080020C9C0E0
All rights reserved. Please visit https://medical-data-
models.org/forms/6878
Gastric Cancer - Advanced On-Study
Form
Crf Header
Coordinating Group Protocol Number
Coordinating Group Code
Protocol Title
Patient Study ID, Coordinating Group
Patient Study ID, Participating Group
Participating Group Code
Http://ctep.info.nih.gov.
(http://ctep.info.nih.gov.)
Institution Name
Affiliate Name
Patient Name, Last
Patient Name, First
Patient Name, Middle
Gastric: Form Administration
Person Completing Form, Last Name
Person Completing Form, First Name
Amended Data Ind
No (NO)
Unknown (UNKNOWN)
Yes (YES)
Gastric: Advanced Disease Description
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Primary Site
Antrum (Antrum)
Body Of Pancreas (Body of pancreas)
Cardia (Cardia)
Cervical Esophagus (Cervical
esophagus)
Diffuse (Diffuse)
Esophagus, Not Otherwise Specified
(Esophagus, NOS)
Fundus (Fundus)
Gastro-esophageal Junction (Gastro-
esophageal junction)
Head Of Pancreas (Head of pancreas)
Linitus Plastica (Linitus plastica)
Lower Thoracic Esophagus, Excluding
The Gastro-esophageal Junction (Lower
thoracic esophagus (excludes G-E
junction))
Mid-thoracic Esophagus (Mid-thoracic
esophagus)
Other, Specify (Other, specify)
Pancreas, Not Otherwise Specified
(Pancreas, NOS)
Pylorus/pyloric Channel (Pylorus/Pyloric
channel)
Stomach, Not Otherwise Specified
(Stomach, NOS)
Tail Of Pancreas (Tail of pancreas)
Uncinate Process (Uncinate process)
Upper Thoracic Esophagus (Upper
thoracic esophagus)
Primary Site, Other
Disease Involvement Site
Adjacent Structures, Specify (Adjacent
structures, specify)
Adjacent Viscera (Adjacent viscera)
Adjacent Viscera/vessels (Adjacent
viscera/vessels)
Bone (Bone)
Distant Lymph Nodes (Distant lymph
nodes)
Liver (Liver)
Lung (Lung)
Other, Specify (Other, specify)
Peritoneal Disease (Peritoneal disease)
Peritoneum (Peritoneum)
Primary Tumor/esophagus (Primary
tumor/esophagus)
Primary Tumor/pancreas (Primary
tumor/pancreas)
Primary Tumor/stomach (Primary
tumor/stomach)
Regional Lymph Nodes (Regional lymph
nodes)
Disease Involvement Site, Adjacent Specify
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Disease Involvement Site, Other
Advanced Disease Registration Status
Initial Diagnosis (Initial Diagnosis)
Recurrence (Recurrence)
Histologic Type
Acinar Cell Carcinoma (Acinar cell
carcinoma)
Adenocarcinoma (Adenocarcinoma)
Adenosquamous Carcinoma
(Adenosquamous carcinoma)
Ductal Adenocarcinoma (Ductal
adenocarcinoma)
Mixed-type (ductal-endocrine Or Acinar-
endocrine) (Mixed-type (ductal-endocrine
or acinar-endocrine))
Mucinous Adenocarcinoma (Mucinous
adenocarcinoma)
Mucinous Noncystic Carcinoma
(Mucinous noncystic carcinoma)
Neuroendocrine Carcinoma
(Neuroendocrine carcinoma)
Other, Specify (Other, specify)
Signet Ring Cell Carcinoma (Signet ring
cell carcinoma)
Small Cell Carcinoma (Small cell
carcinoma)
Squamous Cell Carcinoma (Squamous
cell carcinoma)
Tubular Adenocarcinoma (Tubular
adenocarcinoma)
Undifferentiated (anaplastic) Carcinoma
(Undifferentiated (anaplastic) carcinoma)
Undifferentiated Carcinoma With
Osteoclast-like Giant Cells
(Undifferentiated carcinoma with
osteoclast-like giant cells)
Unknown (Unknown)
Histologic Type, Other Name
Histologic Grade
Tumor Is Moderately Differentiated
According To Who Grading System
(Moderately differentiated (Grade II))
Tumor Is Poorly Differentiated According
To Who Grading System (Poorly
differentiated (Grade III))
Tumor Is Undifferentiated According To
Who Grading System (Undifferentiated
(Grade IV))
Unknown (Unknown)
Tumor Is Well Differentiated According
To Who Grading System (Well
differentiated (Grade I))
T Stage, Pathologic
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T0, According To Ajcc Criteria (T0)
T1, According To Ajcc Criteria (T1)
T2, According To Ajcc Criteria (T2)
T3, According To Ajcc Criteria (T3)
T4, According To Ajcc Criteria (T4)
Tis, According To Ajcc Criteria (Tis)
Tx, According To Ajcc Criteria (TX)
N Stage, Pathologic
No Lymph Node Involvement According
To Ajcc Guidelines (use For Esophageal,
Gastric, And Pancreatic) (N0)
N1, According To Ajcc Criteria (N1)
N2, According To Ajcc Criteria (N2)
N3, According To Ajcc Criteria (N3)
Lymph Node Involvement Cannot Be
Assessed According To Ajcc Guidelines
(use For Esophageal, Gastric, And
Pancreatic) (NX)
M Stage, Pathologic
No Distant Metastases According To
Ajcc Guidelines (M0)
Distant Metastases Present According
To Ajcc Guidelines (M1)
Distant Metastases Presence Or
Absence Cannot Be Assessed According
To Ajcc Guidelines (MX)
Gastric: Advanced Prior Treatment
Prior Surgery Ind
No (NO)
Unknown (UNKNOWN)
Yes (YES)
Prior Chemotherapy Ind
No (NO)
Unknown (UNKNOWN)
Yes (YES)
Prior Immunotherapy Ind
No (NO)
Unknown (UNKNOWN)
Yes (YES)
Prior RT Ind
No (NO)
Unknown (UNKNOWN)
Yes (YES)
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Toxicity - Bladder/Urothelial Cancer -
Toxicity Form - 2019355v2.31
Bladder/Urothelial Cancer - Toxicity Form
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=99CD59C5-
A955-3FA4-E034-080020C9C0E0
All rights reserved. Please visit https://medical-data-
models.org/forms/6880
Bladder/Urothelial Cancer - Toxicity
Form
Crf Header
Coordinating Group Protocol Number
Coordinating Group Code
Protocol Title
Patient Study ID, Coordinating Group
Patient Study ID, Participating Group
Participating Group Code
Institution Name
Affiliate Name
Patient Name, Last
Patient Name, First
Patient Name, Middle
Bladder/urothelial: Form Administration
Person Completing Form, Last Name
Person Completing Form, First Name
Amended Data Ind
No (NO)
Unknown (UNKNOWN)
Yes (YES)
Bladder/urothelial: Adverse Events
CTC Adverse Event Report Begin Date
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Course Identification
CTC Adverse Event Report End Date
CTC Adverse Event Term
Ctep.info.nih.gov/ctc3/ctc.htm
(http://ctep.info.nih.gov/CTC3/ctc.htm)
CTC Adverse Event Grade
Ctep.info.nih.gov/ctc3/ctc.htm
(http://ctep.info.nih.gov/CTC3/ctc.htm)
CTC Adverse Event Attribution Code
Definitely (Definitely)
Possibly (Possibly)
Probably (Probably)
Unlikely (Unlikely)
Unrelated (Unrelated)
CTC Adverse Event Term, Other
Allows Documentation Of Any Additional
Cooments
Comments
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On-Study - Local-Regional Melanoma-On-
study Form - 2020196v2.31
Local-Regional Melanoma-On-study Form
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=99CD59C5-
A998-3FA4-E034-080020C9C0E0
All rights reserved. Please visit https://medical-data-
models.org/forms/6881
Local-Regional Melanoma-On-study
Form
Crf Header
Coordinating Group Protocol Number
Coordinating Group Code
Protocol Title
Patient Study ID, Coordinating Group
Patient Study ID, Participating Group
Participating Group Code
Institution Name
Affiliate Name
Patient Name, Last
Patient Name, First
Patient Name, Middle
Melanoma: Form Administration
Person Completing Form, Last Name
Person Completing Form, First Name
Amended Data Ind
No (NO)
Unknown (UNKNOWN)
Yes (YES)
Melanoma: Disease Description
Initial Diagnosis Date, Pathologic
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Primary Surgery Type
Biopsy (Biopsy)
Excision Of Local Recurrence (Excision
of local recurrence)
Excision Of Satellite Or In-transit
Metastases (Excision of satellite or in-
transit metastases)
Excision/wide Excision Of Primary
(Excision/wide excision of primary)
Lymph Node Dissection (Lymph node
dissection)
Other, Specify (Other, specify)
Primary Surgery, Other Type
Primary Surgery Date
Primary Site
Anogenital (non-mucosal) (Anogenital
(non-mucosal))
Head (Head)
Lower Extremity (Lower extremity)
Mucosal (Mucosal)
Neck (Neck)
Ocular (Ocular)
Other, Specify (Other, specify)
Subungual (Subungual)
Trunk (Trunk)
Unknown (Unknown)
Upper Extremity (Upper extremity)
Primary Site, Other
Primary Tumor Resection Status
Not Recurrent, Resected, No Residual
Tumor (Not recurrent, resected, no
residual tumor)
Not Recurrent, Resected, Residual
Tumor (Not recurrent, resected, residual
tumor)
Recurrent (Recurrent)
Unresected (Unresected)
Involvement Pattern
Acral Lentiginous (acral lentiginous)
Lentigo Maligna Melanoma (lentigo
maligna melanoma)
Nodular (nodular)
Other, Specify (other, specify)
Superficial Spreading (superficial
spreading)
Involvement Pattern, Other
Breslow Depth
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Lab, Chemistry, Lactate Dehydrogenase
Clark Level
I-above Basal Lamina (in Situ) (I-above
basal lamina (in situ))
Ii- Extension Into Papillary Dermis (II-
extension into papillary dermis)
Iii-interface Papillary-reticular Dermis (III-
interface papillary-reticular dermis)
Iv-reticular Dermis (IV-reticular dermis)
V-subcutaneous Fat (V-subcutaneous
fat)
Ulceration Ind
No (No)
Unknown (unknown)
Yes (Yes)
Lymph Node(s) Examined Number
Lymph Node(s) Positive Number
Lymph Node Involvement
Lymph Node(s) With Any
Macroscopic/gross Metastases (Lymph
node(s) with any macroscopic/gross
metastases)
Lymph Node(s) With Only Microscopic
Metastases (Lymph node(s) with only
microscopic metastases)
No Lymph Node Involvement (No lymph
node involvement)
Unknown (Unknown)
Intransit metastases/satellite lesions Ind
No (No)
Unknown (Unknown)
Yes (Yes)
Lymph Nodes, Matted Ind
No (No)
Unknown (Unknown)
Yes (Yes)
T Stage, Pathologic
T1a, According To Ajcc Guidelines (T1a)
T1b, According To Ajcc Guidelines (T1b)
T2a, According To Ajcc Guidelines (T2a)
T2b, According To Ajcc Guidelines (T2b)
T3a, According To Ajcc Guidelines (T3a)
T3b, According To Ajcc Guidelines (T3b)
T4a, According To Ajcc Guidelines (T4a)
T4b, According To Ajcc Guidelines (T4b)
Tx, According To Ajcc Guidelines (TX)
N Stage, Pathologic
N0, According To Ajcc Guidelines (N0)
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N1a, According To Ajcc Guidelines (N1a)
N1b, According To Ajcc Guidelines (N1b)
N2a, According To Ajcc Guidelines (N2a)
N2b, According To Ajcc Guidelines (N2b)
N2c, According To Ajcc Guidelines (N2c)
N3, According To Ajcc Guidelines (N3)
Nx, According To Ajcc Guidelines (NX)
M Stage, Pathologic
M0, According To Ajcc Guidelines (M0)
M1a, According To Ajcc Guidelines
(M1a)
M1b, According To Ajcc Guidelines
(M1b)
M1c, According To Ajcc Guidelines (M1c)
Mx, According To Ajcc Guidelines (MX)
Melanoma: Sentinel Node Biopsy
Sentinel Node Biopsy Ind
No (NO)
Unknown (UNKNOWN)
Yes (YES)
Sentinel Node Biopsy Date
Sentinel Node(s) Examined Number
Sentinel Node(s) Positive Number
Sentinel Node Size
Melanocytes Ind
No (No)
Unknown (unknown)
Yes (Yes)
Naevus cells Ind
No (No)
Unknown (unknown)
Yes (Yes)
Sentinel Node Biopsy Results
Negative (Negative)
Positive (Positive)
Melanoma: Prior Treatment
Prior Surgery Ind
No (NO)
Unknown (UNKNOWN)
Yes (YES)
Prior Surgery Type
Biopsy (Biopsy)
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Excision Of Distant Metastases (Excision
of distant metastases)
Excision Of Local Recurrence (Excision
of local recurrence)
Excision Of Satellite Or In-transit
Metastases (Excision of satellite or in-
transit metastases)
Excision/wide Excision Of Primary
(Excision/wide excision of primary)
Lymph Node Dissection (Lymph node
dissection)
Other, Specify (Other, specify)
Sentinel Lymph Node Biopsy (Sentinel
lymph node biopsy)
Prior Surgery Type, Other
Primary Surgery Date
Prior Vaccine Ind
No (No)
Unknown (unknown)
Yes (Yes)
Prior Vaccine Type
Prior Vaccination Date
Prior ILP Ind
No (No)
Unknown (unknown)
Yes (Yes)
Prior ILP, specify
Prior ILP Date
Prior Hormonal Therapy Ind
No (NO)
Unknown (UNKNOWN)
Yes (YES)
Prior Chemotherapy Ind
No (NO)
Unknown (UNKNOWN)
Yes (YES)
Prior Immunotherapy Ind
No (NO)
Unknown (UNKNOWN)
Yes (YES)
Melanoma: Prior Treatment-systemic
Regimens
5 / 6
On-Study - Local-Regional Melanoma-On-study Form - 2020196v2.31
Prior Treatment Regimen Name(s)
Prior Treatment Regimen Begin Date
Prior Treatment Regimen End Date
Prior Treatment Regimen Type
Allows Documentation Of Any Additional
Cooments
Comments
6 / 6
On-Study - Local-Regional Melanoma-On-study Form - 2020196v2.31
Leukemia NCT01041703 Flow Sheet - E2906 Source
Document Tracking Coversheet Form - 2947795v1.0
E2906 Source Document Tracking Coversheet Form
Clofarabine or Daunorubicin Hydrochloride and Cytarabine
Followed By Decitabine or Observation in Treating Older
Patients With Newly Diagnosed Acute Myeloid Leukemia
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=74BCE806-
5876-4D7A-E040-BB89AD437934
All rights reserved. Please visit https://medical-data-
models.org/forms/6883
E2906 Source Document Tracking
Coversheet Form
Header
ECOG Protocol Number
ECOG Patient ID
DCI Name
Registration Step
Unnamed2
Patient Initials (Last, First)
ECOG Protocol Number
ECOG Patient ID
Participating Group Protocol Number
Participating Group Patient ID
Institution/Affiliate
On Treatment
On Treatment Report Period (Choose one)
At Transplant (At Transplant)
Baseline Step 1 (Baseline Step 1)
Cycle 1 - Consolidation (Cycle 1 -
Consolidation)
Cycle 1 - Induction (Cycle 1 - Induction)
Cycle 1 - Step 3 (Cycle 1 - Step 3)
Cycle 10 - Step 3 (Cycle 10 - Step 3)
Cycle 11 - Step 3 (Cycle 11 - Step 3)
Cycle 12 - Step 3 (Cycle 12 - Step 3)
Cycle 13 - Step 3 (Cycle 13 - Step 3)
Cycle 2 - Consolidation (Cycle 2 -
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Consolidation)
Cycle 2 - Induction (Cycle 2 - Induction)
Cycle 2 - Step 3 (Cycle 2 - Step 3)
Cycle 3 - Step 3 (Cycle 3 - Step 3)
Cycle 4 - Step 3 (Cycle 4 - Step 3)
Cycle 5 - Step 3 (Cycle 5 - Step 3)
Cycle 6 - Step 3 (Cycle 6 - Step 3)
Cycle 7 - Step 3 (Cycle 7 - Step 3)
Cycle 8 - Step 3 (Cycle 8 - Step 3)
Cycle 9 - Step 3 (Cycle 9 - Step 3)
Off Treatment
Off Treatment Report Period (Choose one)
12 Months (12 Months Post Registration)
15 Months (15 Months Post Registration)
18 Months (18 Months Post Registration)
21 Months Post Registration (21 Months
Post Registration)
2 Years (24 Months Post Registration)
3 Months (3 Months Post Registration)
30 Months (30 Months Post Registration)
3 Years (36 Months Post Registration)
42 Months (42 Months Post Registration)
4 Years (48 Months Post Registration)
54 Months (54 Months Post Registration)
6 Months (6 Months Post Registration)
5 Years (60 Months Post Registration)
9 Months (9 Months Post Registration)
Section Ii
Document type (Choose all that apply)
Bone Marrow Report (Bone Marrow
Report)
Csf Report (CSF Report)
Report Created Date (M D Y)
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Coversheet Form - 2947795v1.0
Pathology - Prostate Cancer - Pathology
Form - Prostatectomy - 2020219v3.0
Prostate Cancer - Pathology Form - Prostatectomy
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=19804EB0-
3297-1007-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/6885
Prostate Cancer - Pathology Form -
Prostatectomy
Crf Header
Coordinating Group Protocol Number
Coordinating Group Code
Protocol Title
Patient Study ID, Coordinating Group
Patient Study ID, Participating Group
Participating Group Code
Institution Name
Affiliate Name
Patient Name, Last
Patient Name, First
Patient Name, Middle
Prostate Pathology: Form Administration
Person Completing Form, Last Name
Person Completing Form, First Name
Amended Data Ind
No (NO)
Unknown (UNKNOWN)
Yes (YES)
Pathology: Prostatectomy
Data Source
Outside Source (Outside source)
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Performed Internally And Internally
Reviewed (Performed internally and
internally reviewed)
Performed Outside, But With Internal
Review (Performed outside, but with
internal review)
Therapeutic Effect Ind
No (No)
Unknown (Unknown)
Yes (Yes)
Therapy Name
Hormonal Therapy (Hormonal therapy)
Other (Other)
Radiation Therapy (Radiation therapy)
Unknown (Unknown)
Other Therapy Name
Surgical Procedure Type
Fine Needle Aspiration (Fine needle
aspiration)
Needle Biopsy (Needle biopsy)
Open Biopsy (Open biopsy)
Other, Specify (Other)
Radical Prostatectomy, Laparoscopic
(Radical prostatectomy, laparoscopic)
Radical Prostatectomy, Nos (Radical
prostatectomy, NOS)
Radical Prostatectomy, Perineal (Radical
prostatectomy, perineal)
Radical Prostatectomy, Retropubic
(Radical prostatectomy, retropubic)
Suprapubic Prostatectomy (Suprapubic
prostatectomy)
Transurethral Resection (Transurethral
resection)
Surgical Procedure Other Type
Surgery Date
Specimen Fixative
Formalin (Formalin)
Other (Other)
Unknown (Unknown)
Specimen Other Fixative
PIN Ind, High Grade
No (No)
Unknown (Unknown)
Yes (Yes)
Seminal Vesicle Invasion Ind
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No (No)
Unknown (Unknown)
Yes (Yes)
Seminal Vesicle Invasion, Laterality
Both Sides (Both sides)
Left Side (Left side)
Right Side (Right side)
Side Not Specified (Side not specified)
Pelvic Node Analysis Ind
No (No)
Unknown (Unknown)
Yes (Yes)
Lymph Nodes Type
Other, Specify (Other)
Pelvic Lymph Nodes Which Include, But
Are Not Limited To, Internal Iliac,
External Iliac, Inguinal, And Obturator
(Pelvic (includes internal iliac, external
iliac, inguinal, obturator, etc.))
Lymph Nodes Other Type
Lymph Node(s) Examined Number
Lymph Node(s) Positive Number
Lymph Node, Largest Diameter
Periprostatic Node Involvement Ind
No (No)
Not Examined (Not examined)
Unknown (Unknown)
Yes (Yes)
Prostatectomy Aborted Reason Ind
No (No)
Not Applicable (Not applicable)
Unknown (Unknown)
Yes (Yes)
Extranodal Extension Ind
Indeterminate (Indeterminate)
No (No)
Unknown (Unknown)
Yes (Yes)
Surgical Margin, Anterior
Negative (Negative)
Not Examined (Not examined)
Positive (Positive)
Surgical Margin, Right Posterolateral
Negative (Negative)
Not Examined (Not examined)
Positive (Positive)
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Surgical Margin, Left Posterolateral
Negative (Negative)
Not Examined (Not examined)
Positive (Positive)
Surgical Margin, Right Anterolateral
Negative (Negative)
Not Examined (Not examined)
Positive (Positive)
Surgical Margin, Left Anterolateral
Negative (Negative)
Not Examined (Not examined)
Positive (Positive)
Surgical Margin, Apical
Negative (Negative)
Not Examined (Not examined)
Positive (Positive)
Surgical Margin, Bladder Neck
Negative (Negative)
Not Examined (Not examined)
Positive (Positive)
Surgical Margin, Extent Positive
Extensive (Extensive)
Focal (Focal)
Not Specified (Not specified)
Surgical Margin, Extent Positive
Extensive (Extensive)
Focal (Focal)
Not Specified (Not specified)
Surgical Margin, Extent Positive
Extensive (Extensive)
Focal (Focal)
Not Specified (Not specified)
Surgical Margin, Extent Positive
Extensive (Extensive)
Focal (Focal)
Not Specified (Not specified)
Surgical Margin, Extent Positive
Extensive (Extensive)
Focal (Focal)
Not Specified (Not specified)
Surgical Margin, Extent Positive
Extensive (Extensive)
Focal (Focal)
Not Specified (Not specified)
Surgical Margin, Extent Positive
Extensive (Extensive)
Focal (Focal)
Not Specified (Not specified)
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Pathology: Tumor Description
Tumor Location, Side
Left (Left)
Left Lateral (Left lateral)
Midline (Midline)
Other, Specify (Other, specify)
Right (Right)
Right Lateral (Right lateral)
Unknown (Unknown)
Tumor Location, Other Side
Tumor Location, Area
Apex (Apex)
Base (Base)
Middle (Middle)
Other, Specify (Other, specify)
Seminal Vesicle (Seminal vesicle)
Tumor Location, Other Area
Tumor Location, Zone
Not Specified (Not specified)
Peripheral/central (Peripheral/central)
Transition (Transition)
Unknown (Unknown)
Tumor Location, Relative Position
Anterior (Anterior)
Posterior (Posterior)
Tumor Size, Maximum Diameter
Tumor Size, Total Volume
Tumor Size UOM
Cubic Centimeters (cc)
Cm (cm)
Milliliters (ml)
Mm (mm)
Tumor Size UOM
Cubic Centimeters (cc)
Cm (cm)
Milliliters (ml)
Mm (mm)
Tumor, Cancer Present Percentage
Extraprostatic Extension Ind
No (No)
Unknown (Unknown)
Yes (Yes)
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Extraprostatic Extension Type
Established (Established)
Focal </= 2 Hpf (Focal </= 2 hpf)
Unknown (Unknown)
Extraprostatic Extension Laterality
Bilateral (Bilateral)
Unilateral (Unilateral)
Unknown (Unknown)
Extraprostatic Extension Extent, Vertical
Extraprostatic Extension Extent, Horizontal
Prostate Capsule Invasion at Margin Ind
Indeterminate (Indeterminate)
No (No)
Unknown (Unknown)
Yes (Yes)
Lymphovascular Invasion Ind
Indeterminate (Indeterminate)
No (No)
Unknown (Unknown)
Yes (Yes)
Lymphovascular Invasion Description
Perineural Involvement Ind
Indeterminate (Indeterminate)
No (No)
Unknown (Unknown)
Yes (Yes)
Perineural Invasion Description
Gleason Score, Primary Pattern
Gleason Score, Secondary Pattern
Gleason Score, Combined
Gleason Score, Worst Pattern
Pathology: Disease Assessment
Histologic Type
Adenocarcinoma, Conventional, Not
Otherwise Specified (Adenocarcinoma,
conventional, NOS)
Adenocarcinoma/acinar
(Adenocarcinoma/Acinar)
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Adenosquamous Carcinoma
(Adenosquamous carcinoma)
Basaloid And Adenoid Cystic Carcinoma
(Basaloid and adenoid cystic carcinoma)
Lymphoepithelioma-like Carcinoma
(Lymphoepithelioma-like carcinoma)
Mucinous (colloid) Adenocarcinoma
(Mucinous (colloid) adenocarcinoma)
Other (Other, specify)
Prostatic Duct Adenocarcinoma
(Prostatic duct adenocarcinoma)
Sarcomatoid Carcinoma (Sarcomatoid
carcinoma)
Signet Ring Cell Carcinoma (Signet ring
cell carcinoma)
Small Cell Carcinoma (Small cell
carcinoma)
Squamous Cell Carcinoma (Squamous
cell carcinoma)
Transitional Cell Carcinoma (Transitional
cell carcinoma)
Undifferentiated Carcinoma, Not
Otherwise Specified (Undifferentiated
carcinoma, NOS)
Urothelial Primary In Prostate (Urothelial
primary in prostate)
Histologic Type, Other Name
Histologic Type, Variant
Adenosquamous Carcinoma
(Adenosquamous carcinoma)
Prostatic Duct Adenocarcinoma (Ductal
carcinoma)
Mucinous (colloid) Adenocarcinoma
(Mucinous adenocarcinoma)
Other, Specify (Other, specify)
Sarcomatoid Carcinoma (Sarcomatoid
carcinoma)
Signet Ring Cell Carcinoma (Signet ring
cell carcinoma)
Small Cell Carcinoma (Small cell
carcinoma)
Squamous Cell Carcinoma (Squamous
cell carcinoma)
Histologic Type, Other Variant
Histologic Type, Variant Percent
Histologic Type, Variant Percent
T Stage, Pathologic
Organ Confined (pT2)
Unilateral (pT2a)
Bilateral (pT2b)
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Extraprostatic Extension (pT3)
Extraprostatic Extension (pT3a)
Seminal Vesicle Invasion (pT3b)
Invasion Of Bladder, Restum (pT4)
No Evidence Of Primary Tumor (T0)
T1, Clinically Inapparent Tumor Not
Palpable Or Visible By Imaging (see Ajcc
Definition) (T1, NOS)
T1a, Clinically Inapparent Tumor Not
Palpable Or Visible By Imaging (see Ajcc
Definition) (T1a)
T1b, Clinically Inapparent Tumor Not
Palpable Or Visible By Imaging (see Ajcc
Definition) (T1b)
T1c, Clinically Inapparent Tumor Not
Palpable Or Visible By Imaging (see Ajcc
Definition) (T1c)
T2, Tumor Confined Within The Prostate
(see Ajcc Definition) (T2, NOS)
T2a, Tumor Confined Within The
Prostate (see Ajcc Definition) (T2a)
T2b, Tumor Confined Within The
Prostate (see Ajcc Definition) (T2b)
T3, Tumor Extends Through The
Prostatic Capsule (see Ajcc Definition)
(T3, NOS)
T3a, Tumor Extends Through The
Prostatic Capsule (see Ajcc Definition)
(T3a)
T3b, Tumor Extends Through The
Prostatic Capsule (see Ajcc Definition)
(T3b)
T4, Tumor Is Fixed Or Invades Adjacent
Structures (see Ajcc Definition) (T4,
NOS)
Primary Tumor Cannot Be Assessed
(TX)
Use The Ajcc Staging System Specified
In The Protocol (Use the AJCC staging
system specified in the protocol)
N Stage, Pathologic
No Regional Lymph Node Metastasis
(N0)
Metastatis In Regional Lymph Node Or
Nodes (see Ajcc Definition) (N1)
Regional Lymph Nodes Cannot Be
Assessed (NX)
Use The Ajcc Staging System Specified
In The Protocol (Use the AJCC staging
system specified in the protocol)
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Leukemia NCT01041703 Quality of Life - E2906
Assessment Compliance Form - 2951978v1.0
E2906 Assessment Compliance Form
Clofarabine or Daunorubicin Hydrochloride and Cytarabine
Followed By Decitabine or Observation in Treating Older
Patients With Newly Diagnosed Acute Myeloid Leukemia
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=7585B205-
CAA4-8BDD-E040-BB89AD430415
All rights reserved. Please visit https://medical-data-
models.org/forms/6886
E2906 Assessment Compliance
Form
Header
DCI Name
Registration Step (Place ID Label Here)
Patient Initials (Last, First)
ECOG Protocol Number
ECOG Protocol Number
ECOG Patient ID
ECOG Patient ID
Participating Group Protocol Number
Participating Group Patient ID
Institution/Affiliate
Unnamed2
Please mark an 'X' if data have been amended.
(Please circle amended items in red)
Date data amended (s M D Y)
On Treatment
On Treatment Report Period (Choose one)
100 Days Post Transplant (100 Days
Post Transplant)
At Transplant (At Transplant)
Baseline Step 1 (Baseline Step 1)
Cycle 1 - Consolidation (Cycle 1 -
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Consolidation)
Cycle 1 - Induction (Cycle 1 - Induction)
Cycle 2 - Consolidation (Cycle 2 -
Consolidation)
Cycle 2 - Induction (Cycle 2 - Induction)
E2906 Qol Assessment Not Completed
Date of Assessment (M D Y)
Section Ii - E1a05 Qol Assessment Not
Completed
Was the Assessment Form completed? (E2906
QOL)
Yes
No
Section Ii - Assessments Not Completed
Patient refusal
Yes
No
Unable to accomodate disability or language
needs
Yes
No
Specify disability or language
Patient did not show up in clinic/office
Yes
No
Specify reason patient did not show up
Staff unavailable
Yes
No
Patient not given form by staff
Yes
No
Patient too ill
Yes
No
Patient expired
Yes
No
Assessment not required per protocol
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Yes
No
Specify reason assessment is not required
Staff thought patient too ill
Yes
No
Other
Yes
No
Specify other reason
Section Iii Assessment Completed
Was Assessment self-administered?
Yes
No
How Was The Patient Assisted
Were the questions read aloud to patient
Yes
No
Did the patient require clarification of questions or
instructions
Yes
No
Did the patient require other assistance
Yes
No
Were the forms completed independently by
another person
Yes
No
What Was The Reason For Assistance
Did the patient have a language difficulty
(questions needed to tbe translated)
Yes
No
Specify language
Did the patient have a literacy difficulty (patient
could not read well enough)
Yes
No
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Was the patient disabled
Yes
No
Specify disability
Were the forms completed via a telephone
interview
Yes
No
Other
Yes
No
Specify other reason
Patient Bowel Function/uniscale
Questionnaire: Who Assisted Or
Completed Assessment?
Staff
Yes
No
Family
Yes
No
Friend
Yes
No
Other
Yes
No
Specify other person
Comments
Investigator Signature
Investigator Signature Date (M D Y)
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On-Study - Superficial Bladder Cancer -
On-Study Form - 2019333v2.31
Superficial Bladder Cancer - On-Study Form
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=99CD59C5-
A961-3FA4-E034-080020C9C0E0
All rights reserved. Please visit https://medical-data-
models.org/forms/6888
Superficial Bladder Cancer - On-
Study Form
Crf Header
Coordinating Group Protocol Number
Coordinating Group Code
Protocol Title
Patient Study ID, Coordinating Group
Patient Study ID, Participating Group
Participating Group Code
Institution Name
Affiliate Name
Patient Name, Last
Patient Name, First
Patient Name, Middle
Bladder: Form Administration
Person Completing Form, Last Name
Person Completing Form, First Name
Amended Data Ind
No (NO)
Unknown (UNKNOWN)
Yes (YES)
Bladder: Disease Description For
Superficial Bladder Carcinoma
Initial Diagnosis Date, Pathologic
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Prior Recent Recurrence Date
Pathologic Diagnosis Date
Prior Papillary Occurrences
Prior CIS Occurrences
Bladder Tumors Present
There Is More Than One Bladder Tumor
Present (multiple)
There Is One Bladder Tumor Present
(single)
Bladder Tumors Largest Diameter
The Bladder Tumors Largest Diameter Is
Less Than 3 Centimeters (< 3 cm)
The Bladder Tumors Largest Diameter Is
Equal To Or Greater Than 3 Centimeters
(> or = 3 cm)
Histologic Type
Adenocarcinoma (adenocarcinoma)
Cis Only (CIS only)
Other Specify (other, specify)
Papillary (papillary)
Papillary And Cis (papillary and CIS)
Small Cell Carcinoma (small cell
carcinoma)
Squamous Cell Carcinoma (squamous
cell carcinoma)
Transitional Cell Carcinoma (transitional
cell carcinoma)
Histologic Type, Other Name
Histologic Grade
Tumor Grade Cannot Be Assessed
(grade cannot be assessed (GX))
Moderately Differentiated (moderately
differentiated (G2))
Poorly Differentiated (poorly
differentiated (G3))
Well Differentiated (well differentiated
(G1))
T Stage, Pathologic
No Evidence Of Primary Tumor (T0)
Tumor Invades Subepithelial Connective
Tissue (T1)
Tumor Invades Superficial Muscles (inner
Half) (T2a)
Tumor Invades Deep Muscles (outer
Half) (T2b)
Tumor Invades Perivesical Tissue
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Microscopically (T3a)
Tumor Invades Perivesical Tissue
Macroscopically (extravesical Mass)
(T3b)
Inflammatory Carcinoma (T4)
Noninvasive Papillary Carcinoma (Ta)
Carcinoma In Situ: "flat Tumor" (Tis)
Primary Tumor Cannot Be Assessed (Tx)
Cytology Date
Cytology Result
Inflammatory Changes With Or Without
Dyscariosis (Inflammatory changes with
or without dyscariosis)
Moderate Dysplasia Or Papillary
Clusters (suspect) (Moderate dysplasia
or papillary clusters (suspect))
Negative (Negative)
Normal Tissue (Normal exfoliated cells)
Not Done (Not done)
Numerous Atypical And Malignant Cells
(Numerous atypical and malignant cells)
Other (Other, specify)
Positive (Positive)
Severe Dysplasia (Severe dysplasia)
Cytology Result, Other
Superficial Bladder Disease: Prior
Treatment Affecting The Bladder
Prior Intravesical Therapy Ind
No (No)
Unknown (unknown)
Yes (Yes)
Prior Immunotherapy Type
Bcg (BCG)
Interferon (Interferon)
Other (Other)
Prior Immunotherapy Count
Prior Immunotherapy Other Agent
Prior Intravesical Chemotherapy Type
Mmc (MMC)
Other (Other)
Thiotepa (Thiotepa)
Prior Intravesical Chemotherapy Count
Prior Intravesical Chemotherapy Other Agent
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Prior Pelvic RT Ind
No (No)
Unknown (unknown)
Yes (Yes)
Prior Surgery Ind
No (NO)
Unknown (UNKNOWN)
Yes (YES)
Prior Surgery Type
Patient Previously Had Other Surgery,
Specify (other, specify)
Patient Previosly Had A Partial
Cystectomy (partial cystectomy)
Patient Previosly Had A Radical
Cystectomy (radical cystectomy)
Patient Previosly Had A Turbt (TURBT)
Prior Surgery, TURBT Count
Prior Surgery, Other Type
Prior Other Therapy Ind
No (NO)
Unknown (UNKNOWN)
Yes (YES)
Prior Other Therapy Name
Allows Documentation Of Any Additional
Cooments
Comments
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Pathology - Ovarian Cancer - Pathology
Form - 2019349v2.31
Ovarian Cancer - Pathology Form
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=99CD59C5-
A982-3FA4-E034-080020C9C0E0
All rights reserved. Please visit https://medical-data-
models.org/forms/6890
Ovarian Cancer - Pathology Form
Crf Header
Coordinating Group Protocol Number
Coordinating Group Code
Protocol Title
Patient Study ID, Coordinating Group
Patient Study ID, Participating Group
Participating Group Code
Institution Name
Affiliate Name
Patient Name, Last
Patient Name, First
Patient Name, Middle
Ovarian Pathology: Form Administration
Person Completing Form, Last Name
Person Completing Form, First Name
Pathologist Name, Reviewing
Amended Data Ind
No (NO)
Unknown (UNKNOWN)
Yes (YES)
Ovarian Pathology: Disease Assessment
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Primary Site
Cervix (Cervix)
Endometrium (Endometrium)
Fallopian Tube (Fallopian tube)
Omentum (Omentum)
Other, Specify (Other, specify)
Ovary (Ovary)
Peritoneum (Peritoneal)
Uterine Sarcoma (Uterine Sarcoma)
Uterus (Uterus)
Vagina (Vagina)
Primary Site, Other
Primary Tumor Laterality
Bilateral (Bilateral)
Both (Both)
Left (Left)
Not A Paired Site (Not a Paired site)
Right (Right)
Unilateral, Side Not Specified (Unilateral,
side not specified)
Unknown (Unknown)
Assessment Type
Biopsy (Biopsy)
Biopsy, Not Otherwise Specified (Biopsy,
other)
Bone Scan (Bone scan)
Chest X-ray (Chest X-Ray)
Clinical Examination (Clinical
examination)
Ct Scan (CT Scan)
Cytology (Cytology)
Histology (Histology)
Laparoscopy (Laparoscopy)
Laparotomy (Laparotomy)
Mri (MRI (NMR))
Not Applicable (Not applicable)
Not Evaluated (Not evaluated)
Other (Other)
Other, Specify (Other, specify)
Pathologic (Pathologic)
Physical Exam (Physical exam)
Radiograph (Radiograph)
Spiral Ct Scan (Spiral CT scan)
Tumor Markers (Tumor Markers)
Ultrasound (Ultrasound)
Assessment Type, Cytology Site
Assessment Type, Specify
Assessment Type, Diagnostic
Biopsy, Other Site (Biopsy, other site)
Cytology, Effusion Evaluation, Specify
Site (Cytology, effusion evaluation)
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Fine Needle Aspiration (Fine needle
aspiration)
Laparoscopy (Laparoscopy)
Laparotomy (Laparotomy)
Other, Specify (Other)
Ultrasound Guided Biopsy Or Fine
Needle Aspiration (Ultrasound guided
biopsy/Fine needle aspiration)
Assessment Type, Diagnostic Cytology Site
Assessment Type, Other Diagnostic
Primary Surgery Type
Bilateral Salpingo-oophorectomy
(bilateral salpingo-oophorectomy)
Cervical Conization (cervical conization)
Omentectal Biopsy (Omentectal biopsy)
Omentectomy (omentectomy)
Other, Specify (other, specify)
Para-aortic Node Sampling/dissection
(para-aortic node sampling/dissection)
Partial Hysterectomy (partial
hysterectomy)
Pelvic Lymphadenectomy (pelvic
lymphadenectomy)
Pelvic Node Sampling/dissection (pelvic
node sampling/dissection)
Peritoneal Sampling (Peritoneal
sampling)
Radical Hysterectomy (radical
hysterectomy)
Radical Trachelectomy (radical
trachelectomy)
Total Hysterectomy (total hysterectomy)
Unilateral Salpingo-oophorectomy
(unilateral salpingo-oophorectomy)
Primary Surgery Other Type
Peritoneal Sample Count
Peritoneal Sample Site
Bladder Peritoneum (Bladder
peritoneum)
Cul-de-sac (Cul-de-sac)
Diaphragm (Diaphragm)
Other, Specify (Other, specify)
Paracolic Gutter Left (Paracolic gutter
left)
Paracolic Gutter Right (Paracolic gutter
right)
Pelvic Wall Left (Pelvic wall left)
Pelvic Wall Right (Pelvic wall right)
Peritoneal Sample Other Site
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Specimen Site
Bladder Peritoneum (Bladder
peritoneum)
Bowel Peritoneum/serosa (Bowel
peritoneum/serosa)
Cervix (Cervix)
Corpus (Corpus)
Cul-de-sac (Cul-de-sac)
Diaphragm (Diaphragm)
Endometrium (Endometrium)
Fallopian Tube (Fallopian tube)
Lymph Node(s) (Lymph node(s))
Metastatic Site (Metastatic site)
Omentum (Omentum)
Other (Other)
Ovary (Ovary)
Paracolic Gutter Left (Paracolic gutter
left)
Paracolic Gutter Right (Paracolic gutter
right)
Pelvic Wall Left (Pelvic wall left)
Pelvic Wall Right (Pelvic wall right)
Peritoneum/uterine Serosa
(Peritoneum/uterine serosa)
Vagina (Vagina)
Specimen Site, Lymph Node
Specimen Site, Metastatic
Specimen Site, Other
Lymph Nodes Type
Inguinal (inguinal)
Other, Specify (other, specify)
Para-aortic (para-aortic)
Pelvic (pelvic)
Scalene (scalene)
Lymph Nodes Other Type
Tumor Nodule Ind, 2 cm
No (No)
Unknown (Unknown)
Yes (Yes)
Tumor Nodule Ind, 1 cm
No (No)
Unknown (Unknown)
Yes (Yes)
Histologic Components, Mixed Epithelial
Histologic Type
Adenocarcinoma With Squamous
Differentiation (Adenocarcinoma with
Squamous Differentiation)
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Adenocarcinoma, Unspecified
(Adenocarcinoma, unspecified)
Adenofibroma (Adenofibroma)
Adenosarcoma (Adenosarcoma)
Adenosquamous (Adenosquamous)
Brenner Tumor (benign) (Brenner tumor
(benign))
Brenner Tumor (malignant) (Brenner
tumor (malignant))
Brenner Tumor Of Low Malignant
Potential (Brenner tumor of LMP)
Cancer With Dermoid Cyst, Specify
Types (Cancer with dermoid cyst)
Carcinosarcoma/mesodermal (mullerian)
Mixed Tumor
(Carcinosarcoma/Mesodermal
(Mullerian) mixed tumor)
Choriocarcinoma (Choriocarcinoma)
Clear Cell Carcinoma (Clear cell
carcinoma)
Clear Cell Cystadenofibroma (benign)
(Clear cell cystadenofibroma (benign))
Clear Cell Cystadenoma (benign) (Clear
cell cystadenoma (benign))
Clear Cell Tumor Of Low Malignant
Potential (Clear cell tumor of LMP)
Dysgerminoma (Dysgerminoma)
Embryonal Carcinoma (Embryonal
carcinoma)
Endodermal Sinus Tumor (yolk Sac
Tumor) (Endodermal sinus tumor)
Endometrial Stromal Sarcoma
(Endometrial stromal sarcoma)
Endometrioid Adenocarcinoma
(Endometrioid adenocarcinoma)
Endometrioid Cystadenofibroma (benign)
(Endometrioid cystadenofibroma
(benign))
Endometrioid Cystadenoma (benign)
(Endometrioid cystadenoma (benign))
Endometrioid Tumor Of Low Malignant
Potential (Endometrioid tumor of LMP)
Fibroma (Fibroma)
Germ Cell Tumor, Mixed (Germ cell
tumor, mixed)
Gestational Trophoblastic Disease
(Gestational trophoblastic disease)
Granulosa Cell Tumor (Granulosa cell
tumor)
Gynandroblastoma (Gynandroblastoma)
Mixed Epithelial Carcinoma, Specify
Components (Mixed epithelial
carcinoma)
Mixed Malignant Germ Cell Tumor,
Specify Components (Mixed malignant
germ cell tumor)
Mucinous Adenocarcinoma (Mucinous
adenocarcinoma)
Mucinous Cystadenofibroma (benign)
(Mucinous cystadenofibroma (benign))
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Mucinous Cystadenoma (benign)
(Mucinous cystadenoma (benign))
Mucinous Tumor Of Low Malignant
Potential (Mucinous tumor of LMP)
Other, Specify (Other, specify)
Ovarian Endometriosis (Ovarian
endometriosis)
Physiologic Cyst (corpus Luteum)
(Physiologic cyst (corpus luteum))
Physiologic Cyst (follicle) (Physiologic
cyst (follicle))
Polyembryoma (Polyembryoma)
Serous Adenocarcinoma (Serous
adenocarcinoma)
Serous Cystadenofibroma (benign)
(Serous cystadenofibroma (benign))
Serous Cystadenoma (benign) (Serous
cystadenoma (benign))
Serous Tumor Of Low Malignant
Potential (Serous tumor of LMP)
Sertoli-leydig Cell (androblastoma)
(Sertoli-Leydig cell (Androblastoma))
Sex-cord/stromal, Unclassified (Sex-
cord/stromal, unclassified)
Simple Cyst (Simple cyst)
Squamous Cell Carcinoma (Squamous
cell carcinoma)
Steroid/lipid Cell Tumor (Steroid/Lipid cell
tumor)
Teratoma, Immature, Specify
Components (Teratoma, immature)
Teratoma, Mature (Teratoma, mature)
Transitional Cell Carcinoma, Including
Brenner Tumor (Transitional cell
carcinoma (including Brenner))
Undifferentiated Carcinoma
(Undifferentiated carcinoma)
Histologic Type
Adenocarcinoma With Squamous
Differentiation (Adenocarcinoma with
Squamous Differentiation)
Adenocarcinoma, Unspecified
(Adenocarcinoma, unspecified)
Adenofibroma (Adenofibroma)
Adenosarcoma (Adenosarcoma)
Adenosquamous (Adenosquamous)
Brenner Tumor (benign) (Brenner tumor
(benign))
Brenner Tumor (malignant) (Brenner
tumor (malignant))
Brenner Tumor Of Low Malignant
Potential (Brenner tumor of LMP)
Cancer With Dermoid Cyst, Specify
Types (Cancer with dermoid cyst)
Carcinosarcoma/mesodermal (mullerian)
Mixed Tumor
(Carcinosarcoma/Mesodermal
(Mullerian) mixed tumor)
Choriocarcinoma (Choriocarcinoma)
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Clear Cell Carcinoma (Clear cell
carcinoma)
Clear Cell Cystadenofibroma (benign)
(Clear cell cystadenofibroma (benign))
Clear Cell Cystadenoma (benign) (Clear
cell cystadenoma (benign))
Clear Cell Tumor Of Low Malignant
Potential (Clear cell tumor of LMP)
Dysgerminoma (Dysgerminoma)
Embryonal Carcinoma (Embryonal
carcinoma)
Endodermal Sinus Tumor (yolk Sac
Tumor) (Endodermal sinus tumor)
Endometrial Stromal Sarcoma
(Endometrial stromal sarcoma)
Endometrioid Adenocarcinoma
(Endometrioid adenocarcinoma)
Endometrioid Cystadenofibroma (benign)
(Endometrioid cystadenofibroma
(benign))
Endometrioid Cystadenoma (benign)
(Endometrioid cystadenoma (benign))
Endometrioid Tumor Of Low Malignant
Potential (Endometrioid tumor of LMP)
Fibroma (Fibroma)
Germ Cell Tumor, Mixed (Germ cell
tumor, mixed)
Gestational Trophoblastic Disease
(Gestational trophoblastic disease)
Granulosa Cell Tumor (Granulosa cell
tumor)
Gynandroblastoma (Gynandroblastoma)
Mixed Epithelial Carcinoma, Specify
Components (Mixed epithelial
carcinoma)
Mixed Malignant Germ Cell Tumor,
Specify Components (Mixed malignant
germ cell tumor)
Mucinous Adenocarcinoma (Mucinous
adenocarcinoma)
Mucinous Cystadenofibroma (benign)
(Mucinous cystadenofibroma (benign))
Mucinous Cystadenoma (benign)
(Mucinous cystadenoma (benign))
Mucinous Tumor Of Low Malignant
Potential (Mucinous tumor of LMP)
Other, Specify (Other, specify)
Ovarian Endometriosis (Ovarian
endometriosis)
Physiologic Cyst (corpus Luteum)
(Physiologic cyst (corpus luteum))
Physiologic Cyst (follicle) (Physiologic
cyst (follicle))
Polyembryoma (Polyembryoma)
Serous Adenocarcinoma (Serous
adenocarcinoma)
Serous Cystadenofibroma (benign)
(Serous cystadenofibroma (benign))
Serous Cystadenoma (benign) (Serous
cystadenoma (benign))
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Serous Tumor Of Low Malignant
Potential (Serous tumor of LMP)
Sertoli-leydig Cell (androblastoma)
(Sertoli-Leydig cell (Androblastoma))
Sex-cord/stromal, Unclassified (Sex-
cord/stromal, unclassified)
Simple Cyst (Simple cyst)
Squamous Cell Carcinoma (Squamous
cell carcinoma)
Steroid/lipid Cell Tumor (Steroid/Lipid cell
tumor)
Teratoma, Immature, Specify
Components (Teratoma, immature)
Teratoma, Mature (Teratoma, mature)
Transitional Cell Carcinoma, Including
Brenner Tumor (Transitional cell
carcinoma (including Brenner))
Undifferentiated Carcinoma
(Undifferentiated carcinoma)
Histologic Type
Adenocarcinoma With Squamous
Differentiation (Adenocarcinoma with
Squamous Differentiation)
Adenocarcinoma, Unspecified
(Adenocarcinoma, unspecified)
Adenofibroma (Adenofibroma)
Adenosarcoma (Adenosarcoma)
Adenosquamous (Adenosquamous)
Brenner Tumor (benign) (Brenner tumor
(benign))
Brenner Tumor (malignant) (Brenner
tumor (malignant))
Brenner Tumor Of Low Malignant
Potential (Brenner tumor of LMP)
Cancer With Dermoid Cyst, Specify
Types (Cancer with dermoid cyst)
Carcinosarcoma/mesodermal (mullerian)
Mixed Tumor
(Carcinosarcoma/Mesodermal
(Mullerian) mixed tumor)
Choriocarcinoma (Choriocarcinoma)
Clear Cell Carcinoma (Clear cell
carcinoma)
Clear Cell Cystadenofibroma (benign)
(Clear cell cystadenofibroma (benign))
Clear Cell Cystadenoma (benign) (Clear
cell cystadenoma (benign))
Clear Cell Tumor Of Low Malignant
Potential (Clear cell tumor of LMP)
Dysgerminoma (Dysgerminoma)
Embryonal Carcinoma (Embryonal
carcinoma)
Endodermal Sinus Tumor (yolk Sac
Tumor) (Endodermal sinus tumor)
Endometrial Stromal Sarcoma
(Endometrial stromal sarcoma)
Endometrioid Adenocarcinoma
(Endometrioid adenocarcinoma)
Endometrioid Cystadenofibroma (benign)
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(Endometrioid cystadenofibroma
(benign))
Endometrioid Cystadenoma (benign)
(Endometrioid cystadenoma (benign))
Endometrioid Tumor Of Low Malignant
Potential (Endometrioid tumor of LMP)
Fibroma (Fibroma)
Germ Cell Tumor, Mixed (Germ cell
tumor, mixed)
Gestational Trophoblastic Disease
(Gestational trophoblastic disease)
Granulosa Cell Tumor (Granulosa cell
tumor)
Gynandroblastoma (Gynandroblastoma)
Mixed Epithelial Carcinoma, Specify
Components (Mixed epithelial
carcinoma)
Mixed Malignant Germ Cell Tumor,
Specify Components (Mixed malignant
germ cell tumor)
Mucinous Adenocarcinoma (Mucinous
adenocarcinoma)
Mucinous Cystadenofibroma (benign)
(Mucinous cystadenofibroma (benign))
Mucinous Cystadenoma (benign)
(Mucinous cystadenoma (benign))
Mucinous Tumor Of Low Malignant
Potential (Mucinous tumor of LMP)
Other, Specify (Other, specify)
Ovarian Endometriosis (Ovarian
endometriosis)
Physiologic Cyst (corpus Luteum)
(Physiologic cyst (corpus luteum))
Physiologic Cyst (follicle) (Physiologic
cyst (follicle))
Polyembryoma (Polyembryoma)
Serous Adenocarcinoma (Serous
adenocarcinoma)
Serous Cystadenofibroma (benign)
(Serous cystadenofibroma (benign))
Serous Cystadenoma (benign) (Serous
cystadenoma (benign))
Serous Tumor Of Low Malignant
Potential (Serous tumor of LMP)
Sertoli-leydig Cell (androblastoma)
(Sertoli-Leydig cell (Androblastoma))
Sex-cord/stromal, Unclassified (Sex-
cord/stromal, unclassified)
Simple Cyst (Simple cyst)
Squamous Cell Carcinoma (Squamous
cell carcinoma)
Steroid/lipid Cell Tumor (Steroid/Lipid cell
tumor)
Teratoma, Immature, Specify
Components (Teratoma, immature)
Teratoma, Mature (Teratoma, mature)
Transitional Cell Carcinoma, Including
Brenner Tumor (Transitional cell
carcinoma (including Brenner))
Undifferentiated Carcinoma
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(Undifferentiated carcinoma)
Histologic Components, Immature Teratoma
Histologic Components, Mixed Germ Cell
Histologic Type, Dermoid Cyst
Histologic Type, Other Name
Histologic Type, Other Name
Histologic Type, Other Name
Histologic Grade
Grade 1-well Differentiated (1)
Grade 2-moderately Differentiated (2)
Grade 3-poorly Differentiated (3)
Indeterminate (Indeterminate)
Not Applicable (Not applicable)
Grade Unknown (Unknown)
Tumor Extension
Confined To Ovary (Confined to ovary)
Extension Beyond Pelvic Region
(Extension beyond pelvic region)
Extension To Pelvic Tissue Other Than
Uterus And/or Tubes (Extension to pelvic
tissue other than uterus and/or tubes)
Extension To Uterus And/or Tubes
(Extension to uterus and/or tubes)
Lymph Node(s) Examined Number
Lymph Node(s) Positive Number
Ascites Ind
No (No)
Unknown (unknown)
Yes (Yes)
Ascites/Aspiration Status
Negative (Negative)
Positive (Positive)
Unknown (Unknown)
Pleural Effusion Ind
No (No)
Unknown (Unknown)
Yes (Yes)
Residual Disease
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Ovary, Right Examination Ind
No (No)
Unknown (Unknown)
Yes (Yes)
Ovary, Left Examination Ind
No (No)
Unknown (Unknown)
Yes (Yes)
Ovary, Right Surface Involved Ind
No (No)
Unknown (Unknown)
Yes (Yes)
Ovary, Left Surface Involved Ind
No (No)
Unknown (Unknown)
Yes (Yes)
Ovary, Right Capsule Prior Rupture Ind
No (No)
Unknown (Unknown)
Yes (Yes)
Ovary, Left Capsule Prior Rupture Ind
No (No)
Unknown (Unknown)
Yes (Yes)
Ovary, Right Capsule Surgery Rupture Ind
No (No)
Unknown (Unknown)
Yes (Yes)
Ovary, Left Capsule Surgery Rupture Ind
No (No)
Unknown (Unknown)
Yes (Yes)
T Stage, Pathologic
Refer To Figo And/or Ajcc Staging
Guidelines Per Protocol (T0)
Refer To Figo And/or Ajcc Staging
Guidelines Per Protocol (T1, NOS)
Refer To Figo And/or Ajcc Staging
Guidelines Per Protocol (T1a)
Refer To Figo And/or Ajcc Staging
Guidelines Per Protocol (T1b)
Refer To Figo And/or Ajcc Staging
Guidelines Per Protocol (T1c)
Refer To Figo And/or Ajcc Staging
Guidelines Per Protocol (T2, NOS)
Refer To Figo And/or Ajcc Staging
Guidelines Per Protocol (T2a)
Refer To Figo And/or Ajcc Staging
Guidelines Per Protocol (T2b)
Refer To Figo And/or Ajcc Staging
Guidelines Per Protocol (T3, NOS)
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Refer To Figo And/or Ajcc Staging
Guidelines Per Protocol (T3a)
Refer To Figo And/or Ajcc Staging
Guidelines Per Protocol (T3b)
Refer To Figo And/or Ajcc Staging
Guidelines Per Protocol (T4, NOS)
Refer To Figo And/or Ajcc Staging
Guidelines Per Protocol (TX)
N Stage, Pathologic
No Positive Lymph Nodes Present (n0)
(N0)
Positive Lymph Nodes Present - See
Figo And Ajcc Staging For Complete
Details (N1)
Positive Lymph Nodes Present - See
Figo And Ajcc Staging For Complete
Details (N2)
Lymph Nodes Cannot Be Assessed (nx)
(NX)
M Stage, Pathologic
No Metastases Present (m0) (M0)
Metastases Present - See Figo And Ajcc
Staging For Complete Details (M1)
Metastases Cannot Be Assessed (mx)
(MX)
Stage Grouping
Refer To Figo Staging For Specific
Gynecologic Cancer (I)
Refer To Figo Staging For Specific
Gynecologic Cancer (IA)
Refer To Figo Staging For Specific
Gynecologic Cancer (IA1)
Refer To Figo Staging For Specific
Gynecologic Cancer (IA2)
Refer To Figo Staging For Specific
Gynecologic Cancer (IB)
Refer To Figo Staging For Specific
Gynecologic Cancer (IB1)
Refer To Figo Staging For Specific
Gynecologic Cancer (IB2)
Refer To Figo Staging For Specific
Gynecologic Cancer (IC)
Refer To Figo Staging For Specific
Gynecologic Cancer (II)
Refer To Figo Staging For Specific
Gynecologic Cancer (IIA)
Refer To Figo Staging For Specific
Gynecologic Cancer (IIB)
Refer To Figo Staging For Specific
Gynecologic Cancer (IIC)
Refer To Figo Staging For Specific
Gynecologic Cancer (III)
Refer To Figo Staging For Specific
Gynecologic Cancer (IIIA)
Refer To Figo Staging For Specific
Gynecologic Cancer (IIIB)
Refer To Figo Staging For Specific
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Gynecologic Cancer (IIIC)
Refer To Figo Staging For Specific
Gynecologic Cancer (IV)
Refer To Figo Staging For Specific
Gynecologic Cancer (IVA)
Refer To Figo Staging For Specific
Gynecologic Cancer (IVB)
Stage Grouping Cannot Be Assessed (X)
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On-Study - Advanced Melanoma-On-study
Form - 2020195v2.31
Advanced Melanoma-On-study Form
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=99CD59C5-
A996-3FA4-E034-080020C9C0E0
All rights reserved. Please visit https://medical-data-
models.org/forms/6893
Advanced Melanoma-On-study Form
Crf Header
Coordinating Group Protocol Number
Coordinating Group Code
Protocol Title
Patient Study ID, Coordinating Group
Patient Study ID, Participating Group
Participating Group Code
Institution Name
Affiliate Name
Patient Name, Last
Patient Name, First
Patient Name, Middle
Melanoma: Form Administration
Person Completing Form, Last Name
Person Completing Form, First Name
Amended Data Ind
No (NO)
Unknown (UNKNOWN)
Yes (YES)
Melanoma (advanced): Disease
Description
Initial Diagnosis Date, Pathologic
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Primary Surgery Type
Biopsy (Biopsy)
Excision Of Local Recurrence (Excision
of local recurrence)
Excision Of Satellite Or In-transit
Metastases (Excision of satellite or in-
transit metastases)
Excision/wide Excision Of Primary
(Excision/wide excision of primary)
Lymph Node Dissection (Lymph node
dissection)
Other, Specify (Other, specify)
Primary Surgery, Other Type
Primary Surgery Date
Advanced Disease Registration Status
Initial Diagnosis (Initial Diagnosis)
Recurrence (Recurrence)
Primary Site
Anogenital (non-mucosal) (Anogenital
(non-mucosal))
Head (Head)
Lower Extremity (Lower extremity)
Mucosal (Mucosal)
Neck (Neck)
Ocular (Ocular)
Other, Specify (Other, specify)
Subungual (Subungual)
Trunk (Trunk)
Unknown (Unknown)
Upper Extremity (Upper extremity)
Primary Site, Other
Primary Tumor Resection Status
Not Recurrent, Resected, No Residual
Tumor (Not recurrent, resected, no
residual tumor)
Not Recurrent, Resected, Residual
Tumor (Not recurrent, resected, residual
tumor)
Recurrent (Recurrent)
Unresected (Unresected)
Involvement Pattern
Acral Lentiginous (acral lentiginous)
Lentigo Maligna Melanoma (lentigo
maligna melanoma)
Nodular (nodular)
Other, Specify (other, specify)
Superficial Spreading (superficial
spreading)
Involvement Pattern, Other
2 / 6
On-Study - Advanced Melanoma-On-study Form - 2020195v2.31
Breslow Depth
Lab, Chemistry, Lactate Dehydrogenase
Clark Level
I-above Basal Lamina (in Situ) (I-above
basal lamina (in situ))
Ii- Extension Into Papillary Dermis (II-
extension into papillary dermis)
Iii-interface Papillary-reticular Dermis (III-
interface papillary-reticular dermis)
Iv-reticular Dermis (IV-reticular dermis)
V-subcutaneous Fat (V-subcutaneous
fat)
Ulceration Ind
No (No)
Unknown (unknown)
Yes (Yes)
Lymph Node(s) Examined Number
Lymph Node(s) Positive Number
Lymph Node Involvement
Lymph Node(s) With Any
Macroscopic/gross Metastases (Lymph
node(s) with any macroscopic/gross
metastases)
Lymph Node(s) With Only Microscopic
Metastases (Lymph node(s) with only
microscopic metastases)
No Lymph Node Involvement (No lymph
node involvement)
Unknown (Unknown)
Intransit metastases/satellite lesions Ind
No (No)
Unknown (Unknown)
Yes (Yes)
Lymph Nodes, Matted Ind
No (No)
Unknown (Unknown)
Yes (Yes)
Metastatic Site
Bone (Bone)
Brain (Brain)
Distant Lymph Nodes (Distant lymph
nodes)
Distant Skin/subcutaneous Tissue
(Distant skin/subcutaneous tissue)
Distant Soft Tissue Metastasis (Distant
soft tissue metastasis)
Liver (Liver)
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Lung (Lung)
None (None)
Other Cns (Other CNS)
Other Non-visceral, Specify (Other non-
visceral, specify)
Other Visceral, Specify (Other visceral,
specify)
Metastatic Site, Other Visceral
Metastatic Site, Other Non-visceral
T Stage, Pathologic
T1a, According To Ajcc Guidelines (T1a)
T1b, According To Ajcc Guidelines (T1b)
T2a, According To Ajcc Guidelines (T2a)
T2b, According To Ajcc Guidelines (T2b)
T3a, According To Ajcc Guidelines (T3a)
T3b, According To Ajcc Guidelines (T3b)
T4a, According To Ajcc Guidelines (T4a)
T4b, According To Ajcc Guidelines (T4b)
Tx, According To Ajcc Guidelines (TX)
N Stage, Pathologic
N0, According To Ajcc Guidelines (N0)
N1a, According To Ajcc Guidelines (N1a)
N1b, According To Ajcc Guidelines (N1b)
N2a, According To Ajcc Guidelines (N2a)
N2b, According To Ajcc Guidelines (N2b)
N2c, According To Ajcc Guidelines (N2c)
N3, According To Ajcc Guidelines (N3)
Nx, According To Ajcc Guidelines (NX)
M Stage, Pathologic
M0, According To Ajcc Guidelines (M0)
M1a, According To Ajcc Guidelines
(M1a)
M1b, According To Ajcc Guidelines
(M1b)
M1c, According To Ajcc Guidelines (M1c)
Mx, According To Ajcc Guidelines (MX)
Melanoma (advanced): Sentinel Node
Biopsy
Sentinel Node Biopsy Ind
No (NO)
Unknown (UNKNOWN)
Yes (YES)
Sentinel Node Biopsy Date
Sentinel Node(s) Examined Number
Sentinel Node(s) Positive Number
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Sentinel Node Size
Sentinel Node Biopsy Results
Negative (Negative)
Positive (Positive)
Melanoma (advanced): Prior Treatment
Prior Surgery Ind
No (NO)
Unknown (UNKNOWN)
Yes (YES)
Prior Surgery Type
Biopsy (Biopsy)
Excision Of Distant Metastases (Excision
of distant metastases)
Excision Of Local Recurrence (Excision
of local recurrence)
Excision Of Satellite Or In-transit
Metastases (Excision of satellite or in-
transit metastases)
Excision/wide Excision Of Primary
(Excision/wide excision of primary)
Lymph Node Dissection (Lymph node
dissection)
Other, Specify (Other, specify)
Sentinel Lymph Node Biopsy (Sentinel
lymph node biopsy)
Prior Surgery Type, Other
Primary Surgery Date
Prior RT Ind
No (NO)
Unknown (UNKNOWN)
Yes (YES)
RT Site
Bone (Bone)
Brain (Brain)
Head And Neck (Head and Neck)
Lymph Nodes (soft Tissue) (Lymph
nodes (soft tissue))
Other, Specify (Other, specify)
Prior RT End Date
RT Site, Other
Prior Vaccine Ind
No (No)
Unknown (unknown)
5 / 6
On-Study - Advanced Melanoma-On-study Form - 2020195v2.31
Yes (Yes)
Prior Vaccine Type
Prior Vaccination Date
Prior ILP Ind
No (No)
Unknown (unknown)
Yes (Yes)
Prior ILP, specify
Prior ILP Date
Prior Hormonal Therapy Ind
No (NO)
Unknown (UNKNOWN)
Yes (YES)
Prior Chemotherapy Ind
No (NO)
Unknown (UNKNOWN)
Yes (YES)
Prior Immunotherapy Ind
No (NO)
Unknown (UNKNOWN)
Yes (YES)
Melanoma: Prior Treatment-systemic
Regimens
Prior Treatment Regimen Name(s)
Prior Treatment Regimen Begin Date
Prior Treatment Regimen End Date
Prior Treatment Regimen Type
Allows Documentation Of Any Additional
Cooments
Comments
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On-Study - Primary Ovarian Cancer - On-
Study Form - 2019341v2.31
Primary Ovarian Cancer - On-Study Form
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=99CD59C5-
A972-3FA4-E034-080020C9C0E0
All rights reserved. Please visit https://medical-data-
models.org/forms/6896
Primary Ovarian Cancer - On-Study
Form
Crf Header
Coordinating Group Protocol Number
Coordinating Group Code
Protocol Title
Patient Study ID, Coordinating Group
Patient Study ID, Participating Group
Participating Group Code
Institution Name
Affiliate Name
Patient Name, Last
Patient Name, First
Patient Name, Middle
Ovarian: Form Administration
Person Completing Form, Last Name
Person Completing Form, First Name
Amended Data Ind
No (NO)
Unknown (UNKNOWN)
Yes (YES)
Ovarian: Disease Description
Primary Tumor Diagnosis Date
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Primary Site
Cervix (Cervix)
Endometrium (Endometrium)
Fallopian Tube (Fallopian tube)
Omentum (Omentum)
Other, Specify (Other, specify)
Ovary (Ovary)
Peritoneum (Peritoneal)
Uterine Sarcoma (Uterine Sarcoma)
Uterus (Uterus)
Vagina (Vagina)
Primary Site, Other
Stage Grouping
Refer To Figo Staging For Specific
Gynecologic Cancer (I)
Refer To Figo Staging For Specific
Gynecologic Cancer (IA)
Refer To Figo Staging For Specific
Gynecologic Cancer (IA1)
Refer To Figo Staging For Specific
Gynecologic Cancer (IA2)
Refer To Figo Staging For Specific
Gynecologic Cancer (IB)
Refer To Figo Staging For Specific
Gynecologic Cancer (IB1)
Refer To Figo Staging For Specific
Gynecologic Cancer (IB2)
Refer To Figo Staging For Specific
Gynecologic Cancer (IC)
Refer To Figo Staging For Specific
Gynecologic Cancer (II)
Refer To Figo Staging For Specific
Gynecologic Cancer (IIA)
Refer To Figo Staging For Specific
Gynecologic Cancer (IIB)
Refer To Figo Staging For Specific
Gynecologic Cancer (IIC)
Refer To Figo Staging For Specific
Gynecologic Cancer (III)
Refer To Figo Staging For Specific
Gynecologic Cancer (IIIA)
Refer To Figo Staging For Specific
Gynecologic Cancer (IIIB)
Refer To Figo Staging For Specific
Gynecologic Cancer (IIIC)
Refer To Figo Staging For Specific
Gynecologic Cancer (IV)
Refer To Figo Staging For Specific
Gynecologic Cancer (IVA)
Refer To Figo Staging For Specific
Gynecologic Cancer (IVB)
Stage Grouping Cannot Be Assessed (X)
Histologic Grade
Grade 1-well Differentiated (1)
Grade 2-moderately Differentiated (2)
Grade 3-poorly Differentiated (3)
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Indeterminate (Indeterminate)
Not Applicable (Not applicable)
Grade Unknown (Unknown)
Histologic Type
Adenocarcinoma With Squamous
Differentiation (Adenocarcinoma with
Squamous Differentiation)
Adenocarcinoma, Unspecified
(Adenocarcinoma, unspecified)
Adenofibroma (Adenofibroma)
Adenosarcoma (Adenosarcoma)
Adenosquamous (Adenosquamous)
Brenner Tumor (benign) (Brenner tumor
(benign))
Brenner Tumor (malignant) (Brenner
tumor (malignant))
Brenner Tumor Of Low Malignant
Potential (Brenner tumor of LMP)
Cancer With Dermoid Cyst, Specify
Types (Cancer with dermoid cyst)
Carcinosarcoma/mesodermal (mullerian)
Mixed Tumor
(Carcinosarcoma/Mesodermal
(Mullerian) mixed tumor)
Choriocarcinoma (Choriocarcinoma)
Clear Cell Carcinoma (Clear cell
carcinoma)
Clear Cell Cystadenofibroma (benign)
(Clear cell cystadenofibroma (benign))
Clear Cell Cystadenoma (benign) (Clear
cell cystadenoma (benign))
Clear Cell Tumor Of Low Malignant
Potential (Clear cell tumor of LMP)
Dysgerminoma (Dysgerminoma)
Embryonal Carcinoma (Embryonal
carcinoma)
Endodermal Sinus Tumor (yolk Sac
Tumor) (Endodermal sinus tumor)
Endometrial Stromal Sarcoma
(Endometrial stromal sarcoma)
Endometrioid Adenocarcinoma
(Endometrioid adenocarcinoma)
Endometrioid Cystadenofibroma (benign)
(Endometrioid cystadenofibroma
(benign))
Endometrioid Cystadenoma (benign)
(Endometrioid cystadenoma (benign))
Endometrioid Tumor Of Low Malignant
Potential (Endometrioid tumor of LMP)
Fibroma (Fibroma)
Germ Cell Tumor, Mixed (Germ cell
tumor, mixed)
Gestational Trophoblastic Disease
(Gestational trophoblastic disease)
Granulosa Cell Tumor (Granulosa cell
tumor)
Gynandroblastoma (Gynandroblastoma)
Mixed Epithelial Carcinoma, Specify
Components (Mixed epithelial
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carcinoma)
Mixed Malignant Germ Cell Tumor,
Specify Components (Mixed malignant
germ cell tumor)
Mucinous Adenocarcinoma (Mucinous
adenocarcinoma)
Mucinous Cystadenofibroma (benign)
(Mucinous cystadenofibroma (benign))
Mucinous Cystadenoma (benign)
(Mucinous cystadenoma (benign))
Mucinous Tumor Of Low Malignant
Potential (Mucinous tumor of LMP)
Other, Specify (Other, specify)
Ovarian Endometriosis (Ovarian
endometriosis)
Physiologic Cyst (corpus Luteum)
(Physiologic cyst (corpus luteum))
Physiologic Cyst (follicle) (Physiologic
cyst (follicle))
Polyembryoma (Polyembryoma)
Serous Adenocarcinoma (Serous
adenocarcinoma)
Serous Cystadenofibroma (benign)
(Serous cystadenofibroma (benign))
Serous Cystadenoma (benign) (Serous
cystadenoma (benign))
Serous Tumor Of Low Malignant
Potential (Serous tumor of LMP)
Sertoli-leydig Cell (androblastoma)
(Sertoli-Leydig cell (Androblastoma))
Sex-cord/stromal, Unclassified (Sex-
cord/stromal, unclassified)
Simple Cyst (Simple cyst)
Squamous Cell Carcinoma (Squamous
cell carcinoma)
Steroid/lipid Cell Tumor (Steroid/Lipid cell
tumor)
Teratoma, Immature, Specify
Components (Teratoma, immature)
Teratoma, Mature (Teratoma, mature)
Transitional Cell Carcinoma, Including
Brenner Tumor (Transitional cell
carcinoma (including Brenner))
Undifferentiated Carcinoma
(Undifferentiated carcinoma)
Histologic Type, Other Name
Prior Surgery Ind
No (NO)
Unknown (UNKNOWN)
Yes (YES)
Ovarian: Findings From Primary Surgery
Primary Surgery Type
Bilateral Salpingo-oophorectomy
(bilateral salpingo-oophorectomy)
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Cervical Conization (cervical conization)
Omentectal Biopsy (Omentectal biopsy)
Omentectomy (omentectomy)
Other, Specify (other, specify)
Para-aortic Node Sampling/dissection
(para-aortic node sampling/dissection)
Partial Hysterectomy (partial
hysterectomy)
Pelvic Lymphadenectomy (pelvic
lymphadenectomy)
Pelvic Node Sampling/dissection (pelvic
node sampling/dissection)
Peritoneal Sampling (Peritoneal
sampling)
Radical Hysterectomy (radical
hysterectomy)
Radical Trachelectomy (radical
trachelectomy)
Total Hysterectomy (total hysterectomy)
Unilateral Salpingo-oophorectomy
(unilateral salpingo-oophorectomy)
Primary Surgery Other Type
Primary Surgery Date
Residual Disease
Ascites Ind
No (No)
Unknown (unknown)
Yes (Yes)
Pleural Effusion Ind
No (No)
Unknown (Unknown)
Yes (Yes)
Lymph Nodes Type
Inguinal (inguinal)
Other, Specify (other, specify)
Para-aortic (para-aortic)
Pelvic (pelvic)
Scalene (scalene)
Lymph Node Involvement
The Node Is Considered To Be Negative
But Not Based Upon Histological
Evaluation. (clinically negative)
The Node Is Considered To Be Positive
But Not Based Upon Histological
Evaluation. (clinically positive)
Equivocal (equivocal)
Negative (negative)
Not Evaluated (not evaluated)
The Node Is Considered To Be Negative
Based Upon Histological Evaluation.
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(pathologically negative)
The Node Is Considered To Be Positive
Based Upon Histological Evaluation.
(pathologically positive)
Positive (positive)
Unknown (unknown)
Assessment Type
Biopsy (Biopsy)
Biopsy, Not Otherwise Specified (Biopsy,
other)
Bone Scan (Bone scan)
Chest X-ray (Chest X-Ray)
Clinical Examination (Clinical
examination)
Ct Scan (CT Scan)
Cytology (Cytology)
Histology (Histology)
Laparoscopy (Laparoscopy)
Laparotomy (Laparotomy)
Mri (MRI (NMR))
Not Applicable (Not applicable)
Not Evaluated (Not evaluated)
Other (Other)
Other, Specify (Other, specify)
Pathologic (Pathologic)
Physical Exam (Physical exam)
Radiograph (Radiograph)
Spiral Ct Scan (Spiral CT scan)
Tumor Markers (Tumor Markers)
Ultrasound (Ultrasound)
Lymph Nodes Other Type
Ovarian: Post-operative Findings
Following Surgery
Disease Status, Post-operative
Clinical/Radiologic
No (No)
Not Assessed (not assessed)
Unknown (unknown)
Yes (Yes)
Disease Assessment, Measurable Ind
No (No)
Unknown (Unknown)
Yes (Yes)
Tumor Marker, CA125 Result
Tumor Marker, CA125 Date
Disease Involvement Site
Abdomen (other Than Above) (abdomen
(other than above))
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Bladder (bladder)
Bone (bone)
Colon (colon)
Liver (liver)
Lung (lung)
Other, Specify (other, specify)
Pelvic (other Than Above) (pelvic (other
than above))
Disease Involvement Site, Other
Allows Documentation Of Any Additional
Cooments
Comments
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On-Study - Muscle Invasive Bladder Cancer
- On-Study Form - 2019331v2.31
Muscle Invasive Bladder Cancer - On-Study Form
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=99CD59C5-
A95D-3FA4-E034-080020C9C0E0
All rights reserved. Please visit https://medical-data-
models.org/forms/6899
Muscle Invasive Bladder Cancer -
On-Study Form
Crf Header
Coordinating Group Protocol Number
Coordinating Group Code
Protocol Title
Patient Study ID, Coordinating Group
Patient Study ID, Participating Group
Participating Group Code
Institution Name
Affiliate Name
Patient Name, Last
Patient Name, First
Patient Name, Middle
Bladder: Form Administration
Person Completing Form, Last Name
Person Completing Form, First Name
Amended Data Ind
No (NO)
Unknown (UNKNOWN)
Yes (YES)
Bladder: Disease Description For Muscle
Invasive Bladder Cancer
Prior Superficial Disease Ind
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No (No)
Unknown (unknown)
Yes (Yes)
Prior Papillary Occurrences
Prior CIS Occurrences
Initial Diagnosis Date, Pathologic
Initial Diagnosis Date, Pathologic
Pathologic Diagnosis Date
Prior Recent Recurrence Date
Histologic Type
Adenocarcinoma (adenocarcinoma)
Cis Only (CIS only)
Other Specify (other, specify)
Papillary (papillary)
Papillary And Cis (papillary and CIS)
Small Cell Carcinoma (small cell
carcinoma)
Squamous Cell Carcinoma (squamous
cell carcinoma)
Transitional Cell Carcinoma (transitional
cell carcinoma)
Histologic Type, Other Name
Histologic Grade
Tumor Grade Cannot Be Assessed
(grade cannot be assessed (GX))
Moderately Differentiated (moderately
differentiated (G2))
Poorly Differentiated (poorly
differentiated (G3))
Well Differentiated (well differentiated
(G1))
T Stage, Pathologic
No Evidence Of Primary Tumor (T0)
Tumor Invades Subepithelial Connective
Tissue (T1)
Tumor Invades Superficial Muscles (inner
Half) (T2a)
Tumor Invades Deep Muscles (outer
Half) (T2b)
Tumor Invades Perivesical Tissue
Microscopically (T3a)
Tumor Invades Perivesical Tissue
Macroscopically (extravesical Mass)
(T3b)
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Inflammatory Carcinoma (T4)
Noninvasive Papillary Carcinoma (Ta)
Carcinoma In Situ: "flat Tumor" (Tis)
Primary Tumor Cannot Be Assessed (Tx)
T Stage, Clinical
No Evidence Of Primary Tumor (T0)
Tumor 2 Cm Or Less In Greatest
Dimension (T1)
Tumor More Than 0.1 Cm But Not More
Than 0.5 Cm In Greatest Dimension
(T1a)
Tumor More Than 0.5 Cm But Not More
Than 1 Cm In Greatest Dimension (T1b)
Tumor More Than 1 Cm But Not More
Than 2 Cm In Greatest Dimension (T1c)
Microinvasion 0.1 Cm Or Less In
Greatest Dimension (T1mic)
Tumor More Than 2 Cm But Not More
Than 5 Cm In Greatest Dimension (T2)
Tumor More Than 5 Cm In Greatest
Dimension (T3)
Tumor Of Any Size With Direct Extension
To (a) Chest Wall Or (b) Skin, Only As
Described Below (T4)
Extension To Chest Wall (T4a)
Edema (including Peau D'orange) Or
Ulceration Of The Skin Of The Breast Or
Satellite Skin Nodules Confined To The
Same Breast (T4b)
Both T4a And T4b (T4c)
Inflammatory Carcinoma (T4d)
Carcinoma In Situ: Intraductal
Carcinoma, Lobular Carcinoma In Situ,
Or Paget's Disease Of The Nipple With
No Tumor (Tis)
Primary Tumor Cannot Be Assessed
(TX)
N Stage, Pathologic
Metastasis In A Single Lymph Node, 2
Cm Or Less In Greatest Dimension (N1)
Metastasis In A Single Lymph Node,
More Than 2 Cm But Not More Than 5
Cm In Greatest Dimension; Or Multiple
Lymph Nodes, None More Than 5 Cm In
Greatest Dimension (N2)
Metastasis In A Lymph Node More Than
5 Cm In Greatest Dimension (N3)
No Regional Lymph Node Metastasis
(NO)
Regional Lymph Nodes Cannot Be
Assessed (Nx)
N Stage, Clinical
No Regional Lymph Node Metastasis
(N0)
Metastasis In A Single Lymph Node, 2
Cm Or Less In Greatest Dimension (N1)
Metastasis In A Single Lymph Node,
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More Than 2 Cm But Not More Than 5
Cm In Greatest Dimension; Or Multiple
Lymph Nodes, None More Than 5 Cm In
Greatest Dimension (N2)
Metastasis In A Lymph Node More Than
5 Cm In Greatest Dimension (N3)
Regional Lymph Nodes Cannot Be
Assessed (NX)
Lymph Node(s) Examined Number
Lymph Node(s) Positive Number
Lymph Nodes Type
Common Iliac (common iliac)
External Iliac (external iliac)
Hypogastric (hypogastric)
Internal Iliac (internal iliac)
Other, Specify (other, specify)
Para-aortic (para-aortic)
Lymph Node Involvement
The Node Is Considered To Be Negative
But Not Based Upon Histological
Evaluation. (clinically negative)
The Node Is Considered To Be Positive
But Not Based Upon Histological
Evaluation. (clinically positive)
Lymph Nodes Were Evaluated For
Involvement, And They Were Equivocal
(equivocal)
Lymph Nodes Were Evaluated For
Involvement, And They Were Negative
(negative)
Lymph Nodes Were Not Evaluated For
Involvement (not evaluated)
The Node Is Considered To Be Negative
Based Upon Histological Evaluation.
(pathologically negative)
The Node Is Considered To Be Positive
Based Upon Histological Evaluation.
(pathologically positive)
Lymph Nodes Were Evaluated For
Involvement, And They Were Positive
(positive)
Unknown Whether The Lymph Nodes
Were Evaluated For Involvement
(unknown)
Assessment Type
Biopsy (Biopsy)
Bone Scan (Bone scan)
Chest X-ray (Chest X-Ray)
Clinical Examination (Clinical
examination)
Ct Scan (CT Scan)
Cytology (Cytology)
Histology (Histology)
4 / 7
On-Study - Muscle Invasive Bladder Cancer - On-Study Form -
2019331v2.31
Mri (MRI (NMR))
Not Applicable (Not applicable)
Not Evaluated (Not evaluated)
Other (Other)
Other, Specify (Other, specify)
Pathologic (Pathologic)
Physical Exam (Physical exam)
Radiograph (Radiograph)
Spiral Ct Scan (Spiral CT Scan)
Tumor Markers (Tumor Markers)
Ultrasound (Ultrasound)
Lymph Node Type, Other
Tumor Margin Ind
No (No)
Unknown (unknown)
Yes (Yes)
Tumor Adherence Ind
No (No)
Unknown (unknown)
Yes (Yes)
Muscle Invasive Bladder Disease: Prior
Treatment Affecting The Bladder
Prior Intravesical Therapy Ind
No (No)
Unknown (unknown)
Yes (Yes)
Prior Immunotherapy Type
Bcg (BCG)
Interferon (Interferon)
Other (Other)
Prior Immunotherapy Count
Prior Immunotherapy Other Agent
Prior Intravesical Chemotherapy Type
Mmc (MMC)
Other (Other)
Thiotepa (Thiotepa)
Prior Intravesical Chemotherapy Count
Prior Intravesical Chemotherapy Other Agent
Prior Chemotherapy Ind
No (NO)
Unknown (UNKNOWN)
Yes (YES)
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Prior Neoadjuvant Chemotherapy Ind
No (No)
Unknown (unknown)
Yes (Yes)
Prior Neoadjuvant Chemotherapy Type
Carboplatin/paclitaxel
(Carboplatin/Paclitaxel)
Cisplatin/gemcitabine
(Cisplatin/Gemcitabine)
M-vac (M-VAC)
Other (Other)
Prior Neoadjuvant Chemotherapy Count
Prior Neoadjuvant Chemotherapy Other Type
Prior Adjuvant Chemotherapy Ind
No (NO)
Unknown (UNKNOWN)
Yes (YES)
Prior Adjuvant Chemotherapy Type
Carboplatin/paclitaxel
(Carboplatin/Paclitaxel)
Cisplatin/gemcitabine
(Cisplatin/Gemcitabine)
M-vac (M-VAC)
Other (Other)
Prior Adjuvant Chemotherapy Count
Prior Adjuvant Chemotherapy Other Agent
Prior Pelvic RT Ind
No (No)
Unknown (unknown)
Yes (Yes)
Prior Surgery Ind
No (NO)
Unknown (UNKNOWN)
Yes (YES)
Prior Surgery Type
Patient Previously Had Other Surgery,
Specify (other, specify)
Patient Previosly Had A Partial
Cystectomy (partial cystectomy)
Patient Previosly Had A Radical
Cystectomy (radical cystectomy)
Patient Previosly Had A Turbt (TURBT)
Prior Surgery, TURBT Count
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Prior Surgery, Other Type
Prior Other Therapy Ind
No (NO)
Unknown (UNKNOWN)
Yes (YES)
Prior Other Therapy Name
Allows Documentation Of Any Additional
Cooments
Comments
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On-Study - Esophageal Cancer - Adjuvant
On-Study Form - 2020201v2.31
Esophageal Cancer - Adjuvant On-Study Form
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=99CD59C5-
A9A2-3FA4-E034-080020C9C0E0
All rights reserved. Please visit https://medical-data-
models.org/forms/6901
Esophageal Cancer - Adjuvant On-
Study Form
Crf Header
Coordinating Group Protocol Number
Coordinating Group Code
Protocol Title
Patient Study ID, Coordinating Group
Patient Study ID, Participating Group
Participating Group Code
Http://ctep.info.nih.gov.
(http://ctep.info.nih.gov.)
Institution Name
Affiliate Name
Patient Name, Last
Patient Name, First
Patient Name, Middle
Esophageal: Form Administration
Person Completing Form, Last Name
Person Completing Form, First Name
Amended Data Ind
No (NO)
Unknown (UNKNOWN)
Yes (YES)
Esophageal: Adjuvant Disease
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Description
Primary Site
Antrum (Antrum)
Body Of Pancreas (Body of pancreas)
Cardia (Cardia)
Cervical Esophagus (Cervical
esophagus)
Diffuse (Diffuse)
Esophagus, Not Otherwise Specified
(Esophagus, NOS)
Fundus (Fundus)
Gastro-esophageal Junction (Gastro-
esophageal junction)
Head Of Pancreas (Head of pancreas)
Linitus Plastica (Linitus plastica)
Lower Thoracic Esophagus, Excluding
The Gastro-esophageal Junction (Lower
thoracic esophagus (excludes G-E
junction))
Mid-thoracic Esophagus (Mid-thoracic
esophagus)
Other, Specify (Other, specify)
Pancreas, Not Otherwise Specified
(Pancreas, NOS)
Pylorus/pyloric Channel (Pylorus/Pyloric
channel)
Stomach, Not Otherwise Specified
(Stomach, NOS)
Tail Of Pancreas (Tail of pancreas)
Uncinate Process (Uncinate process)
Upper Thoracic Esophagus (Upper
thoracic esophagus)
Primary Site, Other
Disease Involvement Site
Adjacent Structures, Specify (Adjacent
structures, specify)
Adjacent Viscera (Adjacent viscera)
Adjacent Viscera/vessels (Adjacent
viscera/vessels)
Bone (Bone)
Distant Lymph Nodes (Distant lymph
nodes)
Liver (Liver)
Lung (Lung)
Other, Specify (Other, specify)
Peritoneal Disease (Peritoneal disease)
Peritoneum (Peritoneum)
Primary Tumor/esophagus (Primary
tumor/esophagus)
Primary Tumor/pancreas (Primary
tumor/pancreas)
Primary Tumor/stomach (Primary
tumor/stomach)
Regional Lymph Nodes (Regional lymph
nodes)
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Disease Involvement Site, Adjacent Specify
Disease Involvement Site, Other
Histologic Type
Acinar Cell Carcinoma (Acinar cell
carcinoma)
Adenocarcinoma (Adenocarcinoma)
Adenosquamous Carcinoma
(Adenosquamous carcinoma)
Ductal Adenocarcinoma (Ductal
adenocarcinoma)
Mixed-type (ductal-endocrine Or Acinar-
endocrine) (Mixed-type (ductal-endocrine
or acinar-endocrine))
Mucinous Adenocarcinoma (Mucinous
adenocarcinoma)
Mucinous Noncystic Carcinoma
(Mucinous noncystic carcinoma)
Neuroendocrine Carcinoma
(Neuroendocrine carcinoma)
Other, Specify (Other, specify)
Signet Ring Cell Carcinoma (Signet ring
cell carcinoma)
Small Cell Carcinoma (Small cell
carcinoma)
Squamous Cell Carcinoma (Squamous
cell carcinoma)
Tubular Adenocarcinoma (Tubular
adenocarcinoma)
Undifferentiated (anaplastic) Carcinoma
(Undifferentiated (anaplastic) carcinoma)
Undifferentiated Carcinoma With
Osteoclast-like Giant Cells
(Undifferentiated carcinoma with
osteoclast-like giant cells)
Unknown (Unknown)
Histologic Type, Other Name
Histologic Grade
Tumor Is Moderately Differentiated
According To Who Grading System
(Moderately differentiated (Grade II))
Tumor Is Poorly Differentiated According
To Who Grading System (Poorly
differentiated (Grade III))
Tumor Is Undifferentiated According To
Who Grading System (Undifferentiated
(Grade IV))
Unknown (Unknown)
Tumor Is Well Differentiated According
To Who Grading System (Well
differentiated (Grade I))
T Stage, Pathologic
T0, According To Ajcc Criteria (T0)
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T1, According To Ajcc Criteria (T1)
T2, According To Ajcc Criteria (T2)
T3, According To Ajcc Criteria (T3)
T4, According To Ajcc Criteria (T4)
Tis, According To Ajcc Criteria (Tis)
Tx, According To Ajcc Criteria (TX)
N Stage, Pathologic
No Lymph Node Involvement According
To Ajcc Guidelines (use For Esophageal,
Gastric, And Pancreatic) (N0)
N1, According To Ajcc Criteria (N1)
N2, According To Ajcc Criteria (N2)
N3, According To Ajcc Criteria (N3)
Lymph Node Involvement Cannot Be
Assessed According To Ajcc Guidelines
(use For Esophageal, Gastric, And
Pancreatic) (NX)
M Stage, Pathologic
No Distant Metastases According To
Ajcc Guidelines (M0)
Distant Metastases Present According
To Ajcc Guidelines (M1)
Distant Metastases Presence Or
Absence Cannot Be Assessed According
To Ajcc Guidelines (MX)
Esophageal: Adjuvant Prior Treatment
Prior Surgery Ind
No (NO)
Unknown (UNKNOWN)
Yes (YES)
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Pathology - Colon and Rectum Carcinoma -
Anatomic Pathology Form - 2019345v2.31
Colon and Rectum Carcinoma - Anatomic Pathology Form
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=99CD59C5-
A97A-3FA4-E034-080020C9C0E0
All rights reserved. Please visit https://medical-data-
models.org/forms/6903
Colon and Rectum Carcinoma -
Anatomic Pathology Form
Colorectal: Crf Header
Coordinating Group Protocol Number
Coordinating Group Code
Protocol Title
Patient Study ID, Coordinating Group
Patient Study ID, Participating Group
Participating Group Code
Institution Name
Affiliate Name
Patient Name, Last
Patient Name, First
Patient Name, Middle
Colorectal Pathology: Form Administration
Person Completing Form, Last Name
Person Completing Form, First Name
Person Completing Form, Project Role
Amended Data Ind
No (NO)
Unknown (UNKNOWN)
Yes (YES)
Form Completion Date, Original
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Form Completion Date, Amended
Pathology: Surgical Pathology -
Macroscopic/gross Description
Rectal Tumor Crossing Dentate Ind
Indeterminate (Indeterminate)
No (No)
Unknown (Unknown)
Yes (Yes)
Neoadjuvant Treatment Ind
Indeterminate (Indeterminate)
No (No)
Unknown (Unknown)
Yes (Yes)
Therapy Name
Chemotherapy (Chemotherapy)
Hormonal Therapy (Hormonal therapy)
Immunotherapy (Immunotherapy)
Other (Other)
Radiation Therapy (Radiation therapy)
Surgery (Surgery)
Unknown (Unknown)
Other Therapy Name
Resection Extent
Biopsy Only (Biopsy only)
Bowel Resection (Bowel resection)
Indeterminate (Indeterminate)
Local Excision (Local excision)
Polypectomy (Polypectomy)
Surgery Date
Primary Tumor Multiple Ind
Indeterminate (Indeterminate)
No (No)
Unknown (Unknown)
Yes (Yes)
Tumor Size, Largest Dimension
Tumor Size, Second Dimension
Tumor Size, Third Dimension
Specimen State
Fixed (Fixed)
Fresh (Fresh)
Frozen (Frozen)
Unknown (Unknown)
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Tumor Enbloc Resection Ind
No (No)
Unknown (Unknown)
Yes (Yes)
Tumor Characteristics
Annular (Annular)
Depressed (Depressed)
Flat (Flat)
Linitis Plastica (diffuse Infiltration) (Linitis
plastica (diffuse infiltration))
No Visible Tumor (No visible tumor)
Other (Other)
Pedunculated (Pedunculated)
Polypoid (exophytic) (Polypoid
(exophytic))
Ulcerating (endophytic) (Ulcerating
(endophytic))
Tumor Characteristics, Other
Perforation Ind
Indeterminate (Indeterminate)
No (No)
Unknown (Unknown)
Yes (Yes)
Perforation Within Tumor Ind
Indeterminate (Indeterminate)
No (No)
Unknown (Unknown)
Yes (Yes)
Perforation Outside Tumor Ind
Indeterminate (Indeterminate)
No (No)
Unknown (Unknown)
Yes (Yes)
Surgical Margin, Distance to Closest Longitudinal
Surgical Margin, Distance to Distal
Surgical Margin, Distance to Proximal
Surgical Margin, Distance, Closest to Lateral
Surgical Margin, Distance, Closest to Deep
Tumor Penetration Depth into Muscularis
Mesorectal Description
Indeterminate (Indeterminate)
Shaggy (disrupted) (Shaggy (disrupted))
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Smooth (intact) (Smooth (intact))
Unknown (Unknown)
Pathology: Surgical Pathology -
Microscopic Description
Surgical Margin, Radial
Indeterminate (Indeterminate)
No (No)
Not Applicable (completely
Peritonealized Segment Of Tumor) (Not
applicable (completely peritonealized
segment of tumor))
Unknown (Unknown)
Yes (Yes)
Surgical Margin, Distance to Nearest Radial
Surgical Margin Ind, Mesenteric
Indeterminate (Indeterminate)
No (No)
Unknown (Unknown)
Yes (Yes)
Surgical Margin, Polypectomy Margin Distance
Disease Extent, Extension Site
Bladder (Bladder)
Liver (Liver)
Other (Other)
Ovary (Ovary)
Other Pelvic Site Or Organ (Pelvic (other
than above))
Peritoneum (Peritoneum)
Prostate (Prostate)
Seminal Vesicles (Seminal vesicles)
Ureter (Ureter)
Uterus (Uterus)
Vagina (Vagina)
Disease Extent, Other Extension Site
N Category, Regional
Metastases In 1 To 3 Regional Lymph
Nodes (n1) (Metastases in 1 to 3
regional lymph nodes (N1))
Metastases In 4 Or More Regional
Lymph Nodes (n2) (Metastases in 4 or
more regional lymph nodes (N2))
No Regional Lymph Node Metastases
(n0) (No regional lymph node
metastases (N0))
Regional Lymph Nodes Cannot Be
Assessed (nx) (Regional lymph nodes
cannot be assessed (NX))
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Lymph Nodes Number, Extramural Deposits
Extracapsular Extension Ind
Indeterminate (Indeterminate)
No (No)
Unknown (Unknown)
Yes (Yes)
Metastatic Site, Lymph Node
Metastatic Site, Other
Cytology, Positive Peritoneal Result Ind
Indeterminate (Indeterminate)
No (No)
Unknown (Unknown)
Yes (Yes)
Pericolic Deposits Ind
Indeterminate (Indeterminate)
No (No)
Unknown (Unknown)
Yes (Yes)
Residual Adenoma Ind
Indeterminate (Indeterminate)
No (No)
Unknown (Unknown)
Yes (Yes)
Venous Invasion Ind
Indeterminate (Indeterminate)
No (No)
Unknown (Unknown)
Yes (Yes)
Lymphatic/Small vessel Invasion Ind
Indeterminate (Indeterminate)
No (No)
Unknown (Unknown)
Yes (Yes)
Vascular Invasion Type
Extramural (Extramural)
Indeterminate (Indeterminate)
Intramural (Intramural)
Unknown (Unknown)
Vascular Invasion Type
Extramural (Extramural)
Indeterminate (Indeterminate)
Intramural (Intramural)
Unknown (Unknown)
Perineural Involvement Ind
Indeterminate (Indeterminate)
No (No)
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Unknown (Unknown)
Yes (Yes)
Tumor Border Configuration
Indeterminate (Indeterminate)
Infiltrating (Infiltrating)
Other (Other)
Pushing (Pushing)
Tumor Border Configuration, Other
Host Lymphoid Response
Crohn's Like (Crohn's like)
Indeterminate (Indeterminate)
Intratumoral, Marked (>4 Tumor
Infiltrating Lymphocytes/hpf)
(Intratumoral, marked (>4 tumor
infiltrating lymphocytes/HPF))
Peritumoral, Mild (Peritumoral, mild)
Associated Diseases
Idiopathic Bowel Disease (ibd)
(Idiopathic bowel disease (IBD))
Indeterminate (Indeterminate)
Other (Other)
Polyposis Syndrome (Polyposis
syndrome)
Associated Diseases Other
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On-Study - Esophageal Cancer - Advanced
On-Study Form - 2020202v2.31
Esophageal Cancer - Advanced On-Study Form
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=99CD59C5-
A9A4-3FA4-E034-080020C9C0E0
All rights reserved. Please visit https://medical-data-
models.org/forms/6905
Esophageal Cancer - Advanced On-
Study Form
Crf Header
Coordinating Group Protocol Number
Coordinating Group Code
Protocol Title
Patient Study ID, Coordinating Group
Patient Study ID, Participating Group
Participating Group Code
Http://ctep.info.nih.gov.
(http://ctep.info.nih.gov.)
Institution Name
Affiliate Name
Patient Name, Last
Patient Name, First
Patient Name, Middle
Esophageal: Form Administration
Person Completing Form, Last Name
Person Completing Form, First Name
Amended Data Ind
No (NO)
Unknown (UNKNOWN)
Yes (YES)
Esophageal: Advanced Disease
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Description
Primary Site
Antrum (Antrum)
Body Of Pancreas (Body of pancreas)
Cardia (Cardia)
Cervical Esophagus (Cervical
esophagus)
Diffuse (Diffuse)
Esophagus, Not Otherwise Specified
(Esophagus, NOS)
Fundus (Fundus)
Gastro-esophageal Junction (Gastro-
esophageal junction)
Head Of Pancreas (Head of pancreas)
Linitus Plastica (Linitus plastica)
Lower Thoracic Esophagus, Excluding
The Gastro-esophageal Junction (Lower
thoracic esophagus (excludes G-E
junction))
Mid-thoracic Esophagus (Mid-thoracic
esophagus)
Other, Specify (Other, specify)
Pancreas, Not Otherwise Specified
(Pancreas, NOS)
Pylorus/pyloric Channel (Pylorus/Pyloric
channel)
Stomach, Not Otherwise Specified
(Stomach, NOS)
Tail Of Pancreas (Tail of pancreas)
Uncinate Process (Uncinate process)
Upper Thoracic Esophagus (Upper
thoracic esophagus)
Primary Site, Other
Disease Involvement Site
Adjacent Structures, Specify (Adjacent
structures, specify)
Adjacent Viscera (Adjacent viscera)
Adjacent Viscera/vessels (Adjacent
viscera/vessels)
Bone (Bone)
Distant Lymph Nodes (Distant lymph
nodes)
Liver (Liver)
Lung (Lung)
Other, Specify (Other, specify)
Peritoneal Disease (Peritoneal disease)
Peritoneum (Peritoneum)
Primary Tumor/esophagus (Primary
tumor/esophagus)
Primary Tumor/pancreas (Primary
tumor/pancreas)
Primary Tumor/stomach (Primary
tumor/stomach)
Regional Lymph Nodes (Regional lymph
nodes)
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Disease Involvement Site, Adjacent Specify
Disease Involvement Site, Other
Advanced Disease Registration Status
Initial Diagnosis (Initial Diagnosis)
Recurrence (Recurrence)
Histologic Type
Acinar Cell Carcinoma (Acinar cell
carcinoma)
Adenocarcinoma (Adenocarcinoma)
Adenosquamous Carcinoma
(Adenosquamous carcinoma)
Ductal Adenocarcinoma (Ductal
adenocarcinoma)
Mixed-type (ductal-endocrine Or Acinar-
endocrine) (Mixed-type (ductal-endocrine
or acinar-endocrine))
Mucinous Adenocarcinoma (Mucinous
adenocarcinoma)
Mucinous Noncystic Carcinoma
(Mucinous noncystic carcinoma)
Neuroendocrine Carcinoma
(Neuroendocrine carcinoma)
Other, Specify (Other, specify)
Signet Ring Cell Carcinoma (Signet ring
cell carcinoma)
Small Cell Carcinoma (Small cell
carcinoma)
Squamous Cell Carcinoma (Squamous
cell carcinoma)
Tubular Adenocarcinoma (Tubular
adenocarcinoma)
Undifferentiated (anaplastic) Carcinoma
(Undifferentiated (anaplastic) carcinoma)
Undifferentiated Carcinoma With
Osteoclast-like Giant Cells
(Undifferentiated carcinoma with
osteoclast-like giant cells)
Unknown (Unknown)
Histologic Type, Other Name
Histologic Grade
Tumor Is Moderately Differentiated
According To Who Grading System
(Moderately differentiated (Grade II))
Tumor Is Poorly Differentiated According
To Who Grading System (Poorly
differentiated (Grade III))
Tumor Is Undifferentiated According To
Who Grading System (Undifferentiated
(Grade IV))
Unknown (Unknown)
Tumor Is Well Differentiated According
To Who Grading System (Well
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differentiated (Grade I))
T Stage, Pathologic
T0, According To Ajcc Criteria (T0)
T1, According To Ajcc Criteria (T1)
T2, According To Ajcc Criteria (T2)
T3, According To Ajcc Criteria (T3)
T4, According To Ajcc Criteria (T4)
Tis, According To Ajcc Criteria (Tis)
Tx, According To Ajcc Criteria (TX)
N Stage, Pathologic
No Lymph Node Involvement According
To Ajcc Guidelines (use For Esophageal,
Gastric, And Pancreatic) (N0)
N1, According To Ajcc Criteria (N1)
N2, According To Ajcc Criteria (N2)
N3, According To Ajcc Criteria (N3)
Lymph Node Involvement Cannot Be
Assessed According To Ajcc Guidelines
(use For Esophageal, Gastric, And
Pancreatic) (NX)
M Stage, Pathologic
No Distant Metastases According To
Ajcc Guidelines (M0)
Distant Metastases Present According
To Ajcc Guidelines (M1)
Distant Metastases Presence Or
Absence Cannot Be Assessed According
To Ajcc Guidelines (MX)
Esophageal: Advanced Prior Treatment
Prior Surgery Ind
No (NO)
Unknown (UNKNOWN)
Yes (YES)
Prior Chemotherapy Ind
No (NO)
Unknown (UNKNOWN)
Yes (YES)
Prior Immunotherapy Ind
No (NO)
Unknown (UNKNOWN)
Yes (YES)
Prior RT Ind
No (NO)
Unknown (UNKNOWN)
Yes (YES)
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Treatment - Upper Gastrointestinal Cancers
- Treatment Summary Form - 2020210v2.31
Upper Gastrointestinal Cancers - Treatment Summary
Form
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=99CD59C5-
A9B4-3FA4-E034-080020C9C0E0
All rights reserved. Please visit https://medical-data-
models.org/forms/6907
Upper Gastrointestinal Cancers -
Treatment Summary Form
Crf Header
Coordinating Group Protocol Number
Coordinating Group Code
Protocol Title
Patient Study ID, Coordinating Group
Patient Study ID, Participating Group
Participating Group Code
Http://ctep.info.nih.gov.
(http://ctep.info.nih.gov.)
Institution Name
Affiliate Name
Patient Name, Last
Patient Name, First
Patient Name, Middle
Gi: Treatment Plan
Treatment Begin Date
Treatment End Date
Off Treatment Reason
Alternative Therapy (Alternative therapy)
Death After Beginning Protocol Therapy
(Death after beginning protocol therapy)
Death On Study (Death on study)
Death Prior To Beginning Protocol
Therapy (Death prior to beginning
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protocol therapy)
Disease Progression, Relapse During
Active Treatment (Disease progression,
relapse during active treatment)
Disease Progression, Relapse Prior To
Beginning Protocol Therapy (Disease
progression, relapse prior to beginning
protocol therapy)
Other (Other)
Patient Off-treatment For Other
Complicating Disease (Patient off-
treatment for other complicating disease)
Patient Withdrawal Or Refusal After
Beginning Protocol Therapy (Patient
withdrawal or refusal after beginning
protocol therapy)
Patient Withdrawal Or Refusal Prior To
Beginning Protocol Therapy (Patient
withdrawal or refusal prior to beginning
protocol therapy)
Toxicity/side Effects/complications
(Toxicity/Side effects/Complications)
Treatment Completed Per Protocol
Criteria (Treatment completed per
protocol criteria)
Off Treatment Reason, Other
Gi: Treatment Summary - Surgery
Protocol Treatment, Surgery Ind
No (No)
Unknown (Unknown)
Yes (Yes)
Protocol Surgery Date
Protocol Surgery Type
Surgical Treatment Completed
No, Surgical Treatment Was Modified
From Protocol Specification (specify) (no,
surgical treatment was modified from
protocol specification (specify))
No, Surgical Treatment Was Not Done
(specify) (no, surgical treatment was not
done (specify))
Yes, Surgical Treatment Was Completed
As Per Protocol (Yes)
Surgical Treatment Modification Reason
Gi: Treatment Summary - Radiation
Therapy
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Protocol Treatment, RT Ind
No (No)
Unknown (Unknown)
Yes (Yes)
RT Begin Date
RT End Date
RT Type
Adjuvant Radiation Therapy (Adjuvant
RT)
Brachytherapy (Brachytherapy)
External Beam Radiation (External beam
radiation)
Neoadjuvant Radiation Therapy
(Neoadjuvant RT)
Other, Specify (Other, specify)
Palliative Radiation Therapy (Palliative
RT)
RT Type, Other
RT Site
RT Interruptions Ind
No (No)
Unknown (Unknown)
Yes, Due To Toxicity (Yes, due to toxicity)
Yes, For Other Reasons, Specify (Yes,
for other reasons, specify)
RT Interruptions Reason
Gi: Treatment Summary - Systemic
Therapy
Protocol Treatment, Systemic Therapy Ind
No (No)
Unknown (Unknown)
Yes (Yes)
First Treatment Start Date
Last Treatment Date
Systemic Therapy Type
Chemotherapy (Chemotherapy)
Immunotherapy (Immunotherapy)
Other Specify (Other, specify)
Systemic Therapy Type, Other
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Agent Name
Dose Modification (Change)
No (No)
Unknown (Unknown)
(i.e., The Treatment Was Changed
According To Protocol Guidelines) (Yes,
planned)
(i.e., The Treatment Change Was Not
Part Of Protocol Guidelines) (Yes,
unplanned)
Therapy Modification Name
Therapy Modification Reason
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Treatment - Melanoma-Treatment By Cycle
Form - 2020199v2.31
Melanoma-Treatment By Cycle Form
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=99CD59C5-
A99E-3FA4-E034-080020C9C0E0
All rights reserved. Please visit https://medical-data-
models.org/forms/6908
Melanoma-Treatment By Cycle Form
Crf Header
Coordinating Group Protocol Number
Coordinating Group Code
Protocol Title
Patient Study ID, Coordinating Group
Patient Study ID, Participating Group
Participating Group Code
Institution Name
Affiliate Name
Patient Name, Last
Patient Name, First
Patient Name, Middle
Melanoma: Treatment Cycle Information-
systemic Therapy
Agent Name
Melanoma: Treatment Cycle-systemic
Therapy
Course Begin Date
Course Identification
Agent Total Dose (per course)
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Agent Dose Units
Curie (Ci)
Centimeter (cm)
Deciliter (dL)
Decimeter (dm)
Gram-equivalent Weight (Eq)
Gram (g)
Gravity (in Centrifugation) (gravity)
Hertz (Hz)
International Unit (IU)
Joules Per Centimeter Square (JCM2)
Kilo-electron Volt (keV)
Kilogram (kg)
Kilohertz (kHz)
Kilopascal (kPa)
Liter (L)
Meter (m)
Microcurie (mcCi)
Microgram (mcg)
Millicurie (mCi)
Microliter (mcL)
Micrometer (mcm)
Milliequivalent (mEq)
Million Electron Volts (MeV)
Milligram (mg)
Megahertz (MHz)
Milliunit (milliunit)
Milliliter (mL)
Millimeter (mm)
Milligrams Per Milliliter Per Minute
(MMM)
Millimole (mmol)
Gram-molecular Weight (mole) (mol)
Milliosmole (mOsmol)
Megarad (Mrad)
Million Unit (mU)
Millivolt (mV)
Not Applicable (N/A)
Nanocurie (nCi)
Nanogram (ng)
Nanometer (nm)
Nanometers Of Light (nm light)
Osmole (Osmol)
Pascal (Pa)
Plaque Forming Unit (pfu)
Picogram (pg)
Pounds Per Square Inch (psi)
Unit (unit)
Viral Particles (VP)
Agent Name
Melanoma: Treatment Cycle-vaccine
Therapy
Vaccine Date
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Course Identification
Vaccine Site
Left Lower Extremity (left lower
extremity)
Left Upper Extremity (left upper
extremity)
Other, Specify (other, specify)
Right Lower Extremity (right lower
extremity)
Right Upper Extremity (right upper
extremity)
Trunk (trunk)
Agent Total Dose (per course)
Vaccine Site, Other
Agent Dose Units
Curie (Ci)
Centimeter (cm)
Deciliter (dL)
Decimeter (dm)
Gram-equivalent Weight (Eq)
Gram (g)
Gravity (in Centrifugation) (gravity)
Hertz (Hz)
International Unit (IU)
Joules Per Centimeter Square (JCM2)
Kilo-electron Volt (keV)
Kilogram (kg)
Kilohertz (kHz)
Kilopascal (kPa)
Liter (L)
Meter (m)
Microcurie (mcCi)
Microgram (mcg)
Millicurie (mCi)
Microliter (mcL)
Micrometer (mcm)
Milliequivalent (mEq)
Million Electron Volts (MeV)
Milligram (mg)
Megahertz (MHz)
Milliunit (milliunit)
Milliliter (mL)
Millimeter (mm)
Milligrams Per Milliliter Per Minute
(MMM)
Millimole (mmol)
Gram-molecular Weight (mole) (mol)
Milliosmole (mOsmol)
Megarad (Mrad)
Million Unit (mU)
Millivolt (mV)
Not Applicable (N/A)
Nanocurie (nCi)
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Nanogram (ng)
Nanometer (nm)
Nanometers Of Light (nm light)
Osmole (Osmol)
Pascal (Pa)
Plaque Forming Unit (pfu)
Picogram (pg)
Pounds Per Square Inch (psi)
Unit (unit)
Viral Particles (VP)
Agent Name
Melanoma: Treatment Modifications
Dose Modification (Change)
No (No)
Unknown (Unknown)
(i.e., The Treatment Was Changed
According To Protocol Guidelines) (Yes,
planned)
(i.e., The Treatment Change Was Not
Part Of Protocol Guidelines) (Yes,
unplanned)
Dose Modification Reason
Melanoma: Treatment Schedule-radiation
Therapy
RT Begin Date
Course Identification
RT End Date
RT Site
Bone (Bone)
Brain (Brain)
Head And Neck (Head and Neck)
Lymph Nodes (soft Tissue) (Lymph
nodes (soft tissue))
Other, Specify (Other, specify)
RT Site, Other
RT Total Dose
RT Interruptions Ind
No (No)
Unknown (Unknown)
Yes, Due To Toxicity (Yes, due to toxicity)
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Yes, For Other Reasons, Specify (Yes,
for other reasons, specify)
RT Interruptions Reason
Allows Documentation Of Any Additional
Cooments
Comments
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Treatment - Bladder/Urothelial Cancer -
Treatment Summary Form - 2019328v2.31
Bladder/Urothelial Cancer - Treatment Summary Form
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=99CD59C5-
A957-3FA4-E034-080020C9C0E0
All rights reserved. Please visit https://medical-data-
models.org/forms/6910
Bladder/Urothelial Cancer -
Treatment Summary Form
Crf Header
Coordinating Group Protocol Number
Coordinating Group Code
Protocol Title
Patient Study ID, Coordinating Group
Patient Study ID, Participating Group
Participating Group Code
Institution Name
Affiliate Name
Patient Name, Last
Patient Name, First
Patient Name, Middle
Bladder/urothelial: Form Administration
Person Completing Form, Last Name
Person Completing Form, First Name
Amended Data Ind
No (NO)
Unknown (UNKNOWN)
Yes (YES)
To Record Data On Treatment Of Patient
Using Chemotherapy Agents. Full Block
Name On Form: Bladder/urothelial:
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Treatment Schedule - Chemotherapy
Treatment First Dose Begin Date
Treatment Last Dose End Date
Agent Initial Dose
Agent Dose Units
Curie (Ci)
Centimeter (cm)
Deciliter (dL)
Decimeter (dm)
Gram-equivalent Weight (Eq)
Gram (g)
Gravity (in Centrifugation) (gravity)
Hertz (Hz)
International Unit (IU)
Joules Per Centimeter Square (JCM2)
Kilo-electron Volt (keV)
Kilogram (kg)
Kilohertz (kHz)
Kilopascal (kPa)
Liter (L)
Meter (m)
Microcurie (mcCi)
Microgram (mcg)
Millicurie (mCi)
Microliter (mcL)
Micrometer (mcm)
Milliequivalent (mEq)
Million Electron Volts (MeV)
Milligram (mg)
Megahertz (MHz)
Milliunit (milliunit)
Milliliter (mL)
Millimeter (mm)
Milligrams Per Milliliter Per Minute
(MMM)
Millimole (mmol)
Gram-molecular Weight (mole) (mol)
Milliosmole (mOsmol)
Megarad (Mrad)
Million Unit (mU)
Millivolt (mV)
Not Applicable (N/A)
Nanocurie (nCi)
Nanogram (ng)
Nanometer (nm)
Nanometers Of Light (nm light)
Osmole (Osmol)
Pascal (Pa)
Plaque Forming Unit (pfu)
Picogram (pg)
Pounds Per Square Inch (psi)
Unit (unit)
Viral Particles (VP)
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Agent Name
Bladder/urothelial: Treatment Schedule -
Radiation Therapy
RT Type
Type Of Radiation Therapy Is Adjuvant
(adjuvant)
Type Of Radiation Therapy Is
Neoadjuvant (neoadjuvant)
Type Of Radiation Therapy Is Other
Specify (other specify)
RT Other Type
RT Total Dose, Pelvis
RT Total Dose, Prostate
RT Begin Date
RT End Date
RT Interruptions Ind
No (No)
Unknown (Unknown)
Yes, Due To Toxicity (Yes, due to toxicity)
Yes, For Other Reasons, Specify (Yes,
for other reasons, specify)
RT Interruptions Reason
Bladder/urothelial: Treatment Schedule -
Surgery
Protocol Surgery Date
Protocol Surgery Type
Surgical Treatment Completed
No, Surgical Treatment Was Modified
From Protocol Specification (specify) (no,
surgical treatment was modified from
protocol specification (specify))
No, Surgical Treatment Was Not Done
(specify) (no, surgical treatment was not
done (specify))
Yes, Surgical Treatment Was Completed
As Per Protocol (Yes)
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Surgical Treatment Modification Reason
Bladder/urothelial: Off-treatment &
Modifications
Off Treatment Reason
Alternative Therapy (Alternative therapy)
Death Of Patient Occurred After The
Patient Began Protocol Therapy (Death
after beginning protocol therapy)
Death On Study (Death on study)
Death Prior To Beginning Protocol
Therapy (Death prior to beginning
protocol therapy)
Disease Progression, Relapse During
Active Treatment (Disease progression,
relapse during active treatment)
Progression Of Disease Occurred Prior
To The Patient Beginning Protocol
Therapy (Disease progression, relapse
prior to beginning protocol therapy)
Disease Recurrence (Disease
recurrence)
Other (Other)
Other, Specify (Other, specify)
Patient Off-treatment For Other
Complicating Disease (Patient off-
treatment for other complicating disease)
Patient Withdrawal Or Refusal After
Beginning Protocol Therapy (Patient
withdrawal or refusal after beginning
protocol therapy)
Patient Withdrawal Or Refusal Prior To
Beginning Protocol Therapy (Patient
withdrawal or refusal prior to beginning
protocol therapy)
Toxicity/side Effects/complications
(Toxicity/Side effects/Complications)
Treatment Completed Per Protocol
Criteria (Treatment completed per
protocol criteria)
Off Treatment Reason, Other
Dose Modification (Change)
No (No)
Unknown (Unknown)
(i.e., The Treatment Was Changed
According To Protocol Guidelines) (Yes,
planned)
(i.e., The Treatment Change Was Not
Part Of Protocol Guidelines) (Yes,
unplanned)
Dose Modification Reason
No Dose Modification (No)
Yes, There Was A Planned Dose
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Modification According To Protocol
Guidelines (Yes, planned (i.e., the
treatment was changed according to
protocol guidelines)
Yes, There Was An Unplanned Dose
Modifiction That Was Not Part Of
Protocol Guidelines (Yes, unplanned
(i.e., the treatment change was not part
of protocol guidelines))
Bladder/urothelial: Treatment Schedule -
Non-protocol Therapy
Non-Protocol Therapy Ind, During Protocol
No (No)
Unknown (unknown)
Yes (Yes)
Non-Protocol Chemotherapy Ind
No (NO)
Unknown (UNKNOWN)
Yes (YES)
Non-Protocol RT Ind
No (NO)
Unknown (UNKNOWN)
Yes (YES)
Non-Protocol Surgery Ind
No (NO)
Unknown (UNKNOWN)
Yes (YES)
Non-Protocol Therapy Type
Non-Protocol Therapy Type
Non-Protocol Therapy Type
Other Non-Protocol Therapy Ind
No (NO)
Unknown (UNKNOWN)
Yes (YES)
Other Non-Protocol Therapy Name
Allows Documentation Of Any Additional
Cooments
Comments
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Treatment - Gynecologic Cancer -
Treatment Summary Form - 2019337v2.31
Gynecologic Cancer - Treatment Summary Form
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=99CD59C5-
A96A-3FA4-E034-080020C9C0E0
All rights reserved. Please visit https://medical-data-
models.org/forms/6912
Gynecologic Cancer - Treatment
Summary Form
Crf Header
Coordinating Group Protocol Number
Coordinating Group Code
Protocol Title
Patient Study ID, Coordinating Group
Patient Study ID, Participating Group
Participating Group Code
Institution Name
Affiliate Name
Patient Name, Last
Patient Name, First
Patient Name, Middle
Gyn: Form Administration
Person Completing Form, Last Name
Person Completing Form, First Name
Amended Data Ind
No (NO)
Unknown (UNKNOWN)
Yes (YES)
Interval Report From Date
Interval Report To Date
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Gyn: Surgical Treatment
Protocol Surgery Ind
No (No)
Unknown (unknown)
Yes (Yes)
Protocol Surgery Date
Protocol Surgery Type
Bilateral Salpingo-oophorectomy
(bilateral salpingo-oophorectomy)
Omentectomy (omentectomy)
Other, Specify (other, specify)
Para-aortic Node Sampling/dissection
(para-aortic node sampling/dissection)
Partial Hysterectomy (partial
hysterectomy)
Pelvic Node Sampling/dissection (pelvic
node sampling/dissection)
Radical Hysterectomy (radical
hysterectomy)
Total Hysterectomy (total hysterectomy)
Unilateral Salpingo-oophorectomy
(unilateral salpingo-oophorectomy)
Protocol Surgery Other Type
Protocol Surgery Reason
Interval Debulking (Interval debulking)
Other, Specify (Other, specify)
Palliative Therapy (Palliative therapy)
Second Look Procedure (Second look
procedure)
Protocol Surgery Other Reason
Residual Disease
Protocol Surgery, Qualifying Results Ind
No (No)
Not Applicable (not applicable)
Yes (Yes)
Gyn: Treatment Modifications (surgical
Treatment)
Dose Modification (Change)
No (No)
Unknown (Unknown)
(i.e., The Treatment Was Changed
According To Protocol Guidelines) (Yes,
planned)
(i.e., The Treatment Change Was Not
Part Of Protocol Guidelines) (Yes,
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unplanned)
Dose Modification Reason
Gyn: Treatment Schedule - Radiation
Therapy
RT Type
Adjuvant Rt (adjuvant RT)
Brachytherapy (brachytherapy)
External Beam Radiation (external beam
radiation)
Neoadjuvant Rt (neoadjuvant RT)
Other, Specify (other, specify)
RT Other Type
Brachytherapy Application Method
High Dose Rate (High dose rate)
Low Dose Rate (Low dose rate)
Brachytherapy Begin Date
Brachytherapy End Date
Brachytherapy Total Dose, Right
Brachytherapy Total Dose, Left
Brachytherapy Total Implant Count
RT Begin Date
RT End Date
RT Site
Bladder (Bladder)
Cervix (Cervix)
Specify First Location Or Primary Field
(Location 1, specify)
Specify Second Location Or Primary
Field (Location 2, specify)
Specify Third Location Or Primary Field
(Location 3, specify)
Specify Other Location Not Described
(Other, specify)
Pelvic Region (Pelvis)
Rectum (Rectum)
Small Bowel (Small bowel)
Vagina (Vagina)
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RT Site, Location Name
RT Site, Other
RT Total Dose
RT Total Fraction Count
RT Site, Boost
None (none)
Other, Specify (other, specify)
Para-aortic Nodes (para-aortic nodes)
Pelvic Nodes (pelvic nodes)
Vagina (vagina)
RT Site, Other Boost
RT Total Dose, Boost
RT Total Fraction Count Boost
RT Interruptions Ind
No (No)
Unknown (Unknown)
Yes (Yes)
Yes, Due To Toxicity (Yes, due to toxicity)
Yes, For Other Reasons, Specify (Yes,
for other reasons, specify)
RT Interruptions Reason
Medical Condition, Specify (medical
condition, specify)
Non-medical Reason (non-medical
reason)
Other, Specify (other, specify)
Scheduling Problem (scheduling
problem)
Technical Problem (technical problem)
Toxicity (toxicity)
RT Interruptions Reason, Medical
RT Interruptions Reason, Other
Gyn: Treatment Modifications (radiation
Therapy)
Dose Modification (Change)
No (No)
Unknown (Unknown)
(i.e., The Treatment Was Changed
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According To Protocol Guidelines) (Yes,
planned)
(i.e., The Treatment Change Was Not
Part Of Protocol Guidelines) (Yes,
unplanned)
Dose Modification Reason
Gyn: Treatment Schedule - Systemic
Therapy
First Dose Start Date, First Cycle
First Dose Start Date, Last Cycle
Agent Initial Dose
Agent Dose Units
Centigrays (cGy)
Curie (Ci)
Centimeter (cm)
Deciliter (dL)
Decimeter (dm)
Gram-equivalent Weight (Eq)
Gram (g)
Gravity (in Centrifugation) (gravity)
Grays (Gy)
Hertz (Hz)
International Unit (IU)
Joules Per Centimeter Square (JCM2)
Kilo-electron Volt (keV)
Kilogram (kg)
Kilohertz (kHz)
Kilopascal (kPa)
Liter (L)
Meter (m)
Microcurie (mcCi)
Microgram (mcg)
Millicurie (mCi)
Microliter (mcL)
Micrometer (mcm)
Milliequivalent (mEq)
Million Electron Volts (MeV)
Milligram (mg)
Megahertz (MHz)
Milliunit (milliunit)
Milliliter (mL)
Millimeter (mm)
Milligrams Per Milliliter Per Minute
(MMM)
Millimole (mmol)
Gram-molecular Weight (mole) (mol)
Milliosmole (mOsmol)
Megarad (Mrad)
Million Unit (mU)
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Millivolt (mV)
Not Applicable (N/A)
Nanocurie (nCi)
Nanogram (ng)
Nanometer (nm)
Nanometers Of Light (nm light)
Osmole (Osmol)
Pascal (Pa)
Plaque Forming Unit (pfu)
Picogram (pg)
Pounds Per Square Inch (psi)
Unit (unit)
Viral Particles (VP)
Agent Name
Gyn: Treatment Modifications (systemic
Therapy)
Dose Modification (Change)
No (No)
Unknown (Unknown)
(i.e., The Treatment Was Changed
According To Protocol Guidelines) (Yes,
planned)
(i.e., The Treatment Change Was Not
Part Of Protocol Guidelines) (Yes,
unplanned)
Dose Modification Reason
Gyn: Off-treatment Reason
Off Treatment Reason
Alternative Therapy (Alternative Therapy)
Death Of Patient Occurred After The
Patient Began Protocol Therapy (Death
after beginning protocol therapy)
Death On Study (Death on study)
Death Prior To Beginning Protocol
Therapy (Death prior to beginning
protocol therapy)
Disease Progression, Relapse During
Active Treatment (Disease progression,
relapse during active treatment)
Progression Of Disease Occurred Prior
To The Patient Beginning Protocol
Therapy (Disease progression, relapse
prior to beginning protocol therapy)
Other (Other)
Specify Other Reason (Other, specify)
Patient Off-treatment For Other
Complicating Disease (Patient off-
treatment for other complicating disease)
Patient Withdrawal Or Refusal After
Beginning Protocol Therapy (Patient
withdrawal or refusal after beginning
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protocol therapy)
Patient Withdrawal Or Refusal For
Reason Other Than Toxicity (Patient
withdrawal or refusal for reason other
than toxicity)
Patient Withdrawal Or Refusal Prior To
Beginning Protocol Therapy (Patient
withdrawal or refusal prior to beginning
protocol therapy)
Patient Withdrawal Or Refusal
Subsequent To Toxicity (Patient
withdrawal or refusal subsequent to
toxicity)
Patient Withdrawal, Medically Required
Due To Toxicity (Patient withdrawal,
medically required due to toxicity)
Routine Completion Of Planned Protocol
Treatment (Routine completion of
planned protocol treatment)
Toxicity/side Effects/complications
(Toxicity/Side effects/Complications)
Treatment Completed Per Protocol
Criteria (Treatment completed per
protocol criteria)
Off Treatment Reason, Other
Gyn: Treatment Schedule - Optional
Therapy
Optional Protocol Therapy Ind
No (NO)
Unknown (UNKNOWN)
Yes (YES)
Optional Protocol Therapy Name
User Defined Text Field (User defined
text field)
Gyn: Treatment Schedule - Non-protocol
Therapy
Non-Protocol Therapy Ind, During Treatment
No (No)
Unknown (unknown)
Yes (Yes)
Non-Protocol Chemotherapy Ind
No (NO)
Unknown (UNKNOWN)
Yes (YES)
Non-Protocol Chemotherapy Type
Non-Protocol Hormonal Therapy Ind
No (NO)
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Unknown (UNKNOWN)
Yes (YES)
Non-Protocol Hormonal Therapy Type
Non-Protocol Immunotherapy Ind
No (NO)
Unknown (UNKNOWN)
Yes (YES)
Non-Protocol Immunotherapy Type
Non-Protocol RT Ind
No (NO)
Unknown (UNKNOWN)
Yes (YES)
Non-Protocol RT Type
Non-Protocol Surgery Ind
No (NO)
Unknown (UNKNOWN)
Yes (YES)
Non-Protocol Surgery Type
Other Non-Protocol Therapy Ind
No (NO)
Unknown (UNKNOWN)
Yes (YES)
Other Non-Protocol Therapy Name
Allows Documentation Of Any Additional
Cooments
Comments
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Toxicity - Gynecologic Cancer - Toxicity
Form-Prerna 2 - 2481445v1.0
Gynecologic Cancer - Toxicity Form-Prerna 2
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=13D57CCB-
EEFC-00A5-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/6914
Gynecologic Cancer - Toxicity Form-
Prerna 2
Crf Header
Coordinating Group Protocol Number
Coordinating Group Code
Protocol Title
Patient Study ID, Coordinating Group
Patient Study ID, Participating Group
Participating Group Code
Institution Name
Affiliate Name
Patient Name, Last
Patient Name, First
Patient Name, Middle
Gyn: Form Administration
Person Completing Form, Last Name
Person Completing Form, First Name
Amended Data Ind
No (NO)
Unknown (UNKNOWN)
Yes (YES)
Interval Report From Date
Interval Report To Date
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Responsible Person Last Name
Responsible Person Last Name
Responsible Person Last Name
Gyn: Adverse Events
CTC Adverse Event Report Begin Date
CTC Adverse Event Report End Date
CTC Adverse Event Term
Ctep.info.nih.gov/ctc3/ctc.htm
(http://ctep.info.nih.gov/CTC3/ctc.htm)
CTC Adverse Event Grade
Ctep.info.nih.gov/ctc3/ctc.htm
(http://ctep.info.nih.gov/CTC3/ctc.htm)
CTC Adverse Event Attribution Code
Definitely (Definitely)
Possibly (Possibly)
Probably (Probably)
Unlikely (Unlikely)
Unrelated (Unrelated)
CTC Adverse Event Term, Other
Allows Documentation Of Any Additional
Cooments
Comments
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On-Study - Gastric Cancer - Adjuvant On-
Study Form - 2020203v2.31
Gastric Cancer - Adjuvant On-Study Form
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=99CD59C5-
A9A6-3FA4-E034-080020C9C0E0
All rights reserved. Please visit https://medical-data-
models.org/forms/6915
Gastric Cancer - Adjuvant On-Study
Form
Crf Header
Coordinating Group Protocol Number
Coordinating Group Code
Protocol Title
Patient Study ID, Coordinating Group
Patient Study ID, Participating Group
Participating Group Code
Http://ctep.info.nih.gov.
(http://ctep.info.nih.gov.)
Institution Name
Affiliate Name
Patient Name, Last
Patient Name, First
Patient Name, Middle
Gastric: Form Administration
Person Completing Form, Last Name
Person Completing Form, First Name
Amended Data Ind
No (NO)
Unknown (UNKNOWN)
Yes (YES)
Gastric: Adjuvant Disease Description
1 / 4
Primary Site
Antrum (Antrum)
Body Of Pancreas (Body of pancreas)
Cardia (Cardia)
Cervical Esophagus (Cervical
esophagus)
Diffuse (Diffuse)
Esophagus, Not Otherwise Specified
(Esophagus, NOS)
Fundus (Fundus)
Gastro-esophageal Junction (Gastro-
esophageal junction)
Head Of Pancreas (Head of pancreas)
Linitus Plastica (Linitus plastica)
Lower Thoracic Esophagus, Excluding
The Gastro-esophageal Junction (Lower
thoracic esophagus (excludes G-E
junction))
Mid-thoracic Esophagus (Mid-thoracic
esophagus)
Other, Specify (Other, specify)
Pancreas, Not Otherwise Specified
(Pancreas, NOS)
Pylorus/pyloric Channel (Pylorus/Pyloric
channel)
Stomach, Not Otherwise Specified
(Stomach, NOS)
Tail Of Pancreas (Tail of pancreas)
Uncinate Process (Uncinate process)
Upper Thoracic Esophagus (Upper
thoracic esophagus)
Primary Site, Other
Disease Involvement Site
Adjacent Structures, Specify (Adjacent
structures, specify)
Adjacent Viscera (Adjacent viscera)
Adjacent Viscera/vessels (Adjacent
viscera/vessels)
Bone (Bone)
Distant Lymph Nodes (Distant lymph
nodes)
Liver (Liver)
Lung (Lung)
Other, Specify (Other, specify)
Peritoneal Disease (Peritoneal disease)
Peritoneum (Peritoneum)
Primary Tumor/esophagus (Primary
tumor/esophagus)
Primary Tumor/pancreas (Primary
tumor/pancreas)
Primary Tumor/stomach (Primary
tumor/stomach)
Regional Lymph Nodes (Regional lymph
nodes)
Disease Involvement Site, Adjacent Specify
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Disease Involvement Site, Other
Histologic Type
Acinar Cell Carcinoma (Acinar cell
carcinoma)
Adenocarcinoma (Adenocarcinoma)
Adenosquamous Carcinoma
(Adenosquamous carcinoma)
Ductal Adenocarcinoma (Ductal
adenocarcinoma)
Mixed-type (ductal-endocrine Or Acinar-
endocrine) (Mixed-type (ductal-endocrine
or acinar-endocrine))
Mucinous Adenocarcinoma (Mucinous
adenocarcinoma)
Mucinous Noncystic Carcinoma
(Mucinous noncystic carcinoma)
Neuroendocrine Carcinoma
(Neuroendocrine carcinoma)
Other, Specify (Other, specify)
Signet Ring Cell Carcinoma (Signet ring
cell carcinoma)
Small Cell Carcinoma (Small cell
carcinoma)
Squamous Cell Carcinoma (Squamous
cell carcinoma)
Tubular Adenocarcinoma (Tubular
adenocarcinoma)
Undifferentiated (anaplastic) Carcinoma
(Undifferentiated (anaplastic) carcinoma)
Undifferentiated Carcinoma With
Osteoclast-like Giant Cells
(Undifferentiated carcinoma with
osteoclast-like giant cells)
Unknown (Unknown)
Histologic Type, Other Name
Histologic Grade
Tumor Is Moderately Differentiated
According To Who Grading System
(Moderately differentiated (Grade II))
Tumor Is Poorly Differentiated According
To Who Grading System (Poorly
differentiated (Grade III))
Tumor Is Undifferentiated According To
Who Grading System (Undifferentiated
(Grade IV))
Unknown (Unknown)
Tumor Is Well Differentiated According
To Who Grading System (Well
differentiated (Grade I))
T Stage, Pathologic
T0, According To Ajcc Criteria (T0)
T1, According To Ajcc Criteria (T1)
T2, According To Ajcc Criteria (T2)
T3, According To Ajcc Criteria (T3)
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T4, According To Ajcc Criteria (T4)
Tis, According To Ajcc Criteria (Tis)
Tx, According To Ajcc Criteria (TX)
N Stage, Pathologic
No Lymph Node Involvement According
To Ajcc Guidelines (use For Esophageal,
Gastric, And Pancreatic) (N0)
N1, According To Ajcc Criteria (N1)
N2, According To Ajcc Criteria (N2)
N3, According To Ajcc Criteria (N3)
Lymph Node Involvement Cannot Be
Assessed According To Ajcc Guidelines
(use For Esophageal, Gastric, And
Pancreatic) (NX)
M Stage, Pathologic
No Distant Metastases According To
Ajcc Guidelines (M0)
Distant Metastases Present According
To Ajcc Guidelines (M1)
Distant Metastases Presence Or
Absence Cannot Be Assessed According
To Ajcc Guidelines (MX)
Gastric: Adjuvant Prior Treatment
Prior Surgery Ind
No (NO)
Unknown (UNKNOWN)
Yes (YES)
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On-Study - Recurrent Gynecologic Cancer -
On-study Form - 2019342v2.31
Recurrent Gynecologic Cancer - On-study Form
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=99CD59C5-
A974-3FA4-E034-080020C9C0E0
All rights reserved. Please visit https://medical-data-
models.org/forms/6916
Recurrent Gynecologic Cancer - On-
study Form
Crf Header
Coordinating Group Protocol Number
Coordinating Group Code
Protocol Title
Patient Study ID, Coordinating Group
Patient Study ID, Participating Group
Participating Group Code
Institution Name
Affiliate Name
Patient Name, Last
Patient Name, First
Patient Name, Middle
Gyn: Form Administration
Person Completing Form, Last Name
Person Completing Form, First Name
Amended Data Ind
No (NO)
Unknown (UNKNOWN)
Yes (YES)
Interval Report From Date
Interval Report To Date
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Gyn: Disease Description - Prior History
Primary Tumor Diagnosis Date
Stage Grouping
Refer To Figo Staging For Specific
Gynecologic Cancer (I)
Refer To Figo Staging For Specific
Gynecologic Cancer (IA)
Refer To Figo Staging For Specific
Gynecologic Cancer (IA1)
Refer To Figo Staging For Specific
Gynecologic Cancer (IA2)
Refer To Figo Staging For Specific
Gynecologic Cancer (IB)
Refer To Figo Staging For Specific
Gynecologic Cancer (IB1)
Refer To Figo Staging For Specific
Gynecologic Cancer (IB2)
Refer To Figo Staging For Specific
Gynecologic Cancer (IC)
Refer To Figo Staging For Specific
Gynecologic Cancer (II)
Refer To Figo Staging For Specific
Gynecologic Cancer (IIA)
Refer To Figo Staging For Specific
Gynecologic Cancer (IIB)
Refer To Figo Staging For Specific
Gynecologic Cancer (IIC)
Refer To Figo Staging For Specific
Gynecologic Cancer (III)
Refer To Figo Staging For Specific
Gynecologic Cancer (IIIA)
Refer To Figo Staging For Specific
Gynecologic Cancer (IIIB)
Refer To Figo Staging For Specific
Gynecologic Cancer (IIIC)
Refer To Figo Staging For Specific
Gynecologic Cancer (IV)
Refer To Figo Staging For Specific
Gynecologic Cancer (IVA)
Refer To Figo Staging For Specific
Gynecologic Cancer (IVB)
Stage Grouping Cannot Be Assessed (X)
Histologic Grade
Grade 1-well Differentiated (1)
Grade 2-moderately Differentiated (2)
Grade 3-poorly Differentiated (3)
Indeterminate (Indeterminate)
Not Applicable (Not applicable)
Grade Unknown (Unknown)
Histologic Type
Adenocarcinoma With Squamous
Differentiation (Adenocarcinoma with
Squamous Differentiation)
Adenocarcinoma, Unspecified
(Adenocarcinoma, unspecified)
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Adenofibroma (Adenofibroma)
Adenosarcoma (Adenosarcoma)
Adenosquamous (Adenosquamous)
Brenner Tumor (benign) (Brenner tumor
(benign))
Brenner Tumor (malignant) (Brenner
tumor (malignant))
Brenner Tumor Of Low Malignant
Potential (Brenner tumor of LMP)
Cancer With Dermoid Cyst, Specify
Types (Cancer with dermoid cyst)
Carcinosarcoma/mesodermal (mullerian)
Mixed Tumor
(Carcinosarcoma/Mesodermal
(Mullerian) mixed tumor)
Choriocarcinoma (Choriocarcinoma)
Clear Cell Carcinoma (Clear cell
carcinoma)
Clear Cell Cystadenofibroma (benign)
(Clear cell cystadenofibroma (benign))
Clear Cell Cystadenoma (benign) (Clear
cell cystadenoma (benign))
Clear Cell Tumor Of Low Malignant
Potential (Clear cell tumor of LMP)
Dysgerminoma (Dysgerminoma)
Embryonal Carcinoma (Embryonal
carcinoma)
Endodermal Sinus Tumor (yolk Sac
Tumor) (Endodermal sinus tumor)
Endometrial Stromal Sarcoma
(Endometrial stromal sarcoma)
Endometrioid Adenocarcinoma
(Endometrioid adenocarcinoma)
Endometrioid Cystadenofibroma (benign)
(Endometrioid cystadenofibroma
(benign))
Endometrioid Cystadenoma (benign)
(Endometrioid cystadenoma (benign))
Endometrioid Tumor Of Low Malignant
Potential (Endometrioid tumor of LMP)
Fibroma (Fibroma)
Germ Cell Tumor, Mixed (Germ cell
tumor, mixed)
Gestational Trophoblastic Disease
(Gestational trophoblastic disease)
Granulosa Cell Tumor (Granulosa cell
tumor)
Gynandroblastoma (Gynandroblastoma)
Mixed Epithelial Carcinoma, Specify
Components (Mixed epithelial
carcinoma)
Mixed Malignant Germ Cell Tumor,
Specify Components (Mixed malignant
germ cell tumor)
Mucinous Adenocarcinoma (Mucinous
adenocarcinoma)
Mucinous Cystadenofibroma (benign)
(Mucinous cystadenofibroma (benign))
Mucinous Cystadenoma (benign)
(Mucinous cystadenoma (benign))
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Mucinous Tumor Of Low Malignant
Potential (Mucinous tumor of LMP)
Other, Specify (Other, specify)
Ovarian Endometriosis (Ovarian
endometriosis)
Physiologic Cyst (corpus Luteum)
(Physiologic cyst (corpus luteum))
Physiologic Cyst (follicle) (Physiologic
cyst (follicle))
Polyembryoma (Polyembryoma)
Serous Adenocarcinoma (Serous
adenocarcinoma)
Serous Cystadenofibroma (benign)
(Serous cystadenofibroma (benign))
Serous Cystadenoma (benign) (Serous
cystadenoma (benign))
Serous Tumor Of Low Malignant
Potential (Serous tumor of LMP)
Sertoli-leydig Cell (androblastoma)
(Sertoli-Leydig cell (Androblastoma))
Sex-cord/stromal, Unclassified (Sex-
cord/stromal, unclassified)
Simple Cyst (Simple cyst)
Squamous Cell Carcinoma (Squamous
cell carcinoma)
Steroid/lipid Cell Tumor (Steroid/Lipid cell
tumor)
Teratoma, Immature, Specify
Components (Teratoma, immature)
Teratoma, Mature (Teratoma, mature)
Transitional Cell Carcinoma, Including
Brenner Tumor (Transitional cell
carcinoma (including Brenner))
Undifferentiated Carcinoma
(Undifferentiated carcinoma)
Histologic Type, Other Name
Primary Surgery Type
Bilateral Salpingo-oophorectomy
(bilateral salpingo-oophorectomy)
Cervical Conization (cervical conization)
Omentectal Biopsy (Omentectal biopsy)
Omentectomy (omentectomy)
Other, Specify (other, specify)
Para-aortic Node Sampling/dissection
(para-aortic node sampling/dissection)
Partial Hysterectomy (partial
hysterectomy)
Pelvic Lymphadenectomy (pelvic
lymphadenectomy)
Pelvic Node Sampling/dissection (pelvic
node sampling/dissection)
Peritoneal Sampling (Peritoneal
sampling)
Radical Hysterectomy (radical
hysterectomy)
Radical Trachelectomy (radical
trachelectomy)
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Total Hysterectomy (total hysterectomy)
Unilateral Salpingo-oophorectomy
(unilateral salpingo-oophorectomy)
Primary Surgery Other Type
Primary Surgery Date
Gyn: Disease Description - Current
History
Residual Disease Status
Gross Disease (gross disease)
Microscopic Disease (microscopic
disease)
No Evidence Of Disease (no evidence of
disease)
Unknown/not Documented (unknown/not
documented)
Disease Status
Primary Gyn Disease Continues To Be
Present Following Initial Treatment
(Persistent)
Progression Of Gyn Disease Per Recist
Criteria (Progression)
Recurrence Of Same Gyn Disease
Previously Treated Successfully
(Recurrence)
Progression Date, First
Progression Assessment Method
Clinical Examination (clinical)
Histology (histologic)
Radiographic (radiographic)
Disease Site
Ascites (ascites)
Bladder (bladder)
Bone (bone)
Cervix (cervix)
Cns/brain (CNS/brain)
Colon (colon)
Endometrium (endometrium)
Liver (liver)
Lung (lung)
Lymph Nodes, Specify (lymph nodes,
specify)
Other, Specify (other, specify)
Ovary (ovary)
Parametrial Involvement (parametrial
involvement)
Peritoneum (peritoneum)
Pleura (pleura)
Pleural Effusion (pleural effusion)
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Skin (skin)
Uterus (uterus)
Disease Site, Lymph Nodes
Disease Site, Other
Lymph Nodes Type
Inguinal (inguinal)
Other, Specify (other, specify)
Para-aortic (para-aortic)
Pelvic (pelvic)
Scalene (scalene)
Lymph Node Involvement
The Node Is Considered To Be Negative
But Not Based Upon Histological
Evaluation. (clinically negative)
The Node Is Considered To Be Positive
But Not Based Upon Histological
Evaluation. (clinically positive)
Equivocal (equivocal)
Negative (negative)
Not Evaluated (not evaluated)
The Node Is Considered To Be Negative
Based Upon Histological Evaluation.
(pathologically negative)
The Node Is Considered To Be Positive
Based Upon Histological Evaluation.
(pathologically positive)
Positive (positive)
Unknown (unknown)
Assessment Type
Biopsy (Biopsy)
Biopsy, Not Otherwise Specified (Biopsy,
other)
Bone Scan (Bone scan)
Chest X-ray (Chest X-Ray)
Clinical Examination (Clinical
examination)
Ct Scan (CT Scan)
Cytology (Cytology)
Histology (Histology)
Laparoscopy (Laparoscopy)
Laparotomy (Laparotomy)
Mri (MRI (NMR))
Not Applicable (Not applicable)
Not Evaluated (Not evaluated)
Other (Other)
Other, Specify (Other, specify)
Pathologic (Pathologic)
Physical Exam (Physical exam)
Radiograph (Radiograph)
Spiral Ct Scan (Spiral CT scan)
Tumor Markers (Tumor Markers)
Ultrasound (Ultrasound)
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Lymph Nodes Other Type
Disease Assessment, Measurable Ind
No (No)
Unknown (Unknown)
Yes (Yes)
Gyn: Prior Treatment For Gynecologic
Cancer
Prior Chemotherapy Ind
No (NO)
Unknown (UNKNOWN)
Yes (YES)
First Prior Treatment Begin Date
Prior Chemotherapy End Date
Prior Chemotherapy Regimen
Prior Chemotherapy Regimen, Agent
Prior Chemotherapy Regimen, Other Agent
Prior Hormonal Therapy Ind
No (NO)
Unknown (UNKNOWN)
Yes (YES)
Prior Hormonal Therapy Type
Prior Immunotherapy Ind
No (NO)
Unknown (UNKNOWN)
Yes (YES)
Prior Immunotherapy Type
Prior RT Ind
No (NO)
Unknown (UNKNOWN)
Yes (YES)
RT Recurrence Site Ind
Yes
No
Prior Surgery Ind
No (NO)
Unknown (UNKNOWN)
Yes (YES)
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Allows Documentation Of Any Additional
Cooments
Comments
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Toxicity - Gynecologic Cancer - Toxicity
Form- copy 2 - 2481262v1.0
Gynecologic Cancer - Toxicity Form- copy 2
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=13996779-
2A06-0B29-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/6919
Gynecologic Cancer - Toxicity Form-
copy 2
Crf Header
Coordinating Group Protocol Number
Coordinating Group Code
Protocol Title
Patient Study ID, Coordinating Group
Patient Study ID, Participating Group
Participating Group Code
Institution Name
Affiliate Name
Patient Name, Last
Patient Name, First
Patient Name, Middle
Gyn: Form Administration
Responsible Person Last Name
Person Completing Form, First Name
Amended Data Ind
No (NO)
Unknown (UNKNOWN)
Yes (YES)
Interval Report From Date
Interval Report To Date
1 / 2
Responsible Person Last Name
Responsible Person Last Name
Gyn: Adverse Events
CTC Adverse Event Report Begin Date
CTC Adverse Event Report End Date
CTC Adverse Event Term
Ctep.info.nih.gov/ctc3/ctc.htm
(http://ctep.info.nih.gov/CTC3/ctc.htm)
CTC Adverse Event Grade
Ctep.info.nih.gov/ctc3/ctc.htm
(http://ctep.info.nih.gov/CTC3/ctc.htm)
CTC Adverse Event Attribution Code
Definitely (Definitely)
Possibly (Possibly)
Probably (Probably)
Unlikely (Unlikely)
Unrelated (Unrelated)
CTC Adverse Event Term, Other
Allows Documentation Of Any Additional
Cooments
Comments
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On-Study - Metastatic Bladder/Urothelial
Cancer - On-Study Form - 2019330v2.31
Metastatic Bladder/Urothelial Cancer - On-Study Form
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=99CD59C5-
A95B-3FA4-E034-080020C9C0E0
All rights reserved. Please visit https://medical-data-
models.org/forms/6920
Metastatic Bladder/Urothelial Cancer
- On-Study Form
Crf Header
Coordinating Group Protocol Number
Coordinating Group Code
Protocol Title
Patient Study ID, Coordinating Group
Patient Study ID, Participating Group
Participating Group Code
Institution Name
Affiliate Name
Patient Name, Last
Patient Name, First
Patient Name, Middle
Bladder/urothelial: Form Administration
Person Completing Form, Last Name
Person Completing Form, First Name
Amended Data Ind
No (NO)
Unknown (UNKNOWN)
Yes (YES)
Bladder/urothelial: Disease Description
For Metastatic Bladder/urothelial Cancer
Prior Muscle Invasive Disease Ind
1 / 5
No (No)
Unknown (unknown)
Yes (Yes)
Bladder Tumor Location
The Location Of The Bladder Tumor Is In
The Bladder (bladder)
The Location Of The Bladder Tumor Is In
The Prostate (prostate)
The Location Of The Bladder Tumor Is In
The Renal Pelvis (renal pelvis)
The Location Of The Bladder Tumor Is In
The Ureter (ureter)
The Location Of The Bladder Tumor Is In
The Urethra (urethra)
Initial Diagnosis Date, Pathologic
Initial Diagnosis Date, Locally Advanced
Initial Diagnosis Date, Metastatic
Bladder/urothelial: Site(s) Of Disease
Progression Site, Adjacent Structures
Primary Cancer Has Spread Adjacently
Into The Abdominal Wall (abdominal
wall)
Primary Cancer Has Not Spread To Any
Adjacent Structures (none)
Primary Cancer Has Spread Adjacently
Into Other Structures, Specify (other,
specify)
Primary Cancer Has Spread Adjacently
Into The Pelvic Wall (pelvic wall)
Primary Cancer Has Spread Adjacently
Into Peritoneal Tissue (peritoneum)
Primary Cancer Has Spread Into The
Prostate (prostate)
Primary Cancer Has Spread Into The
Skin Or Subcutaneous Tissue Near To
The Bladder (skin)
Primary Cancer Has Spread Into The
Urethra (urethra)
Primary Cancer Has Spread Into The
Uterus (uterus)
Primary Cancer Has Spread Into The
Vagina (vagina)
Progression Site, Local-Regional Nodes
Primary Cancer Has Spread To The
Common Iliac Lymph Nodes (common
iliac)
Primary Cancer Has Spread To The
External Iliac Lymph Nodes (external
iliac)
2 / 5
On-Study - Metastatic Bladder/Urothelial Cancer - On-Study Form -
2019330v2.31
Primary Cancer Has Spread To The
Hypogastric Lymph Nodes (hypogastric)
Primary Cancer Has Spread To The
Internal Iliac Lymph Nodes (internal iliac)
Primary Cancer Has Not Spread To Any
Local-regional Lymph Nodes (none)
Primary Cancer Has Spread To Other
Local-regional Lymph Nodes, Specify
(other, specify)
Primary Cancer Has Spread To The
Para-aortic Lymph Nodes (para-aortic)
Progression Site, Other
Progression Site, Other
Metastatic Site
Bone (Bone)
Bone Marrow (Bone marrow)
Brain (Brain)
Distant Nodes (Distant nodes)
Distant Skin/subcutaneous Tissue
(Distant skin/subcutaneous tissue)
First Other, Specify (First Other, specify)
Ipsilateral Supraclavicular Nodes
(Ipsilateral supraclavicular nodes)
Liver (Liver)
Lung (Lung)
Opposite Breast (Opposite breast)
Other Cns (Other CNS)
Pleura (Pleura)
Second Other, Specify (Second Other,
specify)
Metastatic Site, Other
Metastatic Site, Other
Lymph Nodes, Distant Location
Bladder/urothelial: Prior Treatment
Affecting The Bladder/urothelium
Prior Intravesical Therapy Ind
No (No)
Unknown (unknown)
Yes (Yes)
Prior Immunotherapy Type
Bcg (BCG)
Interferon (Interferon)
Other (Other)
Prior Immunotherapy Count
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Prior Immunotherapy Other Agent
Prior Intravesical Chemotherapy Type
Mmc (MMC)
Other (Other)
Thiotepa (Thiotepa)
Prior Intravesical Chemotherapy Count
Prior Intravesical Chemotherapy Other Agent
Prior Chemotherapy Ind
No (NO)
Unknown (UNKNOWN)
Yes (YES)
Prior Neoadjuvant Chemotherapy Ind
No (No)
Unknown (unknown)
Yes (Yes)
Prior Neoadjuvant Chemotherapy Type
Carboplatin/paclitaxel
(Carboplatin/Paclitaxel)
Cisplatin/gemcitabine
(Cisplatin/Gemcitabine)
M-vac (M-VAC)
Other (Other)
Prior Neoadjuvant Chemotherapy Count
Prior Neoadjuvant Chemotherapy Other Type
Prior Adjuvant Chemotherapy Ind
No (NO)
Unknown (UNKNOWN)
Yes (YES)
Prior Adjuvant Chemotherapy Type
Carboplatin/paclitaxel
(Carboplatin/Paclitaxel)
Cisplatin/gemcitabine
(Cisplatin/Gemcitabine)
M-vac (M-VAC)
Other (Other)
Prior Adjuvant Chemotherapy Count
Prior Adjuvant Chemotherapy Other Agent
Prior Chemotherapy Ind, Metastatic
No (No)
Unknown (Unknown)
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Yes (Yes)
Prior Metastatic Chemotherapy Type
Carboplatin/paclitaxel
(Carboplatin/Paclitaxel)
Cisplatin/gemcitabine
(Cisplatin/Gemcitabine)
M-vac (M-VAC)
Other (Other)
Prior Metastatic Chemotherapy Count
Prior Metastatic Chemotherapy Other Agent
Prior Pelvic RT Ind
No (No)
Unknown (unknown)
Yes (Yes)
Prior Surgery Ind
No (NO)
Unknown (UNKNOWN)
Yes (YES)
Prior Surgery Type
Patient Previously Had Other Surgery,
Specify (other, specify)
Patient Previosly Had A Partial
Cystectomy (partial cystectomy)
Patient Previosly Had A Radical
Cystectomy (radical cystectomy)
Patient Previosly Had A Turbt (TURBT)
Prior Surgery, TURBT Count
Prior Surgery, Other Type
Prior Other Therapy Ind
No (NO)
Unknown (UNKNOWN)
Yes (YES)
Prior Other Therapy Name
Allows Documentation Of Any Additional
Cooments
Comments
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On-Study - Resectable Pancreatic Cancer -
On-Study Form - 2020205v2.31
Resectable Pancreatic Cancer - On-Study Form
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=99CD59C5-
A9AA-3FA4-E034-080020C9C0E0
All rights reserved. Please visit https://medical-data-
models.org/forms/6922
Resectable Pancreatic Cancer - On-
Study Form
Crf Header
Coordinating Group Protocol Number
Coordinating Group Code
Protocol Title
Patient Study ID, Coordinating Group
Patient Study ID, Participating Group
Participating Group Code
Http://ctep.info.nih.gov.
(http://ctep.info.nih.gov.)
Institution Name
Affiliate Name
Patient Name, Last
Patient Name, First
Patient Name, Middle
Pancreatic: Form Administration
Person Completing Form, Last Name
Person Completing Form, First Name
Amended Data Ind
No (NO)
Unknown (UNKNOWN)
Yes (YES)
Pancreatic: Disease Description
1 / 4
Primary Site
Antrum (Antrum)
Body Of Pancreas (Body of pancreas)
Cardia (Cardia)
Cervical Esophagus (Cervical
esophagus)
Diffuse (Diffuse)
Esophagus, Not Otherwise Specified
(Esophagus, NOS)
Fundus (Fundus)
Gastro-esophageal Junction (Gastro-
esophageal junction)
Head Of Pancreas (Head of pancreas)
Linitus Plastica (Linitus plastica)
Lower Thoracic Esophagus, Excluding
The Gastro-esophageal Junction (Lower
thoracic esophagus (excludes G-E
junction))
Mid-thoracic Esophagus (Mid-thoracic
esophagus)
Other, Specify (Other, specify)
Pancreas, Not Otherwise Specified
(Pancreas, NOS)
Pylorus/pyloric Channel (Pylorus/Pyloric
channel)
Stomach, Not Otherwise Specified
(Stomach, NOS)
Tail Of Pancreas (Tail of pancreas)
Uncinate Process (Uncinate process)
Upper Thoracic Esophagus (Upper
thoracic esophagus)
Primary Site, Other
Disease Involvement Site
Adjacent Structures, Specify (Adjacent
structures, specify)
Adjacent Viscera (Adjacent viscera)
Adjacent Viscera/vessels (Adjacent
viscera/vessels)
Bone (Bone)
Distant Lymph Nodes (Distant lymph
nodes)
Liver (Liver)
Lung (Lung)
Other, Specify (Other, specify)
Peritoneal Disease (Peritoneal disease)
Peritoneum (Peritoneum)
Primary Tumor/esophagus (Primary
tumor/esophagus)
Primary Tumor/pancreas (Primary
tumor/pancreas)
Primary Tumor/stomach (Primary
tumor/stomach)
Regional Lymph Nodes (Regional lymph
nodes)
Disease Involvement Site, Other
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Advanced Disease Registration Status
Initial Diagnosis (Initial Diagnosis)
Recurrence (Recurrence)
Histologic Type
Acinar Cell Carcinoma (Acinar cell
carcinoma)
Adenocarcinoma (Adenocarcinoma)
Adenosquamous Carcinoma
(Adenosquamous carcinoma)
Ductal Adenocarcinoma (Ductal
adenocarcinoma)
Mixed-type (ductal-endocrine Or Acinar-
endocrine) (Mixed-type (ductal-endocrine
or acinar-endocrine))
Mucinous Adenocarcinoma (Mucinous
adenocarcinoma)
Mucinous Noncystic Carcinoma
(Mucinous noncystic carcinoma)
Neuroendocrine Carcinoma
(Neuroendocrine carcinoma)
Other, Specify (Other, specify)
Signet Ring Cell Carcinoma (Signet ring
cell carcinoma)
Small Cell Carcinoma (Small cell
carcinoma)
Squamous Cell Carcinoma (Squamous
cell carcinoma)
Tubular Adenocarcinoma (Tubular
adenocarcinoma)
Undifferentiated (anaplastic) Carcinoma
(Undifferentiated (anaplastic) carcinoma)
Undifferentiated Carcinoma With
Osteoclast-like Giant Cells
(Undifferentiated carcinoma with
osteoclast-like giant cells)
Unknown (Unknown)
Histologic Type, Other Name
Histologic Grade
Tumor Is Moderately Differentiated
According To Who Grading System
(Moderately differentiated (Grade II))
Tumor Is Poorly Differentiated According
To Who Grading System (Poorly
differentiated (Grade III))
Tumor Is Undifferentiated According To
Who Grading System (Undifferentiated
(Grade IV))
Unknown (Unknown)
Tumor Is Well Differentiated According
To Who Grading System (Well
differentiated (Grade I))
T Stage, Pathologic
T0, According To Ajcc Criteria (T0)
T1, According To Ajcc Criteria (T1)
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T2, According To Ajcc Criteria (T2)
T3, According To Ajcc Criteria (T3)
T4, According To Ajcc Criteria (T4)
Tis, According To Ajcc Criteria (Tis)
Tx, According To Ajcc Criteria (TX)
N Stage, Pathologic
No Lymph Node Involvement According
To Ajcc Guidelines (use For Esophageal,
Gastric, And Pancreatic) (N0)
N1, According To Ajcc Criteria (N1)
N2, According To Ajcc Criteria (N2)
N3, According To Ajcc Criteria (N3)
Lymph Node Involvement Cannot Be
Assessed According To Ajcc Guidelines
(use For Esophageal, Gastric, And
Pancreatic) (NX)
M Stage, Pathologic
No Distant Metastases According To
Ajcc Guidelines (M0)
Distant Metastases Present According
To Ajcc Guidelines (M1)
Distant Metastases Presence Or
Absence Cannot Be Assessed According
To Ajcc Guidelines (MX)
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Toxicity - Upper Gastrointestinal Cancers -
Adverse Event Form - 2020207v2.31
Upper Gastrointestinal Cancers - Adverse Event Form
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=99CD59C5-
A9AE-3FA4-E034-080020C9C0E0
All rights reserved. Please visit https://medical-data-
models.org/forms/6924
Upper Gastrointestinal Cancers -
Adverse Event Form
Crf Header
Coordinating Group Protocol Number
Coordinating Group Code
Protocol Title
Patient Study ID, Coordinating Group
Patient Study ID, Participating Group
Participating Group Code
Http://ctep.info.nih.gov.
(http://ctep.info.nih.gov.)
Institution Name
Affiliate Name
Patient Name, Last
Patient Name, First
Patient Name, Middle
Gi: Form Administration
Person Completing Form, Last Name
Person Completing Form, First Name
Amended Data Ind
No (NO)
Unknown (UNKNOWN)
Yes (YES)
Gi: Adverse Events
1 / 2
CTC Adverse Event Report Begin Date
CTC Adverse Event Report End Date
CTC Adverse Event Term
Ctep.info.nih.gov/ctc3/ctc.htm
(http://ctep.info.nih.gov/CTC3/ctc.htm)
CTC Adverse Event Grade
Ctep.info.nih.gov/ctc3/ctc.htm
(http://ctep.info.nih.gov/CTC3/ctc.htm)
CTC Adverse Event Term, Other
Allows Documentation Of Any Additional
Cooments
Comments
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Toxicity - Gynecologic Cancer - Toxicity
Form - 2019335v2.31
Gynecologic Cancer - Toxicity Form
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=99CD59C5-
A965-3FA4-E034-080020C9C0E0
All rights reserved. Please visit https://medical-data-
models.org/forms/6925
Gynecologic Cancer - Toxicity Form
Crf Header
Responsible Person Last Name
Coordinating Group Protocol Number
Coordinating Group Code
Protocol Title
Patient Study ID, Coordinating Group
Patient Study ID, Participating Group
Participating Group Code
Institution Name
Affiliate Name
Patient Name, Last
Patient Name, First
Patient Name, Middle
Gyn: Form Administration
Responsible Person Last Name
Responsible Person Last Name
Responsible Person Last Name
Responsible Person Last Name
Responsible Person Last Name
1 / 2
Responsible Person Last Name
Person Completing Form, Last Name
Person Completing Form, First Name
Amended Data Ind
No (NO)
Unknown (UNKNOWN)
Yes (YES)
Interval Report From Date
Interval Report To Date
Gyn: Adverse Events
CTC Adverse Event Report Begin Date
CTC Adverse Event Report End Date
CTC Adverse Event Term
Ctep.info.nih.gov/ctc3/ctc.htm
(http://ctep.info.nih.gov/CTC3/ctc.htm)
CTC Adverse Event Grade
Ctep.info.nih.gov/ctc3/ctc.htm
(http://ctep.info.nih.gov/CTC3/ctc.htm)
CTC Adverse Event Attribution Code
Definitely (Definitely)
Possibly (Possibly)
Probably (Probably)
Unlikely (Unlikely)
Unrelated (Unrelated)
CTC Adverse Event Term, Other
Allows Documentation Of Any Additional
Cooments
Comments
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Toxicity - Gynecologic Cancer - Toxicity
Form-Prerna - 2481404v1.0
Gynecologic Cancer - Toxicity Form-Prerna
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=13D5637B-
94B2-7453-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/6926
Gynecologic Cancer - Toxicity Form-
Prerna
Crf Header
Coordinating Group Protocol Number
Coordinating Group Code
Protocol Title
Patient Study ID, Coordinating Group
Patient Study ID, Participating Group
Participating Group Code
Institution Name
Affiliate Name
Patient Name, Last
Patient Name, First
Patient Name, Middle
Gyn: Form Administration
Person Completing Form, Last Name
Person Completing Form, First Name
Amended Data Ind
No (NO)
Unknown (UNKNOWN)
Yes (YES)
Interval Report From Date
Interval Report To Date
1 / 2
Responsible Person Last Name
Responsible Person Last Name
Responsible Person Last Name
Gyn: Adverse Events
CTC Adverse Event Report Begin Date
CTC Adverse Event Report End Date
CTC Adverse Event Term
Ctep.info.nih.gov/ctc3/ctc.htm
(http://ctep.info.nih.gov/CTC3/ctc.htm)
CTC Adverse Event Grade
Ctep.info.nih.gov/ctc3/ctc.htm
(http://ctep.info.nih.gov/CTC3/ctc.htm)
CTC Adverse Event Attribution Code
Definitely (Definitely)
Possibly (Possibly)
Probably (Probably)
Unlikely (Unlikely)
Unrelated (Unrelated)
CTC Adverse Event Term, Other
Allows Documentation Of Any Additional
Cooments
Comments
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Toxicity - Melanoma-Adverse Event Form -
2020197v2.31
Melanoma-Adverse Event Form
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=99CD59C5-
A99A-3FA4-E034-080020C9C0E0
All rights reserved. Please visit https://medical-data-
models.org/forms/6927
Melanoma-Adverse Event Form
Crf Header
Coordinating Group Protocol Number
Coordinating Group Code
Protocol Title
Patient Study ID, Coordinating Group
Patient Study ID, Participating Group
Participating Group Code
Institution Name
Affiliate Name
Patient Name, Last
Patient Name, First
Patient Name, Middle
Melanoma: Form Administration
Person Completing Form, Last Name
Person Completing Form, First Name
Amended Data Ind
No (NO)
Unknown (UNKNOWN)
Yes (YES)
Melanoma: Adverse Events
CTC Adverse Event Report Begin Date
1 / 2
CTC Adverse Event Report End Date
CTC Adverse Event Term
Ctep.info.nih.gov/ctc3/ctc.htm
(http://ctep.info.nih.gov/CTC3/ctc.htm)
CTC Adverse Event Grade
Ctep.info.nih.gov/ctc3/ctc.htm
(http://ctep.info.nih.gov/CTC3/ctc.htm)
CTC Adverse Event Term, Other
Melanoma: Vaccine Injection Site Reacton
Assessment Date
Vitiligo Ind
No (No)
Unknown (unknown)
Yes (Yes)
Vaccine Site
Left Lower Extremity (left lower
extremity)
Left Upper Extremity (left upper
extremity)
Other, Specify (other, specify)
Right Lower Extremity (right lower
extremity)
Right Upper Extremity (right upper
extremity)
Trunk (trunk)
Erythema
Induration
Vaccine Site, Other
Allows Documentation Of Any Additional
Cooments
Comments
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Treatment - Gynecologic Cancer -
Treatment by Cycle Form - 2019338v2.31
Gynecologic Cancer - Treatment by Cycle Form
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=99CD59C5-
A96C-3FA4-E034-080020C9C0E0
All rights reserved. Please visit https://medical-data-
models.org/forms/6928
Gynecologic Cancer - Treatment by
Cycle Form
Crf Header
Coordinating Group Protocol Number
Coordinating Group Code
Protocol Title
Patient Study ID, Coordinating Group
Patient Study ID, Participating Group
Participating Group Code
Institution Name
Affiliate Name
Patient Name, Last
Patient Name, First
Patient Name, Middle
Gyn: Form Administration
Person Completing Form, Last Name
Person Completing Form, First Name
Amended Data Ind
No (NO)
Unknown (UNKNOWN)
Yes (YES)
Interval Report From Date
Interval Report To Date
1 / 6
Gyn: Surgical Treatment
Protocol Surgery Ind
No (No)
Unknown (unknown)
Yes (Yes)
Protocol Surgery Date
Protocol Surgery Type
Bilateral Salpingo-oophorectomy
(bilateral salpingo-oophorectomy)
Omentectomy (omentectomy)
Other, Specify (other, specify)
Para-aortic Node Sampling/dissection
(para-aortic node sampling/dissection)
Partial Hysterectomy (partial
hysterectomy)
Pelvic Node Sampling/dissection (pelvic
node sampling/dissection)
Radical Hysterectomy (radical
hysterectomy)
Total Hysterectomy (total hysterectomy)
Unilateral Salpingo-oophorectomy
(unilateral salpingo-oophorectomy)
Protocol Surgery Other Type
Protocol Surgery Reason
Interval Debulking (Interval debulking)
Other, Specify (Other, specify)
Palliative Therapy (Palliative therapy)
Second Look Procedure (Second look
procedure)
Protocol Surgery Other Reason
Residual Disease
Protocol Surgery, Qualifying Results Ind
No (No)
Not Applicable (not applicable)
Yes (Yes)
Gyn: Treatment Modifications (surgical
Treatment)
Dose Modification (Change)
No (No)
Unknown (Unknown)
(i.e., The Treatment Was Changed
According To Protocol Guidelines) (Yes,
planned)
(i.e., The Treatment Change Was Not
Part Of Protocol Guidelines) (Yes,
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unplanned)
Dose Modification Reason
Gyn: Radiation Therapy-treatment Cycle
Information
RT Type
Adjuvant Rt (adjuvant RT)
Brachytherapy (brachytherapy)
External Beam Radiation (external beam
radiation)
Neoadjuvant Rt (neoadjuvant RT)
Other, Specify (other, specify)
RT Other Type
Brachytherapy Application Method
High Dose Rate (High dose rate)
Low Dose Rate (Low dose rate)
Brachytherapy Begin Date
Brachytherapy End Date
Brachytherapy Total Dose, Right
Brachytherapy Total Dose, Left
Brachytherapy Total Implant Count
RT Begin Date
RT End Date
RT Site
Bladder (Bladder)
Cervix (Cervix)
Specify First Location Or Primary Field
(Location 1, specify)
Specify Second Location Or Primary
Field (Location 2, specify)
Specify Third Location Or Primary Field
(Location 3, specify)
Specify Other Location Not Described
(Other, specify)
Pelvic Region (Pelvis)
Rectum (Rectum)
Small Bowel (Small bowel)
Vagina (Vagina)
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RT Site, Location Name
RT Site, Other
RT Total Dose
RT Total Fraction Count
RT Site, Boost
None (none)
Other, Specify (other, specify)
Para-aortic Nodes (para-aortic nodes)
Pelvic Nodes (pelvic nodes)
Vagina (vagina)
RT Site, Other Boost
RT Total Dose, Boost
RT Total Fraction Count Boost
RT Interruptions Ind
No (No)
Unknown (Unknown)
Yes (Yes)
Yes, Due To Toxicity (Yes, due to toxicity)
Yes, For Other Reasons, Specify (Yes,
for other reasons, specify)
RT Interruptions Reason
Medical Condition, Specify (medical
condition, specify)
Non-medical Reason (non-medical
reason)
Other, Specify (other, specify)
Scheduling Problem (scheduling
problem)
Technical Problem (technical problem)
Toxicity (toxicity)
RT Interruptions Reason, Medical
RT Interruptions Reason, Other
Gyn: Treatment Modifications (radiation
Therapy)
Dose Modification (Change)
No (No)
Unknown (Unknown)
(i.e., The Treatment Was Changed
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According To Protocol Guidelines) (Yes,
planned)
(i.e., The Treatment Change Was Not
Part Of Protocol Guidelines) (Yes,
unplanned)
Dose Modification Reason
Gyn: Systemic Therapy-treatment Cycle
Information
Course Begin Date
Course Identification
Agent Total Dose (per course)
Agent Dose Units
Centigrays (cGy)
Curie (Ci)
Centimeter (cm)
Deciliter (dL)
Decimeter (dm)
Gram-equivalent Weight (Eq)
Gram (g)
Gravity (in Centrifugation) (gravity)
Grays (Gy)
Hertz (Hz)
International Unit (IU)
Joules Per Centimeter Square (JCM2)
Kilo-electron Volt (keV)
Kilogram (kg)
Kilohertz (kHz)
Kilopascal (kPa)
Liter (L)
Meter (m)
Microcurie (mcCi)
Microgram (mcg)
Millicurie (mCi)
Microliter (mcL)
Micrometer (mcm)
Milliequivalent (mEq)
Million Electron Volts (MeV)
Milligram (mg)
Megahertz (MHz)
Milliunit (milliunit)
Milliliter (mL)
Millimeter (mm)
Milligrams Per Milliliter Per Minute
(MMM)
Millimole (mmol)
Gram-molecular Weight (mole) (mol)
Milliosmole (mOsmol)
Megarad (Mrad)
Million Unit (mU)
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Millivolt (mV)
Not Applicable (N/A)
Nanocurie (nCi)
Nanogram (ng)
Nanometer (nm)
Nanometers Of Light (nm light)
Osmole (Osmol)
Pascal (Pa)
Plaque Forming Unit (pfu)
Picogram (pg)
Pounds Per Square Inch (psi)
Unit (unit)
Viral Particles (VP)
Agent Name
Gyn: Treatment Modifications (systemic
Therapy)
Dose Modification (Change)
No (No)
Unknown (Unknown)
(i.e., The Treatment Was Changed
According To Protocol Guidelines) (Yes,
planned)
(i.e., The Treatment Change Was Not
Part Of Protocol Guidelines) (Yes,
unplanned)
Dose Modification Reason
Allows Documentation Of Any Additional
Cooments
Comments
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Pathology - Prostate Cancer - Pathology Form
- Transurethral Resection - 2020192v3.0
Prostate Cancer - Pathology Form - Transurethral
Resection
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=198056F5-
3A1B-10BC-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/6930
Prostate Cancer - Pathology Form -
Transurethral Resection
Crf Header
Coordinating Group Protocol Number
Coordinating Group Code
Protocol Title
Patient Study ID, Coordinating Group
Patient Study ID, Participating Group
Participating Group Code
Institution Name
Affiliate Name
Patient Name, Last
Patient Name, First
Patient Name, Middle
Prostate Pathology: Form Administration
Person Completing Form, Last Name
Person Completing Form, First Name
Amended Data Ind
No (NO)
Unknown (UNKNOWN)
Yes (YES)
Pathology: Transurethral Resection (tur)
1 / 5
Data Source
Outside Source (Outside source)
Performed Internally And Internally
Reviewed (Performed internally and
internally reviewed)
Performed Outside, But With Internal
Review (Performed outside, but with
internal review)
Therapeutic Effect Ind
No (No)
Unknown (Unknown)
Yes (Yes)
Therapy Name
Hormonal Therapy (Hormonal therapy)
Other (Other)
Radiation Therapy (Radiation therapy)
Unknown (Unknown)
Other Therapy Name
Surgical Procedure Type
Fine Needle Aspiration (Fine needle
aspiration)
Needle Biopsy (Needle biopsy)
Open Biopsy (Open biopsy)
Other, Specify (Other)
Radical Prostatectomy, Laparoscopic
(Radical prostatectomy, laparoscopic)
Radical Prostatectomy, Nos (Radical
prostatectomy, NOS)
Radical Prostatectomy, Perineal (Radical
prostatectomy, perineal)
Radical Prostatectomy, Retropubic
(Radical prostatectomy, retropubic)
Suprapubic Prostatectomy (Suprapubic
prostatectomy)
Transurethral Resection (Transurethral
resection)
Surgical Procedure Other Type
Surgery Date
Specimen, Resection Weight
Specimen, Examined Tumor Percentage
Specimen, Cancer Chips Count
Specimen, Cancer Present Percentage
PIN Ind, High Grade
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No (No)
Unknown (Unknown)
Yes (Yes)
Extraprostatic Extension Ind
No (No)
Unknown (Unknown)
Yes (Yes)
Extraprostatic Extension Type
Established (Established)
Focal </= 2 Hpf (Focal </= 2 hpf)
Unknown (Unknown)
Extraprostatic Extension Laterality
Bilateral (Bilateral)
Unilateral (Unilateral)
Unknown (Unknown)
Extraprostatic Extension Extent, Vertical
Extraprostatic Extension Extent, Horizontal
Lymphovascular Invasion Ind
Indeterminate (Indeterminate)
No (No)
Unknown (Unknown)
Yes (Yes)
Lymphovascular Invasion Description
Perineural Involvement Ind
Indeterminate (Indeterminate)
No (No)
Unknown (Unknown)
Yes (Yes)
Perineural Invasion Description
Gleason Score, Primary Pattern
Gleason Score, Secondary Pattern
Gleason Score, Combined
Gleason Score, Worst Pattern
Pathology: Disease Assessment
Histologic Type
Adenocarcinoma, Conventional, Not
Otherwise Specified (Adenocarcinoma,
conventional, NOS)
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Adenocarcinoma/acinar
(Adenocarcinoma/Acinar)
Adenosquamous Carcinoma
(Adenosquamous carcinoma)
Basaloid And Adenoid Cystic Carcinoma
(Basaloid and adenoid cystic carcinoma)
Lymphoepithelioma-like Carcinoma
(Lymphoepithelioma-like carcinoma)
Mucinous (colloid) Adenocarcinoma
(Mucinous (colloid) adenocarcinoma)
Other (Other, specify)
Prostatic Duct Adenocarcinoma
(Prostatic duct adenocarcinoma)
Sarcomatoid Carcinoma (Sarcomatoid
carcinoma)
Signet Ring Cell Carcinoma (Signet ring
cell carcinoma)
Small Cell Carcinoma (Small cell
carcinoma)
Squamous Cell Carcinoma (Squamous
cell carcinoma)
Transitional Cell Carcinoma (Transitional
cell carcinoma)
Undifferentiated Carcinoma, Not
Otherwise Specified (Undifferentiated
carcinoma, NOS)
Urothelial Primary In Prostate (Urothelial
primary in prostate)
Histologic Type, Other Name
Histologic Type, Variant
Adenosquamous Carcinoma
(Adenosquamous carcinoma)
Prostatic Duct Adenocarcinoma (Ductal
carcinoma)
Mucinous (colloid) Adenocarcinoma
(Mucinous adenocarcinoma)
Other, Specify (Other, specify)
Sarcomatoid Carcinoma (Sarcomatoid
carcinoma)
Signet Ring Cell Carcinoma (Signet ring
cell carcinoma)
Small Cell Carcinoma (Small cell
carcinoma)
Squamous Cell Carcinoma (Squamous
cell carcinoma)
Histologic Type, Other Variant
Histologic Type, Variant Percent
Histologic Type, Variant Percent
T Stage, Pathologic
Organ Confined (pT2)
Unilateral (pT2a)
Bilateral (pT2b)
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Extraprostatic Extension (pT3)
Extraprostatic Extension (pT3a)
Seminal Vesicle Invasion (pT3b)
Invasion Of Bladder, Restum (pT4)
No Evidence Of Primary Tumor (T0)
T1, Clinically Inapparent Tumor Not
Palpable Or Visible By Imaging (see Ajcc
Definition) (T1, NOS)
T1a, Clinically Inapparent Tumor Not
Palpable Or Visible By Imaging (see Ajcc
Definition) (T1a)
T1b, Clinically Inapparent Tumor Not
Palpable Or Visible By Imaging (see Ajcc
Definition) (T1b)
T1c, Clinically Inapparent Tumor Not
Palpable Or Visible By Imaging (see Ajcc
Definition) (T1c)
T2, Tumor Confined Within The Prostate
(see Ajcc Definition) (T2, NOS)
T2a, Tumor Confined Within The
Prostate (see Ajcc Definition) (T2a)
T2b, Tumor Confined Within The
Prostate (see Ajcc Definition) (T2b)
T3, Tumor Extends Through The
Prostatic Capsule (see Ajcc Definition)
(T3, NOS)
T3a, Tumor Extends Through The
Prostatic Capsule (see Ajcc Definition)
(T3a)
T3b, Tumor Extends Through The
Prostatic Capsule (see Ajcc Definition)
(T3b)
T4, Tumor Is Fixed Or Invades Adjacent
Structures (see Ajcc Definition) (T4,
NOS)
Primary Tumor Cannot Be Assessed
(TX)
Use The Ajcc Staging System Specified
In The Protocol (Use the AJCC staging
system specified in the protocol)
N Stage, Pathologic
No Regional Lymph Node Metastasis
(N0)
Metastatis In Regional Lymph Node Or
Nodes (see Ajcc Definition) (N1)
Regional Lymph Nodes Cannot Be
Assessed (NX)
Use The Ajcc Staging System Specified
In The Protocol (Use the AJCC staging
system specified in the protocol)
5 / 5
Pathology - Prostate Cancer - Pathology Form - Transurethral Resection -
2020192v3.0
Treatment - Bladder/Urothelial Cancer -
Treatment by Cycle Form - 2019329v2.31
Bladder/Urothelial Cancer - Treatment by Cycle Form
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=99CD59C5-
A959-3FA4-E034-080020C9C0E0
All rights reserved. Please visit https://medical-data-
models.org/forms/6931
Bladder/Urothelial Cancer -
Treatment by Cycle Form
Crf Header
Coordinating Group Protocol Number
Coordinating Group Code
Protocol Title
Patient Study ID, Coordinating Group
Patient Study ID, Participating Group
Participating Group Code
Institution Name
Affiliate Name
Patient Name, Last
Patient Name, First
Patient Name, Middle
Bladder/urothelial: Form Administration
Person Completing Form, Last Name
Person Completing Form, First Name
Amended Data Ind
No (NO)
Unknown (UNKNOWN)
Yes (YES)
Bladder/urothelial: Treatment Cycle And
Modifications
Course Begin Date
1 / 4
Course Identification
Agent Total Dose (per course)
Agent Dose Units
Curie (Ci)
Centimeter (cm)
Deciliter (dL)
Decimeter (dm)
Gram-equivalent Weight (Eq)
Gram (g)
Gravity (in Centrifugation) (gravity)
Hertz (Hz)
International Unit (IU)
Joules Per Centimeter Square (JCM2)
Kilo-electron Volt (keV)
Kilogram (kg)
Kilohertz (kHz)
Kilopascal (kPa)
Liter (L)
Meter (m)
Microcurie (mcCi)
Microgram (mcg)
Millicurie (mCi)
Microliter (mcL)
Micrometer (mcm)
Milliequivalent (mEq)
Million Electron Volts (MeV)
Milligram (mg)
Megahertz (MHz)
Milliunit (milliunit)
Milliliter (mL)
Millimeter (mm)
Milligrams Per Milliliter Per Minute
(MMM)
Millimole (mmol)
Gram-molecular Weight (mole) (mol)
Milliosmole (mOsmol)
Megarad (Mrad)
Million Unit (mU)
Millivolt (mV)
Not Applicable (N/A)
Nanocurie (nCi)
Nanogram (ng)
Nanometer (nm)
Nanometers Of Light (nm light)
Osmole (Osmol)
Pascal (Pa)
Plaque Forming Unit (pfu)
Picogram (pg)
Pounds Per Square Inch (psi)
Unit (unit)
Viral Particles (VP)
Agent Name
Dose Modification (Change)
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No (No)
Unknown (Unknown)
(i.e., The Treatment Was Changed
According To Protocol Guidelines) (Yes,
planned)
(i.e., The Treatment Change Was Not
Part Of Protocol Guidelines) (Yes,
unplanned)
Dose Modification Reason
No Dose Modification (No)
Yes, There Was A Planned Dose
Modification According To Protocol
Guidelines (Yes, planned (i.e., the
treatment was changed according to
protocol guidelines)
Yes, There Was An Unplanned Dose
Modifiction That Was Not Part Of
Protocol Guidelines (Yes, unplanned
(i.e., the treatment change was not part
of protocol guidelines))
Bladder/urothelial: Off-treatment
Off Treatment Reason
Alternative Therapy (Alternative therapy)
Death Of Patient Occurred After The
Patient Began Protocol Therapy (Death
after beginning protocol therapy)
Death On Study (Death on study)
Death Prior To Beginning Protocol
Therapy (Death prior to beginning
protocol therapy)
Disease Progression, Relapse During
Active Treatment (Disease progression,
relapse during active treatment)
Progression Of Disease Occurred Prior
To The Patient Beginning Protocol
Therapy (Disease progression, relapse
prior to beginning protocol therapy)
Disease Recurrence (Disease
recurrence)
Other (Other)
Other, Specify (Other, specify)
Patient Off-treatment For Other
Complicating Disease (Patient off-
treatment for other complicating disease)
Patient Withdrawal Or Refusal After
Beginning Protocol Therapy (Patient
withdrawal or refusal after beginning
protocol therapy)
Patient Withdrawal Or Refusal Prior To
Beginning Protocol Therapy (Patient
withdrawal or refusal prior to beginning
protocol therapy)
Toxicity/side Effects/complications
(Toxicity/Side effects/Complications)
Treatment Completed Per Protocol
Criteria (Treatment completed per
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protocol criteria)
Off Treatment Reason, Other
Allows Documentation Of Any Additional
Cooments
Comments
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On-Study - Unresectable Pancreatic Cancer
- On-Study Form - 2020206v2.31
Unresectable Pancreatic Cancer - On-Study Form
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=99CD59C5-
A9AC-3FA4-E034-080020C9C0E0
All rights reserved. Please visit https://medical-data-
models.org/forms/6932
Unresectable Pancreatic Cancer -
On-Study Form
Crf Header
Coordinating Group Protocol Number
Coordinating Group Code
Protocol Title
Patient Study ID, Coordinating Group
Patient Study ID, Participating Group
Participating Group Code
Http://ctep.info.nih.gov.
(http://ctep.info.nih.gov.)
Institution Name
Affiliate Name
Patient Name, Last
Patient Name, First
Patient Name, Middle
Pancreatic: Form Administration
Person Completing Form, Last Name
Person Completing Form, First Name
Amended Data Ind
No (NO)
Unknown (UNKNOWN)
Yes (YES)
Pancreatic: Disease Description
1 / 4
Primary Site
Antrum (Antrum)
Body Of Pancreas (Body of pancreas)
Cardia (Cardia)
Cervical Esophagus (Cervical
esophagus)
Diffuse (Diffuse)
Esophagus, Not Otherwise Specified
(Esophagus, NOS)
Fundus (Fundus)
Gastro-esophageal Junction (Gastro-
esophageal junction)
Head Of Pancreas (Head of pancreas)
Linitus Plastica (Linitus plastica)
Lower Thoracic Esophagus, Excluding
The Gastro-esophageal Junction (Lower
thoracic esophagus (excludes G-E
junction))
Mid-thoracic Esophagus (Mid-thoracic
esophagus)
Other, Specify (Other, specify)
Pancreas, Not Otherwise Specified
(Pancreas, NOS)
Pylorus/pyloric Channel (Pylorus/Pyloric
channel)
Stomach, Not Otherwise Specified
(Stomach, NOS)
Tail Of Pancreas (Tail of pancreas)
Uncinate Process (Uncinate process)
Upper Thoracic Esophagus (Upper
thoracic esophagus)
Primary Site, Other
Disease Involvement Site
Adjacent Structures, Specify (Adjacent
structures, specify)
Adjacent Viscera (Adjacent viscera)
Adjacent Viscera/vessels (Adjacent
viscera/vessels)
Bone (Bone)
Distant Lymph Nodes (Distant lymph
nodes)
Liver (Liver)
Lung (Lung)
Other, Specify (Other, specify)
Peritoneal Disease (Peritoneal disease)
Peritoneum (Peritoneum)
Primary Tumor/esophagus (Primary
tumor/esophagus)
Primary Tumor/pancreas (Primary
tumor/pancreas)
Primary Tumor/stomach (Primary
tumor/stomach)
Regional Lymph Nodes (Regional lymph
nodes)
Disease Involvement Site, Other
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Advanced Disease Registration Status
Initial Diagnosis (Initial Diagnosis)
Recurrence (Recurrence)
Histologic Type
Acinar Cell Carcinoma (Acinar cell
carcinoma)
Adenocarcinoma (Adenocarcinoma)
Adenosquamous Carcinoma
(Adenosquamous carcinoma)
Ductal Adenocarcinoma (Ductal
adenocarcinoma)
Mixed-type (ductal-endocrine Or Acinar-
endocrine) (Mixed-type (ductal-endocrine
or acinar-endocrine))
Mucinous Adenocarcinoma (Mucinous
adenocarcinoma)
Mucinous Noncystic Carcinoma
(Mucinous noncystic carcinoma)
Neuroendocrine Carcinoma
(Neuroendocrine carcinoma)
Other, Specify (Other, specify)
Signet Ring Cell Carcinoma (Signet ring
cell carcinoma)
Small Cell Carcinoma (Small cell
carcinoma)
Squamous Cell Carcinoma (Squamous
cell carcinoma)
Tubular Adenocarcinoma (Tubular
adenocarcinoma)
Undifferentiated (anaplastic) Carcinoma
(Undifferentiated (anaplastic) carcinoma)
Undifferentiated Carcinoma With
Osteoclast-like Giant Cells
(Undifferentiated carcinoma with
osteoclast-like giant cells)
Unknown (Unknown)
Histologic Type, Other Name
Histologic Grade
Tumor Is Moderately Differentiated
According To Who Grading System
(Moderately differentiated (Grade II))
Tumor Is Poorly Differentiated According
To Who Grading System (Poorly
differentiated (Grade III))
Tumor Is Undifferentiated According To
Who Grading System (Undifferentiated
(Grade IV))
Unknown (Unknown)
Tumor Is Well Differentiated According
To Who Grading System (Well
differentiated (Grade I))
T Stage, Pathologic
T0, According To Ajcc Criteria (T0)
T1, According To Ajcc Criteria (T1)
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T2, According To Ajcc Criteria (T2)
T3, According To Ajcc Criteria (T3)
T4, According To Ajcc Criteria (T4)
Tis, According To Ajcc Criteria (Tis)
Tx, According To Ajcc Criteria (TX)
N Stage, Pathologic
No Lymph Node Involvement According
To Ajcc Guidelines (use For Esophageal,
Gastric, And Pancreatic) (N0)
N1, According To Ajcc Criteria (N1)
N2, According To Ajcc Criteria (N2)
N3, According To Ajcc Criteria (N3)
Lymph Node Involvement Cannot Be
Assessed According To Ajcc Guidelines
(use For Esophageal, Gastric, And
Pancreatic) (NX)
M Stage, Pathologic
No Distant Metastases According To
Ajcc Guidelines (M0)
Distant Metastases Present According
To Ajcc Guidelines (M1)
Distant Metastases Presence Or
Absence Cannot Be Assessed According
To Ajcc Guidelines (MX)
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Bladder Cancer NCT00014534 Treatment - NCI Cooperative
Group Treatment Summary Form (CALGB-90104) - 2055978v3.0
NCI Cooperative Group Treatment Summary Form
(CALGB-90104)
Combination Chemotherapy in Treating Patients With
Bladder Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=A9C02140-
B193-2659-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/6933
NCI Cooperative Group Treatment
Summary Form (CALGB-90104)
Mskcc 00-138; Calgb-90104; Ecog
Coordinating Group Protocol Number
Coordinating Group Code
Protocol Title
Patient Study ID, Coordinating Group
Patient Study ID, Participating Group
Participating Group Code
Institution Name
Affiliate
Patient Last Name (initials acceptable)
Patient First Name (initials acceptable)
Patient Middle Name (initials acceptable)
Form Administration
Person Completing Form, Last Name
Person Completing Form, First Name
Are data amended?
Yes
No
Treatment Schedule - Chemotherapy
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Date of First Dose for This Reporting Period
Date of Last Dose for This Reporting Period
Total Number of cycles Given
Off-treatment And Modifications
Reason Treatment Ended (check one)
Alternative Therapy (Alternative therapy)
Death After Beginning Protocol Therapy
(Death after beginning protocol therapy)
Death Prior To Beginning Protocol
Therapy (Death prior to beginning
protocol therapy)
Disease Progression, Relapse During
Active Treatment (Disease progression,
relapse during active treatment)
Disease Progression, Relapse Prior To
Beginning Protocol Therapy (Disease
progression, relapse prior to beginning
protocol therapy)
Disease Progression, Relapse During
Active Treatment (Disease recurrence)
Other (Other complicating disease)
Other (Other, specify)
Patient Withdrawal Or Refusal After
Beginning Protocol Therapy (Patient
withdrawal or refusal after beginning
protocol therapy)
Patient Withdrawal Or Refusal Prior To
Beginning Protocol Therapy (Patient
withdrawal or refusal prior to beginning
protocol therapy)
Toxicity/side Effects/complications
(Toxicity/side effects/complications)
Treatment Completed Per Protocol
Criteria (Treatment completed per
protocol criteria)
Other, specify
Were there any dose modificiations or
additions/omissions to protocol treatment? (check
one)
No (No)
(i.e., The Treatment Was Changed
According To Protocol Guidelines) (Yes,
planned)
(i.e., The Treatment Change Was Not
Part Of Protocol Guidelines) (Yes,
unplanned)
Specify (if yes, unplanned)
2 / 3
Bladder Cancer NCT00014534 Treatment - NCI Cooperative Group
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Ccrr Module For Nci Cooperative Group
Treatment Summary Form (calgb-90104)
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Bladder Cancer NCT00014534 Toxicity - NCI Cooperative
Group Toxicity Form (CALGB-90104) - 2056157v3.0
NCI Cooperative Group Toxicity Form (CALGB-90104)
Combination Chemotherapy in Treating Patients With
Bladder Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=A9BEFBAB-
CF40-25AD-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/6934
NCI Cooperative Group Toxicity
Form (CALGB-90104)
Mskcc 00-138; Calgb 90104; Ecog
Coordinating Group Protocol Number
Coordinating Group Code
Protocol Title
Patient Study ID, Coordinating Group
Patient Study ID, Participating Group
Participating Group Code
Institution Name
Affiliate
Patient Last Name (initials acceptable)
Patient First Name (initials acceptable)
Patient Middle Name (initials acceptable)
Form Administration
Person Completing Form, Last Name
Person Completing Form, First Name
Are data amended? (If data are amended, please
circle in red when using paper form)
Yes
No
Adverse Events
1 / 2
CTC Adverse Event Term
Adverse Event Reporting From Date
Adverse Event Reporting To Date
CTC Adverse Event Grade
CTC Adverse Event Attribution Code
Definitely (definitely)
Possibly (possibly)
Probably (probably)
Unlikely (unlikely)
Unrelated (unrelated)
Treatment?
Yes
No
SAE filed?
Yes
No
Ccrr Module For Nci Cooperative Group
Toxicity Form (calgb-90104)
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Bladder Cancer NCT00014534 On-Study - NCI Cooperative
Group On-Study Form (CALGB-90104) - 2056020v3.0
NCI Cooperative Group On-Study Form (CALGB-90104)
Combination Chemotherapy in Treating Patients With
Bladder Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=A9C0279B-
A154-2673-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/6935
NCI Cooperative Group On-Study
Form (CALGB-90104)
Mskcc 00-138; Calgb-90104; Ecog
Coordinating Group Protocol Number
Coordinating Group Code
Protocol Title
Patient Study ID, Coordinating Group
Patient Study ID, Participating Group
Participating Group Code
Institution Name
Affiliate
Patient Last Name (initials acceptable)
Patient First Name (initials acceptable)
Patient Middle Name (initials acceptable)
Form Administration
Person Completing Form, Last Name
Person Completing Form, First Name
Are data amended?
Yes
No
Disease Description For Muscle Invasive
Bladder Cancer
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Date of Initial Symptom
Has the patient had a prior history of superficial
disease?
Yes
No
No. of Prior Occurrences of Papillary
NO. of Prior Occurrences of CIS
Date of Initial Pathologic Diagnosis
Date of Initial Pathologic Diagnosis
Date of Initial Diagnosis of Metastatic Disease
Date of Current Pathologic Diagnosis
Date of Most Recent Prior Recurrence
Histologic Type (mark all that apply)
Other Specify (Other, specify)
Transitional Cell Carcinoma (Transitional
cell carcinoma)
Other, specify
Histologic Grade (check the highest grade)
Tumor Grade Cannot Be Assessed
(Grade cannot be assessed (GX))
Moderately Differentiated (Moderately
differentiated (G2))
Poorly Differentiated (Poorly
differentiated (G3))
Well Differentiated (Well differentiated
(G1))
Pathologic T Stage (Indicate highest stage at the
current presentation of disease)
No Evidence Of Primary Tumor (T0)
Tumor Invades Subepithelial Connective
Tissue (T1)
Tumor Invades Superficial Muscles (inner
Half) (T2a)
Tumor Invades Deep Muscles (outer
Half) (T2b)
Tumor Invades Perivesical Tissue
Microscopically (T3a)
Tumor Invades Perivesical Tissue
Macroscopically (extravesical Mass)
(T3b)
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Inflammatory Carcinoma (T4)
Pathologic N Stage (Distant Metastasis)
No Regional Lymph Node Metastasis
(N0)
Metastasis In A Single Lymph Node, 2
Cm Or Less In Greatest Dimension (N1)
Metastasis In A Single Lymph Node,
More Than 2 Cm But Not More Than 5
Cm In Greatest Dimension; Or Multiple
Lymph Nodes, None More Than 5 Cm In
Greatest Dimension (N2)
Metastasis In A Lymph Node More Than
5 Cm In Greatest Dimension (N3)
Regional Lymph Nodes Cannot Be
Assessed (Nx)
Pathologic M Stage
M0, According To Ajcc Staging
Definitions (M0)
M1, According To Ajcc Staging
Definitions (M1)
Mx (Mx)
Lymph Node Type
Common Iliac (Common Iliac)
External Iliac (External Iliac)
Hypogastric (Hypogastric)
Internal Iliac (Internal Iliac)
Other, Specify (Other, specify)
Para-aortic (Para-aortic)
Other, specify
Lymph Node Involvement
Equivocal (equivocal)
Negative (negative)
Not Evaluated (not evaluated)
Positive (positive)
Unknown (unknown)
No. of Lymph Nodes Examined
No. of Positive Lymph Nodes
Is the tumor(s) at the surgical margin?
Yes
No
Muscle Invasive Bladder Disease: Prior
Treatment Affecting The Bladder
Prior Intravesical Therapy (Note: If no, skip to
Prior Surgery below)
Yes
No
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Type of Prior Immunotherapy
Bcg (BCG)
Interferon (Interferon)
Other (Other)
No. of Courses
Specify agent
Agent Start Date
Agent End Date
Type of Prior Chemotherapy
Mmc (MMC)
Other (Other)
Thiotepa (Thiotepa)
No. of Courses
Specify agent
Prior Surgery (for urothelial disease)
Yes
No
Prior Surgery Type
Patient Previously Had Other Surgery,
Specify (Other, specify)
Patient Previosly Had A Partial
Cystectomy (Partial cystectomy)
Patient Previosly Had A Radical
Cystectomy (radical cystectomy)
Patient Previosly Had A Turbt (TURBT)
Other, specify
TURBT, Number
Any Other Prior Therapy
Yes
No
Name of other Prior Therapies
Comments
Comments
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Ccrr Module For Nci Cooperative Group
On-study Form (calgb-90104)
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Bladder Cancer NCT00014534 Lab - NCI Cooperative Group Clinical
Chemistry Laboratory Test Form (CALGB-90104) - 2056328v3.0
NCI Cooperative Group Clinical Chemistry Laboratory Test
Form (CALGB-90104)
Combination Chemotherapy in Treating Patients With
Bladder Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=A9C02D4A-
83A3-26C1-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/6936
NCI Cooperative Group Clinical
Chemistry Laboratory Test Form
(CALGB-90104)
Mskcc 00-138; Calgb-90104; Ecog
Coordinating Group Protocol Number
Coordinating Group Code
Protocol Title
Patient Study ID, Coordinating Group
Patient Study ID, Participating Group
Participating Group Code
Institution Name
Affiliate
Patient Last Name (initials acceptable)
Patient First Name (initials acceptable)
Patient Middle Name (initials acceptable)
Form Administration
Person Completing Form, Last Name
Person Completing Form, First Name
Are data amended?
Yes
No
BUN
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Calcium
Bilirubin
Total Protein
Albumin
Alkaline Phosphatase
SGOT (AST)
Glucose
Creatinine
Sodium
Potassium
Chloride
Carbon Dioxide
Magnesium
SGPT (ALT)
Unit (Normal Range)
G/dl (g/dL)
Meq/l (mEq/L)
Mg/dl (mg/dL)
Mmol/l (mmol/L)
U/l (U/L)
Units (Units)
Normal Range-BUN
Normal Range-Calcium
Normal Range-Bilirubin
Normal Range-Total Protein
Normal Range-Albumin
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Chemistry Laboratory Test Form (CALGB-90104) - 2056328v3.0
Normal Range-Alkaline Phosphatase
Normal Range-SGOT (AST)
Normal Range-Glucose
Normal Range-Creatinine
Normal Range-Sodium
Normal Range-Potassium
Normal Range-Chloride
Normal Range-Carbon Dioxide
Normal Range-Magnesium
Normal Range-SGPT (ALT)
Labs, Sample Collection Dates
Comments
Comments
Ccrr Module For Nci Cooperative Group
Clinical Chemistry Laboratory Test Form
(calgb-90104)
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Chemistry Laboratory Test Form (CALGB-90104) - 2056328v3.0
Bladder Cancer NCT00014534 Follow-Up - NCI Cooperative
Group Follow-Up Form (CALGB-90104) - 2056490v3.0
NCI Cooperative Group Follow-Up Form (CALGB-90104)
Combination Chemotherapy in Treating Patients With
Bladder Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=A9C23658-
5AE0-303F-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/6937
NCI Cooperative Group Follow-Up
Form (CALGB-90104)
Mskcc 00-138; Calgb-90104; Ecog
Coordinating Group Protocol Number
Coordinating Group Code
Protocol Title
Patient Study ID, Coordinating Group
Patient Study ID, Participating Group
Participating Group Code
Institution Name
Affiliate
Patient Last Name (initials acceptable)
Patient First Name (initials acceptable)
Patient Middle Name (initials acceptable)
Form Administration
Person Completing Form, Last Name
Person Completing Form, First Name
Are data amended?
Yes
No
Vital Status
1 / 4
Patient's Vital Status
Alive (Alive with Disease)
Alive (Alive-NED)
Dead (Dead)
Primary Cause of Death (check one)
Due to other cause (Due to other cause)
Due To Protocol Treatment (Due to
protocol treatment)
Due To This Disease (Due to this
disease)
Unknown (Unknown)
Describe cause of death
Date of Last Contact or Death (MM DD YYYY)
Disease Follow-up Status
Has the patient had a documented clinical
assessment for this cancer?
Yes
No
Date of Last Clinical Assessment (MM DD YYYY)
Chest X-ray Assessment Date
Abdominal/Pelvic CT Assessment Date
Notice Of Progression
Has the patient been diagnosed with a local
recurrence that has not been previously
reported?
Yes
No
Date of First Local Progression (MM DD YYYY)
Site(s) of First Local Progression (mark all that
apply)
abdominal wall (abdominal wall)
Other, Specify (other, specify)
pelvic wall (pelvic wall)
Peritoneum (peritoneum)
prostate (prostate)
skin (skin)
urethra (urethra)
Uterus (uterus)
vagina (vagina)
2 / 4
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Other, specify
Has the patient been diagnosed with a local-
regional lymph node recurrence?
Yes
No
Date of First Local-Regional Lymph Node
Progression (MM DD YYYY)
Site(s) of First Local-Regional Lymph Node
Progression (mark all that apply)
Disease Is Present In The Common Iliac
Lymph Nodes (common iliac)
Disease Is Present In The External Iliac
Lymph Nodes (external iliac)
Disease Is Present In The Hypogastric
Lymph Nodes (hypogastric)
Disease Is Present In The Internal Iliac
Lymph Nodes (internal iliac)
Disease Is Present In Another Local-
regional Lymph Nodes, Specify (other,
specify)
Disease Is Present In The Para-aortic
Lymph Nodes (para-aortic)
Has the patient been diagnosed with a distant
metastatic progression that has not been
previously reported?
Yes
No
Date of First Distant Progression (MM DD YYYY)
Site(s) of First Distant Progression (mark all that
apply)
Bone (bone)
Central Nervous System (central
nervous system/brain)
Lymph Nodes (distant) (distant nodes,
specify)
Liver (liver)
Lung (lung)
other, specify (other, specify)
Peritoneum (peritoneum)
Pleura (pleura)
Skin (skin)
Distant nodes, specify
Other, specify
Other, specify
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Notice Of New Primary
Has a new primary cancer or myelodysplastic
syndrome (MDS) been diagnosed that has not
been previously reported?
Yes
No
Date of Diagnosis (MM DD YYYY)
Site(s) of New Primary (If new primary site is
AML/MDS, please submit NCI AML/MDS form.)
Notice Of Long Term Toxicity
Has the patient experienced any severe (Grade
>=3), long term toxicity that has not been
previously reported?
No (No)
Unknown (Unknown)
Yes (Yes)
Late Adverse Event Term
Late Adverse Event Grade
Date of Onset of Long-Term Toxicity
Comments
Comments
Ccrr Module For Nci Cooperative Group
Follow-up Form (calgb-90104)
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NCI COOPERATIVE GROUP Patient
Information FORM (CALGB-90104)
NCI COOPERATIVE GROUP Patient Information FORM
(CALGB-90104)
Combination Chemotherapy in Treating Patients With
Bladder Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=A9BED937-
4416-2507-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/6938
NCI COOPERATIVE GROUP Patient
Information FORM (CALGB-90104)
Mskcc 00-138; Calgb-90104; Ecog
Coordinating Group Protocol Number*
Coordinating Group Code*
Protocol Title*
Patient Study ID, Coordinating Group*
Participating Group Code*
Patient Medical Record Number*
Patient Study ID, Participating Group*
Institution Name*
Afiiliate*
Physician of Record*
Protocol Administration
IRB/REB Approval Date*
Person Completing Form, Last Name*
Person Completing Form, First Name*
Date Informed Consent Signed*
Person Completing Form, Phone*
Person Completing Form, Fax*
1 / 4
Projected Start Date of Treatment*
Date of Registration*
Patient Demographics / Pre-treatment
Characteristics
Patient Name, Last (initials acceptable)*
Patient Name, First (initials acceptable)*
Patient Name, Middle (initials acceptable)*
Patient Birth Date (MM DD YYYY)*
Patient Gender*
Female (Female)
Male (Male)
Patient Race/Ethnicity (check one)*
Asian_cdus (Asian)
Black_cdus (Black, not of Hispanic
origin)
A Person Of Mexican, Puerto Rican,
Cuban, Central Or South American Or
Other Spanish Culture Or Origin,
Regardless Of Race (Hispanic)
Pacific_islander_cdus (Native Hawaiian
or other Pacific Islander)
Native_american_cdus (Native North
American)
Other (Other)
Unknown (Unknown)
White_cdus (White, not of Hispanic
origin)
Patient Social Security Number*
Street Address*
City*
State*
Patient?s ZIP Code (USA)*
Country of Residence (if not USA)*
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Patient Height (cm)*
Patient Weight (kg)*
Body Surface Area*
Performance Status (check one)*
2 (Ambulatory and capable of all selfcare
but unable to carry out any work
activities (K 50 - 60))
3 (Capable of only limited selfcare,
confined to bed or chair more than 50%
of waking hours (K 30 - 40))
4 (Completely disabled (K 10 - 20))
0 (Fully active, able to carry on all pre-
disease performance without restriction
(Karnofsky 90 - 100))
1 (Restricted in physically strenuous
activity but ambulatory (K 70 - 80))
Certification Of Eligibility
In the opinion of the investigator is the patient
eligible?*
Yes
No
Protocol Design
Primary Tumor Pathological Stage*
Tumor Invades Subepithelial Connective
Tissue (T1)
Tumor Invades Superficial Muscles (inner
Half) (T2)
Tumor Invades Perivesical Tissue
Microscopically (T3)
Inflammatory Carcinoma (T4)
Number of Nodes Involved By Tumor (check
one)*
>=6 (>=6)
0 (0)
1/5/2002 (1/5/2002)
A (A)
B (B)
Initial Patient Consent For Specimen Use
Patient?s Initial Consent given for specimen use
for research on the patient?s cancer?*
Yes
No
Patient?s Initial Consent given for specien use for
research unrelated to the patient?s cancer?*
Yes
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No
Patient?s Initial Consent given for further contact
regarding specimen?*
Yes
No
Date of Consent for Specimen Use (MM DD
YYYY)*
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Multiple Myeloma and Plasma Cell Neoplasm NCT00602641 Transmittal
- E1A06 Source Document Tracking Coversheet - 2703636v1.0
E1A06 Source Document Tracking Coversheet
Melphalan, Prednisone, and Thalidomide or Lenalidomide
in Treating Patients With Newly Diagnosed Multiple
Myeloma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=4003E839-
33CA-0374-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/6940
E1A06 Source Document Tracking
Coversheet
Header
DCI Name
Registration Step (Place ID Label Here)
Patient Initials (Last, First)
ECOG Protocol Number
ECOG Protocol Number
ECOG Patient ID
ECOG Patient ID
Participating Group Protocol Number
Participating Group Patient ID
Institution/Affiliate
On Treatment
On Treatment Report Period (Maintenance
Therapy: Begins with Cycle 13 - Data submission
begin with Cycle 14)
> Cycle 34 (> Cycle 34)
Cycle 14 (Cycle 14)
Cycle 16 (Cycle 16)
Cycle 18 (Cycle 18)
Cycle 19 (Cycle 19)
Cycle 20 (Cycle 20)
Cycle 21 (Cycle 21)
Cycle 22 (Cycle 22)
Cycle 24 (Cycle 24)
Cycle 26 (Cycle 26)
Cycle 28 (Cycle 28)
Cycle 30 (Cycle 30)
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Cycle 32 (Cycle 32)
Cycle 34 (Cycle 34)
On Treatment Report Period (Maintenance
Therapy: Begins with Cycle 13 - Data submission
begin with Cycle 14)
> Cycle 34 (> Cycle 34)
Cycle 14 (Cycle 14)
Cycle 16 (Cycle 16)
Cycle 18 (Cycle 18)
Cycle 19 (Cycle 19)
Cycle 20 (Cycle 20)
Cycle 21 (Cycle 21)
Cycle 22 (Cycle 22)
Cycle 24 (Cycle 24)
Cycle 26 (Cycle 26)
Cycle 28 (Cycle 28)
Cycle 30 (Cycle 30)
Cycle 32 (Cycle 32)
Cycle 34 (Cycle 34)
Specify Cycle
Off Treatment
Off Treatment Report Period (Choose one)
9 Years (108 months post registration)
12 Months (12 Months Post Registration)
10 Years (120 months post registration)
15 Months (15 Months Post Registration)
18 Months (18 Months Post Registration)
21 Months Post Registration (21 Months
Post Registration)
2 Years (24 Months Post Registration)
3 Months (3 Months Post Registration)
30 Months (30 Months Post Registration)
3 Years (36 Months Post Registration)
42 Months (42 Months Post Registration)
4 Years (48 Months Post Registration)
54 Months (54 Months Post Registration)
6 Months (6 Months Post Registration)
5 Years (60 Months Post Registration)
6 Years (72 Months Post Registration)
84 Months Post Registration (84 Months
Post Registration)
9 Months (9 Months Post Registration)
8 Years (96 months post registration)
Document Type
Document type (Choose all that apply)
Biopsy Reports For Any Soft Tissue
Plasmacytoma (Biopsy Reports for any
Soft Tissue Plasmacytoma)
Bone Marrow Biopsy And Aspirate (Bone
Marrow Biopsy and Aspirate)
Bone X-rays, Or Other Image Reports
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(Bone X-rays, or other image reports)
Peripheral Blood Chemistry (Peripheral
Blood Chemistry)
Serum Free Light Chain Assay (Serum
Free Light Chain assay)
Serum Immunofixation (Serum
Immunofixation)
Serum Protein Electrophoresis (Serum
Protein Electrophoresis)
Serum Quantitative Immunoglobulins
(Serum Quantitative Immunoglobulins)
Urine Immunofixation (Urine
Immunofixation)
Urine Protein Electrophoresis (upep,
24hr) (Urine Protein Electrophoresis
(UPEP, 24hr))
Lab, Hematology, Sample Collection Date (M D
Y)
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Multiple Myeloma and Plasma Cell Neoplasm NCT00602641 Transmittal
- E1A06 Source Document Tracking Coversheet - 2703636v1.0
Multiple Myeloma and Plasma Cell Neoplasm NCT01169337 Transmittal
- E3A06 Source Document Tracking Coversheet - 3086867v1.0
E3A06 Source Document Tracking Coversheet
Lenalidomide or Observation in Treating Patients With
Asymptomatic High-Risk Smoldering Multiple Myeloma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=86D0D05F-
CCF7-87DB-E040-BB89AD4374EF
All rights reserved. Please visit https://medical-data-
models.org/forms/6944
E3A06 Source Document Tracking
Coversheet
Header
DCI Name
Registration Step (Place ID Label Here)
Patient Initials (Last, First)
ECOG Protocol Number
ECOG Protocol Number
ECOG Patient ID
ECOG Patient ID
Participating Group Protocol Number
Participating Group Patient ID
Institution/Affiliate
On Treatment
On Treatment or Observation  Report Period
> Cycle 19 (> Cycle 19)
Baseline (baseline)
Cycle 1 (Cycle 1)
Cycle 10 (Cycle 10)
Cycle 11 (Cycle 11)
Cycle 12 (Cycle 12)
Cycle 13 (Cycle 13)
Cycle 14 (Cycle 14)
Cycle 15 (Cycle 15)
Cycle 16 (Cycle 16)
Cycle 17 (Cycle 17)
Cycle 18 (Cycle 18)
Cycle 19 (Cycle 19)
Cycle 2 (Cycle 2)
1 / 3
Cycle 3 (Cycle 3)
Cycle 4 (cycle 4)
Cycle 5 (Cycle 5)
Cycle 6 (Cycle 6)
Cycle 7 (Cycle 7)
Cycle 8 (cycle 8)
Cycle 9 (Cycle 9)
Specify Cycle
Off Treatment
Off Treatment or Off Observation Report Period
(Choose one)
9 Years (108 months post registration)
12 Months (12 Months Post Registration)
10 Years (120 months post registration)
15 Months (15 Months Post Registration)
18 Months (18 Months Post Registration)
21 Months Post Registration (21 Months
Post Registration)
2 Years (24 Months Post Registration)
3 Months (3 Months Post Registration)
30 Months (30 Months Post Registration)
3 Years (36 Months Post Registration)
42 Months (42 Months Post Registration)
4 Years (48 Months Post Registration)
54 Months (54 Months Post Registration)
6 Months (6 Months Post Registration)
5 Years (60 Months Post Registration)
6 Years (72 Months Post Registration)
84 Months Post Registration (84 Months
Post Registration)
9 Months (9 Months Post Registration)
8 Years (96 months post registration)
Document Type
Document type (Choose all that apply)
Biopsy Reports For Any Soft Tissue
Plasmacytoma (Biopsy Reports for any
Soft Tissue Plasmacytoma)
Bone Marrow Biopsy And Aspirate (Bone
Marrow Biopsy and Aspirate)
Bone X-rays, Or Other Image Reports
(Bone X-rays, or other image reports)
Patient Pill Diary (Patient pill diary)
Peripheral Blood Chemistry (Peripheral
Blood Chemistry)
Serum Free Light Chain Assay (Serum
Free Light Chain assay)
Serum Immunofixation (Serum
Immunofixation)
Serum Protein Electrophoresis (Serum
Protein Electrophoresis)
Serum Quantitative Immunoglobulins
(Serum Quantitative Immunoglobulins)
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Urine Immunofixation (Urine
Immunofixation)
Urine Protein Electrophoresis (upep,
24hr) (Urine Protein Electrophoresis
(UPEP, 24hr))
Lab, Hematology, Sample Collection Date
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- E3A06 Source Document Tracking Coversheet - 3086867v1.0
Multiple Myeloma and Plasma Cell Neoplasm NCT01078454 Transmittal -
E4A08 SOURCE DOCUMENT TRACKING COVERSHEET - 2972557v1.0
E4A08 SOURCE DOCUMENT TRACKING COVERSHEET
Melphalan and Dexamethasone With or Without
Bortezomib in Treating Patients With Previously Untreated
Systemic Light-Chain Amyloidosis
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=7BCCA614-
536C-15BB-E040-BB89AD4326D3
All rights reserved. Please visit https://medical-data-
models.org/forms/6946
E4A08 SOURCE DOCUMENT
TRACKING COVERSHEET
Header
DCI Name
Registration Step (Place ID Label Here)
Patient Initials (Last, First)
ECOG Protocol Number
ECOG Protocol Number
ECOG Patient ID
ECOG Patient ID
Participating Group Protocol Number
Participating Group Patient ID
Institution/Affiliate
On Treatment
Reporting Period (Choose one)
Baseline (baseline)
Cycle 1 (Cycle 1)
Cycle 2 (Cycle 2)
Cycle 3 (Cycle 3)
Cycle 4 (cycle 4)
Cycle 5 (Cycle 5)
Cycle 6 (Cycle 6)
Cycle 7 (Cycle 7)
Cycle 8 (cycle 8)
Cycle 9 (Cycle 9)
Off Treatment
1 / 3
Off Treatment Report Period (since registration -
Choose one)
12 Months (12 Months Post Registration)
15 Months (15 Months Post Registration)
18 Months (18 Months Post Registration)
21 Months Post Registration (21 Months
Post Registration)
2 Years (24 Months Post Registration)
3 Months (3 Months Post Registration)
30 Months (30 Months Post Registration)
3 Years (36 Months Post Registration)
42 Months (42 Months Post Registration)
4 Years (48 Months Post Registration)
54 Months (54 Months Post Registration)
6 Months (6 Months Post Registration)
5 Years (60 Months Post Registration)
9 Months (9 Months Post Registration)
Document Type
Report Created Date
Document type (Choose all that apply)
Echocardiogram (Echocardiogram)
Fecal Fat Excretion Test (Fecal Fat
Excretion test)
Liver Evaluation (Liver evaluation)
Marrow Biopsy And/or Aspirate With
Documentation Of Plasma Cell Clonality
(Marrow biopsy and/or Aspirate with
Documentation of Plasma Cell Clonality)
Nerve Conduction Studies (Nerve
conduction studies)
Neurology Assessment (Neurology
Assessment)
Organ Biopsy Report (Organ Biopsy
Report)
Serum Free Light Chain Assay (Serum
Free Light Chain assay)
Serum Immunofixation (Serum
Immunofixation)
Serum Protein Electrophoresis (Serum
Protein Electrophoresis)
Serum Quantitative Immunoglobulins
(Serum Quantitative Immunoglobulins)
Urine Immunofixation (Urine
Immunofixation)
Urine Protein Electrophoresis (upep,
24hr) (Urine Protein Electrophoresis
(UPEP, 24hr))
Document type (Choose all that apply)
Echocardiogram (Echocardiogram)
Fecal Fat Excretion Test (Fecal Fat
Excretion test)
Liver Evaluation (Liver evaluation)
Marrow Biopsy And/or Aspirate With
Documentation Of Plasma Cell Clonality
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(Marrow biopsy and/or Aspirate with
Documentation of Plasma Cell Clonality)
Nerve Conduction Studies (Nerve
conduction studies)
Neurology Assessment (Neurology
Assessment)
Organ Biopsy Report (Organ Biopsy
Report)
Serum Free Light Chain Assay (Serum
Free Light Chain assay)
Serum Immunofixation (Serum
Immunofixation)
Serum Protein Electrophoresis (Serum
Protein Electrophoresis)
Serum Quantitative Immunoglobulins
(Serum Quantitative Immunoglobulins)
Urine Immunofixation (Urine
Immunofixation)
Urine Protein Electrophoresis (upep,
24hr) (Urine Protein Electrophoresis
(UPEP, 24hr))
Lab, Hematology, Sample Collection Date (M D
Y)
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Multiple Myeloma and Plasma Cell Neoplasm NCT01078454 Transmittal -
E4A08 SOURCE DOCUMENT TRACKING COVERSHEET - 2972557v1.0
Multiple Myeloma and Plasma Cell Neoplasm NCT00522392 Transmittal -
E1A05 Source Document Tracking Coversheet - Form 2857 - 2648777v1.0
E1A05 Source Document Tracking Coversheet - Form 2857
Bortezomib and Dexamethasone With or Without
Lenalidomide in Treating Patients With Multiple Myeloma
Previously Treated With Dexamethasone
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=3256D4E6-
6819-6708-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/6954
E1A05 Source Document Tracking
Coversheet - Form 2857
Header
DCI Name
Registration Step (Place ID Label Here)
Patient Initials (Last, First)
ECOG Protocol Number
ECOG Protocol Number
ECOG Patient ID
ECOG Patient ID
Participating Group Protocol Number
Participating Group Patient ID
Institution/Affiliate
On Treatment
On Treatment Report Period
Baseline (baseline)
Cycle 1 (Cycle 1)
Cycle 2 (Cycle 2)
Cycle 3 (Cycle 3)
Cycle 4 (cycle 4)
Cycle 5 (Cycle 5)
Cycle 6 (Cycle 6)
Cycle 7 (Cycle 7)
Cycle 8 (cycle 8)
Off Treatment
Off Treatment Report Period (Choose one)
1 / 2
9 Years (108 months post registration)
12 Months (12 Months Post Registration)
10 Years (120 months post registration)
15 Months (15 Months Post Registration)
18 Months (18 Months Post Registration)
21 Months Post Registration (21 Months
Post Registration)
2 Years (24 Months Post Registration)
3 Months (3 Months Post Registration)
30 Months (30 Months Post Registration)
3 Years (36 Months Post Registration)
42 Months (42 Months Post Registration)
4 Years (48 Months Post Registration)
54 Months (54 Months Post Registration)
6 Months (6 Months Post Registration)
5 Years (60 Months Post Registration)
6 Years (72 Months Post Registration)
84 Months Post Registration (84 Months
Post Registration)
9 Months (9 Months Post Registration)
8 Years (96 months post registration)
Document Type
Document type
Biopsy Reports For Any Soft Tissue
Plasmacytoma (Biopsy Reports for any
Soft Tissue Plasmacytoma)
Bone Marrow Biopsy And Aspirate (Bone
Marrow Biopsy and Aspirate)
Bone X-rays, Or Other Image Reports
(Bone X-rays, or other image reports)
Serum Free Light Chain Assay (Serum
Free Light Chain assay)
Serum Immunofixation (Serum
Immunofixation)
Serum Protein Electrophoresis (Serum
Protein Electrophoresis)
Serum Quantitative Immunoglobulins
(Serum Quantitative Immunoglobulins)
Urine Immunofixation (Urine
Immunofixation)
Urine Protein Electrophoresis (upep,
24hr) (Urine Protein Electrophoresis
(UPEP, 24hr))
Other, specify
Date Hematology (Blood) Sample Obtained
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Melanoma (Skin) NCT01274338 Quality of Life
- E1609 Quality of Life Form - 3168557v1.0
E1609 Quality of Life Form
Ipilimumab or High-Dose Interferon Alfa-2b in Treating
Patients With High-Risk Stage III or Stage IV Melanoma
That Has Been Removed by Surgery
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=978ABFF8-
A570-C403-E040-BB89AD436599
All rights reserved. Please visit https://medical-data-
models.org/forms/6958
E1609 Quality of Life Form
Header
DCI Name
Registration Step (Place ID Label Here)
Patient Initials (Last, First)
ECOG Protocol Number
ECOG Protocol Number
ECOG Patient ID
ECOG Patient ID
Participating Group Protocol Number
Participating Group Patient ID
Institution/Affiliate
On Treatment
On Treatment Report Period (Choose one)
At Completion Of Treatment (At
Completion of Treatment)
Baseline (baseline)
Week 12 (Week 12)
Week 24 (Week 24)
Week 36 (Week 36)
Week 48 (Week 48)
Week 60 (Week 60)
Header
Off Treatment Report Period
Qol 24 Weeks Follow-up (QOL 24 Weeks
Follow-Up)
Qol 48 Weeks Follow-up (QOL 48 Weeks
Follow-Up)
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Physical Well-being
I have a lack of energy
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have nausea
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
Because of my physical condition, I have trouble
meeting the needs of my family
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have pain
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am bothered by side effects of treatment
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I feel ill
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am forced to spend time in bed
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
Social/family Well-being
I feel close to my friends
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
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Somewhat (Somewhat)
Very Much (Very much)
I get emotional support from my family
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I get support from my friends
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
My family has accepted my illness
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am satisfied with family communication about
my illness
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I feel close to my partner (or the person who is
my main support)
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
Regardless of your current level of sexual activity,
please answer the following question.  If you
prefer not to answer it, please check this box and
go to the next section.
I am satisfied with my sex life
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
Emotional Well-being
I get depressed easily
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
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Somewhat (Somewhat)
Very Much (Very much)
I am satisfied with how I am coping with my
illness
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am losing hope in the fight against my illness
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I feel nervous
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I worry about dying
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I worry that my condition will get worse
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
Functional Well-being
I am able to work (include work at home)
2 (A little bit)
1 (Not at all)
4 (Quite a bit)
3 (Somewhat)
5 (Very much)
My work is fulfilling (include work at home)
2 (A little bit)
1 (Not at all)
4 (Quite a bit)
3 (Somewhat)
5 (Very much)
I am able to enjoy life
2 (A little bit)
1 (Not at all)
4 (Quite a bit)
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3 (Somewhat)
5 (Very much)
I have accepted my illness
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am sleeping well
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am enjoying the things I usually do for fun
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am content with the quality of my life right now
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
Additional Concerns - Mms
I get tired easily
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I feel weak all over
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I get depressed easily
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have a good appetite
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
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I have pain in my joints
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am bothered by the chills
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am bothered by fevers
2 (A little bit)
1 (Not at all)
4 (Quite a bit)
3 (Somewhat)
5 (Very much)
I am bothered by sweating
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have trouble concentrating
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
Have you had difficulty remembering things
2 (A little bit)
1 (Not at all)
4 (Quite a bit)
3 (Somewhat)
5 (Very much)
I get annoyed easily
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have emotional ups and downs
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I feel motivated to do things
A Little Bit (A little bit)
Not At All (Not at all)
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Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
Unnamed2
I have control of my bowels
A Little Bit (a little bit)
Not At All (not at all)
Quite A Bit (quite a bit)
Somewhat (somewhat)
Very Much (very much)
I move my bowels more frequently than usual
A Little Bit (a little bit)
Not At All (not at all)
Quite A Bit (quite a bit)
Somewhat (somewhat)
Very Much (very much)
I am afraid to be far from a toliet
A Little Bit (a little bit)
Not At All (not at all)
Quite A Bit (quite a bit)
Somewhat (somewhat)
Very Much (very much)
I have to limit my social activity because of
diarrhea
A Little Bit (a little bit)
Not At All (not at all)
Quite A Bit (quite a bit)
Somewhat (somewhat)
Very Much (very much)
I have to limit my physical activity because of
diarrhea
A Little Bit (a little bit)
Not At All (not at all)
Quite A Bit (quite a bit)
Somewhat (somewhat)
Very Much (very much)
I have to limit my sexual activity because of
diarrhea
A Little Bit (a little bit)
Not At All (not at all)
Quite A Bit (quite a bit)
Somewhat (somewhat)
Very Much (very much)
I am embarrassed by having diarrhea
A Little Bit (a little bit)
Not At All (not at all)
Quite A Bit (quite a bit)
Somewhat (somewhat)
Very Much (very much)
I have abdominal cramps or discomfort due to my
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diarrhea
A Little Bit (a little bit)
Not At All (not at all)
Quite A Bit (quite a bit)
Somewhat (somewhat)
Very Much (very much)
My problem with diarrhea keeps/wakes me up at
night
A Little Bit (a little bit)
Not At All (not at all)
Quite A Bit (quite a bit)
Somewhat (somewhat)
Very Much (very much)
I must move my bowels frequently to avoid
accidents
A Little Bit (a little bit)
Not At All (not at all)
Quite A Bit (quite a bit)
Somewhat (somewhat)
Very Much (very much)
I wear protection for soiling of stool
A Little Bit (a little bit)
Not At All (not at all)
Quite A Bit (quite a bit)
Somewhat (somewhat)
Very Much (very much)
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Lung Cancer NCT00738881 On-Study - North Central Cancer
Treatment Group CD Submission Form - 2731641v1.0
North Central Cancer Treatment Group CD Submission
Form
Pemetrexed or Erlotinib as Second-Line Therapy in Treating
Patients With Advanced Non-Small Cell Lung Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=46FF5DCC-
3998-16A9-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/6960
North Central Cancer Treatment
Group CD Submission Form
Header
Protocol Number
Patient ID
Patient Initials (L F M)
Institution Number
Institution
Are data amended (If yes, highlight amended
areas)
Yes
No
Header
Current Cycle Number (or)
Date received (CD)
Reporting Period
Event Monitoring Phase (Event
Monitoring Phase)
Were imaging studies performed (check one)
Yes
No
Specify (If no,)
Completed By View Personnel:
Date received (CD)
Was the quality of the scan acceptable
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Yes
No
Reason (If no,)
Gross Artifacts Found (Gross artifacts
found)
Other (Other)
Study Incomplete (Study incomplete)
Technical Parameters Not Compliant
(Technical parameters not compliant)
Other, specify
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Group CD Submission Form - 2731641v1.0
Lung Cancer NCT00738881 On-Study - North Central Cancer
Treatment Group Baseline CD Submission Form - 2731639v1.0
North Central Cancer Treatment Group Baseline CD
Submission Form
Pemetrexed or Erlotinib as Second-Line Therapy in Treating
Patients With Advanced Non-Small Cell Lung Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=46FF5830-
748C-163A-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/6963
North Central Cancer Treatment
Group Baseline CD Submission
Form
Header
Protocol Number
Patient ID
Patient Initials (L F M)
Institution Number
Institution
Are data amended (If yes, highlight amended
areas)
Yes
No
Header
Were imaging studies performed (check one)
Yes
No
Date received (CD)
Specify (If no,)
Image date (mm/dd/yyyy)
Is the imaging equipment accredited by the
American College of Radiology (check one)
Yes
No
Does the imaging equipment meet state and
federal requirements and include annual
equipment inspections (check one)
Yes
No
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Is the imaging technologist certified (check one)
Yes
No
Completed By View Personnel:
Date received (CD)
Was the quality of the scan acceptable
Yes
No
Reason (If no,)
Gross Artifacts Found (Gross artifacts
found)
Other (Other)
Study Incomplete (Study incomplete)
Technical Parameters Not Compliant
(Technical parameters not compliant)
Other, specify
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Group Baseline CD Submission Form - 2731639v1.0
Lung Cancer NCT00738881 Treatment - North Central Cancer Treatment Group
N0723 Concurrent Treatment Form - Active Monitoring Phase - 2731643v1.0
North Central Cancer Treatment Group N0723 Concurrent
Treatment Form - Active Monitoring Phase
Pemetrexed or Erlotinib as Second-Line Therapy in Treating
Patients With Advanced Non-Small Cell Lung Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=46FF63E8-
104D-1831-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/6964
North Central Cancer Treatment
Group N0723 Concurrent Treatment
Form - Active Monitoring Phase
Header
Protocol Number
Patient ID
Patient Initials (L F M)
Institution Number
Institution
Are data amended (If yes, highlight amended
areas)
Yes
No
Header
Current Cycle Number
Date of evaluation (mm/dd/yyyy)
Has there been any change in medications since
the previous visit
Yes
No
Concomitant Medication (If Yes, enter
medications including prescription, over-the-
counter, and alternative medications that have
not been previously reported or no longer being
taken)
Concomitant Medication Reason
Medication No Longer Being Taken
(Medication no longer being taken)
Addition Of New Medication (New
medication)
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Lung Cancer NCT00738881 Treatment - North Central Cancer Treatment
Group N0723 Concurrent Treatment Form - Baseline - 2731645v1.0
North Central Cancer Treatment Group N0723 Concurrent
Treatment Form - Baseline
Pemetrexed or Erlotinib as Second-Line Therapy in Treating
Patients With Advanced Non-Small Cell Lung Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=46FF63E8-
1051-1831-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/6965
North Central Cancer Treatment
Group N0723 Concurrent Treatment
Form - Baseline
Header
Protocol Number
Patient ID
Patient Initials (L F M)
Institution Number
Institution
Are data amended (If yes, highlight amended
areas)
Yes
No
Header
Date of evaluation (mm/dd/yyyy)
Is the patient taking any concomitant medications
(check one)
Yes
No
Concomitant Medication
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Lung Cancer NCT00738881 Treatment - North Central Cancer Treatment
Group N0723 CTEP Report Variables Prior Therapy - 2731647v1.0
North Central Cancer Treatment Group N0723 CTEP
Report Variables Prior Therapy
Pemetrexed or Erlotinib as Second-Line Therapy in Treating
Patients With Advanced Non-Small Cell Lung Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=46FF6C2D-
039A-18FF-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/6968
North Central Cancer Treatment
Group N0723 CTEP Report
Variables Prior Therapy
Header
Protocol Number
Patient ID
Patient Initials (L F M)
Institution Number
Institution
Are data amended (If yes, highlight amended
areas)
Yes
No
Prior Therapy
Prior therapy type
Agents Administered To Control The
Replication And/or Spread Of Viruses
(Anti-retroviral therapy)
Treatment With An Agent That Prevents
Or Impairs The Translation Of The
Genetic Message For Production Of A
Specific Protein (Antisense)
High Dose Chemotherapy Combined
With Transplantation Of Bone Marrow
Cells (Bone marrow transplant)
Non-systemic Chemotherapy Treatment
Or Chemotherapy Not Described By
Chemotherapy Single Agent Systemic Or
Multi-agent Systemic (Chemotherapy
(NOS))
Systemic Chemotherapy With A
Regimen Containing Multiple Agents
(Chemotherapy multiple agents
systemic)
Prior Therapy With Agents That Are Not
Known To Cause Damage To Cycling
Cells (Chemotherapy non-cytotoxic)
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Systemic Chemotherapy With A Single
Agent Regimen (Chemotherapy single
agent systemic)
Drug And/or Immunotherapy (Drug
and/or Immunotherapy)
Treatment Of Human Disease By Gene
Transfer (Gene transfer)
Hematopoietic Stem Cell Transplantation
(Hematopoietic Stem Cell
Transplantation)
Cancer Therapy Which Incorporates
Hormonal Manipulation (Hormonal
therapy)
Image Directed Local Therapy (Image
Directed Local Therapy)
No Previous Exposure To Drug (nos) (No
prior therapy)
Anticancer Treatment With A Live,
Replication-competent Virus (Oncolytic
virotherapy)
Prior Therapy (nos) (Prior therapy NOS)
Targeted Ionizing Radiation Therapy
Utilizing Radioactive Implants Or Seeds
(Radiation therapy)
Surgical Procedure, Or Operation, With
Therapeutic Intent (Surgery)
Therapy Nos (Therapy (NOS))
Substance Or Group Of Substances
Administered To Induce The Immune
System To Recognize And Destroy
Tumors Or Microorganisms (Vaccine)
Number of prior chemotherapy regimens
MedDRA disease code (for primary tumor site:
10029514 [Non-small cell lung cancer, NOS])
Assigned Treatment Arm
Arm A (Arm A)
Arm B (Arm B)
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Group N0723 CTEP Report Variables Prior Therapy - 2731647v1.0
Lung Cancer NCT00738881 Registration - North Central Cancer Treatment
Group N0723 Preregistration Screening Failure Form - 2730828v1.0
North Central Cancer Treatment Group N0723
Preregistration Screening Failure Form
Pemetrexed or Erlotinib as Second-Line Therapy in Treating
Patients With Advanced Non-Small Cell Lung Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=46ACBEC0-
5170-1310-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/6972
North Central Cancer Treatment
Group N0723 Preregistration
Screening Failure Form
Header
Protocol Number
Patient ID
Patient Initials (L F M)
Institution Number
Institution
Are data amended (If yes, highlight amended
areas)
Yes
No
Preregistration Screening Failure
Date aware of preregistration screening failure
(mm/dd/yyyy)
Primary reason screening failed (check one)
Did Not Meet Eligibility Criteria (Did not
meet eligibility criteria)
Investigator Decision (Investigator
decision)
Not Evaluable (per Email Notification)
(Not evaluable (per email notification))
Other (Other)
Patient Decision (Patient decision)
Other, specify
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Lung Cancer NCT00738881 Toxicity - North Central Cancer Treatment
Group N0723 Baseline Adverse Events Form - 2731396v1.0
North Central Cancer Treatment Group N0723 Baseline
Adverse Events Form
Pemetrexed or Erlotinib as Second-Line Therapy in Treating
Patients With Advanced Non-Small Cell Lung Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=46FC7080-
5A71-1051-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/6975
North Central Cancer Treatment
Group N0723 Baseline Adverse
Events Form
Header
Protocol Number
Patient ID
Patient Initials (L F M)
Institution Number
Institution
Are data amended (If yes, highlight amended
areas)
Yes
No
Description Of Primary Disease
CTC Adverse Event Term
Alanine Aminotransferase Increased
(ALT, SGPT (serum glutamic pyruvic
transaminase))
Anorexia (Anorexia)
Aspartate Aminotransferase Increased
(AST, SGOT (serum glutamic oxaloacetic
transaminase))
Blood Bilirubin Increased (Bilirubin
(hyperbilirubinemia))
Blood Creatinine Increased (Creatinine)
Dyspnoea Nos (Dyspnea (shortness of
breath))
Fatigue (Fatigue (asthenia, lethargy,
malaise))
Keratitis Nec (Keratitis (corneal
inflammation/corneal ulceration))
Mucositis/stomatitis (clinical Exam)
(Mucositis/stomatitis (clinical exam) -
Oral cavity)
Stomatitis (Mucositis/stomatitis (clinical
exam) - Pharynx)
Mucositis/stomatitis
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(functional/symptomatic)
(Mucositis/stomatitis
(functional/symptomatic) - Oral cavity)
Mucositis/stomatitis
(functional/symptomatic)
(Mucositis/stomatitis
(functional/symptomatic) - Pharynx)
Nausea (Nausea)
Abdominal Pain Nos (Pain - Abdomen
NOS)
Rash: Acne/acneiform (Rash:
acne/acneiform)
Dermatitis Exfoliative Nos
(Rash/desquamation)
Vomiting Nos (Vomiting)
MedDRA Code (primary tumor site: Metastases
to brain parenchyma)
CTC Adverse Event Grade
Baseline number of stools per day
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Lung Cancer NCT00738881 Toxicity - North Central Cancer Treatment
Group N0723 Baseline Adverse Events Form - 2731396v1.0
Lung Cancer NCT00738881 On-Study - North Central Cancer
Treatment Group N0723 On-Study Form - 2731649v1.0
North Central Cancer Treatment Group N0723 On-Study
Form
Pemetrexed or Erlotinib as Second-Line Therapy in Treating
Patients With Advanced Non-Small Cell Lung Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=46FF63E8-
1055-1831-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/6978
North Central Cancer Treatment
Group N0723 On-Study Form
Header
Protocol Number
Patient ID
Patient Initials (L F M)
Institution Number
Institution
Are data amended (If yes, highlight amended
areas)
Yes
No
Description Of Primary Disease
MedDRA Code ([Non-small cell lung cancer,
NOS])
Histologic Type (check one)
Adenocarcinoma (Adenocarcinoma)
Bronchoalveolar (bac) (Bronchoalveolar
carcinoma (BAC))
Large Cell Undifferentiated (Large cell
undifferentiated)
Non-small Cell Lung Cancer (nsclc), Nos
(Non-small cell lung cancer NOS)
Other (Other specify)
Squamous Cell Carcinoma (Squamous
cell carcinoma)
Specify Other Histologic Type
Histologic Grade (Differentiation) (check one)
Well Differentiated (Grade I)
Moderately Differentiated (Grade II)
Poorly Differentiated (Grade III)
Undifferentiated (Grade IV)
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Chronology Of Diagnoses
Disease Status
First Metastasis (First Metastasis)
Primary Tumor (Primary (Advanced))
Recurrence/relapse (Recurrence)
Method of Evaluation
Biopsy (Biopsy)
Clinical (Clinical)
Cytology (Cytology)
Evaluated But No Disease Found
(Evaluated but no disease found)
Not Evaluated (Not evaluated)
Date (mm/dd/yyyy)
Metastatic Site(s)
Metastatic Site
Adrenal Gland (Adrenal(s))
Bone (Bone)
Bone Marrow (Bone marrow)
Brain (Brain)
Contralateral Lung (Contralateral lung)
Hilar Nodes (Hilar nodes)
Ipsilateral Lung (Ipsilateral lung)
Liver (Liver)
Mediastinal Nodes (Mediastinal nodes)
Other (Other)
Pleura (Pleura)
Skin (Skin)
Supraclavicular Or Scalene Nodes
(Supraclavicular/scalene nodes)
Other specify
Method of Evaluation
Biopsy (Biopsy)
Clinical (Clinical)
Cytology (Cytology)
Evaluated But No Disease Found
(Evaluated but no disease found)
Not Evaluated (Not evaluated)
Previous Surgery Related To The Tumor
Surgical Approach
Bronchoscopy (Bronchoscopy)
Fine Needle Aspirate (Fine Needle
Aspirate)
Mediastinoscopy (Mediastinoscopy)
Other (Other)
Supraclavicular Biopsy (Supraclavicular
biopsy)
Thoracoscopy (thoracoscopy)
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Other, specify
Surgery Results
Negative (Negative)
Not Done (Not Done)
Positive (Positive)
Date of prior surgery (mm/dd/yyyy)
Prior Radiation Therapy
Prior Radiation Therapy (check one)
Yes
No
Prior RT Site
Prior radiation therapy stop date (mm/dd/yyyy)
Prior Systemic (cancer) Therapy
Prior systemic therapy (cancer check one)
Yes
No
Prior Treatment Name
Prior systemic therapy stop date (mm/dd/yyyy)
Descriptive Factors
Has the patient had any prior cancer diagnosed?
(check one)
Yes
No
Site of Prior Cancer (If yes)
Prior Cancer Diagnosis Date (mm/dd/yyyy)
Prior Treatment Regimen Type
Weight Loss (within 3 months of study entry
check one)
<5% Of Body Weight (<5% of body
weight)
>= 10% Of Body Weight (>= 10% of
body weight)
5 To <10% Of Body Weight (5 to < 10%
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of body weight)
Prior Adjuvant Chemotherapy (check one)
Yes
No
Prior Neoadjuvant Chemotherapy (check one)
Yes
No
Prior Chemotherapy for Metastatic Disease
(check one)
Yes
No
Height (cm)
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Lung Cancer NCT00738881 Pathology - North Central Cancer Treatment Group
Arm B Patients Only Blood Specimen Submission Form - 2730739v1.0
North Central Cancer Treatment Group Arm B Patients
Only Blood Specimen Submission Form
Pemetrexed or Erlotinib as Second-Line Therapy in Treating
Patients With Advanced Non-Small Cell Lung Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=46ABB944-
A434-56D2-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/6980
North Central Cancer Treatment
Group Arm B Patients Only Blood
Specimen Submission Form
Header Module
Protocol Number
Patient ID
Patient Initials
Institution Number
Institution
Are data amended (check one if data are
amended, please circle in red when using paper
form)
Yes
No
Header
Current Cycle Number
Patient's Initial Consent given for blood specimen
use for research on the patient's cancer?
Yes
No
Was sample obtained (for proteomic studies [red
top]? check one)
Yes
No
Was sample obtained (for proteomic studies [red
top]? check one)
Yes
No
Specify (If no,)
Specify (If no,)
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Date of collection (mm/dd/yyyy)
Date of collection (mm/dd/yyyy)
Date Specimen Shipped (mm/dd/yyyy)
Date Specimen Shipped (mm/dd/yyyy)
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Lung Cancer NCT00738881 Pathology - North Central Cancer Treatment Group
Arm B Patients Only Blood Specimen Submission Form - 2730739v1.0
Lung Cancer NCT00738881 Pathology - North Central Cancer Treatment
Group Arm A Patient Only Blood Specimen Submission Form - 2730764v1.0
North Central Cancer Treatment Group Arm A Patient Only
Blood Specimen Submission Form
Pemetrexed or Erlotinib as Second-Line Therapy in Treating
Patients With Advanced Non-Small Cell Lung Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=46ABC4A2-
56DB-5935-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/6981
North Central Cancer Treatment
Group Arm A Patient Only Blood
Specimen Submission Form
Header Module
Protocol Number
Patient ID
Patient Initials (L F M)
Institution Number
Institution
Are data amended (check one if data are
amended, please circle in red when using paper
form)
Yes
No
Header
Current Cycle Number
Was sample obtained (prior to treatment Cycle 1
Day 1 check one)
Yes
No
Was sample obtained (prior to treatment Cycle 1
Day 1 check one)
Yes
No
Was sample obtained (prior to treatment Cycle 1
Day 1 check one)
Yes
No
Was sample obtained (prior to treatment Cycle 1
Day 1 check one)
Yes
No
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Specify
Specify
Reporting Period
Cycle 1 (Cycle 1)
Cycle 2 (Cycle 2)
Specify
Specify
Date of collection (mm/dd/yyyy)
Date of collection (mm/dd/yyyy)
Date of collection (mm/dd/yyyy)
Date of collection (mm/dd/yyyy)
Patient's Initial Consent given for blood specimen
use for research on the patient's cancer?
Yes
No
Date Specimen Shipped (mm/dd/yyyy)
Date Specimen Shipped (mm/dd/yyyy)
Date Specimen Shipped (mm/dd/yyyy)
Date Specimen Shipped (mm/dd/yyyy)
Header
Was sample obtained (prior to treatment Cycle 1
Day 1 check one)
Yes
No
Specify
Date of collection (mm/dd/yyyy)
Date Specimen Shipped (mm/dd/yyyy)
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Header
Was sample obtained (prior to treatment Cycle 1
Day 1 check one)
Yes
No
Specify
Date of collection (mm/dd/yyyy)
Date Specimen Shipped (mm/dd/yyyy)
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Neoplasms, Breast NCT00490139 Pathology - North Central Cancer
Treatment Group - Central Her2 Testing Form - IHC - 2639107v1.0
North Central Cancer Treatment Group - Central Her2
Testing Form - IHC
ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment
Optimisation) Study; BIG 2-06/N063D
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=30AFEA0B-
FE87-5E3F-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/6983
North Central Cancer Treatment
Group - Central Her2 Testing Form -
IHC
Header Module
NCCTG Protocol Number
Central Pathology ID
Patient Initials
Institution Number
Institution
Header
Are data amended
Yes
No
For Dr. Ann Mccullough's Laboratory Use
Only
Percentage of invasive tumor cells with complete
membrane staining
Uniformity of staining
Absent (Absent)
Present (Present)
Homogeneous dark circumferential pattern
Absent (Absent)
Present (Present)
IHC Result
Faint Membrane Staining, Partial >10%
Cells (Faint membrane staining, partial
>10% cells (Negative - 1+))
Insufficient Tissue/hybridization Failure
(Insufficient tissue/hybridization failure)
No Staining Or Membranous Staining
<=10% Cells (No staining or
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membranous staining <=10% cells
(Negative - 0))
Strong Staining, Complete >10% <=30%
Cells (Strong staining, complete >10%
<=30% cells (Equivocal - 3+))
Strong Staining, Complete >30% Cells
(Strong staining, complete >30% cells
(Positive - 3+))
Weak To Moderate Staining, Complete
>10% Cells (Weak to moderate staining,
complete >10% cells (Equivocal - 2+))
Histologic Type
Apocrine (Apocrine)
Cribriform (Cribriform)
Ductal Nos (Ductal NOS)
Invasive Nos (Invasive NOS)
Lobular (Lobular (pure > or =90%))
Medullary Carcinoma (Medullary)
Micropapillary (Micropapillary)
Mixed Ductal And Lobular (Mixed ductal
and lobular)
Mucinous Adenocarcinoma (Mucinous)
Other Specify (Other)
Tubular (Tubular (pure > or =90%))
Tubulolobular (Tubulolobular (pure > or
=90%))
Other specify
Is CIS present?
Yes
No
Histologic type
Ductal Breast Carcinoma In Situ (DCIS)
Lobular Carcinoma In Situ (LCIS)
Mixed Ductal And Lobular (Mixed DCIS
& LCIS)
Is Paget's disease of the nipple present?
Yes
No
Histologic Grade
G1 Low Combined Histologic Grade
(favorable) (G1)
G2 Intermediate Combined Histologic
Grade (moderately Favorable) (G2)
G3 High Combined Histologic Grade
(unfavorable) (G3)
Gx Grade Cannot Be Assessed (GX)
Clinical Size of Tumor
Is there vascular invasion
Yes
No
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Neoplasms, Breast NCT00490139 Pathology - North Central Cancer
Treatment Group - Central Her2 Testing Form - IHC - 2639107v1.0
Suitable for TMA
Yes
No
ER % cells stained positive
PgR % cells stained positive
Footer Module
Pathologist CTEP ID
Date
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Neoplasms, Breast NCT00490139 Pathology - North Central Cancer
Treatment Group - Central Her2 Testing Form - IHC - 2639107v1.0
Neoplasms, Breast NCT00490139 Transmittal - North Central Cancer Treatment
Group - Cover Sheet for Final CRF Packet Submission - 2648182v1.0
North Central Cancer Treatment Group - Cover Sheet for
Final CRF Packet Submission
ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment
Optimisation) Study; BIG 2-06/N063D
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=324EF7CB-
7DB5-3C2F-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/6984
North Central Cancer Treatment
Group - Cover Sheet for Final CRF
Packet Submission
Header Module
NCCTG Study No.
Patient Study ID
Patient Initials
Institution Number
Institution
Header
Date CRF shipped to NCCTG
1 / 1
Pathology - Lung Cancer - North Central Cancer Treatment
Group N0723 Pathology Reporting Form - 2731651v1.0
North Central Cancer Treatment Group N0723 Pathology
Reporting Form; ***This CRF DELETED FROM STUDY, so
no response to initial CDE-compliance review.***
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=46FF63E8-
1059-1831-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/6986
Lung Cancer - North Central Cancer
Treatment Group N0723 Pathology
Reporting Form
Header
Protocol Number
Patient Initials (L F M)
Institution Number
NCCTG Patient ID
Institution
Pathology Reporting
Referring Pathologist
Pathology Institution Name
Reviewing Pathologist
Number of specimens submitted
Date specimen submitted (mm/dd/yyyy)
Accession Number
LabTrak sample ID
Lung Surgery
Date Specimen collected (mm/dd/yyyy)
Type of Procedure (check one)
Biopsy (Biopsy)
1 / 5
Lobectomy (Lobectomy)
Pneumonectomy (Pneumonectomy)
Segmentectomy (Segmentectomy)
Disease Characteristics
Condition of Specimen (check one)
Inadequate (Inadequate)
Other (Other)
Satisfactory (Satisfactory)
Unsatisfactory (Unsatisfactory)
Other, specify
Area (check one)
Carina (Carina)
Lower Lobe (left) (Lower Lobe (left))
Lower Lobe (right) (Lower Lobe (right))
Mainstem Bronchus (left) (Mainstem
Bronchus (left))
Mainstem Bronchus (right) (Mainstem
Bronchus (right))
Middle Lobe (right) (Middle Lobe (right))
Multiple Sites (Multiple sites)
Upper Lobe (left) (Upper Lobe (left))
Upper Lobe (right) (Upper Lobe (right))
Zone (check one)
Mid Zone (Mid zone)
Predominantly Central (Predominantly
central)
Predominantly Peripheral (Predominantly
peripheral)
Sum of Products of Greatest Diameters (Enter all
3 dimensions if possible OR the GREATEST
dimension)
Dimension 1 (mm)
Dimension 2 (mm)
Dimension 3 (mm)
Histologic Type (Histologic Features of Primary
Neoplasm)
Adenocarcinoma (Adenocarcinoma)
Bronchoalveolar (bac) (Bronchoalveolar
carcinoma (BAC))
Combined/mixed, Specify Subcategories
(Combined/mixed)
Large Cell Undifferentiated (Large cell
undifferentiated)
Non-small Cell Lung Cancer (nsclc), Nos
2 / 5
Pathology - Lung Cancer - North Central Cancer Treatment Group N0723
Pathology Reporting Form - 2731651v1.0
(Non-small cell lung cancer NOS)
Non-small Cell Lung Carcinoma (Other
Non-Small Cell Lung Cancer)
Other (Other specify)
Small Cell Lung Cancer (Small cell lung
cancer)
Squamous Cell Carcinoma (Squamous
cell carcinoma)
Specify combined/mixed histologic types
Specify subcategories
Other specify (ineligible - Complete Central
Pathology Reviewer initials section then End
Form)
Histologic Grade (Differentiation) (check one)
Well Differentiated (Grade I)
Moderately Differentiated (Grade II)
Poorly Differentiated (Grade III)
Undifferentiated (Grade IV)
Disease Characteristics2
Is local spread confined to lung parenchyma
(check one)
Yes
No
Is the bronchial margin involved (check one)
Yes
No
Is the pleural margin involved (check one)
Yes
No
Number of Positive Lymph Nodes
Number of Negative Lymph Nodes
Lymph nodes specify
Source of Cells used for Analysis (specify
location check one)
Metastatic Tumor With Clinical Evidence
Of Primary Tumor In Lung (Metastatic
tumor with clinical evidence of primary
tumor in lung)
Primary And Metastatic Tumor (Primary
and metastatic tumor)
Primary Tumor (Primary tumor)
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Pathology - Lung Cancer - North Central Cancer Treatment Group N0723
Pathology Reporting Form - 2731651v1.0
Metastatic site specify
Percent Cells Viable
Comments
Comments And Pathology Reporting
Pathologist Completing Form
Report Date (mm/dd/yyyy)
Pathology Review Concordance
Agree With Original Local Diagnosis
(Agree with original local diagnosis)
Disagree With Original Local Diagnosis
(Disagree with original local diagnosis)
Specimen ID Number (Block/Slide numbers to be
used for research/banking)
Comments
Egfr Fish Status
Is this patient evaluable for FISH (check one)
Yes
No
Reason evaluation not performed
Assay Failed (Assay failed)
Inadequate Tissue (Inadequate tissue)
Other (Other)
Specify
Sample test date (mm/dd/yyyy)
NCCTG Patient ID
EGFR FISH score
EGFR FISH status (check one)
Negative Finding (Negative)
Positive Finding (Positive)
Egfr Ihc Status
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Pathology - Lung Cancer - North Central Cancer Treatment Group N0723
Pathology Reporting Form - 2731651v1.0
Is this patient evaluable for immunostaining (IHC)
(check one)
Yes
No
Reason evaluation not performed
Assay Failed (Assay failed)
Inadequate Tissue (Inadequate tissue)
Other (Other)
Specify
Percentage of Invasive Tumor Cells with
Membrane Staining (Assess the total percentage
of tumor cells stained any intensity with EGFR)
EGFR IHC Status (check one)
Negative Finding (Negative)
Positive Finding (Positive)
Uniformity of staining (check one)
Absent (Absent)
Present (Present)
Percentage of Invasive Tumor Cells with
Cytoplasmic Staining (Assess the percentage of
cytoplasmic staining observed)
Comments And Pathology Reporting2
Pathologist Completing Form
Report Date (mm/dd/yyyy)
Comments
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Pathology - Lung Cancer - North Central Cancer Treatment Group N0723
Pathology Reporting Form - 2731651v1.0
NCT01041703 Response - E2906 Acute Leukemia
Disease Assessment Form - 2951828v1.0
E2906 Acute Leukemia Disease Assessment Form
Clofarabine or Daunorubicin Hydrochloride and Cytarabine
Followed By Decitabine or Observation in Treating Older
Patients With Newly Diagnosed Acute Myeloid Leukemia
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=7585B205-
C98E-8BDD-E040-BB89AD430415
All rights reserved. Please visit https://medical-data-
models.org/forms/6988
E2906 Acute Leukemia Disease
Assessment Form
Header
DCI Name
Registration Step (Place ID Label Here)
Patient Initials (Last, First)
ECOG Protocol Number
ECOG Protocol Number
ECOG Patient ID
ECOG Patient ID
Participating Group Protocol Number
Participating Group Patient ID
Institution/Affiliate
On Treatment
On Treatment Report Period
At Transplant (At Transplant)
Cycle 1 - Consolidation (Cycle 1 -
Consolidation)
Cycle 1 - Induction (Cycle 1 - Induction)
Cycle 1 - Step 3 (Cycle 1 - Step 3)
Cycle 10 - Step 3 (Cycle 10 - Step 3)
Cycle 11 - Step 3 (Cycle 11 - Step 3)
Cycle 12 - Step 3 (Cycle 12 - Step 3)
Cycle 13 - Step 3 (Cycle 13 - Step 3)
Cycle 2 - Consolidation (Cycle 2 -
Consolidation)
Cycle 2 - Induction (Cycle 2 - Induction)
Cycle 2 - Step 3 (Cycle 2 - Step 3)
Cycle 3 - Step 3 (Cycle 3 - Step 3)
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Cycle 4 - Step 3 (Cycle 4 - Step 3)
Cycle 5 - Step 3 (Cycle 5 - Step 3)
Cycle 6 - Step 3 (Cycle 6 - Step 3)
Cycle 7 - Step 3 (Cycle 7 - Step 3)
Cycle 8 - Step 3 (Cycle 8 - Step 3)
Cycle 9 - Step 3 (Cycle 9 - Step 3)
Off Treatment
Off Treatment Report Period (since registration to
Step 1 If this form covers an Off Treatment
Report Period Choose one)
12 Months (12 Months Post Registration)
15 Months (15 Months Post Registration)
18 Months (18 Months Post Registration)
21 Months Post Registration (21 Months
Post Registration)
2 Years (24 Months Post Registration)
3 Months (3 Months Post Registration)
30 Months (30 Months Post Registration)
3 Years (36 Months Post Registration)
42 Months (42 Months Post Registration)
4 Years (48 Months Post Registration)
54 Months (54 Months Post Registration)
6 Months (6 Months Post Registration)
5 Years (60 Months Post Registration)
9 Months (9 Months Post Registration)
Unnamed2
Please mark an 'X' if data have been amended.
(Please circle amended items in red)
Date data amended (s M D Y)
Bone Marrow Biopsy Information
Was bone marrow biopsy done (/aspirate
obtained for this reporting period)
No (no)
Unknown (unknown)
Yes (yes)
Date of Bone Marrow Biopsy (second /aspirate if
done M D Y Submit copy of bone marrow report
with E2906 Source Document Tracking
Coversheet attached)
Date of Bone Marrow Biopsy (second /aspirate if
done M D Y Submit copy of bone marrow report
with E2906 Source Document Tracking
Coversheet attached)
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NCT01041703 Response - E2906 Acute Leukemia Disease Assessment
Form - 2951828v1.0
Mark an 'X' if not done (second bone marrow
biopsy/aspirate)
Marrow Cellularity (%)
Are all cell lines maturing
Yes
No
Marrow Blasts (%)
Are auer rods present?
Auer Rods Absent From Bone Marrow
(Absent)
Auer Rods Present In Bone Marrow
(Present)
Was there evidence of persistence of leukemia
associated phenotype by flow cytometry
Yes
No
Were there circulating blasts in peripheral blood
Yes
No
Did the patient achieve morphologic leukemia-
free state
Yes
No
Date patient achieved morphologic leukemia-free
state
Did patient achieve PR
Yes
No
Date of PR (M D Y)
Did patient achieve CR
Yes
No
Date of CR (M D Y)
Was Complete Remission incomplete (CRi)
achieved (If no CR)
Yes
No
Date of CRi (M D Y)
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NCT01041703 Response - E2906 Acute Leukemia Disease Assessment
Form - 2951828v1.0
Is there any extramedullary disease
Yes
No
Specify sites
Comments
Investigator Signature
Investigator Signature Date (MM DD YYYY)
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NCT01041703 Response - E2906 Acute Leukemia Disease Assessment
Form - 2951828v1.0
Neoplasms, Breast NCT00490139 Pathology - North Central Cancer
Treatment Group - Central Her2 Testing Form - FISH - 2639126v1.0
North Central Cancer Treatment Group - Central Her2
Testing Form - FISH
ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment
Optimisation) Study; BIG 2-06/N063D
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=30AFEA0B-
FEAD-5E3F-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/6989
North Central Cancer Treatment
Group - Central Her2 Testing Form -
FISH
Header Module
NCCTG Protocol Number
Central Pathology ID
Patient Initials
Institution Number
Institution
Are data amended
Yes
No
Header
FISH HER2/neu chromosome 17 Ratio
Percentage greater than or equal to 3
Chromosome 17 signals
NACA (No apparent Chromosome 17 anomaly)
Yes
No
Her2 status / FISH via Vysis Probe
Amplified (Amplified)
Equivocal (Equivocal)
No Her2 Result / Not Done (No HER2
result / Not done)
Not Amplified (Not amplified)
Why no result
Hybridization Failure (hybridization
failure)
Insufficient Tissue (Insufficient tissue)
Interductal Only (Interductal only)
No Cancer Tissue (No cancer tissue)
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Other (Other)
Specify
Chromosome 17 copy number
Monosomy (Monosomy)
Normal (Normal)
Polysomy (Polysomy)
Other features
Duplication Of Her2 (Duplication of
HER2)
Most Cells With No Centromere 17 (Most
cells with no centromere 17)
Negative Her2 (Negative HER2)
Normal Her2 (Normal HER2)
Not A Small Clone (Not a small clone)
Other (Other)
Small Clone Of Amplification (Small
clone of amplification)
Specify
Footer Module
Pathologist CTEP ID
Date
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Neoplasms, Breast NCT00490139 Pathology - North Central Cancer
Treatment Group - Central Her2 Testing Form - FISH - 2639126v1.0
Neoplasms, Breast NCT00490139 Pathology - North Central Cancer
Treatment Group - Blood Specimen Compliance Form - 2648135v1.0
North Central Cancer Treatment Group - Blood Specimen
Compliance Form
ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment
Optimisation) Study; BIG 2-06/N063D
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=324F72E6-
4870-2BFA-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/6995
North Central Cancer Treatment
Group - Blood Specimen
Compliance Form
Header Module
NCCTG Study No.
Patient Study ID
Patient Initials
Institution Number
Institution
Are data amended
Yes
No
Header
Date Form Completed
Reporting Period
Approximately 5 Years Post
Randomization (Approximately 5 years
post randomization)
Approximately 52 Weeks Post
Randomization (Approximately 52 weeks
post randomization)
Baseline (Baseline)
Recurrence (Recurrence)
Reason blood specimen was not collected
Death (Death)
Other (Other)
Patient Refused (Patient refused)
Staff Unavailable (Staff unavailable)
Specify
Future booklet(s) expected from this patient
Yes
1 / 2
No
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Neoplasms, Breast NCT00490139 Pathology - North Central Cancer
Treatment Group - Blood Specimen Compliance Form - 2648135v1.0
Neoplasms, Breast NCT00490139 Pathology - North Central Cancer Treatment
Group - Snap Frozen Tissue Specimen Submission Form - 2639145v1.0
North Central Cancer Treatment Group - Snap Frozen
Tissue Specimen Submission Form
ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment
Optimisation) Study; BIG 2-06/N063D
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=30AFEA0B-
FED3-5E3F-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/6996
North Central Cancer Treatment
Group - Snap Frozen Tissue
Specimen Submission Form
Header Module
NCCTG Study No.
Central Lab ID Number
Patient Initials
Institution Number
Institution
Header
Did this patient provide written conset to give
Snap Frozen specimen(s) fo research
Yes
No
Was a research Snap Frozen specimen obtained
Yes
No
Reason (If No,)
Date of collection (If Yes:)
Date Specimen Shipped (If Yes:)
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Neoplasms, Breast NCT00490139 Pathology - North Central Cancer
Treatment Group - Blood Specimen Submission Form - 2639164v1.0
North Central Cancer Treatment Group - Blood Specimen
Submission Form
ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment
Optimisation) Study; BIG 2-06/N063D
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=30AFEA0B-
FEF9-5E3F-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/6997
North Central Cancer Treatment
Group - Blood Specimen Submission
Form
Header Module
NCCTG Study No.
Patient Study ID
Patient Initials
Institution Number
Institution
Are data amended
Yes
No
Header
Reporting Period
Approximately 5 Years Post
Randomization (Approximately 5 years
post randomization)
Approximately 52 Weeks Post
Randomization (Approximately 52 weeks
post randomization)
Baseline (Baseline)
Recurrence (Recurrence)
Patient's Initial Consent given for blood specimen
use for research on the patient's cancer?
Yes
No
Was sample obtained
Yes
No
Reason
Date of collection
1 / 2
Date Specimen Shipped
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Neoplasms, Breast NCT00490139 Pathology - North Central Cancer
Treatment Group - Blood Specimen Submission Form - 2639164v1.0
Brain and Central Nervous System Tumors NCT00887146 On-Study - North
Central Cancer Treatment Group CD Submission Form - 2804515v1.0
North Central Cancer Treatment Group CD Submission
Form
Radiation Therapy or Radiation Therapy and Temozolomide
or Temozolomide Alone in Treating Patients With Newly
Diagnosed Anaplastic Glioma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=5C3973FB-
A21F-4ECE-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/7000
North Central Cancer Treatment
Group CD Submission Form
Header
Protocol Number
Patient ID
Patient Initials (L F M)
Institution Number
Institution
Are data amended (If yes, highlight amended
areas)
Yes
No
Header
Current Cycle Number (or)
Date received (CD)
Reporting Period
Event Monitoring Phase (Event
Monitoring Phase)
Were imaging studies performed (check one)
Yes
No
Specify (If no,)
Completed By View Personnel:
Date received (CD)
Was the quality of the scan acceptable
1 / 2
Yes
No
Reason (If no,)
Gross Artifacts Found (Gross artifacts
found)
Other (Other)
Study Incomplete (Study incomplete)
Technical Parameters Not Compliant
(Technical parameters not compliant)
Other, specify
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Brain and Central Nervous System Tumors NCT00887146 On-Study - North
Central Cancer Treatment Group CD Submission Form - 2804515v1.0
Brain and Central Nervous System Tumors NCT00887146 Treatment - North
Central Cancer Treatment Group N0577 Concurrent Steroid and Anticonvulsant
Treatment Form - Baseline - 2745270v1.0
North Central Cancer Treatment Group N0577 Concurrent
Steroid and Anticonvulsant Treatment Form - Baseline
Radiation Therapy or Radiation Therapy and Temozolomide
or Temozolomide Alone in Treating Patients With Newly
Diagnosed Anaplastic Glioma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=4C07E8C3-
3306-293D-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/7001
North Central Cancer Treatment
Group N0577 Concurrent Steroid
and Anticonvulsant Treatment Form -
Baseline
Header
Protocol Number
Patient ID
Patient Initials (L F M)
Institution Number
Institution
Are data amended (If yes, highlight amended
areas)
Yes
No
Header
Date of evaluation (mm/dd/yyyy)
Concomitant Treatmet
Corticosteriods
Yes
No
Decadron/Dexamethasone
Yes
No
Other Corticosteriod
Yes
No
Specify
Anticonvulsants
1 / 3
Yes
No
Neurontin
Yes
No
Phenytoin/Dilantin
Yes
No
Carbamazepine/Tegretol
Yes
No
Valproic acid/Depakene
Yes
No
Phenobarbital
Yes
No
Keppra
Yes
No
Other anticonvulsant
Yes
No
Specify
Antiemetics
Yes
No
Compazine
Yes
No
Granisetron
Yes
No
Ondansetron
Yes
No
Ativan
Yes
No
Other antiemetic
Yes
No
Specify
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Brain and Central Nervous System Tumors NCT00887146 Treatment - North
Central Cancer Treatment Group N0577 Concurrent Steroid and Anticonvulsant
Treatment Form - Baseline - 2745270v1.0
Total Daily Dose of Agent (or Drug)
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Brain and Central Nervous System Tumors NCT00887146 Treatment - North
Central Cancer Treatment Group N0577 Concurrent Steroid and Anticonvulsant
Treatment Form - Baseline - 2745270v1.0
Brain and Central Nervous System Tumors NCT00887146 Toxicity - North Central
Cancer Treatment Group N0577 Baseline Adverse Events Form - 2745736v1.0
North Central Cancer Treatment Group N0577 Baseline
Adverse Events Form
Radiation Therapy or Radiation Therapy and Temozolomide
or Temozolomide Alone in Treating Patients With Newly
Diagnosed Anaplastic Glioma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=4C096CEC-
612D-47DB-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/7003
North Central Cancer Treatment
Group N0577 Baseline Adverse
Events Form
Header
Protocol Number
Patient ID
Patient Initials (L F M)
Institution Number
Institution
Are data amended (If yes, highlight amended
areas)
Yes
No
Description Of Primary Disease
CTC Adverse Event Term
Dyspnoea Nos (Dyspnea (shortness of
breath))
Nausea (Nausea)
MedDRA Code (primary tumor site: Metastases
to brain parenchyma)
CTC Adverse Event Grade
Baseline number of stools per day
1 / 1
Pathology Reporting Form - Brain Tumor
N0577
North Central Cancer Treatment Group N0577 Pathology
Reporting Form - Brain Tumor
Radiation Therapy or Radiation Therapy and Temozolomide
or Temozolomide Alone in Treating Patients With Newly
Diagnosed Anaplastic Glioma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=4CA85A1E-
6D87-49C3-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/7004
Pathology Reporting Form - Brain
Tumor N0577
Header
Protocol Number*
Patient ID*
Patient Initials (L F M)*
Institution Number*
Institution*
Header2
Referring Pathologist*
Laboratory Name*
Reviewing Pathologist*
Number of slides submitted*
Date shipped*
(Pathology) Slide Number*
Accession Number*
Disease Status*
Primary Tumor (Primary (Advanced))
Recurrence/relapse (Recurrence)
Procedure Date*
Ii. Completed By The Ncctg Pathology
Reviewer
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Nuclear abnormalities*
Absent (Absent)
Present (Present)
Uncertain (Uncertain)
Mitoses*
Absent (Absent)
Present (Present)
Uncertain (Uncertain)
Endothelial proliferation*
Absent (Absent)
Present (Present)
Uncertain (Uncertain)
Necrosis*
Absent (Absent)
Present (Present)
Uncertain (Uncertain)
Histologic Type*
9420-3 Fibrillary Astrocytoma (c71._)
(Fibrillary astrocytoma)
9411-3 Gemistocytic Astrocytoma
(c71._) (Gemistocytic astrocytoma)
9442-3 Gliosarcoma (c71._)
(Gliosarcoma)
9450-3 Oligodendroglioma, Nos (c71._)
(Oligodendroglioma)
9421-1 Pilocytic Astrocytoma (c71._)
(Pilocytic astrocytoma)
9410-3 Protoplasmic Astrocytoma
(c71._) (Protoplasmic astrocytoma)
Histologic Grade*
Moderately Differentiated (grade Ii)
(moderately differentiated (grade II))
Poorly Differentiated (grade Iii) (poorly
differentiated (grade III))
Undifferentiated (grade Iv)
(undifferentiated (grade IV))
Well Differentiated (grade I) (well
differentiated (grade I))
Comments*
Proliferation*
Absent (Absent)
Present (Present)
Uncertain (Uncertain)
Necrosis, thrombosis, sclerosis*
Absent (Absent)
Present (Present)
Uncertain (Uncertain)
Atrophy/Gliosis*
Absent (Absent)
2 / 3
Pathology Reporting Form - Brain Tumor N0577
Present (Present)
Uncertain (Uncertain)
Necrosis*
Absent (Absent)
Present (Present)
Uncertain (Uncertain)
Other*
Absent (Absent)
Present (Present)
Uncertain (Uncertain)
Specify*
Comments And Pathology Reporting
Pathologist Completing Form *
Investigator Signature*
Investigator Signature*
Report Date (mm/dd/yyyy)*
Pathology Review Concordance*
Agree With Original Local Diagnosis
(Agree with original local diagnosis)
Minor Disagreement With Original Local
Diagnosis (Minor disagreement with
original local diagnosis)
Substantial Disagreement With Original
Local Diagnosis (Substantial
disagreement with original local
diagnosis)
Comments*
Specimen ID Number (Block/Slide numbers to be
used for research/banking)*
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Pathology Reporting Form - Brain Tumor N0577
Radiation Therapy Reporting Form N0577
North Central Cancer Treatment Group N0577 Radiation
Therapy Reporting Form
Radiation Therapy or Radiation Therapy and Temozolomide
or Temozolomide Alone in Treating Patients With Newly
Diagnosed Anaplastic Glioma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=4C094A4D-
BDDC-3997-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/7006
Radiation Therapy Reporting Form
N0577
Header
Protocol Number*
Patient ID*
Patient Initials (L F M)*
Institution Number*
Institution*
Are data amended (If yes, highlight amended
areas)*
Yes
No
Brain
Radiation Therapy Start Date*
Radiation Therapy End Date*
Technique
Modality (Primary)*
Cobalt Radioisotopes (Cobalt)
Linear Accelerator (Linear Accelerator)
Other (Other)
Dose*
Field*
Field size*
Field size*
1 / 2
Treatment distance*
Target*
Source To Axis Distance (SAD)
Source To Surface Distance (SSD)
Treatment Areas, Dose and Time
RT Site*
RT Total Dose (cGy)*
Total Number of Fractions*
Elapsed days*
Were there any unscheduled interruptions in
radiation therapy?*
Yes
No
Days Treatment Was Interrupted*
Reasons*
Local Reaction (Local reaction)
Machine Down (Machine down)
Other Specify (other)
Social (Social)
Systemic Reaction (Systemic reaction)
Unknown (Unknown)
Other specify*
Unnamed2
Comments*
Radiation Oncologist's Signature*
Date*
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Radiation Therapy Reporting Form N0577
Brain and Central Nervous System Tumors NCT00887146 Pathology - North
Central Cancer Treatment Group N0577 Baseline Blood Specimen Submission
Form - 2745906v1.0
North Central Cancer Treatment Group N0577 Baseline
Blood Specimen Submission Form
Radiation Therapy or Radiation Therapy and Temozolomide
or Temozolomide Alone in Treating Patients With Newly
Diagnosed Anaplastic Glioma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=4C096CEC-
6297-47DB-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/7007
North Central Cancer Treatment
Group N0577 Baseline Blood
Specimen Submission Form
Header Module
Protocol Number
Patient ID
Patient Initials (L F M)
Institution Number
Institution
Are data amended (check one if data are
amended, please circle in red when using paper
form)
Yes
No
Header
Reporting Period
Baseline (Baseline)
Patient's Initial Consent given for blood specimen
use for research on the patient's cancer?
Yes
No
Was sample obtained
Yes
No
Date of collection (mm/dd/yyyy)
Date Specimen Shipped (mm/dd/yyyy)
Reason (If no, reason)
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Brain and Central Nervous System Tumors NCT00887146 Pathology - North
Central Cancer Treatment Group N0577 Baseline Tissue Specimen Submission
Form - 2745964v1.0
North Central Cancer Treatment Group N0577 Baseline
Tissue Specimen Submission Form
Radiation Therapy or Radiation Therapy and Temozolomide
or Temozolomide Alone in Treating Patients With Newly
Diagnosed Anaplastic Glioma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=4C08FC47-
BF9C-632C-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/7008
North Central Cancer Treatment
Group N0577 Baseline Tissue
Specimen Submission Form
Header
Protocol Number
Patient ID
Patient Initials (L F M)
Institution Number
Institution
Are data amended
Yes
No
Header
Reporting Period
Baseline (Baseline)
Did this patient provide written consent to give
tissue specimen(s) for research
Yes
No
Was a research tissue specimen obtained
Yes
No
Date of collection (If Yes:)
Date Specimen Shipped (If Yes:)
Reason (If No,)
1 / 1
Brain and Central Nervous System Tumors NCT00887146 On-Study - North
Central Cancer Treatment Group Baseline CD Submission Form - 2804462v1.0
North Central Cancer Treatment Group Baseline CD
Submission Form
Radiation Therapy or Radiation Therapy and Temozolomide
or Temozolomide Alone in Treating Patients With Newly
Diagnosed Anaplastic Glioma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=5C397187-
1C79-4DCB-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/7011
North Central Cancer Treatment
Group Baseline CD Submission
Form
Header
Protocol Number
Patient ID
Patient Initials (L F M)
Institution Number
Institution
Are data amended (If yes, highlight amended
areas)
Yes
No
Header
Reporting Period
Baseline (Baseline)
Date received (CD)
Were imaging studies performed (check one)
Yes
No
Specify (If no,)
Image date (mm/dd/yyyy)
Is the imaging equipment accredited by the
American College of Radiology (check one)
Yes
No
Does the imaging equipment meet state and
federal requirements and include annual
1 / 2
equipment inspections (check one)
Yes
No
Is the imaging technologist certified (check one)
Yes
No
Completed By View Personnel:
Date received (CD)
Was the quality of the scan acceptable
Yes
No
Reason (If no,)
Gross Artifacts Found (Gross artifacts
found)
Other (Other)
Study Incomplete (Study incomplete)
Technical Parameters Not Compliant
(Technical parameters not compliant)
Other, specify
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Brain and Central Nervous System Tumors NCT00887146 On-Study - North
Central Cancer Treatment Group Baseline CD Submission Form - 2804462v1.0
Brain and Central Nervous System Tumors NCT00887146 Pathology - North
Central Cancer Treatment Group N0577 Pathology Submission Form - 2745984v1.0
North Central Cancer Treatment Group N0577 Pathology
Submission Form
Radiation Therapy or Radiation Therapy and Temozolomide
or Temozolomide Alone in Treating Patients With Newly
Diagnosed Anaplastic Glioma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=4C08FC47-
BFC6-632C-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/7013
North Central Cancer Treatment
Group N0577 Pathology Submission
Form
Header
Protocol Number
Patient ID
Patient Initials (L F M)
Institution Number
Institution Name
Header
Date Specimen Shipped
Number of slides submitted
Accession Number
Accession Number
Number of blocks sent
Instructions
Contact Person at Institution (Institutional Contact
Information:)
Comments
Street Address
City
1 / 2
Institution Name
State
Postal Code
Phone Number
Fax Number
Unnamed2
Comments
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Brain and Central Nervous System Tumors NCT00887146 Pathology - North
Central Cancer Treatment Group N0577 Pathology Submission Form - 2745984v1.0
Brain and Central Nervous System Tumors NCT00887146 On-Study - North Central
Cancer Treatment Group N0577 Active Monitoring Measurement Form -
2748630v1.0
North Central Cancer Treatment Group N0577 Active
Monitoring Measurement Form
Radiation Therapy or Radiation Therapy and Temozolomide
or Temozolomide Alone in Treating Patients With Newly
Diagnosed Anaplastic Glioma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=4CD2A079-
1EF5-2B7D-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/7014
North Central Cancer Treatment
Group N0577 Active Monitoring
Measurement Form
Header
Protocol Number
Patient ID
Patient Initials (L F M)
Institution Number
Institution
Are data amended (If yes, highlight amended
areas)
Yes
No
Header
Current Cycle Number
Assessment Date
Method of Evaluation
Ct Scan (CT scan)
Mri Scan (MRI scan)
Primary Indicator Lesion Site
CT/MRI Scan Score
Complete Response (CR)
Ned (NED)
Not Done (Not Done)
Progressive Disease (PD)
Partial Response (PR)
Regression (REGR)
Stable Disease (SD)
Neurologic Exam Score
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Better (better)
Not Done (not done)
Same (same)
Worse (worse)
Overall Response Status
Complete Response (CR)
No Evidence Of Disease (NED)
Progressive Disease (PD)
Partial Response (PR)
Regr (REGR)
Stable Disease (SD)
Unknown (Unknown)
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Brain and Central Nervous System Tumors NCT00887146 On-Study - North Central
Cancer Treatment Group N0577 Active Monitoring Measurement Form -
2748630v1.0
Brain and Central Nervous System Tumors NCT00887146 Treatment - North
Central Cancer Treatment Group N0577 Concurrent Treatment Form - Active
Monitoring Phase - 2745292v1.0
North Central Cancer Treatment Group N0577 Concurrent
Treatment Form - Active Monitoring Phase
Radiation Therapy or Radiation Therapy and Temozolomide
or Temozolomide Alone in Treating Patients With Newly
Diagnosed Anaplastic Glioma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=4C0902A6-
F47D-2EB7-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/7015
North Central Cancer Treatment
Group N0577 Concurrent Treatment
Form - Active Monitoring Phase
Header
Protocol Number
Patient ID
Patient Initials (L F M)
Institution Number
Institution
Are data amended (If yes, highlight amended
areas)
Yes
No
Header
Current Cycle Number
Date of evaluation (mm/dd/yyyy)
Has there been any change in medications since
the previous visit
Yes
No
Concomitant Medication (If Yes, enter
medications including prescription, over-the-
counter, and alternative medications that have
not been previously reported or no longer being
taken)
Concomitant Medication Reason
Dose And/or Schedule Change (Dose
and/or schedule change)
Medication No Longer Being Taken
(Medication no longer being taken)
1 / 2
New Medication (New medication)
Dose
Schedule
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Brain and Central Nervous System Tumors NCT00887146 Treatment - North
Central Cancer Treatment Group N0577 Concurrent Treatment Form - Active
Monitoring Phase - 2745292v1.0
Breast Cancer NCT00377156 Pre-Study - North Central Cancer
Treatment Group Functional Independence - 2470805v1.0
North Central Cancer Treatment Group Functional
Independence
Stereotactic Radiation Therapy With or Without Whole-
Brain Radiation Therapy in Treating Patients With Brain
Metastases
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=10DD7D18-
F9F9-2FC3-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/7016
North Central Cancer Treatment
Group Functional Independence
Header
NCCTG Protocol Number
NCCTG Patient ID
Patient Initials (L F M)
Institution
Institution Number
Are data amended (If yes, highlight amended
areas)
Yes
No
Time point
Baseline (baseline)
Current Cycle Number
Date Completed
Barthel Function Index
Feeding
Dependent (Dependent)
Independent. Able To Put On Any
Assistance Device. Eats In Reasonable
Time. (Independent. Able to put on any
assistance device. Eats in reasonable
time.)
Needs Help, E.g., For Cutting Food.
(Needs Help, e.g., for cutting food.)
Chair/bed transfers
Able To Sit, But Need Maximum
Assistance To Transfer. (Able to sit, but
need maximum assistance to transfer.)
Dependent (Dependent)
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Independent. Can Lock A Wheelchair,
Lift Footrests, And Get Out.
(Independent. Can lock a wheelchair, lift
footrests, and get out.)
Minimum Assistance Or Supervision.
(Minimum assistance or supervision.)
Grooming
Independent. Can Wash Face, Comb
Hair, Brush Teeth, Shave (can Manage
Plug In Electric Razor). (Independent.
Can wash face, comb hair, brush teeth,
shave (can manage plug in electric
razor).)
Needs Help With Grooming. (Needs help
with grooming.)
Toilet Transfers
Dependent (Dependent)
Independent. Can Get On And Off,
Handle Clothes, Or Toilet Paper.
(Independent. Can get on and off, handle
clothes, or toilet paper.)
Needs Help For Balance, Handling
Clothes, Or Toilet Paper. (Needs help for
balance, handling clothes, or toilet
paper.)
Bathing
Dependent (Dependent)
Independent. Able To Use Bath Tub,
Shower, Or Take Complete Sponge Bath
Without Supervision. (Independent. Able
to use bath tub, shower, or take complete
sponge bath without supervision.)
Walking
Can Walk With Help For 50 Yards. (Can
walk with help for 50 yards.)
Dependent (Dependent)
Independent To 50 Yards. May Use
Assistive Devices. (Independent to 50
yards. May use assistive devices.)
Unable To Walk, But Independent In
Wheelchair For 50 Yards. (Unable to
walk, but independent in wheelchair for
50 yards.)
Stairs
Independent Up And Down. May Use
Assistive Devices. (Independent up and
down. May use assistive devices.)
Needs Help Or Supervision. (Needs help
or supervision.)
Unable (Unable)
Dressing
Dependent (Dependent)
Independent. Can Tie Shoes, Fasten
Fasteners, Undress. (Independent. Can
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Breast Cancer NCT00377156 Pre-Study - North Central Cancer
Treatment Group Functional Independence - 2470805v1.0
tie shoes, fasten fasteners, undress.)
Needs Help But Does At Least Half Of
Task Within Reasonable Time. (Needs
help but does at least half of task within
reasonable time.)
Bowel Control
Incontinent (Incontinent)
No Accidents. Able To Use Enema Or
Suppository, If Needed. (No accidents.
Able to use enema or suppository, if
needed.)
Occasional Accidents (<1/week) Or
Need Help With External Device.
(Occasional accidents (<1/week) or need
help with external device.)
Bladder Control
Incontinent (Incontinent)
No Accidents. Able To Care For
Collecting Device, If Used. (No
accidents. Able to care for collecting
device, if used.)
Occasional Accidents (<1/day) Or Need
Help With External Device. (Occasional
accidents (<1/day) or need help with
external device.)
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Breast Cancer NCT00377156 Pre-Study - North Central Cancer
Treatment Group Functional Independence - 2470805v1.0
Breast Cancer NCT00377156 RT Submission - North Central Cancer
Treatment Group ARM B Radiation Therapy Reporting Form - 2470699v1.0
North Central Cancer Treatment Group ARM B Radiation
Therapy Reporting Form
Stereotactic Radiation Therapy With or Without Whole-
Brain Radiation Therapy in Treating Patients With Brain
Metastases
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=10D87E75-
C2B0-0CB3-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/7017
North Central Cancer Treatment
Group ARM B Radiation Therapy
Reporting Form
Header
NCCTG Protocol Number
NCCTG Patient ID
Patient Initials (L F M)
Institution
Institution Number
Are data amended (If yes, highlight amended
areas)
Yes
No
Unnamed 1
Date start whole brain radiotherapy
Date end whole brain radiotherapy
Technique
Modality (Primary)
Cobalt Radioisotopes (Cobalt)
Linear Accelerator (Linear Accelerator)
Other (Other)
MV Dose
Field
Field size
Field size
1 / 2
Treatment distance
Target
Source To Axis Distance (SAD)
Source To Surface Distance (SSD)
Unnamed
RT Site
RT Total Dose (cGy)
Total Number of Fractions
Elapsed days
Unnamed3
Were there any unscheduled interruptions in
radiation therapy?
Yes
No
Days Treatment Was Interrupted
Reasons
Local Reaction (Local reaction)
Machine Down (Machine down)
Other Specify (other)
Social (Social)
Systemic Reaction (Systemic reaction)
Unknown (Unknown)
Other specify
Unnamed2
Comments
Radiation Oncology Physician Signature Text
Date
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Breast Cancer NCT00377156 RT Submission - North Central Cancer
Treatment Group ARM B Radiation Therapy Reporting Form - 2470699v1.0
Breast Cancer NCT00377156 Follow-Up - North Central Cancer
Treatment Group Event Monitoring Form - 2470178v1.0
North Central Cancer Treatment Group Event Monitoring
Form
Stereotactic Radiation Therapy With or Without Whole-
Brain Radiation Therapy in Treating Patients With Brain
Metastases
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=10C2A3FE-
45CB-664E-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/7018
North Central Cancer Treatment
Group Event Monitoring Form
Header
NCCTG Protocol Number
NCCTG Patient ID
Patient Initials (L F M)
Institution
Institution Number
Are data amended (If yes, highlight amended
areas)
Yes
No
Unnamed Module
Were you able to obtain any information about
the patient since the last report (If this is the first
event monitoring form check yes, enter
assessment date and complete the rest of the
form.)
Yes
No
Date of last attempt to contact patient
Vital Status
Vital Status
Alive (Alive)
Dead (Dead)
Date of last contact or death
Primary Cause of Death
Due To Other Cause (Due to other
cause)
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Due To Protocol Treatment (Due to
protocol treatment)
Due To This Disease (Due to this
disease)
Due to other cause, specify
Disease Follow-up Status
Has the patient had a documented clinical
assessment for this cancer? (since submission of
the last event monitoring form)
Yes
No
Cancer Follow-up Status Date (If yes,)
Notice Of First Relapse/progression In
The Event Monitoring Phase
Has the patient developed a first relapse or
progression that has not been previously
reported
Yes
No
Date of Relapse or Progression (If yes,)
Site of relapse/progression (scheck all that apply)
Distant Brain Failure (Distant brain
failure)
Local Brain Failure (Local brain failure)
Other (Other)
Systemic Disease (Systemic disease)
Other, specify
Notice Of New Primary
Has a new primary cancer or MDS been
diagnosed that has not been previously reported?
No (No)
Unknown (Unknown)
Yes (Yes)
New Primary Cancer Date (If yes,)
Site of New Primary
Late Adverse Event
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Breast Cancer NCT00377156 Follow-Up - North Central Cancer
Treatment Group Event Monitoring Form - 2470178v1.0
Has the patient experienced (prior to treatment
for progression or relapse or a second primary,
and prior to non-protocol treatment) any severe
(grade >=3) long term toxicity that has not been
previously reported?
No (No)
Unknown (Unknown)
Yes (Yes)
Description Of Primary Disease
Other CTC Adverse Event Term not listed
MedDRA Code (primary tumor site: Metastases
to brain parenchyma)
CTC Adverse Event Grade
CTC AE Attribution Code
Definite (Definite)
Possible (Possible)
Probable (Probable)
Unlikely (Unlikely)
Unrelated (Unrelated)
Late Adverse Event Onset Date
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Breast Cancer NCT00377156 Follow-Up - North Central Cancer
Treatment Group Event Monitoring Form - 2470178v1.0
Brain and Central Nervous System Tumors NCT00887146 Registration - North
Central Cancer Treatment Group N0577 Preregistration Screening Failure Form -
2745776v1.0
North Central Cancer Treatment Group N0577
Preregistration Screening Failure Form
Radiation Therapy or Radiation Therapy and Temozolomide
or Temozolomide Alone in Treating Patients With Newly
Diagnosed Anaplastic Glioma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=4C096CEC-
6180-47DB-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/7022
North Central Cancer Treatment
Group N0577 Preregistration
Screening Failure Form
Header
Protocol Number
Patient ID
Patient Initials (L F M)
Institution Number
Institution
Are data amended (If yes, highlight amended
areas)
Yes
No
Preregistration Screening Failure
Date aware of preregistration screening failure
(mm/dd/yyyy)
Primary reason screening failed (check one)
Did Not Meet Eligibility Criteria (Did not
meet eligibility criteria)
Investigator Decision (Investigator
decision)
Other (Other)
Patient Decision (Patient decision)
Other, specify
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Brain and Central Nervous System Tumors NCT00887146 Treatment - North
Central Cancer Treatment Group N0577 Concurrent Steroid and Anticonvulsant
Treatment Form - Active Monitoring Phase - 2745245v1.0
North Central Cancer Treatment Group N0577 Concurrent
Steroid and Anticonvulsant Treatment Form - Active
Monitoring Phase
Radiation Therapy or Radiation Therapy and Temozolomide
or Temozolomide Alone in Treating Patients With Newly
Diagnosed Anaplastic Glioma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=4C07E8C3-
32D4-293D-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/7024
North Central Cancer Treatment
Group N0577 Concurrent Steroid
and Anticonvulsant Treatment Form -
Active Monitoring Phase
Header
Protocol Number
Patient ID
Patient Initials (L F M)
Institution Number
Institution
Are data amended (If yes, highlight amended
areas)
Yes
No
Header
Current Cycle Number
Date of evaluation (mm/dd/yyyy)
Concomitant Treatmet
Corticosteriods
Yes
No
Decadron/Dexamethasone
Yes
No
Other Corticosteriod
Yes
No
Specify
1 / 3
Anticonvulsants
Yes
No
Neurontin
Yes
No
Phenytoin/Dilantin
Yes
No
Carbamazepine/Tegretol
Yes
No
Valproic acid/Depakene
Yes
No
Phenobarbital
Yes
No
Keppra
Yes
No
Other anticonvulsant
Yes
No
Specify
Antiemetics
Yes
No
Compazine
Yes
No
Granisetron
Yes
No
Ondansetron
Yes
No
Ativan
Yes
No
Other antiemetic
Yes
No
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Brain and Central Nervous System Tumors NCT00887146 Treatment - North
Central Cancer Treatment Group N0577 Concurrent Steroid and Anticonvulsant
Treatment Form - Active Monitoring Phase - 2745245v1.0
Specify
Total Daily Dose of Agent (or Drug)
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Brain and Central Nervous System Tumors NCT00887146 Treatment - North
Central Cancer Treatment Group N0577 Concurrent Steroid and Anticonvulsant
Treatment Form - Active Monitoring Phase - 2745245v1.0
Brain and Central Nervous System Tumors NCT00887146 Treatment - North
Central Cancer Treatment Group N0577 Concurrent Treatment Form - Baseline -
2745317v1.0
North Central Cancer Treatment Group N0577 Concurrent
Treatment Form - Baseline
Radiation Therapy or Radiation Therapy and Temozolomide
or Temozolomide Alone in Treating Patients With Newly
Diagnosed Anaplastic Glioma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=4C07E8C3-
3333-293D-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/7027
North Central Cancer Treatment
Group N0577 Concurrent Treatment
Form - Baseline
Header
Protocol Number
Patient ID
Patient Initials (L F M)
Institution Number
Institution
Are data amended (If yes, highlight amended
areas)
Yes
No
Header
Date of evaluation (mm/dd/yyyy)
Is the patient taking any concomitant medications
No (No)
Unknown (Unknown)
Yes (Yes)
Concomitant Medication (If Yes, enter
medications including prescription, over-the-
counter, and alternative medications that have
not been previously reported or no longer being
taken)
Dose
Schedule
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Brain and Central Nervous System Tumors NCT00887146 Treatment - North
Central Cancer Treatment Group N0577 Pretreatment Measurement Form -
2746048v1.0
North Central Cancer Treatment Group N0577
Pretreatment Measurement Form
Radiation Therapy or Radiation Therapy and Temozolomide
or Temozolomide Alone in Treating Patients With Newly
Diagnosed Anaplastic Glioma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=4C0A4D9C-
15EE-0D5E-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/7032
North Central Cancer Treatment
Group N0577 Pretreatment
Measurement Form
Header
Protocol Number
Patient ID
Patient Initials (L F M)
Institution Number
Institution
Are data amended (If yes, highlight amended
areas)
Yes
No
Header
Assessment Date (mm/dd/yyyy)
Method of Evaluation
Ct Scan (CT scan)
Mri Scan (MRI scan)
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Brain and Central Nervous System Tumors NCT00887146 Treatment - North
Central Cancer Treatment Group N0577 CTEP Report Variables Prior Therapy -
2745128v1.0
North Central Cancer Treatment Group N0577 CTEP
Report Variables Prior Therapy
Radiation Therapy or Radiation Therapy and Temozolomide
or Temozolomide Alone in Treating Patients With Newly
Diagnosed Anaplastic Glioma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=4C07CD25-
64D7-2417-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/7033
North Central Cancer Treatment
Group N0577 CTEP Report
Variables Prior Therapy
Header
Protocol Number
Patient ID
Patient Initials (L F M)
Institution Number
Institution
Are data amended (If yes, highlight amended
areas)
Yes
No
Prior Therapy
Prior therapy type
Agents Administered To Control The
Replication And/or Spread Of Viruses
(Anti-retroviral therapy)
Treatment With An Agent That Prevents
Or Impairs The Translation Of The
Genetic Message For Production Of A
Specific Protein (Antisense)
High Dose Chemotherapy Combined
With Transplantation Of Bone Marrow
Cells (Bone marrow transplant)
Non-systemic Chemotherapy Treatment
Or Chemotherapy Not Described By
Chemotherapy Single Agent Systemic Or
Multi-agent Systemic (Chemotherapy
(NOS))
Systemic Chemotherapy With A
Regimen Containing Multiple Agents
(Chemotherapy multiple agents
systemic)
Prior Therapy With Agents That Are Not
Known To Cause Damage To Cycling
Cells (Chemotherapy non-cytotoxic)
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Systemic Chemotherapy With A Single
Agent Regimen (Chemotherapy single
agent systemic)
Drug And/or Immunotherapy (Drug
and/or Immunotherapy)
Treatment Of Human Disease By Gene
Transfer (Gene transfer)
Hematopoietic Stem Cell Transplantation
(Hematopoietic Stem Cell
Transplantation)
Cancer Therapy Which Incorporates
Hormonal Manipulation (Hormonal
therapy)
Image Directed Local Therapy (Image
Directed Local Therapy)
No Previous Exposure To Drug (nos) (No
prior therapy)
Anticancer Treatment With A Live,
Replication-competent Virus (Oncolytic
virotherapy)
Prior Therapy (nos) (Prior therapy NOS)
Targeted Ionizing Radiation Therapy
Utilizing Radioactive Implants Or Seeds
(Radiation therapy)
Surgical Procedure, Or Operation, With
Therapeutic Intent (Surgery)
Therapy Nos (Therapy (NOS))
Substance Or Group Of Substances
Administered To Induce The Immune
System To Recognize And Destroy
Tumors Or Microorganisms (Vaccine)
MedDRA disease code (for primary tumor site:
10029514 [Non-small cell lung cancer, NOS])
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Brain and Central Nervous System Tumors NCT00887146 Treatment - North
Central Cancer Treatment Group N0577 CTEP Report Variables Prior Therapy -
2745128v1.0
Breast Cancer NCT00377156 Registration - North Central Cancer Treatment
Group Baseline Adverse Events/Symptoms Form - 2467667v1.0
North Central Cancer Treatment Group Baseline Adverse
Events/Symptoms Form
Stereotactic Radiation Therapy With or Without Whole-
Brain Radiation Therapy in Treating Patients With Brain
Metastases
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=108A66F6-
AB30-41E7-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/7038
North Central Cancer Treatment
Group Baseline Adverse
Events/Symptoms Form
Header
NCCTG Protocol Number
NCCTG Patient ID
Patient Initials (L F M)
Institution
Institution Number
Are data amended (If yes, highlight amended
areas)
Yes
No
Description Of Primary Disease
CTC Adverse Event Term
Cns Necrosis/cystic Progression (CNS
necrosis/cystic progression)
Learning Disorder Nos (Cognitive
disturbance)
Alopecia (Hair loss/Alopecia (scalp or
body))
Hearing: Patients With/without Baseline
Audiogram And Enrolled In A Monitoring
Program (Hearing: patients with/without
baseline audiogram and enrolled in a
monitoring program)
Otitis Externa (exc Boil Of Meatus) Nos
(Otitis, external ear (non-infectious))
Retinopathy (Retinopathy)
MedDRA Code (primary tumor site: Metastases
to brain parenchyma)
CTC Adverse Event Grade
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Brain and Central Nervous System Tumors NCT00978458 On-Study -
E3F05 Neurologic Function Status and KPS Form - 2901661v1.0
E3F05 Neurologic Function Status and KPS Form
Radiation Therapy With or Without Temozolomide in
Treating Patients With Low-Grade Glioma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=6C76FF0A-
A486-4EDB-E040-BB89AD4325FA
All rights reserved. Please visit https://medical-data-
models.org/forms/7042
E3F05 Neurologic Function Status
and KPS Form
Header Module
DCI Name
Registration Step (Place ID Label Here)
Patient Initials (Last, First)
ECOG Protocol Number
ECOG Protocol Number
ECOG Patient ID
ECOG Patient ID
Participating Group Protocol Number
Participating Group Patient ID
Institution/Affiliate
On Treatment
On Treatment Report Period (Choose one)
4 Weeks Post End Of Chemoradiation (4
weeks post end of Chemoradiation)
4 Weeks Post End Of Radiation (4
weeks post end of Radiation)
Baseline (baseline)
Cycle 3 (Cycle 3)
Cycles 10 - 12 (Cycles 10 - 12)
Cycles 4 - 6 (Cycles 4 - 6)
Cycles 7 - 9 (Cycles 7 - 9)
End Of Chemoradiation (End of
Chemoradiation)
End Of Radiation (End of Radiation)
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Off Treatment
Off Treatment Report Period (Choose one)
102 Months Post Registration (102
Months Post Registration)
9 Years (108 months post registration)
114 Months Post Registration (114
Months Post Registration)
12 Months (12 Months Post Registration)
10 Years (120 months post registration)
126 Months Post Registration (126
Months Post Registration)
11 Years Post Registration (132 Months
Post Registration)
138 Months Post Registration (138
Months Post Registration)
12 Years Post Registration (144 Months
Post Registration)
15 Months (15 Months Post Registration)
150 Months Post Registration (150
Months Post Registration)
13 Years Post Registration (156 Months
Post Registration)
162 Months Post Registration (162
Months Post Registration)
14 Years Post Registration (168 Months
Post Registration)
174 Months Post Registration (174
Months Post Registration)
18 Months (18 Months Post Registration)
15 Years Post Registration (180 Months
Post Registration)
21 Months Post Registration (21 Months
Post Registration)
2 Years (24 Months Post Registration)
27 Months Post Registration (27 Months
Post Registration)
3 Months (3 Months Post Registration)
30 Months (30 Months Post Registration)
33 Months Post Registration (33 Months
Post Registration)
3 Years (36 Months Post Registration)
39 Months Post Registration (39 Months
Post Registration)
42 Months (42 Months Post Registration)
45 Months Post Registration (45 Months
Post Registration)
4 Years (48 Months Post Registration)
51 Months Post Registration (51 Months
Post Registration)
54 Months (54 Months Post Registration)
57 Months Post Registration (57 Months
Post Registration)
6 Months (6 Months Post Registration)
5 Years (60 Months Post Registration)
66 Months Post Registration (66 Months
Post Registration)
6 Years (72 Months Post Registration)
78 Months Post Registration (78 Months
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Post Registration)
84 Months Post Registration (84 Months
Post Registration)
9 Months (9 Months Post Registration)
90 Months Post Registration (90 Months
Post Registration)
8 Years (96 months post registration)
Amendment
Please mark an 'X' if data have been amended.
(Please circle amended items in red)
Date data amended (s M D Y)
Vital Status
Patient's Vital Status
Alive (Alive)
Dead (Dead)
Date of Last Contact or Death (m d y)
Primary Cause of Death (if applicable)
Due To Other Cause (Due to other
cause)
Due To Protocol Treatment (Due to
protocol treatment)
Due To This Disease (Due to this
disease)
Unknown (Unknown)
Describe cause of death
Patient Characteristics
Neurologic Function Status
Minor Neurologic Symptoms, Fully Active
At Home/work Without Assistance (Minor
neurologic symptoms, fully active at
home/work without assistance)
Moderate Neurologic Symptoms, Fully
Active At Home/work But Requires
Assistance (Moderate neurologic
symptoms, fully active at home/work but
requires assistance)
Moderate Neurologic Symptoms, Less
Than Fully Active At Home/work And
Requires Assitance (Moderate
neurologic symptoms, less than fully
active at home/work and requires
assistance)
No Neurologic Symptoms, Fully Active At
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Home/work Without Assistance (No
neurologic symptoms, fully active at
home/work without assistance)
Severe Neurologic Symptoms, Totally
Inactive Requiring Complete Assistance
At Home Or Institution, Unable To Work
(Severe neurologic symptoms, totally
inactive requiring complete assistance at
home or institution, unable to work)
Karnofsky Performance Status (%)
Dead (0)
Moribund, Fatal Processes Progressing
Rapidly (10)
Normal, No Complaints, No Evidence Of
Disease (100)
Very Sick, Hospitalization Indicated.
Death Not Imminent (20)
Severely Disabled, Hospitalization
Indicated. Death Not Imminent (30)
Disabled, Requires Special Care And
Assistance (40)
Requires Considerable Assistance And
Frequent Medical Care (50)
Requires Occasional Assistance, But Is
Able To Care For Most Of His/her Needs
(60)
Cares For Self, Unable To Carry On
Normal Activity Or To Do Active Work
(70)
Normal Activity With Effort; Some Signs
Or Symptoms Of Disease (80)
Able To Carry On Normal Activity; Minor
Signs Or Symptoms Of Disease (90)
Footer Module
Investigator Signature
Investigator Signature Date (MM DD YYYY)
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Breast Cancer NCT00377156 Registration - North Central Cancer
Treatment Group Preregistration Screening Failure Form - 2467330v1.0
North Central Cancer Treatment Group Preregistration
Screening Failure Form
Stereotactic Radiation Therapy With or Without Whole-
Brain Radiation Therapy in Treating Patients With Brain
Metastases
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=103C1A01-
BDA6-395C-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/7043
North Central Cancer Treatment
Group Preregistration Screening
Failure Form
Header
NCCTG Protocol Number
NCCTG Patient ID
Patient Initials (L F M)
Institution
Institution Number
Are data amended (If yes, highlight amended
areas)
Yes
No
Preregistration Screening Failure
Date aware of preregistration screening failure
Primary reason screening failed
Did Not Meet Eligibility Criteria (Did not
meet eligibility criteria)
Investigator Decision (Investigator
decision)
Other (Other)
Patient Decision (Patient decision)
Other, specify
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Breast Cancer NCT00433511 Follow-Up -
E5103 Hypertension Status Form - 2683669v1.0
E5103 Hypertension Status Form
Doxorubicin, Cyclophosphamide, and Paclitaxel With or
Without Bevacizumab in Treating Patients With Lymph
Node-Positive or High-Risk, Lymph Node-Negative Breast
Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=3AE22206-
73CD-059C-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/7048
E5103 Hypertension Status Form
General information
ECOG Protocol Number*
ECOG Patient ID*
DCI Name*
Registration Step*
Patient Initials (Last, First)*
Participating Group Protocol Number*
Institution/Affiliate*
Participating Group Patient ID*
Please mark an 'X' if data have been amended.
(Please circle amended items in red)*
Date data amended (M D Y)*
Unnamed Module 4
On Treatment Report Period*
Baseline (Baseline)
Cycle 1 (Cycle 1)
Cycle 10 (Cycle 10)
Cycle 11 (Cycle 11)
Cycle 12 (Cycle 12)
Cycle 13 (Cycle 13)
Cycle 14 (Cycle 14)
Cycle 15 (Cycle 15)
Cycle 16 (Cycle 16)
Cycle 17 (Cycle 17)
Cycle 18 (Cycle 18)
Cycle 2 (Cycle 2)
Cycle 3 (Cycle 3)
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Cycle 4 (cycle 4)
Cycle 5 (Cycle 5)
Cycle 6 (Cycle 6)
Cycle 7 (Cycle 7)
Cycle 8 (cycle 8)
Cycle 9 (Cycle 9)
Off Treatment Report Period*
12 Months Post-treatment (12 Months
Post-Treatment)
3 Months Post-treatment (3 Months Post-
Treatment)
6 Months Post-treatment (6 Months Post-
Treatment)
9 Months Post-treatment (9 Months Post-
Treatment)
Blood Pressure, Systolic*
Blood pressure, Diastolic*
Mark an 'X' if not done (during this reporting
period)*
Date of Assessment (most recent)*
Anti-Hypertensive Drugs (Please mark each
agent administered this cycle For Baseline,
indicate agents administered in the last 21 days)*
Ace Inhibitor (ACE inhibitors)
Angiotensin Ii Receptor Blocker
(Angiotensin II inhibitors)
Beta Blocker (Beta blockers)
Calcium Channel Blocker (Calcium
channel blockers)
Diuretic (Diuretics)
No Medication Given (No medication
given)
Other (Other)
Other, specify*
Comments
Investigator Signature*
Investigator Signature Date*
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Brain and Central Nervous System Tumors NCT00978458 Follow-Up - E3F05
Primary Brain Tumor Follow-Up Disease Evaluation Form - 2902962v1.0
E3F05 Primary Brain Tumor Follow-Up Disease Evaluation
Form
Radiation Therapy With or Without Temozolomide in
Treating Patients With Low-Grade Glioma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=6CB91C46-
8BDC-9A0D-E040-BB89AD433170
All rights reserved. Please visit https://medical-data-
models.org/forms/7055
E3F05 Primary Brain Tumor Follow-
Up Disease Evaluation Form
Header
DCI Name
Registration Step (Place ID Label Here)
Patient Initials (Last, First)
ECOG Protocol Number
ECOG Protocol Number
ECOG Patient ID
ECOG Patient ID
Participating Group Protocol Number
Participating Group Patient ID
Institution/Affiliate
Unnamed2
Please mark an 'X' if data have been amended.
(Please circle amended items in red)
Date data amended (s M D Y)
On Treatment
On Treatment Report Period (Choose one since
start of treatment)
4 Weeks Post End Of Chemoradiation (4
weeks post end of Chemoradiation)
4 Weeks Post End Of Radiation (4
weeks post end of Radiation)
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Cycle 3 (Cycle 3)
Cycles 10 - 12 (Cycles 10 - 12)
Cycles 4 - 6 (Cycles 4 - 6)
Cycles 7 - 9 (Cycles 7 - 9)
Off Treatment
Off Treatment Report Period (Choose one since
start of registration)
102 Months Post Registration (102
Months Post Registration)
9 Years (108 months post registration)
114 Months Post Registration (114
Months Post Registration)
12 Months (12 Months Post Registration)
10 Years (120 months post registration)
126 Months Post Registration (126
Months Post Registration)
11 Years Post Registration (132 Months
Post Registration)
138 Months Post Registration (138
Months Post Registration)
12 Years Post Registration (144 Months
Post Registration)
15 Months (15 Months Post Registration)
150 Months Post Registration (150
Months Post Registration)
13 Years Post Registration (156 Months
Post Registration)
162 Months Post Registration (162
Months Post Registration)
14 Years Post Registration (168 Months
Post Registration)
174 Months Post Registration (174
Months Post Registration)
18 Months (18 Months Post Registration)
15 Years Post Registration (180 Months
Post Registration)
21 Months Post Registration (21 Months
Post Registration)
2 Years (24 Months Post Registration)
27 Months Post Registration (27 Months
Post Registration)
3 Months (3 Months Post Registration)
30 Months (30 Months Post Registration)
33 Months Post Registration (33 Months
Post Registration)
3 Years (36 Months Post Registration)
39 Months Post Registration (39 Months
Post Registration)
42 Months (42 Months Post Registration)
45 Months Post Registration (45 Months
Post Registration)
4 Years (48 Months Post Registration)
51 Months Post Registration (51 Months
Post Registration)
54 Months (54 Months Post Registration)
57 Months Post Registration (57 Months
Post Registration)
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6 Months (6 Months Post Registration)
5 Years (60 Months Post Registration)
66 Months Post Registration (66 Months
Post Registration)
6 Years (72 Months Post Registration)
78 Months Post Registration (78 Months
Post Registration)
84 Months Post Registration (84 Months
Post Registration)
9 Months (9 Months Post Registration)
90 Months Post Registration (90 Months
Post Registration)
8 Years (96 months post registration)
Section Iii
Is the patient receiving corticosteroids?
Yes
No
Name of Medication (If yes)
Decadron (Decadron)
Other Specify (Other)
Other,specify
Total Daily Dose of Agent (or Drug) (Decadron or
Dexamethasone equivalent mg)
Agent Start Date (Current Dose M D Y)
Has dose of corticosteroids changed
No (No)
Yes, Decrease (Yes, decrease)
Yes, Increase (Yes, increase)
Increased due to suspected PD (If yes, increase)
Yes
No
Section I Measurable Lesions
Were imaging studies performed (scan this report
period)
Yes
No
Date of MRI (If yes, scans were performed AND
no radiographically visible disease was present,)
Was measurable disease present (at baseline)
Yes
No
Was enhancing measureable disease present at
baseline (if yes, complete T2/FLAIR section
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below and T1/Contrast section below with current
assessment results)
Yes
No
Was non-enhancing measureable disease
present at baseline (if yes, complete T2/FLAIR
section below with current assessment results)
Yes
No
Unnamed3
Lesion Number
Site of Lesion
Date of Evaluation (M D Y)
Longest Bidimensional Measurements of Lesions
(cm)
Longest Bidimensional Measurements of Lesions
(cm)
Product of Longest Bidimensional Measurements
(cm^2)
Tumor Laterality
Bilateral (bilateral)
Left (left)
Right (right)
Site
Basal Ganglia (Basal ganglia)
Brainstem (Brainstem)
Frontal Lobe (Frontal)
Multifocal (Multifocal)
Occipital Lobe (Occipital)
Other (Other)
Parietal Lobe (Parietal)
Temporal Lobe (Temporal)
Unknown (Unknown)
Specify
Does tumor cross midline
Yes
No
Sum of Products of Greatest Diameters (of all
measurable enhancing lesions - cm^2)
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Unnamed3
Lesion Number
Site of Lesion
Date of Evaluation (M D Y)
Longest Bidimensional Measurements of Lesions
(cm)
Longest Bidimensional Measurements of Lesions
(cm)
Product of Longest Bidimensional Measurements
(cm^2)
Tumor Laterality
Bilateral (bilateral)
Left (left)
Right (right)
Site
Basal Ganglia (Basal ganglia)
Brainstem (Brainstem)
Frontal Lobe (Frontal)
Multifocal (Multifocal)
Occipital Lobe (Occipital)
Other (Other)
Parietal Lobe (Parietal)
Temporal Lobe (Temporal)
Unknown (Unknown)
Specify
Does tumor cross midline
Yes
No
Sum of Products of Greatest Diameters (of all
measurable enhancing lesions - cm^2)
Section Ii Non-measurable Lesions
Was non-measurable disease present  (at
baseline)
Yes
No
Was enhancing non-measureable disease
present at baseline (if yes, complete T2/FLAIR
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section below and T1/Contrast section below with
current assessment results - NOTE: If there is
NEW enhancement in a previously reported
lesion, report this newly enhancing component in
Section IV, New CNS Lesions/New
Enhancements of Previously Reported Lesions
under the T1/Contrast section.)
Yes
No
Was non-enhancing non-measureable disease
present at baseline (if yes, complete T2/FLAIR
section below with current assessment results)
Yes
No
Nontarget Lesions
Lesion Number
Site of Lesion
Date of Evaluation (M D Y)
Did this lesion progress
Yes
No
Tumor Laterality
Bilateral (bilateral)
Left (left)
Right (right)
Site
Basal Ganglia (Basal ganglia)
Brainstem (Brainstem)
Frontal Lobe (Frontal)
Multifocal (Multifocal)
Occipital Lobe (Occipital)
Other (Other)
Parietal Lobe (Parietal)
Temporal Lobe (Temporal)
Unknown (Unknown)
Specify
Does tumor cross midline
Yes
No
Nontarget Lesions
Lesion Number
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Site of Lesion
Date of Evaluation (M D Y)
Did this lesion progress
Yes
No
Tumor Laterality
Bilateral (bilateral)
Left (left)
Right (right)
Site
Basal Ganglia (Basal ganglia)
Brainstem (Brainstem)
Frontal Lobe (Frontal)
Multifocal (Multifocal)
Occipital Lobe (Occipital)
Other (Other)
Parietal Lobe (Parietal)
Temporal Lobe (Temporal)
Unknown (Unknown)
Specify
Does tumor cross midline
Yes
No
Section Iv New Cns Lesions
Was the appearance of any new lesions or new
enhancement of previously reported lesions
documented (CNS)
Yes
No
Nontarget Lesions
Lesion Number
Site of Lesion
Date of Evaluation (M D Y)
Tumor Laterality
Bilateral (bilateral)
Left (left)
Right (right)
Site
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Basal Ganglia (Basal ganglia)
Brainstem (Brainstem)
Frontal Lobe (Frontal)
Multifocal (Multifocal)
Occipital Lobe (Occipital)
Other (Other)
Parietal Lobe (Parietal)
Temporal Lobe (Temporal)
Unknown (Unknown)
Specify
Does tumor cross midline
Yes
No
Nontarget Lesions
Lesion Number
Site of Lesion
Date of Evaluation (M D Y)
Tumor Laterality
Bilateral (bilateral)
Left (left)
Right (right)
Site
Basal Ganglia (Basal ganglia)
Brainstem (Brainstem)
Frontal Lobe (Frontal)
Multifocal (Multifocal)
Occipital Lobe (Occipital)
Other (Other)
Parietal Lobe (Parietal)
Temporal Lobe (Temporal)
Unknown (Unknown)
Specify
Does tumor cross midline
Yes
No
Section V Progression
Has the patient developed a first progression (or
relapse) that has not been previously reported?
Yes
No
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Date of Progression (If yes M D Y)
Date of last evaluation demonstrating free from
progression (If no M D Y)
What was the method used to determine
progression (primary - Clinical/Neurological
progression is defined as 1 NFS of "4", or 2 NFS
drop of 2 levels, or 3 increase or start of
corticosteroids for control of neurologic
symptoms)
Both Radiological And
Clinical/neurological (Both radiological
and clinical/neurological)
Clinical/neurological Progression
(Clinical/neurological progression)
Other (Other)
Radiologic (Radiological)
Other specify
Is patient receiving further antitumoral therapy
(Further antitumoral treatment following diagnosis
of progression)
Yes
No
Specify (If yes)
Chemotherapy (Chemotherapy)
Combined Radiation
Therapy/chemotherapy (Combined
Radiation Therapy/Chemotherapy)
Combined Surgery/chemotherapy
(Combined Surgery/Chemotherapy)
Combined Surgery/radiation Therapy
(Combined Surgery/Radiation Therapy)
Other Specify (Other)
Radiation Therapy (Radiation therapy)
Surgery (Surgery)
Unknown (Unknown)
Chemotherapy, specify
Other specify
Comments
Comments
Investigator Signature
Investigator Signature Date (M D Y)
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Breast Cancer NCT00310180 Quality of Life - PACCT-1
TAILORx Assessment Compliance Form - 3071476v1.0
PACCT-1 TAILORx Assessment Compliance Form
Hormone Therapy With or Without Combination
Chemotherapy in Treating Women Who Have Undergone
Surgery for Node-Negative Breast Cancer (The TAILORx
Trial)
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=84B142E1-
7D4C-582E-E040-BB89AD436C2E
All rights reserved. Please visit https://medical-data-
models.org/forms/7058
PACCT-1 TAILORx Assessment
Compliance Form
Header
ECOG Protocol Number
ECOG Patient ID
DCI Name
Report Period
12 Months (12 months)
24 Months (24 months)
3 Months (3 months)
36 Months (36 months)
6 Months (6 months)
Baseline (baseline)
Unnamed2
Are data amended
Yes
No
Date data amended (s M D Y)
Date data amended (s M D Y)
E2906 Qol Assessment Not Completed
Assessment date (M D Y)
Section Ii - E1a05 Qol Assessment Not
Completed
Were all the quality of life forms completed for
this timepoint
Yes
No
Section Ii - Assessments Not Completed
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Patient refusal
Yes
No
Unable to accomodate disability or language
needs
Yes
No
Specify disability or language
Patient did not show up in clinic/office
Yes
No
Specify reason patient did not show up
Staff unavailable
Yes
No
Patient not given form by staff
Yes
No
Patient too ill
Yes
No
Patient expired
Yes
No
Assessment not required per protocol
Yes
No
Specify reason assessment is not required
Staff thought patient too ill
Yes
No
Other
Yes
No
Specify other reason
Section Iii Assessment Completed
Was Assessment self-administered?
Yes
No
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How Was The Patient Assisted
Were the questions read aloud to patient
Yes
No
Did the patient require clarification of questions or
instructions
Yes
No
Did the patient require other assistance
Yes
No
Were the forms completed independently by
another person
Yes
No
What Was The Reason For Assistance
Did the patient have a language difficulty
(questions needed to tbe translated)
Yes
No
Specify language
Did the patient have a literacy difficulty (patient
could not read well enough)
Yes
No
Was the patient disabled
Yes
No
Specify disability
Were the forms completed via a telephone
interview
Yes
No
Other
Yes
No
Specify other reason
Patient Bowel Function/uniscale
Questionnaire: Who Assisted Or
Completed Assessment?
Staff
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Yes
No
Family
Yes
No
Friend
Yes
No
Other
Yes
No
Specify other person
Comments
Investigator Signature
Investigator Signature Date (M D Y)
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Breast Cancer NCT00310180 Quality of Life - PACCT-
1 TAILORx FACT - General Form - 3071611v1.0
PACCT-1 TAILORx FACT - General Form
Hormone Therapy With or Without Combination
Chemotherapy in Treating Women Who Have Undergone
Surgery for Node-Negative Breast Cancer (The TAILORx
Trial)
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=84B142E1-
7E5A-582E-E040-BB89AD436C2E
All rights reserved. Please visit https://medical-data-
models.org/forms/7061
PACCT-1 TAILORx FACT - General
Form
Header
ECOG Protocol Number
ECOG Patient ID
DCI Name
On Treatment
Report Period (since start of Step 2 Choose one)
12 Months (12 months)
36 Months (36 months)
Baseline (baseline)
Unnamed2
Please mark an 'X' if data have been amended.
(Please circle amended items in red)
Date data amended (s M D Y)
Header
Date of Assessment
Physical Well-being
I have a lack of energy
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have nausea
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
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Very Much (Very much)
Because of my physical condition, I have trouble
meeting the needs of my family
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have pain
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am bothered by side effects of treatment
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I feel ill
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am forced to spend time in bed
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
Social/family Well-being
I feel close to my friends
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I get emotional support from my family
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I get support from my friends
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
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My family has accepted my illness
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am satisfied with family communication about
my illness
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I feel close to my partner (or the person who is
my main support)
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
Regardless of your current level of sexual activity,
please answer the following question.  If you
prefer not to answer it, please check this box and
go to the next section.
I am satisfied with my sex life
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
Emotional Well-being
I feel sad
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am satisfied with how I am coping with my
illness
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am losing hope in the fight against my illness
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
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I feel nervous
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I worry about dying
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I worry that my condition will get worse
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
Functional Well-being
I am able to work (include work at home)
2 (A little bit)
1 (Not at all)
4 (Quite a bit)
3 (Somewhat)
5 (Very much)
My work is fulfilling (include work at home)
2 (A little bit)
1 (Not at all)
4 (Quite a bit)
3 (Somewhat)
5 (Very much)
I am able to enjoy life
2 (A little bit)
1 (Not at all)
4 (Quite a bit)
3 (Somewhat)
5 (Very much)
I have accepted my illness
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am sleeping well
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am enjoying the things I usually do for fun
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A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am content with the quality of my life right now
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
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Death Report - 2762971v1.0
The Division of Cancer Prevention's death report case
report form (CRF) template.
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=51746AB3-
F58D-0C29-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/7068
Death Report
Screening
DCP Protocol #
Institution Code
Participant ID
Form Date
Death Report
Date of Death (MM/DD/YYYY)
Place of Death
Hospital (Hospital)
Other, Specify (Other, specify)
Unknown (Unknown)
Other, Specify
Cause of Death
Adverse Event/serious Adverse Event
(AE/SAE)
Other, Specify (Other, specify)
Unknown (Unknown)
Cause of Death other, specify
Autopsy performed?
No (No)
Unknown (Unknown)
Yes (Yes)
Dcp Template Footer
Protocol Title
Protocol Version
Protocol Date
1 / 2
Page #
Total Page Number
DCP Template Version
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Eligibility - Screening - 2762748v1.0
The Division of Cancer Prevention's screening case report
form (CRF) template.
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=516F6F73-
F6A7-27F0-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/7069
Screening
Screening
DCP Protocol #
Institution Code
Participant ID
Visit Type
Visit Date
Screening
Date Screening Informed Consent Signed
Not Obtained (If the screening date is not
applicable check box.)
Not Applicable (Not Applicable)
Not Obtained (If the screening date is not
applicable check box.)
Not Applicable (Not Applicable)
Screening Date
Is the participant a screen failure? (If the
participant is a screen failure, please select the
primary reason for the screen failure.)
Yes
No
If yes, specify primary reason for screen failure
(Select the primary reason for the screen failure.)
Did Not Meet Eligibility Criteria, Specify
(Did not meet eligibility criteria, specify)
Investigator Decision (Investigator
decision)
Other, Specify (Other, specify)
Participant Decision (Participant
Decision)
Other, Specify (Enter the free text for the primary
reason for the screen failure.)
1 / 2
Comments
Who referred participant?
Friend Family (Family/Friend)
Health Care Provider (Health Care
Provider)
Other (Other, specify)
Physician (Physician)
Self (Self)
Other, specify
How did participant find out about the study?
Friend Family (Family/Friend)
Web Site National Cancer Institute (NCI
web site)
Nurse (Nurse)
Specify Other (Other, specify)
Physician (Physician)
Unknown (Unknown)
Written Material (Written material)
Other, specify
Dcp Template Footer
Protocol Title
Protocol Version
Protocol Version
Protocol Date
Page #
Total Page Number
DCP Template Version
2 / 2
Eligibility - Screening - 2762748v1.0
Comments - Comments - 2763098v1.0
The Division of Cancer Prevention's comments case report
form (CRF) template.
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=51762398-
41A9-555A-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/7070
Comments
Screening
DCP Protocol #
Institution Code
Participant ID
Visit Type
Visit Date
Comments
Form Code
Adverse Events (AE)
Ae & Con Med Eval (AECMD)
Agent Interruption Continuation (AGINT)
Participant Contact (CNTCT)
Comments - Page 1 (COMM1)
Comments - Page 2 (COMM2)
Compliance (COMP)
Concomitant Medications (CONMD)
Death Report (DEATH)
Exclusion Criteria (EXCL)
Inclusion Criteria (INCL)
Intervention Admin (INTAD)
Blood Chemistry (LABBC)
Hematology (LABHM)
Other Lab Tests (LABOT)
Urine (LABUR)
Medical/surgical History (MEDHX1)
Medical/surgical History - Page 2
(MEDHX2)
Off Study (OFFST)
Outcome Of Pregnancy (OUTPG)
Physical Exam - Page 1 (PE1)
Physical Exam - Page 2 (PE2)
Pk Blood (PKBLD)
Pharmacokinetics Results Tissue
(PKTS)
Pk Urine (PKURN)
Pregnancy Specimen Data (PREG)
Randomization (RAND)
Registration (REG)
Screening (SCRN)
Specimen Acquisition Blood (SPCBL)
1 / 2
Specimen Acquisition Tissue (SPCTS)
Specimen Acquisition Urine (SPCUR)
Baseline Symptoms - Page 1 (SYMP1)
Baseline Symptoms - Page 2 (SYMP2)
Telephone Contact (TELCO)
Tobacco Use Questionnaire (TOBAC)
Verification (VERIF)
Form Name
Comments
Dcp Template Footer
Protocol Title
Protocol Version
Protocol Date
Page #
Total Page Number
DCP Template Version
2 / 2
Comments - Comments - 2763098v1.0
Eligibility - Exclusion Criteria - 2762780v1.0
The Division of Cancer Prevention's (DCP) Exclusion
Criteria case report form (CRF) template.
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=517078D8-
B52F-52B7-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/7071
Exclusion Criteria
Screening
DCP Protocol #
Institution Code
Participant ID
Visit Type
Visit Date
Inclusion
Eligibility Criteria
Elig Question/Criteria Response
Not Applicable (N/A)
No (No)
Yes (Yes)
Dcp Template Footer
Protocol Title
Protocol Version
Protocol Date
Page #
Total Number of Pages in CRF
DCP Template Version
1 / 1
Eligibility - Inclusion Criteria - 2762855v1.0
The Division of Cancer Prevention's (DCP) Inclusion
Criteria case report form (CRF) template.
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=51721442-
C653-1B67-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/7072
Inclusion Criteria
Screening
DCP Protocol #
Institution Code
Participant ID
Visit Type
Visit Date
Inclusion
Eligibility Criteria
Elig Question/Criteria Response
Not Applicable (N/A)
No (No)
Yes (Yes)
Dcp Template Footer
Protocol Title
Protocol Version
Protocol Date
Page #
Total Page Number
DCP Template Version
1 / 1
Compliance - 2765075v1.0
The Division of Cancer Prevention's compliance case
report form (CRF) template.
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=51ACB3DE-
4427-492A-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/7073
Compliance
Screening
DCP Protocol #
Institution Code
Participant ID
Visit Type
Visit Date
Compliance
First Dose taken this period date
Last Dose taken this period date
Was agent interrupted during this period?
Not Applicable (N/A)
No (No)
Yes (Yes)
If Yes, indicate number of interruptions this period
Was agent regimen modified during this period?
Not Applicable (N/A)
No (No)
Yes (Yes)
Amount of agent provided at last visit.
Not Obtained
Not Applicable (Not Applicable)
Amount of agent returned this visit
Amount of agent taken this period
Amount of agent missing/not accounted for this
period
1 / 2
Is the participant compliant with protocol
intervention?
No (NO)
Unknown (UNKNOWN)
Yes (YES)
If No, specify reason for noncompliance
Was agent provided at this visit?
Not Applicable (N/A)
No (No)
Yes (Yes)
Amount of agent provided at this visit
Dcp Template Footer
Protocol Title
Protocol Version
Protocol Date
Page #
Total Page Number
DCP Template Version
2 / 2
Compliance - 2765075v1.0
Lab - Pregnancy Specimen Data -
2764853v1.0
The Division of Cancer Prevention's pregnancy specimen
data case report form (CRF) template.
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=51AAF1A8-
D0EA-00D5-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/7075
Pregnancy Specimen Data
Screening
DCP Protocol #
Institution Code
Participant ID
Visit Type
Visit Date
Pregnancy Specimen Data
Reason pregnancy data was not collected
Participant Is Female And Not Of
Childbearing Potential (participant is
female and not of childbearing potential)
Participant Is Male (participant is male)
Lab Test
Type of pregnancy test
Serum (Serum)
Urine (Urine)
Result
Negative (negative)
Not Obtained (Not Obtained)
Positive (positive)
Date Specimen collected
Dcp Template Footer
Protocol Title
Protocol Version
Protocol Date
Page #
1 / 2
Total Page Number
DCP Template Version
2 / 2
Lab - Pregnancy Specimen Data - 2764853v1.0
Lab - Clinical Laboratory Data Hematology -
2764800v1.0
The Division of Cancer Prevention's clinical laboratory data
case report form (CRF) template.
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=51AA9953-
0A8A-681C-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/7076
Clinical Laboratory Data Hematology
Screening
DCP Protocol #
Institution Code
Participant ID
Visit Type
Visit Date
Hematology
Date Specimen collected
Lab Test (Please indicate results for all completed
tests or check the Not Obtained box is a test was
not performed.  Indicate if test is out of range as
defined by the lab where the specimen was
analyzed and provide the physician's assessment
of clinical significance for completed test only.)
Basophils, %, Blood (Basophils, %,
Blood)
Eosinophils, %, Blood (Eosinophils, %,
Blood)
Hematocrit, %, Blood (Hematocrit, %,
Blood)
Hemoglobin, Blood (Hemoglobin, Blood)
Lymphocytes, %, Blood (Lymphocytes,
%, Blood)
Monocytes, %, Blood (Monocytes, %,
Blood)
Neutrophil Bands, %, Blood (Neutrophil
Bands, %, Blood)
Neutrophils, %, Blood (Neutrophils, %,
Blood)
Blood Platelets (Platelets, Blood)
Red Blood Cells (rbc), #, Blood (Red
Blood Cells (RBC), #, Blood)
Blood Leukocyte Count (White Blood
Cells (WBC), #, Blood)
Not Obtained
Not Obtained (Not Obtained)
1 / 2
Results
Units
Out of Range
Yes
No
Clinically Significant
No (NO)
Unknown (UNKNOWN)
Yes (YES)
Comments
Dcp Template Footer
Protocol Title
Protocol Version
Protocol Date
Page #
Total Page Number
DCP Template Version
2 / 2
Lab - Clinical Laboratory Data Hematology - 2764800v1.0
Lab - Clinical Laboratory Data Other Lab
Tests - 2765005v1.0
The Division of Cancer Prevention's clinical laboratory data
other lab tests case report form (CRF) template.
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=51AD311F-
13C0-357E-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/7077
Clinical Laboratory Data Other Lab
Tests
Screening
DCP Protocol #
Institution Code
Participant ID
Visit Type
Visit Date
Hematology
Date Specimen collected
Fasting
No (NO)
Unknown (UNKNOWN)
Yes (YES)
Lab Test (Please indicate the test name and
results for all other completed tests.Indicate if test
is out of range as defined by the lab where the
specimen was analyzed and provide the
physician's assessment of clinical significance.)
Results
Units
Out of Range
Yes
No
Clinically Significant
No (NO)
Unknown (UNKNOWN)
Yes (YES)
Comments
1 / 2
Dcp Template Footer
Protocol Title
Protocol Version
Protocol Date
Page #
Total Number of Pages in CRF
DCP Template Version
2 / 2
Lab - Clinical Laboratory Data Other Lab Tests - 2765005v1.0
On-Study - Physical Exam (continued) -
2803398v1.0
The Division of Cancer Prevention's physical exam
(continued) case report form (CRF) template.
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=5C120DDA-
54D8-39FD-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/7078
Physical Exam (continued)
Screening
DCP Protocol #
Institution Code
Participant ID
Visit Type
Visit Date
Baseline Medical/surgical History
Specify Other Body System/Site
Body System
Abnormal (Abnormal)
Normal (Normal)
Comment (Required if Abnormal) (Provide
condition/diagnosis)
Dcp Template Footer
Protocol Title
Protocol Version
Protocol Date
Page #
Total Page Number
DCP Template Version
1 / 1
On-Study - Clinical Laboratory Data Blood
Chemistry - 2803769v1.0
The Division of Cancer Prevention's clinical laboratory data
case report form (CRF) template.
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=5C247239-
71D7-5F80-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/7080
Clinical Laboratory Data Blood
Chemistry
Screening
DCP Protocol #
Institution Code
Participant ID
Visit Type
Visit Date
Hematology
Date Specimen collected
Fasting
No (NO)
Unknown (UNKNOWN)
Yes (YES)
Lab Test (Please indicate results for all completed
tests or check the Not Obtained box is a test was
not performed.  Indicate if test is out of range as
defined by the lab where the specimen was
analyzed and provide the physician's assessment
of clinical significance for completed test only.)
Serum Alanine Aminotransferase Ialt Or
Sgpt) (Alanine Aminostransferase (ALT
or SGPT), Serum)
Albumin, Serum (Albumin, Serum)
Alkaline Phosphatase, Serum (Alkaline
Phosphatase, Serum)
Serum Aspartate Aminotransferase (ast
Or Sgot) (Aspartate Aminotransferase
(AST or SGOT), Serum)
Bicarbonate, Serum (Bicarbonate,
Serum)
Serum Total Bilirubin (Bilirubin, Total,
Serum)
Serum Blood Urea (Blood Urea Nitrogen
(BUN), Serum)
Calcium, Serum (Calcium, Serum)
Chloride, Serum (Chloride, Serum)
Cholesterol, Serum (Cholesterol, Serum)
1 / 2
Serum Creatinine (Creatinine, Serum)
Serum Glucose (Glucose, Serum)
Lactate Dehydrogenase (ldh), Serum
(Lactate Dehydrogenase (LDH), Serum)
Phosphate (inorganic Phosphorus),
Serum (Phosphate (inorganic
Phosphorus), Serum)
Potassium, Serum (Potassium, Serum)
Sodium, Serum (Sodium, Serum)
Triglycerides, Serum (Triglycerides,
Serum)
Urate (uric Acid), Serum (Urate (Uric
Acid), Serum)
Not Obtained
Not Obtained (Not Obtained)
Results
Units
Out of Range
Yes
No
Clinically Significant
No (NO)
Unknown (UNKNOWN)
Yes (YES)
Comments
Dcp Template Footer
Protocol Title
Protocol Version
Protocol Date
Page #
Total Page Number
DCP Template Version
2 / 2
On-Study - Clinical Laboratory Data Blood Chemistry - 2803769v1.0
On-Study - Specimen Acquisition Tissue -
2804222v1.0
The Division of Cancer Prevention's specimen acquisition
tissue case report form (CRF) template.
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=5C36F2B6-
6DB3-0999-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/7081
Specimen Acquisition Tissue
Screening
DCP Protocol #
Institution Code
Participant ID
Visit Type
Visit Date
Specimen Acquisition Blood
Specimen Number
Specimen Number
Not Obtained
Not Obtained (Not Obtained)
Not Obtained
Not Obtained (Not Obtained)
Date Specimen collected (hr:mm per 24 hour
clock - if unknown report UNK)
Date Specimen collected (hr:mm per 24 hour
clock - if unknown report UNK)
Date Specimen collected (hr:mm per 24 hour
clock - if unknown report UNK)
Time Specimen Collected (hr:mm per 24 hour
clock - if unknown report UNK)
Storage Temperature (Centigrade)
Storage Temperature (Centigrade)
1 / 2
Storage Temperature (Centigrade)
Date Specimen Shipped (MM/DD/YYYY)
Date Specimen Shipped (MM/DD/YYYY)
Date Last Study Agent Taken (MM/DD/YYYY)
Time Last Study Agent Taken (hr:mm per 24 hour
clock - if unknown report UNK)
Dcp Template Footer
Protocol Title
Protocol Version
Protocol Date
Page #
Total Page Number
DCP Template Version
2 / 2
On-Study - Specimen Acquisition Tissue - 2804222v1.0
On-Study - Pharmacokinetics Results
Tissue - 2804379v1.0
The Division of Cancer Prevention's pharmacokinetics
results tissue case report form (CRF) template.
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=5C37C68E-
37F3-2ED2-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/7082
Pharmacokinetics Results Tissue
Screening
DCP Protocol #
Institution Code
Participant ID
Visit Type
Visit Date
Pharmacokinetics Results Blood
Specimen Number
Not Obtained
Date Sample Collected (MM/DD/YYYY)
Time Specimen Collected (hr:mm per 24 hour
clock - if unknown report UNK)
Result
Units
Other Result
Below Limit Of Detection (Below limit of
detection)
Not Assayed (Not assayed)
Date Specimen Analyzed (MM/DD/YYYY)
Dcp Template Footer
Protocol Title
Protocol Version
1 / 2
Protocol Date
Page #
Total Page Number
DCP Template Version
2 / 2
On-Study - Pharmacokinetics Results Tissue - 2804379v1.0
Tobacco Use Assessment - 2764420v1.0
The Division of Cancer Prevention's tobacco assessment
case report form (CRF) template.
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=519D5ABC-
8BA7-5C35-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/7083
Tobacco Use Assessment
Screening
DCP Protocol #
Institution Code
Participant ID
Visit Type
Visit Date
Tobacco Assessment
Have you smoked 100 cigarettes or more during
your entire lifetime?
Yes
No
Section 1
Age in years
At what age did you begin smoking regularly?
Don't Know (Don't know)
Never Regular (Never regular)
Do you currently smoke cigarettes regularly?
Yes
No
Age in years
At what age did you stop smoking cigarettes on a
regular basis?
Don't Know (Don't know)
Still Smoking (Still smoking)
Years (How many years have you been smoking
or did smoke regularly?)
Not Obtained
Don't Know (Don't Know)
1 / 2
On the average, about how many cigarettes a day
do (or did) you smoke? (1 pack = 20 cigarettes
Number of Cigarettes per day)
Tobacco Assessment - Section 2
Have you ever smoked this type of tobacco on a
regular basis?
Cigar (Cigar)
Filtered Cigarettes (Filtered cigarettes)
Low Tar Cigarettes (Low tar cigarettes)
Non-filtered (plain) Cigarettes (Non-
filtered (plain) cigarettes)
Pipe (Pipe)
Response
Yes
No
If yes, how many years did you smoke this type of
tobacco?
If yes, how many did you usually smoke in a day?
per
Day (day)
Month (month)
Week (week)
Dcp Template Footer
Protocol Title
Protocol Version
Protocol Date
Page #
Total Page Number
DCP Template Version
2 / 2
Tobacco Use Assessment - 2764420v1.0
On-Study - Baseline Symptoms (continued)
- 2803370v1.0
The Division of Cancer Prevention's baseline symptoms
(continued) case report form (CRF) template.
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=5C10DDAA-
B135-71B7-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/7084
Baseline Symptoms (continued)
Screening
DCP Protocol #
Institution Code
Participant ID
Visit Type
Visit Date
Baseline Medical/surgical History
Symptom Description
Onset Date
Grade
Mild Adverse Event (1)
Moderate Adverse Event (2)
Severe Adverse Event (3)
Life Threatening Adverse Event (4)
Death Related To Adverse Event (5)
Comments
Dcp Template Footer
Protocol Title
Protocol Version
Protocol Date
Page #
Total Page Number
1 / 2
DCP Template Version
2 / 2
On-Study - Baseline Symptoms (continued) - 2803370v1.0
On-Study - Pharmacokinetics Results Blood
- 2804267v1.0
The Division of Cancer Prevention's pharmacokinetics
results case report form (CRF) template.
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=5C385155-
B41A-1B99-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/7085
Pharmacokinetics Results Blood
Screening
DCP Protocol #
Institution Code
Participant ID
Visit Type
Visit Date
Pharmacokinetics Results Blood
Specimen Number
Not Obtained
Date Specimen collected (MM/DD/YYYY)
Time Specimen Collected (hr:mm per 24 hour
clock)
Result
Units
Other Result
Below Limit Of Detection (Below limit of
detection)
Not Assayed (Not assayed)
Date Specimen Analyzed (MM/DD/YYYY)
Dcp Template Footer
Protocol Title
Protocol Version
1 / 2
Protocol Date
Page #
Total Page Number
DCP Template Version
2 / 2
On-Study - Pharmacokinetics Results Blood - 2804267v1.0
On-Study - Pharmacokinetics Results Urine
- 2804343v1.0
The Division of Cancer Prevention's pharmacokinetics
results urine case report form (CRF) template.
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=5C379CCC-
6BD7-26D0-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/7086
Pharmacokinetics Results Urine
Screening
DCP Protocol #
Institution Code
Participant ID
Visit Type
Visit Date
Pharmacokinetics Results Blood
Specimen Number
Not Obtained
Date Specimen collected (MM/DD/YYYY)
Time Specimen Collected (hr:mm per 24 hour
clock - if unknown report UNK)
Result
Units
Other Result
Below Limit Of Detection (Below limit of
detection)
Not Assayed (Not assayed)
Date Specimen Analyzed (MM/DD/YYYY)
Dcp Template Footer
Protocol Title
Protocol Version
1 / 2
Protocol Date
Page #
Total Page Number
DCP Template Version
2 / 2
On-Study - Pharmacokinetics Results Urine - 2804343v1.0
On-Study - Clinical Laboratory Data Urine -
2804305v1.0
The Division of Cancer Prevention's clinical laboratory data
urine case report form (CRF) template.
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=5C379CCC-
6B7F-26D0-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/7087
Clinical Laboratory Data Urine
Screening
DCP Protocol #
Institution Code
Participant ID
Visit Type
Visit Date
Hematology
Date Specimen collected
Lab Test
Appearance, Urine (Appearance, Urine)
Glucose, Spot Urine (Glucose, Spot
Urine)
Hemoglobin, Spot Urine (Hemoglobin,
Spot Urine)
Ketones, Spot Urine (Ketones, Spot
Urine)
Ph, Spot Urine (pH, Spot Urine)
Protein, 24 Hour, Urine (Protein, 24 hour,
Urine)
Specific Gravity, Spot Urine (Specific
Gravity, Spot Urine)
Not Obtained
Not Obtained (Not Obtained)
Results
Out of Range
Yes
No
Clinically Significant
No (NO)
Unknown (UNKNOWN)
Yes (YES)
Comments
1 / 2
Dcp Template Footer
Protocol Title
Protocol Version
Protocol Date
Page #
Total Page Number
DCP Template Version
2 / 2
On-Study - Clinical Laboratory Data Urine - 2804305v1.0
On-Study - Baseline Medical/Surgical
History - 2764025v1.0
The Division of Cancer Prevention's baseline
medical/surgical history case report form (CRF) template.
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=5199EB1D-
38BD-6DDA-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/7088
Baseline Medical/Surgical History
Screening
DCP Protocol #
Institution Code
Participant ID
Visit Type
Visit Date
Baseline Medical/surgical History
Check here if all body systems are normal
All Normal (All Normal)
Body System
Breasts (BREASTS)
Cardiovascular (CARDIOVASCULAR)
Dermatologic (DERMATOLOGIC)
Endocrine/metabolic
(ENDOCRINE/METABOLIC)
Gastrointestinal (GASTROINTESTINAL)
Genitourinary (Genitourinary)
H/e/e/n/t (H/E/E/N/T)
Hematopoietic/lymph
(HEMATOPOIETIC/LYMPH)
Musculoskeletal (MUSCULOSKELETAL)
Neck (NECK)
Neurologic (NEUROLOGIC)
Respiratory (RESPIRATORY)
Body System
Abnormal (Abnormal)
Normal (Normal)
Not Assessed (Not Assessed)
Comment (Required if Abnormal) (Provide
condition/diagnosis)
Does the participant have any allergies?
Yes
No
If Yes, specify
1 / 2
Dcp Template Footer
Protocol Title
Protocol Version
Protocol Date
Page #
Total Page Number
DCP Template Version
2 / 2
On-Study - Baseline Medical/Surgical History - 2764025v1.0
On-Study - Agent Interruption/Modification -
2803972v1.0
The Division of Cancer Prevention's agent
interruption/modification case report form (CRF) template.
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=5C33C988-
5236-20C3-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/7089
Agent Interruption/Modification
Screening
DCP Protocol #
Institution Code
Participant ID
Visit Type
Visit Date
Agent Interruption/modification Form
Interruption Number
Specify date stopped (MM/DD/YYYY)
Specify reason stopped
Ae/sae, Specify (AE/SAE, specify)
Investigator Decision, Specify
(Investigator decision, specify)
Other, Specify (Other, specify)
Participant Decision, Specify (Participant
decision, specify)
Specify reason stopped
Was agent restarted?
Not Applicable (N/A)
No (No)
Yes (Yes)
If Yes, specify date restarted (MM/DD/YYYY)
Specify reason restarted
Investigator Decision (Investigator
decision)
Participant Decision (Participant
decision)
Agent Modifications
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Modification Number
Specify Date Modified
Specify new regimen dose
Specify new regimen units
Specify new regimen frequency
Dcp Template Footer
Protocol Title
Protocol Version
Protocol Date
Page #
Total Page Number
DCP Template Version
2 / 2
On-Study - Agent Interruption/Modification - 2803972v1.0
On-Study - Intervention Administration
(Blinded Study) - 2802926v1.0
The Division of Cancer Prevention's intervention
administration (blinded study) case report form (CRF)
template.
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=5C0DAF39-
FA2E-52F4-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/7090
Intervention Administration (Blinded
Study)
Screening
DCP Protocol #
Institution Code
Participant ID
Visit Type
Visit Date
Intervention Administration (blinded Study)
Agent #
Agent/Placebo
Dose
Dose Units
Percent (%)
Application (app)
Becquerel (Bq)
Capsule (Cap)
Curie (Ci)
Caplet (Cplt)
Dram (DF)
Gram (G)
Gigabequerel (GBq)
Drop (gtt)
International Unit (iu)
International Unit Per Kilogram (iu/kg)
Joule Per Centimeter Squared (J/cm2)
Kilobecquerel (KBq)
Kilogram (kg)
Thousand International Unit (kiu)
Liter (l)
Megabequerel (MBq)
Millicurie (mCi)
Milliequivalent (mEq)
Milligram (mg)
Milligram Per Kilogram (mg/kg)
Milligram Per Square Meter (mg/m2)
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Milli-international Unit (Miu)
Milliliter (mL)
Milliliter (ML)
Millimole (mmol)
Mole (mol)
Nanocurie (nCi)
Nanogram (ng)
Other (Oth)
Picogram (PG)
Puff Dosing Unit (Puff)
Sachet Dosing Unit (Sachet)
Tablet (Tab)
Tablespoon Dosing Unit (tbs)
Teaspoon Dosing Unit (tsp)
Microcurie (uCi)
Microgram (ug)
Microgram Per Kilogram (ug/kg)
Microgram Per Square Meter (ug/m2)
Microliter (UL)
Micromole (UMOL)
Unit Dose (Units)
Unknown (Unk)
Frequency
Date Agent Provided (to participant
MM/DD/YYYY)
Agent Start Date (MM/DD/YYYY)
Dcp Template Footer
Protocol Title
Protocol Version
Protocol Date
Page #
Total Number of Pages in CRF
DCP Template Version
2 / 2
On-Study - Intervention Administration (Blinded Study) - 2802926v1.0
Verification - 2763172v1.0
The Division of Cancer Prevention's verification report case
report form (CRF) template.
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=51765172-
CFD4-5E75-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/7091
Verification
Screening
DCP Protocol #
Institution Code
Participant ID
Form Date
Verification
Investigator's Signature ("I have reviewed all the
Case Report Forms for the above participant and
agree that they are accurate and complete.")
Yes (YES)
Date of Investigator Signature
Investigator Name (PLEASE PRINT)
Dcp Template Footer
Protocol Title
Protocol Version
Protocol Date
Page #
Total Page Number
DCP Template Version
1 / 1
Registration - Registration - 2768468v1.0
The Division of Cancer Prevention's registration case report
form (CRF) template.
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=52C7202A-
91E5-347F-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/7092
Registration
Screening
DCP Protocol #
Institution Code
Participant ID
Visit Type
Visit Date
Registration/randomization
Registering Consortium
Arizona Cancer Center (AZ027)
University Of California Medical Center
At Irvine (CA088)
Northwestern University (IL036)
Mayo Clinic Rochester (MN026)
M D Anderson Cancer Center (TX035)
University Of Wisconsin Hospital And
Clinics (WI020)
Gender
Female Gender (Female)
Male Gender (Male)
Unknown (Unknown)
Unspecified (Unspecified)
Date of Birth (MM/DD/YYYY)
Race (Check all the apply)
A Person Having Origins In Any Of The
Original Peoples Of North And South
America (including Central America),
And Who Maintains Tribal Affiliation Or
Community Attachment. (American
Indian or Alaska Native)
A Person Having Origins In Any Of The
Original Peoples Of The Far East,
Southeast Asia, Or The Indian
Subcontinent Including, For Example,
Cambodia, China, India, Japan, Korea,
Malaysia, Pakistan, The Philippine
Islands, Thailand, And Vietnam. (Asian)
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A Person Having Origins In Any Of The
Black Racial Groups Of Africa. Terms
Such As "haitian" Or "negro" Can Be
Used In Addition To "black Or African
American." (Black or African American)
A Person Having Origins In Any Of The
Original Peoples Of Hawaii, Guam,
Samoa, Or Other Pacific Islands. (Native
Hawaiian or other Pacific Islander)
Not Provided Or Available (Not
Reported)
Could Not Be Determined Or Unsure
(Unknown)
A Person Having Origins In Any Of The
Original Peoples Of Europe, The Middle
East, Or North Africa. (White)
Ethnicity
A Person Of Mexican, Puerto Rican,
Cuban, Central Or South American Or
Other Spanish Culture Or Origin,
Regardless Of Race. (Hispanic or Latino)
A Person Not Meeting The Definition For
Hispanic Or Latino. (Not Hispanic or
Latino)
Not Provided Or Available (Not reported)
Could Not Be Determined Or Unsure
(Unknown)
Date Study Informed Consent Signed
(MM/DD/YYYY)
Date of Registration (MM/DD/YYYY)
Does the participant satisfy all of the eligibility
criteria?
Yes
No
Dcp Template Footer
Protocol Title
Protocol Version
Protocol Date
Page #
Total Page Number
DCP Template Version
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Registration - Registration - 2768468v1.0
On-Study - Baseline Medical/Surgical
History (continued) - 2764083v1.0
The Division of Cancer Prevention's baseline
medical/surgical history continuation case report form
(CRF) template.
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=519B1246-
7E21-742E-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/7093
Baseline Medical/Surgical History
(continued)
Screening
DCP Protocol #
Institution Code
Participant ID
Visit Type
Visit Date
Baseline Medical/surgical History
Specify Other Body System/Site
Body System
Abnormal (Abnormal)
Normal (Normal)
Comment (Required if Abnormal) (Provide
condition/diagnosis)
Dcp Template Footer
Protocol Title
Protocol Version
Protocol Date
Page #
Total Page Number
DCP Template Version
1 / 1
Registration - Randomization -
2802700v1.0
The Division of Cancer Prevention's randomization case
report form (CRF) template.
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=5C0D40B0-
536A-6D0C-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/7094
Randomization
Screening
DCP Protocol #
Institution Code
Participant ID
Visit Type
Visit Date
Randomization
Not Obtained
Not Applicable (Not Applicable)
Not Obtained
Not Applicable (Not Applicable)
Not Obtained
Not Applicable (Not Applicable)
Date Participant Randomized (MM/DD/YYYY)
Randomization Number
Date Run-In Started (MM/DD/YYYY)
Date Run-In Ended (MM/DD/YYYY)
Date Washout Started (MM/DD/YYYY)
Date Washout Ended (MM/DD/YYYY)
Dcp Template Footer
Protocol Title
Protocol Version
1 / 2
Protocol Date
Page #
Total Page Number
DCP Template Version
2 / 2
Registration - Randomization - 2802700v1.0
Off Treatment - Off Study - 2762907v1.0
The Division of Cancer Prevention's off study case report
form (CRF) template.
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=51740570-
60A4-7104-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/7095
Off Study
Screening
DCP Protocol #
Institution Code
Participant ID
Form Date
Off Study
Date on Follow-up
Date Off Follow-up
Date Off Study
Date of Last Contact
Date Last Study Agent Taken
Not Obtained
Not Applicable (Not Applicable)
Not Obtained
Not Applicable (Not Applicable)
Not Obtained
Not Applicable (Not Applicable)
Reason Off Study
Adverse Event/serious Adverse Event
(complete Ae Crf & Sae Form, If
Applicable) (AE/SAE)
Completed Study (COMPLETED
STUDY)
Concomitant Medication (Concomitant
medication)
Death (complete Death Report Crf & Sae
Form) (Death)
Ineligible (Ineligible)
Lost To Follow-up (Lost to follow-up)
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Medical Contraindication (Medical
contraindication)
Non-compliant Participant (Non-
compliant participant)
Other (Other)
Pregnancy (Pregnancy)
Withdraw Consent (Withdraw consent)
Reason
Dcp Template Footer
Protocol Title
Protocol Version
Protocol Date
Page #
Total Page Number
DCP Template Version
2 / 2
Off Treatment - Off Study - 2762907v1.0
On-Study - Specimen Acquisition Urine -
2804182v1.0
The Division of Cancer Prevention's specimen acquisition
urine case report form (CRF) template.
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=5C36B035-
791B-735D-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/7096
Specimen Acquisition Urine
Screening
DCP Protocol #
Institution Code
Participant ID
Visit Type
Visit Date
Specimen Acquisition Blood
Specimen Number
Specimen Number
Not Obtained
Not Obtained (Not Obtained)
Not Obtained
Not Obtained (Not Obtained)
Date Specimen collected
Date Specimen collected
Time Specimen Collected (hr:mm per 24 hour
clock)
Time Specimen Collected (hr:mm per 24 hour
clock)
Date Last Study Agent Taken (MM/DD/YYYY)
Time Last Study Agent Taken (hr:mm per 24 hour
clock)
Date Last Urine Void
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Date Last Urine Void
Time Last Urine Void (hr:mm per 24 hour clock)
Time Last Urine Void (hr:mm per 24 hour clock)
Urine Volume ml
Urine Volume ml
Storage Temperature (Centigrade)
Storage Temperature (Centigrade)
Date Specimen Shipped
Date Specimen Shipped
Dcp Template Footer
Protocol Title
Protocol Version
Protocol Date
Page #
Total Page Number
DCP Template Version
2 / 2
On-Study - Specimen Acquisition Urine - 2804182v1.0
On-Study - Specimen Acquistion Blood -
2804141v1.0
The Division of Cancer Prevention's specimen acquisition
case report form (CRF) template.
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=5C376129-
787E-5E04-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/7098
Specimen Acquistion Blood
Screening
DCP Protocol #
Institution Code
Participant ID
Visit Type
Visit Date
Specimen Acquisition Blood
Specimen Number
Specimen Number
Not Obtained
Not Obtained (Not Obtained)
Not Obtained
Not Obtained (Not Obtained)
Date Sample Collected
Date Sample Collected
Time Specimen Collected (hr:mm per 24 hour
clock)
Time Specimen Collected (hr:mm per 24 hour
clock)
Date Last Study Agent Taken (MM/DD/YYYY)
Time Last Study Agent Taken (hr:mm per 24 hour
clock)
Storage Temperature (Centigrade)
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Storage Temperature (Centigrade)
Date Specimen Shipped
Date Specimen Shipped
Dcp Template Footer
Protocol Title
Protocol Version
Protocol Date
Page #
Total Page Number
DCP Template Version
2 / 2
On-Study - Specimen Acquistion Blood - 2804141v1.0
On-Study - Concomitant Medications -
2803509v1.0
The Division of Cancer Prevention's concomitant
medications case report form (CRF) template.
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=5C1FA3F4-
97AA-308F-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/7099
Concomitant Medications
Screening
DCP Protocol #
Institution Code
Participant ID
Concomitant Medications
At end of study only: check this box if participant
did not take any concomitant medications
None (None)
Medication Reported Date (MM/DD/YYYY)
Medication
Dose
Units
Unit Dose (Units)
Frequency
Reason
Start Date (MM/DD/YYYY)
Stop Date (MM/DD/YYYY)
Continuing
Yes (Yes)
Dcp Template Footer
Protocol Title
Protocol Version
Protocol Date
1 / 2
Page #
Total Page Number
DCP Template Version
2 / 2
On-Study - Concomitant Medications - 2803509v1.0
On-Study - Adverse Events - 2804058v1.0
The Division of Cancer Prevention's adverse events case
report form (CRF) template.
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=5C3563B2-
CBFA-3E8F-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/7100
Adverse Events
Screening
DCP Protocol #
Institution Code
Participant ID
Adverse Events
At end of study only:  check this box if participant
experienced no adverse events
None (None)
Adverse Event Reported Date (MM/DD/YYYY)
Adverse Event Verbatim Term
Event Onset Date (MM/DD/YYYY)
CTCAE Term
Abdominal Distension (Abdominal
distension)
Abdominal Infection (Abdominal
infection)
Abdominal Pain (Abdominal pain)
Abdominal Soft Tissue Necrosis
(Abdominal soft tissue necrosis)
Abducens Nerve Disorder (Abducens
nerve disorder)
Accessory Nerve Disorder (Accessory
nerve disorder)
Acidosis (Acidosis)
Acoustic Nerve Disorder Nos (Acoustic
nerve disorder NOS)
Activated Partial Thromboplastin Time
Prolonged (Activated partial
thromboplastin time prolonged)
Acute Coronary Syndrome (Acute
coronary syndrome)
Acute Kidney Injury (Acute kidney injury)
Adrenal Insufficiency (Adrenal
insufficiency)
Adult Respiratory Distress Syndrome
(Adult respiratory distress syndrome)
Agitation (Agitation)
Akathisia (Akathisia)
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Alanine Aminotransferase Increased
(Alanine aminotransferase increased)
Alcohol Intolerance (Alcohol intolerance)
Alkaline Phosphatase Increased
(Alkaline phosphatase increased)
Alkalosis (Alkalosis)
Allergic Reaction (Allergic reaction)
Allergic Rhinitis (Allergic rhinitis)
Alopecia (Alopecia)
Amnesia (Amnesia)
Anal Fistula (Anal fistula)
Anal Hemorrhage (Anal hemorrhage)
Anal Mucositis (Anal mucositis)
Anal Necrosis (Anal necrosis)
Anal Pain (Anal pain)
Anal Stenosis (Anal stenosis)
Anal Ulcer (Anal ulcer)
Anaphylaxis (Anaphylaxis)
Anemia (Anemia)
Ankle Fracture (Ankle fracture)
Anorectal Infection (Anorectal infection)
Anorexia (Anorexia)
Anorgasmia (Anorgasmia)
Anxiety (Anxiety)
Aortic Injury (Aortic injury)
Aortic Valve Disease (Aortic valve
disease)
Aphonia (Aphonia)
Apnea (Apnea)
Appendicitis (Appendicitis)
Appendicitis Perforated (Appendicitis
perforated)
Arachnoiditis (Arachnoiditis)
Arterial Injury (Arterial injury)
Arteritis Infective (Arteritis infective)
Arthralgia (Arthralgia)
Arthritis (Arthritis)
Ascites (Ascites)
Aspartate Aminotransferase Increased
(Aspartate aminotransferase increased)
Aspiration (Aspiration)
Asystole (Asystole)
Ataxia (Ataxia)
Atelectasis (Atelectasis)
Atrial Fibrillation (Atrial fibrillation)
Atrial Flutter (Atrial flutter)
Atrioventricular Block Complete
(Atrioventricular block complete)
Atrioventricular Block First Degree
(Atrioventricular block first degree)
Autoimmune Disorder (Autoimmune
disorder)
Avascular Necrosis (Avascular necrosis)
Azoospermia (Azoospermia)
Back Pain (Back pain)
Bile Duct Stenosis (Bile duct stenosis)
Biliary Anastomotic Leak (Biliary
anastomotic leak)
Biliary Fistula (Biliary fistula)
Biliary Tract Infection (Biliary tract
2 / 22
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infection)
Bladder Anastomotic Leak (Bladder
anastomotic leak)
Bladder Infection (Bladder infection)
Bladder Perforation (Bladder perforation)
Bladder Spasm (Bladder spasm)
Bloating (Bloating)
Blood And Lymphatic System Disorders -
Other, Specify (Blood and lymphatic
system disorders - Other, Specify)
Blood Antidiuretic Hormone Abnormal
(Blood antidiuretic hormone abnormal)
Blood Bilirubin Increased (Blood bilirubin
increased)
Blood Corticotrophin Decreased (Blood
corticotrophin decreased)
Blood Gonadotrophin Abnormal (Blood
gonadotrophin abnormal)
Blood Prolactin Abnormal (Blood
prolactin abnormal)
Blurred Vision (Blurred vision)
Body Odor (Body odor)
Bone Infection (Bone infection)
Bone Marrow Hypocellular (Bone
marrow hypocellular)
Bone Pain (Bone pain)
Brachial Plexopathy (Brachial
plexopathy)
Breast Atrophy (Breast atrophy)
Breast Infection (Breast infection)
Breast Pain (Breast pain)
Bronchial Fistula (Bronchial fistula)
Bronchial Infection (Bronchial infection)
Bronchial Obstruction (Bronchial
obstruction)
Bronchial Stricture (Bronchial stricture)
Bronchopleural Fistula (Bronchopleural
fistula)
Bronchopulmonary Hemorrhage
(Bronchopulmonary hemorrhage)
Bronchospasm (Bronchospasm)
Bruising (Bruising)
Bullous Dermatitis (Bullous dermatitis)
Burn (Burn)
Buttock Pain (Buttock pain)
Capillary Leak Syndrome (Capillary leak
syndrome)
Carbon Monoxide Diffusing Capacity
Decreased (Carbon monoxide diffusing
capacity decreased)
Cardiac Arrest (Cardiac arrest)
Cardiac Disorders - Other, Specify
(Cardiac disorders - Other, Specify)
Cardiac Troponin I Increased (Cardiac
troponin I increased)
Cardiac Troponin T Increased (Cardiac
troponin T increased)
Cataract (Cataract)
Catheter Related Infection (Catheter
related infection)
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Cd4 Lymphocytes Decreased (CD4
lymphocytes decreased)
Cecal Hemorrhage (Cecal hemorrhage)
Cecal Infection (Cecal infection)
Central Nervous System Necrosis
(Central nervous system necrosis)
Cerebrospinal Fluid Leakage
(Cerebrospinal fluid leakage)
Cervicitis Infection (Cervicitis infection)
Cheilitis (Cheilitis)
Chest Pain - Cardiac (Chest pain -
cardiac)
Chest Wall Pain (Chest wall pain)
Chills (Chills)
Cholecystitis (Cholecystitis)
Cholesterol High (Cholesterol high)
Chronic Kidney Disease (Chronic kidney
disease)
Chylothorax (Chylothorax)
Cognitive Disturbance (Cognitive
disturbance)
Colitis (Colitis)
Colonic Fistula (Colonic fistula)
Colonic Hemorrhage (Colonic
hemorrhage)
Colonic Obstruction (Colonic obstruction)
Colonic Perforation (Colonic perforation)
Colonic Stenosis (Colonic stenosis)
Colonic Ulcer (Colonic ulcer)
Concentration Impairment
(Concentration impairment)
Conduction Disorder (Conduction
disorder)
Confusion (Confusion)
Congenital, Familial And Genetic
Disorders - Other, Specify (Congenital,
familial and genetic disorders - Other,
Specify)
Conjunctivitis (Conjunctivitis)
Conjunctivitis Infective (Conjunctivitis
infective)
Constipation (Constipation)
Constrictive Pericarditis (Constrictive
pericarditis)
Corneal Infection (Corneal infection)
Corneal Ulcer (Corneal ulcer)
Cough (Cough)
Cpk Increased (CPK increased)
Cranial Nerve Infection (Cranial nerve
infection)
Creatinine Increased (Creatinine
increased)
Cushingoid (Cushingoid)
Cystitis Noninfective (Cystitis
noninfective)
Cytokine Release Syndrome (Cytokine
release syndrome)
Death Neonatal (Death neonatal)
Death Nos (Death NOS)
Dehydration (Dehydration)
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Delayed Orgasm (Delayed orgasm)
Delayed Puberty (Delayed puberty)
Delirium (Delirium)
Delusions (Delusions)
Dental Caries (Dental caries)
Depressed Level Of Consciousness
(Depressed level of consciousness)
Depression (Depression)
Dermatitis Radiation (Dermatitis
radiation)
Device Related Infection (Device related
infection)
Diarrhea (Diarrhea)
Disseminated Intravascular Coagulation
(Disseminated intravascular coagulation)
Dizziness (Dizziness)
Dry Eye (Dry eye)
Dry Mouth (Dry mouth)
Dry Skin (Dry skin)
Duodenal Fistula (Duodenal fistula)
Duodenal Hemorrhage (Duodenal
hemorrhage)
Duodenal Infection (Duodenal infection)
Duodenal Obstruction (Duodenal
obstruction)
Duodenal Perforation (Duodenal
perforation)
Duodenal Stenosis (Duodenal stenosis)
Duodenal Ulcer (Duodenal ulcer)
Dysarthria (Dysarthria)
Dysesthesia (Dysesthesia)
Dysgeusia (Dysgeusia)
Dysmenorrhea (Dysmenorrhea)
Dyspareunia (Dyspareunia)
Dyspepsia (Dyspepsia)
Dysphagia (Dysphagia)
Dysphasia (Dysphasia)
Dyspnea (Dyspnea)
Ear And Labyrinth Disorders - Other,
Specify (Ear and labyrinth disorders -
Other, Specify)
Ear Pain (Ear pain)
Edema Cerebral (Edema cerebral)
Edema Face (Edema face)
Edema Limbs (Edema limbs)
Edema Trunk (Edema trunk)
Ejaculation Disorder (Ejaculation
disorder)
Ejection Fraction Decreased (Ejection
fraction decreased)
Electrocardiogram Qt Corrected Interval
Prolonged (Electrocardiogram QT
corrected interval prolonged)
Encephalitis Infection (Encephalitis
infection)
Encephalomyelitis Infection
(Encephalomyelitis infection)
Encephalopathy (Encephalopathy)
Endocarditis Infective (Endocarditis
infective)
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Endocrine Disorders - Other, Specify
(Endocrine disorders - Other, Specify)
Endophthalmitis (Endophthalmitis)
Enterocolitis (Enterocolitis)
Enterocolitis Infectious (Enterocolitis
infectious)
Enterovesical Fistula (Enterovesical
fistula)
Epistaxis (Epistaxis)
Erectile Dysfunction (Erectile
dysfunction)
Erythema Multiforme (Erythema
multiforme)
Erythroderma (Erythroderma)
Esophageal Anastomotic Leak
(Esophageal anastomotic leak)
Esophageal Fistula (Esophageal fistula)
Esophageal Hemorrhage (Esophageal
hemorrhage)
Esophageal Infection (Esophageal
infection)
Esophageal Necrosis (Esophageal
necrosis)
Esophageal Obstruction (Esophageal
obstruction)
Esophageal Pain (Esophageal pain)
Esophageal Perforation (Esophageal
perforation)
Esophageal Stenosis (Esophageal
stenosis)
Esophageal Ulcer (Esophageal ulcer)
Esophageal Varices Hemorrhage
(Esophageal varices hemorrhage)
Esophagitis (Esophagitis)
Euphoria (Euphoria)
Exostosis (Exostosis)
External Ear Inflammation (External ear
inflammation)
External Ear Pain (External ear pain)
Extraocular Muscle Paresis (Extraocular
muscle paresis)
Extrapyramidal Disorder (Extrapyramidal
disorder)
Eye Disorders - Other, Specify (Eye
disorders - Other, Specify)
Eye Infection (Eye infection)
Eye Pain (Eye pain)
Eyelid Function Disorder (Eyelid function
disorder)
Facial Muscle Weakness (Facial muscle
weakness)
Facial Nerve Disorder (Facial nerve
disorder)
Facial Pain (Facial pain)
Fall (Fall)
Fallopian Tube Anastomotic Leak
(Fallopian tube anastomotic leak)
Fallopian Tube Obstruction (Fallopian
tube obstruction)
Fallopian Tube Perforation (Fallopian
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tube perforation)
Fallopian Tube Stenosis (Fallopian tube
stenosis)
Fat Atrophy (Fat atrophy)
Fatigue (Fatigue)
Febrile Neutropenia (Febrile
neutropenia)
Fecal Incontinence (Fecal incontinence)
Female Genital Tract Fistula (Female
genital tract fistula)
Feminization Acquired (Feminization
acquired)
Fetal Death (Fetal death)
Fetal Growth Retardation (Fetal growth
retardation)
Fever (Fever)
Fibrinogen Decreased (Fibrinogen
decreased)
Fibrosis Deep Connective Tissue
(Fibrosis deep connective tissue)
Flank Pain (Flank pain)
Flashing Lights (Flashing lights)
Flatulence (Flatulence)
Floaters (Floaters)
Flu Like Symptoms (Flu like symptoms)
Flushing (Flushing)
Forced Expiratory Volume Decreased
(Forced expiratory volume decreased)
Fracture (Fracture)
Gait Disturbance (Gait disturbance)
Gallbladder Fistula (Gallbladder fistula)
Gallbladder Infection (Gallbladder
infection)
Gallbladder Necrosis (Gallbladder
necrosis)
Gallbladder Obstruction (Gallbladder
obstruction)
Gallbladder Pain (Gallbladder pain)
Gallbladder Perforation (Gallbladder
perforation)
Gastric Anastomotic Leak (Gastric
anastomotic leak)
Gastric Fistula (Gastric fistula)
Gastric Hemorrhage (Gastric
hemorrhage)
Gastric Necrosis (Gastric necrosis)
Gastric Perforation (Gastric perforation)
Gastric Stenosis (Gastric stenosis)
Gastric Ulcer (Gastric ulcer)
Gastritis (Gastritis)
Gastroesophageal Reflux Disease
(Gastroesophageal reflux disease)
Gastrointestinal Anastomotic Leak
(Gastrointestinal anastomotic leak)
Gastrointestinal Disorders - Other,
Specify (Gastrointestinal disorders -
Other, Specify)
Gastrointestinal Fistula (Gastrointestinal
fistula)
Gastrointestinal Pain (Gastrointestinal
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pain)
Gastrointestinal Stoma Necrosis
(Gastrointestinal stoma necrosis)
Gastroparesis (Gastroparesis)
General Disorders And Administration
Site Conditions - Other, Specify (General
disorders and administration site
conditions - Other, Specify)
Generalized Muscle Weakness
(Generalized muscle weakness)
Genital Edema (Genital edema)
Ggt Increased (GGT increased)
Gingival Pain (Gingival pain)
Glaucoma (Glaucoma)
Glossopharyngeal Nerve Disorder
(Glossopharyngeal nerve disorder)
Glucose Intolerance (Glucose
intolerance)
Growth Accelerated (Growth
accelerated)
Growth Hormone Abnormal (Growth
hormone abnormal)
Growth Suppression (Growth
suppression)
Gum Infection (Gum infection)
Gynecomastia (Gynecomastia)
Hallucinations (Hallucinations)
Haptoglobin Decreased (Haptoglobin
decreased)
Head Soft Tissue Necrosis (Head soft
tissue necrosis)
Headache (Headache)
Hearing Impaired (Hearing impaired)
Heart Failure (Heart failure)
Hematoma (Hematoma)
Hematosalpinx (Hematosalpinx)
Hematuria (Hematuria)
Hemoglobin Increased (Hemoglobin
increased)
Hemoglobinuria (Hemoglobinuria)
Hemolysis (Hemolysis)
Hemolytic Uremic Syndrome (Hemolytic
uremic syndrome)
Hemorrhoidal Hemorrhage
(Hemorrhoidal hemorrhage)
Hemorrhoids (Hemorrhoids)
Hepatic Failure (Hepatic failure)
Hepatic Hemorrhage (Hepatic
hemorrhage)
Hepatic Infection (Hepatic infection)
Hepatic Necrosis (Hepatic necrosis)
Hepatic Pain (Hepatic pain)
Hepatitis Viral (Hepatitis viral)
Hepatobiliary Disorders - Other, Specify
(Hepatobiliary disorders - Other, Specify)
Hiccups (Hiccups)
Hip Fracture (Hip fracture)
Hirsutism (Hirsutism)
Hoarseness (Hoarseness)
Hot Flashes (Hot flashes)
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Hydrocephalus (Hydrocephalus)
Hypercalcemia (Hypercalcemia)
Hyperglycemia (Hyperglycemia)
Hyperhidrosis (Hyperhidrosis)
Hyperkalemia (Hyperkalemia)
Hypermagnesemia (Hypermagnesemia)
Hypernatremia (Hypernatremia)
Hyperparathyroidism
(Hyperparathyroidism)
Hypersomnia (Hypersomnia)
Hypertension (Hypertension)
Hyperthyroidism (Hyperthyroidism)
Hypertrichosis (Hypertrichosis)
Hypertriglyceridemia
(Hypertriglyceridemia)
Hyperuricemia (Hyperuricemia)
Hypoalbuminemia (Hypoalbuminemia)
Hypocalcemia (Hypocalcemia)
Hypoglossal Nerve Disorder
(Hypoglossal nerve disorder)
Hypoglycemia (Hypoglycemia)
Hypohidrosis (Hypohidrosis)
Hypokalemia (Hypokalemia)
Hypomagnesemia (Hypomagnesemia)
Hyponatremia (Hyponatremia)
Hypoparathyroidism
(Hypoparathyroidism)
Hypophosphatemia (Hypophosphatemia)
Hypotension (Hypotension)
Hypothermia (Hypothermia)
Hypothyroidism (Hypothyroidism)
Hypoxia (Hypoxia)
Ileal Fistula (Ileal fistula)
Ileal Hemorrhage (Ileal hemorrhage)
Ileal Obstruction (Ileal obstruction)
Ileal Perforation (Ileal perforation)
Ileal Stenosis (Ileal stenosis)
Ileal Ulcer (Ileal ulcer)
Ileus (Ileus)
Immune System Disorders - Other,
Specify (Immune system disorders -
Other, Specify)
Infections And Infestations - Other,
Specify (Infections and infestations -
Other, Specify)
Infective Myositis (Infective myositis)
Infusion Related Reaction (Infusion
related reaction)
Infusion Site Extravasation (Infusion site
extravasation)
Injection Site Reaction (Injection site
reaction)
Injury To Carotid Artery (Injury to carotid
artery)
Injury To Inferior Vena Cava (Injury to
inferior vena cava)
Injury To Jugular Vein (Injury to jugular
vein)
Injury To Superior Vena Cava (Injury to
superior vena cava)
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Injury, Poisoning And Procedural
Complications - Other, Specify (Injury,
poisoning and procedural complications -
Other, Specify)
Inr Increased (INR increased)
Insomnia (Insomnia)
Intestinal Stoma Leak (Intestinal stoma
leak)
Intestinal Stoma Obstruction (Intestinal
stoma obstruction)
Intestinal Stoma Site Bleeding (Intestinal
stoma site bleeding)
Intra-abdominal Hemorrhage (Intra-
abdominal hemorrhage)
Intracranial Hemorrhage (Intracranial
hemorrhage)
Intraoperative Arterial Injury
(Intraoperative arterial injury)
Intraoperative Breast Injury
(Intraoperative breast injury)
Intraoperative Cardiac Injury
(Intraoperative cardiac injury)
Intraoperative Ear Injury (Intraoperative
ear injury)
Intraoperative Endocrine Injury
(Intraoperative endocrine injury)
Intraoperative Gastrointestinal Injury
(Intraoperative gastrointestinal injury)
Intraoperative Head And Neck Injury
(Intraoperative head and neck injury)
Intraoperative Hemorrhage
(Intraoperative hemorrhage)
Intraoperative Hepatobiliary Injury
(Intraoperative hepatobiliary injury)
Intraoperative Musculoskeletal Injury
(Intraoperative musculoskeletal injury)
Intraoperative Neurological Injury
(Intraoperative neurological injury)
Intraoperative Ocular Injury
(Intraoperative ocular injury)
Intraoperative Renal Injury
(Intraoperative renal injury)
Intraoperative Reproductive Tract Injury
(Intraoperative reproductive tract injury)
Intraoperative Respiratory Injury
(Intraoperative respiratory injury)
Intraoperative Skin Injury (Intraoperative
skin injury)
Intraoperative Splenic Injury
(Intraoperative splenic injury)
Intraoperative Urinary Injury
(Intraoperative urinary injury)
Intraoperative Venous Injury
(Intraoperative venous injury)
Investigations - Other, Specify
(Investigations - Other, Specify)
Iron Overload (Iron overload)
Irregular Menstruation (Irregular
menstruation)
Irritability (Irritability)
10 / 22
On-Study - Adverse Events - 2804058v1.0
Ischemia Cerebrovascular (Ischemia
cerebrovascular)
Ivth Nerve Disorder (IVth nerve disorder)
Jejunal Fistula (Jejunal fistula)
Jejunal Hemorrhage (Jejunal
hemorrhage)
Jejunal Obstruction (Jejunal obstruction)
Jejunal Perforation (Jejunal perforation)
Jejunal Stenosis (Jejunal stenosis)
Jejunal Ulcer (Jejunal ulcer)
Joint Effusion (Joint effusion)
Joint Infection (Joint infection)
Joint Range Of Motion Decreased (Joint
range of motion decreased)
Joint Range Of Motion Decreased
Cervical Spine (Joint range of motion
decreased cervical spine)
Joint Range Of Motion Decreased
Lumbar Spine (Joint range of motion
decreased lumbar spine)
Keratitis (Keratitis)
Kidney Anastomotic Leak (Kidney
anastomotic leak)
Kidney Infection (Kidney infection)
Kyphosis (Kyphosis)
Lactation Disorder (Lactation disorder)
Large Intestinal Anastomotic Leak (Large
intestinal anastomotic leak)
Laryngeal Edema (Laryngeal edema)
Laryngeal Fistula (Laryngeal fistula)
Laryngeal Hemorrhage (Laryngeal
hemorrhage)
Laryngeal Inflammation (Laryngeal
inflammation)
Laryngeal Mucositis (Laryngeal
mucositis)
Laryngeal Obstruction (Laryngeal
obstruction)
Laryngeal Stenosis (Laryngeal stenosis)
Laryngitis (Laryngitis)
Laryngopharyngeal Dysesthesia
(Laryngopharyngeal dysesthesia)
Laryngospasm (Laryngospasm)
Left Ventricular Systolic Dysfunction (Left
ventricular systolic dysfunction)
Lethargy (Lethargy)
Leukemia Secondary To Oncology
Chemotherapy (Leukemia secondary to
oncology chemotherapy)
Leukocytosis (Leukocytosis)
Leukoencephalopathy
(Leukoencephalopathy)
Libido Decreased (Libido decreased)
Libido Increased (Libido increased)
Lip Infection (Lip infection)
Lip Pain (Lip pain)
Lipase Increased (Lipase increased)
Lipohypertrophy (Lipohypertrophy)
Localized Edema (Localized edema)
Lordosis (Lordosis)
11 / 22
On-Study - Adverse Events - 2804058v1.0
Lower Gastrointestinal Hemorrhage
(Lower gastrointestinal hemorrhage)
Lung Infection (Lung infection)
Lymph Gland Infection (Lymph gland
infection)
Lymph Leakage (Lymph leakage)
Lymph Node Pain (Lymph node pain)
Lymphedema (Lymphedema)
Lymphocele (Lymphocele)
Lymphocyte Count Decreased
(Lymphocyte count decreased)
Lymphocyte Count Increased
(Lymphocyte count increased)
Malabsorption (Malabsorption)
Malaise (Malaise)
Mania (Mania)
Mediastinal Hemorrhage (Mediastinal
hemorrhage)
Mediastinal Infection (Mediastinal
infection)
Memory Impairment (Memory
impairment)
Meningismus (Meningismus)
Meningitis (Meningitis)
Menopause (Menopause)
Menorrhagia (Menorrhagia)
Metabolism And Nutrition Disorders -
Other, Specify (Metabolism and nutrition
disorders - Other, Specify)
Middle Ear Inflammation (Middle ear
inflammation)
Mitral Valve Disease (Mitral valve
disease)
Mobitz (type) Ii Atrioventricular Block
(Mobitz (type) II atrioventricular block)
Mobitz Type I (Mobitz type I)
Movements Involuntary (Movements
involuntary)
Mucosal Infection (Mucosal infection)
Mucositis Oral (Mucositis oral)
Multi-organ Failure (Multi-organ failure)
Muscle Weakness Left-sided (Muscle
weakness left-sided)
Muscle Weakness Lower Limb (Muscle
weakness lower limb)
Muscle Weakness Right-sided (Muscle
weakness right-sided)
Muscle Weakness Trunk (Muscle
weakness trunk)
Muscle Weakness Upper Limb (Muscle
weakness upper limb)
Musculoskeletal And Connective Tissue
Disorder - Other, Specify
(Musculoskeletal and connective tissue
disorders - Other, Specify)
Musculoskeletal Deformity
(Musculoskeletal deformity)
Myalgia (Myalgia)
Myelitis (Myelitis)
Myelodysplastic Syndrome
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(Myelodysplastic syndrome)
Myocardial Infarction (Myocardial
infarction)
Myocarditis (Myocarditis)
Myositis (Myositis)
Nail Discoloration (Nail discoloration)
Nail Infection (Nail infection)
Nail Loss (Nail loss)
Nail Ridging (Nail ridging)
Nasal Congestion (Nasal congestion)
Nausea (Nausea)
Neck Edema (Neck edema)
Neck Pain (Neck pain)
Neck Soft Tissue Necrosis (Neck soft
tissue necrosis)
Neoplasms Benign, Malignant And
Unspecified (incl Cysts And Polyps) -
Other, Specify (Neoplasms benign,
malignant and unspecified (incl cysts and
polyps) - Other, Specify)
Nervous System Disorders - Other,
Specify (Nervous system disorders -
Other, Specify)
Neuralgia (Neuralgia)
Neutrophil Count Decreased (Neutrophil
count decreased)
Night Blindness (Night blindness)
Nipple Deformity (Nipple deformity)
Non-cardiac Chest Pain (Non-cardiac
chest pain)
Nystagmus (Nystagmus)
Obesity (Obesity)
Obstruction Gastric (Obstruction gastric)
Oculomotor Nerve Disorder (Oculomotor
nerve disorder)
Olfactory Nerve Disorder (Olfactory
nerve disorder)
Oligospermia (Oligospermia)
Optic Nerve Disorder (Optic nerve
disorder)
Oral Cavity Fistula (Oral cavity fistula)
Oral Dysesthesia (Oral dysesthesia)
Oral Hemorrhage (Oral hemorrhage)
Oral Pain (Oral pain)
Osteonecrosis Of Jaw (Osteonecrosis of
jaw)
Osteoporosis (Osteoporosis)
Otitis Externa (Otitis externa)
Otitis Media (Otitis media)
Ovarian Hemorrhage (Ovarian
hemorrhage)
Ovarian Infection (Ovarian infection)
Ovarian Rupture (Ovarian rupture)
Ovulation Pain (Ovulation pain)
Pain (Pain)
Pain In Extremity (Pain in extremity)
Pain Of Skin (Pain of skin)
Palmar-plantar Erythrodysesthesia
Syndrome (Palmar-plantar
erythrodysesthesia syndrome)
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Palpitations (Palpitations)
Pancreas Infection (Pancreas infection)
Pancreatic Anastomotic Leak (Pancreatic
anastomotic leak)
Pancreatic Duct Stenosis (Pancreatic
duct stenosis)
Pancreatic Enzymes Decreased
(Pancreatic enzymes decreased)
Pancreatic Fistula (Pancreatic fistula)
Pancreatic Hemorrhage (Pancreatic
hemorrhage)
Pancreatic Necrosis (Pancreatic
necrosis)
Pancreatitis (Pancreatitis)
Papilledema (Papilledema)
Papulopustular Rash (Papulopustular
rash)
Paresthesia (Paresthesia)
Paronychia (Paronychia)
Paroxysmal Atrial Tachycardia
(Paroxysmal atrial tachycardia)
Pelvic Floor Muscle Weakness (Pelvic
floor muscle weakness)
Pelvic Infection (Pelvic infection)
Pelvic Pain (Pelvic pain)
Pelvic Soft Tissue Necrosis (Pelvic soft
tissue necrosis)
Penile Infection (Penile infection)
Penile Pain (Penile pain)
Perforation Bile Duct (Perforation bile
duct)
Pericardial Effusion (Pericardial effusion)
Pericardial Tamponade (Pericardial
tamponade)
Pericarditis (Pericarditis)
Perineal Pain (Perineal pain)
Periodontal Disease (Periodontal
disease)
Periorbital Edema (Periorbital edema)
Periorbital Infection (Periorbital infection)
Peripheral Ischemia (Peripheral
ischemia)
Peripheral Motor Neuropathy (Peripheral
motor neuropathy)
Peripheral Nerve Infection (Peripheral
nerve infection)
Peripheral Sensory Neuropathy
(Peripheral sensory neuropathy)
Peritoneal Infection (Peritoneal infection)
Peritoneal Necrosis (Peritoneal necrosis)
Personality Change (Personality change)
Phantom Pain (Phantom pain)
Pharyngeal Anastomotic Leak
(Pharyngeal anastomotic leak)
Pharyngeal Fistula (Pharyngeal fistula)
Pharyngeal Hemorrhage (Pharyngeal
hemorrhage)
Pharyngeal Mucositis (Pharyngeal
mucositis)
Pharyngeal Necrosis (Pharyngeal
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necrosis)
Pharyngeal Stenosis (Pharyngeal
stenosis)
Pharyngitis (Pharyngitis)
Pharyngolaryngeal Pain
(Pharyngolaryngeal pain)
Phlebitis (Phlebitis)
Phlebitis Infective (Phlebitis infective)
Photophobia (Photophobia)
Photosensitivity (Photosensitivity)
Platelet Count Decreased (Platelet count
decreased)
Pleural Effusion (Pleural effusion)
Pleural Hemorrhage (Pleural
hemorrhage)
Pleural Infection (Pleural infection)
Pleuritic Pain (Pleuritic pain)
Pneumonitis (Pneumonitis)
Pneumothorax (Pneumothorax)
Portal Hypertension (Portal
hypertension)
Portal Vein Thrombosis (Portal vein
thrombosis)
Postnasal Drip (Postnasal drip)
Postoperative Hemorrhage
(Postoperative hemorrhage)
Postoperative Thoracic Procedure
Complication (Postoperative thoracic
procedure complication)
Precocious Puberty (Precocious
puberty)
Pregnancy, Puerperium And Perinatal
Conditions - Other, Specify (Pregnancy,
puerperium and perinatal conditions -
Other, Specify)
Premature Delivery (Premature delivery)
Premature Menopause (Premature
menopause)
Presyncope (Presyncope)
Proctitis (Proctitis)
Productive Cough (Productive cough)
Prolapse Of Intestinal Stoma (Prolapse
of intestinal stoma)
Prolapse Of Urostomy (Prolapse of
urostomy)
Prostate Infection (Prostate infection)
Prostatic Hemorrhage (Prostatic
hemorrhage)
Prostatic Obstruction (Prostatic
obstruction)
Prostatic Pain (Prostatic pain)
Proteinuria (Proteinuria)
Pruritus (Pruritus)
Psychiatric Disorders - Other, Specify
(Psychiatric disorders - Other, Specify)
Psychosis (Psychosis)
Pulmonary Edema (Pulmonary edema)
Pulmonary Fibrosis (Pulmonary fibrosis)
Pulmonary Fistula (Pulmonary fistula)
Pulmonary Hypertension (Pulmonary
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hypertension)
Pulmonary Valve Disease (Pulmonary
valve disease)
Purpura (Purpura)
Pyramidal Tract Syndrome (Pyramidal
tract syndrome)
Radiation Recall Reaction (dermatologic)
(Radiation recall reaction (dermatologic))
Radiculitis (Radiculitis)
Rash Acneiform (Rash acneiform)
Rash Maculo-papular (Rash maculo-
papular)
Rash Pustular (Rash pustular)
Rectal Anastomotic Leak (Rectal
anastomotic leak)
Rectal Fistula (Rectal fistula)
Rectal Hemorrhage (Rectal hemorrhage)
Rectal Mucositis (Rectal mucositis)
Rectal Necrosis (Rectal necrosis)
Rectal Obstruction (Rectal obstruction)
Rectal Pain (Rectal pain)
Rectal Perforation (Rectal perforation)
Rectal Stenosis (Rectal stenosis)
Rectal Ulcer (Rectal ulcer)
Recurrent Laryngeal Nerve Palsy
(Recurrent laryngeal nerve palsy)
Renal And Urinary Disorders - Other,
Specify (Renal and urinary disorders -
Other, Specify)
Renal Calculi (Renal calculi)
Renal Colic (Renal colic)
Renal Hemorrhage (Renal hemorrhage)
Reproductive System And Breast
Disorders - Other, Specify (Reproductive
system and breast disorders - Other,
Specify)
Respiratory Failure (Respiratory failure)
Respiratory, Thoracic And Mediastinal
Disorders - Other, Specify (Respiratory,
thoracic and mediastinal disorders -
Other, Specify)
Restlessness (Restlessness)
Restrictive Cardiomyopathy (Restrictive
cardiomyopathy)
Retinal Detachment (Retinal
detachment)
Retinal Tear (Retinal tear)
Retinal Vascular Disorder (Retinal
vascular disorder)
Retinoic Acid Syndrome (Retinoic acid
syndrome)
Retinopathy (Retinopathy)
Retroperitoneal Hemorrhage
(Retroperitoneal hemorrhage)
Reversible Posterior
Leukoencephalopathy Syndrome
(Reversible posterior
leukoencephalopathy syndrome)
Rhinitis Infective (Rhinitis infective)
Right Ventricular Dysfunction (Right
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ventricular dysfunction)
Salivary Duct Inflammation (Salivary duct
inflammation)
Salivary Gland Fistula (Salivary gland
fistula)
Salivary Gland Infection (Salivary gland
infection)
Scalp Pain (Scalp pain)
Scleral Disorder (Scleral disorder)
Scoliosis (Scoliosis)
Scrotal Infection (Scrotal infection)
Scrotal Pain (Scrotal pain)
Seizure (Seizure)
Sepsis (Sepsis)
Seroma (Seroma)
Serum Amylase Increased (Serum
amylase increased)
Serum Sickness (Serum sickness)
Sick Sinus Syndrome (Sick sinus
syndrome)
Sinus Bradycardia (Sinus bradycardia)
Sinus Disorder (Sinus disorder)
Sinus Pain (Sinus pain)
Sinus Tachycardia (Sinus tachycardia)
Sinusitis (Sinusitis)
Skin And Subcutaneous Tissue
Disorders - Other, Specify (Skin and
subcutaneous tissue disorders - Other,
Specify)
Skin Atrophy (Skin atrophy)
Skin Hyperpigmentation (Skin
hyperpigmentation)
Skin Hypopigmentation (Skin
hypopigmentation)
Skin Induration (Skin induration)
Skin Infection (Skin infection)
Skin Ulceration (Skin ulceration)
Sleep Apnea (Sleep apnea)
Small Intestinal Anastomotic Leak (Small
intestinal anastomotic leak)
Small Intestinal Mucositis (Small
intestinal mucositis)
Small Intestinal Obstruction (Small
intestinal obstruction)
Small Intestinal Perforation (Small
intestinal perforation)
Small Intestinal Stenosis (Small intestinal
stenosis)
Small Intestine Infection (Small intestine
infection)
Small Intestine Ulcer (Small intestine
ulcer)
Sneezing (Sneezing)
Social Circumstances - Other, Specify
(Social circumstances - Other, Specify)
Soft Tissue Infection (Soft tissue
infection)
Soft Tissue Necrosis Lower Limb (Soft
tissue necrosis lower limb)
Soft Tissue Necrosis Upper Limb (Soft
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tissue necrosis upper limb)
Somnolence (Somnolence)
Sore Throat (Sore throat)
Spasticity (Spasticity)
Spermatic Cord Anastomotic Leak
(Spermatic cord anastomotic leak)
Spermatic Cord Hemorrhage (Spermatic
cord hemorrhage)
Spermatic Cord Obstruction (Spermatic
cord obstruction)
Spinal Fracture (Spinal fracture)
Spleen Disorder (Spleen disorder)
Splenic Infection (Splenic infection)
Stenosis Of Gastrointestinal Stoma
(Stenosis of gastrointestinal stoma)
Stevens-johnson Syndrome (Stevens-
Johnson syndrome)
Stoma Site Infection (Stoma site
infection)
Stomach Pain (Stomach pain)
Stomal Ulcer (Stomal ulcer)
Stridor (Stridor)
Stroke (Stroke)
Sudden Death Nos (Sudden death NOS)
Suicidal Ideation (Suicidal ideation)
Suicide Attempt (Suicide attempt)
Superficial Soft Tissue Fibrosis
(Superficial soft tissue fibrosis)
Superficial Thrombophlebitis (Superficial
thrombophlebitis)
Superior Vena Cava Syndrome (Superior
vena cava syndrome)
Supraventricular Tachycardia
(Supraventricular tachycardia)
Surgical And Medical Procedures -
Other, Specify (Surgical and medical
procedures - Other, Specify)
Syncope (Syncope)
Telangiectasia (Telangiectasia)
Testicular Disorder (Testicular disorder)
Testicular Hemorrhage (Testicular
hemorrhage)
Testicular Pain (Testicular pain)
Thromboembolic Event
(Thromboembolic event)
Thrombotic Thrombocytopenic Purpura
(Thrombotic thrombocytopenic purpura)
Tinnitus (Tinnitus)
Tooth Development Disorder (Tooth
development disorder)
Tooth Discoloration (Tooth discoloration)
Tooth Infection (Tooth infection)
Toothache (Toothache)
Toxic Epidermal Necrolysis (Toxic
epidermal necrolysis)
Tracheal Fistula (Tracheal fistula)
Tracheal Hemorrhage (Tracheal
hemorrhage)
Tracheal Mucositis (Tracheal mucositis)
Tracheal Obstruction (Tracheal
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obstruction)
Tracheal Stenosis (Tracheal stenosis)
Tracheitis (Tracheitis)
Tracheostomy Site Bleeding
(Tracheostomy site bleeding)
Transient Ischemic Attacks (Transient
ischemic attacks)
Treatment Related Secondary
Malignancy (Treatment related
secondary malignancy)
Tremor (Tremor)
Tricuspid Valve Disease (Tricuspid valve
disease)
Trigeminal Nerve Disorder (Trigeminal
nerve disorder)
Trismus (Trismus)
Tumor Lysis Syndrome (Tumor lysis
syndrome)
Tumor Pain (Tumor pain)
Typhlitis (Typhlitis)
Unequal Limb Length (Unequal limb
length)
Unintended Pregnancy (Unintended
pregnancy)
Upper Gastrointestinal Hemorrhage
(Upper gastrointestinal hemorrhage)
Upper Respiratory Infection (Upper
respiratory infection)
Ureteric Anastomotic Leak (Ureteric
anastomotic leak)
Urethral Anastomotic Leak (Urethral
anastomotic leak)
Urethral Infection (Urethral infection)
Urinary Fistula (Urinary fistula)
Urinary Frequency (Urinary frequency)
Urinary Incontinence (Urinary
incontinence)
Urinary Retention (Urinary retention)
Urinary Tract Infection (Urinary tract
infection)
Urinary Tract Obstruction (Urinary tract
obstruction)
Urinary Tract Pain (Urinary tract pain)
Urinary Urgency (Urinary urgency)
Urine Discoloration (Urine discoloration)
Urine Output Decreased (Urine output
decreased)
Urostomy Leak (Urostomy leak)
Urostomy Obstruction (Urostomy
obstruction)
Urostomy Site Bleeding (Urostomy site
bleeding)
Urostomy Stenosis (Urostomy stenosis)
Urticaria (Urticaria)
Uterine Anastomotic Leak (Uterine
anastomotic leak)
Uterine Fistula (Uterine fistula)
Uterine Hemorrhage (Uterine
hemorrhage)
Uterine Infection (Uterine infection)
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Uterine Obstruction (Uterine obstruction)
Uterine Pain (Uterine pain)
Uterine Perforation (Uterine perforation)
Uveitis (Uveitis)
Vaginal Anastomotic Leak (Vaginal
anastomotic leak)
Vaginal Discharge (Vaginal discharge)
Vaginal Dryness (Vaginal dryness)
Vaginal Fistula (Vaginal fistula)
Vaginal Hemorrhage (Vaginal
hemorrhage)
Vaginal Infection (Vaginal infection)
Vaginal Inflammation (Vaginal
inflammation)
Vaginal Obstruction (Vaginal obstruction)
Vaginal Pain (Vaginal pain)
Vaginal Perforation (Vaginal perforation)
Vaginal Stricture (Vaginal stricture)
Vaginismus (Vaginismus)
Vagus Nerve Disorder (Vagus nerve
disorder)
Vas Deferens Anastomotic Leak (Vas
deferens anastomotic leak)
Vascular Access Complication (Vascular
access complication)
Vascular Disorders - Other, Specify
(Vascular disorders - Other, Specify)
Vasculitis (Vasculitis)
Vasovagal Reaction (Vasovagal reaction)
Venous Injury (Venous injury)
Ventricular Arrhythmia (Ventricular
arrhythmia)
Ventricular Fibrillation (Ventricular
fibrillation)
Ventricular Tachycardia (Ventricular
tachycardia)
Vertigo (Vertigo)
Vestibular Disorder (Vestibular disorder)
Virilization (Virilization)
Visceral Arterial Ischemia (Visceral
arterial ischemia)
Vital Capacity Abnormal (Vital capacity
abnormal)
Vitreous Hemorrhage (Vitreous
hemorrhage)
Voice Alteration (Voice alteration)
Vomiting (Vomiting)
Vulval Infection (Vulval infection)
Watering Eyes (Watering eyes)
Weight Gain (Weight gain)
Weight Loss (Weight loss)
Wheezing (Wheezing)
White Blood Cell Decreased (White
blood cell decreased)
Wolff-parkinson-white Syndrome (Wolff-
Parkinson-White syndrome)
Wound Complication (Wound
complication)
Wound Dehiscence (Wound dehiscence)
Wound Infection (Wound infection)
20 / 22
On-Study - Adverse Events - 2804058v1.0
Wrist Fracture (Wrist fracture)
Event End Date (MM/DD/YYYY)
Grade
Mild Adverse Event (1)
Moderate Adverse Event (2)
Severe Adverse Event (3)
Life Threatening Adverse Event (4)
Death Related To Adverse Event (5)
Attribution
Unrelated (1)
Unlikely (2)
Possible (3)
Probable (4)
Definite (5)
Reported as SAE?
Yes (1)
No (2)
Action
Agent Withdrawn (1)
Agent Dose Reduced (2)
Agent Dose Increased (3)
Agent Dose Not Changed (4)
Unknown (5)
Not Applicable (6)
Outcome
Resolved (1)
Resolving (2)
Not Resolved (3)
Resolved With Sequelae (4)
Fatal (5)
Unknown (6)
Dropped due to this AE?
Yes (1)
No (2)
Comments
Dcp Template Footer
Protocol Title
Protocol Version
Protocol Date
Page #
21 / 22
On-Study - Adverse Events - 2804058v1.0
Total Page Number
DCP Template Version
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On-Study - Baseline Symptoms -
2764125v1.0
The Division of Cancer Prevention's baseline symptoms
case report form (CRF) template.
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=519B4D57-
283F-06A9-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/7101
Baseline Symptoms
Screening
DCP Protocol #
Institution Code
Participant ID
Visit Type
Visit Date
Baseline Medical/surgical History
Check here is none reported (no baseline
symptoms)
None (None)
Symptom Description
Onset Date
Grade
Mild Adverse Event (1)
Moderate Adverse Event (2)
Severe Adverse Event (3)
Life Threatening Adverse Event (4)
Death Related To Adverse Event (5)
Comments
Dcp Template Footer
Protocol Title
Protocol Version
Protocol Date
Page #
1 / 2
Total Page Number
DCP Template Version
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On-Study - Baseline Symptoms - 2764125v1.0
On-Study - Intervention Administration (Non-
Blinded Study - Agent is known) - 2803022v1.0
The Division of Cancer Prevention's intervention
administration (non-blinded study - agent is known) case
report form (CRF) template.
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=5C0F60BE-
F382-1C65-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/7102
Intervention Administration (Non-
Blinded Study - Agent is known)
Screening
DCP Protocol #
Institution Code
Participant ID
Visit Type
Visit Date
Intervention Administration (blinded Study)
Agent #
Agent/Placebo
Dose
Dose Units
Percent (%)
Application (app)
Becquerel (Bq)
Capsule (Cap)
Curie (Ci)
Caplet (Cplt)
Dram (DF)
Gram (G)
Gigabequerel (GBq)
Drop (gtt)
International Unit (iu)
International Unit Per Kilogram (iu/kg)
Joule Per Centimeter Squared (J/cm2)
Kilobecquerel (KBq)
Kilogram (kg)
Thousand International Unit (kiu)
Liter (l)
Megabequerel (MBq)
Millicurie (mCi)
Milliequivalent (mEq)
Milligram (mg)
Milligram Per Kilogram (mg/kg)
Milligram Per Square Meter (mg/m2)
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Milli-international Unit (Miu)
Milliliter (mL)
Milliliter (ML)
Millimole (mmol)
Mole (mol)
Nanocurie (nCi)
Nanogram (ng)
Other (Oth)
Picogram (PG)
Puff Dosing Unit (Puff)
Sachet Dosing Unit (Sachet)
Tablet (Tab)
Tablespoon Dosing Unit (tbs)
Teaspoon Dosing Unit (tsp)
Microcurie (uCi)
Microgram (ug)
Microgram Per Kilogram (ug/kg)
Microgram Per Square Meter (ug/m2)
Microliter (UL)
Micromole (UMOL)
Unit Dose (Units)
Unknown (Unk)
Frequency
Date Agent Provided (to participant
MM/DD/YYYY)
Agent Start Date (MM/DD/YYYY)
Dcp Template Footer
Protocol Title
Protocol Version
Protocol Date
Page #
Total Page Number
DCP Template Version
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On-Study - Participant Contact -
2803817v1.0
The Division of Cancer Prevention's participant contact
case report form (CRF) template.
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=5C23CCAA-
6AB8-3B80-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/7103
Participant Contact
Screening
DCP Protocol #
Institution Code
Participant ID
Visit Type
Date of last contact within treatment period
(MM/DD/YYYY)
Participant Contact Form
Contact Type
Contact By Email (Email)
Home Cell (Home Cell)
Home Phone Number (Home phone)
Contact By Regular Mail (Regular Mail)
Work Cell (Work Cell)
Work Email (Work email)
Work Phone (Work phone)
Contact Time (hr:mm per 24 hour clock)
Not Obtained
Unknown (Unknown)
Contact Result
Email Contact With Patient/participant
(Email contact with Patient/Participant)
Left Voicemail Message (Left voicemail
message)
Mail Contact With Patient/participant
(Mail contact with Patient/Participant)
No Contact Made (No contact made)
Spoke To Family Member (Spoke to
family member)
Spoke To Friend (Spoke to friend)
Spoke To Patient/participant (Spoke to
Patient/Participant)
Did the participant report any symptoms or
adverse events?
No (No)
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Too Early To Evaluate (Too early to
evaluate)
Yes (Yes)
Were any changes in concomitant medications
reported? ([Either new medications started or
previous medications stopped]?)
Not Applicable (N/A)
No (No)
Yes (Yes)
Is the participant compliant with protocol
intervention per telephone conversation or email?
No (NO)
Unknown (UNKNOWN)
Yes (YES)
Dcp Template Footer
Protocol Title
Protocol Version
Protocol Date
Page #
Total Page Number
DCP Template Version
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On-Study - AE and Conmed Evaluation -
2803423v1.0
The Division of Cancer Prevention's AE and conmed
evaluation case report form (CRF) template.
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=5C1255DF-
0CBA-43D9-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/7104
AE and Conmed Evaluation
Screening
DCP Protocol #
Institution Code
Participant ID
Ae And Conmed Evaluation Form
Visit Type
Follow Up (Follow up)
Month 1 (Month 1)
Month 2 (Month 2)
Month 3 (Month 3)
Month 4 (Month 4)
Month 5 (Month 5)
Month 6 (Month 6)
Registration/randomization
(Registration/Randomization)
Visit Date (MM/DD/YYYY)
Not Obtained
Not Applicable (Not Applicable)
Were any new or changes in Adverse Events
reported? (either the first report of a new AE or
changes to previously reported AEs? - Footnote -
If Yes is selected; the Adverse Event form must
be completed.  If No and/or N/A is selected for
ALL visits, NONE must be checked on the AE
form)
Not Applicable (N/A)
No (No)
Yes (Yes)
Were any new or changes in Concomitant
Medications reported? (either the first report of a
new Conmed or changes to previously reported
Conmed? - Footnote - If Yes is selected; the
Concomitant Medication form must be completed.
If No and/or N/A is selected for ALL visits, NONE
must be selected on the Concomitant Medication
form)
Not Applicable (N/A)
No (No)
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Not Evaluated (Not Evaluated)
Yes (Yes)
Dcp Template Footer
Protocol Title
Protocol Version
Protocol Date
Page #
Total Page Number
DCP Template Version
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On-Study - AE and Conmed Evaluation - 2803423v1.0
Acute Myeloid Leukemia (AML)Myelodysplastic Syndrome (MDS) -
On-Study Form - RelapseRefractory Treatment 2019378_v3_0
Acute Myeloid Leukemia (AML)/Myelodysplastic Syndrome
(MDS) - On-Study Form - Relapse/Refractory Treatment
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=1B24FD93-
54A8-51C5-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/7107
Acute Myeloid Leukemia
(AML)/Myelodysplastic Syndrome
(MDS) - On-Study Form -
Relapse/Refractory Treatment
CRF-Kopf
Koordinierungsgruppe Protokoll Nr.
Koordinierungsgruppe Code
Protokoll Titel
Studienpatienten-ID
Institution / Einrichtung
Andere Patienten-ID
Teilnehmender Gruppen-Code
Patienteninitialen
Registrierungstyp
Leukämie / MDS : Formular-
Administration
Ausfüllende Person
Werden Daten geändert (Wenn Daten geändert
werden, diese bitte in Rot einkreisen bei der
Verwendung von Papierformularen)
Ja
Nein
AML : Krankheitsbeschreibung, bisher
unbehandelt
Leukämie / MDS -Klassifikation (*Alternativ kann
die CDE WHO-Diagnose eingesetzt werden.)
Krankheit als akute erythroblastische
Leukämie (FAB M6) klassifiziert (Acute
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erythroblastic leukemia (FAB M6))
Krankheit als akute
Megakaryoblastenleukämie (FAB M7)
klassifiziert (Acute megakaryoblastic
leukemia (FAB M7))
Krankheit als akute Monozyten-
Leukämie (FAB M5) klassifiziert (Acute
monocytic leukemia (FAB M5))
Krankheit als akute myeloische
Leukämie mit reifen Zellen (FAB M2)
klassifiziert (Acute myeloid leukemia w/
maturation (FAB M2))
Krankheit als akute myeloische
Leukämie mit unreifen Zellen (FAB M1)
klassifiziert (Acute myeloid leukemia w/o
maturation (FAB M1))
Krankheit als akute myelomonozytische
Leukämie (FAB M4) klassifiziert (Acute
myelomonocytic leukemia (FAB M4))
Krankheit als akute
Promyelozytenleukämie (FAB M3)
klassifiziert (Acute promyelocytic
leukemia (FAB M3))
Krankheit als Akute Undifferenzierte
Leukämie (AUL) klassifiziert (Acute
undifferentiated leukemia (AUL))
Krankheit als AML klassifiziert, nicht
näher bezeichnet (AML, not otherwise
specified (NOS))
Krankheit als chronische
myelomonozytische Leukämie (CMML)
klassifiziert (Chronic myelomonocytic
leukemia (CMML))
Krankheit ist eine mixed-Lineage Akute
Leukämie (Mixed lineage acute
leukemia)
Krankheit als nicht näher bezeichnetes
myelodysplastisches Syndrom (MDS)
klassifiziert (Myelodysplastic syndrome
(MDS) NOS)
Krankheit als nicht näher bezeichnetes
myeloproliferatives Syndrom eingestuft
(Myeloproliferative syndrome NOS)
andere (Other)
Krankheit als refraktäre Anämie (RA)
klassifiziert (Refractory anemia (RA))
Krankheit als refraktäre Anämie mit
Blastenexzess in Transformation (RAEB-
t) klassifiziert (Refractory anemia w/
excess blasts in transformation (RAEB-
t))
Krankheit als refraktäre Anämie mit
Ringsideroblasten (RARS) klassifiziert
(Refractory anemia w/ ring sideroblasts
(RARS))
Krankheit als refraktäre Anämie mit
Blastenüberschuss (RAEB) klassifiziert
(Refractory anemia w/excess blasts
(RAEB))
Krankheit ist eine unklassifizierbare
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akute Leukämie (Unclassifiable acute
leukemia)
Krankheit als undifferenzierte akute
myeloische Leukämie (FAB M0)
klassifiziert (Undifferentiated acute
myeloid leukemia (FAB M0))
andere angeben
Krankheitsstatus
Sonstige, bitte angeben (Other)
Refraktär (refractory NOS)
Refraktär gegenüber der ersten
Induktion (Refractory to 1st induction)
Refraktär zur Reinduktion nach gesamter
Reaktion (Refractory to reinduction after
CR)
Rezidiv (relapse NOS)
Erstes Rezidiv (Relapse: 1st)
Zweites Rezidiv (Relapse: 2nd)
Drittes oder weitere Rezidiv(e) (Relapse:
3rd+)
andere angeben
Was war die Dauer der vorangegangenen
Response? (Für AML/MDS-Rezidiv)
Dauer des Ansprechens Weniger als 6
Monate (< 6 months)
Dauer des Ansprechens Größer als oder
gleich 6 Monate (> or = 6 months)
Dauer des Ansprechens Unbekannt
(Unknown)
Datum Hämatologie (Blut) Erhaltene Stichprobe
(peripheres Blut mm dd yyyy)
Anzahl weißer Blutkörperchen ( x 10^3/mcL )
Periphere Neutrophile / Bands (%)
Periphere Blasten (%)
Datum der Knochenmarksbiopsie
(Knochenmarkbiopsie / Aspirat mm dd yyyy)
Knochenmark Zellularität ( % )
Knochenmarkblasten (%)
Knochenmark Zellularitätsstatus
Zellularitätsstatus des Knochenmarks ist
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aplastisch (stark hypozellulär) (Aplastic
(severely hypocellular))
Zellularität des Knochenmarksstatus
unbekannt, Verfahren führte zu keinem
Untersuchungsmaterial (Dry tap or
inaspirable)
Zellularitätsstatus des Knochenmarks ist
hyperzellulären (Hypercellular)
Zellularitätsstatus des Knochenmarks ist
hypozellulären (Hypocellular)
Zellularitätsstatus des Knochenmarks ist
Normocellular (Normocellular)
Zellularitätsstatus des Knochenmarks ist
gebündelt (intensiv hyperzellulären)
(Packed (intensely hypercellular))
Zuvor Knochenmark oder peripheren
Blutstammzellen transplantiert?
Ja
Nein
Typ von Knochenmark oder PBSC
Knochenmarksstammzellen für
Transplantationen vom Empfänger selbst
entnommen (Autologous bone marrow)
Periphere Blutstammzellen für
Transplantationen vom Empfänger selbst
entnommen (Autologous PBSC)
Knochenmarksstammzellen für
Transplantationen entnommen von
Antigen Matched Geschwistern oder
Familienmitgliedern des Empfängers
(Bone marrow from matched sibling or
family member)
Knochenmarksstammzellen für
Transplantationen entnommen von
Antigen Matched Individuen ohne
Beziehung zum Empfänger (Bone
marrow from matched unrelated donor)
andere angeben (Other)
Periphere Blutstammzellen für
Transplantationen entnommen von
Antigen-Matched Geschwistern oder
Familienmitgliedern des Empfängers
(PBSC from matched sibling or family
member)
Periphere Blutstammzellen für
Transplantationen entnommen von
Antigen-Matched Individuen ohne
Beziehung zum Empfänger (PBSC from
matched unrelated donor)
andere angeben
Ermöglicht Dokumentation aller
zusätzlicher Kommentare
Kommentare
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Colorectal Cancer NCT00079274 Pathology - NCCTG Study
N0147 Pathology Report Submission Form - 2542238v1.0
NCCTG Study N0147 Pathology Report Submission Form
Comparison of Combination Chemotherapy Regimens With
or Without Cetuximab in Treating Patients Who Have
Undergone Surgery For Stage III Colon Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=224E327A-
2678-7307-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/7112
NCCTG Study N0147 Pathology
Report Submission Form
Header
Coordinating Group Protocol Number
Coordinating Group Code
Protocol Title
Patient Study ID
Patient Medical Record Number
Patient Initials (L, FM)
Participating Group Code (Cooperative Group
where credit will be applied)
Institution Name (treating location/performance
site)
Are data amended (If data are amended, please
circle in red when using paper form)
Yes
No
Reporting Period
Pre-therapy (Pre-treatment)
Procedure Date (mm dd yyyy)
Specimen Type
Submission Form Completed by (print name)
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Colorectal Cancer NCT00079274 Registration - North Central Cancer
Treatment Group N0147 Preregistration Screening Failure Form - 2787580v1.0
North Central Cancer Treatment Group N0147
Preregistration Screening Failure Form
Comparison of Combination Chemotherapy Regimens With
or Without Cetuximab in Treating Patients Who Have
Undergone Surgery For Stage III Colon Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=57BB37FE-
4136-38E6-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/7114
North Central Cancer Treatment
Group N0147 Preregistration
Screening Failure Form
Header
Coordinating Group Protocol Number
Coordinating Group Code
Protocol Title
Patient Study ID
Patient Medical Record Number
Patient Initials (L F M)
Participating Group Code (Cooperative Group
where credit will be applied)
Institution Name (treating location/performance
site)
Are data amended (If yes, highlight amended
areas)
Yes
No
Preregistration Screening Failure
Date aware of preregistration screening failure
(mm/dd/yyyy)
Primary reason screening failed (check one)
Did Not Meet Eligibility Criteria (Did not
meet eligibility criteria)
Investigator Decision (Investigator
decision)
Not Evaluable For Kras (Not evaluable
for KRAS)
Other (Other)
Patient Decision (Patient decision)
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Other, specify
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Colorectal Cancer NCT00079274 Registration - North Central Cancer
Treatment Group N0147 Preregistration Screening Failure Form - 2787580v1.0
Colorectal Cancer NCT00079274 Treatment - NCCTG Study
N0147 Operative Report Submission Form - 2542352v1.0
NCCTG Study N0147 Operative Report Submission Form
Comparison of Combination Chemotherapy Regimens With
or Without Cetuximab in Treating Patients Who Have
Undergone Surgery For Stage III Colon Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=224ECF5F-
44CA-491F-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/7117
NCCTG Study N0147 Operative
Report Submission Form
Header
Coordinating Group Protocol Number
Coordinating Group Code
Protocol Title
Patient Study ID
Patient Medical Record Number
Patient Initials (L, FM)
Participating Group Code (Cooperative Group
where credit will be applied)
Institution Name (treating location/performance
site)
Are data amended (If data are amended, please
circle in red when using paper form)
Yes
No
Reporting Period
Pre-therapy (Pre-treatment)
Procedure Date (mm dd yyyy)
Procedure Type
Submission Form Completed by (print name)
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Colorectal Cancer NCT00079274 Treatment - NCCTG Study
N0147 Colonoscopy Report Submission Form - 2542336v1.0
NCCTG Study N0147 Colonoscopy Report Submission
Form
Comparison of Combination Chemotherapy Regimens With
or Without Cetuximab in Treating Patients Who Have
Undergone Surgery For Stage III Colon Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=224EC566-
3DBB-4732-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/7119
NCCTG Study N0147 Colonoscopy
Report Submission Form
Header
Coordinating Group Protocol Number
Coordinating Group Code
Protocol Title
Patient Study ID
Patient Medical Record Number
Patient Initials (L, FM)
Participating Group Code (Cooperative Group
where credit will be applied)
Institution Name (Treating institution/performance
site)
Are data amended (If data are amended, please
circle in red when using paper form)
Yes
No
Reporting Period
Post-treatment (Post-Treatment)
Pre-therapy (Pre-treatment)
Procedure Date (mm dd yyyy)
Submission Form Completed by (print name)
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Follow-Up - Phase II Breast Cancer - Follow-up
Solid Tumor Evaluation Form - 2550183v1.0
Phase II Breast Cancer - Follow-up Solid Tumor Evaluation
Form
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=23E5780A-
30FE-4FBE-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/7126
Phase II Breast Cancer - Follow-up
Solid Tumor Evaluation Form
Crf Header
Coordinating Group Protocol No.
Coordinating Group Code
Protocol Title
Patient Study ID
Registering Group Code
Patient Medical Record Number
Other Patient ID
Institution/Affiliate
Registering Institution Code
Physician of Record
Lung: Adverse Events
Person Completing Form
Date Form Completed
Are data amended (If data are amended, please
circle in red when using paper form)
Yes
No
Cycle Number
Date of Last Clinical Assessment
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Target Lesion(s) Baseline Evaluation
Are there any target lesions?
Yes
No
Lesion Number
Target Lesion Site
Date of Evaluation
Method of Evaluation
Bone Scan (Bone scan)
Chest X-ray (Chest x-ray)
Clinical Examination (pe) (Clinical
examination)
Ct Scan (CT scan)
Cytology (Cytology)
Mri (MRI (NMR))
Other (Other)
Spiral Ct Scan (Spiral CT scan)
Ultrasound (Ultrasound)
Longest Diameter of Lesion(s) (cm)
Sum of Longest Diameters of All Target Lesions
Nontarget Lesion(s) Baseline Evaluation
Are there any nontarget lesions?
Yes
No
Lesion Number
Nontarget Lesion Site
Date of Evaluation
Method of Evaluation
Bone Scan (Bone scan)
Chest X-ray (Chest x-ray)
Clinical Examination (pe) (Clinical
examination)
Ct Scan (CT scan)
Cytology (Cytology)
Mri (MRI (NMR))
Other (Other)
Spiral Ct Scan (Spiral CT scan)
Ultrasound (Ultrasound)
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Follow-Up - Phase II Breast Cancer - Follow-up Solid Tumor Evaluation
Form - 2550183v1.0
Other Specify
New Lesion(s) At Follow-up Evaluation
Is there Symptomatic Deterioration of the
patient's health status requiring discontinuation of
treatment?
Yes
No
Yes specify
Lesion Number
Was the appearance of any new lesions
documented (since the baseline evaluation)
Yes
No
Date of Evaluation
New Lesion Site
Method of Evaluation
Bone Scan (Bone scan)
Chest X-ray (Chest x-ray)
Clinical Examination (pe) (Clinical
examination)
Ct Scan (CT scan)
Cytology (Cytology)
Mri (MRI (NMR))
Other (Other)
Spiral Ct Scan (Spiral CT scan)
Ultrasound (Ultrasound)
Other Specify
Evaluation Summary
Overall Tumor Response Type
Complete Response (CR)
Death Prior To Completion Of Protocol
Criteria (Early death)
Insufficient Evaluation (Insufficient
evaluation to determine response status)
Progressive Disease (PD)
Partial Response (PR)
Stable Disease (SD)
Comments
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Comments
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Follow-Up - Phase II Breast Cancer - Follow-up Solid Tumor Evaluation
Form - 2550183v1.0
Follow-Up - Phase II Lung Cancer - Advanced
Disease Follow-Up Form - 2399268v1.0
Phase II Consortium Phase II Lung Cancer - Advanced
Disease Follow-Up Form
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=FF8E0C9E-
44F2-3242-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/7132
Phase II Lung Cancer - Advanced
Disease Follow-Up Form
Crf Header
Coordinating Group Protocol No.
Coordinating Group Code
Protocol Title
Patient Study ID
Registering Group Code
Patient Medical Record Number
Other Patient ID
Institution/Affiliate
Registering Institution Code
Physician of Record
Form Administration
Person Completing Form
Date Form Completed (MM DD YYYY)
Are data amended (If data are amended, please
circle in red when using paper form)
Yes
No
Lung: Pre-treatment Characteristics
Patient's Vital Status
Alive (Alive)
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Dead (Dead)
Primary Cause of Death
Due To Other Cause (Due to other
cause)
Due To Protocol Treatment (Due to
protocol treatment)
Due To This Disease (Due to this
disease)
Unknown (Unknown)
Describe cause of death
Date of Last Contact or Death (MM DD YYYY)
Lung: Disease Follow-up Status
Has the patient had a documented clinical
assessment for this cancer? (since submission of
the previous follow-up form)
No (No)
Unknown (Unknown)
Yes (Yes)
Date of Last Clinical Assessment (If yes, MM DD
YYYY)
Lung: Notice Of Progression/site
Has the patient developed a first progression (or
relapse) that has not been previously reported?
Yes
No
Date of Progression (MM DD YYYY)
Sites of progression (check all that apply)
Adrenal Gland (Adrenals)
Bone (Bone)
Brain (Brain)
Central Nervous System (CNS
(excluding Brain))
Distant Lymph Nodes (Distant lymph
nodes)
Distant Skin/subcutaneous Tissue
(Distant skin/subcutaneous tissue)
Liver (Liver)
Lung (Lung)
Other (Other)
Pleura (Pleura)
Regional Lymph Nodes (Regional lymph
nodes)
Other specify
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2399268v1.0
Lung: Subsequent Non-protocol Therapy
Is the patient receiving any non-protocol cancer
therapy not previously reported?
Yes
No
Non-Protocol Therapy Type (check all that apply)
Biologic Response Modifier (Biologic
Response Modifier)
Chemotherapy (Chemotherapy)
High-dose Chemotherapy/autologous
Stem Cell Transplant (High-dose
chemotherapy/autologous stem cell
transplant)
Hormonal Therapy (Hormonal Therapy)
Immunotherapy (Immunotherapy)
Other Non-protocol Therapy (Other non-
protocol therapy)
Radiation Therapy (Radiation therapy)
Surgery (Surgery)
Name of Other Non-Protocol Therapy (If yes,)
Date of First Non-Protocol Therapy (MM DD
YYYY)
Lung: Notice Of New Primary
Has a new primary cancer or MDS been
diagnosed that has not been previously reported?
(myelodysplastic syndrome)
No (No)
Unknown (Unknown)
Yes (Yes)
Date of diagnosis (MM DD YYYY)
Site of New Primary (s If new primary site is
AML/MDS, please submit NCI AML/MDS form.)
Lung: Long-term Toxicity
Has the patient experienced (prior to diagnosis of
recurrence or second primary) any severe (Grade
>=3), long term toxicity that has not been
previously reported
No (No)
Unknown (Unknown)
Yes (Yes)
Late Adverse Event Term
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Late Adverse Event Grade
Late Adverse Event Attribution Code
Late Adverse Event Onset Date (MM DD YYYY)
Comments
Comments
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Follow-Up - Head and Neck Cancers -
Follow Up Form - 2268620v3.0
Head and Neck Cancers - Follow Up Form
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=D49693D6-
CE22-5E44-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/7136
Head and Neck Cancers - Follow Up
Form
Crf Header
Coordinating Group Protocol No.
Coordinating Group Code
Protocol Title
Patient Study ID
Institution/Affiliate
Other Patient ID
Participating Group Code
Patient Initials
Head & Neck: Vital Status
Patient's Vital Status
Alive (Alive)
Dead (Dead)
Primary Cause of Death
Due To Other Cause (Due to other
cause)
Due To Protocol Treatment (Due to
protocol treatment)
Due To Second Primary Or Other
Malignancy (Due to second primary or
other malignancy)
Due To This Disease (Due to this
disease)
Unknown (Unknown)
Describe cause of death
Date of Last Contact or Death (mm dd yyyy)
Is the patient off study (and further follow-up
evaluations will not be completed)
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No (No)
Unknown (Unknown)
Yes (Yes)
Off Study Reason (If yes,)
Death (Death)
Other (Other)
Lost To Follow-up (Patient lost to follow-
up)
Patient Refused Follow-up (Patient
refused follow-up)
Protocol-defined Follow-up Completed
(Protocol-defined follow-up completed)
Other specify
Head & Neck: Disease Follow-up Status
Has the patient had a documented clinical
assessment for this cancer? (since submission of
the previous follow-up form?)
No (No)
Unknown (Unknown)
Yes (Yes)
Date of Last Clinical Assessment (mm dd yyyy)
Head & Neck: Notice Of Progression
Has the patient developed a first progression (or
relapse) that has not been previously reported?
Yes
No
Has the patient been diagnosed with first local-
regional recurrence (or progression?)
Yes
No
Site of First Local-Regional Progression (s mark
all that apply)
Lymph Nodes (Lymph nodes)
None (None)
Other Specify (Other)
Primary (Primary Site)
Other specify
Date of First Local-Regional Progression (per
protocol definition leave blank if distant relapse
previously reported)
Has the patient been diagnosed with first distant
recurrence/progression?
Yes
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No
Site of First Distant Progression (s mark all that
apply)
Bone (Bone)
Lung (Lung)
Lymph Nodes (Lymph nodes)
None (None)
Other Specify (Other)
Other specify
Date of First Distant Progression (leave blank if
distant relapse previously reported)
Head & Neck: Notice Of New Primary
Has a new primary cancer or MDS been
diagnosed that has not been previously reported?
(myelodysplastic syndrome)
Yes
No
Is this a Second primary in the Upper Aero-
digestive Tract? (If yes,)
Yes
No
Site of New Primary (If new primary site is
AML/MDS, please submit NCI AML/MDS form.)
Date of Diagnosis (If new primary site is
AML/MDS, please submit NCI AML/MDS form.)
Head & Neck: New Adverse Events
Has the patient experienced (prior to diagnosis of
recurrence or second primary) any severe (Grade
>=3), long term toxicity that has not been
previously reported
No (No)
Unknown (Unknown)
Yes (Yes)
CTC Adverse Event Term
CTC Adverse Event Grade
Head & Neck: Long-term Functional
Assessment
Does the patient currently have swallowing
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problems?
No (No)
Unknown (Unknown)
Yes (Yes)
How long have swallowing problems been
present? (If yes,)
1 To <7 Months (1 to <7 months)
13 To <19 Months (13 to <19 months)
19 To <24 Months (19 to <24 months)
2 Years Or Longer (2 years or longer)
7 To <13 Months (7 to <13 months)
Less Than 1 Month (Less than 1 month)
Unknown (Unknown)
Does the patient currently require tube feeding?
No (No)
Unknown (Unknown)
Yes (Yes)
Is patient dependent on tube feeding for >50% of
nutritional support? (If yes,)
No (No)
Unknown (Unknown)
Yes (Yes)
Was a feeding tube inserted during this reporting
period? (including CTC event dysphagia >=
grade 3)
No (No)
Unknown (Unknown)
Yes (Yes)
Was a feeding tube discontinued during this
reporting period?
No (No)
Unknown (Unknown)
Yes (Yes)
Date Feeding Tube Discontinued (If yes,)
Was a tracheostomy performed during this
reporting period? (e.g., for breathing difficulty)
No (No)
Unknown (Unknown)
Yes (Yes)
Was use of a tracheostomy discontinued during
this reporting period?
No (No)
Not Applicable (Not applicable)
Yes (Yes)
Date Tracheostomy was Closed (If yes,)
Normalcy of Diet Rating (Ask the patient what
kinds of foods are difficult for him/her to eat.
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Begin at the low end of the scale. Move up the
scale, giving examples of foods in each category
and asking patient if s/he can eat those food
items. The patient's score is the highest )
0= Non-oral Feeding (tube Fed) (0)
10= Cold Liquids (10)
100= Full Diet (no Restrictions) (100)
20= Warm Liquids (20)
30= Pureed Foods (in Blender) (30)
40= Soft Foods Requiring No Chewing
(e.g., Mashed Potatoes, Apple Sauce,
Pudding) (40)
50= Soft, Chewable Foods (e.g.,
Macaroni, Canned/soft Fruits, Cooked
Vegetables, Fish, Hamburger, Small
Pieces Of Meat) (50)
60= Dry Bread And Crackers (60)
70= Raw Carrots, Celery (70)
80= All Meat (80)
90= Full Diet (liquid Assist) (90)
Public Eating Rating (Ask the patient where s/he
eats, with whom s/he eats, and whether s/he
alters his/her diet according to where s/he is
eating. Choose the score that best fits the
patient.)
0= Always Eats Alone (0)
100= No Restriction Of Place, Food Or
Companion (eats Out At Any
Opportunity) (100)
25= Eats Only At Home In Presence Of
Selected Persons (25)
50= Eats Only In Presence Of Selected
Persons In Selected Places (50)
75= No Restriction Of Place, But
Restricts Diet When In Public (eats
Anywhere, But May Limit Intake To Less
"messy" Foods, E.g., Liquids) (75)
Understandability of Speech Rating (Score based
on the interviewer's ability to understand the
patient during conversation. Choose the score
that best fits the patient.)
0= Never Understandable; May Use
Written Communication (0)
100= Always Understandable (100)
25= Difficult To Understand (25)
50= Usually Understandable; Face-to-
face Contact Necessary (50)
75= Understandable Most Of The Time;
Occasional Repetition Necessary (75)
Head & Neck: Off-protocol Treatment
Was any off-protocol therapy given after
completion of protocol treatment?
Yes
No
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Off-Protocol Surgery
Yes
No
Yes specify
Off-Protocol Chemotherapy
Yes
No
Yes specify
Off-Protocol Immunotherapy
Yes
No
Yes specify
Off-Protocol Radiation Therapy
Yes
No
Yes specify
Off-Protocol Complementary and Alternative
Medications (CAM)
Yes
No
Yes specify
Other Off-Protocol Therapy
Yes
No
Name of Other Off-Protocol Therapy (If yes,)
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Follow-Up - Phase II Lung Cancer - Localized
Disease Follow-Up Form - 2402852v1.0
Phase II Consortium Phase II Lung Cancer - Localized
Disease Follow-Up Form
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=00212490-
27A3-4F0A-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/7138
Phase II Lung Cancer - Localized
Disease Follow-Up Form
Crf Header
Coordinating Group Protocol No.
Coordinating Group Code
Protocol Title
Patient Study ID
Registering Group Code
Patient Medical Record Number
Other Patient ID
Institution/Affiliate
Registering Institution Code
Physician of Record
Form Administration
Person Completing Form
Date Form Completed (MM DD YYYY)
Are data amended (If data are amended, please
circle in red when using paper form)
Yes
No
Lung: Pre-treatment Characteristics
Patient's Vital Status
Alive (Alive)
1 / 4
Dead (Dead)
Primary Cause of Death
Due To Other Cause (Due to other
cause)
Due To Protocol Treatment (Due to
protocol treatment)
Due To This Disease (Due to this
disease)
Unknown (Unknown)
Describe cause of death
Date of Last Contact or Death (MM DD YYYY)
Lung: Disease Follow-up Status
Has the patient had a documented clinical
assessment for this cancer? (since submission of
the previous follow-up form)
No (No)
Unknown (Unknown)
Yes (Yes)
Date of Last Clinical Assessment (If yes, MM DD
YYYY)
Lung: Notice Of Progression/site
Has the patient developed a first progression (or
relapse) that has not been previously reported?
Yes
No
Date of Progression (MM DD YYYY)
Sites of progression (check all that apply)
Adrenal Gland (Adrenals)
Bone (Bone)
Brain (Brain)
Central Nervous System (CNS
(excluding Brain))
Distant Lymph Nodes (Distant lymph
nodes)
Distant Skin/subcutaneous Tissue
(Distant skin/subcutaneous tissue)
Liver (Liver)
Lung (Lung)
Other (Other)
Pleura (Pleura)
Regional Lymph Nodes (Regional lymph
nodes)
Other specify
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Follow-Up - Phase II Lung Cancer - Localized Disease Follow-Up Form -
2402852v1.0
Disease Progression Site was within Radiation
Portal (use only for protocols with radiation
therapy)
Yes
No
Disease Progression Site was outside Radiation
Portal (use only for protocols with radiation
therapy)
Yes
No
Lung: Subsequent Non-protocol Therapy
Is the patient receiving any non-protocol cancer
therapy not previously reported?
Yes
No
Non-Protocol Therapy Type
Biologic Response Modifier (Biologic
Response Modifier)
Chemotherapy (Chemotherapy)
High-dose Chemotherapy/autologous
Stem Cell Transplant (High-dose
chemotherapy/autologous stem cell
transplant)
Hormonal Therapy (Hormonal Therapy)
Immunotherapy (Immunotherapy)
Other Non-protocol Therapy (Other non-
protocol therapy)
Radiation Therapy (Radiation therapy)
Surgery (Surgery)
Name of Other Non-Protocol Therapy (If yes,)
Date of First Non-Protocol Therapy (MM DD
YYYY)
Lung: Notice Of New Primary
Has a new primary cancer or MDS been
diagnosed that has not been previously reported?
(myelodysplastic syndrome)
No (No)
Unknown (Unknown)
Yes (Yes)
Date of diagnosis (MM DD YYYY)
Site of New Primary (s If new primary site is
AML/MDS, please submit NCI AML/MDS form.)
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Follow-Up - Phase II Lung Cancer - Localized Disease Follow-Up Form -
2402852v1.0
Lung: Long-term Toxicity
Has the patient experienced (prior to diagnosis of
recurrence or second primary) any severe (Grade
>=3), long term toxicity that has not been
previously reported
No (No)
Unknown (Unknown)
Yes (Yes)
Late Adverse Event Term
Late Adverse Event Grade
Late Adverse Event Attribution Code
Late Adverse Event Onset Date (MM DD YYYY)
Comments
Comments
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Follow-Up - Phase II Lung Cancer - Localized Disease Follow-Up Form -
2402852v1.0
Follow-Up - Phase II Lung Cancer - Follow-Up
Solid Tumor Evaluation Form - 2401677v1.0
Phase II Consortium - Phase II Lung Cancer - Follow-Up
Solid Tumor Evaluation Form
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=FFBA2B4C-
A468-079E-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/7139
Phase II Lung Cancer - Follow-Up
Solid Tumor Evaluation Form
Crf Header
Coordinating Group Protocol No.
Coordinating Group Code
Protocol Title
Patient Study ID
Registering Group Code
Patient Medical Record Number
Other Patient ID
Institution/Affiliate
Registering Institution Code
Physician of Record
Lung: Adverse Events
Person Completing Form
Date Form Completed (MM DD YYYY)
Are data amended (If data are amended, please
circle in red when using paper form)
Yes
No
Cycle Number
Date of Last Clinical Assessment (MM DD YYYY)
1 / 4
Target Lesion(s) Baseline Evaluation
Are there any target lesions?
Yes
No
Lesion Number
Target Lesion Site
Date of Evaluation (MM DD YYYY)
Method of Evaluation
Bone Scan (Bone scan)
Chest X-ray (Chest x-ray)
Clinical Examination (pe) (Clinical
examination)
Ct Scan (CT scan)
Cytology (Cytology)
Mri (MRI (NMR))
Other (Other)
Spiral Ct Scan (Spiral CT scan)
Ultrasound (Ultrasound)
Longest Diameter of Lesion(s) (cm)
Sum of Longest Diameters of All Target Lesions
(cm)
Nontarget Lesion(s) Baseline Evaluation
Are there any nontarget lesions?
Yes
No
Lesion Number
Nontarget Lesion Site
Date of Evaluation (MM DD YYYY)
Method of Evaluation
Bone Scan (Bone scan)
Chest X-ray (Chest x-ray)
Clinical Examination (pe) (Clinical
examination)
Ct Scan (CT scan)
Cytology (Cytology)
Mri (MRI (NMR))
Other (Other)
Spiral Ct Scan (Spiral CT scan)
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Follow-Up - Phase II Lung Cancer - Follow-Up Solid Tumor Evaluation
Form - 2401677v1.0
Ultrasound (Ultrasound)
Other Specify (If)
New Lesion(s) At Follow-up Evaluation
Is there symptomatic deterioration of the patient's
health status (requiring discontinuation of
treatment)
Yes
No
Specify symptomatic deterioration
Lesion Number
Was the appearance of any new lesions
documented (since the baseline evaluation)
Yes
No
Date of Evaluation (MM DD YYYY)
New Lesion Site
Method of Evaluation
Bone Scan (Bone scan)
Chest X-ray (Chest x-ray)
Clinical Examination (pe) (Clinical
examination)
Ct Scan (CT scan)
Cytology (Cytology)
Mri (MRI (NMR))
Other (Other)
Spiral Ct Scan (Spiral CT scan)
Ultrasound (Ultrasound)
Other Specify (If)
Evaluation Summary
Overall Response Status at This Assessment
(mark one)
Complete Response (CR)
Death Prior To Completion Of Protocol
Criteria (Early death)
Insufficient Evaluation (Insufficient
evaluation to determine response status)
Progressive Disease (PD)
Partial Response (PR)
Stable Disease (SD)
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Follow-Up - Phase II Lung Cancer - Follow-Up Solid Tumor Evaluation
Form - 2401677v1.0
Comments
Comments
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Follow-Up - Phase II Lung Cancer - Follow-Up Solid Tumor Evaluation
Form - 2401677v1.0
Response - Phase II Breast Cancer - Baseline
Solid Tumor Evaluation Form - 2550519v1.0
Phase II Breast Cancer - Baseline Solid Tumor Evaluation
Form
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=23E4B808-
D135-56BC-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/7154
Phase II Breast Cancer - Baseline
Solid Tumor Evaluation Form
Crf Header
Coordinating Group Protocol No.
Coordinating Group Code
Protocol Title
Patient Study ID
Registering Group Code
Patient Medical Record Number
Other Patient ID
Institution/Affiliate
Registering Institution Code
Physician of Record
Lung: Adverse Events
Person Completing Form
Date Form Completed
Are data amended (If data are amended, please
circle in red when using paper form)
Yes
No
Target Lesion(s) Baseline Evaluation
Are there any target lesions?
Yes
1 / 3
No
Lesion Site Number
Target Lesion Site
Date of Evaluation
Method of Evaluation
Bone Scan (Bone scan)
Chest X-ray (Chest x-ray)
Clinical Examination (pe) (Clinical
examination)
Ct Scan (CT scan)
Cytology (Cytology)
Mri (MRI (NMR))
Other (Other)
Spiral Ct Scan (Spiral CT scan)
Ultrasound (Ultrasound)
Other Specify
Longest Diameter of Lesion(s)
Sum of Longest Diameters of All Target Lesions
Nontarget Lesion(s) Baseline Evaluation
Are there any nontarget lesions?
Yes
No
Lesion Site Number
Nontarget Lesion Site
Date of Evaluation
Method of Evaluation
Bone Scan (Bone scan)
Chest X-ray (Chest x-ray)
Clinical Examination (pe) (Clinical
examination)
Ct Scan (CT scan)
Cytology (Cytology)
Mri (MRI (NMR))
Other (Other)
Spiral Ct Scan (Spiral CT scan)
Ultrasound (Ultrasound)
Other Specify
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Response - Phase II Breast Cancer - Baseline Solid Tumor Evaluation
Form - 2550519v1.0
Comments
Comments
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Response - Phase II Breast Cancer - Baseline Solid Tumor Evaluation
Form - 2550519v1.0
Response - PHASE II LUNG CANCER ¿ BASELINE
SOLID TUMOR EVALUATION FORM - 2400961v1.0
Phase II Consortium - PHASE II LUNG CANCER -
BASELINE SOLID TUMOR EVALUATION FORM
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=FFA78C21-
8B29-096C-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/7155
PHASE II LUNG CANCER ¿
BASELINE SOLID TUMOR
EVALUATION FORM
Crf Header
Coordinating Group Protocol No.
Coordinating Group Code
Protocol Title
Patient Study ID
Registering Group Code
Patient Medical Record Number
Other Patient ID
Institution/Affiliate
Registering Institution Code
Physician of Record
Lung: Adverse Events
Person Completing Form
Date Form Completed
Are data amended (If data are amended, please
circle in red when using paper form)
Yes
No
Target Lesion(s) Baseline Evaluation
Are there any target lesions?
Yes
1 / 3
No
Lesion Site Number
Target Lesion Site
Date of Evaluation
Method of Evaluation
Bone Scan (Bone scan)
Chest X-ray (Chest x-ray)
Clinical Examination (pe) (Clinical
examination)
Ct Scan (CT scan)
Cytology (Cytology)
Mri (MRI (NMR))
Other (Other)
Spiral Ct Scan (Spiral CT scan)
Ultrasound (Ultrasound)
Other Specify
Longest Diameter of Lesion(s)
Sum of Longest Diameters of All Target Lesions
Nontarget Lesion(s) Baseline Evaluation
Are there any nontarget lesions?
Yes
No
Lesion Site Number
Nontarget Lesion Site
Date of Evaluation
Method of Evaluation
Bone Scan (Bone scan)
Chest X-ray (Chest x-ray)
Clinical Examination (pe) (Clinical
examination)
Ct Scan (CT scan)
Cytology (Cytology)
Mri (MRI (NMR))
Other (Other)
Spiral Ct Scan (Spiral CT scan)
Ultrasound (Ultrasound)
Other Specify
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Response - PHASE II LUNG CANCER ¿ BASELINE SOLID TUMOR
EVALUATION FORM - 2400961v1.0
Comments
Comments
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Response - PHASE II LUNG CANCER ¿ BASELINE SOLID TUMOR
EVALUATION FORM - 2400961v1.0
Pathology - Leukemia Pathology Form -
Molecular Parameters - 2019352v3.0
Leukemia Pathology Form - Molecular Parameters
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=1B4D8DDB-
73A4-6BBD-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/7157
Leukemia Pathology Form -
Molecular Parameters
Crf Header
Coordinating Group Protocol No.
Coordinating Group Code
Protocol Title
Patient Study ID
Institution/Affiliate
Other Patient ID
Participating Group Code
Patient Initials
Leukemia/mds: Form Administration
Person Completing Form
Are data amended (If data are amended, please
circle in red when using paper form)
Yes
No
Pathology: Assessment Of Molecular
Parameters
Date of Initial Pathologic Diagnosis (mm dd yyyy
enter test date for first diagnosis of leukemia)
Date Specimen collected (s mm dd yyyy)
Date of Receipt of Specimens ( mm dd yyyy)
Source of Cells used for Analysis
Bone Marrow (Bone marrow)
1 / 3
Cerebrospinal Fluid (Cerebrospinal fluid)
Lymph Node (Lymph node)
Other Specify (Other)
Peripheral Blood (Peripheral blood)
Peritoneal Fluid (Peritoneal fluid)
Pleural Fluid (Pleural fluid)
Soft Tissue Mass (Soft tissue mass)
Other specify
Specimen Condition
Damaged Or Unusable (Damaged or
unusable)
No Specimen Received (No specimen
received)
Usable (Usable)
RT-PCR Marker Type (RT-PCR Polymerase
Chain Reaction for Chimeric Genes)
Aml1-eto Fusion Protein Expression
(AML1/ETO)
Evi1-aml1 Fusion Protein Expression
(AML1/EVI1)
Bcr-abl1 Fusion Protein Expression
(BCR/ABL)
Cbfbeta-myh11 Fusion Protein
Expression (CBF-beta/MYH11)
E2a-pbx1 Fusion Protein Expression
(E2A/PBX1)
Mll-af4 Fusion Protein Expression
(MLL/AF4)
Mll-af9 Fusion Protein Expression
(MLL/AF9)
Plzf-raralpha Fusion Protein Expression
(PLZF/RAR-alpha)
Pml-raralpha Fusion Protein Expression
(PML/RAR-alpha)
Tel-aml1 Fusion Protein Expression
(TEL/AML1)
Specify BCR/ABL transcript (If positive,)
RT-PCR Result
Indeterminate (Indeterminate)
Negative (Negative)
Not Done (Not done)
Positive (Positive)
Marker Type (Mutational Sequence Analysis)
Flt3 Other (FLT3 other)
Flt3/itd (FLT3/ITD)
H-ras (H-RAS)
K-ras (K-RAS)
N-ras (N-RAS)
P53 (p53)
Mutational Sequence Analysis Result
Indeterminate (Indeterminate)
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Pathology - Leukemia Pathology Form - Molecular Parameters -
2019352v3.0
Mutant, Specify (Mutant)
Normal (Normal)
Not Done (Not done)
Mutant specify
Southern/DNA-PCR Marker Type (Southern Blot
Analysis or DNA-PCR)
Bcl-1 (BCL-1)
Bcl-2 (BCL-2)
Igh (IgH)
Mll (MLL)
Myc (MYC)
Tcr (TCR)
Tel (TEL)
Southern Blot/DNA-PCR Result
Germ Line (Germ line)
Indeterminate (Indeterminate)
Not Done (Not done)
Rearranged (Rearranged)
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Pathology - Leukemia Pathology Form - Molecular Parameters -
2019352v3.0
On-Study - Acute Myeloid Leukemia (AML)/Myelodysplastic Syndrome
(MDS) - On-Study Form - Previously Untreated Patients - 2019420v3.0
Acute Myeloid Leukemia (AML)/Myelodysplastic Syndrome
(MDS) - On-Study Form - Previously Untreated Patients
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=1B24E8B9-
F86C-508D-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/7158
Acute Myeloid Leukemia
(AML)/Myelodysplastic Syndrome
(MDS) - On-Study Form - Previously
Untreated Patients
Crf Header
Coordinating Group Protocol No.
Coordinating Group Code
Protocol Title
Patient Study ID
Institution/Affiliate
Other Patient ID
Participating Group Code
Patient Initials
Registration Type
Leukemia/mds: Form Administration
Person Completing Form
Are data amended (If data are amended, please
circle in red when using paper form)
Yes
No
Aml: Disease Description, Previously
Untreated
Date of Initial Pathologic Diagnosis (mm dd yyyy
enter test date for first diagnosis of leukemia)
Leukemia/MDS Classification (*Alternately, the
CDE WHO Diagnosis can be used.)
1 / 5
Disease Classified As Acute
Erythroblastic Leukemia (fab M6) (Acute
erythroblastic leukemia (FAB M6))
Disease Classified As Acute
Megakaryoblastic Leukemia (fab M7)
(Acute megakaryoblastic leukemia (FAB
M7))
Disease Classified As Acute Monocytic
Leukemia (fab M5) (Acute monocytic
leukemia (FAB M5))
Disease Classified As Acute Myeloid
Leukemia W/ Maturation (fab M2) (Acute
myeloid leukemia w/ maturation (FAB
M2))
Disease Classified As Acute Myeloid
Leukemia W/o Maturation (fab M1)
(Acute myeloid leukemia w/o maturation
(FAB M1))
Disease Classified As Acute
Myelomonocytic Leukemia (fab M4)
(Acute myelomonocytic leukemia (FAB
M4))
Disease Classified As Acute
Promyelocytic Leukemia (fab M3) (Acute
promyelocytic leukemia (FAB M3))
Disease Classified As Acute
Undifferentiated Leukemia (aul) (Acute
undifferentiated leukemia (AUL))
Disease Classified As Aml, Not
Otherwise Specified (nos) (AML, not
otherwise specified (NOS))
Disease Classified As Chronic
Myelomonocytic Leukemia (cmml)
(Chronic myelomonocytic leukemia
(CMML))
Disease Is A Mixed Lineage Acute
Leukemia (Mixed lineage acute
leukemia)
Disease Classified As Myelodysplastic
Syndrome (mds) Nos (Myelodysplastic
syndrome (MDS) NOS)
Disease Classified As Myeloproliferative
Syndrome Nos; (Myeloproliferative
syndrome NOS;)
Other (Other)
Disease Classified As Refractory Anemia
(ra) (Refractory anemia (RA))
Disease Classified As Refractory Anemia
W/ Excess Blasts In Transformation
(raeb-t) (Refractory anemia w/ excess
blasts in transformation (RAEB-t))
Disease Classified As Refractory Anemia
W/ Ring Sideroblasts (rars) (Refractory
anemia w/ ring sideroblasts (RARS))
Disease Classified As Refractory Anemia
W/excess Blasts (raeb) (Refractory
anemia w/excess blasts (RAEB))
Disease Is An Unclassifiable Acute
Leukemia (Unclassifiable acute
leukemia)
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On-Study - Acute Myeloid Leukemia (AML)/Myelodysplastic Syndrome
(MDS) - On-Study Form - Previously Untreated Patients - 2019420v3.0
Disease Classified As Undifferentiated
Acute Myeloid Leukemia (fab M0)
(Undifferentiated acute myeloid leukemia
(FAB M0))
Other specify
Date Hematology (Blood) Sample Obtained
(Peripheral Blood mm dd yyyy)
White Blood Cell Count (x 10^3/mcL)
Peripheral Neutrophils/Bands (%)
Peripheral Blasts (%)
Date of Bone Marrow Biopsy (Bone Marrow
Biopsy/Aspirate mm dd yyyy)
Marrow Cellularity (%)
Marrow Blasts (%)
Marrow Cellularity Status
Cellularity Status Of Bone Marrow Is
Aplasitc (severely Hypocellular) (Aplastic
(severely hypocellular))
Cellularity Status Of Bone Marrow
Unknown, Procedure Resulted In No
Material To Analyze (Dry tap or
inaspirable)
Cellularity Status Of Bone Marrow Is
Hypercellular (Hypercellular)
Cellularity Status Of Bone Marrow Is
Hypocellular (Hypocellular)
Cellularity Status Of Bone Marrow Is
Normocellular (Normocellular)
Cellularity Status Of Bone Marrow Is
Packed (intensely Hypercellular) (Packed
(intensely hypercellular))
Extramedullary Disease Involvement (check all
that apply)
Central Nervous System (Central
nervous system)
Granulocytic Sarcoma (Chloroma)
Gingival Hypertrophy (Gingival
hypertrophy)
Other Specify (Other)
Leukaemia Cutis (Skin (leukemia cutis))
Other specify
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On-Study - Acute Myeloid Leukemia (AML)/Myelodysplastic Syndrome
(MDS) - On-Study Form - Previously Untreated Patients - 2019420v3.0
Palpable splenomegaly (Organ Involvement)
Examination Performed And
Splenomegaly Absent (No)
Examination Of Spleen Not Performed
(Not examined)
Spleen Removed Via Prior Surgery
(Surgically absent)
Examination Performed And
Splenomegaly Present (Yes)
Splenomegaly by scan (or x-ray)
Examination Performed And
Splenomegaly Absent (No)
Examination Of Spleen Not Performed
(Not examined)
Spleen Removed Via Prior Surgery
(Surgically absent)
Examination Performed And
Splenomegaly Present (Yes)
Palpable hepatomegaly
Examination Performed And
Hepatomegaly Absent (No)
Examination Of Liver Not Performed (Not
examined)
Examination Performed And
Hepatomegaly Present (Yes)
Hepatomegaly by scan (or x-ray)
Examination Performed And
Hepatomegaly Absent (No)
Examination Of Liver Not Performed (Not
examined)
Examination Performed And
Hepatomegaly Present (Yes)
Palpable lymphadenopathy
Examination Performed And
Lymphadenopathy Absent (No)
Examination Of Lymph Nodes Not
Performed (Not examined)
Examination Performed And
Lymphadenopathy Present (Yes)
Lymphadenopathy by scan (or x-ray)
Examination Performed And
Lymphadenopathy Absent (No)
Examination Of Lymph Nodes Not
Performed (Not examined)
Examination Performed And
Lymphadenopathy Present (Yes)
Clinical Onset of AML (-OR- answer only one)
Aml Without Prior Clinical History Of Mds
Or Potentially Leukemogenic Treatment
(de novo)
Aml Related To/associated With Prior
Clinical History Of Mds (MDS-related)
Aml Related To/associated With Prior
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On-Study - Acute Myeloid Leukemia (AML)/Myelodysplastic Syndrome
(MDS) - On-Study Form - Previously Untreated Patients - 2019420v3.0
Clinical History Of Potentially
Leukemogenic Treatment (Treatment
related)
Clinical Onset of MDS
Mds Without Prior Clinical History Of
Potentially Inducing Therapy (de novo)
Mds Related To/asscoiated With Prior
Clinical History Of Potentially Inducing
Therapy (Treatment related)
Allows Documentation Of Any Additional
Cooments
Comments
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On-Study - Acute Myeloid Leukemia (AML)/Myelodysplastic Syndrome
(MDS) - On-Study Form - Previously Untreated Patients - 2019420v3.0
On-Study - Chronic Lymphocytic Leukemia (CLL) - On-
Study Form - Previously Untreated Patients - 2019400v3.0
Chronic Lymphocytic Leukemia (CLL) - On-Study Form -
Previously Untreated Patients
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=1B4E5764-
C41B-6674-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/7160
Chronic Lymphocytic Leukemia
(CLL) - On-Study Form - Previously
Untreated Patients
Crf Header
Coordinating Group Protocol No.
Coordinating Group Code
Protocol Title
Patient Study ID
Institution/Affiliate
Other Patient ID
Participating Group Code
Patient Initials
Registration Type
Leukemia/mds: Form Administration
Person Completing Form
Are data amended (If data are amended, please
circle in red when using paper form)
Yes
No
Aml: Disease Description, Previously
Untreated
Date of Initial Pathologic Diagnosis (mm dd yyyy
enter test date for first diagnosis of leukemia)
Rai Stage Classification
Lymphocytosis In Blood With
1 / 4
Lymphocyte Count > 15,000/mcl And
Bone Marrow Populated With Mature
Lymphocytes Comprising >40% Of
Nucleated Cells (Stage 0)
Same As Stage 0 With
Lymphadenopathy (Stage I)
Includes Same Degree Of
Lymphocytosis As Stage 0, Plus
Enlarged Spleen And/or Liver (Stage II)
Includes Lymphocytosis And Anemia
Defined As Hgb <11 G/dl Or Hct <33%.
Physical Findings Of Lymphadenopathy,
Hepatomegaly Or Splenomegaly Are Not
Required. No Distinction With Regard To
Type Of Anemia (i.e. Hemolytic) Is Made
(Stage III)
Includes The Findings At Diagnosis Of
Lymphocytosis As Defined In Stage 0,
With Thrombocytopenia <100,000/mcl.
Anemia And Organomegaly May Be
Absent. (Stage IV)
Date Hematology (Blood) Sample Obtained
(Peripheral Blood mm dd yyyy)
White Blood Cell Count (x 10^3/mcL)
Peripheral Platelet Count (x 10^3/mcL)
Hemoglobin (g/dl)
Peripheral Lymphocytes (%)
Peripheral Prolymphocytes (%)
Peripheral Atypical Lymphocytes (%)
Date of Bone Marrow Biopsy (Bone Marrow
Biopsy/Aspirate mm dd yyyy)
Marrow Cellularity (%)
Marrow Lymphocytes (%)
Marrow Cellularity Status
Cellularity Status Of Bone Marrow Is
Aplasitc (severely Hypocellular) (Aplastic
(severely hypocellular))
Cellularity Status Of Bone Marrow
Unknown, Procedure Resulted In No
Material To Analyze (Dry tap or
inaspirable)
Cellularity Status Of Bone Marrow Is
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On-Study - Chronic Lymphocytic Leukemia (CLL) - On-Study Form -
Previously Untreated Patients - 2019400v3.0
Hypercellular (Hypercellular)
Cellularity Status Of Bone Marrow Is
Hypocellular (Hypocellular)
Cellularity Status Of Bone Marrow Is
Normocellular (Normocellular)
Cellularity Status Of Bone Marrow Is
Packed (intensely Hypercellular) (Packed
(intensely hypercellular))
Palpable splenomegaly (Organ Involvement)
Examination Performed And
Splenomegaly Absent (No)
Examination Of Spleen Not Performed
(Not examined)
Spleen Removed Via Prior Surgery
(Surgically absent)
Examination Performed And
Splenomegaly Present (Yes)
Splenomegaly by scan (or x-ray)
Examination Performed And
Splenomegaly Absent (No)
Examination Of Spleen Not Performed
(Not examined)
Spleen Removed Via Prior Surgery
(Surgically absent)
Examination Performed And
Splenomegaly Present (Yes)
Palpable hepatomegaly
Examination Performed And
Hepatomegaly Absent (No)
Examination Of Liver Not Performed (Not
examined)
Examination Performed And
Hepatomegaly Present (Yes)
Hepatomegaly by scan (or x-ray)
Examination Performed And
Hepatomegaly Absent (No)
Examination Of Liver Not Performed (Not
examined)
Examination Performed And
Hepatomegaly Present (Yes)
Palpable lymphadenopathy
Examination Performed And
Lymphadenopathy Absent (No)
Examination Of Lymph Nodes Not
Performed (Not examined)
Examination Performed And
Lymphadenopathy Present (Yes)
Lymphadenopathy by scan (or x-ray)
Examination Performed And
Lymphadenopathy Absent (No)
Examination Of Lymph Nodes Not
Performed (Not examined)
Examination Performed And
Lymphadenopathy Present (Yes)
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On-Study - Chronic Lymphocytic Leukemia (CLL) - On-Study Form -
Previously Untreated Patients - 2019400v3.0
Immunophenotype Lineage
B-cell Immunophenotype (B-cell)
Other Specified Immunophenotype
(Other)
T-cell Immunophenotype (T-cell)
Other specify
Allows Documentation Of Any Additional
Cooments
Comments
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On-Study - Chronic Lymphocytic Leukemia (CLL) - On-Study Form -
Previously Untreated Patients - 2019400v3.0
On-Study - Acute Myeloid Leukemia (AML) - On-Study
Form - Previously Untreated Patients - 2019404v4.0
Acute Myeloid Leukemia (AML) - On-Study Form -
Previously Untreated Patients
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=8D071CA6-
C045-F391-E040-BB89AD4376C0
All rights reserved. Please visit https://medical-data-
models.org/forms/7164
Acute Myeloid Leukemia (AML) - On-
Study Form - Previously Untreated
Patients
Crf Header
Coordinating Group Protocol No.
Coordinating Group Code
Protocol Title
Patient Study ID
Institution/Affiliate
Other Patient ID
Participating Group Code
Patient Initials
Registration Type
Leukemia/mds: Form Administration
Person Completing Form
Are data amended (If data are amended, please
circle in red when using paper form)
Yes
No
Aml: Disease Description, Previously
Untreated
Date of Initial Pathologic Diagnosis (mm dd yyyy
enter test date for first diagnosis of leukemia)
Leukemia/MDS Classification (*Alternately, the
CDE WHO Diagnosis can be used.)
1 / 4
Disease Classified As Acute
Erythroblastic Leukemia (fab M6) (Acute
erythroblastic leukemia (FAB M6))
Disease Classified As Acute
Megakaryoblastic Leukemia (fab M7)
(Acute megakaryoblastic leukemia (FAB
M7))
Disease Classified As Acute Monocytic
Leukemia (fab M5) (Acute monocytic
leukemia (FAB M5))
Disease Classified As Acute Myeloid
Leukemia W/ Maturation (fab M2) (Acute
myeloid leukemia w/ maturation (FAB
M2))
Disease Classified As Acute Myeloid
Leukemia W/o Maturation (fab M1)
(Acute myeloid leukemia w/o maturation
(FAB M1))
Disease Classified As Acute
Myelomonocytic Leukemia (fab M4)
(Acute myelomonocytic leukemia (FAB
M4))
Disease Classified As Acute
Promyelocytic Leukemia (fab M3) (Acute
promyelocytic leukemia (FAB M3))
Disease Classified As Acute
Undifferentiated Leukemia (aul) (Acute
undifferentiated leukemia (AUL))
Disease Classified As Aml, Not
Otherwise Specified (nos) (AML, not
otherwise specified (NOS))
Disease Is A Mixed Lineage Acute
Leukemia (Mixed lineage acute
leukemia)
Other (Other)
Disease Is An Unclassifiable Acute
Leukemia (Unclassifiable acute
leukemia)
Disease Classified As Undifferentiated
Acute Myeloid Leukemia (fab M0)
(Undifferentiated acute myeloid leukemia
(FAB M0))
Other specify
Date Hematology (Blood) Sample Obtained
(Peripheral Blood mm dd yyyy)
White Blood Cell Count (x 10^3/mcL)
Peripheral Neutrophils/Bands (%)
Peripheral Blasts (%)
Date of Bone Marrow Biopsy (Bone Marrow
Biopsy/Aspirate mm dd yyyy)
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Marrow Cellularity (%)
Marrow Blasts (%)
Marrow Cellularity Status
Cellularity Status Of Bone Marrow Is
Aplasitc (severely Hypocellular) (Aplastic
(severely hypocellular))
Cellularity Status Of Bone Marrow
Unknown, Procedure Resulted In No
Material To Analyze (Dry tap or
inaspirable)
Cellularity Status Of Bone Marrow Is
Hypercellular (Hypercellular)
Cellularity Status Of Bone Marrow Is
Hypocellular (Hypocellular)
Cellularity Status Of Bone Marrow Is
Normocellular (Normocellular)
Cellularity Status Of Bone Marrow Is
Packed (intensely Hypercellular) (Packed
(intensely hypercellular))
Extramedullary Disease Involvement (check all
that apply)
Central Nervous System (Central
nervous system)
Granulocytic Sarcoma (Chloroma)
Gingival Hypertrophy (Gingival
hypertrophy)
Other Specify (Other)
Leukaemia Cutis (Skin (leukemia cutis))
Other specify
Palpable splenomegaly (Organ Involvement)
Examination Performed And
Splenomegaly Absent (No)
Examination Of Spleen Not Performed
(Not examined)
Spleen Removed Via Prior Surgery
(Surgically absent)
Examination Performed And
Splenomegaly Present (Yes)
Splenomegaly by scan (or x-ray)
Examination Performed And
Splenomegaly Absent (No)
Examination Of Spleen Not Performed
(Not examined)
Spleen Removed Via Prior Surgery
(Surgically absent)
Examination Performed And
Splenomegaly Present (Yes)
Palpable hepatomegaly
Examination Performed And
Hepatomegaly Absent (No)
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Examination Of Liver Not Performed (Not
examined)
Examination Performed And
Hepatomegaly Present (Yes)
Hepatomegaly by scan (or x-ray)
Examination Performed And
Hepatomegaly Absent (No)
Examination Of Liver Not Performed (Not
examined)
Examination Performed And
Hepatomegaly Present (Yes)
Palpable lymphadenopathy
Examination Performed And
Lymphadenopathy Absent (No)
Examination Of Lymph Nodes Not
Performed (Not examined)
Examination Performed And
Lymphadenopathy Present (Yes)
Lymphadenopathy by scan (or x-ray)
Examination Performed And
Lymphadenopathy Absent (No)
Examination Of Lymph Nodes Not
Performed (Not examined)
Examination Performed And
Lymphadenopathy Present (Yes)
Clinical Onset of AML
Aml Without Prior Clinical History Of Mds
Or Potentially Leukemogenic Treatment
(de novo)
Aml Related To/associated With Prior
Clinical History Of Mds (MDS-related)
Aml Related To/associated With Prior
Clinical History Of Potentially
Leukemogenic Treatment (Treatment
related)
Allows Documentation Of Any Additional
Cooments
Comments
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On-Study - Chronic Myelogenous Leukemia (CML) - On-
Study Form - Relapse/Refractory Treatment - 2019358v3.0
Chronic Myelogenous Leukemia (CML) - On-Study Form -
Relapse/Refractory Treatment
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=1B4E680F-
053F-67CD-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/7167
Chronic Myelogenous Leukemia
(CML) - On-Study Form -
Relapse/Refractory Treatment
Crf Header
Coordinating Group Protocol No.
Coordinating Group Code
Protocol Title
Patient Study ID
Institution/Affiliate
Other Patient ID
Participating Group Code
Patient Initials
Registration Type
Leukemia/mds: Form Administration
Person Completing Form
Are data amended (If data are amended, please
circle in red when using paper form)
Yes
No
Aml: Disease Description, Previously
Untreated
Leukemia Classification (*Alternately, the CDE
WHO Diagnosis can be used.)
Disease Classified As Chronic
Myelogenous Leukemia (cml),
Accelerating Phase; (Chronic
myelogenous leukemia (CML),
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accelerating phase)
Disease Classified As Chronic
Myelogenous Leukemia (cml), Chronic
Phase (Chronic myelogenous leukemia
(CML), chronic phase)
Disease Classified As Chronic
Myelogenous Leukemia, (cml), Blast
Crisis (Chronic myelogenous leukemia,
(CML), blast crisis)
Disease Classified As Cml, Not
Otherwise Specified (nos); (CML, not
otherwise specified (NOS))
Other (Other)
Other specify
CML Lineage
Lymphoid (Lymphoid)
Myeloid (Myeloid)
Not Otherwise Specified: C19594 (Not
otherwise specified)
Other (Other)
Unknown (Unknown)
Other specify
Disease Status
Other, Specify (Other)
Refractory (refractory NOS)
Refractory To First Induction (Refractory
to 1st induction)
Refractory To Reinduction After
Complete Response (Refractory to
reinduction after CR)
Relapse (relapse NOS)
First Relapse (Relapse: 1st)
Second Relapse (Relapse: 2nd)
Third Or Greater Relapse (Relapse:
3rd+)
Other specify
What was the duration of the preceding
response? (For relapsed ALL,)
Duration Of Response Less Than 6
Months (< 6 months)
Duration Of Response Greater Than Or
Equal To 6 Months (> or = 6 months)
Duration Of Response Unknown
(Unknown)
Date Hematology (Blood) Sample Obtained
(Peripheral Blood mm dd yyyy)
White Blood Cell Count (x 10^3/mcL)
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Peripheral Platelet Count (x 10^3/mcL)
Peripheral Neutrophils/Bands (%)
Peripheral Blasts (%)
Date of Bone Marrow Biopsy (Bone Marrow
Biopsy/Aspirate mm dd yyyy)
Marrow Cellularity (%)
Marrow Blasts (%)
Marrow Cellularity Status
Cellularity Status Of Bone Marrow Is
Aplasitc (severely Hypocellular) (Aplastic
(severely hypocellular))
Cellularity Status Of Bone Marrow
Unknown, Procedure Resulted In No
Material To Analyze (Dry tap or
inaspirable)
Cellularity Status Of Bone Marrow Is
Hypercellular (Hypercellular)
Cellularity Status Of Bone Marrow Is
Hypocellular (Hypocellular)
Cellularity Status Of Bone Marrow Is
Normocellular (Normocellular)
Cellularity Status Of Bone Marrow Is
Packed (intensely Hypercellular) (Packed
(intensely hypercellular))
Prior Treatment? (for CML)
Yes
No
Yes specify (If)
Allows Documentation Of Any Additional
Cooments
Comments
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On-Study - Chronic Myelogenous Leukemia (CML) - On-Study Form -
Relapse/Refractory Treatment - 2019358v3.0
On-Study - Hairy Cell Leukemia (HCL) - On-Study
Form - Relapse/Refractory Treatment - 2019360v3.0
Hairy Cell Leukemia (HCL) - On-Study Form -
Relapse/Refractory Treatment
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=1B4E70DB-
BC4A-6870-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/7168
Hairy Cell Leukemia (HCL) - On-
Study Form - Relapse/Refractory
Treatment
Crf Header
Coordinating Group Protocol No.
Coordinating Group Code
Protocol Title
Patient Study ID
Institution/Affiliate
Other Patient ID
Participating Group Code
Patient Initials
Registration Type
Leukemia/mds: Form Administration
Person Completing Form
Are data amended (If data are amended, please
circle in red when using paper form)
Yes
No
Aml: Disease Description, Previously
Untreated
Disease Status
Other, Specify (Other)
Refractory (refractory NOS)
Refractory To First Induction (Refractory
to 1st induction)
Refractory To Reinduction After
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Complete Response (Refractory to
reinduction after CR)
Relapse (relapse NOS)
First Relapse (Relapse: 1st)
Second Relapse (Relapse: 2nd)
Third Or Greater Relapse (Relapse:
3rd+)
Other specify
What was the duration of the preceding
response? (For relapsed ALL,)
Duration Of Response Less Than 6
Months (< 6 months)
Duration Of Response Greater Than Or
Equal To 6 Months (> or = 6 months)
Duration Of Response Unknown
(Unknown)
Date Hematology (Blood) Sample Obtained
(Peripheral Blood mm dd yyyy)
White Blood Cell Count (x 10^3/mcL)
Peripheral Hairy cells (%)
Peripheral Monocytes (%)
Date of Bone Marrow Biopsy (Bone Marrow
Biopsy/Aspirate mm dd yyyy)
Marrow Cellularity (%)
Marrow Hairy Cells (%)
Marrow Cellularity Status
Cellularity Status Of Bone Marrow Is
Aplasitc (severely Hypocellular) (Aplastic
(severely hypocellular))
Cellularity Status Of Bone Marrow
Unknown, Procedure Resulted In No
Material To Analyze (Dry tap or
inaspirable)
Cellularity Status Of Bone Marrow Is
Hypercellular (Hypercellular)
Cellularity Status Of Bone Marrow Is
Hypocellular (Hypocellular)
Cellularity Status Of Bone Marrow Is
Normocellular (Normocellular)
Cellularity Status Of Bone Marrow Is
Packed (intensely Hypercellular) (Packed
(intensely hypercellular))
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Relapse/Refractory Treatment - 2019360v3.0
Palpable splenomegaly (Organ Involvement)
Examination Performed And
Splenomegaly Absent (No)
Examination Of Spleen Not Performed
(Not examined)
Spleen Removed Via Prior Surgery
(Surgically absent)
Examination Performed And
Splenomegaly Present (Yes)
Splenomegaly by scan (or x-ray)
Examination Performed And
Splenomegaly Absent (No)
Examination Of Spleen Not Performed
(Not examined)
Spleen Removed Via Prior Surgery
(Surgically absent)
Examination Performed And
Splenomegaly Present (Yes)
Palpable hepatomegaly
Examination Performed And
Hepatomegaly Absent (No)
Examination Of Liver Not Performed (Not
examined)
Examination Performed And
Hepatomegaly Present (Yes)
Hepatomegaly by scan (or x-ray)
Examination Performed And
Hepatomegaly Absent (No)
Examination Of Liver Not Performed (Not
examined)
Examination Performed And
Hepatomegaly Present (Yes)
Palpable lymphadenopathy
Examination Performed And
Lymphadenopathy Absent (No)
Examination Of Lymph Nodes Not
Performed (Not examined)
Examination Performed And
Lymphadenopathy Present (Yes)
Lymphadenopathy by scan (or x-ray)
Examination Performed And
Lymphadenopathy Absent (No)
Examination Of Lymph Nodes Not
Performed (Not examined)
Examination Performed And
Lymphadenopathy Present (Yes)
Prior Treatment of HCL with alpha-interferon?
Yes
No
Allows Documentation Of Any Additional
Cooments
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Comments
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Relapse/Refractory Treatment - 2019360v3.0
On-Study - Acute Promyelocytic Leukemia (APL) - On-
Study Form - Previously Untreated Patients - 2019398v3.0
Acute Promyelocytic Leukemia (APL) - On-Study Form -
Previously Untreated Patients
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=1B24D4C1-
D3EC-4E1F-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/7169
Acute Promyelocytic Leukemia (APL)
- On-Study Form - Previously
Untreated Patients
Crf Header
Coordinating Group Protocol No.
Coordinating Group Code
Protocol Title
Patient Study ID
Institution/Affiliate
Other Patient ID
Participating Group Code
Patient Initials
Registration Type
Leukemia/mds: Form Administration
Person Completing Form
Are data amended (If data are amended, please
circle in red when using paper form)
Yes
No
Aml: Disease Description, Previously
Untreated
Date of Initial Pathologic Diagnosis (mm dd yyyy
enter test date for first diagnosis of leukemia)
Leukemia Classification (*Alternately, the CDE
WHO Diagnosis can be used.)
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Disease Classified As Acute
Promyelocytic Leukemia (fab M3) (Acute
promyelocytic leukemia (FAB M3))
Disease Classified As Acute
Promyelocytic Leukemia-microgranular
(fab M3v) (Acute promyelocytic
leukemia-microgranular (FAB M3V))
Other (Other)
Other specify
Karyotypic t(15:17) translocation positive?
Indeterminate (Indeterminate)
No (No)
Not Done (Not done)
Yes (Yes)
Date Hematology (Blood) Sample Obtained
(Peripheral Blood mm dd yyyy)
White Blood Cell Count (x 10^3/mcL)
Peripheral Neutrophils/Bands (%)
Peripheral Blasts (%)
Peripheral Promyelocytes (%)
Date of Bone Marrow Biopsy (Bone Marrow
Biopsy/Aspirate mm dd yyyy)
Marrow Cellularity (%)
Marrow Promyelocytes (%)
Marrow Blasts (%)
Marrow Cellularity Status
Cellularity Status Of Bone Marrow Is
Aplasitc (severely Hypocellular) (Aplastic
(severely hypocellular))
Cellularity Status Of Bone Marrow
Unknown, Procedure Resulted In No
Material To Analyze (Dry tap or
inaspirable)
Cellularity Status Of Bone Marrow Is
Hypercellular (Hypercellular)
Cellularity Status Of Bone Marrow Is
Hypocellular (Hypocellular)
Cellularity Status Of Bone Marrow Is
Normocellular (Normocellular)
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Cellularity Status Of Bone Marrow Is
Packed (intensely Hypercellular) (Packed
(intensely hypercellular))
Disseminated Intravascular Coagulation (DIC)
Absent (Absent)
Dic Present With Bleeding (Present
WITH bleeding)
Dic Present, Bleeding Absent (Present
with NO bleeding)
Antigen (Antigen Expression)
Cd56 (CD56)
Hla-dr (HLA-DR)
CD56 Positive Cells (%) (If assessed,)
HLA-DR Positive Cells (%)
Allows Documentation Of Any Additional
Cooments
Comments
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On-Study - Acute Promyelocytic Leukemia (APL) - On-Study Form -
Previously Untreated Patients - 2019398v3.0
On-Study - Hairy Cell Leukemia (HCL) - On-Study
Form - Previously Untreated Patients - 2019401v3.0
Hairy Cell Leukemia (HCL) - On-Study Form - Previously
Untreated Patients
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=1B4E6D15-
F366-6825-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/7170
Hairy Cell Leukemia (HCL) - On-
Study Form - Previously Untreated
Patients
Crf Header
Coordinating Group Protocol No.
Coordinating Group Code
Protocol Title
Patient Study ID
Institution/Affiliate
Other Patient ID
Participating Group Code
Patient Initials
Registration Type
Leukemia/mds: Form Administration
Person Completing Form
Are data amended (If data are amended, please
circle in red when using paper form)
Yes
No
Aml: Disease Description, Previously
Untreated
Date of Initial Pathologic Diagnosis (mm dd yyyy
enter test date for first diagnosis of leukemia)
Date Hematology (Blood) Sample Obtained
(Peripheral Blood mm dd yyyy)
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White Blood Cell Count (x 10^3/mcL)
Peripheral Hairy cells (%)
Peripheral Monocytes (%)
Date of Bone Marrow Biopsy (Bone Marrow
Biopsy/Aspirate mm dd yyyy)
Marrow Cellularity (%)
Marrow Hairy Cells (%)
Marrow Cellularity Status
Cellularity Status Of Bone Marrow Is
Aplasitc (severely Hypocellular) (Aplastic
(severely hypocellular))
Cellularity Status Of Bone Marrow
Unknown, Procedure Resulted In No
Material To Analyze (Dry tap or
inaspirable)
Cellularity Status Of Bone Marrow Is
Hypercellular (Hypercellular)
Cellularity Status Of Bone Marrow Is
Hypocellular (Hypocellular)
Cellularity Status Of Bone Marrow Is
Normocellular (Normocellular)
Cellularity Status Of Bone Marrow Is
Packed (intensely Hypercellular) (Packed
(intensely hypercellular))
Palpable splenomegaly (Organ Involvement)
Examination Performed And
Splenomegaly Absent (No)
Examination Of Spleen Not Performed
(Not examined)
Spleen Removed Via Prior Surgery
(Surgically absent)
Examination Performed And
Splenomegaly Present (Yes)
Splenomegaly by scan (or x-ray)
Examination Performed And
Splenomegaly Absent (No)
Examination Of Spleen Not Performed
(Not examined)
Spleen Removed Via Prior Surgery
(Surgically absent)
Examination Performed And
Splenomegaly Present (Yes)
Palpable hepatomegaly
Examination Performed And
Hepatomegaly Absent (No)
Examination Of Liver Not Performed (Not
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examined)
Examination Performed And
Hepatomegaly Present (Yes)
Hepatomegaly by scan (or x-ray)
Examination Performed And
Hepatomegaly Absent (No)
Examination Of Liver Not Performed (Not
examined)
Examination Performed And
Hepatomegaly Present (Yes)
Palpable lymphadenopathy
Examination Performed And
Lymphadenopathy Absent (No)
Examination Of Lymph Nodes Not
Performed (Not examined)
Examination Performed And
Lymphadenopathy Present (Yes)
Lymphadenopathy by scan (or x-ray)
Examination Performed And
Lymphadenopathy Absent (No)
Examination Of Lymph Nodes Not
Performed (Not examined)
Examination Performed And
Lymphadenopathy Present (Yes)
Allows Documentation Of Any Additional
Cooments
Comments
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On-Study - Hairy Cell Leukemia (HCL) - On-Study Form - Previously
Untreated Patients - 2019401v3.0
Pathology - Leukemia Pathology Form -
Immunophenotype - 2019351v3.0
Leukemia Pathology Form - Immunophenotype
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=1B4D88B8-
2F2F-6AB9-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/7172
Leukemia Pathology Form -
Immunophenotype
Crf Header
Coordinating Group Protocol No.
Coordinating Group Code
Protocol Title
Patient Study ID
Institution/Affiliate
Other Patient ID
Participating Group Code
Patient Initials
Leukemia/mds: Form Administration
Person Completing Form
Are data amended (If data are amended, please
circle in red when using paper form)
Yes
No
Pathology: Immunophenotype
Date of Initial Pathologic Diagnosis (mm dd yyyy
enter test date for first diagnosis of leukemia)
Date Specimen collected (s mm dd yyyy)
Date of Receipt of Specimens ( mm dd yyyy)
Source of Cells used for Analysis
Bone Marrow (Bone marrow)
Cerebrospinal Fluid (Cerebrospinal fluid)
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Lymph Node (Lymph node)
Other Specify (Other)
Peripheral Blood (Peripheral blood)
Peritoneal Fluid (Peritoneal fluid)
Pleural Fluid (Pleural fluid)
Soft Tissue Mass (Soft tissue mass)
Other specify
Type of Sample Used for Immunophenotyping
Fresh Cells (Fresh cells)
Other Specify (Other)
Smears (Smears)
Tissue Section (Tissue section)
Other specify
Specimen Condition
Damaged Or Unusable (Damaged or
unusable)
No Specimen Received (No specimen
received)
Usable (Usable)
Procedure Used for Immunophenotyping
Flow Cytometry, 2 Color (Flow cytometry,
2 color)
Flow Cytometry, 3 Color (Flow cytometry,
3 color)
Flow Cytometry, 4 Or More Color (Flow
cytometry, 4 or more color)
Flow Cytometry, Not Otherwise Specified
(Flow cytometry, not otherwise specified)
Immunofluorescence
(Immunofluorescence)
Immunohistochemistry
(Immunohistochemistry)
Other Specify (Other)
Other specify
How were cells prepared for immunophenotyping
Ficoll-isolated Mnc (Ficoll-isolated MNC)
Whole Tissue (Whole tissue)
Antigen (Antigen Expression Note: In preparing
this form for a new protocol, include only those
questions relevant for study evaluation)
Breast Cancer Resistance/mitoxantrone
Resistance Protein (bcrp/mxr) (Breast
cancer resistance/mitoxantrone
resistance protein (BCRP/MXR))
Bromodeoxyuridine (Bromodeoxyuridine)
Cd10 (CD10)
Cd103 (CD103)
Cd117 (CD117)
Cd11a (CD11a)
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Cd11b (CD11b)
Cd11c (CD11c)
Cd13 (CD13)
Cd133 (CD133)
Cd138 (CD138)
Cd14 (CD14)
Cd15 (CD15)
Cd15s (CD15s)
Cd16 (CD16)
Cd19 (CD19)
Cd1a (CD1a)
Cd2 (CD2)
Cd20 (CD20)
Cd22 Intracytoplasmic (CD22
intracytoplasmic)
Cd22 Surface (CD22 surface)
Cd23 (CD23)
Cd24 (CD24)
Cd25 (CD25)
Cd3 Intracytoplasmic (CD3
intracytoplasmic)
Cd3 Surface (CD3 surface)
Cd30 (CD30)
Cd33 (CD33)
Cd34 (CD34)
Cd36 (CD36)
Cd38 (CD38)
Cd4 (CD4)
Cd40 (CD40)
Cd41 (CD41)
Cd42 (CD42)
Cd43 (CD43)
Cd45 (CD45)
Cd5 (CD5)
Cd52 (CD52)
Cd56 (CD56)
Cd57 (CD57)
Cd61 (CD61)
Cd64 (CD64)
Cd7 (CD7)
Cd71 (CD71)
Cd79a Intracytoplasmic (CD79a
intracytoplasmic)
Cd79a Surface (CD79a surface)
Cd79b Intracytoplasmic (CD79b
intracytoplasmic)
Cd79b Surface (CD79b surface)
Cd8 (CD8)
Glycophorin (Glycophorin)
Ig-kappa Intracytoplasmic (Ig-kappa
intracytoplasmic)
Ig-kappa Surface (Ig-kappa surface)
Ig-lambda Intracytoplasmic (Ig-lambda
intracytoplasmic)
Ig-lambda Surface (Ig-lambda surface)
Iga Surface (IgA surface)
Igd Surface (IgD surface)
Igg Surface (IgG surface)
Igm Intracytoplasmic (IgM
intracytoplasmic)
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Igm Surface (IgM surface)
Ki67 (Ki67)
Lactoferrin (Lactoferrin)
Lung-resistance-related Or Major Vault
Protein (lrp/mvp) (Lung-resistance-
related or major vault protein
(LRP/MVP))
Multidrug Resistance-associated Protein
(mrp) (Multidrug resistance-associated
protein (MRP))
Myeloperoxidase (Myeloperoxidase)
P-glycoprotein (pgp/mdr1) (P-
glycoprotein (Pgp/MDR1))
Terminal Transferase (tdt) (Terminal
Transferase (TdT))
Was expression of the antigen detected on
leukemic cells? (For each marker,)
Indeterminate (Indeterminate)
No (No)
Not Done (Not done)
Yes (Yes)
For TdT, specify Antibody source
Antigen (Fluorochromes *Note: Groups may pre-
print specific antigens being tested by flow
cytometry relevant to protocol instructions.)
Identify the fluorochrome used for analysis (For
each antigen tested by Flow Cytometry,)
Apc (APC)
Ecd (ECD)
Fitc (FITC)
Not Done (Not done)
Other Specify (Other)
Pe (PE)
Pe/tandem (PE/tandem)
Percp (PerCP)
Other specify
How were leukemic cells gated?
Abnormal Cells Using An Antibody Other
Than Cd45 And Light Scatter (Abnormal
cells using an antibody other than CD45
and light scatter)
Abnormal Cells Using Cd45 And Light
Scatter (Abnormal cells using CD45 and
light scatter)
Abnormal Cells Using Fals Versus Rals
(Abnormal cells using FALS versus
RALS)
Lymphoctye Gate Using Fals Versus
Rals (Lymphoctye gate using FALS
versus RALS)
Not Gated (Not gated)
Other (Other)
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Other specify
If an antibody other than CD45, indicate CD used
Percent Cells Viable (%)
Was DNA ploidy tested by flow cytometry?
No (No)
Unknown (Unknown)
Yes (Yes)
Description of DNA Ploidy Results (If yes,)
Diploid (Diploid)
Hyperdiploid (Hyperdiploid)
Hypodiploid (Hypodiploid)
Near Diploid (Near diploid)
Not Evaluable (Not evaluable)
Provide DNA Index of Leukemic Cells
% Cells in S-phase
% Coefficient of Variation
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Pathology - Phase II Breast Pathology Form
- 2549749v1.0
Phase II Breast Pathology Form
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=23E546A1-
97F1-49E5-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/7173
Phase II Breast Pathology Form
Crf Header
Coordinating Group Protocol No.
Coordinating Group Code
Protocol Title
Patient Study ID
Institution/Affiliate
Registering Group Code
Registering Institution Code
Patient Initials
Breast: Form Administration
Person Completing Form
Are data amended (If data are amended, please
circle in red when using paper form)
Yes
No
Pathology: Estrogen And Progesterone
Receptors
Disease Site
Breast, Metastasis/recurrence (Breast,
metastasis/recurrence)
Breast, Primary (Breast, primary)
Lymph Nodes (Lymph nodes)
Other, Specify (Other, specify)
Other specify
Blocks
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Accession Number
Specimen Site
Bone (Bone)
Bone Marrow (Bone marrow)
Brain (Brain)
Contralateral Breast (Contralateral
breast)
Distant Nodes, Specify (Distant nodes)
Ipsilateral Supraclavicular Nodes
(Ipsilateral supraclavicular nodes)
Liver (Liver)
Local-regional (including Ipsilateral
Breast; Chest Wall; Axillary, Internal
Mammary, And Infra-clavicular Nodes;
Local-regional Skin And Subcutaneous
Tissue) (Local-regional)
Lung (Lung)
Mediastinal Nodes (Mediastinal nodes)
Other Specify (Other)
Distant nodes specify
Other specify
Date Specimen collected
Specimen Laterality
Left (Left)
Right (Right)
Unknown/not Applicable (Unknown/Not
applicable)
Method of Evaluation
Autopsy (Autopsy)
Axillary Dissection (Axillary dissection)
Ductal Lavage (Ductal lavage)
Ductoscopic Biopsy (Ductoscopic
biopsy)
Excisional Biopsy Or Lumpectomy
(Excisional biopsy or lumpectomy)
Lumpectomy, With Wire Localization
(Excisional biopsy or lumpectomy, with
wire localization)
Fine Needle Aspiration Biopsy (Fine
needle aspiration biopsy)
Fine Needle Aspiration Biopsy With Wire
Localization (Fine needle aspiration
biopsy, with wire localization)
Fluid Cytology, Ascites (Fluid cytology,
ascites)
Fluid Cytology, Cerebrospinal Fluid (Fluid
cytology, cerebrospinal fluid)
Fluid Cytology, Pleural (Fluid cytology,
pleural)
Incisional Biopsy (Incisional biopsy)
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Incisional Biopsy, With Wire Localization
(Incisional biopsy, with wire localization)
Mastectomy (Mastectomy)
Needle Biopsy (tru-cut Or Core) (Needle
biopsy (tru-cut or core))
Needle Biopsy (tru-cut Or Core), With
Wire Localization (Needle biopsy (tru-cut
or core), with wire localization))
Nipple Fluid (Nipple fluid)
Other, Specify (Other, specify)
Prophalactic Mastectomy (Prophalactic
mastectomy)
Resection/re-excision Of Lumpectomy
Margins (Resection/re-excision of
lumpectomy margins)
Sentinel Node Biopsy (Sentinel node
biopsy)
Other Specify
Pathology: Assessment Of Benign Breast
Tissue
Histologic Type
Adenoid Cystic (Adenoid cystic (pure >
or =90%))
Adenosquamous (Adenosquamous (pure
> or =90%))
Apocrine (Apocrine)
Carcinosarcoma (Carcinosarcoma)
Cribriform (Cribriform (pure > or =90%))
Ductal (Ductal)
Invasive Micropapillary (Invasive
micropapillary)
Lobular (Lobular (pure > or =90%))
Medullary (Medullary (pure > or =90%))
Metaplastic Carcinoma (carcinoma With
Metaplasia) (Metaplastic carcinoma
(carcinoma with metaplasia))
Mucinous Adenocarcinoma (Mucinous
(pure > or =90%))
Other Specify (Other)
Papillary (Papillary (pure > or =90%))
Secretory (Secretory (juvenile; pure > or
=90%))
Squamous (Squamous (pure > or
=90%))
Tubular (Tubular (pure > or =90%))
Tubulolobular (Tubulolobular (pure > or
=90%))
Other specify
Pathology: Cytology
Ductal Lavage/Nipple Aspirate
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Atypical Epithelial Cells (marked)
(Atypical epithelial cells (marked))
Atypical Epithelial Cells (mild Change)
(Atypical epithelial cells (mild change))
Benign Epithelial Cells (Benign epithelial
cells)
Icmd (insufficient Material For Diagnosis)
(ICMD (insufficient material for
diagnosis))
Malignant Epithelial Cells (Malignant
epithelial cells)
Non-epithelial Cells (Non-epithelial cells)
Other (inflammatory, Etc.), Specify
(Other (inflammatory, etc.))
Other specify
Nipple Discharge (fluid)
Atypical (epithelial Cells Present)
(Atypical (epithelial cells present))
Benign (absence Of Epithelium) (Benign
(absence of epithelium))
Malignant (Malignant)
Not Sufficient For Diagnosis
(indeterminate/unsatisfactory) (Not
sufficient for diagnosis
(indeterminate/unsatisfactory))
Other Specify (Other (inflammatory,
etc.))
Suspicious (Suspicious)
Other specify
Fine Needle Aspirate Biopsy
Atypical/indeterminate
(Atypical/Indeterminate)
Benign (Benign)
Malignant (Malignant)
Other (inflammatory, Etc.), Specify
(Other (inflammatory, etc.), specify)
Suspicious (Suspicious)
Unsatisfactory (Unsatisfactory)
Other, specify
Fluid Cytology Ascites
Atypical/indeterminate
(Atypical/Indeterminate)
Benign (Benign)
Malignant (Malignant)
Other (inflammatory, Etc.), Specify
(Other (inflammatory, etc.))
Suspicious (Suspicious)
Unsatisfactory (Unsatisfactory)
Other specify
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Fluid Cytology Pleural
Atypical/indeterminate
(Atypical/Indeterminate)
Benign (Benign)
Malignant (Malignant)
Other (inflammatory, Etc.), Specify
(Other (inflammatory, etc.))
Suspicious (Suspicious)
Unsatisfactory (Unsatisfactory)
Other specify
Pathology: Assessment Of Ductal
Carcinoma In Situ (dcis)
Is DCIS present?
Yes
No
Is an extensive intraductal component (EIC)
present
Yes
No
Is DCIS present with invasive cancer?
Yes
No
Pathologic Primary Tumor Size (Microscopic)
Is cancerization of lobules present?
Yes
No
Dominant Histologic Type
Aprocrine (Aprocrine)
Clinging (Clinging)
Comedo (Comedo)
Cribriform (Cribriform)
Intra-cystic (encysted Papillary) (Intra-
cystic (encysted papillary))
Micropapillary (Micropapillary)
Other, Specify (Other, specify)
Papillary Carcinoma In Situ (papillary)
(Papillary carcinoma in situ (papillary))
Solid (Solid)
Other specify
Nuclear Grade
Small Regular Nuclei (Grade I (low, 1 pt))
Moderate Increase In Size, Etc (Grade II
(intermediate, 2 pts))
Marked Variation In Size, Nucleoli,
Chromatin Clumping, Etc (Grade III
(high, 3 pts))
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Does analysis of tissue show evidence of
therapeutic effects?
No (No)
Unknown (Unknown)
Yes (Yes)
Therapeutic Effect Type (If yes,)
Drug-related Changes (Drug-related
changes)
Other, Specify (Other specify)
Radiation Changes (Radiation changes)
Surgical Changes (Surgical changes)
Other specify
Is Paget's disease of the nipple present?
No (NO)
Unknown (UNKNOWN)
Yes (YES)
Type of Necrosis
Comedonecrosis (Comedonecrosis)
Non-comedonecrosis (Non-
comedonecrosis)
Other Specify (Other)
Other specify
Microcalcifications
None (None)
Present, Involving Benign Ducts (Present
involving benign ducts)
Present, Involving Both Benign Ducts
And Dcis (Present involving both benign
ducts and DCIS)
Present, Involving Dcis (Present
involving DCIS)
Is DCIS at margin?
> Or = 1 Mm To 10 Mm (> or = 1 mm to
10 mm)
Greater Than 10 Mm (Greater than 10
mm)
Involved, Not Otherwise Specified
(Involved NOS)
Less Than 1 Mm (Less than 1 mm)
Not Involved, Not Otherwise Specified
(Not involved NOS)
Transected (Transected)
Unknown (Unknown)
Is necrosis present?
No (NO)
Unknown (UNKNOWN)
Yes (YES)
Is microinvasive cancer present?
6 / 13
Pathology - Phase II Breast Pathology Form - 2549749v1.0
No (NO)
Unknown (UNKNOWN)
Yes (YES)
Pathology: Assessment Of Lobular
Carcinoma In Situ (lcis)
Is LCIS present?
Yes
No
Is LCIS present with invasive cancer?
Yes
No
Extent of LCIS
Extensive (Extensive)
Focal (Focal)
Not Specified (Not specified)
Is LCIS at margin?
> Or = 1 Mm To 10 Mm (> or = 1 mm to
10 mm)
Greater Than 10 Mm (Greater than 10
mm)
Involved, Not Otherwise Specified
(Involved NOS)
Less Than 1 Mm (Less than 1 mm)
Not Involved, Not Otherwise Specified
(Not involved NOS)
Transected (Transected)
Unknown (Unknown)
Pathology: Assessment Of Invasive Tumor
Is an extensive intraductal component (EIC)
present
Yes
No
Pathologic Primary Tumor Size (Microscopic)
Pathologic Primary Tumor Size (Microscopic)
Histologic Type
Adenoid Cystic (Adenoid cystic (pure >
or =90%))
Adenosquamous (Adenosquamous (pure
> or =90%))
Apocrine (Apocrine)
Carcinosarcoma (Carcinosarcoma)
Cribriform (Cribriform (pure > or =90%))
Ductal (Ductal)
Invasive Micropapillary (Invasive
micropapillary)
Lobular (Lobular (pure > or =90%))
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Medullary (Medullary (pure > or =90%))
Metaplastic Carcinoma (carcinoma With
Metaplasia) (Metaplastic carcinoma
(carcinoma with metaplasia))
Mucinous Adenocarcinoma (Mucinous
(pure > or =90%))
Other Specify (Other)
Papillary (Papillary (pure > or =90%))
Secretory (Secretory (juvenile; pure > or
=90%))
Squamous (Squamous (pure > or
=90%))
Tubular (Tubular (pure > or =90%))
Tubulolobular (Tubulolobular (pure > or
=90%))
Other specify
Nuclear Grade
Small Regular Nuclei (Grade I (low, 1 pt))
Moderate Increase In Size, Etc (Grade II
(intermediate, 2 pts))
Marked Variation In Size, Nucleoli,
Chromatin Clumping, Etc (Grade III
(high, 3 pts))
Mitotic Count Corrected
>11 Mitoses Per 10 Hpf (0.44 Mm) Or
>20 Mitoses Per 10 Hpf (0.59 Mm) Or >
23 Mitoses Per 10 Hpf (0.63 Mm) (3 Pts)
(>11 mitoses per 10 HPF (0.44 mm) OR
>20 mitoses per 10 HPF (0.59 mm) OR
> 23 mitoses per 10 HPF (0.63 mm))
0 To 5 Mitoses Per 10 Hpf (0.44 Mm) Or
0-9 Mitoses Per 10 Hpf (0.59 Mm) Or 0-
11 Mitoses Per 10 Hpf (0.63 Mm) (1 Pt)
(0 to 5 mitoses per 10 HPF (0.44 mm)
OR 0-9 mitoses per 10 HPF (0.59 mm)
OR 0-11 mitoses per 10 HPF (0.63 mm))
6 To 10 Mitoses Per 10 Hpf (0.44 Mm) Or
10-20 Mitoses Per 10 Hpf (0.59 Mm) Or
12-23 Mitoses Per 10 Hpf (0.63 Mm) (2
Pts) (6 to 10 mitoses per 10 HPF (0.44
mm) OR 10-20 mitoses per 10 HPF
(0.59 mm) OR 12-23 mitoses per 10
HPF (0.63 mm))
Indeterminate (Indeterminate)
Tubule Formation
Indeterminate (Indeterminate)
Majority Of Tumor, >75% (1 Pt) (Majority
of tumor, >75%)
Minimal, < 10% (3 Pt) (Minimal, <10%)
Moderate, 10% To 75 % (2 Pt)
(Moderate, 10% to 75%)
Total Nottingham Score
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Histologic Grade
G1 Low Combined Histologic Grade
(favorable) (G1)
G2 Intermediate Combined Histologic
Grade (moderately Favorable) (G2)
G3 High Combined Histologic Grade
(unfavorable) (G3)
Gx Grade Cannot Be Assessed (GX)
Is Paget's disease of the nipple present?
No (NO)
Unknown (UNKNOWN)
Yes (YES)
Is there invasion of the dermal lymphatics
(inflammatory)?
No (NO)
Unknown (UNKNOWN)
Yes (YES)
Is there lymphovascular invasion?
No (NO)
Unknown (UNKNOWN)
Yes (YES)
Perineural tumor infiltration or invasion
No (NO)
Unknown (UNKNOWN)
Yes (YES)
Microcalcifications
None (None)
Present, Involving Benign Ducts (Present
involving benign ducts)
Present, Involving Both Benign Ducts
And Dcis (Present involving both benign
ducts and DCIS)
Present, Involving Dcis (Present
involving DCIS)
Is significant lymphocytic/mononuclear cell
reaction present?
No (No)
Unknown (Unknown)
Yes (Yes)
Is necrosis present?
No (NO)
Unknown (UNKNOWN)
Yes (YES)
Extent of Necrosis
Extensive (Extensive)
Indeterminate (Indeterminate)
Moderate (Moderate)
Scant (Scant)
Unknown (Unknown)
Is microinvasive cancer present?
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No (NO)
Unknown (UNKNOWN)
Yes (YES)
Is invasive cancer at margin?
> Or = 1 Mm To 10 Mm (> or = 1 mm to
10 mm)
Greater Than 10 Mm (Greater than 10
mm)
Involved, Nos (Involved NOS)
Less Than 1 Mm (Less than 1 mm)
Not Involved, Nos (Not involved NOS)
Unknown (Unknown)
Pathology: Assessment Of Lymph Nodes
Was sentinel node sampling performed
No (No)
Unknown (Unknown)
Yes (Yes)
Sentinel Node Sampling Site (If yes,)
Axillary (Axillary)
Internal Mammary (Internal Mammary)
Supraclavicular (Supraclavicular)
Unknown (Unknown)
Number of Sentinel Nodes Examined (If yes,)
Total No. Of Other Involved Sentinel Nodes
Number of Positive Sentinel Nodes
Number of Positive Sentinel Nodes by H&E
Number of Positive Sentinel Nodes by
Immunohistochemistry (IHC) only
Measurement of Largest Metastasis
< 2 Mm (< 2 mm)
> Or = 2 Mm (> or = 2 mm)
Was axillary dissection performed?
No (No)
Unknown (Unknown)
Yes (Yes)
Number of Lymph Nodes Examined (If yes,)
Number of Positive Lymph Nodes (For each
type,)
Number of Positive Lymph Nodes (For each
type,)
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Number of Lymph Nodes without
Micrometastases
Number of Lymph Nodes with Micrometastases
Lymph Nodes Type
Axillary (axillary)
Infraclavicular (infraclavicular)
Internal Mammary (internal mammary)
Supraclavicular (supraclavicular)
Lymph Node Involvement
Equivocal (equivocal)
Negative (negative)
Not Evaluated (not evaluated)
Positive (positive)
Unknown (unknown)
Size of Largest Lymph Node
< 0.2 Mm By Ihc Only (< 0.2 mm by IHC
only)
> 2 Cm (> 2 cm)
0.2 To 2 Mm By H&e (0.2 to 2 mm by
H&E)
2 Mm To 2 Cm (2 mm to 2 cm)
Extracapsular Extension?
No (No)
Unknown (Unknown)
Yes (Yes)
Pathology: Disease Staging
T Stage, Pathologic
No Evidence Of Primary Tumor (T0)
Tumor More Than 0.1 Cm But Not More
Than 0.5 Cm In Greatest Dimension
(T1a)
Tumor More Than 0.5 Cm But Not More
Than 1 Cm In Greatest Dimension (T1b)
Tumor More Than 1 Cm But Not More
Than 2 Cm In Greatest Dimension (T1c)
Microinvasion 0.1 Cm Or Less In
Greatest Dimension (T1mic)
Tumor More Than 2 Cm But Not More
Than 5 Cm In Greatest Dimension (T2)
Tumor More Than 5 Cm In Greatest
Dimension (T3)
Tumor Of Any Size With Direct (T4)
Extension To Chest Wall (T4a)
Edema (including Peau D'orange) Or
Ulceration Of The Skin Of The Breast Or
Satellite Skin Nodules Confined To The
Same Breast (T4b)
Both T4a And T4b (T4c)
Inflammatory Carcinoma (T4d)
Carcinoma In Situ: Intraductal
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Carcinoma, Lobular Carcinoma In Situ,
Or Paget's Disease Of The Nipple With
No Tumor (Tis)
Primary Tumor Cannot Be Assessed
(TX)
N Stage, Pathologic
No Regional Lymph Node Metastasis
Histologically, No Additional Examination
For Isolated Tumor Cells (itc) (pN0)
No Regional Lymph Node Metastasis
Histologically, Negative Ihc (pN0(i-))
No Regional Lymph Node Metastasis
Histologically, Positive Ihc, No Ihc Cluster
>0.2 Mm (pN0(i+))
No Regional Lymph Node Metastasis
Histologically, Negative Molecular
Findings (rt-pcr) (pN0(mol-))
No Regionally Lymph Node Metastasis
Histologically, Positive Molecular
Findings (rt-pcr) (pN0(mol+))
Metastasis In 1 To 3 Axillary Lymph
Nodes, And/or In Internal Mammary
Nodes With Microscopic Disease
Detected By Sln Dissection But Not
Clinically Apparent (pN1)
Metastasis In 1 To 3 Axillary Lymph
Nodes (pN1a)
Metastasis In Internal Mammary Nodes
With Microscopic Disease Detected By
Sln Dissection But Not Clinically
Apparent (pN1b)
Metastasis In 1 To 3 Axillary Lymph
Nodes And In Internal Mammary Lymph
Nodes With Microscopic Disease
Detected By Sln Dissection But Not
Clinically Apparent. (pN1c)
Micrometastasis (>0.2 Mm But <=2.0
Mm) (pN1mi)
Metastasis In 4 To 9 Axillary Lymph
Nodes, Or In Clinically Apparent **
Internal Mammary Lymph Nodes In The
Absence Of Axillary Lymph Node
Metastasis To Ipsilateral Axillary Lymph
Node(s) Fixed To Each Other Or To
Other Structures (pN2)
Metastasis In 4 To 9 Axillary Lymph
Nodes (at Least 1 Tumor Deposit >2.0
Mm) (pN2a)
Metastasis In Clinically Apparent*
Internal Mammary Lymph Nodes In The
Absence Of Axillary Lymph Node
Metastasis (pN2b)
Metastasis In >= Axillary Lymph Nodes,
Or In Infraclavicular Lymph Nodes, Or In
Clinically Apparent* Ipsilateral Internal
Mammary Lymph Node(s) In The
Presence Of 1 Or More Positive Axillary
Lymph Node(s); Or, In >3 Axillary Lymph
Nodes With Clinically N (pN3)
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Metastasis In >=10 Axillary Lymph
Nodes (at Least 1 Tumor Deposit >2.0
Mm); Or, Metastasis To The
Infraclavicular Lymph Nodes (pN3a)
Metastasis In Clinically Apparent*
Ipsilateral Internal Mammary Lymph
Nodes In The Presence Of >=1 Positive
Axillary Lymph Node(s); Or, In >3
Axillary Lymph Nodes And In Internal
Mammary Lymph Nodes With
Microscopic Disease Detected By
Sentinel Lymph Node (pN3b)
Metastasis In Ipsilateral Supraclavicular
Lymph Nodes (pN3c)
Regional Lymph Nodes Cannot Be
Assessed (e.g., Not Removed For
Pathologic Study Or Previously
Removed) (pNX)
M Stage, Pathologic
No Distant Metastasis (M0)
Distant Metastasis (M1)
Distant Metastasis Cannot Be Assessed
(MX)
Stage Grouping
Tis, N0, M0 (0)
T1*, N0, M0 (I)
T0, N1, M0 Or T1*, N1, M0 Or T2, N0,
M0 (IIA)
T2, N1, M0 Or T3, N0, M0 (IIB)
T0, N2, M0 Or T1*, N2, M0 Or T2, N2,
M0 Or T3, N1, M0 Or T3, N2, M0 (IIIA)
T4, N0, M0 Or T4, N1, M0 Or T4, N2, M0
(IIIB)
Any T, N3, M0 (IIIC)
Any T, Any N, M1 (IV)
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Treatment - Leukemia/Myelodysplastic Syndrome
(MDS) - Transplant Form - 2019362v3.0
Leukemia/Myelodysplastic Syndrome (MDS) - Transplant
Form
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=1A9B6612-
EEBA-29DB-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/7177
Leukemia/Myelodysplastic Syndrome
(MDS) - Transplant Form
Crf Header
Coordinating Group Protocol No.
Coordinating Group Code
Protocol Title
Patient Study ID
Institution/Affiliate
Other Patient ID
Participating Group Code
Patient Initials
Registration Type
Leukemia/mds: Form Administration
Person Completing Form
Are data amended (If data are amended, please
circle in red when using paper form)
Yes
No
Bm/sct: Transplant Treatment Plan
Did the patient receive protocol transplant?
Yes
No
Date of First Bone Marrow or Peripheral Blood
Stem Cell (PBSC) Infusion (mm dd yyyy)
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Type of Bone Marrow or Peripheral Blood Stem
Cell (PBSC) Transplant
Bone Marrow Stem Cells Used For
Transplant Obtained From Recipient
Him/herself (Autologous bone marrow)
Peripheral Blood Stem Cells Used For
Transplant Obtained From Recipient
Him/herself (Autologous PBSC)
Bone Marrow Stem Cells Used For
Transplant Obtained From Antigen-
matched Sibling Or Family Member Of
Recipient (Bone marrow from matched
sibling or family member)
Bone Marrow Stem Cells Used For
Transplant Obtained From Antigen-
matched Individual Unrelated To
Recipient (Bone marrow from matched
unrelated donor)
Other Specify (Other)
Peripheral Blood Stem Cells Used For
Transplant Obtained From Antigen-
matched Sibling Or Family Member Of
Recipient (PBSC from matched sibling or
family member)
Peripheral Blood Stem Cells Used For
Transplant Obtained From Antigen-
matched Individual Unrelated To
Recipient (PBSC from matched
unrelated donor)
Other specify
Reason Treatment Ended (or not given check
one)
Adverse Event/side Effects/complications
(Adverse Event/Side
Effects/Complications)
Alternative Therapy (Alternative therapy)
Death On Study (Death on study)
Disease Progression Before Active
Treatment (Disease Progression before
active treatment)
Disease Progression, Relapse During
Active Treatment (Disease progression,
relapse during active treatment)
Other (Other)
Patient Off-treatment For Other
Complicating Disease (Patient off-
treatment for other complicating disease)
Patient Withdrawal Or Refusal After
Beginning Protocol Therapy (Patient
withdrawal/refusal after beginning
protocol therapy)
Patient Withdrawal Or Refusal Before
Beginning Protocol Therapy (Patient
withdrawal/refusal prior to beginning
protocol therapy)
Treatment Completed Per Protocol
Criteria (Treatment completed per
2 / 3
Treatment - Leukemia/Myelodysplastic Syndrome (MDS) - Transplant
Form - 2019362v3.0
protocol criteria)
Other specify
Were there any dose modifications or
additions/omissions to protocol treatment? (check
one)
No (No)
Yes, Planned (i.e., The Treatment Was
Changed According To Protocol
Guidelines) (Yes, planned)
Yes, Unplanned (i.e., The Treatment
Change Was Not Part Of Protocol
Guidelines) (Yes, unplanned)
If yes, unplanned, Specify change
Allows Documentation Of Any Additional
Cooments
Comments
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On-Study - Phase II Breast Cancer -
Adjuvant On-Study Form - 2556117v1.0
Phase II Breast Cancer - Adjuvant On-Study Form
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=24E7C2C2-
27C7-70B6-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/7179
Phase II Breast Cancer - Adjuvant
On-Study Form
Crf Header
Coordinating Group Protocol No.
Coordinating Group Code
Protocol Title
Patient Study ID
Institution/Affiliate
Registering Group Code
Registering Institution Code
Patient Initials
Breast: Form Administration
Person Completing Form
Are data amended? (If data are amended, please
circle in red when using paper form)
Yes
No
Breast: Patient Characteristics
Patient Age
Menopausal status
Perimenopausal (Perimenopausal)
Postmenopausal (Postmenopausal (>12
mo since LMP with no prior
ovariectomy))
Postmenopausal (Postmenopausal (prior
bilateral ovariectomy))
Premenopausal (Premenopausal)
Hormone Therapy/Replacement
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Yes
No
Hormone Therapy Type
Estrogen Replacement (Estrogen
Replacement)
Lhrh Agonist (LHRH agonist)
Breast: Surgical Procedures
First Positive Biopsy Date (mm dd yyyy)
Most Extensive Primary Surgery (check one)
Mastectomy, Nos (Mastectomy NOS)
Partial Mastectomy, Lumpectomy Or
Excisional Biopsy (Partial
mastectomy/lumpectomy/excisional
biopsy)
Date of Most Extensive Primary Surgery (if
required, use last re-excision date)
Was sentinel node sampling performed
Yes
No
Sentinel Node Biopsy Date (mm dd yyyy)
Number of Sentinel Nodes Examined
Number of Positive Sentinel Nodes
Sentinel Node Biopsy Results (per protocol)
Negative (Negative)
Positive (Positive)
Was axillary dissection performed?
Yes
No
Date of Axillary Dissection (mm dd yyyy)
Number of Lymph Nodes Examined (If sentinel
node biopsy and axillary node dissection were
performed, enter the sum of nodes examined.)
Number of Positive Lymph Nodes (per
institutional standard)
Breast: Disease Description
Tumor Laterality (check one)
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Bilateral (Bilateral)
Left (Left)
Right (Right)
Receptor Status, ER (If measured in fmols/mg
cytosol protein >=10 is positive. If other measures
are used apply institutional standards; borderline
results should be reported as positive.)
Negative (Negative)
Positive (Positive)
Receptor Status, PgR
Negative (Negative)
Positive (Positive)
Receptor Status, Her2-neu
Negative (Negative)
Positive (Positive)
Marker Test Method
Elisa (ELISA)
Fluorescence In Situ Hybridization (fish)
(Fluorescence in situ hybridization
(FISH))
Immunohistochemistry (ihc)
(Immunohistochemistry (IHC))
Other, Specify (Other)
Other specify
Staining Antibody
Cb-11 Other (CB-11 other)
Cb-11/ventana Kit (CB-11/Ventana Kit)
Dako Herceptest [tm] (DAKO Herceptest
[TM])
Other Specify (Other)
Tab-250 (TAB-250)
Other specify
Intensity of Stained Malignant Nuclei Description
(OR)
Intense (Intense)
Intermediate (Intermediate)
Negative (Negative)
Scant (Scant)
Unknown (Unknown)
Intensity of Stained Malignant Nuclei Scaled (__
of __ Note: Scale for intensity will be protocol
specific.)
Herceptest Score
0 (0)
1+ (1+)
2+ (2+)
3+ (3+)
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Ventana Scoring System (Score)
0 (0)
1+ (1+)
2+ (2+)
3+ (3+)
Kit or Test Type (If FISH,)
Other Specify (Other)
Ventana/oncorprobe[tm]
(Ventana/Oncorprobe)
Vysis/path Vysion[tm] (Vysis/PathVysion)
Other specify
FISH Result
Amplified (Amplified)
Not Amplified (Not amplified)
Header
Pathologic Primary Tumor Size (cm   Maximum
diameter of the invasive component; if multiple
lesions, use longest lesion)
T Stage, Pathologic
No Evidence Of Primary Tumor (T0)
Tumor More Than 0.1 Cm But Not More
Than 0.5 Cm In Greatest Dimension
(T1a)
Tumor More Than 0.5 Cm But Not More
Than 1 Cm In Greatest Dimension (T1b)
Tumor More Than 1 Cm But Not More
Than 2 Cm In Greatest Dimension (T1c)
Microinvasion 0.1 Cm Or Less In
Greatest Dimension (T1mic)
Tumor More Than 2 Cm But Not More
Than 5 Cm In Greatest Dimension (T2)
Tumor More Than 5 Cm In Greatest
Dimension (T3)
Tumor Of Any Size With Direct (T4)
Extension To Chest Wall (T4a)
Edema (including Peau D'orange) Or
Ulceration Of The Skin Of The Breast Or
Satellite Skin Nodules Confined To The
Same Breast (T4b)
Both T4a And T4b (T4c)
Inflammatory Carcinoma (T4d)
Carcinoma In Situ: Intraductal
Carcinoma, Lobular Carcinoma In Situ,
Or Paget's Disease Of The Nipple With
No Tumor (Tis)
Primary Tumor Cannot Be Assessed
(TX)
N Stage, Pathologic
No Regional Lymph Node Metastasis
Histologically, No Additional Examination
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For Isolated Tumor Cells (itc) (pN0)
Metastasis In 1 To 3 Axillary Lymph
Nodes, And/or In Internal Mammary
Nodes With Microscopic Disease
Detected By Sln Dissection But Not
Clinically Apparent (pN1)
Metastasis In 1 To 3 Axillary Lymph
Nodes (pN1a)
Metastasis In Internal Mammary Nodes
With Microscopic Disease Detected By
Sln Dissection But Not Clinically
Apparent (pN1b)
Metastasis In 1 To 3 Axillary Lymph
Nodes And In Internal Mammary Lymph
Nodes With Microscopic Disease
Detected By Sln Dissection But Not
Clinically Apparent. (pN1c)
Micrometastasis (>0.2 Mm But <=2.0
Mm) (pN1mi)
Metastasis In 4 To 9 Axillary Lymph
Nodes, Or In Clinically Apparent **
Internal Mammary Lymph Nodes In The
Absence Of Axillary Lymph Node
Metastasis To Ipsilateral Axillary Lymph
Node(s) Fixed To Each Other Or To
Other Structures (pN2)
Metastasis In 4 To 9 Axillary Lymph
Nodes (at Least 1 Tumor Deposit >2.0
Mm) (pN2a)
Metastasis In Clinically Apparent*
Internal Mammary Lymph Nodes In The
Absence Of Axillary Lymph Node
Metastasis (pN2b)
Metastasis In >= Axillary Lymph Nodes,
Or In Infraclavicular Lymph Nodes, Or In
Clinically Apparent* Ipsilateral Internal
Mammary Lymph Node(s) In The
Presence Of 1 Or More Positive Axillary
Lymph Node(s); Or, In >3 Axillary Lymph
Nodes With Clinically N (pN3)
Metastasis In >=10 Axillary Lymph
Nodes (at Least 1 Tumor Deposit >2.0
Mm); Or, Metastasis To The
Infraclavicular Lymph Nodes (pN3a)
Metastasis In Clinically Apparent*
Ipsilateral Internal Mammary Lymph
Nodes In The Presence Of >=1 Positive
Axillary Lymph Node(s); Or, In >3
Axillary Lymph Nodes And In Internal
Mammary Lymph Nodes With
Microscopic Disease Detected By
Sentinel Lymph Node (pN3b)
Metastasis In Ipsilateral Supraclavicular
Lymph Nodes (pN3c)
Regional Lymph Nodes Cannot Be
Assessed (e.g., Not Removed For
Pathologic Study Or Previously
Removed) (pNX)
M Stage, Pathologic
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No Distant Metastasis (M0)
Distant Metastasis (M1)
Distant Metastasis Cannot Be Assessed
(MX)
Stage Grouping
Tis, N0, M0 (0)
T1*, N0, M0 (I)
T0, N1, M0 Or T1*, N1, M0 Or T2, N0,
M0 (IIA)
T2, N1, M0 Or T3, N0, M0 (IIB)
T0, N2, M0 Or T1*, N2, M0 Or T2, N2,
M0 Or T3, N1, M0 Or T3, N2, M0 (IIIA)
T4, N0, M0 Or T4, N1, M0 Or T4, N2, M0
(IIIB)
Any T, N3, M0 (IIIC)
Any T, Any N, M1 (IV)
Histologic Grade (For breast cancer, the
Nottingham combined histologic grade is
recommended)
G1 Low Combined Histologic Grade
(favorable) (G1)
G2 Intermediate Combined Histologic
Grade (moderately Favorable) (G2)
G3 High Combined Histologic Grade
(unfavorable) (G3)
Gx Grade Cannot Be Assessed (GX)
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On-Study - Myelodysplastic Syndrome (MDS) - On-Study
Form - Previously Untreated Patients - 2019396v3.0
Myelodysplastic Syndrome (MDS) - On-Study Form -
Previously Untreated Patients
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=1B24C8E6-
D14C-4D47-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/7183
Myelodysplastic Syndrome (MDS) -
On-Study Form - Previously
Untreated Patients
Crf Header
Coordinating Group Protocol No.
Coordinating Group Code
Protocol Title
Patient Study ID
Institution/Affiliate
Other Patient ID
Participating Group Code
Patient Initials
Registration Type
Leukemia/mds: Form Administration
Person Completing Form
Are data amended (If data are amended, please
circle in red when using paper form)
Yes
No
Aml: Disease Description, Previously
Untreated
Date of Initial Pathologic Diagnosis (mm dd yyyy
enter test date for first diagnosis of leukemia)
Leukemia/MDS Classification (*Alternately, the
CDE WHO Diagnosis can be used.)
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Disease Classified As Chronic
Myelomonocytic Leukemia (cmml)
(Chronic myelomonocytic leukemia
(CMML))
Disease Classified As Myelodysplastic
Syndrome (mds) Nos (Myelodysplastic
syndrome (MDS) NOS)
Disease Classified As Myeloproliferative
Syndrome Nos; (Myeloproliferative
syndrome NOS;)
Other (Other)
Disease Classified As Refractory Anemia
(ra) (Refractory anemia (RA))
Disease Classified As Refractory Anemia
W/ Excess Blasts In Transformation
(raeb-t) (Refractory anemia w/ excess
blasts in transformation (RAEB-t))
Disease Classified As Refractory Anemia
W/ Ring Sideroblasts (rars) (Refractory
anemia w/ ring sideroblasts (RARS))
Disease Classified As Refractory Anemia
W/excess Blasts (raeb) (Refractory
anemia w/excess blasts (RAEB))
Other specify
Date Hematology (Blood) Sample Obtained
(Peripheral Blood mm dd yyyy)
White Blood Cell Count (x 10^3/mcL)
Peripheral Neutrophils/Bands (%)
Peripheral Blasts (%)
Date of Bone Marrow Biopsy (Bone Marrow
Biopsy/Aspirate mm dd yyyy)
Marrow Cellularity (%)
Marrow Blasts (%)
Marrow Cellularity Status
Cellularity Status Of Bone Marrow Is
Aplasitc (severely Hypocellular) (Aplastic
(severely hypocellular))
Cellularity Status Of Bone Marrow
Unknown, Procedure Resulted In No
Material To Analyze (Dry tap or
inaspirable)
Cellularity Status Of Bone Marrow Is
Hypercellular (Hypercellular)
Cellularity Status Of Bone Marrow Is
Hypocellular (Hypocellular)
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Cellularity Status Of Bone Marrow Is
Normocellular (Normocellular)
Cellularity Status Of Bone Marrow Is
Packed (intensely Hypercellular) (Packed
(intensely hypercellular))
Extramedullary Disease Involvement (check all
that apply)
Central Nervous System (Central
nervous system)
Granulocytic Sarcoma (Chloroma)
Gingival Hypertrophy (Gingival
hypertrophy)
Other Specify (Other)
Leukaemia Cutis (Skin (leukemia cutis))
Other specify
Palpable splenomegaly (Organ Involvement)
Examination Performed And
Splenomegaly Absent (No)
Examination Of Spleen Not Performed
(Not examined)
Spleen Removed Via Prior Surgery
(Surgically absent)
Examination Performed And
Splenomegaly Present (Yes)
Splenomegaly by scan (or x-ray)
Examination Performed And
Splenomegaly Absent (No)
Examination Of Spleen Not Performed
(Not examined)
Spleen Removed Via Prior Surgery
(Surgically absent)
Examination Performed And
Splenomegaly Present (Yes)
Palpable hepatomegaly
Examination Performed And
Hepatomegaly Absent (No)
Examination Of Liver Not Performed (Not
examined)
Examination Performed And
Hepatomegaly Present (Yes)
Hepatomegaly by scan (or x-ray)
Examination Performed And
Hepatomegaly Absent (No)
Examination Of Liver Not Performed (Not
examined)
Examination Performed And
Hepatomegaly Present (Yes)
Palpable lymphadenopathy
Examination Performed And
Lymphadenopathy Absent (No)
Examination Of Lymph Nodes Not
Performed (Not examined)
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Examination Performed And
Lymphadenopathy Present (Yes)
Lymphadenopathy by scan (or x-ray)
Examination Performed And
Lymphadenopathy Absent (No)
Examination Of Lymph Nodes Not
Performed (Not examined)
Examination Performed And
Lymphadenopathy Present (Yes)
Clinical Onset of MDS
Mds Without Prior Clinical History Of
Potentially Inducing Therapy (de novo)
Mds Related To/asscoiated With Prior
Clinical History Of Potentially Inducing
Therapy (Treatment related)
Allows Documentation Of Any Additional
Cooments
Comments
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Response - Baseline Solid Tumor
Evaluation Form - 2278273v3.0
Baseline Solid Tumor Evaluation Form
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=D8884142-
76F1-00F9-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/7188
Baseline Solid Tumor Evaluation
Form
Crf Header
Coordinating Group Protocol No.
Coordinating Group Code
Protocol Title
Patient Study ID
Institution/Affiliate
Other Patient ID
Participating Group Code
Patient Initials
Target Lesion(s) Baseline Evaluation
Are there any target lesions?
Yes
No
Lesion Number
Target Lesion Site
Date of Evaluation (mm dd yyyy)
Method of Evaluation (* use code below Methods
of Evaluation)
Bone Scan (Bone scan)
Chest X-ray (Chest X-ray)
Clinical Examination (pe) (Clinical
examination)
Ct Scan (CT Scan)
Cytology (Cytology)
Mri (MRI (NMR))
Other (Other)
Spiral Ct Scan (Spiral CT Scan)
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Ultrasound (Ultrasound)
Other specify (If)
Longest Diameter of Lesion(s) (cm)
Sum of Longest Diameters of All Target Lesions
(cm)
Nontarget Lesion(s) Baseline Evaluation
Are there any nontarget lesions?
Yes
No
Lesion Number
Nontarget Lesion Site
Date of Evaluation (mm dd yyyy)
Method of Evaluation (* use code below Methods
of Evaluation)
Bone Scan (Bone scan)
Chest X-ray (Chest X-ray)
Clinical Examination (pe) (Clinical
examination)
Ct Scan (CT Scan)
Cytology (Cytology)
Mri (MRI (NMR))
Other (Other)
Spiral Ct Scan (Spiral CT Scan)
Ultrasound (Ultrasound)
Other specify (If)
Comments
Comments
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On-Study - Palliative Treatment for Head and
Neck Cancer - On-Study Form - 2267713v3.0
Palliative Treatment for Head and Neck Cancer - On-Study
Form
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=20B9E4F5-
9DD3-2343-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/7192
Palliative Treatment for Head and
Neck Cancer - On-Study Form
Crf Header
Coordinating Group Protocol No.
Coordinating Group Code
Protocol Title
Patient Study ID
Institution/Affiliate
Other Patient ID
Participating Group Code
Patient Initials
Head & Neck: Form Administration
Person Completing Form
Are data amended? (If data are amended, please
circle in red when using paper form)
Yes
No
Head & Neck: Patient Assessment
Performance Status (check one)
Fully Active, Able To Carry On All Pre-
disease Performance Without
Restriction. (0)
Restricted In Physically Strenuous
Activity But Ambulatory And Able To
Carry Out Work Of A Light Or Sedentary
Nature, E.g., Light Housework, Office
Work. (1)
Ambulatory And Capable Of All Selfcare
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But Unable To Carry Out Any Work
Activities. Up And About More Than 50%
Of Waking Hours. (2)
Capable Of Only Limited Selfcare,
Confined To Bed Or Chair More Than
50% Of Waking Hours. (3)
Completely Disabled. Cannot Carry On
Any Selfcare. Totally Confined To Bed Or
Chair. (4)
Head & Neck: Disease Description - Initial
Diagnosis Of Disease
Date of Initial Pathologic Diagnosis
Primary Site
Antrum (Antrum)
Base Of Tongue (Base of tongue)
Buccal Mucosa (Buccal mucosa)
Ethmoid (Ethmoid)
Faucial Arch (Faucial arch)
Floor Of Mouth (Floor of mouth)
Frontal (Frontal)
Glottic Larynx (Glottic larynx)
Hard Palate (Hard palate)
Hypopharynx Nos (Hypopharynx NOS)
Larynx Nos (Larynx NOS)
Lateral Wall (Lateral wall)
Lip And Oral Cavity (Lip and oral cavity)
Lower Gingiva (Lower gingiva)
Minor Salivary Glands (Minor salivary
glands)
Nasal Cavity (Nasal cavity)
Nasopharynx Nos (Nasopharynx NOS)
Nose Nos (Nose NOS)
Oral Cavity Nos (Oral cavity NOS)
Oral Tongue (Oral Tongue)
Oropharynx Nos (Oropharynx NOS)
Other (Other)
Paranasal Sinuses Nos (Paranasal
sinuses NOS)
Parotid (Parotid)
Postcricoid Area (Postcricoid area)
Posterior Pharyngeal Wall (Posterior
pharyngeal wall)
Posterior Superior Wall (Posterior
superior wall)
Posterior Wall (Posterior wall)
Pyriform Fossa (Pyriform fossa)
Retromolar Trigone (Retromolar trigone)
Salivary Glands Nos (Salivary glands
NOS)
Soft Palate (Soft palate)
Sphenoid (Sphenoid)
Subglottic Larynx (Subglottic larynx)
Sublingual (Sublingual)
Submandibular (Submandibular)
Supraglottic Larynx (Supraglottic larynx)
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Tonsillar Fossa Tonsil (Tonsillar fossa,
tonsil)
Unknown (Unknown)
Upper Gingiva (Upper gingiva)
Other specify
Histologic Type
Acinic Cell Carcinoma (Acinic cell
carcinoma)
Adenocarcinoma (Adenocarcinoma)
Adenoid Cystic Carcinoma (Adenoid
cystic carcinoma)
Adenoid Squamous Cell Carcinoma
(Adenoid squamous cell carcinoma)
Adenosquamous Carcinoma
(Adenosquamous carcinoma)
Atypical Carcinoid Tumor (Atypical
carcinoid tumor)
Basaloid Squamous Cell Carcinoma
(Basaloid squamous cell carcinoma)
Carcinoid Tumor (Carcinoid tumor)
Carcinoma In Pleomorphic Adenoma
(Carcinoma in pleomorphic adenoma)
Carcinoma In Situ (specify Histologic
Type) (Carcinoma in situ)
Clear Cell Carcinoma (Clear cell
carcinoma)
Epithelial-myoepithelial Carcinoma
(Epithelial-myoepithelial carcinoma)
Giant Cell Carcinoma (Giant cell
carcinoma)
Lymphoepithelial Carcinoma
(Lymphoepithelial carcinoma)
Mucoepidermoid Carcinoma
(Mucoepidermoid carcinoma)
Other (Other)
Salivary Duct Carcinoma (Salivary duct
carcinoma)
Small Cell Carcinoma (Small cell
carcinoma)
Spindle Cell Carcinoma (Spindle cell
carcinoma)
Squamous Cell Carcinoma Keratinizing
(Squamous cell carcinoma, keratinizing)
Squamous Cell Carcinoma Non-
keratinizing (Squamous cell carcinoma,
non-keratinizing)
Undifferentiated Carcinoma
(Undifferentiated carcinoma)
Unknown (Unknown)
Verrucous Squamous Cell Carcinoma
(Verrucous squamous cell carcinoma)
Other specify
Clinical T Stage (Clinical Impression of Tumor at
Current Presentation use the version of the AJCC
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staging system specified in the protocol)
T0, According To Ajcc Criteria (T0)
T1, According To Ajcc Criteria (T1)
T2, According To Ajcc Criteria (T2)
T3, According To Ajcc Criteria (T3)
T4a, According To Ajcc Guidelines (T4a)
T4b, According To Ajcc Guidelines (T4b)
Tis, According To Ajcc Criteria (Tis)
Tx, According To Ajcc Criteria (TX)
Clinical N Stage (overall)
N0, According To Ajcc Guidelines (N0)
N1, According To Ajcc Criteria (N1)
N2, According To Ajcc Criteria (N2)
N2a, According To Ajcc Guidelines (N2a)
N2b, According To Ajcc Guidelines (N2b)
N2c, According To Ajcc Guidelines (N2c)
N3, According To Ajcc Guidelines (N3)
Clinical N Stage, Right Side
N0, According To Ajcc Guidelines (N0)
N1, According To Ajcc Criteria (N1)
N2, According To Ajcc Criteria (N2)
N2a, According To Ajcc Guidelines (N2a)
N2b, According To Ajcc Guidelines (N2b)
N2c, According To Ajcc Guidelines (N2c)
N3, According To Ajcc Guidelines (N3)
Clinical N Stage, Left Side
N0, According To Ajcc Guidelines (N0)
N1, According To Ajcc Criteria (N1)
N2, According To Ajcc Criteria (N2)
N2a, According To Ajcc Guidelines (N2a)
N2b, According To Ajcc Guidelines (N2b)
N2c, According To Ajcc Guidelines (N2c)
N3, According To Ajcc Guidelines (N3)
Clinical M Stage
M0, According To Ajcc Guidelines (M0)
M1, According To Ajcc Staging
Definitions (M1)
Mx, According To Ajcc Guidelines (MX)
Head & Neck: Disease Description -
Current Diagnosis
Type of Patient Disease
Metastatic (Metastatic)
Persistent (Persistent)
Recurrent (Recurrent)
Is this a second primary in the upper aero-
digestive tract
Yes
No
Primary Site
Antrum (Antrum)
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Base Of Tongue (Base of tongue)
Buccal Mucosa (Buccal mucosa)
Ethmoid (Ethmoid)
Faucial Arch (Faucial arch)
Floor Of Mouth (Floor of mouth)
Frontal (Frontal)
Glottic Larynx (Glottic larynx)
Hard Palate (Hard palate)
Hypopharynx Nos (Hypopharynx NOS)
Larynx Nos (Larynx NOS)
Lateral Wall (Lateral wall)
Lip And Oral Cavity (Lip and oral cavity)
Lower Gingiva (Lower gingiva)
Minor Salivary Glands (Minor salivary
glands)
Nasal Cavity (Nasal cavity)
Nasopharynx Nos (Nasopharynx NOS)
Nose Nos (Nose NOS)
Oral Cavity Nos (Oral cavity NOS)
Oral Tongue (Oral Tongue)
Oropharynx Nos (Oropharynx NOS)
Other (Other)
Paranasal Sinuses Nos (Paranasal
sinuses NOS)
Parotid (Parotid)
Postcricoid Area (Postcricoid area)
Posterior Pharyngeal Wall (Posterior
pharyngeal wall)
Posterior Superior Wall (Posterior
superior wall)
Posterior Wall (Posterior wall)
Pyriform Fossa (Pyriform fossa)
Retromolar Trigone (Retromolar trigone)
Salivary Glands Nos (Salivary glands
NOS)
Soft Palate (Soft palate)
Sphenoid (Sphenoid)
Subglottic Larynx (Subglottic larynx)
Sublingual (Sublingual)
Submandibular (Submandibular)
Supraglottic Larynx (Supraglottic larynx)
Tonsillar Fossa Tonsil (Tonsillar fossa,
tonsil)
Unknown (Unknown)
Upper Gingiva (Upper gingiva)
Name of Referring Institution (If yes, where initial
tumor was treated)
Other specify
Histologic Type
Acinic Cell Carcinoma (Acinic cell
carcinoma)
Adenocarcinoma (Adenocarcinoma)
Adenoid Cystic Carcinoma (Adenoid
cystic carcinoma)
Adenoid Squamous Cell Carcinoma
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(Adenoid squamous cell carcinoma)
Adenosquamous Carcinoma
(Adenosquamous carcinoma)
Atypical Carcinoid Tumor (Atypical
carcinoid tumor)
Basaloid Squamous Cell Carcinoma
(Basaloid squamous cell carcinoma)
Carcinoid Tumor (Carcinoid tumor)
Carcinoma In Pleomorphic Adenoma
(Carcinoma in pleomorphic adenoma)
Carcinoma In Situ (specify Histologic
Type) (Carcinoma in situ)
Clear Cell Carcinoma (Clear cell
carcinoma)
Epithelial-myoepithelial Carcinoma
(Epithelial-myoepithelial carcinoma)
Giant Cell Carcinoma (Giant cell
carcinoma)
Lymphoepithelial Carcinoma
(Lymphoepithelial carcinoma)
Mucoepidermoid Carcinoma
(Mucoepidermoid carcinoma)
Other (Other)
Salivary Duct Carcinoma (Salivary duct
carcinoma)
Small Cell Carcinoma (Small cell
carcinoma)
Spindle Cell Carcinoma (Spindle cell
carcinoma)
Squamous Cell Carcinoma Keratinizing
(Squamous cell carcinoma, keratinizing)
Squamous Cell Carcinoma Non-
keratinizing (Squamous cell carcinoma,
non-keratinizing)
Undifferentiated Carcinoma
(Undifferentiated carcinoma)
Unknown (Unknown)
Verrucous Squamous Cell Carcinoma
(Verrucous squamous cell carcinoma)
Date of Most Recent Recurrence (Current
Diagnosis of Head and Neck Cancer -
MM/DD/YYYY)
Other specify
Date of Initial Diagnosis of Metastatic Disease
(MM/DD/YYYY)
Clinical T Stage (Clinical Impression of Tumor at
Current Presentation use the version of the AJCC
staging system specified in the protocol)
T0, According To Ajcc Criteria (T0)
T1, According To Ajcc Criteria (T1)
T2, According To Ajcc Criteria (T2)
T3, According To Ajcc Criteria (T3)
T4a, According To Ajcc Guidelines (T4a)
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T4b, According To Ajcc Guidelines (T4b)
Tis, According To Ajcc Criteria (Tis)
Tx, According To Ajcc Criteria (TX)
Date of Current Pathologic Diagnosis
(MM/DD/YYYY)
Clinical N Stage (overall)
N0, According To Ajcc Guidelines (N0)
N1, According To Ajcc Criteria (N1)
N2, According To Ajcc Criteria (N2)
N2a, According To Ajcc Guidelines (N2a)
N2b, According To Ajcc Guidelines (N2b)
N2c, According To Ajcc Guidelines (N2c)
N3, According To Ajcc Guidelines (N3)
Disease Status (at Registration)
Eradicated But Recurred Locally And
Distantly (Eradicated, but recurred
distantly)
Eradicated But Recurred Locally
(Eradicated, but recurred locally)
Eradicated But Recurred Locally And
Distantly (Eradicated, but recurred locally
and distantly)
Initial Diagnosis - Distant And Metastatic
(Initial Diagnosis - distant and
metastatic)
Initial Diagnosis - Distant Only (Initial
Diagnosis - distant only)
Initial Diagnosis - Local Only (Initial
Diagnosis - local only)
Metastatic Only (Metastatic only)
Residual Disease After Prior Therapy
(Residual disease after prior therapy)
Unknown (Unknown)
Untreated (Untreated)
Clinical N Stage, Right Side
N0, According To Ajcc Guidelines (N0)
N1, According To Ajcc Criteria (N1)
N2, According To Ajcc Criteria (N2)
N2a, According To Ajcc Guidelines (N2a)
N2b, According To Ajcc Guidelines (N2b)
N2c, According To Ajcc Guidelines (N2c)
N3, According To Ajcc Guidelines (N3)
Clinical N Stage, Left Side
N0, According To Ajcc Guidelines (N0)
N1, According To Ajcc Criteria (N1)
N2, According To Ajcc Criteria (N2)
N2a, According To Ajcc Guidelines (N2a)
N2b, According To Ajcc Guidelines (N2b)
N2c, According To Ajcc Guidelines (N2c)
N3, According To Ajcc Guidelines (N3)
Clinical M Stage
M0, According To Ajcc Guidelines (M0)
M1, According To Ajcc Staging
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Definitions (M1)
Mx, According To Ajcc Guidelines (MX)
Is extracapsular spread present
No (No)
Unknown (unknown)
Yes (Yes)
Primary Site (Sites of Disease)
Yes
No
Regional Lymph Nodes
Yes
No
Distant Lymph Nodes
Yes
No
Regional soft tissue recurrence
Yes
No
Lung
Yes
No
Liver
Yes
No
Bone
Yes
No
Distant Skin/Subcutaneous Tissue
Yes
No
Other
Yes
No
If sites other than specified, indicate name
Head & Neck: Prior Health History -
Palliative
Does the patient have a chronic disease
Yes
No
Chronic Disease (If yes,)
Coronary Artery Disease (Coronary
Artery disease)
Diabetes (Diabetes)
Gastrointestinal Disease
8 / 13
On-Study - Palliative Treatment for Head and Neck Cancer - On-Study
Form - 2267713v3.0
(Gastrointestinal Disease)
High Blood Pressure (High Blood
Pressure)
Neurologic Disease (Neurologic disease)
Other, Specify (Other)
Peripheral Vascular Disease (Peripheral
Vascular disease)
Respiratory Problems (Respiratory
problems)
Other specify
Does the patient have a history of prior cancer
other than the upper aero-digestive tract
Yes
No
Site of Prior Cancer
Prior Cancer Diagnosis Date (mm dd yyyy)
Weight loss in previous six months (check one)
<5% Of Body Weight (< 5% of body
weight)
> Or = 20% Of Body Weight (> or = 20%
of body weight)
10 To <20% Of Body Weight (10 to <20%
of body weight)
5 To <10% Of Body Weight (5 to < 10%
of body weight)
Does the patient have a past history of
swallowing problems
No (No)
Unknown (Unknown)
Yes (Yes)
How long were swallowing problems apparent (If
yes,)
1 To <7 Months (1 to <7 months)
13 To <19 Months (13 to <19 months)
19 To <24 Months (19 to <24 months)
2 Years Or Longer (2 years or longer)
7 To <13 Months (7 to <13 months)
Less Than 1 Month (Less than 1 month)
Unknown (Unknown)
Does the patient currently have swallowing
problems
No (No)
Unknown (Unknown)
Yes (Yes)
How long have swallowing problems been
present (If yes,)
1 To <7 Months (1 to <7 months)
13 To <19 Months (13 to <19 months)
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19 To <24 Months (19 to <24 months)
2 Years Or Longer (2 years or longer)
7 To <13 Months (7 to <13 months)
Less Than 1 Month (Less than 1 month)
Unknown (Unknown)
Does the patient have a past history of tube
feedings
No (No)
Unknown (Unknown)
Yes (Yes)
How long were tube feedings given (If yes,)
1 To <7 Months (1 to <7 months)
13 To <19 Months (13 to <19 months)
19 To <24 Months (19 to <24 months)
2 Years Or Longer (2 years or longer)
7 To <13 Months (7 to <13 months)
Less Than 1 Month (Less than 1 month)
Unknown (Unknown)
Does the patient currently require tube feeding
No (No)
Unknown (Unknown)
Yes (Yes)
Is patient dependent on tube feeding for >50% of
nutritional support (If yes,)
No (No)
Unknown (Unknown)
Yes (Yes)
Normalcy of Diet Rating (Ask the patient what
kinds of foods are difficult for him/her to eat.
Begin at the low end of the scale. Move up the
scale, giving examples of foods in each category
and asking patient if s/he can eat those food
items. The patient's score is the highest )
0= Non-oral Feeding (tube Fed) (0)
10= Cold Liquids (10)
100= Full Diet (no Restrictions) (100)
20= Warm Liquids (20)
30= Pureed Foods (in Blender) (30)
40= Soft Foods Requiring No Chewing
(e.g., Mashed Potatoes, Apple Sauce,
Pudding) (40)
50= Soft, Chewable Foods (e.g.,
Macaroni, Canned/soft Fruits, Cooked
Vegetables, Fish, Hamburger, Small
Pieces Of Meat) (50)
60= Dry Bread And Crackers (60)
70= Raw Carrots, Celery (70)
80= All Meat (80)
90= Full Diet (liquid Assist) (90)
Public Eating Rating (Ask the patient where s/he
eats, with whom s/he eats, and whether s/he
alters his/her diet according to where s/he is
eating. Choose the score that best fits the
patient.)
10 / 13
On-Study - Palliative Treatment for Head and Neck Cancer - On-Study
Form - 2267713v3.0
0= Always Eats Alone (0)
100= No Restriction Of Place, Food Or
Companion (eats Out At Any
Opportunity) (100)
25= Eats Only At Home In Presence Of
Selected Persons (25)
50= Eats Only In Presence Of Selected
Persons In Selected Places (50)
75= No Restriction Of Place, But
Restricts Diet When In Public (eats
Anywhere, But May Limit Intake To Less
"messy" Foods, E.g., Liquids) (75)
Understandability of Speech Rating (Score based
on the interviewer's ability to understand the
patient during conversation. Choose the score
that best fits the patient.)
0= Never Understandable; May Use
Written Communication (0)
100= Always Understandable (100)
25= Difficult To Understand (25)
50= Usually Understandable; Face-to-
face Contact Necessary (50)
75= Understandable Most Of The Time;
Occasional Repetition Necessary (75)
Head & Neck: Prior Treatement - Systemic
Therapy
Prior systemic therapy
Yes
No
Prior Treatment Regimen Name (s Drug, Agent,
Biologic)
Prior Treatment Regimen Start Date (mm dd
yyyy)
Prior Treatment Regimen End Date (mm dd yyyy)
Prior Treatment Regimen Type (* Prior Treatment
Regimen Type:)
Adjuvant (Adjuvant)
Concurrent With Rt (Concurrent with RT)
Induction (Induction)
Other Specify (Other)
Palliative Therapy (Palliative)
Unknown (Unknown)
Did patient complete prior therapy regimen
No (No)
Unknown (Unknown)
Yes (Yes)
Reason for Ending Prior Therapy (If no,)
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Adverse Event/toxicity (Adverse
Event/Toxicity)
Other (Other)
Progressive Disease (Progressive
Disease)
Unknown (Unknown)
Other specify
Head & Neck: Prior Treatment - Radiation
Therapy
Prior Radiation Therapy
Yes
No
Prior RT Site
Prior Treatment Regimen Start Date (mm dd
yyyy)
Prior Treatment Regimen End Date (mm dd yyyy)
Prior RT Modality (* Prior RT Modality:)
Brachytherapy (Brachytherapy)
External Beam (External beam)
Imrt (IMRT)
Other (Other)
Unknown (Unknown)
Did patient complete prior therapy regimen
No (No)
Unknown (Unknown)
Yes (Yes)
Reason for Ending Prior Therapy (If no,)
Adverse Event/toxicity (Adverse
Event/Toxicity)
Other (Other)
Progressive Disease (Progressive
Disease)
Unknown (Unknown)
Other specify
Head & Neck: Prior Treatment - Surgery
Prior Surgery
Yes
No
Prior Surgery Type (If yes,)
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Prior Surgery Date (mm dd yyyy)
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On-Study - Chronic Lymphocytic Leukemia (CLL) - On-Study
Form - Relapse/Refractory Treatment - 2019359v3.0
Chronic Lymphocytic Leukemia (CLL) - On-Study Form -
Relapse/Refractory Treatment
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=1B4E5CE3-
0004-66BF-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/7204
Chronic Lymphocytic Leukemia
(CLL) - On-Study Form -
Relapse/Refractory Treatment
Crf Header
Coordinating Group Protocol No.
Coordinating Group Code
Protocol Title
Patient Study ID
Institution/Affiliate
Other Patient ID
Participating Group Code
Patient Initials
Registration Type
Leukemia/mds: Form Administration
Person Completing Form
Are data amended (If data are amended, please
circle in red when using paper form)
Yes
No
Aml: Disease Description, Previously
Untreated
Rai Stage Classification
Lymphocytosis In Blood With
Lymphocyte Count > 15,000/mcl And
Bone Marrow Populated With Mature
Lymphocytes Comprising >40% Of
Nucleated Cells (Stage 0)
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Same As Stage 0 With
Lymphadenopathy (Stage I)
Includes Same Degree Of
Lymphocytosis As Stage 0, Plus
Enlarged Spleen And/or Liver (Stage II)
Includes Lymphocytosis And Anemia
Defined As Hgb <11 G/dl Or Hct <33%.
Physical Findings Of Lymphadenopathy,
Hepatomegaly Or Splenomegaly Are Not
Required. No Distinction With Regard To
Type Of Anemia (i.e. Hemolytic) Is Made
(Stage III)
Includes The Findings At Diagnosis Of
Lymphocytosis As Defined In Stage 0,
With Thrombocytopenia <100,000/mcl.
Anemia And Organomegaly May Be
Absent. (Stage IV)
Disease Status
Other, Specify (Other)
Refractory (refractory NOS)
Refractory To First Induction (Refractory
to 1st induction)
Refractory To Reinduction After
Complete Response (Refractory to
reinduction after CR)
Relapse (relapse NOS)
First Relapse (Relapse: 1st)
Second Relapse (Relapse: 2nd)
Third Or Greater Relapse (Relapse:
3rd+)
Other specify
What was the duration of the preceding
response? (For relapsed ALL,)
Duration Of Response Less Than 6
Months (< 6 months)
Duration Of Response Greater Than Or
Equal To 6 Months (> or = 6 months)
Duration Of Response Unknown
(Unknown)
Date Hematology (Blood) Sample Obtained
(Peripheral Blood mm dd yyyy)
White Blood Cell Count (x 10^3/mcL)
Peripheral Platelet Count (x 10^3/mcL)
Hemoglobin (g/dL)
Peripheral Lymphocytes (%)
Peripheral Prolymphocytes (%)
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Peripheral Atypical Lymphocytes (%)
Date of Bone Marrow Biopsy (Bone Marrow
Biopsy/Aspirate mm dd yyyy)
Marrow Cellularity (%)
Marrow Lymphocytes (%)
Marrow Cellularity Status
Cellularity Status Of Bone Marrow Is
Aplasitc (severely Hypocellular) (Aplastic
(severely hypocellular))
Cellularity Status Of Bone Marrow
Unknown, Procedure Resulted In No
Material To Analyze (Dry tap or
inaspirable)
Cellularity Status Of Bone Marrow Is
Hypercellular (Hypercellular)
Cellularity Status Of Bone Marrow Is
Hypocellular (Hypocellular)
Cellularity Status Of Bone Marrow Is
Normocellular (Normocellular)
Cellularity Status Of Bone Marrow Is
Packed (intensely Hypercellular) (Packed
(intensely hypercellular))
Palpable splenomegaly (Organ Involvement)
Examination Performed And
Splenomegaly Absent (No)
Examination Of Spleen Not Performed
(Not examined)
Spleen Removed Via Prior Surgery
(Surgically absent)
Examination Performed And
Splenomegaly Present (Yes)
Splenomegaly by scan (or x-ray)
Examination Performed And
Splenomegaly Absent (No)
Examination Of Spleen Not Performed
(Not examined)
Spleen Removed Via Prior Surgery
(Surgically absent)
Examination Performed And
Splenomegaly Present (Yes)
Palpable hepatomegaly
Examination Performed And
Hepatomegaly Absent (No)
Examination Of Liver Not Performed (Not
examined)
Examination Performed And
Hepatomegaly Present (Yes)
Hepatomegaly by scan (or x-ray)
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Examination Performed And
Hepatomegaly Absent (No)
Examination Of Liver Not Performed (Not
examined)
Examination Performed And
Hepatomegaly Present (Yes)
Palpable lymphadenopathy
Examination Performed And
Lymphadenopathy Absent (No)
Examination Of Lymph Nodes Not
Performed (Not examined)
Examination Performed And
Lymphadenopathy Present (Yes)
Lymphadenopathy by scan (or x-ray)
Examination Performed And
Lymphadenopathy Absent (No)
Examination Of Lymph Nodes Not
Performed (Not examined)
Examination Performed And
Lymphadenopathy Present (Yes)
Prior Chemotherapy Treatment with Fludarabine?
Yes
No
Allows Documentation Of Any Additional
Cooments
Comments
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Treatment - Phase II Breast Cancer - Treatment
Summary Form - Subset of Patients - 2555139v1.0
Phase II Breast Cancer - Treatment Summary Form -
Subset of Patients
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=24E35605-
B9C9-0C9B-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/7210
Phase II Breast Cancer - Treatment
Summary Form - Subset of Patients
Crf Header
Coordinating Group Protocol No.
Coordinating Group Code
Protocol Title
Patient Study ID
Institution/Affiliate
Registering Group Code
Registering Institution Code
Patient Initials
Breast: Form Administration
Person Completing Form
Are data amended? (If data are amended, please
circle in red when using paper form)
Yes
No
Breast: Treatment Cycle Information
Cycle Start Date
Current Cycle Number
Total Dose of Agents/Drugs for this Cycle (use
protocol specified units)
Units
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Agent Name (Some groups may pre-print
protocol agents with appropriate units.)
Comments
Comments
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of Patients - 2555139v1.0
On-Study - Phase II Breast Cancer - Advanced
Disease On-Study Form - 2583382v1.0
Phase II Breast Cancer - Advanced Disease On-Study
Form
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=258957C7-
A3E4-6659-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/7212
Phase II Breast Cancer - Advanced
Disease On-Study Form
Crf Header
Coordinating Group Protocol No.
Coordinating Group Code
Protocol Title
Patient Study ID
Institution/Affiliate
Registering Group Code
Registering Institution Code
Patient Initials
Breast: Form Administration
Person Completing Form
Are data amended? (If data are amended, please
circle in red when using paper form)
Yes
No
Breast: Patient Characteristics
Patient Age
Menopausal Status
Post (prior Bilateral Ovariectomy Or >12
Mo Since Lmp With No Prior
Hysterectomy And Not Currently
Receiving Therapy With Lh-rh Analogs
[e.g., Zoladex]) (Post (prior bilateral
ovariectomy OR >12 mo since LMP with
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no prior hysterectomy AND not currently
receiving therapy with LH-RH analogs
(e.g., Zoladex)))
Post (prior Bilateral Ovariectomy Or >12
Mo Since Lmp With No Prior
Hysterectomy) (Post (prior bilateral
ovariectomy OR >12 mo since LMP with
no prior hysterectomy))
Pre (<6 Mo Since Lmp And No Prior
Bilateral Ovariectomy And Not On
Estrogen Replacement) (Pre (<6 mo
since LMP AND no prior bilateral
ovariectomy AND not on estrogen
replacement))
Hormone therapy
Yes
No
Breast: Advanced Disease Description
Tumor Laterality (check one)
Bilateral (Bilateral)
Left (Left)
Right (Right)
HER2/neu Final Diagnosis (Primary Tumor)
Negative (Negative)
Positive (Positive)
Receptor Status, ER (Metastatic Tumor)
Negative (Negative)
Positive (Positive)
Receptor Status, ER (Metastatic Tumor)
Negative (Negative)
Positive (Positive)
Receptor Status, PgR (Metastatic Tumor)
Negative (Negative)
Positive (Positive)
Receptor Status, PgR (Metastatic Tumor)
Negative (Negative)
Positive (Positive)
Tumor Marker Test Method (Metastatic Tumor)
Elisa (ELISA)
Fluorescence In Situ Hybridization (fish)
(Fluorescence in situ hybridization
(FISH))
Immunohistochemistry (ihc)
(Immunohistochemistry (IHC))
Other, Specify (Other)
Tumor Marker Test Method (Metastatic Tumor)
Elisa (ELISA)
Fluorescence In Situ Hybridization (fish)
(Fluorescence in situ hybridization
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(FISH))
Immunohistochemistry (ihc)
(Immunohistochemistry (IHC))
Other, Specify (Other)
Other specify
Other specify
Date of Initial Diagnosis of Primary Tumor
Date Progressive or Metastatic Disease First
Diagnosed (Unless otherwise specified per
protocol, the diagnosis can be radiologically or
pathologically measured.)
Date of Most Recent Progression
Stage Grouping Assessment Method (Disease
Stage Classification at diagnosis - Indicate
highest stage)
Clinical (Clinical)
Pathologic (Pathologic)
Stage Grouping
Tis, N0, M0 (0)
T1*, N0, M0 (I)
T0, N1, M0 Or T1*, N1, M0 Or T2, N0,
M0 (IIA)
T2, N1, M0 Or T3, N0, M0 (IIB)
T0, N2, M0 Or T1*, N2, M0 Or T2, N2,
M0 Or T3, N1, M0 Or T3, N2, M0 (IIIA)
T4, N0, M0 Or T4, N1, M0 Or T4, N2, M0
(IIIB)
Any T, N3, M0 (IIIC)
Any T, Any N, M1 (IV)
Histologic Grade (For breast cancer, the
Nottingham combined histologic grade is
recommended)
G1 Low Combined Histologic Grade
(favorable) (G1)
G2 Intermediate Combined Histologic
Grade (moderately Favorable) (G2)
G3 High Combined Histologic Grade
(unfavorable) (G3)
Gx Grade Cannot Be Assessed (GX)
Breast: Site(s) Of Progression
Sites of Progression (check all that apply)
Bone (Bone)
Bone Marrow (Bone marrow)
Brain (Brain)
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Distant Lymph Nodes (Distant nodes)
Distant Skin/subcutaneous Tissue
(Distant skin/subcutaneous tissue)
Other Site(s) (First Other, specify)
Ipsilateral Supraclavicular Nodes
(Ipsilateral supraclavicular nodes)
Liver (Liver)
Local-regional (including Ipsilateral
Breast; Chest Wall; Axillary, Internal
Mammary, And Infraclavicular Nodes;
Local-regional Skin And Subcutaneous
Tissue) (Local-regional)
Lung, Nos (Lung)
Contralateral Breast (Opposite breast)
Other Cns (Other CNS)
Pleura (Pleura)
Other Site(s) (Second Other, specify)
If sites other than specified, Indicate Name
If sites other than specified, Indicate Name
Total Number of Sites Involved
Breast: Advanced Treatment - Prior
Systemic Therapy
Prior Adjuvant Hormonal Therapy? (do not
include steroids given with chemotherapy)
Yes
No
Prior Hormonal Therapy for Metastasis or
Recurrence? (do not include steroids given with
chemotherapy)
Yes
No
Prior Adjuvant Chemotherapy? (include pre-op
chemotherapy at diagnosis)
Yes
No
Prior Chemotherapy for Metastasis or
Recurrence?
Yes
No
Prior Adjuvant High Dose
Chemotherapy/Autologous Stem Cell Transplant
(HDC/ASCT)
Yes
No
Prior HDC/ASCT for Metastasis or Recurrence?
Yes
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No
Prior Adjuvant Immunotherapy?
Yes
No
Prior Immunotherapy for Metastasis or
Recurrence?
Yes
No
Prior Adjuvant Biologic Therapy
Yes
No
Prior Biologic Thearpy for Metastatic or
Recurrence
Yes
No
Prior Adjuvant Other Therapy?
Yes
No
Prior Other Therapy for Metastasis or
Recurrence?
Yes
No
Breast: Advanced Prior Treatment -
Systemic Regimens
Number of prior therapy regimens
Agent Name
Agent Start Date
Agent End Date
Agent Total Cumulative Dose
No. of Cycles
Overall Response Duration
Lung: Prior Radiation Therapy ¿ Nsclc
Advanced
Prior Radiation Therapy
Yes
No
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Prior Radiation Therapy Type
Local-regional (Local-Regional)
Metastatic (Metastatic)
Total Dose to Breast (cGy)
Radiation Therapy End Date
Type of Radiation Therapy Administered
External Beam Radiation (External beam
radiation)
Other (Other specify)
Other specify
Radiation Therapy Site
RT Dose per Fraction (units)
Units
Centigrays (cGy)
Millicurie (mCi)
Units
Centigrays (cGy)
Millicurie (mCi)
Total Number of Fractions
RT Total Dose (units)
Were there any unscheduled interruptions in
radiation therapy?
No (No)
Yes, Due To Toxicity (Yes, due to toxicity)
Yes, For Other Reasons, Specify (Yes,
for other reasons)
RT Interruption Reason (Specify)
Breast: Prior Surgery
Prior Surgery
No (No)
Unknown (Unknown)
Yes (Yes)
Most Extensive Primary Surgery (check one)
Mastectomy, Nos (Mastectomy NOS)
Partial Mastectomy, Lumpectomy Or
Excisional Biopsy (Partial
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mastectomy/lumpectomy/excisional
biopsy)
Date of Most Extensive Primary Surgery (if
required, use last re-excision date)
Other tumor excision
Yes
No
Specify
Breast: Prior Surgery
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On-Study - Chronic Myelogenous Leukemia (CML) - On-
Study Form - Previously Untreated Patients - 2019399v3.0
Chronic Myelogenous Leukemia (CML) - On-Study Form -
Previously Untreated Patients
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=1B4E6321-
54CD-675B-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/7214
Chronic Myelogenous Leukemia
(CML) - On-Study Form - Previously
Untreated Patients
Crf Header
Coordinating Group Protocol No.
Coordinating Group Code
Protocol Title
Patient Study ID
Institution/Affiliate
Other Patient ID
Participating Group Code
Patient Initials
Registration Type
Leukemia/mds: Form Administration
Person Completing Form
Are data amended (If data are amended, please
circle in red when using paper form)
Yes
No
Aml: Disease Description, Previously
Untreated
Date of Initial Pathologic Diagnosis (mm dd yyyy
enter test date for first diagnosis of leukemia)
Leukemia Classification (*Alternately, the CDE
WHO Diagnosis can be used.)
1 / 3
Disease Classified As Chronic
Myelogenous Leukemia (cml),
Accelerating Phase; (Chronic
myelogenous leukemia (CML),
accelerating phase)
Disease Classified As Chronic
Myelogenous Leukemia (cml), Chronic
Phase (Chronic myelogenous leukemia
(CML), chronic phase)
Disease Classified As Chronic
Myelogenous Leukemia, (cml), Blast
Crisis (Chronic myelogenous leukemia,
(CML), blast crisis)
Disease Classified As Cml, Not
Otherwise Specified (nos); (CML, not
otherwise specified (NOS))
Other (Other)
Other specify
CML Lineage
Lymphoid (Lymphoid)
Myeloid (Myeloid)
Not Otherwise Specified: C19594 (Not
otherwise specified)
Other (Other)
Unknown (Unknown)
Other specify
Date Hematology (Blood) Sample Obtained
(Peripheral Blood mm dd yyyy)
White Blood Cell Count (x 10^3/mcL)
Peripheral Platelet Count (x 10^3/mcL)
Peripheral Neutrophils/Bands (%)
Peripheral Blasts (%)
Date of Bone Marrow Biopsy (Bone Marrow
Biopsy/Aspirate mm dd yyyy)
Marrow Cellularity (%)
Marrow Blasts (%)
Marrow Cellularity Status
Cellularity Status Of Bone Marrow Is
Aplasitc (severely Hypocellular) (Aplastic
(severely hypocellular))
Cellularity Status Of Bone Marrow
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Unknown, Procedure Resulted In No
Material To Analyze (Dry tap or
inaspirable)
Cellularity Status Of Bone Marrow Is
Hypercellular (Hypercellular)
Cellularity Status Of Bone Marrow Is
Hypocellular (Hypocellular)
Cellularity Status Of Bone Marrow Is
Normocellular (Normocellular)
Cellularity Status Of Bone Marrow Is
Packed (intensely Hypercellular) (Packed
(intensely hypercellular))
Allows Documentation Of Any Additional
Cooments
Comments
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On-Study - Acute Lymphocytic Leukemia (ALL) - On-Study
Form - Relapse/Refractory Treatment - 2019356v3.0
Acute Lymphocytic Leukemia (ALL) - On-Study Form -
Relapse/Refractory Treatment
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=1B24EE5B-
237E-50D5-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/7218
Acute Lymphocytic Leukemia (ALL) -
On-Study Form - Relapse/Refractory
Treatment
Crf Header
Coordinating Group Protocol No.
Coordinating Group Code
Protocol Title
Patient Study ID
Institution/Affiliate
Other Patient ID
Participating Group Code
Patient Initials
Registration Type
Leukemia/mds: Form Administration
Person Completing Form
Are data amended (If data are amended, please
circle in red when using paper form)
Yes
No
Aml: Disease Description, Previously
Untreated
Leukemia Classification (*Alternately, the CDE
WHO Diagnosis can be used.)
Disease Classified As Acute
Lymphoblastic Leukemia (fab L2) (Acute
lymphoblastic leukemia (FAB L2))
Disease Classified As Acute
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Lymphoblastic Leukemia (fab L3) (Acute
lymphoblastic leukemia (FAB L3))
Disease Classified As Acute
Lympoblastic Leukemia (fab L1) (Acute
lympoblastic leukemia (FAB L1))
Disease Classified As Acute
Undifferentiated Leukemia (aul) (Acute
undifferentiated leukemia (AUL))
Disease Classified As All, Not Otherwise
Specified (nos); (ALL, not otherwise
specified (NOS))
Disease Is A Mixed Lineage Acute
Leukemia (Mixed lineage acute
leukemia)
Other (Other)
Disease Is An Unclassifiable Acute
Leukemia (Unclassifiable acute
leukemia)
Other specify
Disease Status
Other, Specify (Other)
Refractory (refractory NOS)
Refractory To First Induction (Refractory
to 1st induction)
Refractory To Reinduction After
Complete Response (Refractory to
reinduction after CR)
Relapse (relapse NOS)
First Relapse (Relapse: 1st)
Second Relapse (Relapse: 2nd)
Third Or Greater Relapse (Relapse:
3rd+)
Other specify
What was the duration of the preceding
response? (For relapsed ALL,)
Duration Of Response Less Than 6
Months (< 6 months)
Duration Of Response Greater Than Or
Equal To 6 Months (> or = 6 months)
Duration Of Response Unknown
(Unknown)
Date Hematology (Blood) Sample Obtained
(Peripheral Blood mm dd yyyy)
White Blood Cell Count (x 10^3/mcL)
Peripheral Lymphocytes (%)
Peripheral Blasts (%)
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Date of Bone Marrow Biopsy (Bone Marrow
Biopsy/Aspirate mm dd yyyy)
Marrow Cellularity (%)
Marrow Lymphocytes (%)
Marrow Blasts (%)
Marrow Cellularity Status
Cellularity Status Of Bone Marrow Is
Aplasitc (severely Hypocellular) (Aplastic
(severely hypocellular))
Cellularity Status Of Bone Marrow
Unknown, Procedure Resulted In No
Material To Analyze (Dry tap or
inaspirable)
Cellularity Status Of Bone Marrow Is
Hypercellular (Hypercellular)
Cellularity Status Of Bone Marrow Is
Hypocellular (Hypocellular)
Cellularity Status Of Bone Marrow Is
Normocellular (Normocellular)
Cellularity Status Of Bone Marrow Is
Packed (intensely Hypercellular) (Packed
(intensely hypercellular))
Extramedullary Disease Involvement (check all
that apply)
Central Nervous System (Central
nervous system)
Granulocytic Sarcoma (Chloroma)
Gingival Hypertrophy (Gingival
hypertrophy)
Mediastinal Mass (Mediastinal mass)
Other Specify (Other)
Peripheral Nervous System (Peripheral
nervous system)
Leukaemia Cutis (Skin (leukemia cutis))
Other specify
Palpable splenomegaly (Organ Involvement)
Examination Performed And
Splenomegaly Absent (No)
Examination Of Spleen Not Performed
(Not examined)
Spleen Removed Via Prior Surgery
(Surgically absent)
Examination Performed And
Splenomegaly Present (Yes)
Splenomegaly by scan (or x-ray)
Examination Performed And
Splenomegaly Absent (No)
Examination Of Spleen Not Performed
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(Not examined)
Spleen Removed Via Prior Surgery
(Surgically absent)
Examination Performed And
Splenomegaly Present (Yes)
Palpable hepatomegaly
Examination Performed And
Hepatomegaly Absent (No)
Examination Of Liver Not Performed (Not
examined)
Examination Performed And
Hepatomegaly Present (Yes)
Hepatomegaly by scan (or x-ray)
Examination Performed And
Hepatomegaly Absent (No)
Examination Of Liver Not Performed (Not
examined)
Examination Performed And
Hepatomegaly Present (Yes)
Palpable lymphadenopathy
Examination Performed And
Lymphadenopathy Absent (No)
Examination Of Lymph Nodes Not
Performed (Not examined)
Examination Performed And
Lymphadenopathy Present (Yes)
Lymphadenopathy by scan (or x-ray)
Examination Performed And
Lymphadenopathy Absent (No)
Examination Of Lymph Nodes Not
Performed (Not examined)
Examination Performed And
Lymphadenopathy Present (Yes)
Prior bone marrow or peripheral blood stem cell
transplant? (for ALL)
Yes
No
Type of Bone Marrow or Peripheral Blood Stem
Cell (PBSC) Transplant (If yes,)
Bone Marrow Stem Cells Used For
Transplant Obtained From Recipient
Him/herself (Autologous bone marrow)
Peripheral Blood Stem Cells Used For
Transplant Obtained From Recipient
Him/herself (Autologous PBSC)
Bone Marrow Stem Cells Used For
Transplant Obtained From Antigen-
matched Sibling Or Family Member Of
Recipient (Bone marrow from matched
sibling or family member)
Bone Marrow Stem Cells Used For
Transplant Obtained From Antigen-
matched Individual Unrelated To
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Recipient (Bone marrow from matched
unrelated donor)
Other Specify (Other)
Peripheral Blood Stem Cells Used For
Transplant Obtained From Antigen-
matched Sibling Or Family Member Of
Recipient (PBSC from matched sibling or
family member)
Peripheral Blood Stem Cells Used For
Transplant Obtained From Antigen-
matched Individual Unrelated To
Recipient (PBSC from matched
unrelated donor)
Other specify
Allows Documentation Of Any Additional
Cooments
Comments
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Form - Previously Untreated Patients - 2019397v3.0
Acute Lymphocytic Leukemia (ALL) - On-Study Form -
Previously Untreated Patients
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=1B24E435-
7CDC-500C-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/7219
Acute Lymphocytic Leukemia (ALL) -
On-Study Form - Previously
Untreated Patients
Crf Header
Coordinating Group Protocol No.
Coordinating Group Code
Protocol Title
Patient Study ID
Institution/Affiliate
Other Patient ID
Participating Group Code
Patient Initials
Registration Type
Leukemia/mds: Form Administration
Person Completing Form
Are data amended (If data are amended, please
circle in red when using paper form)
Yes
No
Aml: Disease Description, Previously
Untreated
Date of Initial Pathologic Diagnosis (mm dd yyyy
enter test date for first diagnosis of leukemia)
Leukemia Classification (*Alternately, the CDE
WHO Diagnosis can be used.)
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Disease Classified As Acute
Lymphoblastic Leukemia (fab L2) (Acute
lymphoblastic leukemia (FAB L2))
Disease Classified As Acute
Lymphoblastic Leukemia (fab L3) (Acute
lymphoblastic leukemia (FAB L3))
Disease Classified As Acute
Lympoblastic Leukemia (fab L1) (Acute
lympoblastic leukemia (FAB L1))
Disease Classified As Acute
Undifferentiated Leukemia (aul) (Acute
undifferentiated leukemia (AUL))
Disease Classified As All, Not Otherwise
Specified (nos); (ALL, not otherwise
specified (NOS))
Disease Is A Mixed Lineage Acute
Leukemia (Mixed lineage acute
leukemia)
Other (Other)
Disease Is An Unclassifiable Acute
Leukemia (Unclassifiable acute
leukemia)
Other specify
Date Hematology (Blood) Sample Obtained
(Peripheral Blood mm dd yyyy)
White Blood Cell Count (x 10^3/mcL)
Peripheral Lymphocytes (%)
Peripheral Blasts (%)
Date of Bone Marrow Biopsy (Bone Marrow
Biopsy/Aspirate mm dd yyyy)
Marrow Cellularity (%)
Marrow Lymphocytes (%)
Marrow Blasts (%)
Marrow Cellularity Status
Cellularity Status Of Bone Marrow Is
Aplasitc (severely Hypocellular) (Aplastic
(severely hypocellular))
Cellularity Status Of Bone Marrow
Unknown, Procedure Resulted In No
Material To Analyze (Dry tap or
inaspirable)
Cellularity Status Of Bone Marrow Is
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Hypercellular (Hypercellular)
Cellularity Status Of Bone Marrow Is
Hypocellular (Hypocellular)
Cellularity Status Of Bone Marrow Is
Normocellular (Normocellular)
Cellularity Status Of Bone Marrow Is
Packed (intensely Hypercellular) (Packed
(intensely hypercellular))
Extramedullary Disease Involvement (check all
that apply)
Central Nervous System (Central
nervous system)
Granulocytic Sarcoma (Chloroma)
Gingival Hypertrophy (Gingival
hypertrophy)
Mediastinal Mass (Mediastinal mass)
Other Specify (Other)
Peripheral Nervous System (Peripheral
nervous system)
Leukaemia Cutis (Skin (leukemia cutis))
Other specify
Palpable splenomegaly (Organ Involvement)
Examination Performed And
Splenomegaly Absent (No)
Examination Of Spleen Not Performed
(Not examined)
Spleen Removed Via Prior Surgery
(Surgically absent)
Examination Performed And
Splenomegaly Present (Yes)
Splenomegaly by scan (or x-ray)
Examination Performed And
Splenomegaly Absent (No)
Examination Of Spleen Not Performed
(Not examined)
Spleen Removed Via Prior Surgery
(Surgically absent)
Examination Performed And
Splenomegaly Present (Yes)
Palpable hepatomegaly
Examination Performed And
Hepatomegaly Absent (No)
Examination Of Liver Not Performed (Not
examined)
Examination Performed And
Hepatomegaly Present (Yes)
Hepatomegaly by scan (or x-ray)
Examination Performed And
Hepatomegaly Absent (No)
Examination Of Liver Not Performed (Not
examined)
Examination Performed And
Hepatomegaly Present (Yes)
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Palpable lymphadenopathy
Examination Performed And
Lymphadenopathy Absent (No)
Examination Of Lymph Nodes Not
Performed (Not examined)
Examination Performed And
Lymphadenopathy Present (Yes)
Lymphadenopathy by scan (or x-ray)
Examination Performed And
Lymphadenopathy Absent (No)
Examination Of Lymph Nodes Not
Performed (Not examined)
Examination Performed And
Lymphadenopathy Present (Yes)
Immunophenotype Lineage
B-cell Immunophenotype (B-cell)
Indeterminate Immunophenotype
(Indeterminate)
Mixed Cells Immunophenotype (Mixed)
Non-t/non-b Cell Immunophenotype
(Non-T/Non-B)
Other Specified Immunophenotype
(Other)
T-cell Immunophenotype (T-cell)
Other specify
Allows Documentation Of Any Additional
Cooments
Comments
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On-Study - Acute Promyelocytic Leukemia (APL) - On-Study
Form - Relapse/Refractory Treatment - 2019357v3.0
Acute Promyelocytic Leukemia (APL) - On-Study Form -
Relapse/Refractory Treatment
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=1B24F56C-
41C2-5165-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/7221
Acute Promyelocytic Leukemia (APL)
- On-Study Form -
Relapse/Refractory Treatment
Crf Header
Coordinating Group Protocol No.
Coordinating Group Code
Protocol Title
Patient Study ID
Institution/Affiliate
Other Patient ID
Participating Group Code
Patient Initials
Registration Type
Leukemia/mds: Form Administration
Person Completing Form
Are data amended (If data are amended, please
circle in red when using paper form)
Yes
No
Aml: Disease Description, Previously
Untreated
Leukemia Classification (*Alternately, the CDE
WHO Diagnosis can be used.)
Disease Classified As Acute
Promyelocytic Leukemia (fab M3) (Acute
promyelocytic leukemia (FAB M3))
Disease Classified As Acute
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Promyelocytic Leukemia-microgranular
(fab M3v) (Acute promyelocytic
leukemia-microgranular (FAB M3V))
Other (Other)
Other specify
Karyotypic t(15:17) translocation positive?
Indeterminate (Indeterminate)
No (No)
Not Done (Not done)
Yes (Yes)
Disease Status
Other, Specify (Other)
Refractory (refractory NOS)
Refractory To First Induction (Refractory
to 1st induction)
Refractory To Reinduction After
Complete Response (Refractory to
reinduction after CR)
Relapse (relapse NOS)
First Relapse (Relapse: 1st)
Second Relapse (Relapse: 2nd)
Third Or Greater Relapse (Relapse:
3rd+)
Other specify
What was the duration of the preceding
response? (For relapsed APL,)
Duration Of Response Less Than 6
Months (< 6 months)
Duration Of Response Greater Than Or
Equal To 6 Months (> or = 6 months)
Duration Of Response Unknown
(Unknown)
Date Hematology (Blood) Sample Obtained
(Peripheral Blood mm dd yyyy)
White Blood Cell Count (x 10^3/mcL)
Peripheral Neutrophils/Bands (%)
Peripheral Blasts (%)
Peripheral Promyelocytes (%)
Date of Bone Marrow Biopsy (Bone Marrow
Biopsy/Aspirate mm dd yyyy)
Marrow Cellularity (%)
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Marrow Promyelocytes (%)
Marrow Blasts (%)
Marrow Cellularity Status
Cellularity Status Of Bone Marrow Is
Aplasitc (severely Hypocellular) (Aplastic
(severely hypocellular))
Cellularity Status Of Bone Marrow
Unknown, Procedure Resulted In No
Material To Analyze (Dry tap or
inaspirable)
Cellularity Status Of Bone Marrow Is
Hypercellular (Hypercellular)
Cellularity Status Of Bone Marrow Is
Hypocellular (Hypocellular)
Cellularity Status Of Bone Marrow Is
Normocellular (Normocellular)
Cellularity Status Of Bone Marrow Is
Packed (intensely Hypercellular) (Packed
(intensely hypercellular))
Disseminated Intravascular Coagulation (DIC)
Absent (Absent)
Dic Present With Bleeding (Present
WITH bleeding)
Dic Present, Bleeding Absent (Present
with NO bleeding)
Antigen (Antigen Expression)
Cd56 (CD56)
Hla-dr (HLA-DR)
CD56 Positive Cells (%) (If assessed,)
HLA-DR Positive Cells (%)
Prior ATRA treatment for APL?
No (No)
Unknown (Unknown)
Yes (Yes)
Prior cytotoxic chemotherapy treatment for APL?
(including hydroxyurea or arsenic trioxide)
No (No)
Unknown (Unknown)
Yes (Yes)
Yes specify  (If)
Allows Documentation Of Any Additional
Cooments
Comments
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On-Study - Acute Myeloid Leukemia (AML)/Myelodysplastic Syndrome
(MDS) - On-Study Form - Relapse/Refractory Treatment - 2019378v3.0
Acute Myeloid Leukemia (AML)/Myelodysplastic Syndrome
(MDS) - On-Study Form - Relapse/Refractory Treatment
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=1B24FD93-
54A8-51C5-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/7223
Acute Myeloid Leukemia
(AML)/Myelodysplastic Syndrome
(MDS) - On-Study Form -
Relapse/Refractory Treatment
Crf Header
Coordinating Group Protocol No.
Coordinating Group Code
Protocol Title
Patient Study ID
Institution/Affiliate
Other Patient ID
Participating Group Code
Patient Initials
Registration Type
Leukemia/mds: Form Administration
Person Completing Form
Are data amended (If data are amended, please
circle in red when using paper form)
Yes
No
Aml: Disease Description, Previously
Untreated
Leukemia/MDS Classification (*Alternately, the
CDE WHO Diagnosis can be used.)
Disease Classified As Acute
Erythroblastic Leukemia (fab M6) (Acute
erythroblastic leukemia (FAB M6))
Disease Classified As Acute
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Megakaryoblastic Leukemia (fab M7)
(Acute megakaryoblastic leukemia (FAB
M7))
Disease Classified As Acute Monocytic
Leukemia (fab M5) (Acute monocytic
leukemia (FAB M5))
Disease Classified As Acute Myeloid
Leukemia W/ Maturation (fab M2) (Acute
myeloid leukemia w/ maturation (FAB
M2))
Disease Classified As Acute Myeloid
Leukemia W/o Maturation (fab M1)
(Acute myeloid leukemia w/o maturation
(FAB M1))
Disease Classified As Acute
Myelomonocytic Leukemia (fab M4)
(Acute myelomonocytic leukemia (FAB
M4))
Disease Classified As Acute
Promyelocytic Leukemia (fab M3) (Acute
promyelocytic leukemia (FAB M3))
Disease Classified As Acute
Undifferentiated Leukemia (aul) (Acute
undifferentiated leukemia (AUL))
Disease Classified As Aml, Not
Otherwise Specified (nos) (AML, not
otherwise specified (NOS))
Disease Classified As Chronic
Myelomonocytic Leukemia (cmml)
(Chronic myelomonocytic leukemia
(CMML))
Disease Is A Mixed Lineage Acute
Leukemia (Mixed lineage acute
leukemia)
Disease Classified As Myelodysplastic
Syndrome (mds) Nos (Myelodysplastic
syndrome (MDS) NOS)
Disease Classified As Myeloproliferative
Syndrome Nos; (Myeloproliferative
syndrome NOS;)
Other (Other)
Disease Classified As Refractory Anemia
(ra) (Refractory anemia (RA))
Disease Classified As Refractory Anemia
W/ Excess Blasts In Transformation
(raeb-t) (Refractory anemia w/ excess
blasts in transformation (RAEB-t))
Disease Classified As Refractory Anemia
W/ Ring Sideroblasts (rars) (Refractory
anemia w/ ring sideroblasts (RARS))
Disease Classified As Refractory Anemia
W/excess Blasts (raeb) (Refractory
anemia w/excess blasts (RAEB))
Disease Is An Unclassifiable Acute
Leukemia (Unclassifiable acute
leukemia)
Disease Classified As Undifferentiated
Acute Myeloid Leukemia (fab M0)
(Undifferentiated acute myeloid leukemia
(FAB M0))
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Other specify
Disease Status
Other, Specify (Other)
Refractory (refractory NOS)
Refractory To First Induction (Refractory
to 1st induction)
Refractory To Reinduction After
Complete Response (Refractory to
reinduction after CR)
Relapse (relapse NOS)
First Relapse (Relapse: 1st)
Second Relapse (Relapse: 2nd)
Third Or Greater Relapse (Relapse:
3rd+)
Other specify
What was the duration of the preceding
response? (For relapsed AML/MDS,)
Duration Of Response Less Than 6
Months (< 6 months)
Duration Of Response Greater Than Or
Equal To 6 Months (> or = 6 months)
Duration Of Response Unknown
(Unknown)
Date Hematology (Blood) Sample Obtained
(Peripheral Blood mm dd yyyy)
White Blood Cell Count (x 10^3/mcL)
Peripheral Neutrophils/Bands (%)
Peripheral Blasts (%)
Date of Bone Marrow Biopsy (Bone Marrow
Biopsy/Aspirate mm dd yyyy)
Marrow Cellularity (%)
Marrow Blasts (%)
Marrow Cellularity Status
Cellularity Status Of Bone Marrow Is
Aplasitc (severely Hypocellular) (Aplastic
(severely hypocellular))
Cellularity Status Of Bone Marrow
Unknown, Procedure Resulted In No
Material To Analyze (Dry tap or
inaspirable)
Cellularity Status Of Bone Marrow Is
3 / 4
On-Study - Acute Myeloid Leukemia (AML)/Myelodysplastic Syndrome
(MDS) - On-Study Form - Relapse/Refractory Treatment - 2019378v3.0
Hypercellular (Hypercellular)
Cellularity Status Of Bone Marrow Is
Hypocellular (Hypocellular)
Cellularity Status Of Bone Marrow Is
Normocellular (Normocellular)
Cellularity Status Of Bone Marrow Is
Packed (intensely Hypercellular) (Packed
(intensely hypercellular))
Prior bone marrow or peripheral blood stem cell
transplant?
Yes
No
Type of Bone Marrow or Peripheral Blood Stem
Cell (PBSC) Transplant (If yes, )
Bone Marrow Stem Cells Used For
Transplant Obtained From Recipient
Him/herself (Autologous bone marrow)
Peripheral Blood Stem Cells Used For
Transplant Obtained From Recipient
Him/herself (Autologous PBSC)
Bone Marrow Stem Cells Used For
Transplant Obtained From Antigen-
matched Sibling Or Family Member Of
Recipient (Bone marrow from matched
sibling or family member)
Bone Marrow Stem Cells Used For
Transplant Obtained From Antigen-
matched Individual Unrelated To
Recipient (Bone marrow from matched
unrelated donor)
Other Specify (Other)
Peripheral Blood Stem Cells Used For
Transplant Obtained From Antigen-
matched Sibling Or Family Member Of
Recipient (PBSC from matched sibling or
family member)
Peripheral Blood Stem Cells Used For
Transplant Obtained From Antigen-
matched Individual Unrelated To
Recipient (PBSC from matched
unrelated donor)
Other specify
Allows Documentation Of Any Additional
Cooments
Comments
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Pathology - Phase II Breast Pathology -
Tumor Marker Form - 2548011v1.0
Phase II Breast Pathology - Tumor Marker Form
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=237C27C7-
4AB3-6DEE-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/7225
Phase II Breast Pathology - Tumor
Marker Form
Crf Header
Coordinating Group Protocol No.
Coordinating Group Code
Protocol Title
Patient Study ID
Institution/Affiliate
Registering Group Code
Registering Institution Code
Patient Initials
Breast: Form Administration
Person Completing Form
Are data amended (If data are amended, please
circle in red when using paper form)
Yes
No
Pathology: Estrogen And Progesterone
Receptors
Tissue Type
Distant Metastases (Metastasis)
Other Specify (Other)
Primary (Primary)
Regional Nodal (Regional nodal)
Other specify
Blocks
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Accession Number
Method of Evaluation
Autopsy (Autopsy)
Axillary Dissection (Axillary dissection)
Ductal Lavage (Ductal lavage)
Ductoscopic Biopsy (Ductoscopic
biopsy)
Excisional Biopsy Or Lumpectomy
(Excisional biopsy or lumpectomy)
Fine Needle Aspiration Biopsy (Fine
needle aspiration biopsy)
Fluid Cytology, Ascites (Fluid cytology,
ascites)
Fluid Cytology, Cerebrospinal Fluid (Fluid
cytology, cerebrospinal fluid)
Fluid Cytology, Pleural (Fluid cytology,
pleural)
Incisional Biopsy (Incisional biopsy)
Mastectomy (Mastectomy)
Needle Biopsy (tru-cut Or Core) (Needle
biopsy (tru-cut or core))
Nipple Fluid (Nipple fluid)
Other, Specify (Other, specify)
Prophalactic Mastectomy (Prophalactic
mastectomy)
Resection/re-excision Of Lumpectomy
Margins (Resection/re-excision of
lumpectomy margins)
Sentinel Node Biopsy (Sentinel node
biopsy)
Other Specify
Marker Test Method
Elisa (ELISA)
Fluorescence In Situ Hybridization (fish)
(Fluorescence in situ hybridization
(FISH))
Immunohistochemistry (ihc)
(Immunohistochemistry (IHC))
Other, Specify (Other)
Type of Hormone Receptor (mark all that apply)
Estrogen Receptor (er) (Estrogen
receptor)
Other Specify (Other)
Progesterone Receptor (pr)
(Progesterone receptor)
Other specify
Other specify
Staining Antibody
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Antigen Retrieval
Yes
No
Yes specify
Intensity of Stained Malignant Nuclei Description
(for invasive component  OR)
Intense (Intense)
Intermediate (Intermediate)
Negative (Negative)
Scant (Scant)
Unknown (Unknown)
Percentage of Invasive Tumor Cells with Nuclear
Staining (%)
Intensity of Stained Malignant Nuclei Scaled (___
of ___   Note: Scale for intensity will be protocol
specific.)
Percentage of DCIS Cells with Nuclear Staining
(%)
Final Receptor Status Diagnosis
Indeterminate (Indeterminate)
Negative (Negative)
Positive (Positive)
Pathology: Breast Tumor Markers
Marker Name (s)
Other Specify (Other)
P53 (p53)
Other specify
Tissue Type
Distant Metastases (Metastasis)
Other Specify (Other)
Primary (Primary)
Regional Nodal (Regional nodal)
Other specify
Blocks
Accession Number
Method of Evaluation
Autopsy (Autopsy)
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Axillary Dissection (Axillary dissection)
Ductal Lavage (Ductal lavage)
Ductoscopic Biopsy (Ductoscopic
biopsy)
Excisional Biopsy Or Lumpectomy
(Excisional biopsy or lumpectomy)
Fine Needle Aspiration Biopsy (Fine
needle aspiration biopsy)
Fluid Cytology, Ascites (Fluid cytology,
ascites)
Fluid Cytology, Cerebrospinal Fluid (Fluid
cytology, cerebrospinal fluid)
Fluid Cytology, Pleural (Fluid cytology,
pleural)
Incisional Biopsy (Incisional biopsy)
Mastectomy (Mastectomy)
Needle Biopsy (tru-cut Or Core) (Needle
biopsy (tru-cut or core))
Nipple Fluid (Nipple fluid)
Other, Specify (Other, specify)
Prophalactic Mastectomy (Prophalactic
mastectomy)
Resection/re-excision Of Lumpectomy
Margins (Resection/re-excision of
lumpectomy margins)
Sentinel Node Biopsy (Sentinel node
biopsy)
Other Specify
Marker Test Method
Elisa (ELISA)
Fluorescence In Situ Hybridization (fish)
(Fluorescence in situ hybridization
(FISH))
Immunohistochemistry (ihc)
(Immunohistochemistry (IHC))
Other, Specify (Other)
Other specify
Staining Antibody
Cb-11 Other (CB-11 other)
Cb-11/ventana Kit (CB-11/Ventana Kit)
Dako Herceptest [tm] (DAKO Herceptest
[TM])
Other Specify (Other)
Tab-250 (TAB-250)
Other specify
Intensity of Stained Malignant Nuclei Description
(for invasive component  OR)
Intense (Intense)
Intermediate (Intermediate)
Negative (Negative)
Scant (Scant)
Unknown (Unknown)
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Intensity of Stained Malignant Nuclei Scaled (___
of ___   Note: Scale for intensity will be protocol
specific.)
Herceptest Score
0 (0)
1+ (1+)
2+ (2+)
3+ (3+)
Ventana Scoring System (Score)
0 (0)
1+ (1+)
2+ (2+)
3+ (3+)
Kit or Test Type (If FISH,)
Other Specify (Other, specify)
Ventana/oncorprobe[tm]
(Ventana/Oncorprobe)
Vysis/path Vysion[tm] (Vysis/PathVysion)
Other, specify
FISH Result
Amplified (Amplified)
Not Amplified (Not amplified)
FISH HER2/neu chromosome 17 Ratio
Mean Number of HER2/neu Signals/Cell (Note:
Enter 99.9 or 999 if unknown)
Amplification Cutpoint
Final Diagnosis with HER2/neu
Equivocal (Equivocal)
Negative (Negative)
Positive (Positive)
Pathology: Immunohistochemistry
Marker Name (s)
Other Specify (Other)
P53 (p53)
Other specify
Tissue Type
Distant Metastases (Metastasis)
Other Specify (Other)
Primary (Primary)
Regional Nodal (Regional nodal)
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Other specify
Blocks
Accession Number
Method of Evaluation
Autopsy (Autopsy)
Axillary Dissection (Axillary dissection)
Ductal Lavage (Ductal lavage)
Ductoscopic Biopsy (Ductoscopic
biopsy)
Excisional Biopsy Or Lumpectomy
(Excisional biopsy or lumpectomy)
Fine Needle Aspiration Biopsy (Fine
needle aspiration biopsy)
Fluid Cytology, Ascites (Fluid cytology,
ascites)
Fluid Cytology, Cerebrospinal Fluid (Fluid
cytology, cerebrospinal fluid)
Fluid Cytology, Pleural (Fluid cytology,
pleural)
Incisional Biopsy (Incisional biopsy)
Mastectomy (Mastectomy)
Needle Biopsy (tru-cut Or Core) (Needle
biopsy (tru-cut or core))
Nipple Fluid (Nipple fluid)
Other, Specify (Other, specify)
Prophalactic Mastectomy (Prophalactic
mastectomy)
Resection/re-excision Of Lumpectomy
Margins (Resection/re-excision of
lumpectomy margins)
Sentinel Node Biopsy (Sentinel node
biopsy)
Other Specify
Primary Antibody
Antigen Retrieval
Yes
No
Cell Type Stained
Epithelial, Malignant (Epithelial
malignant)
Epithelial, Non-malignant (Epithelial non-
malignant)
Other Specify (Other)
Stromal, Non-malignant (Stromal non-
malignant)
Intensity of Stained Malignant Nuclei Description
(for invasive component  OR)
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Intense (Intense)
Intermediate (Intermediate)
Negative (Negative)
Scant (Scant)
Unknown (Unknown)
Other specify
Yes specify
Pattern of Staining
Cytoplasmic (Cytoplasmic)
Membrane (Membrane)
Mixed (nuclear/cytoplasmic) (Mixed
(Nuclear/Cytoplasmic))
Nuclear (Nuclear)
Other Specify (Other)
Secreted (Secreted)
Percentage of Invasive Tumor Cells with Nuclear
Staining (%)
Intensity of Stained Malignant Nuclei Scaled (___
of ___   Note: Scale for intensity will be protocol
specific.)
Other specify
Percentage of DCIS Cells with Nuclear Staining
(%)
Percentage of Non-Malignant Cells with Nuclear
Staining (%)
Final Interpretation of Results (for invasive
component )
Indeterminate (Indeterminate)
Negative (Negative)
Positive (Positive)
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On-Study - Breast Cancer - Adjuvant On-
Study Form - 2263232v3.0
Breast Cancer - Adjuvant On-Study Form
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=DA189DBB-
8EE5-059F-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/7230
Breast Cancer - Adjuvant On-Study
Form
Crf Header
Coordinating Group Protocol No.
Coordinating Group Code
Protocol Title
Patient Study ID
Institution/Affiliate
Other Patient ID
Participating Group Code
Patient Initials
Breast: Form Administration
Person Completing Form
Are data amended? (If data are amended, please
circle in red when using paper form)
Yes
No
Breast: Patient Characteristics
Menopausal Status (check one)
Above Categories Not Applicable And
Age <50 (Above categories not
applicable AND Age < 50)
Above Categories Not Applicable And
Age >= 50 (Above categories not
applicable AND Age >= 50)
Post (prior Bilateral Ovariectomy Or >12
Mo Since Lmp With No Prior
Hysterectomy) (Post (prior bilateral
ovariectomy OR >12 mo since LMP with
no prior hysterectomy))
Pre (<6 Mo Since Lmp And No Prior
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Bilateral Ovariectomy And Not On
Estrogen Replacement) (Pre (<6 mo
since LMP AND no prior bilateral
ovariectomy AND not on estrogen
replacement))
Breast: Surgical Procedures
First Positive Biopsy Date (mm dd yyyy)
Most Extensive Primary Surgery (check one)
Mastectomy, Nos (Mastectomy NOS)
Partial Mastectomy, Lumpectomy Or
Excisional Biopsy (Partial
mastectomy/lumpectomy/excisional
biopsy)
Date of Most Extensive Primary Surgery (if
required, use last re-excision date)
Was sentinel node sampling performed
Yes
No
Sentinel Node Biopsy Date (mm dd yyyy)
Sentinel Node Biopsy Results (per protocol)
Negative (Negative)
Positive (Positive)
Was axillary dissection performed?
Yes
No
Date of Axillary Dissection (mm dd yyyy)
Number of Lymph Nodes Examined (If sentinel
node biopsy and axillary node dissection were
performed, enter the sum of nodes examined.)
Breast: Disease Description
Tumor Laterality (check one)
Bilateral (Bilateral)
Left (Left)
Right (Right)
Receptor Status, ER (If measured in fmols/mg
cytosol protein >=10 is positive. If other measures
are used apply institutional standards; borderline
results should be reported as positive.)
Negative (Negative)
Positive (Positive)
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Receptor Status, PgR
Negative (Negative)
Positive (Positive)
Pathologic Primary Tumor Size (cm Maximum
diameter of the invasive component; if multiple
lesions, use longest lesion)
Histologic Grade (For breast cancer, a combined
histologic grade is used according to SBR/Elston
classification)
Well Differentiated (Grade I (low))
Moderately Differentiated (Grade II
(intermediate))
Poorly Differentiated (Grade III (high))
Number of Positive Lymph Nodes (If sentinel
node biopsy and axillary node dissection were
performed, enter the sum of positive nodes.)
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Treatment - Phase II Breast Cancer - Adjuvant
Radiotherapy Report Form - 2556084v1.0
Phase II Breast Cancer - Adjuvant Radiotherapy Report
Form
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=24E7AFED-
1437-6C1C-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/7233
Phase II Breast Cancer - Adjuvant
Radiotherapy Report Form
Crf Header
Coordinating Group Protocol No.
Coordinating Group Code
Protocol Title
Patient Study ID
Institution/Affiliate
Registering Group Code
Registering Institution Code
Patient Initials
Breast: Form Administration
Person Completing Form
Are data amended? (If data are amended, please
circle in red when using paper form)
Yes
No
Breast: Radiation Treatment
Has the patient received adjuvant RT (prior to
treatment failure or second primary cancer If the
patient did receive radiotherapy, please complete
the remainder of this form.)
Yes
No
Date Adjuvant Radiation Therapy Started
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Date Adjuvant Radiation Therapy Ended
Radiation Therapy Site (Nature of Radiotherapy
check one)
Any Post-mastectomy Radiotherapy (Any
Post-Mastectomy Radiotherapy)
In-breast And Regional Radiotherapy
Following Breast-conserving Surgery (In-
Breast and Regional Radiotherapy
following Breast-Conserving Surgery)
In-breast Radiotherapy Following Breast-
conserving Surgery (In-Breast
Radiotherapy following Breast-
Conserving Surgery)
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On-Study - Curative Treatment for Head and
Neck Cancer - On-Study Form - 2268312v3.0
Curative Treatment for Head and Neck Cancer - On-Study
Form
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=D4976276-
569A-5CEB-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/7244
Curative Treatment for Head and
Neck Cancer - On-Study Form
Crf Header
Coordinating Group Protocol No.
Coordinating Group Code
Protocol Title
Patient Study ID
Institution/Affiliate
Other Patient ID
Participating Group Code
Patient Initials
Head & Neck: Form Administration
Person Completing Form
Are data amended? (If data are amended, please
circle in red when using paper form)
Yes
No
Head & Neck: Patient Assessment
Performance Status (check one)
Fully Active, Able To Carry On All Pre-
disease Performance Without
Restriction. (0)
Restricted In Physically Strenuous
Activity But Ambulatory And Able To
Carry Out Work Of A Light Or Sedentary
Nature, E.g., Light Housework, Office
Work. (1)
Ambulatory And Capable Of All Selfcare
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But Unable To Carry Out Any Work
Activities. Up And About More Than 50%
Of Waking Hours. (2)
Capable Of Only Limited Selfcare,
Confined To Bed Or Chair More Than
50% Of Waking Hours. (3)
Completely Disabled. Cannot Carry On
Any Selfcare. Totally Confined To Bed Or
Chair. (4)
Head & Neck: Disease Description
Date of Initial Pathologic Diagnosis (mm dd yyyy)
Primary Site
Antrum (Antrum)
Base Of Tongue (Base of tongue)
Buccal Mucosa (Buccal mucosa)
Ethmoid (Ethmoid)
Faucial Arch (Faucial arch)
Floor Of Mouth (Floor of mouth)
Frontal (Frontal)
Glottic Larynx (Glottic larynx)
Hard Palate (Hard palate)
Hypopharynx Nos (Hypopharynx NOS)
Larynx Nos (Larynx NOS)
Lateral Wall (Lateral wall)
Lip And Oral Cavity (Lip and oral cavity)
Lower Gingiva (Lower gingiva)
Minor Salivary Glands (Minor salivary
glands)
Nasal Cavity (Nasal cavity)
Nasopharynx Nos (Nasopharynx NOS)
Nose Nos (Nose NOS)
Oral Cavity Nos (Oral cavity NOS)
Oral Tongue (Oral Tongue)
Oropharynx Nos (Oropharynx NOS)
Other (Other)
Paranasal Sinuses Nos (Paranasal
sinuses NOS)
Parotid (Parotid)
Postcricoid Area (Postcricoid area)
Posterior Pharyngeal Wall (Posterior
pharyngeal wall)
Posterior Superior Wall (Posterior
superior wall)
Posterior Wall (Posterior wall)
Pyriform Fossa (Pyriform fossa)
Retromolar Trigone (Retromolar trigone)
Salivary Glands Nos (Salivary glands
NOS)
Soft Palate (Soft palate)
Sphenoid (Sphenoid)
Subglottic Larynx (Subglottic larynx)
Sublingual (Sublingual)
Submandibular (Submandibular)
Supraglottic Larynx (Supraglottic larynx)
Tonsillar Fossa Tonsil (Tonsillar fossa,
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tonsil)
Unknown (Unknown)
Upper Gingiva (Upper gingiva)
Other specify
Is this a second primary in the upper aero-
digestive tract (Note: includes patients with
second primary when curative treatment is
planned.)
Yes
No
Name of Referring Institution (If yes, where initial
tumor was treated)
Histologic Type (values continue on next page)
Acinic Cell Carcinoma (Acinic cell
carcinoma)
Adenocarcinoma (Adenocarcinoma)
Adenoid Cystic Carcinoma (Adenoid
cystic carcinoma)
Adenoid Squamous Cell Carcinoma
(Adenoid squamous cell carcinoma)
Adenosquamous Carcinoma
(Adenosquamous carcinoma)
Atypical Carcinoid Tumor (Atypical
carcinoid tumor)
Basaloid Squamous Cell Carcinoma
(Basaloid squamous cell carcinoma)
Carcinoid Tumor (Carcinoid tumor)
Carcinoma In Pleomorphic Adenoma
(Carcinoma in pleomorphic adenoma)
Carcinoma In Situ (specify Histologic
Type) (Carcinoma in situ)
Clear Cell Carcinoma (Clear cell
carcinoma)
Epithelial-myoepithelial Carcinoma
(Epithelial-myoepithelial carcinoma)
Giant Cell Carcinoma (Giant cell
carcinoma)
Lymphoepithelial Carcinoma
(Lymphoepithelial carcinoma)
Mucoepidermoid Carcinoma
(Mucoepidermoid carcinoma)
Other (Other)
Salivary Duct Carcinoma (Salivary duct
carcinoma)
Small Cell Carcinoma (Small cell
carcinoma)
Spindle Cell Carcinoma (Spindle cell
carcinoma)
Squamous Cell Carcinoma Keratinizing
(Squamous cell carcinoma, keratinizing)
Squamous Cell Carcinoma Non-
keratinizing (Squamous cell carcinoma,
non-keratinizing)
Undifferentiated Carcinoma
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(Undifferentiated carcinoma)
Unknown (Unknown)
Verrucous Squamous Cell Carcinoma
(Verrucous squamous cell carcinoma)
Other specify
Histologic Grade (check highest grade)
Cannot Be Assessed (grade X) (Cannot
be assessed (Grade X))
Moderately Differentiated (grade Ii)
(Moderately differentiated (Grade II))
Poorly Differentiated (grade Iii) (Poorly
differentiated (Grade III))
Undifferentiated (grade Iv)
(Undifferentiated (Grade IV))
Well Differentiated (grade I) (Well
differentiated (Grade I))
Clinical T Stage
T0, According To Ajcc Criteria (T0)
T1, According To Ajcc Criteria (T1)
T2, According To Ajcc Criteria (T2)
T3, According To Ajcc Criteria (T3)
T4a, According To Ajcc Guidelines (T4a)
T4b, According To Ajcc Guidelines (T4b)
Tis, According To Ajcc Criteria (Tis)
Tx, According To Ajcc Criteria (TX)
Clinical N Stage (overall)
N0, According To Ajcc Guidelines (N0)
N1, According To Ajcc Criteria (N1)
N2, According To Ajcc Criteria (N2)
N2a, According To Ajcc Guidelines (N2a)
N2b, According To Ajcc Guidelines (N2b)
N2c, According To Ajcc Guidelines (N2c)
N3, According To Ajcc Guidelines (N3)
Clinical N Stage, Right Side
N0, According To Ajcc Guidelines (N0)
N1, According To Ajcc Criteria (N1)
N2, According To Ajcc Criteria (N2)
N2a, According To Ajcc Guidelines (N2a)
N2b, According To Ajcc Guidelines (N2b)
N2c, According To Ajcc Guidelines (N2c)
N3, According To Ajcc Guidelines (N3)
Clinical N Stage, Left Side
N0, According To Ajcc Guidelines (N0)
N1, According To Ajcc Criteria (N1)
N2, According To Ajcc Criteria (N2)
N2a, According To Ajcc Guidelines (N2a)
N2b, According To Ajcc Guidelines (N2b)
N2c, According To Ajcc Guidelines (N2c)
N3, According To Ajcc Guidelines (N3)
Clinical M Stage
M0, According To Ajcc Guidelines (M0)
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M1, According To Ajcc Staging
Definitions (M1)
Mx, According To Ajcc Guidelines (MX)
Head & Neck: Prior Health History -
Curative
Does the patient have a chronic disease
Yes
No
Chronic Disease (If yes,)
Coronary Artery Disease (Coronary
Artery disease)
Diabetes (Diabetes)
Gastrointestinal Disease
(Gastrointestinal Disease)
High Blood Pressure (High Blood
Pressure)
Neurologic Disease (Neurologic disease)
Other, Specify (Other)
Peripheral Vascular Disease (Peripheral
Vascular disease)
Respiratory Problems (Respiratory
problems)
Other specify
Weight Loss in Previous Six Months (check one)
<5% Of Body Weight (<5% of body
weight)
> Or = 20% Of Body Weight (> or = 20%
of body weight)
10 To <20% Of Body Weight (10 to <20%
of body weight)
5 To <10% Of Body Weight (5 to < 10%
of body weight)
Smoking History
Cigarette Smoker <20 Pack-years
(Cigarette smoker, <20 pack-years)
Cigarette Smoker >40 Pack-years
(Cigarette smoker, >40 pack-years)
Cigarette Smoker 20-40 Pack-years
(Cigarette smoker, 20-40 pack-years)
Never Smoked (Never smoked)
Pipe Or Cigar Smoker Only (Pipe or
cigar smoker only)
Unknown (Unknown)
Does the patient currently smoke
Yes
No
Number of Cigarettes per day (If yes,)
10 To 20 Cigarettes (10 to 20 cigarettes)
Fewer Than 10 Cigarettes (Fewer than
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10 cigarettes)
More Than 20 Cigarettes (more than 20
cigarettes)
Time since last cigarette (If no,)
1 Month To <6 Months (1 month to <6
months)
1 Year To <5 Years (1 year to <5 years)
5 Years To <10 Years (5 years to <10
years)
6 Months To <1 Year (6 months to <1
year)
Less Than 1 Month (Less than 1 month)
More Than 10 Years (More than 10
years)
Never Smoked (Never smoked)
Alcohol Consumption History (1 drink = 1 oz.
Whiskey = 12 oz. Beer)
1 To 12 Drinks Per Month In Average
Year (1 to 12 drinks per month in
average year)
Fewer Than 12 Drinks In Average Year
(Fewer than 12 drinks in average year)
Fewer Than 12 Drinks In Lifetime (Fewer
than 12 drinks in lifetime)
More Than 4 Drinks Per Week In
Average Year (More than 4 drinks per
week in average year)
Unknown (Unknown)
Does the patient currently consume alcohol
Yes
No
Average Alcohol Consumption (If yes, 1 drink = 1
oz. Whiskey = 12 oz. Beer)
1 To 10 Drinks Per Week (1 to 10 drinks
per week)
1 To 5 Drinks Per Month (1 to 5 drinks
per month)
10 To 30 Drinks Per Week (10 to 30
drinks per week)
Less Than 1 Drink Per Month (Less than
1 drink per month)
More Than 30 Drinks Per Week (More
than 30 drinks per week)
Unknown (Unknown)
Is the patient an alcoholic
No (No)
Yes Currently (Yes, currently)
Yes Recovering (Yes, recovering)
Time since last drink (If recovering,)
1 Month To <6 Months (1 month to <6
months)
1 Year To <5 Years (1 year to <5 years)
5 Years To <10 Years (5 years to <10
years)
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6 Months To <1 Year (6 months to <1
year)
Less Than 1 Month (Less than 1 month)
More Than 10 Years (More than 10
years)
Does the patient have a past history of
swallowing problems (Assessment of Swallowing)
No (No)
Unknown (Unknown)
Yes (Yes)
How long were swallowing problems apparent (If
yes,)
1 To <7 Months (1 to <7 months)
13 To <19 Months (13 to <19 months)
19 To <24 Months (19 to <24 months)
2 Years Or Longer (2 years or longer)
7 To <13 Months (7 to <13 months)
Less Than 1 Month (Less than 1 month)
Unknown (Unknown)
Does the patient currently have swallowing
problems
No (No)
Unknown (Unknown)
Yes (Yes)
How long have swallowing problems been
present (If yes,)
1 To <7 Months (1 to <7 months)
13 To <19 Months (13 to <19 months)
19 To <24 Months (19 to <24 months)
2 Years Or Longer (2 years or longer)
7 To <13 Months (7 to <13 months)
Less Than 1 Month (Less than 1 month)
Unknown (Unknown)
Does the patient have a past history of tube
feedings
No (No)
Unknown (Unknown)
Yes (Yes)
How long were tube feedings given (If yes,)
1 To <7 Months (1 to <7 months)
13 To <19 Months (13 to <19 months)
19 To <24 Months (19 to <24 months)
2 Years Or Longer (2 years or longer)
7 To <13 Months (7 to <13 months)
Less Than 1 Month (Less than 1 month)
Unknown (Unknown)
Does the patient currently require tube feeding
No (No)
Unknown (Unknown)
Yes (Yes)
Is patient dependent on tube feeding for >50% of
nutritional support (If yes,)
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No (No)
Unknown (Unknown)
Yes (Yes)
Normalcy of Diet Rating (Ask the patient what
kinds of foods are difficult for him/her to eat.
Begin at the low end of the scale. Move up the
scale, giving examples of foods in each category
and asking patient if s/he can eat those food
items. The patient's score is the highest )
0= Non-oral Feeding (tube Fed) (0)
10= Cold Liquids (10)
100= Full Diet (no Restrictions) (100)
20= Warm Liquids (20)
30= Pureed Foods (in Blender) (30)
40= Soft Foods Requiring No Chewing
(e.g., Mashed Potatoes, Apple Sauce,
Pudding) (40)
50= Soft, Chewable Foods (e.g.,
Macaroni, Canned/soft Fruits, Cooked
Vegetables, Fish, Hamburger, Small
Pieces Of Meat) (50)
60= Dry Bread And Crackers (60)
70= Raw Carrots, Celery (70)
80= All Meat (80)
90= Full Diet (liquid Assist) (90)
Public Eating Rating (Ask the patient where s/he
eats, with whom s/he eats, and whether s/he
alters his/her diet according to where s/he is
eating. Choose the score that best fits the
patient.)
0= Always Eats Alone (0)
100= No Restriction Of Place, Food Or
Companion (eats Out At Any
Opportunity) (100)
25= Eats Only At Home In Presence Of
Selected Persons (25)
50= Eats Only In Presence Of Selected
Persons In Selected Places (50)
75= No Restriction Of Place, But
Restricts Diet When In Public (eats
Anywhere, But May Limit Intake To Less
"messy" Foods, E.g., Liquids) (75)
Understandability of Speech Rating (Score based
on the interviewer's ability to understand the
patient during conversation. Choose the score
that best fits the patient.)
0= Never Understandable; May Use
Written Communication (0)
100= Always Understandable (100)
25= Difficult To Understand (25)
50= Usually Understandable; Face-to-
face Contact Necessary (50)
75= Understandable Most Of The Time;
Occasional Repetition Necessary (75)
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Curative Treatment for Head and
Neck Cancer - On-Study Form
Crf Header
Coordinating Group Protocol No.
Coordinating Group Code
Protocol Title
Patient Study ID
Institution/Affiliate
Other Patient ID
Participating Group Code
Patient Initials
Head & Neck: Form Administration
Person Completing Form
Are data amended? (If data are amended, please
circle in red when using paper form)
Yes
No
Head & Neck: Patient Assessment
Performance Status (check one)
Fully Active, Able To Carry On All Pre-
disease Performance Without
Restriction. (0)
Restricted In Physically Strenuous
Activity But Ambulatory And Able To
Carry Out Work Of A Light Or Sedentary
Nature, E.g., Light Housework, Office
Work. (1)
Ambulatory And Capable Of All Selfcare
1 / 8
But Unable To Carry Out Any Work
Activities. Up And About More Than 50%
Of Waking Hours. (2)
Capable Of Only Limited Selfcare,
Confined To Bed Or Chair More Than
50% Of Waking Hours. (3)
Completely Disabled. Cannot Carry On
Any Selfcare. Totally Confined To Bed Or
Chair. (4)
Head & Neck: Disease Description
Date of Initial Pathologic Diagnosis (mm dd yyyy)
Primary Site
Antrum (Antrum)
Base Of Tongue (Base of tongue)
Buccal Mucosa (Buccal mucosa)
Ethmoid (Ethmoid)
Faucial Arch (Faucial arch)
Floor Of Mouth (Floor of mouth)
Frontal (Frontal)
Glottic Larynx (Glottic larynx)
Hard Palate (Hard palate)
Hypopharynx Nos (Hypopharynx NOS)
Larynx Nos (Larynx NOS)
Lateral Wall (Lateral wall)
Lip And Oral Cavity (Lip and oral cavity)
Lower Gingiva (Lower gingiva)
Minor Salivary Glands (Minor salivary
glands)
Nasal Cavity (Nasal cavity)
Nasopharynx Nos (Nasopharynx NOS)
Nose Nos (Nose NOS)
Oral Cavity Nos (Oral cavity NOS)
Oral Tongue (Oral Tongue)
Oropharynx Nos (Oropharynx NOS)
Other (Other)
Paranasal Sinuses Nos (Paranasal
sinuses NOS)
Parotid (Parotid)
Postcricoid Area (Postcricoid area)
Posterior Pharyngeal Wall (Posterior
pharyngeal wall)
Posterior Superior Wall (Posterior
superior wall)
Posterior Wall (Posterior wall)
Pyriform Fossa (Pyriform fossa)
Retromolar Trigone (Retromolar trigone)
Salivary Glands Nos (Salivary glands
NOS)
Soft Palate (Soft palate)
Sphenoid (Sphenoid)
Subglottic Larynx (Subglottic larynx)
Sublingual (Sublingual)
Submandibular (Submandibular)
Supraglottic Larynx (Supraglottic larynx)
Tonsillar Fossa Tonsil (Tonsillar fossa,
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tonsil)
Unknown (Unknown)
Upper Gingiva (Upper gingiva)
Other specify
Is this a second primary in the upper aero-
digestive tract (Note: includes patients with
second primary when curative treatment is
planned.)
Yes
No
Name of Referring Institution (If yes, where initial
tumor was treated)
Histologic Type (values continue on next page)
Acinic Cell Carcinoma (Acinic cell
carcinoma)
Adenocarcinoma (Adenocarcinoma)
Adenoid Cystic Carcinoma (Adenoid
cystic carcinoma)
Adenoid Squamous Cell Carcinoma
(Adenoid squamous cell carcinoma)
Adenosquamous Carcinoma
(Adenosquamous carcinoma)
Atypical Carcinoid Tumor (Atypical
carcinoid tumor)
Basaloid Squamous Cell Carcinoma
(Basaloid squamous cell carcinoma)
Carcinoid Tumor (Carcinoid tumor)
Carcinoma In Pleomorphic Adenoma
(Carcinoma in pleomorphic adenoma)
Carcinoma In Situ (specify Histologic
Type) (Carcinoma in situ)
Clear Cell Carcinoma (Clear cell
carcinoma)
Epithelial-myoepithelial Carcinoma
(Epithelial-myoepithelial carcinoma)
Giant Cell Carcinoma (Giant cell
carcinoma)
Lymphoepithelial Carcinoma
(Lymphoepithelial carcinoma)
Mucoepidermoid Carcinoma
(Mucoepidermoid carcinoma)
Other (Other)
Salivary Duct Carcinoma (Salivary duct
carcinoma)
Small Cell Carcinoma (Small cell
carcinoma)
Spindle Cell Carcinoma (Spindle cell
carcinoma)
Squamous Cell Carcinoma Keratinizing
(Squamous cell carcinoma, keratinizing)
Squamous Cell Carcinoma Non-
keratinizing (Squamous cell carcinoma,
non-keratinizing)
Undifferentiated Carcinoma
3 / 8
On-Study - Curative Treatment for Head and Neck Cancer - On-Study
Form - 2268312v3.0
(Undifferentiated carcinoma)
Unknown (Unknown)
Verrucous Squamous Cell Carcinoma
(Verrucous squamous cell carcinoma)
Other specify
Histologic Grade (check highest grade)
Cannot Be Assessed (grade X) (Cannot
be assessed (Grade X))
Moderately Differentiated (grade Ii)
(Moderately differentiated (Grade II))
Poorly Differentiated (grade Iii) (Poorly
differentiated (Grade III))
Undifferentiated (grade Iv)
(Undifferentiated (Grade IV))
Well Differentiated (grade I) (Well
differentiated (Grade I))
Clinical T Stage
T0, According To Ajcc Criteria (T0)
T1, According To Ajcc Criteria (T1)
T2, According To Ajcc Criteria (T2)
T3, According To Ajcc Criteria (T3)
T4a, According To Ajcc Guidelines (T4a)
T4b, According To Ajcc Guidelines (T4b)
Tis, According To Ajcc Criteria (Tis)
Tx, According To Ajcc Criteria (TX)
Clinical N Stage (overall)
N0, According To Ajcc Guidelines (N0)
N1, According To Ajcc Criteria (N1)
N2, According To Ajcc Criteria (N2)
N2a, According To Ajcc Guidelines (N2a)
N2b, According To Ajcc Guidelines (N2b)
N2c, According To Ajcc Guidelines (N2c)
N3, According To Ajcc Guidelines (N3)
Clinical N Stage, Right Side
N0, According To Ajcc Guidelines (N0)
N1, According To Ajcc Criteria (N1)
N2, According To Ajcc Criteria (N2)
N2a, According To Ajcc Guidelines (N2a)
N2b, According To Ajcc Guidelines (N2b)
N2c, According To Ajcc Guidelines (N2c)
N3, According To Ajcc Guidelines (N3)
Clinical N Stage, Left Side
N0, According To Ajcc Guidelines (N0)
N1, According To Ajcc Criteria (N1)
N2, According To Ajcc Criteria (N2)
N2a, According To Ajcc Guidelines (N2a)
N2b, According To Ajcc Guidelines (N2b)
N2c, According To Ajcc Guidelines (N2c)
N3, According To Ajcc Guidelines (N3)
Clinical M Stage
M0, According To Ajcc Guidelines (M0)
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M1, According To Ajcc Staging
Definitions (M1)
Mx, According To Ajcc Guidelines (MX)
Head & Neck: Prior Health History -
Curative
Does the patient have a chronic disease
Yes
No
Chronic Disease (If yes,)
Coronary Artery Disease (Coronary
Artery disease)
Diabetes (Diabetes)
Gastrointestinal Disease
(Gastrointestinal Disease)
High Blood Pressure (High Blood
Pressure)
Neurologic Disease (Neurologic disease)
Other, Specify (Other)
Peripheral Vascular Disease (Peripheral
Vascular disease)
Respiratory Problems (Respiratory
problems)
Other specify
Weight Loss in Previous Six Months (check one)
<5% Of Body Weight (<5% of body
weight)
> Or = 20% Of Body Weight (> or = 20%
of body weight)
10 To <20% Of Body Weight (10 to <20%
of body weight)
5 To <10% Of Body Weight (5 to < 10%
of body weight)
Smoking History
Cigarette Smoker <20 Pack-years
(Cigarette smoker, <20 pack-years)
Cigarette Smoker >40 Pack-years
(Cigarette smoker, >40 pack-years)
Cigarette Smoker 20-40 Pack-years
(Cigarette smoker, 20-40 pack-years)
Never Smoked (Never smoked)
Pipe Or Cigar Smoker Only (Pipe or
cigar smoker only)
Unknown (Unknown)
Does the patient currently smoke
Yes
No
Number of Cigarettes per day (If yes,)
10 To 20 Cigarettes (10 to 20 cigarettes)
Fewer Than 10 Cigarettes (Fewer than
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10 cigarettes)
More Than 20 Cigarettes (more than 20
cigarettes)
Time since last cigarette (If no,)
1 Month To <6 Months (1 month to <6
months)
1 Year To <5 Years (1 year to <5 years)
5 Years To <10 Years (5 years to <10
years)
6 Months To <1 Year (6 months to <1
year)
Less Than 1 Month (Less than 1 month)
More Than 10 Years (More than 10
years)
Never Smoked (Never smoked)
Alcohol Consumption History (1 drink = 1 oz.
Whiskey = 12 oz. Beer)
1 To 12 Drinks Per Month In Average
Year (1 to 12 drinks per month in
average year)
Fewer Than 12 Drinks In Average Year
(Fewer than 12 drinks in average year)
Fewer Than 12 Drinks In Lifetime (Fewer
than 12 drinks in lifetime)
More Than 4 Drinks Per Week In
Average Year (More than 4 drinks per
week in average year)
Unknown (Unknown)
Does the patient currently consume alcohol
Yes
No
Average Alcohol Consumption (If yes, 1 drink = 1
oz. Whiskey = 12 oz. Beer)
1 To 10 Drinks Per Week (1 to 10 drinks
per week)
1 To 5 Drinks Per Month (1 to 5 drinks
per month)
10 To 30 Drinks Per Week (10 to 30
drinks per week)
Less Than 1 Drink Per Month (Less than
1 drink per month)
More Than 30 Drinks Per Week (More
than 30 drinks per week)
Unknown (Unknown)
Is the patient an alcoholic
No (No)
Yes Currently (Yes, currently)
Yes Recovering (Yes, recovering)
Time since last drink (If recovering,)
1 Month To <6 Months (1 month to <6
months)
1 Year To <5 Years (1 year to <5 years)
5 Years To <10 Years (5 years to <10
years)
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6 Months To <1 Year (6 months to <1
year)
Less Than 1 Month (Less than 1 month)
More Than 10 Years (More than 10
years)
Does the patient have a past history of
swallowing problems (Assessment of Swallowing)
No (No)
Unknown (Unknown)
Yes (Yes)
How long were swallowing problems apparent (If
yes,)
1 To <7 Months (1 to <7 months)
13 To <19 Months (13 to <19 months)
19 To <24 Months (19 to <24 months)
2 Years Or Longer (2 years or longer)
7 To <13 Months (7 to <13 months)
Less Than 1 Month (Less than 1 month)
Unknown (Unknown)
Does the patient currently have swallowing
problems
No (No)
Unknown (Unknown)
Yes (Yes)
How long have swallowing problems been
present (If yes,)
1 To <7 Months (1 to <7 months)
13 To <19 Months (13 to <19 months)
19 To <24 Months (19 to <24 months)
2 Years Or Longer (2 years or longer)
7 To <13 Months (7 to <13 months)
Less Than 1 Month (Less than 1 month)
Unknown (Unknown)
Does the patient have a past history of tube
feedings
No (No)
Unknown (Unknown)
Yes (Yes)
How long were tube feedings given (If yes,)
1 To <7 Months (1 to <7 months)
13 To <19 Months (13 to <19 months)
19 To <24 Months (19 to <24 months)
2 Years Or Longer (2 years or longer)
7 To <13 Months (7 to <13 months)
Less Than 1 Month (Less than 1 month)
Unknown (Unknown)
Does the patient currently require tube feeding
No (No)
Unknown (Unknown)
Yes (Yes)
Is patient dependent on tube feeding for >50% of
nutritional support (If yes,)
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No (No)
Unknown (Unknown)
Yes (Yes)
Normalcy of Diet Rating (Ask the patient what
kinds of foods are difficult for him/her to eat.
Begin at the low end of the scale. Move up the
scale, giving examples of foods in each category
and asking patient if s/he can eat those food
items. The patient's score is the highest )
0= Non-oral Feeding (tube Fed) (0)
10= Cold Liquids (10)
100= Full Diet (no Restrictions) (100)
20= Warm Liquids (20)
30= Pureed Foods (in Blender) (30)
40= Soft Foods Requiring No Chewing
(e.g., Mashed Potatoes, Apple Sauce,
Pudding) (40)
50= Soft, Chewable Foods (e.g.,
Macaroni, Canned/soft Fruits, Cooked
Vegetables, Fish, Hamburger, Small
Pieces Of Meat) (50)
60= Dry Bread And Crackers (60)
70= Raw Carrots, Celery (70)
80= All Meat (80)
90= Full Diet (liquid Assist) (90)
Public Eating Rating (Ask the patient where s/he
eats, with whom s/he eats, and whether s/he
alters his/her diet according to where s/he is
eating. Choose the score that best fits the
patient.)
0= Always Eats Alone (0)
100= No Restriction Of Place, Food Or
Companion (eats Out At Any
Opportunity) (100)
25= Eats Only At Home In Presence Of
Selected Persons (25)
50= Eats Only In Presence Of Selected
Persons In Selected Places (50)
75= No Restriction Of Place, But
Restricts Diet When In Public (eats
Anywhere, But May Limit Intake To Less
"messy" Foods, E.g., Liquids) (75)
Understandability of Speech Rating (Score based
on the interviewer's ability to understand the
patient during conversation. Choose the score
that best fits the patient.)
0= Never Understandable; May Use
Written Communication (0)
100= Always Understandable (100)
25= Difficult To Understand (25)
50= Usually Understandable; Face-to-
face Contact Necessary (50)
75= Understandable Most Of The Time;
Occasional Repetition Necessary (75)
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Phase II Consortium PHASE II LUNG CANCER ¿
SURGERY FORM
Source Form: NCI FormBuilder:
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n.do?method=getFormDetails&formIdSeq=FF937E14-
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PHASE II LUNG CANCER ¿
SURGERY FORM
Crf Header
Coordinating Group Protocol No.
Coordinating Group Code
Protocol Title
Patient Study ID
Registering Group Code
Patient Medical Record Number
Other Patient ID
Institution/Affiliate
Registering Institution Code
Physician of Record
Form Administration
Person Completing Form
Date Form Completed
Are data amended (If data are amended, please
circle in red when using paper form)
Yes
No
Procedure Description
Surgery Date
1 / 5
Surgical Approach
Thoracoscopy / Video-assisted (vats)
(Thoracoscopy / Video-assisted (VATS))
Thoracoscopy / Video-assisted (vats),
With Conversion To Thoracotomy
(Thoracoscopy / Video-assisted (VATS),
with conversion to Thoracotomy)
Thoracotomy (thoracotomy)
Primary Surgery Type
Bilobectomy (Bilobectomy)
Exploration, No Resection (Exploration,
No Resection)
Lobectomy (Lobectomy)
Pneumonectomy (Pneumonectomy)
Segmentectomy (Segmentectomy)
Wedge Resection (Wedge Resection)
Side (of tumor location)
Both (Both)
Left (Left)
Right (Right)
Unknown (Unknown)
Details of Surgery
Bronchial Sleeve Resection (Bronchial
sleeve resection)
Chest Wall Resection, No
Reconstruction (Chest wall resection, no
reconstruction)
Chest Wall Resection, With
Reconstruction (Chest wall resection,
with reconstruction)
Intrapericardial Reconstruction
(Intrapericardial reconstruction)
Major Vascular Resection, No
Reconstruction (Major vascular
resection, no reconstruction)
Other, Specify (Other, specify)
Vascular Sleeve Resection (Vascular
sleeve resection)
Other, specify
Duration of Surgery (enter hours and minutes
elapsed)
Estimated Blood Loss (cc)
Fluids Administered
Were any whole blood transfusions administered
to the patient for this surgery?
No (No)
Unknown (Unknown)
2 / 5
Treatment - PHASE II LUNG CANCER ¿ SURGERY FORM -
2399824v1.0
Yes (Yes)
Number of intra- and post-operative whole blood
transfusions (units) (within 7 days)
Discharge Summary
Were there any surgical complications?
Yes
No
Number of days on ventilator (days)
Inpatient Discharge Date
Number of post-operative days (to Time of
Discharge days)
Surgical Margins
Margins of surgical resection
All Margins Pathologically Negative (R0)
Microscopically Positive Margins Or
Microscopic Residual Disease (R1)
Macroscopically Positive Margins Or
Gross Residual Disease (R2)
Disease Staging
N Stage, Pathologic (check one)
No Regional Lymph Node Metastasis
(N0)
Metastasis To Ipsilateral Peribronchial
And/or Ipsilateral Hilar Lymph Nodes,
And Intrapulmonary Nodes Including
Involvement By Direct Extension Of The
Primary Tumor (N1)
Metastasis To Ipsilateral Mediastinal
And/or Subcarinal Lymph Node(s) (N2)
Metastasis To Contralateral Mediastinal,
Contralateral Hilar, Ipsilateral Or
Contralateral Scalene, Or
Supraclavicular Lymph Node(s) (N3)
Regional Lymph Nodes Cannot Be
Assessed (NX)
T Stage, Pathologic (check one)
No Evidence Of Primary Tumor (T0)
Tumor 3 Cm Or Less In Greatest
Dimension, Surrounded By Lung Or
Visceral Pleura, Invasion More Proximal
Than The Lobar Bronchus, (i.e., Not In
The Main Bronchus) (T1)
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Tumor With Any Of The Following
Features Of Size Or Extent: More Than
3cm In Greatest Dimension; Invades The
Visceral Pleura; Associated With
Atelectasis Or Obstructive Pneumonitis
That Extends To The Hilar Region But
Does Not Involve The Entire Lung (T2)
Tumor Of Any Size That Directly Invades
Any Of The Following: Chest Wall
(including Superior Sulcus Tumors),
Diaphragm, Mediastinal Pleura, Parietal
Pericardium; Or Tumor In The Main
Bronchus Less Than 2 Cm Distal To The
Carina, But Without Involvement O* (T3)
Tumor Of Any Size That Invades Any Of
The Following: Mediastinum, Heart,
Great Vessels, Trachea, Esophagus,
Vertebral Body, Carina; Or Separate
Tumor Nodules In The Same Lobe; Or
Tumor With A Malignant Pleural Effusion
(T4)
Lymph Node Assessment
Lymph Nodes Type (Station)
Highest Mediastinal Node (Highest
mediastinal (1))
Interlobar Node (Interlobar (11))
Left Hilar Node (Left hilar (10L))
Left Lobar Node (Left lobar (12L))
Left Lower Paratracheal Node (Left lower
paratracheal (4L))
Left Segmental Node (Left segmental
(13L))
Left Subsegmental Node (Left
subsegmental (14L))
Left Upper Paratracheal Node (Left
upper paratracheal (2L))
Para-aortic Node (Para-aortic (6))
Paraesophageal (Paraesophageal (8))
Pre- And Retro Paratracheal Node (Pre-
and retro paratracheal (3))
Pulmonary Ligament (Pulmonary
ligament (9))
Right Hilar Node (Right hilar (10R))
Right Lobar Node (Right lobar (12R))
Right Lower Paratracheal Node (Right
lower paratracheal (4R))
Right Segmental Node (Right segmental
(13R))
Right Subsegmental Node (Right
subsegmental (14R))
Right Upper Paratracheal Node (Right
upper paratracheal (2R))
Subaortic Node (Subaortic (5))
Subcarinal Node (Subcarinal (7))
Lymph Node Involvement Type
Negative Based On Clinical Evaluation
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(clinically negative)
Positive Based On Clinical Evaluation
(clinically positive)
Equivocal (equivocal)
Not Evaluated (not evaluated)
Negative Based On Pathologic
Evaluation (pathologically negative)
Positive Based On Pathologic Evaluation
(pathologically positive)
Unknown (unknown)
Comments
Comments
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Eligibility NCT01190449 Lymphoma - CALGB
50901 Eligibility Checklist Form 3211939_v1_0
CALGB 50901 Eligibility Checklist Form
Ofatumumab in Treating Patients With Previously Untreated
Stage II, Stage III, or Stage IV Follicular Non-Hodgkin
Lymphoma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=9F9012C3-
FDE5-DB91-E040-BB89AD432434
All rights reserved. Please visit https://medical-data-
models.org/forms/7255
CALGB 50901 Eligibility Checklist
Form
Eignungs-Checkliste
Hämatopoetische Diagnose (Mit X ankreuzen.
Siehe Abschnitt 4.1.1 Histologisch gesicherte
follikulären Lymphom , WHO-Klassifikation Grad
1 , 2 oder 3a ohne histologische Transformation,
die im Stadium III , IV oder voluminöses Stadium
II dh einzelne Masse >= 7 cm ist)
Follikulären Lymphom Grad I (Follicular
lymphoma - grade I)
Follikulären Lymphom Grad II (Follicular
lymphoma - grade II)
Follikulären Lymphom Grad IIIa
(Follicular lymphoma - grade IIIa)
Modifizierter Ann Arbor Stage (Mit einem X
versehen. Siehe Abschnitt 4.1.1)
II (II)
IIE (IIE)
III (III)
IIIE (IIIE)
IIIE+S (IIIE+S)
IIIS (IIIS)
IV (IV)
Hat die institutionelle Durchflusszytometrie oder
Immunhistochemie CD20-Antigen-Expressionen
bestätigt (Tumorgewebe müssen bestätigt sein,
um die CD20-Antigen von institutionellen
Durchflusszytometrie oder Immunhistochemie
auszudrücken. Siehe Abschnitt 4.1.2)
Ja
Nein
Baseline längster Durchmesser der Läsion (cm
des größten beteiligten Knotens. Patient muss an
mindestens einer Stelle der messbaren
Erkrankung, die größer als 1 cm im Durchmesser
vorhanden entweder auf körperliche
Untersuchung oder bildgebenden
Untersuchungen ist . Siehe Abschnitt 4.1.3 und
4.5)
Eine vorherige systemische Therapie für NHL
außer beteiligt Bereich Strahlentherapie ( keine
vorherige Therapie bei NHL einschließlich
Chemo-oder Immuntherapie zB monoklonale
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Antikörper -basierte Therapie. Die Patienten
können beteiligte Bereichs Strahlentherapie
erhalten haben. Siehe Abschnitt 4.2.1)
Ja
Nein
Jede Anwendung von Kortikosteroiden innerhalb
von zwei Wochen vor Studienbeginn (außer für
Wartung Therapie von nicht- maligne Erkrankung
Keine Kortikosteroiden innerhalb von zwei
Wochen vor Studienbeginn , mit Ausnahme von
Erhaltungstherapie für eine nicht- malignen
Erkrankungen . Siehe Abschnitt 4.2.2)
Ja
Nein
Anzahl der Knoten- Sites (Mark ein mit einem X
Low oder mittlerem Risiko durch die follikulären
Lymphom internationaler prognostischer Index
Flipi Punktzahl siehe Abschnitt 4.3)
<= 4 Seiten (<= 4 sites)
>= 4 Seiten (> 4 sites)
Hämoglobin (g/dl)
Lactatdehydrogenase (LDH U/l)
Lactatdehydrogenase ULN (LDH U/l)
Flipi Punktzahl (Mit einem X markieren)
>=3 (>=3)
0-1 (0-1)
2 (2)
Performance-Status (ECOG) (Mit einem X
markieren. ECOG Performance Status <= 2 siehe
Abschnitt 4.4)
Voll aktives, fähig um alle Vorkrankheiten
Leistung ohne Einschränkung
durchzuführen. (0)
Eingeschränkt in körperlich
anstrengenden Tätigkeit, jedoch
ambulant und fähig leichte und sitzende
Arbeiten durchzuführen, z. B. Leichte
Hausarbeit , Büroarbeit. (1)
Ambulant und fähig zur Selbstpflege,
jedoch nicht in der Lage, allen Arbeiten
nachzugehen. Bis zu und mehr als 50%
wach. (2)
Jedes bekannte ZNS-Beteiligung ( Keine
bekannte ZNS-Beteiligung von Lymphomen siehe
Abschnitt 4.6)
Ja
Nein
Age (Alter >= 18 Jahre alt siehe Abschnitt 4.7)
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Hat der Patient eine HIV-Infektion (HIV-Patienten
sind teilnahmeberechtigt, sofern sie die
Parameter in Abschnitt 4.8 zutreffen)
Ja
Nein
CD4+ Anzahl (Falls ja, /mm^3)
Der Nachweis der Koinfektion mit Hepatitis B
oder C oder Hinweise auf einen resistenten
Stamm von HIV
Ja
Nein
Patient mit Anti-HIV Therapie
Ja
Nein
HIV-Viruslast (Falls nicht, Kopien von RNA/mL)
HIV-Viruslast (Falls nicht, Kopien von RNA/mL)
Ist der Patient HBV seropositiv (HBsAg + HBV-
positiven Patienten HBsAg + sind
teilnahmeberechtigt, sofern die Parameter in
Abschnitt 4.9 zutreffen)
Ja
Nein
Wenn HBsAg+, ist der HBV-DNA Test
durchgeführt
Ja
Nein
Ist ein Anzeichen einer aktiven HBV Infektion
nachgewiesen
Ja
Nein
Serum oder Urin Beta-HCG (nicht schwangere
und nicht-stillende: siehe Abschnitt 4.10)
negativ (Negative)
nicht anwendbar (Not applicable)
positiv (Positive)
ANC (u/l Granulozyten >= 1.000/ul siehe
Abschnitt 4.11)
Thrombozyten (u/l Thrombozyten >= 75.000/ul
siehe Abschnitt 4.11)
Serum-Kreatinin (ml/min Kreatinin-Clearance >=
30 mL/min siehe Abschnitt 4.11)
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Bilirubin (Bilirubin >= 2x ULN* siehe Abschnitt
4.11 * Wenn nicht sekundär zu Gilberts oder
hepatische Beteiligung der NHL)
Bilirubin ULN
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Anal Cancer NCT00324415 Lab - AMC-045
Hematology Form (F22) - 2720666v1.0
AMC-045 Hematology Form (F22)
Cisplatin, Fluorouracil, Cetuximab, and Radiation Therapy
in Treating Patients With HIV and Stage I, Stage II, or
Stage III Anal Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=43C69839-
22BB-1EAA-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/7257
AMC-045 Hematology Form (F22)
Header Module
Visit number
Sequence number
Date of evaluation (mm/dd/yyyy)
Reporting Period (select one)
Baseline (Baseline)
On Treatment (On treatment)
Post-therapy (Post therapy)
Ccrr Module For Hematology - Rf22
Hemoglobin (g/dl)
Hematocrit (%)
Peripheral WBC Count (1000/mm^3)
Peripheral Neutrophil Count (1000/mm^3 WBC x
% Neutrophils including Bands/100)
Peripheral Lymphocytes (%) (%)
Peripheral Monocytes (%) (%)
Peripheral Eosinophils (%) (%)
Peripheral Basophils (%) (%)
Other, specify test (Hematology)
Other, specify test (Hematology)
Other specify value
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Other specify value
Peripheral Platelet Count (1000/mm^3)
Units (other specify test)
Comments
Comments
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Bladder Cancer NCT01224665 Follow-Up -
S1011 Follow-Up Form (#56311) - 3152339v1.0
S1011 Follow-Up Form (#56311)
Standard or Extended Pelvic Lymphadenectomy in Treating
Patients Undergoing Surgery for Invasive Bladder Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=9339E952-
BB3F-996A-E040-BB89AD43480C
All rights reserved. Please visit https://medical-data-
models.org/forms/7290
S1011 Follow-Up Form (#56311)
Header
SWOG Patient ID
SWOG Study No.
Registration Step
Patient Initials (L, F M)
Institution/Affiliate
Physician
Participating Group Name
Participating Group Study No.
Participating Group Patient ID
Vital Status
Vital Status
Alive (Alive)
Dead (Dead)
Date of last contact or death (MM DD YYYY)
Has the patient had a documented clinical
assessment for this cancer (since submission of
the previous follow-up form)
Yes
No
Date of Last Clinical Assessment (If Yes, MM DD
YYYY)
Has the patient developed a first relapse or
progression that has not been previously
reported
Yes
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No
Date of Relapse or Progression (If Yes, MM DD
YYYY)
Site(s) of Relapse or Progression (select all that
apply)
Distant (Distant)
Local (Local)
Specify location(s) (Local)
Specify location(s) (Distant)
Has a new primary cancer or MDS been
diagnosed that has not been previously reported?
(myelodysplastic syndrome)
Yes
No
Date of Diagnosis (If Yes, MM DD YYYY)
New Primary Site
Has the patient received any non-protocol cancer
therapy not previously reported (prior to
progression/relapse)
Yes
No
Date of First Non-Protocol Therapy (If Yes, MM
DD YYYY)
Agent Name (s)
Has the patient experienced (prior to treatment
for progression or relapse or a second primary,
and prior to non-protocol treatment) any severe
(grade >=3) long term toxicity that has not been
previously reported?
Yes
No
Adverse Events and Grades (If yes,)
Comments
Comments
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Bladder Cancer NCT00445601 Treatment -
S0337 Treatment Summary Form - 2389127v1.0
S0337 Treatment Summary Form
Gemcitabine After Surgery in Treating Patients With Newly
Diagnosed or Recurrent Bladder Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=FE2614FE-
6335-4C27-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/7291
S0337 Treatment Summary Form
Header
SWOG Patient ID
SWOG Study No.
Registration Step
Patient Initials (L, F M)
Institution/Affiliate
Physician
Participating Group Name
Participating Group Study No.
Participating Group Patient ID
Treatment
Treatment Date (date of intravesical treatment)
Was TURBT performed per protocol
Yes
No
No, explain
Histological Grade
Moderately Differentiated (Moderately
differentiated (G2))
Poorly Differentiated (Poorly
differentiated (G3))
Undifferentiated (Undifferentiated (G4))
Well Differentiated (Well differentiated
(G1))
Clinical T Stage (Note: Submit institutional
pathology report from TURBT.)
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Tumor Invades Subepithelial Connective
Tissue (T1)
Tumor More Than 2 Cm But Not More
Than 5 Cm In Greatest Dimension (T2)
Tumor More Than 5 Cm In Greatest
Dimension (T3)
Inflammatory Carcinoma (T4)
Noninvasive Papillary Carcinoma (Ta)
Carcinoma In Situ: "flat Tumor" (Tis)
Was the 100 ml NS solution administered per
protocol
Yes
No
No, explain
Comments
Comments
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Breast Cancer NCT00433589 Lab -
Laboratory results - 2499268v1.0
Laboratory results
Genetic Testing or Clinical Assessment in Determining the
Need for Chemotherapy in Women With Breast Cancer
That Involves No More Than 3 Lymph Nodes
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=196CB82F-
3764-5936-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/7292
Laboratory results
Header
Patient Birth Date
Patient Hospital Number
Institution Name
Institution No.
Physician of Record
Laboratory Results
Sample Period
Sample Or Specimen Collected Before
Patient Received Treatment For Cancer
(Pre-treatment)
Date Specimen Obtained
Hematology
Peripheral WBC Count
Peripheral Neutrophil Count
Peripheral Platelet Count
Biochemistry
Hemoglobin
Total Bilirubin
Alkaline Phosphatase
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SGPT
SGOT
Other
Creatinine
Calcium
CA 15-3, specify value
Comments
Date
Investigator Signature
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Colorectal Cancer NCT01515787 Eligibility
- N1048 Eligibility Checklist - 3287509v1.0
N1048 Eligibility Checklist
Chemotherapy Alone or Chemotherapy Plus Radiation
Therapy in Treating Patients With Locally Advanced Rectal
Cancer Undergoing Surgery
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=AE19C52B-
5D67-27CC-E040-BB89AD437F7F
All rights reserved. Please visit https://medical-data-
models.org/forms/7308
N1048 Eligibility Checklist
Protocol Administration
Date Informed Consent Signed
Required Characteristics
Age >= 18 years (at diagnosis)
Yes
No
Age (>=18)
Diagnosis of rectal adenocarcinoma
Yes
No
Measurable disease as defined in Section 11.0
Yes
No
ECOG performance status (PS) 0, 1, or 2
Yes
No
For this patient, the standard treatment
recommendation in the absence of a clinical trial
would be combined modality neoadjuvant
chemoradiation followed by curative intent
surgical resection
Yes
No
Candidate for sphincter-sparing surgical resection
prior to neoadjuvant therapy according to the
primary surgeon
Yes
No
Primary surgeon is credentialed in Total
Mesorectal Excision (TME) by the Alliance
Surgery Committee (see Appendix IX)
Yes
No
Clinical Stage:  T2N1, T3N0, T3N1.  Clinical
staging should be estimated based on the
combination of the following assessments:
1 / 6
physical exam by the primary surgeon, CT scan
of the chest/abdomen/pelvis, and either a pelvic
MRI or an ultrasound (ERUS).
Yes
No
Preoperative proctoscopy with tumor tissue
evident between 5 to 12 cm from the anal verge,
inclusive.
Yes
No
The following laboratory values obtained <= 28
days prior to registration
Yes
No
Earliest laboratory test date (Note:  These dates
pertain to the following labs only)
Latest laboratory test date (Note:  These dates
pertain to the following labs only)
Absolute neutrophil count (ANC) >=1,500/mm^3
Yes
No
ANC (>=1,500/mm^3)
Platelet count >= 100,000/mm^3
Yes
No
Platelet count (>= 100,000/mm^3)
Hemoglobin >8 g/dL
Yes
No
Hemoglobin (>8 g/dL)
Total bilirubin <=1.5 x upper limit of normal (ULN)
Yes
No
Total Bilirubin (<=1.5 x ULN)
Total Bilirubin ULN
SGOT (AST) <=3 x ULN
Yes
No
SGOT (AST) (<=3 x ULN)
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SGOT (AST) ULN
SGPT (ALT) <=3 x ULN
Yes
No
SGPT (ALT) (<=3 x ULN)
SGPT (ALT) ULN
Creatinine <=1.5 x ULN
Yes
No
Creatinine (<=1.5 x ULN)
Creatinine ULN
Negative pregnancy test done <=7 days prior to
registration, for women of childbearing potential
only. If not a woman of childbearing potential or
male (check NA)
N/a (N/A)
No (No)
Yes (Yes)
Negative pregnancy test date (If a woman of
childbearing potential)
Patient of child-bearing potential is willing to
employ adequate contraception
Yes
No
Provide informed written consent
Yes
No
Willing to return to enrolling medical site for all
study visits
Yes
No
Exclusion Criteria - All Responses In
Section Below Must Be "no."
Clinical T4 tumors
Yes
No
Primary surgeon indicates need for
abdominaloperineal (APR) at baseline
Yes
No
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Evidence that tumor is adjacent to (defined as
within 3 mm of) the mesorectal fascia on pre-
operative MRI or ERUS/pelvic CT scan
Yes
No
Tumor is causing symptomatic bowel obstruction
Yes
No
Chemotherapy within 5 years prior to registration
(Hormonal therapy is allowable if the disease-free
interval is >= 5 years)
Yes
No
Any prior pelvic radiation
Yes
No
Other invasive malignancy <= 5 years prior to
registration.  Exceptions are colonic polyps, non-
melanoma skin cancer or carcinoma-in-situ of the
cervix
Yes
No
Any of the following because this study involves
an agent that has known genotoxic, mutagenic
and teratogenic effects.
-	Pregnant women
-	Nursing women
-	Men or women of childbearing potential who are
unwilling to employ adequate contraception.
Yes
No
Co-morbid systemic illnesses or other concurrent
disease which, in the judgment of the clinician
obtaining informed consent, would make the
patient inappropriate for entry into this study or
interfere significantly with the proper assessment
of safety and toxicity of the prescribed regimens
Yes
No
Pre-registration Check
Consent form signed and dated
Yes
No
Authorization for use and disclosure of protected
health information signed and dated (U.S.A,
institutions only If not a USA institution check NA)
Not Applicable (NA)
No (No)
Yes (Yes)
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Date of authorization (If a USA institution)
Treatment cannot begin prior to registration and
must begin <=21 days after registration
Yes
No
Pretreatment tests/procedures must be
completed <= 28 days prior to registration (see
Section 4.0)
Yes
No
Earliest pretreatment test/procedure date (NOTE:
The earliest pretreatment test date must be less
than or equal to the earliest laboratory test date
and the latest pretreatment test date must be
greater than or equal to the latest laboratory test
date.)
Latest pretreatment test/procedure date
All required baseline conditions must be
documented and graded (see Section 10.51)
Yes
No
Treatment on this protocol must commence at the
accruing membership site under the supervision
of an Alliance or CTSU member physician
Yes
No
Ran
Patient has given permission to the Alliance to
store and use his/her blood samples for use in
future research to learn about, prevent, or treat
cancer
Yes
No
Patient has given permission to the Alliance to
store and use his/her blood samples for use in
future research to learn about, prevent, or treat
other health problems (for example: diabetes,
Alzheimer's disease, or heart disease)
Yes
No
Patient has given permission to the Alliance to
give his/her stored blood samples for use in
future research to outside researchers
Yes
No
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Patient has given permission to the Alliance to
collect and store his/her tissue samples for use in
future research to learn about, prevent, or treat
cancer
Yes
No
Patient has given permission to the Alliance to
collect and store his/her tissue samples for use in
future research to learn about, prevent, or treat
other health problems (for example: diabetes,
Alzheimer's disease, or heart disease)
Yes
No
Patient has given permission for the Alliance to
give his/her stored tissue samples for use in
future research to outside researchers
Yes
No
Grouping Factor
ECOG Performance Status
0 Or 1 (0 or 1)
2 (2)
6 / 6
Colorectal Cancer NCT01515787 Eligibility - N1048 Eligibility Checklist -
3287509v1.0
Breast Cancer NCT01272037 Treatment - S1007
Chemotherapy Form (S1007CHEMO) - 3139708v1.0
S1007 Chemotherapy Form (S1007CHEMO)
Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane
With or Without Chemotherapy in Treating Patients With
Invasive RxPONDER Breast Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=90C9DFFB-
23F1-84DB-E040-BB89AD437DC2
All rights reserved. Please visit https://medical-data-
models.org/forms/7309
S1007 Chemotherapy Form
(S1007CHEMO)
Header
SWOG Patient ID
SWOG Study No.
Registration Step
Patient Initials (L, F M)
Institution/Affiliate
Physician
Participating Group Name
Participating Group Study No.
Participating Group Patient ID
Unnamed2
Chemotherapy Regimen (select one; if drugs
were substituted or omitted during treatment
because of toxicity, indicate the initial planned
regimen)
5-fu, Doxorubicin (or Epirubicin) And
Cyclophosphamide (fac) Followed By
Weekly Paclitaxel X 12 (5-FU,
doxorubicin (or epirubicin) and
cyclophosphamide (FAC) followed by
weekly paclitaxel x 12)
5-fu, Doxorubicin (or Epirubicin) And
Cyclophosphamide Followed By
Docetaxel (3 Cycles Each) (5-FU,
doxorubicin (or epirubicin) and
cyclophosphamide followed by docetaxel
(3 cycles each))
5-fu, Doxorubicin (or Epirubicin) And
Cyclophosphamide Followed By
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Docetaxel (q 3 Weeks, 4 Cycles Each)
(5-FU, doxorubicin (or epirubicin) and
cyclophosphamide followed by docetaxel
(q 3 weeks, 4 cycles each))
5-fu, Doxorubicin (or Epirubicin), And
Cyclophosphamide (5-FU, doxorubicin
(or epirubicin), and cyclophosphamide)
Docetaxel And Cyclophosphamide
(Docetaxel and cyclophosphamide)
Docetaxel, Doxorubicin, And
Cyclophosphamide (6 Cycles)
(Docetaxel, doxorubicin, and
cyclophosphamide (6 cycles))
Dose Dense Doxorubicin And
Cyclophosphamide Followed By Dose
Dense Paclitaxel (q 2 Weeks, 4 Cycles
Each) (Dose dense doxorubicin and
cyclophosphamide followed by dose
dense paclitaxel (q 2 weeks, 4 cycles
each))
Doxorubicin (or Epirubicin) And
Cyclophosphamide (ac/ec) Followed By
Paclitaxel (Doxorubicin (or epirubicin)
and cyclophosphamide (AC/EC) followed
by paclitaxel)
Doxorubicin (or Epirubicin) And
Cyclophosphamide (ac/ec) Followed By
Weekly Paclitaxel X 12 (Doxorubicin (or
epirubicin) and cyclophosphamide
(AC/EC) followed by weekly paclitaxel x
12)
Other Chemotherapy Regimen (Other
chemotherapy regimen)
Other Regimen Given As Part Of A Ctsu
Adjuvant Therapy Protocol (other
regimen given as part of a CTSU
adjuvant therapy protocol)
Weekly Paclitaxel X 12 Followed By 5-fu,
Doxorubicin (or Epirubicin) And
Cyclophosphamide (fac) (Weekly
paclitaxel x 12 followed by 5-FU,
doxorubicin (or epirubicin) and
cyclophosphamide (FAC))
specify study number and treatment arm (other
regimen given as part of a CTSU adjuvant
therapy protocol)
specify drugs and schedule (other chemotherapy
regimen)
Date Chemotherapy Began (date 1st cycle given
MM DD YYYY)
Date Chemotherapy Ended (date last cycle given
MM DD YYYY)
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Total number of chemotherapy cycles completed
Was chemotherapy ever delayed or reduced
because of toxicity
Yes
No
Comments
Comments
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Breast Cancer NCT01272037 Follow-Up -
S1007 Follow-Up Form (64587) - 3140709v1.0
S1007 Follow-Up Form (64587)
Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane
With or Without Chemotherapy in Treating Patients With
Invasive RxPONDER Breast Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=90DA0C1C-
751C-2248-E040-BB89AD435ECD
All rights reserved. Please visit https://medical-data-
models.org/forms/7310
S1007 Follow-Up Form (64587)
Header
SWOG Patient ID
SWOG Study No.
Registration Step
Patient Initials (L, F M)
Institution/Affiliate
Physician
Participating Group Name
Participating Group Study No.
Participating Group Patient ID
Vital Status
Vital Status
Alive (Alive)
Dead (Dead)
Date of last contact or death (MM DD YYYY)
Has the patient had a documented clinical
assessment for this cancer (since submission of
the previous follow-up form)
Yes
No
Date of Last Clinical Assessment (If Yes, MM DD
YYYY)
Has the patient developed a first relapse or
progression that has not been previously
reported
Yes
1 / 2
No
Date of Relapse or Progression (If Yes, MM DD
YYYY)
Site(s) of relapse or progression
Has a new primary cancer or MDS been
diagnosed that has not been previously reported?
(myelodysplastic syndrome)
Yes
No
Date of Diagnosis (If Yes, MM DD YYYY)
New Primary Site
Has the patient received any non-protocol cancer
therapy not previously reported (prior to
progression/relapse)
Yes
No
Date of First Non-Protocol Therapy (If Yes, MM
DD YYYY)
Agent Name (s)
Has the patient experienced (prior to treatment
for progression or relapse or a second primary,
and prior to non-protocol treatment) any severe
(grade >=3) long term toxicity that has not been
previously reported?
Yes
No
Adverse Events and Grades (If yes,)
Comments
Comments
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Breast Cancer NCT01272037 Follow-Up - S1007 Follow-Up Form
(64587) - 3140709v1.0
Breast Cancer NCT01272037 Treatment - S1007
Radiation Therapy Form (S1007RAD) - 3139641v1.0
S1007 Radiation Therapy Form (S1007RAD)
Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane
With or Without Chemotherapy in Treating Patients With
Invasive RxPONDER Breast Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=90C9DFFB-
2367-84DB-E040-BB89AD437DC2
All rights reserved. Please visit https://medical-data-
models.org/forms/7311
S1007 Radiation Therapy Form
(S1007RAD)
Header
SWOG Patient ID
SWOG Study No.
Registration Step
Patient Initials (L, F M)
Institution/Affiliate
Physician
Participating Group Name
Participating Group Study No.
Participating Group Patient ID
Header
Has the patient received radiation therapy to the
breast?
Yes
No
Radiation Therapy Start Date (MM DD YYYY)
Radiation Therapy End Date (MM DD YYYY)
Irradiated?
Whole breast or chest wall
Yes
No
Partial Breast
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Yes
No
Tumor bed or chest wall boost
Yes
No
Ipsilateral supraclavicular / axillary apex field
Yes
No
Separate field for internal mammary nodes
Yes
No
RT Total Dose
Total Number of Fractions
Other specify
Targeted Regions Of Treatment
Breast or chest wall
Yes
No
Level I axilla
Yes
No
Level II axilla
Yes
No
Level III axilla
Yes
No
Supraclavicular fossa
Yes
No
Internal mammary
Yes
No
Other
Yes
No
Partial Breast Irradiation
Partial Breast Irradiation Method
Catheter-based Intercavitary
Brachytherapy (Catheter-based
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Breast Cancer NCT01272037 Treatment - S1007 Radiation Therapy
Form (S1007RAD) - 3139641v1.0
intercavitary brachytherapy)
External Beam Partial Breast Irradiation
(External beam partial breast irradiation)
Interstitial Single Or Double Plan
Brachytherapy (Interstitial single or
double plan brachytherapy)
Intraoperative Single Dose Partial Breast
Irradiation (Intraoperative single dose
partial breast irradiation)
Other (Other)
Specify
Comments
Comments
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Breast Cancer NCT01272037 Treatment - S1007 Radiation Therapy
Form (S1007RAD) - 3139641v1.0
Breast Cancer NCT01272037 Pre-Study -
S1007 Prestudy Form (45282) - 3141026v1.0
S1007 Prestudy Form (45282)
Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane
With or Without Chemotherapy in Treating Patients With
Invasive RxPONDER Breast Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=90DB6C43-
AEA1-137D-E040-BB89AD432116
All rights reserved. Please visit https://medical-data-
models.org/forms/7313
S1007 Prestudy Form (45282)
Header
SWOG Patient ID
SWOG Study No.
Registration Step
Patient Initials (L, F M)
Institution/Affiliate
Physician
Participating Group Name
Participating Group Study No.
Participating Group Patient ID
Disease Description
Performance Status
Weight (kg)
Menopausal Status (select one)
Above Categories Not Applicable And
Age <50 (Above categories not
applicable AND Age < 50)
Above Categories Not Applicable And
Age >= 50 (Above categories not
applicable AND Age >= 50)
Post (prior Bilateral Oophorectomy Or >
12 Mo Since Lmp With No Prior
Hysterectomy) (Post (prior bilateral
oophorectomy OR > 12 mo since LMP
with no prior hysterectomy))
Pre (< 6 Mo Since Lmp And No Prior
Bilateral Oophorectomy And Not On
Estrogen Replacement) (Pre (< 6 mo
1 / 4
since LMP and no prior bilateral
oophorectomy and not on estrogen
replacement))
Date of Initial Diagnosis of Primary Tumor (MM
DD YYYY)
Tumor Laterality (select one)
Bilateral (Bilateral)
Left (Left)
Right (Right)
Pathologic Primary Tumor Size (cm Maximum
diameter of the invasive component; if multiple
lesions, use longest lesion)
Number of Positive Lymph Nodes (If sentinel
node biopsy and axillary node dissection were
performed, enter the sum of positive nodes.)
ER Status
Negative (Negative)
Positive (Positive)
PgR Status
Negative (Negative)
Positive (Positive)
HER2 results/IHC
0 (0)
1+ (1+)
2+ (2+)
FISH ratio
Additional Prestudy Data
Breast cancer was first detected by (select one)
Physical Exam Or Diagnostic
Mammogram Due To Symptoms Of
Breast Cancer Or Other Reason
(Physical exam or diagnostic
mammogram due to symptoms of breast
cancer or other reason)
Screening Mammogram (Screening
mammogram)
Histologic Grade (combined histologic grade by
SBR/Elston classification)
G1 Low Combined Histologic Grade
(favorable) (G1)
G2 Intermediate Combined Histologic
Grade (moderately Favorable) (G2)
G3 High Combined Histologic Grade
(unfavorable) (G3)
Gx Grade Cannot Be Assessed (GX)
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Breast Cancer NCT01272037 Pre-Study - S1007 Prestudy Form (45282)
- 3141026v1.0
Nuclear Grade
High (High)
Intermediate (Intermediate)
Low (Low)
Unknown (Unknown)
Histology
Invasive Ductal Carcinoma, Not
Otherwise Specified (Invasive Ductal
Carcinoma)
Invasive Lobular Breast Carcinoma
(Invasive Lobular Carcinoma)
Invasive Mixed Ductal/lobular Carcinoma
(Invasive mixed ductal/lobular
carcinoma)
Other Specify (Other)
Specify
Lymphovascular space invasion
No (NO)
Unknown (UNKNOWN)
Yes (YES)
Extranodal extension
No (NO)
Unknown (UNKNOWN)
Yes (YES)
Multifocal Tumors
Yes
No
Multicentric Tumors
Yes
No
Breast: Surgical Procedures
Most Extensive Primary Surgery (select one)
Mastectomy, Nos (Mastectomy NOS)
Partial Mastectomy, Lumpectomy Or
Excisional Biopsy (Partial
mastectomy/lumpectomy/excisional
biopsy)
Date of Most Extensive Primary Surgery (MM DD
YYYY If required, use last re-excision date)
Was sentinel node sampling performed
Yes
No
Sentinel Node Biopsy Date (MM DD YYYY)
Sentinel Node Biopsy Results
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- 3141026v1.0
Negative (Negative)
Positive (Positive)
Maximum size of sentinel lymph node metastasis
(mm)
Unknown
Was axillary dissection performed?
Yes
No
Date of Axillary Dissection (MM DD YYYY)
Number of Lymph Nodes Examined (If sentinel
node biopsy and axillary node dissection were
performed, enter the sum of nodes examined.)
Comments
Comments
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Breast Cancer NCT01272037 Pre-Study - S1007 Prestudy Form (45282)
- 3141026v1.0
Breast Cancer NCT01272037 Follow-Up - S1007
Supplementary Follow-Up Form (FUS1007) - 3139763v1.0
S1007 Supplementary Follow-Up Form (FUS1007)
Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane
With or Without Chemotherapy in Treating Patients With
Invasive RxPONDER Breast Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=90C9DFFB-
2463-84DB-E040-BB89AD437DC2
All rights reserved. Please visit https://medical-data-
models.org/forms/7314
S1007 Supplementary Follow-Up
Form (FUS1007)
Header
SWOG Patient ID
SWOG Study No.
Registration Step
Patient Initials (L, F M)
Date of Evaluation (MM DD YYYY)
Institution/Affiliate
Physician
Participating Group Name
Participating Group Study No.
Participating Group Patient ID
Iib - Local-regional Recurrence
Has the patient been diagnosed with a new
invasive primary or recurrence in the opposite
breast (contralateral since submission of last
follow-up form)
Yes
No
Date of diagnosis (MM DD YYYY)
Has the patient been diagnosed with first local-
regional recurrence or progression (do not
include DCIS since submission of last follow-up
form)
Yes
1 / 3
No
Date of First Local-Regional Recurrence (MM DD
YYYY)
Site of first local-regional recurrence (s select all
that apply)
Axilla (Axilla)
Axillary Nodes (Axillary nodes)
Chest Wall (Chest wall)
Infraclavicular Nodes (Infraclavicular
nodes)
Internal Mammary Nodes (Internal
mammary nodes)
Ipsilateral Breast (Ipsilateral breast)
Supraclavicular Nodes (Supraclavicular
nodes)
How was this progression information obtained?
Clinical Assessment (Clinical
assessment)
Patient Self Report Only (Patient self-
report only)
Iic - Distance Recurrence
Has the patient been diagnosed with first distant
recurrence/progression? (since submission of last
follow-up form)
Yes
No
Date of First Distant Progression (MM DD YYYY)
Site of First Distant Progression (s select all that
apply)
Bone (Bone)
Brain (Brain)
Liver (Liver)
Lung (Lung)
Nodes (Nodes)
Other Cns (Other CNS)
Other Nos (Other NOS)
Other Soft Tissue (Other Soft Tissue)
Other Visceral (Other Visceral)
Skin (Skin)
Other, NOS
How was this progression information obtained?
Clinical Assessment (Clinical
assessment)
Patient Self Report Only (Patient self-
report only)
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Up Form (FUS1007) - 3139763v1.0
Comments
Comments
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Breast Cancer NCT01272037 Follow-Up - S1007 Supplementary Follow-
Up Form (FUS1007) - 3139763v1.0
Breast Cancer NCT01272037 Off Treatment - S1007
Off-Protocol Notice Form - Step 1 - 3141184v1.0
S1007 Off-Protocol Notice Form - Step 1
Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane
With or Without Chemotherapy in Treating Patients With
Invasive RxPONDER Breast Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=90DE3C1B-
9D8D-FBC6-E040-BB89AD4313C7
All rights reserved. Please visit https://medical-data-
models.org/forms/7317
S1007 Off-Protocol Notice Form -
Step 1
Header
SWOG Patient ID
SWOG Study No.
Registration Step
Patient Initials (L, F M)
Institution/Affiliate
Physician
Participating Group Name
Participating Group Study No.
Participating Group Patient ID
Oncotype Dx Recurrence Score
Was the Oncotype DX Recurrence Score
obtained
No, Assay Could Not Be Performed (No,
assay could not be performed)
No, Patient Refused (No, patient refused)
Yes (Yes)
Oncotype DX Recurrence Score
Oncotype DX ER Score
Oncotype DX PR Score
Oncotype DX HER2 Score
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Requisition Number
Off Protocol Reason
Off Protocol Reason (select one)
Death (Death)
Disease Progression Or Distant
Recurrence Or New Primary Invasive
Cancer (Disease progression or distant
recurrence or new primary invasive
cancer)
Other (Other)
Recurrence Score <=25 And Patient
Withdrawal/refusal (Recurrence Score
<=25 and patient withdrawal/refusal)
Recurrence Score >25 (Recurrence
Score >25)
Recurrence Score Not Obtained
(Recurrence Score not obtained)
Specify reason
Recurrence Score <=25 and patient
withdrawal/refusal, specify
Sites
Other specify
Off Protocol Date (Date of decision not to
continue on study MM DD YYYY)
Planned Treatment
What treatment is planned for the patient (select
all that apply)
Chemotherapy (Chemotherapy)
Endocrine Therapy (Endocrine Therapy)
Other Therapy (Other Therapy)
Specify
For Patients Participating In The Quality
Of Life And Economic Analysis Substudy
For patients participating in the Quality of Life and
Economic Analysis substudy, was the S1007
Health-Related Quality of Life Questionnaire:
Observational Study Form completed per
protocol section 14.8?
Yes
No
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Breast Cancer NCT01272037 Off Treatment - S1007 Off-Protocol Notice
Form - Step 1 - 3141184v1.0
No, specify reason
Status
Date of Last Contact or Death (MM DD YYYY)
Vital Status
Alive (Alive)
Dead (Dead)
Comments
Comments
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Breast Cancer NCT01272037 Off Treatment - S1007 Off-Protocol Notice
Form - Step 1 - 3141184v1.0
Breast Cancer NCT01272037 Pre-Study - S1007 Prestudy
Form - Randomized Study (6230) - 3141162v1.0
S1007 Prestudy Form - Randomized Study (6230)
Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane
With or Without Chemotherapy in Treating Patients With
Invasive RxPONDER Breast Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=90DE259F-
A7AB-E9EB-E040-BB89AD436D98
All rights reserved. Please visit https://medical-data-
models.org/forms/7319
S1007 Prestudy Form - Randomized
Study (6230)
Header
SWOG Patient ID
SWOG Study No.
Registration Step
Patient Initials (L, F M)
Institution/Affiliate
Physician
Participating Group Name
Participating Group Study No.
Participating Group Patient ID
Patient And Disease Description
Oncotype DX Recurrence Score
Oncotype DX ER Score
Oncotype DX PR Score
Oncotype DX HER2 Score
Requisition Number
Date of Oncotype DX Score Report (MM DD
YYYY)
1 / 2
Has the patient suggested or indicated that she
will not follow the randomized treatment
assignment
Yes
No
Indicate Reason (If yes)
Assigned To Chemotherapy But Does
Not Want To Receive Chemotherapy
(Assigned to chemotherapy but does not
want to receive chemotherapy)
Assigned To No Chemotherapy But
Wants To Receive Chemotherapy
(Assigned to no chemotherapy but wants
to receive chemotherapy)
Comments
Comments
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Breast Cancer NCT01272037 Pre-Study - S1007 Prestudy Form -
Randomized Study (6230) - 3141162v1.0
Colorectal Cancer NCT00070122 Quality of Life - SOUTHWEST ONCOLOGY
GROUP S0303 Chemotherapy Convenience and Satisfaction Questionnaire -
Baseline - 2166850v3.0
SOUTHWEST ONCOLOGY GROUP S0303 Chemotherapy
Convenience and Satisfaction Questionnaire - Baseline
Combination Chemotherapy and Bevacizumab in Treating
Patients With Locally Advanced, Metastatic, or Recurrent
Colorectal Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=BC61E2B0-
373A-1037-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/7320
SOUTHWEST ONCOLOGY GROUP
S0303 Chemotherapy Convenience
and Satisfaction Questionnaire -
Baseline
Header
SWOG Patient ID
SWOG Study No.
Registration Step
Date
Patient Initials (L, F M)
Institution/Affiliate
Physician (Groups Other than SWOG)
Group Name
Study No.
Pt. ID
I believe chemotherapy treatment will take up my
time
A Little Bit (a little bit)
Not At All (not at all)
Quite A Bit (quite a bit)
Somewhat (somewhat)
Very Much (very much)
I believe my chemotherapy treatment will take up
my family's time
A Little Bit (a little bit)
Not At All (not at all)
Quite A Bit (quite a bit)
Somewhat (somewhat)
Very Much (very much)
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I worry about side effects from chemotherapy
treatment
A Little Bit (a little bit)
Not At All (not at all)
Quite A Bit (quite a bit)
Somewhat (somewhat)
Very Much (very much)
I believe my chemotherapy treatment causes me
physical pain
A Little Bit (a little bit)
Not At All (not at all)
Quite A Bit (quite a bit)
Somewhat (somewhat)
Very Much (very much)
I believe receiving chemotherapy will be
inconvenient
A Little Bit (a little bit)
Not At All (not at all)
Quite A Bit (quite a bit)
Somewhat (somewhat)
Very Much (very much)
I worry that my chemotherapy will not be effective
A Little Bit (a little bit)
Not At All (not at all)
Quite A Bit (quite a bit)
Somewhat (somewhat)
Very Much (very much)
I believe chemotherapy treatment will be harmful
to me
A Little Bit (a little bit)
Not At All (not at all)
Quite A Bit (quite a bit)
Somewhat (somewhat)
Very Much (very much)
I believe my chemotherapy schedule will be
stressful to me
A Little Bit (a little bit)
Not At All (not at all)
Quite A Bit (quite a bit)
Somewhat (somewhat)
Very Much (very much)
I believe my chemotherapy schedule will be
stressful to my family
A Little Bit (a little bit)
Not At All (not at all)
Quite A Bit (quite a bit)
Somewhat (somewhat)
Very Much (very much)
I believe I will be bothered by side effects of
treatment
A Little Bit (a little bit)
Not At All (not at all)
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Colorectal Cancer NCT00070122 Quality of Life - SOUTHWEST ONCOLOGY
GROUP S0303 Chemotherapy Convenience and Satisfaction Questionnaire -
Baseline - 2166850v3.0
Quite A Bit (quite a bit)
Somewhat (somewhat)
Very Much (very much)
I am content with the quality of my life right now
A Little Bit (a little bit)
Not At All (not at all)
Quite A Bit (quite a bit)
Somewhat (somewhat)
Very Much (very much)
Ccrr Module For Southwest Oncology
Group S0303 Chemotherapy Convenience
And Satisfaction Questionnaire - Baseline
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Colorectal Cancer NCT00070122 Quality of Life - SOUTHWEST ONCOLOGY
GROUP S0303 Chemotherapy Convenience and Satisfaction Questionnaire -
Baseline - 2166850v3.0
Colorectal Cancer NCT00070122 Quality of Life - SOUTHWEST ONCOLOGY
GROUP S0303 Chemotherapy Convenience and Satisfaction Questionnaire -
Experience - 2167428v3.0
SOUTHWEST ONCOLOGY GROUP S0303 Chemotherapy
Convenience and Satisfaction Questionnaire - Experience
Combination Chemotherapy and Bevacizumab in Treating
Patients With Locally Advanced, Metastatic, or Recurrent
Colorectal Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=BC88C25D-
EB2A-2B36-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/7322
SOUTHWEST ONCOLOGY GROUP
S0303 Chemotherapy Convenience
and Satisfaction Questionnaire -
Experience
Header
SWOG Patient ID
SWOG Study No.
Registration Step
Assessment
Week 13 (Week 13)
Week 25 (Week 25)
Week 7 (Week 7)
Date
Patient Initials (L, F M)
Institution/Affiliate
Physician (Groups Other than SWOG)
Group Name
Study No.
Pt. ID
Chemotherapy treatment takes up my time
A Little Bit (a little bit)
Not At All (not at all)
Quite A Bit (quite a bit)
Somewhat (somewhat)
Very Much (very much)
Chemotherapy treatment takes up my family's
time
A Little Bit (a little bit)
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Not At All (not at all)
Quite A Bit (quite a bit)
Somewhat (somewhat)
Very Much (very much)
I worry about side effects from chemotherapy
treatment
A Little Bit (a little bit)
Not At All (not at all)
Quite A Bit (quite a bit)
Somewhat (somewhat)
Very Much (very much)
My chemotherapy treatment causes me physical
pain
A Little Bit (a little bit)
Not At All (not at all)
Quite A Bit (quite a bit)
Somewhat (somewhat)
Very Much (very much)
Receiving chemotherapy is inconvenient
A Little Bit (a little bit)
Not At All (not at all)
Quite A Bit (quite a bit)
Somewhat (somewhat)
Very Much (very much)
I worry that my chemotherapy will not be effective
A Little Bit (a little bit)
Not At All (not at all)
Quite A Bit (quite a bit)
Somewhat (somewhat)
Very Much (very much)
Chemotherapy treatment seems harmful to me
A Little Bit (a little bit)
Not At All (not at all)
Quite A Bit (quite a bit)
Somewhat (somewhat)
Very Much (very much)
My chemotherapy schedule is stressful to me
A Little Bit (a little bit)
Not At All (not at all)
Quite A Bit (quite a bit)
Somewhat (somewhat)
Very Much (very much)
My chemotherapy schedule is stressful to my
family
A Little Bit (a little bit)
Not At All (not at all)
Quite A Bit (quite a bit)
Somewhat (somewhat)
Very Much (very much)
I am bothered by side effects of treatment
A Little Bit (a little bit)
Not At All (not at all)
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Experience - 2167428v3.0
Quite A Bit (quite a bit)
Somewhat (somewhat)
Very Much (very much)
I am content with the quality of my life right now
A Little Bit (a little bit)
Not At All (not at all)
Quite A Bit (quite a bit)
Somewhat (somewhat)
Very Much (very much)
Are you satisfied with the current results of your
chemotherapy
A Little Bit (a little bit)
Not At All (not at all)
Quite A Bit (quite a bit)
Somewhat (somewhat)
Very Much (very much)
Would you recommend this chemotherapy to
others with your illness
Maybe (maybe)
Not At All (not at all)
Yes (yes)
Would you choose this chemotherapy again
Maybe (maybe)
Not At All (not at all)
Yes (yes)
How would you rate this chemotherapy
Excellent (excellent)
Fair (fair)
Good (good)
Poor (poor)
Very Good (very good)
Ccrr Module For Southwest Oncology
Group S0303 Chemotherapy Convenience
And Satisfaction Questionnaire -
Experience
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Colorectal Cancer NCT00070122 Quality of Life - SOUTHWEST ONCOLOGY
GROUP S0303 Chemotherapy Convenience and Satisfaction Questionnaire -
Experience - 2167428v3.0
Colorectal Cancer NCT00499369 Treatment - Southwest
Oncology Group S0600 Treatment Form - 2813273v1.0
Southwest Oncology Group S0600 Treatment Form
Irinotecan and Cetuximab With or Without Bevacizumab in
Treating Patients With Metastatic Colorectal Cancer That
Progressed During First-Line Therapy
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=5DA30D89-
61BB-0FC6-E040-BB89A643170F
All rights reserved. Please visit https://medical-data-
models.org/forms/7338
Southwest Oncology Group S0600
Treatment Form
Header
SWOG Patient ID
SWOG Study No.
Registration Step
Patient Initials (L, F M)
Institution/Affiliate
Physician (Groups other than SWOG)
Participating Group
Participating Group Study No.
Participating Group Patient ID
Status
Date of Last Contact or Death
Vital Status
Alive (Alive)
Dead (Dead)
Has the patient progressed per the definition of
Section 10.0 of the protocol
Yes
No
Treatment
Assigned Treatment Arm
Arm A: Cetuximab + Chemotherapy
(Arm A: Cetuximab + Chemotherapy)
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Arm B: Bevacizumab + Chemotherapy
(Arm B: Bevacizumab + Chemotherapy)
Concurrent chemotherapy
Irinotecan + 5-fluorouracil/leucovorin
Regimen (folfiri) (FOLFIRI)
Irinotecan Hydrochloride (Single agent
irinotecan)
Cycle Start Date
Date of last treatment for this cycle
Weight (first day this cycle - kg)
BSA (first day this cycle - m2)
Were there any dose modifications or
additions/omissions to protocol treatment?
No (No)
Yes, Planned (i.e., The Treatment Was
Changed According To Protocol
Guidelines) (Yes, planned)
Yes, Unplanned (i.e., The Treatment
Change Was Not Part Of Protocol
Guidelines) (Yes, unplanned)
Was G-CSF received
Yes
No
Agent Name
Total Dose
Units
Milligram (mg)
Ccrr Module For Southwest Oncology
Group S0303 Treatment Form - Arm 1
Comments
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Colorectal Cancer NCT00499369 Treatment - Southwest Oncology
Group S0600 Treatment Form - 2813273v1.0
Colorectal Cancer NCT00499369 Follow-Up - Southwest
Oncology Group Follow Up Form - 2485277v1.0
Southwest Oncology Group Follow Up Form
Irinotecan and Cetuximab With or Without Bevacizumab in
Treating Patients With Metastatic Colorectal Cancer That
Progressed During First-Line Therapy
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=1540A9C1-
B252-6EFF-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/7339
Southwest Oncology Group Follow
Up Form
Header
SWOG Patient ID
SWOG Study No.
Registration Step
Patient Initials (L, F M)
Institution/Affiliate
Physician
Participating Group Name
Participating Group Study No.
Participating Group Patient ID
Vital Status
Vital Status
Alive (Alive)
Dead (Dead)
Date of Last Contact or Death
Has the patient had a documented clinical
assessment for this cancer (since submission of
the previous follow-up form?)
Yes
No
Date of Last Clinical Assessment (If Yes,)
Has the patient developed a first relapse or
progression that has not been previously
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reported
Yes
No
Date of Relapse or Progression (If Yes,)
Site(s) of Relapse or Progression
Has a new primary cancer or MDS been
diagnosed that has not been previously reported?
(myelodysplastic syndrome)
Yes
No
Date of Diagnosis (If Yes,)
New Primary Site
Has the patient received any non-protocol cancer
therapy (prior to progression/relapse) not
previously reported?
Yes
No
Date of First Non-Protocol Therapy (If yes,)
Non-Protocol Therapy Type
Chemotherapy (Chemotherapy)
Hormonal Therapy (Hormonal Therapy)
Immunotherapy (Immunotherapy)
Other Specify (Other)
Radiation Therapy (Radiation therapy)
Surgery (Surgery)
Other, specify
Agent Name (s:)
Has the patient experienced (prior to treatment
for progression or relapse or a second primary,
and prior to
non-protocol treatment) any severe (grade >=3)
long term toxicity that has not been previously
reported?
Yes
No
Adverse Events and Grades (If Yes,)
Comments
Comments
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Group Follow Up Form - 2485277v1.0
Colorectal Cancer NCT00499369 Treatment - Southwest Oncology Group S0600
Treatment Form -  For Patients Registered Before 6/6/2008 Only - 2484941v1.0
Southwest Oncology Group S0600 Treatment Form -  For
Patients Registered Before 6/6/2008 Only
Irinotecan and Cetuximab With or Without Bevacizumab in
Treating Patients With Metastatic Colorectal Cancer That
Progressed During First-Line Therapy
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=15416480-
96F8-679D-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/7342
Southwest Oncology Group S0600
Treatment Form -  For Patients
Registered Before 6/6/2008 Only
Header
SWOG Patient ID
SWOG Study No.
Registration Step
Patient Initials (L, F M)
Institution/Affiliate
Physician (Groups other than SWOG)
Participating Group
Participating Group Study No.
Participating Group Patient ID
Status
Date of Last Contact or Death
Vital Status
Alive (Alive)
Dead (Dead)
Has the patient progressed per the definition of
Section 10.0 of the protocol
Yes
No
Treatment
Assigned Treatment Arm
Arm 1: Cetuximab (Arm 1: Cetuximab)
Arm 2: Cetuximab + Lower-dose
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Bevacizumab (Arm 2: Cetuximab +
lower-dose bevacizumab)
Arm 3: Cetuximab + Higher-dose
Bevacizumab (Arm 3: Cetuximab +
higher-dose bevacizumab)
Concurrent chemotherapy
Irinotecan + 5-fluorouracil/leucovorin
Regimen (folfiri) (FOLFIRI)
Irinotecan Hydrochloride (Single agent
irinotecan)
Cycle Start Date
Date of last treatment for this cycle
Weight (first day this cycle - kg)
BSA (first day this cycle - m2)
Were there any dose modifications or
additions/omissions to protocol treatment?
No (No)
Yes, Planned (i.e., The Treatment Was
Changed According To Protocol
Guidelines) (Yes, planned)
Yes, Unplanned (i.e., The Treatment
Change Was Not Part Of Protocol
Guidelines) (Yes, unplanned)
Was G-CSF received
Yes
No
Agent Name
Total Dose
Units
Milligram (mg)
Dose modification
Dose Delayed (Dose delayed)
Dose Delayed And Reduced (Dose
delayed and reduced)
Dose Held (Dose held)
Dose Reduced (Dose reduced)
Drug Discontinued (Drug discontinued)
No Dose Modification (No dose
modification)
Dose Modification Reason
Adverse Event (Adverse event)
Alternative Therapy For Other Reason
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(Alternative therapy for other reason)
Death (Death)
Disease Progression (Disease
progression)
Dosing Error (Dosing error)
Other (Other)
Patient Refusal/noncompliance (Patient
refusal/noncompliance)
Scheduling (Scheduling)
Other, specify
Modification due to Adverse Event
Arterial Thrombotic Event (Arterial
Thrombotic Event)
Gi Toxicity (GI toxicity)
Hematologic Toxicity (Hematologic
toxicity)
Hepatic Toxicity (Hepatic Toxicity)
Other (Other)
Renal Toxicity (Renal toxicity)
Venous Thrombosis/embolism (Venous
Thrombosis/Embolism)
Other, specify
Ccrr Module For Southwest Oncology
Group S0303 Treatment Form - Arm 1
Comments
3 / 3
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Treatment Form -  For Patients Registered Before 6/6/2008 Only - 2484941v1.0
Fallopian Tube Cancer NCT00565851 Lab -
GOG Specimen Form- Form SP - 2267504v3.0
GOG Specimen Form- Form SP
Carboplatin and Paclitaxel With or Without Bevacizumab
After Surgery in Treating Patients With Recurrent Ovarian
Epithelial Cancer, Primary Peritoneal Cavity Cancer, or
Fallopian Tube Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=D149D7A6-
B552-0F76-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/7343
GOG Specimen Form- Form SP
Ccrr Module For Gog Specimen Form-
Form Sp
Urine collection method
24-hour (24-hour)
clean catch (clean catch)
other (other)
Quantity of items shipped
Processing time
< 1 hour (< 1 hour)
> 4 hours (> 4 hours)
1-2 hours (1-2 hours)
2-4 hours (2-4 hours)
NA (NA)
Storage type
Room temperature
other (other)
refrigerator (refrigerator)
standard non-cycling freezer (standard
non-cycling freezer)
ultracold freezer/liquid N2/dry ice
(ultracold freezer/liquid N2/dry ice)
Other, specify (storage type)
Total volume/weight
Federal Express tracking number
Other, specify (cell type)
Type of blood collection tubes
ACD (ACD)
Citrate (Citrate)
EDTA (EDTA)
Heparin (Heparin)
other (other)
Red top (Red top)
Serum separator (Serum separator)
Cell type
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buccal (buccal)
cervical (cervical)
other (other)
Platelet count required?
Yes
No
Other, specify (processing method)
Processing method
ethanol-fixed (ethanol-fixed)
fixed & parraffin-embedded (fixed &
parraffin-embedded)
formalin-fixed (formalin-fixed)
OCT-frozen (OCT-frozen)
other (other)
snap-frozen (snap-frozen)
Other, specify (urine collection method)
Other, specify (items shipped)
Items shipped
block (block)
OCT-mold (OCT-mold)
other (other)
piece (piece)
slide (slide)
tube/vial (tube/vial)
Other, specify (specimen type)
Unsatisfactory, specify (condition of specimen)
Additional processing required
Yes
No
yes, specify (additional processing)
Not submitted, specify
Other, specify (type of blood collection tubes)
Specimen code
Date form originally completed
Date form amended
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Fallopian Tube Cancer NCT00565851 Lab - GOG Specimen Form- Form
SP - 2267504v3.0
Person amending form, last name
Patient Study ID
GOG Bank ID#
Person completing form, last name
email address
Time point
Submission status
not submitted (not submitted)
submitted (submitted)
Date collected
Time collected
Specimen type
buffy coat (buffy coat)
cells (cells)
Tissue Fixed With Formalin (fixed tissue)
Frozen Tissue, Not Fixed, Without The
Use Of Oct (frozen tissue)
other (other)
plasma (plasma)
Serum (serum)
urine (urine)
Peripheral Blood (whole blood)
Date shipped
Additional information required by protocol
Platelet count
Date of platelet count
yes, specify
yes, specify
Tissue type
Distant Metastases (metastatic tumor)
normal (normal)
Other, Specify (Other)
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pre-malignant (pre-malignant)
Primary (primary tumr)
Recurrent Tumor (recurrent/persistent
tumor)
Other, specify (tissue type)
Receiving Institution
GOG tissue bank (GOG tissue bank)
laboratory (laboratory)
Date received
Units
Condition of received specimens
Useable (satisfactory)
Damaged Or Unusable (unsatisfactory)
Name
phone or email
phone or email
lab name
Participating Group Code
Participating Group Protocol Number
Participating Patient Study ID
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SP - 2267504v3.0
Follow-Up - SOUTHWEST ONCOLOGY
GROUP FOLLOW UP FORM - 2217608v1.0
SOUTHWEST ONCOLOGY GROUP FOLLOW UP FORM
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=F4422C8B-
0B8B-49D1-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/7345
SOUTHWEST ONCOLOGY GROUP
FOLLOW UP FORM
Header
SWOG Patient ID
SWOG Study No.
Registration Step
Patient Initials (L, F M)
Institution/Affiliate
Physician
Participating Group Name
American College Of Surgeons
Oncology Group (ACOSOG)
American College Of Radiology
Oncologic Imaging Network (ACRIN)
Aids-associated Malignancies Clinical
Trials Consortium (AMC)
Cancer And Leukemia Group B (CALGB)
Children's Oncology Group (COG)
Eastern Cooperative Oncology Group
(ECOG)
European Organization For Research
And Treatment Of Cancer (EORTC)
Gynecologic Oncology Group (GOG)
International Breast Cancer Study Group
(IBCSG)
North American Brain Tumor Consortium
(NABTC)
Nabtt Brain Tumor Consortium (NABTT)
North Central Cancer Treatment Group
(NCCTG)
National Cancer Institute Of Canada
Clinical Trials Group (NCIC)
National Surgical Adjuvant Breast And
Bowel Project (NSABP)
Radiation Therapy Oncology Group
(RTOG)
Southwest Oncology Group (SWOG)
Participating Group Study No.
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Participating Group Patient ID
Vital Status
Vital Status
Alive (Alive)
Dead (Dead)
Date of last contact or death
Has the patient had a documented clinical
assessment for this cancer (since submission of
the previous follow-up form)
Yes
No
Date of Last Clinical Assessment (If Yes,)
Has the patient developed a first relapse or
progression that has not been previously
reported
Yes
No
Date of Relapse or Progression (If Yes,)
Site(s) of relapse or progression
Has a new primary cancer or MDS been
diagnosed that has not been previously reported?
(myelodysplastic syndrome)
Yes
No
Date of Diagnosis (If Yes,)
New Primary Site
Has the patient received any non-protocol cancer
therapy not previously reported (prior to
progression/relapse)
Yes
No
Date of First Non-Protocol Therapy (If Yes,)
Agent Name (s)
Has the patient experienced (prior to treatment
for progression or relapse or a second primary,
and prior to non-protocol treatment) any severe
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2217608v1.0
(grade >=3) long term toxicity that has not been
previously reported?
Yes
No
Adverse Events and Grades (If Yes,)
Comments
Comments
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Follow-Up - SOUTHWEST ONCOLOGY GROUP FOLLOW UP FORM -
2217608v1.0
Gastrointestinal Stromal Tumor NCT00324987
Follow-Up - S0502 Follow Up Form - 2321009v1.0
S0502 Follow Up Form
S0502 Imatinib Mesylate With or Without Bevacizumab in
Treating Patients With Metastatic or Unresectable
Gastrointestinal Stromal Tumor
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=FCCFE232-
103D-44EC-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/7350
S0502 Follow Up Form
Header
SWOG Patient ID
SWOG Study No.
Registration Step
Patient Initials (L, F M)
Institution/Affiliate
Physician
Participating Group Name
Participating Group Study No.
Participating Group Patient ID
Vital Status
Vital Status
Alive (Alive)
Dead (Dead)
Date of last contact or death
Has the patient had a documented clinical
assessment for this cancer (since submission of
the previous follow-up form)
Yes
No
Date of Last Clinical Assessment (If Yes,)
Has the patient developed a first relapse or
progression that has not been previously
reported
Yes
No
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Date of Relapse or Progression (If Yes,)
Site(s) of relapse or progression
Has a new primary cancer or MDS been
diagnosed that has not been previously reported?
(myelodysplastic syndrome)
Yes
No
Date of Diagnosis (If Yes,)
New Primary Site
Has the patient received any non-protocol cancer
therapy (prior to progression/relapse) not
previously reported?
Yes
No
Date of First Non-Protocol Therapy (If Yes,)
Type of Therapy
Chemotherapy (Chemotherapy)
Hormonal Therapy (Hormonal therapy)
Immunotherapy (Immunotherapy)
Other (Other)
Radiation Therapy (Radiation therapy)
Surgery (Surgery)
Other specify
Agent Name (s:)
Has the patient experienced any severe long
term toxicity that has not been previously
reported? (prior to treatment for progression or
relapse or a second primary, and prior to non-
protocol treatment grade >=3)
Yes
No
Adverse Events and Grades (If Yes,)
Comments
Comments
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Gastrointestinal Stromal Tumor NCT00324987 Follow-Up - S0502 Follow
Up Form - 2321009v1.0
Kidney Cancer NCT01198158 On-Study -
CALGB 90802 On-Study Form - 3107346v1.0
CALGB 90802 On-Study Form
Everolimus With or Without Bevacizumab in Treating
Patients With Advanced Kidney Cancer That Progressed
After First-Line Therapy
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=88715713-
3A23-2D6C-E040-BB89AD433D3B
All rights reserved. Please visit https://medical-data-
models.org/forms/7351
CALGB 90802 On-Study Form
Ccrr Module For Calgb 90202: Skeletal
Survey Form
CALGB Form
CALGB Study No.
CALGB Patient ID
Are data amended
Yes
No
Patient Initials (Last First Middle)
Patient Hospital No.
Institution/Affiliate
Participating Group
Participating Group Study No.
Participating Group Patient ID
Patient Description
MedDRA Code (disease)
Date of diagnosis (MM DD YYYY)
Karnofsky Performance Status Score (Mark one
with an X.)
Normal, No Complaints, No Evidence Of
Disease (100)
Cares For Self, Unable To Carry On
Normal Activity Or To Do Active Work
(70)
Normal Activity With Effort; Some Signs
Or Symptoms Of Disease (80)
Able To Carry On Normal Activity; Minor
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Signs Or Symptoms Of Disease (90)
History of Prior Malignancy
Yes
No
Specify (If yes type)
Year of Diagnosis (YYYY)
Histologic grade (Mark one with an X.)
Fuhrman Grade 1-2 (Fuhrman grade 1-
2)
Fuhrman Grade 3-4 (Fuhrman grade 3-
4)
Other (Other)
Other, specify
Disease Stage (Mark one with an X.)
Any T, Any N, M1 (Any T, Any N, M1)
Other (Other)
TNM Classification (other, specify)
Sites Of Disease
Sites of Disease (Mark all that apply with an X.)
Adrenal Gland (Adrenals)
Bone (Bone)
Brain (Brain)
Contralateral Renal (Contralateral renal)
Liver (Liver)
Lung (Lung)
Lymph Nodes (Lymph nodes)
Miscellaneous Soft Tissue
(Miscellaneous soft tissue)
Miscellaneous Visceral (Miscellaneous
visceral)
Other (Other)
Renal Primary (Renal primary)
Other specify
Dominant Histology (Mark all that apply with an
X.)
Chromophobe (Chromophobe)
Clear Cell (Clear cell)
Papillary (Papillary)
Tfe- Translocation (TFE- translocation)
Unclassified (Unclassified)
Baseline Lab Values (hematologic)
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Kidney Cancer NCT01198158 On-Study - CALGB 90802 On-Study Form
- 3107346v1.0
WBC (x10^3 microL)
ANC (x10^3 microL)
Platelets (PLT) (x10^3 microL)
Hemoglobin (g/dL)
Serum creatinine (mg/dl)
Calculated creatinine clearance (mL/min)
SGOT (AST)
SGOT (AST) ULN
SGPT (ALT)
SGPT (ALT) ULN
Total Bilirubin (mg/dl)
Bilirubin ULN (mg/dl)
Fasting serum glucose (mg/dL)
Serum cholesterol (mg/dL)
Trigylcerides (mg/dL)
Corrected serum calcium (mg/dL Calculated by:
Serum calcium - [0.707Serum albumin-3.4])
LDH (U/L)
Urinalysis
Urinalysis result (OR)
0 (0)
1+ (1+)
2+ (2+)
3+ (3+)
4+ (4+)
Protein from 24 hour Urine Collection (g of
protein/24 hours AND)
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Kidney Cancer NCT01198158 On-Study - CALGB 90802 On-Study Form
- 3107346v1.0
Urine Protein/Creatinine Ratio (UPC)
If the patient is registered to CALGB 580902
were MRIs submitted to the Central Imaging Core
laboratory for
Week 0 (Week 0)
Week 1 (Week 1)
Prior Treatment
Prior Treatment
Yes
No
Specify (If yes Mark all that apply with an X. Add
date started and ended)
Axitinib (Axitinib)
Chemotherapy (Chemotherapy)
Interferon (Interferon)
Interleukin - 2 (high Dose) (Interleukin - 2
(High Dose))
Interleukin - 2 (other) (Interleukin - 2
(Other))
Nephrectomy (cytoreductive)
(Nephrectomy (cytoreductive))
Nephrectomy (radical) (Nephrectomy
(radical))
Other Investigational Therapy (Other
Investigational Therapy)
Other Tki (Other TKI)
Other Vegfr Tki (Other VEGFR TKI)
Pazopanib (Pazopanib)
Radiation Therapy (Radiation therapy)
Sorafenib (Sorafenib)
Sunitinib (Sunitinib)
Surgery (Surgery)
Therapy Nos (Therapy NOS)
Specify (other VEGFR TKI)
Specify (other TKI)
Specify (Other Investigational Therapy)
Specify (Surgery)
Specify (Chemotherapy cytotoxic)
Specify (Radiation Therapy)
Specify (Therapy NOS)
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- 3107346v1.0
Prior Treatment Regimen Start Date (MM DD
YYYY)
Prior Treatment Regimen End Date (MM DD
YYYY)
Footer
Completed by (Last name, First name)
Date Form Completed (MM DD YYYY)
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Kidney Cancer NCT01198158 On-Study - CALGB 90802 On-Study Form
- 3107346v1.0
Gastrointestinal Stromal Tumor NCT00324987 Treatment -
S0502 Cycle-Specific Treatment Form - 2320335v1.0
S0502 Cycle-Specific Treatment Form
S0502 Imatinib Mesylate With or Without Bevacizumab in
Treating Patients With Metastatic or Unresectable
Gastrointestinal Stromal Tumor
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=FCBF7C37-
6B6E-72A0-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/7352
S0502 Cycle-Specific Treatment
Form
Header
SWOG Patient ID
SWOG Study No.
Registration Step
Patient Initials (L, F M)
Current Cycle Number (see instructions)
Institution/Affiliate
Physician
Participating Group Name
Participating Group Study No.
Participating Group Patient ID
Status
Date of Last Contact or Death
Vital Status
Alive (Alive)
Dead (Dead)
Has the patient progressed per the definition of
Section 10.0 of the protocol?
Yes
No
Treatment For This Cycle
Assigned Treatment Arm (values 1 Arm 1:
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Imatinib plus Bevacizumab and 2 Arm 2: Imatinib
)
Cycle Start Date
Weight (first day this cycle)
Date of last treatment for this cycle
BSA (first day this cycle)
Were there any dose modifications or
additions/omissions to protocol treatment?
No (No)
Yes, Planned (i.e., The Treatment Was
Changed According To Protocol
Guidelines) (Yes, planned)
Yes, Unplanned (i.e., The Treatment
Change Was Not Part Of Protocol
Guidelines) (Yes, unplanned)
Agent Name
Agent Total Cumulative Dose
Units
Milligram (mg)
Dose modification
Dose Delayed (Dose delayed)
Dose Delayed And Reduced (Dose
delayed and reduced)
Dose Held (Dose held)
Dose Reduced (Dose reduced)
Drug Discontinued (Drug discontinued)
No Dose Modification (No dose
modification)
Dose Modification Reason
Adverse Event (Adverse event)
Alternative Therapy For Other Reason
(Alternative therapy for other reason)
Death (Death)
Disease Progression (Disease
progression)
Dosing Error (Dosing error)
Other (Other)
Patient Refusal/noncompliance (Patient
refusal/noncompliance)
Scheduling (Scheduling)
Other, specify
Modification due to Adverse Event
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Specific Treatment Form - 2320335v1.0
Arterial Thrombotic Event (Arterial
Thrombotic Event)
Gi Toxicity (GI toxicity)
Hematologic Toxicity (Hematologic
toxicity)
Hepatic Toxicity (Hepatic Toxicity)
Other (Other)
Renal Toxicity (Renal toxicity)
Venous Thrombosis/embolism (Venous
Thrombosis/Embolism)
Other, specify
Comments
Comments
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Liver Cancer NCT01015833 On-Study -
CALGB 80802 On-Study Form - 2940677v1.0
CALGB 80802 On-Study Form
Sorafenib Tosylate With or Without Doxorubicin
Hydrochloride in Treating Patients With Locally Advanced
or Metastatic Liver Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=73B6D8AE-
497C-7324-E040-BB89AD43648A
All rights reserved. Please visit https://medical-data-
models.org/forms/7358
CALGB 80802 On-Study Form
Ccrr Module For Calgb 90202: Prostate
Specific Antigen Form
CALGB Form (C-1911)
CALGB Study No. (80802)
CALGB Patient ID
Are data amended
Yes
No
Patient Initials (Last, First Middle)
Patient Hospital No.
Institution/Affiliate
Participating Group
Participating Group Study No.
Participating Group Patient ID
Patient Description
MedDRA disease code (10044409)
ECOG Performance Status
Fully Active, Able To Carry On All Pre-
disease Performance Without
Restriction. (0)
Restricted In Physically Strenuous
Activity But Ambulatory And Able To
Carry Out Work Of A Light Or Sedentary
Nature, E.g., Light Housework, Office
Work. (1)
Ambulatory And Capable Of All Selfcare
But Unable To Carry Out Any Work
Activities. Up And About More Than 50%
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Of Waking Hours. (2)
Histologic Grade (Differentiation)
Tumor Grade Cannot Be Assessed
(Grade cannot be assessed (GX))
Moderately Differentiated (Moderately
differentiated (G2))
Poorly Differentiated (Poorly
differentiated (G3))
Undifferentiated (Undifferentiated (G4))
Well Differentiated (Well differentiated
(G1))
Clinical T Stage
T1, According To Ajcc Criteria (T1)
T2, According To Ajcc Criteria (T2)
T3, According To Ajcc Criteria (T3)
T4, According To Ajcc Criteria (T4)
Clinical N Stage
No Lymph Node Involvement According
To Ajcc Guidelines (N0)
N1, According To Ajcc Criteria (N1)
Clinical M Stage
No Distant Metastases According To
Ajcc Guidelines (M0)
Distant Metastases Present According
To Ajcc Guidelines (M1)
AFP Value
Prior Treatment
Prior locoregional therapy
Yes
No
Date of last locoregional therapy
Disease status (If yes, indicate)
Target Lesion(s) Within Field Of Local
Therapy That Has Shown 20% Increase
In Size (Target lesion(s) within field of
local therapy that has shown 20%
increase in size)
Target Lesions That Has Not Been
Subjected To Local Therapy (Target
lesions that has not been subjected to
local therapy)
Prior Adjuvant Chemotherapy
Yes
No
Prior Adjuvant Chemotherapy End Date
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2940677v1.0
Prior Adjuvant Chemotherapy
Prior Surgery
Yes
No
Date of last major surgery
Prior interferon therapy
Yes
No
Date of last treatment with interferon
Prior allografts
Yes
No
Laboratory Values
Peripheral WBC Count
Granulocytes (%)
ANC (x 10^3/mcL)
Platelets (PLT) (x 10^3/mcL)
Creatinine (mg/dL OR)
Creatinine Clearance (mL/min)
SGPT (ALT) (U/L)
SGPT (ALT) ULN (U/L)
SGOT (AST) (AST U/L)
SGOT (AST) ULN (U/L)
Bilirubin (mg/dL)
Bilirubin ULN (mg/dL)
INR
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Child Pugh Classification
Encephalopathy status (per CTCA v3.0)
Grade 1-2 (Grade 1-2)
Grade 3-4 (Grade 3-4)
None (None)
Ascites
Moderate (Moderate)
None (None)
Slight (Slight)
Bilirubin (mg/dl)
< 2 (< 2)
> 3 (> 3)
Albumin (g/dl)
< 2.8 (< 2.8)
> 3.5 (> 3.5)
2.8-3.5 (2.8-3.5)
INR
< 1.7 (< 1.7)
> 2.3 (> 2.3)
1.7-2.3 (1.7-2.3)
Child Pugh Score
Ccrr Module For Calgb: 90202 On-study
Completed by (Last Name, First name)
Date Form Originally Completed (mm dd yyyy)
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2940677v1.0
Kidney Cancer NCT01120249 Follow-Up - Southwest Oncology Group
S0931 Specific Follow Up Form (Form #36343) - 2992168v1.0
Southwest Oncology Group S0931 Specific Follow Up
Form (Form #36343)
Everolimus in Treating Patients With Kidney Cancer Who
Have Undergone Surgery
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=7DFF9CE4-
75AD-C651-E040-BB89AD435F69
All rights reserved. Please visit https://medical-data-
models.org/forms/7359
Southwest Oncology Group S0931
Specific Follow Up Form (Form
#36343)
Header
SWOG Patient ID
SWOG Study No.
Registration Step
Patient Initials (L, F M)
Institution/Affiliate
Physician
Participating Group Name
Participating Group Study No.
Participating Group Patient ID
Vital Status
Vital Status
Alive (Alive)
Dead (Dead)
Date of last contact or death (MM DD YYYY)
Has the patient had a documented clinical
assessment for this cancer (since submission of
the previous follow-up form)
Yes
No
Date of Last Clinical Assessment (If Yes, MM DD
YYYY)
Has a new primary cancer or MDS been
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diagnosed that has not been previously reported?
(myelodysplastic syndrome)
Yes
No
Date of Diagnosis (If Yes, MM DD YYYY)
New Primary Site
Has the patient received any non-protocol cancer
therapy not previously reported (prior to
progression/relapse)
Yes
No
Date of First Non-Protocol Therapy (If Yes, MM
DD YYYY)
Agent Name (s Note: List all agents used in any
treatment regimen received, including all
radiotherapy. If multiple regimens were received,
please specify only the first regimen received
after going off protocol treatment.)
Has the patient experienced (prior to treatment
for progression or relapse or a second primary,
and prior to non-protocol treatment) any severe
(grade >=3) long term toxicity that has not been
previously reported?
Yes
No
Adverse Events and Grades (If yes,)
Comments
Comments
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Kidney Cancer NCT01120249 Follow-Up - Southwest Oncology Group
S0931 Specific Follow Up Form (Form #36343) - 2992168v1.0
Leukemia NCT00492856 Follow-Up - SOUTHWEST
ONCOLOGY GROUP FOLLOW UP FORM - 2416676v1.0
SOUTHWEST ONCOLOGY GROUP FOLLOW UP FORM
Combination Chemotherapy With or Without Gemtuzumab
Followed By Tretinoin, Mercaptopurine, and Methotrexate
or Observation in Treating Patients With Acute
Promyelocytic Leukemia
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=02E11F79-
8367-10DE-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/7362
SOUTHWEST ONCOLOGY GROUP
FOLLOW UP FORM
Header
SWOG Patient ID
SWOG Study No.
Registration Step
Patient Initials (L, F M)
Institution/Affiliate
Physician
Participating Group Name
American College Of Surgeons
Oncology Group (ACOSOG)
American College Of Radiology
Oncologic Imaging Network (ACRIN)
Aids-associated Malignancies Clinical
Trials Consortium (AMC)
Cancer And Leukemia Group B (CALGB)
Children's Oncology Group (COG)
Eastern Cooperative Oncology Group
(ECOG)
European Organization For Research
And Treatment Of Cancer (EORTC)
Gynecologic Oncology Group (GOG)
International Breast Cancer Study Group
(IBCSG)
North American Brain Tumor Consortium
(NABTC)
Nabtt Brain Tumor Consortium (NABTT)
North Central Cancer Treatment Group
(NCCTG)
National Cancer Institute Of Canada
Clinical Trials Group (NCIC)
National Surgical Adjuvant Breast And
Bowel Project (NSABP)
Radiation Therapy Oncology Group
(RTOG)
Southwest Oncology Group (SWOG)
Participating Group Study No.
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Participating Group Patient ID
Vital Status
Vital Status
Alive (Alive)
Dead (Dead)
Date of last contact or death
Has the patient had a documented clinical
assessment for this cancer (since submission of
the previous follow-up form)
Yes
No
Date of Last Clinical Assessment (If Yes,)
Has the patient developed a first relapse or
progression that has not been previously
reported
Yes
No
Date of Relapse or Progression (If Yes,)
Site(s) of relapse or progression
Has a new primary cancer or MDS been
diagnosed that has not been previously reported?
(myelodysplastic syndrome)
Yes
No
Date of Diagnosis (If Yes,)
New Primary Site
Has the patient received any non-protocol cancer
therapy not previously reported? (prior to
progression/relapse)
Yes
No
Date of First Non-Protocol Therapy (If Yes,)
Agent Name (s:)
Has the patient experienced any severe long
term toxicity that has not been previously
reported? (prior to treatment for progression or
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relapse or a second primary, and prior to non-
protocol treatment grade >=3)
Yes
No
Adverse Events and Grades (If Yes,)
Comments
Comments
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Leukemia NCT01041703 Treatment - E2906 Baseline
Data Form - Step 2 (Consolidation) - 3176444v1.0
E2906 Baseline Data Form - Step 2 (Consolidation)
Clofarabine or Daunorubicin Hydrochloride and Cytarabine
Followed By Decitabine or Observation in Treating Older
Patients With Newly Diagnosed Acute Myeloid Leukemia
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=97F3E4CB-
9ED3-20B5-E040-BB89AD437950
All rights reserved. Please visit https://medical-data-
models.org/forms/7364
E2906 Baseline Data Form - Step 2
(Consolidation)
Header
DCI Name
Registration Step (Place ID Label Here)
Patient Initials (Last, First)
ECOG Protocol Number
ECOG Protocol Number
ECOG Patient ID
ECOG Patient ID
Participating Group Protocol Number
Participating Group Patient ID
Institution/Affiliate
On Treatment
Reporting Period
Baseline Step 2 (Baseline step 2)
Unnamed2
Please mark an 'X' if data have been amended.
(Please circle amended items in red)
Date data amended (s M D Y)
Patient Information
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ECOG Performance Status
Fully Active, Able To Carry On All Pre-
disease Performance Without
Restriction. (0)
Restricted In Physically Strenuous
Activity But Ambulatory And Able To
Carry Out Work Of A Light Or Sedentary
Nature, E.g., Light Housework, Office
Work. (1)
Ambulatory And Capable Of All Selfcare
But Unable To Carry Out Any Work
Activities. Up And About More Than 50%
Of Waking Hours. (2)
Capable Of Only Limited Selfcare,
Confined To Bed Or Chair More Than
50% Of Waking Hours. (3)
Completely Disabled. Cannot Carry On
Any Selfcare. Totally Confined To Bed Or
Chair. (4)
Does patient have bacterial or fungal infectious
complications (related to the treatment on the
prior protocol step)?
No (No)
Unknown (Unknown)
Yes (Yes)
Does the patient have any Congestive Heart
Failure (CHF) medical complications (related to
the treatment on the prior protocol step)?
No (No)
Unknown (Unknown)
Yes (Yes)
Assessment Type (Cardiac)
Echocardiogram (Echocardiogram)
Muga Scan (MUGA scan)
Date of Assessment (M D Y)
Resting ejection fraction (%)
Was an EKG done
Yes
No
Date of EKG (If yes,)
Are there any clinically significant abnormalities
Yes
No
Specify
Has patient received transfusion support
No Transfusion (No)
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Transfusion With Platelets (Yes,
platelets)
Yes, Prbc (packed Red Blood Cells) (yes,
PRBC (packed red blood cells))
Bone Marrow
Date of Bone Marrow Biopsy (or aspirate - NOTE:
Also submit biopsy/aspirate report)
Marrow Blasts (%)
Marrow Cellularity (%)
Hematology/chemistry
Absolute granulocyte count LLN (AGC/ANC)
Absolute Granulocyte Count (AGC/ANC)
Alkaline Phosphatase ULN (U/L)
Alkaline Phosphatase (U/L)
Creatinine ULN (mg/dl)
Creatinine (mg/dl)
Creatinine Clearance (mL/min)
Hematocrit LLN (%)
Hematocrit (%)
Hemoglobin (Hgb) (g/dl), LLN (g/dl)
Hemoglobin (g/dl)
LDH ULN (U/L)
LDH (U/L)
Magnesium, LLN
Magnesium, ULN
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Magnesium
Peripheral Blasts (%)
Platelets LLN (x1000)
Platelets (x1000)
SGOT (AST) ULN (U/L)
SGOT (AST) (U/L)
SGPT (ALT) ULN (U/L)
SGPT (ALT) (U/L)
Total bilirubin (mg/dl), ULN (mg/dl)
Total Bilirubin (mg/dl)
Uric Acid ULN (mg/dl)
Uric acid (mg/dl)
WBC count (x1000), LLN (x1000)
WBC Count (x1000)
Date Obtained (M D Y)
Hla Typing
Number of living siblings (potentially eligible to
donate stem cells)
Was HLA typing performed (of siblings)
No, None (No, none)
Yes, All (Yes, all)
Yes, Some (Yes, some)
Number tested (If 'Yes, some')
Baseline Abnormalities
CTC Adverse Event Term (include subterm if
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applicable)
CTC Adverse Event Grade
Mild Adverse Event (1)
Moderate Adverse Event (2)
Severe Adverse Event (3)
Life Threatening Adverse Event (4)
Comments
Investigator Signature
Investigator Signature Date (M D Y)
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Kidney Cancer NCT01120249 Response - Southwest Oncology Group
S0931 Recurrence Assessment Form (Form #46940) - 2998562v1.0
Southwest Oncology Group S0931 Recurrence
Assessment Form (Form #46940)
Everolimus in Treating Patients With Kidney Cancer Who
Have Undergone Surgery
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=7E26385C-
8CD8-C34F-E040-BB89AD434A8D
All rights reserved. Please visit https://medical-data-
models.org/forms/7365
Southwest Oncology Group S0931
Recurrence Assessment Form (Form
#46940)
Header
SWOG Patient ID
SWOG Study No.
Registration Step
Patient Initials (L, F M)
Date of Evaluation (MM DD YYYY)
Institution/Affiliate
Physician
Participating Group Name
Participating Study No.
Participating Patient ID
Clinical Assessment
Has the patient had a documented clinical
assessment for this cancer? (during this report
period)
Yes
No
Date of Last Clinical Assessment (If yes MM DD
YYYY)
Symptomatic Deterioration
Yes
No
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Notice Of Recurrence
Has the patient been diagnosed with recurrence
of disease (during this report period Second
primary is not a basis for recurrence. See section
10.1 for acceptable criteria for recurrence)
Yes
No
Date of First Recurrence (If yes)
How was recurrence discovered (If yes - select
one)
Clinical Evaluation (Clinical evaluation)
Development Of Symptoms
(Development of symptoms)
Other (Other)
Routine Radiologic Evaluation (Routine
radiologic evaluation)
Other, specify
Site of recurrence (If yes  - select all that apply)
Central Nervous System (Central
nervous system)
Liver (Liver)
Lung (Lung)
Recurrent Disease Lymph Node (Lymph
node recurrence)
Other (Other)
Other Organs (Other organs)
Renal Bed (Renal bed)
Skeletal (Skeletal)
Unknown (Unknown)
Explain why (Unknown)
Was biopsy performed
No (No)
Unknown (Unknown)
Yes (Yes)
Date of Biopsy (If yes)
Biopsy Result (If yes)
Atypical/indeterminate
(Atypical/indeterminate)
Benign (Benign)
Malignant (Malignant)
Other (Other)
Other, specify
Comments
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Comments
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Kidney Cancer NCT01120249 Pre-Study - Southwest Oncology
Group S0931 Prestudy Form (Form #6723) - 3000230v1.0
Southwest Oncology Group S0931 Prestudy Form (Form
#6723)
Everolimus in Treating Patients With Kidney Cancer Who
Have Undergone Surgery
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=7E26DCC6-
D288-5564-E040-BB89AD433E24
All rights reserved. Please visit https://medical-data-
models.org/forms/7367
Southwest Oncology Group S0931
Prestudy Form (Form #6723)
Header
SWOG Patient ID
SWOG Study No.
Registration Step
Patient Initials (L, F M)
Institution/Affiliate
Physician
Participating Group Name
Participating Group Study No.
Participating Group Patient ID
Patient And Disease Description
Performance Status
Fully Active, Able To Carry On All Pre-
disease Performance Without
Restriction. (0)
Restricted In Physically Strenuous
Activity But Ambulatory And Able To
Carry Out Work Of A Light Or Sedentary
Nature, E.g., Light Housework, Office
Work. (1)
Ambulatory And Capable Of All Selfcare
But Unable To Carry Out Any Work
Activities. Up And About More Than 50%
Of Waking Hours. (2)
Capable Of Only Limited Selfcare,
Confined To Bed Or Chair More Than
50% Of Waking Hours. (3)
Completely Disabled. Cannot Carry On
Any Selfcare. Totally Confined To Bed Or
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Chair. (4)
Dead (5)
Height (cm)
Weight (kg)
Date of full surgical resection (MM DD YYYY)
Extent of surgical resection (select one)
Partial Nephrectomy (partial
nephrectomy)
Radical Nephrectomy (radical
nephrectomy)
Date of scan of chest, abdomen and pelvis which
rules out evidence of residual or metastatic
disease (MM DD YYYY enter the earliest date if
scans of chest, abdomen and pelvis were
performed on different days)
Pathologic Stage Of Disease
Microvascular invasion of the renal vein
No (No)
Unknown (Unknown)
Yes (Yes)
Primary tumor
Pt1b (pT1b)
Pt2 (pT2)
Pt3a (due To Adrenal Involvement) (pT3a
(due to adrenal involvement))
Pt3a (not Due To Adrenal Involvement)
(pT3a (not due to adrenal involvement))
Pt3b-c (pT3b-c)
Pt4 (pT4)
Ptx, Pt0, Or Pt1a (pTX, pT0, or pT1a)
Regional lymph nodes
Pn+ (fully Resected) (pN+ (fully
resected))
Pn0 (pN0)
Pnx (where Clinically N0) (pNX (where
clinically N0))
Histologic grade
G1 (G1)
G2 (G2)
G3 - 4 (G3 - 4)
Gx (GX)
Laboratory Values
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Peripheral WBC Count
Peripheral WBC count, LLN
Absolute Lymphocyte Count
Absolute Lymphocyte Count, LLN
Absolute neutrophil count (/mcl)
Absolute neutrophil count LLN
Peripheral Platelet Count (/mcl)
Peripheral platelet count, LLN
Hemoglobin
Hemoglobin, LLN
SGOT (AST) (U/L)
SGOT (AST) ULN (U/L)
SGPT (ALT) (U/L)
SGPT (ALT) ULN (U/L)
Collection Date
Collection Date
Collection Date
Collection Date
Collection Date
Collection Date
Collection Date
Collection Date
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Bilirubin (mg/dL)
Bilirubin ULN (mg/dL)
Laboratory Values1
Serum Creatinine (mg/dL)
Serum Creatinine ULN
Calculated creatinine clearance (ml/min)
Fasting total cholesterol (mg/dL)
Fasting total cholesterol, ULN (mg/dL)
Fasting triglycerides (mg/dL)
Fasting triglycerides, ULN (mg/dL)
Fasting glucose
Fasting glucose, ULN (mg/dL)
Collection Date
Collection Date
Collection Date
Collection Date
Collection Date
Comments
Comments
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Leukemia NCT01041703 Treatment - E2906 Baseline
Data Form - Step 1 (Induction) - 2951887v1.0
E2906 Baseline Data Form - Step 1 (Induction)
Clofarabine or Daunorubicin Hydrochloride and Cytarabine
Followed By Decitabine or Observation in Treating Older
Patients With Newly Diagnosed Acute Myeloid Leukemia
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=7585B205-
CA04-8BDD-E040-BB89AD430415
All rights reserved. Please visit https://medical-data-
models.org/forms/7368
E2906 Baseline Data Form - Step 1
(Induction)
Header
DCI Name
Registration Step (Place ID Label Here)
Patient Initials (Last, First)
ECOG Protocol Number
ECOG Protocol Number
ECOG Patient ID
ECOG Patient ID
Participating Group Protocol Number
Participating Group Patient ID
Institution/Affiliate
On Treatment
Reporting Period
Baseline Step 1 (Baseline step 1)
Unnamed2
Please mark an 'X' if data have been amended.
(Please circle amended items in red)
Date data amended (s M D Y)
Patient Information
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Patient Height (cm)
Performance Status
Fully Active, Able To Carry On All Pre-
disease Performance Without
Restriction. (0)
Restricted In Physically Strenuous
Activity But Ambulatory And Able To
Carry Out Work Of A Light Or Sedentary
Nature, E.g., Light Housework, Office
Work. (1)
Ambulatory And Capable Of All Selfcare
But Unable To Carry Out Any Work
Activities. Up And About More Than 50%
Of Waking Hours. (2)
Capable Of Only Limited Selfcare,
Confined To Bed Or Chair More Than
50% Of Waking Hours. (3)
Completely Disabled. Cannot Carry On
Any Selfcare. Totally Confined To Bed Or
Chair. (4)
Leukemia Classification
Date of Initial Pathologic Diagnosis (M D Y)
Leukemia Classification (Choose one)
Disease Classified As Acute
Erythroblastic Leukemia (fab M6) (Acute
erythroblastic leukemia (FAB M6))
Disease Classified As Acute
Megakaryoblastic Leukemia (fab M7)
(Acute megakaryoblastic leukemia (FAB
M7))
Disease Classified As Acute Monocytic
Leukemia (fab M5) (Acute monocytic
leukemia (FAB M5))
Disease Classified As Acute Myeloid
Leukemia W/ Maturation (fab M2) (Acute
myeloid leukemia w/ maturation (FAB
M2))
Disease Classified As Acute Myeloid
Leukemia W/o Maturation (fab M1)
(Acute myeloid leukemia w/o maturation
(FAB M1))
Disease Classified As Acute
Myelomonocytic Leukemia (fab M4)
(Acute myelomonocytic leukemia (FAB
M4))
Disease Classified As Acute
Promyelocytic Leukemia (fab M3) (Acute
promyelocytic leukemia (FAB M3))
Disease Classified As Acute
Undifferentiated Leukemia (aul) (Acute
undifferentiated leukemia (AUL))
Disease Classified As Aml, Not
Otherwise Specified (nos) (AML, not
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otherwise specified (NOS))
Disease Is A Mixed Lineage Acute
Leukemia (Mixed lineage acute
leukemia)
Other (Other)
Disease Is An Unclassifiable Acute
Leukemia (Unclassifiable acute
leukemia)
Disease Classified As Undifferentiated
Acute Myeloid Leukemia (fab M0)
(Undifferentiated acute myeloid leukemia
(FAB M0))
Other specify
Extramedullary Disease Involvement
Central Nervous System (Central
nervous system)
Gingival Hypertrophy (Gingival
hypertrophy)
Mediastinal Mass (Mediastinal mass)
Other Specify (Other)
Peripheral Nervous System (Peripheral
nervous system)
Leukaemia Cutis (Skin (leukemia cutis))
Other specify
Bone Marrow
Date of Bone Marrow Biopsy (M D Y /aspirate)
Marrow Blasts (%)
Marrow Cellularity (%)
Cellularity
Cellularity Status Of Bone Marrow Is
Hypercellular (Hypercellular)
Moderately Hypocellular (Moderately
hypocellular)
Cellularity Status Of Bone Marrow Is
Normocellular (Normocellular)
Unknown (Unknown)
Very Hypocellular (Very hypocellular)
Clinical Onset of AML
Aml Without Prior Clinical History Of Mds
Or Potentially Leukemogenic Treatment
(de novo)
Secondary (Secondary)
If secondary, choose one
Prior Hematologic Disorder (mds) (Prior
hematologic disorder (MDS))
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Prior Hematologic Disorder
(myeloproliferative Disorders) (Prior
hematologic disorder (myeloproliferative
disorders))
Prior Treatment For Other Malignancy
(Prior treatment for other malignancy)
Unexplained Cytopenia (Unexplained
cytopenia)
Specify
Specify malignancy
Prior Treatment For This Disease
Prior chemotherapy for other malignancy
Yes
No
Specify name of chemotherapy regimen (If yes
ex: RCHOP)
Date Chemotherapy Ended (M D Y)
Prior Radiation Therapy for other malignancy
Yes
No
Radiation Therapy Total Dose (If yes cGy)
Mark an 'X' if unknown
Date RT ended (M D Y)
Has the patient received prior treatment for newly
diagnosed AML
Yes
No
Has the patient received the following (If yes)
Hydroxyurea (Hydroxyurea)
Leukopheresis (Leukopheresis)
Hematology/chemistry
Absolute granulocyte count LLN (AGC/ANC)
Absolute Granulocyte Count (AGC/ANC)
Alkaline Phosphatase ULN (U/L)
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Alkaline Phosphatase (U/L)
Creatinine ULN (mg/dl)
Creatinine (mg/dl)
Creatinine Clearance (ml/min)
Hematocrit LLN (%)
Hematocrit (%)
Hemoglobin (g/dl), LLN (g/dl)
Hemoglobin (g/dl)
LDH ULN (U/L)
LDH (U/L)
Peripheral Blasts (%)
Platelets LLN (x1000)
Platelets (x1000)
SGOT (AST) ULN (U/L)
SGOT (AST) (U/L)
SGPT (ALT) ULN (U/L)
SGPT (ALT) (U/L)
Total bilirubin ULN (mg/dl)
Total Bilirubin (mg/dl)
Uric Acid ULN (mg/dl)
Uric acid (mg/dl)
WBC count (x1000), LLN (x1000)
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WBC Count (x1000)
Date Obtained (M D Y)
Pre-registration Evaluation
Method of Evaluation (cardiac test)
Echocardiogram (Echocardiogram)
Muga Scan (MUGA scan)
Date of Assessment (M D Y)
Resting ejection fraction (% See Section 3.0 of
protocol for ejection fraction requirements)
LLN (%)
Were there any clinically significant abnormalities
Yes
No
Specify
Does the patient have a history of cardiovascular
disease
Yes
No
Comorbidities
Arrhythmia
No (No)
Unknown (Unknown)
Yes (Yes)
Cardiac
No (No)
Unknown (Unknown)
Yes (Yes)
Heart valve disease
No (No)
Unknown (Unknown)
Yes (Yes)
Inflammatory bowel disease
No (No)
Unknown (Unknown)
Yes (Yes)
Peptic ulcer disease
No (No)
Unknown (Unknown)
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Yes (Yes)
Diabetes (without complications)
No (No)
Unknown (Unknown)
Yes (Yes)
Cerebrovascular disease
No (No)
Unknown (Unknown)
Yes (Yes)
Psychiatric disturbance
No (No)
Unknown (Unknown)
Yes (Yes)
Obesity
No (No)
Unknown (Unknown)
Yes (Yes)
Infection
No (No)
Unknown (Unknown)
Yes (Yes)
Rheumatologic
No (No)
Unknown (Unknown)
Yes (Yes)
Moderate/severe renal
No (NO)
Unknown (UNKNOWN)
Yes (YES)
Prior solid tumor
No (No)
Unknown (Unknown)
Yes (Yes)
Moderate pulmonary
No (NO)
Unknown (UNKNOWN)
Yes (YES)
Severe pulmonary
No (No)
Unknown (Unknown)
Yes (Yes)
Hepatic, mild
No (No)
Unknown (Unknown)
Yes (Yes)
Moderate/severe hepatic
No (No)
Unknown (Unknown)
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Yes (Yes)
Pre-registration Evaluation1
Does the patient have any chronic disease
Yes
No
Does the patient have any concurrent
malignancies
Yes
No
Specify concurrent malignancy (If yes,)
Therapy Type
Chemotherapy (Chemotherapy)
Radiation Therapy (Radiation therapy)
Surgery (Surgery)
Unknown (Unknown)
Lumbar puncture done
Yes
No
Hla Typing
Number of living siblings (potentially eligable to
donate stem cells)
Was HLA typing performed (of siblings)
No, None (No, none)
Yes, All (Yes, all)
Yes, Some (Yes, some)
Number tested (If 'Yes, some')
Baseline Abnormalities
CTC Adverse Event Term (include subterm if
applicable)
CTC Adverse Event Grade
Mild Adverse Event (1)
Moderate Adverse Event (2)
Severe Adverse Event (3)
Life Threatening Adverse Event (4)
Comments
Investigator Signature
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Investigator Signature Date (M D Y)
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Kidney Cancer NCT01120249 Lab - Southwest Oncology Group S0931
Tumor Specimen Processing Form (Form #55588) - 3000274v1.0
Southwest Oncology Group S0931 Tumor Specimen
Processing Form (Form #55588)
Everolimus in Treating Patients With Kidney Cancer Who
Have Undergone Surgery
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=7E26DCC6-
D28C-5564-E040-BB89AD433E24
All rights reserved. Please visit https://medical-data-
models.org/forms/7370
Southwest Oncology Group S0931
Tumor Specimen Processing Form
(Form #55588)
Header
SWOG Patient ID
SWOG Study No.
Registration Step
Patient Initials (L, F M)
Institution/Affiliate
Physician
Participating Group Name
Participating Group Study No.
Participating Group Patient ID
Tumor Specimen Processing
Surgery Date (MM DD YYYY)
Date of tissue fixation (MM DD YYYY)
Elapsed time from surgical clamp of blood supply
to fixation (min)
Mark an 'X' if unknown
Was the fixation performed within 20 minutes of
the surgical clamp of blood supply (If the exact
minutes are unknown,)
No (no)
Unknown (unknown)
Yes (yes)
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Specimen Fixative
Formalin (Formalin)
Other (Other)
Other, specify
Duration of fixation (hrs)
Comments
Comments
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Leukemia NCT01041703 Treatment - E2906
Baseline Data Form - Step 3 - 3177877v1.0
E2906 Baseline Data Form - Step 3
Clofarabine or Daunorubicin Hydrochloride and Cytarabine
Followed By Decitabine or Observation in Treating Older
Patients With Newly Diagnosed Acute Myeloid Leukemia
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=9805CBE8-
D299-9B64-E040-BB89AD431E80
All rights reserved. Please visit https://medical-data-
models.org/forms/7373
E2906 Baseline Data Form - Step 3
Header
ECOG Protocol Number
ECOG Protocol Number
ECOG Patient ID
ECOG Patient ID
DCI Name
Registration Step (Place ID Label Here)
Patient Initials (Last, First)
Participating Group Protocol Number
Participating Group Patient ID
Institution/Affiliate
On Treatment
Reporting Period
Baseline Step 2 (Baseline step 2)
Unnamed2
Please mark an 'X' if data have been amended.
(Please circle amended items in red)
Date data amended (s M D Y)
Patient Information
ECOG Performance Status
Fully Active, Able To Carry On All Pre-
disease Performance Without
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Restriction. (0)
Restricted In Physically Strenuous
Activity But Ambulatory And Able To
Carry Out Work Of A Light Or Sedentary
Nature, E.g., Light Housework, Office
Work. (1)
Ambulatory And Capable Of All Selfcare
But Unable To Carry Out Any Work
Activities. Up And About More Than 50%
Of Waking Hours. (2)
Capable Of Only Limited Selfcare,
Confined To Bed Or Chair More Than
50% Of Waking Hours. (3)
Completely Disabled. Cannot Carry On
Any Selfcare. Totally Confined To Bed Or
Chair. (4)
Does patient have bacterial or fungal infectious
complications (related to the treatment on the
prior protocol step)?
No (No)
Unknown (Unknown)
Yes (Yes)
Does the patient have any Congestive Heart
Failure (CHF) medical complications (related to
the treatment on the prior protocol step)?
No (No)
Unknown (Unknown)
Yes (Yes)
Assessment Type (Cardiac)
Echocardiogram (Echocardiogram)
Muga Scan (MUGA scan)
Date of Assessment (M D Y)
Resting ejection fraction (%)
Was an EKG done
Yes
No
Date of EKG (If yes,)
Are there any clinically significant abnormalities
Yes
No
Specify
Has patient received transfusion support
No Transfusion (No)
Transfusion With Platelets (Yes,
platelets)
Yes, Prbc (packed Red Blood Cells) (yes,
PRBC (packed red blood cells))
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Bone Marrow
Date of Bone Marrow Biopsy (or aspirate - NOTE:
Also submit biopsy/aspirate report)
Marrow Blasts (%)
Marrow Cellularity (%)
Hematology/chemistry
Absolute granulocyte count LLN (AGC/ANC)
Absolute Granulocyte Count (AGC/ANC)
Alkaline Phosphatase ULN (U/L)
Alkaline Phosphatase (U/L)
Creatinine ULN (mg/dl)
Creatinine (mg/dl)
Creatinine Clearance (mL/min)
Hematocrit LLN (%)
Hematocrit (%)
Hemoglobin (g/dl), LLN (g/dl)
Hemoglobin (g/dl)
LDH ULN (U/L)
LDH (U/L)
Magnesium, LLN
Magnesium, ULN
Magnesium
Peripheral Blasts (%)
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Platelets LLN (x1000)
Platelets (x1000)
SGOT (AST) ULN (U/L)
SGOT (AST) (U/L)
SGPT (ALT) ULN (U/L)
SGPT (ALT) (U/L)
Total bilirubin (mg/dl), ULN (mg/dl)
Total Bilirubin (mg/dl)
Uric Acid ULN (mg/dl)
Uric acid (mg/dl)
WBC count (x1000), LLN (x1000)
WBC Count (x1000)
Date Obtained (M D Y)
Baseline Abnormalities
CTC Adverse Event Term (include subterm if
applicable)
CTC Adverse Event Grade
Mild Adverse Event (1)
Moderate Adverse Event (2)
Severe Adverse Event (3)
Life Threatening Adverse Event (4)
Comments
Investigator Signature
Investigator Signature Date (M D Y)
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Lung Cancer NCT00045162 Pre-Study - SOUTHWEST ONCOLOGY GROUP
EXTENSIVE SMALL CELL LUNG CARCINOMA PRESTUDY FORM - 2402234v1.0
SOUTHWEST ONCOLOGY GROUP EXTENSIVE SMALL
CELL LUNG CARCINOMA PRESTUDY FORM
S0124: Cisplatin Combined With Either Irinotecan or
Etoposide in Treating Patients With Extensive-Stage Small
Cell Lung Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=001A8323-
2611-48BE-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/7374
SOUTHWEST ONCOLOGY GROUP
EXTENSIVE SMALL CELL LUNG
CARCINOMA PRESTUDY FORM
Header
SWOG Patient ID
SWOG Study No.
Registration Step
Patient Initials (L, F M)
Institution/Affiliate
Physician
Participating Group Name
Participating Group Study No.
Participating Group Patient ID
Patient And Disease Description
Performance Status
Fully Active, Able To Carry On All Pre-
disease Performance Without
Restriction. (0)
Restricted In Physically Strenuous
Activity But Ambulatory And Able To
Carry Out Work Of A Light Or Sedentary
Nature, E.g., Light Housework, Office
Work. (1)
Ambulatory And Capable Of All Selfcare
But Unable To Carry Out Any Work
Activities. Up And About More Than 50%
Of Waking Hours. (2)
Capable Of Only Limited Selfcare,
Confined To Bed Or Chair More Than
50% Of Waking Hours. (3)
Completely Disabled. Cannot Carry On
Any Selfcare. Totally Confined To Bed Or
1 / 2
Chair. (4)
Dead (5)
Weight Loss in Previous Six Months
<5% Of Body Weight (< 5% of body
weight)
> Or = 20% Of Body Weight (> or = 20%
of body weight)
10 To <20% Of Body Weight (10 -<20%
of body weight)
5 To <10% Of Body Weight (5 to < 10%
of body weight)
Metastatic Involvement
Multiple Lesions In Multiple Organs
(Multiple lesions in multiple organs)
Multiple Lesions In Single Organ
(Multiple lesions in single site or organ)
Single Lesion In Single Organ (Single
lesion in single site or organ)
Is a pleural effusion present?
Yes
No
Is it Malignant?
Yes
No
Current Laboratory Values
Albumin
Lactate Dehydrogenase (LDH)
Lactate Dehydrogenase ULN
Prior Treatment Related To This Cancer
Prior Surgery
Yes
No
Comments
Comments
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Lung Cancer NCT00045162 Pre-Study - SOUTHWEST ONCOLOGY GROUP
EXTENSIVE SMALL CELL LUNG CARCINOMA PRESTUDY FORM - 2402234v1.0
Lung Cancer NCT00045162 Follow-Up - SOUTHWEST ONCOLOGY
GROUP LUNG CARCINOMA FOLLOW UP FORM - 2402496v1.0
SOUTHWEST ONCOLOGY GROUP LUNG CARCINOMA
FOLLOW UP FORM
S0124: Cisplatin Combined With Either Irinotecan or
Etoposide in Treating Patients With Extensive-Stage Small
Cell Lung Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=001C3566-
4C51-5842-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/7377
SOUTHWEST ONCOLOGY GROUP
LUNG CARCINOMA FOLLOW UP
FORM
Header
SWOG Patient ID
SWOG Study No.
Registration Step
Patient Initials (L, F M)
Institution/Affiliate
Physician
Participating Group Name
American College Of Surgeons
Oncology Group (ACOSOG)
American College Of Radiology
Oncologic Imaging Network (ACRIN)
Aids-associated Malignancies Clinical
Trials Consortium (AMC)
Cancer And Leukemia Group B (CALGB)
Children's Oncology Group (COG)
Eastern Cooperative Oncology Group
(ECOG)
European Organization For Research
And Treatment Of Cancer (EORTC)
Gynecologic Oncology Group (GOG)
International Breast Cancer Study Group
(IBCSG)
North American Brain Tumor Consortium
(NABTC)
Nabtt Brain Tumor Consortium (NABTT)
North Central Cancer Treatment Group
(NCCTG)
National Cancer Institute Of Canada
Clinical Trials Group (NCIC)
National Surgical Adjuvant Breast And
Bowel Project (NSABP)
Radiation Therapy Oncology Group
(RTOG)
Southwest Oncology Group (SWOG)
Participating Group Study No.
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Participating Group Patient ID
Vital Status
Vital Status
Alive (Alive)
Dead (Dead)
Date of last contact or death
Has the patient had a documented clinical
assessment for this cancer (since submission of
the previous follow-up form)
Yes
No
Date of Last Clinical Assessment (If Yes,)
Has the patient developed a first relapse or
progression that has not been previously
reported
Yes
No
Date of Relapse or Progression (If Yes,)
Site(s) of relapse or progression
Has a new primary cancer or MDS been
diagnosed that has not been previously reported?
(myelodysplastic syndrome)
Yes
No
Date of Diagnosis (If Yes,)
New Primary Site
Has the patient received any non-protocol cancer
therapy not previously reported? (prior to
progression/relapse)
Yes
No
Date of First Non-Protocol Therapy (If Yes,)
Agent Name (s:)
Has the patient experienced any severe long
term toxicity that has not been previously
reported? (prior to treatment for progression or
2 / 3
Lung Cancer NCT00045162 Follow-Up - SOUTHWEST ONCOLOGY
GROUP LUNG CARCINOMA FOLLOW UP FORM - 2402496v1.0
relapse or a second primary, and prior to non-
protocol treatment grade >=3)
Yes
No
Adverse Events and Grades (If Yes,)
Comments
Comments
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Lung Cancer NCT00045162 Follow-Up - SOUTHWEST ONCOLOGY
GROUP LUNG CARCINOMA FOLLOW UP FORM - 2402496v1.0
Metastatic Cancer NCT00134056 Response - SOUTHWEST ONCOLOGY
GROUP PROSTATIC SPECIFIC ANTIGEN REPORTING FORM - 2304629v3.0
SOUTHWEST ONCOLOGY GROUP PROSTATIC
SPECIFIC ANTIGEN REPORTING FORM
Docetaxel and Prednisone With or Without Atrasentan in
Treating Patients With Stage IV Prostate Cancer and Bone
Metastases That Did Not Respond to Previous Hormone
Therapy
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=F159832A-
A1FF-27F6-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/7380
SOUTHWEST ONCOLOGY GROUP
PROSTATIC SPECIFIC ANTIGEN
REPORTING FORM
Header
SWOG Patient ID
SWOG Study No.
Registration Step
Patient Initials
Institution/Affiliate
Physician
Participating Group Name
Participating Study No.
Participating Patient ID (All dates are MONTH,
DAY, YEAR. Circle AMENDED items in red. The
same test procedures used for baseline disease
assessment must be used for all required
subsequent disease assessments.)
Psa Measurements
Date of PSA assessment
PSA Value
Comments
Comments
1 / 1
Lung Cancer NCT00632853 On-Study -
CALGB: 30610 On-Study Form - 2688471v1.0
CALGB: 30610 On-Study Form
Three Different Radiation Therapy Regimens in Treating
Patients With Limited-Stage Small Cell Lung Cancer
Receiving Cisplatin and Etoposide
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=3C26256D-
03C2-01FC-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/7384
CALGB: 30610 On-Study Form
Ccrr Module For Calgb 90202: Skeletal
Survey Form
CALGB Form (C-1244)
CALGB Study No.
CALGB Patient ID
Are data amended
Yes
No
Patient Initials (Last, First Middle)
Patient Hospital No.
Institution/Affiliate
Participating Group
Participating Group Study No.
Participating Group Patient ID
Disease Information
Initial Diagnosis Date
MedDRA disease code
Current sites of involvement (mark all that apply)
Contralateral Hilar Lymph Node
(Contralateral hilar lymph nodes)
Contralateral Lung (Contralateral lung)
Contralateral Supraclavicular Lymph
Node (Contralateral supraclavicular
lymph nodes)
Ipsilateral Hilar Lymph Node (Ipsilateral
hilar lymph nodes)
Ipsilateral Supraclavicular Lymph Node
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(Ipsilateral supraclavicular lymph nodes)
Mediastinal Lymph Node (Mediastinal
lymph nodes)
Other (Other)
Ipsilateral Lung (Primary Lung)
Other, specify
Extent of disease
Extensive (Extensive)
Limited (Limited)
Pleural Effusion (visible on plain chest
radiograph)
Yes
No
Malignant pleural or pericardial fluid?
Yes
No
Prior Treatment
Prior radiation therapy or chemotherapy for
SCLC?
Yes
No
Prior mediastinal or thoracic radiation therapy?
Yes
No
Lab Values
Absolute Neutrophil Count
Peripheral Platelet Count
Bilirubin
Bilirubin ULN
SGOT
SGOT (AST) ULN
Creatinine
Creatinine ULN
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Lung Cancer NCT00632853 On-Study - CALGB: 30610 On-Study Form -
2688471v1.0
Creatinine Clearance (Calculated)
Footer
Completed by (Last name, First name)
Date Form Originally Completed
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Lung Cancer NCT00632853 On-Study - CALGB: 30610 On-Study Form -
2688471v1.0
Metastatic Cancer NCT00134056 Pre-Study - SOUTHWEST
ONCOLOGY GROUP Prestudy Form (S0421) - 2306139v3.0
SOUTHWEST ONCOLOGY GROUP Prestudy Form
(S0421)
Docetaxel and Prednisone With or Without Atrasentan in
Treating Patients With Stage IV Prostate Cancer and Bone
Metastases That Did Not Respond to Previous Hormone
Therapy
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=F1F9786C-
0716-36C3-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/7385
SOUTHWEST ONCOLOGY GROUP
Prestudy Form (S0421)
Header
SWOG Patient ID
SWOG Study No.
Registration Step
Patient Initials (L, F M)
Institution/Affiliate
Physician (Participating Group:)
Participating Group Name
Participating Group Study No.
Participating Group Patient ID (Instructions: All
dates are MONTH, DAY, YEAR. Explain any
blank fields or blank dates in the Comments
section.)
Disease Description
Performance Status
Fully Active, Able To Carry On All Pre-
disease Performance Without
Restriction. (0)
Restricted In Physically Strenuous
Activity But Ambulatory And Able To
Carry Out Work Of A Light Or Sedentary
Nature, E.g., Light Housework, Office
Work. (1)
Ambulatory And Capable Of All Selfcare
But Unable To Carry Out Any Work
Activities. Up And About More Than 50%
Of Waking Hours. (2)
Capable Of Only Limited Selfcare,
Confined To Bed Or Chair More Than
1 / 6
50% Of Waking Hours. (3)
Completely Disabled. Cannot Carry On
Any Selfcare. Totally Confined To Bed Or
Chair. (4)
Dead (5)
Is the cause of pain secondary to bone
metastases (If performance status = 3,)
Yes
No
Date of Initial Pathologic Diagnosis
Date current staging assessment completed
Did patient show evidence of bone metastases
on bone scan and/or MRI (prior to registration)
Yes
No
Date of bone scan
Date of MRI (If bone scan result was equivocal -
to determine cause of bone scan abnormality)
Disease deemed unresponsive to hormone
therapy by
Progression Of Measurable Disease
(Progression of measurable disease)
Progression Of Non-measurable Disease
(Progression of non-measurable
disease)
Rising Psa (Rising PSA)
Does the patient have clinical evidence of brain
metastases
Yes
No
Date brain CT or MRI negative for metastatic
disease (If yes,)
Does the patient have third space fluid
accumulation (e.g., ascites or symptomatic
pleural effusion)
Yes
No
Did patient receive CT or MRI scan of the
abdomen or pelvis prior to registration
Yes
No
Date (If yes,)
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Metastatic Cancer NCT00134056 Pre-Study - SOUTHWEST
ONCOLOGY GROUP Prestudy Form (S0421) - 2306139v3.0
Laboratory Values
Collection Date (MM/DD/YYYY)
AGC (/mm3)
Platelets (PLT) (/mm3)
Hemoglobin (g/dL)
SGPT (U/L)
SGPT (ALT) ULN (U/L)
SGOT (U/L)
SGOT (AST) ULN (U/L)
Serum creatinine (mg/dL)
Serum Creatinine ULN (mg/dL)
Testosterone (ng/dL)
Associated Correlative Science Consent
Patient consents to blood submission
Yes
No
Patient consents to tissue submission
Yes
No
Additional Prestudy Data
Gleason Score Combined Pattern Value
Did the patient have evidence of lymph node
metastases at diagnosis, either at surgery or on
imaging
Yes
No
Distant Metastatic Disease
Abdominal nodes
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Metastatic Cancer NCT00134056 Pre-Study - SOUTHWEST
ONCOLOGY GROUP Prestudy Form (S0421) - 2306139v3.0
No (No)
Unknown (Unknown)
Yes (Yes)
Distant nodes
No (No)
Unknown (Unknown)
Yes (Yes)
Lung/pleura
No (No)
Unknown (Unknown)
Yes (Yes)
Liver
No (No)
Unknown (Unknown)
Yes (Yes)
CNS/brain
No (No)
Unknown (Unknown)
Yes (Yes)
Other
No (No)
Unknown (Unknown)
Yes (Yes)
Other, specify
Extermities
No (No)
Unknown (Unknown)
Yes (Yes)
Pelvis
No (No)
Unknown (Unknown)
Yes (Yes)
Chest
No (No)
Unknown (Unknown)
Yes (Yes)
Spine
No (No)
Unknown (Unknown)
Yes (Yes)
Head
No (No)
Unknown (Unknown)
Yes (Yes)
Other bone
No (No)
Unknown (Unknown)
Yes (Yes)
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Metastatic Cancer NCT00134056 Pre-Study - SOUTHWEST
ONCOLOGY GROUP Prestudy Form (S0421) - 2306139v3.0
Other bone, specify
Chemical
Method of castration
Chemical (Chemical)
Surgical (Surgical)
Surgery Date (If surgical,)
LHRH agonist start date (leuprolide/goserelin)
Enter most recent injection date
Did the patient receive finasteride or dutasteride
Yes
No
Last date of finasteride or dutasteride treatment
Did the patient receive non-steroidal
antiandrogen
Yes
No
If yes, then select the following
Bicalutamide (Bicalutamide)
Flutamide (Flutamide)
Ketonconazole (Ketonconazole)
Nilutamide (Nilutamide)
Last date of any non-steroidal antiandrogen
treatment
Did the patient receive any other hormonal
therapy
Yes
No
Hormonal Agent
Aminoglutethimide (Aminoglutethimide)
Diethylstilbestrol (DES)
Estrogen (Estrogen)
Other (Other)
Progestin (Progestins)
Other specify
Last date of other hormonal therapy
Prior Prostatectomy
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Metastatic Cancer NCT00134056 Pre-Study - SOUTHWEST
ONCOLOGY GROUP Prestudy Form (S0421) - 2306139v3.0
Prior Prostatectomy Date (If yes,)
Other surgery related to tumor (besides
prostatectomy or orchiectomy)
Yes
No
Date of other surgery
Did the patient receive radiation therapy
Yes
No
Site (If yes, then complete)
Bone Palliation (Bone palliation)
Other (Other)
Pelvic Lymph Nodes (Pelvic lymph
nodes)
Prostate (Prostate)
Other, specify
Radiation Therapy Start Date
Radiation Therapy End Date
Did the patient receive adjuvant cytotoxic
therapy?
Yes
No
Date adjuvant cytotoxic therapy ended (If yes,)
Regimen
Prior systemic therapy (vaccine or biologic)
Yes
No
Last date of systemic therapy (If yes,)
Comments
Comments
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Metastatic Cancer NCT00134056 Pre-Study - SOUTHWEST
ONCOLOGY GROUP Prestudy Form (S0421) - 2306139v3.0
Multiple Myeloma and Plasma Cell Neoplasm NCT00644228 Follow-Up -
SOUTHWEST ONCOLOGY GROUP FOLLOW UP FORM - 2657807v1.0
SOUTHWEST ONCOLOGY GROUP FOLLOW UP FORM
Lenalidomide and Dexamethasone With or Without
Bortezomib in Treating Patients With Previously Untreated
Multiple Myeloma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=33567017-5119-
711E-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/7386
SOUTHWEST ONCOLOGY GROUP
FOLLOW UP FORM
Header
SWOG Patient ID
SWOG Study No.
Registration Step
Patient Initials (L, F M)
Institution/Affiliate
Physician
Participating Group Name
American College Of Surgeons
Oncology Group (ACOSOG)
American College Of Radiology
Oncologic Imaging Network (ACRIN)
Aids-associated Malignancies Clinical
Trials Consortium (AMC)
Cancer And Leukemia Group B (CALGB)
Children's Oncology Group (COG)
Eastern Cooperative Oncology Group
(ECOG)
European Organization For Research
And Treatment Of Cancer (EORTC)
Gynecologic Oncology Group (GOG)
International Breast Cancer Study Group
(IBCSG)
North American Brain Tumor Consortium
(NABTC)
Nabtt Brain Tumor Consortium (NABTT)
North Central Cancer Treatment Group
(NCCTG)
National Cancer Institute Of Canada
Clinical Trials Group (NCIC)
National Surgical Adjuvant Breast And
Bowel Project (NSABP)
Radiation Therapy Oncology Group
(RTOG)
Southwest Oncology Group (SWOG)
Participating Group Study No.
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Participating Group Patient ID
Vital Status
Vital Status
Alive (Alive)
Dead (Dead)
Date of last contact or death
Has the patient had a documented clinical
assessment for this cancer (since submission of
the previous follow-up form)
Yes
No
Date of Last Clinical Assessment (If Yes,)
Has the patient developed a first relapse or
progression that has not been previously
reported
Yes
No
Date of Relapse or Progression (If Yes,)
Site(s) of relapse or progression
Has a new primary cancer or MDS been
diagnosed that has not been previously reported?
(myelodysplastic syndrome)
Yes
No
Date of Diagnosis (If Yes,)
New Primary Site
Has the patient received any non-protocol cancer
therapy not previously reported? (prior to
progression/relapse)
Yes
No
Date of First Non-Protocol Therapy (If Yes,)
Agent Name (s:)
Has the patient experienced any severe long
term toxicity that has not been previously
reported? (prior to treatment for progression or
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Multiple Myeloma and Plasma Cell Neoplasm NCT00644228 Follow-Up -
SOUTHWEST ONCOLOGY GROUP FOLLOW UP FORM - 2657807v1.0
relapse or a second primary, and prior to non-
protocol treatment grade >=3)
Yes
No
Adverse Events and Grades (If Yes,)
Comments
Comments
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Multiple Myeloma and Plasma Cell Neoplasm NCT00644228 Follow-Up -
SOUTHWEST ONCOLOGY GROUP FOLLOW UP FORM - 2657807v1.0
Multiple Myeloma and Plasma Cell Neoplasm NCT00644228 Pre-Study -
Southwest Oncology Group S0777 Prestudy Form - 2656421v1.0
Southwest Oncology Group S0777 Prestudy Form
Lenalidomide and Dexamethasone With or Without
Bortezomib in Treating Patients With Previously Untreated
Multiple Myeloma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=33319F8E-
13F8-4E7C-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/7389
Southwest Oncology Group S0777
Prestudy Form
Header
SWOG Patient ID
SWOG Study No.
Registration Step
Patient Initials (L, F M)
Institution/Affiliate
Physician
Participating Group Name
Participating Group Study No.
Participating Group Patient ID (Instructions: All
dates are MONTH, DAY, YEAR. Explain any
blank fields or blank dates in the Comments
section.)
Eligibility Verification:
Disease Description
Performance Status
Fully Active, Able To Carry On All Pre-
disease Performance Without
Restriction. (0)
Restricted In Physically Strenuous
Activity But Ambulatory And Able To
Carry Out Work Of A Light Or Sedentary
Nature, E.g., Light Housework, Office
Work. (1)
Ambulatory And Capable Of All Selfcare
But Unable To Carry Out Any Work
Activities. Up And About More Than 50%
1 / 4
Of Waking Hours. (2)
Capable Of Only Limited Selfcare,
Confined To Bed Or Chair More Than
50% Of Waking Hours. (3)
Completely Disabled. Cannot Carry On
Any Selfcare. Totally Confined To Bed Or
Chair. (4)
Dead (5)
Has physician documented that the patient's
multiple myeloma is the central cause of his/her
disability
Yes
No
Laboratory Values
ANC (/mcL)
Peripheral Platelet Count (/mcL)
Hemoglobin (g/dL)
Heavy marrow involvement (at least 30% of
marrow cellularity, with > 50% of the cells being
malignant plasma cells)
Yes
No
Serum Creatinine (mg/dL)
Serum Creatinine ULN
Creatinine Clearance (Measured - OR)
Units
Cubic Centimeters Per Minute (cc/min)
Units
Cubic Centimeters Per Minute (cc/min)
Units
Cubic Centimeters Per Minute (cc/min)
Units
Cubic Centimeters Per Minute (cc/min)
Units
Cubic Centimeters Per Minute (cc/min)
Is patient currently on dialysis due to renal failure
Yes
No
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Multiple Myeloma and Plasma Cell Neoplasm NCT00644228 Pre-Study -
Southwest Oncology Group S0777 Prestudy Form - 2656421v1.0
Date of most recent EKG
Collection Date
Collection Date
Collection Date
Collection Date
Collection Date
Collection Date
Forced Expiratory Volume 1 (FEV1)
Forced Vital Capacity (FVC)
Carbon Monoxide Diffusion (DLCO)
Arterial Blood Gas: PO2
Date of Assessment
Date of Assessment
Date of Assessment
Date of Assessment
CT Result
Abnormal (Abnormal)
Normal (Normal)
Not Done (Not done)
Date of CT Scan
Laboratory Values
Lactate Dehydrogenase (LDH) (Units/l)
Beta-2 Microglobulin (¿g/ml)
CRP (¿g/dl)
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Multiple Myeloma and Plasma Cell Neoplasm NCT00644228 Pre-Study -
Southwest Oncology Group S0777 Prestudy Form - 2656421v1.0
Albumin (g/dl)
Is patient a woman of childbearing potential
Yes
No
Date of pregnancy test
Result of Hepatitis B test
Negative (Negative)
Positive (Positive)
Result of HIV test
Negative (negative)
Positive (positive)
Test date
Test date
Disease History And Diagnosis
Date of Initial Pathologic Diagnosis
Disease Stage at Diagnosis
I (I)
Ii (II)
Iii (III)
Prior Treatment Related To This Cancer
Prior systemic therapy
Yes
No
Prior Radiation Therapy
Yes
No
Was prior radiation therapy to a large area of the
pelvis
Yes
No
Has patient received prior steriod treatment
Yes
No
Comments
Comments
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Multiple Myeloma and Plasma Cell Neoplasm NCT00644228 Pre-Study -
Southwest Oncology Group S0777 Prestudy Form - 2656421v1.0
Lung Cancer NCT00946712 Pre-Study - Southwest
Oncology Group S0819 Treatment Form - 2863805v1.0
Southwest Oncology Group S0819 Treatment Form
Carboplatin and Paclitaxel With or Without Bevacizumab
and/or Cetuximab in Treating Patients With Stage IV or
Recurrent Non-Small Cell Lung Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=684CF883-
684B-1929-E040-BB89AD4373A3
All rights reserved. Please visit https://medical-data-
models.org/forms/7390
Southwest Oncology Group S0819
Treatment Form
Header
SWOG Patient ID
SWOG Study No.
Registration Step
Patient Initials (L, F M)
Current Cycle Number
Institution/Affiliate
Physician
Participating Group Name
Participating Group Study No.
Participating Group Patient ID (Place an X in
appropriate boxes. Circle AMENDED items in red
and write AMENDED across the top of the form.)
Status
Date of Last Contact or Death (MM DD YYYY)
Vital Status
Alive (Alive)
Dead (Dead)
Has the patient progressed per the definition of
Section 10.0 of the protocol
Yes
No
1 / 3
Treatment For This Cycle
Assigned Treatment Arm (select one)
Carboplatin/paclitaxel
(Carboplatin/Paclitaxel)
Carboplatin/paclitaxel/bevacizumab
Followed By Bevacizumab
(Carboplatin/Paclitaxel/Bevacizumab
followed by Bevacizumab)
Carboplatin/paclitaxel/cetuximab
Followed By Cetuximab
(Carboplatin/Paclitaxel/Cetuximab
followed by Cetuximab)
Carboplatin/paclitaxel/cetuximab/bevaciz
umab Followed By
Bevacizumab/cetuximab
(Carboplatin/Paclitaxel/Cetuximab/Bevac
izumab followed by
Bevacizumab/Cetuximab)
Cycle Start Date (MM DD YYYY)
Date of Last Treatment (for this cycle MM DD
YYYY)
Reporting Period End Date (MM DD YYYY)
Weight (first day this cycle)
BSA (first day this cycle)
Serum Creatinine (for carboplatin dosing mg/dl)
AUC
Calculated creatinine clearance (using Cockroft-
Gault Formula ml/min)
Were there any dose modifications or
additions/omissions to protocol treatment?
No (No)
Yes, Planned (i.e., The Treatment Was
Changed According To Protocol
Guidelines) (Yes, planned)
Yes, Unplanned (i.e., The Treatment
Change Was Not Part Of Protocol
Guidelines) (Yes, unplanned)
Treatment
Agent Name
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Lung Cancer NCT00946712 Pre-Study - Southwest Oncology Group
S0819 Treatment Form - 2863805v1.0
Dose (Bevacizumab mg)
Day of cycle
Day 1 (Day 1)
Treatment
Agent Name
Dose (Bevacizumab mg)
Day of cycle
Day 1 (Day 1)
Treatment
Agent Name
Dose (Bevacizumab mg)
Day of cycle
Day 1 (Day 1)
Treatment
Agent Name
Dose (Bevacizumab mg)
Day of cycle
Day 1 (Day 1)
Support Agents
Was G-CSF received (during this cycle)
Yes
No
Was pegfilgrastim received (during this cycle)
Yes
No
Comments
Comments
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Lung Cancer NCT00946712 Pre-Study - Southwest Oncology Group
S0819 Treatment Form - 2863805v1.0
Multiple Myeloma and Plasma Cell Neoplasm null
Pre-Study - S0522 Prestudy Form - 2459879v1.0
S0522 Prestudy Form
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=0F232910-
2A2F-5CD7-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/7391
S0522 Prestudy Form
Header
SWOG Patient ID
SWOG Study No.
Registration Step
Patient Initials (L, F M)
Institution/Affiliate
Physician (Participating Group:)
Participating Group Name
Participating Group Study No.
Participating Group Patient ID
Patient Characteristics
Performance Status
Fully Active, Able To Carry On All Pre-
disease Performance Without
Restriction. (0)
Restricted In Physically Strenuous
Activity But Ambulatory And Able To
Carry Out Work Of A Light Or Sedentary
Nature, E.g., Light Housework, Office
Work. (1)
Ambulatory And Capable Of All Selfcare
But Unable To Carry Out Any Work
Activities. Up And About More Than 50%
Of Waking Hours. (2)
Capable Of Only Limited Selfcare,
Confined To Bed Or Chair More Than
50% Of Waking Hours. (3)
Completely Disabled. Cannot Carry On
Any Selfcare. Totally Confined To Bed Or
Chair. (4)
Dead (5)
Has physician documented that it is solely due to
bone pain (If performance status = 3,)
Yes
1 / 3
No
Laboratory Values
Collection Date (MM DD YYYY)
ANC (/mcL)
Peripheral Platelet Count (/mcL)
Hemoglobin (g/dL)
Heavy marrow involvement
Yes
No
SGOT (U/L)
SGOT (AST) ULN (U/L)
SGPT (U/L)
SGPT (ALT) ULN (U/L)
Serum Creatinine (mg/dL)
Serum Creatinine ULN (mg/dL)
Is patient currently on dialysis due to renal failure
Yes
No
Date of most recent EKG
Lactate Dehydrogenase (LDH) (Units/l)
Beta-2 Microglobulin (¿g/ml)
CRP (¿g/dl)
Albumin (g/dl)
Is patient a woman of childbearing potential
Yes
No
Date of pregnancy test
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Multiple Myeloma and Plasma Cell Neoplasm null Pre-Study - S0522
Prestudy Form - 2459879v1.0
Result of Hepatitis B test
Negative (Negative)
Positive (Positive)
Result of HIV test
Negative (negative)
Positive (positive)
Test date
Test date
Disease History And Diagnosis
Date of Initial Pathologic Diagnosis
Disease Stage at Diagnosis
I (I)
Ii (II)
Iii (III)
Prior Treatment Related To This Cancer
Prior systemic therapy
Yes
No
Was prior systemic therapy <=8 weeks of
thalidomide (If yes,)
Yes
No
Prior Radiation Therapy
Yes
No
Was prior radiation therapy localized and not to
the sole site of evaluable disease (If yes,)
Yes
No
Comments
Comments
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Multiple Myeloma and Plasma Cell Neoplasm null Pre-Study - S0522
Prestudy Form - 2459879v1.0
NCT00075764 Pre-Study - SOUTHWEST ONCOLOGY GROUP
S0226 Advanced Breast Cancer Prestudy - 2174197v3.0
SOUTHWEST ONCOLOGY GROUP S0226 Advanced
Breast Cancer Prestudy
S0226 Anastrozole With or Without Fulvestrant as First-
Line Therapy in Postmenopausal Women With Metastatic
Breast Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=C3227C96-
0C14-2773-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/7392
SOUTHWEST ONCOLOGY GROUP
S0226 Advanced Breast Cancer
Prestudy
Header
SWOG Patient ID
SWOG Study No.
Registration Step
Patient Initials (L, F M)
Institution/Affiliate
Physician (Groups Other than SWOG)
Group Name
Study No.
Pt. ID (Instructions: All dates are MONTH, DAY,
YEAR. Explain any blank fields or blank dates in
the Comments section at the end of the form.
Place an X in appropriate boxes. Circle
AMENDED items in red.)
Disease Description At Diagnosis
Date of initial diagnosis of primary tumor
Date progressive, recurrent or metastatic disease
first diagnosed
Site(s) of Disease
bone (bone)
bone marrow (bone marrow)
brain (brain)
distant nodes (distant nodes)
distant skin/subcutaneous tissue (distant
skin/subcutaneous tissue)
1 / 3
ipsilateral supraclavicular nodes
(ipsilateral supraclavicular nodes)
liver (liver)
local-regional (local-regional)
lung (lung)
opposite breast (opposite breast)
other CNS (other CNS)
Other sites (Other sites)
pleura (pleura)
Other, specify
ER Status
Negative (Negative)
Positive (Positive)
PgR Status
Negative (Negative)
Positive (Positive)
Was Her-2/neu status determined?
Yes
No
HER2/neu Final Diagnosis
Equivocal (Equivocal)
Negative (Negative)
Positive (Positive)
Prior Hormonal Therapy
adjuvant (adjuvant)
neoadjuvant (neoadjuvant)
Prior Systemic Chemotherapy
adjuvant (adjuvant)
neoadjuvant (neoadjuvant)
High Dose Chemotherapy with marrow or stem
cell support
adjuvant (adjuvant)
neoadjuvant (neoadjuvant)
Prior Immunotherapy
adjuvant (adjuvant)
neoadjuvant (neoadjuvant)
Any Other Prior Therapy?
adjuvant (adjuvant)
neoadjuvant (neoadjuvant)
Name of other prior therapies
Comments
Ccrr Module For Southwest Oncology
Group S0226 Advanced Breast Cancer
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NCT00075764 Pre-Study - SOUTHWEST ONCOLOGY GROUP S0226
Advanced Breast Cancer Prestudy - 2174197v3.0
Prestudy
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NCT00075764 Pre-Study - SOUTHWEST ONCOLOGY GROUP S0226
Advanced Breast Cancer Prestudy - 2174197v3.0
Breast Cancer NCT00659373 Treatment - Concomitant
Medications Form (Form 24-CCM) - 2072606v3.0
Concomitant Medications Form (Form 24-CCM)
Brain Function in Premenopausal Women Receiving
Tamoxifen With or Without Ovarian Function Suppression
for Early-Stage Breast Cancer on Clinical Trial IBCSG-2402
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=B0EA006A-
EBFE-628F-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/7393
Concomitant Medications Form
(Form 24-CCM)
Ccrr Module For Concomitant Medications
Form (form 24-ccm)
Patient ID Number (Study No.)
Patient Initials (f m fl sl)
Patient's Date of Birth (day)
Participating Center/Affiliate
Center Code (Ver.#1)
Did patient receive any of the concomitant
medications listed in the Concomitant Medication
Code box below
Yes
No
Concomitant Medication
Anastrozole (Anastrozole)
Androgens (Androgens)
Anti-depressants (Anti-depressants)
Bisphosphonates (Bisphosphonates)
Calcitonin (Calcitonin)
Calcium Supplements (Calcium
supplements)
Estrogen (Estrogen)
Letrozole (Letrozole)
Other Lipid / Cholesterol-lowering Drug
(Other lipid / cholesterol-lowering drug)
Other Relevant Drug, Specify (Other
relevant drug, specify)
Progesterone (Progesterone)
Raloxifene (Raloxifene)
Regular Use Of Sleeping Tablets
(Regular use of sleeping tablets)
Statins (Statins)
Toremifene (Toremifene)
Trastuzumab (Trastuzumab)
Vitamin D3 (Vitamin D3)
Other relevant drug, specify
1 / 2
Agent Name
Agent Start Date
Agent End Date
Primary Reason
Anxiety (Anxiety)
Birth Control (Birth control)
Cardiac Ischemia/infarction (Cardiac
ischemia/infarction)
Cerebrovascular Ischemia (cns)
(Cerebrovascular ischemia (CNS))
Depression (Depression)
Elevated Lipids (Elevated lipids)
Fatigue (Fatigue)
Hormone Replacement Therapy
(Hormone replacement therapy)
Hot Flushes/night Sweats (Hot
flushes/night sweats)
Hypertension (Hypertension)
Insomnia (Insomnia)
Musculoskeletal Pain (Musculoskeletal
pain)
Osteoporosis/bone Mineral Density
(bmd) (Osteoporosis/bone mineral
density (BMD))
Other (Other)
Other Pain (Other pain)
Prevention Of Breast Cancer Relapse
(Prevention of breast cancer relapse)
Libido Decreased (Reduced libido)
Specify other reason
Route of Administration
Injection/transdermal (injection/implant)
Nasal Route Of Administration (nasal)
Ocular (Ocular)
Oral Administration Of Drug (oral)
Other (Other)
Ndc Transdermal - 358
(transdermal/topical)
Vaginal Route Of Administration (vaginal)
Specify other route
Continuing
Investigator/Designee Signature
Date (day month year)
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Breast Cancer NCT00659373 Treatment - Concomitant Medications
Form (Form 24-CCM) - 2072606v3.0
Metastatic Cancer NCT00134056 Follow-Up - SOUTHWEST
ONCOLOGY GROUP FOLLOW UP FORM - 2305135v3.0
SOUTHWEST ONCOLOGY GROUP FOLLOW UP FORM
Docetaxel and Prednisone With or Without Atrasentan in
Treating Patients With Stage IV Prostate Cancer and Bone
Metastases That Did Not Respond to Previous Hormone
Therapy
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=F159EF7E-
D486-319F-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/7395
SOUTHWEST ONCOLOGY GROUP
FOLLOW UP FORM
Header
SWOG Patient ID
SWOG Study No.
Registration Step
Patient Initials (L, F M)
Institution/Affiliate
Physician
Participating Group Name
American College Of Surgeons
Oncology Group (ACOSOG)
American College Of Radiology
Oncologic Imaging Network (ACRIN)
Aids-associated Malignancies Clinical
Trials Consortium (AMC)
Cancer And Leukemia Group B (CALGB)
Children's Oncology Group (COG)
Eastern Cooperative Oncology Group
(ECOG)
European Organization For Research
And Treatment Of Cancer (EORTC)
Gynecologic Oncology Group (GOG)
International Breast Cancer Study Group
(IBCSG)
North American Brain Tumor Consortium
(NABTC)
Nabtt Brain Tumor Consortium (NABTT)
North Central Cancer Treatment Group
(NCCTG)
National Cancer Institute Of Canada
Clinical Trials Group (NCIC)
National Surgical Adjuvant Breast And
Bowel Project (NSABP)
Radiation Therapy Oncology Group
(RTOG)
Southwest Oncology Group (SWOG)
Participating Group Study No.
1 / 3
Participating Group Patient ID
Vital Status
Vital Status
Alive (Alive)
Dead (Dead)
Date of last contact or death
Has the patient had a documented clinical
assessment for this cancer (since submission of
the previous follow-up form)
Yes
No
Date of Last Clinical Assessment (If Yes,)
Has the patient developed a first relapse or
progression that has not been previously
reported
Yes
No
Date of Relapse or Progression (If Yes,)
Site(s) of relapse or progression
Has a new primary cancer or MDS been
diagnosed that has not been previously reported?
(myelodysplastic syndrome)
Yes
No
Date of Diagnosis (If Yes,)
New Primary Site
Has the patient received any non-protocol cancer
therapy not previously reported? (prior to
progression/relapse)
Yes
No
Date of First Non-Protocol Therapy (If Yes,)
Agent Name (s:)
Has the patient experienced any severe long
term toxicity that has not been previously
reported? (prior to treatment for progression or
2 / 3
Metastatic Cancer NCT00134056 Follow-Up - SOUTHWEST
ONCOLOGY GROUP FOLLOW UP FORM - 2305135v3.0
relapse or a second primary, and prior to non-
protocol treatment grade >=3)
Yes
No
Adverse Events and Grades (If Yes,)
Has the patient discontinued Atrasentan or the
matching placebo
Yes
No
Date of discontinuation of blinded treatment (If
yes,)
Comments
Comments
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Metastatic Cancer NCT00134056 Follow-Up - SOUTHWEST
ONCOLOGY GROUP FOLLOW UP FORM - 2305135v3.0
Breast Cancer NCT01275677 Off Treatment - NSABP-B-47
Treatment Discontinuation Form (Form OFF) - 3161872v1.0
NSABP-B-47 Treatment Discontinuation Form (Form OFF)
A Randomized Phase III Trial of Adjuvant Therapy
Comparing Chemotherapy Alone (Six Cycles of Docetaxel
Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus
Cyclophosphamide Followed by Weekly Paclitaxel) to
Chemotherapy Plus Trastuzumab in Women With Node-
Positive or High-Risk Node-Negative HER2-Low Invasive
Breast Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=955983BD-
6DF9-0939-E040-BB89AD430554
All rights reserved. Please visit https://medical-data-
models.org/forms/7396
NSABP-B-47 Treatment
Discontinuation Form (Form OFF)
Header
Patient Initials (Last First Middle)
NSABP Patient ID
Time Point
Time point
Chemotherapy (Chemotherapy)
Trastuzumab (Trastuzumab)
Header Module
Did the patient begin any protocol drug
Yes
No
Last treatment cycle any protocol drug was given
(If yes, TC/AC cycle WP dose)
Agent Name
Was this agent ever started
Yes
No
Primary reason agent was stopped or never
started (Choose from list below)
Alternative Therapy (Alternative therapy)
Death (Death)
Non-protocol-specified Toxicity/adverse
Event (Non-protocol-specified
toxicity/adverse event)
Other (Other)
Patient Withdrawal Or Refusal (Patient
withdrawal or refusal)
Physician Withdrawal (Physician
withdrawal)
Protocol-specified Toxicity/adverse Event
1 / 2
(Protocol-specified toxicity/adverse
event)
Recurrence Or Second Primary Cancer
(Recurrence or second primary cancer)
Treatment Completed Per Protocol
Criteria (Treatment completed per
protocol criteria)
Header Module
Did the patient receive trastuzumab?
Yes
No
Last treatment cycle any trastuzumab was given
(If yes, any TC cycle Group 2A only WP dose
Group 2B only Post-chemotherapy PC dose)
Primary reason agent was stopped or never
started (Choose from list below)
Alternative Therapy (Alternative therapy)
Death (Death)
Non-protocol-specified Toxicity/adverse
Event (Non-protocol-specified
toxicity/adverse event)
Other (Other)
Patient Withdrawal Or Refusal (Patient
withdrawal or refusal)
Physician Withdrawal (Physician
withdrawal)
Protocol-specified Toxicity/adverse Event
(Protocol-specified toxicity/adverse
event)
Recurrence Or Second Primary Cancer
(Recurrence or second primary cancer)
Treatment Completed Per Protocol
Criteria (Treatment completed per
protocol criteria)
Footer
Comments (optional)
Person Completing Form
Date Form Completed (MM DD YYYY)
2 / 2
Breast Cancer NCT01275677 Off Treatment - NSABP-B-47 Treatment
Discontinuation Form (Form OFF) - 3161872v1.0
Lung Cancer NCT00946712 Follow-Up - Southwest Oncology
Group S0819 Lung Carcinoma Follow Up Form - 2863407v1.0
Southwest Oncology Group S0819 Lung Carcinoma Follow
Up Form
Carboplatin and Paclitaxel With or Without Bevacizumab
and/or Cetuximab in Treating Patients With Stage IV or
Recurrent Non-Small Cell Lung Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=684CF883-
6531-1929-E040-BB89AD4373A3
All rights reserved. Please visit https://medical-data-
models.org/forms/7397
Southwest Oncology Group S0819
Lung Carcinoma Follow Up Form
Header
SWOG Patient ID
SWOG Study No.
Registration Step
Patient Initials (L, F M)
Institution/Affiliate
Physician
Participating Group Name
American College Of Surgeons
Oncology Group (ACOSOG)
American College Of Radiology
Oncologic Imaging Network (ACRIN)
Aids-associated Malignancies Clinical
Trials Consortium (AMC)
Cancer And Leukemia Group B (CALGB)
Children's Oncology Group (COG)
Eastern Cooperative Oncology Group
(ECOG)
European Organization For Research
And Treatment Of Cancer (EORTC)
Gynecologic Oncology Group (GOG)
International Breast Cancer Study Group
(IBCSG)
North American Brain Tumor Consortium
(NABTC)
Nabtt Brain Tumor Consortium (NABTT)
North Central Cancer Treatment Group
(NCCTG)
National Cancer Institute Of Canada
Clinical Trials Group (NCIC)
National Surgical Adjuvant Breast And
Bowel Project (NSABP)
Radiation Therapy Oncology Group
(RTOG)
Southwest Oncology Group (SWOG)
Participating Group Study No.
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Participating Group Patient ID
Vital Status
Vital Status
Alive (Alive)
Dead (Dead)
Date of last contact or death (MM DD YYYY)
Has the patient had a documented clinical
assessment for this cancer (since submission of
the previous follow-up form)
Yes
No
Date of Last Clinical Assessment (If Yes, MM DD
YYYY)
Has the patient developed a first relapse or
progression that has not been previously
reported
Yes
No
Date of Relapse or Progression (If Yes, MM DD
YYYY)
Has a new primary cancer or MDS been
diagnosed that has not been previously reported?
(myelodysplastic syndrome)
Yes
No
Date of Diagnosis (If Yes, MM DD YYYY)
New Primary Site
Is the patient receiving any non-protocol cancer
therapy not previously reported? (or has the
patient received)
Yes
No
If yes, please specify
Erlotinib (Erlotinib)
Gefitinib (Gefitinib)
Other (Other)
Pemetrexed (Pemetrexed)
Start Date
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Lung Cancer NCT00946712 Follow-Up - Southwest Oncology Group
S0819 Lung Carcinoma Follow Up Form - 2863407v1.0
Agent Name (s - Note: List all agents used in any
treatment regimen received, including all
radiotherapy. If multiple regimens were received,
please specify only the first regimen received
after going off protocol treatment.)
Has the patient achieved a response? (to this
treatment)
Yes
No
Has the patient received prophylactic cranial
irradiation (PCI)?
Yes
No
PCI Start Date (MM DD YYYY)
Has the patient experienced (prior to treatment
for progression or relapse or a second primary,
and prior to non-protocol treatment) any severe
(grade >=3) long term toxicity that has not been
previously reported?
Yes
No
Adverse Events and Grades (If yes,)
Comments
Comments
3 / 3
Lung Cancer NCT00946712 Follow-Up - Southwest Oncology Group
S0819 Lung Carcinoma Follow Up Form - 2863407v1.0
Breast Cancer NCT01275677 On-Study - NSABP-B-47
Menstrual History Form - Follow-up (Form MH-F) - 3162784v1.0
NSABP-B-47 Menstrual History Form - Follow-up (Form
MH-F)
A Randomized Phase III Trial of Adjuvant Therapy
Comparing Chemotherapy Alone (Six Cycles of Docetaxel
Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus
Cyclophosphamide Followed by Weekly Paclitaxel) to
Chemotherapy Plus Trastuzumab in Women With Node-
Positive or High-Risk Node-Negative HER2-Low Invasive
Breast Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=95D01C7E-
6AE8-38AE-E040-BB89AD4351B3
All rights reserved. Please visit https://medical-data-
models.org/forms/7398
NSABP-B-47 Menstrual History
Form - Follow-up (Form MH-F)
Header
Patient Initials (Last First Middle)
NSABP Patient ID
Time Point
Time point
12-month Follow-up (12-Month Follow-
up)
18-month Follow-up (18-Month Follow-
up)
24-month Follow-up (24-Month Follow-
up)
3-month Follow-up (3-Month Follow-up)
30-month Follow-up (30-Month Follow-
up)
36-month Follow-up (36-Month Follow-
up)
6-month Follow-up (6-Month Follow-up)
Menstrual History
Date Questionnaire Completed (Month Day Year)
Has the patient had a hysterectomy?
No (No)
Unknown (Unknown)
Yes (Yes)
Date of Hysterectomy (If yes Month Day Year)
Has the patient taken hormone therapy to
manage vasomotor (e.g. hot flashes) or vaginal
symptoms during the past month
Yes
No
1 / 2
Has the patient had both ovaries removed?
No (No)
Unknown (Unknown)
Yes (Yes)
Date both (or second) ovaries were removed
(Month Day Year)
Has the patient taken hormonal contraceptives
during the past month
Yes
No
Agent Name (If yes)
Agent Name (If yes)
Date of last menstrual period (Start or vaginal
bleeding Month Day Year)
At any time since the start of treatment, has the
patient stopped having menstrual periods
Yes
No
What is the longest interval of time that has
lapsed between menstrual cycles (Consider the
longest interval of time, since the start of
treatment, that the patient stopped having
menstrual periods or vaginal bleeding first day of
one to first day of the next months Round up to
nearest month)
What was the last date of bleeding before that
interval began (Month Day Year)
Footer
Comments (optional)
Person Completing Form
Date Form Completed
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Breast Cancer NCT01275677 On-Study - NSABP-B-47 Menstrual
History Form - Follow-up (Form MH-F) - 3162784v1.0
Breast Cancer NCT00914043 On-Study - NSABP B-45 Worksheet
for Postoperative Adjuvant Hormonal Therapy Form - 2846464v1.0
NSABP B-45 Worksheet for Postoperative Adjuvant
Hormonal Therapy Form
Studying Biological Markers of Fatigue in Women With
Residual Invasive Breast Cancer Enrolled on Clinical Trial
NSABP-B-45
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=6461E18A-
2098-98F1-E040-BB89AD4303E7
All rights reserved. Please visit https://medical-data-
models.org/forms/7399
NSABP B-45 Worksheet for
Postoperative Adjuvant Hormonal
Therapy Form
Header
Patient Initials (Last First Middle)
NSABP Patient ID
Unnamed Module 1
Report Period
12 Months (12 months)
24 Months (24 months)
36 Months (36 months)
48 Months (48 months)
60 Months (60 months)
72 Months (72 months)
Since being entered on study, has the patient
received any postoperative adjuvant hormonal
treatment? (If yes, continue If no, omit the
remaining questions)
Yes
No
New Data
Does this report contain any new data or has any
data been changed from the last report?
Yes (1)
No (2)
Unnamed Module 2
Agent (OTHER HT)
Begin date (MM DD YYYY)
End date (MM DD YYYY)
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Aromatase Inhibitor
Agent (OTHER HT)
Begin date (MM DD YYYY)
End date (MM DD YYYY)
Other Ht
Agent (OTHER HT)
Begin date (MM DD YYYY)
End date (MM DD YYYY)
Specify (OTHER HT)
Treatment Ended
Has all postoperative adjuvant hormonal
treatment ended?
Yes
No
Reason Treatment Ended (Last Postoperative
Adjuvant HT)
Adverse Event/side Effects/complications
(Adverse event/side
effects/complications)
Death (Death)
New Lesion (including Second Primary
Cancer) Or Other Sign Of Progression
(New lesion (including second primary
cancer) or other sign of progression)
Other (Other)
Patient Withdrawal Or Refusal (Patient
withdrawal or refusal)
Treatment Completed Per Protocol
Criteria (Treatment completed per
protocol criteria)
Other, specify
Footer
Comments (optional)
Person Completing Form
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Breast Cancer NCT00914043 On-Study - NSABP B-45 Worksheet for
Postoperative Adjuvant Hormonal Therapy Form - 2846464v1.0
Date Form Completed (MM DD YYYY)
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Breast Cancer NCT00914043 On-Study - NSABP B-45 Worksheet for
Postoperative Adjuvant Hormonal Therapy Form - 2846464v1.0
Lymphoma NCT01190449 Eligibility - CALGB
50901 Eligibility Checklist Form - 3211939v1.0
CALGB 50901 Eligibility Checklist Form
Ofatumumab in Treating Patients With Previously Untreated
Stage II, Stage III, or Stage IV Follicular Non-Hodgkin
Lymphoma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=9F9012C3-
FDE5-DB91-E040-BB89AD432434
All rights reserved. Please visit https://medical-data-
models.org/forms/7401
CALGB 50901 Eligibility Checklist
Form
Eligibility Checklist
Hematopoietic Diagnosis (Mark one with an X.
see Section 4.1.1 Histologically confirmed
follicular lymphoma, WHO classification grade 1,
2, or 3a without histologic transformation that is
stage III, IV or bulky stage II i.e., single mass >=
7 cm in any uni-dimensional measurement)
Follicular Lymphoma Grade I (Follicular
lymphoma - grade I)
Follicular Lymphoma Grade Ii (Follicular
lymphoma - grade II)
Follicular Lymphoma Grade Iiia
(Follicular lymphoma - grade IIIa)
Modified Ann Arbor Stage (Mark one with an X.
see Section 4.1.1)
Ii (II)
Iie (IIE)
Iii (III)
Iiie (IIIE)
Iiie+s (IIIE+S)
Iiis (IIIS)
Iv (IV)
Does institutional flow cytometry or
immunohistochemistry confirm CD20 antigen
expression (Tumor tissue must be confirmed to
express the CD20 antigen by institutional flow
cytometry or immunohistochemistry. see Section
4.1.2)
Yes
No
Baseline Longest Diameter of Lesion (cm of the
largest involved node Patient must have at least
one site of measurable disease that is greater
than 1 cm in diameter present either on physical
exam or imaging studies. see Section 4.1.3 and
4.5)
Any prior systemic therapy for NHL other than
involved field radiation therapy (No prior therapy
for NHL including chemotherapy or
immunotherapy e.g., monoclonal antibody-based
therapy. Patients may have received involved field
radiation therapy. see Section 4.2.1)
1 / 3
Yes
No
Any corticosteroid use within two weeks prior to
study entry (except for maintenance therapy of
non-malignant disease No corticosteroids within
two weeks prior to study entry, except for
maintenance therapy for a non-malignant
disease. see Section 4.2.2)
Yes
No
Number of nodal sites (Mark one with an X. Low
or intermediate-risk disease by the follicular
lymphoma international prognostic index FLIPI
score see Section 4.3)
<= 4 Sites (<= 4 sites)
> 4 Sites (> 4 sites)
Hemoglobin (g/dl)
Lactate Dehydrogenase (LDH U/l)
Lactate Dehydrogenase ULN (LDH U/l)
FLIPI score (Mark one with an X)
>=3 (>=3)
0-1 (0-1)
2 (2)
Performance Status (ECOG) (Mark one with an X
ECOG performance status <= 2 see Section 4.4)
Fully Active, Able To Carry On All Pre-
disease Performance Without
Restriction. (0)
Restricted In Physically Strenuous
Activity But Ambulatory And Able To
Carry Out Work Of A Light Or Sedentary
Nature, E.g., Light Housework, Office
Work. (1)
Ambulatory And Capable Of All Selfcare
But Unable To Carry Out Any Work
Activities. Up And About More Than 50%
Of Waking Hours. (2)
Any known CNS involvement (No known CNS
involvement by lymphoma see Section 4.6)
Yes
No
Age (Age >= 18 years of age see Section 4.7)
Does the patient have HIV infection (HIV+
patients are eligible, provided they meet the
parameters in Section 4.8)
Yes
2 / 3
Lymphoma NCT01190449 Eligibility - CALGB 50901 Eligibility Checklist
Form - 3211939v1.0
No
CD4+ Count (If yes /mm^3)
Evidence of coinfection with hepatitis B or C or
evidence of a resistant strain of HIV
Yes
No
Patient on anti-HIV therapy
Yes
No
HIV viral load (If no copies HIV RNA/mL)
HIV viral load (If no copies HIV RNA/mL)
Is the patient HBV seropositive (HBsAg + HBV
seropositive patients HBsAg + are eligible,
provided they meet the parameters in Section
4.9)
Yes
No
If HBsAg+, was HBV DNA testing performed
Yes
No
Was evidence of active HBV infection detected
Yes
No
Serum or urine Beta-HCG (Non-pregnant and
non-nursing see Section 4.10)
Negative (Negative)
Not Applicable (Not applicable)
Positive (Positive)
ANC (u/l Granulocytes  >= 1,000/ul see Section
4.11)
Platelets (u/L Platelets >= 75,000/ul see Section
4.11)
Serum Creatinine (mL/min Creatinine clearance
>= 30 mL/min see Section 4.11)
Bilirubin (Bilirubin <= 2x ULN* see Section 4.11 *
Unless secondary to Gilbert's or hepatic
involvement of NHL)
Bilirubin ULN
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Lymphoma NCT01190449 Eligibility - CALGB 50901 Eligibility Checklist
Form - 3211939v1.0
Colorectal Cancer NCT00058474 Quality of Life - NSABP Protocol R-
04 Missing Data Form for Quality of Life Questionnaire - 2082577v3.0
NSABP Protocol R-04 Missing Data Form for Quality of Life
Questionnaire
Radiation Therapy and Either Capecitabine or Fluorouracil
With or Without Oxaliplatin Before Surgery in Treating
Patients With Resectable Rectal Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=B7822FF2-
369B-24FE-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/7402
NSABP Protocol R-04 Missing Data
Form for Quality of Life
Questionnaire
Ccrr Module For Nsabp Protocol R-04
Missing Data Form For Quality Of Life
Questionnaire
First Three Letters of Patients Last Name
Patient Study ID 34
Institution Name / Affiliate Name
Person Completing Form
Last Name
First Name
Are Data Amended?
Yes
No
Time Point for this Form (mark one)
One Year After Surgery (One year after
surgery)
Post Chemotherapy/radiation (Post
chemotherapy/radiation)
Other (specify)
Other (specify)
Reason QOL was Not Assessed During Clinic
Visit (Mark the main reason and add comments
below.)
Clinical Staff Concerned For Patient's
Medical Or Emotional Condition (Clinical
staff concerned for patinet's medical or
emotional condition)
Patient Felt Too Ill Or Emotionally Upset
(Patient felt too ill or emotionally upset)
Patient Refused To Complete
Questionnaire (Patient refused to
1 / 2
complete qustionnaire)
Patient Was Unavailable (e.g.,
Scheduling Or Transportation Difficulties)
(Patient was unavailable)
Staff Oversight Or Understaffing (Staff
oversight or understaffing)
Reason QOL was Not Obtained by Phone or Mail
(Mark all that apply and add comments below.)
Patient Refused (Patient refused)
Staff Oversight Or Understaffing (Staff
oversight or understaffing)
Staff Was Unable To Contact Patient By
Phone (Staff was unable to contact
patient by phone)
Comments
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Colorectal Cancer NCT00058474 Quality of Life - NSABP Protocol R-04
Missing Data Form for Quality of Life Questionnaire - 2082577v3.0
Cervical Cancer NCT01414608 Treatment - ANZGOG-0902
Chemotherapy - adjuvant chemotherapy - 3141464v1.0
ANZGOG-0902 Chemotherapy - adjuvant chemotherapy
Cisplatin and Radiation Therapy With or Without
Carboplatin and Paclitaxel in Patients With Locally
Advanced Cervical Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=90FC354F-
AB7E-8368-E040-BB89AD434A85
All rights reserved. Please visit https://medical-data-
models.org/forms/7403
ANZGOG-0902 Chemotherapy -
adjuvant chemotherapy
Header
Patient Initials
Patient ID
Institution Code
Date of Assessment
Patient Data
Weight
BSA
Creatinine Clearance
ECOG Performance Status
Fully Active, Able To Carry On All Pre-
disease Performance Without
Restriction. (0)
Restricted In Physically Strenuous
Activity But Ambulatory And Able To
Carry Out Work Of A Light Or Sedentary
Nature, E.g., Light Housework, Office
Work. (1)
Ambulatory And Capable Of All Selfcare
But Unable To Carry Out Any Work
Activities. Up And About More Than 50%
Of Waking Hours. (2)
Capable Of Only Limited Selfcare,
Confined To Bed Or Chair More Than
50% Of Waking Hours. (3)
Completely Disabled. Cannot Carry On
Any Selfcare. Totally Confined To Bed Or
Chair. (4)
Dead (5)
Hemoglobin
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Hemoglobin, ULN
Red Blood Cell (RBC) Transfusion
Yes
No
Was G-CSF received
Yes
No
Chemotherapy - Cisplatin
Agent
Date Agent Administered
Total Dose
Dose Modification (Change)
No (No)
Dose Modification Reason
Hematologic Toxicity (Hematologic
toxicity)
Other (Other)
Other, specify
Were there any delays in dose administration
Yes
No
Specify
Footer Module
Investigator Name
Date
Investigator's signature
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Cervical Cancer NCT01414608 Treatment - ANZGOG-0902
Chemotherapy - adjuvant chemotherapy - 3141464v1.0
Lymphoma NCT00598169 Lab - AMC-053
Hematology Form (F22) - 3122876v1.0
AMC-053 Hematology Form (F22)
Bortezomib, Ifosfamide, Carboplatin, and Etoposide, With
or Without Rituximab, in Treating Patients With Relapsed or
Refractory AIDS-Related Non-Hodgkin Lymphoma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=8B73192C-
C15D-46D4-E040-BB89AD433800
All rights reserved. Please visit https://medical-data-
models.org/forms/7404
AMC-053 Hematology Form (F22)
Header Module
Visit number
Sequence number
Date of evaluation (mm/dd/yyyy)
Reporting Period (select one)
Baseline (Baseline)
On Treatment (On treatment)
Post-therapy (Post therapy)
Ccrr Module For Hematology - Rf22
Hemoglobin (g/dl)
Hematocrit (%)
Peripheral WBC Count (1000/mm^3)
Peripheral Neutrophils (%) (including Bands %
1000/mm^3WBC x % Neutrophils including
Bands/100)
Peripheral Neutrophil Count (1000/mm^3 WBC x
% Neutrophils including Bands/100)
Peripheral Lymphocytes (%)
Peripheral Monocytes (%)
Peripheral Eosinophils (%)
Peripheral Basophils (%)
Other, specify test (Hematology)
Other, specify test (Hematology)
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Other specify value (Hematology)
Other specify value (Hematology)
Peripheral Platelet Count (1000/mm^3)
Units
Comments
Comments
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Lymphoma NCT00598169 Lab - AMC-053 Hematology Form (F22) -
3122876v1.0
Lung Cancer NCT00946712 On-Study - Southwest Oncology Group S0819
Lung Carcinoma First Site(s) Of Progression Or Relapse Form - 2863883v1.0
Southwest Oncology Group S0819 Lung Carcinoma First
Site(s) Of Progression Or Relapse Form
Carboplatin and Paclitaxel With or Without Bevacizumab
and/or Cetuximab in Treating Patients With Stage IV or
Recurrent Non-Small Cell Lung Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=684FE956-
5A8B-A7DA-E040-BB89AD432A2B
All rights reserved. Please visit https://medical-data-
models.org/forms/7405
Southwest Oncology Group S0819
Lung Carcinoma First Site(s) Of
Progression Or Relapse Form
Header
SWOG Patient ID
SWOG Study No.
Registration Step
Patient Initials (L, F M)
Institution/Affiliate
Physician
Participating Group Name
Participating Group Study No.
Participating Group Patient ID
Vital Status
Date of Last Contact or Death (MM DD YYYY)
Vital Status
Alive (Alive)
Dead (Dead)
Progression Or Relapse
Date of Relapse or Progression (MM DD YYYY)
Sites of Progression (or Relapse at the time
progression/relapse was detected select all that
apply)
Adrenal Gland (Adrenal glands)
Bone (Bone)
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Brain (Brain)
Bronchial Stump (Bronchial stump)
Contralateral Hilar Mediastinum (nodal)
(Contralateral hilar mediastinum (nodal))
Contralateral Pleural Effusion
(Contralateral pleural effusion)
Contralateral Supraclavicular Nodes
(Contralateral supraclavicular nodes)
Ipsilateral Hilar Mediastinum (nodal)
(Ipsilateral hilar mediastinum (nodal))
Ipsilateral Pleural Effusion (Ipsilateral
pleural effusion)
Ipsilateral Supraclavicular Nodes
(Ipsilateral supraclavicular nodes)
Kidney (Kidney)
Leptomeninges (Leptomeninges)
Liver (Liver)
Lung Parenchyma Adjacent To Primary
Tumor (Lung parenchyma adjacent to
primary tumor)
Contralateral Lung (Opposite lung)
Other (Other)
Pericardial Effusion (Pericardial effusion)
Separate Lobe Of The Ipsilateral Lung
(Separate lobe of the ipsilateral lung)
Subcutaneous/skin (Subcutaneous/Skin)
Other specify (site)
Progression/Relapse site within previous RT field
(For Regional Progression or Relapse select one)
No (No)
Not Applicable (Not Applicable)
Yes (Yes)
Progression/Relapse site within previous RT field
(For Regional Progression or Relapse select one)
No (No)
Not Applicable (Not Applicable)
Yes (Yes)
Comments
Comments
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Lung Cancer NCT00946712 On-Study - Southwest Oncology Group S0819
Lung Carcinoma First Site(s) Of Progression Or Relapse Form - 2863883v1.0
Cervical Cancer NCT01414608 Treatment - ANZGOG-0902
Chemotherapy - cisplatin chemotherapy - 3141384v1.0
ANZGOG-0902 Chemotherapy - cisplatin chemotherapy
Cisplatin and Radiation Therapy With or Without
Carboplatin and Paclitaxel in Patients With Locally
Advanced Cervical Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=90FB59ED-
09B1-C290-E040-BB89AD436574
All rights reserved. Please visit https://medical-data-
models.org/forms/7406
ANZGOG-0902 Chemotherapy -
cisplatin chemotherapy
Header
Patient Initials
Patient ID
Institution Code
Date of Assessment
Patient Data
Hemoglobin
Hemoglobin, ULN
Red Blood Cell (RBC) Transfusion
Yes
No
Chemotherapy - Cisplatin
Agent
Date Agent Administered
Total Dose
Dose Modification (Change)
No (No)
Dose Modification Reason
Hematologic Toxicity (Hematologic
toxicity)
Other (Other)
Other, specify
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Were there any delays in dose administration
Yes
No
Specify
Footer Module
Investigator Name
Date
Investigator's signature
2 / 2
Cervical Cancer NCT01414608 Treatment - ANZGOG-0902
Chemotherapy - cisplatin chemotherapy - 3141384v1.0
Multiple Myeloma and Plasma Cell Neoplasm NCT00644228 Follow-Up -
Southwest Oncology Group Baseline & Follow-up Tumor Assessment Form for
Multiple Myeloma (S0777) - 2656740v1.0
Southwest Oncology Group Baseline & Follow-up Tumor
Assessment Form for Multiple Myeloma (S0777)
Lenalidomide and Dexamethasone With or Without
Bortezomib in Treating Patients With Previously Untreated
Multiple Myeloma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=33462956-
9F7A-2715-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/7416
Southwest Oncology Group Baseline
& Follow-up Tumor Assessment
Form for Multiple Myeloma (S0777)
Header
SWOG Patient ID
SWOG Study No.
Registration Step
Patient Initials (L, F, M)
Institution/Affiliate
Physician
Participating Group Name
Participating Group Study No.
Participating Group Patient ID
Unnamed 2
Date of SPEP
Serum M-Protein Spike
Date of Immunofixation
Serum M-Protein by Immunofixation
Equivocal (equivocal)
Negative (negative)
Not Done (not done)
Positive (positive)
Unknown (unknown)
Kappa Free Light Chain (mg/dL)
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Lambda Free Light Chain (mg/dL)
Kappa/Lambda ratio (mg/dL)
Serum Heavy Chain
A (A)
D (D)
E (E)
G (G)
M (M)
None (None)
Unknown (unknown)
Serum Light Chain
Kappa (kappa)
Lambda (lambda)
Unknown (unknown)
Urine M-protein
Date of UPEP
Date of Immunofixation
Urine M-Protein by Immunofixation
Equivocal (equivocal)
Negative (negative)
Positive (positive)
Unknown (unknown)
Urine M-Protein Light Chain Excretion (mg/24hr)
Urine volume (ml/24hr)
Urine Total Protein (mg/24 hrs)
Urine Light Chain
Kappa (Kappa)
Lambda (Lambda)
Unknown (Unknown)
Bone Marrow Plasmacytosis
Bone Marrow Biopsy Date
Marrow Cellularity (%)
Biopsy Type
Aspirate (Aspirate)
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Multiple Myeloma and Plasma Cell Neoplasm NCT00644228 Follow-Up -
Southwest Oncology Group Baseline & Follow-up Tumor Assessment Form for
Multiple Myeloma (S0777) - 2656740v1.0
Both (Both)
Core Biopsy (Core)
Unknown (Unknown)
Plasma Cells on Biopsy (%)
Clonal cells in bone marrow
Absent (Absent)
Present (Present)
Bone Disease And Anemia
Serum Calcium Date
Serum calcium
Bone lesions of skeletal survey date
Number of lytic lesions
1-3 Lesions (1-3)
4-5 (4-5)
6+ (6+)
None (none)
Osteoporosis (Osteoporosis)
Compared to last survey, bone health is
Improved (Better)
Stable (Stable)
Worse (Worse)
Myeloma: Soft Tissue Plasmacytoma
Response
Soft Tissue Plasmacytoma
No (no)
Not Done (not done)
Unknown (unknown)
Yes (yes)
Yes, Both Previously Existing And New
(yes, both previously existing and new)
Yes, New (yes, new)
Yes, Previously Existing (yes, previously
existing)
Lesion Number
Site of Lesion
Size of Plasmacytoma (Size of Largest or
Indicator Plasmacytoma diameter cm x)
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Multiple Myeloma and Plasma Cell Neoplasm NCT00644228 Follow-Up -
Southwest Oncology Group Baseline & Follow-up Tumor Assessment Form for
Multiple Myeloma (S0777) - 2656740v1.0
Size of Plasmacytoma
Assessment Date
Comments
Comments
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Multiple Myeloma and Plasma Cell Neoplasm NCT00644228 Follow-Up -
Southwest Oncology Group Baseline & Follow-up Tumor Assessment Form for
Multiple Myeloma (S0777) - 2656740v1.0
Colorectal Cancer NCT01189227 Off Treatment - NSABP C-11
Worksheet for Treatment Discontinuation Form - 3107651v1.0
NSABP C-11 Worksheet for Treatment Discontinuation
Form
Combination Chemotherapy Before or After Surgery in
Treating Patients With Colorectal Cancer With Liver
Metastases That Could Be Removed By Surgery
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=88744794-6353-
9657-E040-BB89AD437BFC
All rights reserved. Please visit https://medical-data-
models.org/forms/7422
NSABP C-11 Worksheet for
Treatment Discontinuation Form
Header
Patient Initials (Last First Middle)
NSABP Patient ID
Header Module
Did the patient begin any protocol drug
Yes
No
Last treatment cycle any protocol drug was given
(If yes,)
Agent Name
Was this agent ever started
Yes
No
Primary reason agent was stopped or never
started
Alternative Therapy (Alternative therapy)
Death (Death)
Disease Progression, Recurrence Or
Second Primary Cancer (Disease
progression, recurrence or second
primary cancer)
Non-protocol-specified Toxicity/adverse
Event (Non-protocol-specified
toxicity/adverse event)
Other (Other)
Patient Withdrawal Or Refusal (Patient
withdrawal or refusal)
Physician Withdrawal (Physician
withdrawal)
Protocol-specified Toxicity/adverse Event
(Protocol-specified toxicity/adverse
event)
Surgical Complications (Surgical
complications)
Treatment Completed Per Protocol
Criteria (Treatment completed per
1 / 2
protocol criteria)
Comments (optional)
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Colorectal Cancer NCT01189227 Off Treatment - NSABP C-11
Worksheet for Treatment Discontinuation Form - 3107651v1.0
Colorectal Cancer NCT01150045 Treatment -
CALGB 80702 Treatment Form - 2969857v1.0
CALGB 80702 Treatment Form
Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or
Without Celecoxib in Treating Patients With Stage III Colon
Cancer Previously Treated With Surgery
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=7AD9B90F-
EC60-48A2-E040-BB89AD430CF4
All rights reserved. Please visit https://medical-data-
models.org/forms/7423
CALGB 80702 Treatment Form
Header
CALGB Form
CALGB Study No.
CALGB Patient ID
Date of First dose for this reporting period (MM
DD YYYY)
Reporting Period End Date (MM DD YYYY)
Are data amended
Yes
No
Unnamed2
Patient Initials (Last, First Middle)
Patient Hospital No.
Institution/Affiliate
Participating Group
Participating Group Study No.
Participating Group Patient ID
Patient Data
Cycle Number (during FOLFOX treatment only)
Cycle Number (during FOLFOX treatment only)
BSA (Patient on reporting period start date m^2)
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First Treatment (cycles 1 ¿ 6)
Agent
Agent Total Dose (mg)
Dose Modifications
Were there any dose modifications or
additions/omissions to protocol treatment? (Mark
one with an X.)
No (No)
Yes, Planned (i.e., The Treatment Was
Changed According To Protocol
Guidelines) (Yes, planned)
Yes, Unplanned (i.e., The Treatment
Change Was Not Part Of Protocol
Guidelines) (Yes, unplanned)
Reason Treatment Ended
Number of missed Celecoxib/placebo doses (this
reporting period)
Reason Treatment Ended (If protocol treatment
has been terminated permanently during this
time period Mark one with an X.)
Adverse Event/side Effects/complications
(Adverse Event/Side
Effects/Complications)
Alternative Therapy (Alternative therapy)
Death On Study (Death on study)
Disease Progression, Relapse During
Active Treatment (Disease progression,
relapse during active treatment)
Other (Other)
Patient Off-treatment For Other
Complicating Disease (Patient off-
treatment for other complicating disease)
Patient Withdrawal Or Refusal After
Beginning Protocol Therapy (Patient
withdrawal/refusal after beginning
protocol therapy)
Patient Withdrawal Or Refusal Before
Beginning Protocol Therapy (Patient
withdrawal/refusal prior to beginning
protocol therapy)
Treatment Completed Per Protocol
Criteria (Treatment completed per
protocol criteria)
Other specify
Did the patient receive any ancillary therapy
2 / 3
Colorectal Cancer NCT01150045 Treatment - CALGB 80702 Treatment
Form - 2969857v1.0
during this reporting period
Yes
No
Yes specify
Overall Response
Completed by (Last name, First name)
Date Form Originally Completed (MM DD YYYY)
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Colorectal Cancer NCT01150045 Treatment - CALGB 80702 Treatment
Form - 2969857v1.0
Multiple Myeloma and Plasma Cell Neoplasm null Follow-Up - S0522 Baseline
AND Follow-up Tumor Assessment Form for Multiple Myeloma - 2456693v1.0
S0522 Baseline AND Follow-up Tumor Assessment Form
for Multiple Myeloma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=0EE5FB2C-
6B6F-0581-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/7425
S0522 Baseline AND Follow-up
Tumor Assessment Form for Multiple
Myeloma
Header
SWOG Patient ID
SWOG Study No.
Registration Step
Patient Initials (L, F, M)
Institution/Affiliate
Physician
Participating Group Name
Participating Group Study No.
Participating Group Patient ID
Unnamed 2
Date
M-Component
Date
Monoclonal Protein
Absent (Absent)
Present (Present)
Kappa Free Light Chain (mg/dL)
Lambda Free Light Chain (mg/dL)
Kappa/Lambda ratio (mg/dL)
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IgG (mg/dl)
IgA (mg/dl)
IgM (mg/dl)
IgD (mg/dl)
IgE (mg/dl)
Urine M-protein
Date
M-Component
Urine volume
Urine Total Protein (mg/24 hrs)
Monoclonal Protein
Absent (Absent)
Present (Present)
Urine Light Chain
Kappa (Kappa)
Lambda (Lambda)
Light Chain, Nos (Light Chain, NOS)
Unknown (Unknown)
Date
Bone Marrow Plasmacytosis
Bone Marrow Biopsy Date
Marrow Cellularity (%)
Biopsy Type
Fine Needle Aspirate (Fine needle
aspirate)
Large Bore Needle (Large bore needle)
Other (Other)
Plasma Cells on Differential (%)
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Multiple Myeloma and Plasma Cell Neoplasm null Follow-Up - S0522 Baseline
AND Follow-up Tumor Assessment Form for Multiple Myeloma - 2456693v1.0
Bone Disease And Anemia
Date
Serum calcium
Increasing anemia
Yes
No
Bone Lesions on Skeletal Survey
None (None)
Osteoporosis (Osteoporosis)
Date
Number of lytic lesions
Comments
Comments
3 / 3
Multiple Myeloma and Plasma Cell Neoplasm null Follow-Up - S0522 Baseline
AND Follow-up Tumor Assessment Form for Multiple Myeloma - 2456693v1.0
Multiple Myeloma and Plasma Cell Neoplasm null
Follow-Up - S0522 Follow Up Form - 2454223v1.0
S0522 Follow Up Form
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=0EA7506A-
15C3-635B-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/7426
S0522 Follow Up Form
Header
SWOG Patient ID
SWOG Study No.
Registration Step
Patient Initials (L, F M)
Institution/Affiliate
Physician
Participating Group Name
Participating Group Study No.
Participating Group Patient ID
Vital Status
Vital Status
Alive (Alive)
Dead (Dead)
Date of last contact or death
Has the patient had a documented clinical
assessment for this cancer (since submission of
the previous follow-up form)
Yes
No
Date of Last Clinical Assessment (If Yes,)
Has the patient developed a first relapse or
progression that has not been previously
reported
Yes
No
Date of Relapse or Progression (If Yes,)
1 / 2
Site(s) of relapse or progression
Has a new primary cancer or MDS been
diagnosed that has not been previously reported
(myelodysplastic syndrome)
Yes
No
Date of Diagnosis (If Yes,)
New Primary Site
Has the patient received any non-protocol cancer
therapy not previously reported (prior to
progression/relapse)
Yes
No
Date of First Non-Protocol Therapy (If Yes,)
Agent Name (s:)
Has the patient experienced any severe long
term toxicity that has not been previously
reported (prior to treatment for progression or
relapse or a second primary, and prior to non-
protocol treatment grade >=3)
Yes
No
Adverse Events and Grades (If Yes,)
Comments
Comments
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Multiple Myeloma and Plasma Cell Neoplasm null Follow-Up - S0522
Follow Up Form - 2454223v1.0
Metastatic Cancer NCT00134056 Response - Southwest
Oncology Group - Bisphosphonate Usage Form - 2759910v1.0
Southwest Oncology Group - Bisphosphonate Usage Form
Docetaxel and Prednisone With or Without Atrasentan in
Treating Patients With Stage IV Prostate Cancer and Bone
Metastases That Did Not Respond to Previous Hormone
Therapy
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=4FD609AB-
09CA-1C94-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/7431
Southwest Oncology Group -
Bisphosphonate Usage Form
Header
SWOG Patient ID
SWOG Study No.
Registration Step
Patient Initials
Date Form Completed
Institution/Affiliate
Physician
Participating Group Name
Participating Study No.
Participating Patient ID (All dates are MONTH,
DAY, YEAR. Circle AMENDED items in red. The
same test procedures used for baseline disease
assessment must be used for all required
subsequent disease assessments.)
Psa Measurements
Has the patient received bisphosphonates (prior
to randomization or during protocol treatment)
Yes
No
Bisphosphonate type(s) received
Both Pamidronate And Zoledronic Acid
(both pamidronate and zoledronic acid)
Other (Other)
Pamidronate (pamidronate)
Zoledronic Acid (zoledronic acid)
1 / 2
Bisphosphonates, specify
Dose
Frequency
Daily (Daily)
Monthly (Monthly)
Other (Other)
Weekly (Weekly)
Other, specify
Agent Start Date
Agent End Date
Comments
Comments
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Metastatic Cancer NCT00134056 Response - Southwest Oncology
Group - Bisphosphonate Usage Form - 2759910v1.0
Neuroendocrine Carcinoma NCT00569127 Follow-Up -
Southwest Oncology Group Follow-Up Form - 2458259v1.0
Southwest Oncology Group Follow-Up Form
Octreotide and Interferon Alfa-2b or Bevacizumab in
Treating Patients With Metastatic or Locally Advanced,
High-Risk Neuroendocrine Tumor
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=0EFA926B-
75EB-5AE8-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/7447
Southwest Oncology Group Follow-
Up Form
Header
SWOG Patient ID
SWOG Study No.
Registration Step
Patient Initials (L, F M)
Institution/Affiliate
Physician
Participating Group Name
American College Of Surgeons
Oncology Group (ACOSOG)
American College Of Radiology
Oncologic Imaging Network (ACRIN)
Aids-associated Malignancies Clinical
Trials Consortium (AMC)
Cancer And Leukemia Group B (CALGB)
Children's Oncology Group (COG)
Eastern Cooperative Oncology Group
(ECOG)
European Organization For Research
And Treatment Of Cancer (EORTC)
Gynecologic Oncology Group (GOG)
International Breast Cancer Study Group
(IBCSG)
North American Brain Tumor Consortium
(NABTC)
Nabtt Brain Tumor Consortium (NABTT)
North Central Cancer Treatment Group
(NCCTG)
National Cancer Institute Of Canada
Clinical Trials Group (NCIC)
National Surgical Adjuvant Breast And
Bowel Project (NSABP)
Radiation Therapy Oncology Group
(RTOG)
Southwest Oncology Group (SWOG)
Participating Group Study No.
1 / 3
Participating Group Patient ID
Vital Status
Vital Status
Alive (Alive)
Dead (Dead)
Date of last contact or death
Has the patient had a documented clinical
assessment for this cancer (since submission of
the previous follow-up form)
Yes
No
Date of Last Clinical Assessment (If Yes,)
Has the patient developed a first relapse or
progression that has not been previously
reported
Yes
No
Date of Relapse or Progression (If Yes,)
Site(s) of relapse or progression
Has a new primary cancer or MDS been
diagnosed that has not been previously reported?
(myelodysplastic syndrome)
Yes
No
Date of Diagnosis (If Yes,)
New Primary Site
Has the patient received any non-protocol cancer
therapy not previously reported? (prior to
progression/relapse)
Yes
No
Date of First Non-Protocol Therapy (If Yes,)
Agent Name (s:)
Has the patient experienced any severe long
term toxicity that has not been previously
reported (prior to treatment for progression or
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Neuroendocrine Carcinoma NCT00569127 Follow-Up - Southwest
Oncology Group Follow-Up Form - 2458259v1.0
relapse or a second primary, and prior to non-
protocol treatment grade >=3)
Yes
No
Adverse Events and Grades (If Yes,)
Comments
Comments
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Neuroendocrine Carcinoma NCT00569127 Follow-Up - Southwest
Oncology Group Follow-Up Form - 2458259v1.0
Neuroendocrine Carcinoma NCT00569127 Lab - Southwest Oncology
Group S0518 Tumor Markers Reporting Form - 2501340v1.0
Southwest Oncology Group S0518 Tumor Markers
Reporting Form
Octreotide and Interferon Alfa-2b or Bevacizumab in
Treating Patients With Metastatic or Locally Advanced,
High-Risk Neuroendocrine Tumor
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=19F77AA6-
99CC-36DB-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/7451
Southwest Oncology Group S0518
Tumor Markers Reporting Form
Header
SWOG Patient ID
SWOG Study No.
Registration Step
Patient Initials (L, F M)
Institution/Affiliate
Physician (Participating Group:)
Participating Group
Participating Group Study No.
Participating Group Patient ID (Instructions: All
dates are MONTH, DAY, YEAR. Explain any
blank fields or blank dates in the Comments
section. Place an X in appropriate boxes. Circle
AMENDED items in red and write AMENDED
across the top of the form.)
Chromogranin A
Was Chromogranin A assessed during this
reporting period
Yes
No
Chromogranin A assessment date
Chromogranin A Value (ng/ml)
Neuron Specific Enolase
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Was Neuron specific enolase assessed during
this reporting period
Yes
No
Neuron Specific Enolase assessment date
Neuron Specific Enolase Value (mcg/L)
Urinary 5hiaa
Was Urinary 5HIAA assessed during this
reporting period
Yes
No
Urinary 5HIAA assessment date
Urinary 5HIAA Value (mg/24hr)
Comments
Comments
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Neuroendocrine Carcinoma NCT00569127 Lab - Southwest Oncology
Group S0518 Tumor Markers Reporting Form - 2501340v1.0
Pancreatic Cancer NCT00075686 Pre-Study - S0205
Advanced Pancreas Carcinoma Prestudy Form - 2307178v3.0
S0205 Advanced Pancreas Carcinoma Prestudy Form
S0205 Gemcitabine With or Without Cetuximab as First-
Line Therapy in Treating Patients With Locally Advanced
Unresectable or Metastatic Adenocarcinoma of the
Pancreas
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=F2EB1888-
EFD9-210C-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/7455
S0205 Advanced Pancreas
Carcinoma Prestudy Form
Header
SWOG Patient ID
SWOG Study No.
Registration Step
Patient Initials (L, F M)
Institution/Affiliate
Physician
Description Of Disease
Date of initial pathologic diagnosis (of pancreatic
cancer)
Disease Status
Locally Advanced Unresectable (Locally
advanced unresectable)
Metastatic (Metastatic)
Height (cm)
Weight
BSA
Performance Status
Fully Active, Able To Carry On All Pre-
disease Performance Without
Restriction. (0)
Restricted In Physically Strenuous
Activity But Ambulatory And Able To
Carry Out Work Of A Light Or Sedentary
Nature, E.g., Light Housework, Office
Work. (1)
Ambulatory And Capable Of All Selfcare
1 / 4
But Unable To Carry Out Any Work
Activities. Up And About More Than 50%
Of Waking Hours. (2)
Capable Of Only Limited Selfcare,
Confined To Bed Or Chair More Than
50% Of Waking Hours. (3)
Completely Disabled. Cannot Carry On
Any Selfcare. Totally Confined To Bed Or
Chair. (4)
Dead (5)
Primary Site
Body Of Pancreas (Body of pancreas)
Diffuse (Diffuse)
Head Of Pancreas (Head of pancreas)
Other, Specify (Other)
Pancreas, Not Otherwise Specified
(Pancreas, NOS)
Tail Of Pancreas (Tail of pancreas)
Uncinate Process (Uncinate process)
Other, specify
Sites of involvement (select all that apply for
current disease)
Adjacent Viscera/vessels (Adjacent
viscera/vessels)
Bone (Bone)
Distant Lymph Nodes (Distant lymph
nodes)
Liver (Liver)
Lung (Lung)
Other Specify (Other)
Peritoneum (Peritoneum)
Primary Tumor/pancreas (Primary
tumor/pancreas)
Regional Lymph Nodes (Regional lymph
nodes)
Other, specify
Histologic Type
Ductal Adenocarcinoma (Ductal
adenocarcinoma)
Mixed Ductal-endocrine Carcinoma
(Mixed Ductal-Endocrine Carcinoma)
Neuroendocrine Carcinoma
(Neuroendocrine carcinoma)
Other Specify (Other)
Undifferentiated (anaplastic) Carcinoma
(Undifferentiated (anaplastic) carcinoma)
Other, specify
Histologic grade
Moderately Differentiated (Moderately
differentiated)
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Pancreatic Cancer NCT00075686 Pre-Study - S0205 Advanced
Pancreas Carcinoma Prestudy Form - 2307178v3.0
Poorly Differentiated (Poorly
differentiated)
Undifferentiated (Undifferentiated)
Unknown (Unknown)
Well Differentiated (Well differentiated)
Pathologic T stage (Note: Provide clinical T stage
if pathologic stage is unavailable.)
T0, According To Ajcc Criteria (T0)
T1, According To Ajcc Criteria (T1)
T2, According To Ajcc Criteria (T2)
T3, According To Ajcc Criteria (T3)
T4, According To Ajcc Criteria (T4)
Tis, According To Ajcc Criteria (Tis)
Tx, According To Ajcc Criteria (Tx)
Pathologic N stage
No Lymph Node Involvement According
To Ajcc Guidelines (use For Esophageal,
Gastric, And Pancreatic) (N0)
N1, According To Ajcc Criteria (N1)
Lymph Node Involvement Cannot Be
Assessed According To Ajcc Guidelines
(use For Esophageal, Gastric, And
Pancreatic) (NX)
Pathologic M stage
No Distant Metastases According To
Ajcc Guidelines (M0)
Distant Metastases Present According
To Ajcc Guidelines (M1)
Distant Metastases Presence Or
Absence Cannot Be Assessed According
To Ajcc Guidelines (Mx)
Prior Treatment Related To This Cancer
Prior Systemic Therapy
Yes
No
Agent (If yes,)
Prior systemic therapy start date
Prior systemic therapy stop date
Prior Radiation Therapy
Yes
No
Start Date
Stop Date
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Prior Pancreatomy
Yes
No
Prior panceatectomy date
Prior Immunotherapy
Yes
No
Comments
Comments
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Pancreatic Cancer NCT00075686 Treatment - SOUTHWEST ONCOLOGY
GROUP S0205 TREATMENT SUMMARY FORM - 2307260v3.0
SOUTHWEST ONCOLOGY GROUP S0205 TREATMENT
SUMMARY FORM
S0205 Gemcitabine With or Without Cetuximab as First-
Line Therapy in Treating Patients With Locally Advanced
Unresectable or Metastatic Adenocarcinoma of the
Pancreas
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=F2EB277F-
E272-2226-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/7456
SOUTHWEST ONCOLOGY GROUP
S0205 TREATMENT SUMMARY
FORM
Header
SWOG Patient ID
SWOG Study No.
Registration Step
Patient Initials (L, F M)
Institution/Affiliate
Physician
Participating Group Name
Participating Study No.
Participating Patient ID (Instructions: Please
complete this form after each cycle 1 cycle = 4
weeks. All dates are MONTH, DAY, YEAR.
Explain any blank dates or fields in a Comments
section. Place an X in appropriate boxes. Circle
AMENDED items in red and write AMENDED
across top of form.)
Status
Vital Status
Alive (Alive)
Dead (Dead)
Date of Last Contact or Death
Has the patient progressed per the definition in
Section 10.0 of the protocol?
1 / 3
Yes
No
Treatment
Which treatment did the patient receive?
Arm 1 (Arm 1)
Arm 2 (Arm 2)
Were there any dose modifications or
additions/omissions to protocol treatment?
No (No)
Yes, Planned (i.e., The Treatment Was
Changed According To Protocol
Guidelines) (Yes, planned)
Yes, Unplanned (i.e., The Treatment
Change Was Not Part Of Protocol
Guidelines) (Yes, unplanned)
Gemcitabine Use
cycle number
Treatment start date
Date of last treatment
Date agent administered
Agent total dose (per day)
Were there any delays in dose administration
Yes
No
Reason for Treatment Modification (If yes,)
Delay Per Protocol (Delay per protocol)
Interruption Due To Hypersensitivity
(Interruption due to hypersensitivity)
Other (Other)
Reduction Due To Toxicity (Reduction
due to toxicity)
Cetuximab Use: For Arm 1 Patients Only
cycle number
Treatment start date
Date of last treatment
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Date agent administered
Agent total dose (per day)
Were there any delays in dose administration
Yes
No
Reason for Treatment Modification (If yes,)
Delay Per Protocol (Delay per protocol)
Interruption Due To Hypersensitivity
(Interruption due to hypersensitivity)
Other (Other)
Reduction Due To Toxicity (Reduction
due to toxicity)
Hospitalization
Was patient hospitalized during this reporting
interval
Yes
No
Comments
Comments
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Registration - SOUTHWEST ONCOLOGY
GROUP HEADER FOOTER - 2320245v1.0
SOUTHWEST ONCOLOGY GROUP HEADER FOOTER
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=FCBF58BB-
6A9B-6FDA-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/7457
SOUTHWEST ONCOLOGY GROUP
HEADER FOOTER
Header
SWOG Patient ID
SWOG Study No.
Registration Step
Patient Initials (L, F M)
Institution/Affiliate
Physician
Participating Group Name
Participating Group Study No.
Participating Group Patient ID
Comments
Comments
1 / 1
Bladder Cancer NCT01224665 Pre-Study -
S1011 Prestudy Form (#8218) - 3152929v1.0
S1011 Prestudy Form (#8218)
Standard or Extended Pelvic Lymphadenectomy in Treating
Patients Undergoing Surgery for Invasive Bladder Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=93990004-
B6E8-D71A-E040-BB89AD433C84
All rights reserved. Please visit https://medical-data-
models.org/forms/7461
S1011 Prestudy Form (#8218)
Header
SWOG Patient ID
SWOG Study No.
Registration Step
Patient Initials (L, F M)
Institution/Affiliate
Physician
Participating Group Name
Participating Group Study No.
Participating Group Patient ID
Patient And Disease Description
Zubrod Performance Status Score (see section
10.5 of the protocol)
Normal Activity (0)
Symptoms, But Nearly Fully Ambulatory
(1)
Some Bed Time, But Needs To Be In
Bed <50% Of Normal Daytime (2)
Needs To Be In Bed > 50% Of Normal
Daytime (3)
Unable To Get Out Of Bed (4)
Height (cm)
Weight (kg)
Date of Chest X-ray (MM DD YYYY Please enter
date of chest x-ray to rule out visceral or nodal
metastatic disease)
1 / 4
Date of CT or MRI (MM DD YYYY Please enter
date of CT or MRI to rule out visceral or nodal
metastatic disease)
Date Current Staging Assessment Completed
(MM DD YYYY Please enter date of most recent
TURBT, bimanual exam or cross sectional
imaging for clinical staging of disease. For
patients who have received neoadjuvant
chemotherapy, please list the most recent prior to
the initiation of therapy)
Disease Description
Clinical T Stage
Tumor Invades Muscularis Propria (cT2)
Tumor Invades Perivesical Tissue (cT3)
Tumor Invades Prostatic Stroma, Uterus,
Vagina (cT4a)
Bimanual Exam Result
3 Dimensional Mass (3 dimensional
mass)
Fixed (Fixed)
Induration Only (Induration only)
Normal (Normal)
Histologic Type (Please select all that apply
based on TURBT or biopsy; pure squamous cell
carcinoma or pure adenocarcinoma not eligible)
Adenocarcinoma (Adenocarcinoma)
Micropapillary Transitional Cell
Carcinoma (Micropapillary carcinoma)
Other Specify (Other, specify)
Squamous Cell Carcinoma (Squamous
cell carcinoma)
Urothelial Carcinoma (Urothelial cell
carcinoma)
Other specify
Type of Variant Histology (if selected please
specify)
Adenocarcinoma (< 50%
Adenocarcinoma)
Micropapillary Transitional Cell
Carcinoma (< 50% Micropapillary
carcinoma)
Squamous Cell Carcinoma (< 50%
Squamous cell carcinoma)
Urothelial Carcinoma (< 50% Urothelial
cell carcinoma)
Adenocarcinoma (>= 50%
Adenocarcinoma)
Micropapillary Transitional Cell
Carcinoma (>= 50% Micropapillary
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carcinoma)
Squamous Cell Carcinoma (>= 50%
Squamous cell carcinoma)
Urothelial Carcinoma (>= 50% Urothelial
cell carcinoma)
Date of Planned Surgery (MM DD YYYY)
Laboratory Values
Peripheral Platelet Count (mcl)
WBC (x 10^3/ mcL)
Hemoglobin (g/dL)
Hematocrit (%)
Total Bilirubin (mg/dL)
Total Bilirubin ULN (mg/dL)
SGPT (ALT) (U/L)
SGPT (ALT) ULN (U/L)
Collection Date (MM DD YYYY)
Collection Date (MM DD YYYY)
Collection Date (MM DD YYYY)
Collection Date (MM DD YYYY)
Collection Date (MM DD YYYY)
Collection Date (MM DD YYYY)
Collection Date (MM DD YYYY)
Collection Date (MM DD YYYY)
SGOT (AST) (U/L)
SGOT (AST) ULN (U/L)
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Alkaline Phosphatase (U/L)
Alkaline Phosphatase ULN (U/L)
Laboratory Values1
Serum Creatinine (mg/dL)
Serum Creatinine ULN (mg/dL)
Collection Date (MM DD YYYY)
Prior Treatment Related To This Cancer
Prior Neoadjuvant Chemotherapy
Yes
No
Specify reason treatment not initiated
Neoadjuvant Treatment Related To This
Bladder Cancer
Chemotherapy Regimen (select all that apply)
Carboplatin (Carboplatin)
Cisplatin (Cisplatin)
Gemcitabine (Gemcitabine)
Doxorubicin Vinblastine Methotrexate
Cisplatin (MVAC)
Paclitaxel (Paclitaxel)
Specify agent (other)
Number of Cycles
Treatment Start Date (MM DD YYYY)
Date of Last Treatment (MM DD YYYY)
Comments
Comments
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Bladder Cancer NCT00445601 Follow-Up - S0337
Disease Assessment and Follow Up Form - 2388951v1.0
S0337 Disease Assessment and Follow Up Form
Gemcitabine After Surgery in Treating Patients With Newly
Diagnosed or Recurrent Bladder Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=FE24E804-
D667-471E-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/7462
S0337 Disease Assessment and
Follow Up Form
Header
SWOG Patient ID
SWOG Study No.
Registration Step
Patient Initials (L, F M)
Institution/Affiliate
Physician
Participating Group Name
Participating Group Study No.
Participating Group Patient ID
Vital Status
Vital Status
Alive (Alive)
Dead (Dead)
Date of last contact or death (If Vital status is
Dead, complete and submit Notice of Death
form.)
Has the patient had a documented clinical
assessment for this cancer (since submission of
the previous follow-up form)
Yes
No
Date of Last Clinical Assessment (If Yes,)
1 / 3
Has the patient developed a recurrence that has
not been previously reported
Yes
No
Disease Recurrence Date (If yes,)
Stage of Recurrence
Tumor Invades Subepithelial Connective
Tissue (T1)
Noninvasive Papillary Carcinoma (Ta)
Grade of Recurrence
Moderately Differentiated (Moderately
differentiated (G2))
Well Differentiated (Well differentiated
(G1))
Date of Metastatic Disease
Has the patient been diagnosed with progression
that has not been previously reported  (muscle
invasive disease per section 10 of the protocol)
Yes
No
Date of Progression (If yes,)
Stage of Progression
Moderately Differentiated (Moderately
differentiated (G2))
Poorly Differentiated (Poorly
differentiated (G3))
Undifferentiated (Undifferentiated (G4))
Well Differentiated (Well differentiated
(G1))
Has a new primary cancer or MDS been
diagnosed that has not been previously reported?
(myelodysplastic syndrome)
Yes
No
Date of Diagnosis (If Yes,)
New Primary Site
Has the patient received any non-protocol cancer
therapy not previously reported? (prior to
progression/relapse)
Yes
No
Date of First Non-Protocol Therapy (If Yes,)
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Agent Name (s:)
Has the patient experienced any severe long
term toxicity that has not been previously
reported? (prior to treatment for progression or
relapse or a second primary, and prior to non-
protocol treatment grade >=3)
Yes
No
Adverse Events and Grades (If Yes,)
Has the patient received a cystectomy that has
not been previously reported
Yes
No
Comments
Comments
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Prostate Cancer NCT00567580 Follow-Up - RTOG 0534 F1: Phase III STAD with
Pelvic LN or Prostate only RT for Rising PSA after Radical Prostatectomy Follow-up
Form - 2600005v1.0
RTOG 0534 F1: Phase III STAD with Pelvic LN or Prostate
only RT for Rising PSA after Radical Prostatectomy Follow-
up Form
Prostate Radiation Therapy or Short-Term Androgen
Deprivation Therapy and Pelvic Lymph Node Radiation
Therapy With or Without Prostate Radiation Therapy in
Treating Patients With a Rising PSA After Surgery for
Prostate Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=2A1468A9-
C541-1202-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/7464
RTOG 0534 F1: Phase III STAD with
Pelvic LN or Prostate only RT for
Rising PSA after Radical
Prostatectomy Follow-up Form
Unnamed2
RTOG Study No.
Case #
Institution Name
Institution No.
Patient Initials
RTOG Patient ID
Header
Amended Data
Yes
No
Unnamed 3
Patient's Vital Status
Alive (Alive)
Dead (Dead)
Date of Last Contact or Death
Primary Cause of Death
Due To Other Cause (Due to other
cause)
Due To Protocol Treatment (Due to
protocol treatment)
Due To This Disease (Due to this
disease)
1 / 50
Not Applicable (Not applicable)
Unknown (Unknown)
Due to other cause, specify
Has the patient had a documented clinical
assessment for this cancer (SINCE
SUBMISSION OF THE PREVIOUS FOLLOW-UP
FORM)
No (No)
Unknown (Unknown)
Yes (Yes)
Performance Status (ZUBROD 0-5)
Fully Active, Able To Carry On All Pre-
disease Performance Without
Restriction. (0)
Restricted In Physically Strenuous
Activity But Ambulatory And Able To
Carry Out Work Of A Light Or Sedentary
Nature, E.g., Light Housework, Office
Work. (1)
Ambulatory And Capable Of All Selfcare
But Unable To Carry Out Any Work
Activities. Up And About More Than 50%
Of Waking Hours. (2)
Capable Of Only Limited Selfcare,
Confined To Bed Or Chair More Than
50% Of Waking Hours. (3)
Completely Disabled. Cannot Carry On
Any Selfcare. Totally Confined To Bed Or
Chair. (4)
Dead (5)
Date
Unnamed Module 5
Has the patient been diagnosed with biochemical
recurrence since submission of the last follow-up
form
No (NO)
Unknown (Unknown)
Yes (YES)
Has the patient been diagnosed with a first local
recurrence (SINCE SUBMISSION OF THE LAST
FOLLOW-UP FORM)
No (NO)
Unknown (Unknown)
Yes (YES)
Date
Has the patient been diagnosed with a first local-
regional progression (pelvic node - recurrence or
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Form - 2600005v1.0
- SINCE SUBMISSION OF THE LAST FOLLOW-
UP FORM)
No (NO)
Unknown (Unknown)
Yes (YES)
Date
Site of first regional recurrence
External Iliac (External iliac)
Hypogastric (Hypogastric)
Internal Iliac (Internal iliac)
Other Specify (Other)
Other, specify
Method of Evaluation (DISTANT
PROGRESSION)
Mri (MRI (NMR))
Not Applicable (Not applicable)
Other (Other)
Pathologic (Pathologic)
Physical Exam (Physical exam)
Radiographic (Radiographic)
Method of Evaluation (DISTANT
PROGRESSION)
Mri (MRI (NMR))
Not Applicable (Not applicable)
Other (Other)
Pathologic (Pathologic)
Physical Exam (Physical exam)
Radiographic (Radiographic)
Method of Evaluation (DISTANT
PROGRESSION)
Mri (MRI (NMR))
Not Applicable (Not applicable)
Other (Other)
Pathologic (Pathologic)
Physical Exam (Physical exam)
Radiographic (Radiographic)
Other Specify
Other Specify
Other Specify
Has the patient been diagnosed with first distant
recurrence/progression? (SINCE SUBMISSION
OF THE LAST FOLLOW-UP FORM)
No (No)
Unknown (Unknown)
Yes (Yes)
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Date
Site of first distant progression
Bone (Bone)
Brain (Brain)
Liver (Liver)
Lung (Lung)
Lymph Node (Lymph Node (outside
pelvis))
Other (Other)
Other, specify
Unnamed Module 4a
PSA Date
PSA Value
Method of Assay
Abbott Labs (Abbott)
Bayer (Bayer)
Dpc (DPC)
Hybritech (Hybritech)
Other (Other)
Unknown (Unknown)
Has the patient had a prostatic fossa biopsy
No (No)
Not Done (Not done)
Unknown (Unknown)
Yes, Negative (Yes, negative)
Yes, Positive (Yes, positive)
Yes, Results Unknown (Yes, results
unknown)
Date of Biopsy (If yes,)
Palpable prostatic fossa mass
Equivocal (Equivocal)
No (No)
Not Evaluated (Not evaluated)
Unknown (Unknown)
Yes (Yes)
Testosterone
Abnormal (Abnormal)
Normal (Normal)
Not Done (Not done)
Unknown (Unknown)
Testosterone (Monthly assessment)
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Testosterone Lower Limit Normal
Testosterone Upper Limit Normal
Unit of Measure
Millimole Per Liter (mmol/L)
Nanograms Per Deciliter (ng/dL)
Nanograms Per Milliliter (ng/mL)
Not Otherwise Specified (NOS)
Unit of Measure
Millimole Per Liter (mmol/L)
Nanograms Per Deciliter (ng/dL)
Nanograms Per Milliliter (ng/mL)
Not Otherwise Specified (NOS)
Date
Baseline Lab Values (hematologic)
Testosterone (Monthly assessment)
SGPT (ALT) or SGOT (AST)
Abnormal (Abnormal)
Normal (Normal)
Not Done (Not done)
Unknown (Unknown)
Testosterone (Monthly assessment)
Test
Testosterone Lower Limit Normal
Testosterone Lower Limit Normal
Testosterone Upper Limit Normal
Testosterone Upper Limit Normal
Value
CBC
Abnormal (Abnormal)
Normal (Normal)
Not Done (Not done)
Unknown (Unknown)
Unit of Measure
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Millimole Per Liter (mmol/L)
Nanograms Per Deciliter (ng/dL)
Nanograms Per Milliliter (ng/mL)
Not Otherwise Specified (NOS)
Unit of Measure
Millimole Per Liter (mmol/L)
Nanograms Per Deciliter (ng/dL)
Nanograms Per Milliliter (ng/mL)
Not Otherwise Specified (NOS)
WBC (mm^3)
Date
Hemoglobin (g/dL)
Peripheral Platelet Count (mm^3)
Non-protocol Therapy
Is the patient receiving any non-protocol cancer
therapy not previously reported (PROSTATE If
yes, enter therapy type and date for each therapy
delivered during the follow-up period.)
No (No)
Unknown (Unknown)
Yes (Yes)
Non-Protocol Therapy Type
Chemotherapy (Chemotherapy)
Hormones (Hormones)
None (None)
Other Specify (Other, specify)
Radiation To Other Sites, Specify
(Radiation to other sites, specify)
Radiation To Pelvis (Radiation to pelvis)
Surgery (Surgery)
Date of First Non-Protocol Therapy
Specify
Unnamed Module 7
Has a new primary cancer or MDS been
diagnosed that has not been previously reported?
(MYELODYSPLASTIC SYNDROME)
No (No)
Unknown (Unknown)
Yes (Yes)
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Second Primary Tumor Site
Aml/mds (AML/MDS)
Bcc (BCC)
Bladder Is The Site Of Second Primary
Or Recurrent Tumor (bladder)
Brain Is The Site Of Second Primary Or
Recurrent Tumor (brain)
Colorectal (Colorectal)
Esophageal (Esophageal)
Gastric (Gastric)
Liver Is The Site Of Second Primary Or
Recurrent Tumor (liver)
Lung Is The Site Of Second Primary Or
Recurrent Tumor (lung)
Melanoma (Melanoma)
Nhl (NHL)
Other Hematologic (Other hematologic)
Other Solid (Other solid)
Pancreatic (Pancreatic)
Renal (Renal)
Squamous-skin (Squamous-skin)
Unknown Primary (Unknown primary)
Second Primary Cancer Date
Other specify
Report All Continuing Or New Adverse
Events
Any Treatment Related Adverse Events
No (No)
Unknown (Unknown)
Yes (Yes)
MedDRA Code (BASED ON CTC AE TERM)
CTC Adverse Event Term
Acidosis Nos (Acidosis (metabolic or
respiratory))
Capillary Leak Syndrome (Acute
vascular leak syndrome)
Adrenal Insufficiency (Adrenal
insufficiency)
Adult Respiratory Distress Syndrome
(Adult respiratory distress syndrome
(ARDS))
Blood Albumin Decreased (Albumin,
serum-low (hypoalbuminemia))
Alcohol Intolerance Syndrome
(antabuse-like Syndrome) (Alcohol
intolerance syndrome (antabuse-like
syndrome))
Blood Alkaline Phosphatase Nos
Increased (Alkaline phosphatase)
Alkalosis Nos (Alkalosis (metabolic or
7 / 50
Prostate Cancer NCT00567580 Follow-Up - RTOG 0534 F1: Phase III STAD with
Pelvic LN or Prostate only RT for Rising PSA after Radical Prostatectomy Follow-up
Form - 2600005v1.0
respiratory))
Hypersensitivity Nos (Allergic
reaction/hypersensitivity (including drug
fever))
Rhinitis Allergic Nos (Allergic rhinitis
(including sneezing, nasal stuffiness,
postnasal drip))
Allergy/immunology Other
(Allergy/Immunology-Other (Specify))
Alanine Aminotransferase Increased
(ALT, SGPT (serum glutamic pyruvic
transaminase))
Blood Amylase Increased (Amylase)
Anorexia (Anorexia)
Apnoea (Apnea)
Arachnoiditis
(Arachnoiditis/meningismus/radiculitis)
Arthritis Nos (Arthritis (non-septic))
Ascites (Ascites (non-malignant))
Aspiration (Aspiration)
Aspartate Aminotransferase Increased
(AST, SGOT (serum glutamic oxaloacetic
transaminase))
Ataxia Nec (Ataxia (incoordination))
Atelectasis (Atelectasis)
Atrophy, Skin (Atrophy, skin)
Atrophy, Subcutaneous Fat (Atrophy,
subcutaneous fat)
Auditory/ear Other (Auditory/Ear-Other
(Specify))
Autoimmune Disorder Nos (Autoimmune
reaction)
Blood Bicarbonate Decreased
(Bicarbonate, serum-low)
Blood Bilirubin Increased (Bilirubin
(hyperbilirubinemia))
Bladder Disorder Nos (Bladder spasms)
Blood/bone Marrow Other (Blood/Bone
Marrow-Other (Specify))
Bone Age (alteration In Bone Age) (Bone
age (alteration in bone age))
Bone Growth: Femoral Head; Slipped
Capital Femoral Epiphysis (Bone growth:
femoral head; slipped capital femoral
epiphysis)
Bone Growth: Limb Length Discrepancy
(Bone growth: limb length discrepancy)
Bone Growth: Spine Kyphosis/lordosis
(Bone growth: spine kyphosis/lordosis)
Bone Marrow Depression Nos (Bone
marrow cellularity)
Bone: Spine-scoliosis (Bone: spine-
scoliosis)
Brachial Plexopathy (Brachial
plexopathy)
Breast Function/lactation (Breast
function/lactation)
Breast Nipple/areolar Deformity (Breast
nipple/areolar deformity)
Breast Volume/hypoplasia (Breast
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volume/hypoplasia)
Bronchospasm, Wheezing
(Bronchospasm, wheezing)
Ecchymosis (Bruising (in absence of
grade 3 or 4 thrombocytopenia))
Burn (Burn)
Hypercalcaemia (Calcium, serum-high
(hypercalcemia))
Hypocalcaemia (Calcium, serum-low
(hypocalcemia))
Pulmonary Function Test Nos Decreased
(Carbon monoxide diffusion capacity
(DL(co)))
Arrhythmia Nos (Cardiac Arrhythmia-
Other (Specify))
Cardiac General Other (Cardiac
General-Other (Specify))
Myocardial Ischaemia (Cardiac
ischemia/infarction)
Cardiac Troponin I Increased (Cardiac
troponin I (cTnI))
Cardiac Troponin T Increased (Cardiac
troponin T (cTnT))
Cardiopulmonary Arrest, Cause
Unknown (non-fatal) (Cardiopulmonary
arrest, cause unknown (non-fatal))
Cataract Nec (Cataract)
Cd4 Lymphocytes Decreased (CD4
count)
Cervical Spine-range Of Motion (Cervical
spine-range of motion)
Chelitis (Cheilitis)
Cholecystitis (Cholecystitis)
Hypercholesteraemia (Cholesterol,
serum-high (hypercholesteremia))
Chyle Or Lymph Leakage (Chyle or
lymph leakage)
Chylothorax (Chylothorax)
Cerebral Ischaemia (CNS
cerebrovascular ischemia)
Cns Necrosis/cystic Progression (CNS
necrosis/cystic progression)
Coagulation Disorder Nos (Coagulation-
Other (Specify))
Learning Disorder Nos (Cognitive
disturbance)
Colitis Nos (Colitis)
Colitis, Infectious (e.g., Clostridium
Difficile) (Colitis, infectious (e.g.,
Clostridium difficile))
Ventricular Asystole (Conduction
abnormality/Atrioventricular heart block -
Asystole)
Conduction Abnormality/atrioventricular
Heart Block (Conduction
abnormality/Atrioventricular heart block -
AV block-first degree)
Conduction Abnormality/atrioventricular
Heart Block - Av Block-second Degree
Mobitz Type I (wenckebach) (Conduction
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abnormality/Atrioventricular heart block -
AV block-Second degree Mobitz Type I
(Wenckebach))
Conduction Abnormality/atrioventricular
Heart Block (Conduction
abnormality/Atrioventricular heart block -
AV block-second degree Mobitz Type II)
Conduction Abnormality/atrioventricular
Heart Block (Conduction
abnormality/Atrioventricular heart block -
AV block-third degree (complete AV
block))
Conduction Abnormality/atrioventricular
Heart Block (Conduction
abnormality/Atrioventricular heart block -
Conduction abnormality NOS)
Conduction Abnormality/atrioventricular
Heart Block (Conduction
abnormality/Atrioventricular heart block -
Sick sinus syndrome)
Conduction Abnormality/atrioventricular
Heart Block (Conduction
abnormality/Atrioventricular heart block -
Stokes-Adams syndrome)
Conduction Abnormality/atrioventricular
Heart Block (Conduction
abnormality/Atrioventricular heart block -
Wolff-Parkinson-White syndrome)
Confusion (Confusion)
Constipation (Constipation)
Constitutional Symptoms Other
(Constitutional Symptoms-Other
(Specify))
Cough (Cough)
Blood Creatine Phosphokinase
Increased (CPK (creatine
phosphokinase))
Blood Creatinine Increased (Creatinine)
Cushingoid (Cushingoid appearance
(e.g., moon face, buffalo hump,
centripetal obesity, cutaneous striae))
Cystitis (Cystitis)
Cytokine Release Syndrome/acute
Infusion Reaction (Cytokine release
syndrome/acute infusion reaction)
Death Not Associated With Ctcae Term
(Death not associated with CTCAE term
- Death NOS)
Death Not Associated With Ctcae Term
(Death not associated with CTCAE term
- Disease progression NOS)
Death Not Associated With Ctcae Term
(Death not associated with CTCAE term
- Multi-organ failure)
Death Not Associated With Ctcae Term
(Death not associated with CTCAE term
- Sudden death)
Dehydration (Dehydration)
Dental: Dentures Or Prosthesis (Dental:
dentures or prosthesis)
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Dental: Periodontal Disease (Dental:
periodontal disease)
Dental: Teeth (Dental: teeth)
Dental: Teeth Development (Dental:
teeth development)
Dermal Change Lymphedema,
Phlebolymphedema (Dermal change
lymphedema, phlebolymphedema)
Dermatology/skin Other
(Dermatology/Skin-Other (Specify))
Diarrhoea Nos (Diarrhea)
Disseminated Intravascular Coagulation
(DIC (disseminated intravascular
coagulation))
Distention/bloating, Abdominal
(Distention/bloating, abdominal)
Dizziness (exc Vertigo) (Dizziness)
Dry Eye Nec (Dry eye syndrome)
Dry Mouth (Dry mouth/salivary gland
(xerostomia))
Dry Skin (Dry skin)
Dysphagia (Dysphagia (difficulty
swallowing))
Dyspnoea Nos (Dyspnea (shortness of
breath))
Edema, Larynx (Edema, larynx)
Edema: Head And Neck (Edema: head
and neck)
Oedema Nos (Edema: limb)
Edema: Trunk/genital (Edema:
trunk/genital)
Edema: Viscera (Edema: viscera)
Ejaculatory Dysfunction (Ejaculatory
dysfunction)
Encephalopathy (Encephalopathy)
Endocrine Other (Endocrine-Other
(Specify))
Enteritis (inflammation Of The Small
Bowel) (Enteritis (inflammation of the
small bowel))
Impotence (Erectile dysfunction)
Oesophagitis Nos (Esophagitis)
Exostosis (Exostosis)
Extrapyramidal Disorder Nec
(Extrapyramidal/involuntary
movement/restlessness)
Extremity-lower (gait/walking) (Extremity-
lower (gait/walking))
Extremity-upper (function) (Extremity-
upper (function))
Eyelid Dysfunction (Eyelid dysfunction)
Fatigue (Fatigue (asthenia, lethargy,
malaise))
Febrile Neutropenia (fever Of Unknown
Origin Without Clinically Or
Microbiologically Documented Infection)
(anc <1.0 X 10^9/l, Fever >=38.5
Degrees C) (Febrile neutropenia)
Feminization (Feminization of male)
Forced Expiratory Volume Decreased
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(FEV(1))
Pyrexia (Fever (in the absence of
neutropenia, where neutropenia is
defined as ANC <1.0 x 10^9/L))
Blood Fibrinogen Decreased
(Fibrinogen)
Fibrosis-cosmesis (Fibrosis-cosmesis)
Fibrosis-deep Connective Tissue
(Fibrosis-deep connective tissue)
Fistula, Gi (Fistula, GI - Abdomen NOS)
Anal Fistula (Fistula, GI - Anus)
Fistula, Gi (Fistula, GI - Biliary tree)
Fistula, Gi (Fistula, GI -
Colon/cecum/appendix)
Intestinal Fistula (Fistula, GI -
Duodenum)
Tracheo-oesophageal Fistula Nos
(Fistula, GI - Esophagus)
Fistula, Gi (Fistula, GI - Gallbladder)
Fistula, Gi (Fistula, GI - Ileum)
Fistula, Gi (Fistula, GI - Jejunum)
Fistula, Gi (Fistula, GI - Oral cavity)
Fistula, Gi (Fistula, GI - Pancreas)
Fistula, Gi (Fistula, GI - Pharynx)
Fistula, Gi (Fistula, GI - Rectum)
Fistula, Gi (Fistula, GI - Salivary gland)
Fistula, Gi (Fistula, GI - Small bowel
NOS)
Fistula, Gi (Fistula, GI - Stomach)
Fistula, Gu (Fistula, GU - Bladder)
Fistula, Gu (Fistula, GU - Genital tract-
female)
Fistula, Gu (Fistula, GU - Kidney)
Fistula, Gu (Fistula, GU - Ureter)
Fistula, Gu (Fistula, GU - Urethra)
Fistula, Gu (Fistula, GU - Uterus)
Urogenital Fistula (Fistula, GU - Vagina)
Fistula, Pulmonary/upper Respiratory
(Fistula, pulmonary/upper respiratory -
Bronchus)
Fistula, Pulmonary/upper Respiratory
(Fistula, pulmonary/upper respiratory -
Larynx)
Fistula, Pulmonary/upper Respiratory
(Fistula, pulmonary/upper respiratory -
Lung)
Fistula, Pulmonary/upper Respiratory
(Fistula, pulmonary/upper respiratory -
Oral cavity)
Fistula, Pulmonary/upper Respiratory
(Fistula, pulmonary/upper respiratory -
Pharynx)
Fistula, Pulmonary/upper Respiratory
(Fistula, pulmonary/upper respiratory -
Pleura)
Fistula, Pulmonary/upper Respiratory
(Fistula, pulmonary/upper respiratory -
Trachea)
Flatulence (Flatulence)
Flu-like Syndrome (Flu-like syndrome)
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Flushing (Flushing)
Fracture (Fracture)
Gastritis Nos (Gastritis (including bile
reflux gastritis))
Gastrointestinal Other (Gastrointestinal-
Other (Specify))
Gamma-glutamyltransferase Increased
(GGT (gamma-glutamyl transpeptidase))
Glaucoma Nos (Glaucoma)
Glomerular Filtration Rate (Glomerular
filtration rate)
Hyperglycaemia Nos (Glucose, serum-
high (hyperglycemia))
Hypoglycaemia Nos (Glucose, serum-
low (hypoglycemia))
Growth And Development Other (Growth
and Development-Other (Specify))
Growth Velocity (reduction In Growth
Velocity) (Growth velocity (reduction in
growth velocity))
Gynaecomastia (Gynecomastia)
Alopecia (Hair loss/Alopecia (scalp or
body))
Haptoglobin Decreased (Haptoglobin)
Hearing: Patients With/without Baseline
Audiogram And Enrolled In A Monitoring
Program (Hearing: patients with/without
baseline audiogram and enrolled in a
monitoring program)
Hearing: Patients Without Baseline
Audiogram And Not Enrolled In A
Monitoring Program (Hearing: patients
without baseline audiogram and not
enrolled in a monitoring program)
Dyspepsia (Heartburn/dyspepsia)
Hematoma (Hematoma)
Haemoglobin Decreased (Hemoglobin)
Haemoglobinuria Present
(Hemoglobinuria)
Hemolysis Nos (Hemolysis (e.g.,
immune hemolytic anemia, drug related
hemolysis))
Haemorrhagic Stroke (Hemorrhage,
CNS)
Melaena (Hemorrhage, GI - Abdomen
NOS)
Hemorrhage, Gi (Hemorrhage, GI -
Anus)
Hemorrhage, Gi (Hemorrhage, GI -
Biliary tree)
Hemorrhage, Gi (Hemorrhage, GI -
Cecum/appendix)
Hemorrhage, Gi (Hemorrhage, GI -
Colon)
Hemorrhage, Gi (Hemorrhage, GI -
Duodenum)
Hemorrhage, Gi (Hemorrhage, GI -
Esophagus)
Hemorrhage, Gi (Hemorrhage, GI -
Ileum)
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Hemorrhage, Gi (Hemorrhage, GI -
Jejunum)
Hemorrhage, Gi (Hemorrhage, GI - Liver)
Hemorrhage, Gi (Hemorrhage, GI -
Lower GI NOS)
Hemorrhage, Gi (Hemorrhage, GI - Oral
cavity)
Hemorrhage, Gi (Hemorrhage, GI -
Pancreas)
Hemorrhage, Gi (Hemorrhage, GI -
Peritoneal cavity)
Rectal Bleeding (Hemorrhage, GI -
Rectum)
Hemorrhage, Gi (Hemorrhage, GI -
Stoma)
Haematemesis (Hemorrhage, GI -
Stomach)
Hemorrhage, Gi (Hemorrhage, GI -
Upper GI NOS)
Hemorrhage, Gi (Hemorrhage, GI -
Varices (esophageal))
Hemorrhage, Gi (Hemorrhage, GI -
Varices (rectal))
Hemorrhage, Gu (Hemorrhage, GU -
Bladder)
Hemorrhage, Gu (Hemorrhage, GU -
Fallopian tube)
Hemorrhage, Gu (Hemorrhage, GU -
Kidney)
Hemorrhage, Gu (Hemorrhage, GU -
Ovary)
Hemorrhage, Gu (Hemorrhage, GU -
Prostate)
Hemorrhage, Gu (Hemorrhage, GU -
Retroperitoneum)
Hemorrhage, Gu (Hemorrhage, GU -
Spermatic cord)
Hemorrhage, Gu (Hemorrhage, GU -
Stoma)
Hemorrhage, Gu (Hemorrhage, GU -
Testes)
Hemorrhage, Gu (Hemorrhage, GU -
Ureter)
Hemorrhage, Gu (Hemorrhage, GU -
Urethra)
Haematuria Present (Hemorrhage, GU -
Urinary NOS)
Hemorrhage, Gu (Hemorrhage, GU -
Uterus)
Vaginal Haemorrhage (Hemorrhage, GU
- Vagina)
Hemorrhage, Gu (Hemorrhage, GU - Vas
deferens)
Hemorrhage, Pulmonary/upper
Respiratory (Hemorrhage,
pulmonary/upper respiratory -
Bronchopulmonary NOS)
Hemorrhage, Pulmonary/upper
Respiratory (Hemorrhage,
pulmonary/upper respiratory - Bronchus)
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Hemorrhage, Pulmonary/upper
Respiratory (Hemorrhage,
pulmonary/upper respiratory - Larynx)
Hemorrhage, Pulmonary/upper
Respiratory (Hemorrhage,
pulmonary/upper respiratory - Lung)
Hemorrhage, Pulmonary/upper
Respiratory (Hemorrhage,
pulmonary/upper respiratory -
Mediastinum)
Epistaxis (Hemorrhage, pulmonary/upper
respiratory - Nose)
Hemorrhage, Pulmonary/upper
Respiratory (Hemorrhage,
pulmonary/upper respiratory - Pharynx)
Hemorrhage, Pulmonary/upper
Respiratory (Hemorrhage,
pulmonary/upper respiratory - Pleura)
Haemoptysis (Hemorrhage,
pulmonary/upper respiratory -
Respiratory tract NOS)
Hemorrhage, Pulmonary/upper
Respiratory (Hemorrhage,
pulmonary/upper respiratory - Stoma)
Hemorrhage, Pulmonary/upper
Respiratory (Hemorrhage,
pulmonary/upper respiratory - Trachea)
Post-operative Haemorrhage
(Hemorrhage/bleeding associated with
surgery, intra-operative or post-operative)
Hemorrhage/bleeding Other
(Hemorrhage/Bleeding-Other (Specify))
Hemorrhoids (Hemorrhoids)
Hepatobiliary/pancreas Other
(Hepatobiliary/Pancreas-Other (Specify))
Hiccups (Hiccoughs (hiccups, singultus))
Menopausal Symptoms (Hot
flashes/flushes)
Hydrocephalus (Hydrocephalus)
Skin Discolouration (Hyperpigmentation)
Hypertension Nos (Hypertension)
Hypopigmentation (Hypopigmentation)
Hypotension Nos (Hypotension)
Hypothermia (Hypothermia)
Hypoxia (Hypoxia)
Ileus (Ileus, GI (functional obstruction of
bowel, i.e., neuroconstipation))
Incontinence, Anal (Incontinence, anal)
Urinary Incontinence (Incontinence,
urinary)
Induration/fibrosis (skin And
Subcutaneous Tissue)
(Induration/fibrosis (skin and
subcutaneous tissue))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Abdomen NOS)
15 / 50
Prostate Cancer NCT00567580 Follow-Up - RTOG 0534 F1: Phase III STAD with
Pelvic LN or Prostate only RT for Rising PSA after Radical Prostatectomy Follow-up
Form - 2600005v1.0
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Anal/perianal)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Appendix)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Artery)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Biliary tree)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Bladder (urinary))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Blood)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Bone (osteomyelitis))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Brain (encephalitis,
infectious))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Brain + Spinal cord
(encephalomyelitis))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
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microbiologically) with Grade 3 or 4
neutrophils - Bronchus)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Catheter-related)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Cecum)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Cervix)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Colon)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Conjunctiva)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Cornea)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Dental-tooth)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Duodenum)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Esophagus)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
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microbiologically) with Grade 3 or 4
neutrophils - External ear (otitis externa))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Eye NOS)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Fallopian tube)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Foreign body (e.g., graft,
implant, prosthesis, stent))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Gallbladder (cholecystitis))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Heart (endocarditis))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Ileum)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Jejunum)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Joint)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Kidney)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
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(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Larynx)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Lens)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Lip/perioral)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Liver)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Lung (pneumonia))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Lymphatic)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Mediastinum NOS)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Meninges (meningitis))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Middle ear (otitis media))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Mucosa)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
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(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Muscle (infection myositis))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Neck NOS)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Nerve-cranial)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Nerve-peripheral)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Nose)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Oral cavity-gums
(gingivitis))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Pancreas)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Paranasal)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Pelvis NOS)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Penis)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
20 / 50
Prostate Cancer NCT00567580 Follow-Up - RTOG 0534 F1: Phase III STAD with
Pelvic LN or Prostate only RT for Rising PSA after Radical Prostatectomy Follow-up
Form - 2600005v1.0
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Peristomal)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Peritoneal cavity)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Pharynx)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Pleura (empyema))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Prostate)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Rectum)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Salivary gland)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Scrotum)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Sinus)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Skin (cellulitis))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
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Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Small bowel NOS)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Soft tissue NOS)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Spinal cord (myelitis))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Spleen)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Stomach)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Trachea)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Ungual (nails))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Upper aerodigestive NOS)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Upper airway NOS)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Ureter)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
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Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Urethra)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Urinary tract NOS)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Uterus)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Vagina)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Vein)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Vulva)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Wound)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Abdomen
NOS)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils -
Anal/perianal)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Appendix)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Artery)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Biliary tree)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Bladder
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(urinary))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Blood)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Bone
(osteomyelitis))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Brain
(encephalitis, infectious))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Brain +
Spinal cord (encephalomyelitis))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Bronchus)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Catheter-
related)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Cecum)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Cervix)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Colon)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils -
Conjunctiva)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Cornea)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Dental-
tooth)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Duodenum)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Esophagus)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - External ear
(otitis externa))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Eye NOS)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Fallopian
tube)
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Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Foreign
body (e.g., graft, implant, prosthesis,
stent))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Gallbladder
(cholecystitis))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Heart
(endocarditis))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Ileum)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Jejunum)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Joint)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Kidney)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Larynx)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Lens)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Lip/perioral)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Liver)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Lung
(pneumonia))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Lymphatic)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils -
Mediastinum NOS)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Meninges
(meningitis))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Middle ear
(otitis media))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Mucosa)
Infection With Normal Anc Or Grade 1 Or
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2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Muscle
(infection myositis))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Neck NOS)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Nerve-
cranial)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Nerve-
peripheral)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Nose)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Oral cavity-
gums (gingivitis))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Pancreas)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Paranasal)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Pelvis NOS)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Penis)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Peristomal)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Peritoneal
cavity)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Pharynx)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Pleura
(empyema))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Prostate)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Rectum)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Salivary
gland)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Scrotum)
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Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Sinus)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Skin
(cellulitis))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Small bowel
NOS)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Soft tissue
NOS)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Spinal cord
(myelitis))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Spleen)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Stomach)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Trachea)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Ungual
(nails))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Upper
aerodigestive NOS)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Upper
airway NOS)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Ureter)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Urethra)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Urinary
tract NOS)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Uterus)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Vagina)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Vein)
Infection With Normal Anc Or Grade 1 Or
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2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Vulva)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Wound)
Infection With Unknown Anc (Infection
with unknown ANC - Abdomen NOS)
Infection With Unknown Anc (Infection
with unknown ANC - Anal/perianal)
Infection With Unknown Anc (Infection
with unknown ANC - Appendix)
Infection With Unknown Anc (Infection
with unknown ANC - Artery)
Infection With Unknown Anc (Infection
with unknown ANC - Biliary tree)
Infection With Unknown Anc (Infection
with unknown ANC - Bladder (urinary))
Infection With Unknown Anc (Infection
with unknown ANC - Blood)
Infection With Unknown Anc (Infection
with unknown ANC - Bone
(osteomyelitis))
Infection With Unknown Anc (Infection
with unknown ANC - Brain (encephalitis,
infectious))
Infection With Unknown Anc (Infection
with unknown ANC - Brain + Spinal cord
(encephalomyelitis))
Infection With Unknown Anc (Infection
with unknown ANC - Bronchus)
Implant Infection (Infection with unknown
ANC - Catheter-related)
Infection With Unknown Anc (Infection
with unknown ANC - Cecum)
Infection With Unknown Anc (Infection
with unknown ANC - Cervix)
Infection With Unknown Anc (Infection
with unknown ANC - Colon)
Infection With Unknown Anc (Infection
with unknown ANC - Conjunctiva)
Infection With Unknown Anc (Infection
with unknown ANC - Cornea)
Infection With Unknown Anc (Infection
with unknown ANC - Dental-tooth)
Infection With Unknown Anc (Infection
with unknown ANC - Duodenum)
Infection With Unknown Anc (Infection
with unknown ANC - Esophagus)
Infection With Unknown Anc (Infection
with unknown ANC - External ear (otitis
externa))
Infection With Unknown Anc (Infection
with unknown ANC - Eye NOS)
Infection With Unknown Anc (Infection
with unknown ANC - Fallopian tube)
Infection With Unknown Anc (Infection
with unknown ANC - Foreign body (e.g.,
graft, implant, prosthesis, stent))
Infection With Unknown Anc (Infection
with unknown ANC - Gallbladder
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(cholecystitis))
Infection With Unknown Anc (Infection
with unknown ANC - Heart
(endocarditis))
Infection With Unknown Anc (Infection
with unknown ANC - Ileum)
Infection With Unknown Anc (Infection
with unknown ANC - Jejunum)
Infection With Unknown Anc (Infection
with unknown ANC - Joint)
Infection With Unknown Anc (Infection
with unknown ANC - Kidney)
Infection With Unknown Anc (Infection
with unknown ANC - Larynx)
Infection With Unknown Anc (Infection
with unknown ANC - Lens)
Infection With Unknown Anc (Infection
with unknown ANC - Lip/perioral)
Infection With Unknown Anc (Infection
with unknown ANC - Liver)
Infection With Unknown Anc (Infection
with unknown ANC - Lung (pneumonia))
Infection With Unknown Anc (Infection
with unknown ANC - Lymphatic)
Infection With Unknown Anc (Infection
with unknown ANC - Mediastinum NOS)
Infection With Unknown Anc (Infection
with unknown ANC - Meninges
(meningitis))
Infection With Unknown Anc (Infection
with unknown ANC - Middle ear (otitis
media))
Infection With Unknown Anc (Infection
with unknown ANC - Mucosa)
Infection With Unknown Anc (Infection
with unknown ANC - Muscle (infection
myositis))
Infection With Unknown Anc (Infection
with unknown ANC - Neck NOS)
Infection With Unknown Anc (Infection
with unknown ANC - Nerve-cranial)
Infection With Unknown Anc (Infection
with unknown ANC - Nerve-peripheral)
Infection With Unknown Anc (Infection
with unknown ANC - Nose)
Infection With Unknown Anc (Infection
with unknown ANC - Oral cavity-gums
(gingivitis))
Infection With Unknown Anc (Infection
with unknown ANC - Pancreas)
Infection With Unknown Anc (Infection
with unknown ANC - Paranasal)
Infection With Unknown Anc (Infection
with unknown ANC - Pelvis NOS)
Infection With Unknown Anc (Infection
with unknown ANC - Penis)
Infection With Unknown Anc (Infection
with unknown ANC - Peristomal)
Infection With Unknown Anc (Infection
with unknown ANC - Peritoneal cavity)
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Infection With Unknown Anc (Infection
with unknown ANC - Pharynx)
Infection With Unknown Anc (Infection
with unknown ANC - Pleura (empyema))
Infection With Unknown Anc (Infection
with unknown ANC - Prostate)
Infection With Unknown Anc (Infection
with unknown ANC - Rectum)
Infection With Unknown Anc (Infection
with unknown ANC - Salivary gland)
Infection With Unknown Anc (Infection
with unknown ANC - Scrotum)
Infection With Unknown Anc (Infection
with unknown ANC - Sinus)
Infection With Unknown Anc (Infection
with unknown ANC - Skin (cellulitis))
Infection With Unknown Anc (Infection
with unknown ANC - Small bowel NOS)
Infection With Unknown Anc (Infection
with unknown ANC - Soft tissue NOS)
Infection With Unknown Anc (Infection
with unknown ANC - Spinal cord
(myelitis))
Infection With Unknown Anc (Infection
with unknown ANC - Spleen)
Infection With Unknown Anc (Infection
with unknown ANC - Stomach)
Infection With Unknown Anc (Infection
with unknown ANC - Trachea)
Infection With Unknown Anc (Infection
with unknown ANC - Ungual (nails))
Infection With Unknown Anc (Infection
with unknown ANC - Upper aerodigestive
NOS)
Infection With Unknown Anc (Infection
with unknown ANC - Upper airway NOS)
Infection With Unknown Anc (Infection
with unknown ANC - Ureter)
Infection With Unknown Anc (Infection
with unknown ANC - Urethra)
Infection With Unknown Anc (Infection
with unknown ANC - Urinary tract NOS)
Infection With Unknown Anc (Infection
with unknown ANC - Uterus)
Infection With Unknown Anc (Infection
with unknown ANC - Vagina)
Infection With Unknown Anc (Infection
with unknown ANC - Vein)
Infection With Unknown Anc (Infection
with unknown ANC - Vulva)
Culture Wound Positive (Infection with
unknown ANC - Wound)
Infection Nos (Infection-Other (Specify))
Infertility/sterility (Infertility/sterility)
Injection Site Reaction Nos (Injection site
reaction/extravasation changes)
Prothrombin Time Prolonged (INR
(International Normalized Ratio of
prothrombin time))
Insomnia Nec (Insomnia)
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Intra-operative Injury (Intra-operative
injury - Abdomen NOS)
Intra-operative Injury (Intra-operative
injury - Adrenal gland)
Intra-operative Injury (Intra-operative
injury - Anal sphincter)
Intra-operative Injury (Intra-operative
injury - Anus)
Intra-operative Injury (Intra-operative
injury - Appendix)
Intra-operative Injury (Intra-operative
injury - Artery NOS)
Intra-operative Injury (Intra-operative
injury - Artery-aorta)
Intra-operative Injury (Intra-operative
injury - Artery-carotid)
Intra-operative Injury (Intra-operative
injury - Artery-cerebral)
Intra-operative Injury (Intra-operative
injury - Artery-extremity (lower))
Intra-operative Injury (Intra-operative
injury - Artery-extremity (upper))
Intra-operative Injury (Intra-operative
injury - Artery-hepatic)
Intra-operative Injury (Intra-operative
injury - Artery-major visceral artery)
Intra-operative Injury (Intra-operative
injury - Artery-pulmonary)
Intra-operative Injury (Intra-operative
injury - Biliary tree NOS)
Intra-operative Injury (Intra-operative
injury - Biliary tree-common bile duct)
Intra-operative Injury (Intra-operative
injury - Biliary tree-common hepatic duct)
Intra-operative Injury (Intra-operative
injury - Biliary tree-left hepatic duct)
Intra-operative Injury (Intra-operative
injury - Biliary tree-right hepatic duct)
Bladder Perforation Postoperative (Intra-
operative injury - Bladder)
Intra-operative Injury (Intra-operative
injury - Bone)
Intra-operative Injury (Intra-operative
injury - Brachial plexus)
Intra-operative Injury (Intra-operative
injury - Brain)
Intra-operative Injury (Intra-operative
injury - Breast)
Intra-operative Injury (Intra-operative
injury - Bronchus)
Intra-operative Injury (Intra-operative
injury - Cartilage)
Intra-operative Injury (Intra-operative
injury - Cecum)
Intra-operative Injury (Intra-operative
injury - Cervix)
Intra-operative Injury (Intra-operative
injury - CN I (olfactory))
Intra-operative Injury (Intra-operative
injury - CN II (optic))
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Intra-operative Injury (Intra-operative
injury - CN III (oculomotor))
Intra-operative Injury (Intra-operative
injury - CN IV (trochlear))
Intra-operative Injury (Intra-operative
injury - CN IX (glossopharyngeal) motor
pharynx)
Intra-operative Injury (Intra-operative
injury - CN IX (glossopharyngeal)
sensory ear-pharynx-tongue)
Intra-operative Injury (Intra-operative
injury - CN V (trigeminal) motor)
Intra-operative Injury (Intra-operative
injury - CN V (trigeminal) sensory)
Intra-operative Injury (Intra-operative
injury - CN VI (abducens))
Intra-operative Injury (Intra-operative
injury - CN VII (facial) motor-face)
Intra-operative Injury (Intra-operative
injury - CN VII (facial) sensory-taste)
Intra-operative Injury (Intra-operative
injury - CN VIII (vestibulocochlear))
Intra-operative Injury (Intra-operative
injury - CN X (vagus))
Intra-operative Injury (Intra-operative
injury - CN XI (spinal accessory))
Intra-operative Injury (Intra-operative
injury - CN XII (hypoglossal))
Intra-operative Injury (Intra-operative
injury - Colon)
Intra-operative Injury (Intra-operative
injury - Conjunctiva)
Intra-operative Injury (Intra-operative
injury - Cornea)
Intra-operative Injury (Intra-operative
injury - Cranial nerve or branch NOS)
Intra-operative Injury (Intra-operative
injury - Duodenum)
Intra-operative Injury (Intra-operative
injury - Esophagus)
Intra-operative Injury (Intra-operative
injury - Extremity-lower)
Intra-operative Injury (Intra-operative
injury - Extremity-upper)
Intra-operative Injury (Intra-operative
injury - Eye NOS)
Intra-operative Injury (Intra-operative
injury - Face NOS)
Intra-operative Injury (Intra-operative
injury - Fallopian tube)
Intra-operative Injury (Intra-operative
injury - Gallbladder)
Intra-operative Injury (Intra-operative
injury - Gingiva)
Intra-operative Injury (Intra-operative
injury - Heart)
Intra-operative Injury (Intra-operative
injury - Ileum)
Intra-operative Injury (Intra-operative
injury - Inner ear)
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Intra-operative Injury (Intra-operative
injury - Jejunum)
Intra-operative Injury (Intra-operative
injury - Joint)
Intra-operative Injury (Intra-operative
injury - Kidney)
Intra-operative Injury (Intra-operative
injury - Larynx)
Intra-operative Injury (Intra-operative
injury - Lens)
Intra-operative Injury (Intra-operative
injury - Ligament)
Intra-operative Injury (Intra-operative
injury - Lingual)
Intra-operative Injury (Intra-operative
injury - Lip/perioral area)
Intra-operative Injury (Intra-operative
injury - Liver)
Intra-operative Injury (Intra-operative
injury - Lung)
Intra-operative Injury (Intra-operative
injury - Lung thoracic)
Intra-operative Injury (Intra-operative
injury - Mediastinum)
Intra-operative Injury (Intra-operative
injury - Meninges)
Intra-operative Injury (Intra-operative
injury - Middle ear)
Intra-operative Injury (Intra-operative
injury - Muscle)
Intra-operative Injury (Intra-operative
injury - Nails)
Intra-operative Injury (Intra-operative
injury - Nasal cavity)
Intra-operative Injury (Intra-operative
injury - Nasopharynx)
Intra-operative Injury (Intra-operative
injury - Neck NOS)
Intra-operative Injury (Intra-operative
injury - Nose)
Intra-operative Injury (Intra-operative
injury - Oral)
Intra-operative Injury (Intra-operative
injury - Oral cavity NOS)
Intra-operative Injury (Intra-operative
injury - Outer ear NOS)
Intra-operative Injury (Intra-operative
injury - Outer ear-pinna)
Intra-operative Injury (Intra-operative
injury - Ovary)
Intra-operative Injury (Intra-operative
injury - Pancreas)
Intra-operative Injury (Intra-operative
injury - Pancreatic duct)
Intra-operative Injury (Intra-operative
injury - Parathyroid)
Intra-operative Injury (Intra-operative
injury - Parotid gland)
Intra-operative Injury (Intra-operative
injury - Pelvis NOS)
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Intra-operative Injury (Intra-operative
injury - Penis)
Intra-operative Injury (Intra-operative
injury - Peripheral motor NOS)
Intra-operative Injury (Intra-operative
injury - Peripheral sensory NOS)
Intra-operative Injury (Intra-operative
injury - Peritoneal cavity)
Intra-operative Injury (Intra-operative
injury - Pharynx)
Intra-operative Injury (Intra-operative
injury - Pituitary)
Intra-operative Injury (Intra-operative
injury - Pleura)
Intra-operative Injury (Intra-operative
injury - Prostate)
Intra-operative Injury (Intra-operative
injury - Rectum)
Intra-operative Injury (Intra-operative
injury - Recurrent laryngeal)
Intra-operative Injury (Intra-operative
injury - Retina)
Intra-operative Injury (Intra-operative
injury - Sacral plexus)
Intra-operative Injury (Intra-operative
injury - Salivary duct)
Intra-operative Injury (Intra-operative
injury - Salivary gland)
Intra-operative Injury (Intra-operative
injury - Sciatic)
Intra-operative Injury (Intra-operative
injury - Scrotum)
Intra-operative Injury (Intra-operative
injury - Sinus)
Intra-operative Injury (Intra-operative
injury - Skin)
Intra-operative Injury (Intra-operative
injury - Small bowel NOS)
Intra-operative Injury (Intra-operative
injury - Soft tissue NOS)
Intra-operative Injury (Intra-operative
injury - Spinal cord)
Intra-operative Injury (Intra-operative
injury - Spleen)
Intra-operative Injury (Intra-operative
injury - Stoma (GI))
Intra-operative Injury (Intra-operative
injury - Stomach)
Intra-operative Injury (Intra-operative
injury - Teeth)
Intra-operative Injury (Intra-operative
injury - Tendon)
Intra-operative Injury (Intra-operative
injury - Testis)
Intra-operative Injury (Intra-operative
injury - Thoracic duct)
Intra-operative Injury (Intra-operative
injury - Thoracodorsal)
Intra-operative Injury (Intra-operative
injury - Thyroid)
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Intra-operative Injury (Intra-operative
injury - Tongue)
Intra-operative Injury (Intra-operative
injury - Trachea)
Intra-operative Injury (Intra-operative
injury - Upper aerodigestive NOS)
Intra-operative Injury (Intra-operative
injury - Upper airway NOS)
Intra-operative Injury (Intra-operative
injury - Ureter)
Intra-operative Injury (Intra-operative
injury - Urethra)
Intra-operative Injury (Intra-operative
injury - Urinary conduit)
Intra-operative Injury (Intra-operative
injury - Urinary tract NOS)
Intra-operative Injury (Intra-operative
injury - Uterus)
Intra-operative Injury (Intra-operative
injury - Vagina)
Intra-operative Injury - Vein (Intra-
operative injury - Vein NOS)
Intra-operative Injury (Intra-operative
injury - Vein-extremity (lower))
Intra-operative Injury (Intra-operative
injury - Vein-extremity (upper))
Intra-operative Injury (Intra-operative
injury - Vein-hepatic)
Intra-operative Injury (Intra-operative
injury - Vein-inferior vena cava)
Intra-operative Injury (Intra-operative
injury - Vein-jugular)
Intra-operative Injury (Intra-operative
injury - Vein-major visceral vein)
Intra-operative Injury (Intra-operative
injury - Vein-portal vein)
Intra-operative Injury (Intra-operative
injury - Vein-pulmonary)
Intra-operative Injury (Intra-operative
injury - Vein-superior vena cava)
Intra-operative Injury (Intra-operative
injury - Vulva)
Intra-operative Injury Other (Intra-
operative Injury-Other (Specify))
Iron Overload (Iron overload)
Menstruation Irregular (Irregular menses
(change from baseline))
Irritability (Irritability (children <3 years of
age))
Joint-effusion (Joint-effusion)
Joint-effusion (Joint-function)
Keratitis Nec (Keratitis (corneal
inflammation/corneal ulceration))
Laryngeal Nerve Dysfunction (Laryngeal
nerve dysfunction)
Leak (including Anastomotic), Gi (Leak
(including anastomotic), GI - Biliary tree)
Leak (including Anastomotic), Gi (Leak
(including anastomotic), GI - Esophagus)
Leak (including Anastomotic), Gi (Leak
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(including anastomotic), GI - Large
bowel)
Leak (including Anastomotic), Gi (Leak
(including anastomotic), GI - Leak NOS)
Leak (including Anastomotic), Gi (Leak
(including anastomotic), GI - Pancreas)
Leak (including Anastomotic), Gi (Leak
(including anastomotic), GI - Pharynx)
Leak (including Anastomotic), Gi (Leak
(including anastomotic), GI - Rectum)
Leak (including Anastomotic), Gi (Leak
(including anastomotic), GI - Small
bowel)
Leak (including Anastomotic), Gi (Leak
(including anastomotic), GI - Stoma)
Leak (including Anastomotic), Gi (Leak
(including anastomotic), GI - Stomach)
Leak (including Anastomotic), Gu (Leak
(including anastomotic), GU - Bladder)
Leak (including Anastomotic), Gu (Leak
(including anastomotic), GU - Fallopian
tube)
Leak (including Anastomotic), Gu (Leak
(including anastomotic), GU - Kidney)
Leak (including Anastomotic), Gu (Leak
(including anastomotic), GU - Spermatic
cord)
Leak (including Anastomotic), Gu (Leak
(including anastomotic), GU - Stoma)
Leak (including Anastomotic), Gu (Leak
(including anastomotic), GU - Ureter)
Leak (including Anastomotic), Gu (Leak
(including anastomotic), GU - Urethra)
Leak (including Anastomotic), Gu (Leak
(including anastomotic), GU - Uterus)
Leak (including Anastomotic), Gu (Leak
(including anastomotic), GU - Vagina)
Leak (including Anastomotic), Gu (Leak
(including anastomotic), GU - Vas
deferens)
Leak, Cerebrospinal Fluid (csf) (Leak,
cerebrospinal fluid (CSF))
Left Ventricular Diastolic Dysfunction
(Left ventricular diastolic dysfunction)
Left Ventricular Failure (Left ventricular
systolic dysfunction)
Leucopenia Nos (Leukocytes (total
WBC))
Encephalopathy Nos
(Leukoencephalopathy (radiolographic
findings))
Libido Decreased (Libido)
Lipase Increased (Lipase)
Hepatic Failure (Liver dysfunction/failure
(clinical))
Local Complication - Device/prosthesis-
related (Local complication -
device/prosthesis-related)
Lumbar Spine-range Of Motion (Lumbar
spine-range of motion)
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Lymphatics Other (Lymphatics-Other
(Specify))
Lymphedema-related Fibrosis
(Lymphedema-related fibrosis)
Lymphocele (Lymphocele)
Lymphopenia (Lymphopenia)
Hypermagnesaemia (Magnesium,
serum-high (hypermagnesemia))
Blood Magnesium Decreased
(Magnesium, serum-low
(hypomagnesemia))
Malabsorption (Malabsorption)
Virilism (Masculinization of female)
Amnesia Nec (Memory impairment)
Mental Status (Mental status)
Metabolic/laboratory Other
(Metabolic/Laboratory-Other (Specify))
Mood Alteration - Agitation (Mood
alteration - agitation)
Anxiety Nec (Mood alteration - anxiety)
Depression Nec (Mood alteration -
depression)
Euphoric Mood (Mood alteration -
euphoria)
Mucositis/stomatitis (clinical Exam)
(Mucositis/stomatitis (clinical exam) -
Anus)
Mucositis/stomatitis (clinical Exam)
(Mucositis/stomatitis (clinical exam) -
Esophagus)
Mucositis/stomatitis (clinical Exam)
(Mucositis/stomatitis (clinical exam) -
Large bowel)
Mucositis/stomatitis (clinical Exam)
(Mucositis/stomatitis (clinical exam) -
Larynx)
Mucositis/stomatitis (clinical Exam)
(Mucositis/stomatitis (clinical exam) -
Oral cavity)
Stomatitis (Mucositis/stomatitis (clinical
exam) - Pharynx)
Mucositis/stomatitis (clinical Exam)
(Mucositis/stomatitis (clinical exam) -
Rectum)
Mucositis/stomatitis (clinical Exam)
(Mucositis/stomatitis (clinical exam) -
Small bowel)
Mucositis/stomatitis (clinical Exam)
(Mucositis/stomatitis (clinical exam) -
Stomach)
Mucositis/stomatitis (clinical Exam)
(Mucositis/stomatitis (clinical exam) -
Trachea)
Mucositis/stomatitis
(functional/symptomatic)
(Mucositis/stomatitis
(functional/symptomatic) - Anus)
Mucositis/stomatitis
(functional/symptomatic)
(Mucositis/stomatitis
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(functional/symptomatic) - Esophagus)
Mucositis/stomatitis
(functional/symptomatic)
(Mucositis/stomatitis
(functional/symptomatic) - Large bowel)
Mucositis/stomatitis
(functional/symptomatic)
(Mucositis/stomatitis
(functional/symptomatic) - Larynx)
Mucositis/stomatitis
(functional/symptomatic)
(Mucositis/stomatitis
(functional/symptomatic) - Oral cavity)
Mucositis/stomatitis
(functional/symptomatic)
(Mucositis/stomatitis
(functional/symptomatic) - Pharynx)
Mucositis/stomatitis
(functional/symptomatic)
(Mucositis/stomatitis
(functional/symptomatic) - Rectum)
Mucositis/stomatitis
(functional/symptomatic)
(Mucositis/stomatitis
(functional/symptomatic) - Small bowel)
Mucositis/stomatitis
(functional/symptomatic)
(Mucositis/stomatitis
(functional/symptomatic) - Stomach)
Mucositis/stomatitis
(functional/symptomatic)
(Mucositis/stomatitis
(functional/symptomatic) - Trachea)
Muscle Weakness, Generalized Or
Specific Area (not Due To Neuropathy)
(Muscle weakness, generalized or
specific area (not due to neuropathy) -
Extraocular)
Muscle Weakness, Generalized Or
Specific Area (not Due To Neuropathy)
(Muscle weakness, generalized or
specific area (not due to neuropathy) -
Extremity-lower)
Muscle Weakness, Generalized Or
Specific Area (not Due To Neuropathy)
(Muscle weakness, generalized or
specific area (not due to neuropathy) -
Extremity-upper)
Muscle Weakness, Generalized Or
Specific Area (not Due To Neuropathy)
(Muscle weakness, generalized or
specific area (not due to neuropathy) -
Facial)
Muscle Weakness, Generalized Or
Specific Area (not Due To Neuropathy)
(Muscle weakness, generalized or
specific area (not due to neuropathy) -
Left-sided)
Muscle Weakness, Generalized Or
Specific Area (not Due To Neuropathy)
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(Muscle weakness, generalized or
specific area (not due to neuropathy) -
Ocular)
Muscle Weakness, Generalized Or
Specific Area (not Due To Neuropathy)
(Muscle weakness, generalized or
specific area (not due to neuropathy) -
Pelvic)
Muscle Weakness, Generalized Or
Specific Area (not Due To Neuropathy)
(Muscle weakness, generalized or
specific area (not due to neuropathy) -
Right-sided)
Muscle Weakness, Generalized Or
Specific Area (not Due To Neuropathy)
(Muscle weakness, generalized or
specific area (not due to neuropathy) -
Trunk)
Muscle Weakness Nos (Muscle
weakness, generalized or specific area
(not due to neuropathy) - Whole
body/generalized)
Muscular/skeletal Hypoplasia
(Muscular/skeletal hypoplasia)
Musculoskeletal/soft Tissue Other
(Musculoskeletal/Soft Tissue-Other
(Specify))
Myelitis (Myelitis)
Myelodysplasia (Myelodysplasia)
Myocarditis Nos (Myocarditis)
Myositis (Myositis (inflammation/damage
of muscle))
Nail Abnormality Nos (Nail changes)
Nasal Cavity/paranasal Sinus Reactions
(Nasal cavity/paranasal sinus reactions)
Nausea (Nausea)
Necrosis, Gi (Necrosis, GI - Anus)
Necrosis, Gi (Necrosis, GI -
Colon/cecum/appendix)
Necrosis, Gi (Necrosis, GI - Duodenum)
Necrosis, Gi (Necrosis, GI - Esophagus)
Necrosis, Gi (Necrosis, GI - Gallbladder)
Necrosis, Gi (Necrosis, GI - Hepatic)
Necrosis, Gi (Necrosis, GI - Ileum)
Necrosis, Gi (Necrosis, GI - Jejunum)
Necrosis, Gi (Necrosis, GI - Oral)
Necrosis, Gi (Necrosis, GI - Pancreas)
Necrosis, Gi (Necrosis, GI - Peritoneal
cavity)
Necrosis, Gi (Necrosis, GI - Pharynx)
Necrosis, Gi (Necrosis, GI - Rectum)
Necrosis, Gi (Necrosis, GI - Small bowel
NOS)
Necrosis, Gi (Necrosis, GI - Stoma)
Necrosis, Gi (Necrosis, GI - Stomach)
Neuroendocrine: Acth Deficiency
(Neuroendocrine: ACTH deficiency)
Inappropriate Adh Secretion
(Neuroendocrine: ADH secretion
abnormality (e.g., SIADH or low ADH))
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Neuroendocrine: Gonadotropin Secretion
Abnormality (Neuroendocrine:
gonadotropin secretion abnormality)
Neuroendocrine: Growth Hormone
Secretion Abnormality (Neuroendocrine:
growth hormone secretion abnormality)
Neuroendocrine: Prolactin Hormone
Secretion Abnormality (Neuroendocrine:
prolactin hormone secretion abnormality)
Neurology Other (Neurology-Other
(Specify))
Parosmia (Neuropathy: cranial - CN I
Smell)
Cranial Nerve Injury Nos (Neuropathy:
cranial - CN II Vision)
Neuropathy: Cranial (Neuropathy: cranial
- CN III Pupil, upper eyelid, extra ocular
movements)
Neuropathy: Cranial (Neuropathy: cranial
- CN IV Downward, inward movement of
eye)
Neuropathy: Cranial (Neuropathy: cranial
- CN IX Motor-pharynx; Sensory-ear,
pharynx, tongue)
Neuropathy: Cranial (Neuropathy: cranial
- CN V Motor-jaw muscles; Sensory-
facial)
Neuropathy: Cranial (Neuropathy: cranial
- CN VI Lateral deviation of eye)
Neuropathy: Cranial (Neuropathy: cranial
- CN VII Motor-face; Sensory-taste)
Neuropathy: Cranial (Neuropathy: cranial
- CN VIII Hearing and balance)
Neuropathy: Cranial (Neuropathy: cranial
- CN X Motor-palate; pharynx, larynx)
Neuropathy: Cranial (Neuropathy: cranial
- CN XI Motor-sternomastoid and
trapezius)
Neuropathy: Cranial (Neuropathy: cranial
- CN XII Motor-tongue)
Peripheral Motor Neuropathy
(Neuropathy: motor)
Peripheral Sensory Neuropathy
(Neuropathy: sensory)
Neutropenia (Neutrophils/granulocytes
(ANC/AGC))
Blindness Night (Night blindness
(nyctalopia))
Nystagmus Nos (Nystagmus)
Obesity (Obesity)
Obstruction, Gi (Obstruction, GI -
Cecum)
Obstruction, Gi (Obstruction, GI - Colon)
Obstruction, Gi (Obstruction, GI -
Duodenum)
Obstruction, Gi (Obstruction, GI -
Esophagus)
Obstruction, Gi (Obstruction, GI -
Gallbladder)
Obstruction, Gi (Obstruction, GI - Ileum)
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Obstruction, Gi (Obstruction, GI -
Jejunum)
Obstruction, Gi (Obstruction, GI -
Rectum)
Obstruction, Gi (Obstruction, GI - Small
bowel NOS)
Obstruction, Gi (Obstruction, GI - Stoma)
Obstruction, Gi (Obstruction, GI -
Stomach)
Obstruction, Gu (Obstruction, GU -
Bladder)
Obstruction, Gu (Obstruction, GU -
Fallopian tube)
Obstruction, Gu (Obstruction, GU -
Prostate)
Obstruction, Gu (Obstruction, GU -
Spermatic cord)
Obstruction, Gu (Obstruction, GU -
Stoma)
Obstruction, Gu (Obstruction, GU -
Testes)
Ureteric Obstruction (Obstruction, GU -
Ureter)
Obstruction, Gu (Obstruction, GU -
Urethra)
Obstruction, Gu (Obstruction, GU -
Uterus)
Obstruction, Gu (Obstruction, GU -
Vagina)
Obstruction, Gu (Obstruction, GU - Vas
deferens)
Obstruction/stenosis Of Airway
(Obstruction/stenosis of airway -
Bronchus)
Obstruction/stenosis Of Airway
(Obstruction/stenosis of airway - Larynx)
Obstruction/stenosis Of Airway
(Obstruction/stenosis of airway -
Pharynx)
Obstruction/stenosis Of Airway
(Obstruction/stenosis of airway -
Trachea)
Conjunctivitis Nec (Ocular surface
disease)
Ocular/visual Other (Ocular/Visual-Other
(Specify))
Odor (patient Odor) (Odor (patient odor))
Diplopia (Ophthalmoplegia/diplopia
(double vision))
Opportunistic Infection Associated With
>=grade 2 Lymphopenia (Opportunistic
infection associated with >=Grade 2
lymphopenia)
Optic Disc Edema (Optic disc edema)
Orgasmic Dysfunction (Orgasmic
dysfunction)
Osteonecrosis (Osteonecrosis (avascular
necrosis))
Osteoporosis (Osteoporosis)
Otitis Externa (exc Boil Of Meatus) Nos
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(Otitis, external ear (non-infectious))
Otitis Media Serous Nos (Otitis, middle
ear (non-infectious))
Abdominal Pain Nos (Pain - Abdomen
NOS)
Pain (Pain - Anus)
Pain (Pain - Back)
Pain (Pain - Bladder)
Bone Pain (Pain - Bone)
Pain (Pain - Breast)
Pain (Pain - Buttock)
Pain (Pain - Cardiac/heart)
Pain (Pain - Chest wall)
Chest Pain (Pain - Chest/thorax NOS)
Pain (Pain - Dental/teeth/peridontal)
Pain (Pain - Esophagus)
Earache (Pain - External ear)
Pain (Pain - Extremity-limb)
Pain (Pain - Eye)
Pain (Pain - Face)
Pain (Pain - Gallbladder)
Headache Nos (Pain - Head/headache)
Pain (Pain - Intestine)
Arthralgia (Pain - Joint)
Pain (Pain - Kidney)
Pain (Pain - Larynx)
Pain (Pain - Lip)
Hepatic Pain (Pain - Liver)
Pain (Pain - Lymph node)
Pain (Pain - Middle ear)
Myalgia (Pain - Muscle)
Pain (Pain - Neck)
Neuralgia Nos (Pain -
Neuralgia/peripheral nerve)
Pain (Pain - Oral cavity)
Pain (Pain - Oral-gums)
Pain (Pain - Ovulatory)
Pain (Pain - Pain NOS)
Pelvic Pain Nos (Pain - Pelvis)
Pain (Pain - Penis)
Pain (Pain - Pericardium)
Pain (Pain - Perineum)
Pain (Pain - Peritoneum)
Pain (Pain - Phantom (pain associated
with missing limb))
Pleuritic Pain (Pain - Pleura)
Pain (Pain - Prostate)
Proctalgia (Pain - Rectum)
Pain (Pain - Scalp)
Pain (Pain - Scrotum)
Pain (Pain - Sinus)
Pain (Pain - Skin)
Pain (Pain - Stomach)
Pain (Pain - Testicle)
Pain (Pain - Throat/pharynx/larynx)
Tumour Pain (Pain - Tumor pain)
Dysuria (Pain - Urethra)
Dysmenorrhoea (Pain - Uterus)
Pain (Pain - Vagina)
Pain Other (Pain-Other (Specify))
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Palpitations (Palpitations)
Pancreas, Exocrine Enzyme Deficiency
(Pancreas, exocrine enzyme deficiency)
Pancreatic Endocrine: Glucose
Intolerance (Pancreatic endocrine:
glucose intolerance)
Pancreatitis Nos (Pancreatitis)
Parathyroid Function, Low
(hypoparathyroidism) (Parathyroid
function, low (hypoparathyroidism))
Perforation, Gi (Perforation, GI -
Appendix)
Perforation, Gi (Perforation, GI - Biliary
tree)
Perforation, Gi (Perforation, GI - Cecum)
Perforation, Gi (Perforation, GI - Colon)
Perforation, Gi (Perforation, GI -
Duodenum)
Perforation, Gi (Perforation, GI -
Esophagus)
Perforation, Gi (Perforation, GI -
Gallbladder)
Perforation, Gi (Perforation, GI - Ileum)
Perforation, Gi (Perforation, GI -
Jejunum)
Perforation, Gi (Perforation, GI - Rectum)
Perforation, Gi (Perforation, GI - Small
bowel NOS)
Perforation, Gi (Perforation, GI -
Stomach)
Perforation, Gu (Perforation, GU -
Bladder)
Perforation, Gu (Perforation, GU -
Fallopian tube)
Perforation, Gu (Perforation, GU -
Kidney)
Perforation, Gu (Perforation, GU - Ovary)
Perforation, Gu (Perforation, GU -
Prostate)
Perforation, Gu (Perforation, GU -
Spermatic cord)
Perforation, Gu (Perforation, GU -
Stoma)
Perforation, Gu (Perforation, GU -
Testes)
Perforation, Gu (Perforation, GU - Ureter)
Perforation, Gu (Perforation, GU -
Urethra)
Perforation, Gu (Perforation, GU -
Uterus)
Perforation, Gu (Perforation, GU -
Vagina)
Perforation, Gu (Perforation, GU - Vas
deferens)
Pericardial Effusion (Pericardial effusion
(non-malignant))
Pericarditis (Pericarditis)
Peripheral Ischaemia Nos (Peripheral
arterial ischemia)
Personality Change
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(Personality/behavioral)
Petechiae (Petechiae/purpura
(hemorrhage/bleeding into skin or
mucosa))
Phlebitis Superficial (Phlebitis (including
superficial thrombosis))
Phlebolymphatic Cording
(Phlebolymphatic cording)
Hypophosphataemia (Phosphate, serum-
low (hypophosphatemia))
Photosensitivity Reaction Nos
(Photosensitivity)
Phrenic Nerve Dysfunction (Phrenic
nerve dysfunction)
Platelet Count Decreased (Platelets)
Pleural Effusion (Pleural effusion (non-
malignant))
Pneumonitis Nos
(Pneumonitis/pulmonary infiltrates)
Pneumothorax Nos (Pneumothorax)
Portal Hypertension (Portal vein flow)
Hyperkalaemia (Potassium, serum-high
(hyperkalemia))
Hypokalaemia (Potassium, serum-low
(hypokalemia))
Proctitis Nos (Proctitis)
Prolapse Of Stoma, Gi (Prolapse of
stoma, GI)
Prolapse Of Stoma, Gu (Prolapse of
stoma, GU)
Prolonged Chest Tube Drainage Or Air
Leak After Pulmonary Resection
(Prolonged chest tube drainage or air
leak after pulmonary resection)
Prolonged Intubation After Pulmonary
Resection (>24 Hrs After Surgery)
(Prolonged intubation after pulmonary
resection (>24 hrs after surgery))
Electrocardiogram Qt Prolonged
(Prolonged QTc interval)
Proptosis/enophthalmos
(Proptosis/enophthalmos)
Proteinuria Present (Proteinuria)
Pruritus Nos (Pruritus/itching)
Delusion Nos (Psychosis
(hallucinations/delusions))
Activated Partial Thromboplastin Time
Prolonged (PTT (Partial thromboplastin
time))
Puberty (delayed) (Puberty (delayed))
Puberty (precocious) (Puberty
(precocious))
Pulmonary Fibrosis (Pulmonary fibrosis
(radiographic changes))
Pulmonary Hypertension (Pulmonary
hypertension)
Pulmonary/upper Respiratory Other
(Pulmonary/Upper Respiratory-Other
(Specify))
Upper Motor Neurone Lesion (Pyramidal
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tract dysfunction (e.g., increased tone,
hyperreflexia, positive Babinski,
decreased fine motor coordination))
Rash: Acne/acneiform (Rash:
acne/acneiform)
Radiation Recall Syndrome (Rash:
dermatitis associated with radiation -
Chemoradiation)
Dermatitis Radiation Nos (Rash:
dermatitis associated with radiation -
Radiation)
Erythema Multiforme (Rash: erythema
multiforme (e.g., Stevens-Johnson
syndrome, toxic epidermal necrolysis))
Localised Exfoliation (Rash: hand-foot
skin reaction)
Dermatitis Exfoliative Nos
(Rash/desquamation)
Renal Failure Nos (Renal failure)
Renal/genitourinary Other
(Renal/Genitourinary-Other (Specify))
Restrictive Cardiomyopathy (Restrictive
cardiomyopathy)
Retinal Detachment (Retinal
detachment)
Retinoic Acid Syndrome (Retinoic acid
syndrome")
Retinopathy (Retinopathy)
Right Ventricular Dysfunction (cor
Pulmonale) (Right ventricular dysfunction
(cor pulmonale))
Rigors (Rigors/chills)
Salivary Gland Disorder Nos (Salivary
gland changes/saliva)
Scleral Necrosis/melt (Scleral
necrosis/melt)
Secondary Malignancy Possibly Related
To Cancer Treatment (Secondary
Malignancy-possibly related to cancer
treatment (Specify))
Convulsions Nos (Seizure)
Seroma (Seroma)
Serum Sickness (Serum sickness)
Sexual/reproductive Function Other
(Sexual/Reproductive Function-Other
(Specify))
Short Stature (Short stature)
Skin Breakdown/decubitus Ulcer (Skin
breakdown/decubitus ulcer)
Hypernatraemia (Sodium, serum-high
(hypernatremia))
Hyponatraemia (Sodium, serum-low
(hyponatremia))
Soft Tissue Necrosis (Soft tissue
necrosis - Abdomen)
Soft Tissue Necrosis (Soft tissue
necrosis - Extremity-lower)
Soft Tissue Necrosis (Soft tissue
necrosis - Extremity-upper)
Soft Tissue Necrosis (Soft tissue
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necrosis - Head)
Soft Tissue Necrosis (Soft tissue
necrosis - Neck)
Soft Tissue Necrosis (Soft tissue
necrosis - Pelvic)
Soft Tissue Necrosis (Soft tissue
necrosis - Thorax)
Depressed Level Of Consciousness
(Somnolence/depressed level of
consciousness)
Speech Disorder Nec (Speech
impairment (e.g., dysphasia or aphasia))
Splenic Function (Splenic function)
Striae (Striae)
Stricture/stenosis (including
Anastomotic), Gi (Stricture/stenosis
(including anastomotic), GI - Anus)
Stricture/stenosis (including
Anastomotic), Gi (Stricture/stenosis
(including anastomotic), GI - Biliary tree)
Stricture/stenosis (including
Anastomotic), Gi (Stricture/stenosis
(including anastomotic), GI - Cecum)
Stricture/stenosis (including
Anastomotic), Gi (Stricture/stenosis
(including anastomotic), GI - Colon)
Stricture/stenosis (including
Anastomotic), Gi (Stricture/stenosis
(including anastomotic), GI - Duodenum)
Stricture/stenosis (including
Anastomotic), Gi (Stricture/stenosis
(including anastomotic), GI - Esophagus)
Stricture/stenosis (including
Anastomotic), Gi (Stricture/stenosis
(including anastomotic), GI - Ileum)
Stricture/stenosis (including
Anastomotic), Gi (Stricture/stenosis
(including anastomotic), GI - Jejunum)
Stricture/stenosis (including
Anastomotic), Gi (Stricture/stenosis
(including anastomotic), GI -
Pancreas/pancreatic duct)
Stricture/stenosis (including
Anastomotic), Gi (Stricture/stenosis
(including anastomotic), GI - Pharynx)
Stricture/stenosis (including
Anastomotic), Gi (Stricture/stenosis
(including anastomotic), GI - Rectum)
Stricture/stenosis (including
Anastomotic), Gi (Stricture/stenosis
(including anastomotic), GI - Small bowel
NOS)
Stricture/stenosis (including
Anastomotic), Gi (Stricture/stenosis
(including anastomotic), GI - Stoma)
Stricture/stenosis (including
Anastomotic), Gi (Stricture/stenosis
(including anastomotic), GI - Stomach)
Stricture/stenosis (including
Anastomotic), Gu (Stricture/stenosis
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(including anastomotic), GU - Bladder)
Stricture/stenosis (including
Anastomotic), Gu (Stricture/stenosis
(including anastomotic), GU - Fallopian
tube)
Stricture/stenosis (including
Anastomotic), Gu (Stricture/stenosis
(including anastomotic), GU - Prostate)
Stricture/stenosis (including
Anastomotic), Gu (Stricture/stenosis
(including anastomotic), GU - Spermatic
cord)
Stricture/stenosis (including
Anastomotic), Gu (Stricture/stenosis
(including anastomotic), GU - Stoma)
Stricture/stenosis (including
Anastomotic), Gu (Stricture/stenosis
(including anastomotic), GU - Testes)
Stricture/stenosis (including
Anastomotic), Gu (Stricture/stenosis
(including anastomotic), GU - Ureter)
Stricture/stenosis (including
Anastomotic), Gu (Stricture/stenosis
(including anastomotic), GU - Urethra)
Stricture/stenosis (including
Anastomotic), Gu (Stricture/stenosis
(including anastomotic), GU - Uterus)
Stricture/stenosis (including
Anastomotic), Gu (Stricture/stenosis
(including anastomotic), GU - Vagina)
Stricture/stenosis (including
Anastomotic), Gu (Stricture/stenosis
(including anastomotic), GU - Vas
deferens)
Supraventricular And Nodal Arrhythmia
(Supraventricular and nodal arrhythmia -
Atrial fibrillation)
Supraventricular And Nodal Arrhythmia
(Supraventricular and nodal arrhythmia -
Atrial flutter)
Supraventricular And Nodal Arrhythmia
(Supraventricular and nodal arrhythmia -
Atrial tachycardia/paroxysmal atrial
tachycardia)
Supraventricular And Nodal Arrhythmia
(Supraventricular and nodal arrhythmia -
Nodal/junctional)
Supraventricular And Nodal Arrhythmia
(Supraventricular and nodal arrhythmia -
Sinus arrhythmia)
Sinus Bradycardia (Supraventricular and
nodal arrhythmia - Sinus bradycardia)
Sinus Tachycardia (Supraventricular and
nodal arrhythmia - Sinus tachycardia)
Supraventricular Arrhythmia Nos
(Supraventricular and nodal arrhythmia -
Supraventricular arrhythmia NOS)
Supraventricular And Nodal Arrhythmia -
Supraventricular Extrasystoles
(premature Atrial Contractions;
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Premature Nodal/junctional
Contractions) (Supraventricular and
nodal arrhythmia - Supraventricular
extrasystoles (premature atrial
contractions; premature nodal/junctional
contractions))
Supraventricular And Nodal Arrhythmia
(Supraventricular and nodal arrhythmia -
Supraventricular tachycardia)
Sweating Increased (Sweating
(diaphoresis))
Syncope (Syncope (fainting))
Syndromes Other (Syndromes-Other
(Specify))
Taste Disturbance (Taste alteration
(dysgeusia))
Telangiectasia (Telangiectasia)
Thrombosis/embolism (vascular Access-
related) (Thrombosis/embolism (vascular
access-related))
Thrombosis Nos
(Thrombosis/thrombus/embolism)
Thrombotic Microangiopathy (e.g.,
Thrombotic Thrombocytopenic
Purpura[ttp] Or Hemolytic Uremic
Syndrome[hus]) (Thrombotic
microangiopathy (e.g., thrombotic
thrombocytopenic purpura or hemolytic
uremic syndrome))
Thyroid Function, High (hyperthyroidism,
Thyrotoxicosis) (Thyroid function, high
(hyperthyroidism, thyrotoxicosis))
Hypothyroidism (Thyroid function, low
(hypothyroidism))
Tinnitus (Tinnitus)
Tremor Nec (Tremor)
Hypertriglyceridaemia (Triglyceride,
serum-high (hypertriglyceridemia))
Trismus (difficulty, Restriction Or Pain
When Opening Mouth) (Trismus
(difficulty, restriction or pain when
opening mouth))
Tumour Flare (Tumor flare)
Tumour Lysis Syndrome (Tumor lysis
syndrome)
Caecitis (Typhlitis (cecal inflammation))
Ulcer, Gi (Ulcer, GI - Anus)
Ulcer, Gi (Ulcer, GI - Cecum)
Ulcer, Gi (Ulcer, GI - Colon)
Duodenal Ulcer (Ulcer, GI - Duodenum)
Ulcer, Gi (Ulcer, GI - Esophagus)
Ulcer, Gi (Ulcer, GI - Ileum)
Ulcer, Gi (Ulcer, GI - Jejunum)
Ulcer, Gi (Ulcer, GI - Rectum)
Ulcer, Gi (Ulcer, GI - Small bowel NOS)
Ulcer, Gi (Ulcer, GI - Stoma)
Gastric Ulcer (Ulcer, GI - Stomach)
Ulceration (Ulceration)
Hyperuricaemia (Uric acid, serum-high
(hyperuricemia))
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Fanconi Syndrome (Urinary electrolyte
wasting (e.g., Fanconi's syndrome, renal
tubular acidosis))
Urinary Frequency (Urinary
frequency/urgency)
Urinary Retention (Urinary retention
(including neurogenic bladder))
Urine Discolouration (Urine color
change)
Urticaria Nos (Urticaria (hives, welts,
wheals))
Uveitis (Uveitis)
Vaginal Discharge (non-infectious)
(Vaginal discharge (non-infectious))
Vulvovaginal Dryness (Vaginal dryness)
Vaginal Mucositis (Vaginal mucositis)
Vaginal Stenosis/length (Vaginal
stenosis/length)
Vaginitis (Vaginitis (not due to infection))
Valvular Heart Disease (Valvular heart
disease)
Vascular Other (Vascular-Other
(Specify))
Vasculitis Nos (Vasculitis)
Vasovagal Attack (Vasovagal episode)
Ventricular Arrhythmia (Ventricular
arrhythmia - Bigeminy)
Ventricular Arrhythmia (Ventricular
arrhythmia - Idioventricular rhythm)
Ventricular Arrhythmia (Ventricular
arrhythmia - PVCs)
Ventricular Arrhythmia (Ventricular
arrhythmia - Torsade de pointes)
Ventricular Arrhythmia (Ventricular
arrhythmia - Trigeminy)
Ventricular Arrhythmia Nos (Ventricular
arrhythmia - Ventricular arrhythmia NOS)
Ventricular Arrhythmia (Ventricular
arrhythmia - Ventricular fibrillation)
Ventricular Arrhythmia (Ventricular
arrhythmia - Ventricular flutter)
Ventricular Arrhythmia (Ventricular
arrhythmia - Ventricular tachycardia)
Vessel Injury-artery (Vessel injury-artery
- Aorta)
Vessel Injury-artery (Vessel injury-artery
- Carotid)
Vessel Injury-artery (Vessel injury-artery
- Extremity-lower)
Vessel Injury-artery (Vessel injury-artery
- Extremity-upper)
Vessel Injury-artery (Vessel injury-artery
- Other NOS)
Vessel Injury-artery (Vessel injury-artery
- Visceral)
Vessel Injury-vein (Vessel injury-vein -
Extremity-lower)
Vessel Injury-vein (Vessel injury-vein -
Extremity-upper)
Vessel Injury-vein (Vessel injury-vein -
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IVC)
Vessel Injury-vein (Vessel injury-vein -
Jugular)
Vessel Injury-vein (Vessel injury-vein -
Other NOS)
Vessel Injury-vein (Vessel injury-vein -
SVC)
Vessel Injury-vein (Vessel injury-vein -
Viscera)
Viral Hepatitis (Viral hepatitis)
Visceral Arterial Ischaemia (Visceral
arterial ischemia (non-myocardial))
Vision Blurred (Vision-blurred vision)
Photopsia (Vision-flashing lights/floaters)
Photophobia (Vision-photophobia)
Vital Capacity (Vital capacity)
Vitreous Hemorrhage (Vitreous
hemorrhage)
Dysphonia (Voice changes/dysarthria
(e.g., hoarseness, loss or alteration in
voice, laryngitis))
Vomiting Nos (Vomiting)
Lacrimation Increased (Watery eye
(epiphora, tearing))
Weight Increased (Weight gain)
Weight Decreased (Weight loss)
Culture Wound Negative (Wound
complication, non-infectious)
CTC AE Grade
CTCAE Begin Date
CTC AE Attribution Code (Attribution to Protocol
Treatment See protocol sections 6 & 7 for
definition of "protocol treatment")
Definite (Definite)
Possible (Possible)
Probable (Probable)
Unlikely (Unlikely)
Unrelated (Unrelated)
SAE report submitted
No (No)
Unknown (Unknown)
Yes (Yes)
Other, specify
Footer
Comments
Signature of Person Completing This Form
Date Form Originally Completed
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Infection NCT00513526 On-Study - AMC-
052 On Study Form (F02) - 2676644v1.0
AMC-052 On Study Form (F02)
Human Papillomavirus Vaccine Therapy in Treating Men
With HIV-1 Infection
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=3952E724-
40D1-361E-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/7467
AMC-052 On Study Form (F02)
Header
Visit number
Hiv History
Date of HIV+ diagnosis
Date of AIDS diagnosis
CDC HIV Risk Group
Hemophilia (Hemophiliac)
Heterosexual Contact (Heterosexual
contact)
Homosexual Or Bisexual Contact
(Homosexual or bisexual contact)
Iv Drug User (IV drug user)
Other (Other)
Transfusion Recipient (Transfusion
recipient)
Other, specify
Ccrr Module For On Study Form - Rf02b
Date of Initial Pathologic Diagnosis
Primary site
Anal Canal (Anal)
Cervical (Cervical)
Hd (HD)
Kaposi Sarcoma (KS)
Non-hodgkin's Lymphoma (NHL)
Other Primary Site (Other primary site)
Other specify
Specify tumor histologic category
Ccrr Module For On Study Form - Rf02b
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History of Prior Malignancy
Yes
No
Date of Diagnosis of Previous Malignancy
Primary site
Anal Canal (Anal)
Cervical (Cervical)
Hd (HD)
Kaposi Sarcoma (KS)
Non-hodgkin's Lymphoma (NHL)
Other Primary Site (Other primary site)
Other specify
Specify tumor histologic category
Antiretroviral Therapy
Agent Name
Other, specify
Agent use
Currently Receiving (Currently receiving)
Never Received (Never received)
Previously Received (Previously
received)
Duration if prior agents received
< 3 Months (< 3 months)
> 12 Months (> 12 months)
> 6-12 Months (> 6-12 months)
3-6 Months (3-6 months)
Comments
Comments
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Neuroendocrine Carcinoma NCT00569127 Pre-Study - SOUTHWEST
ONCOLOGY GROUP S0518 Prestudy Form - 2459443v1.0
SOUTHWEST ONCOLOGY GROUP S0518 Prestudy Form
Octreotide and Interferon Alfa-2b or Bevacizumab in
Treating Patients With Metastatic or Locally Advanced,
High-Risk Neuroendocrine Tumor
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=0F1CE67C-
C251-11F5-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/7469
SOUTHWEST ONCOLOGY GROUP
S0518 Prestudy Form
Header
SWOG Patient ID
SWOG Study No.
Registration Step
Patient Initials (L, F M)
Institution/Affiliate
Physician (Participating Group:)
Group Name
Participating Group Study No.
Participating Group Patient ID (Instructions: All
dates are MONTH, DAY, YEAR. Explain any
blank fields or blank dates in the Comments
section. Place an X in appropriate boxes. Circle
AMENDED items in red and write AMENDED
across the top of the form.)
Patient Characteristics
Performance Status
Fully Active, Able To Carry On All Pre-
disease Performance Without
Restriction. (0)
Restricted In Physically Strenuous
Activity But Ambulatory And Able To
Carry Out Work Of A Light Or Sedentary
Nature, E.g., Light Housework, Office
Work. (1)
Ambulatory And Capable Of All Selfcare
But Unable To Carry Out Any Work
Activities. Up And About More Than 50%
Of Waking Hours. (2)
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Capable Of Only Limited Selfcare,
Confined To Bed Or Chair More Than
50% Of Waking Hours. (3)
Completely Disabled. Cannot Carry On
Any Selfcare. Totally Confined To Bed Or
Chair. (4)
Dead (5)
Height (CM)
Site of Involvement (Select all that apply)
Bone (Bone)
Distant Lymph Nodes (Distant lymph
nodes)
Liver (Liver)
Lung (Lung)
Other Specify (Other)
Other Abdominal (Other abdominal)
Primary Site/direct Extension (Primary
site/direct extension)
Regional Lymph Nodes (Regional lymph
nodes)
Other specify
Type of disease
Atypical Carcinoma (atypical carcinoma)
Carcinoid Tumor (Carcinoid)
Intermediate Grade/moderate-
differentiated Neuroendocrine
Carcinoma (Intermediate
grade/moderate-differentiated
neuroendocrine carcinoma)
Low Grade/well-differentiated
Neuroendocrine Carcinoma (Low
grade/well-differentiated neuroendocrine
carcinoma)
Other (Other)
Other, specify
Patient has high risk disease as defined by
(select all that apply)
Atypical Histology And More Than 6
Lesions (Atypical histology and more
than 6 lesions)
Metastatic Colorectal Carcinoid
(Metastatic colorectal carcinoid)
Metastatic Gastric Carcinoid (Metastatic
gastric carcinoid)
Other (Other)
Pd (Progressive Disease)
Refractory Carcinoid Syndrome While
Receiving Octreotide (Refractory
carcinoid syndrome while receiving
octreotide)
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Other, specify
Associated Correlative Science Consent
Patient consents to submission of blood for
testing of angiogenesis marker
Yes
No
Patient consents to use of archived tissue for
testing of VEGF
Yes
No
Laboratory Values
Collection Date (MM DD YYYY)
ANC (/mcL)
Peripheral Platelet Count (/mcL)
Hemoglobin (g/dL)
Total Bilirubin (mg/dL)
Total bilirubin ULN (mg/dL)
SGOT (U/L)
SGOT (AST) ULN (U/L - OR)
SGPT (U/L)
SGPT (ALT) ULN (U/L)
Serum creatinine (mg/dL)
Serum Creatinine ULN (mg/dL)
Urine Protein/Creatinine Ratio
Urinary Protein (if > 0.5, then 24 hour:)
PT (S)
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PT ULN (S)
PTT (sec) (S)
PTT ULN (S)
Is the patient on anticoagulant therapy
Yes
No
International Normalization Ratio (INR) (If yes,)
Blood Pressure
Blood Pressure
Chromogranin A (ng/ml)
Chromogranin A ULN (ng/ml)
Neuron Specific Enolase (mcg/L)
Neuron Specific Enolase ULN (mcg/L)
Urinary 5HIAA (mg/24hr)
Urinary 5HIAA ULN (mg/24hr)
Prior Treatment Related To This Cancer
Prior Therapy Type (select ALL that apply)
Anti-retroviral Therapy (Anti-retroviral
therapy)
Antisense (Antisense)
Bone Marrow Transplant (Bone marrow
transplant)
Chemotherapy Multiple Agents Systemic
(Chemotherapy multiple agents
systemic)
Chemotherapy Non-cytotoxic
(Chemotherapy non-cytotoxic)
Chemotherapy Nos (Chemotherapy
NOS)
Chemotherapy Single Agent Systemic
(Chemotherapy single agent systemic)
Gene Transfer (Gene transfer)
Hepatic Artery Embolization (Hepatic
artery embolization)
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Hormonal Therapy (Hormonal therapy)
Immunotherapy (Immunotherapy)
Oncolytic Virotherapy (Oncolytic
virotherapy)
Other (Other)
Surgery (Surgery)
Vaccine (Vaccine)
Number of prior chemotherapy regimens
Number of prior cytotoxic chemotherapy
regimens
Date of last prior cytotoxic chemotherapy regimen
(MM DD YYYY)
Date of last octreotide treatment (MM DD YYYY)
Radiation Therapy (select one)
Extensive Radiation (Extensive RT)
Limited Radiation (Limited RT)
Not Otherwise Specified (Not otherwise
specified)
Date of last prior limited radiation therapy (MM
DD YYYY)
Date of last prior minor surgery (MM DD YYYY)
Date of last prior major surgery (MM DD YYYY)
Date of embolization
Other therapy, specify
Comments
Comments
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Kaposi's Sarcoma NCT00686842 On-Study - AMC-059
PTC299 Administration and Compliance Form - 2774593v1.0
AMC-059 PTC299 Administration and Compliance Form
PTC299 in Treating Patients With HIV-Related Kaposi
Sarcoma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=546E02D4-
D58C-2B4F-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/7471
AMC-059 PTC299 Administration
and Compliance Form
Header Module
Visit number
Date of evaluation (mm/dd/yyyy)
Ptcc299 Administration
Agent Name
Were tablets returned (PTC299 at this visit)
Yes
No
Date tablets returned (PTC299 mm/dd/yyyy)
Number of tablets returned (PTC299)
Were tablets dispensed (PTC299 at this visit)
Yes
No
Date tablets dispensed (mm/dd/yyyy)
Number of tablets dispensed (PTC299)
Dose used
0.1 Mg/kg/dose Bid (0.1 mg/kg/dose
BID)
0.3 Mg/kg/dose Bid (0.3 mg/kg/dose
BID)
0.6 Mg/kg/dose Bid (0.6 mg/kg/dose
BID)
1.2 Mg/kg/dose Bid (1.2 mg/kg/dose
BID)
Were there any dose modifications or
additions/omissions to protocol treatment?
(during the previous cycle)
No (No)
Unknown (Unknown)
Yes, Planned (i.e., The Treatment Was
Changed According To Protocol
1 / 2
Guidelines) (Yes, planned)
Yes, Unplanned (i.e., The Treatment
Change Was Not Part Of Protocol
Guidelines) (Yes, unplanned)
Comments
Comments
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Lab - URINARY EXCRETION -
2411347v1.0
Urinary Excretion form for C3D 3.12 Adopters
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=016259F3-
A1BE-3224-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/7472
URINARY EXCRETION
Urinary Excretion
Treatment Start Date
Lab Collection Time
Agent Name
Course Number
Course Day Number
Evaluation Date
Start Time
Stop Date
Stop Time
Urine Volume ml
Parent Drug Assay
Parent Drug Assay
Unit
Metric Drop ([drp])
Gallon Us ([gal_us])
International Unit ([iU])
International Unit Of Vitamin A
([iU]{Vitamin A})
International Unit Per Kilogram ([iU]/kg)
International Unit Per Liter ([iU]/L)
International Unit Per Milligram ([iU]/mg)
International Unit Per Milligram Of Alpha-
tocopherol ([iU]/mg{alpha-Tocopherol})
Ounce ([oz_av])
Pound Per Square Inch ([psi])
Rad ([RAD])
Tablespoon Dosing Unit ([tbs_us])
Teaspoon Dosing Unit ([tsp_us])
Application ({Application})
Area Under Curve ({AUC})
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Bottle Dosing Unit ({Bottle})
Caplet Dosing Unit ({Caplet})
Capsule Dosing Unit ({Capsule})
Cell ({Cells})
Course ({Course})
Cycle ({Course})
Dose ({Dose})
Inhalation Dosing Unit ({Inhalation})
Intravenous Bag Dosing Unit ({IV Bag})
Measurement ({Measure})
Source Data Not Available ({No Scre})
Packet Dosing Unit ({packet})
Patch Dosing Unit ({Patch})
Plaque Forming Unit ({pfu})
Puff Dosing Unit ({puff})
Retinol Activity Equivalent ({RAE})
Retinol Equivalent ({RE})
Radioactive Seed Implant Dosing Unit
({Seed})
Session ({Session})
Spray Dosing Unit ({Spray})
Suppository Dosing Unit ({Suppository})
Tablet Dosing Unit ({tbl})
Tissue Culture Infection Dose 50
({TCID50})
Troche Dosing Unit ({Troche})
Unit ({Unit})
Unknown ({Unknown})
Viral Particle Unit ({VP})
Wafer Dosage Form ({Wafer})
Yeast Units ({YU})
Percent (%)
Thousand (10^3)
Hundred Thousand Cells Per Kilogram
(10^5{Cells}/kg)
Million (10^6)
Million Cells Per Kilogram
(10^6{Cells}/kg)
Million Plaque Forming Units (10^6{pfu})
Million Viral Particles (10^6{VP})
Million Electron Volt (10^6eV)
Ten Million Cells Per Kilogram
(10^7{Cells}/kg)
Ten Million Plaque Forming Units
(10^7{pfu})
Hundred Million Plaque Forming Units
(10^8{pfu})
Billion Cells Per Kilogram
(10^9{Cells}/kg)
Billion Plaque Forming Units (10^9{pfu})
Centigray (cGy)
Curie (Ci)
Deciliter (dL)
Equivalent Weight (eq)
Gram (g)
Gram Per Square Meter (g/m2)
Gray (Gy)
Hour (h)
Hertz (Hz)
Joule (J)
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Joule Per Square Centimeter (J/cm2)
Kiloelectronvolt (keV)
Kilogram (kg)
Kilohertz (kHz)
Kilopascal (kPa)
Kilounit (kU)
Kilounit Per Kilogram (kU/kg)
Kilounit Per Liter (kU/L)
Liter (L)
Liter Per Minute (L/min)
Milliinternational Unit (m[iU])
Milliinternational Unit Per Square Meter
(m[iU]/m2)
Megarad (M[RAD])
Millicurie (mCi)
Milliequivalent (meq)
Milliequivalent Per 24 Hours (meq/24.h)
Milliequivalent Per Deciliter (meq/dL)
Milliequivalent Per Hour (meq/h)
Milliequivalent Per Liter (meq/L)
Milligram (mg)
Milligram Per Inhalation (mg/{inhalation})
Milligram Per 24 Hours (mg/24.h)
Milligram Per Deciliter (mg/dL)
Milligram Per Hour (mg/h)
Milligram Per Kilogram (mg/kg)
Milligram Per Square Meter (mg/m2)
Milligram Per Square Meter Per Day
(mg/m2/24.h)
Milligram Per Square Meter Per Hour
(mg/m2/h)
Milligram Per Square Meter Per Week
(mg/m2/wk)
Kilogram Per Cubic Meter (mg/mL)
Milligram Per Week (mg/wk)
Megahertz (MHz)
Minute (min)
Milliliter (mL)
Milliliter Per Hour (mL/h)
Milliliter Per Kilogram (mL/kg)
Millimole (mmol)
Mole (mol)
Milliosmole (mosm)
Milliunit (mU)
Million Units (MU)
Millivolt (mV)
Nanocurie (nCi)
Nanogram (ng)
Nanogram Per Kilogram (ng/kg)
Nanogram Per Liter (ng/L)
Microgram Per Liter (ng/mL)
Nanometer (nm{light})
Nanomole (nmol)
Osmole (osm)
Pascal (Pa)
Picogram (pg)
Second (s)
Dalton (u)
Kilounit Per Kilogram (U/g)
Unit Per Kilogram (U/kg)
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Unit Per Square Meter (U/m2)
Microcurie (uCi)
Microgram (ug)
Microgram Per Square Centimeter
(ug/cm2)
Microgram Per Hour (ug/h)
Microgram Per Kilogram (ug/kg)
Microgram Per Kilogram Per Day
(ug/kg/24.h)
Microgram Per Square Meter (ug/m2)
Microliter (uL)
Micromole (umol)
Parent Drug Mean Concentration
Parent Drug Voided Amount
Metabolite Assay
Metabolite Assay
Metabolite Mean Concentration
Metabolite Amt in Void Uni(s) of Measuret
Metabolite Amt in Void Uni(s) of Measuret
Comments
Note Date
Research Comments Text
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Bladder Cancer NCT00445601 On-Study - S0337
Cystoscopy and Urine Markers Form - 2389143v1.0
S0337 Cystoscopy and Urine Markers Form
Gemcitabine After Surgery in Treating Patients With Newly
Diagnosed or Recurrent Bladder Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=FE26193B-
C3C0-4C67-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/7473
S0337 Cystoscopy and Urine
Markers Form
Header
SWOG Patient ID
SWOG Study No.
Registration Step
Patient Initials (L, F M)
Institution/Affiliate
Physician
Participating Group Name
Participating Group Study No.
Participating Group Patient ID
Planned Assessment
Month 12 (Month 12)
Month 15 (Month 15)
Month 18 (Month 18)
Month 21 (Month 21)
Month 24 (Month 24)
Month 3 (Month 3)
Month 30 (Month 30)
Month 36 (Month 36)
Month 48 (Month 48)
Month 6 (Month 6)
Month 9 (Month 9)
Prestudy (Prestudy)
Unnamed 2
Was a urine sample collected
Yes
No
1 / 2
Urine sample date
Was NMP22-Bladder Chek testing done (for
Month 24 or earlier only)
Yes
No
Result
Invalid (Invalid)
Negative (Negative)
Positive (Positive)
Explain
Was BTA stat testing done (for Month 24 or
earlier only)
Yes
No
Result
Invalid (Invalid)
Negative (Negative)
Positive (Positive)
Explain
Cytoscopy
Was cystoscopy performed
Yes
No
Cystoscopy Date
Explain
Was biopsy performed
Yes
No
Explain
Biopsy Result (If yes,)
Negative (negative)
Positive (positive)
Comments
Comments
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Bladder Cancer NCT00445601 Pre-Study - SOUTHWEST
ONCOLOGY GROUP S0337 Prestudy Form - 2388922v1.0
SOUTHWEST ONCOLOGY GROUP S0337 Prestudy Form
Gemcitabine After Surgery in Treating Patients With Newly
Diagnosed or Recurrent Bladder Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=FE24D648-
5D97-43D5-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/7474
SOUTHWEST ONCOLOGY GROUP
S0337 Prestudy Form
Header
SWOG Patient ID
SWOG Study No.
Registration Step
Patient Initials (L, F M)
Institution/Affiliate
Physician
Participating Group Name
Participating Group Study No.
Participating Group Patient ID
Disease Description
Performance Status
Fully Active, Able To Carry On All Pre-
disease Performance Without
Restriction. (0)
Restricted In Physically Strenuous
Activity But Ambulatory And Able To
Carry Out Work Of A Light Or Sedentary
Nature, E.g., Light Housework, Office
Work. (1)
Ambulatory And Capable Of All Selfcare
But Unable To Carry Out Any Work
Activities. Up And About More Than 50%
Of Waking Hours. (2)
Capable Of Only Limited Selfcare,
Confined To Bed Or Chair More Than
50% Of Waking Hours. (3)
Completely Disabled. Cannot Carry On
Any Selfcare. Totally Confined To Bed Or
1 / 4
Chair. (4)
Dead (5)
Date of Initial Pathologic Diagnosis
Date of Most Recent Prior Recurrence
Date Current Staging Assessment Completed
(Note: if patient has only had initial diagnosis,
enter same date for all three dates above)
Histologic Grade (Current)
Moderately Differentiated (Moderately
differentiated (G2))
Well Differentiated (Well differentiated
(G1))
Clinical T Stage (Highest - at current
diagnosis/depth of invasion)
Tumor Invades Subepithelial Connective
Tissue (T1)
Noninvasive Papillary Carcinoma (Ta)
Is the patient believed, based upon endoscopic
inspection, to have urothelial cancer of the
prostate or more distant urethra (or urethra at all
in women)
Yes
No
Date of endoscopy
Date of negative urine culture (OR negative
urinalysis See Section 5.4 for details)
Laboratory Values
Collection Date (MM DD YYYY)
Peripheral Platelet Count (/mcL)
WBC (X 10^3/mcL)
Hemoglobin (g/dL)
Hematocrit (%)
Total Bilirubin (mg/dL)
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Total bilirubin ULN (mg/dL)
SGOT (U/L)
SGOT (AST) ULN (U/L)
SGPT (U/L)
SGPT (ALT) ULN (U/L)
Alkaline Phosphatase (U/L)
Serum Creatinine (mg/dL)
Serum Creatinine ULN (mg/dL)
Risk Factors
Smoking Status
Currently Smoking (Currently smoking)
Never Smoked (Never smoked)
Smoked In The Past (Smoked in the
past)
Family history of bladder cancer (select one)
No (No)
Yes But Other Relative (Yes, but other
relative)
Yes First Degree Relative (Yes, first
degree relative)
Symptoms leading to current bladder cancer
diagnosis (select all that apply)
Gross Hematuria (Gross hematuria)
Irritative Voiding Symptoms (Irritative
voiding symptoms)
Microscopic Hematuria (Microscopic
hematuria)
Other Specify (Other)
Other, specify
Turbt History
Date (*Best estimate if exact date unknown)
Check box if no prior TURBT
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Prior Treatment Related To This Bladder
Cancer
Prior Intravesical Therapy
Yes
No
No. of Courses of Immunotherapy
Specify agent
No. of Courses of Chemotherapy
Date last course stopped
Date last course stopped
Type of Chemotherapy (select all that apply)
Mmc (MMC)
Other (Other)
Thiotepa (Thiotepa)
Specify Agent
Comments
Comments
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Lab - PHARMACOKINETICS -
2411380v1.0
Pharmacokinetics form for C3D 3.12 Adopters
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=01719877-
565A-4D08-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/7475
PHARMACOKINETICS
Pharmacokinetics--pk1
Course Number
Course Day Number
Agent Name
Stop Time
Specimen Sampling Type
Apheresis Cells (A)
Whole Blood (B)
Csf (C)
Cd33 Myeloid Cells (D)
Cd3 Lymphoid Cells (L)
Pbmc (peripheral Blood Mononuclear
Cells) (M)
Bone Marrow (O)
Plasma (P)
Serum (S)
Tumor Tissue (T)
Urine (U)
Saliva (V)
Cd14/cd15 Myeloid Cells (Y)
Sample ID Number
Sample ID Number
Treatment Start Date
Treatment Start Date
Start Time
Start Time
Planned Collection Time Intervals
Planned Collection Time Intervals
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Dose Time Elapsed Derived Minute Number
Parent Drug Assay
Parent Drug Assay
Parent Drug Mean Concentration
Unit
Metric Drop ([drp])
Gallon Us ([gal_us])
International Unit ([iU])
International Unit Of Vitamin A
([iU]{Vitamin A})
International Unit Per Kilogram ([iU]/kg)
International Unit Per Liter ([iU]/L)
International Unit Per Milligram ([iU]/mg)
International Unit Per Milligram Of Alpha-
tocopherol ([iU]/mg{alpha-Tocopherol})
Ounce ([oz_av])
Pound Per Square Inch ([psi])
Rad ([RAD])
Tablespoon Dosing Unit ([tbs_us])
Teaspoon Dosing Unit ([tsp_us])
Application ({Application})
Area Under Curve ({AUC})
Bottle Dosing Unit ({Bottle})
Caplet Dosing Unit ({Caplet})
Capsule Dosing Unit ({Capsule})
Cell ({Cells})
Course ({Course})
Cycle ({Course})
Dose ({Dose})
Inhalation Dosing Unit ({Inhalation})
Intravenous Bag Dosing Unit ({IV Bag})
Measurement ({Measure})
Source Data Not Available ({No Scre})
Packet Dosing Unit ({packet})
Patch Dosing Unit ({Patch})
Plaque Forming Unit ({pfu})
Puff Dosing Unit ({puff})
Retinol Activity Equivalent ({RAE})
Retinol Equivalent ({RE})
Radioactive Seed Implant Dosing Unit
({Seed})
Session ({Session})
Spray Dosing Unit ({Spray})
Suppository Dosing Unit ({Suppository})
Tablet Dosing Unit ({tbl})
Tissue Culture Infection Dose 50
({TCID50})
Troche Dosing Unit ({Troche})
Unit ({Unit})
Unknown ({Unknown})
Viral Particle Unit ({VP})
Wafer Dosage Form ({Wafer})
2 / 7
Lab - PHARMACOKINETICS - 2411380v1.0
Yeast Units ({YU})
Percent (%)
Thousand (10^3)
Hundred Thousand Cells Per Kilogram
(10^5{Cells}/kg)
Million (10^6)
Million Cells Per Kilogram
(10^6{Cells}/kg)
Million Plaque Forming Units (10^6{pfu})
Million Viral Particles (10^6{VP})
Million Electron Volt (10^6eV)
Ten Million Cells Per Kilogram
(10^7{Cells}/kg)
Ten Million Plaque Forming Units
(10^7{pfu})
Hundred Million Plaque Forming Units
(10^8{pfu})
Billion Cells Per Kilogram
(10^9{Cells}/kg)
Billion Plaque Forming Units (10^9{pfu})
Centigray (cGy)
Curie (Ci)
Deciliter (dL)
Equivalent Weight (eq)
Gram (g)
Gram Per Square Meter (g/m2)
Gray (Gy)
Hour (h)
Hertz (Hz)
Joule (J)
Joule Per Square Centimeter (J/cm2)
Kiloelectronvolt (keV)
Kilogram (kg)
Kilohertz (kHz)
Kilopascal (kPa)
Kilounit (kU)
Kilounit Per Kilogram (kU/kg)
Kilounit Per Liter (kU/L)
Liter (L)
Liter Per Minute (L/min)
Milliinternational Unit (m[iU])
Milliinternational Unit Per Square Meter
(m[iU]/m2)
Megarad (M[RAD])
Millicurie (mCi)
Milliequivalent (meq)
Milliequivalent Per 24 Hours (meq/24.h)
Milliequivalent Per Deciliter (meq/dL)
Milliequivalent Per Hour (meq/h)
Milliequivalent Per Liter (meq/L)
Milligram (mg)
Milligram Per Inhalation (mg/{inhalation})
Milligram Per 24 Hours (mg/24.h)
Milligram Per Deciliter (mg/dL)
Milligram Per Hour (mg/h)
Milligram Per Kilogram (mg/kg)
Milligram Per Square Meter (mg/m2)
Milligram Per Square Meter Per Day
(mg/m2/24.h)
Milligram Per Square Meter Per Hour
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(mg/m2/h)
Milligram Per Square Meter Per Week
(mg/m2/wk)
Kilogram Per Cubic Meter (mg/mL)
Milligram Per Week (mg/wk)
Megahertz (MHz)
Minute (min)
Milliliter (mL)
Milliliter Per Hour (mL/h)
Milliliter Per Kilogram (mL/kg)
Millimole (mmol)
Mole (mol)
Milliosmole (mosm)
Milliunit (mU)
Million Units (MU)
Millivolt (mV)
Nanocurie (nCi)
Nanogram (ng)
Nanogram Per Kilogram (ng/kg)
Nanogram Per Liter (ng/L)
Microgram Per Liter (ng/mL)
Nanometer (nm{light})
Nanomole (nmol)
Osmole (osm)
Pascal (Pa)
Picogram (pg)
Second (s)
Dalton (u)
Kilounit Per Kilogram (U/g)
Unit Per Kilogram (U/kg)
Unit Per Square Meter (U/m2)
Microcurie (uCi)
Microgram (ug)
Microgram Per Square Centimeter
(ug/cm2)
Microgram Per Hour (ug/h)
Microgram Per Kilogram (ug/kg)
Microgram Per Kilogram Per Day
(ug/kg/24.h)
Microgram Per Square Meter (ug/m2)
Microliter (uL)
Micromole (umol)
Unit
Metric Drop ([drp])
Gallon Us ([gal_us])
International Unit ([iU])
International Unit Of Vitamin A
([iU]{Vitamin A})
International Unit Per Kilogram ([iU]/kg)
International Unit Per Liter ([iU]/L)
International Unit Per Milligram ([iU]/mg)
International Unit Per Milligram Of Alpha-
tocopherol ([iU]/mg{alpha-Tocopherol})
Ounce ([oz_av])
Pound Per Square Inch ([psi])
Rad ([RAD])
Tablespoon Dosing Unit ([tbs_us])
Teaspoon Dosing Unit ([tsp_us])
Application ({Application})
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Area Under Curve ({AUC})
Bottle Dosing Unit ({Bottle})
Caplet Dosing Unit ({Caplet})
Capsule Dosing Unit ({Capsule})
Cell ({Cells})
Course ({Course})
Cycle ({Course})
Dose ({Dose})
Inhalation Dosing Unit ({Inhalation})
Intravenous Bag Dosing Unit ({IV Bag})
Measurement ({Measure})
Source Data Not Available ({No Scre})
Packet Dosing Unit ({packet})
Patch Dosing Unit ({Patch})
Plaque Forming Unit ({pfu})
Puff Dosing Unit ({puff})
Retinol Activity Equivalent ({RAE})
Retinol Equivalent ({RE})
Radioactive Seed Implant Dosing Unit
({Seed})
Session ({Session})
Spray Dosing Unit ({Spray})
Suppository Dosing Unit ({Suppository})
Tablet Dosing Unit ({tbl})
Tissue Culture Infection Dose 50
({TCID50})
Troche Dosing Unit ({Troche})
Unit ({Unit})
Unknown ({Unknown})
Viral Particle Unit ({VP})
Wafer Dosage Form ({Wafer})
Yeast Units ({YU})
Percent (%)
Thousand (10^3)
Hundred Thousand Cells Per Kilogram
(10^5{Cells}/kg)
Million (10^6)
Million Cells Per Kilogram
(10^6{Cells}/kg)
Million Plaque Forming Units (10^6{pfu})
Million Viral Particles (10^6{VP})
Million Electron Volt (10^6eV)
Ten Million Cells Per Kilogram
(10^7{Cells}/kg)
Ten Million Plaque Forming Units
(10^7{pfu})
Hundred Million Plaque Forming Units
(10^8{pfu})
Billion Cells Per Kilogram
(10^9{Cells}/kg)
Billion Plaque Forming Units (10^9{pfu})
Centigray (cGy)
Curie (Ci)
Deciliter (dL)
Equivalent Weight (eq)
Gram (g)
Gram Per Square Meter (g/m2)
Gray (Gy)
Hour (h)
Hertz (Hz)
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Joule (J)
Joule Per Square Centimeter (J/cm2)
Kiloelectronvolt (keV)
Kilogram (kg)
Kilohertz (kHz)
Kilopascal (kPa)
Kilounit (kU)
Kilounit Per Kilogram (kU/kg)
Kilounit Per Liter (kU/L)
Liter (L)
Liter Per Minute (L/min)
Milliinternational Unit (m[iU])
Milliinternational Unit Per Square Meter
(m[iU]/m2)
Megarad (M[RAD])
Millicurie (mCi)
Milliequivalent (meq)
Milliequivalent Per 24 Hours (meq/24.h)
Milliequivalent Per Deciliter (meq/dL)
Milliequivalent Per Hour (meq/h)
Milliequivalent Per Liter (meq/L)
Milligram (mg)
Milligram Per Inhalation (mg/{inhalation})
Milligram Per 24 Hours (mg/24.h)
Milligram Per Deciliter (mg/dL)
Milligram Per Hour (mg/h)
Milligram Per Kilogram (mg/kg)
Milligram Per Square Meter (mg/m2)
Milligram Per Square Meter Per Day
(mg/m2/24.h)
Milligram Per Square Meter Per Hour
(mg/m2/h)
Milligram Per Square Meter Per Week
(mg/m2/wk)
Kilogram Per Cubic Meter (mg/mL)
Milligram Per Week (mg/wk)
Megahertz (MHz)
Minute (min)
Milliliter (mL)
Milliliter Per Hour (mL/h)
Milliliter Per Kilogram (mL/kg)
Millimole (mmol)
Mole (mol)
Milliosmole (mosm)
Milliunit (mU)
Million Units (MU)
Millivolt (mV)
Nanocurie (nCi)
Nanogram (ng)
Nanogram Per Kilogram (ng/kg)
Nanogram Per Liter (ng/L)
Microgram Per Liter (ng/mL)
Nanometer (nm{light})
Nanomole (nmol)
Osmole (osm)
Pascal (Pa)
Picogram (pg)
Second (s)
Dalton (u)
Kilounit Per Kilogram (U/g)
6 / 7
Lab - PHARMACOKINETICS - 2411380v1.0
Unit Per Kilogram (U/kg)
Unit Per Square Meter (U/m2)
Microcurie (uCi)
Microgram (ug)
Microgram Per Square Centimeter
(ug/cm2)
Microgram Per Hour (ug/h)
Microgram Per Kilogram (ug/kg)
Microgram Per Kilogram Per Day
(ug/kg/24.h)
Microgram Per Square Meter (ug/m2)
Microliter (uL)
Micromole (umol)
Metabolite Assay
Metabolite Assay
Metabolite Mean Concentration
Comments
Note Date
Research Comments Text
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Lung Cancer NCT00946712 Pre-Study - Southwest
Oncology Group S0819 Prestudy Form - 2863901v1.0
Southwest Oncology Group S0819 Prestudy Form
Carboplatin and Paclitaxel With or Without Bevacizumab
and/or Cetuximab in Treating Patients With Stage IV or
Recurrent Non-Small Cell Lung Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=684FE956-
5AAF-A7DA-E040-BB89AD432A2B
All rights reserved. Please visit https://medical-data-
models.org/forms/7476
Southwest Oncology Group S0819
Prestudy Form
Header
SWOG Patient ID
SWOG Study No.
Registration Step
Patient Initials (L, F M)
Institution/Affiliate
Physician
Participating Group Name
Participating Group Study No.
Participating Group Patient ID
Patient And Disease Description
Performance Status
Fully Active, Able To Carry On All Pre-
disease Performance Without
Restriction. (0)
Restricted In Physically Strenuous
Activity But Ambulatory And Able To
Carry Out Work Of A Light Or Sedentary
Nature, E.g., Light Housework, Office
Work. (1)
Ambulatory And Capable Of All Selfcare
But Unable To Carry Out Any Work
Activities. Up And About More Than 50%
Of Waking Hours. (2)
Capable Of Only Limited Selfcare,
Confined To Bed Or Chair More Than
50% Of Waking Hours. (3)
Completely Disabled. Cannot Carry On
Any Selfcare. Totally Confined To Bed Or
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Chair. (4)
Dead (5)
Height (cm)
Weight (kg)
BSA (m^2)
Type of Patient Disease
New Diagnosis (New diagnosis)
Recurrent After Surgery Or Radiation
(Recurrent after surgery or radiation)
Histology
Adenocarcinoma (Adenocarcinoma)
Bronchoalveolar (bac) (Bronchoalveolar
carcinoma (BAC))
Large Cell Carcinoma (Large cell
carcinoma)
Mixed < 50% Squamous Cell Carcinoma
(Mixed < 50% squamous cell carcinoma)
Mixed >= 50% Squamous Cell
Carcinoma (Mixed >= 50% squamous
cell carcinoma)
Non-small Cell Lung Carcinoma (Other
Non-Small Cell Lung Cancer)
Squamous Cell Carcinoma (Squamous
cell carcinoma)
Specify
Clinical T Stage
No Evidence Of Primary Tumor (T0)
Tumor 3 Cm Or Less In Greatest
Dimension, Surrounded By Lung Or
Visceral Pleura, Invasion More Proximal
Than The Lobar Bronchus, (i.e., Not In
The Main Bronchus) (T1)
Tumor With Any Of The Following
Features Of Size Or Extent: More Than
3cm In Greatest Dimension; Invades The
Visceral Pleura; Associated With
Atelectasis Or Obstructive Pneumonitis
That Extends To The Hilar Region But
Does Not Involve The Entire Lung (T2)
Tumor Of Any Size That Directly Invades
Any Of The Following: Chest Wall
(including Superior Sulcus Tumors),
Diaphragm, Mediastinal Pleura, Parietal
Pericardium; Or Tumor In The Main
Bronchus Less Than 2 Cm Distal To The
Carina, But Without Involvement O* (T3)
Tumor Of Any Size That Directly Invades
Any Of The Following: Chest Wall
(including Superior Sulcus Tumors),
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Diaphragm, Mediastinal Pleura, Parietal
Pericardium; Or Tumor In The Main
Bronchus Less Than 2 Cm Distal To The
Carina, But Without Involvement O* (T4)
Carcinoma In Situ (Tis)
Primary Tumor Cannot Be Assessed, Or
Tumor Proven By The Presence Of
Malignant Cells In Sputum Or Bronchial
Washings But Not Visualized By Imaging
Or Bronchoscopy (Tx)
Clinical N Stage
No Regional Lymph Node Metastasis
(N0)
Metastasis To Ipsilateral Peribronchial
And/or Ipsilateral Hilar Lymph Nodes,
And Intrapulmonary Nodes Including
Involvement By Direct Extension Of The
Primary Tumor (N1)
Metastasis To Ipsilateral Mediastinal
And/or Subcarinal Lymph Node(s) (N2)
Metastasis To Contralateral Mediastinal,
Contralateral Hilar, Ipsilateral Or
Contralateral Scalene, Or
Supraclavicular Lymph Node(s) (N3)
Regional Lymph Nodes Cannot Be
Assessed (NX)
Clinical M Stage
No Distant Metastasis (no Pathologic
M0; Use Clinical M To Complete Stage
Group) (M0)
Separate Tumor Nodule(s) In A
Contralateral Lobe; Tumor With Pleural
Nodules Or Malignant Pleural (or
Pericardial) Effusion (M1a)
Distant Metastasis (M1b)
If M1a, was this staging due to pericardial/pleural
effusion only
Yes
No
Patient And Disease Description1
Smoking History
Current (Current)
Former (Former)
Never (Never)
Does patient have a history of hemoptysis
Yes
No
Amount of hemoptysis (If yes, teaspoons)
Date hemoptysis assessed (MM DD YYYY)
3 / 7
Lung Cancer NCT00946712 Pre-Study - Southwest Oncology Group
S0819 Prestudy Form - 2863901v1.0
Date of pre-treatment CT/MRI of brain (MM DD
YYYY)
Does the patient have clinical evidence of CNS
metastases
Yes
No
Medical History
Abdominal Fistula (Abdominal fistula)
Core Biopsy (Core biopsy)
Gastrointestinal Perforation
(Gastrointestinal perforation)
Intra-abdominal Abscess (Intra-
abdominal abscess)
Open Biopsy (Open biopsy)
Significant Traumatic Injury (Significant
traumatic injury)
Date of most recent event (MM DD YYYY)
Laboratory Values
ANC (mcl)
Peripheral Platelet Count (mcl)
Hemoglobin (mg/dL)
Liver metastases (Hepatic)
Yes
No
Total Bilirubin (mg/dL)
Total Bilirubin ULN (mg/dL)
SGOT (U/L)
SGOT (AST) ULN (U/L)
SGPT (U/L)
SGPT (ALT) ULN (U/L)
Collection Date (MM DD YYYY)
Collection Date (MM DD YYYY)
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Collection Date (MM DD YYYY)
Collection Date (MM DD YYYY)
Collection Date (MM DD YYYY)
Collection Date (MM DD YYYY)
Laboratory Values1
Serum Creatinine (mg/dL Renal)
Serum Creatinine ULN (mg/dL Renal)
Creatinine Clearance (ml/min Measured Renal)
Creatinine clearance (calculated) (ml/min Renal)
Urine Protein/Creatinine Ratio (Renal)
Protein from 24 hour Urine Collection (mg/24-
hours If UPC > 0.5, Renal)
INR (Coagulation)
INR ULN (Coagulation)
Albumin (g/dL)
LDH (U/L)
Collection Date (MM DD YYYY)
Collection Date (MM DD YYYY)
Collection Date (MM DD YYYY)
Collection Date (MM DD YYYY)
Collection Date (MM DD YYYY)
LDH, ULN (U/L)
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Additional Prestudy Data
Weight Loss in Previous Six Months (Estimated)
<5% Of Body Weight (< 5% of body
weight)
> Or = 20% Of Body Weight (> or = 20%
of body weight)
10 To <20% Of Body Weight (10 to <20%
of body weight)
5 To <10% Of Body Weight (5 to < 10%
of body weight)
Does the patient have a history of hemorrhagic
diasthesis or coagulopathy
Yes
No
Is the patient receiving therapeutic
anticoagulation, or regularly using aspirin at >
325 mg per day, or using non-steroidal anti-
inflammatory agents, or other agents known to
inhibit platelet function
Yes
No
Does patient have a non-healing wound, ulcer,
bone fracture, abdominal fistula, GI perforation,
or intraabdominal abscess
Yes
No
Does patient have a cavitary pulmonary lesion
Yes
No
Prior Treatment Related To This Cancer
Prior Therapy Type (s select all that apply)
Adjuvant Systemic Therapy (Adjuvant
systemic therapy)
Radiotherapy (Radiotherapy)
Surgery (Surgery)
Date prior adjuvant systemic therapy completed
(MM DD YYYY)
Date Prior RT Ended (MM DD YYYY)
Date of last prior major surgery (MM DD YYYY)
Date of last prior core biopsy, mediastinoscopy,
pleurodesis or VATS pericardial window (MM DD
YYYY)
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Date of last prior biopsy or surgical procedure
(not specified above MM DD YYYY)
Comments
Comments
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Bladder Cancer NCT01224665 Treatment - S1011 Surgeon's 90-Day
Assessment Form Standard Versus Extended LND (#5223) - 3153915v1.0
S1011 Surgeon's 90-Day Assessment Form Standard
Versus Extended LND (#5223)
Standard or Extended Pelvic Lymphadenectomy in Treating
Patients Undergoing Surgery for Invasive Bladder Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=940453E3-
43A8-BBC7-E040-BB89AD431F9F
All rights reserved. Please visit https://medical-data-
models.org/forms/7478
S1011 Surgeon's 90-Day
Assessment Form Standard Versus
Extended LND (#5223)
Header
SWOG Patient ID
SWOG Study No.
Registration Step
Patient Initials (L, F M)
Date of completion (MM DD YYYY)
Institution/Affiliate
Physician
Participating Group Name
Participating Group Study No.
Participating Group Patient ID
Complications
Was the assessment done
Yes
No
Other, specify
Other, specify
Start date (MM DD YYYY should be the date of
hospital discharge)
Stop date (MM DD YYYY should be 90 days post
surgery)
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Surgical Complications (Record any events that
occurred following hospital discharge to 90 days
post-op)
Acute Renal Failure (Acute renal failure)
Anastomotic Bowel Leak (Anastomotic
bowel leak)
Hemorrhage Postoperative (Bleeding > 4
units postoperative)
Bowel Obstruction (Bowel obstruction)
Cardiac Event With Cpr (Cardiac event
with CPR)
Cerebrovascular Accident Stroke
(CVA/stroke)
Death (Death)
Death Within 30 Days Of Cystectomy
(Death within 30 days of cystectomy)
Deep Vein Thrombosis (Deep venous
thrombosis)
Deep Wound Infection (Deep wound
infection)
Failure To Wean From Ventilator Within
48 Hours (Failure to wean from ventilator
within 48 hours)
Ileus (Ileus)
Lymph Leakage/lymphocele Requiring
Intervention (Lymph leakage/lymphocele
requiring intervention)
Myocardial Infarction (Myocardial
infarction)
Other, Specify (Other, Specify)
Pneumonia (PNEUMONIA)
Pulmonary Embolism (Pulmonary
Embolism)
Intubation (Re-intubation)
Renal Insufficiency Dialysis (Renal
insufficiency requiring dialysis)
Sepsis (Sepsis)
Superficial Wound Infection (Superficial
wound infection)
Symptomatic Lymph
Leakage/lymphocele (Symptomatic
lymph leakage/lymphocele)
Urinary Tract Infection (Urinary tract
infection)
Wound Disruption (Wound disruption)
Surgical Complication Grade
Death (Death of patient)
Interventional Radiology, Therapeutic
Endoscopy, Intubation, Angiography, Or
Operation (Interventional radiology,
therapeutic endoscopy, intubation,
angiography, or operation)
Residual Lasting Disability Requiring
Major Rehabilitation Or Organ Resection
(Residual lasting disability requiring
major rehabilitation or organ resection)
Use Of Intravenous Medication, Total
Parenteral Nutrition (tpn), Enteral
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Nutrition, Or Blood Transfusion (Use of
intravenous medication, total parenteral
nutrition (TPN), enteral nutrition, or blood
transfusion)
Use Of Oral Medications Or Bedside
Intervention (Use of oral medications or
bedside intervention)
Neoadjuvant Treatment Related To This
Bladder Cancer
Prior Adjuvant Chemotherapy
Yes
No
Will the patient receive adjuvant chemotherapy
(Please complete if the answer was "No" to
adjuvant chemotherapy)
Yes
No
Chemotherapy Regimen (Please complete if the
answer was "Yes" to adjuvant chemotherapy
select all that apply)
Carboplatin (Carboplatin)
Cisplatin (Cisplatin)
Gemcitabine (Gemcitabine)
Doxorubicin Vinblastine Methotrexate
Cisplatin (MVAC)
Paclitaxel (Paclitaxel)
Specify agent (other)
Number of Cycles
Treatment Start Date (MM DD YYYY)
Did the patient complete the planned adjuvant
therapy (Please indicate "Yes" if the patient
completed the planned adjuvant chemotherapy
as of this form submission)
Yes
No
Comments
Comments
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Leukemia NCT01041703 Treatment - E2906 Acute
Graft vs. Host Disease Form - Arm G - 2951629v1.0
E2906 Acute Graft vs. Host Disease Form - Arm G
Clofarabine or Daunorubicin Hydrochloride and Cytarabine
Followed By Decitabine or Observation in Treating Older
Patients With Newly Diagnosed Acute Myeloid Leukemia
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=758358AD-
52B1-2ABE-E040-BB89AD430F03
All rights reserved. Please visit https://medical-data-
models.org/forms/7480
E2906 Acute Graft vs. Host Disease
Form - Arm G
Header
DCI Name
Registration Step (Place ID Label Here)
Patient Initials (Last, First)
ECOG Protocol Number
ECOG Protocol Number
ECOG Patient ID
ECOG Patient ID
Participating Group Protocol Number
Participating Group Patient ID
Institution/Affiliate
On Treatment
Report Period
1 Year Post Transplant (1 Year Post
Transplant)
100 Days Post Transplant (100 Days
Post Transplant)
Unnamed2
Please mark an 'X' if data have been amended.
(Please circle amended items in red)
Date data amended (s M D Y)
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Gvhd Information
Did acute GVHD occur
Yes
No
Acute GVHD onset date (M D Y If yes)
Acute GVHD end date (M D Y If yes)
Gvhd Prophylaxis
Specify therapy used to treat acute GVHD
(Record an answer "yes" or "no" for each of the
following)
Corticosteroid (Corticosteroids)
Cyclosporine (cyclosporine)
Daclizumab (Daclizumab)
Mycophenolate Mofetil (Mycophenolate
Mofetil)
Other (other)
Sirolimus (Rapamycin)
Tacrolimus (Tacrolimus)
Other, specify
Agent Name
Date Agent Administered (M D Y Day+1 Day+3
Day+6 Day+11)
Agent Dose (mg)
Comments
Investigator Signature
Investigator Signature Date (MM DD YYYY)
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Bladder Cancer NCT01224665 Treatment - S1011 Intra-Op Surgical
Assessment Form Standard Versus Extended LND (#10689) - 3153877v1.0
S1011 Intra-Op Surgical Assessment Form Standard
Versus Extended LND (#10689)
Standard or Extended Pelvic Lymphadenectomy in Treating
Patients Undergoing Surgery for Invasive Bladder Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=940453E3-
434E-BBC7-E040-BB89AD431F9F
All rights reserved. Please visit https://medical-data-
models.org/forms/7481
S1011 Intra-Op Surgical Assessment
Form Standard Versus Extended
LND (#10689)
Header
SWOG Patient ID
SWOG Study No.
Registration Step
Patient Initials (L, F M)
Protocol Surgery Date (MM DD YYYY)
Institution/Affiliate
Physician
Participating Group Name
Participating Group Study No.
Participating Group Patient ID
Intra-operative Extent-of-disease
Assessment
Clinical T4b (fixed or involvement of pelvic side
wall, abdominal wall, or adjacent viscera e.g.
colon, small bowel)
Yes
No
Specify location of tumor (select all that apply)
Abdominal Wall (Abdominal wall)
Other Specify (Other)
Pelvic Sidewall (Pelvic sidewall)
Rectosigmoid (Rectosigmoid)
Other specify
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Gross Lymphadenopathy (Note: if in the extended
template, must be frozen)
Yes
No
Location of gross lymphadenopathy (Please
complete if the answer was "Yes" to Gross
Lymphadenopathy. Select all that apply)
Above Common Illiac Bifurcation (Above
common illiac bifurcation)
Below Common Illiac Bifurcation (Below
common illiac bifurcation)
Pathologic Lymph Node Assessment (if selected
please specify)
Negative (negative)
Positive (positive)
Description Of How Nodal Packets Were
Submitted To Your Pathologist
Did the participant have surgery per protocol
treatment?
Yes
No
Reason surgery not performed (If no)
Extent of pelvic lymph node dissection
Extended (Extended)
Protocol Defined Standard (Protocol
defined Standard)
Cranial extent of dissection (If "Extended,")
Above Inferior Mesenteric Artery (Above
IMA)
Aorta Bifurcation (Aortic Bifurcation)
Between Aortic Bifurcation And Ima
(Between Aortic Bifurcation and IMA)
Inferior Mesenteric Artery (IMA)
Other (Other)
Specify
Surgical Assessment Of Nodal Dissection
Which lymph node areas were dissected (Please
check all that apply Boundaries for "pelvic" are
defined by the Standard node dissection)
Aorta (Aortic)
Caval (Caval)
Left Common Iliac (Left common iliac)
Left External Iliac Lymph Node (Left
external iliac)
Left Fossa Of Marcille (Left fossa of
Marcille)
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Bladder Cancer NCT01224665 Treatment - S1011 Intra-Op Surgical
Assessment Form Standard Versus Extended LND (#10689) - 3153877v1.0
Left Internal Iliac Lymph Node (Left
internal iliac)
Left Node Of Cloquet (Left node of
cloquet)
Left Obturator Lymph Node (Left
obturator)
Left Pelvis (Left pelvic)
Other Specify (other)
Para-aortic (para-aortic)
Para-caval (Para-caval)
Paravesical (Paravesical)
Pre-aortic (Pre-aortic)
Pre-caval (Pre-caval)
Pre-sacral (Pre-sacral)
Right Common Iliac (Right common iliac)
Right External Iliac (Right external iliac)
Right Fossa Of Marcille (Right fossa of
Marcille)
Right Internal Iliac (Right internal iliac)
Right Node Of Cloquet (Right node of
cloquet)
Right Obturator (Right obturator)
Right Pelvis (Right pelvic)
Other specify
Reconstruction
Surgical Reconstruction
Continent Catheterizable Reservoir
(Continent Catheterizable Reservoir)
Ileal Conduit (Ileal Conduit)
Neobladder (Neobladder)
Other, Specify (Other specify)
Other specify
Anastomosis Performed Type
Entirely Stapled (Entirely stapled)
Hand-sewn (Hand-sewn)
Partially Stapled And Partially Hand-
sewn (Partially stapled and partially
hand-sewn)
Operative Information
Duration of Surgery (skin to skin, in hrs: minutes)
Estimated blood loss (ml)
Total units whole blood (in units equivalent to 500
ml whole blood)
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Bladder Cancer NCT01224665 Treatment - S1011 Intra-Op Surgical
Assessment Form Standard Versus Extended LND (#10689) - 3153877v1.0
Total units PRBC (in units equivalent to 500 ml
whole blood)
Total units fresh frozen plasma (in units
equivalent to 500 ml whole blood)
Total units platelets (in units equivalent to 500 ml
whole blood)
Intraoperative vascular injury
Yes
No
Specify location (If yes)
Perioperative DVT prophylaxis (other than
sequential compression device)
Heparin (Heparin)
Lovenox (Lovenox)
Other (Other)
Other, specify
Epidural anesthesia employed
Yes
No
Nerve sparing
Yes
No
Laterality (Please complete if the answer was
"yes" to nerve sparing. Select all that apply)
Left (Left)
Right (Right)
Nerve-sparing status (if selected please specify)
Complete (Complete)
Partial (Partial)
Photographic documentation (required per
protocol)
Yes
No
Specify
Comments
Comments
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Bladder Cancer NCT01224665 Treatment - S1011 Intra-Op Surgical
Assessment Form Standard Versus Extended LND (#10689) - 3153877v1.0
Metastatic Cancer NCT00134056 Treatment - SOUTHWEST ONCOLOGY GROUP
S0421 PAIN MEDICATION LOG: Step 1 Randomization Form - 2305593v3.0
SOUTHWEST ONCOLOGY GROUP S0421 PAIN
MEDICATION LOG: Step 1 Randomization Form
Docetaxel and Prednisone With or Without Atrasentan in
Treating Patients With Stage IV Prostate Cancer and Bone
Metastases That Did Not Respond to Previous Hormone
Therapy
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=F15B6C7A-
5A30-3964-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/7484
SOUTHWEST ONCOLOGY GROUP
S0421 PAIN MEDICATION LOG:
Step 1 Randomization Form
Administrative documentation
SWOG Patient ID
SWOG Study No.
Registration Step
Patient Initials (L, F M)
Institution/Affiliate
Physician
Participating Group Name
Participating Study No.
Participating Patient ID
Planned Assessment
Prestudy (Prestudy)
Week 10 (Week 10)
Week 13 (Week 13)
Week 16 (Week 16)
Week 19 (Week 19)
Week 22 (Week 22)
Week 25 (Week 25)
Week 28 (Week 28)
Week 31 (Week 31)
Week 34 (Week 34)
Week 37 (Week 37)
Week 4 (Week 4)
Week 7 (Week 7)
Patient Instructions
1 / 2
Date log started
Medication
Name of Pain Medication
Medication Type (*)
Liquid (Liquid)
Patch (Patch)
Pill (Pill)
Pump (Pump)
Analgesic Code (+)
No Analgesic (No analgesic)
Non-narcotic (Non-narcotic)
Strong Opioid (Strong opioid)
Weak Opioid (Weak opioid)
Dose (Units ^)
Number of pain meds taken at this dose (Tallies /)
2 / 2
Metastatic Cancer NCT00134056 Treatment - SOUTHWEST ONCOLOGY GROUP
S0421 PAIN MEDICATION LOG: Step 1 Randomization Form - 2305593v3.0
Pancreatic Cancer NCT00075686 Treatment -
S0205 PAIN MEDICATION LOG - 2291766v3.0
S0205 PAIN MEDICATION LOG
S0205 Gemcitabine With or Without Cetuximab as First-
Line Therapy in Treating Patients With Locally Advanced
Unresectable or Metastatic Adenocarcinoma of the
Pancreas
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=E30D7C36-
2312-0722-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/7485
S0205 PAIN MEDICATION LOG
Administrative documentation
SWOG Patient ID*
SWOG Study No.*
Registration Step*
Patient Initials (L, F M)*
Institution/Affiliate*
Physician*
Treatment Number*
Prestudy (Prestudy)
Week 13 (Week 13)
Week 17 (Week 17)
Week 5 (Week 5)
Week 9 (Week 9)
Date Log Started*
Analgesics
Name of Pain Medication (Nurse and Patient)*
Medication Type*
Pill (1)
Liquid (2)
Pump (3)
Patch (4)
Analgesic Code (+)*
No Analgesic (No analgesic)
Non-narcotic (Non-narcotic)
Strong Opioid (Strong opioid)
Weak Opioid (Weak opioid)
Dose (Units ^)*
1 / 2
Number of pain meds taken at this dose Tallies
(/)*
Number of pain meds taken at this dose Total*
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Pancreatic Cancer NCT00075686 Treatment - S0205 PAIN MEDICATION
LOG - 2291766v3.0
Sarcoma, Kaposi xxx Lab - Hematology -
RF22 - 2266607v3.0
Hematology - RF22
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=CCE367E9-
0073-46CD-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/7489
Hematology - RF22
Ccrr Module For Hematology - Rf22
Reticulocyte count (%)
Hematocrit (%)
Sequence #
Patient Initials
Study#
Site#
ID#
Cycle#
Cycle Day
Date Specimen Obtained
Which evaluation does this represent?
Baseline (Entry/Baseline)
On Treatment (On Treatment)
Post Therapy Evaluation (Post Therapy
Evaluation)
Hemoglobin (g/dl)
WBC (1000/cu mm)
Absolute Neutrophil Count (1000/cu mm) WBC x
(%Neutrophils including Bands)/100
Absolute Neutrophil Count (1000/cu mm) WBC x
(%Neutrophils including Bands)/100
Lymphocytes (%)
Monocytes (%)
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Eosinophils (%)
Basophils (%)
Platelets (1000/cu mm)
RBC (cmm)
PT (Prothrombin Time)
PTT (Partial Thromboplastin Time)
Other hematology tests, specify
Other hematology tests, specify
Other hematology tests, specify
Other hematology tests, specify
Units, specify
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Sarcoma, Kaposi xxx Lab - Hematology - RF22 - 2266607v3.0
Multiple Myeloma and Plasma Cell Neoplasm NCT00644228 Pre-Study -
Southwest Oncology Group S0777 Induction and Maintenance Treatment Summary
Form - 2657456v1.0
Southwest Oncology Group S0777 Induction and
Maintenance Treatment Summary Form
Lenalidomide and Dexamethasone With or Without
Bortezomib in Treating Patients With Previously Untreated
Multiple Myeloma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=334859E2-
7B5F-1097-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/7495
Southwest Oncology Group S0777
Induction and Maintenance
Treatment Summary Form
Header
SWOG Patient ID
SWOG Study No.
Registration Step
Patient Initials (L, F M)
Cycle completed
Induction (Induction)
Maintenance Therapy (Maintenance)
Institution/Affiliate
Physician
Participating Group Name
Participating Group Study No.
Participating Group Patient ID (Instructions: All
dates are MONTH, DAY, YEAR. Explain any
blank fields or blank dates in the Comments
section.)
Status
Date of Last Contact or Death
Vital Status
Alive (Alive)
Dead (Dead)
Has the patient progressed per the definition of
Section 10.0 of the protocol
Yes
1 / 3
No
Treatment
Agent Name
Agent Start Date
Agent End Date
Starting daily dose given
Ending daily dose given
Treatment
Agent Name
Agent Start Date
Agent End Date
Starting daily dose given
Ending daily dose given
Treatment
Agent Name
Agent Start Date
Agent End Date
Starting daily dose given
Ending daily dose given
Treatment
Did patient receive daily aspirin
Yes
No
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Multiple Myeloma and Plasma Cell Neoplasm NCT00644228 Pre-Study -
Southwest Oncology Group S0777 Induction and Maintenance Treatment Summary
Form - 2657456v1.0
Daily dose
Were there any dose modifications or
additions/omissions to protocol treatment?
No (No)
Yes, Planned (i.e., The Treatment Was
Changed According To Protocol
Guidelines) (Yes, planned)
Yes, Unplanned (i.e., The Treatment
Change Was Not Part Of Protocol
Guidelines) (Yes, unplanned)
Has the patient received bisphosphonates
(during this treatment segment)
Yes
No
Bisphosphonates, specify
Disease Description
Weight
BSA
Performance Status
Fully Active, Able To Carry On All Pre-
disease Performance Without
Restriction. (0)
Restricted In Physically Strenuous
Activity But Ambulatory And Able To
Carry Out Work Of A Light Or Sedentary
Nature, E.g., Light Housework, Office
Work. (1)
Ambulatory And Capable Of All Selfcare
But Unable To Carry Out Any Work
Activities. Up And About More Than 50%
Of Waking Hours. (2)
Capable Of Only Limited Selfcare,
Confined To Bed Or Chair More Than
50% Of Waking Hours. (3)
Completely Disabled. Cannot Carry On
Any Selfcare. Totally Confined To Bed Or
Chair. (4)
Dead (5)
Comments
Comments
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Multiple Myeloma and Plasma Cell Neoplasm NCT00644228 Pre-Study -
Southwest Oncology Group S0777 Induction and Maintenance Treatment Summary
Form - 2657456v1.0
Prostate Cancer NCT00430183 On-Study -
CALGB 90203: On-Study Form - 2524962v1.0
CALGB 90203: On-Study Form [Form C-1239]
Surgery With or Without Docetaxel and Leuprolide or
Goserelin in Treating Patients With High-Risk Localized
Prostate Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=1EEA73A2-
08B9-6F29-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/7500
CALGB 90203: On-Study Form
Ccrr Module For Calgb 90202: Prostate
Specific Antigen Form
CALGB Form (C-714)
CALGB Study No.
CALGB Patient ID
Are data amended
Yes
No
Patient Initials (Last, First Middle)
Patient Hospital No.
Institution/Affiliate
Participating Group
Participating Group Study No.
Participating Group Patient ID
Performance Status
ECOG Performance Status (Recommended Term
for CRF text "CTC Performance Status" - Mark
one with an X.)
Fully Active, Able To Carry On All Pre-
disease Performance Without
Restriction. (0)
Restricted In Physically Strenuous
Activity But Ambulatory And Able To
Carry Out Work Of A Light Or Sedentary
Nature, E.g., Light Housework, Office
Work. (1)
Ambulatory And Capable Of All Selfcare
But Unable To Carry Out Any Work
Activities. Up And About More Than 50%
Of Waking Hours. (2)
1 / 6
Initial Diagnosis
Date of Initial Pathologic Diagnosis (mm dd yyyy)
Gleason Grade, Primary (Enter 1-5)
Gleason Grade, Secondary (Enter 1-5)
Gleason Score, Combined (Enter 2-10)
T Stage, Clinical (2002 TNM Classification
System Mark one with an X.)
Clinically Inapparent Tumor Not Palpable
Nor Visible By Imaging (T1)
Tumor Incidental Histologic Finding In
5% Or Less Of Tissue Resected (T1a)
Tumor Incidental Histologic Finding In
More Than 5% Of Tissue Resected
(T1b)
Tumor Identified By Needle Biopsy (eg,
Because Of Elevated Psa) (T1c)
Tumor Confined Within The Prostate (T2)
Tumor Involves One Lobe (T2a)
Tumor Involves Both Lobes (T2b)
Tumor Involves Both Lobes (T2c)
Tumor Extends Through The Prostate
Capule (T3)
Extracapsular Extension (unilateral Or
Bilateral) (T3a)
N Stage, Clinical (radiographic)
No Regional Lymph Node Metastasis
(N0)
Metastatis In Regional Lymph Node Or
Nodes (see Ajcc Definition) (N1)
Regional Lymph Nodes Cannot Be
Assessed (NX)
M Stage, Clinical
No Distant Metastasis (M0)
Distant Metastasis (M1)
Nonregional Lymph Node(s) (M1a)
Bone(s) (M1b)
Other Site(s) (M1c)
Distant Metastasis Cannot Be Assessed
(MX)
Laboratory Values
Peripheral WBC Count (x 10^3/mcL)
Absolute Neutrophil Count (cells/mcL)
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Prostate Cancer NCT00430183 On-Study - CALGB 90203: On-Study
Form - 2524962v1.0
Peripheral Platelet Count (x 10^3/mcL)
Hemoglobin (g/dL)
Bilirubin (mg/dL)
Bilirubin ULN (mg/dL)
SGOT (AST U/L)
SGOT (AST) ULN (U/L)
SGPT (ALT U/L)
SGPT (ALT) ULN (U/L)
Creatinine (mg/dL)
Creatinine ULN (mg/dL)
Alkaline Phosphatase (U/L)
Alkaline Phosphatase LLN (U/L)
Alkaline Phosphatase ULN (U/L)
Lactate Dehydrogenase (LDH) (U/L)
Lactate Dehydrogenase LLN (U/L)
Lactate Dehydrogenase ULN (U/L)
Testosterone
Units (*Units: 1=ng/dL, 2=ng/mL, 3=nmol/L,
4=NOS)
Nanograms Per Deciliter (ng/dL)
Nanograms Per Milliliter (ng/mL)
Nanomoles Per Liter (nmol/l)
Not Otherwise Specified (NOS)
Testosterone LLN
Testosterone ULN
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Prostate Cancer NCT00430183 On-Study - CALGB 90203: On-Study
Form - 2524962v1.0
Kattan Nomogram (predicted progression-free
probability at 5 years after radical prostatectomy
using pre-biopsy PSA)
Ccrr Module For Calgb 90202: Prostate
Specific Antigen Form
PSA Date (mm dd yyyy)
PSA Value (total) (ng/mL)
PSA Assay Type
Abbott Labs (Abbott)
Bayer (Bayer)
Beckman Coulter (Beckman Coulter)
Hybritech (Hybritech)
Immulite (Immulite)
J&j Ortho (J&J Ortho)
Other (Other)
Roche (Roche)
Sandwich (Sandwich)
Siemens (Siemens)
Tosoh Nexia (Tosoh Nexia)
Unknown (Unknown)
Yang Pros-check (Yang)
Other specify
Ccrr Module For Calgb 90202: Prostate
Specific Antigen Form
PSA Date (mm dd yyyy)
PSA Value (total) (ng/mL)
PSA Assay Type
Abbott Labs (Abbott)
Bayer (Bayer)
Beckman Coulter (Beckman Coulter)
Hybritech (Hybritech)
Immulite (Immulite)
J&j Ortho (J&J Ortho)
Other (Other)
Roche (Roche)
Sandwich (Sandwich)
Siemens (Siemens)
Tosoh Nexia (Tosoh Nexia)
Unknown (Unknown)
Yang Pros-check (Yang)
Other specify
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Prostate Cancer NCT00430183 On-Study - CALGB 90203: On-Study
Form - 2524962v1.0
Ccrr Module For Calgb 90202: Prostate
Specific Antigen Form
PSA Date (mm dd yyyy)
PSA Value (total) (ng/mL)
PSA Assay Type
Abbott Labs (Abbott)
Bayer (Bayer)
Beckman Coulter (Beckman Coulter)
Hybritech (Hybritech)
Immulite (Immulite)
J&j Ortho (J&J Ortho)
Other (Other)
Roche (Roche)
Sandwich (Sandwich)
Siemens (Siemens)
Tosoh Nexia (Tosoh Nexia)
Unknown (Unknown)
Yang Pros-check (Yang)
Other specify
Unnamed2
LHRH agonist therapy (Mark all that apply with an
X.)
Goserelin (Goserelin (Zoladex))
Leuprolide Acetate (Leuprolide (Eligard))
Leuprolide Acetate (Leuprolide (Lupron))
Not Taken (Not taken)
Other (Other)
Other specify
LHRH agonist start date (mm dd yyyy)
LHRH agonist last administered date (mm dd
yyyy)
Oral antiandrogen therapy (Mark all that apply
with an X.)
Bicalutamide (Bicalutamide (Casodex))
Flutamide (Flutamide (Eulexin))
Nilutamide (Nilutamide)
Not Taken (Not taken)
Other (Other)
Other specify
Oral Antiandrogen Start Date (Most recent. mm
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Prostate Cancer NCT00430183 On-Study - CALGB 90203: On-Study
Form - 2524962v1.0
dd yyyy)
Oral antiandrogen last administered date (mm dd
yyyy)
Other Prior Therapy
Prior treatment (for benign prostatic hyperplasia
BPH Mark all that apply with an X.)
Laser Therapy (Laser therapy)
None (None)
Other (Other)
Transurethral Microwave Thermotherapy
(tumt) Of Prostate (TUMT (transurethral
microwave therapy))
Transurethral Needle Ablation Of
Prostate (TUNA (transurethral needle
ablation))
Transurethral Prostatic Resection (TURP
(transurethral resection of the prostate))
Other specify
Ccrr Module For Calgb: 90202 On-study
Completed by (Last Name, First name)
Date Form Originally Completed (mm dd yyyy)
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Prostate Cancer NCT00430183 On-Study - CALGB 90203: On-Study
Form - 2524962v1.0
Multiple Myeloma and Plasma Cell Neoplasm NCT00644228 Treatment - Southwest
Oncology Group S0777 Bone Marrow Transplant Summary Form - 2657580v1.0
Southwest Oncology Group S0777 Bone Marrow
Transplant Summary Form
Lenalidomide and Dexamethasone With or Without
Bortezomib in Treating Patients With Previously Untreated
Multiple Myeloma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=33567017-
4F52-711E-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/7501
Southwest Oncology Group S0777
Bone Marrow Transplant Summary
Form
Header
SWOG Patient ID
SWOG Study No.
Patient Initials (L, F M)
Registration Step
Cycle completed
First Transplant (First transplant)
Second Transplant (Second transplant)
Institution/Affiliate
Physician
Participating Group Name
Participating Group Study No.
Participating Group Patient ID
Disease Status
Date of Last Contact or Death
Vital Status
Alive (Alive)
Dead (Dead)
Physical: Start Date Of Treatment
Weight
1 / 2
BSA
ECOG Performance Status
Fully Active, Able To Carry On All Pre-
disease Performance Without
Restriction. (0)
Restricted In Physically Strenuous
Activity But Ambulatory And Able To
Carry Out Work Of A Light Or Sedentary
Nature, E.g., Light Housework, Office
Work. (1)
Ambulatory And Capable Of All Selfcare
But Unable To Carry Out Any Work
Activities. Up And About More Than 50%
Of Waking Hours. (2)
Capable Of Only Limited Selfcare,
Confined To Bed Or Chair More Than
50% Of Waking Hours. (3)
Completely Disabled. Cannot Carry On
Any Selfcare. Totally Confined To Bed Or
Chair. (4)
Dead (5)
Bone Marrow
Date of Peripheral Blood Stem Cell Infusion
Number of CD34-positive cells infused (X10^6
cells/kg)
Comments
Comments
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Multiple Myeloma and Plasma Cell Neoplasm NCT00644228 Treatment - Southwest
Oncology Group S0777 Bone Marrow Transplant Summary Form - 2657580v1.0
Breast Cancer NCT00075764 Follow-Up - SOUTHWEST
ONCOLOGY GROUP S0226 FOLLOW UP FORM - 2173463v3.0
SOUTHWEST ONCOLOGY GROUP S0226 FOLLOW UP
FORM
S0226 Anastrozole With or Without Fulvestrant as First-
Line Therapy in Postmenopausal Women With Metastatic
Breast Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=C32229DC-
31B0-25D5-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/7504
SOUTHWEST ONCOLOGY GROUP
S0226 FOLLOW UP FORM
Header
SWOG Patient ID
SWOG Study No.
Registration Step
Patient Initials (L, F M)
Institution/Affiliate
Physician (Groups other than SWOG)
Group Name
Unnamed2
Vital Status
Vital Status
Alive (Alive)
Dead (Dead)
Date of last contact or death
Disease Follow Up Status
Has the patient had a documented clinical
assessment for this cancer since submission of
the previous follow-up form?
Yes
No
Date of Last Clinical Assessment (If Yes)
Notice Of First Relapse Or Progression
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Has the patient developed a first relapse or
progression that has not been previously
reported?
Yes
No
Date of Relapse or Progression
Site(s) of relapse or progression
First treatment regimen received after first
relapse or progression
Notice Of New Primary
Has a new primary cancer or myelodysplastic
syndrome (MDS) been diagnosed that has not
been previously reported?
Yes
No
Date of Diagnosis (If Yes)
New Primary Site
Non-protocol Treatment
Has the patient received any non-protocol cancer
therapy not previously reported?
Yes
No
Date of First Non-Protocol Therapy
Agents
Long Term Toxicity
Has the patient experienced (prior to treatment
for progression or relapse or a second primary,
and prior to non-protocol treatment) any severe
(grade >= 3) long term toxicity that has not been
previously reported?
Yes
No
Toxicities and Grades
Comments
2 / 3
Breast Cancer NCT00075764 Follow-Up - SOUTHWEST ONCOLOGY
GROUP S0226 FOLLOW UP FORM - 2173463v3.0
Comments
Ccrr Module For Southwest Oncology
Group S0226 Follow Up Form
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Breast Cancer NCT00075764 Follow-Up - SOUTHWEST ONCOLOGY
GROUP S0226 FOLLOW UP FORM - 2173463v3.0
Breast Cancer NCT00070564 Follow-Up - SOUTHWEST ONCOLOGY
GROUP S0221 SUPPLEMENTARY FOLLOW UP FORM - 2101304v3.0
SOUTHWEST ONCOLOGY GROUP S0221
SUPPLEMENTARY FOLLOW UP FORM
Adjuvant Doxorubicin, Cyclophosphamide, and Paclitaxel in
Treating Patients With Breast Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=BACD42B3-
A5E1-6833-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/7507
SOUTHWEST ONCOLOGY GROUP
S0221 SUPPLEMENTARY FOLLOW
UP FORM
Header
SWOG Patient ID
SWOG Study No.
Registration Step
Institution/Affiliate
Physician
Participating Group Name
Participating Group Protocol Number
Participating Group Patient ID
Header
Has the patient been diagnosed with opposite
breast cancer since submission of last follow-up
form?
Yes
No
Date of diagnosis
Has the patient been diagnosed with first local-
regional recurrence since submission of last
follow-up form?
Yes
No
Date of First Local-Regional Progression
Site(s) of First Local-Regional Progression (select
all that apply)
Axilla (Axilla)
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Axillary Breast (Axillary Breast)
Chest wall (Chest wall)
Infraclavicular nodes (Infraclavicular
nodes)
Internal mammary nodes (Internal
mammary nodes)
Ipsilateral Breast (Ipsilateral Breast)
Supraclavicular nodes (Supraclavicular
nodes)
How was this progression information obtained?
Clinical Assessment (Clinical
assessment)
Patient Self Report Only (Patient self-
report only)
How was this progression information obtained?
Clinical Assessment (Clinical
assessment)
Patient Self Report Only (Patient self-
report only)
Has the patient been diagnosed with first distant
recurrence/progression since submission of last
follow-up form?
Yes
No
Date of First Distant Progression
Site(s) of First Distant Progression
Bone (bone)
Central Nervous System (braine)
Liver (liver)
Lung (lung/pleura)
Lymph Nodes (distant) (nodes)
Central Nervous System (other CNS)
Specify Other Location Not Described
(other soft tissue)
Specify Other Location Not Described
(other visceral)
Other, Generalized, Nos, Carcinomatosis
(other, NOS)
Skin (skin)
Other, NOS (site of first distant progression
Comments
Comments
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Breast Cancer NCT00070564 Follow-Up - SOUTHWEST ONCOLOGY
GROUP S0221 SUPPLEMENTARY FOLLOW UP FORM - 2101304v3.0
Lung Cancer NCT00096265 On-Study - I1 RTOG Phase III -
Multiple Brain Mets Initial Evaluation Form - 2277804v3.0
I1 RTOG Phase III - Multiple Brain Mets Initial Evaluation
Form
Radiation Therapy and Stereotactic Radiosurgery With or
Without Temozolomide or Erlotinib in Treating Patients With
Brain Metastases Secondary to Non-Small Cell Lung
Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=D81B6746-
376F-61E1-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/7511
I1 RTOG Phase III - Multiple Brain
Mets Initial Evaluation Form
Header
[RTOG Study No.]
RTOG Study 0320 (RTOG Study 0320)
Case #
Institution
Institution No.
Participant's Initials
Participant's I.D. No.
Module 1
Amended
Yes
No
Patient Characteristics
Performance Status
Neurologic Function
Minor Neurologic Symptoms, Fully Active
At Home/work Without Assistance (Minor
neurologic symptoms; fully active at
home/work without assistance)
Moderate Neurologic Symptoms, Fully
Active At Home/work But Requires
Assistance (Moderate neurologic
symptoms; fully active at home/ work but
requires assistance)
Moderate Neurologic Symptoms, Less
Than Fully Active At Home/work And
Requires Assitance (Moderate
neurologic symptoms; less than fully
active at home/ work and requires
assistance)
No Neurologic Symptoms, Fully Active At
Home/work Without Assistance (No
1 / 3
neurologic symptoms; fully active at
home/ work without assistance)
Severe Neurologic Symptoms, Totally
Inactive Requiring Complete Assistance
At Home Or Institution, Unable To Work
(Severe neurologic symptoms; totally
inactive requiring complete assistance at
home or in institution; unable to work)
Date of diagnosis of primary
Histology type (Lung)
Adenocarcinoma (Adenocarcinoma)
Large Cell (Large cell)
Other, Specify (Non small cell (NOS))
Squamous Cell (Squamous cell)
Metastatic Site(s)
Brain & other metastatic site (Brain &
other metastatic site)
Brain Only (Brain alone)
Prior Surgery (Brain)
Biopsy only (Biopsy only)
None (None)
Partial resection (Partial resection)
Dexamethasone (If yes, daily dose range this
report period)
Other Corticosteroids
No (No)
Unknown (Unknown)
Yes (Yes)
Specify [drug]
Daily Dose
Unit
Lesion Number (Brain)
Size Of Lesion(s)
Date of MRI
Lesion number (3) Largest Diameter (cm)
Lesion number (3) Largest Diameter (cm)
Lesion number (3) Largest Diameter (cm)
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Lesion number (3) Perpendicular (cm)
Lesion number (3) Perpendicular (cm)
Lesion number (3) Perpendicular (cm)
Module 4
Comments
Name of person completing this form
Date form completed, original
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Breast Cancer NCT00127205 Follow-Up - SOUTHWEST ONCOLOGY GROUP
FOLLOW-UP TUMOR ASSESSMENT FORM (S0307) - 2277562v3.0
SOUTHWEST ONCOLOGY GROUP FOLLOW-UP
TUMOR ASSESSMENT FORM (S0307)
Zoledronate, Clodronate, or Ibandronate in Treating Women
Who Have Undergone Surgery for Stage I, Stage II, or
Stage III Breast
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=DEB8F801-
4279-2F2B-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/7517
SOUTHWEST ONCOLOGY GROUP
FOLLOW-UP TUMOR
ASSESSMENT FORM (S0307)
Header
SWOG Patient ID
SWOG Study No.
Registration Step
Patient Initials (L, F M)
Date form completed
Institution/Affiliate
Physician
Participating Group Name
Participating Group Study No.
Participating Group Patient ID
Notice Of Progression - Adjuvant
Has the patient been diagnosed with opposite
breast cancer since submission of last follow-up
form?
Yes
No
Date of diagnosis
Has the patient been diagnosed with first local-
regional recurrence since submission of last
follow-up form?
Yes
No
1 / 3
Date of First Local-Regional Progression
Site(s) of First Local-Regional Progression (select
all that apply)
Axilla (Axilla)
Axilla (Axillary nodes)
Chest Wall (Chest wall)
Infraclavicular Nodes (Infraclavicular
nodes)
Internal Mammary Nodes (Internal
mammary nodes)
Ipsilateral Breast (Ipsilateral breast)
Supraclavicular Nodes (Supraclavicular
nodes)
Has the patient been diagnosed with first distant
recurrence/progression since submission of last
follow-up form?
Yes
No
Date of First Distant Progression
Site(s) of First Distant Progression
Bone (Bone)
Brain (Brain)
Liver (Liver)
Lung (Lung/pleura)
Nodes (Nodes)
Other Cns (Other CNS)
Other Soft Tissue (Other Soft Tissue)
Other Visceral (Other Visceral)
Other Nos (Other, NOS)
Skin (Skin)
Other, NOS
If the patient has been previously diagnosed with
first distant recurrence/progression at a site other
than
bone, has the patient been diagnosed with a
subsequent bone recurrence since submission of
last follow-up form?
Yes
No
Date of Subsequent Bone Progression
How was this progression information obtained?
Clinical Assessment (Clinical
assessment)
Patient Self Report Only (Patient self-
report only)
How was this progression information obtained?
Clinical Assessment (Clinical
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assessment)
Patient Self Report Only (Patient self-
report only)
Has the patient had a fracture since submission
of the last follow-up form?
Yes
No
indicate site (If yes,)
Ankle (Ankle)
Arm (Arm)
Hip (Hip)
Leg (Leg)
Pelvis (Pelvis)
Spine (Spine)
Wrist (Wrist)
Was the fracture traumatic (from greater than
standing height)?
Yes
No
Has the patient had osteonecrosis or
osteomyelitis of the jaw since submission of the
last follow-up form?
Yes
No
Comments
Comments
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Breast Cancer NCT00103233 Pre-Study - SOUTHWEST
ONCOLOGY GROUP Prestudy Form (S0347) - 2412719v1.0
SOUTHWEST ONCOLOGY GROUP Prestudy Form
(S0347)
Vinorelbine With or Without Trastuzumab in Treating
Women With Progressive Metastatic Breast Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=01ECF016-
02E2-1026-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/7519
SOUTHWEST ONCOLOGY GROUP
Prestudy Form (S0347)
Header
SWOG Patient ID
SWOG Study No.
Registration Step
Patient Initials (L, F M)
Institution/Affiliate
Physician (Participating Group:)
Group Name
Participating Group Study No.
Participating Group Patient ID (Instructions: All
dates are MONTH, DAY, YEAR. Explain any
blank fields or blank dates in the Comments
section. Place an X in appropriate boxes. Circle
AMENDED items in red and write AMENDED
across the top of the form.)
Patient Characteristics
Height
Weight
Performance Status
Fully Active, Able To Carry On All Pre-
disease Performance Without Restriction
(karnofsky 90 - 100) (ecog - 0
Asymptomatic) (0)
Restricted In Physically Strenuous
Activity But Ambulatory (k70 - 80) (ecog -
1 / 5
1 Symptomatic - Fully Ambulatory) (1)
Ambulatory And Capable Of All Selfcare
But Unable To Carry Out Any Work
Activities (k 50 - 60) (ecog - 2
Symptomatic; In Bed , 50% Of The Day)
(2)
Menopausal Status
Menopausal Status
Above Categories Not Applicable And
Age <50 (Above not applicable AND age
< 50)
Above Categories Not Applicable And
Age >= 50 (Above not applicable AND
age >=50)
Post (prior Bilateral Ovariectomy Or >12
Mo Since Lmp With No Prior
Hysterectomy And Not Currently
Receiving Therapy With Lh-rh Analogs
[e.g., Zoladex]) (Post (prior bilateral
ovariectomy OR > 12 mo since LMP with
no prior hysterectomy and not currently
receiving therapy with LH-RH analogs
[e.g. Zoladex]))
Pre (<6 Mo Since Lmp And No Prior
Bilateral Ovariectomy And Not On
Estrogen Replacement) (Pre (< 6 mo
since LMP and no prior bilateral
ovariectomy and not on estrogen
replacement))
Disease Description
SWOG Patient ID
ER Result
Negative (Negative)
Not Done (Never Done or Unknown)
Positive (Positive)
SWOG Study No.
ER Time
At Disease Recurrence (At disease
recurrence)
At Initial Primary Diagnosis (At initial
primary diagnosis)
Other (Other)
Registration Step
Patient Initials (L, F M)
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Other, specify
PgR Result
Negative (Negative)
Never Done Or Unknown (Never Done or
Unknown)
Positive (Positive)
PgR Time
At Disease Recurrence (At disease
recurrence)
At Initial Primary Diagnosis (At initial
primary diagnosis)
Other (Other)
Other, specify
HER-2/neu Status
Equivocal (Equivocal)
Negative (Negative)
Never Done Or Unknown (Never Done or
Unknown)
Positive (Positive)
HER-2/neu Time
At Disease Recurrence (At disease
recurrence)
At Initial Primary Diagnosis (At initial
primary diagnosis)
Other (Other)
Other, specify
Date of initial diagnosis of primary tumor
Date progressive, recurrent or metastatic disease
first diagnosed (radiologic or pathologic)
Involved sites at time of entry (select all involved
sites)
Bone (Bone)
Bone Marrow (Bone marrow)
Brain (Brain)
Distant Lymph Nodes (Distant nodes)
Distant Skin/subcutaneous Tissue
(Distant skin/subcutaneous tissue)
Ipsilateral Supraclavicular Nodes
(ipsilateral supraclavicular nodes)
Liver (Liver)
Local-regional (Local-regional)
Lung (Lung)
Opposite Breast (Opposite breast)
Other Cns (Other CNS)
Other (Other sites)
Pleura (Pleura)
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Other sites, specify
Prior Treatment Related To This Cancer
Other therapy, specify
Radiation (select one)
Extensive Radiation (Extensive RT)
Limited Radiation (Limited RT)
Not Otherwise Specified (Not otherwise
specified)
Has the patient had any of the following prior
treatments? (select ALL that apply)
Anti-retroviral Therapy (Anti-retroviral
therapy)
Antisense (Antisense)
Chemotherapy Multi-agent Systemic,
Adjuvant (Chemotherapy multi-agent
systemic, adjuvant)
Chemotherapy Multi-agent Systemic,
Advanced (Chemotherapy multi-agent
systemic, advanced)
Chemotherapy Non-cytotoxic, Advanced
(Chemotherapy non-cytotoxic, advanced)
Chemotherapy Non-cytoxic, Adjuvant
(Chemotherapy non-cytoxic, adjuvant)
Chemotherapy Other, Adjuvant
(Chemotherapy other, adjuvant)
Chemotherapy Other, Advanced
(Chemotherapy other, advanced)
Chemotherapy Single Agent Systemic,
Adjuvant (Chemotherapy single agent
systemic, adjuvant)
Chemotherapy Single Agent Systemic,
Advanced (Chemotherapy single agent
systemic, advanced)
Gene Transfer (Gene transfer)
Herceptin, Adjuvant (Herceptin, adjuvant)
Herceptin, Advanced (Herceptin,
advanced)
High-dose Chemotherapy With Marrow
Or Stem Cell Support, Adjuvant (High-
dose chemotherapy with marrow or stem
cell support, adjuvant)
High-dose Chemotherapy With Marrow
Or Stem Cell Support, Advanced (High-
dose chemotherapy with marrow or stem
cell support, advanced)
Hormonal Therapy, Adjuvant (Hormonal
therapy, adjuvant)
Hormonal Therapy, Advanced (Hormonal
therapy, advanced)
Immunotherapy, Adjuvant
(Immunotherapy, adjuvant)
Immunotherapy, Advanced
(Immunotherapy, advanced)
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Oncolytic Virotherapy (Oncolytic
virotherapy)
Other Therapy, Adjuvant (Other therapy,
adjuvant)
Other Therapy, Advanced (Other therapy,
advanced)
Surgery (Surgery)
Vaccine (Vaccine)
Number of prior chemotherapy regimens
Number of prior chemotherapy regimens for
metastatic disease
Comments
Comments
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Lymphoma NCT01193842 On-Study - AMC-
075 On-Study Form (F02) - 3253140v1.0
AMC-075 On-Study Form (F02)
Vorinostat and Combination Chemotherapy With Rituximab
in Treating Patients With Previously Untreated HIV-Related
Diffuse Large B-Cell Non-Hodgkin Lymphoma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=A80B1BD6-
1FC4-7A17-E040-BB89AD437903
All rights reserved. Please visit https://medical-data-
models.org/forms/7520
AMC-075 On-Study Form (F02)
Header
Visit number
Hiv History
Date of HIV+ diagnosis (mm/dd/yyyy)
Date of AIDS diagnosis (mm/dd/yyyy)
CDC HIV Risk Group
Hemophilia (Hemophiliac)
Heterosexual Contact (Heterosexual
contact)
Homosexual Or Bisexual Contact
(Homosexual or bisexual contact)
Iv Drug User (IV drug user)
Other (Other)
Transfusion Recipient (Transfusion
recipient)
Other, specify
Ccrr Module For On Study Form - Rf02b
Date of Initial Pathologic Diagnosis (mm/dd/yyyy)
Primary site
Anal Canal (Anal)
Cervical (Cervical)
Hd (HD)
Kaposi Sarcoma (KS)
Non-hodgkin's Lymphoma (NHL)
Other Primary Site (Other primary site)
Other specify
Specify tumor histologic category
Prior Treatment? (If "Yes", Check below)
Yes
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No
Prior Systemic Chemotherapy
Yes
No
Prior Biological Response Modifiers or Cytokines
Yes
No
Specify (If "Yes")
Prior Surgery (excluding biopsy)
Yes
No
Prior cryotherapy
Yes
No
Prior systemic steroid therapy
Yes
No
Prior Radiation Therapy
Yes
No
Prior topical/intralesional therapy
Yes
No
Other Prior Therapy (e.g. Hyperthermia, etc.)
Yes
No
Other Prior Therapy (e.g. Hyperthermia, etc.)
Yes
No
Specify (If "Yes" 1 2 3)
Name of other prior therapies (If "Yes")
Ccrr Module For On Study Form - Rf02b
History of Prior Malignancy
Yes
No
Date of Diagnosis of Previous Malignancy
(mm/dd/yyyy)
Primary site
Anal Canal (Anal)
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Cervical (Cervical)
Hd (HD)
Kaposi Sarcoma (KS)
Non-hodgkin's Lymphoma (NHL)
Other Primary Site (Other primary site)
Other specify
Specify tumor histologic category
Prior Treatment? (If "Yes", Check below)
Yes
No
Prior Systemic Chemotherapy
Yes
No
Prior Biological Response Modifiers or Cytokines
Yes
No
Specify (If "Yes")
Prior Surgery (excluding biopsy)
Yes
No
Prior cryotherapy
Yes
No
Prior systemic steroid therapy
Yes
No
Prior Radiation Therapy
Yes
No
Prior topical/intralesional therapy
Yes
No
Other Prior Therapy (e.g. Hyperthermia, etc.)
Yes
No
Other Prior Therapy (e.g. Hyperthermia, etc.)
Yes
No
Specify (If "Yes" 1 2 3)
Name of other prior therapies (If "Yes")
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Antiretroviral Therapy
Agent Name
Other, specify (1 2)
Agent use
Currently Receiving (Currently receiving)
Never Received (Never received)
Previously Received (Previously
received)
Duration if prior agents received
< 3 Months (< 3 months)
> 12 Months (> 12 months)
> 6-12 Months (> 6-12 months)
3-6 Months (3-6 months)
Comments
Comments
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NCT00450320 Treatment - AMC-051 Prior Treatment
History for Kaposi's Sarcoma Form (KS0) - 2636769v1.0
AMC-051 Prior Treatment History for Kaposi's Sarcoma
Form (KS0)
Sirolimus in Treating Patients With HIV-Related Kaposi's
Sarcoma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=2FF93C61-
6D7C-609C-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/7529
AMC-051 Prior Treatment History for
Kaposi's Sarcoma Form (KS0)
Header Module
Visit number
Date of evaluation
Header
Tumor (T check one)
Tumor Is Confined To Skin And/or To
Lymph Nodes And/or Patient Has
Minimal Oral Disease (Tumor is confined
to skin and/or to lymph nodes and/or
patient has minimal oral disease)
Tumor With Edema, Ulceration, Or
Extensive Oral Ks Or Gastro Ks Or Ks In
Other Nonnodal Viscera (Tumor with
edema, ulceration, or extensive oral KS
or gastro KS or KS in other nonnodal
viscera)
Immune System (I check one)
Cd4 Cells <200/ul (CD4 cells <200/uL)
Cd4 Cells >=200/ul (CD4 cells >=200/uL)
Unknown (Unknown)
History of opportunistic infection (OI) and/or
thrush (Systemic Illness S check all that apply)
Yes
No
B-symptoms present (Systemic Illness S check
all that apply)
Yes
No
Karnofsky performance status <70 (Systemic
Illness S check all that apply)
Yes
No
Other HIV-related illness (Systemic Illness S
check all that apply e.g., neurological disease,
lymphoma)
Yes
No
1 / 4
Unnamed2
Has the participant received single-agent
noninvestigational systemic chemotherapy or
immunotherapy for the treatment of Kaposi's
Sarcoma (If No or Unknown, go to Question 2)
No (No)
Unknown (Unknown)
Yes (Yes)
Agent Name
Agent administered
No (No)
Unknown (Unknown)
Yes (Yes)
Tumor Response Type
Clinical Complete Response (Clinical
complete response)
Complete Response (Complete
response)
Not Applicable (N/A)
Partial Response (Partial response)
Progressive Disease (Progressive
disease)
Stable Disease (Stable disease)
Unevaluable (Unevaluable)
Unknown (Unknown)
Source
Clinical Assessment (Clinical
assessment)
Other (Other)
Self Report Only (Self report only)
Other, specify
Other single agent therapy
No (No)
Unknown (Unknown)
Yes (Yes)
Unnamed3
Has the participant received combination or
alternating noninvestigational systemic
chemotherapy or immunotherapy for the
treatment of Kaposi's Sarcoma
No (No)
Unknown (Unknown)
Yes (Yes)
Agents name (Combination or Alternating)
Agent administered
No (No)
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Unknown (Unknown)
Yes (Yes)
Tumor Response Type
Clinical Complete Response (Clinical
complete response)
Complete Response (Complete
response)
Not Applicable (N/A)
Partial Response (Partial response)
Progressive Disease (Progressive
disease)
Stable Disease (Stable disease)
Unevaluable (Unevaluable)
Unknown (Unknown)
Source
Clinical Assessment (Clinical
assessment)
Other (Other)
Self Report Only (Self report only)
Other, specify
Other combination therapy
No (No)
Unknown (Unknown)
Yes (Yes)
Unnamed4
Has the participant received any systemic, local,
or topical therapy other than cytotoxic
chemotherapy for the treatment of Kaposi's
Sarcoma (If No or Unknown, STOP specified in
section 1)
No (No)
Unknown (Unknown)
Yes (Yes)
Specify
Tumor Response Type
Clinical Complete Response (Clinical
complete response)
Complete Response (Complete
response)
Not Applicable (N/A)
Partial Response (Partial response)
Progressive Disease (Progressive
disease)
Stable Disease (Stable disease)
Unevaluable (Unevaluable)
Unknown (Unknown)
Source
Clinical Assessment (Clinical
assessment)
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Other (Other)
Self Report Only (Self report only)
Other, specify
Footer Module
Comments
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Lymphoma NCT01190449 Treatment - CALGB
50901 Protocol Treatment Form - 3211735v1.0
CALGB 50901 Protocol Treatment Form
Ofatumumab in Treating Patients With Previously Untreated
Stage II, Stage III, or Stage IV Follicular Non-Hodgkin
Lymphoma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=9F53BA1C-
E75A-7A0D-E040-BB89AD43616B
All rights reserved. Please visit https://medical-data-
models.org/forms/7533
CALGB 50901 Protocol Treatment
Form
Protocol Treatment
Dose Administered
1000 Mg (1000 mg)
500 Mg (500 mg)
Cycle Start Date
Was the total dose administered
Yes
No
Dose Modification Reason
Were there any delays in dose administration
Yes
No
Reason dose was delayed (If yes)
Were all premedications administered per
protocol
Yes
No
Reason not administered per protocol
Agent Name (Diphenhydramine Glucocorticoid
Acetaminophen)
Agent Dose (mg)
Agent Dose (mg)
If HBsAg+, was HBV DNA testing performed
Yes
No
Was evidence of active HBV infection detected
Yes
No
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Lymphoma NCT00598169 Treatment - AMC-053 Study
Drug Administration Form (SD3) - 2823843v1.0
AMC-053 Study Drug Administration Form (SD3)
Bortezomib, Ifosfamide, Carboplatin, and Etoposide, With
or Without Rituximab, in Treating Patients With Relapsed or
Refractory AIDS-Related Non-Hodgkin Lymphoma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=6061B579-
4524-B185-E040-BB89AD4332D2
All rights reserved. Please visit https://medical-data-
models.org/forms/7536
AMC-053 Study Drug Administration
Form (SD3)
Enter Total Dose Of Study Drug Received
This Cycle And Dose Modification Codes
Cycle Start Date (mm/dd/yyyy)
Agent Name
Dose Modification
Dose Delayed (Dose delayed)
Dose Delayed And Reduced (Dose
delayed and reduced)
Dose Escalated (Dose escalated)
Dose Reduced (Dose reduced)
Drug Discontinued (Drug discontinued)
No Dose Modification (No dose
modification)
Total Dose of Agents/Drugs for this Cycle
(mg/m^2/cycle)
Agent Start Date (mm/dd/yyyy)
Agent End Date (mm/dd/yyyy)
Duration Delay (# Days)
Comments
Comments
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Lymphoma NCT00392834 Treatment - AMC-048
Study Drug Therapy Form (SD8) - 2655736v1.0
AMC-048 Study Drug Therapy Form (SD8)
Rituximab and Combination Chemotherapy in Treating
Patients With Newly Diagnosed, HIV-Associated Burkitt's
Lymphoma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=32E1BD21-
4069-538C-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/7537
AMC-048 Study Drug Therapy Form
(SD8)
Header
Visit number
Cycle Start Date
Enter Total Dose Of Study Drug Received
This Cycle And Dose Modification Codes
Agent Name
Dose Modification
Dose Delayed (Dose delayed)
Dose Delayed And Reduced (Dose
delayed and reduced)
Dose Escalated (Dose escalated)
Dose Reduced (Dose reduced)
Drug Discontinued (Drug discontinued)
No Dose Modification (No dose
modification)
Total Dose of Agents/Drugs for this Cycle
Units
Total number of doses (given for this cycle)
Agent Start Date
Agent End Date
Duration Delay
Comments
Comments
1 / 1
Breast Cancer NCT00382018 Follow-Up - SOUTHWEST
ONCOLOGY GROUP FOLLOW UP FORM - 2436449v1.0
SOUTHWEST ONCOLOGY GROUP FOLLOW UP FORM
Treatment Decision Making Based on Blood Levels of
Tumor Cells in Women With Metastatic Breast Cancer
Receiving Chemotherapy
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=07BF1268-
207C-02AD-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/7538
SOUTHWEST ONCOLOGY GROUP
FOLLOW UP FORM
Header
SWOG Patient ID
SWOG Study No.
Registration Step
Patient Initials (L, F M)
Institution/Affiliate
Physician
Participating Group Name
American College Of Surgeons
Oncology Group (ACOSOG)
American College Of Radiology
Oncologic Imaging Network (ACRIN)
Aids-associated Malignancies Clinical
Trials Consortium (AMC)
Cancer And Leukemia Group B (CALGB)
Children's Oncology Group (COG)
Eastern Cooperative Oncology Group
(ECOG)
European Organization For Research
And Treatment Of Cancer (EORTC)
Gynecologic Oncology Group (GOG)
International Breast Cancer Study Group
(IBCSG)
North American Brain Tumor Consortium
(NABTC)
Nabtt Brain Tumor Consortium (NABTT)
North Central Cancer Treatment Group
(NCCTG)
National Cancer Institute Of Canada
Clinical Trials Group (NCIC)
National Surgical Adjuvant Breast And
Bowel Project (NSABP)
Radiation Therapy Oncology Group
(RTOG)
Southwest Oncology Group (SWOG)
Participating Group Study No.
1 / 3
Participating Group Patient ID
Vital Status
Vital Status
Alive (Alive)
Dead (Dead)
Date of last contact or death
Has the patient had a documented clinical
assessment for this cancer (since submission of
the previous follow-up form)
Yes
No
Date of Last Clinical Assessment (If Yes,)
Has the patient developed a first relapse or
progression that has not been previously
reported
Yes
No
Date of Relapse or Progression (If Yes,)
Site(s) of relapse or progression
Has a new primary cancer or MDS been
diagnosed that has not been previously reported?
(myelodysplastic syndrome)
Yes
No
Date of Diagnosis (If Yes,)
New Primary Site
Has the patient received any non-protocol cancer
therapy not previously reported? (prior to
progression/relapse)
Yes
No
Date of First Non-Protocol Therapy (If Yes,)
Agent Name (s:)
Has the patient experienced any severe long
term toxicity that has not been previously
reported? (prior to treatment for progression or
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relapse or a second primary, and prior to non-
protocol treatment grade >=3)
Yes
No
Adverse Events and Grades (If Yes,)
Comments
Comments
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Breast Cancer NCT00382018 Pre-Study - SOUTHWEST
ONCOLOGY GROUP S0500 Prestudy Form - 2436725v1.0
SOUTHWEST ONCOLOGY GROUP S0500 Prestudy Form
Treatment Decision Making Based on Blood Levels of
Tumor Cells in Women With Metastatic Breast Cancer
Receiving Chemotherapy
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=07D022D9-
F34F-20A8-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/7540
SOUTHWEST ONCOLOGY GROUP
S0500 Prestudy Form
Header
SWOG Patient ID
SWOG Study No.
Registration Step
Patient Initials (L, F M)
Institution/Affiliate
Physician (Participating Group:)
Group Name
Participating Group Study No.
Participating Group Patient ID (Instructions: All
dates are MONTH, DAY, YEAR. Explain any
blank fields or blank dates in the Comments
section. Place an X in appropriate boxes. Circle
AMENDED items in red and write AMENDED
across the top of the form.)
Patient Characteristics
Performance Status
Fully Active, Able To Carry On All Pre-
disease Performance Without
Restriction. (0)
Restricted In Physically Strenuous
Activity But Ambulatory And Able To
Carry Out Work Of A Light Or Sedentary
Nature, E.g., Light Housework, Office
Work. (1)
Ambulatory And Capable Of All Selfcare
But Unable To Carry Out Any Work
Activities. Up And About More Than 50%
Of Waking Hours. (2)
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Date of CT scan or MRI of the chest or abdomen
Date of whole body bone scan
HER-2/neu status
Negative (Negative)
Positive (Positive)
Does the patient have brain metastases
Yes
No
Has the patient had stable disease since the
completion of radiotherapy to the brain
Yes
No
Date of completion of radiotherapy to the brain
Does the patient have leptomeningeal disease
Yes
No
Height (CM)
Weight (KG)
Menopausal Status
Menopausal Status
Above Categories Not Applicable And
Age <50 (Above not applicable AND age
< 50)
Above Categories Not Applicable And
Age >= 50 (Above not applicable AND
age >=50)
Post (prior Bilateral Ovariectomy Or >12
Mo Since Lmp With No Prior
Hysterectomy And Not Currently
Receiving Therapy With Lh-rh Analogs
[e.g., Zoladex]) (Post (prior bilateral
ovariectomy OR > 12 mo since LMP with
no prior hysterectomy and not currently
receiving therapy with LH-RH analogs
[e.g. Zoladex]))
Pre (<6 Mo Since Lmp And No Prior
Bilateral Ovariectomy And Not On
Estrogen Replacement) (Pre (< 6 mo
since LMP and no prior bilateral
ovariectomy and not on estrogen
replacement))
Disease Description
ER Result
Negative (Negative)
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Not Done (Never Done or Unknown)
Positive (Positive)
ER Time
At Disease Recurrence (At disease
recurrence)
At Initial Primary Diagnosis (At initial
primary diagnosis)
Other (Other)
Other, specify
PgR Result
Negative (Negative)
Never Done Or Unknown (Never Done or
Unknown)
Positive (Positive)
PgR Time
At Disease Recurrence (At disease
recurrence)
At Initial Primary Diagnosis (At initial
primary diagnosis)
Other (Other)
Other, specify
Date of initial diagnosis of primary tumor
Date progressive, recurrent or metastatic disease
first diagnosed (Note: Involvement of regional
nodes or locally advanced disease at original
diagnosis is not regarded as metastatic disease.)
Involved sites at time of entry (select all involved
sites)
Bone (Bone)
Bone Marrow (Bone marrow)
Brain (Brain)
Distant Lymph Nodes (Distant nodes)
Distant Skin/subcutaneous Tissue
(Distant skin/subcutaneous tissue)
Ipsilateral Supraclavicular Nodes
(ipsilateral supraclavicular nodes)
Liver (Liver)
Local-regional (Local-regional)
Lung (Lung)
Opposite Breast (Opposite breast)
Other Cns (Other CNS)
Other (Other sites)
Pleura (Pleura)
Other sites, specify
Prior Treatment Related To This Cancer
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Other therapy, specify
Radiation (select one)
Extensive Radiation (Extensive RT)
Limited Radiation (Limited RT)
Not Otherwise Specified (Not otherwise
specified)
Has the patient had any of the following prior
treatments? (select ALL that apply)
Anti-retroviral Therapy (Anti-retroviral
therapy)
Antisense (Antisense)
Gene Transfer (Gene transfer)
Oncolytic Virotherapy (Oncolytic
virotherapy)
Surgery (Surgery)
Vaccine (Vaccine)
Has the patient had any of the following prior
treatments? (select ALL that apply)
Anti-retroviral Therapy (Anti-retroviral
therapy)
Antisense (Antisense)
Gene Transfer (Gene transfer)
Oncolytic Virotherapy (Oncolytic
virotherapy)
Surgery (Surgery)
Vaccine (Vaccine)
Number of prior chemotherapy regimens
Date of completion of adjuvant chemotherapy
Comments
Comments
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Lymphoma NCT00389818 Treatment - AMC-047
Study Drug Therapy Form (SD4) - 2524440v1.0
AMC-047 Study Drug Therapy Form (SD4)
Combination Chemotherapy and Rituximab in Treating
Patients With Newly Diagnosed AIDS-Related B-Cell Non-
Hodgkin's Lymphoma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=1E9998AA-
2609-6F3F-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/7544
AMC-047 Study Drug Therapy Form
(SD4)
Header
Visit number
Cycle Start Date (mm/dd/yyyy)
Enter Total Dose Of Study Drug Received
This Cycle And Dose Modification Codes
Agent Name
Dose Modification
Dose Delayed (Dose delayed)
Dose Delayed And Reduced (Dose
delayed and reduced)
Dose Escalated (Dose escalated)
Dose Reduced (Dose reduced)
Drug Discontinued (Drug discontinued)
No Dose Modification (No dose
modification)
Total Dose of Agents/Drugs for this Cycle
Agent Start Date (mm/dd/yyyy)
Agent End Date (mm/dd/yyyy)
Duration Delay (Days)
Comments
Comments
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Lymphoma NCT00389818 On-Study - AMC-
047 On Study Form (F02) - 2524288v1.0
AMC-047 On Study Form (F02)
Combination Chemotherapy and Rituximab in Treating
Patients With Newly Diagnosed AIDS-Related B-Cell Non-
Hodgkin's Lymphoma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=1E9A7C2E-
DD6D-6ADA-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/7545
AMC-047 On Study Form (F02)
Header
Visit number
Hiv History
Date of HIV+ diagnosis (mm/dd/yyyy)
Date of AIDS diagnosis (mm/dd/yyyy)
CDC HIV Risk Group
Hemophilia (Hemophiliac)
Heterosexual Contact (Heterosexual
contact)
Homosexual Or Bisexual Contact
(Homosexual or bisexual contact)
Iv Drug User (IV drug user)
Other (Other)
Transfusion Recipient (Transfusion
recipient)
Other, specify
Ccrr Module For On Study Form - Rf02b
Date of Initial Pathologic Diagnosis (mm/dd/yyyy)
Primary site
Anal Canal (Anal)
Cervical (Cervical)
Hd (HD)
Kaposi Sarcoma (KS)
Non-hodgkin's Lymphoma (NHL)
Other Primary Site (Other primary site)
Other specify
Specify tumor histologic category
Prior Treatment? (If "Yes", Check below)
Yes
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No
Prior Systemic Chemotherapy
Yes
No
Prior Biological Response Modifiers or Cytokines
Yes
No
Specify (If "Yes",)
Prior Surgery (excluding biopsy)
Yes
No
Prior cryotherapy
Yes
No
Prior systemic steroid treatment
Yes
No
Prior Radiation Therapy
Yes
No
Prior topical/intralesional therapy
Yes
No
Other Prior Therapy (e.g. Hyperthermia, etc.)
Yes
No
Other Prior Therapy (e.g. Hyperthermia, etc.)
Yes
No
Specify (If "Yes", 1 2 3)
Name of other prior therapies
Ccrr Module For On Study Form - Rf02b
History of Prior Malignancy
Yes
No
Date of Diagnosis of Previous Malignancy
Primary site
Anal Canal (Anal)
Cervical (Cervical)
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Hd (HD)
Kaposi Sarcoma (KS)
Non-hodgkin's Lymphoma (NHL)
Other Primary Site (Other primary site)
Other specify
Specify tumor histologic category
Prior Treatment? (If "Yes", Check below)
Yes
No
Prior Systemic Chemotherapy
Yes
No
Prior Biological Response Modifiers or Cytokines
Yes
No
Specify (If "Yes",)
Prior Surgery (excluding biopsy)
Yes
No
Prior cryotherapy
Yes
No
Prior systemic steroid treatment
Yes
No
Prior Radiation Therapy
Yes
No
Prior topical/intralesional therapy
Yes
No
Other Prior Therapy (e.g. Hyperthermia, etc.)
Yes
No
Other Prior Therapy (e.g. Hyperthermia, etc.)
Yes
No
Specify (If "Yes", 1 2 3)
Name of other prior therapies
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Antiretroviral Therapy
Agent Name
Other, specify
Agent use
Currently Receiving (Currently receiving)
Never Received (Never received)
Previously Received (Previously
received)
Duration if prior agents received
< 3 Months (< 3 months)
> 12 Months (> 12 months)
> 6-12 Months (> 6-12 months)
3-6 Months (3-6 months)
Comments
Comments
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2524288v1.0
Lymphoma NCT00392834 On-Study - AMC-
048 On Study Form (F02) - 2655600v1.0
AMC-048 On Study Form (F02)
Rituximab and Combination Chemotherapy in Treating
Patients With Newly Diagnosed, HIV-Associated Burkitt's
Lymphoma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=32E1BD21-
3F41-538C-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/7547
AMC-048 On Study Form (F02)
Header
Visit number
Hiv History
Date of HIV+ diagnosis
Date of AIDS diagnosis
CDC HIV Risk Group
Hemophilia (Hemophiliac)
Heterosexual Contact (Heterosexual
contact)
Homosexual Or Bisexual Contact
(Homosexual or bisexual contact)
Iv Drug User (IV drug user)
Other (Other)
Transfusion Recipient (Transfusion
recipient)
Other, specify
Ccrr Module For On Study Form - Rf02b
Date of Initial Pathologic Diagnosis
Primary site
Anal Canal (Anal)
Cervical (Cervical)
Hd (HD)
Kaposi Sarcoma (KS)
Non-hodgkin's Lymphoma (NHL)
Other Primary Site (Other primary site)
Other specify
Specify tumor histologic category
Ccrr Module For On Study Form - Rf02b
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History of Prior Malignancy
Yes
No
Date of Diagnosis of Previous Malignancy
Primary site
Anal Canal (Anal)
Cervical (Cervical)
Hd (HD)
Kaposi Sarcoma (KS)
Non-hodgkin's Lymphoma (NHL)
Other Primary Site (Other primary site)
Other specify
Specify tumor histologic category
Antiretroviral Therapy
Agent Name
Other, specify
Agent use
Currently Receiving (Currently receiving)
Never Received (Never received)
Previously Received (Previously
received)
Duration if prior agents received
< 3 Months (< 3 months)
> 12 Months (> 12 months)
> 6-12 Months (> 6-12 months)
3-6 Months (3-6 months)
Comments
Comments
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Lymphoma NCT00392834 On-Study - AMC-048 On Study Form (F02) -
2655600v1.0
Lymphoma NCT00598169 On-Study - AMC-
053 On-Study Form (F02) - 3122378v1.0
AMC-053 On-Study Form (F02)
Bortezomib, Ifosfamide, Carboplatin, and Etoposide, With
or Without Rituximab, in Treating Patients With Relapsed or
Refractory AIDS-Related Non-Hodgkin Lymphoma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=8B708D70-
6894-F9DE-E040-BB89AD43114E
All rights reserved. Please visit https://medical-data-
models.org/forms/7549
AMC-053 On-Study Form (F02)
Header
Visit number
Hiv History
Date of HIV+ diagnosis (mm/dd/yyyy)
Date of AIDS diagnosis (mm/dd/yyyy)
CDC HIV Risk Group
Hemophilia (Hemophiliac)
Heterosexual Contact (Heterosexual
contact)
Homosexual Or Bisexual Contact
(Homosexual or bisexual contact)
Iv Drug User (IV drug user)
Other (Other)
Transfusion Recipient (Transfusion
recipient)
Other, specify
Ccrr Module For On Study Form - Rf02b
Date of Initial Pathologic Diagnosis (mm/dd/yyyy)
Primary site
Anal Canal (Anal)
Cervical (Cervical)
Hd (HD)
Kaposi Sarcoma (KS)
Non-hodgkin's Lymphoma (NHL)
Other Primary Site (Other primary site)
Other specify
Specify tumor histologic category
Prior Treatment? (If "Yes", Check below)
Yes
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No
Prior Systemic Chemotherapy
Yes
No
Prior Biological Response Modifiers or Cytokines
Yes
No
Specify (If "Yes")
Prior Surgery (excluding biopsy)
Yes
No
Prior cryotherapy
Yes
No
Prior systemic steroid therapy
Yes
No
Prior Radiation Therapy
Yes
No
Prior topical/intralesional therapy
Yes
No
Other Prior Therapy (e.g. Hyperthermia, etc.)
Yes
No
Other Prior Therapy (e.g. Hyperthermia, etc.)
Yes
No
Specify (If "Yes" 1 2 3)
Name of other prior therapies (If "Yes")
Ccrr Module For On Study Form - Rf02b
History of Prior Malignancy
Yes
No
Date of Diagnosis of Previous Malignancy
(mm/dd/yyyy)
Primary site
Anal Canal (Anal)
2 / 4
Lymphoma NCT00598169 On-Study - AMC-053 On-Study Form (F02) -
3122378v1.0
Cervical (Cervical)
Hd (HD)
Kaposi Sarcoma (KS)
Non-hodgkin's Lymphoma (NHL)
Other Primary Site (Other primary site)
Other specify
Specify tumor histologic category
Prior Treatment? (If "Yes", Check below)
Yes
No
Prior Systemic Chemotherapy
Yes
No
Prior Biological Response Modifiers or Cytokines
Yes
No
Specify (If "Yes")
Prior Surgery (excluding biopsy)
Yes
No
Prior cryotherapy
Yes
No
Prior systemic steroid therapy
Yes
No
Prior Radiation Therapy
Yes
No
Prior topical/intralesional therapy
Yes
No
Other Prior Therapy (e.g. Hyperthermia, etc.)
Yes
No
Other Prior Therapy (e.g. Hyperthermia, etc.)
Yes
No
Specify (If "Yes" 1 2 3)
Name of other prior therapies (If "Yes")
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Antiretroviral Therapy
Agent Name
Other, specify (1 2)
Agent use
Currently Receiving (Currently receiving)
Never Received (Never received)
Previously Received (Previously
received)
Duration if prior agents received
< 3 Months (< 3 months)
> 12 Months (> 12 months)
> 6-12 Months (> 6-12 months)
3-6 Months (3-6 months)
Comments
Comments
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3122378v1.0
Breast Cancer NCT00127205 Follow-Up - SOUTHWEST ONCOLOGY
GROUP S0307 SUPPLEMENTARY FOLLOW-UP FORM - 2287249v3.0
SOUTHWEST ONCOLOGY GROUP S0307
SUPPLEMENTARY FOLLOW-UP FORM
Zoledronate, Clodronate, or Ibandronate in Treating Women
Who Have Undergone Surgery for Stage I, Stage II, or
Stage III Breast
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=DEBA17CF-
62C1-30F0-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/7552
SOUTHWEST ONCOLOGY GROUP
S0307 SUPPLEMENTARY
FOLLOW-UP FORM
Header
SWOG Patient ID
SWOG Study No.
Registration Step
Patient Initials (L, F M)
Date form completed
Institution/Affiliate
Physician
Participating Group Name
Participating Group Study No.
Participating Group Patient ID
Notice Of Progression - Adjuvant
Has the patient been diagnosed with opposite
breast cancer since submission of last follow-up
form?
Yes
No
Date of diagnosis
Has the patient been diagnosed with first local-
regional recurrence since submission of last
follow-up form?
Yes
No
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Date of First Local-Regional Progression
Site(s) of First Local-Regional Progression (select
all that apply)
Axilla (Axilla)
Axilla (Axillary nodes)
Chest Wall (Chest wall)
Infraclavicular Nodes (Infraclavicular
nodes)
Internal Mammary Nodes (Internal
mammary nodes)
Ipsilateral Breast (Ipsilateral breast)
Supraclavicular Nodes (Supraclavicular
nodes)
Has the patient been diagnosed with first distant
recurrence/progression since submission of last
follow-up form?
Yes
No
Date of First Distant Progression
Site(s) of First Distant Progression
Bone (Bone)
Brain (Brain)
Liver (Liver)
Lung (Lung/pleura)
Nodes (Nodes)
Other Specify (Other CNS)
Other Soft Tissue (Other Soft Tissue)
Other Visceral (Other Visceral)
Other Nos (Other, NOS)
Skin (Skin)
Other, NOS
If the patient has been previously diagnosed with
first distant recurrence/progression at a site other
than
bone, has the patient been diagnosed with a
subsequent bone recurrence since submission of
last follow-up form?
Yes
No
Date of Subsequent Bone Progression
How was this progression information obtained?
Clinical Assessment (Clinical
assessment)
Patient Self Report Only (Patient self-
report only)
How was this progression information obtained?
Clinical Assessment (Clinical
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assessment)
Patient Self Report Only (Patient self-
report only)
Has the patient had a fracture since submission
of the last follow-up form?
Yes
No
indicate site (If yes,)
Ankle (Ankle)
Arm (Arm)
Hip (Hip)
Leg (Leg)
Pelvis (Pelvis)
Spine (Spine)
Wrist (Wrist)
Was the fracture traumatic (from greater than
standing height)?
Yes
No
Has the patient had osteonecrosis or
osteomyelitis of the jaw since submission of the
last follow-up form?
Yes
No
Comments
Comments
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Breast Cancer NCT00127205 Lab - SOUTHWEST ONCOLOGY GROUP
(S0307) SERUM CREATININE REPORTING FORM - 2734898v1.0
SOUTHWEST ONCOLOGY GROUP (S0307) SERUM
CREATININE REPORTING FORM
Zoledronate, Clodronate, or Ibandronate in Treating Women
Who Have Undergone Surgery for Stage I, Stage II, or
Stage III Breast
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=4842DB10-
FC97-0D85-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/7554
SOUTHWEST ONCOLOGY GROUP
(S0307) SERUM CREATININE
REPORTING FORM
Header
SWOG Patient ID
SWOG Study No.
Registration Step
Patient Initials (L, F, M)
Institution/Affiliate
Physician
Participating Group Name
Participating Group Study No.
Participating Group Patient ID
Creatinine Values
Collection Date
Serum creatinine
Serum Creatinine ULN
Comments
Comments
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Breast Cancer NCT00127205 Off Treatment - SOUTHWEST ONCOLOGY
GROUPSUPPLEMENTARY OFF TREATMENT NOTICE (S0307) - 2287059v3.0
SOUTHWEST ONCOLOGY GROUPSUPPLEMENTARY
OFF TREATMENT NOTICE (S0307)
Zoledronate, Clodronate, or Ibandronate in Treating Women
Who Have Undergone Surgery for Stage I, Stage II, or
Stage III Breast
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=DEA67F10-
B6B9-1C53-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/7555
SOUTHWEST ONCOLOGY
GROUPSUPPLEMENTARY OFF
TREATMENT NOTICE (S0307)
Header
SWOG Patient ID
SWOG Study No.
Registration Step
Patient Initials (L, F M)
Institution/Affiliate
Physician
Participating Group Name
Participating Group Study No.
Participating Group Patient ID (Instructions:
Submit this form after completion of end-of-study
bone scan. If bone scan was not done, explain in
Comments. All dates are MONTH, DAY, YEAR.
Explain any blank fields or blank dates in the
Comments section. Place an X in appropriate
boxes. Circle AMENDED items in red and write
AMENDED across top of form.)
Bone Scan
Did the patient have a bone scan after completion
or discontinuation of protocol therapy?
Yes
No
date of bone scan (If yes,)
Bone metastases?
Yes
No
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Patient Preference
If oral and intravenous bisphosphonates are
equally effective in preventing breast cancer
recurrence in the bone, which would the patient
prefer to receive?
Intravenous (Intravenous)
Oral (Oral)
Comments
Comments
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Toxicity Reporting Form Cervical Cancer
(NCT00803062)
GOG-0240 Common Toxicity Reporting Form (Form T)
Paclitaxel and Cisplatin or Topotecan With or Without
Bevacizumab in Treating Patients With Stage IVB,
Recurrent, or Persistent Cervical Cancer
NCT00803062
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=45815094-
13E7-14B9-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/7556
Toxicity Reporting Form Cervical
Cancer (NCT00803062)
Header Module
Date form originally completed (m d y)
Date form amended (m d y)
Person amending form, last name
Patient Initials (First, Middle, Last)
Patient Study ID
COMMENTS
Person Completing Form, Last Name
Adverse Events - Section 1
Current Cycle Number
Has the patient received any transfusions during
this course of therapy?
No Transfusion (No)
Transfusion With Platelets (Yes,
platelets)
Transfusion With Red Blood Cells (Yes,
red blood cells)
Was patient hospitalized as a result of reported
adverse events?
Yes
No
Were cytokines administered this course?
Yes
No
Yes specify
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Adverse Events - Section 2
Peripheral WBC count done
Yes
No
Peripheral WBC count (1000/mm3)
WBC Date
CTC Adverse Event Grade
CTC Adverse Event Attribution Scale
Unrelated (1)
Unlikely (2)
Possible (3)
Probable (4)
Definite (5)
SAE report submitted
Yes
No
Peripheral ANC/Granulocytes count done
Yes
No
Peripheral Granulocytes count (ANC/ 1000/mm3)
Date
Peripheral Platelet count done
Yes
No
Peripheral Platelet count (mm3)
Date
Hemoglobin done
Yes
No
Hemoglobin
Date
Adverse Events - Section 3
CTC Adverse Event Term
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Other, specify
Adverse Event Onset Date
AE Present Status
Fatal Or Died (Fatal/Died)
Intervention For Adverse Event
Continues (Intervention for AE
Continues)
Not Recovered Or Not Resolved (Not
recovered/Not resolved)
Recovered Or Resolved With Sequelae
(Recovered/Resolved with Sequelae)
Recovered Or Resolved Without
Sequelae (Recovered/Resolved without
Sequelae)
Recovering Or Resolving
(Recovering/Resolving)
The CTCAE data entered above is
Version 2 (version 2)
Version 3 (version 3)
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Breast Cancer NCT00382018 Pathology - SOUTHWEST ONCOLOGY
GROUP S0500 CTC Blood Draw and Results CRF - 2547492v1.0
SOUTHWEST ONCOLOGY GROUP S0500 CTC Blood
Draw and Results CRF
Treatment Decision Making Based on Blood Levels of
Tumor Cells in Women With Metastatic Breast Cancer
Receiving Chemotherapy
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=234E9C42-
5F69-15FD-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/7559
SOUTHWEST ONCOLOGY GROUP
S0500 CTC Blood Draw and Results
CRF
Header
SWOG Patient ID
SWOG Study No.
Registration Step
Patient Initials (L, F M)
State
Aguascalientes (Aguascalientes)
Alabama (Alabama)
Alaska (Alaska)
Alberta (Alberta)
American Samoa (American Samoa)
Arizona (Arizona)
Arkansas (Arkansas)
Baja California (Baja California)
Baja California Sur (Baja California Sur)
British Columbia (British Columbia)
California (California)
Campeche (Campeche)
Chiapas (Chiapas)
Chihuahua (Chihuahua)
Coahuila De Zaragoza (Coahuila de
Zaragoza)
Colima (Colima)
Colorado (Colorado)
Connecticut (Connecticut)
Delaware (Delaware)
District Of Columbia (District of
Columbia)
Distrito Federal (Distrito Federal)
Durango (Durango)
Florida (Florida)
Georgia (Georgia)
Guam (Guam)
Guanajuato (Guanajuato)
Guerrero (Guerrero)
Hawaii (Hawaii)
Hildalgo (Hildalgo)
Idaho (Idaho)
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Illinois (Illinois)
Indiana (Indiana)
Iowa (Iowa)
Jalisco (Jalisco)
Kansas (Kansas)
Kentucky (Kentucky)
Louisiana (Louisiana)
Maine (Maine)
Manitoba (Manitoba)
Marshall Islands (Marshall Islands)
Maryland (Maryland)
Massachusetts (Massachusetts)
Mexico (Mexico)
Michigan (Michigan)
Michoacan De Ocampo (Michoacan de
Ocampo)
Micronesia (Micronesia)
Minnesota (Minnesota)
Mississippi (Mississippi)
Missouri (Missouri)
Montana (Montana)
Morelos (Morelos)
Nayarit (Nayarit)
Nebraska (Nebraska)
Nevada (Nevada)
New Brunswick (New Brunswick)
New Hampshire (New Hampshire)
New Jersey (New Jersey)
New Mexico (New Mexico)
New York (New York)
Newfoundland (Newfoundland)
North Carolina (North Carolina)
North Dakota (North Dakota)
Northern Mariana Islands (Northern
Mariana Islands)
Northwest Territories (Northwest
Territories)
Nova Scotia (Nova Scotia)
Nuevo Leon (Nuevo Leon)
Nunavut (Nunavut)
Oaxaca (Oaxaca)
Ohio (Ohio)
Oklahoma (Oklahoma)
Ontario (Ontario)
Oregon (Oregon)
Palau (Palau)
Pennsylvania (Pennsylvania)
Prince Edward Island (Prince Edward
Island)
Puebla (Puebla)
Puerto Rico (Puerto Rico)
Quebec (Quebec)
Queretaro De Arteaga (Queretaro de
Arteaga)
Quintana Roo (Quintana Roo)
Rhode Island (Rhode Island)
San Luis Potosi (San Luis Potosi)
Saskatchewan (Saskatchewan)
Sinaloa (Sinaloa)
Sonora (Sonora)
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South Carolina (South Carolina)
South Dakota (South Dakota)
Tabasco (Tabasco)
Tamaulipas (Tamaulipas)
Tennessee (Tennessee)
Texas (Texas)
Tlaxcala (Tlaxcala)
Us Minor Outlying Islands (US Minor
Outlying Islands)
Utah (Utah)
Veracruz-llave (Veracruz-Llave)
Vermont (Vermont)
Virgin Islands Of The Us (Virgin Islands
of the US)
Virginia (Virginia)
Washington (Washington)
West Virginia (West Virginia)
Wisconsin (Wisconsin)
Wyoming (Wyoming)
Yucatan (Yucatan)
Yukon Territory (Yukon Territory)
Zacatecas (Zacatecas)
Time Zone
Institution/Affiliate
Physician (Participating Group:)
Group Name
Participating Group Study No.
Participating Group Patient ID (Instructions: All
dates are MONTH, DAY, YEAR. Explain any
blank fields or blank dates in the Comments
section. Place an X in appropriate boxes. Circle
AMENDED items in red and write AMENDED
across the top of the form.)
Blood Collection Information
Date Collected
Time Collected
Tube #
CellSave Lot #
CellSave Expiration Date
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Collection period
Day 169 (Day 169)
Day 22 (Day 22)
Day 253 (Day 253)
Day 50/57 (Day 50/57)
Day 85 (Day 85)
Pre-treatment (Pre-Treatment)
Time Of Disease Progression/end Of
Study (Time of disease progression/end
of study)
Comments
Comments
This Section To Be Completed By
Immunicon
Date received
Time Received
Sample ID
Quantity received
Date of Processing
Time of Processing
CTC Result #
Sample analyzable
Yes
No
If No, specify
CTC level (select one)
<5 (<5)
>=5 (>=5)
Reviewed by
Date
Communication Of Results To Swog
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Method
Date
Sender name
Confirmation date
Person receiving confirmation
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RTOG-0924 F1: Follow-Up Form
Androgen-Deprivation Therapy and Radiation Therapy in
Treating Patients With Prostate Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=9D83E5D6-
5875-E6AD-E040-BB89AD43030F
All rights reserved. Please visit https://medical-data-
models.org/forms/7561
RTOG-0924 F1: Follow-Up Form
Unnamed2
RTOG Study No.
Case #
Institution Name
Institution No.
Patient Initials
RTOG Patient ID
Header
Amended Data
Yes
No
Unnamed 3
Patient's Vital Status
Alive (Alive)
Dead (Dead)
Date of Last Contact or Death
Primary Cause of Death
Due To Other Cause (Due to other
cause)
Due To Protocol Treatment (Due to
protocol treatment)
Due To This Disease (Due to this
disease)
Not Applicable (Not applicable)
Unknown (Unknown)
Due to other cause, specify
Has the patient had a documented clinical
assessment for this cancer (SINCE
SUBMISSION OF THE PREVIOUS FOLLOW-UP
1 / 25
FORM)
No (No)
Unknown (Unknown)
Yes (Yes)
Date
Performance Status (ZUBROD 0-5, 9-
UNKNOWN)
Fully Active, Able To Carry On All Pre-
disease Performance Without
Restriction. (0)
Restricted In Physically Strenuous
Activity But Ambulatory And Able To
Carry Out Work Of A Light Or Sedentary
Nature, E.g., Light Housework, Office
Work. (1)
Ambulatory And Capable Of All Selfcare
But Unable To Carry Out Any Work
Activities. Up And About More Than 50%
Of Waking Hours. (2)
Capable Of Only Limited Selfcare,
Confined To Bed Or Chair More Than
50% Of Waking Hours. (3)
Completely Disabled. Cannot Carry On
Any Selfcare. Totally Confined To Bed Or
Chair. (4)
Dead (5)
Unnamed Module 6
Has the patient had a prostate biopsy (SINCE
SUBMISSION OF THE LAST FOLLOW-UP
FORM)
No (No)
Unknown (Unknown)
Yes, Negative (Yes, negative)
Yes, Positive (Yes, positive)
Yes, Results Unknown (Yes, results
unknown)
Biopsy Date
Is the tumor palpable
Equivocal (Equivocal)
No (No)
Not Evaluated (Not evaluated)
Unknown (Unknown)
Yes (Yes)
Unnamed Module 5
Has the patient been diagnosed with biochemical
recurrence since submission of the last follow-up
form
No (NO)
Unknown (Unknown)
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Yes (YES)
Has the patient been diagnosed with a first local
recurrence (SINCE SUBMISSION OF LAST
FOLLOW-UP FORM See Protocol Section 11)
No (NO)
Unknown (Unknown)
Yes (YES)
Date
Other Specify
Other Specify
Has the patient been diagnosed with first distant
progression (SINCE SUBMISSION OF THE
LAST FOLLOW-UP FORM)
No (No)
Unknown (Unknown)
Yes (Yes)
Date
Sites of Progression (First distant)
Method of Evaluation (DISTANT
PROGRESSION)
Mri (MRI (NMR))
Not Applicable (Not applicable)
Other (Other)
Pathologic (Pathologic)
Physical Exam (Physical exam)
Radiographic (Radiographic)
Method of Evaluation (DISTANT
PROGRESSION)
Mri (MRI (NMR))
Not Applicable (Not applicable)
Other (Other)
Pathologic (Pathologic)
Physical Exam (Physical exam)
Radiographic (Radiographic)
Baseline Lab Values (hematologic)
WBC (mm^3)
Hemoglobin (g/dL)
Peripheral Platelet Count (mm^3)
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Date (s)
Date (s)
Date (s)
Date (s)
ANC (mm^3)
Unnamed Module 4a
PSA Date (s)
PSA Value (s)
Units
Micrograms Per Liter (mcg/L)
N/milligram (n/mg)
Nanograms Per Deciliter (ng/dL)
Nanograms Per Milliliter (ng/mL)
Not Otherwise Specified (NOS)
Units Per Liter (U/L)
Method of Assay
Abbott Labs (Abbott)
Bayer (Bayer)
Dpc (DPC)
Hybritech (Hybritech)
Other (Other)
Unknown (Unknown)
Non-protocol Therapy
Is the patient receiving any non-protocol cancer
therapy not previously reported (PROSTATE If
yes, enter therapy type and date for each therapy
delivered during the follow-up period.)
No (No)
Unknown (Unknown)
Yes (Yes)
Non-Protocol Therapy Type
Chemotherapy (Chemotherapy)
Hormones (Hormones)
Other Specify (Other)
Radiation To Other Sites, Specify
(Radiation to other sites)
Radiation To Pelvis (Radiation to pelvis)
Surgery (Surgery)
Date of First Non-Protocol Therapy
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Specify
Unnamed Module 7
Has a new primary cancer or MDS been
diagnosed that has not been previously reported?
(MYELODYSPLASTIC SYNDROME)
No (No)
Unknown (Unknown)
Yes (Yes)
Second Primary Tumor Site
Aml/mds (AML/MDS)
Bcc (BCC)
Bladder Is The Site Of Second Primary
Or Recurrent Tumor (bladder)
Brain Is The Site Of Second Primary Or
Recurrent Tumor (brain)
Colorectal (Colorectal)
Esophageal (Esophageal)
Gastric (Gastric)
Liver Is The Site Of Second Primary Or
Recurrent Tumor (liver)
Lung Is The Site Of Second Primary Or
Recurrent Tumor (lung)
Melanoma (Melanoma)
Nhl (NHL)
Other Hematologic (Other hematologic)
Other Solid (Other solid)
Pancreatic (Pancreatic)
Renal (Renal)
Squamous-skin (Squamous-skin)
Unknown Primary (Unknown primary)
Second Primary Cancer Date
Other specify
Protocol Specific Adverse Event
Evaluation
Any Treatment Related Adverse Events
No (No)
Unknown (Unknown)
Yes (Yes)
MedDRA Disease Code
CTC Adverse Event Term
Abdominal Distension (Abdominal
distension)
Abdominal Infection (Abdominal
infection)
Abdominal Pain (Abdominal pain)
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Abdominal Soft Tissue Necrosis
(Abdominal soft tissue necrosis)
Abducens Nerve Disorder (Abducens
nerve disorder)
Accessory Nerve Disorder (Accessory
nerve disorder)
Acidosis (Acidosis)
Acoustic Nerve Disorder Nos (Acoustic
nerve disorder NOS)
Activated Partial Thromboplastin Time
Prolonged (Activated partial
thromboplastin time prolonged)
Acute Coronary Syndrome (Acute
coronary syndrome)
Acute Kidney Injury (Acute kidney injury)
Adrenal Insufficiency (Adrenal
insufficiency)
Adult Respiratory Distress Syndrome
(Adult respiratory distress syndrome)
Agitation (Agitation)
Akathisia (Akathisia)
Alanine Aminotransferase Increased
(Alanine aminotransferase increased)
Alcohol Intolerance (Alcohol intolerance)
Alkaline Phosphatase Increased
(Alkaline phosphatase increased)
Alkalosis (Alkalosis)
Allergic Reaction (Allergic reaction)
Allergic Rhinitis (Allergic rhinitis)
Alopecia (Alopecia)
Amnesia (Amnesia)
Anal Fistula (Anal fistula)
Anal Hemorrhage (Anal hemorrhage)
Anal Mucositis (Anal mucositis)
Anal Necrosis (Anal necrosis)
Anal Pain (Anal pain)
Anal Stenosis (Anal stenosis)
Anal Ulcer (Anal ulcer)
Anaphylaxis (Anaphylaxis)
Anemia (Anemia)
Ankle Fracture (Ankle fracture)
Anorectal Infection (Anorectal infection)
Anorexia (Anorexia)
Anorgasmia (Anorgasmia)
Anxiety (Anxiety)
Aortic Injury (Aortic injury)
Aortic Valve Disease (Aortic valve
disease)
Aphonia (Aphonia)
Apnea (Apnea)
Appendicitis (Appendicitis)
Appendicitis Perforated (Appendicitis
perforated)
Arachnoiditis (Arachnoiditis)
Arterial Injury (Arterial injury)
Arteritis Infective (Arteritis infective)
Arthralgia (Arthralgia)
Arthritis (Arthritis)
Ascites (Ascites)
Aspartate Aminotransferase Increased
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(Aspartate aminotransferase increased)
Aspiration (Aspiration)
Asystole (Asystole)
Ataxia (Ataxia)
Atelectasis (Atelectasis)
Atrial Fibrillation (Atrial fibrillation)
Atrial Flutter (Atrial flutter)
Atrioventricular Block Complete
(Atrioventricular block complete)
Atrioventricular Block First Degree
(Atrioventricular block first degree)
Autoimmune Disorder (Autoimmune
disorder)
Avascular Necrosis (Avascular necrosis)
Azoospermia (Azoospermia)
Back Pain (Back pain)
Bile Duct Stenosis (Bile duct stenosis)
Biliary Anastomotic Leak (Biliary
anastomotic leak)
Biliary Fistula (Biliary fistula)
Biliary Tract Infection (Biliary tract
infection)
Bladder Anastomotic Leak (Bladder
anastomotic leak)
Bladder Infection (Bladder infection)
Bladder Perforation (Bladder perforation)
Bladder Spasm (Bladder spasm)
Bloating (Bloating)
Blood And Lymphatic System Disorders -
Other, Specify (Blood and lymphatic
system disorders - Other, Specify)
Blood Antidiuretic Hormone Abnormal
(Blood antidiuretic hormone abnormal)
Blood Bilirubin Increased (Blood bilirubin
increased)
Blood Corticotrophin Decreased (Blood
corticotrophin decreased)
Blood Gonadotrophin Abnormal (Blood
gonadotrophin abnormal)
Blood Prolactin Abnormal (Blood
prolactin abnormal)
Blurred Vision (Blurred vision)
Body Odor (Body odor)
Bone Infection (Bone infection)
Bone Marrow Hypocellular (Bone
marrow hypocellular)
Bone Pain (Bone pain)
Brachial Plexopathy (Brachial
plexopathy)
Breast Atrophy (Breast atrophy)
Breast Infection (Breast infection)
Breast Pain (Breast pain)
Bronchial Fistula (Bronchial fistula)
Bronchial Infection (Bronchial infection)
Bronchial Obstruction (Bronchial
obstruction)
Bronchial Stricture (Bronchial stricture)
Bronchopleural Fistula (Bronchopleural
fistula)
Bronchopulmonary Hemorrhage
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(Bronchopulmonary hemorrhage)
Bronchospasm (Bronchospasm)
Bruising (Bruising)
Bullous Dermatitis (Bullous dermatitis)
Burn (Burn)
Buttock Pain (Buttock pain)
Capillary Leak Syndrome (Capillary leak
syndrome)
Carbon Monoxide Diffusing Capacity
Decreased (Carbon monoxide diffusing
capacity decreased)
Cardiac Arrest (Cardiac arrest)
Cardiac Disorders - Other, Specify
(Cardiac disorders - Other, Specify)
Cardiac Troponin I Increased (Cardiac
troponin I increased)
Cardiac Troponin T Increased (Cardiac
troponin T increased)
Cataract (Cataract)
Catheter Related Infection (Catheter
related infection)
Cd4 Lymphocytes Decreased (CD4
lymphocytes decreased)
Cecal Hemorrhage (Cecal hemorrhage)
Cecal Infection (Cecal infection)
Central Nervous System Necrosis
(Central nervous system necrosis)
Cerebrospinal Fluid Leakage
(Cerebrospinal fluid leakage)
Cervicitis Infection (Cervicitis infection)
Cheilitis (Cheilitis)
Chest Pain - Cardiac (Chest pain -
cardiac)
Chest Wall Pain (Chest wall pain)
Chills (Chills)
Cholecystitis (Cholecystitis)
Cholesterol High (Cholesterol high)
Chronic Kidney Disease (Chronic kidney
disease)
Chylothorax (Chylothorax)
Cognitive Disturbance (Cognitive
disturbance)
Colitis (Colitis)
Colonic Fistula (Colonic fistula)
Colonic Hemorrhage (Colonic
hemorrhage)
Colonic Obstruction (Colonic obstruction)
Colonic Perforation (Colonic perforation)
Colonic Stenosis (Colonic stenosis)
Colonic Ulcer (Colonic ulcer)
Concentration Impairment
(Concentration impairment)
Conduction Disorder (Conduction
disorder)
Confusion (Confusion)
Congenital, Familial And Genetic
Disorders - Other, Specify (Congenital,
familial and genetic disorders - Other,
Specify)
Conjunctivitis (Conjunctivitis)
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Conjunctivitis Infective (Conjunctivitis
infective)
Constipation (Constipation)
Constrictive Pericarditis (Constrictive
pericarditis)
Corneal Infection (Corneal infection)
Corneal Ulcer (Corneal ulcer)
Cough (Cough)
Cpk Increased (CPK increased)
Cranial Nerve Infection (Cranial nerve
infection)
Creatinine Increased (Creatinine
increased)
Cushingoid (Cushingoid)
Cystitis Noninfective (Cystitis
noninfective)
Cytokine Release Syndrome (Cytokine
release syndrome)
Death Neonatal (Death neonatal)
Death Nos (Death NOS)
Dehydration (Dehydration)
Delayed Orgasm (Delayed orgasm)
Delayed Puberty (Delayed puberty)
Delirium (Delirium)
Delusions (Delusions)
Dental Caries (Dental caries)
Depressed Level Of Consciousness
(Depressed level of consciousness)
Depression (Depression)
Dermatitis Radiation (Dermatitis
radiation)
Device Related Infection (Device related
infection)
Diarrhea (Diarrhea)
Disseminated Intravascular Coagulation
(Disseminated intravascular coagulation)
Dizziness (Dizziness)
Dry Eye (Dry eye)
Dry Mouth (Dry mouth)
Dry Skin (Dry skin)
Duodenal Fistula (Duodenal fistula)
Duodenal Hemorrhage (Duodenal
hemorrhage)
Duodenal Infection (Duodenal infection)
Duodenal Obstruction (Duodenal
obstruction)
Duodenal Perforation (Duodenal
perforation)
Duodenal Stenosis (Duodenal stenosis)
Duodenal Ulcer (Duodenal ulcer)
Dysarthria (Dysarthria)
Dysesthesia (Dysesthesia)
Dysgeusia (Dysgeusia)
Dysmenorrhea (Dysmenorrhea)
Dyspareunia (Dyspareunia)
Dyspepsia (Dyspepsia)
Dysphagia (Dysphagia)
Dysphasia (Dysphasia)
Dyspnea (Dyspnea)
Ear And Labyrinth Disorders - Other,
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Specify (Ear and labyrinth disorders -
Other, Specify)
Ear Pain (Ear pain)
Edema Cerebral (Edema cerebral)
Edema Face (Edema face)
Edema Limbs (Edema limbs)
Edema Trunk (Edema trunk)
Ejaculation Disorder (Ejaculation
disorder)
Ejection Fraction Decreased (Ejection
fraction decreased)
Electrocardiogram Qt Corrected Interval
Prolonged (Electrocardiogram QT
corrected interval prolonged)
Encephalitis Infection (Encephalitis
infection)
Encephalomyelitis Infection
(Encephalomyelitis infection)
Encephalopathy (Encephalopathy)
Endocarditis Infective (Endocarditis
infective)
Endocrine Disorders - Other, Specify
(Endocrine disorders - Other, Specify)
Endophthalmitis (Endophthalmitis)
Enterocolitis (Enterocolitis)
Enterocolitis Infectious (Enterocolitis
infectious)
Enterovesical Fistula (Enterovesical
fistula)
Epistaxis (Epistaxis)
Erectile Dysfunction (Erectile
dysfunction)
Erythema Multiforme (Erythema
multiforme)
Erythroderma (Erythroderma)
Esophageal Anastomotic Leak
(Esophageal anastomotic leak)
Esophageal Fistula (Esophageal fistula)
Esophageal Hemorrhage (Esophageal
hemorrhage)
Esophageal Infection (Esophageal
infection)
Esophageal Necrosis (Esophageal
necrosis)
Esophageal Obstruction (Esophageal
obstruction)
Esophageal Pain (Esophageal pain)
Esophageal Perforation (Esophageal
perforation)
Esophageal Stenosis (Esophageal
stenosis)
Esophageal Ulcer (Esophageal ulcer)
Esophageal Varices Hemorrhage
(Esophageal varices hemorrhage)
Esophagitis (Esophagitis)
Euphoria (Euphoria)
Exostosis (Exostosis)
External Ear Inflammation (External ear
inflammation)
External Ear Pain (External ear pain)
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Extraocular Muscle Paresis (Extraocular
muscle paresis)
Extrapyramidal Disorder (Extrapyramidal
disorder)
Eye Disorders - Other, Specify (Eye
disorders - Other, Specify)
Eye Infection (Eye infection)
Eye Pain (Eye pain)
Eyelid Function Disorder (Eyelid function
disorder)
Facial Muscle Weakness (Facial muscle
weakness)
Facial Nerve Disorder (Facial nerve
disorder)
Facial Pain (Facial pain)
Fall (Fall)
Fallopian Tube Anastomotic Leak
(Fallopian tube anastomotic leak)
Fallopian Tube Obstruction (Fallopian
tube obstruction)
Fallopian Tube Perforation (Fallopian
tube perforation)
Fallopian Tube Stenosis (Fallopian tube
stenosis)
Fat Atrophy (Fat atrophy)
Fatigue (Fatigue)
Febrile Neutropenia (Febrile
neutropenia)
Fecal Incontinence (Fecal incontinence)
Female Genital Tract Fistula (Female
genital tract fistula)
Feminization Acquired (Feminization
acquired)
Fetal Death (Fetal death)
Fetal Growth Retardation (Fetal growth
retardation)
Fever (Fever)
Fibrinogen Decreased (Fibrinogen
decreased)
Fibrosis Deep Connective Tissue
(Fibrosis deep connective tissue)
Flank Pain (Flank pain)
Flashing Lights (Flashing lights)
Flatulence (Flatulence)
Floaters (Floaters)
Flu Like Symptoms (Flu like symptoms)
Flushing (Flushing)
Forced Expiratory Volume Decreased
(Forced expiratory volume decreased)
Fracture (Fracture)
Gait Disturbance (Gait disturbance)
Gallbladder Fistula (Gallbladder fistula)
Gallbladder Infection (Gallbladder
infection)
Gallbladder Necrosis (Gallbladder
necrosis)
Gallbladder Obstruction (Gallbladder
obstruction)
Gallbladder Pain (Gallbladder pain)
Gallbladder Perforation (Gallbladder
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perforation)
Gastric Anastomotic Leak (Gastric
anastomotic leak)
Gastric Fistula (Gastric fistula)
Gastric Hemorrhage (Gastric
hemorrhage)
Gastric Necrosis (Gastric necrosis)
Gastric Perforation (Gastric perforation)
Gastric Stenosis (Gastric stenosis)
Gastric Ulcer (Gastric ulcer)
Gastritis (Gastritis)
Gastroesophageal Reflux Disease
(Gastroesophageal reflux disease)
Gastrointestinal Anastomotic Leak
(Gastrointestinal anastomotic leak)
Gastrointestinal Disorders - Other,
Specify (Gastrointestinal disorders -
Other, Specify)
Gastrointestinal Fistula (Gastrointestinal
fistula)
Gastrointestinal Pain (Gastrointestinal
pain)
Gastrointestinal Stoma Necrosis
(Gastrointestinal stoma necrosis)
Gastroparesis (Gastroparesis)
General Disorders And Administration
Site Conditions - Other, Specify (General
disorders and administration site
conditions - Other, Specify)
Generalized Muscle Weakness
(Generalized muscle weakness)
Genital Edema (Genital edema)
Ggt Increased (GGT increased)
Gingival Pain (Gingival pain)
Glaucoma (Glaucoma)
Glossopharyngeal Nerve Disorder
(Glossopharyngeal nerve disorder)
Glucose Intolerance (Glucose
intolerance)
Growth Accelerated (Growth
accelerated)
Growth Hormone Abnormal (Growth
hormone abnormal)
Growth Suppression (Growth
suppression)
Gum Infection (Gum infection)
Gynecomastia (Gynecomastia)
Hallucinations (Hallucinations)
Haptoglobin Decreased (Haptoglobin
decreased)
Head Soft Tissue Necrosis (Head soft
tissue necrosis)
Headache (Headache)
Hearing Impaired (Hearing impaired)
Heart Failure (Heart failure)
Hematoma (Hematoma)
Hematosalpinx (Hematosalpinx)
Hematuria (Hematuria)
Hemoglobin Increased (Hemoglobin
increased)
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Hemoglobinuria (Hemoglobinuria)
Hemolysis (Hemolysis)
Hemolytic Uremic Syndrome (Hemolytic
uremic syndrome)
Hemorrhoidal Hemorrhage
(Hemorrhoidal hemorrhage)
Hemorrhoids (Hemorrhoids)
Hepatic Failure (Hepatic failure)
Hepatic Hemorrhage (Hepatic
hemorrhage)
Hepatic Infection (Hepatic infection)
Hepatic Necrosis (Hepatic necrosis)
Hepatic Pain (Hepatic pain)
Hepatitis Viral (Hepatitis viral)
Hepatobiliary Disorders - Other, Specify
(Hepatobiliary disorders - Other, Specify)
Hiccups (Hiccups)
Hip Fracture (Hip fracture)
Hirsutism (Hirsutism)
Hoarseness (Hoarseness)
Hot Flashes (Hot flashes)
Hydrocephalus (Hydrocephalus)
Hypercalcemia (Hypercalcemia)
Hyperglycemia (Hyperglycemia)
Hyperhidrosis (Hyperhidrosis)
Hyperkalemia (Hyperkalemia)
Hypermagnesemia (Hypermagnesemia)
Hypernatremia (Hypernatremia)
Hyperparathyroidism
(Hyperparathyroidism)
Hypersomnia (Hypersomnia)
Hypertension (Hypertension)
Hyperthyroidism (Hyperthyroidism)
Hypertrichosis (Hypertrichosis)
Hypertriglyceridemia
(Hypertriglyceridemia)
Hyperuricemia (Hyperuricemia)
Hypoalbuminemia (Hypoalbuminemia)
Hypocalcemia (Hypocalcemia)
Hypoglossal Nerve Disorder
(Hypoglossal nerve disorder)
Hypoglycemia (Hypoglycemia)
Hypohidrosis (Hypohidrosis)
Hypokalemia (Hypokalemia)
Hypomagnesemia (Hypomagnesemia)
Hyponatremia (Hyponatremia)
Hypoparathyroidism
(Hypoparathyroidism)
Hypophosphatemia (Hypophosphatemia)
Hypotension (Hypotension)
Hypothermia (Hypothermia)
Hypothyroidism (Hypothyroidism)
Hypoxia (Hypoxia)
Ileal Fistula (Ileal fistula)
Ileal Hemorrhage (Ileal hemorrhage)
Ileal Obstruction (Ileal obstruction)
Ileal Perforation (Ileal perforation)
Ileal Stenosis (Ileal stenosis)
Ileal Ulcer (Ileal ulcer)
Ileus (Ileus)
13 / 25
Prostate Cancer NCT01368588 Follow-Up - RTOG-0924 F1: Follow-Up
Form - 3194645v1.0
Immune System Disorders - Other,
Specify (Immune system disorders -
Other, Specify)
Infections And Infestations - Other,
Specify (Infections and infestations -
Other, Specify)
Infective Myositis (Infective myositis)
Infusion Related Reaction (Infusion
related reaction)
Infusion Site Extravasation (Infusion site
extravasation)
Injection Site Reaction (Injection site
reaction)
Injury To Carotid Artery (Injury to carotid
artery)
Injury To Inferior Vena Cava (Injury to
inferior vena cava)
Injury To Jugular Vein (Injury to jugular
vein)
Injury To Superior Vena Cava (Injury to
superior vena cava)
Injury, Poisoning And Procedural
Complications - Other, Specify (Injury,
poisoning and procedural complications -
Other, Specify)
Inr Increased (INR increased)
Insomnia (Insomnia)
Intestinal Stoma Leak (Intestinal stoma
leak)
Intestinal Stoma Obstruction (Intestinal
stoma obstruction)
Intestinal Stoma Site Bleeding (Intestinal
stoma site bleeding)
Intra-abdominal Hemorrhage (Intra-
abdominal hemorrhage)
Intracranial Hemorrhage (Intracranial
hemorrhage)
Intraoperative Arterial Injury
(Intraoperative arterial injury)
Intraoperative Breast Injury
(Intraoperative breast injury)
Intraoperative Cardiac Injury
(Intraoperative cardiac injury)
Intraoperative Ear Injury (Intraoperative
ear injury)
Intraoperative Endocrine Injury
(Intraoperative endocrine injury)
Intraoperative Gastrointestinal Injury
(Intraoperative gastrointestinal injury)
Intraoperative Head And Neck Injury
(Intraoperative head and neck injury)
Intraoperative Hemorrhage
(Intraoperative hemorrhage)
Intraoperative Hepatobiliary Injury
(Intraoperative hepatobiliary injury)
Intraoperative Musculoskeletal Injury
(Intraoperative musculoskeletal injury)
Intraoperative Neurological Injury
(Intraoperative neurological injury)
Intraoperative Ocular Injury
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(Intraoperative ocular injury)
Intraoperative Renal Injury
(Intraoperative renal injury)
Intraoperative Reproductive Tract Injury
(Intraoperative reproductive tract injury)
Intraoperative Respiratory Injury
(Intraoperative respiratory injury)
Intraoperative Skin Injury (Intraoperative
skin injury)
Intraoperative Splenic Injury
(Intraoperative splenic injury)
Intraoperative Urinary Injury
(Intraoperative urinary injury)
Intraoperative Venous Injury
(Intraoperative venous injury)
Investigations - Other, Specify
(Investigations - Other, Specify)
Iron Overload (Iron overload)
Irregular Menstruation (Irregular
menstruation)
Irritability (Irritability)
Ischemia Cerebrovascular (Ischemia
cerebrovascular)
Ivth Nerve Disorder (IVth nerve disorder)
Jejunal Fistula (Jejunal fistula)
Jejunal Hemorrhage (Jejunal
hemorrhage)
Jejunal Obstruction (Jejunal obstruction)
Jejunal Perforation (Jejunal perforation)
Jejunal Stenosis (Jejunal stenosis)
Jejunal Ulcer (Jejunal ulcer)
Joint Effusion (Joint effusion)
Joint Infection (Joint infection)
Joint Range Of Motion Decreased (Joint
range of motion decreased)
Joint Range Of Motion Decreased
Cervical Spine (Joint range of motion
decreased cervical spine)
Joint Range Of Motion Decreased
Lumbar Spine (Joint range of motion
decreased lumbar spine)
Keratitis (Keratitis)
Kidney Anastomotic Leak (Kidney
anastomotic leak)
Kidney Infection (Kidney infection)
Kyphosis (Kyphosis)
Lactation Disorder (Lactation disorder)
Large Intestinal Anastomotic Leak (Large
intestinal anastomotic leak)
Laryngeal Edema (Laryngeal edema)
Laryngeal Fistula (Laryngeal fistula)
Laryngeal Hemorrhage (Laryngeal
hemorrhage)
Laryngeal Inflammation (Laryngeal
inflammation)
Laryngeal Mucositis (Laryngeal
mucositis)
Laryngeal Obstruction (Laryngeal
obstruction)
Laryngeal Stenosis (Laryngeal stenosis)
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Laryngitis (Laryngitis)
Laryngopharyngeal Dysesthesia
(Laryngopharyngeal dysesthesia)
Laryngospasm (Laryngospasm)
Left Ventricular Systolic Dysfunction (Left
ventricular systolic dysfunction)
Lethargy (Lethargy)
Leukemia Secondary To Oncology
Chemotherapy (Leukemia secondary to
oncology chemotherapy)
Leukocytosis (Leukocytosis)
Leukoencephalopathy
(Leukoencephalopathy)
Libido Decreased (Libido decreased)
Libido Increased (Libido increased)
Lip Infection (Lip infection)
Lip Pain (Lip pain)
Lipase Increased (Lipase increased)
Lipohypertrophy (Lipohypertrophy)
Localized Edema (Localized edema)
Lordosis (Lordosis)
Lower Gastrointestinal Hemorrhage
(Lower gastrointestinal hemorrhage)
Lung Infection (Lung infection)
Lymph Gland Infection (Lymph gland
infection)
Lymph Leakage (Lymph leakage)
Lymph Node Pain (Lymph node pain)
Lymphedema (Lymphedema)
Lymphocele (Lymphocele)
Lymphocyte Count Decreased
(Lymphocyte count decreased)
Lymphocyte Count Increased
(Lymphocyte count increased)
Malabsorption (Malabsorption)
Malaise (Malaise)
Mania (Mania)
Mediastinal Hemorrhage (Mediastinal
hemorrhage)
Mediastinal Infection (Mediastinal
infection)
Memory Impairment (Memory
impairment)
Meningismus (Meningismus)
Meningitis (Meningitis)
Menopause (Menopause)
Menorrhagia (Menorrhagia)
Metabolism And Nutrition Disorders -
Other, Specify (Metabolism and nutrition
disorders - Other, Specify)
Middle Ear Inflammation (Middle ear
inflammation)
Mitral Valve Disease (Mitral valve
disease)
Mobitz (type) Ii Atrioventricular Block
(Mobitz (type) II atrioventricular block)
Mobitz Type I (Mobitz type I)
Movements Involuntary (Movements
involuntary)
Mucosal Infection (Mucosal infection)
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Mucositis Oral (Mucositis oral)
Multi-organ Failure (Multi-organ failure)
Muscle Weakness Left-sided (Muscle
weakness left-sided)
Muscle Weakness Lower Limb (Muscle
weakness lower limb)
Muscle Weakness Right-sided (Muscle
weakness right-sided)
Muscle Weakness Trunk (Muscle
weakness trunk)
Muscle Weakness Upper Limb (Muscle
weakness upper limb)
Musculoskeletal And Connective Tissue
Disorder - Other, Specify
(Musculoskeletal and connective tissue
disorders - Other, Specify)
Musculoskeletal Deformity
(Musculoskeletal deformity)
Myalgia (Myalgia)
Myelitis (Myelitis)
Myelodysplastic Syndrome
(Myelodysplastic syndrome)
Myocardial Infarction (Myocardial
infarction)
Myocarditis (Myocarditis)
Myositis (Myositis)
Nail Discoloration (Nail discoloration)
Nail Infection (Nail infection)
Nail Loss (Nail loss)
Nail Ridging (Nail ridging)
Nasal Congestion (Nasal congestion)
Nausea (Nausea)
Neck Edema (Neck edema)
Neck Pain (Neck pain)
Neck Soft Tissue Necrosis (Neck soft
tissue necrosis)
Neoplasms Benign, Malignant And
Unspecified (incl Cysts And Polyps) -
Other, Specify (Neoplasms benign,
malignant and unspecified (incl cysts and
polyps) - Other, Specify)
Nervous System Disorders - Other,
Specify (Nervous system disorders -
Other, Specify)
Neuralgia (Neuralgia)
Neutrophil Count Decreased (Neutrophil
count decreased)
Night Blindness (Night blindness)
Nipple Deformity (Nipple deformity)
Non-cardiac Chest Pain (Non-cardiac
chest pain)
Nystagmus (Nystagmus)
Obesity (Obesity)
Obstruction Gastric (Obstruction gastric)
Oculomotor Nerve Disorder (Oculomotor
nerve disorder)
Olfactory Nerve Disorder (Olfactory
nerve disorder)
Oligospermia (Oligospermia)
Optic Nerve Disorder (Optic nerve
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disorder)
Oral Cavity Fistula (Oral cavity fistula)
Oral Dysesthesia (Oral dysesthesia)
Oral Hemorrhage (Oral hemorrhage)
Oral Pain (Oral pain)
Osteonecrosis Of Jaw (Osteonecrosis of
jaw)
Osteoporosis (Osteoporosis)
Otitis Externa (Otitis externa)
Otitis Media (Otitis media)
Ovarian Hemorrhage (Ovarian
hemorrhage)
Ovarian Infection (Ovarian infection)
Ovarian Rupture (Ovarian rupture)
Ovulation Pain (Ovulation pain)
Pain (Pain)
Pain In Extremity (Pain in extremity)
Pain Of Skin (Pain of skin)
Palmar-plantar Erythrodysesthesia
Syndrome (Palmar-plantar
erythrodysesthesia syndrome)
Palpitations (Palpitations)
Pancreas Infection (Pancreas infection)
Pancreatic Anastomotic Leak (Pancreatic
anastomotic leak)
Pancreatic Duct Stenosis (Pancreatic
duct stenosis)
Pancreatic Enzymes Decreased
(Pancreatic enzymes decreased)
Pancreatic Fistula (Pancreatic fistula)
Pancreatic Hemorrhage (Pancreatic
hemorrhage)
Pancreatic Necrosis (Pancreatic
necrosis)
Pancreatitis (Pancreatitis)
Papilledema (Papilledema)
Papulopustular Rash (Papulopustular
rash)
Paresthesia (Paresthesia)
Paronychia (Paronychia)
Paroxysmal Atrial Tachycardia
(Paroxysmal atrial tachycardia)
Pelvic Floor Muscle Weakness (Pelvic
floor muscle weakness)
Pelvic Infection (Pelvic infection)
Pelvic Pain (Pelvic pain)
Pelvic Soft Tissue Necrosis (Pelvic soft
tissue necrosis)
Penile Infection (Penile infection)
Penile Pain (Penile pain)
Perforation Bile Duct (Perforation bile
duct)
Pericardial Effusion (Pericardial effusion)
Pericardial Tamponade (Pericardial
tamponade)
Pericarditis (Pericarditis)
Perineal Pain (Perineal pain)
Periodontal Disease (Periodontal
disease)
Periorbital Edema (Periorbital edema)
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Periorbital Infection (Periorbital infection)
Peripheral Ischemia (Peripheral
ischemia)
Peripheral Motor Neuropathy (Peripheral
motor neuropathy)
Peripheral Nerve Infection (Peripheral
nerve infection)
Peripheral Sensory Neuropathy
(Peripheral sensory neuropathy)
Peritoneal Infection (Peritoneal infection)
Peritoneal Necrosis (Peritoneal necrosis)
Personality Change (Personality change)
Phantom Pain (Phantom pain)
Pharyngeal Anastomotic Leak
(Pharyngeal anastomotic leak)
Pharyngeal Fistula (Pharyngeal fistula)
Pharyngeal Hemorrhage (Pharyngeal
hemorrhage)
Pharyngeal Mucositis (Pharyngeal
mucositis)
Pharyngeal Necrosis (Pharyngeal
necrosis)
Pharyngeal Stenosis (Pharyngeal
stenosis)
Pharyngitis (Pharyngitis)
Pharyngolaryngeal Pain
(Pharyngolaryngeal pain)
Phlebitis (Phlebitis)
Phlebitis Infective (Phlebitis infective)
Photophobia (Photophobia)
Photosensitivity (Photosensitivity)
Platelet Count Decreased (Platelet count
decreased)
Pleural Effusion (Pleural effusion)
Pleural Hemorrhage (Pleural
hemorrhage)
Pleural Infection (Pleural infection)
Pleuritic Pain (Pleuritic pain)
Pneumonitis (Pneumonitis)
Pneumothorax (Pneumothorax)
Portal Hypertension (Portal
hypertension)
Portal Vein Thrombosis (Portal vein
thrombosis)
Postnasal Drip (Postnasal drip)
Postoperative Hemorrhage
(Postoperative hemorrhage)
Postoperative Thoracic Procedure
Complication (Postoperative thoracic
procedure complication)
Precocious Puberty (Precocious
puberty)
Pregnancy, Puerperium And Perinatal
Conditions - Other, Specify (Pregnancy,
puerperium and perinatal conditions -
Other, Specify)
Premature Delivery (Premature delivery)
Premature Menopause (Premature
menopause)
Presyncope (Presyncope)
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Proctitis (Proctitis)
Productive Cough (Productive cough)
Prolapse Of Intestinal Stoma (Prolapse
of intestinal stoma)
Prolapse Of Urostomy (Prolapse of
urostomy)
Prostate Infection (Prostate infection)
Prostatic Hemorrhage (Prostatic
hemorrhage)
Prostatic Obstruction (Prostatic
obstruction)
Prostatic Pain (Prostatic pain)
Proteinuria (Proteinuria)
Pruritus (Pruritus)
Psychiatric Disorders - Other, Specify
(Psychiatric disorders - Other, Specify)
Psychosis (Psychosis)
Pulmonary Edema (Pulmonary edema)
Pulmonary Fibrosis (Pulmonary fibrosis)
Pulmonary Fistula (Pulmonary fistula)
Pulmonary Hypertension (Pulmonary
hypertension)
Pulmonary Valve Disease (Pulmonary
valve disease)
Purpura (Purpura)
Pyramidal Tract Syndrome (Pyramidal
tract syndrome)
Radiation Recall Reaction (dermatologic)
(Radiation recall reaction (dermatologic))
Radiculitis (Radiculitis)
Rash Acneiform (Rash acneiform)
Rash Maculo-papular (Rash maculo-
papular)
Rash Pustular (Rash pustular)
Rectal Anastomotic Leak (Rectal
anastomotic leak)
Rectal Fistula (Rectal fistula)
Rectal Hemorrhage (Rectal hemorrhage)
Rectal Mucositis (Rectal mucositis)
Rectal Necrosis (Rectal necrosis)
Rectal Obstruction (Rectal obstruction)
Rectal Pain (Rectal pain)
Rectal Perforation (Rectal perforation)
Rectal Stenosis (Rectal stenosis)
Rectal Ulcer (Rectal ulcer)
Recurrent Laryngeal Nerve Palsy
(Recurrent laryngeal nerve palsy)
Renal And Urinary Disorders - Other,
Specify (Renal and urinary disorders -
Other, Specify)
Renal Calculi (Renal calculi)
Renal Colic (Renal colic)
Renal Hemorrhage (Renal hemorrhage)
Reproductive System And Breast
Disorders - Other, Specify (Reproductive
system and breast disorders - Other,
Specify)
Respiratory Failure (Respiratory failure)
Respiratory, Thoracic And Mediastinal
Disorders - Other, Specify (Respiratory,
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thoracic and mediastinal disorders -
Other, Specify)
Restlessness (Restlessness)
Restrictive Cardiomyopathy (Restrictive
cardiomyopathy)
Retinal Detachment (Retinal
detachment)
Retinal Tear (Retinal tear)
Retinal Vascular Disorder (Retinal
vascular disorder)
Retinoic Acid Syndrome (Retinoic acid
syndrome)
Retinopathy (Retinopathy)
Retroperitoneal Hemorrhage
(Retroperitoneal hemorrhage)
Reversible Posterior
Leukoencephalopathy Syndrome
(Reversible posterior
leukoencephalopathy syndrome)
Rhinitis Infective (Rhinitis infective)
Right Ventricular Dysfunction (Right
ventricular dysfunction)
Salivary Duct Inflammation (Salivary duct
inflammation)
Salivary Gland Fistula (Salivary gland
fistula)
Salivary Gland Infection (Salivary gland
infection)
Scalp Pain (Scalp pain)
Scleral Disorder (Scleral disorder)
Scoliosis (Scoliosis)
Scrotal Infection (Scrotal infection)
Scrotal Pain (Scrotal pain)
Seizure (Seizure)
Sepsis (Sepsis)
Seroma (Seroma)
Serum Amylase Increased (Serum
amylase increased)
Serum Sickness (Serum sickness)
Sick Sinus Syndrome (Sick sinus
syndrome)
Sinus Bradycardia (Sinus bradycardia)
Sinus Disorder (Sinus disorder)
Sinus Pain (Sinus pain)
Sinus Tachycardia (Sinus tachycardia)
Sinusitis (Sinusitis)
Skin And Subcutaneous Tissue
Disorders - Other, Specify (Skin and
subcutaneous tissue disorders - Other,
Specify)
Skin Atrophy (Skin atrophy)
Skin Hyperpigmentation (Skin
hyperpigmentation)
Skin Hypopigmentation (Skin
hypopigmentation)
Skin Induration (Skin induration)
Skin Infection (Skin infection)
Skin Ulceration (Skin ulceration)
Sleep Apnea (Sleep apnea)
Small Intestinal Anastomotic Leak (Small
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intestinal anastomotic leak)
Small Intestinal Mucositis (Small
intestinal mucositis)
Small Intestinal Obstruction (Small
intestinal obstruction)
Small Intestinal Perforation (Small
intestinal perforation)
Small Intestinal Stenosis (Small intestinal
stenosis)
Small Intestine Infection (Small intestine
infection)
Small Intestine Ulcer (Small intestine
ulcer)
Sneezing (Sneezing)
Social Circumstances - Other, Specify
(Social circumstances - Other, Specify)
Soft Tissue Infection (Soft tissue
infection)
Soft Tissue Necrosis Lower Limb (Soft
tissue necrosis lower limb)
Soft Tissue Necrosis Upper Limb (Soft
tissue necrosis upper limb)
Somnolence (Somnolence)
Sore Throat (Sore throat)
Spasticity (Spasticity)
Spermatic Cord Anastomotic Leak
(Spermatic cord anastomotic leak)
Spermatic Cord Hemorrhage (Spermatic
cord hemorrhage)
Spermatic Cord Obstruction (Spermatic
cord obstruction)
Spinal Fracture (Spinal fracture)
Spleen Disorder (Spleen disorder)
Splenic Infection (Splenic infection)
Stenosis Of Gastrointestinal Stoma
(Stenosis of gastrointestinal stoma)
Stevens-johnson Syndrome (Stevens-
Johnson syndrome)
Stoma Site Infection (Stoma site
infection)
Stomach Pain (Stomach pain)
Stomal Ulcer (Stomal ulcer)
Stridor (Stridor)
Stroke (Stroke)
Sudden Death Nos (Sudden death NOS)
Suicidal Ideation (Suicidal ideation)
Suicide Attempt (Suicide attempt)
Superficial Soft Tissue Fibrosis
(Superficial soft tissue fibrosis)
Superficial Thrombophlebitis (Superficial
thrombophlebitis)
Superior Vena Cava Syndrome (Superior
vena cava syndrome)
Supraventricular Tachycardia
(Supraventricular tachycardia)
Surgical And Medical Procedures -
Other, Specify (Surgical and medical
procedures - Other, Specify)
Syncope (Syncope)
Telangiectasia (Telangiectasia)
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Testicular Disorder (Testicular disorder)
Testicular Hemorrhage (Testicular
hemorrhage)
Testicular Pain (Testicular pain)
Thromboembolic Event
(Thromboembolic event)
Thrombotic Thrombocytopenic Purpura
(Thrombotic thrombocytopenic purpura)
Tinnitus (Tinnitus)
Tooth Development Disorder (Tooth
development disorder)
Tooth Discoloration (Tooth discoloration)
Tooth Infection (Tooth infection)
Toothache (Toothache)
Toxic Epidermal Necrolysis (Toxic
epidermal necrolysis)
Tracheal Fistula (Tracheal fistula)
Tracheal Hemorrhage (Tracheal
hemorrhage)
Tracheal Mucositis (Tracheal mucositis)
Tracheal Obstruction (Tracheal
obstruction)
Tracheal Stenosis (Tracheal stenosis)
Tracheitis (Tracheitis)
Tracheostomy Site Bleeding
(Tracheostomy site bleeding)
Transient Ischemic Attacks (Transient
ischemic attacks)
Treatment Related Secondary
Malignancy (Treatment related
secondary malignancy)
Tremor (Tremor)
Tricuspid Valve Disease (Tricuspid valve
disease)
Trigeminal Nerve Disorder (Trigeminal
nerve disorder)
Trismus (Trismus)
Tumor Lysis Syndrome (Tumor lysis
syndrome)
Tumor Pain (Tumor pain)
Typhlitis (Typhlitis)
Unequal Limb Length (Unequal limb
length)
Unintended Pregnancy (Unintended
pregnancy)
Upper Gastrointestinal Hemorrhage
(Upper gastrointestinal hemorrhage)
Upper Respiratory Infection (Upper
respiratory infection)
Ureteric Anastomotic Leak (Ureteric
anastomotic leak)
Urethral Anastomotic Leak (Urethral
anastomotic leak)
Urethral Infection (Urethral infection)
Urinary Fistula (Urinary fistula)
Urinary Frequency (Urinary frequency)
Urinary Incontinence (Urinary
incontinence)
Urinary Retention (Urinary retention)
Urinary Tract Infection (Urinary tract
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infection)
Urinary Tract Obstruction (Urinary tract
obstruction)
Urinary Tract Pain (Urinary tract pain)
Urinary Urgency (Urinary urgency)
Urine Discoloration (Urine discoloration)
Urine Output Decreased (Urine output
decreased)
Urostomy Leak (Urostomy leak)
Urostomy Obstruction (Urostomy
obstruction)
Urostomy Site Bleeding (Urostomy site
bleeding)
Urostomy Stenosis (Urostomy stenosis)
Urticaria (Urticaria)
Uterine Anastomotic Leak (Uterine
anastomotic leak)
Uterine Fistula (Uterine fistula)
Uterine Hemorrhage (Uterine
hemorrhage)
Uterine Infection (Uterine infection)
Uterine Obstruction (Uterine obstruction)
Uterine Pain (Uterine pain)
Uterine Perforation (Uterine perforation)
Uveitis (Uveitis)
Vaginal Anastomotic Leak (Vaginal
anastomotic leak)
Vaginal Discharge (Vaginal discharge)
Vaginal Dryness (Vaginal dryness)
Vaginal Fistula (Vaginal fistula)
Vaginal Hemorrhage (Vaginal
hemorrhage)
Vaginal Infection (Vaginal infection)
Vaginal Inflammation (Vaginal
inflammation)
Vaginal Obstruction (Vaginal obstruction)
Vaginal Pain (Vaginal pain)
Vaginal Perforation (Vaginal perforation)
Vaginal Stricture (Vaginal stricture)
Vaginismus (Vaginismus)
Vagus Nerve Disorder (Vagus nerve
disorder)
Vas Deferens Anastomotic Leak (Vas
deferens anastomotic leak)
Vascular Access Complication (Vascular
access complication)
Vascular Disorders - Other, Specify
(Vascular disorders - Other, Specify)
Vasculitis (Vasculitis)
Vasovagal Reaction (Vasovagal reaction)
Venous Injury (Venous injury)
Ventricular Arrhythmia (Ventricular
arrhythmia)
Ventricular Fibrillation (Ventricular
fibrillation)
Ventricular Tachycardia (Ventricular
tachycardia)
Vertigo (Vertigo)
Vestibular Disorder (Vestibular disorder)
Virilization (Virilization)
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Visceral Arterial Ischemia (Visceral
arterial ischemia)
Vital Capacity Abnormal (Vital capacity
abnormal)
Vitreous Hemorrhage (Vitreous
hemorrhage)
Voice Alteration (Voice alteration)
Vomiting (Vomiting)
Vulval Infection (Vulval infection)
Watering Eyes (Watering eyes)
Weight Gain (Weight gain)
Weight Loss (Weight loss)
Wheezing (Wheezing)
White Blood Cell Decreased (White
blood cell decreased)
Wolff-parkinson-white Syndrome (Wolff-
Parkinson-White syndrome)
Wound Complication (Wound
complication)
Wound Dehiscence (Wound dehiscence)
Wound Infection (Wound infection)
Wrist Fracture (Wrist fracture)
CTC AE Grade
Absent Adverse Event (0)
Mild Adverse Event (1)
Moderate Adverse Event (2)
Severe Adverse Event (3)
Life Threatening Adverse Event (4)
Death Related To Adverse Event (5)
CTCAE Begin Date
CTC AE Attribution Code
Definite (Definite)
Possible (Possible)
Probable (Probable)
Unlikely (Unlikely)
Unrelated (Unrelated)
SAE report submitted
No (No)
Unknown (Unknown)
Yes (Yes)
Footer
Comments
Signature of Person Completing This Form
Date Form Originally Completed
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NCT01016730 Treatment - AMC-063 Prior Treatment
History for Kaposi's Sarcoma Form (KS0) - 3020879v1.0
AMC-063 Prior Treatment History for Kaposi's Sarcoma
Form (KS0)
Bortezomib in Treating Patients With Relapsed or
Refractory AIDS-Related Kaposi Sarcoma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=8163A333-
BB2E-35E0-E040-BB89AD435080
All rights reserved. Please visit https://medical-data-
models.org/forms/7566
AMC-063 Prior Treatment History for
Kaposi's Sarcoma Form (KS0)
Header Module
Visit number
Date of evaluation (mm/dd/yyyy)
Header
Tumor (T check one)
Tumor Is Confined To Skin And/or To
Lymph Nodes And/or Patient Has
Minimal Oral Disease (Tumor is confined
to skin and/or to lymph nodes and/or
patient has minimal oral disease)
Tumor With Edema, Ulceration, Or
Extensive Oral Ks Or Gastro Ks Or Ks In
Other Nonnodal Viscera (Tumor with
edema, ulceration, or extensive oral KS
or gastro KS or KS in other nonnodal
viscera)
Immune System (I check one)
Cd4 Cells <200/ul (CD4 cells <200/uL)
Cd4 Cells >=200/ul (CD4 cells >=200/uL)
Unknown (Unknown)
History of opportunistic infection (OI) and/or
thrush (Systemic Illness S check all that apply)
Yes
No
B-symptoms present (Systemic Illness S check
all that apply)
Yes
No
Karnofsky performance status <70 (Systemic
Illness S check all that apply)
Yes
No
Other HIV-related illness (Systemic Illness S
check all that apply e.g., neurological disease,
lymphoma)
Yes
No
1 / 4
Unnamed2
Has the participant received single-agent
noninvestigational systemic chemotherapy or
immunotherapy for the treatment of Kaposi's
Sarcoma (If No or Unknown, go to Question 2)
No (No)
Unknown (Unknown)
Yes (Yes)
Agent Name (single agent)
Agent administered
No (No)
Unknown (Unknown)
Yes (Yes)
Tumor Response Type
Clinical Complete Response (Clinical
complete response)
Complete Response (CR)
Not Applicable (N/A)
Progressive Disease (PD)
Partial Response (PR)
Stable Disease (SD)
Unknown (Unknown)
Source
Clinical Assessment (Clinical
assessment)
Other (Other)
Self Report Only (Self report only)
Other, specify
Other single agent therapy
No (No)
Unknown (Unknown)
Yes (Yes)
Unnamed3
Has the participant received combination or
alternating noninvestigational systemic
chemotherapy or immunotherapy for the
treatment of Kaposi's Sarcoma
No (No)
Unknown (Unknown)
Yes (Yes)
Agents name (Combination or Alternating)
Agent administered
No (No)
Unknown (Unknown)
Yes (Yes)
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Tumor Response Type
Clinical Complete Response (Clinical
complete response)
Complete Response (CR)
Not Applicable (N/A)
Progressive Disease (PD)
Partial Response (PR)
Stable Disease (SD)
Unknown (Unknown)
Source
Clinical Assessment (Clinical
assessment)
Other (Other)
Self Report Only (Self report only)
Other, specify
Other combination therapy
No (No)
Unknown (Unknown)
Yes (Yes)
Unnamed4
Has the participant received any systemic, local,
or topical therapy other than cytotoxic
chemotherapy for the treatment of Kaposi's
Sarcoma (If No or Unknown, STOP specified in
section 1)
No (No)
Unknown (Unknown)
Yes (Yes)
Specify
Tumor Response Type
Clinical Complete Response (Clinical
complete response)
Complete Response (CR)
Not Applicable (N/A)
Progressive Disease (PD)
Partial Response (PR)
Stable Disease (SD)
Unknown (Unknown)
Source
Clinical Assessment (Clinical
assessment)
Other (Other)
Self Report Only (Self report only)
Other, specify
Footer Module
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Comments
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Nonneoplastic Condition NCT01057121 Treatment - AMC-070 Prior
Treatment History for Kaposi's Sarcoma Form (KS0) - 3147415v1.0
AMC-070 Prior Treatment History for Kaposi's Sarcoma
Form (KS0)
Lenalidomide in Treating Patients With AIDS-Related
Kaposi Sarcoma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=91E4BBD6-
6A6F-9CA4-E040-BB89AD437D79
All rights reserved. Please visit https://medical-data-
models.org/forms/7567
AMC-070 Prior Treatment History for
Kaposi's Sarcoma Form (KS0)
Header Module
Visit number
Date of evaluation (mm/dd/yyyy)
Header
Tumor (T check one)
Tumor Is Confined To Skin And/or To
Lymph Nodes And/or Patient Has
Minimal Oral Disease (Tumor is confined
to skin and/or to lymph nodes and/or
patient has minimal oral disease)
Tumor With Edema, Ulceration, Or
Extensive Oral Ks Or Gastro Ks Or Ks In
Other Nonnodal Viscera (Tumor with
edema, ulceration, or extensive oral KS
or gastro KS or KS in other nonnodal
viscera)
Immune System (I check one)
Cd4 Cells <200/ul (CD4 cells <200/uL)
Cd4 Cells >=200/ul (CD4 cells >=200/uL)
Unknown (Unknown)
History of opportunistic infection (OI) and/or
thrush (Systemic Illness S check all that apply)
Yes
No
B-symptoms present (Systemic Illness S check
all that apply)
Yes
No
Karnofsky performance status <70 (Systemic
Illness S check all that apply)
Yes
No
Other HIV-related illness (Systemic Illness S
check all that apply e.g., neurological disease,
lymphoma)
Yes
No
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Unnamed2
Has the participant received single-agent
noninvestigational systemic chemotherapy or
immunotherapy for the treatment of Kaposi's
Sarcoma (If No or Unknown, go to Question 2)
No (No)
Unknown (Unknown)
Yes (Yes)
Agent Name (single agent)
Agent administered
No (No)
Unknown (Unknown)
Yes (Yes)
Tumor Response Type
Clinical Complete Response (Clinical
complete response)
Complete Response (CR)
Not Applicable (N/A)
Progressive Disease (PD)
Partial Response (PR)
Stable Disease (SD)
Unknown (Unknown)
Source
Clinical Assessment (Clinical
assessment)
Other (Other)
Self Report Only (Self report only)
Other, specify
Other single agent therapy
No (No)
Unknown (Unknown)
Yes (Yes)
Unnamed3
Has the participant received combination or
alternating noninvestigational systemic
chemotherapy or immunotherapy for the
treatment of Kaposi's Sarcoma
No (No)
Unknown (Unknown)
Yes (Yes)
Agents name (Combination or Alternating)
Agent administered
No (No)
Unknown (Unknown)
Yes (Yes)
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Tumor Response Type
Clinical Complete Response (Clinical
complete response)
Complete Response (CR)
Not Applicable (N/A)
Progressive Disease (PD)
Partial Response (PR)
Stable Disease (SD)
Unknown (Unknown)
Source
Clinical Assessment (Clinical
assessment)
Other (Other)
Self Report Only (Self report only)
Other, specify
Other combination therapy
No (No)
Unknown (Unknown)
Yes (Yes)
Unnamed4
Has the participant received any systemic, local,
or topical therapy other than cytotoxic
chemotherapy for the treatment of Kaposi's
Sarcoma (If No or Unknown, STOP specified in
section 1)
No (No)
Unknown (Unknown)
Yes (Yes)
Specify
Tumor Response Type
Clinical Complete Response (Clinical
complete response)
Complete Response (CR)
Not Applicable (N/A)
Progressive Disease (PD)
Partial Response (PR)
Stable Disease (SD)
Unknown (Unknown)
Source
Clinical Assessment (Clinical
assessment)
Other (Other)
Self Report Only (Self report only)
Other, specify
Footer Module
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Comments
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Neoplasms, Breast NCT00490139 Treatment - BIG 2-06 / NCCTG
N063D / EGF106708 - Post-Event Treatment - 2639434v1.0
BIG 2-06 / NCCTG N063D / EGF106708 - Post-Event
Treatment
ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment
Optimisation) Study; BIG 2-06/N063D
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=30BFA46A-
87D8-4B02-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/7568
BIG 2-06 / NCCTG N063D /
EGF106708 - Post-Event Treatment
Header Module
Centre No.
Subject No.
Chemotherapy
Did the patient receive additional chemotherapy
after recurrence of breast cancer or second
primary malignancy of contralateral breast cancer
Yes
No
Agent Name
Total No. of Cycles
Initial Dose
Dose UOM
Centigray (cGy)
Gray (Gy)
Radiation Absorbed Dose (Rad)
Date Started
Date Stopped
Targeted Therapy
Did the patient receive additional target therapy
after recurrence of breast cancer or second
primary malignancy of contralateral breast cancer
Yes
No
Agent Name
Total No. of Cycles
1 / 3
Initial Dose
Dose UOM
Centigray (cGy)
Gray (Gy)
Radiation Absorbed Dose (Rad)
Date Started
Date Stopped
Chemotherapy
Did the patient receive hormone therapy after
recurrence of breast cancer or second primary
malignancy of contralateral breast cancer
Yes
No
Agent Name
Dose
Units
Milligram (mg)
Not Applicable (N/A)
Date Started
Date Stopped
Chemotherapy
Did the patient receive radiotherapy after
recurrence of breast cancer or second primary
malignancy of contralateral breast cancer
Yes
No
Radiation Therapy Site
Side
Left (Left)
Right (Right)
Total Dose
Dose UOM
Centigray (cGy)
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Neoplasms, Breast NCT00490139 Treatment - BIG 2-06 / NCCTG
N063D / EGF106708 - Post-Event Treatment - 2639434v1.0
Gray (Gy)
Radiation Absorbed Dose (Rad)
Radiation Therapy Start Date
Radiation Therapy End Date
Surgery
Did the patient receive surgery after recurrence
of breast cancer or second primary malignancy of
contralateral breast cancer
Yes
No
Surgical site
Surgery Date
3 / 3
Neoplasms, Breast NCT00490139 Treatment - BIG 2-06 / NCCTG
N063D / EGF106708 - Post-Event Treatment - 2639434v1.0
Sarcoma NCT00450320 Treatment - AMC-051
Study Drug Therapy Form (SD1) - 2636320v1.0
AMC-051 Study Drug Therapy Form (SD1)
Sirolimus in Treating Patients With HIV-Related Kaposi's
Sarcoma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=2FDFA89A-
09CA-6018-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/7570
AMC-051 Study Drug Therapy Form
(SD1)
Enter Total Dose Of Study Drug Received
This Cycle And Dose Modification Codes
Agent Start Date
Agent Name
Dose Modification
Dose Delayed (Dose delayed)
Dose Delayed And Reduced (Dose
delayed and reduced)
Dose Escalated (Dose escalated)
Dose Reduced (Dose reduced)
Drug Discontinued (Drug discontinued)
No Dose Modification (No dose
modification)
Total Dose of Agents/Drugs for this Cycle
Total number of doses (Given for this reporting
period)
Agent continuing at this dose level
Yes
No
Agent End Date (mm/dd/yyyy)
Duration Delay (Days)
Blood Rapamycin Trough Level Results
Was a trough level obtained
Yes
No
Date Specimen Obtained
Trough Level
Comments
Comments
1 / 1
Treatment - Prior Therapy Supplement -
3279607v1.0
Details of prior therapies related to the disease being
studies by the protocol or when the details would be
clinically significant for the evaluation of this study as
indicated on the Prior Treatment Summary case report
form.
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=AD0FD25D-
D2EF-6C5F-E040-BB89AD431DAE
All rights reserved. Please visit https://medical-data-
models.org/forms/7572
Prior Therapy Supplement
Prior Therapy Supplement
Visit Date (Enter the date the form was
completed i.e. the date information was
gathered.)
Date of First Dose (Enter the date of the first
dose of the prior therapy. Partial dates are
acceptable when the day is not known.)
Date of Last Dose (Enter the date of the last dose
of the prior therapy. Partial dates are acceptable
when the day is not known. Leave it blank if the
treatment is currently being received.)
Agent Name (Select the generic name of the
agent that was used. - Note: For standard
regimen multiple agents given as one regimen,
enter one record for each agent.)
Schedule (Select the schedule on which the
agent or combination was given.)
Total Dose (Enter the total dose of the agent.)
Total Dose UOM (Enter the total dose units of
measurement.)
Percent (%)
10e10 Cells (10E10 Cells)
10e3 Cells (10E3 Cells)
10e4 Cells Per Kilogram (10E4 Cell/kg)
10e4 Cells (10E4 Cells)
10e5 Cells Per Kilogram (10E5 Cell/kg)
10e5 Cells (10E5 Cells)
10e6 Cells Per Kilogram (10E6 Cell/kg)
10e6 Cells (10E6 Cells)
10e7 Cells Per Kilogram (10E7 Cell/kg)
10e7 Cells (10E7 Cells)
10e7 Plaque Forming Units (10E7 PFU)
10e8 Cells (10E8 Cells)
10e8 Plaque Forming Units (10E8 PFU)
10e9 Cells (10E9 Cells)
10e9 Plaque Forming Units (10E9 PFU)
Ampule (Ampule)
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Application (Applcatn)
Atomic Unit (au)
Area Under The Curve (AUC)
Billion Pfu (bill PFU)
Bottle (Bottle)
Breaths Per Minute (BPM)
Capful (Capful)
Caplet (Caplet)
Capsule (Capsule)
Cells (Cells)
Cells Per Kilogram (Cells/kg)
Centigray (cGy)
Curie (Ci)
Cycle (Course)
Course (Course)
Deciliter (dL)
Dose (Dose)
Equivalent (Eq)
Grams (g) (g)
Gram Per M2 (g/m2)
Gallon (Gallon)
Drops (gtts)
Gray (Gy)
Hertz (Hz)
Inch (Inch)
Inhalation (Inhalatn)
Iu Vitamin A (IU Vit A)
International Unit Per Milligram (IU/mg)
International Units Or Milligram Alpha
Tocopherol (IU/mg A-TE)
International Unit (IUnit)
International Unit Per Kilogram (IUnit/kg)
International Unit Per Liter (IUnit/L)
Intravenous Bag (IV Bag)
Infectious Viral Replicon Particles (IVRP)
Joules Per Centimeter Squared (Jcm2)
Kib-electron Volt (KeV)
Kilograms (kg)
Kilohertz (kHz)
Kilopascal (kPa)
Kilounit (kU)
Kilounit Per Kilogram (kU/kg)
Kilounit Per Liter (kU/L)
Liter (L)
Liters Per Minute (L/min)
Megabecquerel (MBq)
Millibecquerel (mBq)
Microgram (mcg)
Microgram Per Centimeter Squared
(mcg/cm2)
Microgram Per Hour (mcg/hr)
Microgram Per Kilogram (mcg/kg)
Microgram Per Meter Squared (mcg/m2)
Millicurie (mCi)
Measure (Measure)
Milliequivalent (mEq)
Milliequivalents Per 24 Hours (mEq/24hr)
Milliequivalent Per Deciliter (mEq/dL)
Milliequivalent Per Hour (mEq/hr)
Milliequivalent Per Liter (mEq/L)
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Treatment - Prior Therapy Supplement - 3279607v1.0
Million Electron Volt (MeV)
Milligram (mg)
Milligram Per 24 Hours (mg/24hr)
Milligram Per Deciliter (mg/dL)
Milligram Per Hour (mg/hr)
Milligram Per Inhalation (mg/inh)
Milligram Per Kilogram (mg/kg)
Milligram Per Kilogram Per Day
(mg/kg/day)
Milligram Per Meter Squared (mg/m2)
Milligram Per Milliliter (mg/mL)
Milligram Per Week (mg/wk)
Megahertz (MHz)
Microcurie (microCi)
Microliter (microL)
Micromole (micromol)
Million Plaque Forming Units (mill PFU)
Million (Million)
Milliunit (millunit)
Milliinternational Unit (miu)
Milliinternational Units Per Meter
Squared (miu/m2)
Cubic Centimeter (cc) (mL)
Milliliter (mL)
Milliliter Per Hour (mL/hr)
Milliliter Per Kilogram (mL/kg)
Millimoles Per Liter (mM/L)
Millimole (mmol)
Mole (Mole)
Milliosmole (mosmol)
Megarad (Mrad)
Million Units (MU)
Millivolt (mV)
Million Viral Particles (MVP)
Nanocurie (nCi)
Nanogram (ng)
Nanogram Per Kilogram (ng/kg)
Nanogram Per Liter (ng/L)
Nanograms Per Milliliter (ng/mL)
Nanometer Of Light (nm light)
Nanomole (nmol)
No Source Data (No Srce)
Osmolality (osmol)
Ounce (oz)
Pascal (Pa)
Packet (packet)
Patch (Patch)
Plaque Forming Units (PFU)
Picograms (pg)
Pounds Per Square Inch (psi)
Puff (puff)
Radiation Absorbed Dose (Rad)
Vitamin A Retinol (RAE)
Retinol Equivalents (RE)
Seed (Seed)
Session (Session)
Spray (Spray)
Suppository (Suppstry)
Tablets (Tablet)
Tablespoon (Tbsp)
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Treatment - Prior Therapy Supplement - 3279607v1.0
Tissue Culture Infection Dose (TCID)
Thousand (Thousand)
Troche (Troche)
Teaspoon (tsp)
Unit (Unit)
Unit Per Gram (Unit/g)
Unit Per Kilogram (Unit/kg)
Unit Per Meter Squared (Unit/m2)
Unit Per Milliliter (Unit/mL)
Unknown (Unknown)
Viral Particles (VP)
Yeast Units (YU)
Best Response (Select the best response
encountered:)
Complete Response (CR)
Less Than Partial Response (MR)
Not Assessed (NA)
Not Evauable (NE)
Progressive Disease (PD)
Partial Response (PR)
Stable Disease (SD)
Unknown (UK)
NonResponse Therapy Type (Select the therapy
type for which the conventional response calls
are not appropriate.)
Adjuvant Therapy (AJ)
Neoadjuvant Therapy (NJ)
Palliative Therapy (PA)
Therapy Type
Anti-retroviral Therapy (AR)
Antisense Therapy (AS)
Bone Marrow Transplantation (BM)
Chemotherapy, Nos (C)
Chemotherapy, Multiple Agents Systemic
(CM)
Single Agent Systemic Chemotherapy
(CS)
Gene Transfer (G)
Hormone Therapy (H)
Hematopoietic Stem Cell Transplantation
(HE)
Immunotherapy (I)
Image Directed Local Therapy (ID)
No Prior Therapy (N)
Chemotherapy, Non-cytotoxic (NC)
Oncolytic Virotherapy (OV)
Prior Therapy (PT)
Radiation Therapy (R)
Vaccine Therapy (V)
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Treatment - Prior Therapy Supplement - 3279607v1.0
Sarcoma NCT00427414 Treatment - AMC-050
Study Drug Therapy Form (SD1) - 2737061v1.0
AMC-050 Study Drug Therapy Form (SD1)
Liposomal Daunorubicin in Treating Patients With HIV-
Related Kaposi's Sarcoma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=49597C4E-
12B8-38E4-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/7574
AMC-050 Study Drug Therapy Form
(SD1)
Enter Total Dose Of Study Drug Received
This Cycle And Dose Modification Codes
Visit number
Agent Name
Agent Start Date
Total Dose of Agents/Drugs for this Cycle
(mg/m^2)
Dose Modification
Dose Delayed (Dose delayed)
Dose Delayed And Reduced (Dose
delayed and reduced)
Dose Escalated (Dose escalated)
Dose Reduced (Dose reduced)
Drug Discontinued (Drug discontinued)
No Dose Modification (No dose
modification)
Duration Delay (Days)
Comments
Comments
1 / 1
Sarcoma NCT00450320 On-Study - AMC-
051 On Study Form (F02) - 2636195v1.0
AMC-051 On Study Form (F02)
Sirolimus in Treating Patients With HIV-Related Kaposi's
Sarcoma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=2FDFA89A-
08BB-6018-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/7577
AMC-051 On Study Form (F02)
Header
Visit number
Hiv History
Date of HIV+ diagnosis
Date of AIDS diagnosis
CDC HIV Risk Group
Hemophilia (Hemophiliac)
Heterosexual Contact (Heterosexual
contact)
Homosexual Or Bisexual Contact
(Homosexual or bisexual contact)
Iv Drug User (IV drug user)
Other (Other)
Transfusion Recipient (Transfusion
recipient)
Other, specify
Ccrr Module For On Study Form - Rf02b
Date of Initial Pathologic Diagnosis
Primary site
Anal Canal (Anal)
Cervical (Cervical)
Hd (HD)
Kaposi Sarcoma (KS)
Non-hodgkin's Lymphoma (NHL)
Other Primary Site (Other primary site)
Other specify
Specify tumor histologic category
Prior Treatment?
Yes
No
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Prior Systemic Chemotherapy
Yes
No
Prior Biological Response Modifiers or Cytokines
Yes
No
Specify
Prior Surgery (excluding biopsy)
Yes
No
Prior cryotherapy
Yes
No
Prior systemic steroid treatment
Yes
No
Prior Radiation Therapy
Yes
No
Prior topical/intralesional therapy
Yes
No
Other Prior Therapy (e.g. Hyperthermia, etc.)
Yes
No
Other Prior Therapy (e.g. Hyperthermia, etc.)
Yes
No
Specify (agent name)
Name of other prior therapies
Ccrr Module For On Study Form - Rf02b
History of Prior Malignancy (or concurrent other)
Yes
No
Date of Diagnosis of Previous Malignancy (or
concurrent)
Primary site
Anal Canal (Anal)
Cervical (Cervical)
Hd (HD)
Kaposi Sarcoma (KS)
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Sarcoma NCT00450320 On-Study - AMC-051 On Study Form (F02) -
2636195v1.0
Non-hodgkin's Lymphoma (NHL)
Other Primary Site (Other primary site)
Other specify
Specify tumor histologic category
Prior Treatment?
Yes
No
Prior Systemic Chemotherapy
Yes
No
Prior Biological Response Modifiers or Cytokines
Yes
No
Specify
Prior Surgery (excluding biopsy)
Yes
No
Prior cryotherapy
Yes
No
Prior systemic steroid treatment
Yes
No
Prior Radiation Therapy
Yes
No
Prior topical/intralesional therapy
Yes
No
Other Prior Therapy (e.g. Hyperthermia, etc.)
Yes
No
Other Prior Therapy (e.g. Hyperthermia, etc.)
Yes
No
Specify (agent name)
Name of other prior therapies
Antiretroviral Therapy
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Sarcoma NCT00450320 On-Study - AMC-051 On Study Form (F02) -
2636195v1.0
Agent Name
Other, specify
Agent use
Currently Receiving (Currently receiving)
Never Received (Never received)
Previously Received (Previously
received)
Duration if prior agents received
< 3 Months (< 3 months)
> 12 Months (> 12 months)
> 6-12 Months (> 6-12 months)
3-6 Months (3-6 months)
Comments
Comments
4 / 4
Sarcoma NCT00450320 On-Study - AMC-051 On Study Form (F02) -
2636195v1.0
Sarcoma, Kaposi xxx On-Study - On Study
Form - RF02B - 2266958v3.0
On Study Form - RF02B
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=CCE2BABD-
1F19-494E-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/7579
On Study Form - RF02B
Ccrr Module For On Study Form - Rf02b
Duration of Prior Antiretroviral Therapy
<3 Months (<3 Months)
>12 Months (>12 Months)
>6-12 Months (>6-12 Months)
3-6 Months (3-6 Months)
CDC HIV Risk Group
Hemophiliac (Hemophiliac)
Hetersexual contact (Hetersexual
contact)
Homosexual or bisexual contact
(Homosexual or bisexual contact)
IV drug user (IV drug user)
Other (Other)
Transfusion recipient (Transfusion
recipient)
Date of AIDS diagnosis
Date of HIV+ diagnosis
Biological response modifiers or cytokines,
Specify
Biological response modifiers or cytokines,
Specify
Is patient receiving antiretroviral therapy
concurrently?
Yes
No
Has patient received any antiretroviral therapy
prescribed prior to registration?
Yes
No
Other, Specify
Patient Initials
Study#
Site#
ID#
1 / 5
Date of Enrollment
Institution Name
Date of Malignancy Diagnosis
Other therapy (e.g. hyperthermia, etc.), Specify
Prior or concurrent other malignancy?
Yes
No
Date of Malignancy Diagnosis
Malignancy/Primary Site
Anal (Anal)
Cervical (Cervical)
HD (HD)
KS (KS)
NHL (NHL)
Other (Other)
Malignancy/Primary Site
Anal (Anal)
Cervical (Cervical)
HD (HD)
KS (KS)
NHL (NHL)
Other (Other)
Other, Specify
Other, Specify
Histology
Histology
Prior therapy for this malignancy?
Yes
No
Prior therapy for this malignancy?
Yes
No
If Yes, check all that apply
Biological response modifiers or
cytokines (Biological response modifiers
or cytokines)
Cryotherapy (Cryotherapy)
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Sarcoma, Kaposi xxx On-Study - On Study Form - RF02B - 2266958v3.0
Investigational Drug (Antitumor)
(Investigational Drug (Antitumor))
Other therapy (e.g. hyperthermia, etc.)
(Other therapy (e.g. hyperthermia, etc.))
Radiotherapy (Radiotherapy)
Surgery (excluding biopsy) (Surgery
(excluding biopsy))
Systemic chemotherapy (Systemic
chemotherapy)
Systemic steroid therapy (Systemic
steroid therapy)
Topical/Intralesional Therapy
(Topical/Intralesional Therapy)
If Yes, check all that apply
Biological response modifiers or
cytokines (Biological response modifiers
or cytokines)
Cryotherapy (Cryotherapy)
Investigational Drug (Antitumor)
(Investigational Drug (Antitumor))
Other therapy (e.g. hyperthermia, etc.)
(Other therapy (e.g. hyperthermia, etc.))
Radiotherapy (Radiotherapy)
Surgery (excluding biopsy) (Surgery
(excluding biopsy))
Systemic chemotherapy (Systemic
chemotherapy)
Systemic steroid therapy (Systemic
steroid therapy)
Topical/Intralesional Therapy
(Topical/Intralesional Therapy)
Other 2, Specify
Other 2, Specify
Other 2, Specify
Agent Name - unnamed
3TC (3TC)
Abacavir (Abacavir)
Amprenavir (Amprenavir)
Atazanavir (Atazanavir)
AZT (AZT)
Combivir (Combivir)
d4T (d4T)
ddC (ddC)
ddI (ddI)
Delavirdine (Delavirdine)
Didanosine (Didanosine)
Efavirenz (Efavirenz)
Emtricitabine (Emtricitabine)
Enfuvirtide (Enfuvirtide)
Fosamaprenavir (Fosamaprenavir)
Indinavir (Indinavir)
Kaletra (Kaletra)
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Sarcoma, Kaposi xxx On-Study - On Study Form - RF02B - 2266958v3.0
Nelfinavir (Nelfinavir)
Nevirapine (Nevirapine)
Other (Other)
Other, Specify (Other, Specify)
Ritonavir (Ritonavir)
Saquinavir (Saquinavir)
Tenofovir DF (Tenofovir DF)
Trizivir (Trizivir)
Agent Name - unnamed
3TC (3TC)
Abacavir (Abacavir)
Amprenavir (Amprenavir)
Atazanavir (Atazanavir)
AZT (AZT)
Combivir (Combivir)
d4T (d4T)
ddC (ddC)
ddI (ddI)
Delavirdine (Delavirdine)
Didanosine (Didanosine)
Efavirenz (Efavirenz)
Emtricitabine (Emtricitabine)
Enfuvirtide (Enfuvirtide)
Fosamaprenavir (Fosamaprenavir)
Indinavir (Indinavir)
Kaletra (Kaletra)
Nelfinavir (Nelfinavir)
Nevirapine (Nevirapine)
Other (Other)
Other, Specify (Other, Specify)
Ritonavir (Ritonavir)
Saquinavir (Saquinavir)
Tenofovir DF (Tenofovir DF)
Trizivir (Trizivir)
Agent Name - unnamed
3TC (3TC)
Abacavir (Abacavir)
Amprenavir (Amprenavir)
Atazanavir (Atazanavir)
AZT (AZT)
Combivir (Combivir)
d4T (d4T)
ddC (ddC)
ddI (ddI)
Delavirdine (Delavirdine)
Didanosine (Didanosine)
Efavirenz (Efavirenz)
Emtricitabine (Emtricitabine)
Enfuvirtide (Enfuvirtide)
Fosamaprenavir (Fosamaprenavir)
Indinavir (Indinavir)
Kaletra (Kaletra)
Nelfinavir (Nelfinavir)
Nevirapine (Nevirapine)
Other (Other)
Other, Specify (Other, Specify)
Ritonavir (Ritonavir)
Saquinavir (Saquinavir)
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Sarcoma, Kaposi xxx On-Study - On Study Form - RF02B - 2266958v3.0
Tenofovir DF (Tenofovir DF)
Trizivir (Trizivir)
Agent Name - unnamed
3TC (3TC)
Abacavir (Abacavir)
Amprenavir (Amprenavir)
Atazanavir (Atazanavir)
AZT (AZT)
Combivir (Combivir)
d4T (d4T)
ddC (ddC)
ddI (ddI)
Delavirdine (Delavirdine)
Didanosine (Didanosine)
Efavirenz (Efavirenz)
Emtricitabine (Emtricitabine)
Enfuvirtide (Enfuvirtide)
Fosamaprenavir (Fosamaprenavir)
Indinavir (Indinavir)
Kaletra (Kaletra)
Nelfinavir (Nelfinavir)
Nevirapine (Nevirapine)
Other (Other)
Other, Specify (Other, Specify)
Ritonavir (Ritonavir)
Saquinavir (Saquinavir)
Tenofovir DF (Tenofovir DF)
Trizivir (Trizivir)
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Sarcoma, Kaposi xxx On-Study - On Study Form - RF02B - 2266958v3.0
On-Study - CONCOMITANT MEDS -
2405782v1.0
The Concomitant Meds form for C3D 3.12 Adopters
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=0139B233-
B70B-09D5-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/7581
CONCOMITANT MEDS
Concomitant Measures/medications
Course Number
Course Day Number
Start Date
Stop Date
Agent Name
Concomitant Procedure Name
Complementary And Alternative
Medicine (Alternative Therapy)
Pheresis (Apheresis)
Contraception (Birth Control)
Bronchoalveolar Lavage
(Bronchoscopy/Bronch Lavage)
Cauterization (Cauterization)
Dental Procedure (Dental Procedure)
Ear Tube Placement (Ear Tube(s)
Insertion)
Oesophageal Dilation Procedure
(Esophageal Dilation)
Whole Body Hyperbaric Oxygen Therapy
(Hyperbaric Treatment(s))
Intraaortic Balloon Pump/stent
Placement (IABP/Stent Placement)
Incision And Drainage (Incision &
Drainage)
Intraventricular Shunt Access
(Intraventricular Shunt Access)
Irrigation - Action (Irrigation)
Lymphocyte Infusion (Lymphocyte
Infusion)
Ventilation, Mechanical (Mechanical
Ventilation)
Tubes, Gastrointestinal Decompression
(NG Decompression)
Masks, Air-oxygen, Aerosol
Administration (Oxygen Administration)
Paracentesis (Paracentesis)
Pleurodesis (Pleurodesis)
Radiation (Radiation)
Stent/catheter Change (Stent/Catheter
Change)
Removal Of Stent (Stent/Catheter
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Removal)
Surgical Procedure (Surgical Procedure)
Thoracentesis (Thoracentesis)
Venous Access Device Placement
(Venous Access/IV Placement)
Venous Access Device Removal (Venous
Access/IV Removal)
Concomitant Medication Administered Dose
Actual Dose Administered Unit of Measure Name
Percent (%)
10e4 Cells Per Kilogram (10E4 Cell/kg)
10e5 Cells Per Kilogram (10E5 Cell/kg)
10e6 Cells Per Kilogram (10E6 Cell/kg)
10e7 Cells Per Kilogram (10E7 Cell/kg)
10e7 Plaque Forming Units (10E7 PFU)
10e8 Plaque Forming Units (10E8 PFU)
10e9 Plaque Forming Units (10E9 PFU)
Application (Applcatn)
Atomic Unit (au)
Area Under The Curve (AUC)
Billion Pfu (bill PFU)
Bottle (Bottle)
Caplet (Caplet)
Capsule (Capsule)
Cells (Cells)
Centigray (cGy)
Curie (Ci)
Course (Course)
Cycle (Course)
Deciliter (dL)
Dose (Dose)
Equivalent (Eq)
Grams (g) (g)
Gram Per M2 (g/m2)
Gallon (Gallon)
Drops (gtts)
Gray (Gy)
Hertz (Hz)
Inhalation (Inhalatn)
Iu Vitamin A (IU Vit A)
International Units Or Milligram Alpha
Tocopherol (IU/mg A-TE)
International Unit (IUnit)
International Unit Per Kilogram (IUnit/kg)
International Unit Per Liter (IUnit/L)
Intravenous Bag (IV Bag)
Joules Per Centimeter Squared (Jcm2)
Kib-electron Volt (KeV)
Kilograms (kg)
Kilohertz (kHz)
Kilopascal (kPa)
Kilounit (kU)
Kilounit Per Kilogram (kU/kg)
Kilounit Per Liter (kU/L)
Liter (L)
Liters Per Minute (L/min)
Microgram (mcg)
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On-Study - CONCOMITANT MEDS - 2405782v1.0
Microgram Per Centimeter Squared
(mcg/cm2)
Microgram Per Hour (mcg/hr)
Microgram Per Kilogram (mcg/kg)
Microgram Per Meter Squared (mcg/m2)
Millicurie (mCi)
Measure (Measure)
Milliequivalent (mEq)
Milliequivalents Per 24 Hours (mEq/24hr)
Milliequivalent Per Deciliter (mEq/dL)
Milliequivalent Per Hour (mEq/hr)
Milliequivalent Per Liter (mEq/L)
Million Electron Volt (MeV)
Milligram (mg)
Milligram Per 24 Hours (mg/24hr)
Milligram Per Deciliter (mg/dL)
Milligram Per Hour (mg/hr)
Milligram Per Inhalation (mg/inh)
Milligram Per Kilogram (mg/kg)
Milligram Per Meter Squared (mg/m2)
Milligram Per Milliliter (mg/mL)
Milligram Per Week (mg/wk)
Megahertz (MHz)
Microcurie (microCi)
Microliter (microL)
Micromole (micromol)
Million Plaque Forming Units (mill PFU)
Million (Million)
Milliunit (millunit)
Milliinternational Unit (miu)
Milliinternational Units Per Meter
Squared (miu/m2)
Milliliter (mL)
Cubic Centimeter (cc) (mL)
Milliliter Per Hour (mL/hr)
Milliliter Per Kilogram (mL/kg)
Millimole (mmol)
Mole (Mole)
Milliosmole (mosmol)
Megarad (Mrad)
Million Units (MU)
Millivolt (mV)
Million Viral Particles (MVP)
Nanocurie (nCi)
Nanogram (ng)
Nanogram Per Kilogram (ng/kg)
Nanogram Per Liter (ng/L)
Nanograms Per Milliliter (ng/mL)
Nanometer Of Light (nm light)
Nanomole (nmol)
No Source Data (No Srce)
Osmolality (osmol)
Ounce (oz)
Pascal (Pa)
Packet (packet)
Patch (Patch)
Plaque Forming Units (PFU)
Picograms (pg)
Pounds Per Square Inch (psi)
Puff (puff)
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On-Study - CONCOMITANT MEDS - 2405782v1.0
Radiation Absorbed Dose (Rad)
Vitamin A Retinol (RAE)
Retinol Equivalents (RE)
Seed (Seed)
Session (Session)
Spray (Spray)
Suppository (Suppstry)
Tablets (Tablet)
Tablespoon (Tbsp)
Tissue Culture Infection Dose (TCID)
Thousand (Thousand)
Troche (Troche)
Teaspoon (tsp)
Unit (Unit)
Unit Per Gram (Unit/g)
Unit Per Kilogram (Unit/kg)
Unit Per Meter Squared (Unit/m2)
Unknown (Unknown)
Viral Particles (VP)
Administration Schedule Abbreviated Descriptive
Text
Route
Continuous Intravenous Infusion (CIV)
Endotracheal Route Of Administration
(ENDOTR)
Gastrostomy Tube (G Tube)
Intra-arterial (IA)
Intradermal (ID)
Intrahepatic (IH)
Intrahepatic Infusion (IHI)
Intramuscular (IM)
Inhalation (Inhalatn)
Interstitial Route Of Administration
(Interstl)
Intratumoral (INTUM)
Intraperitoneal (IP)
Intrathecal (IT)
Intravenous Bolus (IV)
Intravenous Infusion (IVI)
Nasal (NASAL)
Nasogastric (NG)
Ophthalmic, Each Eye (Oph Each)
Ophthalmic, Left Eye (Oph Left)
Ophthalmic, Right Eye (Oph Rt)
Auricular Route Of Administration (Otic)
Oral (PO)
Rectal (PR)
Radiation (RT)
Subcutaneous (SC)
Sublingual (Sublingual)
Swish & Spit (SWSP)
Swish & Swallow (SWSW)
Topical (TOP)
Transdermal (Transdermal)
Transmucosal Route (Transmucosal)
Unknown Route Of Administration
(Unknown)
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Vaginal Route (Vaginal)
indication
Accelerate Hematopoietic Recovery
(Accelerate Hematopoietic Recovery)
Acidity (Acidity)
Adrenal Suppression (Adrenal
Suppression)
Hypersensitivity (Allergic Reaction)
Allergy (Allergy)
Alopecia (Alopecia)
Anemia (Anemia)
Anesthetic Agent (Anesthesia)
Angina (Anti-angina)
Anticoagulation (Anticoagulation)
Antipsychotic (Antipsychotic)
Anxiety (Anxiety)
Pheresis (Apheresis)
Appetite (Appetite)
Arrhythmia (Arrhythmia)
Arthralgia (Arthralgia)
Arthritis (Arthritis)
Ascites (Ascites)
Asthma (Asthma)
Attention Deficit Disorder (Attention
Deficit Disorder)
Benign Prostatic Hyperplasia (Benign
Prostatic Hyperplasia)
Bipolar Disorder (Bipolar Disorder)
Contraception (Birth Control)
Blepharitis (Blepharitis (Eyelid
Inflammation))
Bloating (Bloating)
Bony Disease (Bony Disease)
Bronchitis (Bronchitis)
Bronchospasm (Bronchospasm)
Bursitis (Bursitis)
Cardiac (Cardiac)
Cellulitis (Cellulitis)
Chronic Obstructive Pulmonary Disease
(Chronic Obstructive Pulmonary Disease
(COPD))
Cytomegalovirus Therapy (CMV
Therapy)
Central Nervous System Disease Or
Disorder (CNS Disease)
Complicating Disease Or Condition
(Complicating Disease or Condition)
Congestion (Congestion)
Conjunctivitis (Conjunctivitis)
Constipation (Constipation)
Contrast Agent Image Study (Contrast
Study)
Cough (Cough)
Dehydration (Dehydration)
Depression (Depression)
Dermatitis (Dermatitis)
Diabetes Mellitus (Diabetes)
Diarrhea (Diarrhea)
Dryness Skin (Dry Skin)
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Dyspepsia (Dyspepsia)
Dysphagia (Dysphagia)
Dyspnea (Dyspnea)
Dysuria (Dysuria)
Earache (Earache)
Edema (Edema)
Electrolyte Imbalance (Electrolyte
Imbalance)
Empirical Coverage (Empirical
Coverage)
Engraftment (Engraftment)
Epiphora (watery Eyes) (Epiphora
(Watery Eyes))
Epistaxis (Epistaxis)
Impotence (Erectile Dysfunction)
Erythema (Erythema)
Esophagitis (Esophagitis)
Extrapyramidal Symptoms
(Extrapyramidal)
Eye Redness (Eye Redness)
Fatigue (Fatigue)
Fever (Fever)
Fever Leukocyte (Fever w/Low WBC)
Flatulence (Flatulence)
Influenza Symptom (Flu Symptoms)
Fluid Overload (Fluid Overload)
Fluid Retention (Fluid Retention)
Gastric Ulcer (Gastric Ulcer)
Gastritis (Gastritis)
Gastroesophageal Reflux Disease
(Gastroesophageal Reflux Disease)
Gastrointestinal Distress
(Gastrointestinal distress)
Gastrointestinal Decontamination (GI
Decontamination)
Glaucoma (Glaucoma)
Gout (Gout)
Granulocytopenia (Granulocytopenia)
Graft Versus Host Disease Preventive
Intervention (GVHD Prophylaxis)
Graft Versus Host Disease Therapy
(GVHD Therapy)
Palmar-plantar Erythodysthesia (Hand
Foot Syndrome (HFS))
Headache (Headache)
Hemolytic Uremic Syndrome Symptoms
(Hemolytic Urem Syndrome)
Hemorrhage (Hemorrhage)
Hemorrhoid (Hemorrhoids)
Heparin Reversal (Heparin Reversal)
Laboratory Hepatic Abnormality (Hepatic
Lab abnormality)
Hiatal Hernia (Hiatal hernia)
Hiccough (Hiccoughs)
Human Immunodeficiency Virus (HIV)
Hormonal Manipulation (Hormonal
Manipulation)
Hot Flashes (Hot Flashes)
Hypercalcemia (Hypercalcemia)
Hypercholesterolemia
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(Hypercholesterolemia)
Hyperglycemia (Hyperglycemia)
Hyperkalemia (Hyperkalemia)
Hyperlipidemia (Hyperlipidemia)
Hyperparathyroidism
(Hyperparathyroidism)
Hypertension (Hypertension)
Hyperthyroidism (Hyperthyroidism)
Hypoalbuminemia (Hypoalbuminemia)
Hypocalcemia (Hypocalcemia)
Hypokalemia (Hypokalemia)
Hypomagnesemia (Hypomagnesemia)
Hypophosphatemia (Hypophosphatemia)
Hypotension (Hypotension)
Hypothyroidism (Hypothyroidism)
Hypoxia (Hypoxia)
Indigestion (Indigestion)
Sedation (Induce Sedation)
Infection (Infection)
Inflammation (Inflammation)
Injection Site Reaction (Injection Site
Reaction)
Insomnia (Insomnia)
Itching Sensation (Itching)
Dry Eyes (Keratitis sicca (Dry Eyes))
Lactose Intolerance (Lactose
Intolerance)
Leg Cramps (Leg cramps)
Line Occlusion (Line Occlusion)
Line Patency (Line Patency)
Local Anesthesia (Local Anesthesia)
Macular Degeneration (Macular
degeneration)
Malignant Neoplasm (Malignancy)
Malignant Hyperthermia (Malignant
Hyperthermia)
Menopause (Menopausal symptoms)
Metabolic Imbalance (Metabolic
Imbalance)
Mood (Mood)
Mouth Sores (Mouth Sores)
Mucositis (Mucositis)
Muscle Spasm (Muscle Spasm)
Myalgia (Myalgia)
Nail Changes (Nail Changes)
Narcolepsy (Narcolepsy)
Nasal Symptom (Nasal Symptom)
Nausea (Nausea)
Nausea And Vomiting (Nausea and
vomiting)
Neuropathy (Neuropathy)
Neutropenia (Neutropenia)
Nutrition (Nutrition)
Osteoporosis (Osteoporosis)
Pain (Pain)
Palliative Therapy (Palliation)
Parkinson's Disease (Parkinson's
Disease)
Partial Thromboplastin Time (ptt)
Prolongation (Partial Thromboplastin
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Time (PTT) Prolongation)
Periodontal Disease (Periodontal
Disease)
Petechia (Petechiae)
Pharyngitis (Pharyngitis)
Phlebitis (Phlebitis)
Pleural Effusion (Pleural Effusion)
Pneumonia (Pneumonitis)
Occlusion Within Medical Device (Port
Occlusion)
Post Traumatic Stress Disorder (Post
Traumatic Stress Disorder)
After Treatment Completion
(PostTreatment)
Before Chemotherapy
(Prechemotherapy)
Before A Procedure Or Diagnostic
Testing (Preprocedure/Diagnostic
Testing)
Before Treatment (PreTreatment)
Preventive Intervention (Prophylaxis)
Pruritus (Pruritus)
Pseudogout (Pseudogout)
Psoriasis (Psoriasis)
Pulmonary Embolus (Pulmonary
Embolus)
Skin Rash (Rash)
Rectal Bleeding (Rectal Bleeding)
Reflux (Reflux)
Renal Urinary (Renal/Urinary)
Replacement (Replacement)
Respiratory Distress Dyspnea
(Respiratory Distress/Dyspnea)
Restless Leg Syndrome (Restless Leg
Syndrome)
Restlessness (Restlessness)
Rhinorrhea (Rhinorrhea)
Rigors And Shaking (Rigors)
Scabies (Scabies)
Seizure (Seizures)
Sinusitis (Sinusitis)
Skin Irritation (Skin Irritation)
Sleep (Sleep)
Sleep Apnea (Sleep Apnea)
Smoking Cessation (Smoking Cessation)
Stomach Cramps (Stomach Cramps)
Stomatitis (Stomatitis)
Supplement (Supplement)
Thrombocytopenia (Thrombocytopenia)
Blood Clot (Thrombus)
Oral Candidiasis (Thrush)
Tremors (Tremors)
Urinary Urinary (Urinary)
Urticaria (Urticaria)
Dryness Of The Vagina (Vaginal
Dryness)
Vascular Access (Vascular Access)
Vasodilitation (flush) (Vasodilitation
(Flush))
Venous Thrombosis (Venous
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Thrombosis)
Vertigo (Vertigo)
Vitamin (Vitamins)
Vomiting (Vomiting)
Weight Gain (Weight Gain)
Weight Loss (Weight Loss)
Xerosis (Xerosis)
Dry Mouth (Xerostomia)
Comments
Note Date
Research Comments Text
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Pre-Study - PRIOR THERAPY
SUPPLEMENT - 2394210v1.0
Prior Therapy form for C3D 3.12 Adopters
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=FF07B012-
CA3F-1CA3-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/7583
PRIOR THERAPY SUPPLEMENT
Prior Therapy Supplement
Treatment Start Date
Stop Date
Agent Name
Administration Schedule Abbreviated Descriptive
Text
Total Dose Value
Actual Dose Administered Unit of Measure Name
Percent (%)
10e4 Cells Per Kilogram (10E4 Cell/kg)
10e5 Cells Per Kilogram (10E5 Cell/kg)
10e6 Cells Per Kilogram (10E6 Cell/kg)
10e7 Cells Per Kilogram (10E7 Cell/kg)
10e7 Plaque Forming Units (10E7 PFU)
10e8 Plaque Forming Units (10E8 PFU)
10e9 Plaque Forming Units (10E9 PFU)
Application (Applcatn)
Atomic Unit (au)
Area Under The Curve (AUC)
Billion Pfu (bill PFU)
Bottle (Bottle)
Caplet (Caplet)
Capsule (Capsule)
Cells (Cells)
Centigray (cGy)
Curie (Ci)
Course (Course)
Cycle (Course)
Deciliter (dL)
Dose (Dose)
Equivalent (Eq)
Grams (g) (g)
Gram Per M2 (g/m2)
Gallon (Gallon)
Drops (gtts)
Gray (Gy)
Hertz (Hz)
Inhalation (Inhalatn)
Iu Vitamin A (IU Vit A)
International Units Or Milligram Alpha
Tocopherol (IU/mg A-TE)
International Unit (IUnit)
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International Unit Per Kilogram (IUnit/kg)
International Unit Per Liter (IUnit/L)
Intravenous Bag (IV Bag)
Joules Per Centimeter Squared (Jcm2)
Kib-electron Volt (KeV)
Kilograms (kg)
Kilohertz (kHz)
Kilopascal (kPa)
Kilounit (kU)
Kilounit Per Kilogram (kU/kg)
Kilounit Per Liter (kU/L)
Liter (L)
Liters Per Minute (L/min)
Microgram (mcg)
Microgram Per Centimeter Squared
(mcg/cm2)
Microgram Per Hour (mcg/hr)
Microgram Per Kilogram (mcg/kg)
Microgram Per Meter Squared (mcg/m2)
Millicurie (mCi)
Measure (Measure)
Milliequivalent (mEq)
Milliequivalents Per 24 Hours (mEq/24hr)
Milliequivalent Per Deciliter (mEq/dL)
Milliequivalent Per Hour (mEq/hr)
Milliequivalent Per Liter (mEq/L)
Million Electron Volt (MeV)
Milligram (mg)
Milligram Per 24 Hours (mg/24hr)
Milligram Per Deciliter (mg/dL)
Milligram Per Hour (mg/hr)
Milligram Per Inhalation (mg/inh)
Milligram Per Kilogram (mg/kg)
Milligram Per Meter Squared (mg/m2)
Milligram Per Milliliter (mg/mL)
Milligram Per Week (mg/wk)
Megahertz (MHz)
Microcurie (microCi)
Microliter (microL)
Micromole (micromol)
Million Plaque Forming Units (mill PFU)
Million (Million)
Milliunit (millunit)
Milliinternational Unit (miu)
Milliinternational Units Per Meter
Squared (miu/m2)
Milliliter (mL)
Cubic Centimeter (cc) (mL)
Milliliter Per Hour (mL/hr)
Milliliter Per Kilogram (mL/kg)
Millimole (mmol)
Mole (Mole)
Milliosmole (mosmol)
Megarad (Mrad)
Million Units (MU)
Millivolt (mV)
Million Viral Particles (MVP)
Nanocurie (nCi)
Nanogram (ng)
Nanogram Per Kilogram (ng/kg)
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Nanogram Per Liter (ng/L)
Nanograms Per Milliliter (ng/mL)
Nanometer Of Light (nm light)
Nanomole (nmol)
No Source Data (No Srce)
Osmolality (osmol)
Ounce (oz)
Pascal (Pa)
Packet (packet)
Patch (Patch)
Plaque Forming Units (PFU)
Picograms (pg)
Pounds Per Square Inch (psi)
Puff (puff)
Radiation Absorbed Dose (Rad)
Vitamin A Retinol (RAE)
Retinol Equivalents (RE)
Seed (Seed)
Session (Session)
Spray (Spray)
Suppository (Suppstry)
Tablets (Tablet)
Tablespoon (Tbsp)
Tissue Culture Infection Dose (TCID)
Thousand (Thousand)
Troche (Troche)
Teaspoon (tsp)
Unit (Unit)
Unit Per Gram (Unit/g)
Unit Per Kilogram (Unit/kg)
Unit Per Meter Squared (Unit/m2)
Unknown (Unknown)
Viral Particles (VP)
Best Response Assessment Type
Complete Response (CR)
Complete Response Unconfirmed (CRU)
Disease Unchanged (DU)
Less Than Partial Response (MR)
Not Assessed (NA)
Not Evauable (NE)
Not Applicable Per Protocol (NP)
No Response (NR)
Progressive Disease (PD)
Partial Response (PR)
Stable Disease (SD)
Too Early (TE)
Unknown (UK)
Therapy Intent Text Name
Adjuvant (Adjuvant)
Bm Ablation (BM Ablation)
Curative (Curative)
Local Control (Local Control)
Metastatic (Metastatic)
Neo-adjuvant (Neo-Adjuvant)
Palliative (Palliative)
Preventive (Preventive)
Therapy Type
3 / 4
Pre-Study - PRIOR THERAPY SUPPLEMENT - 2394210v1.0
Anti-retroviral Therapy (AR)
Antisense Therapy (AS)
Bone Marrow Transplantation (BM)
Chemotherapy, Nos (C)
Chemotherapy, Multiple Agents Systemic
(CM)
Single Agent Systemic Chemotherapy
(CS)
Extensive Radiation (ER)
Gene Transfer (G)
Hormone Therapy (H)
Hematopoietic Stem Cell Transplantation
(HE)
Immunotherapy (I)
Image Directed Local Therapy (ID)
Limited Radiation Therapy (LR)
No Prior Therapy (N)
Chemotherapy, Non-cytotoxic (NC)
Oncolytic Virotherapy (OV)
Prior Therapy (PT)
Radiation Therapy (R)
Surgery (S)
Vaccine Therapy (V)
Comments
Note Date
Research Comments Text
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Sarcoma, Kaposi xxx On-Study - Prior Treatment
History for Kaposi's Sarcoma - RKS01B - 2267118v3.0
Prior Treatment History for Kaposi's Sarcoma - RKS01B
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=CCE47CB4-
3553-4ED5-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/7586
Prior Treatment History for Kaposi's
Sarcoma - RKS01B
Ccrr Module For Prior Treatment History
For Kaposi's Sarcoma - Rks01b
If Other Source, specify
Specify
Has the patient received any systemic or topical
therapy other than cytotoxic chemotherapy
specified in section 1 for the treatment of
Kaposi's Sarcoma?
No (No)
Unknown (Unknown)
Yes (Yes)
If Other Source, specify
Patient Initials
Study#
Site#
ID#
Date of Visit
Has the patient received non-investigational
systemic chemotherapy or immunotherapy for the
treatment of Kaposi's Sarcoma?
No (No)
Unknown (Unknown)
Yes (Yes)
Single Agents
Adriamycin (Adriamycin)
Adrianmycin/bleomycin/vincristine
(Adrianmycin/bleomycin/vincristine)
Bleomycin (Bleomycin)
Bleomycin/vincristine
(Bleomycin/vincristine)
DaunoXome (DaunoXome)
Doxil (Doxil)
Doxil/bleomycin/vincristine
(Doxil/bleomycin/vincristine)
1 / 2
Etoposide (Etoposide)
Interferon (Interferon)
Other combination therapy (Other
combination therapy)
Other single agent therapy (Other single
agent therapy)
Taxol (Taxol)
Vinblastine (Vinblastine)
Vincristine (Vincristine)
Vincristine/vinblastine
(Vincristine/vinblastine)
Unnamed
No (No)
Unknown (Unknown)
Yes (Yes)
Best Response
Complete Response (Clinical Complete
Response)
Complete Response (Complete
response)
N/A (Phase I Trial) (N/A (Phase I Trial))
Partial Response (Partial Response)
Partial Response (Progressive Disease)
Stable Disease (Stable Disease)
Unknown (Unknown)
Best Response
Complete Response (Clinical Complete
Response)
Complete Response (Complete
response)
N/A (Phase I Trial) (N/A (Phase I Trial))
Partial Response (Partial Response)
Partial Response (Progressive Disease)
Stable Disease (Stable Disease)
Unknown (Unknown)
Source
Clinical Assessment (Clinical/Medical
Record)
Other (Other)
Patient (Patient)
Source
Clinical Assessment (Clinical/Medical
Record)
Other (Other)
Patient (Patient)
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Nonneoplastic Condition NCT01057121 On-Study
- AMC-070 On-Study Form (F02) - 3147138v1.0
AMC-070 On-Study Form (F02)
Lenalidomide in Treating Patients With AIDS-Related
Kaposi Sarcoma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=91E4BBD6-
67FC-9CA4-E040-BB89AD437D79
All rights reserved. Please visit https://medical-data-
models.org/forms/7591
AMC-070 On-Study Form (F02)
Header
Visit number
Hiv History
Date of HIV+ diagnosis (mm/dd/yyyy)
Date of AIDS diagnosis (mm/dd/yyyy)
CDC HIV Risk Group
Hemophilia (Hemophiliac)
Heterosexual Contact (Heterosexual
contact)
Homosexual Or Bisexual Contact
(Homosexual or bisexual contact)
Iv Drug User (IV drug user)
Other (Other)
Transfusion Recipient (Transfusion
recipient)
Other, specify
Ccrr Module For On Study Form - Rf02b
Date of Initial Pathologic Diagnosis (mm/dd/yyyy)
Primary site
Anal Canal (Anal)
Cervical (Cervical)
Hd (HD)
Kaposi Sarcoma (KS)
Non-hodgkin's Lymphoma (NHL)
Other Primary Site (Other primary site)
Other specify
Specify tumor histologic category
Prior Treatment? (If "Yes", Check below)
Yes
No
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Prior Systemic Chemotherapy
Yes
No
Prior Biological Response Modifiers or Cytokines
Yes
No
Specify (If "Yes")
Prior Surgery (excluding biopsy)
Yes
No
Prior cryotherapy
Yes
No
Prior systemic steroid therapy
Yes
No
Prior Radiation Therapy
Yes
No
Prior topical/intralesional therapy
Yes
No
Other Prior Therapy (e.g. Hyperthermia, etc.)
Yes
No
Other Prior Therapy (e.g. Hyperthermia, etc.)
Yes
No
Specify (If "Yes" 1 2 3)
Name of other prior therapies (If "Yes")
Ccrr Module For On Study Form - Rf02b
History of Prior Malignancy
Yes
No
Date of Diagnosis of Previous Malignancy
(mm/dd/yyyy)
Primary site
Anal Canal (Anal)
Cervical (Cervical)
Hd (HD)
Kaposi Sarcoma (KS)
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Non-hodgkin's Lymphoma (NHL)
Other Primary Site (Other primary site)
Other specify
Specify tumor histologic category
Prior Treatment? (If "Yes", Check below)
Yes
No
Prior Systemic Chemotherapy
Yes
No
Prior Biological Response Modifiers or Cytokines
Yes
No
Specify (If "Yes")
Prior Surgery (excluding biopsy)
Yes
No
Prior cryotherapy
Yes
No
Prior systemic steroid therapy
Yes
No
Prior Radiation Therapy
Yes
No
Prior topical/intralesional therapy
Yes
No
Other Prior Therapy (e.g. Hyperthermia, etc.)
Yes
No
Other Prior Therapy (e.g. Hyperthermia, etc.)
Yes
No
Specify (If "Yes" 1 2 3)
Name of other prior therapies (If "Yes")
Antiretroviral Therapy
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Agent Name
Other, specify (1 2)
Agent use
Currently Receiving (Currently receiving)
Never Received (Never received)
Previously Received (Previously
received)
Duration if prior agents received
< 3 Months (< 3 months)
> 12 Months (> 12 months)
> 6-12 Months (> 6-12 months)
3-6 Months (3-6 months)
Comments
Comments
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Lung Cancer NCT00863512 Pre-Study - CALGB 30506
Pre-Study/Surgical Resection Form - 2821782v1.0
CALGB 30506 Pre-Study/Surgical Resection Form
Chemotherapy or Observation in Treating Patients With
Early Stage Non-Small Cell Lung Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=5FE8C8A3-
6705-BC07-E040-BB89AD4332A8
All rights reserved. Please visit https://medical-data-
models.org/forms/7592
CALGB 30506 Pre-Study/Surgical
Resection Form
Ccrr Module For Calgb 90202: Prostate
Specific Antigen Form
CALGB Form
CALGB Study No.
CALGB Patient ID
Are data amended
Yes
No
Patient Initials (Last, First Middle)
Patient Hospital No.
Institution/Affiliate
Participating Group
Participating Group Study No.
Participating Group Patient ID
Vital Status
ECOG Performance Status
Fully Active, Able To Carry On All Pre-
disease Performance Without
Restriction. (0)
Restricted In Physically Strenuous
Activity But Ambulatory And Able To
Carry Out Work Of A Light Or Sedentary
Nature, E.g., Light Housework, Office
Work. (1)
Prior Treatment (for this cancer within the past 5
years)
Yes
No
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Required Laboratory Values
WBC (x 10^3 microL)
ANC (x 10^3 microL)
Granulocytes (%)
Platelets (PLT) (x 10^3 microL)
Bilirubin (mg/dl)
SGOT (AST) (UL)
SGOT (AST) ULN (UL)
Serum creatinine (mg/dl)
Serum Creatinine ULN
Unnamed3
Smoking History
Currently Smoking (Currently smoking)
Never Smoked (Never smoked)
Smoked In The Past (Smoked in the
past)
Number pack years smoked (If former or current
smoker, Pack year = number of packs smoked /
day x number of years smoked)
Pre-surgical Disease Status
Date of Chest X-Ray or CT scan (MM DD YYYY)
Clinical Size of Tumor (on chest/upper abdominal
CT scan cm)
Clinical T Stage
Tumor 3 Cm Or Less In Greatest
Dimension, Surrounded By Lung Or
Visceral Pleura, Invasion More Proximal
Than The Lobar Bronchus, (i.e., Not In
The Main Bronchus) (T1)
Tumor With Any Of The Following
Features Of Size Or Extent: More Than
3cm In Greatest Dimension; Invades The
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Visceral Pleura; Associated With
Atelectasis Or Obstructive Pneumonitis
That Extends To The Hilar Region But
Does Not Involve The Entire Lung (T2)
Clinical N Stage
No Regional Lymph Node Metastasis
(N0)
Metastasis To Ipsilateral Peribronchial
And/or Ipsilateral Hilar Lymph Nodes,
And Intrapulmonary Nodes Including
Involvement By Direct Extension Of The
Primary Tumor (N1)
MedDRA disease code
How were positive nodes ruled out (If nodes were
suspicious for malignancy > 1 cm on pre-op CT
or positive on PET scan)
Anterior Mediatinoscopy (chamberlain)
(Anterior Mediatinoscopy (Chamberlain))
Ebus-fna (EBUS-FNA)
Eus-fna (EUS-FNA)
Mediastinoscopy (Mediastinoscopy)
Thoracotomy (Open thoracotomy)
Transbronchial Aspirate; No Ebus
(Transbronchial aspirate; No EBUS)
Ttnb (TTNB)
Vats Node Biopsy (VATS node biopsy)
Surgical Disease Status
Did patient undergo surgical resection?
Yes
No
Date of Resection (MM DD YYYY)
Specify reason (If no Mark all that apply with an
X.)
Benign Mass (Benign mass)
Carcinoid Tumor (Carcinoid)
Other (Other)
Positive Nodes (Positive nodes)
Tumor < 1.70 Cm (Tumor < 1.70 cm)
Other, specify
Histology (Mark one with an X.)
Adenocarcinoma (Adenocarcinoma)
Adenosquamous Carcinoma
(Adenosquamous)
Non-small Cell Lung Cancer (nsclc), Nos
(Non-small cell lung cancer NOS)
Other (Other specify)
Squamous Cell Carcinoma (Squamous
cell carcinoma)
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Other specify
Pathologic Primary Tumor Size (on path report
cm)
T stage (Patients with tumors < 1.7 cm, T3-4 or
N1-2 disease should NOT be registered to study)
T1 (T1)
T2 (T2)
T3-4 (T3-4)
N stage (Patients with tumors < 1.7 cm, T3-4 or
N1-2 disease should NOT be registered to study)
N0 (N0)
N1 (N1)
N2 (N2)
Planned Treatment
Assigned Treatment Arm
Patient Not Randomized Due To
Ineligibility (Patient not randomized due
to ineligibility)
Patient Not Randomized For Other
Reason (Patient not randomized for other
reason)
Patient Refused Assigned Treatment
After Randomization (Patient refused
assigned treatment after randomization)
Patient Refused To Be Randomized
(Patient refused to be randomized)
Randomized To Observation
(Randomized to observation)
Regimen 1: Vinorelbine And Cisplatin
(Regimen 1: Vinorelbine and Cisplatin)
Regimen 2: Docetaxel And Cisplatin
(Regimen 2: Docetaxel and Cisplatin)
Regimen 3: Gemcitabine And Cisplatin
(Regimen 3: Gemcitabine and Cisplatin)
Specify
Contact Information
Medical oncologist's name
Surgeon Name
E-mail
Phone
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Footer Module
Completed by
Date Form Originally Completed (MM DD YYYY)
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Sarcoma NCT01016730 On-Study - AMC-
063 On-Study Form (F02) - 3019506v1.0
AMC-063 On-Study Form (F02)
Bortezomib in Treating Patients With Relapsed or
Refractory AIDS-Related Kaposi Sarcoma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=8100CE37-
2287-8765-E040-BB89AD431777
All rights reserved. Please visit https://medical-data-
models.org/forms/7593
AMC-063 On-Study Form (F02)
Header
Visit number
Hiv History
Date of HIV+ diagnosis (mm/dd/yyyy)
Date of AIDS diagnosis (mm/dd/yyyy)
CDC HIV Risk Group
Hemophilia (Hemophiliac)
Heterosexual Contact (Heterosexual
contact)
Homosexual Or Bisexual Contact
(Homosexual or bisexual contact)
Iv Drug User (IV drug user)
Other (Other)
Transfusion Recipient (Transfusion
recipient)
Other, specify
Ccrr Module For On Study Form - Rf02b
Date of Initial Pathologic Diagnosis (mm/dd/yyyy)
Primary site
Anal Canal (Anal)
Cervical (Cervical)
Hd (HD)
Kaposi Sarcoma (KS)
Non-hodgkin's Lymphoma (NHL)
Other Primary Site (Other primary site)
Other specify
Specify tumor histologic category
Prior Treatment? (If "Yes", Check below)
Yes
No
1 / 4
Prior Systemic Chemotherapy
Yes
No
Prior Biological Response Modifiers or Cytokines
Yes
No
Specify (If "Yes")
Prior Surgery (excluding biopsy)
Yes
No
Prior cryotherapy
Yes
No
Prior systemic steroid therapy
Yes
No
Prior Radiation Therapy
Yes
No
Prior topical/intralesional therapy
Yes
No
Other Prior Therapy (e.g. Hyperthermia, etc.)
Yes
No
Other Prior Therapy (e.g. Hyperthermia, etc.)
Yes
No
Specify (If "Yes" 1 2 3)
Name of other prior therapies (If "Yes")
Ccrr Module For On Study Form - Rf02b
History of Prior Malignancy
Yes
No
Date of Diagnosis of Previous Malignancy
(mm/dd/yyyy)
Primary site
Anal Canal (Anal)
Cervical (Cervical)
Hd (HD)
Kaposi Sarcoma (KS)
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Sarcoma NCT01016730 On-Study - AMC-063 On-Study Form (F02) -
3019506v1.0
Non-hodgkin's Lymphoma (NHL)
Other Primary Site (Other primary site)
Other specify
Specify tumor histologic category
Prior Treatment? (If "Yes", Check below)
Yes
No
Prior Systemic Chemotherapy
Yes
No
Prior Biological Response Modifiers or Cytokines
Yes
No
Specify (If "Yes")
Prior Surgery (excluding biopsy)
Yes
No
Prior cryotherapy
Yes
No
Prior systemic steroid therapy
Yes
No
Prior Radiation Therapy
Yes
No
Prior topical/intralesional therapy
Yes
No
Other Prior Therapy (e.g. Hyperthermia, etc.)
Yes
No
Other Prior Therapy (e.g. Hyperthermia, etc.)
Yes
No
Specify (If "Yes" 1 2 3)
Name of other prior therapies (If "Yes")
Antiretroviral Therapy
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3019506v1.0
Agent Name
Other, specify (1 2)
Agent use
Currently Receiving (Currently receiving)
Never Received (Never received)
Previously Received (Previously
received)
Duration if prior agents received
< 3 Months (< 3 months)
> 12 Months (> 12 months)
> 6-12 Months (> 6-12 months)
3-6 Months (3-6 months)
Comments
Comments
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NCT00956007 Treatment - RTOG 0920 Phase III Head and
Neck Cancer Treatment Summary Form (TF) - 2808140v1.0
RTOG 0920 Phase III Head and Neck Cancer Treatment
Summary Form (TF)
Radiation Therapy With or Without Cetuximab in Treating
Patients Who Have Undergone Surgery for Locally
Advanced Head and Neck Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=5D3B4F31-
8FDD-6B5A-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/7600
RTOG 0920 Phase III Head and
Neck Cancer Treatment Summary
Form (TF)
Unnamed Module 1
RTOG Study No.
Case #
Institution Name
Institution No.
Patient Initials
RTOG Patient ID
Amended data
Yes
No
Summary Of Systemic Treatment
Assigned Treatment Arm
Arm 2 (Arm 2)
Patient Height (cm)
Arm 2 Only
Patient Weight (kg)
Body Surface Area (M^2)
Agent Name
Agent Start Date (for cycles being reported)
Agent End Date (for cycles being reported)
1 / 14
Agent Total Dose (mg)
Dose per M2
Reason for dose modification
Adverse Event/side Effects/complications
(Adverse event/side
effects/complications)
Alternative Therapy (Alternative therapy)
Death On Study (Death on study)
Disease Progression, Relapse During
Active Treatment (Disease progression,
relapse during active treatment)
No Modification (No modification)
Other (Other)
Other Complicating Disease (Other
complicating disease)
Patient Withdrawal Or Refusal After
Beginning Protocol Therapy (Patient
withdrawal/refusal after beginning
protocol therapy)
Patient Withdrawal Or Refusal Prior To
Beginning Protocol Therapy (Patient
withdrawal/refusal prior to beginning
protocol therapy)
Reason Treatment Ended
Adverse Event/side Effects/complications
(Adverse Event/Side
Effects/Complications)
Alternative Therapy (Alternative therapy)
Death On Study (Death on study)
Disease Progression, Relapse During
Active Treatment (Disease progression,
relapse during active treatment)
Other (Other)
Patient Off-treatment For Other
Complicating Disease (Patient off-
treatment for other complicating disease)
Patient Withdrawal Or Refusal After
Beginning Protocol Therapy (Patient
withdrawal/refusal after beginning
protocol therapy)
Patient Withdrawal Or Refusal Before
Beginning Protocol Therapy (Patient
withdrawal/refusal prior to beginning
protocol therapy)
Treatment Completed Per Protocol
Criteria (Treatment completed per
protocol criteria)
Arm 2 Only
Patient Weight (kg)
Body Surface Area (M^2)
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Treatment Summary Form (TF) - 2808140v1.0
Agent Name
Agent Start Date (for cycles being reported)
Agent End Date (for cycles being reported)
Agent Total Dose (mg)
Dose per M2
Reason for dose modification
Adverse Event/side Effects/complications
(Adverse event/side
effects/complications)
Alternative Therapy (Alternative therapy)
Death On Study (Death on study)
Disease Progression, Relapse During
Active Treatment (Disease progression,
relapse during active treatment)
No Modification (No modification)
Other (Other)
Other Complicating Disease (Other
complicating disease)
Patient Withdrawal Or Refusal After
Beginning Protocol Therapy (Patient
withdrawal/refusal after beginning
protocol therapy)
Patient Withdrawal Or Refusal Prior To
Beginning Protocol Therapy (Patient
withdrawal/refusal prior to beginning
protocol therapy)
Reason Treatment Ended
Adverse Event/side Effects/complications
(Adverse Event/Side
Effects/Complications)
Alternative Therapy (Alternative therapy)
Death On Study (Death on study)
Disease Progression, Relapse During
Active Treatment (Disease progression,
relapse during active treatment)
Other (Other)
Patient Off-treatment For Other
Complicating Disease (Patient off-
treatment for other complicating disease)
Patient Withdrawal Or Refusal After
Beginning Protocol Therapy (Patient
withdrawal/refusal after beginning
protocol therapy)
Patient Withdrawal Or Refusal Before
Beginning Protocol Therapy (Patient
withdrawal/refusal prior to beginning
protocol therapy)
Treatment Completed Per Protocol
Criteria (Treatment completed per
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protocol criteria)
Arm 2 Only
Patient Weight (kg)
Body Surface Area (M^2)
Agent Name
Agent Start Date (for cycles being reported)
Agent End Date (for cycles being reported)
Agent Total Dose (mg)
Dose per M2
Reason for dose modification
Adverse Event/side Effects/complications
(Adverse event/side
effects/complications)
Alternative Therapy (Alternative therapy)
Death On Study (Death on study)
Disease Progression, Relapse During
Active Treatment (Disease progression,
relapse during active treatment)
No Modification (No modification)
Other (Other)
Other Complicating Disease (Other
complicating disease)
Patient Withdrawal Or Refusal After
Beginning Protocol Therapy (Patient
withdrawal/refusal after beginning
protocol therapy)
Patient Withdrawal Or Refusal Prior To
Beginning Protocol Therapy (Patient
withdrawal/refusal prior to beginning
protocol therapy)
Reason Treatment Ended
Adverse Event/side Effects/complications
(Adverse Event/Side
Effects/Complications)
Alternative Therapy (Alternative therapy)
Death On Study (Death on study)
Disease Progression, Relapse During
Active Treatment (Disease progression,
relapse during active treatment)
Other (Other)
Patient Off-treatment For Other
Complicating Disease (Patient off-
treatment for other complicating disease)
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Patient Withdrawal Or Refusal After
Beginning Protocol Therapy (Patient
withdrawal/refusal after beginning
protocol therapy)
Patient Withdrawal Or Refusal Before
Beginning Protocol Therapy (Patient
withdrawal/refusal prior to beginning
protocol therapy)
Treatment Completed Per Protocol
Criteria (Treatment completed per
protocol criteria)
Arm 2 Only
Patient Weight (kg)
Body Surface Area (M^2)
Agent Name
Agent Start Date (for cycles being reported)
Agent End Date (for cycles being reported)
Agent Total Dose (mg)
Dose per M2
Reason for dose modification
Adverse Event/side Effects/complications
(Adverse event/side
effects/complications)
Alternative Therapy (Alternative therapy)
Death On Study (Death on study)
Disease Progression, Relapse During
Active Treatment (Disease progression,
relapse during active treatment)
No Modification (No modification)
Other (Other)
Other Complicating Disease (Other
complicating disease)
Patient Withdrawal Or Refusal After
Beginning Protocol Therapy (Patient
withdrawal/refusal after beginning
protocol therapy)
Patient Withdrawal Or Refusal Prior To
Beginning Protocol Therapy (Patient
withdrawal/refusal prior to beginning
protocol therapy)
Reason Treatment Ended
Adverse Event/side Effects/complications
(Adverse Event/Side
Effects/Complications)
Alternative Therapy (Alternative therapy)
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Death On Study (Death on study)
Disease Progression, Relapse During
Active Treatment (Disease progression,
relapse during active treatment)
Other (Other)
Patient Off-treatment For Other
Complicating Disease (Patient off-
treatment for other complicating disease)
Patient Withdrawal Or Refusal After
Beginning Protocol Therapy (Patient
withdrawal/refusal after beginning
protocol therapy)
Patient Withdrawal Or Refusal Before
Beginning Protocol Therapy (Patient
withdrawal/refusal prior to beginning
protocol therapy)
Treatment Completed Per Protocol
Criteria (Treatment completed per
protocol criteria)
Arm 2 Only
Patient Weight (kg)
Body Surface Area (M^2)
Agent Name
Agent Start Date (for cycles being reported)
Agent End Date (for cycles being reported)
Agent Total Dose (mg)
Dose per M2
Reason for dose modification
Adverse Event/side Effects/complications
(Adverse event/side
effects/complications)
Alternative Therapy (Alternative therapy)
Death On Study (Death on study)
Disease Progression, Relapse During
Active Treatment (Disease progression,
relapse during active treatment)
No Modification (No modification)
Other (Other)
Other Complicating Disease (Other
complicating disease)
Patient Withdrawal Or Refusal After
Beginning Protocol Therapy (Patient
withdrawal/refusal after beginning
protocol therapy)
Patient Withdrawal Or Refusal Prior To
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Beginning Protocol Therapy (Patient
withdrawal/refusal prior to beginning
protocol therapy)
Reason Treatment Ended
Adverse Event/side Effects/complications
(Adverse Event/Side
Effects/Complications)
Alternative Therapy (Alternative therapy)
Death On Study (Death on study)
Disease Progression, Relapse During
Active Treatment (Disease progression,
relapse during active treatment)
Other (Other)
Patient Off-treatment For Other
Complicating Disease (Patient off-
treatment for other complicating disease)
Patient Withdrawal Or Refusal After
Beginning Protocol Therapy (Patient
withdrawal/refusal after beginning
protocol therapy)
Patient Withdrawal Or Refusal Before
Beginning Protocol Therapy (Patient
withdrawal/refusal prior to beginning
protocol therapy)
Treatment Completed Per Protocol
Criteria (Treatment completed per
protocol criteria)
Arm 2 Only
Patient Weight (kg)
Body Surface Area (M^2)
Agent Name
Agent Start Date (for cycles being reported)
Agent End Date (for cycles being reported)
Agent Total Dose (mg)
Dose per M2
Reason for dose modification
Adverse Event/side Effects/complications
(Adverse event/side
effects/complications)
Alternative Therapy (Alternative therapy)
Death On Study (Death on study)
Disease Progression, Relapse During
Active Treatment (Disease progression,
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relapse during active treatment)
No Modification (No modification)
Other (Other)
Other Complicating Disease (Other
complicating disease)
Patient Withdrawal Or Refusal After
Beginning Protocol Therapy (Patient
withdrawal/refusal after beginning
protocol therapy)
Patient Withdrawal Or Refusal Prior To
Beginning Protocol Therapy (Patient
withdrawal/refusal prior to beginning
protocol therapy)
Reason Treatment Ended
Adverse Event/side Effects/complications
(Adverse Event/Side
Effects/Complications)
Alternative Therapy (Alternative therapy)
Death On Study (Death on study)
Disease Progression, Relapse During
Active Treatment (Disease progression,
relapse during active treatment)
Other (Other)
Patient Off-treatment For Other
Complicating Disease (Patient off-
treatment for other complicating disease)
Patient Withdrawal Or Refusal After
Beginning Protocol Therapy (Patient
withdrawal/refusal after beginning
protocol therapy)
Patient Withdrawal Or Refusal Before
Beginning Protocol Therapy (Patient
withdrawal/refusal prior to beginning
protocol therapy)
Treatment Completed Per Protocol
Criteria (Treatment completed per
protocol criteria)
Arm 2 Only
Patient Weight (kg)
Body Surface Area (M^2)
Agent Name
Agent Start Date (for cycles being reported)
Agent End Date (for cycles being reported)
Agent Total Dose (mg)
Dose per M2
8 / 14
NCT00956007 Treatment - RTOG 0920 Phase III Head and Neck Cancer
Treatment Summary Form (TF) - 2808140v1.0
Reason for dose modification
Adverse Event/side Effects/complications
(Adverse event/side
effects/complications)
Alternative Therapy (Alternative therapy)
Death On Study (Death on study)
Disease Progression, Relapse During
Active Treatment (Disease progression,
relapse during active treatment)
No Modification (No modification)
Other (Other)
Other Complicating Disease (Other
complicating disease)
Patient Withdrawal Or Refusal After
Beginning Protocol Therapy (Patient
withdrawal/refusal after beginning
protocol therapy)
Patient Withdrawal Or Refusal Prior To
Beginning Protocol Therapy (Patient
withdrawal/refusal prior to beginning
protocol therapy)
Reason Treatment Ended
Adverse Event/side Effects/complications
(Adverse Event/Side
Effects/Complications)
Alternative Therapy (Alternative therapy)
Death On Study (Death on study)
Disease Progression, Relapse During
Active Treatment (Disease progression,
relapse during active treatment)
Other (Other)
Patient Off-treatment For Other
Complicating Disease (Patient off-
treatment for other complicating disease)
Patient Withdrawal Or Refusal After
Beginning Protocol Therapy (Patient
withdrawal/refusal after beginning
protocol therapy)
Patient Withdrawal Or Refusal Before
Beginning Protocol Therapy (Patient
withdrawal/refusal prior to beginning
protocol therapy)
Treatment Completed Per Protocol
Criteria (Treatment completed per
protocol criteria)
Arm 2 Only
Patient Weight (kg)
Body Surface Area (M^2)
Agent Name
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Agent Start Date (for cycles being reported)
Agent End Date (for cycles being reported)
Agent Total Dose (mg)
Dose per M2
Reason for dose modification
Adverse Event/side Effects/complications
(Adverse event/side
effects/complications)
Alternative Therapy (Alternative therapy)
Death On Study (Death on study)
Disease Progression, Relapse During
Active Treatment (Disease progression,
relapse during active treatment)
No Modification (No modification)
Other (Other)
Other Complicating Disease (Other
complicating disease)
Patient Withdrawal Or Refusal After
Beginning Protocol Therapy (Patient
withdrawal/refusal after beginning
protocol therapy)
Patient Withdrawal Or Refusal Prior To
Beginning Protocol Therapy (Patient
withdrawal/refusal prior to beginning
protocol therapy)
Reason Treatment Ended
Adverse Event/side Effects/complications
(Adverse Event/Side
Effects/Complications)
Alternative Therapy (Alternative therapy)
Death On Study (Death on study)
Disease Progression, Relapse During
Active Treatment (Disease progression,
relapse during active treatment)
Other (Other)
Patient Off-treatment For Other
Complicating Disease (Patient off-
treatment for other complicating disease)
Patient Withdrawal Or Refusal After
Beginning Protocol Therapy (Patient
withdrawal/refusal after beginning
protocol therapy)
Patient Withdrawal Or Refusal Before
Beginning Protocol Therapy (Patient
withdrawal/refusal prior to beginning
protocol therapy)
Treatment Completed Per Protocol
Criteria (Treatment completed per
protocol criteria)
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Arm 2 Only
Patient Weight (kg)
Body Surface Area (M^2)
Agent Name
Agent Start Date (for cycles being reported)
Agent End Date (for cycles being reported)
Agent Total Dose (mg)
Dose per M2
Reason for dose modification
Adverse Event/side Effects/complications
(Adverse event/side
effects/complications)
Alternative Therapy (Alternative therapy)
Death On Study (Death on study)
Disease Progression, Relapse During
Active Treatment (Disease progression,
relapse during active treatment)
No Modification (No modification)
Other (Other)
Other Complicating Disease (Other
complicating disease)
Patient Withdrawal Or Refusal After
Beginning Protocol Therapy (Patient
withdrawal/refusal after beginning
protocol therapy)
Patient Withdrawal Or Refusal Prior To
Beginning Protocol Therapy (Patient
withdrawal/refusal prior to beginning
protocol therapy)
Reason Treatment Ended
Adverse Event/side Effects/complications
(Adverse Event/Side
Effects/Complications)
Alternative Therapy (Alternative therapy)
Death On Study (Death on study)
Disease Progression, Relapse During
Active Treatment (Disease progression,
relapse during active treatment)
Other (Other)
Patient Off-treatment For Other
Complicating Disease (Patient off-
treatment for other complicating disease)
Patient Withdrawal Or Refusal After
Beginning Protocol Therapy (Patient
withdrawal/refusal after beginning
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protocol therapy)
Patient Withdrawal Or Refusal Before
Beginning Protocol Therapy (Patient
withdrawal/refusal prior to beginning
protocol therapy)
Treatment Completed Per Protocol
Criteria (Treatment completed per
protocol criteria)
Arm 2 Only
Patient Weight (kg)
Body Surface Area (M^2)
Agent Name
Agent Start Date (for cycles being reported)
Agent End Date (for cycles being reported)
Agent Total Dose (mg)
Dose per M2
Reason for dose modification
Adverse Event/side Effects/complications
(Adverse event/side
effects/complications)
Alternative Therapy (Alternative therapy)
Death On Study (Death on study)
Disease Progression, Relapse During
Active Treatment (Disease progression,
relapse during active treatment)
No Modification (No modification)
Other (Other)
Other Complicating Disease (Other
complicating disease)
Patient Withdrawal Or Refusal After
Beginning Protocol Therapy (Patient
withdrawal/refusal after beginning
protocol therapy)
Patient Withdrawal Or Refusal Prior To
Beginning Protocol Therapy (Patient
withdrawal/refusal prior to beginning
protocol therapy)
Reason Treatment Ended
Adverse Event/side Effects/complications
(Adverse Event/Side
Effects/Complications)
Alternative Therapy (Alternative therapy)
Death On Study (Death on study)
Disease Progression, Relapse During
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Active Treatment (Disease progression,
relapse during active treatment)
Other (Other)
Patient Off-treatment For Other
Complicating Disease (Patient off-
treatment for other complicating disease)
Patient Withdrawal Or Refusal After
Beginning Protocol Therapy (Patient
withdrawal/refusal after beginning
protocol therapy)
Patient Withdrawal Or Refusal Before
Beginning Protocol Therapy (Patient
withdrawal/refusal prior to beginning
protocol therapy)
Treatment Completed Per Protocol
Criteria (Treatment completed per
protocol criteria)
Arm 2 Only
Patient Weight (kg)
Body Surface Area (M^2)
Agent Name
Agent Start Date (for cycles being reported)
Agent End Date (for cycles being reported)
Agent Total Dose (mg)
Dose per M2
Reason for dose modification
Adverse Event/side Effects/complications
(Adverse event/side
effects/complications)
Alternative Therapy (Alternative therapy)
Death On Study (Death on study)
Disease Progression, Relapse During
Active Treatment (Disease progression,
relapse during active treatment)
No Modification (No modification)
Other (Other)
Other Complicating Disease (Other
complicating disease)
Patient Withdrawal Or Refusal After
Beginning Protocol Therapy (Patient
withdrawal/refusal after beginning
protocol therapy)
Patient Withdrawal Or Refusal Prior To
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Beginning Protocol Therapy (Patient
withdrawal/refusal prior to beginning
protocol therapy)
Reason Treatment Ended
Adverse Event/side Effects/complications
(Adverse Event/Side
Effects/Complications)
Alternative Therapy (Alternative therapy)
Death On Study (Death on study)
Disease Progression, Relapse During
Active Treatment (Disease progression,
relapse during active treatment)
Other (Other)
Patient Off-treatment For Other
Complicating Disease (Patient off-
treatment for other complicating disease)
Patient Withdrawal Or Refusal After
Beginning Protocol Therapy (Patient
withdrawal/refusal after beginning
protocol therapy)
Patient Withdrawal Or Refusal Before
Beginning Protocol Therapy (Patient
withdrawal/refusal prior to beginning
protocol therapy)
Treatment Completed Per Protocol
Criteria (Treatment completed per
protocol criteria)
Unnamed Module 3
Was any non-protocol supportive therapy given
(during treatment)
Yes
No
Type of supportive care given, specify (If yes,)
Was the patient hospitalized for any treatment
related complications in this report period?
No (No)
Unknown (Unknown)
Yes (Yes)
Unnamed Module 4
Comments
Investigator Signature
Date
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Anal Cancer NCT00324415 On-Study - AMC-
045 On Study Form (F02) - 2936986v1.0
AMC-045 On Study Form (F02)
Cisplatin, Fluorouracil, Cetuximab, and Radiation Therapy
in Treating Patients With HIV and Stage I, Stage II, or
Stage III Anal Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=7284A0F2-
BE97-FDEC-E040-BB89AD43537B
All rights reserved. Please visit https://medical-data-
models.org/forms/7606
AMC-045 On Study Form (F02)
Header
Visit number
Hiv History
Date of HIV+ diagnosis (mm/dd/yyyy)
Date of AIDS diagnosis (mm/dd/yyyy)
CDC HIV Risk Group
Hemophilia (Hemophiliac)
Heterosexual Contact (Heterosexual
contact)
Homosexual Or Bisexual Contact
(Homosexual or bisexual contact)
Iv Drug User (IV drug user)
Other (Other)
Transfusion Recipient (Transfusion
recipient)
Other, specify
Ccrr Module For On Study Form - Rf02b
Date of Initial Pathologic Diagnosis (mm/dd/yyyy)
Primary site
Anal Canal (Anal)
Cervical (Cervical)
Hd (HD)
Kaposi Sarcoma (KS)
Non-hodgkin's Lymphoma (NHL)
Other Primary Site (Other primary site)
Other specify
Specify tumor histologic category
Prior Treatment? (If "Yes", Check below)
Yes
1 / 4
No
Prior Systemic Chemotherapy
Yes
No
Prior Biological Response Modifiers or Cytokines
Yes
No
Specify (If "Yes")
Prior Surgery (excluding biopsy)
Yes
No
Prior cryotherapy
Yes
No
Prior systemic steroid treatment
Yes
No
Prior Radiation Therapy
Yes
No
Prior topical/intralesional therapy
Yes
No
Other Prior Therapy (e.g. Hyperthermia, etc.)
Yes
No
Other Prior Therapy (e.g. Hyperthermia, etc.)
Yes
No
Specify (If "Yes" 1 2 3)
Name of other prior therapies
Ccrr Module For On Study Form - Rf02b
History of Prior Malignancy
Yes
No
Date of Diagnosis of Previous Malignancy
(mm/dd/yyyy)
Primary site
Anal Canal (Anal)
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Anal Cancer NCT00324415 On-Study - AMC-045 On Study Form (F02) -
2936986v1.0
Cervical (Cervical)
Hd (HD)
Kaposi Sarcoma (KS)
Non-hodgkin's Lymphoma (NHL)
Other Primary Site (Other primary site)
Other specify
Specify tumor histologic category
Prior Treatment? (If "Yes", Check below)
Yes
No
Prior Systemic Chemotherapy
Yes
No
Prior Biological Response Modifiers or Cytokines
Yes
No
Specify (If "Yes")
Prior Surgery (excluding biopsy)
Yes
No
Prior cryotherapy
Yes
No
Prior systemic steroid treatment
Yes
No
Prior Radiation Therapy
Yes
No
Prior topical/intralesional therapy
Yes
No
Other Prior Therapy (e.g. Hyperthermia, etc.)
Yes
No
Other Prior Therapy (e.g. Hyperthermia, etc.)
Yes
No
Specify (If "Yes" 1 2 3)
Name of other prior therapies
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Antiretroviral Therapy
Agent Name
Other, specify (1 2)
Agent use
Currently Receiving (Currently receiving)
Never Received (Never received)
Previously Received (Previously
received)
Duration if prior agents received
< 3 Months (< 3 months)
> 12 Months (> 12 months)
> 6-12 Months (> 6-12 months)
3-6 Months (3-6 months)
Comments
Comments
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Drug/Agent Toxicity by Tissue/Organ NCT00057811
Eligibility - ANHL01P1: Eligibility Worksheet - 2091107v3.0
ANHL01P1: Eligibility Worksheet
Rituximab, Rasburicase, and Combination Chemotherapy
in Treating Young Patients With Newly Diagnosed
Advanced B-Cell Leukemia or Lymphoma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=B9F4CEB9-
15F1-2736-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/7607
ANHL01P1: Eligibility Worksheet
Header
Institution
Name
Study Number
COG Number
Patient Name
Today's date
Date worksheet entered into RDE
Unnamed2
Does patient have newly diagnosed mature
(CD20 positive) high-grade B-lineage lymphoma,
i.e. diffuse large B-Cell Lymphoma, Burkitt's
lymphoma or Burkitt's-like lymphoma? (Answer
must be yes.  If answer is 'no', terminate
registration process.)
Yes
No
Does patient have pre-cursor B-cell lymphoblastic
lymphoma? (Answer must be no.  If answer is
'yes', terminate registration process.)
Yes
No
Is patient >= 1 year and <30 years at study
enrollment? (Answer must be yes.  If answer is
'no', terminate registration process.)
Yes
No
Did patient receive any previous chemotherapy
prior to registration? (Answer must be no.  If yes,
terminate registration process.)
Yes
No
Did patient receive emergency irradiation and/or
1 / 4
steroid therapy, prior to registration? (If yes, the
following 3 questions must be answered.)
Yes
No
Will the patient start protocol therapy within 72
hours of emergency treatment? (Only required if
patient received emergency treatment.  Then the
answer must be yes, or the registration process
must be terminated.)
Yes
No
Were steroids given? (Can be yes or no)
Yes
No
were bone marrow and CSF exams obtained
prior to steroids? (Required only if answer to
question above is yes.  Must be yes or N/A.  If no,
terminate registration process.)
N/A (N/A)
No (No)
Yes (Yes)
Did the patient receive corticosteroids for more
than 10 days and/or the patient receive
corticosteroids within 8 days from diagnosis and
initial work-up?
N/a (N/A)
No (No)
Yes (Yes)
Did the patient receive any steroids, other than
corticosteroids, in the week prior to diagnosis?
(To be eligible, patient must not have received
any steroids except in emergency situation, as
noted above 8 days prior to diagnosis.)
Yes
No
Karnofsky Performance Score (For patients
greater than 10 years of age)
90 (Able to carry on normal activity,
minor signs or symptoms of disease)
70 (Cares for self. Unable to carry on
normal activity or to do active work)
0 (Dead)
40 (Disabled, requires special care and
assistance)
20 (Hospitalization necessary, very sick,
active supportive treatment necessary)
10 (Moribund, fatal processes
progressing rapidly)
80 (Normal activity with effort, some
signs or symptoms of disease)
100 (Normal, no complaints, no evidence
of disease)
50 (Requires considerable assistance
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and frequent medical care)
60 (Requires occasional assistance, but
is able to care for most of own needs)
30 (Severely disabled, hospitalization is
indicated although death is not imminent)
Lansky Play Score (For patients less than or
equal to 10 years of age)
80 (Active, but tires more quickly)
70 (Both greater restriction of and less
time spent in play activity)
100 (Fully active, normal)
50 (Gets dressed but lies around much
of the day, no active play, able to
participate in all quiet play and activities)
30 (In bed; needs assistance even for
quiet play)
90 (Minor restrictions in physically
strenuous activity)
40 (Mostly in bed; participates in quiet
activities)
10 (No play; does not get out of bed)
20 (Often sleeping; play entirely limited
to very passive activities)
0 (Unresponsive)
60 (Up and around, but minimal active
play; keeps busy with quieter activities)
Has patient had any prior solid organ
transplantation? (Must be no. If yes, terminate
registration process.)
Yes
No
Does patient have G6PD deficiency? (Can be yes
or no)
Yes
No
Does patient have a congenital or acquired
immune deficiency?
Yes
No
Murphy Stage (Institution must pick one.)
1 (1)
2 (2)
3 (3)
4 (4)
Therapy Stratification (If Group A is chosen,
patient is not eligible, terminate registration
process.)
Group A: Completely resected
abdominal Murphy stage II lesions
(Group A: Completely resected
abdominal Murphy stage II lesions)
Group A: Completely resected Murphy
stage I disease (any site) (Group A:
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Drug/Agent Toxicity by Tissue/Organ NCT00057811 Eligibility -
ANHL01P1: Eligibility Worksheet - 2091107v3.0
Completely resected Murphy stage I
disease (any site))
Group B: Not eligible for Group A or
Group C (Group B: Not eligible for Group
A or Group C)
Group C: any CNS or bone marrow
involvement >=25% blasts. (Group C:
any CNS or bone marrow involvement
>=25% blasts.)
was pregnancy test obtained? (If post-menarchal
female,)
N/A, not post-menarchal, or patient is
male (N/A, not post-menarchal, or
patient is male)
N/a, Patient Is Female, But Not Post-
menarchal (N/A, patient is female, but
not post-menarchal)
N/a, Patient Is Male (N/A, patient is
male)
No (No)
Yes (Yes)
is patient pregnant and/or breastfeeding? (If post-
menarchal female,)
N/A (N/A)
No (No)
No, And Not Nursing (no, and not
nursing)
No, But Nursing (no, but nursing)
Yes (Yes)
has patient agreed to use contraceptive during
protocol? (If patient is of reproductive potential,)
No (No)
Unknown (Unknown)
Yes (Yes)
Have patient and/or their parents or legal
guardians signed a written informed consent? (To
be eligible, all patients and/or parents or legal
guardians must have signed a written informed
consent.)
Yes
No
Date of Start Treatment (NOTE: If the study does
not have a start date e.g., a biology study, then
enter in the current date, or if entering on
AADM01P1, enter consent date.)
COMMENTS
Ccrr Module For Anhl01p1: Eligibility
Worksheet
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Drug/Agent Toxicity by Tissue/Organ NCT00057811 Eligibility -
ANHL01P1: Eligibility Worksheet - 2091107v3.0
Anal Cancer NCT00324415 Treatment - AMC-045
Study Drug Therapy Form (SDT) - 2514584v1.0
AMC-045 Study Drug Therapy Form (SDT)
Cisplatin, Fluorouracil, Cetuximab, and Radiation Therapy
in Treating Patients With HIV and Stage I, Stage II, or
Stage III Anal Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=1BB1575F-
CA34-29C3-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/7608
AMC-045 Study Drug Therapy Form
(SDT)
Header
Visit number
Cycle Start Date (mm/dd/yyyy)
Type of Radiation Therapy Administered
External Beam Radiation (External beam
radiation)
Imrt (IMRT)
Enter Total Dose Of Study Drug Received
This Cycle And Dose Modification Codes
Agent Name
Dose Modification
Dose Delayed (Dose delayed)
Dose Delayed And Reduced (Dose
delayed and reduced)
Dose Escalated (Dose escalated)
Dose Reduced (Dose reduced)
Drug Discontinued (Drug discontinued)
No Dose Modification (No dose
modification)
Total Dose of Agents/Drugs for this Cycle
(mg/m^2)
Total number of doses (Given for this cycle)
Agent Start Date (mm/dd/yyyy)
Agent End Date (mm/dd/yyyy)
Duration Delay (Days)
Comments
Comments
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Bladder Cancer NCT00014534 Treatment -
CALGB: 90104 Eligibility Checklist - 2169226v3.0
CALGB: 90104 Eligibility Checklist
Combination Chemotherapy in Treating Patients With
Bladder Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=BE19FD2A-
E369-6ABF-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/7611
CALGB: 90104 Eligibility Checklist
Ccrr Module For Calgb: 90104 Eligibility
Checklist
CALGB Study No.
CALGB Patient ID
Patient's Initials
Participating Group
Patient Medical Record Number
Participating Group Protocol Number
Main Member Institution/Adjunct
Participating Group Patient No.
Patients must have pathologic confirmation of
complete resection of T3-4 and/or pelvic node
positive transitional cell carcinoma of the bladder
with negative margins
Pathological stages for patients with bladder
cancer eligible for this trial include: Tany, N=, Mo;
T3a, N0, M0; T3b, N0, M0; T4a, N0, M0
Patients must have undergone
cystoprostatectomy plus pelvic lympn node
dissection for bladder cancer in men and
cystectomy/total abdominal
hysterectomy/bilateral/salpingo-oophorectomy
plus pelvic lymph node dissection for bladder
cancer in women
No prior systemic chemotherapy for any reason
or irradiation of the bladder
Greater than or equal to 6 weeks since the
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definitive surgery but not more than 3 years
Paraffin tissue blocks or unstained slides of the
primary tumor for immunohistochemical studies
must be available
No evidence of another active cancer within 5
years prior to registration, except for non-
melanoma carcinoma of the skin or in situ
carcinoma of the cervix curatively treated.
Patients who have a prostate cancer in the
resected specimen are eligible, pro
Normal cardiac function, no evidence of NYHA
functional class III or IV heart disease
Normal cardiac function, patients must have no
serious cardiac arrhythmias; including first,
second and third degree heart block
ECOG performace status 0-1
Age greater than or equal to 18 years
ANC greater than or equal to 1500/mm^3
Platelet count greater than or equal to
150,000/mm^3
Bilirubin less than or equal to 1.5 x ULN
Serum creatinine less than 1.5 mg/dl or
calculated creatinine clearance greater than or
equal to 60 ml/min/1.73m^2 using Cockcroft-
Gault equation
Alkaline phosphatase less than 2.0 x ULN
AST less than 2.0 x ULN
ANC patient's value
Platelet count patient's value
Bilirubin ULN
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Bladder Cancer NCT00014534 Treatment - CALGB: 90104 Eligibility
Checklist - 2169226v3.0
Bilirubin Patient's value
Serum creatinine patient's value
Alkaline phosphatase ULN
Alkaline phosphatase patient's value
AST ULN
AST patient's value
Completed by
Date
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Checklist - 2169226v3.0
Lung Cancer NCT01336894 Transmittal - ACOSOG-
Z4099 Imaging Report Submission Form - 3220472v1.0
ACOSOG-Z4099 Imaging Report Submission Form
Surgery With or Without Internal Radiation Therapy
Compared With Stereotactic Body Radiation Therapy in
Treating Patients With High-Risk Stage I Non-Small Cell
Lung Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=A01C569D-
F032-05E1-E040-BB89AD4349E3
All rights reserved. Please visit https://medical-data-
models.org/forms/7620
ACOSOG-Z4099 Imaging Report
Submission Form
Header Module
Protocol Number
Patient ID
Patient Initials (L F M)
Institution Number
Institution
Are data amended (check one if data amended,
please circle in red when using paper forms)
Yes
No
Visit
Visit (check one)
12 Months After Surgery/completion Of
Stereotactic Body Radiation Therapy (12
months after surgery/completion of
SBRT)
15 Months After Surgery/completion Of
Stereotactic Body Radiation Therapy (15
months after surgery/completion of
SBRT)
18 Months After Surgery/completion Of
Stereotactic Body Radiation Therapy (18
months after surgery/completion of
SBRT)
21 Months After Surgery/completion Of
Stereotactic Body Radiation Therapy (21
months after surgery/completion of
SBRT)
24 Months After Surgery/completion Of
Stereotactic Body Radiation Therapy (24
months after surgery/completion of
SBRT)
3 Months After Surgery/completion Of
Stereotactic Body Radiation Therapy (3
months after surgery/completion of
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SBRT)
30 Months After Surgery/completion Of
Stereotactic Body Radiation Therapy (30
months after surgery/completion of
SBRT)
36 Months After Surgery/completion Of
Stereotactic Body Radiation Therapy (36
months after surgery/completion of
SBRT)
4 Weeks After Surgery (4 weeks after
surgery)
48 Months After Surgery/completion Of
Stereotactic Body Radiation Therapy (48
months after surgery/completion of
SBRT)
6 Months After Surgery/completion Of
Stereotactic Body Radiation Therapy (6
months after surgery/completion of
SBRT)
60 Months After Surgery/completion Of
Stereotactic Body Radiation Therapy (60
months after surgery/completion of
SBRT)
9 Months After Surgery/completion Of
Stereotactic Body Radiation Therapy (9
months after surgery/completion of
SBRT)
At Time Of Disease Relapse/pd (At time
of disease relapse/PD)
Registration (Registration)
Method Used For Report Submission
Imaging report submitted (check one)
Both Pet/ct Scan And Ct Scan (Both
PET/CT scan and CT scan)
Computed Tomography (CT scan)
Pet/ct Scan (PET/CT scan)
Method used for report submission (check one)
Electronic Attachment (Electronic
attachment)
Surface Mail (Surface mail)
Date Sent (If Surface mail, dd MMM yyyy)
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Lung Cancer NCT01336894 Transmittal - ACOSOG-Z4099 Imaging
Report Submission Form - 3220472v1.0
Lung Cancer NCT01336894 Response - ACOSOG-Z4099 Active
Monitoring RECIST Measurement Form (Arm 2) - 3178204v1.0
ACOSOG-Z4099 Active Monitoring RECIST Measurement
Form (Arm 2)
Surgery With or Without Internal Radiation Therapy
Compared With Stereotactic Body Radiation Therapy in
Treating Patients With High-Risk Stage I Non-Small Cell
Lung Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=9815654D-
3AFA-EB3D-E040-BB89AD437C70
All rights reserved. Please visit https://medical-data-
models.org/forms/7621
ACOSOG-Z4099 Active Monitoring
RECIST Measurement Form (Arm 2)
Header Module
Protocol Number
Patient ID
Patient Initials (L F M)
Institution Number
Institution
Are data amended (check one if data amended,
please circle in red when using paper forms)
Yes
No
Visit
Visit (check one)
12 Months After Completion Of
Stereotactic Body Radiation Therapy (12
months after completion of SBRT)
3 Months After Completion Of
Stereotactic Body Radiation Therapy (3
months after completion of SBRT)
4 Weeks After Surgery/completion Of
Stereotactic Body Radiation Therapy (4
weeks after surgery/completion of SBRT)
6 Months After Completion Of
Stereotactic Body Radiation Therapy (6
months after completion of SBRT)
9 Months After Completion Of
Stereotactic Body Radiation Therapy (9
months after completion of SBRT)
Overall Response Status
Overall Response Status at This Assessment
(check one)
Complete Response (CR)
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Not Evaluated (Not evaluated)
Progressive Disease (PD)
Partial Response (PR)
Stable Disease (SD)
Was the appearance of any new lesions
documented (If PD: check one NOTE: If PD is
selected for Overall Response Status, and Yes is
selected for "Was the appearance of any new
lesions documented" end form)
Yes
No
Overall Response Status
Assessment date (dd MMM yyyy Assessment
date is the date reflecting type of assessment,
not the physician interpretation date. If tumor
measurements are not required this cycle per
Section 4.0, Assessment Date is the date the
patient was evaluated )
Non-nodal target lesion site(s) (Primary Tumor)
Method of Evaluation
Ct Scan (CT scan)
Pet/ct Scan (PET/CT scan)
Non-Nodal Longest Diameter of Lesion(s)
(Primary Tumor cm)
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Lung Cancer NCT01336894 Response - ACOSOG-Z4099 Active
Monitoring RECIST Measurement Form (Arm 2) - 3178204v1.0
Lung Cancer NCT01336894 Transmittal - ACOSOG-Z4099 Biopsy Pathology
Clinical Report Submission Form (Arm 1 patients only) - 3193449v1.0
ACOSOG-Z4099 Biopsy Pathology Clinical Report
Submission Form (Arm 1 patients only)
Surgery With or Without Internal Radiation Therapy
Compared With Stereotactic Body Radiation Therapy in
Treating Patients With High-Risk Stage I Non-Small Cell
Lung Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=9D1F6BBF-
433E-0B69-E040-BB89AD436323
All rights reserved. Please visit https://medical-data-
models.org/forms/7623
ACOSOG-Z4099 Biopsy Pathology
Clinical Report Submission Form
(Arm 1 patients only)
Header Module
Protocol Number
Patient ID
Patient Initials (L F M)
Institution Number
Institution
Are data amended (check one if data amended,
please circle in red when using paper forms)
Yes
No
Visit
Visit (check one)
At Time Of Surgery (At time of surgery)
Method Used For Report Submission
Method used for report submission (check one)
Electronic Attachment (Electronic
attachment)
Surface Mail (Surface mail)
Date Sent (If Surface mail, dd MMM yyyy)
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Lung Cancer NCT01336894 Follow-Up -
ACOSOG-Z4099 Follow-up Form - 3193089v1.0
ACOSOG-Z4099 Follow-up Form
Surgery With or Without Internal Radiation Therapy
Compared With Stereotactic Body Radiation Therapy in
Treating Patients With High-Risk Stage I Non-Small Cell
Lung Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=9D0BC0FA-
1BE5-3C0D-E040-BB89AD436CC0
All rights reserved. Please visit https://medical-data-
models.org/forms/7625
ACOSOG-Z4099 Follow-up Form
Header Module
Protocol Number
Patient ID
Patient Initials (L F M)
Institution Number
Institution
Are data amended (check one if data amended,
please circle in red when using paper forms)
Yes
No
Visit
Visit (check one)
12 Months After Surgery/completion Of
Stereotactic Body Radiation Therapy (12
months after surgery/completion of
SBRT)
3 Months After Surgery/completion Of
Stereotactic Body Radiation Therapy (3
months after surgery/completion of
SBRT)
6 Months After Surgery/completion Of
Stereotactic Body Radiation Therapy (6
months after surgery/completion of
SBRT)
9 Months After Surgery/completion Of
Stereotactic Body Radiation Therapy (9
months after surgery/completion of
SBRT)
Unnamed Module
Were you able to obtain any information about
the patient since the last report
Yes
No
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Date of last attempt to contact patient (If No, dd
MMM yyyy End form)
Header
Vital status
Alive (Alive)
Dead (Dead)
Date of Last Contact or Death (dd MMM yyyy)
Primary Cause of Death (check one)
Due To Other Cause (Due to other
cause)
Due To Protocol Treatment (Due to
protocol treatment)
Due To This Disease (Due to this
disease)
Due to other cause specify
Patient Information
Patient residing (check one)
Assisted Living (Assisted living)
Extended Care (Extended care)
Home (Home)
Homeless (Homeless)
Hospital (Hospital)
Other (Other)
Other, specify
Current oxygen use (check one)
Yes
No
Oxygen Use Type (If yes check one)
Continuous (Continuous)
Intermittent (Intermittent)
Disease Follow-up Status
Has the patient had a documented clinical
assessment for this cancer? (since submission of
the last extended follow-up form If this is the first
follow-up form check yes, enter cancer follow-up
status date and complete the rest of the form)
Yes
No
Cancer Follow-up Status Date (If yes, dd MMM
yyyy)
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Lung Cancer NCT01336894 Follow-Up - ACOSOG-Z4099 Follow-up
Form - 3193089v1.0
Chest CT scan performed (Upper Abdominal
includes CT, PET/CT, or both CT and PET/CT:
check one)
Yes
No
Date of CT Scan (report earliest date if both CT
and PET/CT dd MMM yyyy)
Chest CT Scan Result (Upper Abdominal check
one)
No Evidence Of Recurrence (No
evidence of recurrence)
Recurrent Cancer (Recurrent cancer)
Pft's
Pulmonary function tests performed? (this visit
check one)
Yes
No
Forced Expiratory Volume 1 (FEV1) (mL)
Forced Expiratory Volume 1 (%Predicted FEV1)
(%)
Carbon Monoxide Diffusion (% predicted DLCO)
(%)
Forced Vital Capacity (FVC1) (mL)
Forced Vital Capacity (% predicted FVC1) (%)
Notice Of First Recurrence Or Progression
In The Extended Follow-up Phase
Has the patient developed a first relapse or
progression that has not been previously
reported (recurrence failure)
Yes
No
Site of First Local, Regional, or Distant
Recurrence (If yes s Failure see Section 7.2
check all that apply)
Distant Recurrence (Distant Recurrence)
Local Recurrence (Local Recurrence)
Regional Recurrence (Regional
Recurrence)
Date of first local recurrence (dd MMM yyyy)
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Lung Cancer NCT01336894 Follow-Up - ACOSOG-Z4099 Follow-up
Form - 3193089v1.0
Area of Local Recurrence (check one)
Involved Lobe Failure (Involved Lobe
failure)
Marginal Failure (Marginal failure)
Other (Other)
Port Site/wound Failure (Port site/wound
failure)
Primary Tumor Failure (Primary tumor
failure)
Date of first regional recurrence (dd MMM yyyy)
Area of Regional Recurrence (check one)
Hilar Nodal Failure (Hilar nodal failure)
Ipsilateral Mediastinal Nodal Failure
(Ipsilateral mediastinal nodal failure)
Non-primary Lobe Failure (Non-primary
lobe failure)
Other (Other)
Other, specify
Other, specify
Other, specify
Date of First Distant Recurrence (dd MMM yyyy)
Area of Distant Recurrence (check one)
Distant Metastatic Failure (Distant
metastatic failure)
Distant Nodal Failure (Distant nodal
failure)
Other (Other)
Has a biopsy been performed to confirm first
recurrence (check one)
Yes
No
Notice Of First Subsequent Treatment
Has the patient received subsequent treatment
for this cancer that has not been previously
reported
No (No)
Unknown (Unknown)
Yes (Yes)
Reason non-protocol cancer therapy began (If
yes check all that apply)
Adjuvant Cancer Therapy (Adjuvant
cancer therapy for primary cancer)
Other (Other)
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Lung Cancer NCT01336894 Follow-Up - ACOSOG-Z4099 Follow-up
Form - 3193089v1.0
Treatment For Local Or Regional
Recurrence (Treatment for local or
regional recurrence)
Treatment For New Primary Or Distant
Recurrence (Treatment for new primary
or distant recurrence)
Type of local salvage therapy (check one)
Chemotherapy (Chemotherapy)
Other (Other)
Radiofrequency Ablation
(Radiofrequency Ablation)
Stereotactic Body Radiation Therapy
(SBRT)
Surgery (Surgery)
Other, specify
Specify treament (modality)
Notice Of New Primary
Has a new primary cancer or MDS been
diagnosed that has not been previously reported?
(myelodyplastic syndrome)
No (No)
Unknown (Unknown)
Yes (Yes)
New Primary Cancer Date (If yes, Date of
Diagnosis dd MMM yyyy)
Site of New Primary
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Lung Cancer NCT01336894 Follow-Up - ACOSOG-Z4099 Follow-up
Form - 3193089v1.0
Breast Cancer NCT00433511 Treatment -
E5103 Radiation Therapy Form - 2543728v1.0
E5103 Radiation Therapy Form
Doxorubicin, Cyclophosphamide, and Paclitaxel With or
Without Bevacizumab in Treating Patients With Lymph
Node-Positive or High-Risk, Lymph Node-Negative Breast
Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=22AFD24B-
EC68-5512-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/7627
E5103 Radiation Therapy Form
Header
ECOG Protocol Number
ECOG Patient ID
DCI Name
Registration Step
Reporting Period
Radiation Therapy (End of radiation
therapy)
Unnamed2
Patient Initials (Last,First)
ECOG Protocol Number
ECOG Patient ID
Participating Group Protocol Number
Participating Group Patient ID
Institution/Affiliate
Header
Did the patient have protocol-defined radiation
therapy as part of protocol treatment?
Yes
No
Radiation therapy not administered reason (if
applicable - Note: Information regarding patients
that are receiving Radiation Therapy per
protocol/physician discretion must be collected on
- this form.)
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Local, Regional Or Distant Recurrence
Prior To Rt (Local, Regional or Distant
recurrence prior to RT)
Mastectomy (Mastectomy)
Other (Other)
Other, specify
When did the patient start receiving radiation
therapy as part of protocol treatment?
Post-chemotherapy (Post chemotherapy)
Before Chemotherapy (Prior to
chemotherapy)
Radiation Therapy Start Date (m/d/y)
Radiation Therapy End Date (m/d/y)
Whole Breast, boost (Site All fields must be
completed. - Irradiated? 1=no, 2=yes)
Yes
No
Whole Breast, no boost
Yes
No
Partial Breast
Yes
No
Chest Wall (if mastectomy)
Yes
No
Ipsilateral Supraclavicular
Yes
No
Axilla
Yes
No
Internal Mammary Lymph Nodes
Yes
No
Other
Yes
No
Other, specify (If)
Unnamed2
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Breast Cancer NCT00433511 Treatment - E5103 Radiation Therapy
Form - 2543728v1.0
Total Dose Prior to Boost (Gy)
Total Number of Fractions Prior to Boost
RT Total Dose to Boost Field (If boost was given,
complete the following: - Gy)
Total Number of Fractions to Boost Field
Total Dose of Radiation Therapy (PBI - Gy)
Partial Breast Irradiation
Total Number of Fractions (PBI)
Method
External Beam Radiation Therapy
(External beam)
Intra-operative Radiation Therapy
(Intraoperative)
Mammosite Balloon Catheter
(MammoSite Balloon Catheter)
Other (Other)
Other Brachytherapy (Other
Brachytherapy)
Specify
Total Dose of Radiation Therapy (PBI - Gy)
Is patient on Partial Breast Irradiation Protocol
Study
No (No)
Unknown (Unknown)
Yes, Nsabp B39 Or Rtog 0413 (Yes,
NSABP B39 or RTOG 0413)
Yes, Other (Yes, other)
Other, specify
Comments (Note: If the patient has bilateral
breast cancer and received radiation therapy on
both sides, only report the observed fractions for
one side in the fields provided above. Add
comments below providing the same information
for the other side and state whether the right or
left side is being reported below here in the
comments)
Investigator Signature
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Breast Cancer NCT00433511 Treatment - E5103 Radiation Therapy
Form - 2543728v1.0
Investigator Signature Date
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Breast Cancer NCT00433511 Treatment - E5103 Radiation Therapy
Form - 2543728v1.0
AIDS-Related Lymphoma NCT00310128 Treatment - Study
Drug Therapy Form for Protocol #010--PR1003 - 2399688v3.0
Study Drug Therapy Form for Protocol #010--PR1003
Combination Chemotherapy Followed by Rituximab and
Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients
With Relapsed or Refractory AIDS-Related Non-Hodgkin's
Lymphoma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=FF9311DF-
A3A4-2D7C-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/7628
Study Drug Therapy Form for
Protocol #010--PR1003
General info
Patient Initials
Participating Group Study No.
NCI Institution No
Coordinating Group Patient ID
Cycle Number
Date of Assessment
Cycle Start Date
Height
Weight
BSA
Initial Prescribed Dose Of Study Drug
Agent Name
Total Dose of Agents/Drugs for this Cycle
Enter Total Dose Of Study Drug Received
This Cycle And Dose Modification Codes
Agent Name
Dose Modification
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Escalated (Escalated)
No Dose Modification (No modification)
Drug Discontinued (Permanently
discontinued)
Dose Reduced (Reduced)
Dose Delayed (Temporarily discontinued)
Total Protocol Dose of Agents/Drugs for this cycle
Date Agent Administered
Duration Delay
Agent Start Date
Agent End Date
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AIDS-Related Lymphoma NCT00310128 Treatment - Study Drug
Therapy Form for Protocol #010--PR1003 - 2399688v3.0
Colorectal Cancer NCT00058474 Quality of Life -
NSABP Protocol R-04 Quality of Life - 2086124v3.0
NSABP Protocol R-04 Quality of Life
Radiation Therapy and Either Capecitabine or Fluorouracil
With or Without Oxaliplatin Before Surgery in Treating
Patients With Resectable Rectal Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=B781948E-
B324-266C-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/7630
NSABP Protocol R-04 Quality of Life
Physical Well-being
I have a lack of energy
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have nausea
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
Because of my physical condition, I have trouble
meeting the needs of my family
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
I have pain
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am bothered by side effects of treatment
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I feel ill
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am forced to spend time in bed
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
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Social/family Well-being
I feel close to my friends
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I get emotional support from my family
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I get support from my friends
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
My family has accepted my illness
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am satisfied with family communication about
my illness
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I feel close to my partner (or the person who is
my main support) (Regardless of your current
level of sexual activity, please answer the
following question. If you prefer not to answer it,
please check this box and go to the next section.)
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am satisfied with my sex life
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
Emotional Well-being
I feel sad
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Colorectal Cancer NCT00058474 Quality of Life - NSABP Protocol R-04
Quality of Life - 2086124v3.0
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am satisfied with how I am coping with my
illness
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am losing hope in the fight against my illness
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I feel nervous
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I worry about dying
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I worry that my condition will get worse
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
Functional Well-being
I am able to work (include work at home)
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
My work (include work at home) is fulfilling
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am able to enjoy life
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A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have accepted my illness
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am sleeping well
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am content with the quality of my life right now
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am content with the quality of my life right now
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
Additional Concerns
I have swelling or cramps in my stomach area
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am losing weight
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have control of my bowels
A Little Bit (A little bit)
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Somewhat (Somewhat)
Very Much (Very much)
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Very Much (Very much)
I have diarrhea
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have a good appetite
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I like the appearance of my body
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
Do you have an ostomy appliance?
Yes
No
I am embarrassed by my ostomy appliance
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
Caring for my ostomy appliance is difficult
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
Additional Concerns
I feel fatigued
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I feel weak all over
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I feel listless ("washed out")
A Little Bit (A little bit)
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Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I feel tired
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have trouble starting things because I am tired
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have trouble finishing things because I am tired
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have energy
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am able to do my usual activities
A Great Deal (A GREAT DEAL)
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I need to sleep during the day
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am too tired to eat
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I need help doing my usual activities
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
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Very Much (Very much)
I am frustrated by being too tired to do the things
I want to do
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have to limit my social activity because I am
tired
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
Did you feel full of life?
A Lot Of The Time (A good bit of the
time)
A Little Of The Time (A little of the time)
All Of The Time (All of the time)
Most Of The Time (Most of the time)
None Of The Time (None of the time)
Some Of The Time (Some of the time)
Did you have a lot of energy?
A Lot Of The Time (A good bit of the
time)
All Of The Time (All of the time)
Most Of The Time (Most of the time)
None Of The Time (None of the time)
Did you feel worn out?
A Lot Of The Time (A good bit of the
time)
A Little Of The Time (A little of the time)
All Of The Time (All of the time)
Most Of The Time (Most of the time)
None Of The Time (None of the time)
Some Of The Time (Some of the time)
Did you feel tired? (Please indicate how much
you have been bothered by each of the following
problems during the past 7 days.  )
A Lot Of The Time (A good bit of the
time)
A Little Of The Time (A little of the time)
All Of The Time (All of the time)
Most Of The Time (Most of the time)
None Of The Time (None of the time)
Some Of The Time (Some of the time)
Diarrhea
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
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Abdominal pain or cramping
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
Gas pain
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
Mouth sores
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
Vomiting
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
Constipation
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
Skin problems (rash, irritation, redness)
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
Skin redness or peeling on hands and feet
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
Fever or shivering (shaking, chills)
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
Numbness or tingling in the hands or feet
A Little Bit (A little bit)
Not At All (Not at all)
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Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
Hair Loss
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
Chest Pain
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
Shortness of breath
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
Pain at intravenous (I.V.) site
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
Eye Problems (irritation or redness)
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
Hearing problems (ringing in the ears)
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
Other problems
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
Did you urinate frequently during the day?
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Very Much (Very much)
Did you urinate frequently during the night?
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A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Very Much (Very much)
Did you have pain when you urinated?
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Very Much (Very much)
Did you have a bloated feeling in your abdomen?
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Very Much (Very much)
Did you have abdominal pain?
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Very Much (Very much)
Did you have pain in your buttocks?
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Very Much (Very much)
Were you bothered by gas (flatulence)?
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Very Much (Very much)
Did you belch?
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Very Much (Very much)
Have you lost weight?
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Very Much (Very much)
Did you have a dry mouth?
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Very Much (Very much)
Have you had thin or lifeless hair as a result of
your disease?
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Very Much (Very much)
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Did food and drink taste different from usual?
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Very Much (Very much)
Have you felt physically less attractive as a result
of your disease or treatment?
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Very Much (Very much)
Have you been feeling less feminine/masculine
as a result of your disease or treatment?
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Very Much (Very much)
Have you been dissatisfied with your body?
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Very Much (Very much)
Were you worried about your health in the future?
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Very Much (Very much)
During The Past Four Weeks:
To what extent were you interested in sex?
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Very Much (Very much)
To what extent were you sexually active (with or
without intercourse)?
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Very Much (Very much)
To what extent was sex enjoyable for you?
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Very Much (Very much)
During The Past Four Weeks:
Did you have difficulty getting or maintaining an
erection?
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A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Did you have problems with ejaculation (e.g., so
called "dry ejaculation")? ( Patients sometimes
report that they have the following symptoms or
problems. Please indicate the extent to which you
have experienced these symptoms or problems
during the past week. Please answer by circling
the number that best applies to you.)
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Very Much (Very much)
Did you have a dry vagina during intercourse?
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Very Much (Very much)
Did you have pain during intercourse?
Not At All (Not at all)
Quite A Bit (Quite a bit)
Very Much (Very much)
Do you have a stoma (colostomy bag)? (During
the past week:)
Yes
No
Did you have frequent bowel movements during
the day?
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Very Much (Very much)
Did you have frequent bowel movements during
the night?
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Very Much (Very much)
Did you feel the urge to move your bowels without
actually producing any stools?
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Very Much (Very much)
Have you had any unintentional release of
stools?
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Very Much (Very much)
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Have you had blood with your stools?
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Very Much (Very much)
Have you had difficulty in moving your bowels?
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Very Much (Very much)
Have your bowel movements been painful? (Only
for patients WITH a stoma colostomy bag:)
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Very Much (Very much)
Were you afraid that other people would be able
to hear your stoma?
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Very Much (Very much)
Were you afraid that other people would be able
to smell your stools?
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Very Much (Very much)
Were you worried about possible leakage from
the stoma bag?
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Very Much (Very much)
Did you have problems with caring for your
stoma?
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Very Much (Very much)
Was your skin around the stoma irritated?
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Very Much (Very much)
Did you feel embarrassed because of your
stoma?
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Very Much (Very much)
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Did you feel less complete because of your
stoma? (During the past month, how would you
describe your experience with your treatment. )
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Very Much (Very much)
Receiving treatment is convenient for me
A Little Bit (A little bit)
I Have Not Received Treatment In The
Past Month (I have not received
treatment in the past month)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am satisfied with my current treatment...........
A Little Bit (A little bit)
I Have Not Received Treatment In The
Past Month (I have not received
treatment in the past month)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
Ccrr Module For Nsabp Protocol R-04
Quality Of Life
First Three Letters of Patient's Last Name
Patient Study ID
Institution Name / Affiliate Name
Staff Member Administering Form, Last Name
Staff Member Administering Form, First Name
Staff Member Administering Form, Phone
Today's Date (Month Day Year)
Are data amended?
Yes
No
Time Point for this Questionnaire
Baseline (Baseline)
One Year after surgery (One Year after
surgery)
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Post chemotherapy/radiation (Post
chemotherapy/radiation)
Post-Surgery Chemotherapy Agents
5-FU (5-FU)
5-FU/Leucovorin (5-FU/Leucovorin)
5-FU/Leucovorin/Irinotecan (5-
FU/Leucovorin/Irinotecan)
Capecitabine (Capecitabine)
Irinotecan (Irinotecan)
Other (specify) (Other (specify))
This form is being filled out:
1 By Clinical Staff On Phone With Patient
(By clinical staff on phone with patient)
0 By Patient In Office (By patient in
office)
By patient mailed to office (By patient
mailed to office)
Date this questionnaiare is completed:
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Lung Cancer NCT01336894 Transmittal - ACOSOG-Z4099 Operative
Clinical Report Submission Form (Arm 1 patients only) - 3186075v1.0
ACOSOG-Z4099 Operative Clinical Report Submission
Form (Arm 1 patients only)
Surgery With or Without Internal Radiation Therapy
Compared With Stereotactic Body Radiation Therapy in
Treating Patients With High-Risk Stage I Non-Small Cell
Lung Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=9A9EAFDB-
A01C-B99C-E040-BB89AD4313A1
All rights reserved. Please visit https://medical-data-
models.org/forms/7634
ACOSOG-Z4099 Operative Clinical
Report Submission Form (Arm 1
patients only)
Header Module
Protocol Number
Patient ID
Patient Initials (L F M)
Institution Number
Institution
Are data amended (check one if data amended,
please circle in red when using paper forms)
Yes
No
Visit
Visit (check one)
At Time Of Surgery (At time of surgery)
Method Used For Report Submission
Method used for report submission (check one)
Electronic Attachment (Electronic
attachment)
Surface Mail (Surface mail)
Date Sent (If Surface mail, dd MMM yyyy)
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Lung Cancer NCT01336894 Response - ACOSOG-Z4099
Pretreatment RECIST Measurement Form (Arm 2) - 3178401v1.0
ACOSOG-Z4099 Pretreatment RECIST Measurement
Form (Arm 2)
Surgery With or Without Internal Radiation Therapy
Compared With Stereotactic Body Radiation Therapy in
Treating Patients With High-Risk Stage I Non-Small Cell
Lung Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=986988FF-
3289-FDB7-E040-BB89AD4317E3
All rights reserved. Please visit https://medical-data-
models.org/forms/7635
ACOSOG-Z4099 Pretreatment
RECIST Measurement Form (Arm 2)
Header Module
Protocol Number
Patient ID
Patient Initials (L F M)
Institution Number
Institution
Are data amended (check one if data amended,
please circle in red when using paper forms)
Yes
No
Visit
Visit
Registration (Registration)
Overall Response Status
Assessment date (dd MMM yyyy assessment
date is the date reflecting type of assessment,
not the physician interpretation date)
Non-nodal target lesion site(s) (Primary Tumor)
Method of Evaluation
Ct Scan (CT scan)
Pet/ct Scan (PET/CT scan)
Non-Nodal Longest Diameter of Lesion(s)
(Primary Tumor cm)
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Comorbidity Index (CCI) Scoring Sheet Form - 3179637v1.0
ACOSOG-Z4099 Charlson Comorbidity Index (CCI)
Scoring Sheet Form
Surgery With or Without Internal Radiation Therapy
Compared With Stereotactic Body Radiation Therapy in
Treating Patients With High-Risk Stage I Non-Small Cell
Lung Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=98F2A8AC-
D8D1-9DE5-E040-BB89AD434043
All rights reserved. Please visit https://medical-data-
models.org/forms/7637
ACOSOG-Z4099 Charlson
Comorbidity Index (CCI) Scoring
Sheet Form
Header Module
Protocol Number
Patient ID
Patient Initials (L F M)
Institution Number
Institution
Are data amended (check one if data amended,
please circle in red when using paper forms)
Yes
No
Visit
Visit (after registration and before SBRT or
surgery)
Registration (Registration)
Comorbid Conditions
Comorbidity (check one)
Aids (AIDS)
Cerebrovascular Disease
(Cerebrovascular disease)
Chronic Pulmonary Disease (Chronic
pulmonary disease)
Congestive Heart Failure (Congestive
heart failure)
Connective Tissue Disease (Connective
tissue disease)
Dementia (Dementia)
Diabetes (Diabetes)
Diabetes Complication (Diabetes with
end organ damage)
Hemiplegia (Hemiplegia)
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Leukemia (Leukemia)
Lymphoma, Multiple Myeloma, Nhl,
Hodgkin's, Waldenstrom (Lymphoma,
Multiple Myeloma, NHL, Hodgkin's,
Waldenstrom)
Mild Liver Disease (Mild liver disease)
Liver And Biliary Tract Disorder
(Moderate or severe liver disease)
Renal Disorder (Moderate or severe
renal disease)
Myocardial Infarction (Myocardial
infarction)
Peripheral Vascular Disease (Peripheral
vascular disease)
Second Metastatic Solid Tumor (Second
Metastatic solid tumor)
Second Solid Tumor (Second Solid
tumor)
Ulcer (Ulcer disease)
Present (check one)
Yes
No
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Lung Cancer NCT01336894 Transmittal - ACOSOG-Z4099 Pathology Clinical
Report Submission Form (Include Staple Line Cytology) (Arm 1 patients only) -
3186095v1.0
ACOSOG-Z4099 Pathology Clinical Report Submission
Form (Include Staple Line Cytology) (Arm 1 patients only)
Surgery With or Without Internal Radiation Therapy
Compared With Stereotactic Body Radiation Therapy in
Treating Patients With High-Risk Stage I Non-Small Cell
Lung Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=9A9EBA2B-
411A-6403-E040-BB89AD432B43
All rights reserved. Please visit https://medical-data-
models.org/forms/7639
ACOSOG-Z4099 Pathology Clinical
Report Submission Form (Include
Staple Line Cytology) (Arm 1
patients only)
Header Module
Protocol Number
Patient ID
Patient Initials (L F M)
Institution Number
Institution
Are data amended (check one if data amended,
please circle in red when using paper forms)
Yes
No
Visit
Visit (check one)
At Time Of Surgery (At time of surgery)
Method Used For Report Submission
Method used for report submission (check one)
Electronic Attachment (Electronic
attachment)
Surface Mail (Surface mail)
Date Sent (If Surface mail, dd MMM yyyy)
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Lung Cancer NCT01336894 Transmittal - ACOSOG-Z4099
PFT Clinical Report Submission Form - 3186046v1.0
ACOSOG-Z4099 PFT Clinical Report Submission Form
Surgery With or Without Internal Radiation Therapy
Compared With Stereotactic Body Radiation Therapy in
Treating Patients With High-Risk Stage I Non-Small Cell
Lung Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=9A9EAFDB-
9FEC-B99C-E040-BB89AD4313A1
All rights reserved. Please visit https://medical-data-
models.org/forms/7640
ACOSOG-Z4099 PFT Clinical
Report Submission Form
Header Module
Protocol Number
Patient ID
Patient Initials (L F M)
Institution Number
Institution
Are data amended (check one if data amended,
please circle in red when using paper forms)
Yes
No
Visit
Visit (check one)
12 Months After Surgery/completion Of
Stereotactic Body Radiation Therapy (12
months after surgery/completion of
SBRT)
24 Months After Surgery/completion Of
Stereotactic Body Radiation Therapy (24
months after surgery/completion of
SBRT)
3 Months After Surgery/completion Of
Stereotactic Body Radiation Therapy (3
months after surgery/completion of
SBRT)
6 Months After Surgery/completion Of
Stereotactic Body Radiation Therapy (6
months after surgery/completion of
SBRT)
Registration (Registration)
Method Used For Report Submission
Method used for report submission (check one)
Electronic Attachment (Electronic
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attachment)
Surface Mail (Surface mail)
Date Sent (If Surface mail, dd MMM yyyy)
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Lung Cancer NCT01336894 Transmittal - ACOSOG-Z4099 PFT Clinical
Report Submission Form - 3186046v1.0
Lung Cancer NCT01336894 Follow-Up - ACOSOG-
Z4099 Extended Follow-up Form - 3170757v1.0
ACOSOG-Z4099 Extended Follow-up Form
Surgery With or Without Internal Radiation Therapy
Compared With Stereotactic Body Radiation Therapy in
Treating Patients With High-Risk Stage I Non-Small Cell
Lung Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=97A1FC42-
86ED-24D6-E040-BB89AD43382F
All rights reserved. Please visit https://medical-data-
models.org/forms/7643
ACOSOG-Z4099 Extended Follow-
up Form
Header Module
Protocol Number
Patient ID
Patient Initials (L F M)
Institution Number
Institution
Are data amended (check one if data amended,
please circle in red when using paper forms)
Yes
No
Visit
Visit (check one)
15 Months After Surgery/completion Of
Stereotactic Body Radiation Therapy (15
months after surgery/completion of
SBRT)
18 Months After Surgery/completion Of
Stereotactic Body Radiation Therapy (18
months after surgery/completion of
SBRT)
21 Months After Surgery/completion Of
Stereotactic Body Radiation Therapy (21
months after surgery/completion of
SBRT)
24 Months After Surgery/completion Of
Stereotactic Body Radiation Therapy (24
months after surgery/completion of
SBRT)
30 Months After Surgery/completion Of
Stereotactic Body Radiation Therapy (30
months after surgery/completion of
SBRT)
36 Months After Surgery/completion Of
Stereotactic Body Radiation Therapy (36
months after surgery/completion of
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SBRT)
48 Months After Surgery/completion Of
Stereotactic Body Radiation Therapy (48
months after surgery/completion of
SBRT)
60 Months After Surgery/completion Of
Stereotactic Body Radiation Therapy (60
months after surgery/completion of
SBRT)
Unnamed Module
Were you able to obtain any information about
the patient since the last report
Yes
No
Date of last attempt to contact patient (If No, dd
MMM yyyy End form)
Header
Vital status
Alive (Alive)
Dead (Dead)
Date of Last Contact or Death (dd MMM yyyy)
Primary Cause of Death (check one)
Due To Other Cause (Due to other
cause)
Due To Protocol Treatment (Due to
protocol treatment)
Due To This Disease (Due to this
disease)
Due to other cause specify
Patient Information
Patient residing (check one)
Assisted Living (Assisted living)
Extended Care (Extended care)
Home (Home)
Homeless (Homeless)
Hospital (Hospital)
Other (Other)
Other, specify
Current oxygen use (check one)
Yes
No
Oxygen Use Type (If yes check one)
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Continuous (Continuous)
Intermittent (Intermittent)
Disease Follow-up Status
Has the patient had a documented clinical
assessment for this cancer? (since submission of
the last extended follow-up form)
Yes
No
Cancer Follow-up Status Date (If yes, dd MMM
yyyy)
Chest CT scan performed (Upper Abdominal
includes CT, PET/CT, or both CT and PET/CT:
check one)
Yes
No
Date of CT Scan (If yes report earliest date if
both CT and PET/CT dd MMM yyyy)
Chest CT Scan Result (Upper Abdominal check
one)
No Evidence Of Recurrence (No
evidence of recurrence)
Recurrent Cancer (Recurrent cancer)
Pft's
Pulmonary function tests performed? (this visit
check one)
Yes
No
Forced Expiratory Volume 1 (FEV1) (mL)
Forced Expiratory Volume 1 (%Predicted FEV1)
(%)
Carbon Monoxide Diffusion (% predicted DLCO)
(% predicted DLCO %)
Forced Vital Capacity (FVC1) (mL)
Forced Vital Capacity (% predicted FVC1) (%)
Notice Of First Recurrence Or Progression
In The Extended Follow-up Phase
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Has the patient developed a first relapse or
progression that has not been previously
reported (recurrence failure)
Yes
No
Site of First Local, Regional, or Distant
Recurrence (If yes s Failure see Section 7.2
check all that apply)
Distant Recurrence (Distant Recurrence)
Local Recurrence (Local Recurrence)
Regional Recurrence (Regional
Recurrence)
Date of first local recurrence (dd MMM yyyy)
Area of Local Recurrence (check one)
Involved Lobe Failure (Involved Lobe
failure)
Marginal Failure (Marginal failure)
Other (Other)
Port Site/wound Failure (Port site/wound
failure)
Primary Tumor Failure (Primary tumor
failure)
Date of first regional recurrence (dd MMM yyyy)
Area of Regional Recurrence (check one)
Hilar Nodal Failure (Hilar nodal failure)
Ipsilateral Mediastinal Nodal Failure
(Ipsilateral mediastinal nodal failure)
Non-primary Lobe Failure (Non-primary
lobe failure)
Other (Other)
Other, specify
Other, specify
Other, specify
Date of First Distant Recurrence (dd MMM yyyy)
Area of Distant Recurrence (check one)
Distant Metastatic Failure (Distant
metastatic failure)
Distant Nodal Failure (Distant nodal
failure)
Other (Other)
Has a biopsy been performed to confirm first
recurrence (check one)
Yes
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No
Notice Of First Subsequent Treatment
Has the patient received subsequent treatment
for this cancer that has not been previously
reported
No (No)
Unknown (Unknown)
Yes (Yes)
Reason non-protocol cancer therapy began (If
yes check all that apply)
Adjuvant Cancer Therapy (Adjuvant
cancer therapy for primary cancer)
Other (Other)
Treatment For Local Or Regional
Recurrence (Treatment for local or
regional recurrence)
Treatment For New Primary Or Distant
Recurrence (Treatment for new primary
or distant recurrence)
Type of local salvage therapy (check one)
Chemotherapy (Chemotherapy)
Other (Other)
Radiofrequency Ablation
(Radiofrequency Ablation)
Stereotactic Body Radiation Therapy
(SBRT)
Surgery (Surgery)
Other, specify
Specify treament (modality)
Notice Of New Primary
Has a new primary cancer or MDS been
diagnosed that has not been previously reported?
(myelodyplastic syndrome)
No (No)
Unknown (Unknown)
Yes (Yes)
New Primary Cancer Date (If yes, Date of
Diagnosis dd MMM yyyy)
Site of New Primary
Late Adverse Event
Has the patient experienced (prior to treatment
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for progression or relapse or a second primary,
and prior to non-protocol treatment) any severe
(grade >=3) long term toxicity that has not been
previously reported? (Adverse events at least
possibly attributed to treatment on this study.
Death within 30 days of treatment regardless of
relationship. Death >30 days at least possibly
treatment related)
No (No)
Unknown (Unknown)
Yes (Yes)
Description Of Primary Disease
CTC Adverse Event Term (CTCAE v.4.0)
Abdominal Distension (Abdominal
distension)
Abdominal Infection (Abdominal
infection)
Abdominal Pain (Abdominal pain)
Abdominal Soft Tissue Necrosis
(Abdominal soft tissue necrosis)
Abducens Nerve Disorder (Abducens
nerve disorder)
Accessory Nerve Disorder (Accessory
nerve disorder)
Acidosis (Acidosis)
Acoustic Nerve Disorder Nos (Acoustic
nerve disorder NOS)
Activated Partial Thromboplastin Time
Prolonged (Activated partial
thromboplastin time prolonged)
Acute Coronary Syndrome (Acute
coronary syndrome)
Acute Kidney Injury (Acute kidney injury)
Adrenal Insufficiency (Adrenal
insufficiency)
Adult Respiratory Distress Syndrome
(Adult respiratory distress syndrome)
Agitation (Agitation)
Akathisia (Akathisia)
Alanine Aminotransferase Increased
(Alanine aminotransferase increased)
Alcohol Intolerance (Alcohol intolerance)
Alkaline Phosphatase Increased
(Alkaline phosphatase increased)
Alkalosis (Alkalosis)
Allergic Reaction (Allergic reaction)
Allergic Rhinitis (Allergic rhinitis)
Alopecia (Alopecia)
Amnesia (Amnesia)
Anal Fistula (Anal fistula)
Anal Hemorrhage (Anal hemorrhage)
Anal Mucositis (Anal mucositis)
Anal Necrosis (Anal necrosis)
Anal Pain (Anal pain)
Anal Stenosis (Anal stenosis)
Anal Ulcer (Anal ulcer)
Anaphylaxis (Anaphylaxis)
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Anemia (Anemia)
Ankle Fracture (Ankle fracture)
Anorectal Infection (Anorectal infection)
Anorexia (Anorexia)
Anorgasmia (Anorgasmia)
Anxiety (Anxiety)
Aortic Injury (Aortic injury)
Aortic Valve Disease (Aortic valve
disease)
Aphonia (Aphonia)
Apnea (Apnea)
Appendicitis (Appendicitis)
Appendicitis Perforated (Appendicitis
perforated)
Arachnoiditis (Arachnoiditis)
Arterial Injury (Arterial injury)
Arteritis Infective (Arteritis infective)
Arthralgia (Arthralgia)
Arthritis (Arthritis)
Ascites (Ascites)
Aspartate Aminotransferase Increased
(Aspartate aminotransferase increased)
Aspiration (Aspiration)
Asystole (Asystole)
Ataxia (Ataxia)
Atelectasis (Atelectasis)
Atrial Fibrillation (Atrial fibrillation)
Atrial Flutter (Atrial flutter)
Atrioventricular Block Complete
(Atrioventricular block complete)
Atrioventricular Block First Degree
(Atrioventricular block first degree)
Autoimmune Disorder (Autoimmune
disorder)
Avascular Necrosis (Avascular necrosis)
Azoospermia (Azoospermia)
Back Pain (Back pain)
Bile Duct Stenosis (Bile duct stenosis)
Biliary Anastomotic Leak (Biliary
anastomotic leak)
Biliary Fistula (Biliary fistula)
Biliary Tract Infection (Biliary tract
infection)
Bladder Anastomotic Leak (Bladder
anastomotic leak)
Bladder Infection (Bladder infection)
Bladder Perforation (Bladder perforation)
Bladder Spasm (Bladder spasm)
Bloating (Bloating)
Blood And Lymphatic System Disorders -
Other, Specify (Blood and lymphatic
system disorders - Other, Specify)
Blood Antidiuretic Hormone Abnormal
(Blood antidiuretic hormone abnormal)
Blood Bilirubin Increased (Blood bilirubin
increased)
Blood Corticotrophin Decreased (Blood
corticotrophin decreased)
Blood Gonadotrophin Abnormal (Blood
gonadotrophin abnormal)
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Blood Prolactin Abnormal (Blood
prolactin abnormal)
Blurred Vision (Blurred vision)
Body Odor (Body odor)
Bone Infection (Bone infection)
Bone Marrow Hypocellular (Bone
marrow hypocellular)
Bone Pain (Bone pain)
Brachial Plexopathy (Brachial
plexopathy)
Breast Atrophy (Breast atrophy)
Breast Infection (Breast infection)
Breast Pain (Breast pain)
Bronchial Fistula (Bronchial fistula)
Bronchial Infection (Bronchial infection)
Bronchial Obstruction (Bronchial
obstruction)
Bronchial Stricture (Bronchial stricture)
Bronchopleural Fistula (Bronchopleural
fistula)
Bronchopulmonary Hemorrhage
(Bronchopulmonary hemorrhage)
Bronchospasm (Bronchospasm)
Bruising (Bruising)
Bullous Dermatitis (Bullous dermatitis)
Burn (Burn)
Buttock Pain (Buttock pain)
Capillary Leak Syndrome (Capillary leak
syndrome)
Carbon Monoxide Diffusing Capacity
Decreased (Carbon monoxide diffusing
capacity decreased)
Cardiac Arrest (Cardiac arrest)
Cardiac Disorders - Other, Specify
(Cardiac disorders - Other, Specify)
Cardiac Troponin I Increased (Cardiac
troponin I increased)
Cardiac Troponin T Increased (Cardiac
troponin T increased)
Cataract (Cataract)
Catheter Related Infection (Catheter
related infection)
Cd4 Lymphocytes Decreased (CD4
lymphocytes decreased)
Cecal Hemorrhage (Cecal hemorrhage)
Cecal Infection (Cecal infection)
Central Nervous System Necrosis
(Central nervous system necrosis)
Cerebrospinal Fluid Leakage
(Cerebrospinal fluid leakage)
Cervicitis Infection (Cervicitis infection)
Cheilitis (Cheilitis)
Chest Pain - Cardiac (Chest pain -
cardiac)
Chest Wall Pain (Chest wall pain)
Chills (Chills)
Cholecystitis (Cholecystitis)
Cholesterol High (Cholesterol high)
Chronic Kidney Disease (Chronic kidney
disease)
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Chylothorax (Chylothorax)
Cognitive Disturbance (Cognitive
disturbance)
Colitis (Colitis)
Colonic Fistula (Colonic fistula)
Colonic Hemorrhage (Colonic
hemorrhage)
Colonic Obstruction (Colonic obstruction)
Colonic Perforation (Colonic perforation)
Colonic Stenosis (Colonic stenosis)
Colonic Ulcer (Colonic ulcer)
Concentration Impairment
(Concentration impairment)
Conduction Disorder (Conduction
disorder)
Confusion (Confusion)
Congenital, Familial And Genetic
Disorders - Other, Specify (Congenital,
familial and genetic disorders - Other,
Specify)
Conjunctivitis (Conjunctivitis)
Conjunctivitis Infective (Conjunctivitis
infective)
Constipation (Constipation)
Constrictive Pericarditis (Constrictive
pericarditis)
Corneal Infection (Corneal infection)
Corneal Ulcer (Corneal ulcer)
Cough (Cough)
Cpk Increased (CPK increased)
Cranial Nerve Infection (Cranial nerve
infection)
Creatinine Increased (Creatinine
increased)
Cushingoid (Cushingoid)
Cystitis Noninfective (Cystitis
noninfective)
Cytokine Release Syndrome (Cytokine
release syndrome)
Death Neonatal (Death neonatal)
Death Nos (Death NOS)
Dehydration (Dehydration)
Delayed Orgasm (Delayed orgasm)
Delayed Puberty (Delayed puberty)
Delirium (Delirium)
Delusions (Delusions)
Dental Caries (Dental caries)
Depressed Level Of Consciousness
(Depressed level of consciousness)
Depression (Depression)
Dermatitis Radiation (Dermatitis
radiation)
Device Related Infection (Device related
infection)
Diarrhea (Diarrhea)
Disseminated Intravascular Coagulation
(Disseminated intravascular coagulation)
Dizziness (Dizziness)
Dry Eye (Dry eye)
Dry Mouth (Dry mouth)
9 / 25
Lung Cancer NCT01336894 Follow-Up - ACOSOG-Z4099 Extended
Follow-up Form - 3170757v1.0
Dry Skin (Dry skin)
Duodenal Fistula (Duodenal fistula)
Duodenal Hemorrhage (Duodenal
hemorrhage)
Duodenal Infection (Duodenal infection)
Duodenal Obstruction (Duodenal
obstruction)
Duodenal Perforation (Duodenal
perforation)
Duodenal Stenosis (Duodenal stenosis)
Duodenal Ulcer (Duodenal ulcer)
Dysarthria (Dysarthria)
Dysesthesia (Dysesthesia)
Dysgeusia (Dysgeusia)
Dysmenorrhea (Dysmenorrhea)
Dyspareunia (Dyspareunia)
Dyspepsia (Dyspepsia)
Dysphagia (Dysphagia)
Dysphasia (Dysphasia)
Dyspnea (Dyspnea)
Ear And Labyrinth Disorders - Other,
Specify (Ear and labyrinth disorders -
Other, Specify)
Ear Pain (Ear pain)
Edema Cerebral (Edema cerebral)
Edema Face (Edema face)
Edema Limbs (Edema limbs)
Edema Trunk (Edema trunk)
Ejaculation Disorder (Ejaculation
disorder)
Ejection Fraction Decreased (Ejection
fraction decreased)
Electrocardiogram Qt Corrected Interval
Prolonged (Electrocardiogram QT
corrected interval prolonged)
Encephalitis Infection (Encephalitis
infection)
Encephalomyelitis Infection
(Encephalomyelitis infection)
Encephalopathy (Encephalopathy)
Endocarditis Infective (Endocarditis
infective)
Endocrine Disorders - Other, Specify
(Endocrine disorders - Other, Specify)
Endophthalmitis (Endophthalmitis)
Enterocolitis (Enterocolitis)
Enterocolitis Infectious (Enterocolitis
infectious)
Enterovesical Fistula (Enterovesical
fistula)
Epistaxis (Epistaxis)
Erectile Dysfunction (Erectile
dysfunction)
Erythema Multiforme (Erythema
multiforme)
Erythroderma (Erythroderma)
Esophageal Anastomotic Leak
(Esophageal anastomotic leak)
Esophageal Fistula (Esophageal fistula)
Esophageal Hemorrhage (Esophageal
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hemorrhage)
Esophageal Infection (Esophageal
infection)
Esophageal Necrosis (Esophageal
necrosis)
Esophageal Obstruction (Esophageal
obstruction)
Esophageal Pain (Esophageal pain)
Esophageal Perforation (Esophageal
perforation)
Esophageal Stenosis (Esophageal
stenosis)
Esophageal Ulcer (Esophageal ulcer)
Esophageal Varices Hemorrhage
(Esophageal varices hemorrhage)
Esophagitis (Esophagitis)
Euphoria (Euphoria)
Exostosis (Exostosis)
External Ear Inflammation (External ear
inflammation)
External Ear Pain (External ear pain)
Extraocular Muscle Paresis (Extraocular
muscle paresis)
Extrapyramidal Disorder (Extrapyramidal
disorder)
Eye Disorders - Other, Specify (Eye
disorders - Other, Specify)
Eye Infection (Eye infection)
Eye Pain (Eye pain)
Eyelid Function Disorder (Eyelid function
disorder)
Facial Muscle Weakness (Facial muscle
weakness)
Facial Nerve Disorder (Facial nerve
disorder)
Facial Pain (Facial pain)
Fall (Fall)
Fallopian Tube Anastomotic Leak
(Fallopian tube anastomotic leak)
Fallopian Tube Obstruction (Fallopian
tube obstruction)
Fallopian Tube Perforation (Fallopian
tube perforation)
Fallopian Tube Stenosis (Fallopian tube
stenosis)
Fat Atrophy (Fat atrophy)
Fatigue (Fatigue)
Febrile Neutropenia (Febrile
neutropenia)
Fecal Incontinence (Fecal incontinence)
Female Genital Tract Fistula (Female
genital tract fistula)
Feminization Acquired (Feminization
acquired)
Fetal Death (Fetal death)
Fetal Growth Retardation (Fetal growth
retardation)
Fever (Fever)
Fibrinogen Decreased (Fibrinogen
decreased)
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Fibrosis Deep Connective Tissue
(Fibrosis deep connective tissue)
Flank Pain (Flank pain)
Flashing Lights (Flashing lights)
Flatulence (Flatulence)
Floaters (Floaters)
Flu Like Symptoms (Flu like symptoms)
Flushing (Flushing)
Forced Expiratory Volume Decreased
(Forced expiratory volume decreased)
Fracture (Fracture)
Gait Disturbance (Gait disturbance)
Gallbladder Fistula (Gallbladder fistula)
Gallbladder Infection (Gallbladder
infection)
Gallbladder Necrosis (Gallbladder
necrosis)
Gallbladder Obstruction (Gallbladder
obstruction)
Gallbladder Pain (Gallbladder pain)
Gallbladder Perforation (Gallbladder
perforation)
Gastric Anastomotic Leak (Gastric
anastomotic leak)
Gastric Fistula (Gastric fistula)
Gastric Hemorrhage (Gastric
hemorrhage)
Gastric Necrosis (Gastric necrosis)
Gastric Perforation (Gastric perforation)
Gastric Stenosis (Gastric stenosis)
Gastric Ulcer (Gastric ulcer)
Gastritis (Gastritis)
Gastroesophageal Reflux Disease
(Gastroesophageal reflux disease)
Gastrointestinal Anastomotic Leak
(Gastrointestinal anastomotic leak)
Gastrointestinal Disorders - Other,
Specify (Gastrointestinal disorders -
Other, Specify)
Gastrointestinal Fistula (Gastrointestinal
fistula)
Gastrointestinal Pain (Gastrointestinal
pain)
Gastrointestinal Stoma Necrosis
(Gastrointestinal stoma necrosis)
Gastroparesis (Gastroparesis)
General Disorders And Administration
Site Conditions - Other, Specify (General
disorders and administration site
conditions - Other, Specify)
Generalized Muscle Weakness
(Generalized muscle weakness)
Genital Edema (Genital edema)
Ggt Increased (GGT increased)
Gingival Pain (Gingival pain)
Glaucoma (Glaucoma)
Glossopharyngeal Nerve Disorder
(Glossopharyngeal nerve disorder)
Glucose Intolerance (Glucose
intolerance)
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Growth Accelerated (Growth
accelerated)
Growth Hormone Abnormal (Growth
hormone abnormal)
Growth Suppression (Growth
suppression)
Gum Infection (Gum infection)
Gynecomastia (Gynecomastia)
Hallucinations (Hallucinations)
Haptoglobin Decreased (Haptoglobin
decreased)
Head Soft Tissue Necrosis (Head soft
tissue necrosis)
Headache (Headache)
Hearing Impaired (Hearing impaired)
Heart Failure (Heart failure)
Hematoma (Hematoma)
Hematosalpinx (Hematosalpinx)
Hematuria (Hematuria)
Hemoglobin Increased (Hemoglobin
increased)
Hemoglobinuria (Hemoglobinuria)
Hemolysis (Hemolysis)
Hemolytic Uremic Syndrome (Hemolytic
uremic syndrome)
Hemorrhoidal Hemorrhage
(Hemorrhoidal hemorrhage)
Hemorrhoids (Hemorrhoids)
Hepatic Failure (Hepatic failure)
Hepatic Hemorrhage (Hepatic
hemorrhage)
Hepatic Infection (Hepatic infection)
Hepatic Necrosis (Hepatic necrosis)
Hepatic Pain (Hepatic pain)
Hepatitis Viral (Hepatitis viral)
Hepatobiliary Disorders - Other, Specify
(Hepatobiliary disorders - Other, Specify)
Hiccups (Hiccups)
Hip Fracture (Hip fracture)
Hirsutism (Hirsutism)
Hoarseness (Hoarseness)
Hot Flashes (Hot flashes)
Hydrocephalus (Hydrocephalus)
Hypercalcemia (Hypercalcemia)
Hyperglycemia (Hyperglycemia)
Hyperhidrosis (Hyperhidrosis)
Hyperkalemia (Hyperkalemia)
Hypermagnesemia (Hypermagnesemia)
Hypernatremia (Hypernatremia)
Hyperparathyroidism
(Hyperparathyroidism)
Hypersomnia (Hypersomnia)
Hypertension (Hypertension)
Hyperthyroidism (Hyperthyroidism)
Hypertrichosis (Hypertrichosis)
Hypertriglyceridemia
(Hypertriglyceridemia)
Hyperuricemia (Hyperuricemia)
Hypoalbuminemia (Hypoalbuminemia)
Hypocalcemia (Hypocalcemia)
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Hypoglossal Nerve Disorder
(Hypoglossal nerve disorder)
Hypoglycemia (Hypoglycemia)
Hypohidrosis (Hypohidrosis)
Hypokalemia (Hypokalemia)
Hypomagnesemia (Hypomagnesemia)
Hyponatremia (Hyponatremia)
Hypoparathyroidism
(Hypoparathyroidism)
Hypophosphatemia (Hypophosphatemia)
Hypotension (Hypotension)
Hypothermia (Hypothermia)
Hypothyroidism (Hypothyroidism)
Hypoxia (Hypoxia)
Ileal Fistula (Ileal fistula)
Ileal Hemorrhage (Ileal hemorrhage)
Ileal Obstruction (Ileal obstruction)
Ileal Perforation (Ileal perforation)
Ileal Stenosis (Ileal stenosis)
Ileal Ulcer (Ileal ulcer)
Ileus (Ileus)
Immune System Disorders - Other,
Specify (Immune system disorders -
Other, Specify)
Infections And Infestations - Other,
Specify (Infections and infestations -
Other, Specify)
Infective Myositis (Infective myositis)
Infusion Related Reaction (Infusion
related reaction)
Infusion Site Extravasation (Infusion site
extravasation)
Injection Site Reaction (Injection site
reaction)
Injury To Carotid Artery (Injury to carotid
artery)
Injury To Inferior Vena Cava (Injury to
inferior vena cava)
Injury To Jugular Vein (Injury to jugular
vein)
Injury To Superior Vena Cava (Injury to
superior vena cava)
Injury, Poisoning And Procedural
Complications - Other, Specify (Injury,
poisoning and procedural complications -
Other, Specify)
Inr Increased (INR increased)
Insomnia (Insomnia)
Intestinal Stoma Leak (Intestinal stoma
leak)
Intestinal Stoma Obstruction (Intestinal
stoma obstruction)
Intestinal Stoma Site Bleeding (Intestinal
stoma site bleeding)
Intra-abdominal Hemorrhage (Intra-
abdominal hemorrhage)
Intracranial Hemorrhage (Intracranial
hemorrhage)
Intraoperative Arterial Injury
(Intraoperative arterial injury)
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Intraoperative Breast Injury
(Intraoperative breast injury)
Intraoperative Cardiac Injury
(Intraoperative cardiac injury)
Intraoperative Ear Injury (Intraoperative
ear injury)
Intraoperative Endocrine Injury
(Intraoperative endocrine injury)
Intraoperative Gastrointestinal Injury
(Intraoperative gastrointestinal injury)
Intraoperative Head And Neck Injury
(Intraoperative head and neck injury)
Intraoperative Hemorrhage
(Intraoperative hemorrhage)
Intraoperative Hepatobiliary Injury
(Intraoperative hepatobiliary injury)
Intraoperative Musculoskeletal Injury
(Intraoperative musculoskeletal injury)
Intraoperative Neurological Injury
(Intraoperative neurological injury)
Intraoperative Ocular Injury
(Intraoperative ocular injury)
Intraoperative Renal Injury
(Intraoperative renal injury)
Intraoperative Reproductive Tract Injury
(Intraoperative reproductive tract injury)
Intraoperative Respiratory Injury
(Intraoperative respiratory injury)
Intraoperative Skin Injury (Intraoperative
skin injury)
Intraoperative Splenic Injury
(Intraoperative splenic injury)
Intraoperative Urinary Injury
(Intraoperative urinary injury)
Intraoperative Venous Injury
(Intraoperative venous injury)
Investigations - Other, Specify
(Investigations - Other, Specify)
Iron Overload (Iron overload)
Irregular Menstruation (Irregular
menstruation)
Irritability (Irritability)
Ischemia Cerebrovascular (Ischemia
cerebrovascular)
Ivth Nerve Disorder (IVth nerve disorder)
Jejunal Fistula (Jejunal fistula)
Jejunal Hemorrhage (Jejunal
hemorrhage)
Jejunal Obstruction (Jejunal obstruction)
Jejunal Perforation (Jejunal perforation)
Jejunal Stenosis (Jejunal stenosis)
Jejunal Ulcer (Jejunal ulcer)
Joint Effusion (Joint effusion)
Joint Infection (Joint infection)
Joint Range Of Motion Decreased (Joint
range of motion decreased)
Joint Range Of Motion Decreased
Cervical Spine (Joint range of motion
decreased cervical spine)
Joint Range Of Motion Decreased
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Lumbar Spine (Joint range of motion
decreased lumbar spine)
Keratitis (Keratitis)
Kidney Anastomotic Leak (Kidney
anastomotic leak)
Kidney Infection (Kidney infection)
Kyphosis (Kyphosis)
Lactation Disorder (Lactation disorder)
Large Intestinal Anastomotic Leak (Large
intestinal anastomotic leak)
Laryngeal Edema (Laryngeal edema)
Laryngeal Fistula (Laryngeal fistula)
Laryngeal Hemorrhage (Laryngeal
hemorrhage)
Laryngeal Inflammation (Laryngeal
inflammation)
Laryngeal Mucositis (Laryngeal
mucositis)
Laryngeal Obstruction (Laryngeal
obstruction)
Laryngeal Stenosis (Laryngeal stenosis)
Laryngitis (Laryngitis)
Laryngopharyngeal Dysesthesia
(Laryngopharyngeal dysesthesia)
Laryngospasm (Laryngospasm)
Left Ventricular Systolic Dysfunction (Left
ventricular systolic dysfunction)
Lethargy (Lethargy)
Leukemia Secondary To Oncology
Chemotherapy (Leukemia secondary to
oncology chemotherapy)
Leukocytosis (Leukocytosis)
Leukoencephalopathy
(Leukoencephalopathy)
Libido Decreased (Libido decreased)
Libido Increased (Libido increased)
Lip Infection (Lip infection)
Lip Pain (Lip pain)
Lipase Increased (Lipase increased)
Lipohypertrophy (Lipohypertrophy)
Localized Edema (Localized edema)
Lordosis (Lordosis)
Lower Gastrointestinal Hemorrhage
(Lower gastrointestinal hemorrhage)
Lung Infection (Lung infection)
Lymph Gland Infection (Lymph gland
infection)
Lymph Leakage (Lymph leakage)
Lymph Node Pain (Lymph node pain)
Lymphedema (Lymphedema)
Lymphocele (Lymphocele)
Lymphocyte Count Decreased
(Lymphocyte count decreased)
Lymphocyte Count Increased
(Lymphocyte count increased)
Malabsorption (Malabsorption)
Malaise (Malaise)
Mania (Mania)
Mediastinal Hemorrhage (Mediastinal
hemorrhage)
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Mediastinal Infection (Mediastinal
infection)
Memory Impairment (Memory
impairment)
Meningismus (Meningismus)
Meningitis (Meningitis)
Menopause (Menopause)
Menorrhagia (Menorrhagia)
Metabolism And Nutrition Disorders -
Other, Specify (Metabolism and nutrition
disorders - Other, Specify)
Middle Ear Inflammation (Middle ear
inflammation)
Mitral Valve Disease (Mitral valve
disease)
Mobitz (type) Ii Atrioventricular Block
(Mobitz (type) II atrioventricular block)
Mobitz Type I (Mobitz type I)
Movements Involuntary (Movements
involuntary)
Mucosal Infection (Mucosal infection)
Mucositis Oral (Mucositis oral)
Multi-organ Failure (Multi-organ failure)
Muscle Weakness Left-sided (Muscle
weakness left-sided)
Muscle Weakness Lower Limb (Muscle
weakness lower limb)
Muscle Weakness Right-sided (Muscle
weakness right-sided)
Muscle Weakness Trunk (Muscle
weakness trunk)
Muscle Weakness Upper Limb (Muscle
weakness upper limb)
Musculoskeletal And Connective Tissue
Disorder - Other, Specify
(Musculoskeletal and connective tissue
disorders - Other, Specify)
Musculoskeletal Deformity
(Musculoskeletal deformity)
Myalgia (Myalgia)
Myelitis (Myelitis)
Myelodysplastic Syndrome
(Myelodysplastic syndrome)
Myocardial Infarction (Myocardial
infarction)
Myocarditis (Myocarditis)
Myositis (Myositis)
Nail Discoloration (Nail discoloration)
Nail Infection (Nail infection)
Nail Loss (Nail loss)
Nail Ridging (Nail ridging)
Nasal Congestion (Nasal congestion)
Nausea (Nausea)
Neck Edema (Neck edema)
Neck Pain (Neck pain)
Neck Soft Tissue Necrosis (Neck soft
tissue necrosis)
Neoplasms Benign, Malignant And
Unspecified (incl Cysts And Polyps) -
Other, Specify (Neoplasms benign,
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malignant and unspecified (incl cysts and
polyps) - Other, Specify)
Nervous System Disorders - Other,
Specify (Nervous system disorders -
Other, Specify)
Neuralgia (Neuralgia)
Neutrophil Count Decreased (Neutrophil
count decreased)
Night Blindness (Night blindness)
Nipple Deformity (Nipple deformity)
Non-cardiac Chest Pain (Non-cardiac
chest pain)
Nystagmus (Nystagmus)
Obesity (Obesity)
Obstruction Gastric (Obstruction gastric)
Oculomotor Nerve Disorder (Oculomotor
nerve disorder)
Olfactory Nerve Disorder (Olfactory
nerve disorder)
Oligospermia (Oligospermia)
Optic Nerve Disorder (Optic nerve
disorder)
Oral Cavity Fistula (Oral cavity fistula)
Oral Dysesthesia (Oral dysesthesia)
Oral Hemorrhage (Oral hemorrhage)
Oral Pain (Oral pain)
Osteonecrosis Of Jaw (Osteonecrosis of
jaw)
Osteoporosis (Osteoporosis)
Otitis Externa (Otitis externa)
Otitis Media (Otitis media)
Ovarian Hemorrhage (Ovarian
hemorrhage)
Ovarian Infection (Ovarian infection)
Ovarian Rupture (Ovarian rupture)
Ovulation Pain (Ovulation pain)
Pain (Pain)
Pain In Extremity (Pain in extremity)
Pain Of Skin (Pain of skin)
Palmar-plantar Erythrodysesthesia
Syndrome (Palmar-plantar
erythrodysesthesia syndrome)
Palpitations (Palpitations)
Pancreas Infection (Pancreas infection)
Pancreatic Anastomotic Leak (Pancreatic
anastomotic leak)
Pancreatic Duct Stenosis (Pancreatic
duct stenosis)
Pancreatic Enzymes Decreased
(Pancreatic enzymes decreased)
Pancreatic Fistula (Pancreatic fistula)
Pancreatic Hemorrhage (Pancreatic
hemorrhage)
Pancreatic Necrosis (Pancreatic
necrosis)
Pancreatitis (Pancreatitis)
Papilledema (Papilledema)
Papulopustular Rash (Papulopustular
rash)
Paresthesia (Paresthesia)
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Paronychia (Paronychia)
Paroxysmal Atrial Tachycardia
(Paroxysmal atrial tachycardia)
Pelvic Floor Muscle Weakness (Pelvic
floor muscle weakness)
Pelvic Infection (Pelvic infection)
Pelvic Pain (Pelvic pain)
Pelvic Soft Tissue Necrosis (Pelvic soft
tissue necrosis)
Penile Infection (Penile infection)
Penile Pain (Penile pain)
Perforation Bile Duct (Perforation bile
duct)
Pericardial Effusion (Pericardial effusion)
Pericardial Tamponade (Pericardial
tamponade)
Pericarditis (Pericarditis)
Perineal Pain (Perineal pain)
Periodontal Disease (Periodontal
disease)
Periorbital Edema (Periorbital edema)
Periorbital Infection (Periorbital infection)
Peripheral Ischemia (Peripheral
ischemia)
Peripheral Motor Neuropathy (Peripheral
motor neuropathy)
Peripheral Nerve Infection (Peripheral
nerve infection)
Peripheral Sensory Neuropathy
(Peripheral sensory neuropathy)
Peritoneal Infection (Peritoneal infection)
Peritoneal Necrosis (Peritoneal necrosis)
Personality Change (Personality change)
Phantom Pain (Phantom pain)
Pharyngeal Anastomotic Leak
(Pharyngeal anastomotic leak)
Pharyngeal Fistula (Pharyngeal fistula)
Pharyngeal Hemorrhage (Pharyngeal
hemorrhage)
Pharyngeal Mucositis (Pharyngeal
mucositis)
Pharyngeal Necrosis (Pharyngeal
necrosis)
Pharyngeal Stenosis (Pharyngeal
stenosis)
Pharyngitis (Pharyngitis)
Pharyngolaryngeal Pain
(Pharyngolaryngeal pain)
Phlebitis (Phlebitis)
Phlebitis Infective (Phlebitis infective)
Photophobia (Photophobia)
Photosensitivity (Photosensitivity)
Platelet Count Decreased (Platelet count
decreased)
Pleural Effusion (Pleural effusion)
Pleural Hemorrhage (Pleural
hemorrhage)
Pleural Infection (Pleural infection)
Pleuritic Pain (Pleuritic pain)
Pneumonitis (Pneumonitis)
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Pneumothorax (Pneumothorax)
Portal Hypertension (Portal
hypertension)
Portal Vein Thrombosis (Portal vein
thrombosis)
Postnasal Drip (Postnasal drip)
Postoperative Hemorrhage
(Postoperative hemorrhage)
Postoperative Thoracic Procedure
Complication (Postoperative thoracic
procedure complication)
Precocious Puberty (Precocious
puberty)
Pregnancy, Puerperium And Perinatal
Conditions - Other, Specify (Pregnancy,
puerperium and perinatal conditions -
Other, Specify)
Premature Delivery (Premature delivery)
Premature Menopause (Premature
menopause)
Presyncope (Presyncope)
Proctitis (Proctitis)
Productive Cough (Productive cough)
Prolapse Of Intestinal Stoma (Prolapse
of intestinal stoma)
Prolapse Of Urostomy (Prolapse of
urostomy)
Prostate Infection (Prostate infection)
Prostatic Hemorrhage (Prostatic
hemorrhage)
Prostatic Obstruction (Prostatic
obstruction)
Prostatic Pain (Prostatic pain)
Proteinuria (Proteinuria)
Pruritus (Pruritus)
Psychiatric Disorders - Other, Specify
(Psychiatric disorders - Other, Specify)
Psychosis (Psychosis)
Pulmonary Edema (Pulmonary edema)
Pulmonary Fibrosis (Pulmonary fibrosis)
Pulmonary Fistula (Pulmonary fistula)
Pulmonary Hypertension (Pulmonary
hypertension)
Pulmonary Valve Disease (Pulmonary
valve disease)
Purpura (Purpura)
Pyramidal Tract Syndrome (Pyramidal
tract syndrome)
Radiation Recall Reaction (dermatologic)
(Radiation recall reaction (dermatologic))
Radiculitis (Radiculitis)
Rash Acneiform (Rash acneiform)
Rash Maculo-papular (Rash maculo-
papular)
Rash Pustular (Rash pustular)
Rectal Anastomotic Leak (Rectal
anastomotic leak)
Rectal Fistula (Rectal fistula)
Rectal Hemorrhage (Rectal hemorrhage)
Rectal Mucositis (Rectal mucositis)
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Rectal Necrosis (Rectal necrosis)
Rectal Obstruction (Rectal obstruction)
Rectal Pain (Rectal pain)
Rectal Perforation (Rectal perforation)
Rectal Stenosis (Rectal stenosis)
Rectal Ulcer (Rectal ulcer)
Recurrent Laryngeal Nerve Palsy
(Recurrent laryngeal nerve palsy)
Renal And Urinary Disorders - Other,
Specify (Renal and urinary disorders -
Other, Specify)
Renal Calculi (Renal calculi)
Renal Colic (Renal colic)
Renal Hemorrhage (Renal hemorrhage)
Reproductive System And Breast
Disorders - Other, Specify (Reproductive
system and breast disorders - Other,
Specify)
Respiratory Failure (Respiratory failure)
Respiratory, Thoracic And Mediastinal
Disorders - Other, Specify (Respiratory,
thoracic and mediastinal disorders -
Other, Specify)
Restlessness (Restlessness)
Restrictive Cardiomyopathy (Restrictive
cardiomyopathy)
Retinal Detachment (Retinal
detachment)
Retinal Tear (Retinal tear)
Retinal Vascular Disorder (Retinal
vascular disorder)
Retinoic Acid Syndrome (Retinoic acid
syndrome)
Retinopathy (Retinopathy)
Retroperitoneal Hemorrhage
(Retroperitoneal hemorrhage)
Reversible Posterior
Leukoencephalopathy Syndrome
(Reversible posterior
leukoencephalopathy syndrome)
Rhinitis Infective (Rhinitis infective)
Right Ventricular Dysfunction (Right
ventricular dysfunction)
Salivary Duct Inflammation (Salivary duct
inflammation)
Salivary Gland Fistula (Salivary gland
fistula)
Salivary Gland Infection (Salivary gland
infection)
Scalp Pain (Scalp pain)
Scleral Disorder (Scleral disorder)
Scoliosis (Scoliosis)
Scrotal Infection (Scrotal infection)
Scrotal Pain (Scrotal pain)
Seizure (Seizure)
Sepsis (Sepsis)
Seroma (Seroma)
Serum Amylase Increased (Serum
amylase increased)
Serum Sickness (Serum sickness)
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Sick Sinus Syndrome (Sick sinus
syndrome)
Sinus Bradycardia (Sinus bradycardia)
Sinus Disorder (Sinus disorder)
Sinus Pain (Sinus pain)
Sinus Tachycardia (Sinus tachycardia)
Sinusitis (Sinusitis)
Skin And Subcutaneous Tissue
Disorders - Other, Specify (Skin and
subcutaneous tissue disorders - Other,
Specify)
Skin Atrophy (Skin atrophy)
Skin Hyperpigmentation (Skin
hyperpigmentation)
Skin Hypopigmentation (Skin
hypopigmentation)
Skin Induration (Skin induration)
Skin Infection (Skin infection)
Skin Ulceration (Skin ulceration)
Sleep Apnea (Sleep apnea)
Small Intestinal Anastomotic Leak (Small
intestinal anastomotic leak)
Small Intestinal Mucositis (Small
intestinal mucositis)
Small Intestinal Obstruction (Small
intestinal obstruction)
Small Intestinal Perforation (Small
intestinal perforation)
Small Intestinal Stenosis (Small intestinal
stenosis)
Small Intestine Infection (Small intestine
infection)
Small Intestine Ulcer (Small intestine
ulcer)
Sneezing (Sneezing)
Social Circumstances - Other, Specify
(Social circumstances - Other, Specify)
Soft Tissue Infection (Soft tissue
infection)
Soft Tissue Necrosis Lower Limb (Soft
tissue necrosis lower limb)
Soft Tissue Necrosis Upper Limb (Soft
tissue necrosis upper limb)
Somnolence (Somnolence)
Sore Throat (Sore throat)
Spasticity (Spasticity)
Spermatic Cord Anastomotic Leak
(Spermatic cord anastomotic leak)
Spermatic Cord Hemorrhage (Spermatic
cord hemorrhage)
Spermatic Cord Obstruction (Spermatic
cord obstruction)
Spinal Fracture (Spinal fracture)
Spleen Disorder (Spleen disorder)
Splenic Infection (Splenic infection)
Stenosis Of Gastrointestinal Stoma
(Stenosis of gastrointestinal stoma)
Stevens-johnson Syndrome (Stevens-
Johnson syndrome)
Stoma Site Infection (Stoma site
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infection)
Stomach Pain (Stomach pain)
Stomal Ulcer (Stomal ulcer)
Stridor (Stridor)
Stroke (Stroke)
Sudden Death Nos (Sudden death NOS)
Suicidal Ideation (Suicidal ideation)
Suicide Attempt (Suicide attempt)
Superficial Soft Tissue Fibrosis
(Superficial soft tissue fibrosis)
Superficial Thrombophlebitis (Superficial
thrombophlebitis)
Superior Vena Cava Syndrome (Superior
vena cava syndrome)
Supraventricular Tachycardia
(Supraventricular tachycardia)
Surgical And Medical Procedures -
Other, Specify (Surgical and medical
procedures - Other, Specify)
Syncope (Syncope)
Telangiectasia (Telangiectasia)
Testicular Disorder (Testicular disorder)
Testicular Hemorrhage (Testicular
hemorrhage)
Testicular Pain (Testicular pain)
Thromboembolic Event
(Thromboembolic event)
Thrombotic Thrombocytopenic Purpura
(Thrombotic thrombocytopenic purpura)
Tinnitus (Tinnitus)
Tooth Development Disorder (Tooth
development disorder)
Tooth Discoloration (Tooth discoloration)
Tooth Infection (Tooth infection)
Toothache (Toothache)
Toxic Epidermal Necrolysis (Toxic
epidermal necrolysis)
Tracheal Fistula (Tracheal fistula)
Tracheal Hemorrhage (Tracheal
hemorrhage)
Tracheal Mucositis (Tracheal mucositis)
Tracheal Obstruction (Tracheal
obstruction)
Tracheal Stenosis (Tracheal stenosis)
Tracheitis (Tracheitis)
Tracheostomy Site Bleeding
(Tracheostomy site bleeding)
Transient Ischemic Attacks (Transient
ischemic attacks)
Treatment Related Secondary
Malignancy (Treatment related
secondary malignancy)
Tremor (Tremor)
Tricuspid Valve Disease (Tricuspid valve
disease)
Trigeminal Nerve Disorder (Trigeminal
nerve disorder)
Trismus (Trismus)
Tumor Lysis Syndrome (Tumor lysis
syndrome)
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Tumor Pain (Tumor pain)
Typhlitis (Typhlitis)
Unequal Limb Length (Unequal limb
length)
Unintended Pregnancy (Unintended
pregnancy)
Upper Gastrointestinal Hemorrhage
(Upper gastrointestinal hemorrhage)
Upper Respiratory Infection (Upper
respiratory infection)
Ureteric Anastomotic Leak (Ureteric
anastomotic leak)
Urethral Anastomotic Leak (Urethral
anastomotic leak)
Urethral Infection (Urethral infection)
Urinary Fistula (Urinary fistula)
Urinary Frequency (Urinary frequency)
Urinary Incontinence (Urinary
incontinence)
Urinary Retention (Urinary retention)
Urinary Tract Infection (Urinary tract
infection)
Urinary Tract Obstruction (Urinary tract
obstruction)
Urinary Tract Pain (Urinary tract pain)
Urinary Urgency (Urinary urgency)
Urine Discoloration (Urine discoloration)
Urine Output Decreased (Urine output
decreased)
Urostomy Leak (Urostomy leak)
Urostomy Obstruction (Urostomy
obstruction)
Urostomy Site Bleeding (Urostomy site
bleeding)
Urostomy Stenosis (Urostomy stenosis)
Urticaria (Urticaria)
Uterine Anastomotic Leak (Uterine
anastomotic leak)
Uterine Fistula (Uterine fistula)
Uterine Hemorrhage (Uterine
hemorrhage)
Uterine Infection (Uterine infection)
Uterine Obstruction (Uterine obstruction)
Uterine Pain (Uterine pain)
Uterine Perforation (Uterine perforation)
Uveitis (Uveitis)
Vaginal Anastomotic Leak (Vaginal
anastomotic leak)
Vaginal Discharge (Vaginal discharge)
Vaginal Dryness (Vaginal dryness)
Vaginal Fistula (Vaginal fistula)
Vaginal Hemorrhage (Vaginal
hemorrhage)
Vaginal Infection (Vaginal infection)
Vaginal Inflammation (Vaginal
inflammation)
Vaginal Obstruction (Vaginal obstruction)
Vaginal Pain (Vaginal pain)
Vaginal Perforation (Vaginal perforation)
Vaginal Stricture (Vaginal stricture)
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Vaginismus (Vaginismus)
Vagus Nerve Disorder (Vagus nerve
disorder)
Vas Deferens Anastomotic Leak (Vas
deferens anastomotic leak)
Vascular Access Complication (Vascular
access complication)
Vascular Disorders - Other, Specify
(Vascular disorders - Other, Specify)
Vasculitis (Vasculitis)
Vasovagal Reaction (Vasovagal reaction)
Venous Injury (Venous injury)
Ventricular Arrhythmia (Ventricular
arrhythmia)
Ventricular Fibrillation (Ventricular
fibrillation)
Ventricular Tachycardia (Ventricular
tachycardia)
Vertigo (Vertigo)
Vestibular Disorder (Vestibular disorder)
Virilization (Virilization)
Visceral Arterial Ischemia (Visceral
arterial ischemia)
Vital Capacity Abnormal (Vital capacity
abnormal)
Vitreous Hemorrhage (Vitreous
hemorrhage)
Voice Alteration (Voice alteration)
Vomiting (Vomiting)
Vulval Infection (Vulval infection)
Watering Eyes (Watering eyes)
Weight Gain (Weight gain)
Weight Loss (Weight loss)
Wheezing (Wheezing)
White Blood Cell Decreased (White
blood cell decreased)
Wolff-parkinson-white Syndrome (Wolff-
Parkinson-White syndrome)
Wound Complication (Wound
complication)
Wound Dehiscence (Wound dehiscence)
Wound Infection (Wound infection)
Wrist Fracture (Wrist fracture)
MedDRA Code (v.12.0 must be completed)
CTC Adverse Event Grade (highest grade)
Severe Adverse Event (3)
Life Threatening Adverse Event (4)
Death Related To Adverse Event (5)
CTC AE Attribution Code
Definite (Definite)
Possible (Possible)
Probable (Probable)
Unlikely (Unlikely)
Unrelated (Unrelated)
Late Adverse Event Onset Date (dd MMM yyyy)
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Breast Cancer NCT01242800 Off Treatment
- E2108 End-of-Study Form - 3128917v1.0
E2108 End-of-Study Form
Early Surgery or Standard Palliative Therapy in Treating
Patients With Stage IV Breast Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=8DF34112-
9349-8BCA-E040-BB89AD4347FD
All rights reserved. Please visit https://medical-data-
models.org/forms/7650
E2108 End-of-Study Form
Header
ECOG Protocol Number
ECOG Patient ID
DCI Name
Registration Step
Reporting Period
End Of Treatment (End of treatment)
Unnamed2
ECOG Protocol Number
Patient Initials (Last, First)
ECOG Patient ID
Participating Group Protocol Number
Institution/Affiliate
Participating Group Patient ID
Unnamed4
Please mark an 'X' if data have been amended.
(Please circle amended items in red)
Date data amended (s M D Y)
Vital Status
Patient's Vital Status
Alive (Alive)
Dead (Dead)
1 / 2
Date of last contact or death (M D Y)
Primary Cause of Death (if applicable)
Due To Other Cause (Due to other
cause)
Due To Protocol Treatment (Due to
protocol treatment)
Due To This Disease (Due to this
disease)
Unknown (Unknown)
Describe cause of death
Section I
Reason Treatment Ended (this step)
Death On Study (Death on study)
Other (Other)
Patient Withdrawal Or Refusal After
Beginning Protocol Therapy (Patient
withdrawal/refusal after beginning
protocol therapy)
Other specify
Comments
Investigator Signature
Investigator Signature Date
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Breast Cancer NCT01242800 On-Study - E2108
Step 1 On-Study Form - ARM S - 3130381v1.0
E2108 Step 1 On-Study Form - ARM S
Early Surgery or Standard Palliative Therapy in Treating
Patients With Stage IV Breast Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=8E2ED499-
121B-8389-E040-BB89AD4330F7
All rights reserved. Please visit https://medical-data-
models.org/forms/7653
E2108 Step 1 On-Study Form - ARM
S
Header
ECOG Protocol Number
DCI Name
Registration Step
Reporting Period
Baseline Step 1 (Baseline step 1)
ECOG Patient ID
Unnamed2
Patient Initials (Last, First)
ECOG Protocol Number
Participating Group Protocol Number
Institution/Affiliate
ECOG Patient ID
Participating Group Patient ID
Unnamed4
Please mark an 'X' if data have been amended.
(Please circle amended items in red)
Date data amended (s M D Y)
Unnamed3
1 / 5
ECOG Performance Status (Day 1 of this cycle)
Fully Active, Able To Carry On All Pre-
disease Performance Without
Restriction. (0)
Restricted In Physically Strenuous
Activity But Ambulatory And Able To
Carry Out Work Of A Light Or Sedentary
Nature, E.g., Light Housework, Office
Work. (1)
Ambulatory And Capable Of All Selfcare
But Unable To Carry Out Any Work
Activities. Up And About More Than 50%
Of Waking Hours. (2)
Capable Of Only Limited Selfcare,
Confined To Bed Or Chair More Than
50% Of Waking Hours. (3)
Completely Disabled. Cannot Carry On
Any Selfcare. Totally Confined To Bed Or
Chair. (4)
Height (cm)
Weight (kg)
Menopausal status (Definitions of Menopausal
Status: Postmenopausal: Defined as at least one
of the following: 1 age >55 with no spontaneous
menses for at least 12 months, or 2 age </= 55
years with no spontaneous menses within the
past 12 months e.g. spontaneous or secondary to
hysterectomy AND with an FSH level in the
postmenopausal range according to local
institutional/laboratory standards or > 34.4 IU/L if
the institutional range is not available, or 3 history
of bilateral oophorectomy, or 4 receiving
gonadotropin releasing hormone to suppress
ovarian function during the entire period of
planned hormonal therapy. Premenopausal:
Defined as spontaneous menses occurring within
3 months prior to pre-randomization, and no prior
history of bilateral oophorectomy.
Perimenopausal: Not meeting criteria for
premenopausal or postmenopausal)
Perimenopausal (Perimenopausal)
Postmenopausal (Postmenopausal)
Premenopausal (Premenopausal)
Unknown (Unknown)
Disease Description
Is primary tumor palpable?
Yes
No
Her2/neu expression status by
immunohistochemistry
0 (0)
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1+ (1+)
2+ (2+)
3+ (3+)
Not Done: C49484 (not done)
FISH HER2/neu chromosome 17 Ratio
Mark an 'X' if unknown
ER Status
Negative (Negative)
Not Done (NOT DONE)
Positive (Positive)
Unknown (Unknown)
PgR Status
Negative (Negative)
Not Done (NOT DONE)
Positive (Positive)
Unknown (Unknown)
Date of biopsy confirming diagnosis of primary
tumor
Biopsy type
Incisional (Incisional)
Needle Biopsy (Needle biopsy)
Disease Description
Date of Initial Diagnosis of Metastatic Disease (M
D Y)
Opposite Breast
No (NO)
Unknown (UNKNOWN)
Yes (YES)
Mark an 'X' if unknown
Distant Lymph Nodes
No (NO)
Unknown (UNKNOWN)
Yes (YES)
Distant Skin/subcutaneous Tissue
No (No)
Unknown (Unknown)
Yes (Yes)
Bone
No (NO)
Unknown (UNKNOWN)
Yes (YES)
Bone Marrow
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No (No)
Unknown (Unknown)
Yes (Yes)
Biopsy type
Incisional (Incisional)
Needle Biopsy (Needle biopsy)
Lung
No (NO)
Unknown (UNKNOWN)
Yes (YES)
Liver
No (NO)
Unknown (UNKNOWN)
Yes (YES)
Pleura
No (NO)
Unknown (UNKNOWN)
Yes (YES)
Brain
No (NO)
Unknown (UNKNOWN)
Yes (YES)
Other CNS
No (NO)
Unknown (UNKNOWN)
Yes (YES)
Other
No (NO)
Unknown (UNKNOWN)
Yes (YES)
Other specify
Date of biopsy confirming diagnosis of metastatic
disease (If only one site of metastatic disease
coded above:)
Iib - Local-regional Recurrence
Axillary Node(s) and/or Soft Tissue
Yes
No
Infraclavicular Node(s)
Yes
No
Skin of breast
Yes
No
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Internal mammary node
Yes
No
Breast
Yes
No
Supraclavicular Node(s)
Yes
No
Skin of the chest wall
Yes
No
Status Of Local-regional Disease
Skin nodules present?
Yes
No
Sum of longest diameter of largest five nodules (If
yes,)
Ulceration present?
Yes
No
Area of Ulceration (If yes,)
Area of Ulceration
Tumor Mobility
Attached To Fascia (Attached to fascia)
Chest Wall Fixation (Chest wall fixation)
Free (Free)
Is direct invasion of tumor into skin present?
Yes
No
Longest dimension of skin invasion (If yes,)
Asymptomatic tumor in the intact breast present?
Yes
No
Comments
Investigator Signature
Investigator Signature Date
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Disease Evaluation Form (RECIST 1.1) - 3129560v1.0
E2108 Baseline Disease Evaluation Form (RECIST 1.1)
Early Surgery or Standard Palliative Therapy in Treating
Patients With Stage IV Breast Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=8E091CE3-
49A1-4A3C-E040-BB89AD4304A1
All rights reserved. Please visit https://medical-data-
models.org/forms/7655
E2108 Baseline Disease Evaluation
Form (RECIST 1.1)
Header
ECOG Protocol Number
ECOG Patient ID
DCI Name
Registration Step
Report Period
Randomization (Randomization)
Registration (Registration)
Unnamed2
Patient Initials (Last, First)
ECOG Protocol Number
ECOG Patient ID
Participating Group Protocol Number
Participating Group Patient ID
Institution/Affiliate
Unnamed 2a
Please mark an 'X' if data have been amended.
(Please circle amended items in red)
Date data amended (s M D Y)
Unnamed3
1 / 4
Are there any target lesions
Yes
No
Unnamed3
Lesion Number
Site of Lesion (Multiple nontarget lesions within
an organ may be combined as a single site;
report in a consistent manner on subsequent
forms)
Site Code
Bone (bone)
Brain (Brain)
Breast (Breast)
Effusion/ascites (Effusion/Ascites)
Gi (GI)
Gu (GU)
Head & Neck (Head & Neck)
Liver (Liver)
Lung (Lung)
Nodes (Nodes)
Other (other)
Skin (Skin)
Method of Evaluation
Bone Scan (Bone scan)
Chest X-ray (Chest X-Ray)
Clinical (Clinical Examination)
Ct Scan (CT Scan)
Mri (MRI (NMR))
Other (other)
Pet/ct Scan (PET/CT scan)
Date of Evaluation (M D Y)
Longest Diameter of Lesion(s) (mm)
Sum of Longest Diameters of All Non-Nodal
Lesions (mm)
Unnamed3
Lesion Number
Site of Lesion (Multiple nontarget lesions within
an organ may be combined as a single site;
report in a consistent manner on subsequent
forms)
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Site Code
Bone (bone)
Brain (Brain)
Breast (Breast)
Effusion/ascites (Effusion/Ascites)
Gi (GI)
Gu (GU)
Head & Neck (Head & Neck)
Liver (Liver)
Lung (Lung)
Nodes (Nodes)
Other (other)
Skin (Skin)
Method of Evaluation
Bone Scan (Bone scan)
Chest X-ray (Chest X-Ray)
Clinical (Clinical Examination)
Ct Scan (CT Scan)
Mri (MRI (NMR))
Other (other)
Pet/ct Scan (PET/CT scan)
Date of Evaluation (M D Y)
Shortest Axis of Lesions (mm)
Sum of Shortest Axes of All Nodal Lesions (mm)
Sum of Longest (Non-Nodal) and Shortest
(Nodal) Axes of All Target Lesions (mm)
Nontarget Lesions
Lesion Number
Site of Lesion (Multiple nontarget lesions within
an organ may be combined as a single site;
report in a consistent manner on subsequent
forms)
Site Code
Bone (bone)
Brain (Brain)
Breast (Breast)
Effusion/ascites (Effusion/Ascites)
Gi (GI)
Gu (GU)
Head & Neck (Head & Neck)
Liver (Liver)
Lung (Lung)
Nodes (Nodes)
Other (other)
Skin (Skin)
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Method of Evaluation
Bone Scan (Bone scan)
Chest X-ray (Chest X-Ray)
Clinical (Clinical Examination)
Ct Scan (CT Scan)
Mri (MRI (NMR))
Other (other)
Pet/ct Scan (PET/CT scan)
Date of Evaluation (M D Y)
Cytology Result (For Site Code 04
effusion/ascites ONLY:)
Negative (Negative)
Not Done (Not done)
Positive (Positive)
Comments
Comments
Investigator Signature
Investigator Signature Date (M D Y)
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Evaluation Form (RECIST 1.1) - 3129560v1.0
Treatment Form Breast Cancer
(NCT00785291)
CALGB-40502 Treatment Form
Paclitaxel, Paclitaxel Albumin-Stabilized Nanoparticle
Formulation, or Ixabepilone With or Without Bevacizumab
in Treating Patients With Stage IIIC or Stage IV Breast
Cancer
NCT00785291 
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=51FC385E-
3E0F-0F32-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/7656
Treatment Form Breast Cancer
(NCT00785291)
Header
CALGB Form
CALGB Study No
CALGB Patient ID
Patient Initials (Last, First Middle)
Patient Hospital No.
Institution/Affiliate
Participating Group
Participating Group Study No.
Participating Group Patient ID
Are data amended
Yes
No
Comments
Completed by (Last name, First name)
Date form completed (MM DD YYYY)
Bevacizumab/placebo
Assigned Treatment Arm
Arm A (Arm A)
Arm B (Arm B)
Arm C (Arm C)
Current Cycle Number
1 / 4
Cycle Start Date (MM DD YYYY)
Cycle end date (MM DD YYYY)
Weight (kg)
Bevacizumab/placebo
Agent (BEVACIZUMAB)
Prescribed dose (mg/kg)
Total Actual Dose of Agents/Drugs for this cycle
(mg)
Were there any delays in dose administration
Yes
No
Reason dose was delayed
Days Treatment Was Interrupted
Modified Dose (mg/m^2)
Was treatment discontinued during this period?
Yes
No
Treatment End date
Bevacizumab/placebo
Agent (BEVACIZUMAB)
Prescribed dose (mg/kg)
Total Actual Dose of Agents/Drugs for this cycle
(mg)
Were there any delays in dose administration
Yes
No
Reason dose was delayed
Days Treatment Was Interrupted
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Modified Dose (mg/m^2)
Was treatment discontinued during this period?
Yes
No
Specify
Treatment End date
Bevacizumab/placebo
Agent (BEVACIZUMAB)
Prescribed dose (mg/kg)
Total Actual Dose of Agents/Drugs for this cycle
(mg)
Were there any delays in dose administration
Yes
No
Reason dose was delayed
Days Treatment Was Interrupted
Modified Dose (mg/m^2)
Was treatment discontinued during this period?
Yes
No
Treatment End date
Bevacizumab/placebo
Agent (BEVACIZUMAB)
Prescribed dose (mg/kg)
Total Actual Dose of Agents/Drugs for this cycle
(mg)
Were there any delays in dose administration
Yes
No
Reason dose was delayed
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Days Treatment Was Interrupted
Was treatment discontinued during this period?
Yes
No
Treatment End date
Prophylatic Myeloid Growth Factor
Was growth factor support employed?
Yes
No
Growth factor
Filgrastim (Filgrastim)
Sargramostim (Sargramostim)
Growth factor dose
Did the patient require packed red blood cell
(PRBC) transfusions (this cycle)
Yes
No
Total number of units PRBC
Required Laboratory Values
ANC (x10^3 uL)
Peripheral Platelet Count (x10^3 uL)
SGPT (UL)
SGOT (UL)
Bilirubin (mg/dL)
Creatinine (mg/dL)
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Breast Cancer NCT01242800 Quality of Life - E2108
Assessment Compliance Form - 3128759v1.0
E2108 Assessment Compliance Form
Early Surgery or Standard Palliative Therapy in Treating
Patients With Stage IV Breast Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=8DF2D222-
1D4F-10F8-E040-BB89AD432CF6
All rights reserved. Please visit https://medical-data-
models.org/forms/7659
E2108 Assessment Compliance
Form
Header
ECOG Protocol Number
DCI Name
Registration Step
ECOG Patient ID
Unnamed2
Patient Initials (Last, First)
ECOG Protocol Number
Participating Group Protocol Number
Institution/Affiliate
ECOG Patient ID
Participating Group Patient ID
Unnamed4
Report Period (since start of treatment Choose
one)
18 Months Post Randomization (18
Months Post Randomization)
30 Months Post Randomization (30
Months Post Randomization)
6 Months Post Randomization (6 Months
Post Randomization)
At Decision For Local Therapy (At
Decision for Local Therapy)
Baseline Step 1 (Baseline step 1)
Baseline Step 2 (Baseline step 2)
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Unnamed3
Please mark an 'X' if data have been amended.
(Please circle amended items in red)
Date data amended (s M D Y)
Section I
Assessment date (M D Y If not completed, enter
date scheduled per E2108 protocol)
Section Ii - E1a05 Qol Assessment Not
Completed
Was the Assessment Form completed? (E2108
FACT-B + 10)
Yes
No
Section Ii - Assessments Not Completed
Patient refusal
Yes
No
Unable to accomodate disability or language
needs
Yes
No
Specify disability or language
Patient did not show up in clinic/office
Yes
No
Specify reason patient did not show up
Staff unavailable
Yes
No
Patient not given form by staff
Yes
No
Patient too ill
Yes
No
Patient expired
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Yes
No
Assessment not required per protocol
Yes
No
Specify reason assessment is not required
Staff thought patient too ill
Yes
No
Other
Yes
No
Specify other reason
Section Iii Assessment Completed
Was Assessment self-administered?
Yes
No
How Was The Patient Assisted
Were the questions read aloud to patient
Yes
No
Did the patient require clarification of questions or
instructions
Yes
No
Did the patient require other assistance
Yes
No
Were the forms completed independently by
another person
Yes
No
What Was The Reason For Assistance
Did the patient have a language difficulty
(questions needed to be translated)
Yes
No
Specify language
Did the patient have a literacy difficulty (patient
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Breast Cancer NCT01242800 Quality of Life - E2108 Assessment
Compliance Form - 3128759v1.0
could not read well enough)
Yes
No
Was the patient disabled
Yes
No
Specify disability
Were the forms completed via a telephone
interview
Yes
No
Other
Yes
No
Specify other reason
Patient Bowel Function/uniscale
Questionnaire: Who Assisted Or
Completed Assessment?
Staff
Yes
No
Family
Yes
No
Friend
Yes
No
Other
Yes
No
Specify other person
Comments
Investigator Signature
Investigator Signature Date
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Compliance Form - 3128759v1.0
Cycle Dose Drug Form D2R GOG-0219
(NCT00262821)
Cycle Dose Drug Form, Form D2R, GOG-0219
Cisplatin and Radiation Therapy With or Without
Tirapazamine in Treating Patients With Cervical Cancer
NCT00262821
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=EF8A7753-
7CC3-0A93-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/7661
Cycle Dose Drug Form D2R GOG-
0219 (NCT00262821)
Header Module
Date form originally completed (m d y)
Date form amended (m d y)
Person amending form, last name
Patient Initials (First, Middle, Last)
Patient Study ID
COMMENTS
Participating Group Code
Participating Group Protocol Number
Participating Group Patient ID
Person Completing Form, Last Name
Treatment Cycle And Modification
Cycle start date (Day 1 m d y)
Current cycle number
Cycle delayed
Yes
No
Number of days treatment course was delayed
Agent name (Drug)
1 / 3
Agent Dose level
Were there any dose modifications or
additions/omissions to protocol treatment (1=Yes,
planned; 2 =Yes, unplanned; 3=No)
No (No)
Yes, Planned (i.e., The Treatment Was
Changed According To Protocol
Guidelines) (Yes, planned)
Yes, Unplanned (i.e., The Treatment
Change Was Not Part Of Protocol
Guidelines) (Yes, unplanned)
Total dose of agents/drugs for this cycle (eg.
mg/m2)
Units (eg. mg, kg)
Patient weight (kg)
Body surface area (m2)
Performance status (Zubrod)
Fully Active, Able To Carry On All Pre-
disease Performance Without
Restriction. (0)
Restricted In Physically Strenuous
Activity But Ambulatory And Able To
Carry Out Work Of A Light Or Sedentary
Nature, E.g., Light Housework, Office
Work. (1)
Ambulatory And Capable Of All Selfcare
But Unable To Carry Out Any Work
Activities. Up And About More Than 50%
Of Waking Hours. (2)
Capable Of Only Limited Selfcare,
Confined To Bed Or Chair More Than
50% Of Waking Hours. (3)
Completely Disabled. Cannot Carry On
Any Selfcare. Totally Confined To Bed Or
Chair. (4)
Pretreatment Hematology And Chemistry
Values
Assessment date (m d y)
Hemoglobin
Peripheral hematocrit count (1000/L)
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Peripheral WBC count (mm3)
Peripheral granulocytes count (mm3)
Peripheral platelet count (mm3)
BUN (mg/dl)
Creatinine (mg/dl)
Creatinine Clearance (ml/min)
SGOT (IU/ml)
Bilirubin (mg %)
Result of CA125 (IU/ml)
Other specify (test)
Other specify (value)
Other specify (test) 2
Other specify (value) 2
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Cycle Dose Drug Form D2R GOG-0219 (NCT00262821)
Cycle Dose Drug Form (D2R) Cervical
Cancer (NCT00803062)
GOG-0240 Cycle Dose Drug Form (Form D2R)
Paclitaxel and Cisplatin or Topotecan With or Without
Bevacizumab in Treating Patients With Stage IVB,
Recurrent, or Persistent Cervical Cancer
NCT00803062
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=4580B20A-
FA66-2748-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/7662
Cycle Dose Drug Form (D2R)
Cervical Cancer (NCT00803062)
Header Module
Date form originally completed (m d y)
Date form amended (m d y)
Person amending form, last name
Patient Initials (First, Middle, Last)
Patient Study ID
COMMENTS
Person Completing Form, Last Name
Treatment Cycle And Modification
Current Cycle Number
Cycle Delayed?
Yes
No
Number of days treatment cycle was delayed
Cycle delayed reason
Non Protocol Illness (Non protocol
illness)
Patient Refusal (Patient refusal)
Personal Reasons (Personal reasons)
Protocol Related Ae (Protocol related
AE)
Scheduling (Scheduling)
Cycle start date (Day 1 m d y)
Agent name (Drug)
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Agent Dose level (e.g. mg/m^2)
Were there any dose modifications or
additions/omissions to protocol treatment (1=Yes,
planned; 2 =Yes, unplanned; 3=No)
No (No)
Yes, Planned (i.e., The Treatment Was
Changed According To Protocol
Guidelines) (Yes, planned)
Yes, Unplanned (i.e., The Treatment
Change Was Not Part Of Protocol
Guidelines) (Yes, unplanned)
Total dose of agents/drugs for this cycle
Units (eg. mg, kg)
Patient weight (kg)
Body Surface Area (m^2)
Performance status (Zubrod)
Fully Active, Able To Carry On All Pre-
disease Performance Without
Restriction. (0)
Restricted In Physically Strenuous
Activity But Ambulatory And Able To
Carry Out Work Of A Light Or Sedentary
Nature, E.g., Light Housework, Office
Work. (1)
Ambulatory And Capable Of All Selfcare
But Unable To Carry Out Any Work
Activities. Up And About More Than 50%
Of Waking Hours. (2)
Capable Of Only Limited Selfcare,
Confined To Bed Or Chair More Than
50% Of Waking Hours. (3)
Completely Disabled. Cannot Carry On
Any Selfcare. Totally Confined To Bed Or
Chair. (4)
Pretreatment Hematology And Chemistry
Values
Assessment Date (m d y)
Hemoglobin
Peripheral Hematocrit Count (1000/L)
Peripheral WBC Count (mm3)
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Cycle Dose Drug Form (D2R) Cervical Cancer (NCT00803062)
Peripheral Granulocytes Count (mm3)
Peripheral Platelet Count (mm3)
PT (sec)
PTT (sec) (sec)
BUN (mg/dl)
Creatinine (mg/dl)
Creatinine Clearance (ml/min)
SGOT (IU/ml)
Bilirubin (mg %)
Alkaline Phosphatase
Result of CA125 (IU/ml)
International Normalization Ratio (INR)
Other, specify test
Other specify value
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Breast Cancer NCT01242800 Quality of Life -
E2108 FACT-B + Local Symptoms-9 - 3129088v1.0
E2108 FACT-B + Local Symptoms-9
Early Surgery or Standard Palliative Therapy in Treating
Patients With Stage IV Breast Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=8E06DE1E-
7AF1-0A7A-E040-BB89AD43472D
All rights reserved. Please visit https://medical-data-
models.org/forms/7664
E2108 FACT-B + Local Symptoms-9
Header
DCI Name
Registration Step (Place ID Label Here)
Patient Initials (Last, First)
ECOG Protocol Number
ECOG Protocol Number
ECOG Patient ID
ECOG Patient ID
Participating Group Protocol Number
Participating Group Patient ID
Institution/Affiliate
On Treatment
Reporting Period (Choose one)
18 Months Post Randomization (18
Months Post Randomization)
30 Months Post Randomization (30
Months Post Randomization)
6 Months Post Randomization (6 Months
Post Randomization)
At Decision For Local Therapy (At
Decision for Local Therapy)
Baseline Step 1 (Baseline step 1)
Baseline Step 2 (Baseline step 2)
Header
Date of Assessment
1 / 7
Physical Well-being
I have a lack of energy
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have nausea
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
Because of my physical condition, I have trouble
meeting the needs of my family
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have pain
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am bothered by side effects of treatment
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I feel ill
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am forced to spend time in bed
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
Functional Well-being
I am able to work (include work at home)
2 (A little bit)
1 (Not at all)
4 (Quite a bit)
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3 (Somewhat)
5 (Very much)
My work is fulfilling (include work at home)
2 (A little bit)
1 (Not at all)
4 (Quite a bit)
3 (Somewhat)
5 (Very much)
I am able to enjoy life
2 (A little bit)
1 (Not at all)
4 (Quite a bit)
3 (Somewhat)
5 (Very much)
I have accepted my illness
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am sleeping well
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am enjoying the things I usually do for fun
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am content with the quality of my life right now
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
Social/family Well-being
I feel close to my friends
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I get emotional support from my family
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
3 / 7
Breast Cancer NCT01242800 Quality of Life - E2108 FACT-B + Local
Symptoms-9 - 3129088v1.0
I get support from my friends
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
My family has accepted my illness
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am satisfied with family communication about
my illness
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I feel close to my partner (or the person who is
my main support)
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am satisfied with my sex life
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
Emotional Well-being
I feel sad
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am satisfied with how I am coping with my
illness
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am losing hope in the fight against my illness
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
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Very Much (Very much)
I feel nervous
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I worry about dying
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I worry that my condition will get worse
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
Additional Concerns
I have been short of breath (B2)
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am self-concious about the way I dress (B3)
A Little (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
One or both of my arms are swollen and tender
(B4)
A Little (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I feel sexually attractive (B5)
A Little (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am bothered by my hair loss (B6)
A Little (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
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Very Much (Very much)
I worry that other members of my family might
someday get the same illness I have (B7)
A Little (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I worry about the effects of stress on my illness
(B8)
A Little (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am bothered by a change in weight (B9)
A Little (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am able to feel like a woman
A Little (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have certain areas of my body where I
experience significant pain
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I worry about the effects of stress on my illness
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have pain or discomfort in my breast and/or
chest wall
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
The pain or discomfort in my breast and/or chest
wall has limited my ability to work (including work
at home)
A Little Bit (A little bit)
Not At All (Not at all)
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Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
The lumps or open sores in my breast and/or
chest wall have limited my ability to work
(including work at home)
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
The lumps or open sores in my breast and/or
chest wall have limited my social activities
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
On which side was your breast cancer
Left (Left)
Right (Right)
Movement of my arm on this side is painful
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have a poor range of arm movements on this
side
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
My arm on this side feels numb
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have stiffness of my arm on this side
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
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Cycle Dose Drug Form (D2R) Endometrial
Cancer (NCT00942357)
GOG-0258 Cycle Dose Drug Form (D2R)
Carboplatin and Paclitaxel With or Without Cisplatin and
Radiation Therapy in Treating Patients With Stage I, Stage
II, Stage III, or Stage IVA Endometrial Cancer
NCT00942357
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=644E6D14-
3E4C-95F3-E040-BB89AD4357FF
All rights reserved. Please visit https://medical-data-
models.org/forms/7666
Cycle Dose Drug Form (D2R)
Endometrial Cancer (NCT00942357)
Header Module
Date form originally completed (m d y)
Date form amended (m d y)
Person amending form, last name
Patient Initials (First, Middle, Last)
Patient Study ID
COMMENTS
Person Completing Form, Last Name
Treatment Cycle And Modification
Current Cycle Number
Cycle Delayed?
Yes
No
Number of days treatment cycle was delayed
Cycle delayed reason
Non Protocol Illness (Non protocol
illness)
Patient Refusal (Patient refusal)
Personal Reasons (Personal reasons)
Protocol Related Ae (Protocol related
AE)
Scheduling (Scheduling)
Cycle start date (Day 1 m d y)
Agent name (Drug)
1 / 3
Agent Dose level (e.g. mg/m^2)
Were there any dose modifications or
additions/omissions to protocol treatment (1=Yes,
planned; 2 =Yes, unplanned; 3=No)
No (No)
Yes, Planned (i.e., The Treatment Was
Changed According To Protocol
Guidelines) (Yes, planned)
Yes, Unplanned (i.e., The Treatment
Change Was Not Part Of Protocol
Guidelines) (Yes, unplanned)
Total dose of agents/drugs for this cycle
Units (eg. mg, kg)
Patient weight (kg)
Body Surface Area (m^2)
Performance status (Zubrod)
Fully Active, Able To Carry On All Pre-
disease Performance Without
Restriction. (0)
Restricted In Physically Strenuous
Activity But Ambulatory And Able To
Carry Out Work Of A Light Or Sedentary
Nature, E.g., Light Housework, Office
Work. (1)
Ambulatory And Capable Of All Selfcare
But Unable To Carry Out Any Work
Activities. Up And About More Than 50%
Of Waking Hours. (2)
Capable Of Only Limited Selfcare,
Confined To Bed Or Chair More Than
50% Of Waking Hours. (3)
Completely Disabled. Cannot Carry On
Any Selfcare. Totally Confined To Bed Or
Chair. (4)
Pretreatment Hematology And Chemistry
Values
Assessment Date (m d y)
Hemoglobin
Peripheral Hematocrit Count (1000/L)
Peripheral WBC Count (mm3)
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Peripheral Granulocytes Count (mm3)
Peripheral Platelet Count (mm3)
PT (sec)
PTT (sec) (sec)
BUN (mg/dl)
Creatinine (mg/dl)
Creatinine Clearance (ml/min)
SGOT (IU/ml)
Bilirubin (mg %)
Alkaline Phosphatase
Result of CA125 (IU/ml)
International Normalization Ratio (INR)
Other, specify test
Other specify value
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Cycle Dose Drug Form D2R Fallopian Tube
Cancer (NCT00108745)
Cycle Dose Drug Form, GOG-0212, Form D2R
Paclitaxel or Polyglutamate Paclitaxel or Observation in
Treating Patients With Stage III or Stage IV Ovarian
Epithelial or Peritoneal Cancer or Fallopian Tube Cancer
NCT00108745
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=E74972BD-
ECF1-48B2-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/7668
Cycle Dose Drug Form D2R
Fallopian Tube Cancer
(NCT00108745)
Header Module
Date form originally completed (m d y)
Date form amended (m d y)
Person amending form, last name
Patient Initials (First, Middle, Last)
Patient Study ID
Participating Group Code
Participating Group Protocol Number
Participating Group Patient ID
COMMENT
Person Completing Form, Last Name
Treatment Cycle And Modification
Current cycle number
Cycle delayed
Yes
No
Number of days treatment cycle was delayed
Cycle delayed reason
Non Protocol Illness (Non protocol
illness)
Patient Refusal (Patient refusal)
Personal Reasons (Personal reasons)
Protocol Related Ae (Protocol related
1 / 3
AE)
Scheduling (Scheduling)
Cycle start date (Day 1 m d y)
Agent name (Drug)
Agent Dose level (eg. mg/m2)
Were there any dose modifications or
additions/omissions to protocol treatment (1=Yes,
planned; 2 =Yes, unplanned; 3=No)
No (No)
Yes, Planned (i.e., The Treatment Was
Changed According To Protocol
Guidelines) (Yes, planned)
Yes, Unplanned (i.e., The Treatment
Change Was Not Part Of Protocol
Guidelines) (Yes, unplanned)
Total dose of agents/drugs for this cycle
Units (eg. mg, kg)
Patient weight (kg)
Body surface area (m2)
Performance status (Zubrod)
Fully Active, Able To Carry On All Pre-
disease Performance Without Restriction
(karnofsky 90 - 100) (ecog - 0
Asymptomatic) (0)
Restricted In Physically Strenuous
Activity But Ambulatory (k70 - 80) (ecog -
1 Symptomatic - Fully Ambulatory) (1)
Ambulatory And Capable Of All Selfcare
But Unable To Carry Out Any Work
Activities (k 50 - 60) (ecog - 2
Symptomatic; In Bed , 50% Of The Day)
(2)
Capable Of Limited Selfcare, Confined
To Bed Or Chair More Than 50% Of
Waking Hours. (k 30 - 40) (ecog - 3
Symptomatic; In Bed > 50% Of The Day
But Not Bedridden) (3)
Completely Disabled (k10 - 20) (ecog - 4
Bedridden) (4)
Pretreatment Hematology And Chemistry
Values
Assessment date (m d y)
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Hemoglobin
Peripheral hematocrit count (1000/L)
Peripheral WBC count (mm3)
Peripheral granulocytes count (mm3)
Peripheral platelet count (mm3)
PT (sec)
PTT (sec)
International Normalization Ratio (INR)
BUN (mg/dl)
Creatinine (mg/dl)
Creatinine Clearance (ml/min)
SGOT (IU/ml)
Bilirubin (mg %)
Alkaline phosphatase
Result of CA125 (IU/ml)
Other specify (test)
Other specify (value)
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Cycle Dose Drug Form Fallopian Tube
Cancer (NCT00262847)
GOG-0218 Cycle Dose Drug Form
Carboplatin and Paclitaxel With or Without Bevacizumab in
Treating Patients With Stage III or Stage IV Ovarian
Epithelial, Primary Peritoneal Cancer, or Fallopian Tube
Cancer
NCT00262847
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=F11B7C47-
A6FE-54E9-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/7669
Cycle Dose Drug Form Fallopian
Tube Cancer (NCT00262847)
Header Module
Date form originally completed
Date form amended
Person amending form, last name
Patient Initials
Patient Study ID
COMMENTS
Person Completing Form, Last Name
Treatment Cycle And Modification
Current cycle number
Cycle delayed
Yes
No
Cycle start date (Day 1)
Number of days treatment cycle was delayed
Cycle delayed reason
Non Protocol Illness (Non protocol
illness)
Patient Refusal (Patient refusal)
Personal Reasons (Personal reasons)
Protocol Related Ae (Protocol related
AE)
Scheduling (Scheduling)
Agent name (/Drug)
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Agent Dose level (eg. mg/m2)
Were there any dose modifications or
additions/omissions to protocol treatment (1=Yes,
planned 2 =Yes, unplanned 3=No)
No (No)
Yes, Planned (i.e., The Treatment Was
Changed According To Protocol
Guidelines) (Yes, planned)
Yes, Unplanned (i.e., The Treatment
Change Was Not Part Of Protocol
Guidelines) (Yes, unplanned)
Total dose of agents/drugs for this cycle
Units (eg. mg, kg)
Patient weight
Body surface area
Performance status (Zubrod)
Fully Active, Able To Carry On All Pre-
disease Performance Without
Restriction. (0)
Restricted In Physically Strenuous
Activity But Ambulatory And Able To
Carry Out Work Of A Light Or Sedentary
Nature, E.g., Light Housework, Office
Work. (1)
Ambulatory And Capable Of All Selfcare
But Unable To Carry Out Any Work
Activities. Up And About More Than 50%
Of Waking Hours. (2)
Capable Of Only Limited Selfcare,
Confined To Bed Or Chair More Than
50% Of Waking Hours. (3)
Completely Disabled. Cannot Carry On
Any Selfcare. Totally Confined To Bed Or
Chair. (4)
Pretreatment Hematology And Chemistry
Values
Assessment date
Hemoglobin
Peripheral hematocrit count
Peripheral WBC count
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Peripheral granulocytes count
Peripheral platelet count
PT
PTT
BUN
Creatinine
Creatinine Clearance
SGOT
Bilirubin
Alkaline Phosphatase
Result of CA125
International Normalization Ratio (INR)
Other specify (test)
Other specify (value)
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Lung Cancer NCT01336894 Toxicity - ACOSOG-
Z4099 Adverse Event Form - 3171942v1.0
ACOSOG-Z4099 Adverse Event Form
Surgery With or Without Internal Radiation Therapy
Compared With Stereotactic Body Radiation Therapy in
Treating Patients With High-Risk Stage I Non-Small Cell
Lung Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=97DED333-
F731-8590-E040-BB89AD43483A
All rights reserved. Please visit https://medical-data-
models.org/forms/7670
ACOSOG-Z4099 Adverse Event
Form
Header Module
Protocol Number
Patient ID
Patient Initials (L F M)
Institution Number
Institution
Are data amended (check one if data amended,
please circle in red when using paper forms)
Yes
No
Header Module
Date of evaluation (dd MMM yyyy)
Was patient hospitalized during this reporting
interval (check one)
Yes
No
Unnamed3
CTC Adverse Event Term (Other Not Listed
CTCAE v.4.0)
Abdominal Distension (Abdominal
distension)
Abdominal Infection (Abdominal
infection)
Abdominal Pain (Abdominal pain)
Abdominal Soft Tissue Necrosis
(Abdominal soft tissue necrosis)
Abducens Nerve Disorder (Abducens
nerve disorder)
Accessory Nerve Disorder (Accessory
nerve disorder)
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Acidosis (Acidosis)
Acoustic Nerve Disorder Nos (Acoustic
nerve disorder NOS)
Activated Partial Thromboplastin Time
Prolonged (Activated partial
thromboplastin time prolonged)
Acute Coronary Syndrome (Acute
coronary syndrome)
Acute Kidney Injury (Acute kidney injury)
Adrenal Insufficiency (Adrenal
insufficiency)
Adult Respiratory Distress Syndrome
(Adult respiratory distress syndrome)
Agitation (Agitation)
Akathisia (Akathisia)
Alanine Aminotransferase Increased
(Alanine aminotransferase increased)
Alcohol Intolerance (Alcohol intolerance)
Alkaline Phosphatase Increased
(Alkaline phosphatase increased)
Alkalosis (Alkalosis)
Allergic Reaction (Allergic reaction)
Allergic Rhinitis (Allergic rhinitis)
Alopecia (Alopecia)
Amnesia (Amnesia)
Anal Fistula (Anal fistula)
Anal Hemorrhage (Anal hemorrhage)
Anal Mucositis (Anal mucositis)
Anal Necrosis (Anal necrosis)
Anal Pain (Anal pain)
Anal Stenosis (Anal stenosis)
Anal Ulcer (Anal ulcer)
Anaphylaxis (Anaphylaxis)
Anemia (Anemia)
Ankle Fracture (Ankle fracture)
Anorectal Infection (Anorectal infection)
Anorexia (Anorexia)
Anorgasmia (Anorgasmia)
Anxiety (Anxiety)
Aortic Injury (Aortic injury)
Aortic Valve Disease (Aortic valve
disease)
Aphonia (Aphonia)
Apnea (Apnea)
Appendicitis (Appendicitis)
Appendicitis Perforated (Appendicitis
perforated)
Arachnoiditis (Arachnoiditis)
Arterial Injury (Arterial injury)
Arteritis Infective (Arteritis infective)
Arthralgia (Arthralgia)
Arthritis (Arthritis)
Ascites (Ascites)
Aspartate Aminotransferase Increased
(Aspartate aminotransferase increased)
Aspiration (Aspiration)
Asystole (Asystole)
Ataxia (Ataxia)
Atelectasis (Atelectasis)
Atrial Fibrillation (Atrial fibrillation)
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Atrial Flutter (Atrial flutter)
Atrioventricular Block Complete
(Atrioventricular block complete)
Atrioventricular Block First Degree
(Atrioventricular block first degree)
Autoimmune Disorder (Autoimmune
disorder)
Avascular Necrosis (Avascular necrosis)
Azoospermia (Azoospermia)
Back Pain (Back pain)
Bile Duct Stenosis (Bile duct stenosis)
Biliary Anastomotic Leak (Biliary
anastomotic leak)
Biliary Fistula (Biliary fistula)
Biliary Tract Infection (Biliary tract
infection)
Bladder Anastomotic Leak (Bladder
anastomotic leak)
Bladder Infection (Bladder infection)
Bladder Perforation (Bladder perforation)
Bladder Spasm (Bladder spasm)
Bloating (Bloating)
Blood And Lymphatic System Disorders -
Other, Specify (Blood and lymphatic
system disorders - Other, Specify)
Blood Antidiuretic Hormone Abnormal
(Blood antidiuretic hormone abnormal)
Blood Bilirubin Increased (Blood bilirubin
increased)
Blood Corticotrophin Decreased (Blood
corticotrophin decreased)
Blood Gonadotrophin Abnormal (Blood
gonadotrophin abnormal)
Blood Prolactin Abnormal (Blood
prolactin abnormal)
Blurred Vision (Blurred vision)
Body Odor (Body odor)
Bone Infection (Bone infection)
Bone Marrow Hypocellular (Bone
marrow hypocellular)
Bone Pain (Bone pain)
Brachial Plexopathy (Brachial
plexopathy)
Breast Atrophy (Breast atrophy)
Breast Infection (Breast infection)
Breast Pain (Breast pain)
Bronchial Fistula (Bronchial fistula)
Bronchial Infection (Bronchial infection)
Bronchial Obstruction (Bronchial
obstruction)
Bronchial Stricture (Bronchial stricture)
Bronchopleural Fistula (Bronchopleural
fistula)
Bronchopulmonary Hemorrhage
(Bronchopulmonary hemorrhage)
Bronchospasm (Bronchospasm)
Bruising (Bruising)
Bullous Dermatitis (Bullous dermatitis)
Burn (Burn)
Buttock Pain (Buttock pain)
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Capillary Leak Syndrome (Capillary leak
syndrome)
Carbon Monoxide Diffusing Capacity
Decreased (Carbon monoxide diffusing
capacity decreased)
Cardiac Arrest (Cardiac arrest)
Cardiac Disorders - Other, Specify
(Cardiac disorders - Other, Specify)
Cardiac Troponin I Increased (Cardiac
troponin I increased)
Cardiac Troponin T Increased (Cardiac
troponin T increased)
Cataract (Cataract)
Catheter Related Infection (Catheter
related infection)
Cd4 Lymphocytes Decreased (CD4
lymphocytes decreased)
Cecal Hemorrhage (Cecal hemorrhage)
Cecal Infection (Cecal infection)
Central Nervous System Necrosis
(Central nervous system necrosis)
Cerebrospinal Fluid Leakage
(Cerebrospinal fluid leakage)
Cervicitis Infection (Cervicitis infection)
Cheilitis (Cheilitis)
Chest Pain - Cardiac (Chest pain -
cardiac)
Chest Wall Pain (Chest wall pain)
Chills (Chills)
Cholecystitis (Cholecystitis)
Cholesterol High (Cholesterol high)
Chronic Kidney Disease (Chronic kidney
disease)
Chylothorax (Chylothorax)
Cognitive Disturbance (Cognitive
disturbance)
Colitis (Colitis)
Colonic Fistula (Colonic fistula)
Colonic Hemorrhage (Colonic
hemorrhage)
Colonic Obstruction (Colonic obstruction)
Colonic Perforation (Colonic perforation)
Colonic Stenosis (Colonic stenosis)
Colonic Ulcer (Colonic ulcer)
Concentration Impairment
(Concentration impairment)
Conduction Disorder (Conduction
disorder)
Confusion (Confusion)
Congenital, Familial And Genetic
Disorders - Other, Specify (Congenital,
familial and genetic disorders - Other,
Specify)
Conjunctivitis (Conjunctivitis)
Conjunctivitis Infective (Conjunctivitis
infective)
Constipation (Constipation)
Constrictive Pericarditis (Constrictive
pericarditis)
Corneal Infection (Corneal infection)
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Corneal Ulcer (Corneal ulcer)
Cough (Cough)
Cpk Increased (CPK increased)
Cranial Nerve Infection (Cranial nerve
infection)
Creatinine Increased (Creatinine
increased)
Cushingoid (Cushingoid)
Cystitis Noninfective (Cystitis
noninfective)
Cytokine Release Syndrome (Cytokine
release syndrome)
Death Neonatal (Death neonatal)
Death Nos (Death NOS)
Dehydration (Dehydration)
Delayed Orgasm (Delayed orgasm)
Delayed Puberty (Delayed puberty)
Delirium (Delirium)
Delusions (Delusions)
Dental Caries (Dental caries)
Depressed Level Of Consciousness
(Depressed level of consciousness)
Depression (Depression)
Dermatitis Radiation (Dermatitis
radiation)
Device Related Infection (Device related
infection)
Diarrhea (Diarrhea)
Disseminated Intravascular Coagulation
(Disseminated intravascular coagulation)
Dizziness (Dizziness)
Dry Eye (Dry eye)
Dry Mouth (Dry mouth)
Dry Skin (Dry skin)
Duodenal Fistula (Duodenal fistula)
Duodenal Hemorrhage (Duodenal
hemorrhage)
Duodenal Infection (Duodenal infection)
Duodenal Obstruction (Duodenal
obstruction)
Duodenal Perforation (Duodenal
perforation)
Duodenal Stenosis (Duodenal stenosis)
Duodenal Ulcer (Duodenal ulcer)
Dysarthria (Dysarthria)
Dysesthesia (Dysesthesia)
Dysgeusia (Dysgeusia)
Dysmenorrhea (Dysmenorrhea)
Dyspareunia (Dyspareunia)
Dyspepsia (Dyspepsia)
Dysphagia (Dysphagia)
Dysphasia (Dysphasia)
Dyspnea (Dyspnea)
Ear And Labyrinth Disorders - Other,
Specify (Ear and labyrinth disorders -
Other, Specify)
Ear Pain (Ear pain)
Edema Cerebral (Edema cerebral)
Edema Face (Edema face)
Edema Limbs (Edema limbs)
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Edema Trunk (Edema trunk)
Ejaculation Disorder (Ejaculation
disorder)
Ejection Fraction Decreased (Ejection
fraction decreased)
Electrocardiogram Qt Corrected Interval
Prolonged (Electrocardiogram QT
corrected interval prolonged)
Encephalitis Infection (Encephalitis
infection)
Encephalomyelitis Infection
(Encephalomyelitis infection)
Encephalopathy (Encephalopathy)
Endocarditis Infective (Endocarditis
infective)
Endocrine Disorders - Other, Specify
(Endocrine disorders - Other, Specify)
Endophthalmitis (Endophthalmitis)
Enterocolitis (Enterocolitis)
Enterocolitis Infectious (Enterocolitis
infectious)
Enterovesical Fistula (Enterovesical
fistula)
Epistaxis (Epistaxis)
Erectile Dysfunction (Erectile
dysfunction)
Erythema Multiforme (Erythema
multiforme)
Erythroderma (Erythroderma)
Esophageal Anastomotic Leak
(Esophageal anastomotic leak)
Esophageal Fistula (Esophageal fistula)
Esophageal Hemorrhage (Esophageal
hemorrhage)
Esophageal Infection (Esophageal
infection)
Esophageal Necrosis (Esophageal
necrosis)
Esophageal Obstruction (Esophageal
obstruction)
Esophageal Pain (Esophageal pain)
Esophageal Perforation (Esophageal
perforation)
Esophageal Stenosis (Esophageal
stenosis)
Esophageal Ulcer (Esophageal ulcer)
Esophageal Varices Hemorrhage
(Esophageal varices hemorrhage)
Esophagitis (Esophagitis)
Euphoria (Euphoria)
Exostosis (Exostosis)
External Ear Inflammation (External ear
inflammation)
External Ear Pain (External ear pain)
Extraocular Muscle Paresis (Extraocular
muscle paresis)
Extrapyramidal Disorder (Extrapyramidal
disorder)
Eye Disorders - Other, Specify (Eye
disorders - Other, Specify)
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Eye Infection (Eye infection)
Eye Pain (Eye pain)
Eyelid Function Disorder (Eyelid function
disorder)
Facial Muscle Weakness (Facial muscle
weakness)
Facial Nerve Disorder (Facial nerve
disorder)
Facial Pain (Facial pain)
Fall (Fall)
Fallopian Tube Anastomotic Leak
(Fallopian tube anastomotic leak)
Fallopian Tube Obstruction (Fallopian
tube obstruction)
Fallopian Tube Perforation (Fallopian
tube perforation)
Fallopian Tube Stenosis (Fallopian tube
stenosis)
Fat Atrophy (Fat atrophy)
Fatigue (Fatigue)
Febrile Neutropenia (Febrile
neutropenia)
Fecal Incontinence (Fecal incontinence)
Female Genital Tract Fistula (Female
genital tract fistula)
Feminization Acquired (Feminization
acquired)
Fetal Death (Fetal death)
Fetal Growth Retardation (Fetal growth
retardation)
Fever (Fever)
Fibrinogen Decreased (Fibrinogen
decreased)
Fibrosis Deep Connective Tissue
(Fibrosis deep connective tissue)
Flank Pain (Flank pain)
Flashing Lights (Flashing lights)
Flatulence (Flatulence)
Floaters (Floaters)
Flu Like Symptoms (Flu like symptoms)
Flushing (Flushing)
Forced Expiratory Volume Decreased
(Forced expiratory volume decreased)
Fracture (Fracture)
Gait Disturbance (Gait disturbance)
Gallbladder Fistula (Gallbladder fistula)
Gallbladder Infection (Gallbladder
infection)
Gallbladder Necrosis (Gallbladder
necrosis)
Gallbladder Obstruction (Gallbladder
obstruction)
Gallbladder Pain (Gallbladder pain)
Gallbladder Perforation (Gallbladder
perforation)
Gastric Anastomotic Leak (Gastric
anastomotic leak)
Gastric Fistula (Gastric fistula)
Gastric Hemorrhage (Gastric
hemorrhage)
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Gastric Necrosis (Gastric necrosis)
Gastric Perforation (Gastric perforation)
Gastric Stenosis (Gastric stenosis)
Gastric Ulcer (Gastric ulcer)
Gastritis (Gastritis)
Gastroesophageal Reflux Disease
(Gastroesophageal reflux disease)
Gastrointestinal Anastomotic Leak
(Gastrointestinal anastomotic leak)
Gastrointestinal Disorders - Other,
Specify (Gastrointestinal disorders -
Other, Specify)
Gastrointestinal Fistula (Gastrointestinal
fistula)
Gastrointestinal Pain (Gastrointestinal
pain)
Gastrointestinal Stoma Necrosis
(Gastrointestinal stoma necrosis)
Gastroparesis (Gastroparesis)
General Disorders And Administration
Site Conditions - Other, Specify (General
disorders and administration site
conditions - Other, Specify)
Generalized Muscle Weakness
(Generalized muscle weakness)
Genital Edema (Genital edema)
Ggt Increased (GGT increased)
Gingival Pain (Gingival pain)
Glaucoma (Glaucoma)
Glossopharyngeal Nerve Disorder
(Glossopharyngeal nerve disorder)
Glucose Intolerance (Glucose
intolerance)
Growth Accelerated (Growth
accelerated)
Growth Hormone Abnormal (Growth
hormone abnormal)
Growth Suppression (Growth
suppression)
Gum Infection (Gum infection)
Gynecomastia (Gynecomastia)
Hallucinations (Hallucinations)
Haptoglobin Decreased (Haptoglobin
decreased)
Head Soft Tissue Necrosis (Head soft
tissue necrosis)
Headache (Headache)
Hearing Impaired (Hearing impaired)
Heart Failure (Heart failure)
Hematoma (Hematoma)
Hematosalpinx (Hematosalpinx)
Hematuria (Hematuria)
Hemoglobin Increased (Hemoglobin
increased)
Hemoglobinuria (Hemoglobinuria)
Hemolysis (Hemolysis)
Hemolytic Uremic Syndrome (Hemolytic
uremic syndrome)
Hemorrhoidal Hemorrhage
(Hemorrhoidal hemorrhage)
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Hemorrhoids (Hemorrhoids)
Hepatic Failure (Hepatic failure)
Hepatic Hemorrhage (Hepatic
hemorrhage)
Hepatic Infection (Hepatic infection)
Hepatic Necrosis (Hepatic necrosis)
Hepatic Pain (Hepatic pain)
Hepatitis Viral (Hepatitis viral)
Hepatobiliary Disorders - Other, Specify
(Hepatobiliary disorders - Other, Specify)
Hiccups (Hiccups)
Hip Fracture (Hip fracture)
Hirsutism (Hirsutism)
Hoarseness (Hoarseness)
Hot Flashes (Hot flashes)
Hydrocephalus (Hydrocephalus)
Hypercalcemia (Hypercalcemia)
Hyperglycemia (Hyperglycemia)
Hyperhidrosis (Hyperhidrosis)
Hyperkalemia (Hyperkalemia)
Hypermagnesemia (Hypermagnesemia)
Hypernatremia (Hypernatremia)
Hyperparathyroidism
(Hyperparathyroidism)
Hypersomnia (Hypersomnia)
Hypertension (Hypertension)
Hyperthyroidism (Hyperthyroidism)
Hypertrichosis (Hypertrichosis)
Hypertriglyceridemia
(Hypertriglyceridemia)
Hyperuricemia (Hyperuricemia)
Hypoalbuminemia (Hypoalbuminemia)
Hypocalcemia (Hypocalcemia)
Hypoglossal Nerve Disorder
(Hypoglossal nerve disorder)
Hypoglycemia (Hypoglycemia)
Hypohidrosis (Hypohidrosis)
Hypokalemia (Hypokalemia)
Hypomagnesemia (Hypomagnesemia)
Hyponatremia (Hyponatremia)
Hypoparathyroidism
(Hypoparathyroidism)
Hypophosphatemia (Hypophosphatemia)
Hypotension (Hypotension)
Hypothermia (Hypothermia)
Hypothyroidism (Hypothyroidism)
Hypoxia (Hypoxia)
Ileal Fistula (Ileal fistula)
Ileal Hemorrhage (Ileal hemorrhage)
Ileal Obstruction (Ileal obstruction)
Ileal Perforation (Ileal perforation)
Ileal Stenosis (Ileal stenosis)
Ileal Ulcer (Ileal ulcer)
Ileus (Ileus)
Immune System Disorders - Other,
Specify (Immune system disorders -
Other, Specify)
Infections And Infestations - Other,
Specify (Infections and infestations -
Other, Specify)
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Infective Myositis (Infective myositis)
Infusion Related Reaction (Infusion
related reaction)
Infusion Site Extravasation (Infusion site
extravasation)
Injection Site Reaction (Injection site
reaction)
Injury To Carotid Artery (Injury to carotid
artery)
Injury To Inferior Vena Cava (Injury to
inferior vena cava)
Injury To Jugular Vein (Injury to jugular
vein)
Injury To Superior Vena Cava (Injury to
superior vena cava)
Injury, Poisoning And Procedural
Complications - Other, Specify (Injury,
poisoning and procedural complications -
Other, Specify)
Inr Increased (INR increased)
Insomnia (Insomnia)
Intestinal Stoma Leak (Intestinal stoma
leak)
Intestinal Stoma Obstruction (Intestinal
stoma obstruction)
Intestinal Stoma Site Bleeding (Intestinal
stoma site bleeding)
Intra-abdominal Hemorrhage (Intra-
abdominal hemorrhage)
Intracranial Hemorrhage (Intracranial
hemorrhage)
Intraoperative Arterial Injury
(Intraoperative arterial injury)
Intraoperative Breast Injury
(Intraoperative breast injury)
Intraoperative Cardiac Injury
(Intraoperative cardiac injury)
Intraoperative Ear Injury (Intraoperative
ear injury)
Intraoperative Endocrine Injury
(Intraoperative endocrine injury)
Intraoperative Gastrointestinal Injury
(Intraoperative gastrointestinal injury)
Intraoperative Head And Neck Injury
(Intraoperative head and neck injury)
Intraoperative Hemorrhage
(Intraoperative hemorrhage)
Intraoperative Hepatobiliary Injury
(Intraoperative hepatobiliary injury)
Intraoperative Musculoskeletal Injury
(Intraoperative musculoskeletal injury)
Intraoperative Neurological Injury
(Intraoperative neurological injury)
Intraoperative Ocular Injury
(Intraoperative ocular injury)
Intraoperative Renal Injury
(Intraoperative renal injury)
Intraoperative Reproductive Tract Injury
(Intraoperative reproductive tract injury)
Intraoperative Respiratory Injury
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(Intraoperative respiratory injury)
Intraoperative Skin Injury (Intraoperative
skin injury)
Intraoperative Splenic Injury
(Intraoperative splenic injury)
Intraoperative Urinary Injury
(Intraoperative urinary injury)
Intraoperative Venous Injury
(Intraoperative venous injury)
Investigations - Other, Specify
(Investigations - Other, Specify)
Iron Overload (Iron overload)
Irregular Menstruation (Irregular
menstruation)
Irritability (Irritability)
Ischemia Cerebrovascular (Ischemia
cerebrovascular)
Ivth Nerve Disorder (IVth nerve disorder)
Jejunal Fistula (Jejunal fistula)
Jejunal Hemorrhage (Jejunal
hemorrhage)
Jejunal Obstruction (Jejunal obstruction)
Jejunal Perforation (Jejunal perforation)
Jejunal Stenosis (Jejunal stenosis)
Jejunal Ulcer (Jejunal ulcer)
Joint Effusion (Joint effusion)
Joint Infection (Joint infection)
Joint Range Of Motion Decreased (Joint
range of motion decreased)
Joint Range Of Motion Decreased
Cervical Spine (Joint range of motion
decreased cervical spine)
Joint Range Of Motion Decreased
Lumbar Spine (Joint range of motion
decreased lumbar spine)
Keratitis (Keratitis)
Kidney Anastomotic Leak (Kidney
anastomotic leak)
Kidney Infection (Kidney infection)
Kyphosis (Kyphosis)
Lactation Disorder (Lactation disorder)
Large Intestinal Anastomotic Leak (Large
intestinal anastomotic leak)
Laryngeal Edema (Laryngeal edema)
Laryngeal Fistula (Laryngeal fistula)
Laryngeal Hemorrhage (Laryngeal
hemorrhage)
Laryngeal Inflammation (Laryngeal
inflammation)
Laryngeal Mucositis (Laryngeal
mucositis)
Laryngeal Obstruction (Laryngeal
obstruction)
Laryngeal Stenosis (Laryngeal stenosis)
Laryngitis (Laryngitis)
Laryngopharyngeal Dysesthesia
(Laryngopharyngeal dysesthesia)
Laryngospasm (Laryngospasm)
Left Ventricular Systolic Dysfunction (Left
ventricular systolic dysfunction)
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Lethargy (Lethargy)
Leukemia Secondary To Oncology
Chemotherapy (Leukemia secondary to
oncology chemotherapy)
Leukocytosis (Leukocytosis)
Leukoencephalopathy
(Leukoencephalopathy)
Libido Decreased (Libido decreased)
Libido Increased (Libido increased)
Lip Infection (Lip infection)
Lip Pain (Lip pain)
Lipase Increased (Lipase increased)
Lipohypertrophy (Lipohypertrophy)
Localized Edema (Localized edema)
Lordosis (Lordosis)
Lower Gastrointestinal Hemorrhage
(Lower gastrointestinal hemorrhage)
Lung Infection (Lung infection)
Lymph Gland Infection (Lymph gland
infection)
Lymph Leakage (Lymph leakage)
Lymph Node Pain (Lymph node pain)
Lymphedema (Lymphedema)
Lymphocele (Lymphocele)
Lymphocyte Count Decreased
(Lymphocyte count decreased)
Lymphocyte Count Increased
(Lymphocyte count increased)
Malabsorption (Malabsorption)
Malaise (Malaise)
Mania (Mania)
Mediastinal Hemorrhage (Mediastinal
hemorrhage)
Mediastinal Infection (Mediastinal
infection)
Memory Impairment (Memory
impairment)
Meningismus (Meningismus)
Meningitis (Meningitis)
Menopause (Menopause)
Menorrhagia (Menorrhagia)
Metabolism And Nutrition Disorders -
Other, Specify (Metabolism and nutrition
disorders - Other, Specify)
Middle Ear Inflammation (Middle ear
inflammation)
Mitral Valve Disease (Mitral valve
disease)
Mobitz (type) Ii Atrioventricular Block
(Mobitz (type) II atrioventricular block)
Mobitz Type I (Mobitz type I)
Movements Involuntary (Movements
involuntary)
Mucosal Infection (Mucosal infection)
Mucositis Oral (Mucositis oral)
Multi-organ Failure (Multi-organ failure)
Muscle Weakness Left-sided (Muscle
weakness left-sided)
Muscle Weakness Lower Limb (Muscle
weakness lower limb)
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Muscle Weakness Right-sided (Muscle
weakness right-sided)
Muscle Weakness Trunk (Muscle
weakness trunk)
Muscle Weakness Upper Limb (Muscle
weakness upper limb)
Musculoskeletal And Connective Tissue
Disorder - Other, Specify
(Musculoskeletal and connective tissue
disorders - Other, Specify)
Musculoskeletal Deformity
(Musculoskeletal deformity)
Myalgia (Myalgia)
Myelitis (Myelitis)
Myelodysplastic Syndrome
(Myelodysplastic syndrome)
Myocardial Infarction (Myocardial
infarction)
Myocarditis (Myocarditis)
Myositis (Myositis)
Nail Discoloration (Nail discoloration)
Nail Infection (Nail infection)
Nail Loss (Nail loss)
Nail Ridging (Nail ridging)
Nasal Congestion (Nasal congestion)
Nausea (Nausea)
Neck Edema (Neck edema)
Neck Pain (Neck pain)
Neck Soft Tissue Necrosis (Neck soft
tissue necrosis)
Neoplasms Benign, Malignant And
Unspecified (incl Cysts And Polyps) -
Other, Specify (Neoplasms benign,
malignant and unspecified (incl cysts and
polyps) - Other, Specify)
Nervous System Disorders - Other,
Specify (Nervous system disorders -
Other, Specify)
Neuralgia (Neuralgia)
Neutrophil Count Decreased (Neutrophil
count decreased)
Night Blindness (Night blindness)
Nipple Deformity (Nipple deformity)
Non-cardiac Chest Pain (Non-cardiac
chest pain)
Nystagmus (Nystagmus)
Obesity (Obesity)
Obstruction Gastric (Obstruction gastric)
Oculomotor Nerve Disorder (Oculomotor
nerve disorder)
Olfactory Nerve Disorder (Olfactory
nerve disorder)
Oligospermia (Oligospermia)
Optic Nerve Disorder (Optic nerve
disorder)
Oral Cavity Fistula (Oral cavity fistula)
Oral Dysesthesia (Oral dysesthesia)
Oral Hemorrhage (Oral hemorrhage)
Oral Pain (Oral pain)
Osteonecrosis Of Jaw (Osteonecrosis of
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jaw)
Osteoporosis (Osteoporosis)
Otitis Externa (Otitis externa)
Otitis Media (Otitis media)
Ovarian Hemorrhage (Ovarian
hemorrhage)
Ovarian Infection (Ovarian infection)
Ovarian Rupture (Ovarian rupture)
Ovulation Pain (Ovulation pain)
Pain (Pain)
Pain In Extremity (Pain in extremity)
Pain Of Skin (Pain of skin)
Palmar-plantar Erythrodysesthesia
Syndrome (Palmar-plantar
erythrodysesthesia syndrome)
Palpitations (Palpitations)
Pancreas Infection (Pancreas infection)
Pancreatic Anastomotic Leak (Pancreatic
anastomotic leak)
Pancreatic Duct Stenosis (Pancreatic
duct stenosis)
Pancreatic Enzymes Decreased
(Pancreatic enzymes decreased)
Pancreatic Fistula (Pancreatic fistula)
Pancreatic Hemorrhage (Pancreatic
hemorrhage)
Pancreatic Necrosis (Pancreatic
necrosis)
Pancreatitis (Pancreatitis)
Papilledema (Papilledema)
Papulopustular Rash (Papulopustular
rash)
Paresthesia (Paresthesia)
Paronychia (Paronychia)
Paroxysmal Atrial Tachycardia
(Paroxysmal atrial tachycardia)
Pelvic Floor Muscle Weakness (Pelvic
floor muscle weakness)
Pelvic Infection (Pelvic infection)
Pelvic Pain (Pelvic pain)
Pelvic Soft Tissue Necrosis (Pelvic soft
tissue necrosis)
Penile Infection (Penile infection)
Penile Pain (Penile pain)
Perforation Bile Duct (Perforation bile
duct)
Pericardial Effusion (Pericardial effusion)
Pericardial Tamponade (Pericardial
tamponade)
Pericarditis (Pericarditis)
Perineal Pain (Perineal pain)
Periodontal Disease (Periodontal
disease)
Periorbital Edema (Periorbital edema)
Periorbital Infection (Periorbital infection)
Peripheral Ischemia (Peripheral
ischemia)
Peripheral Motor Neuropathy (Peripheral
motor neuropathy)
Peripheral Nerve Infection (Peripheral
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nerve infection)
Peripheral Sensory Neuropathy
(Peripheral sensory neuropathy)
Peritoneal Infection (Peritoneal infection)
Peritoneal Necrosis (Peritoneal necrosis)
Personality Change (Personality change)
Phantom Pain (Phantom pain)
Pharyngeal Anastomotic Leak
(Pharyngeal anastomotic leak)
Pharyngeal Fistula (Pharyngeal fistula)
Pharyngeal Hemorrhage (Pharyngeal
hemorrhage)
Pharyngeal Mucositis (Pharyngeal
mucositis)
Pharyngeal Necrosis (Pharyngeal
necrosis)
Pharyngeal Stenosis (Pharyngeal
stenosis)
Pharyngitis (Pharyngitis)
Pharyngolaryngeal Pain
(Pharyngolaryngeal pain)
Phlebitis (Phlebitis)
Phlebitis Infective (Phlebitis infective)
Photophobia (Photophobia)
Photosensitivity (Photosensitivity)
Platelet Count Decreased (Platelet count
decreased)
Pleural Effusion (Pleural effusion)
Pleural Hemorrhage (Pleural
hemorrhage)
Pleural Infection (Pleural infection)
Pleuritic Pain (Pleuritic pain)
Pneumonitis (Pneumonitis)
Pneumothorax (Pneumothorax)
Portal Hypertension (Portal
hypertension)
Portal Vein Thrombosis (Portal vein
thrombosis)
Postnasal Drip (Postnasal drip)
Postoperative Hemorrhage
(Postoperative hemorrhage)
Postoperative Thoracic Procedure
Complication (Postoperative thoracic
procedure complication)
Precocious Puberty (Precocious
puberty)
Pregnancy, Puerperium And Perinatal
Conditions - Other, Specify (Pregnancy,
puerperium and perinatal conditions -
Other, Specify)
Premature Delivery (Premature delivery)
Premature Menopause (Premature
menopause)
Presyncope (Presyncope)
Proctitis (Proctitis)
Productive Cough (Productive cough)
Prolapse Of Intestinal Stoma (Prolapse
of intestinal stoma)
Prolapse Of Urostomy (Prolapse of
urostomy)
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Prostate Infection (Prostate infection)
Prostatic Hemorrhage (Prostatic
hemorrhage)
Prostatic Obstruction (Prostatic
obstruction)
Prostatic Pain (Prostatic pain)
Proteinuria (Proteinuria)
Pruritus (Pruritus)
Psychiatric Disorders - Other, Specify
(Psychiatric disorders - Other, Specify)
Psychosis (Psychosis)
Pulmonary Edema (Pulmonary edema)
Pulmonary Fibrosis (Pulmonary fibrosis)
Pulmonary Fistula (Pulmonary fistula)
Pulmonary Hypertension (Pulmonary
hypertension)
Pulmonary Valve Disease (Pulmonary
valve disease)
Purpura (Purpura)
Pyramidal Tract Syndrome (Pyramidal
tract syndrome)
Radiation Recall Reaction (dermatologic)
(Radiation recall reaction (dermatologic))
Radiculitis (Radiculitis)
Rash Acneiform (Rash acneiform)
Rash Maculo-papular (Rash maculo-
papular)
Rash Pustular (Rash pustular)
Rectal Anastomotic Leak (Rectal
anastomotic leak)
Rectal Fistula (Rectal fistula)
Rectal Hemorrhage (Rectal hemorrhage)
Rectal Mucositis (Rectal mucositis)
Rectal Necrosis (Rectal necrosis)
Rectal Obstruction (Rectal obstruction)
Rectal Pain (Rectal pain)
Rectal Perforation (Rectal perforation)
Rectal Stenosis (Rectal stenosis)
Rectal Ulcer (Rectal ulcer)
Recurrent Laryngeal Nerve Palsy
(Recurrent laryngeal nerve palsy)
Renal And Urinary Disorders - Other,
Specify (Renal and urinary disorders -
Other, Specify)
Renal Calculi (Renal calculi)
Renal Colic (Renal colic)
Renal Hemorrhage (Renal hemorrhage)
Reproductive System And Breast
Disorders - Other, Specify (Reproductive
system and breast disorders - Other,
Specify)
Respiratory Failure (Respiratory failure)
Respiratory, Thoracic And Mediastinal
Disorders - Other, Specify (Respiratory,
thoracic and mediastinal disorders -
Other, Specify)
Restlessness (Restlessness)
Restrictive Cardiomyopathy (Restrictive
cardiomyopathy)
Retinal Detachment (Retinal
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detachment)
Retinal Tear (Retinal tear)
Retinal Vascular Disorder (Retinal
vascular disorder)
Retinoic Acid Syndrome (Retinoic acid
syndrome)
Retinopathy (Retinopathy)
Retroperitoneal Hemorrhage
(Retroperitoneal hemorrhage)
Reversible Posterior
Leukoencephalopathy Syndrome
(Reversible posterior
leukoencephalopathy syndrome)
Rhinitis Infective (Rhinitis infective)
Right Ventricular Dysfunction (Right
ventricular dysfunction)
Salivary Duct Inflammation (Salivary duct
inflammation)
Salivary Gland Fistula (Salivary gland
fistula)
Salivary Gland Infection (Salivary gland
infection)
Scalp Pain (Scalp pain)
Scleral Disorder (Scleral disorder)
Scoliosis (Scoliosis)
Scrotal Infection (Scrotal infection)
Scrotal Pain (Scrotal pain)
Seizure (Seizure)
Sepsis (Sepsis)
Seroma (Seroma)
Serum Amylase Increased (Serum
amylase increased)
Serum Sickness (Serum sickness)
Sick Sinus Syndrome (Sick sinus
syndrome)
Sinus Bradycardia (Sinus bradycardia)
Sinus Disorder (Sinus disorder)
Sinus Pain (Sinus pain)
Sinus Tachycardia (Sinus tachycardia)
Sinusitis (Sinusitis)
Skin And Subcutaneous Tissue
Disorders - Other, Specify (Skin and
subcutaneous tissue disorders - Other,
Specify)
Skin Atrophy (Skin atrophy)
Skin Hyperpigmentation (Skin
hyperpigmentation)
Skin Hypopigmentation (Skin
hypopigmentation)
Skin Induration (Skin induration)
Skin Infection (Skin infection)
Skin Ulceration (Skin ulceration)
Sleep Apnea (Sleep apnea)
Small Intestinal Anastomotic Leak (Small
intestinal anastomotic leak)
Small Intestinal Mucositis (Small
intestinal mucositis)
Small Intestinal Obstruction (Small
intestinal obstruction)
Small Intestinal Perforation (Small
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intestinal perforation)
Small Intestinal Stenosis (Small intestinal
stenosis)
Small Intestine Infection (Small intestine
infection)
Small Intestine Ulcer (Small intestine
ulcer)
Sneezing (Sneezing)
Social Circumstances - Other, Specify
(Social circumstances - Other, Specify)
Soft Tissue Infection (Soft tissue
infection)
Soft Tissue Necrosis Lower Limb (Soft
tissue necrosis lower limb)
Soft Tissue Necrosis Upper Limb (Soft
tissue necrosis upper limb)
Somnolence (Somnolence)
Sore Throat (Sore throat)
Spasticity (Spasticity)
Spermatic Cord Anastomotic Leak
(Spermatic cord anastomotic leak)
Spermatic Cord Hemorrhage (Spermatic
cord hemorrhage)
Spermatic Cord Obstruction (Spermatic
cord obstruction)
Spinal Fracture (Spinal fracture)
Spleen Disorder (Spleen disorder)
Splenic Infection (Splenic infection)
Stenosis Of Gastrointestinal Stoma
(Stenosis of gastrointestinal stoma)
Stevens-johnson Syndrome (Stevens-
Johnson syndrome)
Stoma Site Infection (Stoma site
infection)
Stomach Pain (Stomach pain)
Stomal Ulcer (Stomal ulcer)
Stridor (Stridor)
Stroke (Stroke)
Sudden Death Nos (Sudden death NOS)
Suicidal Ideation (Suicidal ideation)
Suicide Attempt (Suicide attempt)
Superficial Soft Tissue Fibrosis
(Superficial soft tissue fibrosis)
Superficial Thrombophlebitis (Superficial
thrombophlebitis)
Superior Vena Cava Syndrome (Superior
vena cava syndrome)
Supraventricular Tachycardia
(Supraventricular tachycardia)
Surgical And Medical Procedures -
Other, Specify (Surgical and medical
procedures - Other, Specify)
Syncope (Syncope)
Telangiectasia (Telangiectasia)
Testicular Disorder (Testicular disorder)
Testicular Hemorrhage (Testicular
hemorrhage)
Testicular Pain (Testicular pain)
Thromboembolic Event
(Thromboembolic event)
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Thrombotic Thrombocytopenic Purpura
(Thrombotic thrombocytopenic purpura)
Tinnitus (Tinnitus)
Tooth Development Disorder (Tooth
development disorder)
Tooth Discoloration (Tooth discoloration)
Tooth Infection (Tooth infection)
Toothache (Toothache)
Toxic Epidermal Necrolysis (Toxic
epidermal necrolysis)
Tracheal Fistula (Tracheal fistula)
Tracheal Hemorrhage (Tracheal
hemorrhage)
Tracheal Mucositis (Tracheal mucositis)
Tracheal Obstruction (Tracheal
obstruction)
Tracheal Stenosis (Tracheal stenosis)
Tracheitis (Tracheitis)
Tracheostomy Site Bleeding
(Tracheostomy site bleeding)
Transient Ischemic Attacks (Transient
ischemic attacks)
Treatment Related Secondary
Malignancy (Treatment related
secondary malignancy)
Tremor (Tremor)
Tricuspid Valve Disease (Tricuspid valve
disease)
Trigeminal Nerve Disorder (Trigeminal
nerve disorder)
Trismus (Trismus)
Tumor Lysis Syndrome (Tumor lysis
syndrome)
Tumor Pain (Tumor pain)
Typhlitis (Typhlitis)
Unequal Limb Length (Unequal limb
length)
Unintended Pregnancy (Unintended
pregnancy)
Upper Gastrointestinal Hemorrhage
(Upper gastrointestinal hemorrhage)
Upper Respiratory Infection (Upper
respiratory infection)
Ureteric Anastomotic Leak (Ureteric
anastomotic leak)
Urethral Anastomotic Leak (Urethral
anastomotic leak)
Urethral Infection (Urethral infection)
Urinary Fistula (Urinary fistula)
Urinary Frequency (Urinary frequency)
Urinary Incontinence (Urinary
incontinence)
Urinary Retention (Urinary retention)
Urinary Tract Infection (Urinary tract
infection)
Urinary Tract Obstruction (Urinary tract
obstruction)
Urinary Tract Pain (Urinary tract pain)
Urinary Urgency (Urinary urgency)
Urine Discoloration (Urine discoloration)
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Urine Output Decreased (Urine output
decreased)
Urostomy Leak (Urostomy leak)
Urostomy Obstruction (Urostomy
obstruction)
Urostomy Site Bleeding (Urostomy site
bleeding)
Urostomy Stenosis (Urostomy stenosis)
Urticaria (Urticaria)
Uterine Anastomotic Leak (Uterine
anastomotic leak)
Uterine Fistula (Uterine fistula)
Uterine Hemorrhage (Uterine
hemorrhage)
Uterine Infection (Uterine infection)
Uterine Obstruction (Uterine obstruction)
Uterine Pain (Uterine pain)
Uterine Perforation (Uterine perforation)
Uveitis (Uveitis)
Vaginal Anastomotic Leak (Vaginal
anastomotic leak)
Vaginal Discharge (Vaginal discharge)
Vaginal Dryness (Vaginal dryness)
Vaginal Fistula (Vaginal fistula)
Vaginal Hemorrhage (Vaginal
hemorrhage)
Vaginal Infection (Vaginal infection)
Vaginal Inflammation (Vaginal
inflammation)
Vaginal Obstruction (Vaginal obstruction)
Vaginal Pain (Vaginal pain)
Vaginal Perforation (Vaginal perforation)
Vaginal Stricture (Vaginal stricture)
Vaginismus (Vaginismus)
Vagus Nerve Disorder (Vagus nerve
disorder)
Vas Deferens Anastomotic Leak (Vas
deferens anastomotic leak)
Vascular Access Complication (Vascular
access complication)
Vascular Disorders - Other, Specify
(Vascular disorders - Other, Specify)
Vasculitis (Vasculitis)
Vasovagal Reaction (Vasovagal reaction)
Venous Injury (Venous injury)
Ventricular Arrhythmia (Ventricular
arrhythmia)
Ventricular Fibrillation (Ventricular
fibrillation)
Ventricular Tachycardia (Ventricular
tachycardia)
Vertigo (Vertigo)
Vestibular Disorder (Vestibular disorder)
Virilization (Virilization)
Visceral Arterial Ischemia (Visceral
arterial ischemia)
Vital Capacity Abnormal (Vital capacity
abnormal)
Vitreous Hemorrhage (Vitreous
hemorrhage)
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Voice Alteration (Voice alteration)
Vomiting (Vomiting)
Vulval Infection (Vulval infection)
Watering Eyes (Watering eyes)
Weight Gain (Weight gain)
Weight Loss (Weight loss)
Wheezing (Wheezing)
White Blood Cell Decreased (White
blood cell decreased)
Wolff-parkinson-white Syndrome (Wolff-
Parkinson-White syndrome)
Wound Complication (Wound
complication)
Wound Dehiscence (Wound dehiscence)
Wound Infection (Wound infection)
Wrist Fracture (Wrist fracture)
MedDRA Code (v.12.0 must be completed)
CTC Adverse Event Grade (highest grade this
cycle)
Mild Adverse Event (1)
Moderate Adverse Event (2)
Severe Adverse Event (3)
Life Threatening Adverse Event (4)
Death Related To Adverse Event (5)
CTC AE Attribution Code
Definite (Definite)
Possible (Possible)
Probable (Probable)
Unlikely (Unlikely)
Unrelated (Unrelated)
Has an Adverse Event Expedited Report been
submitted? (See Section 8 of the protocol)
Yes
No
Surgical Complication
Were adverse events assessed during this report
period (other check one)
No (No)
Yes, And Reportable Adverse Events
Occurred (Yes, and reportable adverse
events occurred)
Yes, But No Reportable Adverse Events
Occurred (Yes, but no reportable adverse
events occurred)
CTC Adverse Event Term (Other Not Listed
CTCAE v.4.0)
Abdominal Distension (Abdominal
distension)
Abdominal Infection (Abdominal
infection)
Abdominal Pain (Abdominal pain)
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Abdominal Soft Tissue Necrosis
(Abdominal soft tissue necrosis)
Abducens Nerve Disorder (Abducens
nerve disorder)
Accessory Nerve Disorder (Accessory
nerve disorder)
Acidosis (Acidosis)
Acoustic Nerve Disorder Nos (Acoustic
nerve disorder NOS)
Activated Partial Thromboplastin Time
Prolonged (Activated partial
thromboplastin time prolonged)
Acute Coronary Syndrome (Acute
coronary syndrome)
Acute Kidney Injury (Acute kidney injury)
Adrenal Insufficiency (Adrenal
insufficiency)
Adult Respiratory Distress Syndrome
(Adult respiratory distress syndrome)
Agitation (Agitation)
Akathisia (Akathisia)
Alanine Aminotransferase Increased
(Alanine aminotransferase increased)
Alcohol Intolerance (Alcohol intolerance)
Alkaline Phosphatase Increased
(Alkaline phosphatase increased)
Alkalosis (Alkalosis)
Allergic Reaction (Allergic reaction)
Allergic Rhinitis (Allergic rhinitis)
Alopecia (Alopecia)
Amnesia (Amnesia)
Anal Fistula (Anal fistula)
Anal Hemorrhage (Anal hemorrhage)
Anal Mucositis (Anal mucositis)
Anal Necrosis (Anal necrosis)
Anal Pain (Anal pain)
Anal Stenosis (Anal stenosis)
Anal Ulcer (Anal ulcer)
Anaphylaxis (Anaphylaxis)
Anemia (Anemia)
Ankle Fracture (Ankle fracture)
Anorectal Infection (Anorectal infection)
Anorexia (Anorexia)
Anorgasmia (Anorgasmia)
Anxiety (Anxiety)
Aortic Injury (Aortic injury)
Aortic Valve Disease (Aortic valve
disease)
Aphonia (Aphonia)
Apnea (Apnea)
Appendicitis (Appendicitis)
Appendicitis Perforated (Appendicitis
perforated)
Arachnoiditis (Arachnoiditis)
Arterial Injury (Arterial injury)
Arteritis Infective (Arteritis infective)
Arthralgia (Arthralgia)
Arthritis (Arthritis)
Ascites (Ascites)
Aspartate Aminotransferase Increased
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(Aspartate aminotransferase increased)
Aspiration (Aspiration)
Asystole (Asystole)
Ataxia (Ataxia)
Atelectasis (Atelectasis)
Atrial Fibrillation (Atrial fibrillation)
Atrial Flutter (Atrial flutter)
Atrioventricular Block Complete
(Atrioventricular block complete)
Atrioventricular Block First Degree
(Atrioventricular block first degree)
Autoimmune Disorder (Autoimmune
disorder)
Avascular Necrosis (Avascular necrosis)
Azoospermia (Azoospermia)
Back Pain (Back pain)
Bile Duct Stenosis (Bile duct stenosis)
Biliary Anastomotic Leak (Biliary
anastomotic leak)
Biliary Fistula (Biliary fistula)
Biliary Tract Infection (Biliary tract
infection)
Bladder Anastomotic Leak (Bladder
anastomotic leak)
Bladder Infection (Bladder infection)
Bladder Perforation (Bladder perforation)
Bladder Spasm (Bladder spasm)
Bloating (Bloating)
Blood And Lymphatic System Disorders -
Other, Specify (Blood and lymphatic
system disorders - Other, Specify)
Blood Antidiuretic Hormone Abnormal
(Blood antidiuretic hormone abnormal)
Blood Bilirubin Increased (Blood bilirubin
increased)
Blood Corticotrophin Decreased (Blood
corticotrophin decreased)
Blood Gonadotrophin Abnormal (Blood
gonadotrophin abnormal)
Blood Prolactin Abnormal (Blood
prolactin abnormal)
Blurred Vision (Blurred vision)
Body Odor (Body odor)
Bone Infection (Bone infection)
Bone Marrow Hypocellular (Bone
marrow hypocellular)
Bone Pain (Bone pain)
Brachial Plexopathy (Brachial
plexopathy)
Breast Atrophy (Breast atrophy)
Breast Infection (Breast infection)
Breast Pain (Breast pain)
Bronchial Fistula (Bronchial fistula)
Bronchial Infection (Bronchial infection)
Bronchial Obstruction (Bronchial
obstruction)
Bronchial Stricture (Bronchial stricture)
Bronchopleural Fistula (Bronchopleural
fistula)
Bronchopulmonary Hemorrhage
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(Bronchopulmonary hemorrhage)
Bronchospasm (Bronchospasm)
Bruising (Bruising)
Bullous Dermatitis (Bullous dermatitis)
Burn (Burn)
Buttock Pain (Buttock pain)
Capillary Leak Syndrome (Capillary leak
syndrome)
Carbon Monoxide Diffusing Capacity
Decreased (Carbon monoxide diffusing
capacity decreased)
Cardiac Arrest (Cardiac arrest)
Cardiac Disorders - Other, Specify
(Cardiac disorders - Other, Specify)
Cardiac Troponin I Increased (Cardiac
troponin I increased)
Cardiac Troponin T Increased (Cardiac
troponin T increased)
Cataract (Cataract)
Catheter Related Infection (Catheter
related infection)
Cd4 Lymphocytes Decreased (CD4
lymphocytes decreased)
Cecal Hemorrhage (Cecal hemorrhage)
Cecal Infection (Cecal infection)
Central Nervous System Necrosis
(Central nervous system necrosis)
Cerebrospinal Fluid Leakage
(Cerebrospinal fluid leakage)
Cervicitis Infection (Cervicitis infection)
Cheilitis (Cheilitis)
Chest Pain - Cardiac (Chest pain -
cardiac)
Chest Wall Pain (Chest wall pain)
Chills (Chills)
Cholecystitis (Cholecystitis)
Cholesterol High (Cholesterol high)
Chronic Kidney Disease (Chronic kidney
disease)
Chylothorax (Chylothorax)
Cognitive Disturbance (Cognitive
disturbance)
Colitis (Colitis)
Colonic Fistula (Colonic fistula)
Colonic Hemorrhage (Colonic
hemorrhage)
Colonic Obstruction (Colonic obstruction)
Colonic Perforation (Colonic perforation)
Colonic Stenosis (Colonic stenosis)
Colonic Ulcer (Colonic ulcer)
Concentration Impairment
(Concentration impairment)
Conduction Disorder (Conduction
disorder)
Confusion (Confusion)
Congenital, Familial And Genetic
Disorders - Other, Specify (Congenital,
familial and genetic disorders - Other,
Specify)
Conjunctivitis (Conjunctivitis)
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Conjunctivitis Infective (Conjunctivitis
infective)
Constipation (Constipation)
Constrictive Pericarditis (Constrictive
pericarditis)
Corneal Infection (Corneal infection)
Corneal Ulcer (Corneal ulcer)
Cough (Cough)
Cpk Increased (CPK increased)
Cranial Nerve Infection (Cranial nerve
infection)
Creatinine Increased (Creatinine
increased)
Cushingoid (Cushingoid)
Cystitis Noninfective (Cystitis
noninfective)
Cytokine Release Syndrome (Cytokine
release syndrome)
Death Neonatal (Death neonatal)
Death Nos (Death NOS)
Dehydration (Dehydration)
Delayed Orgasm (Delayed orgasm)
Delayed Puberty (Delayed puberty)
Delirium (Delirium)
Delusions (Delusions)
Dental Caries (Dental caries)
Depressed Level Of Consciousness
(Depressed level of consciousness)
Depression (Depression)
Dermatitis Radiation (Dermatitis
radiation)
Device Related Infection (Device related
infection)
Diarrhea (Diarrhea)
Disseminated Intravascular Coagulation
(Disseminated intravascular coagulation)
Dizziness (Dizziness)
Dry Eye (Dry eye)
Dry Mouth (Dry mouth)
Dry Skin (Dry skin)
Duodenal Fistula (Duodenal fistula)
Duodenal Hemorrhage (Duodenal
hemorrhage)
Duodenal Infection (Duodenal infection)
Duodenal Obstruction (Duodenal
obstruction)
Duodenal Perforation (Duodenal
perforation)
Duodenal Stenosis (Duodenal stenosis)
Duodenal Ulcer (Duodenal ulcer)
Dysarthria (Dysarthria)
Dysesthesia (Dysesthesia)
Dysgeusia (Dysgeusia)
Dysmenorrhea (Dysmenorrhea)
Dyspareunia (Dyspareunia)
Dyspepsia (Dyspepsia)
Dysphagia (Dysphagia)
Dysphasia (Dysphasia)
Dyspnea (Dyspnea)
Ear And Labyrinth Disorders - Other,
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Specify (Ear and labyrinth disorders -
Other, Specify)
Ear Pain (Ear pain)
Edema Cerebral (Edema cerebral)
Edema Face (Edema face)
Edema Limbs (Edema limbs)
Edema Trunk (Edema trunk)
Ejaculation Disorder (Ejaculation
disorder)
Ejection Fraction Decreased (Ejection
fraction decreased)
Electrocardiogram Qt Corrected Interval
Prolonged (Electrocardiogram QT
corrected interval prolonged)
Encephalitis Infection (Encephalitis
infection)
Encephalomyelitis Infection
(Encephalomyelitis infection)
Encephalopathy (Encephalopathy)
Endocarditis Infective (Endocarditis
infective)
Endocrine Disorders - Other, Specify
(Endocrine disorders - Other, Specify)
Endophthalmitis (Endophthalmitis)
Enterocolitis (Enterocolitis)
Enterocolitis Infectious (Enterocolitis
infectious)
Enterovesical Fistula (Enterovesical
fistula)
Epistaxis (Epistaxis)
Erectile Dysfunction (Erectile
dysfunction)
Erythema Multiforme (Erythema
multiforme)
Erythroderma (Erythroderma)
Esophageal Anastomotic Leak
(Esophageal anastomotic leak)
Esophageal Fistula (Esophageal fistula)
Esophageal Hemorrhage (Esophageal
hemorrhage)
Esophageal Infection (Esophageal
infection)
Esophageal Necrosis (Esophageal
necrosis)
Esophageal Obstruction (Esophageal
obstruction)
Esophageal Pain (Esophageal pain)
Esophageal Perforation (Esophageal
perforation)
Esophageal Stenosis (Esophageal
stenosis)
Esophageal Ulcer (Esophageal ulcer)
Esophageal Varices Hemorrhage
(Esophageal varices hemorrhage)
Esophagitis (Esophagitis)
Euphoria (Euphoria)
Exostosis (Exostosis)
External Ear Inflammation (External ear
inflammation)
External Ear Pain (External ear pain)
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Extraocular Muscle Paresis (Extraocular
muscle paresis)
Extrapyramidal Disorder (Extrapyramidal
disorder)
Eye Disorders - Other, Specify (Eye
disorders - Other, Specify)
Eye Infection (Eye infection)
Eye Pain (Eye pain)
Eyelid Function Disorder (Eyelid function
disorder)
Facial Muscle Weakness (Facial muscle
weakness)
Facial Nerve Disorder (Facial nerve
disorder)
Facial Pain (Facial pain)
Fall (Fall)
Fallopian Tube Anastomotic Leak
(Fallopian tube anastomotic leak)
Fallopian Tube Obstruction (Fallopian
tube obstruction)
Fallopian Tube Perforation (Fallopian
tube perforation)
Fallopian Tube Stenosis (Fallopian tube
stenosis)
Fat Atrophy (Fat atrophy)
Fatigue (Fatigue)
Febrile Neutropenia (Febrile
neutropenia)
Fecal Incontinence (Fecal incontinence)
Female Genital Tract Fistula (Female
genital tract fistula)
Feminization Acquired (Feminization
acquired)
Fetal Death (Fetal death)
Fetal Growth Retardation (Fetal growth
retardation)
Fever (Fever)
Fibrinogen Decreased (Fibrinogen
decreased)
Fibrosis Deep Connective Tissue
(Fibrosis deep connective tissue)
Flank Pain (Flank pain)
Flashing Lights (Flashing lights)
Flatulence (Flatulence)
Floaters (Floaters)
Flu Like Symptoms (Flu like symptoms)
Flushing (Flushing)
Forced Expiratory Volume Decreased
(Forced expiratory volume decreased)
Fracture (Fracture)
Gait Disturbance (Gait disturbance)
Gallbladder Fistula (Gallbladder fistula)
Gallbladder Infection (Gallbladder
infection)
Gallbladder Necrosis (Gallbladder
necrosis)
Gallbladder Obstruction (Gallbladder
obstruction)
Gallbladder Pain (Gallbladder pain)
Gallbladder Perforation (Gallbladder
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perforation)
Gastric Anastomotic Leak (Gastric
anastomotic leak)
Gastric Fistula (Gastric fistula)
Gastric Hemorrhage (Gastric
hemorrhage)
Gastric Necrosis (Gastric necrosis)
Gastric Perforation (Gastric perforation)
Gastric Stenosis (Gastric stenosis)
Gastric Ulcer (Gastric ulcer)
Gastritis (Gastritis)
Gastroesophageal Reflux Disease
(Gastroesophageal reflux disease)
Gastrointestinal Anastomotic Leak
(Gastrointestinal anastomotic leak)
Gastrointestinal Disorders - Other,
Specify (Gastrointestinal disorders -
Other, Specify)
Gastrointestinal Fistula (Gastrointestinal
fistula)
Gastrointestinal Pain (Gastrointestinal
pain)
Gastrointestinal Stoma Necrosis
(Gastrointestinal stoma necrosis)
Gastroparesis (Gastroparesis)
General Disorders And Administration
Site Conditions - Other, Specify (General
disorders and administration site
conditions - Other, Specify)
Generalized Muscle Weakness
(Generalized muscle weakness)
Genital Edema (Genital edema)
Ggt Increased (GGT increased)
Gingival Pain (Gingival pain)
Glaucoma (Glaucoma)
Glossopharyngeal Nerve Disorder
(Glossopharyngeal nerve disorder)
Glucose Intolerance (Glucose
intolerance)
Growth Accelerated (Growth
accelerated)
Growth Hormone Abnormal (Growth
hormone abnormal)
Growth Suppression (Growth
suppression)
Gum Infection (Gum infection)
Gynecomastia (Gynecomastia)
Hallucinations (Hallucinations)
Haptoglobin Decreased (Haptoglobin
decreased)
Head Soft Tissue Necrosis (Head soft
tissue necrosis)
Headache (Headache)
Hearing Impaired (Hearing impaired)
Heart Failure (Heart failure)
Hematoma (Hematoma)
Hematosalpinx (Hematosalpinx)
Hematuria (Hematuria)
Hemoglobin Increased (Hemoglobin
increased)
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Hemoglobinuria (Hemoglobinuria)
Hemolysis (Hemolysis)
Hemolytic Uremic Syndrome (Hemolytic
uremic syndrome)
Hemorrhoidal Hemorrhage
(Hemorrhoidal hemorrhage)
Hemorrhoids (Hemorrhoids)
Hepatic Failure (Hepatic failure)
Hepatic Hemorrhage (Hepatic
hemorrhage)
Hepatic Infection (Hepatic infection)
Hepatic Necrosis (Hepatic necrosis)
Hepatic Pain (Hepatic pain)
Hepatitis Viral (Hepatitis viral)
Hepatobiliary Disorders - Other, Specify
(Hepatobiliary disorders - Other, Specify)
Hiccups (Hiccups)
Hip Fracture (Hip fracture)
Hirsutism (Hirsutism)
Hoarseness (Hoarseness)
Hot Flashes (Hot flashes)
Hydrocephalus (Hydrocephalus)
Hypercalcemia (Hypercalcemia)
Hyperglycemia (Hyperglycemia)
Hyperhidrosis (Hyperhidrosis)
Hyperkalemia (Hyperkalemia)
Hypermagnesemia (Hypermagnesemia)
Hypernatremia (Hypernatremia)
Hyperparathyroidism
(Hyperparathyroidism)
Hypersomnia (Hypersomnia)
Hypertension (Hypertension)
Hyperthyroidism (Hyperthyroidism)
Hypertrichosis (Hypertrichosis)
Hypertriglyceridemia
(Hypertriglyceridemia)
Hyperuricemia (Hyperuricemia)
Hypoalbuminemia (Hypoalbuminemia)
Hypocalcemia (Hypocalcemia)
Hypoglossal Nerve Disorder
(Hypoglossal nerve disorder)
Hypoglycemia (Hypoglycemia)
Hypohidrosis (Hypohidrosis)
Hypokalemia (Hypokalemia)
Hypomagnesemia (Hypomagnesemia)
Hyponatremia (Hyponatremia)
Hypoparathyroidism
(Hypoparathyroidism)
Hypophosphatemia (Hypophosphatemia)
Hypotension (Hypotension)
Hypothermia (Hypothermia)
Hypothyroidism (Hypothyroidism)
Hypoxia (Hypoxia)
Ileal Fistula (Ileal fistula)
Ileal Hemorrhage (Ileal hemorrhage)
Ileal Obstruction (Ileal obstruction)
Ileal Perforation (Ileal perforation)
Ileal Stenosis (Ileal stenosis)
Ileal Ulcer (Ileal ulcer)
Ileus (Ileus)
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Immune System Disorders - Other,
Specify (Immune system disorders -
Other, Specify)
Infections And Infestations - Other,
Specify (Infections and infestations -
Other, Specify)
Infective Myositis (Infective myositis)
Infusion Related Reaction (Infusion
related reaction)
Infusion Site Extravasation (Infusion site
extravasation)
Injection Site Reaction (Injection site
reaction)
Injury To Carotid Artery (Injury to carotid
artery)
Injury To Inferior Vena Cava (Injury to
inferior vena cava)
Injury To Jugular Vein (Injury to jugular
vein)
Injury To Superior Vena Cava (Injury to
superior vena cava)
Injury, Poisoning And Procedural
Complications - Other, Specify (Injury,
poisoning and procedural complications -
Other, Specify)
Inr Increased (INR increased)
Insomnia (Insomnia)
Intestinal Stoma Leak (Intestinal stoma
leak)
Intestinal Stoma Obstruction (Intestinal
stoma obstruction)
Intestinal Stoma Site Bleeding (Intestinal
stoma site bleeding)
Intra-abdominal Hemorrhage (Intra-
abdominal hemorrhage)
Intracranial Hemorrhage (Intracranial
hemorrhage)
Intraoperative Arterial Injury
(Intraoperative arterial injury)
Intraoperative Breast Injury
(Intraoperative breast injury)
Intraoperative Cardiac Injury
(Intraoperative cardiac injury)
Intraoperative Ear Injury (Intraoperative
ear injury)
Intraoperative Endocrine Injury
(Intraoperative endocrine injury)
Intraoperative Gastrointestinal Injury
(Intraoperative gastrointestinal injury)
Intraoperative Head And Neck Injury
(Intraoperative head and neck injury)
Intraoperative Hemorrhage
(Intraoperative hemorrhage)
Intraoperative Hepatobiliary Injury
(Intraoperative hepatobiliary injury)
Intraoperative Musculoskeletal Injury
(Intraoperative musculoskeletal injury)
Intraoperative Neurological Injury
(Intraoperative neurological injury)
Intraoperative Ocular Injury
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(Intraoperative ocular injury)
Intraoperative Renal Injury
(Intraoperative renal injury)
Intraoperative Reproductive Tract Injury
(Intraoperative reproductive tract injury)
Intraoperative Respiratory Injury
(Intraoperative respiratory injury)
Intraoperative Skin Injury (Intraoperative
skin injury)
Intraoperative Splenic Injury
(Intraoperative splenic injury)
Intraoperative Urinary Injury
(Intraoperative urinary injury)
Intraoperative Venous Injury
(Intraoperative venous injury)
Investigations - Other, Specify
(Investigations - Other, Specify)
Iron Overload (Iron overload)
Irregular Menstruation (Irregular
menstruation)
Irritability (Irritability)
Ischemia Cerebrovascular (Ischemia
cerebrovascular)
Ivth Nerve Disorder (IVth nerve disorder)
Jejunal Fistula (Jejunal fistula)
Jejunal Hemorrhage (Jejunal
hemorrhage)
Jejunal Obstruction (Jejunal obstruction)
Jejunal Perforation (Jejunal perforation)
Jejunal Stenosis (Jejunal stenosis)
Jejunal Ulcer (Jejunal ulcer)
Joint Effusion (Joint effusion)
Joint Infection (Joint infection)
Joint Range Of Motion Decreased (Joint
range of motion decreased)
Joint Range Of Motion Decreased
Cervical Spine (Joint range of motion
decreased cervical spine)
Joint Range Of Motion Decreased
Lumbar Spine (Joint range of motion
decreased lumbar spine)
Keratitis (Keratitis)
Kidney Anastomotic Leak (Kidney
anastomotic leak)
Kidney Infection (Kidney infection)
Kyphosis (Kyphosis)
Lactation Disorder (Lactation disorder)
Large Intestinal Anastomotic Leak (Large
intestinal anastomotic leak)
Laryngeal Edema (Laryngeal edema)
Laryngeal Fistula (Laryngeal fistula)
Laryngeal Hemorrhage (Laryngeal
hemorrhage)
Laryngeal Inflammation (Laryngeal
inflammation)
Laryngeal Mucositis (Laryngeal
mucositis)
Laryngeal Obstruction (Laryngeal
obstruction)
Laryngeal Stenosis (Laryngeal stenosis)
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Laryngitis (Laryngitis)
Laryngopharyngeal Dysesthesia
(Laryngopharyngeal dysesthesia)
Laryngospasm (Laryngospasm)
Left Ventricular Systolic Dysfunction (Left
ventricular systolic dysfunction)
Lethargy (Lethargy)
Leukemia Secondary To Oncology
Chemotherapy (Leukemia secondary to
oncology chemotherapy)
Leukocytosis (Leukocytosis)
Leukoencephalopathy
(Leukoencephalopathy)
Libido Decreased (Libido decreased)
Libido Increased (Libido increased)
Lip Infection (Lip infection)
Lip Pain (Lip pain)
Lipase Increased (Lipase increased)
Lipohypertrophy (Lipohypertrophy)
Localized Edema (Localized edema)
Lordosis (Lordosis)
Lower Gastrointestinal Hemorrhage
(Lower gastrointestinal hemorrhage)
Lung Infection (Lung infection)
Lymph Gland Infection (Lymph gland
infection)
Lymph Leakage (Lymph leakage)
Lymph Node Pain (Lymph node pain)
Lymphedema (Lymphedema)
Lymphocele (Lymphocele)
Lymphocyte Count Decreased
(Lymphocyte count decreased)
Lymphocyte Count Increased
(Lymphocyte count increased)
Malabsorption (Malabsorption)
Malaise (Malaise)
Mania (Mania)
Mediastinal Hemorrhage (Mediastinal
hemorrhage)
Mediastinal Infection (Mediastinal
infection)
Memory Impairment (Memory
impairment)
Meningismus (Meningismus)
Meningitis (Meningitis)
Menopause (Menopause)
Menorrhagia (Menorrhagia)
Metabolism And Nutrition Disorders -
Other, Specify (Metabolism and nutrition
disorders - Other, Specify)
Middle Ear Inflammation (Middle ear
inflammation)
Mitral Valve Disease (Mitral valve
disease)
Mobitz (type) Ii Atrioventricular Block
(Mobitz (type) II atrioventricular block)
Mobitz Type I (Mobitz type I)
Movements Involuntary (Movements
involuntary)
Mucosal Infection (Mucosal infection)
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Mucositis Oral (Mucositis oral)
Multi-organ Failure (Multi-organ failure)
Muscle Weakness Left-sided (Muscle
weakness left-sided)
Muscle Weakness Lower Limb (Muscle
weakness lower limb)
Muscle Weakness Right-sided (Muscle
weakness right-sided)
Muscle Weakness Trunk (Muscle
weakness trunk)
Muscle Weakness Upper Limb (Muscle
weakness upper limb)
Musculoskeletal And Connective Tissue
Disorder - Other, Specify
(Musculoskeletal and connective tissue
disorders - Other, Specify)
Musculoskeletal Deformity
(Musculoskeletal deformity)
Myalgia (Myalgia)
Myelitis (Myelitis)
Myelodysplastic Syndrome
(Myelodysplastic syndrome)
Myocardial Infarction (Myocardial
infarction)
Myocarditis (Myocarditis)
Myositis (Myositis)
Nail Discoloration (Nail discoloration)
Nail Infection (Nail infection)
Nail Loss (Nail loss)
Nail Ridging (Nail ridging)
Nasal Congestion (Nasal congestion)
Nausea (Nausea)
Neck Edema (Neck edema)
Neck Pain (Neck pain)
Neck Soft Tissue Necrosis (Neck soft
tissue necrosis)
Neoplasms Benign, Malignant And
Unspecified (incl Cysts And Polyps) -
Other, Specify (Neoplasms benign,
malignant and unspecified (incl cysts and
polyps) - Other, Specify)
Nervous System Disorders - Other,
Specify (Nervous system disorders -
Other, Specify)
Neuralgia (Neuralgia)
Neutrophil Count Decreased (Neutrophil
count decreased)
Night Blindness (Night blindness)
Nipple Deformity (Nipple deformity)
Non-cardiac Chest Pain (Non-cardiac
chest pain)
Nystagmus (Nystagmus)
Obesity (Obesity)
Obstruction Gastric (Obstruction gastric)
Oculomotor Nerve Disorder (Oculomotor
nerve disorder)
Olfactory Nerve Disorder (Olfactory
nerve disorder)
Oligospermia (Oligospermia)
Optic Nerve Disorder (Optic nerve
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disorder)
Oral Cavity Fistula (Oral cavity fistula)
Oral Dysesthesia (Oral dysesthesia)
Oral Hemorrhage (Oral hemorrhage)
Oral Pain (Oral pain)
Osteonecrosis Of Jaw (Osteonecrosis of
jaw)
Osteoporosis (Osteoporosis)
Otitis Externa (Otitis externa)
Otitis Media (Otitis media)
Ovarian Hemorrhage (Ovarian
hemorrhage)
Ovarian Infection (Ovarian infection)
Ovarian Rupture (Ovarian rupture)
Ovulation Pain (Ovulation pain)
Pain (Pain)
Pain In Extremity (Pain in extremity)
Pain Of Skin (Pain of skin)
Palmar-plantar Erythrodysesthesia
Syndrome (Palmar-plantar
erythrodysesthesia syndrome)
Palpitations (Palpitations)
Pancreas Infection (Pancreas infection)
Pancreatic Anastomotic Leak (Pancreatic
anastomotic leak)
Pancreatic Duct Stenosis (Pancreatic
duct stenosis)
Pancreatic Enzymes Decreased
(Pancreatic enzymes decreased)
Pancreatic Fistula (Pancreatic fistula)
Pancreatic Hemorrhage (Pancreatic
hemorrhage)
Pancreatic Necrosis (Pancreatic
necrosis)
Pancreatitis (Pancreatitis)
Papilledema (Papilledema)
Papulopustular Rash (Papulopustular
rash)
Paresthesia (Paresthesia)
Paronychia (Paronychia)
Paroxysmal Atrial Tachycardia
(Paroxysmal atrial tachycardia)
Pelvic Floor Muscle Weakness (Pelvic
floor muscle weakness)
Pelvic Infection (Pelvic infection)
Pelvic Pain (Pelvic pain)
Pelvic Soft Tissue Necrosis (Pelvic soft
tissue necrosis)
Penile Infection (Penile infection)
Penile Pain (Penile pain)
Perforation Bile Duct (Perforation bile
duct)
Pericardial Effusion (Pericardial effusion)
Pericardial Tamponade (Pericardial
tamponade)
Pericarditis (Pericarditis)
Perineal Pain (Perineal pain)
Periodontal Disease (Periodontal
disease)
Periorbital Edema (Periorbital edema)
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Periorbital Infection (Periorbital infection)
Peripheral Ischemia (Peripheral
ischemia)
Peripheral Motor Neuropathy (Peripheral
motor neuropathy)
Peripheral Nerve Infection (Peripheral
nerve infection)
Peripheral Sensory Neuropathy
(Peripheral sensory neuropathy)
Peritoneal Infection (Peritoneal infection)
Peritoneal Necrosis (Peritoneal necrosis)
Personality Change (Personality change)
Phantom Pain (Phantom pain)
Pharyngeal Anastomotic Leak
(Pharyngeal anastomotic leak)
Pharyngeal Fistula (Pharyngeal fistula)
Pharyngeal Hemorrhage (Pharyngeal
hemorrhage)
Pharyngeal Mucositis (Pharyngeal
mucositis)
Pharyngeal Necrosis (Pharyngeal
necrosis)
Pharyngeal Stenosis (Pharyngeal
stenosis)
Pharyngitis (Pharyngitis)
Pharyngolaryngeal Pain
(Pharyngolaryngeal pain)
Phlebitis (Phlebitis)
Phlebitis Infective (Phlebitis infective)
Photophobia (Photophobia)
Photosensitivity (Photosensitivity)
Platelet Count Decreased (Platelet count
decreased)
Pleural Effusion (Pleural effusion)
Pleural Hemorrhage (Pleural
hemorrhage)
Pleural Infection (Pleural infection)
Pleuritic Pain (Pleuritic pain)
Pneumonitis (Pneumonitis)
Pneumothorax (Pneumothorax)
Portal Hypertension (Portal
hypertension)
Portal Vein Thrombosis (Portal vein
thrombosis)
Postnasal Drip (Postnasal drip)
Postoperative Hemorrhage
(Postoperative hemorrhage)
Postoperative Thoracic Procedure
Complication (Postoperative thoracic
procedure complication)
Precocious Puberty (Precocious
puberty)
Pregnancy, Puerperium And Perinatal
Conditions - Other, Specify (Pregnancy,
puerperium and perinatal conditions -
Other, Specify)
Premature Delivery (Premature delivery)
Premature Menopause (Premature
menopause)
Presyncope (Presyncope)
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Proctitis (Proctitis)
Productive Cough (Productive cough)
Prolapse Of Intestinal Stoma (Prolapse
of intestinal stoma)
Prolapse Of Urostomy (Prolapse of
urostomy)
Prostate Infection (Prostate infection)
Prostatic Hemorrhage (Prostatic
hemorrhage)
Prostatic Obstruction (Prostatic
obstruction)
Prostatic Pain (Prostatic pain)
Proteinuria (Proteinuria)
Pruritus (Pruritus)
Psychiatric Disorders - Other, Specify
(Psychiatric disorders - Other, Specify)
Psychosis (Psychosis)
Pulmonary Edema (Pulmonary edema)
Pulmonary Fibrosis (Pulmonary fibrosis)
Pulmonary Fistula (Pulmonary fistula)
Pulmonary Hypertension (Pulmonary
hypertension)
Pulmonary Valve Disease (Pulmonary
valve disease)
Purpura (Purpura)
Pyramidal Tract Syndrome (Pyramidal
tract syndrome)
Radiation Recall Reaction (dermatologic)
(Radiation recall reaction (dermatologic))
Radiculitis (Radiculitis)
Rash Acneiform (Rash acneiform)
Rash Maculo-papular (Rash maculo-
papular)
Rash Pustular (Rash pustular)
Rectal Anastomotic Leak (Rectal
anastomotic leak)
Rectal Fistula (Rectal fistula)
Rectal Hemorrhage (Rectal hemorrhage)
Rectal Mucositis (Rectal mucositis)
Rectal Necrosis (Rectal necrosis)
Rectal Obstruction (Rectal obstruction)
Rectal Pain (Rectal pain)
Rectal Perforation (Rectal perforation)
Rectal Stenosis (Rectal stenosis)
Rectal Ulcer (Rectal ulcer)
Recurrent Laryngeal Nerve Palsy
(Recurrent laryngeal nerve palsy)
Renal And Urinary Disorders - Other,
Specify (Renal and urinary disorders -
Other, Specify)
Renal Calculi (Renal calculi)
Renal Colic (Renal colic)
Renal Hemorrhage (Renal hemorrhage)
Reproductive System And Breast
Disorders - Other, Specify (Reproductive
system and breast disorders - Other,
Specify)
Respiratory Failure (Respiratory failure)
Respiratory, Thoracic And Mediastinal
Disorders - Other, Specify (Respiratory,
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thoracic and mediastinal disorders -
Other, Specify)
Restlessness (Restlessness)
Restrictive Cardiomyopathy (Restrictive
cardiomyopathy)
Retinal Detachment (Retinal
detachment)
Retinal Tear (Retinal tear)
Retinal Vascular Disorder (Retinal
vascular disorder)
Retinoic Acid Syndrome (Retinoic acid
syndrome)
Retinopathy (Retinopathy)
Retroperitoneal Hemorrhage
(Retroperitoneal hemorrhage)
Reversible Posterior
Leukoencephalopathy Syndrome
(Reversible posterior
leukoencephalopathy syndrome)
Rhinitis Infective (Rhinitis infective)
Right Ventricular Dysfunction (Right
ventricular dysfunction)
Salivary Duct Inflammation (Salivary duct
inflammation)
Salivary Gland Fistula (Salivary gland
fistula)
Salivary Gland Infection (Salivary gland
infection)
Scalp Pain (Scalp pain)
Scleral Disorder (Scleral disorder)
Scoliosis (Scoliosis)
Scrotal Infection (Scrotal infection)
Scrotal Pain (Scrotal pain)
Seizure (Seizure)
Sepsis (Sepsis)
Seroma (Seroma)
Serum Amylase Increased (Serum
amylase increased)
Serum Sickness (Serum sickness)
Sick Sinus Syndrome (Sick sinus
syndrome)
Sinus Bradycardia (Sinus bradycardia)
Sinus Disorder (Sinus disorder)
Sinus Pain (Sinus pain)
Sinus Tachycardia (Sinus tachycardia)
Sinusitis (Sinusitis)
Skin And Subcutaneous Tissue
Disorders - Other, Specify (Skin and
subcutaneous tissue disorders - Other,
Specify)
Skin Atrophy (Skin atrophy)
Skin Hyperpigmentation (Skin
hyperpigmentation)
Skin Hypopigmentation (Skin
hypopigmentation)
Skin Induration (Skin induration)
Skin Infection (Skin infection)
Skin Ulceration (Skin ulceration)
Sleep Apnea (Sleep apnea)
Small Intestinal Anastomotic Leak (Small
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intestinal anastomotic leak)
Small Intestinal Mucositis (Small
intestinal mucositis)
Small Intestinal Obstruction (Small
intestinal obstruction)
Small Intestinal Perforation (Small
intestinal perforation)
Small Intestinal Stenosis (Small intestinal
stenosis)
Small Intestine Infection (Small intestine
infection)
Small Intestine Ulcer (Small intestine
ulcer)
Sneezing (Sneezing)
Social Circumstances - Other, Specify
(Social circumstances - Other, Specify)
Soft Tissue Infection (Soft tissue
infection)
Soft Tissue Necrosis Lower Limb (Soft
tissue necrosis lower limb)
Soft Tissue Necrosis Upper Limb (Soft
tissue necrosis upper limb)
Somnolence (Somnolence)
Sore Throat (Sore throat)
Spasticity (Spasticity)
Spermatic Cord Anastomotic Leak
(Spermatic cord anastomotic leak)
Spermatic Cord Hemorrhage (Spermatic
cord hemorrhage)
Spermatic Cord Obstruction (Spermatic
cord obstruction)
Spinal Fracture (Spinal fracture)
Spleen Disorder (Spleen disorder)
Splenic Infection (Splenic infection)
Stenosis Of Gastrointestinal Stoma
(Stenosis of gastrointestinal stoma)
Stevens-johnson Syndrome (Stevens-
Johnson syndrome)
Stoma Site Infection (Stoma site
infection)
Stomach Pain (Stomach pain)
Stomal Ulcer (Stomal ulcer)
Stridor (Stridor)
Stroke (Stroke)
Sudden Death Nos (Sudden death NOS)
Suicidal Ideation (Suicidal ideation)
Suicide Attempt (Suicide attempt)
Superficial Soft Tissue Fibrosis
(Superficial soft tissue fibrosis)
Superficial Thrombophlebitis (Superficial
thrombophlebitis)
Superior Vena Cava Syndrome (Superior
vena cava syndrome)
Supraventricular Tachycardia
(Supraventricular tachycardia)
Surgical And Medical Procedures -
Other, Specify (Surgical and medical
procedures - Other, Specify)
Syncope (Syncope)
Telangiectasia (Telangiectasia)
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Testicular Disorder (Testicular disorder)
Testicular Hemorrhage (Testicular
hemorrhage)
Testicular Pain (Testicular pain)
Thromboembolic Event
(Thromboembolic event)
Thrombotic Thrombocytopenic Purpura
(Thrombotic thrombocytopenic purpura)
Tinnitus (Tinnitus)
Tooth Development Disorder (Tooth
development disorder)
Tooth Discoloration (Tooth discoloration)
Tooth Infection (Tooth infection)
Toothache (Toothache)
Toxic Epidermal Necrolysis (Toxic
epidermal necrolysis)
Tracheal Fistula (Tracheal fistula)
Tracheal Hemorrhage (Tracheal
hemorrhage)
Tracheal Mucositis (Tracheal mucositis)
Tracheal Obstruction (Tracheal
obstruction)
Tracheal Stenosis (Tracheal stenosis)
Tracheitis (Tracheitis)
Tracheostomy Site Bleeding
(Tracheostomy site bleeding)
Transient Ischemic Attacks (Transient
ischemic attacks)
Treatment Related Secondary
Malignancy (Treatment related
secondary malignancy)
Tremor (Tremor)
Tricuspid Valve Disease (Tricuspid valve
disease)
Trigeminal Nerve Disorder (Trigeminal
nerve disorder)
Trismus (Trismus)
Tumor Lysis Syndrome (Tumor lysis
syndrome)
Tumor Pain (Tumor pain)
Typhlitis (Typhlitis)
Unequal Limb Length (Unequal limb
length)
Unintended Pregnancy (Unintended
pregnancy)
Upper Gastrointestinal Hemorrhage
(Upper gastrointestinal hemorrhage)
Upper Respiratory Infection (Upper
respiratory infection)
Ureteric Anastomotic Leak (Ureteric
anastomotic leak)
Urethral Anastomotic Leak (Urethral
anastomotic leak)
Urethral Infection (Urethral infection)
Urinary Fistula (Urinary fistula)
Urinary Frequency (Urinary frequency)
Urinary Incontinence (Urinary
incontinence)
Urinary Retention (Urinary retention)
Urinary Tract Infection (Urinary tract
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infection)
Urinary Tract Obstruction (Urinary tract
obstruction)
Urinary Tract Pain (Urinary tract pain)
Urinary Urgency (Urinary urgency)
Urine Discoloration (Urine discoloration)
Urine Output Decreased (Urine output
decreased)
Urostomy Leak (Urostomy leak)
Urostomy Obstruction (Urostomy
obstruction)
Urostomy Site Bleeding (Urostomy site
bleeding)
Urostomy Stenosis (Urostomy stenosis)
Urticaria (Urticaria)
Uterine Anastomotic Leak (Uterine
anastomotic leak)
Uterine Fistula (Uterine fistula)
Uterine Hemorrhage (Uterine
hemorrhage)
Uterine Infection (Uterine infection)
Uterine Obstruction (Uterine obstruction)
Uterine Pain (Uterine pain)
Uterine Perforation (Uterine perforation)
Uveitis (Uveitis)
Vaginal Anastomotic Leak (Vaginal
anastomotic leak)
Vaginal Discharge (Vaginal discharge)
Vaginal Dryness (Vaginal dryness)
Vaginal Fistula (Vaginal fistula)
Vaginal Hemorrhage (Vaginal
hemorrhage)
Vaginal Infection (Vaginal infection)
Vaginal Inflammation (Vaginal
inflammation)
Vaginal Obstruction (Vaginal obstruction)
Vaginal Pain (Vaginal pain)
Vaginal Perforation (Vaginal perforation)
Vaginal Stricture (Vaginal stricture)
Vaginismus (Vaginismus)
Vagus Nerve Disorder (Vagus nerve
disorder)
Vas Deferens Anastomotic Leak (Vas
deferens anastomotic leak)
Vascular Access Complication (Vascular
access complication)
Vascular Disorders - Other, Specify
(Vascular disorders - Other, Specify)
Vasculitis (Vasculitis)
Vasovagal Reaction (Vasovagal reaction)
Venous Injury (Venous injury)
Ventricular Arrhythmia (Ventricular
arrhythmia)
Ventricular Fibrillation (Ventricular
fibrillation)
Ventricular Tachycardia (Ventricular
tachycardia)
Vertigo (Vertigo)
Vestibular Disorder (Vestibular disorder)
Virilization (Virilization)
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Visceral Arterial Ischemia (Visceral
arterial ischemia)
Vital Capacity Abnormal (Vital capacity
abnormal)
Vitreous Hemorrhage (Vitreous
hemorrhage)
Voice Alteration (Voice alteration)
Vomiting (Vomiting)
Vulval Infection (Vulval infection)
Watering Eyes (Watering eyes)
Weight Gain (Weight gain)
Weight Loss (Weight loss)
Wheezing (Wheezing)
White Blood Cell Decreased (White
blood cell decreased)
Wolff-parkinson-white Syndrome (Wolff-
Parkinson-White syndrome)
Wound Complication (Wound
complication)
Wound Dehiscence (Wound dehiscence)
Wound Infection (Wound infection)
Wrist Fracture (Wrist fracture)
MedDRA Code (v.12.0 must be completed)
CTC Adverse Event Grade (highest grade this
cycle)
Mild Adverse Event (1)
Moderate Adverse Event (2)
Severe Adverse Event (3)
Life Threatening Adverse Event (4)
Death Related To Adverse Event (5)
CTC AE Attribution Code
Definite (Definite)
Possible (Possible)
Probable (Probable)
Unlikely (Unlikely)
Unrelated (Unrelated)
Has an Adverse Event Expedited Report been
submitted? (See Section 8 of the protocol)
Yes
No
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Cycle Dose Drug Form D2R Fallopian Tube
Cancer (NCT00565851)
GYNECOLOGIC ONCOLOGY GROUP Cycle Dose Drug
Form - FORM D2R
Carboplatin and Paclitaxel With or Without Bevacizumab
After Surgery in Treating Patients With Recurrent Ovarian
Epithelial Cancer, Primary Peritoneal Cavity Cancer, or
Fallopian Tube Cancer
NCT00565851
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=DA671E4E-
F217-4DDB-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/7671
Cycle Dose Drug Form D2R
Fallopian Tube Cancer
(NCT00565851)
Header
Date form originally completed (m/d/y)
Date form amended (m/d/y)
Person amending form last name
Patient Initials (First, Middle, Last)
Patient Study ID
Comments
Participating group code
Participating group protocol number
Participating group patient ID
Person completing form, last name
Treatment Cycle And Modification
Cycle start date (Day 1)
Current cycle number
Number of days treatment course was delayed
Agent name (/drug)
Agent dose level
1 / 3
Were there any dose modifications or
additions/omissions to protocol treatment? (*)
No (No)
Yes, Planned (i.e., The Treatment Was
Changed According To Protocol
Guidelines) (Yes, planned)
Yes, Unplanned (i.e., The Treatment
Change Was Not Part Of Protocol
Guidelines) (Yes, unplanned)
Total dose of agents/drugs for this cycle
Units
Patient weight (kg)
Body surface area (m^2)
Performance status (Zubrod)
Fully Active, Able To Carry On All Pre-
disease Performance Without Restriction
(karnofsky 90 - 100) (ecog - 0
Asymptomatic) (0)
Restricted In Physically Strenuous
Activity But Ambulatory (k70 - 80) (ecog -
1 Symptomatic - Fully Ambulatory) (1)
Ambulatory And Capable Of All Selfcare
But Unable To Carry Out Any Work
Activities (k 50 - 60) (ecog - 2
Symptomatic; In Bed , 50% Of The Day)
(2)
Capable Of Limited Selfcare, Confined
To Bed Or Chair More Than 50% Of
Waking Hours. (k 30 - 40) (ecog - 3
Symptomatic; In Bed > 50% Of The Day
But Not Bedridden) (3)
Completely Disabled (k10 - 20) (ecog - 4
Bedridden) (4)
Assessment date (m/d/y)
Hemoglobin
Peripheral hematocrit count (1000/L)
Peripheral WBC count (mm3)
Peripheral granulocytes count (mm3)
Peripheral platelet count (mm3)
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BUN (mg/dl)
Creatinine (mg/dl)
Creatinine clearance (ml/min)
SGOT (IU/ml)
Bilirubin (mg %)
Result of CA125 (IU/ml)
Other, specify (test)
Other, specify (value)
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Breast Cancer NCT01242800 On-Study -
E2108 Step 2 On-Study Form - 3130597v1.0
E2108 Step 2 On-Study Form
Early Surgery or Standard Palliative Therapy in Treating
Patients With Stage IV Breast Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=8E2EE15D-
B7A5-69C7-E040-BB89AD431929
All rights reserved. Please visit https://medical-data-
models.org/forms/7672
E2108 Step 2 On-Study Form
Header
ECOG Protocol Number
DCI Name
Registration Step
Reporting Period
Baseline Step 2 (Baseline step 2)
ECOG Patient ID
Unnamed2
Patient Initials (Last, First)
ECOG Protocol Number
Participating Group Protocol Number
Institution/Affiliate
ECOG Patient ID
Participating Group Patient ID
Unnamed4
Please mark an 'X' if data have been amended.
(Please circle amended items in red)
Date data amended (s M D Y)
Unnamed3
ECOG Performance Status (Day 1 of this cycle)
Fully Active, Able To Carry On All Pre-
disease Performance Without
1 / 4
Restriction. (0)
Restricted In Physically Strenuous
Activity But Ambulatory And Able To
Carry Out Work Of A Light Or Sedentary
Nature, E.g., Light Housework, Office
Work. (1)
Ambulatory And Capable Of All Selfcare
But Unable To Carry Out Any Work
Activities. Up And About More Than 50%
Of Waking Hours. (2)
Capable Of Only Limited Selfcare,
Confined To Bed Or Chair More Than
50% Of Waking Hours. (3)
Completely Disabled. Cannot Carry On
Any Selfcare. Totally Confined To Bed Or
Chair. (4)
Weight (kg)
Menopausal status (Definitions of Menopausal
Status: Postmenopausal: Defined as at least one
of the following: 1 age >55 with no spontaneous
menses for at least 12 months, or 2 age </= 55
years with no spontaneous menses within the
past 12 months e.g. spontaneous or secondary to
hysterectomy AND with an FSH level in the
postmenopausal range according to local
institutional/laboratory standards or > 34.4 IU/L if
the institutional range is not available, or 3 history
of bilateral oophorectomy, or 4 receiving
gonadotropin releasing hormone to suppress
ovarian function during the entire period of
planned hormonal therapy. Premenopausal:
Defined as spontaneous menses occurring within
3 months prior to pre-randomization, and no prior
history of bilateral oophorectomy.
Perimenopausal: Not meeting criteria for
premenopausal or postmenopausal)
Perimenopausal (Perimenopausal)
Postmenopausal (Postmenopausal)
Premenopausal (Premenopausal)
Unknown (Unknown)
Disease Description
Her2/neu expression status by
immunohistochemistry
0 (0)
1+ (1+)
2+ (2+)
3+ (3+)
Not Done: C49484 (not done)
FISH HER2/neu chromosome 17 Ratio
Mark an 'X' if not done
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ER Status (Receptor Status as defined by local
laboratory; borderline results should be reported
as positive)
Negative (Negative)
Not Done (NOT DONE)
Positive (Positive)
Unknown (Unknown)
PgR Status (Receptor Status as defined by local
laboratory; borderline results should be reported
as positive)
Negative (Negative)
Not Done (NOT DONE)
Positive (Positive)
Unknown (Unknown)
Opposite Breast (Sites of Involvement At
Randomization Record an answer for each site
including "Other")
No (NO)
Unknown (UNKNOWN)
Yes (YES)
Distant Lymph Nodes
No (NO)
Unknown (UNKNOWN)
Yes (YES)
Distant Skin/subcutaneous Tissue
No (No)
Unknown (Unknown)
Yes (Yes)
Bone
No (NO)
Unknown (UNKNOWN)
Yes (YES)
Bone Marrow
No (No)
Unknown (Unknown)
Yes (Yes)
Lung
No (NO)
Unknown (UNKNOWN)
Yes (YES)
Liver
No (NO)
Unknown (UNKNOWN)
Yes (YES)
Pleura
No (NO)
Unknown (UNKNOWN)
Yes (YES)
Brain
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No (NO)
Unknown (UNKNOWN)
Yes (YES)
Other CNS
No (NO)
Unknown (UNKNOWN)
Yes (YES)
Other
No (NO)
Unknown (UNKNOWN)
Yes (YES)
Other specify
Treatment Plan
Is further treatment (with Chemotherapy) planned
for this patient?
Yes
No
Is further treatment (with Hormone therapy)
planned for this patient?
Yes
No
Overall Response Per Recist Criteria -
Target, Nontarget And New Lesions
Were circulating tumor cells (CTCs) assessed
Yes
No
Date of Enumeration
CTC Count (#CTC/mL)
Comments
Investigator Signature
Investigator Signature Date
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Cycle Dose Drug Form D2R Fallopian Tube
Cancer (NCT00951496)
Gynecologic Oncology Group Cycle Dose Drug Form
(Form D2R)
Bevacizumab and Intravenous or Intraperitoneal
Chemotherapy in Treating Patients With Stage II, Stage III,
or Stage IV Ovarian Epithelial Cancer, Fallopian Tube
Cancer, or Primary Peritoneal Cancer
NCT00951496
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=4F53E994-
CCD2-730F-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/7673
Cycle Dose Drug Form D2R
Fallopian Tube Cancer
(NCT00951496)
Header Module
Date form originally completed (m d y)
Date form amended (m d y)
Person amending form, last name
Patient Initials (First, Middle, Last)
Patient Study ID
COMMENTS
Person Completing Form, Last Name
Treatment Cycle And Modification
Current Cycle Number
Cycle Delayed?
Yes
No
Number of days treatment cycle was delayed
Cycle Start Date (Day 1)
Cycle delayed reason
Non Protocol Illness (Non protocol
illness)
Patient Refusal (Patient refusal)
Personal Reasons (Personal reasons)
Protocol Related Ae (Protocol related
AE)
Scheduling (Scheduling)
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Agent name (/Drug)
Agent Dose level (e.g. mg/m^2)
Dose modification status
Agent Not Scheduled For This Cycle
(Agent not scheduled for this cycle)
Dose Held (Dose held)
Dose Increased (since Last Report)
(Dose increased (since last report))
Dose Reduced (since Last Report)
(Dose reduced (since last report))
Drug Discontinued (Drug discontinued)
No Dose Modification (No dose
modification)
Other (Other)
Dose Modification (Change)
No (No)
Yes, Planned (i.e., The Treatment Was
Changed According To Protocol
Guidelines) (Yes, planned)
Yes, Unplanned (i.e., The Treatment
Change Was Not Part Of Protocol
Guidelines) (Yes, unplanned)
Dose Modification Reason
Adverse Event (Adverse event)
Death (Death)
Device/procedure Failure
(Device/procedure failure)
Disease Progression (Disease
progression)
Dosing Error (Dosing error)
Other (Other)
Patient Refusal/noncompliance (Patient
refusal/noncompliance)
Therapy Complete (Treatment
completed)
Weight Change (Weight change)
Adverse Event
Allergic Reaction/hypersensitivity
(Allergic reaction/hypersensitivity)
Cardiac Toxicity (Cardiac Toxicity)
Gi Toxicity (GI toxicity)
Hematologic Toxicity (Hematologic
toxicity)
Hemorrhage (Hemorrhage)
Hepatic Toxicity (Hepatic Toxicity)
Infection (Infection)
Musculoskeletal (Musculoskeletal)
Neurotoxicity (Neurotoxicity)
Other (Other)
Pulmonary Toxicity
(Pulmonary/respiratory Toxicity)
Renal Toxicity (Renal toxicity)
Vascular Toxicity (Vascular Toxicity)
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Total Dose of Agents/Drugs for this Cycle
Units (eg. mg, kg)
Patient weight (kg)
Body Surface Area (m^2)
Performance status (Zubrod)
Fully Active, Able To Carry On All Pre-
disease Performance Without
Restriction. (0)
Restricted In Physically Strenuous
Activity But Ambulatory And Able To
Carry Out Work Of A Light Or Sedentary
Nature, E.g., Light Housework, Office
Work. (1)
Ambulatory And Capable Of All Selfcare
But Unable To Carry Out Any Work
Activities. Up And About More Than 50%
Of Waking Hours. (2)
Capable Of Only Limited Selfcare,
Confined To Bed Or Chair More Than
50% Of Waking Hours. (3)
Completely Disabled. Cannot Carry On
Any Selfcare. Totally Confined To Bed Or
Chair. (4)
Pretreatment Hematology And Chemistry
Values
Assessment Date (m d y)
Hemoglobin
Peripheral Hematocrit Count (1000/L)
Peripheral WBC Count (mm3)
Peripheral Granulocytes Count (mm3)
Peripheral Platelet Count (mm3)
PT (sec)
PTT (sec) (sec)
BUN (mg/dl)
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Creatinine (mg/dl)
Creatinine Clearance (ml/min)
SGOT (IU/ml)
Bilirubin (mg %)
Alkaline Phosphatase
Result of CA125 (IU/ml)
International Normalization Ratio (INR)
Other, specify test
Other specify value
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Cycle Dose Drug Form (D2R) Ovarian
Cancer (NCT00954174)
GOG-0261: Cycle Dose Drug Form (D2R)
Paclitaxel and Carboplatin or Ifosfamide in Treating Patients
With Newly Diagnosed Persistent or Recurrent Uterine or
Ovarian Cancer
NCT00954174
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=64F29740-
0457-692F-E040-BB89AD432164
All rights reserved. Please visit https://medical-data-
models.org/forms/7674
Cycle Dose Drug Form (D2R)
Ovarian Cancer (NCT00954174)
Header Module
Date form originally completed (m d y)
Date form amended (m d y)
Person amending form, last name
Patient Initials (First, Middle, Last)
Patient Study ID
COMMENTS
Person Completing Form, Last Name
Treatment Cycle And Modification
Current Cycle Number
Cycle Delayed?
Yes
No
Number of days treatment cycle was delayed
Cycle delayed reason
Non Protocol Illness (Non protocol
illness)
Patient Refusal (Patient refusal)
Personal Reasons (Personal reasons)
Protocol Related Ae (Protocol related
AE)
Scheduling (Scheduling)
Cycle start date (Day 1 m d y)
Agent name (Drug)
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Agent Dose level (e.g. mg/m^2)
Were there any dose modifications or
additions/omissions to protocol treatment (1=Yes,
planned; 2 =Yes, unplanned; 3=No)
No (No)
Yes, Planned (i.e., The Treatment Was
Changed According To Protocol
Guidelines) (Yes, planned)
Yes, Unplanned (i.e., The Treatment
Change Was Not Part Of Protocol
Guidelines) (Yes, unplanned)
Total dose of agents/drugs for this cycle
Units (eg. mg, kg)
Patient weight (kg)
Body Surface Area (m^2)
Performance status (Zubrod)
Fully Active, Able To Carry On All Pre-
disease Performance Without
Restriction. (0)
Restricted In Physically Strenuous
Activity But Ambulatory And Able To
Carry Out Work Of A Light Or Sedentary
Nature, E.g., Light Housework, Office
Work. (1)
Ambulatory And Capable Of All Selfcare
But Unable To Carry Out Any Work
Activities. Up And About More Than 50%
Of Waking Hours. (2)
Capable Of Only Limited Selfcare,
Confined To Bed Or Chair More Than
50% Of Waking Hours. (3)
Completely Disabled. Cannot Carry On
Any Selfcare. Totally Confined To Bed Or
Chair. (4)
Pretreatment Hematology And Chemistry
Values
Assessment Date (m d y)
Hemoglobin
Peripheral Hematocrit Count (1000/L)
Peripheral WBC Count (mm3)
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Peripheral Granulocytes Count (mm3)
Peripheral Platelet Count (mm3)
PT (sec)
PTT (sec) (sec)
BUN (mg/dl)
Creatinine (mg/dl)
Creatinine Clearance (ml/min)
SGOT (IU/ml)
Bilirubin (mg %)
Alkaline Phosphatase
Result of CA125 (IU/ml)
International Normalization Ratio (INR)
Other, specify test
Other specify value
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Follow-Up Form Kidney Cancer
(NCT01198158)
CALGB 90802 Follow-Up Form
Everolimus With or Without Bevacizumab in Treating
Patients With Advanced Kidney Cancer That Progressed
After First-Line Therapy
NCT01198158
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=87856A36-
E884-CA3E-E040-BB89AD431C27
All rights reserved. Please visit https://medical-data-
models.org/forms/7681
Follow-Up Form Kidney Cancer
(NCT01198158)
Header Module
CALGB Form
CALGB Study No.
CALGB Patient ID
Reporting Period Start Date (MM DD YYYY)
Date of Last Contact or Death (last known alive
MM DD YYYY)
Are data amended
Yes
No
Patient Initials (Last First Middle)
Patient Hospital No.
Institution/Affiliate
Participating Group
Participating Group Study No.
Participating Group Patient ID
Completed by
Date Form Completed (MM DD YYYY)
Comments
1 / 5
Vital Status
Patient's Vital Status (Mark one with an X. If the
patient is lost, follow instructions on form C-1742
and in the CALGB Policies and Procedures
chapter 8 to have Data Operations change a
patient's survival status to: "Confirmed lost to
follow-up")
Alive (Alive)
Dead (Dead)
Primary Cause of Death (Mark one with an X.)
Due To Other Cause (Due to other
cause)
Due To Protocol Treatment (Due to
protocol treatment)
Due To This Disease (Due to this
disease)
Describe cause of death
Karnofsky Performance Status Score (Mark one
with an X.)
Dead (0)
Moribund, Fatal Processes Progressing
Rapidly (10)
Normal, No Complaints, No Evidence Of
Disease (100)
Very Sick, Hospitalization Indicated.
Death Not Imminent (20)
Severely Disabled, Hospitalization
Indicated. Death Not Imminent (30)
Disabled, Requires Special Care And
Assistance (40)
Requires Considerable Assistance And
Frequent Medical Care (50)
Requires Occasional Assistance, But Is
Able To Care For Most Of His/her Needs
(60)
Cares For Self, Unable To Carry On
Normal Activity Or To Do Active Work
(70)
Normal Activity With Effort; Some Signs
Or Symptoms Of Disease (80)
Able To Carry On Normal Activity; Minor
Signs Or Symptoms Of Disease (90)
Disease Follow-up Status
Has the patient had a documented clinical
assessment for this cancer? (since submission of
the previous follow-up form)
Yes
No
Date of Last Clinical Assessment (MM DD YYYY)
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Most recent CT/MRI scan date (MM DD YYYY)
Patient Weight (kg)
Treatment Status (Mark one with an X)
Follow-up, Off Protocol Therapy (Follow-
up, off protocol therapy)
On Study, On Protocol Treatment (On
study, on protocol treatment)
Measurable Disease Response
Response Status at This Assessment (Mark one
with an X.)
Complete Response (CR)
Insufficient Evaluation (Insufficient
evaluation to determine response status)
Progressive Disease (PD)
Partial Response (PR)
Stable Disease (SD)
Complete Response (CR) First Observed Date
(MM DD YYYY)
Partial Response (PR) First Observed Date (MM
DD YYYY)
Progressive Disease First Observed Date (MM
DD YYYY)
Sites of Progression (during this reporting period
Mark all that apply with an X.)
Bladder (Bladder)
Bone (Bone)
Central Nervous System/brain
(CNS/Brain)
Liver (Liver)
Lung, Nos (Lung)
Lymph Nodes, Specify (Lymph nodes)
Other (Other)
Pleura (Pleura)
Urothelial Tract (Urothelial Tract)
Other specify
Baseline Lab Values (hematologic)
WBC (x10^3 microL)
ANC (x10^3 microL)
Platelets (PLT) (x10^3 microL)
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Hemoglobin (g/dL)
Hemoglobin, ULN
Serum creatinine (mg/dl)
Calculated creatinine clearance (mL/min)
SGOT (AST)
SGOT (AST) ULN
Total Bilirubin (mg/dl)
Bilirubin ULN (mg/dl)
Fasting serum glucose (mg/dL)
Serum cholesterol (mg/dL)
Trigylcerides (mg/dL)
Corrected serum calcium (mg/dL Calculated by:
Serum calcium - [0.707Serum albumin-3.4])
Notice Of New Primary
Has a new primary cancer or MDS been
diagnosed that has not been previously reported?
Yes
No
New Primary Cancer Date (MM DD YYYY)
Site of New Primary (s)
New Primary, Histologic type
Long-term Toxicity
Has the patient experienced post diagnosis of
progression or new primary, any severe (Grade >
3), long-term toxicity that has not been previously
reported
Yes
No
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Non-protocol Therapy
Has the patient received any non-protocol cancer
therapy during this reporting period?
Yes
No
Specify (If yes, Mark all that apply with an X
below.)
Chemotherapy (Chemotherapy)
Other Non-protocol Therapy (Other non-
protocol therapy)
Radiation Therapy (Radiation therapy)
Surgery (Surgery)
Specify (Radiation therapy)
Specify (Chemotherapy)
Specify (Surgery)
Specify (Other non-protocol therapy)
Non-protocol Therapy Start Date (MM DD YYYY
or date performed)
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Lung Cancer NCT00096265 Treatment - TF RTOG Phase III -
Multiple Brain Mets Treatment Summary Form - 2277910v3.0
TF RTOG Phase III - Multiple Brain Mets Treatment
Summary Form
Radiation Therapy and Stereotactic Radiosurgery With or
Without Temozolomide or Erlotinib in Treating Patients With
Brain Metastases Secondary to Non-Small Cell Lung
Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=D81D1978-
6B15-04EC-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/7683
TF RTOG Phase III - Multiple Brain
Mets Treatment Summary Form
Header
RTOG Study No.
RTOG Study 0320 (RTOG Study 0320)
Calc. Creatinine Clearance, Normal Range
Other, Normal Range
Uric Acid (mg%), Normal Range
Total Protein (gm%), Normal Range
Treament Week
Case #
Institution
Institution No.
Participant's Initials
Participant's I.D. No.
If this is a revised or corrected form, indicate by
checking box
Yes
No
height
weight
BSA
Treatment phase being reported
Concurrent (Concurrent)
1 / 5
Post WBRT (Post WBRT)
Protocol Drug
Treatment Evaluation Period Type
12 Months (12 months)
15 Months (15 months)
18 Months (18 months)
3 Months (3 months)
6 Months (6 months)
9 Months (9 months)
End Of Wdrt (End of WDRT)
Other (Other)
Course being reported
Other, specify
Is protocol chemotherapy continuing?
Yes
No
Treatment begin date
Treament End date
Agent total cumulative dose
Total number of courses
Dose modification
Reason treatment ended
Alternative Therapy (Alternative therapy,
specify)
Death On Study (Death on study)
Disease Progression, Relapse During
Active Treatment (Disease progression,
relapse during active treatment)
Treatment Completed Per Protocol
Criteria (None)
Other (Other complicating disease,
specify)
Other (Other, specify)
Patient Withdrawal Or Refusal After
Beginning Protocol Therapy (Patient
withdrawal or refusal after beginning
protocol therapy)
Patient Withdrawal Or Refusal Prior To
Beginning Protocol Therapy (Patient
withdrawal or refusal prior to beginning
protocol therapy)
Adverse Event/side Effects/complications
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(Toxicity/side effects/complications)
Treatment Completed Per Protocol
Criteria (Treatment completed per
protocol criteria)
Alternative therapy, specify
Other complicating disease, specify
Other, specify
Date
Hgb (gms)
Hgb (gms), Normal Range
Hct (%), Normal Range
Hct (%), Normal Range
WBC (x1000)
WBC (x1000), Normal Range
Platelets (x1000)
platelets (x1000), Normal Range
Neutrophils/gran (%)
neutrophils/gran (%), Normal Range
ANC
ANC, Normal Range
BUN
BUN, Normal Range
Creatinine (mg%)
Creatinine (mg%), Normal Range
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Brain Mets Treatment Summary Form - 2277910v3.0
Calc. Creatinine Clearance
Bilirubin (total (Mg%)
bilirubin (total (Mg%), Normal Range
Aklaline Phosphotase
aklaline Phosphotase, Normal Range
LDH
LDH, Normal Range
SGOT
SGOT, Normal Range
SGPT
SGPT, Normal Range
Total Protein (gm%)
Uric Acid (mg%)
Albumin (gm%)
Albumin (gm%), Normal Range
Potassium (mg/L)
potassium (mg/L), Normal Range
Calcium (mg/d)
calcium (mg/d), Normal Range
Glucose
glucose, Normal Range
Sodium (meq/L)
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sodium (meq/L), Normal Range
Other
Comments
Signature
Date
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Colorectal Cancer NCT00303628 Quality of
Life - E5204 FACT/GOG-Ntx - 2440880v1.0
E5204 FACT/GOG-Neurotoxicity
Combination Chemotherapy With or Without Bevacizumab
in Treating Patients Who Have Had Surgery for Stage II or
Stage III Rectal Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=08FF61C8-
655A-6373-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/7684
E5204 FACT/GOG-Ntx
Header
DCI Name
Registration Step
Reporting Period
12 Months Post-chemotherapy (12
months post-chemotherapy)
3 Months Post-chemotherapy (3 months
post-chemotherapy)
Baseline (Baseline)
Cycle 4, Day 1 (Cycle 4, Day 1)
Patient Initials (PLACE ID LABEL HERE Last,
First)
ECOG Protocol Number
ECOG Protocol Number
ECOG Patient ID
ECOG Patient ID
Participating Group Protocol No.
Participating Group Patient ID
Institution/Affiliate
Assessment Date
Unnamed2
I have numbness or tingling in my hands
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
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Somewhat (Somewhat)
Very Much (Very much)
I have numbness or tingling in my feet
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I feel discomfort in my hands
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I feel discomfort in my feet
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have joint pain or muscle cramps
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I feel weak all over
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have trouble hearing
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I get a ringing or buzzing in my ears
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have trouble buttoning buttons
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have trouble feeling the shape of small objects
when they are in my hand
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A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have trouble walking
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have pain in my hands or feet when I am
exposed to cold temperatures
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have difficulty breathing when I am exposed to
cold temperatures
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
Investigator Signature
Investigator Signature
Investigator Signature Date
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Leukemia NCT00492856 Treatment - SOUTHWEST ONCOLOGY
GROUP APL Disease Assessment Form (S0521) - 2415460v1.0
SOUTHWEST ONCOLOGY GROUP APL Disease
Assessment Form (S0521)
Combination Chemotherapy With or Without Gemtuzumab
Followed By Tretinoin, Mercaptopurine, and Methotrexate
or Observation in Treating Patients With Acute
Promyelocytic Leukemia
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=02C9A3A8-
9B14-5BA0-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/7689
SOUTHWEST ONCOLOGY GROUP
APL Disease Assessment Form
(S0521)
Header
SWOG Patient ID
SWOG Study No.
Registration Step
Patient Initials (L, F M)
Reporting Period Start Date
Reporting Period End Date
Institution/Affiliate
Physician (Participating Group:)
Participating Group Name
American College Of Surgeons
Oncology Group (ACOSOG)
American College Of Radiology
Oncologic Imaging Network (ACRIN)
Aids-associated Malignancies Clinical
Trials Consortium (AMC)
Cancer And Leukemia Group B (CALGB)
Children's Oncology Group (COG)
Eastern Cooperative Oncology Group
(ECOG)
European Organization For Research
And Treatment Of Cancer (EORTC)
Gynecologic Oncology Group (GOG)
International Breast Cancer Study Group
(IBCSG)
North American Brain Tumor Consortium
(NABTC)
Nabtt Brain Tumor Consortium (NABTT)
North Central Cancer Treatment Group
(NCCTG)
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National Cancer Institute Of Canada
Clinical Trials Group (NCIC)
National Surgical Adjuvant Breast And
Bowel Project (NSABP)
Radiation Therapy Oncology Group
(RTOG)
Southwest Oncology Group (SWOG)
Participating Group Study No.
Participating Group Patient ID (Instructions: All
dates are MONTH, DAY, YEAR. Explain any
blank fields or blank dates in the Comments
section. Place an X in appropriate boxes. Circle
AMENDED items in red and write AMENDED
across the top of the form.)
Patient And Disease Description
Date of Last Contact or Death
Vital Status
Alive (Alive)
Dead (Dead)
Physical
Has the patient had a documented clinical
assessment for this cancer? (during the reporting
period APL)
No (No)
Unknown (Unknown)
Yes (Yes)
Date of Last Clinical Assessment (only provide
date if assessment during this reporting period)
Response
Did the patient achieve a complete response
according to clinical/ hematologic criteria during
this reporting period? (CR, CRi, or PR see
Section 10.0 for response criteria)
No (NO)
Unknown (Unknown)
Yes (YES)
Response Observed Date (If yes, only provide
date if relapse occurred during this reporting
period and complete "Laboratory Values and
Extramedullary Disease" on the next page for the
examinations that document relapse)
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Relapse
Has the patient had a relapse of their disease
following previous response (complete or partial
See Section 10.0 for relapse criteria)
No (No)
Unknown (Unknown)
Yes (Yes)
Date of Most Recent Relapse (If yes, only provide
date if relapse occurred during this reporting
period and complete "Laboratory Values and
Extramedullary Disease" on the next page for the
examinations that document relapse  )
Laboratory Values And Extramedullary
Disease: Peripheral Blood Examination
Did the patient have a peripheral blood
examination during this reporting period?
(aspiration and/or biopsy)
No (no)
Unknown (unknown)
Yes (yes)
Date Hematology (Blood) Sample Obtained
Hemoglobin (HGB)
Peripheral Platelet Count (x 10^3)
Peripheral WBC Count (x 10^3)
Peripheral Blasts (%)
Peripheral Neutrophils (%) (band, seg, PMN)
Peripheral Promyelocytes (%)
Laboratory Values And Extramedullary
Disease: Bone Marrow Examination
Did the patient have a bone marrow examination
during this reporting period? (aspiration and/or
biopsy)
No (No)
Unknown (Unknown)
Yes (Yes)
Date of Bone Marrow Biopsy (/aspiration)
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Marrow Cellularity (%)
Marrow Blasts (%)
Marrow Promyelocytes (%)
Marrow Cellularity Status (Select one)
Cellularity Status Of Bone Marrow Is
Aplasitc (severely Hypocellular) (Aplastic
(severely hypocellular))
Cellularity Status Of Bone Marrow
Unknown, Procedure Resulted In No
Material To Analyze (Dry tap or
inaspirable)
Cellularity Status Of Bone Marrow Is
Hypercellular (Hypercellular)
Cellularity Status Of Bone Marrow Is
Hypocellular (Hypocellular)
Cellularity Status Of Bone Marrow Is
Normocellular (Normocellular)
Cellularity Status Of Bone Marrow Is
Packed (intensely Hypercellular) (Packed
(intensely hypercellular))
Laboratory Values And Extramedullary
Disease: Extramedullary Disease
Involvement
Was the patient examined for extramedullary
disease during this reporting period?
No (No)
Unknown (Unknown)
Yes (Yes)
Date of Examination for Extramedullary Disease
Extramedullary Disease Involvement (Select all
that apply)
Gingival Hypertrophy (Gingival
hypertrophy)
Mediastinal Mass (Mediastinal mass)
Other Specify (Other)
Peripheral Nervous System (Peripheral
nervous system)
Skin (Skin (cutaneous))
Other, specify
Comments
Comments
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Breast Cancer NCT01101438 Pre-Study -
NCIC MA.32 Baseline Report - 3027459v1.0
NCIC MA.32 Baseline Report
A Phase III Randomized Trial of Metformin vs Placebo in
Early Stage Breast Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=81E21D11-
128C-1198-E040-BB89AD434372
All rights reserved. Please visit https://medical-data-
models.org/forms/7694
NCIC MA.32 Baseline Report
Tobacco Smoking History - Baseline
Has the patient previously been a smoker?
No (no)
Unknown (unknown)
Yes (yes)
Does the patient currently smoke
Yes
No
Average number of cigarettes smoked per day
Date of quitting smoking
Smoking history
100 Or Fewer Cigarettes During Lifetime
(100 or fewer cigarettes during lifetime)
Greater Than 100 Cigarettes During
Lifetime (greater than 100 cigarettes
during lifetime)
Pipe Or Cigar Smoker Only (Pipe or
cigar smoker only)
Date started smoking
Number of years smoked cigarettes
Average per day over lifetime of smoking
Number pack years smoked
Alcohol Consumption - Question
Alcohol Use in the Past Year
Yes
No
Average Alcohol Consumption
1 To 10 Drinks Per Week (1 to 10 drinks
per week)
1 To 5 Drinks Per Month (1 to 5 drinks
per month)
11 To 30 Drinks Per Week (11 to 30
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drinks per week)
Less Than 1 Drink Per Month (Less than
1 drink per month)
More Than 30 Drinks Per Week (More
than 30 drinks per week)
Unknown (Unknown)
Bilateral Breast Carcinoma - Question
Was this subject enrolled as having bilateral
breast carcinoma
Yes
No
Bilateral Breast Carcinoma
Pathologic T Stage
No Evidence Of Primary Tumor (T0)
Tumor 2 Cm Or Less In Greatest
Dimension (T1)
Tumor More Than 0.1 Cm But Not More
Than 0.5 Cm In Greatest Dimension
(T1a)
Tumor More Than 0.5 Cm But Not More
Than 1 Cm In Greatest Dimension (T1b)
Tumor More Than 1 Cm But Not More
Than 2 Cm In Greatest Dimension (T1c)
Microinvasion 0.1 Cm Or Less In
Greatest Dimension (T1mic)
Tumor More Than 2 Cm But Not More
Than 5 Cm In Greatest Dimension (T2)
Tumor More Than 5 Cm In Greatest
Dimension (T3)
Tumor Of Any Size With Direct (T4)
Extension To Chest Wall (T4a)
Edema (including Peau D'orange) Or
Ulceration Of The Skin Of The Breast Or
Satellite Skin Nodules Confined To The
Same Breast (T4b)
Both T4a And T4b (T4c)
Inflammatory Carcinoma (T4d)
Carcinoma In Situ: Intraductal
Carcinoma, Lobular Carcinoma In Situ,
Or Paget's Disease Of The Nipple With
No Tumor (Tis)
Ductal Carcinoma In Situ (Tis (DCIS))
Lobular Carcinoma In Situ (Tis (LCIS))
Paget's Disease Of The Nipple With No
Tumor. [note: Paget's Disease
Associated With A Tumor Is Classified
According To The Size Of The Tumor.]
(Tis (Paget's))
Primary Tumor Cannot Be Assessed
(TX)
Pathologic N Stage
No Regional Lymph Node Metastasis
Histologically, No Additional Examination
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For Isolated Tumor Cells (itc) (pN0)
No Regional Lymph Node Metastasis
Histologically, Negative Ihc (pN0(i-))
No Regional Lymph Node Metastasis
Histologically, Positive Ihc, No Ihc Cluster
>0.2 Mm (pN0(i+))
No Regional Lymph Node Metastasis
Histologically, Negative Molecular
Findings (rt-pcr) (pN0(mol-))
No Regionally Lymph Node Metastasis
Histologically, Positive Molecular
Findings (rt-pcr) (pN0(mol+))
Metastasis In 1 To 3 Axillary Lymph
Nodes, And/or In Internal Mammary
Nodes With Microscopic Disease
Detected By Sln Dissection But Not
Clinically Apparent (pN1)
Metastasis In 1 To 3 Axillary Lymph
Nodes (pN1a)
Metastasis In Internal Mammary Nodes
With Microscopic Disease Detected By
Sln Dissection But Not Clinically
Apparent (pN1b)
Metastasis In 1 To 3 Axillary Lymph
Nodes And In Internal Mammary Lymph
Nodes With Microscopic Disease
Detected By Sln Dissection But Not
Clinically Apparent. (pN1c)
Micrometastasis (>0.2 Mm But <=2.0
Mm) (pN1mi)
Metastasis In 4 To 9 Axillary Lymph
Nodes, Or In Clinically Apparent **
Internal Mammary Lymph Nodes In The
Absence Of Axillary Lymph Node
Metastasis To Ipsilateral Axillary Lymph
Node(s) Fixed To Each Other Or To
Other Structures (pN2)
Metastasis In 4 To 9 Axillary Lymph
Nodes (at Least 1 Tumor Deposit >2.0
Mm) (pN2a)
Metastasis In Clinically Apparent*
Internal Mammary Lymph Nodes In The
Absence Of Axillary Lymph Node
Metastasis (pN2b)
Metastasis In >= Axillary Lymph Nodes,
Or In Infraclavicular Lymph Nodes, Or In
Clinically Apparent* Ipsilateral Internal
Mammary Lymph Node(s) In The
Presence Of 1 Or More Positive Axillary
Lymph Node(s); Or, In >3 Axillary Lymph
Nodes With Clinically N (pN3)
Metastasis In >=10 Axillary Lymph
Nodes (at Least 1 Tumor Deposit >2.0
Mm); Or, Metastasis To The
Infraclavicular Lymph Nodes (pN3a)
Metastasis In Clinically Apparent*
Ipsilateral Internal Mammary Lymph
Nodes In The Presence Of >=1 Positive
Axillary Lymph Node(s); Or, In >3
Axillary Lymph Nodes And In Internal
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Mammary Lymph Nodes With
Microscopic Disease Detected By
Sentinel Lymph Node (pN3b)
Metastasis In Ipsilateral Supraclavicular
Lymph Nodes (pN3c)
Regional Lymph Nodes Cannot Be
Assessed (e.g., Not Removed For
Pathologic Study Or Previously
Removed) (pNX)
Pathologic M Stage
No Distant Metastasis (M0)
Distant Metastasis (M1)
Distant Metastasis Cannot Be Assessed
(MX)
Was sentinel node sampling performed
Yes
No
Sentinel Node Biopsy Date
Number of Sentinel Nodes Examined
Number of Positive Sentinel Nodes
Was axillary dissection performed?
Yes
No
Date of Axillary Node Biopsy
Number of axillary nodes examined
Number of positive axillary nodes
Number of Lymph Nodes Examined
Number of Positive Lymph Nodes
Baseline Adverse Events - Question
Did the participant report any symptoms or
adverse events?
Yes
No
Baseline Advers Events
CTCAE Term
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Grade
AE Ongoing
Yes
No
Cardiovascular History - Question
Has the patient suffered cardiovascular disease?
Yes
No
Cardiovascular History
Problem, cardiovascular
Angina Requiring Coronary Artery
Bypass Graft (Angina requiring coronary
artery bypass graft)
Angina Requiring Transluminal Coronary
Angioplasty (Angina requiring
transluminal coronary angioplasty)
Myocardial Infarction (Myocardial
Infarction)
New Or Worsening Angina (New or
worsening angina)
Other (Other)
Transient Ischemic Attack
Cerebrovascular Accident (Stroke /
transient inschemic attack TIA)
Thromboembolism (Thromboembolic
Event)
Specify
Baseline Concomitant Medications
Did the participant report taking any concomitant
medication
Yes
No
Concomitant Medication
Reason for Administration
Is this medication continuing?
Yes
No
Adjuvant Radiation Therapy
Has the patient received adjuvant RT
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Yes
No
Date Adjuvant Radiation Therapy Started
Date Adjuvant Radiation Therapy Ended
Total Dose of Radiation Therapy (cGy)
Systemic Therapy
Has the patient received systemic therapy?
No (No)
Unknown (Unknown)
Yes (Yes)
Agent Name
Non-protocol Therapy Start Date
Continuing
Yes
No
Non-protocol Therapy End Date
Therapy Intent
Adjuvant (Adjuvant)
Advanced/recurrent/metastatic Disease
(Advanced/recurrent/metastatic disease)
Neoadjuvant Therapy (Neoadjuvant)
Other Specify (Other)
Specify
Major Medical Problems At Baseline
Concomitant Diseases and/or Relevant Medical
Conditions
Ongoing
Yes
No
Ongoing
Yes
No
Other Clinical Trial Participation
Is the subject participating in another clinical trial
of Breast Cancer treatment
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Yes
No
Clinical Trial Protocol ID
Clinical Trial Sponsor Name
Patient Entry Date
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Treatment Form for Docetaxel/Capecitabine Cycles
in Groups 2A and 2B (NSABP Protocol B-40)
NSABP Protocol B-40 - Treatment Form for
Docetaxel/Capecitabine Cycles in Groups 2A and 2B
A Randomized Phase III Trial of Neoadjuvant Therapy in
Patients With Palpable and Operable Breast Cancer
Evaluating the Effect on Pathologic Complete Response
(pCR) of Adding Capecitabine or Gemcitabine to Docetaxel
When Administered Before AC With or Without
Bevacizumab and Correlative Science Studies Attempting
to Identify Predictors of High Likelihood for pCR With Each
of the Regimens
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=1AFCAF2E-
F48D-14C6-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/7703
Treatment Form for
Docetaxel/Capecitabine Cycles in
Groups 2A and 2B (NSABP Protocol
B-40)
Administrative documentation
Patient Initials (Last First Middle)
NSABP Patient ID*
Institution/Affiliate*
Treating MD Last Name*
Treating MD First Name*
Treating MD Phone*
Person Completing Form, Last Name*
Person Completing Form, First Name*
Person Completing Form, Phone*
Are data amended*
Yes
No
Therapy course
Total Number of Cycles Given
(Docetaxel/Gemcitabine)*
1 (1)
2 (2)
3 (3)
4 (4)
None (None)
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Why did treatment end or not begin
(Docetaxel/Gemcitabine)*
Adverse Event/side Effects/complications
(Adverse event/side
effects/complications)
Alternative Therapy (Alternative therapy)
Death (Death)
New Lesion (including Second Primary
Cancer) Or Other Sign Of Progression
(New lesion (including second primary
cancer) or other sign of progression)
Other (Other)
Treatment Completed Per Protocol
Criteria (Treatment completed per
protocol criteria)
Other, specify*
Cycle Number
Cycle Start Date*
Agent Name (Docetaxel, Gemcitabine Day 1,
Gemcitabine Day 8)*
Agent Dose (per M^2 - mg/m^2  - Dose used to
calculate the amount of drug to be administered.
In Groups 3A and 3B, full dose of docetaxel is 75
mg/m^2.  Full dose of gemcitabine is 1000
mg/m^2.)*
Number of Capecitabine Doses Administered (0-
28 doses)*
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Colorectal Cancer NCT00068692 Response - E3201
Cover Page for Adverse Event Form - 2079303v3.0
E3201 Cover Page for Adverse Event Form
Comparison of Adjuvant Chemotherapy Regimens in
Treating Patients With Stage II or Stage III Rectal Cancer
Who Are Receiving Radiation Therapy and Fluorouracil
Before or After Surgery
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=B5521C52-
8F40-6D30-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/7708
E3201 Cover Page for Adverse
Event Form
Header
DCI Name
Patient Group
Group I (Group I)
Group II (Group II)
Patient Initials
ECOG Protocol Number
ECOG Protocol Number
ECOG Patient ID
ECOG Patient ID
Participating Group Protocol Number
Participating Group Patient ID
Institution/Affiliate
On Treatment
On Treatment Time Period (Group I)
Completion Of Concurrent Chemo/rt
(Completion of Concurrent Chemo/RT)
Off Treatment Step 2 (Off Treatment Step
2)
One Month Post Surgery, Or 8 Weeks
Post Chemo/rt If Surgery Not Performed
(One month post surgery, or 8 weeks
post Chemo/RT if surgery not performed)
On Treatment Time Period (Group II)
Completion Of Concurrent Chemo/rt
(Completion of Concurrent Chemo/RT)
Completion Of First Portion Of Chemo
(arms D And E After 4 Cycles, Arm F
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After 1 Cycle) (Completion of First
Portion of Chemo (Arms D and E after 4
cycles, Arm F after 1 cycle))
Off Treatment Step 2 (Off Treatment Step
2)
Off Treatment Time Period
108 months (9 years) (108 months (9
years))
12 Months (12 months)
120 months (10 years) (120 months (10
years))
15 Months (15 months)
18 Months (18 months)
24 Months (24 months)
3 Months (3 months)
30 Months (30 months)
36 Months (36 months)
42 Months (42 months)
48 Months (48 months)
54 Months (54 months)
6 Months (6 months)
60 Months (60 months)
72 months (6 years) (72 months (6
years))
84 months (7 years) (84 months (7
years))
9 Months (9 months)
96 months (8 years) (96 months (8
years))
Ccrr Module For E3201 Cover Page For
Adverse Event Form
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Lung Cancer NCT01336894 Lab - ACOSOG-Z4099
Blood Sample Submission Form - 3179946v1.0
ACOSOG-Z4099 Blood Sample Submission Form
Surgery With or Without Internal Radiation Therapy
Compared With Stereotactic Body Radiation Therapy in
Treating Patients With High-Risk Stage I Non-Small Cell
Lung Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=98F5C2FC-
A054-2C3B-E040-BB89AD430553
All rights reserved. Please visit https://medical-data-
models.org/forms/7712
ACOSOG-Z4099 Blood Sample
Submission Form
Header Module
Protocol Number
Patient ID
Patient Initials (L F M)
Institution Number
Institution
Are data amended (check one if data amended,
please circle in red when using paper forms)
Yes
No
Visit
Visit
12 Months After Surgery/completion Of
Stereotactic Body Radiation Therapy (12
months after surgery/completion of
SBRT)
18 Months After Surgery/completion Of
Stereotactic Body Radiation Therapy (18
months after surgery/completion of
SBRT)
24 Months After Surgery/completion Of
Stereotactic Body Radiation Therapy (24
months after surgery/completion of
SBRT)
36 Months After Surgery/completion Of
Stereotactic Body Radiation Therapy (36
months after surgery/completion of
SBRT)
4 Weeks After Surgery/before Final
Stereotactic Body Radiation Therapy (4
weeks after surgery/before final SBRT)
48 Months After Surgery/completion Of
Stereotactic Body Radiation Therapy (48
months after surgery/completion of
SBRT)
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6 Months After Surgery/completion Of
Stereotactic Body Radiation Therapy (6
months after surgery/completion of
SBRT)
60 Months After Surgery/completion Of
Stereotactic Body Radiation Therapy (60
months after surgery/completion of
SBRT)
To Be Completed By Clinical Site
Was sample obtained (blood check one)
Yes
No
Date of collection (If yes dd MMM yyyy)
Date Specimen Shipped (dd MMM yyyy)
Specimen Type (check all that apply)
Plasma (Frozen Plasma)
Serum (Frozen serum)
Number of specimens submitted
Reason (If no)
Institution Contact Information
Contact Person at Institution (for Specimen
Submission CRA/Nurse)
Phone number
Email address
Courier Tracking Number (FedEx)
Fax Number
To Be Completed By Acosog Central
Specimen Bank
Date of Receipt of Specimens (dd MMM yyyy)
Specimen ID Number (CSB Tracking Number
Parent Specimen Label)
Specimen Type (check all that apply)
Plasma (Frozen Plasma)
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Serum (Frozen serum)
Condition of Specimen (s check one)
Damaged Or Unusable (Damaged or
unusable)
No Specimen Received (No specimen
received)
Quantity Not Sufficient (Quantity Not
Sufficient)
Usable (Usable)
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Lung Cancer NCT01336894 Lab - ACOSOG-Z4099 Tissue
Sample Submission Form (Arm 1 only) - 3180018v1.0
ACOSOG-Z4099 Tissue Sample Submission Form (Arm 1
only)
Surgery With or Without Internal Radiation Therapy
Compared With Stereotactic Body Radiation Therapy in
Treating Patients With High-Risk Stage I Non-Small Cell
Lung Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=98F5C2FC-
A0F3-2C3B-E040-BB89AD430553
All rights reserved. Please visit https://medical-data-
models.org/forms/7714
ACOSOG-Z4099 Tissue Sample
Submission Form (Arm 1 only)
Header Module
Protocol Number
Patient ID
Patient Initials (L F M)
Institution Number
Institution
Are data amended (check one if data amended,
please circle in red when using paper forms)
Yes
No
Visit
Visit
At Time Of Surgery/stereotactic Body
Radiation Therapy (At time of
surgery/SBRT)
To Be Completed By Clinical Site
Patient's Initial Consent given for tissue specimen
use for research on the patient's cancer? (check
one)
Yes
No
Was sample obtained (tissue at time of surgery
check one)
Yes
No
Date of collection (If yes dd MMM yyyy)
Date Specimen Shipped (dd MMM yyyy)
1 / 2
Number of specimens submitted (snap frozen
tissue)
Reason (If no)
Institution Contact Information
Contact Person at Institution (for Specimen
Submission CRA/Nurse)
Phone number
Email address
Courier Tracking Number (FedEx)
Fax Number
To Be Completed By Acosog Central
Specimen Bank
Date of Receipt of Specimens (dd MMM yyyy)
Specimen ID Number (CSB Tracking Number
Parent Specimen Label)
Specimen Type
Frozen Tissue, Not Fixed, Without The
Use Of Oct (Snap frozen tumor/tissue)
Condition of Specimen (s check one)
Damaged Or Unusable (Damaged or
unusable)
No Specimen Received (No specimen
received)
Quantity Not Sufficient (Quantity Not
Sufficient)
Usable (Usable)
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Leukemia NCT01041703 Treatment - E2906 Baseline Data
Form - Maintenance - Arm E and Arm F - 2951934v1.0
E2906 Baseline Data Form - Maintenance - Arm E and Arm
F
Clofarabine or Daunorubicin Hydrochloride and Cytarabine
Followed By Decitabine or Observation in Treating Older
Patients With Newly Diagnosed Acute Myeloid Leukemia
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=7585B205-
CA52-8BDD-E040-BB89AD430415
All rights reserved. Please visit https://medical-data-
models.org/forms/7739
E2906 Baseline Data Form -
Maintenance - Arm E and Arm F
Header
DCI Name
Registration Step (Place ID Label Here)
Patient Initials (Last, First)
ECOG Protocol Number
ECOG Protocol Number
ECOG Patient ID
ECOG Patient ID
Participating Group Protocol Number
Participating Group Patient ID
Institution/Affiliate
On Treatment
On Treatment Report Period
Baseline Step 3 (Baseline Step 3)
Unnamed2
Please mark an 'X' if data have been amended.
(Please circle amended items in red)
Date data amended (s M D Y)
Pre-registration Evaluation
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ECOG Performance Status
Fully Active, Able To Carry On All Pre-
disease Performance Without
Restriction. (0)
Restricted In Physically Strenuous
Activity But Ambulatory And Able To
Carry Out Work Of A Light Or Sedentary
Nature, E.g., Light Housework, Office
Work. (1)
Ambulatory And Capable Of All Selfcare
But Unable To Carry Out Any Work
Activities. Up And About More Than 50%
Of Waking Hours. (2)
Capable Of Only Limited Selfcare,
Confined To Bed Or Chair More Than
50% Of Waking Hours. (3)
Completely Disabled. Cannot Carry On
Any Selfcare. Totally Confined To Bed Or
Chair. (4)
Does patient have bacterial or fungal infectious
complications (related to the treatment on the
prior protocol step)
No (No)
Unknown (Unknown)
Yes (Yes)
Does the patient have any congestive heart
failure medical complications (related to the
treatment on the prior protocol step)
Yes
No
Assessment Type (cardiac)
Echocardiogram (Echocardiogram)
Muga Scan (MUGA scan)
Date of Assessment (M D Y)
Resting ejection fraction (% See Section 3.0 of
protocol for ejection fraction requirements)
Was an EKG done
Yes
No
Date of EKG (M D Y)
Are there any clinically significant abnormalities
Yes
No
Specify
Has patient received transfusion support
No Transfusion (No)
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Transfusion With Platelets (Yes,
platelets)
Yes, Prbc (packed Red Blood Cells) (yes,
PRBC (packed red blood cells))
Bone Marrow
Date of Bone Marrow Biopsy (M D Y or Aspirate
NOTE: Also submit biopsy/aspirate report)
Marrow Blasts (%)
Marrow Cellularity (%)
Hematology/chemistry
WBC count (x1000), LLN (x1000)
WBC Count (x1000)
Peripheral Blasts (%)
Absolute Granulocyte Count (AGC/ANC)
Platelets LLN (x1000)
Platelets (PLT) (x1000)
Hemoglobin (Hgb) (g/dl), LLN (g/dl)
Hemoglobin (g/dl)
Hematocrit LLN (%)
Hematocrit (%)
Creatinine ULN (mg/dl)
Creatinine (mg/dl)
Total bilirubin (mg/dl), ULN (mg/dl)
Total Bilirubin (mg/dl)
Alkaline Phosphatase ULN (U/L)
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Alkaline Phosphatase (U/L)
SGOT (AST) ULN (U/L)
SGOT (AST) (U/L)
SGPT (ALT) ULN (U/L)
SGPT (ALT) (U/L)
Uric Acid ULN (mg/dl)
Uric acid (mg/dl)
LDH ULN (U/L)
LDH (U/L)
Magnesium, LLN (mg/dl)
Magnesium (mg/dl)
Date Obtained (M D Y)
Baseline Abnormalities
CTC Adverse Event Term
CTC Adverse Event Grade
Mild Adverse Event (1)
Moderate Adverse Event (2)
Severe Adverse Event (3)
Life Threatening Adverse Event (4)
Comments
Investigator Signature
Investigator Signature Date (MM DD YYYY)
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Head and Neck Cancer NCT00588770 On-Study - ECOG
Baseline Disease Evaluation Form  (RECIST) - 2500959v1.0
ECOG Baseline Disease Evaluation Form  (RECIST)
Chemotherapy With or Without Bevacizumab in Treating
Patients With Recurrent or Metastatic Head and Neck
Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=19F70873-
B8E3-2933-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/7743
ECOG Baseline Disease Evaluation
Form  (RECIST)
Header
ECOG Protocol Number
ECOG Patient ID
DCI Name
Registration Step
Report Period
Baseline (Baseline)
Unnamed 2a
Please mark an 'X' if data have been amended.
(Please circle amended items in red)
Date data amended
Unnamed2
Patient Initials
ECOG Protocol Number
ECOG Patient ID
Participating Group Protocol Number
Participating Group Patient ID
Institution/Affiliate
Unnamed3
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Are there any target lesions
Yes
No
Lesion Number
Site of Lesion (Comments - Multiple nontarget
lesions within an organ may be combined as a
single site; report in a consistent manner on
subsequent forms.)
Site Code
Bone (bone)
Brain (Brain)
Breast (Breast)
Effusion/ascites (Effusion/Ascites)
Gi (GI)
Gu (GU)
Head & Neck (Head & Neck)
Liver (Liver)
Lung (Lung)
Nodes (Nodes)
Other (other)
Skin (Skin)
Method of Evaluation
Bone Scan (Bone scan)
Chest X-ray (Chest X-Ray)
Clinical (Clinical Examination)
Ct Scan (CT Scan)
Mri (MRI)
Other (other)
Spiral Ct Scan (Spiral CT scan)
Ultrasound (Ultrasound)
Longest Diameter of Lesion (s cm)
Date of Evaluation
Sum of longest diameters of all target lesions
Nontarget Lesions
Lesion Number
Site of Lesion (Comments - Multiple nontarget
lesions within an organ may be combined as a
single site; report in a consistent manner on
subsequent forms.)
Site Code
Bone (bone)
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Brain (Brain)
Breast (Breast)
Effusion/ascites (Effusion/Ascites)
Gi (GI)
Gu (GU)
Head & Neck (Head & Neck)
Liver (Liver)
Lung (Lung)
Nodes (Nodes)
Other (other)
Skin (Skin)
Method of Evaluation
Bone Scan (Bone scan)
Chest X-ray (Chest X-Ray)
Clinical (Clinical Examination)
Ct Scan (CT Scan)
Mri (MRI)
Other (other)
Spiral Ct Scan (Spiral CT scan)
Ultrasound (Ultrasound)
Date of Evaluation
Cytology Result
Negative (Negative)
Not Done (Not done)
Positive (Positive)
Comments
Comments
Investigator Signature
Investigator Signature Date
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Lung Cancer NCT01336894 Lab - ACOSOG-Z4099
Baseline Blood Sample Submission Form - 3179803v1.0
ACOSOG-Z4099 Baseline Blood Sample Submission Form
Surgery With or Without Internal Radiation Therapy
Compared With Stereotactic Body Radiation Therapy in
Treating Patients With High-Risk Stage I Non-Small Cell
Lung Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=98F4F3C7-
A245-CB5A-E040-BB89AD436644
All rights reserved. Please visit https://medical-data-
models.org/forms/7748
ACOSOG-Z4099 Baseline Blood
Sample Submission Form
Header Module
Protocol Number
Patient ID
Patient Initials (L F M)
Institution Number
Institution
Are data amended (check one if data amended,
please circle in red when using paper forms)
Yes
No
Visit
Visit
Registration (Registration)
To Be Completed By Clinical Site
Patient's Initial Consent given for blood specimen
use for research on the patient's cancer?
(optional check one)
Yes
No
Was sample obtained (blood pre-intervention
check one)
Yes
No
Date of collection (If yes dd MMM yyyy)
Specimen Type (check all that apply)
Plasma (Frozen Plasma)
Serum (Frozen serum)
Whole Blood (Whole Blood)
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Date Specimen Shipped (dd MMM yyyy)
Number of specimens submitted
Reason (If no)
Institution Contact Information
Contact Person at Institution (for Specimen
Submission CRA/Nurse)
Phone number
Email address
Courier Tracking Number (FedEx)
Fax Number
To Be Completed By Acosog Central
Specimen Bank
Date of Receipt of Specimens (dd MMM yyyy)
Specimen ID Number (CSB Tracking Number
Parent Specimen Label)
Specimen Type (check all that apply)
Plasma (Frozen Plasma)
Serum (Frozen serum)
Whole Blood (Whole Blood)
Condition of Specimen (s check one)
Damaged Or Unusable (Damaged or
unusable)
No Specimen Received (No specimen
received)
Quantity Not Sufficient (Quantity Not
Sufficient)
Usable (Usable)
2 / 2
Lung Cancer NCT01336894 Lab - ACOSOG-Z4099 Baseline Blood
Sample Submission Form - 3179803v1.0
Brain and Central Nervous System Tumors NCT00890747
On-Study - AMC-061 On Study Form (F02) - 2935131v1.0
AMC-061 On Study Form (F02)
Sunitinib Malate in Treating HIV-Positive Patients With
Cancer Undergoing Highly Active Antiretroviral Therapy
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=71988CF7-
F9B0-68F0-E040-BB89AD4358A1
All rights reserved. Please visit https://medical-data-
models.org/forms/7750
AMC-061 On Study Form (F02)
Header
Visit number
Hiv History
Date of HIV+ diagnosis (mm/dd/yyyy)
Date of AIDS diagnosis (mm/dd/yyyy)
CDC HIV Risk Group
Hemophilia (Hemophiliac)
Heterosexual Contact (Heterosexual
contact)
Homosexual Or Bisexual Contact
(Homosexual or bisexual contact)
Iv Drug User (IV drug user)
Other (Other)
Transfusion Recipient (Transfusion
recipient)
Other, specify
Ccrr Module For On Study Form - Rf02b
Date of Initial Pathologic Diagnosis (mm/dd/yyyy)
Primary site
Anal Canal (Anal)
Cervical (Cervical)
Hd (HD)
Kaposi Sarcoma (KS)
Non-hodgkin's Lymphoma (NHL)
Other Primary Site (Other primary site)
Other specify
Specify tumor histologic category
Prior Treatment? (If "Yes", Check below)
Yes
No
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Prior Systemic Chemotherapy
Yes
No
Number of chemotherapy regimens (If "Yes",  A
regimen is described as a distinctive planned
collection of agents and/or modalities to be
utilized to-gether during a cycle or course of
therapy. The total number should include a
chemotherapy regimen that was discontinued for
any reason e.g., completion of therapy, Adverse
Event, or disease progression. If a prior treatment
was ABVD/CHOP, it should be coded as one
chemotherapy regimen.)
Prior Biological Response Modifiers or Cytokines
Yes
No
Specify (If "Yes")
Prior Surgery (excluding biopsy)
Yes
No
Prior cryotherapy
Yes
No
Prior systemic steroid therapy
Yes
No
Prior Radiation Therapy
Yes
No
Prior topical/intralesional therapy
Yes
No
Other Prior Therapy (e.g. Hyperthermia, etc.)
Yes
No
Other Prior Therapy (e.g. Hyperthermia, etc.)
Yes
No
Specify (If "Yes" 1 2 3)
Name of other prior therapies (If "Yes")
Ccrr Module For On Study Form - Rf02b
History of Prior Malignancy
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Yes
No
Date of Diagnosis of Previous Malignancy
(mm/dd/yyyy)
Primary site
Anal Canal (Anal)
Cervical (Cervical)
Hd (HD)
Kaposi Sarcoma (KS)
Non-hodgkin's Lymphoma (NHL)
Other Primary Site (Other primary site)
Other specify
Specify tumor histologic category
Prior Treatment? (If "Yes", Check below)
Yes
No
Prior Systemic Chemotherapy
Yes
No
Prior Biological Response Modifiers or Cytokines
Yes
No
Specify (If "Yes")
Prior Surgery (excluding biopsy)
Yes
No
Prior cryotherapy
Yes
No
Prior systemic steroid therapy
Yes
No
Prior Radiation Therapy
Yes
No
Prior topical/intralesional therapy
Yes
No
Other Prior Therapy (e.g. Hyperthermia, etc.)
Yes
No
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Other Prior Therapy (e.g. Hyperthermia, etc.)
Yes
No
Specify (If "Yes" 1 2 3)
Name of other prior therapies (If "Yes")
Antiretroviral Therapy
Agent Name
Other, specify (1 2)
Agent use
Currently Receiving (Currently receiving)
Never Received (Never received)
Previously Received (Previously
received)
Duration if prior agents received
< 3 Months (< 3 months)
> 12 Months (> 12 months)
> 6-12 Months (> 6-12 months)
3-6 Months (3-6 months)
Comments
Comments
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Pancreatic Cancer NCT00733746 Registration -
ACOSOG-Z5041 Registration Worksheet - 2921129v1.0
ACOSOG-Z5041 Registration Worksheet
Gemcitabine and Erlotinib Before and After Surgery in
Treating Patients With Pancreatic Cancer That Can Be
Removed by Surgery
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=6F3D4C5B-
FB42-7755-E040-BB89AD432E97
All rights reserved. Please visit https://medical-data-
models.org/forms/7751
ACOSOG-Z5041 Registration
Worksheet
Header Module
Protocol Number
Patient ID
Patient Initials (L F M)
Institution Number
Institution
Are data amended (if data are amended, please
circle in red when using paper form)
Yes
No
Eligibility Criteria
Cytologic or histologic proof of adenocarcinoma
of the pancreatic head or uncinate process
(NOTE: Patients with tumors of the pancreatic
neck, body or tail are not eligible. Patients with
evidence of Neuroendocrine tumors, duodenal
adenocarcinoma, or ampullary adenocarcinoma
are not eligible)
Yes
No
Localized, potentially resectable tumors (as
defined below. All patients must be staged with a
chest X-ray or CT, and abdominal CT contrast-
enhanced, helical thin-cut or MRI. Radiological
resectability is defined by the following criteria on
abdominal imaging: a No evidence of tumor
extension to the celiac axis, hepatic artery or
superior mesenteric artery b No evidence of
tumor encasement or occlusion of the superior
mesenteric vein SMV or the SMV/portal vein
confluence c No evidence of visceral or
peritoneal metastases NOTE: Patients with
borderline resectable or marginally resectable
pancreatic cancer are not eligible. Patients must
1 / 4
meet all objective imaging criteria outlined above)
Yes
No
Age >= 18 years (Age=)
Yes
No
ECOG Performance Status 0-1 (/Zubrod
ECOG/Zubrod PS =)
Yes
No
Baseline weight loss <=15% of premorbid weight
Yes
No
CA19-9 <1000
Yes
No
WBC (Patients must have adequate hematologic,
renal, and hepatic function as defined by WBC >=
2,000 cells/mm^3)
ANC (Patients must have adequate hematologic,
renal, and hepatic function as defined by ANC >=
1,500 cells/mm^3)
Platelet count (Patients must have adequate
hematologic, renal, and hepatic function as
defined by Platelets >= 100,000 cells/mm^3)
Total Bilirubin (Patients must have adequate
hematologic, renal, and hepatic function as
defined by Serum bilirubin <=2.5 mg/dL)
Serum Creatinine (Patients must have adequate
hematologic, renal, and hepatic function as
defined by Serum creatinine <=1.5 mg/dL or a
calculated creatinine clearance of >=50 ml/min
24-hour urine collection)
Calculated creatinine clearance (Patients must
have adequate hematologic, renal, and hepatic
function as defined by Serum creatinine <=1.5
mg/dL or a calculated creatinine clearance of
>=50 ml/min 24-hour urine collection)
SGPT (ALT) (Patients must have adequate
hematologic, renal, and hepatic function as
defined by ALT <2.5 times ULN)
SGPT (ALT) ULN (Patients must have adequate
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hematologic, renal, and hepatic function as
defined by )
SGOT (AST) (Patients must have adequate
hematologic, renal, and hepatic function as
defined by AST <2.5 times ULN)
SGOT (AST) ULN (Patients must have adequate
hematologic, renal, and hepatic function as
defined by )
Albumin (Patients must have adequate
hematologic, renal, and hepatic function as
defined by Albumin >= 3.2 g/dl)
No history of prior EGFR targeted therapy or
therapy for pancreatic cancer or active infection
requiring intravenous antibiotics at the time of
registration
Yes
No
Non-pregnant and non-breast-feeding (Female
participants of child-bearing potential must have
a negative urine or serum pregnancy test prior to
registration. Perimenopausal participants must be
amenorrheic > 12 months to be considered not of
childbearing potential. All patients of reproductive
potential must agree to use an effective method
of birth-control while receiving study therapy. If
not a female of child-bearing potential or male
check NA)
N/a (N/A)
No (No)
Yes (Yes)
Negative urine or serum pregnancy test date (If
female of child-bearing potential mm/dd/yyyy)
No prior malignancy within 5 years of registration
(Exceptions: non-melanoma skin cancer, in-situ
cancers)
Yes
No
Diagnosis And Therapy
Date of Definitive Histologic Diagnosis of Primary
Tumor (of pancreatic cancer mm/dd/yyyy)
Previous or concurrent malignancy (check one)
Yes
No
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Specify diagnosis (If Yes)
Date of Diagnosis of Previous Malignancy
(mm/dd/yyyy)
History of prior EGFR targeted therapy or therapy
for pancreatic cancer (check one)
Yes
No
Specimen Banking Consent
Patient's biological specimens may be kept for
use in future research to learn about, prevent, or
treat cancer
Yes
No
Patient's biological specimen may be kept for
future use in research to learn about, prevent, or
treat other health problems (for example:
diabetes, Alzheimer's disease, or heart disease)
Yes
No
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Breast Cancer NCT00066703 On-Study - Prior
Treatment History Form (Form 25/26-H) - 2167885v3.0
Prior Treatment History Form (Form 25/26-H)
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=BD161C88-
1558-4F8F-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/7757
Prior Treatment History Form (Form
25/26-H)
Ccrr Module For Prior Treatment History
Form (form 25/26-h)
IBCSG Patient ID
Patient Initials
Patient's Date of Birth
Participating Center/Affiliate
Center Code
Agent Name
Months
Agent End Date
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Lung Cancer NCT01336894 On-Study -
ACOSOG-Z4099 On-Study Form - 3181084v1.0
ACOSOG-Z4099 On-Study Form
Surgery With or Without Internal Radiation Therapy
Compared With Stereotactic Body Radiation Therapy in
Treating Patients With High-Risk Stage I Non-Small Cell
Lung Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=990BA4F9-
52BF-85C0-E040-BB89AD433BEA
All rights reserved. Please visit https://medical-data-
models.org/forms/7763
ACOSOG-Z4099 On-Study Form
Header Module
Protocol Number
Patient ID
Patient Initials (L F M)
Institution Number
Institution
Are data amended (check one if data amended,
please circle in red when using paper forms)
Yes
No
Visit
Visit
Registration (Registration)
Histologic Information
Diagnosis Date (dd MMM yyyy)
Histologic Type (check one)
Adenocarcinoma (Adenocarcinoma)
Bronchoalveolar (bac) (Bronchoalveolar
carcinoma (BAC))
Large Cell Undifferentiated (Large cell
undifferentiated)
Non-small Cell Lung Cancer (nsclc), Nos
(Non-small cell lung cancer NOS)
Other (Other)
Squamous Cell Carcinoma (Squamous
cell carcinoma)
Specify Other Histologic Type
Histologic grade (Differentiation check one)
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Well Differentiated (G1)
Moderately Differentiated (G2)
Poorly Differentiated (G3)
Undifferentiated (G4)
Cannot Be Assessed (GX)
Patient Information
Patient residing (check one)
Assisted Living (Assisted living)
Extended Care (Extended care)
Home (Home)
Homeless (Homeless)
Hospital (Hospital)
Other (Other)
Other, specify
Current oxygen use (check one)
Yes
No
Oxygen Use Type (If yes check one)
Continuous (Continuous)
Intermittent (Intermittent)
Number of hospitalizations within the last year
Baseline Pet Findings
Pre-treatment PET-SUV MAX
Surgery Risk Factors
Major (check one)
Yes
No
FEV1 <= 50 % predicted (If Yes)
Yes
No
DLCO <= 50 % predicted (If Yes)
Yes
No
Minor (check one)
Yes
No
Age >= 75 (If Yes)
Yes
No
FEV1 51-60 % predicted (If Yes)
Yes
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No
DLCO 51-60 % predicted (If Yes)
Yes
No
Pulmonary hypertension as estimated by
echocardiography or right heart catherization (If
Yes defined as a pulmonary artery systolic
pressure greater than 40mmHg)
Yes
No
Poor left ventricular function (If Yes defined as an
ejection fraction or 40% or less)
Yes
No
Resting or Exercise Arterial pO2 <= 55 mm Hg or
SpO2 <= 88% (If Yes)
Yes
No
Modified Medical Research Council (MMRC)
Dyspnea Scale >= 3 (If Yes)
Yes
No
Clinical Stage
T Stage (check one in each row)
Tumor <=3 Cm In Greatest Dimension,
Surrounded By Lung Or Visceral Pleura,
Without Bronchoscopic Evidence Of
Invasion More Proximal Than The Lobar
Bronchus (i.e., Not In The Main
Bronchus) (T1)
Tumor <=2 Cm In Greatest Dimension
(T1a)
Tumor > 2 Cm But <=3 Cm In Greatest
Dimension (T1b)
Tumor > 3 Cm But <=7 Cm Involves Main
Bronchus, >=2 Cm Distal To The Carina
Invades Visceral Pleura (pl1 Or Pl2)
Associated With Atelectasis Or
Obstructive Pneumonitis That Extends
To The Hilar Region But Does Not
Involve The Entire Lung (T2)
Tumor > 3 Cm But <=5 Cm In Greatest
Dimension (T2a)
Tumor > 5 Cm But <=7 Cm In Greatest
Dimension (T2b)
Tumor > 7 Cm Or One That Directly
Invades Any Of The Following: Parietal
Pleural (pl3) Chest Wall (including
Superior Sulcus Tumors), Diaphragm,
Phrenic Nerve, Mediastinal Pleura,
Parietal Pericardium; Or Tumor In The
Main Bronchus (T3)
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Tumor Of Any Size That Invades Any Of
The Following: Mediastinum, Heart,
Great Vessels, Trachea, Recurrent
Laryngeal Nerve, Esophagus, Vertebral
Body, Carina, Separate Tumor Nodule(s)
In A Different Ipsilateral Lobe (T4)
N Stage (check one in each row)
No Regional Lymph Node Metastasis
(N0)
Metastasis In Ipsilateral Peribronchial
And/or Ipsilateral Hilar Lymph Nodes
And Intrapulmonary Nodes, Including
Involvement By Direct Extension (N1)
Metastasis In Ipsilateral Mediastinal
And/or Subcarinal Lymph Node(s) (N2)
Metastasis In Contralateral Mediastinal,
Contralateral Hilar, Ipsilateral Or
Contralateral Scalene, Or
Supraclavicular Lymph Node(s) (N3)
M Stage (check one in each row)
No Distant Metastasis (no Pathologic
M0; Use Clinical M To Complete Stage
Group) (M0)
Distant Metastasis (M1)
Separate Tumor Nodule(s) In A
Contralateral Lobe; Tumor With Pleural
Nodules Or Malignant Pleural (or
Pericardial) Effusion (M1a)
Distant Metastasis (M1b)
Pft's
Pulmonary function tests performed? (check one)
Yes
No
Forced Expiratory Volume 1 (FEV1) (mL)
Forced Expiratory Volume 1 (%Predicted FEV1)
(%)
Carbon Monoxide Diffusion (% predicted DLCO)
(%)
Forced Vital Capacity (FVC1) (mL)
Forced Vital Capacity (% predicted FVC1) (%)
Smoking Status
Have you smoked at least 100 cigarettes in your
entire life? (check one)
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No (No)
Unknown (Unknown)
Yes (Yes)
How old were you when you first started to
smoke regularly? (If yes Age)
On average, how many cigarettes do/did you
smoke per day
Do you now smoke cigarettes? (smoked in the
past 30 days check one)
No (No)
Unknown (Unknown)
Yes (Yes)
Number of years smoked cigarettes (If No years)
Estimated date of last use (cigarettes dd MMM
yyyy)
Cigar (check one)
Yes
No
Pipe (check one)
Yes
No
Snuff (check one)
Yes
No
Chewing tobacco (check one)
Yes
No
Other (check one)
Yes
No
Other, specify (If yes)
For how many years (If Yes, years)
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Kidney Cancer NCT00326898 Lab - E2805
Virtual Frozen Tissue Bank Form - 2611700v1.0
E2805 Virtual Frozen Tissue Bank Form
Sunitinib or Sorafenib in Treating Patients With Kidney
Cancer That Was Removed By Surgery
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=2B9224EB-
5DDE-5590-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/7764
E2805 Virtual Frozen Tissue Bank
Form
Header
ECOG Protocol Number
ECOG Patient ID
DCI Name
Registration Step
Reporting Period
Baseline (Baseline)
Patient Information
Patient Initials (Last First Middle)
Investigator's First Name
Investigator's Last Name
Registered Investigator (NCI Investigator #)
Frozen Tissue Information
Patient Medical Record Number
Date Specimen collected (for frozen tissue)
Pathology Institution Name (at which frozen
tissue is held)
Dept/Building
Street Name and Number
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City
State/Province
Country
Postal Code
Investigator Signature
Investigator Signature
Person Completing Form, Last Name
Person Completing Form, First Name
Form Completion Date, Original
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Lung Cancer NCT01336894 Treatment - ACOSOG-
Z4099 Evaluation/Treatment Form - 3181065v1.0
ACOSOG-Z4099 Evaluation/Treatment Form
Surgery With or Without Internal Radiation Therapy
Compared With Stereotactic Body Radiation Therapy in
Treating Patients With High-Risk Stage I Non-Small Cell
Lung Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=990BA4F9-
5291-85C0-E040-BB89AD433BEA
All rights reserved. Please visit https://medical-data-
models.org/forms/7770
ACOSOG-Z4099
Evaluation/Treatment Form
Header Module
Protocol Number
Patient ID
Patient Initials (L F M)
Institution Number
Institution
Are data amended (check one if data amended,
please circle in red when using paper forms)
Yes
No
Visit
Visit
At Time Of Surgery/stereotactic Body
Radiation Therapy (At time of
surgery/SBRT)
Which treatment did the patient receive (check
one)
No Treatment Received (No treatment
received)
Stereotactic Body Radiation Therapy
Only (SBRT only)
Surgery With Brachytherapy (Surgery
with brachytherapy)
Surgery Without Brachytherapy (Surgery
without brachytherapy)
ECOG Performance Status (used for this visit:
check one)
Fully Active, Able To Carry On All Pre-
disease Performance Without
Restriction. (0)
Restricted In Physically Strenuous
Activity But Ambulatory And Able To
Carry Out Work Of A Light Or Sedentary
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Nature, E.g., Light Housework, Office
Work. (1)
Ambulatory And Capable Of All Selfcare
But Unable To Carry Out Any Work
Activities. Up And About More Than 50%
Of Waking Hours. (2)
Capable Of Only Limited Selfcare,
Confined To Bed Or Chair More Than
50% Of Waking Hours. (3)
Completely Disabled. Cannot Carry On
Any Selfcare. Totally Confined To Bed Or
Chair. (4)
Header
Surgery Date (dd MMM yyyy)
Was surgery Robot assisted (check one)
No (No)
Unknown (Unknown)
Yes (Yes)
Area (Check all that apply)
Lingula (Lingula)
Lower Lobe (left) (Lower Lobe (left))
Lower Lobe (right) (Lower Lobe (right))
Middle Lobe (right) (Middle Lobe (right))
Upper Lobe (left) (Upper Lobe (left))
Upper Lobe (right) (Upper Lobe (right))
Surgical Approach (check one)
Thoracoscopy / Video-assisted (vats)
(Thoracoscopy / Video-assisted (VATS))
Thoracotomy (thoracotomy)
Most Extensive Primary Surgery (check one)
Exploration, No Resection (Exploration,
No Resection)
Segmentectomy (Segmentectomy)
Wedge Resection (Wedge Resection)
Total Number of Segments
Number of lymph node stations
Size of Margin (cm)
ASA Class (check one)
Healthy Patient, No Medical Problems (I)
Mild Systemic Disease (II)
Severe Systemic Disease, But Not
Incapaitating (III)
Severe Systemic Disease That Is A
Constant Threat To Life (IV)
Moribund, Not Expected To Live 24
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Hours Irrespective Of Operation (V)
Time patient entered OR (use 24 hr clock: 00:00-
23:59 h h m m)
Skin Incision Start Time (use 24 hr clock: 00:00-
23:59 h h m m)
Skin Incision Stop Time (use 24 hr clock: 00:00-
23:59 h h m m)
Time patient exited OR (use 24 hr clock: 00:00-
23:59 h h m m)
Final Pathological Stage
Pathologic T Stage (check one)
Tumor <=3 Cm In Greatest Dimension,
Surrounded By Lung Or Visceral Pleura,
Without Bronchoscopic Evidence Of
Invasion More Proximal Than The Lobar
Bronchus (i.e., Not In The Main
Bronchus) (T1)
Tumor <=2 Cm In Greatest Dimension
(T1a)
Tumor > 2 Cm But <=3 Cm In Greatest
Dimension (T1b)
Tumor > 3 Cm But <=7 Cm Involves Main
Bronchus, >=2 Cm Distal To The Carina
Invades Visceral Pleura (pl1 Or Pl2)
Associated With Atelectasis Or
Obstructive Pneumonitis That Extends
To The Hilar Region But Does Not
Involve The Entire Lung (T2)
Tumor > 3 Cm But <=5 Cm In Greatest
Dimension (T2a)
Tumor > 5 Cm But <=7 Cm In Greatest
Dimension (T2b)
Tumor > 7 Cm Or One That Directly
Invades Any Of The Following: Parietal
Pleural (pl3) Chest Wall (including
Superior Sulcus Tumors), Diaphragm,
Phrenic Nerve, Mediastinal Pleura,
Parietal Pericardium; Or Tumor In The
Main Bronchus (T3)
Tumor Of Any Size That Invades Any Of
The Following: Mediastinum, Heart,
Great Vessels, Trachea, Recurrent
Laryngeal Nerve, Esophagus, Vertebral
Body, Carina, Separate Tumor Nodule(s)
In A Different Ipsilateral Lobe (T4)
Pathologic N Stage (check one)
No Regional Lymph Node Metastasis
(N0)
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Metastasis In Ipsilateral Peribronchial
And/or Ipsilateral Hilar Lymph Nodes
And Intrapulmonary Nodes, Including
Involvement By Direct Extension (N1)
Metastasis In Ipsilateral Mediastinal
And/or Subcarinal Lymph Node(s) (N2)
Metastasis In Contralateral Mediastinal,
Contralateral Hilar, Ipsilateral Or
Contralateral Scalene, Or
Supraclavicular Lymph Node(s) (N3)
Regional Lymph Nodes Cannot Be
Assessed (NX)
Distant metastases present? (check one)
Yes
No
Pathologic M Stage (If yes check one)
Distant Metastasis (M1)
Separate Tumor Nodule(s) In A
Contralateral Lobe; Tumor With Pleural
Nodules Or Malignant Pleural (or
Pericardial) Effusion (M1a)
Distant Metastasis (M1b)
Staple line Cytology (check one)
Negative (Negative)
Positive (Positive)
Staple line Histology (check one)
Negative (Negative)
Positive (Positive)
Pathologic Primary Tumor Size (check one)
> 4.0 Cm (> 4.0 cm)
0 - 1.0 Cm (0 - 1.0 cm)
1.1 - 2.0 Cm (1.1 - 2.0 cm)
2.1 - 3.0 Cm (2.1 - 3.0 cm)
3.1 - 4.0 Cm (3.1 - 4.0 cm)
Total number of lymph nodes removed
Discharge
Discharge Date (dd MMM yyyy)
Date chest tube removed (CT dd MMM yyyy)
Surgeon Name, Last (PRINT)
Surgeon Name, First (PRINT)
Header
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Brachytherapy technique (check one)
Double Strand (Double strand)
Mesh (Mesh)
Length (If Mesh cm)
Width (If Mesh cm)
Mesh type used (check one)
Mesh Pre-fabricated By Manufacturer
(Mesh pre-fabricated by manufacturer)
Mesh Seeds Manually Threaded (Mesh
seeds manually threaded)
Strand
Length (cm)
Seeds per strand
Activity/Seed (mCi)
Total activity (Strand mCi)
Have all Stereotactic Body Radiation Therapy
Quality Assurance documentation and imaging
materials been submitted to the Image-guided
Therapy Center (SBRT see Section 5.4.3 ITC
check one)
Yes
No
Total # Seeds
Total Activity (mCi)
Prescription (Gy)
Date of post-implant CT (dd MMM yyyy)
Sbrt Fraction (1)
Was fraction delivered (check one)
Yes
No
Date (dd MMM yyyy)
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Total Dose (Gy)
Sbrt Fraction (1)
Was fraction delivered (check one)
Yes
No
Date (dd MMM yyyy)
Total Dose (Gy)
Sbrt Fraction (1)
Was fraction delivered (check one)
Yes
No
Date (dd MMM yyyy)
Total Dose (Gy)
Stereotactic Body Radiation Therapy
Were there any unscheduled interruptions in
radiation therapy? (stereotactic body check one)
Yes
No
Treatment interruption start date (If yes dd MMM
yyyy)
Treatment interruption end date (If yes dd MMM
yyyy)
Days Treatment Was Interrupted (number)
Reasons
Anc (ANC)
Dysphagia (Dysphagia)
Febrile Neutropenia (Febrile
neutropenia)
Machine Down (Machine down)
Other Specify (other)
Other Nonhematologic (Other
nonhematologic)
Platelets (Platelets)
Skin Reaction (Skin reaction)
Social (Social)
Systemic Reaction (Systemic reaction)
Unknown (Unknown)
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Specify
Due to
Chemotherapy (Chemotherapy)
Combination Therapy (Combination
Therapy)
Other (Other)
Radiotherapy (Radiotherapy)
Unknown (Unknown)
Other specify
Have all Stereotactic Body Radiation Therapy
Quality Assurance documentation and imaging
materials been submitted to the Image-guided
Therapy Center (SBRT see Section 5.4.3 ITC
check one)
Yes
No
Footer Module
Comments
Radiation Oncologist's Name, Last (PRINT)
Radiation Oncologist's Name, First (PRINT)
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Evaluation/Treatment Form - 3181065v1.0
Lung Cancer NCT01336894 Off Treatment - ACOSOG-
Z4099 End of Intervention Form - 3178441v1.0
ACOSOG-Z4099 End of Intervention Form
Surgery With or Without Internal Radiation Therapy
Compared With Stereotactic Body Radiation Therapy in
Treating Patients With High-Risk Stage I Non-Small Cell
Lung Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=9869A599-
BCAB-139E-E040-BB89AD432862
All rights reserved. Please visit https://medical-data-
models.org/forms/7775
ACOSOG-Z4099 End of Intervention
Form
Header Module
Protocol Number
Patient ID
Patient Initials (L F M)
Institution Number
Institution
Are data amended (check one if data amended,
please circle in red when using paper forms)
Yes
No
Preregistration Screening Failure
Last Date (any modality of) protocol therapy was
given (dd MMM yyyy date of surgery or last
SBRT fraction on this study or date decision
made not to initiate protocol treatment)
Off Treatment Date (dd MMM yyyy date decision
was made to end active treatment or not to
initiate protocol treatment)
Reason Treatment Ended (Intervention check
one)
Adverse Event/side Effects/complications
(Adverse Event/Side
Effects/Complications)
Alternative Therapy (Alternative therapy)
Death On Study (Death on study)
Disease Progression Before Active
Treatment (Disease Progression before
active treatment)
Disease Progression, Relapse During
Active Treatment (Disease progression,
relapse during active treatment)
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Other (Other)
Patient Off-treatment For Other
Complicating Disease (Patient off-
treatment for other complicating disease)
Patient Withdrawal Or Refusal After
Beginning Protocol Therapy (Patient
withdrawal/refusal after beginning
protocol therapy)
Patient Withdrawal Or Refusal Before
Beginning Protocol Therapy (Patient
withdrawal/refusal prior to beginning
protocol therapy)
Treatment Completed Per Protocol
Criteria (Treatment completed per
protocol criteria)
Patient withdrawal/refusal after beginning
protocol therapy specify
Patient withdrawal/refusal prior to beginning
protocol therapy specify
Adverse event/side effects/complications specify
Alternative Therapy, specify
Patient off-treatment for other complicating
disease, Specify
Other specify
2 / 2
Lung Cancer NCT01336894 Off Treatment - ACOSOG-Z4099 End of
Intervention Form - 3178441v1.0
Breast Cancer NCT00601900 On-Study - CALGB
40503 ON-STUDY FORM - 2551476v1.0
CALGB 40503 ON-STUDY FORM
Tamoxifen or Letrozole With or Without Bevacizumab in
Treating Women With Stage III or Stage IV Breast Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=24087EF3-
EA58-6B28-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/7785
CALGB 40503 ON-STUDY FORM
Header
CALGB Form
CALGB Study No.
CALGB Patient ID
Are data amended
Yes
No
Unnamed2
Patient Initials (Last, First Middle)
Patient Hospital No.
Institution/Affiliate
Participating Group
Participating Group Study No.
Participating Group Patient ID
Patient Characteristics
ECOG Performance Status (Mark one with an X.)
Fully Active, Able To Carry On All Pre-
disease Performance Without
Restriction. (0)
Restricted In Physically Strenuous
Activity But Ambulatory And Able To
Carry Out Work Of A Light Or Sedentary
Nature, E.g., Light Housework, Office
Work. (1)
Menstrual period within the last 12 months?
Yes
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No
Date of last menstrual cycle (MM DD YYYY)
Ovarian Function Suppression Type (If the patient
was pre-menopausal)
Bilateral Oophorectomy (Bilateral
oophorectomy)
Lhrh Agonist (LHRH Agonist)
MedDRA Disease Code
Disease Description
ER status (Mark one with an X.)
Negative (Negative)
Positive (Positive)
Unknown (Unknown)
Other, specify
PgR status  (Mark one with an X.)
Negative (Negative)
Positive (Positive)
Unknown (Unknown)
Timing of assay  (Mark one with an X.)
At Recurrence (At recurrence)
Initial Diagnosis (Initial diagnosis)
Other (Other)
Timing of assay  (Mark one with an X.)
At Recurrence (At recurrence)
Initial Diagnosis (Initial diagnosis)
Other (Other)
Other, specify
Date of Initial Diagnosis of Primary Tumor (MM
DD YYYY)
Date Progressive or Metastatic Disease First
Diagnosed (MM DD YYYY)
Site Of Progression Or Recurrence
Sites of Progression (s)
Bone (Bone)
Bone Marrow (Bone marrow)
Brain (Brain)
Distant Lymph Nodes (Distant nodes)
Distant Skin/subcutaneous Tissue
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(Distant skin/subcutaneous tissue)
Ipsilateral Supraclavicular Nodes
(Ipsilateral supraclavicular nodes)
Liver (Liver)
Local-regional (including Ipsilateral
Breast; Chest Wall; Axillary, Internal
Mammary, And Infraclavicular Nodes;
Local-regional Skin And Subcutaneous
Tissue) (Local-regional)
Lung, Nos (Lung)
Contralateral Breast (Opposite breast)
Other (Other)
Other Cns (Other CNS)
Pleura (Pleura)
Other specify
Required Laboratory Values
Peripheral Granulocytes Count (x 10^3/mmicroL)
Peripheral Platelet Count (x 10^3/mmicroL)
Creatinine (mg/dL)
Bilirubin (mg/dL)
Bilirubin ULN (mg/dL)
SGPT (ALT) (U/L)
SGPT (ALT) ULN (U/L)
SGOT (AST) (U/L)
SGOT (AST) ULN (U/L)
International Normalization Ratio (INR)
Urinalysis
Urine Protein (Mark one with an X.)
0 (0)
1+ (1+)
2+ (2+)
3+ (3+)
4+ (4+)
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Protein from 24 hour Urine Collection (g of
protein / 24 hours)
Urine Protein/Creatinine Ratio (UPC Or if
UPC<=1)
Immunohistochemistry
Immunohistochemistry Kit or Test Type  (Mark all
that apply with an X.)
Cb-11 Other (CB-11 other)
Cb-11/ventana Kit (CB-11/Ventana Kit)
Dako Herceptest [tm] (DAKO Herceptest
[TM])
FISH Kit or Test Type (Mark all that apply with an
X.)
Other Specify (Other)
Ventana Inform (Ventana INFORM)
Vysis/path Vysion[tm] (Vysis/PathVysion)
Final Diagnosis with HER2/neu (Mark one with
an X.)
Negative (Negative)
Positive (Positive)
Prior Treatment - Systemic Regimens
Prior anthracycline Treatment
Yes
No
Prior Treatment Regimen Name (s Include all
therapies chemotherapy, hormonal, radiotherapy,
etc.)
Prior Treatment Regimen Start Date (MM DD
YYYY)
Prior Treatment Regimen End Date (MM DD
YYYY)
Footer Module
Completed by
Date Form Completed
4 / 4
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FORM - 2551476v1.0
Neoplasms, Breast NCT00490139 Treatment - BIG 2-06 / NCCTG N063D /
EGF106708 - Administration of Study Drug Trastuzumab - 2640601v1.0
BIG 2-06 / NCCTG N063D / EGF106708 - Administration of
Study Drug Trastuzumab
ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment
Optimisation) Study; BIG 2-06/N063D
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=31134C18-
531D-195E-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/7818
BIG 2-06 / NCCTG N063D /
EGF106708 - Administration of
Study Drug Trastuzumab
Header Module
Centre No.
Subject No.
Administration Of Paclitaxel Concomitantly
With Biological Therapy (design 2)
Date Agent Administered
Dose
Total Dose
Was treatment delayed
Yes
No
Specify code
Administrative Reasons (Administrative
reasons)
Adverse Event Other Than Hematologic
Or Cardiac (Adverse event other than
hematologic or cardiac)
Cardiac Adverse Event (Cardiac adverse
event)
Dosing Error (Dosing error)
Hematologic Adverse Event
(Hematologic adverse event)
Other (Other)
Subject Non-compliance (Subject non-
compliance)
Specify
Was dose interrupted
Yes
No
Specify code
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Administrative Reasons (Administrative
reasons)
Adverse Event Other Than Hematologic
Or Cardiac (Adverse event other than
hematologic or cardiac)
Cardiac Adverse Event (Cardiac adverse
event)
Dosing Error (Dosing error)
Hematologic Adverse Event
(Hematologic adverse event)
Other (Other)
Subject Non-compliance (Subject non-
compliance)
Specify
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Neoplasms, Breast NCT00490139 Treatment - BIG 2-06 / NCCTG N063D /
EGF106708 - Administration of Study Drug Trastuzumab - 2640601v1.0
Neoplasms, Breast NCT00490139 Treatment - BIG 2-06 / NCCTG N063D /
EGF106708 - Administration of Study Drug Paclitaxel - 2640557v1.0
BIG 2-06 / NCCTG N063D / EGF106708 - Administration of
Study Drug Paclitaxel
ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment
Optimisation) Study; BIG 2-06/N063D
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=310FD8B6-
7A8E-517A-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/7819
BIG 2-06 / NCCTG N063D /
EGF106708 - Administration of
Study Drug Paclitaxel
Header Module
Centre No.
Subject No.
Administration Of Paclitaxel Concomitantly
With Biological Therapy (design 2)
Date Agent Administered
Dose
Total Dose
Was treatment delayed
Yes
No
Specify code
Administrative Reasons (Administrative
reasons)
Adverse Event Other Than Hematologic
Or Cardiac (Adverse event other than
hematologic or cardiac)
Cardiac Adverse Event (Cardiac adverse
event)
Dosing Error (Dosing error)
Hematologic Adverse Event
(Hematologic adverse event)
Other (Other)
Subject Non-compliance (Subject non-
compliance)
Specify
Was dose reduced
Yes
No
Specify code
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Administrative Reasons (Administrative
reasons)
Adverse Event Other Than Hematologic
Or Cardiac (Adverse event other than
hematologic or cardiac)
Cardiac Adverse Event (Cardiac adverse
event)
Dosing Error (Dosing error)
Hematologic Adverse Event
(Hematologic adverse event)
Other (Other)
Subject Non-compliance (Subject non-
compliance)
Specify
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Neoplasms, Breast NCT00490139 Treatment - BIG 2-06 / NCCTG N063D /
EGF106708 - Administration of Study Drug Paclitaxel - 2640557v1.0
Neoplasms, Breast NCT00490139 Treatment - BIG 2-06 /
NCCTG N063D / EGF106708 - Hormonotherapy - 2645219v1.0
BIG 2-06 / NCCTG N063D / EGF106708 - Hormonotherapy
ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment
Optimisation) Study; BIG 2-06/N063D
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=31B3D899-
6213-1BF8-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/7820
BIG 2-06 / NCCTG N063D /
EGF106708 - Hormonotherapy
Header Module
Centre No.
Subject No.
Ecg
Has the patient received hormone therapy before
or during the trial
Yes
No
Name of treatment or surgical procedure
Dose
Units
Milligram (mg)
Not Applicable (N/A)
Begin date
End date
Ongoing at time of study completion
Yes (Yes)
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TREATMENT FORM Prostate Cancer
(NCT00110214)
CALGB: 90401 TREATMENT FORM
Docetaxel and Prednisone With or Without Bevacizumab in
Treating Patients With Prostate Cancer That Did Not
Respond to Hormone Therapy
NCT00110214
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=EF49A3AB-
7EC3-51E0-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/7822
TREATMENT FORM Prostate
Cancer (NCT00110214)
Header
CALGB Form
CALGB Study No.
CALGB Patient ID
Patient Initials
Patient Hospital No.
Institution/Affiliate
Participating Group
Participating Group Study No.
Participating Group Patient ID
Are data amended
Yes
No
Patient has withdrawn consent for clinical follow-
up.
Yes
No
Patient has withdrawn consent for survival follow-
up.
Yes
No
Withdrawn consent date
Completed by
Date form completed
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Clinical Data
Currrent cycle number
Cycle start date
Cycle end date
Height
Weight
BSA
Agent name
Dose
No. of days administered
Administered?
Yes
No
Dose modification (^1)
Dose Delayed (Dose delayed)
Dose Delayed And Reduced (Dose
delayed and reduced)
Dose Held (Dose held)
Dose Reduced (Dose reduced)
Drug Discontinued (Drug discontinued)
No Dose Modification (No dose
modification)
Dose modification reason (^2)
Cardiotoxicity (Cardiotoxicity)
Change In Bsa (Change in BSA)
Cns Toxicity (CNS toxicity)
Dosing Error (Dosing error)
Gi Toxicity (GI toxicity)
Hematologic Toxicity (Hematologic
toxicity)
Hepatic Dysfunction (Hepatic
dysfunction)
Hypersensitivity (Hypersensitivity)
Infection/fever (Infection/fever)
Other (Other)
Patient Refusal/noncompliance (Patient
refusal/noncompliance)
Pns Toxicity (PNS toxicity)
Pulmonary Toxicity (Pulmonary toxicity)
Renal Toxicity (Renal toxicity)
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Scheduling (Scheduling)
If dose modification = 99, specify
Concomitant medications received this cycle
(Mark all that apply with an X.)
Anti-coagulant Agents (Anti-coagulant
agents)
Anti-platelet Agents (Anti-platelet agents)
Aspirin (Aspirin)
Growth Factor (Growth factor)
Lipid-lowering Drugs (Lipid-lowering
drugs)
Growth factor (Use per NCCN / ASCO guidelines
described in 90401 memorandum dated 8/15/07.
Mark all that apply with an X.)
Epoetin Alfa (Epoetin)
Granulocyte-macrophage Colony-
stimulating Factor (G-CSF)
Oprelvekin (Neumega)
Other (Other)
Other, specify
Aspirin (Mark one with an X.)
325 Mg/daily (325 mg/daily)
81 Mg/daily (81 mg/daily)
Agent code (*)
Clopidogrel (clopidogrel)
Dipyridamole (dipyridamole)
Other (Other)
Ticlopidine (ticlopidine)
Other, specify generic name
Frequency (no. of daily doses)
Agent start date
Agent end date
Agent code (**)
Low Molecular Weight Heparin (Low
molecular weight heparin)
Other (Other)
Warfarin (Warfarin)
Other, specify generic name
Agent code (***)
Atorvastatin (atorvastatin)
Cholestyramine (cholestyramine)
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Fenofibrate (fenofibrate)
Fluvastatin (fluvastatin)
Gemfibrozil (gemfibrozil)
Lovastatin (lovastatin)
Other (Other)
Pravastatin (pravastatin)
Rosuvastatin (rosuvastatin)
Simvastatin (simvastatin)
Other, specify generic name
Was treatment permanently discontinued during
this cycle (bevacizumab/placebo)
Yes
No
Reason treatment ended (*)
Adverse Event/side Effects/complications
(Adverse event/side
effects/complications)
Alternative Therapy (Alternative therapy)
Death On Study (Death on study)
Disease Progression, Relapse During
Active Treatment (Disease progression,
relapse during active treatment)
Other (Other)
Patient Off-treatment For Other
Complicating Disease (Patient off-
treatment for other complicating disease)
Patient Withdrawal Or Refusal (Patient
withdrawal or refusal prior to beginning
protocol therapy)
Patient Withdrawal Or Refusal After
Beginning Protocol Therapy (Patient
withdrawal/refusal after beginning
protocol therapy)
Treatment Completed Per Protocol
Criteria (Treatment completed per
protocol criteria)
If Other reason, specify:
Total number of cycles completed
(bevacizumab/placebo)
last dose date (bevacizumab/placebo)
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Lung Cancer NCT01107626 Treatment - E5508
Treatment Form - Step 2 - 2910090v1.0
E5508 Treatment Form - Step 2
Bevacizumab or Pemetrexed Disodium Alone or In
Combination After Induction Therapy in Treating Patients
With Advanced Non-Squamous Non-Small Cell Lung
Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=6D45EDA8-
0AF1-B703-E040-BB89AD430413
All rights reserved. Please visit https://medical-data-
models.org/forms/7832
E5508 Treatment Form - Step 2
Header
DCI Name
Registration Step (Place ID Label Here)
Patient Initials (Last, First)
ECOG Protocol Number
ECOG Protocol Number
ECOG Patient ID
ECOG Patient ID
Participating Group Protocol Number
Participating Group Patient ID
Institution/Affiliate
Unnamed2
Please mark an 'X' if data have been amended.
(Please circle amended items in red)
Date data amended (s M D Y)
On Treatment
On Treatment Report Period (Choose one)
> Cycle 18 - Step 2 (> Cycle 18 - Step 2)
Cycle 1 Step 2 (Cycle 1 Step 2)
Cycle 10 Step 2 (Cycle 10 Step 2)
Cycle 11 Step 2 (Cycle 11 Step 2)
Cycle 12 Step 2 (Cycle 12 Step 2)
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Cycle 13-step 2 (Cycle 13-Step 2)
Cycle 14-step 2 (Cycle 14-Step 2)
Cycle 15 Step 2 (Cycle 15 Step 2)
Cycle 16-step 2 (Cycle 16-Step 2)
Cycle 17 Step 2 (Cycle 17 Step 2)
Cycle 18-step 2 (Cycle 18-Step 2)
Cycle 2 Step 2 (Cycle 2 Step 2)
Cycle 3 Step 2 (Cycle 3 Step 2)
Cycle 4 Step 2 (Cycle 4 Step 2)
Cycle 5 Step 2 (Cycle 5 Step 2)
Cycle 6 Step 2 (Cycle 6 Step 2)
Cycle 7 Step 2 (Cycle 7 Step 2)
Cycle 8 Step 2 (Cycle 8 Step 2)
Cycle 9 Step 2 (Cycle 9 Step 2)
Specify Cycle
Section Ii - Reporting Period
Reporting Period Start Date (M D Y)
Reporting Period End Date (M D Y)
Vital Status
Patient's Vital Status (IMPORTANT: As soon as a
grade 5 adverse event is reported, it is necessary
to submit ALL outstanding data in addition to the
adverse event form and AdEERS report)
Alive (Alive)
Dead (Dead)
Date of Last Contact or Death (M D Y)
Primary Cause of Death (if applicable)
Due To Other Cause (Due to other
cause)
Due To Protocol Treatment (Due to
protocol treatment)
Due To This Disease (Due to this
disease)
Unknown (Unknown)
Describe cause of death
Unnamed Module 3
Weight (kg Day 1 of this cycle [Note: code weight
loss/gain on E5508 Adverse Event Form])
Blood Pressure, Systolic (on Day 1 of this cycle
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mm/Hg)
Blood pressure, Diastolic (on Day 1 of this cycle
mm/Hg)
Mark an 'X' if not done
Hemoglobin (Hgb g/dl <24 horus of Day 1 of this
cycle)
Test not done
Anti-Hypertensive Drugs (Please mark an 'X' for
each and every type of agent administered this
reporting period. If no medication was given,
please mark an 'X' next to "No medication
given.")
Ace Inhibitor (ACE inhibitors)
Angiotensin Ii Receptor Blocker
(Angiotensin II inhibitors)
Beta Blocker (Beta blockers)
Calcium Channel Blocker (Calcium
channel blockers)
Diuretic (Diuretics)
No Medication Given (No medication
given)
Other (Other)
Other, specify
Unnamed Module 4
Agent Name (Pemetrexed)
Was the agent administered during this reporting
period? (Pemetrexed)
Yes
No
Date Agent Administered (If yes M D Y)
Agent Dose (mg)
Unnamed Module 4
Agent Name (Pemetrexed)
Was the agent administered during this reporting
period? (Pemetrexed)
3 / 4
Lung Cancer NCT01107626 Treatment - E5508 Treatment Form - Step 2
- 2910090v1.0
Yes
No
Date Agent Administered (If yes M D Y)
Agent Dose (mg)
Treatment Modifications
Was agent modified (decreased/increased) or
omitted? (this cycle)
Yes
No
Dose Modification Reason
Adverse Event (Adverse event)
Dosing Error (Dosing error)
Other (Other)
Patient Refusal/noncompliance (Patient
refusal/noncompliance)
Scheduling (Scheduling)
Other, specify
Non-protocol Therapy
Was any non-protocol therapy given during
protocol treatment? (not previously reported )
Yes
No
Comments
Investigator Signature
Investigator Signature Date (MM DD YYYY)
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Lung Cancer NCT01107626 Treatment - E5508
Treatment Form - Step 1 - 2909955v1.0
E5508 Treatment Form - Step 1
Bevacizumab or Pemetrexed Disodium Alone or In
Combination After Induction Therapy in Treating Patients
With Advanced Non-Squamous Non-Small Cell Lung
Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=6D44FB53-
DDFC-46CC-E040-BB89AD43155D
All rights reserved. Please visit https://medical-data-
models.org/forms/7833
E5508 Treatment Form - Step 1
Header
DCI Name
Registration Step (Place ID Label Here)
Patient Initials (Last, First)
ECOG Protocol Number
ECOG Protocol Number
ECOG Patient ID
ECOG Patient ID
Participating Group Protocol Number
Participating Group Patient ID
Institution/Affiliate
Unnamed2
Please mark an 'X' if data have been amended.
(Please circle amended items in red)
Date data amended (s M D Y)
On Treatment
On Treatment Report Period (Choose one)
Cycle 1 Step 1 (Cycle 1 Step 1)
Cycle 2 Step 1 (Cycle 2 Step 1)
Cycle 3 Step 1 (Cycle 3 Step 1)
Cycle 4 Step 1 (Cycle 4 Step 1)
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Section Ii - Reporting Period
Reporting Period Start Date (M D Y)
Reporting Period End Date (M D Y)
Vital Status
Patient's Vital Status
Alive (Alive)
Dead (Dead)
Date of Last Contact or Death (M D Y)
Primary Cause of Death (if applicable)
Due To Other Cause (Due to other
cause)
Due To Protocol Treatment (Due to
protocol treatment)
Due To This Disease (Due to this
disease)
Unknown (Unknown)
Describe cause of death
Unnamed Module 3
Weight (kg Day 1 of this cycle [Note: code weight
loss/gain on E5508 Adverse Event Form])
Blood Pressure, Systolic (on Day 1 of this cycle
mm/Hg)
Blood pressure, Diastolic (on Day 1 of this cycle
mm/Hg)
Mark an 'X' if not done
Anti-Hypertensive Drugs (Please mark an 'X' for
each and every type of agent administered this
reporting period. If no medication was given,
please mark an 'X' next to "No medication
given.")
Ace Inhibitor (ACE inhibitors)
Angiotensin Ii Receptor Blocker
(Angiotensin II inhibitors)
Beta Blocker (Beta blockers)
Calcium Channel Blocker (Calcium
channel blockers)
Diuretic (Diuretics)
No Medication Given (No medication
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Lung Cancer NCT01107626 Treatment - E5508 Treatment Form - Step 1
- 2909955v1.0
given)
Other (Other)
Other, specify
Unnamed Module 4
Agent Name (Bevacizumab)
Was the agent administered during this reporting
period? (Bevacizumab)
Yes
No
Date Agent Administered (If yes M D Y)
Agent Dose (mg)
Unnamed Module 4
Agent Name (Bevacizumab)
Was the agent administered during this reporting
period? (Bevacizumab)
Yes
No
Date Agent Administered (If yes M D Y)
Agent Dose (mg)
Unnamed Module 4
Agent Name (Bevacizumab)
Was the agent administered during this reporting
period? (Bevacizumab)
Yes
No
Date Agent Administered (If yes M D Y)
Agent Dose (mg)
Treatment Modifications
Was agent modified (decreased/increased) or
omitted? (this cycle)
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Lung Cancer NCT01107626 Treatment - E5508 Treatment Form - Step 1
- 2909955v1.0
Yes
No
Dose Modification Reason
Adverse Event (Adverse event)
Dosing Error (Dosing error)
Other (Other)
Patient Refusal/noncompliance (Patient
refusal/noncompliance)
Scheduling (Scheduling)
Other, specify
Non-protocol Therapy
Was any non-protocol therapy given during
protocol treatment? (not previously reported )
Yes
No
Comments
Investigator Signature
Investigator Signature Date (MM DD YYYY)
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- 2909955v1.0
Lung Cancer NCT01107626 Flow Sheet - E5508 Source
Document Tracking Coversheet Form - 2908022v1.0
E5508 Source Document Tracking Coversheet Form
Bevacizumab or Pemetrexed Disodium Alone or In
Combination After Induction Therapy in Treating Patients
With Advanced Non-Squamous Non-Small Cell Lung
Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=6D435D37-
53F7-AA13-E040-BB89AD43538D
All rights reserved. Please visit https://medical-data-
models.org/forms/7839
E5508 Source Document Tracking
Coversheet Form
Header
ECOG Protocol Number
ECOG Patient ID
DCI Name
Registration Step
Reporting Period
Baseline Step 1 (Baseline step 1)
Unnamed2
Patient Initials (Last, First)
ECOG Protocol Number
Participating Group Protocol Number
ECOG Patient ID
Participating Group Patient ID
Institution/Affiliate
Section Ii
Document type (Choose all that apply)
Pathology Report (Pathology Report)
Report Created Date (List an identifiable date
from the source document, such as date of the
biopsy/surgery/assay/recurrence/second primary,
date materials sent to central laboratory. M D Y)
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Breast Cancer NCT00433589 Treatment -
Endocrine therapy checklist - 2499128v1.0
Endocrine therapy checklist
Genetic Testing or Clinical Assessment in Determining the
Need for Chemotherapy in Women With Breast Cancer
That Involves No More Than 3 Lymph Nodes
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=1969BCFD-
8837-1309-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/7847
Endocrine therapy checklist
Header
Patient Birth Date
Patient Hospital Number
Institution Name
Institution No.
Physician of Record
Header
Agent Start Date
Date Informed Consent Signed
Thromboembolic event
Yes
No
Prior Immunotherapy
Yes
No
Date Prior Adjuvant Hormonal Therapy Started
Date Prior Adjuvant Hormonal Therapy Ended
Did patient receive Ovarian Function Suppression
(OFS) during this follow-up period?
No, Will Never Start. (No, will never
start.)
No, Will Start Later, Submit With Next
Follow-up Form (No, will start later,
submit with next Follow-Up Form)
Yes, But Stopped Early. (Yes, but
stopped early.)
Yes, Completed Per Protocol (Yes,
completed per protocol)
Yes, Continuing (Yes, continuing)
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Assigned Treatment Arm
Endocrine therapy
No (No)
Unknown (Unknown)
Yes (Yes)
Endocrine therapy
No (No)
Unknown (Unknown)
Yes (Yes)
Comments
Date
Investigator Signature
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Breast Cancer NCT00433589 Treatment - Endocrine therapy checklist -
2499128v1.0
Breast Cancer NCT00914043 Treatment - NSABP B-45 Worksheet
for Reporting Initiation of Sunitinib/Placebo - 2830516v1.0
NSABP B-45 Worksheet for Reporting Initiation of
Sunitinib/Placebo
Studying Biological Markers of Fatigue in Women With
Residual Invasive Breast Cancer Enrolled on Clinical Trial
NSABP-B-45
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=61A68212-
D8B0-0740-E040-BB89AD431DF9
All rights reserved. Please visit https://medical-data-
models.org/forms/7849
NSABP B-45 Worksheet for
Reporting Initiation of
Sunitinib/Placebo
Header Module
Patient Initials (Last First Middle)
NSABP Patient ID
All Patients
Did the patient begin Sunitinib/Placebo
Yes
No
Agent Start Date (Sunitinib/Placebo Month Day
Year)
Reason Treatment did not begin
(Sunitinib/Placebo)
Alternative Therapy (Alternative therapy)
Death (Death)
New Lesion (including Second Primary
Cancer) Or Other Sign Of Progression
(New lesion (including second primary
cancer) or other sign of progression)
Other (Other)
Patient Withdrawal Or Refusal (Patient
withdrawal or refusal)
Other, specify
Footer Module
Comments (optional)
Person Completing Form
Date Form Completed (MM DD YYYY)
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Breast Cancer NCT00914043 Treatment - NSABP B-45
Worksheet for Sunitinib/Placebo Treatment Form - 2830664v1.0
NSABP B-45 Worksheet for Sunitinib/Placebo Treatment
Form
Studying Biological Markers of Fatigue in Women With
Residual Invasive Breast Cancer Enrolled on Clinical Trial
NSABP-B-45
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=61BA6471-
86CD-B427-E040-BB89AD43714B
All rights reserved. Please visit https://medical-data-
models.org/forms/7850
NSABP B-45 Worksheet for
Sunitinib/Placebo Treatment Form
Header
Patient Initials (Last First Middle)
NSABP Patient ID
Reporting Period
Reporting Period (mark one)
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
7 (7)
Section 1. Sunitinib/placebo For All
Patients
Agent Start Date (Date drug dispensed Month
Day Year)
Were there any physician-directed treatment
modifications during this interval
Yes
No
Dose modification (if yes mark all that apply)
Dose Held (Dose held)
Dose Reduced (Dose reduced)
Drug Permanently Discontinued Prior To
Completion (Drug permanently
discontinued prior to completion)
Agent End Date (Sunitinib/Placebo Date of last
Sunitinib/Placebo dose Month Day Year)
Agent End Date (Sunitinib/Placebo Date of last
Sunitinib/Placebo dose Month Day Year)
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Reason Treatment Ended (If hormonal therapy
was discontinued during this interval Hormonal
Therapy)
Adverse Event/side Effects/complications
(Adverse event/side
effects/complications)
Death (Death)
New Lesion (including Second Primary
Cancer) Or Other Sign Of Progression
(New lesion (including second primary
cancer) or other sign of progression)
Other (Other)
Patient Withdrawal Or Refusal (Patient
withdrawal or refusal)
Other, specify
Estimate Of Patient Compliance
What percentage of the expected number of
capsules did the patient take (Sunitinib/Placebo)
About Half (About half)
About One-fourth (About one-fourth)
About Three-fourths (About three-
fourths)
All Or Almost All (All or almost all)
Only A Few (Only a few)
How was the number of capsules taken during
this period determined (mark all that apply)
Patient Diary, Calendar, Or Other Tool
(Patient diary, calendar, or other tool)
Patient Estimate (Patient Estimate)
Pill Count (Pill Count)
Section 2. Adjuvant Hormonal Therapy
During Sunitinib/placebo Treatment
Has the patient received any hormone therapy
during this reporting period? (Sunitinib/Placebo)
Yes
No
Was all hormonal therapy discontinued this report
period (Sunitinib/Placebo)
Yes
No
Hormone therapy end date (Month Day Year date
of last hormonal therapy dose)
Hormonal Agent When Hormonal Therapy was
Permanently Discontinued
Aromatase Inhibitor (Aromatase
Inhibitor)
Other (Other)
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Breast Cancer NCT00914043 Treatment - NSABP B-45 Worksheet for
Sunitinib/Placebo Treatment Form - 2830664v1.0
Tamoxifen (Tamoxifen)
Other, specify
Was the discontinuation of hormonal therapy
physician-directed
Yes
No
Reason Treatment Ended (If hormonal therapy
was discontinued during this interval Hormonal
Therapy)
Adverse Event/side Effects/complications
(Adverse event/side
effects/complications)
Death (Death)
New Lesion (including Second Primary
Cancer) Or Other Sign Of Progression
(New lesion (including second primary
cancer) or other sign of progression)
Other (Other)
Patient Withdrawal Or Refusal (Patient
withdrawal or refusal)
Other, specify
Footer
Comments (optional)
Person Completing Form
Date Form Completed (MM DD YYYY)
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Breast Cancer NCT00914043 Treatment - NSABP B-45 Worksheet for
Sunitinib/Placebo Treatment Form - 2830664v1.0
Fallopian Tube Cancer NCT00951496 On-Study - GOG-0252
Ovarian Cancer Surgery Reporting (OCR) - 2839109v1.0
GOG-0252 Ovarian Cancer Surgery Reporting (OCR)
Bevacizumab and Intravenous or Intraperitoneal
Chemotherapy in Treating Patients With Stage II, Stage III,
or Stage IV Ovarian Epithelial Cancer, Fallopian Tube
Cancer, or Primary Peritoneal Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=62BEE31D-
C4C9-F3A9-E040-BB89AD434182
All rights reserved. Please visit https://medical-data-
models.org/forms/7854
GOG-0252 Ovarian Cancer Surgery
Reporting (OCR)
Header Module
Date form originally completed
Date form amended
Person amending form, last name
Patient Initials
Patient Study ID
Person Completing Form, Last Name
Ovarian Cancer Surgery
Date of cancer debulking surgery
Date of IP port placement
Brand and model of peritoneal access device
How was the port placed
Ovarian Debulking Surgery (ovarian
debulking surgery)
Using Interventional Radiology (using
interventional radiology)
Using Laparoscopy (using laparoscopy)
Using Mini-laparotomy (using mini-
laparotomy)
Surgery Information
Hysterectomy
Yes
No
Total hysterectomy
Yes
No
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Supracervical hysterectomy
Yes
No
Appendectomy
Yes
No
Small bowel resection
Yes
No
Right colon resection
Yes
No
Left colon resection
Yes
No
Pelvic nodes
Yes
No
Pelvic nodes
Negative Finding (Negative)
Positive Finding (Positive)
Para-aortic nodes
Yes
No
Paraaortic nodes
Negative Finding (Negative)
Positive Finding (Positive)
Rectosigmoid resection
Yes
No
Colostomy
Yes
No
Ileostomy
Yes
No
Diaphragm stripping
Yes
No
Gastrostomy
Yes
No
Feeding jejunostomy
Yes
No
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Fallopian Tube Cancer NCT00951496 On-Study - GOG-0252 Ovarian
Cancer Surgery Reporting (OCR) - 2839109v1.0
Diaphragm resection
Yes
No
Surgery Information2
Date regular diet started (MM DD YYYY)
Lab, Chemistry, Albumin
Serum prealbumin
Total Protein
Post-op fever requiring IV antibiotics
Yes
No
Discharged home on antibiotics
Yes
No
Started antibiotics as outpatient
Yes
No
Wound complication
Yes
No
Leaking ascites
Yes
No
Infection opened
Yes
No
Hernia
Yes
No
Fascia separation
Yes
No
Seroma opened
Yes
No
Reoperation for repair
Yes
No
Other
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Fallopian Tube Cancer NCT00951496 On-Study - GOG-0252 Ovarian
Cancer Surgery Reporting (OCR) - 2839109v1.0
Yes
No
Specify
Abscess on CT
Yes
No
Date abscess found
Was the abscess drained
Yes
No
Was the culture positive
Yes
No
Were antibiotics given
Yes
No
Date Started (MM DD YYYY)
Date Started (MM DD YYYY)
Date Stopped (MM DD YYYY)
Date Stopped (MM DD YYYY)
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Fallopian Tube Cancer NCT00951496 On-Study - GOG-0252 Ovarian
Cancer Surgery Reporting (OCR) - 2839109v1.0
Neoplasms, Breast NCT00490139 Treatment - BIG 2-06 / NCCTG
N063D / EGF106708 - Concomitant Treatment - 2651585v1.0
BIG 2-06 / NCCTG N063D / EGF106708 - Concomitant
Treatment
ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment
Optimisation) Study; BIG 2-06/N063D
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=32A4BA27-
3D14-3F3A-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/7864
BIG 2-06 / NCCTG N063D /
EGF106708 - Concomitant
Treatment
Header Module
Centre No.
Subject No.
Concomitant Relevant Treatments And/or
Surgical Procedures
Name of treatment
Indication for use
Curative Treatment (Curative)
Prevention (Prophylaxis)
Date Started
Date Stopped
Ongoing?
Yes (Yes)
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Nonneoplastic Condition NCT01057121 Treatment - AMC-070
Lenalidomide Study Drug Administration (DA0) - 3147561v1.0
AMC-070 Lenalidomide Study Drug Administration (DA0)
Lenalidomide in Treating Patients With AIDS-Related
Kaposi Sarcoma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=91E526F8-
7537-7599-E040-BB89AD432D60
All rights reserved. Please visit https://medical-data-
models.org/forms/7865
AMC-070 Lenalidomide Study Drug
Administration (DA0)
Header Module
Visit number
Enter Total Dose Of Study Drug Received
This Cycle And Dose Modification Codes
Cycle Start Date (mm/dd/yyyy)
Agent Dose Level
10 Mg/day (10 mg/day)
15 Mg/day (15 mg/day)
20 Mg/day (20 mg/day)
25 Mg/day (25 mg/day)
5 Mg/day (5 mg/day)
Dose Modification
Dose Delayed (Dose delayed)
Dose Delayed And Reduced (Dose
delayed and reduced)
Dose Escalated (Dose escalated)
Dose Reduced (Dose reduced)
Drug Discontinued (Drug discontinued)
No Dose Modification (No dose
modification)
Total Dose of Agents/Drugs for this Cycle
(mg/cycle)
Number of Doses Missed (Missed doses should
be reported for any dose that was missed
regardless of the reason. If the subject missed a
dose due to an adverse event, please ensure the
corresponding adverse event has been reported
per the AE reporting requirements of this
protocol)
Agent Start Date (mm/dd/yyyy)
Agent End Date (mm/dd/yyyy)
Duration Delay (Days)
1 / 2
Comments
Comments
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Nonneoplastic Condition NCT01057121 Treatment - AMC-070
Lenalidomide Study Drug Administration (DA0) - 3147561v1.0
Neoplasms, Breast NCT00490139 Treatment - BIG 2-06 / NCCTG N063D /
EGF106708 - Administration of Study Drug Lapatinib - 2646027v1.0
BIG 2-06 / NCCTG N063D / EGF106708 - Administration of
Study Drug Lapatinib
ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment
Optimisation) Study; BIG 2-06/N063D
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=31D240FB-
CF19-6486-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/7866
BIG 2-06 / NCCTG N063D /
EGF106708 - Administration of
Study Drug Lapatinib
Header Module
Centre No.
Subject No.
Administration Of Paclitaxel Concomitantly
With Biological Therapy (design 2)
Date Started
Date Stopped
Total Daily Dose of Agent (or Drug) (mg)
Was treatment interrupted
Yes
No
Specify code
Administrative Reasons (Administrative
reasons)
Adverse Event Other Than Hematologic
Or Cardiac (Adverse event other than
hematologic or cardiac)
Cardiac Adverse Event (Cardiac adverse
event)
Dosing Error (Dosing error)
Hematologic Adverse Event
(Hematologic adverse event)
Other (Other)
Subject Non-compliance (Subject non-
compliance)
Specify
Was dose reduced
Yes
No
Specify code
1 / 2
Administrative Reasons (Administrative
reasons)
Adverse Event Other Than Hematologic
Or Cardiac (Adverse event other than
hematologic or cardiac)
Cardiac Adverse Event (Cardiac adverse
event)
Dosing Error (Dosing error)
Hematologic Adverse Event
(Hematologic adverse event)
Other (Other)
Subject Non-compliance (Subject non-
compliance)
Specify
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Neoplasms, Breast NCT00490139 Treatment - BIG 2-06 / NCCTG N063D /
EGF106708 - Administration of Study Drug Lapatinib - 2646027v1.0
Anal Cancer NCT00550589 Treatment - AMC-046
Cidofovir Administration Form (SD6) - 2769716v1.0
AMC-046 Cidofovir Administration Form (SD6)
Cidofovir in Treating HIV-Infected Patients With High-Grade
Squamous Intraepithelial Lesions of the Skin Near the Anus
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=5353F4EF-
C96C-5488-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/7873
AMC-046 Cidofovir Administration
Form (SD6)
Header Module
Visit number
Cidofovir Administration
Day of cycle
Day 1 (Day 1)
Day 2 (Day 2)
Day 3 (Day 3)
Day 4 (Day 4)
Day 5 (Day 5)
Agent Start Date (medicine applied mm/dd/yyyy)
Agent start time (medicine applied hh:mm)
Agent End Date (medicine washed off
mm/dd/yyyy)
Agent end time (medicine washed off hh:mm)
Dose Modification
No Dose Modification (No dose
modifications)
Yes, Modification For >= Grade 3
Cutaneous Toxicity (Yes, modification for
>= grade 3 cutaneous toxicity)
Yes, Modification For Hematologic Or
Noncutaneous Nonhematologic Toxicity
(Yes, modification for hematologic or
noncutaneous nonhematologic toxicity)
Yes, Modification For Related >= Grade
2 Metabolic Toxicity (Yes, modification for
related >= grade 2 metabolic toxicity)
Yes, Modification For Second
Occurrence Of Grade 2 Cutaneous
Toxicity (Yes, modification for second
occurrence of grade 2 cutaneous toxicity)
Yes, Non-protocol Defined Modification
(Yes, non-protocol defined modification)
Comments
1 / 2
Comments
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Anal Cancer NCT00550589 Treatment - AMC-046 Cidofovir
Administration Form (SD6) - 2769716v1.0
Lung Cancer NCT00324805 Demographic - ECOG-
E1505 Baseline Smoking Survey - 2438323v1.0
ECOG-E1505 Baseline Smoking Survey
Chemotherapy With or Without Bevacizumab in Treating
Patients With Stage IB, Stage II, or Stage IIIA Non-Small
Lung Cancer That Was Removed By Surgery
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=080E30C9-
4544-68FF-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/7880
ECOG-E1505 Baseline Smoking
Survey
Header module
ECOG Protocol Number*
ECOG Protocol Number*
ECOG Patient ID*
ECOG Patient ID*
DCI Name*
Registration Step*
Reporting Period*
Baseline (Baseline)
Patient Initials (Last, First)*
ECOG Protocol Number*
ECOG Protocol Number*
Participating Group Protocol Number*
Institution/Affiliate*
ECOG Patient ID*
ECOG Patient ID*
Participating Group Patient ID*
Please mark an 'X' if data have been amended
(Please circle amended data in red.)*
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Date data amended (M D Y)*
Smoking history and status
Date data obtained*
Has the patient ever smoked during his/her entire
life*
No (No)
Patient Refused To Answer (Patient
Refused to Answer)
Unknown (Unknown)
Yes (Yes)
Has the patient smoked at least 100 cigarettes
during his/her entire life*
No (No)
Patient Refused To Answer (Patient
Refused to Answer)
Unknown (Unknown)
Yes (Yes)
How old was the patient when (s)he started
smoking cigarettes on a daily basis (Years If
applicable)*
Does the patient currently smoke*
No (No)
Patient Refused To Answer (Patient
Refused to Answer)
Unknown (Unknown)
Yes (Yes)
At what age did the patient stop smoking
cigarettes completely (Years)*
Did the patient stop smoking after (s)he was
diagnosed with lung cancer*
No (No)
Patient Refused To Answer (Patient
Refused to Answer)
Unknown (Unknown)
Yes (Yes)
On average of the entire time the patient smoked,
how many cigarettes per day did (s)he smoke
(Cigarettes per day)*
Does the patient smoke cigars*
No (No)
Patient Refused To Answer (Patient
Refused to Answer)
Unknown (Unknown)
Yes (Yes)
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Lung Cancer NCT00324805 Demographic - ECOG-E1505 Baseline
Smoking Survey - 2438323v1.0
Cigars per day (If yes)*
Nic Alert Test Result
NicAlert Test Performed*
Yes
No
Cotinine Concentration Level (If yes)*
Level 0 (Level 0)
Level 1 (Level 1)
Level 2 (Level 2)
Level 3 (Level 3)
Level 4 (Level 4)
Level 5 (Level 5)
Level 6 (Level 6)
Date of Nic Alert Test (M D Y)*
Investigator signature
Investigator Signature*
Investigator Signature Date*
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Lung Cancer NCT00324805 Demographic - ECOG-E1505 Baseline
Smoking Survey - 2438323v1.0
Brain and Central Nervous System Tumors NCT00890747 Treatment -
AMC-061 Study Drug Administration Form (DA1) - 2913633v1.0
AMC-061 Study Drug Administration Form (DA1)
Sunitinib Malate in Treating HIV-Positive Patients With
Cancer Undergoing Highly Active Antiretroviral Therapy
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=6DBDC738-
4455-D324-E040-BB89AD433B23
All rights reserved. Please visit https://medical-data-
models.org/forms/7881
AMC-061 Study Drug Administration
Form (DA1)
Header Module
Visit number
Enter Total Dose Of Study Drug Received
This Cycle And Dose Modification Codes
Cycle Start Date (mm/dd/yyyy)
Agent Dose Level
12.5 Mg/day (12.5 mg/day)
25 Mg/day (25 mg/day)
37.5 Mg/day (37.5 mg/day)
50 Mg/day (50 mg/day)
Dose Modification
Dose Delayed (Dose delayed)
Dose Delayed And Reduced (Dose
delayed and reduced)
Dose Escalated (Dose escalated)
Dose Reduced (Dose reduced)
Drug Discontinued (Drug discontinued)
No Dose Modification (No dose
modification)
Total Dose of Agents/Drugs for this Cycle
(mg/cycle)
Agent Start Date (mm/dd/yyyy)
Agent End Date (mm/dd/yyyy)
Duration Delay (Days)
Comments
Comments
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Breast Cancer NCT01242800 Follow-Up -
E2108 Surgical Resection Form - 3145725v1.0
E2108 Surgical Resection Form
Early Surgery or Standard Palliative Therapy in Treating
Patients With Stage IV Breast Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=91CE8B54-
1649-B633-E040-BB89AD433125
All rights reserved. Please visit https://medical-data-
models.org/forms/7883
E2108 Surgical Resection Form
General information
ECOG Protocol Number*
ECOG Protocol Number*
ECOG Patient ID*
ECOG Patient ID*
DCI Name*
Report Period (Choose one)*
Surgery (Surgery)
Patient Initials (Last, First)*
ECOG Protocol Number*
ECOG Protocol Number*
Participating Group Protocol Number*
Institution/Affiliate*
ECOG Patient ID*
ECOG Patient ID*
Participating Group Patient ID*
Please mark an 'X' if data have been amended.
(Please circle amended items in red)*
Date data amended (M D Y)*
Surgery
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Surgery Date*
Hospital Discharge Date*
Intent of Surgery*
Curative (1)
Palliative (2)
Type of surgery (resection)*
Breast Conservation Treatment (Breast
Conservation Surgery)
Other (Other)
Total Mastectomy (Total Mastectomy)
Other, specify*
Was axillary dissection performed?*
Yes
No
Was sentinel node biopsy performed*
Yes
No
Were free surgical margins achieved?*
Yes
No
If reconstruction is planned or has already
occurred, indicate below which type(s):*
Breast Tissue Expander (Expander)
Breast Implant (Implant)
Latissimus Dorsi Flap (Latissimus)
Transverse Rectus Abdominus
Myocutaneous Flap (TRAM)
Comments
Investigator Signature*
Investigator Signature Date*
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Breast Cancer NCT01242800 Follow-Up - E2108 Surgical Resection
Form - 3145725v1.0
Quality of Life Assessment Form (E1105)
E1105 Quality of Life Assessment Form
First-Line Chemotherapy and Trastuzumab With or Without
Bevacizumab in Treating Patients With Metastatic Breast
Cancer That Overexpresses HER-2/NEU
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=17363D95-
6129-3B27-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/7901
Quality of Life Assessment Form
(E1105)
Unbenannt1
ECOG Protokollnr.*
ECOG Patienten-ID*
DCI Vorname*
Registrierungsschritt*
Patienteninitialen (Nachname, Vorname)*
ECOG Protokollnr.*
Teilnehmende Gruppenprotokoll Nr*
Institution / Einrichtung*
ECOG Patienten-ID*
Teilnehmenden Gruppe: Patienten-ID*
Bitte markieren Sie ein 'X', wenn Daten geändert
worden sind (Bitte geänderten Wert rot
einkreisen)*
Änderungsdatum des Wertes (M T J)*
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Brain and Central Nervous System Tumors NCT00978458 Quality of Life
- E3F05 Quality of Life Assessment Form - FACT-BR - 3299831v1.0
E3F05 Quality of Life Assessment Form - FACT-BR
Radiation Therapy With or Without Temozolomide in
Treating Patients With Low-Grade Glioma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=B0EE8BE4-
1DEE-C782-E040-BB89AD433D2E
All rights reserved. Please visit https://medical-data-
models.org/forms/7904
E3F05 Quality of Life Assessment
Form - FACT-BR
Header
DCI Name
Registration Step (Place ID Label Here)
Patient Initials (Last, First)
ECOG Protocol Number
ECOG Protocol Number
ECOG Patient ID
ECOG Patient ID
Participating Group Protocol Number
Participating Group Patient ID
Institution/Affiliate
On Treatment
Report Period (NOTE: Select the "Progression"
timepoint when patient's disease progresses at
ANY POINT even if it falls within an annual
assessment, eg: 48 Months Post Registaration.
Please do not select an annual report period
AND the progression report period.)
108 Months Post Registration (108
Months Post Registration)
12 Months Post Registration (12 Months
Post Registration)
120 Months Post Registration (120
Months Post Registration)
132 Months Post Registration (132
Months Post Registration)
144 Months Post Registration (144
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Months Post Registration)
156 Months Post Registration (156
Months Post Registration)
168 Months Post Registration (168
Months Post Registration)
168 Months Post Registration (168
Months Post Registration)
180 Months Post Registration (180
Months Post Registration)
180 Months Post Registration (180
Months Post Registration)
24 Months Post Registration (24 Months
Post Registration)
36 Months Post Registration (36 Months
Post Registration)
48 Months Post Registration (48 Months
Post Registration)
60 Months Post Registration (60 Months
Post Registration)
72 Months Post Registration (72 Months
Post Registration)
84 Months Post Registration (84 Months
Post Registration)
96 Months Post Registration (96 Months
Post Registration)
Baseline (Baseline)
Progression (Progression)
Progression (Progression)
Header
Date of Assessment
Patient's age (in years, at time of assessment)
Physical Well-being
I have a lack of energy
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have nausea
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
Because of my physical condition, I have trouble
meeting the needs of my family
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
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Somewhat (Somewhat)
Very Much (Very much)
I have pain
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am bothered by side effects of treatment
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I feel ill
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am forced to spend time in bed
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
Social/family Well-being
I feel close to my friends
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I get emotional support from my family
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I get support from my friends
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
My family has accepted my illness
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
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I am satisfied with family communication about
my illness
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I feel close to my partner (or the person who is
my main support)
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
Regardless of your current level of sexual activity,
please answer the following question.  If you
prefer not to answer it, please check this box and
go to the next section.
I am satisfied with my sex life
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
Emotional Well-being
I feel sad
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am satisfied with how I am coping with my
illness
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am losing hope in the fight against my illness
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I feel nervous
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
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Very Much (Very much)
I worry about dying
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I worry that my condition will get worse
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
Functional Well-being
I am able to work (include work at home)
2 (A little bit)
1 (Not at all)
4 (Quite a bit)
3 (Somewhat)
5 (Very much)
My work is fulfilling (include work at home)
2 (A little bit)
1 (Not at all)
4 (Quite a bit)
3 (Somewhat)
5 (Very much)
I am able to enjoy life
2 (A little bit)
1 (Not at all)
4 (Quite a bit)
3 (Somewhat)
5 (Very much)
I have accepted my illness
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am sleeping well
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am enjoying the things I usually do for fun
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
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I am content with the quality of my life right now
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
Additional Concerns
I am able to concentrate
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have had seizures (convulsions)
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I can remember new things
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I get frustrated that I cannot do things I used to
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am afraid of having a seizure (convulsion)
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have trouble with my eyesight
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I feel independent
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have trouble hearing
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A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am able to find the right word(s) to say what I
mean
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have difficulty expressing my thoughts
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am bothered by the change in my personality
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am able to make decisions and take
responsibility
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am bothered by the drop in my contribution to
the family
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am able to put my thoughts together
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I need help in caring for myself (bathing,
dressing, eating, etc.)
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am able to put my thoughts into action
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A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am able to read like I used to
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am able to write like I used to
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am able to drive a vehicle (my car, truck, etc.)
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have trouble feeling sensations in my arms,
hands, or legs
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have weakness in my arms or legs
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have trouble with coordination
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I get headaches
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
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Breast Cancer NCT00310180 Registration - PACCT-
1 TAILORx Cross Registration Form - 2431734v1.0
PACCT-1 TAILORx Cross Registration Form
Hormone Therapy With or Without Combination
Chemotherapy in Treating Women Who Have Undergone
Surgery for Node-Negative Breast Cancer (The TAILORx
Trial)
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=05DDB2DB-
35DB-70D0-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/7908
PACCT-1 TAILORx Cross
Registration Form
Header
ECOG Protocol Number
ECOG Patient ID
DCI Name
Registration Step Number
Reporting Period
6 Months Post Pre-registration (6 Months
Post Pre-Registration)
Header
Has the patient been enrolled on another
cooperative group study
Yes
No
Coordinating Group Protocol No. (If Yes:)
Coordinating Group Patient ID
Date of Registration
Footer Module
Investigator Signature
Investigator Signature Date
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Breast Cancer NCT00310180 Lab - PACCT-1 TAILORx
Source Document Tracking Coversheet - 2430791v1.0
PACCT-1 TAILORx Source Document Tracking Coversheet
Hormone Therapy With or Without Combination
Chemotherapy in Treating Women Who Have Undergone
Surgery for Node-Negative Breast Cancer (The TAILORx
Trial)
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=05D8F2BE-
C5D0-4050-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/7909
PACCT-1 TAILORx Source
Document Tracking Coversheet
Header
ECOG Protocol Number
ECOG Patient ID
DCI Name
Registration Step
Reporting Period (Choose one x)
Baseline (Baseline)
Death (Death)
Recurrence (Recurrence)
Second Primary Cancer (Second
primary)
Header
Document type (Choose one x)
Er/pr Report (ER/PR Report)
Her2/neu Report (Her2/neu Report)
Lab Report (Lab Report)
Mammogram Report (Mammogram
Report)
Pathology Report (Pathology Report)
Physician Note (Physician Note)
Radiology Report (Radiology Report)
Surgical Report (Surgical Report)
Date of this Report (List the date the source
document was created below.)
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Breast Cancer NCT00310180 Pathology - PACCT-1
TAILORx Virtual Frozen Tissue Bank Form - 2518507v1.0
PACCT-1 TAILORx Virtual Frozen Tissue Bank Form
Hormone Therapy With or Without Combination
Chemotherapy in Treating Women Who Have Undergone
Surgery for Node-Negative Breast Cancer (The TAILORx
Trial)
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=1CCEFBDC-
5252-021E-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/7910
PACCT-1 TAILORx Virtual Frozen
Tissue Bank Form
Header
ECOG Protocol Number
ECOG Patient ID
DCI Name
Registration Step Number
Reporting Period
Baseline (Baseline)
Patient Information
Patient Initials (Last First Middle)
Investigator's First Name
Investigator's Last Name
Registered Investigator (NCI Investigator #)
Frozen Tissue Information
Patient Medical Record Number
Collection Date (Specimen for frozen tissue
m/d/y)
Pathology Institution Name (at which frozen
tissue is held)
Dept/Building (Address:)
Street Name and Number
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City
State/Province
Country
Postal Code
Footer Module
Investigator Signature
Person Completing Form, Last Name
Person Completing Form, First Name
Form Completion Date, Original (m/d/y)
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Breast Cancer NCT00310180 Pathology - PACCT-1 TAILORx Virtual
Frozen Tissue Bank Form - 2518507v1.0
Breast Cancer NCT00310180 Registration - PACCT-
1 TAILORx Pre-Registration Form - 2442999v1.0
PACCT-1 TAILORx Pre-Registration Form
Hormone Therapy With or Without Combination
Chemotherapy in Treating Women Who Have Undergone
Surgery for Node-Negative Breast Cancer (The TAILORx
Trial)
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=0A2EF9D6-
F0E2-1C86-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/7915
PACCT-1 TAILORx Pre-Registration
Form
Header
ECOG Protocol Number
ECOG Patient ID
DCI Name
Registration Step Number
Reporting Period
Preregistration (Pre-registration)
Header
Reason patient not registered
Adverse Event/side Effects/complications
(Adverse events/side
effects/complications)
Death Before Beginning Protocol
Therapy (Death before beginning
protocol therapy)
Disease Progression, Relapse Prior To
Beginning Protocol Therapy (Disease
progression, relapse before protocol
treatment)
Medical Decision (Medical decision)
Other (Other)
Patient_ineligible (Patient ineligible)
Patient Withdrawal/refusal Before
Beginning Protocol Therapy (Patient
withdrawal/refusal before beginning
protocol therapy)
Other specify
Oncotype DX Recurrence Score
Mark an 'X' if unknown
Footer Module
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Investigator Signature
Investigator Signature Date
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Breast Cancer NCT00310180 Registration - PACCT-1 TAILORx Pre-
Registration Form - 2442999v1.0
Breast Cancer NCT00310180 Treatment - PACCT-1
TAILORx Radiation Therapy Form - 2431830v1.0
PACCT-1 TAILORx Radiation Therapy Form
Hormone Therapy With or Without Combination
Chemotherapy in Treating Women Who Have Undergone
Surgery for Node-Negative Breast Cancer (The TAILORx
Trial)
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=05DDE05E-
BAB7-050B-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/7916
PACCT-1 TAILORx Radiation
Therapy Form
Header
ECOG Protocol Number
ECOG Patient ID
DCI Name
Registration Step Number
Reporting Period
1 (1)
Header
Did the patient have protocol-defined radiation
therapy as part of protocol treatment?
Yes
No
Radiation Therapy Start Date
Radiation Therapy End Date
Whole Breast, no boost
Yes
No
Whole Breast, boost
Yes
No
Partial Breast
Yes
No
Ipsilateral Supraclavicular
Yes
No
Other
Yes
No
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Other, specify (If)
Unnamed2
Total Dose Prior to Boost (Gy)
Total Number of Fractions Prior to Boost
RT Total Dose to Boost Field (If boost was given,
complete the following: - Gy)
Total Number of Fractions to Boost Field
Partial Breast Irradiation
Total Dose of Radiation Therapy (PBI - Gy)
Total Number of Fractions (PBI)
Method
Mammosite Balloon Catheter
(MammoSite Balloon Catheter)
Other (Other)
Other Brachytherapy (Other
Brachytherapy)
Specify
Investigator Signature Text
Investigator Signature Date
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Breast Cancer NCT00310180 Treatment - PACCT-1 TAILORx Radiation
Therapy Form - 2431830v1.0
Breast Cancer NCT00310180 Follow-Up -
TAILORx Second Primary Form - 3236572v1.0
TAILORx Second Primary Form
Hormone Therapy With or Without Combination
Chemotherapy in Treating Women Who Have Undergone
Surgery for Node-Negative Breast Cancer (The TAILORx
Trial)
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=A3BB68BA-
CCE2-8DF9-E040-BB89AD43631B
All rights reserved. Please visit https://medical-data-
models.org/forms/7918
TAILORx Second Primary Form
Header
ECOG Protocol Number
ECOG Patient ID
DCI Name
Registration Step
Reporting Period
Second Primary Cancer (Second
primary)
Completed By Central Lab
Date of Diagnosis of Second Primary Cancer
(mm/dd/yyyy)
Site of Second Primary Cancer
Acute Lymphocytic Leukemia (Acute
Lymphocytic Leukemia (ALL))
Acute Myelogenous Leukemia (Acute
Myelogenous Leukemia (AML))
Adrenal (Adrenal)
Aids-related Lymphoma (AIDS-related
Lymphoma)
Anal Canal (Anal Canal)
Basal Cell Carcinoma (Basal Cell
Carcinoma)
Bladder, Urinary Tract (Bladder, Urinary
Tract)
Brain Tumor (Brain Tumor)
Breast (Breast)
Breast, In Situ (Breast, in situ)
Carcinoid (Carcinoid)
Cervix (Cervix)
Chronic Lymphocytic Leukemia (Chronic
Lymphocytic Leukemia (CLL))
Chronic Myelogenous Leukemia, Bcr-
abl1 Positive (Chronic Myelogenous
Leukemia (CML))
Colon (Colon)
Endometrium, Uterine Corpus
(Endometrium, Uterine Corpus)
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Esophagus (Esophagus)
Gastric Cancer (Gastric Cancer)
Hairy Cell Leukemia (Hairy Cell
Leukemia)
Head And Neck (Head and Neck)
Hodgkin's Lymphoma (Hodgkin's
Disease)
Islet Cell/carcinoid (Islet Cell/Carcinoid)
Kaposi Sarcoma (Kaposi sarcoma)
Leukemia (Leukemia)
Liver, Gall Bladder, Bile Duct (Liver, Gall
Bladder, Bile Duct)
Lung Cancer (Lung cancer)
Lymphoma (Lymphoma)
Lymphosarcoma (Lymphosarcoma)
Melanoma (Melanoma)
Mesothelioma (Mesothelioma)
Myelodysplastic Syndrome
(Myelodysplastic Syndrome)
Myeloma (Myeloma)
Non-hodgkin Lymphoma (Non-Hodgkin's
Lymphoma)
Non-small Cell Lung Cancer (Non-Small
Cell Lung Cancer)
Osteosarcoma (Osteosarcoma)
Other (Other)
Other Gyn (Other GYN)
Other Non-melanoma Skin Cancer
(Other non-melanoma skin cancer)
Ovarian (Ovarian)
Pancreas (Pancreas)
Penile (Penile)
Pleural Effusion (Pleural effusion)
Promyelocytic Leukemia (Promyelocytic
Leukemia (APL))
Prostate (Prostate)
Rectum (Rectum)
Renal Cell (Renal Cell)
Sarcoma (Sarcoma)
Small Intestine (Small Intestine)
Small-cell Lung Cancer (Small-Cell Lung
Cancer)
Spinal Cord (Spinal Cord)
Testis, Germ Cell, Seminoma (Testis,
Germ Cell, Seminoma)
Thymoma (Thymoma)
Thyroid (Thyroid)
Waldenstrom's Macroglobulinemia
(Waldenstrom's Macroglobulinemia)
Include information on histologic subtype (s
Please attach copies of any corroborating
pathology reports.)
Comments
Investigator Signature
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Form - 3236572v1.0
Investigator Signature Date
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Breast Cancer NCT00433511 Lab - E5103
Material Submission Form - 2543143v1.0
E5103 Material Submission Form
Doxorubicin, Cyclophosphamide, and Paclitaxel With or
Without Bevacizumab in Treating Patients With Lymph
Node-Positive or High-Risk, Lymph Node-Negative Breast
Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=22731766-
5C46-4971-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/7924
E5103 Material Submission Form
Header
ECOG Protocol Number
ECOG Patient ID
Registration Step
DCI Name
Reporting Period
Lab Data (Lab data)
Unnamed2
Patient Initials (Last,First)
ECOG Protocol Number
ECOG Patient ID
Participating Group Protocol Number
Participating Group Patient ID
Institution/Affiliate
Unnamed3
Date material(s) sent to central laboratory
Shipped to
Ecog Pathology Coordinating Office
(ECOG Pathology Coordinating Office)
Other Central Laboratory (Other Central
Laboratory)
Informed consent signed?
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Yes
No
Sample No.
Date Specimen collected (MM/DD/YYYY)
Specimen Type
Edta Lavender Top Tube (EDTA
Lavender Top Tube)
Other (Other)
Serum Red Top (Serum Red Top)
Timing of material collection
Baseline (Baseline)
Other (other)
Number of specimens submitted (tubes, slides,
etc.)
Completed By Central Lab
Date of Receipt of Specimens ( m/d/y)
Condition of Specimen (s)
Damaged Or Unusable (Damaged or
unusable)
Usable (Useable)
Unnamed 4
Contact Person at Institution
Physician of Record
Institution contact phone number (International)
Institution contact fax number (International)
Central Laboratory contact name
Central Lab Contact Phone Number
(International)
Central Lab Contact FAX Number (International)
Comments
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2543143v1.0
Comments
Comments
Physician of Record
Date
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Breast Cancer NCT00433511 Lab - E5103 Material Submission Form -
2543143v1.0
Breast Cancer NCT00601900 Lab - CALGB 40503
BLOOD SPECIMEN SUBMISSION FORM - 2550740v1.0
CALGB 40503 BLOOD SPECIMEN SUBMISSION FORM
Tamoxifen or Letrozole With or Without Bevacizumab in
Treating Women With Stage III or Stage IV Breast Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=240454EE-
9EE3-347C-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/7928
CALGB 40503 BLOOD SPECIMEN
SUBMISSION FORM
Header
CALGB Form
CALGB Study No.
CALGB Patient ID
Are data amended
Yes
No
Unnamed2
Patient Initials (Last, First, Middle)
Patient Hospital No.
Institution/Affiliate
Participating Group
Participating Group Study No.
Participating Group Patient ID
To Be Completed By Submitting Institution
Does specimen accompany this form
Yes
No
Specify reason
Institution Error (Institution error)
Patient Refusal (Patient refusal)
Sample Lost Or Destroyed (Sample lost
or destroyed)
Specimen Type
Whole Blood (Whole blood)
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Type of specimen submitted (Mark one with an
X.)
10 Ml Cpt (10 ml CPT)
10 Ml Sst/tiger (10 ml SST/Tiger)
5 Cc Green (5 cc Green)
7.5 Cc Cell Saver (7.5 cc Cell Saver)
Pharmacogenomics Edta (purple Top)
(Pharmacogenomics EDTA (Purple Top))
Time Specimen Collected (24-hour clock)
Date specimen collected (MM DD YYYY)
LabTrak shipment ID
Sample period (^1 For sample period, enter the
cycle number completed prior to specimen
collection or scheduled collection if specimen no
obtained; or enter "0" for pre-study.)
Number of tubes submitted
Approximate volume of sample (ml)
Completed by (Last name, First name)
Date form completed (MM DD YYYY)
Phone number to be used in event of sample
problems
Email Address
To Be Completed By Receiving
Institution/laboratory
Sample condition (Mark one with an X.)
Clotted (Clotted)
Damaged (Damaged)
Damaged But Stored (Damaged but
stored)
Frozen But Stored (Frozen but stored)
Improperly Stored (Improperly stored)
Insufficient Amount (Insufficient amount)
Missing (Missing)
Okay (Okay)
Thawed But Stored (Thawed but stored)
Received Date (MM DD YYYY)
Number of tubes banked
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SUBMISSION FORM - 2550740v1.0
Average volume per tube (ml)
3 / 3
Breast Cancer NCT00601900 Lab - CALGB 40503 BLOOD SPECIMEN
SUBMISSION FORM - 2550740v1.0
Colorectal Cancer NCT00077233 Response - CALGB:
80203 Solid Tumor Evaluation Form - 2101473v3.0
CALGB: 80203 Solid Tumor Evaluation Form
Fluorouracil and Leucovorin Plus Either Irinotecan or
Oxaliplatin With or Without Cetuximab in Treating Patients
With Previously Untreated Metastatic Adenocarcinoma of
the Colon or Rectum
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=BB6E5D42-
FA40-4373-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/7959
CALGB: 80203 Solid Tumor
Evaluation Form
Ccrr Module For Calgb: 80203 Solid
Tumor Evaluation Form
CALGB Form
CALGB Study No.
CALGB Patient ID
Are data amended?
Yes (Yes)
Patient Initials
Patient Hospital Number
Main member/Affiliate
Participating Group
Participating Group Protocol No.
Participating Group Patient ID
Observer
Date of evaluation
Lesion, anatomic site, target
Longest diameter of lesion(s)
Lesion, anatomic site, non-target
method of evaluation
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method of evaluation
Assessment
Complete Response (Absent)
Progressive Disease (Increased)
Stable Disease Or Unchanged (Present)
Assessment
Complete Response (Absent)
Progressive Disease (Increased)
Stable Disease Or Unchanged (Present)
Complete by
Date completed
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Colorectal Cancer NCT00077233 Response - CALGB: 80203 Solid
Tumor Evaluation Form - 2101473v3.0
Colorectal Cancer NCT01150045 On-Study -
CALGB 80702 On-Study Form - 2970013v1.0
CALGB 80702 On-Study Form
Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or
Without Celecoxib in Treating Patients With Stage III Colon
Cancer Previously Treated With Surgery
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=7ADB9225-
BFE2-FA4C-E040-BB89AD4369EB
All rights reserved. Please visit https://medical-data-
models.org/forms/7962
CALGB 80702 On-Study Form
Header
CALGB Form
CALGB Study No
CALGB Patient ID
Are data amended
Yes
No
Unnamed2
Patient Initials (Last, First, Middle)
Patient Hospital No.
Institution/Affiliate
Participating Group
Participating Group Study No.
Participating Group Patient ID
Patient Description
Date of original diagnosis of colon cancer (MM
DD YYYY)
MedDRA Code (disease)
Has the patient had any prior cancer diagnosed?
(other than colon)
Yes
No
Type of Prior Cancer (If Yes,)
1 / 3
Prior Cancer Diagnosis Date (year YYYY)
Clinical T Stage (TMN Stage prior to surgery
Mark one with an X.)
Tumor Invades Submucosa (T1)
Tumor Invades Muscularis Propria (T2)
Tumor Invades Through The Muscularis
Propria Into Pericolorectal Tissues (T3)
Tumor Penetrates To The Surface Of The
Visceral Peritoneum (T4a)
Tumor Directly Invades Or Is Adherent To
Other Organs Or Structures (T4b)
Clinical N Stage (TMN Stage prior to surgery
Mark one with an X.)
Metastasis In 1 To 3 Regional Lymph
Nodes (N1)
Metastasis In 4 Or More Regional Lymph
Nodes (N2)
Clinical M Stage (TMN Stage prior to surgery
Mark one with an X.)
No Distant Metastasis (M0)
Distant Metastasis (M1)
Tnm Stage/surgical Data
Date of surgical resection (MM DD YYYY)
Number of positive nodes
Number of Lymph Nodes Examined
Lab Data At Protocol Entry
WBC (x10^3 microL)
ANC (x10^3 microL)
Granulocytes (%)
Platelet count (x10^3 microL)
Creatinine (mg/dL)
Creatinine ULN (mg/dL)
Bilirubin (mg/dL)
Bilirubin ULN (mg/dL)
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Cardiac Risk Factors
Uncontrolled high blood pressure (systolic blood
pressure >150)
Yes
No
Unstable angina
Yes
No
Symptomatic congestive heart failure
Yes
No
History of documented myocardial infarction or
cerebrovascular accident
Yes
No
New York Heart Association Class III or IV heart
failure
Yes
No
Neurosensory or neuromotor toxicity >= grade 2
Yes
No
History of upper gastrointestinal ulceration,
bleeding or perforation within the past 3 yrs
Yes
No
Ongoing treatment with aspirin or NSAIDS
including celecoxib (except low-dose aspirin <
100mg/day)
Yes
No
In the past five years prior to the diagnosis of
colon cancer, was the patient a regular user of
any NSAIDS, aspirin or celecoxib (Regular use is
defined as at least two tablets per week, on
average for more than 9 months of the year.
Please ask the patient this question at time of
study entry.)
Yes
No
Footer Module
Completed by (Last name, First name)
Date Form Completed (MM DD YYYY)
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Kidney Cancer NCT01198158 Lab - CALGB
90802 Tissue Tracking Form - 3103135v1.0
CALGB 90802 Tissue Tracking Form
Everolimus With or Without Bevacizumab in Treating
Patients With Advanced Kidney Cancer That Progressed
After First-Line Therapy
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=8785791C-
4B67-B01E-E040-BB89AD433770
All rights reserved. Please visit https://medical-data-
models.org/forms/7965
CALGB 90802 Tissue Tracking Form
Header
CALGB Form
CALGB Study No.
CALGB Patient ID
Are data amended
Yes
No
Unnamed2
Patient Initials (Last First Middle)
Patient Hospital No.
Institution/Affiliate
Participating Group
Participating Group Study No.
Participating Group Patient ID
Unnamed3
Does institutional pathology report accompany
this form
Yes
No
Does specimen accompany this form (If Yes,
complete the remainder of this form)
Yes
No
Form without specimen, reason
1 / 2
Date specimen collected (MM DD YYYY)
Tissue pathology (Mark all that apply with an X.)
Metastasis (Metastasis)
Primary Tumor (Primary tumor)
Specify site
Method of extraction (Mark one with an X.)
Biopsy (Biopsy)
General Surgery, Nos (General surgery,
NOS)
Re-excision (Re-excision)
Type of specimen submitted (Mark one with an
X.)
Formalin Fixed Paraffin Embedded
Tissue Block (Formalin fixed paraffin
embedded tissue block)
Other (Other)
Formalin fixed paraffin embedded tissue block,
specify number
Other, specify
Specify number (other )
Institutional surgical pathology number
LabTrak shipment ID
Date shipped (MM DD YYYY)
Date shipped (MM DD YYYY)
Responsible CRA (Last name, First name)
CRA phone number
CRA e-mail
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Medication Form Melanoma
(NCT01274338)
E1609 Corticosteroid/Immunosuppressant/Hormone
Replacement Medication Form
Ipilimumab or High-Dose Interferon Alfa-2b in Treating
Patients With High-Risk Stage III or Stage IV Melanoma
That Has Been Removed by Surgery
NCT01274338
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=B1F0BB2E-
39FF-B3FA-E040-BB89AD430140
All rights reserved. Please visit https://medical-data-
models.org/forms/7967
Medication Form Melanoma
(NCT01274338)
Header
ECOG Protocol Number
ECOG Patient ID
DCI Name
Registration Step
Patient Initials
Participating Group Protocol Number
Institution/Affiliate
Participating Group Patient ID
Please mark an 'X' if data have been amended.
(Please circle amended items in red)
Date data amended (s - mm/dd/yyyy)
Comments
Investigator Signature
Investigator Signature Date
On Treatment Reporting Period
On Treatment Reporting Period
Week 1 (Week 1)
Week 13 (Week 13)
Week 19 (Week 19)
Week 25 (Week 25)
Week 31 (Week 31)
1 / 24
Week 37 (Week 37)
Week 43 (Week 43)
Week 49 (Week 49)
Week 5 (Week 5)
Week 9 (Week 9)
Reporting period Start Date
Reporting period End Date
Off Treatment
Off Treatment Report Period (Choose one)
12 Months (12 Months Post Registration)
15 Months (15 Months Post Registration)
18 Months (18 Months Post Registration)
21 Months Post Registration (21 Months
Post Registration)
2 Years (24 Months Post Registration)
3 Months (3 Months Post Registration)
30 Months (30 Months Post Registration)
3 Years (36 Months Post Registration)
6 Months (6 Months Post Registration)
9 Months (9 Months Post Registration)
Section I - Corticosteroid Medication
Were Corticosteroid medications given due to
treatment-related Adverse Events this report
period?
Yes
No
Corticosteroid Name
Budesonide (Budesonide)
Dexamethasone (Dexamethasone)
Fludrocortisone (Fludrocortisone)
Therapeutic Hydrocortisone
(Hydrocortisone)
Methylprednisolone (Methylprednisolone)
Other (Other)
Prednisolone (Prednisolone)
Prednisone (Prednisone)
Triamcinolone (Triamcinolone)
Adverse Event (If selected 5=Other for
Treatment-Related Adverse Event CTCv4 Code
List, specify)
Abdominal Distension (Abdominal
distension)
Abdominal Infection (Abdominal
infection)
Abdominal Pain (Abdominal pain)
Abdominal Soft Tissue Necrosis
(Abdominal soft tissue necrosis)
Abducens Nerve Disorder (Abducens
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nerve disorder)
Accessory Nerve Disorder (Accessory
nerve disorder)
Acidosis (Acidosis)
Acoustic Nerve Disorder Nos (Acoustic
nerve disorder NOS)
Activated Partial Thromboplastin Time
Prolonged (Activated partial
thromboplastin time prolonged)
Acute Coronary Syndrome (Acute
coronary syndrome)
Acute Kidney Injury (Acute kidney injury)
Adrenal Insufficiency (Adrenal
insufficiency)
Adult Respiratory Distress Syndrome
(Adult respiratory distress syndrome)
Agitation (Agitation)
Akathisia (Akathisia)
Alanine Aminotransferase Increased
(Alanine aminotransferase increased)
Alcohol Intolerance (Alcohol intolerance)
Alkaline Phosphatase Increased
(Alkaline phosphatase increased)
Alkalosis (Alkalosis)
Allergic Reaction (Allergic reaction)
Allergic Rhinitis (Allergic rhinitis)
Alopecia (Alopecia)
Amnesia (Amnesia)
Anal Fistula (Anal fistula)
Anal Hemorrhage (Anal hemorrhage)
Anal Mucositis (Anal mucositis)
Anal Necrosis (Anal necrosis)
Anal Pain (Anal pain)
Anal Stenosis (Anal stenosis)
Anal Ulcer (Anal ulcer)
Anaphylaxis (Anaphylaxis)
Anemia (Anemia)
Ankle Fracture (Ankle fracture)
Anorectal Infection (Anorectal infection)
Anorexia (Anorexia)
Anorgasmia (Anorgasmia)
Anxiety (Anxiety)
Aortic Injury (Aortic injury)
Aortic Valve Disease (Aortic valve
disease)
Aphonia (Aphonia)
Apnea (Apnea)
Appendicitis (Appendicitis)
Appendicitis Perforated (Appendicitis
perforated)
Arachnoiditis (Arachnoiditis)
Arterial Injury (Arterial injury)
Arteritis Infective (Arteritis infective)
Arthralgia (Arthralgia)
Arthritis (Arthritis)
Ascites (Ascites)
Aspartate Aminotransferase Increased
(Aspartate aminotransferase increased)
Aspiration (Aspiration)
Asystole (Asystole)
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Ataxia (Ataxia)
Atelectasis (Atelectasis)
Atrial Fibrillation (Atrial fibrillation)
Atrial Flutter (Atrial flutter)
Atrioventricular Block Complete
(Atrioventricular block complete)
Atrioventricular Block First Degree
(Atrioventricular block first degree)
Autoimmune Disorder (Autoimmune
disorder)
Avascular Necrosis (Avascular necrosis)
Azoospermia (Azoospermia)
Back Pain (Back pain)
Bile Duct Stenosis (Bile duct stenosis)
Biliary Anastomotic Leak (Biliary
anastomotic leak)
Biliary Fistula (Biliary fistula)
Biliary Tract Infection (Biliary tract
infection)
Bladder Anastomotic Leak (Bladder
anastomotic leak)
Bladder Infection (Bladder infection)
Bladder Perforation (Bladder perforation)
Bladder Spasm (Bladder spasm)
Bloating (Bloating)
Blood And Lymphatic System Disorders -
Other, Specify (Blood and lymphatic
system disorders - Other, Specify)
Blood Antidiuretic Hormone Abnormal
(Blood antidiuretic hormone abnormal)
Blood Bilirubin Increased (Blood bilirubin
increased)
Blood Corticotrophin Decreased (Blood
corticotrophin decreased)
Blood Gonadotrophin Abnormal (Blood
gonadotrophin abnormal)
Blood Prolactin Abnormal (Blood
prolactin abnormal)
Blurred Vision (Blurred vision)
Body Odor (Body odor)
Bone Infection (Bone infection)
Bone Marrow Hypocellular (Bone
marrow hypocellular)
Bone Pain (Bone pain)
Brachial Plexopathy (Brachial
plexopathy)
Breast Atrophy (Breast atrophy)
Breast Infection (Breast infection)
Breast Pain (Breast pain)
Bronchial Fistula (Bronchial fistula)
Bronchial Infection (Bronchial infection)
Bronchial Obstruction (Bronchial
obstruction)
Bronchial Stricture (Bronchial stricture)
Bronchopleural Fistula (Bronchopleural
fistula)
Bronchopulmonary Hemorrhage
(Bronchopulmonary hemorrhage)
Bronchospasm (Bronchospasm)
Bruising (Bruising)
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Bullous Dermatitis (Bullous dermatitis)
Burn (Burn)
Buttock Pain (Buttock pain)
Capillary Leak Syndrome (Capillary leak
syndrome)
Carbon Monoxide Diffusing Capacity
Decreased (Carbon monoxide diffusing
capacity decreased)
Cardiac Arrest (Cardiac arrest)
Cardiac Disorders - Other, Specify
(Cardiac disorders - Other, Specify)
Cardiac Troponin I Increased (Cardiac
troponin I increased)
Cardiac Troponin T Increased (Cardiac
troponin T increased)
Cataract (Cataract)
Catheter Related Infection (Catheter
related infection)
Cd4 Lymphocytes Decreased (CD4
lymphocytes decreased)
Cecal Hemorrhage (Cecal hemorrhage)
Cecal Infection (Cecal infection)
Central Nervous System Necrosis
(Central nervous system necrosis)
Cerebrospinal Fluid Leakage
(Cerebrospinal fluid leakage)
Cervicitis Infection (Cervicitis infection)
Cheilitis (Cheilitis)
Chest Pain - Cardiac (Chest pain -
cardiac)
Chest Wall Pain (Chest wall pain)
Chills (Chills)
Cholecystitis (Cholecystitis)
Cholesterol High (Cholesterol high)
Chronic Kidney Disease (Chronic kidney
disease)
Chylothorax (Chylothorax)
Cognitive Disturbance (Cognitive
disturbance)
Colitis (Colitis)
Colonic Fistula (Colonic fistula)
Colonic Hemorrhage (Colonic
hemorrhage)
Colonic Obstruction (Colonic obstruction)
Colonic Perforation (Colonic perforation)
Colonic Stenosis (Colonic stenosis)
Colonic Ulcer (Colonic ulcer)
Concentration Impairment
(Concentration impairment)
Conduction Disorder (Conduction
disorder)
Confusion (Confusion)
Congenital, Familial And Genetic
Disorders - Other, Specify (Congenital,
familial and genetic disorders - Other,
Specify)
Conjunctivitis (Conjunctivitis)
Conjunctivitis Infective (Conjunctivitis
infective)
Constipation (Constipation)
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Constrictive Pericarditis (Constrictive
pericarditis)
Corneal Infection (Corneal infection)
Corneal Ulcer (Corneal ulcer)
Cough (Cough)
Cpk Increased (CPK increased)
Cranial Nerve Infection (Cranial nerve
infection)
Creatinine Increased (Creatinine
increased)
Cushingoid (Cushingoid)
Cystitis Noninfective (Cystitis
noninfective)
Cytokine Release Syndrome (Cytokine
release syndrome)
Death Neonatal (Death neonatal)
Death Nos (Death NOS)
Dehydration (Dehydration)
Delayed Orgasm (Delayed orgasm)
Delayed Puberty (Delayed puberty)
Delirium (Delirium)
Delusions (Delusions)
Dental Caries (Dental caries)
Depressed Level Of Consciousness
(Depressed level of consciousness)
Depression (Depression)
Dermatitis Radiation (Dermatitis
radiation)
Device Related Infection (Device related
infection)
Diarrhea (Diarrhea)
Disseminated Intravascular Coagulation
(Disseminated intravascular coagulation)
Dizziness (Dizziness)
Dry Eye (Dry eye)
Dry Mouth (Dry mouth)
Dry Skin (Dry skin)
Duodenal Fistula (Duodenal fistula)
Duodenal Hemorrhage (Duodenal
hemorrhage)
Duodenal Infection (Duodenal infection)
Duodenal Obstruction (Duodenal
obstruction)
Duodenal Perforation (Duodenal
perforation)
Duodenal Stenosis (Duodenal stenosis)
Duodenal Ulcer (Duodenal ulcer)
Dysarthria (Dysarthria)
Dysesthesia (Dysesthesia)
Dysgeusia (Dysgeusia)
Dysmenorrhea (Dysmenorrhea)
Dyspareunia (Dyspareunia)
Dyspepsia (Dyspepsia)
Dysphagia (Dysphagia)
Dysphasia (Dysphasia)
Dyspnea (Dyspnea)
Ear And Labyrinth Disorders - Other,
Specify (Ear and labyrinth disorders -
Other, Specify)
Ear Pain (Ear pain)
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Edema Cerebral (Edema cerebral)
Edema Face (Edema face)
Edema Limbs (Edema limbs)
Edema Trunk (Edema trunk)
Ejaculation Disorder (Ejaculation
disorder)
Ejection Fraction Decreased (Ejection
fraction decreased)
Electrocardiogram Qt Corrected Interval
Prolonged (Electrocardiogram QT
corrected interval prolonged)
Encephalitis Infection (Encephalitis
infection)
Encephalomyelitis Infection
(Encephalomyelitis infection)
Encephalopathy (Encephalopathy)
Endocarditis Infective (Endocarditis
infective)
Endocrine Disorders - Other, Specify
(Endocrine disorders - Other, Specify)
Endophthalmitis (Endophthalmitis)
Enterocolitis (Enterocolitis)
Enterocolitis Infectious (Enterocolitis
infectious)
Enterovesical Fistula (Enterovesical
fistula)
Epistaxis (Epistaxis)
Erectile Dysfunction (Erectile
dysfunction)
Erythema Multiforme (Erythema
multiforme)
Erythroderma (Erythroderma)
Esophageal Anastomotic Leak
(Esophageal anastomotic leak)
Esophageal Fistula (Esophageal fistula)
Esophageal Hemorrhage (Esophageal
hemorrhage)
Esophageal Infection (Esophageal
infection)
Esophageal Necrosis (Esophageal
necrosis)
Esophageal Obstruction (Esophageal
obstruction)
Esophageal Pain (Esophageal pain)
Esophageal Perforation (Esophageal
perforation)
Esophageal Stenosis (Esophageal
stenosis)
Esophageal Ulcer (Esophageal ulcer)
Esophageal Varices Hemorrhage
(Esophageal varices hemorrhage)
Esophagitis (Esophagitis)
Euphoria (Euphoria)
Exostosis (Exostosis)
External Ear Inflammation (External ear
inflammation)
External Ear Pain (External ear pain)
Extraocular Muscle Paresis (Extraocular
muscle paresis)
Extrapyramidal Disorder (Extrapyramidal
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disorder)
Eye Disorders - Other, Specify (Eye
disorders - Other, Specify)
Eye Infection (Eye infection)
Eye Pain (Eye pain)
Eyelid Function Disorder (Eyelid function
disorder)
Facial Muscle Weakness (Facial muscle
weakness)
Facial Nerve Disorder (Facial nerve
disorder)
Facial Pain (Facial pain)
Fall (Fall)
Fallopian Tube Anastomotic Leak
(Fallopian tube anastomotic leak)
Fallopian Tube Obstruction (Fallopian
tube obstruction)
Fallopian Tube Perforation (Fallopian
tube perforation)
Fallopian Tube Stenosis (Fallopian tube
stenosis)
Fat Atrophy (Fat atrophy)
Fatigue (Fatigue)
Febrile Neutropenia (Febrile
neutropenia)
Fecal Incontinence (Fecal incontinence)
Female Genital Tract Fistula (Female
genital tract fistula)
Feminization Acquired (Feminization
acquired)
Fetal Death (Fetal death)
Fetal Growth Retardation (Fetal growth
retardation)
Fever (Fever)
Fibrinogen Decreased (Fibrinogen
decreased)
Fibrosis Deep Connective Tissue
(Fibrosis deep connective tissue)
Flank Pain (Flank pain)
Flashing Lights (Flashing lights)
Flatulence (Flatulence)
Floaters (Floaters)
Flu Like Symptoms (Flu like symptoms)
Flushing (Flushing)
Forced Expiratory Volume Decreased
(Forced expiratory volume decreased)
Fracture (Fracture)
Gait Disturbance (Gait disturbance)
Gallbladder Fistula (Gallbladder fistula)
Gallbladder Infection (Gallbladder
infection)
Gallbladder Necrosis (Gallbladder
necrosis)
Gallbladder Obstruction (Gallbladder
obstruction)
Gallbladder Pain (Gallbladder pain)
Gallbladder Perforation (Gallbladder
perforation)
Gastric Anastomotic Leak (Gastric
anastomotic leak)
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Gastric Fistula (Gastric fistula)
Gastric Hemorrhage (Gastric
hemorrhage)
Gastric Necrosis (Gastric necrosis)
Gastric Perforation (Gastric perforation)
Gastric Stenosis (Gastric stenosis)
Gastric Ulcer (Gastric ulcer)
Gastritis (Gastritis)
Gastroesophageal Reflux Disease
(Gastroesophageal reflux disease)
Gastrointestinal Anastomotic Leak
(Gastrointestinal anastomotic leak)
Gastrointestinal Disorders - Other,
Specify (Gastrointestinal disorders -
Other, Specify)
Gastrointestinal Fistula (Gastrointestinal
fistula)
Gastrointestinal Pain (Gastrointestinal
pain)
Gastrointestinal Stoma Necrosis
(Gastrointestinal stoma necrosis)
Gastroparesis (Gastroparesis)
General Disorders And Administration
Site Conditions - Other, Specify (General
disorders and administration site
conditions - Other, Specify)
Generalized Muscle Weakness
(Generalized muscle weakness)
Genital Edema (Genital edema)
Ggt Increased (GGT increased)
Gingival Pain (Gingival pain)
Glaucoma (Glaucoma)
Glossopharyngeal Nerve Disorder
(Glossopharyngeal nerve disorder)
Glucose Intolerance (Glucose
intolerance)
Growth Accelerated (Growth
accelerated)
Growth Hormone Abnormal (Growth
hormone abnormal)
Growth Suppression (Growth
suppression)
Gum Infection (Gum infection)
Gynecomastia (Gynecomastia)
Hallucinations (Hallucinations)
Haptoglobin Decreased (Haptoglobin
decreased)
Head Soft Tissue Necrosis (Head soft
tissue necrosis)
Headache (Headache)
Hearing Impaired (Hearing impaired)
Heart Failure (Heart failure)
Hematoma (Hematoma)
Hematosalpinx (Hematosalpinx)
Hematuria (Hematuria)
Hemoglobin Increased (Hemoglobin
increased)
Hemoglobinuria (Hemoglobinuria)
Hemolysis (Hemolysis)
Hemolytic Uremic Syndrome (Hemolytic
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uremic syndrome)
Hemorrhoidal Hemorrhage
(Hemorrhoidal hemorrhage)
Hemorrhoids (Hemorrhoids)
Hepatic Failure (Hepatic failure)
Hepatic Hemorrhage (Hepatic
hemorrhage)
Hepatic Infection (Hepatic infection)
Hepatic Necrosis (Hepatic necrosis)
Hepatic Pain (Hepatic pain)
Hepatitis Viral (Hepatitis viral)
Hepatobiliary Disorders - Other, Specify
(Hepatobiliary disorders - Other, Specify)
Hiccups (Hiccups)
Hip Fracture (Hip fracture)
Hirsutism (Hirsutism)
Hoarseness (Hoarseness)
Hot Flashes (Hot flashes)
Hydrocephalus (Hydrocephalus)
Hypercalcemia (Hypercalcemia)
Hyperglycemia (Hyperglycemia)
Hyperhidrosis (Hyperhidrosis)
Hyperkalemia (Hyperkalemia)
Hypermagnesemia (Hypermagnesemia)
Hypernatremia (Hypernatremia)
Hyperparathyroidism
(Hyperparathyroidism)
Hypersomnia (Hypersomnia)
Hypertension (Hypertension)
Hyperthyroidism (Hyperthyroidism)
Hypertrichosis (Hypertrichosis)
Hypertriglyceridemia
(Hypertriglyceridemia)
Hyperuricemia (Hyperuricemia)
Hypoalbuminemia (Hypoalbuminemia)
Hypocalcemia (Hypocalcemia)
Hypoglossal Nerve Disorder
(Hypoglossal nerve disorder)
Hypoglycemia (Hypoglycemia)
Hypohidrosis (Hypohidrosis)
Hypokalemia (Hypokalemia)
Hypomagnesemia (Hypomagnesemia)
Hyponatremia (Hyponatremia)
Hypoparathyroidism
(Hypoparathyroidism)
Hypophosphatemia (Hypophosphatemia)
Hypotension (Hypotension)
Hypothermia (Hypothermia)
Hypothyroidism (Hypothyroidism)
Hypoxia (Hypoxia)
Ileal Fistula (Ileal fistula)
Ileal Hemorrhage (Ileal hemorrhage)
Ileal Obstruction (Ileal obstruction)
Ileal Perforation (Ileal perforation)
Ileal Stenosis (Ileal stenosis)
Ileal Ulcer (Ileal ulcer)
Ileus (Ileus)
Immune System Disorders - Other,
Specify (Immune system disorders -
Other, Specify)
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Infections And Infestations - Other,
Specify (Infections and infestations -
Other, Specify)
Infective Myositis (Infective myositis)
Infusion Related Reaction (Infusion
related reaction)
Infusion Site Extravasation (Infusion site
extravasation)
Injection Site Reaction (Injection site
reaction)
Injury To Carotid Artery (Injury to carotid
artery)
Injury To Inferior Vena Cava (Injury to
inferior vena cava)
Injury To Jugular Vein (Injury to jugular
vein)
Injury To Superior Vena Cava (Injury to
superior vena cava)
Injury, Poisoning And Procedural
Complications - Other, Specify (Injury,
poisoning and procedural complications -
Other, Specify)
Inr Increased (INR increased)
Insomnia (Insomnia)
Intestinal Stoma Leak (Intestinal stoma
leak)
Intestinal Stoma Obstruction (Intestinal
stoma obstruction)
Intestinal Stoma Site Bleeding (Intestinal
stoma site bleeding)
Intra-abdominal Hemorrhage (Intra-
abdominal hemorrhage)
Intracranial Hemorrhage (Intracranial
hemorrhage)
Intraoperative Arterial Injury
(Intraoperative arterial injury)
Intraoperative Breast Injury
(Intraoperative breast injury)
Intraoperative Cardiac Injury
(Intraoperative cardiac injury)
Intraoperative Ear Injury (Intraoperative
ear injury)
Intraoperative Endocrine Injury
(Intraoperative endocrine injury)
Intraoperative Gastrointestinal Injury
(Intraoperative gastrointestinal injury)
Intraoperative Head And Neck Injury
(Intraoperative head and neck injury)
Intraoperative Hemorrhage
(Intraoperative hemorrhage)
Intraoperative Hepatobiliary Injury
(Intraoperative hepatobiliary injury)
Intraoperative Musculoskeletal Injury
(Intraoperative musculoskeletal injury)
Intraoperative Ocular Injury
(Intraoperative ocular injury)
Intraoperative Renal Injury
(Intraoperative renal injury)
Intraoperative Reproductive Tract Injury
(Intraoperative reproductive tract injury)
11 / 24
Medication Form Melanoma (NCT01274338)
Intraoperative Respiratory Injury
(Intraoperative respiratory injury)
Intraoperative Skin Injury (Intraoperative
skin injury)
Intraoperative Splenic Injury
(Intraoperative splenic injury)
Intraoperative Urinary Injury
(Intraoperative urinary injury)
Intraoperative Venous Injury
(Intraoperative venous injury)
Intraoperative Neurological Injury
(Intraopperative neurological injury)
Investigations - Other, Specify
(Investigations - Other, Specify)
Iron Overload (Iron overload)
Irregular Menstruation (Irregular
menstruation)
Irritability (Irritability)
Ischemia Cerebrovascular (Ischemia
cerebrovascular)
Ivth Nerve Disorder (IVth nerve disorder)
Jejunal Fistula (Jejunal fistula)
Jejunal Hemorrhage (Jejunal
hemorrhage)
Jejunal Obstruction (Jejunal obstruction)
Jejunal Perforation (Jejunal perforation)
Jejunal Stenosis (Jejunal stenosis)
Jejunal Ulcer (Jejunal ulcer)
Joint Effusion (Joint effusion)
Joint Infection (Joint infection)
Joint Range Of Motion Decreased (Joint
range of motion decreased)
Joint Range Of Motion Decreased
Cervical Spine (Joint range of motion
decreased cervical spine)
Joint Range Of Motion Decreased
Lumbar Spine (Joint range of motion
decreased lumbar spine)
Keratitis (Keratitis)
Kidney Anastomotic Leak (Kidney
anastomotic leak)
Kidney Infection (Kidney infection)
Kyphosis (Kyphosis)
Lactation Disorder (Lactation disorder)
Large Intestinal Anastomotic Leak (Large
intestinal anastomotic leak)
Laryngeal Edema (Laryngeal edema)
Laryngeal Fistula (Laryngeal fistula)
Laryngeal Hemorrhage (Laryngeal
hemorrhage)
Laryngeal Inflammation (Laryngeal
inflammation)
Laryngeal Mucositis (Laryngeal
mucositis)
Laryngeal Obstruction (Laryngeal
obstruction)
Laryngeal Stenosis (Laryngeal stenosis)
Laryngitis (Laryngitis)
Laryngopharyngeal Dysesthesia
(Laryngopharyngeal dysesthesia)
12 / 24
Medication Form Melanoma (NCT01274338)
Laryngospasm (Laryngospasm)
Left Ventricular Systolic Dysfunction (Left
ventricular systolic dysfunction)
Lethargy (Lethargy)
Leukemia Secondary To Oncology
Chemotherapy (Leukemia secondary to
oncology chemotherapy)
Leukocytosis (Leukocytosis)
Leukoencephalopathy
(Leukoencephalopathy)
Libido Decreased (Libido decreased)
Libido Increased (Libido increased)
Lip Infection (Lip infection)
Lip Pain (Lip pain)
Lipase Increased (Lipase increased)
Lipohypertrophy (Lipohypertrophy)
Localized Edema (Localized edema)
Lordosis (Lordosis)
Lower Gastrointestinal Hemorrhage
(Lower gastrointestinal hemorrhage)
Lung Infection (Lung infection)
Lymph Gland Infection (Lymph gland
infection)
Lymph Leakage (Lymph leakage)
Lymph Node Pain (Lymph node pain)
Lymphedema (Lymphedema)
Lymphocele (Lymphocele)
Lymphocyte Count Decreased
(Lymphocyte count decreased)
Lymphocyte Count Increased
(Lymphocyte count increased)
Malabsorption (Malabsorption)
Malaise (Malaise)
Mania (Mania)
Mediastinal Hemorrhage (Mediastinal
hemorrhage)
Mediastinal Infection (Mediastinal
infection)
Memory Impairment (Memory
impairment)
Meningismus (Meningismus)
Meningitis (Meningitis)
Menopause (Menopause)
Menorrhagia (Menorrhagia)
Metabolism And Nutrition Disorders -
Other, Specify (Metabolism and nutrition
disorders - Other, Specify)
Middle Ear Inflammation (Middle ear
inflammation)
Mitral Valve Disease (Mitral valve
disease)
Mobitz (type) Ii Atrioventricular Block
(Mobitz (type) II atrioventricular block)
Mobitz Type I (Mobitz type I)
Movements Involuntary (Movements
involuntary)
Mucosal Infection (Mucosal infection)
Mucositis Oral (Mucositis oral)
Multi-organ Failure (Multi-organ failure)
Muscle Weakness Left-sided (Muscle
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weakness left-sided)
Muscle Weakness Lower Limb (Muscle
weakness lower limb)
Muscle Weakness Right-sided (Muscle
weakness right-sided)
Muscle Weakness Trunk (Muscle
weakness trunk)
Muscle Weakness Upper Limb (Muscle
weakness upper limb)
Musculoskeletal And Connective Tissue
Disorder - Other, Specify
(Musculoskeletal and connective tissue
disorders - Other, Specify)
Musculoskeletal Deformity
(Musculoskeletal deformity)
Myalgia (Myalgia)
Myelitis (Myelitis)
Myelodysplastic Syndrome
(Myelodysplastic syndrome)
Myocardial Infarction (Myocardial
infarction)
Myocarditis (Myocarditis)
Myositis (Myositis)
Nail Discoloration (Nail discoloration)
Nail Infection (Nail infection)
Nail Loss (Nail loss)
Nail Ridging (Nail ridging)
Nasal Congestion (Nasal congestion)
Nausea (Nausea)
Neck Edema (Neck edema)
Neck Pain (Neck pain)
Neck Soft Tissue Necrosis (Neck soft
tissue necrosis)
Neoplasms Benign, Malignant And
Unspecified (incl Cysts And Polyps) -
Other, Specify (Neoplasms benign,
malignant and unspecified (incl cysts and
polyps) - Other, Specify)
Nervous System Disorders - Other,
Specify (Nervous system disorders -
Other, Specify)
Neuralgia (Neuralgia)
Neutrophil Count Decreased (Neutrophil
count decreased)
Night Blindness (Night blindness)
Nipple Deformity (Nipple deformity)
Non-cardiac Chest Pain (Non-cardiac
chest pain)
Nystagmus (Nystagmus)
Obesity (Obesity)
Obstruction Gastric (Obstruction gastric)
Oculomotor Nerve Disorder (Oculomotor
nerve disorder)
Olfactory Nerve Disorder (Olfactory
nerve disorder)
Oligospermia (Oligospermia)
Optic Nerve Disorder (Optic nerve
disorder)
Oral Cavity Fistula (Oral cavity fistula)
Oral Dysesthesia (Oral dysesthesia)
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Oral Hemorrhage (Oral hemorrhage)
Oral Pain (Oral pain)
Osteonecrosis Of Jaw (Osteonecrosis of
jaw)
Osteoporosis (Osteoporosis)
Otitis Externa (Otitis externa)
Otitis Media (Otitis media)
Ovarian Hemorrhage (Ovarian
hemorrhage)
Ovarian Infection (Ovarian infection)
Ovarian Rupture (Ovarian rupture)
Ovulation Pain (Ovulation pain)
Pain (Pain)
Pain In Extremity (Pain in extremity)
Pain Of Skin (Pain of skin)
Palmar-plantar Erythrodysesthesia
Syndrome (Palmar-plantar
erythrodysesthesia syndrome)
Palpitations (Palpitations)
Pancreas Infection (Pancreas infection)
Pancreatic Anastomotic Leak (Pancreatic
anastomotic leak)
Pancreatic Duct Stenosis (Pancreatic
duct stenosis)
Pancreatic Enzymes Decreased
(Pancreatic enzymes decreased)
Pancreatic Fistula (Pancreatic fistula)
Pancreatic Hemorrhage (Pancreatic
hemorrhage)
Pancreatic Necrosis (Pancreatic
necrosis)
Pancreatitis (Pancreatitis)
Papilledema (Papilledema)
Papulopustular Rash (Papulopustular
rash)
Paresthesia (Paresthesia)
Paronychia (Paronychia)
Paroxysmal Atrial Tachycardia
(Paroxysmal atrial tachycardia)
Pelvic Floor Muscle Weakness (Pelvic
floor muscle weakness)
Pelvic Infection (Pelvic infection)
Pelvic Pain (Pelvic pain)
Pelvic Soft Tissue Necrosis (Pelvic soft
tissue necrosis)
Penile Infection (Penile infection)
Penile Pain (Penile pain)
Perforation Bile Duct (Perforation bile
duct)
Pericardial Effusion (Pericardial effusion)
Pericardial Tamponade (Pericardial
tamponade)
Pericarditis (Pericarditis)
Perineal Pain (Perineal pain)
Periodontal Disease (Periodontal
disease)
Periorbital Edema (Periorbital edema)
Periorbital Infection (Periorbital infection)
Peripheral Ischemia (Peripheral
ischemia)
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Peripheral Motor Neuropathy (Peripheral
motor neuropathy)
Peripheral Nerve Infection (Peripheral
nerve infection)
Peripheral Sensory Neuropathy
(Peripheral sensory neuropathy)
Peritoneal Infection (Peritoneal infection)
Peritoneal Necrosis (Peritoneal necrosis)
Personality Change (Personality change)
Phantom Pain (Phantom pain)
Pharyngeal Anastomotic Leak
(Pharyngeal anastomotic leak)
Pharyngeal Fistula (Pharyngeal fistula)
Pharyngeal Hemorrhage (Pharyngeal
hemorrhage)
Pharyngeal Mucositis (Pharyngeal
mucositis)
Pharyngeal Necrosis (Pharyngeal
necrosis)
Pharyngeal Stenosis (Pharyngeal
stenosis)
Pharyngitis (Pharyngitis)
Pharyngolaryngeal Pain
(Pharyngolaryngeal pain)
Phlebitis (Phlebitis)
Phlebitis Infective (Phlebitis infective)
Photophobia (Photophobia)
Photosensitivity (Photosensitivity)
Platelet Count Decreased (Platelet count
decreased)
Pleural Effusion (Pleural effusion)
Pleural Hemorrhage (Pleural
hemorrhage)
Pleural Infection (Pleural infection)
Pleuritic Pain (Pleuritic pain)
Pneumonitis (Pneumonitis)
Pneumothorax (Pneumothorax)
Portal Hypertension (Portal
hypertension)
Portal Vein Thrombosis (Portal vein
thrombosis)
Postnasal Drip (Postnasal drip)
Postoperative Hemorrhage
(Postoperative hemorrhage)
Postoperative Thoracic Procedure
Complication (Postoperative thoracic
procedure complication)
Precocious Puberty (Precocious
puberty)
Pregnancy, Puerperium And Perinatal
Conditions - Other, Specify (Pregnancy,
puerperium and perinatal conditions -
Other, Specify)
Premature Delivery (Premature delivery)
Premature Menopause (Premature
menopause)
Presyncope (Presyncope)
Proctitis (Proctitis)
Productive Cough (Productive cough)
Prolapse Of Intestinal Stoma (Prolapse
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of intestinal stoma)
Prolapse Of Urostomy (Prolapse of
urostomy)
Prostate Infection (Prostate infection)
Prostatic Hemorrhage (Prostatic
hemorrhage)
Prostatic Obstruction (Prostatic
obstruction)
Prostatic Pain (Prostatic pain)
Proteinuria (Proteinuria)
Pruritus (Pruritus)
Psychiatric Disorders - Other, Specify
(Psychiatric disorders - Other, Specify)
Psychosis (Psychosis)
Pulmonary Edema (Pulmonary edema)
Pulmonary Fibrosis (Pulmonary fibrosis)
Pulmonary Fistula (Pulmonary fistula)
Pulmonary Hypertension (Pulmonary
hypertension)
Pulmonary Valve Disease (Pulmonary
valve disease)
Purpura (Purpura)
Pyramidal Tract Syndrome (Pyramidal
tract syndrome)
Radiation Recall Reaction (dermatologic)
(Radiation recall reaction (dermatologic))
Radiculitis (Radiculitis)
Rash Acneiform (Rash acneiform)
Rash Maculo-papular (Rash maculo-
papular)
Rash Pustular (Rash pustular)
Rectal Anastomotic Leak (Rectal
anastomotic leak)
Rectal Fistula (Rectal fistula)
Rectal Hemorrhage (Rectal hemorrhage)
Rectal Mucositis (Rectal mucositis)
Rectal Necrosis (Rectal necrosis)
Rectal Obstruction (Rectal obstruction)
Rectal Pain (Rectal pain)
Rectal Perforation (Rectal perforation)
Rectal Stenosis (Rectal stenosis)
Rectal Ulcer (Rectal ulcer)
Recurrent Laryngeal Nerve Palsy
(Recurrent laryngeal nerve palsy)
Renal And Urinary Disorders - Other,
Specify (Renal and urinary disorders -
Other, Specify)
Renal Calculi (Renal calculi)
Renal Colic (Renal colic)
Renal Hemorrhage (Renal hemorrhage)
Reproductive System And Breast
Disorders - Other, Specify (Reproductive
system and breast disorders - Other,
Specify)
Respiratory Failure (Respiratory failure)
Respiratory, Thoracic And Mediastinal
Disorders - Other, Specify (Respiratory,
thoracic and mediastinal disorders -
Other, Specify)
Restlessness (Restlessness)
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Restrictive Cardiomyopathy (Restrictive
cardiomyopathy)
Retinal Detachment (Retinal
detachment)
Retinal Tear (Retinal tear)
Retinal Vascular Disorder (Retinal
vascular disorder)
Retinoic Acid Syndrome (Retinoic acid
syndrome)
Retinopathy (Retinopathy)
Retroperitoneal Hemorrhage
(Retroperitoneal hemorrhage)
Reversible Posterior
Leukoencephalopathy Syndrome
(Reversible posterior
leukoencephalopathy syndrome)
Rhinitis Infective (Rhinitis infective)
Right Ventricular Dysfunction (Right
ventricular dysfunction)
Salivary Duct Inflammation (Salivary duct
inflammation)
Salivary Gland Fistula (Salivary gland
fistula)
Salivary Gland Infection (Salivary gland
infection)
Scalp Pain (Scalp pain)
Scleral Disorder (Scleral disorder)
Scoliosis (Scoliosis)
Scrotal Infection (Scrotal infection)
Scrotal Pain (Scrotal pain)
Seizure (Seizure)
Sepsis (Sepsis)
Seroma (Seroma)
Serum Amylase Increased (Serum
amylase increased)
Serum Sickness (Serum sickness)
Sick Sinus Syndrome (Sick sinus
syndrome)
Sinus Bradycardia (Sinus bradycardia)
Sinus Disorder (Sinus disorder)
Sinus Pain (Sinus pain)
Sinus Tachycardia (Sinus tachycardia)
Sinusitis (Sinusitis)
Skin And Subcutaneous Tissue
Disorders - Other, Specify (Skin and
subcutaneous tissue disorders - Other,
Specify)
Skin Atrophy (Skin atrophy)
Skin Hyperpigmentation (Skin
hyperpigmentation)
Skin Hypopigmentation (Skin
hypopigmentation)
Skin Induration (Skin induration)
Skin Infection (Skin infection)
Skin Ulceration (Skin ulceration)
Sleep Apnea (Sleep apnea)
Small Intestinal Anastomotic Leak (Small
intestinal anastomotic leak)
Small Intestinal Mucositis (Small
intestinal mucositis)
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Small Intestinal Obstruction (Small
intestinal obstruction)
Small Intestinal Perforation (Small
intestinal perforation)
Small Intestinal Stenosis (Small intestinal
stenosis)
Small Intestine Infection (Small intestine
infection)
Small Intestine Ulcer (Small intestine
ulcer)
Sneezing (Sneezing)
Social Circumstances - Other, Specify
(Social circumstances - Other, Specify)
Soft Tissue Infection (Soft tissue
infection)
Soft Tissue Necrosis Lower Limb (Soft
tissue necrosis lower limb)
Soft Tissue Necrosis Upper Limb (Soft
tissue necrosis upper limb)
Somnolence (Somnolence)
Sore Throat (Sore throat)
Spasticity (Spasticity)
Spermatic Cord Anastomotic Leak
(Spermatic cord anastomotic leak)
Spermatic Cord Hemorrhage (Spermatic
cord hemorrhage)
Spermatic Cord Obstruction (Spermatic
cord obstruction)
Spinal Fracture (Spinal fracture)
Spleen Disorder (Spleen disorder)
Splenic Infection (Splenic infection)
Stenosis Of Gastrointestinal Stoma
(Stenosis of gastrointestinal stoma)
Stevens-johnson Syndrome (Stevens-
Johnson syndrome)
Stoma Site Infection (Stoma site
infection)
Stomach Pain (Stomach pain)
Stomal Ulcer (Stomal ulcer)
Stridor (Stridor)
Stroke (Stroke)
Sudden Death Nos (Sudden death NOS)
Suicidal Ideation (Suicidal ideation)
Suicide Attempt (Suicide attempt)
Superficial Soft Tissue Fibrosis
(Superficial soft tissue fibrosis)
Superficial Thrombophlebitis (Superficial
thrombophlebitis)
Superior Vena Cava Syndrome (Superior
vena cava syndrome)
Supraventricular Tachycardia
(Supraventricular tachycardia)
Surgical And Medical Procedures -
Other, Specify (Surgical and medical
procedures - Other, Specify)
Syncope (Syncope)
Telangiectasia (Telangiectasia)
Testicular Disorder (Testicular disorder)
Testicular Hemorrhage (Testicular
hemorrhage)
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Testicular Pain (Testicular pain)
Thromboembolic Event
(Thromboembolic event)
Thrombotic Thrombocytopenic Purpura
(Thrombotic thrombocytopenic purpura)
Tinnitus (Tinnitus)
Tooth Development Disorder (Tooth
development disorder)
Tooth Discoloration (Tooth discoloration)
Tooth Infection (Tooth infection)
Toothache (Toothache)
Toxic Epidermal Necrolysis (Toxic
epidermal necrolysis)
Tracheal Fistula (Tracheal fistula)
Tracheal Hemorrhage (Tracheal
hemorrhage)
Tracheal Mucositis (Tracheal mucositis)
Tracheal Obstruction (Tracheal
obstruction)
Tracheal Stenosis (Tracheal stenosis)
Tracheitis (Tracheitis)
Tracheostomy Site Bleeding
(Tracheostomy site bleeding)
Transient Ischemic Attacks (Transient
ischemic attacks)
Treatment Related Secondary
Malignancy (Treatment related
secondary malignancy)
Tremor (Tremor)
Tricuspid Valve Disease (Tricuspid valve
disease)
Trigeminal Nerve Disorder (Trigeminal
nerve disorder)
Trismus (Trismus)
Tumor Lysis Syndrome (Tumor lysis
syndrome)
Tumor Pain (Tumor pain)
Typhlitis (Typhlitis)
Unequal Limb Length (Unequal limb
length)
Unintended Pregnancy (Unintended
pregnancy)
Upper Gastrointestinal Hemorrhage
(Upper gastrointestinal hemorrhage)
Upper Respiratory Infection (Upper
respiratory infection)
Ureteric Anastomotic Leak (Ureteric
anastomotic leak)
Urethral Anastomotic Leak (Urethral
anastomotic leak)
Urethral Infection (Urethral infection)
Urinary Fistula (Urinary fistula)
Urinary Frequency (Urinary frequency)
Urinary Incontinence (Urinary
incontinence)
Urinary Retention (Urinary retention)
Urinary Tract Infection (Urinary tract
infection)
Urinary Tract Obstruction (Urinary tract
obstruction)
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Urinary Tract Pain (Urinary tract pain)
Urinary Urgency (Urinary urgency)
Urine Discoloration (Urine discoloration)
Urine Output Decreased (Urine output
decreased)
Urostomy Leak (Urostomy leak)
Urostomy Obstruction (Urostomy
obstruction)
Urostomy Site Bleeding (Urostomy site
bleeding)
Urostomy Stenosis (Urostomy stenosis)
Urticaria (Urticaria)
Uterine Anastomotic Leak (Uterine
anastomotic leak)
Uterine Fistula (Uterine fistula)
Uterine Hemorrhage (Uterine
hemorrhage)
Uterine Infection (Uterine infection)
Uterine Obstruction (Uterine obstruction)
Uterine Pain (Uterine pain)
Uterine Perforation (Uterine perforation)
Uveitis (Uveitis)
Vaginal Anastomotic Leak (Vaginal
anastomotic leak)
Vaginal Discharge (Vaginal discharge)
Vaginal Dryness (Vaginal dryness)
Vaginal Fistula (Vaginal fistula)
Vaginal Hemorrhage (Vaginal
hemorrhage)
Vaginal Infection (Vaginal infection)
Vaginal Inflammation (Vaginal
inflammation)
Vaginal Obstruction (Vaginal obstruction)
Vaginal Pain (Vaginal pain)
Vaginal Perforation (Vaginal perforation)
Vaginal Stricture (Vaginal stricture)
Vaginismus (Vaginismus)
Vagus Nerve Disorder (Vagus nerve
disorder)
Vas Deferens Anastomotic Leaak (Vas
deferens anastomotic leak)
Vascular Access Complication (Vascular
access complication)
Vascular Disorders - Other, Specify
(Vascular disorders - Other, Specify)
Vasculitis (Vasculitis)
Vasovagal Reaction (Vasovagal reaction)
Venous Injury (Venous injury)
Ventricular Arrhythmia (Ventricular
arrhythmia)
Ventricular Fibrillation (Ventricular
fibrillation)
Ventricular Tachycardia (Ventricular
tachycardia)
Vertigo (Vertigo)
Vestibular Disorder (Vestibular disorder)
Virilization (Virilization)
Visceral Arterial Ischemia (Visceral
arterial ischemia)
Vital Capacity Abnormal (Vital capacity
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abnormal)
Vitreous Hemorrhage (Vitreous
hemorrhage)
Voice Alteration (Voice alteration)
Vomiting (Vomiting)
Vulval Infection (Vulval infection)
Watering Eyes (Watering eyes)
Weight Gain (Weight gain)
Weight Loss (Weight loss)
Wheezing (Wheezing)
White Blood Cell Decreased (White
blood cell decreased)
Wolff-parkinson-white Syndrome (Wolff-
Parkinson-White syndrome)
Wound Complication (Wound
complication)
Wound Dehiscence (Wound dehiscence)
Wound Infection (Wound infection)
Wrist Fracture (Wrist fracture)
Dose
Units
Capsules (capsules)
Drops (drops)
Gram (gram)
Inch (inch)
Kilograms (kilogram)
Liter (liter)
Microgram (microgram)
Milliequivalent (milliequivalent)
Milligram (milligram)
Milliliter (milliliter)
Other (other)
Ounce (ounce)
Tablespoon (tablespoon)
Tablets (tablets)
Teaspoon (teaspoon)
Unit (unit)
Unknown (Unknown)
Frequency
After Meals (p.c.) (after meals)
As Needed (p.r.n) (as needed)
At Bedtime Or Hour Of Sleep (h.s.) (at
bedtime or hour of sleep)
Before Meals (a.c.) (before meals)
Every 12 Hours (q12hr) (every 12 hours)
Every 4 Hours (q4hr) (every 4 hours)
Every 6 Hours (q6hr) (every 6 hours)
Every 8 Hours (q8hr) (every 8 hours)
Every Day (q.d.) (every day)
Every Other Day (q.o.d.) (every other
day)
Four Times A Day (q.i.d) (four times a
day)
Immediately (stat) (immediately)
Other (other)
Three Times A Day (t.i.d) (three times a
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day)
Three Times A Week (t.i.w) (three times
a week)
Twice A Day (b.i.d) (twice a day)
Twice A Week (b.i.w) (twice a week)
Unknown (Unknown)
other, specify
Route
Intramuscular (IM)
Inhaled (inhaled)
Intradermal (intradermal)
Intravenous (IV)
Nasal (nasal)
Other (other)
Oral (PO)
Rectal (rectal)
Subcutaneous (SC)
Sublingual (sublingual)
Topical (topical)
Transdermal (transdermal)
Unknown (Unknown)
other, specify
Agent Start Date (Leave blank if continuing from
a prior report period)
Is this medication continuing?
Yes
No
Agent End Date (Leave blank if continuing)
Section II - Immunosuppressant
Medication
Were Immunosuppressant medications given due
to treatment-related Adverse Events this report
period?
Yes
No
Immunosuppressant Name
Cyclosporine (Cyclosporine)
Infliximab (Infliximab)
Mycophenolate (Mycophenolate)
Other (Other)
Tacrolimus (Tacrolimus)
Other, specify
Section III - Hormonal Replacement
Therapy Medication
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Were Hormonal Replacement medications given
due to treatment-related Adverse Events this
report period?
Yes
No
Hormonal Replacement Therapy Name
Therapeutic Hydrocortisone
(Hydrocortisone)
Levothyroxine (Levothyroxine)
Liothyronine (Liothyronine)
Liotrix (Liotrix)
Other (Other)
Thyroid Usp (Thyroid USP)
Other, specify
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Kidney Cancer NCT01198158 Lab - CALGB 90802
Blood/Plasma/Serum/Urine Specimen Submission Form - 3103085v1.0
CALGB 90802 Blood/Plasma/Serum/Urine Specimen
Submission Form
Everolimus With or Without Bevacizumab in Treating
Patients With Advanced Kidney Cancer That Progressed
After First-Line Therapy
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=87856350-
8B09-AE02-E040-BB89AD43100A
All rights reserved. Please visit https://medical-data-
models.org/forms/7970
CALGB 90802
Blood/Plasma/Serum/Urine
Specimen Submission Form
Header
CALGB Form
CALGB Study No.
CALGB Patient ID
Are data amended
Yes
No
Unnamed2
Patient Initials (Last First Middle)
Patient Hospital No.
Institution/Affiliate
Participating Group
Participating Group Study No.
Participating Group Patient ID
To Be Completed By Submitting Institution
Does specimen accompany this form
Yes
No
Specify reason
Institution Error (Institution error)
Other (Other)
Patient Refusal (Patient refusal)
Sample Lost Or Destroyed (Sample lost
or destroyed)
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Date form submitted (MM DD YYYY)
LabTrak shipment ID (Required of all CALGB
institutions)
Specimen Type
Platelet-poor Plasma (Platelet-poor
plasma)
Urine (Urine)
Whole Blood (edta) (1 X 7ml) (Whole
blood (EDTA) (1 x 7ml))
Whole Blood (edta) (2 X 5ml) (Whole
Blood (EDTA) (2 x 5ml))
Time Specimen Collected (24-hour clock)
Date specimen collected (MM DD YYYY)
Date shipped (MM DD YYYY)
Sample period (For sample period, enter the
cycle number completed prior to specimen
collection or scheduled collection if specimen not
obtained; or enter "0" for pre-study and 99 for
progression.)
Number of tubes submitted
Approximate volume of sample (s ml)
Responsible CRA
CRA phone number
CRA e-mail
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Liver Cancer NCT01015833 On-Study - CALGB Solid
Tumor Evaluation Form (RECIST 1.1) - 2946223v1.0
CALGB Solid Tumor Evaluation Form (RECIST 1.1)
Sorafenib Tosylate With or Without Doxorubicin
Hydrochloride in Treating Patients With Locally Advanced
or Metastatic Liver Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=746D8651-
FF47-E158-E040-BB89AD4366AF
All rights reserved. Please visit https://medical-data-
models.org/forms/7974
CALGB Solid Tumor Evaluation Form
(RECIST 1.1)
Header
CALGB Form
CALGB Study No.
CALGB Patient ID
Date of Evaluation (MM DD YYYY)
Are data amended
Yes
No
Unnamed2
Patient Initials (Last, First Middle)
Patient Hospital No.
Institution/Affiliate
Participating Group
Participating Group Study No
Participating Group Patient ID
Report Period
Report Period (Mark one with an X.)
Baseline (Baseline)
Post-treatment (Post-Treatment)
Restaging (Restaging)
Cycle Number (if applicable)
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Reporting Period
Are there any target lesions?
Yes
No
Target Lesion Site
Method of Evaluation (Mark one with an X.)
Ct Scan (CT scan)
Mri (MRI (NMR))
Other (Other)
X-ray (X-ray)
Lesion size (mm)
Lesion type (Mark one with an X.)
Lymph Node (Lymph node)
Non-nodal (Non-nodal)
Lesion status (Mark one with an X.)
Absent (Absent)
New Lesion (New lesion)
Not Evaluable (Not evaluable)
Present (Present)
Progression (Unequivocal progression)
Baseline Sum (mm)
Smallest sum since baseline (mm)
Total tumor size (mm)
Percent change from baseline (%)
Percent change from smallest sum (%)
Comments
Comments
Non-target Lesion(s) Follow-up Evaluation
Are there any non-target lesions
Yes
No
Nontarget Lesion Site
Method of Evaluation (Mark one with an X.)
Ct Scan (CT scan)
Mri (MRI (NMR))
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Other (Other)
X-ray (X-ray)
Overall response at this assessment (tumor Mark
one with an X.)
Complete Response (Complete
Response)
Not Evaluable (Not evaluable)
Partial Response (Partial Response)
Progressive Disease (Progressive
Disease)
Stable Disease (Stable disease)
Lesion status (Mark one with an X.)
Absent (Absent)
New Lesion (New lesion)
Not Evaluable (Not evaluable)
Present (Present)
Progression (Unequivocal progression)
Was the appearance of any new lesions
documented
Yes
No
Specify
Is there symptomatic deterioration of the patient's
health status
Yes
No
Overall Response
Completed by (Last name, First name)
Date Form Originally Completed (MM DD YYYY)
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Leukemia NCT00651261 On-Study - CALGB:
10603 On-Study Form - 2719613v1.0
CALGB:  10603 On-Study Form
Daunorubicin, Cytarabine, and Midostaurin in Treating
Patients With Newly Diagnosed Acute Myeloid Leukemia
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=437820BA-
0A20-2BB7-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/7978
CALGB:  10603 On-Study Form
Header
CALGB Form (C-1619)
CALGB Study No
CALGB Patient ID
Are data amended
Yes
No
Ccrr Module For Calgb 90202: Prostate
Specific Antigen Form
Patient Initials (Last, First Middle)
Patient Hospital No.
Institution/Affiliate
Participating Group (Country Name for
International site:)
Participating Group Protocol Number
Participating Group Patient ID
Patient Description
Date of Initial Pathologic Diagnosis
MedDRA disease code
Date of first abnormal bone marrow for
antecedent myelodysplasia
Patient/Participant Age
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Leukemia Classification (who/fab)
WHO Diagnosis
Acute Basophilic Leukemia (Acute
basophilic leukemia)
Acute Erythroid Leukemia (Acute
erythroid leukemia)
Acute Megakaryoblastic Leukemia
(Acute megakaryoblastic leukemia)
Acute Myelomonocytic Leukemia (Acute
myelomonocytic leukemia)
Acute Panmyelosis With Myelofibrosis
(Acute panmyelosis with myelofibrosis)
Acute Myeloid Leukemia With 11q23
(mll) Abnormalities (AML with 11q23
(MLL) abnormalities)
Acute Myeloid Leukemia With
Inv(16)(p13q22) Or T(16;16)(p13;q22),
(cbf-beta/myh11) (AML with
inv(16)(p13q22) or t(16;16)(p13;q22))
Acute Myeloid Leukemia With Maturation
(AML with maturation)
Acute Myeloid Leukemia With
Multilineage Dysplasia Without Prior
Myelodysplastic Syndrome (AML with
multilineage dysplasia w/o prior MDS)
Acute Myeloid Leukemia With
Multilineage Dysplasia With Prior
Myelodysplastic Syndrome (AML with
multilineage dysplasia with prior MDS)
Acute Myeloid Leukemia With
T(8;21)(q22;q22), (aml1/eto) (AML with
t(8;21)(q22;q22))
Acute Myeloid Leukemia Without
Maturation (AML without maturation)
Acute Myeloid Leukemia, Minimally
Differentiated (AML, minimally
differentiated)
Myeloid Sarcoma (Myeloid sarcoma)
Other Specify (Other)
Other specify
Leukemia Classification (FAB)
Disease Classified As Acute
Erythroblastic Leukemia (fab M6) (Acute
erythroblastic leukemia (FAB M6))
Disease Classified As Acute
Megakaryoblastic Leukemia (fab M7)
(Acute megakaryoblastic leukemia (FAB
M7))
Disease Classified As Acute Monocytic
Leukemia (fab M5) (Acute monocytic
leukemia (FAB M5))
Disease Classified As Acute Myeloid
Leukemia W/ Maturation (fab M2) (Acute
myeloid leukemia w/ maturation (FAB
M2))
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Disease Classified As Acute Myeloid
Leukemia W/o Maturation (fab M1)
(Acute myeloid leukemia w/o maturation
(FAB M1))
Disease Classified As Acute
Myelomonocytic Leukemia (fab M4)
(Acute myelomonocytic leukemia (FAB
M4))
Other Specify (Other specify)
Disease Classified As Undifferentiated
Acute Myeloid Leukemia (fab M0)
(Undifferentiated acute myeloid leukemia
(FAB M0))
Other specify
Clinical Onset Of Aml
Clinical Onset of AML
Aml Without Prior Clinical History Of Mds
Or Potentially Leukemogenic Treatment
(de novo)
Aml Related To/associated With Prior
Clinical History Of Mds (MDS-related)
Aml Related To/associated With Prior
Clinical History Of Potentially
Leukemogenic Treatment (Treatment
related)
Prior treatment for leukemia or myelodysplasia
Yes
No
Did the patient receive cytotoxic treatment for the
MDS (If the patient had antecedent MDS,)
Yes
No
Number of days hydroxyurea received
Extramedullary Disease Involvement
Extramedullary Disease Involvement
Central Nervous System (Central
nervous system)
Gingival Hypertrophy (Gingival
hypertrophy)
Mediastinal Mass (Mediastinal mass)
Other Specify (Other)
Peripheral Nervous System (Peripheral
nervous system)
Leukaemia Cutis (Skin (leukemia cutis))
Other specify
Are auer rods present?
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Leukemia NCT00651261 On-Study - CALGB:  10603 On-Study Form -
2719613v1.0
Auer Rods Absent From Bone Marrow
(Absent)
Auer Rods Present In Bone Marrow
(Present)
Not done
Organ Involvement
Palpable splenomegaly
Examination Performed And
Splenomegaly Absent (No)
Examination Of Spleen Not Performed
(Not examined)
Spleen Removed Via Prior Surgery
(Surgically absent)
Examination Performed And
Splenomegaly Present (Yes)
Splenomegaly by scan (or X-ray)
Examination Performed And
Splenomegaly Absent (No)
Examination Of Spleen Not Performed
(Not examined)
Spleen Removed Via Prior Surgery
(Surgically absent)
Examination Performed And
Splenomegaly Present (Yes)
Palpable hepatomegaly
Examination Performed And
Hepatomegaly Absent (No)
Examination Of Liver Not Performed (Not
examined)
Examination Performed And
Hepatomegaly Present (Yes)
Hepatomegaly by scan (or X-ray)
Examination Performed And
Hepatomegaly Absent (No)
Examination Of Liver Not Performed (Not
examined)
Examination Performed And
Hepatomegaly Present (Yes)
Palpable lymphadenopathy
Examination Performed And
Lymphadenopathy Absent (No)
Examination Of Lymph Nodes Not
Performed (Not examined)
Examination Performed And
Lymphadenopathy Present (Yes)
Lymphadenopathy by scan
Examination Performed And
Lymphadenopathy Absent (No)
Examination Of Lymph Nodes Not
Performed (Not examined)
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Leukemia NCT00651261 On-Study - CALGB:  10603 On-Study Form -
2719613v1.0
Examination Performed And
Lymphadenopathy Present (Yes)
Current Symptoms
Current Infection
Life Threatening Or Disabling Adverse
Event (Life-threatening)
Moderate Adverse Event (Moderate)
None (None)
Severe Adverse Event (Severe)
Bleeding/Hemorrage
Active, Requiring Transfusion (Active,
requiring transfusion)
Mild, Not Requiring Transfusion (Mild,
not requiring transfusion)
None (None)
Lab Data At Study Entry
Chest X-Ray Result
Abnormal (Abnormal)
Normal (Normal)
Abnormal, specify
Date of Chest X-ray
Bilirubin
Bilirubin ULN
EKG result
Abnormal (Abnormal)
Normal (Normal)
Not Done (Not done)
Specify nature of abnormalities
Date of EKG
LVEF (%)
Method to determine ejection fraction
Echocardiogram (Echocardiogram)
Radionuclide Ventriculogram Scan
(Multiple Gated Acquisition (MUGA))
Overall Response
5 / 6
Leukemia NCT00651261 On-Study - CALGB:  10603 On-Study Form -
2719613v1.0
Completed by (print or type name)
Date Form Completed (MM DD YYYY)
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Leukemia NCT00651261 On-Study - CALGB:  10603 On-Study Form -
2719613v1.0
Liver Cancer NCT01015833 Lab - CALGB:
80802 Sample Submission Form - 2943746v1.0
CALGB: 80802 Sample Submission Form
Sorafenib Tosylate With or Without Doxorubicin
Hydrochloride in Treating Patients With Locally Advanced
or Metastatic Liver Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=741BA0BF-
5B36-06EF-E040-BB89AD434B15
All rights reserved. Please visit https://medical-data-
models.org/forms/7980
CALGB: 80802 Sample Submission
Form
Ccrr Module For Calgb 90202: Prostate
Specific Antigen Form
CALGB Form (C-1928)
CALGB Study No. (80802)
CALGB Patient ID
Date form submitted
Are data amended
Yes
No
Patient Initials (Last, First Middle)
Patient Hospital No.
Institution/Affiliate
Participating Group
Participating Group Study No.
Participating Group Patient ID
Unnamed3
Reporting Period
Baseline (Baseline)
Recurrence/progression
(Recurrence/progression)
Restaging (Restaging)
Cycle Number
Do specimen(s) accompany this form
1 / 2
Yes
No
Type of specimen submitted
Plasma (Plasma)
Serum (Serum)
Specify reason (If no,)
Institution Error (Institution error)
Other (Other)
Patient Refusal (Patient refusal)
Sample Lost Or Destroyed (Sample lost
or destroyed)
Date Specimen collected
Date Specimen Shipped
LabTrak sample ID (for CALGB institutions only)
Shipping Information
LabTrak shipment ID (for CALGB institutions
only)
Submitted by
Phone
Email
Footer Module
Completed by
Date Form Originally Completed
2 / 2
Liver Cancer NCT01015833 Lab - CALGB: 80802 Sample Submission
Form - 2943746v1.0
Infection NCT00513526 Treatment - AMC-052
Concomitant Medication Form (MED) - 2676790v1.0
AMC-052 Concomitant Medication Form (MED)
Human Papillomavirus Vaccine Therapy in Treating Men
With HIV-1 Infection
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=3952E724-
4217-361E-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/7986
AMC-052 Concomitant Medication
Form (MED)
Ccrr Module For Concomitant
Antiretroviral Medications - Rf08
Agent Name
Agent Start Date
Total Daily Dose of Agent (or Drug)
Units
Capsules (Capsules)
Drops (Drops)
International Unit (International Unit)
Microgram (Microgram)
Milligram (Milligram)
Milliliter (Milliliter)
Other (Other)
Tablets (Tablets)
Unit (Unit)
Other, specify
Frequency
>4x/day (>4X/day)
As Needed (p.r.n) (as needed (P.R.N))
At Bedtime Or Hour Of Sleep (h.s.) (at
bedtime or hour of sleep (H.S.))
Every 12 Hours (q12hr) (every 12 hours
(Q12hr))
Every 4 Hours (q4hr) (every 4 hours
(Q4hr))
Every 6 Hours (q6hr) (every 6 hours
(Q6hr))
Every 8 Hours (q8hr) (every 8 hours
(Q8hr))
Every Other Day (q.o.d.) (every other day
(Q.O.D.))
Four Times A Day (q.i.d) (four times a
day (Q.I.D))
Monthly (Monthly)
Once A Day (q.d.) (Once a day (Q.D.))
Other (Other)
Three Times A Day (t.i.d) (three times a
day (T.I.D))
Twice A Day (b.i.d) (twice a day (B.I.D))
Weekly (Weekly)
1 / 2
Other, specify
Is this an antiretroviral agent
Yes
No
Please provide indication (If no)
Is use of this agent ongoing
Yes
No
Date last taken (If no)
Comments
Comments
2 / 2
Infection NCT00513526 Treatment - AMC-052 Concomitant Medication
Form (MED) - 2676790v1.0
Lymphoma NCT00598169 Treatment - AMC-053
Concomitant Medication Form (MED) - 3122080v1.0
AMC-053 Concomitant Medication Form (MED)
Bortezomib, Ifosfamide, Carboplatin, and Etoposide, With
or Without Rituximab, in Treating Patients With Relapsed or
Refractory AIDS-Related Non-Hodgkin Lymphoma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=8B7087AC-
42A1-0CD3-E040-BB89AD431A82
All rights reserved. Please visit https://medical-data-
models.org/forms/7989
AMC-053 Concomitant Medication
Form (MED)
Ccrr Module For Concomitant
Antiretroviral Medications - Rf08
Agent Name
Dose Level Start Date
Total Daily Dose of Agent (or Drug)
Units
Capsules (Capsules)
Drops (Drops)
International Unit (International Unit)
Microgram (Microgram)
Milligram (Milligram)
Milliliter (Milliliter)
Other (Other)
Tablets (Tablets)
Unit (Unit)
Other, specify
Frequency
>4x/day (>4X/day)
As Needed (p.r.n) (as needed (P.R.N))
At Bedtime Or Hour Of Sleep (h.s.) (at
bedtime or hour of sleep (H.S.))
Every 12 Hours (q12hr) (every 12 hours
(Q12hr))
Every 4 Hours (q4hr) (every 4 hours
(Q4hr))
Every 6 Hours (q6hr) (every 6 hours
(Q6hr))
Every 8 Hours (q8hr) (every 8 hours
(Q8hr))
Every Other Day (q.o.d.) (every other day
(Q.O.D.))
Four Times A Day (q.i.d) (four times a
day (Q.I.D))
Monthly (Monthly)
Once A Day (q.d.) (Once a day (Q.D.))
Other (Other)
Three Times A Day (t.i.d) (three times a
day (T.I.D))
Twice A Day (b.i.d) (twice a day (B.I.D))
1 / 2
Weekly (Weekly)
Other, specify
Is this an antiretroviral agent
Yes
No
Please provide indication (If "no")
Is use of this agent ongoing
Yes
No
Date last taken (If "no" mm/dd/yyyy)
Comments
Comments
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Lymphoma NCT00598169 Treatment - AMC-053 Concomitant
Medication Form (MED) - 3122080v1.0
Lymphoma NCT00389818 Treatment - AMC-047
Concomitant Medication Form (MED) - 2525405v1.0
AMC-047 Concomitant Medication Form (MED)
Combination Chemotherapy and Rituximab in Treating
Patients With Newly Diagnosed AIDS-Related B-Cell Non-
Hodgkin's Lymphoma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=1EFE3AED-
8233-7169-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/7992
AMC-047 Concomitant Medication
Form (MED)
Ccrr Module For Concomitant
Antiretroviral Medications - Rf08
Agent Name
Dose Level Start Date
Total Daily Dose of Agent (or Drug)
Units
Capsules (Capsules)
Drops (Drops)
International Unit (International Unit)
Microgram (Microgram)
Milligram (Milligram)
Milliliter (Milliliter)
Other (Other)
Tablets (Tablets)
Unit (Unit)
Other, specify
Frequency
>4x/day (>4X/day)
As Needed (p.r.n) (as needed (P.R.N))
At Bedtime Or Hour Of Sleep (h.s.) (at
bedtime or hour of sleep (H.S.))
Every 12 Hours (q12hr) (every 12 hours
(Q12hr))
Every 4 Hours (q4hr) (every 4 hours
(Q4hr))
Every 6 Hours (q6hr) (every 6 hours
(Q6hr))
Every 8 Hours (q8hr) (every 8 hours
(Q8hr))
Every Other Day (q.o.d.) (every other day
(Q.O.D.))
Four Times A Day (q.i.d) (four times a
day (Q.I.D))
Monthly (Monthly)
Once A Day (q.d.) (Once a day (Q.D.))
Other (Other)
Three Times A Day (t.i.d) (three times a
day (T.I.D))
Twice A Day (b.i.d) (twice a day (B.I.D))
1 / 2
Weekly (Weekly)
Other, specify
Is this an antiretroviral agent
Yes
No
Please provide indication (If "No")
Is use of this agent ongoing
Yes
No
Date last taken (If "No")
Comments
Comments
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Lymphoma NCT00389818 Treatment - AMC-047 Concomitant
Medication Form (MED) - 2525405v1.0
Lymphoma NCT00392834 Treatment - AMC-048
Concomitant Medication (MED) - 2655200v1.0
AMC-048 Concomitant Medication (MED)
Rituximab and Combination Chemotherapy in Treating
Patients With Newly Diagnosed, HIV-Associated Burkitt's
Lymphoma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=32E18FA2-
335A-4AF2-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/7993
AMC-048 Concomitant Medication
(MED)
Ccrr Module For Concomitant
Antiretroviral Medications - Rf08
Agent Name
Agent Start Date
Total Daily Dose of Agent (or Drug)
Units
Capsules (Capsules)
Drops (Drops)
International Unit (International Unit)
Microgram (Microgram)
Milligram (Milligram)
Milliliter (Milliliter)
Other (Other)
Tablets (Tablets)
Unit (Unit)
Other, specify
Frequency
>4x/day (>4X/day)
As Needed (p.r.n) (as needed (P.R.N))
At Bedtime Or Hour Of Sleep (h.s.) (at
bedtime or hour of sleep (H.S.))
Every 12 Hours (q12hr) (every 12 hours
(Q12hr))
Every 4 Hours (q4hr) (every 4 hours
(Q4hr))
Every 6 Hours (q6hr) (every 6 hours
(Q6hr))
Every 8 Hours (q8hr) (every 8 hours
(Q8hr))
Every Other Day (q.o.d.) (every other day
(Q.O.D.))
Four Times A Day (q.i.d) (four times a
day (Q.I.D))
Monthly (Monthly)
Once A Day (q.d.) (Once a day (Q.D.))
Other (Other)
Three Times A Day (t.i.d) (three times a
day (T.I.D))
Twice A Day (b.i.d) (twice a day (B.I.D))
1 / 2
Weekly (Weekly)
Other, specify
Is this an antiretroviral agent
Yes
No
Please provide indication
Is use of this agent ongoing
Yes
No
Date last taken
Comments
Comments
2 / 2
Lymphoma NCT00392834 Treatment - AMC-048 Concomitant
Medication (MED) - 2655200v1.0
Nonneoplastic Condition NCT01057121 Treatment - AMC-
070 Concomitant Medication Form (MED) - 3146336v1.0
AMC-070 Concomitant Medication Form (MED)
Lenalidomide in Treating Patients With AIDS-Related
Kaposi Sarcoma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=91E333A1-
423B-701C-E040-BB89AD433C30
All rights reserved. Please visit https://medical-data-
models.org/forms/7994
AMC-070 Concomitant Medication
Form (MED)
Ccrr Module For Concomitant
Antiretroviral Medications - Rf08
Agent Name
Dose Level Start Date
Total Daily Dose of Agent (or Drug)
Units
Capsules (Capsules)
Drops (Drops)
International Unit (International Unit)
Microgram (Microgram)
Milligram (Milligram)
Milliliter (Milliliter)
Other (Other)
Tablets (Tablets)
Unit (Unit)
Other, specify
Frequency
>4x/day (>4X/day)
As Needed (p.r.n) (as needed (P.R.N))
At Bedtime Or Hour Of Sleep (h.s.) (at
bedtime or hour of sleep (H.S.))
Every 12 Hours (q12hr) (every 12 hours
(Q12hr))
Every 4 Hours (q4hr) (every 4 hours
(Q4hr))
Every 6 Hours (q6hr) (every 6 hours
(Q6hr))
Every 8 Hours (q8hr) (every 8 hours
(Q8hr))
Every Other Day (q.o.d.) (every other day
(Q.O.D.))
Four Times A Day (q.i.d) (four times a
day (Q.I.D))
Monthly (Monthly)
Once A Day (q.d.) (Once a day (Q.D.))
Other (Other)
Three Times A Day (t.i.d) (three times a
day (T.I.D))
Twice A Day (b.i.d) (twice a day (B.I.D))
Weekly (Weekly)
1 / 2
Other, specify
Is this an antiretroviral agent
Yes
No
Please provide indication (If "no")
Is use of this agent ongoing
Yes
No
Date last taken (If "no" mm/dd/yyyy)
Comments
Comments
2 / 2
Nonneoplastic Condition NCT01057121 Treatment - AMC-070
Concomitant Medication Form (MED) - 3146336v1.0
Sarcoma NCT01016730 Treatment - AMC-063
Concomitant Medication Form (MED) - 3020125v1.0
AMC-063 Concomitant Medication Form (MED)
Bortezomib in Treating Patients With Relapsed or
Refractory AIDS-Related Kaposi Sarcoma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=815F9798-
9FA1-E20D-E040-BB89AD435094
All rights reserved. Please visit https://medical-data-
models.org/forms/7995
AMC-063 Concomitant Medication
Form (MED)
Ccrr Module For Concomitant
Antiretroviral Medications - Rf08
Agent Name
Dose Level Start Date
Total Daily Dose of Agent (or Drug)
Units
Capsules (Capsules)
Drops (Drops)
International Unit (International Unit)
Microgram (Microgram)
Milligram (Milligram)
Milliliter (Milliliter)
Other (Other)
Tablets (Tablets)
Unit (Unit)
Other, specify
Frequency
>4x/day (>4X/day)
As Needed (p.r.n) (as needed (P.R.N))
At Bedtime Or Hour Of Sleep (h.s.) (at
bedtime or hour of sleep (H.S.))
Every 12 Hours (q12hr) (every 12 hours
(Q12hr))
Every 4 Hours (q4hr) (every 4 hours
(Q4hr))
Every 6 Hours (q6hr) (every 6 hours
(Q6hr))
Every 8 Hours (q8hr) (every 8 hours
(Q8hr))
Every Other Day (q.o.d.) (every other day
(Q.O.D.))
Four Times A Day (q.i.d) (four times a
day (Q.I.D))
Monthly (Monthly)
Once A Day (q.d.) (Once a day (Q.D.))
Other (Other)
Three Times A Day (t.i.d) (three times a
day (T.I.D))
Twice A Day (b.i.d) (twice a day (B.I.D))
Weekly (Weekly)
1 / 2
Other, specify
Is this an antiretroviral agent
Yes
No
Please provide indication (If "no")
Is use of this agent ongoing
Yes
No
Date last taken (If "no" mm/dd/yyyy)
Comments
Comments
2 / 2
Sarcoma NCT01016730 Treatment - AMC-063 Concomitant Medication
Form (MED) - 3020125v1.0
Sarcoma NCT00450320 Treatment - AMC-051
Concomitant Medication Form (MED) - 2635933v1.0
AMC-051 Concomitant Medication Form (MED)
Sirolimus in Treating Patients With HIV-Related Kaposi's
Sarcoma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=2FDFA89A-
0682-6018-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/7996
AMC-051 Concomitant Medication
Form (MED)
Ccrr Module For Concomitant
Antiretroviral Medications - Rf08
Agent Name
Agent Start Date
Total Daily Dose of Agent (or Drug)
Units
Capsules (Capsules)
Drops (Drops)
International Unit (International Unit)
Microgram (Microgram)
Milligram (Milligram)
Milliliter (Milliliter)
Other (Other)
Tablets (Tablets)
Unit (Unit)
Other, specify
Frequency
>4x/day (>4X/day)
As Needed (p.r.n) (as needed (P.R.N))
At Bedtime Or Hour Of Sleep (h.s.) (at
bedtime or hour of sleep (H.S.))
Every 12 Hours (q12hr) (every 12 hours
(Q12hr))
Every 4 Hours (q4hr) (every 4 hours
(Q4hr))
Every 6 Hours (q6hr) (every 6 hours
(Q6hr))
Every 8 Hours (q8hr) (every 8 hours
(Q8hr))
Every Other Day (q.o.d.) (every other day
(Q.O.D.))
Four Times A Day (q.i.d) (four times a
day (Q.I.D))
Monthly (Monthly)
Once A Day (q.d.) (Once a day (Q.D.))
Other (Other)
Three Times A Day (t.i.d) (three times a
day (T.I.D))
Twice A Day (b.i.d) (twice a day (B.I.D))
Weekly (Weekly)
1 / 2
Other, specify
Is this an antiretroviral agent
Yes
No
Please provide indication (If no)
Is use of this agent ongoing
Yes
No
Date last taken (If no)
Comments
Comments
2 / 2
Sarcoma NCT00450320 Treatment - AMC-051 Concomitant Medication
Form (MED) - 2635933v1.0
Anal Cancer NCT00550589 Treatment - AMC-046
Concomitant Medication Form (MED) - 2989341v1.0
AMC-046 Concomitant Medication Form (MED)
Cidofovir in Treating HIV-Infected Patients With High-Grade
Squamous Intraepithelial Lesions of the Skin Near the Anus
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=7D8985E5-
2DD3-08A5-E040-BB89AD434A3B
All rights reserved. Please visit https://medical-data-
models.org/forms/7998
AMC-046 Concomitant Medication
Form (MED)
Ccrr Module For Concomitant
Antiretroviral Medications - Rf08
Agent Name
Dose Level Start Date
Total Daily Dose of Agent (or Drug)
Units
Capsules (Capsules)
Drops (Drops)
International Unit (International Unit)
Microgram (Microgram)
Milligram (Milligram)
Milliliter (Milliliter)
Other (Other)
Tablets (Tablets)
Unit (Unit)
Other, specify
Frequency
>4x/day (>4X/day)
As Needed (p.r.n) (as needed (P.R.N))
At Bedtime Or Hour Of Sleep (h.s.) (at
bedtime or hour of sleep (H.S.))
Every 12 Hours (q12hr) (every 12 hours
(Q12hr))
Every 4 Hours (q4hr) (every 4 hours
(Q4hr))
Every 6 Hours (q6hr) (every 6 hours
(Q6hr))
Every 8 Hours (q8hr) (every 8 hours
(Q8hr))
Every Other Day (q.o.d.) (every other day
(Q.O.D.))
Four Times A Day (q.i.d) (four times a
day (Q.I.D))
Monthly (Monthly)
Once A Day (q.d.) (Once a day (Q.D.))
Other (Other)
Three Times A Day (t.i.d) (three times a
day (T.I.D))
Twice A Day (b.i.d) (twice a day (B.I.D))
Weekly (Weekly)
1 / 2
Other, specify
Is this an antiretroviral agent
Yes
No
Please provide indication (If "no")
Is use of this agent ongoing
Yes
No
Date last taken (If "no" mm/dd/yyyy)
Comments
Comments
2 / 2
Anal Cancer NCT00550589 Treatment - AMC-046 Concomitant
Medication Form (MED) - 2989341v1.0
Lung Cancer NCT00632853 Lab - CALGB:
30610 Sample Submission Form - 2689059v1.0
CALGB: 30610 Sample Submission Form
Three Different Radiation Therapy Regimens in Treating
Patients With Limited-Stage Small Cell Lung Cancer
Receiving Cisplatin and Etoposide
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=3C4C999B-
DE4C-38A5-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/7999
CALGB: 30610 Sample Submission
Form
Ccrr Module For Calgb 90202: Prostate
Specific Antigen Form
CALGB Form (C-714)
CALGB Study No.
CALGB Patient ID
Date form submitted
Are data amended
Yes
No
Patient Initials (Last, First Middle)
Patient Hospital No.
Institution/Affiliate
Participating Group
Participating Group Study No.
Participating Group Patient ID
Unnamed3
Reporting Period
Baseline (Baseline)
Day 21 (pre-chemotherapy) (Day 21
(pre-chemotherapy))
First Follow-up Visit After Completion Of
All Protocol Therapy (First follow-up visit
after completion of all protocol therapy)
Recurrence (Recurrence)
Does specimen accompany this form?
1 / 2
Yes
No
Specify reason (If no,)
Institution Error (Institution error)
Other (Other)
Patient Refusal (Patient refusal)
Sample Lost Or Destroyed (Sample lost
or destroyed)
Date Specimen collected
Date Specimen Shipped
LabTrak sample ID
Shipping Information
LabTrak shipment ID (3 Required of all CALGB
institutions. Access Labtrak application via the
member site at www.calgb.org. Anyone accessing
LabTrak for the first time must have an assigned
CALGB PIN Participant ID Number and contact
the CALGB help desk...to set up LabTrak.)
Shipped by
Contact Phone Number
Contact Person E-Mail
Footer Module
Completed by
Date Form Originally Completed
2 / 2
Lung Cancer NCT00632853 Lab - CALGB: 30610 Sample Submission
Form - 2689059v1.0
Brain and Central Nervous System Tumors NCT00890747 Treatment -
AMC-061 Concomitant Medication Form (MED) - 2935086v1.0
AMC-061 Concomitant Medication Form (MED)
Sunitinib Malate in Treating HIV-Positive Patients With
Cancer Undergoing Highly Active Antiretroviral Therapy
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=71988CF7-
F951-68F0-E040-BB89AD4358A1
All rights reserved. Please visit https://medical-data-
models.org/forms/8000
AMC-061 Concomitant Medication
Form (MED)
Ccrr Module For Concomitant
Antiretroviral Medications - Rf08
Agent Name
Dose Level Start Date
Total Daily Dose of Agent (or Drug)
Units
Capsules (Capsules)
Drops (Drops)
International Unit (International Unit)
Microgram (Microgram)
Milligram (Milligram)
Milliliter (Milliliter)
Other (Other)
Tablets (Tablets)
Unit (Unit)
Other, specify
Frequency
>4x/day (>4X/day)
As Needed (p.r.n) (as needed (P.R.N))
At Bedtime Or Hour Of Sleep (h.s.) (at
bedtime or hour of sleep (H.S.))
Every 12 Hours (q12hr) (every 12 hours
(Q12hr))
Every 4 Hours (q4hr) (every 4 hours
(Q4hr))
Every 6 Hours (q6hr) (every 6 hours
(Q6hr))
Every 8 Hours (q8hr) (every 8 hours
(Q8hr))
Every Other Day (q.o.d.) (every other day
(Q.O.D.))
Four Times A Day (q.i.d) (four times a
day (Q.I.D))
Monthly (Monthly)
Once A Day (q.d.) (Once a day (Q.D.))
Other (Other)
Three Times A Day (t.i.d) (three times a
day (T.I.D))
Twice A Day (b.i.d) (twice a day (B.I.D))
Weekly (Weekly)
1 / 2
Other, specify
Is this an antiretroviral agent
Yes
No
Please provide indication (If "no")
Is use of this agent ongoing
Yes
No
Date last taken (If "no" mm/dd/yyyy)
Comments
Comments
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Brain and Central Nervous System Tumors NCT00890747 Treatment -
AMC-061 Concomitant Medication Form (MED) - 2935086v1.0
Kidney Cancer NCT00326898 Treatment - E2805
Concomitant Medication Form - 2444090v1.0
E2805 Concomitant Medication Form
Sunitinib or Sorafenib in Treating Patients With Kidney
Cancer That Was Removed By Surgery
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=0B593E1B-
ACB3-37BB-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/8004
E2805 Concomitant Medication
Form
Administrative documentation
ECOG Protocol Number*
ECOG Protocol Number*
ECOG Patient ID*
ECOG Patient ID*
DCI Name*
Registration Step*
Patient Initials*
ECOG Protocol Number*
ECOG Protocol Number*
Participating Group Protocol Number*
Institution/Affiliate*
ECOG Patient ID*
ECOG Patient ID*
Participating Group Patient ID*
Concomitant medication
Agent Name (Generic Name)*
Reporting period Start Date*
1 / 3
Reporting period End Date*
Dose*
Units (*)*
Capsules (capsules)
Drops (drops)
Gram (gram)
Inch (inch)
Kilograms (kilogram)
Liter (liter)
Microgram (microgram)
Milliequivalent (milliequivalent)
Milligram (milligram)
Milliliter (milliliter)
Other (other)
Ounce (ounce)
Tablespoon (tablespoon)
Tablets (tablets)
Teaspoon (teaspoon)
Unit (unit)
Unknown (Unknown)
other, specify*
Frequency (**)*
After Meals (p.c.) (after meals)
As Needed (p.r.n) (as needed)
At Bedtime Or Hour Of Sleep (h.s.) (at
bedtime or hour of sleep)
Before Meals (a.c.) (before meals)
Every 12 Hours (q12hr) (every 12 hours)
Every 4 Hours (q4hr) (every 4 hours)
Every 6 Hours (q6hr) (every 6 hours)
Every 8 Hours (q8hr) (every 8 hours)
Every Day (q.d.) (every day)
Every Other Day (q.o.d.) (every other
day)
Four Times A Day (q.i.d) (four times a
day)
Immediately (stat) (immediately)
Other (other)
Three Times A Day (t.i.d) (three times a
day)
Three Times A Week (t.i.w) (three times
a week)
Twice A Day (b.i.d) (twice a day)
Twice A Week (b.i.w) (twice a week)
Unknown (Unknown)
other, specify*
Route (***)*
Intramuscular (IM)
Inhaled (inhaled)
Intradermal (intradermal)
2 / 3
Kidney Cancer NCT00326898 Treatment - E2805 Concomitant
Medication Form - 2444090v1.0
Intravenous (IV)
Nasal (nasal)
Other (other)
Oral (PO)
Rectal (rectal)
Subcutaneous (SC)
Sublingual (sublingual)
Topical (topical)
Transdermal (transdermal)
Unknown (Unknown)
other, specify*
Agent Start Date (Leave blank if continuing from
a prior report period)*
Is this medication continuing?*
Yes
No
Agent End Date (Leave blank if continuing)*
On Treatment Report Period (since start of
treatment If treatment was delayed, choose the
intended time period without delays.)*
Baseline (Baseline)
Cycle 1 (Cycle 1)
Cycle 2 (Cycle 2)
Cycle 3 (Cycle 3)
Cycle 4 (Cycle 4)
Cycle 5 (Cycle 5)
Cycle 6 (Cycle 6)
Cycle 7 (Cycle 7)
Cycle 8 (Cycle 8)
Cycle 9 (Cycle 9)
Were concomitant medications used during this
reporting period? (reportable)*
Yes
No
Please mark an 'X' if data have been amended.*
Date data amended*
Comments
Comments*
Investigator Signature*
Investigator Signature Date*
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Kidney Cancer NCT00326898 Treatment - E2805 Concomitant
Medication Form - 2444090v1.0
Lung Cancer NCT00693992 Lab - CALGB:
30607 Sample Submission Form - 2664096v1.0
CALGB: 30607 Sample Submission Form
Sunitinib as Maintenance Therapy in Treating Patients With
Stage III or Stage IV Non-Small Cell Lung Cancer
Previously Treated With Combination Chemotherapy
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=35619BB4-
5837-4CFC-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/8005
CALGB: 30607 Sample Submission
Form
Ccrr Module For Calgb 90202: Prostate
Specific Antigen Form
CALGB Form (C-714)
CALGB Study No.
CALGB Patient ID
Date of Submission of This Form
Are data amended
Yes
No
Patient Initials (Last, First Middle)
Patient Hospital No.
Institution/Affiliate
Participating Group
Participating Group Study No.
Participating Group Patient ID
Unnamed3
Reporting Period
Post Cycle 1 (Post Cycle 1)
Post Cycle 2 (Post Cycle 2)
Pre-therapy (Pre-treatment)
Specimen Type
Peripheral Blood (Blood)
None (None)
Plasma (Plasma)
1 / 2
Date Specimen Obtained
LabTrak sample ID
Shipping Information
LabTrak shipment ID (3 Required of all CALGB
institutions. Access Labtrak application via the
member site at www.calgb.org. Anyone accessing
LabTrak for the first time must have an assigned
CALGB PIN Participant ID Number and contact
the CALGB help desk...to set up LabTrak.)
Shipped by
Contact Phone Number
Contact Person E-Mail
Footer Module
Completed by
Date Form Originally Completed
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Lung Cancer NCT00693992 Lab - CALGB: 30607 Sample Submission
Form - 2664096v1.0
Lung Cancer NCT01041781 Lab - CALGB: 30801
PK Sample Submission Form - 2891263v1.0
CALGB: 30801 PK Sample Submission Form
Gemcitabine Hydrochloride or Pemetrexed Disodium and
Carboplatin With or Without Celecoxib in Treating Patients
With Advanced Non-Small Cell Lung Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=6AF26CA3-
DCE9-EEE0-E040-BB89AD436D54
All rights reserved. Please visit https://medical-data-
models.org/forms/8009
CALGB: 30801 PK Sample
Submission Form
Ccrr Module For Calgb 90202: Prostate
Specific Antigen Form
CALGB Form
CALGB Study No.
CALGB Patient ID
Shipment date (MM DD YYYY)
Are data amended
Yes
No
Patient Initials (Last, First Middle)
Patient Hospital No.
Institution/Affiliate
Participating Group (Country Name for
International Studies)
Participating Group Study No.
Participating Group Patient ID
Previous Celecoxib/placebo Dose
Date (MM DD YYYY)
Time (HH M)
Sample Submission Data
1 / 2
Does specimen accompany this form?
Yes
No
Date Specimen collected (If yes MM DD YYYY)
Planned Time of Collection (HH M)
Actual Time of Collection (HH M)
Comments
Comments
Shipping Information
Responsible CRA
CRA email
CRA Fax Number
CRA phone number
Courier Tracking Number
Shipped by
LabTrak shipment ID (for CALGB institutions
only)
Footer Module
Completed by (Last name, First name)
Date Form Originally Completed (MM DD YYYY)
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Lung Cancer NCT01041781 Lab - CALGB: 30801 PK Sample
Submission Form - 2891263v1.0
Lung Cancer NCT00863512 Toxicity - CALGB
30506 Baseline Abnormalities Form - 2817620v1.0
CALGB 30506 Baseline Abnormalities Form
Chemotherapy or Observation in Treating Patients With
Early Stage Non-Small Cell Lung Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=5E92C67F-
DA08-CFB0-E040-BB89AD432DA1
All rights reserved. Please visit https://medical-data-
models.org/forms/8010
CALGB 30506 Baseline
Abnormalities Form
Header
CALGB Form
CALGB Study No
CALGB Patient ID
Date of baseline symptom/event assessment
(MM DD YYYY)
Are data amended
Yes
No
Unnamed2
Patient Initials (Last, First Middle)
Patient Hospital No.
Institution/Affiliate
Participating Group
Participating Group Study No.
Participating Group Patient ID
Expected Adverse Events
MedDRA Code (Specify any other baseline
abnormalities)
MedDRA Code (Specify any other baseline
abnormalities)
1 / 2
CTC adverse event term
CTC adverse event term
CTC AE grade (at baseline)
CTC AE grade (at baseline)
Completed by (Last name, First name)
Date Form Completed (MM DD YYYY)
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Lung Cancer NCT00863512 Toxicity - CALGB 30506 Baseline
Abnormalities Form - 2817620v1.0
Lung Cancer NCT01041781 Lab - CALGB:
30801 Sample Submission Form - 2891187v1.0
CALGB: 30801 Sample Submission Form
Gemcitabine Hydrochloride or Pemetrexed Disodium and
Carboplatin With or Without Celecoxib in Treating Patients
With Advanced Non-Small Cell Lung Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=6AF26CA3-
DC35-EEE0-E040-BB89AD436D54
All rights reserved. Please visit https://medical-data-
models.org/forms/8012
CALGB: 30801 Sample Submission
Form
Ccrr Module For Calgb 90202: Prostate
Specific Antigen Form
CALGB Form
CALGB Study No.
CALGB Patient ID
Shipment date (MM DD YYYY)
Are data amended
Yes
No
Patient Initials (Last, First Middle)
Patient Hospital No.
Institution/Affiliate
Participating Group
Participating Group Study No.
Participating Group Patient ID
Unnamed3
Sample Period (Mark one with an X.)
Baseline (Baseline)
Cycle 1 - Day 8 (Cycle 1 - Day 8)
Pre-registration (Pre-registration)
Specimen Type (Mark one with an X.)
Peripheral Blood (Blood)
Urine (Urine)
Date Specimen collected (MM DD YYYY)
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LabTrak sample ID (for CALGB institutions only)
LabTrak shipment ID (for CALGB institutions
only)
Responsible CRA
CRA phone number
CRA email
Footer Module
Completed by (Last name, First name)
Date Form Originally Completed (MM DD YYYY)
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Lung Cancer NCT01041781 Lab - CALGB: 30801 Sample Submission
Form - 2891187v1.0
Lung Cancer NCT01041781 Lab - CALGB: 30801
COX-2 Sample Submission Form - 2891225v1.0
CALGB: 30801 COX-2 Sample Submission Form
Gemcitabine Hydrochloride or Pemetrexed Disodium and
Carboplatin With or Without Celecoxib in Treating Patients
With Advanced Non-Small Cell Lung Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=6AF26CA3-
DC8F-EEE0-E040-BB89AD436D54
All rights reserved. Please visit https://medical-data-
models.org/forms/8016
CALGB: 30801 COX-2 Sample
Submission Form
Ccrr Module For Calgb 90202: Prostate
Specific Antigen Form
CALGB Form
CALGB Study No.
CALGB Patient ID
Date Form Completed (MM DD YYYY)
Are data amended
Yes
No
Patient Initials (Last, First Middle)
Patient Hospital No.
Institution/Affiliate
Participating Group
Participating Group Study No.
Participating Group Patient ID
Comments
Comments
Shipping Information
Date Specimen collected (MM DD YYYY)
Date Specimen Shipped (MM DD YYYY)
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LabTrak shipment ID
Responsible CRA
CRA email
CRA phone number
Footer Module
Completed by
Date Form Originally Completed (MM DD YYYY)
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Lung Cancer NCT01041781 Lab - CALGB: 30801 COX-2 Sample
Submission Form - 2891225v1.0
NCT00430183 Quality of Life - CALGB 90203: The Expanded
Prostate Cancer Index Composite Survey Instrument - 2527357v1.0
CALGB 90203: The Expanded Prostate Cancer Index
Composite (EPIC) Survey Instrument - Short Form [Form
C-1145 v1 10/23/2006]
Surgery With or Without Docetaxel and Leuprolide or
Goserelin in Treating Patients With High-Risk Localized
Prostate Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=1F9FC2EA-
E06D-5BE7-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/8018
CALGB 90203: The Expanded
Prostate Cancer Index Composite
Survey Instrument
Ccrr Module For Calgb 90202: Prostate
Specific Antigen Form
CALGB Form (C-714)
CALGB Study No.
CALGB Patient ID
Assessment Date (mm dd yyyy)
Are data amended
Yes
No
Patient Initials (Last, First Middle)
Patient Hospital No.
Institution/Affiliate
Participating Group
Participating Group Study No.
Participating Group Patient ID
Interviewer Module
Person Completing Form (Recommended Term
for CRF Text "Responsible Person Name" Long
Name of Recommended CDE, but not Doc Text
Interviewer or CRA)
Assessment No.
1 / 6
Quality Of Life Module
Over the past 4 weeks how often have you leaked
urine
Once A Day (About once a day)
About Once A Week (About once a
week)
More Than Once A Day (More than once
a day)
More Than Once A Week (More than
once a week)
Rarely (Rarely or never)
Which of the following best describes your
urinary control during the last 4 weeks
Frequent Dribbling (Frequent dribbling)
No Urinary Control (No urinary control
whatsoever)
Occasional Dribbling (Occasional
dribbling)
Normal Urinary Control (Total control)
How many pads or adult diapers per day did you
usually use to control leakage during the last 4
weeks
1 Per Day (1 pad per day)
2 Per Day (2 pads per day)
3+ Per Day (3 or more pads per day)
None (No pads)
Dripping or leaking urine (How big a problem, if
any, has each of the following been for you during
the last 4 weeks? Select one answer in each
line.)
Severe Problem (Big problem)
Moderate Problem (Moderate problem)
No Problem (No problem)
Mild To Moderate Problem (Small
problem)
Mild Problem (Very small problem)
Pain or burning on urination
Severe Problem (Big problem)
Moderate Problem (Moderate problem)
No Problem (No problem)
Mild To Moderate Problem (Small
problem)
Mild Problem (Very small problem)
Bleeding with urination
Severe Problem (Big problem)
Moderate Problem (Moderate problem)
No Problem (No problem)
Mild To Moderate Problem (Small
problem)
Mild Problem (Very small problem)
Weak urine stream or incomplete emptying
Severe Problem (Big problem)
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NCT00430183 Quality of Life - CALGB 90203: The Expanded Prostate
Cancer Index Composite Survey Instrument - 2527357v1.0
Moderate Problem (Moderate problem)
No Problem (No problem)
Mild To Moderate Problem (Small
problem)
Mild Problem (Very small problem)
Need to urinate frequently during the day
Severe Problem (Big problem)
Moderate Problem (Moderate problem)
No Problem (No problem)
Mild To Moderate Problem (Small
problem)
Mild Problem (Very small problem)
Overall, how big a problem has your urinary
function been for you during the last 4 weeks
(Select one.)
Severe Problem (Big problem)
Moderate Problem (Moderate problem)
No Problem (No problem)
Mild To Moderate Problem (Small
problem)
Mild Problem (Very small problem)
Urgency to have a bowel movement (How big a
problem, if any, has each of the following been for
you? Select one answer in each line.)
Severe Problem (Big problem)
Moderate Problem (Moderate problem)
No Problem (No problem)
Mild To Moderate Problem (Small
problem)
Mild Problem (Very small problem)
Increased frequency of bowel movements
Severe Problem (Big problem)
Moderate Problem (Moderate problem)
No Problem (No problem)
Mild To Moderate Problem (Small
problem)
Mild Problem (Very small problem)
Losing control of your stools
Severe Problem (Big problem)
Moderate Problem (Moderate problem)
No Problem (No problem)
Mild To Moderate Problem (Small
problem)
Mild Problem (Very small problem)
Bloody stools
Severe Problem (Big problem)
Moderate Problem (Moderate problem)
No Problem (No problem)
Mild To Moderate Problem (Small
problem)
Mild Problem (Very small problem)
Abdominal/pelvic/rectal pain
Severe Problem (Big problem)
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Cancer Index Composite Survey Instrument - 2527357v1.0
Moderate Problem (Moderate problem)
No Problem (No problem)
Mild To Moderate Problem (Small
problem)
Mild Problem (Very small problem)
Overall, how big a problem have your bowel
habits been for you during the last 4 weeks
(Select one.)
Severe Problem (Big problem)
Moderate Problem (Moderate problem)
No Problem (No problem)
Mild To Moderate Problem (Small
problem)
Mild Problem (Very small problem)
Your ability to have an erection (How would you
rate each of the following during the last 4
weeks? Select one answer in each line.)
Fair (Fair)
Good (Good)
Poor (Poor)
Very Good (Very Good)
None (Very poor to None)
Your ability to reach orgasm (climax)
Fair (Fair)
Good (Good)
Poor (Poor)
Very Good (Very Good)
None (Very poor to None)
How would you describe the usual QUALITY of
your erections during the last 4 weeks
Firm Enough For Intercourse (Firm
enough for intercourse)
Firm Enough For Masturbation And
Foreplay Only (Firm enough for
masturbation and foreplay only)
None (None at all)
Not Firm Enough For Any Sexual Activity
(Not firm enough for any sexual activity)
How would you describe the FREQUENCY of
your erections during the last 4 weeks
About Half (approximately 50%) (I had
an erection ABOUT HALF the time I
wanted one)
Less Than Half (I had an erection LESS
THAN HALF the time I wanted one)
More Than Half (I had an erection MORE
THAN HALF the time I wanted one)
Normal (I had an erection WHENEVER I
wanted one)
Never (I NEVER had an erection when I
wanted one)
Overall, how would you rate your ability to
function sexually during the last 4 weeks
Fair (Fair)
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Good (Good)
Poor (Poor)
Very Good (Very Good)
Very Poor (Very poor)
Overall, how big a problem has your sexual
function or lack of sexual function been for you
during the last 4 weeks
Severe Problem (Big problem)
Moderate Problem (Moderate problem)
No Problem (No problem)
Mild To Moderate Problem (Small
problem)
Mild Problem (Very small problem)
Hot flashes (How big a problem during the last 4
weeks, if any, has each of the following been for
you? Select one answer in each line.)
Severe Problem (Big problem)
Moderate Problem (Moderate problem)
No Problem (No problem)
Mild To Moderate Problem (Small
problem)
Mild Problem (Very small problem)
Breast tenderness/enlargement
Severe Problem (Big problem)
Moderate Problem (Moderate problem)
No Problem (No problem)
Mild To Moderate Problem (Small
problem)
Mild Problem (Very small problem)
Feeling depressed
Severe Problem (Big problem)
Moderate Problem (Moderate problem)
No Problem (No problem)
Mild To Moderate Problem (Small
problem)
Mild Problem (Very small problem)
Lack of energy
Severe Problem (Big problem)
Moderate Problem (Moderate problem)
No Problem (No problem)
Mild To Moderate Problem (Small
problem)
Mild Problem (Very small problem)
Change in body weight
Severe Problem (Big problem)
Moderate Problem (Moderate problem)
No Problem (No problem)
Mild To Moderate Problem (Small
problem)
Mild Problem (Very small problem)
Ccrr Module For Calgb 90202: Prostate
Specific Antigen Form
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NCT00430183 Quality of Life - CALGB 90203: The Expanded Prostate
Cancer Index Composite Survey Instrument - 2527357v1.0
Completed by (Last name, First Name)
Date Form Completed (mm dd yyyy)
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NCT00430183 Quality of Life - CALGB 90203: The Expanded Prostate
Cancer Index Composite Survey Instrument - 2527357v1.0
Lung Cancer NCT00863512 Lab - CALGB
30506 Sample Submission Form - 2817459v1.0
CALGB 30506 Sample Submission Form
Chemotherapy or Observation in Treating Patients With
Early Stage Non-Small Cell Lung Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=5E92C67F-
D8B2-CFB0-E040-BB89AD432DA1
All rights reserved. Please visit https://medical-data-
models.org/forms/8019
CALGB 30506 Sample Submission
Form
Ccrr Module For Calgb 90202: Prostate
Specific Antigen Form
CALGB Form
CALGB Study No.
CALGB Patient ID
Are data amended
Yes
No
Patient Initials (Last, First Middle)
Patient Hospital No.
Institution/Affiliate
Participating Group
Participating Group Study No.
Participating Group Patient ID
Unnamed3
Date Specimen collected (MM DD YYYY)
Date Specimen Shipped (MM DD YYYY)
Number of cryovials shipped
Shipping Information
Submitted by
Phone
1 / 2
Email
Footer Module
Comments
Completed by
Date Form Originally Completed (MM DD YYYY)
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Lung Cancer NCT00863512 Lab - CALGB 30506 Sample Submission
Form - 2817459v1.0
Cervical Cancer NCT00064077 Toxicity - GOG
Common Toxicity Reporting Form - 2059265v3.0
GOG Common Toxicity Reporting Form
Comparison of Four Combination Chemotherapy Regimens
Using Cisplatin in Treating Patients With Stage IVB,
Recurrent, or Persistent Cancer of the Cervix
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=ABA3B3D1-
8528-2473-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/8021
GOG Common Toxicity Reporting
Form
Header Module
Date form originally completed (m d y)
Date form amended (m d y)
Person amending form, last name
Patient Name, Last
Patient Name, First
Patient Study ID
Person Completing Form, Last Name
Adverse Events - Section 1
Current course number (The toxicities listed
below occurred following this course of therapy)
Has the patient received any transfusions during
this course of therapy?
No Transfusion (No)
Transfusion With Platelets (Yes,
platelets)
Transfusion With Red Blood Cells (Yes,
pRBC)
Was patient hospitalized as a result of reported
adverse events?
Yes
No
Were cytokines administered this course?
No (No)
Yes (Yes, specify)
Yes (Cytokines), specify
1 / 3
Has an Adverse Drug Reaction Report been
filed?
Yes
No
Adverse Events - Section 2
Peripheral WBC count, Done
Yes
No
Peripheral WBC count (1000/mm3 Nadir)
Peripheral WBC count, Date (m d y)
Peripheral Granulocytes count, Done
Yes
No
Peripheral Granulocytes count (ANC, 1000/mm3
Nadir)
Peripheral Granulocytes count, Date
Peripheral Platelet count, Done
Yes
No
Peripheral Platelet count (mm3 Nadir)
Peripheral Platelet count, Date
Hemoglobin, Done
Yes
No
Hemoglobin (G/DL Nadir)
Hemoglobin, Date
CTC Adverse Event Grade
CTC Adverse Event Attribution (* Attribution
Codes for Relationship of Event to Treatment: 1 =
Unrelated, 2 = Unlikely, 3 = Possibly, 4 =
Probably, 5 = Definitely)
Definitely (Definitely)
Possibly (Possibly)
Probably (Probably)
Unlikely (Unlikely)
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Cervical Cancer NCT00064077 Toxicity - GOG Common Toxicity
Reporting Form - 2059265v3.0
Unrelated (Unrelated)
Adverse Events - Section 3
CTC Adverse Event Term
CTC Adverse Event Grade
CTC Adverse Event Attribution (* Attribution
Codes for Relationship of Event to Treatment: 1 =
Unrelated, 2 = Unlikely, 3 = Possibly, 4 =
Probably, 5 = Definitely)
Definitely (Definitely)
Possibly (Possibly)
Probably (Probably)
Unlikely (Unlikely)
Unrelated (Unrelated)
Comments
COMMENTS
Footer Module
Participating Group Code
Participating Group Protocol Number
Participating Patient Study ID
Ccrr Module For Gog Common Toxicity
Reporting Form
3 / 3
Cervical Cancer NCT00064077 Toxicity - GOG Common Toxicity
Reporting Form - 2059265v3.0
Ovarian Cancer NCT00954174 Toxicity - GOG-0261:
Common Toxicity Reporting Form (T) - 2847941v1.0
GOG-0261:  Common Toxicity Reporting Form (T)
Paclitaxel and Carboplatin or Ifosfamide in Treating Patients
With Newly Diagnosed Persistent or Recurrent Uterine or
Ovarian Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=64F29740-
050F-692F-E040-BB89AD432164
All rights reserved. Please visit https://medical-data-
models.org/forms/8023
GOG-0261:  Common Toxicity
Reporting Form (T)
Header Module
Date form originally completed (m d y)
Date form amended (m d y)
Person amending form, last name
Patient Initials (First, Middle, Last)
Patient Study ID
Person Completing Form, Last Name
Adverse Events - Section 1
Current Course Number (The toxicities listed
below occurred following this course of therapy)
Has the patient received any transfusions during
this course of therapy?
No Transfusion (No)
Transfusion With Platelets (Yes,
platelets)
Transfusion With Red Blood Cells (Yes,
red blood cells)
Was patient hospitalized as a result of reported
adverse events?
Yes
No
Were cytokines administered this course?
Yes
No
Yes specify
Has an Adverse Drug Reaction Report been
filed?
Yes
No
1 / 45
Adverse Events - Section 2
Peripheral WBC count done (1000/mm3)
Yes
No
Peripheral Granulocytes count done (ANC/)
Yes
No
Peripheral Platelet count done
Yes
No
Hemoglobin done
Yes
No
Nadir
Date (m d y)
CTC Adverse Event Grade
CTC Adverse Event Attribution Code
Definite (Definite)
Possible (Possible)
Probable (Probable)
Unlikely (Unlikely)
Unrelated (Unrelated)
Adverse Events - Section 3
CTC Adverse Event Term
Acidosis Nos (Acidosis (metabolic or
respiratory))
Capillary Leak Syndrome (Acute
vascular leak syndrome)
Adrenal Insufficiency (Adrenal
insufficiency)
Adult Respiratory Distress Syndrome
(Adult respiratory distress syndrome
(ARDS))
Blood Albumin Decreased (Albumin,
serum-low (hypoalbuminemia))
Alcohol Intolerance Syndrome
(antabuse-like Syndrome) (Alcohol
intolerance syndrome (antabuse-like
syndrome))
Blood Alkaline Phosphatase Nos
Increased (Alkaline phosphatase)
Alkalosis Nos (Alkalosis (metabolic or
respiratory))
Hypersensitivity Nos (Allergic
reaction/hypersensitivity (including drug
fever))
2 / 45
Ovarian Cancer NCT00954174 Toxicity - GOG-0261:  Common Toxicity
Reporting Form (T) - 2847941v1.0
Rhinitis Allergic Nos (Allergic rhinitis
(including sneezing, nasal stuffiness,
postnasal drip))
Allergy/immunology Other
(Allergy/Immunology-Other (Specify))
Alanine Aminotransferase Increased
(ALT, SGPT (serum glutamic pyruvic
transaminase))
Blood Amylase Increased (Amylase)
Anorexia (Anorexia)
Apnoea (Apnea)
Arachnoiditis
(Arachnoiditis/meningismus/radiculitis)
Arthritis Nos (Arthritis (non-septic))
Ascites (Ascites (non-malignant))
Aspiration (Aspiration)
Aspartate Aminotransferase Increased
(AST, SGOT (serum glutamic oxaloacetic
transaminase))
Ataxia Nec (Ataxia (incoordination))
Atelectasis (Atelectasis)
Atrophy, Skin (Atrophy, skin)
Atrophy, Subcutaneous Fat (Atrophy,
subcutaneous fat)
Auditory/ear Other (Auditory/Ear-Other
(Specify))
Autoimmune Disorder Nos (Autoimmune
reaction)
Blood Bicarbonate Decreased
(Bicarbonate, serum-low)
Blood Bilirubin Increased (Bilirubin
(hyperbilirubinemia))
Bladder Disorder Nos (Bladder spasms)
Blood/bone Marrow Other (Blood/Bone
Marrow-Other (Specify))
Bone Age (alteration In Bone Age) (Bone
age (alteration in bone age))
Bone Growth: Femoral Head; Slipped
Capital Femoral Epiphysis (Bone growth:
femoral head; slipped capital femoral
epiphysis)
Bone Growth: Limb Length Discrepancy
(Bone growth: limb length discrepancy)
Bone Growth: Spine Kyphosis/lordosis
(Bone growth: spine kyphosis/lordosis)
Bone Marrow Depression Nos (Bone
marrow cellularity)
Bone: Spine-scoliosis (Bone: spine-
scoliosis)
Brachial Plexopathy (Brachial
plexopathy)
Breast Function/lactation (Breast
function/lactation)
Breast Nipple/areolar Deformity (Breast
nipple/areolar deformity)
Breast Volume/hypoplasia (Breast
volume/hypoplasia)
Bronchospasm, Wheezing
(Bronchospasm, wheezing)
Ecchymosis (Bruising (in absence of
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grade 3 or 4 thrombocytopenia))
Burn (Burn)
Hypercalcaemia (Calcium, serum-high
(hypercalcemia))
Hypocalcaemia (Calcium, serum-low
(hypocalcemia))
Pulmonary Function Test Nos Decreased
(Carbon monoxide diffusion capacity
(DL(co)))
Arrhythmia Nos (Cardiac Arrhythmia-
Other (Specify))
Cardiac General Other (Cardiac
General-Other (Specify))
Myocardial Ischaemia (Cardiac
ischemia/infarction)
Cardiac Troponin I Increased (Cardiac
troponin I (cTnI))
Cardiac Troponin T Increased (Cardiac
troponin T (cTnT))
Cardiopulmonary Arrest, Cause
Unknown (non-fatal) (Cardiopulmonary
arrest, cause unknown (non-fatal))
Cataract Nec (Cataract)
Cd4 Lymphocytes Decreased (CD4
count)
Cervical Spine-range Of Motion (Cervical
spine-range of motion)
Chelitis (Cheilitis)
Cholecystitis (Cholecystitis)
Hypercholesteraemia (Cholesterol,
serum-high (hypercholesteremia))
Chyle Or Lymph Leakage (Chyle or
lymph leakage)
Chylothorax (Chylothorax)
Cerebral Ischaemia (CNS
cerebrovascular ischemia)
Cns Necrosis/cystic Progression (CNS
necrosis/cystic progression)
Coagulation Disorder Nos (Coagulation-
Other (Specify))
Learning Disorder Nos (Cognitive
disturbance)
Colitis Nos (Colitis)
Colitis, Infectious (e.g., Clostridium
Difficile) (Colitis, infectious (e.g.,
Clostridium difficile))
Ventricular Asystole (Conduction
abnormality/Atrioventricular heart block -
Asystole)
Conduction Abnormality/atrioventricular
Heart Block (Conduction
abnormality/Atrioventricular heart block -
AV block-first degree)
Conduction Abnormality/atrioventricular
Heart Block - Av Block-second Degree
Mobitz Type I (wenckebach) (Conduction
abnormality/Atrioventricular heart block -
AV block-Second degree Mobitz Type I
(Wenckebach))
Conduction Abnormality/atrioventricular
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Heart Block (Conduction
abnormality/Atrioventricular heart block -
AV block-second degree Mobitz Type II)
Conduction Abnormality/atrioventricular
Heart Block (Conduction
abnormality/Atrioventricular heart block -
AV block-third degree (complete AV
block))
Conduction Abnormality/atrioventricular
Heart Block (Conduction
abnormality/Atrioventricular heart block -
Conduction abnormality NOS)
Conduction Abnormality/atrioventricular
Heart Block (Conduction
abnormality/Atrioventricular heart block -
Sick sinus syndrome)
Conduction Abnormality/atrioventricular
Heart Block (Conduction
abnormality/Atrioventricular heart block -
Stokes-Adams syndrome)
Conduction Abnormality/atrioventricular
Heart Block (Conduction
abnormality/Atrioventricular heart block -
Wolff-Parkinson-White syndrome)
Confusion (Confusion)
Constipation (Constipation)
Constitutional Symptoms Other
(Constitutional Symptoms-Other
(Specify))
Cough (Cough)
Blood Creatine Phosphokinase
Increased (CPK (creatine
phosphokinase))
Blood Creatinine Increased (Creatinine)
Cushingoid (Cushingoid appearance
(e.g., moon face, buffalo hump,
centripetal obesity, cutaneous striae))
Cystitis (Cystitis)
Cytokine Release Syndrome/acute
Infusion Reaction (Cytokine release
syndrome/acute infusion reaction)
Death Not Associated With Ctcae Term
(Death not associated with CTCAE term
- Death NOS)
Death Not Associated With Ctcae Term
(Death not associated with CTCAE term
- Disease progression NOS)
Death Not Associated With Ctcae Term
(Death not associated with CTCAE term
- Multi-organ failure)
Death Not Associated With Ctcae Term
(Death not associated with CTCAE term
- Sudden death)
Dehydration (Dehydration)
Dental: Dentures Or Prosthesis (Dental:
dentures or prosthesis)
Dental: Periodontal Disease (Dental:
periodontal disease)
Dental: Teeth (Dental: teeth)
Dental: Teeth Development (Dental:
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teeth development)
Dermal Change Lymphedema,
Phlebolymphedema (Dermal change
lymphedema, phlebolymphedema)
Dermatology/skin Other
(Dermatology/Skin-Other (Specify))
Diarrhoea Nos (Diarrhea)
Disseminated Intravascular Coagulation
(DIC (disseminated intravascular
coagulation))
Distention/bloating, Abdominal
(Distention/bloating, abdominal)
Dizziness (exc Vertigo) (Dizziness)
Dry Eye Nec (Dry eye syndrome)
Dry Mouth (Dry mouth/salivary gland
(xerostomia))
Dry Skin (Dry skin)
Dysphagia (Dysphagia (difficulty
swallowing))
Dyspnoea Nos (Dyspnea (shortness of
breath))
Edema, Larynx (Edema, larynx)
Edema: Head And Neck (Edema: head
and neck)
Oedema Nos (Edema: limb)
Edema: Trunk/genital (Edema:
trunk/genital)
Edema: Viscera (Edema: viscera)
Ejaculatory Dysfunction (Ejaculatory
dysfunction)
Encephalopathy (Encephalopathy)
Endocrine Other (Endocrine-Other
(Specify))
Enteritis (inflammation Of The Small
Bowel) (Enteritis (inflammation of the
small bowel))
Impotence (Erectile dysfunction)
Oesophagitis Nos (Esophagitis)
Exostosis (Exostosis)
Extrapyramidal Disorder Nec
(Extrapyramidal/involuntary
movement/restlessness)
Extremity-lower (gait/walking) (Extremity-
lower (gait/walking))
Extremity-upper (function) (Extremity-
upper (function))
Eyelid Dysfunction (Eyelid dysfunction)
Fatigue (Fatigue (asthenia, lethargy,
malaise))
Febrile Neutropenia (fever Of Unknown
Origin Without Clinically Or
Microbiologically Documented Infection)
(anc <1.0 X 10^9/l, Fever >=38.5
Degrees C) (Febrile neutropenia)
Feminization (Feminization of male)
Forced Expiratory Volume Decreased
(FEV(1))
Pyrexia (Fever (in the absence of
neutropenia, where neutropenia is
defined as ANC <1.0 x 10^9/L))
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Blood Fibrinogen Decreased
(Fibrinogen)
Fibrosis-cosmesis (Fibrosis-cosmesis)
Fibrosis-deep Connective Tissue
(Fibrosis-deep connective tissue)
Fistula, Gi (Fistula, GI - Abdomen NOS)
Anal Fistula (Fistula, GI - Anus)
Fistula, Gi (Fistula, GI - Biliary tree)
Fistula, Gi (Fistula, GI -
Colon/cecum/appendix)
Intestinal Fistula (Fistula, GI -
Duodenum)
Tracheo-oesophageal Fistula Nos
(Fistula, GI - Esophagus)
Fistula, Gi (Fistula, GI - Gallbladder)
Fistula, Gi (Fistula, GI - Ileum)
Fistula, Gi (Fistula, GI - Jejunum)
Fistula, Gi (Fistula, GI - Oral cavity)
Fistula, Gi (Fistula, GI - Pancreas)
Fistula, Gi (Fistula, GI - Pharynx)
Fistula, Gi (Fistula, GI - Rectum)
Fistula, Gi (Fistula, GI - Salivary gland)
Fistula, Gi (Fistula, GI - Small bowel
NOS)
Fistula, Gi (Fistula, GI - Stomach)
Fistula, Gu (Fistula, GU - Bladder)
Fistula, Gu (Fistula, GU - Genital tract-
female)
Fistula, Gu (Fistula, GU - Kidney)
Fistula, Gu (Fistula, GU - Ureter)
Fistula, Gu (Fistula, GU - Urethra)
Fistula, Gu (Fistula, GU - Uterus)
Urogenital Fistula (Fistula, GU - Vagina)
Fistula, Pulmonary/upper Respiratory
(Fistula, pulmonary/upper respiratory -
Bronchus)
Fistula, Pulmonary/upper Respiratory
(Fistula, pulmonary/upper respiratory -
Larynx)
Fistula, Pulmonary/upper Respiratory
(Fistula, pulmonary/upper respiratory -
Lung)
Fistula, Pulmonary/upper Respiratory
(Fistula, pulmonary/upper respiratory -
Oral cavity)
Fistula, Pulmonary/upper Respiratory
(Fistula, pulmonary/upper respiratory -
Pharynx)
Fistula, Pulmonary/upper Respiratory
(Fistula, pulmonary/upper respiratory -
Pleura)
Fistula, Pulmonary/upper Respiratory
(Fistula, pulmonary/upper respiratory -
Trachea)
Flatulence (Flatulence)
Flu-like Syndrome (Flu-like syndrome)
Flushing (Flushing)
Fracture (Fracture)
Gastritis Nos (Gastritis (including bile
reflux gastritis))
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Gastrointestinal Other (Gastrointestinal-
Other (Specify))
Gamma-glutamyltransferase Increased
(GGT (gamma-glutamyl transpeptidase))
Glaucoma Nos (Glaucoma)
Glomerular Filtration Rate (Glomerular
filtration rate)
Hyperglycaemia Nos (Glucose, serum-
high (hyperglycemia))
Hypoglycaemia Nos (Glucose, serum-
low (hypoglycemia))
Growth And Development Other (Growth
and Development-Other (Specify))
Growth Velocity (reduction In Growth
Velocity) (Growth velocity (reduction in
growth velocity))
Gynaecomastia (Gynecomastia)
Alopecia (Hair loss/Alopecia (scalp or
body))
Haptoglobin Decreased (Haptoglobin)
Hearing: Patients With/without Baseline
Audiogram And Enrolled In A Monitoring
Program (Hearing: patients with/without
baseline audiogram and enrolled in a
monitoring program)
Hearing: Patients Without Baseline
Audiogram And Not Enrolled In A
Monitoring Program (Hearing: patients
without baseline audiogram and not
enrolled in a monitoring program)
Dyspepsia (Heartburn/dyspepsia)
Hematoma (Hematoma)
Haemoglobin Decreased (Hemoglobin)
Haemoglobinuria Present
(Hemoglobinuria)
Hemolysis Nos (Hemolysis (e.g.,
immune hemolytic anemia, drug related
hemolysis))
Haemorrhagic Stroke (Hemorrhage,
CNS)
Melaena (Hemorrhage, GI - Abdomen
NOS)
Hemorrhage, Gi (Hemorrhage, GI -
Anus)
Hemorrhage, Gi (Hemorrhage, GI -
Biliary tree)
Hemorrhage, Gi (Hemorrhage, GI -
Cecum/appendix)
Hemorrhage, Gi (Hemorrhage, GI -
Colon)
Hemorrhage, Gi (Hemorrhage, GI -
Duodenum)
Hemorrhage, Gi (Hemorrhage, GI -
Esophagus)
Hemorrhage, Gi (Hemorrhage, GI -
Ileum)
Hemorrhage, Gi (Hemorrhage, GI -
Jejunum)
Hemorrhage, Gi (Hemorrhage, GI - Liver)
Hemorrhage, Gi (Hemorrhage, GI -
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Lower GI NOS)
Hemorrhage, Gi (Hemorrhage, GI - Oral
cavity)
Hemorrhage, Gi (Hemorrhage, GI -
Pancreas)
Hemorrhage, Gi (Hemorrhage, GI -
Peritoneal cavity)
Rectal Bleeding (Hemorrhage, GI -
Rectum)
Hemorrhage, Gi (Hemorrhage, GI -
Stoma)
Haematemesis (Hemorrhage, GI -
Stomach)
Hemorrhage, Gi (Hemorrhage, GI -
Upper GI NOS)
Hemorrhage, Gi (Hemorrhage, GI -
Varices (esophageal))
Hemorrhage, Gi (Hemorrhage, GI -
Varices (rectal))
Hemorrhage, Gu (Hemorrhage, GU -
Bladder)
Hemorrhage, Gu (Hemorrhage, GU -
Fallopian tube)
Hemorrhage, Gu (Hemorrhage, GU -
Kidney)
Hemorrhage, Gu (Hemorrhage, GU -
Ovary)
Hemorrhage, Gu (Hemorrhage, GU -
Prostate)
Hemorrhage, Gu (Hemorrhage, GU -
Retroperitoneum)
Hemorrhage, Gu (Hemorrhage, GU -
Spermatic cord)
Hemorrhage, Gu (Hemorrhage, GU -
Stoma)
Hemorrhage, Gu (Hemorrhage, GU -
Testes)
Hemorrhage, Gu (Hemorrhage, GU -
Ureter)
Hemorrhage, Gu (Hemorrhage, GU -
Urethra)
Haematuria Present (Hemorrhage, GU -
Urinary NOS)
Hemorrhage, Gu (Hemorrhage, GU -
Uterus)
Vaginal Haemorrhage (Hemorrhage, GU
- Vagina)
Hemorrhage, Gu (Hemorrhage, GU - Vas
deferens)
Hemorrhage, Pulmonary/upper
Respiratory (Hemorrhage,
pulmonary/upper respiratory -
Bronchopulmonary NOS)
Hemorrhage, Pulmonary/upper
Respiratory (Hemorrhage,
pulmonary/upper respiratory - Bronchus)
Hemorrhage, Pulmonary/upper
Respiratory (Hemorrhage,
pulmonary/upper respiratory - Larynx)
Hemorrhage, Pulmonary/upper
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Respiratory (Hemorrhage,
pulmonary/upper respiratory - Lung)
Hemorrhage, Pulmonary/upper
Respiratory (Hemorrhage,
pulmonary/upper respiratory -
Mediastinum)
Epistaxis (Hemorrhage, pulmonary/upper
respiratory - Nose)
Hemorrhage, Pulmonary/upper
Respiratory (Hemorrhage,
pulmonary/upper respiratory - Pharynx)
Hemorrhage, Pulmonary/upper
Respiratory (Hemorrhage,
pulmonary/upper respiratory - Pleura)
Haemoptysis (Hemorrhage,
pulmonary/upper respiratory -
Respiratory tract NOS)
Hemorrhage, Pulmonary/upper
Respiratory (Hemorrhage,
pulmonary/upper respiratory - Stoma)
Hemorrhage, Pulmonary/upper
Respiratory (Hemorrhage,
pulmonary/upper respiratory - Trachea)
Post-operative Haemorrhage
(Hemorrhage/bleeding associated with
surgery, intra-operative or post-operative)
Hemorrhage/bleeding Other
(Hemorrhage/Bleeding-Other (Specify))
Hemorrhoids (Hemorrhoids)
Hepatobiliary/pancreas Other
(Hepatobiliary/Pancreas-Other (Specify))
Hiccups (Hiccoughs (hiccups, singultus))
Menopausal Symptoms (Hot
flashes/flushes)
Hydrocephalus (Hydrocephalus)
Skin Discolouration (Hyperpigmentation)
Hypertension Nos (Hypertension)
Hypopigmentation (Hypopigmentation)
Hypotension Nos (Hypotension)
Hypothermia (Hypothermia)
Hypoxia (Hypoxia)
Ileus (Ileus, GI (functional obstruction of
bowel, i.e., neuroconstipation))
Incontinence, Anal (Incontinence, anal)
Urinary Incontinence (Incontinence,
urinary)
Induration/fibrosis (skin And
Subcutaneous Tissue)
(Induration/fibrosis (skin and
subcutaneous tissue))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Abdomen NOS)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
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microbiologically) with Grade 3 or 4
neutrophils - Anal/perianal)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Appendix)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Artery)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Biliary tree)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Bladder (urinary))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Blood)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Bone (osteomyelitis))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Brain (encephalitis,
infectious))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Brain + Spinal cord
(encephalomyelitis))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Bronchus)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
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Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Catheter-related)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Cecum)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Cervix)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Colon)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Conjunctiva)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Cornea)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Dental-tooth)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Duodenum)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Esophagus)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - External ear (otitis externa))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
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Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Eye NOS)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Fallopian tube)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Foreign body (e.g., graft,
implant, prosthesis, stent))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Gallbladder (cholecystitis))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Heart (endocarditis))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Ileum)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Jejunum)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Joint)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Kidney)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Larynx)
Infection (documented Clinically Or
13 / 45
Ovarian Cancer NCT00954174 Toxicity - GOG-0261:  Common Toxicity
Reporting Form (T) - 2847941v1.0
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Lens)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Lip/perioral)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Liver)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Lung (pneumonia))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Lymphatic)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Mediastinum NOS)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Meninges (meningitis))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Middle ear (otitis media))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Mucosa)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Muscle (infection myositis))
Infection (documented Clinically Or
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Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Neck NOS)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Nerve-cranial)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Nerve-peripheral)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Nose)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Oral cavity-gums
(gingivitis))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Pancreas)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Paranasal)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Pelvis NOS)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Penis)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Peristomal)
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Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Peritoneal cavity)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Pharynx)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Pleura (empyema))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Prostate)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Rectum)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Salivary gland)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Scrotum)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Sinus)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Skin (cellulitis))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Small bowel NOS)
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Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Soft tissue NOS)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Spinal cord (myelitis))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Spleen)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Stomach)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Trachea)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Ungual (nails))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Upper aerodigestive NOS)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Upper airway NOS)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Ureter)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Urethra)
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Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Urinary tract NOS)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Uterus)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Vagina)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Vein)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Vulva)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Wound)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Abdomen
NOS)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils -
Anal/perianal)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Appendix)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Artery)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Biliary tree)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Bladder
(urinary))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Blood)
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Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Bone
(osteomyelitis))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Brain
(encephalitis, infectious))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Brain +
Spinal cord (encephalomyelitis))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Bronchus)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Catheter-
related)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Cecum)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Cervix)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Colon)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils -
Conjunctiva)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Cornea)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Dental-
tooth)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Duodenum)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Esophagus)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - External ear
(otitis externa))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Eye NOS)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Fallopian
tube)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Foreign
body (e.g., graft, implant, prosthesis,
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stent))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Gallbladder
(cholecystitis))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Heart
(endocarditis))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Ileum)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Jejunum)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Joint)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Kidney)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Larynx)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Lens)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Lip/perioral)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Liver)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Lung
(pneumonia))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Lymphatic)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils -
Mediastinum NOS)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Meninges
(meningitis))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Middle ear
(otitis media))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Mucosa)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Muscle
(infection myositis))
Infection With Normal Anc Or Grade 1 Or
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2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Neck NOS)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Nerve-
cranial)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Nerve-
peripheral)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Nose)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Oral cavity-
gums (gingivitis))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Pancreas)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Paranasal)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Pelvis NOS)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Penis)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Peristomal)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Peritoneal
cavity)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Pharynx)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Pleura
(empyema))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Prostate)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Rectum)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Salivary
gland)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Scrotum)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Sinus)
Infection With Normal Anc Or Grade 1 Or
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2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Skin
(cellulitis))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Small bowel
NOS)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Soft tissue
NOS)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Spinal cord
(myelitis))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Spleen)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Stomach)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Trachea)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Ungual
(nails))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Upper
aerodigestive NOS)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Upper
airway NOS)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Ureter)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Urethra)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Urinary
tract NOS)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Uterus)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Vagina)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Vein)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Vulva)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
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or Grade 1 or 2 neutrophils - Wound)
Infection With Unknown Anc (Infection
with unknown ANC - Abdomen NOS)
Infection With Unknown Anc (Infection
with unknown ANC - Anal/perianal)
Infection With Unknown Anc (Infection
with unknown ANC - Appendix)
Infection With Unknown Anc (Infection
with unknown ANC - Artery)
Infection With Unknown Anc (Infection
with unknown ANC - Biliary tree)
Infection With Unknown Anc (Infection
with unknown ANC - Bladder (urinary))
Infection With Unknown Anc (Infection
with unknown ANC - Blood)
Infection With Unknown Anc (Infection
with unknown ANC - Bone
(osteomyelitis))
Infection With Unknown Anc (Infection
with unknown ANC - Brain (encephalitis,
infectious))
Infection With Unknown Anc (Infection
with unknown ANC - Brain + Spinal cord
(encephalomyelitis))
Infection With Unknown Anc (Infection
with unknown ANC - Bronchus)
Implant Infection (Infection with unknown
ANC - Catheter-related)
Infection With Unknown Anc (Infection
with unknown ANC - Cecum)
Infection With Unknown Anc (Infection
with unknown ANC - Cervix)
Infection With Unknown Anc (Infection
with unknown ANC - Colon)
Infection With Unknown Anc (Infection
with unknown ANC - Conjunctiva)
Infection With Unknown Anc (Infection
with unknown ANC - Cornea)
Infection With Unknown Anc (Infection
with unknown ANC - Dental-tooth)
Infection With Unknown Anc (Infection
with unknown ANC - Duodenum)
Infection With Unknown Anc (Infection
with unknown ANC - Esophagus)
Infection With Unknown Anc (Infection
with unknown ANC - External ear (otitis
externa))
Infection With Unknown Anc (Infection
with unknown ANC - Eye NOS)
Infection With Unknown Anc (Infection
with unknown ANC - Fallopian tube)
Infection With Unknown Anc (Infection
with unknown ANC - Foreign body (e.g.,
graft, implant, prosthesis, stent))
Infection With Unknown Anc (Infection
with unknown ANC - Gallbladder
(cholecystitis))
Infection With Unknown Anc (Infection
with unknown ANC - Heart
(endocarditis))
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Infection With Unknown Anc (Infection
with unknown ANC - Ileum)
Infection With Unknown Anc (Infection
with unknown ANC - Jejunum)
Infection With Unknown Anc (Infection
with unknown ANC - Joint)
Infection With Unknown Anc (Infection
with unknown ANC - Kidney)
Infection With Unknown Anc (Infection
with unknown ANC - Larynx)
Infection With Unknown Anc (Infection
with unknown ANC - Lens)
Infection With Unknown Anc (Infection
with unknown ANC - Lip/perioral)
Infection With Unknown Anc (Infection
with unknown ANC - Liver)
Infection With Unknown Anc (Infection
with unknown ANC - Lung (pneumonia))
Infection With Unknown Anc (Infection
with unknown ANC - Lymphatic)
Infection With Unknown Anc (Infection
with unknown ANC - Mediastinum NOS)
Infection With Unknown Anc (Infection
with unknown ANC - Meninges
(meningitis))
Infection With Unknown Anc (Infection
with unknown ANC - Middle ear (otitis
media))
Infection With Unknown Anc (Infection
with unknown ANC - Mucosa)
Infection With Unknown Anc (Infection
with unknown ANC - Muscle (infection
myositis))
Infection With Unknown Anc (Infection
with unknown ANC - Neck NOS)
Infection With Unknown Anc (Infection
with unknown ANC - Nerve-cranial)
Infection With Unknown Anc (Infection
with unknown ANC - Nerve-peripheral)
Infection With Unknown Anc (Infection
with unknown ANC - Nose)
Infection With Unknown Anc (Infection
with unknown ANC - Oral cavity-gums
(gingivitis))
Infection With Unknown Anc (Infection
with unknown ANC - Pancreas)
Infection With Unknown Anc (Infection
with unknown ANC - Paranasal)
Infection With Unknown Anc (Infection
with unknown ANC - Pelvis NOS)
Infection With Unknown Anc (Infection
with unknown ANC - Penis)
Infection With Unknown Anc (Infection
with unknown ANC - Peristomal)
Infection With Unknown Anc (Infection
with unknown ANC - Peritoneal cavity)
Infection With Unknown Anc (Infection
with unknown ANC - Pharynx)
Infection With Unknown Anc (Infection
with unknown ANC - Pleura (empyema))
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Infection With Unknown Anc (Infection
with unknown ANC - Prostate)
Infection With Unknown Anc (Infection
with unknown ANC - Rectum)
Infection With Unknown Anc (Infection
with unknown ANC - Salivary gland)
Infection With Unknown Anc (Infection
with unknown ANC - Scrotum)
Infection With Unknown Anc (Infection
with unknown ANC - Sinus)
Infection With Unknown Anc (Infection
with unknown ANC - Skin (cellulitis))
Infection With Unknown Anc (Infection
with unknown ANC - Small bowel NOS)
Infection With Unknown Anc (Infection
with unknown ANC - Soft tissue NOS)
Infection With Unknown Anc (Infection
with unknown ANC - Spinal cord
(myelitis))
Infection With Unknown Anc (Infection
with unknown ANC - Spleen)
Infection With Unknown Anc (Infection
with unknown ANC - Stomach)
Infection With Unknown Anc (Infection
with unknown ANC - Trachea)
Infection With Unknown Anc (Infection
with unknown ANC - Ungual (nails))
Infection With Unknown Anc (Infection
with unknown ANC - Upper aerodigestive
NOS)
Infection With Unknown Anc (Infection
with unknown ANC - Upper airway NOS)
Infection With Unknown Anc (Infection
with unknown ANC - Ureter)
Infection With Unknown Anc (Infection
with unknown ANC - Urethra)
Infection With Unknown Anc (Infection
with unknown ANC - Urinary tract NOS)
Infection With Unknown Anc (Infection
with unknown ANC - Uterus)
Infection With Unknown Anc (Infection
with unknown ANC - Vagina)
Infection With Unknown Anc (Infection
with unknown ANC - Vein)
Infection With Unknown Anc (Infection
with unknown ANC - Vulva)
Culture Wound Positive (Infection with
unknown ANC - Wound)
Infection Nos (Infection-Other (Specify))
Infertility/sterility (Infertility/sterility)
Injection Site Reaction Nos (Injection site
reaction/extravasation changes)
Prothrombin Time Prolonged (INR
(International Normalized Ratio of
prothrombin time))
Insomnia Nec (Insomnia)
Intra-operative Injury (Intra-operative
injury - Abdomen NOS)
Intra-operative Injury (Intra-operative
injury - Adrenal gland)
25 / 45
Ovarian Cancer NCT00954174 Toxicity - GOG-0261:  Common Toxicity
Reporting Form (T) - 2847941v1.0
Intra-operative Injury (Intra-operative
injury - Anal sphincter)
Intra-operative Injury (Intra-operative
injury - Anus)
Intra-operative Injury (Intra-operative
injury - Appendix)
Intra-operative Injury (Intra-operative
injury - Artery NOS)
Intra-operative Injury (Intra-operative
injury - Artery-aorta)
Intra-operative Injury (Intra-operative
injury - Artery-carotid)
Intra-operative Injury (Intra-operative
injury - Artery-cerebral)
Intra-operative Injury (Intra-operative
injury - Artery-extremity (lower))
Intra-operative Injury (Intra-operative
injury - Artery-extremity (upper))
Intra-operative Injury (Intra-operative
injury - Artery-hepatic)
Intra-operative Injury (Intra-operative
injury - Artery-major visceral artery)
Intra-operative Injury (Intra-operative
injury - Artery-pulmonary)
Intra-operative Injury (Intra-operative
injury - Biliary tree NOS)
Intra-operative Injury (Intra-operative
injury - Biliary tree-common bile duct)
Intra-operative Injury (Intra-operative
injury - Biliary tree-common hepatic duct)
Intra-operative Injury (Intra-operative
injury - Biliary tree-left hepatic duct)
Intra-operative Injury (Intra-operative
injury - Biliary tree-right hepatic duct)
Bladder Perforation Postoperative (Intra-
operative injury - Bladder)
Intra-operative Injury (Intra-operative
injury - Bone)
Intra-operative Injury (Intra-operative
injury - Brachial plexus)
Intra-operative Injury (Intra-operative
injury - Brain)
Intra-operative Injury (Intra-operative
injury - Breast)
Intra-operative Injury (Intra-operative
injury - Bronchus)
Intra-operative Injury (Intra-operative
injury - Cartilage)
Intra-operative Injury (Intra-operative
injury - Cecum)
Intra-operative Injury (Intra-operative
injury - Cervix)
Intra-operative Injury (Intra-operative
injury - CN I (olfactory))
Intra-operative Injury (Intra-operative
injury - CN II (optic))
Intra-operative Injury (Intra-operative
injury - CN III (oculomotor))
Intra-operative Injury (Intra-operative
injury - CN IV (trochlear))
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Intra-operative Injury (Intra-operative
injury - CN IX (glossopharyngeal) motor
pharynx)
Intra-operative Injury (Intra-operative
injury - CN IX (glossopharyngeal)
sensory ear-pharynx-tongue)
Intra-operative Injury (Intra-operative
injury - CN V (trigeminal) motor)
Intra-operative Injury (Intra-operative
injury - CN V (trigeminal) sensory)
Intra-operative Injury (Intra-operative
injury - CN VI (abducens))
Intra-operative Injury (Intra-operative
injury - CN VII (facial) motor-face)
Intra-operative Injury (Intra-operative
injury - CN VII (facial) sensory-taste)
Intra-operative Injury (Intra-operative
injury - CN VIII (vestibulocochlear))
Intra-operative Injury (Intra-operative
injury - CN X (vagus))
Intra-operative Injury (Intra-operative
injury - CN XI (spinal accessory))
Intra-operative Injury (Intra-operative
injury - CN XII (hypoglossal))
Intra-operative Injury (Intra-operative
injury - Colon)
Intra-operative Injury (Intra-operative
injury - Conjunctiva)
Intra-operative Injury (Intra-operative
injury - Cornea)
Intra-operative Injury (Intra-operative
injury - Cranial nerve or branch NOS)
Intra-operative Injury (Intra-operative
injury - Duodenum)
Intra-operative Injury (Intra-operative
injury - Esophagus)
Intra-operative Injury (Intra-operative
injury - Extremity-lower)
Intra-operative Injury (Intra-operative
injury - Extremity-upper)
Intra-operative Injury (Intra-operative
injury - Eye NOS)
Intra-operative Injury (Intra-operative
injury - Face NOS)
Intra-operative Injury (Intra-operative
injury - Fallopian tube)
Intra-operative Injury (Intra-operative
injury - Gallbladder)
Intra-operative Injury (Intra-operative
injury - Gingiva)
Intra-operative Injury (Intra-operative
injury - Heart)
Intra-operative Injury (Intra-operative
injury - Ileum)
Intra-operative Injury (Intra-operative
injury - Inner ear)
Intra-operative Injury (Intra-operative
injury - Jejunum)
Intra-operative Injury (Intra-operative
injury - Joint)
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Intra-operative Injury (Intra-operative
injury - Kidney)
Intra-operative Injury (Intra-operative
injury - Larynx)
Intra-operative Injury (Intra-operative
injury - Lens)
Intra-operative Injury (Intra-operative
injury - Ligament)
Intra-operative Injury (Intra-operative
injury - Lingual)
Intra-operative Injury (Intra-operative
injury - Lip/perioral area)
Intra-operative Injury (Intra-operative
injury - Liver)
Intra-operative Injury (Intra-operative
injury - Lung)
Intra-operative Injury (Intra-operative
injury - Lung thoracic)
Intra-operative Injury (Intra-operative
injury - Mediastinum)
Intra-operative Injury (Intra-operative
injury - Meninges)
Intra-operative Injury (Intra-operative
injury - Middle ear)
Intra-operative Injury (Intra-operative
injury - Muscle)
Intra-operative Injury (Intra-operative
injury - Nails)
Intra-operative Injury (Intra-operative
injury - Nasal cavity)
Intra-operative Injury (Intra-operative
injury - Nasopharynx)
Intra-operative Injury (Intra-operative
injury - Neck NOS)
Intra-operative Injury (Intra-operative
injury - Nose)
Intra-operative Injury (Intra-operative
injury - Oral)
Intra-operative Injury (Intra-operative
injury - Oral cavity NOS)
Intra-operative Injury (Intra-operative
injury - Outer ear NOS)
Intra-operative Injury (Intra-operative
injury - Outer ear-pinna)
Intra-operative Injury (Intra-operative
injury - Ovary)
Intra-operative Injury (Intra-operative
injury - Pancreas)
Intra-operative Injury (Intra-operative
injury - Pancreatic duct)
Intra-operative Injury (Intra-operative
injury - Parathyroid)
Intra-operative Injury (Intra-operative
injury - Parotid gland)
Intra-operative Injury (Intra-operative
injury - Pelvis NOS)
Intra-operative Injury (Intra-operative
injury - Penis)
Intra-operative Injury (Intra-operative
injury - Peripheral motor NOS)
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Intra-operative Injury (Intra-operative
injury - Peripheral sensory NOS)
Intra-operative Injury (Intra-operative
injury - Peritoneal cavity)
Intra-operative Injury (Intra-operative
injury - Pharynx)
Intra-operative Injury (Intra-operative
injury - Pituitary)
Intra-operative Injury (Intra-operative
injury - Pleura)
Intra-operative Injury (Intra-operative
injury - Prostate)
Intra-operative Injury (Intra-operative
injury - Rectum)
Intra-operative Injury (Intra-operative
injury - Recurrent laryngeal)
Intra-operative Injury (Intra-operative
injury - Retina)
Intra-operative Injury (Intra-operative
injury - Sacral plexus)
Intra-operative Injury (Intra-operative
injury - Salivary duct)
Intra-operative Injury (Intra-operative
injury - Salivary gland)
Intra-operative Injury (Intra-operative
injury - Sciatic)
Intra-operative Injury (Intra-operative
injury - Scrotum)
Intra-operative Injury (Intra-operative
injury - Sinus)
Intra-operative Injury (Intra-operative
injury - Skin)
Intra-operative Injury (Intra-operative
injury - Small bowel NOS)
Intra-operative Injury (Intra-operative
injury - Soft tissue NOS)
Intra-operative Injury (Intra-operative
injury - Spinal cord)
Intra-operative Injury (Intra-operative
injury - Spleen)
Intra-operative Injury (Intra-operative
injury - Stoma (GI))
Intra-operative Injury (Intra-operative
injury - Stomach)
Intra-operative Injury (Intra-operative
injury - Teeth)
Intra-operative Injury (Intra-operative
injury - Tendon)
Intra-operative Injury (Intra-operative
injury - Testis)
Intra-operative Injury (Intra-operative
injury - Thoracic duct)
Intra-operative Injury (Intra-operative
injury - Thoracodorsal)
Intra-operative Injury (Intra-operative
injury - Thyroid)
Intra-operative Injury (Intra-operative
injury - Tongue)
Intra-operative Injury (Intra-operative
injury - Trachea)
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Intra-operative Injury (Intra-operative
injury - Upper aerodigestive NOS)
Intra-operative Injury (Intra-operative
injury - Upper airway NOS)
Intra-operative Injury (Intra-operative
injury - Ureter)
Intra-operative Injury (Intra-operative
injury - Urethra)
Intra-operative Injury (Intra-operative
injury - Urinary conduit)
Intra-operative Injury (Intra-operative
injury - Urinary tract NOS)
Intra-operative Injury (Intra-operative
injury - Uterus)
Intra-operative Injury (Intra-operative
injury - Vagina)
Intra-operative Injury - Vein (Intra-
operative injury - Vein NOS)
Intra-operative Injury (Intra-operative
injury - Vein-extremity (lower))
Intra-operative Injury (Intra-operative
injury - Vein-extremity (upper))
Intra-operative Injury (Intra-operative
injury - Vein-hepatic)
Intra-operative Injury (Intra-operative
injury - Vein-inferior vena cava)
Intra-operative Injury (Intra-operative
injury - Vein-jugular)
Intra-operative Injury (Intra-operative
injury - Vein-major visceral vein)
Intra-operative Injury (Intra-operative
injury - Vein-portal vein)
Intra-operative Injury (Intra-operative
injury - Vein-pulmonary)
Intra-operative Injury (Intra-operative
injury - Vein-superior vena cava)
Intra-operative Injury (Intra-operative
injury - Vulva)
Intra-operative Injury Other (Intra-
operative Injury-Other (Specify))
Iron Overload (Iron overload)
Menstruation Irregular (Irregular menses
(change from baseline))
Irritability (Irritability (children <3 years of
age))
Joint-effusion (Joint-effusion)
Joint-effusion (Joint-function)
Keratitis Nec (Keratitis (corneal
inflammation/corneal ulceration))
Laryngeal Nerve Dysfunction (Laryngeal
nerve dysfunction)
Leak (including Anastomotic), Gi (Leak
(including anastomotic), GI - Biliary tree)
Leak (including Anastomotic), Gi (Leak
(including anastomotic), GI - Esophagus)
Leak (including Anastomotic), Gi (Leak
(including anastomotic), GI - Large
bowel)
Leak (including Anastomotic), Gi (Leak
(including anastomotic), GI - Leak NOS)
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Leak (including Anastomotic), Gi (Leak
(including anastomotic), GI - Pancreas)
Leak (including Anastomotic), Gi (Leak
(including anastomotic), GI - Pharynx)
Leak (including Anastomotic), Gi (Leak
(including anastomotic), GI - Rectum)
Leak (including Anastomotic), Gi (Leak
(including anastomotic), GI - Small
bowel)
Leak (including Anastomotic), Gi (Leak
(including anastomotic), GI - Stoma)
Leak (including Anastomotic), Gi (Leak
(including anastomotic), GI - Stomach)
Leak (including Anastomotic), Gu (Leak
(including anastomotic), GU - Bladder)
Leak (including Anastomotic), Gu (Leak
(including anastomotic), GU - Fallopian
tube)
Leak (including Anastomotic), Gu (Leak
(including anastomotic), GU - Kidney)
Leak (including Anastomotic), Gu (Leak
(including anastomotic), GU - Spermatic
cord)
Leak (including Anastomotic), Gu (Leak
(including anastomotic), GU - Stoma)
Leak (including Anastomotic), Gu (Leak
(including anastomotic), GU - Ureter)
Leak (including Anastomotic), Gu (Leak
(including anastomotic), GU - Urethra)
Leak (including Anastomotic), Gu (Leak
(including anastomotic), GU - Uterus)
Leak (including Anastomotic), Gu (Leak
(including anastomotic), GU - Vagina)
Leak (including Anastomotic), Gu (Leak
(including anastomotic), GU - Vas
deferens)
Leak, Cerebrospinal Fluid (csf) (Leak,
cerebrospinal fluid (CSF))
Left Ventricular Diastolic Dysfunction
(Left ventricular diastolic dysfunction)
Left Ventricular Failure (Left ventricular
systolic dysfunction)
Leucopenia Nos (Leukocytes (total
WBC))
Encephalopathy Nos
(Leukoencephalopathy (radiolographic
findings))
Libido Decreased (Libido)
Lipase Increased (Lipase)
Hepatic Failure (Liver dysfunction/failure
(clinical))
Local Complication - Device/prosthesis-
related (Local complication -
device/prosthesis-related)
Lumbar Spine-range Of Motion (Lumbar
spine-range of motion)
Lymphatics Other (Lymphatics-Other
(Specify))
Lymphedema-related Fibrosis
(Lymphedema-related fibrosis)
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Lymphocele (Lymphocele)
Lymphopenia (Lymphopenia)
Hypermagnesaemia (Magnesium,
serum-high (hypermagnesemia))
Blood Magnesium Decreased
(Magnesium, serum-low
(hypomagnesemia))
Malabsorption (Malabsorption)
Virilism (Masculinization of female)
Amnesia Nec (Memory impairment)
Mental Status (Mental status)
Metabolic/laboratory Other
(Metabolic/Laboratory-Other (Specify))
Mood Alteration - Agitation (Mood
alteration - agitation)
Anxiety Nec (Mood alteration - anxiety)
Depression Nec (Mood alteration -
depression)
Euphoric Mood (Mood alteration -
euphoria)
Mucositis/stomatitis (clinical Exam)
(Mucositis/stomatitis (clinical exam) -
Anus)
Mucositis/stomatitis (clinical Exam)
(Mucositis/stomatitis (clinical exam) -
Esophagus)
Mucositis/stomatitis (clinical Exam)
(Mucositis/stomatitis (clinical exam) -
Large bowel)
Mucositis/stomatitis (clinical Exam)
(Mucositis/stomatitis (clinical exam) -
Larynx)
Mucositis/stomatitis (clinical Exam)
(Mucositis/stomatitis (clinical exam) -
Oral cavity)
Stomatitis (Mucositis/stomatitis (clinical
exam) - Pharynx)
Mucositis/stomatitis (clinical Exam)
(Mucositis/stomatitis (clinical exam) -
Rectum)
Mucositis/stomatitis (clinical Exam)
(Mucositis/stomatitis (clinical exam) -
Small bowel)
Mucositis/stomatitis (clinical Exam)
(Mucositis/stomatitis (clinical exam) -
Stomach)
Mucositis/stomatitis (clinical Exam)
(Mucositis/stomatitis (clinical exam) -
Trachea)
Mucositis/stomatitis
(functional/symptomatic)
(Mucositis/stomatitis
(functional/symptomatic) - Anus)
Mucositis/stomatitis
(functional/symptomatic)
(Mucositis/stomatitis
(functional/symptomatic) - Esophagus)
Mucositis/stomatitis
(functional/symptomatic)
(Mucositis/stomatitis
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(functional/symptomatic) - Large bowel)
Mucositis/stomatitis
(functional/symptomatic)
(Mucositis/stomatitis
(functional/symptomatic) - Larynx)
Mucositis/stomatitis
(functional/symptomatic)
(Mucositis/stomatitis
(functional/symptomatic) - Oral cavity)
Mucositis/stomatitis
(functional/symptomatic)
(Mucositis/stomatitis
(functional/symptomatic) - Pharynx)
Mucositis/stomatitis
(functional/symptomatic)
(Mucositis/stomatitis
(functional/symptomatic) - Rectum)
Mucositis/stomatitis
(functional/symptomatic)
(Mucositis/stomatitis
(functional/symptomatic) - Small bowel)
Mucositis/stomatitis
(functional/symptomatic)
(Mucositis/stomatitis
(functional/symptomatic) - Stomach)
Mucositis/stomatitis
(functional/symptomatic)
(Mucositis/stomatitis
(functional/symptomatic) - Trachea)
Muscle Weakness, Generalized Or
Specific Area (not Due To Neuropathy)
(Muscle weakness, generalized or
specific area (not due to neuropathy) -
Extraocular)
Muscle Weakness, Generalized Or
Specific Area (not Due To Neuropathy)
(Muscle weakness, generalized or
specific area (not due to neuropathy) -
Extremity-lower)
Muscle Weakness, Generalized Or
Specific Area (not Due To Neuropathy)
(Muscle weakness, generalized or
specific area (not due to neuropathy) -
Extremity-upper)
Muscle Weakness, Generalized Or
Specific Area (not Due To Neuropathy)
(Muscle weakness, generalized or
specific area (not due to neuropathy) -
Facial)
Muscle Weakness, Generalized Or
Specific Area (not Due To Neuropathy)
(Muscle weakness, generalized or
specific area (not due to neuropathy) -
Left-sided)
Muscle Weakness, Generalized Or
Specific Area (not Due To Neuropathy)
(Muscle weakness, generalized or
specific area (not due to neuropathy) -
Ocular)
Muscle Weakness, Generalized Or
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Specific Area (not Due To Neuropathy)
(Muscle weakness, generalized or
specific area (not due to neuropathy) -
Pelvic)
Muscle Weakness, Generalized Or
Specific Area (not Due To Neuropathy)
(Muscle weakness, generalized or
specific area (not due to neuropathy) -
Right-sided)
Muscle Weakness, Generalized Or
Specific Area (not Due To Neuropathy)
(Muscle weakness, generalized or
specific area (not due to neuropathy) -
Trunk)
Muscle Weakness Nos (Muscle
weakness, generalized or specific area
(not due to neuropathy) - Whole
body/generalized)
Muscular/skeletal Hypoplasia
(Muscular/skeletal hypoplasia)
Musculoskeletal/soft Tissue Other
(Musculoskeletal/Soft Tissue-Other
(Specify))
Myelitis (Myelitis)
Myelodysplasia (Myelodysplasia)
Myocarditis Nos (Myocarditis)
Myositis (Myositis (inflammation/damage
of muscle))
Nail Abnormality Nos (Nail changes)
Nasal Cavity/paranasal Sinus Reactions
(Nasal cavity/paranasal sinus reactions)
Nausea (Nausea)
Necrosis, Gi (Necrosis, GI - Anus)
Necrosis, Gi (Necrosis, GI -
Colon/cecum/appendix)
Necrosis, Gi (Necrosis, GI - Duodenum)
Necrosis, Gi (Necrosis, GI - Esophagus)
Necrosis, Gi (Necrosis, GI - Gallbladder)
Necrosis, Gi (Necrosis, GI - Hepatic)
Necrosis, Gi (Necrosis, GI - Ileum)
Necrosis, Gi (Necrosis, GI - Jejunum)
Necrosis, Gi (Necrosis, GI - Oral)
Necrosis, Gi (Necrosis, GI - Pancreas)
Necrosis, Gi (Necrosis, GI - Peritoneal
cavity)
Necrosis, Gi (Necrosis, GI - Pharynx)
Necrosis, Gi (Necrosis, GI - Rectum)
Necrosis, Gi (Necrosis, GI - Small bowel
NOS)
Necrosis, Gi (Necrosis, GI - Stoma)
Necrosis, Gi (Necrosis, GI - Stomach)
Neuroendocrine: Acth Deficiency
(Neuroendocrine: ACTH deficiency)
Inappropriate Adh Secretion
(Neuroendocrine: ADH secretion
abnormality (e.g., SIADH or low ADH))
Neuroendocrine: Gonadotropin Secretion
Abnormality (Neuroendocrine:
gonadotropin secretion abnormality)
Neuroendocrine: Growth Hormone
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Secretion Abnormality (Neuroendocrine:
growth hormone secretion abnormality)
Neuroendocrine: Prolactin Hormone
Secretion Abnormality (Neuroendocrine:
prolactin hormone secretion abnormality)
Neurology Other (Neurology-Other
(Specify))
Parosmia (Neuropathy: cranial - CN I
Smell)
Cranial Nerve Injury Nos (Neuropathy:
cranial - CN II Vision)
Neuropathy: Cranial (Neuropathy: cranial
- CN III Pupil, upper eyelid, extra ocular
movements)
Neuropathy: Cranial (Neuropathy: cranial
- CN IV Downward, inward movement of
eye)
Neuropathy: Cranial (Neuropathy: cranial
- CN IX Motor-pharynx; Sensory-ear,
pharynx, tongue)
Neuropathy: Cranial (Neuropathy: cranial
- CN V Motor-jaw muscles; Sensory-
facial)
Neuropathy: Cranial (Neuropathy: cranial
- CN VI Lateral deviation of eye)
Neuropathy: Cranial (Neuropathy: cranial
- CN VII Motor-face; Sensory-taste)
Neuropathy: Cranial (Neuropathy: cranial
- CN VIII Hearing and balance)
Neuropathy: Cranial (Neuropathy: cranial
- CN X Motor-palate; pharynx, larynx)
Neuropathy: Cranial (Neuropathy: cranial
- CN XI Motor-sternomastoid and
trapezius)
Neuropathy: Cranial (Neuropathy: cranial
- CN XII Motor-tongue)
Peripheral Motor Neuropathy
(Neuropathy: motor)
Peripheral Sensory Neuropathy
(Neuropathy: sensory)
Neutropenia (Neutrophils/granulocytes
(ANC/AGC))
Blindness Night (Night blindness
(nyctalopia))
Nystagmus Nos (Nystagmus)
Obesity (Obesity)
Obstruction, Gi (Obstruction, GI -
Cecum)
Obstruction, Gi (Obstruction, GI - Colon)
Obstruction, Gi (Obstruction, GI -
Duodenum)
Obstruction, Gi (Obstruction, GI -
Esophagus)
Obstruction, Gi (Obstruction, GI -
Gallbladder)
Obstruction, Gi (Obstruction, GI - Ileum)
Obstruction, Gi (Obstruction, GI -
Jejunum)
Obstruction, Gi (Obstruction, GI -
Rectum)
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Obstruction, Gi (Obstruction, GI - Small
bowel NOS)
Obstruction, Gi (Obstruction, GI - Stoma)
Obstruction, Gi (Obstruction, GI -
Stomach)
Obstruction, Gu (Obstruction, GU -
Bladder)
Obstruction, Gu (Obstruction, GU -
Fallopian tube)
Obstruction, Gu (Obstruction, GU -
Prostate)
Obstruction, Gu (Obstruction, GU -
Spermatic cord)
Obstruction, Gu (Obstruction, GU -
Stoma)
Obstruction, Gu (Obstruction, GU -
Testes)
Ureteric Obstruction (Obstruction, GU -
Ureter)
Obstruction, Gu (Obstruction, GU -
Urethra)
Obstruction, Gu (Obstruction, GU -
Uterus)
Obstruction, Gu (Obstruction, GU -
Vagina)
Obstruction, Gu (Obstruction, GU - Vas
deferens)
Obstruction/stenosis Of Airway
(Obstruction/stenosis of airway -
Bronchus)
Obstruction/stenosis Of Airway
(Obstruction/stenosis of airway - Larynx)
Obstruction/stenosis Of Airway
(Obstruction/stenosis of airway -
Pharynx)
Obstruction/stenosis Of Airway
(Obstruction/stenosis of airway -
Trachea)
Conjunctivitis Nec (Ocular surface
disease)
Ocular/visual Other (Ocular/Visual-Other
(Specify))
Odor (patient Odor) (Odor (patient odor))
Diplopia (Ophthalmoplegia/diplopia
(double vision))
Opportunistic Infection Associated With
>=grade 2 Lymphopenia (Opportunistic
infection associated with >=Grade 2
lymphopenia)
Optic Disc Edema (Optic disc edema)
Orgasmic Dysfunction (Orgasmic
dysfunction)
Osteonecrosis (Osteonecrosis (avascular
necrosis))
Osteoporosis (Osteoporosis)
Otitis Externa (exc Boil Of Meatus) Nos
(Otitis, external ear (non-infectious))
Otitis Media Serous Nos (Otitis, middle
ear (non-infectious))
Abdominal Pain Nos (Pain - Abdomen
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NOS)
Pain (Pain - Anus)
Pain (Pain - Back)
Pain (Pain - Bladder)
Bone Pain (Pain - Bone)
Pain (Pain - Breast)
Pain (Pain - Buttock)
Pain (Pain - Cardiac/heart)
Pain (Pain - Chest wall)
Chest Pain (Pain - Chest/thorax NOS)
Pain (Pain - Dental/teeth/peridontal)
Pain (Pain - Esophagus)
Earache (Pain - External ear)
Pain (Pain - Extremity-limb)
Pain (Pain - Eye)
Pain (Pain - Face)
Pain (Pain - Gallbladder)
Headache Nos (Pain - Head/headache)
Pain (Pain - Intestine)
Arthralgia (Pain - Joint)
Pain (Pain - Kidney)
Pain (Pain - Larynx)
Pain (Pain - Lip)
Hepatic Pain (Pain - Liver)
Pain (Pain - Lymph node)
Pain (Pain - Middle ear)
Myalgia (Pain - Muscle)
Pain (Pain - Neck)
Neuralgia Nos (Pain -
Neuralgia/peripheral nerve)
Pain (Pain - Oral cavity)
Pain (Pain - Oral-gums)
Pain (Pain - Ovulatory)
Pain (Pain - Pain NOS)
Pelvic Pain Nos (Pain - Pelvis)
Pain (Pain - Penis)
Pain (Pain - Pericardium)
Pain (Pain - Perineum)
Pain (Pain - Peritoneum)
Pain (Pain - Phantom (pain associated
with missing limb))
Pleuritic Pain (Pain - Pleura)
Pain (Pain - Prostate)
Proctalgia (Pain - Rectum)
Pain (Pain - Scalp)
Pain (Pain - Scrotum)
Pain (Pain - Sinus)
Pain (Pain - Skin)
Pain (Pain - Stomach)
Pain (Pain - Testicle)
Pain (Pain - Throat/pharynx/larynx)
Tumour Pain (Pain - Tumor pain)
Dysuria (Pain - Urethra)
Dysmenorrhoea (Pain - Uterus)
Pain (Pain - Vagina)
Pain Other (Pain-Other (Specify))
Palpitations (Palpitations)
Pancreas, Exocrine Enzyme Deficiency
(Pancreas, exocrine enzyme deficiency)
Pancreatic Endocrine: Glucose
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Intolerance (Pancreatic endocrine:
glucose intolerance)
Pancreatitis Nos (Pancreatitis)
Parathyroid Function, Low
(hypoparathyroidism) (Parathyroid
function, low (hypoparathyroidism))
Perforation, Gi (Perforation, GI -
Appendix)
Perforation, Gi (Perforation, GI - Biliary
tree)
Perforation, Gi (Perforation, GI - Cecum)
Perforation, Gi (Perforation, GI - Colon)
Perforation, Gi (Perforation, GI -
Duodenum)
Perforation, Gi (Perforation, GI -
Esophagus)
Perforation, Gi (Perforation, GI -
Gallbladder)
Perforation, Gi (Perforation, GI - Ileum)
Perforation, Gi (Perforation, GI -
Jejunum)
Perforation, Gi (Perforation, GI - Rectum)
Perforation, Gi (Perforation, GI - Small
bowel NOS)
Perforation, Gi (Perforation, GI -
Stomach)
Perforation, Gu (Perforation, GU -
Bladder)
Perforation, Gu (Perforation, GU -
Fallopian tube)
Perforation, Gu (Perforation, GU -
Kidney)
Perforation, Gu (Perforation, GU - Ovary)
Perforation, Gu (Perforation, GU -
Prostate)
Perforation, Gu (Perforation, GU -
Spermatic cord)
Perforation, Gu (Perforation, GU -
Stoma)
Perforation, Gu (Perforation, GU -
Testes)
Perforation, Gu (Perforation, GU - Ureter)
Perforation, Gu (Perforation, GU -
Urethra)
Perforation, Gu (Perforation, GU -
Uterus)
Perforation, Gu (Perforation, GU -
Vagina)
Perforation, Gu (Perforation, GU - Vas
deferens)
Pericardial Effusion (Pericardial effusion
(non-malignant))
Pericarditis (Pericarditis)
Peripheral Ischaemia Nos (Peripheral
arterial ischemia)
Personality Change
(Personality/behavioral)
Petechiae (Petechiae/purpura
(hemorrhage/bleeding into skin or
mucosa))
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Phlebitis Superficial (Phlebitis (including
superficial thrombosis))
Phlebolymphatic Cording
(Phlebolymphatic cording)
Hypophosphataemia (Phosphate, serum-
low (hypophosphatemia))
Photosensitivity Reaction Nos
(Photosensitivity)
Phrenic Nerve Dysfunction (Phrenic
nerve dysfunction)
Platelet Count Decreased (Platelets)
Pleural Effusion (Pleural effusion (non-
malignant))
Pneumonitis Nos
(Pneumonitis/pulmonary infiltrates)
Pneumothorax Nos (Pneumothorax)
Portal Hypertension (Portal vein flow)
Hyperkalaemia (Potassium, serum-high
(hyperkalemia))
Hypokalaemia (Potassium, serum-low
(hypokalemia))
Proctitis Nos (Proctitis)
Prolapse Of Stoma, Gi (Prolapse of
stoma, GI)
Prolapse Of Stoma, Gu (Prolapse of
stoma, GU)
Prolonged Chest Tube Drainage Or Air
Leak After Pulmonary Resection
(Prolonged chest tube drainage or air
leak after pulmonary resection)
Prolonged Intubation After Pulmonary
Resection (>24 Hrs After Surgery)
(Prolonged intubation after pulmonary
resection (>24 hrs after surgery))
Electrocardiogram Qt Prolonged
(Prolonged QTc interval)
Proptosis/enophthalmos
(Proptosis/enophthalmos)
Proteinuria Present (Proteinuria)
Pruritus Nos (Pruritus/itching)
Delusion Nos (Psychosis
(hallucinations/delusions))
Activated Partial Thromboplastin Time
Prolonged (PTT (Partial thromboplastin
time))
Puberty (delayed) (Puberty (delayed))
Puberty (precocious) (Puberty
(precocious))
Pulmonary Fibrosis (Pulmonary fibrosis
(radiographic changes))
Pulmonary Hypertension (Pulmonary
hypertension)
Pulmonary/upper Respiratory Other
(Pulmonary/Upper Respiratory-Other
(Specify))
Upper Motor Neurone Lesion (Pyramidal
tract dysfunction (e.g., increased tone,
hyperreflexia, positive Babinski,
decreased fine motor coordination))
Rash: Acne/acneiform (Rash:
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acne/acneiform)
Radiation Recall Syndrome (Rash:
dermatitis associated with radiation -
Chemoradiation)
Dermatitis Radiation Nos (Rash:
dermatitis associated with radiation -
Radiation)
Erythema Multiforme (Rash: erythema
multiforme (e.g., Stevens-Johnson
syndrome, toxic epidermal necrolysis))
Localised Exfoliation (Rash: hand-foot
skin reaction)
Dermatitis Exfoliative Nos
(Rash/desquamation)
Renal Failure Nos (Renal failure)
Renal/genitourinary Other
(Renal/Genitourinary-Other (Specify))
Restrictive Cardiomyopathy (Restrictive
cardiomyopathy)
Retinal Detachment (Retinal
detachment)
Retinoic Acid Syndrome (Retinoic acid
syndrome)
Retinopathy (Retinopathy)
Right Ventricular Dysfunction (cor
Pulmonale) (Right ventricular dysfunction
(cor pulmonale))
Rigors (Rigors/chills)
Salivary Gland Disorder Nos (Salivary
gland changes/saliva)
Scleral Necrosis/melt (Scleral
necrosis/melt)
Secondary Malignancy Possibly Related
To Cancer Treatment (Secondary
Malignancy-possibly related to cancer
treatment (Specify))
Convulsions Nos (Seizure)
Seroma (Seroma)
Serum Sickness (Serum sickness)
Sexual/reproductive Function Other
(Sexual/Reproductive Function-Other
(Specify))
Short Stature (Short stature)
Skin Breakdown/decubitus Ulcer (Skin
breakdown/decubitus ulcer)
Hypernatraemia (Sodium, serum-high
(hypernatremia))
Hyponatraemia (Sodium, serum-low
(hyponatremia))
Soft Tissue Necrosis (Soft tissue
necrosis - Abdomen)
Soft Tissue Necrosis (Soft tissue
necrosis - Extremity-lower)
Soft Tissue Necrosis (Soft tissue
necrosis - Extremity-upper)
Soft Tissue Necrosis (Soft tissue
necrosis - Head)
Soft Tissue Necrosis (Soft tissue
necrosis - Neck)
Soft Tissue Necrosis (Soft tissue
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necrosis - Pelvic)
Soft Tissue Necrosis (Soft tissue
necrosis - Thorax)
Depressed Level Of Consciousness
(Somnolence/depressed level of
consciousness)
Speech Disorder Nec (Speech
impairment (e.g., dysphasia or aphasia))
Splenic Function (Splenic function)
Striae (Striae)
Stricture/stenosis (including
Anastomotic), Gi (Stricture/stenosis
(including anastomotic), GI - Anus)
Stricture/stenosis (including
Anastomotic), Gi (Stricture/stenosis
(including anastomotic), GI - Biliary tree)
Stricture/stenosis (including
Anastomotic), Gi (Stricture/stenosis
(including anastomotic), GI - Cecum)
Stricture/stenosis (including
Anastomotic), Gi (Stricture/stenosis
(including anastomotic), GI - Colon)
Stricture/stenosis (including
Anastomotic), Gi (Stricture/stenosis
(including anastomotic), GI - Duodenum)
Stricture/stenosis (including
Anastomotic), Gi (Stricture/stenosis
(including anastomotic), GI - Esophagus)
Stricture/stenosis (including
Anastomotic), Gi (Stricture/stenosis
(including anastomotic), GI - Ileum)
Stricture/stenosis (including
Anastomotic), Gi (Stricture/stenosis
(including anastomotic), GI - Jejunum)
Stricture/stenosis (including
Anastomotic), Gi (Stricture/stenosis
(including anastomotic), GI -
Pancreas/pancreatic duct)
Stricture/stenosis (including
Anastomotic), Gi (Stricture/stenosis
(including anastomotic), GI - Pharynx)
Stricture/stenosis (including
Anastomotic), Gi (Stricture/stenosis
(including anastomotic), GI - Rectum)
Stricture/stenosis (including
Anastomotic), Gi (Stricture/stenosis
(including anastomotic), GI - Small bowel
NOS)
Stricture/stenosis (including
Anastomotic), Gi (Stricture/stenosis
(including anastomotic), GI - Stoma)
Stricture/stenosis (including
Anastomotic), Gi (Stricture/stenosis
(including anastomotic), GI - Stomach)
Stricture/stenosis (including
Anastomotic), Gu (Stricture/stenosis
(including anastomotic), GU - Bladder)
Stricture/stenosis (including
Anastomotic), Gu (Stricture/stenosis
(including anastomotic), GU - Fallopian
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tube)
Stricture/stenosis (including
Anastomotic), Gu (Stricture/stenosis
(including anastomotic), GU - Prostate)
Stricture/stenosis (including
Anastomotic), Gu (Stricture/stenosis
(including anastomotic), GU - Spermatic
cord)
Stricture/stenosis (including
Anastomotic), Gu (Stricture/stenosis
(including anastomotic), GU - Stoma)
Stricture/stenosis (including
Anastomotic), Gu (Stricture/stenosis
(including anastomotic), GU - Testes)
Stricture/stenosis (including
Anastomotic), Gu (Stricture/stenosis
(including anastomotic), GU - Ureter)
Stricture/stenosis (including
Anastomotic), Gu (Stricture/stenosis
(including anastomotic), GU - Urethra)
Stricture/stenosis (including
Anastomotic), Gu (Stricture/stenosis
(including anastomotic), GU - Uterus)
Stricture/stenosis (including
Anastomotic), Gu (Stricture/stenosis
(including anastomotic), GU - Vagina)
Stricture/stenosis (including
Anastomotic), Gu (Stricture/stenosis
(including anastomotic), GU - Vas
deferens)
Supraventricular And Nodal Arrhythmia
(Supraventricular and nodal arrhythmia -
Atrial fibrillation)
Supraventricular And Nodal Arrhythmia
(Supraventricular and nodal arrhythmia -
Atrial flutter)
Supraventricular And Nodal Arrhythmia
(Supraventricular and nodal arrhythmia -
Atrial tachycardia/paroxysmal atrial
tachycardia)
Supraventricular And Nodal Arrhythmia
(Supraventricular and nodal arrhythmia -
Nodal/junctional)
Supraventricular And Nodal Arrhythmia
(Supraventricular and nodal arrhythmia -
Sinus arrhythmia)
Sinus Bradycardia (Supraventricular and
nodal arrhythmia - Sinus bradycardia)
Sinus Tachycardia (Supraventricular and
nodal arrhythmia - Sinus tachycardia)
Supraventricular Arrhythmia Nos
(Supraventricular and nodal arrhythmia -
Supraventricular arrhythmia NOS)
Supraventricular And Nodal Arrhythmia -
Supraventricular Extrasystoles
(premature Atrial Contractions;
Premature Nodal/junctional
Contractions) (Supraventricular and
nodal arrhythmia - Supraventricular
extrasystoles (premature atrial
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contractions; premature nodal/junctional
contractions))
Supraventricular And Nodal Arrhythmia
(Supraventricular and nodal arrhythmia -
Supraventricular tachycardia)
Sweating Increased (Sweating
(diaphoresis))
Syncope (Syncope (fainting))
Syndromes Other (Syndromes-Other
(Specify))
Taste Disturbance (Taste alteration
(dysgeusia))
Telangiectasia (Telangiectasia)
Thrombosis/embolism (vascular Access-
related) (Thrombosis/embolism (vascular
access-related))
Thrombosis Nos
(Thrombosis/thrombus/embolism)
Thrombotic Microangiopathy (e.g.,
Thrombotic Thrombocytopenic
Purpura[ttp] Or Hemolytic Uremic
Syndrome[hus]) (Thrombotic
microangiopathy (e.g., thrombotic
thrombocytopenic purpura or hemolytic
uremic syndrome))
Thyroid Function, High (hyperthyroidism,
Thyrotoxicosis) (Thyroid function, high
(hyperthyroidism, thyrotoxicosis))
Hypothyroidism (Thyroid function, low
(hypothyroidism))
Tinnitus (Tinnitus)
Tremor Nec (Tremor)
Hypertriglyceridaemia (Triglyceride,
serum-high (hypertriglyceridemia))
Trismus (difficulty, Restriction Or Pain
When Opening Mouth) (Trismus
(difficulty, restriction or pain when
opening mouth))
Tumour Flare (Tumor flare)
Tumour Lysis Syndrome (Tumor lysis
syndrome)
Caecitis (Typhlitis (cecal inflammation))
Ulcer, Gi (Ulcer, GI - Anus)
Ulcer, Gi (Ulcer, GI - Cecum)
Ulcer, Gi (Ulcer, GI - Colon)
Duodenal Ulcer (Ulcer, GI - Duodenum)
Ulcer, Gi (Ulcer, GI - Esophagus)
Ulcer, Gi (Ulcer, GI - Ileum)
Ulcer, Gi (Ulcer, GI - Jejunum)
Ulcer, Gi (Ulcer, GI - Rectum)
Ulcer, Gi (Ulcer, GI - Small bowel NOS)
Ulcer, Gi (Ulcer, GI - Stoma)
Gastric Ulcer (Ulcer, GI - Stomach)
Ulceration (Ulceration)
Hyperuricaemia (Uric acid, serum-high
(hyperuricemia))
Fanconi Syndrome (Urinary electrolyte
wasting (e.g., Fanconi's syndrome, renal
tubular acidosis))
Urinary Frequency (Urinary
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frequency/urgency)
Urinary Retention (Urinary retention
(including neurogenic bladder))
Urine Discolouration (Urine color
change)
Urticaria Nos (Urticaria (hives, welts,
wheals))
Uveitis (Uveitis)
Vaginal Discharge (non-infectious)
(Vaginal discharge (non-infectious))
Vulvovaginal Dryness (Vaginal dryness)
Vaginal Mucositis (Vaginal mucositis)
Vaginal Stenosis/length (Vaginal
stenosis/length)
Vaginitis (Vaginitis (not due to infection))
Valvular Heart Disease (Valvular heart
disease)
Vascular Other (Vascular-Other
(Specify))
Vasculitis Nos (Vasculitis)
Vasovagal Attack (Vasovagal episode)
Ventricular Arrhythmia (Ventricular
arrhythmia - Bigeminy)
Ventricular Arrhythmia (Ventricular
arrhythmia - Idioventricular rhythm)
Ventricular Arrhythmia (Ventricular
arrhythmia - PVCs)
Ventricular Arrhythmia (Ventricular
arrhythmia - Torsade de pointes)
Ventricular Arrhythmia (Ventricular
arrhythmia - Trigeminy)
Ventricular Arrhythmia Nos (Ventricular
arrhythmia - Ventricular arrhythmia NOS)
Ventricular Arrhythmia (Ventricular
arrhythmia - Ventricular fibrillation)
Ventricular Arrhythmia (Ventricular
arrhythmia - Ventricular flutter)
Ventricular Arrhythmia (Ventricular
arrhythmia - Ventricular tachycardia)
Vessel Injury-artery (Vessel injury-artery
- Aorta)
Vessel Injury-artery (Vessel injury-artery
- Carotid)
Vessel Injury-artery (Vessel injury-artery
- Extremity-lower)
Vessel Injury-artery (Vessel injury-artery
- Extremity-upper)
Vessel Injury-artery (Vessel injury-artery
- Other NOS)
Vessel Injury-artery (Vessel injury-artery
- Visceral)
Vessel Injury-vein (Vessel injury-vein -
Extremity-lower)
Vessel Injury-vein (Vessel injury-vein -
Extremity-upper)
Vessel Injury-vein (Vessel injury-vein -
IVC)
Vessel Injury-vein (Vessel injury-vein -
Jugular)
Vessel Injury-vein (Vessel injury-vein -
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Other NOS)
Vessel Injury-vein (Vessel injury-vein -
SVC)
Vessel Injury-vein (Vessel injury-vein -
Viscera)
Viral Hepatitis (Viral hepatitis)
Visceral Arterial Ischaemia (Visceral
arterial ischemia (non-myocardial))
Vision Blurred (Vision-blurred vision)
Photopsia (Vision-flashing lights/floaters)
Photophobia (Vision-photophobia)
Vital Capacity (Vital capacity)
Vitreous Hemorrhage (Vitreous
hemorrhage)
Dysphonia (Voice changes/dysarthria
(e.g., hoarseness, loss or alteration in
voice, laryngitis))
Vomiting Nos (Vomiting)
Lacrimation Increased (Watery eye
(epiphora, tearing))
Weight Increased (Weight gain)
Weight Decreased (Weight loss)
Culture Wound Negative (Wound
complication, non-infectious)
The CTCAE data entered above is
Version 2 (version 2)
Version 3 (version 3)
CTC Adverse Event Grade
CTC Adverse Event Attribution Code
Definite (Definite)
Possible (Possible)
Probable (Probable)
Unlikely (Unlikely)
Unrelated (Unrelated)
Comments
COMMENTS
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Cervical Cancer NCT00262821 Toxicity - Common Toxicity
Reporting Form, Form T, GOG-0219 - 2302373v3.0
Common Toxicity Reporting Form, Form T, GOG-0219
Cisplatin and Radiation Therapy With or Without
Tirapazamine in Treating Patients With Cervical Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=EF898257-
6B3B-0B28-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/8024
Common Toxicity Reporting Form,
Form T, GOG-0219
Header Module
Date form originally completed (m d y)
Date form amended (m d y)
Person amending form, last name
Patient Initials (First, Middle, Last)
Patient Study ID
Person Completing Form, Last Name
Adverse Events - Section 1
Current course number (The toxicities listed
below occurred following this course of therapy)
Has the patient received any transfusions during
this course of therapy?
No Transfusion (No)
Transfusion With Platelets (Yes,
platelets)
Transfusion With Red Blood Cells (Yes,
red blood cells)
Was patient hospitalized as a result of reported
adverse events?
Yes
No
Were cytokines administered this course?
Yes
No
Yes specify
Has an Adverse Drug Reaction Report been
filed?
Yes
No
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Adverse Events - Section 2
Peripheral WBC count done?
Yes
No
Peripheral WBC count (1000/mm3)
Peripheral WBC count, Date (m d y)
Peripheral Granulocytes count done? (ANC/)
Yes
No
Peripheral Granulocytes count (ANC/ 1000/mm3)
Peripheral Granulocytes count, Date
Peripheral Platelet count done?
Yes
No
Peripheral Platelet count (mm3)
Peripheral Platelet count, Date
Hemoglobin done?
Yes
No
Hemoglobin (G/DL)
Hemoglobin, Date
CTC Adverse Event Grade
CTC Adverse Event Grade
CTC Adverse Event Grade
CTC Adverse Event Grade
CTC Adverse Event Attribution Code (Attribution
Codes for Relationship of Event to Treatment:
1=Unrelated, 2=Unlikely, 3=Possibly, 4=Probably,
5=Definitely)
Definite (Definitely)
Possible (Possibly)
Probable (Probably)
Unlikely (Unlikely)
Unrelated (Unrelated)
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Form, Form T, GOG-0219 - 2302373v3.0
CTC Adverse Event Attribution Code (Attribution
Codes for Relationship of Event to Treatment:
1=Unrelated, 2=Unlikely, 3=Possibly, 4=Probably,
5=Definitely)
Definite (Definitely)
Possible (Possibly)
Probable (Probably)
Unlikely (Unlikely)
Unrelated (Unrelated)
CTC Adverse Event Attribution Code (Attribution
Codes for Relationship of Event to Treatment:
1=Unrelated, 2=Unlikely, 3=Possibly, 4=Probably,
5=Definitely)
Definite (Definitely)
Possible (Possibly)
Probable (Probably)
Unlikely (Unlikely)
Unrelated (Unrelated)
CTC Adverse Event Attribution Code (Attribution
Codes for Relationship of Event to Treatment:
1=Unrelated, 2=Unlikely, 3=Possibly, 4=Probably,
5=Definitely)
Definite (Definitely)
Possible (Possibly)
Probable (Probably)
Unlikely (Unlikely)
Unrelated (Unrelated)
Adverse Events - Section 3
CTC Adverse Event Term
The CTCAE data entered above is
Version 2 (version 2)
Version 3 (version 3)
CTC Adverse Event Grade
CTC Adverse Event Attribution Code (Attribution
Codes for Relationship of Event to Treatment:
1=Unrelated, 2=Unlikely, 3=Possibly, 4=Probably,
5=Definitely)
Definite (Definitely)
Possible (Possibly)
Probable (Probably)
Unlikely (Unlikely)
Unrelated (Unrelated)
Comments
COMMENTS
Footer Module
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Form, Form T, GOG-0219 - 2302373v3.0
Participating Group Code
Participating Group Protocol Number
Participating Group Patient ID
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Cervical Cancer NCT01101451 Toxicity - GOG-0263:
Common Toxicity Reporting Form (Form T) - 2933725v1.0
GOG-0263: Common Toxicity Reporting Form (Form T)
Radiation Therapy With or Without Chemotherapy in
Patients With Stage I or Stage II Cervical Cancer Who
Previously Underwent Surgery
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=7170934C-
5E7F-20E2-E040-BB89AD434964
All rights reserved. Please visit https://medical-data-
models.org/forms/8027
GOG-0263: Common Toxicity
Reporting Form (Form T)
Header Module
Date form originally completed (m d y)
Date form amended (m d y)
Person amending form, last name
Patient Initials (First, Middle, Last)
Patient Study ID
Person Completing Form, Last Name
Adverse Events - Section 1
Current Cycle Number
Has the patient received any transfusions during
this course of therapy?
No Transfusion (No)
Transfusion With Platelets (Yes,
platelets)
Transfusion With Red Blood Cells (Yes,
red blood cells)
Was patient hospitalized as a result of reported
adverse events?
Yes
No
Were cytokines administered this course?
Yes
No
Yes specify
Adverse Events - Section 2
Peripheral WBC count done
Yes
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No
Peripheral WBC count (1000/mm3)
Date (m d y)
CTC Adverse Event Grade
CTC Adverse Event Grade
CTC Adverse Event Grade
CTC Adverse Event Grade
CTC Adverse Event Attribution Code (Attribution
Codes for Relationship of Event to Treatment:
1=Unrelated, 2=Unlikely, 3=Possibly, 4=Probably,
5=Definitely)
Definite (Definite)
Possible (Possible)
Probable (Probable)
Unlikely (Unlikely)
Unrelated (Unrelated)
CTC Adverse Event Attribution Code (Attribution
Codes for Relationship of Event to Treatment:
1=Unrelated, 2=Unlikely, 3=Possibly, 4=Probably,
5=Definitely)
Definite (Definite)
Possible (Possible)
Probable (Probable)
Unlikely (Unlikely)
Unrelated (Unrelated)
CTC Adverse Event Attribution Code (Attribution
Codes for Relationship of Event to Treatment:
1=Unrelated, 2=Unlikely, 3=Possibly, 4=Probably,
5=Definitely)
Definite (Definite)
Possible (Possible)
Probable (Probable)
Unlikely (Unlikely)
Unrelated (Unrelated)
CTC Adverse Event Attribution Code (Attribution
Codes for Relationship of Event to Treatment:
1=Unrelated, 2=Unlikely, 3=Possibly, 4=Probably,
5=Definitely)
Definite (Definite)
Possible (Possible)
Probable (Probable)
Unlikely (Unlikely)
Unrelated (Unrelated)
Peripheral ANC/Granulocytes count done (ANC/)
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Yes
No
Peripheral Granulocytes count (ANC/ 1000/mm3)
Date
SAE report submitted
Yes
No
SAE report submitted
Yes
No
SAE report submitted
Yes
No
SAE report submitted
Yes
No
Peripheral Platelet count done
Yes
No
Peripheral Platelet count (mm3)
Date
Hemoglobin done
Yes
No
Hemoglobin (G/DL)
Date
Adverse Events - Section 3
CTC Adverse Event Term
Current Cycle Number
Specify
CTC Adverse Event Grade
CTC Adverse Event Attribution Code (Attribution
Codes for Relationship of Event to Treatment:
1=Unrelated, 2=Unlikely, 3=Possibly, 4=Probably,
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5=Definitely)
Definite (Definite)
Possible (Possible)
Probable (Probable)
Unlikely (Unlikely)
Unrelated (Unrelated)
AE Onset Date (MM DD YYYY)
Present Status
Fatal Or Died (Fatal/Died)
Intervention For Adverse Event
Continues (Intervention for AE
Continues)
Not Recovered Or Not Resolved (Not
recovered/Not resolved)
Recovered Or Resolved With Sequelae
(Recovered/Resolved with Sequelae)
Recovered Or Resolved Without
Sequelae (Recovered/Resolved without
Sequelae)
Recovering Or Resolving
(Recovering/Resolving)
The CTCAE data entered above is
Version 2 (version 2)
Version 3 (version 3)
SAE report submitted
Yes
No
Comments
COMMENTS
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Fallopian Tube Cancer NCT00108745 Toxicity - Common
Toxicity Reporting Form, GOG-0212, Form T - 2296465v3.0
Common Toxicity Reporting Form, GOG-0212, Form T
Paclitaxel or Polyglutamate Paclitaxel or Observation in
Treating Patients With Stage III or Stage IV Ovarian
Epithelial or Peritoneal Cancer or Fallopian Tube Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=E748A322-
B72E-4C98-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/8030
Common Toxicity Reporting Form,
GOG-0212, Form T
Header Module
Date form originally completed (m d y)
Date form amended (m d y)
Person amending form, last name
Patient Initials (First, Middle, Last)
Patient Study ID
Person Completing Form, Last Name
Adverse Events - Section 1
Current course number (The toxicities listed
below occurred following this course of therapy)
Has the patient received any transfusions during
this course of therapy?
No Transfusion (No)
Transfusion With Platelets (Yes,
platelets)
Transfusion With Red Blood Cells (Yes,
red blood cells)
Was patient hospitalized as a result of reported
adverse events?
Yes
No
Were cytokines administered this course?
Yes
No
Yes specify
Has an Adverse Drug Reaction Report been
filed?
Yes
No
1 / 3
Adverse Events - Section 2
Peripheral Platelet count, Date
Peripheral Granulocytes count, Date
Peripheral WBC count done?
Yes
No
Peripheral WBC count (1000/mm3 Nadir)
Peripheral Granulocytes count done? (ANC/)
Yes
No
Peripheral Granulocytes count (ANC/ 1000/mm3
Nadir)
Peripheral Platelet count done?
Yes
No
Peripheral Platelet count (mm3 Nadir)
Hemoglobin done?
Yes
No
Hemoglobin (G/DL Nadir)
Hemoglobin, Date
Hemoglobin, Date
CTC Adverse Event Grade
CTC Adverse Event Attribution Code (Attribution
Codes for Relationship of Event to Treatment:
1=Unrelated, 2=Unlikely, 3=Possibly, 4=Probably,
5=Definitely)
Definite (Definitely)
Possible (Possibly)
Probable (Probably)
Unlikely (Unlikely)
Unrelated (Unrelated)
Adverse Events - Section 3
CTC Adverse Event Term
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Reporting Form, GOG-0212, Form T - 2296465v3.0
Hypersensitivity Nos (Allergic reaction)
Alopecia (Alopecia)
Arthralgia (Arthralgia)
Dehydration (Dehydration)
Diarrhoea Nos (Diarrhea)
Fatigue (Fatigue)
Febrile Neutropenia (fever Of Unknown
Origin Without Clinically Or
Microbiologically Documented Infection)
(anc <1.0 X 10^9/l, Fever >=38.5
Degrees C) (Febrile neutropenia)
Infection Nos (Infection - Other (specify))
Myalgia (Myalgia)
Nausea (Nausea)
Peripheral Motor Neuropathy
(Neuropathy-motor)
Peripheral Sensory Neuropathy
(Neuropathy-sensory)
Vomiting Nos (Vomiting)
The CTCAE data entered above is
Version 2 (version 2)
Version 3 (version 3)
CTC Adverse Event Grade
CTC Adverse Event Attribution Code (Attribution
Codes for Relationship of Event to Treatment:
1=Unrelated, 2=Unlikely, 3=Possibly, 4=Probably,
5=Definitely)
Definite (Definitely)
Possible (Possibly)
Probable (Probably)
Unlikely (Unlikely)
Unrelated (Unrelated)
Comments
COMMENTS
Footer Module
Participating Group Code
Participating Group Protocol Number
Participating Group Patient ID
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Fallopian Tube Cancer NCT00108745 Toxicity - Common Toxicity
Reporting Form, GOG-0212, Form T - 2296465v3.0
Prostate Cancer NCT00430183 Lab - CALGB 90203:
Frozen Tissue Submission Form - 2524829v1.0
CALGB 90203: Frozen Tissue Submission Form [Form C-
1513 v 1 11/10/2006]
Surgery With or Without Docetaxel and Leuprolide or
Goserelin in Treating Patients With High-Risk Localized
Prostate Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=1EDAAE35-
2970-4FAE-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/8031
CALGB 90203: Frozen Tissue
Submission Form
Ccrr Module For Calgb 90202: Prostate
Specific Antigen Form
CALGB Form (C-714)
CALGB Study No.
CALGB Patient ID
Date Specimen collected (1 Or scheduled date, if
not collected. mm dd yyyy)
Are data amended
Yes
No
Patient Initials (Last, First Middle)
Patient Hospital No.
Institution/Affiliate
Participating Group
Participating Group Study No.
Participating Group Patient ID
Unnamed3
Are samples collected at surgery being submitted
Yes
No
Specify reason (s Mark all taht apply with an X.)
Institution Error (Institution error)
Not Available (Not available)
Other (Other)
1 / 3
Patient Refusal (Patient refusal)
Sample Lost Or Destroyed (Sample lost
or destroyed)
Specify (Other)
Unnamed4
Specimen Source
Frozen Normal Prostate Tissue (Frozen
Normal Prostate Tissue)
Frozen Prostate Tumor (Frozen Prostate
Tumor 1)
Frozen Prostate Tumor (Frozen Prostate
Tumor 2)
Frozen Tumor From Lymph Node (Frozen
Tumor from Lymph Node)
Number of specimens submitted
Locations sampled (Mark all that apply with an X.
See codes below. - Location sampled codes for
prostate: RB=right base,... For lymph nodes:
RO=right obturator,...If other lymph nodes,
specify.  NOTE: Representative tumor from lymph
nodes will be submitted for patients...)
Apex Of The Prostate (Left apex)
Base Of The Prostate (Left base)
External Iliac Lymph Node Group (Left
external iliac)
Internal Iliac Lymph Node (Left internal
iliac)
Middle Lobe Of The Prostate (Left
midgland)
Obturator Lymph Node (Left obturator)
Other (Other)
Apex Of The Prostate (Right apex)
Base Of The Prostate (Right base)
External Iliac Lymph Node Group (Right
external iliac)
Internal Iliac Lymph Node (Right internal
iliac)
Middle Lobe Of The Prostate (Right
midgland)
Obturator Lymph Node (Right obturator)
Other specify (If - ...If other lymph nodes,
specify.)
Shipping Information
Date shipped (s mm dd yyyy)
LabTrak shipment ID (3 Required of all CALGB
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Prostate Cancer NCT00430183 Lab - CALGB 90203: Frozen Tissue
Submission Form - 2524829v1.0
institutions. Access Labtrak application via the
member site at www.calgb.org. Anyone accessing
LabTrak for the first time must have an assigned
CALGB PIN Participant ID Number and contact
the CALGB help desk...to set up LabTrak.)
Contact Person Name
Contact Phone Number
Contact Person E-Mail
Date Form Completed (mm dd yyyy)
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Prostate Cancer NCT00430183 Lab - CALGB 90203: Frozen Tissue
Submission Form - 2524829v1.0
Endometrial Cancer NCT00942357 Toxicity - GOG-0258
Common Toxicity Reporting Form (T) - 2845153v1.0
GOG-0258 Common Toxicity Reporting Form (T)
Carboplatin and Paclitaxel With or Without Cisplatin and
Radiation Therapy in Treating Patients With Stage I, Stage
II, Stage III, or Stage IVA Endometrial Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=644E86D7-
E2E5-D7C8-E040-BB89AD4321CC
All rights reserved. Please visit https://medical-data-
models.org/forms/8032
GOG-0258 Common Toxicity
Reporting Form (T)
Header Module
Date form originally completed (m d y)
Date form amended (m d y)
Person amending form, last name
Patient Initials (First, Middle, Last)
Patient Study ID
Person Completing Form, Last Name
Adverse Events - Section 1
Current Cycle Number
Has the patient received any transfusions during
this course of therapy?
No Transfusion (No)
Transfusion With Platelets (Yes,
platelets)
Transfusion With Red Blood Cells (Yes,
red blood cells)
Was patient hospitalized as a result of reported
adverse events?
Yes
No
Were cytokines administered this course?
Yes
No
Yes specify
Adverse Events - Section 2
Peripheral WBC count done
Yes
1 / 4
No
Peripheral WBC count (1000/mm3)
Date (m d y)
CTC Adverse Event Grade
CTC Adverse Event Grade
CTC Adverse Event Grade
CTC Adverse Event Grade
CTC Adverse Event Attribution Code (Attribution
Codes for Relationship of Event to Treatment:
1=Unrelated, 2=Unlikely, 3=Possibly, 4=Probably,
5=Definitely)
Definite (Definite)
Possible (Possible)
Probable (Probable)
Unlikely (Unlikely)
Unrelated (Unrelated)
CTC Adverse Event Attribution Code (Attribution
Codes for Relationship of Event to Treatment:
1=Unrelated, 2=Unlikely, 3=Possibly, 4=Probably,
5=Definitely)
Definite (Definite)
Possible (Possible)
Probable (Probable)
Unlikely (Unlikely)
Unrelated (Unrelated)
CTC Adverse Event Attribution Code (Attribution
Codes for Relationship of Event to Treatment:
1=Unrelated, 2=Unlikely, 3=Possibly, 4=Probably,
5=Definitely)
Definite (Definite)
Possible (Possible)
Probable (Probable)
Unlikely (Unlikely)
Unrelated (Unrelated)
CTC Adverse Event Attribution Code (Attribution
Codes for Relationship of Event to Treatment:
1=Unrelated, 2=Unlikely, 3=Possibly, 4=Probably,
5=Definitely)
Definite (Definite)
Possible (Possible)
Probable (Probable)
Unlikely (Unlikely)
Unrelated (Unrelated)
Peripheral Granulocytes count done (ANC/)
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Endometrial Cancer NCT00942357 Toxicity - GOG-0258 Common
Toxicity Reporting Form (T) - 2845153v1.0
Yes
No
Peripheral Granulocytes count (ANC/ 1000/mm3)
Date
SAE report submitted
Yes
No
SAE report submitted
Yes
No
SAE report submitted
Yes
No
SAE report submitted
Yes
No
Peripheral Platelet count done
Yes
No
Peripheral Platelet count (mm3)
Date
Hemoglobin done
Yes
No
Hemoglobin (G/DL)
Date
Adverse Events - Section 3
CTC Adverse Event Term
Current Cycle Number
Other, specify
CTC Adverse Event Grade
CTC Adverse Event Attribution Code (Attribution
Codes for Relationship of Event to Treatment:
1=Unrelated, 2=Unlikely, 3=Possibly, 4=Probably,
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Endometrial Cancer NCT00942357 Toxicity - GOG-0258 Common
Toxicity Reporting Form (T) - 2845153v1.0
5=Definitely)
Definite (Definite)
Possible (Possible)
Probable (Probable)
Unlikely (Unlikely)
Unrelated (Unrelated)
AE Onset Date
Present Status
Fatal Or Died (Fatal/Died)
Intervention For Adverse Event
Continues (Intervention for AE
Continues)
Not Recovered Or Not Resolved (Not
recovered/Not resolved)
Recovered Or Resolved With Sequelae
(Recovered/Resolved with Sequelae)
Recovered Or Resolved Without
Sequelae (Recovered/Resolved without
Sequelae)
Recovering Or Resolving
(Recovering/Resolving)
The CTCAE data entered above is
Version 2 (version 2)
Version 3 (version 3)
SAE report submitted
Yes
No
Comments
COMMENTS
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Endometrial Cancer NCT00942357 Toxicity - GOG-0258 Common
Toxicity Reporting Form (T) - 2845153v1.0
Fallopian Tube Cancer NCT00262847 Toxicity - GOG-
0218 Common Toxicity Reporting Form - 2305920v3.0
GOG-0218 Common Toxicity Reporting Form
Carboplatin and Paclitaxel With or Without Bevacizumab in
Treating Patients With Stage III or Stage IV Ovarian
Epithelial, Primary Peritoneal Cancer, or Fallopian Tube
Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=F1B8AE82-
9F7E-1D11-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/8034
GOG-0218 Common Toxicity
Reporting Form
Header Module
Date form originally completed
Date form amended
Person amending form, last name
Patient Initials
Patient Study ID
Person Completing Form, Last Name
Adverse Events - Section 1
Current course number (The toxicities listed
below occurred following this course of therapy)
Has the patient received any transfusions during
this course of therapy?
No Transfusion (No)
Transfusion With Platelets (Yes,
platelets)
Transfusion With Red Blood Cells (Yes,
red blood cells)
Was patient hospitalized as a result of reported
adverse events?
Yes
No
Were cytokines administered this course?
Yes
No
Yes specify
Has an Adverse Drug Reaction Report been
filed?
Yes
No
1 / 4
Adverse Events - Section 2
Peripheral WBC count done?
Yes
No
Peripheral WBC count
Peripheral WBC count, Date
Peripheral Granulocytes count done? (ANC/)
Yes
No
Peripheral Granulocytes count (ANC)
Peripheral Granulocytes count, Date
Peripheral Platelet count done?
Yes
No
Peripheral Platelet count
Peripheral Platelet count, Date
Hemoglobin done?
Yes
No
Hemoglobin
Hemoglobin, Date
CTC Adverse Event Grade
CTC Adverse Event Grade
CTC Adverse Event Grade
CTC Adverse Event Grade
CTC Adverse Event Attribution Code
Definite (Definitely)
Possible (Possibly)
Probable (Probably)
Unlikely (Unlikely)
Unrelated (Unrelated)
CTC Adverse Event Attribution Code
2 / 4
Fallopian Tube Cancer NCT00262847 Toxicity - GOG-0218 Common
Toxicity Reporting Form - 2305920v3.0
Definite (Definitely)
Possible (Possibly)
Probable (Probably)
Unlikely (Unlikely)
Unrelated (Unrelated)
CTC Adverse Event Attribution Code
Definite (Definitely)
Possible (Possibly)
Probable (Probably)
Unlikely (Unlikely)
Unrelated (Unrelated)
CTC Adverse Event Attribution Code
Definite (Definitely)
Possible (Possibly)
Probable (Probably)
Unlikely (Unlikely)
Unrelated (Unrelated)
Adverse Events - Section 3
CTC Adverse Event Term
Diarrhoea Nos (DIARRHEA)
Fatigue (FATIGUE)
Hypertension Nos (HYPERTENSION)
Proteinuria Present (PROTEINURIA)
Dermatitis Exfoliative Nos (RASH)
Thrombosis Nos
(THROMBOSIS/THROMBUS/EMBOLIS
M)
The CTCAE data entered above is
Version 2 (version 2)
Version 3 (version 3)
CTC Adverse Event Grade
CTC Adverse Event Attribution Code
Definite (Definitely)
Possible (Possibly)
Probable (Probably)
Unlikely (Unlikely)
Unrelated (Unrelated)
Comments
COMMENTS
Footer Module
Participating Group Code
Participating Group Protocol Number
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Fallopian Tube Cancer NCT00262847 Toxicity - GOG-0218 Common
Toxicity Reporting Form - 2305920v3.0
Participating Group Patient ID
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Fallopian Tube Cancer NCT00262847 Toxicity - GOG-0218 Common
Toxicity Reporting Form - 2305920v3.0
Prostate Cancer NCT00079001 On-Study - CALGB
90202: Skeletal Survey Form - 2083769v3.0
CALGB 90202: Skeletal Survey Form
Zoledronate in Preventing Skeletal (Bone)-Related Events
in Patients Who Are Receiving Androgen Deprivation
Therapy For Prostate Cancer and Bone Metastases
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=B7BE7E12-
C8DF-7003-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/8036
CALGB 90202: Skeletal Survey
Form
Ccrr Module For Calgb 90202: Skeletal
Survey Form
CALGB Form
CALGB Study No.
CALGB Patient ID
Date completed
Are data amended?
Yes
No
Patient Initials
Patient Medical Record No.
Institution/Affiliate
Participating Group
Participating Group Protocol No.
Participating Group Patient ID
Reporting Period
Annual Survey (Annual survey)
Baseline Survey (Baseline survey)
Submitted to QARC by (Films and scans)
Date submitted to QARC
Is there evidence of any vertebral body fracture in
current films relative to previous ones?
Yes
1 / 2
No
Review Date
Anterior vertebral height
Posterior vertebral height
Total vertebral height
Comments
Completed by
Date form completed
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Prostate Cancer NCT00079001 On-Study - CALGB 90202: Skeletal
Survey Form - 2083769v3.0
Fallopian Tube Cancer NCT01081262 Toxicity - GOG-
0241 Common Toxicity Reporting Form (T) - 3126386v1.0
GOG-0241 Common Toxicity Reporting Form (T)
Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine,
With or Without Bevacizumab, as First-Line Therapy in
Treating Patients With Newly Diagnosed Stage II, Stage III,
Stage IV, or Recurrent Stage I Epithelial Ovarian Cancer or
Fallopian Tube Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=8D16EFA4-
522E-082B-E040-BB89AD434B01
All rights reserved. Please visit https://medical-data-
models.org/forms/8037
GOG-0241 Common Toxicity
Reporting Form (T)
Header Module
Date form originally completed (m d y)
Date form amended (m d y)
Person amending form, last name
Patient Initials (First, Middle, Last)
Patient Study ID
Person Completing Form, Last Name
Adverse Events - Section 1
Current Cycle Number
Has the patient received any transfusions during
this course of therapy?
No Transfusion (No)
Transfusion With Platelets (Yes,
platelets)
Transfusion With Red Blood Cells (Yes,
red blood cells)
Was patient hospitalized as a result of reported
adverse events?
Yes
No
Were cytokines administered this course?
Yes
No
Yes specify
Adverse Events - Section 2
Peripheral WBC count done
Yes
1 / 4
No
Peripheral WBC count (mm3)
Date (m d y)
CTC Adverse Event Grade
CTC Adverse Event Grade
CTC Adverse Event Grade
CTC Adverse Event Grade
CTC Adverse Event Attribution Code
Definite (Definite)
Possible (Possible)
Probable (Probable)
Unlikely (Unlikely)
Unrelated (Unrelated)
CTC Adverse Event Attribution Code
Definite (Definite)
Possible (Possible)
Probable (Probable)
Unlikely (Unlikely)
Unrelated (Unrelated)
CTC Adverse Event Attribution Code
Definite (Definite)
Possible (Possible)
Probable (Probable)
Unlikely (Unlikely)
Unrelated (Unrelated)
CTC Adverse Event Attribution Code
Definite (Definite)
Possible (Possible)
Probable (Probable)
Unlikely (Unlikely)
Unrelated (Unrelated)
Peripheral ANC/Granulocytes count done
Yes
No
Peripheral Granulocytes count (Nadir ANC/ mm3)
Date
SAE report submitted
Yes
No
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Fallopian Tube Cancer NCT01081262 Toxicity - GOG-0241 Common
Toxicity Reporting Form (T) - 3126386v1.0
SAE report submitted
Yes
No
SAE report submitted
Yes
No
SAE report submitted
Yes
No
Peripheral Platelet count done
Yes
No
Peripheral Platelet count (Nadir mm3)
Date
Hemoglobin done
Yes
No
Hemoglobin (Nadir G/DL)
Date
Adverse Events - Section 3
CTC Adverse Event Term
Current Cycle Number
Specify
CTC Adverse Event Grade
CTC Adverse Event Attribution Code
Definite (Definite)
Possible (Possible)
Probable (Probable)
Unlikely (Unlikely)
Unrelated (Unrelated)
AE Onset Date (m d y)
Present Status
Fatal Or Died (Fatal/Died)
Intervention For Adverse Event
Continues (Intervention for AE
Continues)
Not Recovered Or Not Resolved (Not
3 / 4
Fallopian Tube Cancer NCT01081262 Toxicity - GOG-0241 Common
Toxicity Reporting Form (T) - 3126386v1.0
recovered/Not resolved)
Recovered Or Resolved With Sequelae
(Recovered/Resolved with Sequelae)
Recovered Or Resolved Without
Sequelae (Recovered/Resolved without
Sequelae)
Recovering Or Resolving
(Recovering/Resolving)
The CTCAE data entered above is
Version 2 (version 2)
Version 3 (version 3)
SAE report submitted
Yes
No
Comments
Comments
4 / 4
Fallopian Tube Cancer NCT01081262 Toxicity - GOG-0241 Common
Toxicity Reporting Form (T) - 3126386v1.0
Prostate Cancer NCT00430183 Pathology - CALGB
90203: Surgery and Pathology Summary - 2526235v1.0
CALGB 90203: Surgery and Pathology Summary [Form C-
1243 v1 11/06/2006]
Surgery With or Without Docetaxel and Leuprolide or
Goserelin in Treating Patients With High-Risk Localized
Prostate Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=1F629E0A-
52FD-74AF-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/8039
CALGB 90203: Surgery and
Pathology Summary
Ccrr Module For Calgb 90202: Prostate
Specific Antigen Form
CALGB Form (C-714)
CALGB Study No.
CALGB Patient ID
Are data amended
Yes
No
Patient Initials (Last, First Middle)
Patient Hospital No.
Institution/Affiliate
Participating Group
Participating Group Study No.
Participating Group Patient ID
Intraoperative Report (prostatectomy)
Length of hospital stay (number of days)
Duration of Surgery (hrs min)
Estimated Blood Loss (cc)
Did the patient require red blood cell (RBC)
tranfusion (Recommended Term for CRF text
"Was red cell transfusion required
intraoperatively")
1 / 6
Yes
No
Number of autologous units
Number of autologous units
Number of banked units
Number of banked units
Did the patient require red blood cell (RBC)
transfusion postoperatively
Yes
No
Pathology: Prostatectomy
Surgery Date (Recommended Term for CRF Text
"Date of radical prostatectomy" - mm dd yyyy)
Type of Procedure (Recommended Term for CRF
Text "Type of radical prostatectomy" - Mark one
with an X.)
Radical Prostatectomy Laparoscopic
Retropubic (Radical prostatectomy
laparoscopic retropubic)
Radical Prostatectomy, Retropubic
(Radical prostatectomy open retropubic)
Radical Prostatectomy, Perineal (Radical
prostatectomy perineal)
Radical Prostatectomy Robotic-assisted
(Radical prostatectomy robotic-assisted)
Was a complete resection of the primary tumor
done (Recommended Term for CRF Text "Was
complete resection of the prostate achieved")
Yes
No
Apical Surgical Margin (Surgical margin status
For each, mark one with an X.)
Negative (Negative)
Not Examined (Not examined)
Positive (Positive)
Anterior Surgical Margin
Negative (Negative)
Not Examined (Not examined)
Positive (Positive)
Posterior Surgical Margin
Negative (Negative)
Not Examined (Not examined)
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Prostate Cancer NCT00430183 Pathology - CALGB 90203: Surgery and
Pathology Summary - 2526235v1.0
Positive (Positive)
Posterolateral Surgical Margin
Negative (Negative)
Not Examined (Not examined)
Positive (Positive)
Bladder Neck Surgical Margin
Negative (Negative)
Not Examined (Not examined)
Positive (Positive)
Tumor Location Relative Position (Recommended
Term for CRF Text "Location of tumor in prostate"
- Mark all that apply with an X.)
Anterior (Anterior)
Posterior (Posterior)
Area
Apex (Apex)
Base (Base)
Middle (Middle)
Other, Specify (Other)
Seminal Vesicle (Seminal vesicle)
Other specify
Zone
Not Specified (Not specified)
Peripheral/central (Peripheral/central)
Transition (Transition)
Unknown (Unknown)
Capsular invasion (Mark one with an X.)
Established Extracapsular Extension
(Established extracapsular extension)
Focal Extracapsular Extension (Focal
extracapsular extension)
Capsular Invasion (Invasion into but not
through the capsule)
None (None)
Invasion of seminal vesicle
Yes
No
Seminal Vesicle Laterality (If yes, Mark one with
an X.)
Both Seminal Vesicles (Both sides)
Structure Of Left Seminal Vesicle (Left
side)
Structure Of Right Seminal Vesicle
(Right side)
Side Not Specified (Side not specified)
Tumor invasion into bladder neck
Yes
No
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Pathology Summary - 2526235v1.0
Tumor Laterality (Mark one with an X.)
Bilateral (Bilateral)
Unilateral (Unilateral)
Tumor Size, Maximum Diameter (cm)
Total Tumor Volume (as measured by computer
assisted morphometry cc/mL)
Percent Involved (Recommended Term for CRF
text "Percent of gland involved by carcinoma" by
visual inspection %)
Gleason Grade, Primary
Gleason Grade, Secondary
Gleason Score, Combined
Histologic Type (In addition to adenocarcinoma,
mark all that apply with an X.)
Adenosquamous Carcinoma
(Adenosquamous carcinoma)
Mucinous (colloid) Adenocarcinoma
(Mucinous (colloid) adenocarcinoma)
Other Specify (Other)
Prostatic Duct Adenocarcinoma
(Prostatic duct adenocarcinoma)
Sarcomatoid Carcinoma (Sarcomatoid
carcinoma)
Signet Ring Cell Carcinoma (Signet ring
cell carcinoma)
Small Cell Carcinoma (Small cell
carcinoma)
Squamous Cell Carcinoma (Squamous
cell carcinoma)
Urothelial Primary In Prostate (Urothelial
primary in prostate)
Other specify
Pathology: Lymphadenectomy
Pelvic lymphadenectomy Date (mm dd yyyy)
Number of Lymph Nodes Examined
Number of Positive Lymph Nodes
Which lymph node areas were dissected (Mark
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Pathology Summary - 2526235v1.0
all that apply with an X.)
External Iliac (external iliac)
Hypogastric (hypogastric)
Obturator Lymph Node (obturator)
Other Specify (other)
Other specify
Were the nodes grossly positive
Yes
No
Were positive lymph nodes the reason for
aborting the prostatectomy
Yes
No
Extranodal extension (Mark one with an X.)
Indeterminate (INDETERMINATE)
No (NO)
Unknown (UNKNOWN)
Yes (YES)
Was a frozen section of the lymph node(s)
performed
Yes
No
Pathologic Disease Classification
T Stage, Pathologic (CRF must use existing CDE
which matches CAP/AJCC 2006 versions - no
pathologic staging of tumor for T0/T1 in that
system.)
Organ Confined (pT2)
Unilateral (pT2a)
Bilateral (pT2b)
Bilateral (pT2c)
Extraprostatic Extension (pT3)
Extraprostatic Extension (pT3a)
Seminal Vesicle Invasion (pT3b)
Invasion Of Bladder, Rectum (pT4)
Clinically Inapparent Tumor Not Palpable
Nor Visible By Imaging (T1)
N Stage, Pathologic
No Regional Lymph Node Metastasis
(pN0)
Metastatis In Regional Lymph Node Or
Nodes (see Ajcc Definition) (pN1)
Regional Lymph Nodes Cannot Be
Assessed (pNX)
Ccrr Module For Calgb: 90202 Adverse
Event Form
Completed by (Last name, First name)
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Prostate Cancer NCT00430183 Pathology - CALGB 90203: Surgery and
Pathology Summary - 2526235v1.0
Date Form Completed (mm dd yyyy)
6 / 6
Prostate Cancer NCT00430183 Pathology - CALGB 90203: Surgery and
Pathology Summary - 2526235v1.0
Fallopian Tube Cancer NCT00951496 Toxicity - Gynecologic
Oncology Group Common Toxicity Reporting Form - 2758462v1.0
Gynecologic Oncology Group Common Toxicity Reporting
Form
Bevacizumab and Intravenous or Intraperitoneal
Chemotherapy in Treating Patients With Stage II, Stage III,
or Stage IV Ovarian Epithelial Cancer, Fallopian Tube
Cancer, or Primary Peritoneal Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=4F550492-
CC47-047C-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/8040
Gynecologic Oncology Group
Common Toxicity Reporting Form
Header Module
Date form originally completed (m d y)
Date form amended (m d y)
Person amending form, last name
Patient Initials (First, Middle, Last)
Patient Study ID
Person Completing Form, Last Name
Adverse Events - Section 1
Current Cycle Number
Has the patient received any transfusions during
this course of therapy?
No Transfusion (No)
Transfusion With Platelets (Yes,
platelets)
Transfusion With Red Blood Cells (Yes,
red blood cells)
Was patient hospitalized as a result of reported
adverse events?
Yes
No
Were cytokines administered this course?
Yes
No
Yes specify
Adverse Events - Section 2
Peripheral WBC count done
Yes
1 / 4
No
Peripheral WBC count (1000/mm3)
Date (m d y)
CTC Adverse Event Grade
CTC Adverse Event Grade
CTC Adverse Event Grade
CTC Adverse Event Grade
CTC Adverse Event Attribution Code (Attribution
Codes for Relationship of Event to Treatment:
1=Unrelated, 2=Unlikely, 3=Possibly, 4=Probably,
5=Definitely)
Definite (Definite)
Possible (Possible)
Probable (Probable)
Unlikely (Unlikely)
Unrelated (Unrelated)
CTC Adverse Event Attribution Code (Attribution
Codes for Relationship of Event to Treatment:
1=Unrelated, 2=Unlikely, 3=Possibly, 4=Probably,
5=Definitely)
Definite (Definite)
Possible (Possible)
Probable (Probable)
Unlikely (Unlikely)
Unrelated (Unrelated)
CTC Adverse Event Attribution Code (Attribution
Codes for Relationship of Event to Treatment:
1=Unrelated, 2=Unlikely, 3=Possibly, 4=Probably,
5=Definitely)
Definite (Definite)
Possible (Possible)
Probable (Probable)
Unlikely (Unlikely)
Unrelated (Unrelated)
CTC Adverse Event Attribution Code (Attribution
Codes for Relationship of Event to Treatment:
1=Unrelated, 2=Unlikely, 3=Possibly, 4=Probably,
5=Definitely)
Definite (Definite)
Possible (Possible)
Probable (Probable)
Unlikely (Unlikely)
Unrelated (Unrelated)
Peripheral Granulocytes count done (ANC/)
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Fallopian Tube Cancer NCT00951496 Toxicity - Gynecologic Oncology
Group Common Toxicity Reporting Form - 2758462v1.0
Yes
No
Peripheral Granulocytes count (ANC/ 1000/mm3)
Date
SAE report submitted
Yes
No
SAE report submitted
Yes
No
SAE report submitted
Yes
No
SAE report submitted
Yes
No
Peripheral Platelet count done
Yes
No
Peripheral Platelet count (mm3)
Date
Hemoglobin done
Yes
No
Hemoglobin (G/DL)
Date
Adverse Events - Section 3
CTC Adverse Event Term
Current Cycle Number
Other, specify
CTC Adverse Event Grade
CTC Adverse Event Attribution Code (Attribution
Codes for Relationship of Event to Treatment:
1=Unrelated, 2=Unlikely, 3=Possibly, 4=Probably,
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Group Common Toxicity Reporting Form - 2758462v1.0
5=Definitely)
Definite (Definite)
Possible (Possible)
Probable (Probable)
Unlikely (Unlikely)
Unrelated (Unrelated)
Onset Date (MM DD YYYY)
Present Status
Fatal Or Died (Fatal/Died)
Intervention For Adverse Event
Continues (Intervention for AE
Continues)
Not Recovered Or Not Resolved (Not
recovered/Not resolved)
Recovered Or Resolved With Sequelae
(Recovered/Resolved with Sequelae)
Recovered Or Resolved Without
Sequelae (Recovered/Resolved without
Sequelae)
Recovering Or Resolving
(Recovering/Resolving)
The CTCAE data entered above is
Version 2 (version 2)
Version 3 (version 3)
SAE report submitted
Yes
No
Comments
COMMENTS
4 / 4
Fallopian Tube Cancer NCT00951496 Toxicity - Gynecologic Oncology
Group Common Toxicity Reporting Form - 2758462v1.0
Fallopian Tube Cancer NCT01167712 Toxicity - GOG-0262:
Common Toxicity Reporting Form (Form T) - 2918112v1.0
GOG-0262: Common Toxicity Reporting Form (Form T)
Paclitaxel and Carboplatin With or Without Bevacizumab in
Treating Patients With Stage II, Stage III, or Stage IV
Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or
Fallopian Tube Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=6E5FD374-
D92A-C069-E040-BB89AD4333F9
All rights reserved. Please visit https://medical-data-
models.org/forms/8041
GOG-0262: Common Toxicity
Reporting Form (Form T)
Header Module
Date form originally completed (m d y)
Date form amended (m d y)
Person amending form, last name
Patient Initials (First, Middle, Last)
Patient Study ID
Person Completing Form, Last Name
Adverse Events - Section 1
Current Cycle Number
Has the patient received any transfusions during
this course of therapy?
No Transfusion (No)
Transfusion With Platelets (Yes,
platelets)
Transfusion With Red Blood Cells (Yes,
red blood cells)
Was patient hospitalized as a result of reported
adverse events?
Yes
No
Were cytokines administered this course?
Yes
No
Yes specify
Adverse Events - Section 2
Peripheral WBC count done
Yes
1 / 4
No
Peripheral WBC count (1000/mm3)
Date (m d y)
CTC Adverse Event Grade
CTC Adverse Event Grade
CTC Adverse Event Grade
CTC Adverse Event Grade
CTC Adverse Event Attribution Code (Attribution
Codes for Relationship of Event to Treatment:
1=Unrelated, 2=Unlikely, 3=Possibly, 4=Probably,
5=Definitely)
Definite (Definite)
Possible (Possible)
Probable (Probable)
Unlikely (Unlikely)
Unrelated (Unrelated)
CTC Adverse Event Attribution Code (Attribution
Codes for Relationship of Event to Treatment:
1=Unrelated, 2=Unlikely, 3=Possibly, 4=Probably,
5=Definitely)
Definite (Definite)
Possible (Possible)
Probable (Probable)
Unlikely (Unlikely)
Unrelated (Unrelated)
CTC Adverse Event Attribution Code (Attribution
Codes for Relationship of Event to Treatment:
1=Unrelated, 2=Unlikely, 3=Possibly, 4=Probably,
5=Definitely)
Definite (Definite)
Possible (Possible)
Probable (Probable)
Unlikely (Unlikely)
Unrelated (Unrelated)
CTC Adverse Event Attribution Code (Attribution
Codes for Relationship of Event to Treatment:
1=Unrelated, 2=Unlikely, 3=Possibly, 4=Probably,
5=Definitely)
Definite (Definite)
Possible (Possible)
Probable (Probable)
Unlikely (Unlikely)
Unrelated (Unrelated)
Peripheral ANC/Granulocytes count done
2 / 4
Fallopian Tube Cancer NCT01167712 Toxicity - GOG-0262: Common
Toxicity Reporting Form (Form T) - 2918112v1.0
Yes
No
Peripheral Granulocytes count (ANC/ 1000/mm3)
Date
SAE report submitted
Yes
No
SAE report submitted
Yes
No
SAE report submitted
Yes
No
SAE report submitted
Yes
No
Peripheral Platelet count done
Yes
No
Peripheral Platelet count (mm3)
Date
Hemoglobin done
Yes
No
Hemoglobin (G/DL)
Date
Adverse Events - Section 3
CTC Adverse Event Term
Current Cycle Number
Specify
CTC Adverse Event Grade
CTC Adverse Event Attribution Code (Attribution
Codes for Relationship of Event to Treatment:
1=Unrelated, 2=Unlikely, 3=Possibly, 4=Probably,
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Toxicity Reporting Form (Form T) - 2918112v1.0
5=Definitely)
Definite (Definite)
Possible (Possible)
Probable (Probable)
Unlikely (Unlikely)
Unrelated (Unrelated)
AE Onset Date (m d y)
Present Status
Fatal Or Died (Fatal/Died)
Intervention For Adverse Event
Continues (Intervention for AE
Continues)
Not Recovered Or Not Resolved (Not
recovered/Not resolved)
Recovered Or Resolved With Sequelae
(Recovered/Resolved with Sequelae)
Recovered Or Resolved Without
Sequelae (Recovered/Resolved without
Sequelae)
Recovering Or Resolving
(Recovering/Resolving)
The CTCAE data entered above is
Version 2 (version 2)
Version 3 (version 3)
SAE report submitted
Yes
No
Comments
COMMENTS
4 / 4
Fallopian Tube Cancer NCT01167712 Toxicity - GOG-0262: Common
Toxicity Reporting Form (Form T) - 2918112v1.0
Sarcoma NCT01012297 Toxicity - GOG-0250 Common
Toxicity Reporting Form (Form T) - 2838388v1.0
GOG-0250 Common Toxicity Reporting Form (Form T)
Gemcitabine Hydrochloride and Docetaxel With or Without
Bevacizumab in Treating Patients With Advanced or
Recurrent Uterine Leiomyosarcoma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=62982C6D-
B6F4-DF51-E040-BB89AD431C98
All rights reserved. Please visit https://medical-data-
models.org/forms/8046
GOG-0250 Common Toxicity
Reporting Form (Form T)
Header Module
Date form originally completed (m d y)
Date form amended (m d y)
Person amending form, last name
Patient Initials (First, Middle, Last)
Patient Study ID
Person Completing Form, Last Name
Adverse Events - Section 1
Current Cycle Number
Has the patient received any transfusions during
this course of therapy?
No Transfusion (No)
Transfusion With Platelets (Yes,
platelets)
Transfusion With Red Blood Cells (Yes,
red blood cells)
Was patient hospitalized as a result of reported
adverse events?
Yes
No
Were cytokines administered this course?
Yes
No
Yes specify
Adverse Events - Section 2
Peripheral WBC count done
Yes
1 / 4
No
Peripheral WBC count (1000/mm3)
CTC Adverse Event Grade
CTC Adverse Event Grade
CTC Adverse Event Grade
Date (m d y)
CTC Adverse Event Grade
CTC Adverse Event Attribution Code (Attribution
Codes for Relationship of Event to Treatment:
1=Unrelated, 2=Unlikely, 3=Possibly, 4=Probably,
5=Definitely)
Definite (Definite)
Possible (Possible)
Probable (Probable)
Unlikely (Unlikely)
Unrelated (Unrelated)
CTC Adverse Event Attribution Code (Attribution
Codes for Relationship of Event to Treatment:
1=Unrelated, 2=Unlikely, 3=Possibly, 4=Probably,
5=Definitely)
Definite (Definite)
Possible (Possible)
Probable (Probable)
Unlikely (Unlikely)
Unrelated (Unrelated)
CTC Adverse Event Attribution Code (Attribution
Codes for Relationship of Event to Treatment:
1=Unrelated, 2=Unlikely, 3=Possibly, 4=Probably,
5=Definitely)
Definite (Definite)
Possible (Possible)
Probable (Probable)
Unlikely (Unlikely)
Unrelated (Unrelated)
CTC Adverse Event Attribution Code (Attribution
Codes for Relationship of Event to Treatment:
1=Unrelated, 2=Unlikely, 3=Possibly, 4=Probably,
5=Definitely)
Definite (Definite)
Possible (Possible)
Probable (Probable)
Unlikely (Unlikely)
Unrelated (Unrelated)
SAE report submitted
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No (No)
Unknown (Unknown)
Yes (Yes)
SAE report submitted
No (No)
Unknown (Unknown)
Yes (Yes)
SAE report submitted
No (No)
Unknown (Unknown)
Yes (Yes)
SAE report submitted
No (No)
Unknown (Unknown)
Yes (Yes)
Peripheral ANC/Granulocytes count done
Yes
No
Peripheral Granulocytes count (ANC/ 1000/mm3)
Date
Peripheral Platelet count done
Yes
No
Peripheral Platelet count (mm3)
Date
Hemoglobin done
Yes
No
Hemoglobin (G/DL)
Date
Comments
COMMENTS
Adverse Events - Section 3
CTC Adverse Event Term
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Reporting Form (Form T) - 2838388v1.0
Specify
CTC Adverse Event Grade
CTC Adverse Event Attribution Code (Attribution
Codes for Relationship of Event to Treatment:
1=Unrelated, 2=Unlikely, 3=Possibly, 4=Probably,
5=Definitely)
Definite (Definite)
Possible (Possible)
Probable (Probable)
Unlikely (Unlikely)
Unrelated (Unrelated)
SAE report submitted
No (No)
Unknown (Unknown)
Yes (Yes)
AE Onset Date
Present Status
Fatal Or Died (Fatal/Died)
Intervention For Adverse Event
Continues (Intervention for AE
Continues)
Not Recovered Or Not Resolved (Not
recovered/Not resolved)
Recovered Or Resolved With Sequelae
(Recovered/Resolved with Sequelae)
Recovered Or Resolved Without
Sequelae (Recovered/Resolved without
Sequelae)
Recovering Or Resolving
(Recovering/Resolving)
Footer Module
The CTCAE data entered above is version
Current Cycle Number
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Prostate Cancer NCT00430183 Toxicity - CALGB 90203:
Surgical Complications and Morbidity Form - 2523307v1.0
CALGB 90203: Surgical Complications and Morbidity Form
Surgery With or Without Docetaxel and Leuprolide or
Goserelin in Treating Patients With High-Risk Localized
Prostate Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=1E7757FC-
C08D-1B9B-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/8047
CALGB 90203: Surgical
Complications and Morbidity Form
Header
CALGB Form (C-1241)
CALGB Study No.
CALGB Patient ID
Date of Evaluation
Reporting Period (Entry required; mark one with
an X.)
0 To 3 Days After Surgery (Day 0-3 after
surgery)
4 To 30 Days After Surgery (Day 4-30
after surgery)
Are data amended
Yes
No
Unnamed2
Patient Initials (Last, First Middle)
Patient Hospital No.
Institution/Affiliate
Participating Group
Participating Group Study No.
Participating Group Patient ID
Unnamed3
MedDRA Code
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CTC AE Grade
CTC Adverse Event Term
Arrhythmia Nos (Cardiac Arrhythmia-
Other (Specify))
Myocardial Ischaemia (Cardiac
ischemia/infarction)
Cerebral Ischaemia (CNS
cerebrovascular ischemia)
Oedema Nos (Edema: limb)
Edema: Trunk/genital (Edema:
trunk/genital)
Leak (including Anastomotic), Gu (Leak
(including anastomotic), GU - Urethra)
Lymphocele (Lymphocele)
Peripheral Ischaemia Nos (Peripheral
arterial ischemia)
Stricture/stenosis (including
Anastomotic), Gu (Stricture/stenosis
(including anastomotic), GU - Bladder)
Supraventricular Arrhythmia Nos
(Supraventricular and nodal arrhythmia -
Supraventricular arrhythmia NOS)
Thrombosis Nos
(Thrombosis/thrombus/embolism)
Urinary Retention (Urinary retention
(including neurogenic bladder))
Ventricular Arrhythmia Nos (Ventricular
arrhythmia - Ventricular arrhythmia NOS)
Other Specify
Expected Adverse Events
MedDRA Code
CTC AE Grade
CTC Adverse Event Term
Arrhythmia Nos (Cardiac Arrhythmia-
Other (Specify))
Myocardial Ischaemia (Cardiac
ischemia/infarction)
Cerebral Ischaemia (CNS
cerebrovascular ischemia)
Oedema Nos (Edema: limb)
Edema: Trunk/genital (Edema:
trunk/genital)
Leak (including Anastomotic), Gu (Leak
(including anastomotic), GU - Urethra)
Lymphocele (Lymphocele)
Peripheral Ischaemia Nos (Peripheral
arterial ischemia)
Stricture/stenosis (including
Anastomotic), Gu (Stricture/stenosis
(including anastomotic), GU - Bladder)
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Supraventricular Arrhythmia Nos
(Supraventricular and nodal arrhythmia -
Supraventricular arrhythmia NOS)
Thrombosis Nos
(Thrombosis/thrombus/embolism)
Urinary Retention (Urinary retention
(including neurogenic bladder))
Ventricular Arrhythmia Nos (Ventricular
arrhythmia - Ventricular arrhythmia NOS)
Duration (number of days [for Postoperative fever
>38.5 degrees C 101.5 degrees F])
Wound complication, non-infectious (Mark one
with an X._)
Dehiscence Requiring Local Wound
Care Only (Dehiscence requiring local
wound care only)
Dehiscence Requiring Return To
Operating Wound (Dehiscence requiring
return to operating wound)
Other Specify (for Infection - other, specify)
Postoperative events (Recommended term - no
Question on CRF following "Respiratory failure
ARDS?"  mark all that apply with an X:)
Reintubation (Reintubation required >24
hours post-operatively)
Tracheostomy (Tracheostomy)
Requiring Assisted Ventilation
(Ventilation required >24 hours post-
operatively)
Duration (number of days [for Ventilation required
>24 hours post-operatively])
Duration (number of days [for Reintubation
required >24 hours post-operatively])
Expected Adverse Events
MedDRA Code
CTC AE Grade
CTC Adverse Event Term
Arrhythmia Nos (Cardiac Arrhythmia-
Other (Specify))
Myocardial Ischaemia (Cardiac
ischemia/infarction)
Cerebral Ischaemia (CNS
cerebrovascular ischemia)
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Oedema Nos (Edema: limb)
Edema: Trunk/genital (Edema:
trunk/genital)
Leak (including Anastomotic), Gu (Leak
(including anastomotic), GU - Urethra)
Lymphocele (Lymphocele)
Peripheral Ischaemia Nos (Peripheral
arterial ischemia)
Stricture/stenosis (including
Anastomotic), Gu (Stricture/stenosis
(including anastomotic), GU - Bladder)
Supraventricular Arrhythmia Nos
(Supraventricular and nodal arrhythmia -
Supraventricular arrhythmia NOS)
Thrombosis Nos
(Thrombosis/thrombus/embolism)
Urinary Retention (Urinary retention
(including neurogenic bladder))
Ventricular Arrhythmia Nos (Ventricular
arrhythmia - Ventricular arrhythmia NOS)
Other Specify (for Cardiac Arrhythmia, specify)
If known specify type (for Ventricular arrhythmia -
NOS)
If known specify type (for Ventricular arrhythmia -
NOS)
Specify type of corrective procedure (for Stricture,
anastomotic, GU-bladder)
Total number of corrective procedures (since
surgery)
Ccrr Module For Calgb: 90202 Adverse
Event Form
Comments
Completed by (Last name, First name)
Date Form Completed (mm dd yyyy)
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Colorectal Cancer NCT01167725 Eligibility - USMCI
8214/Z6091: Systemic Therapy Form - 2831237v1.0
USMCI 8214/Z6091: Systemic Therapy Form
Standard Therapy With or Without Surgery and Mitomycin
C in Treating Patients With Advanced Limited Peritoneal
Dissemination of Colon Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=62075F41-
0F8D-15EF-E040-BB89AD43299C
All rights reserved. Please visit https://medical-data-
models.org/forms/8048
USMCI 8214/Z6091: Systemic
Therapy Form
Header Module
Visit*
Systemic Therapy (Systemic Therapy)
Patient ID*
Institution No.*
Institution Name*
Header Module
Current Cycle Number*
Cycle Start Date*
Cycle end date*
Systemic therapy
Treating physician*
Weight*
Performance Status (ECOG)*
Fully Active, Able To Carry On All Pre-
disease Performance Without
Restriction. (0)
Restricted In Physically Strenuous
Activity But Ambulatory And Able To
Carry Out Work Of A Light Or Sedentary
Nature, E.g., Light Housework, Office
Work. (1)
Ambulatory And Capable Of All Selfcare
But Unable To Carry Out Any Work
Activities. Up And About More Than 50%
Of Waking Hours. (2)
Capable Of Only Limited Selfcare,
Confined To Bed Or Chair More Than
1 / 3
50% Of Waking Hours. (3)
Completely Disabled. Cannot Carry On
Any Selfcare. Totally Confined To Bed Or
Chair. (4)
Was treatment given during this cycle*
Yes
No
Was this cycle of treatment delayed*
Yes
No
Reason*
Adverse Event (Adverse Event)
Other, Specify (Other, specify)
Specify*
Agent Name*
Other, specify*
Was agent administered*
Yes
No
Treatment dose modified*
Yes
No
Agent Total Dose*
Did the patient receive cytokine support*
Yes
No
Type*
Darbopoietin (Darbopoietin)
Erythropoietin (Erythropoietin)
Filgastrim (Filgastrim)
Other (Other)
Pegfilgastrim (Pegfilgastrim)
Specify*
Did the patient receive PRBC*
Yes
No
Did the patient receive platelet transfusion*
Did the patient receive FFP transfusion*
Yes
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Systemic Therapy Form - 2831237v1.0
Prostate Cancer NCT00430183 Lab - CALGB 90203:
Paraffin Tissue Submission Form - 2524687v1.0
CALGB 90203: Paraffin Tissue Submission Form
Surgery With or Without Docetaxel and Leuprolide or
Goserelin in Treating Patients With High-Risk Localized
Prostate Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=1ED975EC-
81ED-73D2-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/8061
CALGB 90203: Paraffin Tissue
Submission Form
Ccrr Module For Calgb 90202: Prostate
Specific Antigen Form
CALGB Form (C-714)
CALGB Study No.
CALGB Patient ID
Date Specimen collected
Are data amended
Yes
No
Patient Initials (Last, First Middle)
Patient Hospital No.
Institution/Affiliate
Participating Group
Participating Group Study No.
Participating Group Patient ID
Unnamed3
Timing of material collection (Mark one)
Biopsy (Biopsy)
Prostatectomy (Prostatectomy)
Specimen Type
Cores From Normal Prostate Tissue
(Cores from normal prostate tissue)
Cores From Prostate Tumor Tissue
(Cores from prostate tumor tissue)
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Representative primary tumor from prostate
Tissue, Paraffin (Paraffin block)
Unstained Specimen (Unstained slide)
Representative primary tumor from seminal
vesicle
Tissue, Paraffin (Paraffin block)
Unstained Specimen (Unstained slide)
Representative primary tumor from lymph node
Tissue, Paraffin (Paraffin block)
Unstained Specimen (Unstained slide)
Date shipped (mm dd yyyy)
Number of specimens submitted
Block number/letter
If none submitted, specify reason
Instituition Won't Release (Instituition
won't release)
Institution Error (Institution error)
Insufficient/scant Sample
(Insufficient/scant sample)
Other (Other)
Patient Refusal (Patient refusal)
Patient Unable To Submit Sample
(Patient unable to submit sample)
Sample Lost Or Destroyed (Sample lost
or destroyed)
Sample Not Required (Sample not
required)
Accession Number
Module 4
Is institution requesting return of blocks
Yes
No
Date of return
Is the patient registered to TMA substudy 150413
Yes
No
Are TMA samples being submitted at
prostatectomy (If yes,)
Yes
No
Sample type (Mark one with an X)
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Core Biopsy (Cores)
Paraffin Blocks (Parraffin block)
Unnamed3
Specimen Type
Cores From Normal Prostate Tissue
(Cores from normal prostate tissue)
Cores From Prostate Tumor Tissue
(Cores from prostate tumor tissue)
Number of specimens submitted
Block number/letter
If none submitted, specify reason
Instituition Won't Release (Instituition
won't release)
Institution Error (Institution error)
Insufficient/scant Sample
(Insufficient/scant sample)
Other (Other)
Patient Refusal (Patient refusal)
Patient Unable To Submit Sample
(Patient unable to submit sample)
Sample Lost Or Destroyed (Sample lost
or destroyed)
Sample Not Required (Sample not
required)
Shipping Information
Submitting Institution
Contact Person Name
Contact Phone Number
Contact Person E-Mail
LabTrak shipment ID (LabTrak use is required of
all CALGB institutions. Access LabTrak users
application via calgb.org member website. First
time users must contact CALGB Help Desk at 1-
877-44CALGB to set up LabTrak account.)
Date shipped (mm dd yyyy)
Footer Module Pg2
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Comments
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Prostate Cancer NCT00430183 Lab - CALGB
90203: Testosterone Form - 2523180v1.0
CALGB 90203: Testosterone Form [Form C-744 v2
10/17/2006]
Surgery With or Without Docetaxel and Leuprolide or
Goserelin in Treating Patients With High-Risk Localized
Prostate Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=1E771152-
85FD-12A7-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/8064
CALGB 90203: Testosterone Form
Ccrr Module For Calgb 90202: Prostate
Specific Antigen Form
CALGB Form (C-714)
CALGB Study No.
CALGB Patient ID
Are data amended
Yes
No
Patient Initials (Last, First Middle)
Patient Hospital No.
Institution/Affiliate
Participating Group
Participating Group Study No.
Participating Group Patient ID
Ccrr Module For Calgb 90202: Prostate
Specific Antigen Form
Assessment Date (mm dd yyyy)
Testosterone (ng/mL)
Status (1 Status Codes: 1= pre-study value, 2=
baseline value,...)
Baseline Value (baseline value)
Follow-up, Off Treatment Value (follow-
up, off treatment value)
Pre-study Value (pre-study value)
Protocol Treatment Value (protocol
treatment value)
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Completed by (Last name, First Name)
Date Form Completed (mm dd yyyy)
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- 2523180v1.0
On-Study - CALGB Non-Small Cell Lung Cancer
Staging Form (AJCC V.7.0) - 3082176v1.0
CALGB Non-Small Cell Lung Cancer Staging Form (AJCC
V.7.0)
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=85DE3B43-
56B5-4D38-E040-BB89AD4369BA
All rights reserved. Please visit https://medical-data-
models.org/forms/8070
CALGB Non-Small Cell Lung Cancer
Staging Form (AJCC V.7.0)
Header
CALGB Form
CALGB Study No.
CALGB Patient ID
Date Current Staging Assessment Completed
(MM DD YYYY)
Are data amended
Yes
No
Unnamed2
Patient Initials (Last, First Middle)
Patient Hospital No.
Institution/Affiliate
Participating Group
Participating Group Study No
Participating Group Patient ID
Staging
Method of Evaluation (Staging Method)
Chest Radiography (Chest CT)
Chest X-ray (Chest x-ray)
Cytology (Cytology)
Histology (Histology)
Pet Scan (PET scan)
TNM descriptors (Mark all that apply with an X.
as determined by the Staging Method indicated
above)
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Multiple Primary Tumors (m)
Recurrent (r)
Post-treatment (y)
Tumor Size (cm)
Clinical T Stage
T Stage (Primary tumor)
No Evidence Of Primary Tumor (T0)
Tumor <=3 Cm In Greatest Dimension,
Surrounded By Lung Or Visceral Pleura,
Without Bronchoscopic Evidence Of
Invasion More Proximal Than The Lobar
Bronchus (i.e., Not In The Main
Bronchus) (T1)
Tumor > 3 Cm But <=7 Cm Involves Main
Bronchus, >=2 Cm Distal To The Carina
Invades Visceral Pleura (pl1 Or Pl2)
Associated With Atelectasis Or
Obstructive Pneumonitis That Extends
To The Hilar Region But Does Not
Involve The Entire Lung (T2)
Tumor > 7 Cm Or One That Directly
Invades Any Of The Following: Parietal
Pleural (pl3) Chest Wall (including
Superior Sulcus Tumors), Diaphragm,
Phrenic Nerve, Mediastinal Pleura,
Parietal Pericardium; Or Tumor In The
Main Bronchus (T3)
Tumor Of Any Size That Invades Any Of
The Following: Mediastinum, Heart,
Great Vessels, Trachea, Recurrent
Laryngeal Nerve, Esophagus, Vertebral
Body, Carina, Separate Tumor Nodule(s)
In A Different Ipsilateral Lobe (T4)
Tis Carcinoma In Situ (Tis)
Primary Tumor Cannot Be Assessed
(TX)
T2 tumor with any of the following (Mark all that
apply with an X.)
> 3 But <= 7 Cm (> 3 but <= 7 cm)
Atelectasis/obstructive Pneumonia
Extending To Hilum But Not Involving
The Entire Lung (Atelectasis/obstructive
pneumonia extending to hilum but not
involving the entire lung)
Invades Visceral Pleura (Invades visceral
pleura)
Involves Main Bronchus >= 2 Cm Distal
To The Carina (Involves main bronchus
>= 2 cm distal to the carina)
T3 tumor with any of the following (Mark all that
apply with an X.)
> 7 Cm (> 7 cm)
Atelectasis/obstructive Pneumonia Of
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Entire Lung (Atelectasis/obstructive
pneumonia of entire lung)
Directly Invading Chest Wall, Diaphragm,
Phrenic Nerve, Mediastinal Pleura, Or
Parietal Pericardium (Directly invading
chest wall, diaphragm, phrenic nerve,
mediastinal pleura, or parietal
pericardium)
Separate Tumor Nodule(s) In The Same
Lobe (as Primary Tumor) (Separate
tumor nodule(s) in the same lobe (as
primary tumor))
Tumor In The Main Bronchus < 2 Cm
Distal To The Carina (Tumor in the main
bronchus < 2 cm distal to the carina)
T4 tumor of any size with invasion of (Mark all
that apply with an X.)
Carina (Carina)
Esophagus (Esophagus)
Great Vessels (Great vessels)
Heart (Heart)
Mediastinum (Mediastinum)
Recurrent Laryngeal Nerve (Recurrent
laryngeal nerve)
Separate Tumor Nodules In A Different
Ipsilateral Lobe (Separate tumor nodules
in a different ipsilateral lobe)
Trachea (Trachea)
Vertebra (Vertebra)
Clinical N Stage
N Stage (Regional lymph nodes)
No Regional Lymph Node Metastasis
(N0)
Metastasis In Ipsilateral Peribronchial
And/or Ipsilateral Hilar Lymph Nodes
And Intrapulmonary Nodes, Including
Involvement By Direct Extension (N1)
Metastasis In Ipsilateral Mediastinal
And/or Subcarinal Lymph Node(s) (N2)
Metastasis In Contralateral Mediastinal,
Contralateral Hilar, Ipsilateral Or
Contralateral Scalene, Or
Supraclavicular Lymph Node(s) (N3)
Regional Lymph Nodes Cannot Be
Assessed (NX)
Clinical M Stage
M Stage (Metastasis)
No Distant Metastasis (no Pathologic
M0; Use Clinical M To Complete Stage
Group) (M0)
Separate Tumor Nodule(s) In A
Contralateral Lobe; Tumor With Pleural
Nodules Or Malignant Pleural (or
Pericardial) Effusion (M1a)
Distant Metastasis (M1b)
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M1a metastasis with any of the following (Mark all
that apply with an X.)
Separate Tumor Nodules In A
Contralateral Lobe (Separate tumor
nodules in a contralateral lobe)
Tumor With Pleural Nodules Or
Malignant Pleural (or Pericardial)
Effusion (Tumor with pleural nodules or
malignant pleural (or pericardial)
effusion)
Specify site
Clinical T Stage
T Stage
No Evidence Of Primary Tumor (T0)
Tumor <=3 Cm In Greatest Dimension,
Surrounded By Lung Or Visceral Pleura,
Without Bronchoscopic Evidence Of
Invasion More Proximal Than The Lobar
Bronchus (i.e., Not In The Main
Bronchus) (T1)
Tumor <=2 Cm In Greatest Dimension
(T1a)
Tumor > 2 Cm But <=3 Cm In Greatest
Dimension (T1b)
Tumor > 3 Cm But <=7 Cm Involves Main
Bronchus, >=2 Cm Distal To The Carina
Invades Visceral Pleura (pl1 Or Pl2)
Associated With Atelectasis Or
Obstructive Pneumonitis That Extends
To The Hilar Region But Does Not
Involve The Entire Lung (T2)
Tumor > 3 Cm But <=5 Cm In Greatest
Dimension (T2a)
Tumor > 5 Cm But <=7 Cm In Greatest
Dimension (T2b)
Tumor > 7 Cm Or One That Directly
Invades Any Of The Following: Parietal
Pleural (pl3) Chest Wall (including
Superior Sulcus Tumors), Diaphragm,
Phrenic Nerve, Mediastinal Pleura,
Parietal Pericardium; Or Tumor In The
Main Bronchus (T3)
Tumor Of Any Size That Invades Any Of
The Following: Mediastinum, Heart,
Great Vessels, Trachea, Recurrent
Laryngeal Nerve, Esophagus, Vertebral
Body, Carina, Separate Tumor Nodule(s)
In A Different Ipsilateral Lobe (T4)
Tis Carcinoma In Situ (Tis)
Primary Tumor Cannot Be Assessed
(TX)
T2 tumor with any of the following (Mark all that
apply with an X.)
> 3 But <= 7 Cm (> 3 but <= 7 cm)
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Atelectasis/obstructive Pneumonia
Extending To Hilum But Not Involving
The Entire Lung (Atelectasis/obstructive
pneumonia extending to hilum but not
involving the entire lung)
Invades Visceral Pleura (Invades visceral
pleura)
Involves Main Bronchus >= 2 Cm Distal
To The Carina (Involves main bronchus
>= 2 cm distal to the carina)
T3 tumor with any of the following (Mark all that
apply with an X.)
> 7 Cm (> 7 cm)
Atelectasis/obstructive Pneumonia Of
Entire Lung (Atelectasis/obstructive
pneumonia of entire lung)
Directly Invading Chest Wall, Diaphragm,
Phrenic Nerve, Mediastinal Pleura, Or
Parietal Pericardium (Directly invading
chest wall, diaphragm, phrenic nerve,
mediastinal pleura, or parietal
pericardium)
Separate Tumor Nodule(s) In The Same
Lobe (as Primary Tumor) (Separate
tumor nodule(s) in the same lobe (as
primary tumor))
Tumor In The Main Bronchus < 2 Cm
Distal To The Carina (Tumor in the main
bronchus < 2 cm distal to the carina)
T4 tumor of any size with invasion of (Mark all
that apply with an X.)
Carina (Carina)
Esophagus (Esophagus)
Great Vessels (Great vessels)
Heart (Heart)
Mediastinum (Mediastinum)
Recurrent Laryngeal Nerve (Recurrent
laryngeal nerve)
Separate Tumor Nodules In A Different
Ipsilateral Lobe (Separate tumor nodules
in a different ipsilateral lobe)
Trachea (Trachea)
Vertebra (Vertebra)
Clinical N Stage
N Stage
No Regional Lymph Node Metastasis
(N0)
Metastasis In Ipsilateral Peribronchial
And/or Ipsilateral Hilar Lymph Nodes
And Intrapulmonary Nodes, Including
Involvement By Direct Extension (N1)
Metastasis In Ipsilateral Mediastinal
And/or Subcarinal Lymph Node(s) (N2)
Metastasis In Contralateral Mediastinal,
Contralateral Hilar, Ipsilateral Or
Contralateral Scalene, Or
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Supraclavicular Lymph Node(s) (N3)
Regional Lymph Nodes Cannot Be
Assessed (NX)
Clinical M Stage
M Stage
Distant Metastasis (M1)
Separate Tumor Nodule(s) In A
Contralateral Lobe; Tumor With Pleural
Nodules Or Malignant Pleural (or
Pericardial) Effusion (M1a)
Distant Metastasis (M1b)
M1a metastasis with any of the following (Mark all
that apply with an X.)
Separate Tumor Nodules In A
Contralateral Lobe (Separate tumor
nodules in a contralateral lobe)
Tumor With Pleural Nodules Or
Malignant Pleural (or Pericardial)
Effusion (Tumor with pleural nodules or
malignant pleural (or pericardial)
effusion)
Specify site
Overall Response
Completed by (Last name, First name)
Date Form Originally Completed (MM DD YYYY)
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Cervical Cancer NCT00980954 Treatment - RTOG 0724 Phase III Cervix Chemo
RT (+)/(-) Adjuvant Chemotherapy:  Radiotherapy Form (T1) - 2806681v1.0
RTOG 0724 Phase III Cervix Chemo RT (+)/(-) Adjuvant
Chemotherapy:  Radiotherapy Form (T1)
Chemotherapy and Pelvic Radiation Therapy With or
Without Additional Chemotherapy in Treating Patients With
High-Risk Early-Stage Cervical Cancer After Radical
Hysterectomy
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=5CFDEE98-
073C-2FA7-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/8071
RTOG 0724 Phase III Cervix Chemo
RT (+)/(-) Adjuvant Chemotherapy:
Radiotherapy Form (T1)
Module 1
RTOG Study No.
Case #
Institution Name
Institution No.
Patient Initials
RTOG Patient ID
Amended Data
Yes
No
Radiation Therapy Start Date (MM DD YYYY
External Beam RT)
Radiation Therapy End Date (MM DD YYYY
External Beam RT)
Total elapsed days (including both external
radiation therapy and brachytherapy)
RT Total Fraction Count
RT Total Dose  (TO PTV Gy)
Were there any unscheduled interruptions in
radiation therapy? (excluding holidays)
No (No)
Yes, Due To Other Reason (Yes, due to
other reason)
Yes, Due To Toxicity (Yes, due to toxicity)
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Specify RT interruption reason
Reason Treatment Ended
Adverse Event/side Effects/complications
(Adverse Event/Side
Effects/Complications)
Alternative Therapy (Alternative therapy)
Death On Study (Death on study)
Disease Progression, Relapse During
Active Treatment (Disease progression,
relapse during active treatment)
Other (Other)
Patient Off-treatment For Other
Complicating Disease (Patient off-
treatment for other complicating disease)
Patient Withdrawal Or Refusal After
Beginning Protocol Therapy (Patient
withdrawal/refusal after beginning
protocol therapy)
Patient Withdrawal Or Refusal Before
Beginning Protocol Therapy (Patient
withdrawal/refusal prior to beginning
protocol therapy)
Treatment Completed Per Protocol
Criteria (Treatment completed per
protocol criteria)
Alternative Therapy (specify)
Other specify
Type of Radiation Therapy Administered
3d Conformal (3D conformal)
Imrt (IMRT)
Brachytherapy
Reason brachytherapy treatment completed or
not utilized
Alternative Therapy Given (Alternative
therapy given)
Death (Death)
Inadequate To Treat Extent Of Disease
(Inadequate to treat extent of disease)
Md Preference (MD preference)
Na Dose Administered Within Protocol
Specifications (NA Dose administered
within protocol specifications)
Not Technically Feasible (Not technically
feasible)
Other Reason, Specify (Other reason,
specify)
Patient Refused (Patient refused)
Progression Or Relapse (Progression or
relapse)
Toxicity Or Treatment Reaction (Toxicity
or treatment reaction)
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Cervical Cancer NCT00980954 Treatment - RTOG 0724 Phase III Cervix Chemo
RT (+)/(-) Adjuvant Chemotherapy:  Radiotherapy Form (T1) - 2806681v1.0
Specify therapy
Other reason, specify
Date of implant (#3)
Date of implant (#3)
Date of implant (#3)
Time of implant (#3)
Time of implant (#3)
Time of implant (#3)
Total elapsed days (including both external
radiation therapy and brachytherapy)
Type Of Brachytherapy Administered
Hdr (HDR)
Ldr (LDR)
Not Applicable (N/A)
Footer Module
Comments
Person Completing Form
Date Form Originally Completed (MM DD YYYY)
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Cervical Cancer NCT00980954 Treatment - RTOG 0724 Phase III Cervix Chemo
RT (+)/(-) Adjuvant Chemotherapy:  Radiotherapy Form (T1) - 2806681v1.0
Prostate Cancer NCT00430183 Lab - CALGB 90203:
Blood Sample Submission Form - 2521872v1.0
CALGB 90203: Blood Sample Submission Form [Form C-
1277 v 1 11/06/2006]
Surgery With or Without Docetaxel and Leuprolide or
Goserelin in Treating Patients With High-Risk Localized
Prostate Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=1E607A17-
B6EF-4302-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/8072
CALGB 90203: Blood Sample
Submission Form
Ccrr Module For Calgb 90202: Prostate
Specific Antigen Form
CALGB Form (C-714)
CALGB Study No.
CALGB Patient ID
Date Specimen collected (1 Or scheduled date, if
not collected. mm dd yyyy)
Are data amended
Yes
No
Patient Initials (Last, First Middle)
Patient Hospital No.
Institution/Affiliate
Participating Group
Participating Group Study No.
Participating Group Patient ID
Unnamed3
Does specimen accompany this form?
(Recommended term for CRF text "Are blood
specimens being submitted collected per
protocol?")
Yes
No
Specify reason (s Mark all taht apply with an X.)
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Institution Error (Institution error)
Not Available (Not available)
Other (Other)
Patient Refusal (Patient refusal)
Sample Lost Or Destroyed (Sample lost
or destroyed)
Specify (Other)
Unnamed4
Timing of material collection (Recommended
Term: CRF text says "Sample collection
timepoint" Mark one with an X)
Post-surgery (Post-Surgery)
Prior To Initiation Of Protocol Therapy
(Prior to initiation of protocol therapy)
Prior To Radical Prostatectomy (Prior to
radical prostatectomy)
Progression (Progression)
Time since surgery (specify - years)
Time since surgery (specify - months)
Number of serum tubes submitted (SST -
red/black marble top 2 Label each tube with
CALGB 90203, CALGB Patient ID, Procurement
Date, Serum or Plasma)
Number of plasma tubes submitted (EDTA -
purple top 2 Label each tube with CALGB 90203,
CALGB Patient ID, Procurement Date, Serum or
Plasma)
LabTrak sample ID (Plasma)
LabTrak sample ID (Plasma)
Shipping Information
Date shipped (s mm dd yyyy)
LabTrak shipment ID (3 Required of all CALGB
institutions. Access Labtrak application via the
member site at www.calgb.org. Anyone accessing
LabTrak for the first time must have an assigned
CALGB PIN Participant ID Number and contact
the CALGB help desk...to set up LabTrak.)
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Prostate Cancer NCT00430183 Lab - CALGB 90203: Blood Sample
Submission Form - 2521872v1.0
Contact Person Name
Contact Phone Number
Contact Person E-Mail
Date Form Completed (mm dd yyyy)
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Prostate Cancer NCT00430183 Lab - CALGB 90203: Blood Sample
Submission Form - 2521872v1.0
Prostate Cancer NCT00430183 Lab - CALGB 90203:
Prostate Specific Antigen Form - 2521789v1.0
CALGB 90203: Prostate Specific Antigen Form [Form C-
714 v1 10/24/2006]
Surgery With or Without Docetaxel and Leuprolide or
Goserelin in Treating Patients With High-Risk Localized
Prostate Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=1E5ED5AA-
6D79-2E73-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/8074
CALGB 90203: Prostate Specific
Antigen Form
Ccrr Module For Calgb 90202: Prostate
Specific Antigen Form
CALGB Form (C-714)
CALGB Study No.
CALGB Patient ID
Are data amended
Yes
No
Patient Initials (Last, First Middle)
Patient Hospital No.
Institution/Affiliate
Participating Group
Participating Group Study No.
Participating Group Patient ID
Ccrr Module For Calgb 90202: Prostate
Specific Antigen Form
Date of PSA Assessment (mm dd yyyy)
PSA Value (total) (ng/mL)
Status
Baseline Value (baseline value)
Follow-up, Off Treatment Value (follow-
up, off treatment value)
Pre-study Value (pre-study value)
Pre Surgery (Pre-surgery)
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Protocol Treatment Value (protocol
treatment value)
PSA Assay Type
Abbott Labs (Abbott)
Hybritech (Hybritech)
Other (Other)
Roche (Roche)
Tosoh Nexia (Tosoh Nexia)
Yang Pros-check (Yang)
PSA Assay Other Type
Completed by (Last name, First Name)
Date Form Completed (mm dd yyyy)
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Prostate Cancer NCT00430183 Lab - CALGB 90203: Prostate Specific
Antigen Form - 2521789v1.0
Lung Cancer NCT00693992 On-Study - CALGB:
30607 Respiratory On-Study Form - 2663922v1.0
CALGB: 30607 Respiratory On-Study Form
Sunitinib as Maintenance Therapy in Treating Patients With
Stage III or Stage IV Non-Small Cell Lung Cancer
Previously Treated With Combination Chemotherapy
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=3525C2EE-
8272-3D39-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/8079
CALGB: 30607 Respiratory On-
Study Form
Ccrr Module For Calgb 90202: Skeletal
Survey Form
CALGB Form (C-1244)
CALGB Study No.
CALGB Patient ID
Treatment Start Date
Are data amended
Yes
No
Patient Initials (Last, First Middle)
Patient Hospital No.
Institution/Affiliate
Participating Group
Participating Group Study No.
Participating Group Patient ID
Disease Status
MedDRA disease code
Histologic Grade (Differentiation)
Well Differentiated (Grade I)
Moderately Differentiated (Grade II)
Poorly Differentiated (Grade III)
Is measurable disease present?
Yes
1 / 4
No
Does the patient have evidence of brain
metastasis, spinal cord or carcinomatous
meningitis
Yes
No
Smoking History
Currently Smoking (Currently smoking)
Never Smoked (Never smoked)
Smoked In The Past (Smoked in the
past)
Number pack years smoked
Vital Status
Performance Status (Mark one with an X.)
Fully Active, Able To Carry On All Pre-
disease Performance Without
Restriction. (0)
Restricted In Physically Strenuous
Activity But Ambulatory And Able To
Carry Out Work Of A Light Or Sedentary
Nature, E.g., Light Housework, Office
Work. (1)
Does the patient have active hemoptysis
Yes
No
Prior Therapy
Prior radiation therapy
Yes
No
Number of prior cycles of platinum-based therapy
Date of the last dose of chemotherapy
Has the patient received Bevacizumab
Yes
No
Specify number of cycles received
Lab Data At Protocol Entry
WBC
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Lung Cancer NCT00693992 On-Study - CALGB: 30607 Respiratory On-
Study Form - 2663922v1.0
Granulocytes
ANC
Platelet count
Bilirubin
Bilirubin ULN
SGOT
SGOT (AST) ULN
Creatinine
Tnm Staging
T Stage, Clinical
No Evidence Of Primary Tumor (T0)
Tumor 3 Cm Or Less In Greatest
Dimension, Surrounded By Lung Or
Visceral Pleura, Invasion More Proximal
Than The Lobar Bronchus, (i.e., Not In
The Main Bronchus) (T1)
Tumor With Any Of The Following
Features Of Size Or Extent: More Than
3cm In Greatest Dimension; Invades The
Visceral Pleura; Associated With
Atelectasis Or Obstructive Pneumonitis
That Extends To The Hilar Region But
Does Not Involve The Entire Lung (T2)
Tumor Of Any Size That Directly Invades
Any Of The Following: Chest Wall
(including Superior Sulcus Tumors),
Diaphragm, Mediastinal Pleura, Parietal
Pericardium; Or Tumor In The Main
Bronchus Less Than 2 Cm Distal To The
Carina, But Without Involvement O* (T3)
Tumor Of Any Size That Directly Invades
Any Of The Following: Chest Wall
(including Superior Sulcus Tumors),
Diaphragm, Mediastinal Pleura, Parietal
Pericardium; Or Tumor In The Main
Bronchus Less Than 2 Cm Distal To The
Carina, But Without Involvement O* (T4)
Carcinoma In Situ (Tis)
Primary Tumor Cannot Be Assessed, Or
Tumor Proven By The Presence Of
Malignant Cells In Sputum Or Bronchial
Washings But Not Visualized By Imaging
Or Bronchoscopy (Tx)
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Lung Cancer NCT00693992 On-Study - CALGB: 30607 Respiratory On-
Study Form - 2663922v1.0
N Stage, Clinical
No Regional Lymph Node Metastasis
(N0)
Metastasis To Ipsilateral Peribronchial
And/or Ipsilateral Hilar Lymph Nodes,
And Intrapulmonary Nodes Including
Involvement By Direct Extension Of The
Primary Tumor (N1)
Metastasis To Ipsilateral Mediastinal
And/or Subcarinal Lymph Node(s) (N2)
Metastasis To Contralateral Mediastinal,
Contralateral Hilar, Ipsilateral Or
Contralateral Scalene, Or
Supraclavicular Lymph Node(s) (N3)
Regional Lymph Nodes Cannot Be
Assessed (NX)
M Stage, Clinical
No Distant Metastasis (M0)
Distant Metastasis Present (M1)
Distant Metastasis Cannot Be Assessed
(MX)
Footer
Completed by (Last name, First name)
Date Form Originally Completed
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Lung Cancer NCT00693992 On-Study - CALGB: 30607 Respiratory On-
Study Form - 2663922v1.0
Lung Cancer NCT00499330 On-Study -
CALGB: 140503 On-Study Form - 2537927v1.0
CALGB: 140503 On-Study Form
Comparison of Different Types of Surgery in Treating
Patients With Stage IA Non-Small Cell Lung Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=218D3F85-
A366-6278-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/8081
CALGB: 140503 On-Study Form
Ccrr Module For Calgb 90202: Skeletal
Survey Form
CALGB Form (C-1244)
CALGB Study No.
CALGB Patient ID
Are data amended
Yes
No
Patient Initials (Last, First Middle)
Patient Hospital No.
Institution/Affiliate
Participating Group
Participating Group Study No.
Participating Group Patient ID
Vital Status
ECOG Performance Status (Mark one with an X.)
Fully Active, Able To Carry On All Pre-
disease Performance Without
Restriction. (0)
Restricted In Physically Strenuous
Activity But Ambulatory And Able To
Carry Out Work Of A Light Or Sedentary
Nature, E.g., Light Housework, Office
Work. (1)
Ambulatory And Capable Of All Selfcare
But Unable To Carry Out Any Work
Activities. Up And About More Than 50%
Of Waking Hours. (2)
Prior Treatment? (for this cancer)
1 / 3
Yes
No
Has the patient had a prior malignancy within the
past 5 years (other than non-melanoma skin
cancer or superficial bladder cancer)
Yes
No
Tumor Location Area
Lingula (Lingula)
Lower Lobe (left) (Lower Lobe (left))
Lower Lobe (right) (Lower Lobe (right))
Middle Lobe (right) (Middle Lobe (right))
Upper Lobe (left) (Upper Lobe (left))
Upper Lobe (right) (Upper Lobe (right))
Tumor Location, Zone (in lobe)
Predominantly Central (Predominantly
central)
Predominantly Peripheral (Predominantly
peripheral)
Is necrosis present? (by presence of a low-
attenuation component on CT)
Yes
No
Was a pre-operative needle biopsy performed
Yes
No
Date of biopsy
Histology
Adenocarcinoma (Adenocarcinoma)
Benign Mass (Benign mass)
Carcinoid (Carcinoid)
Non-small Cell Lung Cancer (nsclc), Nos
(Non-small cell lung cancer NOS)
Other (Other specify)
Squamous Cell Carcinoma (Squamous
cell carcinoma)
Unknown (Unknown)
Other specify
MedDRA disease code
Unnamed2
Date of Pulmonary Function Test
Forced Expiratory Volume 1 (%Predicted FEV1)
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Lung Cancer NCT00499330 On-Study - CALGB: 140503 On-Study Form
- 2537927v1.0
Forced Vital Capacity (% predicted) (FVC)
Forced Expiratory Volume 1 (FEV1) (Observed)
Forced Vital Capacity (FVC) (Observed)
Unnamed3
Smoking History
Currently Smoking (Currently smoking)
Never Smoked (Never smoked)
Smoked In The Past (Smoked in the
past)
Number pack years smoked (Pack year = number
of packs smoked / day x number of years
smoked)
Assigned Treatment Arm
Lobectomy (Lobectomy)
Patient Not Randomized (Patient not
randomized)
Wedge Resection (Wedge resection)
Patient not randomized, specify reason
Benign (Benign Mass)
Carcinoid Tumor (Carcinoid)
Other (Other)
Positive Lymph Node (Positive Nodes
(pre- or intra-operatively))
Other, specify
Footer
Completed by (Last name, First name)
Date Form Originally Completed
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Lung Cancer NCT00499330 On-Study - CALGB: 140503 On-Study Form
- 2537927v1.0
Lung Cancer NCT01041781 On-Study - CALGB:
30801 Respiratory On-Study Form - 2891327v1.0
CALGB: 30801 Respiratory On-Study Form
Gemcitabine Hydrochloride or Pemetrexed Disodium and
Carboplatin With or Without Celecoxib in Treating Patients
With Advanced Non-Small Cell Lung Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=6AF26CA3-
DD74-EEE0-E040-BB89AD436D54
All rights reserved. Please visit https://medical-data-
models.org/forms/8082
CALGB: 30801 Respiratory On-
Study Form
Ccrr Module For Calgb 90202: Skeletal
Survey Form
CALGB Form
CALGB Study No.
CALGB Patient ID
Treatment Begin Date (MM DD YYYY)
Are data amended
Yes
No
Patient Initials (Last, First Middle)
Patient Hospital No.
Institution/Affiliate
Participating Group
Participating Group Study No.
Participating Group Patient ID
Disease Status
MedDRA Code (disease)
Histologic Type (Mark one with an X.)
Adenocarcinoma (Adenocarcinoma)
Bronchoalveolar (bac) (Bronchoalveolar
carcinoma (BAC))
Large Cell Carcinoma (Large cell
carcinoma)
Other (Other specify)
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Squamous Cell Carcinoma (Squamous
cell carcinoma)
Other specify
Medical History (Does the patient have any of the
following)
Active Ulcer Disease (Active ulcer
disease)
Known Hypersensitivity To Aspirin, Nsaid
Or Sulfonamides (Known hypersensitivity
to aspirin, NSAID or sulfonamides)
Prior Treatment With Other
Investigational Therapy (Prior treatment
with other investigational therapy)
Untreated Cns Metastases (Untreated
CNS metastases)
Using Current Regimen Of Another
Nsaid (Using current regimen of another
NSAID)
Smoking History (Mark one with an X.)
Currently Smoking (Currently smoking)
Never Smoked (Never smoked)
Smoked In The Past (Smoked in the
past)
Number pack years smoked (If former or current
smoker Pack year = number of packs
smoked/day x number of years smoked)
Vital Status
Performance Status (Mark one with an X.)
Fully Active, Able To Carry On All Pre-
disease Performance Without
Restriction. (0)
Restricted In Physically Strenuous
Activity But Ambulatory And Able To
Carry Out Work Of A Light Or Sedentary
Nature, E.g., Light Housework, Office
Work. (1)
Ambulatory And Capable Of All Selfcare
But Unable To Carry Out Any Work
Activities. Up And About More Than 50%
Of Waking Hours. (2)
Prior Therapy
Prior radiation therapy
Yes
No
Prior radiation therapy stop date (MM DD YYYY)
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Lung Cancer NCT01041781 On-Study - CALGB: 30801 Respiratory On-
Study Form - 2891327v1.0
Prior chemotherapy, immunotherapy or systemic
treatment for NSCLC
Yes
No
Prior Surgery
Yes
No
Date of prior surgery (MM DD YYYY)
Stage (Indicate extent of disease prior to surgery
Mark one with an X.)
I (I)
Ii (II)
Iiia (IIIA)
Iiib (IIIB)
Iv (IV)
Stage (Indicate extent of disease prior to surgery
Mark one with an X.)
I (I)
Ii (II)
Iiia (IIIA)
Iiib (IIIB)
Iv (IV)
Prior steroid therapy for CNS metastases
Yes
No
Steroid Therapy End Date (MM DD YYYY)
Lab Data At Protocol Entry
WBC (10^3/microL)
Granulocytes (%)
ANC (10^3/microL)
Platelet count (10^3/microL)
Estimated creatinine clearance (calculated
ml/min)
Bilirubin (mg/dL)
SGOT (AST) (U/L)
SGOT (AST) ULN (U/L)
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Lung Cancer NCT01041781 On-Study - CALGB: 30801 Respiratory On-
Study Form - 2891327v1.0
SGPT (ALT) (U/L)
SGPT (ALT) ULN (U/L)
Albumin (g/dL)
Tnm Staging
Clinical T Stage (Mark one with an X.)
No Evidence Of Primary Tumor (T0)
Tumor 3 Cm Or Less In Greatest
Dimension, Surrounded By Lung Or
Visceral Pleura, Invasion More Proximal
Than The Lobar Bronchus, (i.e., Not In
The Main Bronchus) (T1)
Tumor With Any Of The Following
Features Of Size Or Extent: More Than
3cm In Greatest Dimension; Invades The
Visceral Pleura; Associated With
Atelectasis Or Obstructive Pneumonitis
That Extends To The Hilar Region But
Does Not Involve The Entire Lung (T2)
Tumor Of Any Size That Directly Invades
Any Of The Following: Chest Wall
(including Superior Sulcus Tumors),
Diaphragm, Mediastinal Pleura, Parietal
Pericardium; Or Tumor In The Main
Bronchus Less Than 2 Cm Distal To The
Carina, But Without Involvement O* (T3)
Tumor Of Any Size That Directly Invades
Any Of The Following: Chest Wall
(including Superior Sulcus Tumors),
Diaphragm, Mediastinal Pleura, Parietal
Pericardium; Or Tumor In The Main
Bronchus Less Than 2 Cm Distal To The
Carina, But Without Involvement O* (T4)
Carcinoma In Situ (Tis)
Primary Tumor Cannot Be Assessed, Or
Tumor Proven By The Presence Of
Malignant Cells In Sputum Or Bronchial
Washings But Not Visualized By Imaging
Or Bronchoscopy (Tx)
Clinical N Stage (Mark one with an X.)
No Regional Lymph Node Metastasis
(N0)
Metastasis To Ipsilateral Peribronchial
And/or Ipsilateral Hilar Lymph Nodes,
And Intrapulmonary Nodes Including
Involvement By Direct Extension Of The
Primary Tumor (N1)
Metastasis To Ipsilateral Mediastinal
And/or Subcarinal Lymph Node(s) (N2)
Metastasis To Contralateral Mediastinal,
Contralateral Hilar, Ipsilateral Or
Contralateral Scalene, Or
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Lung Cancer NCT01041781 On-Study - CALGB: 30801 Respiratory On-
Study Form - 2891327v1.0
Supraclavicular Lymph Node(s) (N3)
Regional Lymph Nodes Cannot Be
Assessed (NX)
Clinical M Stage (Mark one with an X.)
No Distant Metastasis (M0)
Distant Metastasis Present (M1)
Distant Metastasis Cannot Be Assessed
(MX)
Footer
Completed by (Last name, First name)
Date Form Completed (MM DD YYYY)
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Lung Cancer NCT01041781 On-Study - CALGB: 30801 Respiratory On-
Study Form - 2891327v1.0
Bladder Cancer NCT00014534 Follow-Up - CALGB:
90104 New Primary Cancer Form - 2169482v3.0
CALGB: 90104 New Primary Cancer Form
Combination Chemotherapy in Treating Patients With
Bladder Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=BE1B57B8-
FFB5-70FA-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/8083
CALGB: 90104 New Primary Cancer
Form
Ccrr Module For Calgb: 90104 New
Primary Cancer Form
CALGB Form
CALGB Study No
CALGB Patient ID
Are data amended?
Yes (Yes)
Patient's Initials
Patient Hospital No.
Institution/Affiliate
Participating Group
Participating Group Protocol No.
Participating Group Patient ID
Site(s) of new primary
New primary, histologic type
date of diagnosis
Comments
Completed by
date form completed
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Bladder Cancer NCT00014534 Pathology - CALGB:
90104 Tracking Form (Tissue Blocks) - 2169446v3.0
CALGB: 90104 Tracking Form (Tissue Blocks)
Combination Chemotherapy in Treating Patients With
Bladder Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=BE1B5174-
9296-70EF-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/8086
CALGB: 90104 Tracking Form
(Tissue Blocks)
Ccrr Module For Calgb: 90104 Tracking
Form (tissue Blocks)
CALGB Form
CALGB Study No
CALGB Patient ID
Are data amended?
Yes (Yes)
Patient Initials
Patient Medical Record Number
Institution/Affiliate
Participating Group
Participating Group Protocol Number
Participating Group Patient ID
Do tissue block/slides accompany this form?
If no, specify reason (no blocks)
Surgical procedure date
Date blocks and pathology reports submitted
Tissue pathology
Lymph Node (Lymph node metastasis)
Primary Tumor (Primary tumor)
Method of extraction
Sample Or Specimen Collected Via
Biopsy (biopsy)
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cystectomy (cystectomy)
pelvic lymph (pelvic lymph)
pathology/accession number
submitted by
phone numer
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Bladder Cancer NCT00014534 Pathology - CALGB: 90104 Tracking
Form (Tissue Blocks) - 2169446v3.0
Bladder Cancer NCT00942331 Lab - CALGB 90601
Plasma/Serum Specimen Submission Form - 2849064v1.0
CALGB 90601 Plasma/Serum Specimen Submission Form
Gemcitabine Hydrochloride and Cisplatin With or Without
Bevacizumab in Treating Patients With Advanced Urinary
Tract Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=65402ABE-
C3B7-902C-E040-BB89AD435D5A
All rights reserved. Please visit https://medical-data-
models.org/forms/8088
CALGB 90601 Plasma/Serum
Specimen Submission Form
Administrative documentation
CALGB Form*
CALGB Study No.*
CALGB Patient ID*
Are data amended*
Yes
No
Patient Initials (Last, First, Middle)*
Patient Hospital No.*
Institution/Affiliate*
Participating Group*
Participating Group Study No.*
Participating Group Patient ID*
To Be Completed By Submitting Institution
Does specimen accompany this form*
Specify reason*
Institution Error (Institution error)
Other (Other)
Patient Refusal (Patient refusal)
Sample Lost Or Destroyed (Sample lost
or destroyed)
LabTrak shipment ID*
Specimen Type*
Citrated Plasma (Citrated plasma)
Plasma (Plasma)
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Serum (Serum)
Whole Blood (Whole blood)
Time Specimen Collected (24-hour clock)*
Date specimen collected (MM DD YYYY)*
Date shipped (MM DD YYYY)*
Sample period (^1 For sample period, enter the
cycle number completed prior to specimen
collection or scheduled collection if specimen no
obtained; or enter "0" for pre-study.)*
Number of tubes submitted*
Approximate volume of sample (ml)*
Responsible CRA*
CRA phone number*
CRA email*
2 / 2
Bladder Cancer NCT00942331 Lab - CALGB 90601 Plasma/Serum
Specimen Submission Form - 2849064v1.0
Colorectal Cancer NCT00077233 Pathology -
CALGB: 80203 Blook Tracking Form - 2078840v3.0
CALGB: 80203 Blook Tracking Form
Fluorouracil and Leucovorin Plus Either Irinotecan or
Oxaliplatin With or Without Cetuximab in Treating Patients
With Previously Untreated Metastatic Adenocarcinoma of
the Colon or Rectum
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=B4C3B265-
93E2-0730-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/8089
CALGB: 80203 Blook Tracking Form
To Be Completed By Institution
Does specimen accompany this form?
Yes
No
If no, specify reason (no specimen)
Date sample collected
Time sample collected
Number of tubes of whole blood submitted with
this form
Sample time point
1-pre-study (pre-study)
Submitted by
Date sample received
Sample ID no.
Sample Condition
clotted (clotted)
Damaged Or Unusable (damaged)
Insufficient Amount (insufficient amount)
No Specimen Received (missing)
Useable (Okay)
thawed (thawed)
Is sample evaluable for analysis?
No, Procedural Deviations Definitely
Affect Analysis (no, procedural deviates
definitely affect analysis)
Unsure, Procedural Deviations May
Affect Analysis (Unsure, procedural
deviations may affect analysis)
Yes, Sample Is Evaluable (Yes, sample is
evaluable)
Received by
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Phone number
Phone number
Comments
Ccrr Module For Calgb: 80203 Blook
Tracking Form
CALGB Form
CALGB Study No.
CALGB Patient ID
Date form submitted
Are data amended?
Yes
No
Patient Initials
Patient Hospital No.
Institution/Affiliate
Participating Group
Participating Group Protocol No.
Participating Group Patient ID
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Colorectal Cancer NCT00077233 Pathology - CALGB: 80203 Blook
Tracking Form - 2078840v3.0
Colorectal Cancer NCT00077233 Pathology - CALGB:
80203 Blood and Serum Submission Form - 2101445v3.0
CALGB: 80203 Blood and Serum Submission Form
Fluorouracil and Leucovorin Plus Either Irinotecan or
Oxaliplatin With or Without Cetuximab in Treating Patients
With Previously Untreated Metastatic Adenocarcinoma of
the Colon or Rectum
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=BB6E5A8F-
59CF-4370-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/8090
CALGB: 80203 Blood and Serum
Submission Form
To Be Completed By Institution
Number of tubes of serum submitted with this
form
Sample type
serum (serum)
Whole blood (Whole blood)
Does specimen accompany this form?
Yes
No
Specify reason (specimen does not accompany
form)
institution error (institution error)
other (other)
patient refusal (patient refusal)
sample lost of destroyed (sample lost of
destroyed)
Sample time point
1-pre-study (pre-study)
number of tubes of whole blood submitted with
this form
Submitted by
Phone number
Ccrr Module For Calgb: 80203 Blood And
Serum Submission Form
CALGB Form
CALGB Study No.
CALGB Patient ID
Date form submitted
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Are data amended?
Yes
No
Patient Initials
Patient Hospital No.
Institution/Affiliate
Participating Group
Participating Group Protocol No.
Participating Group Patient ID
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Colorectal Cancer NCT00077233 Pathology - CALGB: 80203 Blood and
Serum Submission Form - 2101445v3.0
Esophageal Cancer NCT00655876 Treatment - T1: Radiation Therapy
Oncology Group Phase III Esophagus Radiotherapy Form - 2602016v1.0
T1: Radiation Therapy Oncology Group Phase III
Esophagus Radiotherapy Form
Paclitaxel, Cisplatin, and Radiation Therapy With or Without
Cetuximab in Treating Patients With Locally Advanced
Esophageal Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=2A160E28-
BC2A-4E10-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/8112
T1: Radiation Therapy Oncology
Group Phase III Esophagus
Radiotherapy Form
Module 1
RTOG Study No.
Case #
Institution Name
Institution No.
Patient Initials
RTOG Patient ID
AMENDED DATA
Yes
No
RADIATION THERAPY START DATE
RADIATION THERAPY END DATE
ELAPSED DAYS
RT Total Fraction Count
RT Total Dose  (Gy)
WERE THERE ANY UNSCHEDULED
INTERRUPTIONS IN RADIATION THERAPY?
No (No)
Yes, Due To Other Reason (Yes, due to
other reason)
Yes, Due To Toxicity (Yes, due to toxicity)
Specify RT interruption reason
Reason Treatment Ended
1 / 2
Adverse Event/side Effects/complications
(Adverse Event/Side
Effects/Complications)
Alternative Therapy (Alternative therapy)
Death On Study (Death on study)
Disease Progression, Relapse During
Active Treatment (Disease progression,
relapse during active treatment)
Other (Other)
Patient Off-treatment For Other
Complicating Disease (Patient off-
treatment for other complicating disease)
Patient Withdrawal Or Refusal After
Beginning Protocol Therapy (Patient
withdrawal/refusal after beginning
protocol therapy)
Patient Withdrawal Or Refusal Before
Beginning Protocol Therapy (Patient
withdrawal/refusal prior to beginning
protocol therapy)
Treatment Completed Per Protocol
Criteria (Treatment completed per
protocol criteria)
Alternative Therapy
Other specify
Comments
Person Completing Form
Date form originally completed
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Esophageal Cancer NCT00655876 Treatment - T1: Radiation Therapy
Oncology Group Phase III Esophagus Radiotherapy Form - 2602016v1.0
Esophageal Cancer NCT00655876 Treatment - F2: Radiation Therapy Oncology
Group Phase III Esophagus Post Treatment Response Form - 2606191v1.0
F2: Radiation Therapy Oncology Group Phase III
Esophagus Post Treatment Response Form
Paclitaxel, Cisplatin, and Radiation Therapy With or Without
Cetuximab in Treating Patients With Locally Advanced
Esophageal Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=2AF0C0C5-
AC6E-474E-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/8113
F2: Radiation Therapy Oncology
Group Phase III Esophagus Post
Treatment Response Form
Module 1
RTOG Study No.
Case #
Institution Name
Institution No.
Patient Initials
RTOG Patient ID
AMENDED DATA
Yes
No
Header
Reason evaluation not done (If not evaluated,)
Death (Death)
Md Preference (MD Preference)
Other (Other)
Patient Refusal (Patient refusal)
Specify
Date of endoscopy
Clinical disease status
Complete Remission (Complete clinical
response)
No Evaluation Done (No evaluation
done)
Residual Disease (Residual disease or
suspicion of residual disease)
Was biopsy performed
Yes
No
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Reason biopsy not done (If not biopsied,)
Death (Death)
Not Required Per Protocol (Not required
per protocol)
Other (Other)
Patient Refusal (Patient refusal)
Specify
Biopsy Result
Negative (negative)
Positive (positive)
Footer Module
Comments
Person Completing Form (The reported case
report form information has been reviewed and
confirmed by the principal Investigator.)
Form Completion Date, Original
2 / 2
Esophageal Cancer NCT00655876 Treatment - F2: Radiation Therapy Oncology
Group Phase III Esophagus Post Treatment Response Form - 2606191v1.0
Head and Neck Cancer NCT00113399 Follow-Up - Radiation Therapy Oncology
Group Follow-up Form Phase III Recurrent Head and Neck Study Follow-up Form -
2299564v3.0
Radiation Therapy Oncology Group Follow-up Form Phase
III Recurrent Head and Neck Study Follow-up Form
Combination Chemotherapy With or Without Radiation
Therapy in Treating Patients With Recurrent Head and
Neck Cancer That Cannot Be Removed By Surgery
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=EB74C29B-
D3BF-298D-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/8119
Radiation Therapy Oncology Group
Follow-up Form Phase III Recurrent
Head and Neck Study Follow-up
Form
Header
RTOG Study
Case #
Institution Name
Institution No.
Patient Initials
Patient Study No.
Amended data
Yes
No
PATIENT'S VITAL STATUS
Alive (Alive)
Dead (Dead)
DATE LAST CONTACT OR DEATH
PRIMARY CAUSE OF DEATH
Due To Other Cause (Due to other
cause)
Due To Protocol Treatment (Due to
protocol treatment)
Due To Second Primary Or Other
Malignancy (Due to second primary or
other malignancy)
Due To This Disease (Due to this
disease)
Unknown (Unknown)
PERFORMANCE STATUS HAS THE PATIENT
HAD A DOCUMENTED CLINICAL
ASSESSMENT FOR THIS CANCER SINCE
SUBMISSION OF THE PREVIOUS FOLLOW-UP
1 / 5
FORM? (ZUBROD)
No (No)
Unknown (Unknown)
Yes (Yes)
DATE OF LAST CLINICAL ASSESSMENT
HAS THE PATIENT BEEN DIAGNOSED WITH
FIRST LOCAL RECURRENCE OR
PROGRESSION (SINCE SUBMISSION OF THE
PREVIOUS FOLLOW-UP FORM)
No (No)
Not Applicable, Patient Has Not Been
Assessed (Not applicable, patient has
not been assessed)
Unknown (Unknown)
Yes (Yes)
DATE OF FIRST LOCAL PROGRESSION
HAS THE PATIENT BEEN DIAGNOSED WITH
FIRST REGIONAL RECURRENCE OR
PROGRESSION (SINCE SUBMISSION OF THE
PREVIOUS FOLLOW-UP FORM)
No (No)
Not Applicable, Patient Has Not Been
Assessed (Not applicable, patient has
not been assessed)
Unknown (Unknown)
Yes (Yes)
DATE OF FIRST REGIONAL PROGRESSION
HAS THE PATIENT BEEN DIAGNOSED WITH
FIRST DISTANT RECURRENCE OR
PROGRESSION (SINCE SUBMISSION OF THE
PREVIOUS FOLLOW-UP FORM)
No (No)
Not Applicable, Patient Has Not Been
Assessed (Not applicable, patient has
not been assessed)
Unknown (Unknown)
Yes (Yes)
DATE OF FIRST DISTANT PROGRESSION
SITE(S) OF DISTANT PROGRESSION (USE
CODETABLE FROM Q8)
Aml/mds (AML/MDS*)
Bcc (BCC)
Bladder (Bladder)
Brain (Brain)
Colorectal (Colorectal)
Esophageal (Esophageal)
Gastric (Gastric)
Hypopharynx (Hypopharynx)
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Head and Neck Cancer NCT00113399 Follow-Up - Radiation Therapy Oncology
Group Follow-up Form Phase III Recurrent Head and Neck Study Follow-up Form -
2299564v3.0
Larynx (Larynx)
Liver (Liver)
Lung (Lung)
Melanoma (Melanoma)
Nasopharynx (Nasopharynx)
Nhl (NHL)
None (None)
Oral Cavity (Oral cavity)
Oropharynx (Oropharynx)
Other H + N (Other H + N)
Other Hematologic (Other Hematologic)
Other Solid (Other solid)
Pancreatic (Pancreatic)
Prostate (Prostate)
Renal (Renal)
Squamous-skin (Squamous-Skin)
Unknown Primary (Unknown primary)
Other Hematologic,specify
Other solid, specify
HAS A NEW PRIMARY CANCER OR MDS
BEEN DIAGNOSED (MYELODYSPLASTIC
SYNDROME SINCE SUBMISSION OF THE
PREVIOUS FOLLOW-UP FORM?)
No (No)
Not Applicable, Patient Has Not Been
Assessed (Not applicable, patient has
not been assessed)
Unknown (Unknown)
Yes (Yes)
DATE OF DIAGNOSIS
SITE(S) OF NEW PRIMARY (USE CODETABLE
BELOW)
Aml/mds (AML/MDS*)
Bcc (BCC)
Bladder (Bladder)
Brain (Brain)
Colorectal (Colorectal)
Esophageal (Esophageal)
Gastric (Gastric)
Hypopharynx (Hypopharynx)
Larynx (Larynx)
Liver (Liver)
Lung (Lung)
Melanoma (Melanoma)
Nasopharynx (Nasopharynx)
Nhl (NHL)
None (None)
Oral Cavity (Oral cavity)
Oropharynx (Oropharynx)
Other H + N (Other H + N)
Other Hematologic (Other Hematologic)
Other Solid (Other solid)
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Pancreatic (Pancreatic)
Prostate (Prostate)
Renal (Renal)
Squamous-skin (Squamous-Skin)
Unknown Primary (Unknown primary)
Other Hematologic,specify
Other solid, specify
NON-PROTOCOL SURGERY
No (No)
Unknown (Unknown)
Yes (Yes)
NON-PROTOCOL CHEMOTHERAPY
No (No)
Unknown (Unknown)
Yes (Yes)
NON-PROTOCOL BIOLOGIC THERAPY
No (No)
Unknown (Unknown)
Yes (Yes)
NON-PROTOCOL RADIATION THERAPY
No (No)
Unknown (Unknown)
Yes (Yes)
NON-PROTOCOL RT START DATE
OTHER NON-PROTOCOL THERAPY
No (No)
Unknown (Unknown)
Yes (Yes)
NEW OR CONTINUING ADVERSE EVENTS?
Yes
No
DOES THE PATIENT CURRENTLY HAVE
SWALLOWING PROBLEMS?
No (No)
Unknown (Unknown)
Yes (Yes)
IF YES, HOW LONG HAVE SWALLOWING
PROBLEMS BEEN PRESENT?
1 To <7 Months (1 to <7 months)
13 To <19 Months (13 to <19 months)
19 To <24 Months (19 to <24 months)
2 Years Or Longer (2 years or longer)
7 To <13 Months (7 to <13 months)
Less Than 1 Month (Less than 1 month)
Unknown (Unknown)
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Head and Neck Cancer NCT00113399 Follow-Up - Radiation Therapy Oncology
Group Follow-up Form Phase III Recurrent Head and Neck Study Follow-up Form -
2299564v3.0
DOES THE PATIENT CURRENTLY REQUIRE
TUBE FEEDING?
No (No)
Unknown (Unknown)
Yes (Yes)
IS PATIENT DEPENDENT ON TUBE FEEDING
FOR >50% OF NUTRITIONAL SUPPORT? (If
yes,)
No (No)
Unknown (Unknown)
Yes (Yes)
WAS A FEEDING TUBE INSERTED DURING
THIS REPORTING PERIOD? (including CTCAE
event dysphagia >= grade 3)
No (No)
Unknown (Unknown)
Yes (Yes)
WAS A FEEDING TUBE DISCONTINUED
DURING THIS REPORTING PERIOD?
No (No)
Unknown (Unknown)
Yes (Yes)
DATE FEEDING TUBE DISCONTINUED (IF
YES,)
WAS A TRACHEOSTOMY PERFORMED
DURING THIS REPORTING PERIOD? (e.g., for
breathing difficulty)
No (No)
Unknown (Unknown)
Yes (Yes)
WAS USE OF A TRACHEOSTOMY
DISCONTINUED DURING THIS REPORTING
PERIOD?
No (No)
Not Applicable (Unknown)
Yes (Yes)
DATE TRACHEOSTOMY WAS CLOSED (IF
YES,)
Comments
COMMENTS
Person completing form
Form completion date, original
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Head and Neck Cancer NCT00113399 Follow-Up - Radiation Therapy Oncology
Group Follow-up Form Phase III Recurrent Head and Neck Study Follow-up Form -
2299564v3.0
Head and Neck Cancer NCT00265941 Treatment -
RTOG-0522 T1: Radiotherapy Form - 2222762v1.0
RTOG-0522 T1: RadiotherapyForm
Radiation Therapy and Cisplatin With or Without Cetuximab
in Treating Patients With Stage III or Stage IV Head and
Neck Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=F6206E4A-
5744-3EFE-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/8123
RTOG-0522 T1: Radiotherapy Form
Module 1
RTOG Study No.
Case #
Institution Name
Institution No.
Patient Initials
RTOG Patient ID
AMENDED DATA
Yes
No
RADIATION THERAPY START DATE
RADIATION THERAPY END DATE
ELAPSED DAYS
RT Total Fraction Count
RT Total Dose  (Gy)
WERE THERE ANY UNSCHEDULED
INTERRUPTIONS IN RADIATION THERAPY?
No (No)
Yes, Due To Other Reason (Yes, due to
other reason)
Yes, Due To Toxicity (Yes, due to toxicity)
Specify RT interruption reason
Reason Treatment Ended
Adverse Event/side Effects/complications
(Adverse Event/Side
1 / 2
Effects/Complications)
Alternative Therapy (Alternative therapy)
Death On Study (Death on study)
Disease Progression, Relapse During
Active Treatment (Disease progression,
relapse during active treatment)
Other (Other)
Patient Off-treatment For Other
Complicating Disease (Patient off-
treatment for other complicating disease)
Patient Withdrawal Or Refusal After
Beginning Protocol Therapy (Patient
withdrawal/refusal after beginning
protocol therapy)
Patient Withdrawal Or Refusal Before
Beginning Protocol Therapy (Patient
withdrawal/refusal prior to beginning
protocol therapy)
Treatment Completed Per Protocol
Criteria (Treatment completed per
protocol criteria)
Alternative therapy, specify
Other complicating disease, specify
Other, specify
Type of Radiation Therapy Administered
3d Conformal (3D conformal)
Imrt (IMRT)
Comments
Signature of person completing this form
Date form originally completed
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Head and Neck Cancer NCT00265941 Treatment - RTOG-0522 T1:
Radiotherapy Form - 2222762v1.0
Head and Neck Cancer NCT01302834 Treatment - RTOG 1016 S1:  Radiation
Therapy Oncology Group Phase III Head a& Neck Cancer Surgery Form -
3183854v1.0
RTOG 1016 S1:  Radiation Therapy Oncology Group
Phase III Head a& Neck Cancer Surgery Form
Radiation Therapy With Cisplatin or Cetuximab in Treating
Patients With Oropharyngeal Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=9A132BA5-
915B-FFE2-E040-BB89AD43727A
All rights reserved. Please visit https://medical-data-
models.org/forms/8126
RTOG 1016 S1:  Radiation Therapy
Oncology Group Phase III Head a&
Neck Cancer Surgery Form
Unnamed Module 1
RTOG Study No.
Case #
Institution Name
Institution No.
Patient Initials
RTOG Patient ID
Amended Data
Yes
No
Module 2
Location of remaining disease
Location of remaining disease
Location of remaining disease
Primary Surgery Date
Primary Site (Pathologic Assessment)
No Tumor Demonstrable On Final
Pathology Specimen (No tumor
demonstrable on final pathology
specimen)
Not Operated (Not operated)
Tumor Present All Margins Clear On
Final Pathology Specimen (Tumor
present all margins clear on final
pathology specimen)
Tumor Present, Margin Involved On Final
1 / 4
Specimen (Tumor present margin
involved on final pathology specimen)
Unknown (Unknown)
Primary Site (Pathologic Assessment)
No Tumor Demonstrable On Final
Pathology Specimen (No tumor
demonstrable on final pathology
specimen)
Not Operated (Not operated)
Tumor Present All Margins Clear On
Final Pathology Specimen (Tumor
present all margins clear on final
pathology specimen)
Tumor Present, Margin Involved On Final
Specimen (Tumor present margin
involved on final pathology specimen)
Unknown (Unknown)
Nodal surgery
Bilateral Node Dissection (Bilateral node
dissection)
None (None)
Unilateral Lymph Node Dissection Left
(Unilateral node dissection (left))
Unilateral Lymph Node Dissection Right
(Unilateral node dissection (right))
Unknown (Unknown)
Neck nodal site right
Complete Resection Of All Gross Tumor
(Complete resection of all gross disease)
Incomplete/partial Resection Of Gross
Tumor (Incomplete/partial resection of
gross tumor)
Not Operated (Not operated)
Neck nodal site left
Complete Resection Of All Gross Tumor
(Complete resection of all gross disease)
Incomplete/partial Resection Of Gross
Tumor (Incomplete/partial resection of
gross tumor)
Not Operated (Not operated)
Nodal Surgery Date (Left)
Nodal Surgery Date (Left)
Neck Nodal Sites (pathologic
Assessment)
Location
Left - Level I (submandibular) (Left -
Level I (Submandibular))
Left - Level Ii (upper 1/3 Internal Jugular)
(Left - Level II (Upper 1/3 Internal
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Head and Neck Cancer NCT01302834 Treatment - RTOG 1016 S1:  Radiation
Therapy Oncology Group Phase III Head a& Neck Cancer Surgery Form -
3183854v1.0
Jugular))
Left - Level Iii (mid 1/3 Internal Jugular)
(Left - Level III (Mid 1/3 Internal Jugular))
Left - Level Iv (lower 1/3 Internal Jugular)
(Left - Level IV (Lower 1/3 Internal
Jugular))
Left - Level V (posterior Triangle) (Left -
Level V (Posterior Triangle))
Left - Other (Left - Other specify)
Right - Level I (submandibular) (Right -
Level I (Submandibular))
Right - Level Ii (upper 1/3 Internal
Jugular) (Right - Level II (Upper 1/3
Internal Jugular))
Right - Level Iii (mid 1/3 Internal Jugular)
(Right - Level III (Mid 1/3 Internal
Jugular))
Right - Level Iv (lower 1/3 Internal
Jugular) (Right - Level IV (Lower 1/3
Internal Jugular))
Right - Level V (posterior Triangle) (Right
- Level V (Posterior Triangle))
Right - Other (Right - Other specify)
Other specify (location)
Other specify (location)
Number of Positive Lymph Nodes
Number of Lymph Nodes Examined
Extracapsular Extension?
No (No)
Unknown (Unknown)
Yes (Yes)
Total Nodes Positive Right
Total Nodes Examined Right
Total Nodes Positive Left
Total Nodes Examined Left
Was tumor present in the soft tissue of the neck
without an identifiable lymph node present?
No (No)
Not Operated (Not operated)
Unknown (Unknown)
Yes (Yes)
Yes specify level
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Footer Module
Comments
Signature of Person Completing This Form
Form Completion Date, Original
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Therapy Oncology Group Phase III Head a& Neck Cancer Surgery Form -
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Lung Cancer NCT00113386 On-Study - RTOG-
0412 I1: Initial Evaluation Form - 2288131v3.0
RTOG-0412 I1: Initial Evaluation Form
Cisplatin and Docetaxel With or Without Radiation Therapy
in Treating Patients Who Are Undergoing Surgery for Newly
Diagnosed Stage III Non-Small Cell Lung Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=E489FECB-
49D8-0477-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/8135
RTOG-0412 I1: Initial Evaluation
Form
Module 1
RTOG Study 0412
Case #
Institution
Institution No.
Participant's Initials
Participant's I.D. No.
Amended Data (Instructions: Submit this form at
patient's entry on study. Dates are recorded mm-
dd-yyyy  unless otherwise specified.)
Yes
No
Pre-treatment Chacteristics
Performance Status (Zubrod)
Fully Active, Able To Carry On All Pre-
disease Performance Without Restriction
(karnofsky 90 - 100) (ecog - 0
Asymptomatic) (0)
Restricted In Physically Strenuous
Activity But Ambulatory (k70 - 80) (ecog -
1 Symptomatic - Fully Ambulatory) (1)
Ambulatory And Capable Of All Selfcare
But Unable To Carry Out Any Work
Activities (k 50 - 60) (ecog - 2
Symptomatic; In Bed , 50% Of The Day)
(2)
Capable Of Limited Selfcare, Confined
To Bed Or Chair More Than 50% Of
Waking Hours. (k 30 - 40) (ecog - 3
Symptomatic; In Bed > 50% Of The Day
But Not Bedridden) (3)
Completely Disabled (k10 - 20) (ecog - 4
Bedridden) (4)
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Weight loss in previous 6 Months (%)
Forced Expiratory Volume (FEV1) (L/SEC) (OR,
IF APPLICABLE)
Predicted Postresection FEV1 based on
Quantitative V/Q Scan (L/SEC)
PRIOR RADIATION THERAPY
Yes
No
PRIOR CHEMOTHERAPY
Yes
No
T STAGE (T1-3)
N STAGE (N2)
M STAGE (MO)
HISTOLOGIC TYPE
Adenocarcinoma (Adenocarcinoma)
Bronchoalveolar (bac) (Bronchoalveolar
carcinoma)
Large Cell Undifferentiated (Large cell
undifferentiated)
Non-small Cell Lung Cancer (nsclc), Nos
(Non-small cell, nos)
Squamous Cell Carcinoma (Squamous
cell carcinoma)
Lymph Node Assessment
CLINICAL (Lymph Node Assessment)
Equivocal (Equivocal)
Negative (Negative)
Not Evaluated (Not evaluated)
Positive (Positive)
Unknown (Unknown)
PATHOLOGIC (Lymph Node Assessment)
Equivocal (Equivocal)
Negative (Negative)
Not Evaluated (Not evaluated)
Positive (Positive)
Unknown (Unknown)
UNNAMED Question to Add
Highest Mediastinal Node (Highest
mediastinal (1))
Interlobar Node (Interlobar (11))
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Left Hilar Node (Left hilar (10L))
Left Lobar Node (Left lobar (12L))
Left Lower Paratracheal Node (Left lower
paratracheal (4L))
Left Segmental Node (Left segmental
(13L))
Left Subsegmental Node (Left
subsegmental (14L))
Left Upper Paratracheal Node (Left
upper paratracheal (2L))
Para-aortic Node (Para-aortic (6))
Paraesophageal (Paraesophageal (8))
Pre- And Retro Paratracheal Node (Pre
and retro paratracheal (3))
Pulmonary Ligament (Pulmonary
ligament (9))
Right Hilar Node (Right hilar (10R))
Right Lobar Node (Right lobar (12R))
Right Lower Paratracheal Node (Right
lower paratracheal (4R))
Right Segmental Node (Right segmental
(13R))
Right Subsegmental Node (Right
subsegmental (14R))
Right Upper Paratracheal Node (Right
upper paratracheal (2R))
Subaortic Node (Subaortic (5))
Subcarinal Node (Subcarinal (7))
Comments
Name of person completing form
Form completion date, original
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Lung Cancer NCT00096265 Quality of Life - QF
RTOG Phase III-Multiple Brain Mets - 2277089v3.0
QF RTOG Phase III-Multiple Brain Mets
Radiation Therapy and Stereotactic Radiosurgery With or
Without Temozolomide or Erlotinib in Treating Patients With
Brain Metastases Secondary to Non-Small Cell Lung
Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=D7FA4A0B-
63F5-6417-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/8136
QF RTOG Phase III-Multiple Brain
Mets
Header
[RTOG Study No.]
RTOG Study 0320 (RTOG Study 0320)
Case #
Institution
Institution No.
Participant's Initials
Participant's I.D. No.
Date Form Completed
Module 1
Mobility (Please circle one statement in each
group below which best describes your health
today.)
I Am Confined To Bed (I am confined to
bed)
I Have No Problems In Walking About (I
have no problems in walking about)
I Have Some Problems In Walking About
(I have some problems in walking about)
Self-Care (Please circle one statement in each
group below which best describes your health
today.)
I Am Unable To Wash Or Dress Myself (I
am unable to wash or dress myself)
I Have No Problems With Self-care (I
have no problems with self-care)
I Have Some Problems Washing Or
Dressing Myself (I have some problems
washing or dressing myself)
Usual Activities (Please circle one statement in
each group below which best describes your
health today.)
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I Am Unable To Perform My Usual
Activities (I am unable to perform my
usual activities)
I Have No Problems With Performing My
Usual Activities (I have no problems with
performing my usual activities)
I Have Some Problems With Performing
My Usual Activities (I have some
problems with performing my usual
activities)
Pain/Discomfort (Please circle one statement in
each group below which best describes your
health today.)
I Have Extreme Pain Or Discomfort (I
have extreme pain or discomfort)
I Have Moderate Pain Or Discomfort (I
have moderate pain or discomfort)
I Have No Pain Or Discomfort (I have no
pain or discomfort)
Anxiety/Depression (Please circle one statement
in each group below which best describes your
health today.)
I Am Extremely Anxious Or Depressed (I
am extremely anxious or depressed)
I Am Moderately Anxious Or Depressed
(I am moderately anxious or depressed)
I Am Not Anxious Or Depressed (I am
not anxious or depressed)
Module 2
Your own health state today
Patient's signature
Date
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Lung Cancer NCT00096265 Quality of Life - QF RTOG Phase III-Multiple
Brain Mets - 2277089v3.0
Lung Cancer NCT00113386 Treatment - RTOG-0412
T1: Radiotherapy Summary Form - 2293318v3.0
RTOG-0412 T1: Radiotherapy Summary Form
Cisplatin and Docetaxel With or Without Radiation Therapy
in Treating Patients Who Are Undergoing Surgery for Newly
Diagnosed Stage III Non-Small Cell Lung Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=E4C16844-
9A5B-4CEC-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/8138
RTOG-0412 T1: Radiotherapy
Summary Form
Module 1
RTOG Study 0412
Case #
Institution
Institution No.
Participant's Initials
Participant's I.D. No.
AMENDED DATA
Yes
No
RADIATION THERAPY START DATE
RADIATION THERAPY END DATE
ELAPSED DAYS
TOTAL FRACTIONS
TOTAL DOSE   (Gy)
WERE THERE ANY UNSCHEDULED
INTERRUPTIONS IN RADIATION THERAPY?
No (No)
Yes, Due To Other Reason (Yes, due to
other reason)
Yes, Due To Toxicity (Yes, due to toxicity)
Specify RT interruption reason
REASON RADIATION THERAPY TREATMENT
ENDED
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Alternative Therapy (Alternative therapy)
Death On Study (Death on study)
Disease Progression, Relapse During
Active Treatment (Disease progression,
relapse during active treatment)
Other (Other)
Other Complicating Disease (Other
complicating disease)
Patient Withdrawal Or Refusal After
Beginning Protocol Therapy (Patient
withdrawal or refusal after beginning
protocol therapy)
Patient Withdrawal Or Refusal Prior To
Beginning Protocol Therapy (Patient
withdrawal or refusal prior to beginning
protocol therapy)
Toxicity/side Effects/complications
(Toxicity/side effects/complications)
Treatment Completed Per Protocol
Criteria (Treatment completed per
protocol criteria)
Alternative therapy, specify
Other complicating disease, specify
Other, specify
NEW OR CONTINUING ADVERSE EVENTS?
(IF PATIENT EXERIENCED ANY TREATMENT
RELATED ADVERSE EVENTS DURING THIS
REPORT PERIOD, SUBMIT ADVERSE EVENT
FORM AE)
Yes
No
Comments
Signature of person completing form
Date form completed, original
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Lung Cancer NCT00113386 Treatment - RTOG-0412 T1: Radiotherapy
Summary Form - 2293318v3.0
Lung Cancer NCT00533949 Quality of Life - DP: Radiation Therapy Oncology
Group Phase III Lung High-dose vs Standard-dose Conformal XRT with
Chemotherapy Patient Swallowing Diary - 2676246v1.0
DP: Radiation Therapy Oncology Group Phase III Lung
High-dose vs Standard-dose Conformal XRT with
Chemotherapy Patient Swallowing Diary
High-Dose or Standard-Dose Radiation Therapy and
Chemotherapy With or Without Cetuximab in Treating
Patients With Newly Diagnosed Stage III Non-Small Cell
Lung Cancer That Cannot Be Removed by Surgery
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=38F09A37-
5AFD-12D5-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/8141
DP: Radiation Therapy Oncology
Group Phase III Lung High-dose vs
Standard-dose Conformal XRT with
Chemotherapy Patient Swallowing
Diary
Header
RTOG Study No.
Case #
Institution Name
Institution No.
Patient Initials
RTOG Patient ID
Pretreatment
Date
Have you had any problems swallowing today?
Can Swallow Solids With Some Difficulty
(Can swallow solids with some difficulty)
Cannot Swallow Liquids (Cannot swallow
liquids)
Cannot Swallow Solids (Cannot swallow
solids)
Mild Soreness Only (Mild soreness only)
None (None)
Comments
Pretreatment
Date
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Have you had any problems swallowing today?
Can Swallow Solids With Some Difficulty
(Can swallow solids with some difficulty)
Cannot Swallow Liquids (Cannot swallow
liquids)
Cannot Swallow Solids (Cannot swallow
solids)
Mild Soreness Only (Mild soreness only)
None (None)
Comments
Pretreatment
Date
Have you had any problems swallowing today?
Can Swallow Solids With Some Difficulty
(Can swallow solids with some difficulty)
Cannot Swallow Liquids (Cannot swallow
liquids)
Cannot Swallow Solids (Cannot swallow
solids)
Mild Soreness Only (Mild soreness only)
None (None)
Comments
Pretreatment
Date
Have you had any problems swallowing today?
Can Swallow Solids With Some Difficulty
(Can swallow solids with some difficulty)
Cannot Swallow Liquids (Cannot swallow
liquids)
Cannot Swallow Solids (Cannot swallow
solids)
Mild Soreness Only (Mild soreness only)
None (None)
Comments
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Lung Cancer NCT00533949 Quality of Life - DP: Radiation Therapy Oncology
Group Phase III Lung High-dose vs Standard-dose Conformal XRT with
Chemotherapy Patient Swallowing Diary - 2676246v1.0
Lung Cancer NCT00096265 Quality of Life - PQ RTOG Phase
III Multiple Brain Metastases Fact Subscale - 2277326v3.0
PQ RTOG Phase III Multiple Brain Metastases Fact
Subscale
Radiation Therapy and Stereotactic Radiosurgery With or
Without Temozolomide or Erlotinib in Treating Patients With
Brain Metastases Secondary to Non-Small Cell Lung
Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=D7FA7BFE-
292F-6626-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/8144
PQ RTOG Phase III Multiple Brain
Metastases Fact Subscale
Header
[RTOG Study No.]
RTOG Study 0320 (RTOG Study 0320)
Case #
Institution
Institution No.
Participant's Initials
Participant's I.D. No.
Physical Well-being
I am able to concentrate
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am able to put my thoughts together
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I need help in caring for myself (bathing,
dressing, eating)
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am able to put my thoughts into action
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
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Very Much (Very much)
I am able to read like I used to
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am able to write like I used to
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am able to drive a vehicle (my car, truck, etc.)
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have trouble feeling sensations in my arms,
hands, or legs
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have weakness in my arms or legs
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have trouble with coordination
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am bothered by the drop in my contribution to
the family
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am able to make decisions and take
responsibility
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
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I am bothered by the change in my personality
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have had seizures (convulsions)
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I can remember new things
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I get frustrated that I cannot do things I used to
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am afraid of having a seizure (convulsion)
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have trouble with my eyesight
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I feel independent
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have trouble hearing
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am able to find the right word(s) to say what I
mean
A Little Bit (A little bit)
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Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have difficulty expressing my thoughts
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I get headaches
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
Additional Concerns
I regret smoking
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
If yes
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
Have you ever smoked?
Yes
No
Patient's signature
I have been short of breath
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am losing weight
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
My thinking is clear
A Little Bit (A little bit)
Not At All (Not at all)
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Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have been coughing
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am bothered by hair loss
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have a good appetite
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I feel tightness in my chest
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
Breathing is easy for me
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
Comments
Date
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Lung Cancer NCT00096265 Quality of Life - PQ RTOG Phase III Multiple
Brain Metastases Fact Subscale - 2277326v3.0
Lung Cancer NCT00096265 Quality of Life - PF RTOG Phase
III Multiple Brain Metastases Fact General - 2277123v3.0
PF RTOG Phase III Multiple Brain Metastases Fact General
Radiation Therapy and Stereotactic Radiosurgery With or
Without Temozolomide or Erlotinib in Treating Patients With
Brain Metastases Secondary to Non-Small Cell Lung
Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=D7FA4FF6-
6FF6-643F-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/8146
PF RTOG Phase III Multiple Brain
Metastases Fact General
Header
[RTOG Study No.]
RTOG Study 0320 (RTOG Study 0320)
Case #
Institution
Institution No.
Participant's Initials
Participant's I.D. No.
Physical Well-being
I have a lack of energy
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have nausea
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
Because of my physical condition, I have trouble
meeting the needs of my family
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have pain
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
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Very Much (Very much)
I am bothered by side effects of treatment
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I feel ill
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am forced to spend time in bed
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
Social/family Well-being
I feel close to my friends
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I get emotional support from my family
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I get support from my friends
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
My family has accepted my illness
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am satisfied with family communication about
my illness
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
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Very Much (Very much)
I feel close to my partner (or the person who is
my main support)
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am satisfied with my sex life
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
Emotional Well-being
I feel sad
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am satisfied with how I?m coping with my illness
2 (A little bit)
1 (Not at all)
4 (Quite a bit)
3 (Somewhat)
5 (Very much)
I am losing hope in the fight against my illness
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I feel nervous
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I worry about dying
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I worry that my condition will get worse
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
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Very Much (Very much)
Functional Well-being
Patient's signature
I am able to work (include work at home)
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
My work (including work at home) is fulfilling
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am able to enjoy life
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have accepted my illness
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am sleeping well
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am enjoying the things I usually do for fun
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am content with the quality of my life right now
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
Comments
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Date
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NCT00936390 Treatment - RTOG 0815 T1: Radiation Therapy Oncology Group
Phase III Randomized Study of Dose-Escalated Radiotherapy With/Without STAD
for Intermediate-Risk Prostate Cancer - 2853676v1.0
RTOG 0815 T1: Radiation Therapy Oncology Group Phase
III Randomized Study of Dose-Escalated Radiotherapy
With/Without STAD for Intermediate-Risk Prostate Cancer
Radiation Therapy With or Without Androgen-Deprivation
Therapy in Treating Patients With Prostate Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=657DC836-
E445-2DC7-E040-BB89AD437499
All rights reserved. Please visit https://medical-data-
models.org/forms/8151
RTOG 0815 T1: Radiation Therapy
Oncology Group Phase III
Randomized Study of Dose-
Escalated Radiotherapy
With/Without STAD for Intermediate-
Risk Prostate Cancer
Unnamed Module 1
RTOG Study No.
Case #
Institution Name
Institution No.
Patient Initials
RTOG Patient ID
Amended data
Yes
No
Module 1
Radiation Therapy Start Date
Radiation Therapy End Date
Total elapsed days (INCLUDING BOTH
EXTERNAL RADIATION THERAPY AND
BRACHYTHERAPY)
RT Total Fraction Count
RT Total Dose  (Gy)
Were there any unscheduled interruptions in
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radiation therapy?
No (No)
Yes, Due To Other Reason (Yes, due to
other reason)
Yes, Due To Toxicity (Yes, due to toxicity)
Specify RT interruption reason
Reason Treatment Ended
Adverse Event/side Effects/complications
(Adverse Event/Side
Effects/Complications)
Alternative Therapy (Alternative therapy)
Death On Study (Death on study)
Disease Progression, Relapse During
Active Treatment (Disease progression,
relapse during active treatment)
Other (Other)
Patient Off-treatment For Other
Complicating Disease (Patient off-
treatment for other complicating disease)
Patient Withdrawal Or Refusal After
Beginning Protocol Therapy (Patient
withdrawal/refusal after beginning
protocol therapy)
Patient Withdrawal Or Refusal Before
Beginning Protocol Therapy (Patient
withdrawal/refusal prior to beginning
protocol therapy)
Treatment Completed Per Protocol
Criteria (Treatment completed per
protocol criteria)
Alternative Therapy
Patient off-treatment for other complicating
disease, specify
Other specify
Type of Radiation Therapy Administered
3d Conformal (3D conformal)
High-dose Rate Brachytherapy 3-
dimensional Conformal Radiation
Therapy (3DCRT + Brachytherapy HDR)
Low-dose Treatment Brachytherapy 3-
dimensional Conformal Radiation
Therapy (3DCRT + Brachytherapy LDR)
Imrt (IMRT)
High-dose Rate Brachytherapy Imrt
(IMRT + Brachytherapy HDR)
Low-dose Treatment Brachytherapy Imrt
(IMRT + Brachytherapy LDR)
What method of daily prostate localization was
used
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NCT00936390 Treatment - RTOG 0815 T1: Radiation Therapy Oncology Group
Phase III Randomized Study of Dose-Escalated Radiotherapy With/Without STAD
for Intermediate-Risk Prostate Cancer - 2853676v1.0
Cone Beam (Cone beam)
Fiducial Markers (Fiducial markers)
No Daily Localization Used (No Daily
Localization Used)
Other (Other)
Ultra Sound (Ultra sound)
Other, specify
Brachytherapy
IF BRACHYTHERAPY NOT UTILIZED,
PROVIDE REASON
Alternative Therapy Given (Alternative
therapy given)
Death (Death)
Inadequate To Treat Extent Of Disease
(Inadequate to treat extent of disease)
Md Preference (MD preference)
Na Dose Administered Within Protocol
Specifications (NA Dose administered
within protocol specifications)
Not Technically Feasible (Not technically
feasible)
Other Reason, Specify (Other reason,
specify)
Patient Refused (Patient refused)
Progression Or Relapse (Progression or
relapse)
Toxicity Or Treatment Reaction (Toxicity
or treatment reaction)
Specify therapy
Other reason, specify
Low-dose Radiation
Date of implant
Date of post-implant CT
Seed loss
No (No)
Unknown (Unknown)
Yes (Yes)
WAS AN INDWELLING URINARY CATHETER
INSERTED SINCE IMPLANT
No (No)
Unknown (Unknown)
Yes (Yes)
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Phase III Randomized Study of Dose-Escalated Radiotherapy With/Without STAD
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Date inserted (Provide estimate if exact date
unknown)
Date removed (Provide estimate if exact date
unknown)
High-dose Radiation
Date of implant fraction #1
Time of implant fraction #1
Date of implant fraction #2
Total elapsed days (INCLUDING BOTH
EXTERNAL RADIATION THERAPY AND
BRACHYTHERAPY)
Time of implant fraction #2
Number of implant catheters used
Footer
Comments
Signature of Person Completing This Form
Date Form Originally Completed
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NCT00936390 Treatment - RTOG 0815 T1: Radiation Therapy Oncology Group
Phase III Randomized Study of Dose-Escalated Radiotherapy With/Without STAD
for Intermediate-Risk Prostate Cancer - 2853676v1.0
Breast Cancer NCT01101438 Follow-Up - NCIC
MA.32 Telephone Follow-Up Report - 3025096v1.0
NCIC MA.32 Telephone Follow-Up Report
A Phase III Randomized Trial of Metformin vs Placebo in
Early Stage Breast Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=81DC7457-
3943-EA84-E040-BB89AD43055B
All rights reserved. Please visit https://medical-data-
models.org/forms/8156
NCIC MA.32 Telephone Follow-Up
Report
Timing Of Report - Telephone Follow-up
Date of Telephone Contact
Metformin/placebo Administration
Date of Initial Dose
Has subject taken protocol medication every day
Yes
No
How many pills does the subject report having
missed (If no,)
Dose Modification Reason (If no, please enter the
reasons for dose modifications in the table
below:)
Adverse Event (Adverse event)
Dosing Error (Dosing error)
Hold For Procedure (Hold for procedure)
Intercurrent Illness (Intercurrent illness)
Other (Other)
Patient Forgot (Patient forgot)
Patient Request (Patient request)
Specify
Was this dose modification or addition/omission
as per protocol guidelines
Yes
No
Date subject scheduled to begin full dose
Date subject reports full dose begun
Serious Adverse Event - Question
Did the patient experience a Serious Adverse
Event, as defined in protocol section 11, during
this reporting period
1 / 22
Yes
No
Adverse Events On Treatment - Question
Were any additional adverse events experienced
by the patient
No (No)
Not Assessed (Not assessed)
Yes (Yes)
Adverse Events
Would you like to carry forward the adverse
events (indicated as continuing) from the previous
reporting period
Yes
No
CTCAE Term
Abdominal Distention (Abdominal
distension)
Abdominal Infection (Abdominal
infection)
Abdominal Pain (Abdominal pain)
Abdominal Soft Tissue Necrotic Lesion
(Abdominal soft tissue necrosis)
Abducens Nerve Disorder (Abducens
nerve disorder)
Accessory Nerve Disorder (Accessory
nerve disorder)
Acidosis (Acidosis)
Vestibulocochlear Nerve Disorder
(Acoustic nerve disorder NOS)
Prolonged Partial Thromboplastin Time
(Activated partial thromboplastin time
prolonged)
Acute Coronary Syndrome (Acute
coronary syndrome)
Acute Renal Failure (Acute kidney injury)
Adrenal Gland Insufficiency (Adrenal
insufficiency)
Adult Respiratory Distress Syndrome
(Adult respiratory distress syndrome)
Agitation (Agitation)
Akathisia (Akathisia)
Alanine Aminotransferase Increased
(Alanine aminotransferase increased)
Alcohol Intolerance (Alcohol intolerance)
Blood Alkaline Phosphatase Increased
(Alkaline phosphatase increased)
Alkalosis (Alkalosis)
Hypersensitivity (Allergic reaction)
Allergic Rhinitis (Allergic rhinitis)
Alopecia (Alopecia)
Amnesia (Amnesia)
Anorectal Fistula (Anal fistula)
Anal Hemorrhage (Anal hemorrhage)
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Anal Mucositis (Anal mucositis)
Anal Necrotic Lesion (Anal necrosis)
Anal Pain (Anal pain)
Anal Stenosis (Anal stenosis)
Anal Ulcer (Anal ulcer)
Anaphylactic Shock (Anaphylaxis)
Anemia (Anemia)
Ankle Fracture (Ankle fracture)
Anorectal Infection (Anorectal infection)
Anorexia (Anorexia)
Anorgasmia (Anorgasmia)
Anxiety (Anxiety)
Aortic Injury (Aortic injury)
Aortic Valve Disorder (Aortic valve
disease)
Aphonia (Aphonia)
Apnea (Apnea)
Acute Appendicitis (Appendicitis)
Acute Perforated Appendicitis
(Appendicitis perforated)
Arachnoiditis (Arachnoiditis)
Arterial Injury (Arterial injury)
Arteritis (Arteritis infective)
Arthralgia (Arthralgia)
Arthritis (Arthritis)
Ascites (Ascites)
Aspartate Aminotransferase Increased
(Aspartate aminotransferase increased)
Aspiration (Aspiration)
Cardiac Arrest (Asystole)
Ataxia (Ataxia)
Atelectasis (Atelectasis)
Atrial Fibrillation (Atrial fibrillation)
Atrial Flutter (Atrial flutter)
Av Block Third Degree (Atrioventricular
block complete)
Av Block First Degree (Atrioventricular
block first degree)
Autoimmune Disease (Autoimmune
disorder)
Bone Necrosis (Avascular necrosis)
Azoospermia (Azoospermia)
Back Pain (Back pain)
Bile Duct Stenosis (Bile duct stenosis)
Biliary Anastomotic Leakage (Biliary
anastomotic leak)
Biliary Fistula (Biliary fistula)
Cholangitis (Biliary tract infection)
Bladder Anastomotic Leakage (Bladder
anastomotic leak)
Cystitis (Bladder infection)
Bladder Perforation (Bladder perforation)
Bladder Spasm (Bladder spasm)
Bloating (Bloating)
Hematopoietic And Lymphoid System
Disorder Other Specify (Blood and
lymphatic system disorders - Other,
specify)
Abnormal Blood Antidiuretic Hormone
(Blood antidiuretic hormone abnormal)
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Elevated Bilirubin (Blood bilirubin
increased)
Blood Corticotrophin Decreased (Blood
corticotrophin decreased)
Abnormal Blood Gonadotrophin (Blood
gonadotrophin abnormal)
Abnormal Blood Prolactin (Blood
prolactin abnormal)
Blurred Vision (Blurred vision)
Body Odor (Body odor)
Bone Infection (Bone infection)
Hypocellular Bone Marrow (Bone
marrow hypocellular)
Bone Pain (Bone pain)
Brachial Plexopathy (Brachial
plexopathy)
Breast Atrophy (Breast atrophy)
Mastitis (Breast infection)
Breast Pain (Breast pain)
Bronchial Fistula (Bronchial fistula)
Bronchitis (Bronchial infection)
Bronchial Obstruction (Bronchial
obstruction)
Bronchial Stricture (Bronchial stricture)
Bronchopleural Fistula (Bronchopleural
fistula)
Bronchial Hemorrhage
(Bronchopulmonary hemorrhage)
Bronchospasm (Bronchospasm)
Bruise (Bruising)
Bullous Dermatitis (Bullous dermatitis)
Burn (Burn)
Buttock Pain (Buttock pain)
Capillary Leak Syndrome Capillary Leak
Syndrome (Capillary leak syndrome)
Decreased Carbon Monoxide Diffusing
Capacity (Carbon monoxide diffusing
capacity decreased)
Cardiac Arrest (Cardiac arrest)
Heart Disorder Other Specify (Cardiac
disorders - Other, specify)
Blood Cardiac Troponin I Increased
(Cardiac troponin I increased)
Blood Cardiac Troponin T Increased
(Cardiac troponin T increased)
Cataract (Cataract)
Catheter-related Infection (Catheter
related infection)
Cd4 Lymphocytes Decreased (CD4
lymphocytes decreased)
Cecal Hemorrhage (Cecal hemorrhage)
Cecal Infection (Cecal infection)
Central Nervous System Necrotic Lesion
(Central nervous system necrosis)
Cerebrospinal Fluid Leakage
(Cerebrospinal fluid leakage)
Infectious Cervicitis (Cervicitis infection)
Cheilitis (Cheilitis)
Angina (Chest pain - cardiac)
Chest Wall Pain (Chest wall pain)
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Chills (Chills)
Cholecystitis (Cholecystitis)
Hypercholesterolemia (Cholesterol high)
Chronic Kidney Disease (Chronic kidney
disease)
Chylothorax (Chylothorax)
Cognitive Disturbance (Cognitive
disturbance)
Colitis (Colitis)
Colonic Fistula (Colonic fistula)
Colonic Hemorrhage (Colonic
hemorrhage)
Colonic Obstruction (Colonic obstruction)
Colonic Perforation (Colonic perforation)
Colonic Stenosis (Colonic stenosis)
Colonic Ulcer (Colonic ulcer)
Concentration Impairment
(Concentration impairment)
Heart Conduction Disorder (Conduction
disorder)
Confusion (Confusion)
Congenital, Familial And Genetic
Disorder Class Other Specify
(Congenital, familial and genetic
disorders - Other, specify)
Conjunctivitis (Conjunctivitis)
Acute Contagious Conjunctivitis
(Conjunctivitis infective)
Constipation (Constipation)
Constrictive Pericarditis (Constrictive
pericarditis)
Keratitis (Corneal infection)
Corneal Ulcer (Corneal ulcer)
Cough (Cough)
Creatine Phosphokinase Increased (CPK
increased)
Cranial Nerve Infection (Cranial nerve
infection)
Increased Creatinine (Creatinine
increased)
Cushingoid (Cushingoid)
Non-infectious Cystitis (Cystitis
noninfective)
Cytokine Release Syndrome (Cytokine
release syndrome)
Neonatal Death (Death neonatal)
Death (Death NOS)
Dehydration (Dehydration)
Delayed Orgasm (Delayed orgasm)
Delayed Puberty (Delayed puberty)
Delirium (Delirium)
Delusion (Delusions)
Caries (Dental caries)
Depressed Level Of Consciousness
(Depressed level of consciousness)
Depression (Depression)
Radiation-induced Dermatitis (Dermatitis
radiation)
Prosthesis-related Infection (Device
related infection)
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Diarrhea (Diarrhea)
Disseminated Intravascular Coagulation
(Disseminated intravascular coagulation)
Dizziness (Dizziness)
Dry Eye Syndrome (Dry eye)
Xerostomia (Dry mouth)
Dry Skin (Dry Skin)
Duodenal Fistula (Duodenal fistula)
Duodenal Hemorrhage (Duodenal
hemorrhage)
Duodenal Infection (Duodenal infection)
Duodenal Obstruction (Duodenal
obstruction)
Duodenal Perforation (Duodenal
perforation)
Duodenal Stenosis (Duodenal stenosis)
Duodenal Ulcer (Duodenal ulcer)
Dysarthria (Dysarthria)
Dysesthesia (Dysesthesia)
Dysgeusia (Dysgeusia)
Dysmenorrhea (Dysmenorrhea)
Dyspareunia (Dyspareunia)
Dyspepsia (Dyspepsia)
Dysphagia (Dysphagia)
Dysphasia (Dysphasia)
Dyspnea (Dyspnea)
Ear And Labyrinth Disorder Class Other
Specify (Ear and labyrinth disorders -
Other, specify)
Earache (Ear pain)
Cerebral Edema (Edema cerebral)
Face Edema (Edema face)
Edema Limbs (Edema limbs)
Edema Trunk (Edema trunk)
Ejaculation Disorder (Ejaculation
disorder)
Ejection Fraction Decreased (Ejection
fraction decreased)
Prolonged Qt Interval (Electrocardiogram
QT corrected interval prolonged)
Infectious Encephalitis (Encephalitis
infection)
Infectious Encephalomyelitis
(Encephalomyelitis infection)
Encephalopathy (Encephalopathy)
Infective Endocarditis (Endocarditis
infective)
Endocrine Disorder Other Specify
(Endocrine disorders - Other, specify)
Endophthalmitis (Endophthalmitis)
Enterocolitis (Enterocolitis)
Infectious Enterocolitis (Enterocolitis
infectious)
Enterovesical Fistula (Enterovesical
fistula)
Epistaxis (Epistaxis)
Impotence (Erectile dysfunction)
Erythema Multiforme (Erythema
multiforme)
Erythroderma (Erythroderma)
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Esophageal Anastomotic Leakage
(Esophageal anastomotic leak)
Esophageal Fistula (Esophageal fistula)
Esophageal Hemorrhage (Esophageal
hemorrhage)
Esophageal Infection (Esophageal
infection)
Esophageal Necrotic Lesion
(Esophageal necrosis)
Esophageal Obstruction (Esophageal
obstruction)
Esophageal Pain (Esophageal pain)
Perforation Of Esophagus (Esophageal
perforation)
Esophageal Stricture (Esophageal
stenosis)
Esophageal Ulcer (Esophageal ulcer)
Esophageal Varices Hemorrhage
(Esophageal varices hemorrhage)
Esophagitis (Esophagitis)
Euphoria (Euphoria)
Exostosis (Exostosis)
External Ear Inflammation (External ear
inflammation)
External Ear Pain (External ear pain)
Extraocular Muscle Paresis (Extraocular
muscle paresis)
Extrapyramidal Disorder (Extrapyramidal
disorder)
Eye Disorder Other Specify (Eye
disorders - Other, specify)
Eye Infection (Eye infection)
Eye Pain (Eye pain)
Eyelid Function Disorder (Eyelid function
disorder)
Facial Muscle Weakness (Facial muscle
weakness)
Facial Nerve Disorder (Facial nerve
disorder)
Facial Pain (Facial pain)
Fall (Fall)
Fallopian Tube Anastomotic Leakage
(Fallopian tube anastomotic leak)
Fallopian Tube Obstruction (Fallopian
tube obstruction)
Fallopian Tube Perforation (Fallopian
tube perforation)
Fallopian Tube Stenosis (Fallopian tube
stenosis)
Adipose Tissue Atrophy (Fat atrophy)
Fatigue (Fatigue)
Neutropenic Fever (Febrile neutropenia)
Fecal Incontinence (Fecal incontinence)
Female Genital Tract Fistula (Female
genital tract fistula)
Acquired Feminization (Feminization
acquired)
Intrauterine Fetal Death (Fetal death)
Fetal Growth Retardation (Fetal growth
retardation)
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Fever (Fever)
Fibrinogen Decreased (Fibrinogen
decreased)
Deep Connective Tissue Fibrosis
(Fibrosis deep connective tissue)
Flank Pain (Flank pain)
Flasher (Flashing lights)
Flatulence (Flatulence)
Floaters (Floaters)
Flu-like Symptoms (Flu like symptoms)
Flushing (Flushing)
Decreased Forced Expiratory Volume
(Forced expiratory volume decreased)
Fracture (Fracture)
Gait Disturbance (Gait disturbance)
Gallbladder Fistula (Gallbladder fistula)
Gallbladder Infection (Gallbladder
infection)
Gallbladder Necrotic Lesion (Gallbladder
necrosis)
Gallbladder Obstruction (Gallbladder
obstruction)
Gallbladder Pain (Gallbladder pain)
Gallbladder Perforation (Gallbladder
perforation)
Gastric Anastomotic Leakage (Gastric
anastomotic leak)
Gastric Fistula (Gastric fistula)
Gastric Hemorrhage (Gastric
hemorrhage)
Gastric Necrotic Lesion (Gastric
necrosis)
Gastric Perforation (Gastric perforation)
Gastric Stenosis (Gastric stenosis)
Gastric Ulcer (Gastric ulcer)
Gastritis (Gastritis)
Gastroesophageal Reflux Disease
(Gastroesophageal reflux disease)
Gastrointestinal System Anastomotic
Leakage (Gastrointestinal anastomotic
leak)
Gastrointestinal Disorder Other Specify
(Gastrointestinal disorders - Other,
specify)
Gastrointestinal Fistula (Gastrointestinal
fistula)
Gastrointestinal Pain (Gastrointestinal
pain)
Gastrointestinal Stoma Necrotic Lesion
(Gastrointestinal stoma necrosis)
Gastroparesis (Gastroparesis)
General Disorders And Administration
Site Conditions Class Other Specify
(General disorders and administration
site conditions - Other, specify)
Generalized Muscle Weakness
(Generalized muscle weakness)
Genital Edema (Genital edema)
Gamma-glutamyltransferase Increased
(GGT increased)
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Gingival Pain (Gingival pain)
Glaucoma (Glaucoma)
Glossopharyngeal Nerve Disorder
(Glossopharyngeal nerve disorder)
Glucose Intolerance (Glucose
intolerance)
Accelerated Growth (Growth
accelerated)
Abnormal Growth Hormone (Growth
hormone abnormal)
Growth Retardation (Growth
suppression)
Gum Infection (Gum infection)
Gynecomastia (Gynecomastia)
Hallucination (Hallucinations)
Haptoglobin Decreased (Haptoglobin
decreased)
Head Soft Tissue Necrotic Lesion (Head
soft tissue necrosis)
Headache (Headache)
Hearing Impairment (Hearing impaired)
Heart Failure (Heart failure)
Hematoma (Hematoma)
Hematosalpinx (Hematosalpinx)
Hematuria (Hematuria)
Hemoglobin Increased (Hemoglobin
increased)
Hemoglobinuria (Hemoglobinuria)
Hemolysis (Hemolysis)
Hemolytic Uremic Syndrome (Hemolytic
uremic syndrome)
Hemorrhoidal Hemorrhage
(Hemorrhoidal hemorrhage)
Hemorrhoid (Hemorrhoids)
Hepatic Failure (Hepatic failure)
Hepatic Hemorrhage (Hepatic
hemorrhage)
Hepatic Infection (Hepatic infection)
Hepatic Necrotic Lesion (Hepatic
necrosis)
Hepatic Pain (Hepatic pain)
Viral Hepatitis (Hepatitis viral)
Liver And Biliary Tract Disorder Other
Specify (Hepatobiliary disorders - Other,
specify)
Hiccough (Hiccups)
Hip Fracture (Hip fracture)
Hirsutism (Hirsutism)
Hoarseness (Hoarseness)
Hot Flashes (Hot flashes)
Hydrocephalus (Hydrocephalus)
Hypercalcemia (Hypercalcemia)
Hyperglycemia (Hyperglycemia)
Hyperhidrosis (Hyperhidrosis)
Hyperkalemia (Hyperkalemia)
Hypermagnesemia (Hypermagnesemia)
Hypernatremia (Hypernatremia)
Hyperparathyroidism
(Hyperparathyroidism)
Hypersomnia (Hypersomnia)
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Hypertension (Hypertension)
Hyperthyroidism (Hyperthyroidism)
Hypertrichosis (Hypertrichosis)
Hypertriglyceridemia
(Hypertriglyceridemia)
Hyperuricemia (Hyperuricemia)
Hypoalbuminemia (Hypoalbuminemia)
Hypocalcemia (Hypocalcemia)
Hypoglossal Nerve Disorder
(Hypoglossal nerve disorder)
Hypoglycemia (Hypoglycemia)
Hypohidrosis (Hypohidrosis)
Hypokalemia (Hypokalemia)
Hypomagnesemia (Hypomagnesemia)
Hyponatremia (Hyponatremia)
Hypoparathyroidism
(Hypoparathyroidism)
Hypophosphatemia (Hypophosphatemia)
Hypotension (Hypotension)
Hypothermia (Hypothermia)
Hypothyroidism (Hypothyroidism)
Hypoxia (Hypoxia)
Ileal Fistula (Ileal fistula)
Ileal Hemorrhage (Ileal hemorrhage)
Ileal Obstruction (Ileal obstruction)
Ileal Perforation (Ileal perforation)
Ileal Stenosis (Ileal stenosis)
Ileal Ulcer (Ileal ulcer)
Ileus (Ileus)
Immune System Disorder Other Specify
(Immune system disorders - Other,
specify)
Infection Other Specify (Infections and
infestations - Other, specify)
Infectious Myositis (Infective myositis)
Infusion-related Reaction (Infusion
related reaction)
Infusion Site Extravasation (Infusion site
extravasation)
Injection Site Reaction (Injection site
reaction)
Injury To Carotid Artery (Injury to carotid
artery)
Injury To Inferior Vena Cava (Injury to
inferior vena cava)
Injury To Jugular Vein (Injury to jugular
vein)
Injury To Superior Vena Cava (Injury to
superior vena cava)
Injury, Poisoning And Procedural
Complication Class Other Specify (Injury,
poisoning and procedural complications -
Other, specify)
Inr Increased (INR increased)
Insomnia (Insomnia)
Intestinal Stoma Leakage (Intestinal
stoma leak)
Intestinal Stoma Obstruction (Intestinal
stoma obstruction)
Intestinal Stoma Site Hemorrhage
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(Intestinal stoma site bleeding)
Intra-abdominal Hemorrhage (Intra-
abdominal hemorrhage)
Intracranial Hemorrhage (Intracranial
hemorrhage)
Intraoperative Arterial Injury
(Intraoperative arterial injury)
Intraoperative Breast Injury
(Intraoperative breast injury)
Intraoperative Cardiac Injury
(Intraoperative cardiac injury)
Intraoperative Ear Injury (Intraoperative
ear injury)
Intraoperative Endocrine Injury
(Intraoperative endocrine injury)
Intraoperative Gastrointestinal Injury
(Intraoperative gastrointestinal injury)
Intraoperative Head And Neck Injury
(Intraoperative head and neck injury)
Intraoperative Hemorrhage
(Intraoperative hemorrhage)
Intraoperative Hepatobiliary Injury
(Intraoperative hepatobiliary injury)
Intraoperative Musculoskeletal Injury
(Intraoperative musculoskeletal injury)
Intraoperative Neurological Injury
(Intraoperative neurological injury)
Intraoperative Ocular Injury
(Intraoperative ocular injury)
Intraoperative Renal Injury
(Intraoperative renal injury)
Intraoperative Reproductive System
Injury (Intraoperative reproductive tract
injury)
Intraoperative Respiratory Injury
(Intraoperative respiratory injury)
Intraoperative Skin Injury (Intraoperative
skin injury)
Intraoperative Splenic Injury
(Intraoperative splenic injury)
Intraoperative Urinary System Injury
(Intraoperative urinary injury)
Intraoperative Venous Injury
(Intraoperative venous injury)
Investigation Other Specify
(Investigations - Other, specify)
Iron Overload (Iron overload)
Irregular Menstruation (Irregular
menstruation)
Irritability (Irritability)
Cerebrovascular Ischemia (Ischemia
cerebrovascular)
Trochlear Nerve Disorder (IVth nerve
disorder)
Jejunal Fistula (Jejunal fistula)
Jejunal Hemorrhage (Jejunal
hemorrhage)
Jejunal Obstruction (Jejunal obstruction)
Jejunal Perforation (Jejunal perforation)
Jejunal Stenosis (Jejunal stenosis)
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Jejunal Ulcer (Jejunal ulcer)
Joint Effusion (Joint effusion)
Joint Infection (Joint infection)
Joint Range Of Motion Decreased (Joint
range of motion decreased)
Cervical Spine Joint Range Of Motion
Decreased (Joint range of motion
decreased cervical spine)
Lumbar Spine Joint Range Of Motion
Decreased (Joint range of motion
decreased lumbar spine)
Keratitis (Keratitis)
Kidney Anastomotic Leakage (Kidney
anastomotic leak)
Pyelonephritis (Kidney infection)
Kyphosis (Kyphosis)
Lactation Disorder (Lactation disorder)
Large Intestinal Anastomotic Leakage
(Large intestinal anastomotic leak)
Laryngeal Edema (Laryngeal edema)
Laryngeal Fistula (Laryngeal fistula)
Laryngeal Hemorrhage (Laryngeal
hemorrhage)
Laryngitis (Laryngeal inflammation)
Laryngeal Mucositis (Laryngeal
mucositis)
Laryngeal Obstruction (Laryngeal
obstruction)
Laryngeal Stenosis (Laryngeal stenosis)
Laryngitis (Laryngitis)
Laryngopharyngeal Dysesthesia
(Laryngopharyngeal dysesthesia)
Laryngospasm (Laryngospasm)
Left Ventricular Systolic Dysfunction (Left
ventricular systolic dysfunction)
Lethargy (Lethargy)
Chemotherapy-related Leukemia
(Leukemia secondary to oncology
chemotherapy)
Leukocytosis (Leukocytosis)
Leukoencephalopathy
(Leukoencephalopathy)
Decreased Libido (Libido decreased)
Increased Libido (Libido increased)
Lip Infection (Lip infection)
Lip Pain (Lip pain)
Lipase Increased (Lipase increased)
Lipohypertrophy (Lipohypertrophy)
Localized Edema (Localized edema)
Lordosis (Lordosis)
Lower Gastrointestinal Hemorrhage
(Lower gastrointestinal hemorrhage)
Infectious Lung Disorder (Lung infection)
Lymphadenitis (Lymph gland infection)
Lymph Leakage (Lymph leakage)
Lymph Node Pain (Lymph node pain)
Lymphedema (Lymphedema)
Lymphocele (Lymphocele)
Lymphopenia (Lymphocyte count
decreased)
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Lymphocytosis (Lymphocyte count
increased)
Malabsorption Syndrome
(Malabsorption)
Malaise (Malaise)
Mania (Mania)
Mediastinal Hemorrhage (Mediastinal
hemorrhage)
Mediastinitis (Mediastinal infection)
Memory Impairment (Memory
impairment)
Meningismus (Meningismus)
Meningitis (Meningitis)
Menopause (Menopause)
Menorrhagia (Menorrhagia)
Metabolism And Nutrition Disorder Class
Other Specify (Metabolism and nutrition
disorders - Other, specify)
Otitis Media (Middle ear inflammation)
Mitral Valve Disorder (Mitral valve
disease)
Av Block Second Degree Mobitz Type Ii
(Mobitz (type) II atrioventricular block)
Av Block Second Degree Mobitz Type I
(Mobitz type I)
Involuntary Movements (Movements
involuntary)
Mucosal Infection (Mucosal infection)
Stomatitis (Mucositis oral)
Multiple Organ Failure (Multi-organ
failure)
Muscle Weakness Left-sided (Muscle
weakness left-sided)
Muscle Weakness Lower Limb (Muscle
weakness lower limb)
Muscle Weakness Right-sided (Muscle
weakness right-sided)
Muscle Weakness Trunk (Muscle
weakness trunk)
Muscle Weakness Upper Limb (Muscle
weakness upper limb)
Connective And Soft Tissue Disorder
Other Specify (Musculoskeletal and
connective tissue disorder -  Other,
specify)
Musculoskeletal Deformity
(Musculoskeletal deformity)
Myalgia (Myalgia)
Myelitis (Myelitis)
Mds (Myelodysplastic syndrome)
Myocardial Infarction (Myocardial
infarction)
Myocarditis (Myocarditis)
Myositis (Myositis)
Nail Discoloration (Nail discoloration)
Nail Infection (Nail infection)
Nail Loss (Nail loss)
Nail Ridging (Nail ridging)
Nasal Congestion (Nasal congestion)
Nausea (Nausea)
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Neck Edema (Neck edema)
Neck Pain (Neck pain)
Neck Soft Tissue Necrotic Lesion (Neck
soft tissue necrosis)
Neoplasm Other Specify (Neoplasms
benign, malignant and unspecified (incl
cysts and polyps) - Other, specify)
Nervous System Disorder Other Specify
(Nervous system disorders - Other,
specify)
Neuralgia (Neuralgia)
Neutrophil Count Decreased (Neutrophil
count decreased)
Night Blindness (Night blindness)
Nipple Deformity (Nipple deformity)
Non-cardiac Chest Pain (Non-cardiac
chest pain)
Nystagmus (Nystagmus)
Obesity (Obesity)
Gastric Obstruction (Obstruction gastric)
Oculomotor Nerve Disorder (Oculomotor
nerve disorder)
Olfactory Nerve Disorder (Olfactory
nerve disorder)
Oligospermia (Oligospermia)
Optic Nerve Disorder (Optic nerve
disorder)
Oral Cavity Fistula (Oral cavity fistula)
Burning Mouth Syndrome (Oral
dysesthesia)
Oral Hemorrhage (Oral hemorrhage)
Oral Pain (Oral pain)
Osteonecrosis Of Jaw (Osteonecrosis of
jaw)
Osteoporosis (Osteoporosis)
External Ear Infection (Otitis externa)
Otitis Media (Otitis media)
Ovarian Hemorrhage (Ovarian
hemorrhage)
Ovarian Infection (Ovarian infection)
Ovarian Rupture (Ovarian rupture)
Ovulatory Pain (Ovulation pain)
Pain (Pain)
Pain In Extremity (Pain in extremity)
Skin Pain (Pain of skin)
Palmar-plantar Erythodysthesia (Palmar-
plantar erythrodysesthesia syndrome)
Palpitation (Palpitations)
Pancreatic Infection (Pancreas infection)
Pancreatic Anastomotic Leakage
(Pancreatic anastomotic leak)
Pancreatic Duct Stenosis (Pancreatic
duct stenosis)
Pancreatic Enzymes Decreased
(Pancreatic enzymes decreased)
Pancreatic Fistula (Pancreatic fistula)
Pancreatic Hemorrhage (Pancreatic
hemorrhage)
Pancreatic Necrotic Lesion (Pancreatic
necrosis)
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Pancreatitis (Pancreatitis)
Papilledema (Papilledema)
Papulopustular Rash (Papulopustular
rash)
Paresthesia (Paresthesia)
Paronychia (Paronychia)
Paroxysmal Atrial Tachycardia
(Paroxysmal atrial tachycardia)
Pelvic Floor Muscle Weakness (Pelvic
floor muscle weakness)
Pelvic Inflammatory Disease (Pelvic
infection)
Pelvic Pain (Pelvic pain)
Pelvic Soft Tissue Necrotic Lesion
(Pelvic soft tissue necrosis)
Penile Infection (Penile infection)
Penile Pain (Penile pain)
Bile Duct Perforation (Perforation bile
duct)
Pericardial Effusion (Pericardial effusion)
Cardiac Tamponade (Pericardial
tamponade)
Pericarditis (Pericarditis)
Perineal Pain (Perineal pain)
Periodontal Disorder (Periodontal
disease)
Periorbital Edema (Periorbital edema)
Periorbital Infection (Periorbital infection)
Peripheral Ischemia (Peripheral
ischemia)
Peripheral Motor Neuropathy (Peripheral
motor neuropathy)
Peripheral Nervous System Infectious
Disorder (Peripheral nerve infection)
Peripheral Sensory Neuropathy
(Peripheral sensory neuropathy)
Peritoneal Infection (Peritoneal infection)
Peritoneal Necrotic Lesion (Peritoneal
necrosis)
Personality Change (Personality change)
Phantom Pain (Phantom pain)
Pharyngeal Anastomotic Leakage
(Pharyngeal anastomotic leak)
Pharyngeal Fistula (Pharyngeal fistula)
Pharyngeal Hemorrhage (Pharyngeal
hemorrhage)
Pharyngeal Mucositis (Pharyngeal
mucositis)
Pharyngeal Necrotic Lesion (Pharyngeal
necrosis)
Pharyngeal Stenosis (Pharyngeal
stenosis)
Pharyngitis (Pharyngitis)
Pharyngolaryngeal Pain
(Pharyngolaryngeal pain)
Phlebitis (Phlebitis)
Infective Phlebitis (Phlebitis infective)
Photophobia (Photophobia)
Photosensitivity (Photosensitivity)
Thrombocytopenia (Platelet count
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decreased)
Pleural Effusion (Pleural effusion)
Hemothorax (Pleural hemorrhage)
Pleural Infection (Pleural infection)
Pleuritic Pain (Pleuritic pain)
Pneumonia (Pneumonitis)
Pneumothorax (Pneumothorax)
Portal Hypertension (Portal
Hypertension)
Portal Vein Thrombosis (Portal vein
thrombosis)
Post-nasal Drip (Postnasal drip)
Postoperative Bleeding (Postoperative
hemorrhage)
Thoracic Procedure Postoperative
Complication (Postoperative thoracic
procedure complication)
Precocious Puberty (Precocious
puberty)
Pregnancy, Puerperium And Perinatal
Condition Class Other Specify
(Pregnancy, puerperium and perinatal
conditions - Other, specify)
Premature Labor (Premature delivery)
Premature Menopause (Premature
menopause)
Presyncope (Presyncope)
Proctitis (Proctitis)
Productive Cough (Productive cough)
Intestinal Stoma Prolapse (Prolapse of
intestinal stoma)
Urostomy Prolapse (Prolapse of
urostomy)
Prostatic Infection (Prostate infection)
Prostatic Hemorrhage (Prostatic
hemorrhage)
Prostatic Obstruction (Prostatic
obstruction)
Prostatic Pain (Prostatic pain)
Proteinuria (Proteinuria)
Pruritus (Pruritus)
Psychiatric Disorder Other Specify
(Psychiatric disorders - Other, specify)
Psychosis (Psychosis)
Pulmonary Edema (Pulmonary edema)
Pulmonary Fibrosis (Pulmonary fibrosis)
Pulmonary Fistula (Pulmonary fistula)
Pulmonary Hypertension (Pulmonary
hypertension)
Pulmonary Valve Disorder (Pulmonary
valve disease)
Purpura (Purpura)
Pyramidal Tract Dysfunction (Pyramidal
tract syndrome)
Radiation-recall Dermatitis (Radiation
recall reaction (dermatologic))
Radiculitis (Radiculitis)
Acneiform Dermatitis (Rash acneiform)
Maculopapular Lesion (Rash maculo-
papular)
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Papulopustular Rash (Rash pustular)
Rectal Anastomotic Leakage (Rectal
anastomotic leak)
Rectal Fistula (Rectal fistula)
Rectal Hemorrhage (Rectal hemorrhage)
Rectal Mucositis (Rectal mucositis)
Rectal Necrotic Lesion (Rectal necrosis)
Rectal Obstruction (Rectal obstruction)
Rectal Pain (Rectal pain)
Rectal Perforation (Rectal perforation)
Rectal Stenosis (Rectal stenosis)
Rectal Ulcer (Rectal ulcer)
Recurrent Laryngeal Nerve Paralysis
(Recurrent laryngeal nerve palsy)
Urinary Tract Disorder Other Specify
(Renal and urinary disorders - Other,
specify)
Renal Stone (Renal calculi)
Renal Colic (Renal colic)
Renal Hemorrhage (Renal hemorrhage)
Reproductive System And Breast
Disorder Class Other Specify
(Reproductive system and breast
disorders - Other, specify)
Respiratory Failure (Respiratory failure)
Respiratory And Thoracic Disorder Other
Specify (Respiratory, thoracic and
mediastinal disorders - Other, specify)
Restlessness (Restlessness)
Restrictive Cardiomyopathy (Restrictive
cardiomyopathy)
Retinal Detachment (Retinal
detachment)
Retinal Tear (Retinal tear)
Retinal Vascular Disorder (Retinal
vascular disorder)
Retinoic Acid Syndrome (Retinoic acid
syndrome)
Retinopathy (Retinopathy)
Retroperitoneal Hemorrhage
(Retroperitoneal hemorrhage)
Reversible Posterior
Leukoencephalopathy Syndrome
(Reversible posterior
leukoencephalopathy syndrome)
Infectious Rhinitis (Rhinitis infective)
Right Ventricular Dysfunction (Right
ventricular dysfunction)
Salivary Duct Inflammation (Salivary duct
inflammation)
Salivary Gland Fistula (Salivary gland
fistula)
Salivary Gland Infection (Salivary gland
infection)
Scalp Pain (Scalp pain)
Sclera Disorder (Scleral disorder)
Scoliosis (Scoliosis)
Scrotal Infection (Scrotal infection)
Scrotal Pain (Scrotal pain)
Seizure (Seizure)
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Septicemia (Sepsis)
Seroma (Seroma)
Serum Amylase Increased (Serum
amylase increased)
Serum Sickness (Serum sickness)
Sick Sinus Syndrome (Sick sinus
syndrome)
Sinus Bradycardia (Sinus bradycardia)
Paranasal Sinus Disorder (Sinus
disorder)
Sinus Pain (Sinus pain)
Sinus Tachycardia (Sinus tachycardia)
Sinusitis (Sinusitis)
Skin Disorder Other Specify (Skin and
subcutaneous tissue disorders - Other,
specify)
Skin Atrophy (Skin atrophy)
Skin Hyperpigmentation (Skin
hyperpigmentation)
Skin Hypopigmentation (Skin
hypopigmentation)
Skin Induration (Skin induration)
Skin Infection (Skin infection)
Skin Ulcer (Skin ulceration)
Sleep Apnea (Sleep apnea)
Small Intestinal Anastomotic Leakage
(Small intestinal anastomotic leak)
Small Intestinal Mucositis (Small
intestinal mucositis)
Small Intestinal Obstruction (Small
intestinal obstruction)
Small Intestinal Perforation (Small
intestinal perforation)
Small Intestinal Stenosis (Small intestinal
stenosis)
Small Intestinal Infection (Small intestine
infection)
Small Intestinal Ulcer (Small intestine
ulcer)
Sneezing (Sneezing)
Social Circumstances Other Specify
(Social circumstances - Other, specify)
Soft Tissue Infection (Soft tissue
infection)
Lower Limb Soft Tissue Necrotic Lesion
(Soft tissue necrosis lower limb)
Upper Limb Soft Tissue Necrotic Lesion
(Soft tissue necrosis upper limb)
Somnolence (Somnolence)
Sore Throat (Sore throat)
Spasticity (Spasticity)
Spermatic Cord Anastomotic Leakage
(Spermatic cord anastomotic leak)
Spermatic Cord Hemorrhage (Spermatic
cord hemorrhage)
Spermatic Cord Obstruction (Spermatic
cord obstruction)
Vertebral Fracture (Spinal fracture)
Splenic Disorder (Spleen disorder)
Splenic Infection (Splenic infection)
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Gastrointestinal Stoma Stenosis
(Stenosis of gastrointestinal stoma)
Stevens-johnson Syndrome (Stevens-
Johnson syndrome)
Stoma Site Infection (Stoma site
infection)
Stomach Pain (Stomach pain)
Stomal Ulcer (Stomal ulcer)
Stridor (Stridor)
Cerebrovascular Accident (Stroke)
Sudden Cardiac Death (Sudden death
NOS)
Suicidal Ideation (Suicidal ideation)
Suicide Attempt (Suicide attempt)
Superficial Soft Tissue Fibrosis
(Superficial soft tissue fibrosis)
Superficial Thrombophlebitis (Superficial
thrombophlebitis)
Superior Vena Cava Syndrome (Superior
vena cava syndrome)
Supraventricular Tachycardia
(Supraventricular tachycardia)
Intervention Or Procedure Other Specify
(Surgical and medical procedures -
Other, specify)
Syncope (Syncope)
Telangiectasia (Telangiectasia)
Testicular Disorder (Testicular disorder)
Testicular Hemorrhage (Testicular
hemorrhage)
Testicular Pain (Testicular pain)
Thromboembolism (Thromboembolic
event)
Thrombotic Thrombocytopenic Purpura
(Thrombotic thrombocytopenic purpura)
Tinnitus (Tinnitus)
Dental Developmental Disorder (Tooth
development disorder)
Tooth Discoloration (Tooth discoloration)
Tooth Infection (Tooth infection)
Toothache (Toothache)
Toxic Epidermal Necrolysis (Toxic
epidermal necrolysis)
Tracheal Fistula (Tracheal fistula)
Tracheal Hemorrhage (Tracheal
hemorrhage)
Tracheal Mucositis (Tracheal mucositis)
Tracheal Obstruction (Tracheal
obstruction)
Tracheal Stenosis (Tracheal stenosis)
Tracheitis (Tracheitis)
Tracheostomy Site Bleeding
(Tracheostomy site bleeding)
Transient Ischemic Attack (Transient
ischemic attacks)
Therapy-related Malignant Neoplasm
(Treatment related secondary
malignancy)
Tremor (Tremor)
Tricuspid Valve Disorder (Tricuspid valve
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disease)
Trigeminal Nerve Disorder (Trigeminal
nerve disorder)
Trismus (Trismus)
Tumor Lysis Syndrome (Tumor lysis
syndrome)
Tumor Pain (Tumor pain)
Typhlitis (Typhlitis)
Unequal Limb Length (Unequal limb
length)
Unintended Pregnancy (Unintended
pregnancy)
Upper Gastrointestinal Hemorrhage
(Upper gastrointestinal hemorrhage)
Upper Respiratory Tract Infection (Upper
respiratory infection)
Ureteric Anastomotic Leakage (Ureteric
anastomotic leak)
Urethral Anastomotic Leakage (Urethral
anastomotic leak)
Urethral Infection (Urethral infection)
Urinary Tract Fistula (Urinary fistula)
Urinary Frequency (Urinary frequency)
Urinary Incontinence (Urinary
incontinence)
Urinary Retention (Urinary retention)
Urinary Tract Infection (Urinary tract
infection)
Urinary Tract Obstruction (Urinary tract
obstruction)
Urinary Tract Pain (Urinary tract pain)
Urinary Urgency (Urinary urgency)
Urine Discoloration (Urine discoloration)
Urine Output Decreased (Urine output
decreased)
Urostomy Leakage (Urostomy leak)
Urostomy Obstruction (Urostomy
obstruction)
Urostomy Site Bleeding (Urostomy site
bleeding)
Urostomy Stenosis (Urostomy stenosis)
Urticaria (Urticaria)
Uterine Anastomotic Leakage (Uterine
anastomotic leak)
Uterine Fistula (Uterine fistula)
Uterine Hemorrhage (Uterine
hemorrhage)
Endometritis (Uterine infection)
Uterine Obstruction (Uterine obstruction)
Uterine Pain (Uterine pain)
Uterine Perforation (Uterine perforation)
Uveitis (Uveitis)
Vaginal Anastomotic Leakage (Vaginal
anastomotic leak)
Vaginal Discharge (Vaginal discharge)
Vaginal Dryness (Vaginal dryness)
Vaginal Fistula (Vaginal fistula)
Vaginal Hemorrhage (Vaginal
hemorrhage)
Vaginitis (Vaginal infection)
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Vaginitis (Vaginal inflammation)
Vaginal Obstruction (Vaginal obstruction)
Vaginal Pain (Vaginal pain)
Vaginal Perforation (Vaginal perforation)
Vaginal Stricture (Vaginal stricture)
Vaginismus (Vaginismus)
Vagus Nerve Disorder (Vagus nerve
disorder)
Vas Deferens Anastomotic Leakage (Vas
deferens anastomotic leak)
Vascular Access Complication (Vascular
access complication)
Vascular Disorder Other Specify
(Vascular disorders - Other, specify)
Vasculitis (Vasculitis)
Vasovagal Reaction (Vasovagal reaction)
Venous Injury (Venous injury)
Ventricular Arrhythmia (Ventricular
arrhythmia)
Ventricular Fibrillation (Ventricular
fibrillation)
Ventricular Tachycardia (Ventricular
tachycardia)
Vertigo (Vertigo)
Internal Ear Disorder (Vestibular
disorder)
Virilization (Virilization)
Visceral Artery Ischemia (Visceral
arterial ischemia)
Abnormal Vital Capacity (Vital capacity
abnormal)
Vitreous Hemorrhage (Vitreous
hemorrhage)
Voice Alternation (Voice alteration)
Vomiting (Vomiting)
Vulval Infection (Vulval infection)
Watering Eyes (Watering eyes)
Weight Gain (Weight gain)
Weight Loss (Weight loss)
Wheezing (Wheezing)
Leukopenia (White blood cell decreased)
Wolff-parkinson-white Syndrome (Wolff-
Parkinson-White Syndrome)
Wound Complication (Wound
complication)
Wound Dehiscence (Wound dehiscence)
Wound Infection (Wound infection)
Wrist Fracture (Wrist fracture)
AE Ongoing
No (No)
Not Assessed (Not assessed)
Yes (Yes)
Grade
Seriousness Attributed to Adverse Event
Congenital Anomaly (Congenital
anomaly)
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Death (Death)
Disability (Disability/incapacity)
Hospitalized (Hospitalization, initial or
prolonged)
Life Threatening (Life threatening)
Not Serious (Not serious)
Intervention Required (Required
intervention to prevent permanent
impairment/damage)
Attribution
Definite (Definite)
Possible (Possible)
Probable (Probable)
Unlikely (Unlikely)
Unrelated (Unrelated)
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NCT00265941 Treatment - RTOG-0522 S1: Radiation Therapy Oncology
Group Phase III Head and Neck Cancer Surgery Form - 2228661v1.0
RTOG-0522 S1: Radiation Therapy Oncology Group Phase
III Head and Neck Cancer Surgery Form
Radiation Therapy and Cisplatin With or Without Cetuximab
in Treating Patients With Stage III or Stage IV Head and
Neck Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=F7024665-
89F4-412D-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/8159
RTOG-0522 S1: Radiation Therapy
Oncology Group Phase III Head and
Neck Cancer Surgery Form
Module 1
RTOG Study No.
Case #
Institution Name
Institution No.
Patient Initials
RTOG Patient ID
AMENDED DATA
Yes
No
Module 2
Primary Site (Pathologic Assessment)
No Tumor Demonstrable On Final
Pathology Specimen (No tumor
demonstrable on final pathology
specimen)
Not Operated (Not operated)
Tumor Present All Margins Clear On
Final Pathology Specimen (Tumor
present all margins clear on final
pathology specimen)
Tumor Present, Margin Involved On Final
Specimen (Tumor present margin
involved on final pathology specimen)
Unknown (Unknown)
Primary Site (Pathologic Assessment)
No Tumor Demonstrable On Final
Pathology Specimen (No tumor
demonstrable on final pathology
specimen)
Not Operated (Not operated)
Tumor Present All Margins Clear On
Final Pathology Specimen (Tumor
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present all margins clear on final
pathology specimen)
Tumor Present, Margin Involved On Final
Specimen (Tumor present margin
involved on final pathology specimen)
Unknown (Unknown)
Primary Surgery Date
Nodal surgery
Bilateral Node Dissection (Bilateral node
dissection)
None (None)
Unilateral Lymph Node Dissection Left
(Unilateral node dissection (left))
Unilateral Lymph Node Dissection Right
(Unilateral node dissection (right))
Unknown (Unknown)
Reason nodal surgery not done
Medically Inoperable (Medically
inoperable)
Not Applicable (Not applicable)
Not Required Patient Achieved A
Complete Clinical And Radiographic
Response (Not required)
Other Specify (Other)
Patient Refusal (Patient refusal)
Technically Unresectable (Technically
unresectable)
Toxicity Due To Other Treatment (Toxicity
due to other treatment)
Unknown (Unknown)
Other specify
Neck nodal site right
Complete Resection Of All Gross Tumor
(Complete resection of all gross disease)
Incomplete/partial Resection Of Gross
Tumor (Incomplete/partial resection of
gross tumor)
Not Operated (Not operated)
Neck nodal site left
Complete Resection Of All Gross Tumor
(Complete resection of all gross disease)
Incomplete/partial Resection Of Gross
Tumor (Incomplete/partial resection of
gross tumor)
Not Operated (Not operated)
Location of remaining disease
Location of remaining disease
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Location of remaining disease
Nodal Surgery Date (Left)
Nodal Surgery Date (Left)
Neck Nodal Sites (pathologic
Assessment)
Location
Left - Level I (submandibular) (Left -
Level I (Submandibular))
Left - Level Ii (upper 1/3 Internal Jugular)
(Left - Level II (Upper 1/3 Internal
Jugular))
Left - Level Iii (mid 1/3 Internal Jugular)
(Left - Level III (Mid 1/3 Internal Jugular))
Left - Level Iv (lower 1/3 Internal Jugular)
(Left - Level IV (Lower 1/3 Internal
Jugular))
Left - Level V (posterior Triangle) (Left -
Level V (Posterior Triangle))
Left - Other (Left - Other specify)
Right - Level I (submandibular) (Right -
Level I (Submandibular))
Right - Level Ii (upper 1/3 Internal
Jugular) (Right - Level II (Upper 1/3
Internal Jugular))
Right - Level Iii (mid 1/3 Internal Jugular)
(Right - Level III (Mid 1/3 Internal
Jugular))
Right - Level Iv (lower 1/3 Internal
Jugular) (Right - Level IV (Lower 1/3
Internal Jugular))
Right - Level V (posterior Triangle) (Right
- Level V (Posterior Triangle))
Right - Other (Right - Other specify)
Other specify (location)
Other specify (location)
Number of Positive Lymph Nodes
Number of Lymph Nodes Examined
Extracapsular Extension?
No (No)
Unknown (Unknown)
Yes (Yes)
Total Nodes Positive Right
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Total Nodes Examined Right
Total Nodes Positive Left
Total Nodes Examined Left
Was tumor present in the soft tissue of the neck
without an identifiable lymph node present?
No (No)
Not Operated (Not operated)
Unknown (Unknown)
Yes (Yes)
Yes specify level
Footer
Signature of Person Completing This Form
Form Completion Date, Original
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Breast Cancer NCT01101438 Off Treatment -
NCIC MA.32 Death Report Form - 3017307v1.0
NCIC MA.32 Death Report Form
A Phase III Randomized Trial of Metformin vs Placebo in
Early Stage Breast Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=805B03D5-
89D0-F93C-E040-BB89AD433826
All rights reserved. Please visit https://medical-data-
models.org/forms/8164
NCIC MA.32 Death Report Form
Date/cause Of Death/autopsy
Date of Death (dd mmm yyyy)
Other primary malignancy
Absent (Absent)
Present (Present)
Primary cause of death
Adverse Event Possibly, Probably Or
Definitely Related To Protocol Treatment
(Adverse event possibly, probably or
definitely related to protocol treatment)
Breast Cancer Only (Breast Cancer only)
Complication From A Non-protocol
Treatment For This Malignancy
(malignant Disease May Or May Not Be
Contributory) (Complication from a non-
protocol treatment for this malignancy
(malignant disease may or may not be
contributory))
Other Condition Or Circumstance (Other
condition or circumstance)
Other Primary Malignancy (Other
primary malignancy)
Primary Cardiovascular Disease
(Primary Cardiovascular Disease)
Due to other cause specify
Comments
Autopsy
Was autopsy performed
No (No)
Unknown (Unknown)
Yes (Yes)
Cause of death (autopsy finding)
Adverse Event Possibly, Probably Or
Definitely Related To Protocol Treatment
(Adverse event possibly, probably or
definitely related to protocol treatment)
Breast Cancer Only (Breast Cancer only)
Complication From A Non-protocol
Treatment For This Malignancy
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(malignant Disease May Or May Not Be
Contributory) (Complication from a non-
protocol treatment for this malignancy
(malignant disease may or may not be
contributory))
Other Condition Or Circumstance (Other
condition or circumstance)
Other Primary Malignancy (Other
primary malignancy)
Primary Cardiovascular Disease
(Primary Cardiovascular Disease)
Specify
Adverse Events - Death Report
Has there been a new diagnosis of diabetes
since the last report
No (No)
Unknown (Unknown)
Yes (Yes)
CTC Adverse Event Term
Grade
Attribution
Definite (Definite)
Possible (Possible)
Probable (Probable)
Unlikely (Unlikely)
Unrelated (Unrelated)
Seriousness Attributed to Adverse Event
Congenital Anomaly (Congenital
anomaly)
Death (Death)
Disability (Disability/incapacity)
Hospitalized (Hospitalization, initial or
prolonged)
Life Threatening (Life threatening)
Not Serious (Not serious)
Intervention Required (Required
intervention to prevent permanent
impairment/damage)
Cardiovascular Mobidity
Problem, cardiovascular
Angina Requiring Coronary Artery
Bypass Graft (Angina requiring coronary
artery bypass graft)
Angina Requiring Transluminal Coronary
Angioplasty (Angina requiring
transluminal coronary angioplasty)
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Myocardial Infarction (Myocardial
Infarction)
New Or Worsening Angina (New or
worsening angina)
Other (Other)
Transient Ischemic Attack
Cerebrovascular Accident (Stroke /
transient inschemic attack TIA)
Thromboembolism (Thromboembolic
Event)
Specify
Date of hospital admission
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Cervical Cancer NCT01414608 Follow-Up -
ANZGOG-0902 Toxicity - Follow-up - 3141494v1.0
ANZGOG-0902 Toxicity - Follow-up
Cisplatin and Radiation Therapy With or Without
Carboplatin and Paclitaxel in Patients With Locally
Advanced Cervical Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=90FC354F-
ABB9-8368-E040-BB89AD434A85
All rights reserved. Please visit https://medical-data-
models.org/forms/8165
ANZGOG-0902 Toxicity - Follow-up
Header
Patient Initials
Patient ID
Institution Code
Date of Symptom/Event Assessment
Has the patient experienced any toxicities related
to study treatment since the last report?
Yes
No
Toxicities
CTCAE V4.0 Term
Alanine Aminotransferase Increased
(Alanine aminotransferase increased)
Allergic Reaction (Allergic reaction)
Alopecia (Alopecia)
Anemia (Anemia)
Aspartate Aminotransferase Increased
(Aspartate aminotransferase increased)
Colitis (Colitis)
Creatinine Increased (Creatinine
increased)
Cystitis Noninfective (Cystitis
noninfective)
Dehydration (Dehydration)
Dermatitis Radiation (Dermatitis
radiation)
Diarrhea (Diarrhea)
Enterocolitis (Enterocolitis)
Fatigue (Fatigue)
Febrile Neutropenia (Febrile
neutropenia)
Hearing Impaired (Hearing impaired)
Lymphocyte Count Decreased
(Lymphocyte count decreased)
Mucositis Oral (Mucositis oral)
Myalgia (Myalgia)
Nausea (Nausea)
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Neutrophil Count Decreased (Neutrophil
count decreased)
Peripheral Motor Neuropathy (Peripheral
motor neuropathy)
Peripheral Sensory Neuropathy
(Peripheral sensory neuropathy)
Platelet Count Decreased (Platelet count
decreased)
Proctitis (Proctitis)
Rectal Hemorrhage (Rectal hemorrhage)
Thromboembolic Event
(Thromboembolic event)
Vomiting (Vomiting)
CTCAE v4.0 - Other, Specify
CTC Adverse Event Grade
Mild Adverse Event (1)
Moderate Adverse Event (2)
Severe Adverse Event (3)
Life Threatening Adverse Event (4)
Death Related To Adverse Event (5)
CTC AE Attribution Code
Definite (Definite)
Possible (Possible)
Probable (Probable)
Unlikely (Unlikely)
Unrelated (Unrelated)
Footer Module
Investigator Name
Date
Investigator's signature
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NCT00956007 Treatment - RTOG 0920 Phase III Head
and Neck Cancer Radiotherapy Form (T1) - 2807789v1.0
RTOG 0920 Phase III Head and Neck Cancer Radiotherapy
Form (T1)
Radiation Therapy With or Without Cetuximab in Treating
Patients Who Have Undergone Surgery for Locally
Advanced Head and Neck Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=5D1164A3-
C392-12C3-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/8166
RTOG 0920 Phase III Head and
Neck Cancer Radiotherapy Form
(T1)
Module 1
RTOG Study No.
Case #
Institution Name
Institution No.
Patient Initials
RTOG Patient ID
Amended Data
Yes
No
Radiation Therapy Start Date (MM DD YYYY)
Radiation Therapy End Date (MM DD YYYY)
Elapsed days
RT Total Fraction Count
RT Total Dose  (Gy)
Were there any unscheduled interruptions in
radiation therapy? (excluding holidays)
No (No)
Yes, Due To Other Reason (Yes, due to
other reason)
Yes, Due To Toxicity (Yes, due to toxicity)
Specify RT interruption reason
Reason Treatment Ended
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Adverse Event/side Effects/complications
(Adverse Event/Side
Effects/Complications)
Alternative Therapy (Alternative therapy)
Death On Study (Death on study)
Disease Progression, Relapse During
Active Treatment (Disease progression,
relapse during active treatment)
Other (Other)
Patient Off-treatment For Other
Complicating Disease (Patient off-
treatment for other complicating disease)
Patient Withdrawal Or Refusal After
Beginning Protocol Therapy (Patient
withdrawal/refusal after beginning
protocol therapy)
Patient Withdrawal Or Refusal Before
Beginning Protocol Therapy (Patient
withdrawal/refusal prior to beginning
protocol therapy)
Treatment Completed Per Protocol
Criteria (Treatment completed per
protocol criteria)
Alternative Therapy
Other specify
Type of Radiation Therapy Administered
Imrt (IMRT)
Imrt And Igrt (IMRT and IGRT)
Was immobilization used
Yes
No
Margin used for PTV expansion?
Comments
Person Completing Form
Date Form Originally Completed (MM DD YYYY)
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Cervical Cancer NCT01414608 Toxicity -
ANZGOG-0902 Toxicity - Treatment - 3142570v1.0
ANZGOG-0902 Toxicity - Treatment
Cisplatin and Radiation Therapy With or Without
Carboplatin and Paclitaxel in Patients With Locally
Advanced Cervical Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=9104F873-
2730-FB60-E040-BB89AD437958
All rights reserved. Please visit https://medical-data-
models.org/forms/8167
ANZGOG-0902 Toxicity - Treatment
Header
Patient Initials
Patient ID
Institution Code
Date of Symptom/Event Assessment
Has the patient experienced any toxicities related
to study treatment since the last report?
Yes
No
Toxicities
CTCAE V4.0 Term
Colitis (Colitis)
Creatinine Increased (Creatinine
increased)
Diarrhea (Diarrhea)
Enterocolitis (Enterocolitis)
Fatigue (Fatigue)
Female Genital Tract Fistula (Female
genital tract fistula)
Fibrosis Deep Connective Tissue
(Fibrosis deep connective tissue)
Gastrointestinal Fistula (Gastrointestinal
fistula)
Hearing Impaired (Hearing impaired)
Lymphedema (Lymphedema)
Obstruction Gastric (Obstruction gastric)
Pain (Pain)
Peripheral Motor Neuropathy (Peripheral
motor neuropathy)
Peripheral Sensory Neuropathy
(Peripheral sensory neuropathy)
Proctitis (Proctitis)
Rectal Hemorrhage (Rectal hemorrhage)
Telangiectasia (Telangiectasia)
Uterine Obstruction (Uterine obstruction)
Vaginal Discharge (Vaginal discharge)
Vaginal Dryness (Vaginal dryness)
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Vaginal Stricture (Vaginal stricture)
CTCAE v4.0 - Other, Specify
CTC Adverse Event Grade
Mild Adverse Event (1)
Moderate Adverse Event (2)
Severe Adverse Event (3)
Life Threatening Adverse Event (4)
Death Related To Adverse Event (5)
CTC AE Attribution Code
Definite (Definite)
Possible (Possible)
Probable (Probable)
Unlikely (Unlikely)
Unrelated (Unrelated)
Footer Module
Investigator Name
Date
Investigator's signature
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NCT01302834 Quality of Life - RTOG 1016 QP:  Radiation Therapy Oncology
Group Phase III Head and Neck Cancer Miscellaneous Patient Assessment Form -
3158700v1.0
RTOG 1016 QP:  Radiation Therapy Oncology Group
Phase III Head and Neck Cancer Miscellaneous Patient
Assessment Form
Radiation Therapy With Cisplatin or Cetuximab in Treating
Patients With Oropharyngeal Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=94CE2BCD-
7B3B-56A6-E040-BB89AD431367
All rights reserved. Please visit https://medical-data-
models.org/forms/8173
RTOG 1016 QP:  Radiation Therapy
Oncology Group Phase III Head and
Neck Cancer Miscellaneous Patient
Assessment Form
Unnamed Module 1
RTOG Study No.
Case #
Institution Name
Institution No.
Patient Initials
RTOG Patient ID
Unamed Module 2
SCHEDULED DATA POINT (CHECK ONE)
Other (Other)
Other Followup (other followup)
Pre Treatment Assessment (Pre
treatment assessment)
other followup (specify calendar date or followup
interval, e.g., 3 months, 2 years, etc.)
Other, specify
IF NO PATIENT ASSESSMENT, SPECIFY
REASON (CHECK ONE)
Other Reason (Other reason)
Patient Refused, Including Attempts By
Telephone Interview (Patient refused,
including attempts by telephone
interview)
Patient Refused, Telephone Interview
Not Attempted (Patient refused,
telephone interview not attempted)
Patient Unable To Be Contacted (Patient
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unable to be contacted)
Patient Was Too Ill (Patient was too ill)
Questionnaire Not Completed Due To
Institutional Error (Questionnaire not
completed due to institutional error)
Patient refused, including attempts by telephone
interview, specify reason for refusal
Patient refused, telephone interview not
attempted, specify reason for refusal
Other reason, specify
WAS INFORMATION OBTAINED BY
TELEPHONE INTERVIEW (CHECK ONE)
Yes
No
Date of Evaluation
RATER'S NAME
Normalcy of Diet Rating (CHECK ONE)
0= Non-oral Feeding (tube Fed) (0)
10= Cold Liquids (10)
100= Full Diet (no Restrictions) (100)
20= Warm Liquids (20)
30= Pureed Foods (in Blender) (30)
40= Soft Foods Requiring No Chewing
(e.g., Mashed Potatoes, Apple Sauce,
Pudding) (40)
50= Soft, Chewable Foods (e.g.,
Macaroni, Canned/soft Fruits, Cooked
Vegetables, Fish, Hamburger, Small
Pieces Of Meat) (50)
60= Dry Bread And Crackers (60)
70= Raw Carrots, Celery (70)
80= All Meat (80)
90= Full Diet (liquid Assist) (90)
Public Eating Rating (CHECK ONE)
0= Always Eats Alone (0)
100= No Restriction Of Place, Food Or
Companion (eats Out At Any
Opportunity) (100)
25= Eats Only At Home In Presence Of
Selected Persons (25)
50= Eats Only In Presence Of Selected
Persons In Selected Places (50)
75= No Restriction Of Place, But
Restricts Diet When In Public (eats
Anywhere, But May Limit Intake To Less
"messy" Foods, E.g., Liquids) (75)
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Understandability of Speech Rating (CHECK
ONE)
0= Never Understandable; May Use
Written Communication (0)
100= Always Understandable (100)
25= Difficult To Understand (25)
50= Usually Understandable; Face-to-
face Contact Necessary (50)
75= Understandable Most Of The Time;
Occasional Repetition Necessary (75)
Comments
COMMENTS
Completed by
Date Form Originally Completed (MM DD YYYY)
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Colorectal Cancer NCT00726622 Toxicity - Z6051
Late Complications Form (LCF) - 2718039v1.0
Z6051 Late Complications Form (LCF)
Laparoscopic-Assisted Resection or Open Resection in
Treating Patients With Stage IIA, Stage IIIA, or Stage IIIB
Rectal Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=42C1B1EA-
11D5-09AA-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/8176
Z6051 Late Complications Form
(LCF)
Header Module
Visit
4-6 Weeks Post-surgery (4-6 weeks
post-surgery)
Month 12 (Month 12)
Month 18 (Month 18)
Month 24 (Month 24)
Month 3 (Month 3)
Month 6 (Month 6)
Patient ID (Pt. ID issued during registration or
previously issued Patient ID)
Patient Initials
Institution No.
Institution No.
Institution Name
Instruction Module
Date of Symptom/Event Assessment
Was patient hospitalized during this reporting
interval?
Yes
No
Has an Adverse Event Expedited Report been
submitted?
Yes
No
Ae Module
CTC Adverse Event Term
Not Assessed (Also mark if Grade 1 or 2)
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CTC Adverse Event Grade (1-5)
Not present
CTC AE Attribution Code (see above)
Definite (definite)
Possible (possible)
Probable (probable)
Unlikely (unlikely)
Unrelated (unrelated)
Header
Were any additional adverse events experienced
by the patient
Yes
No
Other Ae Module
CTC Adverse Event Term
CTC Adverse Event Grade (1-5)
CTC AE Attribution Code (see above)
Definite (definite)
Possible (possible)
Probable (probable)
Unlikely (unlikely)
Unrelated (unrelated)
Completed by
Form Complete Date
2 / 2
Colorectal Cancer NCT00726622 Toxicity - Z6051 Late Complications
Form (LCF) - 2718039v1.0
Endometrial Cancer NCT00942357 Toxicity - Gynecologic Oncology Group
Follow-Up Period Adverse Event Reporting Form (TLC) - 2845009v1.0
Gynecologic Oncology Group Follow-Up Period Adverse
Event Reporting Form (TLC)
Carboplatin and Paclitaxel With or Without Cisplatin and
Radiation Therapy in Treating Patients With Stage I, Stage
II, Stage III, or Stage IVA Endometrial Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=644E86D7-
E1C5-D7C8-E040-BB89AD4321CC
All rights reserved. Please visit https://medical-data-
models.org/forms/8187
Gynecologic Oncology Group
Follow-Up Period Adverse Event
Reporting Form (TLC)
Header Module
Date form originally completed (m d y)
Date form amended (m d y)
Person amending form, last name
Patient Initials
Patient Study ID
Person Completing Form, Last Name
Adverse Events - Section 1
Reporting Period
Are there any adverse events to report
No (No)
Patient Not Evaluated (Patient not
evaluated)
Yes (Yes)
Date of Most Recent Adverse Event Assessment
(m d y)
Was patient hospitalized as a result of reported
adverse events? (during this reporting period)
Yes
No
Adverse Events - Section 3
CTC Adverse Event Term
CTC Adverse Event Grade
CTC Adverse Event Attribution Code (Attribution
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Codes for Relationship of Event to Treatment:
1=Unrelated, 2=Unlikely, 3=Possibly, 4=Probably,
5=Definitely)
Definite (Definite)
Possible (Possible)
Probable (Probable)
Unlikely (Unlikely)
Unrelated (Unrelated)
SAE report submitted
Yes
No
AE Onset Date
Present Status
Ae Status Not Evaluated (AE status not
evaluated)
Fatal Or Died (Fatal/Died)
Intervention For Adverse Event
Continues (Intervention for AE
Continues)
Not Recovered Or Not Resolved (Not
recovered/Not resolved)
Recovered Or Resolved With Sequelae
(Recovered/Resolved with Sequelae)
Recovered Or Resolved Without
Sequelae (Recovered/Resolved without
Sequelae)
Recovering Or Resolving
(Recovering/Resolving)
Comments
COMMENTS
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Endometrial Cancer NCT00942357 Toxicity - Gynecologic Oncology Group
Follow-Up Period Adverse Event Reporting Form (TLC) - 2845009v1.0
Endometrial Cancer NCT00807768 Toxicity - GOG-0249 Follow-
Up Period Adverse Event Reporting Form - 2760083v1.0
GOG-0249 Follow-Up Period Adverse Event Reporting
Form
Pelvic Radiation Therapy or Vaginal Implant Radiation
Therapy, Paclitaxel, and Carboplatin in Treating Patients
With High-Risk Stage I or Stage II Endometrial Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=4FF32E53-
FBDD-394B-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/8189
GOG-0249 Follow-Up Period
Adverse Event Reporting Form
Header Module
Date form originally completed (m d y)
Date form amended (m d y)
Person amending form, last name
Patient Initials
Patient Study ID
Person Completing Form, Last Name
Adverse Events - Section 1
Reporting Period
Are there any adverse events to report
No (No)
Patient Not Evaluated (Patient not
evaluated)
Yes (Yes)
Were adverse events assessed during most
recent period
Yes
No
Date of Most Recent Adverse Event Assessment
(m d y)
Was patient hospitalized as a result of reported
adverse events? (during this reporting period)
Yes
No
Adverse Events - Section 3
CTC Adverse Event Term
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CTC Adverse Event Grade
CTC Adverse Event Attribution Code (Attribution
Codes for Relationship of Event to Treatment:
1=Unrelated, 2=Unlikely, 3=Possibly, 4=Probably,
5=Definitely)
Definite (Definite)
Possible (Possible)
Probable (Probable)
Unlikely (Unlikely)
Unrelated (Unrelated)
SAE report submitted
No (No)
Unknown (Unknown)
Yes (Yes)
AE Onset Date
Present Status
Ae Status Not Evaluated (AE status not
evaluated)
Fatal Or Died (Fatal/Died)
Intervention For Adverse Event
Continues (Intervention for AE
Continues)
Not Recovered Or Not Resolved (Not
recovered/Not resolved)
Recovered Or Resolved With Sequelae
(Recovered/Resolved with Sequelae)
Recovered Or Resolved Without
Sequelae (Recovered/Resolved without
Sequelae)
Recovering Or Resolving
(Recovering/Resolving)
Comments
COMMENTS
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Endometrial Cancer NCT00807768 Toxicity - GOG-0249 Follow-Up
Period Adverse Event Reporting Form - 2760083v1.0
Lung Cancer NCT00107172 Toxicity - Z4032
Radiation Therapy Toxicities - 2306569v3.0
Z4032 Radiation Therapy Toxicities
Surgery With or Without Internal Radiation Therapy in
Treating Patients With Stage I Non-Small Cell Lung Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=F21DFC13-
296B-7064-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/8194
Z4032 Radiation Therapy Toxicities
Header Module
Visit
Day 0 (Day 0)
Month 30 (Month 30)
Month 36 (Month 36)
Month 48 (Month 48)
Month 60 (Month 60)
Registration (Registration)
Patient ID
Patient Initials (F M L)
Institution No.
Institution
Date of Symptom/Event Assessment
Header
Has the patient experienced any radiation-related
toxicities since the last visit (*)
Yes
No
Common Toxicity Criteria Adverse Event Term
Type
Adult Respiratory Distress Syndrome
(Adult respiratory distress syndrome
(ARDS))
Fistula, Pulmonary/upper Respiratory
(Fistula, pulmonary/upper respiratory -
Bronchus)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Lung (pneumonia))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
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neutrophils - Pleura (empyema))
Culture Wound Positive (Infection with
unknown ANC - Wound)
Prolonged Chest Tube Drainage Or Air
Leak After Pulmonary Resection
(Prolonged chest tube drainage or air
leak after pulmonary resection)
Not present
CTC Adverse Event Grade
CTC AE Attribution Code
Definite (definite)
Possible (possible)
Probable (probable)
Unlikely (unlikely)
Unrelated (unrelated)
Footer Module
Completed by
Date Form Completed
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Lung Cancer NCT00107172 Toxicity - Z4032 Radiation Therapy Toxicities
- 2306569v3.0
Lung Cancer NCT00107172 Toxicity -
Z4032 Adverse Events Form - 2305695v3.0
Z4032 Adverse Events Form
Surgery With or Without Internal Radiation Therapy in
Treating Patients With Stage I Non-Small Cell Lung Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=F20AB755-
5BF4-19FB-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/8195
Z4032 Adverse Events Form
Header Module
Visit
Day 0 (Day 0)
Month 1 (Month 1)
Month 12 (Month 12)
Month 18 (Month 18)
Month 24 (Month 24)
Month 3 (Month 3)
Month 6 (Month 6)
Patient ID (Pt. ID issued during registration or
previously issued Patient ID)
Patient Initials
Institution ID
Institution ID
Institution
Instruction Module
Date of Symptom/Event Assessment
Was patient hospitalized during this reporting
interval?
Yes
No
Has an Adverse Event Expedited Report been
submitted?
Yes
No
Ae Module
CTC Adverse Event Term
Not Assessed (Also mark if Grade 1 or 2)
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Not present
CTCAE v3.0 Grade (1-5)
Treatment Attribution (see above)
Definite (definite)
Possible (possible)
Probable (probable)
Unlikely (unlikely)
Unrelated (unrelated)
Header
Check box if no additional adverse events were
experienced by the patient.
Other Ae Module
CTC Adverse Event Term
CTCAE v3.0 Grade (1-5)
Completed by
Treatment Attribution (see above)
Definite (definite)
Possible (possible)
Probable (probable)
Unlikely (unlikely)
Unrelated (unrelated)
Form Complete Date
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Lung Cancer NCT00107172 Toxicity - Z4032 Adverse Events Form -
2305695v3.0
Lymphoma NCT01190449 Toxicity - CALGB
50901 Late Adverse Event Form - 3209346v1.0
CALGB 50901 Late Adverse Event Form
Ofatumumab in Treating Patients With Previously Untreated
Stage II, Stage III, or Stage IV Follicular Non-Hodgkin
Lymphoma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=9F3B86AC-
0E36-9C11-E040-BB89AD435C6C
All rights reserved. Please visit https://medical-data-
models.org/forms/8196
CALGB 50901 Late Adverse Event
Form
Protocol Specific Adverse Event
Evaluation
New or continuing adverse events
Yes
No
CTC Adverse Event Term
Abdominal Distension (Abdominal
distension)
Abdominal Infection (Abdominal
infection)
Abdominal Pain (Abdominal pain)
Abdominal Soft Tissue Necrosis
(Abdominal soft tissue necrosis)
Abducens Nerve Disorder (Abducens
nerve disorder)
Accessory Nerve Disorder (Accessory
nerve disorder)
Acidosis (Acidosis)
Acoustic Nerve Disorder Nos (Acoustic
nerve disorder NOS)
Activated Partial Thromboplastin Time
Prolonged (Activated partial
thromboplastin time prolonged)
Acute Coronary Syndrome (Acute
coronary syndrome)
Acute Kidney Injury (Acute kidney injury)
Adrenal Insufficiency (Adrenal
insufficiency)
Adult Respiratory Distress Syndrome
(Adult respiratory distress syndrome)
Agitation (Agitation)
Akathisia (Akathisia)
Alanine Aminotransferase Increased
(Alanine aminotransferase increased)
Alcohol Intolerance (Alcohol intolerance)
Alkaline Phosphatase Increased
(Alkaline phosphatase increased)
Alkalosis (Alkalosis)
Allergic Reaction (Allergic reaction)
Allergic Rhinitis (Allergic rhinitis)
Alopecia (Alopecia)
Amnesia (Amnesia)
Anal Fistula (Anal fistula)
Anal Hemorrhage (Anal hemorrhage)
Anal Mucositis (Anal mucositis)
Anal Necrosis (Anal necrosis)
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Anal Pain (Anal pain)
Anal Stenosis (Anal stenosis)
Anal Ulcer (Anal ulcer)
Anaphylaxis (Anaphylaxis)
Anemia (Anemia)
Ankle Fracture (Ankle fracture)
Anorectal Infection (Anorectal infection)
Anorexia (Anorexia)
Anorgasmia (Anorgasmia)
Anxiety (Anxiety)
Aortic Injury (Aortic injury)
Aortic Valve Disease (Aortic valve
disease)
Aphonia (Aphonia)
Apnea (Apnea)
Appendicitis (Appendicitis)
Appendicitis Perforated (Appendicitis
perforated)
Arachnoiditis (Arachnoiditis)
Arterial Injury (Arterial injury)
Arteritis Infective (Arteritis infective)
Arthralgia (Arthralgia)
Arthritis (Arthritis)
Ascites (Ascites)
Aspartate Aminotransferase Increased
(Aspartate aminotransferase increased)
Aspiration (Aspiration)
Asystole (Asystole)
Ataxia (Ataxia)
Atelectasis (Atelectasis)
Atrial Fibrillation (Atrial fibrillation)
Atrial Flutter (Atrial flutter)
Atrioventricular Block Complete
(Atrioventricular block complete)
Atrioventricular Block First Degree
(Atrioventricular block first degree)
Autoimmune Disorder (Autoimmune
disorder)
Avascular Necrosis (Avascular necrosis)
Azoospermia (Azoospermia)
Back Pain (Back pain)
Bile Duct Stenosis (Bile duct stenosis)
Biliary Anastomotic Leak (Biliary
anastomotic leak)
Biliary Fistula (Biliary fistula)
Biliary Tract Infection (Biliary tract
infection)
Bladder Anastomotic Leak (Bladder
anastomotic leak)
Bladder Infection (Bladder infection)
Bladder Perforation (Bladder perforation)
Bladder Spasm (Bladder spasm)
Bloating (Bloating)
Blood And Lymphatic System Disorders -
Other, Specify (Blood and lymphatic
system disorders - Other, Specify)
Blood Antidiuretic Hormone Abnormal
(Blood antidiuretic hormone abnormal)
Blood Bilirubin Increased (Blood bilirubin
increased)
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Blood Corticotrophin Decreased (Blood
corticotrophin decreased)
Blood Gonadotrophin Abnormal (Blood
gonadotrophin abnormal)
Blood Prolactin Abnormal (Blood
prolactin abnormal)
Blurred Vision (Blurred vision)
Body Odor (Body odor)
Bone Infection (Bone infection)
Bone Marrow Hypocellular (Bone
marrow hypocellular)
Bone Pain (Bone pain)
Brachial Plexopathy (Brachial
plexopathy)
Breast Atrophy (Breast atrophy)
Breast Infection (Breast infection)
Breast Pain (Breast pain)
Bronchial Fistula (Bronchial fistula)
Bronchial Infection (Bronchial infection)
Bronchial Obstruction (Bronchial
obstruction)
Bronchial Stricture (Bronchial stricture)
Bronchopleural Fistula (Bronchopleural
fistula)
Bronchopulmonary Hemorrhage
(Bronchopulmonary hemorrhage)
Bronchospasm (Bronchospasm)
Bruising (Bruising)
Bullous Dermatitis (Bullous dermatitis)
Burn (Burn)
Buttock Pain (Buttock pain)
Capillary Leak Syndrome (Capillary leak
syndrome)
Carbon Monoxide Diffusing Capacity
Decreased (Carbon monoxide diffusing
capacity decreased)
Cardiac Arrest (Cardiac arrest)
Cardiac Disorders - Other, Specify
(Cardiac disorders - Other, Specify)
Cardiac Troponin I Increased (Cardiac
troponin I increased)
Cardiac Troponin T Increased (Cardiac
troponin T increased)
Cataract (Cataract)
Catheter Related Infection (Catheter
related infection)
Cd4 Lymphocytes Decreased (CD4
lymphocytes decreased)
Cecal Hemorrhage (Cecal hemorrhage)
Cecal Infection (Cecal infection)
Central Nervous System Necrosis
(Central nervous system necrosis)
Cerebrospinal Fluid Leakage
(Cerebrospinal fluid leakage)
Cervicitis Infection (Cervicitis infection)
Cheilitis (Cheilitis)
Chest Pain - Cardiac (Chest pain -
cardiac)
Chest Wall Pain (Chest wall pain)
Chills (Chills)
3 / 21
Lymphoma NCT01190449 Toxicity - CALGB 50901 Late Adverse Event
Form - 3209346v1.0
Cholecystitis (Cholecystitis)
Cholesterol High (Cholesterol high)
Chronic Kidney Disease (Chronic kidney
disease)
Chylothorax (Chylothorax)
Cognitive Disturbance (Cognitive
disturbance)
Colitis (Colitis)
Colonic Fistula (Colonic fistula)
Colonic Hemorrhage (Colonic
hemorrhage)
Colonic Obstruction (Colonic obstruction)
Colonic Perforation (Colonic perforation)
Colonic Stenosis (Colonic stenosis)
Colonic Ulcer (Colonic ulcer)
Concentration Impairment
(Concentration impairment)
Conduction Disorder (Conduction
disorder)
Confusion (Confusion)
Congenital, Familial And Genetic
Disorders - Other, Specify (Congenital,
familial and genetic disorders - Other,
Specify)
Conjunctivitis (Conjunctivitis)
Conjunctivitis Infective (Conjunctivitis
infective)
Constipation (Constipation)
Constrictive Pericarditis (Constrictive
pericarditis)
Corneal Infection (Corneal infection)
Corneal Ulcer (Corneal ulcer)
Cough (Cough)
Cpk Increased (CPK increased)
Cranial Nerve Infection (Cranial nerve
infection)
Creatinine Increased (Creatinine
increased)
Cushingoid (Cushingoid)
Cystitis Noninfective (Cystitis
noninfective)
Cytokine Release Syndrome (Cytokine
release syndrome)
Death Neonatal (Death neonatal)
Death Nos (Death NOS)
Dehydration (Dehydration)
Delayed Orgasm (Delayed orgasm)
Delayed Puberty (Delayed puberty)
Delirium (Delirium)
Delusions (Delusions)
Dental Caries (Dental caries)
Depressed Level Of Consciousness
(Depressed level of consciousness)
Depression (Depression)
Dermatitis Radiation (Dermatitis
radiation)
Device Related Infection (Device related
infection)
Diarrhea (Diarrhea)
Disseminated Intravascular Coagulation
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(Disseminated intravascular coagulation)
Dizziness (Dizziness)
Dry Eye (Dry eye)
Dry Mouth (Dry mouth)
Dry Skin (Dry skin)
Duodenal Fistula (Duodenal fistula)
Duodenal Hemorrhage (Duodenal
hemorrhage)
Duodenal Infection (Duodenal infection)
Duodenal Obstruction (Duodenal
obstruction)
Duodenal Perforation (Duodenal
perforation)
Duodenal Stenosis (Duodenal stenosis)
Duodenal Ulcer (Duodenal ulcer)
Dysarthria (Dysarthria)
Dysesthesia (Dysesthesia)
Dysgeusia (Dysgeusia)
Dysmenorrhea (Dysmenorrhea)
Dyspareunia (Dyspareunia)
Dyspepsia (Dyspepsia)
Dysphagia (Dysphagia)
Dysphasia (Dysphasia)
Dyspnea (Dyspnea)
Ear And Labyrinth Disorders - Other,
Specify (Ear and labyrinth disorders -
Other, Specify)
Ear Pain (Ear pain)
Edema Cerebral (Edema cerebral)
Edema Face (Edema face)
Edema Limbs (Edema limbs)
Edema Trunk (Edema trunk)
Ejaculation Disorder (Ejaculation
disorder)
Ejection Fraction Decreased (Ejection
fraction decreased)
Electrocardiogram Qt Corrected Interval
Prolonged (Electrocardiogram QT
corrected interval prolonged)
Encephalitis Infection (Encephalitis
infection)
Encephalomyelitis Infection
(Encephalomyelitis infection)
Encephalopathy (Encephalopathy)
Endocarditis Infective (Endocarditis
infective)
Endocrine Disorders - Other, Specify
(Endocrine disorders - Other, Specify)
Endophthalmitis (Endophthalmitis)
Enterocolitis (Enterocolitis)
Enterocolitis Infectious (Enterocolitis
infectious)
Enterovesical Fistula (Enterovesical
fistula)
Epistaxis (Epistaxis)
Erectile Dysfunction (Erectile
dysfunction)
Erythema Multiforme (Erythema
multiforme)
Erythroderma (Erythroderma)
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Esophageal Anastomotic Leak
(Esophageal anastomotic leak)
Esophageal Fistula (Esophageal fistula)
Esophageal Hemorrhage (Esophageal
hemorrhage)
Esophageal Infection (Esophageal
infection)
Esophageal Necrosis (Esophageal
necrosis)
Esophageal Obstruction (Esophageal
obstruction)
Esophageal Pain (Esophageal pain)
Esophageal Perforation (Esophageal
perforation)
Esophageal Stenosis (Esophageal
stenosis)
Esophageal Ulcer (Esophageal ulcer)
Esophageal Varices Hemorrhage
(Esophageal varices hemorrhage)
Esophagitis (Esophagitis)
Euphoria (Euphoria)
Exostosis (Exostosis)
External Ear Inflammation (External ear
inflammation)
External Ear Pain (External ear pain)
Extraocular Muscle Paresis (Extraocular
muscle paresis)
Extrapyramidal Disorder (Extrapyramidal
disorder)
Eye Disorders - Other, Specify (Eye
disorders - Other, Specify)
Eye Infection (Eye infection)
Eye Pain (Eye pain)
Eyelid Function Disorder (Eyelid function
disorder)
Facial Muscle Weakness (Facial muscle
weakness)
Facial Nerve Disorder (Facial nerve
disorder)
Facial Pain (Facial pain)
Fall (Fall)
Fallopian Tube Anastomotic Leak
(Fallopian tube anastomotic leak)
Fallopian Tube Obstruction (Fallopian
tube obstruction)
Fallopian Tube Perforation (Fallopian
tube perforation)
Fallopian Tube Stenosis (Fallopian tube
stenosis)
Fat Atrophy (Fat atrophy)
Fatigue (Fatigue)
Febrile Neutropenia (Febrile
neutropenia)
Fecal Incontinence (Fecal incontinence)
Female Genital Tract Fistula (Female
genital tract fistula)
Feminization Acquired (Feminization
acquired)
Fetal Death (Fetal death)
Fetal Growth Retardation (Fetal growth
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retardation)
Fever (Fever)
Fibrinogen Decreased (Fibrinogen
decreased)
Fibrosis Deep Connective Tissue
(Fibrosis deep connective tissue)
Flank Pain (Flank pain)
Flashing Lights (Flashing lights)
Flatulence (Flatulence)
Floaters (Floaters)
Flu Like Symptoms (Flu like symptoms)
Flushing (Flushing)
Forced Expiratory Volume Decreased
(Forced expiratory volume decreased)
Fracture (Fracture)
Gait Disturbance (Gait disturbance)
Gallbladder Fistula (Gallbladder fistula)
Gallbladder Infection (Gallbladder
infection)
Gallbladder Necrosis (Gallbladder
necrosis)
Gallbladder Obstruction (Gallbladder
obstruction)
Gallbladder Pain (Gallbladder pain)
Gallbladder Perforation (Gallbladder
perforation)
Gastric Anastomotic Leak (Gastric
anastomotic leak)
Gastric Fistula (Gastric fistula)
Gastric Hemorrhage (Gastric
hemorrhage)
Gastric Necrosis (Gastric necrosis)
Gastric Perforation (Gastric perforation)
Gastric Stenosis (Gastric stenosis)
Gastric Ulcer (Gastric ulcer)
Gastritis (Gastritis)
Gastroesophageal Reflux Disease
(Gastroesophageal reflux disease)
Gastrointestinal Anastomotic Leak
(Gastrointestinal anastomotic leak)
Gastrointestinal Disorders - Other,
Specify (Gastrointestinal disorders -
Other, Specify)
Gastrointestinal Fistula (Gastrointestinal
fistula)
Gastrointestinal Pain (Gastrointestinal
pain)
Gastrointestinal Stoma Necrosis
(Gastrointestinal stoma necrosis)
Gastroparesis (Gastroparesis)
General Disorders And Administration
Site Conditions - Other, Specify (General
disorders and administration site
conditions - Other, Specify)
Generalized Muscle Weakness
(Generalized muscle weakness)
Genital Edema (Genital edema)
Ggt Increased (GGT increased)
Gingival Pain (Gingival pain)
Glaucoma (Glaucoma)
7 / 21
Lymphoma NCT01190449 Toxicity - CALGB 50901 Late Adverse Event
Form - 3209346v1.0
Glossopharyngeal Nerve Disorder
(Glossopharyngeal nerve disorder)
Glucose Intolerance (Glucose
intolerance)
Growth Accelerated (Growth
accelerated)
Growth Hormone Abnormal (Growth
hormone abnormal)
Growth Suppression (Growth
suppression)
Gum Infection (Gum infection)
Gynecomastia (Gynecomastia)
Hallucinations (Hallucinations)
Haptoglobin Decreased (Haptoglobin
decreased)
Head Soft Tissue Necrosis (Head soft
tissue necrosis)
Headache (Headache)
Hearing Impaired (Hearing impaired)
Heart Failure (Heart failure)
Hematoma (Hematoma)
Hematosalpinx (Hematosalpinx)
Hematuria (Hematuria)
Hemoglobin Increased (Hemoglobin
increased)
Hemoglobinuria (Hemoglobinuria)
Hemolysis (Hemolysis)
Hemolytic Uremic Syndrome (Hemolytic
uremic syndrome)
Hemorrhoidal Hemorrhage
(Hemorrhoidal hemorrhage)
Hemorrhoids (Hemorrhoids)
Hepatic Failure (Hepatic failure)
Hepatic Hemorrhage (Hepatic
hemorrhage)
Hepatic Infection (Hepatic infection)
Hepatic Necrosis (Hepatic necrosis)
Hepatic Pain (Hepatic pain)
Hepatitis Viral (Hepatitis viral)
Hepatobiliary Disorders - Other, Specify
(Hepatobiliary disorders - Other, Specify)
Hiccups (Hiccups)
Hip Fracture (Hip fracture)
Hirsutism (Hirsutism)
Hoarseness (Hoarseness)
Hot Flashes (Hot flashes)
Hydrocephalus (Hydrocephalus)
Hypercalcemia (Hypercalcemia)
Hyperglycemia (Hyperglycemia)
Hyperhidrosis (Hyperhidrosis)
Hyperkalemia (Hyperkalemia)
Hypermagnesemia (Hypermagnesemia)
Hypernatremia (Hypernatremia)
Hyperparathyroidism
(Hyperparathyroidism)
Hypersomnia (Hypersomnia)
Hypertension (Hypertension)
Hyperthyroidism (Hyperthyroidism)
Hypertrichosis (Hypertrichosis)
Hypertriglyceridemia
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(Hypertriglyceridemia)
Hyperuricemia (Hyperuricemia)
Hypoalbuminemia (Hypoalbuminemia)
Hypocalcemia (Hypocalcemia)
Hypoglossal Nerve Disorder
(Hypoglossal nerve disorder)
Hypoglycemia (Hypoglycemia)
Hypohidrosis (Hypohidrosis)
Hypokalemia (Hypokalemia)
Hypomagnesemia (Hypomagnesemia)
Hyponatremia (Hyponatremia)
Hypoparathyroidism
(Hypoparathyroidism)
Hypophosphatemia (Hypophosphatemia)
Hypotension (Hypotension)
Hypothermia (Hypothermia)
Hypothyroidism (Hypothyroidism)
Hypoxia (Hypoxia)
Ileal Fistula (Ileal fistula)
Ileal Hemorrhage (Ileal hemorrhage)
Ileal Obstruction (Ileal obstruction)
Ileal Perforation (Ileal perforation)
Ileal Stenosis (Ileal stenosis)
Ileal Ulcer (Ileal ulcer)
Ileus (Ileus)
Immune System Disorders - Other,
Specify (Immune system disorders -
Other, Specify)
Infections And Infestations - Other,
Specify (Infections and infestations -
Other, Specify)
Infective Myositis (Infective myositis)
Infusion Related Reaction (Infusion
related reaction)
Infusion Site Extravasation (Infusion site
extravasation)
Injection Site Reaction (Injection site
reaction)
Injury To Carotid Artery (Injury to carotid
artery)
Injury To Inferior Vena Cava (Injury to
inferior vena cava)
Injury To Jugular Vein (Injury to jugular
vein)
Injury To Superior Vena Cava (Injury to
superior vena cava)
Injury, Poisoning And Procedural
Complications - Other, Specify (Injury,
poisoning and procedural complications -
Other, Specify)
Inr Increased (INR increased)
Insomnia (Insomnia)
Intestinal Stoma Leak (Intestinal stoma
leak)
Intestinal Stoma Obstruction (Intestinal
stoma obstruction)
Intestinal Stoma Site Bleeding (Intestinal
stoma site bleeding)
Intra-abdominal Hemorrhage (Intra-
abdominal hemorrhage)
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Intracranial Hemorrhage (Intracranial
hemorrhage)
Intraoperative Arterial Injury
(Intraoperative arterial injury)
Intraoperative Breast Injury
(Intraoperative breast injury)
Intraoperative Cardiac Injury
(Intraoperative cardiac injury)
Intraoperative Ear Injury (Intraoperative
ear injury)
Intraoperative Endocrine Injury
(Intraoperative endocrine injury)
Intraoperative Gastrointestinal Injury
(Intraoperative gastrointestinal injury)
Intraoperative Head And Neck Injury
(Intraoperative head and neck injury)
Intraoperative Hemorrhage
(Intraoperative hemorrhage)
Intraoperative Hepatobiliary Injury
(Intraoperative hepatobiliary injury)
Intraoperative Musculoskeletal Injury
(Intraoperative musculoskeletal injury)
Intraoperative Neurological Injury
(Intraoperative neurological injury)
Intraoperative Ocular Injury
(Intraoperative ocular injury)
Intraoperative Renal Injury
(Intraoperative renal injury)
Intraoperative Reproductive Tract Injury
(Intraoperative reproductive tract injury)
Intraoperative Respiratory Injury
(Intraoperative respiratory injury)
Intraoperative Skin Injury (Intraoperative
skin injury)
Intraoperative Splenic Injury
(Intraoperative splenic injury)
Intraoperative Urinary Injury
(Intraoperative urinary injury)
Intraoperative Venous Injury
(Intraoperative venous injury)
Investigations - Other, Specify
(Investigations - Other, Specify)
Iron Overload (Iron overload)
Irregular Menstruation (Irregular
menstruation)
Irritability (Irritability)
Ischemia Cerebrovascular (Ischemia
cerebrovascular)
Ivth Nerve Disorder (IVth nerve disorder)
Jejunal Fistula (Jejunal fistula)
Jejunal Hemorrhage (Jejunal
hemorrhage)
Jejunal Obstruction (Jejunal obstruction)
Jejunal Perforation (Jejunal perforation)
Jejunal Stenosis (Jejunal stenosis)
Jejunal Ulcer (Jejunal ulcer)
Joint Effusion (Joint effusion)
Joint Infection (Joint infection)
Joint Range Of Motion Decreased (Joint
range of motion decreased)
10 / 21
Lymphoma NCT01190449 Toxicity - CALGB 50901 Late Adverse Event
Form - 3209346v1.0
Joint Range Of Motion Decreased
Cervical Spine (Joint range of motion
decreased cervical spine)
Joint Range Of Motion Decreased
Lumbar Spine (Joint range of motion
decreased lumbar spine)
Keratitis (Keratitis)
Kidney Anastomotic Leak (Kidney
anastomotic leak)
Kidney Infection (Kidney infection)
Kyphosis (Kyphosis)
Lactation Disorder (Lactation disorder)
Large Intestinal Anastomotic Leak (Large
intestinal anastomotic leak)
Laryngeal Edema (Laryngeal edema)
Laryngeal Fistula (Laryngeal fistula)
Laryngeal Hemorrhage (Laryngeal
hemorrhage)
Laryngeal Inflammation (Laryngeal
inflammation)
Laryngeal Mucositis (Laryngeal
mucositis)
Laryngeal Obstruction (Laryngeal
obstruction)
Laryngeal Stenosis (Laryngeal stenosis)
Laryngitis (Laryngitis)
Laryngopharyngeal Dysesthesia
(Laryngopharyngeal dysesthesia)
Laryngospasm (Laryngospasm)
Left Ventricular Systolic Dysfunction (Left
ventricular systolic dysfunction)
Lethargy (Lethargy)
Leukemia Secondary To Oncology
Chemotherapy (Leukemia secondary to
oncology chemotherapy)
Leukocytosis (Leukocytosis)
Leukoencephalopathy
(Leukoencephalopathy)
Libido Decreased (Libido decreased)
Libido Increased (Libido increased)
Lip Infection (Lip infection)
Lip Pain (Lip pain)
Lipase Increased (Lipase increased)
Lipohypertrophy (Lipohypertrophy)
Localized Edema (Localized edema)
Lordosis (Lordosis)
Lower Gastrointestinal Hemorrhage
(Lower gastrointestinal hemorrhage)
Lung Infection (Lung infection)
Lymph Gland Infection (Lymph gland
infection)
Lymph Leakage (Lymph leakage)
Lymph Node Pain (Lymph node pain)
Lymphedema (Lymphedema)
Lymphocele (Lymphocele)
Lymphocyte Count Decreased
(Lymphocyte count decreased)
Lymphocyte Count Increased
(Lymphocyte count increased)
Malabsorption (Malabsorption)
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Malaise (Malaise)
Mania (Mania)
Mediastinal Hemorrhage (Mediastinal
hemorrhage)
Mediastinal Infection (Mediastinal
infection)
Memory Impairment (Memory
impairment)
Meningismus (Meningismus)
Meningitis (Meningitis)
Menopause (Menopause)
Menorrhagia (Menorrhagia)
Metabolism And Nutrition Disorders -
Other, Specify (Metabolism and nutrition
disorders - Other, Specify)
Middle Ear Inflammation (Middle ear
inflammation)
Mitral Valve Disease (Mitral valve
disease)
Mobitz (type) Ii Atrioventricular Block
(Mobitz (type) II atrioventricular block)
Mobitz Type I (Mobitz type I)
Movements Involuntary (Movements
involuntary)
Mucosal Infection (Mucosal infection)
Mucositis Oral (Mucositis oral)
Multi-organ Failure (Multi-organ failure)
Muscle Weakness Left-sided (Muscle
weakness left-sided)
Muscle Weakness Lower Limb (Muscle
weakness lower limb)
Muscle Weakness Right-sided (Muscle
weakness right-sided)
Muscle Weakness Trunk (Muscle
weakness trunk)
Muscle Weakness Upper Limb (Muscle
weakness upper limb)
Musculoskeletal And Connective Tissue
Disorder - Other, Specify
(Musculoskeletal and connective tissue
disorders - Other, Specify)
Musculoskeletal Deformity
(Musculoskeletal deformity)
Myalgia (Myalgia)
Myelitis (Myelitis)
Myelodysplastic Syndrome
(Myelodysplastic syndrome)
Myocardial Infarction (Myocardial
infarction)
Myocarditis (Myocarditis)
Myositis (Myositis)
Nail Discoloration (Nail discoloration)
Nail Infection (Nail infection)
Nail Loss (Nail loss)
Nail Ridging (Nail ridging)
Nasal Congestion (Nasal congestion)
Nausea (Nausea)
Neck Edema (Neck edema)
Neck Pain (Neck pain)
Neck Soft Tissue Necrosis (Neck soft
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tissue necrosis)
Neoplasms Benign, Malignant And
Unspecified (incl Cysts And Polyps) -
Other, Specify (Neoplasms benign,
malignant and unspecified (incl cysts and
polyps) - Other, Specify)
Nervous System Disorders - Other,
Specify (Nervous system disorders -
Other, Specify)
Neuralgia (Neuralgia)
Neutrophil Count Decreased (Neutrophil
count decreased)
Night Blindness (Night blindness)
Nipple Deformity (Nipple deformity)
Non-cardiac Chest Pain (Non-cardiac
chest pain)
Nystagmus (Nystagmus)
Obesity (Obesity)
Obstruction Gastric (Obstruction gastric)
Oculomotor Nerve Disorder (Oculomotor
nerve disorder)
Olfactory Nerve Disorder (Olfactory
nerve disorder)
Oligospermia (Oligospermia)
Optic Nerve Disorder (Optic nerve
disorder)
Oral Cavity Fistula (Oral cavity fistula)
Oral Dysesthesia (Oral dysesthesia)
Oral Hemorrhage (Oral hemorrhage)
Oral Pain (Oral pain)
Osteonecrosis Of Jaw (Osteonecrosis of
jaw)
Osteoporosis (Osteoporosis)
Otitis Externa (Otitis externa)
Otitis Media (Otitis media)
Ovarian Hemorrhage (Ovarian
hemorrhage)
Ovarian Infection (Ovarian infection)
Ovarian Rupture (Ovarian rupture)
Ovulation Pain (Ovulation pain)
Pain (Pain)
Pain In Extremity (Pain in extremity)
Pain Of Skin (Pain of skin)
Palmar-plantar Erythrodysesthesia
Syndrome (Palmar-plantar
erythrodysesthesia syndrome)
Palpitations (Palpitations)
Pancreas Infection (Pancreas infection)
Pancreatic Anastomotic Leak (Pancreatic
anastomotic leak)
Pancreatic Duct Stenosis (Pancreatic
duct stenosis)
Pancreatic Enzymes Decreased
(Pancreatic enzymes decreased)
Pancreatic Fistula (Pancreatic fistula)
Pancreatic Hemorrhage (Pancreatic
hemorrhage)
Pancreatic Necrosis (Pancreatic
necrosis)
Pancreatitis (Pancreatitis)
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Papilledema (Papilledema)
Papulopustular Rash (Papulopustular
rash)
Paresthesia (Paresthesia)
Paronychia (Paronychia)
Paroxysmal Atrial Tachycardia
(Paroxysmal atrial tachycardia)
Pelvic Floor Muscle Weakness (Pelvic
floor muscle weakness)
Pelvic Infection (Pelvic infection)
Pelvic Pain (Pelvic pain)
Pelvic Soft Tissue Necrosis (Pelvic soft
tissue necrosis)
Penile Infection (Penile infection)
Penile Pain (Penile pain)
Perforation Bile Duct (Perforation bile
duct)
Pericardial Effusion (Pericardial effusion)
Pericardial Tamponade (Pericardial
tamponade)
Pericarditis (Pericarditis)
Perineal Pain (Perineal pain)
Periodontal Disease (Periodontal
disease)
Periorbital Edema (Periorbital edema)
Periorbital Infection (Periorbital infection)
Peripheral Ischemia (Peripheral
ischemia)
Peripheral Motor Neuropathy (Peripheral
motor neuropathy)
Peripheral Nerve Infection (Peripheral
nerve infection)
Peripheral Sensory Neuropathy
(Peripheral sensory neuropathy)
Peritoneal Infection (Peritoneal infection)
Peritoneal Necrosis (Peritoneal necrosis)
Personality Change (Personality change)
Phantom Pain (Phantom pain)
Pharyngeal Anastomotic Leak
(Pharyngeal anastomotic leak)
Pharyngeal Fistula (Pharyngeal fistula)
Pharyngeal Hemorrhage (Pharyngeal
hemorrhage)
Pharyngeal Mucositis (Pharyngeal
mucositis)
Pharyngeal Necrosis (Pharyngeal
necrosis)
Pharyngeal Stenosis (Pharyngeal
stenosis)
Pharyngitis (Pharyngitis)
Pharyngolaryngeal Pain
(Pharyngolaryngeal pain)
Phlebitis (Phlebitis)
Phlebitis Infective (Phlebitis infective)
Photophobia (Photophobia)
Photosensitivity (Photosensitivity)
Platelet Count Decreased (Platelet count
decreased)
Pleural Effusion (Pleural effusion)
Pleural Hemorrhage (Pleural
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hemorrhage)
Pleural Infection (Pleural infection)
Pleuritic Pain (Pleuritic pain)
Pneumonitis (Pneumonitis)
Pneumothorax (Pneumothorax)
Portal Hypertension (Portal
hypertension)
Portal Vein Thrombosis (Portal vein
thrombosis)
Postnasal Drip (Postnasal drip)
Postoperative Hemorrhage
(Postoperative hemorrhage)
Postoperative Thoracic Procedure
Complication (Postoperative thoracic
procedure complication)
Precocious Puberty (Precocious
puberty)
Pregnancy, Puerperium And Perinatal
Conditions - Other, Specify (Pregnancy,
puerperium and perinatal conditions -
Other, Specify)
Premature Delivery (Premature delivery)
Premature Menopause (Premature
menopause)
Presyncope (Presyncope)
Proctitis (Proctitis)
Productive Cough (Productive cough)
Prolapse Of Intestinal Stoma (Prolapse
of intestinal stoma)
Prolapse Of Urostomy (Prolapse of
urostomy)
Prostate Infection (Prostate infection)
Prostatic Hemorrhage (Prostatic
hemorrhage)
Prostatic Obstruction (Prostatic
obstruction)
Prostatic Pain (Prostatic pain)
Proteinuria (Proteinuria)
Pruritus (Pruritus)
Psychiatric Disorders - Other, Specify
(Psychiatric disorders - Other, Specify)
Psychosis (Psychosis)
Pulmonary Edema (Pulmonary edema)
Pulmonary Fibrosis (Pulmonary fibrosis)
Pulmonary Fistula (Pulmonary fistula)
Pulmonary Hypertension (Pulmonary
hypertension)
Pulmonary Valve Disease (Pulmonary
valve disease)
Purpura (Purpura)
Pyramidal Tract Syndrome (Pyramidal
tract syndrome)
Radiation Recall Reaction (dermatologic)
(Radiation recall reaction (dermatologic))
Radiculitis (Radiculitis)
Rash Acneiform (Rash acneiform)
Rash Maculo-papular (Rash maculo-
papular)
Rash Pustular (Rash pustular)
Rectal Anastomotic Leak (Rectal
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anastomotic leak)
Rectal Fistula (Rectal fistula)
Rectal Hemorrhage (Rectal hemorrhage)
Rectal Mucositis (Rectal mucositis)
Rectal Necrosis (Rectal necrosis)
Rectal Obstruction (Rectal obstruction)
Rectal Pain (Rectal pain)
Rectal Perforation (Rectal perforation)
Rectal Stenosis (Rectal stenosis)
Rectal Ulcer (Rectal ulcer)
Recurrent Laryngeal Nerve Palsy
(Recurrent laryngeal nerve palsy)
Renal And Urinary Disorders - Other,
Specify (Renal and urinary disorders -
Other, Specify)
Renal Calculi (Renal calculi)
Renal Colic (Renal colic)
Renal Hemorrhage (Renal hemorrhage)
Reproductive System And Breast
Disorders - Other, Specify (Reproductive
system and breast disorders - Other,
Specify)
Respiratory Failure (Respiratory failure)
Respiratory, Thoracic And Mediastinal
Disorders - Other, Specify (Respiratory,
thoracic and mediastinal disorders -
Other, Specify)
Restlessness (Restlessness)
Restrictive Cardiomyopathy (Restrictive
cardiomyopathy)
Retinal Detachment (Retinal
detachment)
Retinal Tear (Retinal tear)
Retinal Vascular Disorder (Retinal
vascular disorder)
Retinoic Acid Syndrome (Retinoic acid
syndrome)
Retinopathy (Retinopathy)
Retroperitoneal Hemorrhage
(Retroperitoneal hemorrhage)
Reversible Posterior
Leukoencephalopathy Syndrome
(Reversible posterior
leukoencephalopathy syndrome)
Rhinitis Infective (Rhinitis infective)
Right Ventricular Dysfunction (Right
ventricular dysfunction)
Salivary Duct Inflammation (Salivary duct
inflammation)
Salivary Gland Fistula (Salivary gland
fistula)
Salivary Gland Infection (Salivary gland
infection)
Scalp Pain (Scalp pain)
Scleral Disorder (Scleral disorder)
Scoliosis (Scoliosis)
Scrotal Infection (Scrotal infection)
Scrotal Pain (Scrotal pain)
Seizure (Seizure)
Sepsis (Sepsis)
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Seroma (Seroma)
Serum Amylase Increased (Serum
amylase increased)
Serum Sickness (Serum sickness)
Sick Sinus Syndrome (Sick sinus
syndrome)
Sinus Bradycardia (Sinus bradycardia)
Sinus Disorder (Sinus disorder)
Sinus Pain (Sinus pain)
Sinus Tachycardia (Sinus tachycardia)
Sinusitis (Sinusitis)
Skin And Subcutaneous Tissue
Disorders - Other, Specify (Skin and
subcutaneous tissue disorders - Other,
Specify)
Skin Atrophy (Skin atrophy)
Skin Hyperpigmentation (Skin
hyperpigmentation)
Skin Hypopigmentation (Skin
hypopigmentation)
Skin Induration (Skin induration)
Skin Infection (Skin infection)
Skin Ulceration (Skin ulceration)
Sleep Apnea (Sleep apnea)
Small Intestinal Anastomotic Leak (Small
intestinal anastomotic leak)
Small Intestinal Mucositis (Small
intestinal mucositis)
Small Intestinal Obstruction (Small
intestinal obstruction)
Small Intestinal Perforation (Small
intestinal perforation)
Small Intestinal Stenosis (Small intestinal
stenosis)
Small Intestine Infection (Small intestine
infection)
Small Intestine Ulcer (Small intestine
ulcer)
Sneezing (Sneezing)
Social Circumstances - Other, Specify
(Social circumstances - Other, Specify)
Soft Tissue Infection (Soft tissue
infection)
Soft Tissue Necrosis Lower Limb (Soft
tissue necrosis lower limb)
Soft Tissue Necrosis Upper Limb (Soft
tissue necrosis upper limb)
Somnolence (Somnolence)
Sore Throat (Sore throat)
Spasticity (Spasticity)
Spermatic Cord Anastomotic Leak
(Spermatic cord anastomotic leak)
Spermatic Cord Hemorrhage (Spermatic
cord hemorrhage)
Spermatic Cord Obstruction (Spermatic
cord obstruction)
Spinal Fracture (Spinal fracture)
Spleen Disorder (Spleen disorder)
Splenic Infection (Splenic infection)
Stenosis Of Gastrointestinal Stoma
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(Stenosis of gastrointestinal stoma)
Stevens-johnson Syndrome (Stevens-
Johnson syndrome)
Stoma Site Infection (Stoma site
infection)
Stomach Pain (Stomach pain)
Stomal Ulcer (Stomal ulcer)
Stridor (Stridor)
Stroke (Stroke)
Sudden Death Nos (Sudden death NOS)
Suicidal Ideation (Suicidal ideation)
Suicide Attempt (Suicide attempt)
Superficial Soft Tissue Fibrosis
(Superficial soft tissue fibrosis)
Superficial Thrombophlebitis (Superficial
thrombophlebitis)
Superior Vena Cava Syndrome (Superior
vena cava syndrome)
Supraventricular Tachycardia
(Supraventricular tachycardia)
Surgical And Medical Procedures -
Other, Specify (Surgical and medical
procedures - Other, Specify)
Syncope (Syncope)
Telangiectasia (Telangiectasia)
Testicular Disorder (Testicular disorder)
Testicular Hemorrhage (Testicular
hemorrhage)
Testicular Pain (Testicular pain)
Thromboembolic Event
(Thromboembolic event)
Thrombotic Thrombocytopenic Purpura
(Thrombotic thrombocytopenic purpura)
Tinnitus (Tinnitus)
Tooth Development Disorder (Tooth
development disorder)
Tooth Discoloration (Tooth discoloration)
Tooth Infection (Tooth infection)
Toothache (Toothache)
Toxic Epidermal Necrolysis (Toxic
epidermal necrolysis)
Tracheal Fistula (Tracheal fistula)
Tracheal Hemorrhage (Tracheal
hemorrhage)
Tracheal Mucositis (Tracheal mucositis)
Tracheal Obstruction (Tracheal
obstruction)
Tracheal Stenosis (Tracheal stenosis)
Tracheitis (Tracheitis)
Tracheostomy Site Bleeding
(Tracheostomy site bleeding)
Transient Ischemic Attacks (Transient
ischemic attacks)
Treatment Related Secondary
Malignancy (Treatment related
secondary malignancy)
Tremor (Tremor)
Tricuspid Valve Disease (Tricuspid valve
disease)
Trigeminal Nerve Disorder (Trigeminal
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nerve disorder)
Trismus (Trismus)
Tumor Lysis Syndrome (Tumor lysis
syndrome)
Tumor Pain (Tumor pain)
Typhlitis (Typhlitis)
Unequal Limb Length (Unequal limb
length)
Unintended Pregnancy (Unintended
pregnancy)
Upper Gastrointestinal Hemorrhage
(Upper gastrointestinal hemorrhage)
Upper Respiratory Infection (Upper
respiratory infection)
Ureteric Anastomotic Leak (Ureteric
anastomotic leak)
Urethral Anastomotic Leak (Urethral
anastomotic leak)
Urethral Infection (Urethral infection)
Urinary Fistula (Urinary fistula)
Urinary Frequency (Urinary frequency)
Urinary Incontinence (Urinary
incontinence)
Urinary Retention (Urinary retention)
Urinary Tract Infection (Urinary tract
infection)
Urinary Tract Obstruction (Urinary tract
obstruction)
Urinary Tract Pain (Urinary tract pain)
Urinary Urgency (Urinary urgency)
Urine Discoloration (Urine discoloration)
Urine Output Decreased (Urine output
decreased)
Urostomy Leak (Urostomy leak)
Urostomy Obstruction (Urostomy
obstruction)
Urostomy Site Bleeding (Urostomy site
bleeding)
Urostomy Stenosis (Urostomy stenosis)
Urticaria (Urticaria)
Uterine Anastomotic Leak (Uterine
anastomotic leak)
Uterine Fistula (Uterine fistula)
Uterine Hemorrhage (Uterine
hemorrhage)
Uterine Infection (Uterine infection)
Uterine Obstruction (Uterine obstruction)
Uterine Pain (Uterine pain)
Uterine Perforation (Uterine perforation)
Uveitis (Uveitis)
Vaginal Anastomotic Leak (Vaginal
anastomotic leak)
Vaginal Discharge (Vaginal discharge)
Vaginal Dryness (Vaginal dryness)
Vaginal Fistula (Vaginal fistula)
Vaginal Hemorrhage (Vaginal
hemorrhage)
Vaginal Infection (Vaginal infection)
Vaginal Inflammation (Vaginal
inflammation)
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Vaginal Obstruction (Vaginal obstruction)
Vaginal Pain (Vaginal pain)
Vaginal Perforation (Vaginal perforation)
Vaginal Stricture (Vaginal stricture)
Vaginismus (Vaginismus)
Vagus Nerve Disorder (Vagus nerve
disorder)
Vas Deferens Anastomotic Leak (Vas
deferens anastomotic leak)
Vascular Access Complication (Vascular
access complication)
Vascular Disorders - Other, Specify
(Vascular disorders - Other, Specify)
Vasculitis (Vasculitis)
Vasovagal Reaction (Vasovagal reaction)
Venous Injury (Venous injury)
Ventricular Arrhythmia (Ventricular
arrhythmia)
Ventricular Fibrillation (Ventricular
fibrillation)
Ventricular Tachycardia (Ventricular
tachycardia)
Vertigo (Vertigo)
Vestibular Disorder (Vestibular disorder)
Virilization (Virilization)
Visceral Arterial Ischemia (Visceral
arterial ischemia)
Vital Capacity Abnormal (Vital capacity
abnormal)
Vitreous Hemorrhage (Vitreous
hemorrhage)
Voice Alteration (Voice alteration)
Vomiting (Vomiting)
Vulval Infection (Vulval infection)
Watering Eyes (Watering eyes)
Weight Gain (Weight gain)
Weight Loss (Weight loss)
Wheezing (Wheezing)
White Blood Cell Decreased (White
blood cell decreased)
Wolff-parkinson-white Syndrome (Wolff-
Parkinson-White syndrome)
Wound Complication (Wound
complication)
Wound Dehiscence (Wound dehiscence)
Wound Infection (Wound infection)
Wrist Fracture (Wrist fracture)
CTC Adverse Event Grade
Absent Adverse Event (0)
Mild Adverse Event (1)
Moderate Adverse Event (2)
Severe Adverse Event (3)
Life Threatening Adverse Event (4)
Death Related To Adverse Event (5)
CTC Adverse Event Attribution Code
Definite (Definite)
Possible (Possible)
Probable (Probable)
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Unlikely (Unlikely)
Unrelated (Unrelated)
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Prostate Cancer NCT01368588 Treatment -
RTOG-0924 T1: Treatment Form - 3196837v1.0
RTOG-0924 T1: Treatment Form
Androgen-Deprivation Therapy and Radiation Therapy in
Treating Patients With Prostate Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=9D869ED1-
F383-8812-E040-BB89AD432EA8
All rights reserved. Please visit https://medical-data-
models.org/forms/8198
RTOG-0924 T1: Treatment Form
Unnamed Module 1
RTOG Study No.
Case #
Institution Name
Institution No.
Patient Initials
RTOG Patient ID
Amended data
Yes
No
Module 1
Radiation Therapy Start Date
Radiation Therapy End Date
Total elapsed days (INCLUDING BOTH
EXTERNAL RADIATION THERAPY AND
BRACHYTHERAPY)
RT Total Fraction Count
RT Total Dose  (TO PTV)
Were there any unscheduled interruptions in
radiation therapy? (EXCLUDING HOLIDAYS)
No (No)
Yes, Due To Other Reason (Yes, due to
other reason)
Yes, Due To Toxicity (Yes, due to toxicity)
Specify RT interruption reason
1 / 4
Reason Treatment Ended
Adverse Event/side Effects/complications
(Adverse Event/Side
Effects/Complications)
Alternative Therapy (Alternative therapy)
Death On Study (Death on study)
Disease Progression, Relapse During
Active Treatment (Disease progression,
relapse during active treatment)
Other (Other)
Patient Off-treatment For Other
Complicating Disease (Patient off-
treatment for other complicating disease)
Patient Withdrawal Or Refusal After
Beginning Protocol Therapy (Patient
withdrawal/refusal after beginning
protocol therapy)
Patient Withdrawal Or Refusal Before
Beginning Protocol Therapy (Patient
withdrawal/refusal prior to beginning
protocol therapy)
Treatment Completed Per Protocol
Criteria (Treatment completed per
protocol criteria)
Alternative Therapy, specify
Other specify
Type of Radiation Therapy Administered
3d Conformal + Imrt Boost (3D
Conformal + IMRT Boost)
High-dose Rate Brachytherapy 3-
dimensional Conformal Radiation
Therapy (3DCRT + Brachytherapy HDR)
Low-dose Treatment Brachytherapy 3-
dimensional Conformal Radiation
Therapy (3DCRT + Brachytherapy LDR)
Imrt (IMRT)
High-dose Rate Brachytherapy Imrt
(IMRT + Brachytherapy HDR)
Low-dose Treatment Brachytherapy Imrt
(IMRT + Brachytherapy LDR)
What method of daily prostate localization was
used
Cbct (CBCT)
Ct On Rails (CT on Rails)
Helical Ct (Helical CT)
No Daily Localization Used (No Daily
Localization Used)
Optical Tracking (Optical Tracking)
Other (Other)
Portal Image/epid (Portal Image/EPID)
Ultra Sound (Ultra sound)
Other, specify
2 / 4
Prostate Cancer NCT01368588 Treatment - RTOG-0924 T1: Treatment
Form - 3196837v1.0
Brachytherapy
IF BRACHYTHERAPY NOT UTILIZED,
PROVIDE REASON
Alternative Therapy Given (Alternative
therapy given)
Death (Death)
Inadequate To Treat Extent Of Disease
(Inadequate to treat extent of disease)
Md Preference (MD preference)
Na Dose Administered Within Protocol
Specifications (NA Dose administered
within protocol specifications)
Not Technically Feasible (Not technically
feasible)
Other Reason, Specify (Other reason,
specify)
Patient Refused (Patient refused)
Progression Or Relapse (Progression or
relapse)
Toxicity Or Treatment Reaction (Toxicity
or treatment reaction)
Specify therapy
Other reason, specify
Low-dose Radiation
Date of implant
Date of post-implant CT
Seed loss (were seeds expelled within the 3
weeks of implant? If yes, report details in
Comment section.)
No (No)
Unknown (Unknown)
Yes (Yes)
Was an indwelling urinary catheter inserted since
implant
No (No)
Unknown (Unknown)
Yes (Yes)
Date inserted (Provide estimate if exact date
unknown)
Date removed (Provide estimate if exact date
unknown)
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High-dose Radiation
Date of implant fraction #1
Time of implant fraction #1
Date of implant fraction #2
Total elapsed days (INCLUDING BOTH
EXTERNAL RADIATION THERAPY AND
BRACHYTHERAPY)
Time of implant fraction #2
Number of implant catheters used
Footer
Comments
Signature of Person Completing This Form
Date Form Originally Completed
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NCT01302834 Quality of Life - RTOG 1016 FM: Radiation Therapy Oncology Group
Phase III Head and Neck Cancer Work Status Questionnaire Follow-Up Survey -
3209056v1.0
RTOG 1016 FM: Radiation Therapy Oncology Group
Phase III Head and Neck Cancer Work Status
Questionnaire Follow-Up Survey
Radiation Therapy With Cisplatin or Cetuximab in Treating
Patients With Oropharyngeal Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=9F2D8F51-
F2B1-6515-E040-BB89AD434E1D
All rights reserved. Please visit https://medical-data-
models.org/forms/8199
RTOG 1016 FM: Radiation Therapy
Oncology Group Phase III Head and
Neck Cancer Work Status
Questionnaire Follow-Up Survey
Unnamed Module 1
RTOG Study No.
Case #
Institution Name
Institution No.
Patient Initials
RTOG Patient ID
Amended data
Yes
No
Follow-up Survey
Which of the following best describes your
current work status
Currently Working In At Least One Full
Time Job (Currently working in at least
one FULL time job)
Currently Working In At Least One Part
Time Job (Currently working in at least
one PART time job)
Unknown (Don't know)
Not Employed (Not employed)
Not Working Outside Of The Home (Not
working outside of the home)
On Disability (On disability)
On Sick Leave (On sick leave)
Other (Other)
Retired (Retired)
Student, Full-time (Student, full-time)
Student, Part-time (Student, part-time)
Please specify (Other)
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How many hours per week are you currently
working
Since the last time of the last survey about how
many days were you absent from work for at least
half of the day
Would you say your employer has been good at
accommodating your illness and need for
treatment (If you are not currently working, please
tell us about your last employer)
Agree (Agree)
Disagree (Disagree)
Not Applicable (Not Applicable)
Refused (Refused)
Strongly Agree (Strongly agree)
Strongly Disagree (Strongly disagree)
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CALGB 50901 Adverse Event Other Form
Ofatumumab in Treating Patients With Previously Untreated
Stage II, Stage III, or Stage IV Follicular Non-Hodgkin
Lymphoma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=9F2B6FF6-
91A0-EEB7-E040-BB89AD436484
All rights reserved. Please visit https://medical-data-
models.org/forms/8204
CALGB 50901 Adverse Event Other
Form
Protocol Specific Adverse Event
Evaluation
Other CTC Adverse Event term not listed
Yes
No
CTC Adverse Event Term
Abdominal Distension (Abdominal
distension)
Abdominal Infection (Abdominal
infection)
Abdominal Pain (Abdominal pain)
Abdominal Soft Tissue Necrosis
(Abdominal soft tissue necrosis)
Abducens Nerve Disorder (Abducens
nerve disorder)
Accessory Nerve Disorder (Accessory
nerve disorder)
Acidosis (Acidosis)
Acoustic Nerve Disorder Nos (Acoustic
nerve disorder NOS)
Activated Partial Thromboplastin Time
Prolonged (Activated partial
thromboplastin time prolonged)
Acute Coronary Syndrome (Acute
coronary syndrome)
Acute Kidney Injury (Acute kidney injury)
Adrenal Insufficiency (Adrenal
insufficiency)
Adult Respiratory Distress Syndrome
(Adult respiratory distress syndrome)
Agitation (Agitation)
Akathisia (Akathisia)
Alanine Aminotransferase Increased
(Alanine aminotransferase increased)
Alcohol Intolerance (Alcohol intolerance)
Alkaline Phosphatase Increased
(Alkaline phosphatase increased)
Alkalosis (Alkalosis)
Allergic Reaction (Allergic reaction)
Allergic Rhinitis (Allergic rhinitis)
Alopecia (Alopecia)
Amnesia (Amnesia)
Anal Fistula (Anal fistula)
Anal Hemorrhage (Anal hemorrhage)
Anal Mucositis (Anal mucositis)
Anal Necrosis (Anal necrosis)
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Anal Pain (Anal pain)
Anal Stenosis (Anal stenosis)
Anal Ulcer (Anal ulcer)
Anaphylaxis (Anaphylaxis)
Anemia (Anemia)
Ankle Fracture (Ankle fracture)
Anorectal Infection (Anorectal infection)
Anorexia (Anorexia)
Anorgasmia (Anorgasmia)
Anxiety (Anxiety)
Aortic Injury (Aortic injury)
Aortic Valve Disease (Aortic valve
disease)
Aphonia (Aphonia)
Apnea (Apnea)
Appendicitis (Appendicitis)
Appendicitis Perforated (Appendicitis
perforated)
Arachnoiditis (Arachnoiditis)
Arterial Injury (Arterial injury)
Arteritis Infective (Arteritis infective)
Arthralgia (Arthralgia)
Arthritis (Arthritis)
Ascites (Ascites)
Aspartate Aminotransferase Increased
(Aspartate aminotransferase increased)
Aspiration (Aspiration)
Asystole (Asystole)
Ataxia (Ataxia)
Atelectasis (Atelectasis)
Atrial Fibrillation (Atrial fibrillation)
Atrial Flutter (Atrial flutter)
Atrioventricular Block Complete
(Atrioventricular block complete)
Atrioventricular Block First Degree
(Atrioventricular block first degree)
Autoimmune Disorder (Autoimmune
disorder)
Avascular Necrosis (Avascular necrosis)
Azoospermia (Azoospermia)
Back Pain (Back pain)
Bile Duct Stenosis (Bile duct stenosis)
Biliary Anastomotic Leak (Biliary
anastomotic leak)
Biliary Fistula (Biliary fistula)
Biliary Tract Infection (Biliary tract
infection)
Bladder Anastomotic Leak (Bladder
anastomotic leak)
Bladder Infection (Bladder infection)
Bladder Perforation (Bladder perforation)
Bladder Spasm (Bladder spasm)
Bloating (Bloating)
Blood And Lymphatic System Disorders -
Other, Specify (Blood and lymphatic
system disorders - Other, Specify)
Blood Antidiuretic Hormone Abnormal
(Blood antidiuretic hormone abnormal)
Blood Bilirubin Increased (Blood bilirubin
increased)
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Blood Corticotrophin Decreased (Blood
corticotrophin decreased)
Blood Gonadotrophin Abnormal (Blood
gonadotrophin abnormal)
Blood Prolactin Abnormal (Blood
prolactin abnormal)
Blurred Vision (Blurred vision)
Body Odor (Body odor)
Bone Infection (Bone infection)
Bone Marrow Hypocellular (Bone
marrow hypocellular)
Bone Pain (Bone pain)
Brachial Plexopathy (Brachial
plexopathy)
Breast Atrophy (Breast atrophy)
Breast Infection (Breast infection)
Breast Pain (Breast pain)
Bronchial Fistula (Bronchial fistula)
Bronchial Infection (Bronchial infection)
Bronchial Obstruction (Bronchial
obstruction)
Bronchial Stricture (Bronchial stricture)
Bronchopleural Fistula (Bronchopleural
fistula)
Bronchopulmonary Hemorrhage
(Bronchopulmonary hemorrhage)
Bronchospasm (Bronchospasm)
Bruising (Bruising)
Bullous Dermatitis (Bullous dermatitis)
Burn (Burn)
Buttock Pain (Buttock pain)
Capillary Leak Syndrome (Capillary leak
syndrome)
Carbon Monoxide Diffusing Capacity
Decreased (Carbon monoxide diffusing
capacity decreased)
Cardiac Arrest (Cardiac arrest)
Cardiac Disorders - Other, Specify
(Cardiac disorders - Other, Specify)
Cardiac Troponin I Increased (Cardiac
troponin I increased)
Cardiac Troponin T Increased (Cardiac
troponin T increased)
Cataract (Cataract)
Catheter Related Infection (Catheter
related infection)
Cd4 Lymphocytes Decreased (CD4
lymphocytes decreased)
Cecal Hemorrhage (Cecal hemorrhage)
Cecal Infection (Cecal infection)
Central Nervous System Necrosis
(Central nervous system necrosis)
Cerebrospinal Fluid Leakage
(Cerebrospinal fluid leakage)
Cervicitis Infection (Cervicitis infection)
Cheilitis (Cheilitis)
Chest Pain - Cardiac (Chest pain -
cardiac)
Chest Wall Pain (Chest wall pain)
Chills (Chills)
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Cholecystitis (Cholecystitis)
Cholesterol High (Cholesterol high)
Chronic Kidney Disease (Chronic kidney
disease)
Chylothorax (Chylothorax)
Cognitive Disturbance (Cognitive
disturbance)
Colitis (Colitis)
Colonic Fistula (Colonic fistula)
Colonic Hemorrhage (Colonic
hemorrhage)
Colonic Obstruction (Colonic obstruction)
Colonic Perforation (Colonic perforation)
Colonic Stenosis (Colonic stenosis)
Colonic Ulcer (Colonic ulcer)
Concentration Impairment
(Concentration impairment)
Conduction Disorder (Conduction
disorder)
Confusion (Confusion)
Congenital, Familial And Genetic
Disorders - Other, Specify (Congenital,
familial and genetic disorders - Other,
Specify)
Conjunctivitis (Conjunctivitis)
Conjunctivitis Infective (Conjunctivitis
infective)
Constipation (Constipation)
Constrictive Pericarditis (Constrictive
pericarditis)
Corneal Infection (Corneal infection)
Corneal Ulcer (Corneal ulcer)
Cough (Cough)
Cpk Increased (CPK increased)
Cranial Nerve Infection (Cranial nerve
infection)
Creatinine Increased (Creatinine
increased)
Cushingoid (Cushingoid)
Cystitis Noninfective (Cystitis
noninfective)
Cytokine Release Syndrome (Cytokine
release syndrome)
Death Neonatal (Death neonatal)
Death Nos (Death NOS)
Dehydration (Dehydration)
Delayed Orgasm (Delayed orgasm)
Delayed Puberty (Delayed puberty)
Delirium (Delirium)
Delusions (Delusions)
Dental Caries (Dental caries)
Depressed Level Of Consciousness
(Depressed level of consciousness)
Depression (Depression)
Dermatitis Radiation (Dermatitis
radiation)
Device Related Infection (Device related
infection)
Diarrhea (Diarrhea)
Disseminated Intravascular Coagulation
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(Disseminated intravascular coagulation)
Dizziness (Dizziness)
Dry Eye (Dry eye)
Dry Mouth (Dry mouth)
Dry Skin (Dry skin)
Duodenal Fistula (Duodenal fistula)
Duodenal Hemorrhage (Duodenal
hemorrhage)
Duodenal Infection (Duodenal infection)
Duodenal Obstruction (Duodenal
obstruction)
Duodenal Perforation (Duodenal
perforation)
Duodenal Stenosis (Duodenal stenosis)
Duodenal Ulcer (Duodenal ulcer)
Dysarthria (Dysarthria)
Dysesthesia (Dysesthesia)
Dysgeusia (Dysgeusia)
Dysmenorrhea (Dysmenorrhea)
Dyspareunia (Dyspareunia)
Dyspepsia (Dyspepsia)
Dysphagia (Dysphagia)
Dysphasia (Dysphasia)
Dyspnea (Dyspnea)
Ear And Labyrinth Disorders - Other,
Specify (Ear and labyrinth disorders -
Other, Specify)
Ear Pain (Ear pain)
Edema Cerebral (Edema cerebral)
Edema Face (Edema face)
Edema Limbs (Edema limbs)
Edema Trunk (Edema trunk)
Ejaculation Disorder (Ejaculation
disorder)
Ejection Fraction Decreased (Ejection
fraction decreased)
Electrocardiogram Qt Corrected Interval
Prolonged (Electrocardiogram QT
corrected interval prolonged)
Encephalitis Infection (Encephalitis
infection)
Encephalomyelitis Infection
(Encephalomyelitis infection)
Encephalopathy (Encephalopathy)
Endocarditis Infective (Endocarditis
infective)
Endocrine Disorders - Other, Specify
(Endocrine disorders - Other, Specify)
Endophthalmitis (Endophthalmitis)
Enterocolitis (Enterocolitis)
Enterocolitis Infectious (Enterocolitis
infectious)
Enterovesical Fistula (Enterovesical
fistula)
Epistaxis (Epistaxis)
Erectile Dysfunction (Erectile
dysfunction)
Erythema Multiforme (Erythema
multiforme)
Erythroderma (Erythroderma)
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Esophageal Anastomotic Leak
(Esophageal anastomotic leak)
Esophageal Fistula (Esophageal fistula)
Esophageal Hemorrhage (Esophageal
hemorrhage)
Esophageal Infection (Esophageal
infection)
Esophageal Necrosis (Esophageal
necrosis)
Esophageal Obstruction (Esophageal
obstruction)
Esophageal Pain (Esophageal pain)
Esophageal Perforation (Esophageal
perforation)
Esophageal Stenosis (Esophageal
stenosis)
Esophageal Ulcer (Esophageal ulcer)
Esophageal Varices Hemorrhage
(Esophageal varices hemorrhage)
Esophagitis (Esophagitis)
Euphoria (Euphoria)
Exostosis (Exostosis)
External Ear Inflammation (External ear
inflammation)
External Ear Pain (External ear pain)
Extraocular Muscle Paresis (Extraocular
muscle paresis)
Extrapyramidal Disorder (Extrapyramidal
disorder)
Eye Disorders - Other, Specify (Eye
disorders - Other, Specify)
Eye Infection (Eye infection)
Eye Pain (Eye pain)
Eyelid Function Disorder (Eyelid function
disorder)
Facial Muscle Weakness (Facial muscle
weakness)
Facial Nerve Disorder (Facial nerve
disorder)
Facial Pain (Facial pain)
Fall (Fall)
Fallopian Tube Anastomotic Leak
(Fallopian tube anastomotic leak)
Fallopian Tube Obstruction (Fallopian
tube obstruction)
Fallopian Tube Perforation (Fallopian
tube perforation)
Fallopian Tube Stenosis (Fallopian tube
stenosis)
Fat Atrophy (Fat atrophy)
Fatigue (Fatigue)
Febrile Neutropenia (Febrile
neutropenia)
Fecal Incontinence (Fecal incontinence)
Female Genital Tract Fistula (Female
genital tract fistula)
Feminization Acquired (Feminization
acquired)
Fetal Death (Fetal death)
Fetal Growth Retardation (Fetal growth
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retardation)
Fever (Fever)
Fibrinogen Decreased (Fibrinogen
decreased)
Fibrosis Deep Connective Tissue
(Fibrosis deep connective tissue)
Flank Pain (Flank pain)
Flashing Lights (Flashing lights)
Flatulence (Flatulence)
Floaters (Floaters)
Flu Like Symptoms (Flu like symptoms)
Flushing (Flushing)
Forced Expiratory Volume Decreased
(Forced expiratory volume decreased)
Fracture (Fracture)
Gait Disturbance (Gait disturbance)
Gallbladder Fistula (Gallbladder fistula)
Gallbladder Infection (Gallbladder
infection)
Gallbladder Necrosis (Gallbladder
necrosis)
Gallbladder Obstruction (Gallbladder
obstruction)
Gallbladder Pain (Gallbladder pain)
Gallbladder Perforation (Gallbladder
perforation)
Gastric Anastomotic Leak (Gastric
anastomotic leak)
Gastric Fistula (Gastric fistula)
Gastric Hemorrhage (Gastric
hemorrhage)
Gastric Necrosis (Gastric necrosis)
Gastric Perforation (Gastric perforation)
Gastric Stenosis (Gastric stenosis)
Gastric Ulcer (Gastric ulcer)
Gastritis (Gastritis)
Gastroesophageal Reflux Disease
(Gastroesophageal reflux disease)
Gastrointestinal Anastomotic Leak
(Gastrointestinal anastomotic leak)
Gastrointestinal Disorders - Other,
Specify (Gastrointestinal disorders -
Other, Specify)
Gastrointestinal Fistula (Gastrointestinal
fistula)
Gastrointestinal Pain (Gastrointestinal
pain)
Gastrointestinal Stoma Necrosis
(Gastrointestinal stoma necrosis)
Gastroparesis (Gastroparesis)
General Disorders And Administration
Site Conditions - Other, Specify (General
disorders and administration site
conditions - Other, Specify)
Generalized Muscle Weakness
(Generalized muscle weakness)
Genital Edema (Genital edema)
Ggt Increased (GGT increased)
Gingival Pain (Gingival pain)
Glaucoma (Glaucoma)
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Glossopharyngeal Nerve Disorder
(Glossopharyngeal nerve disorder)
Glucose Intolerance (Glucose
intolerance)
Growth Accelerated (Growth
accelerated)
Growth Hormone Abnormal (Growth
hormone abnormal)
Growth Suppression (Growth
suppression)
Gum Infection (Gum infection)
Gynecomastia (Gynecomastia)
Hallucinations (Hallucinations)
Haptoglobin Decreased (Haptoglobin
decreased)
Head Soft Tissue Necrosis (Head soft
tissue necrosis)
Headache (Headache)
Hearing Impaired (Hearing impaired)
Heart Failure (Heart failure)
Hematoma (Hematoma)
Hematosalpinx (Hematosalpinx)
Hematuria (Hematuria)
Hemoglobin Increased (Hemoglobin
increased)
Hemoglobinuria (Hemoglobinuria)
Hemolysis (Hemolysis)
Hemolytic Uremic Syndrome (Hemolytic
uremic syndrome)
Hemorrhoidal Hemorrhage
(Hemorrhoidal hemorrhage)
Hemorrhoids (Hemorrhoids)
Hepatic Failure (Hepatic failure)
Hepatic Hemorrhage (Hepatic
hemorrhage)
Hepatic Infection (Hepatic infection)
Hepatic Necrosis (Hepatic necrosis)
Hepatic Pain (Hepatic pain)
Hepatitis Viral (Hepatitis viral)
Hepatobiliary Disorders - Other, Specify
(Hepatobiliary disorders - Other, Specify)
Hiccups (Hiccups)
Hip Fracture (Hip fracture)
Hirsutism (Hirsutism)
Hoarseness (Hoarseness)
Hot Flashes (Hot flashes)
Hydrocephalus (Hydrocephalus)
Hypercalcemia (Hypercalcemia)
Hyperglycemia (Hyperglycemia)
Hyperhidrosis (Hyperhidrosis)
Hyperkalemia (Hyperkalemia)
Hypermagnesemia (Hypermagnesemia)
Hypernatremia (Hypernatremia)
Hyperparathyroidism
(Hyperparathyroidism)
Hypersomnia (Hypersomnia)
Hypertension (Hypertension)
Hyperthyroidism (Hyperthyroidism)
Hypertrichosis (Hypertrichosis)
Hypertriglyceridemia
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(Hypertriglyceridemia)
Hyperuricemia (Hyperuricemia)
Hypoalbuminemia (Hypoalbuminemia)
Hypocalcemia (Hypocalcemia)
Hypoglossal Nerve Disorder
(Hypoglossal nerve disorder)
Hypoglycemia (Hypoglycemia)
Hypohidrosis (Hypohidrosis)
Hypokalemia (Hypokalemia)
Hypomagnesemia (Hypomagnesemia)
Hyponatremia (Hyponatremia)
Hypoparathyroidism
(Hypoparathyroidism)
Hypophosphatemia (Hypophosphatemia)
Hypotension (Hypotension)
Hypothermia (Hypothermia)
Hypothyroidism (Hypothyroidism)
Hypoxia (Hypoxia)
Ileal Fistula (Ileal fistula)
Ileal Hemorrhage (Ileal hemorrhage)
Ileal Obstruction (Ileal obstruction)
Ileal Perforation (Ileal perforation)
Ileal Stenosis (Ileal stenosis)
Ileal Ulcer (Ileal ulcer)
Ileus (Ileus)
Immune System Disorders - Other,
Specify (Immune system disorders -
Other, Specify)
Infections And Infestations - Other,
Specify (Infections and infestations -
Other, Specify)
Infective Myositis (Infective myositis)
Infusion Related Reaction (Infusion
related reaction)
Infusion Site Extravasation (Infusion site
extravasation)
Injection Site Reaction (Injection site
reaction)
Injury To Carotid Artery (Injury to carotid
artery)
Injury To Inferior Vena Cava (Injury to
inferior vena cava)
Injury To Jugular Vein (Injury to jugular
vein)
Injury To Superior Vena Cava (Injury to
superior vena cava)
Injury, Poisoning And Procedural
Complications - Other, Specify (Injury,
poisoning and procedural complications -
Other, Specify)
Inr Increased (INR increased)
Insomnia (Insomnia)
Intestinal Stoma Leak (Intestinal stoma
leak)
Intestinal Stoma Obstruction (Intestinal
stoma obstruction)
Intestinal Stoma Site Bleeding (Intestinal
stoma site bleeding)
Intra-abdominal Hemorrhage (Intra-
abdominal hemorrhage)
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Intracranial Hemorrhage (Intracranial
hemorrhage)
Intraoperative Arterial Injury
(Intraoperative arterial injury)
Intraoperative Breast Injury
(Intraoperative breast injury)
Intraoperative Cardiac Injury
(Intraoperative cardiac injury)
Intraoperative Ear Injury (Intraoperative
ear injury)
Intraoperative Endocrine Injury
(Intraoperative endocrine injury)
Intraoperative Gastrointestinal Injury
(Intraoperative gastrointestinal injury)
Intraoperative Head And Neck Injury
(Intraoperative head and neck injury)
Intraoperative Hemorrhage
(Intraoperative hemorrhage)
Intraoperative Hepatobiliary Injury
(Intraoperative hepatobiliary injury)
Intraoperative Musculoskeletal Injury
(Intraoperative musculoskeletal injury)
Intraoperative Neurological Injury
(Intraoperative neurological injury)
Intraoperative Ocular Injury
(Intraoperative ocular injury)
Intraoperative Renal Injury
(Intraoperative renal injury)
Intraoperative Reproductive Tract Injury
(Intraoperative reproductive tract injury)
Intraoperative Respiratory Injury
(Intraoperative respiratory injury)
Intraoperative Skin Injury (Intraoperative
skin injury)
Intraoperative Splenic Injury
(Intraoperative splenic injury)
Intraoperative Urinary Injury
(Intraoperative urinary injury)
Intraoperative Venous Injury
(Intraoperative venous injury)
Investigations - Other, Specify
(Investigations - Other, Specify)
Iron Overload (Iron overload)
Irregular Menstruation (Irregular
menstruation)
Irritability (Irritability)
Ischemia Cerebrovascular (Ischemia
cerebrovascular)
Ivth Nerve Disorder (IVth nerve disorder)
Jejunal Fistula (Jejunal fistula)
Jejunal Hemorrhage (Jejunal
hemorrhage)
Jejunal Obstruction (Jejunal obstruction)
Jejunal Perforation (Jejunal perforation)
Jejunal Stenosis (Jejunal stenosis)
Jejunal Ulcer (Jejunal ulcer)
Joint Effusion (Joint effusion)
Joint Infection (Joint infection)
Joint Range Of Motion Decreased (Joint
range of motion decreased)
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Joint Range Of Motion Decreased
Cervical Spine (Joint range of motion
decreased cervical spine)
Joint Range Of Motion Decreased
Lumbar Spine (Joint range of motion
decreased lumbar spine)
Keratitis (Keratitis)
Kidney Anastomotic Leak (Kidney
anastomotic leak)
Kidney Infection (Kidney infection)
Kyphosis (Kyphosis)
Lactation Disorder (Lactation disorder)
Large Intestinal Anastomotic Leak (Large
intestinal anastomotic leak)
Laryngeal Edema (Laryngeal edema)
Laryngeal Fistula (Laryngeal fistula)
Laryngeal Hemorrhage (Laryngeal
hemorrhage)
Laryngeal Inflammation (Laryngeal
inflammation)
Laryngeal Mucositis (Laryngeal
mucositis)
Laryngeal Obstruction (Laryngeal
obstruction)
Laryngeal Stenosis (Laryngeal stenosis)
Laryngitis (Laryngitis)
Laryngopharyngeal Dysesthesia
(Laryngopharyngeal dysesthesia)
Laryngospasm (Laryngospasm)
Left Ventricular Systolic Dysfunction (Left
ventricular systolic dysfunction)
Lethargy (Lethargy)
Leukemia Secondary To Oncology
Chemotherapy (Leukemia secondary to
oncology chemotherapy)
Leukocytosis (Leukocytosis)
Leukoencephalopathy
(Leukoencephalopathy)
Libido Decreased (Libido decreased)
Libido Increased (Libido increased)
Lip Infection (Lip infection)
Lip Pain (Lip pain)
Lipase Increased (Lipase increased)
Lipohypertrophy (Lipohypertrophy)
Localized Edema (Localized edema)
Lordosis (Lordosis)
Lower Gastrointestinal Hemorrhage
(Lower gastrointestinal hemorrhage)
Lung Infection (Lung infection)
Lymph Gland Infection (Lymph gland
infection)
Lymph Leakage (Lymph leakage)
Lymph Node Pain (Lymph node pain)
Lymphedema (Lymphedema)
Lymphocele (Lymphocele)
Lymphocyte Count Decreased
(Lymphocyte count decreased)
Lymphocyte Count Increased
(Lymphocyte count increased)
Malabsorption (Malabsorption)
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Malaise (Malaise)
Mania (Mania)
Mediastinal Hemorrhage (Mediastinal
hemorrhage)
Mediastinal Infection (Mediastinal
infection)
Memory Impairment (Memory
impairment)
Meningismus (Meningismus)
Meningitis (Meningitis)
Menopause (Menopause)
Menorrhagia (Menorrhagia)
Metabolism And Nutrition Disorders -
Other, Specify (Metabolism and nutrition
disorders - Other, Specify)
Middle Ear Inflammation (Middle ear
inflammation)
Mitral Valve Disease (Mitral valve
disease)
Mobitz (type) Ii Atrioventricular Block
(Mobitz (type) II atrioventricular block)
Mobitz Type I (Mobitz type I)
Movements Involuntary (Movements
involuntary)
Mucosal Infection (Mucosal infection)
Mucositis Oral (Mucositis oral)
Multi-organ Failure (Multi-organ failure)
Muscle Weakness Left-sided (Muscle
weakness left-sided)
Muscle Weakness Lower Limb (Muscle
weakness lower limb)
Muscle Weakness Right-sided (Muscle
weakness right-sided)
Muscle Weakness Trunk (Muscle
weakness trunk)
Muscle Weakness Upper Limb (Muscle
weakness upper limb)
Musculoskeletal And Connective Tissue
Disorder - Other, Specify
(Musculoskeletal and connective tissue
disorders - Other, Specify)
Musculoskeletal Deformity
(Musculoskeletal deformity)
Myalgia (Myalgia)
Myelitis (Myelitis)
Myelodysplastic Syndrome
(Myelodysplastic syndrome)
Myocardial Infarction (Myocardial
infarction)
Myocarditis (Myocarditis)
Myositis (Myositis)
Nail Discoloration (Nail discoloration)
Nail Infection (Nail infection)
Nail Loss (Nail loss)
Nail Ridging (Nail ridging)
Nasal Congestion (Nasal congestion)
Nausea (Nausea)
Neck Edema (Neck edema)
Neck Pain (Neck pain)
Neck Soft Tissue Necrosis (Neck soft
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tissue necrosis)
Neoplasms Benign, Malignant And
Unspecified (incl Cysts And Polyps) -
Other, Specify (Neoplasms benign,
malignant and unspecified (incl cysts and
polyps) - Other, Specify)
Nervous System Disorders - Other,
Specify (Nervous system disorders -
Other, Specify)
Neuralgia (Neuralgia)
Neutrophil Count Decreased (Neutrophil
count decreased)
Night Blindness (Night blindness)
Nipple Deformity (Nipple deformity)
Non-cardiac Chest Pain (Non-cardiac
chest pain)
Nystagmus (Nystagmus)
Obesity (Obesity)
Obstruction Gastric (Obstruction gastric)
Oculomotor Nerve Disorder (Oculomotor
nerve disorder)
Olfactory Nerve Disorder (Olfactory
nerve disorder)
Oligospermia (Oligospermia)
Optic Nerve Disorder (Optic nerve
disorder)
Oral Cavity Fistula (Oral cavity fistula)
Oral Dysesthesia (Oral dysesthesia)
Oral Hemorrhage (Oral hemorrhage)
Oral Pain (Oral pain)
Osteonecrosis Of Jaw (Osteonecrosis of
jaw)
Osteoporosis (Osteoporosis)
Otitis Externa (Otitis externa)
Otitis Media (Otitis media)
Ovarian Hemorrhage (Ovarian
hemorrhage)
Ovarian Infection (Ovarian infection)
Ovarian Rupture (Ovarian rupture)
Ovulation Pain (Ovulation pain)
Pain (Pain)
Pain In Extremity (Pain in extremity)
Pain Of Skin (Pain of skin)
Palmar-plantar Erythrodysesthesia
Syndrome (Palmar-plantar
erythrodysesthesia syndrome)
Palpitations (Palpitations)
Pancreas Infection (Pancreas infection)
Pancreatic Anastomotic Leak (Pancreatic
anastomotic leak)
Pancreatic Duct Stenosis (Pancreatic
duct stenosis)
Pancreatic Enzymes Decreased
(Pancreatic enzymes decreased)
Pancreatic Fistula (Pancreatic fistula)
Pancreatic Hemorrhage (Pancreatic
hemorrhage)
Pancreatic Necrosis (Pancreatic
necrosis)
Pancreatitis (Pancreatitis)
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Papilledema (Papilledema)
Papulopustular Rash (Papulopustular
rash)
Paresthesia (Paresthesia)
Paronychia (Paronychia)
Paroxysmal Atrial Tachycardia
(Paroxysmal atrial tachycardia)
Pelvic Floor Muscle Weakness (Pelvic
floor muscle weakness)
Pelvic Infection (Pelvic infection)
Pelvic Pain (Pelvic pain)
Pelvic Soft Tissue Necrosis (Pelvic soft
tissue necrosis)
Penile Infection (Penile infection)
Penile Pain (Penile pain)
Perforation Bile Duct (Perforation bile
duct)
Pericardial Effusion (Pericardial effusion)
Pericardial Tamponade (Pericardial
tamponade)
Pericarditis (Pericarditis)
Perineal Pain (Perineal pain)
Periodontal Disease (Periodontal
disease)
Periorbital Edema (Periorbital edema)
Periorbital Infection (Periorbital infection)
Peripheral Ischemia (Peripheral
ischemia)
Peripheral Motor Neuropathy (Peripheral
motor neuropathy)
Peripheral Nerve Infection (Peripheral
nerve infection)
Peripheral Sensory Neuropathy
(Peripheral sensory neuropathy)
Peritoneal Infection (Peritoneal infection)
Peritoneal Necrosis (Peritoneal necrosis)
Personality Change (Personality change)
Phantom Pain (Phantom pain)
Pharyngeal Anastomotic Leak
(Pharyngeal anastomotic leak)
Pharyngeal Fistula (Pharyngeal fistula)
Pharyngeal Hemorrhage (Pharyngeal
hemorrhage)
Pharyngeal Mucositis (Pharyngeal
mucositis)
Pharyngeal Necrosis (Pharyngeal
necrosis)
Pharyngeal Stenosis (Pharyngeal
stenosis)
Pharyngitis (Pharyngitis)
Pharyngolaryngeal Pain
(Pharyngolaryngeal pain)
Phlebitis (Phlebitis)
Phlebitis Infective (Phlebitis infective)
Photophobia (Photophobia)
Photosensitivity (Photosensitivity)
Platelet Count Decreased (Platelet count
decreased)
Pleural Effusion (Pleural effusion)
Pleural Hemorrhage (Pleural
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hemorrhage)
Pleural Infection (Pleural infection)
Pleuritic Pain (Pleuritic pain)
Pneumonitis (Pneumonitis)
Pneumothorax (Pneumothorax)
Portal Hypertension (Portal
hypertension)
Portal Vein Thrombosis (Portal vein
thrombosis)
Postnasal Drip (Postnasal drip)
Postoperative Hemorrhage
(Postoperative hemorrhage)
Postoperative Thoracic Procedure
Complication (Postoperative thoracic
procedure complication)
Precocious Puberty (Precocious
puberty)
Pregnancy, Puerperium And Perinatal
Conditions - Other, Specify (Pregnancy,
puerperium and perinatal conditions -
Other, Specify)
Premature Delivery (Premature delivery)
Premature Menopause (Premature
menopause)
Presyncope (Presyncope)
Proctitis (Proctitis)
Productive Cough (Productive cough)
Prolapse Of Intestinal Stoma (Prolapse
of intestinal stoma)
Prolapse Of Urostomy (Prolapse of
urostomy)
Prostate Infection (Prostate infection)
Prostatic Hemorrhage (Prostatic
hemorrhage)
Prostatic Obstruction (Prostatic
obstruction)
Prostatic Pain (Prostatic pain)
Proteinuria (Proteinuria)
Pruritus (Pruritus)
Psychiatric Disorders - Other, Specify
(Psychiatric disorders - Other, Specify)
Psychosis (Psychosis)
Pulmonary Edema (Pulmonary edema)
Pulmonary Fibrosis (Pulmonary fibrosis)
Pulmonary Fistula (Pulmonary fistula)
Pulmonary Hypertension (Pulmonary
hypertension)
Pulmonary Valve Disease (Pulmonary
valve disease)
Purpura (Purpura)
Pyramidal Tract Syndrome (Pyramidal
tract syndrome)
Radiation Recall Reaction (dermatologic)
(Radiation recall reaction (dermatologic))
Radiculitis (Radiculitis)
Rash Acneiform (Rash acneiform)
Rash Maculo-papular (Rash maculo-
papular)
Rash Pustular (Rash pustular)
Rectal Anastomotic Leak (Rectal
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anastomotic leak)
Rectal Fistula (Rectal fistula)
Rectal Hemorrhage (Rectal hemorrhage)
Rectal Mucositis (Rectal mucositis)
Rectal Necrosis (Rectal necrosis)
Rectal Obstruction (Rectal obstruction)
Rectal Pain (Rectal pain)
Rectal Perforation (Rectal perforation)
Rectal Stenosis (Rectal stenosis)
Rectal Ulcer (Rectal ulcer)
Recurrent Laryngeal Nerve Palsy
(Recurrent laryngeal nerve palsy)
Renal And Urinary Disorders - Other,
Specify (Renal and urinary disorders -
Other, Specify)
Renal Calculi (Renal calculi)
Renal Colic (Renal colic)
Renal Hemorrhage (Renal hemorrhage)
Reproductive System And Breast
Disorders - Other, Specify (Reproductive
system and breast disorders - Other,
Specify)
Respiratory Failure (Respiratory failure)
Respiratory, Thoracic And Mediastinal
Disorders - Other, Specify (Respiratory,
thoracic and mediastinal disorders -
Other, Specify)
Restlessness (Restlessness)
Restrictive Cardiomyopathy (Restrictive
cardiomyopathy)
Retinal Detachment (Retinal
detachment)
Retinal Tear (Retinal tear)
Retinal Vascular Disorder (Retinal
vascular disorder)
Retinoic Acid Syndrome (Retinoic acid
syndrome)
Retinopathy (Retinopathy)
Retroperitoneal Hemorrhage
(Retroperitoneal hemorrhage)
Reversible Posterior
Leukoencephalopathy Syndrome
(Reversible posterior
leukoencephalopathy syndrome)
Rhinitis Infective (Rhinitis infective)
Right Ventricular Dysfunction (Right
ventricular dysfunction)
Salivary Duct Inflammation (Salivary duct
inflammation)
Salivary Gland Fistula (Salivary gland
fistula)
Salivary Gland Infection (Salivary gland
infection)
Scalp Pain (Scalp pain)
Scleral Disorder (Scleral disorder)
Scoliosis (Scoliosis)
Scrotal Infection (Scrotal infection)
Scrotal Pain (Scrotal pain)
Seizure (Seizure)
Sepsis (Sepsis)
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Seroma (Seroma)
Serum Amylase Increased (Serum
amylase increased)
Serum Sickness (Serum sickness)
Sick Sinus Syndrome (Sick sinus
syndrome)
Sinus Bradycardia (Sinus bradycardia)
Sinus Disorder (Sinus disorder)
Sinus Pain (Sinus pain)
Sinus Tachycardia (Sinus tachycardia)
Sinusitis (Sinusitis)
Skin And Subcutaneous Tissue
Disorders - Other, Specify (Skin and
subcutaneous tissue disorders - Other,
Specify)
Skin Atrophy (Skin atrophy)
Skin Hyperpigmentation (Skin
hyperpigmentation)
Skin Hypopigmentation (Skin
hypopigmentation)
Skin Induration (Skin induration)
Skin Infection (Skin infection)
Skin Ulceration (Skin ulceration)
Sleep Apnea (Sleep apnea)
Small Intestinal Anastomotic Leak (Small
intestinal anastomotic leak)
Small Intestinal Mucositis (Small
intestinal mucositis)
Small Intestinal Obstruction (Small
intestinal obstruction)
Small Intestinal Perforation (Small
intestinal perforation)
Small Intestinal Stenosis (Small intestinal
stenosis)
Small Intestine Infection (Small intestine
infection)
Small Intestine Ulcer (Small intestine
ulcer)
Sneezing (Sneezing)
Social Circumstances - Other, Specify
(Social circumstances - Other, Specify)
Soft Tissue Infection (Soft tissue
infection)
Soft Tissue Necrosis Lower Limb (Soft
tissue necrosis lower limb)
Soft Tissue Necrosis Upper Limb (Soft
tissue necrosis upper limb)
Somnolence (Somnolence)
Sore Throat (Sore throat)
Spasticity (Spasticity)
Spermatic Cord Anastomotic Leak
(Spermatic cord anastomotic leak)
Spermatic Cord Hemorrhage (Spermatic
cord hemorrhage)
Spermatic Cord Obstruction (Spermatic
cord obstruction)
Spinal Fracture (Spinal fracture)
Spleen Disorder (Spleen disorder)
Splenic Infection (Splenic infection)
Stenosis Of Gastrointestinal Stoma
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(Stenosis of gastrointestinal stoma)
Stevens-johnson Syndrome (Stevens-
Johnson syndrome)
Stoma Site Infection (Stoma site
infection)
Stomach Pain (Stomach pain)
Stomal Ulcer (Stomal ulcer)
Stridor (Stridor)
Stroke (Stroke)
Sudden Death Nos (Sudden death NOS)
Suicidal Ideation (Suicidal ideation)
Suicide Attempt (Suicide attempt)
Superficial Soft Tissue Fibrosis
(Superficial soft tissue fibrosis)
Superficial Thrombophlebitis (Superficial
thrombophlebitis)
Superior Vena Cava Syndrome (Superior
vena cava syndrome)
Supraventricular Tachycardia
(Supraventricular tachycardia)
Surgical And Medical Procedures -
Other, Specify (Surgical and medical
procedures - Other, Specify)
Syncope (Syncope)
Telangiectasia (Telangiectasia)
Testicular Disorder (Testicular disorder)
Testicular Hemorrhage (Testicular
hemorrhage)
Testicular Pain (Testicular pain)
Thromboembolic Event
(Thromboembolic event)
Thrombotic Thrombocytopenic Purpura
(Thrombotic thrombocytopenic purpura)
Tinnitus (Tinnitus)
Tooth Development Disorder (Tooth
development disorder)
Tooth Discoloration (Tooth discoloration)
Tooth Infection (Tooth infection)
Toothache (Toothache)
Toxic Epidermal Necrolysis (Toxic
epidermal necrolysis)
Tracheal Fistula (Tracheal fistula)
Tracheal Hemorrhage (Tracheal
hemorrhage)
Tracheal Mucositis (Tracheal mucositis)
Tracheal Obstruction (Tracheal
obstruction)
Tracheal Stenosis (Tracheal stenosis)
Tracheitis (Tracheitis)
Tracheostomy Site Bleeding
(Tracheostomy site bleeding)
Transient Ischemic Attacks (Transient
ischemic attacks)
Treatment Related Secondary
Malignancy (Treatment related
secondary malignancy)
Tremor (Tremor)
Tricuspid Valve Disease (Tricuspid valve
disease)
Trigeminal Nerve Disorder (Trigeminal
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nerve disorder)
Trismus (Trismus)
Tumor Lysis Syndrome (Tumor lysis
syndrome)
Tumor Pain (Tumor pain)
Typhlitis (Typhlitis)
Unequal Limb Length (Unequal limb
length)
Unintended Pregnancy (Unintended
pregnancy)
Upper Gastrointestinal Hemorrhage
(Upper gastrointestinal hemorrhage)
Upper Respiratory Infection (Upper
respiratory infection)
Ureteric Anastomotic Leak (Ureteric
anastomotic leak)
Urethral Anastomotic Leak (Urethral
anastomotic leak)
Urethral Infection (Urethral infection)
Urinary Fistula (Urinary fistula)
Urinary Frequency (Urinary frequency)
Urinary Incontinence (Urinary
incontinence)
Urinary Retention (Urinary retention)
Urinary Tract Infection (Urinary tract
infection)
Urinary Tract Obstruction (Urinary tract
obstruction)
Urinary Tract Pain (Urinary tract pain)
Urinary Urgency (Urinary urgency)
Urine Discoloration (Urine discoloration)
Urine Output Decreased (Urine output
decreased)
Urostomy Leak (Urostomy leak)
Urostomy Obstruction (Urostomy
obstruction)
Urostomy Site Bleeding (Urostomy site
bleeding)
Urostomy Stenosis (Urostomy stenosis)
Urticaria (Urticaria)
Uterine Anastomotic Leak (Uterine
anastomotic leak)
Uterine Fistula (Uterine fistula)
Uterine Hemorrhage (Uterine
hemorrhage)
Uterine Infection (Uterine infection)
Uterine Obstruction (Uterine obstruction)
Uterine Pain (Uterine pain)
Uterine Perforation (Uterine perforation)
Uveitis (Uveitis)
Vaginal Anastomotic Leak (Vaginal
anastomotic leak)
Vaginal Discharge (Vaginal discharge)
Vaginal Dryness (Vaginal dryness)
Vaginal Fistula (Vaginal fistula)
Vaginal Hemorrhage (Vaginal
hemorrhage)
Vaginal Infection (Vaginal infection)
Vaginal Inflammation (Vaginal
inflammation)
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Vaginal Obstruction (Vaginal obstruction)
Vaginal Pain (Vaginal pain)
Vaginal Perforation (Vaginal perforation)
Vaginal Stricture (Vaginal stricture)
Vaginismus (Vaginismus)
Vagus Nerve Disorder (Vagus nerve
disorder)
Vas Deferens Anastomotic Leak (Vas
deferens anastomotic leak)
Vascular Access Complication (Vascular
access complication)
Vascular Disorders - Other, Specify
(Vascular disorders - Other, Specify)
Vasculitis (Vasculitis)
Vasovagal Reaction (Vasovagal reaction)
Venous Injury (Venous injury)
Ventricular Arrhythmia (Ventricular
arrhythmia)
Ventricular Fibrillation (Ventricular
fibrillation)
Ventricular Tachycardia (Ventricular
tachycardia)
Vertigo (Vertigo)
Vestibular Disorder (Vestibular disorder)
Virilization (Virilization)
Visceral Arterial Ischemia (Visceral
arterial ischemia)
Vital Capacity Abnormal (Vital capacity
abnormal)
Vitreous Hemorrhage (Vitreous
hemorrhage)
Voice Alteration (Voice alteration)
Vomiting (Vomiting)
Vulval Infection (Vulval infection)
Watering Eyes (Watering eyes)
Weight Gain (Weight gain)
Weight Loss (Weight loss)
Wheezing (Wheezing)
White Blood Cell Decreased (White
blood cell decreased)
Wolff-parkinson-white Syndrome (Wolff-
Parkinson-White syndrome)
Wound Complication (Wound
complication)
Wound Dehiscence (Wound dehiscence)
Wound Infection (Wound infection)
Wrist Fracture (Wrist fracture)
CTC Adverse Event Grade
Absent Adverse Event (0)
Mild Adverse Event (1)
Moderate Adverse Event (2)
Severe Adverse Event (3)
Life Threatening Adverse Event (4)
Death Related To Adverse Event (5)
CTC Adverse Event Attribution Code
Definite (Definite)
Possible (Possible)
Probable (Probable)
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Unlikely (Unlikely)
Unrelated (Unrelated)
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Prostate Cancer NCT00567580 Treatment - RTOG
0534 T1: Radiotherapy Form - 2599936v1.0
RTOG 0534 T1: Radiotherapy Form
Prostate Radiation Therapy or Short-Term Androgen
Deprivation Therapy and Pelvic Lymph Node Radiation
Therapy With or Without Prostate Radiation Therapy in
Treating Patients With a Rising PSA After Surgery for
Prostate Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=2A12DAA2-
E3FB-7166-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/8206
RTOG 0534 T1: Radiotherapy Form
Module 1
RTOG Study No.
Case #
Institution Name
Institution No.
Patient Initials
RTOG Patient ID
Amended Data
Yes
No
Radiation Therapy Start Date
Radiation Therapy End Date
Elapsed days
RT Total Fraction Count
RT Total Dose  (Gy)
Were there any unscheduled interruptions in
radiation therapy?
No (No)
Yes, Due To Other Reason (Yes, due to
other reason)
Yes, Due To Toxicity (Yes, due to toxicity)
Specify RT interruption reason
Reason Treatment Ended
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Adverse Event/side Effects/complications
(Adverse Event/Side
Effects/Complications)
Alternative Therapy (Alternative therapy)
Death On Study (Death on study)
Disease Progression, Relapse During
Active Treatment (Disease progression,
relapse during active treatment)
Other (Other)
Patient Off-treatment For Other
Complicating Disease (Patient off-
treatment for other complicating disease)
Patient Withdrawal Or Refusal After
Beginning Protocol Therapy (Patient
withdrawal/refusal after beginning
protocol therapy)
Patient Withdrawal Or Refusal Before
Beginning Protocol Therapy (Patient
withdrawal/refusal prior to beginning
protocol therapy)
Treatment Completed Per Protocol
Criteria (Treatment completed per
protocol criteria)
Alternative Therapy
Patient off-treatment for other complicating
disease, specify
Other specify
Type of Radiation Therapy Administered
3d Conformal (3D conformal)
Imrt (IMRT)
Comments
Signature of person completing this form
Date form originally completed
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Prostate Cancer NCT01546987 Treatment - RTOG 1115 T1: Phase III
RT + Standard ADT vs RT + Enhanced ADT + TAK-700 - 3289078v1.0
RTOG 1115 T1: Phase III RT + Standard ADT vs RT +
Enhanced ADT + TAK-700
Hormone Therapy, Radiation Therapy, and Steroid 17alpha-
monooxygenase TAK-700 in Treating Patients With High-
Risk Prostate Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=AE8E92E1-
C7D4-6523-E040-BB89AD436A37
All rights reserved. Please visit https://medical-data-
models.org/forms/8208
RTOG 1115 T1: Phase III RT +
Standard ADT vs RT + Enhanced
ADT + TAK-700
Unnamed Module 1
RTOG Study No.
Case #
Institution Name
Institution No.
Patient Initials
RTOG Patient ID
Amended data
Yes
No
Module 1
Radiation Therapy Start Date
Radiation Therapy End Date
RT Total Fraction Count
RT Total Dose  (TO PTV)
Total elapsed days (INCLUDING BOTH
EXTERNAL RADIATION THERAPY AND
BRACHYTHERAPY)
Were there any unscheduled interruptions in
radiation therapy? (EXCLUDING HOLIDAYS)
No (No)
Yes, Due To Other Reason (Yes, due to
other reason)
Yes, Due To Toxicity (Yes, due to toxicity)
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Specify RT interruption reason
Reason Treatment Ended
Adverse Event/side Effects/complications
(Adverse Event/Side
Effects/Complications)
Alternative Therapy (Alternative therapy)
Death On Study (Death on study)
Disease Progression, Relapse During
Active Treatment (Disease progression,
relapse during active treatment)
Other (Other)
Patient Off-treatment For Other
Complicating Disease (Patient off-
treatment for other complicating disease)
Patient Withdrawal Or Refusal After
Beginning Protocol Therapy (Patient
withdrawal/refusal after beginning
protocol therapy)
Patient Withdrawal Or Refusal Before
Beginning Protocol Therapy (Patient
withdrawal/refusal prior to beginning
protocol therapy)
Treatment Completed Per Protocol
Criteria (Treatment completed per
protocol criteria)
Alternative Therapy, specify
Other specify
Type of Radiation Therapy Administered
3d Conformal + Imrt Boost (3D
Conformal + IMRT Boost)
High-dose Rate Brachytherapy 3-
dimensional Conformal Radiation
Therapy (3DCRT + Brachytherapy HDR)
Low-dose Treatment Brachytherapy 3-
dimensional Conformal Radiation
Therapy (3DCRT + Brachytherapy LDR)
Imrt (IMRT)
High-dose Rate Brachytherapy Imrt
(IMRT + Brachytherapy HDR)
Low-dose Treatment Brachytherapy Imrt
(IMRT + Brachytherapy LDR)
What method of daily prostate localization was
used
Cbct (CBCT)
Ct On Rails (CT on Rails)
Helical Ct (Helical CT)
No Daily Localization Used (No Daily
Localization Used)
Optical Tracking (Optical Tracking)
Other (Other)
Portal Image/epid (Portal Image/EPID)
Ultra Sound (Ultra sound)
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Other, specify
Brachytherapy
IF BRACHYTHERAPY NOT UTILIZED,
PROVIDE REASON
Alternative Therapy Given (Alternative
therapy given)
Death (Death)
Inadequate To Treat Extent Of Disease
(Inadequate to treat extent of disease)
Md Preference (MD preference)
Na Dose Administered Within Protocol
Specifications (NA Dose administered
within protocol specifications)
Not Technically Feasible (Not technically
feasible)
Other Reason, Specify (Other reason,
specify)
Patient Refused (Patient refused)
Progression Or Relapse (Progression or
relapse)
Toxicity Or Treatment Reaction (Toxicity
or treatment reaction)
Specify therapy
Other reason, specify
Low-dose Radiation
Date of implant
Date of post-implant CT
Seed loss (were seeds expelled within the 3
weeks of implant? If yes, report details in
Comment section.)
No (No)
Unknown (Unknown)
Yes (Yes)
Was an indwelling urinary catheter inserted since
implant
No (No)
Unknown (Unknown)
Yes (Yes)
Date inserted (Provide estimate if exact date
unknown)
Date removed (Provide estimate if exact date
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unknown)
High-dose Radiation
Date of implant fraction #1
Time of implant fraction #1
Date of implant fraction #2
Time of implant fraction #2
Number of implant catheters used
Total elapsed days (INCLUDING BOTH
EXTERNAL RADIATION THERAPY AND
BRACHYTHERAPY)
Footer
Comments
Signature of Person Completing This Form
Date Form Originally Completed
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Pancreatic Cancer NCT01013649 Treatment - RTOG 0848: Phase III Pancreas-
Resected + Adjuvant Treatment Radiotherapy Form (T1) - 2866961v1.0
RTOG 0848: Phase III Pancreas-Resected + Adjuvant
Treatment Radiotherapy Form (T1)
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=69073BF6-
D406-B01F-E040-BB89AD4319AC
All rights reserved. Please visit https://medical-data-
models.org/forms/8209
RTOG 0848: Phase III Pancreas-
Resected + Adjuvant Treatment
Radiotherapy Form (T1)
Module 1
RTOG Study No.
Case #
Institution Name
Institution No.
Patient Initials
RTOG Patient ID
Amended Data
Yes
No
Radiation Therapy Start Date
Radiation Therapy End Date
Elapsed days
RT Total Fraction Count
RT Total Dose  (Gy)
Were there any unscheduled interruptions in
radiation therapy?
No (No)
Yes, Due To Other Reason (Yes, due to
other reason)
Yes, Due To Toxicity (Yes, due to toxicity)
Specify RT interruption reason
Reason Treatment Ended
Adverse Event/side Effects/complications
(Adverse Event/Side
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Effects/Complications)
Alternative Therapy (Alternative therapy)
Death On Study (Death on study)
Disease Progression, Relapse During
Active Treatment (Disease progression,
relapse during active treatment)
Other (Other)
Patient Off-treatment For Other
Complicating Disease (Patient off-
treatment for other complicating disease)
Patient Withdrawal Or Refusal After
Beginning Protocol Therapy (Patient
withdrawal/refusal after beginning
protocol therapy)
Patient Withdrawal Or Refusal Before
Beginning Protocol Therapy (Patient
withdrawal/refusal prior to beginning
protocol therapy)
Treatment Completed Per Protocol
Criteria (Treatment completed per
protocol criteria)
Alternative Therapy
Other specify
Type of Radiation Therapy Administered
3d Conformal (3D conformal)
Imrt (IMRT)
Comments
Person Completing Form
Date form originally completed
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NCT01302834 Quality of Life - RTOG 1016 QL35: Radiation Therapy Oncology
Group Phase III Head and Neck Cancer EORTC-QLQ-H&N35 - 3159340v1.0
RTOG 1016 QL35: Radiation Therapy Oncology Group
Phase III Head and Neck Cancer EORTC-QLQ-H&N35
Radiation Therapy With Cisplatin or Cetuximab in Treating
Patients With Oropharyngeal Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=95322CC4-
A66C-8D67-E040-BB89AD431C52
All rights reserved. Please visit https://medical-data-
models.org/forms/8216
RTOG 1016 QL35: Radiation
Therapy Oncology Group Phase III
Head and Neck Cancer EORTC-
QLQ-H&N35
Unnamed Module 1
RTOG Study No.
Case #
Institution Name
Institution No.
Patient Initials
RTOG Patient ID
Amended data
Yes
No
Eortc Qlq-h&n35
Have you had pain in your mouth
A Little (A little)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Very Much (Very much)
Have you had a pain in your jaw
A Little (A little)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Very Much (Very much)
Have you had soreness in your mouth
A Little (A little)
1 (Not at all)
4 (Quite a bit)
5 (Very much)
Have you had a painful throat
A Little (A little)
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Not At All (Not at all)
Quite A Bit (Quite a bit)
Very Much (Very much)
Have you had problems swallowing liquids
A Little (A little)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Very Much (Very much)
Have you had problems swallowing pureed food
A Little (A little)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Very Much (Very much)
Have you had problems swallowing solid food
A Little (A little)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Very Much (Very much)
Have you choked when swallowing
A Little (A little)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Very Much (Very much)
Have you had problems with your teeth
A Little (A little)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Very Much (Very much)
Have you had problems opening your mouth wide
A Little (A little)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Very Much (Very much)
Have you had a dry mouth
A Little (A little)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Very Much (Very much)
Eortc Qlq-h&n35 (cont)
Have you had sticky saliva
A Little (A little)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Very Much (Very much)
Have you had problems with your sense of smell
A Little (A little)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Very Much (Very much)
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Have you had problems with your sense of taste
A Little (A little)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Very Much (Very much)
Have you coughed
A Little (A little)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Very Much (Very much)
Have you been hoarse
A Little (A little)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Very Much (Very much)
Have you felt ill
A Little (A little)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Very Much (Very much)
Have your appearance bothered you
A Little (A little)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Very Much (Very much)
Eortc Qlq-h&n35 (cont2)
Have you had trouble eating
A Little (A little)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Very Much (Very much)
Have you had trouble eating in front of your family
A Little (A little)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Very Much (Very much)
Have you had trouble eating in front of other
people
A Little (A little)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Very Much (Very much)
Have you had trouble enjoying your meals
A Little (A little)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Very Much (Very much)
Have you had trouble talking with other people
A Little (A little)
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Not At All (Not at all)
Quite A Bit (Quite a bit)
Very Much (Very much)
Have you had trouble talking on the telephone
A Little (A little)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Very Much (Very much)
Have you had trouble having social contact with
your family
A Little (A little)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Very Much (Very much)
Have you had trouble having social contact with
friends
A Little (A little)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Very Much (Very much)
Have you had trouble going out in public
A Little (A little)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Very Much (Very much)
Have you had trouble having physical contact
with family or friends
A Little (A little)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Very Much (Very much)
Have you felt less interest in sex
A Little (A little)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Very Much (Very much)
Have you felt less sexual enjoyment
A Little (A little)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Very Much (Very much)
Eortc Qlq-h&n35 (cont3)
Have you used pain-killers
Yes
No
Have you taken any nutritional supplements
(excluding vitamins)
Yes
No
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Have you used a feeding tube
Yes
No
Have you lost weight
Yes
No
Have you gained weight
Yes
No
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NCT00956007 Quality of Life - RTOG 0920 Phase III Head and Neck
Cancer Miscellaneous Patient Assessment Form (QP) - 2811379v1.0
RTOG 0920 Phase III Head and Neck Cancer
Miscellaneous Patient Assessment Form (QP)
Radiation Therapy With or Without Cetuximab in Treating
Patients Who Have Undergone Surgery for Locally
Advanced Head and Neck Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=5D3C3F4A-
8D56-21E8-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/8217
RTOG 0920 Phase III Head and
Neck Cancer Miscellaneous Patient
Assessment Form (QP)
Unnamed Module 1
RTOG Study No.
Case #
Institution Name
Institution No.
Patient Initials
RTOG Patient ID
Unamed Module 2
SCHEDULED DATA POINT (CHECK ONE)
Other (Other)
Other Followup (other followup)
Pre Treatment Assessment (Pre
treatment assessment)
other followup (specify calendar date or followup
interval, e.g., 3 months, 2 years, etc.)
Other, specify
IF NO PATIENT ASSESSMENT, SPECIFY
REASON (CHECK ONE)
Other Reason (Other reason)
Patient Refused, Including Attempts By
Telephone Interview (Patient refused,
including attempts by telephone
interview)
Patient Refused, Telephone Interview
Not Attempted (Patient refused,
telephone interview not attempted)
Patient Unable To Be Contacted (Patient
unable to be contacted)
Patient Was Too Ill (Patient was too ill)
Questionnaire Not Completed Due To
Institutional Error (Questionnaire not
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completed due to institutional error)
Patient refused, including attempts by telephone
interview, specify reason for refusal
Patient refused, telephone interview not
attempted, specify reason for refusal
Other reason, specify
WAS INFORMATION OBTAINED BY
TELEPHONE INTERVIEW (CHECK ONE)
Yes
No
Date of Evaluation
RATER'S NAME
Normalcy of Diet Rating (CHECK ONE)
0= Non-oral Feeding (tube Fed) (0)
10= Cold Liquids (10)
100= Full Diet (no Restrictions) (100)
20= Warm Liquids (20)
30= Pureed Foods (in Blender) (30)
40= Soft Foods Requiring No Chewing
(e.g., Mashed Potatoes, Apple Sauce,
Pudding) (40)
50= Soft, Chewable Foods (e.g.,
Macaroni, Canned/soft Fruits, Cooked
Vegetables, Fish, Hamburger, Small
Pieces Of Meat) (50)
60= Dry Bread And Crackers (60)
70= Raw Carrots, Celery (70)
80= All Meat (80)
90= Full Diet (liquid Assist) (90)
Public Eating Rating (CHECK ONE)
0= Always Eats Alone (0)
100= No Restriction Of Place, Food Or
Companion (eats Out At Any
Opportunity) (100)
25= Eats Only At Home In Presence Of
Selected Persons (25)
50= Eats Only In Presence Of Selected
Persons In Selected Places (50)
75= No Restriction Of Place, But
Restricts Diet When In Public (eats
Anywhere, But May Limit Intake To Less
"messy" Foods, E.g., Liquids) (75)
Understandability of Speech Rating (CHECK
ONE)
0= Never Understandable; May Use
Written Communication (0)
2 / 3
NCT00956007 Quality of Life - RTOG 0920 Phase III Head and Neck
Cancer Miscellaneous Patient Assessment Form (QP) - 2811379v1.0
100= Always Understandable (100)
25= Difficult To Understand (25)
50= Usually Understandable; Face-to-
face Contact Necessary (50)
75= Understandable Most Of The Time;
Occasional Repetition Necessary (75)
Comments
COMMENTS
Completed by
Date Form Originally Completed (MM DD YYYY)
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NCT01302834 Quality of Life - RTOG 1016 QN: Radiation Therapy Oncology Group
Phase III Head and Neck Cancer Hearing Handicap Inventory for Adults (HHIA-S) -
3183758v1.0
RTOG 1016 QN: Radiation Therapy Oncology Group
Phase III Head and Neck Cancer Hearing Handicap
Inventory for Adults (HHIA-S)
Radiation Therapy With Cisplatin or Cetuximab in Treating
Patients With Oropharyngeal Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=9A132BA5-
9085-FFE2-E040-BB89AD43727A
All rights reserved. Please visit https://medical-data-
models.org/forms/8218
RTOG 1016 QN: Radiation Therapy
Oncology Group Phase III Head and
Neck Cancer Hearing Handicap
Inventory for Adults (HHIA-S)
Unnamed Module 1
RTOG Study No.
Case #
Institution Name
Institution No.
Patient Initials
RTOG Patient ID
Amended data
Yes
No
Hearing Handicap Inventory For Adults
Screening Questionnaire (newmaent Al.,
1990; Newmaent Al., 1991)
Date
Does a hearing problem cause you to feel
embarrassed when meeting new people
No (No)
Sometimes (Sometimes)
Yes (Yes)
Does a hearing problem cause you to feel
frustrated when talking to members of your family
No (No)
Sometimes (Sometimes)
Yes (Yes)
Does a hearing problem cause you difficulty
hearing/understanding coworkers, clients, or
customers
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No (No)
Sometimes (Sometimes)
Yes (Yes)
Do you feel handicapped by a hearing problem
No (No)
Sometimes (Sometimes)
Yes (Yes)
Does a hearing problem cause you difficulty
when visiting friends, relatives, or neighbors
No (No)
Sometimes (Sometimes)
Yes (Yes)
Does a hearing problem cause you difficulty in
the movies or theater
No (No)
Sometimes (Sometimes)
Yes (Yes)
Does a hearing problem cause you to have
arguments with family members
No (No)
Sometimes (Sometimes)
Yes (Yes)
Does a hearing problem cause you difficulty
when listening to TV or radio
No (No)
Sometimes (Sometimes)
Yes (Yes)
Do you feel that any difficulty with your hearing
limits or hampers your personal or social life
No (No)
Sometimes (Sometimes)
Yes (Yes)
Does a hearing problem cause you difficulty
when in a restaurant with relatives or friends
No (No)
Sometimes (Sometimes)
Yes (Yes)
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NCT01302834 Treatment - RTOG 1016 T1: Radiation Therapy Oncology
Group Phase III Head and Neck Cancer Radiotherapy Form - 3156940v1.0
RTOG 1016 T1: Radiation Therapy Oncology Group Phase
III Head and Neck Cancer Radiotherapy Form
Radiation Therapy With Cisplatin or Cetuximab in Treating
Patients With Oropharyngeal Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=944181D6-
51CC-82FB-E040-BB89AD43799B
All rights reserved. Please visit https://medical-data-
models.org/forms/8221
RTOG 1016 T1: Radiation Therapy
Oncology Group Phase III Head and
Neck Cancer Radiotherapy Form
Module 1
RTOG Study No.
Case #
Institution Name
Institution No.
Patient Initials
RTOG Patient ID
Amended Data
Yes
No
Radiation Therapy Start Date (MM DD YYYY)
Radiation Therapy End Date (MM DD YYYY)
Elapsed days
RT Total Fraction Count
RT Total Dose  (Gy)
Number Of Days Radiotherapy Interrupted Due
To Toxicity (Do not include weekends or days on
which patient would not be treated)
Number Of Days Radiotherapy Interrupted Due
To Other Reasons (Do not include weekends or
days on which patient would not be treated)
Reason Treatment Ended
Adverse Event/side Effects/complications
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(Adverse Event/Side
Effects/Complications)
Alternative Therapy (Alternative therapy)
Death On Study (Death on study)
Disease Progression, Relapse During
Active Treatment (Disease progression,
relapse during active treatment)
Other (Other)
Patient Off-treatment For Other
Complicating Disease (Patient off-
treatment for other complicating disease)
Patient Withdrawal Or Refusal After
Beginning Protocol Therapy (Patient
withdrawal/refusal after beginning
protocol therapy)
Patient Withdrawal Or Refusal Before
Beginning Protocol Therapy (Patient
withdrawal/refusal prior to beginning
protocol therapy)
Treatment Completed Per Protocol
Criteria (Treatment completed per
protocol criteria)
Alternative Therapy
Other specify
Margin used for PTV expansion?
Comments
Person Completing Form
Date Form Originally Completed (MM DD YYYY)
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Pancreatic Cancer NCT01013649 On-Study - RTOG 0848:  Phase III Pancreas-
Resected + Adjuvant Treatment Post ARM 1 or 2 Tumor Status Form (F3) -
2865008v1.0
RTOG 0848:  Phase III Pancreas-Resected + Adjuvant
Treatment Post ARM 1 or 2 Tumor Status Form (F3)
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=68A15631-
F4DE-4C22-E040-BB89AD431280
All rights reserved. Please visit https://medical-data-
models.org/forms/8223
RTOG 0848:  Phase III Pancreas-
Resected + Adjuvant Treatment Post
ARM 1 or 2 Tumor Status Form (F3)
Unnamed Module 1
RTOG Study No.
Case #
Institution Name
Institution No.
Patient Initials
RTOG Patient ID
Amended Data
Yes
No
Has Patient Been Diagnosed With A New
Progression?
Date of Assessment
Was the patient evaluated
Yes
No
Reason evaluation not done
Death (Death)
Md Preference (MD Preference)
Other (Other)
Patient Refusal (Patient refusal)
Specify
Local tumor
Disease Absent (Disease absent)
Disease Present (Disease present)
Distant metastasis
Disease Absent (Disease absent)
Disease Present (Disease present)
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Method of Evaluation
Ct W/contrast (CT w/contrast)
Mri (MRI (NMR))
Event
Appearance Of Bone Metastasis
(Appearance of bone metastasis)
Appearance Of Distant Nodes
(Appearance of distant nodes)
Appearance Of Liver Metastasis
(Appearance of liver metastasis)
Appearance Of Lung Metastasis
(Appearance of lung metastasis)
Appearance Of Other Metastasis
(Appearance of other metastasis)
Appearance Of Second Primary
(Appearance of second primary)
Nodal Progression (Nodal progression)
Progression (Progression)
Date
Specify
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NCT01302834 Quality of Life - RTOG 1016 HP: Radiation Therapy Oncology Group
Phase III Head and Neck Cancer The Health Utility Measurement Euro (EQ-5D) -
3159942v1.0
RTOG 1016 HP: Radiation Therapy Oncology Group Phase
III Head and Neck Cancer The Health Utility Measurement
Euro (EQ-5D)
Radiation Therapy With Cisplatin or Cetuximab in Treating
Patients With Oropharyngeal Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=95334267-
A54C-00F8-E040-BB89AD43108C
All rights reserved. Please visit https://medical-data-
models.org/forms/8227
RTOG 1016 HP: Radiation Therapy
Oncology Group Phase III Head and
Neck Cancer The Health Utility
Measurement Euro (EQ-5D)
Unnamed Module 1
RTOG Study No.
Case #
Institution Name
Institution No.
Patient Initials
RTOG Patient ID
Amended data
Yes
No
Unamed Module 2
Mobility
I Am Confined To Bed (I am confined to
bed)
I Have No Problems In Walking About (I
have no problems in walking about)
I Have Some Problems In Walking About
(I have some problems in walking about)
Self care
I Am Unable To Wash Or Dress Myself (I
am unable to wash or dress myself)
I Have No Problems With Self Care (I
have no problems with self care)
I Have Some Problems Washing Or
Dressing Myself (I have some problems
washing or dressing myself)
Usual activities (e.g. work, study, housework,
family, or leisure activities)
I Am Unable To Perform My Usual
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Activities (I am unable to perform my
usual activities)
I Have No Problems With Performing My
Usual Activities (I have no problems with
performing my usual activities)
I Have Some Problems With Performing
My Usual Activities (I have some
problems with performing my usual
activities)
Pain/discomfort
I Have Extreme Pain Or Discomfort (I
have extreme pain or discomfort)
I Have Moderate Pain Or Discomfort (I
have moderate pain or discomfort)
I Have No Pain Or Discomfort (I have no
pain or discomfort)
Anxiety/depression
I Am Extremely Anxious Or Depressed (I
am extremely anxious or depressed)
I Am Moderately Anxious Or Depressed
(I am moderately anxious or depressed)
I Am Not Anxious Or Depressed (I am
not anxious or depressed)
Unnamed Module 3
Your own health state today
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NCT01349322 Quality of Life - RTOG-1005 BQ: Radiation Therapy Oncology Group
Phase III Whole Breast Irradiation for Early Stage Breast Cancer Patient Cosmesis
Questionnaire - 3194282v1.0
RTOG-1005 BQ: Radiation Therapy Oncology Group
Phase III Whole Breast Irradiation for Early Stage Breast
Cancer Patient Cosmesis Questionnaire
Higher-Dose Radiation Therapy or Standard Radiation
Therapy in Treating Patients With Early-Stage Breast
Cancer That Was Removed by Surgery
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=9D7B30AD-
FE61-0FB3-E040-BB89AD435271
All rights reserved. Please visit https://medical-data-
models.org/forms/8228
RTOG-1005 BQ: Radiation Therapy
Oncology Group Phase III Whole
Breast Irradiation for Early Stage
Breast Cancer Patient Cosmesis
Questionnaire
Unnamed Module 1
RTOG Study No.
Case #
Institution Name
Institution No.
Patient Initials
RTOG Patient ID
Are data amended
Yes
No
Unamed Module 2
Time point
1 Month Post Rt Completion (1 month
post RT Completion)
1 Year Post Rt Completion (1 year post
RT Completion)
2 Years Post Rt Completion (2 years post
RT Completion)
3 Years Post Rt Completion (3 years post
RT Completion)
6 Months Post Rt Completion (6 months
post RT Completion)
At End Of Rt (At end of RT)
Pretreatment (Pretreatment)
Treatment Start Date
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Was patient questionnaire completed
Yes
No
Date patient questionnaire completed
Reason Questionnaire was not Completed
(PATIENT)
Institution Error (Institutional error)
Not Applicable, Questionnaire Was
Completed (Not applicable,
questionnaire was completed)
Other Reason (Other reason)
Patient Refused Due To Illness (Patient
refused due to illness)
Patient Refused For Other Reason
(Patient refused for other reason)
Patient Unable To Be Contacted (Patient
unable to be contacted)
Patient Withdrew Consent Prior/after
(Patient withdrew consent prior/after)
Tool Not Availalble In Patient's Language
(Tool not available in patient's language)
Unknown (Unknown)
Patient refused for other reason, specify
Other reason, specify
Specify method of completion
At Appointment (At appointment)
By Mail (By mail)
By Telephone (By telephone)
Not Applicable (Not applicable)
Unknown (Unknown)
Did the patient require any assistance in
completing the questionnaire?
No (No)
Not Applicable (Not applicable)
Unknown If Assistance Given (Unknown
if assistance given)
Yes (Yes)
Specify the person who assisted the patient
Family (Family)
Not Applicable (Not applicable)
Other (Other)
Staff Member (Staff member)
Unknown (Unknown)
Other, specify
Extent of the assistance
Combination Of Above (Combination of
above)
Interpreted Items For Patient (Interpreted
items for patient)
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Marked Items Per Patient's Response
(Marked items per patient's response)
Not Applicable (Not applicable)
Other (Other)
Read Items To Patient (Read items to
patient)
Unknown (Unknown)
Combination of above, specify
Other, specify
Signature of Person Completing This Form
Date Form Completed (MM DD YYYY)
Difference Between Treated And
Untreated Breast And Area
Breast size
Large (Large)
Moderate (Moderate)
None (None)
Slight (Slight)
Breast texture
Large (Large)
Moderate (Moderate)
None (None)
Slight (Slight)
Arm heaviness
Large (Large)
Moderate (Moderate)
None (None)
Slight (Slight)
Nipple appearance
Large (Large)
Moderate (Moderate)
None (None)
Slight (Slight)
Should movement
Large (Large)
Moderate (Moderate)
None (None)
Slight (Slight)
Arm movement
Large (Large)
Moderate (Moderate)
None (None)
Slight (Slight)
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Breast pain
Large (Large)
Moderate (Moderate)
None (None)
Slight (Slight)
Ability to lift objects
Large (Large)
Moderate (Moderate)
None (None)
Slight (Slight)
Fit of shirt sleeve
Large (Large)
Moderate (Moderate)
None (None)
Slight (Slight)
Breast tenderness
Large (Large)
Moderate (Moderate)
None (None)
Slight (Slight)
Shoulder stiffness
Large (Large)
Moderate (Moderate)
None (None)
Slight (Slight)
Breast shape
Large (Large)
Moderate (Moderate)
None (None)
Slight (Slight)
Breast elevation
Large (Large)
Moderate (Moderate)
None (None)
Slight (Slight)
Scar tissue
Large (Large)
Moderate (Moderate)
None (None)
Slight (Slight)
Shoulder pain
Large (Large)
Moderate (Moderate)
None (None)
Slight (Slight)
Arm pain
Large (Large)
Moderate (Moderate)
None (None)
Slight (Slight)
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Arm swelling
Large (Large)
Moderate (Moderate)
None (None)
Slight (Slight)
Breast swelling
Large (Large)
Moderate (Moderate)
None (None)
Slight (Slight)
Arm stiffness
Large (Large)
Moderate (Moderate)
None (None)
Slight (Slight)
Fit of bra
Large (Large)
Moderate (Moderate)
None (None)
Slight (Slight)
Breast sensitivity
Large (Large)
Moderate (Moderate)
None (None)
Slight (Slight)
Fit of clothing
Large (Large)
Moderate (Moderate)
None (None)
Slight (Slight)
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Prostate Cancer NCT00033631 Treatment - T1 Radiation Therapy Oncology
Group Phase III Prostate 3D / IMRT Radiotherapy Form - 2478411v1.0
T1 Radiation Therapy Oncology Group Phase III Prostate
3D / IMRT Radiotherapy Form
Radiation Therapy in Treating Patients With Stage II
Prostate Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=11E22AA5-
BFC0-32E2-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/8229
T1 Radiation Therapy Oncology
Group Phase III Prostate 3D / IMRT
Radiotherapy Form
Module 1
RTOG Study No.
Case #
Institution
Institution No.
Participant's Initials
Participant's I.D. No.
If this is a revised or corrected form, indicate by
checking box.
RADIATION THERAPY START DATE
RADIATION THERAPY END DATE
ELAPSED DAYS
TOTAL FRACTIONS
TOTAL DOSE   (Gy)
Performance Status (Zubrod 0-4)
2 (Ambulatory and capable of all selfcare
but unable to carry out any work
activities (K 50 - 60))
3 (Capable of only limited selfcare,
confined to bed or chair more than 50%
of waking hours (K 30 - 40))
4 (Completely disabled  (K 10 - 20))
0 (Fully active, able to carry on all pre-
disease performance without restriction
(Karnofsky 90 - 100))
1 (Restricted in physically strenuous
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activity but ambulatory (K 70 -     80))
WERE THERE ANY UNSCHEDULED
INTERRUPTIONS IN RADIATION THERAPY?
No (No)
Yes, Due To Other Reason (Yes, due to
other reason)
Yes, Due To Toxicity (Yes, due to toxicity)
Specify RT interruption reason
REASON RADIATION THERAPY TREATMENT
ENDED
Alternative Therapy (Alternative therapy)
Death On Study (Death on study)
Disease Progression, Relapse During
Active Treatment (Disease progression,
relapse during active treatment)
Other (Other)
Other Complicating Disease (Other
complicating disease)
Patient Withdrawal Or Refusal After
Beginning Protocol Therapy (Patient
withdrawal or refusal after beginning
protocol therapy)
Patient Withdrawal Or Refusal Prior To
Beginning Protocol Therapy (Patient
withdrawal or refusal prior to beginning
protocol therapy)
Toxicity/side Effects/complications
(Toxicity/side effects/complications)
Treatment Completed Per Protocol
Criteria (Treatment completed per
protocol criteria)
Alternative therapy, specify
Other complicating disease, specify
Other, specify
Type of Radiation Therapy Administered (Which
modality was used to treat this patient)
3d Conformal (3D conformal)
Imrt (IMRT)
Comments
Signature of person completing form
Date form completed, original
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Adenocarcinoma of the Gastroesophageal Junction NCT01196390
On-Study - RTOG 1010 Initial Evaluation Form (I1) - 3088432v1.0
RTOG 1010 Initial Evaluation Form (I1)
Radiation Therapy, Paclitaxel, and Carboplatin With or
Without Trastuzumab in Treating Patients With Esophageal
Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=86E3B1E3-
58EB-2570-E040-BB89AD433A07
All rights reserved. Please visit https://medical-data-
models.org/forms/8234
RTOG 1010 Initial Evaluation Form
(I1)
Unnamed Module 1
RTOG Study No.
Case #
Institution Name
Institution No.
Patient Initials
RTOG Patient ID
Amended Data
Yes
No
Unnamed Module 1
Patient Age
Performance Status (Zubrod)
Normal Activity (0)
Symptoms, But Nearly Fully Ambulatory
(1)
Some Bed Time, But Needs To Be In
Bed <50% Of Normal Daytime (2)
Needs To Be In Bed > 50% Of Normal
Daytime (3)
Unable To Get Out Of Bed (4)
Weight (kg)
Oral alimentation
No (No)
Unknown (Unknown)
Yes (Yes)
Nasogastric tube feeding
No (No)
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Unknown (Unknown)
Yes (Yes)
Ostomy feeding
No (No)
Unknown (Unknown)
Yes (Yes)
Intravenous hyperalimentation
No (No)
Unknown (Unknown)
Yes (Yes)
Other
No (No)
Unknown (Unknown)
Yes (Yes)
Other Specify
Estimate of daily caloric intake
< 1500 Cal/day (< 1500 cal/day)
>= 1500 Cal/day (>= 1500 cal/day)
Tumor Location
Distal Esophagus (Distal Esophagus)
Esophagogastric Junction
(Esophagogastric Junction)
Mid Esophagus (Mid esophagus)
Disease Extent
Clinical T Stage
Tumor Invades Lamina Propria,
Muscularis Mucosae, Or Submucosa
(T1)
Tumor Invades Muscularis Propria (T2)
Tumor Invades Adventitia (T3)
Clinical N Stage
No Regional Lymph Node Metastasis
(N0)
Regional Lymph Node Metastases
Involving 1 To 2 Nodes (N1)
Regional Lymph Node Metastases
Involving 3 To 6 Nodes (N2)
Clinical M Stage
No Distant Metastasis (M0)
Distant Metastasis (M1)
Study Cancer
Pathologically Confirmed Primary
Adenocarcinoma of the Esophagus
Yes
No
Cervical esophagus
2 / 7
Adenocarcinoma of the Gastroesophageal Junction NCT01196390 On-
Study - RTOG 1010 Initial Evaluation Form (I1) - 3088432v1.0
Yes
No
Invasion into the trachea or major bronchi
Yes
No
Is the tumor proximal thoracic (15-24cm)
Yes
No
Sites of Lymphadenopathy
Celiac (Celiac)
Gastric (Gastric)
Gastrohepatic (Gastrohepatic)
Para-esophageal (Para-Esophageal)
Celiac lymph nodes <= 2 cm (if present)
Yes
No
Tumor at the level of the carina
Yes
No
Evidence of tracheoesophageal fistule
Yes
No
Involvement of stomach
Yes
No
Involvement of stomach <= 5 cm (if present)
Yes
No
Baseline Lab Values (hematologic)
WBC (mm^3)
Date (MM DD YYYY)
Date (MM DD YYYY)
ANC (mm^3)
Date (MM DD YYYY)
Platelet count (mm^3)
Date (MM DD YYYY)
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Hemoglobin (g/dL)
Date (MM DD YYYY)
Serum creatinine (mg/dl)
Creatinine ULN (SERUM mg/dl)
Total Bilirubin (mg/dl)
Date (MM DD YYYY)
Bilirubin ULN (mg/dl)
SGOT (AST) (IU/L)
Date (MM DD YYYY)
SGOT (AST) ULN (IU/L)
LVEF (%)
LVEF LLN (% Institutions lower limit of normal)
Date LVEF performed (MM DD YYYY)
Diagnosis Work-up
History and Physical
Yes
No
CT scan of the chest/abdomen/pelvis
Yes
No
Endoscopic biopsy of esophageal tumor
Yes
No
EKG
Yes
No
Bronchoscopy
Yes
No
PET/CT (Whole body)
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Yes
No
MUGA Scan
Yes
No
Cardiac ECHO
Yes
No
Lymphadenopathy by scan (REGIONAL)
Yes
No
Examination Date (MM DD YYYY)
Was a surgical oncology consultation performed
(DOCUMENTATING THAT THE PATIENT WILL
BE ABLE TO UNDERGO CURATIVE
RESECTION AFTER COMPLETION OF
CHEMORADIATION)
Yes
No
Was a radiation oncology consultation performed
(DOCUMENTING THAT THE DISEASE CAN BE
ENCOMPASSED IN A RADIOTHERAPY FIELD)
Yes
No
Was a medical oncology consultation performed
Yes
No
Date of Assessment (MM DD YYYY)
Date of Assessment (MM DD YYYY)
Date of Assessment (MM DD YYYY)
Severe Active Comorbidity
History of Prior Malignancy (invasive)
Yes
No
Date eradicated (If yes MM DD YYYY)
Prior systemic chemotherapy for current study
cancer
Yes
No
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Prior radiation therapy for current study cancer
Yes
No
Prior radiation therapy (chest)
Yes
No
Prior anthracycline Treatment
Yes
No
Prior Taxane Therapy
Yes
No
Prior therapy that targeted EGFR pathway
Yes
No
Prior allergic reaction to study agents
Yes
No
History of documented congestive heart failure
Yes
No
Unstable angina in last 6 months
Yes
No
Acute bacterial or fungal infection requiring
intravenous antibiotics at the time of registration
Yes
No
Acquired Immune Deficiency Syndrome based
upon current CDC definition (AIDS)
Yes
No
Transmural MI in last 6 months (myocardial
infarction)
Yes
No
Medical contraindication to esophagectomy
Yes
No
Is patient a woman of childbearing potential
Yes
No
Negative serum pregnancy test
Yes
No
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Negative serum pregnancy test date (MM DD
YYYY)
Footer Module
Comments
Investigator Signature
Date
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Study - RTOG 1010 Initial Evaluation Form (I1) - 3088432v1.0
Adenocarcinoma of the Gastroesophageal Junction NCT01196390
Treatment - RTOG 1010 Post Treatment Response Form (F2) - 3180385v1.0
RTOG 1010 Post Treatment Response Form (F2)
Radiation Therapy, Paclitaxel, and Carboplatin With or
Without Trastuzumab in Treating Patients With Esophageal
Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=99087049-
39B3-FC29-E040-BB89AD43284B
All rights reserved. Please visit https://medical-data-
models.org/forms/8235
RTOG 1010 Post Treatment
Response Form (F2)
Unnamed Module 1
RTOG Study No.
Case #
Institution Name
Institution No.
Patient Initials
RTOG Patient ID
Amended Data
Yes
No
Unnamed 1
CT scan chest/abdomen/pelvis
Yes
No
Was a whole body PET scan done (POST RT)
Yes
No
Reason evaluation not done
Death (Death)
Md Preference (MD Preference)
Other (Other)
Patient Refusal (Patient refusal)
Specify
Date of Assessment
Clinical disease status
Complete Remission (Complete clinical
response)
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Residual Disease (Residual disease or
suspicion of residual disease)
Was biopsy performed
Yes
No
Reason biopsy not done
Death (Death)
Not Required Per Protocol (Not required
per protocol)
Other (Other)
Patient Refusal (Patient refusal)
Specify
Biopsy Result
Negative (negative)
Not Applicable (Not applicable)
Positive (positive)
Footer Module
Comments
Person Completing Form
Date Form Completed (MM DD YYYY)
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Adenocarcinoma of the Gastroesophageal Junction NCT01196390
Treatment - RTOG 1010 Surgery Form (S1) - 3104579v1.0
RTOG 1010 Surgery Form (S1)
Radiation Therapy, Paclitaxel, and Carboplatin With or
Without Trastuzumab in Treating Patients With Esophageal
Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=87FDA2A8-
3F52-6C0D-E040-BB89AD433137
All rights reserved. Please visit https://medical-data-
models.org/forms/8239
RTOG 1010 Surgery Form (S1)
Unnamed Module 1
RTOG Study No.
Case #
Institution Name
Institution No.
Patient Initials
RTOG Patient ID
Amended Data
Yes
No
Endoscopy/biopsy/surgery
Endoscopic biopsy of esophageal tumor
Yes
No
Reason biopsy not done (ENDOSCOPY WITH)
Metastatic Disease (Metastatic disease)
Not Applicable (Not applicable)
Other (Other)
Patient Refusal (Patient refusal)
Physician Decision (Physician decision)
Progression (Progression)
Specify
Specify (other)
Date of Biopsy (endoscopic)
Biopsy Result
Negative (negative)
Not Applicable (Not applicable)
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Other (Other)
Positive (positive)
Other, specify
Surgical Resection
Was resection attempted?
Yes
No
Reason surgery not performed
Metastatic Disease (Metastatic disease)
Not Applicable (Not applicable)
Other (Other)
Patient Refusal (Patient refusal)
Physician Decision (Physician decision)
Progression (Progression)
Other, specify
Date of surgical resection (MM DD YYYY)
Protocol Surgery Type
Mckeon (McKeon)
Other (other)
Thoracoabdominal Esophagectomy
(Thoracoabdominal esophagectomy)
Transhiatal Esophagectomy (Transhiatal
esophagectomy)
Transthoracic (Transthoracic)
Other specify
Was patient nodal status determined (STAGING
INCLUDE LEVELS 7,8,9,15,16,17 AND 20)
Yes
No
Resection Classification
All Margins Pathologically Negative (R0)
Microscopically Positive Margins Or
Microscopic Residual Disease (R1)
Macroscopically Positive Margins Or
Gross Residual Disease (R2)
Footer Module
Comments
Person Completing Form
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Prostate Cancer NCT00499174 Follow-Up - NCIC-PR.11 Form
5S - Follow-Up after Distant Progression - 2457398v1.0
NCIC-PR.11 Form 5S - Follow-Up after Distant Progression
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=0EF819B0-
5956-1C96-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/8245
NCIC-PR.11 Form 5S - Follow-Up
after Distant Progression
Patient Information
NCIC Patient ID (NCIC CTG Patient Serial
Number issued at the time of randomization)
Patient Initials (first-middle-last)
Patient Medical Record Number (if permitted by
IRB)
Intergroup Patient Serial No
Institution Name
NCI Institution Number (CTEP assigned)
Investigator First Name
Investigator Last Name
Investigator Number (NCI Investigator Number)
Month Of Report
Month of report (circle one)
12 (12)
18 (18)
24 (24)
36 (36)
48 (48)
6 (6)
60 (60)
Other Month (OTHER)
Other
Physical Exam
Date of Last Clinical Assessment (yyyy - mmm -
dd)
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Adverse Event Status
Has the patient experienced any new or
continuing symptoms or adverse events since the
last report? (possibly, probably or definitely
related to protocol therapy)
Yes
No
CTC Adverse Event Term (CTCAE Version 4.0)
Abdominal Pain (Abdominal pain)
Alopecia (Alopecia)
Non-infectious Cystitis (Cystitis
noninfective)
Diarrhea (Diarrhea)
Impotence (Erectile dysfunction)
Fatigue (Fatigue)
Proctitis (Proctitis)
Urinary Frequency (Urinary frequency)
Urinary Incontinence (Urinary
incontinence)
Urinary Retention (Urinary retention)
Grade (Worst this time period If event no present,
leave this field blank.)
Absent Adverse Event (0)
Mild Adverse Event (1)
Moderate Adverse Event (2)
Severe Adverse Event (3)
Life Threatening Adverse Event (4)
Death Related To Adverse Event (5)
CTC Adverse Event Attribution Code (*Serious
Adverse Event form required only if malignancy is
thought to be possibly, probably, or definitely
related to protocol therapy. See protocol...)
Definite (Definite)
Possible (Possible)
Probable (Probable)
Unlikely (Unlikely)
Unrelated (Unrelated)
Seriousness Attributed to Adverse Event (Enter
appropriate code as follows: 0=not serious;
1=death; 2=life threatening; 3=hospitalization,
initial or prolonged; 4=disability...)
Congenital Anomaly (Congenital
anomaly)
Death (Death)
Disability (Disability/incapacity)
Hospitalized (Hospitalization, initial or
prolonged)
Life Threatening (Life threatening)
Not Serious (Not serious)
Other (Other)
Intervention Required (Required
intervention to prevent permanent
impairment/damage)
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SAE report submitted (NCIC CTG use only
Default=N enter Y only for adverse events
recorded on SAE report)
Yes
No
Therapy For Lower Urinary Tract
Symptoms/prostate Cancer Since The
Last Report
Non-protocol 5 alpha reductase inhibitors
Yes
No
Agent
Reason for use
Non-protocol non-steroidal antiandrogen therapy
Yes
No
Agent
Non-protocol LHRH analogues
Yes
No
Agent
Non-Protocol Surgery? (for prostate cancer )
Yes
No
Date of Non-protocol therapy (If yes, Date of Non-
protocol surgery yyyy-mmm-dd )
Non-Protocol Surgery Type
Non-Protocol Radiation Therapy? (for prostate
cancer )
Yes
No
Non-Protocol Radiation Therapy Start Date (If
yes, yyyy-mmm-dd )
Non-Protocol RT Type
Complementary and alternative medicines (for
lower urinary tract symptoms or prostate cancer?
CRF: Complementary and Alternative Medicines)
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Yes
No
Agent (If yes, *e.g. Saw Palmetto, Vitamin B/E,
Selenium, Lycopene  CRF: Agent)
Other Non-Protocol Therapy (for prostate cancer)
Yes
No
Name of Other Non-Protocol Therapy (If yes, for
Prostate Cancer )
Date of First Non-Protocol Therapy (for Prostate
Cancer yyyy-mmm-dd)
Date of First Non-Protocol Therapy (for Prostate
Cancer yyyy-mmm-dd)
Date of First Non-Protocol Therapy (for Prostate
Cancer yyyy-mmm-dd)
Date of First Non-Protocol Therapy (for Prostate
Cancer yyyy-mmm-dd)
Other Malignancies Or Marrow Dysplasia
Has a new primary cancer or MDS been
diagnosed that has not been previously reported?
(myelodysplastic syndrome)
Yes
No
Date of Diagnosis (yyyy-mmm-dd)
Malignancy Type (e.g., bladder)
New Primary Diagnosis
(Histology/Cytopathology)
CTC Adverse Event Attribution Code (*Serious
Adverse Event form required only if malignancy is
thought to be possibly, probably, or definitely
related to protocol therapy. See protocol...)
Definite (Definite)
Possible (Possible)
Probable (Probable)
Unlikely (Unlikely)
Unrelated (Unrelated)
Comments
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Comments
Supporting Documentation
Investigator Signature
Person Completing Form, Last Name
Person Completing Form, First Name
Date Form Originally Completed (yyyy - mmm -
dd)
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Prostate Cancer NCT00499174 Follow-Up - NCIC-PR.11
Form 5M - Minimal Follow-Up Report - 2584175v1.0
NCIC-PR.11 Form 5M - Minimal Follow-Up Report
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=26171A55-
EECB-3CBB-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/8249
NCIC-PR.11 Form 5M - Minimal
Follow-Up Report
Patient Information
NCIC Patient ID (NCIC CTG Patient Serial
Number issued at the time of randomization)
Patient Initials (first-middle-last)
Investigator's Last Name (RECOMMENDED
TERM for "Investigator or Delegate Last Name")
Patient Medical Record Number (if permitted by
IRB)
Investigator's First Name (RECOMMENDED
TERM for "Investigator or Delegate First Name")
Intergroup Patient Serial No
Institution Name
NCI Institution Number (CTEP assigned)
Investigator Number (NCI Investigator Number)
Cause Of Death
Date of Last Contact or Death (yyyy mmm dd)
Patient's Vital Status
Alive (Alive)
Dead (Dead)
Primary Cause of Death
Due To Other Cause (Due to other
cause)
Due To Protocol Treatment (Due to
protocol treatment)
Due To This Disease (Due to this
disease)
Unknown (Unknown)
Due to other cause specify
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Has the patient been diagnosed with first distant
recurrence/progression?
Yes
No
Date of First Distant Progression (yyyy mmm dd)
Other Malignancies Or Marrow Dysplasia
Has a new primary cancer or MDS been
diagnosed that has not been previously reported?
(myelodysplastic syndrome)
Yes
No
Date of Diagnosis (yyyy-mmm-dd)
Malignancy Type (e.g., bladder)
New Primary Diagnosis
(Histology/Cytopathology)
CTC Adverse Event Attribution Code (*Serious
Adverse Event form required only if malignancy is
thought to be possibly, probably, or definitely
related to protocol therapy. See protocol...)
Definite (Definite)
Possible (Possible)
Probable (Probable)
Unlikely (Unlikely)
Unrelated (Unrelated)
Comments
Comments
Investigator Signature
Investigator Signature (RECOMMENDED TERM
for "Investigator or Delegate Signature")
Investigator's Last Name (RECOMMENDED
TERM for "Investigator or Delegate Last Name")
Investigator's First Name (RECOMMENDED
TERM for "Investigator or Delegate First Name")
Person Completing Form, Last Name (*if different
from above)
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Person Completing Form, First Name (*if different
from above)
Date Form Originally Completed (yyyy - mmm -
dd)
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Breast Cancer NCT01101438 Follow-Up - NCIC
MA.32 Short Follow-Up Report Form - 3026031v1.0
NCIC MA.32 Short Follow-Up Report Form
A Phase III Randomized Trial of Metformin vs Placebo in
Early Stage Breast Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=81DD7330-
A8C4-A3E4-E040-BB89AD43612E
All rights reserved. Please visit https://medical-data-
models.org/forms/8260
NCIC MA.32 Short Follow-Up Report
Form
Physical Exam
Post-treatment follow-up visit date
Off Treatment Report Period
12 Months (12 months)
24 Months (24 months)
36 Months (36 months)
48 Months (48 months)
60 Months (60 months)
72 Months (72 months)
Other (Other)
Assessment Period, Specify
Visit Type
After Contralateral Breast Carcinoma
Only (After contralateral breast
carcinoma only)
After Distant Recurrence/progression
(After distant recurrence/progression)
After Local Breast Cancer Recurrence
But No Distant Recurrence (After local
breast cancer recurrence but no distant
recurrence)
After New Non-breast Primary
Malignancy, Incurable (After new non-
breast primary malignancy, incurable)
After New Non-breast Primary
Malignancy, Treated With Curative Intent
(After new non-breast primary
malignancy, treated with curative intent)
Prior To The Appearance Of Any
Invasive Cancer (Prior to the appearance
of any invasive cancer)
Weight (kg)
BMI
Disease Status
Status of Most Recent Clinical Assessment
Cancer Present (Cancer present)
No Evidence Of Disease (No evidence of
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disease)
In Situ Disease Follow-up
Since the last report has there been a biopsy
proven diagnosis of DCIS
Yes
No
Tumor Laterality (If yes,)
Date of radiologic detection of DCIS (If yes,)
Date of histologic DCIS diagnosis (If yes,)
Kit Return - Question
Have any treatment kits been returned this
reporting period
Yes
No
Kit Return
Kit number
Number of pills returned
Kit Dispension - Question
Have any treatment kits been dispensed this
reporting period
Yes
No
Kit Dispensation
Kit number
Date dispensed
Metformin/placebo Administration - Ramp-
up
Date of Initial Dose
Date subject scheduled to begin full dose
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Date subject reports full dose begun
Metformin/placebo Administration
Has subject taken protocol medication every day
Yes
No
How many pills does the subject report having
missed (If no,)
Dose Modification Reason (If no, please enter the
reasons for dose modifications in the table
below:)
Adverse Event (Adverse event)
Dosing Error (Dosing error)
Hold For Procedure (Hold for procedure)
Intercurrent Illness (Intercurrent illness)
Other (Other)
Patient Forgot (Patient forgot)
Patient Request (Patient request)
Specify
Was this dose modification or addition/omission
as per protocol guidelines
Yes
No
Radiology Investigations - Question
Was a mammogram performed
No (No)
Not Applicable (Not Applicable)
Yes (Yes)
Mammogram laterality
Bilateral (Bilateral)
Unilateral (unilateral)
Specify side
Left (Left)
Right (Right)
Was imaging done to assess for recurrence
(other than mammogram)
Yes
No
Radiology Investigations
Type of imaging
Mammography (Mammography)
Magnetic Resonance Imaging (MRI)
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Other (Other)
Scan - Bone (Scan - bone)
Scan - Ct Abdomen (Scan - CT
abdomen)
Scan - Ct Brain (Scan - CT brain)
Scan - Ct Chest (Scan - CT chest)
Scan - Ct Pelvis (Scan - CT pelvis)
Ultrasound - Abdomen (Ultrasound -
abdomen)
Ultrasound - Pelvis (Ultrasound - pelvis)
Xray - Chest (Xray - chest)
Specify
Date of test
Result
Abnormal, Malignant (Abnormal,
malignant)
Abnormal, Non-malignant (Abnormal,
non-malignant)
Normal (Normal)
Hematology
Lab, Hematology, Sample Collection Date
Date
Was sample obtained
Yes
No
Hemoglobin
Hemoglobin (Hgb) (g/dl), LLN
Hemoglobin, ULN
Platelet count
Platelets LLN
Platelets ULN
WBC
WBC count (x1000), LLN
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Peripheral WBC count, ULN
Peripheral Granulocytes Count
Peripheral Granulocytes Count LLN
Granulocytes, ULN
Mean Corpuscular Volume
Units
Units
Units
Units
Units
Mean Corpuscular Volume, LLN
Mean Corpuscular Volume, ULN
Biochemistry
Date Specimen collected (biochemical
investigations)
Date
Was sample obtained
Yes
No
Alkaline Phosphatase
Alkaline Phosphatase LLN
Alkaline Phosphatase ULN
SGPT (ALT)
SGPT (ALT) LLN
5 / 29
Breast Cancer NCT01101438 Follow-Up - NCIC MA.32 Short Follow-Up
Report Form - 3026031v1.0
SGPT (ALT) ULN
SGOT (AST)
SGOT (AST) LLN
SGOT (AST) ULN
Total Bilirubin
Total bilirubin LLN
Total Bilirubin ULN
Serum Creatinine
Units
Units
Units
Units
Units
Serum Creatinine LLN
Serum Creatinine ULN
Serum Vitamin B12
Serum Vitamin B12, LLN
Serum Vitamin B12, ULN
Fasting glucose
Fasting glucose, LLN
Fasting glucose, ULN
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Serious Adverse Event - Question
Did the patient experience a Serious Adverse
Event, as defined in protocol section 11, during
this reporting period
Yes
No
Adverse Events On Treatment - Question
Were any additional adverse events experienced
by the patient
No (No)
Not Assessed (Not assessed)
Yes (Yes)
Has a new primary cancer or MDS been
diagnosed that has not been previously reported?
Yes
No
Has there been a new diagnosis of diabetes
since the last report
Yes
No
Adverse Events
Would you like to carry forward the adverse
events (indicated as continuing) from the previous
reporting period
Yes
No
CTCAE Term
Abdominal Distention (Abdominal
distension)
Abdominal Infection (Abdominal
infection)
Abdominal Pain (Abdominal pain)
Abdominal Soft Tissue Necrotic Lesion
(Abdominal soft tissue necrosis)
Abducens Nerve Disorder (Abducens
nerve disorder)
Accessory Nerve Disorder (Accessory
nerve disorder)
Acidosis (Acidosis)
Vestibulocochlear Nerve Disorder
(Acoustic nerve disorder NOS)
Prolonged Partial Thromboplastin Time
(Activated partial thromboplastin time
prolonged)
Acute Coronary Syndrome (Acute
coronary syndrome)
Acute Renal Failure (Acute kidney injury)
Adrenal Gland Insufficiency (Adrenal
insufficiency)
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Adult Respiratory Distress Syndrome
(Adult respiratory distress syndrome)
Agitation (Agitation)
Akathisia (Akathisia)
Alanine Aminotransferase Increased
(Alanine aminotransferase increased)
Alcohol Intolerance (Alcohol intolerance)
Blood Alkaline Phosphatase Increased
(Alkaline phosphatase increased)
Alkalosis (Alkalosis)
Hypersensitivity (Allergic reaction)
Allergic Rhinitis (Allergic rhinitis)
Alopecia (Alopecia)
Amnesia (Amnesia)
Anorectal Fistula (Anal fistula)
Anal Hemorrhage (Anal hemorrhage)
Anal Mucositis (Anal mucositis)
Anal Necrotic Lesion (Anal necrosis)
Anal Pain (Anal pain)
Anal Stenosis (Anal stenosis)
Anal Ulcer (Anal ulcer)
Anaphylactic Shock (Anaphylaxis)
Anemia (Anemia)
Ankle Fracture (Ankle fracture)
Anorectal Infection (Anorectal infection)
Anorexia (Anorexia)
Anorgasmia (Anorgasmia)
Anxiety (Anxiety)
Aortic Injury (Aortic injury)
Aortic Valve Disorder (Aortic valve
disease)
Aphonia (Aphonia)
Apnea (Apnea)
Acute Appendicitis (Appendicitis)
Acute Perforated Appendicitis
(Appendicitis perforated)
Arachnoiditis (Arachnoiditis)
Arterial Injury (Arterial injury)
Arteritis (Arteritis infective)
Arthralgia (Arthralgia)
Arthritis (Arthritis)
Ascites (Ascites)
Aspartate Aminotransferase Increased
(Aspartate aminotransferase increased)
Aspiration (Aspiration)
Cardiac Arrest (Asystole)
Ataxia (Ataxia)
Atelectasis (Atelectasis)
Atrial Fibrillation (Atrial fibrillation)
Atrial Flutter (Atrial flutter)
Av Block Third Degree (Atrioventricular
block complete)
Av Block First Degree (Atrioventricular
block first degree)
Autoimmune Disease (Autoimmune
disorder)
Bone Necrosis (Avascular necrosis)
Azoospermia (Azoospermia)
Back Pain (Back pain)
Bile Duct Stenosis (Bile duct stenosis)
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Biliary Anastomotic Leakage (Biliary
anastomotic leak)
Biliary Fistula (Biliary fistula)
Cholangitis (Biliary tract infection)
Bladder Anastomotic Leakage (Bladder
anastomotic leak)
Cystitis (Bladder infection)
Bladder Perforation (Bladder perforation)
Bladder Spasm (Bladder spasm)
Bloating (Bloating)
Hematopoietic And Lymphoid System
Disorder Other Specify (Blood and
lymphatic system disorders - Other,
specify)
Abnormal Blood Antidiuretic Hormone
(Blood antidiuretic hormone abnormal)
Elevated Bilirubin (Blood bilirubin
increased)
Blood Corticotrophin Decreased (Blood
corticotrophin decreased)
Abnormal Blood Gonadotrophin (Blood
gonadotrophin abnormal)
Abnormal Blood Prolactin (Blood
prolactin abnormal)
Blurred Vision (Blurred vision)
Body Odor (Body odor)
Bone Infection (Bone infection)
Hypocellular Bone Marrow (Bone
marrow hypocellular)
Bone Pain (Bone pain)
Brachial Plexopathy (Brachial
plexopathy)
Breast Atrophy (Breast atrophy)
Mastitis (Breast infection)
Breast Pain (Breast pain)
Bronchial Fistula (Bronchial fistula)
Bronchitis (Bronchial infection)
Bronchial Obstruction (Bronchial
obstruction)
Bronchial Stricture (Bronchial stricture)
Bronchopleural Fistula (Bronchopleural
fistula)
Bronchial Hemorrhage
(Bronchopulmonary hemorrhage)
Bronchospasm (Bronchospasm)
Bruise (Bruising)
Bullous Dermatitis (Bullous dermatitis)
Burn (Burn)
Buttock Pain (Buttock pain)
Capillary Leak Syndrome Capillary Leak
Syndrome (Capillary leak syndrome)
Decreased Carbon Monoxide Diffusing
Capacity (Carbon monoxide diffusing
capacity decreased)
Cardiac Arrest (Cardiac arrest)
Heart Disorder Other Specify (Cardiac
disorders - Other, specify)
Blood Cardiac Troponin I Increased
(Cardiac troponin I increased)
Blood Cardiac Troponin T Increased
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(Cardiac troponin T increased)
Cataract (Cataract)
Catheter-related Infection (Catheter
related infection)
Cd4 Lymphocytes Decreased (CD4
lymphocytes decreased)
Cecal Hemorrhage (Cecal hemorrhage)
Cecal Infection (Cecal infection)
Central Nervous System Necrotic Lesion
(Central nervous system necrosis)
Cerebrospinal Fluid Leakage
(Cerebrospinal fluid leakage)
Infectious Cervicitis (Cervicitis infection)
Cheilitis (Cheilitis)
Angina (Chest pain - cardiac)
Chest Wall Pain (Chest wall pain)
Chills (Chills)
Cholecystitis (Cholecystitis)
Hypercholesterolemia (Cholesterol high)
Chronic Kidney Disease (Chronic kidney
disease)
Chylothorax (Chylothorax)
Cognitive Disturbance (Cognitive
disturbance)
Colitis (Colitis)
Colonic Fistula (Colonic fistula)
Colonic Hemorrhage (Colonic
hemorrhage)
Colonic Obstruction (Colonic obstruction)
Colonic Perforation (Colonic perforation)
Colonic Stenosis (Colonic stenosis)
Colonic Ulcer (Colonic ulcer)
Concentration Impairment
(Concentration impairment)
Heart Conduction Disorder (Conduction
disorder)
Confusion (Confusion)
Congenital, Familial And Genetic
Disorder Class Other Specify
(Congenital, familial and genetic
disorders - Other, specify)
Conjunctivitis (Conjunctivitis)
Acute Contagious Conjunctivitis
(Conjunctivitis infective)
Constipation (Constipation)
Constrictive Pericarditis (Constrictive
pericarditis)
Keratitis (Corneal infection)
Corneal Ulcer (Corneal ulcer)
Cough (Cough)
Creatine Phosphokinase Increased (CPK
increased)
Cranial Nerve Infection (Cranial nerve
infection)
Increased Creatinine (Creatinine
increased)
Cushingoid (Cushingoid)
Non-infectious Cystitis (Cystitis
noninfective)
Cytokine Release Syndrome (Cytokine
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release syndrome)
Neonatal Death (Death neonatal)
Death (Death NOS)
Dehydration (Dehydration)
Delayed Orgasm (Delayed orgasm)
Delayed Puberty (Delayed puberty)
Delirium (Delirium)
Delusion (Delusions)
Caries (Dental caries)
Depressed Level Of Consciousness
(Depressed level of consciousness)
Depression (Depression)
Radiation-induced Dermatitis (Dermatitis
radiation)
Prosthesis-related Infection (Device
related infection)
Diarrhea (Diarrhea)
Disseminated Intravascular Coagulation
(Disseminated intravascular coagulation)
Dizziness (Dizziness)
Dry Eye Syndrome (Dry eye)
Xerostomia (Dry mouth)
Dry Skin (Dry Skin)
Duodenal Fistula (Duodenal fistula)
Duodenal Hemorrhage (Duodenal
hemorrhage)
Duodenal Infection (Duodenal infection)
Duodenal Obstruction (Duodenal
obstruction)
Duodenal Perforation (Duodenal
perforation)
Duodenal Stenosis (Duodenal stenosis)
Duodenal Ulcer (Duodenal ulcer)
Dysarthria (Dysarthria)
Dysesthesia (Dysesthesia)
Dysgeusia (Dysgeusia)
Dysmenorrhea (Dysmenorrhea)
Dyspareunia (Dyspareunia)
Dyspepsia (Dyspepsia)
Dysphagia (Dysphagia)
Dysphasia (Dysphasia)
Dyspnea (Dyspnea)
Ear And Labyrinth Disorder Class Other
Specify (Ear and labyrinth disorders -
Other, specify)
Earache (Ear pain)
Cerebral Edema (Edema cerebral)
Face Edema (Edema face)
Edema Limbs (Edema limbs)
Edema Trunk (Edema trunk)
Ejaculation Disorder (Ejaculation
disorder)
Ejection Fraction Decreased (Ejection
fraction decreased)
Prolonged Qt Interval (Electrocardiogram
QT corrected interval prolonged)
Infectious Encephalitis (Encephalitis
infection)
Infectious Encephalomyelitis
(Encephalomyelitis infection)
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Encephalopathy (Encephalopathy)
Infective Endocarditis (Endocarditis
infective)
Endocrine Disorder Other Specify
(Endocrine disorders - Other, specify)
Endophthalmitis (Endophthalmitis)
Enterocolitis (Enterocolitis)
Infectious Enterocolitis (Enterocolitis
infectious)
Enterovesical Fistula (Enterovesical
fistula)
Epistaxis (Epistaxis)
Impotence (Erectile dysfunction)
Erythema Multiforme (Erythema
multiforme)
Erythroderma (Erythroderma)
Esophageal Anastomotic Leakage
(Esophageal anastomotic leak)
Esophageal Fistula (Esophageal fistula)
Esophageal Hemorrhage (Esophageal
hemorrhage)
Esophageal Infection (Esophageal
infection)
Esophageal Necrotic Lesion
(Esophageal necrosis)
Esophageal Obstruction (Esophageal
obstruction)
Esophageal Pain (Esophageal pain)
Perforation Of Esophagus (Esophageal
perforation)
Esophageal Stricture (Esophageal
stenosis)
Esophageal Ulcer (Esophageal ulcer)
Esophageal Varices Hemorrhage
(Esophageal varices hemorrhage)
Esophagitis (Esophagitis)
Euphoria (Euphoria)
Exostosis (Exostosis)
External Ear Inflammation (External ear
inflammation)
External Ear Pain (External ear pain)
Extraocular Muscle Paresis (Extraocular
muscle paresis)
Extrapyramidal Disorder (Extrapyramidal
disorder)
Eye Disorder Other Specify (Eye
disorders - Other, specify)
Eye Infection (Eye infection)
Eye Pain (Eye pain)
Eyelid Function Disorder (Eyelid function
disorder)
Facial Muscle Weakness (Facial muscle
weakness)
Facial Nerve Disorder (Facial nerve
disorder)
Facial Pain (Facial pain)
Fall (Fall)
Fallopian Tube Anastomotic Leakage
(Fallopian tube anastomotic leak)
Fallopian Tube Obstruction (Fallopian
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tube obstruction)
Fallopian Tube Perforation (Fallopian
tube perforation)
Fallopian Tube Stenosis (Fallopian tube
stenosis)
Adipose Tissue Atrophy (Fat atrophy)
Fatigue (Fatigue)
Neutropenic Fever (Febrile neutropenia)
Fecal Incontinence (Fecal incontinence)
Female Genital Tract Fistula (Female
genital tract fistula)
Acquired Feminization (Feminization
acquired)
Intrauterine Fetal Death (Fetal death)
Fetal Growth Retardation (Fetal growth
retardation)
Fever (Fever)
Fibrinogen Decreased (Fibrinogen
decreased)
Deep Connective Tissue Fibrosis
(Fibrosis deep connective tissue)
Flank Pain (Flank pain)
Flasher (Flashing lights)
Flatulence (Flatulence)
Floaters (Floaters)
Flu-like Symptoms (Flu like symptoms)
Flushing (Flushing)
Decreased Forced Expiratory Volume
(Forced expiratory volume decreased)
Fracture (Fracture)
Gait Disturbance (Gait disturbance)
Gallbladder Fistula (Gallbladder fistula)
Gallbladder Infection (Gallbladder
infection)
Gallbladder Necrotic Lesion (Gallbladder
necrosis)
Gallbladder Obstruction (Gallbladder
obstruction)
Gallbladder Pain (Gallbladder pain)
Gallbladder Perforation (Gallbladder
perforation)
Gastric Anastomotic Leakage (Gastric
anastomotic leak)
Gastric Fistula (Gastric fistula)
Gastric Hemorrhage (Gastric
hemorrhage)
Gastric Necrotic Lesion (Gastric
necrosis)
Gastric Perforation (Gastric perforation)
Gastric Stenosis (Gastric stenosis)
Gastric Ulcer (Gastric ulcer)
Gastritis (Gastritis)
Gastroesophageal Reflux Disease
(Gastroesophageal reflux disease)
Gastrointestinal System Anastomotic
Leakage (Gastrointestinal anastomotic
leak)
Gastrointestinal Disorder Other Specify
(Gastrointestinal disorders - Other,
specify)
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Gastrointestinal Fistula (Gastrointestinal
fistula)
Gastrointestinal Pain (Gastrointestinal
pain)
Gastrointestinal Stoma Necrotic Lesion
(Gastrointestinal stoma necrosis)
Gastroparesis (Gastroparesis)
General Disorders And Administration
Site Conditions Class Other Specify
(General disorders and administration
site conditions - Other, specify)
Generalized Muscle Weakness
(Generalized muscle weakness)
Genital Edema (Genital edema)
Gamma-glutamyltransferase Increased
(GGT increased)
Gingival Pain (Gingival pain)
Glaucoma (Glaucoma)
Glossopharyngeal Nerve Disorder
(Glossopharyngeal nerve disorder)
Glucose Intolerance (Glucose
intolerance)
Accelerated Growth (Growth
accelerated)
Abnormal Growth Hormone (Growth
hormone abnormal)
Growth Retardation (Growth
suppression)
Gum Infection (Gum infection)
Gynecomastia (Gynecomastia)
Hallucination (Hallucinations)
Haptoglobin Decreased (Haptoglobin
decreased)
Head Soft Tissue Necrotic Lesion (Head
soft tissue necrosis)
Headache (Headache)
Hearing Impairment (Hearing impaired)
Heart Failure (Heart failure)
Hematoma (Hematoma)
Hematosalpinx (Hematosalpinx)
Hematuria (Hematuria)
Hemoglobin Increased (Hemoglobin
increased)
Hemoglobinuria (Hemoglobinuria)
Hemolysis (Hemolysis)
Hemolytic Uremic Syndrome (Hemolytic
uremic syndrome)
Hemorrhoidal Hemorrhage
(Hemorrhoidal hemorrhage)
Hemorrhoid (Hemorrhoids)
Hepatic Failure (Hepatic failure)
Hepatic Hemorrhage (Hepatic
hemorrhage)
Hepatic Infection (Hepatic infection)
Hepatic Necrotic Lesion (Hepatic
necrosis)
Hepatic Pain (Hepatic pain)
Viral Hepatitis (Hepatitis viral)
Liver And Biliary Tract Disorder Other
Specify (Hepatobiliary disorders - Other,
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specify)
Hiccough (Hiccups)
Hip Fracture (Hip fracture)
Hirsutism (Hirsutism)
Hoarseness (Hoarseness)
Hot Flashes (Hot flashes)
Hydrocephalus (Hydrocephalus)
Hypercalcemia (Hypercalcemia)
Hyperglycemia (Hyperglycemia)
Hyperhidrosis (Hyperhidrosis)
Hyperkalemia (Hyperkalemia)
Hypermagnesemia (Hypermagnesemia)
Hypernatremia (Hypernatremia)
Hyperparathyroidism
(Hyperparathyroidism)
Hypersomnia (Hypersomnia)
Hypertension (Hypertension)
Hyperthyroidism (Hyperthyroidism)
Hypertrichosis (Hypertrichosis)
Hypertriglyceridemia
(Hypertriglyceridemia)
Hyperuricemia (Hyperuricemia)
Hypoalbuminemia (Hypoalbuminemia)
Hypocalcemia (Hypocalcemia)
Hypoglossal Nerve Disorder
(Hypoglossal nerve disorder)
Hypoglycemia (Hypoglycemia)
Hypohidrosis (Hypohidrosis)
Hypokalemia (Hypokalemia)
Hypomagnesemia (Hypomagnesemia)
Hyponatremia (Hyponatremia)
Hypoparathyroidism
(Hypoparathyroidism)
Hypophosphatemia (Hypophosphatemia)
Hypotension (Hypotension)
Hypothermia (Hypothermia)
Hypothyroidism (Hypothyroidism)
Hypoxia (Hypoxia)
Ileal Fistula (Ileal fistula)
Ileal Hemorrhage (Ileal hemorrhage)
Ileal Obstruction (Ileal obstruction)
Ileal Perforation (Ileal perforation)
Ileal Stenosis (Ileal stenosis)
Ileal Ulcer (Ileal ulcer)
Ileus (Ileus)
Immune System Disorder Other Specify
(Immune system disorders - Other,
specify)
Infection Other Specify (Infections and
infestations - Other, specify)
Infectious Myositis (Infective myositis)
Infusion-related Reaction (Infusion
related reaction)
Infusion Site Extravasation (Infusion site
extravasation)
Injection Site Reaction (Injection site
reaction)
Injury To Carotid Artery (Injury to carotid
artery)
Injury To Inferior Vena Cava (Injury to
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inferior vena cava)
Injury To Jugular Vein (Injury to jugular
vein)
Injury To Superior Vena Cava (Injury to
superior vena cava)
Injury, Poisoning And Procedural
Complication Class Other Specify (Injury,
poisoning and procedural complications -
Other, specify)
Inr Increased (INR increased)
Insomnia (Insomnia)
Intestinal Stoma Leakage (Intestinal
stoma leak)
Intestinal Stoma Obstruction (Intestinal
stoma obstruction)
Intestinal Stoma Site Hemorrhage
(Intestinal stoma site bleeding)
Intra-abdominal Hemorrhage (Intra-
abdominal hemorrhage)
Intracranial Hemorrhage (Intracranial
hemorrhage)
Intraoperative Arterial Injury
(Intraoperative arterial injury)
Intraoperative Breast Injury
(Intraoperative breast injury)
Intraoperative Cardiac Injury
(Intraoperative cardiac injury)
Intraoperative Ear Injury (Intraoperative
ear injury)
Intraoperative Endocrine Injury
(Intraoperative endocrine injury)
Intraoperative Gastrointestinal Injury
(Intraoperative gastrointestinal injury)
Intraoperative Head And Neck Injury
(Intraoperative head and neck injury)
Intraoperative Hemorrhage
(Intraoperative hemorrhage)
Intraoperative Hepatobiliary Injury
(Intraoperative hepatobiliary injury)
Intraoperative Musculoskeletal Injury
(Intraoperative musculoskeletal injury)
Intraoperative Neurological Injury
(Intraoperative neurological injury)
Intraoperative Ocular Injury
(Intraoperative ocular injury)
Intraoperative Renal Injury
(Intraoperative renal injury)
Intraoperative Reproductive System
Injury (Intraoperative reproductive tract
injury)
Intraoperative Respiratory Injury
(Intraoperative respiratory injury)
Intraoperative Skin Injury (Intraoperative
skin injury)
Intraoperative Splenic Injury
(Intraoperative splenic injury)
Intraoperative Urinary System Injury
(Intraoperative urinary injury)
Intraoperative Venous Injury
(Intraoperative venous injury)
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Investigation Other Specify
(Investigations - Other, specify)
Iron Overload (Iron overload)
Irregular Menstruation (Irregular
menstruation)
Irritability (Irritability)
Cerebrovascular Ischemia (Ischemia
cerebrovascular)
Trochlear Nerve Disorder (IVth nerve
disorder)
Jejunal Fistula (Jejunal fistula)
Jejunal Hemorrhage (Jejunal
hemorrhage)
Jejunal Obstruction (Jejunal obstruction)
Jejunal Perforation (Jejunal perforation)
Jejunal Stenosis (Jejunal stenosis)
Jejunal Ulcer (Jejunal ulcer)
Joint Effusion (Joint effusion)
Joint Infection (Joint infection)
Joint Range Of Motion Decreased (Joint
range of motion decreased)
Cervical Spine Joint Range Of Motion
Decreased (Joint range of motion
decreased cervical spine)
Lumbar Spine Joint Range Of Motion
Decreased (Joint range of motion
decreased lumbar spine)
Keratitis (Keratitis)
Kidney Anastomotic Leakage (Kidney
anastomotic leak)
Pyelonephritis (Kidney infection)
Kyphosis (Kyphosis)
Lactation Disorder (Lactation disorder)
Large Intestinal Anastomotic Leakage
(Large intestinal anastomotic leak)
Laryngeal Edema (Laryngeal edema)
Laryngeal Fistula (Laryngeal fistula)
Laryngeal Hemorrhage (Laryngeal
hemorrhage)
Laryngitis (Laryngeal inflammation)
Laryngeal Mucositis (Laryngeal
mucositis)
Laryngeal Obstruction (Laryngeal
obstruction)
Laryngeal Stenosis (Laryngeal stenosis)
Laryngitis (Laryngitis)
Laryngopharyngeal Dysesthesia
(Laryngopharyngeal dysesthesia)
Laryngospasm (Laryngospasm)
Left Ventricular Systolic Dysfunction (Left
ventricular systolic dysfunction)
Lethargy (Lethargy)
Chemotherapy-related Leukemia
(Leukemia secondary to oncology
chemotherapy)
Leukocytosis (Leukocytosis)
Leukoencephalopathy
(Leukoencephalopathy)
Decreased Libido (Libido decreased)
Increased Libido (Libido increased)
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Lip Infection (Lip infection)
Lip Pain (Lip pain)
Lipase Increased (Lipase increased)
Lipohypertrophy (Lipohypertrophy)
Localized Edema (Localized edema)
Lordosis (Lordosis)
Lower Gastrointestinal Hemorrhage
(Lower gastrointestinal hemorrhage)
Infectious Lung Disorder (Lung infection)
Lymphadenitis (Lymph gland infection)
Lymph Leakage (Lymph leakage)
Lymph Node Pain (Lymph node pain)
Lymphedema (Lymphedema)
Lymphocele (Lymphocele)
Lymphopenia (Lymphocyte count
decreased)
Lymphocytosis (Lymphocyte count
increased)
Malabsorption Syndrome
(Malabsorption)
Malaise (Malaise)
Mania (Mania)
Mediastinal Hemorrhage (Mediastinal
hemorrhage)
Mediastinitis (Mediastinal infection)
Memory Impairment (Memory
impairment)
Meningismus (Meningismus)
Meningitis (Meningitis)
Menopause (Menopause)
Menorrhagia (Menorrhagia)
Metabolism And Nutrition Disorder Class
Other Specify (Metabolism and nutrition
disorders - Other, specify)
Otitis Media (Middle ear inflammation)
Mitral Valve Disorder (Mitral valve
disease)
Av Block Second Degree Mobitz Type Ii
(Mobitz (type) II atrioventricular block)
Av Block Second Degree Mobitz Type I
(Mobitz type I)
Involuntary Movements (Movements
involuntary)
Mucosal Infection (Mucosal infection)
Stomatitis (Mucositis oral)
Multiple Organ Failure (Multi-organ
failure)
Muscle Weakness Left-sided (Muscle
weakness left-sided)
Muscle Weakness Lower Limb (Muscle
weakness lower limb)
Muscle Weakness Right-sided (Muscle
weakness right-sided)
Muscle Weakness Trunk (Muscle
weakness trunk)
Muscle Weakness Upper Limb (Muscle
weakness upper limb)
Connective And Soft Tissue Disorder
Other Specify (Musculoskeletal and
connective tissue disorder -  Other,
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specify)
Musculoskeletal Deformity
(Musculoskeletal deformity)
Myalgia (Myalgia)
Myelitis (Myelitis)
Mds (Myelodysplastic syndrome)
Myocardial Infarction (Myocardial
infarction)
Myocarditis (Myocarditis)
Myositis (Myositis)
Nail Discoloration (Nail discoloration)
Nail Infection (Nail infection)
Nail Loss (Nail loss)
Nail Ridging (Nail ridging)
Nasal Congestion (Nasal congestion)
Nausea (Nausea)
Neck Edema (Neck edema)
Neck Pain (Neck pain)
Neck Soft Tissue Necrotic Lesion (Neck
soft tissue necrosis)
Neoplasm Other Specify (Neoplasms
benign, malignant and unspecified (incl
cysts and polyps) - Other, specify)
Nervous System Disorder Other Specify
(Nervous system disorders - Other,
specify)
Neuralgia (Neuralgia)
Neutrophil Count Decreased (Neutrophil
count decreased)
Night Blindness (Night blindness)
Nipple Deformity (Nipple deformity)
Non-cardiac Chest Pain (Non-cardiac
chest pain)
Nystagmus (Nystagmus)
Obesity (Obesity)
Gastric Obstruction (Obstruction gastric)
Oculomotor Nerve Disorder (Oculomotor
nerve disorder)
Olfactory Nerve Disorder (Olfactory
nerve disorder)
Oligospermia (Oligospermia)
Optic Nerve Disorder (Optic nerve
disorder)
Oral Cavity Fistula (Oral cavity fistula)
Burning Mouth Syndrome (Oral
dysesthesia)
Oral Hemorrhage (Oral hemorrhage)
Oral Pain (Oral pain)
Osteonecrosis Of Jaw (Osteonecrosis of
jaw)
Osteoporosis (Osteoporosis)
External Ear Infection (Otitis externa)
Otitis Media (Otitis media)
Ovarian Hemorrhage (Ovarian
hemorrhage)
Ovarian Infection (Ovarian infection)
Ovarian Rupture (Ovarian rupture)
Ovulatory Pain (Ovulation pain)
Pain (Pain)
Pain In Extremity (Pain in extremity)
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Skin Pain (Pain of skin)
Palmar-plantar Erythodysthesia (Palmar-
plantar erythrodysesthesia syndrome)
Palpitation (Palpitations)
Pancreatic Infection (Pancreas infection)
Pancreatic Anastomotic Leakage
(Pancreatic anastomotic leak)
Pancreatic Duct Stenosis (Pancreatic
duct stenosis)
Pancreatic Enzymes Decreased
(Pancreatic enzymes decreased)
Pancreatic Fistula (Pancreatic fistula)
Pancreatic Hemorrhage (Pancreatic
hemorrhage)
Pancreatic Necrotic Lesion (Pancreatic
necrosis)
Pancreatitis (Pancreatitis)
Papilledema (Papilledema)
Papulopustular Rash (Papulopustular
rash)
Paresthesia (Paresthesia)
Paronychia (Paronychia)
Paroxysmal Atrial Tachycardia
(Paroxysmal atrial tachycardia)
Pelvic Floor Muscle Weakness (Pelvic
floor muscle weakness)
Pelvic Inflammatory Disease (Pelvic
infection)
Pelvic Pain (Pelvic pain)
Pelvic Soft Tissue Necrotic Lesion
(Pelvic soft tissue necrosis)
Penile Infection (Penile infection)
Penile Pain (Penile pain)
Bile Duct Perforation (Perforation bile
duct)
Pericardial Effusion (Pericardial effusion)
Cardiac Tamponade (Pericardial
tamponade)
Pericarditis (Pericarditis)
Perineal Pain (Perineal pain)
Periodontal Disorder (Periodontal
disease)
Periorbital Edema (Periorbital edema)
Periorbital Infection (Periorbital infection)
Peripheral Ischemia (Peripheral
ischemia)
Peripheral Motor Neuropathy (Peripheral
motor neuropathy)
Peripheral Nervous System Infectious
Disorder (Peripheral nerve infection)
Peripheral Sensory Neuropathy
(Peripheral sensory neuropathy)
Peritoneal Infection (Peritoneal infection)
Peritoneal Necrotic Lesion (Peritoneal
necrosis)
Personality Change (Personality change)
Phantom Pain (Phantom pain)
Pharyngeal Anastomotic Leakage
(Pharyngeal anastomotic leak)
Pharyngeal Fistula (Pharyngeal fistula)
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Pharyngeal Hemorrhage (Pharyngeal
hemorrhage)
Pharyngeal Mucositis (Pharyngeal
mucositis)
Pharyngeal Necrotic Lesion (Pharyngeal
necrosis)
Pharyngeal Stenosis (Pharyngeal
stenosis)
Pharyngitis (Pharyngitis)
Pharyngolaryngeal Pain
(Pharyngolaryngeal pain)
Phlebitis (Phlebitis)
Infective Phlebitis (Phlebitis infective)
Photophobia (Photophobia)
Photosensitivity (Photosensitivity)
Thrombocytopenia (Platelet count
decreased)
Pleural Effusion (Pleural effusion)
Hemothorax (Pleural hemorrhage)
Pleural Infection (Pleural infection)
Pleuritic Pain (Pleuritic pain)
Pneumonia (Pneumonitis)
Pneumothorax (Pneumothorax)
Portal Hypertension (Portal
Hypertension)
Portal Vein Thrombosis (Portal vein
thrombosis)
Post-nasal Drip (Postnasal drip)
Postoperative Bleeding (Postoperative
hemorrhage)
Thoracic Procedure Postoperative
Complication (Postoperative thoracic
procedure complication)
Precocious Puberty (Precocious
puberty)
Pregnancy, Puerperium And Perinatal
Condition Class Other Specify
(Pregnancy, puerperium and perinatal
conditions - Other, specify)
Premature Labor (Premature delivery)
Premature Menopause (Premature
menopause)
Presyncope (Presyncope)
Proctitis (Proctitis)
Productive Cough (Productive cough)
Intestinal Stoma Prolapse (Prolapse of
intestinal stoma)
Urostomy Prolapse (Prolapse of
urostomy)
Prostatic Infection (Prostate infection)
Prostatic Hemorrhage (Prostatic
hemorrhage)
Prostatic Obstruction (Prostatic
obstruction)
Prostatic Pain (Prostatic pain)
Proteinuria (Proteinuria)
Pruritus (Pruritus)
Psychiatric Disorder Other Specify
(Psychiatric disorders - Other, specify)
Psychosis (Psychosis)
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Pulmonary Edema (Pulmonary edema)
Pulmonary Fibrosis (Pulmonary fibrosis)
Pulmonary Fistula (Pulmonary fistula)
Pulmonary Hypertension (Pulmonary
hypertension)
Pulmonary Valve Disorder (Pulmonary
valve disease)
Purpura (Purpura)
Pyramidal Tract Dysfunction (Pyramidal
tract syndrome)
Radiation-recall Dermatitis (Radiation
recall reaction (dermatologic))
Radiculitis (Radiculitis)
Acneiform Dermatitis (Rash acneiform)
Maculopapular Lesion (Rash maculo-
papular)
Papulopustular Rash (Rash pustular)
Rectal Anastomotic Leakage (Rectal
anastomotic leak)
Rectal Fistula (Rectal fistula)
Rectal Hemorrhage (Rectal hemorrhage)
Rectal Mucositis (Rectal mucositis)
Rectal Necrotic Lesion (Rectal necrosis)
Rectal Obstruction (Rectal obstruction)
Rectal Pain (Rectal pain)
Rectal Perforation (Rectal perforation)
Rectal Stenosis (Rectal stenosis)
Rectal Ulcer (Rectal ulcer)
Recurrent Laryngeal Nerve Paralysis
(Recurrent laryngeal nerve palsy)
Urinary Tract Disorder Other Specify
(Renal and urinary disorders - Other,
specify)
Renal Stone (Renal calculi)
Renal Colic (Renal colic)
Renal Hemorrhage (Renal hemorrhage)
Reproductive System And Breast
Disorder Class Other Specify
(Reproductive system and breast
disorders - Other, specify)
Respiratory Failure (Respiratory failure)
Respiratory And Thoracic Disorder Other
Specify (Respiratory, thoracic and
mediastinal disorders - Other, specify)
Restlessness (Restlessness)
Restrictive Cardiomyopathy (Restrictive
cardiomyopathy)
Retinal Detachment (Retinal
detachment)
Retinal Tear (Retinal tear)
Retinal Vascular Disorder (Retinal
vascular disorder)
Retinoic Acid Syndrome (Retinoic acid
syndrome)
Retinopathy (Retinopathy)
Retroperitoneal Hemorrhage
(Retroperitoneal hemorrhage)
Reversible Posterior
Leukoencephalopathy Syndrome
(Reversible posterior
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leukoencephalopathy syndrome)
Infectious Rhinitis (Rhinitis infective)
Right Ventricular Dysfunction (Right
ventricular dysfunction)
Salivary Duct Inflammation (Salivary duct
inflammation)
Salivary Gland Fistula (Salivary gland
fistula)
Salivary Gland Infection (Salivary gland
infection)
Scalp Pain (Scalp pain)
Sclera Disorder (Scleral disorder)
Scoliosis (Scoliosis)
Scrotal Infection (Scrotal infection)
Scrotal Pain (Scrotal pain)
Seizure (Seizure)
Septicemia (Sepsis)
Seroma (Seroma)
Serum Amylase Increased (Serum
amylase increased)
Serum Sickness (Serum sickness)
Sick Sinus Syndrome (Sick sinus
syndrome)
Sinus Bradycardia (Sinus bradycardia)
Paranasal Sinus Disorder (Sinus
disorder)
Sinus Pain (Sinus pain)
Sinus Tachycardia (Sinus tachycardia)
Sinusitis (Sinusitis)
Skin Disorder Other Specify (Skin and
subcutaneous tissue disorders - Other,
specify)
Skin Atrophy (Skin atrophy)
Skin Hyperpigmentation (Skin
hyperpigmentation)
Skin Hypopigmentation (Skin
hypopigmentation)
Skin Induration (Skin induration)
Skin Infection (Skin infection)
Skin Ulcer (Skin ulceration)
Sleep Apnea (Sleep apnea)
Small Intestinal Anastomotic Leakage
(Small intestinal anastomotic leak)
Small Intestinal Mucositis (Small
intestinal mucositis)
Small Intestinal Obstruction (Small
intestinal obstruction)
Small Intestinal Perforation (Small
intestinal perforation)
Small Intestinal Stenosis (Small intestinal
stenosis)
Small Intestinal Infection (Small intestine
infection)
Small Intestinal Ulcer (Small intestine
ulcer)
Sneezing (Sneezing)
Social Circumstances Other Specify
(Social circumstances - Other, specify)
Soft Tissue Infection (Soft tissue
infection)
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Lower Limb Soft Tissue Necrotic Lesion
(Soft tissue necrosis lower limb)
Upper Limb Soft Tissue Necrotic Lesion
(Soft tissue necrosis upper limb)
Somnolence (Somnolence)
Sore Throat (Sore throat)
Spasticity (Spasticity)
Spermatic Cord Anastomotic Leakage
(Spermatic cord anastomotic leak)
Spermatic Cord Hemorrhage (Spermatic
cord hemorrhage)
Spermatic Cord Obstruction (Spermatic
cord obstruction)
Vertebral Fracture (Spinal fracture)
Splenic Disorder (Spleen disorder)
Splenic Infection (Splenic infection)
Gastrointestinal Stoma Stenosis
(Stenosis of gastrointestinal stoma)
Stevens-johnson Syndrome (Stevens-
Johnson syndrome)
Stoma Site Infection (Stoma site
infection)
Stomach Pain (Stomach pain)
Stomal Ulcer (Stomal ulcer)
Stridor (Stridor)
Cerebrovascular Accident (Stroke)
Sudden Cardiac Death (Sudden death
NOS)
Suicidal Ideation (Suicidal ideation)
Suicide Attempt (Suicide attempt)
Superficial Soft Tissue Fibrosis
(Superficial soft tissue fibrosis)
Superficial Thrombophlebitis (Superficial
thrombophlebitis)
Superior Vena Cava Syndrome (Superior
vena cava syndrome)
Supraventricular Tachycardia
(Supraventricular tachycardia)
Intervention Or Procedure Other Specify
(Surgical and medical procedures -
Other, specify)
Syncope (Syncope)
Telangiectasia (Telangiectasia)
Testicular Disorder (Testicular disorder)
Testicular Hemorrhage (Testicular
hemorrhage)
Testicular Pain (Testicular pain)
Thromboembolism (Thromboembolic
event)
Thrombotic Thrombocytopenic Purpura
(Thrombotic thrombocytopenic purpura)
Tinnitus (Tinnitus)
Dental Developmental Disorder (Tooth
development disorder)
Tooth Discoloration (Tooth discoloration)
Tooth Infection (Tooth infection)
Toothache (Toothache)
Toxic Epidermal Necrolysis (Toxic
epidermal necrolysis)
Tracheal Fistula (Tracheal fistula)
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Tracheal Hemorrhage (Tracheal
hemorrhage)
Tracheal Mucositis (Tracheal mucositis)
Tracheal Obstruction (Tracheal
obstruction)
Tracheal Stenosis (Tracheal stenosis)
Tracheitis (Tracheitis)
Tracheostomy Site Bleeding
(Tracheostomy site bleeding)
Transient Ischemic Attack (Transient
ischemic attacks)
Therapy-related Malignant Neoplasm
(Treatment related secondary
malignancy)
Tremor (Tremor)
Tricuspid Valve Disorder (Tricuspid valve
disease)
Trigeminal Nerve Disorder (Trigeminal
nerve disorder)
Trismus (Trismus)
Tumor Lysis Syndrome (Tumor lysis
syndrome)
Tumor Pain (Tumor pain)
Typhlitis (Typhlitis)
Unequal Limb Length (Unequal limb
length)
Unintended Pregnancy (Unintended
pregnancy)
Upper Gastrointestinal Hemorrhage
(Upper gastrointestinal hemorrhage)
Upper Respiratory Tract Infection (Upper
respiratory infection)
Ureteric Anastomotic Leakage (Ureteric
anastomotic leak)
Urethral Anastomotic Leakage (Urethral
anastomotic leak)
Urethral Infection (Urethral infection)
Urinary Tract Fistula (Urinary fistula)
Urinary Frequency (Urinary frequency)
Urinary Incontinence (Urinary
incontinence)
Urinary Retention (Urinary retention)
Urinary Tract Infection (Urinary tract
infection)
Urinary Tract Obstruction (Urinary tract
obstruction)
Urinary Tract Pain (Urinary tract pain)
Urinary Urgency (Urinary urgency)
Urine Discoloration (Urine discoloration)
Urine Output Decreased (Urine output
decreased)
Urostomy Leakage (Urostomy leak)
Urostomy Obstruction (Urostomy
obstruction)
Urostomy Site Bleeding (Urostomy site
bleeding)
Urostomy Stenosis (Urostomy stenosis)
Urticaria (Urticaria)
Uterine Anastomotic Leakage (Uterine
anastomotic leak)
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Uterine Fistula (Uterine fistula)
Uterine Hemorrhage (Uterine
hemorrhage)
Endometritis (Uterine infection)
Uterine Obstruction (Uterine obstruction)
Uterine Pain (Uterine pain)
Uterine Perforation (Uterine perforation)
Uveitis (Uveitis)
Vaginal Anastomotic Leakage (Vaginal
anastomotic leak)
Vaginal Discharge (Vaginal discharge)
Vaginal Dryness (Vaginal dryness)
Vaginal Fistula (Vaginal fistula)
Vaginal Hemorrhage (Vaginal
hemorrhage)
Vaginitis (Vaginal infection)
Vaginitis (Vaginal inflammation)
Vaginal Obstruction (Vaginal obstruction)
Vaginal Pain (Vaginal pain)
Vaginal Perforation (Vaginal perforation)
Vaginal Stricture (Vaginal stricture)
Vaginismus (Vaginismus)
Vagus Nerve Disorder (Vagus nerve
disorder)
Vas Deferens Anastomotic Leakage (Vas
deferens anastomotic leak)
Vascular Access Complication (Vascular
access complication)
Vascular Disorder Other Specify
(Vascular disorders - Other, specify)
Vasculitis (Vasculitis)
Vasovagal Reaction (Vasovagal reaction)
Venous Injury (Venous injury)
Ventricular Arrhythmia (Ventricular
arrhythmia)
Ventricular Fibrillation (Ventricular
fibrillation)
Ventricular Tachycardia (Ventricular
tachycardia)
Vertigo (Vertigo)
Internal Ear Disorder (Vestibular
disorder)
Virilization (Virilization)
Visceral Artery Ischemia (Visceral
arterial ischemia)
Abnormal Vital Capacity (Vital capacity
abnormal)
Vitreous Hemorrhage (Vitreous
hemorrhage)
Voice Alternation (Voice alteration)
Vomiting (Vomiting)
Vulval Infection (Vulval infection)
Watering Eyes (Watering eyes)
Weight Gain (Weight gain)
Weight Loss (Weight loss)
Wheezing (Wheezing)
Leukopenia (White blood cell decreased)
Wolff-parkinson-white Syndrome (Wolff-
Parkinson-White Syndrome)
Wound Complication (Wound
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complication)
Wound Dehiscence (Wound dehiscence)
Wound Infection (Wound infection)
Wrist Fracture (Wrist fracture)
AE Ongoing
No (No)
Not Assessed (Not assessed)
Yes (Yes)
Grade
Seriousness Attributed to Adverse Event
Congenital Anomaly (Congenital
anomaly)
Death (Death)
Disability (Disability/incapacity)
Hospitalized (Hospitalization, initial or
prolonged)
Life Threatening (Life threatening)
Not Serious (Not serious)
Intervention Required (Required
intervention to prevent permanent
impairment/damage)
Attribution
Definite (Definite)
Possible (Possible)
Probable (Probable)
Unlikely (Unlikely)
Unrelated (Unrelated)
Cardiovascular Morbidity - Question
Has there been a hospitalization for a
cardiovascular event since the last report
Yes
No
Cardiovascular Mobidity
Problem, cardiovascular
Angina Requiring Coronary Artery
Bypass Graft (Angina requiring coronary
artery bypass graft)
Angina Requiring Transluminal Coronary
Angioplasty (Angina requiring
transluminal coronary angioplasty)
Myocardial Infarction (Myocardial
Infarction)
New Or Worsening Angina (New or
worsening angina)
Other (Other)
Transient Ischemic Attack
Cerebrovascular Accident (Stroke /
transient inschemic attack TIA)
Thromboembolism (Thromboembolic
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Event)
Specify
Date of hospital admission
Cancer Treatment Since Last Report ¿
Question
Has patient received any new treatment for
breast cancer since the last report
No (No)
Unknown (Unknown)
Yes (Yes)
Cancer Treatment Since Last Report
Non-Protocol Therapy Type
Other Specify (Other)
Radiation Therapy (Radiation therapy)
Surgery (Surgery)
Systemic Therapy (Systemic therapy)
Specify
Name of Other Non-Protocol Therapy
Non protocol surgery
Non-protocol Therapy Start Date
Major Medical Problems
Concomitant Diseases and/or Relevant Medical
Conditions
Quality Of Life Questionnaire
Was this subject one of the sub-set of subjects
who completed questionnaires at baseline
Yes
No
Questionnaire
Block Alive Screener (Block Alive
screener)
Nhs Ii - Physical Activity (NHS II -
Physical Activity)
Quality Of Life (Quality of Life)
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Done
Yes
No
Date patient filled out questionnaire
Date patient filled out questionnaire
Reason questionnaire was not completed
Other Reason (Other reason)
Patient Could Not Be Contacted (Patient
could not be contacted)
Patient Did Not Keep Appointment
(Patient did not keep appointment)
Patient Kept Appointment For
Examination, But Could Not Complete
Questionnaire Due To Illness (Patient
kept appointment for examination, but
could not complete questionnaire due to
illness)
Patient Kept Appointment For
Examination, But Refused To Complete
Questionnaire For Reasons Other Than
Illness (Patient kept appointment for
examination, but refused to complete
questionnaire for reasons other)
Test Omitted Due To
Institution/investigator Error
(Questionnaire not administered due to
institutional error)
Specify
Comments
Comments
Contact Information
CRA Name
Phone number
Fax Number
Institution Name
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RTOG 1115 F0: Phase III RT + Standard ADT vs RT +
Enhanced ADT + TAK-700  Interim Evaluation/Treatment
Summary
Hormone Therapy, Radiation Therapy, and Steroid 17alpha-
monooxygenase TAK-700 in Treating Patients With High-
Risk Prostate Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=AFAD1170-
E5FD-A42E-E040-BB89AD435386
All rights reserved. Please visit https://medical-data-
models.org/forms/8270
RTOG 1115 F0: Phase III RT +
Standard ADT vs RT + Enhanced
ADT + TAK-700  Interim
Evaluation/Treatment Summary
Unnamed2
RTOG Study No.
Case #
Institution Name
Institution No.
Patient Initials
RTOG Patient ID
Header
Amended Data
Yes
No
Unnamed 3
Patient's Vital Status
Alive (Alive)
Dead (Dead)
Date of Last Contact or Death
Primary Cause of Death
Due To Other Cause (Due to other
cause)
Due To Protocol Treatment (Due to
protocol treatment)
Due To This Disease (Due to this
disease)
Not Applicable (Not applicable)
Unknown (Unknown)
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Due to other cause, specify
Has the patient had a documented clinical
assessment for this cancer (SINCE
SUBMISSION OF THE PREVIOUS FOLLOW-UP
FORM)
No (No)
Unknown (Unknown)
Yes (Yes)
Date
Performance Status
Fully Active, Able To Carry On All Pre-
disease Performance Without
Restriction. (0)
Restricted In Physically Strenuous
Activity But Ambulatory And Able To
Carry Out Work Of A Light Or Sedentary
Nature, E.g., Light Housework, Office
Work. (1)
Ambulatory And Capable Of All Selfcare
But Unable To Carry Out Any Work
Activities. Up And About More Than 50%
Of Waking Hours. (2)
Capable Of Only Limited Selfcare,
Confined To Bed Or Chair More Than
50% Of Waking Hours. (3)
Completely Disabled. Cannot Carry On
Any Selfcare. Totally Confined To Bed Or
Chair. (4)
Dead (5)
Mark an 'X' if unknown
Unnamed Module 6
Has the patient had a prostate biopsy (SINCE
SUBMISSION OF THE LAST FOLLOW-UP
FORM)
No (No)
Unknown (Unknown)
Yes, Negative (Yes, negative)
Yes, Positive (Yes, positive)
Yes, Results Unknown (Yes, results
unknown)
Biopsy Date
Is the tumor palpable
Equivocal (Equivocal)
No (No)
Not Evaluated (Not evaluated)
Unknown (Unknown)
Yes (Yes)
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Unnamed Module 5
Has the patient been diagnosed with biochemical
recurrence since submission of the last follow-up
form
No (NO)
Unknown (Unknown)
Yes (YES)
Has the patient been diagnosed with a first local
recurrence (SINCE SUBMISSION OF LAST
FOLLOW-UP FORM See Protocol Section 11)
No (NO)
Unknown (Unknown)
Yes (YES)
Date
Other Specify
Other Specify
Has the patient been diagnosed with first distant
progression (SINCE SUBMISSION OF THE
LAST FOLLOW-UP FORM)
No (No)
Unknown (Unknown)
Yes (Yes)
Date
Sites of Progression (First distant)
Method of Evaluation (DISTANT
PROGRESSION)
Mri (MRI (NMR))
Not Applicable (Not applicable)
Other (Other)
Pathologic (Pathologic)
Physical Exam (Physical exam)
Radiographic (Radiographic)
Method of Evaluation (DISTANT
PROGRESSION)
Mri (MRI (NMR))
Not Applicable (Not applicable)
Other (Other)
Pathologic (Pathologic)
Physical Exam (Physical exam)
Radiographic (Radiographic)
Unnamed Module 4a
PSA Date
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PSA Value
Method of Assay
Abbott Labs (Abbott)
Bayer (Bayer)
Dpc (DPC)
Hybritech (Hybritech)
Other (Other)
Unknown (Unknown)
Units
Nanograms Per Deciliter (ng/dL)
Nanograms Per Milliliter (ng/mL)
Not Otherwise Specified (NOS)
Treatment Schedule (lhrh Agonist)
Reason Treatment Ended (LHRH Agonist)
Adverse Event/side Effects/complications
(Adverse Event/Side
Effects/Complications)
Alternative Therapy (Alternative therapy)
Death On Study (Death on study)
Disease Progression, Relapse During
Active Treatment (Disease progression,
relapse during active treatment)
Other (Other)
Patient Off-treatment For Other
Complicating Disease (Patient off-
treatment for other complicating disease)
Patient Withdrawal Or Refusal After
Beginning Protocol Therapy (Patient
withdrawal/refusal after beginning
protocol therapy)
Patient Withdrawal Or Refusal Before
Beginning Protocol Therapy (Patient
withdrawal/refusal prior to beginning
protocol therapy)
Treatment Completed Per Protocol
Criteria (Treatment completed per
protocol criteria)
Alternative Therapy, specify
Patient off-treatment for other complicating
disease, specify
Other specify
Total Dose (TO DATE FROM START OF
TREATMENT)
Non-protocol Therapy
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Is the patient receiving any non-protocol cancer
therapy not previously reported (PROSTATE If
yes, enter therapy type and date for each therapy
delivered during the follow-up period.)
No (No)
Unknown (Unknown)
Yes (Yes)
Non-Protocol Therapy Type
Chemotherapy (Chemotherapy)
Hormones (Hormones)
None (None)
Other Specify (Other, specify)
Radiation To Other Sites, Specify
(Radiation to other sites, specify)
Radiation To Pelvis (Radiation to pelvis)
Surgery (Surgery)
Date of First Non-Protocol Therapy
Specify
Unnamed Module 7
Has a new primary cancer or MDS been
diagnosed that has not been previously reported
No (No)
Unknown (Unknown)
Yes (Yes)
Second Primary Tumor Site
Aml/mds (AML/MDS)
Bcc (BCC)
Bladder Is The Site Of Second Primary
Or Recurrent Tumor (bladder)
Brain Is The Site Of Second Primary Or
Recurrent Tumor (brain)
Colorectal (Colorectal)
Esophageal (Esophageal)
Gastric (Gastric)
Liver Is The Site Of Second Primary Or
Recurrent Tumor (liver)
Lung Is The Site Of Second Primary Or
Recurrent Tumor (lung)
Melanoma (Melanoma)
Nhl (NHL)
Other Hematologic (Other hematologic)
Other Solid (Other solid)
Pancreatic (Pancreatic)
Renal (Renal)
Squamous-skin (Squamous-skin)
Unknown Primary (Unknown primary)
Second Primary Cancer Date
Other specify
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Baseline Lab Values (hematologic)
Chemistry Panel
No (no)
Unknown (unknown)
Yes (yes)
Date
Sodium (mEq/L)
Sodium LLN
Sodium ULN
Potassium (mEq/L)
Potassium LLN
Potassium ULN
Chloride (mmol/L)
Chloride LLN
Chloride ULN
Bicarbonate (mEq/L) (mmol/L)
Bicarbonate, LLN
Bicarbonate ULN
BUN (mg/dL)
BUN LNL
BUN ULN
Creatinine (mg/dL)
Creatinine LLN
Creatinine ULN
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Fasting glucose (mg/dL)
Fasting glucose, LLN
Fasting glucose, ULN
Magnesium (mg/dL)
Magnesium, LLN
Magnesium, ULN
Phosphorus
Phosphorus LLN
Phosphorus ULN
Baseline Lab Values (hematologic)
Was another chemistry panel obtained
No (no)
Unknown (unknown)
Yes (yes)
Date
Sodium (mEq/L)
Sodium LLN
Sodium ULN
Potassium (mEq/L)
Potassium LLN
Potassium ULN
Chloride (mmol/L)
Chloride LLN
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Chloride ULN
Bicarbonate (mEq/L) (mmol/L)
Bicarbonate, LLN
Bicarbonate ULN
BUN (mg/dL)
BUN LNL
BUN ULN
Creatinine (mg/dL)
Creatinine LLN
Creatinine ULN
Fasting glucose (mg/dL)
Fasting glucose, LLN
Fasting glucose, ULN
Magnesium (mg/dL)
Magnesium, LLN
Magnesium, ULN
Phosphorus
Phosphorus LLN
Phosphorus ULN
Baseline Lab Values (hematologic)
Was another chemistry panel obtained
No (no)
Unknown (unknown)
Yes (yes)
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Date
Sodium (mEq/L)
Sodium LLN
Sodium ULN
Potassium (mEq/L)
Potassium LLN
Potassium ULN
Chloride (mmol/L)
Chloride LLN
Chloride ULN
Bicarbonate (mEq/L) (mmol/L)
Bicarbonate, LLN
Bicarbonate ULN
BUN (mg/dL)
BUN LNL
BUN ULN
Creatinine (mg/dL)
Creatinine LLN
Creatinine ULN
Fasting glucose (mg/dL)
Fasting glucose, LLN
Fasting glucose, ULN
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Magnesium (mg/dL)
Magnesium, LLN
Magnesium, ULN
Phosphorus
Phosphorus LLN
Phosphorus ULN
Baseline Lab Values (hematologic)
Liver Panel
No (no)
Unknown (unknown)
Yes (yes)
Date
Albumin (g/dL)
Albumin LLN
Albumin ULN
AST (IU/L)
AST ULN
AST LLN
ALT (U/L)
ALT LLN
ALT ULN
Alkaline Phosphatase (IU/L)
Alkaline Phosphatase LLN
Alkaline Phosphatase ULN
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Total Bilirubin (mg/dL)
Total bilirubin LLN
Total bilirubin ULN
Direct Bilirubin (mg/dL)
Direct Bilirubin LLN
Direct Bilirubin ULN
Baseline Lab Values (hematologic)
Was another liver panel obtained
No (no)
Unknown (unknown)
Yes (yes)
Date
Albumin (g/dL)
Albumin LLN
Albumin ULN
AST (IU/L)
AST ULN
AST LLN
ALT (U/L)
ALT LLN
ALT ULN
Alkaline Phosphatase (IU/L)
Alkaline Phosphatase LLN
Alkaline Phosphatase ULN
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Total Bilirubin (mg/dL)
Total bilirubin LLN
Total bilirubin ULN
Direct Bilirubin (mg/dL)
Direct Bilirubin LLN
Direct Bilirubin ULN
Baseline Lab Values (hematologic)
Was another liver panel obtained
No (no)
Unknown (unknown)
Yes (yes)
Date
Albumin (g/dL)
Albumin LLN
Albumin ULN
AST (IU/L)
AST ULN
AST LLN
ALT (U/L)
ALT LLN
ALT ULN
Alkaline Phosphatase (IU/L)
Alkaline Phosphatase LLN
Alkaline Phosphatase ULN
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Total Bilirubin (mg/dL)
Total bilirubin LLN
Total bilirubin ULN
Direct Bilirubin (mg/dL)
Direct Bilirubin LLN
Direct Bilirubin ULN
Fasting Lipid Panel
Fasting lipids
No (No)
Unknown (Unknown)
Yes (Yes)
Date
Cholesterol (mg/dL)
Cholesterol LLN
Cholesterol ULN
HDL (mg/dL)
HDL LLN
HDL ULN
LDL (mg/dL)
LDL LLN
LDL ULN
Triglycerides (mg/dL)
Triglycerides LLN
Triglycerides ULN
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Hemoglobin A1 C (%)
Hemoglobin A1C (%)
No (No)
Unknown (Unknown)
Yes (Yes)
Hemogloblin A1C
Hemoglobin A1C LLN
Hemoglobin A1C ULN
Serum Testosterone
Serum testosterone
No (No)
Unknown (Unknown)
Yes (Yes)
Date
Testosterone
Testosterone LLN
Testosterone ULN
Units
Nanograms Per Deciliter (ng/dL)
Nanograms Per Milliliter (ng/mL)
Not Otherwise Specified (NOS)
Patient Evaluations
Weight (kg)
Date
Survivorship
Diabetes Mellitus
No (No)
Unknown (Unknown)
Yes (Yes)
Coronary Artery Disease
No (No)
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Unknown (Unknown)
Yes (Yes)
Myocardial infarction
No (No)
Unknown (Unknown)
Yes (Yes)
Stroke
No (No)
Unknown (Unknown)
Yes (Yes)
Pulmonary embolism
No (No)
Unknown (Unknown)
Yes (Yes)
Deep vein thrombosis
No (No)
Unknown (Unknown)
Yes (Yes)
Osteoporotic fracture
No (No)
Unknown (Unknown)
Yes (Yes)
Protocol Specific Adverse Event
Evaluation
Any Treatment Related Adverse Events
No (No)
Unknown (Unknown)
Yes (Yes)
MedDRA Disease Code
CTC Adverse Event Term
Abdominal Distension (Abdominal
distension)
Abdominal Infection (Abdominal
infection)
Abdominal Pain (Abdominal pain)
Abdominal Soft Tissue Necrosis
(Abdominal soft tissue necrosis)
Abducens Nerve Disorder (Abducens
nerve disorder)
Accessory Nerve Disorder (Accessory
nerve disorder)
Acidosis (Acidosis)
Acoustic Nerve Disorder Nos (Acoustic
nerve disorder NOS)
Activated Partial Thromboplastin Time
Prolonged (Activated partial
thromboplastin time prolonged)
Acute Coronary Syndrome (Acute
coronary syndrome)
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Acute Kidney Injury (Acute kidney injury)
Adrenal Insufficiency (Adrenal
insufficiency)
Adult Respiratory Distress Syndrome
(Adult respiratory distress syndrome)
Agitation (Agitation)
Akathisia (Akathisia)
Alanine Aminotransferase Increased
(Alanine aminotransferase increased)
Alcohol Intolerance (Alcohol intolerance)
Alkaline Phosphatase Increased
(Alkaline phosphatase increased)
Alkalosis (Alkalosis)
Allergic Reaction (Allergic reaction)
Allergic Rhinitis (Allergic rhinitis)
Alopecia (Alopecia)
Amnesia (Amnesia)
Anal Fistula (Anal fistula)
Anal Hemorrhage (Anal hemorrhage)
Anal Mucositis (Anal mucositis)
Anal Necrosis (Anal necrosis)
Anal Pain (Anal pain)
Anal Stenosis (Anal stenosis)
Anal Ulcer (Anal ulcer)
Anaphylaxis (Anaphylaxis)
Anemia (Anemia)
Ankle Fracture (Ankle fracture)
Anorectal Infection (Anorectal infection)
Anorexia (Anorexia)
Anorgasmia (Anorgasmia)
Anxiety (Anxiety)
Aortic Injury (Aortic injury)
Aortic Valve Disease (Aortic valve
disease)
Aphonia (Aphonia)
Apnea (Apnea)
Appendicitis (Appendicitis)
Appendicitis Perforated (Appendicitis
perforated)
Arachnoiditis (Arachnoiditis)
Arterial Injury (Arterial injury)
Arteritis Infective (Arteritis infective)
Arthralgia (Arthralgia)
Arthritis (Arthritis)
Ascites (Ascites)
Aspartate Aminotransferase Increased
(Aspartate aminotransferase increased)
Aspiration (Aspiration)
Asystole (Asystole)
Ataxia (Ataxia)
Atelectasis (Atelectasis)
Atrial Fibrillation (Atrial fibrillation)
Atrial Flutter (Atrial flutter)
Atrioventricular Block Complete
(Atrioventricular block complete)
Atrioventricular Block First Degree
(Atrioventricular block first degree)
Autoimmune Disorder (Autoimmune
disorder)
Avascular Necrosis (Avascular necrosis)
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Azoospermia (Azoospermia)
Back Pain (Back pain)
Bile Duct Stenosis (Bile duct stenosis)
Biliary Anastomotic Leak (Biliary
anastomotic leak)
Biliary Fistula (Biliary fistula)
Biliary Tract Infection (Biliary tract
infection)
Bladder Anastomotic Leak (Bladder
anastomotic leak)
Bladder Infection (Bladder infection)
Bladder Perforation (Bladder perforation)
Bladder Spasm (Bladder spasm)
Bloating (Bloating)
Blood And Lymphatic System Disorders -
Other, Specify (Blood and lymphatic
system disorders - Other, Specify)
Blood Antidiuretic Hormone Abnormal
(Blood antidiuretic hormone abnormal)
Blood Bilirubin Increased (Blood bilirubin
increased)
Blood Corticotrophin Decreased (Blood
corticotrophin decreased)
Blood Gonadotrophin Abnormal (Blood
gonadotrophin abnormal)
Blood Prolactin Abnormal (Blood
prolactin abnormal)
Blurred Vision (Blurred vision)
Body Odor (Body odor)
Bone Infection (Bone infection)
Bone Marrow Hypocellular (Bone
marrow hypocellular)
Bone Pain (Bone pain)
Brachial Plexopathy (Brachial
plexopathy)
Breast Atrophy (Breast atrophy)
Breast Infection (Breast infection)
Breast Pain (Breast pain)
Bronchial Fistula (Bronchial fistula)
Bronchial Infection (Bronchial infection)
Bronchial Obstruction (Bronchial
obstruction)
Bronchial Stricture (Bronchial stricture)
Bronchopleural Fistula (Bronchopleural
fistula)
Bronchopulmonary Hemorrhage
(Bronchopulmonary hemorrhage)
Bronchospasm (Bronchospasm)
Bruising (Bruising)
Bullous Dermatitis (Bullous dermatitis)
Burn (Burn)
Buttock Pain (Buttock pain)
Capillary Leak Syndrome (Capillary leak
syndrome)
Carbon Monoxide Diffusing Capacity
Decreased (Carbon monoxide diffusing
capacity decreased)
Cardiac Arrest (Cardiac arrest)
Cardiac Disorders - Other, Specify
(Cardiac disorders - Other, Specify)
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Cardiac Troponin I Increased (Cardiac
troponin I increased)
Cardiac Troponin T Increased (Cardiac
troponin T increased)
Cataract (Cataract)
Catheter Related Infection (Catheter
related infection)
Cd4 Lymphocytes Decreased (CD4
lymphocytes decreased)
Cecal Hemorrhage (Cecal hemorrhage)
Cecal Infection (Cecal infection)
Central Nervous System Necrosis
(Central nervous system necrosis)
Cerebrospinal Fluid Leakage
(Cerebrospinal fluid leakage)
Cervicitis Infection (Cervicitis infection)
Cheilitis (Cheilitis)
Chest Pain - Cardiac (Chest pain -
cardiac)
Chest Wall Pain (Chest wall pain)
Chills (Chills)
Cholecystitis (Cholecystitis)
Cholesterol High (Cholesterol high)
Chronic Kidney Disease (Chronic kidney
disease)
Chylothorax (Chylothorax)
Cognitive Disturbance (Cognitive
disturbance)
Colitis (Colitis)
Colonic Fistula (Colonic fistula)
Colonic Hemorrhage (Colonic
hemorrhage)
Colonic Obstruction (Colonic obstruction)
Colonic Perforation (Colonic perforation)
Colonic Stenosis (Colonic stenosis)
Colonic Ulcer (Colonic ulcer)
Concentration Impairment
(Concentration impairment)
Conduction Disorder (Conduction
disorder)
Confusion (Confusion)
Congenital, Familial And Genetic
Disorders - Other, Specify (Congenital,
familial and genetic disorders - Other,
Specify)
Conjunctivitis (Conjunctivitis)
Conjunctivitis Infective (Conjunctivitis
infective)
Constipation (Constipation)
Constrictive Pericarditis (Constrictive
pericarditis)
Corneal Infection (Corneal infection)
Corneal Ulcer (Corneal ulcer)
Cough (Cough)
Cpk Increased (CPK increased)
Cranial Nerve Infection (Cranial nerve
infection)
Creatinine Increased (Creatinine
increased)
Cushingoid (Cushingoid)
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Cystitis Noninfective (Cystitis
noninfective)
Cytokine Release Syndrome (Cytokine
release syndrome)
Death Neonatal (Death neonatal)
Death Nos (Death NOS)
Dehydration (Dehydration)
Delayed Orgasm (Delayed orgasm)
Delayed Puberty (Delayed puberty)
Delirium (Delirium)
Delusions (Delusions)
Dental Caries (Dental caries)
Depressed Level Of Consciousness
(Depressed level of consciousness)
Depression (Depression)
Dermatitis Radiation (Dermatitis
radiation)
Device Related Infection (Device related
infection)
Diarrhea (Diarrhea)
Disseminated Intravascular Coagulation
(Disseminated intravascular coagulation)
Dizziness (Dizziness)
Dry Eye (Dry eye)
Dry Mouth (Dry mouth)
Dry Skin (Dry skin)
Duodenal Fistula (Duodenal fistula)
Duodenal Hemorrhage (Duodenal
hemorrhage)
Duodenal Infection (Duodenal infection)
Duodenal Obstruction (Duodenal
obstruction)
Duodenal Perforation (Duodenal
perforation)
Duodenal Stenosis (Duodenal stenosis)
Duodenal Ulcer (Duodenal ulcer)
Dysarthria (Dysarthria)
Dysesthesia (Dysesthesia)
Dysgeusia (Dysgeusia)
Dysmenorrhea (Dysmenorrhea)
Dyspareunia (Dyspareunia)
Dyspepsia (Dyspepsia)
Dysphagia (Dysphagia)
Dysphasia (Dysphasia)
Dyspnea (Dyspnea)
Ear And Labyrinth Disorders - Other,
Specify (Ear and labyrinth disorders -
Other, Specify)
Ear Pain (Ear pain)
Edema Cerebral (Edema cerebral)
Edema Face (Edema face)
Edema Limbs (Edema limbs)
Edema Trunk (Edema trunk)
Ejaculation Disorder (Ejaculation
disorder)
Ejection Fraction Decreased (Ejection
fraction decreased)
Electrocardiogram Qt Corrected Interval
Prolonged (Electrocardiogram QT
corrected interval prolonged)
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Encephalitis Infection (Encephalitis
infection)
Encephalomyelitis Infection
(Encephalomyelitis infection)
Encephalopathy (Encephalopathy)
Endocarditis Infective (Endocarditis
infective)
Endocrine Disorders - Other, Specify
(Endocrine disorders - Other, Specify)
Endophthalmitis (Endophthalmitis)
Enterocolitis (Enterocolitis)
Enterocolitis Infectious (Enterocolitis
infectious)
Enterovesical Fistula (Enterovesical
fistula)
Epistaxis (Epistaxis)
Erectile Dysfunction (Erectile
dysfunction)
Erythema Multiforme (Erythema
multiforme)
Erythroderma (Erythroderma)
Esophageal Anastomotic Leak
(Esophageal anastomotic leak)
Esophageal Fistula (Esophageal fistula)
Esophageal Hemorrhage (Esophageal
hemorrhage)
Esophageal Infection (Esophageal
infection)
Esophageal Necrosis (Esophageal
necrosis)
Esophageal Obstruction (Esophageal
obstruction)
Esophageal Pain (Esophageal pain)
Esophageal Perforation (Esophageal
perforation)
Esophageal Stenosis (Esophageal
stenosis)
Esophageal Ulcer (Esophageal ulcer)
Esophageal Varices Hemorrhage
(Esophageal varices hemorrhage)
Esophagitis (Esophagitis)
Euphoria (Euphoria)
Exostosis (Exostosis)
External Ear Inflammation (External ear
inflammation)
External Ear Pain (External ear pain)
Extraocular Muscle Paresis (Extraocular
muscle paresis)
Extrapyramidal Disorder (Extrapyramidal
disorder)
Eye Disorders - Other, Specify (Eye
disorders - Other, Specify)
Eye Infection (Eye infection)
Eye Pain (Eye pain)
Eyelid Function Disorder (Eyelid function
disorder)
Facial Muscle Weakness (Facial muscle
weakness)
Facial Nerve Disorder (Facial nerve
disorder)
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Facial Pain (Facial pain)
Fall (Fall)
Fallopian Tube Anastomotic Leak
(Fallopian tube anastomotic leak)
Fallopian Tube Obstruction (Fallopian
tube obstruction)
Fallopian Tube Perforation (Fallopian
tube perforation)
Fallopian Tube Stenosis (Fallopian tube
stenosis)
Fat Atrophy (Fat atrophy)
Fatigue (Fatigue)
Febrile Neutropenia (Febrile
neutropenia)
Fecal Incontinence (Fecal incontinence)
Female Genital Tract Fistula (Female
genital tract fistula)
Feminization Acquired (Feminization
acquired)
Fetal Death (Fetal death)
Fetal Growth Retardation (Fetal growth
retardation)
Fever (Fever)
Fibrinogen Decreased (Fibrinogen
decreased)
Fibrosis Deep Connective Tissue
(Fibrosis deep connective tissue)
Flank Pain (Flank pain)
Flashing Lights (Flashing lights)
Flatulence (Flatulence)
Floaters (Floaters)
Flu Like Symptoms (Flu like symptoms)
Flushing (Flushing)
Forced Expiratory Volume Decreased
(Forced expiratory volume decreased)
Fracture (Fracture)
Gait Disturbance (Gait disturbance)
Gallbladder Fistula (Gallbladder fistula)
Gallbladder Infection (Gallbladder
infection)
Gallbladder Necrosis (Gallbladder
necrosis)
Gallbladder Obstruction (Gallbladder
obstruction)
Gallbladder Pain (Gallbladder pain)
Gallbladder Perforation (Gallbladder
perforation)
Gastric Anastomotic Leak (Gastric
anastomotic leak)
Gastric Fistula (Gastric fistula)
Gastric Hemorrhage (Gastric
hemorrhage)
Gastric Necrosis (Gastric necrosis)
Gastric Perforation (Gastric perforation)
Gastric Stenosis (Gastric stenosis)
Gastric Ulcer (Gastric ulcer)
Gastritis (Gastritis)
Gastroesophageal Reflux Disease
(Gastroesophageal reflux disease)
Gastrointestinal Anastomotic Leak
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(Gastrointestinal anastomotic leak)
Gastrointestinal Disorders - Other,
Specify (Gastrointestinal disorders -
Other, Specify)
Gastrointestinal Fistula (Gastrointestinal
fistula)
Gastrointestinal Pain (Gastrointestinal
pain)
Gastrointestinal Stoma Necrosis
(Gastrointestinal stoma necrosis)
Gastroparesis (Gastroparesis)
General Disorders And Administration
Site Conditions - Other, Specify (General
disorders and administration site
conditions - Other, Specify)
Generalized Muscle Weakness
(Generalized muscle weakness)
Genital Edema (Genital edema)
Ggt Increased (GGT increased)
Gingival Pain (Gingival pain)
Glaucoma (Glaucoma)
Glossopharyngeal Nerve Disorder
(Glossopharyngeal nerve disorder)
Glucose Intolerance (Glucose
intolerance)
Growth Accelerated (Growth
accelerated)
Growth Hormone Abnormal (Growth
hormone abnormal)
Growth Suppression (Growth
suppression)
Gum Infection (Gum infection)
Gynecomastia (Gynecomastia)
Hallucinations (Hallucinations)
Haptoglobin Decreased (Haptoglobin
decreased)
Head Soft Tissue Necrosis (Head soft
tissue necrosis)
Headache (Headache)
Hearing Impaired (Hearing impaired)
Heart Failure (Heart failure)
Hematoma (Hematoma)
Hematosalpinx (Hematosalpinx)
Hematuria (Hematuria)
Hemoglobin Increased (Hemoglobin
increased)
Hemoglobinuria (Hemoglobinuria)
Hemolysis (Hemolysis)
Hemolytic Uremic Syndrome (Hemolytic
uremic syndrome)
Hemorrhoidal Hemorrhage
(Hemorrhoidal hemorrhage)
Hemorrhoids (Hemorrhoids)
Hepatic Failure (Hepatic failure)
Hepatic Hemorrhage (Hepatic
hemorrhage)
Hepatic Infection (Hepatic infection)
Hepatic Necrosis (Hepatic necrosis)
Hepatic Pain (Hepatic pain)
Hepatitis Viral (Hepatitis viral)
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Hepatobiliary Disorders - Other, Specify
(Hepatobiliary disorders - Other, Specify)
Hiccups (Hiccups)
Hip Fracture (Hip fracture)
Hirsutism (Hirsutism)
Hoarseness (Hoarseness)
Hot Flashes (Hot flashes)
Hydrocephalus (Hydrocephalus)
Hypercalcemia (Hypercalcemia)
Hyperglycemia (Hyperglycemia)
Hyperhidrosis (Hyperhidrosis)
Hyperkalemia (Hyperkalemia)
Hypermagnesemia (Hypermagnesemia)
Hypernatremia (Hypernatremia)
Hyperparathyroidism
(Hyperparathyroidism)
Hypersomnia (Hypersomnia)
Hypertension (Hypertension)
Hyperthyroidism (Hyperthyroidism)
Hypertrichosis (Hypertrichosis)
Hypertriglyceridemia
(Hypertriglyceridemia)
Hyperuricemia (Hyperuricemia)
Hypoalbuminemia (Hypoalbuminemia)
Hypocalcemia (Hypocalcemia)
Hypoglossal Nerve Disorder
(Hypoglossal nerve disorder)
Hypoglycemia (Hypoglycemia)
Hypohidrosis (Hypohidrosis)
Hypokalemia (Hypokalemia)
Hypomagnesemia (Hypomagnesemia)
Hyponatremia (Hyponatremia)
Hypoparathyroidism
(Hypoparathyroidism)
Hypophosphatemia (Hypophosphatemia)
Hypotension (Hypotension)
Hypothermia (Hypothermia)
Hypothyroidism (Hypothyroidism)
Hypoxia (Hypoxia)
Ileal Fistula (Ileal fistula)
Ileal Hemorrhage (Ileal hemorrhage)
Ileal Obstruction (Ileal obstruction)
Ileal Perforation (Ileal perforation)
Ileal Stenosis (Ileal stenosis)
Ileal Ulcer (Ileal ulcer)
Ileus (Ileus)
Immune System Disorders - Other,
Specify (Immune system disorders -
Other, Specify)
Infections And Infestations - Other,
Specify (Infections and infestations -
Other, Specify)
Infective Myositis (Infective myositis)
Infusion Related Reaction (Infusion
related reaction)
Infusion Site Extravasation (Infusion site
extravasation)
Injection Site Reaction (Injection site
reaction)
Injury To Carotid Artery (Injury to carotid
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artery)
Injury To Inferior Vena Cava (Injury to
inferior vena cava)
Injury To Jugular Vein (Injury to jugular
vein)
Injury To Superior Vena Cava (Injury to
superior vena cava)
Injury, Poisoning And Procedural
Complications - Other, Specify (Injury,
poisoning and procedural complications -
Other, Specify)
Inr Increased (INR increased)
Insomnia (Insomnia)
Intestinal Stoma Leak (Intestinal stoma
leak)
Intestinal Stoma Obstruction (Intestinal
stoma obstruction)
Intestinal Stoma Site Bleeding (Intestinal
stoma site bleeding)
Intra-abdominal Hemorrhage (Intra-
abdominal hemorrhage)
Intracranial Hemorrhage (Intracranial
hemorrhage)
Intraoperative Arterial Injury
(Intraoperative arterial injury)
Intraoperative Breast Injury
(Intraoperative breast injury)
Intraoperative Cardiac Injury
(Intraoperative cardiac injury)
Intraoperative Ear Injury (Intraoperative
ear injury)
Intraoperative Endocrine Injury
(Intraoperative endocrine injury)
Intraoperative Gastrointestinal Injury
(Intraoperative gastrointestinal injury)
Intraoperative Head And Neck Injury
(Intraoperative head and neck injury)
Intraoperative Hemorrhage
(Intraoperative hemorrhage)
Intraoperative Hepatobiliary Injury
(Intraoperative hepatobiliary injury)
Intraoperative Musculoskeletal Injury
(Intraoperative musculoskeletal injury)
Intraoperative Neurological Injury
(Intraoperative neurological injury)
Intraoperative Ocular Injury
(Intraoperative ocular injury)
Intraoperative Renal Injury
(Intraoperative renal injury)
Intraoperative Reproductive Tract Injury
(Intraoperative reproductive tract injury)
Intraoperative Respiratory Injury
(Intraoperative respiratory injury)
Intraoperative Skin Injury (Intraoperative
skin injury)
Intraoperative Splenic Injury
(Intraoperative splenic injury)
Intraoperative Urinary Injury
(Intraoperative urinary injury)
Intraoperative Venous Injury
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(Intraoperative venous injury)
Investigations - Other, Specify
(Investigations - Other, Specify)
Iron Overload (Iron overload)
Irregular Menstruation (Irregular
menstruation)
Irritability (Irritability)
Ischemia Cerebrovascular (Ischemia
cerebrovascular)
Ivth Nerve Disorder (IVth nerve disorder)
Jejunal Fistula (Jejunal fistula)
Jejunal Hemorrhage (Jejunal
hemorrhage)
Jejunal Obstruction (Jejunal obstruction)
Jejunal Perforation (Jejunal perforation)
Jejunal Stenosis (Jejunal stenosis)
Jejunal Ulcer (Jejunal ulcer)
Joint Effusion (Joint effusion)
Joint Infection (Joint infection)
Joint Range Of Motion Decreased (Joint
range of motion decreased)
Joint Range Of Motion Decreased
Cervical Spine (Joint range of motion
decreased cervical spine)
Joint Range Of Motion Decreased
Lumbar Spine (Joint range of motion
decreased lumbar spine)
Keratitis (Keratitis)
Kidney Anastomotic Leak (Kidney
anastomotic leak)
Kidney Infection (Kidney infection)
Kyphosis (Kyphosis)
Lactation Disorder (Lactation disorder)
Large Intestinal Anastomotic Leak (Large
intestinal anastomotic leak)
Laryngeal Edema (Laryngeal edema)
Laryngeal Fistula (Laryngeal fistula)
Laryngeal Hemorrhage (Laryngeal
hemorrhage)
Laryngeal Inflammation (Laryngeal
inflammation)
Laryngeal Mucositis (Laryngeal
mucositis)
Laryngeal Obstruction (Laryngeal
obstruction)
Laryngeal Stenosis (Laryngeal stenosis)
Laryngitis (Laryngitis)
Laryngopharyngeal Dysesthesia
(Laryngopharyngeal dysesthesia)
Laryngospasm (Laryngospasm)
Left Ventricular Systolic Dysfunction (Left
ventricular systolic dysfunction)
Lethargy (Lethargy)
Leukemia Secondary To Oncology
Chemotherapy (Leukemia secondary to
oncology chemotherapy)
Leukocytosis (Leukocytosis)
Leukoencephalopathy
(Leukoencephalopathy)
Libido Decreased (Libido decreased)
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Libido Increased (Libido increased)
Lip Infection (Lip infection)
Lip Pain (Lip pain)
Lipase Increased (Lipase increased)
Lipohypertrophy (Lipohypertrophy)
Localized Edema (Localized edema)
Lordosis (Lordosis)
Lower Gastrointestinal Hemorrhage
(Lower gastrointestinal hemorrhage)
Lung Infection (Lung infection)
Lymph Gland Infection (Lymph gland
infection)
Lymph Leakage (Lymph leakage)
Lymph Node Pain (Lymph node pain)
Lymphedema (Lymphedema)
Lymphocele (Lymphocele)
Lymphocyte Count Decreased
(Lymphocyte count decreased)
Lymphocyte Count Increased
(Lymphocyte count increased)
Malabsorption (Malabsorption)
Malaise (Malaise)
Mania (Mania)
Mediastinal Hemorrhage (Mediastinal
hemorrhage)
Mediastinal Infection (Mediastinal
infection)
Memory Impairment (Memory
impairment)
Meningismus (Meningismus)
Meningitis (Meningitis)
Menopause (Menopause)
Menorrhagia (Menorrhagia)
Metabolism And Nutrition Disorders -
Other, Specify (Metabolism and nutrition
disorders - Other, Specify)
Middle Ear Inflammation (Middle ear
inflammation)
Mitral Valve Disease (Mitral valve
disease)
Mobitz (type) Ii Atrioventricular Block
(Mobitz (type) II atrioventricular block)
Mobitz Type I (Mobitz type I)
Movements Involuntary (Movements
involuntary)
Mucosal Infection (Mucosal infection)
Mucositis Oral (Mucositis oral)
Multi-organ Failure (Multi-organ failure)
Muscle Weakness Left-sided (Muscle
weakness left-sided)
Muscle Weakness Lower Limb (Muscle
weakness lower limb)
Muscle Weakness Right-sided (Muscle
weakness right-sided)
Muscle Weakness Trunk (Muscle
weakness trunk)
Muscle Weakness Upper Limb (Muscle
weakness upper limb)
Musculoskeletal And Connective Tissue
Disorder - Other, Specify
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(Musculoskeletal and connective tissue
disorders - Other, Specify)
Musculoskeletal Deformity
(Musculoskeletal deformity)
Myalgia (Myalgia)
Myelitis (Myelitis)
Myelodysplastic Syndrome
(Myelodysplastic syndrome)
Myocardial Infarction (Myocardial
infarction)
Myocarditis (Myocarditis)
Myositis (Myositis)
Nail Discoloration (Nail discoloration)
Nail Infection (Nail infection)
Nail Loss (Nail loss)
Nail Ridging (Nail ridging)
Nasal Congestion (Nasal congestion)
Nausea (Nausea)
Neck Edema (Neck edema)
Neck Pain (Neck pain)
Neck Soft Tissue Necrosis (Neck soft
tissue necrosis)
Neoplasms Benign, Malignant And
Unspecified (incl Cysts And Polyps) -
Other, Specify (Neoplasms benign,
malignant and unspecified (incl cysts and
polyps) - Other, Specify)
Nervous System Disorders - Other,
Specify (Nervous system disorders -
Other, Specify)
Neuralgia (Neuralgia)
Neutrophil Count Decreased (Neutrophil
count decreased)
Night Blindness (Night blindness)
Nipple Deformity (Nipple deformity)
Non-cardiac Chest Pain (Non-cardiac
chest pain)
Nystagmus (Nystagmus)
Obesity (Obesity)
Obstruction Gastric (Obstruction gastric)
Oculomotor Nerve Disorder (Oculomotor
nerve disorder)
Olfactory Nerve Disorder (Olfactory
nerve disorder)
Oligospermia (Oligospermia)
Optic Nerve Disorder (Optic nerve
disorder)
Oral Cavity Fistula (Oral cavity fistula)
Oral Dysesthesia (Oral dysesthesia)
Oral Hemorrhage (Oral hemorrhage)
Oral Pain (Oral pain)
Osteonecrosis Of Jaw (Osteonecrosis of
jaw)
Osteoporosis (Osteoporosis)
Otitis Externa (Otitis externa)
Otitis Media (Otitis media)
Ovarian Hemorrhage (Ovarian
hemorrhage)
Ovarian Infection (Ovarian infection)
Ovarian Rupture (Ovarian rupture)
27 / 35
Prostate Cancer NCT01546987 Treatment - RTOG 1115 F0: Phase III RT +
Standard ADT vs RT + Enhanced ADT + TAK-700  Interim Evaluation/Treatment
Summary - 3294865v1.0
Ovulation Pain (Ovulation pain)
Pain (Pain)
Pain In Extremity (Pain in extremity)
Pain Of Skin (Pain of skin)
Palmar-plantar Erythrodysesthesia
Syndrome (Palmar-plantar
erythrodysesthesia syndrome)
Palpitations (Palpitations)
Pancreas Infection (Pancreas infection)
Pancreatic Anastomotic Leak (Pancreatic
anastomotic leak)
Pancreatic Duct Stenosis (Pancreatic
duct stenosis)
Pancreatic Enzymes Decreased
(Pancreatic enzymes decreased)
Pancreatic Fistula (Pancreatic fistula)
Pancreatic Hemorrhage (Pancreatic
hemorrhage)
Pancreatic Necrosis (Pancreatic
necrosis)
Pancreatitis (Pancreatitis)
Papilledema (Papilledema)
Papulopustular Rash (Papulopustular
rash)
Paresthesia (Paresthesia)
Paronychia (Paronychia)
Paroxysmal Atrial Tachycardia
(Paroxysmal atrial tachycardia)
Pelvic Floor Muscle Weakness (Pelvic
floor muscle weakness)
Pelvic Infection (Pelvic infection)
Pelvic Pain (Pelvic pain)
Pelvic Soft Tissue Necrosis (Pelvic soft
tissue necrosis)
Penile Infection (Penile infection)
Penile Pain (Penile pain)
Perforation Bile Duct (Perforation bile
duct)
Pericardial Effusion (Pericardial effusion)
Pericardial Tamponade (Pericardial
tamponade)
Pericarditis (Pericarditis)
Perineal Pain (Perineal pain)
Periodontal Disease (Periodontal
disease)
Periorbital Edema (Periorbital edema)
Periorbital Infection (Periorbital infection)
Peripheral Ischemia (Peripheral
ischemia)
Peripheral Motor Neuropathy (Peripheral
motor neuropathy)
Peripheral Nerve Infection (Peripheral
nerve infection)
Peripheral Sensory Neuropathy
(Peripheral sensory neuropathy)
Peritoneal Infection (Peritoneal infection)
Peritoneal Necrosis (Peritoneal necrosis)
Personality Change (Personality change)
Phantom Pain (Phantom pain)
Pharyngeal Anastomotic Leak
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(Pharyngeal anastomotic leak)
Pharyngeal Fistula (Pharyngeal fistula)
Pharyngeal Hemorrhage (Pharyngeal
hemorrhage)
Pharyngeal Mucositis (Pharyngeal
mucositis)
Pharyngeal Necrosis (Pharyngeal
necrosis)
Pharyngeal Stenosis (Pharyngeal
stenosis)
Pharyngitis (Pharyngitis)
Pharyngolaryngeal Pain
(Pharyngolaryngeal pain)
Phlebitis (Phlebitis)
Phlebitis Infective (Phlebitis infective)
Photophobia (Photophobia)
Photosensitivity (Photosensitivity)
Platelet Count Decreased (Platelet count
decreased)
Pleural Effusion (Pleural effusion)
Pleural Hemorrhage (Pleural
hemorrhage)
Pleural Infection (Pleural infection)
Pleuritic Pain (Pleuritic pain)
Pneumonitis (Pneumonitis)
Pneumothorax (Pneumothorax)
Portal Hypertension (Portal
hypertension)
Portal Vein Thrombosis (Portal vein
thrombosis)
Postnasal Drip (Postnasal drip)
Postoperative Hemorrhage
(Postoperative hemorrhage)
Postoperative Thoracic Procedure
Complication (Postoperative thoracic
procedure complication)
Precocious Puberty (Precocious
puberty)
Pregnancy, Puerperium And Perinatal
Conditions - Other, Specify (Pregnancy,
puerperium and perinatal conditions -
Other, Specify)
Premature Delivery (Premature delivery)
Premature Menopause (Premature
menopause)
Presyncope (Presyncope)
Proctitis (Proctitis)
Productive Cough (Productive cough)
Prolapse Of Intestinal Stoma (Prolapse
of intestinal stoma)
Prolapse Of Urostomy (Prolapse of
urostomy)
Prostate Infection (Prostate infection)
Prostatic Hemorrhage (Prostatic
hemorrhage)
Prostatic Obstruction (Prostatic
obstruction)
Prostatic Pain (Prostatic pain)
Proteinuria (Proteinuria)
Pruritus (Pruritus)
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Psychiatric Disorders - Other, Specify
(Psychiatric disorders - Other, Specify)
Psychosis (Psychosis)
Pulmonary Edema (Pulmonary edema)
Pulmonary Fibrosis (Pulmonary fibrosis)
Pulmonary Fistula (Pulmonary fistula)
Pulmonary Hypertension (Pulmonary
hypertension)
Pulmonary Valve Disease (Pulmonary
valve disease)
Purpura (Purpura)
Pyramidal Tract Syndrome (Pyramidal
tract syndrome)
Radiation Recall Reaction (dermatologic)
(Radiation recall reaction (dermatologic))
Radiculitis (Radiculitis)
Rash Acneiform (Rash acneiform)
Rash Maculo-papular (Rash maculo-
papular)
Rash Pustular (Rash pustular)
Rectal Anastomotic Leak (Rectal
anastomotic leak)
Rectal Fistula (Rectal fistula)
Rectal Hemorrhage (Rectal hemorrhage)
Rectal Mucositis (Rectal mucositis)
Rectal Necrosis (Rectal necrosis)
Rectal Obstruction (Rectal obstruction)
Rectal Pain (Rectal pain)
Rectal Perforation (Rectal perforation)
Rectal Stenosis (Rectal stenosis)
Rectal Ulcer (Rectal ulcer)
Recurrent Laryngeal Nerve Palsy
(Recurrent laryngeal nerve palsy)
Renal And Urinary Disorders - Other,
Specify (Renal and urinary disorders -
Other, Specify)
Renal Calculi (Renal calculi)
Renal Colic (Renal colic)
Renal Hemorrhage (Renal hemorrhage)
Reproductive System And Breast
Disorders - Other, Specify (Reproductive
system and breast disorders - Other,
Specify)
Respiratory Failure (Respiratory failure)
Respiratory, Thoracic And Mediastinal
Disorders - Other, Specify (Respiratory,
thoracic and mediastinal disorders -
Other, Specify)
Restlessness (Restlessness)
Restrictive Cardiomyopathy (Restrictive
cardiomyopathy)
Retinal Detachment (Retinal
detachment)
Retinal Tear (Retinal tear)
Retinal Vascular Disorder (Retinal
vascular disorder)
Retinoic Acid Syndrome (Retinoic acid
syndrome)
Retinopathy (Retinopathy)
Retroperitoneal Hemorrhage
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(Retroperitoneal hemorrhage)
Reversible Posterior
Leukoencephalopathy Syndrome
(Reversible posterior
leukoencephalopathy syndrome)
Rhinitis Infective (Rhinitis infective)
Right Ventricular Dysfunction (Right
ventricular dysfunction)
Salivary Duct Inflammation (Salivary duct
inflammation)
Salivary Gland Fistula (Salivary gland
fistula)
Salivary Gland Infection (Salivary gland
infection)
Scalp Pain (Scalp pain)
Scleral Disorder (Scleral disorder)
Scoliosis (Scoliosis)
Scrotal Infection (Scrotal infection)
Scrotal Pain (Scrotal pain)
Seizure (Seizure)
Sepsis (Sepsis)
Seroma (Seroma)
Serum Amylase Increased (Serum
amylase increased)
Serum Sickness (Serum sickness)
Sick Sinus Syndrome (Sick sinus
syndrome)
Sinus Bradycardia (Sinus bradycardia)
Sinus Disorder (Sinus disorder)
Sinus Pain (Sinus pain)
Sinus Tachycardia (Sinus tachycardia)
Sinusitis (Sinusitis)
Skin And Subcutaneous Tissue
Disorders - Other, Specify (Skin and
subcutaneous tissue disorders - Other,
Specify)
Skin Atrophy (Skin atrophy)
Skin Hyperpigmentation (Skin
hyperpigmentation)
Skin Hypopigmentation (Skin
hypopigmentation)
Skin Induration (Skin induration)
Skin Infection (Skin infection)
Skin Ulceration (Skin ulceration)
Sleep Apnea (Sleep apnea)
Small Intestinal Anastomotic Leak (Small
intestinal anastomotic leak)
Small Intestinal Mucositis (Small
intestinal mucositis)
Small Intestinal Obstruction (Small
intestinal obstruction)
Small Intestinal Perforation (Small
intestinal perforation)
Small Intestinal Stenosis (Small intestinal
stenosis)
Small Intestine Infection (Small intestine
infection)
Small Intestine Ulcer (Small intestine
ulcer)
Sneezing (Sneezing)
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Social Circumstances - Other, Specify
(Social circumstances - Other, Specify)
Soft Tissue Infection (Soft tissue
infection)
Soft Tissue Necrosis Lower Limb (Soft
tissue necrosis lower limb)
Soft Tissue Necrosis Upper Limb (Soft
tissue necrosis upper limb)
Somnolence (Somnolence)
Sore Throat (Sore throat)
Spasticity (Spasticity)
Spermatic Cord Anastomotic Leak
(Spermatic cord anastomotic leak)
Spermatic Cord Hemorrhage (Spermatic
cord hemorrhage)
Spermatic Cord Obstruction (Spermatic
cord obstruction)
Spinal Fracture (Spinal fracture)
Spleen Disorder (Spleen disorder)
Splenic Infection (Splenic infection)
Stenosis Of Gastrointestinal Stoma
(Stenosis of gastrointestinal stoma)
Stevens-johnson Syndrome (Stevens-
Johnson syndrome)
Stoma Site Infection (Stoma site
infection)
Stomach Pain (Stomach pain)
Stomal Ulcer (Stomal ulcer)
Stridor (Stridor)
Stroke (Stroke)
Sudden Death Nos (Sudden death NOS)
Suicidal Ideation (Suicidal ideation)
Suicide Attempt (Suicide attempt)
Superficial Soft Tissue Fibrosis
(Superficial soft tissue fibrosis)
Superficial Thrombophlebitis (Superficial
thrombophlebitis)
Superior Vena Cava Syndrome (Superior
vena cava syndrome)
Supraventricular Tachycardia
(Supraventricular tachycardia)
Surgical And Medical Procedures -
Other, Specify (Surgical and medical
procedures - Other, Specify)
Syncope (Syncope)
Telangiectasia (Telangiectasia)
Testicular Disorder (Testicular disorder)
Testicular Hemorrhage (Testicular
hemorrhage)
Testicular Pain (Testicular pain)
Thromboembolic Event
(Thromboembolic event)
Thrombotic Thrombocytopenic Purpura
(Thrombotic thrombocytopenic purpura)
Tinnitus (Tinnitus)
Tooth Development Disorder (Tooth
development disorder)
Tooth Discoloration (Tooth discoloration)
Tooth Infection (Tooth infection)
Toothache (Toothache)
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Toxic Epidermal Necrolysis (Toxic
epidermal necrolysis)
Tracheal Fistula (Tracheal fistula)
Tracheal Hemorrhage (Tracheal
hemorrhage)
Tracheal Mucositis (Tracheal mucositis)
Tracheal Obstruction (Tracheal
obstruction)
Tracheal Stenosis (Tracheal stenosis)
Tracheitis (Tracheitis)
Tracheostomy Site Bleeding
(Tracheostomy site bleeding)
Transient Ischemic Attacks (Transient
ischemic attacks)
Treatment Related Secondary
Malignancy (Treatment related
secondary malignancy)
Tremor (Tremor)
Tricuspid Valve Disease (Tricuspid valve
disease)
Trigeminal Nerve Disorder (Trigeminal
nerve disorder)
Trismus (Trismus)
Tumor Lysis Syndrome (Tumor lysis
syndrome)
Tumor Pain (Tumor pain)
Typhlitis (Typhlitis)
Unequal Limb Length (Unequal limb
length)
Unintended Pregnancy (Unintended
pregnancy)
Upper Gastrointestinal Hemorrhage
(Upper gastrointestinal hemorrhage)
Upper Respiratory Infection (Upper
respiratory infection)
Ureteric Anastomotic Leak (Ureteric
anastomotic leak)
Urethral Anastomotic Leak (Urethral
anastomotic leak)
Urethral Infection (Urethral infection)
Urinary Fistula (Urinary fistula)
Urinary Frequency (Urinary frequency)
Urinary Incontinence (Urinary
incontinence)
Urinary Retention (Urinary retention)
Urinary Tract Infection (Urinary tract
infection)
Urinary Tract Obstruction (Urinary tract
obstruction)
Urinary Tract Pain (Urinary tract pain)
Urinary Urgency (Urinary urgency)
Urine Discoloration (Urine discoloration)
Urine Output Decreased (Urine output
decreased)
Urostomy Leak (Urostomy leak)
Urostomy Obstruction (Urostomy
obstruction)
Urostomy Site Bleeding (Urostomy site
bleeding)
Urostomy Stenosis (Urostomy stenosis)
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Urticaria (Urticaria)
Uterine Anastomotic Leak (Uterine
anastomotic leak)
Uterine Fistula (Uterine fistula)
Uterine Hemorrhage (Uterine
hemorrhage)
Uterine Infection (Uterine infection)
Uterine Obstruction (Uterine obstruction)
Uterine Pain (Uterine pain)
Uterine Perforation (Uterine perforation)
Uveitis (Uveitis)
Vaginal Anastomotic Leak (Vaginal
anastomotic leak)
Vaginal Discharge (Vaginal discharge)
Vaginal Dryness (Vaginal dryness)
Vaginal Fistula (Vaginal fistula)
Vaginal Hemorrhage (Vaginal
hemorrhage)
Vaginal Infection (Vaginal infection)
Vaginal Inflammation (Vaginal
inflammation)
Vaginal Obstruction (Vaginal obstruction)
Vaginal Pain (Vaginal pain)
Vaginal Perforation (Vaginal perforation)
Vaginal Stricture (Vaginal stricture)
Vaginismus (Vaginismus)
Vagus Nerve Disorder (Vagus nerve
disorder)
Vas Deferens Anastomotic Leak (Vas
deferens anastomotic leak)
Vascular Access Complication (Vascular
access complication)
Vascular Disorders - Other, Specify
(Vascular disorders - Other, Specify)
Vasculitis (Vasculitis)
Vasovagal Reaction (Vasovagal reaction)
Venous Injury (Venous injury)
Ventricular Arrhythmia (Ventricular
arrhythmia)
Ventricular Fibrillation (Ventricular
fibrillation)
Ventricular Tachycardia (Ventricular
tachycardia)
Vertigo (Vertigo)
Vestibular Disorder (Vestibular disorder)
Virilization (Virilization)
Visceral Arterial Ischemia (Visceral
arterial ischemia)
Vital Capacity Abnormal (Vital capacity
abnormal)
Vitreous Hemorrhage (Vitreous
hemorrhage)
Voice Alteration (Voice alteration)
Vomiting (Vomiting)
Vulval Infection (Vulval infection)
Watering Eyes (Watering eyes)
Weight Gain (Weight gain)
Weight Loss (Weight loss)
Wheezing (Wheezing)
White Blood Cell Decreased (White
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blood cell decreased)
Wolff-parkinson-white Syndrome (Wolff-
Parkinson-White syndrome)
Wound Complication (Wound
complication)
Wound Dehiscence (Wound dehiscence)
Wound Infection (Wound infection)
Wrist Fracture (Wrist fracture)
CTC AE Grade
Absent Adverse Event (0)
Mild Adverse Event (1)
Moderate Adverse Event (2)
Severe Adverse Event (3)
Life Threatening Adverse Event (4)
Death Related To Adverse Event (5)
CTCAE Begin Date
CTC AE Attribution Code
Definite (Definite)
Possible (Possible)
Probable (Probable)
Unlikely (Unlikely)
Unrelated (Unrelated)
SAE report submitted
No (No)
Unknown (Unknown)
Yes (Yes)
Footer
Comments
Signature of Person Completing This Form
Date Form Originally Completed
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Breast Cancer NCT00513292 Pre-Study - Z1041: Tumor
Measurement Report Baseline (TMR-B) - 2533540v1.0
Z1041: Tumor Measurement Report Baseline (TMR-B)
Combination Chemotherapy and Paclitaxel Plus
Trastuzumab in Treating Women With Palpable Breast
Cancer That Can Be Removed by Surgery
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=21155A6B-
93AC-0F34-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/8278
Z1041: Tumor Measurement Report
Baseline (TMR-B)
Header Module
Visit
Baseline (Baseline)
Patient Study ID
Patient Initials
Institution No.
Institution Name
Header
Date of Evaluation
Lesion Number
Organ
Axilla (Axilla)
Target Lesion Site
Longest Diameter of Lesion(s)
Header
Date of Evaluation
Lesion Number
Organ
Axilla (Axilla)
Target Lesion Site
Longest Diameter of Lesion(s)
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Baseline sum of the longest diameter
Non-target Lesions
Are there any nontarget lesions? (If yes, record
below)
Yes
No
Date of Evaluation
Lesion Number
Organ
Breast (Breast)
Lymph Node (Lymph node)
Nontarget Lesion Site
Method of Evaluation
Ct Scan (CT scan)
Mri Scan (MRI scan)
Other (Other)
Physical Exam (Physical exam)
Spiral Ct Scan (Spiral CT scan)
Ultrasound (Ultrasound)
X-ray (X-ray)
Footer
Completed by
Date Form Completed
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Cervical Cancer NCT00064077 Quality of Life - Quality
of Life Questionnaire, GOG-0204 - 2079887v3.0
Quality of Life Questionnaire, GOG-0204
Comparison of Four Combination Chemotherapy Regimens
Using Cisplatin in Treating Patients With Stage IVB,
Recurrent, or Persistent Cancer of the Cervix
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=B58D04F2-
7ACB-11E8-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/8280
Quality of Life Questionnaire, GOG-
0204
Header
Name
Today's Date (mo; day; year)
Inst
Protocol
Seq
Physical Well-being
I have a lack of energy
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have nausea
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
Because of my physical condition, I have trouble
meeting the needs of my family
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have pain
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am bothered by side effects of treatment
1 / 7
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I feel ill
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am forced to spend time in bed
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
Social/family Well-being
I feel close to my friends
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I get emotional support from my family
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I get support from my friends and neighbors
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
My family has accepted my illness
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am satisfied with family communication about
my illness
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I feel close to my partner (or the person who is
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my main support)
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
If you prefer not to answer it, please mark this
oval (Regardless of your current level of sexual
activity, please answer the following question)
I am satisfied with my sex life
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
Emotional Well-being
I feel sad
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am satisfied with how I am coping with my
illness
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am losing hope in the fight against my illness
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I feel nervous
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I worry about dying
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I worry that my condition will get worse
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A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
Functional Well-being
I am able to work (include work at home)
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
My work (include work at home) is fulfilling
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am able to enjoy life
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have accepted my illness
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am sleeping well
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am enjoying the things I usually do for fun
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am content with the quality of my life right now
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
Overall Quality Of Life
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Please rate your current quality of life (lowest
quality; highest quality)
Additional Concerns
I am bothered by discharge or bleeding from my
vagina
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am bothered by odor coming from my vagina
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am afraid to have sex
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I feel sexually attractive
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
My vagina feels too narrow or short
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have concerns about my ability to have children
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am afraid the treatment may harm my body
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am interested in having sex
A Little Bit (A little bit)
Not At All (Not at all)
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Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I like the appearance of my body
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am bothered by constipation
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have a good appetite
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have trouble controlling my urine
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
It burns when I urinate
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have discomfort when I urinate
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am able to eat the foods that I like
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have numbness or tingling in my hands
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
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I have numbness or tingling in my feet
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I feel discomfort in my hands
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I feel discomfort in my feet
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
Brief Pain Inventory
Brief Pain Inventory (Please rate your pain by
shading the one number that best describes your
pain at its worst in the last 24 hours; No pain;
Pain as bad as you can imagine)
Ccrr Module For Quality Of Life
Questionnaire, Gog-0204
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Breast Cancer NCT00513292 Registration - Z1041:
Draft Registration Worksheet - 2736526v1.0
Z1041: Registration Worksheet
Combination Chemotherapy and Paclitaxel Plus
Trastuzumab in Treating Women With Palpable Breast
Cancer That Can Be Removed by Surgery
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=48F5A763-
9F56-54EF-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/8284
Z1041: Draft Registration Worksheet
Header
Pt ID# (Local Patient Identifier)
First
Middle
Last
E-mail (for Registration Confirmation)
Has patient previously been registered to an
ACOSOG study
Yes
No
Coordinating Group Patient ID (if applicable)
Date of Birth
Date Informed Consent Signed
Patient meets all eligibility criteria
Yes
No
Primary Tumor Biopsy
Receptor Status, ER (mark one)
Negative (Negative)
Positive (Positive)
Receptor Status, PgR (mark one)
Negative (Negative)
Positive (Positive)
Tumor size
Z1041-f1-l5 (Clinical tumor size < 2.0 cm
with nodal metastases < 2.0 cm)
Z1041-f1-l4 (Clinical tumor size < 2.0 cm
with nodal metastases >= 2.0 cm)
Z1041-f1-l1 (Tumor 2.0-4.0cm)
1 / 2
Z1041-f1-l2 (Tumor size > 4.0cm)
Patient/Participant Age
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Breast Cancer NCT00513292 Registration - ACOSOG-
Z1041 OPEN Registration Worksheet - 3114475v1.0
ACOSOG-Z1041 OPEN Registration Worksheet
Combination Chemotherapy and Paclitaxel Plus
Trastuzumab in Treating Women With Palpable Breast
Cancer That Can Be Removed by Surgery
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=89DFC49B-
B721-6DA7-E040-BB89AD43356A
All rights reserved. Please visit https://medical-data-
models.org/forms/8285
ACOSOG-Z1041 OPEN Registration
Worksheet
Patient Information
Date of Birth (month day year)
Gender of a Person
Female Gender (Female Gender)
Male Gender (Male Gender)
Unknown (Unknown)
Ethnicity
A Person Of Mexican, Puerto Rican,
Cuban, Central Or South American Or
Other Spanish Culture Or Origin,
Regardless Of Race. (Hispanic or Latino)
A Person Not Meeting The Definition For
Hispanic Or Latino. (Not Hispanic or
Latino)
Not Provided Or Available (Not reported)
Country of Residence
Zip code
Race
A Person Having Origins In Any Of The
Original Peoples Of North And South
America (including Central America),
And Who Maintains Tribal Affiliation Or
Community Attachment. (American
Indian or Alaska Native)
A Person Having Origins In Any Of The
Original Peoples Of The Far East,
Southeast Asia, Or The Indian
Subcontinent Including, For Example,
Cambodia, China, India, Japan, Korea,
Malaysia, Pakistan, The Philippine
Islands, Thailand, And Vietnam. (Asian)
A Person Having Origins In Any Of The
Black Racial Groups Of Africa. Terms
Such As "haitian" Or "negro" Can Be
Used In Addition To "black Or African
American." (Black or African American)
A Person Having Origins In Any Of The
Original Peoples Of Hawaii, Guam,
Samoa, Or Other Pacific Islands. (Native
Hawaiian or other Pacific Islander)
Not Provided Or Available (Not
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Reported)
Could Not Be Determined Or Unsure
(Unknown)
A Person Having Origins In Any Of The
Original Peoples Of Europe, The Middle
East, Or North Africa. (White)
Method of Payment
Medicaid (Medicaid)
Medicaid And Medicare (Medicaid and
Medicare)
Medicare (Medicare)
Medicare And Private Insurance
(Medicare and Private Insurance)
Military Or Veterans Sponsored Nos
(Military or Veterans Sponsored, Not
Otherwise Specified (NOS))
Military Sponsored (including Champus
& Tricare) (Military Sponsored (including
CHAMPUS & TRICARE))
No Means Of Payment (no Insurance)
(No means of payment (no insurance))
Other (Other)
Private Insurance (Private Insurance)
Self Pay (no Insurance) (Self Pay (No
Insurance))
Unknown (Unknown)
Veterans Sponsored (Veterans
Sponsored)
General Information
Pt ID# (Local Patient Identifier)
Last (initial)
First (initial)
Middle (initial optional)
E-mail (for Registration Confirmation)
Has patient previously been registered to an
ACOSOG study
Yes
No
Coordinating Group Patient ID (if yes previously
issued ACOSOG Patient ID)
Date Informed Consent Signed (month day year)
Was HIPAA Authorization included in Study
Informed Consent
2 / 8
Breast Cancer NCT00513292 Registration - ACOSOG-Z1041 OPEN
Registration Worksheet - 3114475v1.0
Yes
No
HIPAA Authorization Date (If no month day year)
Stratification Factors
Clinical Tumor Size (mark one)
Z1041-f1-l5 (Breast tumor size < 2 cm
and nodal metastases < 2 cm)
Z1041-f1-l4 (Breast tumor size < 2 cm
and nodal metastases >= 2 cm)
Z1041-f1-l2 (Breast tumor size > 4 cm
(any nodal))
Z1041-f1-l1 (Breast tumor size 2 cm - 4
cm (any nodal))
Hormone Receptor Status (mark one)
Er- And Pgr-negative (ER- and PgR-
negative)
Er- And/or Pgr-positive (ER- and/or PgR-
positive)
Age (mark one)
< 50 (< 50)
>= 50 (>= 50)
Eligibility Criteria
Female (Patients must be)
Yes
No
Age >= 18 years
Yes
No
ECOG Performance Status 0-1
Yes
No
ECOG Performance Status (0 or 1)
Fully Active, Able To Carry On All Pre-
disease Performance Without
Restriction. (0)
Restricted In Physically Strenuous
Activity But Ambulatory And Able To
Carry Out Work Of A Light Or Sedentary
Nature, E.g., Light Housework, Office
Work. (1)
The diagnosis of invasive adenocarcinoma of the
breast must have been made by core needle
biopsy (NOTE: FNA is acceptable for evaluation
of breast primaries < 2 cm and lymph node
metastases)
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Yes
No
Patients must have a breast primary >= 2.0 cm
and/or one or more biopsy-positive lymph nodes
(Patients with prior excisional biopsy of the breast
primary are eligible, provided biopsy-positive
lymph nodes are present)
Yes
No
The breast cancer must be determined to be
HER2-positive prior to study entry (Assays
performed using fluorescent in situ hybridization
FISH require gene amplification. Assays using
immunohistochemistry IHC require a strongly
positive 3+ staining intensity score)
Yes
No
Within 3 months prior to entry, the patient must
have a baseline left ventricular ejection fraction
(LVEF) measured by MUGA scan >= 55 (Note:
Echocardiogram may be substituted for MUGA at
baseline, but the same method of assessment
should be used throughout the study. See
Section 3.1,#7 "Note" regarding LVEF and
MUGA)
Yes
No
ANC >= 1200/mm^3
Yes
No
ANC (>= 1200)
Platelet count >= 100,000/mm^3
Yes
No
Platelet count (>= 100000)
Total bilirubin <= ULN unless the patient has a
grade 1 bilirubin elevation (> ULN to 1.5 x ULN)
resulting from Gilbert's disease or similar
syndrome due to slow conjugation of bilirubin
Yes
No
Does this patient have a grade 1 bilirubin
elevation (> ULN to 1.5 x ULN) resulting from
Gilbert's disease or similar syndrome due to slow
conjugation of bilirubin
Yes
No
Total Bilirubin (If No, <= ULN)
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Total Bilirubin (If No, <= ULN)
Total Bilirubin ULN
Total Bilirubin ULN
Alkaline phosphatase <= 2.5 x ULN
Yes
No
Alkaline Phosphatase (<= 2.5 x ULN)
Alkaline Phosphatase ULN
SGOT (AST) <= 1.5 x ULN
Yes
No
SGOT (AST) (<= 1.5 x ULN)
SGOT (AST) ULN
Creatinine <= ULN
Yes
No
Creatinine (<= ULN)
Creatinine ULN
Patients with either skeletal pain or alkaline
phosphatase that is > ULN but <= 2.5 x ULN are
eligible for inclusion in the study if bone scans fail
to demonstrate metastatic disease (Suspicious
findings on bone scan must be confirmed as
benign by x-ray, MRI, or biopsy)
Yes
No
Patients with a history of DCIS or synchronous
DCIS of the contralateral breast regardless of
therapy are eligible (Those with synchronous
invasive breast cancer are NOT eligible)
Yes
No
Patients with a history of ipsilateral DCIS treated
by local excision with or without hormonal therapy
are eligible (Those treated with radiation therapy
are NOT eligible)
Yes
No
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Patients with a history of non-breast malignancies
are eligible if they have remained disease-free for
5 years since completing their initial treatment
regimen and are deemed by their physician to be
at low risk for recurrence (Patients with the
following cancers are eligible if diagnosed and
treated within the past 5 years: carcinoma in situ
of the cervix, colon carcinoma in situ, melanoma
in situ, and basal cell and squamous cell
carcinoma of the skin)
Yes
No
Patients must not have had any surgical axillary
staging procedure prior to study entry (However,
patients who have had non-excisional biopsy of
an axillary node are eligible)
Yes
No
Patients must not have definitive clinical or
radiologic evidence of metastatic disease
Yes
No
Patients must not have a prior history of invasive
breast cancer
Yes
No
Patients must not have had treatment given for
this breast cancer prior to study entry (The only
exception is hormonal therapy, which may have
been given for up to a total of 28 days anytime
after diagnosis and before study entry. In such a
case, hormonal therapy must stop at or before
study entry and be re-started, if indicated,
following surgery.)
Yes
No
Patients must not be taking any sex hormonal
therapy, e.g., birth control pills, ovarian hormonal
replacement therapy, etc. (Patients are eligible if
this therapy is discontinued prior to study entry.
Women of reproductive potential must agree to
use an effective non-hormonal method of
contraception during therapy)
Yes
No
Patients must not be receiving therapy with any
hormonal agent such as raloxifene, tamoxifen, or
other selective estrogen receptor modulator
(SERM), either for osteoporosis or breast cancer
prevention (Patients are eligible only if these
medications are discontinued prior to study
entry.)
Yes
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No
Patients must not have had prior therapy with
anthracyclines or taxanes for any malignancy
Yes
No
Patients must not have non-malignant systemic
disease (cardiovascular, renal, hepatic, etc.) that
would preclude treatment with either of the
treatment regimens
Yes
No
Patients must not have cardiac disease that
would preclude the use of epirubicin or
trastuzumab (This includes: Active cardiac
disease angina pectoris that requires the use of
antianginal medication; cardiac arrhythmia
requiring medication; severe conduction
abnormality; clinically significant valvular disease;
cardiomegaly on chest x-ray; ventricular
hypertrophy on EKG; or poorly controlled
hypertension, i.e., diastolic greater than 100
mm/Hg. Patients with hypertension that is well
controlled on medication are eligible. History of
cardiac disease myocardial infarction
documented as a clinical diagnosis or by EKG or
any other tests; documented congestive heart
failure; or documented cardiomyopathy)
Yes
No
Patients must not have sensory/motor neuropathy
>= grade 2, as defined by the NCI's Common
Terminology Criteria for Adverse Events Version
3.0
Yes
No
Patients must not have had administration of any
investigational agents within 30 days before study
entry
Yes
No
Women of child-bearing potential must have a
negative urine or serum pregnancy test within 2
weeks of registration (Women who are breast
feeding are NOT eligible. If not a female of child-
bearing potential check NA)
N/a (N/A)
No (No)
Yes (Yes)
Negative pregnancy test date (If female of child-
bearing potential urine or serum mm/dd/yyyy)
Patients must not have psychiatric or addictive
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disorders or other conditions that, in the opinion
of the investigator, would preclude the patient
from meeting the study requirements
Yes
No
Randomization
Randomization
Fec-75 Q 3 Weeks X 4 Cycles Paclitaxel
80 Mg/m^2 Iv Weekly X 12 +
Trastuzumab Weekly X 12 (FEC-75 q 3
weeks x 4 cycles Paclitaxel 80 mg/m^2
IV weekly x 12 + Trastuzumab weekly x
12)
Paclitaxel 80 Mg/m^2 Iv Weekly X 12 +
Trastuzumab Weekly X 12 Fec-75 Q 3
Weeks X 4 Cycles + Trastuzumab
Weekly X 12 (Paclitaxel 80 mg/m^2 IV
weekly x 12 + Trastuzumab weekly x 12
FEC-75 q 3 weeks x 4 cycles +
Trastuzumab weekly x 12)
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Prostate Cancer NCT01368588 Pre-Study - RTOG-
0924 I1: Initial Evaluation Form - 3197613v1.0
RTOG-0924 I1: Initial Evaluation Form
Androgen-Deprivation Therapy and Radiation Therapy in
Treating Patients With Prostate Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=9D96A377-
788F-275E-E040-BB89AD437DB1
All rights reserved. Please visit https://medical-data-
models.org/forms/8286
RTOG-0924 I1: Initial Evaluation
Form
Unnamed Module 1
RTOG Study No.
Case #
Institution Name
Institution No.
Patient Initials
RTOG Patient ID
Amended Data
Yes
No
Unnamed Module 2
Performance Status (Zubrod) (0-4)
Normal Activity (0)
Symptoms, But Nearly Fully Ambulatory
(1)
Some Bed Time, But Needs To Be In
Bed <50% Of Normal Daytime (2)
Needs To Be In Bed > 50% Of Normal
Daytime (3)
Unable To Get Out Of Bed (4)
History and physical/digital rectal
Yes
No
Date Performed
Has the patient had any prior cancer diagnosed
(invasive other than study site)
Yes
No
Prior malignancy site
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Aml/mds (AML/MDS)
Bcc (BCC)
Bladder Is The Site Of Second Primary
Or Recurrent Tumor (bladder)
Brain Is The Site Of Second Primary Or
Recurrent Tumor (brain)
Colorectal (Colorectal)
Esophageal (Esophageal)
Gastric (Gastric)
Liver Is The Site Of Second Primary Or
Recurrent Tumor (liver)
Lung Is The Site Of Second Primary Or
Recurrent Tumor (lung)
Melanoma (Melanoma)
Nhl (NHL)
Other Hematologic (Other hematologic)
Other Solid (Other solid)
Pancreatic (Pancreatic)
Renal (Renal)
Squamous-skin (Squamous-skin)
Unknown Primary (Unknown primary)
Specify
Date Eradicated (mm-yyyy)
Other Patient Disease Type
Heart problems (unstable angina and/or
Congestive heart failure requiring hospitalization
Within the last 6 months)
Yes
No
Heart problems (transmural myocardial infarction
within the last 6 months)
Yes
No
Infection (acute bacterial or fungal infection
Requiring intravenous antibiotics at the time of
Registration)
Yes
No
COPD exacerbation or other respiratory illness
requiring hospitalization or precluding study
therapy at registration ([within 30 days of
registration])
Yes
No
Hepatic Insufficiency (resulting in clinical
Jaundice and/or coagulation defects)
Yes
No
Does the patient have AIDS (based upon Current
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CDC definition)
Yes
No
Prostate: Prior Treatment
Prior surgery (RADICAL PROSTATECTOMY,
CRYOSURGERY [OR HIGH-INTENSITY
FOCUSED ULTRASOUND HIFU])
Yes
No
Prior radiation therapy ([RT INCLUDING
BRACHYTHERAPY, TO THE REGION OF
STUDY THAT WOULD RESULT IN OVERLAP
OF RT FIELDS])
Yes
No
Prior chemotherapy
Yes
No
Prior Hormonal Therapy (LHRH AGONIST, ANTI-
ANDROGEN THERAPY, ESTOGEN, BILATERAL
ORCHIECTOMY, TESTOSTERONE- REPORT
PROTOCOL HORMONES STARTED PRIOR TO
REGISTRATION IN Q24)
Yes
No
Prior finasteride therapy
Yes
No
Prior finasteride therapy end date
Prior dutasteride therapy
Yes
No
Prior dutasteride therapy end date
Prostate: Initial Diagnosis
Histologic Type
Adenocarcinoma, Conventional, Not
Otherwise Specified (Adenocarcinoma,
conventional NOS)
Other Specify (Other)
Other specify
Diagnosis Date
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Total number of core biopsies taken
Number of positive core biopsies
Total % of positive core biopsies taken
Gleason Score, Primary Pattern ([most frequently
seen] 1-5, 9=unknown)
Gleason Score, Secondary Pattern ([second
most frequently seen] 1-5, 9=unknown)
Gleason Score, Worst Pattern ([worst
pathological grade seen in any specimen] 1-5,
9=unknown)
Gleason Score, Combined
Study Entry Psa Measurements
Baseline PSA Date
Baseline PSA Value
Units
Micrograms Per Liter (mcg/L)
N/milligram (n/mg)
Nanograms Per Deciliter (ng/dL)
Nanograms Per Milliliter (ng/mL)
Not Otherwise Specified (NOS)
Units Per Liter (U/L)
Method of Assay
Abbott Labs (Abbott)
Bayer (Bayer)
Dpc (DPC)
Hybritech (Hybritech)
Other (Other)
Unknown (Unknown)
Unnamed Module 4a
Pre-diagnostic PSA measurements (Additional
PSA's obtained within 1 year prior to diagnosis if
available)
Yes
No
PSA Date (s)
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PSA Value (s)
Units
Micrograms Per Liter (mcg/L)
N/milligram (n/mg)
Nanograms Per Deciliter (ng/dL)
Nanograms Per Milliliter (ng/mL)
Not Otherwise Specified (NOS)
Units Per Liter (U/L)
Method of Assay
Abbott Labs (Abbott)
Bayer (Bayer)
Dpc (DPC)
Hybritech (Hybritech)
Other (Other)
Unknown (Unknown)
Unnamed Module 3
Was the tumor palpable? (at study entry)
No (No)
Yes, <= 1/2 Of One Lobe (Yes, <= 1/2 of
one lobe)
Yes, > 1/2 Of One Lobe (Yes, > 1/2 of
one lobe)
Yes, Both Lobes (Yes, both lobes)
Yes, Nos (Yes, NOS)
Extracapsular Extension? (by clinical
examination)
Yes
No
T Stage, Clinical (AJCC 7TH EDITION)
Tumor Incidental Histologic Finding In
5% Or Less Of Tissue Resected (T1a)
Tumor Incidental Histologic Finding In
More Than 5% Of Tissue Resected
(T1b)
Tumor Identified By Needle Biopsy (eg,
Because Of Elevated Psa) (T1c)
Tumor Confined Within The Prostate (T2)
Tumor Involves One-half Of One Lobe Or
Less (T2a)
Tumor Involves More Than One-half Of
One Lobe But Not Both Lobes (T2b)
Tumor Involves Both Lobes (T2c)
Tumor Extends Through The Prostate
Capule (T3)
Extracapsular Extension (unilateral Or
Bilateral) (T3a)
Tumor Invades Seminal Vesicle(s) (T3b)
Tumor Is Fixed Or Invades Adjacent
Structures Other Than Seminal Vesicles:
Such As External Sphincter, Rectum,
Bladder, Levator Muscles, And/or Pelvic
Wall (T4)
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Primary Tumor Cannot Be Assessed
(TX)
N Stage, Pathologic
No Positive Regional Nodes (pN0)
Metastases In Regional Node(s) (pN1)
Regional Nodes Not Sampled (pNX)
N Stage, Clinical (RADIOGRAPHIC)
No Regional Lymph Node Metastasis
(N0)
Metastasis In Regional Lymph Node(s)
(N1)
Regional Lymph Nodes Were Not
Assessed (NX)
M Stage, Clinical
No Distant Metastasis (M0)
Distant Metastasis (M1)
Nonregional Lymph Node(s) (M1a)
Bone(s) (M1b)
Other Site(s) With Or Without Bone
Disease (M1c)
Regional lymph node dissection (OR
SAMPLING)
Yes
No
Baseline Lab Values (hematologic)
WBC
Hemoglobin ([g/dl])
Peripheral Platelet Count ([cells/mm^3])
ANC ([cells/mm^3])
Date performed
Date performed
SGPT (ALT)
SGPT (ALT) ULN
Date performed
SGOT (AST)
6 / 8
Prostate Cancer NCT01368588 Pre-Study - RTOG-0924 I1: Initial
Evaluation Form - 3197613v1.0
SGOT (AST) ULN
Unnamed
Is patient receiving brachytherapy (LDR/HDR)
Yes
No
CT/MRI abdomen/pelvis
Yes
No
Date Performed
Bone scan
Yes
No
Date performed
Transrectal Ultrasound (Brachytherapy only)
No (No)
Not Applicable (Not Applicable)
Yes (Yes)
Prostate volume
Date performed
Treatment Schedule (lhrh Agonist)
Is patient on protocol hormone (antiandrogen
started prior to registration)
Yes
No
LHRH agonist (or antagonist)
Eligard (Eligard)
Lupron (Lupron)
Other (Other)
Viadur (Viadur)
Zoladex (Zoladex)
Other, specify
LHRH agonist start date (or antagonist prior to
registration)
Total Dose (administered prior to registration)
Treatment Schedule (oral Antiandrogen)
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Is patient on protocol hormone (antiandrogen
started prior to registration)
Yes
No
Oral antiandrogen taken
Casodex (Casodex)
Eulexin (Eulexin)
Other (Other)
Other, specify
Oral Antiandrogen Start Date (prior to
registration)
Total Dose (administered prior to registration)
Footer
Comments
Signature of Person Completing This Form
Date Form Originally Completed
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Neuroblastoma NCT00053326 Pre-Study - ANBL0321:
CT/MRI Sites of Disease at study entry - 2089140v3.0
ANBL0321: CT/MRI Sites of Disease at study entry
Fenretinide in Treating Children With Recurrent or
Resistant Neuroblastoma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=B966743D-
6A11-0A66-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/8289
ANBL0321: CT/MRI Sites of Disease
at study entry
Header
Name
Study Number
Study Number
COG Number
Patient Name
Today's date
Date worksheet entered into RDE
Sites Of Measurable Disease At The Time
Of Study Entry
Did patient have measurable lesions on CT
and/or MRI at study entry? (Required field)
Yes
No
Disease measurement at study entry (defined as
sum of the longest diameter for all target lesions)
Method of measurement (2c)
Ct Scan (Computed Tomography-
Conventional)
Spiral Ct Scan (Computed Tomography-
spiral)
Mri (MRI)
Other, Specify (Other, Specify)
Method of measurement (2c)
Ct Scan (Computed Tomography-
Conventional)
Spiral Ct Scan (Computed Tomography-
spiral)
Mri (MRI)
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Other, Specify (Other, Specify)
other, Specify (1. If other is selected as method of
measurement, this must be completed.)
other, Specify (1. If other is selected as method of
measurement, this must be completed.)
ICD-O Topography Code of Lesion (2a)
ICD-O Topography Code of Lesion (2a)
Largest Dimension (2b)
Largest Dimension (2b)
Were any other lesions detected at study entry?
(1. Required field)
Yes
No
Comments
Ccrr Module For Anbl0321: Ct/mri Sites Of
Disease At Study Entry
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Breast Cancer NCT00513292 Lab - Z1041: Blood
Specimen Bank Submission (BSBS) Form - 2533204v1.0
Z1041: Blood Specimen Bank Submission (BSBS) Form
Combination Chemotherapy and Paclitaxel Plus
Trastuzumab in Treating Women With Palpable Breast
Cancer That Can Be Removed by Surgery
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=21086647-
E20B-53D5-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/8290
Z1041: Blood Specimen Bank
Submission (BSBS) Form
Unnamed 1
Visit
Baseline (Baseline)
C4d21 (C4D21)
C8d21 (C8D21)
Unscheduled (Unscheduled)
Date
Patient ID
Patient Initials (F M L)
Institution No.
Institution Name
To Be Completed By Clinical Site
Were specimen(s) submitted to the ACOSOG
Central Specimen Bank
Yes
No
If not submitted, specify reason
Specimen Type
Plasma (Plasma)
Serum (Serum)
Whole Blood (Whole Blood)
Blood collection
After 1st Chemo Regimen (After 1st
chemo regimen)
After 2nd Chemo Regimen (After 2nd
chemo regimen)
Baseline (Baseline)
Date Specimen Shipped
Date Specimen collected
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Number of specimens submitted
Shipment type (Mark one)
Dry Ice (Dry ice)
Wetpack (Wetpack)
Shipped by
Courier Tracking Number
Contact Person at Institution
Phone
E-mail
Fax
To Be Completed By Acosog Central
Specimen Bank
Date of Receipt of Specimens (s)
Specimen Type
Plasma (Plasma)
Serum (Serum)
Whole Blood (Whole Blood)
No specimen received (Check if none)
Specimen Received Count
Condition of Specimen (s)
Damaged Or Unusable (Damaged or
unusable)
Usable (Usable)
Completed by
Date Form Completed
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Brain and Central Nervous System Tumors NCT00304031 RT Submission - RTOG-
0525 SR: Radiation Therapy Oncology Group Phase III GBM RT & TMZ Followed
by Adjuvant TMZ Central Radiology Review Form - 2402984v1.0
RTOG-0525 SR: Radiation Therapy Oncology Group
Phase III GBM RT & TMZ Followed by Adjuvant TMZ
Central Radiology Review Form
Radiation Therapy and Temozolomide in Treating Patients
With Newly Diagnosed Glioblastoma or Gliosarcoma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=0032097F-
A80D-47A4-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/8294
RTOG-0525 SR: Radiation Therapy
Oncology Group Phase III GBM RT
& TMZ Followed by Adjuvant TMZ
Central Radiology Review Form
Module 1
RTOG Study No.
Case #
Institution Name
Institution No.
Patient Initials
RTOG Patient ID
AMENDED DATA
Yes
No
Date of Assessment
Assessment Method Type
Ct Scan (CT scan)
Mri Scan (MRI scan)
Other (Other)
Other Specify
Response Status at This Assessment, Imaging
Complete Response (CR)
Insufficient Evaluation To Determine
Response Status (insufficient evaluation
to determine response status)
Minor Response (MR)
Progressive Disease (PD)
Partial Response (PR)
Stable Disease (SD)
Comments
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Brain and Central Nervous System Tumors NCT00884741 Treatment - RTOG 0825
Phase III GBM Salvage Treatment Guideline Questionnaire (SX) - 2797409v1.0
RTOG 0825 Phase III GBM Salvage Treatment Guideline
Questionnaire (SX)
Temozolomide and Radiation Therapy With or Without
Bevacizumab in Treating Patients With Newly Diagnosed
Glioblastoma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=5AE28686-
9246-64D7-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/8296
RTOG 0825 Phase III GBM Salvage
Treatment Guideline Questionnaire
(SX)
Module 1
RTOG Study No.
Case #
Institution Name
Institution No.
Patient Initials
RTOG Patient ID
Amended Data (INSTRUCTIONS: Complete form
on web to unblind the protocol treatment arm)
Yes
No
Inclusion Criteria
Inclusion Criteria
For Females Of Childbearing Potential
Was A Negative Serum Pregnancy Test
Done (For females of childbearing
potential was a negative serum
pregnancy test done)
Has The Patient Received Any
Chemotherapy, Radiotherapy, Or Other
Treatment Intended As An Anti-cancer
Therapy Since The Protocol Based
Treatment (rt, Temozolomide +/-
Bevacizumab/placebo) On The Blinded
Component Of The Study (Has the
patient received any chemotherapy,
radiotherapy, or other treatment intended
as an anti-cancer therapy since the
protocol based treatment (RT,
temozolomide +/- bevacizumab/placebo)
on the blinded component of the study)
Has The Patient Recovered From The
Effects Of Surgery, Postoperative
Infection, And Other Complications (Has
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the patient recovered from the effects of
surgery, postoperative infection, and
other complications)
Has The Patient Undergone Resection
Of The Recurrent Tumor/tumors (Has the
patient undergone resection of the
recurrent tumor/tumors)
If On Full Dose Anticoagulants, Have
Both Of The Following Criteria Been Met
No Active Bleeding Or Pathological
Condition That Carries A High Risk Of
Bleeding; In-range Inr On A Stable Dose
Of Oral Anticoagulant (If on full dose
anticoagulants, have both of the following
criteria been met No active bleeding or
pathological condition that carries a high
risk of bleeding; In-range INR on a stable
dose of oral anticoagulant)
Is Systolic Blood Pressure <=160 Mg Hg
Or Diastolic Pressure <= 90 Mg Hg (Is
systolic blood pressure <=160 mg hg or
diastolic pressure <= 90 mg hg)
Is The Electrocardiogram Without
Evidence Of Acute Cardiac Ischemia (Is
the electrocardiogram without evidence
of acute cardiac ischemia)
Is The Karnofsky Performance Status >
60 (Is the Karnofsky performance status
> 60)
Is The Patient On Full-dose
Anticoagulants (e.g., Warfarin Or Lmw
Heparin) (Is the patient on full-dose
anticoagulants (e.g., warfarin or LMW
heparin))
Is The Prothrombin Time/international
Normalized Ratio (pt Inr) < 1.4 For
Patients Not On Warfarin Confirmed By
Testing (Is the prothrombin
time/international normalized ratio (PT
INR) < 1.4 for patients not on warfarin
confirmed by testing)
Is There Adequate Bone Marrow
Function Defined As Follows Absolute
Neutrophil Count (anc) >= 1,500
Cells/mm^3; Platelets >= 100,000
Cells/mm^3; Hemoglobin >= 10.0 G/dl
(note: The Use Of Transfusion Or Other
Intervention Is Acceptable) (Is there
adequate bone marrow function defined
as follows Absolute neutrophil count
(ANC) >= 1,500 cells/mm^3; Platelets >=
100,000 cells/mm^3; Hemoglobin >=
10.0 g/dl (Note: The use of transfusion or
other intervention is acceptable))
Is There Adequate Hepatic Function, As
Defined Below Bilirubin <= 2.0 Mg/dl;
Alt/ast <= 3 X Normal Range (Is there
adequate hepatic function, as defined
below Bilirubin <= 2.0 mg/dl; ALT/AST <=
3 x normal range)
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Is There Adequate Renal Function, As
Defined Below Bun <= 30 Mg/dl;
Creatinine <= 1.7 Mg/dl; Urine Protein
Screened By Urine Analysis For Urine
Protein Creatinine (upc) Ratio. For Upc
Ratio > 0.5, 24-hour Urine Protein
Should Be Obtained (Is there adequate
renal function, as defined below BUN <=
30 mg/dl; Creatinine <= 1.7 mg/dl; Urine
protein screened by urine analysis for
urine protein creatinine (UPC) ratio. For
UPC ratio > 0.5, 24-hour urine protein
should be obtained)
Planned Start Date For Salvage
Treatment (Planned start date for
salvage treatment)
Was An Mri Or Ct Scan Obtained That
Demonstrates The Following:
Postoperative Hemorrhage Defined As >
1 Cm Diameter Of Blood (if > 1 Cm Of
Acute Blood Is Detected, The Patient
May Not Receive Unblinded
Bevacizumab) (Was an MRI or CT scan
obtained that demonstrates the following:
postoperative hemorrhage defined as > 1
cm diameter of blood (if > 1 cm of acute
blood is detected, the patient may not
receive unblinded bevacizumab))
Was The Patient Diagnosed With
Recurrance Or Progression (must Be
Diagnosed By Imaging Only) (Was the
patient diagnosed with recurrance or
progression (must be diagnosed by
imaging only))
Performance Status (Karnofsky)
Dead (0)
Moribund, Fatal Processes Progressing
Rapidly (10)
Normal, No Complaints, No Evidence Of
Disease (100)
Very Sick, Hospitalization Indicated.
Death Not Imminent (20)
Severely Disabled, Hospitalization
Indicated. Death Not Imminent (30)
Disabled, Requires Special Care And
Assistance (40)
Requires Considerable Assistance And
Frequent Medical Care (50)
Requires Occasional Assistance, But Is
Able To Care For Most Of His/her Needs
(60)
Cares For Self, Unable To Carry On
Normal Activity Or To Do Active Work
(70)
Normal Activity With Effort; Some Signs
Or Symptoms Of Disease (80)
Able To Carry On Normal Activity; Minor
Signs Or Symptoms Of Disease (90)
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Negative serum pregnancy test
Yes
No
Planned start date for salvage treatment
Footer Module
Investigator Signature
Date (MM DD YYYY)
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Breast Cancer NCT00881361 Registration - ACOSOG-
Z1071 OPEN Registration Worksheet - 3014456v1.0
ACOSOG-Z1071 OPEN Registration Worksheet
Surgery to Remove the Sentinel Lymph Node and Axillary
Lymph Nodes After Chemotherapy in Treating Women With
Stage II, Stage IIIA, or Stage IIIB Breast Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=80369EB7-
995B-793A-E040-BB89AD437095
All rights reserved. Please visit https://medical-data-
models.org/forms/8297
ACOSOG-Z1071 OPEN Registration
Worksheet
Patient Information
Date of Birth (month day year)
Gender of a Person
Female Gender (Female Gender)
Male Gender (Male Gender)
Unknown (Unknown)
Ethnicity
A Person Of Mexican, Puerto Rican,
Cuban, Central Or South American Or
Other Spanish Culture Or Origin,
Regardless Of Race. (Hispanic or Latino)
A Person Not Meeting The Definition For
Hispanic Or Latino. (Not Hispanic or
Latino)
Not Provided Or Available (Not reported)
Country of Residence
Zip code
Race
A Person Having Origins In Any Of The
Original Peoples Of North And South
America (including Central America),
And Who Maintains Tribal Affiliation Or
Community Attachment. (American
Indian or Alaska Native)
A Person Having Origins In Any Of The
Original Peoples Of The Far East,
Southeast Asia, Or The Indian
Subcontinent Including, For Example,
Cambodia, China, India, Japan, Korea,
Malaysia, Pakistan, The Philippine
Islands, Thailand, And Vietnam. (Asian)
A Person Having Origins In Any Of The
Black Racial Groups Of Africa. Terms
Such As "haitian" Or "negro" Can Be
Used In Addition To "black Or African
American." (Black or African American)
A Person Having Origins In Any Of The
Original Peoples Of Hawaii, Guam,
Samoa, Or Other Pacific Islands. (Native
Hawaiian or other Pacific Islander)
Not Provided Or Available (Not
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Reported)
Could Not Be Determined Or Unsure
(Unknown)
A Person Having Origins In Any Of The
Original Peoples Of Europe, The Middle
East, Or North Africa. (White)
Method of Payment
Medicaid (Medicaid)
Medicaid And Medicare (Medicaid and
Medicare)
Medicare (Medicare)
Medicare And Private Insurance
(Medicare and Private Insurance)
Military Or Veterans Sponsored Nos
(Military or Veterans Sponsored, Not
Otherwise Specified (NOS))
Military Sponsored (including Champus
& Tricare) (Military Sponsored (including
CHAMPUS & TRICARE))
No Means Of Payment (no Insurance)
(No means of payment (no insurance))
Other (Other)
Private Insurance (Private Insurance)
Self Pay (no Insurance) (Self Pay (No
Insurance))
Unknown (Unknown)
Veterans Sponsored (Veterans
Sponsored)
General Information
Pt ID# (Local Patient Identifier)
Last (initial)
First (initial)
Middle (initial optional)
E-mail (for Registration Confirmation)
Has patient previously been registered to an
ACOSOG study
Yes
No
Coordinating Group Patient ID (if yes previously
issued ACOSOG Patient ID)
Date Informed Consent Signed (month day year)
Was HIPAA Authorization included in Study
Informed Consent
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Yes
No
HIPAA Authorization Date (If no month day year)
Eligibility Checklist
Age >= 18 years
Yes
No
ECOG Performance Status 0-1 (Zubrod)
Yes
No
ECOG Performance Status (Zubrod 0 or 1)
Fully Active, Able To Carry On All Pre-
disease Performance Without
Restriction. (0)
Restricted In Physically Strenuous
Activity But Ambulatory And Able To
Carry Out Work Of A Light Or Sedentary
Nature, E.g., Light Housework, Office
Work. (1)
Female (NOTE: Men are excluded from this study
because the number of men with breast cancer is
insufficient to provide a statistical basis for
assessment of effects in this subpopulation of
people with breast cancer)
Yes
No
Histologic diagnosis of invasive breast cancer,
clinical stage T0-4 N1-2 M0 (excluding
inflammatory breast cancer)
Yes
No
FNA biopsy or core needle biopsy of an axillary
node documenting nodal disease at time of
diagnosis and prior to preoperative chemotherapy
Yes
No
Preoperative chemotherapy must be completed
or planned for patient (NOTE: Patients enrolling
on studies involving preoperative chemotherapy
through cooperative groups or institutional
studies may be eligible for this study, provided
sentinel node surgery prior to preoperative
chemotherapy was not required in the other
studies)
Yes
No
No prior ipsilateral axillary surgery, such as
excisional biopsy of lymph node(s) or treatment
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of hidradenitis
Yes
No
No prior SLN surgery/excisional lymph node
biopsy for pathological confirmation of axillary
status
Yes
No
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GBM Neurocognitive Evaluation Summary
Form (CS) RTOG 0825 Phase III
RTOG 0825 Phase III GBM Neurocognitive Evaluation
Summary Form (CS)
Temozolomide and Radiation Therapy With or Without
Bevacizumab in Treating Patients With Newly Diagnosed
Glioblastoma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=5BE60D36-
11E5-00FF-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/8298
GBM Neurocognitive Evaluation
Summary Form (CS) RTOG 0825
Phase III
Header Module
RTOG Study No.*
Case #*
Institution Name*
Institution No.*
Patient Initials*
RTOG Patient ID*
Amended Data*
Yes
No
Time point of this assessment*
Other Followup (Other follow-ups)
Registration (Registration)
Week 10 (Week 10)
Week 22 (Week 22)
Week 34 (Week 34)
Week 46 (Week 46)
Week 6 (week 6)
Week 62 (Week 62)
Date of evaluation (MM DD YYYY)*
Hopkins Verbal Learning Test - Revised
Administration
HVLT-R reason not completed*
Discontinue Due To Disability
(Discontinued due to disability)
Discontinue, Other Reason
(Discontinued, other reason)
Not Applicable (Not Applicable)
Not Tested Due To Disability (Not tested
due to disability)
Not Tested, Other Reason (Not tested,
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other reason)
Reason Unknown (Reason unknown)
Not tested, other reason specify*
Discontinued, other reason specify*
Free Recall (Trial #3)*
Free Recall (Trial #3)*
Free Recall (Trial #3)*
Free Recall Total Score*
Free Recall Stop Time*
Delayed Recall Start Time*
Delayed Recall Total Score*
Delayed Recognition Total Score*
Trail Making Test Part A
Sample A completed*
Yes
No
Trail Making Test A reason not complete*
Discontinue Due To Disability
(Discontinued due to disability)
Discontinue, Other Reason
(Discontinued, other reason)
Not Applicable (Not Applicable)
Not Tested Due To Disability (Not tested
due to disability)
Not Tested, Other Reason (Not tested,
other reason)
Reason Unknown (Reason unknown)
Not tested, other reason specify*
Discontinued, other reason specify*
Total time to completion (Part A)*
Trail Making Test Part A
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Sample B completed*
Yes
No
Trail Making Test B reason not completed*
Discontinue Due To Disability
(Discontinued due to disability)
Discontinue, Other Reason
(Discontinued, other reason)
Not Applicable (Not Applicable)
Not Tested Due To Disability (Not tested
due to disability)
Not Tested, Other Reason (Not tested,
other reason)
Reason Unknown (Reason unknown)
Not tested, other reason specify*
Discontinued, other reason specify*
Total time to completion (Part A)*
Contolled Oral Word Association (cowa)
COWA reason not completed*
Discontinue Due To Disability
(Discontinued due to disability)
Discontinue, Other Reason
(Discontinued, other reason)
Not Applicable (Not Applicable)
Not Tested Due To Disability (Not tested
due to disability)
Not Tested, Other Reason (Not tested,
other reason)
Reason Unknown (Reason unknown)
Not tested, other reason specify*
Discontinued, other reason specify*
First letter column (COWA Results)*
Second letter column (COWA Results)*
Third letter column (COWA Results)*
Footer
Comments*
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Signature of Person Completing This Form*
Date Form Originally Completed*
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Prostate Cancer NCT01546987 Follow-Up - RTOG 1115 F1: Phase III RT +
Standard ADT vs RT + Enhanced ADT + TAK-700 Follow-Up Form - 3289581v1.0
RTOG 1115 F1: Phase III RT + Standard ADT vs RT +
Enhanced ADT + TAK-700 Follow-Up Form
Hormone Therapy, Radiation Therapy, and Steroid 17alpha-
monooxygenase TAK-700 in Treating Patients With High-
Risk Prostate Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=AE931EC8-
EB71-0470-E040-BB89AD430843
All rights reserved. Please visit https://medical-data-
models.org/forms/8301
RTOG 1115 F1: Phase III RT +
Standard ADT vs RT + Enhanced
ADT + TAK-700 Follow-Up Form
Unnamed2
RTOG Study No.
Case #
Institution Name
Institution No.
Patient Initials
RTOG Patient ID
Header
Amended Data
Yes
No
Unnamed 3
Patient's Vital Status
Alive (Alive)
Dead (Dead)
Date of Last Contact or Death
Primary Cause of Death
Due To Other Cause (Due to other
cause)
Due To Protocol Treatment (Due to
protocol treatment)
Due To This Disease (Due to this
disease)
Not Applicable (Not applicable)
Unknown (Unknown)
Due to other cause, specify
Has the patient had a documented clinical
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assessment for this cancer (SINCE
SUBMISSION OF THE PREVIOUS FOLLOW-UP
FORM)
No (No)
Unknown (Unknown)
Yes (Yes)
Date
Performance Status (ZUBROD 0-5, 9-
UNKNOWN)
Fully Active, Able To Carry On All Pre-
disease Performance Without
Restriction. (0)
Restricted In Physically Strenuous
Activity But Ambulatory And Able To
Carry Out Work Of A Light Or Sedentary
Nature, E.g., Light Housework, Office
Work. (1)
Ambulatory And Capable Of All Selfcare
But Unable To Carry Out Any Work
Activities. Up And About More Than 50%
Of Waking Hours. (2)
Capable Of Only Limited Selfcare,
Confined To Bed Or Chair More Than
50% Of Waking Hours. (3)
Completely Disabled. Cannot Carry On
Any Selfcare. Totally Confined To Bed Or
Chair. (4)
Dead (5)
Mark an 'X' if unknown
Unnamed Module 6
Has the patient had a prostate biopsy (SINCE
SUBMISSION OF THE LAST FOLLOW-UP
FORM)
No (No)
Unknown (Unknown)
Yes, Negative (Yes, negative)
Yes, Positive (Yes, positive)
Yes, Results Unknown (Yes, results
unknown)
Biopsy Date
Is the tumor palpable
Equivocal (Equivocal)
No (No)
Not Evaluated (Not evaluated)
Unknown (Unknown)
Yes (Yes)
Unnamed Module 5
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Has the patient been diagnosed with biochemical
recurrence since submission of the last follow-up
form
No (NO)
Unknown (Unknown)
Yes (YES)
Has the patient been diagnosed with a first local
recurrence (SINCE SUBMISSION OF LAST
FOLLOW-UP FORM See Protocol Section 11)
No (NO)
Unknown (Unknown)
Yes (YES)
Date
Method of Evaluation (DISTANT
PROGRESSION)
Mri (MRI (NMR))
Not Applicable (Not applicable)
Other (Other)
Pathologic (Pathologic)
Physical Exam (Physical exam)
Radiographic (Radiographic)
Method of Evaluation (DISTANT
PROGRESSION)
Mri (MRI (NMR))
Not Applicable (Not applicable)
Other (Other)
Pathologic (Pathologic)
Physical Exam (Physical exam)
Radiographic (Radiographic)
Has the patient been diagnosed with first distant
progression (SINCE SUBMISSION OF THE
LAST FOLLOW-UP FORM)
No (No)
Unknown (Unknown)
Yes (Yes)
Date
Sites of Progression (First distant)
Other Specify
Other Specify
Baseline Lab Values (hematologic)
Fasting glucose
No (no)
Unknown (unknown)
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Yes (yes)
Date
Fasting glucose (mg/dL)
Fasting glucose, LLN
Fasting glucose, ULN
Fasting Lipid Panel
Fasting lipids
No (No)
Unknown (Unknown)
Yes (Yes)
Date
Cholesterol (mg/dL)
Cholesterol LLN
Cholesterol ULN
HDL (mg/dL)
HDL LLN
HDL ULN
LDL (mg/dL)
LDL LLN
LDL ULN
Triglycerides (mg/dL)
Triglycerides LLN
Triglycerides ULN
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Hemoglobin A1 C (%)
Hemoglobin A1C (%)
No (No)
Unknown (Unknown)
Yes (Yes)
Hemogloblin A1C
Hemoglobin A1C LLN
Hemoglobin A1C ULN
Serum Testosterone
Serum testosterone
No (No)
Unknown (Unknown)
Yes (Yes)
Date
Testosterone
Testosterone LLN
Testosterone ULN
Units
Micrograms Per Liter (mcg/L)
N/milligram (n/mg)
Nanograms Per Deciliter (ng/dL)
Nanograms Per Milliliter (ng/mL)
Not Otherwise Specified (NOS)
Units Per Liter (U/L)
Unnamed Module 4a
PSA Date (s)
PSA Value (s)
Method of Assay
Abbott Labs (Abbott)
Bayer (Bayer)
Dpc (DPC)
Hybritech (Hybritech)
Other (Other)
Unknown (Unknown)
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Units
Micrograms Per Liter (mcg/L)
N/milligram (n/mg)
Nanograms Per Deciliter (ng/dL)
Nanograms Per Milliliter (ng/mL)
Not Otherwise Specified (NOS)
Units Per Liter (U/L)
Non-protocol Therapy
Is the patient receiving any non-protocol cancer
therapy not previously reported (PROSTATE If
yes, enter therapy type and date for each therapy
delivered during the follow-up period.)
No (No)
Unknown (Unknown)
Yes (Yes)
Non-Protocol Therapy Type
Chemotherapy (Chemotherapy)
Hormones (Hormones)
Other Specify (Other)
Radiation To Other Sites, Specify
(Radiation to other sites)
Radiation To Pelvis (Radiation to pelvis)
Surgery (Surgery)
Date of First Non-Protocol Therapy
Specify
Unnamed Module 7
Has a new primary cancer or MDS been
diagnosed that has not been previously reported?
(MYELODYSPLASTIC SYNDROME)
No (No)
Unknown (Unknown)
Yes (Yes)
Second Primary Tumor Site
Aml/mds (AML/MDS)
Bcc (BCC)
Bladder Is The Site Of Second Primary
Or Recurrent Tumor (bladder)
Brain Is The Site Of Second Primary Or
Recurrent Tumor (brain)
Colorectal (Colorectal)
Esophageal (Esophageal)
Gastric (Gastric)
Liver Is The Site Of Second Primary Or
Recurrent Tumor (liver)
Lung Is The Site Of Second Primary Or
Recurrent Tumor (lung)
Melanoma (Melanoma)
Nhl (NHL)
Other Hematologic (Other hematologic)
6 / 28
Prostate Cancer NCT01546987 Follow-Up - RTOG 1115 F1: Phase III RT +
Standard ADT vs RT + Enhanced ADT + TAK-700 Follow-Up Form - 3289581v1.0
Other Solid (Other solid)
Pancreatic (Pancreatic)
Renal (Renal)
Squamous-skin (Squamous-skin)
Unknown Primary (Unknown primary)
Second Primary Cancer Date
Other specify
Patient Evaluations
Weight (kg)
Date
Survivorship
Diabetes Mellitus
No (No)
Unknown (Unknown)
Yes (Yes)
Coronary Artery Disease
No (No)
Unknown (Unknown)
Yes (Yes)
Myocardial infarction
No (No)
Unknown (Unknown)
Yes (Yes)
Stroke
No (No)
Unknown (Unknown)
Yes (Yes)
Pulmonary embolism
No (No)
Unknown (Unknown)
Yes (Yes)
Deep vein thrombosis
No (No)
Unknown (Unknown)
Yes (Yes)
Osteoporotic fracture
No (No)
Unknown (Unknown)
Yes (Yes)
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Concomitant Medications
Any changes in medication
No (No)
Unknown (Unknown)
Yes (Yes)
Medication
Dose
Change in medication
Addition (Addition)
Discontinued (Discontinued)
Lower Dose (Dose decrease)
Dose Increased (Dose increase)
Other (Other change)
Specify
Protocol Specific Adverse Event
Evaluation
Any Treatment Related Adverse Events
No (No)
Unknown (Unknown)
Yes (Yes)
MedDRA Disease Code
CTC Adverse Event Term
Abdominal Distension (Abdominal
distension)
Abdominal Infection (Abdominal
infection)
Abdominal Pain (Abdominal pain)
Abdominal Soft Tissue Necrosis
(Abdominal soft tissue necrosis)
Abducens Nerve Disorder (Abducens
nerve disorder)
Accessory Nerve Disorder (Accessory
nerve disorder)
Acidosis (Acidosis)
Acoustic Nerve Disorder Nos (Acoustic
nerve disorder NOS)
Activated Partial Thromboplastin Time
Prolonged (Activated partial
thromboplastin time prolonged)
Acute Coronary Syndrome (Acute
coronary syndrome)
Acute Kidney Injury (Acute kidney injury)
Adrenal Insufficiency (Adrenal
insufficiency)
Adult Respiratory Distress Syndrome
(Adult respiratory distress syndrome)
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Agitation (Agitation)
Akathisia (Akathisia)
Alanine Aminotransferase Increased
(Alanine aminotransferase increased)
Alcohol Intolerance (Alcohol intolerance)
Alkaline Phosphatase Increased
(Alkaline phosphatase increased)
Alkalosis (Alkalosis)
Allergic Reaction (Allergic reaction)
Allergic Rhinitis (Allergic rhinitis)
Alopecia (Alopecia)
Amnesia (Amnesia)
Anal Fistula (Anal fistula)
Anal Hemorrhage (Anal hemorrhage)
Anal Mucositis (Anal mucositis)
Anal Necrosis (Anal necrosis)
Anal Pain (Anal pain)
Anal Stenosis (Anal stenosis)
Anal Ulcer (Anal ulcer)
Anaphylaxis (Anaphylaxis)
Anemia (Anemia)
Ankle Fracture (Ankle fracture)
Anorectal Infection (Anorectal infection)
Anorexia (Anorexia)
Anorgasmia (Anorgasmia)
Anxiety (Anxiety)
Aortic Injury (Aortic injury)
Aortic Valve Disease (Aortic valve
disease)
Aphonia (Aphonia)
Apnea (Apnea)
Appendicitis (Appendicitis)
Appendicitis Perforated (Appendicitis
perforated)
Arachnoiditis (Arachnoiditis)
Arterial Injury (Arterial injury)
Arteritis Infective (Arteritis infective)
Arthralgia (Arthralgia)
Arthritis (Arthritis)
Ascites (Ascites)
Aspartate Aminotransferase Increased
(Aspartate aminotransferase increased)
Aspiration (Aspiration)
Asystole (Asystole)
Ataxia (Ataxia)
Atelectasis (Atelectasis)
Atrial Fibrillation (Atrial fibrillation)
Atrial Flutter (Atrial flutter)
Atrioventricular Block Complete
(Atrioventricular block complete)
Atrioventricular Block First Degree
(Atrioventricular block first degree)
Autoimmune Disorder (Autoimmune
disorder)
Avascular Necrosis (Avascular necrosis)
Azoospermia (Azoospermia)
Back Pain (Back pain)
Bile Duct Stenosis (Bile duct stenosis)
Biliary Anastomotic Leak (Biliary
anastomotic leak)
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Biliary Fistula (Biliary fistula)
Biliary Tract Infection (Biliary tract
infection)
Bladder Anastomotic Leak (Bladder
anastomotic leak)
Bladder Infection (Bladder infection)
Bladder Perforation (Bladder perforation)
Bladder Spasm (Bladder spasm)
Bloating (Bloating)
Blood And Lymphatic System Disorders -
Other, Specify (Blood and lymphatic
system disorders - Other, Specify)
Blood Antidiuretic Hormone Abnormal
(Blood antidiuretic hormone abnormal)
Blood Bilirubin Increased (Blood bilirubin
increased)
Blood Corticotrophin Decreased (Blood
corticotrophin decreased)
Blood Gonadotrophin Abnormal (Blood
gonadotrophin abnormal)
Blood Prolactin Abnormal (Blood
prolactin abnormal)
Blurred Vision (Blurred vision)
Body Odor (Body odor)
Bone Infection (Bone infection)
Bone Marrow Hypocellular (Bone
marrow hypocellular)
Bone Pain (Bone pain)
Brachial Plexopathy (Brachial
plexopathy)
Breast Atrophy (Breast atrophy)
Breast Infection (Breast infection)
Breast Pain (Breast pain)
Bronchial Fistula (Bronchial fistula)
Bronchial Infection (Bronchial infection)
Bronchial Obstruction (Bronchial
obstruction)
Bronchial Stricture (Bronchial stricture)
Bronchopleural Fistula (Bronchopleural
fistula)
Bronchopulmonary Hemorrhage
(Bronchopulmonary hemorrhage)
Bronchospasm (Bronchospasm)
Bruising (Bruising)
Bullous Dermatitis (Bullous dermatitis)
Burn (Burn)
Buttock Pain (Buttock pain)
Capillary Leak Syndrome (Capillary leak
syndrome)
Carbon Monoxide Diffusing Capacity
Decreased (Carbon monoxide diffusing
capacity decreased)
Cardiac Arrest (Cardiac arrest)
Cardiac Disorders - Other, Specify
(Cardiac disorders - Other, Specify)
Cardiac Troponin I Increased (Cardiac
troponin I increased)
Cardiac Troponin T Increased (Cardiac
troponin T increased)
Cataract (Cataract)
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Catheter Related Infection (Catheter
related infection)
Cd4 Lymphocytes Decreased (CD4
lymphocytes decreased)
Cecal Hemorrhage (Cecal hemorrhage)
Cecal Infection (Cecal infection)
Central Nervous System Necrosis
(Central nervous system necrosis)
Cerebrospinal Fluid Leakage
(Cerebrospinal fluid leakage)
Cervicitis Infection (Cervicitis infection)
Cheilitis (Cheilitis)
Chest Pain - Cardiac (Chest pain -
cardiac)
Chest Wall Pain (Chest wall pain)
Chills (Chills)
Cholecystitis (Cholecystitis)
Cholesterol High (Cholesterol high)
Chronic Kidney Disease (Chronic kidney
disease)
Chylothorax (Chylothorax)
Cognitive Disturbance (Cognitive
disturbance)
Colitis (Colitis)
Colonic Fistula (Colonic fistula)
Colonic Hemorrhage (Colonic
hemorrhage)
Colonic Obstruction (Colonic obstruction)
Colonic Perforation (Colonic perforation)
Colonic Stenosis (Colonic stenosis)
Colonic Ulcer (Colonic ulcer)
Concentration Impairment
(Concentration impairment)
Conduction Disorder (Conduction
disorder)
Confusion (Confusion)
Congenital, Familial And Genetic
Disorders - Other, Specify (Congenital,
familial and genetic disorders - Other,
Specify)
Conjunctivitis (Conjunctivitis)
Conjunctivitis Infective (Conjunctivitis
infective)
Constipation (Constipation)
Constrictive Pericarditis (Constrictive
pericarditis)
Corneal Infection (Corneal infection)
Corneal Ulcer (Corneal ulcer)
Cough (Cough)
Cpk Increased (CPK increased)
Cranial Nerve Infection (Cranial nerve
infection)
Creatinine Increased (Creatinine
increased)
Cushingoid (Cushingoid)
Cystitis Noninfective (Cystitis
noninfective)
Cytokine Release Syndrome (Cytokine
release syndrome)
Death Neonatal (Death neonatal)
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Death Nos (Death NOS)
Dehydration (Dehydration)
Delayed Orgasm (Delayed orgasm)
Delayed Puberty (Delayed puberty)
Delirium (Delirium)
Delusions (Delusions)
Dental Caries (Dental caries)
Depressed Level Of Consciousness
(Depressed level of consciousness)
Depression (Depression)
Dermatitis Radiation (Dermatitis
radiation)
Device Related Infection (Device related
infection)
Diarrhea (Diarrhea)
Disseminated Intravascular Coagulation
(Disseminated intravascular coagulation)
Dizziness (Dizziness)
Dry Eye (Dry eye)
Dry Mouth (Dry mouth)
Dry Skin (Dry skin)
Duodenal Fistula (Duodenal fistula)
Duodenal Hemorrhage (Duodenal
hemorrhage)
Duodenal Infection (Duodenal infection)
Duodenal Obstruction (Duodenal
obstruction)
Duodenal Perforation (Duodenal
perforation)
Duodenal Stenosis (Duodenal stenosis)
Duodenal Ulcer (Duodenal ulcer)
Dysarthria (Dysarthria)
Dysesthesia (Dysesthesia)
Dysgeusia (Dysgeusia)
Dysmenorrhea (Dysmenorrhea)
Dyspareunia (Dyspareunia)
Dyspepsia (Dyspepsia)
Dysphagia (Dysphagia)
Dysphasia (Dysphasia)
Dyspnea (Dyspnea)
Ear And Labyrinth Disorders - Other,
Specify (Ear and labyrinth disorders -
Other, Specify)
Ear Pain (Ear pain)
Edema Cerebral (Edema cerebral)
Edema Face (Edema face)
Edema Limbs (Edema limbs)
Edema Trunk (Edema trunk)
Ejaculation Disorder (Ejaculation
disorder)
Ejection Fraction Decreased (Ejection
fraction decreased)
Electrocardiogram Qt Corrected Interval
Prolonged (Electrocardiogram QT
corrected interval prolonged)
Encephalitis Infection (Encephalitis
infection)
Encephalomyelitis Infection
(Encephalomyelitis infection)
Encephalopathy (Encephalopathy)
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Endocarditis Infective (Endocarditis
infective)
Endocrine Disorders - Other, Specify
(Endocrine disorders - Other, Specify)
Endophthalmitis (Endophthalmitis)
Enterocolitis (Enterocolitis)
Enterocolitis Infectious (Enterocolitis
infectious)
Enterovesical Fistula (Enterovesical
fistula)
Epistaxis (Epistaxis)
Erectile Dysfunction (Erectile
dysfunction)
Erythema Multiforme (Erythema
multiforme)
Erythroderma (Erythroderma)
Esophageal Anastomotic Leak
(Esophageal anastomotic leak)
Esophageal Fistula (Esophageal fistula)
Esophageal Hemorrhage (Esophageal
hemorrhage)
Esophageal Infection (Esophageal
infection)
Esophageal Necrosis (Esophageal
necrosis)
Esophageal Obstruction (Esophageal
obstruction)
Esophageal Pain (Esophageal pain)
Esophageal Perforation (Esophageal
perforation)
Esophageal Stenosis (Esophageal
stenosis)
Esophageal Ulcer (Esophageal ulcer)
Esophageal Varices Hemorrhage
(Esophageal varices hemorrhage)
Esophagitis (Esophagitis)
Euphoria (Euphoria)
Exostosis (Exostosis)
External Ear Inflammation (External ear
inflammation)
External Ear Pain (External ear pain)
Extraocular Muscle Paresis (Extraocular
muscle paresis)
Extrapyramidal Disorder (Extrapyramidal
disorder)
Eye Disorders - Other, Specify (Eye
disorders - Other, Specify)
Eye Infection (Eye infection)
Eye Pain (Eye pain)
Eyelid Function Disorder (Eyelid function
disorder)
Facial Muscle Weakness (Facial muscle
weakness)
Facial Nerve Disorder (Facial nerve
disorder)
Facial Pain (Facial pain)
Fall (Fall)
Fallopian Tube Anastomotic Leak
(Fallopian tube anastomotic leak)
Fallopian Tube Obstruction (Fallopian
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tube obstruction)
Fallopian Tube Perforation (Fallopian
tube perforation)
Fallopian Tube Stenosis (Fallopian tube
stenosis)
Fat Atrophy (Fat atrophy)
Fatigue (Fatigue)
Febrile Neutropenia (Febrile
neutropenia)
Fecal Incontinence (Fecal incontinence)
Female Genital Tract Fistula (Female
genital tract fistula)
Feminization Acquired (Feminization
acquired)
Fetal Death (Fetal death)
Fetal Growth Retardation (Fetal growth
retardation)
Fever (Fever)
Fibrinogen Decreased (Fibrinogen
decreased)
Fibrosis Deep Connective Tissue
(Fibrosis deep connective tissue)
Flank Pain (Flank pain)
Flashing Lights (Flashing lights)
Flatulence (Flatulence)
Floaters (Floaters)
Flu Like Symptoms (Flu like symptoms)
Flushing (Flushing)
Forced Expiratory Volume Decreased
(Forced expiratory volume decreased)
Fracture (Fracture)
Gait Disturbance (Gait disturbance)
Gallbladder Fistula (Gallbladder fistula)
Gallbladder Infection (Gallbladder
infection)
Gallbladder Necrosis (Gallbladder
necrosis)
Gallbladder Obstruction (Gallbladder
obstruction)
Gallbladder Pain (Gallbladder pain)
Gallbladder Perforation (Gallbladder
perforation)
Gastric Anastomotic Leak (Gastric
anastomotic leak)
Gastric Fistula (Gastric fistula)
Gastric Hemorrhage (Gastric
hemorrhage)
Gastric Necrosis (Gastric necrosis)
Gastric Perforation (Gastric perforation)
Gastric Stenosis (Gastric stenosis)
Gastric Ulcer (Gastric ulcer)
Gastritis (Gastritis)
Gastroesophageal Reflux Disease
(Gastroesophageal reflux disease)
Gastrointestinal Anastomotic Leak
(Gastrointestinal anastomotic leak)
Gastrointestinal Disorders - Other,
Specify (Gastrointestinal disorders -
Other, Specify)
Gastrointestinal Fistula (Gastrointestinal
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fistula)
Gastrointestinal Pain (Gastrointestinal
pain)
Gastrointestinal Stoma Necrosis
(Gastrointestinal stoma necrosis)
Gastroparesis (Gastroparesis)
General Disorders And Administration
Site Conditions - Other, Specify (General
disorders and administration site
conditions - Other, Specify)
Generalized Muscle Weakness
(Generalized muscle weakness)
Genital Edema (Genital edema)
Ggt Increased (GGT increased)
Gingival Pain (Gingival pain)
Glaucoma (Glaucoma)
Glossopharyngeal Nerve Disorder
(Glossopharyngeal nerve disorder)
Glucose Intolerance (Glucose
intolerance)
Growth Accelerated (Growth
accelerated)
Growth Hormone Abnormal (Growth
hormone abnormal)
Growth Suppression (Growth
suppression)
Gum Infection (Gum infection)
Gynecomastia (Gynecomastia)
Hallucinations (Hallucinations)
Haptoglobin Decreased (Haptoglobin
decreased)
Head Soft Tissue Necrosis (Head soft
tissue necrosis)
Headache (Headache)
Hearing Impaired (Hearing impaired)
Heart Failure (Heart failure)
Hematoma (Hematoma)
Hematosalpinx (Hematosalpinx)
Hematuria (Hematuria)
Hemoglobin Increased (Hemoglobin
increased)
Hemoglobinuria (Hemoglobinuria)
Hemolysis (Hemolysis)
Hemolytic Uremic Syndrome (Hemolytic
uremic syndrome)
Hemorrhoidal Hemorrhage
(Hemorrhoidal hemorrhage)
Hemorrhoids (Hemorrhoids)
Hepatic Failure (Hepatic failure)
Hepatic Hemorrhage (Hepatic
hemorrhage)
Hepatic Infection (Hepatic infection)
Hepatic Necrosis (Hepatic necrosis)
Hepatic Pain (Hepatic pain)
Hepatitis Viral (Hepatitis viral)
Hepatobiliary Disorders - Other, Specify
(Hepatobiliary disorders - Other, Specify)
Hiccups (Hiccups)
Hip Fracture (Hip fracture)
Hirsutism (Hirsutism)
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Hoarseness (Hoarseness)
Hot Flashes (Hot flashes)
Hydrocephalus (Hydrocephalus)
Hypercalcemia (Hypercalcemia)
Hyperglycemia (Hyperglycemia)
Hyperhidrosis (Hyperhidrosis)
Hyperkalemia (Hyperkalemia)
Hypermagnesemia (Hypermagnesemia)
Hypernatremia (Hypernatremia)
Hyperparathyroidism
(Hyperparathyroidism)
Hypersomnia (Hypersomnia)
Hypertension (Hypertension)
Hyperthyroidism (Hyperthyroidism)
Hypertrichosis (Hypertrichosis)
Hypertriglyceridemia
(Hypertriglyceridemia)
Hyperuricemia (Hyperuricemia)
Hypoalbuminemia (Hypoalbuminemia)
Hypocalcemia (Hypocalcemia)
Hypoglossal Nerve Disorder
(Hypoglossal nerve disorder)
Hypoglycemia (Hypoglycemia)
Hypohidrosis (Hypohidrosis)
Hypokalemia (Hypokalemia)
Hypomagnesemia (Hypomagnesemia)
Hyponatremia (Hyponatremia)
Hypoparathyroidism
(Hypoparathyroidism)
Hypophosphatemia (Hypophosphatemia)
Hypotension (Hypotension)
Hypothermia (Hypothermia)
Hypothyroidism (Hypothyroidism)
Hypoxia (Hypoxia)
Ileal Fistula (Ileal fistula)
Ileal Hemorrhage (Ileal hemorrhage)
Ileal Obstruction (Ileal obstruction)
Ileal Perforation (Ileal perforation)
Ileal Stenosis (Ileal stenosis)
Ileal Ulcer (Ileal ulcer)
Ileus (Ileus)
Immune System Disorders - Other,
Specify (Immune system disorders -
Other, Specify)
Infections And Infestations - Other,
Specify (Infections and infestations -
Other, Specify)
Infective Myositis (Infective myositis)
Infusion Related Reaction (Infusion
related reaction)
Infusion Site Extravasation (Infusion site
extravasation)
Injection Site Reaction (Injection site
reaction)
Injury To Carotid Artery (Injury to carotid
artery)
Injury To Inferior Vena Cava (Injury to
inferior vena cava)
Injury To Jugular Vein (Injury to jugular
vein)
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Injury To Superior Vena Cava (Injury to
superior vena cava)
Injury, Poisoning And Procedural
Complications - Other, Specify (Injury,
poisoning and procedural complications -
Other, Specify)
Inr Increased (INR increased)
Insomnia (Insomnia)
Intestinal Stoma Leak (Intestinal stoma
leak)
Intestinal Stoma Obstruction (Intestinal
stoma obstruction)
Intestinal Stoma Site Bleeding (Intestinal
stoma site bleeding)
Intra-abdominal Hemorrhage (Intra-
abdominal hemorrhage)
Intracranial Hemorrhage (Intracranial
hemorrhage)
Intraoperative Arterial Injury
(Intraoperative arterial injury)
Intraoperative Breast Injury
(Intraoperative breast injury)
Intraoperative Cardiac Injury
(Intraoperative cardiac injury)
Intraoperative Ear Injury (Intraoperative
ear injury)
Intraoperative Endocrine Injury
(Intraoperative endocrine injury)
Intraoperative Gastrointestinal Injury
(Intraoperative gastrointestinal injury)
Intraoperative Head And Neck Injury
(Intraoperative head and neck injury)
Intraoperative Hemorrhage
(Intraoperative hemorrhage)
Intraoperative Hepatobiliary Injury
(Intraoperative hepatobiliary injury)
Intraoperative Musculoskeletal Injury
(Intraoperative musculoskeletal injury)
Intraoperative Neurological Injury
(Intraoperative neurological injury)
Intraoperative Ocular Injury
(Intraoperative ocular injury)
Intraoperative Renal Injury
(Intraoperative renal injury)
Intraoperative Reproductive Tract Injury
(Intraoperative reproductive tract injury)
Intraoperative Respiratory Injury
(Intraoperative respiratory injury)
Intraoperative Skin Injury (Intraoperative
skin injury)
Intraoperative Splenic Injury
(Intraoperative splenic injury)
Intraoperative Urinary Injury
(Intraoperative urinary injury)
Intraoperative Venous Injury
(Intraoperative venous injury)
Investigations - Other, Specify
(Investigations - Other, Specify)
Iron Overload (Iron overload)
Irregular Menstruation (Irregular
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menstruation)
Irritability (Irritability)
Ischemia Cerebrovascular (Ischemia
cerebrovascular)
Ivth Nerve Disorder (IVth nerve disorder)
Jejunal Fistula (Jejunal fistula)
Jejunal Hemorrhage (Jejunal
hemorrhage)
Jejunal Obstruction (Jejunal obstruction)
Jejunal Perforation (Jejunal perforation)
Jejunal Stenosis (Jejunal stenosis)
Jejunal Ulcer (Jejunal ulcer)
Joint Effusion (Joint effusion)
Joint Infection (Joint infection)
Joint Range Of Motion Decreased (Joint
range of motion decreased)
Joint Range Of Motion Decreased
Cervical Spine (Joint range of motion
decreased cervical spine)
Joint Range Of Motion Decreased
Lumbar Spine (Joint range of motion
decreased lumbar spine)
Keratitis (Keratitis)
Kidney Anastomotic Leak (Kidney
anastomotic leak)
Kidney Infection (Kidney infection)
Kyphosis (Kyphosis)
Lactation Disorder (Lactation disorder)
Large Intestinal Anastomotic Leak (Large
intestinal anastomotic leak)
Laryngeal Edema (Laryngeal edema)
Laryngeal Fistula (Laryngeal fistula)
Laryngeal Hemorrhage (Laryngeal
hemorrhage)
Laryngeal Inflammation (Laryngeal
inflammation)
Laryngeal Mucositis (Laryngeal
mucositis)
Laryngeal Obstruction (Laryngeal
obstruction)
Laryngeal Stenosis (Laryngeal stenosis)
Laryngitis (Laryngitis)
Laryngopharyngeal Dysesthesia
(Laryngopharyngeal dysesthesia)
Laryngospasm (Laryngospasm)
Left Ventricular Systolic Dysfunction (Left
ventricular systolic dysfunction)
Lethargy (Lethargy)
Leukemia Secondary To Oncology
Chemotherapy (Leukemia secondary to
oncology chemotherapy)
Leukocytosis (Leukocytosis)
Leukoencephalopathy
(Leukoencephalopathy)
Libido Decreased (Libido decreased)
Libido Increased (Libido increased)
Lip Infection (Lip infection)
Lip Pain (Lip pain)
Lipase Increased (Lipase increased)
Lipohypertrophy (Lipohypertrophy)
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Localized Edema (Localized edema)
Lordosis (Lordosis)
Lower Gastrointestinal Hemorrhage
(Lower gastrointestinal hemorrhage)
Lung Infection (Lung infection)
Lymph Gland Infection (Lymph gland
infection)
Lymph Leakage (Lymph leakage)
Lymph Node Pain (Lymph node pain)
Lymphedema (Lymphedema)
Lymphocele (Lymphocele)
Lymphocyte Count Decreased
(Lymphocyte count decreased)
Lymphocyte Count Increased
(Lymphocyte count increased)
Malabsorption (Malabsorption)
Malaise (Malaise)
Mania (Mania)
Mediastinal Hemorrhage (Mediastinal
hemorrhage)
Mediastinal Infection (Mediastinal
infection)
Memory Impairment (Memory
impairment)
Meningismus (Meningismus)
Meningitis (Meningitis)
Menopause (Menopause)
Menorrhagia (Menorrhagia)
Metabolism And Nutrition Disorders -
Other, Specify (Metabolism and nutrition
disorders - Other, Specify)
Middle Ear Inflammation (Middle ear
inflammation)
Mitral Valve Disease (Mitral valve
disease)
Mobitz (type) Ii Atrioventricular Block
(Mobitz (type) II atrioventricular block)
Mobitz Type I (Mobitz type I)
Movements Involuntary (Movements
involuntary)
Mucosal Infection (Mucosal infection)
Mucositis Oral (Mucositis oral)
Multi-organ Failure (Multi-organ failure)
Muscle Weakness Left-sided (Muscle
weakness left-sided)
Muscle Weakness Lower Limb (Muscle
weakness lower limb)
Muscle Weakness Right-sided (Muscle
weakness right-sided)
Muscle Weakness Trunk (Muscle
weakness trunk)
Muscle Weakness Upper Limb (Muscle
weakness upper limb)
Musculoskeletal And Connective Tissue
Disorder - Other, Specify
(Musculoskeletal and connective tissue
disorders - Other, Specify)
Musculoskeletal Deformity
(Musculoskeletal deformity)
Myalgia (Myalgia)
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Myelitis (Myelitis)
Myelodysplastic Syndrome
(Myelodysplastic syndrome)
Myocardial Infarction (Myocardial
infarction)
Myocarditis (Myocarditis)
Myositis (Myositis)
Nail Discoloration (Nail discoloration)
Nail Infection (Nail infection)
Nail Loss (Nail loss)
Nail Ridging (Nail ridging)
Nasal Congestion (Nasal congestion)
Nausea (Nausea)
Neck Edema (Neck edema)
Neck Pain (Neck pain)
Neck Soft Tissue Necrosis (Neck soft
tissue necrosis)
Neoplasms Benign, Malignant And
Unspecified (incl Cysts And Polyps) -
Other, Specify (Neoplasms benign,
malignant and unspecified (incl cysts and
polyps) - Other, Specify)
Nervous System Disorders - Other,
Specify (Nervous system disorders -
Other, Specify)
Neuralgia (Neuralgia)
Neutrophil Count Decreased (Neutrophil
count decreased)
Night Blindness (Night blindness)
Nipple Deformity (Nipple deformity)
Non-cardiac Chest Pain (Non-cardiac
chest pain)
Nystagmus (Nystagmus)
Obesity (Obesity)
Obstruction Gastric (Obstruction gastric)
Oculomotor Nerve Disorder (Oculomotor
nerve disorder)
Olfactory Nerve Disorder (Olfactory
nerve disorder)
Oligospermia (Oligospermia)
Optic Nerve Disorder (Optic nerve
disorder)
Oral Cavity Fistula (Oral cavity fistula)
Oral Dysesthesia (Oral dysesthesia)
Oral Hemorrhage (Oral hemorrhage)
Oral Pain (Oral pain)
Osteonecrosis Of Jaw (Osteonecrosis of
jaw)
Osteoporosis (Osteoporosis)
Otitis Externa (Otitis externa)
Otitis Media (Otitis media)
Ovarian Hemorrhage (Ovarian
hemorrhage)
Ovarian Infection (Ovarian infection)
Ovarian Rupture (Ovarian rupture)
Ovulation Pain (Ovulation pain)
Pain (Pain)
Pain In Extremity (Pain in extremity)
Pain Of Skin (Pain of skin)
Palmar-plantar Erythrodysesthesia
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Syndrome (Palmar-plantar
erythrodysesthesia syndrome)
Palpitations (Palpitations)
Pancreas Infection (Pancreas infection)
Pancreatic Anastomotic Leak (Pancreatic
anastomotic leak)
Pancreatic Duct Stenosis (Pancreatic
duct stenosis)
Pancreatic Enzymes Decreased
(Pancreatic enzymes decreased)
Pancreatic Fistula (Pancreatic fistula)
Pancreatic Hemorrhage (Pancreatic
hemorrhage)
Pancreatic Necrosis (Pancreatic
necrosis)
Pancreatitis (Pancreatitis)
Papilledema (Papilledema)
Papulopustular Rash (Papulopustular
rash)
Paresthesia (Paresthesia)
Paronychia (Paronychia)
Paroxysmal Atrial Tachycardia
(Paroxysmal atrial tachycardia)
Pelvic Floor Muscle Weakness (Pelvic
floor muscle weakness)
Pelvic Infection (Pelvic infection)
Pelvic Pain (Pelvic pain)
Pelvic Soft Tissue Necrosis (Pelvic soft
tissue necrosis)
Penile Infection (Penile infection)
Penile Pain (Penile pain)
Perforation Bile Duct (Perforation bile
duct)
Pericardial Effusion (Pericardial effusion)
Pericardial Tamponade (Pericardial
tamponade)
Pericarditis (Pericarditis)
Perineal Pain (Perineal pain)
Periodontal Disease (Periodontal
disease)
Periorbital Edema (Periorbital edema)
Periorbital Infection (Periorbital infection)
Peripheral Ischemia (Peripheral
ischemia)
Peripheral Motor Neuropathy (Peripheral
motor neuropathy)
Peripheral Nerve Infection (Peripheral
nerve infection)
Peripheral Sensory Neuropathy
(Peripheral sensory neuropathy)
Peritoneal Infection (Peritoneal infection)
Peritoneal Necrosis (Peritoneal necrosis)
Personality Change (Personality change)
Phantom Pain (Phantom pain)
Pharyngeal Anastomotic Leak
(Pharyngeal anastomotic leak)
Pharyngeal Fistula (Pharyngeal fistula)
Pharyngeal Hemorrhage (Pharyngeal
hemorrhage)
Pharyngeal Mucositis (Pharyngeal
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mucositis)
Pharyngeal Necrosis (Pharyngeal
necrosis)
Pharyngeal Stenosis (Pharyngeal
stenosis)
Pharyngitis (Pharyngitis)
Pharyngolaryngeal Pain
(Pharyngolaryngeal pain)
Phlebitis (Phlebitis)
Phlebitis Infective (Phlebitis infective)
Photophobia (Photophobia)
Photosensitivity (Photosensitivity)
Platelet Count Decreased (Platelet count
decreased)
Pleural Effusion (Pleural effusion)
Pleural Hemorrhage (Pleural
hemorrhage)
Pleural Infection (Pleural infection)
Pleuritic Pain (Pleuritic pain)
Pneumonitis (Pneumonitis)
Pneumothorax (Pneumothorax)
Portal Hypertension (Portal
hypertension)
Portal Vein Thrombosis (Portal vein
thrombosis)
Postnasal Drip (Postnasal drip)
Postoperative Hemorrhage
(Postoperative hemorrhage)
Postoperative Thoracic Procedure
Complication (Postoperative thoracic
procedure complication)
Precocious Puberty (Precocious
puberty)
Pregnancy, Puerperium And Perinatal
Conditions - Other, Specify (Pregnancy,
puerperium and perinatal conditions -
Other, Specify)
Premature Delivery (Premature delivery)
Premature Menopause (Premature
menopause)
Presyncope (Presyncope)
Proctitis (Proctitis)
Productive Cough (Productive cough)
Prolapse Of Intestinal Stoma (Prolapse
of intestinal stoma)
Prolapse Of Urostomy (Prolapse of
urostomy)
Prostate Infection (Prostate infection)
Prostatic Hemorrhage (Prostatic
hemorrhage)
Prostatic Obstruction (Prostatic
obstruction)
Prostatic Pain (Prostatic pain)
Proteinuria (Proteinuria)
Pruritus (Pruritus)
Psychiatric Disorders - Other, Specify
(Psychiatric disorders - Other, Specify)
Psychosis (Psychosis)
Pulmonary Edema (Pulmonary edema)
Pulmonary Fibrosis (Pulmonary fibrosis)
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Pulmonary Fistula (Pulmonary fistula)
Pulmonary Hypertension (Pulmonary
hypertension)
Pulmonary Valve Disease (Pulmonary
valve disease)
Purpura (Purpura)
Pyramidal Tract Syndrome (Pyramidal
tract syndrome)
Radiation Recall Reaction (dermatologic)
(Radiation recall reaction (dermatologic))
Radiculitis (Radiculitis)
Rash Acneiform (Rash acneiform)
Rash Maculo-papular (Rash maculo-
papular)
Rash Pustular (Rash pustular)
Rectal Anastomotic Leak (Rectal
anastomotic leak)
Rectal Fistula (Rectal fistula)
Rectal Hemorrhage (Rectal hemorrhage)
Rectal Mucositis (Rectal mucositis)
Rectal Necrosis (Rectal necrosis)
Rectal Obstruction (Rectal obstruction)
Rectal Pain (Rectal pain)
Rectal Perforation (Rectal perforation)
Rectal Stenosis (Rectal stenosis)
Rectal Ulcer (Rectal ulcer)
Recurrent Laryngeal Nerve Palsy
(Recurrent laryngeal nerve palsy)
Renal And Urinary Disorders - Other,
Specify (Renal and urinary disorders -
Other, Specify)
Renal Calculi (Renal calculi)
Renal Colic (Renal colic)
Renal Hemorrhage (Renal hemorrhage)
Reproductive System And Breast
Disorders - Other, Specify (Reproductive
system and breast disorders - Other,
Specify)
Respiratory Failure (Respiratory failure)
Respiratory, Thoracic And Mediastinal
Disorders - Other, Specify (Respiratory,
thoracic and mediastinal disorders -
Other, Specify)
Restlessness (Restlessness)
Restrictive Cardiomyopathy (Restrictive
cardiomyopathy)
Retinal Detachment (Retinal
detachment)
Retinal Tear (Retinal tear)
Retinal Vascular Disorder (Retinal
vascular disorder)
Retinoic Acid Syndrome (Retinoic acid
syndrome)
Retinopathy (Retinopathy)
Retroperitoneal Hemorrhage
(Retroperitoneal hemorrhage)
Reversible Posterior
Leukoencephalopathy Syndrome
(Reversible posterior
leukoencephalopathy syndrome)
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Rhinitis Infective (Rhinitis infective)
Right Ventricular Dysfunction (Right
ventricular dysfunction)
Salivary Duct Inflammation (Salivary duct
inflammation)
Salivary Gland Fistula (Salivary gland
fistula)
Salivary Gland Infection (Salivary gland
infection)
Scalp Pain (Scalp pain)
Scleral Disorder (Scleral disorder)
Scoliosis (Scoliosis)
Scrotal Infection (Scrotal infection)
Scrotal Pain (Scrotal pain)
Seizure (Seizure)
Sepsis (Sepsis)
Seroma (Seroma)
Serum Amylase Increased (Serum
amylase increased)
Serum Sickness (Serum sickness)
Sick Sinus Syndrome (Sick sinus
syndrome)
Sinus Bradycardia (Sinus bradycardia)
Sinus Disorder (Sinus disorder)
Sinus Pain (Sinus pain)
Sinus Tachycardia (Sinus tachycardia)
Sinusitis (Sinusitis)
Skin And Subcutaneous Tissue
Disorders - Other, Specify (Skin and
subcutaneous tissue disorders - Other,
Specify)
Skin Atrophy (Skin atrophy)
Skin Hyperpigmentation (Skin
hyperpigmentation)
Skin Hypopigmentation (Skin
hypopigmentation)
Skin Induration (Skin induration)
Skin Infection (Skin infection)
Skin Ulceration (Skin ulceration)
Sleep Apnea (Sleep apnea)
Small Intestinal Anastomotic Leak (Small
intestinal anastomotic leak)
Small Intestinal Mucositis (Small
intestinal mucositis)
Small Intestinal Obstruction (Small
intestinal obstruction)
Small Intestinal Perforation (Small
intestinal perforation)
Small Intestinal Stenosis (Small intestinal
stenosis)
Small Intestine Infection (Small intestine
infection)
Small Intestine Ulcer (Small intestine
ulcer)
Sneezing (Sneezing)
Social Circumstances - Other, Specify
(Social circumstances - Other, Specify)
Soft Tissue Infection (Soft tissue
infection)
Soft Tissue Necrosis Lower Limb (Soft
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tissue necrosis lower limb)
Soft Tissue Necrosis Upper Limb (Soft
tissue necrosis upper limb)
Somnolence (Somnolence)
Sore Throat (Sore throat)
Spasticity (Spasticity)
Spermatic Cord Anastomotic Leak
(Spermatic cord anastomotic leak)
Spermatic Cord Hemorrhage (Spermatic
cord hemorrhage)
Spermatic Cord Obstruction (Spermatic
cord obstruction)
Spinal Fracture (Spinal fracture)
Spleen Disorder (Spleen disorder)
Splenic Infection (Splenic infection)
Stenosis Of Gastrointestinal Stoma
(Stenosis of gastrointestinal stoma)
Stevens-johnson Syndrome (Stevens-
Johnson syndrome)
Stoma Site Infection (Stoma site
infection)
Stomach Pain (Stomach pain)
Stomal Ulcer (Stomal ulcer)
Stridor (Stridor)
Stroke (Stroke)
Sudden Death Nos (Sudden death NOS)
Suicidal Ideation (Suicidal ideation)
Suicide Attempt (Suicide attempt)
Superficial Soft Tissue Fibrosis
(Superficial soft tissue fibrosis)
Superficial Thrombophlebitis (Superficial
thrombophlebitis)
Superior Vena Cava Syndrome (Superior
vena cava syndrome)
Supraventricular Tachycardia
(Supraventricular tachycardia)
Surgical And Medical Procedures -
Other, Specify (Surgical and medical
procedures - Other, Specify)
Syncope (Syncope)
Telangiectasia (Telangiectasia)
Testicular Disorder (Testicular disorder)
Testicular Hemorrhage (Testicular
hemorrhage)
Testicular Pain (Testicular pain)
Thromboembolic Event
(Thromboembolic event)
Thrombotic Thrombocytopenic Purpura
(Thrombotic thrombocytopenic purpura)
Tinnitus (Tinnitus)
Tooth Development Disorder (Tooth
development disorder)
Tooth Discoloration (Tooth discoloration)
Tooth Infection (Tooth infection)
Toothache (Toothache)
Toxic Epidermal Necrolysis (Toxic
epidermal necrolysis)
Tracheal Fistula (Tracheal fistula)
Tracheal Hemorrhage (Tracheal
hemorrhage)
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Tracheal Mucositis (Tracheal mucositis)
Tracheal Obstruction (Tracheal
obstruction)
Tracheal Stenosis (Tracheal stenosis)
Tracheitis (Tracheitis)
Tracheostomy Site Bleeding
(Tracheostomy site bleeding)
Transient Ischemic Attacks (Transient
ischemic attacks)
Treatment Related Secondary
Malignancy (Treatment related
secondary malignancy)
Tremor (Tremor)
Tricuspid Valve Disease (Tricuspid valve
disease)
Trigeminal Nerve Disorder (Trigeminal
nerve disorder)
Trismus (Trismus)
Tumor Lysis Syndrome (Tumor lysis
syndrome)
Tumor Pain (Tumor pain)
Typhlitis (Typhlitis)
Unequal Limb Length (Unequal limb
length)
Unintended Pregnancy (Unintended
pregnancy)
Upper Gastrointestinal Hemorrhage
(Upper gastrointestinal hemorrhage)
Upper Respiratory Infection (Upper
respiratory infection)
Ureteric Anastomotic Leak (Ureteric
anastomotic leak)
Urethral Anastomotic Leak (Urethral
anastomotic leak)
Urethral Infection (Urethral infection)
Urinary Fistula (Urinary fistula)
Urinary Frequency (Urinary frequency)
Urinary Incontinence (Urinary
incontinence)
Urinary Retention (Urinary retention)
Urinary Tract Infection (Urinary tract
infection)
Urinary Tract Obstruction (Urinary tract
obstruction)
Urinary Tract Pain (Urinary tract pain)
Urinary Urgency (Urinary urgency)
Urine Discoloration (Urine discoloration)
Urine Output Decreased (Urine output
decreased)
Urostomy Leak (Urostomy leak)
Urostomy Obstruction (Urostomy
obstruction)
Urostomy Site Bleeding (Urostomy site
bleeding)
Urostomy Stenosis (Urostomy stenosis)
Urticaria (Urticaria)
Uterine Anastomotic Leak (Uterine
anastomotic leak)
Uterine Fistula (Uterine fistula)
Uterine Hemorrhage (Uterine
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hemorrhage)
Uterine Infection (Uterine infection)
Uterine Obstruction (Uterine obstruction)
Uterine Pain (Uterine pain)
Uterine Perforation (Uterine perforation)
Uveitis (Uveitis)
Vaginal Anastomotic Leak (Vaginal
anastomotic leak)
Vaginal Discharge (Vaginal discharge)
Vaginal Dryness (Vaginal dryness)
Vaginal Fistula (Vaginal fistula)
Vaginal Hemorrhage (Vaginal
hemorrhage)
Vaginal Infection (Vaginal infection)
Vaginal Inflammation (Vaginal
inflammation)
Vaginal Obstruction (Vaginal obstruction)
Vaginal Pain (Vaginal pain)
Vaginal Perforation (Vaginal perforation)
Vaginal Stricture (Vaginal stricture)
Vaginismus (Vaginismus)
Vagus Nerve Disorder (Vagus nerve
disorder)
Vas Deferens Anastomotic Leak (Vas
deferens anastomotic leak)
Vascular Access Complication (Vascular
access complication)
Vascular Disorders - Other, Specify
(Vascular disorders - Other, Specify)
Vasculitis (Vasculitis)
Vasovagal Reaction (Vasovagal reaction)
Venous Injury (Venous injury)
Ventricular Arrhythmia (Ventricular
arrhythmia)
Ventricular Fibrillation (Ventricular
fibrillation)
Ventricular Tachycardia (Ventricular
tachycardia)
Vertigo (Vertigo)
Vestibular Disorder (Vestibular disorder)
Virilization (Virilization)
Visceral Arterial Ischemia (Visceral
arterial ischemia)
Vital Capacity Abnormal (Vital capacity
abnormal)
Vitreous Hemorrhage (Vitreous
hemorrhage)
Voice Alteration (Voice alteration)
Vomiting (Vomiting)
Vulval Infection (Vulval infection)
Watering Eyes (Watering eyes)
Weight Gain (Weight gain)
Weight Loss (Weight loss)
Wheezing (Wheezing)
White Blood Cell Decreased (White
blood cell decreased)
Wolff-parkinson-white Syndrome (Wolff-
Parkinson-White syndrome)
Wound Complication (Wound
complication)
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Wound Dehiscence (Wound dehiscence)
Wound Infection (Wound infection)
Wrist Fracture (Wrist fracture)
CTC AE Grade
Absent Adverse Event (0)
Mild Adverse Event (1)
Moderate Adverse Event (2)
Severe Adverse Event (3)
Life Threatening Adverse Event (4)
Death Related To Adverse Event (5)
CTCAE Begin Date
CTC AE Attribution Code
Definite (Definite)
Possible (Possible)
Probable (Probable)
Unlikely (Unlikely)
Unrelated (Unrelated)
SAE report submitted
No (No)
Unknown (Unknown)
Yes (Yes)
Footer
Comments
Signature of Person Completing This Form
Date Form Originally Completed
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Cervical Cancer NCT01414608 On-Study -
ANZGOG-0902 Nodal Assessment - 3140392v1.0
ANZGOG-0902 Nodal Assessment
Cisplatin and Radiation Therapy With or Without
Carboplatin and Paclitaxel in Patients With Locally
Advanced Cervical Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=90CA1C57-
4699-A228-E040-BB89AD43458D
All rights reserved. Please visit https://medical-data-
models.org/forms/8303
ANZGOG-0902 Nodal Assessment
Header
Patient Initials
Patient ID
Institution Code
Pet Scan
Time point
Baseline (baseline)
Date of PET/CT exam
Blood glucose at start of PET imaging
SUV
Method of Evaluation
Pet Scan (PET scan)
Pet/ct Scan (PET/CT scan)
Reported Leisons (see Notes)
Lymph Node Involvement
Yes
No
Number of positive nodes
SUV Max
New Lesions (at Baseline, Report As
U=unknown)
New Lesion
Yes
No
Are any of the target lesions in a previously
irradiated field
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Yes
No
Positive para-aortic nodes
Yes
No
Mediastinal nodes
Yes
No
Supraclavicular Node(s)
Yes
No
Soft tissue specify
SUV Max
Qualitative Response
Overall Tumor Response
Complete Response (CR)
Progressive Disease (PD)
Partial Response (PR)
Stable Disease (SD)
Mri Scan
Total Tumor Volume
Lymph Node Involvement
Yes
No
Number of positive nodes
Maximum Diameter (cm)
Footer Module
Investigator Name
Date
Investigator's signature
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Cervical Cancer NCT00064077 Quality of Life - Quality
of Life Cover Sheet GOG-0204 - 2079938v3.0
Quality of Life Cover Sheet GOG-0204
Comparison of Four Combination Chemotherapy Regimens
Using Cisplatin in Treating Patients With Stage IVB,
Recurrent, or Persistent Cancer of the Cervix
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=B58BEE8C-
6980-1187-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/8306
Quality of Life Cover Sheet GOG-
0204
Module 1
Name (last)
Name First
GOG# (INST., PROT., SEQ.)
Section
Institution Name
Scheduled time to obtain Quality of Life
Questionnaire and cover sheet
9 Months After Registration (9 months
after registration)
Pre-course 2 (Pre-course 2)
Pre-course 5 (Pre-course 5)
Prior To Randomization (Prior to
randomization)
Module 2
Was QoL Questionnaire completed?
Yes
No
Date Completed (m/d/y)
Please indicate reason (If no, check one)
Other (Other)
Patient Died (Patient died)
Patient Kept Appointment For
Examination, But Could Not Complete
Questionnaire Due To Illness (Patient
kept appointment for examination, but
could not complete questionnaire due to
illness)
Patient Kept Appointment For
Examination, But Refused To Complete
Questionnaire For Reasons Other Than
Illness (Patient kept appointment for
1 / 2
examination, but refused to complete
questionnaire for reasons other than
illness.)
Patient Off Study Treatment And Cannot
Be Contacted For Follow-up (Patient off
study treatment and cannot be contacted
for follow-up)
Test Omitted Due To
Institution/investigator Error
(Questionnaire not administered due to
institutional error)
Specify reason (patient refused)
Other. Please specify (reason)
Where was questionnaire administered (If yes,)
In The Clinic (In the clinic)
Other (Other)
Other (location)
Module 3
If questionnaire was completed, did patient
require assistance
Yes
No
If yes, describe (assistance)
Module 4
Data Manager/Nurse Oncologist
Phone
Date (m/d/y)
Ccrr Module For Quality Of Life Cover
Sheet Gog-0204
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Treatment - Prostate Cancer - Treatment
Summary Form - 2263572v3.0
Prostate Cancer - Treatment Summary Form
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=DC4FF132-
B1B1-5EBA-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/8307
Prostate Cancer - Treatment
Summary Form
Crf Header
Coordinating Group Protocol No.
Coordinating Group Code
Protocol Title
Patient Study ID
Institution/Affiliate
Other Patient ID
Participating Group Code
Patient Name (initials acceptable)
Prostate: Treatment Plan
Treatment Step (according to protocol)
First Date (any modality of) Protocol Therapy
Was Given
Last Date (any modality of) Protocol Therapy
Was Given
Reason Treatment Ended
Adverse Event/side Effects/complications
(Adverse event/Side
effects/Complications)
Alternative Therapy (Alternative therapy)
Death On Study (Death on study)
Disease Progression, Relapse During
Active Treatment (Disease progression,
relapse during active treatment)
Other (Other)
Patient Off-treatment For Other
Complicating Disease (Patient off-
treatment for other complicating disease)
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Patient Withdrawal Or Refusal After
Beginning Protocol Therapy (Patient
withdrawal/refusal after beginning
protocol therapy)
Patient Withdrawal Or Refusal Before
Beginning Protocol Therapy (Patient
withdrawal/refusal prior to beginning
protocol therapy)
Treatment Completed Per Protocol
Criteria (Treatment completed per
protocol criteria)
Alternative Therapy (Specify)
Complicating Disease (Specify)
Other (specify)
Prostate: Treatment Schedule - Systemic
Therapy
Were there any dose modifications or
additions/omissions to protocol treatment?
No (No)
Unknown (Unknown)
Yes, Planned (i.e., The Treatment Was
Changed According To Protocol
Guidelines) (Yes, planned)
Yes, Unplanned (i.e., The Treatment
Change Was Not Part Of Protocol
Guidelines) (Yes, unplanned)
Name of Therapy
Reason for Therapy Modification
Prostate: Treatment Schedule - Radiation
Therapy
Total Dose to Pelvis (cGy)
Total Dose to Prostate (cGy to be defined in the
protocol)
Radiation Therapy Start Date
Radiation Therapy End Date
Were there any unscheduled interruptions in
radiation therapy?
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No (No)
Yes, Due To Toxicity (Yes, due to toxicity)
Yes, For Other Reasons, Specify (Yes,
for other reasons, specify)
RT Interruptions Reason (Specify)
Prostate: Treatment Schedule - Surgery
Protocol Surgery Date
Protocol Surgery Type (protocol specific)
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Neurocognitive Evaluation Summary Form
(RTOG 0834)
RTOG 0834/EORTC 26053_22054/NCIC CTG CEC.1:
Neurocognitive Evaluation Summary Form
Radiation Therapy With or Without Temozolomide in
Treating Patients With Anaplastic Glioma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=5A667C59-
2D09-6D69-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/8309
Neurocognitive Evaluation Summary
Form (RTOG 0834)
Header
RTOG Study No.*
Case #*
Institution Name*
Institution No.*
Patient Initials*
RTOG Patient ID*
Amended Data*
Yes
No
Time point*
Baseline (baseline)
Year 1 (Year 1)
Year 2 (Year 2)
Year 3 (Year 3)
Year 4 (Year 4)
Year 5 (Year 5)
Year 6 (Year 6)
Date of evaluation*
Hopkins Verbal Learning Test - Revised
Administration
HVLT-R reason not completed*
Discontinue Due To Disability
(Discontinue due to disability)
Discontinue, Other Reason (Discontinue,
other reason)
Not Applicable (Not Applicable)
Not Tested Due To Disability (Not tested
due to disability)
Not Tested, Other Reason (Not tested,
other reason)
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Reason Unknown (Reason unknown)
Not tested, other reason specify*
Discontinued, other reason specify*
Free Recall (Trial #3)*
Free Recall (Trial #3)*
Free Recall (Trial #3)*
Free Recall Total Score*
Free Recall Stop Time*
Delayed Recall Start Time*
Delayed Recall Total Score*
Delayed Recognition Total Score*
Trail Making Test Part A
Sample B completed*
Yes
No
Trail Making Test B reason not completed*
Discontinue Due To Disability
(Discontinue due to disability)
Discontinue, Other Reason (Discontinue,
other reason)
Not Applicable (Not Applicable)
Not Tested Due To Disability (Not tested
due to disability)
Not Tested, Other Reason (Not tested,
other reason)
Reason Unknown (Reason unknown)
Not tested, other reason specify*
Discontinued, other reason specify*
Total time to completion (Part A)*
Trail Making Test Part A
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Neurocognitive Evaluation Summary Form (RTOG 0834)
Sample B completed*
Yes
No
Trail Making Test B reason not completed*
Discontinue Due To Disability
(Discontinue due to disability)
Discontinue, Other Reason (Discontinue,
other reason)
Not Applicable (Not Applicable)
Not Tested Due To Disability (Not tested
due to disability)
Not Tested, Other Reason (Not tested,
other reason)
Reason Unknown (Reason unknown)
Not tested, other reason specify*
Discontinued, other reason specify*
Total time to completion (Part A)*
Contolled Oral Word Association (cowa)
COWA reason not completed*
Discontinue Due To Disability
(Discontinue due to disability)
Discontinue, Other Reason (Discontinue,
other reason)
Not Applicable (Not Applicable)
Not Tested Due To Disability (Not tested
due to disability)
Not Tested, Other Reason (Not tested,
other reason)
Reason Unknown (Reason unknown)
Not tested, other reason specify*
Discontinued, other reason specify*
COWA Results (Total number of correct words
after 1 minute - Third letter column)*
COWA Results (Total number of correct words
after 1 minute - Third letter column)*
COWA Results (Total number of correct words
after 1 minute - Third letter column)*
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Neurocognitive Evaluation Summary Form (RTOG 0834)
Treatment - Lung Cancer - Treatment
Summary Form - 2263415v3.0
Lung Cancer - Treatment Summary Form
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=DE329218-
46CF-3E0C-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/8310
Lung Cancer - Treatment Summary
Form
Crf Header
Coordinating Group Protocol No.
Coordinating Group Code
Protocol Title
Patient Study ID
Institution/Affiliate
Other Patient ID
Participating Group Code
Patient Name (initials acceptable)
Lung: Treatment Plan
First Date (any modality of) Protocol Therapy
Was Given
Last Date (any modality of) protocol therapy was
given
Reason Treatment Ended
Adverse Event/side Effects/complications
(Adverse Event/Side
Effects/Complications)
Alternative Therapy (Alternative therapy)
Death On Study (Death on study)
Disease Progression, Relapse During
Active Treatment (Disease progression,
relapse during active treatment)
Other (Other)
Patient Off-treatment For Other
Complicating Disease (Patient off-
treatment for other complicating disease)
Patient Withdrawal Or Refusal After
Beginning Protocol Therapy (Patient
withdrawal/refusal after beginning
1 / 2
protocol therapy)
Patient Withdrawal Or Refusal Before
Beginning Protocol Therapy (Patient
withdrawal/refusal prior to beginning
protocol therapy)
Treatment Completed Per Protocol
Criteria (Treatment completed per
protocol criteria)
Alternative Therapy (Specify)
Complicating Disease (Specify)
Other (specify)
Lung: Treatment Schedule - Systemic
Therapy
Total Number of Cycles Given
Were there any dose modifications or
additions/omissions to protocol treatment?
No (No)
Yes, Planned (i.e., The Treatment Was
Changed According To Protocol
Guidelines) (Yes, planned)
Yes, Unplanned (i.e., The Treatment
Change Was Not Part Of Protocol
Guidelines) (Yes, unplanned)
Lung: Treatment Schedule - Radiation
Therapy
Total Dose to Lung (cGy)
Were there any unscheduled interruptions in
radiation therapy?
No (No)
Yes, Due To Toxicity (Yes, due to toxicity)
Yes, For Other Reasons, Specify (Yes,
for other reasons, specify)
RT Interruptions Reason (Specify)
Comments
Comments
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Treatment - Breast Cancer - Adjuvant
Treatment Summary Form - 2282124v3.0
Breast Cancer - Adjuvant Treatment Summary Form - All
Patients
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=DB75318A-
8E91-2B7E-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/8311
Breast Cancer - Adjuvant Treatment
Summary Form
Crf Header
Coordinating Group Protocol No.
Coordinating Group Code
Protocol Title
Patient Study ID
Institution/Affiliate
Other Patient ID
Participating Group Code
Patient Name (initials acceptable)
Breast: Form Administration
Person Completing Form
Are data amended? (If data are amended, please
circle in red when using paper form)
Yes
No
Breast: Treatment Plan
First Date (any modality of) Protocol Therapy
Was Given
Initial Dose (of Cycle 1 use protocol specified
units)
Units
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Agent Name (protocol specific Some groups may
pre-print protocol agents with appropriate units.)
Last Date (any modality of) Protocol Therapy
Was Given
Reason Treatment Ended
Adverse Event/side Effects/complications
(Adverse event/Side
effects/Complications)
Alternative Therapy (Alternative therapy)
Death On Study (Death on study)
Disease Progression, Relapse During
Active Treatment (Disease progression,
relapse during active treatment)
Other (Other)
Patient Off-treatment For Other
Complicating Disease (Patient off-
treatment for other complicating disease)
Patient Withdrawal Or Refusal After
Beginning Protocol Therapy (Patient
withdrawal/refusal after beginning
protocol therapy)
Patient Withdrawal Or Refusal Before
Beginning Protocol Therapy (Patient
withdrawal/refusal prior to beginning
protocol therapy)
Treatment Completed Per Protocol
Criteria (Treatment completed per
protocol criteria)
Breast: Treatment Schedule - Systemic
Therapy
Were there any dose modifications or
additions/omissions to protocol treatment? (check
one)
No (No)
Unknown (Unknown)
Yes, Planned (i.e., The Treatment Was
Changed According To Protocol
Guidelines) (Yes, planned)
Yes, Unplanned (i.e., The Treatment
Change Was Not Part Of Protocol
Guidelines) (Yes, unplanned)
Breast: Treatment Schedule - Other
Therapy
Were any optional therapies given?
Yes
No
Optional Protocol Therapy Name (If yes,)
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Treatment - Breast Cancer - Adjuvant Treatment Summary Form -
2282124v3.0
Was any non-protocol therapy given during
protocol treatment?
Yes
No
Concurrent Non-Protocol Chemotherapy? (If yes,)
Yes
No
Concurrent Non-Protocol Hormonal Therapy?
Yes
No
Concurrent Non-Protocol Biologic Response
Modifier Therapy?
Yes
No
Concurrent Non-Protocol Radiation Therapy?
Yes
No
Concurrent Non-Protocol High Dose
Chemotherapy/Autologous Stem Cell Transplant?
Yes
No
Comments
Comments
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Treatment - Breast Cancer - Adjuvant Treatment Summary Form -
2282124v3.0
Cervical Cancer NCT01414608 Treatment - ANZGOG-0902
Patient and Disease Status (Follow-up Form) - 3141627v1.0
ANZGOG-0902 Patient and Disease Status (Follow-up
Form)
Cisplatin and Radiation Therapy With or Without
Carboplatin and Paclitaxel in Patients With Locally
Advanced Cervical Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=9102E14A-
0438-2C8A-E040-BB89AD435470
All rights reserved. Please visit https://medical-data-
models.org/forms/8313
ANZGOG-0902 Patient and Disease
Status (Follow-up Form)
Header
Patient Initials
Patient ID
Institution Code
Date of Assessment
Patient Data
Patient's Vital Status
Alive (Alive)
Dead (Dead)
Date of Last Contact or Death
Primary Cause of Death
Due To Other Cause (Due to other
cause)
Due To This Disease (Due to this
disease)
Describe cause of death
Source of Survival Information
Documentation Of Hospital Or Clinic Visit
(Documentation of hospital or clinic visit)
Other (Other)
Phone Contact To Patient (Phone
contact to patient)
Other, specify
ECOG Performance Status
Fully Active, Able To Carry On All Pre-
disease Performance Without
Restriction. (0)
Restricted In Physically Strenuous
Activity But Ambulatory And Able To
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Carry Out Work Of A Light Or Sedentary
Nature, E.g., Light Housework, Office
Work. (1)
Ambulatory And Capable Of All Selfcare
But Unable To Carry Out Any Work
Activities. Up And About More Than 50%
Of Waking Hours. (2)
Capable Of Only Limited Selfcare,
Confined To Bed Or Chair More Than
50% Of Waking Hours. (3)
Completely Disabled. Cannot Carry On
Any Selfcare. Totally Confined To Bed Or
Chair. (4)
Dead (5)
Weight
Disease Status
Method of Evaluation
Clinical (Clinical)
Pathologic (Pathologic)
Radiology (Radiological)
Non-progression Date
Non-protocol Therapy
Has the patient received any non-protocol cancer
therapy not previously reported
Yes
No
Non-Protocol Therapy Type
Biologic Response Modifier (Biologic
Response Modifier)
Chemotherapy (Chemotherapy)
Hormonal Therapy (Hormonal Therapy)
Other Specify (Other)
Radiation Therapy (Radiation therapy)
Surgery (Surgery)
Non-Protocol Chemotherapy Type
Date Non-Protocol Biologic Response Modifier
Non-protocol Immunotherapy/Biological
Response Modifiers, Specify
Date Non-Protocol Hormonal Therapy
Non-Protocol Hormonal Therapy Type
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Cervical Cancer NCT01414608 Treatment - ANZGOG-0902 Patient and
Disease Status (Follow-up Form) - 3141627v1.0
Non-protocol Radiation Therapy Start Date
Date Non-Protocol Surgery
Non-protocol Therapy Start Date
Non-protocol Therapy Start Date
Name of Other Non-Protocol Therapy
Footer Module
Investigator Name
Date
Investigator's signature
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Cervical Cancer NCT01414608 Treatment - ANZGOG-0902 Patient and
Disease Status (Follow-up Form) - 3141627v1.0
Treatment - Multiple Myeloma - Treatment
Summary Form - 2273579v3.0
Multiple Myeloma - Treatment Summary Form
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=D6792069-
D295-0A74-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/8314
Multiple Myeloma - Treatment
Summary Form
Crf Header
Coordinating Group Protocol No.
Coordinating Group Code
Protocol Title
Patient Study ID
Institution/Affiliate
Other Patient ID
Participating Group Code
Patient Name (initials acceptable)
Myeloma: Treatment Plan
First Date (any modality of) Protocol Therapy
Was Given
Last Date (any modality of) protocol therapy was
given
Reason Treatment Ended (check one)
Adverse Event/side Effects/complications
(Adverse Event/Side
Effects/Complications)
Alternative Therapy (Alternative therapy)
Cytogenetic Resistance (Cytogenetic
Resistance)
Death On Study (Death on study)
Disease Progression Before Active
Treatment (Disease Progression before
active treatment)
Disease Progression, Relapse During
Active Treatment (Disease progression,
relapse during active treatment)
Lost To Follow-up (Lost to follow-up)
Other (Other)
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Patient Off-treatment For Other
Complicating Disease (Patient off-
treatment for other complicating disease)
Patient Withdrawal Or Refusal After
Beginning Protocol Therapy (Patient
withdrawal/refusal after beginning
protocol therapy)
Patient Withdrawal Or Refusal Before
Beginning Protocol Therapy (Patient
withdrawal/refusal prior to beginning
protocol therapy)
Treatment Completed Per Protocol
Criteria (Treatment completed per
protocol criteria)
Other
Myeloma: Treatment Summary - Systemic
Therapy
Type of Systemic Therapy (check all that apply)
Chemotherapy (Chemotherapy)
Immunotherapy (Immunotherapy)
Other Specify (Other)
Other specify
Start Date of First Dose of First Cycle
Start Date of First Dose of Last Cycle
Total No. of Courses Administered
Agent Name (protocol specific)
Total Agent Dose for Cycle 1 (Some groups may
pre-print protocol agents with appropriate units.)
units (Vaccine name may be pre-printed with
appropriate units.)
Were there any dose modifications or
additions/omissions to protocol treatment? (check
one)
No (No)
Unknown (Unknown)
Yes, Planned (i.e., The Treatment Was
Changed According To Protocol
Guidelines) (Yes, planned)
Yes, Unplanned (i.e., The Treatment
Change Was Not Part Of Protocol
Guidelines) (Yes, unplanned)
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Treatment - Multiple Myeloma - Treatment Summary Form - 2273579v3.0
Name of Therapy (If yes,)
Reason for Therapy Modification
Myeloma: Treatment Summary -
Radiopharmaceuticals
Start Date of First Dose of First Cycle
Start Date of First Dose of Last Cycle
Total No. of Courses Administered
Agent Name (protocol specific)
Total Agent Dose for Cycle 1 (Some groups may
pre-print protocol agents with appropriate units.)
units (Vaccine name may be pre-printed with
appropriate units.)
Were there any dose modifications or
additions/omissions to protocol treatment? (check
one)
No (No)
Unknown (Unknown)
Yes, Planned (i.e., The Treatment Was
Changed According To Protocol
Guidelines) (Yes, planned)
Yes, Unplanned (i.e., The Treatment
Change Was Not Part Of Protocol
Guidelines) (Yes, unplanned)
Name of Therapy (If yes,)
Reason for Therapy Modification
Myeloma: Treatment Summary - Vaccine
Therapy
Date of First Vaccination
Date of Last Vaccination
Vaccination Site (s check all that apply)
Left Lower Extremity (Left Lower
Extremity)
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Treatment - Multiple Myeloma - Treatment Summary Form - 2273579v3.0
Left Upper Extremity (Left Upper
Extremity)
Other Specify (Other)
Right Lower Extremity (Right Lower
Extremity)
Right Upper Extremity (Right Upper
Extremity)
Trunk (Trunk)
Other specify
Agent Name (protocol specific)
Total Agent Dose for Cycle 1 (Some groups may
pre-print protocol agents with appropriate units.)
units (Vaccine name may be pre-printed with
appropriate units.)
Were there any dose modifications or
additions/omissions to protocol treatment? (check
one)
No (No)
Unknown (Unknown)
Yes, Planned (i.e., The Treatment Was
Changed According To Protocol
Guidelines) (Yes, planned)
Yes, Unplanned (i.e., The Treatment
Change Was Not Part Of Protocol
Guidelines) (Yes, unplanned)
Name of Therapy (If yes,)
Reason for Therapy Modification
Myeloma: Supportive Care
Was any supportive care given during protocol
treatment
Yes
No
Has the patient received any transfusions during
this course of therapy? (If yes,)
No Transfusion (No)
Unknown (Unknown)
Yes (Yes)
Transfusion given (If yes, describe)
Both (Both)
Other (Other)
Platelets (Platelets)
Rbc (RBC)
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Other specify
Has the patient received erythropoietin-type
agents (e.g., Epogen, Procrit or Aranesp) (during
this course of therapy?)
No (No)
Unknown (Unknown)
Yes (Yes)
Has the patient received bisphosphonates
(during this course of therapy?)
No (No)
Unknown (Unknown)
Yes (Yes)
Myeloma: Treatment Schedule - Non-
protocol Therapy
Was any non-protocol therapy given during
protocol treatment?
Yes
No
Non-protocol surgery?
Yes
No
Yes specify
Non-Protocol Bone Marrow Transplant
Yes
No
Yes specify
Non-Protocol Chemotherapy
Yes
No
Yes specify
Non-Protocol Immunotherapy?
Yes
No
Yes specify
Non-Protocol Radiation Therapy?
Yes
No
Yes specify
Non-Protocol Vaccine Therapy
Yes
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No
Yes specify
Other non-protocol Therapy
Yes
No
Name of Other Non-Protocol Therapy (If yes,)
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Treatment - Multiple Myeloma - Treatment Summary Form - 2273579v3.0
Cervical Cancer NCT00262821 Pre-Study - GOG-
0219 Pre-Treatment Summary Form - 2430333v1.0
GOG-0219 Pre-Treatment Summary Form
Cisplatin and Radiation Therapy With or Without
Tirapazamine in Treating Patients With Cervical Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=05D798D6-
4049-2457-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/8315
GOG-0219 Pre-Treatment Summary
Form
Header Module
Date form originally completed
Date form amended
Person amending form last name
Patient Initials
Patient Study ID
Person completing form, last name
Non-invasive Diagnostic Procedures
Chest X-Ray Result
Abnormal (Abnormal)
Normal (Normal)
Not Done (Not done)
Date of Chest X-Ray
EKG Result
Abnormal (Abnormal)
Normal (Normal)
Not Done (Not done)
Date of EKG
MRI Result
Abnormal (Abnormal)
Normal (Normal)
Not Done (Not done)
Date of MRI
CT Result
Abnormal (Abnormal)
Normal (Normal)
Not Done (Not done)
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Date CT Scan
Other Procedure Performed
Abnormal (Abnormal)
Normal (Normal)
Not Done (Not done)
Abnormal, specify
Abnormal, specify
Abnormal, specify
Abnormal, specify
Abnormal, specify
Procedure Date
Does the patient have target lesions
Yes
No
Comments
Comments
Footer Module
Participating Group Code
Participating Group Protocol Number
Participating Group Patient ID
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Cervical Cancer NCT00262821 Pre-Study - GOG-0219 Pre-Treatment
Summary Form - 2430333v1.0
Brain and Central Nervous System Tumors NCT00884741 Transmittal -
RTOG 0825 Phase III GBM Code Breaking Form (CX) - 2797360v1.0
RTOG 0825 Phase III GBM Code Breaking Form (CX)
Temozolomide and Radiation Therapy With or Without
Bevacizumab in Treating Patients With Newly Diagnosed
Glioblastoma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=5AE1E7F4-
0A01-483F-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/8316
RTOG 0825 Phase III GBM Code
Breaking Form (CX)
Module 1
RTOG Study No.
Case #
Institution Name
Institution No.
Patient Initials
RTOG Patient ID
Amended Data (INSTRUCTIONS: Complete form
on web to unblind the protocol treatment arm)
Yes
No
Recurrence Or Progression
Has the patient been diagnosed with first
recurrence or progression (MUST BE
DIAGNOSED BY IMAGING ONLY)
No (No)
Yes, Ct/mri Scan (Yes, CT/MRI scan)
Contact Information For Treating Physician
Name
Email
Fax
Treating physician phone
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Footer Module
Completed by
Form Completion Date, Original (MM DD YYYY)
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Brain and Central Nervous System Tumors NCT00884741 Transmittal -
RTOG 0825 Phase III GBM Code Breaking Form (CX) - 2797360v1.0
Lung Cancer NCT00096265 Treatment - T1 RTOG GBM-EBXRT & RT
Phase III - Multiple Brain Mets Radiotherapy Summary Form - 2277868v3.0
T1 RTOG GBM-EBXRT & RT Phase III - Multiple Brain
Mets Radiotherapy Summary Form
Radiation Therapy and Stereotactic Radiosurgery With or
Without Temozolomide or Erlotinib in Treating Patients With
Brain Metastases Secondary to Non-Small Cell Lung
Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=D81A9D08-
29A3-641E-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/8317
T1 RTOG GBM-EBXRT & RT Phase
III - Multiple Brain Mets Radiotherapy
Summary Form
Header
[RTOG Study No.]
RTOG Study 0320 (RTOG Study 0320)
Case #
Institution
Institution No.
Participant's Initials
Participant's I.D. No.
Module 1
If this is a revised or corrected form, indicate by
checking box.
Date of First Treatment
Date of Last Treatment
Dose Summary
SRT Fractions
SRT Fractions
SRT Dose (Gy)
SRT Dose (Gy)
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Total to Site Fractions
Total to Site Dose (Gy)
Module 3
Split Course Interruption. Total number of days
interrupted for split between first and second
course.
Alternative RX given, specify RX
Alternative RX given, specify RX
Other reason, specify
Other reason, specify
Other reason, specify
Total # of treatment days RT interrupted for
toxicity
Total # of treatment days RT interrupted for other
reasons
Total # of treatment days RT interrupted for other
reasons, specify
Signature
Date
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Lung Cancer NCT00096265 Treatment - T1 RTOG GBM-EBXRT & RT
Phase III - Multiple Brain Mets Radiotherapy Summary Form - 2277868v3.0
Cervical Cancer NCT00262821 Treatment - Radiation
Treatment Form, Form G, GOG-0219 - 2302118v3.0
Radiation Treatment Form, Form G, GOG-0219
Cisplatin and Radiation Therapy With or Without
Tirapazamine in Treating Patients With Cervical Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=EF8A5EDA-
337B-090E-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/8318
Radiation Treatment Form, Form G,
GOG-0219
Header Module
Date form originally completed (m d y)
Date form amended (m d y)
Person amending form, last name
Patient Initials (First, Middle, Last)
Patient Study ID
Person Completing Form, Last Name
Radiation Location
Radiation Oncology Facility
City
State
Radiation Treatment Summary
Specific field receiving RT treatment
Boost field(s) treated by radiation therapy
Total number of fractions
Total number of fractions
Radiation Therapy start date (m d y)
Radiation Therapy start date (m d y)
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Radiation Therapy end date (m d y)
Radiation Therapy end date (m d y)
Total dose of radiation therapy (Gy)
Total dose of radiation therapy (Gy)
Reason for delays (of >4 days) or reduced
fractional dose (Use form Q0 for reporting reason
for discontinuing therapy)
No Delays Or Reduction Of Fractional
Doses (N/A)
Other (Other)
Patient Non-compliant (non-medical
Reason) (Patient non-compliant (non-
medical reason))
Technical Or Scheduling Problem
(Technical or scheduling problem)
Adverse Event (Toxicity)
Treating Physician Modified For Other
Medical Condition (Treating physician
modified for other medical condition)
Treating physician modified for other medical
condition
Other specify
Comments
COMMENTS
Footer Module
Participating Group Code
Participating Group Protocol Number
Participating Group Patient ID
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Cervical Cancer NCT00262821 Treatment - Radiation Treatment Form,
Form G, GOG-0219 - 2302118v3.0
Lung Cancer NCT00113386 Treatment - RTOG-0412 S1:
Post-Op Immunotherapy/RT Surgery Form - 2293382v3.0
RTOG-0412 S1: Post-Op Immunotherapy/RT Surgery Form
Cisplatin and Docetaxel With or Without Radiation Therapy
in Treating Patients Who Are Undergoing Surgery for Newly
Diagnosed Stage III Non-Small Cell Lung Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=E4C3CDDF-
D8AA-1A4C-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/8319
RTOG-0412 S1: Post-Op
Immunotherapy/RT Surgery Form
Module 1
RTOG Study
Case #
Institution
Institution No.
Participant's Initials
Participant's I.D. No.
AMENDED DATA (INSTRUCTIONS: This form is
submitted on all surgically resected patients.
Record dates as mm-dd-yyyy unless otherwise
specified.)
Yes
No
SURGERY DATE
TYPE OF PRIMARY SURGERY
Bilobectomy (Bilobectomy)
Lobectomy (Lobectomy)
Pneumonectomy (Pneumonectomy)
Sleeve Resection (Sleeve Resection)
DURATION OF SURGERY (hour:minutes)
ESTIMATED BLOOD LOSS (cc)
INTRAOP AND PERIOP (TRANSFUSIONS OF
WHOLE BLOOD OR PACKED CELLS) (units)
INTRAOP AND PERIOP (TRANSFUSIONS OF
OTHER BLOOD PRODUCT) (units)
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Surgical Pathological Results
CHECK ATTACHMENTS
RESECTION PATHOLOGY
REPORT(S5) (RESECTION
PATHOLOGY REPORT(S5))
SURGICAL REPORT(S2) (SURGICAL
REPORT(S2))
R0 (all margins pathologically negative)
Yes
No
R1 (microscopically positive margins or
microscopic residual disease)
Yes
No
R2 (macroscopically positive margins or gross
residual disease)
Yes
No
N Stage, Pathologic (N0, N1, N2, N3)
No Regional Lymph Node Metastasis
(N0)
Metastasis To Ipsilateral Peribronchial
And/or Ipsilateral Hilar Lymph Nodes,
And Intrapulmonary Nodes Including
Involvement By Direct Extension Of The
Primary Tumor (N1)
Metastasis To Ipsilateral Mediastinal
And/or Subcarinal Lymph Node(s) (N2)
Metastasis To Contralateral Mediastinal,
Contralateral Hilar, Ipsilateral Or
Contralateral Scalene, Or
Supraclavicular Lymph Node(s) (N3)
No (No)
Regional Lymph Nodes Cannot Be
Assessed (NX)
Yes (Yes)
T Stage, Pathologic (T1, T2, T3, T4)
No (No)
Tumor 3 Cm Or Less In Greatest
Dimension, Surrounded By Lung Or
Visceral Pleura, Invasion More Proximal
Than The Lobar Bronchus, (i.e., Not In
The Main Bronchus) (T1)
Tumor With Any Of The Following
Features Of Size Or Extent: More Than
3cm In Greatest Dimension; Invades The
Visceral Pleura; Associated With
Atelectasis Or Obstructive Pneumonitis
That Extends To The Hilar Region But
Does Not Involve The Entire Lung (T2)
Tumor Of Any Size That Directly Invades
Any Of The Following: Chest Wall
(including Superior Sulcus Tumors),
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Lung Cancer NCT00113386 Treatment - RTOG-0412 S1: Post-Op
Immunotherapy/RT Surgery Form - 2293382v3.0
Diaphragm, Mediastinal Pleura, Parietal
Pericardium; Or Tumor In The Main
Bronchus Less Than 2 Cm Distal To The
Carina, But Without Involvement O* (T3)
Tumor Of Any Size That Invades Any Of
The Following: Mediastinum, Heart,
Great Vessels, Trachea, Esophagus,
Vertebral Body, Carina; Or Separate
Tumor Nodules In The Same Lobe; Or
Tumor With A Malignant Pleural Effusion
(T4)
Yes (Yes)
Lymph Node Type
Highest Mediastinal (Highest
Mediastinal)
Interlobar Node (Interlobar)
Left Hilar Node (Left hilar)
Left Lobar Node (Left lobar)
Left Lower Paratracheal Node (Left lower
paratracheal)
Left Segmental Node (Left segmental)
Left Subsegmental Node (Left
subsegmental)
Left Upper Paratracheal Node (Left
upper paratracheal)
Para-aortic Node (Para-aortic)
Paraesophageal Node (Paraesophageal)
Pre And Retro Paratracheal Node (Pre
and retro paratracheal)
Pulmonary Ligament (Pulmonary
ligament)
Right Hilar Node (Right hilar)
Right Lobar Node (Right lobar)
Right Lower Paratracheal Node (Right
lower paratracheal)
Right Segmental Node (Right segmental)
Right Subsegmental Node (Right
subsegmental)
Right Upper Paratracheal Node (Right
upper paratracheal)
Subaortic Node (Subaortic)
Subcarinal Node (Subcarinal)
Lymph Node Involvement
Equivocal (equivocal)
Negative (negative)
Not Evaluated (not evaluated)
Positive (positive)
Unknown (unknown)
NUMBER OF DAYS ON VENTILATOR
INPATIENT DISCHARGE DATE
NUMBER OF POST-OPERATIVE DAYS TO
TIME OF DISCHARGE
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Immunotherapy/RT Surgery Form - 2293382v3.0
SEVERITY GRADE
AE
Atelectasis (ATELECTASIS)
Myocardial Ischaemia (CARDIAC
ISCHEMIA/INFARCTION)
Chylothorax (CHYLOTHORAX)
Death Not Associated With Ctcae Term
(DEATH)
Fistula, Pulmonary/upper Respiratory
(FISTULA PULMONARY/UPPER
RESPIRATORY)
Post-operative Haemorrhage
(HEMORRHAGE (POST-OPERATIVE))
Culture Wound Positive (INFECTION
(WOUND))
Pleural Effusion (PLEURAL EFFUSION)
Pneumonitis Nos
(PNEUMONITIS/PULMONARY
INFILTRATES)
Pneumothorax Nos (PNEUMOTHORAX)
Prolonged Chest Tube Drainage Or Air
Leak After Pulmonary Resection
(Prolonged chest tube drainage or air
leak after pulmonary resection)
Supraventricular Arrhythmia Nos
(SUPRAVENTRICULAR ARRHYTHMIA
(ATRIAL))
Thrombosis Nos
(THROMBOSIS/EMBOLISM
(PULMONARY))
Adverse Event Assessment Date
COMMENTS
Signature of surgeon
Name of person completing form
Form completion date, original
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Lung Cancer NCT00113386 Treatment - RTOG-0412 S1: Post-Op
Immunotherapy/RT Surgery Form - 2293382v3.0
Treatment - Colorectal Cancer - Advanced
Disease Treatment Summary Form - 2282254v3.0
Colorectal Cancer - Advanced Disease Treatment
Summary Form
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=DB75746A-
4036-2E85-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/8320
Colorectal Cancer - Advanced
Disease Treatment Summary Form
Crf Header
Coordinating Group Protocol No.
Coordinating Group Code
Protocol Title
Patient Study ID
Institution/Affiliate
Other Patient ID
Participating Group Code
Patient Name (initials acceptable)
Colorectal: Form Administration
Person Completing Form
Are data amended? (If data are amended, please
circle in red when using paper form)
Yes
No
Colorectal: Treatment Plan
First Date (any modality of) Protocol Therapy
Was Given
Last Date (any modality of) Protocol Therapy
Was Given
Reason Treatment Ended
Adverse Event/side Effects/complications
1 / 2
(Adverse event/Side
effects/Complications)
Alternative Therapy (Alternative therapy)
Death On Study (Death on study)
Disease Progression, Relapse During
Active Treatment (Disease progression,
relapse during active treatment)
Other (Other)
Patient Off-treatment For Other
Complicating Disease (Patient off-
treatment for other complicating disease)
Patient Withdrawal Or Refusal After
Beginning Protocol Therapy (Patient
withdrawal/refusal after beginning
protocol therapy)
Patient Withdrawal Or Refusal Before
Beginning Protocol Therapy (Patient
withdrawal/refusal prior to beginning
protocol therapy)
Treatment Completed Per Protocol
Criteria (Treatment completed per
protocol criteria)
Colorectal: Treatment Schedule -
Systemic Therapy
Total Number of Cycles Given (for this reporting
period)
Were there any dose modifications or
additions/omissions to protocol treatment? (for
this reporting period)
No (No)
Unknown (Unknown)
Yes, Planned (i.e., The Treatment Was
Changed According To Protocol
Guidelines) (Yes, planned)
Yes, Unplanned (i.e., The Treatment
Change Was Not Part Of Protocol
Guidelines) (Yes, unplanned)
Name of Therapy
Reason for Therapy Modification
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Treatment - Colorectal Cancer - Advanced Disease Treatment Summary
Form - 2282254v3.0
Cervical Cancer NCT00262821 Lab - Specimen
Form, Form SP, GOG-0219 - 2302462v3.0
Specimen Form, Form SP, GOG-0219
Cisplatin and Radiation Therapy With or Without
Tirapazamine in Treating Patients With Cervical Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=EF898F9F-
93F3-0C07-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/8321
Specimen Form, Form SP, GOG-
0219
Header Module
Date form originally completed (m d y)
Date form amended (m d y)
Person amending form, last name
Patient Study ID
GOG Bank ID#
Person Completing Form, Last Name
Site Contact Information
Phone (or)
Email
General Specimen Information
Specimen Code
Time point
Submission Status
Not Submitted (Not submitted)
Submitted (Submitted)
Not submitted, specify
Date collected (m d y)
Time collected (when required by the protocol)
Specimen type
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Buffy Coat (Buffy coat)
Cells (Cells)
Fixed Tissue (Fixed tissue)
Frozen Tissue (Frozen tissue)
Other (Other specify)
Plasma (Plasma)
Serum (Serum)
Urine (Urine)
Whole Blood (Whole blood)
Other specify
Items shipped
Block (Block)
Oct-mold (OCT-mold)
Other (Other specify)
Piece (Piece)
Slide (Slide)
Tube/vial (Tube/Vial)
Other specify
Quantity of items shipped
Processing time
<1 Hour (<1 hour)
>4 Hours (>4 hours)
1-2 Hours (1-2 hours)
2-4 Hours (2-4 hours)
N/a (NA)
Storage type
Other (Other specify)
Refrigerator (Refrigerator)
Room Temperature (Room temperature)
Standard Non-cycling Freezer (Standard
non-cycling freezer)
Ultracold Freezer/liquid N2/dry Ice
(Ultracold freezer/liquid N2/dry ice)
Other specify
Date shipped (m d y)
Federal Express tracking number
Additional information required by protocol
Blood/fluid Products
Type of blood collection tube
Acid Citrate Dextrose (acd) (ACD)
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Cervical Cancer NCT00262821 Lab - Specimen Form, Form SP, GOG-
0219 - 2302462v3.0
Citrate (Citrate)
Edta (EDTA)
Heparin (Heparin)
Other (Other specify)
Red Top (Red top)
Serum Separator (Serum separator)
Other specify
Platelet count required?
Yes
No
Platelet count (/mcL)
Date of platelet count (m d y)
Preservative?
Yes
No
Yes specify below (preservative)
Urine collection method
24-hour (24-hour)
Clean Catch (Clean catch)
Other (Other specify)
Other specify
Tissue/cells
Tissue type
Metastatic Tumor (Metastatic tumor)
Normal (Normal)
Other (Other specify)
Pre-malignant (Pre-malignant)
Primary Tumor (Primary tumor)
Recurrent/persistent Tumor
(Recurrent/persistent tumor)
Other specify
Processing method
Ethanol-fixed (Ethanol-fixed)
Fixed & Paraffin-embedded (Fixed &
paraffin-embedded)
Formalin-fixed (Formalin-fixed)
Oct-frozen (OCT-frozen)
Other (Other)
Snap-frozen (Snap-frozen)
Other specify
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Cervical Cancer NCT00262821 Lab - Specimen Form, Form SP, GOG-
0219 - 2302462v3.0
Cell type
Buccal (Buccal)
Cervical (Cervical)
Other (Other)
Other specify
Gog Tissue Bank/laboratory Information
Receiving institution
Gog Tissue Bank (GOG Tissue Bank)
Laboratory (Laboratory)
Phone (or)
Name (Staff at GOG Tissue Bank/Lab receiving
specimens)
Email
Lab name
Date received (m d y)
Total volume/weight
Units
Additional processing required
Yes
No
Yes specify below (processing)
Condition of received specimens
Satisfactory (Satisfactory)
Unsatisfactory (Unsatisfactory)
Unsatisfactory specify
Footer Module
Participating Group Code
Participating Group Protocol Number
Participating Patient Study ID
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Cervical Cancer NCT00262821 Lab - Specimen Form, Form SP, GOG-
0219 - 2302462v3.0
Treatment - Sarcoma - Treatment Summary
Form - 2288541v3.0
Sarcoma - Treatment Summary Form
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=E298C5A0-
38B0-0A67-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/8322
Sarcoma - Treatment Summary
Form
Crf Header
Coordinating Group Protocol No.
Coordinating Group Code
Protocol Title
Patient Study ID
Institution/Affiliate
Other Patient ID
Participating Group Code
Patient Name (initials acceptable)
Sarcoma: Treatment Plan
First Date (any modality of) Protocol Therapy
Was Given (MM DD YYYY)
Last Date (any modality of) protocol therapy was
given (MM DD YYYY)
Reason Treatment Ended
Adverse Event/side Effects/complications
(Adverse Event/Side
Effects/Complications)
Alternative Therapy (Alternative therapy)
Cytogenetic Resistance (Cytogenetic
Resistance)
Death On Study (Death on study)
Disease Progression Before Active
Treatment (Disease Progression before
active treatment)
Disease Progression, Relapse During
Active Treatment (Disease progression,
relapse during active treatment)
Lost To Follow-up (Lost to follow-up)
Other (Other)
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Patient Off-treatment For Other
Complicating Disease (Patient off-
treatment for other complicating disease)
Patient Withdrawal Or Refusal After
Beginning Protocol Therapy (Patient
withdrawal/refusal after beginning
protocol therapy)
Patient Withdrawal Or Refusal Before
Beginning Protocol Therapy (Patient
withdrawal/refusal prior to beginning
protocol therapy)
Treatment Completed Per Protocol
Criteria (Treatment completed per
protocol criteria)
Other (specify)
Sarcoma: Surgical Treatment
Did the patient have surgery as part of protocol
treatment? (definitive or therapeutic)
Yes
No
Protocol Surgery Date (MM DD YYYY)
Protocol Surgery Type
Do surgery results qualify patient for further
protocol therapy
Not Applicable (N/A)
No (No)
Yes (Yes)
Sarcoma: Treatment Summary - Radiation
Therapy
Type of Radiation Therapy Administered (check
all that apply)
Brachytherapy (Brachytherapy)
External Beam Radiation (External beam
radiation)
Other (Other specify)
Photodynamic Therapy (Photodynamic
therapy)
Radiofrequency Ablation
(Radiofrequency ablation)
Other specify
Method of Brachytherapy Application
High Dose Rate (High dose rate)
Low Dose Rate (Low dose rate)
Brachytherapy Start Date (MM DD YYYY)
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Treatment - Sarcoma - Treatment Summary Form - 2288541v3.0
Brachytherapy End Date (MM DD YYYY)
Brachytherapy Isotope
Brachytherapy Site(s) (protocol specific)
Total Number of Brachytherapy Applications
Radiation Therapy Start Date (MM DD YYYY)
Radiation Therapy End Date (MM DD YYYY)
Radiation Therapy Site (protocol specific)
RT Total Dose Per Field (Gy)
RT Total Dose Per Field (Gy)
Total Number of Fractions
Boost Field(s) treated by Radiation Therapy
None (None)
Other, Specify (Other specify)
Primary Tumor (Primary tumor)
Other specify
RT Total Dose to Boost Field (s Gy)
Total Number of Fractions to Boost Field (s)
Were there any unscheduled interruptions in
radiation therapy?
No (No)
Unknown (Unknown)
Yes, Due To Toxicity (Yes, due to toxicity)
Yes, For Other Reasons, Specify (Yes,
for other reasons, specify)
RT Interruptions Reason
Sarcoma: Treatment Summary - Systemic
Therapy
Date of First Dose of Protocol Systemic Therapy
(MM DD YYYY)
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Treatment - Sarcoma - Treatment Summary Form - 2288541v3.0
Date of Last Dose of Protocol Systemic Therapy
(MM DD YYYY)
Agent Total Cumulative Dose
Units
Agent Name (protocol specific)
Were there any dose modifications or
additions/omissions to protocol treatment? (check
one)
No (No)
Unknown (Unknown)
Yes, Planned (i.e., The Treatment Was
Changed According To Protocol
Guidelines) (Yes, planned)
Yes, Unplanned (i.e., The Treatment
Change Was Not Part Of Protocol
Guidelines) (Yes, unplanned)
Name of Therapy (If yes,)
Reason for Therapy Modification
Sarcoma: Treatment Summary - Non-
protocol Therapy
Was any non-protocol therapy given during
protocol treatment?
Yes
No
Non-Protocol Chemotherapy
Yes
No
Yes specify
Non-Protocol Hormonal Therapy?
Yes
No
Yes specify
Non-Protocol Immunotherapy?
Yes
No
Yes specify
Non-Protocol Radiation Therapy?
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Yes
No
Yes specify
Non-Protocol Surgery?
Yes
No
Yes specify
Other Non-Protocol Therapy
Yes
No
Name of Other Non-Protocol Therapy (If yes,)
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Treatment - Sarcoma - Treatment Summary Form - 2288541v3.0
Cervical Cancer NCT00262821 Lab - Hemoglobin
Levels During RT, Form HGB, GOG-0219 - 2302019v3.0
Hemoglobin Levels During RT, Form HGB, GOG-0219
Cisplatin and Radiation Therapy With or Without
Tirapazamine in Treating Patients With Cervical Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=EF8A4FD1-
0DF8-0835-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/8324
Hemoglobin Levels During RT, Form
HGB, GOG-0219
Header Module
Date form originally completed (m d y)
Date form amended (m d y)
Person amending form, last name
Patient Initials (First, Middle, Last)
Patient Study ID
Person Completing Form, Last Name
Module 2
Date radiation therapy began (m d y)
Week of radiation therapy
Pretreatment (Pretreatment)
Week 1 (Week 1)
Week 10 (Week 10)
Week 2 (Week 2)
Week 3 (Week 3)
Week 4 (Week 4)
Week 5 (Week 5)
Week 6 (Week 6)
Week 7 (Week 7)
Week 8 (Week 8)
Week 9 (Week 9)
Hgb Nadir
Date (m d y)
Transfusions (No. of Units)
Comments
1 / 2
Comments
COMMENTS
Footer Module
Participating Group Code
Participating Group Protocol Number
Participating Group Patient ID
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Cervical Cancer NCT00262821 Lab - Hemoglobin Levels During RT,
Form HGB, GOG-0219 - 2302019v3.0
Treatment - Colorectal Cancer - Adjuvant Disease
Treatment Summary Form - 2282169v3.0
Colorectal Cancer - Adjuvant Disease Treatment Summary
Form
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=DB755F37-
4D9A-2D8C-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/8325
Colorectal Cancer - Adjuvant
Disease Treatment Summary Form
Crf Header
Coordinating Group Protocol No.
Coordinating Group Code
Protocol Title
Patient Study ID
Institution/Affiliate
Other Patient ID
Participating Group Code
Patient Name (initials acceptable)
Colorectal: Form Administration
Person Completing Form
Are data amended? (If data are amended, please
circle in red when using paper form)
Yes
No
Colorectal: Treatment Plan
First Date (any modality of) Protocol Therapy
Was Given
Last Date (any modality of) Protocol Therapy
Was Given
Reason Treatment Ended
Adverse Event/side Effects/complications
1 / 3
(Adverse event/Side
effects/Complications)
Alternative Therapy (Alternative therapy)
Death On Study (Death on study)
Disease Progression, Relapse During
Active Treatment (Disease progression,
relapse during active treatment)
Other (Other)
Patient Off-treatment For Other
Complicating Disease (Patient off-
treatment for other complicating disease)
Patient Withdrawal Or Refusal After
Beginning Protocol Therapy (Patient
withdrawal/refusal after beginning
protocol therapy)
Patient Withdrawal Or Refusal Before
Beginning Protocol Therapy (Patient
withdrawal/refusal prior to beginning
protocol therapy)
Treatment Completed Per Protocol
Criteria (Treatment completed per
protocol criteria)
Colorectal: Treatment Schedule -
Systemic Therapy
Total Number of Cycles Given (for this reporting
period)
Were there any dose modifications or
additions/omissions to protocol treatment? (for
this reporting period)
No (No)
Unknown (Unknown)
Yes, Planned (i.e., The Treatment Was
Changed According To Protocol
Guidelines) (Yes, planned)
Yes, Unplanned (i.e., The Treatment
Change Was Not Part Of Protocol
Guidelines) (Yes, unplanned)
Name of Therapy
Reason for Therapy Modification
Colorectal: Treatment Schedule -
Radiation Therapy
Total Dose to Bowel (cGy)
Were there any unscheduled interruptions in
radiation therapy?
No (No)
Unknown (Unknown)
Yes, Due To Toxicity (Yes, due to toxicity)
2 / 3
Treatment - Colorectal Cancer - Adjuvant Disease Treatment Summary
Form - 2282169v3.0
Yes, For Other Reasons, Specify (Yes,
for other reasons, specify)
RT Interruptions Reason
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Treatment - Colorectal Cancer - Adjuvant Disease Treatment Summary
Form - 2282169v3.0
Cervical Cancer NCT00262821 Treatment - LDR Intracavitary
Radiation Oncology Form, Form LDR, GOG-0219 - 2301943v3.0
LDR Intracavitary Radiation Oncology Form, Form LDR,
GOG-0219
Cisplatin and Radiation Therapy With or Without
Tirapazamine in Treating Patients With Cervical Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=EF8A4419-
CCDF-0767-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/8326
LDR Intracavitary Radiation
Oncology Form, Form LDR, GOG-
0219
Header Module
Date form originally completed (m d y)
Date form amended (m d y)
Person amending form, last name
Patient Initials (First, Middle, Last)
Patient Study ID
Person Completing Form, Last Name
Radiation
Application
Application #1 (Application #1)
Application #2 (Application #2)
Physicist's name
Radiation Oncologist's name
Form Completed by
Brachytherapy facility
Isotope
Applicator type
Date (m d y)
Total hours
Dose to point A - Rt (Gy)
1 / 3
Dose to point A - Lt (Gy)
Dose to point B - Rt (Gy)
Dose to point B - Lt (Gy)
Bladder dose (Gy)
ICRU Bladder dose (Gy)
Rectal dose (Gy)
ICRU Rectal dose (Gy)
Total Dose to point A - Rt (Gy)
Total Dose to point A - Lt (Gy)
Total Dose to point B - Rt (Gy)
Total Dose to point B - Lt (Gy)
Total Bladder dose (Gy)
Total ICRU Bladder dose (Gy)
Total Rectal dose (Gy)
Total ICRU Rectal dose (Gy)
Magnification
Application
Application #1 (Application #1)
Application #2 (Application #2)
AP
Lateral
Diagram
Source
1 (1)
2 (2)
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Cervical Cancer NCT00262821 Treatment - LDR Intracavitary Radiation
Oncology Form, Form LDR, GOG-0219 - 2301943v3.0
3 (3)
4 (4)
5 (5)
6 (6)
Total (Total)
Source Strength #1
Source Strength #2
Total Source Strength #1
Total Source Strength #2
Comments
COMMENTS
Footer Module
Participating Group Code
Participating Group Protocol Number
Participating Group Patient ID
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Cervical Cancer NCT00262821 Treatment - LDR Intracavitary Radiation
Oncology Form, Form LDR, GOG-0219 - 2301943v3.0
Treatment - Lymphoma - Treatment
Summary Form - 2269116v3.0
Lymphoma - Treatment Summary Form
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=D4BE6408-
A222-699D-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/8327
Lymphoma - Treatment Summary
Form
Crf Header
Coordinating Group Protocol No.
Coordinating Group Code
Protocol Title
Patient Study ID
Institution/Affiliate
Other Patient ID
Participating Group Code
Patient Name (initials acceptable)
Lymphoma: Treatment Plan
First Date (any modality of) Protocol Therapy
Was Given
Last Date (any modality of) protocol therapy was
given
Reason Treatment Ended (check one)
Adverse Event/side Effects/complications
(Adverse Event/Side
Effects/Complications)
Alternative Therapy (Alternative therapy)
Cytogenetic Resistance (Cytogenetic
Resistance)
Death On Study (Death on study)
Disease Progression Before Active
Treatment (Disease Progression before
active treatment)
Disease Progression, Relapse During
Active Treatment (Disease progression,
relapse during active treatment)
Lost To Follow-up (Lost to follow-up)
Other (Other)
1 / 3
Patient Off-treatment For Other
Complicating Disease (Patient off-
treatment for other complicating disease)
Patient Withdrawal Or Refusal After
Beginning Protocol Therapy (Patient
withdrawal/refusal after beginning
protocol therapy)
Patient Withdrawal Or Refusal Before
Beginning Protocol Therapy (Patient
withdrawal/refusal prior to beginning
protocol therapy)
Treatment Completed Per Protocol
Criteria (Treatment completed per
protocol criteria)
Other
Lymphoma: Treatment Schedule - Non-
protocol Therapy
Was any non-protocol therapy given during
protocol treatment?
Yes
No
Type of First Non-Protocol Therapy (If yes,)
Chemotherapy (Chemotherapy)
Immuno-radiolabeled Therapy (Immuno-
radiolabeled therapy)
Immunotherapy (Immunotherapy)
Other (Other)
Radiation Therapy (Radiation therapy)
Surgery (Surgery)
Transplant (Transplant)
Vaccine Therapy (Vaccine therapy)
Other specify
Date of First Non-Protocol Therapy
Non-protocol surgery?
Yes
No
Yes specify
Non-Protocol Bone Marrow Transplant?
Yes
No
Yes specify
Non-Protocol Chemotherapy?
Yes
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No
Yes specify
Non-Protocol Immunotherapy?
Yes
No
Yes specify
Non-Protocol Immuno-radiolabeled therapy?
Yes
No
Yes specify
Non-Protocol Radiation Therapy?
Yes
No
Yes specify
Non-Protocol Vaccine Therapy?
Yes
No
Yes specify
Other non-protocol Therapy?
Yes
No
Name of Other Non-Protocol Therapy (If yes,)
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Treatment - Lymphoma - Treatment Summary Form - 2269116v3.0
NCT01349322 Quality of Life - RTOG-1005 T7: Radiation Therapy Oncology Group
Phase III Whole Breast Irradiation for Early Stage Breast Cancer Photograph
Submission Notification Form - 3202750v1.0
RTOG-1005 T7: Radiation Therapy Oncology Group Phase
III Whole Breast Irradiation for Early Stage Breast Cancer
Photograph Submission Notification Form
Higher-Dose Radiation Therapy or Standard Radiation
Therapy in Treating Patients With Early-Stage Breast
Cancer That Was Removed by Surgery
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=9E3CC0E2-
B278-1265-E040-BB89AD430CE0
All rights reserved. Please visit https://medical-data-
models.org/forms/8328
RTOG-1005 T7: Radiation Therapy
Oncology Group Phase III Whole
Breast Irradiation for Early Stage
Breast Cancer Photograph
Submission Notification Form
Unnamed Module 1
RTOG Study No.
Case #
Institution Name
Institution No.
Patient Initials
RTOG Patient ID
Are data amended
Yes
No
Unamed Module 2
Will cosmesis photographs be submitted for this
time period?
Yes
No
Time point
1 Year Post Rt Completion (1 year post
RT Completion)
3 Years Post Rt Completion (3 years post
RT Completion)
Baseline (baseline)
Date photographs taken
Date photographs submitted via RTOG website
1 / 2
Reason photographs not submitted
Other (Other)
Patient Death (Patient death)
Patient Refused (Patient refused)
Patient Too Ill (Patient too ill)
Patient Withdrew Consent (Patient
withdrew consent)
Photographs Not Taken (institution Error)
(Photographs not taken (Institution
Error))
Recurrence / Second Primary
(Recurrence / Second Primary)
Other, specify
Signature of Person Completing This Form
Date Form Completed
2 / 2
NCT01349322 Quality of Life - RTOG-1005 T7: Radiation Therapy Oncology Group
Phase III Whole Breast Irradiation for Early Stage Breast Cancer Photograph
Submission Notification Form - 3202750v1.0
Cervical Cancer NCT01414608 Treatment - ANZGOG-
0902 End of Study Treatment - 3141537v1.0
ANZGOG-0902 End of Study Treatment
Cisplatin and Radiation Therapy With or Without
Carboplatin and Paclitaxel in Patients With Locally
Advanced Cervical Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=90FC354F-
AC0F-8368-E040-BB89AD434A85
All rights reserved. Please visit https://medical-data-
models.org/forms/8329
ANZGOG-0902 End of Study
Treatment
Header
Patient Initials
Patient ID
Institution Code
Date of Assessment
Patient Data
Last date protocol therapy was given
Reason Treatment Ended
Adverse Event/side Effects/complications
(Adverse Event/Side
Effects/Complications)
Death On Study (Death on study)
Disease Progression, Relapse During
Active Treatment (Disease progression,
relapse during active treatment)
Other (Other)
Patient Withdrawal Or Refusal After
Beginning Protocol Therapy (Patient
withdrawal/refusal after beginning
protocol therapy)
Treatment Completed Per Protocol
Criteria (Treatment completed per
protocol criteria)
Adverse event/side effects/complications specify
Other specify
ECOG Performance Status
Fully Active, Able To Carry On All Pre-
disease Performance Without
Restriction. (0)
Restricted In Physically Strenuous
Activity But Ambulatory And Able To
Carry Out Work Of A Light Or Sedentary
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Nature, E.g., Light Housework, Office
Work. (1)
Ambulatory And Capable Of All Selfcare
But Unable To Carry Out Any Work
Activities. Up And About More Than 50%
Of Waking Hours. (2)
Capable Of Only Limited Selfcare,
Confined To Bed Or Chair More Than
50% Of Waking Hours. (3)
Completely Disabled. Cannot Carry On
Any Selfcare. Totally Confined To Bed Or
Chair. (4)
Dead (5)
Weight
Footer Module
Investigator Name
Date
Investigator's signature
2 / 2
Cervical Cancer NCT01414608 Treatment - ANZGOG-0902 End of Study
Treatment - 3141537v1.0
NCT01302834 Quality of Life - RTOG 1016 FQ: Radiation Therapy Oncology Group
Phase III Head and Neck Cancer Work Status Questionnaire - 3160066v1.0
RTOG 1016 FQ: Radiation Therapy Oncology Group Phase
III Head and Neck Cancer Work Status Questionnaire
Radiation Therapy With Cisplatin or Cetuximab in Treating
Patients With Oropharyngeal Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=953353B4-
562C-83C2-E040-BB89AD433EAB
All rights reserved. Please visit https://medical-data-
models.org/forms/8330
RTOG 1016 FQ: Radiation Therapy
Oncology Group Phase III Head and
Neck Cancer Work Status
Questionnaire
Unnamed Module 1
RTOG Study No.
Case #
Institution Name
Institution No.
Patient Initials
RTOG Patient ID
Amended data
Yes
No
Eortc Qlq-h&n35
Patient gender
Female Gender (Female)
Male Gender (Male)
Patient Age
Patient Ethnicity
Hispanic Or Latino (Hispanic or Latino)
Not Hispanic Or Latino (Not Hispanic or
Latino)
Patient Race
American Indian Or Alaska Native
(American Indian or Alaska Native)
Asian (Asian)
Black Or African American (Black or
African American)
Native Hawaiian Or Other Pacific
Islander (Native Hawaiian or other Pacific
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Islander)
Not Reported (Not Reported)
Unknown (Unknown)
White (White)
Paternal Race
American Indian Or Alaska Native
(American Indian or Alaska Native)
Asian (Asian)
Black Or African American (Black or
African American)
Native Hawaiian Or Other Pacific
Islander (Native Hawaiian or other Pacific
Islander)
Not Reported (Not Reported)
Unknown (Unknown)
White (White)
Maternal Race
American Indian Or Alaska Native
(American Indian or Alaska Native)
Asian (Asian)
Black Or African American (Black or
African American)
Native Hawaiian Or Other Pacific
Islander (Native Hawaiian or other Pacific
Islander)
Not Reported (Not Reported)
Unknown (Unknown)
White (White)
Marital Status
Divorced: C51776 (Divorced)
Domestic Partner (Domestic Partnership)
Married: C51773 (Married)
Never Married (Never Married)
Separated (Separated)
Widowed (Widowed)
Where do you live now
Homeless Or Homeless Shelter
(Homeless or homeless shelter)
In A Condominium Or House That You
Own (In a condominium or house that
you own)
In A Rented Apartment Or House Where
You Pay All Of The Bills (In a rented
apartment or house where you pay all of
the bills)
In A Rented Apartment Or House Where
You Pay Some Of The Bills (In a rented
apartment or house where you pay some
of the bills)
In Public Assistance Housing (In public
assistance housing)
Living With Relative Or Friends Who Pay
All The Bills (Living with relative or
friends who pay all the bills)
Other (Other)
Which of the following best describes your
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NCT01302834 Quality of Life - RTOG 1016 FQ: Radiation Therapy Oncology Group
Phase III Head and Neck Cancer Work Status Questionnaire - 3160066v1.0
current work status
Currently Working In At Least One Full
Time Job (Currently working in at least
one FULL time job)
Currently Working In At Least One Part
Time Job (Currently working in at least
one PART time job)
Unknown (Don't know)
Not Employed (Not employed)
Not Working Outside Of The Home (Not
working outside of the home)
On Disability (On disability)
On Sick Leave (On sick leave)
Other (Other)
Retired (Retired)
Student, Full-time (Student, full-time)
Student, Part-time (Student, part-time)
Please specify (Other)
Highest educational level
Graduation Or Professional Degree
(Advanced degree)
Bachelor's Degree (Bachelor's Degree)
Grade School (Grade School)
High School Completion Or General
Equivalency Diploma (ged) Completion
(High school graduate (including
equivalency))
No Formal Schooling (No formal
education)
Not High School Graduate (Not high
school graduate)
Some College Or Associates Degree
(Some college or associate degree)
Went To Vocational/technical School
(Went to vocational/technical school)
In the year before you were diagnosed with
ORAL/OROPHARYNX cancer, about how many
months did you work?
1 Month (1 month)
10 Months (10 months)
11 Months (11 months)
12 Months (12 months)
2 Months (2 months)
3 Months (3 months)
4 Months (4 months)
5 Months (5 months)
6 Months (6 months)
7 Months (7 months)
8 Months (8 months)
9 Months (9 months)
I Did Not Do Paid Work (0 Months) (I did
not do paid work (0 months))
How many hours per week do you work?
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Which industry would you say best describes
your workplace?
Construction (Construction)
Education (Education)
Finance, Insurance, Or Real Estate
(Finance, insurance, or real estate)
Government (Government)
Legal (Legal)
Manufacturing (Manufacturing)
Medical (Medical)
Other (Other)
Retail Trade (Retail trade)
Service (Service)
Transportation And Public Utilities
(Transportation and public utilities)
Wholesale Trade (Wholesale trade)
Please specify
Which occupational category best describes your
work?
Arts, Media Or Athletics (Arts, media or
athletics)
Managerial Or Professional Specialty
(Managerial or professional specialty)
Operator, Fabricator, Or Laborer
(Operator, fabricator, or laborer)
Other (Other)
Sales, Technical, Or Administrative
Support (Sales, technical, or
administrative support)
Service (Service)
Please specify
Are you covered by a health plan provided
through your current or former employer or
union?
Don't Know (Don't know)
No (No)
Yes (Yes)
In addition to you, who else in your household is
covered by your insurance plan?
Don't Know (Don't know)
Myself And Child(ren) (myself and
child(ren))
Myself And Spouse And Child(ren)
(myself and spouse and child(ren))
Myself And Spouse Only (myself and
spouse only)
Myself Only (myself only)
If you needed it, would you get any paid sick
leave or disability benefits from your current job
Don't Know (Don't know)
No (No)
Yes (Yes)
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Which category is closest to your INDIVIDUAL
total income during the year before your
oral/oropharynx cancer diagnosis?
$10,000 To $19,999 ($10,000 to
$19,999)
$100,000 To $149,999 ($100,000 to
$149,999)
$150,000 To $199,999 ($150,000 to
$199,999)
$20,000 To $29,999 ($20,000 to
$29,999)
$200,000 Or More ($200,000 or more)
$30,000 To $39,999 ($30,000 to
$39,999)
$40,000 To $49,999 ($40,000 to
$49,999)
$50,000 To $59,999 ($50,000 to
$59,999)
$60,000 To $69,999 ($60,000 to
$69,999)
$70,000 To $79,999 ($70,000 to
$79,999)
$80,000 To $89,999 ($80,000 to
$89,999)
$90,000 To $99,999 ($90,000 to
$99,999)
Less Than $10,000 (Less than $10,000)
Which category is closest to your household's
total COMBINED income during the year before
your oral/oropharynx cancer diagnosis?
$10,000 To $19,999 ($10,000 to
$19,999)
$100,000 To $149,999 ($100,000 to
$149,999)
$150,000 To $199,999 ($150,000 to
$199,999)
$20,000 To $29,999 ($20,000 to
$29,999)
$200,000 Or More ($200,000 or more)
$30,000 To $39,999 ($30,000 to
$39,999)
$40,000 To $49,999 ($40,000 to
$49,999)
$50,000 To $59,999 ($50,000 to
$59,999)
$60,000 To $69,999 ($60,000 to
$69,999)
$70,000 To $79,999 ($70,000 to
$79,999)
$80,000 To $89,999 ($80,000 to
$89,999)
$90,000 To $99,999 ($90,000 to
$99,999)
Less Than $10,000 (Less than $10,000)
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Bladder Cancer NCT00014534 Treatment - CALGB:
90104 Off Treatment Notice Revised - 2169415v3.0
CALGB: 90104 Off Treatment Notice Revised
Combination Chemotherapy in Treating Patients With
Bladder Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=BE1B4CED-
A464-70DB-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/8331
CALGB: 90104 Off Treatment Notice
Revised
Ccrr Module For Calgb: 90104 Off
Treatment Notice Revised
CALGB Form
CALGB Study No
CALGB Patient ID
Amended data?
Yes (Yes)
Patient's Name
Participating Group
Patient Hospital Number
Participating Group Protocol No.
Main Member Institution/Adjunct
Participating Group Patient No.
REASON OFF TREATMENT (select ONE
REASON ONLY by placing an X in the
appropriate box)
Adverse Event/side Effects/complications
(Adverse event)
Other (Other, specify)
Patient Off-treatment For Other
Complicating Disease (Patient developed
other disease)
Patient did not respond to therapy
(Patient did not respond to therapy)
Death On Study (Patient died during
treatment)
Disease Progression, Relapse During
Active Treatment (Patient had disease
progression or relapse during active
treatment)
Patient Withdrawal Or Refusal After
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Beginning Protocol Therapy (Patient
refused further protocol treatment, but
consented to be followed)
Patient Withdrawal Or Refusal Before
Beginning Protocol Therapy (Patient
refused further protocol treatment,
withdrew consent to be followed. Patient
is lost to follow-up.)
Alternative Therapy (Patient taken off of
protocol treatment to receive non-
protocol therapy during active protocol
treatment)
Patient Withdrawal Or Refusal Before
Beginning Protocol Therapy (Patient
withdrawal or refusal prior to beginning
protocol therapy)
Treatment Completed Per Protocol
Criteria (Treatment completed per
protocol)
Patient Withdrawal Or Refusal Before
Beginning Protocol Therapy (Treatment
never started)
Patient developed other disease. Specify
Reason why treatment was not started
Specify type of non-protocol treatment
Other, specify (off treatment reason)
LAST DATE OF PROTOCOL TREATMENT (M D
Y)
Comments
(Print or Type Name)
(Print or Type Name)
Date Completed
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Cervical Cancer NCT01414608 On-Study - ANZGOG-
0902 Follow-Up Tumour Assessment - 3142734v1.0
ANZGOG-0902 Follow-Up Tumour Assessment
Cisplatin and Radiation Therapy With or Without
Carboplatin and Paclitaxel in Patients With Locally
Advanced Cervical Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=9105E9F2-
1E57-6805-E040-BB89AD4376E8
All rights reserved. Please visit https://medical-data-
models.org/forms/8332
ANZGOG-0902 Follow-Up Tumour
Assessment
Header
Patient Initials
Patient ID
Institution Code
Tumour Assessment
Method of Evaluation
Mri Scan (MRI scan)
Not Evaluated (Not evaluated)
Other (Other)
Spiral Ct (Spiral CT)
Other Specify
Date of Assessment
Was the appearance of any new lesions
documented
Yes
No
Target Lesions
Organ
Method of Evaluation
Mri Scan (MRI scan)
Not Evaluated (Not evaluated)
Other (Other)
Spiral Ct (Spiral CT)
Specify
Sum of Longest (Non-Nodal) and Shortest
(Nodal) Axes of All Target Lesions
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Non-target Lesions
Organ
Method of Evaluation
Mri Scan (MRI scan)
Not Evaluated (Not evaluated)
Other (Other)
Spiral Ct (Spiral CT)
Specify
Follow-up status of lesion
Absent (Absent)
Present (Present)
Unequivocal Pd (Unequivocal PD)
Unevaluable (Unevaluable)
New Lesions
New Lesion Site
Method of Evaluation
Mri Scan (MRI scan)
Not Evaluated (Not evaluated)
Other (Other)
Spiral Ct (Spiral CT)
Specify
Footer Module
Investigator Name
Date
Investigator's signature
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Cervical Cancer NCT01414608 On-Study - ANZGOG-0902 Follow-Up
Tumour Assessment - 3142734v1.0
Cervical Cancer NCT01414608 On-Study - ANZGOG-
0902 Baseline Tumour Assessment - 3142645v1.0
ANZGOG-0902 Baseline Tumour Assessment
Cisplatin and Radiation Therapy With or Without
Carboplatin and Paclitaxel in Patients With Locally
Advanced Cervical Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=91053C20-
5527-9526-E040-BB89AD4367F4
All rights reserved. Please visit https://medical-data-
models.org/forms/8334
ANZGOG-0902 Baseline Tumour
Assessment
Header
Patient Initials
Patient ID
Institution Code
Tumour Assessment
Method of Evaluation
Ct Scan (CT scan)
Not Evaluated (Not evaluated)
Other (Other)
Spiral Ct (Spiral CT)
Other Specify
Date of Assessment
Are there any target lesions?
Yes
No
Was the non-target lesion identified on the
baseline evaluation
Yes
No
Target Lesions
Organ
Method of Evaluation
Ct Scan (CT scan)
Not Evaluated (Not evaluated)
Other (Other)
Spiral Ct (Spiral CT)
Specify
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Sum of Longest (Non-Nodal) and Shortest
(Nodal) Axes of All Target Lesions
Non-target Lesions
Organ
Method of Evaluation
Ct Scan (CT scan)
Not Evaluated (Not evaluated)
Other (Other)
Spiral Ct (Spiral CT)
Specify
Footer Module
Investigator Name
Date
Investigator's signature
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Tumour Assessment - 3142645v1.0
NCT01302834 Quality of Life - RTOG 1016 PQ: Radiation Therapy Oncology Group
Phase III Head and Neck Cancer PRO-CTCAE Assessment - 3159842v1.0
RTOG 1016 PQ: Radiation Therapy Oncology Group
Phase III Head and Neck Cancer PRO-CTCAE
Assessment
Radiation Therapy With Cisplatin or Cetuximab in Treating
Patients With Oropharyngeal Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=95331A4F-
A6A2-25A3-E040-BB89AD432C5C
All rights reserved. Please visit https://medical-data-
models.org/forms/8336
RTOG 1016 PQ: Radiation Therapy
Oncology Group Phase III Head and
Neck Cancer PRO-CTCAE
Assessment
Unnamed Module 1
RTOG Study No.
Case #
Institution Name
Institution No.
Patient Initials
RTOG Patient ID
Amended data
Yes
No
Eortc Qlq-h&n35
How OFTEN did you have NAUSEA?
Almost Constantly (Almost constantly)
Frequently (Frequently)
Never (Never)
Occasionally (Occasionally)
Rarely (Rarely)
What was the SEVERITY of your NAUSEA at its
WORSE
Mild (Mild)
Moderate (Moderate)
None (none)
Severe (severe)
Very Severe (Very severe)
Did you LOSE ANY FINGERNAILS OR
TOENAILS
Yes
No
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What was the SEVERITY of your ACNE OR
PIMPLES ON THE FACE OR CHEST at its
WORST
Mild (Mild)
Moderate (Moderate)
None (none)
Severe (severe)
Very Severe (Very severe)
What was the SEVERITY of your NUMBNESS
OR TINGLING IN YOUR HANDS OR FEET at its
WORST
Mild (Mild)
Moderate (Moderate)
None (none)
Severe (severe)
Very Severe (Very severe)
How much did NUMBNESS OR TINGLING IN
YOUR HANDS OR FEET INTERFERE with your
usual or daily activities
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
What was the SEVERITY of your COUGH at its
WORST
Mild (Mild)
Moderate (Moderate)
None (none)
Severe (severe)
Very Severe (Very severe)
How much did COUGH INTERFERE with your
usual or daily activities
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
Pro-ctcae Assessment (cont.1)
Did you have any RASH
Yes
No
How OFTEN did you FEEL ANXIETY
Almost Constantly (Almost constantly)
Frequently (Frequently)
Never (Never)
Occasionally (Occasionally)
Rarely (Rarely)
What was the SEVERITY of your ANXIETY at its
WORST
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Mild (Mild)
Moderate (Moderate)
None (none)
Severe (severe)
Very Severe (Very severe)
How much did ANXIETY INTERFERE with your
usual or daily activities
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
What was the SEVERITY of your INSOMNIA
(INCLUDING DIFFICULTY FALLING ASLEEP,
STAYING ASLEEP, OR WAKING UP EARLY) at
its WORST
Mild (Mild)
Moderate (Moderate)
None (none)
Severe (severe)
Very Severe (Very severe)
How much did INSOMNIA (INCLUDING
DIFFICULTY FALLING ASLEEP, STAYING
ASLEEP, OR WAKING UP EARLY INTERFERE
with your usual or daily activities
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
How OFTEN did you have SAD OR UNHAPPY
FEELINGS
Almost Constantly (Almost constantly)
Frequently (Frequently)
Never (Never)
Occasionally (Occasionally)
Rarely (Rarely)
What was the SEVERITY of your SAD OR
UNHAPPY FEELINGS at their WORST
Mild (Mild)
Moderate (Moderate)
None (none)
Severe (severe)
Very Severe (Very severe)
How much did SAD OR UNHAPPY FEELINGS
INTERFERE with your usual or daily activities
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
Pro-ctcae Assessment (cont.2)
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How OFTEN did you FEEL THAT NOTHING
COULD CHEER YOU UP
Almost Constantly (Almost constantly)
Frequently (Frequently)
Never (Never)
Occasionally (Occasionally)
Rarely (Rarely)
What was the SEVERITY of your FEELINGS
THAT NOTHING COULD CHEER YOU UP at
their WORST
Mild (Mild)
Moderate (Moderate)
None (none)
Severe (severe)
Very Severe (Very severe)
How much did FEELING THAT NOTHING
COULD CHEER YOU UP INTERFERE with your
usual or daily activities
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
What was the SEVERITY of your MOUTH OR
THROAT SORES at their WORST
Mild (Mild)
Moderate (Moderate)
None (none)
Severe (severe)
Very Severe (Very severe)
How much did MOUTH OR THROAT SORES
INTERFERE with your usual or daily activities
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
Did you have any HAIR LOSS
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
What was the SEVERITY of your DIFFICULTY
SWALLOWING at its WORST
Mild (Mild)
Moderate (Moderate)
None (none)
Severe (severe)
Very Severe (Very severe)
How OFTEN did you have VOMITING
Almost Constantly (Almost constantly)
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Frequently (Frequently)
Never (Never)
Occasionally (Occasionally)
Rarely (Rarely)
What was the SEVERITY of your VOMITING at
its WORST
Mild (Mild)
Moderate (Moderate)
None (none)
Severe (severe)
Very Severe (Very severe)
Pro-ctcae Assessment (cont.3)
How OFTEN did you have HEARTBURN
Almost Constantly (Almost constantly)
Frequently (Frequently)
Never (Never)
Occasionally (Occasionally)
Rarely (Rarely)
What was the SEVERITY of your HEARTBURN
at its WORST
Mild (Mild)
Moderate (Moderate)
None (none)
Severe (severe)
Very Severe (Very severe)
What was the SEVERITY of your FATIGUE,
TIREDNESS OR LACK OF ENERGY at its
WORST
Mild (Mild)
Moderate (Moderate)
None (none)
Severe (severe)
Very Severe (Very severe)
How much did FATIGUE, TIREDNESS, OR LACK
OF ENERGY INTERFERE with your usual or
daily activities
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
What was the SEVERITY of your
CONSTIPATION at its WORST
Mild (Mild)
Moderate (Moderate)
None (none)
Severe (severe)
Very Severe (Very severe)
What was the SEVERITY of your SKIN BURNS
FROM RADIATION at their WORST
Mild (Mild)
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Moderate (Moderate)
None (none)
Severe (severe)
Very Severe (Very severe)
What was the SEVERITY of your RINGING IN
YOUR EARS at its WORST
Mild (Mild)
Moderate (Moderate)
None (none)
Severe (severe)
Very Severe (Very severe)
What was the SEVERITY of your ITCHY SKIN at
its WORST
Mild (Mild)
Moderate (Moderate)
None (none)
Severe (severe)
Very Severe (Very severe)
Pro-ctcae Assessment (cont.4)
What was the SEVERITY of your DRY SKIN at its
WORST
Mild (Mild)
Moderate (Moderate)
None (none)
Severe (severe)
Very Severe (Very severe)
What was the SEVERITY of your DECREASED
APPETITE at their WORST
Mild (Mild)
Moderate (Moderate)
None (none)
Severe (severe)
Very Severe (Very severe)
How much did DECREASED APPETITE
INTERFERE with your usual or daily activities
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
What was the SEVERITY of your DRY MOUTH at
its WORST
Mild (Mild)
Moderate (Moderate)
None (none)
Severe (severe)
Very Severe (Very severe)
What was the SEVERITY of your HOARSE
VOICE at its WORST
Mild (Mild)
Moderate (Moderate)
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None (none)
Severe (severe)
Very Severe (Very severe)
How OFTEN did you have PAIN
Almost Constantly (Almost constantly)
Frequently (Frequently)
Never (Never)
Occasionally (Occasionally)
Rarely (Rarely)
What was the SEVERITY of PAIN at its WORST
Mild (Mild)
Moderate (Moderate)
None (none)
Severe (severe)
Very Severe (Very severe)
How much did PAIN INTERFERE with your usual
or daily activities
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
What was the SEVERITY of your PROBLEMS
WITH TASTING FOOD OR DRINK at their
WORST
Mild (Mild)
Moderate (Moderate)
None (none)
Severe (severe)
Very Severe (Very severe)
How OFTEN did you have LOOSE OR WATERY
STOOLS (DIARRHEA)
Almost Constantly (Almost constantly)
Frequently (Frequently)
Never (Never)
Occasionally (Occasionally)
Rarely (Rarely)
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Prostate Cancer NCT00079001 Off Treatment - CALGB:
90202 OFF TREATMENT NOTICE - 2075955v3.0
CALGB: 90202 OFF TREATMENT NOTICE
Zoledronate in Preventing Skeletal (Bone)-Related Events
in Patients Who Are Receiving Androgen Deprivation
Therapy For Prostate Cancer and Bone Metastases
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=B460546D-
46F1-0505-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/8337
CALGB: 90202 OFF TREATMENT
NOTICE
Ccrr Module For Calgb: 90202 Off
Treatment Notice
CALGB Form
CALGB Study No
CALGB Patient ID
Amended data?
Yes (Yes)
Patient's Name
Participating Group
Patient Hospital Number
Participating Group Protocol No
Main Member Institution/Adjunct
Participating Group Patient No
REASON OFF TREATMENT (select ONE
REASON ONLY by placing an X in the
appropriate box)
Adverse Event/side Effects/complications
(Adverse event)
Other (Other, specify)
Patient Off-treatment For Other
Complicating Disease (Patient developed
other disease)
Patient did not respond to therapy
(Patient did not respond to therapy)
Death On Study (Patient died during
treatment)
Disease Progression, Relapse During
Active Treatment (Patient had disease
progression or relapse during active
treatment)
Patient Withdrawal Or Refusal Before
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Beginning Protocol Therapy (Patient
refused further protocol treatment, but
consented to be followed)
Lost To Follow-up (Patient refused
further protocol treatment, withdrew
consent to be followed. Patient is lost to
follow-up.)
Alternative Therapy (Patient taken off of
protocol treatment to receive non-
protocol therapy during active protocol
treatment)
Patient Withdrawal Or Refusal Before
Beginning Protocol Therapy (Patient
withdrawal or refusal prior to beginning
protocol therapy)
Treatment Completed Per Protocol
Criteria (Treatment completed per
protocol)
Patient Withdrawal Or Refusal Before
Beginning Protocol Therapy (Treatment
never started)
Patient developed other disease. Specify
Reason why treatment was not started
Specify type of non-protocol treatment
Other, specify (off treatment reason)
LAST DATE OF PROTOCOL TREATMENT (M D
Y)
Comments
(Print or Type Name)
(Print or Type Name)
Date Completed
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Follow-Up - Gynecologic Cancer - Follow-
Up Form - 2019334v3.0
Gynecologic Cancer - Follow-Up Form
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=16AA07EB-
A6F0-6710-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/8338
Gynecologic Cancer - Follow-Up
Form
Crf Header
Coordinating Group Protocol No.
Coordinating Group Code
Protocol Title
Patient Study ID
Institution/Affiliate
Other Patient ID
Participating Group Code
Patient Name (initials acceptable)
Sarcoma: Follow-up Reporting Period
Person Completing Form
Are data amended (If amended, please circle the
changed data in red when using paper form)
Yes
No
Reporting Period Start Date (MM DD YYYY)
Reporting Period End Date (MM DD YYYY)
Sarcoma: Vital Status
Patient's Vital Status
Alive (Alive)
Dead (Dead)
Primary Cause of Death (check only one)
Due To Other Cause (Due to other
cause)
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Due To Protocol Treatment (Due to
protocol treatment)
Due To This Disease (Due to this
disease)
Unknown (Unknown)
Describe cause of death
Date of Last Contact or Death (MM/DD/YYYY)
Sarcoma: Disease Follow-up Status
Has the patient had a documented clinical
assessment for this cancer? (since submission of
the previous follow-up form)
Yes
No
Date of Most Recent Clinical Assessment (only
provide date if assessment since submission of
previous follow-up form)
Status of Most Recent Clinical Assessment
Cancer Present (Cancer present)
No Evidence Of Disease (No evidence of
disease)
Result of CA125
Date of CA125
Result of second-look or debulking surgery
All Biopsies Negative (All biopsies
negative)
Gross Disease (Gross disease)
Microscopic Disease Only (Microscopic
disease only)
Tbd
Has the patient developed a first progression (or
relapse) that has not been previously reported?
Yes
No
Date of Progression
Site of Progression (s - mark all that apply)
Ascites (Ascites)
Bladder (Bladder)
Bone (Bone)
Cervix (Cervix)
Cns/brain (CNS/Brain)
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Colon (Colon)
Endometrium (Endometrium)
Liver (Liver)
Lung (Lung)
Lymph Nodes (Lymph Nodes)
Other Specify (Other)
Ovary (Ovary)
Parametrial Involvement (Parametrial
Involvement)
Peritoneum (Peritoneum)
Pleura (Pleura)
Pleural Effusion (Pleural Effusion)
Skin (Skin)
Uterus (Uterus)
Other specify (Lymph nodes, )
Other specify
How was this progression information obtained?
Clinical Assessment (Clinical
assessment)
Patient Self Report Only (Patient self-
report only)
Was salvage therapy performed prior to
progression?
Yes
No
Is the site of recurrence within the field previously
treated by radiation therapy? (or progression)
Yes
No
Sarcoma: Notice Of New Primary
Has a new primary cancer or MDS been
diagnosed that has not been previously reported?
(myelodysplastic syndrome)
Yes
No
Date of Diagnosis (MM DD YYYY)
Site of New Primary (If new primary site is
AML/MDS, please submit NCI AML/MDS form.)
Gyn: Long-term Toxicity
Has the patient experienced (prior to diagnosis of
recurrence or second primary) any severe (Grade
>=3), long term toxicity that has not been
previously reported (or is continuing)
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Yes
No
Late Adverse Event Term
Late Adverse Event Status
Continuing Late Adverse Event
(continuing)
New Late Adverse Event (new)
Late Adverse Event Grade
Date of Onset of Long-Term Toxicity
Lung: Non-protocol Therapy
Is the patient receiving any non-protocol cancer
therapy not previously reported?
Yes
No
Non-Protocol Surgery?
Yes
No
Yes specify
Non-Protocol Chemotherapy
Yes
No
Yes specify
Non-Protocol Hormonal Therapy?
Yes
No
Yes specify
Non-Protocol Immunotherapy?
Yes
No
Yes specify
Non-Protocol Radiation Therapy?
Yes
No
Yes specify
Other Non-Protocol Therapy
Yes
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No
Name of Other Non-Protocol Therapy (If yes,)
Treatment Start Date (If yes,)
Treatment Start Date (If yes,)
Treatment Start Date (If yes,)
Treatment Start Date (If yes,)
Treatment Start Date (If yes,)
Treatment Start Date (If yes,)
Allows Documentation Of Any Additional
Cooments
Research Comments Text
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Cervical Cancer NCT00262821 Treatment - HDR Intracavitary
Radiation Oncology Form, Form HDR, GOG-0219 - 2302057v3.0
HDR Intracavitary Radiation Oncology Form, Form HDR,
GOG-0219
Cisplatin and Radiation Therapy With or Without
Tirapazamine in Treating Patients With Cervical Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=EF8A5601-
2346-0891-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/8339
HDR Intracavitary Radiation
Oncology Form, Form HDR, GOG-
0219
Header Module
Date form originally completed (m d y)
Date form amended (m d y)
Person amending form, last name
Patient Initials (First, Middle, Last)
Patient Study ID
Person Completing Form, Last Name
Radiation
Application
Application #1 (Application #1)
Application #2 (Application #2)
Application #3 (Application #3)
Application #4 (Application #4)
Application #5 (Application #5)
Isot
Applicator type
Date (m d y)
Dose to point A - Rt (Gy)
Dose to point A - Lt (Gy)
Dose to point B - Rt (Gy)
Dose to point B - Lt (Gy)
Bladder dose (Gy)
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ICRU Bladder dose (Gy)
Rectal dose (Gy)
ICRU Rectal dose (Gy)
AP (Magnification)
Lateral (Magnification)
Totals
Total Dose to point A - Rt (Gy)
Total Dose to point A - Lt (Gy)
Total Dose to point B - Rt (Gy)
Total Dose to point B - Lt (Gy)
Total Bladder dose (Gy)
Total ICRU Bladder dose (Gy)
Total Rectal dose (Gy)
Total ICRU Rectal dose (Gy)
Physicist's name
Radiation Oncologist's name
Form Completed by
Brachytherapy facility
Comments
COMMENTS
Footer Module
Participating Group Code
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Cervical Cancer NCT00262821 Treatment - HDR Intracavitary Radiation
Oncology Form, Form HDR, GOG-0219 - 2302057v3.0
Participating Group Protocol Number
Participating Group Patient ID
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Cervical Cancer NCT00262821 Treatment - HDR Intracavitary Radiation
Oncology Form, Form HDR, GOG-0219 - 2302057v3.0
Breast Cancer NCT01101438 Off Treatment - NCIC
MA.32 End of Treatment Form - 3018635v1.0
NCIC MA.32 End of Treatment Form
A Phase III Randomized Trial of Metformin vs Placebo in
Early Stage Breast Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=80D68B0D-
F9C5-D6E6-E040-BB89AD43104A
All rights reserved. Please visit https://medical-data-
models.org/forms/8340
NCIC MA.32 End of Treatment Form
Off Protocol Therapy
Treatment End Date
Reason Treatment Ended
Adverse Event/side Effects/complications
(Adverse Event/Side
Effects/Complications)
Death On Study (Death on study)
Disease Progression, Relapse During
Active Treatment (Disease progression,
relapse during active treatment)
Other (Other)
Patient Off-treatment For Other
Complicating Disease (Patient off-
treatment for other complicating disease)
Patient Withdrawal Or Refusal After
Beginning Protocol Therapy (Patient
withdrawal/refusal after beginning
protocol therapy)
Treatment Completed Per Protocol
Criteria (Treatment completed per
protocol criteria)
Specify
CTC Adverse Event Term
CTC Adverse Event Grade
Attribution
Definite (Definite)
Possible (Possible)
Probable (Probable)
Unlikely (Unlikely)
Unrelated (Unrelated)
End Of Treatment Glucose
Date
Was sample obtained
Yes
No
1 / 2
Fasting glucose (Value)
Units
Fasting glucose, LLN
Fasting glucose, ULN
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Breast Cancer NCT01101438 Off Treatment - NCIC MA.32 End of
Treatment Form - 3018635v1.0
Endometrial Cancer NCT00265759 Follow-Up
- Operative - Reports Form - 2427172v1.0
Operative - Reports Form
Exemestane, Letrozole, or Anastrozole in Treating
Postmenopausal Women Who Are Undergoing Surgery for
Stage II or Stage III Breast Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=051461F3-
A535-72A9-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/8343
Operative - Reports Form
Header Module
Visit
30 Days Post Surgery (30 Days post
surgery)
Day 1 (Day 1)
Prior To Registration (Prior to
Registration)
Surgery (Surgery)
Week 12 (Week 12)
Week 15 (Week 15)
Week 16 (Week 16)
Week 4 (Week 4)
Week 8 (Week 8)
Within 14 Days Prior To Intervention
(Within 14 days prior to intervention)
Year 10 (Year 10)
Year 2 (Year 2)
Year 4 (Year 4)
Year 6 (Year 6)
Year 8 (Year 8)
Patient ID
Institution ID
Patient Initials
Institution
Header
CTSU reports
Operative Report (Operative Report)
Assessment Date
Footer
Completed by
Date Form Completed
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Follow-Up - Follow-Up Brain Tumor
Evaluation Form - 2290890v3.0
Follow-Up Brain Tumor Evaluation Form
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=E12EA69C-
FEB7-54BA-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/8344
Follow-Up Brain Tumor Evaluation
Form
Crf Header
Coordinating Group Protocol No.
Coordinating Group Code
Protocol Title
Patient Study ID
Institution/Affiliate
Other Patient ID
Participating Group Code
Patient Name (initials acceptable)
Brain: Follow-up Form Administration
Reporting Period Start Date (MM DD YYYY)
Reporting Period End Date (MM DD YYYY)
Date of Last Clinical Assessment (MM DD YYYY)
Brain: Baseline Status
Was the patient NED at baseline?
No (No)
Unknown (Unknown)
Yes (Yes)
Brain: Measurable Lesion(s) Follow-up
Evaluation
Is measurable disease present?
Yes
No
1 / 4
Lesion Number
Site of Lesion (New)
Longest Bidimensional Measurements of Lesions
(cm)
Longest Bidimensional Measurements of Lesions
(x cm)
Method of Evaluation
Clinical Examination (pe) (Clinical
examination)
Ct Scan (CT Scan)
Mri (MRI (NMR))
Other (Other)
Pet Scan (PET scan)
Other Specify (If)
Date of Evaluation (MM DD YYYY)
Sum of Longest Transverse Diameters (of All
Measureable Lesions)
Sum of Products of Greatest Diameters (of All
Measurable Lesions)
Response Status at This Assessment, Imaging
(mark one)
Complete Response (CR)
Insufficient Evaluation To Determine
Response Status (Insufficient evaluation
to determine response status)
Progressive Disease (PD)
Regr (REGR)
Stable Disease (SD)
Response Status at This Assessment, Treating
Physician (mark one)
Complete Response (CR)
Insufficient Evaluation To Determine
Response Status (Insufficient evaluation
to determine response status)
Progressive Disease (PD)
Regr (REGR)
Stable Disease (SD)
Brain: Non-measureable/evaluable
Lesion(s) Follow-up Evaluation
Is non-measurable disease present?
Yes
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No
Lesion Number
Site of Lesion (New)
Method of Evaluation
Clinical Examination (pe) (Clinical
examination)
Ct Scan (CT Scan)
Mri (MRI (NMR))
Other (Other)
Pet Scan (PET scan)
Other Specify (If)
Follow-up Status of Lesion (s)
Complete Response (CR)
Progressive Disease (PD)
Regr (REGR)
Stable Disease (SD)
Date of Evaluation (MM DD YYYY)
Response Status at This Assessment, Imaging
(mark one)
Complete Response (CR)
Insufficient Evaluation To Determine
Response Status (Insufficient evaluation
to determine response status)
Progressive Disease (PD)
Regr (REGR)
Stable Disease (SD)
Response Status at This Assessment, Treating
Physician (mark one)
Complete Response (CR)
Insufficient Evaluation To Determine
Response Status (Insufficient evaluation
to determine response status)
Progressive Disease (PD)
Regr (REGR)
Stable Disease (SD)
Brain: New Lesion(s) At Follow-up
Evaluation
Was the appearance of any new lesions
documented (since the baseline evaluation?)
Yes
No
Lesion Number
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Site of Lesion (New)
Method of Evaluation
Clinical Examination (pe) (Clinical
examination)
Ct Scan (CT Scan)
Mri (MRI (NMR))
Other (Other)
Pet Scan (PET scan)
Other Specify (If)
Date of Evaluation (MM DD YYYY)
Brain: Evaluation Summary
Neurologic Exam Score
Better (Better)
Not Done (Not Done)
Same (Same)
Worse (Worse)
Is there Symptomatic Deterioration of the
patient's health status requiring discontinuation of
treatment?
Yes
No
Yes specify
Overall Response Status at This Assessment
(mark one)
Complete Response (CR)
Death Prior To Completion Of Protocol
Criteria (Early death)
Insufficient Evaluation (Insufficient
evaluation to determine response status)
Not An Approved Recist Value (NED)
Progressive Disease (PD)
Partial Response (PR)
Not An Approved Recist Value (REGR)
Stable Disease (SD)
Comments
Comments
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Follow-Up - Follow-Up Brain Tumor Evaluation Form - 2290890v3.0
Colorectal Cancer NCT00726622 Follow-
Up - Study Comments Form - 2684550v1.0
Study Comments Form
Laparoscopic-Assisted Resection or Open Resection in
Treating Patients With Stage IIA, Stage IIIA, or Stage IIIB
Rectal Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=3AF72964-
C3EB-6A1B-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/8347
Study Comments Form
Header Module
Patient ID (Pt. ID issued during registration or
previously issued patient ID)
Patient Initials (F M L)
Institution No.
Institution Name
Comments
Date
Data Entry Initials
Visit
Form
Comments
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Colorectal Cancer NCT01167725 Quality of Life -
USMCI 8214/Z6091:  FACT-C (Version 4) - 2855174v1.0
USMCI 8214/Z6091:  FACT-C (Version 4)
Standard Therapy With or Without Surgery and Mitomycin
C in Treating Patients With Advanced Limited Peritoneal
Dissemination of Colon Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=65DE3C5B-
20E0-5AC6-E040-BB89AD435458
All rights reserved. Please visit https://medical-data-
models.org/forms/8349
USMCI 8214/Z6091:  FACT-C
(Version 4)
Header Module
Patient ID
Institution No.
Protocol No.
Physical Well-being
I have a lack of energy
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have nausea
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
Because of my physical condition, I have trouble
meeting the needs of my family
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have pain
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am bothered by side effects of treatment
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
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I feel ill
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am forced to spend time in bed
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
Social/family Well-being
I feel close to my friends
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I get emotional support from my family
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I get support from my friends
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
My family has accepted my illness
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am satisfied with family communication about
my illness
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I feel close to my partner (or the person who is
my main support)
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
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Colorectal Cancer NCT01167725 Quality of Life - USMCI 8214/Z6091:
FACT-C (Version 4) - 2855174v1.0
Regardless of your current level of sexual activity,
please answer the following question.  If you
prefer not to answer it, please check this box and
go to the next section.
I am satisfied with my sex life
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
Emotional Well-being
I feel sad
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am satisfied with how I am coping with my
illness
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am losing hope in the fight against my illness
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I feel nervous
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I worry about dying
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I worry that my condition will get worse
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
Functional Well-being
3 / 5
Colorectal Cancer NCT01167725 Quality of Life - USMCI 8214/Z6091:
FACT-C (Version 4) - 2855174v1.0
I am able to work (include work at home)
2 (A little bit)
1 (Not at all)
4 (Quite a bit)
3 (Somewhat)
5 (Very much)
My work is fulfilling (include work at home)
2 (A little bit)
1 (Not at all)
4 (Quite a bit)
3 (Somewhat)
5 (Very much)
I am able to enjoy life
2 (A little bit)
1 (Not at all)
4 (Quite a bit)
3 (Somewhat)
5 (Very much)
I have accepted my illness
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am sleeping well
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am enjoying the things I usually do for fun
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am content with the quality of my life right now
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
Unnamed 1
I have swelling or cramps in my stomach area
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
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FACT-C (Version 4) - 2855174v1.0
I am losing weight
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have control of my bowels
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I can digest my food well
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have diarrhea
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have a good appetite
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I like the appearance of my body
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
Do you have an ostomy appliance?
No (Not at all)
Yes (yes)
I am embarrassed by my ostomy appliance
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
Caring for my ostomy appliance is difficult
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
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Colorectal Cancer NCT01167725 Quality of Life - USMCI 8214/Z6091:
FACT-C (Version 4) - 2855174v1.0
Follow-Up - Sarcoma - Follow-Up Form -
2290562v3.0
Sarcoma - Follow-Up Form
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=E405767F-
8C6A-3312-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/8350
Sarcoma - Follow-Up Form
Crf Header
Coordinating Group Protocol No.
Coordinating Group Code
Protocol Title
Patient Study ID
Institution/Affiliate
Other Patient ID
Participating Group Code
Patient Name (initials acceptable)
Sarcoma: Follow-up Reporting Period
Reporting Period Start Date (MM DD YYYY)
Reporting Period End Date (MM DD YYYY)
Sarcoma: Vital Status
Patient's Vital Status
Alive (Alive)
Dead (Dead)
Primary Cause of Death (check only one)
Due To Other Cause (Due to other
cause)
Due To Protocol Treatment (Due to
protocol treatment)
Due To This Disease (Due to this
disease)
Unknown (Unknown)
Describe cause of death
1 / 3
Date of Last Contact or Death (MM/DD/YYYY)
Sarcoma: Disease Follow-up Status
Has the patient had a documented clinical
assessment for this cancer? (since submission of
the previous follow-up form)
No (No)
Unknown (Unknown)
Yes (Yes)
Date of Last Clinical Assessment (MM DD YYYY)
Sarcoma: Notice Of Progression
Has the patient developed a first progression (or
relapse) that has not been previously reported?
Yes
No
Has the patient been diagnosed with first local-
regional recurrence
Yes
No
Has the patient been diagnosed with first distant
recurrence/progression?
Yes
No
Has the patient been diagnosed with a local-
regional lymph node recurrence that has not
been previously reported
Yes
No
Date of Progression (MM DD YYYY)
Site(s) of Progression (mark all that apply)
Bone (Bone)
Bone Marrow (Bone marrow)
Central Nervous System/brain
(CNS/brain)
Distant Lymph Nodes (Distant lymph
nodes)
Liver (Liver)
Other (Other specify)
Regional Lymph Nodes (Regional lymph
nodes)
Subcutaneous/skin (Subcutaneous/skin)
Other specify
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Sarcoma: Notice Of New Primary
Has a new primary cancer or MDS been
diagnosed that has not been previously reported?
Yes
No
Date of Diagnosis (MM DD YYYY)
Site of New Primary (If new primary site is
AML/MDS, please submit NCI AML/MDS form.)
Is there a history of prior radiation therapy to the
primary site?
No (No)
Unknown (Unknown)
Yes (Yes)
New Primary, Histologic Type (check all that
apply)
Angiosarcoma (Angiosarcoma)
Extraskeletal Osteosarcoma
(Extraskeletal osteosarcoma)
Maligant Peripheral Nerve Sheath Tumor
(Malignant peripheral nerve sheath
tumor)
Other Specify (Other specify)
Soft Tissue Sarcoma Nos (Soft tissue
sarcoma NOS)
Undifferentiated Pleomorphic
Sarcoma/"mfh" (Undifferentiated
pleomorphic sarcoma/"MFH")
Undifferentiated Spindle Cell Sarcoma
(Undifferentiated spindle cell sarcoma)
Other specify
Sarcoma: Long-term Toxicity
Has the patient experienced (prior to diagnosis of
recurrence or second primary) any severe (Grade
>=3), long term toxicity that has not been
previously reported
No (No)
Unknown (Unknown)
Yes (Yes)
Late Adverse Event Term
Late Adverse Event Grade
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Follow-Up - Sarcoma - Follow-Up Form - 2290562v3.0
Response - Summary Response / Progression
Form for Lymphoma - 2270576v3.0
Summary Response / Progression Form for Lymphoma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=D5EAF3A8-
6FAE-741E-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/8353
Summary Response / Progression
Form for Lymphoma
Crf Header
Coordinating Group Protocol No.
Coordinating Group Code
Protocol Title
Patient Study ID
Institution/Affiliate
Other Patient ID
Participating Group Code
Patient Name (initials acceptable)
Lymphoma Response: Form
Administration
Reporting Period Start Date
Reporting Period End Date
Date of Last Clinical Assessment
Lymphoma: Response Assessment
Has the patient achieved a response?
Yes
No
Partial Response (PR) First Observed Date
Complete Response Uncertain (CRu) First
Observed Date
Complete Response (CR) First Observed Date
1 / 2
Is complete response confirmed
Yes
No
Stable Disease First Observed Date (SD)
Has the patient been diagnosed with a new
progression (during this reporting period not
previously reported)
Yes
No
Progressive Disease (PD) Observed Date
Progressive Disease for Lymphoma
Appearance Of One Or More New
Lesions (Appearance of one or more
new lesions)
Increase By >=50% From Nadir In The
Sum Of The Products Of Greatest
Diameters Of Any Previously Identified
Abnormal Node For Partial Or Non-
responders (Increase by >=50% from
nadir in the Sum of the Products of
Greatest Diameters of any previously
identified abnormal node for partial or
non-responders)
Increase By >=50% In The Size Of
Previously Involved Sites (Increase by
>=50% in the size of previously involved
sites)
Other (Other)
Other specify (Note: Record all anatomic sites of
progression on the Follow-Up form for
lymphoma.)
Date Response Last Documented
Comments
Comments
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Response - Summary Response / Progression Form for Lymphoma -
2270576v3.0
Treatment - Multiple Myeloma - Treatment
By Cycle Form - 2273483v3.0
Multiple Myeloma - Treatment By Cycle Form
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=D67911B3-
CDF3-0A17-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/8355
Multiple Myeloma - Treatment By
Cycle Form
Crf Header
Coordinating Group Protocol No.
Coordinating Group Code
Protocol Title
Patient Study ID
Institution/Affiliate
Other Patient ID
Participating Group Code
Patient Name (initials acceptable)
Myeloma: Treatment Reporting Interval
Reporting Period Start Date
Reporting Period End Date
Patient Weight (kg)
Body Surface Area (m^2)
Myeloma: Treatment Cycle Information -
Systemic Therapy
Type of Systemic Therapy (check all that apply)
Chemotherapy (Chemotherapy)
Immunotherapy (Immunotherapy)
Other Specify (Other)
Other specify
Current Cycle Number
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Cycle Start Date
Agent Name (protocol specific)
Total Dose of Agents/Drugs for this Cycle
(Vaccine name may be pre-printed with
appropriate units.)
units
Were there any dose modifications or
additions/omissions to protocol treatment? (check
one)
No (No)
Unknown (Unknown)
Yes, Planned (i.e., The Treatment Was
Changed According To Protocol
Guidelines) (Yes, planned)
Yes, Unplanned (i.e., The Treatment
Change Was Not Part Of Protocol
Guidelines) (Yes, unplanned)
Name of Therapy (If yes,)
Reason for Therapy Modification
Myeloma: Treatment Cycle Information -
Radiopharmaceuticals
Current Cycle Number
Cycle Start Date
Agent Name (protocol specific)
Total Dose of Agents/Drugs for this Cycle
(Vaccine name may be pre-printed with
appropriate units.)
units
Were there any dose modifications or
additions/omissions to protocol treatment? (check
one)
No (No)
Unknown (Unknown)
Yes, Planned (i.e., The Treatment Was
Changed According To Protocol
Guidelines) (Yes, planned)
Yes, Unplanned (i.e., The Treatment
Change Was Not Part Of Protocol
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Guidelines) (Yes, unplanned)
Name of Therapy (If yes,)
Reason for Therapy Modification
Myeloma: Treatment Cycle Information -
Vaccine Therapy
Date of Vaccination
Current Cycle Number
Vaccination Site (s check all that apply)
Left Lower Extremity (Left Lower
Extremity)
Left Upper Extremity (Left Upper
Extremity)
Other Specify (Other)
Right Lower Extremity (Right Lower
Extremity)
Right Upper Extremity (Right Upper
Extremity)
Trunk (Trunk)
Other specify
Agent Name (protocol specific)
Total Dose of Agents/Drugs for this Cycle
(Vaccine name may be pre-printed with
appropriate units.)
units
Were there any dose modifications or
additions/omissions to protocol treatment? (check
one)
No (No)
Unknown (Unknown)
Yes, Planned (i.e., The Treatment Was
Changed According To Protocol
Guidelines) (Yes, planned)
Yes, Unplanned (i.e., The Treatment
Change Was Not Part Of Protocol
Guidelines) (Yes, unplanned)
Name of Therapy (If yes,)
Reason for Therapy Modification
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Treatment - Breast Cancer - Advanced
Treatment Summary Form - 2263821v3.0
Breast Cancer - Advanced Treatment Summary Form - All
Patients
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=DB753C69-
FAEF-2BCD-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/8357
Breast Cancer - Advanced Treatment
Summary Form
Crf Header
Coordinating Group Protocol No.
Coordinating Group Code
Protocol Title
Patient Study ID
Institution/Affiliate
Other Patient ID
Participating Group Code
Patient Name (initials acceptable)
Breast: Form Administration
Person Completing Form
Are data amended? (If data are amended, please
circle in red when using paper form)
Yes
No
Breast: Treatment Reporting Interval
Reporting Period Start Date
Reporting Period End Date
Breast: Advanced Treatment Plan
Date of First Dose for This Reporting Period
1 / 3
Date of Last Dose for This Reporting Period
Initial Dose (of Cycle 1 use protocol specified
units)
Units
Agent Name (protocol specific Some groups may
pre-print protocol agents with appropriate units.)
Reason Treatment Ended
Adverse Event/side Effects/complications
(Adverse event/Side
effects/Complications)
Alternative Therapy (Alternative therapy)
Death On Study (Death on study)
Disease Progression, Relapse During
Active Treatment (Disease progression,
relapse during active treatment)
Other (Other)
Patient Off-treatment For Other
Complicating Disease (Patient off-
treatment for other complicating disease)
Patient Withdrawal Or Refusal After
Beginning Protocol Therapy (Patient
withdrawal/refusal after beginning
protocol therapy)
Patient Withdrawal Or Refusal Before
Beginning Protocol Therapy (Patient
withdrawal/refusal prior to beginning
protocol therapy)
Treatment Completed Per Protocol
Criteria (Treatment completed per
protocol criteria)
Optional Protocol Therapy Name (If yes,)
Were there any dose modifications or
additions/omissions to protocol treatment? (check
one)
No (No)
Unknown (Unknown)
Yes, Planned (i.e., The Treatment Was
Changed According To Protocol
Guidelines) (Yes, planned)
Yes, Unplanned (i.e., The Treatment
Change Was Not Part Of Protocol
Guidelines) (Yes, unplanned)
Were any optional therapies given?
Yes
No
Was any non-protocol therapy given during
protocol treatment?
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Yes
No
Concurrent Non-Protocol Chemotherapy? (If yes,)
Yes
No
Concurrent Non-Protocol Hormonal Therapy?
Yes
No
Concurrent Non-Protocol Biologic Response
Modifier Therapy?
Yes
No
Concurrent Non-Protocol Radiation Therapy?
Yes
No
Concurrent Non-Protocol High Dose
Chemotherapy/Autologous Stem Cell Transplant?
Yes
No
Comments
Comments
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Endometrial Cancer NCT00063999 On-Study - Primary Gynecologic
Cancer - On Study Form, GOG-0209, Form OSE - 2450967v1.0
Primary Gynecologic Cancer - On Study Form, GOG-0209,
Form OSE
Combination Chemotherapy in Treating Patients With Stage
III, Stage IV, or Recurrent Endometrial Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=0CC45F2A-
6926-41E8-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/8360
Primary Gynecologic Cancer - On
Study Form, GOG-0209, Form OSE
Header Module
Date form originally completed (m d y)
Date form amended (m d y)
Person amending form, last name
Patient Initials (First, Middle, Last)
Patient Study ID
Person Completing Form, Last Name
Disease Description - Prior History
Date of definitive histologic diagnosis of primary
tumor (m d y  Note: Word ?tumor? obstructed by
graphic)
Stage (at diagnosis FIGO)
Refer To Figo Staging For Specific
Gynecologic Cancer (IA)
Refer To Figo Staging For Specific
Gynecologic Cancer (IB)
Refer To Figo Staging For Specific
Gynecologic Cancer (IC)
Refer To Figo Staging For Specific
Gynecologic Cancer (II)
Refer To Figo Staging For Specific
Gynecologic Cancer (IIA)
Refer To Figo Staging For Specific
Gynecologic Cancer (IIB)
Refer To Figo Staging For Specific
Gynecologic Cancer (III)
Refer To Figo Staging For Specific
Gynecologic Cancer (IIIA)
Refer To Figo Staging For Specific
Gynecologic Cancer (IIIB)
Refer To Figo Staging For Specific
Gynecologic Cancer (IIIC)
Refer To Figo Staging For Specific
Gynecologic Cancer (IV)
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Refer To Figo Staging For Specific
Gynecologic Cancer (IVA)
Refer To Figo Staging For Specific
Gynecologic Cancer (IVB)
Lymph Node Type
Other Specify (other)
Para-aortic (para-aortic)
Pelvic (pelvic)
Other specify
Lymph Node Involvement (*Indicate node
involvement 0=not evaluated; 1=positive;
2=negative; 3=equivocal; 9=unknown)
Equivocal (equivocal)
Negative (negative)
Not Evaluated (not evaluated)
Positive (positive)
Unknown (unknown)
Number of Positive Lymph Nodes
Depth of Tumor Penetration into Myometrial
Tissue
<50% Thickness (<50% thickness)
> Or = 50% Thickness (> or = 50%
thickness)
None (None)
Does the patient have vascular-lymphatic
involvement at study entry?
No (NO)
Unknown (UNKNOWN)
Yes (YES)
Size of Residual Disease (cm Note: maximum
size after resection is complete: 0=microscopic)
Prior Treatment For Gynecologic Cancer
Comments
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Endometrial Cancer NCT00063999 On-Study - Primary Gynecologic
Cancer - On Study Form, GOG-0209, Form OSE - 2450967v1.0
Response - Summary Response/Progression
Form for Multiple Myeloma - 2274272v3.0
Summary Response/Progression Form for Multiple
Myeloma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=D6E1D5FF-
F9E0-5430-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/8361
Summary Response/Progression
Form for Multiple Myeloma
Crf Header
Coordinating Group Protocol No.
Coordinating Group Code
Protocol Title
Patient Study ID
Institution/Affiliate
Other Patient ID
Participating Group Code
Patient Name (initials acceptable)
Myeloma Response: Form Administration
Reporting Period Start Date
Reporting Period End Date
Myeloma: Response Assessment
Best Overall Response to Date
Complete Response (Complete
Response)
Minimal Response (Minimal Response)
Near Complete Response (Near
Complete Response)
No Response/stable Disease (No
response/Stable Disease)
Partial Response (Partial Response)
Progressive Disease (Progressive
Disease)
Unevaluable (Unevaluable)
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Very Good Partial Response (Very Good
Partial Response)
Complete Response (CR) First Observed Date
(For the Best Response observed, give date of
onset)
Very Good Partial Response First Observed Date
(VGPR)
Partial Response (PR) First Observed Date
Near Complete Response First Observed Date
(NCR)
Minimal Response First Observed Date (MR)
Stable Disease First Observed Date (SD)
Progressive Disease First Observed Date (OR
PD)
Was a confirmation date (or second date to
confirm response) observed
Yes
No
Confirmation Date (for Best Response observed)
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Response - Summary Response/Progression Form for Multiple Myeloma
- 2274272v3.0
Treatment - Sarcoma - Treatment Reporting
Period Form - 2290511v3.0
Sarcoma - Treatment Reporting Period Form
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=E298B865-
351E-09AF-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/8363
Sarcoma - Treatment Reporting
Period Form
Crf Header
Coordinating Group Protocol No.
Coordinating Group Code
Protocol Title
Patient Study ID
Institution/Affiliate
Other Patient ID
Participating Group Code
Patient Name (initials acceptable)
Sarcoma: Treatment Reporting Period
Reporting Period Start Date (MM DD YYYY)
Reporting Period End Date (MM DD YYYY)
Sarcoma: Treatment Summary - Radiation
Therapy
Type of Radiation Therapy Administered (check
all that apply)
Brachytherapy (Brachytherapy)
External Beam Radiation (External beam
radiation)
Other (Other specify)
Photodynamic Therapy (Photodynamic
therapy)
Radiofrequency Ablation
(Radiofrequency ablation)
Other specify
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Method of Brachytherapy Application
High Dose Rate (High dose rate)
Low Dose Rate (Low dose rate)
Brachytherapy Start Date (MM DD YYYY)
Brachytherapy End Date (MM DD YYYY)
Brachytherapy Isotope
Brachytherapy Site(s) (protocol specific)
Total Number of Brachytherapy Applications
Radiation Therapy Start Date (MM DD YYYY)
Radiation Therapy End Date (MM DD YYYY)
RT Total Dose Per Field (Gy)
RT Total Dose Per Field (Gy)
Total Number of Fractions
Boost Field(s) treated by Radiation Therapy
None (None)
Other, Specify (Other specify)
Primary Tumor (Primary tumor)
Other specify
Radiation Therapy Site (Boost Field)
Radiation Therapy Site (Boost Field)
RT Total Dose to Boost Field (Gy)
Total Number of Fractions to Boost Field
Were there any unscheduled interruptions in
radiation therapy?
No (No)
Unknown (Unknown)
Yes, Due To Toxicity (Yes, due to toxicity)
Yes, For Other Reasons, Specify (Yes,
for other reasons, specify)
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Treatment - Sarcoma - Treatment Reporting Period Form - 2290511v3.0
RT Interruptions Reason
Sarcoma: Treatment Schedule - Systemic
Therapy
Patient Height (cm)
Patient Weight (kg)
Agent Name (use protocol specified agents and
units)
Total Dose of Agents/Drugs for this Cycle
Units
Were there any dose modifications or
additions/omissions to protocol treatment? (check
one)
No (No)
Unknown (Unknown)
Yes, Planned (i.e., The Treatment Was
Changed According To Protocol
Guidelines) (Yes, planned)
Yes, Unplanned (i.e., The Treatment
Change Was Not Part Of Protocol
Guidelines) (Yes, unplanned)
Name of Therapy (If yes,)
Reason for Therapy Modification
Comments
Comments
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Treatment - Sarcoma - Treatment Reporting Period Form - 2290511v3.0
Endometrial Cancer NCT00265759 Follow-Up -
Miscellaneous - Reports Form - 2427135v1.0
Miscellaneous - Reports Form
Exemestane, Letrozole, or Anastrozole in Treating
Postmenopausal Women Who Are Undergoing Surgery for
Stage II or Stage III Breast Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=05145510-
13D8-711A-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/8364
Miscellaneous - Reports Form
Header Module
Visit
30 Days Post Surgery (30 Days post
surgery)
Day 1 (Day 1)
Prior To Registration (Prior to
Registration)
Surgery (Surgery)
Week 12 (Week 12)
Week 15 (Week 15)
Week 16 (Week 16)
Week 4 (Week 4)
Week 8 (Week 8)
Within 14 Days Prior To Intervention
(Within 14 days prior to intervention)
Year 10 (Year 10)
Year 2 (Year 2)
Year 4 (Year 4)
Year 6 (Year 6)
Year 8 (Year 8)
Patient ID
Institution ID
Patient Initials
Institution
Header
CTSU reports (Check one only)
Autopsy Report (Autopsy Report)
Death Report (Death Report)
Other (Other)
Other, specify
Assessment Date
Footer
1 / 2
Completed by
Date Form Completed
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Endometrial Cancer NCT00265759 Follow-Up - Miscellaneous - Reports
Form - 2427135v1.0
Treatment - Lymphoma - Radiation Therapy
Form - 2269197v3.0
Lymphoma - Radiation Therapy Form
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=D4BFD3C1-
F527-0D6F-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/8367
Lymphoma - Radiation Therapy
Form
Crf Header
Coordinating Group Protocol No.
Coordinating Group Code
Protocol Title
Patient Study ID
Institution/Affiliate
Other Patient ID
Participating Group Code
Patient Name (initials acceptable)
Lymphoma: Radiation Therapy Reporting
Interval
Reporting Period Start Date
Reporting Period End Date
Lymphoma: Treatment Schedule -
Radiation Therapy
Radiation Therapy Start Date
Radiation Therapy End Date
Type of Radiation Therapy Administered
External Beam Radiation (External beam
radiation)
Other (Other specify)
Other specify
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Radiation Therapy Field (* protocol specific
Radiation Therapy Field:)
Cranial (Cranial)
Cranial & Spinal (Cranial & Spinal)
Extended Mantle (Extended Mantle)
Inverted Y (Inverted Y)
Local (Local)
Mantle (Mantle)
Mantle & Periaortic (Mantle & Periaortic)
Other (Other)
Regional (Regional)
Total Nodal (Total Nodal)
Whole Body (Whole Body)
Other specify (If)
RT Dose per Fraction
Total Number of Fractions
RT Total Dose
units
Grays (Gy)
Millicurie (mCi)
units
Grays (Gy)
Millicurie (mCi)
Were there any unscheduled interruptions in
radiation therapy?
No (No)
Unknown (Unknown)
Yes, Due To Toxicity (Yes, due to toxicity)
Yes, For Other Reasons, Specify (Yes,
for other reasons, specify)
RT Interruptions Reason (If Other, specify)
Comments
Comments
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Treatment - Lymphoma - Radiation Therapy Form - 2269197v3.0
On-Study - Primary Cervical Cancer - On-
Study Form - 2019339v3.0
Primary Cervical Cancer - On-Study Form
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=16D0D1CF-
B7EB-34E6-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/8369
Primary Cervical Cancer - On-Study
Form
Crf Header
Coordinating Group Protocol No.
Coordinating Group Code
Protocol Title
Patient Study ID
Institution/Affiliate
Other Patient ID
Participating Group Code
Patient Name (initials acceptable)
Sarcoma: Follow-up Reporting Period
Person Completing Form
Are data amended (If amended, please circle the
changed data in red when using paper form)
Yes
No
Reporting Period Start Date (MM DD YYYY)
Reporting Period End Date (MM DD YYYY)
Cervical: Disease Description
Date of Definitive Histologic Diagnosis of Primary
Tumor
Stage (at Diagnosis - FIGO/Clinical)
Refer To Figo Staging For Specific
Gynecologic Cancer (IA1)
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Refer To Figo Staging For Specific
Gynecologic Cancer (IA2)
Refer To Figo Staging For Specific
Gynecologic Cancer (IB1)
Refer To Figo Staging For Specific
Gynecologic Cancer (IB2)
Refer To Figo Staging For Specific
Gynecologic Cancer (IIA)
Refer To Figo Staging For Specific
Gynecologic Cancer (IIB)
Refer To Figo Staging For Specific
Gynecologic Cancer (IIIA)
Refer To Figo Staging For Specific
Gynecologic Cancer (IIIB)
Refer To Figo Staging For Specific
Gynecologic Cancer (IVA)
Refer To Figo Staging For Specific
Gynecologic Cancer (IVB)
Does the patient have parametrial involvement
with this disease
No (None)
Yes, Bilateral (Yes bilateral)
Yes, Unilateral (Yes unilateral)
Histologic Grade (check highest grade)
Grade 1-well Differentiated (1)
Grade 2-moderately Differentiated (2)
Grade 3-poorly Differentiated (3)
Histologic Type (check all that apply)
Adenocarcinoma, Unspecified
(Adenocarcinoma, unspecified)
Adenosquamous (Adenosquamous
carcinoma)
Other, Specify (Other specify)
Squamous Cell Carcinoma (Squamous
cell carcinoma)
Other specify
Site of Involvement (s - for Advanced Disease
Studies)
Abdomen (other Than Above) (Abdomen
(other than above))
Bladder (Bladder)
Bone (Bone)
Colon (Colon)
Liver (Liver)
Lung (Lung)
Other Specify (Other)
Pelvic (other Than Above) (Pelvic (other
than above))
Other specify
Lymph Nodes Type (Lymph Node Involvement
Indicate the most sensitive method of evaluation
2 / 3
On-Study - Primary Cervical Cancer - On-Study Form - 2019339v3.0
with a positive finding)
Other Specify (other)
Para-aortic (para-aortic)
Pelvic (pelvic)
Other specify
Lymph Node Involvement
Equivocal (equivocal)
Negative (negative)
Not Evaluated (not evaluated)
Positive (positive)
Unknown (unknown)
Method of Evaluation
Ct Scan (CT scan)
Mri (MRI (NMR))
Not Applicable (Not applicable)
Other, Specify (Other, specify)
Pathologic (Pathologic)
Physical Exam (Physical exam)
Ultrasound (Ultrasound)
Clinical Size of Tumor (at Diagnosis - If
microscopic, enter 0 - cm - Note:  Record either
the maximum diameter of the tumor or the
diameter of the expanded cervix principally
involved with cancer)
Allows Documentation Of Any Additional
Cooments
Comments
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On-Study - Primary Cervical Cancer - On-Study Form - 2019339v3.0
Endometrial Cancer NCT00265759 Follow-Up -
Z1031: Extended Follow-up Form - 2316464v3.0
Z1031: Extended Follow-up Form
Exemestane, Letrozole, or Anastrozole in Treating
Postmenopausal Women Who Are Undergoing Surgery for
Stage II or Stage III Breast Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=FAD6C4E6-
87C2-1268-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/8371
Z1031: Extended Follow-up Form
Header Module
Visit
30 Days Post Surgery (30 Days post
surgery)
Year 10 (Year 10)
Year 2 (Year 2)
Year 4 (Year 4)
Year 6 (Year 6)
Year 8 (Year 8)
Patient ID (Patient ID issued during registration or
previously issued Patient ID.)
Institution No.
Patient Initials (F M L)
Institution Name
Header
Vital status
Alive (Alive)
Dead (Dead)
Date of Last Contact or Death (Year Month e.g.,
JAN Day)
Primary cause of death (If deceased,)
Due To Other Cause (Due to other
cause)
Due To Protocol Treatment (Due to
protocol treatment)
Due To This Disease (Due to this
disease)
Describe cause of death
Was imaging done to assess for recurrence
(Mam, U/S, MRI, etc.)
Yes
No
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Image date
Notice Of First Recurrence/progression
Has the patient developed a first progression (or
relapse) that has not been previously reported?
Yes
No
First recurrence/progression
Distant (Distant)
Local (Local)
Regional (Regional)
Date of first recurrence/progression
Site of first recurrence/progression
Bone (Bone)
Liver (Liver)
Ln (LN)
Lung/pleura (Lung/pleura)
Other (Other)
Other, specify
Notice Of New Primary
Has a new primary cancer or MDS been
diagnosed that has not been previously reported?
Yes
No
Date of diagnosis
New Primary, Histologic type
Footer Module
Completed by
Date Form Completed
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Endometrial Cancer NCT00265759 Follow-Up - Z1031: Extended Follow-
up Form - 2316464v3.0
Treatment - Colorectal Cancer - Treatment
Form - Subset of Patients - 2282365v3.0
Colorectal Cancer - Treatment Form - Subset of Patients
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=DB74932D-
A052-302E-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/8372
Colorectal Cancer - Treatment Form
- Subset of Patients
Crf Header
Coordinating Group Protocol No.
Coordinating Group Code
Protocol Title
Patient Study ID
Institution/Affiliate
Other Patient ID
Participating Group Code
Patient Name (initials acceptable)
Colorectal: Form Administration
Person Completing Form
Are data amended? (If data are amended, please
circle in red when using paper form)
Yes
No
Colorectal: Treatment Reporting Interval
Reporting Period Start Date
Reporting Period End Date
Colorectal: Treatment Dosing Information
Agent Name
Agent Total Cumulative Dose
1 / 2
Units
Colorectal: Treatment Schedule -
Systemic Therapy
Total Number of Cycles Given (for this reporting
period)
Were there any dose modifications or
additions/omissions to protocol treatment? (for
this reporting period)
No (No)
Unknown (Unknown)
Yes, Planned (i.e., The Treatment Was
Changed According To Protocol
Guidelines) (Yes, planned)
Yes, Unplanned (i.e., The Treatment
Change Was Not Part Of Protocol
Guidelines) (Yes, unplanned)
Name of Therapy
Reason for Therapy Modification
Comments
Comments
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Treatment - Colorectal Cancer - Treatment Form - Subset of Patients -
2282365v3.0
Treatment - Lymphoma - Systemic
Treatment By Cycle Form - 2269265v3.0
Lymphoma - Systemic Treatment By Cycle Form
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=D4BFF450-
9917-0FD6-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/8375
Lymphoma - Systemic Treatment By
Cycle Form
Crf Header
Coordinating Group Protocol No.
Coordinating Group Code
Protocol Title
Patient Study ID
Institution/Affiliate
Other Patient ID
Participating Group Code
Patient Name (initials acceptable)
Lymphoma: Treatment Reporting Interval
Reporting Period Start Date
Reporting Period End Date
Patient Weight (kg)
Body Surface Area (m^2)
Lymphoma: Chemotherapy Cycle
Information
Cycle Start Date
Current Cycle Number
Agent Name (protocol specific)
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Total Dose of Agents/Drugs for this Cycle
(Vaccine name may be pre-printed with
appropriate units.)
units
Were there any dose modifications or
additions/omissions to protocol treatment? (check
one)
No (No)
Unknown (Unknown)
Yes, Planned (i.e., The Treatment Was
Changed According To Protocol
Guidelines) (Yes, planned)
Yes, Unplanned (i.e., The Treatment
Change Was Not Part Of Protocol
Guidelines) (Yes, unplanned)
Name of Therapy (If yes,)
Reason for Therapy Modification
Lymphoma: Immunotherapy Cycle
Information
Cycle Start Date
Current Cycle Number
Agent Name (protocol specific)
Total Dose of Agents/Drugs for this Cycle
(Vaccine name may be pre-printed with
appropriate units.)
units
Were there any dose modifications or
additions/omissions to protocol treatment? (check
one)
No (No)
Unknown (Unknown)
Yes, Planned (i.e., The Treatment Was
Changed According To Protocol
Guidelines) (Yes, planned)
Yes, Unplanned (i.e., The Treatment
Change Was Not Part Of Protocol
Guidelines) (Yes, unplanned)
Name of Therapy (If yes,)
2 / 4
Treatment - Lymphoma - Systemic Treatment By Cycle Form -
2269265v3.0
Reason for Therapy Modification
Lymphoma: Immuno-radiolabeled Therapy
Cycle Information
Cycle Start Date
Current Cycle Number
Agent Name (protocol specific)
Total Dose of Agents/Drugs for this Cycle
(Vaccine name may be pre-printed with
appropriate units.)
units
Were there any dose modifications or
additions/omissions to protocol treatment? (check
one)
No (No)
Unknown (Unknown)
Yes, Planned (i.e., The Treatment Was
Changed According To Protocol
Guidelines) (Yes, planned)
Yes, Unplanned (i.e., The Treatment
Change Was Not Part Of Protocol
Guidelines) (Yes, unplanned)
Name of Therapy (If yes,)
Reason for Therapy Modification
Lymphoma: Vaccine Therapy Cycle
Information
Date of Vaccination
Current Cycle Number
Vaccination Site (s check all that apply)
Left Lower Extremity (Left Lower
Extremity)
Left Upper Extremity (Left Upper
Extremity)
Other Specify (Other)
Right Lower Extremity (Right Lower
Extremity)
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Treatment - Lymphoma - Systemic Treatment By Cycle Form -
2269265v3.0
Right Upper Extremity (Right Upper
Extremity)
Trunk (Trunk)
Agent Name (protocol specific)
Total Dose of Agents/Drugs for this Cycle
(Vaccine name may be pre-printed with
appropriate units.)
Other specify
units
Were there any dose modifications or
additions/omissions to protocol treatment? (check
one)
No (No)
Unknown (Unknown)
Yes, Planned (i.e., The Treatment Was
Changed According To Protocol
Guidelines) (Yes, planned)
Yes, Unplanned (i.e., The Treatment
Change Was Not Part Of Protocol
Guidelines) (Yes, unplanned)
Name of Therapy (If yes,)
Reason for Therapy Modification
Comments
Comments
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Treatment - Lymphoma - Systemic Treatment By Cycle Form -
2269265v3.0
Brain and Central Nervous System Tumors NCT00304031
Treatment - RTOG-0525 T1: Radiotherapy Form - 2388768v1.0
RTOG-0525 T1: RadiotherapyForm
Radiation Therapy and Temozolomide in Treating Patients
With Newly Diagnosed Glioblastoma or Gliosarcoma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=FE14506D-
7AFC-4C09-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/8377
RTOG-0525 T1: Radiotherapy Form
Module 1
RTOG Study No.
Case #
Institution Name
Institution No.
Patient Initials
RTOG Patient ID
AMENDED DATA
Yes
No
RADIATION THERAPY START DATE
RADIATION THERAPY END DATE
ELAPSED DAYS
RT Total Fraction Count
RT Total Dose  (Gy)
WERE THERE ANY UNSCHEDULED
INTERRUPTIONS IN RADIATION THERAPY?
No (No)
Yes, Due To Other Reason (Yes, due to
other reason)
Yes, Due To Toxicity (Yes, due to toxicity)
Specify RT interruption reason
Reason Treatment Ended
Adverse Event/side Effects/complications
(Adverse Event/Side
1 / 2
Effects/Complications)
Alternative Therapy (Alternative therapy)
Death On Study (Death on study)
Disease Progression, Relapse During
Active Treatment (Disease progression,
relapse during active treatment)
Other (Other)
Patient Off-treatment For Other
Complicating Disease (Patient off-
treatment for other complicating disease)
Patient Withdrawal Or Refusal After
Beginning Protocol Therapy (Patient
withdrawal/refusal after beginning
protocol therapy)
Patient Withdrawal Or Refusal Before
Beginning Protocol Therapy (Patient
withdrawal/refusal prior to beginning
protocol therapy)
Treatment Completed Per Protocol
Criteria (Treatment completed per
protocol criteria)
Alternative Therapy
Other specify
Comments
Signature of person completing this form
Date form originally completed
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Brain and Central Nervous System Tumors NCT00304031 Treatment -
RTOG-0525 T1: Radiotherapy Form - 2388768v1.0
Colorectal Cancer NCT00499369 Toxicity - Southwest Oncology Group S0600
Adverse Event Form - For Patients Registered Before 6/6/2008 Only - 2484995v1.0
Southwest Oncology Group S0600 Adverse Event Form -
For Patients Registered Before 6/6/2008 Only
Irinotecan and Cetuximab With or Without Bevacizumab in
Treating Patients With Metastatic Colorectal Cancer That
Progressed During First-Line Therapy
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=15409265-
EC74-6C7E-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/8378
Southwest Oncology Group S0600
Adverse Event Form - For Patients
Registered Before 6/6/2008 Only
Header
SWOG Patient ID
SWOG Study No.
Patient Initials (L, F M)
Registration Step
Current Cycle Number
Institution/Affiliate
Physician
Participating Group Name
Participating Group Study No.
Participating Group Patient ID
Adverse Events
Reporting Period Start Date (Day 1 of this cycle)
Reporting Period End Date (Day one of next
cycle. If final cycle, date of first visit or contact
after resolution of acute adverse events.)
Were adverse events assessed during this time
period?
No (No)
Yes, And Reportable Adverse Events
Occurred (Yes, and reportable adverse
events occurred)
Yes, But No Reportable Adverse Events
Occurred (Yes, but no reportable adverse
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events occurred)
CTC Adverse Event Term
Blood Alkaline Phosphatase Nos
Increased (Alkaline phosphatase)
Hypersensitivity Nos (Allergic
reaction/hypersensitivity (including drug
fever))
Rhinitis Allergic Nos (Allergic rhinitis
(including sneezing, nasal stuffiness,
postnasal drip))
Alanine Aminotransferase Increased
(ALT, SGPT (serum glutamic pyruvic
transaminase))
Anorexia (Anorexia)
Aspartate Aminotransferase Increased
(AST, SGOT (serum glutamic oxaloacetic
transaminase))
Ataxia Nec (Ataxia (incoordination))
Blood Bilirubin Increased (Bilirubin
(hyperbilirubinemia))
Bronchospasm, Wheezing
(Bronchospasm, wheezing)
Myocardial Ischaemia (Cardiac
ischemia/infarction)
Cardiac Troponin I Increased (Cardiac
troponin I (cTnI))
Cerebral Ischaemia (CNS
cerebrovascular ischemia)
Colitis Nos (Colitis)
Constipation (Constipation)
Cough (Cough)
Blood Creatinine Increased (Creatinine)
Cytokine Release Syndrome/acute
Infusion Reaction (Cytokine release
syndrome/acute infusion reaction)
Dehydration (Dehydration)
Diarrhoea Nos (Diarrhea)
Dizziness (exc Vertigo) (Dizziness)
Dyspnoea Nos (Dyspnea (shortness of
breath))
Fatigue (Fatigue (asthenia, lethargy,
malaise))
Pyrexia (Fever (in the absence of
neutropenia, where neutropenia is
defined as ANC <1.0 x 10^9/L))
Fistula, Gi (Fistula, GI - Abdomen NOS)
Alopecia (Hair loss/Alopecia (scalp or
body))
Dyspepsia (Heartburn/dyspepsia)
Haemoglobin Decreased (Hemoglobin)
Haemorrhagic Stroke (Hemorrhage,
CNS)
Melaena (Hemorrhage, GI - Abdomen
NOS)
Hemorrhage, Gi (Hemorrhage, GI -
Colon)
Hemorrhage, Gi (Hemorrhage, GI -
Lower GI NOS)
Rectal Bleeding (Hemorrhage, GI -
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Colorectal Cancer NCT00499369 Toxicity - Southwest Oncology Group S0600
Adverse Event Form - For Patients Registered Before 6/6/2008 Only - 2484995v1.0
Rectum)
Hemorrhage, Gi (Hemorrhage, GI -
Upper GI NOS)
Hemorrhage, Pulmonary/upper
Respiratory (Hemorrhage,
pulmonary/upper respiratory - Lung)
Epistaxis (Hemorrhage, pulmonary/upper
respiratory - Nose)
Skin Discolouration (Hyperpigmentation)
Hypertension Nos (Hypertension)
Hypotension Nos (Hypotension)
Hypoxia (Hypoxia)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Abdomen
NOS)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Colon)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Lung
(pneumonia))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Pleura
(empyema))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Rectum)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Small bowel
NOS)
Leak (including Anastomotic), Gi (Leak
(including anastomotic), GI - Large
bowel)
Left Ventricular Diastolic Dysfunction
(Left ventricular diastolic dysfunction)
Left Ventricular Failure (Left ventricular
systolic dysfunction)
Leucopenia Nos (Leukocytes (total
WBC))
Blood Magnesium Decreased
(Magnesium, serum-low
(hypomagnesemia))
Mucositis/stomatitis (clinical Exam)
(Mucositis/stomatitis (clinical exam) -
Large bowel)
Mucositis/stomatitis (clinical Exam)
(Mucositis/stomatitis (clinical exam) -
Small bowel)
Mucositis/stomatitis
(functional/symptomatic)
(Mucositis/stomatitis
(functional/symptomatic) - Large bowel)
Mucositis/stomatitis
(functional/symptomatic)
(Mucositis/stomatitis
(functional/symptomatic) - Oral cavity)
3 / 5
Colorectal Cancer NCT00499369 Toxicity - Southwest Oncology Group S0600
Adverse Event Form - For Patients Registered Before 6/6/2008 Only - 2484995v1.0
Mucositis/stomatitis
(functional/symptomatic)
(Mucositis/stomatitis
(functional/symptomatic) - Small bowel)
Nail Abnormality Nos (Nail changes)
Nasal Cavity/paranasal Sinus Reactions
(Nasal cavity/paranasal sinus reactions)
Nausea (Nausea)
Necrosis, Gi (Necrosis, GI - Rectum)
Peripheral Sensory Neuropathy
(Neuropathy: sensory)
Neutropenia (Neutrophils/granulocytes
(ANC/AGC))
Obstruction, Gi (Obstruction, GI - Colon)
Obstruction, Gi (Obstruction, GI - Small
bowel NOS)
Abdominal Pain Nos (Pain - Abdomen
NOS)
Pain (Pain - Back)
Chest Pain (Pain - Chest/thorax NOS)
Headache Nos (Pain - Head/headache)
Arthralgia (Pain - Joint)
Myalgia (Pain - Muscle)
Perforation, Gi (Perforation, GI - Colon)
Perforation, Gi (Perforation, GI - Small
bowel NOS)
Pneumonitis Nos
(Pneumonitis/pulmonary infiltrates)
Proteinuria Present (Proteinuria)
Pruritus Nos (Pruritus/itching)
Dermatitis Exfoliative Nos
(Rash/desquamation)
Renal Failure Nos (Renal failure)
Rigors (Rigors/chills)
Speech Disorder Nec (Speech
impairment (e.g., dysphasia or aphasia))
Supraventricular Arrhythmia Nos
(Supraventricular and nodal arrhythmia -
Supraventricular arrhythmia NOS)
Thrombosis Nos
(Thrombosis/thrombus/embolism)
Urticaria Nos (Urticaria (hives, welts,
wheals))
Ventricular Arrhythmia (Ventricular
arrhythmia - Ventricular fibrillation)
Visceral Arterial Ischaemia (Visceral
arterial ischemia (non-myocardial))
Vision Blurred (Vision-blurred vision)
Dysphonia (Voice changes/dysarthria
(e.g., hoarseness, loss or alteration in
voice, laryngitis))
Vomiting Nos (Vomiting)
Weight Decreased (Weight loss)
CTC AE Grade (3.0 1-5)
CTC Adverse Event Attribution Code (*
Attribution codes: 1-unrelated 2-unlikely 3-
possible 4-probably 5-definite)
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Definite (Definite)
Possible (Possible)
Probable (Probable)
Unlikely (Unlikely)
Unrelated (Unrelated)
Adverse Event Onset Date
Adverse Event End Date
Adverse event status code (** Status codes since
baseline or last cycle: 1-new 2-continues at same
or lower grade 3-increased grade OR improved
then worsened)
Continues At Same Or Lower Grade
(Continues at same or lower grade)
Increased Grade Or Improved Then
Worsened (Increased grade or improved
then worsened)
New (New)
CTC Adverse Event Term Other (specify using
CTCAE 3.0 terminology)
Comments
Comments
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Endometrial Cancer NCT00063999 Pre-Study - Pre-Treatment
Summary Form, GOG-0209, Form DR - 2451160v1.0
Pre-Treatment Summary Form, GOG-0209, Form DR
Combination Chemotherapy in Treating Patients With Stage
III, Stage IV, or Recurrent Endometrial Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=0CC6A86E-
9AAD-737C-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/8381
Pre-Treatment Summary Form,
GOG-0209, Form DR
Header Module
Date form originally completed (m d y)
Date form amended (m d y)
Person amending form, last name
Patient Initials (First, Middle, Last)
Patient Study ID
Person completing form, last name
Non-invasive Diagnostic Procedures
Chest X-Ray Result
Abnormal (Abnormal)
Normal (Normal)
Not Done (Not done)
Date of Chest X-Ray (m d y)
EKG Result
Abnormal (Abnormal)
Normal (Normal)
Not Done (Not done)
Date of EKG (m d y)
MRI Result
Abnormal (Abnormal)
Normal (Normal)
Not Done (Not done)
Date of MRI (m d y)
CT Result
Abnormal (Abnormal)
Normal (Normal)
Not Done (Not done)
1 / 2
Date CT Scan (m d y)
Other Procedure Performed
Abnormal (Abnormal)
Normal (Normal)
Not Done (Not done)
Abnormal specify
Abnormal specify
Abnormal specify
Abnormal specify
Abnormal specify
Procedure Date (m d y)
Does the patient have target lesions
(RECOMMENDED TERM: Are there any target
lesions?)
Yes
No
Comments
Comments
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Brain and Central Nervous System Tumors NCT00884741 Treatment -
RTOG 0825 Phase III GBM Radiotherapy Form (T1) - 2796276v1.0
RTOG 0825 Phase III GBM Radiotherapy Form (T1)
Temozolomide and Radiation Therapy With or Without
Bevacizumab in Treating Patients With Newly Diagnosed
Glioblastoma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=5A7BC3C4-
2306-2CB9-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/8382
RTOG 0825 Phase III GBM
Radiotherapy Form (T1)
Module 1
RTOG Study No.
Case #
Institution Name
Institution No.
Patient Initials
RTOG Patient ID
Amended Data
Yes
No
Radiation Therapy Start Date (MM DD YYYY)
Radiation Therapy End Date (MM DD YYYY)
Elapsed days
RT Total Fraction Count
RT Total Dose  (Gy)
Were there any unscheduled interruptions in
radiation therapy? (excluding holidays)
No (No)
Yes, Due To Other Reason (Yes, due to
other reason)
Yes, Due To Toxicity (Yes, due to toxicity)
Specify RT interruption reason
Reason Treatment Ended
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Adverse Event/side Effects/complications
(Adverse Event/Side
Effects/Complications)
Alternative Therapy (Alternative therapy)
Death On Study (Death on study)
Disease Progression, Relapse During
Active Treatment (Disease progression,
relapse during active treatment)
Other (Other)
Patient Off-treatment For Other
Complicating Disease (Patient off-
treatment for other complicating disease)
Patient Withdrawal Or Refusal After
Beginning Protocol Therapy (Patient
withdrawal/refusal after beginning
protocol therapy)
Patient Withdrawal Or Refusal Before
Beginning Protocol Therapy (Patient
withdrawal/refusal prior to beginning
protocol therapy)
Treatment Completed Per Protocol
Criteria (Treatment completed per
protocol criteria)
Alternative Therapy
Other specify
Type of Radiation Therapy Administered
3d Conformal (3D conformal)
Imrt (IMRT)
Comments
Signature of Person Completing This Form
Form Completion Date, Original (MM DD YYYY)
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RTOG 0825 Phase III GBM Radiotherapy Form (T1) - 2796276v1.0
Follow-Up - Hodgkins Lymphoma - Follow
Up Form - 2269788v3.0
Hodgkin's Lymphoma - Follow Up Form
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=D5EB76B5-
458F-6D24-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/8385
Hodgkins Lymphoma - Follow Up
Form
Crf Header
Coordinating Group Protocol No.
Coordinating Group Code
Protocol Title
Patient Study ID
Institution/Affiliate
Other Patient ID
Participating Group Code
Patient Name (initials acceptable)
Lymphoma: Vital Status
Patient Vital Status
Alive (Alive)
Dead (Dead)
Primary Cause of Death
Due To Other Cause (Due to other
cause)
Due To Protocol Treatment (Due to
protocol treatment)
Due To This Disease (Due to this
disease)
Unknown (Unknown)
Was the cause cardiac, infection, or other (If due
to protocol treatment,)
Cardiac (Cardiac)
Infection (Infection)
Other (Other)
Other specify
Describe cause of death
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Date of Last Contact or Death (MM/DD/YYYY)
Medical Symptoms Present at Time of Death
(possible contributing causes)
Cardiovascular Disease. (Cardiovascular
disease)
Cerebrovascular Disease
(Cerebrovascular disease)
Infection (Infection)
Other (Other)
Pulmonary Disease (Pulmonary disease)
Secondary Cancer (Secondary cancer)
Other specify
is patient still being followed (If patient is alive,)
No (No)
Unknown (Unknown)
Yes (Yes)
Is the patient off study
No (No)
Unknown (Unknown)
Yes (Yes)
Off Study Reason (If yes,)
Adverse Event/side Effects/complications
(Adverse Event/Side
Effects/Complications)
Death (Death)
Other (Other)
Lost To Follow-up (Patient lost to follow-
up)
Patient Refused Follow-up (Patient
refused follow-up)
Protocol-defined Follow-up Completed
(Protocol-defined follow-up completed)
Other (specify)
Lymphoma: Disease Follow-up Status
Has the patient had a documented clinical
assessment for this cancer? (since submission of
the previous follow-up form)
No (No)
Unknown (Unknown)
Yes (Yes)
Date of Last Clinical Assessment
Lymphoma: Notice Of Progression Of
Hodgkin's Disease
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Has the patient developed a first progression (or
relapse) that has not been previously reported?
Yes
No
Date of Progression
Sites of Progression (mark all that apply)
Bone (Bone)
Bone Marrow (Bone marrow)
Colon (Colon)
Distant Lymph Nodes (Distant lymph
nodes)
Kidney (Kidney)
Liver (Liver)
Lung, Nos (Lung)
Other (Other)
Ovary (Ovary)
Pleura (Pleura)
Regional Lymph Nodes (Regional lymph
nodes)
Skin (Skin (cutaneous))
Small Bowel (Small bowel)
Spleen (Spleen)
Stomach (Stomach)
Testes (Testes)
Regional lymph nodes specify
Distant lymph nodes specify
Other specify
Lymphoma: Post-protocol Treatment
Is the patient going to start any new treatment
after protocol treatment is completed
No (No)
Unknown (Unknown)
Yes (Yes)
Type of Next Treatment (If yes,)
Maintenance (Maintenance)
Other (Other)
Transplant (Transplant)
Other specify
Time to Next Treatment
Units
Days (days)
Months (months)
Weeks (weeks)
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Time to Transplant Criteria
Units
Days (days)
Months (months)
Weeks (weeks)
Lymphoma: Notice Of New Primary
Has a new primary cancer or MDS been
diagnosed that has not been previously reported?
(myelodysplastic syndrome)
Yes
No
Date of Diagnosis
Site of New Primary (s If new primary site is
AML/MDS, please submit NCI AML/MDS form.)
Lymphoma: Long-term Toxicity
Has the patient experienced (prior to diagnosis of
recurrence or second primary) any severe (Grade
>=3), long term toxicity that has not been
previously reported?
No (No)
Unknown (Unknown)
Yes (Yes)
Late Adverse Event Term
Late Adverse Event Grade
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Dental Caries NCT01268605 Demographic -
PRL1013 - Demographics Form - 3134118v1.0
PRL1013 - Demographics Form
Postoperative Hypersensitivity Randomized Comparative
Effectiveness Research Trial (POH RCERT)
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=8F23FC3B-
D3B5-13C1-E040-BB89AD434902
All rights reserved. Please visit https://medical-data-
models.org/forms/8386
PRL1013 - Demographics Form
Header
Site Number
Patient Initials (First, Last)
Patient ID
Date of visit
Demographics
Patient Initials (First, Last)
Patient's Date of Birth
Gender
Female Gender (FEMALE)
Male Gender (MALE)
Unknown (UNKNOWN)
Ethnicity
A Person Of Mexican, Puerto Rican,
Cuban, Central Or South American Or
Other Spanish Culture Or Origin,
Regardless Of Race. (Hispanic or Latino)
A Person Not Meeting The Definition For
Hispanic Or Latino. (Not Hispanic or
Latino)
Could Not Be Determined Or Unsure
(Unknown)
Race
A Person Having Origins In Any Of The
Original Peoples Of North And South
America (including Central America),
And Who Maintains Tribal Affiliation Or
Community Attachment. (American
Indian or Alaska Native)
A Person Having Origins In Any Of The
Original Peoples Of The Far East,
Southeast Asia, Or The Indian
Subcontinent Including, For Example,
Cambodia, China, India, Japan, Korea,
Malaysia, Pakistan, The Philippine
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Islands, Thailand, And Vietnam. (Asian)
A Person Having Origins In Any Of The
Black Racial Groups Of Africa. Terms
Such As "haitian" Or "negro" Can Be
Used In Addition To "black Or African
American." (Black or African American)
A Person Having Origins In Any Of The
Original Peoples Of Hawaii, Guam,
Samoa, Or Other Pacific Islands. (Native
Hawaiian or other Pacific Islander)
Could Not Be Determined Or Unsure
(Unknown)
A Person Having Origins In Any Of The
Original Peoples Of Europe, The Middle
East, Or North Africa. (White)
Patient Zip Code
Preferred method of contact
E-mail (E-mail)
Telephone (Phone)
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Form - 3134118v1.0
Endometrial Cancer NCT00063999 Response - Solid Tumor
Evaluation Form, GOG-0209, Form D2M - 2077278v3.0
Solid Tumor Evaluation Form, GOG-0209, Form D2M
Combination Chemotherapy in Treating Patients With Stage
III, Stage IV, or Recurrent Endometrial Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=B240191E-
E5FE-0EF8-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/8387
Solid Tumor Evaluation Form, GOG-
0209, Form D2M
Header Module
Date form originally completed (m d y)
Date form amended (m d y)
Person amending form, last name
Patient Name, Last
Patient Name, First
Patient Study ID
Person Completing Form, Last Name
Target Lesion(s) Evaluation
Lesion Number (unnamed)
Site of Lesion
Date of Evaluation (m d y)
Method of Evaluation (coded values)
Chest X-ray (Chest X-ray)
Clinical Examination (pe) (Clinical
examination)
Ct Scan (CT Scan)
Mri (MRI (NMR))
Other (Other)
Spiral Ct Scan (Spiral CT Scan)
Ultrasound (Ultrasound)
If Other, specify (Method of Eval)
Longest Diameter of Lesions (cm)
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Sum of longest diameters of all target lesions
Non-target Lesion(s) Evaluation
Are there any nontarget lesions?
Yes
No
Lesion Number (unnamed)
Site of Lesion
Date of Evaluation (m d y)
Method of Evaluation (coded values)
Chest X-ray (Chest X-ray)
Clinical Examination (pe) (Clinical
examination)
Ct Scan (CT Scan)
Mri (MRI (NMR))
Other (Other)
Spiral Ct Scan (Spiral CT Scan)
Ultrasound (Ultrasound)
If Other, specify (Method of Eval)
Follow-Up Status of Lesions
Complete Response (Complete
Response)
Progressive Disease (Progressive
Disease)
Stable Disease Or Unchanged (Stable)
New Target Lesion(s) At Follow-up
Evaluation
Was the appearance of any new lesions
documented since the baseline evaluation?
Yes
No
Lesion Number (unnamed)
Site of Lesion
Date of Evaluation (m d y)
Method of Evaluation (coded values)
Chest X-ray (Chest X-ray)
Clinical Examination (pe) (Clinical
examination)
Ct Scan (CT Scan)
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Form, GOG-0209, Form D2M - 2077278v3.0
Mri (MRI (NMR))
Other (Other)
Spiral Ct Scan (Spiral CT Scan)
Ultrasound (Ultrasound)
If Other, specify (Method of Eval)
Overall Response
Overall response status at this assessment
(check one)
Complete Response (CR)
Insufficient Evaluation (Insufficient
evaluation to determine response status)
Progressive Disease (PD)
Partial Response (PR)
Stable Disease (SD)
Response confirmed date (m d y)
COMMENTS
Footer Module
Participating Group Code
Participating Group Protocol Number
Patient Study ID, Participating Group
Ccrr Module For Solid Tumor Evaluation
Form, Gog-0209, Form D2m
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Form, GOG-0209, Form D2M - 2077278v3.0
Follow-Up - Multiple Myeloma - Follow Up
Form - 2272994v3.0
Multiple Myeloma - Follow Up Form
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=D677C10D-
ECA6-0200-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/8390
Multiple Myeloma - Follow Up Form
Crf Header
Coordinating Group Protocol No.
Coordinating Group Code
Protocol Title
Patient Study ID
Institution/Affiliate
Other Patient ID
Participating Group Code
Patient Name (initials acceptable)
Myeloma: Vital Status
Patient Vital Status
Alive (Alive)
Dead (Dead)
Primary Cause of Death
Due To Other Cause (Due to other
cause)
Due To Protocol Treatment (Due to
protocol treatment)
Due To This Disease (Due to this
disease)
Unknown (Unknown)
Describe cause of death
Date of Last Contact or Death
Is the patient off study
No (No)
Unknown (Unknown)
Yes (Yes)
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Off Study Reason (If yes,)
Adverse Event/side Effects/complications
(Adverse Event/Side
Effects/Complications)
Death (Death)
Other (Other)
Lost To Follow-up (Patient lost to follow-
up)
Patient Refused Follow-up (Patient
refused follow-up)
Protocol-defined Follow-up Completed
(Protocol-defined follow-up completed)
Other (specify)
Myeloma: Disease Follow-up Status
Has the patient had a documented clinical
assessment for this cancer? (since submission of
the previous follow-up form)
No (No)
Unknown (Unknown)
Yes (Yes)
Date of Last Clinical Assessment
Myeloma: Notice Of Progression
Has the patient developed a first progression (or
relapse) that has not been previously reported?
No (No)
Unknown (Unknown)
Yes (Yes)
Date of Progression
Sites of Progression (mark all that apply)
Blood (spep, Immunofixation, Or
Quantitative Immunoglobulins) (Blood
(SPEP, immunofixation, or quantitative
immunoglobulins))
Bone Marrow (Bone marrow)
New Or Larger Bone Lesions (New or
larger bone lesions)
Other (Other)
Plasmacytoma (Plasmacytoma)
Serum Calcium (Serum calcium)
Unknown (Unknown)
Urine (upep Or Immunofixation) (Urine
(UPEP or immunofixation))
Other specify
Evidence of Progression
2 / 3
Follow-Up - Multiple Myeloma - Follow Up Form - 2272994v3.0
Anemia (Anemia)
Bone (Bone)
Calcium (Calcium)
Other (Other)
Peripheral Blood (Peripheral blood)
Plasmacytoma (Plasmacytoma)
Serum M-protein (spep Or
Immunofixation) (Serum M-protein
(SPEP or immunofixation))
Unknown (Unknown)
Urine (Urine)
Urine M-protein (upep Or
Immunofixation) (Urine M-protein (UPEP
or immunofixation))
Other specify
Subsequent Treatment
No (No)
Unknown (Unknown)
Yes (Yes)
Subsequent Treatment Type (If yes,)
Date of Subsequent Treatment
Myeloma: Notice Of New Primary
Has a new primary cancer or MDS been
diagnosed that has not been previously reported?
(myelodysplastic syndrome)
Yes
No
Date of Diagnosis
Site of New Primary (s If new primary site is
AML/MDS, please submit NCI AML/MDS form.)
Myeloma: Long-term Toxicity
Has the patient experienced (prior to diagnosis of
recurrence or second primary) any severe (Grade
>=3), long term toxicity that has not been
previously reported
No (No)
Unknown (Unknown)
Yes (Yes)
Late Adverse Event Term
Late Adverse Event Grade
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Endometrial Cancer NCT00265759 Follow-Up - Z1031:
Early Termination of Follow-up (ETFU) - 2316526v3.0
Z1031: Early Termination of Follow-up (ETFU)
Exemestane, Letrozole, or Anastrozole in Treating
Postmenopausal Women Who Are Undergoing Surgery for
Stage II or Stage III Breast Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=FAD5B1B8-
C17F-0689-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/8392
Z1031: Early Termination of Follow-
up (ETFU)
Header Module
Visit
Post Surgery (Post Surgery)
Pre Intervention (Pre Intervention)
Surgery (Surgery)
Week 12 (Week 12)
Week 15 (Week 15)
Week 16 (Week 16)
Week 4 (Week 4)
Week 8 (Week 8)
Year 10 (Year 10)
Year 2 (Year 2)
Year 4 (Year 4)
Year 6 (Year 6)
Year 8 (Year 8)
Patient ID (Pt. ID issued during registration or
previously issued patient ID)
Institution No.
Patient Initials (F M L)
Institution Name
Header
Date of Early Termination of Follow-up
Reason for early termination of patient follow-up
(mark only one)
Lost Contact With Patient (Lost contact
with patient)
Other (Other)
Patient Refusal For Further Study
Follow-up (Patient refusal for further
study follow-up)
Patient Withdrew Consent. (Patient
withdrew consent)
Other, specify
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Footer Module
Completed by
Date Form Completed
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Endometrial Cancer NCT00265759 Follow-Up - Z1031: Early Termination
of Follow-up (ETFU) - 2316526v3.0
Follow-Up - Lung Cancer - Advanced
Disease Follow Up Form - 2019424v2.31
Lung Cancer - Advanced Disease Follow Up Form
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=99CD59C5-
A8E5-3FA4-E034-080020C9C0E0
All rights reserved. Please visit https://medical-data-
models.org/forms/8394
Lung Cancer - Advanced Disease
Follow Up Form
Crf Header
Coordinating Group Protocol No.
Coordinating Group Code
Protocol Title
Patient Study ID
Institution/Affiliate
Other Patient ID
Participating Group Code
Patient Name (initials acceptable)
Tbd
Vital Status
Alive (Alive)
Dead (Dead)
Primary Cause of Death
Due To Other Cause, Specify (Due to
other cause, specify)
Due To Protocol Treatment (Due to
protocol treatment)
Due To This Disease (Due to this
disease)
Unknown (Unknown)
Describe cause of death
Date of Last Contact or Death
Tbd
Has the patient had a documented clinical
assessment for this cancer? (since submission of
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the previous follow-up form)
No (No)
Unknown (Unknown)
Yes (Yes)
Date of Last Clinical Assessment
Tbd
Has the patient developed a first progression (or
relapse) that has not been previously reported?
Yes
No
Date of Progression
Lung: Non-protocol Therapy
Is the patient receiving any non-protocol cancer
therapy not previously reported?
Yes
No
Non-Protocol Hormonal Therapy? (includes
medical and surgical)
Yes
No
Non-Protocol Chemotherapy
Yes
No
Non-Protocol Immunotherapy?
Yes
No
Non-Protocol Biologic Response Modifier?
Yes
No
Non-Protocol High Dose
Chemotherapy/Autologous Stem Cell Transplant
Yes
No
Non-Protocol Radiation Therapy?
Yes
No
Non-Protocol Surgery?
Yes
No
Other Non-Protocol Therapy
Yes
No
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Name of Other Non-Protocol Therapy (If yes,)
Date of First Non-Protocol Therapy
Tbd
Has a new primary cancer or MDS been
diagnosed that has not been previously reported?
(myelodysplastic syndrome)
No (No)
Unknown (Unknown)
Yes (Yes)
Date of diagnosis
Site of New Primary (s)
Tbd
Has the patient experienced (prior to diagnosis of
recurrence or second primary) any severe (Grade
>=3), long term toxicity that has not been
previously reported
No (No)
Unknown (Unknown)
Yes (Yes)
Late Adverse Event Term
Late Adverse Event Grade
Allows Documentation Of Any Additional
Cooments
Comments
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Colorectal Cancer NCT01167725 On-Study - USMCI
8214/Z6091:  On-Study Form - 2823136v1.0
USMCI 8214/Z6091:  On-Study Form
Standard Therapy With or Without Surgery and Mitomycin
C in Treating Patients With Advanced Limited Peritoneal
Dissemination of Colon Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=60004F3F-
C2F6-CADB-E040-BB89AD43053A
All rights reserved. Please visit https://medical-data-
models.org/forms/8395
USMCI 8214/Z6091:  On-Study
Form
Header Module
Visit
Baseline (Baseline)
Patient ID
Institution No.
Institution Name
Patient Demographics
Date of Registration
Weight
Height
Body Surface Area
Extenet Of Peritoneal Disease
Has the patient had laparoscopic staging
Yes
No
CT-PCI
Epi-gastric mass size
Small Bowel Obstruction
Yes
No
Pathology Information
Tumor type
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Peritoneal Neoplasm (Peritoneal Surface
Tumor)
Primary Colon Neoplasm (Primary Colon
Tumor)
T Stage
Tumor Invades Submucosa (T1)
Tumor Invades Muscularis Propria (T2)
Tumor Invades Through The Muscularis
Propria Into The Subserosa, Or Into
Nonperitonealized Pericolic Or Perirectal
Tissues (T3)
Tumor Directly Invades Other Organs Or
Structures, And/or Perforates Visceral
Peritoneum (T4)
Carcinoma In Situ: Intraepithelial Or
Invasion Of Lamina Propria (Tis)
Primary Tumor Cannot Be Assessed
(TX)
N Stage
Metastasis In 1 To 3 Regional Lymph
Nodes (N1)
Metastasis In 4 Or More Regional Lymph
Nodes (N2)
Regional Lymph Node Cannot Be
Assessed (NX)
Grade
Well Differentiated (G1)
Moderately Differentiated (G2)
Poorly Differentiated (G3)
Undifferentiated (G4)
Grade Cannot Be Assessed (GX)
Lymphovascular Invasion
Not Determined (ND)
No (NO)
Yes (YES)
Mucin producing tumor
Not Determined (ND)
No (No)
Yes (Yes)
Intra-tumor K-ras mutation
Absent (Absent)
Not Determined (ND)
Present (Present)
Intra-tumoral thymidylate synthase expression
High (High)
Low (Low)
Not Determined (ND)
Intra-tumoral microsatellite instability
Microsatellite Instability Negative Finding
(MSI-Negative)
Microsatellite Instability (MSI-Positive)
Not Determined (ND)
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Colorectal Cancer NCT01167725 On-Study - USMCI 8214/Z6091:  On-
Study Form - 2823136v1.0
Prior Treatment
Has the patient received prior adjuvant
chemotherapy for Stage II or III colon carcinoma
Yes
No
Prior chemotherapy agent
Year
Has the patient had prior surgery for stage II or III
colon carcinoma
Yes
No
Prior Surgery Type
Date
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Colorectal Cancer NCT01167725 On-Study - USMCI 8214/Z6091:  On-
Study Form - 2823136v1.0
Follow-Up - Non-Hodgkins Lymphoma -
Follow Up Form - 2270441v3.0
Non-Hodgkin's Lymphoma - Follow Up Form
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=D5EACC20-
1E3D-7370-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/8397
Non-Hodgkins Lymphoma - Follow
Up Form
Crf Header
(Information contained in this section is optional
and may be included at the discretion of the
group; for example: preprinted labels or
electronically populated fields may be used)
Coordinating Group Code
Protocol Title
Patient Study ID
Institution/Affiliate
Other Patient ID
Participating Group Code
Patient Name (initials acceptable)
Lymphoma: Vital Status
Patient Vital Status
Alive (Alive)
Dead (Dead)
Primary Cause of Death
Due To Other Cause (Due to other
cause)
Due To Protocol Treatment (Due to
protocol treatment)
Due To This Disease (Due to this
disease)
Unknown (Unknown)
Was the cause cardiac, infection, or other (If due
to protocol treatment,)
Cardiac (Cardiac)
Infection (Infection)
Other (Other)
Other specify
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Describe cause of death
Date of Last Contact or Death (MM/DD/YYYY)
Medical Symptoms Present at Time of Death
(possible contributing causes)
Cardiovascular Disease. (Cardiovascular
disease)
Cerebrovascular Disease
(Cerebrovascular disease)
Infection (Infection)
Other (Other)
Pulmonary Disease (Pulmonary disease)
Secondary Cancer (Secondary cancer)
Other specify
is patient still being followed (If patient is alive,)
No (No)
Unknown (Unknown)
Yes (Yes)
Is the patient off study
No (No)
Unknown (Unknown)
Yes (Yes)
Off Study Reason (If yes,)
Adverse Event/side Effects/complications
(Adverse Event/Side
Effects/Complications)
Death (Death)
Other (Other)
Lost To Follow-up (Patient lost to follow-
up)
Patient Refused Follow-up (Patient
refused follow-up)
Protocol-defined Follow-up Completed
(Protocol-defined follow-up completed)
Other (specify)
Lymphoma: Disease Follow-up Status
Has the patient had a documented clinical
assessment for this cancer? (since submission of
the previous follow-up form)
No (No)
Unknown (Unknown)
Yes (Yes)
Date of Last Clinical Assessment
2 / 4
Follow-Up - Non-Hodgkins Lymphoma - Follow Up Form - 2270441v3.0
Lymphoma: Notice Of Progression Of
Non-hodgkin's Lymphoma
Has the patient developed a first progression (or
relapse) that has not been previously reported?
Yes
No
Date of Progression
Sites of Progression (mark all that apply)
Bone (Bone)
Bone Marrow (Bone marrow)
Brain - Parenchymal (Brain -
parenchymal)
Cns - Epidural (CNS - epidural)
Cns - Leptomeninges (CNS -
leptomeninges)
Cns - Vitreal (CNS - vitreal)
Colon (Colon)
Distant Lymph Nodes (Distant lymph
nodes)
Kidney (Kidney)
Liver (Liver)
Lung, Nos (Lung)
Other (Other)
Ovary (Ovary)
Parotid Gland (Parotid gland)
Pleura (Pleura)
Regional Lymph Nodes (Regional lymph
nodes)
Skin (Skin (cutaneous))
Small Bowel (Small bowel)
Spine - Parenchymal (Spine -
parenchymal)
Spleen (Spleen)
Stomach (Stomach)
Submandibular Gland (Submandibular
gland)
Testes (Testes)
Thymus (Thymus)
Thyroid (Thyroid)
Regional lymph nodes specify
Distant lymph nodes specify
Other specify
Lymphoma: Post-protocol Treatment
Is the patient going to start any new treatment
after protocol treatment is completed
No (No)
Unknown (Unknown)
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Follow-Up - Non-Hodgkins Lymphoma - Follow Up Form - 2270441v3.0
Yes (Yes)
Type of Next Treatment (If yes,)
Maintenance (Maintenance)
Other (Other)
Transplant (Transplant)
Other specify
Time to Next Treatment
Units
Days (days)
Months (months)
Weeks (weeks)
Time to Transplant Criteria
Units
Days (days)
Months (months)
Weeks (weeks)
Lymphoma: Notice Of New Primary
Has a new primary cancer or MDS been
diagnosed that has not been previously reported?
(myelodysplastic syndrome)
Yes
No
Date of Diagnosis
Site of New Primary (s If new primary site is
AML/MDS, please submit NCI AML/MDS form.)
Lymphoma: Long-term Toxicity
Has the patient experienced (prior to diagnosis of
recurrence or second primary) any severe (Grade
>=3), long term toxicity that has not been
previously reported
No (No)
Unknown (Unknown)
Yes (Yes)
Late Adverse Event Term
Late Adverse Event Grade
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Follow-Up - Non-Hodgkins Lymphoma - Follow Up Form - 2270441v3.0
Follow-Up - Colorectal Cancer - Follow-Up
Form - 2282337v3.0
Colorectal Cancer - Follow-Up Form
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=DB748B98-
21DB-2FC3-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/8400
Colorectal Cancer - Follow-Up Form
Crf Header
Coordinating Group Protocol No.
Coordinating Group Code
Protocol Title
Patient Study ID
Institution/Affiliate
Other Patient ID
Participating Group Code
Patient Name (initials acceptable)
Colorectal: Vital Status
Patient's Vital Status
Alive (Alive)
Dead (Dead)
Date of Last Contact or Death
Colorectal: Disease Follow-up Status
Has the patient had a documented clinical
assessment for this cancer? (since submission of
the previous follow-up form)
Yes
No
Date of Last Clinical Assessment (only provide
date if assessment since submission of previous
follow-up form)
Colorectal: Notice Of Progression
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Has the patient developed a first progression (or
relapse) that has not been previously reported?
Yes
No
Date of  Progression
Sites of Progression
Colorectal: Notice Of New Primary
Has a new primary cancer or MDS been
diagnosed that has not been previously reported?
(myelodysplastic syndrome)
No (No)
Unknown (Unknown)
Yes (Yes)
Date of Diagnosis
Site of New Primary (s If new primary site is
AML/MDS, please submit NCI AML/MDS form.)
Comments
Comments
2 / 2
Follow-Up - Colorectal Cancer - Follow-Up Form - 2282337v3.0
Kidney Cancer NCT01120249 Toxicity - Southwest Oncology
Group S0931 Adverse Event Form (Form #552) - 2998452v1.0
Southwest Oncology Group S0931 Adverse Event Form
(Form #552)
Everolimus in Treating Patients With Kidney Cancer Who
Have Undergone Surgery
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=7E26385C-
8BFB-C34F-E040-BB89AD434A8D
All rights reserved. Please visit https://medical-data-
models.org/forms/8401
Southwest Oncology Group S0931
Adverse Event Form (Form #552)
Header
SWOG Patient ID
SWOG Study No.
Registration Step
Patient Initials (L, F M)
Current Cycle Number
Institution/Affiliate
Physician
Participating Group Name
Participating Group Study No.
Participating Group Patient ID
Adverse Events
Reporting Period Start Date (MM DD YYYY Day
1 of this Cycle)
CTC Adverse Event Term (Other)
Reporting Period End Date (MM DD YYYY Day
one of next cycle. If final cycle, date of first visit or
contact after resolution of acute adverse events.)
CTC AE Grade
Mild Adverse Event (1)
Moderate Adverse Event (2)
Severe Adverse Event (3)
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Life Threatening Adverse Event (4)
Death Related To Adverse Event (5)
Were adverse events assessed during this time
period?
No (No)
Yes, And Reportable Adverse Events
Occurred (Yes, and reportable adverse
events occurred)
Yes, But No Reportable Adverse Events
Occurred (Yes, but no reportable adverse
events occurred)
CTC Adverse Event Attribution Code
Definite (Definite)
Possible (Possible)
Probable (Probable)
Unlikely (Unlikely)
Unrelated (Unrelated)
Adverse event status code
Continues At Same Or Lower Grade
(Continues at same or lower grade)
Increased Grade Or Improved Then
Worsened (Increased grade or improved
then worsened)
New (New)
Ctc Adverse Event Term, Other
CTC Adverse Event Term (Other)
CTC AE Grade
Mild Adverse Event (1)
Moderate Adverse Event (2)
Severe Adverse Event (3)
Life Threatening Adverse Event (4)
Death Related To Adverse Event (5)
CTC Adverse Event Attribution Code
Definite (Definite)
Possible (Possible)
Probable (Probable)
Unlikely (Unlikely)
Unrelated (Unrelated)
Adverse event status code
Continues At Same Or Lower Grade
(Continues at same or lower grade)
Increased Grade Or Improved Then
Worsened (Increased grade or improved
then worsened)
New (New)
Comments
Comments
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Kidney Cancer NCT01120249 Toxicity - Southwest Oncology Group
S0931 Adverse Event Form (Form #552) - 2998452v1.0
Colorectal Cancer NCT01167725 Follow-Up - USMCI
8214/Z6091:  Crossover Form - 3086267v1.0
USMCI 8214/Z6091:  Crossover Form
Standard Therapy With or Without Surgery and Mitomycin
C in Treating Patients With Advanced Limited Peritoneal
Dissemination of Colon Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=86892E20-
76ED-E852-E040-BB89AD43495E
All rights reserved. Please visit https://medical-data-
models.org/forms/8402
USMCI 8214/Z6091:  Crossover
Form
Header Module
Visit
Crossover (Crossover)
Patient ID
Institution No.
Institution Name
Header
Date of last dose (on Group 1)
Did the patient crossover
Yes
No
Date of Progression
Reason (If no,)
Other (Other)
Patient Ineligible (Patient ineligible)
Patient Refusal (Patient refusal)
Specify
Footer Module
Completed by
Date Form Completed
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Follow-Up - Brain Cancer - Event
Monitoring Form - 2287724v3.0
Brain Cancer - Event Monitoring Form
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=E51DD029-
A8BB-3E76-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/8403
Brain Cancer - Event Monitoring
Form
Crf Header
Coordinating Group Protocol No.
Coordinating Group Code
Protocol Title
Patient Study ID
Institution/Affiliate
Other Patient ID
Participating Group Code
Patient Name (initials acceptable)
Brain: Vital Status
Date of Last Contact or Death
Patient Vital Status
Alive (Alive)
Dead (Dead)
Primary Cause of Death
Due To Other Cause (Due to other
cause)
Due To Protocol Treatment (Due to
protocol treatment)
Due To This Disease (Due to this
disease)
Unknown (Unknown)
Type of Cancer (If cancer was primary cause of
death, indicate)
Brain Cancer (Brain cancer)
Cancer At Other Site (Cancer at other
site)
Describe cause of death
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Brain: Off Study Reason
Off Study Date (MM DD YYYY)
Off Study Reason
Adverse Event/side Effects/complications
(Adverse Event/side
effects/complications)
Death (Death)
Other (Other)
Lost To Follow-up (Patient lost to follow-
up)
Patient Refused Follow-up (Patient
refused follow-up)
Protocol-defined Follow-up Completed
(Protocol-defined follow-up completed)
Other specify
Brain: Disease Follow-up Status
Has the patient had a documented clinical
assessment for this cancer? (since submission of
the previous follow-up form)
No (No)
Unknown (Unknown)
Yes (Yes)
Date of Last Clinical Assessment (MM DD YYYY)
Brain: Notice Of Progression
Has the patient developed a first progression (or
relapse) that has not been previously reported?
Yes
No
Date of Progression (MM DD YYYY)
Basis of Diagnosis
Clinical (Clinical)
Histology (Histology)
Imaging Only (Imaging only)
Site(s) of Progression (mark all that apply)
Aqueduct Of Sylvius (Aqueduct of
sylvius)
Basal Ganglia (Basal ganglia)
Brainstem (Brainstem)
Cauda Equina (Cauda equina)
Cavernous Sinus (Cavernous sinus)
Cerebellar Hemisphere (Cerebellar
hemisphere)
Cerebellar Peduncle (Cerebellar
peduncle)
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Follow-Up - Brain Cancer - Event Monitoring Form - 2287724v3.0
Cerebellar Vermis (Cerebellar vermis)
Cerebellum (Cerebellum)
Cervical (Cervical)
Cisterna Magna (Cisterna magna)
Conus (Conus)
Corpus Callosum (Corpus callosum)
Dorsal Exophytic Brainstem (Dorsal
exophytic brainstem)
Fourth Ventricle (Fourth ventricle)
Frontal (Frontal)
Hypothalamus (Hypothalamus)
Lateral Ventricle (Lateral ventricle)
Leptomeningeal (Leptomeningeal)
Lumbar (Lumbar)
Medulla (Medulla)
Midbrain (Midbrain)
Occipital (Occipital)
Optic Chiasm (Optic chiasm)
Optic Nerve (Optic nerve)
Other Specify (Other specify)
Parietal (Parietal)
Pineal (Pineal)
Pons (Pons)
Spinal Cord (c1 And Below) (Spinal cord)
Temporal (Temporal)
Thalamus (Thalamus)
Third Ventricle (Third ventricle)
Thoracic (Thoracic)
Other specify
Brain: Notice Of New Primary
Has a new primary cancer or MDS been
diagnosed that has not been previously reported?
(myelodysplastic syndrome)
Yes
No
Date of Diagnosis (MM DD YYYY)
Site of New Primary (If new primary site is
AML/MDS, please submit NCI AML/MDS form.)
Brain: Long-term Toxicity
Has the patient experienced (prior to diagnosis of
recurrence or second primary) any severe (Grade
>=3), long term toxicity that has not been
previously reported
No (No)
Unknown (Unknown)
Yes (Yes)
Late Adverse Event Term
Late Adverse Event Grade
3 / 3
Follow-Up - Brain Cancer - Event Monitoring Form - 2287724v3.0
Follow-Up - Advanced Bladder/Urothelial
Cancer - Follow-Up Form - 2019343v2.31
Advanced Bladder/Urothelial Cancer - Follow-Up Form
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=99CD59C5-
A976-3FA4-E034-080020C9C0E0
All rights reserved. Please visit https://medical-data-
models.org/forms/8407
Advanced Bladder/Urothelial Cancer
- Follow-Up Form
Crf Header
Coordinating Group Protocol No.
Coordinating Group Code
Protocol Title
Patient Study ID
Other Patient ID
Institution/Affiliate
Participating Group Code
Patient Name (initials acceptable)
Breast: Form Administration
Person Completing Form
Are data amended (If data are amended, please
circle in red when using paper form)
Yes
No
Bladder/urothelial: Vital Status
Patient Vital Status
Alive (Alive)
Dead (Dead)
Primary Cause of Death (check one)
Due To Other Cause (Due to other
cause)
Due To Protocol Treatment (Due to
protocol treatment)
Due To This Disease (Due to this
disease)
Unknown (Unknown)
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Describe cause of death
Date of Last Contact or Death
Bladder/urothelial: Disease Follow-up
Status
Has the patient had a documented clinical
assessment for this cancer? (since submission of
the previous follow-up form)
Yes
No
Date of Last Clinical Assessment (only provide
date if assessment since submission of previous
follow-up form)
Bladder/urothelial: Notice Of Progression
Has the patient been diagnosed with a local
recurrence (non-nodal site) (that has not been
previously reported)
Yes
No
Date of First Local Progression
Site of First Local Progression (s - mark all that
apply)
Abdominal Wall (Abdominal wall)
Other Specify (Other)
Pelvic Wall (Pelvic wall)
Peritoneum (Peritoneum)
Prostate Gland (Prostate)
Skin (Skin)
Urethra (Urethra)
Uterus (Uterus)
Vagina (Vagina)
Other specify
Has the patient been diagnosed with a local-
regional lymph node recurrence that has not
been previously reported
Yes
No
Date of First Local-Regional Lymph Node
Progression
Site of First Local-Regional Lymph Node
Progression (s - mark all that apply)
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Follow-Up - Advanced Bladder/Urothelial Cancer - Follow-Up Form -
2019343v2.31
Common Iliac (Common iliac)
External Iliac (External iliac)
Hypogastric (Hypogastric)
Internal Iliac (Internal iliac)
Other Specify (Other)
Para-aortic (Para-aortic)
Has the patient been diagnosed with a distant
metastatic progression that has not been
previously reported
Yes
No
Date of First Distant Progression
Progression Site, First Distant
Bone (bone)
Central Nervous System Or Brain
(central nervous system/brain)
Distant Lymph Nodes (distant nodes)
Liver (liver)
Lung (lung)
Other, Specify (other)
Peritoneum (peritoneum)
Pleura (pleura)
Skin (skin)
Distant Nodes, specify
Sites of progression, Other Specify
Sites of progression, Other Specify
Bladder/urothelial: Notice Of New Primary
New Primary Cancer Ind
No (NO)
Unknown (UNKNOWN)
Yes (YES)
New Primary Cancer Date
New Primary Site
Bladder/urothelial: Long-term Toxicity
Late Adverse Event Ind
No (NO)
Unknown (UNKNOWN)
Yes (YES)
Late Adverse Event Term
Use Rtog/eortc Grading System (see Ctc
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Follow-Up - Advanced Bladder/Urothelial Cancer - Follow-Up Form -
2019343v2.31
Version 2.0.
Http://ctep.info.nih.gov/ctc3/ctc.htm).
(Use RTOG/EORTC grading system
(See CTC version 2.0.
http://ctep.info.nih.gov/CTC3/ctc.htm).)
Late Adverse Event Grade
Late Adverse Event Onset Date
Allows Documentation Of Any Additional
Cooments
Comments
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Follow-Up - Advanced Bladder/Urothelial Cancer - Follow-Up Form -
2019343v2.31
Endometrial Cancer NCT00265759 Follow-Up
- Z1031: Missed Visit Form - 2316588v3.0
Z1031: Missed Visit Form
Exemestane, Letrozole, or Anastrozole in Treating
Postmenopausal Women Who Are Undergoing Surgery for
Stage II or Stage III Breast Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=FAD4E3B9-
30EF-72AE-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/8408
Z1031: Missed Visit Form
Header Module
Visit
30 Days Post Surgery (30 Days post
surgery)
Year 10 (Year 10)
Year 2 (Year 2)
Year 4 (Year 4)
Year 6 (Year 6)
Year 8 (Year 8)
Patient ID (Pt. ID issued during registration or
previously issued patient ID)
Institution No.
Patient Initials (F M L)
Institution Name
Header
Missed Visit Date (Year Month e.g., JAN Day)
Reason patient missed visit (Mark only one.)
Distance From Home To Clinical Site
(Distance from home to clinical site)
Health Reasons (Health reasons)
Other (Other)
Scheduling Difficulties (Scheduling
difficulties)
Other, specify
Footer Module
Completed by
Date Form Completed
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Endometrial Cancer NCT00265759 Follow-Up
- Mammogram - Reports Form - 2427063v1.0
Mammogram - Reports Form
Exemestane, Letrozole, or Anastrozole in Treating
Postmenopausal Women Who Are Undergoing Surgery for
Stage II or Stage III Breast Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=05129D06-
2D9E-635D-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/8409
Mammogram - Reports Form
Header Module
Visit
30 Days Post Surgery (30 Days post
surgery)
Day 1 (Day 1)
Prior To Registration (Prior to
Registration)
Surgery (Surgery)
Week 12 (Week 12)
Week 15 (Week 15)
Week 16 (Week 16)
Week 4 (Week 4)
Week 8 (Week 8)
Within 14 Days Prior To Intervention
(Within 14 days prior to intervention)
Year 10 (Year 10)
Year 2 (Year 2)
Year 4 (Year 4)
Year 6 (Year 6)
Year 8 (Year 8)
Patient ID
Institution ID
Patient Initials
Institution
Header
CTSU reports
Mammogram Report (Mammogram
Report)
Assessment Date
Footer
Completed by
Date Form Completed
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Follow-Up - Breast Cancer - Advanced
Disease Follow-Up Form - 2280124v3.0
Breast Cancer - Advanced Disease Follow-Up Form
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=DA18BF01-
4294-073C-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/8412
Breast Cancer - Advanced Disease
Follow-Up Form
Crf Header
Coordinating Group Protocol No.
Coordinating Group Code
Protocol Title
Patient Study ID
Institution/Affiliate
Other Patient ID
Participating Group Code
Patient Name (initials acceptable)
Breast: Form Administration
Person Completing Form
Are data amended? (If data are amended, please
circle in red when using paper form)
Yes
No
Breast: Vital Status
Patient Vital Status
Alive (Alive)
Dead (Dead)
Primary Cause of Death (check one)
Due To Other Cause (Due to other
cause)
Due To Protocol Treatment (Due to
protocol treatment)
Due To This Disease (Due to this
disease)
Unknown (Unknown)
1 / 3
Describe cause of death
Date of Last Contact or Death
Breast: Disease Follow-up Status
Has the patient had a documented clinical
assessment for this cancer? (since submission of
the previous follow-up form)
Yes
No
Date of Last Clinical Assessment (only provide
date if assessment since submission of previous
follow-up form)
Breast: Notice Of Progression - Advanced
Disease
Has the patient developed a first progression (or
relapse) that has not been previously reported?
No (No)
Unknown (Unknown)
Yes (Yes)
Date of Progression
Breast: Non-protocol Therapy
Is the patient receiving any non-protocol cancer
therapy not previously reported?
Yes
No
Non-Protocol Hormonal Therapy? (includes
medical and surgical)
Yes
No
Non-Protocol Surgery?
Yes
No
Non-Protocol Radiation Therapy?
Yes
No
Other Non-Protocol Therapy
Yes
No
Name of Other Non-Protocol Therapy (If yes,)
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Follow-Up - Breast Cancer - Advanced Disease Follow-Up Form -
2280124v3.0
Date of First Non-Protocol Therapy
Breast: Notice Of New Primary
Has a new primary cancer or MDS been
diagnosed that has not been previously reported?
(myelodysplastic syndrome)
Yes
No
Date of Diagnosis
Site of New Primary (s If new primary site is
AML/MDS, please submit NCI AML/MDS form.)
Comments
Comments
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Follow-Up - Breast Cancer - Advanced Disease Follow-Up Form -
2280124v3.0
Follow-Up - Lung Cancer - Localized
Disease Follow-Up Form - 2019386v2.31
Lung Cancer - Localized Disease Follow-Up Form
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=99CD59C5-
A8FE-3FA4-E034-080020C9C0E0
All rights reserved. Please visit https://medical-data-
models.org/forms/8414
Lung Cancer - Localized Disease
Follow-Up Form
Crf Header
Coordinating Group Protocol No.
Coordinating Group Code
Protocol Title
Patient Study ID
Institution/Affiliate
Other Patient ID
Participating Group Code
Patient Name (initials acceptable)
Tbd
Vital Status
Alive (Alive)
Dead (Dead)
Primary Cause of Death
Due To Other Cause, Specify (Due to
other cause, specify)
Due To Protocol Treatment (Due to
protocol treatment)
Due To This Disease (Due to this
disease)
Unknown (Unknown)
Describe cause of death
Date of Last Contact or Death
Tbd
Has the patient had a documented clinical
assessment for this cancer? (since submission of
1 / 4
the previous follow-up form)
No (No)
Unknown (Unknown)
Yes (Yes)
Date of Last Clinical Assessment
Information On Progression Or Relapse
Of Localized Lung Cancer (both Nsclc
And Sclc Trials)
Has the patient developed a first progression (or
relapse) that has not been previously reported?
Yes
No
Date of Progression
Lung
Yes
No
Liver
Yes
No
Pleura
Yes
No
CNS (excluding Brain)
Yes
No
Brain
Yes
No
Bone
Yes
No
Opposite Lung
Yes
No
Regional Lymph Nodes
Yes
No
Distant Lymph Nodes
Yes
No
Distant Skin/subcutaneous Tissue
Yes
No
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Follow-Up - Lung Cancer - Localized Disease Follow-Up Form -
2019386v2.31
Other
Yes
No
If sites other than specified, indicate name
Disease Progression Site was within Radiation
Portal (use only for protocols with radiation
therapy)
Yes
No
Disease Progression Site was outside Radiation
Portal
Yes
No
Tbd
Is the patient receiving any non-protocol cancer
therapy not previously reported?
Yes
No
Non-Protocol Hormonal Therapy?
Yes
No
Non-Protocol Chemotherapy
Yes
No
Non-Protocol Immunotherapy?
Yes
No
Non-Protocol Biologic Response Modifier?
Yes
No
Non-Protocol High Dose
Chemotherapy/Autologous Stem Cell Transplant
Yes
No
Non-Protocol Radiation Therapy?
Yes
No
Non-Protocol Surgery?
Yes
No
Other Non-Protocol Therapy
Yes
No
Name of Other Non-Protocol Therapy (If yes,)
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Follow-Up - Lung Cancer - Localized Disease Follow-Up Form -
2019386v2.31
Date of First Non-Protocol Therapy
Tbd
Has a new primary cancer or MDS been
diagnosed that has not been previously reported?
(myelodysplastic syndrome)
No (No)
Unknown (Unknown)
Yes (Yes)
Date of diagnosis
Site of New Primary (s - If new primary is
AML/MDS, please submit NCI AML/MDS form.)
Tbd
Has the patient experienced (prior to diagnosis of
recurrence or second primary) any severe (Grade
>=3), long term toxicity that has not been
previously reported
No (No)
Unknown (Unknown)
Yes (Yes)
Late Adverse Event Term
Late Adverse Event Grade
Allows Documentation Of Any Additional
Cooments
Comments (optional)
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Follow-Up - Lung Cancer - Localized Disease Follow-Up Form -
2019386v2.31
Dental Caries NCT01268605 Demographic -
PRL1013 - Baseline Evaluation Form - 3153809v1.0
PRL1013 - Baseline Evaluation Form
Postoperative Hypersensitivity Randomized Comparative
Effectiveness Research Trial (POH RCERT)
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=93FFF84B-
84F7-2161-E040-BB89AD4349B9
All rights reserved. Please visit https://medical-data-
models.org/forms/8416
PRL1013 - Baseline Evaluation Form
Header
Site Code
Date of visit
Subject ID
Subject Initials
Treatment arm
Restoration With Dba (RD)
Restoration With Rmgi (RR)
Pre-treatment Evaluation
Date of evaluation
Has the patient noticed his/her sleep bruxism
Yes
No
Has the patient's partner noted the patient's sleep
bruxism
Yes
No
Is enlargement of masseter muscle present
Yes
No
Is enlargement due to sleep bruxism (If "Yes")
Yes
No
Is heavy wear of the study tooth a result of sleep
bruxism
Yes
No
Does the patient experience jaw muscle
discomfort, fatigue or pain and jaw lock upon
awakening
Yes
No
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Is the patient being treated for sleep bruxism
Yes
No
Evaluation Of Caries
Tooth quadrant
Lower Left Quadrant (Lower Left)
Lower Right Quadrant (Lower Right)
Upper Left Quadrant (Upper Left)
Upper Right Quadrant (Upper Right)
Caries stage
Distinct Cavity With Visible Dentin,
Extensive Lesion (Distinct cavity with
visible dentin, extensive lesion)
Localized Enamel Breakdown, Loss Of
Cementum, Dentin Shadow (Localized
enamel breakdown, loss of cementum,
dentin shadow)
Visual Change In Enamel Or Cementum
(Visual change in enamel or cementum)
Rank dentin caries activity
Firm But Discolored (Firm but
discolored)
Leathery (Leathery)
Soft, Dry (Soft, dry)
Soft, Dry, Granular (Soft, dry, granular)
Soft, Serous (Soft, serous)
Visual presence of a crack(s) in the pulpal floor
dentin
Yes
No
Cavity Measurements
Deepest Cavity Depth (mm)
Shallowest Cavity Depth (mm)
Cavity Length (mm)
Greatest Cavity Width (mm)
Narrowest Cavity Width (mm)
Treatment
Curing light output (mW/cm2 [a minimum of 400
mW/cm2])
2 / 3
Dental Caries NCT01268605 Demographic - PRL1013 - Baseline
Evaluation Form - 3153809v1.0
Is patient randomized into the RMGI liner with
DBA arm
Yes
No
RMGI Liner applied and cured (If "Yes")
Yes
No
Self-etch dentin bonding agent (DBA) applied
and cured
Yes
No
Hybrid resin-based composite (RBC) applied and
cured
Yes
No
Restoration finished?
Yes
No
What is your ranking of the risk of future caries in
this patient
High (High)
Low (Low)
Moderate (Moderate)
Footer Module
Comments
3 / 3
Dental Caries NCT01268605 Demographic - PRL1013 - Baseline
Evaluation Form - 3153809v1.0
Follow-Up - Breast Cancer - Adjuvant
Follow-Up Form - 2279997v3.0
Breast Cancer - Adjuvant Follow-Up Form
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=DA188C45-
CBCA-04EA-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/8417
Breast Cancer - Adjuvant Follow-Up
Form
Crf Header
Coordinating Group Protocol No.
Coordinating Group Code
Protocol Title
Patient Study ID
Institution/Affiliate
Other Patient ID
Participating Group Code
Patient Name (initials acceptable)
Breast: Form Administration
Person Completing Form
Are data amended? (If data are amended, please
circle in red when using paper form)
Yes
No
Breast: Vital Status
Patient Vital Status
Alive (Alive)
Dead (Dead)
Primary Cause of Death (check one)
Due To Other Cause (Due to other
cause)
Due To Protocol Treatment (Due to
protocol treatment)
Due To This Disease (Due to this
disease)
Unknown (Unknown)
1 / 3
Describe cause of death
Date of Last Contact or Death
Breast: Disease Follow-up Status
Has the patient had a documented clinical
assessment for this cancer? (since submission of
the previous follow-up form)
Yes
No
Date of Last Clinical Assessment (only provide
date if assessment since submission of previous
follow-up form)
Breast: Notice Of Progression - Adjuvant
Has the patient been diagnosed with first local-
regional recurrence (since submission of last
follow-up form)
Yes
No
Date of First Local-Regional Progression
Site of First Local-Regional Progression (s mark
all that apply)
Axilla (Axilla)
Axillary Nodes (Axillary nodes)
Chest Wall (Chest wall)
Infraclavicular Nodes (Infraclavicular
nodes)
Internal Mammary Nodes (Internal
mammary nodes)
Ipsilateral Breast (Ipsilateral Breast)
Supraclavicular Nodes (Supraclavicular
nodes)
Has the patient been diagnosed with first distant
recurrence/progression? (since submission of last
follow-up form)
Yes
No
Date of First Distant Progression
Site of First Distant Progression (s)
How was this progression information obtained?
Clinical Assessment (Clinical
assessment)
Patient Self Report Only (Patient self-
report only)
2 / 3
Follow-Up - Breast Cancer - Adjuvant Follow-Up Form - 2279997v3.0
How was this progression information obtained?
Clinical Assessment (Clinical
assessment)
Patient Self Report Only (Patient self-
report only)
Breast: Notice Of New Primary
Has a new primary cancer or MDS been
diagnosed that has not been previously reported?
(myelodysplastic syndrome)
Yes
No
Date of Diagnosis
Site of New Primary (s If new primary site is
AML/MDS, please submit NCI AML/MDS form.)
Breast: Long-term Toxicity
Has the patient experienced (prior to diagnosis of
recurrence or second primary) any severe (Grade
>=3), long term toxicity that has not been
previously reported
Yes
No
Late Adverse Event Term
Late Adverse Event Grade
Date of Onset of Long-Term Toxicity
Breast: Long-term Therapy
Did this patient receive any tamoxifen?
Yes
No
Is the patient still receiving tamoxifen?
Yes
No
If patient discontinued tamoxifen since last follow-
up, give date
Comments
Comments
3 / 3
Follow-Up - Breast Cancer - Adjuvant Follow-Up Form - 2279997v3.0
Colorectal Cancer NCT00726622 Follow-Up -
Z6051 Extended Follow-up (EFU) - 2717820v1.0
Z6051 Extended Follow-up (EFU)
Laparoscopic-Assisted Resection or Open Resection in
Treating Patients With Stage IIA, Stage IIIA, or Stage IIIB
Rectal Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=42BEFB76-
7A1D-58A8-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/8418
Z6051 Extended Follow-up (EFU)
Header Module
Visit
Month 12 (Month 12)
Month 18 (Month 18)
Month 24 (Month 24)
Month 3 (Month 3)
Month 36 (Month 36)
Month 48 (Month 48)
Month 6 (Month 6)
Month 60 (Month 60)
Patient ID (Patient ID issued during registration or
previously issued Patient ID.)
Patient Initials
Institution Name
Institution No.
Header
Has any patient information been obtained since
the last report?
Yes
No
Vital status
Alive (Alive)
Dead (Dead)
Date of Last Contact or Death
Primary Cause of Death (If deceased,)
Due To Other Cause (Other)
Due To This Disease (This cancer)
Due To Protocol Treatment (Treatment
related to this protocol)
Describe cause of death
Adjuvant Therapy Data
1 / 3
Did patient receive adjuvant therapy
Yes
No
Adjuvant therapy received (If yes, - mark all that
apply)
Bevacizumab (Bevacizumab)
Fluorouracil (Fluorouracil)
Irinotecan (Irinotecan)
Other (Other)
Oxaliplatin (Oxaliplatin)
Radiation Therapy (Radiation Therapy)
Other specify
Disease Assessment Data
Was disease status radiologically or
endoscopically assessed (since the last visit)
Yes
No
Date of most recent scan or endoscopic exam
Notice Of First Recurrence (local,
Regional Or Distant)
Has the patient been diagnosed with first
recurrence/progression not previously reported
Yes
No
First recurrence/progression
Metastatic (Distant)
Local (Local)
Regional (Regional)
Wound/trocar Site (Wound/trocar site)
Distant
Liver (Liver)
Lung (Lung)
Other (Other)
Peritoneum (Peritoneum)
Other specify
Date of First Recurrence (or progression)
Notice Of New Primary
Has a new primary cancer or MDS been
diagnosed that has not been previously reported?
Yes
No
2 / 3
Colorectal Cancer NCT00726622 Follow-Up - Z6051 Extended Follow-up
(EFU) - 2717820v1.0
Date of diagnosis
New Primary Histologic type
Footer Module
Completed by
Date Form Completed
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Colorectal Cancer NCT00726622 Follow-Up - Z6051 Extended Follow-up
(EFU) - 2717820v1.0
Follow-Up - Sarcoma - Functional Evaluation
Form for Extremity Primary - 2290878v3.0
Sarcoma - Functional Evaluation Form for Extremity
Primary
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=E298AD03-
E4A8-0934-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/8420
Sarcoma - Functional Evaluation
Form for Extremity Primary
Crf Header
Coordinating Group Protocol No.
Coordinating Group Code
Protocol Title
Patient Study ID
Institution/Affiliate
Other Patient ID
Participating Group Code
Patient Name (initials acceptable)
Sarcoma: Form Administration
Person Completing Form
Are data amended (If data are amended, please
circle in red when using paper form)
Yes
No
Sarcoma: Functional Evaluation
Function (Lower Limb Assessment)
No Restriction (No restriction)
Partial Disability (Partial disability)
Recreational Restriction (Recreational
restriction)
Total Disability (Total disability)
Supports
1 Cane Or Crutch (1 cane or crutch)
2 Canes Or Crutches (2 canes or
1 / 3
crutches)
Brace (Brace)
None (None)
Walking
Inside Only (Inside only)
Limited (Limited)
Not Independently (Not independently)
Unlimited (Unlimited)
Gait
Major Cosmetic, Minor Handicap (Major
cosmetic, minor handicap)
Major Handicap (Major handicap)
Minor Cosmetic (Minor cosmetic)
Normal (Normal)
Pain
Moderate (Moderate)
Modest (Modest)
None (None)
Severe (Severe)
Emotional Acceptance
Accepts (Accepts)
Dislikes (Dislikes)
Enthused (Enthused)
Intermediate (Intermediate)
Likes (Likes)
Satisfied (Satisfied)
Function (Upper Limb Assessment)
No Restriction (No restriction)
Partial Disability (Partial disability)
Recreational Restriction (Recreational
restriction)
Total Disability (Total disability)
Hand Position
Flail (Flail)
No Limitations (No limitations)
Not Above Shoulder Or No
Pro/supination (Not above shoulder or no
pro/supination)
Not Above Waist (Not above waist)
Dexterity
Cannot Grasp (Cannot grasp)
Cannot Pinch (Cannot pinch)
Loss Of Fine Movement (Loss of fine
movement)
Normal (Normal)
Lifting
Cannot Be Used To Help (Cannot be
used to help)
Helping Capacity Only (Helping capacity
only)
Limited (Limited)
Normal (Normal)
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Follow-Up - Sarcoma - Functional Evaluation Form for Extremity Primary
- 2290878v3.0
Pain
Moderate (Moderate)
Modest (Modest)
None (None)
Severe (Severe)
Emotional Acceptance
Accepts (Accepts)
Dislikes (Dislikes)
Enthused (Enthused)
Intermediate (Intermediate)
Likes (Likes)
Satisfied (Satisfied)
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Follow-Up - Sarcoma - Functional Evaluation Form for Extremity Primary
- 2290878v3.0
Colorectal Cancer NCT01167725 Follow-Up - USMCI 8214/Z6091
Early Termination of Follow-up (ETFU) - 3135012v1.0
USMCI 8214/Z6091 Early Termination of Follow-up (ETFU)
Standard Therapy With or Without Surgery and Mitomycin
C in Treating Patients With Advanced Limited Peritoneal
Dissemination of Colon Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=8FAFF4D8-
E3FD-9D2E-E040-BB89AD435E44
All rights reserved. Please visit https://medical-data-
models.org/forms/8421
USMCI 8214/Z6091 Early
Termination of Follow-up (ETFU)
Header Module
Visit (This form is not scheduled)
Patient ID
Institution No.
Institution Name
Header
Date of Early Termination of Follow-up
Reason for early termination of patient follow-up
(Mark only one)
Lost Contact With Patient (Lost contact
with patient)
Other (Other)
Patient Refusal For Further Study
Follow-up (Patient refusal for further
study follow-up)
Patient Withdrew Consent. (Patient
withdrew consent)
Other, specify
Footer Module
Completed by
Date Form Completed
1 / 1
Colorectal Cancer NCT00726622 Follow-Up - Z6051
Early Termination of Follow-up (ETFU) - 2717776v1.0
Z6051 Early Termination of Follow-up (ETFU)
Laparoscopic-Assisted Resection or Open Resection in
Treating Patients With Stage IIA, Stage IIIA, or Stage IIIB
Rectal Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=42BEDFEF-
2DFC-4E04-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/8422
Z6051 Early Termination of Follow-
up (ETFU)
Header Module
Visit
1-2 Weeks (1-2 Weeks)
4-6 Weeks (4-6 Weeks)
Day 3 (Day 3)
Month 12 (Month 12)
Month 18 (Month 18)
Month 24 (Month 24)
Month 3 (Month 3)
Month 36 (Month 36)
Month 48 (Month 48)
Month 6 (Month 6)
Month 60 (Month 60)
Pre-operative (Pre-Op)
Pre-registration (Pre-Reg)
Surgery (Surgery)
Patient ID (Pt. ID issued during registration
unless pt. previously registered to an ACOSOG
study.)
Patient Initials
Institution Name
Institution No.
Header
Date of Early Termination of Follow-up
Reason for early termination of patient follow-up
(mark x only one)
Other (Other)
Patient Did Not Have Surgery (Patient
did not have surgery)
Patient Withdrew Consent. (Patient
withdrew consent)
Other, specify
1 / 2
Footer Module
Completed by
Date Form Completed
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Colorectal Cancer NCT00726622 Follow-Up - Z6051 Early Termination of
Follow-up (ETFU) - 2717776v1.0
Follow-Up - Waldenstroms Macroglobulinemia
- Follow Up Form - 2274166v3.0
Waldenstrom's Macroglobulinemia - Follow Up Form
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=D67977AD-
1633-1008-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/8423
Waldenstroms Macroglobulinemia -
Follow Up Form
Crf Header
Coordinating Group Protocol No.
Coordinating Group Code
Protocol Title
Patient Study ID
Institution/Affiliate
Other Patient ID
Participating Group Code
Patient Name (initials acceptable)
Waldenstrom's: Vital Status
Patient Vital Status
Alive (Alive)
Dead (Dead)
Primary Cause of Death
Due To Other Cause (Due to other
cause)
Due To Protocol Treatment (Due to
protocol treatment)
Due To This Disease (Due to this
disease)
Unknown (Unknown)
Describe cause of death
Date of Last Contact or Death
Is the patient off study
No (No)
Unknown (Unknown)
Yes (Yes)
1 / 3
Off Study Reason (If yes,)
Adverse Event/side Effects/complications
(Adverse Event/Side
Effects/Complications)
Death (Death)
Other (Other)
Lost To Follow-up (Patient lost to follow-
up)
Patient Refused Follow-up (Patient
refused follow-up)
Protocol-defined Follow-up Completed
(Protocol-defined follow-up completed)
Other (specify)
Waldenstrom's: Disease Follow-up Status
Has the patient had a documented clinical
assessment for this cancer? (since submission of
the previous follow-up form)
No (No)
Unknown (Unknown)
Yes (Yes)
Date of Last Clinical Assessment
Waldenstrom's: Notice Of Progression
Has the patient developed a first progression (or
relapse) that has not been previously reported?
No (No)
Unknown (Unknown)
Yes (Yes)
Date of Progression
Sites of Progression
Blood (spep, Immunofixation, Or
Quantitative Igm) (Blood (SPEP,
immunofixation, or quantitative IgM))
Bone Marrow (Bone Marrow)
Liver (Liver)
Lymph Nodes (Lymph nodes)
Other (Other)
Peripheral Blood (Peripheral blood)
Spleen (Spleen)
Unknown (Unknown)
Other specify
Evidence of Progression
Bone Marrow/lymphocytosis (Bone
marrow/lymphocytosis)
Ct Scan (CT scan)
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Follow-Up - Waldenstroms Macroglobulinemia - Follow Up Form -
2274166v3.0
Hemoglobin (Hemoglobin)
Hepatomegaly (Hepatomegaly)
Igm (IgM)
M-protein/paraprotein Spike (M-
protein/paraprotein spike)
Other (Other)
Peripheral Blood (Peripheral blood)
Splenomegaly (Splenomegaly)
Unknown (Unknown)
Urine Light Chain (Urine light chain)
Other specify
Subsequent Treatment
No (No)
Unknown (Unknown)
Yes (Yes)
Subsequent Treatment Type (If yes,)
Date of Subsequent Treatment
Waldenstrom's: Notice Of New Primary
Has a new primary cancer or MDS been
diagnosed that has not been previously reported?
(myelodysplastic syndrome)
Yes
No
Date of Diagnosis
Site of New Primary (s If new primary site is
AML/MDS, please submit NCI AML/MDS form.)
Waldenstrom's: Long-term Toxicity
Has the patient experienced (prior to diagnosis of
recurrence or second primary) any severe (Grade
>=3), long term toxicity that has not been
previously reported
No (No)
Unknown (Unknown)
Yes (Yes)
Late Adverse Event Term
Late Adverse Event Grade
3 / 3
Follow-Up - Waldenstroms Macroglobulinemia - Follow Up Form -
2274166v3.0
Colorectal Cancer NCT01167725 On-Study - USMCI 8214/Z6091:
Quality of Life Questionnaires (cover sheet) - 2891901v1.0
USMCI 8214/Z6091:  Quality of Life Questionnaires (cover
sheet)
Standard Therapy With or Without Surgery and Mitomycin
C in Treating Patients With Advanced Limited Peritoneal
Dissemination of Colon Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=6AFDAEC3-
1F36-0D02-E040-BB89AD4312D1
All rights reserved. Please visit https://medical-data-
models.org/forms/8425
USMCI 8214/Z6091:  Quality of Life
Questionnaires (cover sheet)
Header Module
Protocol No.
Institution No.
Patient ID
Patient Initials
Visit
Quality Of Life (QOL)
Visit time point
Baseline (Baseline)
Month 12 (Month 12)
Month 24 (Month 24)
Month 3 (Month 3)
Month 6 (Month 6)
Cycle Number
Date of collection
Unnamed2
CES-D
Yes
No
SF-36
Yes
No
FACT-C
Yes
No
Brief Pain Inventory
Yes
No
1 / 1
Endometrial Cancer NCT00265759 Follow-Up
- Pathology - Reports Form - 2427204v1.0
Pathology - Reports Form
Exemestane, Letrozole, or Anastrozole in Treating
Postmenopausal Women Who Are Undergoing Surgery for
Stage II or Stage III Breast Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=05146325-
44DA-7256-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/8426
Pathology - Reports Form
Header Module
Visit
30 Days Post Surgery (30 Days post
surgery)
Day 1 (Day 1)
Prior To Registration (Prior to
Registration)
Surgery (Surgery)
Week 12 (Week 12)
Week 15 (Week 15)
Week 16 (Week 16)
Week 4 (Week 4)
Week 8 (Week 8)
Within 14 Days Prior To Intervention
(Within 14 days prior to intervention)
Year 10 (Year 10)
Year 2 (Year 2)
Year 4 (Year 4)
Year 6 (Year 6)
Year 8 (Year 8)
Patient ID
Institution ID
Patient Initials
Institution
Header
CTSU reports
Pathology Report (Pathology Report)
Assessment Date
Footer
Completed by
Date Form Completed
1 / 1
Follow-Up - Primary Amyloidosis - Follow
Up Form - 2273817v3.0
Primary Amyloidosis - Follow Up Form
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=D6794088-
D3E7-0C48-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/8429
Primary Amyloidosis - Follow Up
Form
Crf Header
Coordinating Group Protocol No.
Coordinating Group Code
Protocol Title
Patient Study ID
Institution/Affiliate
Other Patient ID
Participating Group Code
Patient Name (initials acceptable)
Amyloidosis: Vital Status
Patient Vital Status
Alive (Alive)
Dead (Dead)
Primary Cause of Death
Due To Other Cause (Due to other
cause)
Due To Protocol Treatment (Due to
protocol treatment)
Due To This Disease (Due to this
disease)
Unknown (Unknown)
Describe cause of death
Date of Last Contact or Death
Is the patient off study
No (No)
Unknown (Unknown)
Yes (Yes)
1 / 3
Off Study Reason (If yes,)
Adverse Event/side Effects/complications
(Adverse Event/Side
Effects/Complications)
Death (Death)
Other (Other)
Lost To Follow-up (Patient lost to follow-
up)
Patient Refused Follow-up (Patient
refused follow-up)
Protocol-defined Follow-up Completed
(Protocol-defined follow-up completed)
Other (specify)
Amyloidosis: Disease Follow-up Status
Has the patient had a documented clinical
assessment for this cancer? (since submission of
the previous follow-up form)
No (No)
Unknown (Unknown)
Yes (Yes)
Date of Last Clinical Assessment
Amyloidosis: Notice Of Progression
Has the patient developed a first progression (or
relapse) that has not been previously reported?
No (No)
Unknown (Unknown)
Yes (Yes)
Date of Progression
Type of Progression (mark all that apply)
Hematologic (Hematologic)
Organ (Organ)
Other (Other)
Unknown (Unknown)
Other specify
Hematologic
Bone Marrow (Bone marrow)
Serum Monoclonal Protein (Serum
monoclonal protein)
Urine Monoclonal Protein (Urine
monoclonal protein)
Organ
Cardiac (echo) (Cardiac (echo))
Gastrointestinal (fecal Fat)
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Follow-Up - Primary Amyloidosis - Follow Up Form - 2273817v3.0
(Gastrointestinal (fecal fat))
Liver (liver Size Or Alkaline
Phosphatase) (Liver (liver size or alkaline
phosphatase))
Nerve (Nerve)
Renal (urine Total Protein) (Renal (urine
total protein))
Soft Tissue (Soft tissue)
Subsequent Treatment
No (No)
Unknown (Unknown)
Yes (Yes)
Subsequent Treatment Type (If yes,)
Date of Subsequent Treatment
Amyloidosis: Notice Of New Primary
Has a new primary cancer or MDS been
diagnosed that has not been previously reported?
(myelodysplastic syndrome)
Yes
No
Date of Diagnosis
Site of New Primary (s If new primary site is
AML/MDS, please submit NCI AML/MDS form.)
Amyloidosis: Long-term Toxicity
Has the patient experienced (prior to diagnosis of
recurrence or second primary) any severe (Grade
>=3), long term toxicity that has not been
previously reported
No (No)
Unknown (Unknown)
Yes (Yes)
Late Adverse Event Term
Late Adverse Event Grade
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Follow-Up - Primary Amyloidosis - Follow Up Form - 2273817v3.0
Endometrial Cancer NCT00265759 Follow-Up
- Ultrasound - Reports Form - 2427235v1.0
Ultrasound - Reports Form
Exemestane, Letrozole, or Anastrozole in Treating
Postmenopausal Women Who Are Undergoing Surgery for
Stage II or Stage III Breast Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=0514688D-
BDAA-7332-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/8430
Ultrasound - Reports Form
Header Module
Visit
30 Days Post Surgery (30 Days post
surgery)
Day 1 (Day 1)
Prior To Registration (Prior to
Registration)
Surgery (Surgery)
Week 12 (Week 12)
Week 15 (Week 15)
Week 16 (Week 16)
Week 4 (Week 4)
Week 8 (Week 8)
Within 14 Days Prior To Intervention
(Within 14 days prior to intervention)
Year 10 (Year 10)
Year 2 (Year 2)
Year 4 (Year 4)
Year 6 (Year 6)
Year 8 (Year 8)
Patient ID
Institution ID
Patient Initials
Institution
Header
CTSU reports
Ultrasound Report (Ultrasound Report)
Assessment Date
Footer
Completed by
Date Form Completed
1 / 1
Follow-Up - Prostate Cancer - Follow-Up
Form - 2283616v3.0
Prostate Cancer - Follow-Up Form
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=DC4FC43C-
3456-5CA7-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/8433
Prostate Cancer - Follow-Up Form
Crf Header
Coordinating Group Protocol No.
Coordinating Group Code
Protocol Title
Patient Study ID
Institution/Affiliate
Other Patient ID
Participating Group Code
Patient Name (initials acceptable)
Prostate: Vital Status
Patient's Vital Status
Alive (Alive)
Dead (Dead)
Primary Cause of Death
Due To Other Cause (Due to other
cause)
Due To Protocol Treatment (Due to
protocol treatment)
Due To This Disease (Due to this
disease)
Unknown (Unknown)
Describe cause of death
Date of Last Contact or Death
Prostate: Disease Follow-up Status
Has the patient had a documented clinical
assessment for this cancer? (since submission of
1 / 3
the previous follow-up form)
No (No)
Unknown (Unknown)
Yes (Yes)
Date of Last Clinical Assessment
Prostate: Notice Of Progression
Has the patient developed a first progression (or
relapse) that has not been previously reported?
Yes
No
Date of First Biochemical Progression (per
protocol definition leave blank if distant relapse
previously reported)
Unit of Measure
Micrograms Per Liter (mcg/L)
Milligrams Per Liter (mg/L)
N/milligram (n/mg)
Nanograms Per Deciliter (ng/dL)
Nanograms Per Milliliter (ng/mL)
Units Per Liter (U/L)
PSA Value at Progression (per protocol definition)
Date of First Local-Regional Progression (per
protocol definition leave blank if distant relapse
previously reported)
Site of First Local-Regional Progression (s)
Date of First Distant Progression (leave blank if
distant relapse previously reported)
Site of First Distant Progression (s)
Prostate: Psa Measurements
PSA Value (total)
Unit of Measure
Micrograms Per Liter (mcg/L)
Milligrams Per Liter (mg/L)
N/milligram (n/mg)
Nanograms Per Deciliter (ng/dL)
Nanograms Per Milliliter (ng/mL)
Units Per Liter (U/L)
Date of PSA Assessment
2 / 3
Follow-Up - Prostate Cancer - Follow-Up Form - 2283616v3.0
Prostate: Non-protocol Therapy
Is the patient receiving any non-protocol cancer
therapy not previously reported?
Yes
No
Non-Protocol Hormonal Therapy? (includes
medical and surgical)
Yes
No
Non-Protocol Surgery?
Yes
No
Non-Protocol Radiation Therapy?
Yes
No
Other Non-Protocol Therapy
Yes
No
Name of Other Non-Protocol Therapy (If yes,)
Date of First Non-Protocol Therapy
Prostate: Notice Of New Primary
Has a new primary cancer or MDS been
diagnosed that has not been previously reported?
(myelodysplastic syndrome)
Yes
No
Date of Diagnosis
Site of New Primary (s If new primary site is
AML/MDS, please submit NCI AML/MDS form.)
Prostate: Long-term Toxicity
Has the patient experienced (prior to diagnosis of
recurrence or second primary) any severe (Grade
>=3), long term toxicity that has not been
previously reported
Yes
No
Late Adverse Event Term
Late Adverse Event Grade
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Follow-Up - Prostate Cancer - Follow-Up Form - 2283616v3.0
On-Study - Pediatric Soft Tissue Sarcoma - On-Study
Form Newly Diagnosed Patients - 2292713v3.0
Pediatric Soft Tissue Sarcoma - On-Study Form Newly
Diagnosed Patients
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=E4051BFF-
CFA4-2D00-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/8436
Pediatric Soft Tissue Sarcoma - On-
Study Form Newly Diagnosed
Patients
Crf Header
Coordinating Group Protocol No.
Coordinating Group Code
Protocol Title
Patient Study ID
Institution/Affiliate
Other Patient ID
Participating Group Code
Patient Name (initials acceptable)
Sarcoma: Form Administration
Person Completing Form
Are data amended (If data are amended, please
circle in red when using paper form)
Yes
No
Pediatric Soft Tissue Sarcoma: Disease
Description
Date of Initial Pathologic Diagnosis (MM DD
YYYY)
Biopsy Type
Excisional (Excisional)
Incisional (Incisional)
Large Bore Needle (Large bore needle)
Other, Specify (Other specify)
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Trucut Needle (TruCut needle)
Other specify
Primary Site
Bladder (Bladder)
Eye And Orbit (Eye and orbit)
Genitourinary, Nos (Genitourinary NOS)
Intra-abdominal, Nos (Intra-abdominal)
Lower Extremity (Lower extremity)
Non-parameningeal Head And Neck
(Non-parameningeal head and neck)
Other Specify (Other)
Parameningeal (Parameningeal)
Perineum/anus (Perineum/anus)
Prostate (Prostate)
Retroperitoneum (Retroperitoneum)
Thorax (Thorax)
Trunk (Trunk)
Upper Extremity (Upper extremity)
Other specify
Tumor Location, Side
Both (Both)
Left (Left)
Right (Right)
Unknown (Unknown)
Intracranial Tumor Extension (check all that
apply)
Base Of Skull Erosion (Base of skull
erosion)
Cranial Nerve Palsy (Cranial nerve
palsy)
Intracranial Extension (Intracranial
extension)
Other, Specify (Other specify)
Other specify
Metastatic Site (s - For high risk/advanced
studies, - check all that apply)
Ascites (Ascites)
Bone (Bone)
Bone Marrow (Bone marrow)
Cerebrospinal Fluid (csf) (Cerebrospinal
fluid (CSF))
Cns/brain (CNS/Brain)
Distant Nodes, Specify (Distant Nodes)
Liver (Liver)
Lung (Lung)
Other Specify (Other)
Peritoneal Nodules (Peritoneal nodules)
Pleural Effusion (Pleural effusion)
Pleural Nodules (Pleural nodules)
Soft Tissue (Soft tissue)
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On-Study - Pediatric Soft Tissue Sarcoma - On-Study Form Newly
Diagnosed Patients - 2292713v3.0
Distant nodes specify
Other specify
Number of Regional Lymph Nodes Examined
Number of Positive Lymph Nodes
Dimension 1 (Longest)
Dimension 2 (cm)
Dimension 3 (cm)
Status of Primary Tumor
Not Recurrent, Resected, No Residual
Tumor (Not recurrent, resected, no
residual tumor)
Not Recurrent, Resected, Residual
Tumor (Not recurrent, resected, residual
tumor)
Recurrent (Recurrent)
Unresected (Unresected)
Histologic Type (check all that apply)
Alveolar Rhabdomyosarcoma (Alveolar
rhabdomyosarcoma)
Alveolar Soft Part Sarcoma (Alveolar soft
part sarcoma)
Angiosarcoma (Angiosarcoma)
Botryoid Rhabdomyosarcoma (Botryoid
rhabdomyosarcoma)
Clear Cell Sarcoma (mmsp) (Clear cell
sarcoma (MMSP))
Dedifferentiated Liposarcoma
(Dedifferentiated liposarcoma)
Dermatofibrosarcoma Protuberans
(Dermatofibrosarcoma protuberans)
Desmoplastic Small Cell Tumor
(Desmoplastic small cell tumor)
Embryonal Rhabdomyosarcoma
(Embryonal rhabdomyosarcoma)
Endometrial Stromal Sarcoma
(Endometrial stromal sarcoma)
Epithelioid Sarcoma (Epithelioid
sarcoma)
Extraskeletal Ewing's/pnet (Extraskeletal
Ewing's/PNET)
Extraskeletal Mesenchymal
Chondrosarcoma (Extraskeletal
mesenchymal chondrosarcoma)
Extraskeletal Myxoid Chondrosarcoma
(Extraskeletal myxoid chondrosarcoma)
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Extraskeletal Osteosarcoma
(Extraskeletal osteosarcoma)
Fibrosacoma, Nos (Fibrosacoma NOS)
Gastrointestinal Stromal Tumor (gist)
(Gastrointestinal stromal tumor (GIST))
Infantile Fibrosarcoma (Infantile
fibrosarcoma)
Kaposi Sarcoma (Kaposi sarcoma)
Leiomyosarcoma (Leiomyosarcoma)
Liposarcoma Nos (Liposarcoma NOS)
Malignant Mesenchymoma (Malignant
mesenchymoma)
Maligant Peripheral Nerve Sheath Tumor
(Malignant peripheral nerve sheath
tumor)
Myxofibrosarcoma (Myxofibrosarcoma)
Myxoid Liposarcoma (Myxoid
liposarcoma)
Other Specify (Other specify)
Pleomorphic Liposarcoma (Pleomorphic
liposarcoma)
Pleomorphic Rhabdomyosarcoma
(Pleomorphic rhabdomyosarcoma)
Rhabdomyosarcoma Nos
(Rhabdomyosarcoma NOS)
Soft Tissue Sarcoma Nos (Soft tissue
sarcoma NOS)
Solitary Fibrous
Tumor/hemangiopericytoma (Solitary
fibrous tumor/hemangiopericytoma)
Spindle Cell Rhabdomyosarcoma
(Spindle cell rhabdomyosarcoma)
Synovial Sarcoma (Synovial sarcoma)
Undifferentiated Pleomorphic
Sarcoma/"mfh" (Undifferentiated
pleomorphic sarcoma/"MFH")
Undifferentiated Sarcoma
(Undifferentiated sarcoma)
Uterine Carcinosarcoma (mixed
Mesodermal Sarcoma) (Uterine
carcinosarcoma (mixed mesodermal
sarcoma))
Uterine Leiomyosarcoma (Uterine
leiomyosarcoma)
Uterine Sarcoma Nos (Uterine sarcoma
NOS)
Well Differentiated Liposarcoma (Well
differentiated liposarcoma)
Other specify
Histologic Subtype (specify)
Histologic Grade, French System (check highest
grade)
Grade I (Grade I)
Grade Ii (Grade II)
Grade Iii (Grade III)
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Unknown (Unknown)
Pathologic T Stage
Pt0 (pT0)
Pt1 (pT1)
Pt2 (pT2)
Pt3 (pT3)
Pt4 (pT4)
Ptx (pTX)
Pathologic N Stage
Pn0 (pN0)
Pn1 (pN1)
Pn2 (pN2)
Pn3 (pN3)
Pnx (pNX)
Pathologic M Stage
Pm0 (pM0)
Pm1 (pM1)
Pmx (pMX)
Clinical T Stage
T0 (T0)
T1 (T1)
T2 (T2)
T3 (T3)
T4 (T4)
Tx (TX)
Clinical N Stage
N0 (N0)
N1 (N1)
N2 (N2)
N3 (N3)
Nx (NX)
Clinical M Stage
M0 (M0)
M1 (M1)
Mx (MX)
Depth (cm)
Pediatric Soft Tissue Sarcoma: Prior
Health History
Does the patient have a chronic disease
associated with this cancer?
Yes
No
Current Medical Conditions (currently
symptomatic or on medications for)
Cardiac Disease (Cardiac disease)
Cerebrovascular Disease
(Cerebrovascular disease)
Deep Vein Thrombosis (Deep vein
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thrombosis)
Diabetes (Diabetes)
Gastrointestinal Disease
(Gastrointestinal disease)
High Blood Pressure (High blood
pressure)
Neurologic Disease (Neurologic disease)
Other Malignancies, Specify (Other
malignancies specify)
Other, Specify (Other specify)
Peripheral Vascular Disease (Peripheral
vascular disease)
Respiratory Problems (Respiratory
problems)
Other malignancies specify
Other specify
Congenital abnormalities
Downs Syndrome (Downs syndrome)
Hemihypertrophy (Hemihypertrophy)
Li-fraumeni Syndrome (Li-Fraumeni
syndrome)
Neurofibromatosis (Neurofibromatosis)
None (None)
Other, Specify (Other specify)
Other specify
Family history of neurofibromatosis?
Yes
No
Comments
Comments
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Endometrial Cancer NCT00063999 Pathology -
Pathology Form, GOG-0209, Form F - 2077159v3.0
Pathology Form, GOG-0209, Form F
Combination Chemotherapy in Treating Patients With Stage
III, Stage IV, or Recurrent Endometrial Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=B2400A33-
1109-0EE9-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/8438
Pathology Form, GOG-0209, Form F
Header Module
Date form originally completed (m d y)
Date form amended (m d y)
Person amending form, last name
Patient Name, Last
Patient Name, First
Patient Study ID
Person Completing Form, Last Name
Primary Disease Assessment
Primary site
Cervix (Cervix)
Endometrium (Endometrium)
Fallopian Tube (Fallopian tube)
Gestational Trophoblastic Disease (GTD)
Other, Specify (Other, specify)
Ovary (Ovary)
Peritoneum (Peritoneum)
Uterine Sarcoma (Uterine sarcoma)
Vagina (Vagina)
Vulva (Vulva)
Other, specify (Primary Site)
Histologic type (check one)
Adenocarcinoma With Squamous
Differentiation (Adenocarcinoma with
squamous differentiation)
Adenocarcinoma, Unspecified
(Adenocarcinoma, unspecified)
Adenosquamous (Adenosquamous
carcinoma)
Benign (Benign NOS)
Carcinosarcoma/mesodermal (mullerian)
Mixed Tumor (Carcinosarcoma,
heterologous)
Carcinosarcoma/mesodermal (mullerian)
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Mixed Tumor (Carcinosarcoma,
homologous)
Clear Cell Carcinoma (Clear cell
carcinoma)
Dysgerminoma (Dysgerminoma)
Endodermal Sinus Tumor (yolk Sac
Tumor) (Endodermal sinus tumor)
Endometrial Stromal Sarcoma
(Endometrial stromal sarcoma, high
grade)
Endometrioid Adenocarcinoma
(Endometrioid adenocarcinoma)
Fibroma (Fibroma)
Germ Cell Tumor, Mixed (Germ cell
tumor, mixed)
Granulosa Cell Tumor (Granulosa cell
tumor)
Leiomyosarcoma (Leiomyosarcoma)
Mixed Epithelial Carcinoma, Specify
Components (Mixed epithelial
carcinoma)
Mixed serous/mucinous LMP (Mixed
serous/mucinous LMP)
Mucinous Adenocarcinoma (Mucinous
adenocarcinoma)
Mucinous Cystadenoma (benign)
(Mucinous cystadenoma (benign))
Mucinous Tumor Of Low Malignant
Potential (Mucinous tumor of LMP)
Normal Tissue (Normal tissue)
Other, Specify (Other, specify)
Serous Adenocarcinoma (Serous
adenocarcinoma)
Serous Cystadenoma (benign) (Serous
cystadenoma (benign))
Serous Tumor Of Low Malignant
Potential (Serous tumor of LMP)
Sex-cord/stromal, Unclassified (Sex
cord/stromal, unclassified)
Small Cell Carcinoma (Small cell
carcinoma)
Squamous Cell Carcinoma (Squamous
cell carcinoma, invasive)
Teratoma, Immature, Specify
Components (Teratoma, immature)
Teratoma, Mature (Teratoma, mature
cystic)
Transitional Cell Carcinoma, Including
Brenner Tumor (Transitional cell
carcinoma (including Brenner))
Undifferentiated Carcinoma
(Undifferentiated carcinoma)
Villoglandular Carcinoma (Villoglandular
carcinoma)
Other, specify (Histologic Type)
Histologic grade (Differentiation)
Grade 1-well Differentiated (1)
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Grade 2-moderately Differentiated (2)
Grade 3-poorly Differentiated (3)
Indeterminate (Indeterminate)
Not Applicable (Not applicable)
Grade Unknown (Unknown)
Method of evaluation
Biopsy (Biopsy)
Cytology (Cytology)
Other, Specify (Other, specify)
Persistent (Persistent)
Recurrence (Recurrence)
Second look (Second look)
Surgery (Surgery)
Date of evaluation (m d y)
ID # of the blocks/slides
Specimen site
Bladder Peritoneum (Bladder
peritoneum)
Bowel Peritoneum/serosa (Bowel
peritoneum/serosa)
Cervix (Cervix)
Corpus (Corpus)
Cul-de-sac (Cul-de-sac)
Diaphragm (Diaphragm)
Endometrium (Endometrium)
Fallopian Tube (Fallopian tube)
Lymph Node(s) (Lymph nodes, specify)
Metastatic Site (Metastatic site, specify)
Omentum (Omentum)
Other (Other, specify)
Ovary (Ovary)
Paracolic Gutter Left (Paracolic gutter
left)
Paracolic Gutter Right (Paracolic gutter
right)
Pelvic Wall Left (Pelvic wall left)
Pelvic Wall Right (Pelvic wall right)
Peritoneum/uterine Serosa
(Peritoneum/uterine serosa)
Lymph nodes, specify (Specimen Site)
Metastatic site, specify (Specimen Site)
Other, specify (Specimen Site)
Secondary Disease Assessment
Method of evaluation
Biopsy (Biopsy)
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Cytology (Cytology)
Other, Specify (Other, specify)
Persistent (Persistent)
Recurrence (Recurrence)
Second look (Second look)
Surgery (Surgery)
Date of evaluation (m d y)
ID # of the blocks/slides
Specimen site
Bladder Peritoneum (Bladder
peritoneum)
Bowel Peritoneum/serosa (Bowel
peritoneum/serosa)
Cervix (Cervix)
Corpus (Corpus)
Cul-de-sac (Cul-de-sac)
Diaphragm (Diaphragm)
Endometrium (Endometrium)
Fallopian Tube (Fallopian tube)
Lymph Node(s) (Lymph nodes, specify)
Metastatic Site (Metastatic site, specify)
Omentum (Omentum)
Other (Other, specify)
Ovary (Ovary)
Paracolic Gutter Left (Paracolic gutter
left)
Paracolic Gutter Right (Paracolic gutter
right)
Pelvic Wall Left (Pelvic wall left)
Pelvic Wall Right (Pelvic wall right)
Peritoneum/uterine Serosa
(Peritoneum/uterine serosa)
Lymph nodes, specify (Specimen Site)
Metastatic site, specify (Specimen Site)
Other, specify (Specimen Site)
Footer Module
Participating Group Code
Participating Group Protocol Number
Patient Study ID, Participating Group
Ccrr Module For Pathology Form, Gog-
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Other, Specify
Disease Status
Primary Gyn Disease Continues To Be
Present Following Initial Treatment
(Persistent)
Progression Of Gyn Disease Per Recist
Criteria (Progression)
Recurrence Of Same Gyn Disease
Previously Treated Successfully
(Recurrence)
Other, Specify
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On-Study - Multiple Myeloma - On-Study
Form - 2274325v3.0
Multiple Myeloma - On-Study Form
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=D6E1DCBD-
670E-54A2-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/8439
Multiple Myeloma - On-Study Form
Crf Header
Coordinating Group Protocol No.
Coordinating Group Code
Protocol Title
Patient Study ID
Institution/Affiliate
Other Patient ID
Participating Group Code
Patient Name (initials acceptable)
Myeloma: Form Administration
Person Completing Form
Are data amended (If data are amended, please
circle in red when using paper form)
Yes
No
Myeloma: Disease Description
Date of Initial Pathologic Diagnosis
Type of Disease
Nonsecretory (no Positive
Immunofixation Of Serum Or Urine At
Baseline) (Nonsecretory (no positive
immunofixation of serum or urine at
baseline))
Oligosecretory (at Diagnosis, M-protein
Is Present By Immunofixation Of Serum
Or Urine But Not Quantifiable In Either
Serum Or Urine) (Oligosecretory (at
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diagnosis, M-protein is present by
immunofixation of serum or urine but not
quantifiable in either serum or urine))
Secretory (Secretory)
Durie-Salmon Stage (at Initial Diagnosis)
I - All Of The Following Must Be Present
(hemoglobin >10 G/dl; Serum Calcium
<12 Mg/dl; Urine Light Chains <4 G/24
Hrs; Normal Bones On Radiograph Or
Solitary Plasmacytoma; Igg <5 G/dl; Iga
<3 G/dl) (I - ALL of the following must be
present)
Ii - Fitting Neither Stage I Or Stage Iii (II -
Fitting neither Stage I or Stage III)
Iii - One Of The Following Must Be
Present (hemoglobin <8.5 G/dl; Serum
Calcium >12 Mg/dl; Urine Light Chains
>12 G/24 Hrs; Advanced Lytic Bone
Lesions (>3 Lytic Lesions); Igg >7 G/dl;
Iga >5 G/dl) (III - One of the following
must be present)
Unknown (Unknown)
Durie-Salmon Sub-stage (at Initial Diagnosis)
A (relatively Normal Renal Function -
Serum Creatinine <2.0 Mg/dl) (A
(Relatively normal renal function - serum
creatinine <2.0 mg/dl))
B (abnormal Renal Function - Serum
Creatinine >= 2.0 Mg/dl) (B (Abnormal
renal function - serum creatinine >= 2.0
mg/dl))
Unknown (Unknown)
Serum Total Protein (SPEP at diagnosis)
Serum M-Protein Spike (SPEP If immunofixation
is positive but M-spike is not quantifiable, enter
.01 or follow protocol guidelines for entering M-
spike.)
Serum M-Protein by Immunofixation (at
diagnosis)
Equivocal (Equivocal)
Negative (Negative)
Positive (Positive)
Unknown (Unknown)
Serum Heavy Chain (If positive or equivocal,
check all that apply)
A (A)
D (D)
E (E)
G (G)
M (M)
Unknown (Unknown)
2 / 7
On-Study - Multiple Myeloma - On-Study Form - 2274325v3.0
Serum Light Chain (check all that apply)
Kappa (Kappa)
Lambda (Lambda)
Unknown (Unknown)
Biclonal
Yes
No
Yes specify
Oligoclonal
Yes
No
Yes specify
Urine Total Protein (UPEP at diagnosis)
Unit of Measure
Grams/24 Hours (g/24 hrs)
Milligrams/24 Hours (mg/24 hrs)
Unit of Measure
Grams/24 Hours (g/24 hrs)
Milligrams/24 Hours (mg/24 hrs)
Urine M-Protein Light Chain Excretion (If
immunofixation is positive but M-protein is not
quantifiable, enter .01 or follow protocol
guidelines for entering M-protein.)
Urine M-Protein by Immunofixation (at diagnosis)
Equivocal (Equivocal)
Negative (Negative)
Positive (Positive)
Unknown (Unknown)
Urine Light Chain (If positive or equivocal,)
Kappa (Kappa)
Lambda (Lambda)
Unknown (Unknown)
Myeloma Symptoms (* Note: Detailed definitions
and/or coding instructions for myeloma
classification should be provided in the protocol
as needed)
Asymptomatic Myeloma (includes
Smoldering And Indolent) (Asymptomatic
myeloma (includes Smoldering and
Indolent))
Symptomatic Myeloma (includes Active)
(Symptomatic myeloma (includes
Active))
Hematopoietic Diagnosis (WHO * Note: Detailed
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definitions and/or coding instructions for myeloma
classification should be provided in the protocol
as needed)
Extraosseous Plasmacytoma
(Extraosseous plasmacytoma)
Monoclonal Gammopathy Of
Undetermined Significance (mgus)
(Monoclonal gammopathy of
undetermined significance)
Other Specify (Other)
Plasma Cell Myeloma (Plasma cell
myeloma)
Other specify
Is disease primary or secondary (If Plasma Cell
Leukemia,)
Primary (de Novo) (Primary (de novo))
Secondary (Secondary)
Did patient receive a transfusion in the previous 4
weeks
No (No)
Unknown (Unknown)
Yes (Yes)
Did patient receive erythropoietin-type agents
(e.g., Epogen, Procrit or Aranesp) within the
previous 4 weeks
No (No)
Unknown (Unknown)
Yes (Yes)
Myeloma: Prior Treatment
Prior Treatment? (If yes, respond to treatment-
specific questions below.)
Yes
No
No. of Planned Regimens (If yes, Note: Multiple
drug/staged regimens count as 1; e.g., VAD +
transplant)
Prior Treatment Regimen Name(s) (* Prior
Treatment Regimen Name)
Abcm (ABCM)
Bisphosphonates (e.g., Pamidronate Or
Zoledronic Acid) (Bisphosphonates (e.g.,
pamidronate or zoledronic acid))
Blt-d (BLT-D)
C-vamp (C-VAMP)
Cad (CAD)
Cp (CP)
Cyclophosphamide Iv High Dose
(>=2400 Mg/m2/month)
(Cyclophosphamide IV high dose
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(>=2400 mg/m2/month))
Cyclophosphamide Iv Low Dose (<2400
Mg/m2/month) (Cyclophosphamide IV
low dose (<2400 mg/m2/month))
D-pace (D-PACE)
Dcep (DCEP)
Dt-pace (DT-PACE)
Edap/echep (EDAP/ECHEP)
High Dose Steroids (e.g., Dex, Solu-
medrol) (High dose steroids (e.g., Dex,
Solu-Medrol))
Hypercvad (HyperCVAD)
Interferon (Interferon)
Melphalan (lpam) (Melphalan (LPAM,
single agent))
Melphalan Iv High Dose (other Than
Transplant, E.g., >=25 Mg/m2/month)
(Melphalan IV high dose (other than
transplant, e.g., >=25 mg/m2/month))
Mocca (MOCCA)
Mp (MP)
Nitrosurea (Nitrosurea)
Other (Other)
Prednisone (Prednisone)
Ps-341 (PS-341)
Revimid (Revimid)
Thal-dex (Thal-Dex)
Thalidomide (Thalidomide)
Transplant (Transplant)
Vad (VAD)
Vamp (VAMP)
Vbap (VBAP)
Vbmcp (m-2) (VBMCP (M-2))
Vmcp (VMCP)
Other Prior Regimen Name (** If Other specify)
Prior Treatment Regimen Start Date
Prior Treatment Regimen End Date
Maintenance Only
Yes
No
Reason Stopped (?  Reason Stopped)
Alternative Treatment (Alternative
treatment)
Completed Treatment (Completed
treatment)
Maintenance Only (Maintenance only)
Patient Refusal (Patient refusal)
Progression (Progression)
Toxicity (Toxicity)
Unknown (Unknown)
Best Response (Best Response)
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Inevaluable (Inevaluable)
Plateau/stable (Plateau/Stable)
Progression (Progression)
Response/improvement
(Response/Improvement)
Unknown (Unknown)
Prior Radiation Therapy
Yes
No
Prior Radiation Therapy Type (If yes,)
Local (Local)
Other (Other)
Other specify
Prior Bone Marrow or Peripheral Blood Stem Cell
Transplant?
Yes
No
Prior Transplant Type (If yes,)
Allogeneic (Allogeneic)
Autologous (Autologous)
Number of autologous transplants
Date of Last Transplant
Number of allogeneic transplants
Allogeneic Transplant Type
Mini (non-myeloablative) (Mini (non-
myeloablative))
Myeloablative (Myeloablative)
Unknown (Unknown)
Date of Transplant
DLI
Yes
No
Date of Last DLI (If yes,)
Total body irradiation
No (No)
Unknown (Unknown)
Yes (Yes)
Skeletal Targeted Irradiation
No (No)
Unknown (Unknown)
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Yes (Yes)
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Colorectal Cancer NCT01167725 Follow-Up - USMCI
8214/Z6091:  Study Comments (COMM) - 2883971v1.0
USMCI 8214/Z6091:  Study Comments (COMM)
Standard Therapy With or Without Surgery and Mitomycin
C in Treating Patients With Advanced Limited Peritoneal
Dissemination of Colon Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=6A83C463-
D9EF-C8FB-E040-BB89AD43731A
All rights reserved. Please visit https://medical-data-
models.org/forms/8440
USMCI 8214/Z6091:  Study
Comments (COMM)
Header Module
Patient ID
Institution No.
Institution Name
Comments
Date
Form
Comments
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Soft Tissue Sarcoma - Definitive Surgery Form
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=E2A30653-
4030-1046-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/8443
Soft Tissue Sarcoma - Definitive
Surgery Form
Crf Header
Coordinating Group Protocol No.
Coordinating Group Code
Protocol Title
Patient Study ID
Institution/Affiliate
Other Patient ID
Participating Group Code
Patient Name (initials acceptable)
Sarcoma: Form Administration
Person Completing Form
Are data amended (If data are amended, please
circle in red when using paper form)
Yes
No
Soft Tissue Sarcoma: Summary Of
Definitive Surgery
Primary Surgery Date (MM DD YYYY)
Site of Primary Surgery
Primary Surgery Type
Amputation (Amputation)
Cryosurgery (Cryosurgery)
En Bloc Resection (En bloc resection)
Intramural Resection, Gross Residual
Disease (Intramural resection, gross
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residual disease)
Lymph Node Removal (Lymph node
removal)
Marginal Excision (Marginal excision)
Other, Specify (Other specify)
Radical Excision (Radical excision)
Wide Excision (Wide excision)
Other specify
Surgical Reconstruction
Composite (allograft And Prosthesis)
(Composite (allograft and prosthesis))
Endoprosthesis (Endoprosthesis)
Excision Without Amputation (Excision
without amputation)
Free Tissue Transfer (Free tissue
transfer)
Mesh (chest Wall) (Mesh (chest wall))
Metallic Prosthesis (Metallic prosthesis)
Myocutaneous Flap (Myocutaneous flap)
No Bony Reconstruction (No bony
reconstruction)
Other, Specify (Other specify)
Other specify
Tumor Location, Side
Both (Both)
Left (Left)
Right (Right)
Unknown (Unknown)
Dimension 1 (Longest)
Dimension 2 (cm)
Dimension 3 (cm)
Does the tumor involve the surgical margin
Yes
No
Distance from surgical margin (If no,)
Margins of surgical resection
All Margins Pathologically Negative (R0)
Microscopically Positive Margins Or
Microscopic Residual Disease (R1)
Macroscopically Positive Margins Or
Gross Residual Disease (R2)
Does analysis of tissue show evidence of
therapeutic effects?
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No (No)
Unknown (Unknown)
Yes (Yes)
Type of Therapeutic Effect (If Yes,)
Drug-related Changes (Drug-related
changes)
Other, Specify (Other specify)
Radiation Changes (Radiation changes)
Surgical Changes (Surgical changes)
Other specify
Soft Tissue Sarcoma: Surgical Pathology
Microscopic Description
Specimen Cell Source
Bone, Specify (Bone specify)
Lymph Node (Lymph node)
Non-malignant Tumor (Non-malignant
tumor)
Other, Specify (Other specify)
Primary Tumor (Primary tumor)
Tissue Suspicious For Abnormality
(Tissue suspicious for abnormality)
Bone specify
Other specify
Histologic Type (check all that apply)
Alveolar Rhabdomyosarcoma (Alveolar
rhabdomyosarcoma)
Alveolar Soft Part Sarcoma (Alveolar soft
part sarcoma)
Angiosarcoma (Angiosarcoma)
Botryoid Rhabdomyosarcoma (Botryoid
rhabdomyosarcoma)
Clear Cell Sarcoma (mmsp) (Clear cell
sarcoma (MMSP))
Dedifferentiated Liposarcoma
(Dedifferentiated liposarcoma)
Dermatofibrosarcoma Protuberans
(Dermatofibrosarcoma protuberans)
Desmoplastic Small Cell Tumor
(Desmoplastic small cell tumor)
Embryonal Rhabdomyosarcoma
(Embryonal rhabdomyosarcoma)
Endometrial Stromal Sarcoma
(Endometrial stromal sarcoma)
Epithelioid Hemagioendothelioma
(Epithelioid hemangioendothelioma)
Epithelioid Sarcoma (Epithelioid
sarcoma)
Extraskeletal Ewing's/pnet (Extraskeletal
Ewing's/PNET)
Extraskeletal Mesenchymal
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Chondrosarcoma (Extraskeletal
mesenchymal chondrosarcoma)
Extraskeletal Myxoid Chondrosarcoma
(Extraskeletal myxoid chondrosarcoma)
Extraskeletal Osteosarcoma
(Extraskeletal osteosarcoma)
Fibrosarcoma (Fibrosarcoma)
Gastrointestinal Stromal Tumor (gist)
(Gastrointestinal stromal tumor (GIST))
Kaposi Sarcoma (Kaposi sarcoma)
Leiomyosarcoma (Leiomyosarcoma)
Liposarcoma Nos (Liposarcoma NOS)
Malignant Mesenchymoma (Malignant
mesenchymoma)
Maligant Peripheral Nerve Sheath Tumor
(Malignant peripheral nerve sheath
tumor)
Myxofibrosarcoma (Myxofibrosarcoma)
Myxoid Liposarcoma (Myxoid
liposarcoma)
Other Specify (Other specify)
Pleomorphic Liposarcoma (Pleomorphic
liposarcoma)
Pleomorphic Rhabdomyosarcoma
(Pleomorphic rhabdomyosarcoma)
Rhabdomyosarcoma Nos
(Rhabdomyosarcoma NOS)
Sarcoma Nos (Sarcoma NOS)
Solitary Fibrous
Tumor/hemangiopericytoma (Solitary
fibrous tumor/hemangiopericytoma)
Spindle Cell Rhabdomyosarcoma
(Spindle cell rhabdomyosarcoma)
Synovial Sarcoma (Synovial sarcoma)
Undifferentiated Pleomorphic
Sarcoma/"mfh" (Undifferentiated
pleomorphic sarcoma/"MFH")
Undifferentiated Sarcoma
(Undifferentiated sarcoma)
Uterine Carcinosarcoma (mixed
Mesodermal Sarcoma) (Uterine
carcinosarcoma (mixed mesodermal
sarcoma))
Uterine Leiomyosarcoma (Uterine
leiomyosarcoma)
Uterine Sarcoma Nos (Uterine sarcoma
NOS)
Well Differentiated Liposarcoma (Well
differentiated liposarcoma)
Other specify
Histologic Subtype (specify)
Histologic Grade, French System
Grade I (Grade I)
Grade Ii (Grade II)
Grade Iii (Grade III)
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Were lymph nodes assessed?
Yes
No
Type of Lymph Node Assessment (If yes,)
Dissection (Dissection)
Lymph Nodes Attached To Primary
Tumor (Lymph nodes attached to primary
tumor)
Random Biopsy (Random biopsy)
Sampling (Sampling)
Sentinel Node (Sentinel node)
Number of Lymph Nodes Examined
Number of Positive Lymph Nodes
Regional Lymph Node Status
Involved, Completely Resected
(Involved, completely resected)
Involved, Not Completely Resected
(Involved, not completely resected)
Uninvolved (Uninvolved)
Unknown (Unknown)
Is there lymphovascular invasion?
No (No)
Unknown (Unknown)
Yes (Yes)
Soft Tissue Sarcoma: Surgical-pathology
Result
Pathologic T Stage
Pt0 (pT0)
Pt1 (pT1)
Pt2 (pT2)
Pt3 (pT3)
Pt4 (pT4)
Ptx (pTX)
Pathologic N Stage
Pn0 (pN0)
Pn1 (pN1)
Pn2 (pN2)
Pn3 (pN3)
Pnx (pNX)
Pathologic M Stage
Pm0 (pM0)
Pm1 (pM1)
Pmx (pMX)
Depth (cm)
Stage Grouping, Pathologic
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0, According To Current Ajcc Guidelines
(0)
Ia, According To Current Ajcc Guidelines
(IA)
Ib, According To Current Ajcc Guidelines
(IB)
Iia, According To Current Ajcc Guidelines
(IIA)
Iib, According To Current Ajcc Guidelines
(IIB)
Iiia, According To Current Ajcc
Guidelines (IIIA)
Iiib, According To Current Ajcc
Guidelines (IIIB)
Iv, According To Current Ajcc Guidelines
(IV)
Comments
Comments
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Colorectal Cancer NCT01167725 Transmittal - USMCI
8214/Z6091:  Blood Sample Submission Form - 2833605v1.0
USMCI 8214/Z6091:  Blood Sample Submission Form
(Group 2 Only or crossover patients from Group 1)
Standard Therapy With or Without Surgery and Mitomycin
C in Treating Patients With Advanced Limited Peritoneal
Dissemination of Colon Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=622E716B-
38C7-5CAB-E040-BB89AD43601A
All rights reserved. Please visit https://medical-data-
models.org/forms/8444
USMCI 8214/Z6091:  Blood Sample
Submission Form
Header Module
Patient ID
Institution No.
Institution Name
Visit
Baseline (Baseline)
Follow-up (Follow-Up)
Post Surgery (Post Surgery)
Systemic Therapy (Systemic Therapy)
Visit time point
Month 12 (Month 12)
Month 15 (Month 15)
Month 18 (Month 18)
Month 21 (Month 21)
Month 24 (Month 24)
Month 27 (Month 27)
Month 3 (Month 3)
Month 30 (Month 30)
Month 33 (Month 33)
Month 36 (Month 36)
Month 42 (Month 42)
Month 48 (Month 48)
Month 54 (Month 54)
Month 6 (Month 6)
Month 60 (Month 60)
Month 9 (Month 9)
Post Surgery (Post Surgery)
Post Surgery (6 Wks) (Post Surgery (6
wks))
Current Cycle Number
Header
Was sample obtained
Yes
No
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Reason (If no,)
Date Specimen collected
Footern Module
First Name (Submitted by)
Last name
Date Specimen Shipped
Email Address
Phone
Fax
Specimen Received Date
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Colorectal Cancer NCT01167725 Transmittal - USMCI 8214/Z6091:
Blood Sample Submission Form - 2833605v1.0
On-Study - Lung Cancer - NSCLC Second
Line On-Study Form - 2286443v3.0
Lung Cancer - NSCLC Second Line On-Study Form
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=DE93C06F-
F07B-21D0-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/8447
Lung Cancer - NSCLC Second Line
On-Study Form
Crf Header
Coordinating Group Protocol No.
Coordinating Group Code
Protocol Title
Patient Study ID
Institution/Affiliate
Other Patient ID
Participating Group Code
Patient Name (initials acceptable)
Lung: Pre-treatment Characteristics
Patient Height (cm)
Patient Weight (kg)
Body Surface Area (m^2)
Performance Status (check one)
Fully Active, Able To Carry On All Pre-
disease Performance Without
Restriction. (0)
Restricted In Physically Strenuous
Activity But Ambulatory And Able To
Carry Out Work Of A Light Or Sedentary
Nature, E.g., Light Housework, Office
Work. (1)
Ambulatory And Capable Of All Selfcare
But Unable To Carry Out Any Work
Activities. Up And About More Than 50%
Of Waking Hours. (2)
Capable Of Only Limited Selfcare,
Confined To Bed Or Chair More Than
1 / 4
50% Of Waking Hours. (3)
Completely Disabled. Cannot Carry On
Any Selfcare. Totally Confined To Bed Or
Chair. (4)
Weight loss in previous six months (check one)
<5% Of Body Weight (< 5% of body
weight)
> Or = 20% Of Body Weight (> or = 20%
of body weight)
10 To <20% Of Body Weight (10 to <20%
of body weight)
5 To <10% Of Body Weight (5 to < 10%
of body weight)
Lung: Disease Description - Nsclc 2nd
Line
Histologic Type
Adenocarcinoma (Adenocarcinoma)
Bronchoalveolar (bac) (Bronchoalveolar
carcinoma (BAC))
Large Cell Undifferentiated (Large cell
undifferentiated)
Non-small Cell Lung Cancer (nsclc), Nos
(Non-small cell lung cancer NOS)
Other (Other specify)
Squamous Cell Carcinoma (Squamous
cell carcinoma)
Specify Other Histologic Type
Is measurable disease present? (only applicable
in studies where there is residual disease at
baseline)
Yes
No
Is non-measurable disease present? (only
applicable in studies where there is residual
disease at baseline)
Yes
No
Metastatic Site (check all that apply)
Adrenal Gland (Adrenal(s))
Bone (Bone)
Bone Marrow (Bone marrow)
Brain (Brain)
Contralateral Lung (Contralateral lung)
Hilar Nodes (Hilar nodes)
Ipsilateral Lung (Ipsilateral lung)
Liver (Liver)
Mediastinal Nodes (Mediastinal nodes)
Pleura (Pleura)
Skin (Skin)
Supraclavicular Or Scalene Nodes
(Supraclavicular/scalene nodes)
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Is pleural effusion present?
Yes
No
Is it Malignant? (If yes,)
No (No)
Unknown (Unknown (not tapped))
Yes (Yes)
Units used for labs
Imperial (Imperial)
Scientific/international (S/I)
Albumin (g/dl)
Hemoglobin (g/dl)
Lactate Dehydrogenase (LDH) (U/L only collect if
RT study)
Lactate Dehydrogenase ULN (U/L Provide
laboratory's upper limit of normal)
Lung: Prior Treatment - 2nd Line
Prior Surgery (Code "No" if incisional/needle
biopsy is the only prior surgery)
Yes
No
Prior Radiation Therapy
Yes
No
Prior Systemic Chemotherapy
Yes
No
Agent Name
Agent Start Date
Agent End Date
Agent Total Cumulative Dose
Units
Overall Response Duration (weeks)
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Comments
Comments
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Endometrial Cancer NCT00063999 Quality of Life -
Quality of Life Cover Sheet GOG-0209 - 2077624v3.0
Quality of Life Cover Sheet GOG-0209
Combination Chemotherapy in Treating Patients With Stage
III, Stage IV, or Recurrent Endometrial Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=B2404BEA-
88CA-0F7B-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/8448
Quality of Life Cover Sheet GOG-
0209
Ccrr Module For Quality Of Life Cover
Sheet Gog-0209
Date Form Originally Completed (m d y)
Date Form Amended (m d y)
Person amending form, last name
Patient Initials
Patient Study ID
Person Completing Form, Last Name
Module 2
Scheduled time to obtain Quality of Life
Questionnaire and cover sheet
15 Weeks After Starting Treatment (15
weeks after starting study therapy)
26 Weeks After Starting Study Therapy
(26 weeks after starting study therapy)
6 Weeks After Starting Treatment (6
weeks after starting study therapy)
Prior To Randomization (Prior to
randomization)
Was QoL Questionnaire completed?
Yes
No
Date Questionnaire Due (If no, m/d/y)
Date Questionnaire Completed (If yes, m/d/y)
Please indicate reason (If no, check one)
Other (Other)
Patient Died (Patient died)
Patient Kept Appointment For
Examination, But Could Not Complete
Questionnaire Due To Illness (Patient
kept appointment for examination, but
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could not complete questionnaire due to
illness)
Patient Kept Appointment For
Examination, But Refused To Complete
Questionnaire For Reasons Other Than
Illness (Patient kept appointment for
examination, but refused to complete
questionnaire for reasons other than
illness.)
Patient Off Study Treatment And Cannot
Be Contacted For Follow-up (Patient off
study treatment and cannot be contacted
for follow-up)
Test Omitted Due To
Institution/investigator Error
(Questionnaire not administered due to
institutional error)
Specify reason
Other please specify
Neuropathy Sensory Grade (CTC v. 2.0)
Module 4
Signature of Person Completing This Form (Data
Manager/Nurse Oncologist)
Phone
Date (m d y)
Footer
Participating Group Code
Participating Group Protocol Number
Participating Group Patient ID
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Endometrial Cancer NCT00063999 Quality of Life - Quality of Life Cover
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Treatment - Breast Cancer - Treatment Summary
Form - Subset of Patients - 2262449v3.0
Breast Cancer - Treatment Summary Form - Subset of
Patients
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=DA18D962-
FE6F-0836-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/8449
Breast Cancer - Treatment Summary
Form - Subset of Patients
Crf Header
Coordinating Group Protocol No.
Coordinating Group Code
Protocol Title
Patient Study ID
Institution/Affiliate
Other Patient ID
Participating Group Code
Patient Name (initials acceptable)
Breast: Form Administration
Person Completing Form
Are data amended? (If data are amended, please
circle in red when using paper form)
Yes
No
Breast: Treatment Cycle Information
Cycle Start Date
Current Cycle Number
Total Dose of Agents/Drugs for this Cycle (use
protocol specified units)
Units
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Agent Name (Some groups may pre-print
protocol agents with appropriate units.)
Comments
Comments
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Endometrial Cancer NCT00265759 Treatment -
Z1031: Study Drug Completion Form - 2316795v3.0
Z1031: Study Drug Completion Form
Exemestane, Letrozole, or Anastrozole in Treating
Postmenopausal Women Who Are Undergoing Surgery for
Stage II or Stage III Breast Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=FA5CA46C-
366F-70D2-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/8450
Z1031: Study Drug Completion Form
Unnamed 1
Visit
Week 12 (Week 12)
Week 16 (Week 16)
Week 4 (Week 4)
Week 8 (Week 8)
Patient ID (Pt. ID issued during registration or
previously issued patient ID)
Institution No.
Patient Initials (F M L)
Institution Name
Unnamed 2
Date of Assessment (mm dd yyyy)
Date of First dose for this reporting period (mm
dd yyyy)
Date of Last dose for this reporting period (mm
dd yyyy)
Was patient randomized to Exemestane (prior to
Amendment A7)
Yes
No
Did patient continue to receive Exemestane (If
yes)
No Change Anastrozole (No, switched to
Anastrozole)
No Change Letrozole (No, switched to
Letrozole)
Yes (Yes)
Date of switch (mm dd yyyy)
Were there any dose modifications or
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additions/omissions to protocol treatment?
No (No)
Yes, Planned (i.e., The Treatment Was
Changed According To Protocol
Guidelines) (Yes, planned)
Yes, Unplanned (i.e., The Treatment
Change Was Not Part Of Protocol
Guidelines) (Yes, unplanned)
Dose Modification Reason
Adverse Event (Adverse event)
Disease Progression (Disease
progression)
Other (Other)
Patient Refusal/noncompliance (Patient
refusal/noncompliance)
Other, specify
Completed by
Date Form Completed (mm dd yyyy)
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Endometrial Cancer NCT00265759 Treatment - Z1031: Study Drug
Completion Form - 2316795v3.0
On-Study - Non-Hodgkins Lymphoma - On-
Study Form - 2271898v3.0
Non-Hodgkin's Lymphoma - On-Study Form
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=D5ECD56A-
D766-0F4E-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/8451
Non-Hodgkins Lymphoma - On-
Study Form
Crf Header
Coordinating Group Protocol No.
Coordinating Group Code
Protocol Title
Patient Study ID
Institution/Affiliate
Other Patient ID
Participating Group Code
Patient Name (initials acceptable)
Lymphoma: Form Administration
Person Completing Form
Are data amended? (If data are amended, please
circle in red when using paper form)
Yes
No
Non-hodgkin's Lymphoma: Disease
Description
Date of Initial Pathologic Diagnosis
Modified Ann Arbor Stage (at study entry * Note:
Where specified by protocol, replace Ann Arbor
Classification with Murphy Stage.)
I (I)
Ie (IE)
Ii (II)
Iie (IIE)
Iii (III)
Iiie (IIIE)
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Iiie+s (IIIE+S)
Iiis (IIIS)
Iv (IV)
Disease Status at Registration (For advanced or
recurrent studies,)
Initial Diagnosis (Initial Diagnosis)
Refractory (Refractory)
Relapsed (Relapsed)
Hematopoietic Diagnosis
Adult T-cell Leukemia/lymphoma (Adult
T-cell leukemia/lymphoma)
Aggressive Nk-cell Leukemia
(Aggressive NK-cell leukemia)
Anaplastic Large Cell Lymphoma -
Primary Cutaneous (Anaplastic large cell
lymphoma - primary cutaneous)
Anaplastic Large Cell Lymphoma -
Primary Systemic (Anaplastic large cell
lymphoma - primary systemic)
Angioimmunoblastic T-cell Lymphoma
(Angioimmunoblastic T-cell lymphoma)
Blastic Nk-cell Lymphoma (Blastic NK-
cell lymphoma)
Burkitt Lymphoma/leukemia (Burkitt
lymphoma/leukemia)
Burkitt-like Lymphoma (Burkitt-like
lymphoma)
Chronic Lymphocytic Leukemia/small
Lymphocytic Lymphoma (Chronic
lymphocytic leukemia/small lymphocytic
lymphoma)
Composite B-cell (Composite B-cell)
Composite T-cell (Composite T-cell)
Diffuse Large B-cell Lymphoma Not
Further Classifiable (Diffuse large B-cell
lymphoma not further classifiable)
Enteropathy-type T-cell Lymphoma
(Enteropathy-type T-cell lymphoma)
Extranodal Marginal Zone B-cell
Lymphoma Of Musosa-associated
Lymphoid Tissue (malt-lymphoma)
(Extranodal marginal zone B-cell
lymphoma of mucosa-associated
lymphoid tissue (MALT lymphoma))
Extranodal Nk/t Cell Lymphoma Nasal
Type (Extranodal NK/T cell lymphoma
nasal type)
Follicular Lymphoma Grade I (Follicular
lymphoma - grade I)
Follicular Lymphoma Grade Ii (Follicular
lymphoma - grade II)
Follicular Lymphoma Grade Iiia
(Follicular lymphoma - grade IIIa)
Follicular Lymphoma Grade Iiib
(Follicular lymphoma - grade IIIb)
Follicular Lymphoma Not Further
Classifiable (Follicular lymphoma not
further classifiable)
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Hepatosplenic T-cell Lymphoma
(Hepatosplenic T-cell lymphoma)
Intravascular Large B-cell Lymphoma
(Intravascular large B-cell lymphoma)
Lymphomatoid Papulosis (Lymphomatoid
papulosis)
Lymphoplasmacytic Lymphoma
(waldenstrom Macroglobulinemia)
(Lymphoplasmacytic lymphoma)
Mantle Cell Lymphoma (Mantle cell
lymphoma)
Mediastinal (thymic) Large B-cell
Lymphoma (Mediastinal (thymic) large B-
cell lymphoma)
Mycosis Fungoides (Mycosis fungoides)
Nodal Marginal Zone B-cell Lymphoma
(Nodal marginal zone B-cell lymphoma)
Other (Other)
Peripheral T-cell Lymphoma Unspecified
(Peripheral T-cell lymphoma unspecified)
Precursor B Lymphoblastic
Leukemia/lymphoma (precursor B-cell
Acute Lymphoblastic Leukemia)
(Precursor B lymphoblastic
leukemia/lymphoma)
Precursor T Lymphoblastic
Leukemia/lymphoma (precursor T-cell
Acute Lymphoblastic Leukemia)
(Precursor T lymphoblastic
leukemia/lymphoma)
Primary Effusion Lymphoma (Primary
Effusion lymphoma)
Sezary Syndrome (Sezary syndrome)
Splenic Marginal Zone Lymphoma
(Splenic marginal zone lymphoma)
Subcutaneous Panniculitis-like T-cell
Lymphoma (Subcutaneous panniculitis-
like T-cell lymphoma)
T-cell Large Granular Lymphocytic
Leukemia (T-cell large granular
lymphocytic leukemia)
T-cell Prolymphocytic Leukemia (T-cell
prolymphocytic leukemia)
Unclassifiable B-cell (Unclassifiable B-
cell)
Unclassifiable Cd30-positive Cutaneous
Lymphoproliferative Disorder
(Unclassifiable CD30-positive cutaneous
lymphoproliferative disorder)
Unclassifiable T-cell (Unclassifiable T-
cell)
Other specify
Morphologic Subtype (* For indicated diagnoses,
specify)
REAL Lymphoma Classification
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Adult T-cell Lymphoma/leukemia (Adult
T-cell lymphoma/leukemia)
Anaplastic Large Cell Lymphoma T- And
Null-cell Types (Anaplastic large cell
lymphoma T- and null-cell types)
Angiocentric Lymphoma (Angiocentric
lymphoma)
Angioimmunoblastic T-cell Lymphoma
(Angioimmunoblastic T-cell lymphoma)
Burkitt's Lymphoma (Burkitt's lymphoma)
Diffuse Large B-cell Lymphoma (Diffuse
large B-cell lymphoma)
Diffuse Predominantly Small Cell
(provisional) (Diffuse predominantly
small cell (provisional))
Extranodal Marginal Zone B-cell
Lymphoma (low Grade B-cell Lymphoma
Of Malt Type) (Extranodal marginal zone
B-cell lymphoma (low grade B-cell
lymphoma of MALT type))
Follicle Center Lymphoma-i (Follicle
center lymphoma-I)
Follicle Center Lymphoma-ii (Follicle
center lymphoma-II)
Follicle Center Lymphoma-iii (Follicle
center lymphoma-III)
Hepatosplenic T-cell Lymphoma
(provisional Subtype Of Peripheral T-cell
Lymphoma) (Hepatosplenic T-cell
lymphoma (provisional subtype of
peripheral T-cell lymphoma))
High Grade B-cell Lymphoma Burkitt-like
(provisional) (High grade B-cell
lymphoma Burkitt-like (provisional))
Intestinal T-cell Lymphoma (+/- Gluten-
sensitive Enteropathy) (Intestinal T-cell
lymphoma (+/-  gluten-sensitive
enteropathy))
Mantle Cell Lymphoma (Mantle cell
lymphoma)
Mycosis Fungoides/sezary's Syndrome
(Mycosis fungoides/Sezary's syndrome)
Nodal Marginal Zone B-cell Lymphoma
(monocytoid B-cell Lymphoma)
(provisional) (Nodal marginal zone B-cell
lymphoma (monocytoid B-cell
lymphoma) (provisional))
Peripheral T-cell Lymphomas
Unspecified (including Provisional
Subtype: Subcutaneous Panniculitic T-
cell Lymphoma) (Peripheral T-cell
lymphomas unspecified (including
provisional subtype: subcutaneous
panniculitic T-cell lymphoma))
Precursor T-lymphoblastic
Lymphoma/leukemia (Precursor T-
lymphoblastic lymphoma/leukemia)
Primary Mediastinal B-cell Lymphoma
(Primary mediastinal B-cell lymphoma)
Small Lymphocytic Lymphoma (Small
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lymphocytic lymphoma)
Splenic Marginal Zone B-cell Lymphoma
(provisional) (Splenic marginal zone B-
cell lymphoma (provisional))
T-cell Chronic Lymphocytic
Leukemia/prolymphocytic Leukemia (T-
cell chronic lymphocytic
leukemia/prolymphocytic leukemia)
Unclassifiable (Unclassifiable)
Unknown (Unknown)
Any lymph node or aggregate with a diameter
greater than 10 cm (if pediatric, >6 cm)
No (No)
Unknown (Unknown)
Yes (Yes)
Mediastinal mass
No (No)
Unknown (Unknown)
Yes (Yes)
Are B-symptoms present
Yes
No
Date of First Symptoms (If yes,)
Unexplained, persistent fever >38 degrees C (or
>100 degrees F) in the previous month
Yes
No
Recurring, drenching night sweats during the
previous month
Yes
No
Unexplained weight loss >10% of body weight in
the previous 6 months
Yes
No
Lymph Node Type
Axillary/brachial (Axillary/Brachial)
Celiac Axis/retrocrural (Celiac
axis/Retrocrural)
Cervical (Cervical)
Common Pelvic (Common pelvic)
Epitrochlear (Epitrochlear)
External/internal Iliac (External/internal
iliac)
Hilar (Hilar)
Infraclavicular (Infraclavicular)
Inguinal/femoral (Inguinal/Femoral)
Mediastinal (Mediastinal)
Mesenteric (Mesenteric)
Occipital (Occipital)
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Orbital (Orbital)
Other (Other)
Para-aortic (Para-aortic)
Paratracheal (Paratracheal)
Pectoral (Pectoral)
Popliteal (Popliteal)
Porta Caval (Porta caval)
Porta Hepatis (Porta hepatis)
Pre-auricular (Pre-auricular)
Retroperitoneal (Retroperitoneal)
Splenic Hilar (Splenic hilar)
Supraclavicular (Supraclavicular)
Waldeyer's Ring (Waldeyer's ring)
Other specify
Lymph Node Involvement (* Indicate Lymph Node
Involvement)
Equivocal (Equivocal)
Involved (Involved)
Not Evaluated (not evaluated)
Not Involved (not involved)
Unknown (Unknown)
Method of Evaluation (? Indicate Method of
Evaluation)
Clinical (clinical)
Pathologic (Pathologic)
Unknown (unknown)
Method of Evaluation (? Indicate Method of
Evaluation)
Clinical (clinical)
Pathologic (Pathologic)
Unknown (unknown)
Lung (Is this site involved?)
No (No)
Unknown (Unknown)
Yes (Yes)
Liver
No (No)
Unknown (Unknown)
Yes (Yes)
Spleen
No (No)
Unknown (Unknown)
Yes (Yes)
Bone Marrow
No (No)
Unknown (Unknown)
Yes (Yes)
Bone
No (No)
Unknown (Unknown)
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Yes (Yes)
Pleura
No (No)
Unknown (Unknown)
Yes (Yes)
Kidney
No (No)
Unknown (Unknown)
Yes (Yes)
Skin (cutaneous)
No (No)
Unknown (Unknown)
Yes (Yes)
Parotid Gland
No (No)
Unknown (Unknown)
Yes (Yes)
Submandibular gland
No (No)
Unknown (Unknown)
Yes (Yes)
Thymus
No (No)
Unknown (Unknown)
Yes (Yes)
Other Site
No (No)
Unknown (Unknown)
Yes (Yes)
Thyroid
No (No)
Unknown (Unknown)
Yes (Yes)
Testes
No (No)
Unknown (Unknown)
Yes (Yes)
Ovaries
No (No)
Unknown (Unknown)
Yes (Yes)
Stomach
No (No)
Unknown (Unknown)
Yes (Yes)
Small Bowel
No (No)
Unknown (Unknown)
7 / 12
On-Study - Non-Hodgkins Lymphoma - On-Study Form - 2271898v3.0
Yes (Yes)
Colon
No (No)
Unknown (Unknown)
Yes (Yes)
Brain - parenchymal
No (No)
Unknown (Unknown)
Yes (Yes)
Spine - parenchymal
No (No)
Unknown (Unknown)
Yes (Yes)
CNS - epidural
No (No)
Unknown (Unknown)
Yes (Yes)
CNS - leptomeninges
No (No)
Unknown (Unknown)
Yes (Yes)
CNS - vitreal
No (No)
Unknown (Unknown)
Yes (Yes)
Other Site Name
Was cerebrospinal fluid cell count done
No (No)
Unknown (Unknown)
Yes (Yes)
White Blood Cell Count (If yes, cells/mcl)
Blasts Present in cytocentrifuge (%)
Total Number of cells counted in cytocentrifuge
(cells)
Does patient have cranial nerve palsy (not
explained by extracranial tumor)
No (No)
Unknown (Unknown)
Yes (Yes)
Does patient have clinical spinal cord
compression
No (No)
Unknown (Unknown)
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Yes (Yes)
Does patient have an intracerebral mass
No (No)
Unknown (Unknown)
Yes (Yes)
Does the patient have HIV or AIDS
No (No)
Unknown (Unknown)
Yes (Yes)
Does the patient have post-transplant
lymphoproliferative disease
No (No)
Unknown (Unknown)
Yes (Yes)
Does the patient have immunodeficiency
No (No)
Unknown (Unknown)
Yes (Yes)
Non-hodgkin's Lymphoma: Baseline
Hematology/chemistry
Peripheral WBC Count (x 10^3/mcl)
Hemoglobin (g/dl)
Peripheral Platelet Count (x 10^3/mcl)
Absolute Lymphocyte Count
Bilirubin (mg/dl)
Creatinine (mg/dl age-adjusted)
Uric Acid (mg/dl)
Lactate Dehydrogenase (LDH) (U/l)
Lactate Dehydrogenase ULN (LDH U/l * Note:
Record institutional limits of normal)
Beta-2 Microglobulin (mcg/ml)
Beta-2 Microglobulin ULN (mcg/ml * Note:
Record institutional limits of normal)
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Lymphoma: Prior Treatment
Prior Treatment?
Yes
No
No. of Prior Regimens (If yes, Note: Multiple
drug/staged regimens count as 1; e.g.,
chemo+transplant)
Best Response to Most Recent Prior Treatment
Cr (CR)
Cru (CRU)
Pd (PD)
Pr (PR)
Sd (SD)
Unknown (Unknown)
Prior Surgical Resection
Yes
No
Prior Bone Marrow or Peripheral Blood Stem Cell
Transplant?
Yes
No
Type of Transplant (If yes,)
Allogeneic (Allogeneic)
Autologous (Autologous)
Cord Blood (Cord blood)
Nonmyeloablative (Nonmyeloablative)
Other (Other)
Tandem (Tandem)
Other specify
Prior Radiation Therapy
Yes
No
Radiation Therapy Field (* Radiation Therapy
Field)
Cranial (Cranial)
Cranial & Spinal (Cranial & Spinal)
Extended Mantle (Extended Mantle)
Inverted Y (Inverted Y)
Local (Local)
Mantle (Mantle)
Mantle & Periaortic (Mantle & Periaortic)
Other (Other)
Regional (Regional)
Total Nodal (Total Nodal)
Whole Body (Whole Body)
Other specify (++ If)
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RT Total Dose
units
Grays (Gy)
Millicurie (mCi)
Prior Systemic Chemotherapy
Yes
No
Prior Immunotherapy
Yes
No
Prior Immuno-radiolabeled therapy
Yes
No
Prior Treatment Regimen Name(s)
(Drugs/Agents)
Prior Treatment Regimen Type (Chemotherapy,
Immunotherapy, Immuno-radiolabeled therapy,
etc.)
Total No. of Cycles
Prior Vaccine Therapy?
Yes
No
Prior Vaccine Type
Total No. of Doses
Lymphoma: Relapsed Disease
Disease Status (current)
Other, Specify (Other)
Refractory (Refractory NOS)
Refractory To First Induction (Refractory
to 1st induction)
Refractory To Reinduction After
Complete Response (Refractory to
reinduction after CR)
Relapse (Relapse NOS)
First Relapse (Relapse: 1st)
Second Relapse (Relapse: 2nd)
Third Or Greater Relapse (Relapse:
3rd+)
Other (specify)
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Best Response to Initial Therapy
Cr (CR)
Pd (PD)
Pr (PR)
Sd (SD)
Date of Initial Response to Therapy
Date of First Relapse
Date of Most Recent Response to Therapy
Date of Most Recent Relapse
Performance Status (at Time of Treatment Failure
For CDUS reporting, please convert Karnofsky
and Lansky scores to this Zubrod Score)
Fully Active, Able To Carry On All Pre-
disease Performance Without
Restriction. (0)
Restricted In Physically Strenuous
Activity But Ambulatory And Able To
Carry Out Work Of A Light Or Sedentary
Nature, E.g., Light Housework, Office
Work. (1)
Ambulatory And Capable Of All Selfcare
But Unable To Carry Out Any Work
Activities. Up And About More Than 50%
Of Waking Hours. (2)
Capable Of Only Limited Selfcare,
Confined To Bed Or Chair More Than
50% Of Waking Hours. (3)
Completely Disabled. Cannot Carry On
Any Selfcare. Totally Confined To Bed Or
Chair. (4)
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Endometrial Cancer NCT00265759 Treatment - Z1031:
Axillary Surgery Report Form (ASR) - 2316862v3.0
Z1031: Axillary Surgery Report Form (ASR)
Exemestane, Letrozole, or Anastrozole in Treating
Postmenopausal Women Who Are Undergoing Surgery for
Stage II or Stage III Breast Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=FA6171FB-
1066-1A92-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/8452
Z1031: Axillary Surgery Report Form
(ASR)
Unnamed 1
Visit
Surgery (Surgery)
Patient ID (Pt. ID issued during registration or
previously issued patient ID)
Institution No.
Patient Initials (F M L)
Institution Name
Axillary Surgical Procedures (slnd/alnd)
Was sentinel node biopsy performed
Yes
No
Sentinel Node Biopsy Date (mm dd yyyy)
Number of Sentinel Nodes Examined
Number of Positive Sentinel Nodes by H&E
Number of Positive Sentinel Nodes by
Immunohistochemistry (IHC) only (Enter 'NOT
DONE', if test not done)
Was axillary dissection performed?
Yes
No
Date of Axillary Dissection (mm dd yyyy)
Total number of axillary lymph nodes examined
(Do not include previously counted sentinel
nodes for either the total number of nodes
1 / 2
excised or for the number of positive nodes)
Number of positive axillary nodes by H&E
Number of positive axillary nodes by IHC only
(Enter 'NOT DONE', if test not done)
Completed by
Date Form Completed (mm dd yyyy)
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Endometrial Cancer NCT00265759 Treatment - Z1031: Axillary Surgery
Report Form (ASR) - 2316862v3.0
Fallopian Tube Cancer NCT00108745 Registration -
Registration Form, GOG-0212, Form R - 2295804v3.0
Registration Form, GOG-0212, Form R
Paclitaxel or Polyglutamate Paclitaxel or Observation in
Treating Patients With Stage III or Stage IV Ovarian
Epithelial or Peritoneal Cancer or Fallopian Tube Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=E747EA8B-
589F-3EA8-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/8455
Registration Form, GOG-0212, Form
R
Header Module
Date form originally completed (m d y)
Date form amended (m d y)
Person amending form, last name
Patient Name, Last
Patient Name, First
Patient Study ID
Person Completing Form, Last Name
Tracking Information
Institution name (affiliate)
Treating physician
Patient medical record number
Patient's date of birth (m d y)
Patient social security number
Patient's zip code (USA)
Country of residence (if not USA)
Demographic Information
Patient race (mark all that apply)
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A Person Having Origins In Any Of The
Original Peoples Of North And South
America (including Central America),
And Who Maintains Tribal Affiliation Or
Community Attachment (American Indian
or Alaska Native)
A Person Having Origins In Any Of The
Original Peoples Of The Far East,
Southeast Asia, Or The Indian
Subcontinent Including, For Example,
Cambodia, China, India, Japan, Korea,
Malaysia, Pakistan, The Philippine
Islands, Thailand, And Vietnam. (Asian)
A Person Having Origins In Any Of The
Black Racial Groups Of Africa. Terms
Such As "haitian" Or "negro" Can Be
Used In Addition To "black Or African
American." (Black or African American)
A Person Having Origins In Any Of The
Original Peoples Of Hawaii, Guam,
Samoa, Or Other Pacific Islands (Native
Hawaiian or other Pacific Islander)
Patient Is Unsure Of Their Race
(Unknown)
A Person Having Origins In Any Of The
Original Peoples Of Europe, The Middle
East, Or North Africa. (White)
Patient ethnicity (check one)
A Person Of Mexican, Puerto Rican,
Cuban, Central Or South American Or
Other Spanish Culture Or Origin,
Regardless Of Race (Hispanic or Latino)
A Person Not Meeting The Definition For
Hispanic Or Latino. (Non-Hispanic)
Patient Is Unsure Of Their Ethnicity
(Unknown)
Method of payment
Medicaid (Medicaid)
Medicaid And Medicare (Medicaid &
Medicare)
Medicare (Medicare)
Medicare And Private Insurance
(Medicare & Private Insurance)
Military Or Veterans Sponsored Nos
(Military or Veterans Sponsored NOS)
Military Sponsored (including Champus
& Tricare) (Military Sponsored (including
Champus & Tricare))
No Means Of Payment (no Insurance)
(No means of payment (no insurance))
Other (Other)
Private Insurance (Private Insurance)
Self Pay (no Insurance) (Self pay (no
insurance))
Unknown (Unknown)
Veterans Sponsored (Veterans
Sponsored)
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Fallopian Tube Cancer NCT00108745 Registration - Registration Form,
GOG-0212, Form R - 2295804v3.0
Patient height (cm)
Patient weight (kg)
Performance status (Zubrod)
Fully Active, Able To Carry On All Pre-
disease Performance Without Restriction
(karnofsky 90 - 100) (ecog - 0
Asymptomatic) (0)
Restricted In Physically Strenuous
Activity But Ambulatory (k70 - 80) (ecog -
1 Symptomatic - Fully Ambulatory) (1)
Ambulatory And Capable Of All Selfcare
But Unable To Carry Out Any Work
Activities (k 50 - 60) (ecog - 2
Symptomatic; In Bed , 50% Of The Day)
(2)
Capable Of Limited Selfcare, Confined
To Bed Or Chair More Than 50% Of
Waking Hours. (k 30 - 40) (ecog - 3
Symptomatic; In Bed > 50% Of The Day
But Not Bedridden) (3)
Completely Disabled (k10 - 20) (ecog - 4
Bedridden) (4)
Has the patient had any prior cancer diagnosed?
Yes
No
Prior cancer type
Prior cancer diagnosis date (m d y)
Comments
COMMENTS
Footer Module
Participating Group Code
Participating Group Protocol Number
Participating Group Patient ID
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Fallopian Tube Cancer NCT00108745 Registration - Registration Form,
GOG-0212, Form R - 2295804v3.0
Fallopian Tube Cancer NCT00108745 On-Study - On Study
Ovarian Maintenance, GOG-0212, Form OSOM - 2295874v3.0
On Study Ovarian Maintenance, GOG-0212, Form OSOM
Paclitaxel or Polyglutamate Paclitaxel or Observation in
Treating Patients With Stage III or Stage IV Ovarian
Epithelial or Peritoneal Cancer or Fallopian Tube Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=E747F94E-
9700-3F80-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/8456
On Study Ovarian Maintenance,
GOG-0212, Form OSOM
Header Module
Date form originally completed (m d y)
Date form amended (m d y)
Person amending form, last name
Patient Initials (First, Middle, Last)
Patient Study ID
Person Completing Form, Last Name
Ovarian: Disease Description
Date of definitive histologic diagnosis of primary
tumor (m d y)
Primary Site
Fallopian Tube (Fallopian tube)
Other, Specify (Other specify)
Ovary (Ovary)
Peritoneum (Peritoneal)
Other specify
Stage (at diagnosis FIGO)
Refer To Figo Staging For Specific
Gynecologic Cancer (IA)
Refer To Figo Staging For Specific
Gynecologic Cancer (IB)
Refer To Figo Staging For Specific
Gynecologic Cancer (IC)
Refer To Figo Staging For Specific
Gynecologic Cancer (IIA)
Refer To Figo Staging For Specific
Gynecologic Cancer (IIB)
Refer To Figo Staging For Specific
Gynecologic Cancer (IIC)
Refer To Figo Staging For Specific
Gynecologic Cancer (III)
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Refer To Figo Staging For Specific
Gynecologic Cancer (IIIA)
Refer To Figo Staging For Specific
Gynecologic Cancer (IIIB)
Refer To Figo Staging For Specific
Gynecologic Cancer (IIIC)
Refer To Figo Staging For Specific
Gynecologic Cancer (IV)
Histologic Grade
Grade 1-well Differentiated (1)
Grade 2-moderately Differentiated (2)
Grade 3-poorly Differentiated (3)
Grade Unknown (Unknown)
Histologic Type (check all that apply)
Adenocarcinoma, Unspecified
(Adenocarcinoma, unspecified)
Clear Cell Carcinoma (Clear cell
carcinoma)
Endometrioid Adenocarcinoma
(Endometrioid adenocarcinoma)
Mixed Epithelial Carcinoma, Specify
Components (Mixed epithelial
carcinoma)
Mucinous Adenocarcinoma (Mucinous
adenocarcinoma)
Other, Specify (Other specify)
Serous Adenocarcinoma (Serous
adenocarcinoma)
Other specify
Ovarian: Findings From Primary Surgery
Primary surgery type (check all that apply)
Bilateral Salpingo-oophorectomy
(Bilateral Salpingo-Oophorectomy)
Other, Specify (Other specify)
Para-aortic Node Sampling/dissection
(Para-aortic node sampling/dissection)
Pelvic Node Sampling/dissection (Pelvic
node sampling/dissection)
Total Hysterectomy (Total hysterectomy)
Unilateral Salpingo-oophorectomy
(Unilateral Salpingo-Oophorectomy)
Other specify
Primary surgery date (m d y)
Size of residual disease (cm Maximum size after
resection is complete. If none or microscopic
only, enter 0.)
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Fallopian Tube Cancer NCT00108745 On-Study - On Study Ovarian
Maintenance, GOG-0212, Form OSOM - 2295874v3.0
Prior Treatment For Gynecologic Cancer
Prior hormonal therapy?
Yes
No
Yes specify
Prior immunological therapy?
Yes
No
Yes specify
Other biologic agent?
Yes
No
Yes specify
Prior radiation therapy?
Yes
No
Yes specify
Prior Chemotherapy Information
Date started (m d y)
Date ended (m d y)
No. of courses
Specify agents/dose
Best response (Best response definitions:
C=Complete response; P=Partial response;
S=Stable disease; I=Increasing disease; X=Not
measurable, not applicable; U=Not available,
unknown)
Complete Response (Complete
Response)
Increasing Disease (Increasing disease)
Unknown (Not available, unknown)
Not Applicable (Not measurable, not
applicable)
Partial Response (Partial Response)
Stable Disease (Stable disease)
Date of best response (m d y)
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Fallopian Tube Cancer NCT00108745 On-Study - On Study Ovarian
Maintenance, GOG-0212, Form OSOM - 2295874v3.0
Pre-treatment Ca125
Result of CA125 (U/mL pre-treatment)
Date of CA125 (m d y)
CA125 Laboratory upper limit of normal (U/mL)
Comments
COMMENTS
Footer Module
Participating Group Code
Participating Group Protocol Number
Participating Group Patient ID
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Fallopian Tube Cancer NCT00108745 On-Study - On Study Ovarian
Maintenance, GOG-0212, Form OSOM - 2295874v3.0
Endometrial Cancer NCT00265759 Treatment -
Z1031 Chemotherapy Form (CHEMO) - 2940221v1.0
Z1031 Chemotherapy Form (CHEMO)
Exemestane, Letrozole, or Anastrozole in Treating
Postmenopausal Women Who Are Undergoing Surgery for
Stage II or Stage III Breast Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=739D9DB4-
530A-7818-E040-BB89AD4371E4
All rights reserved. Please visit https://medical-data-
models.org/forms/8458
Z1031 Chemotherapy Form
(CHEMO)
Unnamed 1
Visit
Surgery (Surgery)
Patient ID (Pt. ID issued during registration or
previously issued patient ID)
Institution No.
Patient Initials (F M L)
Institution Name
Chemotherapy/treatment Information
Did the patient receive chemotherapy?
Yes
No
Date Chemotherapy Started (mm dd yyyy)
Date Chemotherapy Ended (mm dd yyyy)
NCCN Preferred Regimen received
Doxorubicin And Cyclophosphamide
Every 2 Weeks For Four Cycles
Followed By Paclitaxel Every 2 Weeks
For Four Cycles (Doxorubicin and
Cyclophosphamide every 2 weeks for
four Cycles followed by Paclitaxel every 2
weeks for four cycles)
Doxorubicin And Cyclophosphamide
Every 3 Weeks For Four Cycles
(Doxorubicin and Cyclophosphamide
every 3 weeks for four cycles)
Doxorubicin And Cyclophosphamide
Every 3 Weeks For Four Cycles
Followed By Paclitaxel Every Week For
Twelve Weeks (Doxorubicin and
Cyclophosphamide every 3 weeks for
four Cycles followed by Paclitaxel every
1 / 2
week for twelve weeks)
Other Nccn Approved Regimen (Other
NCCN approved regimen)
Taxotere And Cyclophosphamide Every
3 Weeks For Four Cycles (Taxotere and
Cyclophosphamide every 3 weeks for
four Cycles)
Taxotere, Doxoburicin And
Cyclophosphamide For Six Cycles
(Taxotere, Doxoburicin and
Cyclophosphamide for six cycles)
Specify
Were all cycles of the regimen completed
Yes
No
Total number of cycles completed
Reason Treatment Ended
Adverse Event/side Effects/complications
(Adverse event/side
effects/complications)
Other (Other)
Patient Withdrawal/refusal After
Beginning Therapy (Patient
withdrawal/refusal after beginning
therapy)
Other specify
Footer Module
Completed by
Date Form Completed (mm dd yyyy)
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Endometrial Cancer NCT00265759 Treatment - Z1031 Chemotherapy
Form (CHEMO) - 2940221v1.0
Endometrial Cancer NCT00265759 On-Study - Z1031 Preoperative
Endocrine Prognostic Index Form (PEPI) - 2940238v1.0
Z1031 Preoperative Endocrine Prognostic Index Form
(PEPI)
Exemestane, Letrozole, or Anastrozole in Treating
Postmenopausal Women Who Are Undergoing Surgery for
Stage II or Stage III Breast Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=739D9DB4-
532C-7818-E040-BB89AD4371E4
All rights reserved. Please visit https://medical-data-
models.org/forms/8459
Z1031 Preoperative Endocrine
Prognostic Index Form (PEPI)
Unnamed 1
Visit
30 Days Post Surgery (30 Days post
surgery)
Patient ID (Pt. ID issued during registration or
previously issued patient ID)
Institution No.
Patient Initials (F M L)
Institution Name
Preoperative Endocrine Prognostic
Index/treatment Information
Did patient complete protocol AI therapy
Yes
No
Date results received from Central Lab (mm dd
yyyy)
Ki67 Score (%)
Allred score
PEPI Score
Treatment Plan (Per protocol: Chemotherapy is
not recommended for patients with PEPI score =
0 and pathological stage T1N0 or T0N0
pathologic complete response)
Adjuvant Chemotherapy (Adjuvant
chemotherapy)
No Chemotherapy (No chemotherapy)
Footer Module
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Completed by
Date Form Completed (mm dd yyyy)
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Endometrial Cancer NCT00265759 On-Study - Z1031 Preoperative
Endocrine Prognostic Index Form (PEPI) - 2940238v1.0
Fallopian Tube Cancer NCT00108745 Pre-Study - Clinical
Assessment Form, GOG-0212, Form DCA - 2321370v1.0
Clinical Assessment Form, GOG-0212, Form DCA
Paclitaxel or Polyglutamate Paclitaxel or Observation in
Treating Patients With Stage III or Stage IV Ovarian
Epithelial or Peritoneal Cancer or Fallopian Tube Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=FD0DEC56-
A99D-220C-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/8460
Clinical Assessment Form, GOG-
0212, Form DCA
Header Module
Date form originally completed (m d y)
Date form amended (m d y)
Person amending form, last name
Patient Initials (First, Middle, Last)
Patient Study ID
Person Completing Form, Last Name
Non-invasive Diagnostic Procedures
Current Cycle Number
Has the patient had a documented clinical
assessment for this cancer?
Yes
No
Chest X-Ray Result
Abnormal (Abnormal)
Normal (Normal)
Not Done (Not done)
Chest X-ray Result Abnormal Specify
Date of Chest X-ray
EKG result
Abnormal (Abnormal)
Normal (Normal)
Not Done (Not done)
Heart Echocardiogram Test Abnormal Specify
Date of EKG
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MRI result
Abnormal (Abnormal)
Normal (Normal)
Not Done (Not done)
Abnormal, specify
Date of MRI
CT Result
Abnormal (Abnormal)
Normal (Normal)
Not Done (Not done)
Diagnostic CT Result Abnormal Specify
Date of CT Scan
Other Procedure Performed
Abnormal (Abnormal)
Normal (Normal)
Not Done (Not done)
Evaluation Result Abnormal Specify
Procedure Date
Comment
COMMENT
Footer Module
Participating Group Code
Participating Group Protocol Number
Participating Group Patient ID
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Fallopian Tube Cancer NCT00108745 Pre-Study - Clinical Assessment
Form, GOG-0212, Form DCA - 2321370v1.0
Fallopian Tube Cancer NCT00108745 Lab - Specimen
Form, GOG-0212, Form SP - 2297741v3.0
Specimen Form, GOG-0212, Form SP
Paclitaxel or Polyglutamate Paclitaxel or Observation in
Treating Patients With Stage III or Stage IV Ovarian
Epithelial or Peritoneal Cancer or Fallopian Tube Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=E79A185F-
51CE-71A1-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/8461
Specimen Form, GOG-0212, Form
SP
Header Module
Date form originally completed (m d y)
Date form amended (m d y)
Person amending form, last name
Patient Study ID
GOG Bank ID#
Person Completing Form, Last Name
Site Contact Information
Phone or email
Phone or email
General Specimen Information
Specimen Code
Time point
Other specify
Submission Status
Not Submitted (Not submitted)
Submitted (Submitted)
Not submitted, specify
Date collected (m d y)
Time collected (when required by the protocol)
1 / 4
Specimen type
Buffy Coat (Buffy coat)
Cells (Cells)
Fixed Tissue (Fixed tissue)
Frozen Tissue (Frozen tissue)
Other (Other specify)
Plasma (Plasma)
Serum (Serum)
Urine (Urine)
Whole Blood (Whole blood)
Items shipped
Block (Block)
Oct-mold (OCT-mold)
Other (Other specify)
Piece (Piece)
Slide (Slide)
Tube/vial (Tube/Vial)
Other specify
Quantity of items shipped
Processing time
<1 Hour (<1 hour)
>4 Hours (>4 hours)
1-2 Hours (1-2 hours)
2-4 Hours (2-4 hours)
N/a (NA)
Storage type
Other (Other specify)
Refrigerator (Refrigerator)
Room Temperature (Room temperature)
Standard Non-cycling Freezer (Standard
non-cycling freezer)
Ultracold Freezer/liquid N2/dry Ice
(Ultracold freezer/liquid N2/dry ice)
Other specify
Date shipped (m d y)
Federal Express tracking number
Additional information required by protocol
Blood/fluid Products
Type of blood collection tube
Acid Citrate Dextrose (acd) (ACD)
Citrate (Citrate)
Edta (EDTA)
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Fallopian Tube Cancer NCT00108745 Lab - Specimen Form, GOG-0212,
Form SP - 2297741v3.0
Heparin (Heparin)
Other (Other specify)
Red Top (Red top)
Serum Separator (Serum separator)
Other specify
Platelet count required?
Yes
No
Platelet count (/mcL)
Date of platelet count (m d y)
Preservative?
Yes
No
Yes specify below (preservative)
Urine collection method
24-hour (24-hour)
Clean Catch (Clean catch)
Other (Other specify)
Other specify
Tissue/cells
Tissue type
Metastatic Tumor (Metastatic tumor)
Normal (Normal)
Other (Other specify)
Pre-malignant (Pre-malignant)
Primary Tumor (Primary tumor)
Recurrent/persistent Tumor
(Recurrent/persistent tumor)
Other specify
Processing method
Ethanol-fixed (Ethanol-fixed)
Fixed & Paraffin-embedded (Fixed &
paraffin-embedded)
Formalin-fixed (Formalin-fixed)
Oct-frozen (OCT-frozen)
Other (Other)
Snap-frozen (Snap-frozen)
Other specify
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Fallopian Tube Cancer NCT00108745 Lab - Specimen Form, GOG-0212,
Form SP - 2297741v3.0
Cell type
Buccal (Buccal)
Cervical (Cervical)
Other (Other)
Other specify
Gog Tissue Bank/laboratory Information
Receiving institution
Gog Tissue Bank (GOG Tissue Bank)
Laboratory (Laboratory)
Name (Staff at GOG Tissue Bank/Lab receiving
specimens)
Phone or email
Phone or email
Lab name
Date received (m d y)
Total volume/weight
Units
Additional processing required
Yes
No
Yes specify below (processing)
Condition of received specimens
Satisfactory (Satisfactory)
Unsatisfactory (Unsatisfactory)
Unsatisfactory specify
Footer Module
Participating Group Code
Participating Group Protocol Number
Participating Group Patient ID
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Fallopian Tube Cancer NCT00108745 Lab - Specimen Form, GOG-0212,
Form SP - 2297741v3.0
Pathology - Breast Pathology Form -
2020193v3.0
Breast Pathology Form
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=146367B0-
88EA-3172-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/8462
Breast Pathology Form
Crf Header
Coordinating Group Protocol No.
Coordinating Group Code
Protocol Title
Patient Study ID
Other Patient ID
Institution/Affiliate
Participating Group Code
Patient Name (initials acceptable)
Breast: Form Administration
Person Completing Form
Are data amended (If data are amended, please
circle in red when using paper form)
Yes
No
Pathology: Estrogen And Progesterone
Receptors
Tissue Type
Distant Metastases (Metastasis)
Other, Specify (Other)
Primary (Primary)
Regional Nodal (Regional nodal)
Blocks
Blocks
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Accession Number
Other, specify
Method of Evaluation
Autopsy (Autopsy)
Axillary Dissection (Axillary dissection)
Ductal Lavage (Ductal lavage)
Ductoscopic Biopsy (Ductoscopic
biopsy)
Excisional Biopsy Or Lumpectomy
(Excisional biopsy or lumpectomy)
Fine Needle Aspiration Biopsy (Fine
needle aspiration biopsy)
Fluid Cytology, Ascites (Fluid cytology,
ascites)
Fluid Cytology, Cerebrospinal Fluid (Fluid
cytology, cerebrospinal fluid)
Fluid Cytology, Pleural (Fluid cytology,
pleural)
Incisional Biopsy (Incisional biopsy)
Mastectomy (Mastectomy)
Needle Biopsy (tru-cut Or Core) (Needle
biopsy (tru-cut or core))
Nipple Fluid (Nipple fluid)
Other, Specify (Other, specify)
Prophalactic Mastectomy (Prophalactic
mastectomy)
Resection/re-excision Of Lumpectomy
Margins (Resection/re-excision of
lumpectomy margins)
Sentinel Node Biopsy (Sentinel node
biopsy)
Other Specify
Marker Test Method
Elisa (ELISA)
Fluorescence In Situ Hybridization (fish)
(Fluorescence in situ hybridization
(FISH))
Immunohistochemistry (ihc)
(Immunohistochemistry (IHC))
Other, Specify (Other)
Other specify
Type of Hormone Receptor (mark all that apply)
Estrogen Receptor (er) (Estrogen
receptor)
Other Specify (Other)
Progesterone Receptor (pr)
(Progesterone receptor)
Other specify
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Staining Antibody
Antigen Retrieval
Yes
No
Yes specify
Percentage of Invasive Tumor Cells with Nuclear
Staining (%)
Percentage of DCIS Cells with Nuclear Staining
(%)
Intensity of Stained Malignant Nuclei, Description
(OR)
Intense (Intense)
Intermediate (Intermediate)
Negative (Negative)
Scant (Scant)
Unknown (Unknown)
Intensity of Stained Malignant Nuclei, Scaled
(___ of ___ Note: Scale for intensity will be
protocol specific.)
Final Receptor Status Diagnosis
Indeterminate (Indeterminate)
Negative (Negative)
Positive (Positive)
Pathology: Breast Disease Assessment
Disease Site
Breast, Metastasis/recurrence (Breast,
metastasis/recurrence)
Breast, Primary (Breast, primary)
Lymph Nodes (Lymph nodes)
Other, Specify (Other, specify)
Blocks
Accession Number
Disease Site, Other
Specimen Site
Bone (Bone)
Bone Marrow (Bone marrow)
Brain (Brain)
Contralateral Breast (Contralateral
breast)
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Pathology - Breast Pathology Form - 2020193v3.0
Distant Nodes, Specify (Distant nodes,
specify)
Ipsilateral Supraclavicular Nodes
(Ipsilateral supraclavicular nodes)
Liver (Liver)
Local-regional (including Ipsilateral
Breast; Chest Wall; Axillary, Internal
Mammary, And Infra-clavicular Nodes;
Local-regional Skin And Subcutaneous
Tissue) (Local-regional)
Lung (Lung)
Mediastinal Nodes (Mediastinal nodes)
Other, Specify (Other, specify)
Specimen Site, Distant Nodes
Specimen Site, Other
Specimen Laterality
Left (Left)
Right (Right)
Unknown/not Applicable (Unknown/Not
Applicable)
Assessment Type
Autopsy (autopsy)
Axillary Dissection (axillary dissection)
Bone Scan (Bone scan)
Chest X-ray (Chest X-Ray)
Clinical Examination (pe) (Clinical
examination)
Ct Scan (CT Scan)
Cytology (Cytology)
Ductal Lavage (ductal lavage)
Ductoscopic Biopsy (ductoscopic biopsy)
Excisional Biopsy Or Lumpectomy
(excisional biopsy or lumpectomy)
Lumpectomy, With Wire Localization
(excisional biopsy or lumpectomy, with
wire localization)
Fine Needle Aspriation Biopsy (Fine
needle aspriation biopsy)
Fine Needle Aspriation Biopsy, With Wire
Localization (Fine needle aspriation
biopsy, with wire localization)
Fluid Cytology, Ascites (fluid cytology,
ascites)
Fluid Cytology, Cerebrospinal Fluid (fluid
cytology, cerebrospinal fluid)
Fluid Cytology, Pleural (fluid cytology,
pleural)
Histology (Histology)
Incisional Biopsy (Incisional biopsy)
Incisional Biopsy, With Wire Localization
(Incisional biopsy, With wire localization)
Mastectomy (Mastectomy)
Mri (MRI (NMR))
Needle Biopsy (tru-cut Or Core) (Needle
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biopsy (tru-cut or core))
Needle Biopsy (tru-cut Or Core), With
Wire Localization (Needle biopsy (tru-cut
or core), with wire localization)
Nipple Fluid (nipple fluid)
Not Evaluated (Not evaluated)
Other (Other)
Other, Specify (other, specify)
Prophalactic Mastectomy (prophalactic
mastectomy)
Resection/re-excision Of Lumpectomy
Margins (Resection/re-excision of
lumpectomy margins)
Sentinel Node Biopsy (sentinel node
biopsy)
Spiral Ct Scan (Spiral CT scan)
Tumor Markers (Tumor markers)
Ultrasound (Ultrasound)
Assessment Type, Specify
Pathology: Assessment Of Benign Breast
Tissue
Histologic Type, Other Name
Pathology: Cytology
Ductal Lavage/Nipple Aspirate Result
Atypical Epithelial Cells (marked)
(Atypical epithelial cells (marked))
Atypical Epithelial Cells (mild Change)
(Atypical epithelial cells (mild change))
Benign Epithelial Cells (Benign epithelial
cells)
Icmd (insufficient Material For Diagnosis)
(ICMD (insufficient material for
diagnosis))
Malignant Epithelial Cells (Malignant
epithelial cells)
Non-epithelial Cells (Non-epithelial cells)
Other (inflammatory, Etc.), Specify
(Other (inflammatory, etc.), specify)
Ductal Lavage/Nipple Aspirate Result, Other
Nipple Discharge Result
Atypical (epithelial Cells Present)
(Atypical (epithelial cells present))
Benign (absence Of Epithelium) (Benign
(absence of epithelium))
Malignant (Malignant)
Not Sufficient For Diagnosis
(indeterminate/unsatisfactory (Not
sufficient for diagnosis
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(indeterminate/unsatisfactory)
Other (inflammatory, Etc.), Specify
(Other (inflammatory, etc.), specify)
Suspicious (Suspicious)
Nipple Discharge Result, Other
Fine Needle Aspirate Biopsy Result
Atypical/indeterminate
(Atypical/Indeterminate)
Benign (Benign)
Malignant (Malignant)
Other (inflammatory, Etc.), Specify
(Other (inflammatory, etc.), specify)
Suspicious (Suspicious)
Unsatisfactory (Unsatisfactory)
Fine Needle Aspirate Biopsy Result, Other
Fluid Cytology, Ascites Result
Atypical/indeterminate
(Atypical/Indeterminate)
Benign (Benign)
Malignant (Malignant)
Other (inflammatory, Etc.), Specify
(Other (inflammatory, etc.), specify)
Suspicious (Suspicious)
Unsatisfactory (Unsatisfactory)
Fluid Cytology, Ascites Result, Other
Fluid Cytology, Pleural Result
Atypical/indeterminate
(Atypical/Indeterminate)
Benign (Benign)
Malignant (Malignant)
Other (inflammatory, Etc.), Specify
(Other (inflammatory, etc.), specify)
Suspicious (Suspicious)
Unsatisfactory (Unsatisfactory)
Fluid Cytology, Pleural Result, Other
Pathology: Assessment Of Ductal
Carcinoma In Situ (dcis)
DCIS Ind
Yes
No
DCIS Ind, Invasive Cancer
Yes
No
Pathologic Primary Tumor Size
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Lobule Cancerization Ind
Yes
No
Histologic Type, Other Name
Histologic Type, Dominant
Aprocrine (Aprocrine)
Clinging (Clinging)
Comedo (Comedo)
Cribriform (Cribriform)
Intra-cystic (encysted Papillary) (Intra-
cystic (encysted papillary))
Micropapillary (Micropapillary)
Other, Specify (Other, specify)
Papillary Carcinoma In Situ (papillary)
(Papillary carcinoma in situ (papillary))
Solid (Solid)
Histologic Type, Dominant, Other
Therapeutic Effect Ind
No (No)
Unknown (Unknown)
Yes (Yes)
Paget's Disease Ind
No (No)
Unknown (Unknown)
Yes (Yes)
Therapeutic Effect Type
Drug-related Changes (Drug-related
changes)
Other, Specify (Other, specify)
Radiation Changes (Radiation changes)
Surgical Changes (Surgical changes)
Therapeutic Effect Type, Other
Necrosis Type
Comedonecrosis (Comedonecrosis)
Non-comedonecrosis (Non-
comedonecrosis)
Other, Specify (Other, specify)
Microcalcifications
None (None)
Present, Involving Benign Ducts
(Present, involving benign ducts)
Present, Involving Both Benign Ducts
And Dcis (Present, involving both benign
ducts and DCIS)
Present, Involving Dcis (Present,
involving DCIS)
Necrosis Type, Other
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Necrosis Ind
Yes
No
DCIS, Margin Result
> Or = 1 Mm To 10 Mm (> or = 1 mm to
10 mm)
Greater Than 10 Mm (Greater than 10
mm)
Involved, Not Otherwise Specified
(Involved, NOS)
Less Than 1 Mm (Less than 1 mm)
Not Involved, Not Otherwise Specified
(Not involved, NOS)
Transected (Transected)
Unknown (Unknown)
Microinvasive Cancer Ind
Indeterminate (Indeterminate)
No (No)
Yes (Yes)
Pathology: Assessment Of Lobular
Carcinoma In Situ (lcis)
LCIS Ind
Yes
No
LCIS Ind, Invasive Cancer
Yes
No
LCIS Extent
Extensive (Extensive)
Focal (Focal)
Not Specified (Not specified)
LCIS, Margin Result
> Or = 1 Mm To 10 Mm (> or = 1 mm to
10 mm)
Greater Than 10 Mm (Greater than 10
mm)
Involved, Nos (Involved, NOS)
Less Than 1 Mm (Less than 1 mm)
Not Involved, Nos (Not involved, NOS)
Transected (Transected)
Unknown (Unknown)
Pathology: Assessment Of Invasive Tumor
Pathologic Primary Tumor Size
Pathologic Primary Tumor Size
Histologic Type, Other Name
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Mitotic Count, Corrected
>11 Mitoses Per 10 Hpf (0.44 Mm) Or
>20 Mitoses Per 10 Hpf (0.59 Mm) Or >
23 Mitoses Per 10 Hpf (0.63 Mm) (3 Pts)
(>11 mitoses per 10 HPF (0.44 mm) OR
>20 mitoses per 10 HPF (0.59 mm) OR
> 23 mitoses per 10 HPF (0.63 mm))
0 To 5 Mitoses Per 10 Hpf (0.44 Mm) Or
0-9 Mitoses Per 10 Hpf (0.59 Mm) Or 0-
11 Mitoses Per 10 Hpf (0.63 Mm) (1 Pt)
(0 to 5 mitoses per 10 HPF (0.44 mm)
OR 0-9 mitoses per 10 HPF (0.59 mm)
OR 0-11 mitoses per 10 HPF (0.63 mm))
6 To 10 Mitoses Per 10 Hpf (0.44 Mm) Or
10-20 Mitoses Per 10 Hpf (0.59 Mm) Or
12-23 Mitoses Per 10 Hpf (0.63 Mm) (2
Pts) (6 to 10 mitoses per 10 HPF (0.44
mm) OR 10-20 mitoses per 10 HPF
(0.59 mm) OR 12-23 mitoses per 10
HPF (0.63 mm))
Indeterminate (Indeterminate)
Tubule Formation
Indeterminate (Indeterminate)
Majority Of Tumor, >75% (1 Pt) (Majority
of tumor, >75%)
Minimal, < 10% (3 Pt) (Minimal, < 10%)
Moderate, 10% To 75 % (2 Pt)
(Moderate, 10% to 75 %)
Total Nottingham Score
Paget's Disease Ind
No (No)
Unknown (Unknown)
Yes (Yes)
Dermal Lymphatics Invasion Ind
No (No)
Unknown (Unknown)
Yes (Yes)
Lymphovascular Invasion Ind
No (No)
Unknown (Unknown)
Yes (Yes)
Perineural Tumor Invasion Ind
No (No)
Unknown (Unknown)
Yes (Yes)
Microcalcifications
None (None)
Present, Involving Benign Ducts
(Present, involving benign ducts)
Present, Involving Both Benign Ducts
And Dcis (Present, involving both benign
ducts and DCIS)
9 / 13
Pathology - Breast Pathology Form - 2020193v3.0
Present, Involving Dcis (Present,
involving DCIS)
Lymphocytic/Mononuclear Cell Reaction Ind
No (No)
Unknown (Unknown)
Yes (Yes)
Necrosis Ind
Yes
No
Necrosis Extent
Extensive (Extensive)
Indeterminate (Indeterminate)
Moderate (Moderate)
Scant (Scant)
Unknown (Unknown)
Microinvasive Cancer Ind
Indeterminate (Indeterminate)
No (No)
Yes (Yes)
Invasive Cancer, Margin Result
> Or = 1 Mm To 10 Mm (> or = 1 mm to
10 mm)
Greater Than 10 Mm (Greater than 10
mm)
Involved, Nos (Involved, NOS)
Less Than 1 Mm (Less than 1 mm)
Not Involved, Nos (Not involved, NOS)
Unknown (Unknown)
Pathology: Assessment Of Lymph Nodes
Sentinel Node Biopsy Ind
No (NO)
Unknown (UNKNOWN)
Yes (YES)
Sentinel Node Site
Axillary (Axillary)
Internal Mammary (Internal Mammary)
Supraclavicular (Supraclavicular)
Unknown (Unknown)
Sentinel Node(s) Examined Number
Sentinel Node(s), Other Involved Number
Sentinel Node(s) Positive Number
Sentinel Node(s) Positive Number, H&E
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Sentinel Node(s) Positive Number, IHC
Sentinel Node, Largest Metastasis Size
< 2 Mm (< 2 mm)
> Or = 2 Mm (> or = 2 mm)
Axillary Dissection Ind
No (NO)
Unknown (UNKNOWN)
Yes (YES)
Lymph Node(s) Examined Number
Lymph Node(s) without Micromets
Lymph Node(s) with Micromets
Lymph Nodes Type
Axillary (axillary)
Infraclavicular (infraclavicular)
Internal Mammary (internal mammary)
Ipsilateral (ipsilateral)
Supraclavicular (supraclavicular)
Lymph Node Involvement
Equivocal (equivocal)
Negative (negative)
Not Evaluated (not evaluated)
Positive (positive)
Unknown (unknown)
Largest Lymph Node Size
< 0.2 Mm By Ihc Only (< 0.2 mm by IHC
only)
> 2 Cm (> 2 cm)
0.2 To 2 Mm By H&e (0.2 to 2 mm by
H&E)
2 Mm To 2 Cm (2 mm to 2 cm)
Lymph Node(s) Positive Number
Lymph Node(s) Positive Number
Extracapsular Extension Ind
No (No)
Unknown (Unknown)
Yes (Yes)
Pathology: Disease Staging
T Stage, Pathologic
No Evidence Of Primary Tumor (T0)
Tumor 2 Cm Or Less In Greatest
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Dimension (T1)
Tumor More Than 0.1 Cm But Not More
Than 0.5 Cm In Greatest Dimension
(T1a)
Tumor More Than 0.5 Cm But Not More
Than 1 Cm In Greatest Dimension (T1b)
Tumor More Than 1 Cm But Not More
Than 2 Cm In Greatest Dimension (T1c)
Microinvasion 0.1 Cm Or Less In
Greatest Dimension (T1mic)
Tumor More Than 2 Cm But Not More
Than 5 Cm In Greatest Dimension (T2)
Tumor More Than 5 Cm In Greatest
Dimension (T3)
Tumor Of Any Size With Direct (T4)
Extension To Chest Wall (T4a)
Edema (including Peau D'orange) Or
Ulceration Of The Skin Of The Breast Or
Satellite Skin Nodules Confined To The
Same Breast (T4b)
Both T4a And T4b (T4c)
Inflammatory Carcinoma (T4d)
Carcinoma In Situ: Intraductal
Carcinoma, Lobular Carcinoma In Situ,
Or Paget's Disease Of The Nipple With
No Tumor (Tis)
Primary Tumor Cannot Be Assessed
(TX)
N Stage, Pathologic
N0, According To Ajcc Criteria (N0)
N1, According To Ajcc Criteria (N1)
N1a, According To Ajcc Criteria (N1a)
N1b, According To Ajcc Criteria (N1b)
N1bi, According To Ajcc Criteria (N1bi)
N1bii, According To Ajcc Criteria (N1bii)
N1biii, According To Ajcc Criteria (N1biii)
N1biv, According To Ajcc Criteria (N1biv)
N2, According To Ajcc Criteria (N2)
N3, According To Ajcc Criteria (N3)
Nx, According To Ajcc Criteria (NX)
No Regional Lymph Node Metastasis
(pN0)
Metastasis To Movable Ipsilateral Axillary
Lymph Node(s) (pN1)
Only Micrometastasis (none Larger Than
0.2 Cm) (pN1a)
Metastasis To Lymph Node(s), Any
Larger Than 0.2 Cm (pN1b)
Metastasis In 1 To 3 Lymph Nodes, Any
More Than 0.2 Cm And All Less Than 2
Cm In Greatest Dimension (pN1bi)
Metastasis To 4 Or More Lymph Nodes,
Any More Than 0.2 Cm And All Less
Than 2 Cm In Greatest Dimension
(pN1bii)
Extension Of Tumor Beyond The
Capsule Of A Lymph Node Metastasis
Less Than 2 Cm In Greatest Dimension
(pN1biii)
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Metastasis To A Lymph Node 2 Cm Or
More In Greatest Dimension (pN1biv)
Metastasis To Ipsilateral Axillary Lymph
Nodes That Are Fixed To One Another
Or T Other Structure (pN2)
Metastasis To Ipsilateral Internal
Mammary Lymph Node(s) (pN3)
Regional Lymph Nodes Cannot Be
Assessed (e.g., Previously Removed Or
Not Removed For Pathologic Study)
(pNX)
Stage Grouping
0 (0)
The Cancer Is No Bigger Than 2
Centimeters (about 1 Inch) And Has Not
Spread Outside The Breast. (I)
Iia (IIA)
Iib (IIB)
Defined By Either Of The Following: The
Cancer Is Smaller Than 5 Centimeters
And Has Spread To The Lymh Nodes
Under The Arm, Which Have Grown Into
Each Other Or Into Other Structures And
Are Attached To Them. The Cancer Is
Bigger Than 5 Cm And Has Spre* (IIIA)
Defined By Either Of The Following.: The
Cancer Has Spread To Tissues Near
The Breast (skin, Chest Wall, Including
The Ribs And The Muscles In The
Chest). The Cancer Has Spread To
Lymph Nodes Inside The Chest Wall
Along The Breast Bone. (IIIB)
The Cancer Has Spread To Other
Organs Of The Body, Most Often The
Bones, Lungs, Liver, Or Brain. Or, Tumor
Has Spread Locally To The Skin And
Lymph Nodes Inside The Neck, Near
The Collarbone. (IV)
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Fallopian Tube Cancer NCT00108745 Pathology -
Pathology Form, GOG-0212, Form F - 2296111v3.0
Pathology Form, GOG-0212, Form F
Paclitaxel or Polyglutamate Paclitaxel or Observation in
Treating Patients With Stage III or Stage IV Ovarian
Epithelial or Peritoneal Cancer or Fallopian Tube Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=E74949DE-
AB5E-451A-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/8464
Pathology Form, GOG-0212, Form F
Header Module
Date form originally completed (m d y)
Date form amended (m d y)
Person amending form, last name
Patient Initials (First, Middle, Last)
Patient Study ID
Person Completing Form, Last Name
Primary Disease Assessment
Primary site
Cervix (Cervix)
Endometrium (Endometrium)
Fallopian Tube (Fallopian tube)
Gestational Trophoblastic Disease (GTD)
Other, Specify (Other specify)
Ovary (Ovary)
Peritoneum (Peritoneum)
Uterine Sarcoma (Uterine sarcoma)
Vagina (Vagina)
Vulva (Vulva)
Other specify
Histologic type (check one)
Adenocarcinoma With Squamous
Differentiation (Adenocarcinoma with
squamous differentiation)
Adenocarcinoma, Unspecified
(Adenocarcinoma, unspecified)
Adenosquamous (Adenosquamous
carcinoma)
Benign (Benign NOS)
Carcinosarcoma/mesodermal (mullerian)
Mixed Tumor (Carcinosarcoma MMT)
Clear Cell Carcinoma (Clear cell
carcinoma)
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Dysgerminoma (Dysgerminoma)
Endodermal Sinus Tumor (yolk Sac
Tumor) (Endodermal sinus tumor)
Endometrial Stromal Sarcoma
(Endometrial stromal sarcoma)
Endometrioid Adenocarcinoma
(Endometrioid adenocarcinoma)
Fibroma (Fibroma)
Germ Cell Tumor, Mixed (Germ cell
tumor, mixed)
Granulosa Cell Tumor (Granulosa cell
tumor)
Leiomyosarcoma (Leiomyosarcoma)
Mixed Epithelial Carcinoma, Specify
Components (Mixed epithelial
carcinoma)
Mucinous Adenocarcinoma (Mucinous
adenocarcinoma)
Mucinous Cystadenoma (benign)
(Mucinous cystadenoma (benign))
Mucinous Tumor Of Low Malignant
Potential (Mucinous tumor of LMP)
Normal Tissue (Normal tissue)
Other, Specify (Other specify)
Serous Adenocarcinoma (Serous
adenocarcinoma)
Serous Cystadenoma (benign) (Serous
cystadenoma (benign))
Serous Tumor Of Low Malignant
Potential (Serous tumor of LMP)
Sex-cord/stromal, Unclassified (Sex
cord/stromal, unclassified)
Small Cell Carcinoma (Small cell
carcinoma)
Squamous Cell Carcinoma (Squamous
cell carcinoma invasive)
Teratoma, Immature, Specify
Components (Teratoma, immature)
Teratoma, Mature (Teratoma, mature)
Transitional Cell Carcinoma, Including
Brenner Tumor (Transitional cell
carcinoma (including Brenner))
Undifferentiated Carcinoma
(Undifferentiated carcinoma)
Villoglandular Carcinoma (Villoglandular
carcinoma)
Other specify
Histologic grade (Differentiation)
Grade 1-well Differentiated (1)
Grade 2-moderately Differentiated (2)
Grade 3-poorly Differentiated (3)
Indeterminate (Indeterminate)
Not Applicable (Not applicable)
Grade Unknown (Unknown)
Method of evaluation
Biopsy (Biopsy)
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Cytology (Cytology)
Other (Other specify)
Surgery (Surgery)
Other specify
Date of evaluation (m d y)
Specimen ID (of the blocks/slides)
Specimen site
Bladder Peritoneum (Bladder
peritoneum)
Bowel Peritoneum/serosa (Bowel
peritoneum/serosa)
Cervix (Cervix)
Corpus (Corpus)
Cul-de-sac (Cul-de-sac)
Diaphragm (Diaphragm)
Endometrium (Endometrium)
Fallopian Tube (Fallopian tube)
Lymph Node(s) (Lymph node(s))
Metastatic Site (Metastatic site)
Omentum (Omentum)
Other (Other)
Ovary (Ovary)
Paracolic Gutter Left (Paracolic gutter
left)
Paracolic Gutter Right (Paracolic gutter
right)
Pelvic Wall Left (Pelvic wall left)
Pelvic Wall Right (Pelvic wall right)
Peritoneum/uterine Serosa
(Peritoneum/uterine serosa)
Lymph nodes specify
Metastatic site specify
Other specify
Secondary Disease Assessment
Disease Status
Disease Continues To Be Present
Following Initial Treatment (Persistent)
Progression (Progression)
Recurrence/relapse (Recurrence)
Method of evaluation
Biopsy (Biopsy)
Cytology (Cytology)
Other (Other specify)
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Surgery (Surgery)
Other specify
Date of evaluation (m d y)
Specimen ID (of the blocks/slides)
Specimen site
Bladder Peritoneum (Bladder
peritoneum)
Bowel Peritoneum/serosa (Bowel
peritoneum/serosa)
Cervix (Cervix)
Corpus (Corpus)
Cul-de-sac (Cul-de-sac)
Diaphragm (Diaphragm)
Endometrium (Endometrium)
Fallopian Tube (Fallopian tube)
Lymph Node(s) (Lymph node(s))
Metastatic Site (Metastatic site)
Omentum (Omentum)
Other (Other)
Ovary (Ovary)
Paracolic Gutter Left (Paracolic gutter
left)
Paracolic Gutter Right (Paracolic gutter
right)
Pelvic Wall Left (Pelvic wall left)
Pelvic Wall Right (Pelvic wall right)
Peritoneum/uterine Serosa
(Peritoneum/uterine serosa)
Lymph nodes specify
Metastatic site specify
Other specify
Footer Module
Participating Group Code
Participating Group Protocol Number
Participating Group Patient ID
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Endometrial Cancer NCT00265759 Pathology - Z1031
Central Pathology Review Form (CPR) - 2940201v1.0
Z1031 Central Pathology Review Form (CPR)
Exemestane, Letrozole, or Anastrozole in Treating
Postmenopausal Women Who Are Undergoing Surgery for
Stage II or Stage III Breast Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=739D9DB4-
52E2-7818-E040-BB89AD4371E4
All rights reserved. Please visit https://medical-data-
models.org/forms/8467
Z1031 Central Pathology Review
Form (CPR)
Unnamed 1
Visit
Week 2 (Week 2)
Week 4 (Week 4)
Patient ID (Pt. ID issued during registration or
previously issued patient ID)
Institution No.
Patient Initials (F M L)
Institution Name
Pathology/treatment Information
Biopsy Date (mm dd yyyy)
Date results received from Central Lab (mm dd
yyyy)
Invasive cancer
Not Present (Not present)
Present (Present)
Will patient rebiopsy at the 4 week visit (Skip to
end of form)
Not Available (N/A)
No (No)
Yes (Yes)
Ki67 Score (Or %)
Allred score
Treatment Plan (Requirements per protocol: If
Ki67 score > 10% and/or Allred score < 3,
chemotherapy or immediate surgery is required If
Ki67 score <= 10% and/or Allred score > 3,
continuing with assigned AI is required)
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Chemotherapy (Chemotherapy)
Continue Protocol Ai Therapy (Continue
protocol AI therapy)
Off Protocol Therapy (Off protocol
therapy)
Surgery (Surgery)
Projected Start Date of Treatment (mm dd yyyy)
Footer Module
Completed by
Date Form Completed (mm dd yyyy)
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Endometrial Cancer NCT00265759 Registration -
Z1031 Registration Worksheet Form - 2417050v1.0
Z1031 Registration Worksheet Form
Exemestane, Letrozole, or Anastrozole in Treating
Postmenopausal Women Who Are Undergoing Surgery for
Stage II or Stage III Breast Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=02F0FC02-
607A-58B8-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/8468
Z1031 Registration Worksheet Form
Header Module
Visit
Prior To Registration (Prior to
Registration)
Patient ID (Pt. ID issued during registration or
previously issued patient ID)
Patient Initials (F M L)
Institution No.
Institution Name
Registration Date (mm dd yyyy)
Header
Has patient previously been registered to an
ACOSOG study
Yes
No
Coordinating Group Protocol Number
Patient Information
Date of Birth (mm dd yyyy)
Gender
Female (Female)
Male (Male)
Race (Mark all that apply)
A Person Having Origins In Any Of The
Original Peoples Of North And South
America (including Central America),
And Who Maintains Tribal Affiliation Or
Community Attachment. (American
Indian or Alaska native)
A Person Having Origins In Any Of The
Original Peoples Of The Far East,
Southeast Asia, Or The Indian
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Subcontinent Including, For Example,
Cambodia, China, India, Japan, Korea,
Malaysia, Pakistan, The Philippine
Islands, Thailand, And Vietnam. (Asian)
A Person Having Origins In Any Of The
Black Racial Groups Of Africa. Terms
Such As "haitian" Or "negro" Can Be
Used In Addition To "black Or African
American." (Black or African American)
A Person Having Origins In Any Of The
Original Peoples Of Hawaii, Guam,
Samoa, Or Other Pacific Islands. (Native
Hawaiian or other Pacific Islander)
Could Not Be Determined Or Unsure
(Unknown)
A Person Having Origins In Any Of The
Original Peoples Of Europe, The Middle
East, Or North Africa. (White)
Ethnicity (Mark only one)
A Person Of Mexican, Puerto Rican,
Cuban, Central Or South American Or
Other Spanish Culture Or Origin,
Regardless Of Race. (HISPANIC OR
LATINO)
A Person Not Meeting The Definition For
Hispanic Or Latino. (NOT HISPANIC OR
LATINO)
Could Not Be Determined Or Unsure
(UNKNOWN)
Method of payment (Mark all that apply)
Medicaid (Medicaid)
Medicaid And Medicare (Medicaid and
medicare)
Medicare (Medicare)
Medicare And Private Insurance
(Medicare and private insurance)
Military Or Veterans Sponsored Nos
(Military or veterans sponsored NOS)
Military Sponsored (including Champus
& Tricare) (Military sponsored)
No Means Of Payment (no Insurance)
(No means of payment)
Other (Other)
Private Insurance (Private insurance)
Self Pay (no Insurance) (Self pay)
Veterans Sponsored (Veterans
sponsored)
Other, specify (e.g., Provincial Insurance Plan)
Weight (kg)
Height (cm)
Patient Zip Code (USA)
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Postal code (Or Canada)
Other Country Postal Code
Country of Residence (If other than USA or
Canada)
Date Informed Consent Signed (mm dd yyyy)
HIPAA Authorization form
Included In Study Informed Consent
(Included in Study Informed Consent)
HIPAA Authorization Date (If signed as a
separate form mm dd yyyy)
Unnamed 4
Consent for correlative studies and specimen
banking signed
Yes
No
Date signed (mm dd yyyy If yes, [Complete the
Specimen Banking Consent SBC CRF.])
Inclusion Criteria
Patient must have an ECOG performance status
of <= 2 (Zubrod)
Not Available (N/A)
No (No)
Yes (Yes)
Patient must have T2-T4c, any N, M0 breast
cancer, by clinical staging (NOTE: Primary tumor
must be palpable and measure > 2 cm by tape,
ruler or caliper measurements in at least one
dimension)
Yes
No
Patient must be postmenopausal, verified by
bilateral surgical oophorectomy, no spontaneous
menses >= 1 year, or no menses for < 1 year with
FSH and estradiol levels in postmenopausal
range, according to institutional standards
Yes
No
Patient, as documented by the treating physician,
is clinically staged as one of the following: T4 a-c
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for whom modified radical mastectomy with
negative margins is the goal T2 or T3 for whom
conversion from needing mastectomy to breast
conservation is the goal T2 for whom lumpectomy
at first attempt is the goal
Not Available (N/A)
No (No)
Yes (Yes)
Patient has ER+ tumor with an Allred score of 6,
7, or 8 (NOTE: patients with > 66.6% two-thirds of
cells staining positive have a minimum Allred
score of 6 and are eligible)
Yes
No
Patient must have mammogram and ultrasound
within 42 days prior to registration
Yes
No
If patient is a cancer survivor, all of the following
criteria must be met Patient has undergone
potentially curative therapy for all prior
malignancies, No evidence of any prior
malignancies for at least 5 years with no evidence
of recurrence (except for successfully treated
cervical carcinoma in situ, lobular carcinoma in
situ of the breast, contralateral DCIS treated with
mastectomy or lumpectomy and radiation but
without tamoxifen treatment, or non-melanoma
skin cancer with no evidence of recurrence), and
Patient is deemed by their treating physician to
be at low risk for recurrence from prior
malignancies
Not Applicable (NA)
No (No)
Yes (Yes)
Exclusion Criteria
Patient has inflammatory breast cancer defined
as clinically significant erythema of the breast
and/or documented dermal lymphatic invasion
(not direct skin invasion by tumor or peau
d'orange without erythema NOTE: Patient with
T4d disease are ineligible)
Yes
No
Patient has received prior treatment for breast
cancer, including radiation, endocrine therapy,
chemotherapy or investigational agent. Patients
whose diagnosis was established by incisional
biopsy are not eligible
Yes
No
Patient has received hormone replacement
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therapy of any type, megestrol acetate, or
raloxifene within one week prior to registration
Yes
No
Patient has distant metastasis (M1), excluding
isolated ipsilateral supraclavicular node
involvement
Yes
No
Patient does not agree to undergo mastectomy or
lumpectomy after neoadjuvant aromatose
inhibitor therapy
Yes
No
Patient is enrolled in another neoadjuvant clinical
trial for treatment of the existing breast cancer
Yes
No
Patient has undergone prior sentinel lymph node
biopsy (Cohort B only)
Yes
No
Unnamed Module 3
In the opinion of the investigator, is the patient
eligible?
Yes
No
Assessment Date (mm dd yyyy)
Baseline Performace Status (ECOG/Zubrod scale
Note: Document patient's performance status in
the medical record.)
Fully Active, Able To Carry On All Pre-
disease Performance Without Restriction
(0)
Restricted In Physically Strenuous
Activity But Ambulatory And Able To
Carry Out Work Of A Light Or Sedentary
Nature, E.g., Light Housework, Office
Work. (1)
Ambulatory And Capable Of All Selfcare
But Unable To Carry Out Any Work
Activities. Up And About More Than 50%
Of Waking Hours. (2)
Capable Of Only Limited Selfcare,
Confined To Bed Or Chair More Than
50% Of Waking Hours. (3)
Completely Disabled. Cannot Carry On
Any Selfcare. Totally Confined To Bed Or
Chair. (4)
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Clinical Stage
Clinical T Stage (mark one)
T2 (T2)
T3 (T3)
T4a-c (T4a-c)
Clinical N Stage (mark one)
No Regional Lymph Node Metastasis
(N0)
Metastasis To Movable Ipsilateral Axillary
Lymph Node(s) (N1)
Metastasis To Ipsilateral Axillary Lymph
Node(s) Fixed Or Matted, Or In Clinically
Apparent* Ipsilateral Internal Mammary
Nodes In The Absence Of Clinically
Evident Lymph Node Metastasis (N2)
Metastasis In Ipsilateral Infraclavicular
Lymph Node(s) With Or Without Axillary
Lymph Node Involvement, Or In Clinically
Apparent* Ipsilateral Internal Mammary
Lymph Node(s) And In The Presence Of
Clinically Evident Axillary Lymph Node
Metastasis; Or, Me (N3)
Dimension 1 (Longest axis cm)
Dimension 2 (Longest perpendicular axis cm)
Primary Tumor Biopsy
Receptor Status, ER
Negative (Negative)
Positive (Positive)
Marker Test Method (Mark one. If both were
performed, mark confirmatory test)
Fluorescence In Situ Hybridization (fish)
(Fluorescence in situ hybridization
(FISH))
Immunohistochemistry (ihc)
(Immunohistochemistry (IHC))
HER-2/neu status
Negative (Negative)
Never Done Or Unknown (Never done or
unknown)
Positive (Positive)
Histologic Grade (mark one)
Small Regular Nuclei (Grade I (low, 1 pt))
Moderate Increase In Size, Etc (Grade II
(intermediate, 2 pts))
Marked Variation In Size, Nucleoli,
Chromatin Clumping, Etc (Grade III
(high, 3 pts))
Histologic Type (mark one)
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Ductal (Ductal)
Lobular (Lobular (pure > or =90%))
Other Specify (Other)
Other specify
Was FNA done on the axillary nodes prior to
study initiation
Yes
No
Date of FNA (mm dd yyyy)
FNA Results (biopsy)
Negative (Negative)
Positive (Positive)
Allred score (refer to the Appendix section for
table and scoring instructions)
Method of Evaluation (imaging within 42 days
prior to registration)
Mammogram (Mammogram)
Ultrasound (Ultrasound)
Not done
Image Date (mm dd yyyy)
Postmenopausal verification (mark one)
Bilateral Surgical Oophorectomy
(Bilateral surgical oophorectomy)
No Spontaneous Menses < 1 Year, With
Fsh And Estradiol Levels In
Postmenopausal Range, According To
Local Institutional Standards (No
spontaneous menses < 1 year, with FSH
and estradiol levels in postmenopausal
range, according to local institutional
standards)
No Spontaneous Menses >= 1 Year, Not
Related To Hormone Replacement
Therapy (hrt) (No spontaneous menses
>= 1 year, not related to hormone
replacement therapy (HRT))
Surgery status according to investigator (mark
one)
Candidate For Lumpectomy (Candidate
for lumpectomy)
Candidate For Modified Radical
Mastectomy (Candidate for modified
radical mastectomy)
Inoperable (Inoperable)
Treatment Arm (Please indicate which aromatase
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inhibitor the patient will receive)
Anastrozole: Neoadjuvant Treatment For
16 Weeks With Anastrozole 1 Mg (1
Capsule) Once Daily Followed By
Surgery (Anastrozole: Neoadjuvant
treatment for 16 weeks with anastrozole
1 mg (1 capsule) once daily followed by
surgery)
Letrozole: Neoadjuvant Treatment For 16
Weeks With Letrozole 2.5 Mg (1
Capsule) Once Daily Followed By
Surgery (Letrozole: Neoadjuvant
treatment for 16 weeks with letrozole 2.5
mg (1 capsule) once daily followed by
surgery)
Investigator Signature (I have reviewed all data
recorded on the Registration form and certify that
they are accurate and complete to the best of my
knowledge)
Date Signed (mm dd yyyy)
Did the Investigator sign the CRF indicating
review of all data and certifying data are accurate
and complete to the best of their knowledge
Yes
No
Date of Investigator Signature (mm dd yyyy)
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Treatment - Bone Sarcoma - Diagnostic
Surgery Form - 2289499v3.0
Bone Sarcoma - Diagnostic Surgery Form
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=E208DD65-
F9ED-158F-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/8471
Bone Sarcoma - Diagnostic Surgery
Form
Crf Header
Coordinating Group Protocol No.
Coordinating Group Code
Protocol Title
Patient Study ID
Institution/Affiliate
Other Patient ID
Participating Group Code
Patient Name (initials acceptable)
Sarcoma: Form Administration
Person Completing Form
Are data amended (If data are amended, please
circle in red when using paper form)
Yes
No
Bone Sarcoma: Summary Of Diagnostic
Surgery
Surgery Date (MM DD YYYY)
Site of Surgery
Primary Surgery Type
Amputation (Amputation)
Biopsy (Biopsy)
Cryosurgery (Cryosurgery)
En Bloc Resection (En bloc resection)
Intraepiphyseal Resection
1 / 3
(Intraepiphyseal resection)
Intramural Resection, Gross Residual
Disease (Intramural resection, gross
residual disease)
Lymph Node Removal (Lymph node
removal)
Marginal Excision (Marginal excision)
Other, Specify (Other specify)
Radical Excision (Radical excision)
Transmedullary Amputation
(Transmedullary amputation)
Wide Excision (Wide excision)
Other specify
Biopsy Type (If Biopsy,)
Excisional (Excisional)
Incisional (Incisional)
Large Bore Needle (Large bore needle)
Other, Specify (Other specify)
Trucut Needle (TruCut needle)
Other specify
Status of Primary Tumor
Not Recurrent, Resected, No Residual
Tumor (Not recurrent, resected, no
residual tumor)
Not Recurrent, Resected, Residual
Tumor (Not recurrent, resected, residual
tumor)
Recurrent (Recurrent)
Unresected (Unresected)
Tumor Location, Side
Both (Both)
Left (Left)
Right (Right)
Unknown (Unknown)
Tumor Location, Area
Distal (Distal)
Midshaft (Midshaft)
Other, Specify (Other specify)
Proximal (Proximal)
Other specify
Dimension 1 (Longest)
Dimension 2 (cm)
Dimension 3 (cm)
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Does the tumor involve the surgical margin
Yes
No
Margins of surgical resection
All Margins Pathologically Negative (R0)
Microscopically Positive Margins Or
Microscopic Residual Disease (R1)
Macroscopically Positive Margins Or
Gross Residual Disease (R2)
Histologic Grade, French System
Grade I (Grade I)
Grade Ii (Grade II)
Grade Iii (Grade III)
Comments
Comments
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Fallopian Tube Cancer NCT00108745 On-Study - Pre-Treatment
Summary Form, GOG-0212, Form DR - 2296068v3.0
Pre-Treatment Summary Form, GOG-0212, Form DR
Paclitaxel or Polyglutamate Paclitaxel or Observation in
Treating Patients With Stage III or Stage IV Ovarian
Epithelial or Peritoneal Cancer or Fallopian Tube Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=E7492F0A-
739E-4378-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/8473
Pre-Treatment Summary Form,
GOG-0212, Form DR
Header Module
Date form originally completed (m d y)
Date form amended (m d y)
Person amending form, last name
Patient Initials (First, Middle, Last)
Patient Study ID
Person Completing Form, Last Name
Non-invasive Diagnostic Procedures
Chest X-ray Result
Abnormal (Abnormal)
Normal (Normal)
Not Done (Not done)
EKG Result
Abnormal (Abnormal)
Normal (Normal)
Not Done (Not done)
MRI Result
Abnormal (Abnormal)
Normal (Normal)
Not Done (Not done)
CT Result
Abnormal (Abnormal)
Normal (Normal)
Not Done (Not done)
Other Result
Abnormal (Abnormal)
Normal (Normal)
Not Done (Not done)
Abnormal specify
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Abnormal specify
Abnormal specify
Abnormal specify
Abnormal specify
Tumor Evaluation
Are there any target lesions? (If yes, sketch target
lesions and complete form D2M. Label the sketch
with the corresponding target lesion number on
the D2M form.)
Yes
No
Comments
COMMENTS
Footer Module
Participating Group Code
Participating Group Protocol Number
Participating Group Patient ID
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Summary Form, GOG-0212, Form DR - 2296068v3.0
On-Study - Hodgkins Lymphoma - On-
Study Form - 2271441v3.0
Hodgkin's Lymphoma - On-Study Form
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=D5EC9E8E-
4085-0DC0-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/8474
Hodgkins Lymphoma - On-Study
Form
Crf Header
Coordinating Group Protocol No.
Coordinating Group Code
Protocol Title
Patient Study ID
Institution/Affiliate
Other Patient ID
Participating Group Code
Patient Name (initials acceptable)
Lymphoma: Form Administration
Person Completing Form
Are data amended? (If data are amended, please
circle in red when using paper form)
Yes
No
Hodgkin's Lymphoma: Disease
Description
Date of Initial Pathologic Diagnosis
Modified Ann Arbor Stage
I (I)
Ie (IE)
Ii (II)
Iie (IIE)
Iii (III)
Iiie (IIIE)
Iiie+s (IIIE+S)
Iiis (IIIS)
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Iv (IV)
Disease Status at Registration (For advanced or
recurrent studies,)
Initial Diagnosis (Initial Diagnosis)
Refractory (Refractory)
Relapsed (Relapsed)
Hematopoietic Diagnosis
Classical Hodgkin Lymphoma Not
Further Classifiable (Classical Hodgkin
lymphoma not further classifiable)
Composite Hodgkin Lymphoma
(Composite Hodgkin lymphoma)
Lymphocyte-depleted Classical Hodgkin
Lymphoma (Lymphocyte-depleted
Classical Hodgkin lymphoma)
Lymphocyte-rich Classical Hodgkin
Lymphoma (Lymphocyte-rich Classical
Hodgkin lymphoma)
Mixed Cellularity Classical Hodgkin
Lymphoma (Mixed cellularity Classical
Hodgkin lymphoma)
Nodular Lymphocyte Predominant
Hodgkin Lymphoma (Nodular
lymphocyte predominant Hodgkin
lymphoma)
Nodular Sclerosis Classical Hodgkin
Lymphoma (Nodular sclerosis Classical
Hodgkin lymphoma)
Other (Other)
Other specify
REAL Lymphoma Classification
Lymphocyte Depletion (Lymphocyte
depletion)
Lymphocyte Predominance (Lymphocyte
predominance)
Lymphocyte-rich Classical Hodgkin's
Disease (provisional Category)
(Lymphocyte-rich classical Hodgkin's
disease (provisional category))
Mixed Cellularity (Mixed cellularity)
Nodular Sclerosis (Nodular sclerosis)
Unclassifiable (Unclassifiable)
Unknown (Unknown)
Any lymph node or aggregate with a diameter
greater than 10 cm (if pediatric, >6 cm)
No (No)
Unknown (Unknown)
Yes (Yes)
Mediastinal mass
No (No)
Unknown (Unknown)
Yes (Yes)
2 / 11
On-Study - Hodgkins Lymphoma - On-Study Form - 2271441v3.0
Any mass greater than 1/3 of the diameter of the
chest (either measured as maximum chest
diameter or the chest diameter at the same T
level as the lesion)
No (No)
Unknown (Unknown)
Yes (Yes)
Are B-symptoms present
Yes
No
Date of First Symptoms (If yes,)
Unexplained, persistent fever >38 degrees C (or
>100 degrees F) in the previous month
Yes
No
Recurring, drenching night sweats during the
previous month
Yes
No
Unexplained weight loss >10% of body weight in
the previous 6 months
Yes
No
Lymph Node Type
Axillary/brachial (Axillary/Brachial)
Celiac Axis/retrocrural (Celiac
axis/Retrocrural)
Cervical (Cervical)
Common Pelvic (Common pelvic)
Epitrochlear (Epitrochlear)
External/internal Iliac (External/internal
iliac)
Hilar (Hilar)
Infraclavicular (Infraclavicular)
Inguinal/femoral (Inguinal/Femoral)
Mediastinal (Mediastinal)
Mesenteric (Mesenteric)
Occipital (Occipital)
Orbital (Orbital)
Other (Other)
Para-aortic (Para-aortic)
Paratracheal (Paratracheal)
Pectoral (Pectoral)
Popliteal (Popliteal)
Porta Caval (Porta caval)
Porta Hepatis (Porta hepatis)
Pre-auricular (Pre-auricular)
Retroperitoneal (Retroperitoneal)
Splenic Hilar (Splenic hilar)
Supraclavicular (Supraclavicular)
Waldeyer's Ring (Waldeyer's ring)
Other specify
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Lymph Node Involvement (* Indicate Lymph Node
Involvement)
Equivocal (equivocal)
Involved (involved)
Not Evaluated (not evaluated)
Not Involved (not involved)
Unknown (unknown)
Lung (Is this site involved?)
No (No)
Unknown (Unknown)
Yes (Yes)
Liver
No (No)
Unknown (Unknown)
Yes (Yes)
Spleen
No (No)
Unknown (Unknown)
Yes (Yes)
Bone Marrow
No (No)
Unknown (Unknown)
Yes (Yes)
Bone
No (No)
Unknown (Unknown)
Yes (Yes)
Pleura
No (No)
Unknown (Unknown)
Yes (Yes)
Kidney
No (No)
Unknown (Unknown)
Yes (Yes)
Other Site
No (No)
Unknown (Unknown)
Yes (Yes)
Skin (cutaneous)
No (No)
Unknown (Unknown)
Yes (Yes)
Testes
No (No)
Unknown (Unknown)
Yes (Yes)
Ovaries
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No (No)
Unknown (Unknown)
Yes (Yes)
Stomach
No (No)
Unknown (Unknown)
Yes (Yes)
Small Bowel
No (No)
Unknown (Unknown)
Yes (Yes)
Colon
No (No)
Unknown (Unknown)
Yes (Yes)
Other Site Name
Method of Evaluation (? Indicate Method of
Evaluation)
Clinical (clinical)
Pathologic (pathologic)
Unknown (unknown)
Method of Evaluation (? Indicate Method of
Evaluation)
Clinical (clinical)
Pathologic (pathologic)
Unknown (unknown)
Does the patient have HIV or AIDS
No (No)
Unknown (Unknown)
Yes (Yes)
Does the patient have post-transplant
lymphoproliferative disease
No (No)
Unknown (Unknown)
Yes (Yes)
Does the patient have immunodeficiency
No (No)
Unknown (Unknown)
Yes (Yes)
Hodgkin's Lymphoma: Baseline
Hematology/chemistry
Peripheral WBC Count (x 10^3/mcl)
Hemoglobin (g/dl)
5 / 11
On-Study - Hodgkins Lymphoma - On-Study Form - 2271441v3.0
Peripheral Platelet Count (x 10^3/mcl)
Absolute Lymphocyte Count
Erythrocyte Sedimentation Rate (mm/hr)
Albumin (g/dl)
Lactate Dehydrogenase (LDH) (U/l)
Lactate Dehydrogenase ULN (LDH U/l * Note:
Record institutional limits of normal)
Lymphoma: Prior Treatment
Prior Treatment?
Yes
No
No. of Prior Regimens (If yes, Note: Multiple
drug/staged regimens count as 1; e.g.,
chemo+transplant)
Best Response to Most Recent Prior Treatment
Ccr (CCR)
Cr (CR)
Pd (PD)
Pr (PR)
Sd (SD)
Unknown (Unknown)
Prior Surgical Resection
Yes
No
Prior Bone Marrow or Peripheral Blood Stem Cell
Transplant?
Yes
No
Type of Transplant (If yes,)
Allogeneic (Allogeneic)
Autologous (Autologous)
Cord Blood (Cord blood)
Nonmyeloablative (Nonmyeloablative)
Other (Other)
Tandem (Tandem)
Other specify
Prior Radiation Therapy
Yes
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No
Radiation Therapy Field (* Radiation Therapy
Field)
Cranial (Cranial)
Cranial & Spinal (Cranial & Spinal)
Extended Mantle (Extended Mantle)
Inverted Y (Inverted Y)
Local (Local)
Mantle (Mantle)
Mantle & Periaortic (Mantle & Periaortic)
Other (Other)
Regional (Regional)
Total Nodal (Total Nodal)
Whole Body (Whole Body)
Other specify (++ If)
RT Total Dose
units
Grays (Gy)
Millicurie (mCi)
Prior Systemic Chemotherapy
Yes
No
Prior Immunotherapy
Yes
No
Prior Immuno-radiolabeled therapy
Yes
No
Prior Treatment Regimen Name(s)
(Drugs/Agents)
Prior Treatment Regimen Type (Chemotherapy,
Immunotherapy, Immuno-radiolabeled therapy,
etc.)
Total No. of Cycles
Prior Vaccine Therapy?
Yes
No
Prior Vaccine Type
Total No. of Doses
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Lymphoma: Relapsed Disease
Disease Status (current)
Other, Specify (Other)
Refractory (Refractory NOS)
Refractory To First Induction (Refractory
to 1st induction)
Refractory To Reinduction After
Complete Response (Refractory to
reinduction after CR)
Relapse (Relapse NOS)
First Relapse (Relapse: 1st)
Second Relapse (Relapse: 2nd)
Third Or Greater Relapse (Relapse:
3rd+)
Other (specify)
Best Response to Initial Therapy
Cr (CR)
Pd (PD)
Pr (PR)
Sd (SD)
Date of Initial Response to Therapy
Date of First Relapse
Date of Most Recent Response to Therapy
Date of Most Recent Relapse
Performance Status (at Time of Treatment Failure
For CDUS reporting, please convert Karnofsky
and Lansky scores to this Zubrod Score)
Fully Active, Able To Carry On All Pre-
disease Performance Without
Restriction. (0)
Restricted In Physically Strenuous
Activity But Ambulatory And Able To
Carry Out Work Of A Light Or Sedentary
Nature, E.g., Light Housework, Office
Work. (1)
Ambulatory And Capable Of All Selfcare
But Unable To Carry Out Any Work
Activities. Up And About More Than 50%
Of Waking Hours. (2)
Capable Of Only Limited Selfcare,
Confined To Bed Or Chair More Than
50% Of Waking Hours. (3)
Completely Disabled. Cannot Carry On
Any Selfcare. Totally Confined To Bed Or
Chair. (4)
Lymphoma: Cardiac Evaluation
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Cardiac Status
Asymptomatic (Asymptomatic)
Symptomatic (Symptomatic)
Was a MUGA performed (If symptomatic,)
No (No)
Unknown (Unknown)
Yes (Yes)
Left Ventricular Ejection Fraction at Rest (If yes,
%)
LVEF Institutional Lower Limit of Normal (%)
Does ejection fraction percent improve with
exercise
No (No)
Unknown (Unknown)
Yes (Yes)
Was an echocardiogram (ECHO) performed
No (No)
Unknown (Unknown)
Yes (Yes)
Shortening Fraction (If yes, %)
Lymphoma: Pulmonary Evaluation
Pulmonary Status
Asymptomatic (Asymptomatic)
Symptomatic (Symptomatic)
Carbon Monoxide Diffusion (DLCO) (If
symptomatic, % of predicted, corrected for
anemia %)
Forced Vital Capacity (FVC) (mL)
Total Lung Capacity (TLC) (mL)
Forced Expiratory Volume 1 (FEV1) (mL)
Is the patient less than 5 years old
Yes
No
Was oximetry done (If yes,)
No (No)
Unknown (Unknown)
Yes (Yes)
Percent of Oximetry at Rest (If yes, %)
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Lymphoma: Endocrine Evaluation
Menstrual Function
Amenorrheic (Amenorrheic)
Cannot Assess Specify Reason (e.g.,
Hysterectomy) (Cannot assess specify
reason (e.g., hysterectomy))
Hormonal Therapy (replacement, Birth
Control) (Hormonal therapy
(replacement, birth control))
Irregular Menses (Irregular menses)
Regular Menses (Regular menses)
Cannot assess specify reason
Year of Menopause
Number of pregnancies
Number of miscarriages/spontaneous abortions
Number of Therapeutic abortions
Estradiol (pg/ml)
Follicle Stimulating Hormone (FSH IU/L)
Luteinizing Hormone (LH IU/L)
Institutional ULN for FSH (IU/L)
Institutional ULN for LH (IU/L)
Number of Conceptions
Number of Conceptions
miscarried/spontaneously aborted
Number of Conceptions therapeutically aborted
Sperm Motility (%)
Number of Sperm in Ejaculate (# million/ml x
concentration)
Testosterone (ng/dL)
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Patient Height (cm)
Growth Velocity (cm/year)
Patient Weight (kg)
Was Tanner staging done
Yes
No
Genitalia Stage (enter 1-5)
Testicular Volume (mL)
Pubic Hair Stage (enter 1-5)
Pubic Hair Stage (enter 1-5)
Breasts Stage (enter 1-5)
Menarche
Yes
No
Patient Age at Menarche (If yes, year)
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Fallopian Tube Cancer NCT00108745 Quality of Life - Quality of
Life Cover Sheet, GOG-0212, FORM QCS-0212 - 2296548v3.0
Quality of Life Cover Sheet, GOG-0212, FORM QCS-0212
Paclitaxel or Polyglutamate Paclitaxel or Observation in
Treating Patients With Stage III or Stage IV Ovarian
Epithelial or Peritoneal Cancer or Fallopian Tube Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=E748AF0E-
46E2-4D60-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/8477
Quality of Life Cover Sheet, GOG-
0212, FORM QCS-0212
Header Module
Date form originally completed (m d y)
Date form amended (m d y)
Person amending form, last name
Patient Initials (First, Middle, Last)
Patient Study ID
Person Completing Form, Last Name
Quality Of Life Tracking Information
Scheduled time to obtain Quality of Life
Questionnaire and cover sheet
12 Months Post Cycle 12 Or 24 Months
From Date On-study (12 months post
cycle 12 or 24 months from date on-
study)
Pretreatment (Pre - treatment)
Pre-cycle 12 Or 12 Months From Date
On-study (Pre-cycle 12 or 12 months
from date on-study)
Pre-cycle 3 Or 2 Months From Date On-
study (Pre-cycle 3 or 2 months from date
on-study)
Pre-cycle 5 Or 4 Months From Date On-
study (Pre-cycle 5 or 4 months from date
on-study)
Pre-cycle 7 Or 6 Months From Date On-
study (Pre-cycle 7 or 6 months from date
on-study)
Was QoL Questionnaire completed?
Yes
No
Date Questionnaire Due (m d y)
Date Questionnaire Completed (m d y)
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Please indicate reason (If no, check one)
Other (Other)
Patient Died (Patient died)
Patient Kept Appointment For
Examination, But Could Not Complete
Questionnaire Due To Illness (Patient
kept appointment for examination, but
could not complete questionnaire due to
illness)
Patient Kept Appointment For
Examination, But Refused To Complete
Questionnaire For Reasons Other Than
Illness (Patient kept appointment for
examination, but refused to complete
questionnaire for reasons other than
illness)
Patient Off Study Treatment And Cannot
Be Contacted For Follow-up (Patient off
study treatment and cannot be contacted
for follow-up)
Test Omitted Due To
Institution/investigator Error
(Questionnaire not administered due to
institutional error)
specify reason (patient refused)
Other (please specify)
Footer Module
Participating Group Code
Participating Group Protocol Number
Participating Group Patient ID
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Fallopian Tube Cancer NCT00262847 Lab -
GOG-0218 Specimen Form - 2303734v3.0
GOG-0218 Specimen Form
Carboplatin and Paclitaxel With or Without Bevacizumab in
Treating Patients With Stage III or Stage IV Ovarian
Epithelial, Primary Peritoneal Cancer, or Fallopian Tube
Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=F0E16A95-
3A2C-5BBD-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/8480
GOG-0218 Specimen Form
Header Module
Date form originally completed
Date form amended
Person amending form, last name
Patient Study ID
GOG Bank ID #
Person Completing Form, Last Name
Site Contact Information
Phone number
E-mail
General Specimen Information
Specimen Code
Time point
Collected
Yes
No
No, specify
Collection date
Collection time (when required by the protocol)
Specimen type
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Buffy Coat (Buffy coat)
Cells (Cells)
Fixed Tissue (Fixed tissue)
Frozen Tissue (Frozen tissue)
Other (Other)
Plasma (Plasma)
Serum (Serum)
Urine (Urine)
Whole Blood (Whole blood)
Other specify
Items shipped
Block (Block)
Oct-mold (OCT-mold)
Other (Other)
Piece (Piece)
Slide (Slide)
Tube/vial (Tube/Vial)
Other specify
Quantity of items shipped
Processing time
<1 Hour (<1 hour)
>4 Hours (>4 hours)
1-2 Hours (1-2 hours)
2-4 Hours (2-4 hours)
N/a (NA)
Storage type
Other (Other)
Refrigerator (Refrigerator)
Room Temperature (Room temperature)
Standard Non-cycling Freezer (Standard
non-cycling freezer)
Ultracold Freezer/liquid N2/dry Ice
(Ultracold freezer/liquid N2/dry ice)
Other specify
Date shipped
Courier tracking number
Research Comments Text
Blood/fluid Products
Type of blood collection tube
Acid Citrate Dextrose (acd) (ACD)
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2303734v3.0
Citrate (Citrate)
Edta (EDTA)
Heparin (Heparin)
Other (Other)
Red Top (Red top)
Serum Separator (Serum separator)
Other specify
Platelet count required
Yes
No
Platelet count
Platelet Date
Preservative
Yes
No
Yes, specify below
Urine collection method
24-hour (24-hour)
Clean Catch (Clean catch)
Other (Other)
Other, specify
Tissue/cells
Tissue type
Metastatic Tumor (Metastatic tumor)
Normal (Normal)
Other (Other)
Pre-malignant (Pre-malignant)
Primary Tumor (Primary tumor)
Recurrent/persistent Tumor
(Recurrent/persistent tumor)
Other, specify
Processing method
Ethanol-fixed (Ethanol-fixed)
Fixed & Paraffin-embedded (Fixed &
paraffin-embedded)
Formalin-fixed (Formalin-fixed)
Oct-frozen (OCT-frozen)
Other (Other)
Snap-frozen (Snap-frozen)
Other, specify below
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Cell type
Buccal (Buccal)
Cervical (Cervical)
Other (Other)
Other, specify below
Gog Tissue Bank/laboratory Information
Receiving institution
Gog Tissue Bank (GOG Tissue Bank)
Laboratory (Laboratory)
Phone number
Name (Staff at GOG Tissue Bank/Lab receiving
specimens)
E-mail
Specimen received date
Total volume/weight
Units
Additional processing required
Yes
No
Yes, specify
Specimen condition
Satisfactory (Satisfactory)
Unsatisfactory (Unsatisfactory)
Unsatisfactory, specify
Lab name
Footer Module
Participating Group Code
Participating Group Protocol Number
Participating Patient Study ID
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Treatment - Lymphoma - Transplant Graft
Vs. Host Disease Form - 2271273v3.0
Lymphoma - Transplant Graft Vs. Host Disease Form
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=D5EC8620-
1084-0D3B-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/8486
Lymphoma - Transplant Graft Vs.
Host Disease Form
Crf Header
Coordinating Group Protocol No.
Coordinating Group Code
Protocol Title
Patient Study ID
Institution/Affiliate
Other Patient ID
Participating Group Code
Patient Name (initials acceptable)
Lymphoma: Form Administration
Person Completing Form
Are data amended? (If data are amended, please
circle in red when using paper form)
Yes
No
Lymphoma Transplant: Allogeneic - Acute
Graft Vs. Host Disease
Date of Evaluation
Prophylaxis Given following Transplant (Note:
Provide pre-printed list of agents approved for
prophylaxis per protocol.)
Did acute Graft vs. Host Disease occur (GVHD)
No (No)
Not Evaluable (Not evaluable)
Unknown (Unknown)
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Yes (Yes)
Date of Onset of Acute GVHD (If yes,)
Overall Stage of Acute GVHD
0 (0)
1 (1)
2 (2)
3 (3)
4 (4)
Unknown (Unknown)
GVHD Organ Involvement Site
Gastrointestinal Tract (Gastrointestinal
tract)
Liver (Liver)
Other (Other)
Skin (Skin)
Other specify
Maximum stage of organ involvement attributed
to GVHD (since the last evaluation)
0 (0)
1 (1)
2 (2)
3 (3)
4 (4)
Unknown (Unknown)
Therapy Given for GVHD
Lymphoma Transplant: Allogeneic -
Chronic Graft Vs. Host Disease
Date of Onset of Chronic GVHD
Did chronic graft vs. host disease occur
No (No)
Unknown (Unknown)
Yes (Yes)
GVHD Organ Involvement (mark all that apply)
Constitutional (Constitutional)
Esophagus (Esophagus)
Eyes (Eyes)
Hematologic (Hematologic)
Intestinal (Intestinal)
Kidney (Kidney)
Liver (Liver)
Lung (Lung)
Mouth (Mouth)
Musculoskeletal (Musculoskeletal)
Other (Other)
Skin (Skin)
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Spleen (Spleen)
Vagina (Vagina)
Other specify
Maximum severity of chronic GVHD (since the
time of last report Note: Include definitions for
limited and extensive per protocol.)
Extensive (Extensive)
Limited (Limited)
Not Evaluated (Not evaluated)
Unknown (Unknown)
Overall Grade of Chronic GVHD
Extensive (Extensive)
Limited (Limited)
Not Evaluated (Not evaluated)
Unknown (Unknown)
Comments
Comments
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On-Study - Primary Endometrial Cancer -
On-Study Form - 2019340v3.0
Primary Endometrial Cancer - On-Study Form
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=16D70DED-
556D-4F42-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/8488
Primary Endometrial Cancer - On-
Study Form
Crf Header
Coordinating Group Protocol No.
Coordinating Group Code
Protocol Title
Patient Study ID
Institution/Affiliate
Other Patient ID
Participating Group Code
Patient Name (initials acceptable)
Sarcoma: Follow-up Reporting Period
Person Completing Form
Are data amended (If amended, please circle the
changed data in red when using paper form)
Yes
No
Endometrial: Disease Description
Date of Definitive Histologic Diagnosis of Primary
Tumor
Stage (at Diagnosis FIGO)
Refer To Figo Staging For Specific
Gynecologic Cancer (IA)
Refer To Figo Staging For Specific
Gynecologic Cancer (IB)
Refer To Figo Staging For Specific
Gynecologic Cancer (IC)
Refer To Figo Staging For Specific
Gynecologic Cancer (IIA)
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Refer To Figo Staging For Specific
Gynecologic Cancer (IIB)
Refer To Figo Staging For Specific
Gynecologic Cancer (IIIA)
Refer To Figo Staging For Specific
Gynecologic Cancer (IIIB)
Refer To Figo Staging For Specific
Gynecologic Cancer (IIIC)
Refer To Figo Staging For Specific
Gynecologic Cancer (IVA)
Refer To Figo Staging For Specific
Gynecologic Cancer (IVB)
Histologic Grade (check highest grade)
Grade 1-well Differentiated (1)
Grade 2-moderately Differentiated (2)
Grade 3-poorly Differentiated (3)
Histologic Type (check all that apply)
Adenocarcinoma With Squamous
Differentiation (Adenocarcinoma with
Squamous Differentiation)
Adenocarcinoma, Unspecified
(Adenocarcinoma, unspecified)
Adenosquamous (Adenosquamous
carcinoma)
Clear Cell Carcinoma (Clear cell
carcinoma)
Endometrioid Adenocarcinoma
(Endometrioid adenocarcinoma)
Mixed Epithelial Carcinoma, Specify
Components (Mixed epithelial
carcinoma)
Other, Specify (Other specify)
Serous Adenocarcinoma (Serous
adenocarcinoma)
Other specify
Site of Involvement (s for Advanced Disease
Studies)
Abdomen (other Than Above) (Abdomen
(other than above))
Bladder (Bladder)
Bone (Bone)
Colon (Colon)
Liver (Liver)
Lung (Lung)
Other Specify (Other)
Pelvic (other Than Above) (Pelvic (other
than above))
Other specify
Lymph Node Type (Lymph Node Involvement
Indicate the most sensitive method of evaluation
with a positive finding)
Other Specify (other)
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Para-aortic (para-aortic)
Pelvic (pelvic)
Other specify
Lymph Node Involvement
Equivocal (equivocal)
Negative (negative)
Not Evaluated (not evaluated)
Positive (positive)
Unknown (unknown)
Method of Evaluation
Ct Scan (CT scan)
Mri (MRI (NMR))
Not Applicable (Not applicable)
Other, Specify (Other, specify)
Pathologic (Pathologic)
Physical Exam (Physical exam)
Ultrasound (Ultrasound)
Other Specify
Endometrial: Disease Treatment And
Status At Entry
Primary Surgery Type
Bilateral Salpingo-oophorectomy
(bilateral salpingo-oophorectomy)
Cervical Conization (cervical conization)
Omentectal Biopsy (Omentectal biopsy)
Omentectomy (omentectomy)
Other, Specify (other, specify)
Para-aortic Node Sampling/dissection
(para-aortic node sampling/dissection)
Partial Hysterectomy (partial
hysterectomy)
Pelvic Lymphadenectomy (pelvic
lymphadenectomy)
Pelvic Node Sampling/dissection (pelvic
node sampling/dissection)
Peritoneal Sampling (Peritoneal
sampling)
Radical Hysterectomy (radical
hysterectomy)
Radical Trachelectomy (radical
trachelectomy)
Total Hysterectomy (total hysterectomy)
Unilateral Salpingo-oophorectomy
(unilateral salpingo-oophorectomy)
Primary Surgery Other Type
Primary Surgery Date
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Myometrial Invasion Depth
<50% Thickness (<50% thickness)
> Or = 50% Thickness (> or = 50%
thickness)
None (None)
Vascular Lymphatic Invasion Ind
No (No)
Unknown (unknown)
Yes (Yes)
Residual Disease
Allows Documentation Of Any Additional
Cooments
Comments
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Fallopian Tube Cancer NCT01081262 On-Study - GOG-0241
Primary Ovarian Cancer - On Study Form (OSO) - 3126804v1.0
GOG-0241 Primary Ovarian Cancer - On Study Form
(OSO)
Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine,
With or Without Bevacizumab, as First-Line Therapy in
Treating Patients With Newly Diagnosed Stage II, Stage III,
Stage IV, or Recurrent Stage I Epithelial Ovarian Cancer or
Fallopian Tube Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=8D17F7CB-
7001-90BC-E040-BB89AD435566
All rights reserved. Please visit https://medical-data-
models.org/forms/8490
GOG-0241 Primary Ovarian Cancer
- On Study Form (OSO)
Header Module
Date form originally completed
Date form amended
Person amending form, last name
Patient Initials
Patient Study ID
Person Completing Form, Last Name
Ovarian: Disease Description
Date of definitive histologic diagnosis of primary
tumor (m d y)
Primary Site
Fallopian Tube (Fallopian tube)
Ovary (Ovary)
Peritoneum (Peritoneum)
Stage (at diagnosis FIGO)
Refer To Figo Staging For Specific
Gynecologic Cancer (IA)
Refer To Figo Staging For Specific
Gynecologic Cancer (IB)
Refer To Figo Staging For Specific
Gynecologic Cancer (IC)
Refer To Figo Staging For Specific
Gynecologic Cancer (IIA)
Refer To Figo Staging For Specific
Gynecologic Cancer (IIB)
Refer To Figo Staging For Specific
Gynecologic Cancer (IIC)
Refer To Figo Staging For Specific
Gynecologic Cancer (III)
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Refer To Figo Staging For Specific
Gynecologic Cancer (IIIA)
Refer To Figo Staging For Specific
Gynecologic Cancer (IIIB)
Refer To Figo Staging For Specific
Gynecologic Cancer (IIIC)
Refer To Figo Staging For Specific
Gynecologic Cancer (IV)
Histologic grade (check all that apply)
Grade 1-well Differentiated (1)
Grade 2-moderately Differentiated (2)
Grade 3-poorly Differentiated (3)
Grade Unknown (Unknown)
Histologic type (check all that apply)
Adenocarcinoma, Unspecified
(Adenocarcinoma, unspecified)
Clear Cell Carcinoma (Clear cell
carcinoma)
Endometrioid Adenocarcinoma
(Endometrioid adenocarcinoma)
Mixed Epithelial Carcinoma, Specify
Components (Mixed epithelial
carcinoma)
Mucinous Adenocarcinoma (Mucinous
adenocarcinoma)
Other, Specify (Other)
Serous Adenocarcinoma (Serous
adenocarcinoma)
Other, specify
Ovarian: Findings From Primary Surgery
Primary Surgery Type (check all that apply)
Bilateral Salpingo-oophorectomy
(bilateral salpingo-oophorectomy)
Other, Specify (other specify)
Para-aortic Node Sampling/dissection
(para-aortic node sampling/dissection)
Pelvic Node Sampling/dissection (pelvic
node sampling/dissection)
Total Hysterectomy (total hysterectomy)
Unilateral Salpingo-oophorectomy
(unilateral salpingo-oophorectomy)
Other, specify
Size of Residual Disease (Maximum size after
resection is complete. If none or microscopic
only, enter 0.)
Is ascites present (prior to initial staging surgery)
No (No)
Unknown (Unknown)
Yes (Yes)
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Cytology result (pelvic)
Negative (Negative)
Not Done (Not done)
Positive (Positive)
Moderate Dysplasia Or Papillary
Clusters (suspect) (Suspicious)
Is pleural effusion present
No (No)
Unknown (Unknown)
Yes (Yes)
Is it malignant
No (No)
Unknown (Unknown)
Yes (Yes)
Ovarian: Post-operative Findings
Following Primary Surgery
Site of Involvement (s at surgery)
Abdomen (other Than Above)
(Abdominal)
Colon (Colon)
Liver (Liver)
Lung (Lung)
Omentum (Omentum)
Other Specify (Other)
Para-aortic Nodes (Para-aortic nodes)
Pelvic (other Than Above) (Pelvic)
Pelvic Nodes (Pelvic nodes)
Other, specify
Involvement (* Indicate involvement 0=not
evaluated 1=positive 2=negative 3=equivocal
9=unknown)
Equivocal (equivocal)
Negative (negative)
Not Evaluated (not evaluated)
Positive (positive)
Unknown (unknown)
Result of CA125 (pre-treatment U/mL)
Date of CA125 (m d y)
CA125 Laboratory upper limit of normal (U/mL)
Comments
Comments
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Pathology - Lung Cancer - Pathology Form
- Cytology - 2019347v3.0
Lung Cancer - Pathology Form - Cytology
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=1695E623-
661D-07D4-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/8491
Lung Cancer - Pathology Form -
Cytology
Crf Header
Coordinating Group Protocol No.
Coordinating Group Code
Protocol Title
Patient Study ID
Institution/Affiliate
Other Patient ID
Participating Group Code
Patient Name (initials acceptable)
Lung Pathology: Form Administration
Person Completing Form
Are data amended (If data are amended, please
circle in red when using paper form)
Yes
No
Pathology: Cytology Specimen Submitted
Date Specimen Obtained (s - surgical procedure)
Specimen ID
Specimen Collection Method
Sample Or Specimen Collected Via
Abdominal Effusion Or Ascites
(Abdominal/ascites effusion)
Sample Or Specimen Collected Via
Biopsy (Biopsy)
Sample Or Specimen Collected Via
1 / 4
Bronchial Alveolar Lavage (Bronchial
alveolar lavage (BAL))
Sample Or Specimen Collected Via
Bronchial Brushing Or Washing
(Bronchial brushing/washing)
Sample Or Specimen Collected Via Fine
Needle Aspiration (Fine needle
aspiration, specify site)
Sample Or Specimen Collected Via
Mediastinoscopy (Mediastinoscopy)
Other Specify (Other, specify)
Sample Or Specimen Collected Via
Pericardial Effusion (Pericardial effusion)
Sample Or Specimen Collected Via
Pleural Effusion (Pleural effusion)
Sample Or Specimen Collected Via
Pleural Lavage (Pleural lavage)
Sample Or Specimen Collected Via
Induced Sputum (Sputum, induced)
Sample Or Specimen Collected Via
Spontaneous Sputum (Sputum,
spontaneous)
Fine needle aspiration specify site
Other specify
Sample Period
Other Specify (Other, specify)
Sample Or Specimen Collected After
Patient Received Treatment For Cancer
(Post-treatment)
Sample Or Specimen Collected Before
Patient Was Diagnosed With Cancer
(Pre-diagnosis)
Sample Or Specimen Collected Before
Patient Received Treatment For Cancer
(Pre-treatment)
Unknown (Unknown)
Other specify
Specify Type of Treatment (If post-treatment,)
Specimen Cell Source
Bronchial Tissue, Suspicious For
Abnormality (Bronchial tissue, suspicious
for abnormality)
Bronchus (Bronchus, specify)
Lymph Node (Lymph node)
Non-malignant Lung (Non-malignant
lung)
Other, Specify (Other, specify)
Primary Tumor (Primary tumor)
Bronchus specify
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Other specify
Pathology: Description Of Primary Tumor
Tumor Location Side
Both (Both)
Left (Left)
Right (Right)
Unilateral Side Not Specified (Unilateral,
side not specified)
Unknown (Unknown)
Tumor Location Area
Carina (Carina)
Lower Lobe (Lower lobe)
Mainstem Bronchus (Mainstem
bronchus)
Middle Lobe (Middle lobe)
Other, Specify (Other)
Upper Lobe (Upper lobe)
Other specify
Are the tumors multifocal
No (NO)
Unknown (UNKNOWN)
Yes (YES)
Are there multiple primary tumors
No (NO)
Unknown (UNKNOWN)
Yes (YES)
Specify number of lesions (If yes, - If multiple
specimens, complete separate form for each
specimen.)
Pathology: Cytology Microscopic
Description
Histologic Type (WHO - check all that apply)
Adenocarcinoma (Adenocarcinoma)
Bronchoalveolar (bac) (Bronchoalveolar
carcinoma (BAC))
Carcinoid (Carcinoid)
Combined/mixed, Specify Subcategories
(Combined/mixed)
Large Cell Carcinoma (Large cell
carcinoma)
No Malignancy Observed (No
malignancy observed)
Non-small Cell Lung Cancer (nsclc), Nos
(Non-small cell lung cancer NOS)
Other (Other specify)
Pre-malignant Changes Observed (Pre-
malignant changes observed)
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Small Cell Carcinoma (oat Cell) (Small
cell carcinoma (oat cell))
Squamous Cell Carcinoma (Squamous
cell carcinoma)
Specify subcategories
Other specify
Associated Pre-Malignant Histologic Changes (If
Pre-Malignant Changes Observed, - check all
that apply)
Atypical Adenomatous Hyperplasia
(Atypical adenomatous hyperplasia)
Basal Cell Hyperplasia (Basal cell
hyperplasia)
Basal Cell Hyperplasia With Angiogenic
Squamous Dysplasia Changes (Basal
cell hyperplasia with ASD changes)
Carcinoma In Situ (Carcinoma in situ)
Mild Dysplasia (Mild dysplasia)
Mild Dyplasia With Angiogenic
Squamous Dysplasia Changes (Mild
dysplasia with ASD changes)
Moderate Dysplasia (Moderate
dysplasia)
Moderate Dysplasia With Angiogenic
Squamous Dysplasia Changes
(Moderate dysplasia with ASD changes)
Other, Specify (Other, specify)
Severe Dysplasia (Severe dysplasia)
Severe Dysplasia With Angiogenic
Squamous Dysplasia Changes (Severe
dysplasia with ASD changes)
Squamous Metaplasia (Squamous
Metaplasia)
Squamous Metaplasia With Angiogenic
Squamous Dysplasia Changes
(Squamous metaplasia with ASD
changes)
Other, specify
Was lymph node sampling done (Lymph Nodes)
No (No)
Unknown (Unknown)
Yes (Yes)
Number of Lymph Nodes Examined (If yes,)
Number of Positive Lymph Nodes
Reviewing Pathologist
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Fallopian Tube Cancer NCT00951496 On-Study - GOG-0252
Primary Ovarian Cancer -  On Study Form - 2835512v1.0
GOG-0252 Primary Ovarian Cancer -  On Study Form
Bevacizumab and Intravenous or Intraperitoneal
Chemotherapy in Treating Patients With Stage II, Stage III,
or Stage IV Ovarian Epithelial Cancer, Fallopian Tube
Cancer, or Primary Peritoneal Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=62457734-
8B2A-C973-E040-BB89AD430DDB
All rights reserved. Please visit https://medical-data-
models.org/forms/8492
GOG-0252 Primary Ovarian Cancer
-  On Study Form
Header Module
Date form originally completed
Date form amended
Person amending form, last name
Patient Initials
Patient Study ID
Person Completing Form, Last Name
Ovarian: Disease Description
Date of definitive histologic diagnosis of primary
tumor
Primary Site
Fallopian Tube (Fallopian tube)
Ovary (Ovary)
Peritoneum (Peritoneum)
Stage (at diagnosis FIGO)
Refer To Figo Staging For Specific
Gynecologic Cancer (IA)
Refer To Figo Staging For Specific
Gynecologic Cancer (IB)
Refer To Figo Staging For Specific
Gynecologic Cancer (IC)
Refer To Figo Staging For Specific
Gynecologic Cancer (IIA)
Refer To Figo Staging For Specific
Gynecologic Cancer (IIB)
Refer To Figo Staging For Specific
Gynecologic Cancer (IIC)
Refer To Figo Staging For Specific
Gynecologic Cancer (III)
Refer To Figo Staging For Specific
Gynecologic Cancer (IIIA)
Refer To Figo Staging For Specific
Gynecologic Cancer (IIIB)
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Refer To Figo Staging For Specific
Gynecologic Cancer (IIIC)
Refer To Figo Staging For Specific
Gynecologic Cancer (IV)
Histologic grade
Grade 1-well Differentiated (1)
Grade 2-moderately Differentiated (2)
Grade 3-poorly Differentiated (3)
Grade Unknown (Unknown)
Histologic type (check all that apply)
Adenocarcinoma, Unspecified
(Adenocarcinoma, unspecified)
Clear Cell Carcinoma (Clear cell
carcinoma)
Endometrioid Adenocarcinoma
(Endometrioid adenocarcinoma)
Mixed Epithelial Carcinoma, Specify
Components (Mixed epithelial
carcinoma)
Mucinous Adenocarcinoma (Mucinous
adenocarcinoma)
Other, Specify (Other)
Serous Adenocarcinoma (Serous
adenocarcinoma)
Other, specify
Ovarian: Findings From Primary Surgery
Primary Surgery Type
Bilateral Salpingo-oophorectomy
(bilateral salpingo-oophorectomy)
Other, Specify (other specify)
Para-aortic Node Sampling/dissection
(para-aortic node sampling/dissection)
Pelvic Node Sampling/dissection (pelvic
node sampling/dissection)
Total Hysterectomy (total hysterectomy)
Unilateral Salpingo-oophorectomy
(unilateral salpingo-oophorectomy)
Other, specify
Size of Residual Disease
Is ascites present (prior to initial staging surgery)
No (No)
Unknown (Unknown)
Yes (Yes)
Cytology result (pelvic)
Negative (Negative)
Not Done (Not done)
Positive (Positive)
Moderate Dysplasia Or Papillary
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Clusters (suspect) (Suspicious)
Is pleural effusion present
No (No)
Unknown (Unknown)
Yes (Yes)
Is it malignant
No (No)
Unknown (Unknown)
Yes (Yes)
Ovarian: Post-operative Findings
Following Primary Surgery
Site of Involvement (s)
Abdomen (other Than Above)
(Abdominal)
Colon (Colon)
Liver (Liver)
Lung (Lung)
Omentum (Omentum)
Other Specify (Other)
Para-aortic Nodes (Para-aortic nodes)
Pelvic (other Than Above) (Pelvic)
Pelvic Nodes (Pelvic nodes)
Other, specify
Involvement (*)
Equivocal (equivocal)
Negative (negative)
Not Evaluated (not evaluated)
Positive (positive)
Unknown (unknown)
Result of CA125 (pre-treatment)
Date of CA125
CA125 Laboratory upper limit of normal
Comments
COMMENTS
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On-Study - Bone Sarcoma - On-Study Form
Recurrent Treatment - 2290047v3.0
Bone Sarcoma - On-Study Form Recurrent Treatment
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=E20A02D1-
D3E7-176A-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/8494
Bone Sarcoma - On-Study Form
Recurrent Treatment
Crf Header
Coordinating Group Protocol No.
Coordinating Group Code
Protocol Title
Patient Study ID
Institution/Affiliate
Other Patient ID
Participating Group Code
Patient Name (initials acceptable)
Sarcoma: Form Administration
Person Completing Form
Are data amended (If data are amended, please
circle in red when using paper form)
Yes
No
Bone Sarcoma: Recurrent Disease
Description
Date of Initial Pathologic Diagnosis (not relapse)
Recurrence date (MM DD YYYY)
Biopsy Type (at time of relapse)
Excisional (Excisional)
Fine Needle Aspirate (Fine needle
aspirate)
Incisional (Incisional)
Large Bore Needle (Large bore needle)
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Other, Specify (Other specify)
Trucut Needle (TruCut needle)
Other specify
Primary Site
Clavicle (Clavicle)
Femur (Femur)
Fibula (Fibula)
Humerus (Humerus)
Ilium (Ilium)
Ischium (Ischium)
Mandible (Mandible)
Maxilla (Maxilla)
Other, Specify (Other specify)
Pubis (Pubis)
Radius (Radius)
Ribs (Ribs)
Scapula (Scapula)
Skull (Skull)
Sternum (Sternum)
Tibia (Tibia)
Ulna (Ulna)
Vertebra (Vertebra)
Other specify
Tumor Location, Side
Both (Both)
Left (Left)
Right (Right)
Unknown (Unknown)
Area (If long bone,)
Diaphysis (Diaphysis)
Epiphysis (Epiphysis)
Metaphysis (Metaphysis)
Unknown (Unknown)
Site(s) of Disease (at Study Entry)
Abdominal Organs (Abdominal organs)
Ascites (Ascites)
Bone (Bone)
Bone Marrow (Bone marrow)
Chest Wall/ribs (Chest wall/ribs)
Cns/brain (CNS/brain)
Liver (Liver)
Lung (Lung)
Lymph Nodes, Specify (Lymph nodes
specify)
Mediastinum (Mediastinum)
Other, Specify (Other specify)
Pericardium (Pericardium)
Peritoneum (Peritoneum)
Pleura (Pleura)
Retroperitoneum (Retroperitoneum)
Skin (Skin)
Soft Tissue (Soft tissue)
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Lymph Nodes Specify
Other specify
Regional lymph nodes
No (No)
Unknown (Unknown)
Yes (Yes)
Distant lymph nodes
No (No)
Unknown (Unknown)
Yes (Yes)
Metastatic Site (s - check all that apply)
Ascites (Ascites)
Bone (Bone)
Bone Marrow (Bone marrow)
Cerebrospinal Fluid (csf) (Cerebrospinal
fluid (CSF))
Cns/brain (CNS/Brain)
Distant Nodes, Specify (Distant Nodes)
Liver (Liver)
Lung (Lung)
Other Specify (Other)
Peritoneal Nodules (Peritoneal nodules)
Pleural Effusion (Pleural effusion)
Pleural Nodules (Pleural nodules)
Soft Tissue (Soft tissue)
Distant nodes specify
Other specify
Lung Specificity
Bilateral (Bilateral)
Unilateral (Unilateral)
Number of pulmonary nodules, left
1 (1)
2 (2)
3 (3)
4 (4)
5 Or More (5 or more)
Number of pulmonary nodules, right
1 (1)
2 (2)
3 (3)
4 (4)
5 Or More (5 or more)
Are skip metastases present?
No (No)
Unknown (Unknown)
Yes (Yes)
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Dimension 1 (Longest)
Dimension 2 (cm)
Dimension 3 (cm)
Status of Primary Tumor
Not Recurrent, Resected, No Residual
Tumor (Not recurrent, resected, no
residual tumor)
Not Recurrent, Resected, Residual
Tumor (Not recurrent, resected, residual
tumor)
Recurrent (Recurrent)
Unresected (Unresected)
Histologic Type (check all that apply)
Angiosarcoma (Angiosarcoma)
Chondrosarcoma (Chondrosarcoma)
Chordoma (Chordoma)
Clear Cell Chondrosarcoma (Clear cell
chondrosarcoma)
Conventional Central Osteosarcoma
(Conventional central osteosarcoma)
Dedifferentiated Chondrosarcoma
(Dedifferentiated chondrosarcoma)
Epithelioid Hemagioendothelioma
(Epithelioid hemangioendothelioma)
Ewing's Sarcoma/pnet (Ewing's
sarcoma/PNET)
Fibrosarcoma (Fibrosarcoma)
Hemagioendothelioma Nos
(Hemangioendothelioma NOS)
Hematopoietic Malignancy Nos
(Hematopoietic malignancy NOS)
Intraosseous Osteosarcoma
(Intraosseous osteosarcoma)
Leiomyosarcoma (Leiomyosarcoma)
Liposarcoma Nos (Liposarcoma NOS)
Lymphoma (primary) (Lymphoma
(primary))
Malignant Giant Cell Tumor (Malignant
giant cell tumor)
Maligant Peripheral Nerve Sheath Tumor
(Malignant peripheral nerve sheath
tumor)
Mesenchymal Chondrosarcoma
(Mesenchymal chondrosarcoma)
Osteosarcoma Nos (Osteosarcoma
NOS)
Other Specify (Other specify)
Parosteal (juxtacortical) Osteosarcoma
(Parosteal (juxtacortical) osteosarcoma)
Periosteal Osteosarcoma (Periosteal
osteosarcoma)
Sarcoma Nos (Sarcoma NOS)
Small Cell Osteosarcoma (Small cell
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osteosarcoma)
Surface Osteosarcoma, High-grade
(Surface osteosarcoma, high-grade)
Telangiectatic Osteosarcoma
(Telangiectatic osteosarcoma)
Undifferentiated Pleomorphic
Sarcoma/"mfh" (Undifferentiated
pleomorphic sarcoma/"MFH")
Other specify
Histologic Subtype (specify)
Bone Sarcoma: Prior Health History
Prior Radiation Therapy for Other Disease?
No (No)
Unknown (Unknown)
Yes (Yes)
Prior Radiation Therapy Site (If Yes,)
Is there a history of prior radiation therapy to the
primary site?
No (No)
Unknown (Unknown)
Yes (Yes)
Specify (If Yes,)
Is there a history of retinoblastoma?
No (No)
Unknown (Unknown)
Yes (Yes)
Specify (If Yes,)
Is there a history of Paget's Disease?
No (No)
Unknown (Unknown)
Yes (Yes)
Specify (If Yes,)
Is there a history of Li-Fraumeni syndrome?
No (No)
Unknown (Unknown)
Yes (Yes)
Specify (If Yes,)
Are there any other prior medical conditions, such
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as any bone abnormalities?
No (No)
Unknown (Unknown)
Yes (Yes)
Specify (If Yes,)
Sarcoma: Prior Treatment
Prior Treatment?
Yes
No
Prior Systemic Chemotherapy
Yes
No
Prior Immunotherapy
Yes
No
Prior Radiation Therapy
Yes
No
Prior Surgery
Yes
No
Type of Prior Primary Surgery
Prior Primary Surgery Date (MM DD YYYY)
Any Other Prior Therapy?
Yes
No
Yes, specify
Sarcoma: Prior Treatment - Systemic
Regimens
Prior Treatment Regimen Name (Drug, Agent,
Biologic)
Prior Treatment Regimen Start Date (MM DD
YYYY)
Prior Treatment Regimen End Date (MM DD
YYYY)
Prior Treatment Regimen Type (Adjuvant, High
Dose)
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Comments
Comments
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Fallopian Tube Cancer NCT01167712 On-Study - GOG-0262:
Primary Ovarian Cancer -  On Study Form - 2918240v1.0
GOG-0262: Primary Ovarian Cancer -  On Study Form
Paclitaxel and Carboplatin With or Without Bevacizumab in
Treating Patients With Stage II, Stage III, or Stage IV
Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or
Fallopian Tube Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=6E60272A-
2D16-BA9E-E040-BB89AD434554
All rights reserved. Please visit https://medical-data-
models.org/forms/8495
GOG-0262: Primary Ovarian Cancer
-  On Study Form
Header Module
Date form originally completed
Date form amended
Person amending form, last name
Patient Initials
Patient Study ID
Person Completing Form, Last Name
Ovarian: Disease Description
Date of definitive histologic diagnosis of primary
tumor
Primary Site
Fallopian Tube (Fallopian tube)
Ovary (Ovary)
Peritoneum (Peritoneum)
Stage (at diagnosis FIGO)
Refer To Figo Staging For Specific
Gynecologic Cancer (IA)
Refer To Figo Staging For Specific
Gynecologic Cancer (IB)
Refer To Figo Staging For Specific
Gynecologic Cancer (IC)
Refer To Figo Staging For Specific
Gynecologic Cancer (IIA)
Refer To Figo Staging For Specific
Gynecologic Cancer (IIB)
Refer To Figo Staging For Specific
Gynecologic Cancer (IIC)
Refer To Figo Staging For Specific
Gynecologic Cancer (III)
Refer To Figo Staging For Specific
Gynecologic Cancer (IIIA)
Refer To Figo Staging For Specific
Gynecologic Cancer (IIIB)
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Refer To Figo Staging For Specific
Gynecologic Cancer (IIIC)
Refer To Figo Staging For Specific
Gynecologic Cancer (IV)
Histologic grade
Grade 1-well Differentiated (1)
Grade 2-moderately Differentiated (2)
Grade 3-poorly Differentiated (3)
Grade Unknown (Unknown)
Histologic type (check all that apply)
Adenocarcinoma, Unspecified
(Adenocarcinoma, unspecified)
Clear Cell Carcinoma (Clear cell
carcinoma)
Endometrioid Adenocarcinoma
(Endometrioid adenocarcinoma)
Mixed Epithelial Carcinoma, Specify
Components (Mixed epithelial
carcinoma)
Mucinous Adenocarcinoma (Mucinous
adenocarcinoma)
Other, Specify (Other)
Serous Adenocarcinoma (Serous
adenocarcinoma)
Other, specify
Ovarian: Findings From Primary Surgery
Primary Surgery Type
Bilateral Salpingo-oophorectomy
(bilateral salpingo-oophorectomy)
Other, Specify (other specify)
Para-aortic Node Sampling/dissection
(para-aortic node sampling/dissection)
Pelvic Node Sampling/dissection (pelvic
node sampling/dissection)
Total Hysterectomy (total hysterectomy)
Unilateral Salpingo-oophorectomy
(unilateral salpingo-oophorectomy)
Other, specify
Size of Residual Disease
Is ascites present (prior to initial staging surgery)
No (No)
Unknown (Unknown)
Yes (Yes)
Cytology result (pelvic)
Negative (Negative)
Not Done (Not done)
Positive (Positive)
Moderate Dysplasia Or Papillary
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Fallopian Tube Cancer NCT01167712 On-Study - GOG-0262: Primary
Ovarian Cancer -  On Study Form - 2918240v1.0
Clusters (suspect) (Suspicious)
Is pleural effusion present
No (No)
Unknown (Unknown)
Yes (Yes)
Is it malignant
No (No)
Unknown (Unknown)
Yes (Yes)
Ovarian: Post-operative Findings
Following Primary Surgery
Site of Involvement (s)
Abdomen (other Than Above)
(Abdominal)
Colon (Colon)
Liver (Liver)
Lung (Lung)
Omentum (Omentum)
Other Specify (Other)
Para-aortic Nodes (Para-aortic nodes)
Pelvic (other Than Above) (Pelvic)
Pelvic Nodes (Pelvic nodes)
Other, specify
Involvement (*)
Equivocal (equivocal)
Negative (negative)
Not Evaluated (not evaluated)
Positive (positive)
Unknown (unknown)
Result of CA125 (pre-treatment)
Date of CA125
CA125 Laboratory upper limit of normal
Comments
COMMENTS
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Fallopian Tube Cancer NCT01167712 On-Study - GOG-0262: Primary
Ovarian Cancer -  On Study Form - 2918240v1.0
Fallopian Tube Cancer NCT00262847 Registration -
GOG-0218 Registration Form - 2303844v3.0
GOG-0218 Registration Form
Carboplatin and Paclitaxel With or Without Bevacizumab in
Treating Patients With Stage III or Stage IV Ovarian
Epithelial, Primary Peritoneal Cancer, or Fallopian Tube
Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=F0E0A34C-
6E2F-614E-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/8496
GOG-0218 Registration Form
Header Module
Date form originally completed
Date form amended
Person amending form, last name
Patient Name, Last
Patient Name, First
Patient Study ID
Person Completing Form, Last Name
Tracking Information
Institution name (/affiliate)
Treating physician
Patient medical record number
Patient's date of birth
Patient social security number
Patient's zip code (USA)
Country of residence (if not USA)
Demographic Information
Patient race (mark all that apply)
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A Person Having Origins In Any Of The
Original Peoples Of North And South
America (including Central America),
And Who Maintains Tribal Affiliation Or
Community Attachment. (American
Indian or Alaska Native)
A Person Having Origins In Any Of The
Original Peoples Of The Far East,
Southeast Asia, Or The Indian
Subcontinent Including, For Example,
Cambodia, China, India, Japan, Korea,
Malaysia, Pakistan, The Philippine
Islands, Thailand, And Vietnam. (Asian)
A Person Having Origins In Any Of The
Black Racial Groups Of Africa. Terms
Such As "haitian" Or "negro" Can Be
Used In Addition To "black Or African
American." (Black or African American)
A Person Having Origins In Any Of The
Original Peoples Of Hawaii, Guam,
Samoa, Or Other Pacific Islands. (Native
Hawaiian or other Pacific Islander)
Could Not Be Determined Or Unsure
(Unknown)
A Person Having Origins In Any Of The
Original Peoples Of Europe, The Middle
East, Or North Africa. (White)
Patient ethnicity (check one)
A Person Of Mexican, Puerto Rican,
Cuban, Central Or South American Or
Other Spanish Culture Or Origin,
Regardless Of Race (Hispanic or Latino)
A Person Not Meeting The Definition For
Hispanic Or Latino. (Non-Hispanic)
Could Not Be Determined Or Unsure
(Unknown)
Method of payment
Medicaid (Medicaid)
Medicaid And Medicare (Medicaid &
Medicare)
Medicare (Medicare)
Medicare And Private Insurance
(Medicare & Private Insurance)
Military Or Veterans Sponsored Nos
(Military or Veterans Sponsored NOS)
Military Sponsored (including Champus
& Tricare) (Military Sponsored)
No Means Of Payment (no Insurance)
(No means of payment)
Other (Other)
Private Insurance (Private Insurance)
Self Pay (no Insurance) (Self pay)
Unknown (Unknown)
Veterans Sponsored (Veterans
Sponsored)
Patient height
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Fallopian Tube Cancer NCT00262847 Registration - GOG-0218
Registration Form - 2303844v3.0
Patient weight
Performance status (Zubrod)
Fully Active, Able To Carry On All Pre-
disease Performance Without
Restriction. (0)
Restricted In Physically Strenuous
Activity But Ambulatory And Able To
Carry Out Work Of A Light Or Sedentary
Nature, E.g., Light Housework, Office
Work. (1)
Ambulatory And Capable Of All Selfcare
But Unable To Carry Out Any Work
Activities. Up And About More Than 50%
Of Waking Hours. (2)
Capable Of Only Limited Selfcare,
Confined To Bed Or Chair More Than
50% Of Waking Hours. (3)
Completely Disabled. Cannot Carry On
Any Selfcare. Totally Confined To Bed Or
Chair. (4)
Has the patient had any prior cancer diagnosed
Yes
No
Prior cancer type
Prior cancer diagnosis date
Comments
COMMENTS
Footer Module
Participating Group Code
Participating Group Protocol Number
Participating Group Patient ID
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Fallopian Tube Cancer NCT00262847 Registration - GOG-0218
Registration Form - 2303844v3.0
Fallopian Tube Cancer NCT00262847 On-Study - GOG-0218
Primary Ovarian Cancer -  On Study Form - 2303628v3.0
GOG-0218 Primary Ovarian Cancer -  On Study Form
Carboplatin and Paclitaxel With or Without Bevacizumab in
Treating Patients With Stage III or Stage IV Ovarian
Epithelial, Primary Peritoneal Cancer, or Fallopian Tube
Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=F0E13298-
CD9B-5802-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/8497
GOG-0218 Primary Ovarian Cancer
-  On Study Form
Header Module
Date form originally completed
Date form amended
Person amending form, last name
Patient Initials
Patient Study ID
Person Completing Form, Last Name
Ovarian: Disease Description
Date of definitive histologic diagnosis of primary
tumor
Primary site
Fallopian Tube (Fallopian tube)
Ovary (Ovary)
Peritoneum (Peritoneum)
Stage (at diagnosis FIGO)
Refer To Figo Staging For Specific
Gynecologic Cancer (IA)
Refer To Figo Staging For Specific
Gynecologic Cancer (IB)
Refer To Figo Staging For Specific
Gynecologic Cancer (IC)
Refer To Figo Staging For Specific
Gynecologic Cancer (IIA)
Refer To Figo Staging For Specific
Gynecologic Cancer (IIB)
Refer To Figo Staging For Specific
Gynecologic Cancer (IIC)
Refer To Figo Staging For Specific
Gynecologic Cancer (III)
Refer To Figo Staging For Specific
Gynecologic Cancer (IIIA)
Refer To Figo Staging For Specific
Gynecologic Cancer (IIIB)
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Refer To Figo Staging For Specific
Gynecologic Cancer (IIIC)
Refer To Figo Staging For Specific
Gynecologic Cancer (IV)
Histologic grade
Grade 1-well Differentiated (1)
Grade 2-moderately Differentiated (2)
Grade 3-poorly Differentiated (3)
Grade Unknown (Unknown)
Histologic type (check all that apply)
Adenocarcinoma, Unspecified
(Adenocarcinoma, unspecified)
Clear Cell Carcinoma (Clear cell
carcinoma)
Endometrioid Adenocarcinoma
(Endometrioid adenocarcinoma)
Mixed Epithelial Carcinoma, Specify
Components (Mixed epithelial
carcinoma)
Mucinous Adenocarcinoma (Mucinous
adenocarcinoma)
Other, Specify (Other)
Serous Adenocarcinoma (Serous
adenocarcinoma)
Other, specify
Ovarian: Findings From Primary Surgery
Primary surgery type (check all that apply)
Bilateral Salpingo-oophorectomy
(Bilateral Salpingo-Oophorectomy)
Other, Specify (Other)
Para-aortic Node Sampling/dissection
(Para-aortic node sampling/dissection)
Pelvic Node Sampling/dissection (Pelvic
node sampling/dissection)
Total Hysterectomy (Total hysterectomy)
Unilateral Salpingo-oophorectomy
(Unilateral Salpingo-Oophorectomy)
Other, specify
Size of residual disease (Maximum size after
resection is complete. If none or microscopic
only, enter 0.)
Is ascites present (prior to initial staging surgery)
No (No)
Unknown (Unknown)
Yes (Yes)
Cytology result (pelvic)
Negative (Negative)
Not Done (Not done)
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Ovarian Cancer -  On Study Form - 2303628v3.0
Positive (Positive)
Moderate Dysplasia Or Papillary
Clusters (suspect) (Suspicious)
Is pleural effusion present
No (No)
Unknown (Unknown)
Yes (Yes)
Is it malignant
No (No)
Unknown (Unknown)
Yes (Yes)
Ovarian: Post-operative Findings
Following Primary Surgery
Site of Involvement (s)
Abdomen (other Than Above)
(Abdominal)
Colon (Colon)
Liver (Liver)
Lung (Lung)
Omentum (Omentum)
Other Specify (Other)
Para-aortic Nodes (Para-aortic nodes)
Pelvic (other Than Above) (Pelvic)
Pelvic Nodes (Pelvic nodes)
Other, specify
Involvement (*)
Equivocal (equivocal)
Negative (negative)
Not Evaluated (not evaluated)
Positive (positive)
Unknown (unknown)
Result of CA125 (pre-treatment)
Date of CA125
Comments
COMMENTS
Footer Module
Participating Group Code
Participating Group Protocol Number
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Fallopian Tube Cancer NCT00262847 On-Study - GOG-0218 Primary
Ovarian Cancer -  On Study Form - 2303628v3.0
Participating Group Patient ID
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Fallopian Tube Cancer NCT00262847 On-Study - GOG-0218 Primary
Ovarian Cancer -  On Study Form - 2303628v3.0
Treatment - Breast Cancer - Adjuvant
Radiotherapy Report Form - 2280049v3.0
Breast Cancer - Adjuvant Radiotherapy Report Form
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=DA18A97F-
D17C-0637-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/8498
Breast Cancer - Adjuvant
Radiotherapy Report Form
Crf Header
Coordinating Group Protocol No.
Coordinating Group Code
Protocol Title
Patient Study ID
Institution/Affiliate
Other Patient ID
Participating Group Code
Patient Name (initials acceptable)
Breast: Form Administration
Person Completing Form
Are data amended? (If data are amended, please
circle in red when using paper form)
Yes
No
Breast: Radiation Treatment
Has the patient received adjuvant RT (prior to
treatment failure or second primary cancer If the
patient did receive radiotherapy, please complete
the remainder of this form.)
Yes
No
Date Adjuvant Radiation Therapy Started
Date Adjuvant Radiation Therapy Ended
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Radiation Therapy Site (Nature of Radiotherapy
check one)
Any Post-mastectomy Radiotherapy (Any
Post-Mastectomy Radiotherapy)
In-breast And Regional Radiotherapy
Following Breast-conserving Surgery (In-
Breast and Regional Radiotherapy
following Breast-Conserving Surgery)
In-breast Radiotherapy Following Breast-
conserving Surgery (In-Breast
Radiotherapy following Breast-
Conserving Surgery)
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Treatment - Breast Cancer - Adjuvant Radiotherapy Report Form -
2280049v3.0
Fallopian Tube Cancer NCT00262847 On-Study - GOG-
0218 Solid Tumor Evaluation Form - 2304366v3.0
GOG-0218 Solid Tumor Evaluation Form
Carboplatin and Paclitaxel With or Without Bevacizumab in
Treating Patients With Stage III or Stage IV Ovarian
Epithelial, Primary Peritoneal Cancer, or Fallopian Tube
Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=F13FBFE4-
EF5E-3CD4-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/8500
GOG-0218 Solid Tumor Evaluation
Form
Header Module
Date form originally completed
Date form amended
Person amending form, last name
Patient Initials
Patient Study ID
Person completing form, last name
Target Lesion(s) Evaluation
Site of Lesion
Date of evaluation
Method of evaluation (*)
Chest X-ray (Chest X-ray)
Clinical Examination (pe) (Clinical
examination)
Ct Scan (CT scan)
Mri (MRI)
Other (Other)
Spiral Ct Scan (Spiral CT scan)
Ultrasound (Ultrasound)
If other, specify
Longest diameter of lesion (s)
Sum of longest diameters of all target lesions
Non-target Lesion(s) Evaluation
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Are there any nontarget lesions (If no, skip to the
New Lesions section below.)
Yes
No
Site of Lesion
Date of evaluation
Method of evaluation (*)
Chest X-ray (Chest X-ray)
Clinical Examination (pe) (Clinical
examination)
Ct Scan (CT scan)
Mri (MRI)
Other (Other)
Spiral Ct Scan (Spiral CT scan)
Ultrasound (Ultrasound)
If other, specify
Follow-up status of lesion (s^)
Complete Response (CR)
Progressive Disease (PD)
Stable Disease (S)
New Target Lesion(s) At Follow-up
Evaluation
Was the appearance of any new lesions
documented since the baseline evaluation (If no,
skip to the Overall Response section below.)
Yes
No
Site of Lesion
Date of evaluation
Method of evaluation (*)
Chest X-ray (Chest X-ray)
Clinical Examination (pe) (Clinical
examination)
Ct Scan (CT scan)
Mri (MRI)
Other (Other)
Spiral Ct Scan (Spiral CT scan)
Ultrasound (Ultrasound)
If other, specify
Overall Response
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Fallopian Tube Cancer NCT00262847 On-Study - GOG-0218 Solid
Tumor Evaluation Form - 2304366v3.0
Overall response status at this assessment
(check one)
Complete Response (CR)
Insufficient Evaluation (Insufficient
evaluation to determine response status)
Progressive Disease (PD)
Partial Response (PR)
Stable Disease (SD)
Response confirmed date
Comments
Comments
Footer Module
Participating group code
Participating group protocol number
Participating group patient ID
3 / 3
Fallopian Tube Cancer NCT00262847 On-Study - GOG-0218 Solid
Tumor Evaluation Form - 2304366v3.0
Pathology - Prostate Cancer - Pathology
Form - Biopsy - 2019353v3.0
Prostate Cancer - Pathology Form - Biopsy
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=19804734-
1DD7-0F92-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/8501
Prostate Cancer - Pathology Form -
Biopsy
Crf Header
Coordinating Group Protocol No.
Coordinating Group Code
Protocol Title
Patient Study ID
Institution/Affiliate
Other Patient ID
Participating Group Code
Patient Name (initials acceptable)
Brain: Form Administration
Person Completing Form
Are data amended (If data are amended, please
circle in red when using paper form)
Yes
No
Pathology: Prostatic Biopsy
Data Source
Does analysis of tissue show evidence of
therapeutic effects?
No (No)
Unknown (Unknown)
Yes (Yes)
Type of Therapy (If yes.)
Hormonal Therapy (Hormonal therapy)
Other (Other)
Radiation Therapy (Radiation therapy)
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Other specify
Type of Procedure
Fine Needle Aspiration (Fine needle
aspiration)
Needle Biopsy (Needle biopsy)
Other Specify (Other)
Other specify
Biopsy Date
Tumor Location, Side
Left (Left)
Left Lateral (Left lateral)
Midline (Midline)
Other, Specify (Other, specify)
Right (Right)
Right Lateral (Right lateral)
Unknown (Unknown)
Tumor Location, Other Side
Tumor Location, Area
Apex (Apex)
Base (Base)
Middle (Middle)
Other, Specify (Other, specify)
Seminal Vesicle (Seminal vesicle)
Tumor Location, Other Area
Tumor Location, Zone
Not Specified (Not specified)
Peripheral/central (Peripheral/central)
Transition (Transition)
Unknown (Unknown)
Biopsy, Core Length
Biopsy, Cancer Present Measurement
Biopsy, Cancer Present Percentage
Biopsy, Measurement of Gleason 4-5
PIN Ind, High Grade
No (No)
Unknown (Unknown)
Yes (Yes)
Extraprostatic Extension Ind
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No (No)
Unknown (Unknown)
Yes (Yes)
Extraprostatic Extension Type
Established (Established)
Focal </= 2 Hpf (Focal </= 2 hpf)
Unknown (Unknown)
Extraprostatic Extension Laterality
Bilateral (Bilateral)
Unilateral (Unilateral)
Unknown (Unknown)
Extraprostatic Extension Extent, Vertical
Extraprostatic Extension Extent, Horizontal
Gleason Score, Primary Pattern
Gleason Score, Secondary Pattern
Gleason Score, Combined
Gleason Score, Worst Pattern
Pathology: Disease Assessment - Biopsy
Histologic Type
Adenocarcinoma, Conventional, Not
Otherwise Specified (Adenocarcinoma,
conventional, NOS)
Adenocarcinoma/acinar
(Adenocarcinoma/Acinar)
Adenosquamous Carcinoma
(Adenosquamous carcinoma)
Basaloid And Adenoid Cystic Carcinoma
(Basaloid and adenoid cystic carcinoma)
Lymphoepithelioma-like Carcinoma
(Lymphoepithelioma-like carcinoma)
Mucinous (colloid) Adenocarcinoma
(Mucinous (colloid) adenocarcinoma)
Other (Other, specify)
Prostatic Duct Adenocarcinoma
(Prostatic duct adenocarcinoma)
Sarcomatoid Carcinoma (Sarcomatoid
carcinoma)
Signet Ring Cell Carcinoma (Signet ring
cell carcinoma)
Small Cell Carcinoma (Small cell
carcinoma)
Squamous Cell Carcinoma (Squamous
cell carcinoma)
Transitional Cell Carcinoma (Transitional
cell carcinoma)
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Pathology - Prostate Cancer - Pathology Form - Biopsy - 2019353v3.0
Undifferentiated Carcinoma, Not
Otherwise Specified (Undifferentiated
carcinoma, NOS)
Urothelial Primary In Prostate (Urothelial
primary in prostate)
Histologic Type, Other Name
Histologic Type, Variant
Adenosquamous Carcinoma
(Adenosquamous carcinoma)
Prostatic Duct Adenocarcinoma (Ductal
carcinoma)
Mucinous (colloid) Adenocarcinoma
(Mucinous adenocarcinoma)
Other, Specify (Other, specify)
Sarcomatoid Carcinoma (Sarcomatoid
carcinoma)
Signet Ring Cell Carcinoma (Signet ring
cell carcinoma)
Small Cell Carcinoma (Small cell
carcinoma)
Squamous Cell Carcinoma (Squamous
cell carcinoma)
Histologic Type, Other Variant
Histologic Type, Variant Percent
Histologic Type, Variant Percent
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Fallopian Tube Cancer NCT00262847 Pre-Study - GOG-
0218 Pre-Treatment Summary Form - 2304053v3.0
GOG-0218 Pre-Treatment Summary Form
Carboplatin and Paclitaxel With or Without Bevacizumab in
Treating Patients With Stage III or Stage IV Ovarian
Epithelial, Primary Peritoneal Cancer, or Fallopian Tube
Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=F11AB4BB-
0589-56C9-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/8502
GOG-0218 Pre-Treatment Summary
Form
Header Module
Date form originally completed
Date form amended
Person amending form last name
Patient Initials
Patient Study ID
Person completing form, last name
Non-invasive Diagnostic Procedures
Chest X-Ray Result
Abnormal (Abnormal)
Normal (Normal)
Not Done (Not done)
Date of Chest X-Ray
EKG Result
Abnormal (Abnormal)
Normal (Normal)
Not Done (Not done)
Date of EKG
MRI Result
Abnormal (Abnormal)
Normal (Normal)
Not Done (Not done)
Date of MRI
CT Result
Abnormal (Abnormal)
Normal (Normal)
Not Done (Not done)
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Date CT Scan
Other Procedure Performed
Abnormal (Abnormal)
Normal (Normal)
Not Done (Not done)
Abnormal, specify
Abnormal, specify
Abnormal, specify
Abnormal, specify
Abnormal, specify
Procedure Date
Does the patient have target lesions
Yes
No
Comments
Comments
Footer Module
Participating Group Code
Participating Group Protocol Number
Participating Group Patient ID
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Fallopian Tube Cancer NCT00262847 Pre-Study - GOG-0218 Pre-
Treatment Summary Form - 2304053v3.0
Pathology - Prostate Cancer - Pathology
Form - Metastatic Specimens - 2279630v3.0
Prostate Cancer - Pathology Form - Metastatic Specimens
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=D93A0F3F-
981F-266C-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/8504
Prostate Cancer - Pathology Form -
Metastatic Specimens
Crf Header
Coordinating Group Protocol No.
Coordinating Group Code
Protocol Title
Patient Study ID
Institution/Affiliate
Other Patient ID
Participating Group Code
Patient Name (initials acceptable)
Pathology: Form Administration
Person Completing Form
Are data amended? (If data are amended, please
circle in red when using paper form)
Yes
No
Pathology: Metastatic Specimen(s)
Does analysis of tissue show evidence of
therapeutic effects?
No (No)
Unknown (Unknown)
Yes (Yes)
Type of Therapy (If yes,)
Hormonal Therapy (Hormonal therapy)
Other (Other)
Radiation Therapy (Radiation therapy)
Other specify
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Metastatic Site(s)
Bone (Bone)
Brain (Brain)
Cns (excluding Brain) (CNS (excluding
brain))
Liver (Liver)
Lung (Lung)
Lymph Node (outside Pelvis) (Lymph
Node (outside pelvis))
None (None)
Other, Specify (Other)
Pleura (Pleura)
Soft Tissue (Soft tissue)
Bone specify
Lymph Nodes specify
Other specify
Type of Procedure
Fine Needle Aspiration (Fine needle
aspiration)
Needle Biopsy (Needle biopsy)
Open Biopsy (Open biopsy)
Other Specify (Other)
Other specify
Biopsy Date
Other Malignancy
Indeterminate (Indeterminate)
No (No)
Unknown (Unknown)
Yes (Yes)
Specify Malignancy (If yes,)
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Fallopian Tube Cancer NCT00262847 Pathology
- GOG-0218 Pathology Form - 2303493v3.0
GOG-0218 Pathology Form
Carboplatin and Paclitaxel With or Without Bevacizumab in
Treating Patients With Stage III or Stage IV Ovarian
Epithelial, Primary Peritoneal Cancer, or Fallopian Tube
Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=F0DFFB93-
11B7-4CA5-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/8505
GOG-0218 Pathology Form
Header Module
Date form originally completed
Date form amended
Person amending form, last name
Patient Initials
Patient Study ID
Person Completing Form, Last Name
Primary Disease Assessment
Primary site
Cervix (Cervix)
Endometrium (Endometrium)
Fallopian Tube (Fallopian tube)
Gestational Trophoblastic Disease (GTD)
Other, Specify (Other)
Ovary (Ovary)
Peritoneum (Peritoneum)
Uterine Sarcoma (Uterine sarcoma)
Vagina (Vagina)
Vulva (Vulva)
Other, specify
Histologic type (check one)
Adenocarcinoma With Squamous
Differentiation (Adenocarcinoma with
squamous differentiation)
Adenocarcinoma, Unspecified
(Adenocarcinoma, unspecified)
Adenosquamous (Adenosquamous
carcinoma)
Benign (Benign NOS)
Carcinosarcoma/mesodermal (mullerian)
Mixed Tumor (Carcinosarcoma, MMT)
Clear Cell Carcinoma (Clear cell
carcinoma)
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Dysgerminoma (Dysgerminoma)
Endodermal Sinus Tumor (yolk Sac
Tumor) (Endodermal sinus tumor)
Endometrial Stromal Sarcoma
(Endometrial stromal sarcoma)
Endometrioid Adenocarcinoma
(Endometrioid adenocarcinoma)
Fibroma (Fibroma)
Germ Cell Tumor, Mixed (Germ cell
tumor, mixed)
Granulosa Cell Tumor (Granulosa cell
tumor)
Leiomyosarcoma (Leiomyosarcoma)
Mixed Epithelial Carcinoma, Specify
Components (Mixed epithelial
carcinoma)
Mucinous Adenocarcinoma (Mucinous
adenocarcinoma)
Mucinous Cystadenoma (benign)
(Mucinous cystadenoma)
Mucinous Tumor Of Low Malignant
Potential (Mucinous tumor of LMP)
Normal Tissue (Normal tissue)
Other, Specify (Other)
Serous Adenocarcinoma (Serous
adenocarcinoma)
Serous Cystadenoma (benign) (Serous
cystadenoma)
Serous Tumor Of Low Malignant
Potential (Serous tumor of LMP)
Sex-cord/stromal, Unclassified (Sex
cord/stromal, unclassified)
Small Cell Carcinoma (Small cell
carcinoma)
Squamous Cell Carcinoma (Squamous
cell carcinoma, invasive)
Teratoma, Immature, Specify
Components (Teratoma, immature)
Teratoma, Mature (Teratoma, mature)
Transitional Cell Carcinoma, Including
Brenner Tumor (Transitional cell
carcinoma)
Undifferentiated Carcinoma
(Undifferentiated carcinoma)
Villoglandular Carcinoma (Villoglandular
carcinoma)
Other, specify
Histologic grade (Differentiation)
Grade 1-well Differentiated (1)
Grade 2-moderately Differentiated (2)
Grade 3-poorly Differentiated (3)
Indeterminate (Indeterminate)
Not Applicable (Not applicable)
Grade Unknown (Unknown)
Method of evaluation
Biopsy (Biopsy)
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Fallopian Tube Cancer NCT00262847 Pathology - GOG-0218 Pathology
Form - 2303493v3.0
Cytology (Cytology)
Other (Other)
Surgery (Surgery)
Other specify
Date of evaluation
Specimen ID (of the blocks/slides)
Specimen site
Bladder Peritoneum (Bladder
peritoneum)
Bowel Peritoneum/serosa (Bowel
peritoneum/serosa)
Cervix (Cervix)
Corpus (Corpus)
Cul-de-sac (Cul-de-sac)
Diaphragm (Diaphragm)
Endometrium (Endometrium)
Fallopian Tube (Fallopian tube)
Lymph Node(s) (Lymph node)
Metastatic Site (Metastatic site)
Omentum (Omentum)
Other (Other)
Ovary (Ovary)
Paracolic Gutter Left (Paracolic gutter
left)
Paracolic Gutter Right (Paracolic gutter
right)
Pelvic Wall Left (Pelvic wall left)
Pelvic Wall Right (Pelvic wall right)
Peritoneum/uterine Serosa
(Peritoneum/uterine serosa)
Lymph node, specify (s)
Metastatic site, specify
Other, specify
Secondary Disease Assessment
Disease Status
Disease Continues To Be Present
Following Initial Treatment (Persistent)
Progression (Progression)
Recurrence/relapse (Recurrence)
Method of evaluation
Biopsy (Biopsy)
Cytology (Cytology)
Other (Other)
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Surgery (Surgery)
Other specify
Date of evaluation
Specimen ID (of the blocks/slides)
Specimen site
Bladder Peritoneum (Bladder
peritoneum)
Bowel Peritoneum/serosa (Bowel
peritoneum/serosa)
Cervix (Cervix)
Corpus (Corpus)
Cul-de-sac (Cul-de-sac)
Diaphragm (Diaphragm)
Endometrium (Endometrium)
Fallopian Tube (Fallopian tube)
Lymph Node(s) (Lymph node)
Metastatic Site (Metastatic site)
Omentum (Omentum)
Other (Other)
Ovary (Ovary)
Paracolic Gutter Left (Paracolic gutter
left)
Paracolic Gutter Right (Paracolic gutter
right)
Pelvic Wall Left (Pelvic wall left)
Pelvic Wall Right (Pelvic wall right)
Peritoneum/uterine Serosa
(Peritoneum/uterine serosa)
Lymph node, specify (s)
Metastatic site, specify
Other, specify
Footer Module
Participating Group Code
Participating Group Protocol Number
Participating Group Patient ID
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On-Study - Primary Brain Cancer - On-Study
Form Newly Diagnosed Patients - 2293729v3.0
Primary Brain Cancer - On-Study Form Newly Diagnosed
Patients
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=E51E77B9-
7E48-3A03-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/8506
Primary Brain Cancer - On-Study
Form Newly Diagnosed Patients
Crf Header
Coordinating Group Protocol No.
Coordinating Group Code
Protocol Title
Patient Study ID
Institution/Affiliate
Other Patient ID
Participating Group Code
Patient Name (initials acceptable)
Brain: Form Administration
Person Completing Form
Are data amended (If data are amended, please
circle in red when using paper form)
Yes
No
Brain: Disease Description
Date of Initial Diagnosis of Primary Tumor (MM
DD YYYY)
Basis of Diagnosis
Histology (Histology)
Imaging Only (Imaging only)
Infratentorial Involvement
No (No)
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Unknown (Unknown)
Yes (Yes)
Supratentorial Involvement
No (No)
Unknown (Unknown)
Yes (Yes)
Site of Lesion (check all that apply)
Aqueduct Of Sylvius (Aqueduct of
sylvius)
Basal Ganglia (Basal ganglia)
Brainstem (Brainstem)
Cauda Equina (Cauda equina)
Cavernous Sinus (Cavernous sinus)
Cerebellar Hemisphere (Cerebellar
hemisphere)
Cerebellar Peduncle (Cerebellar
peduncle)
Cerebellar Vermis (Cerebellar vermis)
Cerebellum (Cerebellum)
Cervical (Cervical)
Cisterna Magna (Cisterna magna)
Conus (Conus)
Corpus Callosum (Corpus callosum)
Dorsal Exophytic Brainstem (Dorsal
exophytic brainstem)
Fourth Ventricle (Fourth ventricle)
Frontal Lobe (Frontal)
Hypothalamus (Hypothalamus)
Lateral Ventricle (Lateral ventricle)
Leptomeningeal (Leptomeningeal)
Lumbar (Lumbar)
Medulla (Medulla)
Midbrain (Midbrain)
Occipital Lobe (Occipital)
Optic Chiasm (Optic chiasm)
Optic Nerve (Optic nerve)
Other, Specify (Other specify)
Parietal Lobe (Parietal)
Pineal (Pineal)
Pons (Pons)
Spinal Cord (c1 And Below) (Spinal cord)
Temporal Lobe (Temporal)
Thalamus (Thalamus)
Third Ventricle (Third ventricle)
Thoracic (Thoracic)
Other specify
Side
Both (Both)
Left (Left)
Right (Right)
Unknown (Unknown)
Histologic Type
9351-1 Craniopharyngioma,
Adamantinomatous (c75.2)
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(Adamantinomatous)
9401-3 Astrocytoma, Anaplastic (c71._)
(Anaplastic astrocytoma)
9392-3 Ependymoma, Anaplastic (c71._)
(Anaplastic ependymoma)
9505-3 Ganglioglioma, Anaplastic
(Anaplastic ganglioglioma)
Anaplastic Meningioma (Anaplastic
meningioma)
Anaplastic Oligoastrocytoma (Anaplastic
oligoastrocytoma)
9451-3 Oligodendroglioma, Anaplastic
(c71._) (Anaplastic oligodendroglioma)
9534-0 Angiomatous Meningioma
(Angiomatous meningioma)
9430-3 Astroblastoma (c71._)
(Astroblastoma)
9539-1 Atypical Meningioma (Atypical
meningioma)
9508-3 Atypical Teratoid-rhabdoid Tumor
(c71._) (Atypical teratoid/rhabdoid tumor)
9506-1 Central Neurocytoma (Central
neurocytoma)
Cerebellar Liponeurocytoma (Cerebellar
liponeurocytoma)
Chordoid Glioma Of The Third Ventricle
(Chordoid glioma of the third ventricle)
Chordoid Meningioma (Chordoid
meningioma)
Choriocarcinoma (Choriocarcinoma)
9390-3 Choroid Plexus Carcinoma
(c71.5) (Choroid plexus carcinoma)
9390-0 Choroid Plexus Papilloma, Nos
(c71.5) (Choroid plexus papilloma)
9538-1 Clear Cell Meningioma (Clear
cell meningioma)
9350-1 Craniopharyngioma (c75.2)
(Craniopharyngioma)
Desmoplastic Infantile
Astrocytoma/ganglioma (Desmoplastic
infantile astrocytoma/ganglioma)
Desmoplastic Medulloblastoma
(Desmoplastic medulloblastoma)
Diffuse Astrocytoma (Diffuse
astrocytoma)
9413-0 Dysembryoplastic Neuroepithelial
Tumor (Dysembryoplastic neuroepithelial
tumor)
9493-0 Dysplastic Gangliocytoma Of
Cerebellum (lhermitte-duclos) (c71.6)
(Dysplastic gangliocytoma of cerebellum)
Embryonal Carcinoma (Embryonal
carcinoma)
Ependymoblastoma
(Ependymoblastoma)
9391-3 Ependymoma, Nos (c71._)
(Ependymoma)
9420-3 Fibrillary Astrocytoma (c71._)
(Fibrillary astrocytoma)
9532-0 Fibrous Meningioma (Fibrous
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meningioma)
9492-0 Gangliocytoma (Gangliocytoma)
9505-1 Ganglioglioma, Nos
(Ganglioglioma)
9490-3 Ganglioneuroblastoma
(Ganglioneuroblastoma)
9411-3 Gemistocytic Astrocytoma
(c71._) (Gemistocytic astrocytoma)
9064-3 Germinoma (Germinoma)
9441-3 Giant Cell Glioblastoma (c71._)
(Giant cell glioblastoma)
9440-3 Glioblastoma, Nos (c71._)
(Glioblastoma)
9381-3 Gliomatosis Cerebri (c71._)
(Gliomatosis cerebri)
9442-3 Gliosarcoma (c71._)
(Gliosarcoma)
9580-0 Granular Cell Tumor, Nos
(Granular cell tumor)
High Grade Astrocytoma, Nos (High
grade astrocytoma NOS)
9474-3 Large Cell Medulloblastoma
(c71.6) (Large cell medulloblastoma)
Low Grade Astrocytoma, Nos (Low
grade astrocytoma NOS)
Lymphoplasmacyte-rich Meningioma
(Lymphoplasmacyte-rich meningioma)
9470-3 Medulloblastoma, Nos (c71.6)
(Medulloblastoma)
9501-3 Medulloepithelioma, Nos
(Medulloepithelioma)
9472-3 Medullomyoblastoma (c71.6)
(Medullomyoblastoma)
Melanotic Medulloblastoma (Melanotic
medulloblastoma)
9531-0 Meningothelial Meningioma
(Meningothelial meningioma)
Metaplastic Meningioma (Metaplastic
meningioma)
Microcystic Meningioma (Microcystic
meningioma)
Mixed Germ Cell Tumor (Mixed germ cell
tumors)
9394-1 Myxopapillary Ependymoma
(c72.0) (Myxopapillary ependymoma)
9500-3 Neuroblastoma, Nos
(Neuroblastoma)
Neuroblastomas Of The Adrenal Gland
And Sympathetic Nervous System
(Neuroblastomas of the adrenal gland
and sympathetic nervous system)
9522-3 Olfactory Neuroblastoma (c30.0)
(Olfactory neuroblastoma)
9523-3 Olfactory Neuroepithelioma
(c30.0) (Olfactory neuroepithelioma)
Oligoastrocytoma (Oligoastrocytoma)
9450-3 Oligodendroglioma, Nos (c71._)
(Oligodendroglioma)
Other, Specify (Other specify)
9352-1 Craniopharyngioma, Papillary
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(c75.2) (Papillary)
9538-3 Papillary Meningioma (Papillary
meningioma)
Paraganglioma Of The Filum Terminale
(Paraganglioma of the filum terminale)
9421-1 Pilocytic Astrocytoma (c71._)
(Pilocytic astrocytoma)
Pineal Parenchymal Tumor Of
Indeterminate Differentiation (Pineal
parenchymal tumor of indeterminate
differentiation)
9362-3 Pineoblastoma (c75.3)
(Pineoblastoma)
9361-1 Pineocytoma (c75.3)
(Pineocytoma)
9424-3 Pleomorphic Xanthoastrocytoma
(c71._) (Pleomorphic
xanthoastrocytoma)
9410-3 Protoplasmic Astrocytoma
(c71._) (Protoplasmic astrocytoma)
9533-0 Psammomatous Meningioma
(Psammomatous meningioma)
Rhabdoid Meningioma (Rhabdoid
meningioma)
Schwannoma (neurilemmoma,
Neurinoma) (Schwannoma)
Secretory Meningioma (Secretory
meningioma)
9384-1 Subependymal Giant Cell
Astrocytoma (c71._) (Subependymal
giant cell astrocytoma)
9383-1 Subependymoma (c71._)
(Subependymoma)
Supratentorial Primitive
Neuroectodermal Tumor (pnet)
(Supratentorial primitive
neuroectodermal tumor)
Teratoma (Teratoma)
9537-0 Transitional Meningioma
(Transitional meningioma)
Yolk Sac Tumor (Yolk sac tumor)
Other specify
Histologic Grade (WHO)
Moderately Differentiated (grade Ii)
(Moderately Differentiated (Grade II))
Poorly Differentiated (grade Iii) (Poorly
Differentiated (Grade III))
Undifferentiated (grade Iv)
(Undifferentiated (Grade IV))
Unknown (Unknown)
Well Differentiated (grade I) (Well
differentiated (Grade I))
CSF Cytology
Negative (Negative)
Not Done (Not Done)
Positive (Positive)
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Undetermined (Undetermined)
CSF Involvement
No (No)
Unknown (Unknown)
Yes (Yes)
Brain: Neurologic Function
Neurologic Function Status
Minor Neurologic Symptoms, Fully Active
At Home/work Without Assistance (Minor
neurologic symptoms, fully active at
home/work without assistance)
Moderate Neurologic Symptoms, Fully
Active At Home/work But Requires
Assistance (Moderate neurologic
symptoms, fully active at home/work but
requires assistance)
Moderate Neurologic Symptoms, Less
Than Fully Active At Home/work And
Requires Assitance (Moderate
neurologic symptoms, less than fully
active at home/work and requires
assistance)
No Neurologic Symptoms, Fully Active At
Home/work Without Assistance (No
neurologic symptoms, fully active at
home/work without assistance)
Severe Neurologic Symptoms, Totally
Inactive Requiring Complete Assistance
At Home Or Institution, Unable To Work
(Severe neurologic symptoms, totally
inactive requiring complete assistance at
home or institution, unable to work)
Brain: Prior Health History
Has the patient experienced an intracranial
hemorrhage?
Yes
No
Date of Most Recent (MM DD YYYY)
Has the patient experienced an intraocular
hemorrhage?
Yes
No
Date of Most Recent (MM DD YYYY)
Current Medical Conditions (currently
symptomatic or on medications for)
Cardiac Disease (Cardiac disease)
Cerebrovascular Disease
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(Cerebrovascular disease)
Deep Vein Thrombosis (Deep vein
thrombosis)
Diabetes (Diabetes)
Hypertension (Hypertension)
Other Malignancies, Specify (Other
malignancies specify)
Other, Specify (Other specify)
Other malignancies specify
Other specify
Brain: Concomitant Medications
Is the person receiving anti-convulsant
medication?
No (No)
Unknown (Unknown)
Yes (Yes)
Is this anti-convulsant medication enzyme-
inducing?
No (No)
Unknown (Unknown)
Yes (Yes)
Is the patient receiving corticosteroids?
No (No)
Unknown (Unknown)
Yes (Yes)
Agent Total Dose (per day)
Is the patient receiving other medications?
No (No)
Unknown (Unknown)
Yes (Yes)
Agent Name (If Yes,)
Agent Name (If Yes,)
Agent Name (If Yes,)
Agent Start Date (MM DD YYYY)
Agent Start Date (MM DD YYYY)
Agent Start Date (MM DD YYYY)
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Brain: Prior Surgical Treatment For
Primary Site
Primary Surgery Date (MM DD YYYY)
Extent of Resection (at primary site)
Biopsy (Biopsy)
Subtotal (Subtotal)
Total (gross) (Total (gross))
Enhancing residual disease?
Indeterminate (Indeterminate)
No (No)
Yes (Yes)
Non-enhancing residual disease?
Indeterminate (Indeterminate)
No (No)
Yes (Yes)
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Fallopian Tube Cancer NCT00262847 On-Study - GOG-0218
Primary Ovarian Cancer -  Medical History Form - 2480320v1.0
GOG-0218 Primary Ovarian Cancer -  Medical History
Form
Carboplatin and Paclitaxel With or Without Bevacizumab in
Treating Patients With Stage III or Stage IV Ovarian
Epithelial, Primary Peritoneal Cancer, or Fallopian Tube
Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=12F90295-
11E7-7122-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/8507
GOG-0218 Primary Ovarian Cancer
-  Medical History Form
Header Module
Date form originally completed
Date form amended
Person amending form, last name
Patient Initials
Patient Study ID
Person Completing Form, Last Name
Ovarian: Disease Description
Ovarian: Findings From Primary Surgery
Ovarian: Post-operative Findings
Following Primary Surgery
Footer Module
Comments
COMMENTS
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On-Study - Lung Cancer - SCLC Extensive
On-Study Form - 2262596v3.0
Lung Cancer - SCLC Extensive On-Study Form
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=DE33769F-
8545-3C96-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/8511
Lung Cancer - SCLC Extensive On-
Study Form
Crf Header
Coordinating Group Protocol No.
Coordinating Group Code
Protocol Title
Patient Study ID
Institution/Affiliate
Other Patient ID
Participating Group Code
Patient Name (initials acceptable)
Lung: Pre-treatment Characteristics
Patient Height (cm)
Patient Weight (kg)
Body Surface Area (m^2)
Performance Status (check one)
Fully Active, Able To Carry On All Pre-
disease Performance Without
Restriction. (0)
Restricted In Physically Strenuous
Activity But Ambulatory And Able To
Carry Out Work Of A Light Or Sedentary
Nature, E.g., Light Housework, Office
Work. (1)
Ambulatory And Capable Of All Selfcare
But Unable To Carry Out Any Work
Activities. Up And About More Than 50%
Of Waking Hours. (2)
Capable Of Only Limited Selfcare,
Confined To Bed Or Chair More Than
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50% Of Waking Hours. (3)
Completely Disabled. Cannot Carry On
Any Selfcare. Totally Confined To Bed Or
Chair. (4)
Weight loss in previous six months (check one)
<5% Of Body Weight (< 5% of body
weight)
> Or = 20% Of Body Weight (> or = 20%
of body weight)
10 To <20% Of Body Weight (10 to <20%
of body weight)
5 To <10% Of Body Weight (5 to < 10%
of body weight)
Lung: Disease Description - Sclc
Is measurable disease present? (only applicable
in studies where there is residual disease at
baseline)
Yes
No
Is non-measurable disease present? (only
applicable in studies where there is residual
disease at baseline)
Yes
No
Degree of Involvement of Metastatic Sites (to be
included only if needed for stratification factor
verification)
Multiple Lesions In Multiple Organs
(Multiple lesions in multiple organs)
Multiple Lesions In Single Organ
(Multiple lesions in single site or organ)
Single Lesion In Single Organ (Single
lesion in single site or organ)
Is pleural effusion present?
Yes
No
Is it Malignant? (If yes,)
No (No)
Unknown (Unknown (not tapped))
Yes (Yes)
Units used for labs
Imperial (Imperial)
Scientific/international (S/I)
Albumin (g/dl)
Hemoglobin (g/dl)
Lactate Dehydrogenase (LDH) (U/L only collect if
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RT study)
Lactate Dehydrogenase ULN (U/L Provide
laboratory's upper limit of normal)
Lung: Prior Treatment - Extensive Sclc
Prior Surgery (Code "No" if incisional/needle
biopsy is the only prior surgery)
Yes
No
Prior Radiation Therapy
Yes
No
Prior Systemic Chemotherapy
Yes
No
Comments
Comments
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Fallopian Tube Cancer NCT00951496 Toxicity - GOG-
0252 Port Complications (Form PCF) - 2840248v1.0
GOG-0252 Port Complications (Form PCF)
Bevacizumab and Intravenous or Intraperitoneal
Chemotherapy in Treating Patients With Stage II, Stage III,
or Stage IV Ovarian Epithelial Cancer, Fallopian Tube
Cancer, or Primary Peritoneal Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=6362EF9C-
F4F7-7D80-E040-BB89AD433D31
All rights reserved. Please visit https://medical-data-
models.org/forms/8512
GOG-0252 Port Complications (Form
PCF)
Header Module
Date form originally completed
Date form amended
Person amending form, last name
Patient Initials
Patient Study ID
Person Completing Form, Last Name
Ovarian Cancer Surgery
Current Cycle Number
Date of complication
Port Complications
Were there complications related to the port
Yes
No
Were there complications related to the port
Abdominal Pain Sufficient To Prevent
Treatment (Abdominal pain sufficient to
prevent treatment)
Abscess In Abdomen Or Pelvis By Ct Or
Surgically Drained (Abscess in abdomen
or pelvis by CT or surgically drained)
Bowel Complication Not Requiring
Surgery (Bowel complication not
requiring surgery)
Bowel Complication Requiring Surgery
(Bowel complication requiring surgery)
Cellutitis Surrounding Port (Cellutitis
surrounding port)
Dyspnea With Ip Chemotherapy Infusion
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(Dyspnea with IP chemotherapy infusion)
Fever, Abdominal Pain, And
Hospitalization Suspected To Be
Peritonitis (Fever, abdominal pain, and
hospitalization suspected to be
peritonitis)
Leaking Of Ascites Or Chemotherapy
Out Vagina Or Wound (Leaking of
ascites or chemotherapy out vagina or
wound)
Reflux Of Fluid Or Leaking Of Fluid
Around Port Pocket (Reflux of fluid or
leaking of fluid around port pocket)
Removal Of Port Required (Removal of
port required)
Unable To Access Port With Huber
Needle (Unable to access port with
huber needle)
Unable To Infuse Ip Chemotherapy (i.e.,
Blocked Catheter) (Unable to infuse IP
chemotherapy (i.e., blocked catheter))
Cultures positive
Yes
No
Organism (was)
Access device replaced or revised
Yes
No
Was IP chemotherapy regimen stopped
prematurely
Yes
No
Was IP chemotherapy regimen stopped
prematurely
Abdominal Pain (Abdominal pain)
Bowel Complication (Bowel complication)
Disease Progression (Disease
progression)
Fluid Out Vagina Or Wound (Fluid out
vagina or wound)
Nausea/vomiting/dehydration
(Nausea/vomiting/dehydration)
Neuropathy (Neuropathy)
Other (Other)
Patient Refusal (Patient refusal)
Port Complication (Port complication)
Renal/metabolic (Renal/metabolic)
Grade
Attempted port replacement
Yes
No
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Other specify
Footer Module
Comments
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Follow-Up - USMCI 8214: Missed Visit (MV)
- 2883985v1.0
USMCI 8214: Missed Visit (MV){No longer part of CRFs for
this study}
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=6A8391E2-
F5F4-41D6-E040-BB89AD431721
All rights reserved. Please visit https://medical-data-
models.org/forms/8513
USMCI 8214: Missed Visit (MV)
Header Module
Visit
Baseline (Baseline)
Mo12fu (Mo12FU)
Mo15fu (Mo15FU)
Mo18fu (Mo18FU)
Mo21fu (Mo21FU)
Mo24fu (Mo24FU)
Mo30fu (Mo30FU)
Mo36fu (Mo36FU)
Mo3fu (Mo3FU)
Mo42fu (Mo42FU)
Mo48fu (Mo48FU)
Mo54fu (Mo54FU)
Mo60fu (Mo60FU)
Mo6fu (Mo6FU)
Mo9fu (Mo9FU)
Post Surgery (Post Surgery)
Post Surgery (6 Wks) (Post Surgery (6
wks))
Patient ID
Institution No.
Institution Name
Header
Missed Visit Date (originally scheduled date)
Reason patient missed visit (Mark only one)
Distance From Home To Clinical Site
(Distance from home to clinical site)
Health Reasons (Health reasons)
Other (Other)
Scheduling Difficulties (Scheduling
difficulties)
Other, specify
Footer Module
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Completed by
Date Form Completed
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Treatment - Soft Tissue Sarcoma -
Diagnostic Surgery Form - 2290700v3.0
Soft Tissue Sarcoma - Diagnostic Surgery Form
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=E298F5F1-
BEA2-0C9C-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/8514
Soft Tissue Sarcoma - Diagnostic
Surgery Form
Crf Header
Coordinating Group Protocol No.
Coordinating Group Code
Protocol Title
Patient Study ID
Institution/Affiliate
Other Patient ID
Participating Group Code
Patient Name (initials acceptable)
Sarcoma: Form Administration
Person Completing Form
Are data amended (If data are amended, please
circle in red when using paper form)
Yes
No
Soft Tissue Sarcoma: Summary Of
Diagnostic Surgery
Surgery Date (MM DD YYYY)
Site of Primary Surgery
Surgical Procedure Type
Amputation (Amputation)
Biopsy (Biopsy)
Cryosurgery (Cryosurgery)
En Bloc Resection (En bloc resection)
Intraepiphyseal Resection
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(Intraepiphyseal resection)
Intramural Resection, Gross Residual
Disease (Intramural resection, gross
residual disease)
Lymph Node Removal (Lymph node
removal)
Marginal Excision (Marginal excision)
Other, Specify (Other specify)
Radical Excision (Radical excision)
Wide Excision (Wide excision)
Other specify
Biopsy Type (If Biopsy,)
Excisional (Excisional)
Incisional (Incisional)
Large Bore Needle (Large bore needle)
Other, Specify (Other specify)
Trucut Needle (TruCut needle)
Other specify
Status of Primary Tumor
Not Recurrent, Resected, No Residual
Tumor (Not recurrent, resected, no
residual tumor)
Not Recurrent, Resected, Residual
Tumor (Not recurrent, resected, residual
tumor)
Recurrent (Recurrent)
Unresected (Unresected)
Tumor Location, Side
Both (Both)
Left (Left)
Right (Right)
Unknown (Unknown)
Dimension 1 (Longest)
Dimension 2 (cm)
Dimension 3 (cm)
Does the tumor involve the surgical margin
Yes
No
Distance from surgical margin (If No,)
Margins of surgical resection
All Margins Pathologically Negative (R0)
Microscopically Positive Margins Or
Microscopic Residual Disease (R1)
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Macroscopically Positive Margins Or
Gross Residual Disease (R2)
Histologic Grade, French System
Grade I (Grade I)
Grade Ii (Grade II)
Grade Iii (Grade III)
Is there lymphovascular invasion?
No (No)
Unknown (Unknown)
Yes (Yes)
Comments
Comments
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Lung Cancer NCT00107172 Follow-Up -
Z4032 Reports Form - 2220579v1.0
Z4032 Reports Form
Surgery With or Without Internal Radiation Therapy in
Treating Patients With Stage I Non-Small Cell Lung Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=F52FF219-
5A88-049B-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/8515
Z4032 Reports Form
Header Module
Visit
Day 0 (Day 0)
Month 1 (Month 1)
Month 12 (Month 12)
Month 18 (Month 18)
Month 24 (Month 24)
Month 3 (Month 3)
Month 30 (Month 30)
Month 36 (Month 36)
Month 48 (Month 48)
Month 6 (Month 6)
Month 60 (Month 60)
Registration (Registration)
Patient ID (Pt. ID issued during registration or
previously issued patient ID)
Institution ID
Patient Initials
Institution
Header
Assessment Date
CTSU reports
Abdominal Ct Report (Abdominal CT
Report)
Autopsy Report (Autopsy Report)
Chest Ct Report (Chest CT Report)
Death Report (Death Report)
Operative Report (Operative Report)
Other (Other)
Pathology Report (Pathology Report)
Pet Report (PET Report)
Pft Report (PFT Report)
Staple Line Cytology Report (Staple Line
Cytology Report)
Other, specify
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Lung Cancer NCT00107172 Quality of Life - Z4032 UCSD
- Shortness of Breath Questionnaire - 2306605v3.0
Z4032 UCSD - Shortness of Breath Questionnaire
Surgery With or Without Internal Radiation Therapy in
Treating Patients With Stage I Non-Small Cell Lung Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=F21FBFC2-
16CA-105F-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/8516
Z4032 UCSD - Shortness of Breath
Questionnaire
Header Module
Visit
Month 12 (Month 12)
Month 24 (Month 24)
Month 3 (Month 3)
Registration (Registration)
Patient ID (Pt. ID issued during registration or
previously issued Patient ID)
Institution ID
Patient Initials
Institution
How Short Of Breath Do You Get
At rest
Not At All (0)
1 (1)
2 (2)
3 (3)
4 (4)
Maximum (5)
Walking on a level at your own pace
Not At All (0)
1 (1)
2 (2)
3 (3)
4 (4)
Maximum (5)
Walking on a level with others your age
Not At All (0)
1 (1)
2 (2)
3 (3)
4 (4)
Maximum (5)
Walking up a hill
Not At All (0)
1 (1)
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2 (2)
3 (3)
4 (4)
Maximum (5)
Walking up stairs
Not At All (0)
1 (1)
2 (2)
3 (3)
4 (4)
Maximum (5)
While eating
Not At All (0)
1 (1)
2 (2)
3 (3)
4 (4)
Maximum (5)
Standing up from a chair
Not At All (0)
1 (1)
2 (2)
3 (3)
4 (4)
Maximum (5)
Brushing teeth
Not At All (0)
1 (1)
2 (2)
3 (3)
4 (4)
Maximum (5)
Shaving and/or brushing hair
Not At All (0)
1 (1)
2 (2)
3 (3)
4 (4)
Maximum (5)
Showering/bathing
Not At All (0)
1 (1)
2 (2)
3 (3)
4 (4)
Maximum (5)
Dressing
Not At All (0)
1 (1)
2 (2)
3 (3)
4 (4)
Maximum (5)
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Picking up and straightening
Not At All (0)
1 (1)
2 (2)
3 (3)
4 (4)
Maximum (5)
Doing dishes
Not At All (0)
1 (1)
2 (2)
3 (3)
4 (4)
Maximum (5)
Sweeping/vacuuming
Not At All (0)
1 (1)
2 (2)
3 (3)
4 (4)
Maximum (5)
Making bed
Not At All (0)
1 (1)
2 (2)
3 (3)
4 (4)
Maximum (5)
Shopping
Not At All (0)
1 (1)
2 (2)
3 (3)
4 (4)
Maximum (5)
Doing laundry
Not At All (0)
1 (1)
2 (2)
3 (3)
4 (4)
Maximum (5)
Washing car
Not At All (0)
1 (1)
2 (2)
3 (3)
4 (4)
Maximum (5)
Mowing lawn
Not At All (0)
1 (1)
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2 (2)
3 (3)
4 (4)
Maximum (5)
Watering lawn
Not At All (0)
1 (1)
2 (2)
3 (3)
4 (4)
Maximum (5)
Sexual activities
Not At All (0)
1 (1)
2 (2)
3 (3)
4 (4)
Maximum (5)
How Much Do These Limit Your Daily Life
Shortness of breath
Not At All (0)
1 (1)
2 (2)
3 (3)
4 (4)
Maximum (5)
Fear of "hurting myself" by overexerting
Not At All (0)
1 (1)
2 (2)
3 (3)
4 (4)
Maximum (5)
Fear of shortness of breath
Not At All (0)
1 (1)
2 (2)
3 (3)
4 (4)
Maximum (5)
Footer Module
Date Form Completed
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On-Study - Lung Cancer - SCLC Second
Line On-Study Form - 2262433v3.0
Lung Cancer - SCLC Second Line On-Study Form
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=DE3366B5-
6F98-3BBE-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/8519
Lung Cancer - SCLC Second Line
On-Study Form
Crf Header
Coordinating Group Protocol No.
Coordinating Group Code
Protocol Title
Patient Study ID
Institution/Affiliate
Other Patient ID
Participating Group Code
Patient Name (initials acceptable)
Lung: Pre-treatment Characteristics
Patient Height (cm)
Patient Weight (kg)
Body Surface Area (m^2)
Performance Status (check one)
Fully Active, Able To Carry On All Pre-
disease Performance Without
Restriction. (0)
Restricted In Physically Strenuous
Activity But Ambulatory And Able To
Carry Out Work Of A Light Or Sedentary
Nature, E.g., Light Housework, Office
Work. (1)
Ambulatory And Capable Of All Selfcare
But Unable To Carry Out Any Work
Activities. Up And About More Than 50%
Of Waking Hours. (2)
Capable Of Only Limited Selfcare,
Confined To Bed Or Chair More Than
1 / 3
50% Of Waking Hours. (3)
Completely Disabled. Cannot Carry On
Any Selfcare. Totally Confined To Bed Or
Chair. (4)
Weight loss in previous six months (check one)
<5% Of Body Weight (< 5% of body
weight)
> Or = 20% Of Body Weight (> or = 20%
of body weight)
10 To <20% Of Body Weight (10 to <20%
of body weight)
5 To <10% Of Body Weight (5 to < 10%
of body weight)
Lung: Disease Description - Sclc
Is measurable disease present? (only applicable
in studies where there is residual disease at
baseline)
Yes
No
Is non-measurable disease present? (only
applicable in studies where there is residual
disease at baseline)
Yes
No
Degree of Involvement of Metastatic Sites (to be
included only if needed for stratification factor
verification)
Multiple Lesions In Multiple Organs
(Multiple lesions in multiple organs)
Multiple Lesions In Single Organ
(Multiple lesions in single site or organ)
Single Lesion In Single Organ (Single
lesion in single site or organ)
Is pleural effusion present?
Yes
No
Is it Malignant? (If yes,)
No (No)
Unknown (Unknown (not tapped))
Yes (Yes)
Units used for labs
Imperial (Imperial)
Scientific/international (S/I)
Albumin (g/dl)
Hemoglobin (g/dl)
Lactate Dehydrogenase (LDH) (U/L only collect if
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RT study)
Lactate Dehydrogenase ULN (U/L Provide
laboratory's upper limit of normal)
Lung: Prior Treatment - 2nd Line
Prior Surgery (Code "No" if incisional/needle
biopsy is the only prior surgery)
Yes
No
Prior Radiation Therapy
Yes
No
Prior Systemic Chemotherapy
Yes
No
Agent Name
Agent Start Date
Agent End Date
Agent Total Cumulative Dose
Units
Overall Response Duration (weeks)
Comments
Comments
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Treatment - Multiple Myeloma - Transplant
Engraftment Form - 2273076v3.0
Multiple Myeloma - Transplant Engraftment Form
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=D677D5D4-
54B0-04AF-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/8520
Multiple Myeloma - Transplant
Engraftment Form
Crf Header
Coordinating Group Protocol No.
Coordinating Group Code
Protocol Title
Patient Study ID
Institution/Affiliate
Other Patient ID
Participating Group Code
Patient Name (initials acceptable)
Myeloma: Form Administration
Person Completing Form
Are data amended? (If data are amended, please
circle in red when using paper form)
Yes
No
Myeloma Transplant: Engraftment
Date of Evaluation
Was patient neutropenic prior to therapy
No (No)
Unknown (Unknown)
Yes (Yes)
Did absolute neutrophil count (ANC) fall below
500 following therapy (If no,)
No (No)
Unknown (Unknown)
Yes (Yes)
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Did patient engraft neutrophils (ANC >=500 for 3
consecutive days)
No (No)
Unknown (Unknown)
Yes (Yes)
Neutrophil Engraftment Date (If yes, Note:
Record the first date of 3 consecutive days of
ANC >=500)
Was patient thrombocytopenic prior to therapy
No (No)
Unknown (Unknown)
Yes (Yes)
Did patient become thrombocytopenic following
therapy (If no,)
No (No)
Unknown (Unknown)
Yes (Yes)
Did patient reconstitute platelets where the
patient did not receive platelet transfusion for the
next 7 days (platelets >= 20,000 for 2 consecutive
days)
No (No)
Unknown (Unknown)
Yes (Yes)
Platelet Engraftment Date (If yes, Note: Record
the first date of 2 consecutive days of platelets
>=20,000)
Was patient lymphopenic prior to therapy
No (No)
Unknown (Unknown)
Yes (Yes)
Did patient become lymphopenic following
therapy (If no,)
No (No)
Unknown (Unknown)
Yes (Yes)
Did patient reconstitute lymphocytes
(lymphocytes >= 20,000 for 2 consecutive days)
No (No)
Unknown (Unknown)
Yes (Yes)
Lymphocyte Engraftment Date (If yes, Note:
Record the first date of 2 consecutive days of
lymphocytes >= 20,000)
Did the patient experience late graft failure (follow
definition per protocol)
No (No)
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Unknown (Unknown)
Yes (Yes)
Date of Late Graft Failure (If yes,)
Comments
Comments
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Lung Cancer NCT00107172 Treatment -
Z4032 Surgical Report - 2306402v3.0
Z4032 Surgical Report
Surgery With or Without Internal Radiation Therapy in
Treating Patients With Stage I Non-Small Cell Lung Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=F20EC551-
2CBE-6F47-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/8521
Z4032 Surgical Report
Header Module
Visit
Day 0 (Day 0)
Patient ID (Patient ID issued during registration or
previously issued Patient ID.)
Patient Initials
Institution No.
Institution Name
Header
Did the patient have surgery as part of protocol
treatment?
No (No)
Unknown (Not done)
Yes (Yes)
Date of Surgery
Area (Mark all that apply)
Lingula (Lingula)
Lower Lobe (left) (LLL)
Upper Lobe (left) (LUL)
Lower Lobe (right) (RLL)
Middle Lobe (right) (RML)
Upper Lobe (right) (RUL)
Surgical Approach
Thoracotomy (Thoracotomy)
Thoracoscopy / Video-assisted (vats)
(Video-Assisted)
Most Extensive Primary Surgery
Segmentectomy (Formal
segmentectomy)
Exploration, No Resection (No resection)
Wedge Resection (Wedge resection)
ASA Class
Healthy Patient, No Medical Problems (I)
1 / 2
Mild Systemic Disease (II)
Severe Systemic Disease, But Not
Incapaitating (III)
Severe Systemic Disease That Is A
Constant Threat To Life (IV)
Moribund, Not Expected To Live 24
Hours Irrespective Of Operation (V)
Time patient entered OR (use 24 hr clock: 00:00-
23:59)
Skin Incision Start Time (use 24 hr clock: 00:00-
23:59)
Skin Incision Stop Time (use 24 hr clock: 00:00-
23:59)
Time patient exited OR (use 24 hr clock: 00:00-
23:59)
Footer Module
Surgeon Name
Completed by
Date Form Completed
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Lung Cancer NCT00107172 Follow-Up -
Z4032 Extended Follow-up - 2306877v3.0
Z4032 Extended Follow-up
Surgery With or Without Internal Radiation Therapy in
Treating Patients With Stage I Non-Small Cell Lung Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=F2209346-
6E1D-1A8A-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
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Z4032 Extended Follow-up
Header Module
Visit
Month 1 (Month 1)
Month 12 (Month 12)
Month 18 (Month 18)
Month 24 (Month 24)
Month 3 (Month 3)
Month 30 (Month 30)
Month 36 (Month 36)
Month 48 (Month 48)
Month 6 (Month 6)
Month 60 (Month 60)
Patient ID (Patient ID issued during registration or
previously issued Patient ID.)
Patient Initials
Institution No.
Institution
Header
Vital status
Alive (Alive)
Dead (Dead)
Date of Last Contact or Death
Primary Cause of Death (If deceased,)
Due To Other Cause (Other)
Due To This Disease (This cancer)
Due To Protocol Treatment (Treatment
related to this protocol)
Describe cause of death
Has the patient received any non-protocol cancer
therapy during this reporting period?
Yes
No
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Reason non-protocol cancer therapy began
Adjuvant Cancer Therapy (Adjuvant
cancer therapy for primary cancer)
Treatment For New Primary (Treatment
for new primary or recurrence)
Other, specify
Chest CT Scan performed (submit report on CT
Shuttle Form)
Yes
No
Date of CT Scan
Chest CT Scan Result
No Evidence Of Recurrence (No
evidence of recurrence)
Recurrent Cancer (Recurrent cancer)
Pft's
Date of Pulmonary Function Test (OR)
Check if test not required at this visit
Forced Expiratory Volume 1 (FEV1)
Forced Expiratory Volume 1 (%Predicted FEV1)
Carbon Monoxide Diffusion (DLCO)
Forced Vital Capacity (% predicted)
Notice Of First Recurrence (local,
Regional Or Distant)
Has the patient been diagnosed with first
recurrence since submission of the last follow-up
form?
Yes
No
Site of First Local Recurrence
Date of First Local Recurrence
Site of First Regional Recurrence
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Date of First Regional Recurrence
Site of First Distant Recurrence
Date of First Distant Recurrence
Notice Of New Primary
Area of Local Recurrence
At Staple Line (At staple line)
In Hilar Lymph Nodes (In hilar lymph
nodes)
Same Lobe But Away From Staple Line
(Same lobe but away from staple line)
Area of Regional Recurrence
Ipsilateral Pleura (Ipsilateral pleura)
Mediastinal Nodes (Mediastinal nodes)
Same Lung But Different Lobe (Same
lung but different lobe)
Has a biopsy been performed to confirm first
recurrence
Yes
No
Has a new primary cancer or MDS been
diagnosed that has not been previously reported?
Yes
No
Date of diagnosis
Site of New Primary
Footer Module
Date Form Completed
Completed by
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On-Study - Adult Soft Tissue Sarcoma - On-Study
Form Newly Diagnosed Patients - 2281236v3.0
Adult Soft Tissue Sarcoma - On-Study Form Newly
Diagnosed Patients
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=E208B008-
C978-135C-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
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Adult Soft Tissue Sarcoma - On-
Study Form Newly Diagnosed
Patients
Crf Header
Coordinating Group Protocol No.
Coordinating Group Code
Protocol Title
Patient Study ID
Institution/Affiliate
Other Patient ID
Participating Group Code
Patient Name (initials acceptable)
Sarcoma: Form Administration
Person Completing Form
Are data amended (If data are amended, please
circle in red when using paper form)
Yes
No
Adult Soft Tissue Sarcoma: Disease
Description
Date of Initial Pathologic Diagnosis (MM DD
YYYY)
Primary Site
Eye And Orbit (Eye and orbit)
Gastrointestinal Stromal Tumor (gist)
(Gastrointestinal stromal tumor (GIST))
Genitourinary (Genitourinary)
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Intra-abdominal (Intra-abdominal)
Lower Extremity (Lower extremity)
Non-parameningeal Head And Neck
(Non-parameningeal head and neck)
Other Specify (Other specify)
Parameningeal (Parameningeal)
Thorax (Thorax)
Trunk (Trunk)
Upper Extremity (Upper extremity)
Uterine Sarcoma (Uterine sarcoma)
Other specify
Tumor Location, Side
Both (Both)
Left (Left)
Right (Right)
Unknown (Unknown)
Metastatic Site (s - For advanced studies, - check
all that apply)
Ascites (Ascites)
Bone (Bone)
Bone Marrow (Bone marrow)
Cerebrospinal Fluid (csf) (Cerebrospinal
fluid (CSF))
Cns/brain (CNS/Brain)
Distant Nodes, Specify (Distant Nodes)
Liver (Liver)
Lung (Lung)
Other Specify (Other)
Peritoneal Nodules (Peritoneal nodules)
Pleural Effusion (Pleural effusion)
Pleural Nodules (Pleural nodules)
Soft Tissue (Soft tissue)
Distant nodes specify
Other specify
Dimension 1 (Longest)
Dimension 2 (cm)
Dimension 3 (cm)
Status of Primary Tumor
Not Recurrent, Resected, No Residual
Tumor (Not recurrent, resected, no
residual tumor)
Not Recurrent, Resected, Residual
Tumor (Not recurrent, resected, residual
tumor)
Recurrent (Recurrent)
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Unresected (Unresected)
Histologic Type (check all that apply)
Alveolar Rhabdomyosarcoma (Alveolar
rhabdomyosarcoma)
Alveolar Soft Part Sarcoma (Alveolar soft
part sarcoma)
Angiosarcoma (Angiosarcoma)
Botryoid Rhabdomyosarcoma (Botryoid
rhabdomyosarcoma)
Clear Cell Sarcoma (mmsp) (Clear cell
sarcoma (MMSP))
Dedifferentiated Liposarcoma
(Dedifferentiated liposarcoma)
Dermatofibrosarcoma Protuberans
(Dermatofibrosarcoma protuberans)
Desmoplastic Small Cell Tumor
(Desmoplastic small cell tumor)
Embryonal Rhabdomyosarcoma
(Embryonal rhabdomyosarcoma)
Endometrial Stromal Sarcoma
(Endometrial stromal sarcoma)
Epithelioid Hemagioendothelioma
(Epithelioid hemangioendothelioma)
Epithelioid Sarcoma (Epithelioid
sarcoma)
Extraskeletal Ewing's/pnet (Extraskeletal
Ewing's/PNET)
Extraskeletal Mesenchymal
Chondrosarcoma (Extraskeletal
mesenchymal chondrosarcoma)
Extraskeletal Myxoid Chondrosarcoma
(Extraskeletal myxoid chondrosarcoma)
Extraskeletal Osteosarcoma
(Extraskeletal osteosarcoma)
Fibrosarcoma (Fibrosarcoma)
Gastrointestinal Stromal Tumor (gist)
(Gastrointestinal stromal tumor (GIST))
Kaposi Sarcoma (Kaposi sarcoma)
Leiomyosarcoma (Leiomyosarcoma)
Liposarcoma Nos (Liposarcoma NOS)
Malignant Mesenchymoma (Malignant
mesenchymoma)
Maligant Peripheral Nerve Sheath Tumor
(Malignant peripheral nerve sheath
tumor)
Myxofibrosarcoma (Myxofibrosarcoma)
Myxoid Liposarcoma (Myxoid
liposarcoma)
Other Specify (Other specify)
Pleomorphic Liposarcoma (Pleomorphic
liposarcoma)
Pleomorphic Rhabdomyosarcoma
(Pleomorphic rhabdomyosarcoma)
Rhabdomyosarcoma Nos
(Rhabdomyosarcoma NOS)
Sarcoma Nos (Sarcoma NOS)
Solitary Fibrous
Tumor/hemangiopericytoma (Solitary
fibrous tumor/hemangiopericytoma)
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Spindle Cell Rhabdomyosarcoma
(Spindle cell rhabdomyosarcoma)
Synovial Sarcoma (Synovial sarcoma)
Undifferentiated Pleomorphic
Sarcoma/"mfh" (Undifferentiated
pleomorphic sarcoma/"MFH")
Uterine Carcinosarcoma (mixed
Mesodermal Sarcoma) (Uterine
carcinosarcoma (mixed mesodermal
sarcoma))
Uterine Leiomyosarcoma (Uterine
leiomyosarcoma)
Uterine Sarcoma Nos (Uterine sarcoma
NOS)
Well Differentiated Liposarcoma (Well
differentiated liposarcoma)
Other specify
Histologic Subtype (specify)
Histologic Grade, French System (check highest
grade)
Grade I (Grade I)
Grade Ii (Grade II)
Grade Iii (Grade III)
Unknown (Unknown)
Pathologic T Stage (Tumor Staging use the AJCC
staging system specified in the protocol)
Pt0 (pT0)
Pt1 (pT1)
Pt2 (pT2)
Pt3 (pT3)
Pt4 (pT4)
Ptx (pTX)
Pathologic N Stage
Pn0 (pN0)
Pn1 (pN1)
Pn2 (pN2)
Pn3 (pN3)
Pnx (pNX)
Pathologic M Stage
Pm0 (pM0)
Pm1 (pM1)
Pmx (pMX)
Clinical T Stage (Note: Provide Clinical staging
only if Pathologic staging is unavailable.)
T0 (T0)
T1 (T1)
T2 (T2)
T3 (T3)
T4 (T4)
Tx (TX)
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Clinical N Stage
N0 (N0)
N1 (N1)
N2 (N2)
N3 (N3)
Nx (NX)
Clinical M Stage
M0 (M0)
M1 (M1)
Mx (MX)
Stage
I (I)
Iia (IIA)
Iib (IIB)
Iic (IIC)
Iii (III)
Iv (IV)
Depth (cm)
Adult Soft Tissue Sarcoma: Prior Health
History
Prior Radiation Therapy for Other Disease?
No (No)
Unknown (Unknown)
Yes (Yes)
Prior Radiation Therapy Site (If Yes,)
Is there a history of prior radiation therapy to the
primary site?
No (No)
Unknown (Unknown)
Yes (Yes)
Comments
Comments
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Lung Cancer NCT00107172 Quality of Life -
Z4032 Quality of Life - 2265031v3.0
Z4032 Quality of Life
Surgery With or Without Internal Radiation Therapy in
Treating Patients With Stage I Non-Small Cell Lung Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=F313536F-
52BF-2260-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
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Z4032 Quality of Life
Header Module
Visit
Month 12 (Month 12)
Month 24 (Month 24)
Month 3 (Month 3)
Registration (Registration)
Patient ID (Pt. ID issued during registration or
previously issued Patient ID)
Institution ID
Patient Initials
Institution
Header
In general, would you say your health is
Excellent (Excellent)
Fair (Fair)
Good (Good)
Poor (Poor)
Very Good (Very good)
Compared to one year ago, how would you rate
your health in general now
About The Same As One Year Ago
(About the same as one year ago)
Much Better Now Than One Year Ago
(Much better now than one year ago)
Much Worse Now Than One Year Ago
(Much worse now than one year ago)
Somewhat Better Now Than One Year
Ago (Somewhat better now than one
year ago)
Somewhat Worse Now Than One Year
Ago (Somewhat worse now than one
year ago)
Module Question 3
Vigorous activities, such as running, lifting heavy
objects, participating in strenuous sports
No, Not Limited At All (No, not limited at
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all)
Yes, Limited A Little (Yes, limited a little)
Yes, Limited A Lot (Yes, limited a lot)
Moderate activities, such as moving a table,
pushing a vacuum cleaner, bowling, or playing
golf
No, Not Limited At All (No, not limited at
all)
Yes, Limited A Little (Yes, limited a little)
Yes, Limited A Lot (Yes, limited a lot)
Lifting or carrying groceries
No, Not Limited At All (No, not limited at
all)
Yes, Limited A Little (Yes, limited a little)
Yes, Limited A Lot (Yes, limited a lot)
Climbing several flights of stairs
No, Not Limited At All (No, not limited at
all)
Yes, Limited A Little (Yes, limited a little)
Yes, Limited A Lot (Yes, limited a lot)
Climbing one flight of stairs
No, Not Limited At All (No, not limited at
all)
Yes, Limited A Little (Yes, limited a little)
Yes, Limited A Lot (Yes, limited a lot)
Bending, kneeling or stooping
No, Not Limited At All (No, not limited at
all)
Yes, Limited A Little (Yes, limited a little)
Yes, Limited A Lot (Yes, limited a lot)
Walking more than a mile
No, Not Limited At All (No, not limited at
all)
Yes, Limited A Little (Yes, limited a little)
Yes, Limited A Lot (Yes, limited a lot)
Walking several blocks
No, Not Limited At All (No, not limited at
all)
Yes, Limited A Little (Yes, limited a little)
Yes, Limited A Lot (Yes, limited a lot)
Walking one block
No, Not Limited At All (No, not limited at
all)
Yes, Limited A Little (Yes, limited a little)
Yes, Limited A Lot (Yes, limited a lot)
Bathing or dressing yourself
No, Not Limited At All (No, not limited at
all)
Yes, Limited A Little (Yes, limited a little)
Yes, Limited A Lot (Yes, limited a lot)
2 / 6
Lung Cancer NCT00107172 Quality of Life - Z4032 Quality of Life -
2265031v3.0
Module Question 4
Cut down on the amount of time you spent on
work or other activities
Yes
No
Accomplished less than you would like
Yes
No
Were limited in the kind of work or other activities
Yes
No
Had difficulty performing the work or other
activities (for example, it took extra effort)
Yes
No
Module Question 5
Cut down on the amount of time you spent on
work or other activities
Yes
No
Accomplished less than you would like
Yes
No
Did work or other activities less carefully than
usual
Yes
No
During the past 4 weeks, to what extent has your
physical health or emotional problems interfered
with your normal social activities with family,
friends, neighbors, or groups
Extremely (Extremely)
Moderately (Moderately)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Slightly (Slightly)
How much bodily pain have you had during the
past 4 weeks
Mild (Mild)
Moderate (Moderate)
None (None)
Severe (Severe)
Very Mild (Very mild)
Very Severe (Very severe)
During the past 4 weeks, how much did pain
interfere with your normal work (including both
work outside the home and housework)
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A Little Bit (A little bit)
Extremely (Extremely)
Moderately (Moderately)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Module Question 9
Did you feel full of pep
A Good Bit Of The Time (A good bit of
the time)
A Little Of The Time (A little of the time)
All Of The Time (All of the time)
Most Of The Time (Most of the time)
None Of The Time (None of the time)
Some Of The Time (Some of the time)
Have you been a very nervous person
A Good Bit Of The Time (A good bit of
the time)
A Little Of The Time (A little of the time)
All Of The Time (All of the time)
Most Of The Time (Most of the time)
None Of The Time (None of the time)
Some Of The Time (Some of the time)
Have you felt so down in the dumps that nothing
could cheer you up
A Good Bit Of The Time (A good bit of
the time)
A Little Of The Time (A little of the time)
All Of The Time (All of the time)
Most Of The Time (Most of the time)
None Of The Time (None of the time)
Some Of The Time (Some of the time)
Have you felt calm and peaceful
A Good Bit Of The Time (A good bit of
the time)
A Little Of The Time (A little of the time)
All Of The Time (All of the time)
Most Of The Time (Most of the time)
None Of The Time (None of the time)
Some Of The Time (Some of the time)
Did you have a lot of energy
A Good Bit Of The Time (A good bit of
the time)
A Little Of The Time (A little of the time)
All Of The Time (All of the time)
Most Of The Time (Most of the time)
None Of The Time (None of the time)
Some Of The Time (Some of the time)
Have you felt downhearted and blue
A Good Bit Of The Time (A good bit of
the time)
A Little Of The Time (A little of the time)
All Of The Time (All of the time)
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Most Of The Time (Most of the time)
None Of The Time (None of the time)
Some Of The Time (Some of the time)
Did you feel worn out
A Good Bit Of The Time (A good bit of
the time)
A Little Of The Time (A little of the time)
All Of The Time (All of the time)
Most Of The Time (Most of the time)
None Of The Time (None of the time)
Some Of The Time (Some of the time)
Have you been a happy person
A Good Bit Of The Time (A good bit of
the time)
A Little Of The Time (A little of the time)
All Of The Time (All of the time)
Most Of The Time (Most of the time)
None Of The Time (None of the time)
Some Of The Time (Some of the time)
Did you feel tired
A Good Bit Of The Time (A good bit of
the time)
A Little Of The Time (A little of the time)
All Of The Time (All of the time)
Most Of The Time (Most of the time)
None Of The Time (None of the time)
Some Of The Time (Some of the time)
During the past 4 weeks, how much of the time
has your physical health or emotional problems
interfered with your social activities (like visiting
friends, relatives, etc.)
A Little Of The Time (A little of the time)
All Of The Time (All of the time)
Most Of The Time (Most of the time)
None Of The Time (None of the time)
Some Of The Time (Some of the time)
Module Question 11
I seem to get sick a little easier than other people
Definitely False (Definitely false)
Definitely True (Definitely true)
Don't Know (Don't know)
Mostly False (Mostly false)
Mostly True (Mostly true)
I am as healthy as anybody I know
Definitely False (Definitely false)
Definitely True (Definitely true)
Don't Know (Don't know)
Mostly False (Mostly false)
Mostly True (Mostly true)
I expect my health to get worse
Definitely False (Definitely false)
Definitely True (Definitely true)
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Don't Know (Don't know)
Mostly False (Mostly false)
Mostly True (Mostly true)
My health is excellent
Definitely False (Definitely false)
Definitely True (Definitely true)
Don't Know (Don't know)
Mostly False (Mostly false)
Mostly True (Mostly true)
Footer Module
Date Form Completed
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On-Study - Breast Cancer - Advanced
Disease On-Study Form - 2262184v3.0
Breast Cancer - Advanced Disease On-Study Form
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=DE332B4F-
910E-38FA-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/8526
Breast Cancer - Advanced Disease
On-Study Form
Crf Header
Coordinating Group Protocol No.
Coordinating Group Code
Protocol Title
Patient Study ID
Institution/Affiliate
Other Patient ID
Participating Group Code
Patient Name (initials acceptable)
Breast: Form Administration
Person Completing Form
Are data amended? (If data are amended, please
circle in red when using paper form)
Yes
No
Breast: Patient Characteristics
Menopausal Status (check one)
Above Categories Not Applicable And
Age <50 (Above categories not
applicable AND Age < 50)
Above Categories Not Applicable And
Age >= 50 (Above categories not
applicable AND Age >= 50)
Post (prior Bilateral Ovariectomy Or >12
Mo Since Lmp With No Prior
Hysterectomy And Not Currently
Receiving Therapy With Lh-rh Analogs
[e.g., Zoladex]) (Post (prior bilateral
ovariectomy OR >12 mo since LMP with
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no prior hysterectomy AND not currently
receiving therapy with LH-RH analogs
(e.g., Zoladex)))
Pre (<6 Mo Since Lmp And No Prior
Bilateral Ovariectomy And Not On
Estrogen Replacement) (Pre (<6 mo
since LMP AND no prior bilateral
ovariectomy AND not on estrogen
replacement))
Breast: Advanced Disease Description
ER Status (If measured in fmols/mg cytosol
protein >=10 is positive. If other measures are
used apply institutional standards; borderline
results should be reported as positive.)
Negative (Negative)
Positive (Positive)
Unknown (Unknown)
ER Timing, Other, specify (If)
PgR Status
Negative (Negative)
Positive (Positive)
Unknown (Unknown)
Timing of Assay
At Recurrence (At recurrence)
Initial Diagnosis (Initial diagnosis)
Other (Other)
Timing of Assay
At Recurrence (At recurrence)
Initial Diagnosis (Initial diagnosis)
Other (Other)
PgR Timing, Other, specify (If)
Date of Initial Diagnosis of Primary Tumor
Date Progressive or Metastatic Disease First
Diagnosed (Unless otherwise specified per
protocol, the diagnosis can be radiologically or
pathologically measured.)
Breast: Site(s) Of Progression
Sites of Progression (check all that apply)
Bone (Bone)
Bone Marrow (Bone marrow)
Brain (Brain)
Distant Lymph Nodes (Distant nodes)
Distant Skin/subcutaneous Tissue
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(Distant skin/subcutaneous tissue)
Other Site(s) (First Other, specify)
Ipsilateral Supraclavicular Nodes
(Ipsilateral supraclavicular nodes)
Liver (Liver)
Local-regional (including Ipsilateral
Breast; Chest Wall; Axillary, Internal
Mammary, And Infraclavicular Nodes;
Local-regional Skin And Subcutaneous
Tissue) (Local-regional)
Lung, Nos (Lung)
Contralateral Breast (Opposite breast)
Other Cns (Other CNS)
Pleura (Pleura)
Other Site(s) (Second Other, specify)
If sites other than specified, Indicate Name
If sites other than specified, Indicate Name
Breast: Advanced Treatment - Prior
Systemic Therapy
Prior Adjuvant Hormonal Therapy? (do not
include steroids given with chemotherapy)
Yes
No
Prior Hormonal Therapy for Metastasis or
Recurrence? (do not include steroids given with
chemotherapy)
Yes
No
Prior Adjuvant Chemotherapy? (include pre-op
chemotherapy at diagnosis)
Yes
No
Prior Chemotherapy for Metastasis or
Recurrence?
Yes
No
Prior Adjuvant High Dose
Chemotherapy/Autologous Stem Cell Transplant
(HDC/ASCT)
Yes
No
Prior HDC/ASCT for Metastasis or Recurrence?
Yes
No
Prior Adjuvant Immunotherapy?
Yes
No
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Prior Immunotherapy for Metastasis or
Recurrence?
Yes
No
Prior Adjuvant Other Therapy?
Yes
No
Prior Other Therapy for Metastasis or
Recurrence?
Yes
No
Breast: Advanced Prior Treatment -
Systemic Regimens
Prior Treatment Regimen Name(s)
Prior Treatment Regimen Start Date
Prior Treatment Regimen End Date
Prior Treatment Regimen Type (Adjuvant, High
Dose)
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Response - Non-Hodgkins Lymphoma - Baseline
Disease Assessment Form - 2270115v3.0
Non-Hodgkin's Lymphoma - Baseline Disease Assessment
Form
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=D5EAA15D-
A849-71DB-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/8528
Non-Hodgkins Lymphoma - Baseline
Disease Assessment Form
Crf Header
Coordinating Group Protocol No.
Coordinating Group Code
Protocol Title
Patient Study ID
Institution/Affiliate
Other Patient ID
Participating Group Code
Patient Name (initials acceptable)
Lymphoma: Form Administration
Person Completing Form
Are data amended? (If data are amended, please
circle in red when using paper form)
Yes
No
Lymphoma: Dominant Nodes
Are there any dominant nodes
Yes
No
Lesion Number
Site of Lesion
Method of Evaluation (* use code below * Method
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of Evaluation Code)
Bone Scan (Bone Scan)
Chest X-ray (Chest X-ray)
Ct Scan (CT Scan)
Gallium Scan (Gallium scan)
Mri (MRI (NMR))
Other (Other)
Pet Scan (PET scan)
Spiral Ct Scan (Spiral CT Scan)
Ultrasound (Ultrasound)
Other Specify (If)
Greatest Perpendicular Measurements (cm)
Greatest Perpendicular Measurements (cm)
Product of Measurements (cm^2)
Date of Evaluation
Sum of Products of Measurements (cm^2)
Lymphoma: Nondominant Nodes
Are there any nondominant nodes
Yes
No
Lesion Number
Site of Lesion
Method of Evaluation (* use code below * Method
of Evaluation Code)
Bone Scan (Bone Scan)
Chest X-ray (Chest X-ray)
Ct Scan (CT Scan)
Gallium Scan (Gallium scan)
Mri (MRI (NMR))
Other (Other)
Pet Scan (PET scan)
Spiral Ct Scan (Spiral CT Scan)
Ultrasound (Ultrasound)
Other Specify (If)
Greatest Perpendicular Measurements (cm)
Greatest Perpendicular Measurements (cm)
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Product of Measurements (cm^2)
Date of Evaluation
Sum of Products of Measurements (cm^2)
Lymphoma: Measurable Hepatic/splenic
Nodules
Are there any measurable hepatic or splenic
nodules
Yes
No
Lesion Number
Site of Lesion
Method of Evaluation (* use code below * Method
of Evaluation Code)
Bone Scan (Bone Scan)
Chest X-ray (Chest X-ray)
Ct Scan (CT Scan)
Gallium Scan (Gallium scan)
Mri (MRI (NMR))
Other (Other)
Pet Scan (PET scan)
Spiral Ct Scan (Spiral CT Scan)
Ultrasound (Ultrasound)
Other Specify (If)
Greatest Perpendicular Measurements (cm)
Greatest Perpendicular Measurements (cm)
Product of Measurements (cm^2)
Date of Evaluation
Sum of Products of Measurements (cm^2)
Lymphoma: Non-measurable Lesions
Is non-measurable disease present?
Yes
No
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Lesion Number
Site of Lesion
Method of Evaluation (* use code below * Method
of Evaluation Code)
Bone Scan (Bone Scan)
Chest X-ray (Chest X-ray)
Ct Scan (CT Scan)
Gallium Scan (Gallium scan)
Mri (MRI (NMR))
Other (Other)
Pet Scan (PET scan)
Spiral Ct Scan (Spiral CT Scan)
Ultrasound (Ultrasound)
Other Specify (If)
Date of Evaluation
Lymphoma: Bone Marrow, Liver And
Spleen Assessment
Is there bone marrow involvement
No (No)
Unknown (Unknown)
Yes (Yes)
Was bone marrow biopsy done (If yes,)
No (No)
Unknown (Unknown)
Yes (Yes)
Bone Marrow Biopsy Result (If yes,)
Equivocal (Equivocal)
Involved (Involved)
Not Involved (Not Involved)
Date of Bone Marrow Biopsy
Method of Evaluation (* use code below * Method
of Evaluation Code)
Bone Scan (Bone Scan)
Chest X-ray (Chest X-ray)
Ct Scan (CT Scan)
Gallium Scan (Gallium scan)
Mri (MRI (NMR))
Other (Other)
Pet Scan (PET scan)
Spiral Ct Scan (Spiral CT Scan)
Ultrasound (Ultrasound)
Method of Evaluation (* use code below * Method
of Evaluation Code)
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Bone Scan (Bone Scan)
Chest X-ray (Chest X-ray)
Ct Scan (CT Scan)
Gallium Scan (Gallium scan)
Mri (MRI (NMR))
Other (Other)
Pet Scan (PET scan)
Spiral Ct Scan (Spiral CT Scan)
Ultrasound (Ultrasound)
Other Specify (If)
Other Specify (If)
Was bone marrow aspirate done
No (No)
Unknown (Unknown)
Yes (Yes)
Bone Marrow Aspirate Result (If yes,)
Equivocal (Equivocal)
Involved (Involved)
Not Involved (Not Involved)
Date of Bone Marrow Aspirate
Is there hepatomegaly
No (No)
Unknown (Unknown)
Yes (Yes)
Palpable Hepatomegaly
Examination Performed And
Hepatomegaly Absent (No)
Examination Of Liver Not Performed (Not
examined)
Examination Performed And
Hepatomegaly Present (Yes)
Date of Liver Palpation (If done,)
Hepatomegaly by scan
Examination Performed And
Hepatomegaly Absent (No)
Examination Of Liver Not Performed (Not
examined)
Examination Performed And
Hepatomegaly Present (Yes)
Date of Liver Evaluation (If done,)
Is there splenomegaly
No (No)
Unknown (Unknown)
Yes (Yes)
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Palpable Splenomegaly
Examination Performed And
Splenomegaly Absent (No)
Examination Of Spleen Not Performed
(Not examined)
Spleen Removed Via Prior Surgery
(Surgically absent)
Examination Performed And
Splenomegaly Present (Yes)
Date of Spleen Palpation (If done,)
Splenomegaly by scan
Examination Performed And
Splenomegaly Absent (No)
Examination Of Spleen Not Performed
(Not examined)
Spleen Removed Via Prior Surgery
(Surgically absent)
Examination Performed And
Splenomegaly Present (Yes)
Date of Spleen Evaluation (If done,)
Lymphoma: Scanning/imaging
Imaging Site
Abdomen (Abdomen)
Abdomen (Abdomen)
Bone (Bone)
Chest (Chest)
Chest (Chest)
Chest (Chest)
Head/neck (Head/Neck)
Other (Other)
Other (Other)
Pelvis (Pelvis)
Pelvis (Pelvis)
Bone Specify
Method of Evaluation (* use code below * Method
of Evaluation Code)
Bone Scan (Bone Scan)
Chest X-ray (Chest X-ray)
Ct Scan (CT Scan)
Gallium Scan (Gallium scan)
Mri (MRI (NMR))
Other (Other)
Pet Scan (PET scan)
Spiral Ct Scan (Spiral CT Scan)
Ultrasound (Ultrasound)
Other Specify
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Other Specify (If)
Other Specify
Imaging Result (** use code below ** Imaging
Result)
Equivocal (Equivocal)
Indeterminate (Indeterminate)
Involved (Involved)
Negative (Negative)
Not Done (Not Done)
Date of Evaluation
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Lung Cancer NCT00107172 Follow-Up -
Z4032 Missed Visit - 2306815v3.0
Z4032 Missed Visit
Surgery With or Without Internal Radiation Therapy in
Treating Patients With Stage I Non-Small Cell Lung Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=F21FF20E-
5774-1338-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/8531
Z4032 Missed Visit
Header Module
Visit
Day 0 (Day 0)
Month 1 (Month 1)
Month 12 (Month 12)
Month 18 (Month 18)
Month 24 (Month 24)
Month 3 (Month 3)
Month 30 (Month 30)
Month 36 (Month 36)
Month 48 (Month 48)
Month 6 (Month 6)
Month 60 (Month 60)
Registration (Registration)
Patient ID (Pt. ID issued during registration or
previously issued patient ID)
Institution ID
Patient Initials
Institution
Header
Missed Visit Date (originally scheduled date)
Reason patient missed visit (Mark only one.)
Distance From Home To Clinical Site
(Distance from home to clinical site)
Health Reasons (Health reasons)
Other (Other)
Scheduling Difficulties (Scheduling
difficulties)
Other, specify
Footer Module
Completed by
Date Form Completed
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Lung Cancer NCT00107172 Treatment - Z4032
Intraoperative Confirmation Worksheet - 2306452v3.0
Z4032 Intraoperative Confirmation Worksheet
Surgery With or Without Internal Radiation Therapy in
Treating Patients With Stage I Non-Small Cell Lung Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=F2103DF3-
E082-063A-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/8532
Z4032 Intraoperative Confirmation
Worksheet
Header Module
Visit
Registration (Registration)
Patient ID
Patient Initials
Institution No.
Institution Name
Randomization
Randomization
Sr + Brachytherapy And Acquisition Of
Specimens For Central Specimen Bank
(SR + Brachytherapy and acquisition of
specimens for Central Specimen Bank)
Sublobar Resection (sr) And Acquisition
Of Specimens For Central Specimen
Bank (Sublobar resection (SR) and
acquisition of specimens for Central
Specimen Bank)
Intra-operative Criteria
Patient must have biopsy-proven NSCLC
Yes
No
Patient must have all suspicious mediastinal
lymph nodes assessed by one of the following
methods to confirm negative involvement with
NSCLC (> 1 cm short-axis dimension on CT scan
or positive on PET scan)
Yes
No
Patient meets all eligibility criteria
Yes
No
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Footer Module
Did the Investigator sign the CRF indicating
review of all data and certifying data are accurate
and complete to the best of their knowledge
Yes (Yes)
Date of Investigator Signature
Completed by
Date Form Completed
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Lung Cancer NCT00107172 Follow-Up - Z4032: Early
Termination of Follow-up (ETFU) - 2306853v3.0
Z4032: Early Termination of Follow-up (ETFU)
Surgery With or Without Internal Radiation Therapy in
Treating Patients With Stage I Non-Small Cell Lung Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=F2215A32-
913A-17FB-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/8533
Z4032: Early Termination of Follow-
up (ETFU)
Header Module
Visit
Month 1 (Month 1)
Month 12 (Month 12)
Month 18 (Month 18)
Month 24 (Month 24)
Month 3 (Month 3)
Month 30 (Month 30)
Month 36 (Month 36)
Month 48 (Month 48)
Month 6 (Month 6)
Month 60 (Month 60)
Patient ID (Pt. ID issued during registration
unless pt. previously registered to an ACOSOG
study.)
Institution ID
Patient Initials
Institution
Header
Date of Early Termination of Follow-up
Reason for early termination of patient follow-up
(mark only one)
Lost Contact With Patient (Lost contact
with patient)
Other (Other)
Patient Refusal For Further Study
Follow-up (Patient refusal for further
study follow-up)
Patient Withdrew Consent. (Patient
withdrew consent)
Other, specify
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Footer Module
Completed by
Date Form Completed
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Follow-up (ETFU) - 2306853v3.0
Lung Cancer NCT01336894 Quality of Life -
ACOSOG-Z4099 EQ-5D Form - 3178742v1.0
ACOSOG-Z4099 EQ-5D Form
Surgery With or Without Internal Radiation Therapy
Compared With Stereotactic Body Radiation Therapy in
Treating Patients With High-Risk Stage I Non-Small Cell
Lung Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=986A2EC8-
D147-882B-E040-BB89AD4356EB
All rights reserved. Please visit https://medical-data-
models.org/forms/8536
ACOSOG-Z4099 EQ-5D Form
Header Module
Patient Study ID
Patient Initials (L F M)
Date Completed (dd MMM yyyy)
Unamed Module 2
Mobility
I Am Confined To Bed (I am confined to
bed)
I Have No Problems In Walking About (I
have no problems in walking about)
I Have Some Problems In Walking About
(I have some problems in walking about)
Self care
I Am Unable To Wash Or Dress Myself (I
am unable to wash or dress myself)
I Have No Problems With Self Care (I
have no problems with self care)
I Have Some Problems Washing Or
Dressing Myself (I have some problems
washing or dressing myself)
Usual activities (e.g. work, study, housework,
family, or leisure activities)
I Am Unable To Perform My Usual
Activities (I am unable to perform my
usual activities)
I Have No Problems With Performing My
Usual Activities (I have no problems with
performing my usual activities)
I Have Some Problems With Performing
My Usual Activities (I have some
problems with performing my usual
activities)
Pain/discomfort
I Have Extreme Pain Or Discomfort (I
have extreme pain or discomfort)
I Have Moderate Pain Or Discomfort (I
have moderate pain or discomfort)
I Have No Pain Or Discomfort (I have no
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pain or discomfort)
Anxiety/depression
I Am Extremely Anxious Or Depressed (I
am extremely anxious or depressed)
I Am Moderately Anxious Or Depressed
(I am moderately anxious or depressed)
I Am Not Anxious Or Depressed (I am
not anxious or depressed)
Unnamed Module 3
Your own health state today
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Response - Hodgkins Lymphoma - Follow-Up
Disease Assessment Form - 2269525v3.0
Hodgkin's Lymphoma - Follow-Up Disease Assessment
Form
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=D5EB536B-
A765-64B5-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/8537
Hodgkins Lymphoma - Follow-Up
Disease Assessment Form
Crf Header
Coordinating Group Protocol No.
Coordinating Group Code
Protocol Title
Patient Study ID
Institution/Affiliate
Other Patient ID
Participating Group Code
Patient Name (initials acceptable)
Lymphoma: Form Administration
Person Completing Form
Are data amended? (If data are amended, please
circle in red when using paper form)
Yes
No
Lymphoma: Measurable Disease
Response
Is measurable disease present?
Yes
No
Lesion Number
Site of Lesion
1 / 5
Method of Evaluation (* Method of Evaluation
Code)
Bone Scan (Bone Scan)
Chest X-ray (Chest X-ray)
Clinical Examination (pe) (Clinical
examination)
Ct Scan (CT Scan)
Gallium Scan (Gallium scan)
Mri (MRI (NMR))
Not Done (Not done)
Other (Other)
Pet Scan (PET scan)
Spiral Ct Scan (Spiral CT Scan)
Ultrasound (Ultrasound)
Other Specify (If)
Greatest Perpendicular Measurements (cm)
Greatest Perpendicular Measurements (cm)
Product of Measurements (cm^2)
Date of Evaluation
Sum of Products of Measurements (cm^2)
Lymphoma: Non-measurable Disease
Response
Is non-measurable disease present?
Yes
No
Lesion Number
Site of Lesion
Method of Evaluation (* Method of Evaluation
Code)
Bone Scan (Bone Scan)
Chest X-ray (Chest X-ray)
Clinical Examination (pe) (Clinical
examination)
Ct Scan (CT Scan)
Gallium Scan (Gallium scan)
Mri (MRI (NMR))
Not Done (Not done)
Other (Other)
Pet Scan (PET scan)
Spiral Ct Scan (Spiral CT Scan)
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Ultrasound (Ultrasound)
Other Specify (If)
Lesion Assessment (? Assessment Codes)
Disappearance (Disappearance)
Improvement (Improvement)
No Change (No change)
Not Evaluated (Not evaluated)
Progression - Increase (Progression -
increase)
Worsening (Worsening)
Date of Evaluation
Lymphoma: New Lesions
Was the appearance of any new lesions
documented (since the baseline evaluation?)
Yes
No
Location of New Lesions (If yes, Record new
bone marrow involvement in the Bone Marrow
module.  Record all other new involvement in this
module.)
Bone Marrow And Other (Bone marrow
and other)
Bone Marrow Only (Bone Marrow only)
Other (Other)
Lesion Number
Site of Lesion
Method of Evaluation (* Method of Evaluation
Code)
Bone Scan (Bone Scan)
Chest X-ray (Chest X-ray)
Clinical Examination (pe) (Clinical
examination)
Ct Scan (CT Scan)
Gallium Scan (Gallium scan)
Mri (MRI (NMR))
Not Done (Not done)
Other (Other)
Pet Scan (PET scan)
Spiral Ct Scan (Spiral CT Scan)
Ultrasound (Ultrasound)
Other Specify (If)
Date of Evaluation
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Lymphoma: Bone Marrow And Liver
Assessment
Was bone marrow biopsy done
No (No)
Unknown (Unknown)
Yes (Yes)
Bone Marrow Biopsy Result (If yes,)
Equivocal (Equivocal)
Involved (Involved)
Not Involved (Not Involved)
Date of Bone Marrow Biopsy
Was bone marrow aspirate done
No (No)
Unknown (Unknown)
Yes (Yes)
Bone Marrow Aspirate Result (If yes,)
Equivocal (Equivocal)
Involved (Involved)
Not Involved (Not Involved)
Date of Bone Marrow Aspirate
Was a liver biopsy done (this reporting period?)
No (No)
Unknown (Unknown)
Yes (Yes)
Liver Biopsy Result (If yes,)
Equivocal (Equivocal)
Involved (Involved)
Not Involved (Not involved)
Date of Liver Biopsy
Hodgkin's Lymphoma: Biochemical And B
Symptoms
Status of disease-related B-symptoms
Not Present At Baseline (Not present at
baseline)
Not Resolved (Not resolved)
Resolved (Resolved)
Describe unresolved B-symptoms (If not
resolved,)
Was a gallium scan done (this reporting period?)
No (No)
Unknown (Unknown)
Yes (Yes)
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Gallium scan Result (If yes,)
Equivocal (Equivocal)
Negative (Negative)
Positive (Positive)
Date of Gallium Scan
Hodgkin's Lymphoma: Response
Assessment
Has the overall response changed (Since
previous evaluation,)
Yes
No
Has an unconfirmed response changed to a
confirmed response (If no,)
Yes
No
Objective status at This Evaluation
Clinical Complete Response (Clinical
Complete Response)
Complete Response (Complete
Response)
Partial Response (Partial response)
Progressive Disease (Progressive
Disease)
Stable Disease (Stable Disease)
Unevaluable (Unevaluable)
Has response been confirmed by second
assessment? (Follow protocol guidelines for
confirmation of response.)
Yes
No
Complete Response (CR) First Observed Date (If
yes,)
Clinical Complete Response (CCR) First
Observed Date
Partial Response (PR) First Observed Date
Stable Disease First Observed Date (For SD: SD)
Progressive Disease First Observed Date (For
PD: PD)
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NCT00954174 On-Study - GOG-0261: Primary
Ovarian Cancer -  On Study Form - 3072737v1.0
GOG-0261: Primary Ovarian Cancer -  On Study Form
Paclitaxel and Carboplatin or Ifosfamide in Treating Patients
With Newly Diagnosed Persistent or Recurrent Uterine or
Ovarian Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=84C04E8A-
314B-D474-E040-BB89AD435DDB
All rights reserved. Please visit https://medical-data-
models.org/forms/8538
GOG-0261: Primary Ovarian Cancer
-  On Study Form
Header Module
Date form originally completed
Date form amended
Person amending form, last name
Patient Initials
Patient Study ID
Person Completing Form, Last Name
Ovarian: Disease Description
Date of definitive histologic diagnosis of primary
tumor
Primary Site
Fallopian Tube (Fallopian tube)
Ovary (Ovary)
Peritoneum (Peritoneum)
Stage (at diagnosis FIGO)
Refer To Figo Staging For Specific
Gynecologic Cancer (IA)
Refer To Figo Staging For Specific
Gynecologic Cancer (IB)
Refer To Figo Staging For Specific
Gynecologic Cancer (IC)
Refer To Figo Staging For Specific
Gynecologic Cancer (IIA)
Refer To Figo Staging For Specific
Gynecologic Cancer (IIB)
Refer To Figo Staging For Specific
Gynecologic Cancer (IIC)
Refer To Figo Staging For Specific
Gynecologic Cancer (III)
Refer To Figo Staging For Specific
Gynecologic Cancer (IIIA)
Refer To Figo Staging For Specific
Gynecologic Cancer (IIIB)
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Refer To Figo Staging For Specific
Gynecologic Cancer (IIIC)
Refer To Figo Staging For Specific
Gynecologic Cancer (IV)
Histologic grade
Grade 1-well Differentiated (1)
Grade 2-moderately Differentiated (2)
Grade 3-poorly Differentiated (3)
Grade Unknown (Unknown)
Histologic type (check all that apply)
Adenocarcinoma, Unspecified
(Adenocarcinoma, unspecified)
Clear Cell Carcinoma (Clear cell
carcinoma)
Endometrioid Adenocarcinoma
(Endometrioid adenocarcinoma)
Mixed Epithelial Carcinoma, Specify
Components (Mixed epithelial
carcinoma)
Mucinous Adenocarcinoma (Mucinous
adenocarcinoma)
Other, Specify (Other)
Serous Adenocarcinoma (Serous
adenocarcinoma)
Other, specify
Ovarian: Findings From Primary Surgery
Primary Surgery Type
Bilateral Salpingo-oophorectomy
(bilateral salpingo-oophorectomy)
Other, Specify (other specify)
Para-aortic Node Sampling/dissection
(para-aortic node sampling/dissection)
Pelvic Node Sampling/dissection (pelvic
node sampling/dissection)
Total Hysterectomy (total hysterectomy)
Unilateral Salpingo-oophorectomy
(unilateral salpingo-oophorectomy)
Other, specify
Size of Residual Disease (Maximum size after
resection is complete.  If none or microscopic
only, enter 0.  cm)
Is ascites present (prior to initial staging surgery)
No (No)
Unknown (Unknown)
Yes (Yes)
Cytology result (pelvic)
Negative (Negative)
Not Done (Not done)
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Positive (Positive)
Moderate Dysplasia Or Papillary
Clusters (suspect) (Suspicious)
Is pleural effusion present
No (No)
Unknown (Unknown)
Yes (Yes)
Is it malignant
No (No)
Unknown (Unknown (not tapped))
Yes (Yes)
Ovarian: Post-operative Findings
Following Primary Surgery
Site of Involvement (at surgery s)
Abdomen (other Than Above) (Abdomen
(other than above))
Colon (Colon)
Liver (Liver)
Lung (Lung)
Omentum (Omentum)
Other Specify (Other)
Para-aortic Nodes (Para-aortic nodes)
Pelvic (other Than Above) (Pelvic (other
than above))
Pelvic Nodes (Pelvic nodes)
Other, specify
Involvement (*)
Equivocal (equivocal)
Negative (negative)
Not Evaluated (not evaluated)
Positive (positive)
Unknown (unknown)
Result of CA125 (pre-treatment U/mL)
Date of CA125
CA125 Laboratory upper limit of normal (U/mL)
Comments
COMMENTS
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NCT00262821 On-Study - Primary Cervical Cancer
On Study Form, Form OSC, GOG-0219 - 2302778v3.0
Primary Cervical Cancer On Study Form, Form OSC,
GOG-0219
Cisplatin and Radiation Therapy With or Without
Tirapazamine in Treating Patients With Cervical Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=EF89BED2-
919C-0FDF-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/8540
Primary Cervical Cancer On Study
Form, Form OSC, GOG-0219
Header Module
Date form originally completed
Date form amended
Person amending form, last name
Patient Initials
Patient Study ID
Person Completing Form, Last Name
Cervical: Disease Description
Date of definitive histologic diagnosis of primary
tumor (m d y)
Staging System
1995 (1995)
2009 (2009)
Stage
Stage I Cervical Cancer (I)
Stage Ia Cervical Cancer (IA)
Stage Ia1 Cervical Cancer (IA1)
Stage Ia2 Cervical Cancer (IA2)
Stage Ib Cervical Cancer (IB)
Stage Ib1 Cervical Cancer (IB1)
Stage Ib2 Cervical Cancer (IB2)
Stage Ii Cervical Cancer (II)
Stage Iia Cervical Cancer (IIA)
Stage Iib Cervical Cancer (IIB)
Stage Iii Cervical Cancer (III)
Stage Iiia Cervical Cancer (IIIA)
Stage Iiib Cervical Cancer (IIIB)
Stage Iv Cervical Cancer (IV)
Stage Iva Cervical Cancer (IVA)
Stage Ivb Cervical Cancer (IVB)
Does the patient have parametrial involvement
with this disease
1 / 3
No (None)
Yes, Bilateral (Yes bilateral)
Yes, Unilateral (Yes unilateral)
Site(s) of Involvement (at study entry for
Advanced Disease Studies)
Abdomen (other Than Above) (Abdomen
(other than above))
Bladder (Bladder)
Bone (Bone)
Colon (Colon)
Liver (Liver)
Lung (Lung)
Other Specify (Other specify)
Pelvic (other Than Above) (Pelvic (other
than above))
Other specify
Lymph Nodes Type
Other Specify (other)
Para-aortic (para-aortic)
Pelvic (pelvic)
Other specify
Lymph Node Involvement (* Indicate node
involvement 0=not evaluated, 1=positive,
2=negative, 3=equivocal, 9=unknown)
Equivocal (equivocal)
Negative (negative)
Not Evaluated (not evaluated)
Positive (positive)
Unknown (unknown)
Method of Evaluation (^ Indicate method of
evaluation 0=not applicable, 1=CT scan,
2=MRINMR, 3=pathologic, 4=physical exam,
7=ultrasound, 8=other, specify)
Ct Scan (CT scan)
Mri (MRI (NMR))
Not Applicable (not applicable)
Other (other)
Pathologic (pathologic)
Physical Exam (physical exam)
Ultrasound (ultrasound)
Clinical size of tumor (at diagnosis if microscopic,
enter 0)
Comments
COMMENTS
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Footer Module
Participating Group Code
Participating Group Protocol Number
Participating Group Patient ID
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Form OSC, GOG-0219 - 2302778v3.0
Pathology - Breast Pathology - Tumor
Marker Form - 2020194v3.0
Breast Pathology - Tumor Marker Form
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=13EAB392-
277F-3887-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/8541
Breast Pathology - Tumor Marker
Form
Crf Header
Coordinating Group Protocol No.
Coordinating Group Code
Protocol Title
Patient Study ID
Other Patient ID
Institution/Affiliate
Participating Group Code
Patient Name (initials acceptable)
Breast: Form Administration
Person Completing Form
Are data amended (If data are amended, please
circle in red when using paper form)
Yes
No
Pathology: Estrogen And Progesterone
Receptors
Tissue Type
Distant Metastases (Metastasis)
Other, Specify (Other)
Primary (Primary)
Regional Nodal (Regional nodal)
Other, specify
Blocks
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Blocks
Accession Number
Method of Evaluation
Autopsy (Autopsy)
Axillary Dissection (Axillary dissection)
Ductal Lavage (Ductal lavage)
Ductoscopic Biopsy (Ductoscopic
biopsy)
Excisional Biopsy Or Lumpectomy
(Excisional biopsy or lumpectomy)
Fine Needle Aspiration Biopsy (Fine
needle aspiration biopsy)
Fluid Cytology, Ascites (Fluid cytology,
ascites)
Fluid Cytology, Cerebrospinal Fluid (Fluid
cytology, cerebrospinal fluid)
Fluid Cytology, Pleural (Fluid cytology,
pleural)
Incisional Biopsy (Incisional biopsy)
Mastectomy (Mastectomy)
Needle Biopsy (tru-cut Or Core) (Needle
biopsy (tru-cut or core))
Nipple Fluid (Nipple fluid)
Other, Specify (Other, specify)
Prophalactic Mastectomy (Prophalactic
mastectomy)
Resection/re-excision Of Lumpectomy
Margins (Resection/re-excision of
lumpectomy margins)
Sentinel Node Biopsy (Sentinel node
biopsy)
Other Specify
Marker Test Method
Elisa (ELISA)
Fluorescence In Situ Hybridization (fish)
(Fluorescence in situ hybridization
(FISH))
Immunohistochemistry (ihc)
(Immunohistochemistry (IHC))
Other, Specify (Other)
Type of Hormone Receptor (mark all that apply)
Estrogen Receptor (er) (Estrogen
receptor)
Other Specify (Other)
Progesterone Receptor (pr)
(Progesterone receptor)
Other specify
Other specify
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Other, specify
Antigen Retrieval
Yes
No
Yes specify
Intensity of Stained Malignant Nuclei, Description
Intense (Intense)
Intermediate (Intermediate)
Negative (Negative)
Scant (Scant)
Unknown (Unknown)
Stained Malignant Nuclei Intensity Scaled (__ of
__ - Note: Scale for intensity will be protocol
specific.)
Percentage of Invasive Tumor Cells with Nuclear
Staining
Percentage of DCIS Cells with Nuclear Staining
Final Receptor Status Diagnosis
Indeterminate (Indeterminate)
Negative (Negative)
Positive (Positive)
Pathology: Breast Tumor Markers
Marker Name (s)
Other Specify (Other)
P53 (p53)
Other specify
Tissue Type
Distant Metastases (Metastasis)
Other, Specify (Other)
Primary (Primary)
Regional Nodal (Regional nodal)
Other, specify
Blocks
Accession Number
Method of Evaluation
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Autopsy (Autopsy)
Axillary Dissection (Axillary dissection)
Ductal Lavage (Ductal lavage)
Ductoscopic Biopsy (Ductoscopic
biopsy)
Excisional Biopsy Or Lumpectomy
(Excisional biopsy or lumpectomy)
Fine Needle Aspiration Biopsy (Fine
needle aspiration biopsy)
Fluid Cytology, Ascites (Fluid cytology,
ascites)
Fluid Cytology, Cerebrospinal Fluid (Fluid
cytology, cerebrospinal fluid)
Fluid Cytology, Pleural (Fluid cytology,
pleural)
Incisional Biopsy (Incisional biopsy)
Mastectomy (Mastectomy)
Needle Biopsy (tru-cut Or Core) (Needle
biopsy (tru-cut or core))
Nipple Fluid (Nipple fluid)
Other, Specify (Other, specify)
Prophalactic Mastectomy (Prophalactic
mastectomy)
Resection/re-excision Of Lumpectomy
Margins (Resection/re-excision of
lumpectomy margins)
Sentinel Node Biopsy (Sentinel node
biopsy)
Other Specify
Marker Test Method
Elisa (ELISA)
Fluorescence In Situ Hybridization (fish)
(Fluorescence in situ hybridization
(FISH))
Immunohistochemistry (ihc)
(Immunohistochemistry (IHC))
Other, Specify (Other)
Other specify
Staining Antibody
Cb-11 Other (CB-11 other)
Cb-11/ventana Kit (CB-11/Ventana Kit)
Dako Herceptest [tm] (DAKO Herceptest
[TM])
Other, Specify (Other, specify)
Tab-250 (TAB-250)
Other, specify
Percentage of Invasive Tumor Cells with
Membrane Staining (If IHC, )
Intensity of Stained Malignant Nuclei, Description
Intense (Intense)
Intermediate (Intermediate)
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Negative (Negative)
Scant (Scant)
Unknown (Unknown)
Stained Malignant Nuclei Intensity Scaled (__ of
__ - Note: Scale for intensity will be protocol
specific.)
Scoring System (Score) (If Herceptest[TM])
0 (0)
1+ (1+)
2+ (2+)
3+ (3+)
Ventana Scoring System (Score)
0 (0)
1+ (1+)
2+ (2+)
3+ (3+)
Kit or Test Type (If FISH,)
Other Specify (Other, specify)
Ventana/oncorprobe[tm]
(Ventana/Oncorprobe)
Vysis/path Vysion[tm] (Vysis/PathVysion)
Other, specify
FISH Result
Amplified (Amplified)
Not Amplified (Not amplified)
FISH HER2/neu chromosome 17 Ratio
Mean Number of HER2/neu Signals/Cell  (Note:
Enter 99.9 or 999 if unknown)
Amplification Cutpoint
Final Diagnosis with HER2/neu
Equivocal (Equivocal)
Negative (Negative)
Positive (Positive)
Pathology: Immunohistochemistry
Marker Name (s)
Other Specify (Other)
P53 (p53)
Other specify
Tissue Type
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Distant Metastases (Metastasis)
Other, Specify (Other)
Primary (Primary)
Regional Nodal (Regional nodal)
Other, specify
Blocks
Accession Number
Method of Evaluation
Autopsy (Autopsy)
Axillary Dissection (Axillary dissection)
Ductal Lavage (Ductal lavage)
Ductoscopic Biopsy (Ductoscopic
biopsy)
Excisional Biopsy Or Lumpectomy
(Excisional biopsy or lumpectomy)
Fine Needle Aspiration Biopsy (Fine
needle aspiration biopsy)
Fluid Cytology, Ascites (Fluid cytology,
ascites)
Fluid Cytology, Cerebrospinal Fluid (Fluid
cytology, cerebrospinal fluid)
Fluid Cytology, Pleural (Fluid cytology,
pleural)
Incisional Biopsy (Incisional biopsy)
Mastectomy (Mastectomy)
Needle Biopsy (tru-cut Or Core) (Needle
biopsy (tru-cut or core))
Nipple Fluid (Nipple fluid)
Other, Specify (Other, specify)
Prophalactic Mastectomy (Prophalactic
mastectomy)
Resection/re-excision Of Lumpectomy
Margins (Resection/re-excision of
lumpectomy margins)
Sentinel Node Biopsy (Sentinel node
biopsy)
Other Specify
Primary Antibody
Cell Type Stained (check all that apply)
Epithelail, Maligant (Epithelail, maligant)
Epithelial, Non-malignant (Epithelial,
non-malignant)
Other, Specify (Other, specify)
Stromal, Non-malignant (Stromal, non-
malignant)
Antigen Retrieval
Yes
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No
Other, specify
Intensity of Stained Malignant Nuclei, Description
Intense (Intense)
Intermediate (Intermediate)
Negative (Negative)
Scant (Scant)
Unknown (Unknown)
Pattern of Staining
Cytoplasmic (Cytoplasmic)
Membrane (Membrane)
Mixed (nuclear/cytoplasmic) (Mixed
(Nuclear/Cytoplasmic))
Nuclear (Nuclear)
Other, Specify (Other, specify)
Secreted (Secreted)
Yes specify
Other, specify
Percentage of Invasive Tumor Cells with Nuclear
Staining
Stained Malignant Nuclei Intensity Scaled (__ of
__ - Note: Scale for intensity will be protocol
specific.)
Percentage of DCIS Cells with Nuclear Staining
Percentage of Non-Malignant Cells with Nuclear
Staining
Final Interpretation of Results (for invasive
component)
Indeterminate (Indeterminate)
Negative (Negative)
Positive (Positive)
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Lung Cancer NCT01336894 Quality of Life - ACOSOG-
Z4099 USCD Shortness of Breath Form - 3178502v1.0
ACOSOG-Z4099 USCD Shortness of Breath Form
Surgery With or Without Internal Radiation Therapy
Compared With Stereotactic Body Radiation Therapy in
Treating Patients With High-Risk Stage I Non-Small Cell
Lung Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=9869A599-
BD3E-139E-E040-BB89AD432862
All rights reserved. Please visit https://medical-data-
models.org/forms/8542
ACOSOG-Z4099 USCD Shortness
of Breath Form
Header Module
Patient Study ID
Patient Initials (L F M)
Date Completed (dd MMM yyyy)
How Short Of Breath Do You Get
At rest
Not At All (0)
1 (1)
2 (2)
3 (3)
4 (4)
Maximum (5)
Walking on a level at your own pace
Not At All (0)
1 (1)
2 (2)
3 (3)
4 (4)
Maximum (5)
Walking on a level with others your age
Not At All (0)
1 (1)
2 (2)
3 (3)
4 (4)
Maximum (5)
Walking up a hill
Not At All (0)
1 (1)
2 (2)
3 (3)
4 (4)
Maximum (5)
Walking up stairs
Not At All (0)
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1 (1)
2 (2)
3 (3)
4 (4)
Maximum (5)
While eating
Not At All (0)
1 (1)
2 (2)
3 (3)
4 (4)
Maximum (5)
Standing up from a chair
Not At All (0)
1 (1)
2 (2)
3 (3)
4 (4)
Maximum (5)
Brushing teeth
Not At All (0)
1 (1)
2 (2)
3 (3)
4 (4)
Maximum (5)
Shaving and/or brushing hair
Not At All (0)
1 (1)
2 (2)
3 (3)
4 (4)
Maximum (5)
Showering/bathing
Not At All (0)
1 (1)
2 (2)
3 (3)
4 (4)
Maximum (5)
Dressing
Not At All (0)
1 (1)
2 (2)
3 (3)
4 (4)
Maximum (5)
Picking up and straightening
Not At All (0)
1 (1)
2 (2)
3 (3)
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4 (4)
Maximum (5)
Doing dishes
Not At All (0)
1 (1)
2 (2)
3 (3)
4 (4)
Maximum (5)
Sweeping/vacuuming
Not At All (0)
1 (1)
2 (2)
3 (3)
4 (4)
Maximum (5)
Making bed
Not At All (0)
1 (1)
2 (2)
3 (3)
4 (4)
Maximum (5)
Shopping
Not At All (0)
1 (1)
2 (2)
3 (3)
4 (4)
Maximum (5)
Doing laundry
Not At All (0)
1 (1)
2 (2)
3 (3)
4 (4)
Maximum (5)
Washing car
Not At All (0)
1 (1)
2 (2)
3 (3)
4 (4)
Maximum (5)
Mowing lawn
Not At All (0)
1 (1)
2 (2)
3 (3)
4 (4)
Maximum (5)
Watering lawn
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Not At All (0)
1 (1)
2 (2)
3 (3)
4 (4)
Maximum (5)
Sexual activities
Not At All (0)
1 (1)
2 (2)
3 (3)
4 (4)
Maximum (5)
How Much Do These Limit Your Daily Life
Shortness of breath
Not At All (0)
1 (1)
2 (2)
3 (3)
4 (4)
Maximum (5)
Fear of "hurting myself" by overexerting
Not At All (0)
1 (1)
2 (2)
3 (3)
4 (4)
Maximum (5)
Fear of shortness of breath
Not At All (0)
1 (1)
2 (2)
3 (3)
4 (4)
Maximum (5)
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On-Study - Prostate Cancer - Localized
Disease On-Study Form - 2262683v3.0
Prostate Cancer - Localized Disease On-Study Form
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=DC4FD317-
E0EB-5D4E-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/8545
Prostate Cancer - Localized Disease
On-Study Form
Crf Header
Coordinating Group Protocol No.
Coordinating Group Code
Protocol Title
Patient Study ID
Institution/Affiliate
Other Patient ID
Participating Group Code
Patient Name (initials acceptable)
Prostate: Disease Description - Localized
Date of Initial Diagnosis of Primary Tumor (first
positive biopsy date)
Baseline PSA Value (per protocol definition)
Unit of Measure ([n/mg, ng/mL, U/L, mg/L, ng/dL,
mcg/L])
Micrograms Per Liter (mcg/L)
Milligrams Per Liter (mg/L)
N/milligram (n/mg)
Nanograms Per Deciliter (ng/dL)
Nanograms Per Milliliter (ng/mL)
Units Per Liter (U/L)
Date of Baseline PSA
Gleason Score, Primary Pattern (1-5, 9:unknown)
Gleason Score, Secondary Pattern (1-5,
9:unknown)
1 / 2
Gleason Score, Worst Pattern (1-5, 9:unknown)
Gleason Score Based on Specimen Type
Biopsy (Biopsy (including TURP))
Surgical Specimen (Surgical specimen)
Gleason Score, Combined (2-10 if primary and
secondary patterns unavailable)
T Stage, Clinical (Clinical Stage use the AJCC
staging system specified in the protocol)
N Stage, Clinical
T Stage, Pathologic (Pathologic Stage use the
AJCC staging system specified in the protocol)
N Stage, Pathologic
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On-Study - Lung Cancer - SCLC Limited
On-Study Form - 2262564v3.0
Lung Cancer - SCLC Limited On-Study Form
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=DE32845E-
1DA8-3D2D-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/8546
Lung Cancer - SCLC Limited On-
Study Form
Crf Header
Coordinating Group Protocol No.
Coordinating Group Code
Protocol Title
Patient Study ID
Institution/Affiliate
Other Patient ID
Participating Group Code
Patient Name (initials acceptable)
Lung: Pre-treatment Characteristics
Patient Height (cm)
Patient Weight (kg)
Body Surface Area (m^2)
Performance Status (check one)
Fully Active, Able To Carry On All Pre-
disease Performance Without
Restriction. (0)
Restricted In Physically Strenuous
Activity But Ambulatory And Able To
Carry Out Work Of A Light Or Sedentary
Nature, E.g., Light Housework, Office
Work. (1)
Ambulatory And Capable Of All Selfcare
But Unable To Carry Out Any Work
Activities. Up And About More Than 50%
Of Waking Hours. (2)
Capable Of Only Limited Selfcare,
Confined To Bed Or Chair More Than
1 / 3
50% Of Waking Hours. (3)
Completely Disabled. Cannot Carry On
Any Selfcare. Totally Confined To Bed Or
Chair. (4)
Weight loss in previous six months (check one)
<5% Of Body Weight (< 5% of body
weight)
> Or = 20% Of Body Weight (> or = 20%
of body weight)
10 To <20% Of Body Weight (10 to <20%
of body weight)
5 To <10% Of Body Weight (5 to < 10%
of body weight)
Lung: Disease Description - Limited Sclc
Is measurable disease present? (only applicable
in studies where there is residual disease at
baseline)
Yes
No
Is non-measurable disease present? (only
applicable in studies where there is residual
disease at baseline)
Yes
No
Is pleural effusion present?
Yes
No
Is it Malignant? (If yes,)
No (No)
Unknown (Unknown (not tapped))
Yes (Yes)
Units used for labs
Imperial (Imperial)
Scientific/international (S/I)
Albumin (g/dl)
Hemoglobin (g/dl)
Lactate Dehydrogenase (LDH) (U/L only collect if
RT study)
Lactate Dehydrogenase ULN (U/L Provide
laboratory's upper limit of normal)
Lung: Prior Treatment - Limited Sclc
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Prior Surgery (Code "No" if incisional/needle
biopsy is the only prior surgery)
Yes
No
Was a complete resection done?
Yes
No
Prior Radiation Therapy
Yes
No
Prior Systemic Chemotherapy
Yes
No
Comments
Comments
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On-Study - Bone Sarcoma - On-Study Form
Newly Diagnosed Patients - 2291479v3.0
Bone Sarcoma - On-Study Form Newly Diagnosed Patients
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=E208E9A0-
535D-1660-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/8547
Bone Sarcoma - On-Study Form
Newly Diagnosed Patients
Crf Header
Coordinating Group Protocol No.
Coordinating Group Code
Protocol Title
Patient Study ID
Institution/Affiliate
Other Patient ID
Participating Group Code
Patient Name (initials acceptable)
Sarcoma: Form Administration
Person Completing Form
Are data amended (If data are amended, please
circle in red when using paper form)
Yes
No
Bone Sarcoma: Disease Description
Date of Initial Pathologic Diagnosis (MM DD
YYYY)
Biopsy Type
Excisional (Excisional)
Incisional (Incisional)
Large Bore Needle (Large bore needle)
Other, Specify (Other specify)
Trucut Needle (TruCut needle)
Other specify
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Primary Site
Clavicle (Clavicle)
Femur (Femur)
Fibula (Fibula)
Humerus (Humerus)
Ilium (Ilium)
Ischium (Ischium)
Mandible (Mandible)
Maxilla (Maxilla)
Other, Specify (Other specify)
Pubis (Pubis)
Radius (Radius)
Ribs (Ribs)
Scapula (Scapula)
Skull (Skull)
Sternum (Sternum)
Tibia (Tibia)
Ulna (Ulna)
Vertebra (Vertebra)
Other specify
Tumor Location, Side
Both (Both)
Left (Left)
Right (Right)
Unknown (Unknown)
Area (If long bone,)
Diaphysis (Diaphysis)
Epiphysis (Epiphysis)
Metaphysis (Metaphysis)
Unknown (Unknown)
Metastatic Site (s - For advanced or recurrent
studies, - check all that apply)
Ascites (Ascites)
Bone (Bone)
Bone Marrow (Bone marrow)
Cerebrospinal Fluid (csf) (Cerebrospinal
fluid (CSF))
Cns/brain (CNS/Brain)
Distant Nodes, Specify (Distant Nodes)
Liver (Liver)
Lung (Lung)
Other Specify (Other)
Peritoneal Nodules (Peritoneal nodules)
Pleural Effusion (Pleural effusion)
Pleural Nodules (Pleural nodules)
Soft Tissue (Soft tissue)
Distant nodes specify
Other specify
Regional lymph nodes
No (No)
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Unknown (Unknown)
Yes (Yes)
Distant lymph nodes
No (No)
Unknown (Unknown)
Yes (Yes)
Lung Specificity
Bilateral (Bilateral)
Unilateral (Unilateral)
Number of pulmonary nodules, left
1 (1)
2 (2)
3 (3)
4 (4)
5 Or More (5 or more)
Number of pulmonary nodules, right
1 (1)
2 (2)
3 (3)
4 (4)
5 Or More (5 or more)
Are skip metastases present?
No (No)
Unknown (Unknown)
Yes (Yes)
Dimension 1 (Longest)
Dimension 2 (cm)
Dimension 3 (cm)
Status of Primary Tumor
Not Recurrent, Resected, No Residual
Tumor (Not recurrent, resected, no
residual tumor)
Not Recurrent, Resected, Residual
Tumor (Not recurrent, resected, residual
tumor)
Recurrent (Recurrent)
Unresected (Unresected)
Histologic Type (check all that apply)
Angiosarcoma (Angiosarcoma)
Chondrosarcoma (Chondrosarcoma)
Chordoma (Chordoma)
Clear Cell Chondrosarcoma (Clear cell
chondrosarcoma)
Conventional Central Osteosarcoma
(Conventional central osteosarcoma)
Dedifferentiated Chondrosarcoma
(Dedifferentiated chondrosarcoma)
Epithelioid Hemagioendothelioma
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(Epithelioid hemangioendothelioma)
Ewing's Sarcoma/pnet (Ewing's
sarcoma/PNET)
Fibrosarcoma (Fibrosarcoma)
Hemagioendothelioma Nos
(Hemangioendothelioma NOS)
Hematopoietic Malignancy Nos
(Hematopoietic malignancy NOS)
Intraosseous Osteosarcoma
(Intraosseous osteosarcoma)
Leiomyosarcoma (Leiomyosarcoma)
Liposarcoma Nos (Liposarcoma NOS)
Lymphoma (primary) (Lymphoma
(primary))
Malignant Giant Cell Tumor (Malignant
giant cell tumor)
Maligant Peripheral Nerve Sheath Tumor
(Malignant peripheral nerve sheath
tumor)
Mesenchymal Chondrosarcoma
(Mesenchymal chondrosarcoma)
Osteosarcoma Nos (Osteosarcoma
NOS)
Other Specify (Other specify)
Parosteal (juxtacortical) Osteosarcoma
(Parosteal (juxtacortical) osteosarcoma)
Periosteal Osteosarcoma (Periosteal
osteosarcoma)
Sarcoma Nos (Sarcoma NOS)
Small Cell Osteosarcoma (Small cell
osteosarcoma)
Surface Osteosarcoma, High-grade
(Surface osteosarcoma, high-grade)
Telangiectatic Osteosarcoma
(Telangiectatic osteosarcoma)
Undifferentiated Pleomorphic
Sarcoma/"mfh" (Undifferentiated
pleomorphic sarcoma/"MFH")
Other specify
Histologic Subtype (specify)
Pathologic T Stage (Note: Provide clinical staging
only if pathologic staging is unavailable.)
Pt0 (pT0)
Pt1 (pT1)
Pt2 (pT2)
Pt3 (pT3)
Pt4 (pT4)
Ptx (pTX)
Pathologic N Stage
Pn0 (pN0)
Pn1 (pN1)
Pn2 (pN2)
Pn3 (pN3)
Pnx (pNX)
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Pathologic M Stage
Pm0 (pM0)
Pm1 (pM1)
Pmx (pMX)
Stage
I (I)
Iia (IIA)
Iib (IIB)
Iic (IIC)
Iii (III)
Iv (IV)
Bone Sarcoma: Prior Health History
Prior Radiation Therapy for Other Disease?
No (No)
Unknown (Unknown)
Yes (Yes)
Prior Radiation Therapy Site (If Yes,)
Is there a history of prior radiation therapy to the
primary site?
No (No)
Unknown (Unknown)
Yes (Yes)
Specify (If Yes,)
Is there a history of retinoblastoma?
No (No)
Unknown (Unknown)
Yes (Yes)
Specify (If Yes,)
Is there a history of Paget's Disease?
No (No)
Unknown (Unknown)
Yes (Yes)
Specify (If Yes,)
Is there a history of Li-Fraumeni syndrome?
No (No)
Unknown (Unknown)
Yes (Yes)
Specify (If Yes,)
Are there any other prior medical conditions, such
as any bone abnormalities?
No (No)
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Unknown (Unknown)
Yes (Yes)
Specify (If Yes,)
Comments
Comments
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Lung Cancer NCT00738881 Follow-Up - North Central Cancer
Treatment Group N0723 Event Monitoring Form - 2731425v1.0
North Central Cancer Treatment Group N0723 Event
Monitoring Form
Pemetrexed or Erlotinib as Second-Line Therapy in Treating
Patients With Advanced Non-Small Cell Lung Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=46FB8C2F-
3D9F-1548-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/8548
North Central Cancer Treatment
Group N0723 Event Monitoring Form
Header
Protocol Number
Patient ID
Patient Initials (L F M)
Institution Number
Institution
Are data amended (If yes, highlight amended
areas)
Yes
No
Unnamed Module
Were you able to obtain any information about
the patient since the last report (If this is the first
event monitoring form check yes, enter
assessment date and complete the rest of the
form.)
Yes
No
Date of last attempt to contact patient (If No,
mm/dd/yyyy)
Vital Status
Vital Status
Alive (Alive)
Dead (Dead)
Date of Last Contact or Death (mm/dd/yyyy)
Primary Cause of Death
Due To Other Cause (Due to other
1 / 3
cause)
Due To Protocol Treatment (Due to
protocol treatment)
Due To This Disease (Due to this
disease)
Due to other cause, specify
Disease Follow-up Status
Has the patient had a documented clinical
assessment for this cancer? (since submission of
the last event monitoring form)
Yes
No
Cancer Follow-up Status Date (If yes,)
Notice Of First Relapse/progression In
The Event Monitoring Phase
Has the patient developed a first relapse or
progression that has not been previously
reported
Yes
No
Date of Relapse or Progression (If yes,)
Notice Of First Subsequent Treatment
Has the patient received subsequent treatment
for this cancer that has not been previously
reported
No (No)
Unknown (Unknown)
Yes (Yes)
Date of Subsequent Treatment (If yes
mm/dd/yyyy)
Subsequent Treatment Type
Notice Of New Primary
Has a new primary cancer or MDS been
diagnosed that has not been previously reported?
(myelodyplastic syndrome)
No (No)
Unknown (Unknown)
Yes (Yes)
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New Primary Cancer Date (If yes,)
Site of New Primary
Late Adverse Event
Has the patient experienced (prior to treatment
for progression or relapse or a second primary,
and prior to non-protocol treatment) any severe
(grade >=3) long term toxicity that has not been
previously reported?
No (No)
Unknown (Unknown)
Yes (Yes)
Description Of Primary Disease
CTC Adverse Event Term
MedDRA Code (primary tumor site: Metastases
to brain parenchyma)
CTC Adverse Event Grade (Highest Grade)
CTC AE Attribution Code
Definite (Definite)
Possible (Possible)
Probable (Probable)
Unlikely (Unlikely)
Unrelated (Unrelated)
Late Adverse Event Onset Date (mm/dd/yyyy)
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Lung Cancer NCT01336894 Quality of Life - ACOSOG-Z4099
Linear Analogue Self Assessment Form - 3178862v1.0
ACOSOG-Z4099 Linear Analogue Self Assessment Form
Surgery With or Without Internal Radiation Therapy
Compared With Stereotactic Body Radiation Therapy in
Treating Patients With High-Risk Stage I Non-Small Cell
Lung Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=986A2EC8-
D259-882B-E040-BB89AD4356EB
All rights reserved. Please visit https://medical-data-
models.org/forms/8550
ACOSOG-Z4099 Linear Analogue
Self Assessment Form
Header Module
Patient Study ID
Patient Initials (L F M)
Date Completed (dd MMM yyyy)
Unnamed2
your overall mental (intellectual) well being?
Whole Number (0)
Whole Number (1)
Whole Number (10)
Whole Number (2)
Whole Number (3)
Whole Number (4)
Whole Number (5)
Whole Number (6)
Whole Number (7)
Whole Number (8)
Whole Number (9)
your overall physical well being
Whole Number (0)
Whole Number (1)
Whole Number (10)
Whole Number (2)
Whole Number (3)
Whole Number (4)
Whole Number (5)
Whole Number (6)
Whole Number (7)
Whole Number (8)
Whole Number (9)
your overall emotional well being?
Whole Number (0)
Whole Number (1)
Whole Number (10)
Whole Number (2)
Whole Number (3)
Whole Number (4)
Whole Number (5)
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Whole Number (6)
Whole Number (7)
Whole Number (8)
Whole Number (9)
Your level of social activity
0 (0)
1 (1)
10 (10)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
7 (7)
8 (8)
9 (9)
your overall spiritual well being?
Whole Number (0)
Whole Number (1)
Whole Number (10)
Whole Number (2)
Whole Number (3)
Whole Number (4)
Whole Number (5)
Whole Number (6)
Whole Number (7)
Whole Number (8)
Whole Number (9)
Your level of support from friends and family
0 (0)
1 (1)
10 (10)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
7 (7)
8 (8)
9 (9)
Your financial concerns
0 (0)
1 (1)
10 (10)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
7 (7)
8 (8)
9 (9)
Your legal concerns (will, advanced directives,
etc.)
0 (0)
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1 (1)
10 (10)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
7 (7)
8 (8)
9 (9)
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Pathology - Lung Cancer - Pathology Form
- Bronchoscopy - 2019346v3.0
Lung Cancer - Pathology Form - Bronchoscopy
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=152C7A2C-
614F-698F-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/8551
Lung Cancer - Pathology Form -
Bronchoscopy
Crf Header
Coordinating Group Protocol No.
Coordinating Group Code
Protocol Title
Patient Study ID
Institution/Affiliate
Other Patient ID
Participating Group Code
Patient Name (initials acceptable)
Lung Pathology: Form Administration
Person Completing Form
Are data amended (If data are amended, please
circle in red when using paper form)
Yes
No
Pathology: Bronchoscopy Tissues
Samples
Date Specimen Collected (s - surgical procedure)
Bronchoscopy Reason (Note:  Only list values
needed for protocol)
Chemoprevention (Chemoprevention)
Diagnosis (Diagnosis)
Early Detection (Early detection)
Staging (Staging)
Surveillance (Surveillance)
Specimen ID
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Specimen Cell Source
Bronchial Tissue, Suspicious For
Abnormality (Bronchial tissue, suspicious
for abnormality)
Dysplastic Site (Dysplastic site)
Normal Tissue (Normal tissue)
Other, Specify (Other, specify)
Primary Tumor (Primary tumor)
Other specify
Type of Bronchoscopy (check all that apply)
Fluorescence (Fluorescence)
Other, Specify (Other, specify)
Rigid (Rigid)
White Light (White light)
Other, specify
Bronchoscopic Findings
Abnormal/malignant
(Abnormal/malignant)
Inflammatory (Inflammatory)
Normal Bronchial Epithelium (Normal
bronchial epithelium)
Other, Specify (Other, specify)
Unknown (Unknown)
Other, specify
By what type of bronchoscopy was the
abnormality detected (If abnormality was
observed, - for Chemoprevention trials - check all
that apply)
Fluorescence (Fluorescence)
Other, Specify (Other, specify)
Rigid (Rigid)
White Light (White light)
Other specify
Bronchial Site (check all that apply - Note:  Only
list values needed for protocol)
Carina Between Left Bronchus 1 A And
B, Left Bronchus 1a/b (Carina between
LB1 A and B, LB1A/B)
Carina Between Left Bronchus 1 A And
C, Left Bronchus 1a/c (Carina between
LB1 A and C, LB1A/C)
Carina Between Left Bronchus 1 And
Left Bronchus 2, Left Bronchus 1/2
(Carina between LB1 and LB2, LB1/2)
Carina Between Left Bronchus 1 B And
C, Left Bronchus 1b/c (Carina between
LB1 B and C, LB1B/C)
Carina Between Left Bronchus 1+2 And
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Left Bronchus 3, Left Bronchus 1+2/3
(Carina between LB1+2 and LB3,
LB1+2/3)
Carina Between Left Bronchus 10 A And
B, Left Bronchus 10a/b (Carina between
LB10 A and B, LB10A/B)
Carina Between Left Bronchus 10 A And
C, Left Bronchus 10a/c (Carina between
LB10 A and C, LB10A/C)
Carina Between Left Bronchus 10 B And
C, Left Bronchus 10b/c (Carina between
LB10 B and C, LB10B/C)
Carina Between Left Bronchus 2 A And
B, Left Bronchus 2a/b (Carina between
LB2 A and B, LB2A/B)
Carina Between Left Bronchus 2 A And
C, Left Bronchus 2a/c (Carina between
LB2 A and C, LB2A/C)
Carina Between Left Bronchus 2 B And
C, Left Bronchus 2b/c (Carina between
LB2 B and C, LB2B/C)
Carina Between Left Bronchus 3 A And
B, Left Bronchus 3a/b (Carina between
LB3 A and B, LB3A/B)
Carina Between Left Bronchus 4 A And
B, Left Bronchus 4a/b (Carina between
LB4 A and B, LB4A/B)
Carina Between Left Bronchus 4 And
Left Bronchus 5, Left Bronchus 4/5
(Carina between LB4 and LB5, LB4/5)
Carina Between Left Bronchus 5 A And
B, Left Bronchus 5a/b (Carina between
LB5 A and B, LB5A/B)
Carina Between Left Bronchus 6 A And
B, Left Bronchus 6a/b (Carina between
LB6 A and B, LB6A/B)
Carina Between Left Bronchus 6 A And
C, Left Bronchus 6a/c (Carina between
LB6 A and C, LB6A/C)
Carina Between Left Bronchus 6 B And
C, Left Bronchus 6b/c (Carina between
LB6 B and C, LB6B/C)
Carina Between Left Bronchus 8 A And
B, Left Bronchus 8a/b (Carina between
LB8 A and B, LB8A/B)
Carina Between Left Bronchus 8 And
Left Bronchus 9, Left Bronchus 8/9
(Carina between LB8 and LB9, LB8/9)
Carina Between Left Bronchus 9 A And
B, Left Bronchus 9a/b (Carina between
LB9 A and B, LB9A/B)
Carina Between Left Bronchus 9 And
Left Bronchus 10, Left Bronchus 9/10
(Carina between LB9 and LB10, LB9/10)
Carina Between Right Bronchus 9 A And
B, Right Bronchus 9a/b (Carina between
RB 9 A and B, RB9A/B)
Carina Between Right Bronchus 1 A And
B, Right Bronchus 1a/b (Carina between
RB1 A and B, RB1A/B)
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Carina Between Right Bronchus 1 And
Right Bronchus 2, Right Bronchus 1/2
(Carina between RB1 and RB2, RB1/2)
Carina Between Right Bronchus 1 And
Right Bronchus 3, Right Bronchus 1/3
(Carina between RB1 and RB3, RB1/3)
Carina Between Right Bronchus 10 A
And B, Right Bronchus 10a/b (Carina
between RB10 A and B, RB10A/B)
Carina Between Right Bronchus 10 A
And C, Right Bronchus 10a/c (Carina
between RB10 A and C, RB10A/C)
Carina Between Right Bronchus 10 B
And C, Right Bronchus 10b/c (Carina
between RB10 B and C, RB10B/C)
Carina Between Right Bronchus 2 A And
B, Right Bronchus 2a/b (Carina between
RB2 A and B, RB2A/B)
Carina Between Right Bronchus 2 And
Right Bronchus 3, Right Bronchus 2/3
(Carina between RB2 and RB3, RB2/3)
Carina Between Right Bronchus 3 A And
B, Right Bronchus 3a/b (Carina between
RB3 A and B, RB3A/B)
Carina Between Right Bronchus 4 A And
B, Right Bronchus 4a/b (Carina between
RB4 A and B, RB4A/B)
Carina Between Right Bronchus 4 And
Right Bronchus 5, Right Bronchus 4/5
(Carina between RB4 and RB5, RB4/5)
Carina Between Right Bronchus 5 A And
B, Right Bronchus 5a/b (Carina between
RB5 A and B, RB5A/B)
Carina Between Right Bronchus 6 A And
B, Right Bronchus 6a/b (Carina between
RB6 A and B, RB6A/B)
Carina Between Right Bronchus 6 A And
C, Right Bronchus 6a/c (Carina between
RB6 A and C, RB6A/C)
Carina Between Right Bronchus 6 B And
C, Right Bronchus 6b/c (Carina between
RB6 B and C, RB6B/C)
Carina Between Right Bronchus 7 A And
B, Right Bronchus 7a/b (Carina between
RB7 A and B, RB7A/B)
Carina Between Right Bronchus 8 A And
B, Right Bronchus 8a/b (Carina between
RB8 A and B, RB8A/B)
Carina Between Right Bronchus 8 And
Right Bronchus 9, Right Bronchus 8/9
(Carina between RB8 and RB9, RB8/9)
Carina Between Right Bronchus 9 And
Right Bronchus 10, Right Bronchus 9/10
(Carina between RB9 and RB10,
RB9/10)
Carina, Not Otherwise Specified (Carina,
NOS)
Other, Specify (OTHER, SPECIFY)
Other, specify
4 / 6
Pathology - Lung Cancer - Pathology Form - Bronchoscopy -
2019346v3.0
Histologic Type (WHO - check all that apply)
Adenocarcinoma (Adenocarcinoma)
Bronchoalveolar (bac) (Bronchoalveolar
carcinoma (BAC))
Carcinoid (Carcinoid)
Combined/mixed, Specify Subcategories
(Combined/mixed)
Large Cell Carcinoma (Large cell
carcinoma)
No Malignancy Observed (No
malignancy observed)
Non-small Cell Lung Cancer (nsclc), Nos
(Non-small cell lung cancer NOS)
Other (Other specify)
Pre-malignant Changes Observed (Pre-
malignant changes observed)
Small Cell Carcinoma (oat Cell) (Small
cell carcinoma (oat cell))
Squamous Cell Carcinoma (Squamous
cell carcinoma)
Specify subcategories
Other specify
Associated Pre-Malignant Histologic Changes (If
Pre-Malignant Changes Observed, - check all
that apply)
Atypical Adenomatous Hyperplasia
(Atypical adenomatous hyperplasia)
Basal Cell Hyperplasia (Basal cell
hyperplasia)
Basal Cell Hyperplasia With Angiogenic
Squamous Dysplasia Changes (Basal
cell hyperplasia with ASD changes)
Carcinoma In Situ (Carcinoma in situ)
Mild Dysplasia (Mild dysplasia)
Mild Dyplasia With Angiogenic
Squamous Dysplasia Changes (Mild
dysplasia with ASD changes)
Moderate Dysplasia (Moderate
dysplasia)
Moderate Dysplasia With Angiogenic
Squamous Dysplasia Changes
(Moderate dysplasia with ASD changes)
Other, Specify (Other, specify)
Severe Dysplasia (Severe dysplasia)
Severe Dysplasia With Angiogenic
Squamous Dysplasia Changes (Severe
dysplasia with ASD changes)
Squamous Metaplasia (Squamous
Metaplasia)
Squamous Metaplasia With Angiogenic
Squamous Dysplasia Changes
(Squamous metaplasia with ASD
changes)
Other, specify
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Specimen Condition
Inadequate (Inadequate)
Satisfactory (Satisfactory)
Suboptimal (Suboptimal)
Inflammatory Change
Specimen Or Sample Is Comprised Of
Less Than 10% Inflammatory Cells
(<10% inflammatory cells)
Specimen Or Sample Is Comprised Of
More Than 75% Inflammatory Cells
(>75% inflammatory cells)
Specimen Or Sample Is Comprised Of
10% To 75% (inclusive) Inflammatory
Cells (10-75% inflammatory cells)
Additional Diagnoses Specify
Reviewing Pathologist
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Neoplasms, Breast NCT00490139 On-Study - BIG 2-06 / NCCTG N063D
/ EGF106708 - Unscheduled Radiological Exams - 2644437v1.0
BIG 2-06 / NCCTG N063D / EGF106708 - Unscheduled
Radiological Exams
ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment
Optimisation) Study; BIG 2-06/N063D
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=319E6E02-
8CAD-7131-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/8553
BIG 2-06 / NCCTG N063D /
EGF106708 - Unscheduled
Radiological Exams
Header Module
Centre No.
Subject No.
Ecg
Type of radiological examination
Bone Scan (Bone scan)
Computed Tomography (CT scan)
Endoscopy (Endoscopy)
Lymphangiogram (Lymphangiogram)
Mammography (Mammography)
Magnetic Resonance Imaging (MRI)
Nuclear Scan (Nuclear scan)
Other (Other)
Positron Emission Tomography (PET
scan)
Pet/ct Scan (PET/CT scan)
Transvaginal Ultrasound (Transvaginal
Ultrasound)
Ultrasound (Ultrasound)
X-ray (X-ray)
Anatomical site
Abdomen (Abdomen)
Abdomen/abdominal Wall
(Abdomen/abdominal wall)
Bladder (Bladder)
Bone (Bone)
Breast (Breast)
Cervix Uteri (Cervix)
Chest (Chest)
Central Nervous System (CNS)
Colon (Colon)
Colorectal (Colorectal)
Esophagus (Esophagus/Oesophagus)
Head And Neck (Head and Neck)
Heart (Heart)
Kidney (Kidney)
Liver (Liver)
Lung (Lung)
Lymph Node (Lymph Node)
Mouth (Oral Cavity)
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Other (Other)
Ovary (Ovary)
Pancreas (Pancreas)
Pelvis (Pelvis)
Peritoneum (Peritoneum)
Pleura (Pleura)
Prostate Gland (Prostate)
Rectum (Rectum)
Skin (Skin)
Small Intestine (Small Intestine)
Spleen (Spleen)
Stomach (Stomach)
Testis (Testicle)
Thyroid Gland (Thyroid)
Date of test
Are there any clinically significant abnormalities
Yes
No
Specify
2 / 2
Neoplasms, Breast NCT00490139 On-Study - BIG 2-06 / NCCTG N063D
/ EGF106708 - Unscheduled Radiological Exams - 2644437v1.0
Sarcoma, Kaposi xxx Lab - Chemistries,
LFT's - RF23 - 2266142v3.0
Chemistries, LFT's - RF23
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=CCE1C5E4-
2834-4238-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/8554
Chemistries, LFT's - RF23
Ccrr Module For Chemistries, Lft's - Rf23
Globulin (g/dl)
Magnesium
Phosphorous (mg/dl)
Sequence #
Cycle Day
Total Triglycerides (mg/dl)
CPK (Creatinine Phosphokinase) (U/L)
Amylase (U/L)
Lipase (U/L)
Patient Initials
Study#
Site#
ID#
Cycle#
Date Specimen Obtained
Which evaluation does this represent?
Entry/Baseline (Entry/Baseline)
On Treatment (On Treatment)
Post Therapy Evaluation (Post Therapy
Evaluation)
Sodium (mEq/L)
Potassium (mEq/L)
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Chloride (mEq/L)
Calcium (mg/dl)
CO2 (Bicarbonate) (mEq/L)
Alkaline Phosphatase (mU/ml)
SGOT (AST) (mU/ml)
SGPT (ALT) (mU/ml)
LDH (Lactic Dehydrogenase) (mU/ml)
Urea Nitrogen (BUN) (mg/dl)
Creatinine (mg/dl)
Uric Acid (mg/dl)
Glucose (mg/dl)
Total Bilirubin (mg/dl)
Total Protein (mg/dl)
Albumin (g/dl)
LDL (mg/dl)
HDL (mg/dl)
Total Cholesterol (mg/dl)
Other, specify
Other, specify
Units, specify
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Treatment - Brain Cancer - Definitive
Surgery Form - 2286489v3.0
Brain Cancer - Definitive Surgery Form
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=DE9506AA-
7EEF-2525-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/8555
Brain Cancer - Definitive Surgery
Form
Crf Header
Coordinating Group Protocol No.
Coordinating Group Code
Protocol Title
Patient Study ID
Institution/Affiliate
Other Patient ID
Participating Group Code
Patient Name (initials acceptable)
Brain: Form Administration
Person Completing Form
Are data amended (If data are amended, please
circle in red when using paper form)
Yes
No
Brain: Surgical Treatment For Primary Site
Primary Surgery Date (MM DD YYYY)
Site of Primary Surgery
Extent of Resection
Biopsy (Biopsy)
Subtotal (Subtotal)
Total (gross) (Total (gross))
Brain: Most Recent Surgery
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Date of Most Recent Surgery (MM DD YYYY)
Enhancing residual disease?
Indeterminate (Indeterminate)
No (No)
Yes (Yes)
Extent of Resection
Biopsy (Biopsy)
Subtotal (Subtotal)
Total (gross) (Total (gross))
Non-enhancing residual disease?
Indeterminate (Indeterminate)
No (No)
Yes (Yes)
Was there gross evidence of tumor?
No (No)
Unknown (Unknown)
Yes (Yes)
Is necrosis present?
No (NO)
Unknown (UNKNOWN)
Yes (YES)
Comments
Comments
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Quality of Life - Z4032 Lung Cancer Quality
of Life - 2858710v1.0
Z4032 Quality of Life
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=665C50CD-
E03C-DFF5-E040-BB89AD43117E
All rights reserved. Please visit https://medical-data-
models.org/forms/8556
Z4032 Lung Cancer Quality of Life
Header Module
Visit
Month 12 (Month 12)
Month 24 (Month 24)
Month 3 (Month 3)
Registration (Registration)
Patient ID (Pt. ID issued during registration or
previously issued Patient ID)
Institution ID
Patient Initials
Institution
Header
In general, would you say your health is
Excellent (Excellent)
Fair (Fair)
Good (Good)
Poor (Poor)
Very Good (Very good)
Compared to one year ago, how would you rate
your health in general now
About The Same As One Year Ago
(About the same as one year ago)
Much Better Now Than One Year Ago
(Much better now than one year ago)
Much Worse Now Than One Year Ago
(Much worse now than one year ago)
Somewhat Better Now Than One Year
Ago (Somewhat better now than one
year ago)
Somewhat Worse Now Than One Year
Ago (Somewhat worse now than one
year ago)
Module Question 3
Vigorous activities, such as running, lifting heavy
objects, participating in strenuous sports
No, Not Limited At All (No, not limited at
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all)
Yes, Limited A Little (Yes, limited a little)
Yes, Limited A Lot (Yes, limited a lot)
Moderate activities, such as moving a table,
pushing a vacuum cleaner, bowling, or playing
golf
No, Not Limited At All (No, not limited at
all)
Yes, Limited A Little (Yes, limited a little)
Yes, Limited A Lot (Yes, limited a lot)
Lifting or carrying groceries
No, Not Limited At All (No, not limited at
all)
Yes, Limited A Little (Yes, limited a little)
Yes, Limited A Lot (Yes, limited a lot)
Climbing several flights of stairs
No, Not Limited At All (No, not limited at
all)
Yes, Limited A Little (Yes, limited a little)
Yes, Limited A Lot (Yes, limited a lot)
Climbing one flight of stairs
No, Not Limited At All (No, not limited at
all)
Yes, Limited A Little (Yes, limited a little)
Yes, Limited A Lot (Yes, limited a lot)
Bending, kneeling or stooping
No, Not Limited At All (No, not limited at
all)
Yes, Limited A Little (Yes, limited a little)
Yes, Limited A Lot (Yes, limited a lot)
Walking more than a mile
No, Not Limited At All (No, not limited at
all)
Yes, Limited A Little (Yes, limited a little)
Yes, Limited A Lot (Yes, limited a lot)
Walking several blocks
No, Not Limited At All (No, not limited at
all)
Yes, Limited A Little (Yes, limited a little)
Yes, Limited A Lot (Yes, limited a lot)
Walking one block
No, Not Limited At All (No, not limited at
all)
Yes, Limited A Little (Yes, limited a little)
Yes, Limited A Lot (Yes, limited a lot)
Bathing or dressing yourself
No, Not Limited At All (No, not limited at
all)
Yes, Limited A Little (Yes, limited a little)
Yes, Limited A Lot (Yes, limited a lot)
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Module Question 4
Cut down on the amount of time you spent on
work or other activities
Yes
No
Accomplished less than you would like
Yes
No
Were limited in the kind of work or other activities
Yes
No
Had difficulty performing the work or other
activities (for example, it took extra effort)
Yes
No
Module Question 5
Cut down on the amount of time you spent on
work or other activities
Yes
No
Accomplished less than you would like
Yes
No
Did work or other activities less carefully than
usual
Yes
No
During the past 4 weeks, to what extent has your
physical health or emotional problems interfered
with your normal social activities with family,
friends, neighbors, or groups
Extremely (Extremely)
Moderately (Moderately)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Slightly (Slightly)
How much bodily pain have you had during the
past 4 weeks
Mild (Mild)
Moderate (Moderate)
None (None)
Severe (Severe)
Very Mild (Very mild)
Very Severe (Very severe)
During the past 4 weeks, how much did pain
interfere with your normal work (including both
work outside the home and housework)
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A Little Bit (A little bit)
Extremely (Extremely)
Moderately (Moderately)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Module Question 9
Did you feel full of pep
A Good Bit Of The Time (A good bit of
the time)
A Little Of The Time (A little of the time)
All Of The Time (All of the time)
Most Of The Time (Most of the time)
None Of The Time (None of the time)
Some Of The Time (Some of the time)
Have you been a very nervous person
A Good Bit Of The Time (A good bit of
the time)
A Little Of The Time (A little of the time)
All Of The Time (All of the time)
Most Of The Time (Most of the time)
None Of The Time (None of the time)
Some Of The Time (Some of the time)
Have you felt so down in the dumps that nothing
could cheer you up
A Good Bit Of The Time (A good bit of
the time)
A Little Of The Time (A little of the time)
All Of The Time (All of the time)
Most Of The Time (Most of the time)
None Of The Time (None of the time)
Some Of The Time (Some of the time)
Have you felt calm and peaceful
A Good Bit Of The Time (A good bit of
the time)
A Little Of The Time (A little of the time)
All Of The Time (All of the time)
Most Of The Time (Most of the time)
None Of The Time (None of the time)
Some Of The Time (Some of the time)
Did you have a lot of energy
A Good Bit Of The Time (A good bit of
the time)
A Little Of The Time (A little of the time)
All Of The Time (All of the time)
Most Of The Time (Most of the time)
None Of The Time (None of the time)
Some Of The Time (Some of the time)
Have you felt downhearted and blue
A Good Bit Of The Time (A good bit of
the time)
A Little Of The Time (A little of the time)
All Of The Time (All of the time)
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Most Of The Time (Most of the time)
None Of The Time (None of the time)
Some Of The Time (Some of the time)
Did you feel worn out
A Good Bit Of The Time (A good bit of
the time)
A Little Of The Time (A little of the time)
All Of The Time (All of the time)
Most Of The Time (Most of the time)
None Of The Time (None of the time)
Some Of The Time (Some of the time)
Have you been a happy person
A Good Bit Of The Time (A good bit of
the time)
A Little Of The Time (A little of the time)
All Of The Time (All of the time)
Most Of The Time (Most of the time)
None Of The Time (None of the time)
Some Of The Time (Some of the time)
Did you feel tired
A Good Bit Of The Time (A good bit of
the time)
A Little Of The Time (A little of the time)
All Of The Time (All of the time)
Most Of The Time (Most of the time)
None Of The Time (None of the time)
Some Of The Time (Some of the time)
During the past 4 weeks, how much of the time
has your physical health or emotional problems
interfered with your social activities (like visiting
friends, relatives, etc.)
A Little Of The Time (A little of the time)
All Of The Time (All of the time)
Most Of The Time (Most of the time)
None Of The Time (None of the time)
Some Of The Time (Some of the time)
Module Question 11
I seem to get sick a little easier than other people
Definitely False (Definitely false)
Definitely True (Definitely true)
Don't Know (Don't know)
Mostly False (Mostly false)
Mostly True (Mostly true)
I am as healthy as anybody I know
Definitely False (Definitely false)
Definitely True (Definitely true)
Don't Know (Don't know)
Mostly False (Mostly false)
Mostly True (Mostly true)
I expect my health to get worse
Definitely False (Definitely false)
Definitely True (Definitely true)
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Don't Know (Don't know)
Mostly False (Mostly false)
Mostly True (Mostly true)
My health is excellent
Definitely False (Definitely false)
Definitely True (Definitely true)
Don't Know (Don't know)
Mostly False (Mostly false)
Mostly True (Mostly true)
Footer Module
Date Form Completed
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Response - Baseline Brain Tumor
Evaluation Form - 2291059v3.0
Baseline Brain Tumor Evaluation Form
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=E12EBFF4-
9ABA-55D4-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/8558
Baseline Brain Tumor Evaluation
Form
Crf Header
Coordinating Group Protocol No.
Coordinating Group Code
Protocol Title
Patient Study ID
Institution/Affiliate
Other Patient ID
Participating Group Code
Patient Name (initials acceptable)
Brain: Disease At Baseline
Is the patient NED?
No (No)
Unknown (Unknown)
Yes (Yes)
Brain: Measurable Lesion(s) Baseline
Evaluation
Is measurable disease present?
Yes
No
Lesion Number
Site of Lesion
Longest Bidimensional Measurements of Lesions
(cm)
Longest Bidimensional Measurements of Lesions
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(x cm)
Method of Evaluation
Clinical Examination (pe) (Clinical
examination)
Ct Scan (CT Scan)
Mri (MRI (NMR))
Other (Other)
Pet Scan (PET scan)
Other Specify (If)
Date of Evaluation (MM DD YYYY)
Prior RT to Lesion Site?
New Lesion In Previously Irradiated Field
(New lesion in previously irradiated field)
None (None)
Outside All Previously Irradiated Fields
(Outside all previously irradiated fields)
Previously Irradiated Lesion (Previously
irradiated lesion)
Sum of Longest Transverse Diameters (of All
Measureable Lesions)
Sum of Products of Greatest Diameters (of All
Measurable Lesions)
Brain: Non-measurable/evaluable
Lesion(s) Baseline Evaluation
Is non-measurable disease present?
Yes
No
Lesion Number
Site of Lesion
Method of Evaluation
Clinical Examination (pe) (Clinical
examination)
Ct Scan (CT Scan)
Mri (MRI (NMR))
Other (Other)
Pet Scan (PET scan)
Other Specify (If)
Date of Evaluation (MM DD YYYY)
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Prior RT to Lesion Site?
New Lesion In Previously Irradiated Field
(New lesion in previously irradiated field)
None (None)
Outside All Previously Irradiated Fields
(Outside all previously irradiated fields)
Previously Irradiated Lesion (Previously
irradiated lesion)
Comments
Comments
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On-Study - Prostate Cancer - Non-Localized
Disease On-Study Form - 2263681v3.0
Prostate Cancer - Non-Localized Disease On-Study Form
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=DC4FE213-
706E-5DF9-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/8559
Prostate Cancer - Non-Localized
Disease On-Study Form
Crf Header
Coordinating Group Protocol No.
Coordinating Group Code
Protocol Title
Patient Study ID
Institution/Affiliate
Other Patient ID
Participating Group Code
Patient Name (initials acceptable)
Prostate: Initial Diagnosis
PSA Value at Diagnosis
Gleason Score, Primary Pattern (1-5, 9:unknown)
Unit of Measure ([n/mg, ng/mL, U/L, mg/L, ng/dL,
mcg/L])
Micrograms Per Liter (mcg/L)
Milligrams Per Liter (mg/L)
N/milligram (n/mg)
Nanograms Per Deciliter (ng/dL)
Nanograms Per Milliliter (ng/mL)
Units Per Liter (U/L)
Gleason Score, Secondary Pattern (1-5,
9:unknown)
Gleason Score, Worst Pattern (1-5, 9:unknown)
Gleason Score Based on Specimen Type
Biopsy (Biopsy (including TURP))
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Surgical Specimen (Surgical specimen)
Gleason Score, Combined (2-10 if primary and
secondary patterns unavailable)
Prostate: Prior Treatment
Prior Prostatectomy?
Yes
No
Prior Prostatectomy Date
Prior Radiation Therapy
Yes
No
Prior Radiation Therapy Type
Brachytherapy (implant) (Brachytherapy
(implant))
External Beam (External beam)
Date Prior RT Started
Date Prior RT Ended
Prior Hormonal Therapy
Yes
No
Prior Hormonal Therapy Type
Orchiectomy (Orchiectomy)
Other (Other)
Total Androgen Suppression (Total
Androgen Suppression)
Date Prior Hormonal Therapy Started
Date Prior Hormonal Therapy Ended
Prior Systemic Chemotherapy
Yes
No
Date Prior Chemotherapy Started
Date Prior Chemotherapy Ended
Any other Prior Therapy?
Yes
No
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Name of Other Prior Therapies
Date Other Prior Therapy Started
Date Other Prior Therapy Ended
Start Date of First Prior Treatment
Prostate: Disease Status
Date of First Clinical Progression (per protocol
definition)
Date of First Biochemical Progression (per
protocol definition)
Baseline PSA Value (per protocol definition)
Unit of Measure ([n/mg, ng/mL, U/L, mg/L, ng/dL,
mcg/L])
Micrograms Per Liter (mcg/L)
Milligrams Per Liter (mg/L)
N/milligram (n/mg)
Nanograms Per Deciliter (ng/dL)
Nanograms Per Milliliter (ng/mL)
Units Per Liter (U/L)
Date of Baseline PSA
Prostate: Metastatic/recurrent Site(s)
Is the Primary Site or tumor bed involved
Yes
No
Lung
Yes
No
Liver
Yes
No
Pleura
Yes
No
CNS (excluding Brain)
Yes
No
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Bone
Yes
No
Soft Tissue
Yes
No
Other
Yes
No
If sites other than specified, Indicate Name
Was only PSA elevated?
Yes
No
Is measurable disease present? (only applicable
in studies where there is residual disease at
baseline)
Yes
No
Is non-measurable disease present? (only
applicable in studies where there is residual
disease at baseline)
Yes
No
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Neoplasms, Breast NCT00490139 On-Study - BIG 2-06 / NCCTG N063D /
EGF106708 - Second Primary Malignancy and Contralateral Breast Cancer -
2640082v1.0
BIG 2-06 / NCCTG N063D / EGF106708 - Second Primary
Malignancy and Contralateral Breast Cancer
ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment
Optimisation) Study; BIG 2-06/N063D
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=30FE4342-
8C69-1B74-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/8561
BIG 2-06 / NCCTG N063D /
EGF106708 - Second Primary
Malignancy and Contralateral Breast
Cancer
Header Module
Centre No.
Subject No.
Second Primary Malignancy And
Contralateral Breast Cancer
Type of recurrence
Date of First Recurrence or Progression
Method of Evaluation
Clinical (Clinical)
Radiology (Radiological)
Biopsy
Yes
No
Biopsy Date
Specify Other Histologic Type
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Sarcoma, Kaposi xxx On-Study - Kaposi's
Sarcoma Evaluation - RKS02B - 2266721v3.0
Kaposi's Sarcoma Evaluation - RKS02B
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=CCE28BEA-
7B40-47F1-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/8562
Kaposi's Sarcoma Evaluation -
RKS02B
Ccrr Module For Kaposi's Sarcoma
Evaluation - Rks02b
Visc Eval
A complete resolution of visceral disease
since baseline (A complete resolution of
visceral disease since baseline)
A decrease in visceral disease since
baseline (A decrease in visceral disease
since baseline)
A worsening of visceral disease since
baseline, or since the best response (A
worsening of visceral disease since
baseline, or since the best response)
Evidence of a new site of visceral
disease (Evidence of a new site of
visceral disease)
No change (No change)
Not applicable, Entry/Baseline evaluation
(Not applicable, Entry/Baseline
evaluation)
Unnamed
Flat Lesion (Flat Lesion)
Raised Lesion (Raised Lesion)
Sum of Products
Are there any oral cavity lesions present at this
evaluation
Yes
No
Kaposi's Sarcoma Present
Yes
No
Oral lesions
A resolution of all oral lesions since
baseline (A resolution of all oral lesions
since baseline)
A worsening of oral lesions since
baseline or best response (A worsening
of oral lesions since baseline or best
response)
An improvement of oral lesions since
baseline (An improvement of oral lesions
since baseline)
New oral lesions (New oral lesions)
None of the above (None of the above)
1 / 5
Is there any tumor-associated edema at this
evaluation
Yes
No
Edema Site
Genital (Genital)
Left Arm (Left Arm)
Left Foot (Left Foot)
Left Hand (Left Hand)
Left Leg (Left Leg)
Other (Other)
Periorbital (Periorbital)
Right Arm (Right Arm)
Right Foot (Right Foot)
Right Hand (Right Hand)
Right Leg (Right Leg)
Other specify
Edema Present
Yes
No
Tumor associated edema
A resolution of all tumor-associated
edema since baseline (A resolution of all
tumor-associated edema since baseline)
A worsening of tumor-associated edema
since baseline or best response (A
worsening of tumor-associated edema
since baseline or best response)
An improvement of tumor-associated
edema since baseline (An improvement
of tumor-associated edema since
baseline)
New tumor-associated edema (New
tumor-associated edema)
No change (No change)
Site Code
Specify Site
KS Invol
Absent (Absent)
Present (Present)
Product of Diameters
Perpendicular Diameters
Total Number Raised Lesions
Character of cutaneous lesions
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>=25% increase in the number of raised
lesions since baseline or since best
response (>=25% increase in the
number of raised lesions since baseline
or since best response)
None of the above (None of the above)
Since baseline, >=50% of raised have
become flat (Since baseline, >=50% of
raised have become flat)
What is the present status of the best response?
No relapse ovserved, but patient died
(No relapse ovserved, but patient died)
Not applicable (Not applicable)
Relapse occurred after a response was
achieved (Relapse occurred after a
response was achieved)
Response continuing or first time at this
response (Response continuing or first
time at this response)
Number of lesions
>=25% increase in the number of lesions
since baseline or since best response
(>=25% increase in the number of
lesions since baseline or since best
response)
>=50% decrease in the number of
lesions since baseline (>=50% decrease
in the number of lesions since baseline)
Complete Resolution (Complete
Resolution)
None of the above (None of the above)
Total Number Flat Lesions
Patient Initials
Study#
Site#
ID#
Cycle #
Date of Procedure
Date of Procedure
Which Karposi's Sarcoma evaluation does this
represent?
End Of Therapy (End of therapy)
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Prior To Study Entry (Entry/Baseline)
Not Done (Not done)
Off Treatment (Off treatment)
On Study (On Treatment)
Other, Specify (Other, specify)
Follow-up (Post Therapy Evaluation)
Lesion Count
Yes
No
Specify
Number of lesions
Progressive Disease (>=25% increse in
the sum of the products of the diameters
of all marker lesions since baseline, or
since best response)
Incomplete Response Or Stable
Disesase (>=50% decrease in the sum
of the product of the diameters of all
marker lesions since baseline)
Complete Response (Complete
Resolution)
Death Prior To Completion Of Protocol
Criteria (Early death)
Incomplete Response Or Stable
Disesase (Incomplete response/SD)
Insufficient Evaluation (Insufficient
evaluation to determine response status)
None of the above (None of the above)
Stable Disease (SD)
Oral Site
Buccal Mucosa (Buccal Mucosa)
Floor of Mouth (Floor of Mouth)
Gingiva/Gums (Gingiva/Gums)
Hard Palate (Hard Palate)
Posterior Pharnyx (Posterior Pharnyx)
Soft Palate (Soft Palate)
Tongue (Tongue)
Tonsils (Tonsils)
Uvula (Uvula)
Oral Site
Buccal Mucosa (Buccal Mucosa)
Floor of Mouth (Floor of Mouth)
Gingiva/Gums (Gingiva/Gums)
Hard Palate (Hard Palate)
Posterior Pharnyx (Posterior Pharnyx)
Soft Palate (Soft Palate)
Tongue (Tongue)
Tonsils (Tonsils)
Uvula (Uvula)
Oral Site
Buccal Mucosa (Buccal Mucosa)
Floor of Mouth (Floor of Mouth)
Gingiva/Gums (Gingiva/Gums)
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Hard Palate (Hard Palate)
Posterior Pharnyx (Posterior Pharnyx)
Soft Palate (Soft Palate)
Tongue (Tongue)
Tonsils (Tonsils)
Uvula (Uvula)
Has a visceral disease evaluation been done
since the last KS evaluation
Yes
No
Proced
Bronchoscopy (Bronchoscopy)
Chest X-ray (Chest X-ray)
Colonoscopy (Colonoscopy)
Ct Scan (Computerized tomography)
Other (Other)
Sigmoldoscopy (Sigmoldoscopy)
Upper endoscopy (Upper endoscopy)
Specify Procedure
Best overall response attained since
Entry/Baseline:
Complete Response (Clinical complete
response)
Complete Response (Complete.)
Death Prior To Completion Of Protocol
Criteria (Early death)
Incomplete Response Or Stable
Disesase (Incomplete response/SD)
Partial Response (Partial Response)
Progressive Disease (PD)
Partial Response (Progression)
Stable Disease (Stable)
Insufficient Evaluation (Unevaluable)
Unknown (Unknown)
Date of relapse, if applicable
Complete response date
Clinical complete response date
Partial Response date
Progression with no prior response date
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On-Study - Primary Brain Cancer - On-Study
Form Recurrent Treatment - 2293986v3.0
Primary Brain Cancer - On-Study Form Recurrent
Treatment
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=E51DA7FB-
264B-3B94-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/8563
Primary Brain Cancer - On-Study
Form Recurrent Treatment
Crf Header
Coordinating Group Protocol No.
Coordinating Group Code
Protocol Title
Patient Study ID
Institution/Affiliate
Other Patient ID
Participating Group Code
Patient Name (initials acceptable)
Brain: Form Administration
Person Completing Form
Are data amended (If data are amended, please
circle in red when using paper form)
Yes
No
Brain: Recurrent Disease Description
Date of Initial Diagnosis of Primary Tumor (MM
DD YYYY)
Basis of Diagnosis
Histology (Histology)
Imaging Only (Imaging only)
Basis of Diagnosis
Histology (Histology)
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Imaging Only (Imaging only)
Histologic Type (most recent)
9351-1 Craniopharyngioma,
Adamantinomatous (c75.2)
(Adamantinomatous)
9401-3 Astrocytoma, Anaplastic (c71._)
(Anaplastic astrocytoma)
9392-3 Ependymoma, Anaplastic (c71._)
(Anaplastic ependymoma)
9505-3 Ganglioglioma, Anaplastic
(Anaplastic ganglioglioma)
Anaplastic Meningioma (Anaplastic
meningioma)
Anaplastic Oligoastrocytoma (Anaplastic
oligoastrocytoma)
9451-3 Oligodendroglioma, Anaplastic
(c71._) (Anaplastic oligodendroglioma)
9534-0 Angiomatous Meningioma
(Angiomatous meningioma)
9430-3 Astroblastoma (c71._)
(Astroblastoma)
9539-1 Atypical Meningioma (Atypical
meningioma)
9508-3 Atypical Teratoid-rhabdoid Tumor
(c71._) (Atypical teratoid/rhabdoid tumor)
9506-1 Central Neurocytoma (Central
neurocytoma)
Cerebellar Liponeurocytoma (Cerebellar
liponeurocytoma)
Chordoid Glioma Of The Third Ventricle
(Chordoid glioma of the third ventricle)
Chordoid Meningioma (Chordoid
meningioma)
Choriocarcinoma (Choriocarcinoma)
9390-3 Choroid Plexus Carcinoma
(c71.5) (Choroid plexus carcinoma)
9390-0 Choroid Plexus Papilloma, Nos
(c71.5) (Choroid plexus papilloma)
9538-1 Clear Cell Meningioma (Clear
cell meningioma)
9350-1 Craniopharyngioma (c75.2)
(Craniopharyngioma)
Desmoplastic Infantile
Astrocytoma/ganglioma (Desmoplastic
infantile astrocytoma/ganglioma)
Desmoplastic Medulloblastoma
(Desmoplastic medulloblastoma)
Diffuse Astrocytoma (Diffuse
astrocytoma)
9413-0 Dysembryoplastic Neuroepithelial
Tumor (Dysembryoplastic neuroepithelial
tumor)
9493-0 Dysplastic Gangliocytoma Of
Cerebellum (lhermitte-duclos) (c71.6)
(Dysplastic gangliocytoma of cerebellum)
Embryonal Carcinoma (Embryonal
carcinoma)
Ependymoblastoma
(Ependymoblastoma)
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9391-3 Ependymoma, Nos (c71._)
(Ependymoma)
9420-3 Fibrillary Astrocytoma (c71._)
(Fibrillary astrocytoma)
9532-0 Fibrous Meningioma (Fibrous
meningioma)
9492-0 Gangliocytoma (Gangliocytoma)
9505-1 Ganglioglioma, Nos
(Ganglioglioma)
9490-3 Ganglioneuroblastoma
(Ganglioneuroblastoma)
9411-3 Gemistocytic Astrocytoma
(c71._) (Gemistocytic astrocytoma)
9064-3 Germinoma (Germinoma)
9441-3 Giant Cell Glioblastoma (c71._)
(Giant cell glioblastoma)
9440-3 Glioblastoma, Nos (c71._)
(Glioblastoma)
9381-3 Gliomatosis Cerebri (c71._)
(Gliomatosis cerebri)
9442-3 Gliosarcoma (c71._)
(Gliosarcoma)
9580-0 Granular Cell Tumor, Nos
(Granular cell tumor)
High Grade Astrocytoma, Nos (High
grade astrocytoma NOS)
9474-3 Large Cell Medulloblastoma
(c71.6) (Large cell medulloblastoma)
Low Grade Astrocytoma, Nos (Low
grade astrocytoma NOS)
Lymphoplasmacyte-rich Meningioma
(Lymphoplasmacyte-rich meningioma)
9470-3 Medulloblastoma, Nos (c71.6)
(Medulloblastoma)
9501-3 Medulloepithelioma, Nos
(Medulloepithelioma)
9472-3 Medullomyoblastoma (c71.6)
(Medullomyoblastoma)
Melanotic Medulloblastoma (Melanotic
medulloblastoma)
9531-0 Meningothelial Meningioma
(Meningothelial meningioma)
Metaplastic Meningioma (Metaplastic
meningioma)
Microcystic Meningioma (Microcystic
meningioma)
Mixed Germ Cell Tumor (Mixed germ cell
tumors)
9394-1 Myxopapillary Ependymoma
(c72.0) (Myxopapillary ependymoma)
9500-3 Neuroblastoma, Nos
(Neuroblastoma)
Neuroblastomas Of The Adrenal Gland
And Sympathetic Nervous System
(Neuroblastomas of the adrenal gland
and sympathetic nervous system)
9522-3 Olfactory Neuroblastoma (c30.0)
(Olfactory neuroblastoma)
9523-3 Olfactory Neuroepithelioma
(c30.0) (Olfactory neuroepithelioma)
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Oligoastrocytoma (Oligoastrocytoma)
9450-3 Oligodendroglioma, Nos (c71._)
(Oligodendroglioma)
Other, Specify (Other specify)
9352-1 Craniopharyngioma, Papillary
(c75.2) (Papillary)
9538-3 Papillary Meningioma (Papillary
meningioma)
Paraganglioma Of The Filum Terminale
(Paraganglioma of the filum terminale)
9421-1 Pilocytic Astrocytoma (c71._)
(Pilocytic astrocytoma)
Pineal Parenchymal Tumor Of
Indeterminate Differentiation (Pineal
parenchymal tumor of indeterminate
differentiation)
9362-3 Pineoblastoma (c75.3)
(Pineoblastoma)
9361-1 Pineocytoma (c75.3)
(Pineocytoma)
9424-3 Pleomorphic Xanthoastrocytoma
(c71._) (Pleomorphic
xanthoastrocytoma)
9410-3 Protoplasmic Astrocytoma
(c71._) (Protoplasmic astrocytoma)
9533-0 Psammomatous Meningioma
(Psammomatous meningioma)
Rhabdoid Meningioma (Rhabdoid
meningioma)
Schwannoma (neurilemmoma,
Neurinoma) (Schwannoma)
Secretory Meningioma (Secretory
meningioma)
9384-1 Subependymal Giant Cell
Astrocytoma (c71._) (Subependymal
giant cell astrocytoma)
9383-1 Subependymoma (c71._)
(Subependymoma)
Supratentorial Primitive
Neuroectodermal Tumor (pnet)
(Supratentorial primitive
neuroectodermal tumor)
Teratoma (Teratoma)
9537-0 Transitional Meningioma
(Transitional meningioma)
Yolk Sac Tumor (Yolk sac tumor)
Histologic Type (most recent)
9351-1 Craniopharyngioma,
Adamantinomatous (c75.2)
(Adamantinomatous)
9401-3 Astrocytoma, Anaplastic (c71._)
(Anaplastic astrocytoma)
9392-3 Ependymoma, Anaplastic (c71._)
(Anaplastic ependymoma)
9505-3 Ganglioglioma, Anaplastic
(Anaplastic ganglioglioma)
Anaplastic Meningioma (Anaplastic
meningioma)
Anaplastic Oligoastrocytoma (Anaplastic
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oligoastrocytoma)
9451-3 Oligodendroglioma, Anaplastic
(c71._) (Anaplastic oligodendroglioma)
9534-0 Angiomatous Meningioma
(Angiomatous meningioma)
9430-3 Astroblastoma (c71._)
(Astroblastoma)
9539-1 Atypical Meningioma (Atypical
meningioma)
9508-3 Atypical Teratoid-rhabdoid Tumor
(c71._) (Atypical teratoid/rhabdoid tumor)
9506-1 Central Neurocytoma (Central
neurocytoma)
Cerebellar Liponeurocytoma (Cerebellar
liponeurocytoma)
Chordoid Glioma Of The Third Ventricle
(Chordoid glioma of the third ventricle)
Chordoid Meningioma (Chordoid
meningioma)
Choriocarcinoma (Choriocarcinoma)
9390-3 Choroid Plexus Carcinoma
(c71.5) (Choroid plexus carcinoma)
9390-0 Choroid Plexus Papilloma, Nos
(c71.5) (Choroid plexus papilloma)
9538-1 Clear Cell Meningioma (Clear
cell meningioma)
9350-1 Craniopharyngioma (c75.2)
(Craniopharyngioma)
Desmoplastic Infantile
Astrocytoma/ganglioma (Desmoplastic
infantile astrocytoma/ganglioma)
Desmoplastic Medulloblastoma
(Desmoplastic medulloblastoma)
Diffuse Astrocytoma (Diffuse
astrocytoma)
9413-0 Dysembryoplastic Neuroepithelial
Tumor (Dysembryoplastic neuroepithelial
tumor)
9493-0 Dysplastic Gangliocytoma Of
Cerebellum (lhermitte-duclos) (c71.6)
(Dysplastic gangliocytoma of cerebellum)
Embryonal Carcinoma (Embryonal
carcinoma)
Ependymoblastoma
(Ependymoblastoma)
9391-3 Ependymoma, Nos (c71._)
(Ependymoma)
9420-3 Fibrillary Astrocytoma (c71._)
(Fibrillary astrocytoma)
9532-0 Fibrous Meningioma (Fibrous
meningioma)
9492-0 Gangliocytoma (Gangliocytoma)
9505-1 Ganglioglioma, Nos
(Ganglioglioma)
9490-3 Ganglioneuroblastoma
(Ganglioneuroblastoma)
9411-3 Gemistocytic Astrocytoma
(c71._) (Gemistocytic astrocytoma)
9064-3 Germinoma (Germinoma)
9441-3 Giant Cell Glioblastoma (c71._)
5 / 12
On-Study - Primary Brain Cancer - On-Study Form Recurrent Treatment -
2293986v3.0
(Giant cell glioblastoma)
9440-3 Glioblastoma, Nos (c71._)
(Glioblastoma)
9381-3 Gliomatosis Cerebri (c71._)
(Gliomatosis cerebri)
9442-3 Gliosarcoma (c71._)
(Gliosarcoma)
9580-0 Granular Cell Tumor, Nos
(Granular cell tumor)
High Grade Astrocytoma, Nos (High
grade astrocytoma NOS)
9474-3 Large Cell Medulloblastoma
(c71.6) (Large cell medulloblastoma)
Low Grade Astrocytoma, Nos (Low
grade astrocytoma NOS)
Lymphoplasmacyte-rich Meningioma
(Lymphoplasmacyte-rich meningioma)
9470-3 Medulloblastoma, Nos (c71.6)
(Medulloblastoma)
9501-3 Medulloepithelioma, Nos
(Medulloepithelioma)
9472-3 Medullomyoblastoma (c71.6)
(Medullomyoblastoma)
Melanotic Medulloblastoma (Melanotic
medulloblastoma)
9531-0 Meningothelial Meningioma
(Meningothelial meningioma)
Metaplastic Meningioma (Metaplastic
meningioma)
Microcystic Meningioma (Microcystic
meningioma)
Mixed Germ Cell Tumor (Mixed germ cell
tumors)
9394-1 Myxopapillary Ependymoma
(c72.0) (Myxopapillary ependymoma)
9500-3 Neuroblastoma, Nos
(Neuroblastoma)
Neuroblastomas Of The Adrenal Gland
And Sympathetic Nervous System
(Neuroblastomas of the adrenal gland
and sympathetic nervous system)
9522-3 Olfactory Neuroblastoma (c30.0)
(Olfactory neuroblastoma)
9523-3 Olfactory Neuroepithelioma
(c30.0) (Olfactory neuroepithelioma)
Oligoastrocytoma (Oligoastrocytoma)
9450-3 Oligodendroglioma, Nos (c71._)
(Oligodendroglioma)
Other, Specify (Other specify)
9352-1 Craniopharyngioma, Papillary
(c75.2) (Papillary)
9538-3 Papillary Meningioma (Papillary
meningioma)
Paraganglioma Of The Filum Terminale
(Paraganglioma of the filum terminale)
9421-1 Pilocytic Astrocytoma (c71._)
(Pilocytic astrocytoma)
Pineal Parenchymal Tumor Of
Indeterminate Differentiation (Pineal
parenchymal tumor of indeterminate
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differentiation)
9362-3 Pineoblastoma (c75.3)
(Pineoblastoma)
9361-1 Pineocytoma (c75.3)
(Pineocytoma)
9424-3 Pleomorphic Xanthoastrocytoma
(c71._) (Pleomorphic
xanthoastrocytoma)
9410-3 Protoplasmic Astrocytoma
(c71._) (Protoplasmic astrocytoma)
9533-0 Psammomatous Meningioma
(Psammomatous meningioma)
Rhabdoid Meningioma (Rhabdoid
meningioma)
Schwannoma (neurilemmoma,
Neurinoma) (Schwannoma)
Secretory Meningioma (Secretory
meningioma)
9384-1 Subependymal Giant Cell
Astrocytoma (c71._) (Subependymal
giant cell astrocytoma)
9383-1 Subependymoma (c71._)
(Subependymoma)
Supratentorial Primitive
Neuroectodermal Tumor (pnet)
(Supratentorial primitive
neuroectodermal tumor)
Teratoma (Teratoma)
9537-0 Transitional Meningioma
(Transitional meningioma)
Yolk Sac Tumor (Yolk sac tumor)
Advanced Disease Status at Registration
No Visible Disease (No visible disease)
Recurrent/progressive
(Recurrent/Progressive)
Residual (Residual)
Date of Progression (MM DD YYYY)
Date of Most Recent Pathologic Diagnosis (MM
DD YYYY)
Other specify
Other specify
Site of Lesion (current lesion; check all that
apply)
Aqueduct Of Sylvius (Aqueduct of
sylvius)
Basal Ganglia (Basal ganglia)
Brainstem (Brainstem)
Cauda Equina (Cauda equina)
Cavernous Sinus (Cavernous sinus)
Cerebellar Hemisphere (Cerebellar
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hemisphere)
Cerebellar Peduncle (Cerebellar
peduncle)
Cerebellar Vermis (Cerebellar vermis)
Cerebellum (Cerebellum)
Cervical (Cervical)
Cisterna Magna (Cisterna magna)
Conus (Conus)
Corpus Callosum (Corpus callosum)
Dorsal Exophytic Brainstem (Dorsal
exophytic brainstem)
Fourth Ventricle (Fourth ventricle)
Frontal Lobe (Frontal)
Hypothalamus (Hypothalamus)
Lateral Ventricle (Lateral ventricle)
Leptomeningeal (Leptomeningeal)
Lumbar (Lumbar)
Medulla (Medulla)
Midbrain (Midbrain)
Occipital Lobe (Occipital)
Optic Chiasm (Optic chiasm)
Optic Nerve (Optic nerve)
Other, Specify (Other specify)
Parietal Lobe (Parietal)
Pineal (Pineal)
Pons (Pons)
Spinal Cord (c1 And Below) (Spinal cord)
Temporal Lobe (Temporal)
Thalamus (Thalamus)
Third Ventricle (Third ventricle)
Thoracic (Thoracic)
Other specify
Side
Both (Both)
Left (Left)
Right (Right)
Unknown (Unknown)
Does analysis of tissue show evidence of
therapeutic effects?
No (No)
Unknown (Unknown)
Yes (Yes)
Type of Therapeutic Effect (If Yes,)
Drug-related Changes (Drug-related
changes)
Other, Specify (Other specify)
Radiation Changes (Radiation changes)
Surgical Changes (Surgical changes)
Other specify
Histologic Grade (WHO)
Moderately Differentiated (grade Ii)
(Moderately Differentiated (Grade II))
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Poorly Differentiated (grade Iii) (Poorly
Differentiated (Grade III))
Undifferentiated (grade Iv)
(Undifferentiated (Grade IV))
Unknown (Unknown)
Well Differentiated (grade I) (Well
differentiated (Grade I))
CSF Cytology
Negative (Negative)
Not Done (Not done)
Positive (Positive)
Undetermined (Undetermined)
CSF Involvement
No (No)
Unknown (Unknown)
Yes (Yes)
Brain: Neurologic Function
Neurologic Function Status
Minor Neurologic Symptoms, Fully Active
At Home/work Without Assistance (Minor
neurologic symptoms, fully active at
home/work without assistance)
Moderate Neurologic Symptoms, Fully
Active At Home/work But Requires
Assistance (Moderate neurologic
symptoms, fully active at home/work but
requires assistance)
Moderate Neurologic Symptoms, Less
Than Fully Active At Home/work And
Requires Assitance (Moderate
neurologic symptoms, less than fully
active at home/work and requires
assistance)
No Neurologic Symptoms, Fully Active At
Home/work Without Assistance (No
neurologic symptoms, fully active at
home/work without assistance)
Severe Neurologic Symptoms, Totally
Inactive Requiring Complete Assistance
At Home Or Institution, Unable To Work
(Severe neurologic symptoms, totally
inactive requiring complete assistance at
home or institution, unable to work)
Brain: Concomitant Medications
Is the person receiving anti-convulsant
medication?
No (No)
Unknown (Unknown)
Yes (Yes)
Agent Name (If Yes,)
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Agent Name (If Yes,)
Agent Name (If Yes,)
Agent Start Date (MM DD YYYY)
Agent Start Date (MM DD YYYY)
Agent Start Date (MM DD YYYY)
Is this anti-convulsant medication enzyme-
inducing?
No (No)
Unknown (Unknown)
Yes (Yes)
Is the patient receiving corticosteroids?
No (No)
Unknown (Unknown)
Yes (Yes)
Agent Total Dose (per day)
Is the patient receiving other medications?
No (No)
Unknown (Unknown)
Yes (Yes)
Brain: Prior Health History
Has the patient experienced an intracranial
hemorrhage?
Yes
No
Date of Most Recent (MM DD YYYY)
Has the patient experienced an intraocular
hemorrhage?
Yes
No
Date of Most Recent (MM DD YYYY)
Current Medical Conditions (currently
symptomatic or on medications for)
Cardiac Disease (Cardiac disease)
Cerebrovascular Disease
(Cerebrovascular disease)
Deep Vein Thrombosis (Deep vein
thrombosis)
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Diabetes (Diabetes)
Hypertension (Hypertension)
Other Malignancies, Specify (Other
malignancies specify)
Other, Specify (Other specify)
Other malignancies specify
Other specify
Brain: Prior Treatment
Prior Treatment?
Yes
No
Prior Systemic Chemotherapy?
Yes
No
Prior Immunotherapy?
Yes
No
Prior Radiation Therapy?
Yes
No
Prior Surgery?
Yes
No
Prior Radiosurgery?
Yes
No
Prior Radiosensitizer Therapy?
Yes
No
Any Other Prior Therapy?
Yes
No
Name of other prior therapies (If yes,)
Brain: Prior Treatment - Systemic
Regimens
Prior Treatment Regimen Name (Drug, Agent,
Biologic)
Prior Treatment Regimen Start Date (MM DD
YYYY)
11 / 12
On-Study - Primary Brain Cancer - On-Study Form Recurrent Treatment -
2293986v3.0
Prior Treatment Regimen End Date (MM DD
YYYY)
Prior Treatment Regimen Type (Adjuvant, High
Dose)
Comments
Comments
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Neoplasms, Breast NCT00490139 Treatment - BIG 2-06 /
NCCTG N063D / EGF106708 - Radiotherapy - 2645024v1.0
BIG 2-06 / NCCTG N063D / EGF106708 - Radiotherapy
ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment
Optimisation) Study; BIG 2-06/N063D
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=31B0B9C3-
961B-3A56-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/8564
BIG 2-06 / NCCTG N063D /
EGF106708 - Radiotherapy
Header Module
Centre No.
Subject No.
Ecg
Prior Radiation Therapy
Yes
No
RT Site
Side
Left (Left)
Right (Right)
RT Total Dose
Dose UOM
Centigray (cGy)
Gray (Gy)
Radiation Absorbed Dose (Rad)
Radiation Therapy Start Date
Radiation Therapy End Date
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Sarcoma, Kaposi xxx On-Study - Complete
Physical Exam - RF21 - 2266187v3.0
Complete Physical Exam - RF21
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=CCE1D1CA-
AC78-42E9-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/8565
Complete Physical Exam - RF21
Ccrr Module For Complete Physical Exam
- Rf21
Describe abnormal findings
Unnamed
Abnormal (Abnormal)
Normal (Normal)
Not Evaluated (Not Evaluated)
If this is not a baseline evaluation and if there are
no changes from the previous exam, check here
Patient Initials
Study#
Site#
ID#
Cycle#
Date of Visit
Which evaluation does this represent?
Entry/Baseline (Entry/Baseline)
On Treatment (On Treatment)
Post Therapy Evaluation (Post Therapy
Evaluation)
Site
Abdomen (Abdomen)
Chest (Chest)
Ears (Ears)
Extremities (Extremities)
Eyes (Eyes)
Genital (Genital)
Head (Head)
Heart (Heart)
Liver (Liver)
Lungs (Lungs)
Lymph Nodes (Lymph Nodes)
Mouth (Mouth)
Neck (Neck)
Neurological (Neurological)
1 / 2
Other (Other)
Rectal (Rectal)
Skin (Skin)
Spleen (Spleen)
Other, specify
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Sarcoma, Kaposi xxx On-Study - Complete Physical Exam - RF21 -
2266187v3.0
Sarcoma, Kaposi xxx On-Study - History of AIDS
Defining Diseases - RF03B - 2266635v3.0
History of AIDS Defining Diseases - RF03B
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=CCE36D78-
FA64-4758-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/8566
History of AIDS Defining Diseases -
RF03B
Ccrr Module For History Of Aids Defining
Diseases - Rf03b
Patient Initials
Study#
Site#
ID#
Cycle #
Date of Visit
Diseases
Candidiasis of bronchi, trachea or lungs
(Candidiasis of bronchi, trachea or lungs)
Candidiasis, esophageal (Candidiasis,
esophageal)
Cervical cancer, invasive (Cervical
cancer, invasive)
CMV other than liver, spleen or nodes
(CMV other than liver, spleen or nodes)
CMV retinitis (CMV retinitis)
Coccidioidomycosis, disseminated or
extrapulmunary (Coccidioidomycosis,
disseminated or extrapulmunary)
Cryptococcosis, extrapulmonary
(Cryptococcosis, extrapulmonary)
Cryptosporidiosis, chronic intestinal
(Cryptosporidiosis, chronic intestinal)
Encephalopathy, HIV-related
(Encephalopathy, HIV-related)
Herpes simplex, chronic ulcer or
bronchitis, pneumasitic or esophagitis
(Herpes simplex, chronic ulcer or
bronchitis, pneumasitic or esophagitis)
Histoplasmosis, disseminated or
extrapulmonary (Histoplasmosis,
disseminated or extrapulmonary)
Isosporiasis, chronic intestinal (>1 mon)
(Isosporiasis, chronic intestinal (>1
mon))
Kaposi's sarcoma (Kaposi's sarcoma)
Lymphoma, primary CNS (Lymphoma,
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primary CNS)
Lymphoma, systemic non-Hodgkin's
(Lymphoma, systemic non-Hodgkin's)
Mycobacterium avium complex,
disseminated or extrapulmonary
(Mycobacterium avium complex,
disseminated or extrapulmonary)
Mycobacterium tuberculosis
(Mycobacterium tuberculosis)
Mycobacterium, other disseminated or
extrapulmonary (Mycobacterium, other
disseminated or extrapulmonary)
Nocardiosis (Nocardiosis)
Pneumocystis carinii pneumonia
(Pneumocystis carinii pneumonia)
Pneumonia, recurrent (Pneumonia,
recurrent)
Progressive multi-focal
leukoencephalopathy (Progressive multi-
focal leukoencephalopathy)
Salmonella septicemia (Salmonella
septicemia)
Toxoplasmosis of the brain
(Toxoplasmosis of the brain)
Wasting syndrome, due to HIV (Wasting
syndrome, due to HIV)
Check if still active
Check if still active
Check if still active
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Sarcoma, Kaposi xxx On-Study - History of AIDS Defining Diseases -
RF03B - 2266635v3.0
Sarcoma, Kaposi xxx On-Study - Flavopiridol Administration
Form for Protocol #40 - PR4002 - 2266473v3.0
Flavopiridol Administration Form for Protocol #40 - PR4002
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=CCE307DB-
E83A-447E-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/8567
Flavopiridol Administration Form for
Protocol #40 - PR4002
Ccrr Module For Flavopiridol
Administration Form For Protocol #40 -
Pr4002
Patient Initials
Study#
Site#
ID#
Cycle#
Visit Date
Height
Weight
Units
kg (kg)
lb (lb)
Units
kg (kg)
lb (lb)
Body Surface Area
Karnofsky's Performance Score
Week
Date of Infusion (mm/dd/yyyy)
Total Flavopiridol Dose
Dose Change?
No (No)
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Unknown (Unknown)
Yes, Planned (i.e., The Treatment Was
Changed According To Protocol
Guidelines) (Yes, planned (according to
protocol))
Yes, Unplanned (i.e., The Treatment
Change Was Not Part Of Protocol
Guidelines) (Yes, unplanned)
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Sarcoma, Kaposi xxx On-Study - Flavopiridol Administration Form for
Protocol #40 - PR4002 - 2266473v3.0
Neoplasms, Breast NCT00490139 On-Study - BIG 2-06 / NCCTG
N063D / EGF106708 - Recurrence of Disease - 2640505v1.0
BIG 2-06 / NCCTG N063D / EGF106708 - Recurrence of
Disease
ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment
Optimisation) Study; BIG 2-06/N063D
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=31017C1F-
0E28-721B-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/8568
BIG 2-06 / NCCTG N063D /
EGF106708 - Recurrence of Disease
Header Module
Centre No.
Subject No.
Second Primary Malignancy And
Contralateral Breast Cancer
Type of recurrence
Date of recurrence
Method of Evaluation
Clinical (Clinical)
Radiology (Radiological)
Biopsy
Yes
No
Biopsy Date
Histology type
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Sarcoma, Kaposi xxx Lab - Urinalysis -
RF25 - 2267334v3.0
Urinalysis - RF25
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=CCE3C24A-
B0A1-5094-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/8569
Urinalysis - RF25
Ccrr Module For Urinalysis - Rf25
Bacteria
1+ (1+)
2+ (2+)
3+ (3+)
4+ (4+)
Negative/trace (Negative/trace)
Ph
Ketones
1+ (1+)
2+ (2+)
3+ (3+)
4+ (4+)
Negative/trace (Negative/trace)
Color
Amber (Amber)
Brown (Brown)
Clear (Clear)
Straw (Straw)
Yellow (Yellow)
Appearance
Clear (Clear)
Cloudy (Cloudy)
Hazy (Hazy)
Opaque (Opaque)
Protein
1+ (1+)
2+ (2+)
3+ (3+)
4+ (4+)
Negative/trace (Negative/trace)
Urobilingogen
Sequence #
Cycle Day
WBC
RBC
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Cast
Crystals
1+ (1+)
2+ (2+)
3+ (3+)
4+ (4+)
Negative/trace (Negative/trace)
Glucose
Patient Initials
Study#
Site#
ID#
Cycle#
Date Specimen Obtained
Which evaluation does this represent?
Entry/Baseline (Entry/Baseline)
On Treatment (On Treatment)
Post Therapy Evaluation (Post Therapy
Evaluation)
Specific Grav
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Sarcoma, Kaposi xxx Lab - Urinalysis - RF25 - 2267334v3.0
Sarcoma, Kaposi xxx Off Treatment - Off
Study Summary - RF50 - 2266945v3.0
Off Study Summary - RF50
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=CCE2A7D1-
BA6A-48FF-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/8571
Off Study Summary - RF50
Ccrr Module For Off Study Summary -
Rf50
Patient Initials
Study#
Site#
ID#
Date of Visit
Off Study Date
Reason off study (check one of the following
items)
Death (Death)
Protocol-defined Follow-up Completed
(Follow-up completed per protocol)
Adverse Event/side Effects/complications
(Off follow-up because of adverse event,
side effects or complications)
Other (Other)
Lost To Follow-up (Patient lost to follow-
up)
Patient Refused Follow-up (Patient
refused follow-up)
Other, specify
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NCT01336894 Quality of Life - ACOSOG-Z4099 Lung
Cancer Symptom Scale (LCSS) Form - 3180568v1.0
ACOSOG-Z4099 Lung Cancer Symptom Scale (LCSS)
Form
Surgery With or Without Internal Radiation Therapy
Compared With Stereotactic Body Radiation Therapy in
Treating Patients With High-Risk Stage I Non-Small Cell
Lung Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=990876FE-
87A9-F817-E040-BB89AD433C2C
All rights reserved. Please visit https://medical-data-
models.org/forms/8572
ACOSOG-Z4099 Lung Cancer
Symptom Scale (LCSS) Form
Header Module
Patient Study ID
Patient Initials (L F M)
Date Completed (dd MMM yyyy)
M.d. Anderson Symptom Inventory
(mdasi-bt)
How is your appetite
How much fatigue do you have
How much coughing do you have
How much shortness of breath do you have
How much blood do you see in your sputum
How much pain do you have
How bad are your symptoms from lung cancer
How much has your illness affected your ability to
carry out normal activities
How would you rate the quality of your life today
0 (0)
1 (1)
10 (10)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
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7 (7)
8 (8)
9 (9)
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NCT01336894 Quality of Life - ACOSOG-Z4099 Lung Cancer Symptom
Scale (LCSS) Form - 3180568v1.0
On-Study - Colorectal Cancer - Adjuvant
On-Study Form - 2263800v3.0
Colorectal Cancer - Adjuvant On-Study Form
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=DB75551B-
5D8C-2D1C-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/8573
Colorectal Cancer - Adjuvant On-
Study Form
Crf Header
Coordinating Group Protocol No.
Coordinating Group Code
Protocol Title
Patient Study ID
Institution/Affiliate
Other Patient ID
Participating Group Code
Patient Name (initials acceptable)
Colorectal: Form Administration
Person Completing Form
Are data amended? (If data are amended, please
circle in red when using paper form)
Yes
No
Colorectal: Disease Characteristics
Primary Site
Ascending Colon (Ascending Colon)
Cecum (Cecum)
Descending Colon (Descending Colon)
Hepatic Flexure (Hepatic Flexure)
Rectum (Rectum)
Sigmoid Colon (Sigmoid Colon)
Splenic Flexure (Splenic Flexure)
Transverse Colon (Transverse Colon)
Was there bowel obstruction
Yes
No
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Was there bowel perforation
Yes
No
Disease Extent
Tx (Primary tumor cannot be assessed
(TX))
T4 (Tumor directly invades or is adherent
to other organs or structures and/or
involves the visceral peritoneum (T4))
T2 (Tumor invades muscularis propria
(T2))
T1 (Tumor invades submucosa (T1))
T3 (Tumor invades through the
muscularis propria into the subserosa, or
into nonperitonealized pericolic or
perirectal tissue (T3))
Number of Lymph Nodes Examined
Number of Positive Lymph Nodes
Histologic Grade (Differentiation)
Moderately Differentiated (Moderately
Differentiated (Grade II))
Poorly Differentiated (Poorly
differentiated (Grade III))
Undifferentiated (Undifferentiated (Grade
IV))
Well Differentiated (Well Differentiated
(Grade I))
Comments
Comments
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On-Study - Colorectal Cancer - Adjuvant On-Study Form - 2263800v3.0
Neoplasms, Breast NCT00490139 On-Study - BIG 2-06 / NCCTG
N063D / EGF106708 - Unscheduled LVEF - 2644284v1.0
BIG 2-06 / NCCTG N063D / EGF106708 - Unscheduled
LVEF
ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment
Optimisation) Study; BIG 2-06/N063D
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=313CA32E-
D7F9-016C-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/8574
BIG 2-06 / NCCTG N063D /
EGF106708 - Unscheduled LVEF
Header Module
Centre No.
Subject No.
Cardiac Monitoring
Date of LVEF
LVEF
Method of Evaluation
Echocardiogram (Echocardiogram)
Muga Scan (MUGA scan)
LVEF status
Abnormal - Clinically Significant
(Abnormal - Clinically significant)
Abnormal - Not Clinically Significant
(Abnormal - Not clinically significant)
Normal (Normal)
Symptomatic CHF
Yes
No
New York Heart Association Classification
Patients With Cardiac Disease But
Without Resulting Limitation Of Physical
Activity. Ordinary Physical Activity Does
Not Cause Undue Fatigue, Palpitation,
Dyspnea Or Anginal Pain. (Class I)
Patients With Cardiac Disease Resulting
In Slight Limitation Of Physical Activity.
They Are Comfortable At Rest. Ordinary
Physical Activity Results In Fatigue,
Palpitation, Dyspnea Or Anginal Pain.
(Class II)
Patients With Cardiac Disease Resulting
In Marked Limitation Of Physical Activity.
They Are Comfortable At Rest. Less
Than Ordinary Activity Causes Fatigue,
Palpitation, Dyspnea Or Anginal Pain.
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(Class III)
Patients With Cardiac Disease Resulting
In Inability To Carry On Any Physical
Activity Without Discomfort. Symptoms
Of Heart Failure Or The Anginal
Syndrome May Be Present Even At
Rest. If Any Physical Activity Is
Undertaken, Discomfort Increases.
(Class IV)
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Neoplasms, Breast NCT00490139 On-Study - BIG 2-06 / NCCTG N063D
/ EGF106708 - Unscheduled LVEF - 2644284v1.0
On-Study - Waldenstroms Macroglobulinemia
- On-Study Form - 2273908v3.0
Waldenstrom's Macroglobulinemia - On-Study Form
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=D6795205-
A4D9-0CD9-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/8576
Waldenstroms Macroglobulinemia -
On-Study Form
Crf Header
Coordinating Group Protocol No.
Coordinating Group Code
Protocol Title
Patient Study ID
Institution/Affiliate
Other Patient ID
Participating Group Code
Patient Name (initials acceptable)
Waldenstrom's: Form Administration
Person Completing Form
Are data amended (If data are amended, please
circle in red when using paper form)
Yes
No
Waldenstrom's: Disease Description
Date of Initial Pathologic Diagnosis
Disease Status at Registration (For advanced or
recurrent studies,)
Initial Diagnosis (Initial Diagnosis)
Refractory (Refractory)
Relapsed (Relapsed)
Hematopoietic Diagnosis (WHO)
Lymphoplasmacytic Lymphoma
(waldenstrom Macroglobulinemia)
(Lymphoplasmacytic lymphoma)
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Other Specify (Other)
Other specify
Disease Symptoms Present (current check all
that apply)
Any Other Bleeding (Any other bleeding)
Dizziness (Dizziness)
Dyspnea (Dyspnea)
Epistaxis (Epistaxis)
Fatigue (Fatigue)
Headaches (Headaches)
Other (Other)
Paresthesias Or Painful/numb Feet
(Paresthesias or painful/numb feet)
Retinal Hemorrhage (Retinal
hemorrhage)
Visual Disturbance (Visual disturbance)
Weakness (Weakness)
Other specify
Any other bleeding specify
Are B-symptoms present
Yes
No
Date of First Symptoms (If yes,)
Unexplained, persistent fever >38 degrees C (or
>100 degrees F) in the previous month
Yes
No
Recurring, drenching night sweats during the
previous month
Yes
No
Unexplained weight loss >10% of body weight in
the previous 6 months
Yes
No
Was extramedullary immunocytoma present at
baseline
No (No)
Unknown (Unknown)
Yes (Yes)
Site of Involvement (If yes, s)
Bone (Bone)
Bone Marrow (Bone Marrow)
Brain (Brain)
Gastrointestinal Tract (GI Tract)
Kidney (Kidney)
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Liver (Liver)
Lung (Lung)
Lymph Nodes (Lymph nodes)
Other Specify (Other)
Pleura (Pleura)
Skin (Skin (cutaneous))
Spleen (Spleen)
Other specify
Method of Evaluation
Biopsy (Biopsy)
Clinical Examination (pe) (Clinical
examination)
Ct Scan (CT Scan)
Mri (MRI (NMR))
Other (Other)
Ultrasound (Ultrasound)
Other specify
Did patient receive a transfusion in the previous 4
weeks
No (No)
Unknown (Unknown)
Yes (Yes)
Did patient receive erythropoietin-type agents
(e.g., Epogen, Procrit or Aranesp) within the
previous 4 weeks
No (No)
Unknown (Unknown)
Yes (Yes)
Waldenstrom's: Prior Treatment
Prior Treatment? (If yes, respond to treatment-
specific questions below.)
Yes
No
No. of Planned Regimens (If yes, Note: Multiple
drug/staged regimens count as 1)
Prior Treatment Regimen Name(s) (* Prior
Treatment Regimen Name)
2-cda/rituxan (2-CDA/Rituxan)
2-chloro-deoxy-adenosine (2-cda) (2-
chloro-deoxy-adenosine (2-CDA))
Anti-cd20 Antibody (Anti-CD20 antibody)
Bexxar ([131]-i-anti-cd20) (Bexxar ([131]-
I-anti-CD20))
Chlorambucil (Chlorambucil)
Chlorambucil/prednisone
(Chlorambucil/prednisone)
Chop (CHOP)
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Corticosteroids (Corticosteroids)
Cvp (CVP)
Cyclophosphamide (Cyclophosphamide)
Cyclophosphamide/prednisone
(Cyclophosphamide/prednisone)
Etoposide (vp16) (Etoposide (VP16))
Fludara/ctx (Fludara/CTX)
Fludara/ctx/rituxan (fcr)
(Fludara/CTX/Rituxan (FCR))
Fludara/rituxan (Fludara/Rituxan)
Fludarabine (Fludarabine)
Interferon (Interferon)
Interleukin-2 (Interleukin-2)
Other (Other)
Prednisone (Prednisone)
R-chop (R-CHOP)
Rituxan (Rituxan)
Thalidomide (Thalidomide)
Transplant (Transplant)
Zevalin (yttrium-90-anti-cd20) (Zevalin
(Yttrium-90-anti-CD20))
Other Prior Regimen Name (** If Other specify)
Prior Treatment Regimen Start Date
Prior Treatment Regimen End Date
Maintenance Only
Yes
No
Reason Stopped (?  Reason Stopped)
Alternative Treatment (Alternative
treatment)
Completed Treatment (Completed
treatment)
Maintenance Only (Maintenance only)
Patient Refusal (Patient refusal)
Progression (Progression/Relapse)
Toxicity (Toxicity)
Unknown (Unknown)
Best Response (Best Response)
Inevaluable (Inevaluable)
Plateau/stable (Plateau/Stable)
Progression (Progression)
Response/improvement
(Response/Improvement)
Unknown (Unknown)
Prior Bone Marrow or Peripheral Blood Stem Cell
Transplant?
Yes
No
Prior Transplant Type (If yes,)
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Allogeneic (Allogeneic)
Autologous (Autologous)
Number of autologous transplants
Date of Last Transplant
Number of allogeneic transplants
Allogeneic Transplant Type
Mini (non-myeloablative) (Mini (non-
myeloablative))
Myeloablative (Myeloablative)
Unknown (Unknown)
Date of Transplant
DLI
Yes
No
Date of Last DLI (If yes,)
Total body irradiation
No (No)
Unknown (Unknown)
Yes (Yes)
Prior Immuno-radiolabeled therapy (as transplant
conditioning)
Yes
No
Prior Surgery
Yes
No
Prior Surgery Type (If yes,)
Waldenstrom's: Relapsed Disease
Disease Status (current)
Other, Specify (Other)
Refractory (Refractory NOS)
Refractory To First Induction (Refractory
to 1st induction)
Refractory To Reinduction After
Complete Response (Refractory to
reinduction after CR)
Relapse (Relapse NOS)
First Relapse (Relapse: 1st)
Second Relapse (Relapse: 2nd)
Third Or Greater Relapse (Relapse:
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3rd+)
Other (specify)
Best Response to Initial Therapy
Cr (CR)
Mr (MR)
Pd (PD)
Pr (PR)
Sd (SD)
Date of Initial Response to Therapy
Date of First Relapse
Performance Status (at Time of Treatment Failure
For CDUS reporting, please convert Karnofsky
and Lansky scores to this Zubrod Score)
Fully Active, Able To Carry On All Pre-
disease Performance Without
Restriction. (0)
Restricted In Physically Strenuous
Activity But Ambulatory And Able To
Carry Out Work Of A Light Or Sedentary
Nature, E.g., Light Housework, Office
Work. (1)
Ambulatory And Capable Of All Selfcare
But Unable To Carry Out Any Work
Activities. Up And About More Than 50%
Of Waking Hours. (2)
Capable Of Only Limited Selfcare,
Confined To Bed Or Chair More Than
50% Of Waking Hours. (3)
Completely Disabled. Cannot Carry On
Any Selfcare. Totally Confined To Bed Or
Chair. (4)
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Treatment - Lymphoma - Transplant
Engraftment Form - 2269377v3.0
Lymphoma - Transplant Engraftment Form
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=D4C10C9D-
17DD-11CF-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/8579
Lymphoma - Transplant Engraftment
Form
Crf Header
Coordinating Group Protocol No.
Coordinating Group Code
Protocol Title
Patient Study ID
Institution/Affiliate
Other Patient ID
Participating Group Code
Patient Name (initials acceptable)
Lymphoma: Form Administration
Person Completing Form
Are data amended? (If data are amended, please
circle in red when using paper form)
Yes
No
Lymphoma Transplant: Engraftment
Date of Evaluation
Was patient neutropenic prior to therapy
No (No)
Unknown (Unknown)
Yes (Yes)
Did absolute neutrophil count (ANC) fall below
500 following therapy (If no,)
No (No)
Unknown (Unknown)
Yes (Yes)
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Did patient engraft neutrophils (ANC >=500 for 3
consecutive days)
No (No)
Unknown (Unknown)
Yes (Yes)
Neutrophil Engraftment Date (If yes, Note:
Record the first date of 3 consecutive days of
ANC >=500)
Was patient thrombocytopenic prior to therapy
No (No)
Unknown (Unknown)
Yes (Yes)
Did patient become thrombocytopenic following
therapy (If no,)
No (No)
Unknown (Unknown)
Yes (Yes)
Did patient reconstitute platelets where the
patient did not receive platelet transfusion for the
next 7 days (platelets >= 20,000 for 2 consecutive
days)
No (No)
Unknown (Unknown)
Yes (Yes)
Platelet Engraftment Date (If yes, Note: Record
the first date of 2 consecutive days of platelets
>=20,000)
Was patient lymphopenic prior to therapy
No (No)
Unknown (Unknown)
Yes (Yes)
Did patient become lymphopenic following
therapy (If no,)
No (No)
Unknown (Unknown)
Yes (Yes)
Did patient reconstitute lymphocytes
(lymphocytes >= 20,000 for 2 consecutive days)
No (No)
Unknown (Unknown)
Yes (Yes)
Lymphocyte Engraftment Date (If yes, Note:
Record the first date of 2 consecutive days of
lymphocytes >= 20,000)
Did the patient experience late graft failure (follow
definition per protocol)
No (No)
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Unknown (Unknown)
Yes (Yes)
Date of Late Graft Failure (If yes,)
Comments
Comments
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Treatment - Bone Sarcoma - Definitive
Surgery Form - 2288645v3.0
Bone Sarcoma - Definitive Surgery Form
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=E2A31F0C-
C2AC-1196-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/8580
Bone Sarcoma - Definitive Surgery
Form
Crf Header
Coordinating Group Protocol No.
Coordinating Group Code
Protocol Title
Patient Study ID
Institution/Affiliate
Other Patient ID
Participating Group Code
Patient Name (initials acceptable)
Sarcoma: Form Administration
Person Completing Form
Are data amended (If data are amended, please
circle in red when using paper form)
Yes
No
Bone Sarcoma: Summary Of Definitive
Surgery
Primary Surgery Date (MM DD YYYY)
Site of Primary Surgery
Primary Surgery Type
Amputation (Amputation)
Cryosurgery (Cryosurgery)
En Bloc Resection (En bloc resection)
Intraepiphyseal Resection
(Intraepiphyseal resection)
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Intramural Resection, Gross Residual
Disease (Intramural resection, gross
residual disease)
Lymph Node Removal (Lymph node
removal)
Marginal Excision (Marginal excision)
Other, Specify (Other specify)
Radical Excision (Radical excision)
Transmedullary Amputation
(Transmedullary amputation)
Wide Excision (Wide excision)
Other specify
Number of Lymph Nodes Examined
Number of Positive Lymph Nodes
Surgical Reconstruction
Allograft Arthrodesis (Allograft
arthrodesis)
Arthrodesis (Arthrodesis)
Arthroscopy (Arthroscopy)
Autograft Arthrodesis (Autograft
arthrodesis)
Composite (allograft And Prosthesis)
(Composite (allograft and prosthesis))
Endoprosthesis (Endoprosthesis)
Excision Without Amputation (Excision
without amputation)
Free Tissue Transfer (Free tissue
transfer)
Intercalary Allograft (Intercalary allograft)
Intercalary Autograft (Intercalary
autograft)
Mesh (chest Wall) (Mesh (chest wall))
Metallic Prosthesis (Metallic prosthesis)
No Bony Reconstruction (No bony
reconstruction)
Osteoarticular Allograft (Osteoarticular
allograft)
Other, Specify (Other specify)
Rotationplasty (Rotationplasty)
Vascularized Fibular Autograft
(Vascularized fibular autograft)
Vascularized Fibular Autograft And
Allograft (Vascularized fibular autograft
and allograft)
Other specify
Tumor Location, Side
Both (Both)
Left (Left)
Right (Right)
Unknown (Unknown)
2 / 6
Treatment - Bone Sarcoma - Definitive Surgery Form - 2288645v3.0
Tumor Location, Area
Distal (Distal)
Midshaft (Midshaft)
Other, Specify (Other specify)
Proximal (Proximal)
Other specify
Dimension 1 (Longest)
Dimension 2 (Enter all 3 dimensions if available)
Dimension 3 (cm)
Does the tumor involve the surgical margin
Yes
No
Margins of surgical resection
All Margins Pathologically Negative (R0)
Microscopically Positive Margins Or
Microscopic Residual Disease (R1)
Macroscopically Positive Margins Or
Gross Residual Disease (R2)
Bone Sarcoma: Surgical Pathology
Microscopic Description
Is necrosis present?
No (NO)
Unknown (UNKNOWN)
Yes (YES)
Percent Necrosis (If Yes,)
<= 50% (<= 50%)
<= 90% And > 50% (<= 90% and > 50%)
<= 98% And > 90% (<= 98% and > 90%)
> 98% (> 98%)
Does analysis of tissue show evidence of
therapeutic effects?
No (No)
Unknown (Unknown)
Yes (Yes)
Type of Therapeutic Effect (If Yes,)
Drug-related Changes (Drug-related
changes)
Other, Specify (Other specify)
Radiation Changes (Radiation changes)
Surgical Changes (Surgical changes)
Other specify
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Specimen Cell Source
Bone, Specify (Bone specify)
Lymph Node (Lymph node)
Non-malignant Tumor (Non-malignant
tumor)
Other, Specify (Other specify)
Primary Tumor (Primary tumor)
Tissue Suspicious For Abnormality
(Tissue suspicious for abnormality)
Bone specify
Other specify
Histologic Type (check all that apply)
Angiosarcoma (Angiosarcoma)
Chondrosarcoma (Chondrosarcoma)
Chordoma (Chordoma)
Clear Cell Chondrosarcoma (Clear cell
chondrosarcoma)
Conventional Central Osteosarcoma
(Conventional central osteosarcoma)
Dedifferentiated Chondrosarcoma
(Dedifferentiated chondrosarcoma)
Epithelioid Hemagioendothelioma
(Epithelioid hemangioendothelioma)
Ewing's Sarcoma/pnet (Ewing's
sarcoma/PNET)
Fibrosarcoma (Fibrosarcoma)
Hemagioendothelioma Nos
(Hemangioendothelioma NOS)
Hematopoietic Malignancy Nos
(Hematopoietic malignancy NOS)
Intraosseous Osteosarcoma
(Intraosseous osteosarcoma)
Leiomyosarcoma (Leiomyosarcoma)
Liposarcoma Nos (Liposarcoma NOS)
Lymphoma (primary) (Lymphoma
(primary))
Malignant Giant Cell Tumor (Malignant
giant cell tumor)
Maligant Peripheral Nerve Sheath Tumor
(Malignant peripheral nerve sheath
tumor)
Mesenchymal Chondrosarcoma
(Mesenchymal chondrosarcoma)
Osteosarcoma Nos (Osteosarcoma
NOS)
Other Specify (Other specify)
Parosteal (juxtacortical) Osteosarcoma
(Parosteal (juxtacortical) osteosarcoma)
Periosteal Osteosarcoma (Periosteal
osteosarcoma)
Sarcoma Nos (Sarcoma NOS)
Small Cell Osteosarcoma (Small cell
osteosarcoma)
Surface Osteosarcoma, High-grade
(Surface osteosarcoma, high-grade)
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Telangiectatic Osteosarcoma
(Telangiectatic osteosarcoma)
Undifferentiated Pleomorphic
Sarcoma/"mfh" (Undifferentiated
pleomorphic sarcoma/"MFH")
Other specify
Histologic Subtype (specify)
Histologic Grade, French System
Grade I (Grade I)
Grade Ii (Grade II)
Grade Iii (Grade III)
Bone Sarcoma: Surgical-pathology Result
Pathologic T Stage
Pt0 (pT0)
Pt1 (pT1)
Pt2 (pT2)
Pt3 (pT3)
Pt4 (pT4)
Ptx (pTX)
Pathologic N Stage
Pn0 (pN0)
Pn1 (pN1)
Pn2 (pN2)
Pn3 (pN3)
Pnx (pNX)
Pathologic M Stage
Pm0 (pM0)
Pm1 (pM1)
Pmx (pMX)
Depth (cm)
Stage Grouping, Pathologic
0, According To Current Ajcc Guidelines
(0)
Ia, According To Current Ajcc Guidelines
(IA)
Ib, According To Current Ajcc Guidelines
(IB)
Iia, According To Current Ajcc Guidelines
(IIA)
Iib, According To Current Ajcc Guidelines
(IIB)
Iiia, According To Current Ajcc
Guidelines (IIIA)
Iiib, According To Current Ajcc
Guidelines (IIIB)
Iv, According To Current Ajcc Guidelines
(IV)
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Comments
Comments
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Treatment - Multiple Myeloma - Transplant
Treatment Form - 2273247v3.0
Multiple Myeloma - Transplant Treatment Form
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=D677F87F-
A4D6-081D-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/8581
Multiple Myeloma - Transplant
Treatment Form
Crf Header
Coordinating Group Protocol No.
Coordinating Group Code
Protocol Title
Patient Study ID
Institution/Affiliate
Other Patient ID
Participating Group Code
Patient Name (initials acceptable)
Myeloma: Form Administration
Person Completing Form
Are data amended? (If data are amended, please
circle in red when using paper form)
Yes
No
Myeloma Transplant: Treatment Plan
Did the patient receive protocol transplant?
Yes
No
Date of Admission for Transplant
Date of Bone Marrow or Peripheral Blood Stem
Cell Infusion
Date of Discharge following Transplant
1 / 7
Type of Transplant
Allogeneic (Allogeneic)
Autologous (Autologous)
Nonmyeloablative (Nonmyeloablative)
Other (Other)
Syngeneic (Syngeneic)
Other specify
Type of Donor Match (If allogeneic,)
Matched Sibling Or Family Member
(Matched sibling or family member)
Matched Unrelated Donor (Matched
unrelated donor)
Mismatched Sibling Or Family Member
(Mismatched sibling or family member)
Mismatched Unrelated Donor
(Mismatched unrelated donor)
Other (Other)
Other specify
Source of Cells Transplanted
Bone Marrow (Bone marrow)
Bone Marrow And Pbsc (Bone marrow
and PBSC)
Cord Blood (Cord blood)
Other (Other)
Peripheral Blood Stem Cells (Peripheral
blood stem cells)
Other specify
How were cells manipulated (mark all that apply)
Cd34 Positive Selection To Purge
Malignant Cells (CD34 positive selection
to purge malignant cells)
Cryopreservation (Cryopreservation)
Direct Purging Of Malignant Cells (not By
Cd34+ Selection) (Direct purging of
malignant cells (not by CD34+ selection))
Other (Other)
Plasma Depletion (Plasma depletion)
Red Cell Depletion (Red cell depletion)
T-cell Depletion (T-cell depletion)
Other specify
Technique (If T-cell Depletion, mark all that apply)
Cd34 Selection (column) (CD34
selection (column))
Centrifugal Elutriation (Centrifugal
elutriation)
Immunomagnetic Beads
(Immunomagnetic beads)
Immunotoxin (Immunotoxin)
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Lectin Depletion (Lectin depletion)
Monoclonal Antibody (Monoclonal
antibody)
Other (Other)
Other specify
Number of CD34-positive cells infused (cells/kg x
10^6)
Number of CD3-positive cells infused (cells/kg x
10^6)
Number of mononuclear cells infused (cells/kg x
10^8)
Does patient have positive antibody titer to
cytomegalovirus (CMV)
No (No)
Unknown (Unknown)
Yes (Yes)
Does patient have positive antibody titer to
Epstein-Barr virus (EBV)
No (No)
Unknown (Unknown)
Yes (Yes)
Does patient have positive titer to hepatitis B
surface antibody
No (No)
Unknown (Unknown)
Yes (Yes)
Does patient have positive titer to hepatitis B core
antibody
No (No)
Unknown (Unknown)
Yes (Yes)
Does patient have positive titer to hepatitis B
surface antigen (HBSAg)
No (No)
Unknown (Unknown)
Yes (Yes)
Does patient have positive antibody titer to
hepatitis C virus (HCV)
No (No)
Unknown (Unknown)
Yes (Yes)
Does patient have positive antibody titer to
herpes simplex virus (HSV)
No (No)
Unknown (Unknown)
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Yes (Yes)
Does patient have positive antibody titer to
human immunodeficiency virus (HIV)
No (No)
Unknown (Unknown)
Yes (Yes)
Myeloma Transplant: Donor Lymphocyte
Infusions
Date of DLI
Number of DLI
Reason for DLI
Due To Relapse (Due to relapse)
Other (Other)
Planned Per Protocol (Planned per
protocol)
Other specify
Total Number of cells infused (cells/kg x 10^6)
Number of dendritic cells infused (cells/kg x 10^6)
Number of CD34-positive cells infused (cells/kg x
10^6)
Number of CD3-positive cells infused (cells/kg x
10^6)
Myeloma Transplant: Allogeneic - Donor
Information
Donor's relationship to patient
Child (Child)
Fraternal Twin (or Multiple) (Fraternal
twin (or multiple))
Identical Twin (or Multiple) (Identical twin
(or multiple))
Not Related (Not related)
Other (Other)
Parent (Parent)
Sibling (Sibling)
Unknown (Unknown)
Other specify
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Donor Birth Date
Donor Gender
Female (Female)
Male (Male)
Does donor have any children (including the
transplant recipient)
No (No)
Unknown (Unknown)
Yes (Yes)
Does donor have positive antibody titer to
cytomegalovirus (CMV)
No (No)
Unknown (Unknown)
Yes (Yes)
Does donor have positive antibody titer to
Epstein-Barr virus (EBV)
No (No)
Unknown (Unknown)
Yes (Yes)
Does donor have positive titer to hepatitis B
surface antibody
No (No)
Unknown (Unknown)
Yes (Yes)
Does donor have positive titer to hepatitis B core
antibody
No (No)
Unknown (Unknown)
Yes (Yes)
Does donor have positive titer to hepatitis B
surface antigen (HBSAg)
No (No)
Unknown (Unknown)
Yes (Yes)
Does donor have positive antibody titer to
hepatitis C virus (HCV)
No (No)
Unknown (Unknown)
Yes (Yes)
Does donor have positive antibody titer to herpes
simplex virus (HSV)
No (No)
Unknown (Unknown)
Yes (Yes)
Does donor have positive antibody titer to human
immunodeficiency virus (HIV)
No (No)
Unknown (Unknown)
Yes (Yes)
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Result of Histocompatibility Tests (HLA-A, etc.)
Matched 1 Of 6 (Matched 1 of 6)
Matched 2 Of 6 (Matched 2 of 6)
Matched 3 Of 6 (Matched 3 of 6)
Matched 4 Of 6 (Matched 4 of 6)
Matched 5 Of 6 (Matched 5 of 6)
Matched 6 Of 6 (Matched 6 of 6)
Other (Other)
Unknown (Unknown)
Other specify
Are patient and donor mismatched at HLA-A
No (No)
Unknown (Unknown)
Yes (Yes)
Are patient and donor mismatched at HLA-B
No (No)
Unknown (Unknown)
Yes (Yes)
Are patient and donor mismatched at HLA-C
No (No)
Unknown (Unknown)
Yes (Yes)
Are patient and donor mismatched at HLA-DrB1
No (No)
Unknown (Unknown)
Yes (Yes)
Are patient and donor mismatched at HLA-DQB1
No (No)
Unknown (Unknown)
Yes (Yes)
Method used for Donor Matching
Dna (DNA)
Other (Other)
Serology (Serology)
Method used for Donor Matching
Dna (DNA)
Other (Other)
Serology (Serology)
Method used for Donor Matching
Dna (DNA)
Other (Other)
Serology (Serology)
Method used for Donor Matching
Dna (DNA)
Other (Other)
Serology (Serology)
Method used for Donor Matching
Dna (DNA)
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Other (Other)
Serology (Serology)
Other specify
Other specify
Other specify
Other specify
Other specify
Comments
Comments
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Event Monitoring Form N0577
North Central Cancer Treatment Group N0577 Event
Monitoring Form
Radiation Therapy or Radiation Therapy and Temozolomide
or Temozolomide Alone in Treating Patients With Newly
Diagnosed Anaplastic Glioma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=4C090D31-
BB06-2FAA-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/8583
Event Monitoring Form N0577
Header
Protocol Number*
Patient ID*
Patient Initials (L F M)*
Institution Number*
Institution*
Are data amended (If yes, highlight amended
areas)*
Yes
No
Were you able to obtain any information about
the patient since the last report (If this is the first
event monitoring form check yes, enter
assessment date and complete the rest of the
form.)*
Yes
No
Date of last attempt to contact patient (If No,
mm/dd/yyyy)*
Vital Status
Vital Status*
Alive (Alive)
Dead (Dead)
Date of Last Contact or Death (mm/dd/yyyy)*
Primary Cause of Death*
Due To Other Cause (Due to other
cause)
Due To Protocol Treatment (Due to
protocol treatment)
Due To This Disease (Due to this
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disease)
Due to other cause, specify*
Disease Follow-up Status
Has the patient had a documented clinical
assessment for this cancer? (since submission of
the last event monitoring form)*
Yes
No
Cancer Follow-up Status Date (If yes,)*
Notice Of First Relapse/progression In
The Event Monitoring Phase
Has the patient developed a first relapse or
progression that has not been previously
reported*
Yes
No
Date of Relapse or Progression (If yes,)*
Site of relapse/progression (s)*
Distant Brain Failure (Distant brain
failure)
Local Brain Failure (Local brain failure)
Other (Other)
Other, specify*
Method of Evaluation*
Clinical (Clinical)
Other (Other)
Pathologic (Pathologic)
Radiology (Radiologic)
Other Specify*
Notice Of First Subsequent Treatment
Has the patient received subsequent treatment
for this cancer that has not been previously
reported*
No (No)
Unknown (Unknown)
Yes (Yes)
Date of Subsequent Treatment (If yes
mm/dd/yyyy)*
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Subsequent Treatment Type*
Notice Of New Primary
Has a new primary cancer or MDS been
diagnosed that has not been previously reported?
(myelodyplastic syndrome)*
No (No)
Unknown (Unknown)
Yes (Yes)
New Primary Cancer Date (If yes,)*
Site of New Primary*
Description Of Primary Disease
Has the patient experienced (prior to treatment
for progression or relapse or a second primary,
and prior to non-protocol treatment) any severe
(grade >=3) long term toxicity that has not been
previously reported?*
No (No)
Unknown (Unknown)
Yes (Yes)
CTC Adverse Event Term*
MedDRA Code (primary tumor site: Metastases
to brain parenchyma)*
CTC Adverse Event Grade (Highest Grade)*
CTC AE Attribution Code*
Definite (Definite)
Possible (Possible)
Probable (Probable)
Unlikely (Unlikely)
Unrelated (Unrelated)
Late Adverse Event Onset Date (mm/dd/yyyy)*
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Breast Cancer NCT00377156 Treatment - North Central Cancer
Treatment Group Radiosurgery (SRS) Reporting Form - 2470949v1.0
North Central Cancer Treatment Group Radiosurgery
(SRS) Reporting Form
Stereotactic Radiation Therapy With or Without Whole-
Brain Radiation Therapy in Treating Patients With Brain
Metastases
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=10DCBEEF-
8D3C-3745-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/8584
North Central Cancer Treatment
Group Radiosurgery (SRS)
Reporting Form
Header
NCCTG Protocol Number
NCCTG Patient ID
Patient Initials (L F M)
Institution
Institution Number
Are data amended (If yes, highlight amended
areas)
Yes
No
Header
Radiosurgery Treating Institution
Target Lesion Site (as entered on the
Pretreatment Measurement Form: check one)
Site 1 (Site 1)
Site 2 (Site 2)
Site 3 (Site 3)
Date of Radiosurgery Procedure (mm/dd/yyyy)
Treatment Unit
Treatment Unit (check one)
Gamma Knife (Gamma Knife)
Linear Accelerator (Linear Accelerator)
Manufacturer Name
Model Number
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Energy (Linear Accelerator - MV)
Technique
Technique (check one)
Isocenters Or Beam-center Positions
(Isocenters or beam-center positions)
Stationary Beams (Stationary beams)
Number of isocenters or beam-center positions
Number of stationary beams
Number of arcs
Sum of degrees per arc for all arcs (If applicable,)
Collimator diameter(s): isocenter (#2)
Collimator diameter(s): isocenter (#2)
Target Volume
Largest measure in any direction (mm)
Left-right measure (mm)
Anterior-posterior measure (mm)
Cephalad-caudad measure (mm)
Target volume (cm^3)
Prescription Dose
Prescription Dose (Gy)
% isodose contour
Minimum within target volume (Gy)
Maximum within target volume (Gy)
Volume inside prescription isodose surface
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(cm^3)
Ratio of Prescription Isodose Volume/Target
Volume
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Treatment - Brain Cancer - Radiation
Therapy Treatment Form - 2286709v3.0
Brain Cancer - Radiation Therapy Treatment Form
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=DE952E13-
775D-272C-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/8585
Brain Cancer - Radiation Therapy
Treatment Form
Crf Header
Coordinating Group Protocol No.
Coordinating Group Code
Protocol Title
Patient Study ID
Institution/Affiliate
Other Patient ID
Participating Group Code
Patient Name (initials acceptable)
Brain: Radiation Therapy
Radiation Therapy Start Date (MM DD YYYY)
Radiation Therapy End Date (MM DD YYYY)
Radiation Therapy Site (protocol specific)
RT Total Dose per Field (cGY)
Total Number of Fractions
Type of Radiation Therapy Administered (check
all that apply)
Brachytherapy (Brachytherapy)
Conformal (Conformal)
Electron Beam (Electron Beam)
External Beam Radiation (External beam
radiation)
Hyperfractionated (Hyperfractionated)
Imrt (IMRT)
Other (Other specify)
1 / 2
Photon Beam (Photon Beam)
Proton Beam (Proton Beam)
Radiosurgery (Radiosurgery)
Other specify
Were there any unscheduled interruptions in
radiation therapy?
No (No)
Unknown (Unknown)
Yes, Due To Toxicity (Yes, due to toxicity)
Yes, For Other Reasons, Specify (Yes,
for other reasons, specify)
RT Interruption Reason
Comments
Comments
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On-Study - Colorectal Cancer - Advanced
On-Study Form - 2282222v3.0
Colorectal Cancer - Advanced On-Study Form
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=DB756AA2-
EEA3-2E27-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/8586
Colorectal Cancer - Advanced On-
Study Form
Crf Header
Coordinating Group Protocol No.
Coordinating Group Code
Protocol Title
Patient Study ID
Institution/Affiliate
Other Patient ID
Participating Group Code
Patient Name (initials acceptable)
Colorectal: Form Administration
Person Completing Form
Are data amended? (If data are amended, please
circle in red when using paper form)
Yes
No
Colorectal: Disease Description
Is the Primary Site or tumor bed involved
Yes
No
Regional Lymph Nodes
Yes
No
Distant Lymph Nodes
Yes
No
Lung
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Yes
No
Liver
Yes
No
Other Abdominal
Yes
No
Bone
Yes
No
Brain
Yes
No
Distant Skin/Subcutaneous Tissue
Yes
No
Other
Yes
No
If sites other than specified, Indicate Name
Advanced Disease Status at Registration
Initial Diagnosis (Initial Diagnosis)
Recurrence (Recurrence)
Colorectal: Prior Treatment
Prior Surgery
Yes
No
Prior Radiation Therapy
Yes
No
Prior Adjuvant Chemotherapy?
Yes
No
Prior Adjuvant Immunotherapy?
Yes
No
Comments
Comments
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Registration - NCI Cooperative Group
Registration Form - 2263990v3.0
NCI Cooperative Group Registration Form
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=D8879517-
2F12-048F-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/8588
NCI Cooperative Group Registration
Form
Registration Header
Coordinating Group Protocol No.
Coordinating Group Code
Protocol Title
Patient Study ID
Participating Group Code
Patient Medical Record Number
Other Patient ID
Institution/Affiliate
Physician of Record
Protocol Administration
IRB/REB Approval Date
Date Informed Consent Signed
Projected Start Date of Treatment
Date of Registration (mm dd yyyy)
Person Completing Form, Last Name
Person Completing Form, First Name
Person Completing Form, Phone
Person Completing Form, Fax
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Patient Demographics/pre-treatment
Characteristics
Patient Name (initials acceptable)
Patient Birth Date (mm dd yyyy)
Patient Gender
Female (Female)
Male (Male)
Patient Race (check all that apply U.S. and
Canada only)
A Person Having Origins In Any Of The
Original Peoples Of North And South
America (including Central America),
And Who Maintains Tribal Affiliation Or
Community Attachment. (American
Indian or Alaska Native)
A Person Having Origins In Any Of The
Original Peoples Of The Far East,
Southeast Asia, Or The Indian
Subcontinent Including, For Example,
Cambodia, China, India, Japan, Korea,
Malaysia, Pakistan, The Philippine
Islands, Thailand, And Vietnam. (Asian)
A Person Having Origins In Any Of The
Black Racial Groups Of Africa. Terms
Such As "haitian" Or "negro" Can Be
Used In Addition To "black Or African
American." (Black or African American)
A Person Having Origins In Any Of The
Original Peoples Of Hawaii, Guam,
Samoa, Or Other Pacific Islands. (Native
Hawaiian or other Pacific Islander)
Could Not Be Determined Or Unsure
(Unknown)
A Person Having Origins In Any Of The
Original Peoples Of Europe, The Middle
East, Or North Africa. (White)
Patient Ethnicity (U.S. and Canada only)
A Person Of Mexican, Puerto Rican,
Cuban, Central Or South American Or
Other Spanish Culture Or Origin,
Regardless Of Race. (HISPANIC OR
LATINO)
A Person Not Meeting The Definition For
Hispanic Or Latino. (NOT HISPANIC OR
LATINO)
Could Not Be Determined Or Unsure
(UNKNOWN)
Patient Social Security Number (USA only)
Patient Zip Code (USA)
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Country of Residence (if not USA)
Patient Height (cm)
Patient Weight (kg)
Body Surface Area (m^2)
Performance Status (check one)
Fully Active, Able To Carry On All Pre-
disease Performance Without
Restriction. (0)
Restricted In Physically Strenuous
Activity But Ambulatory And Able To
Carry Out Work Of A Light Or Sedentary
Nature, E.g., Light Housework, Office
Work. (1)
Ambulatory And Capable Of All Selfcare
But Unable To Carry Out Any Work
Activities. Up And About More Than 50%
Of Waking Hours. (2)
Capable Of Only Limited Selfcare,
Confined To Bed Or Chair More Than
50% Of Waking Hours. (3)
Completely Disabled. Cannot Carry On
Any Selfcare. Totally Confined To Bed Or
Chair. (4)
Method of Payment (check one USA only)
Medicaid (Medicaid)
Medicaid And Medicare (Medicaid and
Medicare)
Medicare (Medicare)
Medicare And Private Insurance
(Medicare and Private Insurance)
Military Or Veterans Sponsored Nos
(Military or Veterans Sponsored, Not
Otherwise Specified (NOS))
Military Sponsored (including Champus
& Tricare) (Military Sponsored (including
CHAMPUS & TRICARE))
No Means Of Payment (no Insurance)
(No means of payment (no insurance))
Other (Other)
Private Insurance (Private Insurance)
Self Pay (no Insurance) (Self Pay (No
Insurance))
Unknown (Unknown)
Veterans Sponsored (Veterans
Sponsored)
Certification Of Eligibility
In the opinion of the investigator, is the patient
eligible?
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Yes
No
Protocol Design
Stratification Factors (protocol specific)
Assigned Treatment Arm (protocol specific)
Initial Patient Consent For Specimen Use
Patient's Initial Consent given for specimen use
for research on the patient's cancer?
Yes
No
Patient's Initial Consent given for specimen use
for research unrelated to the patient's cancer?
Yes
No
Patient's Initial Consent given for further contact
regarding specimen?
Yes
No
Date of Consent for Specimen Use (mm dd yyyy)
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Treatment - Lymphoma - Transplant
Treatment Form - 2269914v3.0
Lymphoma - Transplant Treatment Form
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=D5EA8AC6-
6F28-703F-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/8591
Lymphoma - Transplant Treatment
Form
Crf Header
Coordinating Group Protocol No.
Coordinating Group Code
Protocol Title
Patient Study ID
Institution/Affiliate
Other Patient ID
Participating Group Code
Patient Name (initials acceptable)
Lymphoma: Form Administration
Person Completing Form
Are data amended? (If data are amended, please
circle in red when using paper form)
Yes
No
Lymphoma Transplant: Treatment Plan
Did the patient receive protocol transplant?
Yes
No
Date of Admission for Transplant
Date of Bone Marrow or Peripheral Blood Stem
Cell Infusion
Date of Discharge following Transplant
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Type of Transplant
Allogeneic (Allogeneic)
Autologous (Autologous)
Nonmyeloablative (Nonmyeloablative)
Other (Other)
Syngeneic (Syngeneic)
Other specify
Type of Donor Match (If allogeneic,)
Matched Sibling Or Family Member
(Matched sibling or family member)
Matched Unrelated Donor (Matched
unrelated donor)
Mismatched Sibling Or Family Member
(Mismatched sibling or family member)
Mismatched Unrelated Donor
(Mismatched unrelated donor)
Other (Other)
Other specify
Source of Cells Transplanted
Bone Marrow (Bone marrow)
Bone Marrow And Pbsc (Bone marrow
and PBSC)
Cord Blood (Cord blood)
Other (Other)
Peripheral Blood Stem Cells (Peripheral
blood stem cells)
Other specify
How were cells manipulated
Cd34 Positive Selection To Purge
Malignant Cells (CD34 positive selection
to purge malignant cells)
Cryopreservation (Cryopreservation)
Direct Purging Of Malignant Cells (not By
Cd34+ Selection) (Direct purging of
malignant cells (not by CD34+ selection))
Other (Other)
Plasma Depletion (Plasma depletion)
Red Cell Depletion (Red cell depletion)
T-cell Depletion (T-cell depletion)
Other specify
Technique (If T-cell Depletion,)
Cd34 Selection (column) (CD34
selection (column))
Centrifugal Elutriation (Centrifugal
elutriation)
Immunomagnetic Beads
(Immunomagnetic beads)
Immunotoxin (Immunotoxin)
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Lectin Depletion (Lectin depletion)
Monoclonal Antibody (Monoclonal
antibody)
Other (Other)
Other specify
Number of CD34-positive cells infused (cells/kg x
10^6)
Number of CD3-positive cells infused (cells/kg x
10^6)
Lymphoma Transplant: Donor Lymphocyte
Infusions
Date of DLI
Number of DLI
Reason for DLI
Due To Relapse (Due to relapse)
Other (Other)
Planned Per Protocol (Planned per
protocol)
Other specify
Total Number of cells infused (cells/kg x 10^6)
Number of dendritic cells infused (cells/kg x 10^6)
Number of CD34-positive cells infused (cells/kg x
10^6)
Number of CD3-positive cells infused (cells/kg x
10^6)
Lymphoma Transplant: Allogeneic - Donor
Information
Donor's relationship to patient
Child (Child)
Fraternal Twin (or Multiple) (Fraternal
twin (or multiple))
Identical Twin (or Multiple) (Identical twin
(or multiple))
Not Related (Not related)
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Other (Other)
Parent (Parent)
Sibling (Sibling)
Unknown (Unknown)
Other specify
Donor Birth Date
Donor Gender
Female (Female)
Male (Male)
Does donor have any children (including the
transplant recipient)
No (No)
Unknown (Unknown)
Yes (Yes)
Does donor have positive antibody titer to
cytomegalovirus (CMV)
No (No)
Unknown (Unknown)
Yes (Yes)
Does donor have positive antibody titer to
Epstein-Barr virus (EBV)
No (No)
Unknown (Unknown)
Yes (Yes)
Does donor have positive titer to hepatitis B
surface antibody
No (No)
Unknown (Unknown)
Yes (Yes)
Does donor have positive titer to hepatitis B core
antibody
No (No)
Unknown (Unknown)
Yes (Yes)
Does donor have positive titer to hepatitis B
surface antigen (HBSAg)
No (No)
Unknown (Unknown)
Yes (Yes)
Does donor have positive antibody titer to
hepatitis C virus (HCV)
No (No)
Unknown (Unknown)
Yes (Yes)
Does donor have positive antibody titer to herpes
simplex virus (HSV)
No (No)
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Unknown (Unknown)
Yes (Yes)
Does donor have positive antibody titer to human
immunodeficiency virus (HIV)
No (No)
Unknown (Unknown)
Yes (Yes)
Result of Histocompatibility Tests (HLA-A, etc.)
Matched 1 Of 6 (Matched 1 of 6)
Matched 2 Of 6 (Matched 2 of 6)
Matched 3 Of 6 (Matched 3 of 6)
Matched 4 Of 6 (Matched 4 of 6)
Matched 5 Of 6 (Matched 5 of 6)
Matched 6 Of 6 (Matched 6 of 6)
Other (Other)
Unknown (Unknown)
Other specify
Are patient and donor mismatched at HLA-A
No (No)
Unknown (Unknown)
Yes (Yes)
Are patient and donor mismatched at HLA-B
No (No)
Unknown (Unknown)
Yes (Yes)
Are patient and donor mismatched at HLA-C
No (No)
Unknown (Unknown)
Yes (Yes)
Are patient and donor mismatched at HLA-DrB1
No (No)
Unknown (Unknown)
Yes (Yes)
Are patient and donor mismatched at HLA-DQB1
No (No)
Unknown (Unknown)
Yes (Yes)
Method used for Donor Matching
Dna (DNA)
Other (Other)
Serology (Serology)
Method used for Donor Matching
Dna (DNA)
Other (Other)
Serology (Serology)
Method used for Donor Matching
Dna (DNA)
Other (Other)
5 / 6
Treatment - Lymphoma - Transplant Treatment Form - 2269914v3.0
Serology (Serology)
Method used for Donor Matching
Dna (DNA)
Other (Other)
Serology (Serology)
Method used for Donor Matching
Dna (DNA)
Other (Other)
Serology (Serology)
Other specify
Other specify
Other specify
Other specify
Other specify
Comments
Comments
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Adverse Event Toxicity - AdEERs Screen
Labels - 2264300v3.0
a set of data elements recommended for mapping the
electronic fields for the ADEERS system for data collection.
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=D9131777-
7F1F-3B56-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/8592
AdEERs Screen Labels
AE report
AE_REPORT*
Ticket Number*
Amendment Number*
REPORT_TYPE*
Present Status*
Assessment Comments*
Review*
Death Unrelated to an AE*
Sent to FDA?*
IS_24_HOUR_REPORT*
Report Created Date*
Date Submitted to Group*
Date Submitted to NCI*
Date Submitted to FDA*
AE_CREATED_USER*
ELECTRONIC_REPORT*
LEAD_OGN_ID*
PI_ID*
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Reporter_information
First Name*
Last Name*
Middle Name*
Phone*
Email*
Fax*
Physician_information
First Name*
Last Name*
Middle Name*
Phone*
Email*
Fax*
Submitter_information
First Name*
Last Name*
Middle Name*
Phone*
Email*
Fax*
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Course_information
Treatment Assignment Code*
Description*
Other Treatment Assignment*
Start date of first course (MM/DD/YYYY)*
Start Date of course associated with Expedited*
Start Date of Primary AE*
End Date of Primary AE*
Course Number on which AE occurred*
Total number of courses to date*
Description_of_event
Description and Treatment of Event(s)*
Present Status*
Date of Recovery or Death*
Retreated*
Removed from Protocol Treatment*
Date Removed from Protocol Treatment*
Cause of Death*
Primary Organ System failure Causing Death*
Death Date*
Autopsy Performed*
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Institution_information
Institution*
CTEP Enterprise (CTEP Enterprise)
CTEP ID*
INSTITUTION_ID*
Protocol_information
NCI_PROTOCOL_NUMBER_ID*
Title*
Phase*
Protocol Status*
Type of Study*
Lead Institution*
Principal Investigator*
Lead Drug Monitor*
CTCAE Version*
NCI_PROTOCOL_NUMBER_ID*
Patient_information
Patient ID*
Birth Date (MM/YYYY)*
Race*
A Person Having Origins In Any Of The
Original Peoples Of North And South
America (including Central America),
And Who Maintains Tribal Affiliation Or
Community Attachment (American Indian
or Alaska Native)
A Person Having Origins In Any Of The
Original Peoples Of The Far East,
Southeast Asia, Or The Indian
4 / 12
Adverse Event Toxicity - AdEERs Screen Labels - 2264300v3.0
Subcontinent Including, For Example,
Cambodia, China, India, Japan, Korea,
Malaysia, Pakistan, The Philippine
Islands, Thailand, And Vietnam. (Asian)
A Person Having Origins In Any Of The
Black Racial Groups Of Africa. Terms
Such As "haitian" Or "negro" Can Be
Used In Addition To "black Or African
American." (Black or African American)
Hispanic or Latino (Hispanic or Latino)
More than one race (More than one
race)
Gender*
Female (Female)
Male (Male)
Unknown (Unknown)
Ethnicity*
A Person Of Mexican, Puerto Rican,
Cuban, Central Or South American Or
Other Spanish Culture Or Origin,
Regardless Of Race (Hispanic or Latino)
A Person Not Meeting The Definition For
Hispanic Or Latino. (Not Hispanic or
Latino)
Patient Refused Or Data Not Available
(Not Reported)
Patient Is Unsure Of Their Ethnicity
(Unknown)
Height*
Weight*
Baseline Performance status at Initiation of
protocol ECOG/Zubrod scale*
Fully Active, Able To Carry On All Pre-
disease Performance Without Restriction
(karnofsky 90 - 100) (ecog - 0
Asymptomatic) (0)
Restricted In Physically Strenuous
Activity But Ambulatory (k70 - 80) (ecog -
1 Symptomatic - Fully Ambulatory) (1)
Ambulatory And Capable Of All Selfcare
But Unable To Carry Out Any Work
Activities (k 50 - 60) (ecog - 2
Symptomatic; In Bed , 50% Of The Day)
(2)
Capable Of Limited Selfcare, Confined
To Bed Or Chair More Than 50% Of
Waking Hours. (k 30 - 40) (ecog - 3
Symptomatic; In Bed > 50% Of The Day
But Not Bedridden) (3)
Completely Disabled (k10 - 20) (ecog - 4
Bedridden) (4)
Disease Name*
Based on MedDRA v6.0 (Based on
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MedDRA v6.0)
Disease Category*
Disease Name Not Listed*
Primary Site of Disease*
CTEP Enterprise (CTEP Enterprise)
Date of Initial Diagnosis*
Other Primary Site of Disease*
Prior_therapy
Therapy*
Based on MedDRA v6.0 (Based on
MedDRA v6.0)
Therapy Start Date*
Therapy End Date*
Comments*
Chemoagents
Agent*
CTEP Enterprise (CTEP Enterprise)
Pre_existing_condition
Pre-Existing Condition*
Other Pre-Existing Condition*
Based on MedDRA v6.0 (Based on
MedDRA v6.0)
Site_name
Site of Metastatic Disease*
CTEP Enterprise (CTEP Enterprise)
Other Body Site*
Protocol_agent
Agent*
CTEP Enterprise (CTEP Enterprise)
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NSC*
Total Dose Administered this course*
Last Administered Date*
Total Dose UOM*
Billion Pfu (billion pfu)
Cells (cells)
Curie (Ci)
Centimeter (cm)
Deciliter (dL)
Decimeter (dm)
Gram-equivalent Weight (Eq)
Gram (g)
Gravity (in Centrifugation) (gravity)
Hertz (Hz)
International Unit (IU)
Joules Per Centimeter Square (JCM2)
Kilo-electron Volt (keV)
Kilogram (kg)
Kilohertz (kHz)
Kilopascal (kPa)
Liter (L)
Meter (m)
Microcurie (mcCi)
Microgram (mcg)
Millicurie (mCi)
Microliter (mcL)
Micrometer (mcm)
Micromole (mcmol)
Milliequivalent (mEq)
Million Electron Volts (MeV)
Milligram (mg)
Meter (MHz)
Million International Units (million IU)
Million Pfu (million pfu)
Milliunit (milliunit)
Milliliter (mL)
Millimeter (mm)
Millimeter (MMM)
Millimole (mmol)
Gram-molecular Weight (mole) (mol)
Milliosmole (mOsmol)
Megarad (Mrad)
Million Unit (mU)
Millivolt (mV)
mVP (mVP)
Not Applicable (N/A)
Nanocurie (nCi)
Nanogram (ng)
Nanometer (nm)
Nanometers Of Light (nm light)
Osmole (Osmol)
Pascal (Pa)
Percent (Percent)
Plaque Forming Unit (pfu)
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Picogram (pg)
Pounds Per Square Inch (psi)
Tissue Culture Infections Dose (TCID)
Unit (unit)
Viral Particles (VP)
Comments*
Agent Adjustment*
Dose increased (Dose increased)
Dose not changed (Dose not changed)
Dose reduced (Dose reduced)
Drug withdrawn (Drug withdrawn)
Not applicable (Not applicable)
Agent Delayed*
Yes
No
Delay*
Delay UOM*
Concomitant_medication
Name of Concomitant  Medication*
CONCOM_REPORTED_BY*
Other_contributing_cause
Other Contributing Cause*
Cause Reported by*
Adverse_event_ctc
Category*
Adverse Event (Latest CTCAE Version)*
MedDRA Code (Latest CTCAE Version)*
Grade (Latest CTCAE Version)*
Adverse Event (Latest CTCAE Version)*
Adverse Event (Latest CTCAE Version)*
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CTCAE Category (Latest CTCAE Version)*
Adverse Event (Latest CTCAE Version)*
MedDRA Code (Latest CTCAE Version)*
Grade (Latest CTCAE Version)*
Other Adverse Event (specify)*
Hospitalization/Prolongation of Hospitalization*
Yes
No
Comments*
AE_REPORTED_BY*
LATEST_VERSION_GRADE_ID*
Attribution_for_ae
ATTRIBUTED_TO_TYPE*
ATTRIBUTED_TO*
ATTRIBUTED_TO_BY*
Attribution*
Definite (Definite)
Possible (Possible)
Probable (Probable)
Unlikely (Unlikely)
Unrelated (Unrelated)
Attribution By*
Lab_result
Lab Category*
Bone Marrow Biopsy (Bone Marrow
Biopsy)
Chemistry (Chemistry)
Coagulation (Coagulation)
Hematologic (Hematologic)
Microbiology (Microbiology)
Respiratory (Respiratory)
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Lab*
Activated partial thromboplastin time
(APTT) (Activated partial thromboplastin
time (APTT))
Albumin - blood (Albumin - blood)
Alkaline phosphates NOS (Alkaline
phosphates NOS)
Amylase - blood (Amylase - blood)
ANC (ANC)
Bacterial infection NOS (Bacterial
infection NOS)
Bilirubin direct - blood (Bilirubin direct -
blood)
Bilirubin total - blood (Bilirubin total -
blood)
Blood bicarbonate (Blood bicarbonate)
Blood carbon dioxide (Blood carbon
dioxide)
Blood neutrophils (ANC) (Blood
neutrophils (ANC))
Blood Urea Nitrogen (BUN) (Blood Urea
Nitrogen (BUN))
Bone Marrow blasts (Bone Marrow
blasts)
Bone Marrow Cellularity (Bone Marrow
Cellularity)
Calcium - blood (Ca) (Calcium - blood
(Ca))
Carbon dioxide - blood (CO2) (Carbon
dioxide - blood (CO2))
Chloride - blood (Chloride - blood)
Cholesterol - blood (Cholesterol - blood)
Creatine phosphokinase - blood (CK)
(Creatine phosphokinase - blood (CK))
Creatinine - serum (Cr) (Creatinine -
serum (Cr))
Creatinine clearance (CrCl) (Creatinine
clearance (CrCl))
Fibrin D-dimer (Fibrin D-dimer)
Fibrin degradation products (FDP) (Fibrin
degradation products (FDP))
Fibrinogen - blood (Fibrinogen - blood)
Fungal infection NOS (Fungal infection
NOS)
Glucose - blood (Glucose - blood)
Glutamic-oxaloacetic transferase (AST,
SGOT) (Glutamic-oxaloacetic transferase
(AST, SGOT))
Glutamic-pyruvate transferase (ALT,
SGPT) (Glutamic-pyruvate transferase
(ALT, SGPT))
Hematocrit (Hct) (Hematocrit (Hct))
Hemoglobin (Hb) (Hemoglobin (Hb))
International normalised ratio (INR)
(International normalised ratio (INR))
Lactate dehydrogenase - blood (LDH)
(Lactate dehydrogenase - blood (LDH))
Lipase (Lipase)
Magnesium - blood (Mg) (Magnesium -
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blood (Mg))
Oxygen saturation (Oxygen saturation)
Peripheral Blasts count (Peripheral
Blasts count)
pH NOS (pH NOS)
Phosphorus (Phosphorus)
Platelet count (PLT) (Platelet count
(PLT))
pO2 (pO2)
Potassium - blood (K) (Potassium - blood
(K))
Protein NOS (Total) (Protein NOS
(Total))
Prothrombin time (PT) (Prothrombin time
(PT))
Sodium - blood (Sodium - blood)
Triglycerides (Triglycerides)
Urine analysis (Urine analysis)
Viral infection NOS (Viral infection NOS)
White blood cell count (WBC) (White
blood cell count (WBC))
Other Lab*
Baseline Date*
Baseline Value*
Baseline UOM*
Percent (%)
1000 Per Cubic Millimiter (1000/mm3)
10^3 Per Microliter (1000/uL)
Cubic Centimeters Per Minute (cc/min)
Cells Per Liter (cells/L)
Grams Per Deciliter (g/dL)
Grams Per Liter (g/L)
Grams (gm)
Grams Per Deciliter (gm/dl)
International Units Per Liter (iU/L)
Kilopascal (kPa)
Milliequivalent Per Liter (mEq/L)
Milligrams Per Deciliter (mg/dL)
mg/dl (mg/dl)
Milligrams Per Liter (mg/L)
Minutes (min)
Milliliters Per Minute (mL/Min/1.73m2)
Cubic Millimeters (mm3)
Millimeters Of Mercury (mmHg)
Millimole Per Liter (mmol/L)
Not Applicable (n/a)
Number (number)
Seconds (seconds)
Units Per Liter (U/L)
ug/mL (ug/mL)
ul (ul)
umol/L (umol/L)
Vol Frac (Vol Frac)
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Recovery Latest Date*
Recovery Latest Value*
Recovery Latest UOM*
Worst Date*
Worst Value*
Worst UOM*
Site*
Microbiology Date*
Infectious Agent*
Additional_info
Additional Information*
Autopsy Report (Autopsy Report)
Consults (Consults)
Discharge Summary (Discharge
Summary)
Flow Sheets/ Case Report Forms (Flow
Sheets/ Case Report Forms)
Laboratory Reports (Laboratory Reports)
OBA Form (OBA Form)
Operative Report (Operative Report)
Other (Other)
Pathology Report (Pathology Report)
Progress Notes (Progress Notes)
Radiology Reports (Radiology Reports)
Referral Letters (Referral Letters)
Summary Report Sent to IRB (Summary
Report Sent to IRB)
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Neoplasms, Breast NCT00490139 On-Study - BIG 2-06 / NCCTG
N063D / EGF106708 - Unscheduled ECG - 2644256v1.0
BIG 2-06 / NCCTG N063D / EGF106708 - Unscheduled
ECG
ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment
Optimisation) Study; BIG 2-06/N063D
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=313C56F0-
CDB4-544C-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/8595
BIG 2-06 / NCCTG N063D /
EGF106708 - Unscheduled ECG
Header Module
Centre No.
Subject No.
Ecg
Date of EKG
Result
Abnormal - Clinically Significant
(Abnormal - Clinically significant)
Abnormal - Not Clinically Significant
(Abnormal - Not clinically significant)
Normal (Normal)
1 / 1
Sarcoma NCT00090987 Lab - AMC Clinical Trials -
Pharmacodynamics Form for Protocol #042 - PR4203 - 2264950v3.0
AMC Clinical Trials - Pharmacodynamics Form for Protocol
#042 - PR4203
Imatinib Mesylate in Treating Patients With HIV-Related
Kaposi's Sarcoma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=EA0B2B47-
3919-38D6-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/8597
AMC Clinical Trials -
Pharmacodynamics Form for
Protocol #042 - PR4203
Unnamed 1
Total Gleevec taken on day1 or day 15
Sampling Time
0 Hour (0 Hour)
0.5 Hour (0.5 Hour)
1.0 Hour (1.0 Hour)
2.0 Hour (2.0 Hour)
24 Hours (24 Hours)
3.0 Hour (3.0 Hour)
4.0 Hour (4.0 Hour)
8.0 Hour (8.0 Hour)
Sampling Time (Military Clock)
Patient Initials
Patient Study ID
Current Cycle Number
Date of Visit
Date
1 / 1
On-Study - Adult Soft Tissue Sarcoma - On-
Study Form Recurrent Treatment - 2289393v3.0
Adult Soft Tissue Sarcoma - On-Study Form Recurrent
Treatment
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=E208C610-
4FB8-1481-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/8598
Adult Soft Tissue Sarcoma - On-
Study Form Recurrent Treatment
Crf Header
Coordinating Group Protocol No.
Coordinating Group Code
Protocol Title
Patient Study ID
Institution/Affiliate
Other Patient ID
Participating Group Code
Patient Name (initials acceptable)
Sarcoma: Form Administration
Person Completing Form
Are data amended (If data are amended, please
circle in red when using paper form)
Yes
No
Adult Soft Tissue Sarcoma: Recurrent
Disease Description
Date of Initial Pathologic Diagnosis (not relapse)
Recurrence date (MM DD YYYY)
Biopsy Type (at time of relapse)
Excisional (Excisional)
Fine Needle Aspirate (Fine needle
1 / 6
aspirate)
Incisional (Incisional)
Large Bore Needle (Large bore needle)
Other, Specify (Other specify)
Trucut Needle (TruCut needle)
Other specify
Primary Site
Eye And Orbit (Eye and orbit)
Gastrointestinal Stromal Tumor (gist)
(Gastrointestinal stromal tumor (GIST))
Genitourinary (Genitourinary)
Intra-abdominal (Intra-abdominal)
Lower Extremity (Lower extremity)
Non-parameningeal Head And Neck
(Non-parameningeal head and neck)
Other Specify (Other specify)
Parameningeal (Parameningeal)
Thorax (Thorax)
Trunk (Trunk)
Upper Extremity (Upper extremity)
Uterine Sarcoma (Uterine sarcoma)
Other specify
Tumor Location, Side
Both (Both)
Left (Left)
Right (Right)
Unknown (Unknown)
Site(s) of Disease (at Study Entry)
Abdominal Organs (Abdominal organs)
Ascites (Ascites)
Bone (Bone)
Bone Marrow (Bone marrow)
Chest Wall/ribs (Chest wall/ribs)
Cns/brain (CNS/brain)
Liver (Liver)
Lung (Lung)
Lymph Nodes, Specify (Lymph nodes
specify)
Mediastinum (Mediastinum)
Other, Specify (Other specify)
Pericardium (Pericardium)
Peritoneum (Peritoneum)
Pleura (Pleura)
Retroperitoneum (Retroperitoneum)
Skin (Skin)
Soft Tissue (Soft tissue)
Lymph Nodes Specify
Other specify
2 / 6
On-Study - Adult Soft Tissue Sarcoma - On-Study Form Recurrent
Treatment - 2289393v3.0
Metastatic Site (s - For advanced studies, - check
all that apply)
Ascites (Ascites)
Bone (Bone)
Bone Marrow (Bone marrow)
Cerebrospinal Fluid (csf) (Cerebrospinal
fluid (CSF))
Cns/brain (CNS/Brain)
Distant Nodes, Specify (Distant Nodes)
Liver (Liver)
Lung (Lung)
Other Specify (Other)
Peritoneal Nodules (Peritoneal nodules)
Pleural Effusion (Pleural effusion)
Pleural Nodules (Pleural nodules)
Soft Tissue (Soft tissue)
Distant nodes specify
Other specify
Dimension 1 (Longest)
Dimension 2 (cm)
Dimension 3 (cm)
Status of Primary Tumor
Not Recurrent, Resected, No Residual
Tumor (Not recurrent, resected, no
residual tumor)
Not Recurrent, Resected, Residual
Tumor (Not recurrent, resected, residual
tumor)
Recurrent (Recurrent)
Unresected (Unresected)
Histologic Type (check all that apply)
Alveolar Rhabdomyosarcoma (Alveolar
rhabdomyosarcoma)
Alveolar Soft Part Sarcoma (Alveolar soft
part sarcoma)
Angiosarcoma (Angiosarcoma)
Botryoid Rhabdomyosarcoma (Botryoid
rhabdomyosarcoma)
Clear Cell Sarcoma (mmsp) (Clear cell
sarcoma (MMSP))
Dedifferentiated Liposarcoma
(Dedifferentiated liposarcoma)
Dermatofibrosarcoma Protuberans
(Dermatofibrosarcoma protuberans)
Desmoplastic Small Cell Tumor
(Desmoplastic small cell tumor)
Embryonal Rhabdomyosarcoma
(Embryonal rhabdomyosarcoma)
Endometrial Stromal Sarcoma
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On-Study - Adult Soft Tissue Sarcoma - On-Study Form Recurrent
Treatment - 2289393v3.0
(Endometrial stromal sarcoma)
Epithelioid Hemagioendothelioma
(Epithelioid hemangioendothelioma)
Epithelioid Sarcoma (Epithelioid
sarcoma)
Extraskeletal Ewing's/pnet (Extraskeletal
Ewing's/PNET)
Extraskeletal Mesenchymal
Chondrosarcoma (Extraskeletal
mesenchymal chondrosarcoma)
Extraskeletal Myxoid Chondrosarcoma
(Extraskeletal myxoid chondrosarcoma)
Extraskeletal Osteosarcoma
(Extraskeletal osteosarcoma)
Fibrosarcoma (Fibrosarcoma)
Gastrointestinal Stromal Tumor (gist)
(Gastrointestinal stromal tumor (GIST))
Kaposi Sarcoma (Kaposi sarcoma)
Leiomyosarcoma (Leiomyosarcoma)
Liposarcoma Nos (Liposarcoma NOS)
Malignant Mesenchymoma (Malignant
mesenchymoma)
Maligant Peripheral Nerve Sheath Tumor
(Malignant peripheral nerve sheath
tumor)
Myxofibrosarcoma (Myxofibrosarcoma)
Myxoid Liposarcoma (Myxoid
liposarcoma)
Other Specify (Other specify)
Pleomorphic Liposarcoma (Pleomorphic
liposarcoma)
Pleomorphic Rhabdomyosarcoma
(Pleomorphic rhabdomyosarcoma)
Rhabdomyosarcoma Nos
(Rhabdomyosarcoma NOS)
Sarcoma Nos (Sarcoma NOS)
Solitary Fibrous
Tumor/hemangiopericytoma (Solitary
fibrous tumor/hemangiopericytoma)
Spindle Cell Rhabdomyosarcoma
(Spindle cell rhabdomyosarcoma)
Synovial Sarcoma (Synovial sarcoma)
Undifferentiated Pleomorphic
Sarcoma/"mfh" (Undifferentiated
pleomorphic sarcoma/"MFH")
Uterine Carcinosarcoma (mixed
Mesodermal Sarcoma) (Uterine
carcinosarcoma (mixed mesodermal
sarcoma))
Uterine Leiomyosarcoma (Uterine
leiomyosarcoma)
Uterine Sarcoma Nos (Uterine sarcoma
NOS)
Well Differentiated Liposarcoma (Well
differentiated liposarcoma)
Other specify
Histologic Subtype (specify)
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On-Study - Adult Soft Tissue Sarcoma - On-Study Form Recurrent
Treatment - 2289393v3.0
Histologic Grade, French System (check highest
grade)
Grade I (Grade I)
Grade Ii (Grade II)
Grade Iii (Grade III)
Unknown (Unknown)
Adult Soft Tissue Sarcoma: Prior Health
History
Prior Radiation Therapy for Other Disease?
No (No)
Unknown (Unknown)
Yes (Yes)
Prior Radiation Therapy Site (If Yes,)
Is there a history of prior radiation therapy to the
primary site?
No (No)
Unknown (Unknown)
Yes (Yes)
Sarcoma: Prior Treatment
Prior Treatment?
Yes
No
Prior Systemic Chemotherapy
Yes
No
Prior Immunotherapy
Yes
No
Prior Radiation Therapy
Yes
No
Prior Surgery
Yes
No
Type of Prior Primary Surgery
Prior Primary Surgery Date (MM DD YYYY)
Any Other Prior Therapy?
Yes
No
Yes, specify
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Treatment - 2289393v3.0
Sarcoma: Prior Treatment - Systemic
Regimens
Prior Treatment Regimen Name (Drug, Agent,
Biologic)
Prior Treatment Regimen Start Date (MM DD
YYYY)
Prior Treatment Regimen End Date (MM DD
YYYY)
Prior Treatment Regimen Type (Adjuvant, High
Dose)
Comments
Comments
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Sarcoma, Kaposi xxx On-Study - Vital
Signs Form - RF20 - 2267389v3.0
Vital Signs Form - RF20
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=CCE3C7B8-
F06C-50A8-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/8599
Vital Signs Form - RF20
Ccrr Module For Vital Signs Form - Rf20
Respirations
Patient Initials
Study#
Site#
ID#
Cycle #
military clock
Date of Visit
Height
Blood Pressure
Pulse Rate
Weight
Oral Temperature
Units
C (C)
F (F)
Units
C (C)
F (F)
Units
C (C)
F (F)
Body Surface Area
Karnofsky's Performance Score
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Neoplasms, Breast NCT00490139 Follow-Up - BIG 2-06 / NCCTG
N063D / EGF106708 - Treatment Completion - 2644342v1.0
BIG 2-06 / NCCTG N063D / EGF106708 - Treatment
Completion
ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment
Optimisation) Study; BIG 2-06/N063D
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=314FE254-
F5BC-36C0-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/8605
BIG 2-06 / NCCTG N063D /
EGF106708 - Treatment Completion
Header Module
Centre No.
Subject No.
Treatment Completion
Did the patient complete Lapatinib as per
protocol
No (No)
Not Applicable (Not Applicable)
Yes (Yes)
Did the patient complete Trastuzumab as per
protocol
No (No)
Not Applicable (Not Applicable)
Yes (Yes)
Did the patient complete Paclitaxel as per
protocol
No (No)
Not Applicable (Not Applicable)
Yes (Yes)
Reasons for treatment discontinuation
Adverse Event (Adverse Event)
Death (Death)
Lost To Follow-up: C48227 (Lost to
follow-up)
Protocol Violation (Protocol violation)
Recurrence Of Disease Or Second
Primary Malignancy Or Contralateral
Breast Cancer (Recurrence of disease or
second primary malignancy or
contralateral breast cancer)
Subject Decided To Withdraw From
Investigational Product But Is Continuing
To Be Followed Per Protocol (Subject
decided to withdraw from investigational
product but is continuing to be followed
per protocol)
Subject Decided To Withdraw From The
Study (Subject decided to withdraw from
the study)
1 / 2
Date of last contact within treatment period
Additional Comments And Investigator's
Signature
CRF page number
Comments
Investigator Signature
Date
2 / 2
Neoplasms, Breast NCT00490139 Follow-Up - BIG 2-06 / NCCTG
N063D / EGF106708 - Treatment Completion - 2644342v1.0
Sarcoma, Kaposi xxx On-Study - KS Biopsy
Form - RF32 - 2266873v3.0
KS Biopsy Form - RF32
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=CCE29A61-
50BB-4840-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/8608
KS Biopsy Form - RF32
Ccrr Module For Ks Biopsy Form - Rf32
Size (mm x mm)
Patient Initials
Study#
Site#
ID#
Cycle #
Date of Visit
Site Code
Abdomen (Abdomen)
Back (Back)
Chest (Chest)
Genital (Genital)
Head (Head)
Left Arm (Left Arm)
Left Foot (Left Foot)
Left Hand (Left Hand)
Left Leg (Left Leg)
Neck (Neck)
Right Arm (Right Arm)
Right Foot (Right Foot)
Right Hand (Right Hand)
Right Leg (Right Leg)
Specify
Preservative
Formalin (Formalin)
Other (Glutaraldehyde)
Other (OCT Media)
Other (Saline)
Unknown (Unknown)
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Response - Non-Hodgkins Lymphoma - Follow-
Up Disease Assessment Form - 2270621v3.0
Non-Hodgkin's Lymphoma - Follow-Up Disease
Assessment Form
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=D5EC0BF1-
C6F3-750B-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/8609
Non-Hodgkins Lymphoma - Follow-
Up Disease Assessment Form
Crf Header
Coordinating Group Protocol No.
Coordinating Group Code
Protocol Title
Patient Study ID
Institution/Affiliate
Other Patient ID
Participating Group Code
Patient Name (initials acceptable)
Lymphoma: Form Administration
Person Completing Form
Are data amended? (If data are amended, please
circle in red when using paper form)
Yes
No
Lymphoma: Dominant Node Response
Are there any dominant nodes
Yes
No
Lesion Number
Site of Lesion
Method of Evaluation
1 / 8
Ct Scan (CT Scan)
Gallium Scan (Gallium scan)
Mri (MRI (NMR))
Other (Other)
Pet Scan (PET scan)
Spiral Ct Scan (Spiral CT Scan)
Other Specify
Greatest Perpendicular Measurements (cm)
Greatest Perpendicular Measurements (cm)
Product of Measurements (cm^2)
Date of Evaluation
Sum of Products of Measurements (cm^2)
Lymphoma: Nondominant Lesion
Response
Do the dominant nodes show a response of CR,
CRu, or PR
Yes
No
Lesion Number
Site of Lesion
Method of Evaluation
Ct Scan (CT Scan)
Gallium Scan (Gallium scan)
Mri (MRI (NMR))
Other (Other)
Pet Scan (PET scan)
Spiral Ct Scan (Spiral CT Scan)
Other Specify
Greatest Perpendicular Measurements (cm)
Lesion Assessment (? Assessment Codes)
Disappearance (Disappearance)
Improvement (Improvement)
No Change (No change)
Not Evaluated (Not evaluated)
Progression - Increase (Progression -
increase)
2 / 8
Response - Non-Hodgkins Lymphoma - Follow-Up Disease Assessment
Form - 2270621v3.0
Worsening (Worsening)
Greatest Perpendicular Measurements (cm)
Product of Measurements (cm^2)
Date of Evaluation
Sum of Products of Measurements (cm^2)
Lymphoma: Measurable Hepatic/splenic
Nodule Response
Are there any measurable hepatic or splenic
nodules
Yes
No
Lesion Number
Site of Lesion
Method of Evaluation
Ct Scan (CT Scan)
Gallium Scan (Gallium scan)
Mri (MRI (NMR))
Other (Other)
Pet Scan (PET scan)
Spiral Ct Scan (Spiral CT Scan)
Other Specify
Greatest Perpendicular Measurements (cm)
Greatest Perpendicular Measurements (cm)
Product of Measurements (cm^2)
Date of Evaluation
Sum of Products of Measurements (cm^2)
Lymphoma: Non-measurable Lesion
Response
Is non-measurable disease present?
Yes
No
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Response - Non-Hodgkins Lymphoma - Follow-Up Disease Assessment
Form - 2270621v3.0
Lesion Number
Site of Lesion
Method of Evaluation
Ct Scan (CT Scan)
Gallium Scan (Gallium scan)
Mri (MRI (NMR))
Other (Other)
Pet Scan (PET scan)
Spiral Ct Scan (Spiral CT Scan)
Other Specify
Lesion Assessment (? Assessment Codes)
Disappearance (Disappearance)
Improvement (Improvement)
No Change (No change)
Not Evaluated (Not evaluated)
Progression - Increase (Progression -
increase)
Worsening (Worsening)
Date of Evaluation
Lymphoma: New Lesions
Was the appearance of any new lesions
documented (since the baseline evaluation?)
Yes
No
Location of New Lesions (If yes, Record new
bone marrow involvement in the Bone Marrow
module.  Record all other new involvement in this
module.)
Bone Marrow And Other (Bone marrow
and other)
Bone Marrow Only (Bone Marrow only)
Other (Other)
Lesion Number
Site of Lesion
Method of Evaluation
Ct Scan (CT Scan)
Gallium Scan (Gallium scan)
Mri (MRI (NMR))
Other (Other)
Pet Scan (PET scan)
Spiral Ct Scan (Spiral CT Scan)
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Response - Non-Hodgkins Lymphoma - Follow-Up Disease Assessment
Form - 2270621v3.0
Other Specify
Date of Evaluation
Lymphoma: Bone Marrow, Liver And
Spleen Response Assessment
Was bone marrow biopsy done
No (No)
Unknown (Unknown)
Yes (Yes)
Bone Marrow Biopsy Result (If yes,)
Equivocal (Equivocal)
Involved (Involved)
Not Involved (Not Involved)
Date of Bone Marrow Biopsy
Was bone marrow aspirate done
No (No)
Unknown (Unknown)
Yes (Yes)
Method of Evaluation
Ct Scan (CT Scan)
Gallium Scan (Gallium scan)
Mri (MRI (NMR))
Other (Other)
Pet Scan (PET scan)
Spiral Ct Scan (Spiral CT Scan)
Method of Evaluation
Ct Scan (CT Scan)
Gallium Scan (Gallium scan)
Mri (MRI (NMR))
Other (Other)
Pet Scan (PET scan)
Spiral Ct Scan (Spiral CT Scan)
Other Specify
Other Specify
Bone Marrow Aspirate Result (If yes,)
Equivocal (Equivocal)
Involved (Involved)
Not Involved (Not Involved)
Date of Bone Marrow Aspirate
Palpable Hepatomegaly
Examination Performed And
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Response - Non-Hodgkins Lymphoma - Follow-Up Disease Assessment
Form - 2270621v3.0
Hepatomegaly Absent (No)
Examination Of Liver Not Performed (Not
examined)
Examination Performed And
Hepatomegaly Present (Yes)
Date of Liver Palpation (If done,)
Hepatomegaly by scan
Examination Performed And
Hepatomegaly Absent (No)
Examination Of Liver Not Performed (Not
examined)
Examination Performed And
Hepatomegaly Present (Yes)
Date of Liver Evaluation (If done,)
Palpable Splenomegaly
Examination Performed And
Splenomegaly Absent (No)
Examination Of Spleen Not Performed
(Not examined)
Spleen Removed Via Prior Surgery
(Surgically absent)
Examination Performed And
Splenomegaly Present (Yes)
Date of Spleen Palpation (If done,)
Splenomegaly by scan
Examination Performed And
Splenomegaly Absent (No)
Examination Of Spleen Not Performed
(Not examined)
Spleen Removed Via Prior Surgery
(Surgically absent)
Examination Performed And
Splenomegaly Present (Yes)
Date of Spleen Evaluation (If done,)
Non-hodgkin's Lymphoma: Biochemical
And B Symptoms
Lactate Dehydrogenase (LDH) (U/l)
Lactate Dehydrogenase ULN (LDH U/l *Note:
Record institutional limits of normal)
To what is LDH elevation attributable (If LDH is >
ULN,)
Non-hodgkin's Lymphoma (Non-
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Response - Non-Hodgkins Lymphoma - Follow-Up Disease Assessment
Form - 2270621v3.0
Hodgkin's lymphoma)
Other (Other)
Other Specify
Status of disease-related B-symptoms
Not Present At Baseline (Not present at
baseline)
Not Resolved (Not resolved)
Resolved (Resolved)
Describe unresolved B-symptoms (If not
resolved,)
Non-hodgkin's Lymphoma: Response
Assessment
Has the overall response changed (Since
previous evaluation,)
Yes
No
Has an unconfirmed response changed to a
confirmed response (If no,)
Yes
No
Objective Status at This Evaluation
Complete Response (Complete
Response)
Complete Response Uncertain
(Complete Response uncertain)
Partial Response (Partial response)
Progressive Disease (Progressive
Disease)
Stable Disease (Stable Disease)
Unevaluable (Unevaluable)
Has response been confirmed by second
assessment? (Follow protocol guidelines for
confirmation of response.)
Yes
No
Complete Response (CR) First Observed Date (If
yes,)
Complete Response uncertain (CRu) First
Observed Date
Partial Response (PR) First Observed Date
Stable Disease First Observed Date (For SD: SD)
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Response - Non-Hodgkins Lymphoma - Follow-Up Disease Assessment
Form - 2270621v3.0
Progressive Disease First Observed Date (For
PD: PD)
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Response - Non-Hodgkins Lymphoma - Follow-Up Disease Assessment
Form - 2270621v3.0
Neoplasms, Breast NCT00490139 Follow-Up - BIG 2-06 / NCCTG
N063D / EGF106708 - Survival Follow-Up - 2639409v1.0
BIG 2-06 / NCCTG N063D / EGF106708 - Survival Follow-
Up
ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment
Optimisation) Study; BIG 2-06/N063D
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=30BF8A98-
19AF-47AC-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/8610
BIG 2-06 / NCCTG N063D /
EGF106708 - Survival Follow-Up
Header Module
Centre No.
Subject No.
Header
Vital Status
Alive (Alive)
Dead (Dead)
Lost To Follow-up (Lost to follow-up)
Date of Last Contact or Death
Investigator Signature
Date
1 / 1
Sarcoma, Kaposi xxx Lab - HIV T-Cell
Laboratory Values - RF24 - 2266672v3.0
HIV T-Cell Laboratory Values - RF24
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=CCE3794C-
8984-4792-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/8612
HIV T-Cell Laboratory Values - RF24
Ccrr Module For Hiv T-cell Laboratory
Values - Rf24
T-Supressor, CD8 (%)
T-Cell, CD3 (%)
T-Helper, CD4 Absolute Count
T-Helper, CD4 (%)
T-Cell, CD3 Absolute Count
B-Cell, CD19 (%)
Sequence #
Cycle Day
B-Cell, CD19 Absolute Count
T-Cell, CD20 (%)
T-Cell, CD20 Absolute Count
CD38 expresson on CD4 positive T-cells
T-Supressor, CD8 Absolute Count
Patient Initials
Study#
Site#
ID#
Cycle#
1 / 2
Date of Visit
Which evaluation does this represent?
Entry/Baseline (Entry/Baseline)
On Treatment (On Treatment)
Post Therapy Evaluation (Post Therapy
Evaluation)
Other, (Positive lymphocytes) Absolute Count
Other, (Positive lymphocytes) Absolute Count
Other, specify (Positive lymphocytes)
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Sarcoma, Kaposi xxx Lab - HIV T-Cell Laboratory Values - RF24 -
2266672v3.0
Sarcoma, Kaposi xxx Lab - HIV Viral Load
Form - RF40B - 2266698v3.0
HIV Viral Load Form - RF40B
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=CCE281C6-
8084-47D9-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/8613
HIV Viral Load Form - RF40B
Ccrr Module For Hiv Viral Load Form -
Rf40b
Date of Assay
Limits of Detection
Other
Standard (Standard)
Ultra (Ultra)
Roche Amplicor Monitor Assay
Standard (Standard)
Ultra (Ultra)
Method of Detection
Results
<Less than (<Less than)
=Equal To (=Equal To)
>Greater than (>Greater than)
Undetectable (Undetectable)
Patient Initials
Study#
Site#
ID#
Cycle#
Date of visit
Date of Collection
Name of Site
1 / 1
Sarcoma, Kaposi xxx Comments -
Comments Form - RF34 - 2266179v3.0
Comments Form - RF34
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=CCE1CE9F-
A5EF-42E0-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/8615
Comments Form - RF34
Ccrr Module For Comments Form - Rf34
Patient Initials
Study#
Site#
ID#
Cycle #
Date
Explain why drug was interrupted, reduced or
discontinued.  If does was reduced, record what it
was reduced for and to (i.e., from 100 to 75
mg/m2/day). Record all relevant dates of action.
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Sarcoma, Kaposi xxx On-Study - Missed
Visit Form - RF35 - 2266901v3.0
Missed Visit Form - RF35
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=CCE29EA7-
C5A3-48CE-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/8616
Missed Visit Form - RF35
Ccrr Module For Missed Visit Form - Rf35
Resolution
Adverse event report (fill out RF28). Also
fill out NCI form if applicable. (Adverse
event report (fill out RF28). Also fill out
NCI form if applicable.)
Discontinued study (Discontinued study)
Next visit scheduled.  Items missed will
be made up at the new visit. (Next visit
scheduled.  Items missed will be made
up at the new visit.)
Patient Initials
Study#
Site#
ID#
Cycle # Missed
Date of Missed Visit
Reason for missed visit
Other (Other)
Patient could not get off work (Patient
could not get off work)
Health Reasons (Patient felt too sick to
come in)
Patient forgot (Patient forgot)
Patient had decided to discontinue study
(Patient had decided to discontinue
study)
Patient had transportation problems
(Patient had transportation problems)
Health Reasons (Patient hospitalized)
Patient unable to obtain dependent care
(Patient unable to obtain dependent
care)
Patient unhappy with frequency of visits
(Patient unhappy with frequency of visits)
Scheduling Difficulties (Scheduling
conflict)
Other, Specify
1 / 1
Colorectal Cancer NCT00726622 Quality of Life - Z6051 International
Index of Erectile Function Questionnaire (IIEF) - 2740994v1.0
Z6051 International Index of Erectile Function
Questionnaire (IIEF)
Laparoscopic-Assisted Resection or Open Resection in
Treating Patients With Stage IIA, Stage IIIA, or Stage IIIB
Rectal Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=4AE9A885-
FEFA-574B-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/8617
Z6051 International Index of Erectile
Function Questionnaire (IIEF)
Header Module
Type of Visit
Pre-operative (1)
4-6 Weeks Post-surgery (2)
Month 3 (3)
Month 12 (4)
Patient ID (Pt. ID issued during registration
unless pt. previously registered to an ACOSOG
study.)
Patient Initials
Institution Name
Institution No.
Date of Assessment
IIEF
Over the past 4 weeks, how often were you able
to have an erection during sexual activity
A Few Times (1)
Almost Always/ Always (2)
Almost Never/ Never (3)
Most Times (4)
No Sexual Activity (5)
Sometimes (6)
Over the past 4 weeks, when you had erections
with sexual stimulation, how often were your
erections hard enough for penetration
A Few Times (1)
Almost Always/ Always (2)
Almost Never/ Never (3)
Most Times (4)
No Sexual Activity (5)
Sometimes (6)
Over the past 4 weeks, when you attempted
sexual intercourse, how often were you able to
1 / 4
penetrate (enter) your partner
A Few Times (1)
Almost Always/ Always (2)
Almost Never/ Never (3)
Most Times (4)
No Sexual Activity (5)
Sometimes (6)
Over the past 4 weeks, during sexual intercourse,
how often were you able to maintain your erection
after you had penetrated (entered) your partner
A Few Times (A few times)
Almost Always/ Always (almost always/
always)
Almost Never/ Never (almost never/
never)
Did Not Attempt Intercourse (Did not
attempt intercourse)
Most Times (Most times)
Sometimes (Sometimes)
Over the past 4 weeks, during sexual intercourse,
how difficult was it to maintain your erection to
complete intercourse
Did Not Attempt Intercourse (Did not
attempt intercourse)
Difficult (Difficult)
Extremely Difficult (Extremely difficult)
Not Difficult (Not difficult)
Slightly Difficult (Slightly difficult)
Very Difficult (Very difficult)
Over the past 4 weeks, how many times did you
attempt sexual intercourse
Five To Six Attempts (Five to six
attempts)
More Than Eleven Attempts (More than
eleven attempts)
No Attempt (No attempt)
One To Two Attempts (One to two
attempts)
Seven To Ten Attempts (Seven to ten
attempts)
Three To Four Attempts (Three to four
attempts)
Over the past 4 weeks, when you attempted
sexual intercourse, how often was it satisfactory
for you
A Few Times (A few times)
Almost Always/ Always (almost always/
always)
Almost Never/ Never (almost never/
never)
Did Not Attempt Intercourse (Did not
attempt intercourse)
Most Times (Most times)
Sometimes (Sometimes)
2 / 4
Colorectal Cancer NCT00726622 Quality of Life - Z6051 International
Index of Erectile Function Questionnaire (IIEF) - 2740994v1.0
Over the past 4 weeks, how much did you enjoy
sexual intercourse
Fairly Enjoyable (Fairly enjoyable)
Highly Enjoyable (Highly enjoyable)
No Enjoyment (No enjoyment)
No Intercourse (No intercourse)
Not Very Enjoyable (Not very enjoyable)
Very Highly Enjoyable (Very highly
enjoyable)
Over the past 4 weeks, when you had sexual
stimulation or intercourse, how often did you
ejaculate
A Few Times (A few times)
Almost Always/ Always (almost always/
always)
Almost Never/ Never (almost never/
never)
Did Not Attempt Intercourse (Did not
attempt intercourse)
Most Times (Most times)
Sometimes (Sometimes)
Over the past 4 weeks, when you had sexual
stimulation or intercourse, how often did you have
the feeling of orgasm or climax
A Few Times (A few times)
Almost Always/ Always (almost always/
always)
Almost Never/ Never (almost never/
never)
Most Times (Most times)
Sometimes (Sometimes)
Over the past 4 weeks, how often did you feel
sexual desire
A Few Times (A few times)
Almost Always/ Always (almost always/
always)
Almost Never/ Never (almost never/
never)
Most Times (Most times)
Sometimes (Sometimes)
Over the past 4 weeks, how would you rate your
level of sexual desire
High (High)
Low (Low)
Moderation (Moderate)
Very High (Very high)
Very Low Or None At All (Very low or
none at all)
Over the past 4 weeks, how satisfied have you
been with your overall sexual life
About Equally Satisfied And Dissatisfied
(About equally satisfied and dissatisfied)
Moderately Dissatisfied (Moderately
dissatisfied)
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Moderately Satisfied (Moderately
satisfied)
Very Dissatisfied (Very dissatisfied)
Very Satisfied (Very satisfied)
Over the past 4 weeks, how satisfied have you
been with your sexual relationship with your
partner
About Equally Satisfied And Dissatisfied
(About equally satisfied and dissatisfied)
Moderately Dissatisfied (Moderately
dissatisfied)
Moderately Satisfied (Moderately
satisfied)
Very Dissatisfied (Very dissatisfied)
Very Satisfied (Very satisfied)
Over the past 4 weeks, how do you rate your
confidence that you could have and keep an
erection
High (High)
Low (Low)
Moderation (Moderate)
Very High (Very high)
Very Low (Very low)
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On-Study - Pediatric Soft Tissue Sarcoma - On-
Study Form Recurrent Treatment - 2292588v3.0
Pediatric Soft Tissue Sarcoma - On-Study Form Recurrent
Treatment
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=E4053EE1-
90D1-2ED9-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/8620
Pediatric Soft Tissue Sarcoma - On-
Study Form Recurrent Treatment
Crf Header
Coordinating Group Protocol No.
Coordinating Group Code
Protocol Title
Patient Study ID
Institution/Affiliate
Other Patient ID
Participating Group Code
Patient Name (initials acceptable)
Sarcoma: Form Administration
Person Completing Form
Are data amended (If data are amended, please
circle in red when using paper form)
Yes
No
Pediatric Soft Tissue Sarcoma: Recurrent
Disease Description
Date of Initial Pathologic Diagnosis (not relapse)
Recurrence date (MM DD YYYY)
Biopsy Type (at time of relapse)
Excisional (Excisional)
Incisional (Incisional)
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Large Bore Needle (Large bore needle)
Other, Specify (Other specify)
Trucut Needle (TruCut needle)
Other specify
Site(s) of Disease (check all that apply)
Abdominal Organs (Abdominal organs)
Ascites (Ascites)
Bone (Bone)
Bone Marrow (Bone marrow)
Chest Wall/ribs (Chest wall/ribs)
Cns/brain (CNS/brain)
Liver (Liver)
Lung (Lung)
Lymph Nodes, Specify (Lymph nodes
specify)
Mediastinum (Mediastinum)
Other, Specify (Other specify)
Pericardium (Pericardium)
Peritoneum (Peritoneum)
Pleura (Pleura)
Retroperitoneum (Retroperitoneum)
Skin (Skin)
Soft Tissue (Soft tissue)
Lymph Nodes Specify
Other specify (If Yes,)
Other specify (If Yes,)
Intracranial Tumor Extension (check all that
apply)
Base Of Skull Erosion (Base of skull
erosion)
Cranial Nerve Palsy (Cranial nerve
palsy)
Intracranial Extension (Intracranial
extension)
Other, Specify (Other specify)
Other specify
Relapsed at primary site?
Yes
No
Relapsed at regional site?
Yes
No
Relapsed at distant site?
Yes
No
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Number of Regional Lymph Nodes Examined
Number of Positive Lymph Nodes
Regional lymph nodes
No (No)
Unknown (Unknown)
Yes (Yes)
Distant lymph nodes
No (No)
Unknown (Unknown)
Yes (Yes)
Other distant or metastatic site?
No (NO)
Unknown (UNKNOWN)
Yes (YES)
Status of Primary Tumor
Not Recurrent, Resected, No Residual
Tumor (Not recurrent, resected, no
residual tumor)
Not Recurrent, Resected, Residual
Tumor (Not recurrent, resected, residual
tumor)
Recurrent (Recurrent)
Unresected (Unresected)
Histologic Type (check all that apply)
Alveolar Rhabdomyosarcoma (Alveolar
rhabdomyosarcoma)
Alveolar Soft Part Sarcoma (Alveolar soft
part sarcoma)
Angiosarcoma (Angiosarcoma)
Botryoid Rhabdomyosarcoma (Botryoid
rhabdomyosarcoma)
Clear Cell Sarcoma (mmsp) (Clear cell
sarcoma (MMSP))
Dedifferentiated Liposarcoma
(Dedifferentiated liposarcoma)
Dermatofibrosarcoma Protuberans
(Dermatofibrosarcoma protuberans)
Desmoplastic Small Cell Tumor
(Desmoplastic small cell tumor)
Embryonal Rhabdomyosarcoma
(Embryonal rhabdomyosarcoma)
Endometrial Stromal Sarcoma
(Endometrial stromal sarcoma)
Epithelioid Sarcoma (Epithelioid
sarcoma)
Extraskeletal Ewing's/pnet (Extraskeletal
Ewing's/PNET)
Extraskeletal Mesenchymal
Chondrosarcoma (Extraskeletal
mesenchymal chondrosarcoma)
Extraskeletal Myxoid Chondrosarcoma
(Extraskeletal myxoid chondrosarcoma)
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Extraskeletal Osteosarcoma
(Extraskeletal osteosarcoma)
Fibrosacoma, Nos (Fibrosacoma NOS)
Gastrointestinal Stromal Tumor (gist)
(Gastrointestinal stromal tumor (GIST))
Infantile Fibrosarcoma (Infantile
fibrosarcoma)
Kaposi Sarcoma (Kaposi sarcoma)
Leiomyosarcoma (Leiomyosarcoma)
Liposarcoma Nos (Liposarcoma NOS)
Malignant Mesenchymoma (Malignant
mesenchymoma)
Maligant Peripheral Nerve Sheath Tumor
(Malignant peripheral nerve sheath
tumor)
Myxofibrosarcoma (Myxofibrosarcoma)
Myxoid Liposarcoma (Myxoid
liposarcoma)
Other Specify (Other specify)
Pleomorphic Liposarcoma (Pleomorphic
liposarcoma)
Pleomorphic Rhabdomyosarcoma
(Pleomorphic rhabdomyosarcoma)
Rhabdomyosarcoma Nos
(Rhabdomyosarcoma NOS)
Soft Tissue Sarcoma Nos (Soft tissue
sarcoma NOS)
Solitary Fibrous
Tumor/hemangiopericytoma (Solitary
fibrous tumor/hemangiopericytoma)
Spindle Cell Rhabdomyosarcoma
(Spindle cell rhabdomyosarcoma)
Synovial Sarcoma (Synovial sarcoma)
Undifferentiated Pleomorphic
Sarcoma/"mfh" (Undifferentiated
pleomorphic sarcoma/"MFH")
Undifferentiated Sarcoma
(Undifferentiated sarcoma)
Unknown (Unknown)
Uterine Carcinosarcoma (mixed
Mesodermal Sarcoma) (Uterine
carcinosarcoma (mixed mesodermal
sarcoma))
Uterine Leiomyosarcoma (Uterine
leiomyosarcoma)
Uterine Sarcoma Nos (Uterine sarcoma
NOS)
Well Differentiated Liposarcoma (Well
differentiated liposarcoma)
Other specify
Histologic Subtype (specify)
Histologic Grade, French System (check highest
grade)
Grade I (Grade I)
Grade Ii (Grade II)
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Grade Iii (Grade III)
Unknown (Unknown)
Pediatric Soft Tissue Sarcoma: Prior
Health History
Does the patient have a chronic disease
associated with this cancer?
Yes
No
Current Medical Conditions (currently
symptomatic or on medications for)
Cardiac Disease (Cardiac disease)
Cerebrovascular Disease
(Cerebrovascular disease)
Deep Vein Thrombosis (Deep vein
thrombosis)
Diabetes (Diabetes)
Gastrointestinal Disease
(Gastrointestinal disease)
High Blood Pressure (High blood
pressure)
Neurologic Disease (Neurologic disease)
Other Malignancies, Specify (Other
malignancies specify)
Other, Specify (Other specify)
Peripheral Vascular Disease (Peripheral
vascular disease)
Respiratory Problems (Respiratory
problems)
Other malignancies specify
Other specify
Congenital abnormalities
Downs Syndrome (Downs syndrome)
Hemihypertrophy (Hemihypertrophy)
Li-fraumeni Syndrome (Li-Fraumeni
syndrome)
Neurofibromatosis (Neurofibromatosis)
None (None)
Other, Specify (Other specify)
Other specify
Family history of neurofibromatosis?
Yes
No
Sarcoma: Prior Treatment
Prior Treatment?
Yes
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No
Prior Systemic Chemotherapy?
Yes
No
Prior Immunotherapy?
Yes
No
Prior Radiation Therapy?
Yes
No
Prior Surgery?
Yes
No
Type of Prior Primary Surgery
Prior Primary Surgery Date (MM DD YYYY)
Any Other Prior Therapy?
Yes
No
Yes, specify
Sarcoma: Prior Treatment - Systemic
Regimens
Prior Treatment Regimen Name (Drug, Agent,
Biologic)
Prior Treatment Regimen Start Date (MM DD
YYYY)
Prior Treatment Regimen End Date (MM DD
YYYY)
Prior Treatment Regimen Type (Adjuvant, High
Dose)
Comments
Comments
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Treatment - Multiple Myeloma - Transplant
Graft Vs. Host Disease Form - 2273155v3.0
Multiple Myeloma - Transplant Graft Vs. Host Disease Form
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=D677EBEC-
CA4A-07B2-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/8625
Multiple Myeloma - Transplant Graft
Vs. Host Disease Form
Crf Header
Coordinating Group Protocol No.
Coordinating Group Code
Protocol Title
Patient Study ID
Institution/Affiliate
Other Patient ID
Participating Group Code
Patient Name (initials acceptable)
Myeloma: Form Administration
Person Completing Form
Are data amended? (If data are amended, please
circle in red when using paper form)
Yes
No
Myeloma Transplant: Allogeneic - Acute
Graft Vs. Host Disease
Date of Evaluation
Prophylaxis Given following Transplant (Note:
Provide pre-printed list of agents approved for
prophylaxis per protocol.)
Did acute Graft vs. Host Disease occur (GVHD)
No (No)
Not Evaluable (Not evaluable)
Unknown (Unknown)
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Yes (Yes)
Date of Onset of Acute GVHD (If yes,)
Overall Stage of Acute GVHD
0 (0)
1 (1)
2 (2)
3 (3)
4 (4)
Unknown (Unknown)
GVHD Organ Involvement Site
Gastrointestinal Tract (Gastrointestinal
tract)
Liver (Liver)
Other (Other)
Skin (Skin)
Other specify
Maximum stage of organ involvement attributed
to GVHD (since the last evaluation)
0 (0)
1 (1)
2 (2)
3 (3)
4 (4)
Unknown (Unknown)
Therapy Given for GVHD
Myeloma Transplant: Allogeneic - Chronic
Graft Vs. Host Disease
Date of Onset of Chronic GVHD
Did chronic graft vs. host disease occur
No (No)
Unknown (Unknown)
Yes (Yes)
GVHD Organ Involvement (mark all that apply)
Constitutional (Constitutional)
Esophagus (Esophagus)
Eyes (Eyes)
Hematologic (Hematologic)
Intestinal (Intestinal)
Kidney (Kidney)
Liver (Liver)
Lung (Lung)
Mouth (Mouth)
Musculoskeletal (Musculoskeletal)
Other (Other)
Skin (Skin)
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Spleen (Spleen)
Vagina (Vagina)
Other specify
Maximum severity of chronic GVHD (since the
time of last report Note: Include definitions for
limited and extensive per protocol.)
Extensive (Extensive)
Limited (Limited)
Not Evaluated (Not evaluated)
Unknown (Unknown)
Overall Grade of Chronic GVHD
Extensive (Extensive)
Limited (Limited)
Not Evaluated (Not evaluated)
Unknown (Unknown)
Comments
Comments
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Response - Hodgkins Lymphoma - Baseline
Disease Assessment Form - 2271087v3.0
Hodgkin's Lymphoma - Baseline Disease Assessment
Form
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=D5ED6599-
B61D-0C20-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/8629
Hodgkins Lymphoma - Baseline
Disease Assessment Form
Crf Header
Coordinating Group Protocol No.
Coordinating Group Code
Protocol Title
Patient Study ID
Institution/Affiliate
Other Patient ID
Participating Group Code
Patient Name (initials acceptable)
Lymphoma: Form Administration
Person Completing Form
Are data amended? (If data are amended, please
circle in red when using paper form)
Yes
No
Lymphoma: Measurable Disease
Is measurable disease present?
Yes
No
Lesion Number
Site of Lesion
Method of Evaluation (* use code below * Method
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of Evaluation Code)
Bone Scan (Bone Scan)
Chest X-ray (Chest X-ray)
Ct Scan (CT Scan)
Gallium Scan (Gallium scan)
Mri (MRI (NMR))
Other (Other)
Pet Scan (PET scan)
Spiral Ct Scan (Spiral CT Scan)
Ultrasound (Ultrasound)
Other Specify (If)
Greatest Perpendicular Measurements (cm)
Greatest Perpendicular Measurements (cm)
Product of Measurements (cm^2)
Date of Evaluation
Sum of Products of Measurements (cm^2)
Lymphoma: Non-measurable Disease
Is non-measurable disease present?
Yes
No
Lesion Number
Site of Lesion
Method of Evaluation (* use code below * Method
of Evaluation Code)
Bone Scan (Bone Scan)
Chest X-ray (Chest X-ray)
Ct Scan (CT Scan)
Gallium Scan (Gallium scan)
Mri (MRI (NMR))
Other (Other)
Pet Scan (PET scan)
Spiral Ct Scan (Spiral CT Scan)
Ultrasound (Ultrasound)
Other Specify (If)
Date of Evaluation
Lymphoma: Bone Marrow Assessment
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Is there bone marrow involvement
No (No)
Unknown (Unknown)
Yes (Yes)
Was bone marrow biopsy done (If yes,)
No (No)
Unknown (Unknown)
Yes (Yes)
Bone Marrow Biopsy Result (If yes,)
Equivocal (Equivocal)
Involved (Involved)
Not Involved (Not Involved)
Date of Bone Marrow Biopsy
Was bone marrow aspirate done
No (No)
Unknown (Unknown)
Yes (Yes)
Bone Marrow Aspirate Result (If yes,)
Equivocal (Equivocal)
Involved (Involved)
Not Involved (Not Involved)
Date of Bone Marrow Aspirate
Lymphoma: Scanning/imaging
Imaging Site
Abdomen (Abdomen)
Bone (Bone)
Chest (Chest)
Chest (Chest)
Other (Other)
Other (Other)
Pelvis (Pelvis)
Bone specify
Method of Evaluation (* use code below * Method
of Evaluation Code)
Bone Scan (Bone Scan)
Chest X-ray (Chest X-ray)
Ct Scan (CT Scan)
Gallium Scan (Gallium scan)
Mri (MRI (NMR))
Other (Other)
Pet Scan (PET scan)
Spiral Ct Scan (Spiral CT Scan)
Ultrasound (Ultrasound)
Other specify
Other Specify (If)
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Other specify
Imaging Result (** use code below ** Imaging
Result)
Equivocal (Equivocal)
Indeterminate (Indeterminate)
Involved (Involved)
Negative (Negative)
Not Done (Not Done)
Date of Evaluation
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On-Study - Metastatic Brain Cancer - On-
Study Form - 2287553v3.0
Metastatic Brain Cancer - On-Study Form
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=EF3A8ACE-
5457-4C56-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/8630
Metastatic Brain Cancer - On-Study
Form
Crf Header
Coordinating Group Protocol No.
Coordinating Group Code
Protocol Title
Patient Study ID
Institution/Affiliate
Other Patient ID
Participating Group Code
Patient Name (initials acceptable)
Brain: Form Administration
Person Completing Form
Are data amended (If data are amended, please
circle in red when using paper form)
Yes
No
Non-cns: Initial Disease Description
Date of Initial Diagnosis of Primary Tumor (MM
DD YYYY)
Primary Site
Breast (Breast)
Lung (Lung)
Other Specify (Other specify)
Skin/melanoma (Skin/melanoma)
Unknown Primary (Unknown primary)
Other specify
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Extent of Disease
Absent (Absent)
Present (Present)
Unknown (Unknown)
Histologic Type (Initial)
Adenocarcinoma (adenocarcinoma)
Large Cell (large cell)
Melanoma (melanoma)
Other, Specify (Other specify)
Small Cell (small cell)
Squamous Cell (squamous cell)
Other specify
Brain: Current Disease Description
Are there more than five brain metastases?
No (No)
Unknown (Unknown)
Yes (Yes)
Metastatic Involvement
Brain And Other Metastatic Site (Brain
and other metastatic site)
Brain Only (Brain only)
Metastatic Sites
Bone (Bone)
Liver (Liver)
Lung (Lung)
Other Specify (Other)
Regional Node (Regional node)
Soft Tissue (Soft tissue)
Other specify
Extent of Disease
Absent (Absent)
Present (Present)
Unknown (Unknown)
Date of Metastatic Diagnosis (MM DD YYYY)
Date of Metastatic Diagnosis (MM DD YYYY)
Specify number of lesions (under study)
Brain: Concomitant Medications
Is the person receiving anti-convulsant
medication?
No (No)
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Unknown (Unknown)
Yes (Yes)
Is this anti-convulsant medication enzyme-
inducing?
No (No)
Unknown (Unknown)
Yes (Yes)
Is the patient receiving corticosteroids?
No (No)
Unknown (Unknown)
Yes (Yes)
Agent Total Dose (per day)
Is the patient receiving other medications?
No (No)
Unknown (Unknown)
Yes (Yes)
Agent Name (If Yes,)
Agent Name (If Yes,)
Agent Name (If Yes,)
Agent Start Date (MM DD YYYY)
Agent Start Date (MM DD YYYY)
Agent Start Date (MM DD YYYY)
Metastatic Brain: Prior Health History
Does the patient have a chronic disease
associated with this cancer?
Yes
No
Has the patient experienced an intracranial
hemorrhage?
Yes
No
Date of Most Recent (MM DD YYYY)
Has the patient experienced an intraoccular
hemorrhage?
Yes
No
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Date of Most Recent (MM DD YYYY)
Current Medical Conditions (currently
symptomatic or on medications for)
Cardiac Disease (Cardiac disease)
Cerebrovascular Disease
(Cerebrovascular disease)
Deep Vein Thrombosis (Deep vein
thrombosis)
Diabetes (Diabetes)
Hypertension (Hypertension)
Other Malignancies, Specify (Other
malignancies specify)
Other, Specify (Other specify)
Other malignancies specify
Other specify
Metastatic Brain: Prior Treatment
Prior Treatment?
Yes
No
Prior Systemic Chemotherapy?
Yes
No
Prior Immunotherapy?
Yes
No
Prior Radiation Therapy? (except radiosurgery)
Yes
No
Prior Resection of Brain Metastases?
Yes
No
Prior Surgery?
Yes
No
Prior Radiosurgery?
Yes
No
Prior Radiosensitizer Therapy?
Yes
No
Any Other Prior Therapy?
Yes
No
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Name of other prior therapies (If Yes,)
Brain: Prior Treatment - Systemic
Regimens
Prior Treatment Regimen Name (Drug, Agent,
Biologic)
Prior Treatment Regimen Start Date (MM DD
YYYY)
Prior Treatment Regimen End Date (MM DD
YYYY)
Prior Treatment Regimen Type (Adjuvant, High
Dose)
Brain: Prior Treatment - Cns Rt
Prior RT Site
Prior Treatment Regimen Start Date (MM DD
YYYY)
Prior Treatment Regimen End Date (MM DD
YYYY)
Prior Radiation Therapy Type (Hyperfractionated;
Brachytherapy; Photon Beam; Radiosurgery;
EBRT; IMRT; Electron Beam; Conformal; Proton
Beam)
Brain: Prior Treatment - Cns Surgery
Prior Surgery Type
Prior Surgery Date (MM DD YYYY)
Was a complete resection done?
Yes
No
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Registration - Phase II Breast Cancer
Registration Form - 2550280v1.0
Phase II Breast Cancer Registration Form
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=23E49B63-
1DBC-53B8-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/8633
Phase II Breast Cancer Registration
Form
Crf Header
Coordinating Group Protocol No.
Coordinating Group Code
Protocol Title
Patient Study ID
Registering Group Code
Patient Medical Record Number
Other Patient ID
Institution/Affiliate
Registering Institution Code
Physician of Record
Form Administration
IRB/REB  Approval Date
Date Informed Consent Signed
Date Informed Consent Expired
Projected Start Date of Treatment
Date of Registration
HIPAA Authorization Date
Date Form Completed
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Person Completing Form, Last Name
Person Completing Form, First Name
Person Completing Form, Phone
Person Completing Form, Fax
Patient Demographics / Pre-treatment
Characteristics
Patient Name (initials acceptable)
Patient Birth Date
Patient Gender
Female (FEMALE)
Male (MALE)
Patient Race (check all that applyU.S. and
Canada only)
A Person Having Origins In Any Of The
Original Peoples Of North And South
America (including Central America),
And Who Maintains Tribal Affiliation Or
Community Attachment. (American
Indian or Alaska Native)
A Person Having Origins In Any Of The
Original Peoples Of The Far East,
Southeast Asia, Or The Indian
Subcontinent Including, For Example,
Cambodia, China, India, Japan, Korea,
Malaysia, Pakistan, The Philippine
Islands, Thailand, And Vietnam. (Asian)
A Person Having Origins In Any Of The
Black Racial Groups Of Africa. Terms
Such As "haitian" Or "negro" Can Be
Used In Addition To "black Or African
American." (Black or African American)
A Person Having Origins In Any Of The
Original Peoples Of Hawaii, Guam,
Samoa, Or Other Pacific Islands. (Native
Hawaiian or other Pacific Islander)
Not Provided Or Available (Not
Reported)
Could Not Be Determined Or Unsure
(Unknown)
A Person Having Origins In Any Of The
Original Peoples Of Europe, The Middle
East, Or North Africa. (White)
Patient Ethnicity (U.S. and Canada only)
A Person Of Mexican, Puerto Rican,
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Cuban, Central Or South American Or
Other Spanish Culture Or Origin,
Regardless Of Race. (HISPANIC OR
LATINO)
A Person Not Meeting The Definition For
Hispanic Or Latino. (NOT HISPANIC OR
LATINO)
Could Not Be Determined Or Unsure
(UNKNOWN)
Patient Social Security Number (USA only)
Patient Zip Code (USA)
Country of Residence (if not USA)
Patient Height (cm)
Patient Weight (kg)
Body Surface Area (m^2)
ECOG Performance Status (check one)
Fully Active, Able To Carry On All Pre-
disease Performance Without
Restriction. (0)
Restricted In Physically Strenuous
Activity But Ambulatory And Able To
Carry Out Work Of A Light Or Sedentary
Nature, E.g., Light Housework, Office
Work. (1)
Ambulatory And Capable Of All Selfcare
But Unable To Carry Out Any Work
Activities. Up And About More Than 50%
Of Waking Hours. (2)
Capable Of Only Limited Selfcare,
Confined To Bed Or Chair More Than
50% Of Waking Hours. (3)
Completely Disabled. Cannot Carry On
Any Selfcare. Totally Confined To Bed Or
Chair. (4)
Karnofsky Performance Status Score (check one)
Moribund, Fatal Processes Progressing
Rapidly (10)
Normal, No Complaints, No Evidence Of
Disease (100)
Very Sick, Hospitalization Indicated.
Death Not Imminent (20)
Severely Disabled, Hospitalization
Indicated. Death Not Imminent (30)
Disabled, Requires Special Care And
Assistance (40)
Requires Considerable Assistance And
Frequent Medical Care (50)
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Requires Occasional Assistance, But Is
Able To Care For Most Of His/her Needs
(60)
Cares For Self, Unable To Carry On
Normal Activity Or To Do Active Work
(70)
Normal Activity With Effort; Some Signs
Or Symptoms Of Disease (80)
Able To Carry On Normal Activity; Minor
Signs Or Symptoms Of Disease (90)
Method of Payment (check oneUSA only)
Medicaid (Medicaid)
Medicaid And Medicare (Medicaid and
Medicare)
Medicare (Medicare)
Medicare And Private Insurance
(Medicare and Private Insurance)
Military Or Veterans Sponsored Nos
(Military or Veterans Sponsored, Not
Otherwise Specified (NOS))
Military Sponsored (including Champus
& Tricare) (Military Sponsored (including
CHAMPUS & TRICARE))
No Means Of Payment (no Insurance)
(No means of payment (no insurance))
Other (Other)
Private Insurance (Private Insurance)
Self Pay (no Insurance) (Self Pay (No
Insurance))
Unknown (Unknown)
Veterans Sponsored (Veterans
Sponsored)
Certification Of Eligibility
In the opinion of the investigator, is the patient
eligible?
Yes
No
Protocol Design
Stratification Factors (protocol specific)
Assigned Treatment Arm (protocol specific)
Treatment Assignment Code (protocol specific)
NSC Number (Please check the CTEP Home
Page for a list of agent NSC numbers.)
Agent Name
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Agent Dose
Units
Billion Pfu (billion pfu)
Cells (cells)
Centigrays (cGy)
Curie (Ci)
Centimeter (cm)
Deciliter (dL)
Decimeter (dm)
Gram-equivalent Weight (Eq)
Gram (g)
Gravity (in Centrifugation) (gravity)
Grays (Gy)
Hertz (Hz)
International Unit (IU)
Joules Per Centimeter Square (J/cm^2)
Kilo-electron Volt (keV)
Kilogram (kg)
Kilohertz (kHz)
Kilopascal (kPa)
Liter (L)
Meter (m)
Microcurie (mcCi)
Microgram (mcg)
Millicurie (mCi)
Microliter (mcL)
Micrometer (mcm)
Micromole (mcmol)
Milliequivalent (mEq)
Million Electron Volts (MeV)
Milligram (mg)
Megahertz (MHz)
Million International Units (million IU)
Million Pfu (million pfu)
Milliunit (milliunit)
Milliliter (mL)
Millimeter (mm)
Milligrams Per Milliliter Per Minute
(MMM)
Millimole (mmol)
Gram-molecular Weight (mole) (mol)
Milliosmole (mOsmol)
Megarad (Mrad)
Million Unit (MU)
Millivolt (mV)
Million Viral Particles (mVP)
Not Applicable (N/A)
Nanocurie (nCi)
Nanogram (ng)
Nanometer (nm)
Nanometers Of Light (nm light)
Osmole (Osmol)
Pascal (Pa)
Percent (percent)
Plaque Forming Unit (pfu)
Picogram (pg)
Pounds Per Square Inch (psi)
Tissue Culture Infections Dose (TCID)
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Unit (unit)
Viral Particles (VP)
Route
Intramuscular (IM)
Intravenous (intravenous)
Intravenous (IV)
Nasal (Nasal)
Oral (oral)
Oral (PO)
Subcutaneous (Subcutaneous)
Topical (Topical)
Transdermal (Transdermal)
Vaginal (vaginal)
Frequency
After Meals (p.c.) (after meals (P.C.))
Am (AM)
As Needed (p.r.n) (as needed (P.R.N))
At Bedtime Or Hour Of Sleep (h.s.) (at
bedtime or hour of sleep (H.S.))
Before Meals (a.c.) (before meals (A.C.))
Daily (Daily)
Every 1 To 2 Hours (Every 1 to 2 hours)
Every 10 Hours (Every 10 hours)
Every 11 Hours (Every 11 hours)
Every 12 Hours (q12hr) (every 12 hours
(Q12hr))
Every 13 Hours (Every 13 hours)
Every 14 Hours (Every 14 hours)
Every 15 Hours (Every 15 hours)
Every 16 Hours (Every 16 hours)
Every 17 Hours (Every 17 hours)
Every 18 Hours (Every 18 hours)
Every 19 Hours (Every 19 hours)
Every 2 Hours (Every 2 hours)
Every 20 Hours (Every 20 hours)
Every 21 Hours (Every 21 hours)
Every 22 Hours (Every 22 hours)
Every 23 Hours (Every 23 hours)
Every 24 Hours (Every 24 hours)
Every 3 Hours (Every 3 hours)
Every 3 To 4 Hours (Every 3 to 4 hours)
Every 4 Hours (q4hr) (every 4 hours
(Q4hr))
Every 4 To 5 Hours (Every 4 to 5 hours)
Every 4 To 6 Hours (Every 4 to 6 hours)
Every 5 Hours (Every 5 hours)
Every 6 Hours (Every 6 hours)
Every 6 Hours (q6hr) (every 6 hours
(Q6hr))
Every 7 Hours (Every 7 hours)
Every 8 Hours (q8hr) (every 8 hours
(Q8hr))
Every 9 Hours (Every 9 hours)
Every Day (q.d.) (every day (Q.D.))
Every Evening (Every evening)
Every Hour (Every hour)
Every Morning (Every morning)
Every Other Day (q.o.d.) (every other day
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(Q.O.D.))
Five Times Daily (Five times daily)
Four Times A Day (q.i.d) (four times a
day (Q.I.D))
Immediately (stat) (immediately (Stat))
Monthly (Monthly)
Not Specified (Not specified)
Once A Day (q.d.) (Once a day (Q.D.))
Other (Other)
Pm/bedtime (PM/bedtime)
Three Times A Day (t.i.d) (three times a
day (T.I.D))
Three Times A Week (t.i.w) (three times
a week (T.I.W))
Twice A Day (b.i.d) (twice a day (B.I.D))
Twice A Week (b.i.w) (twice a week
(B.I.W))
Unknown (Unknown)
Weekly (Weekly)
Schedule
Initial Patient Consent For Specimen Use
Patient's Initial Consent given for specimen use
for research on the patient's cancer?
Yes
No
Patient's Initial Consent given for specimen use
for research unrelated to the patient's cancer?
Yes
No
Patient's initial consent given for further contact
regarding specimen?
Yes
No
Date of Consent for Specimen Use
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Neoplasms, Breast NCT00490139 On-Study - BIG 2-06 /
NCCTG N063D / EGF106708 - Months 36 and 48 - 2645379v1.0
BIG 2-06 / NCCTG N063D / EGF106708 - Months 36 and
48
ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment
Optimisation) Study; BIG 2-06/N063D
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=31C48E60-
A8B2-6CAB-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/8634
BIG 2-06 / NCCTG N063D /
EGF106708 - Months 36 and 48
Header Module
Centre No.
Subject No.
Patient Status
Date of Physical Exam
Not done
Are there any changes since the previous
assessment
Yes
No
Are there any changes since the previous
assessment
Adverse Event (Adverse Event)
Death (Death)
Lost To Follow-up (Lost To Follow-up)
Patient Withdrew Study Consent (Patient
withdrew study consent)
Recurrence Of Disease (Recurrence of
disease)
Second Primary Malignancy Or
Contralateral Breast Cancer (Second
primary malignancy or contralateral
breast cancer)
Significant Cardiac Disease (Significant
cardiac disease)
Date of Last Contact
ECOG Performance Status
Fully Active, Able To Carry On All Pre-
disease Performance Without
Restriction. (0)
Restricted In Physically Strenuous
Activity But Ambulatory And Able To
Carry Out Work Of A Light Or Sedentary
Nature, E.g., Light Housework, Office
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Work. (1)
Ambulatory And Capable Of All Selfcare
But Unable To Carry Out Any Work
Activities. Up And About More Than 50%
Of Waking Hours. (2)
Capable Of Only Limited Selfcare,
Confined To Bed Or Chair More Than
50% Of Waking Hours. (3)
Completely Disabled. Cannot Carry On
Any Selfcare. Totally Confined To Bed Or
Chair. (4)
Dead (5)
Blood Pressure, Systolic
Blood pressure, Diastolic
Cardiac Monitoring
Date of LVEF
LVEF
Method of Evaluation
Echocardiogram (Echocardiogram)
Muga Scan (MUGA scan)
Result
Abnormal - Clinically Significant
(Abnormal - Clinically significant)
Abnormal - Not Clinically Significant
(Abnormal - Not clinically significant)
Normal (Normal)
Symptomatic CHF
Yes
No
New York Heart Association Classification
Patients With Cardiac Disease But
Without Resulting Limitation Of Physical
Activity. Ordinary Physical Activity Does
Not Cause Undue Fatigue, Palpitation,
Dyspnea Or Anginal Pain. (Class I)
Patients With Cardiac Disease Resulting
In Slight Limitation Of Physical Activity.
They Are Comfortable At Rest. Ordinary
Physical Activity Results In Fatigue,
Palpitation, Dyspnea Or Anginal Pain.
(Class II)
Patients With Cardiac Disease Resulting
In Marked Limitation Of Physical Activity.
They Are Comfortable At Rest. Less
Than Ordinary Activity Causes Fatigue,
Palpitation, Dyspnea Or Anginal Pain.
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(Class III)
Patients With Cardiac Disease Resulting
In Inability To Carry On Any Physical
Activity Without Discomfort. Symptoms
Of Heart Failure Or The Anginal
Syndrome May Be Present Even At
Rest. If Any Physical Activity Is
Undertaken, Discomfort Increases.
(Class IV)
Hematology And Biochemistry
Date of blood specimen collection
Result
Abnormal - Clinically Significant
(Abnormal - Clinically significant)
Abnormal - Not Clinically Significant
(Abnormal - Not clinically significant)
Normal (Normal)
Ecg
Type of radiological examination
Abdominal Ct-scan (Abdominal CT-scan)
Bilateral Mammogram (Bilateral
mammogram)
Bone Scan (Bone scan (scintigraphy))
Bone X-ray (Bone X-ray)
Ct Scan Of Chest (Chest CT-scan)
Chest X-ray (Chest X-Ray)
Left Mammogram, Only (Left
mammogram, only)
Right Mammogram, Only (Right
mammogram, only)
Not done
Type of radiological examination (Other
examinations)
Bone Scan (Bone scan)
Computed Tomography (CT scan)
Endoscopy (Endoscopy)
Lymphangiogram (Lymphangiogram)
Mammography (Mammography)
Magnetic Resonance Imaging (MRI)
Nuclear Scan (Nuclear scan)
Other (Other)
Positron Emission Tomography (PET
scan)
Pet/ct Scan (PET/CT scan)
Transvaginal Ultrasound (Transvaginal
Ultrasound)
Ultrasound (Ultrasound)
X-ray (X-ray)
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Specify
Anatomical site
Abdomen (Abdomen)
Abdomen/abdominal Wall
(Abdomen/abdominal wall)
Bladder (Bladder)
Bone (Bone)
Breast (Breast)
Cervix Uteri (Cervix)
Chest (Chest)
Central Nervous System (CNS)
Colon (Colon)
Colorectal (Colorectal)
Esophagus (Esophagus/Oesophagus)
Head And Neck (Head and Neck)
Heart (Heart)
Kidney (Kidney)
Liver (Liver)
Lung (Lung)
Lymph Node (Lymph Node)
Mouth (Oral Cavity)
Other (Other)
Ovary (Ovary)
Pancreas (Pancreas)
Pelvis (Pelvis)
Peritoneum (Peritoneum)
Pleura (Pleura)
Prostate Gland (Prostate)
Rectum (Rectum)
Skin (Skin)
Small Intestine (Small Intestine)
Spleen (Spleen)
Stomach (Stomach)
Testis (Testicle)
Thyroid Gland (Thyroid)
Date of test
Date of test
Are there any clinically significant abnormalities
Yes
No
Are there any clinically significant abnormalities
Yes
No
Specify
Specify
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Neoplasms, Breast NCT00490139 On-Study - BIG 2-06 /
NCCTG N063D / EGF106708 - Month 18 - 2651314v1.0
BIG 2-06 / NCCTG N063D / EGF106708 - Month 18
ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment
Optimisation) Study; BIG 2-06/N063D
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=32A4946F-
3AB8-3AAA-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/8635
BIG 2-06 / NCCTG N063D /
EGF106708 - Month 18
Header Module
Centre No.
Subject No.
Patient Status
Date of Physical Exam
Not done
Are there any changes since the previous
assessment
Yes
No
Are there any changes since the previous
assessment
Adverse Event (Adverse Event)
Death (Death)
Lost To Follow-up (Lost To Follow-up)
Patient Withdrew Study Consent (Patient
withdrew study consent)
Recurrence Of Disease (Recurrence of
disease)
Second Primary Malignancy Or
Contralateral Breast Cancer (Second
primary malignancy or contralateral
breast cancer)
Significant Cardiac Disease (Significant
cardiac disease)
Date of Last Contact
Weight (kg)
ECOG Performance Status
Fully Active, Able To Carry On All Pre-
disease Performance Without
Restriction. (0)
Restricted In Physically Strenuous
Activity But Ambulatory And Able To
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Carry Out Work Of A Light Or Sedentary
Nature, E.g., Light Housework, Office
Work. (1)
Ambulatory And Capable Of All Selfcare
But Unable To Carry Out Any Work
Activities. Up And About More Than 50%
Of Waking Hours. (2)
Capable Of Only Limited Selfcare,
Confined To Bed Or Chair More Than
50% Of Waking Hours. (3)
Completely Disabled. Cannot Carry On
Any Selfcare. Totally Confined To Bed Or
Chair. (4)
Dead (5)
Blood Pressure, Systolic
Blood pressure, Diastolic
Cardiac Monitoring
Date of LVEF
LVEF
Method of Evaluation
Echocardiogram (Echocardiogram)
Muga Scan (MUGA scan)
Result
Abnormal - Clinically Significant
(Abnormal - Clinically significant)
Abnormal - Not Clinically Significant
(Abnormal - Not clinically significant)
Normal (Normal)
Symptomatic CHF
Yes
No
New York Heart Association Classification
Patients With Cardiac Disease But
Without Resulting Limitation Of Physical
Activity. Ordinary Physical Activity Does
Not Cause Undue Fatigue, Palpitation,
Dyspnea Or Anginal Pain. (Class I)
Patients With Cardiac Disease Resulting
In Slight Limitation Of Physical Activity.
They Are Comfortable At Rest. Ordinary
Physical Activity Results In Fatigue,
Palpitation, Dyspnea Or Anginal Pain.
(Class II)
Patients With Cardiac Disease Resulting
In Marked Limitation Of Physical Activity.
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They Are Comfortable At Rest. Less
Than Ordinary Activity Causes Fatigue,
Palpitation, Dyspnea Or Anginal Pain.
(Class III)
Patients With Cardiac Disease Resulting
In Inability To Carry On Any Physical
Activity Without Discomfort. Symptoms
Of Heart Failure Or The Anginal
Syndrome May Be Present Even At
Rest. If Any Physical Activity Is
Undertaken, Discomfort Increases.
(Class IV)
Hematology And Biochemistry
Date of blood specimen collection
Result
Abnormal - Clinically Significant
(Abnormal - Clinically significant)
Abnormal - Not Clinically Significant
(Abnormal - Not clinically significant)
Normal (Normal)
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/ EGF106708 - Month 18 - 2651314v1.0
Neoplasms, Breast NCT00490139 On-Study - BIG 2-06 / NCCTG
N063D / EGF106708 - Years 6, 7, 8, 9, and 10 - 2645883v1.0
BIG 2-06 / NCCTG N063D / EGF106708 - Years 6, 7, 8, 9,
and 10
ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment
Optimisation) Study; BIG 2-06/N063D
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=31CC04B5-
603D-3CA0-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/8636
BIG 2-06 / NCCTG N063D /
EGF106708 - Years 6, 7, 8, 9, and
10
Header Module
Centre No.
Subject No.
Patient Status
Date of Physical Exam
Not done
Are there any changes since the previous
assessment
Yes
No
Are there any changes since the previous
assessment
Adverse Event (Adverse Event)
Death (Death)
Lost To Follow-up (Lost To Follow-up)
Patient Withdrew Study Consent (Patient
withdrew study consent)
Recurrence Of Disease (Recurrence of
disease)
Second Primary Malignancy Or
Contralateral Breast Cancer (Second
primary malignancy or contralateral
breast cancer)
Significant Cardiac Disease (Significant
cardiac disease)
Date of Last Contact
ECOG Performance Status
Fully Active, Able To Carry On All Pre-
disease Performance Without
Restriction. (0)
Restricted In Physically Strenuous
Activity But Ambulatory And Able To
Carry Out Work Of A Light Or Sedentary
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Nature, E.g., Light Housework, Office
Work. (1)
Ambulatory And Capable Of All Selfcare
But Unable To Carry Out Any Work
Activities. Up And About More Than 50%
Of Waking Hours. (2)
Capable Of Only Limited Selfcare,
Confined To Bed Or Chair More Than
50% Of Waking Hours. (3)
Completely Disabled. Cannot Carry On
Any Selfcare. Totally Confined To Bed Or
Chair. (4)
Dead (5)
Blood Pressure, Systolic
Blood pressure, Diastolic
Cardiac Monitoring
Date of LVEF
LVEF
Method of Evaluation
Echocardiogram (Echocardiogram)
Muga Scan (MUGA scan)
Result
Abnormal - Clinically Significant
(Abnormal - Clinically significant)
Abnormal - Not Clinically Significant
(Abnormal - Not clinically significant)
Normal (Normal)
Symptomatic CHF
Yes
No
New York Heart Association Classification
Patients With Cardiac Disease But
Without Resulting Limitation Of Physical
Activity. Ordinary Physical Activity Does
Not Cause Undue Fatigue, Palpitation,
Dyspnea Or Anginal Pain. (Class I)
Patients With Cardiac Disease Resulting
In Slight Limitation Of Physical Activity.
They Are Comfortable At Rest. Ordinary
Physical Activity Results In Fatigue,
Palpitation, Dyspnea Or Anginal Pain.
(Class II)
Patients With Cardiac Disease Resulting
In Marked Limitation Of Physical Activity.
They Are Comfortable At Rest. Less
Than Ordinary Activity Causes Fatigue,
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Palpitation, Dyspnea Or Anginal Pain.
(Class III)
Patients With Cardiac Disease Resulting
In Inability To Carry On Any Physical
Activity Without Discomfort. Symptoms
Of Heart Failure Or The Anginal
Syndrome May Be Present Even At
Rest. If Any Physical Activity Is
Undertaken, Discomfort Increases.
(Class IV)
Ecg
Mammogram
Bilateral (Bilateral)
Left (Left)
Right (Right)
Date of test
Not done
Are there any clinically significant abnormalities
Yes
No
Specify
Hematology And Biochemistry
Date of blood specimen collection
Result
Abnormal - Clinically Significant
(Abnormal - Clinically significant)
Abnormal - Not Clinically Significant
(Abnormal - Not clinically significant)
Normal (Normal)
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Registration - Phase II Lung Cancer -
Registration Form - 2401069v1.0
Phase II Consortium Phase II Lung Cancer - Registration
Form
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=FFB64E4B-
01F0-2740-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/8637
Phase II Lung Cancer - Registration
Form
Crf Header
Coordinating Group Protocol No.
Coordinating Group Code
Protocol Title
Patient Study ID
Registering Group Code
Patient Medical Record Number
Other Patient ID
Institution/Affiliate
Registering Institution Code
Physician of Record
Form Administration
IRB/REB  Approval Date (MM DD YYYY)
Date Informed Consent Signed (MM DD YYYY)
Date Informed Consent Expired (MM DD YYYY)
Projected Start Date of Treatment (MM DD
YYYY)
Date of Registration (MM DD YYYY)
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HIPAA Authorization Date (MM DD YYYY)
Date Form Completed (MM DD YYYY)
Person Completing Form, Last Name
Person Completing Form, First Name
Person Completing Form, Phone
Person Completing Form, Fax
Patient Demographics / Pre-treatment
Characteristics
Patient Name (initials acceptable)
Patient Birth Date
Patient Gender
Female (FEMALE)
Male (MALE)
Patient Race (check all that applyU.S. and
Canada only)
A Person Having Origins In Any Of The
Original Peoples Of North And South
America (including Central America),
And Who Maintains Tribal Affiliation Or
Community Attachment. (American
Indian or Alaska Native)
A Person Having Origins In Any Of The
Original Peoples Of The Far East,
Southeast Asia, Or The Indian
Subcontinent Including, For Example,
Cambodia, China, India, Japan, Korea,
Malaysia, Pakistan, The Philippine
Islands, Thailand, And Vietnam. (Asian)
A Person Having Origins In Any Of The
Black Racial Groups Of Africa. Terms
Such As "haitian" Or "negro" Can Be
Used In Addition To "black Or African
American." (Black or African American)
A Person Having Origins In Any Of The
Original Peoples Of Hawaii, Guam,
Samoa, Or Other Pacific Islands. (Native
Hawaiian or other Pacific Islander)
Not Provided Or Available (Not
Reported)
Could Not Be Determined Or Unsure
(Unknown)
A Person Having Origins In Any Of The
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Original Peoples Of Europe, The Middle
East, Or North Africa. (White)
Patient Ethnicity (U.S. and Canada only)
A Person Of Mexican, Puerto Rican,
Cuban, Central Or South American Or
Other Spanish Culture Or Origin,
Regardless Of Race. (HISPANIC OR
LATINO)
A Person Not Meeting The Definition For
Hispanic Or Latino. (NOT HISPANIC OR
LATINO)
Could Not Be Determined Or Unsure
(UNKNOWN)
Patient Social Security Number (USA only)
Patient Zip Code (USA)
Country of Residence (if not USA)
Patient Height (cm)
Patient Weight (kg)
Body Surface Area (m^2)
ECOG Performance Status (check one)
Fully Active, Able To Carry On All Pre-
disease Performance Without
Restriction. (0)
Restricted In Physically Strenuous
Activity But Ambulatory And Able To
Carry Out Work Of A Light Or Sedentary
Nature, E.g., Light Housework, Office
Work. (1)
Ambulatory And Capable Of All Selfcare
But Unable To Carry Out Any Work
Activities. Up And About More Than 50%
Of Waking Hours. (2)
Capable Of Only Limited Selfcare,
Confined To Bed Or Chair More Than
50% Of Waking Hours. (3)
Completely Disabled. Cannot Carry On
Any Selfcare. Totally Confined To Bed Or
Chair. (4)
Karnofsky Performance Status Score (check one)
Moribund, Fatal Processes Progressing
Rapidly (10)
Normal, No Complaints, No Evidence Of
Disease (100)
Very Sick, Hospitalization Indicated.
Death Not Imminent (20)
Severely Disabled, Hospitalization
Indicated. Death Not Imminent (30)
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Disabled, Requires Special Care And
Assistance (40)
Requires Considerable Assistance And
Frequent Medical Care (50)
Requires Occasional Assistance, But Is
Able To Care For Most Of His/her Needs
(60)
Cares For Self, Unable To Carry On
Normal Activity Or To Do Active Work
(70)
Normal Activity With Effort; Some Signs
Or Symptoms Of Disease (80)
Able To Carry On Normal Activity; Minor
Signs Or Symptoms Of Disease (90)
Method of Payment (check oneUSA only)
Medicaid (Medicaid)
Medicaid And Medicare (Medicaid and
Medicare)
Medicare (Medicare)
Medicare And Private Insurance
(Medicare and Private Insurance)
Military Or Veterans Sponsored Nos
(Military or Veterans Sponsored, Not
Otherwise Specified (NOS))
Military Sponsored (including Champus
& Tricare) (Military Sponsored (including
CHAMPUS & TRICARE))
No Means Of Payment (no Insurance)
(No means of payment (no insurance))
Other (Other)
Private Insurance (Private Insurance)
Self Pay (no Insurance) (Self Pay (No
Insurance))
Unknown (Unknown)
Veterans Sponsored (Veterans
Sponsored)
Certification Of Eligibility
In the opinion of the investigator, is the patient
eligible?
Yes
No
Protocol Design
Stratification Factors (protocol specific)
Assigned Treatment Arm (protocol specific)
Treatment Assignment Code (protocol specific)
Agent NSC/GPI Number (Please check the CTEP
Home Page for a list of agent NSC numbers.)
4 / 7
Registration - Phase II Lung Cancer - Registration Form - 2401069v1.0
Agent Name
Agent Dose
Units
Billion Pfu (billion pfu)
Cells (cells)
Centigrays (cGy)
Curie (Ci)
Centimeter (cm)
Deciliter (dL)
Decimeter (dm)
Gram-equivalent Weight (Eq)
Gram (g)
Gravity (in Centrifugation) (gravity)
Grays (Gy)
Hertz (Hz)
International Unit (IU)
Joules Per Centimeter Square (J/cm^2)
Kilo-electron Volt (keV)
Kilogram (kg)
Kilohertz (kHz)
Kilopascal (kPa)
Liter (L)
Meter (m)
Microcurie (mcCi)
Microgram (mcg)
Millicurie (mCi)
Microliter (mcL)
Micrometer (mcm)
Micromole (mcmol)
Milliequivalent (mEq)
Million Electron Volts (MeV)
Milligram (mg)
Megahertz (MHz)
Million International Units (million IU)
Million Pfu (million pfu)
Milliunit (milliunit)
Milliliter (mL)
Millimeter (mm)
Milligrams Per Milliliter Per Minute
(MMM)
Millimole (mmol)
Gram-molecular Weight (mole) (mol)
Milliosmole (mOsmol)
Megarad (Mrad)
Million Unit (MU)
Millivolt (mV)
Million Viral Particles (mVP)
Not Applicable (N/A)
Nanocurie (nCi)
Nanogram (ng)
Nanometer (nm)
Nanometers Of Light (nm light)
Osmole (Osmol)
Pascal (Pa)
Percent (percent)
Plaque Forming Unit (pfu)
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Picogram (pg)
Pounds Per Square Inch (psi)
Tissue Culture Infections Dose (TCID)
Unit (unit)
Viral Particles (VP)
Route
Intramuscular (IM)
Intravenous (intravenous)
Intravenous (IV)
Nasal (Nasal)
Oral (oral)
Oral (PO)
Subcutaneous (Subcutaneous)
Topical (Topical)
Transdermal (Transdermal)
Vaginal (vaginal)
Frequency
Before Meals (AC)
Twice Daily (BID)
Twice A Week (BIW)
Five Times Daily (FID)
At Bedtime (HS)
Other (Oth)
After Meals (PC)
As Needed (PRN)
Every 1 To 2 Hours (Q1-2H)
Every 10 Hours (Q10H)
Every 11 Hours (Q11H)
Every 12 Hours (Q12H)
Every 13 Hours (Q13H)
Every 14 Hours (Q14H)
Every 15 Hours (Q15H)
Every 16 Hours (Q16H)
Every 17 Hours (Q17H)
Every 18 Hours (Q18H)
Every 19 Hours (Q19H)
Every Hour (Q1H)
Every 20 Hours (Q20H)
Every 21 Hours (Q21H)
Every 22 Hours (Q22H)
Every 23 Hours (Q23H)
Every 24 Hours (Q24H)
Every 2 Hours (Q2H)
Every 3 To 4 Hours (Q3-4H)
Every 3 Hours (Q3H)
Every 4 To 5 Hours (Q4-5H)
Every 4 To 6 Hours (Q4-6H)
Every 4 Hours (Q4H)
Every 5 Hours (Q5H)
Every 6 Hours (Q6H)
Every 7 Hours (Q7H)
Every 8 Hours (Q8H)
Every 9 Hours (Q9H)
Every Morning (QAM)
Every Day (QD)
Every Hour (QH)
Four Times Daily (QID)
Every Other Day (QOD)
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Every Evening (QPM)
Once Weekly (QW)
Immediately (STAT)
Three Times Daily (TID)
Three Times A Week (TIW)
Unknown (Unk)
Schedule
Initial Patient Consent For Specimen Use
Patient's Initial Consent given for specimen use
for research on the patient's cancer?
Yes
No
Patient's Initial Consent given for specimen use
for research unrelated to the patient's cancer?
Yes
No
Patient's initial consent given for further contact
regarding specimen?
Yes
No
Date of Consent for Specimen Use
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Colorectal Cancer NCT00726622 Quality of Life -
Z6051 EORTC QLQ-CR38 (CR38) - 2741819v1.0
Z6051 EORTC QLQ-CR38 (CR38)
Laparoscopic-Assisted Resection or Open Resection in
Treating Patients With Stage IIA, Stage IIIA, or Stage IIIB
Rectal Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=4AECD651-
8870-09DC-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/8639
Z6051 EORTC QLQ-CR38 (CR38)
Header Module
Visit
1-2 Weeks Post-surgery (1-2 weeks
post-surgery)
4-6 Weeks Post-surgery (4-6 weeks
post-surgery)
Day 3 (Day 3)
Month 12 (Month 12)
Month 3 (Month 3)
Pre-operative (Pre-Op)
Patient ID (Pt. ID issued during registration
unless pt. previously registered to an ACOSOG
study.)
Patient Initials
Institution Name
Institution No.
Date
Additional Concerns
Did you urinate frequently during the day
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Very Much (Very much)
Did you urinate frequently during the night?
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Very Much (Very much)
Did you have pain when you urinated?
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Very Much (Very much)
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Did you have a bloated feeling in your abdomen?
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Very Much (Very much)
Did you have abdominal pain?
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Very Much (Very much)
Did you have pain in your buttocks?
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Very Much (Very much)
Were you bothered by gas (flatulence)?
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Very Much (Very much)
Did you belch?
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Very Much (Very much)
Have you lost weight?
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Very Much (Very much)
Did you have a dry mouth?
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Very Much (Very much)
Have you had thin or lifeless hair as a result of
your disease?
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Very Much (Very much)
Did food and drink taste different from usual?
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Very Much (Very much)
Have you felt physically less attractive as a result
of your disease or treatment?
A Little Bit (A little bit)
Not At All (Not at all)
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Quite A Bit (Quite a bit)
Very Much (Very much)
Have you been feeling less feminine/masculine
as a result of your disease or treatment?
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Very Much (Very much)
Have you been dissatisfied with your body?
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Very Much (Very much)
Were you worried about your health in the future?
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Very Much (Very much)
During The Past Four Weeks:
To what extent were you interested in sex?
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Very Much (Very much)
To what extent were you sexually active (with or
without intercourse)?
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Very Much (Very much)
To what extent was sex enjoyable for you?
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Very Much (Very much)
Did you have difficulty getting or maintaining an
erection?
A Little (A little)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Very Much (Very much)
Did you have problems with ejaculation (e.g., so-
called 'dry ejaculation')?
A Little (A little)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Very Much (Very much)
Did you have a dry vagina during intercourse?
A Little (A little)
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Not At All (Not at all)
Quite A Bit (Quite a bit)
Very Much (Very much)
Did you have pain during intercourse?
A Little (A little)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Very Much (Very much)
Stoma
Do you have a stoma (colostomy bag)?
Yes
No
Only For Patients Without A Stoma
(colostomy Bag):
Did you have frequent bowel movements during
the day?
A Little (A little)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Very Much (Very much)
Did you have frequent bowel movements during
the night?
A Little (A little)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Very Much (Very much)
Did you feel the urge to move your bowels without
actually producing any stools
A Little (A little)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Very Much (Very much)
Have you had any unintentional release of stools
A Little (A little)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Very Much (Very much)
Have you had blood with your stools
A Little (A little)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Very Much (Very much)
Have you had difficulty in moving your bowels
A Little (A little)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Very Much (Very much)
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Have you had difficulty in moving your bowels?
A Little (A little)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Very Much (Very much)
Have your bowel movements been painful?
A Little (A little)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Very Much (Very much)
Unnamed 4
Were you afraid that other people would be able
to hear your stoma
A Little (A little)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Very Much (Very much)
Were you afraid that other people would be able
to smell your stools
A Little (A little)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Very Much (Very much)
Were you worried about possible leakage from
the stoma bag?
A Little (A little)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Very Much (Very much)
Did you have problems with caring for your stoma
A Little (A little)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Very Much (Very much)
Was your skin around the stoma irritated
A Little (A little)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Very Much (Very much)
Did you feel embarassed because of your stoma
A Little (A little)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Very Much (Very much)
Did you feel less complete because of your stoma
A Little (A little)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Very Much (Very much)
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Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=1697592E-
3E1B-11FC-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/8640
Lung Cancer - Pathology Form -
Major Surgical Resection
Crf Header
Coordinating Group Protocol No.
Coordinating Group Code
Protocol Title
Patient Study ID
Institution/Affiliate
Other Patient ID
Participating Group Code
Patient Name (initials acceptable)
Lung Pathology: Form Administration
Person Completing Form
Are data amended (If data are amended, please
circle in red when using paper form)
Yes
No
Pathology: Surgical Specimen Submitted
Date Specimen Collected (s - surgical procedure)
Sample Period
Other Specify (Other, specify)
Sample Or Specimen Collected After
Patient Received Treatment For Cancer
(Post-treatment)
Sample Or Specimen Collected Before
Patient Was Diagnosed With Cancer
(Pre-diagnosis)
Sample Or Specimen Collected Before
Patient Received Treatment For Cancer
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(Pre-treatment)
Unknown (Unknown)
Other, specify
Specify Type of Treatment (If post-treatment,)
Specimen ID
Specimen Cell Source
Bronchial Tissue, Suspicious For
Abnormality (Bronchial tissue, suspicious
for abnormality)
Bronchus (Bronchus, specify)
Lymph Node (Lymph node)
Non-malignant Lung (Non-malignant
lung)
Other, Specify (Other, specify)
Primary Tumor (Primary tumor)
Bronchus specify
Other specify
Surgical Approach
Thoracoscopy / Video-assisted (vats)
(Thoracoscopy / Video-assisted (VATS))
Thoracoscopy / Video-assisted (vats),
With Conversion To Thoracotomy
(Thoracoscopy / Video-assisted (VATS),
with conversion to Thoracotomy)
Thoracotomy (thoracotomy)
Surgical Procedure Type
Bilobectomy (Bilobectomy)
Lobectomy (Lobectomy)
Pneumonectomy (Pneumonectomy)
Segmentectomy (Segmentectomy)
Wedge Resection (Wedge resection)
Pathology: Description Of Primary Tumor
Tumor Location Side
Both (Both)
Left (Left)
Right (Right)
Unilateral Side Not Specified (Unilateral,
side not specified)
Unknown (Unknown)
Tumor Location Area (check all that apply)
Carina (Carina)
Lower Lobe (Lower lobe)
Mainstem Bronchus (Mainstem
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bronchus)
Middle Lobe (Middle lobe)
Other, Specify (Other)
Upper Lobe (Upper lobe)
Other specify
Are the tumors multifocal
No (NO)
Unknown (UNKNOWN)
Yes (YES)
Are there multiple primary tumors
No (NO)
Unknown (UNKNOWN)
Yes (YES)
Specify number of lesions (If yes, - If multiple
specimens, complete separate form for each
specimen.)
Pathology: Surgical Gross Description
Tumor Size, Maximum Diameter (cm - Record
longest or largest diameter of tumor.)
Tumor Location, Zone (check all that apply)
Indeterminate (Indeterminate)
Predominantly Central (Predominantly
central)
Predominantly Peripheral (Predominantly
peripheral)
Unknown (Unknown)
Does the tumor involve the pleura
No (NO)
Unknown (UNKNOWN)
Yes (YES)
Distance from Pleura (If no, - cm)
Does the tumor involve the surgical margin
Yes
No
Distance from Surgical Margin (If no, - cm)
Tumor Extension (check all that apply)
Chest Wall (Chest wall)
Diaphragm (Diaphragm)
Esophagus (Esophagus)
Mediastinum (Mediastinum)
Other, Specify (Other)
Pericardium (Pericardium)
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Other specify
Associated Diseases (check all that apply)
Emphysema (Emphysema)
Granulomatous Disease (Granulomatous
disease)
Interstitial Fibrosis (Interstitial fibrosis)
Other (Other)
Pneumoconiosis (Pneumoconiosis)
Pneumonia (Pneumonia)
Other, specify
If granulomatous disease, specify
Fungal (Fungal)
Sarcoid (Sarcoid)
Tuberculosis (Tuberculosis)
If pneumoconiosis, specify
Asbestosis (Asbestosis)
Silicosis (Silicosis)
Sites of Gross Residual Disease (check all that
apply)
Blood Vessels (aorta, Innominate Vein,
Superior Vena Cava) (Blood vessels
(aorta, innominate vein, superior vena
cava))
Blood Vessels (main Pulmonary Artery
Or Vein) (Blood vessels (main pulmonary
artery or vein))
Bronchial Resection Margin (Bronchial
resection margin)
Chest Wall (parietal Pleura, Ribs,
Muscle) (Chest wall (parietal pleura, ribs,
muscle))
Contralateral Hilar Nodes (Contralateral
hilar nodes)
Contralateral Mediastinal Nodes
(Contralateral mediastinal nodes)
Ipsilateral Hilar Nodes (Ipsilateral hilar
nodes)
Ipsilateral Mediastinal Nodes (Ipsilateral
mediastinal nodes)
Lung, At Original Tumor Site (Lung, at
original tumor site)
Lung, Elsewhere (Lung, elsewhere)
Mediastinal Structures (other Than
Nodes) (Mediastinal structures (other
than nodes))
Other (Other)
Vascular Resection Margin (Vascular
resection margin)
Other specify
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Pathology: Surgical Microscopic
Description
Histologic Type (WHO - check all that apply)
Adenocarcinoma (Adenocarcinoma)
Bronchoalveolar (bac) (Bronchoalveolar
carcinoma (BAC))
Carcinoid (Carcinoid)
Combined/mixed, Specify Subcategories
(Combined/mixed)
Large Cell Carcinoma (Large cell
carcinoma)
No Malignancy Observed (No
malignancy observed)
Non-small Cell Lung Cancer (nsclc), Nos
(Non-small cell lung cancer NOS)
Other (Other specify)
Pre-malignant Changes Observed (Pre-
malignant changes observed)
Small Cell Carcinoma (oat Cell) (Small
cell carcinoma (oat cell))
Squamous Cell Carcinoma (Squamous
cell carcinoma)
Specify subcategories
Other specify
Histologic Grade (WHO)
Well Differentiated (Grade I)
Moderately Differentiated (Grade II)
Poorly Differentiated (Grade III)
Are surgical margins microscopically involved
No (NO)
Unknown (UNKNOWN)
Yes (YES)
Is the pleural margin involved
No (NO)
Unknown (UNKNOWN)
Yes (YES)
Distance from pleural margin (If no,  - cm)
Is the bronchial margin involved
No (NO)
Unknown (UNKNOWN)
Yes (YES)
Distance from bronchial margin (mm)
Is there vascular invasion
No (NO)
Unknown (UNKNOWN)
Yes (YES)
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Perineural tumor infiltration or invasion
No (NO)
Unknown (UNKNOWN)
Yes (YES)
Is the visceral pleural margin involved
No (No)
Unknown (Unknown)
Yes (Yes)
Is the parietal pleural margin involved
No (No)
Unknown (Unknown)
Yes (Yes)
Was lymph node sampling done (Lymph Nodes)
No (No)
Unknown (Unknown)
Yes (Yes)
Number of Lymph Nodes Examined (If yes,)
Number of Positive Lymph Nodes
Lymph Node Type (Lymph Node Assessment -
Station - Note:  Involvement indicates that a node
was sampled and pathologically determined.)
Highest Mediastinal Node (Highest
mediastinal (1))
Interlobar Node (Interlobar (11))
Left Hilar Node (Left hilar (10L))
Left Lobar Node (Left lobar (12L))
Left Lower Paratracheal Node (Left lower
paratracheal (4L))
Left Segmental Node (Left segmental
(13L))
Left Subsegmental Node (Left
subsegmental (14L))
Left Upper Paratracheal Node (Left
upper paratracheal (2L))
Para-aortic Node (Para-aortic (6))
Paraesophageal (Paraesophageal (8))
Pre- And Retro Paratracheal Node (Pre-
and retro paratracheal (3))
Pulmonary Ligament (Pulmonary
ligament (9))
Right Hilar Node (Right hilar (10R))
Right Lobar Node (Right lobar (12R))
Right Lower Paratracheal Node (Right
lower paratracheal (4R))
Right Segmental Node (Right segmental
(13R))
Right Subsegmental Node (Right
subsegmental (14R))
Right Upper Paratracheal Node (Right
upper paratracheal (2R))
Subaortic Node (Subaortic (5))
Subcarinal Node (Subcarinal (7))
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Lymph Node Involvement
Negative Based On Clinical Evaluation
(clinically negative)
Positive Based On Clinical Evaluation
(clinically positive)
Equivocal (equivocal)
Not Evaluated (not evaluated)
Negative Based On Pathologic
Evaluation (pathologically negative)
Positive Based On Pathologic Evaluation
(pathologically positive)
Unknown (unknown)
Associated Pre-Malignant Histologic Changes (If
Pre-Malignant Changes Observed, - check all
that apply)
Atypical Adenomatous Hyperplasia
(Atypical adenomatous hyperplasia)
Basal Cell Hyperplasia (Basal cell
hyperplasia)
Basal Cell Hyperplasia With Angiogenic
Squamous Dysplasia Changes (Basal
cell hyperplasia with ASD changes)
Carcinoma In Situ (Carcinoma in situ)
Mild Dysplasia (Mild dysplasia)
Mild Dyplasia With Angiogenic
Squamous Dysplasia Changes (Mild
dysplasia with ASD changes)
Moderate Dysplasia (Moderate
dysplasia)
Moderate Dysplasia With Angiogenic
Squamous Dysplasia Changes
(Moderate dysplasia with ASD changes)
Other, Specify (Other, specify)
Severe Dysplasia (Severe dysplasia)
Severe Dysplasia With Angiogenic
Squamous Dysplasia Changes (Severe
dysplasia with ASD changes)
Squamous Metaplasia (Squamous
Metaplasia)
Squamous Metaplasia With Angiogenic
Squamous Dysplasia Changes
(Squamous metaplasia with ASD
changes)
Other, specify
T Stage, Pathologic (Pathologic Disease
Classification - Note:  Follow AJCC criteria for
completing form, and indicate the highest stage.)
No Evidence Of Primary Tumor (pT0)
Tumor 3cm Or Less In Greatest
Dimension, Surrounded By Lung Or
Visceral Pleura, Invasion More Proximal
Than The Lobar Bronchus (i.e. Not In
The Main Bronchus) (pT1)
Tumor With Any Of The Following
Features Of Size Or Extent: More Than
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3cm In Greatest Dimension; Invades The
Visceral Pleura; Associated With
Atelectasis Or Obstructive Pneumonitis
That Extends To The Hilar Region But
Does Not Involve The Entire Lung (pT2)
Tumor Of Any Size That Directly Invades
Any Of The Following: Chest Wall
(including Superior Sulcus Tumors),
Diaphragm, Mediastinal Pleura, Parietal
Pericardium; Or Tumor In The Main
Bronchus Less Than 2 Cm Distal To The
Carina, But Without Involvement O*
(pT3)
Tumor Of Any Size That Invades Any Of
The Following: Mediastinum, Heart,
Great Vessels, Trachea, Esophagus,
Vertebral Body, Carina; Or Separate
Tumor Nodules In The Same Lobe; Or
Tumor With A Malignant Pleural Effusion
(pT4)
Carcinoma In Situ (pTis)
Primary Tumor Cannot Be Assessed, Or
Tumor Proven By The Presence Of
Malignant Cells In Sputum Or Bronchial
Washings But Not Visualized By Imaging
Or Bronchoscopy (pTX)
N Stage, Pathologic
No Lymph Node Metastasis (pN0)
Metastasis To Ipsilateral Peribronchial
And/or Ipsilateral Hilar Lymph Nodes,
And Intrapulmonary Nodes Including
Involvement By Direct Extension Of The
Primary Tumor (pN1)
Metastasis To Ipsilateral Mediastinal
And/or Subcarinal Lymph Node(s) (pN2)
Metastasis To Contralateral Mediastinal,
Contralateral Hilar, Ipsilateral Or
Contralateral Scalene, Or
Supraclavicular Lymph Node(s) (pN3)
Regional Lymph Nodes Cannot Be
Assessed (pNX)
M Stage, Pathologic
No Distant Metastasis (pM0)
Distant Metastasis Present (pM1)
Distant Metastasis Cannot Be Assessed
(pMX)
Stage Grouping, Pathologic
0, According To Current Ajcc Guidelines
(0)
Ia, According To Current Ajcc Guidelines
(IA)
Ib, According To Current Ajcc Guidelines
(IB)
Iia, According To Current Ajcc Guidelines
(IIA)
Iib, According To Current Ajcc Guidelines
(IIB)
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Iiia, According To Current Ajcc
Guidelines (IIIA)
Iiib, According To Current Ajcc
Guidelines (IIIB)
Iv, According To Current Ajcc Guidelines
(IV)
Sites of Microscopic Residual Disease (from
pathology report - check all that apply)
Blood Vessels (aorta, Innominate Vein,
Superior Vena Cava) (Blood vessels
(aorta, innominate vein, superior vena
cava))
Blood Vessels (main Pulmonary Artery
Or Vein) (Blood vessels (main pulmonary
artery or vein))
Bronchial Resection Margin (Bronchial
resection margin)
Chest Wall (parietal Pleura, Ribs,
Muscle) (Chest wall (parietal pleura, ribs,
muscle))
Contralateral Hilar Nodes (Contralateral
hilar nodes)
Contralateral Mediastinal Nodes
(Contralateral mediastinal nodes)
Ipsilateral Hilar Nodes (Ipsilateral hilar
nodes)
Ipsilateral Mediastinal Nodes (Ipsilateral
mediastinal nodes)
Lung, At Original Tumor Site (Lung, at
original tumor site)
Lung, Elsewhere (Lung, elsewhere)
Mediastinal Structures (other Than
Nodes) (Mediastinal structures (other
than nodes))
Other (Other)
Vascular Resection Margin (Vascular
resection margin)
Other specify
Reviewing Pathologist
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On-Study - Lung Cancer - NSCLC Stage I-
III On-Study Form - 2019422v3.0
(for Adjuvant Studies and Inoperable Stage III)
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=1518EC72-
3397-4058-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/8644
Lung Cancer - NSCLC Stage I-III
On-Study Form
Crf Header
Coordinating Group Protocol No.
Coordinating Group Code
Protocol Title
Patient Study ID
Institution/Affiliate
Other Patient ID
Participating Group Code
Patient Name (initials acceptable)
Lung: Pre-treatment Characteristics
Patient Height (cm)
Patient Weight (kg)
Body Surface Area (m^2)
Performance Status (check one)
Fully Active, Able To Carry On All Pre-
disease Performance Without
Restriction. (0)
Restricted In Physically Strenuous
Activity But Ambulatory And Able To
Carry Out Work Of A Light Or Sedentary
Nature, E.g., Light Housework, Office
Work. (1)
Ambulatory And Capable Of All Selfcare
But Unable To Carry Out Any Work
Activities. Up And About More Than 50%
Of Waking Hours. (2)
Capable Of Only Limited Selfcare,
Confined To Bed Or Chair More Than
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50% Of Waking Hours. (3)
Completely Disabled. Cannot Carry On
Any Selfcare. Totally Confined To Bed Or
Chair. (4)
Weight loss in previous six months (check one)
<5% Of Body Weight (< 5% of body
weight)
> Or = 20% Of Body Weight (> or = 20%
of body weight)
10 To <20% Of Body Weight (10 to <20%
of body weight)
5 To <10% Of Body Weight (5 to < 10%
of body weight)
Lung: Disease Description - Stage I-iii
T Stage, Clinical (leave blank if not done)
No Evidence Of Primary Tumor (T0)
Tumor 3 Cm Or Less In Greatest
Dimension, Surrounded By Lung Or
Visceral Pleura, Invasion More Proximal
Than The Lobar Bronchus, (i.e., Not In
The Main Bronchus) (T1)
Tumor With Any Of The Following
Features Of Size Or Extent: More Than
3cm In Greatest Dimension; Invades The
Visceral Pleura; Associated With
Atelectasis Or Obstructive Pneumonitis
That Extends To The Hilar Region But
Does Not Involve The Entire Lung (T2)
Tumor Of Any Size That Directly Invades
Any Of The Following: Chest Wall
(including Superior Sulcus Tumors),
Diaphragm, Mediastinal Pleura, Parietal
Pericardium; Or Tumor In The Main
Bronchus Less Than 2 Cm Distal To The
Carina, But Without Involvement O* (T3)
Tumor Of Any Size That Directly Invades
Any Of The Following: Chest Wall
(including Superior Sulcus Tumors),
Diaphragm, Mediastinal Pleura, Parietal
Pericardium; Or Tumor In The Main
Bronchus Less Than 2 Cm Distal To The
Carina, But Without Involvement O* (T4)
Carcinoma In Situ (Tis)
Primary Tumor Cannot Be Assessed, Or
Tumor Proven By The Presence Of
Malignant Cells In Sputum Or Bronchial
Washings But Not Visualized By Imaging
Or Bronchoscopy (Tx)
N Stage, Clinical (leave blank if not done)
No Regional Lymph Node Metastasis
(N0)
Metastasis To Ipsilateral Peribronchial
And/or Ipsilateral Hilar Lymph Nodes,
And Intrapulmonary Nodes Including
Involvement By Direct Extension Of The
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Primary Tumor (N1)
Metastasis To Ipsilateral Mediastinal
And/or Subcarinal Lymph Node(s) (N2)
Metastasis To Contralateral Mediastinal,
Contralateral Hilar, Ipsilateral Or
Contralateral Scalene, Or
Supraclavicular Lymph Node(s) (N3)
Regional Lymph Nodes Cannot Be
Assessed (NX)
M Stage, Clinical (leave blank if not done)
No Distant Metastasis (M0)
Distant Metastasis Present (M1)
Distant Metastasis Cannot Be Assessed
(MX)
T Stage, Pathologic (leave blank if not done)
No Evidence Of Primary Tumor (pT0)
Tumor 3cm Or Less In Greatest
Dimension, Surrounded By Lung Or
Visceral Pleura, Invasion More Proximal
Than The Lobar Bronchus (i.e. Not In
The Main Bronchus) (pT1)
Tumor With Any Of The Following
Features Of Size Or Extent: More Than
3cm In Greatest Dimension; Invades The
Visceral Pleura; Associated With
Atelectasis Or Obstructive Pneumonitis
That Extends To The Hilar Region But
Does Not Involve The Entire Lung (pT2)
Tumor Of Any Size That Directly Invades
Any Of The Following: Chest Wall
(including Superior Sulcus Tumors),
Diaphragm, Mediastinal Pleura, Parietal
Pericardium; Or Tumor In The Main
Bronchus Less Than 2 Cm Distal To The
Carina, But Without Involvement O*
(pT3)
Tumor Of Any Size That Invades Any Of
The Following: Mediastinum, Heart,
Great Vessels, Trachea, Esophagus,
Vertebral Body, Carina; Or Separate
Tumor Nodules In The Same Lobe; Or
Tumor With A Malignant Pleural Effusion
(pT4)
Carcinoma In Situ (pTis)
Primary Tumor Cannot Be Assessed, Or
Tumor Proven By The Presence Of
Malignant Cells In Sputum Or Bronchial
Washings But Not Visualized By Imaging
Or Bronchoscopy (pTX)
N Stage, Pathologic (leave blank if not done)
No Lymph Node Metastasis (pN0)
Metastasis To Ipsilateral Peribronchial
And/or Ipsilateral Hilar Lymph Nodes,
And Intrapulmonary Nodes Including
Involvement By Direct Extension Of The
Primary Tumor (pN1)
Metastasis To Ipsilateral Mediastinal
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And/or Subcarinal Lymph Node(s) (pN2)
Metastasis To Contralateral Mediastinal,
Contralateral Hilar, Ipsilateral Or
Contralateral Scalene, Or
Supraclavicular Lymph Node(s) (pN3)
Regional Lymph Nodes Cannot Be
Assessed (pNX)
M Stage, Pathologic (leave blank if not done)
No Distant Metastasis (pM0)
Distant Metastasis Present (pM1)
Distant Metastasis Cannot Be Assessed
(pMX)
Pathologic Stage based on Mediastinoscopy?
Yes
No
Pathologic Stage based on Bronchoscopy?
Yes
No
Pathologic Stage based on
Thoracotomy/Sternotomy?
Yes
No
Histologic Type
Adenocarcinoma (Adenocarcinoma)
Bronchoalveolar (bac) (Bronchoalveolar
carcinoma (BAC))
Large Cell Undifferentiated (Large cell
undifferentiated)
Non-small Cell Lung Cancer (nsclc), Nos
(Non-small cell lung cancer NOS)
Other (Other specify)
Squamous Cell Carcinoma (Squamous
cell carcinoma)
Specify Other Histologic Type
Status of Primary Tumor
Not Recurrent, Resected, No Residual
Tumor (Not recurrent, resected, no
residual tumor)
Not Recurrent, Resected, Residual
Tumor (Not recurrent, resected, residual
tumor)
Recurrent (Recurrent)
Unresected (Unresected)
Is measurable disease present? (only applicable
in studies where there is residual disease at
baseline)
Yes
No
Is non-measurable disease present? (only
applicable in studies where there is residual
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disease at baseline)
Yes
No
Units used for labs
Imperial (Imperial)
Scientific/international (S/I)
Albumin (g/dL)
Hemoglobin (g/dL)
Lactate Dehydrogenase (LDH) (only collect if RT
study - U/L)
Lactate Dehydrogenase ULN (only collect if RT
study - U/L - Provide laboratory's upper limit of
normal)
Lung: Prior Treatment - Nsclc Stage I-iii
Prior Surgery
Yes
No
Primary Surgery Type
Bilobectomy (Bilobectomy)
Exploration, No Resection (Exploration,
No Resection)
Pneumonectomy (Pneumonectomy)
Segmentectomy (Segmentectomy)
Sleeve Resection (Sleeve resection)
Wedge Resection (Wedge Resection)
Primary Surgery Date
Prior Radiation Therapy
Yes
No
Prior Systemic Chemotherapy
Yes
No
Allows Documentation Of Any Additional
Cooments
Comments (optional)
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2019422v3.0
On-Study - Lung Cancer - NSCLC
Advanced On-Study Form - 2263427v3.0
Lung Cancer - NSCLC Advanced On-Study Form
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=DE93D710-
5D45-22F0-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/8646
Lung Cancer - NSCLC Advanced
On-Study Form
Crf Header
Coordinating Group Protocol No.
Coordinating Group Code
Protocol Title
Patient Study ID
Institution/Affiliate
Other Patient ID
Participating Group Code
Patient Name (initials acceptable)
Lung: Pre-treatment Characteristics
Patient Height (cm)
Patient Weight (kg)
Body Surface Area (m^2)
Performance Status (check one)
Fully Active, Able To Carry On All Pre-
disease Performance Without
Restriction. (0)
Restricted In Physically Strenuous
Activity But Ambulatory And Able To
Carry Out Work Of A Light Or Sedentary
Nature, E.g., Light Housework, Office
Work. (1)
Ambulatory And Capable Of All Selfcare
But Unable To Carry Out Any Work
Activities. Up And About More Than 50%
Of Waking Hours. (2)
Capable Of Only Limited Selfcare,
Confined To Bed Or Chair More Than
1 / 3
50% Of Waking Hours. (3)
Completely Disabled. Cannot Carry On
Any Selfcare. Totally Confined To Bed Or
Chair. (4)
Weight loss in previous six months (check one)
<5% Of Body Weight (< 5% of body
weight)
> Or = 20% Of Body Weight (> or = 20%
of body weight)
10 To <20% Of Body Weight (10 to <20%
of body weight)
5 To <10% Of Body Weight (5 to < 10%
of body weight)
Lung: Disease Description - Nsclc
Advanced
Stage
Stage Iiib (IIIB (not recurrent))
Stage Iv (IV (not recurrent))
Recurrent (Recurrent)
Histologic Type
Adenocarcinoma (Adenocarcinoma)
Bronchoalveolar (bac) (Bronchoalveolar
carcinoma (BAC))
Large Cell Undifferentiated (Large cell
undifferentiated)
Non-small Cell Lung Cancer (nsclc), Nos
(Non-small cell lung cancer NOS)
Other (Other specify)
Squamous Cell Carcinoma (Squamous
cell carcinoma)
Specify Other Histologic Type
Is measurable disease present? (only applicable
in studies where there is residual disease at
baseline)
Yes
No
Is non-measurable disease present? (only
applicable in studies where there is residual
disease at baseline)
Yes
No
Metastatic Sites (check all that apply)
Adrenal Gland (Adrenal(s))
Bone (Bone)
Bone Marrow (Bone marrow)
Brain (Brain)
Contralateral Lung (Contralateral lung)
Hilar Nodes (Hilar nodes)
Ipsilateral Lung (Ipsilateral lung)
Liver (Liver)
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2263427v3.0
Mediastinal Nodes (Mediastinal nodes)
Pleura (Pleura)
Skin (Skin)
Supraclavicular Or Scalene Nodes
(Supraclavicular/scalene nodes)
Is pleural effusion present?
Yes
No
Is it Malignant? (If yes,)
No (No)
Unknown (Unknown (not tapped))
Yes (Yes)
Units used for labs
Imperial (Imperial)
Scientific/international (S/I)
Albumin (g/dl)
Hemoglobin (g/dl)
Lactate Dehydrogenase (LDH) (U/L only collect if
RT study)
Lactate Dehydrogenase ULN (U/L Provide
laboratory's upper limit of normal)
Lung: Prior Treatment - Nsclc Advanced
Prior Surgery (Code "No" if incisional/needle
biopsy is the only prior surgery)
Yes
No
Prior Radiation Therapy
Yes
No
Prior Systemic Chemotherapy
Yes
No
Comments
Comments
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2263427v3.0
Cervical Cancer NCT01414608 Pre-Study -
ANZGOG-0902 Baseline - 3140312v1.0
ANZGOG-0902 Baseline
Cisplatin and Radiation Therapy With or Without
Carboplatin and Paclitaxel in Patients With Locally
Advanced Cervical Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=90CA1C57-
45F8-A228-E040-BB89AD43458D
All rights reserved. Please visit https://medical-data-
models.org/forms/8647
ANZGOG-0902 Baseline
Header
Patient Initials
Patient ID
Institution Code
Date
Date of Assessment
Demographic Data
Race
A Person Having Origins In Any Of The
Original Peoples Of North And South
America (including Central America),
And Who Maintains Tribal Affiliation Or
Community Attachment. (American
Indian or Alaska Native)
A Person Having Origins In Any Of The
Original Peoples Of The Far East,
Southeast Asia, Or The Indian
Subcontinent Including, For Example,
Cambodia, China, India, Japan, Korea,
Malaysia, Pakistan, The Philippine
Islands, Thailand, And Vietnam. (Asian)
A Person Having Origins In Any Of The
Black Racial Groups Of Africa. Terms
Such As "haitian" Or "negro" Can Be
Used In Addition To "black Or African
American." (Black or African American)
A Person Having Origins In Any Of The
Original Peoples Of Hawaii, Guam,
Samoa, Or Other Pacific Islands. (Native
Hawaiian or other Pacific Islander)
Not Provided Or Available (Not
Reported)
Could Not Be Determined Or Unsure
(Unknown)
A Person Having Origins In Any Of The
Original Peoples Of Europe, The Middle
East, Or North Africa. (White)
1 / 3
Cancer Australia Data - For Cancer
Australia Trails Only
Country
What language is spoken at home?
Address Postal Code
Vital Signs
Height
Weight
Body Surface Area
Cancer Stage And Grade (details At Initial
Diagnosis)
Date of Initial Pathologic Diagnosis
Method of Evaluation
Ct Scan (CT scan)
Mri Scan (MRI scan)
Pet Scan (PET scan)
Surgery (Surgery)
Histologic Grade
Well Differentiated (G1-Well
Differentiated)
Moderately Differentiated (G2-
Moderately Differentiated)
Poorly Differentiated (G3-Poorly
Differentiated)
Undifferentiated (G4-Undifferentiated)
Grade Cannot Be Assessed (Gx-Grade
cannot be assessed)
Tumor Size, Maximum Diameter
Baseline
Smoking
Current Smoker (Current smoker)
Ever-smoker (Ever-smoker)
Not At All (Never)
Footer Module
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3140312v1.0
Investigator Name
Date
Investigator's signature
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3140312v1.0
Treatment - Lung Cancer - Surgery Form -
2019344v3.0
Lung Cancer - Surgery Form
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=16A97536-
D6F7-57EF-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/8648
Lung Cancer - Surgery Form
Crf Header
Coordinating Group Protocol No.
Coordinating Group Code
Protocol Title
Patient Study ID
Institution/Affiliate
Other Patient ID
Participating Group Code
Patient Name (initials acceptable)
Lung Pathology: Form Administration
Person Completing Form
Are data amended (If data are amended, please
circle in red when using paper form)
Yes
No
Lung: Surgical Procedure
Surgery Date (Surgical Procedure Description)
Surgical Approach
Thoracoscopy / Video-assisted (vats)
(Thoracoscopy / Video-assisted (VATS))
Thoracoscopy / Video-assisted (vats),
With Conversion To Thoracotomy
(Thoracoscopy / Video-assisted (VATS),
with conversion to Thoracotomy)
Thoracotomy (thoracotomy)
Type of Procedure
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Bilobectomy (Bilobectomy)
Exploration, No Resection (Exploration,
no resection)
Lobectomy (Lobectomy)
Pneumonectomy (Pneumonectomy)
Segmentectomy (Segmentectomy)
Wedge Resection (Wedge resection)
Side (of tumor location)
Both (Both)
Left (Left)
Right (Right)
Unknown (Unknown)
Details of Surgery
Bronchial Sleeve Resection (Bronchial
sleeve resection)
Chest Wall Resection, No
Reconstruction (Chest wall resection, no
reconstruction)
Chest Wall Resection, With
Reconstruction (Chest wall resection,
with reconstruction)
Intrapericardial Reconstruction
(Intrapericardial reconstruction)
Major Vascular Resection, No
Reconstruction (Major vascular
resection, no reconstruction)
Other, Specify (Other, specify)
Vascular Sleeve Resection (Vascular
sleeve resection)
Other, specify
Duration of Surgery (skin to skin time - enter
hours and minutes elapsed)
Estimated Blood Loss (cc)
Were any whole blood transfusions administered
to the patient for this surgery? (Fluids
Administered)
Yes
No
Number of intra- and post-operative whole blood
transfusions (units) (within 7 days)
Were there any surgical complications?
(Discharge Summary)
Yes
No
Number of days on ventilator (days)
Inpatient Discharge Date
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Number of post-operative days (to Time of
Discharge - days)
Lung: Surgical-pathological Results
Margins of surgical resection (Surgical Margins)
All Margins Pathologically Negative (R0)
Microscopically Positive Margins Or
Microscopic Residual Disease (R1)
Macroscopically Positive Margins Or
Gross Residual Disease (R2)
N Stage, Pathologic (Disease Staging - Indicate
highest stage based on evaluation of surgical and
pathological evidence - check one)
No Regional Lymph Node Metastasis
(N0)
Metastasis To Ipsilateral Peribronchial
And/or Ipsilateral Hilar Lymph Nodes,
And Intrapulmonary Nodes Including
Involvement By Direct Extension Of The
Primary Tumor (N1)
Metastasis To Ipsilateral Mediastinal
And/or Subcarinal Lymph Node(s) (N2)
Metastasis To Contralateral Mediastinal,
Contralateral Hilar, Ipsilateral Or
Contralateral Scalene, Or
Supraclavicular Lymph Node(s) (N3)
Regional Lymph Nodes Cannot Be
Assessed (NX)
T Stage, Pathologic (check one)
Tumor 3 Cm Or Less In Greatest
Dimension, Surrounded By Lung Or
Visceral Pleura, Invasion More Proximal
Than The Lobar Bronchus, (i.e., Not In
The Main Bronchus) (T1)
Tumor With Any Of The Following
Features Of Size Or Extent: More Than
3cm In Greatest Dimension; Invades The
Visceral Pleura; Associated With
Atelectasis Or Obstructive Pneumonitis
That Extends To The Hilar Region But
Does Not Involve The Entire Lung (T2)
Tumor Of Any Size That Directly Invades
Any Of The Following: Chest Wall
(including Superior Sulcus Tumors),
Diaphragm, Mediastinal Pleura, Parietal
Pericardium; Or Tumor In The Main
Bronchus Less Than 2 Cm Distal To The
Carina, But Without Involvement O* (T3)
Tumor Of Any Size That Invades Any Of
The Following: Mediastinum, Heart,
Great Vessels, Trachea, Esophagus,
Vertebral Body, Carina; Or Separate
Tumor Nodules In The Same Lobe; Or
Tumor With A Malignant Pleural Effusion
(T4)
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Lymph Nodes Type (Station)
Highest Mediastinal Node (Highest
mediastinal (1))
Interlobar Node (Interlobar (11))
Left Hilar Node (Left hilar (10L))
Left Lobar Node (Left lobar (12L))
Left Lower Paratracheal Node (Left lower
paratracheal (4L))
Left Segmental Node (Left segmental
(13L))
Left Subsegmental Node (Left
subsegmental (14L))
Left Upper Paratracheal Node (Left
upper paratracheal (2L))
Para-aortic Node (Para-aortic (6))
Paraesophageal (Paraesophageal (8))
Pre- And Retro Paratracheal Node (Pre-
and retro paratracheal (3))
Pulmonary Ligament (Pulmonary
ligament (9))
Right Hilar Node (Right hilar (10R))
Right Lobar Node (Right lobar (12R))
Right Lower Paratracheal Node (Right
lower paratracheal (4R))
Right Segmental Node (Right segmental
(13R))
Right Subsegmental Node (Right
subsegmental (14R))
Right Upper Paratracheal Node (Right
upper paratracheal (2R))
Subaortic Node (Subaortic (5))
Subcarinal Node (Subcarinal (7))
Lymph Node Involvement
Negative Based On Clinical Evaluation
(clinically negative)
Positive Based On Clinical Evaluation
(clinically positive)
Equivocal (equivocal)
Not Evaluated (not evaluated)
Negative Based On Pathologic
Evaluation (pathologically negative)
Positive Based On Pathologic Evaluation
(pathologically positive)
Unknown (unknown)
Allows Documentation Of Any Additional
Cooments
Comments
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Fallopian Tube Cancer NCT01167712 Pre-Study - GOG-
0262: Medical History Form (Form MEDH) - 2917582v1.0
GOG-0262: Medical History Form (Form MEDH)
Paclitaxel and Carboplatin With or Without Bevacizumab in
Treating Patients With Stage II, Stage III, or Stage IV
Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or
Fallopian Tube Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=6E5EB14F-
2030-D8EE-E040-BB89AD4349C7
All rights reserved. Please visit https://medical-data-
models.org/forms/8649
GOG-0262: Medical History Form
(Form MEDH)
Header Module
Date form originally completed
Date form amended
Person amending form, last name
Patient Initials
Patient Study ID
Person Completing Form, Last Name
Ovarian: Disease Description
Have you ever been treated for hypertension that
required medication
No (No)
Yes, Currently (Yes, currently)
Yes, In The Past (Yes, in the past)
Peripheral vascular disease with claudication
Yes
No
Myocardial infarction or cerebrovascular accident
Yes
No
Have you smoked during the past year
Yes
No
If you smoke, how many packs of cigarettes do
you average per day
How many cigars/pipes do you average per day
How many years have you smoked
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Do you currently take medication for diabetes
No (No)
Yes - Insulin (Yes - Insulin)
Yes - Oral Hypoglycemics (Yes - Oral
hypoglycemics)
Ovarian: Findings From Primary Surgery
Have you ever been diagnosed with an
autoimmune disease
Yes
No
Ovarian: Post-operative Findings
Following Primary Surgery
Have you ever had peptic ulcer disease,
documented by endoscopy
Yes
No
Have you ever had an intestinal obstruction,
documented radiographically
Yes
No
Have you ever had inflammatory bowel disease
No (No)
Yes - Crohn's Disease (Yes - Crohn's
disease)
Yes - Ulcerative Colitis (Yes - Ulcerative
colitis)
If you have had inflammatory bowel disease, did
you require medication and/or surgery
Yes
No
Have you ever had diverticulitis that required
hospitalization or outpatient antibiotics and
dietary modification
Yes
No
Have you ever had C. difficile colitis
Yes
No
Have you ever had small bowel resection with
anastomosis
Yes
No
At primary debulking surgery
Yes
No
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History Form (Form MEDH) - 2917582v1.0
Have you ever had large bowel resection with
anastomosis
Yes
No
At primary debulking surgery
Yes
No
Footer Module
Do you use corticosteroids for a chronic condition
Yes
No
Do you use NSAID chronically
Yes
No
Comments
COMMENTS
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History Form (Form MEDH) - 2917582v1.0
Fallopian Tube Cancer NCT00951496 Pre-Study - GOG-
0252 Medical History Form (Form MEDH) - 2838693v1.0
GOG-0252 Medical History Form (Form MEDH)
Bevacizumab and Intravenous or Intraperitoneal
Chemotherapy in Treating Patients With Stage II, Stage III,
or Stage IV Ovarian Epithelial Cancer, Fallopian Tube
Cancer, or Primary Peritoneal Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=62A7BF0E-
D4CA-903B-E040-BB89AD43563B
All rights reserved. Please visit https://medical-data-
models.org/forms/8650
GOG-0252 Medical History Form
(Form MEDH)
Header Module
Date form originally completed
Date form amended
Person amending form, last name
Patient Initials
Patient Study ID
Person Completing Form, Last Name
Ovarian: Disease Description
Have you ever been treated for hypertension that
required medication
No (No)
Yes, Currently (Yes, currently)
Yes, In The Past (Yes, in the past)
Peripheral vascular disease with claudication
Yes
No
Myocardial infarction or cerebrovascular accident
Yes
No
Have you smoked during the past year
Yes
No
If you smoke, how many packs of cigarettes do
you average per day
How many cigars/pipes do you average per day
How many years have you smoked
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Do you currently take medication for diabetes
No (No)
Yes - Insulin (Yes - Insulin)
Yes - Oral Hypoglycemics (Yes - Oral
hypoglycemics)
Ovarian: Findings From Primary Surgery
Have you ever been diagnosed with an
autoimmune disease
Yes
No
Ovarian: Post-operative Findings
Following Primary Surgery
Have you ever had peptic ulcer disease,
documented by endoscopy
Yes
No
Have you ever had an intestinal obstruction,
documented radiographically
Yes
No
Have you ever had inflammatory bowel disease
No (No)
Yes - Crohn's Disease (Yes - Crohn's
disease)
Yes - Ulcerative Colitis (Yes - Ulcerative
colitis)
If you have had inflammatory bowel disease, did
you require medication and/or surgery
Yes
No
Have you ever had diverticulitis that required
hospitalization or outpatient antibiotics and
dietary modification
Yes
No
Have you ever had C. difficile colitis
Yes
No
Have you ever had small bowel resection with
anastomosis
Yes
No
At primary debulking surgery
Yes
No
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Have you ever had large bowel resection with
anastomosis
Yes
No
At primary debulking surgery
Yes
No
Footer Module
Do you use corticosteroids for a chronic condition
Yes
No
Do you use NSAID chronically
Yes
No
Comments
COMMENTS
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Treatment - Brain Cancer - Neurologic
Evaluation Form - 2286577v3.0
Brain Cancer - Neurologic Evaluation Form
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=DE951920-
1FCC-25F8-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/8651
Brain Cancer - Neurologic Evaluation
Form
Crf Header
Coordinating Group Protocol No.
Coordinating Group Code
Protocol Title
Patient Study ID
Institution/Affiliate
Other Patient ID
Participating Group Code
Patient Name (initials acceptable)
Brain: Form Administration
Person Completing Form
Are data amended (If data are amended, please
circle in red when using paper form)
Yes
No
Brain: Neurologic Evaluation
Headache
Incapacitating And Continuous Despite
Medication (Incapacitating and
continuous despite medication)
Minor And Intermittent (Minor and
intermittent)
None (None)
Requires Narcotic Preparations
(Requires narcotic preparations)
Requires Non-narcotic Analgesics
(Requires non-narcotic analgesics)
Unknown (Unknown)
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Visual Disturbance
Acuity Decreases (Acuity decreases)
Blind/bilaterally (Blind/bilaterally)
Blind/unilaterally (Blind/unilaterally)
Diplopia (Diplopia)
Field Defect (Field defect)
None (None)
Unknown (Unknown)
Speech Impairment
Minor, Intermittent (Minor, intermittent)
Moderate (Moderate)
None (None)
Severe (Severe)
Unknown (Unknown)
Sensory Symptoms
Minor, Intermittent (Minor, intermittent)
Moderate (Moderate)
None (None)
Severe (Severe)
Unknown (Unknown)
Motor Symptoms
Minor, Intermittent (Minor, intermittent)
Moderate (Moderate)
None (None)
Severe (Severe)
Unknown (Unknown)
Memory Symptoms
Both Recent And Remote (Both recent
and remote)
None (None)
Recent Event (Recent event)
Remote Event (Remote event)
Unknown (Unknown)
Personality Changes
Minor, Intermittent (Minor, intermittent)
Moderate (Moderate)
None (None)
Severe (Severe)
Unknown (Unknown)
Seizures
Frequent (>1 Per Week) Seizures With
Patient Taking Anticonvulsants (Frequent
(>1 per week) seizures with patient
taking anticonvulsants)
None (None)
Occasional Seizure (<1 Per Week)
Occurring Without Anticonvulsants
(occasional seizure (<1 per week)
occurring without anticonvulsants)
Occasional Seizure With Patient Taking
Anticonvulsants (Occasional seizure with
patient taking anticonvulsants)
Uncontrollable Status Epilepticus
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(Uncontrollable status epilepticus)
Unknown (Unknown)
Other Neurologic Symptoms
Minimal (Minimal)
Moderate (Moderate)
None (None)
Severe, Specify (Severe, specify)
Unknown (Unknown)
Severe, specify
Mental Status (Neurologic exam)
Gross Confusion But Awake (Gross
confusion but awake)
Minor Mental Confusion (Minor mental
confusion)
Normal Function (Normal function)
Unknown (Unknown)
Somnolence
Coma (Coma)
Lethargy (Lethargy)
None (None)
Rousable With Difficulty (Rousable with
difficulty)
Unknown (Unknown)
Papilledema
Definite Papilledema Or Exudate
(Definite papilledema or exudate)
Definitive Hemorrhage Atrophy (definitive
hemorrhage atrophy)
None (None)
Post Papilledema (Post papilledema)
Suggestive Changes Only (Suggestive
changes only)
Unknown (Unknown)
Motor Deficit
<50% Decrease In Function (<50%
decrease in function)
>50% Decrease In Function (>50%
decrease in function)
Complete Paralysis, Specify Area
(Complete paralysis, specify area)
Normal Function (Normal function)
Symptomatic Weakness Only
(Symptomatic weakness only)
Unknown (Unknown)
Complete paralysis, specify area
Cranial Nerve Deficit
Minor, Intermittent (Minor, intermittent)
Moderate (Moderate)
None (None)
Severe (Severe)
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Unknown (Unknown)
Severe, specify nerves involved
Sensory Deficit
Minor, Intermittent (Minor, intermittent)
Moderate (Moderate)
None (None)
Severe, Specify Areas (Severe, specify
areas)
Unknown (Unknown)
Severe, specify areas
Visual Test
Deficit (Deficit)
Intact (Intact)
Cerebral Deficit
Minor, Intermittent (Minor, intermittent)
Moderate (Moderate)
None (None)
Severe (Severe)
Unknown (Unknown)
Reflex Function
Abnormal (Abnormal)
Normal (Normal)
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Treatment - Gynecologic Oncology Group
Surgical Status Form - 2918053v1.0
Gynecologic Oncology Group Surgical Status Form
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=6E5EDF6F-
8B38-E23E-E040-BB89AD435A10
All rights reserved. Please visit https://medical-data-
models.org/forms/8654
Gynecologic Oncology Group
Surgical Status Form
Header Module
Date form originally completed
Date form amended
Person amending form, last name
Patient Initials
Patient Study ID
Person completing form, last name
Surgical Information
Has the patient had a major surgical procedure
since being registered onto the GOG0218?
Yes
No
First Surgical Procedure
Procedure Name
Procedure Intent
Procedure Date
Date of last Bevacizumab administration prior to
procedure
Did the patient experience a significant wound-
related bleeding or healing complication ([grade 3
or 4])
Yes
No
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Second Surgical Procedure
Procedure Name
Procedure Intent
Procedure Date
Date of last Bevacizumab administration prior to
procedure
Did the patient experience a significant wound-
related bleeding or healing complication ([grade 3
or 4])
Yes
No
Third Surgical Procedure
Procedure Name
Procedure Intent
Procedure Date
Date of last Bevacizumab administration prior to
procedure
Did the patient experience a significant wound-
related bleeding or healing complication ([grade 3
or 4])
Yes
No
Fourth Surgical Procedure
Procedure Name
Procedure Intent
Procedure Date
Date of last Bevacizumab administration prior to
procedure
Did the patient experience a significant wound-
related bleeding or healing complication ([grade 3
or 4])
Yes
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No
Comments
Comments
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Fallopian Tube Cancer NCT00951496 Treatment - Gynecologic
Oncology Group Surgical Status Form - 2305792v3.0
Gynecologic Oncology Group Surgical Status Form
Bevacizumab and Intravenous or Intraperitoneal
Chemotherapy in Treating Patients With Stage II, Stage III,
or Stage IV Ovarian Epithelial Cancer, Fallopian Tube
Cancer, or Primary Peritoneal Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=F17BE4C4-
06A3-1816-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/8655
Gynecologic Oncology Group
Surgical Status Form
Header Module
Date form originally completed
Date form amended
Person amending form, last name
Patient Initials
Patient Study ID
Person completing form, last name
Surgical Information
Has the patient had a major surgical procedure
since being registered onto the protocol
Yes
No
First Surgical Procedure
Procedure Name
Procedure Intent
Procedure Date
Date of last Bevacizumab administration prior to
procedure
Did the patient experience a significant wound-
related bleeding or healing complication ([grade 3
or 4])
Yes
No
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Second Surgical Procedure
Procedure Name
Procedure Intent
Procedure Date
Date of last Bevacizumab administration prior to
procedure
Did the patient experience a significant wound-
related bleeding or healing complication ([grade 3
or 4])
Yes
No
Third Surgical Procedure
Procedure Name
Procedure Intent
Procedure Date
Date of last Bevacizumab administration prior to
procedure
Did the patient experience a significant wound-
related bleeding or healing complication ([grade 3
or 4])
Yes
No
Fourth Surgical Procedure
Procedure Name
Procedure Intent
Procedure Date
Date of last Bevacizumab administration prior to
procedure
Did the patient experience a significant wound-
related bleeding or healing complication ([grade 3
or 4])
Yes
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No
Comments
Comments
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Colorectal Cancer NCT01167725 Quality of Life - USMCI 8214/Z6091:  Center
for Epidemiological Studies Depression Scale (CES-D) - 2895901v1.0
USMCI 8214/Z6091:  Center for Epidemiological Studies
Depression Scale (CES-D)
Standard Therapy With or Without Surgery and Mitomycin
C in Treating Patients With Advanced Limited Peritoneal
Dissemination of Colon Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=6B3EABF4-
20BB-57C5-E040-BB89AD430C2F
All rights reserved. Please visit https://medical-data-
models.org/forms/8659
USMCI 8214/Z6091:  Center for
Epidemiological Studies Depression
Scale (CES-D)
Header Module
Patient ID
Institution No.
Protocol No.
Quality of life
Date
You were bothered by things that don't usually
bother you
Most Of The Time (Most or all of the time
(5-7 days))
Moderate (Occasionally or a moderate
amount of the time (3-4 days))
None Of The Time (Rarely or none of the
time (less than 1 day))
Some Of The Time (Some or a little of
the time (1-2 days))
You did not feel like eating; your appetite was
poor
Most Of The Time (Most or all of the time
(5-7 days))
Moderate (Occasionally or a moderate
amount of the time (3-4 days))
None Of The Time (Rarely or none of the
time (less than 1 day))
Some Of The Time (Some or a little of
the time (1-2 days))
You felt that you could not shake off the blues
even with the help of your family and friends
Most Of The Time (Most or all of the time
(5-7 days))
Moderate (Occasionally or a moderate
amount of the time (3-4 days))
None Of The Time (Rarely or none of the
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time (less than 1 day))
Some Of The Time (Some or a little of
the time (1-2 days))
You felt that you were just as good as other
people
Most Of The Time (Most or all of the time
(5-7 days))
Moderate (Occasionally or a moderate
amount of the time (3-4 days))
None Of The Time (Rarely or none of the
time (less than 1 day))
Some Of The Time (Some or a little of
the time (1-2 days))
You had trouble keeping your mind on what you
were doing
Most Of The Time (Most or all of the time
(5-7 days))
Moderate (Occasionally or a moderate
amount of the time (3-4 days))
None Of The Time (Rarely or none of the
time (less than 1 day))
Some Of The Time (Some or a little of
the time (1-2 days))
You felt depressed
Most Of The Time (Most or all of the time
(5-7 days))
Moderate (Occasionally or a moderate
amount of the time (3-4 days))
None Of The Time (Rarely or none of the
time (less than 1 day))
Some Of The Time (Some or a little of
the time (1-2 days))
You felt that everything you did was an effort
Most Of The Time (Most or all of the time
(5-7 days))
Moderate (Occasionally or a moderate
amount of the time (3-4 days))
None Of The Time (Rarely or none of the
time (less than 1 day))
Some Of The Time (Some or a little of
the time (1-2 days))
You felt hopeful about the future
Most Of The Time (Most or all of the time
(5-7 days))
Moderate (Occasionally or a moderate
amount of the time (3-4 days))
None Of The Time (Rarely or none of the
time (less than 1 day))
Some Of The Time (Some or a little of
the time (1-2 days))
You thought your life had been a failure
Most Of The Time (Most or all of the time
(5-7 days))
Moderate (Occasionally or a moderate
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amount of the time (3-4 days))
None Of The Time (Rarely or none of the
time (less than 1 day))
Some Of The Time (Some or a little of
the time (1-2 days))
You felt fearful
Most Of The Time (Most or all of the time
(5-7 days))
Moderate (Occasionally or a moderate
amount of the time (3-4 days))
None Of The Time (Rarely or none of the
time (less than 1 day))
Some Of The Time (Some or a little of
the time (1-2 days))
Your sleep was restless
Most Of The Time (Most or all of the time
(5-7 days))
Moderate (Occasionally or a moderate
amount of the time (3-4 days))
None Of The Time (Rarely or none of the
time (less than 1 day))
Some Of The Time (Some or a little of
the time (1-2 days))
You were happy
Most Of The Time (Most or all of the time
(5-7 days))
Moderate (Occasionally or a moderate
amount of the time (3-4 days))
None Of The Time (Rarely or none of the
time (less than 1 day))
Some Of The Time (Some or a little of
the time (1-2 days))
You talked less than usual
Most Of The Time (Most or all of the time
(5-7 days))
Moderate (Occasionally or a moderate
amount of the time (3-4 days))
None Of The Time (Rarely or none of the
time (less than 1 day))
Some Of The Time (Some or a little of
the time (1-2 days))
You felt lonely
Most Of The Time (Most or all of the time
(5-7 days))
Moderate (Occasionally or a moderate
amount of the time (3-4 days))
None Of The Time (Rarely or none of the
time (less than 1 day))
Some Of The Time (Some or a little of
the time (1-2 days))
People were unfriendly
Most Of The Time (Most or all of the time
(5-7 days))
Moderate (Occasionally or a moderate
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amount of the time (3-4 days))
None Of The Time (Rarely or none of the
time (less than 1 day))
Some Of The Time (Some or a little of
the time (1-2 days))
You enjoyed life
Most Of The Time (Most or all of the time
(5-7 days))
Moderate (Occasionally or a moderate
amount of the time (3-4 days))
None Of The Time (Rarely or none of the
time (less than 1 day))
Some Of The Time (Some or a little of
the time (1-2 days))
You had crying spells
Most Of The Time (Most or all of the time
(5-7 days))
Moderate (Occasionally or a moderate
amount of the time (3-4 days))
None Of The Time (Rarely or none of the
time (less than 1 day))
Some Of The Time (Some or a little of
the time (1-2 days))
You felt sad
Most Of The Time (Most or all of the time
(5-7 days))
Moderate (Occasionally or a moderate
amount of the time (3-4 days))
None Of The Time (Rarely or none of the
time (less than 1 day))
Some Of The Time (Some or a little of
the time (1-2 days))
You felt that people disliked you
Most Of The Time (Most or all of the time
(5-7 days))
Moderate (Occasionally or a moderate
amount of the time (3-4 days))
None Of The Time (Rarely or none of the
time (less than 1 day))
Some Of The Time (Some or a little of
the time (1-2 days))
You could not get "going"
Most Of The Time (Most or all of the time
(5-7 days))
Moderate (Occasionally or a moderate
amount of the time (3-4 days))
None Of The Time (Rarely or none of the
time (less than 1 day))
Some Of The Time (Some or a little of
the time (1-2 days))
Total Score QoL
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Lung Cancer NCT00863512 Registration - CALGB
30506 Registration Worksheet Form - 2817354v1.0
CALGB 30506 Registration Worksheet Form
Chemotherapy or Observation in Treating Patients With
Early Stage Non-Small Cell Lung Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=5E92C67F-
D7CA-CFB0-E040-BB89AD432DA1
All rights reserved. Please visit https://medical-data-
models.org/forms/8660
CALGB 30506 Registration
Worksheet Form
Header Module
Lead Institution
CALGB Patient ID (Assigned)
Institution/Affiliate
Physician of Record
Participating Group Name
Protocol Administration
IRB Approval Date (MM DD YYYY)
Date Informed Consent Signed (MM DD YYYY)
Projected Start Date of Treatment (MM DD
YYYY)
HIPAA Authorization Date (MM DD YYYY)
Institution contact
Phone
Fax
Patient Demographics/pre-treatment
Characteristics
Patient Initials (Last, First Middle)
Date of Birth (MM DD YYYY)
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Patient Social Security Number
Patient Hospital No.
Gender
Female (FEMALE)
Male (MALE)
Patient Demographics/pre-treatment
Characteristics2
Performance Status (ECOG/Zubrod scale)
Fully Active, Able To Carry On All Pre-
disease Performance Without
Restriction. (0)
Restricted In Physically Strenuous
Activity But Ambulatory And Able To
Carry Out Work Of A Light Or Sedentary
Nature, E.g., Light Housework, Office
Work. (1)
Ambulatory And Capable Of All Selfcare
But Unable To Carry Out Any Work
Activities. Up And About More Than 50%
Of Waking Hours. (2)
Capable Of Only Limited Selfcare,
Confined To Bed Or Chair More Than
50% Of Waking Hours. (3)
Completely Disabled. Cannot Carry On
Any Selfcare. Totally Confined To Bed Or
Chair. (4)
Dead (5)
Method of Payment (USA only Mark one)
Medicaid (Medicaid)
Medicaid And Medicare (Medicaid and
Medicare)
Medicare (Medicare)
Medicare And Private Insurance
(Medicare and Private Insurance)
Military Sponsored (including Champus
& Tricare) (Military Sponsored (including
CHAMPUS & TRICARE))
No Means Of Payment (no Insurance)
(No means of payment (no insurance))
Other (Other)
Private Insurance (Private Insurance)
Self Pay (no Insurance) (Self Pay (No
Insurance))
Unknown (Unknown)
Veterans Sponsored (Veterans
Sponsored)
Patient Demographics/pre-treatment
Characteristics3
Disease
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Patient Zip Code
Country of Residence (If not USA)
Certification Of Eligibility And Protocol
Design
In the opinion of the investigator, is the patient
eligible?
Yes
No
Protocol Design
Stratification Factors
Pathologic type
Assigned Treatment Arm
Initial Patient Consent For Specimen Use
Patient's Initial Consent given for specimen use
for research on the patient's cancer
Yes
No
Patient's Initial Consent given for specimen use
for research unrelated to the patient's cancer?
Yes
No
Patient's initial consent given for further contact
regarding specimen?
Yes
No
Patient has consented to take part in the Quality
of Life Study (register the patient to 70809 during
registration to 30506 and provide the following
notes)
Yes
No
Patient Name
Patient Mailing Address
Patient Phone Number
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Worksheet Form - 2817354v1.0
Registration Information
CALGB Patient ID (Assigned)
Registration Date (MM DD YYYY)
Participating Group Patient ID (Assigned)
Registrar's Signature
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Breast Cancer NCT01082211 Demographic - A0 Form -
1014 Ph II 3D-CRT Recurrent Breast Form - 3107774v1.0
A0 Form - 1014 Ph II 3D-CRT Recurrent Breast Form
Radiation Therapy in Treating Women With Locally
Recurrent Breast Cancer Previously Treated With Repeat
Breast-Preserving Surgery
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=8876AA44-
3947-792F-E040-BB89AD434A3F
All rights reserved. Please visit https://medical-data-
models.org/forms/8662
A0 Form - 1014 Ph II 3D-CRT
Recurrent Breast Form
Module 1
Institutional person randomizing case
Has the eligibility checklist been completed
Yes
No
In the opinion of the investigator, is the patient
eligible?
Yes
No
Date Informed Consent Signed (mm/dd/yyyy)
Verifying physician
Patient ID
Race
A Person Having Origins In Any Of The
Original Peoples Of North And South
America (including Central America),
And Who Maintains Tribal Affiliation Or
Community Attachment. (American
Indian or Alaska Native)
A Person Having Origins In Any Of The
Original Peoples Of The Far East,
Southeast Asia, Or The Indian
Subcontinent Including, For Example,
Cambodia, China, India, Japan, Korea,
Malaysia, Pakistan, The Philippine
Islands, Thailand, And Vietnam. (Asian)
A Person Having Origins In Any Of The
Black Racial Groups Of Africa. Terms
Such As "haitian" Or "negro" Can Be
Used In Addition To "black Or African
American." (Black or African American)
More Than One Race (More than one
race)
A Person Having Origins In Any Of The
Original Peoples Of Hawaii, Guam,
Samoa, Or Other Pacific Islands. (Native
Hawaiian or other Pacific Islander)
Could Not Be Determined Or Unsure
(Unknown)
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A Person Having Origins In Any Of The
Original Peoples Of Europe, The Middle
East, Or North Africa. (White)
Any care at VA or military hospital
Yes
No
Calendar base date
Randomization Date
Medical oncologist's name
Have you obtained the patient's consent for his or
her tissue to be used for research to learn about,
prevent or treat cancer?
Yes
No
Have you obtained the patient's consent for his or
her blood to be
kept for use in research to learn about, prevent,
treat, or cure cancer?
Yes
No
Have you obtained the patient's consent for his or
her tissue to be kept for use research about other
health problems (for example: causes of
diabetes, Alzheimer's disease, and heart
disease)?
Yes
No
Have you obtained the patient's consent for his or
her blood to be kept for use research about other
health problems (for example: causes of
diabetes, Alzheimer's disease, and heart
disease)?
Yes
No
Have you obtained the patient's consent for allow
someone from this institution to contact him or
her in the future to ask him or her to take part in
more research
Yes
No
Patient has consented to participate in the
cosmesis study
Yes
No
If no, provide reason
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Not Approved By Institutional Irb (Not
approved by institutional IRB)
Other, Specify (Other, specify)
Patient Refused Due To Illness (Patient
refused due to illness)
Patient Refused For Other Reason
(Patient refused for other reason)
Other, specify
Other reason, specify
Patient has consented to take part in the
circulating tumor cell portion of the trial
Yes
No
If no, provide reason
Not Approved By Institutional Irb (Not
approved by institutional IRB)
Other, Specify (Other, specify)
Patient Refused Due To Illness (Patient
refused due to illness)
Patient Refused For Other Reason
(Patient refused for other reason)
Other, specify
Other reason, specify
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NCT01101451 On-Study - GOG-0263: Primary
Cervical Cancer -  On Study Form - 2933511v1.0
GOG-0263: Primary Cervical Cancer -  On Study Form
Radiation Therapy With or Without Chemotherapy in
Patients With Stage I or Stage II Cervical Cancer Who
Previously Underwent Surgery
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=7170934C-
5CE5-20E2-E040-BB89AD434964
All rights reserved. Please visit https://medical-data-
models.org/forms/8663
GOG-0263: Primary Cervical Cancer
-  On Study Form
Header Module
Date form originally completed
Date form amended
Person amending form, last name
Patient Initials
Patient Study ID
Person Completing Form, Last Name
CERVICAL:  DISEASE DESCRIPTION
Date of definitive histologic diagnosis of primary
tumor
Stage
Stage I (I)
Stage Ia (IA)
Stage Ia1 (IA1)
Stage Ia2 (IA2)
Stage Ib (IB)
Stage Ib1 (IB1)
Stage Ib2 (IB2)
Stage Ii (II)
Stage Iia (IIA)
Stage Iia1 (IIA1)
Stage Iia2 (IIA2)
Stage Iib (IIB)
Stage Iii (III)
Stage Iiia (IIIA)
Stage Iiib (IIIB)
Stage Iv (IV)
Stage Iva (IVA)
Stage Ivb (IVB)
Staging System
1995 (1995)
2009 (2009)
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Does the patient have parametrial involvement
with this disease
No (None)
Yes, Bilateral (Yes bilateral)
Yes, Unilateral (Yes unilateral)
Post-operative Findings Following Primary
Surgery
Site of Involvement (s - at study entry for
Advanced Disease Studies)
Abdomen (other Than Above) (Abdomen
(other than above))
Bladder (Bladder)
Bone (Bone)
Colon (Colon)
Liver (Liver)
Lung (Lung)
Other Specify (Other)
Pelvic (other Than Above) (Pelvic (other
than above))
Other, specify
Lymph Nodes Type
Other Specify (other)
Para-aortic (para-aortic)
Pelvic (pelvic)
Other specify
Lymph Node Involvement
Equivocal (equivocal)
Negative (negative)
Not Evaluated (not evaluated)
Positive (positive)
Method of Evaluation
Ct Scan (CT scan)
Mri (MRI (NMR))
Not Applicable (Not applicable)
Other, Specify (Other, specify)
Pathologic (Pathologic)
Physical Exam (Physical exam)
Ultrasound (Ultrasound)
Clinical Size of Tumor (at diagnosis if
microscopic, enter 0 - cm)
Comments
COMMENTS
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Colorectal Cancer NCT00265850 Registration - CALGB
80405 REGISTRATION WORKSHEET - 2672321v1.0
A Phase III Trial of Irinotecan/5-FU/Leucovorin or
Oxaliplatin/5-FU/Leucovorin with Bevacizumab,or
Cetuximab (C225), or with the Combination of
Bevacizumab and Cetuximab for Patientswith Untreated
Metastatic Adenocarcinoma of the Colon or Rectum
Cetuximab and/or Bevacizumab Combined With
Combination Chemotherapy in Treating Patients With
Metastatic Colorectal Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=37A89102-
B023-3CED-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/8664
CALGB 80405 REGISTRATION
WORKSHEET
Header Module
Lead Institution (Main member)
CALGB Patient ID (Assigned)
Institution/Affiliate
Physician of Record
Participating Group Name
Protocol Administration
IRB Approval Date
Date Informed Consent Signed
Projected Start Date of Treatment
HIPAA Authorization Date
Contact Person at Institution
Phone
Fax
Patient Demographics/pre-treatment
Characteristics
Last (Patient initials)
First
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Middle
Patient Social Security Number
Patient's Date of Birth (MM DD YYYY)
Patient Hospital No.
Gender
Female (FEMALE)
Male (MALE)
Ethnicity (Mark one)
A Person Of Mexican, Puerto Rican,
Cuban, Central Or South American Or
Other Spanish Culture Or Origin,
Regardless Of Race. (Hispanic or Latino)
A Person Not Meeting The Definition For
Hispanic Or Latino. (Not Hispanic or
Latino)
Could Not Be Determined Or Unsure
(Unknown)
Performance Status (ECOG/Zubrod scale)
Fully Active, Able To Carry On All Pre-
disease Performance Without
Restriction. (0)
Restricted In Physically Strenuous
Activity But Ambulatory And Able To
Carry Out Work Of A Light Or Sedentary
Nature, E.g., Light Housework, Office
Work. (1)
Ambulatory And Capable Of All Selfcare
But Unable To Carry Out Any Work
Activities. Up And About More Than 50%
Of Waking Hours. (2)
Capable Of Only Limited Selfcare,
Confined To Bed Or Chair More Than
50% Of Waking Hours. (3)
Completely Disabled. Cannot Carry On
Any Selfcare. Totally Confined To Bed Or
Chair. (4)
Dead (5)
Height (cm)
Weight (kg)
Body Surface Area (m^2)
Method of Payment
Medicaid (Medicaid)
Medicaid And Medicare (Medicaid and
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Medicare)
Medicare (Medicare)
Medicare And Private Insurance
(Medicare and Private Insurance)
Military Sponsored (including Champus
& Tricare) (Military Sponsored (including
CHAMPUS & TRICARE))
No Means Of Payment (no Insurance)
(No means of payment (no insurance))
Other (Other)
Private Insurance (Private Insurance)
Self Pay (no Insurance) (Self Pay (No
Insurance))
Unknown (Unknown)
Veterans Sponsored (Veterans
Sponsored)
Disease
Stage
Pathologic type
Patient Zip Code
Country of Residence (if not USA)
Race
Race
A Person Having Origins In Any Of The
Original Peoples Of North And South
America (including Central America),
And Who Maintains Tribal Affiliation Or
Community Attachment. (American
Indian or Alaska Native)
A Person Having Origins In Any Of The
Original Peoples Of The Far East,
Southeast Asia, Or The Indian
Subcontinent Including, For Example,
Cambodia, China, India, Japan, Korea,
Malaysia, Pakistan, The Philippine
Islands, Thailand, And Vietnam. (Asian)
A Person Having Origins In Any Of The
Black Racial Groups Of Africa. Terms
Such As "haitian" Or "negro" Can Be
Used In Addition To "black Or African
American." (Black or African American)
A Person Having Origins In Any Of The
Original Peoples Of Hawaii, Guam,
Samoa, Or Other Pacific Islands. (Native
Hawaiian or other Pacific Islander)
Not Provided Or Available (Not
Reported)
Could Not Be Determined Or Unsure
(Unknown)
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A Person Having Origins In Any Of The
Original Peoples Of Europe, The Middle
East, Or North Africa. (White)
Certification Of Eligibility And Protocol
Design
In the opinion of the investigator, is the patient
eligible?
Yes
No
Planned protocol chemotherapy
Fluorouracil, Leucovorin, And Irinotecan
(FOLFIRI)
5-fluorouracil, Leucovorin And Oxaliplatin
(FOLFOX)
Prior Adjuvant Chemotherapy
Yes
No
Prior Pelvic Radiation Therapy
Yes
No
Assigned Treatment Arm
Arm A: Folfox Or Folfiri Plus
Bevacizumab (Arm A: FOLFOX or
FOLFIRI plus Bevacizumab)
Arm B: Folfox Or Folfiri Plus Cetuximab
(Arm B: FOLFOX or FOLFIRI plus
Cetuximab)
Arm C: Folfox Or Folfiri Plus
Bevacizumab And Cetuximab (Arm C:
FOLFOX or FOLFIRI plus Bevacizumab
and Cetuximab)
Companion Studies
Did patient consent to take part in the Diet and
Lifestyle Study
Yes
No
Responsible CRA
CRA phone number
CRA mailing address
Institution
Consent given to contact patient for telephone
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interview
Yes
No
Patient's Name
Patient Phone Number
Patient Mailing Address
Patient's Initial Consent given for specimen kept
for future use in research to learn about, prevent,
or treat cancer
Yes
No
Patient's initial consent given for specimen(s)
may be kept for use in research to learn about,
prevent, or treat other health problems (for
example:
diabetes, Alzheimer's disease, or heart disease)
Yes
No
Patient's initial consent given for further contact
regarding specimen?
Yes
No
Patient's initial consent given for blood specimen
use for genetic research on patient's cancer?
Yes
No
Registration Information
CALGB Patient ID (Assigned)
Registration Date
Participating Group Patient ID (Assigned)
Registrar's Signature
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Adenocarcinoma of the Gastroesophageal Junction NCT01196390
Demographic - RTOG-1010 A2 Registration Worksheet Form - 3137821v1.0
RTOG-1010 A2 Registration Worksheet Form
Radiation Therapy, Paclitaxel, and Carboplatin With or
Without Trastuzumab in Treating Patients With Esophageal
Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=903C5206-
194A-6ECF-E040-BB89AD435F63
All rights reserved. Please visit https://medical-data-
models.org/forms/8665
RTOG-1010 A2 Registration
Worksheet Form
Module 1
Institutional person randomizing case*
Is the patient going to receive protocol treatment*
Yes
No
If no, provide reason*
Does Not Meet Eligibility Requirements
(Does not meet eligibility requirements)
Her2 Negative (HER2 negative)
Other (Other)
Other Complicating Disease (Other
complicating disease)
Patient Refusal (Patient refusal)
Physician Preference (Physician
preference)
Participant Initials (FML)*
Verifying physician*
Patient ID*
Calendar base date ([for step 2])*
Randomization Date*
Has the Step 2 eligibility checklist been
completed*
Yes
No
In the opinion of the investigator, is the patient
eligible?*
Yes
No
Medical oncologist's name*
Surgeon Name*
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Patient has consented to take part in the Quality
of Life Study*
Yes
No
If no, provide reason*
Not Approved By Institutional Irb (Not
approved by institutional IRB)
Other, Specify (Other, specify)
Patient Refused Due To Illness (Patient
refused due to illness)
Patient Refused For Other Reason
(Patient refused for other reason)
Tool Not Available In Patient's Language
(Tool not available in patient's language)
Other reason, specify*
Other, specify*
Presence of adenopathy*
No (No)
Yes Adenopathy And Celiac Present <=
2 Cm (Yes adenopathy and celiac
present <= 2 cm)
Yes Adenopathy, But Celiac Absent (Yes
adenopathy, but celiac absent)
Other specify*
Does not meet eligibility requirements, specify*
Other complicating disease, specify*
Is the patient HER2 positive*
Yes
No
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Adenocarcinoma of the Gastroesophageal Junction NCT01196390
Demographic - RTOG-1010 A0 Registration Worksheet Form - 3137697v1.0
RTOG-1010 A0 Registration Worksheet Form
Radiation Therapy, Paclitaxel, and Carboplatin With or
Without Trastuzumab in Treating Patients With Esophageal
Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=903C5206-
1852-6ECF-E040-BB89AD435F63
All rights reserved. Please visit https://medical-data-
models.org/forms/8668
RTOG-1010 A0 Registration
Worksheet Form
Module 1
Institutional person randomizing case*
Has the Step 1 eligibility checklist been
completed*
Yes
No
In the opinion of the investigator, is the patient
eligible?*
Yes
No
Date Informed Consent Signed*
Verifying physician*
Patient ID*
Race*
A Person Having Origins In Any Of The
Original Peoples Of North And South
America (including Central America),
And Who Maintains Tribal Affiliation Or
Community Attachment. (American
Indian or Alaska Native)
A Person Having Origins In Any Of The
Original Peoples Of The Far East,
Southeast Asia, Or The Indian
Subcontinent Including, For Example,
Cambodia, China, India, Japan, Korea,
Malaysia, Pakistan, The Philippine
Islands, Thailand, And Vietnam. (Asian)
A Person Having Origins In Any Of The
Black Racial Groups Of Africa. Terms
Such As "haitian" Or "negro" Can Be
Used In Addition To "black Or African
American." (Black or African American)
More Than One Race (More than one
race)
A Person Having Origins In Any Of The
Original Peoples Of Hawaii, Guam,
Samoa, Or Other Pacific Islands. (Native
Hawaiian or other Pacific Islander)
Could Not Be Determined Or Unsure
(Unknown)
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A Person Having Origins In Any Of The
Original Peoples Of Europe, The Middle
East, Or North Africa. (White)
Any care at VA or military hospital*
No (No)
Unknown (Unknown)
Yes (Yes)
Calendar base date*
Randomization Date*
Have you obtained the patient's consent for his or
her tissue to be kept for use in research to learn
about, prevent, treat or cure cancer*
Yes
No
Have you obtained the patient's consent for his or
her blood to be
kept for use in research to learn about, prevent,
treat, or cure cancer?*
Yes
No
Have you obtained the patient's consent for his or
her urine to be kept for use in research to learn
about, prevent, treat, or cure cancer*
Yes
No
Have you obtained the patient's consent for his or
her tissue to be kept for use in research about
other health problems (for example: causes of
diabetes, Alzheimer's disease and heart
disease)?*
Yes
No
Have you obtained the patient's consent for his or
her blood to be kept for use research about other
health problems (for example: causes of
diabetes, Alzheimer's disease, and heart
disease)?*
Yes
No
Have you obtained the patient's consent for his or
her urine to be kept for use in research about
other health problems (for example: causes of
diabetes, Alzheimer's disease, and heart
disease)*
Yes
No
Have you obtained the patient's consent to allow
someone from this institution to contact him or
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her in the future to take part in more research*
Yes
No
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Breast Cancer NCT01349322 Demographic
- A0 OPEN Form - 1005 - 3198937v1.0
A0 OPEN Form - 1005
Higher-Dose Radiation Therapy or Standard Radiation
Therapy in Treating Patients With Early-Stage Breast
Cancer That Was Removed by Surgery
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=9DA9F360-
A112-1EA4-E040-BB89AD432FA2
All rights reserved. Please visit https://medical-data-
models.org/forms/8669
A0 OPEN Form - 1005
Module 1
Institutional person randomizing case
Has the eligibility checklist been completed
Yes
No
In the opinion of the investigator, is the patient
eligible?
Yes
No
Date Informed Consent Signed (mm/dd/yyyy)
First
Middle
Last
Verifying physician
Patient ID
Race
American Indian Or Alaska Native
(American Indian or Alaska Native)
Asian (Asian)
Black Or African American (Black or
African American)
More Than One Race (More than one
race)
Native Hawaiian Or Other Pacific
Islander (Native Hawaiian or other Pacific
Islander)
Unknown (Unknown)
White (White)
Any care at VA or military hospital
No (No)
Unknown (Unknown)
Yes (Yes)
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Calendar base date
Randomization Date
Module 1
Have you obtained the patient's consent for her
tissue to be kept for use in research to learn
about, prevent, treat, or cure cancer?
Yes
No
Have you obtained the patient's consent for her
blood to be kept for use in  research to learn
about, prevent, treat, or cure cancer?
Yes
No
Have you obtained the patient's consent for her
tissue to be kept for use in research about other
health problems (for example: causes of
diabetes, Alzheimer's disease, and heart
disease)?
Yes
No
Have you obtained the patient's consent for her
blood to be kept for use in research about other
health problems (for example: diabetes,
Alzheimer's disease, or heart disease)?
Yes
No
Have you obtained the patient's consent to allow
someone from this institution to contact her in the
future to take part in more research?
Yes
No
Patient has consented to participate in the
cosmesis study
Yes
No
If no, provide reason
Not Approved By Institutional Irb (Not
approved by institutional IRB)
Other, Specify (Other, specify)
Patient Refused Due To Illness (Patient
refused due to illness)
Patient Refused For Other Reason
(Patient refused for other reason)
Tool Not Available In Patient's Language
(Tool not available in patient's language)
Patient refused for other reason: specify
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Other, specify
Age
< 50 (< 50)
>= 50 (>= 50)
Intention to receive chemotherapy
Yes
No
ER Status
Negative (Negative)
Positive (Positive)
Histologic Grade
Grade 1 And 2 (G1-2)
Grade 3 (G3)
Patient
Radiation Therapy Technique
3-dimensional Conformal Radiation
Therapy (3D-CRT)
Imrt (intensity Modulated Rt) (IMRT)
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Breast Cancer NCT00068601 Registration - Southwest
Oncology Group Registration Form (S0230) - 2170399v3.0
Southwest Oncology Group Registration Form (S0230)
Goserelin in Preventing Ovarian Failure in Women
Receiving Chemotherapy for Breast Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=BEA482FC-
617F-0320-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/8673
Southwest Oncology Group
Registration Form (S0230)
Stratification Factors
Patient's Age
<40 (<40)
40-49 (40-49)
Chemotherapy Regimen
3 Month Anthracycline Based (3 month
anthracycline based)
6 Month/cycle Anthracycline Based (6
month/cycle anthracycline based)
6 Month/cycle Non-anthracycline
Regimen (6 month/cycle non-
anthracycline regimen)
Ccrr Module For Southwest Oncology
Group Registration Form (s0230)
Assigned Treatment Arm
Activation Date
Last Amended Date
Patient's Name
SWOG Patient ID
Other Group Patient Number
Participating Group/Protocol Number
Caller's SWOG Roster ID
IRB Approval Date
Projected Start Date of Treatment
Date Informed Consent Signed
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SWOG Investigator Number
SWOG Treating Institution Number
Other Group Investigator Name and Number
Other Group Investigator Name and Number
Patient's Date of Birth
Patient Gender
Female (Female)
Male (Male)
Other, specify at registration
Other, specify at registration
Patient's Ethnicity
A Person Of Mexican, Puerto Rican,
Cuban, Central Or South American Or
Other Spanish Culture Or Origin,
Regardless Of Race (HISPANIC OR
LATINO)
No (No)
A Person Not Meeting The Definition For
Hispanic Or Latino. (NON-HISPANIC)
Patient Is Unsure Of Their Ethnicity
(Unknown)
Yes, Central American (Yes, Central
American)
Yes, Cuban (Yes, Cuban)
Yes, Mexican (Yes, Mexican)
Yes, NOS (Yes, NOS)
Yes, Other (Yes, Other)
Yes, Puerto Rican (Yes, Puerto Rican)
Yes, South American (Yes, South
American)
Patient's Race (select all that apply)
A Person Having Origins In Any Of The
Original Peoples Of North And South
America (including Central America),
And Who Maintains Tribal Affiliation Or
Community Attachment (American Indian
or Alaska Native)
A Person Having Origins In Any Of The
Original Peoples Of The Far East,
Southeast Asia, Or The Indian
Subcontinent Including, For Example,
Cambodia, China, India, Japan, Korea,
Malaysia, Pakistan, The Philippine
Islands, Thailand, And Vietnam. (Asian)
A Person Having Origins In Any Of The
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Black Racial Groups Of Africa. Terms
Such As "haitian" Or "negro" Can Be
Used In Addition To "black Or African
American." (Black or African American)
A Person Having Origins In Any Of The
Original Peoples Of Hawaii, Guam,
Samoa, Or Other Pacific Islands (Native
Hawaiian or Other Pacific Islander)
Patient Is Unsure Of Their Race
(Unknown)
A Person Having Origins In Any Of The
Original Peoples Of Europe, The Middle
East, Or North Africa. (White)
Patient Social Security Number
Patient's Zip Code
Country of Residence (if not USA)
Social Insurance Number (Postal Code)
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Endometrial Cancer NCT00063999 On-Study - Recurrent Gynecologic
Cancer - On Study Form, GOG-0209, Form OS-R - 2077062v3.0
Recurrent Gynecologic Cancer - On Study Form, GOG-
0209, Form OS-R
Combination Chemotherapy in Treating Patients With Stage
III, Stage IV, or Recurrent Endometrial Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=B2400102-
D1C7-0EDF-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/8675
Recurrent Gynecologic Cancer - On
Study Form, GOG-0209, Form OS-R
Header Module
Date form originally completed (m d y)
Date form amended (m d y)
Person amending form, last name
Patient Last Name
Patient First Name
Patient Study ID
Person Completing Form, Last Name
Disease Description - Prior History
Date of definitive histologic diagnosis of primary
tumor (m d y  Note: Word ?tumor? obstructed by
graphic)
Stage (at diagnosis FIGO)
Refer To Figo Staging For Specific
Gynecologic Cancer (I)
Refer To Figo Staging For Specific
Gynecologic Cancer (II)
Refer To Figo Staging For Specific
Gynecologic Cancer (III)
Refer To Figo Staging For Specific
Gynecologic Cancer (IV)
Primary surgery date (m d y)
Primary surgery type (check all that apply)
Bilateral Salpingo-oophorectomy
(Bilateral Salpingo-Oophorectomy)
Cervical Conization (Cervical conization)
Omentectomy (Omenectomy)
Other, Specify (Other, specify)
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Para-aortic Node Sampling/dissection
(Para-aortic node sampling/dissection)
Partial Hysterectomy (Partial
hysterectomy)
Pelvic Node Sampling/dissection (Pelvic
node sampling/dissection)
Radical Hysterectomy (Radical
hysterectomy)
Radical Trachelectomy (Radical
Trachelectomy)
Total Hysterectomy (Total hysterectomy)
Unilateral Salpingo-oophorectomy
(Unilateral Salpingo-Oophorectomy)
Other, specify (Primary Surgery Type)
Disease Description - Current History
Current status of disease
Primary Gyn Disease Continues To Be
Present Following Initial Treatment
(Persistent)
Primary Tumor (Primary (Advanced))
Progression Of Gyn Disease Per Recist
Criteria (Progression)
Recurrence Of Same Gyn Disease
Previously Treated Successfully
(Recurrence)
Date of first recurrence or progression (m d y)
What was the method used to determine
progression? (recurrence or check all that apply)
Clinical Examination (Clinical)
Histology (Histologic)
Radiographic (Radiographic)
Sites of disease (at study entry check all that
apply)
Ascites (Ascites)
Bladder (Bladder)
Bone (Bone)
Cervix (Cervix)
Cns/brain (CNS/Brain)
Colon (Colon)
Endometrium (Endometrium)
Liver (Liver)
Lung (Lung)
Lymph Nodes, Specify (Lymph nodes,
specify)
Other, Specify (Other, specify)
Ovary (Ovary)
Parametrial Involvement (Parametrial
involvement)
Peritoneum (Peritoneum)
Pleura (Pleura)
Pleural Effusion (Pleural effusion)
Skin (Skin)
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Uterus (Uterus)
Lymph nodes, specify
Other, specify (Sites of Disease)
Prior Treatment For Gynecologic Cancer
Prior systemic chemotherapy?
Yes
No
Date prior chemotherapy started (m d y)
Date prior chemotherapy ended
Chemotherapy regimen
First Line Agent (First line, specify
agents)
Other, Specify (Other, specify agents)
Second Line Agent (Second line, specify
agents)
Other, specify agents
Other, specify agents
Other, specify agents
No. of courses (other)
No. of courses (other)
No. of courses (other)
Prior hormonal therapy?
No (No)
Yes (Yes, specify)
Yes, specify (Prior Hormonal)
Non-protocol biologic response modifier?
No (No)
Yes (Yes, specify)
Yes, specify (Non-protocol BRM)
Prior radiation therapy?
Yes
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No
Yes, specify (Prior RT)
Is the site of recurrence within the field previously
treated by radiation therapy?
Yes
No
COMMENTS
Footer Module
Participating Group Code
Participating Group Protocol Number
Patient Study ID, Participating Group
Ccrr Module For Recurrent Gynecologic
Cancer - On Study Form, Gog-0209, Form
Os-r
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Colorectal Cancer NCT00726622 Treatment -
Z6051 Rectal Surgery Form (RS) - 2718972v1.0
Z6051 Rectal Surgery Form (RS)
Laparoscopic-Assisted Resection or Open Resection in
Treating Patients With Stage IIA, Stage IIIA, or Stage IIIB
Rectal Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=433B815D-
7043-2896-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/8679
Z6051 Rectal Surgery Form (RS)
Header Module
Visit
1-2 Weeks Post-surgery (1-2 weeks
post-surgery)
Patient ID (Pt. ID issued during registration
unless pt. previously registered to an ACOSOG
study.)
Patient Initials
Institution Name
Institution No.
Surgery
Did the patient have surgery as part of protocol
treatment?
Yes
No
Reason surgery not performed
Other (Other)
Patient Refusal And Withdrawal From
Trial (Patient refusal and withdrawal from
trial)
Physician Decision (Physician decision)
Other, specify
Date of Resection
Surgical Approach
Abdominal Perineal Resection
(Abdominal perineal resection)
Low Anterior Resection (Low anterior
resection)
Low Anterior Resection Plus Coloanal
Anastomosis (Low Anterior Resection  +
Coloanal Anastomosis)
Low Hartmann (Low Hartmann)
Proctocolectomy (Total Proctocolectomy)
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Was an ostomy created at the time of resection?
No (No)
Yes, Colostomy (Yes, colostomy)
Yes, Ileostomy (Yes, ileostomy)
Open to close operative time (minutes)
Estimated blood loss (Total - ml)
Sphincter preservation planned prior to surgery
Yes
No
Final incision length (cm)
Margins examined by frozen section
Yes
No
Intra-operative distal margin length (cm)
Rectum intact
Yes
No
Video documentation
Yes
No
Was attempted surgery complete
Yes
No
For Patients Randomized To Laproscopic
Surgery Only
Surgical approach
Hand-assisted (Hand-assisted)
Laparoscopic Surgery (Laparoscopic)
Laparoscopic-assisted (Laparoscopic-
assisted)
Robotic-assisted (Robotic-assisted)
Port Number
Port Size
Port Size
Port Pattern
Left Lower Quadrant (LLQ)
Left Lateral Abdomen (Lt Lateral Abd)
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Left Middle Abdomen (Lt Mid Abd)
Left Upper Quadrant (LUQ)
Right Lower Quadrant (RLQ)
Right Lateral Abdomen (Rt Lateral Abd)
Right Middle Abdomen (Rt Mid Abd)
Right Upper Quadrant (RUQ)
Xiphoid Process (Sub Xiphoid)
Pubic Bone (Super Pubic)
Umbilicus (Umbilicus)
Hand Port
Yes
No
Site
Left Lower Quadrant (LLQ)
Left Upper Quadrant (LUQ)
Right Lower Quadrant (RLQ)
Right Upper Quadrant (RUQ)
Pubic Bone (Super Pubic)
Umbilicus (Umbilicus)
Ligation Method
Sugical Clip (Clips)
Enseal (Enseal)
Harmonic Scalpel (Harmonic)
Ligasure (Ligasure)
Other (Other)
Surgical Staple (Staples)
Suture Dosage Form (Suture)
Other specify
TME Dissection Instrument
Cautery Scissors (Cautery scissors)
Enseal (Enseal)
Harmonic Scalpel (Harmonic)
Hook Cautery (Hook cautery)
Ligature (Ligature)
Other (Other)
Other specify
Low Rectal Transection Stapler Type
Curvilinear, 45 Mm (Curvilinear, 45 mm)
Endo-cutter 30 Mm (Endo-cutter 30 mm)
Endo-cutter 45 Mm (Endo-cutter 45 mm)
Endo-cutter 60 Mm (Endo-cutter 60 mm)
Other (Other)
Power Medical Gia (Power medical GIA)
Transverse Linear, 30 Mm (Transverse
linear, 30 mm)
Transverse Linear, 60 Mm (Transverse
linear, 60 mm)
Number of firing
Other, specify
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Scope Used
Flexible (Flexible)
Other (Other)
Rigid, 0 Degree (Rigid, 0 degree)
Rigid, 30 Degree (Rigid, 30 degree)
Other specify
Was a change in ports required
Yes
No
Were retractors needed
Yes
No
Type of retractor
10mm Grasper (10mm grasper)
5mm Grasper (5mm grasper)
Fan Retractor (Fan retractor)
Liver Retractor (Liver retractor)
Other (Other)
Other, specify
Was there organ displacement
Yes
No
Retractor used
10mm Grasper (10mm grasper)
5mm Grasper (5mm grasper)
Fan Retractor (Fan retractor)
Liver Retractor (Liver retractor)
Other (Other)
Other, specify
Was a smoke evacuator used
Yes
No
Anastomosis
Yes
No
Method used
Double Stapled End To End (Double
stapled end to end)
Hand Sewn Coloanal (Hand sewn
coloanal)
Hand Sewn End To End (Hand sewn end
to end)
Side To Side Functional End To End
(Side to side functional end to end)
Single Stapled End To End (Single
stapled end to end)
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Was laparoscopic resection converted to open
Yes
No
Reason laparoscopic resection was converted to
open
Adhesion (Adhesions)
Complication/adverse Event During
Surgery (Complication/adverse event
during surgery)
Locally Advanced Disease Discovered At
Surgery (Locally advanced disease
discovered at surgery)
Other (Other)
Unable To Complete Anastomosis Safely
(Unable to complete anastomosis safely)
Unable To Complete Rectal Dissection
Safely (Unable to complete rectal
dissection safely)
Other specify
Intra-operative Complications
Intra-operative Complications
Yes
No
Intra-operative Complications
Hemorrhage/bleeding Associated With
Surgery (Hemorrhage/bleeding
associated with surgery)
Intra-operative Injury, Other: Air
Embolism (Intra-operative injury, other:
Air embolism)
Intra-operative Injury: Abdomen Nos
(Intra-operative injury: Abdomen NOS)
Artery Intraoperative Complication (Intra-
operative injury: Artery NOS)
Intra-operative Injury: Bladder (Intra-
operative injury: Bladder)
Intra-operative Injury: Colon (Intra-
operative injury: Colon)
Intra-operative Injury: Rectum (Intra-
operative injury: Rectum)
Intra-operative Injury: Small Bowel Nos
(Intra-operative injury: Small bowel NOS)
Intra-operative Injury: Spleen (Intra-
operative injury: Spleen)
Gastrointestinal Tract Stoma
Intraoperative Complication (Intra-
operative injury: Stoma (GI))
Intra-operative Injury: Ureter (Intra-
operative injury: Ureter)
Intra-operative Injury: Vein Nos (Intra-
operative injury: Vein NOS)
Other (Other)
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Other, specify
Complication due to
Grasping (Grasping)
Ligation (Ligation)
Transection (Transection)
Footer Module
Completed by
Date Form Completed
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Dental Caries NCT01268605 Eligibility -
PRL1013: Enrollment Form (ENR) - 3246000v1.0
PRL1013: Enrollment Form (ENR)
Postoperative Hypersensitivity Randomized Comparative
Effectiveness Research Trial (POH RCERT)
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=A63D65F7-
CD34-5822-E040-BB89AD4372DF
All rights reserved. Please visit https://medical-data-
models.org/forms/8682
PRL1013: Enrollment Form (ENR)
Header Module
Site Code
Date of visit
Subject ID
Subject Initials
Inclusion Criteria
Subject's age
How many teeth are being enrolled on this
protocol
Tooth Number With Occlusal Caries
Tooth number with occlusal caries
1st Bicuspid (1st Premolar) Permanent
Arch Upper Left (12)
2nd Bicuspid (2nd Premolar) Permanent
Arch Upper Left (13)
1st Molar (6-yr. Molar) Permanent Arch
Upper Left (14)
2nd Molar (12-yr. Molar) Permanent Arch
Upper Left (15)
2nd Molar (12-yr. Molar) Permanent Arch
Lower Left (18)
1st Molar (6-yr. Molar) Permanent Arch
Lower Left (19)
2nd Molar (12-yr. Molar) Permanent Arch
Upper Right (2)
2nd Bicuspid (2nd Premolar) Permanent
Arch Lower Left (20)
1st Bicuspid (1st Premolar) Permanent
Arch Lower Left (21)
1st Bicuspid (1st Premolar) Permanent
Arch Lower Right (28)
2nd Bicuspid (2nd Premolar) Permanent
Arch Lower Right (29)
1st Molar (6-yr. Molar) Permanent Arch
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Upper Right (3)
1st Molar (6-yr. Molar) Permanent Arch
Lower Right (30)
2nd Molar (12-yr. Molar) Permanent Arch
Lower Right (31)
2nd Bicuspid (2nd Premolar) Permanent
Arch Upper Right (4)
1st Bicuspid (1st Premolar) Permanent
Arch Upper Right (5)
Tooth quadrant
Lower Left Quadrant (Lower Left)
Lower Right Quadrant (Lower Right)
Upper Left Quadrant (Upper Left)
Upper Right Quadrant (Upper Right)
Air velocity
Air stimulation pain level
0 (0)
1 (1)
10 (10)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
7 (7)
8 (8)
9 (9)
Does the pain linger >4 seconds (after removal of
air blast)
Yes
No
Cold stimulation pain level
0 (0)
1 (1)
10 (10)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
7 (7)
8 (8)
9 (9)
Time to cold sensation
Does the pain linger > 4 seconds
Yes
No
Gingival index
Mild Inflammation; Slight Change In
Color And Mild Edema (Mild
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inflammation; slight change in color and
mild edema)
Moderate Inflammation; Redness,
Edema And Glazing; Bleeding On
Probing (Moderate inflammation;
redness, edema and glazing; bleeding
on probing)
Normal Appearance, No Bleeding
(Normal appearance, no bleeding)
Severe Inflammation; Marked Redness
And Edema; Ulceration; Spontaneous
Bleeding (Severe inflammation; marked
redness and edema; ulceration;
spontaneous bleeding)
Inclusion Criteria
Does the subject have solely adult dentition
Yes
No
Are all protocol teeth permanent posterior teeth
and present withthe clinical diagnosis of new
Class I caries extending into dentinwith or without
radiographic confirmation
Yes
No
Are these the only teeth that meet the eligibility
criteria
Yes
No
Are these the only teeth that will be treated (will
receive restoration) at this time
Yes
No
Inclusion Criteria (cont.1)
Is/Are the radiographic depth(s) of the lesion(s),
when visible, less than or equal to half the Dento-
Enamel Junction (DEJ) to the pulp
No (No)
Not Visible, But Confirmed Clinically (Not
visible, but confirmed clinically)
Yes (Yes)
Tooth Number
3rd Molar (wisdom Tooth) Permanent
Arch Upper Right (1)
Lateral Incisor Permanent Arch Upper
Left (10)
Cuspid (canine/eye Tooth) Permanent
Arch Upper Left (11)
1st Bicuspid (1st Premolar) Permanent
Arch Upper Left (12)
2nd Bicuspid (2nd Premolar) Permanent
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Arch Upper Left (13)
1st Molar (6-yr. Molar) Permanent Arch
Upper Left (14)
2nd Molar (12-yr. Molar) Permanent Arch
Upper Left (15)
3rd Molar (wisdom Tooth) Permanent
Arch Upper Left (16)
3rd Molar (wisdom Tooth) Permanent
Arch Lower Left (17)
2nd Molar (12-yr. Molar) Permanent Arch
Lower Left (18)
1st Molar (6-yr. Molar) Permanent Arch
Lower Left (19)
2nd Molar (12-yr. Molar) Permanent Arch
Upper Right (2)
2nd Bicuspid (2nd Premolar) Permanent
Arch Lower Left (20)
1st Bicuspid (1st Premolar) Permanent
Arch Lower Left (21)
Cuspid (canine/eye Tooth) Permanent
Arch Lower Left (22)
Lateral Incisor Permanent Arch Lower
Left (23)
Central Incisor Permanent Arch Lower
Left (24)
Central Incisor Permanent Arch Lower
Right (25)
Lateral Incisor Permanent Arch Lower
Right (26)
Cuspid (canine/eye Tooth) Permanent
Arch Lower Right (27)
1st Bicuspid (1st Premolar) Permanent
Arch Lower Right (28)
2nd Bicuspid (2nd Premolar) Permanent
Arch Lower Right (29)
1st Molar (6-yr. Molar) Permanent Arch
Upper Right (3)
1st Molar (6-yr. Molar) Permanent Arch
Lower Right (30)
2nd Molar (12-yr. Molar) Permanent Arch
Lower Right (31)
3rd Molar (wisdom Tooth) Permanent
Arch Lower Right (32)
2nd Bicuspid (2nd Premolar) Permanent
Arch Upper Right (4)
1st Bicuspid (1st Premolar) Permanent
Arch Upper Right (5)
Supernumerary 3rd Molar (wisdom
Tooth) Permanent Arch Upper Right (51)
Supernumerary 2nd Molar (12-yr. Molar)
Permanent Arch Upper Right (52)
Supernumerary 1st Molar (6-yr. Molar)
Permanent Arch Upper Right (53)
Supernumerary 2nd Bicuspid (2nd
Premolar) Permanent Arch Upper Right
(54)
Supernumerary 1st Bicuspid (1st
Premolar) Permanent Arch Upper Right
(55)
Supernumerary Cuspid (canine/eye
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Tooth) Permanent Arch Upper Right (56)
Supernumerary Lateral Incisor
Permanent Arch Upper Right (57)
Supernumerary Central Incisor
Permanent Arch Upper Right (58)
Supernumerary Central Incisor
Permanent Arch Upper Left (59)
Cuspid (canine/eye Tooth) Permanent
Arch Upper Right (6)
Supernumerary Lateral Incisor
Permanent Arch Upper Left (60)
Supernumerary Cuspid (canine/eye
Tooth) Permanent Arch Upper Left (61)
Supernumerary 1st Bicuspid (1st
Premolar) Permanent Arch Upper Left
(62)
Supernumerary 2nd Bicuspid (2nd
Premolar) Permanent Arch Upper Left
(63)
Supernumerary 1st Molar (6-yr. Molar)
Permanent Arch Upper Left (64)
Supernumerary 2nd Molar (12-yr. Molar)
Permanent Arch Upper Left (65)
Supernumerary 3rd Molar (wisdom
Tooth) Permanent Arch Upper Left (66)
Supernumerary 3rd Molar (wisdom
Tooth) Permanent Arch Lower Left (67)
Supernumerary 2nd Molar (12-yr. Molar)
Permanent Arch Lower Left (68)
Supernumerary 1st Molar (6-yr. Molar)
Permanent Arch Lower Left (69)
Lateral Incisor Permanent Arch Upper
Right (7)
Supernumerary 2nd Bicuspid (2nd
Premolar) Permanent Arch Lower Left
(70)
Supernumerary 1st Bicuspid (1st
Premolar) Permanent Arch Lower Left
(71)
Supernumerary Cuspid (canine/eye
Tooth) Permanent Arch Lower Left (72)
Supernumerary Lateral Incisor
Permanent Arch Lower Left (73)
Supernumerary Central Incisor
Permanent Arch Lower Left (74)
Supernumerary Central Incisor
Permanent Arch Lower Right (75)
Supernumerary Lateral Incisor
Permanent Arch Lower Right (76)
Supernumerary Cuspid (canine/eye
Tooth) Permanent Arch Lower Right (77)
Supernumerary 1st Bicuspid (1st
Premolar) Permanent Arch Lower Right
(78)
Supernumerary 2nd Bicuspid (2nd
Premolar) Permanent Arch Lower Right
(79)
Central Incisor Permanent Arch Upper
Right (8)
Supernumerary 1st Molar (6-yr. Molar)
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Permanent Arch Lower Right (80)
Supernumerary 2nd Molar (12-yr. Molar)
Permanent Arch Lower Right (81)
Supernumerary 3rd Molar (wisdom
Tooth) Permanent Arch Lower Right (82)
Central Incisor Permanent Arch Upper
Left (9)
Second Molar Primary Arch Upper Right
(A)
Supernumerary Second Molar Primary
Arch Upper Right (AS)
First Molar Primary Arch Upper Right (B)
Supernumerary First Molar Primary Arch
Upper Right (BS)
Canine(cuspid) Primary Arch Upper
Right (C)
Supernumerary Canine(cuspid) Primary
Arch Upper Right (CS)
Lateral Incisor Primary Arch Upper Right
(D)
Supernumerary Lateral Incisor Primary
Arch Upper Right (DS)
Central Incisor Primary Arch Upper Right
(E)
Supernumerary Central Incisor Primary
Arch Upper Right (ES)
Central Incisor Primary Arch Upper Left
(F)
Supernumerary Central Incisor Primary
Arch Upper Left (FS)
Lateral Incisor Primary Arch Upper Left
(G)
Supernumerary Lateral Incisor Primary
Arch Upper Left (GS)
Canine (cuspid) Primary Arch Upper Left
(H)
Supernumerary Canine (cuspid) Primary
Arch Upper Left (HS)
First Molar Primary Arch Upper Left (I)
Supernumerary First Molar Primary Arch
Upper Left (IS)
Second Molar Primary Arch Upper Left
(J)
Supernumerary Second Molar Primary
Arch Upper Left (JS)
Second Molar Primary Arch Lower Left
(K)
Supernumerary Second Molar Primary
Arch Lower Left (KS)
First Molar Primary Arch Lower Left (L)
Supernumerary First Molar Primary Arch
Lower Left (LS)
Canine (cuspid) Primary Arch Lower Left
(M)
Supernumerary Canine (cuspid) Primary
Arch Lower Left (MS)
Lateral Incisor Primary Arch Lower Left
(N)
Supernumerary Lateral Incisor Primary
Arch Lower Left (NS)
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Central Incisor Primary Arch Lower Left
(O)
Supernumerary Central Incisor Primary
Arch Lower Left (OS)
Central Incisor Primary Arch Lower Right
(P)
Supernumerary Central Incisor Primary
Arch Lower Right (PS)
Lateral Incisor Primary Arch Lower Right
(Q)
Supernumerary Lateral Incisor Primary
Arch Lower Right (QS)
Canine (cuspid) Primary Arch Lower
Right (R)
Supernumerary Canine (cuspid) Primary
Arch Lower Right (RS)
First Molar Primary Arch Lower Right (S)
Supernumerary First Molar Primary Arch
Lower Right (SS)
Second Molar Primary Arch Lower Right
(T)
Supernumerary Second Molar Primary
Arch Lower Right (TS)
Tooth quadrant
Lower Left Quadrant (Lower Left)
Lower Right Quadrant (Lower Right)
Upper Left Quadrant (Upper Left)
Upper Right Quadrant (Upper Right)
What was the date of theradiograph (If yes, -
Referring Question is in prior Module Is/Are the
radiographic depths of the lesions, when visible,
less than or equal to half the Dento-Enamel
Junction DEJ to the pulp?)
Inclusion Criteria (cont.2)
Is/Are the protocol tooth/teeth in occlusion with a
natural tooth
Yes
No
Would a resin-based composite restoration be
the standard of care for the lesion(s)
Yes
No
Is/Are the protocol tooth/teeth free of evidence of
a pulpitis (no report of lingering pain associated
with any stimulus)
Yes
No
Is the subject available for contact for at least four
weeks post-treatment
Yes
No
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Has the subject signed and dated the IRB-
approved informed consent form or assent form
for individuals under 18 years old
Yes
No
Date of signed, witnessed, and dated informed
consent/assent
Exclusion Criteria (all Responses Must Be
Checked "no" To Be Eligible)
Is/Are the protocol tooth/teeth periodontally
involved (mobility of 2 or greater or inflamed
gingival tissues)
Yes
No
Does/Do the protocol tooth/teeth have existing
restoration(s)
Yes
No
Has/Have the protocol tooth/teeth been clinically
assessed to be fractured
Yes
No
Is/Are the protocol tooth/teeth an abutment(s) for
a removable partial denture
Yes
No
Does/Do the protocol tooth/teeth have
subgingival calculus(eligible if removed during the
treatment visit)
Yes
No
Is the subject undergoing active orthodontic
treatment other than the use of a retainer
Yes
No
Is the subject currently enrolled or have they
completed in the past month a tooth bleaching
program
Yes
No
Has the subject had a prior reaction or have an
inability to tolerate any of the dental products
being used (such as severe topical or
hypersensitivity reaction)
Yes
No
Is the subject under treatment for medical
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disorders including dementia, Parkinson's
disease, severe depression, severe anxiety, and
any other medical condition that, in the opinion of
the P-I, would affect the subject's judgment of
post-operative hypersensitivity and/or ability to
understand the informed consent process
Yes
No
Is the subject in another ongoing dental research
study
Yes
No
Footer Module
Preferred method of contact
E-mail (E-mail)
Telephone (Phone)
Comments
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Breast Cancer NCT00433511 Eligibility - E5103
Registration Worksheet (step 2) - 2746746v1.0
E5103 Registration Worksheet (step 2)
Doxorubicin, Cyclophosphamide, and Paclitaxel With or
Without Bevacizumab in Treating Patients With Lymph
Node-Positive or High-Risk, Lymph Node-Negative Breast
Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=4C815F91-
A867-3175-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/8685
E5103 Registration Worksheet (step
2)
Eligibility
First initial
Last initial
Has the eligibility checklist been completed
Yes
No
In the opinion of the investigator, is the patient
eligible?
Yes
No
Did the patient receive treatment Arm C on step 1
of treatment?
Yes
No
Patient Weight (kg)
Patient weight (lb)
Do you wish to use an express carrier to ship the
drugs (at your expense)?
No (no)
Unknown (unknown)
Yes (yes)
Name of express carrier
Airborne Express (Airborne Express)
Dhl (DHL)
Federal Express (Federal Express)
Other (Other)
Unknown (Unknown)
Ups (UPS)
Express account number
Contact person for drug ordering
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Phone
E-mail address
Patient's ECOG sequence number
Patient Demographics / Pre-treatment
Characteristics
Patient's Sex
Female (F)
Male (M)
Birthdate (mm/yy)
Patient Race (check all that applyU.S. and
Canada only)
A Person Having Origins In Any Of The
Original Peoples Of North And South
America (including Central America),
And Who Maintains Tribal Affiliation Or
Community Attachment. (American
Indian or Alaska Native)
A Person Having Origins In Any Of The
Original Peoples Of The Far East,
Southeast Asia, Or The Indian
Subcontinent Including, For Example,
Cambodia, China, India, Japan, Korea,
Malaysia, Pakistan, The Philippine
Islands, Thailand, And Vietnam. (Asian)
A Person Having Origins In Any Of The
Black Racial Groups Of Africa. Terms
Such As "haitian" Or "negro" Can Be
Used In Addition To "black Or African
American." (Black or African American)
A Person Having Origins In Any Of The
Original Peoples Of Hawaii, Guam,
Samoa, Or Other Pacific Islands. (Native
Hawaiian or other Pacific Islander)
Not Provided Or Available (Not
Reported)
Could Not Be Determined Or Unsure
(Unknown)
A Person Having Origins In Any Of The
Original Peoples Of Europe, The Middle
East, Or North Africa. (White)
ZIP Code
Patient Ethnicity
A Person Of Mexican, Puerto Rican,
Cuban, Central Or South American Or
Other Spanish Culture Or Origin,
Regardless Of Race. (Hispanic or Latino)
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A Person Not Meeting The Definition For
Hispanic Or Latino. (Not Hispanic or
Latino)
Not Provided Or Available (Not reported)
Could Not Be Determined Or Unsure
(Unknown)
Patient Hospital No.
Patient Social Security Number
Method of payment (check one)
Medicaid (Medicaid)
Medicaid And Medicare (Medicaid and
Medicare)
Medicare (Medicare)
Medicare And Private Insurance
(Medicare and Private Insurance)
Military Or Veterans Sponsored Nos
(Military or Veterans Sponsored, Not
Otherwise Specified (NOS))
Military Sponsored (including Champus
& Tricare) (Military Sponsored (including
CHAMPUS & TRICARE))
National Health Service (National Health
Service)
No Means Of Payment (no Insurance)
(No means of payment (no insurance))
Other (Other)
Private Insurance (Private Insurance)
Self Pay (no Insurance) (Self Pay (No
Insurance))
Unknown (Unknown)
Veterans Sponsored (Veterans
Sponsored)
Attending Physician
Institution contact
Registrar
Country of Residence
Comments
Signature of treating physician (I have reviewed
the above data and agree the date are accurate
and correct)
Date (Note: Date must be on or before date of
registration)
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Breast Cancer NCT00520975 Eligibility - E1105
Registration Worksheet (step 1) - 2762341v1.0
E1105 Registration Worksheet (step 1)
First-Line Chemotherapy and Trastuzumab With or Without
Bevacizumab in Treating Patients With Metastatic Breast
Cancer That Overexpresses HER-2/NEU
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=510E74ED-
19F1-52F7-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/8688
E1105 Registration Worksheet (step
1)
Eligibility
First initial
Last initial
Has the eligibility checklist been completed
Yes
No
In the opinion of the investigator, is the patient
eligible?
Yes
No
Has written informed consent been obtained
Yes
No
Date Informed Consent Signed
Has HIPAA authorization been obtained
Exempt - Non-usa Participant (Exempt -
non-USA participant)
No: C49487 (No)
Yes: C49488 (Yes)
HIPAA Authorization Date
Prior adjuvant trastuzumab?
Yes
No
Prior Taxane Therapy
Yes
No
Disease Free Interval
Greater Than 24 Months (Greater than
24 months)
Less Than Or Equal To 24 Months (Less
than or equal to 24 months)
Carboplatin planned
Yes
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No
Principal Investigator
Phone
Fax Number
Email address
Senior Clinical Research Associate/Data
Manager
Phone
Fax Number
Email address
Patient Weight (kg)
Patient weight (Lb)
Do you wish to use an express carrier to ship the
drugs (at your expense)?
No (no)
Unknown (unknown)
Yes (yes)
Name of express carrier
Airborne Express (Airborne Express)
Dhl (DHL)
Federal Express (Federal Express)
Other (Other)
Unknown (Unknown)
Ups (UPS)
Express account number
Contact person for drug ordering
Phone
E-mail address
QOL contact person
Phone
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Email address
My specimens may be kept for use in research to
learn about, prevent, treat, or cure cancer.
Yes
No
My specimens may be kept for research about
other health problems (for example: causes of
diabetes, Alzheimer's disease, and heart
disease)
Yes
No
Someone may contact me in the future to ask me
to allow other uses of my specimens.
No (No)
Unknown (Unknown)
Yes (Yes)
Name of the contact person responsible for
sample submission
Phone number of the contact person responsible
for sample submission
Fax number of the contact person responsible for
sample submission
E-mail address of the contact person responsible
for sample submission
Patient Demographics / Pre-treatment
Characteristics
Patient's Sex
Female (F)
Male (M)
Birthdate (mm/yy)
Patient Race (check all that applyU.S. and
Canada only)
A Person Having Origins In Any Of The
Original Peoples Of North And South
America (including Central America),
And Who Maintains Tribal Affiliation Or
Community Attachment. (American
Indian or Alaska Native)
A Person Having Origins In Any Of The
Original Peoples Of The Far East,
Southeast Asia, Or The Indian
Subcontinent Including, For Example,
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Cambodia, China, India, Japan, Korea,
Malaysia, Pakistan, The Philippine
Islands, Thailand, And Vietnam. (Asian)
A Person Having Origins In Any Of The
Black Racial Groups Of Africa. Terms
Such As "haitian" Or "negro" Can Be
Used In Addition To "black Or African
American." (Black or African American)
A Person Having Origins In Any Of The
Original Peoples Of Hawaii, Guam,
Samoa, Or Other Pacific Islands. (Native
Hawaiian or other Pacific Islander)
Not Provided Or Available (Not
Reported)
Could Not Be Determined Or Unsure
(Unknown)
A Person Having Origins In Any Of The
Original Peoples Of Europe, The Middle
East, Or North Africa. (White)
ZIP Code
Patient Ethnicity
A Person Of Mexican, Puerto Rican,
Cuban, Central Or South American Or
Other Spanish Culture Or Origin,
Regardless Of Race. (Hispanic or Latino)
A Person Not Meeting The Definition For
Hispanic Or Latino. (Not Hispanic or
Latino)
Not Provided Or Available (Not reported)
Could Not Be Determined Or Unsure
(Unknown)
Patient Hospital No.
Patient Social Security Number
Method of payment (check one)
Medicaid (Medicaid)
Medicaid And Medicare (Medicaid and
Medicare)
Medicare (Medicare)
Medicare And Private Insurance
(Medicare and Private Insurance)
Military Or Veterans Sponsored Nos
(Military or Veterans Sponsored, Not
Otherwise Specified (NOS))
Military Sponsored (including Champus
& Tricare) (Military Sponsored (including
CHAMPUS & TRICARE))
National Health Service (National Health
Service)
No Means Of Payment (no Insurance)
(No means of payment (no insurance))
Other (Other)
Private Insurance (Private Insurance)
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Self Pay (no Insurance) (Self Pay (No
Insurance))
Unknown (Unknown)
Veterans Sponsored (Veterans
Sponsored)
Attending Physician
Institution contact
Registrar
Country of Residence
Comments
Signature of treating physician (I have reviewed
the above data and agree the date are accurate
and correct)
Date (Note: Date must be on or before date of
registration)
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Breast Cancer NCT00433511 Eligibility - E5103
Registration Worksheet (step 1) - 2746547v1.0
E5103 Registration Worksheet (step 1)
Doxorubicin, Cyclophosphamide, and Paclitaxel With or
Without Bevacizumab in Treating Patients With Lymph
Node-Positive or High-Risk, Lymph Node-Negative Breast
Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=4C7BBF65-
46E3-4B47-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/8694
E5103 Registration Worksheet (step
1)
Eligibility
First initial
Last initial
Has the eligibility checklist been completed
Yes
No
In the opinion of the investigator, is the patient
eligible?
Yes
No
Has written informed consent been obtained
Yes
No
Date Informed Consent Signed
Has HIPAA authorization been obtained
Exempt - Non-usa Participant (Exempt -
non-USA participant)
No: C49487 (No)
Yes: C49488 (Yes)
HIPAA Authorization Date
Is the tumor ER positive
Yes
No
Lymph Node Involvement
>=4 (>=4)
1-3 (1-3)
Negative (negative)
Type of surgery and planned radiotherapy
Breast Conserving Surgery Plus
Accelerated, Partial Breast Irradiation
Before And/or After Chemotherapy
(Breast conserving surgery (APBI
pre/post chemo))
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Breast Conserving Surgery Plus Whole
Breast Radiation Therapy (Breast
conserving surgery (WBRT))
Mastectomy With Either Local Or
Regional Rt (Mastectomy with either
local or regional RT)
Mastectomy Without Rt (Mastectomy
without RT)
AC shedule planned
Standard Chemotherapy Regimen
Delivered Every 3 Weeks (Classical -
every 3 weeks)
Dose Dense Chemotherapy Regimen
Administered Every 2 Weeks (Dose
dense - every 2 weeks)
Principal Investigator
Phone
Fax Number
Email address
Senior Clinical Research Associate/Data
Manager
Phone
Fax Number
Email address
Patient Weight (kg)
Patient weight (lb)
Do you wish to use an express carrier to ship the
drugs (at your expense)?
No (no)
Unknown (unknown)
Yes (yes)
Name of express carrier
Airborne Express (Airborne Express)
Dhl (DHL)
Federal Express (Federal Express)
Other (Other)
Unknown (Unknown)
Ups (UPS)
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Express account number
Contact person for drug ordering
Phone
E-mail address
QOL contact person
Phone
Email address
I agree to participate in the laboratory research
studies that are being done as part of this clinical
trial.
Yes
No
I agree to provide additional blood for research.
Yes
No
I agree to provide urine for research.
Yes
No
My specimens may be kept for use in research to
learn about, prevent, treat, or cure cancer.
Yes
No
My specimens may be kept for research about
other health problems (for example: causes of
diabetes, Alzheimer's disease, and heart
disease)
Yes
No
Someone from this institution may contact me in
the future to ask me to take part in more
research.
Yes
No
Name of the contact person responsible for
sample submission
Phone number of the contact person responsible
for sample submission
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Fax number of the contact person responsible for
sample submission
E-mail address of the contact person responsible
for sample submission
Patient Demographics / Pre-treatment
Characteristics
Patient's Sex
Female (F)
Male (M)
Birthdate (mm/yy)
Patient Race (check all that applyU.S. and
Canada only)
A Person Having Origins In Any Of The
Original Peoples Of North And South
America (including Central America),
And Who Maintains Tribal Affiliation Or
Community Attachment. (American
Indian or Alaska Native)
A Person Having Origins In Any Of The
Original Peoples Of The Far East,
Southeast Asia, Or The Indian
Subcontinent Including, For Example,
Cambodia, China, India, Japan, Korea,
Malaysia, Pakistan, The Philippine
Islands, Thailand, And Vietnam. (Asian)
A Person Having Origins In Any Of The
Black Racial Groups Of Africa. Terms
Such As "haitian" Or "negro" Can Be
Used In Addition To "black Or African
American." (Black or African American)
A Person Having Origins In Any Of The
Original Peoples Of Hawaii, Guam,
Samoa, Or Other Pacific Islands. (Native
Hawaiian or other Pacific Islander)
Not Provided Or Available (Not
Reported)
Could Not Be Determined Or Unsure
(Unknown)
A Person Having Origins In Any Of The
Original Peoples Of Europe, The Middle
East, Or North Africa. (White)
ZIP Code
Patient Ethnicity
A Person Of Mexican, Puerto Rican,
Cuban, Central Or South American Or
Other Spanish Culture Or Origin,
Regardless Of Race. (Hispanic or Latino)
A Person Not Meeting The Definition For
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Hispanic Or Latino. (Not Hispanic or
Latino)
Not Provided Or Available (Not reported)
Could Not Be Determined Or Unsure
(Unknown)
Patient Hospital No.
Patient Social Security Number
Method of payment (check one)
Medicaid (Medicaid)
Medicaid And Medicare (Medicaid and
Medicare)
Medicare (Medicare)
Medicare And Private Insurance
(Medicare and Private Insurance)
Military Or Veterans Sponsored Nos
(Military or Veterans Sponsored, Not
Otherwise Specified (NOS))
Military Sponsored (including Champus
& Tricare) (Military Sponsored (including
CHAMPUS & TRICARE))
National Health Service (National Health
Service)
No Means Of Payment (no Insurance)
(No means of payment (no insurance))
Other (Other)
Private Insurance (Private Insurance)
Self Pay (no Insurance) (Self Pay (No
Insurance))
Unknown (Unknown)
Veterans Sponsored (Veterans
Sponsored)
Attending Physician
Institution contact
Registrar
Country of Residence
Comments
Signature of treating physician (I have reviewed
the above data and agree the date are accurate
and correct)
Date (Note: Date must be on or before date of
registration)
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Esophageal Cancer NCT00757172 Registration - ACOSOG-
Z4051 OPEN Registration Worksheet - 3013492v1.0
ACOSOG-Z4051 OPEN Registration Worksheet
Panitumumab, Docetaxel, Cisplatin, Radiation Therapy, and
Surgery in Treating Patients With Newly Diagnosed, Locally
Advanced Esophageal Cancer or Cancer of the
Gastroesophageal Junction
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=7FFA1514-
8109-A58F-E040-BB89AD4376E5
All rights reserved. Please visit https://medical-data-
models.org/forms/8696
ACOSOG-Z4051 OPEN Registration
Worksheet
Patient Information
Date of Birth (month day year)
Gender of a Person
Female Gender (Female Gender)
Male Gender (Male Gender)
Unknown (Unknown)
Ethnicity
A Person Of Mexican, Puerto Rican,
Cuban, Central Or South American Or
Other Spanish Culture Or Origin,
Regardless Of Race. (Hispanic or Latino)
A Person Not Meeting The Definition For
Hispanic Or Latino. (Not Hispanic or
Latino)
Not Provided Or Available (Not reported)
Country of Residence
Zip code
Race
A Person Having Origins In Any Of The
Original Peoples Of North And South
America (including Central America),
And Who Maintains Tribal Affiliation Or
Community Attachment. (American
Indian or Alaska Native)
A Person Having Origins In Any Of The
Original Peoples Of The Far East,
Southeast Asia, Or The Indian
Subcontinent Including, For Example,
Cambodia, China, India, Japan, Korea,
Malaysia, Pakistan, The Philippine
Islands, Thailand, And Vietnam. (Asian)
A Person Having Origins In Any Of The
Black Racial Groups Of Africa. Terms
Such As "haitian" Or "negro" Can Be
Used In Addition To "black Or African
American." (Black or African American)
A Person Having Origins In Any Of The
Original Peoples Of Hawaii, Guam,
Samoa, Or Other Pacific Islands. (Native
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Hawaiian or other Pacific Islander)
Not Provided Or Available (Not
Reported)
Could Not Be Determined Or Unsure
(Unknown)
A Person Having Origins In Any Of The
Original Peoples Of Europe, The Middle
East, Or North Africa. (White)
Method of Payment
Medicaid (Medicaid)
Medicaid And Medicare (Medicaid and
Medicare)
Medicare (Medicare)
Medicare And Private Insurance
(Medicare and Private Insurance)
Military Or Veterans Sponsored Nos
(Military or Veterans Sponsored, Not
Otherwise Specified (NOS))
Military Sponsored (including Champus
& Tricare) (Military Sponsored (including
CHAMPUS & TRICARE))
No Means Of Payment (no Insurance)
(No means of payment (no insurance))
Other (Other)
Private Insurance (Private Insurance)
Self Pay (no Insurance) (Self Pay (No
Insurance))
Unknown (Unknown)
Veterans Sponsored (Veterans
Sponsored)
General Information
Pt ID# (Local Patient Identifier)
Last (initial)
First (initial)
Middle (initial optional)
E-mail (for Registration Confirmation)
Has patient previously been registered to an
ACOSOG study
Yes
No
Coordinating Group Patient ID (if yes previously
issued ACOSOG Patient ID)
Date Informed Consent Signed (month day year)
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Was HIPAA Authorization included in Study
Informed Consent
Yes
No
HIPAA Authorization Date (If no month day year)
Eligibility Criteria
Age >= 18 years
Yes
No
ECOG Performance Status 0-1 (Zubrod)
Yes
No
ECOG Performance Status (Zubrod 0 or 1)
Fully Active, Able To Carry On All Pre-
disease Performance Without
Restriction. (0)
Restricted In Physically Strenuous
Activity But Ambulatory And Able To
Carry Out Work Of A Light Or Sedentary
Nature, E.g., Light Housework, Office
Work. (1)
Biopsy-proven resectable primary (nonrecurrent)
adenocarcinoma of the distal esophagus or GE
junction (Siewert Type I or II)
Yes
No
Pre-registration EUS, CT of chest and upper
abdomen, and PET must support a clinical stage
of T3N0M0, T2-3N1M0 or T2-3N0-1M1a (celiac
adenopathy must be <=2 cm by EUS) (Clinically
staged T1 tumors and T2N0M0 tumors are not
eligible. N1 does not require biopsy/FNA. Note:
Patients requiring a stent for nutrition must have
staging examinations and scans completed
before stent placement)
Yes
No
No definitive radiological evidence of distant
metastases
Yes
No
No pre-existing grade 2 or greater peripheral
neuropathy (CTCAE V3) of any etiology
Yes
No
WBC >= 3000/mm^3
Yes
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No
WBC (>= 3000)
ANC >= 1,500/mm^3
Yes
No
ANC (>= 1500)
Hemoglobin >= 9.5 g/dL
Yes
No
Hemoglobin (>= 9.5)
Platelet count >= 100,000/mm^3
Yes
No
Platelet count (>= 100000)
Creatinine <= 1.5 mg/dL
Yes
No
Creatinine (<= 1.5)
Total bilirubin <= 3 mg/dL
Yes
No
Total Bilirubin (<= 3)
SGOT (AST) <= 2.0 times ULN
Yes
No
SGOT (AST) (<= 2.0 x ULN)
SGOT (AST) ULN
SGPT (ALT) <= 2.0 times ULN
Yes
No
SGPT (ALT) (<= 2.0 x ULN)
SGPT (ALT) ULN
Alkaline phosphatase <= 2.0 times ULN
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Yes
No
Alkaline Phosphatase (<= 2.0 x ULN)
Alkaline Phosphatase ULN
Albumin >= 2.0 g/dL or prealbumin >= 15 mg/dL
Yes
No
Albumin (>= 2.0 OR)
Prealbumin (>= 15)
Magnesium >= LLN
Yes
No
Magnesium (>= LLN)
Magnesium, LLN
Patient must be evaluated before registration by
medical oncologist, radiation oncologist and
surgeon and deemed fit for protocol therapy and
surgery
Yes
No
No prior invasive malignancy, unless disease-free
for >= 5 years (Exceptions: non-melanoma skin
cancer, in-situ cancers)
Yes
No
Non-pregnant and non-breast-feeding (Female
participants of child-bearing potential must have
a negative urine or serum pregnancy test prior to
registration. Perimenopausal participants must be
amenorrheic >= 12 months to be considered not
of childbearing potential. All patients of
reproductive potential must agree to use an
effective method of birth-control while receiving
study therapy and for six months after completion
of therapy. If not a female of child-bearing
potential or male check NA)
N/a (N/A)
No (No)
Yes (Yes)
Negative pregnancy test date (If female of child-
bearing potential urine or serum mm/dd/yyyy)
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No prior chest or upper abdomen radiotherapy;
prior therapy with cisplatin, docetaxel,
panitumumab or other anti-EGFR therapy; or
prior esophageal or gastric surgery (Exception:
prior surgery to treat reflux disease)
Yes
No
No uncontrolled intercurrent illness including, but
not limited to, ongoing or active infection,
symptomatic congestive heart failure, unstable
angina pectoris, cardiac arrhythmia, or psychiatric
illness/social situations that would limit
compliance with study requirements
Yes
No
No history of interstitial lung disease e.g.
pneumonitis or pulmonary fibrosis or any
evidence of interstitial lung disease on baseline
chest CT scan
Yes
No
No history of any medical or psychiatric condition
or laboratory abnormality that in the opinion of
the investigator may increase the risks
associated with the study participation or
investigational product(s) administration or may
interfere with the interpretation of the results
Yes
No
Specimen Banking Consent
Patient has given permission to collect and keep
blood specimens for use in this research study
Yes
No
Patient has given permission to collect and keep
tissue specimens for use in this research study
Yes
No
Patient has given permission to keep blood and
tissue specimens for use in future research to
learn about, prevent or treat cancer
Yes
No
Patient has given permission to keep blood and
tissue specimens for use in future research to
learn about, prevent or treat other health
problems (for example: diabetes, Alzheimer's
disease, or heart disease)
Yes
No
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Patient has given permission to keep blood and
tissue specimens for use in future genetic
research
Yes
No
Patient has given permission to be contacted in
the future to take part in more research
Yes
No
7 / 7
Esophageal Cancer NCT00757172 Registration - ACOSOG-Z4051
OPEN Registration Worksheet - 3013492v1.0
Breast Cancer NCT00769379 Registration - NSABP Protocol
B-43 - Protocol Entry Form Worksheet - 2679593v1.0
NSABP Protocol B-43 - Protocol Entry Form Worksheet
Radiation Therapy With or Without Trastuzumab in Treating
Women With Ductal Carcinoma In Situ Who Have
Undergone Lumpectomy
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=39C95E6B-
CA7A-3A5C-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/8697
NSABP Protocol B-43 - Protocol
Entry Form Worksheet
Header
Last
First
Middle
Site Name
Patient Birth Date
Treating physician
Patient Social Security Number (USA Only)
Race
Race
A Person Having Origins In Any Of The
Original Peoples Of North And South
America (including Central America),
And Who Maintains Tribal Affiliation Or
Community Attachment. (American
Indian or Alaska Native)
A Person Having Origins In Any Of The
Original Peoples Of The Far East,
Southeast Asia, Or The Indian
Subcontinent Including, For Example,
Cambodia, China, India, Japan, Korea,
Malaysia, Pakistan, The Philippine
Islands, Thailand, And Vietnam. (Asian)
A Person Having Origins In Any Of The
Black Racial Groups Of Africa. Terms
Such As "haitian" Or "negro" Can Be
Used In Addition To "black Or African
American." (Black or African American)
A Person Having Origins In Any Of The
Original Peoples Of Hawaii, Guam,
Samoa, Or Other Pacific Islands. (Native
Hawaiian or other Pacific Islander)
Not Provided Or Available (Not
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Reported)
Could Not Be Determined Or Unsure
(Unknown)
A Person Having Origins In Any Of The
Original Peoples Of Europe, The Middle
East, Or North Africa. (White)
Person Completing Form, Last Name
Method of Payment (mark primary method only)
Medicaid (Medicaid)
Medicaid And Medicare (Medicaid and
Medicare)
Medicare (Medicare)
Medicare And Private Insurance
(Medicare and Private Insurance)
Military Or Veterans Sponsored Nos
(Military or Veterans Sponsored, Not
Otherwise Specified (NOS))
Military Sponsored (including Champus
& Tricare) (Military Sponsored (including
CHAMPUS & TRICARE))
No Means Of Payment (no Insurance)
(No means of payment (no insurance))
Other (Other)
Private Insurance (Private Insurance)
Self Pay (no Insurance) (Self Pay (No
Insurance))
Unknown (Unknown)
Veterans Sponsored (Veterans
Sponsored)
Ethnicity
A Person Of Mexican, Puerto Rican,
Cuban, Central Or South American Or
Other Spanish Culture Or Origin,
Regardless Of Race. (HISPANIC OR
LATINO)
A Person Not Meeting The Definition For
Hispanic Or Latino. (NOT HISPANIC OR
LATINO)
Could Not Be Determined Or Unsure
(UNKNOWN)
Country of Residence (if not USA)
Canada (CA)
Other (Other)
Puerto Rico (PR)
Usa (US)
Country of Residence (Other)
Patient Zip Code (USA)
Receptor Status
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Receptor Status, ER
Negative (Negative)
Positive (Positive)
Unknown (Unknown)
Receptor Status, PgR
Negative (Negative)
Positive (Positive)
Unknown (Unknown)
Treatment
Nuclear Grade
High (High)
Intermediate (Intermediate)
Low (Low)
Plan for hormonal therapy
Yes
No
Patient Characteristics
Patient Height
Patient Weight
Unnamed4
Date Informed Consent Signed
Did patient consent to future contact about more
research?
Yes
No
Has the patient authorized the release of
Protected Health Information to the NSABP?
No: C49487 (No)
Not Applicable (Not Applicable)
Yes: C49488 (Yes)
In the opinion of the investigator, is the patient
eligible?
Yes
No
NSABP Specimen ID for Central Testing
Determination Of Pre-entry Menopausal
Status
Prior documented bilateral oophorectomy
Yes
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No
History of at least 12 months without
spontaneous menstrual bleeding
Yes
No
Age 55 or older with a prior hysterectomy
Yes
No
Age 54 or younger with a prior hysterectomy
without oophorectomy (or in whom the status of
the ovaries is unknown), with a documented FSH
level demonstrating confirmatory elevation in the
lab's postmenopausal range
Yes
No
Is the patient postmenopausal
Yes
No
Date of Onset of Most Recent Menstrual Period
(If premenopausal,)
Footer Module
Person Completing Form
Date Form Completed
NSABP Patient ID
4 / 4
Breast Cancer NCT00769379 Registration - NSABP Protocol B-43 -
Protocol Entry Form Worksheet - 2679593v1.0
Esophageal Cancer NCT00655876 Treatment - TF: Radiation Therapy Oncology
Group Phase III Esophagus Systemic Treatment Summary Form - 2598533v1.0
TF: Radiation Therapy Oncology Group Phase III
Esophagus Systemic Treatment Summary Form
Paclitaxel, Cisplatin, and Radiation Therapy With or Without
Cetuximab in Treating Patients With Locally Advanced
Esophageal Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=2A02FE34-
6EF5-5B5C-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/8698
TF: Radiation Therapy Oncology
Group Phase III Esophagus
Systemic Treatment Summary Form
Module 1
RTOG Study No.
Case #
Institution
Institution No.
Patient Initials
RTOG Patient ID
AMENDED DATA
Yes
No
Patient Characteristics
Height (cm)
Weight (kg)
BSA (m2)
Was dose modified due to weight loss
Yes
No
Day the dose was modified
Day #1 (Day #1)
Day #15 (Day #15)
Day #22 (Day #22)
Day #29 (Day #29)
Day #36 (Day #36)
Day #8 (Day #8)
Unnamed Module 1
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Agent Name
Agent Start Date
Agent End Date
Total No. of Doses
Day #1
Day #8
Day #15
Day #22
Day #29
Day #36
Agent Total Cumulative Dose
Units
Milligram (mg)
Were there any dose modifications or
additions/omissions to protocol treatment?
No (No)
Unknown (Unknown)
Yes, Planned (i.e., The Treatment Was
Changed According To Protocol
Guidelines) (Yes, planned)
Yes, Unplanned (i.e., The Treatment
Change Was Not Part Of Protocol
Guidelines) (Yes, unplanned)
Reason Treatment Ended
Adverse Event/side Effects/complications
(Adverse Event/Side
Effects/Complications)
Alternative Therapy (Alternative therapy)
Death On Study (Death on study)
Disease Progression, Relapse During
Active Treatment (Disease progression,
relapse during active treatment)
Other (Other)
Patient Off-treatment For Other
Complicating Disease (Patient off-
treatment for other complicating disease)
Patient Withdrawal Or Refusal After
Beginning Protocol Therapy (Patient
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withdrawal/refusal after beginning
protocol therapy)
Patient Withdrawal Or Refusal Before
Beginning Protocol Therapy (Patient
withdrawal/refusal prior to beginning
protocol therapy)
Treatment Completed Per Protocol
Criteria (Treatment completed per
protocol criteria)
Alternative therapy, specify alternative therapy
Other specify
Report All Continuing Or New Adverse
Events
MedDRA Code
MedDRA Code
CTC AE Term
Acidosis Nos (Acidosis (metabolic or
respiratory))
Capillary Leak Syndrome (Acute
vascular leak syndrome)
Adrenal Insufficiency (Adrenal
insufficiency)
Adult Respiratory Distress Syndrome
(Adult respiratory distress syndrome
(ARDS))
Blood Albumin Decreased (Albumin,
serum-low (hypoalbuminemia))
Alcohol Intolerance Syndrome
(antabuse-like Syndrome) (Alcohol
intolerance syndrome (antabuse-like
syndrome))
Blood Alkaline Phosphatase Nos
Increased (Alkaline phosphatase)
Alkalosis Nos (Alkalosis (metabolic or
respiratory))
Hypersensitivity Nos (Allergic
reaction/hypersensitivity (including drug
fever))
Rhinitis Allergic Nos (Allergic rhinitis
(including sneezing, nasal stuffiness,
postnasal drip))
Allergy/immunology Other
(Allergy/Immunology-Other (Specify))
Alanine Aminotransferase Increased
(ALT, SGPT (serum glutamic pyruvic
transaminase))
Blood Amylase Increased (Amylase)
Anorexia (Anorexia)
Apnoea (Apnea)
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Arachnoiditis
(Arachnoiditis/meningismus/radiculitis)
Arthritis Nos (Arthritis (non-septic))
Ascites (Ascites (non-malignant))
Aspiration (Aspiration)
Aspartate Aminotransferase Increased
(AST, SGOT (serum glutamic oxaloacetic
transaminase))
Ataxia Nec (Ataxia (incoordination))
Atelectasis (Atelectasis)
Atrophy, Skin (Atrophy, skin)
Atrophy, Subcutaneous Fat (Atrophy,
subcutaneous fat)
Auditory/ear Other (Auditory/Ear-Other
(Specify))
Autoimmune Disorder Nos (Autoimmune
reaction)
Blood Bicarbonate Decreased
(Bicarbonate, serum-low)
Blood Bilirubin Increased (Bilirubin
(hyperbilirubinemia))
Bladder Disorder Nos (Bladder spasms)
Blood/bone Marrow Other (Blood/Bone
Marrow-Other (Specify))
Bone Age (alteration In Bone Age) (Bone
age (alteration in bone age))
Bone Growth: Femoral Head; Slipped
Capital Femoral Epiphysis (Bone growth:
femoral head; slipped capital femoral
epiphysis)
Bone Growth: Limb Length Discrepancy
(Bone growth: limb length discrepancy)
Bone Growth: Spine Kyphosis/lordosis
(Bone growth: spine kyphosis/lordosis)
Bone Marrow Depression Nos (Bone
marrow cellularity)
Bone: Spine-scoliosis (Bone: spine-
scoliosis)
Brachial Plexopathy (Brachial
plexopathy)
Breast Function/lactation (Breast
function/lactation)
Breast Nipple/areolar Deformity (Breast
nipple/areolar deformity)
Breast Volume/hypoplasia (Breast
volume/hypoplasia)
Bronchospasm, Wheezing
(Bronchospasm, wheezing)
Ecchymosis (Bruising (in absence of
grade 3 or 4 thrombocytopenia))
Burn (Burn)
Hypercalcaemia (Calcium, serum-high
(hypercalcemia))
Hypocalcaemia (Calcium, serum-low
(hypocalcemia))
Pulmonary Function Test Nos Decreased
(Carbon monoxide diffusion capacity
(DL(co)))
Arrhythmia Nos (Cardiac Arrhythmia-
Other (Specify))
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Cardiac General Other (Cardiac
General-Other (Specify))
Myocardial Ischaemia (Cardiac
ischemia/infarction)
Cardiac Troponin I Increased (Cardiac
troponin I (cTnI))
Cardiac Troponin T Increased (Cardiac
troponin T (cTnT))
Cardiopulmonary Arrest, Cause
Unknown (non-fatal) (Cardiopulmonary
arrest, cause unknown (non-fatal))
Cataract Nec (Cataract)
Cd4 Lymphocytes Decreased (CD4
count)
Cervical Spine-range Of Motion (Cervical
spine-range of motion)
Chelitis (Cheilitis)
Cholecystitis (Cholecystitis)
Hypercholesteraemia (Cholesterol,
serum-high (hypercholesteremia))
Chyle Or Lymph Leakage (Chyle or
lymph leakage)
Chylothorax (Chylothorax)
Cerebral Ischaemia (CNS
cerebrovascular ischemia)
Cns Necrosis/cystic Progression (CNS
necrosis/cystic progression)
Coagulation Disorder Nos (Coagulation-
Other (Specify))
Learning Disorder Nos (Cognitive
disturbance)
Colitis Nos (Colitis)
Colitis, Infectious (e.g., Clostridium
Difficile) (Colitis, infectious (e.g.,
Clostridium difficile))
Ventricular Asystole (Conduction
abnormality/Atrioventricular heart block -
Asystole)
Conduction Abnormality/atrioventricular
Heart Block (Conduction
abnormality/Atrioventricular heart block -
AV block-first degree)
Conduction Abnormality/atrioventricular
Heart Block - Av Block-second Degree
Mobitz Type I (wenckebach) (Conduction
abnormality/Atrioventricular heart block -
AV block-Second degree Mobitz Type I
(Wenckebach))
Conduction Abnormality/atrioventricular
Heart Block (Conduction
abnormality/Atrioventricular heart block -
AV block-second degree Mobitz Type II)
Conduction Abnormality/atrioventricular
Heart Block (Conduction
abnormality/Atrioventricular heart block -
AV block-third degree (complete AV
block))
Conduction Abnormality/atrioventricular
Heart Block (Conduction
abnormality/Atrioventricular heart block -
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Conduction abnormality NOS)
Conduction Abnormality/atrioventricular
Heart Block (Conduction
abnormality/Atrioventricular heart block -
Sick sinus syndrome)
Conduction Abnormality/atrioventricular
Heart Block (Conduction
abnormality/Atrioventricular heart block -
Stokes-Adams syndrome)
Conduction Abnormality/atrioventricular
Heart Block (Conduction
abnormality/Atrioventricular heart block -
Wolff-Parkinson-White syndrome)
Confusion (Confusion)
Constipation (Constipation)
Constitutional Symptoms Other
(Constitutional Symptoms-Other
(Specify))
Cough (Cough)
Blood Creatine Phosphokinase
Increased (CPK (creatine
phosphokinase))
Blood Creatinine Increased (Creatinine)
Cushingoid (Cushingoid appearance
(e.g., moon face, buffalo hump,
centripetal obesity, cutaneous striae))
Cystitis (Cystitis)
Cytokine Release Syndrome/acute
Infusion Reaction (Cytokine release
syndrome/acute infusion reaction)
Death Not Associated With Ctcae Term
(Death not associated with CTCAE term
- Death NOS)
Death Not Associated With Ctcae Term
(Death not associated with CTCAE term
- Disease progression NOS)
Death Not Associated With Ctcae Term
(Death not associated with CTCAE term
- Multi-organ failure)
Death Not Associated With Ctcae Term
(Death not associated with CTCAE term
- Sudden death)
Dehydration (Dehydration)
Dental: Dentures Or Prosthesis (Dental:
dentures or prosthesis)
Dental: Periodontal Disease (Dental:
periodontal disease)
Dental: Teeth (Dental: teeth)
Dental: Teeth Development (Dental:
teeth development)
Dermal Change Lymphedema,
Phlebolymphedema (Dermal change
lymphedema, phlebolymphedema)
Dermatology/skin Other
(Dermatology/Skin-Other (Specify))
Diarrhoea Nos (Diarrhea)
Disseminated Intravascular Coagulation
(DIC (disseminated intravascular
coagulation))
Distention/bloating, Abdominal
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(Distention/bloating, abdominal)
Dizziness (exc Vertigo) (Dizziness)
Dry Eye Nec (Dry eye syndrome)
Dry Mouth (Dry mouth/salivary gland
(xerostomia))
Dry Skin (Dry skin)
Dysphagia (Dysphagia (difficulty
swallowing))
Dyspnoea Nos (Dyspnea (shortness of
breath))
Edema, Larynx (Edema, larynx)
Edema: Head And Neck (Edema: head
and neck)
Oedema Nos (Edema: limb)
Edema: Trunk/genital (Edema:
trunk/genital)
Edema: Viscera (Edema: viscera)
Ejaculatory Dysfunction (Ejaculatory
dysfunction)
Encephalopathy (Encephalopathy)
Endocrine Other (Endocrine-Other
(Specify))
Enteritis (inflammation Of The Small
Bowel) (Enteritis (inflammation of the
small bowel))
Impotence (Erectile dysfunction)
Oesophagitis Nos (Esophagitis)
Exostosis (Exostosis)
Extrapyramidal Disorder Nec
(Extrapyramidal/involuntary
movement/restlessness)
Extremity-lower (gait/walking) (Extremity-
lower (gait/walking))
Extremity-upper (function) (Extremity-
upper (function))
Eyelid Dysfunction (Eyelid dysfunction)
Fatigue (Fatigue (asthenia, lethargy,
malaise))
Febrile Neutropenia (fever Of Unknown
Origin Without Clinically Or
Microbiologically Documented Infection)
(anc <1.0 X 10^9/l, Fever >=38.5
Degrees C) (Febrile neutropenia)
Feminization (Feminization of male)
Forced Expiratory Volume Decreased
(FEV(1))
Pyrexia (Fever (in the absence of
neutropenia, where neutropenia is
defined as ANC <1.0 x 10^9/L))
Blood Fibrinogen Decreased
(Fibrinogen)
Fibrosis-cosmesis (Fibrosis-cosmesis)
Fibrosis-deep Connective Tissue
(Fibrosis-deep connective tissue)
Fistula, Gi (Fistula, GI - Abdomen NOS)
Anal Fistula (Fistula, GI - Anus)
Fistula, Gi (Fistula, GI - Biliary tree)
Fistula, Gi (Fistula, GI -
Colon/cecum/appendix)
Intestinal Fistula (Fistula, GI -
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Duodenum)
Tracheo-oesophageal Fistula Nos
(Fistula, GI - Esophagus)
Fistula, Gi (Fistula, GI - Gallbladder)
Fistula, Gi (Fistula, GI - Ileum)
Fistula, Gi (Fistula, GI - Jejunum)
Fistula, Gi (Fistula, GI - Oral cavity)
Fistula, Gi (Fistula, GI - Pancreas)
Fistula, Gi (Fistula, GI - Pharynx)
Fistula, Gi (Fistula, GI - Rectum)
Fistula, Gi (Fistula, GI - Salivary gland)
Fistula, Gi (Fistula, GI - Small bowel
NOS)
Fistula, Gi (Fistula, GI - Stomach)
Fistula, Gu (Fistula, GU - Bladder)
Fistula, Gu (Fistula, GU - Genital tract-
female)
Fistula, Gu (Fistula, GU - Kidney)
Fistula, Gu (Fistula, GU - Ureter)
Fistula, Gu (Fistula, GU - Urethra)
Fistula, Gu (Fistula, GU - Uterus)
Urogenital Fistula (Fistula, GU - Vagina)
Fistula, Pulmonary/upper Respiratory
(Fistula, pulmonary/upper respiratory -
Bronchus)
Fistula, Pulmonary/upper Respiratory
(Fistula, pulmonary/upper respiratory -
Larynx)
Fistula, Pulmonary/upper Respiratory
(Fistula, pulmonary/upper respiratory -
Lung)
Fistula, Pulmonary/upper Respiratory
(Fistula, pulmonary/upper respiratory -
Oral cavity)
Fistula, Pulmonary/upper Respiratory
(Fistula, pulmonary/upper respiratory -
Pharynx)
Fistula, Pulmonary/upper Respiratory
(Fistula, pulmonary/upper respiratory -
Pleura)
Fistula, Pulmonary/upper Respiratory
(Fistula, pulmonary/upper respiratory -
Trachea)
Flatulence (Flatulence)
Flu-like Syndrome (Flu-like syndrome)
Flushing (Flushing)
Fracture (Fracture)
Gastritis Nos (Gastritis (including bile
reflux gastritis))
Gastrointestinal Other (Gastrointestinal-
Other (Specify))
Gamma-glutamyltransferase Increased
(GGT (gamma-glutamyl transpeptidase))
Glaucoma Nos (Glaucoma)
Glomerular Filtration Rate (Glomerular
filtration rate)
Hyperglycaemia Nos (Glucose, serum-
high (hyperglycemia))
Hypoglycaemia Nos (Glucose, serum-
low (hypoglycemia))
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Growth And Development Other (Growth
and Development-Other (Specify))
Growth Velocity (reduction In Growth
Velocity) (Growth velocity (reduction in
growth velocity))
Gynaecomastia (Gynecomastia)
Alopecia (Hair loss/Alopecia (scalp or
body))
Haptoglobin Decreased (Haptoglobin)
Hearing: Patients With/without Baseline
Audiogram And Enrolled In A Monitoring
Program (Hearing: patients with/without
baseline audiogram and enrolled in a
monitoring program)
Hearing: Patients Without Baseline
Audiogram And Not Enrolled In A
Monitoring Program (Hearing: patients
without baseline audiogram and not
enrolled in a monitoring program)
Dyspepsia (Heartburn/dyspepsia)
Hematoma (Hematoma)
Haemoglobin Decreased (Hemoglobin)
Haemoglobinuria Present
(Hemoglobinuria)
Hemolysis Nos (Hemolysis (e.g.,
immune hemolytic anemia, drug related
hemolysis))
Haemorrhagic Stroke (Hemorrhage,
CNS)
Melaena (Hemorrhage, GI - Abdomen
NOS)
Hemorrhage, Gi (Hemorrhage, GI -
Anus)
Hemorrhage, Gi (Hemorrhage, GI -
Biliary tree)
Hemorrhage, Gi (Hemorrhage, GI -
Cecum/appendix)
Hemorrhage, Gi (Hemorrhage, GI -
Colon)
Hemorrhage, Gi (Hemorrhage, GI -
Duodenum)
Hemorrhage, Gi (Hemorrhage, GI -
Esophagus)
Hemorrhage, Gi (Hemorrhage, GI -
Ileum)
Hemorrhage, Gi (Hemorrhage, GI -
Jejunum)
Hemorrhage, Gi (Hemorrhage, GI - Liver)
Hemorrhage, Gi (Hemorrhage, GI -
Lower GI NOS)
Hemorrhage, Gi (Hemorrhage, GI - Oral
cavity)
Hemorrhage, Gi (Hemorrhage, GI -
Pancreas)
Hemorrhage, Gi (Hemorrhage, GI -
Peritoneal cavity)
Rectal Bleeding (Hemorrhage, GI -
Rectum)
Hemorrhage, Gi (Hemorrhage, GI -
Stoma)
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Haematemesis (Hemorrhage, GI -
Stomach)
Hemorrhage, Gi (Hemorrhage, GI -
Upper GI NOS)
Hemorrhage, Gi (Hemorrhage, GI -
Varices (esophageal))
Hemorrhage, Gi (Hemorrhage, GI -
Varices (rectal))
Hemorrhage, Gu (Hemorrhage, GU -
Bladder)
Hemorrhage, Gu (Hemorrhage, GU -
Fallopian tube)
Hemorrhage, Gu (Hemorrhage, GU -
Kidney)
Hemorrhage, Gu (Hemorrhage, GU -
Ovary)
Hemorrhage, Gu (Hemorrhage, GU -
Prostate)
Hemorrhage, Gu (Hemorrhage, GU -
Retroperitoneum)
Hemorrhage, Gu (Hemorrhage, GU -
Spermatic cord)
Hemorrhage, Gu (Hemorrhage, GU -
Stoma)
Hemorrhage, Gu (Hemorrhage, GU -
Testes)
Hemorrhage, Gu (Hemorrhage, GU -
Ureter)
Hemorrhage, Gu (Hemorrhage, GU -
Urethra)
Haematuria Present (Hemorrhage, GU -
Urinary NOS)
Hemorrhage, Gu (Hemorrhage, GU -
Uterus)
Vaginal Haemorrhage (Hemorrhage, GU
- Vagina)
Hemorrhage, Gu (Hemorrhage, GU - Vas
deferens)
Hemorrhage, Pulmonary/upper
Respiratory (Hemorrhage,
pulmonary/upper respiratory -
Bronchopulmonary NOS)
Hemorrhage, Pulmonary/upper
Respiratory (Hemorrhage,
pulmonary/upper respiratory - Bronchus)
Hemorrhage, Pulmonary/upper
Respiratory (Hemorrhage,
pulmonary/upper respiratory - Larynx)
Hemorrhage, Pulmonary/upper
Respiratory (Hemorrhage,
pulmonary/upper respiratory - Lung)
Hemorrhage, Pulmonary/upper
Respiratory (Hemorrhage,
pulmonary/upper respiratory -
Mediastinum)
Epistaxis (Hemorrhage, pulmonary/upper
respiratory - Nose)
Hemorrhage, Pulmonary/upper
Respiratory (Hemorrhage,
pulmonary/upper respiratory - Pharynx)
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Hemorrhage, Pulmonary/upper
Respiratory (Hemorrhage,
pulmonary/upper respiratory - Pleura)
Haemoptysis (Hemorrhage,
pulmonary/upper respiratory -
Respiratory tract NOS)
Hemorrhage, Pulmonary/upper
Respiratory (Hemorrhage,
pulmonary/upper respiratory - Stoma)
Hemorrhage, Pulmonary/upper
Respiratory (Hemorrhage,
pulmonary/upper respiratory - Trachea)
Post-operative Haemorrhage
(Hemorrhage/bleeding associated with
surgery, intra-operative or post-operative)
Hemorrhage/bleeding Other
(Hemorrhage/Bleeding-Other (Specify))
Hemorrhoids (Hemorrhoids)
Hepatobiliary/pancreas Other
(Hepatobiliary/Pancreas-Other (Specify))
Hiccups (Hiccoughs (hiccups, singultus))
Menopausal Symptoms (Hot
flashes/flushes)
Hydrocephalus (Hydrocephalus)
Skin Discolouration (Hyperpigmentation)
Hypertension Nos (Hypertension)
Hypopigmentation (Hypopigmentation)
Hypotension Nos (Hypotension)
Hypothermia (Hypothermia)
Hypoxia (Hypoxia)
Ileus (Ileus, GI (functional obstruction of
bowel, i.e., neuroconstipation))
Incontinence, Anal (Incontinence, anal)
Urinary Incontinence (Incontinence,
urinary)
Induration/fibrosis (skin And
Subcutaneous Tissue)
(Induration/fibrosis (skin and
subcutaneous tissue))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Abdomen NOS)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Anal/perianal)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Appendix)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
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(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Artery)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Biliary tree)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Bladder (urinary))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Blood)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Bone (osteomyelitis))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Brain (encephalitis,
infectious))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Brain + Spinal cord
(encephalomyelitis))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Bronchus)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Catheter-related)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Cecum)
Infection (documented Clinically Or
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Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Cervix)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Colon)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Conjunctiva)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Cornea)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Dental-tooth)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Duodenum)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Esophagus)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - External ear (otitis externa))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Eye NOS)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Fallopian tube)
Infection (documented Clinically Or
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Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Foreign body (e.g., graft,
implant, prosthesis, stent))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Gallbladder (cholecystitis))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Heart (endocarditis))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Ileum)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Jejunum)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Joint)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Kidney)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Larynx)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Lens)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Lip/perioral)
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Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Liver)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Lung (pneumonia))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Lymphatic)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Mediastinum NOS)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Meninges (meningitis))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Middle ear (otitis media))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Mucosa)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Muscle (infection myositis))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Neck NOS)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Nerve-cranial)
15 / 91
Esophageal Cancer NCT00655876 Treatment - TF: Radiation Therapy Oncology
Group Phase III Esophagus Systemic Treatment Summary Form - 2598533v1.0
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Nerve-peripheral)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Nose)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Oral cavity-gums
(gingivitis))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Pancreas)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Paranasal)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Pelvis NOS)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Penis)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Peristomal)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Peritoneal cavity)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
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neutrophils - Pharynx)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Pleura (empyema))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Prostate)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Rectum)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Salivary gland)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Scrotum)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Sinus)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Skin (cellulitis))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Small bowel NOS)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Soft tissue NOS)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
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neutrophils - Spinal cord (myelitis))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Spleen)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Stomach)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Trachea)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Ungual (nails))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Upper aerodigestive NOS)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Upper airway NOS)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Ureter)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Urethra)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Urinary tract NOS)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
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neutrophils - Uterus)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Vagina)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Vein)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Vulva)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Wound)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Abdomen
NOS)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils -
Anal/perianal)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Appendix)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Artery)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Biliary tree)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Bladder
(urinary))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Blood)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Bone
(osteomyelitis))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Brain
(encephalitis, infectious))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Brain +
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Spinal cord (encephalomyelitis))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Bronchus)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Catheter-
related)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Cecum)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Cervix)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Colon)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils -
Conjunctiva)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Cornea)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Dental-
tooth)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Duodenum)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Esophagus)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - External ear
(otitis externa))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Eye NOS)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Fallopian
tube)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Foreign
body (e.g., graft, implant, prosthesis,
stent))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Gallbladder
(cholecystitis))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Heart
(endocarditis))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
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or Grade 1 or 2 neutrophils - Ileum)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Jejunum)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Joint)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Kidney)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Larynx)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Lens)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Lip/perioral)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Liver)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Lung
(pneumonia))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Lymphatic)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils -
Mediastinum NOS)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Meninges
(meningitis))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Middle ear
(otitis media))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Mucosa)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Muscle
(infection myositis))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Neck NOS)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Nerve-
cranial)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Nerve-
peripheral)
Infection With Normal Anc Or Grade 1 Or
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2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Nose)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Oral cavity-
gums (gingivitis))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Pancreas)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Paranasal)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Pelvis NOS)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Penis)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Peristomal)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Peritoneal
cavity)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Pharynx)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Pleura
(empyema))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Prostate)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Rectum)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Salivary
gland)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Scrotum)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Sinus)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Skin
(cellulitis))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Small bowel
NOS)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Soft tissue
NOS)
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Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Spinal cord
(myelitis))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Spleen)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Stomach)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Trachea)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Ungual
(nails))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Upper
aerodigestive NOS)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Upper
airway NOS)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Ureter)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Urethra)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Urinary
tract NOS)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Uterus)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Vagina)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Vein)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Vulva)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Wound)
Infection With Unknown Anc (Infection
with unknown ANC - Abdomen NOS)
Infection With Unknown Anc (Infection
with unknown ANC - Anal/perianal)
Infection With Unknown Anc (Infection
with unknown ANC - Appendix)
Infection With Unknown Anc (Infection
with unknown ANC - Artery)
Infection With Unknown Anc (Infection
with unknown ANC - Biliary tree)
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Infection With Unknown Anc (Infection
with unknown ANC - Bladder (urinary))
Infection With Unknown Anc (Infection
with unknown ANC - Blood)
Infection With Unknown Anc (Infection
with unknown ANC - Bone
(osteomyelitis))
Infection With Unknown Anc (Infection
with unknown ANC - Brain (encephalitis,
infectious))
Infection With Unknown Anc (Infection
with unknown ANC - Brain + Spinal cord
(encephalomyelitis))
Infection With Unknown Anc (Infection
with unknown ANC - Bronchus)
Implant Infection (Infection with unknown
ANC - Catheter-related)
Infection With Unknown Anc (Infection
with unknown ANC - Cecum)
Infection With Unknown Anc (Infection
with unknown ANC - Cervix)
Infection With Unknown Anc (Infection
with unknown ANC - Colon)
Infection With Unknown Anc (Infection
with unknown ANC - Conjunctiva)
Infection With Unknown Anc (Infection
with unknown ANC - Cornea)
Infection With Unknown Anc (Infection
with unknown ANC - Dental-tooth)
Infection With Unknown Anc (Infection
with unknown ANC - Duodenum)
Infection With Unknown Anc (Infection
with unknown ANC - Esophagus)
Infection With Unknown Anc (Infection
with unknown ANC - External ear (otitis
externa))
Infection With Unknown Anc (Infection
with unknown ANC - Eye NOS)
Infection With Unknown Anc (Infection
with unknown ANC - Fallopian tube)
Infection With Unknown Anc (Infection
with unknown ANC - Foreign body (e.g.,
graft, implant, prosthesis, stent))
Infection With Unknown Anc (Infection
with unknown ANC - Gallbladder
(cholecystitis))
Infection With Unknown Anc (Infection
with unknown ANC - Heart
(endocarditis))
Infection With Unknown Anc (Infection
with unknown ANC - Ileum)
Infection With Unknown Anc (Infection
with unknown ANC - Jejunum)
Infection With Unknown Anc (Infection
with unknown ANC - Joint)
Infection With Unknown Anc (Infection
with unknown ANC - Kidney)
Infection With Unknown Anc (Infection
with unknown ANC - Larynx)
Infection With Unknown Anc (Infection
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with unknown ANC - Lens)
Infection With Unknown Anc (Infection
with unknown ANC - Lip/perioral)
Infection With Unknown Anc (Infection
with unknown ANC - Liver)
Infection With Unknown Anc (Infection
with unknown ANC - Lung (pneumonia))
Infection With Unknown Anc (Infection
with unknown ANC - Lymphatic)
Infection With Unknown Anc (Infection
with unknown ANC - Mediastinum NOS)
Infection With Unknown Anc (Infection
with unknown ANC - Meninges
(meningitis))
Infection With Unknown Anc (Infection
with unknown ANC - Middle ear (otitis
media))
Infection With Unknown Anc (Infection
with unknown ANC - Mucosa)
Infection With Unknown Anc (Infection
with unknown ANC - Muscle (infection
myositis))
Infection With Unknown Anc (Infection
with unknown ANC - Neck NOS)
Infection With Unknown Anc (Infection
with unknown ANC - Nerve-cranial)
Infection With Unknown Anc (Infection
with unknown ANC - Nerve-peripheral)
Infection With Unknown Anc (Infection
with unknown ANC - Nose)
Infection With Unknown Anc (Infection
with unknown ANC - Oral cavity-gums
(gingivitis))
Infection With Unknown Anc (Infection
with unknown ANC - Pancreas)
Infection With Unknown Anc (Infection
with unknown ANC - Paranasal)
Infection With Unknown Anc (Infection
with unknown ANC - Pelvis NOS)
Infection With Unknown Anc (Infection
with unknown ANC - Penis)
Infection With Unknown Anc (Infection
with unknown ANC - Peristomal)
Infection With Unknown Anc (Infection
with unknown ANC - Peritoneal cavity)
Infection With Unknown Anc (Infection
with unknown ANC - Pharynx)
Infection With Unknown Anc (Infection
with unknown ANC - Pleura (empyema))
Infection With Unknown Anc (Infection
with unknown ANC - Prostate)
Infection With Unknown Anc (Infection
with unknown ANC - Rectum)
Infection With Unknown Anc (Infection
with unknown ANC - Salivary gland)
Infection With Unknown Anc (Infection
with unknown ANC - Scrotum)
Infection With Unknown Anc (Infection
with unknown ANC - Sinus)
Infection With Unknown Anc (Infection
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with unknown ANC - Skin (cellulitis))
Infection With Unknown Anc (Infection
with unknown ANC - Small bowel NOS)
Infection With Unknown Anc (Infection
with unknown ANC - Soft tissue NOS)
Infection With Unknown Anc (Infection
with unknown ANC - Spinal cord
(myelitis))
Infection With Unknown Anc (Infection
with unknown ANC - Spleen)
Infection With Unknown Anc (Infection
with unknown ANC - Stomach)
Infection With Unknown Anc (Infection
with unknown ANC - Trachea)
Infection With Unknown Anc (Infection
with unknown ANC - Ungual (nails))
Infection With Unknown Anc (Infection
with unknown ANC - Upper aerodigestive
NOS)
Infection With Unknown Anc (Infection
with unknown ANC - Upper airway NOS)
Infection With Unknown Anc (Infection
with unknown ANC - Ureter)
Infection With Unknown Anc (Infection
with unknown ANC - Urethra)
Infection With Unknown Anc (Infection
with unknown ANC - Urinary tract NOS)
Infection With Unknown Anc (Infection
with unknown ANC - Uterus)
Infection With Unknown Anc (Infection
with unknown ANC - Vagina)
Infection With Unknown Anc (Infection
with unknown ANC - Vein)
Infection With Unknown Anc (Infection
with unknown ANC - Vulva)
Culture Wound Positive (Infection with
unknown ANC - Wound)
Infection Nos (Infection-Other (Specify))
Infertility/sterility (Infertility/sterility)
Injection Site Reaction Nos (Injection site
reaction/extravasation changes)
Prothrombin Time Prolonged (INR
(International Normalized Ratio of
prothrombin time))
Insomnia Nec (Insomnia)
Intra-operative Injury (Intra-operative
injury - Abdomen NOS)
Intra-operative Injury (Intra-operative
injury - Adrenal gland)
Intra-operative Injury (Intra-operative
injury - Anal sphincter)
Intra-operative Injury (Intra-operative
injury - Anus)
Intra-operative Injury (Intra-operative
injury - Appendix)
Intra-operative Injury (Intra-operative
injury - Artery NOS)
Intra-operative Injury (Intra-operative
injury - Artery-aorta)
Intra-operative Injury (Intra-operative
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injury - Artery-carotid)
Intra-operative Injury (Intra-operative
injury - Artery-cerebral)
Intra-operative Injury (Intra-operative
injury - Artery-extremity (lower))
Intra-operative Injury (Intra-operative
injury - Artery-extremity (upper))
Intra-operative Injury (Intra-operative
injury - Artery-hepatic)
Intra-operative Injury (Intra-operative
injury - Artery-major visceral artery)
Intra-operative Injury (Intra-operative
injury - Artery-pulmonary)
Intra-operative Injury (Intra-operative
injury - Biliary tree NOS)
Intra-operative Injury (Intra-operative
injury - Biliary tree-common bile duct)
Intra-operative Injury (Intra-operative
injury - Biliary tree-common hepatic duct)
Intra-operative Injury (Intra-operative
injury - Biliary tree-left hepatic duct)
Intra-operative Injury (Intra-operative
injury - Biliary tree-right hepatic duct)
Bladder Perforation Postoperative (Intra-
operative injury - Bladder)
Intra-operative Injury (Intra-operative
injury - Bone)
Intra-operative Injury (Intra-operative
injury - Brachial plexus)
Intra-operative Injury (Intra-operative
injury - Brain)
Intra-operative Injury (Intra-operative
injury - Breast)
Intra-operative Injury (Intra-operative
injury - Bronchus)
Intra-operative Injury (Intra-operative
injury - Cartilage)
Intra-operative Injury (Intra-operative
injury - Cecum)
Intra-operative Injury (Intra-operative
injury - Cervix)
Intra-operative Injury (Intra-operative
injury - CN I (olfactory))
Intra-operative Injury (Intra-operative
injury - CN II (optic))
Intra-operative Injury (Intra-operative
injury - CN III (oculomotor))
Intra-operative Injury (Intra-operative
injury - CN IV (trochlear))
Intra-operative Injury (Intra-operative
injury - CN IX (glossopharyngeal) motor
pharynx)
Intra-operative Injury (Intra-operative
injury - CN IX (glossopharyngeal)
sensory ear-pharynx-tongue)
Intra-operative Injury (Intra-operative
injury - CN V (trigeminal) motor)
Intra-operative Injury (Intra-operative
injury - CN V (trigeminal) sensory)
Intra-operative Injury (Intra-operative
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injury - CN VI (abducens))
Intra-operative Injury (Intra-operative
injury - CN VII (facial) motor-face)
Intra-operative Injury (Intra-operative
injury - CN VII (facial) sensory-taste)
Intra-operative Injury (Intra-operative
injury - CN VIII (vestibulocochlear))
Intra-operative Injury (Intra-operative
injury - CN X (vagus))
Intra-operative Injury (Intra-operative
injury - CN XI (spinal accessory))
Intra-operative Injury (Intra-operative
injury - CN XII (hypoglossal))
Intra-operative Injury (Intra-operative
injury - Colon)
Intra-operative Injury (Intra-operative
injury - Conjunctiva)
Intra-operative Injury (Intra-operative
injury - Cornea)
Intra-operative Injury (Intra-operative
injury - Cranial nerve or branch NOS)
Intra-operative Injury (Intra-operative
injury - Duodenum)
Intra-operative Injury (Intra-operative
injury - Esophagus)
Intra-operative Injury (Intra-operative
injury - Extremity-lower)
Intra-operative Injury (Intra-operative
injury - Extremity-upper)
Intra-operative Injury (Intra-operative
injury - Eye NOS)
Intra-operative Injury (Intra-operative
injury - Face NOS)
Intra-operative Injury (Intra-operative
injury - Fallopian tube)
Intra-operative Injury (Intra-operative
injury - Gallbladder)
Intra-operative Injury (Intra-operative
injury - Gingiva)
Intra-operative Injury (Intra-operative
injury - Heart)
Intra-operative Injury (Intra-operative
injury - Ileum)
Intra-operative Injury (Intra-operative
injury - Inner ear)
Intra-operative Injury (Intra-operative
injury - Jejunum)
Intra-operative Injury (Intra-operative
injury - Joint)
Intra-operative Injury (Intra-operative
injury - Kidney)
Intra-operative Injury (Intra-operative
injury - Larynx)
Intra-operative Injury (Intra-operative
injury - Lens)
Intra-operative Injury (Intra-operative
injury - Ligament)
Intra-operative Injury (Intra-operative
injury - Lingual)
Intra-operative Injury (Intra-operative
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injury - Lip/perioral area)
Intra-operative Injury (Intra-operative
injury - Liver)
Intra-operative Injury (Intra-operative
injury - Lung)
Intra-operative Injury (Intra-operative
injury - Lung thoracic)
Intra-operative Injury (Intra-operative
injury - Mediastinum)
Intra-operative Injury (Intra-operative
injury - Meninges)
Intra-operative Injury (Intra-operative
injury - Middle ear)
Intra-operative Injury (Intra-operative
injury - Muscle)
Intra-operative Injury (Intra-operative
injury - Nails)
Intra-operative Injury (Intra-operative
injury - Nasal cavity)
Intra-operative Injury (Intra-operative
injury - Nasopharynx)
Intra-operative Injury (Intra-operative
injury - Neck NOS)
Intra-operative Injury (Intra-operative
injury - Nose)
Intra-operative Injury (Intra-operative
injury - Oral)
Intra-operative Injury (Intra-operative
injury - Oral cavity NOS)
Intra-operative Injury (Intra-operative
injury - Outer ear NOS)
Intra-operative Injury (Intra-operative
injury - Outer ear-pinna)
Intra-operative Injury (Intra-operative
injury - Ovary)
Intra-operative Injury (Intra-operative
injury - Pancreas)
Intra-operative Injury (Intra-operative
injury - Pancreatic duct)
Intra-operative Injury (Intra-operative
injury - Parathyroid)
Intra-operative Injury (Intra-operative
injury - Parotid gland)
Intra-operative Injury (Intra-operative
injury - Pelvis NOS)
Intra-operative Injury (Intra-operative
injury - Penis)
Intra-operative Injury (Intra-operative
injury - Peripheral motor NOS)
Intra-operative Injury (Intra-operative
injury - Peripheral sensory NOS)
Intra-operative Injury (Intra-operative
injury - Peritoneal cavity)
Intra-operative Injury (Intra-operative
injury - Pharynx)
Intra-operative Injury (Intra-operative
injury - Pituitary)
Intra-operative Injury (Intra-operative
injury - Pleura)
Intra-operative Injury (Intra-operative
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injury - Prostate)
Intra-operative Injury (Intra-operative
injury - Rectum)
Intra-operative Injury (Intra-operative
injury - Recurrent laryngeal)
Intra-operative Injury (Intra-operative
injury - Retina)
Intra-operative Injury (Intra-operative
injury - Sacral plexus)
Intra-operative Injury (Intra-operative
injury - Salivary duct)
Intra-operative Injury (Intra-operative
injury - Salivary gland)
Intra-operative Injury (Intra-operative
injury - Sciatic)
Intra-operative Injury (Intra-operative
injury - Scrotum)
Intra-operative Injury (Intra-operative
injury - Sinus)
Intra-operative Injury (Intra-operative
injury - Skin)
Intra-operative Injury (Intra-operative
injury - Small bowel NOS)
Intra-operative Injury (Intra-operative
injury - Soft tissue NOS)
Intra-operative Injury (Intra-operative
injury - Spinal cord)
Intra-operative Injury (Intra-operative
injury - Spleen)
Intra-operative Injury (Intra-operative
injury - Stoma (GI))
Intra-operative Injury (Intra-operative
injury - Stomach)
Intra-operative Injury (Intra-operative
injury - Teeth)
Intra-operative Injury (Intra-operative
injury - Tendon)
Intra-operative Injury (Intra-operative
injury - Testis)
Intra-operative Injury (Intra-operative
injury - Thoracic duct)
Intra-operative Injury (Intra-operative
injury - Thoracodorsal)
Intra-operative Injury (Intra-operative
injury - Thyroid)
Intra-operative Injury (Intra-operative
injury - Tongue)
Intra-operative Injury (Intra-operative
injury - Trachea)
Intra-operative Injury (Intra-operative
injury - Upper aerodigestive NOS)
Intra-operative Injury (Intra-operative
injury - Upper airway NOS)
Intra-operative Injury (Intra-operative
injury - Ureter)
Intra-operative Injury (Intra-operative
injury - Urethra)
Intra-operative Injury (Intra-operative
injury - Urinary conduit)
Intra-operative Injury (Intra-operative
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injury - Urinary tract NOS)
Intra-operative Injury (Intra-operative
injury - Uterus)
Intra-operative Injury (Intra-operative
injury - Vagina)
Intra-operative Injury - Vein (Intra-
operative injury - Vein NOS)
Intra-operative Injury (Intra-operative
injury - Vein-extremity (lower))
Intra-operative Injury (Intra-operative
injury - Vein-extremity (upper))
Intra-operative Injury (Intra-operative
injury - Vein-hepatic)
Intra-operative Injury (Intra-operative
injury - Vein-inferior vena cava)
Intra-operative Injury (Intra-operative
injury - Vein-jugular)
Intra-operative Injury (Intra-operative
injury - Vein-major visceral vein)
Intra-operative Injury (Intra-operative
injury - Vein-portal vein)
Intra-operative Injury (Intra-operative
injury - Vein-pulmonary)
Intra-operative Injury (Intra-operative
injury - Vein-superior vena cava)
Intra-operative Injury (Intra-operative
injury - Vulva)
Intra-operative Injury Other (Intra-
operative Injury-Other (Specify))
Iron Overload (Iron overload)
Menstruation Irregular (Irregular menses
(change from baseline))
Irritability (Irritability (children <3 years of
age))
Joint-effusion (Joint-effusion)
Joint-effusion (Joint-function)
Keratitis Nec (Keratitis (corneal
inflammation/corneal ulceration))
Laryngeal Nerve Dysfunction (Laryngeal
nerve dysfunction)
Leak (including Anastomotic), Gi (Leak
(including anastomotic), GI - Biliary tree)
Leak (including Anastomotic), Gi (Leak
(including anastomotic), GI - Esophagus)
Leak (including Anastomotic), Gi (Leak
(including anastomotic), GI - Large
bowel)
Leak (including Anastomotic), Gi (Leak
(including anastomotic), GI - Leak NOS)
Leak (including Anastomotic), Gi (Leak
(including anastomotic), GI - Pancreas)
Leak (including Anastomotic), Gi (Leak
(including anastomotic), GI - Pharynx)
Leak (including Anastomotic), Gi (Leak
(including anastomotic), GI - Rectum)
Leak (including Anastomotic), Gi (Leak
(including anastomotic), GI - Small
bowel)
Leak (including Anastomotic), Gi (Leak
(including anastomotic), GI - Stoma)
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Leak (including Anastomotic), Gi (Leak
(including anastomotic), GI - Stomach)
Leak (including Anastomotic), Gu (Leak
(including anastomotic), GU - Bladder)
Leak (including Anastomotic), Gu (Leak
(including anastomotic), GU - Fallopian
tube)
Leak (including Anastomotic), Gu (Leak
(including anastomotic), GU - Kidney)
Leak (including Anastomotic), Gu (Leak
(including anastomotic), GU - Spermatic
cord)
Leak (including Anastomotic), Gu (Leak
(including anastomotic), GU - Stoma)
Leak (including Anastomotic), Gu (Leak
(including anastomotic), GU - Ureter)
Leak (including Anastomotic), Gu (Leak
(including anastomotic), GU - Urethra)
Leak (including Anastomotic), Gu (Leak
(including anastomotic), GU - Uterus)
Leak (including Anastomotic), Gu (Leak
(including anastomotic), GU - Vagina)
Leak (including Anastomotic), Gu (Leak
(including anastomotic), GU - Vas
deferens)
Leak, Cerebrospinal Fluid (csf) (Leak,
cerebrospinal fluid (CSF))
Left Ventricular Diastolic Dysfunction
(Left ventricular diastolic dysfunction)
Left Ventricular Failure (Left ventricular
systolic dysfunction)
Leucopenia Nos (Leukocytes (total
WBC))
Encephalopathy Nos
(Leukoencephalopathy (radiolographic
findings))
Libido Decreased (Libido)
Lipase Increased (Lipase)
Hepatic Failure (Liver dysfunction/failure
(clinical))
Local Complication - Device/prosthesis-
related (Local complication -
device/prosthesis-related)
Lumbar Spine-range Of Motion (Lumbar
spine-range of motion)
Lymphatics Other (Lymphatics-Other
(Specify))
Lymphedema-related Fibrosis
(Lymphedema-related fibrosis)
Lymphocele (Lymphocele)
Lymphopenia (Lymphopenia)
Hypermagnesaemia (Magnesium,
serum-high (hypermagnesemia))
Blood Magnesium Decreased
(Magnesium, serum-low
(hypomagnesemia))
Malabsorption (Malabsorption)
Virilism (Masculinization of female)
Amnesia Nec (Memory impairment)
Mental Status (Mental status)
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Metabolic/laboratory Other
(Metabolic/Laboratory-Other (Specify))
Mood Alteration - Agitation (Mood
alteration - agitation)
Anxiety Nec (Mood alteration - anxiety)
Depression Nec (Mood alteration -
depression)
Euphoric Mood (Mood alteration -
euphoria)
Mucositis/stomatitis (clinical Exam)
(Mucositis/stomatitis (clinical exam) -
Anus)
Mucositis/stomatitis (clinical Exam)
(Mucositis/stomatitis (clinical exam) -
Esophagus)
Mucositis/stomatitis (clinical Exam)
(Mucositis/stomatitis (clinical exam) -
Large bowel)
Mucositis/stomatitis (clinical Exam)
(Mucositis/stomatitis (clinical exam) -
Larynx)
Mucositis/stomatitis (clinical Exam)
(Mucositis/stomatitis (clinical exam) -
Oral cavity)
Stomatitis (Mucositis/stomatitis (clinical
exam) - Pharynx)
Mucositis/stomatitis (clinical Exam)
(Mucositis/stomatitis (clinical exam) -
Rectum)
Mucositis/stomatitis (clinical Exam)
(Mucositis/stomatitis (clinical exam) -
Small bowel)
Mucositis/stomatitis (clinical Exam)
(Mucositis/stomatitis (clinical exam) -
Stomach)
Mucositis/stomatitis (clinical Exam)
(Mucositis/stomatitis (clinical exam) -
Trachea)
Mucositis/stomatitis
(functional/symptomatic)
(Mucositis/stomatitis
(functional/symptomatic) - Anus)
Mucositis/stomatitis
(functional/symptomatic)
(Mucositis/stomatitis
(functional/symptomatic) - Esophagus)
Mucositis/stomatitis
(functional/symptomatic)
(Mucositis/stomatitis
(functional/symptomatic) - Large bowel)
Mucositis/stomatitis
(functional/symptomatic)
(Mucositis/stomatitis
(functional/symptomatic) - Larynx)
Mucositis/stomatitis
(functional/symptomatic)
(Mucositis/stomatitis
(functional/symptomatic) - Oral cavity)
Mucositis/stomatitis
(functional/symptomatic)
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(Mucositis/stomatitis
(functional/symptomatic) - Pharynx)
Mucositis/stomatitis
(functional/symptomatic)
(Mucositis/stomatitis
(functional/symptomatic) - Rectum)
Mucositis/stomatitis
(functional/symptomatic)
(Mucositis/stomatitis
(functional/symptomatic) - Small bowel)
Mucositis/stomatitis
(functional/symptomatic)
(Mucositis/stomatitis
(functional/symptomatic) - Stomach)
Mucositis/stomatitis
(functional/symptomatic)
(Mucositis/stomatitis
(functional/symptomatic) - Trachea)
Muscle Weakness, Generalized Or
Specific Area (not Due To Neuropathy)
(Muscle weakness, generalized or
specific area (not due to neuropathy) -
Extraocular)
Muscle Weakness, Generalized Or
Specific Area (not Due To Neuropathy)
(Muscle weakness, generalized or
specific area (not due to neuropathy) -
Extremity-lower)
Muscle Weakness, Generalized Or
Specific Area (not Due To Neuropathy)
(Muscle weakness, generalized or
specific area (not due to neuropathy) -
Extremity-upper)
Muscle Weakness, Generalized Or
Specific Area (not Due To Neuropathy)
(Muscle weakness, generalized or
specific area (not due to neuropathy) -
Facial)
Muscle Weakness, Generalized Or
Specific Area (not Due To Neuropathy)
(Muscle weakness, generalized or
specific area (not due to neuropathy) -
Left-sided)
Muscle Weakness, Generalized Or
Specific Area (not Due To Neuropathy)
(Muscle weakness, generalized or
specific area (not due to neuropathy) -
Ocular)
Muscle Weakness, Generalized Or
Specific Area (not Due To Neuropathy)
(Muscle weakness, generalized or
specific area (not due to neuropathy) -
Pelvic)
Muscle Weakness, Generalized Or
Specific Area (not Due To Neuropathy)
(Muscle weakness, generalized or
specific area (not due to neuropathy) -
Right-sided)
Muscle Weakness, Generalized Or
Specific Area (not Due To Neuropathy)
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(Muscle weakness, generalized or
specific area (not due to neuropathy) -
Trunk)
Muscle Weakness Nos (Muscle
weakness, generalized or specific area
(not due to neuropathy) - Whole
body/generalized)
Muscular/skeletal Hypoplasia
(Muscular/skeletal hypoplasia)
Musculoskeletal/soft Tissue Other
(Musculoskeletal/Soft Tissue-Other
(Specify))
Myelitis (Myelitis)
Myelodysplasia (Myelodysplasia)
Myocarditis Nos (Myocarditis)
Myositis (Myositis (inflammation/damage
of muscle))
Nail Abnormality Nos (Nail changes)
Nasal Cavity/paranasal Sinus Reactions
(Nasal cavity/paranasal sinus reactions)
Nausea (Nausea)
Necrosis, Gi (Necrosis, GI - Anus)
Necrosis, Gi (Necrosis, GI -
Colon/cecum/appendix)
Necrosis, Gi (Necrosis, GI - Duodenum)
Necrosis, Gi (Necrosis, GI - Esophagus)
Necrosis, Gi (Necrosis, GI - Gallbladder)
Necrosis, Gi (Necrosis, GI - Hepatic)
Necrosis, Gi (Necrosis, GI - Ileum)
Necrosis, Gi (Necrosis, GI - Jejunum)
Necrosis, Gi (Necrosis, GI - Oral)
Necrosis, Gi (Necrosis, GI - Pancreas)
Necrosis, Gi (Necrosis, GI - Peritoneal
cavity)
Necrosis, Gi (Necrosis, GI - Pharynx)
Necrosis, Gi (Necrosis, GI - Rectum)
Necrosis, Gi (Necrosis, GI - Small bowel
NOS)
Necrosis, Gi (Necrosis, GI - Stoma)
Necrosis, Gi (Necrosis, GI - Stomach)
Neuroendocrine: Acth Deficiency
(Neuroendocrine: ACTH deficiency)
Inappropriate Adh Secretion
(Neuroendocrine: ADH secretion
abnormality (e.g., SIADH or low ADH))
Neuroendocrine: Gonadotropin Secretion
Abnormality (Neuroendocrine:
gonadotropin secretion abnormality)
Neuroendocrine: Growth Hormone
Secretion Abnormality (Neuroendocrine:
growth hormone secretion abnormality)
Neuroendocrine: Prolactin Hormone
Secretion Abnormality (Neuroendocrine:
prolactin hormone secretion abnormality)
Neurology Other (Neurology-Other
(Specify))
Parosmia (Neuropathy: cranial - CN I
Smell)
Cranial Nerve Injury Nos (Neuropathy:
cranial - CN II Vision)
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Neuropathy: Cranial (Neuropathy: cranial
- CN III Pupil, upper eyelid, extra ocular
movements)
Neuropathy: Cranial (Neuropathy: cranial
- CN IV Downward, inward movement of
eye)
Neuropathy: Cranial (Neuropathy: cranial
- CN IX Motor-pharynx; Sensory-ear,
pharynx, tongue)
Neuropathy: Cranial (Neuropathy: cranial
- CN V Motor-jaw muscles; Sensory-
facial)
Neuropathy: Cranial (Neuropathy: cranial
- CN VI Lateral deviation of eye)
Neuropathy: Cranial (Neuropathy: cranial
- CN VII Motor-face; Sensory-taste)
Neuropathy: Cranial (Neuropathy: cranial
- CN VIII Hearing and balance)
Neuropathy: Cranial (Neuropathy: cranial
- CN X Motor-palate; pharynx, larynx)
Neuropathy: Cranial (Neuropathy: cranial
- CN XI Motor-sternomastoid and
trapezius)
Neuropathy: Cranial (Neuropathy: cranial
- CN XII Motor-tongue)
Peripheral Motor Neuropathy
(Neuropathy: motor)
Peripheral Sensory Neuropathy
(Neuropathy: sensory)
Neutropenia (Neutrophils/granulocytes
(ANC/AGC))
Blindness Night (Night blindness
(nyctalopia))
Nystagmus Nos (Nystagmus)
Obesity (Obesity)
Obstruction, Gi (Obstruction, GI -
Cecum)
Obstruction, Gi (Obstruction, GI - Colon)
Obstruction, Gi (Obstruction, GI -
Duodenum)
Obstruction, Gi (Obstruction, GI -
Esophagus)
Obstruction, Gi (Obstruction, GI -
Gallbladder)
Obstruction, Gi (Obstruction, GI - Ileum)
Obstruction, Gi (Obstruction, GI -
Jejunum)
Obstruction, Gi (Obstruction, GI -
Rectum)
Obstruction, Gi (Obstruction, GI - Small
bowel NOS)
Obstruction, Gi (Obstruction, GI - Stoma)
Obstruction, Gi (Obstruction, GI -
Stomach)
Obstruction, Gu (Obstruction, GU -
Bladder)
Obstruction, Gu (Obstruction, GU -
Fallopian tube)
Obstruction, Gu (Obstruction, GU -
Prostate)
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Obstruction, Gu (Obstruction, GU -
Spermatic cord)
Obstruction, Gu (Obstruction, GU -
Stoma)
Obstruction, Gu (Obstruction, GU -
Testes)
Ureteric Obstruction (Obstruction, GU -
Ureter)
Obstruction, Gu (Obstruction, GU -
Urethra)
Obstruction, Gu (Obstruction, GU -
Uterus)
Obstruction, Gu (Obstruction, GU -
Vagina)
Obstruction, Gu (Obstruction, GU - Vas
deferens)
Obstruction/stenosis Of Airway
(Obstruction/stenosis of airway -
Bronchus)
Obstruction/stenosis Of Airway
(Obstruction/stenosis of airway - Larynx)
Obstruction/stenosis Of Airway
(Obstruction/stenosis of airway -
Pharynx)
Obstruction/stenosis Of Airway
(Obstruction/stenosis of airway -
Trachea)
Conjunctivitis Nec (Ocular surface
disease)
Ocular/visual Other (Ocular/Visual-Other
(Specify))
Odor (patient Odor) (Odor (patient odor))
Diplopia (Ophthalmoplegia/diplopia
(double vision))
Opportunistic Infection Associated With
>=grade 2 Lymphopenia (Opportunistic
infection associated with >=Grade 2
lymphopenia)
Optic Disc Edema (Optic disc edema)
Orgasmic Dysfunction (Orgasmic
dysfunction)
Osteonecrosis (Osteonecrosis (avascular
necrosis))
Osteoporosis (Osteoporosis)
Otitis Externa (exc Boil Of Meatus) Nos
(Otitis, external ear (non-infectious))
Otitis Media Serous Nos (Otitis, middle
ear (non-infectious))
Abdominal Pain Nos (Pain - Abdomen
NOS)
Pain (Pain - Anus)
Pain (Pain - Back)
Pain (Pain - Bladder)
Bone Pain (Pain - Bone)
Pain (Pain - Breast)
Pain (Pain - Buttock)
Pain (Pain - Cardiac/heart)
Pain (Pain - Chest wall)
Chest Pain (Pain - Chest/thorax NOS)
Pain (Pain - Dental/teeth/peridontal)
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Pain (Pain - Esophagus)
Earache (Pain - External ear)
Pain (Pain - Extremity-limb)
Pain (Pain - Eye)
Pain (Pain - Face)
Pain (Pain - Gallbladder)
Headache Nos (Pain - Head/headache)
Pain (Pain - Intestine)
Arthralgia (Pain - Joint)
Pain (Pain - Kidney)
Pain (Pain - Larynx)
Pain (Pain - Lip)
Hepatic Pain (Pain - Liver)
Pain (Pain - Lymph node)
Pain (Pain - Middle ear)
Myalgia (Pain - Muscle)
Pain (Pain - Neck)
Neuralgia Nos (Pain -
Neuralgia/peripheral nerve)
Pain (Pain - Oral cavity)
Pain (Pain - Oral-gums)
Pain (Pain - Ovulatory)
Pain (Pain - Pain NOS)
Pelvic Pain Nos (Pain - Pelvis)
Pain (Pain - Penis)
Pain (Pain - Pericardium)
Pain (Pain - Perineum)
Pain (Pain - Peritoneum)
Pain (Pain - Phantom (pain associated
with missing limb))
Pleuritic Pain (Pain - Pleura)
Pain (Pain - Prostate)
Proctalgia (Pain - Rectum)
Pain (Pain - Scalp)
Pain (Pain - Scrotum)
Pain (Pain - Sinus)
Pain (Pain - Skin)
Pain (Pain - Stomach)
Pain (Pain - Testicle)
Pain (Pain - Throat/pharynx/larynx)
Tumour Pain (Pain - Tumor pain)
Dysuria (Pain - Urethra)
Dysmenorrhoea (Pain - Uterus)
Pain (Pain - Vagina)
Pain Other (Pain-Other (Specify))
Palpitations (Palpitations)
Pancreas, Exocrine Enzyme Deficiency
(Pancreas, exocrine enzyme deficiency)
Pancreatic Endocrine: Glucose
Intolerance (Pancreatic endocrine:
glucose intolerance)
Pancreatitis Nos (Pancreatitis)
Parathyroid Function, Low
(hypoparathyroidism) (Parathyroid
function, low (hypoparathyroidism))
Perforation, Gi (Perforation, GI -
Appendix)
Perforation, Gi (Perforation, GI - Biliary
tree)
Perforation, Gi (Perforation, GI - Cecum)
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Perforation, Gi (Perforation, GI - Colon)
Perforation, Gi (Perforation, GI -
Duodenum)
Perforation, Gi (Perforation, GI -
Esophagus)
Perforation, Gi (Perforation, GI -
Gallbladder)
Perforation, Gi (Perforation, GI - Ileum)
Perforation, Gi (Perforation, GI -
Jejunum)
Perforation, Gi (Perforation, GI - Rectum)
Perforation, Gi (Perforation, GI - Small
bowel NOS)
Perforation, Gi (Perforation, GI -
Stomach)
Perforation, Gu (Perforation, GU -
Bladder)
Perforation, Gu (Perforation, GU -
Fallopian tube)
Perforation, Gu (Perforation, GU -
Kidney)
Perforation, Gu (Perforation, GU - Ovary)
Perforation, Gu (Perforation, GU -
Prostate)
Perforation, Gu (Perforation, GU -
Spermatic cord)
Perforation, Gu (Perforation, GU -
Stoma)
Perforation, Gu (Perforation, GU -
Testes)
Perforation, Gu (Perforation, GU - Ureter)
Perforation, Gu (Perforation, GU -
Urethra)
Perforation, Gu (Perforation, GU -
Uterus)
Perforation, Gu (Perforation, GU -
Vagina)
Perforation, Gu (Perforation, GU - Vas
deferens)
Pericardial Effusion (Pericardial effusion
(non-malignant))
Pericarditis (Pericarditis)
Peripheral Ischaemia Nos (Peripheral
arterial ischemia)
Personality Change
(Personality/behavioral)
Petechiae (Petechiae/purpura
(hemorrhage/bleeding into skin or
mucosa))
Phlebitis Superficial (Phlebitis (including
superficial thrombosis))
Phlebolymphatic Cording
(Phlebolymphatic cording)
Hypophosphataemia (Phosphate, serum-
low (hypophosphatemia))
Photosensitivity Reaction Nos
(Photosensitivity)
Phrenic Nerve Dysfunction (Phrenic
nerve dysfunction)
Platelet Count Decreased (Platelets)
39 / 91
Esophageal Cancer NCT00655876 Treatment - TF: Radiation Therapy Oncology
Group Phase III Esophagus Systemic Treatment Summary Form - 2598533v1.0
Pleural Effusion (Pleural effusion (non-
malignant))
Pneumonitis Nos
(Pneumonitis/pulmonary infiltrates)
Pneumothorax Nos (Pneumothorax)
Portal Hypertension (Portal vein flow)
Hyperkalaemia (Potassium, serum-high
(hyperkalemia))
Hypokalaemia (Potassium, serum-low
(hypokalemia))
Proctitis Nos (Proctitis)
Prolapse Of Stoma, Gi (Prolapse of
stoma, GI)
Prolapse Of Stoma, Gu (Prolapse of
stoma, GU)
Prolonged Chest Tube Drainage Or Air
Leak After Pulmonary Resection
(Prolonged chest tube drainage or air
leak after pulmonary resection)
Prolonged Intubation After Pulmonary
Resection (>24 Hrs After Surgery)
(Prolonged intubation after pulmonary
resection (>24 hrs after surgery))
Electrocardiogram Qt Prolonged
(Prolonged QTc interval)
Proptosis/enophthalmos
(Proptosis/enophthalmos)
Proteinuria Present (Proteinuria)
Pruritus Nos (Pruritus/itching)
Delusion Nos (Psychosis
(hallucinations/delusions))
Activated Partial Thromboplastin Time
Prolonged (PTT (Partial thromboplastin
time))
Puberty (delayed) (Puberty (delayed))
Puberty (precocious) (Puberty
(precocious))
Pulmonary Fibrosis (Pulmonary fibrosis
(radiographic changes))
Pulmonary Hypertension (Pulmonary
hypertension)
Pulmonary/upper Respiratory Other
(Pulmonary/Upper Respiratory-Other
(Specify))
Upper Motor Neurone Lesion (Pyramidal
tract dysfunction (e.g., increased tone,
hyperreflexia, positive Babinski,
decreased fine motor coordination))
Rash: Acne/acneiform (Rash:
acne/acneiform)
Radiation Recall Syndrome (Rash:
dermatitis associated with radiation -
Chemoradiation)
Dermatitis Radiation Nos (Rash:
dermatitis associated with radiation -
Radiation)
Erythema Multiforme (Rash: erythema
multiforme (e.g., Stevens-Johnson
syndrome, toxic epidermal necrolysis))
Localised Exfoliation (Rash: hand-foot
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skin reaction)
Dermatitis Exfoliative Nos
(Rash/desquamation)
Renal Failure Nos (Renal failure)
Renal/genitourinary Other
(Renal/Genitourinary-Other (Specify))
Restrictive Cardiomyopathy (Restrictive
cardiomyopathy)
Retinal Detachment (Retinal
detachment)
Retinoic Acid Syndrome (Retinoic acid
syndrome)
Retinopathy (Retinopathy)
Right Ventricular Dysfunction (cor
Pulmonale) (Right ventricular dysfunction
(cor pulmonale))
Rigors (Rigors/chills)
Salivary Gland Disorder Nos (Salivary
gland changes/saliva)
Scleral Necrosis/melt (Scleral
necrosis/melt)
Secondary Malignancy Possibly Related
To Cancer Treatment (Secondary
Malignancy-possibly related to cancer
treatment (Specify))
Convulsions Nos (Seizure)
Seroma (Seroma)
Serum Sickness (Serum sickness)
Sexual/reproductive Function Other
(Sexual/Reproductive Function-Other
(Specify))
Short Stature (Short stature)
Skin Breakdown/decubitus Ulcer (Skin
breakdown/decubitus ulcer)
Hypernatraemia (Sodium, serum-high
(hypernatremia))
Hyponatraemia (Sodium, serum-low
(hyponatremia))
Soft Tissue Necrosis (Soft tissue
necrosis - Abdomen)
Soft Tissue Necrosis (Soft tissue
necrosis - Extremity-lower)
Soft Tissue Necrosis (Soft tissue
necrosis - Extremity-upper)
Soft Tissue Necrosis (Soft tissue
necrosis - Head)
Soft Tissue Necrosis (Soft tissue
necrosis - Neck)
Soft Tissue Necrosis (Soft tissue
necrosis - Pelvic)
Soft Tissue Necrosis (Soft tissue
necrosis - Thorax)
Depressed Level Of Consciousness
(Somnolence/depressed level of
consciousness)
Speech Disorder Nec (Speech
impairment (e.g., dysphasia or aphasia))
Splenic Function (Splenic function)
Striae (Striae)
Stricture/stenosis (including
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Anastomotic), Gi (Stricture/stenosis
(including anastomotic), GI - Anus)
Stricture/stenosis (including
Anastomotic), Gi (Stricture/stenosis
(including anastomotic), GI - Biliary tree)
Stricture/stenosis (including
Anastomotic), Gi (Stricture/stenosis
(including anastomotic), GI - Cecum)
Stricture/stenosis (including
Anastomotic), Gi (Stricture/stenosis
(including anastomotic), GI - Colon)
Stricture/stenosis (including
Anastomotic), Gi (Stricture/stenosis
(including anastomotic), GI - Duodenum)
Stricture/stenosis (including
Anastomotic), Gi (Stricture/stenosis
(including anastomotic), GI - Esophagus)
Stricture/stenosis (including
Anastomotic), Gi (Stricture/stenosis
(including anastomotic), GI - Ileum)
Stricture/stenosis (including
Anastomotic), Gi (Stricture/stenosis
(including anastomotic), GI - Jejunum)
Stricture/stenosis (including
Anastomotic), Gi (Stricture/stenosis
(including anastomotic), GI -
Pancreas/pancreatic duct)
Stricture/stenosis (including
Anastomotic), Gi (Stricture/stenosis
(including anastomotic), GI - Pharynx)
Stricture/stenosis (including
Anastomotic), Gi (Stricture/stenosis
(including anastomotic), GI - Rectum)
Stricture/stenosis (including
Anastomotic), Gi (Stricture/stenosis
(including anastomotic), GI - Small bowel
NOS)
Stricture/stenosis (including
Anastomotic), Gi (Stricture/stenosis
(including anastomotic), GI - Stoma)
Stricture/stenosis (including
Anastomotic), Gi (Stricture/stenosis
(including anastomotic), GI - Stomach)
Stricture/stenosis (including
Anastomotic), Gu (Stricture/stenosis
(including anastomotic), GU - Bladder)
Stricture/stenosis (including
Anastomotic), Gu (Stricture/stenosis
(including anastomotic), GU - Fallopian
tube)
Stricture/stenosis (including
Anastomotic), Gu (Stricture/stenosis
(including anastomotic), GU - Prostate)
Stricture/stenosis (including
Anastomotic), Gu (Stricture/stenosis
(including anastomotic), GU - Spermatic
cord)
Stricture/stenosis (including
Anastomotic), Gu (Stricture/stenosis
(including anastomotic), GU - Stoma)
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Stricture/stenosis (including
Anastomotic), Gu (Stricture/stenosis
(including anastomotic), GU - Testes)
Stricture/stenosis (including
Anastomotic), Gu (Stricture/stenosis
(including anastomotic), GU - Ureter)
Stricture/stenosis (including
Anastomotic), Gu (Stricture/stenosis
(including anastomotic), GU - Urethra)
Stricture/stenosis (including
Anastomotic), Gu (Stricture/stenosis
(including anastomotic), GU - Uterus)
Stricture/stenosis (including
Anastomotic), Gu (Stricture/stenosis
(including anastomotic), GU - Vagina)
Stricture/stenosis (including
Anastomotic), Gu (Stricture/stenosis
(including anastomotic), GU - Vas
deferens)
Supraventricular And Nodal Arrhythmia
(Supraventricular and nodal arrhythmia -
Atrial fibrillation)
Supraventricular And Nodal Arrhythmia
(Supraventricular and nodal arrhythmia -
Atrial flutter)
Supraventricular And Nodal Arrhythmia
(Supraventricular and nodal arrhythmia -
Atrial tachycardia/paroxysmal atrial
tachycardia)
Supraventricular And Nodal Arrhythmia
(Supraventricular and nodal arrhythmia -
Nodal/junctional)
Supraventricular And Nodal Arrhythmia
(Supraventricular and nodal arrhythmia -
Sinus arrhythmia)
Sinus Bradycardia (Supraventricular and
nodal arrhythmia - Sinus bradycardia)
Sinus Tachycardia (Supraventricular and
nodal arrhythmia - Sinus tachycardia)
Supraventricular Arrhythmia Nos
(Supraventricular and nodal arrhythmia -
Supraventricular arrhythmia NOS)
Supraventricular And Nodal Arrhythmia -
Supraventricular Extrasystoles
(premature Atrial Contractions;
Premature Nodal/junctional
Contractions) (Supraventricular and
nodal arrhythmia - Supraventricular
extrasystoles (premature atrial
contractions; premature nodal/junctional
contractions))
Supraventricular And Nodal Arrhythmia
(Supraventricular and nodal arrhythmia -
Supraventricular tachycardia)
Sweating Increased (Sweating
(diaphoresis))
Syncope (Syncope (fainting))
Syndromes Other (Syndromes-Other
(Specify))
Taste Disturbance (Taste alteration
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(dysgeusia))
Telangiectasia (Telangiectasia)
Thrombosis/embolism (vascular Access-
related) (Thrombosis/embolism (vascular
access-related))
Thrombosis Nos
(Thrombosis/thrombus/embolism)
Thrombotic Microangiopathy (e.g.,
Thrombotic Thrombocytopenic
Purpura[ttp] Or Hemolytic Uremic
Syndrome[hus]) (Thrombotic
microangiopathy (e.g., thrombotic
thrombocytopenic purpura or hemolytic
uremic syndrome))
Thyroid Function, High (hyperthyroidism,
Thyrotoxicosis) (Thyroid function, high
(hyperthyroidism, thyrotoxicosis))
Hypothyroidism (Thyroid function, low
(hypothyroidism))
Tinnitus (Tinnitus)
Tremor Nec (Tremor)
Hypertriglyceridaemia (Triglyceride,
serum-high (hypertriglyceridemia))
Trismus (difficulty, Restriction Or Pain
When Opening Mouth) (Trismus
(difficulty, restriction or pain when
opening mouth))
Tumour Flare (Tumor flare)
Tumour Lysis Syndrome (Tumor lysis
syndrome)
Caecitis (Typhlitis (cecal inflammation))
Ulcer, Gi (Ulcer, GI - Anus)
Ulcer, Gi (Ulcer, GI - Cecum)
Ulcer, Gi (Ulcer, GI - Colon)
Duodenal Ulcer (Ulcer, GI - Duodenum)
Ulcer, Gi (Ulcer, GI - Esophagus)
Ulcer, Gi (Ulcer, GI - Ileum)
Ulcer, Gi (Ulcer, GI - Jejunum)
Ulcer, Gi (Ulcer, GI - Rectum)
Ulcer, Gi (Ulcer, GI - Small bowel NOS)
Ulcer, Gi (Ulcer, GI - Stoma)
Gastric Ulcer (Ulcer, GI - Stomach)
Ulceration (Ulceration)
Hyperuricaemia (Uric acid, serum-high
(hyperuricemia))
Fanconi Syndrome (Urinary electrolyte
wasting (e.g., Fanconi's syndrome, renal
tubular acidosis))
Urinary Frequency (Urinary
frequency/urgency)
Urinary Retention (Urinary retention
(including neurogenic bladder))
Urine Discolouration (Urine color
change)
Urticaria Nos (Urticaria (hives, welts,
wheals))
Uveitis (Uveitis)
Vaginal Discharge (non-infectious)
(Vaginal discharge (non-infectious))
Vulvovaginal Dryness (Vaginal dryness)
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Vaginal Mucositis (Vaginal mucositis)
Vaginal Stenosis/length (Vaginal
stenosis/length)
Vaginitis (Vaginitis (not due to infection))
Valvular Heart Disease (Valvular heart
disease)
Vascular Other (Vascular-Other
(Specify))
Vasculitis Nos (Vasculitis)
Vasovagal Attack (Vasovagal episode)
Ventricular Arrhythmia (Ventricular
arrhythmia - Bigeminy)
Ventricular Arrhythmia (Ventricular
arrhythmia - Idioventricular rhythm)
Ventricular Arrhythmia (Ventricular
arrhythmia - PVCs)
Ventricular Arrhythmia (Ventricular
arrhythmia - Torsade de pointes)
Ventricular Arrhythmia (Ventricular
arrhythmia - Trigeminy)
Ventricular Arrhythmia Nos (Ventricular
arrhythmia - Ventricular arrhythmia NOS)
Ventricular Arrhythmia (Ventricular
arrhythmia - Ventricular fibrillation)
Ventricular Arrhythmia (Ventricular
arrhythmia - Ventricular flutter)
Ventricular Arrhythmia (Ventricular
arrhythmia - Ventricular tachycardia)
Vessel Injury-artery (Vessel injury-artery
- Aorta)
Vessel Injury-artery (Vessel injury-artery
- Carotid)
Vessel Injury-artery (Vessel injury-artery
- Extremity-lower)
Vessel Injury-artery (Vessel injury-artery
- Extremity-upper)
Vessel Injury-artery (Vessel injury-artery
- Other NOS)
Vessel Injury-artery (Vessel injury-artery
- Visceral)
Vessel Injury-vein (Vessel injury-vein -
Extremity-lower)
Vessel Injury-vein (Vessel injury-vein -
Extremity-upper)
Vessel Injury-vein (Vessel injury-vein -
IVC)
Vessel Injury-vein (Vessel injury-vein -
Jugular)
Vessel Injury-vein (Vessel injury-vein -
Other NOS)
Vessel Injury-vein (Vessel injury-vein -
SVC)
Vessel Injury-vein (Vessel injury-vein -
Viscera)
Viral Hepatitis (Viral hepatitis)
Visceral Arterial Ischaemia (Visceral
arterial ischemia (non-myocardial))
Vision Blurred (Vision-blurred vision)
Photopsia (Vision-flashing lights/floaters)
Photophobia (Vision-photophobia)
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Vital Capacity (Vital capacity)
Vitreous Hemorrhage (Vitreous
hemorrhage)
Dysphonia (Voice changes/dysarthria
(e.g., hoarseness, loss or alteration in
voice, laryngitis))
Vomiting Nos (Vomiting)
Lacrimation Increased (Watery eye
(epiphora, tearing))
Weight Increased (Weight gain)
Weight Decreased (Weight loss)
Culture Wound Negative (Wound
complication, non-infectious)
CTC AE Grade
CTCAE Begin Date
Adverse Event Reporting to Date
CTC Adverse Event Attribution (Attribution to
Protocol Treatment See protocol sections 6 & 7
for definition of "protocol treatment")
Definite (Definite)
Possible (Possible)
Probable (Probable)
Unlikely (Unlikely)
Unrelated (Unrelated)
Has an AdEERS been filed
No (No)
Unknown (Unknown)
Yes (Yes)
Was this SAE per NCI definitions
Yes
No
Is there a reasonable possibility that the event
may have been caused by the investigational
agent
No (No)
Unknown (Unknown)
Yes (Yes)
Action taken regarding study therapy
Dose Delayed/omitted (Dose
delayed/omitted)
Dose Reduced (Dose reduced)
Agent Stopped (Dose stopped)
Drug Discontinued (Drug discontinued)
Iv Rate Decreased (IV rate decreased)
No Dose Modification (No dose
modification)
Treatment required
Concomitant Medication (Concomitant
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medication)
No Treatment Administered (None)
Surgical Procedure (Procedural Surgery)
Present Status
Not Recovered Or Not Resolved (Not
recovered/Not resolved)
Recovered Or Resolved With Sequelae
(Recovered/Resolved with Sequelae)
Recovered Or Resolved Without
Sequelae (Recovered/Resolved without
Sequelae)
Recovering Or Resolving
(Recovering/Resolving)
Report All Continuing Or New Adverse
Events
New or continuing adverse events
No (No)
Unknown (Unknown)
Yes (Yes)
MedDRA Code
CTC AE Term
Acidosis Nos (Acidosis (metabolic or
respiratory))
Capillary Leak Syndrome (Acute
vascular leak syndrome)
Adrenal Insufficiency (Adrenal
insufficiency)
Adult Respiratory Distress Syndrome
(Adult respiratory distress syndrome
(ARDS))
Blood Albumin Decreased (Albumin,
serum-low (hypoalbuminemia))
Alcohol Intolerance Syndrome
(antabuse-like Syndrome) (Alcohol
intolerance syndrome (antabuse-like
syndrome))
Blood Alkaline Phosphatase Nos
Increased (Alkaline phosphatase)
Alkalosis Nos (Alkalosis (metabolic or
respiratory))
Hypersensitivity Nos (Allergic
reaction/hypersensitivity (including drug
fever))
Rhinitis Allergic Nos (Allergic rhinitis
(including sneezing, nasal stuffiness,
postnasal drip))
Allergy/immunology Other
(Allergy/Immunology-Other (Specify))
Alanine Aminotransferase Increased
(ALT, SGPT (serum glutamic pyruvic
transaminase))
Blood Amylase Increased (Amylase)
Anorexia (Anorexia)
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Apnoea (Apnea)
Arachnoiditis
(Arachnoiditis/meningismus/radiculitis)
Arthritis Nos (Arthritis (non-septic))
Ascites (Ascites (non-malignant))
Aspiration (Aspiration)
Aspartate Aminotransferase Increased
(AST, SGOT (serum glutamic oxaloacetic
transaminase))
Ataxia Nec (Ataxia (incoordination))
Atelectasis (Atelectasis)
Atrophy, Skin (Atrophy, skin)
Atrophy, Subcutaneous Fat (Atrophy,
subcutaneous fat)
Auditory/ear Other (Auditory/Ear-Other
(Specify))
Autoimmune Disorder Nos (Autoimmune
reaction)
Blood Bicarbonate Decreased
(Bicarbonate, serum-low)
Blood Bilirubin Increased (Bilirubin
(hyperbilirubinemia))
Bladder Disorder Nos (Bladder spasms)
Blood/bone Marrow Other (Blood/Bone
Marrow-Other (Specify))
Bone Age (alteration In Bone Age) (Bone
age (alteration in bone age))
Bone Growth: Femoral Head; Slipped
Capital Femoral Epiphysis (Bone growth:
femoral head; slipped capital femoral
epiphysis)
Bone Growth: Limb Length Discrepancy
(Bone growth: limb length discrepancy)
Bone Growth: Spine Kyphosis/lordosis
(Bone growth: spine kyphosis/lordosis)
Bone Marrow Depression Nos (Bone
marrow cellularity)
Bone: Spine-scoliosis (Bone: spine-
scoliosis)
Brachial Plexopathy (Brachial
plexopathy)
Breast Function/lactation (Breast
function/lactation)
Breast Nipple/areolar Deformity (Breast
nipple/areolar deformity)
Breast Volume/hypoplasia (Breast
volume/hypoplasia)
Bronchospasm, Wheezing
(Bronchospasm, wheezing)
Ecchymosis (Bruising (in absence of
grade 3 or 4 thrombocytopenia))
Burn (Burn)
Hypercalcaemia (Calcium, serum-high
(hypercalcemia))
Hypocalcaemia (Calcium, serum-low
(hypocalcemia))
Pulmonary Function Test Nos Decreased
(Carbon monoxide diffusion capacity
(DL(co)))
Arrhythmia Nos (Cardiac Arrhythmia-
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Other (Specify))
Cardiac General Other (Cardiac
General-Other (Specify))
Myocardial Ischaemia (Cardiac
ischemia/infarction)
Cardiac Troponin I Increased (Cardiac
troponin I (cTnI))
Cardiac Troponin T Increased (Cardiac
troponin T (cTnT))
Cardiopulmonary Arrest, Cause
Unknown (non-fatal) (Cardiopulmonary
arrest, cause unknown (non-fatal))
Cataract Nec (Cataract)
Cd4 Lymphocytes Decreased (CD4
count)
Cervical Spine-range Of Motion (Cervical
spine-range of motion)
Chelitis (Cheilitis)
Cholecystitis (Cholecystitis)
Hypercholesteraemia (Cholesterol,
serum-high (hypercholesteremia))
Chyle Or Lymph Leakage (Chyle or
lymph leakage)
Chylothorax (Chylothorax)
Cerebral Ischaemia (CNS
cerebrovascular ischemia)
Cns Necrosis/cystic Progression (CNS
necrosis/cystic progression)
Coagulation Disorder Nos (Coagulation-
Other (Specify))
Learning Disorder Nos (Cognitive
disturbance)
Colitis Nos (Colitis)
Colitis, Infectious (e.g., Clostridium
Difficile) (Colitis, infectious (e.g.,
Clostridium difficile))
Ventricular Asystole (Conduction
abnormality/Atrioventricular heart block -
Asystole)
Conduction Abnormality/atrioventricular
Heart Block (Conduction
abnormality/Atrioventricular heart block -
AV block-first degree)
Conduction Abnormality/atrioventricular
Heart Block - Av Block-second Degree
Mobitz Type I (wenckebach) (Conduction
abnormality/Atrioventricular heart block -
AV block-Second degree Mobitz Type I
(Wenckebach))
Conduction Abnormality/atrioventricular
Heart Block (Conduction
abnormality/Atrioventricular heart block -
AV block-second degree Mobitz Type II)
Conduction Abnormality/atrioventricular
Heart Block (Conduction
abnormality/Atrioventricular heart block -
AV block-third degree (complete AV
block))
Conduction Abnormality/atrioventricular
Heart Block (Conduction
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abnormality/Atrioventricular heart block -
Conduction abnormality NOS)
Conduction Abnormality/atrioventricular
Heart Block (Conduction
abnormality/Atrioventricular heart block -
Sick sinus syndrome)
Conduction Abnormality/atrioventricular
Heart Block (Conduction
abnormality/Atrioventricular heart block -
Stokes-Adams syndrome)
Conduction Abnormality/atrioventricular
Heart Block (Conduction
abnormality/Atrioventricular heart block -
Wolff-Parkinson-White syndrome)
Confusion (Confusion)
Constipation (Constipation)
Constitutional Symptoms Other
(Constitutional Symptoms-Other
(Specify))
Cough (Cough)
Blood Creatine Phosphokinase
Increased (CPK (creatine
phosphokinase))
Blood Creatinine Increased (Creatinine)
Cushingoid (Cushingoid appearance
(e.g., moon face, buffalo hump,
centripetal obesity, cutaneous striae))
Cystitis (Cystitis)
Cytokine Release Syndrome/acute
Infusion Reaction (Cytokine release
syndrome/acute infusion reaction)
Death Not Associated With Ctcae Term
(Death not associated with CTCAE term
- Death NOS)
Death Not Associated With Ctcae Term
(Death not associated with CTCAE term
- Disease progression NOS)
Death Not Associated With Ctcae Term
(Death not associated with CTCAE term
- Multi-organ failure)
Death Not Associated With Ctcae Term
(Death not associated with CTCAE term
- Sudden death)
Dehydration (Dehydration)
Dental: Dentures Or Prosthesis (Dental:
dentures or prosthesis)
Dental: Periodontal Disease (Dental:
periodontal disease)
Dental: Teeth (Dental: teeth)
Dental: Teeth Development (Dental:
teeth development)
Dermal Change Lymphedema,
Phlebolymphedema (Dermal change
lymphedema, phlebolymphedema)
Dermatology/skin Other
(Dermatology/Skin-Other (Specify))
Diarrhoea Nos (Diarrhea)
Disseminated Intravascular Coagulation
(DIC (disseminated intravascular
coagulation))
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Distention/bloating, Abdominal
(Distention/bloating, abdominal)
Dizziness (exc Vertigo) (Dizziness)
Dry Eye Nec (Dry eye syndrome)
Dry Mouth (Dry mouth/salivary gland
(xerostomia))
Dry Skin (Dry skin)
Dysphagia (Dysphagia (difficulty
swallowing))
Dyspnoea Nos (Dyspnea (shortness of
breath))
Edema, Larynx (Edema, larynx)
Edema: Head And Neck (Edema: head
and neck)
Oedema Nos (Edema: limb)
Edema: Trunk/genital (Edema:
trunk/genital)
Edema: Viscera (Edema: viscera)
Ejaculatory Dysfunction (Ejaculatory
dysfunction)
Encephalopathy (Encephalopathy)
Endocrine Other (Endocrine-Other
(Specify))
Enteritis (inflammation Of The Small
Bowel) (Enteritis (inflammation of the
small bowel))
Impotence (Erectile dysfunction)
Oesophagitis Nos (Esophagitis)
Exostosis (Exostosis)
Extrapyramidal Disorder Nec
(Extrapyramidal/involuntary
movement/restlessness)
Extremity-lower (gait/walking) (Extremity-
lower (gait/walking))
Extremity-upper (function) (Extremity-
upper (function))
Eyelid Dysfunction (Eyelid dysfunction)
Fatigue (Fatigue (asthenia, lethargy,
malaise))
Febrile Neutropenia (fever Of Unknown
Origin Without Clinically Or
Microbiologically Documented Infection)
(anc <1.0 X 10^9/l, Fever >=38.5
Degrees C) (Febrile neutropenia)
Feminization (Feminization of male)
Forced Expiratory Volume Decreased
(FEV(1))
Pyrexia (Fever (in the absence of
neutropenia, where neutropenia is
defined as ANC <1.0 x 10^9/L))
Blood Fibrinogen Decreased
(Fibrinogen)
Fibrosis-cosmesis (Fibrosis-cosmesis)
Fibrosis-deep Connective Tissue
(Fibrosis-deep connective tissue)
Fistula, Gi (Fistula, GI - Abdomen NOS)
Anal Fistula (Fistula, GI - Anus)
Fistula, Gi (Fistula, GI - Biliary tree)
Fistula, Gi (Fistula, GI -
Colon/cecum/appendix)
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Intestinal Fistula (Fistula, GI -
Duodenum)
Tracheo-oesophageal Fistula Nos
(Fistula, GI - Esophagus)
Fistula, Gi (Fistula, GI - Gallbladder)
Fistula, Gi (Fistula, GI - Ileum)
Fistula, Gi (Fistula, GI - Jejunum)
Fistula, Gi (Fistula, GI - Oral cavity)
Fistula, Gi (Fistula, GI - Pancreas)
Fistula, Gi (Fistula, GI - Pharynx)
Fistula, Gi (Fistula, GI - Rectum)
Fistula, Gi (Fistula, GI - Salivary gland)
Fistula, Gi (Fistula, GI - Small bowel
NOS)
Fistula, Gi (Fistula, GI - Stomach)
Fistula, Gu (Fistula, GU - Bladder)
Fistula, Gu (Fistula, GU - Genital tract-
female)
Fistula, Gu (Fistula, GU - Kidney)
Fistula, Gu (Fistula, GU - Ureter)
Fistula, Gu (Fistula, GU - Urethra)
Fistula, Gu (Fistula, GU - Uterus)
Urogenital Fistula (Fistula, GU - Vagina)
Fistula, Pulmonary/upper Respiratory
(Fistula, pulmonary/upper respiratory -
Bronchus)
Fistula, Pulmonary/upper Respiratory
(Fistula, pulmonary/upper respiratory -
Larynx)
Fistula, Pulmonary/upper Respiratory
(Fistula, pulmonary/upper respiratory -
Lung)
Fistula, Pulmonary/upper Respiratory
(Fistula, pulmonary/upper respiratory -
Oral cavity)
Fistula, Pulmonary/upper Respiratory
(Fistula, pulmonary/upper respiratory -
Pharynx)
Fistula, Pulmonary/upper Respiratory
(Fistula, pulmonary/upper respiratory -
Pleura)
Fistula, Pulmonary/upper Respiratory
(Fistula, pulmonary/upper respiratory -
Trachea)
Flatulence (Flatulence)
Flu-like Syndrome (Flu-like syndrome)
Flushing (Flushing)
Fracture (Fracture)
Gastritis Nos (Gastritis (including bile
reflux gastritis))
Gastrointestinal Other (Gastrointestinal-
Other (Specify))
Gamma-glutamyltransferase Increased
(GGT (gamma-glutamyl transpeptidase))
Glaucoma Nos (Glaucoma)
Glomerular Filtration Rate (Glomerular
filtration rate)
Hyperglycaemia Nos (Glucose, serum-
high (hyperglycemia))
Hypoglycaemia Nos (Glucose, serum-
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low (hypoglycemia))
Growth And Development Other (Growth
and Development-Other (Specify))
Growth Velocity (reduction In Growth
Velocity) (Growth velocity (reduction in
growth velocity))
Gynaecomastia (Gynecomastia)
Alopecia (Hair loss/Alopecia (scalp or
body))
Haptoglobin Decreased (Haptoglobin)
Hearing: Patients With/without Baseline
Audiogram And Enrolled In A Monitoring
Program (Hearing: patients with/without
baseline audiogram and enrolled in a
monitoring program)
Hearing: Patients Without Baseline
Audiogram And Not Enrolled In A
Monitoring Program (Hearing: patients
without baseline audiogram and not
enrolled in a monitoring program)
Dyspepsia (Heartburn/dyspepsia)
Hematoma (Hematoma)
Haemoglobin Decreased (Hemoglobin)
Haemoglobinuria Present
(Hemoglobinuria)
Hemolysis Nos (Hemolysis (e.g.,
immune hemolytic anemia, drug related
hemolysis))
Haemorrhagic Stroke (Hemorrhage,
CNS)
Melaena (Hemorrhage, GI - Abdomen
NOS)
Hemorrhage, Gi (Hemorrhage, GI -
Anus)
Hemorrhage, Gi (Hemorrhage, GI -
Biliary tree)
Hemorrhage, Gi (Hemorrhage, GI -
Cecum/appendix)
Hemorrhage, Gi (Hemorrhage, GI -
Colon)
Hemorrhage, Gi (Hemorrhage, GI -
Duodenum)
Hemorrhage, Gi (Hemorrhage, GI -
Esophagus)
Hemorrhage, Gi (Hemorrhage, GI -
Ileum)
Hemorrhage, Gi (Hemorrhage, GI -
Jejunum)
Hemorrhage, Gi (Hemorrhage, GI - Liver)
Hemorrhage, Gi (Hemorrhage, GI -
Lower GI NOS)
Hemorrhage, Gi (Hemorrhage, GI - Oral
cavity)
Hemorrhage, Gi (Hemorrhage, GI -
Pancreas)
Hemorrhage, Gi (Hemorrhage, GI -
Peritoneal cavity)
Rectal Bleeding (Hemorrhage, GI -
Rectum)
Hemorrhage, Gi (Hemorrhage, GI -
53 / 91
Esophageal Cancer NCT00655876 Treatment - TF: Radiation Therapy Oncology
Group Phase III Esophagus Systemic Treatment Summary Form - 2598533v1.0
Stoma)
Haematemesis (Hemorrhage, GI -
Stomach)
Hemorrhage, Gi (Hemorrhage, GI -
Upper GI NOS)
Hemorrhage, Gi (Hemorrhage, GI -
Varices (esophageal))
Hemorrhage, Gi (Hemorrhage, GI -
Varices (rectal))
Hemorrhage, Gu (Hemorrhage, GU -
Bladder)
Hemorrhage, Gu (Hemorrhage, GU -
Fallopian tube)
Hemorrhage, Gu (Hemorrhage, GU -
Kidney)
Hemorrhage, Gu (Hemorrhage, GU -
Ovary)
Hemorrhage, Gu (Hemorrhage, GU -
Prostate)
Hemorrhage, Gu (Hemorrhage, GU -
Retroperitoneum)
Hemorrhage, Gu (Hemorrhage, GU -
Spermatic cord)
Hemorrhage, Gu (Hemorrhage, GU -
Stoma)
Hemorrhage, Gu (Hemorrhage, GU -
Testes)
Hemorrhage, Gu (Hemorrhage, GU -
Ureter)
Hemorrhage, Gu (Hemorrhage, GU -
Urethra)
Haematuria Present (Hemorrhage, GU -
Urinary NOS)
Hemorrhage, Gu (Hemorrhage, GU -
Uterus)
Vaginal Haemorrhage (Hemorrhage, GU
- Vagina)
Hemorrhage, Gu (Hemorrhage, GU - Vas
deferens)
Hemorrhage, Pulmonary/upper
Respiratory (Hemorrhage,
pulmonary/upper respiratory -
Bronchopulmonary NOS)
Hemorrhage, Pulmonary/upper
Respiratory (Hemorrhage,
pulmonary/upper respiratory - Bronchus)
Hemorrhage, Pulmonary/upper
Respiratory (Hemorrhage,
pulmonary/upper respiratory - Larynx)
Hemorrhage, Pulmonary/upper
Respiratory (Hemorrhage,
pulmonary/upper respiratory - Lung)
Hemorrhage, Pulmonary/upper
Respiratory (Hemorrhage,
pulmonary/upper respiratory -
Mediastinum)
Epistaxis (Hemorrhage, pulmonary/upper
respiratory - Nose)
Hemorrhage, Pulmonary/upper
Respiratory (Hemorrhage,
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pulmonary/upper respiratory - Pharynx)
Hemorrhage, Pulmonary/upper
Respiratory (Hemorrhage,
pulmonary/upper respiratory - Pleura)
Haemoptysis (Hemorrhage,
pulmonary/upper respiratory -
Respiratory tract NOS)
Hemorrhage, Pulmonary/upper
Respiratory (Hemorrhage,
pulmonary/upper respiratory - Stoma)
Hemorrhage, Pulmonary/upper
Respiratory (Hemorrhage,
pulmonary/upper respiratory - Trachea)
Post-operative Haemorrhage
(Hemorrhage/bleeding associated with
surgery, intra-operative or post-operative)
Hemorrhage/bleeding Other
(Hemorrhage/Bleeding-Other (Specify))
Hemorrhoids (Hemorrhoids)
Hepatobiliary/pancreas Other
(Hepatobiliary/Pancreas-Other (Specify))
Hiccups (Hiccoughs (hiccups, singultus))
Menopausal Symptoms (Hot
flashes/flushes)
Hydrocephalus (Hydrocephalus)
Skin Discolouration (Hyperpigmentation)
Hypertension Nos (Hypertension)
Hypopigmentation (Hypopigmentation)
Hypotension Nos (Hypotension)
Hypothermia (Hypothermia)
Hypoxia (Hypoxia)
Ileus (Ileus, GI (functional obstruction of
bowel, i.e., neuroconstipation))
Incontinence, Anal (Incontinence, anal)
Urinary Incontinence (Incontinence,
urinary)
Induration/fibrosis (skin And
Subcutaneous Tissue)
(Induration/fibrosis (skin and
subcutaneous tissue))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Abdomen NOS)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Anal/perianal)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Appendix)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
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Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Artery)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Biliary tree)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Bladder (urinary))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Blood)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Bone (osteomyelitis))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Brain (encephalitis,
infectious))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Brain + Spinal cord
(encephalomyelitis))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Bronchus)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Catheter-related)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Cecum)
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Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Cervix)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Colon)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Conjunctiva)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Cornea)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Dental-tooth)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Duodenum)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Esophagus)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - External ear (otitis externa))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Eye NOS)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Fallopian tube)
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Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Foreign body (e.g., graft,
implant, prosthesis, stent))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Gallbladder (cholecystitis))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Heart (endocarditis))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Ileum)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Jejunum)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Joint)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Kidney)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Larynx)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Lens)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
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neutrophils - Lip/perioral)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Liver)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Lung (pneumonia))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Lymphatic)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Mediastinum NOS)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Meninges (meningitis))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Middle ear (otitis media))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Mucosa)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Muscle (infection myositis))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Neck NOS)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
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neutrophils - Nerve-cranial)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Nerve-peripheral)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Nose)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Oral cavity-gums
(gingivitis))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Pancreas)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Paranasal)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Pelvis NOS)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Penis)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Peristomal)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Peritoneal cavity)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
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microbiologically) with Grade 3 or 4
neutrophils - Pharynx)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Pleura (empyema))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Prostate)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Rectum)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Salivary gland)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Scrotum)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Sinus)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Skin (cellulitis))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Small bowel NOS)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Soft tissue NOS)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
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microbiologically) with Grade 3 or 4
neutrophils - Spinal cord (myelitis))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Spleen)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Stomach)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Trachea)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Ungual (nails))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Upper aerodigestive NOS)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Upper airway NOS)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Ureter)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Urethra)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Urinary tract NOS)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
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microbiologically) with Grade 3 or 4
neutrophils - Uterus)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Vagina)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Vein)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Vulva)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Wound)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Abdomen
NOS)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils -
Anal/perianal)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Appendix)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Artery)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Biliary tree)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Bladder
(urinary))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Blood)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Bone
(osteomyelitis))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Brain
(encephalitis, infectious))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
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or Grade 1 or 2 neutrophils - Brain +
Spinal cord (encephalomyelitis))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Bronchus)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Catheter-
related)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Cecum)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Cervix)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Colon)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils -
Conjunctiva)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Cornea)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Dental-
tooth)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Duodenum)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Esophagus)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - External ear
(otitis externa))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Eye NOS)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Fallopian
tube)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Foreign
body (e.g., graft, implant, prosthesis,
stent))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Gallbladder
(cholecystitis))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Heart
(endocarditis))
Infection With Normal Anc Or Grade 1 Or
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2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Ileum)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Jejunum)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Joint)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Kidney)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Larynx)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Lens)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Lip/perioral)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Liver)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Lung
(pneumonia))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Lymphatic)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils -
Mediastinum NOS)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Meninges
(meningitis))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Middle ear
(otitis media))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Mucosa)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Muscle
(infection myositis))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Neck NOS)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Nerve-
cranial)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Nerve-
peripheral)
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Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Nose)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Oral cavity-
gums (gingivitis))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Pancreas)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Paranasal)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Pelvis NOS)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Penis)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Peristomal)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Peritoneal
cavity)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Pharynx)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Pleura
(empyema))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Prostate)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Rectum)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Salivary
gland)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Scrotum)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Sinus)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Skin
(cellulitis))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Small bowel
NOS)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Soft tissue
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NOS)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Spinal cord
(myelitis))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Spleen)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Stomach)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Trachea)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Ungual
(nails))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Upper
aerodigestive NOS)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Upper
airway NOS)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Ureter)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Urethra)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Urinary
tract NOS)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Uterus)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Vagina)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Vein)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Vulva)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Wound)
Infection With Unknown Anc (Infection
with unknown ANC - Abdomen NOS)
Infection With Unknown Anc (Infection
with unknown ANC - Anal/perianal)
Infection With Unknown Anc (Infection
with unknown ANC - Appendix)
Infection With Unknown Anc (Infection
with unknown ANC - Artery)
Infection With Unknown Anc (Infection
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with unknown ANC - Biliary tree)
Infection With Unknown Anc (Infection
with unknown ANC - Bladder (urinary))
Infection With Unknown Anc (Infection
with unknown ANC - Blood)
Infection With Unknown Anc (Infection
with unknown ANC - Bone
(osteomyelitis))
Infection With Unknown Anc (Infection
with unknown ANC - Brain (encephalitis,
infectious))
Infection With Unknown Anc (Infection
with unknown ANC - Brain + Spinal cord
(encephalomyelitis))
Infection With Unknown Anc (Infection
with unknown ANC - Bronchus)
Implant Infection (Infection with unknown
ANC - Catheter-related)
Infection With Unknown Anc (Infection
with unknown ANC - Cecum)
Infection With Unknown Anc (Infection
with unknown ANC - Cervix)
Infection With Unknown Anc (Infection
with unknown ANC - Colon)
Infection With Unknown Anc (Infection
with unknown ANC - Conjunctiva)
Infection With Unknown Anc (Infection
with unknown ANC - Cornea)
Infection With Unknown Anc (Infection
with unknown ANC - Dental-tooth)
Infection With Unknown Anc (Infection
with unknown ANC - Duodenum)
Infection With Unknown Anc (Infection
with unknown ANC - Esophagus)
Infection With Unknown Anc (Infection
with unknown ANC - External ear (otitis
externa))
Infection With Unknown Anc (Infection
with unknown ANC - Eye NOS)
Infection With Unknown Anc (Infection
with unknown ANC - Fallopian tube)
Infection With Unknown Anc (Infection
with unknown ANC - Foreign body (e.g.,
graft, implant, prosthesis, stent))
Infection With Unknown Anc (Infection
with unknown ANC - Gallbladder
(cholecystitis))
Infection With Unknown Anc (Infection
with unknown ANC - Heart
(endocarditis))
Infection With Unknown Anc (Infection
with unknown ANC - Ileum)
Infection With Unknown Anc (Infection
with unknown ANC - Jejunum)
Infection With Unknown Anc (Infection
with unknown ANC - Joint)
Infection With Unknown Anc (Infection
with unknown ANC - Kidney)
Infection With Unknown Anc (Infection
with unknown ANC - Larynx)
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Infection With Unknown Anc (Infection
with unknown ANC - Lens)
Infection With Unknown Anc (Infection
with unknown ANC - Lip/perioral)
Infection With Unknown Anc (Infection
with unknown ANC - Liver)
Infection With Unknown Anc (Infection
with unknown ANC - Lung (pneumonia))
Infection With Unknown Anc (Infection
with unknown ANC - Lymphatic)
Infection With Unknown Anc (Infection
with unknown ANC - Mediastinum NOS)
Infection With Unknown Anc (Infection
with unknown ANC - Meninges
(meningitis))
Infection With Unknown Anc (Infection
with unknown ANC - Middle ear (otitis
media))
Infection With Unknown Anc (Infection
with unknown ANC - Mucosa)
Infection With Unknown Anc (Infection
with unknown ANC - Muscle (infection
myositis))
Infection With Unknown Anc (Infection
with unknown ANC - Neck NOS)
Infection With Unknown Anc (Infection
with unknown ANC - Nerve-cranial)
Infection With Unknown Anc (Infection
with unknown ANC - Nerve-peripheral)
Infection With Unknown Anc (Infection
with unknown ANC - Nose)
Infection With Unknown Anc (Infection
with unknown ANC - Oral cavity-gums
(gingivitis))
Infection With Unknown Anc (Infection
with unknown ANC - Pancreas)
Infection With Unknown Anc (Infection
with unknown ANC - Paranasal)
Infection With Unknown Anc (Infection
with unknown ANC - Pelvis NOS)
Infection With Unknown Anc (Infection
with unknown ANC - Penis)
Infection With Unknown Anc (Infection
with unknown ANC - Peristomal)
Infection With Unknown Anc (Infection
with unknown ANC - Peritoneal cavity)
Infection With Unknown Anc (Infection
with unknown ANC - Pharynx)
Infection With Unknown Anc (Infection
with unknown ANC - Pleura (empyema))
Infection With Unknown Anc (Infection
with unknown ANC - Prostate)
Infection With Unknown Anc (Infection
with unknown ANC - Rectum)
Infection With Unknown Anc (Infection
with unknown ANC - Salivary gland)
Infection With Unknown Anc (Infection
with unknown ANC - Scrotum)
Infection With Unknown Anc (Infection
with unknown ANC - Sinus)
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Infection With Unknown Anc (Infection
with unknown ANC - Skin (cellulitis))
Infection With Unknown Anc (Infection
with unknown ANC - Small bowel NOS)
Infection With Unknown Anc (Infection
with unknown ANC - Soft tissue NOS)
Infection With Unknown Anc (Infection
with unknown ANC - Spinal cord
(myelitis))
Infection With Unknown Anc (Infection
with unknown ANC - Spleen)
Infection With Unknown Anc (Infection
with unknown ANC - Stomach)
Infection With Unknown Anc (Infection
with unknown ANC - Trachea)
Infection With Unknown Anc (Infection
with unknown ANC - Ungual (nails))
Infection With Unknown Anc (Infection
with unknown ANC - Upper aerodigestive
NOS)
Infection With Unknown Anc (Infection
with unknown ANC - Upper airway NOS)
Infection With Unknown Anc (Infection
with unknown ANC - Ureter)
Infection With Unknown Anc (Infection
with unknown ANC - Urethra)
Infection With Unknown Anc (Infection
with unknown ANC - Urinary tract NOS)
Infection With Unknown Anc (Infection
with unknown ANC - Uterus)
Infection With Unknown Anc (Infection
with unknown ANC - Vagina)
Infection With Unknown Anc (Infection
with unknown ANC - Vein)
Infection With Unknown Anc (Infection
with unknown ANC - Vulva)
Culture Wound Positive (Infection with
unknown ANC - Wound)
Infection Nos (Infection-Other (Specify))
Infertility/sterility (Infertility/sterility)
Injection Site Reaction Nos (Injection site
reaction/extravasation changes)
Prothrombin Time Prolonged (INR
(International Normalized Ratio of
prothrombin time))
Insomnia Nec (Insomnia)
Intra-operative Injury (Intra-operative
injury - Abdomen NOS)
Intra-operative Injury (Intra-operative
injury - Adrenal gland)
Intra-operative Injury (Intra-operative
injury - Anal sphincter)
Intra-operative Injury (Intra-operative
injury - Anus)
Intra-operative Injury (Intra-operative
injury - Appendix)
Intra-operative Injury (Intra-operative
injury - Artery NOS)
Intra-operative Injury (Intra-operative
injury - Artery-aorta)
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Intra-operative Injury (Intra-operative
injury - Artery-carotid)
Intra-operative Injury (Intra-operative
injury - Artery-cerebral)
Intra-operative Injury (Intra-operative
injury - Artery-extremity (lower))
Intra-operative Injury (Intra-operative
injury - Artery-extremity (upper))
Intra-operative Injury (Intra-operative
injury - Artery-hepatic)
Intra-operative Injury (Intra-operative
injury - Artery-major visceral artery)
Intra-operative Injury (Intra-operative
injury - Artery-pulmonary)
Intra-operative Injury (Intra-operative
injury - Biliary tree NOS)
Intra-operative Injury (Intra-operative
injury - Biliary tree-common bile duct)
Intra-operative Injury (Intra-operative
injury - Biliary tree-common hepatic duct)
Intra-operative Injury (Intra-operative
injury - Biliary tree-left hepatic duct)
Intra-operative Injury (Intra-operative
injury - Biliary tree-right hepatic duct)
Bladder Perforation Postoperative (Intra-
operative injury - Bladder)
Intra-operative Injury (Intra-operative
injury - Bone)
Intra-operative Injury (Intra-operative
injury - Brachial plexus)
Intra-operative Injury (Intra-operative
injury - Brain)
Intra-operative Injury (Intra-operative
injury - Breast)
Intra-operative Injury (Intra-operative
injury - Bronchus)
Intra-operative Injury (Intra-operative
injury - Cartilage)
Intra-operative Injury (Intra-operative
injury - Cecum)
Intra-operative Injury (Intra-operative
injury - Cervix)
Intra-operative Injury (Intra-operative
injury - CN I (olfactory))
Intra-operative Injury (Intra-operative
injury - CN II (optic))
Intra-operative Injury (Intra-operative
injury - CN III (oculomotor))
Intra-operative Injury (Intra-operative
injury - CN IV (trochlear))
Intra-operative Injury (Intra-operative
injury - CN IX (glossopharyngeal) motor
pharynx)
Intra-operative Injury (Intra-operative
injury - CN IX (glossopharyngeal)
sensory ear-pharynx-tongue)
Intra-operative Injury (Intra-operative
injury - CN V (trigeminal) motor)
Intra-operative Injury (Intra-operative
injury - CN V (trigeminal) sensory)
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Intra-operative Injury (Intra-operative
injury - CN VI (abducens))
Intra-operative Injury (Intra-operative
injury - CN VII (facial) motor-face)
Intra-operative Injury (Intra-operative
injury - CN VII (facial) sensory-taste)
Intra-operative Injury (Intra-operative
injury - CN VIII (vestibulocochlear))
Intra-operative Injury (Intra-operative
injury - CN X (vagus))
Intra-operative Injury (Intra-operative
injury - CN XI (spinal accessory))
Intra-operative Injury (Intra-operative
injury - CN XII (hypoglossal))
Intra-operative Injury (Intra-operative
injury - Colon)
Intra-operative Injury (Intra-operative
injury - Conjunctiva)
Intra-operative Injury (Intra-operative
injury - Cornea)
Intra-operative Injury (Intra-operative
injury - Cranial nerve or branch NOS)
Intra-operative Injury (Intra-operative
injury - Duodenum)
Intra-operative Injury (Intra-operative
injury - Esophagus)
Intra-operative Injury (Intra-operative
injury - Extremity-lower)
Intra-operative Injury (Intra-operative
injury - Extremity-upper)
Intra-operative Injury (Intra-operative
injury - Eye NOS)
Intra-operative Injury (Intra-operative
injury - Face NOS)
Intra-operative Injury (Intra-operative
injury - Fallopian tube)
Intra-operative Injury (Intra-operative
injury - Gallbladder)
Intra-operative Injury (Intra-operative
injury - Gingiva)
Intra-operative Injury (Intra-operative
injury - Heart)
Intra-operative Injury (Intra-operative
injury - Ileum)
Intra-operative Injury (Intra-operative
injury - Inner ear)
Intra-operative Injury (Intra-operative
injury - Jejunum)
Intra-operative Injury (Intra-operative
injury - Joint)
Intra-operative Injury (Intra-operative
injury - Kidney)
Intra-operative Injury (Intra-operative
injury - Larynx)
Intra-operative Injury (Intra-operative
injury - Lens)
Intra-operative Injury (Intra-operative
injury - Ligament)
Intra-operative Injury (Intra-operative
injury - Lingual)
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Intra-operative Injury (Intra-operative
injury - Lip/perioral area)
Intra-operative Injury (Intra-operative
injury - Liver)
Intra-operative Injury (Intra-operative
injury - Lung)
Intra-operative Injury (Intra-operative
injury - Lung thoracic)
Intra-operative Injury (Intra-operative
injury - Mediastinum)
Intra-operative Injury (Intra-operative
injury - Meninges)
Intra-operative Injury (Intra-operative
injury - Middle ear)
Intra-operative Injury (Intra-operative
injury - Muscle)
Intra-operative Injury (Intra-operative
injury - Nails)
Intra-operative Injury (Intra-operative
injury - Nasal cavity)
Intra-operative Injury (Intra-operative
injury - Nasopharynx)
Intra-operative Injury (Intra-operative
injury - Neck NOS)
Intra-operative Injury (Intra-operative
injury - Nose)
Intra-operative Injury (Intra-operative
injury - Oral)
Intra-operative Injury (Intra-operative
injury - Oral cavity NOS)
Intra-operative Injury (Intra-operative
injury - Outer ear NOS)
Intra-operative Injury (Intra-operative
injury - Outer ear-pinna)
Intra-operative Injury (Intra-operative
injury - Ovary)
Intra-operative Injury (Intra-operative
injury - Pancreas)
Intra-operative Injury (Intra-operative
injury - Pancreatic duct)
Intra-operative Injury (Intra-operative
injury - Parathyroid)
Intra-operative Injury (Intra-operative
injury - Parotid gland)
Intra-operative Injury (Intra-operative
injury - Pelvis NOS)
Intra-operative Injury (Intra-operative
injury - Penis)
Intra-operative Injury (Intra-operative
injury - Peripheral motor NOS)
Intra-operative Injury (Intra-operative
injury - Peripheral sensory NOS)
Intra-operative Injury (Intra-operative
injury - Peritoneal cavity)
Intra-operative Injury (Intra-operative
injury - Pharynx)
Intra-operative Injury (Intra-operative
injury - Pituitary)
Intra-operative Injury (Intra-operative
injury - Pleura)
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Intra-operative Injury (Intra-operative
injury - Prostate)
Intra-operative Injury (Intra-operative
injury - Rectum)
Intra-operative Injury (Intra-operative
injury - Recurrent laryngeal)
Intra-operative Injury (Intra-operative
injury - Retina)
Intra-operative Injury (Intra-operative
injury - Sacral plexus)
Intra-operative Injury (Intra-operative
injury - Salivary duct)
Intra-operative Injury (Intra-operative
injury - Salivary gland)
Intra-operative Injury (Intra-operative
injury - Sciatic)
Intra-operative Injury (Intra-operative
injury - Scrotum)
Intra-operative Injury (Intra-operative
injury - Sinus)
Intra-operative Injury (Intra-operative
injury - Skin)
Intra-operative Injury (Intra-operative
injury - Small bowel NOS)
Intra-operative Injury (Intra-operative
injury - Soft tissue NOS)
Intra-operative Injury (Intra-operative
injury - Spinal cord)
Intra-operative Injury (Intra-operative
injury - Spleen)
Intra-operative Injury (Intra-operative
injury - Stoma (GI))
Intra-operative Injury (Intra-operative
injury - Stomach)
Intra-operative Injury (Intra-operative
injury - Teeth)
Intra-operative Injury (Intra-operative
injury - Tendon)
Intra-operative Injury (Intra-operative
injury - Testis)
Intra-operative Injury (Intra-operative
injury - Thoracic duct)
Intra-operative Injury (Intra-operative
injury - Thoracodorsal)
Intra-operative Injury (Intra-operative
injury - Thyroid)
Intra-operative Injury (Intra-operative
injury - Tongue)
Intra-operative Injury (Intra-operative
injury - Trachea)
Intra-operative Injury (Intra-operative
injury - Upper aerodigestive NOS)
Intra-operative Injury (Intra-operative
injury - Upper airway NOS)
Intra-operative Injury (Intra-operative
injury - Ureter)
Intra-operative Injury (Intra-operative
injury - Urethra)
Intra-operative Injury (Intra-operative
injury - Urinary conduit)
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Intra-operative Injury (Intra-operative
injury - Urinary tract NOS)
Intra-operative Injury (Intra-operative
injury - Uterus)
Intra-operative Injury (Intra-operative
injury - Vagina)
Intra-operative Injury - Vein (Intra-
operative injury - Vein NOS)
Intra-operative Injury (Intra-operative
injury - Vein-extremity (lower))
Intra-operative Injury (Intra-operative
injury - Vein-extremity (upper))
Intra-operative Injury (Intra-operative
injury - Vein-hepatic)
Intra-operative Injury (Intra-operative
injury - Vein-inferior vena cava)
Intra-operative Injury (Intra-operative
injury - Vein-jugular)
Intra-operative Injury (Intra-operative
injury - Vein-major visceral vein)
Intra-operative Injury (Intra-operative
injury - Vein-portal vein)
Intra-operative Injury (Intra-operative
injury - Vein-pulmonary)
Intra-operative Injury (Intra-operative
injury - Vein-superior vena cava)
Intra-operative Injury (Intra-operative
injury - Vulva)
Intra-operative Injury Other (Intra-
operative Injury-Other (Specify))
Iron Overload (Iron overload)
Menstruation Irregular (Irregular menses
(change from baseline))
Irritability (Irritability (children <3 years of
age))
Joint-effusion (Joint-effusion)
Joint-effusion (Joint-function)
Keratitis Nec (Keratitis (corneal
inflammation/corneal ulceration))
Laryngeal Nerve Dysfunction (Laryngeal
nerve dysfunction)
Leak (including Anastomotic), Gi (Leak
(including anastomotic), GI - Biliary tree)
Leak (including Anastomotic), Gi (Leak
(including anastomotic), GI - Esophagus)
Leak (including Anastomotic), Gi (Leak
(including anastomotic), GI - Large
bowel)
Leak (including Anastomotic), Gi (Leak
(including anastomotic), GI - Leak NOS)
Leak (including Anastomotic), Gi (Leak
(including anastomotic), GI - Pancreas)
Leak (including Anastomotic), Gi (Leak
(including anastomotic), GI - Pharynx)
Leak (including Anastomotic), Gi (Leak
(including anastomotic), GI - Rectum)
Leak (including Anastomotic), Gi (Leak
(including anastomotic), GI - Small
bowel)
Leak (including Anastomotic), Gi (Leak
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(including anastomotic), GI - Stoma)
Leak (including Anastomotic), Gi (Leak
(including anastomotic), GI - Stomach)
Leak (including Anastomotic), Gu (Leak
(including anastomotic), GU - Bladder)
Leak (including Anastomotic), Gu (Leak
(including anastomotic), GU - Fallopian
tube)
Leak (including Anastomotic), Gu (Leak
(including anastomotic), GU - Kidney)
Leak (including Anastomotic), Gu (Leak
(including anastomotic), GU - Spermatic
cord)
Leak (including Anastomotic), Gu (Leak
(including anastomotic), GU - Stoma)
Leak (including Anastomotic), Gu (Leak
(including anastomotic), GU - Ureter)
Leak (including Anastomotic), Gu (Leak
(including anastomotic), GU - Urethra)
Leak (including Anastomotic), Gu (Leak
(including anastomotic), GU - Uterus)
Leak (including Anastomotic), Gu (Leak
(including anastomotic), GU - Vagina)
Leak (including Anastomotic), Gu (Leak
(including anastomotic), GU - Vas
deferens)
Leak, Cerebrospinal Fluid (csf) (Leak,
cerebrospinal fluid (CSF))
Left Ventricular Diastolic Dysfunction
(Left ventricular diastolic dysfunction)
Left Ventricular Failure (Left ventricular
systolic dysfunction)
Leucopenia Nos (Leukocytes (total
WBC))
Encephalopathy Nos
(Leukoencephalopathy (radiolographic
findings))
Libido Decreased (Libido)
Lipase Increased (Lipase)
Hepatic Failure (Liver dysfunction/failure
(clinical))
Local Complication - Device/prosthesis-
related (Local complication -
device/prosthesis-related)
Lumbar Spine-range Of Motion (Lumbar
spine-range of motion)
Lymphatics Other (Lymphatics-Other
(Specify))
Lymphedema-related Fibrosis
(Lymphedema-related fibrosis)
Lymphocele (Lymphocele)
Lymphopenia (Lymphopenia)
Hypermagnesaemia (Magnesium,
serum-high (hypermagnesemia))
Blood Magnesium Decreased
(Magnesium, serum-low
(hypomagnesemia))
Malabsorption (Malabsorption)
Virilism (Masculinization of female)
Amnesia Nec (Memory impairment)
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Mental Status (Mental status)
Metabolic/laboratory Other
(Metabolic/Laboratory-Other (Specify))
Mood Alteration - Agitation (Mood
alteration - agitation)
Anxiety Nec (Mood alteration - anxiety)
Depression Nec (Mood alteration -
depression)
Euphoric Mood (Mood alteration -
euphoria)
Mucositis/stomatitis (clinical Exam)
(Mucositis/stomatitis (clinical exam) -
Anus)
Mucositis/stomatitis (clinical Exam)
(Mucositis/stomatitis (clinical exam) -
Esophagus)
Mucositis/stomatitis (clinical Exam)
(Mucositis/stomatitis (clinical exam) -
Large bowel)
Mucositis/stomatitis (clinical Exam)
(Mucositis/stomatitis (clinical exam) -
Larynx)
Mucositis/stomatitis (clinical Exam)
(Mucositis/stomatitis (clinical exam) -
Oral cavity)
Stomatitis (Mucositis/stomatitis (clinical
exam) - Pharynx)
Mucositis/stomatitis (clinical Exam)
(Mucositis/stomatitis (clinical exam) -
Rectum)
Mucositis/stomatitis (clinical Exam)
(Mucositis/stomatitis (clinical exam) -
Small bowel)
Mucositis/stomatitis (clinical Exam)
(Mucositis/stomatitis (clinical exam) -
Stomach)
Mucositis/stomatitis (clinical Exam)
(Mucositis/stomatitis (clinical exam) -
Trachea)
Mucositis/stomatitis
(functional/symptomatic)
(Mucositis/stomatitis
(functional/symptomatic) - Anus)
Mucositis/stomatitis
(functional/symptomatic)
(Mucositis/stomatitis
(functional/symptomatic) - Esophagus)
Mucositis/stomatitis
(functional/symptomatic)
(Mucositis/stomatitis
(functional/symptomatic) - Large bowel)
Mucositis/stomatitis
(functional/symptomatic)
(Mucositis/stomatitis
(functional/symptomatic) - Larynx)
Mucositis/stomatitis
(functional/symptomatic)
(Mucositis/stomatitis
(functional/symptomatic) - Oral cavity)
Mucositis/stomatitis
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(functional/symptomatic)
(Mucositis/stomatitis
(functional/symptomatic) - Pharynx)
Mucositis/stomatitis
(functional/symptomatic)
(Mucositis/stomatitis
(functional/symptomatic) - Rectum)
Mucositis/stomatitis
(functional/symptomatic)
(Mucositis/stomatitis
(functional/symptomatic) - Small bowel)
Mucositis/stomatitis
(functional/symptomatic)
(Mucositis/stomatitis
(functional/symptomatic) - Stomach)
Mucositis/stomatitis
(functional/symptomatic)
(Mucositis/stomatitis
(functional/symptomatic) - Trachea)
Muscle Weakness, Generalized Or
Specific Area (not Due To Neuropathy)
(Muscle weakness, generalized or
specific area (not due to neuropathy) -
Extraocular)
Muscle Weakness, Generalized Or
Specific Area (not Due To Neuropathy)
(Muscle weakness, generalized or
specific area (not due to neuropathy) -
Extremity-lower)
Muscle Weakness, Generalized Or
Specific Area (not Due To Neuropathy)
(Muscle weakness, generalized or
specific area (not due to neuropathy) -
Extremity-upper)
Muscle Weakness, Generalized Or
Specific Area (not Due To Neuropathy)
(Muscle weakness, generalized or
specific area (not due to neuropathy) -
Facial)
Muscle Weakness, Generalized Or
Specific Area (not Due To Neuropathy)
(Muscle weakness, generalized or
specific area (not due to neuropathy) -
Left-sided)
Muscle Weakness, Generalized Or
Specific Area (not Due To Neuropathy)
(Muscle weakness, generalized or
specific area (not due to neuropathy) -
Ocular)
Muscle Weakness, Generalized Or
Specific Area (not Due To Neuropathy)
(Muscle weakness, generalized or
specific area (not due to neuropathy) -
Pelvic)
Muscle Weakness, Generalized Or
Specific Area (not Due To Neuropathy)
(Muscle weakness, generalized or
specific area (not due to neuropathy) -
Right-sided)
Muscle Weakness, Generalized Or
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Specific Area (not Due To Neuropathy)
(Muscle weakness, generalized or
specific area (not due to neuropathy) -
Trunk)
Muscle Weakness Nos (Muscle
weakness, generalized or specific area
(not due to neuropathy) - Whole
body/generalized)
Muscular/skeletal Hypoplasia
(Muscular/skeletal hypoplasia)
Musculoskeletal/soft Tissue Other
(Musculoskeletal/Soft Tissue-Other
(Specify))
Myelitis (Myelitis)
Myelodysplasia (Myelodysplasia)
Myocarditis Nos (Myocarditis)
Myositis (Myositis (inflammation/damage
of muscle))
Nail Abnormality Nos (Nail changes)
Nasal Cavity/paranasal Sinus Reactions
(Nasal cavity/paranasal sinus reactions)
Nausea (Nausea)
Necrosis, Gi (Necrosis, GI - Anus)
Necrosis, Gi (Necrosis, GI -
Colon/cecum/appendix)
Necrosis, Gi (Necrosis, GI - Duodenum)
Necrosis, Gi (Necrosis, GI - Esophagus)
Necrosis, Gi (Necrosis, GI - Gallbladder)
Necrosis, Gi (Necrosis, GI - Hepatic)
Necrosis, Gi (Necrosis, GI - Ileum)
Necrosis, Gi (Necrosis, GI - Jejunum)
Necrosis, Gi (Necrosis, GI - Oral)
Necrosis, Gi (Necrosis, GI - Pancreas)
Necrosis, Gi (Necrosis, GI - Peritoneal
cavity)
Necrosis, Gi (Necrosis, GI - Pharynx)
Necrosis, Gi (Necrosis, GI - Rectum)
Necrosis, Gi (Necrosis, GI - Small bowel
NOS)
Necrosis, Gi (Necrosis, GI - Stoma)
Necrosis, Gi (Necrosis, GI - Stomach)
Neuroendocrine: Acth Deficiency
(Neuroendocrine: ACTH deficiency)
Inappropriate Adh Secretion
(Neuroendocrine: ADH secretion
abnormality (e.g., SIADH or low ADH))
Neuroendocrine: Gonadotropin Secretion
Abnormality (Neuroendocrine:
gonadotropin secretion abnormality)
Neuroendocrine: Growth Hormone
Secretion Abnormality (Neuroendocrine:
growth hormone secretion abnormality)
Neuroendocrine: Prolactin Hormone
Secretion Abnormality (Neuroendocrine:
prolactin hormone secretion abnormality)
Neurology Other (Neurology-Other
(Specify))
Parosmia (Neuropathy: cranial - CN I
Smell)
Cranial Nerve Injury Nos (Neuropathy:
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cranial - CN II Vision)
Neuropathy: Cranial (Neuropathy: cranial
- CN III Pupil, upper eyelid, extra ocular
movements)
Neuropathy: Cranial (Neuropathy: cranial
- CN IV Downward, inward movement of
eye)
Neuropathy: Cranial (Neuropathy: cranial
- CN IX Motor-pharynx; Sensory-ear,
pharynx, tongue)
Neuropathy: Cranial (Neuropathy: cranial
- CN V Motor-jaw muscles; Sensory-
facial)
Neuropathy: Cranial (Neuropathy: cranial
- CN VI Lateral deviation of eye)
Neuropathy: Cranial (Neuropathy: cranial
- CN VII Motor-face; Sensory-taste)
Neuropathy: Cranial (Neuropathy: cranial
- CN VIII Hearing and balance)
Neuropathy: Cranial (Neuropathy: cranial
- CN X Motor-palate; pharynx, larynx)
Neuropathy: Cranial (Neuropathy: cranial
- CN XI Motor-sternomastoid and
trapezius)
Neuropathy: Cranial (Neuropathy: cranial
- CN XII Motor-tongue)
Peripheral Motor Neuropathy
(Neuropathy: motor)
Peripheral Sensory Neuropathy
(Neuropathy: sensory)
Neutropenia (Neutrophils/granulocytes
(ANC/AGC))
Blindness Night (Night blindness
(nyctalopia))
Nystagmus Nos (Nystagmus)
Obesity (Obesity)
Obstruction, Gi (Obstruction, GI -
Cecum)
Obstruction, Gi (Obstruction, GI - Colon)
Obstruction, Gi (Obstruction, GI -
Duodenum)
Obstruction, Gi (Obstruction, GI -
Esophagus)
Obstruction, Gi (Obstruction, GI -
Gallbladder)
Obstruction, Gi (Obstruction, GI - Ileum)
Obstruction, Gi (Obstruction, GI -
Jejunum)
Obstruction, Gi (Obstruction, GI -
Rectum)
Obstruction, Gi (Obstruction, GI - Small
bowel NOS)
Obstruction, Gi (Obstruction, GI - Stoma)
Obstruction, Gi (Obstruction, GI -
Stomach)
Obstruction, Gu (Obstruction, GU -
Bladder)
Obstruction, Gu (Obstruction, GU -
Fallopian tube)
Obstruction, Gu (Obstruction, GU -
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Prostate)
Obstruction, Gu (Obstruction, GU -
Spermatic cord)
Obstruction, Gu (Obstruction, GU -
Stoma)
Obstruction, Gu (Obstruction, GU -
Testes)
Ureteric Obstruction (Obstruction, GU -
Ureter)
Obstruction, Gu (Obstruction, GU -
Urethra)
Obstruction, Gu (Obstruction, GU -
Uterus)
Obstruction, Gu (Obstruction, GU -
Vagina)
Obstruction, Gu (Obstruction, GU - Vas
deferens)
Obstruction/stenosis Of Airway
(Obstruction/stenosis of airway -
Bronchus)
Obstruction/stenosis Of Airway
(Obstruction/stenosis of airway - Larynx)
Obstruction/stenosis Of Airway
(Obstruction/stenosis of airway -
Pharynx)
Obstruction/stenosis Of Airway
(Obstruction/stenosis of airway -
Trachea)
Conjunctivitis Nec (Ocular surface
disease)
Ocular/visual Other (Ocular/Visual-Other
(Specify))
Odor (patient Odor) (Odor (patient odor))
Diplopia (Ophthalmoplegia/diplopia
(double vision))
Opportunistic Infection Associated With
>=grade 2 Lymphopenia (Opportunistic
infection associated with >=Grade 2
lymphopenia)
Optic Disc Edema (Optic disc edema)
Orgasmic Dysfunction (Orgasmic
dysfunction)
Osteonecrosis (Osteonecrosis (avascular
necrosis))
Osteoporosis (Osteoporosis)
Otitis Externa (exc Boil Of Meatus) Nos
(Otitis, external ear (non-infectious))
Otitis Media Serous Nos (Otitis, middle
ear (non-infectious))
Abdominal Pain Nos (Pain - Abdomen
NOS)
Pain (Pain - Anus)
Pain (Pain - Back)
Pain (Pain - Bladder)
Bone Pain (Pain - Bone)
Pain (Pain - Breast)
Pain (Pain - Buttock)
Pain (Pain - Cardiac/heart)
Pain (Pain - Chest wall)
Chest Pain (Pain - Chest/thorax NOS)
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Pain (Pain - Dental/teeth/peridontal)
Pain (Pain - Esophagus)
Earache (Pain - External ear)
Pain (Pain - Extremity-limb)
Pain (Pain - Eye)
Pain (Pain - Face)
Pain (Pain - Gallbladder)
Headache Nos (Pain - Head/headache)
Pain (Pain - Intestine)
Arthralgia (Pain - Joint)
Pain (Pain - Kidney)
Pain (Pain - Larynx)
Pain (Pain - Lip)
Hepatic Pain (Pain - Liver)
Pain (Pain - Lymph node)
Pain (Pain - Middle ear)
Myalgia (Pain - Muscle)
Pain (Pain - Neck)
Neuralgia Nos (Pain -
Neuralgia/peripheral nerve)
Pain (Pain - Oral cavity)
Pain (Pain - Oral-gums)
Pain (Pain - Ovulatory)
Pain (Pain - Pain NOS)
Pelvic Pain Nos (Pain - Pelvis)
Pain (Pain - Penis)
Pain (Pain - Pericardium)
Pain (Pain - Perineum)
Pain (Pain - Peritoneum)
Pain (Pain - Phantom (pain associated
with missing limb))
Pleuritic Pain (Pain - Pleura)
Pain (Pain - Prostate)
Proctalgia (Pain - Rectum)
Pain (Pain - Scalp)
Pain (Pain - Scrotum)
Pain (Pain - Sinus)
Pain (Pain - Skin)
Pain (Pain - Stomach)
Pain (Pain - Testicle)
Pain (Pain - Throat/pharynx/larynx)
Tumour Pain (Pain - Tumor pain)
Dysuria (Pain - Urethra)
Dysmenorrhoea (Pain - Uterus)
Pain (Pain - Vagina)
Pain Other (Pain-Other (Specify))
Palpitations (Palpitations)
Pancreas, Exocrine Enzyme Deficiency
(Pancreas, exocrine enzyme deficiency)
Pancreatic Endocrine: Glucose
Intolerance (Pancreatic endocrine:
glucose intolerance)
Pancreatitis Nos (Pancreatitis)
Parathyroid Function, Low
(hypoparathyroidism) (Parathyroid
function, low (hypoparathyroidism))
Perforation, Gi (Perforation, GI -
Appendix)
Perforation, Gi (Perforation, GI - Biliary
tree)
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Perforation, Gi (Perforation, GI - Cecum)
Perforation, Gi (Perforation, GI - Colon)
Perforation, Gi (Perforation, GI -
Duodenum)
Perforation, Gi (Perforation, GI -
Esophagus)
Perforation, Gi (Perforation, GI -
Gallbladder)
Perforation, Gi (Perforation, GI - Ileum)
Perforation, Gi (Perforation, GI -
Jejunum)
Perforation, Gi (Perforation, GI - Rectum)
Perforation, Gi (Perforation, GI - Small
bowel NOS)
Perforation, Gi (Perforation, GI -
Stomach)
Perforation, Gu (Perforation, GU -
Bladder)
Perforation, Gu (Perforation, GU -
Fallopian tube)
Perforation, Gu (Perforation, GU -
Kidney)
Perforation, Gu (Perforation, GU - Ovary)
Perforation, Gu (Perforation, GU -
Prostate)
Perforation, Gu (Perforation, GU -
Spermatic cord)
Perforation, Gu (Perforation, GU -
Stoma)
Perforation, Gu (Perforation, GU -
Testes)
Perforation, Gu (Perforation, GU - Ureter)
Perforation, Gu (Perforation, GU -
Urethra)
Perforation, Gu (Perforation, GU -
Uterus)
Perforation, Gu (Perforation, GU -
Vagina)
Perforation, Gu (Perforation, GU - Vas
deferens)
Pericardial Effusion (Pericardial effusion
(non-malignant))
Pericarditis (Pericarditis)
Peripheral Ischaemia Nos (Peripheral
arterial ischemia)
Personality Change
(Personality/behavioral)
Petechiae (Petechiae/purpura
(hemorrhage/bleeding into skin or
mucosa))
Phlebitis Superficial (Phlebitis (including
superficial thrombosis))
Phlebolymphatic Cording
(Phlebolymphatic cording)
Hypophosphataemia (Phosphate, serum-
low (hypophosphatemia))
Photosensitivity Reaction Nos
(Photosensitivity)
Phrenic Nerve Dysfunction (Phrenic
nerve dysfunction)
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Platelet Count Decreased (Platelets)
Pleural Effusion (Pleural effusion (non-
malignant))
Pneumonitis Nos
(Pneumonitis/pulmonary infiltrates)
Pneumothorax Nos (Pneumothorax)
Portal Hypertension (Portal vein flow)
Hyperkalaemia (Potassium, serum-high
(hyperkalemia))
Hypokalaemia (Potassium, serum-low
(hypokalemia))
Proctitis Nos (Proctitis)
Prolapse Of Stoma, Gi (Prolapse of
stoma, GI)
Prolapse Of Stoma, Gu (Prolapse of
stoma, GU)
Prolonged Chest Tube Drainage Or Air
Leak After Pulmonary Resection
(Prolonged chest tube drainage or air
leak after pulmonary resection)
Prolonged Intubation After Pulmonary
Resection (>24 Hrs After Surgery)
(Prolonged intubation after pulmonary
resection (>24 hrs after surgery))
Electrocardiogram Qt Prolonged
(Prolonged QTc interval)
Proptosis/enophthalmos
(Proptosis/enophthalmos)
Proteinuria Present (Proteinuria)
Pruritus Nos (Pruritus/itching)
Delusion Nos (Psychosis
(hallucinations/delusions))
Activated Partial Thromboplastin Time
Prolonged (PTT (Partial thromboplastin
time))
Puberty (delayed) (Puberty (delayed))
Puberty (precocious) (Puberty
(precocious))
Pulmonary Fibrosis (Pulmonary fibrosis
(radiographic changes))
Pulmonary Hypertension (Pulmonary
hypertension)
Pulmonary/upper Respiratory Other
(Pulmonary/Upper Respiratory-Other
(Specify))
Upper Motor Neurone Lesion (Pyramidal
tract dysfunction (e.g., increased tone,
hyperreflexia, positive Babinski,
decreased fine motor coordination))
Rash: Acne/acneiform (Rash:
acne/acneiform)
Radiation Recall Syndrome (Rash:
dermatitis associated with radiation -
Chemoradiation)
Dermatitis Radiation Nos (Rash:
dermatitis associated with radiation -
Radiation)
Erythema Multiforme (Rash: erythema
multiforme (e.g., Stevens-Johnson
syndrome, toxic epidermal necrolysis))
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Localised Exfoliation (Rash: hand-foot
skin reaction)
Dermatitis Exfoliative Nos
(Rash/desquamation)
Renal Failure Nos (Renal failure)
Renal/genitourinary Other
(Renal/Genitourinary-Other (Specify))
Restrictive Cardiomyopathy (Restrictive
cardiomyopathy)
Retinal Detachment (Retinal
detachment)
Retinoic Acid Syndrome (Retinoic acid
syndrome)
Retinopathy (Retinopathy)
Right Ventricular Dysfunction (cor
Pulmonale) (Right ventricular dysfunction
(cor pulmonale))
Rigors (Rigors/chills)
Salivary Gland Disorder Nos (Salivary
gland changes/saliva)
Scleral Necrosis/melt (Scleral
necrosis/melt)
Secondary Malignancy Possibly Related
To Cancer Treatment (Secondary
Malignancy-possibly related to cancer
treatment (Specify))
Convulsions Nos (Seizure)
Seroma (Seroma)
Serum Sickness (Serum sickness)
Sexual/reproductive Function Other
(Sexual/Reproductive Function-Other
(Specify))
Short Stature (Short stature)
Skin Breakdown/decubitus Ulcer (Skin
breakdown/decubitus ulcer)
Hypernatraemia (Sodium, serum-high
(hypernatremia))
Hyponatraemia (Sodium, serum-low
(hyponatremia))
Soft Tissue Necrosis (Soft tissue
necrosis - Abdomen)
Soft Tissue Necrosis (Soft tissue
necrosis - Extremity-lower)
Soft Tissue Necrosis (Soft tissue
necrosis - Extremity-upper)
Soft Tissue Necrosis (Soft tissue
necrosis - Head)
Soft Tissue Necrosis (Soft tissue
necrosis - Neck)
Soft Tissue Necrosis (Soft tissue
necrosis - Pelvic)
Soft Tissue Necrosis (Soft tissue
necrosis - Thorax)
Depressed Level Of Consciousness
(Somnolence/depressed level of
consciousness)
Speech Disorder Nec (Speech
impairment (e.g., dysphasia or aphasia))
Splenic Function (Splenic function)
Striae (Striae)
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Stricture/stenosis (including
Anastomotic), Gi (Stricture/stenosis
(including anastomotic), GI - Anus)
Stricture/stenosis (including
Anastomotic), Gi (Stricture/stenosis
(including anastomotic), GI - Biliary tree)
Stricture/stenosis (including
Anastomotic), Gi (Stricture/stenosis
(including anastomotic), GI - Cecum)
Stricture/stenosis (including
Anastomotic), Gi (Stricture/stenosis
(including anastomotic), GI - Colon)
Stricture/stenosis (including
Anastomotic), Gi (Stricture/stenosis
(including anastomotic), GI - Duodenum)
Stricture/stenosis (including
Anastomotic), Gi (Stricture/stenosis
(including anastomotic), GI - Esophagus)
Stricture/stenosis (including
Anastomotic), Gi (Stricture/stenosis
(including anastomotic), GI - Ileum)
Stricture/stenosis (including
Anastomotic), Gi (Stricture/stenosis
(including anastomotic), GI - Jejunum)
Stricture/stenosis (including
Anastomotic), Gi (Stricture/stenosis
(including anastomotic), GI -
Pancreas/pancreatic duct)
Stricture/stenosis (including
Anastomotic), Gi (Stricture/stenosis
(including anastomotic), GI - Pharynx)
Stricture/stenosis (including
Anastomotic), Gi (Stricture/stenosis
(including anastomotic), GI - Rectum)
Stricture/stenosis (including
Anastomotic), Gi (Stricture/stenosis
(including anastomotic), GI - Small bowel
NOS)
Stricture/stenosis (including
Anastomotic), Gi (Stricture/stenosis
(including anastomotic), GI - Stoma)
Stricture/stenosis (including
Anastomotic), Gi (Stricture/stenosis
(including anastomotic), GI - Stomach)
Stricture/stenosis (including
Anastomotic), Gu (Stricture/stenosis
(including anastomotic), GU - Bladder)
Stricture/stenosis (including
Anastomotic), Gu (Stricture/stenosis
(including anastomotic), GU - Fallopian
tube)
Stricture/stenosis (including
Anastomotic), Gu (Stricture/stenosis
(including anastomotic), GU - Prostate)
Stricture/stenosis (including
Anastomotic), Gu (Stricture/stenosis
(including anastomotic), GU - Spermatic
cord)
Stricture/stenosis (including
Anastomotic), Gu (Stricture/stenosis
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(including anastomotic), GU - Stoma)
Stricture/stenosis (including
Anastomotic), Gu (Stricture/stenosis
(including anastomotic), GU - Testes)
Stricture/stenosis (including
Anastomotic), Gu (Stricture/stenosis
(including anastomotic), GU - Ureter)
Stricture/stenosis (including
Anastomotic), Gu (Stricture/stenosis
(including anastomotic), GU - Urethra)
Stricture/stenosis (including
Anastomotic), Gu (Stricture/stenosis
(including anastomotic), GU - Uterus)
Stricture/stenosis (including
Anastomotic), Gu (Stricture/stenosis
(including anastomotic), GU - Vagina)
Stricture/stenosis (including
Anastomotic), Gu (Stricture/stenosis
(including anastomotic), GU - Vas
deferens)
Supraventricular And Nodal Arrhythmia
(Supraventricular and nodal arrhythmia -
Atrial fibrillation)
Supraventricular And Nodal Arrhythmia
(Supraventricular and nodal arrhythmia -
Atrial flutter)
Supraventricular And Nodal Arrhythmia
(Supraventricular and nodal arrhythmia -
Atrial tachycardia/paroxysmal atrial
tachycardia)
Supraventricular And Nodal Arrhythmia
(Supraventricular and nodal arrhythmia -
Nodal/junctional)
Supraventricular And Nodal Arrhythmia
(Supraventricular and nodal arrhythmia -
Sinus arrhythmia)
Sinus Bradycardia (Supraventricular and
nodal arrhythmia - Sinus bradycardia)
Sinus Tachycardia (Supraventricular and
nodal arrhythmia - Sinus tachycardia)
Supraventricular Arrhythmia Nos
(Supraventricular and nodal arrhythmia -
Supraventricular arrhythmia NOS)
Supraventricular And Nodal Arrhythmia -
Supraventricular Extrasystoles
(premature Atrial Contractions;
Premature Nodal/junctional
Contractions) (Supraventricular and
nodal arrhythmia - Supraventricular
extrasystoles (premature atrial
contractions; premature nodal/junctional
contractions))
Supraventricular And Nodal Arrhythmia
(Supraventricular and nodal arrhythmia -
Supraventricular tachycardia)
Sweating Increased (Sweating
(diaphoresis))
Syncope (Syncope (fainting))
Syndromes Other (Syndromes-Other
(Specify))
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Taste Disturbance (Taste alteration
(dysgeusia))
Telangiectasia (Telangiectasia)
Thrombosis/embolism (vascular Access-
related) (Thrombosis/embolism (vascular
access-related))
Thrombosis Nos
(Thrombosis/thrombus/embolism)
Thrombotic Microangiopathy (e.g.,
Thrombotic Thrombocytopenic
Purpura[ttp] Or Hemolytic Uremic
Syndrome[hus]) (Thrombotic
microangiopathy (e.g., thrombotic
thrombocytopenic purpura or hemolytic
uremic syndrome))
Thyroid Function, High (hyperthyroidism,
Thyrotoxicosis) (Thyroid function, high
(hyperthyroidism, thyrotoxicosis))
Hypothyroidism (Thyroid function, low
(hypothyroidism))
Tinnitus (Tinnitus)
Tremor Nec (Tremor)
Hypertriglyceridaemia (Triglyceride,
serum-high (hypertriglyceridemia))
Trismus (difficulty, Restriction Or Pain
When Opening Mouth) (Trismus
(difficulty, restriction or pain when
opening mouth))
Tumour Flare (Tumor flare)
Tumour Lysis Syndrome (Tumor lysis
syndrome)
Caecitis (Typhlitis (cecal inflammation))
Ulcer, Gi (Ulcer, GI - Anus)
Ulcer, Gi (Ulcer, GI - Cecum)
Ulcer, Gi (Ulcer, GI - Colon)
Duodenal Ulcer (Ulcer, GI - Duodenum)
Ulcer, Gi (Ulcer, GI - Esophagus)
Ulcer, Gi (Ulcer, GI - Ileum)
Ulcer, Gi (Ulcer, GI - Jejunum)
Ulcer, Gi (Ulcer, GI - Rectum)
Ulcer, Gi (Ulcer, GI - Small bowel NOS)
Ulcer, Gi (Ulcer, GI - Stoma)
Gastric Ulcer (Ulcer, GI - Stomach)
Ulceration (Ulceration)
Hyperuricaemia (Uric acid, serum-high
(hyperuricemia))
Fanconi Syndrome (Urinary electrolyte
wasting (e.g., Fanconi's syndrome, renal
tubular acidosis))
Urinary Frequency (Urinary
frequency/urgency)
Urinary Retention (Urinary retention
(including neurogenic bladder))
Urine Discolouration (Urine color
change)
Urticaria Nos (Urticaria (hives, welts,
wheals))
Uveitis (Uveitis)
Vaginal Discharge (non-infectious)
(Vaginal discharge (non-infectious))
88 / 91
Esophageal Cancer NCT00655876 Treatment - TF: Radiation Therapy Oncology
Group Phase III Esophagus Systemic Treatment Summary Form - 2598533v1.0
Vulvovaginal Dryness (Vaginal dryness)
Vaginal Mucositis (Vaginal mucositis)
Vaginal Stenosis/length (Vaginal
stenosis/length)
Vaginitis (Vaginitis (not due to infection))
Valvular Heart Disease (Valvular heart
disease)
Vascular Other (Vascular-Other
(Specify))
Vasculitis Nos (Vasculitis)
Vasovagal Attack (Vasovagal episode)
Ventricular Arrhythmia (Ventricular
arrhythmia - Bigeminy)
Ventricular Arrhythmia (Ventricular
arrhythmia - Idioventricular rhythm)
Ventricular Arrhythmia (Ventricular
arrhythmia - PVCs)
Ventricular Arrhythmia (Ventricular
arrhythmia - Torsade de pointes)
Ventricular Arrhythmia (Ventricular
arrhythmia - Trigeminy)
Ventricular Arrhythmia Nos (Ventricular
arrhythmia - Ventricular arrhythmia NOS)
Ventricular Arrhythmia (Ventricular
arrhythmia - Ventricular fibrillation)
Ventricular Arrhythmia (Ventricular
arrhythmia - Ventricular flutter)
Ventricular Arrhythmia (Ventricular
arrhythmia - Ventricular tachycardia)
Vessel Injury-artery (Vessel injury-artery
- Aorta)
Vessel Injury-artery (Vessel injury-artery
- Carotid)
Vessel Injury-artery (Vessel injury-artery
- Extremity-lower)
Vessel Injury-artery (Vessel injury-artery
- Extremity-upper)
Vessel Injury-artery (Vessel injury-artery
- Other NOS)
Vessel Injury-artery (Vessel injury-artery
- Visceral)
Vessel Injury-vein (Vessel injury-vein -
Extremity-lower)
Vessel Injury-vein (Vessel injury-vein -
Extremity-upper)
Vessel Injury-vein (Vessel injury-vein -
IVC)
Vessel Injury-vein (Vessel injury-vein -
Jugular)
Vessel Injury-vein (Vessel injury-vein -
Other NOS)
Vessel Injury-vein (Vessel injury-vein -
SVC)
Vessel Injury-vein (Vessel injury-vein -
Viscera)
Viral Hepatitis (Viral hepatitis)
Visceral Arterial Ischaemia (Visceral
arterial ischemia (non-myocardial))
Vision Blurred (Vision-blurred vision)
Photopsia (Vision-flashing lights/floaters)
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Photophobia (Vision-photophobia)
Vital Capacity (Vital capacity)
Vitreous Hemorrhage (Vitreous
hemorrhage)
Dysphonia (Voice changes/dysarthria
(e.g., hoarseness, loss or alteration in
voice, laryngitis))
Vomiting Nos (Vomiting)
Lacrimation Increased (Watery eye
(epiphora, tearing))
Weight Increased (Weight gain)
Weight Decreased (Weight loss)
Culture Wound Negative (Wound
complication, non-infectious)
CTCAE Begin Date
Adverse Event Reporting to Date
CTC Adverse Event Attribution (Attribution to
Protocol Treatment See protocol sections 6 & 7
for definition of "protocol treatment")
Definite (Definite)
Possible (Possible)
Probable (Probable)
Unlikely (Unlikely)
Unrelated (Unrelated)
Has an AdEERS been filed
No (No)
Unknown (Unknown)
Yes (Yes)
Was this SAE per NCI definitions
Yes
No
Is there a reasonable possibility that the event
may have been caused by the investigational
agent
No (No)
Unknown (Unknown)
Yes (Yes)
Action taken regarding study therapy
Dose Delayed/omitted (Dose
delayed/omitted)
Dose Reduced (Dose reduced)
Agent Stopped (Dose stopped)
Drug Discontinued (Drug discontinued)
Iv Rate Decreased (IV rate decreased)
No Dose Modification (No dose
modification)
Treatment required
Concomitant Medication (Concomitant
medication)
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No Treatment Administered (None)
Surgical Procedure (Procedural Surgery)
Present Status
Not Recovered Or Not Resolved (Not
recovered/Not resolved)
Recovered Or Resolved With Sequelae
(Recovered/Resolved with Sequelae)
Recovered Or Resolved Without
Sequelae (Recovered/Resolved without
Sequelae)
Recovering Or Resolving
(Recovering/Resolving)
Footer
Comments
Investigator Signature
Date
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Esophageal Cancer NCT00655876 Demographic
- A0 HQ Confirmation - 2904861v1.0
A0 HQ Confirmation - PHASE III ESOPHAGEAL:
RT/PACLITAXEL/CISPLATIN +/
Paclitaxel, Cisplatin, and Radiation Therapy With or Without
Cetuximab in Treating Patients With Locally Advanced
Esophageal Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=6D4170C3-
6E1D-4980-E040-BB89AD435BA5
All rights reserved. Please visit https://medical-data-
models.org/forms/8699
A0 HQ Confirmation
Module 1
Institutional person randomizing case
Has the eligibility checklist been completed
Yes
No
In the opinion of the investigator, is the patient
eligible?
Yes
No
Date Informed Consent Signed (mm/dd/yyyy)
Participant Initials
Verifying physician
Patient ID
Date of Birth
Patient Zip Code
Race
A Person Having Origins In Any Of The
Original Peoples Of North And South
America (including Central America),
And Who Maintains Tribal Affiliation Or
Community Attachment. (American
Indian or Alaska Native)
A Person Having Origins In Any Of The
Original Peoples Of The Far East,
Southeast Asia, Or The Indian
Subcontinent Including, For Example,
Cambodia, China, India, Japan, Korea,
Malaysia, Pakistan, The Philippine
Islands, Thailand, And Vietnam. (Asian)
A Person Having Origins In Any Of The
Black Racial Groups Of Africa. Terms
Such As "haitian" Or "negro" Can Be
Used In Addition To "black Or African
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American." (Black or African American)
More Than One Race (More than one
race)
A Person Having Origins In Any Of The
Original Peoples Of Hawaii, Guam,
Samoa, Or Other Pacific Islands. (Native
Hawaiian or other Pacific Islander)
Could Not Be Determined Or Unsure
(Unknown)
A Person Having Origins In Any Of The
Original Peoples Of Europe, The Middle
East, Or North Africa. (White)
Ethnicity
A Person Of Mexican, Puerto Rican,
Cuban, Central Or South American Or
Other Spanish Culture Or Origin,
Regardless Of Race. (Hispanic or Latino)
A Person Not Meeting The Definition For
Hispanic Or Latino. (Not Hispanic or
Latino)
Could Not Be Determined Or Unsure
(Unknown)
Gender
Female Gender (FEMALE)
Male Gender (MALE)
Unknown (UNKNOWN)
Country of Residence (if not USA)
Ascension Island (AC)
Andorra (AD)
United Arab Emirates (AE)
Afghanistan (AF)
Antigua And Barbuda (AG)
Anguilla (AI)
Albania (AL)
Armenia (AM)
Netherland Antilles (AN)
Angola (AO)
Antarctica (AQ)
Argentina (AR)
American Samoa (AS)
Austria (AT)
Australia (AU)
Aruba (AW)
Azerbaidjan (AZ)
Bosnia-herzegovina (BA)
Barbados (BB)
Bangladesh (BD)
Belgium (BE)
Burkina Faso (BF)
Bulgaria (BG)
Bahrain (BH)
Burundi (BI)
Benin (BJ)
Bermuda (BM)
Brunei Darussalam (BN)
Bolivia (BO)
Brazil (BR)
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Bahamas (BS)
Bhutan (BT)
Bouvet Island (BV)
Botswana (BW)
Belarus (BY)
Belize (BZ)
Canada (CA)
Cocos Isl. (CC)
Rep. Dem. Congo (CD)
Central African Rep. (CF)
Congo (CG)
Switzerland (CH)
Ivory Coast (CI)
Cook Islands (CK)
Chile (CL)
Cameroon (CM)
China (CN)
Colombia (CO)
Costa Rica (CR)
Cuba (CU)
Cape Verde (CV)
Christmas Island (CX)
Cyprus (CY)
Czech Republic (CZ)
Germany (DE)
Djibouti (DJ)
Denmark (DK)
Dominica (DM)
Dominican Republic (DO)
Algeria (DZ)
Ecuador (EC)
Estonia (EE)
Egypt (EG)
Western Sahara (EH)
Eritrea (ER)
Spain (ES)
Ethiopia (ET)
Finland (FI)
Fiji (FJ)
Falkland Isl. (FK)
Micronesia (FM)
Faroe Islands (FO)
France (FR)
France (european Ter.) (FX)
Gabon (GA)
Great Britain (GB)
Grenada (GD)
Georgia (GE)
Guiana (fr.) (GF)
Guernsey (GG)
Ghana (GH)
Gibraltar (GI)
Greenland (GL)
Gambia (GM)
Guinea (GN)
Guadeloupe (fr.) (GP)
Equatorial Guinea (GQ)
Greece (GR)
South Georgia And South Sandwich
Islands (GS)
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Guatemala (GT)
Guam (us) (GU)
Guinea Bissau (GW)
Guyana (GY)
Hong Kong (HK)
Heard & Mcdonald Isl. (HM)
Honduras (HN)
Croatia (HR)
Haiti (HT)
Hungary (HU)
Indonesia (ID)
Ireland (IE)
Israel (IL)
Isle Of Man (IM)
India (IN)
British Indian O. Ter. (IO)
Iraq (IQ)
Iran (IR)
Iceland (IS)
Italy (IT)
Jersey (JE)
Jamaica (JM)
Jordan (JO)
Japan (JP)
Kenya (KE)
Kyrgyz Republic (KG)
Cambodia (KH)
Kiribati (KI)
Comoros (KM)
St. Kitts Nevis Anguilla (KN)
Korea (north) (KP)
Korea (south) (KR)
Kuwait (KW)
Cayman Islands (KY)
Kazakstan (KZ)
Laos (LA)
Lebanon (LB)
Saint Lucia (LC)
Liechtenstein (LI)
Sri Lanka (LK)
Liberia (LR)
Lesotho (LS)
Lithuania (LT)
Luxembourg (LU)
Latvia (LV)
Libya (LY)
Morocco (MA)
Monaco (MC)
Moldova (MD)
Madagascar (MG)
Marshall Islands (MH)
Macedonia (MK)
Mali (ML)
Myanmar (MM)
Mongolia (MN)
Macau (MO)
Northern Mariana Isl. (MP)
Martinique (fr.) (MQ)
Mauritania (MR)
Montserrat (MS)
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Malta (MT)
Mauritius (MU)
Maldives (MV)
Malawi (MW)
Mexico (MX)
Malaysia (MY)
Mozambique (MZ)
Namibia (NA)
New Caledonia (fr.) (NC)
Niger (NE)
Norfolk Island (NF)
Nigeria (NG)
Nicaragua (NI)
Netherlands (NL)
Norway (NO)
Nepal (NP)
Nauru (NR)
Niue (NU)
New Zealand (NZ)
Oman (OM)
Other (Other)
Panama (PA)
Peru (PE)
Polynesia (fr.) (PF)
Papua New Guinea (PG)
Philippines (PH)
Pakistan (PK)
Poland (PL)
St. Pierre & Miquelon (PM)
Pitcairn (PN)
Puerto Rico (PR)
Portugal (PT)
Palau (PW)
Paraguay (PY)
Qatar (QA)
Reunion (fr.) (RE)
Romania (RO)
Russian Federation (RU)
Rwanda (RW)
Saudi Arabia (SA)
Solomon Islands (SB)
Seychelles (SC)
Sudan (SD)
Sweden (SE)
Singapore (SG)
St. Helena (SH)
Slovenia (SI)
Svalbard & Jan Mayen Isl. (SJ)
Slovakia (SK)
Sierra Leone (SL)
San Marino (SM)
Senegal (SN)
Somalia (SO)
Suriname (SR)
St. Tome And Principe (ST)
Soviet Union (SU)
El Salvador (SV)
Syria (SY)
Swaziland (SZ)
Turks & Caicos Islands (TC)
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Chad (TD)
French Southern Terr. (TF)
Togo (TG)
Thailand (TH)
Tadjikistan (TJ)
Tokelau (TK)
Turkmenistan (TM)
Tunisia (TN)
Tonga (TO)
East Timor (TP)
Turkey (TR)
Trinidad & Tobago (TT)
Tuvalu (TV)
Taiwan (TW)
Tanzania (TZ)
Ukraine (UA)
Uganda (UG)
United Kingdom (UK)
Us Minor Outlying Isl. (UM)
Usa (US)
Uruguay (UY)
Uzbekistan (UZ)
Vatican City State (VA)
St. Vincent & Grenadines (VC)
Venezuela (VE)
Virgin Islands (brit) (VG)
Virgin Islands (us) (VI)
Vietnam (VN)
Vanuatu (VU)
Wallis & Futuna Islands (WF)
Western Samoa (WS)
Yemen (YE)
Mayotte (YT)
Yugoslavia (YU)
South Africa (ZA)
Zambia (ZM)
Dem. Rep. Of Congo (ZR)
Zimbabwe (ZW)
Zip code (U.S. Residents)
Method of Payment
Medicaid (Medicaid)
Medicaid And Medicare (Medicaid and
Medicare)
Medicare (Medicare)
Medicare And Private Insurance
(Medicare and Private Insurance)
Military Or Veterans Sponsored Nos
(Military or Veterans Sponsored, Not
Otherwise Specified (NOS))
No Means Of Payment (no Insurance)
(No means of payment (no insurance))
Other (Other)
Private Insurance (Private Insurance)
Self Pay (no Insurance) (Self Pay (No
Insurance))
Unknown (Unknown)
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Any care at VA or military hospital
No (No)
Unknown (Unknown)
Yes (Yes)
Calendar base date
Randomization Date
Medical oncologist's name
Did this patient provide written consent to give
tissue specimen(s) for research
Yes
No
Patient's Initial Consent given for specimen use
for research unrelated to the patient's cancer?
Yes
No
Did patient consent to future contact about more
research?
Yes
No
Histology
Adenocarcinoma (Adenocarcinoma)
Squamous Cell Carcinoma (Squamous
cell carcinoma)
Cancer lesion size
<5 Cm (<5 cm)
=> 5 Cm (=> 5 cm)
Celiac node status
Absent (Absent)
Present (Present)
Patient has consented to take part in the Quality
of Life Study
Yes
No
If no, provide reason
Not Approved By Institutional Irb (Not
approved by institutional IRB)
Other, Specify (Other, specify)
Patient Refused Due To Illness (Patient
refused due to illness)
Patient Refused For Other Reason
(Patient refused for other reason)
Tool Not Available In Patient's Language
(Tool not available in patient's language)
Other reason, specify
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Cervical Cancer NCT00803062 Registration - GOG-
0240 Registration Form (Form R) - 2727769v1.0
GOG-0240 Registration Form (Form R)
Paclitaxel and Cisplatin or Topotecan With or Without
Bevacizumab in Treating Patients With Stage IVB,
Recurrent, or Persistent Cervical Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=45817A3A-
81A1-1CA2-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/8700
GOG-0240 Registration Form (Form
R)
Header Module
Date form originally completed (m d y)
Date form amended (m d y)
Person amending form, last name
Patient Name, Last
Patient Name, First
Patient Study ID
Person Completing Form, Last Name
Tracking Information
Institution name (affiliate)
Treating physician
Patient medical record number
Patient's date of birth (m d y)
Patient Social Security Number
Patient Zip Code
Country of residence (if not USA)
Demographic Information
Patient race (mark all that apply)
1 / 3
A Person Having Origins In Any Of The
Original Peoples Of North And South
America (including Central America),
And Who Maintains Tribal Affiliation Or
Community Attachment. (American
Indian or Alaska Native)
A Person Having Origins In Any Of The
Original Peoples Of The Far East,
Southeast Asia, Or The Indian
Subcontinent Including, For Example,
Cambodia, China, India, Japan, Korea,
Malaysia, Pakistan, The Philippine
Islands, Thailand, And Vietnam. (Asian)
A Person Having Origins In Any Of The
Black Racial Groups Of Africa. Terms
Such As "haitian" Or "negro" Can Be
Used In Addition To "black Or African
American." (Black or African American)
A Person Having Origins In Any Of The
Original Peoples Of Hawaii, Guam,
Samoa, Or Other Pacific Islands. (Native
Hawaiian or other Pacific Islander)
Could Not Be Determined Or Unsure
(Unknown)
A Person Having Origins In Any Of The
Original Peoples Of Europe, The Middle
East, Or North Africa. (White)
Patient Ethnicity
A Person Of Mexican, Puerto Rican,
Cuban, Central Or South American Or
Other Spanish Culture Or Origin,
Regardless Of Race. (Hispanic or Latino)
A Person Not Meeting The Definition For
Hispanic Or Latino. (Not Hispanic or
Latino)
Could Not Be Determined Or Unsure
(Unknown)
Method of payment
Medicaid (Medicaid)
Medicaid And Medicare (Medicaid &
Medicare)
Medicare (Medicare)
Medicare And Private Insurance
(Medicare & Private Insurance)
Military Or Veterans Sponsored Nos
(Military or Veterans Sponsored NOS)
Military Sponsored (including Champus
& Tricare) (Military Sponsored (including
Champus & Tricare))
No Means Of Payment (no Insurance)
(No means of payment (no insurance))
Other (Other)
Private Insurance (Private Insurance)
Self Pay (no Insurance) (Self pay (no
insurance))
Unknown (Unknown)
Veterans Sponsored (Veterans
Sponsored)
2 / 3
Cervical Cancer NCT00803062 Registration - GOG-0240 Registration
Form (Form R) - 2727769v1.0
Patient Height
Patient weight (kg)
Performance status (Zubrod)
Fully Active, Able To Carry On All Pre-
disease Performance Without
Restriction. (0)
Restricted In Physically Strenuous
Activity But Ambulatory And Able To
Carry Out Work Of A Light Or Sedentary
Nature, E.g., Light Housework, Office
Work. (1)
Ambulatory And Capable Of All Selfcare
But Unable To Carry Out Any Work
Activities. Up And About More Than 50%
Of Waking Hours. (2)
Capable Of Only Limited Selfcare,
Confined To Bed Or Chair More Than
50% Of Waking Hours. (3)
Completely Disabled. Cannot Carry On
Any Selfcare. Totally Confined To Bed Or
Chair. (4)
Has the patient had any prior cancer diagnosed?
Yes
No
Prior cancer type
Prior cancer diagnosis date (m d y)
Comments
Brief clinical history
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Colorectal Cancer NCT00303628 Eligibility - E5204
Registration Worksheet (step 1) - 2762495v1.0
E5204 Registration Worksheet (step 1)
Combination Chemotherapy With or Without Bevacizumab
in Treating Patients Who Have Had Surgery for Stage II or
Stage III Rectal Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=510DE449-
8B3B-632C-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/8702
E5204 Registration Worksheet (step
1)
Eligibility
First initial
Last initial
Has the eligibility checklist been completed
Yes
No
In the opinion of the investigator, is the patient
eligible?
Yes
No
Has written informed consent been obtained
Yes
No
Date Informed Consent Signed
Has HIPAA authorization been obtained
Exempt (Exempt)
No: C49487 (No)
Yes: C49488 (Yes)
HIPAA Authorization Date
ECOG Performance Status
Fully Active, Able To Carry On All Pre-
disease Performance Without
Restriction. (0)
Restricted In Physically Strenuous
Activity But Ambulatory And Able To
Carry Out Work Of A Light Or Sedentary
Nature, E.g., Light Housework, Office
Work. (1)
Ambulatory And Capable Of All Selfcare
But Unable To Carry Out Any Work
Activities. Up And About More Than 50%
Of Waking Hours. (2)
Capable Of Only Limited Selfcare,
Confined To Bed Or Chair More Than
50% Of Waking Hours. (3)
Completely Disabled. Cannot Carry On
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Any Selfcare. Totally Confined To Bed Or
Chair. (4)
Dead (5)
What is the patient's clinical staging risk status
T3n+m0, T4nanym0 (High risk)
T1-t2n+m0, T3n0m0 (Low risk)
What is the patient's clinical staging risk status
T3n+m0, T4nanym0 (High risk)
T1-t2n+m0, T3n0m0 (Low risk)
Did the patient receive prior pre-operative
oxaliplatin
Yes
No
Did the patient participate on NSABP R-04 trial
Yes
No
Total pre-operative radiation dose
Forty To Fifty Gy (Forty to fifty Gy)
Greater Than Fifty But Less Than Or
Equal To 55.8 Gy (Greater than Fifty but
less than or equal to 55.8 Gy)
I agree to participate in the laboratory research
studies that are being done as part of this clinical
trial.
Yes
No
I agree to participate in the protein and DNA
studies that are being done as part of this clinical
trial.
Yes
No
My specimens may be kept for use in research to
learn about, prevent, treat, or cure cancer.
Yes
No
My specimens may be kept for research about
other health problems (for example: causes of
diabetes, Alzheimer's disease, and heart
disease)
Yes
No
Someone from this institution may contact me in
the future to ask me to take part in more
research.
Yes
No
QOL contact person
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Phone
Email address
Name of the contact person responsible for
sample submission
Phone number of the contact person responsible
for sample submission
Fax number of the contact person responsible for
sample submission
E-mail address of the contact person responsible
for sample submission
Patient Demographics / Pre-treatment
Characteristics
Patient's Sex
Female (F)
Male (M)
Birthdate (mm/yy)
Patient Race (check all that applyU.S. and
Canada only)
A Person Having Origins In Any Of The
Original Peoples Of North And South
America (including Central America),
And Who Maintains Tribal Affiliation Or
Community Attachment. (American
Indian or Alaska Native)
A Person Having Origins In Any Of The
Original Peoples Of The Far East,
Southeast Asia, Or The Indian
Subcontinent Including, For Example,
Cambodia, China, India, Japan, Korea,
Malaysia, Pakistan, The Philippine
Islands, Thailand, And Vietnam. (Asian)
A Person Having Origins In Any Of The
Black Racial Groups Of Africa. Terms
Such As "haitian" Or "negro" Can Be
Used In Addition To "black Or African
American." (Black or African American)
A Person Having Origins In Any Of The
Original Peoples Of Hawaii, Guam,
Samoa, Or Other Pacific Islands. (Native
Hawaiian or other Pacific Islander)
Not Provided Or Available (Not
Reported)
Could Not Be Determined Or Unsure
(Unknown)
A Person Having Origins In Any Of The
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Original Peoples Of Europe, The Middle
East, Or North Africa. (White)
ZIP Code
Patient Ethnicity
A Person Of Mexican, Puerto Rican,
Cuban, Central Or South American Or
Other Spanish Culture Or Origin,
Regardless Of Race. (Hispanic or Latino)
A Person Not Meeting The Definition For
Hispanic Or Latino. (Not Hispanic or
Latino)
Not Provided Or Available (Not reported)
Could Not Be Determined Or Unsure
(Unknown)
Patient Hospital No.
Patient Social Security Number
Method of payment (check one)
Medicaid (Medicaid)
Medicaid And Medicare (Medicaid and
Medicare)
Medicare (Medicare)
Medicare And Private Insurance
(Medicare and Private Insurance)
Military Or Veterans Sponsored Nos
(Military or Veterans Sponsored, Not
Otherwise Specified (NOS))
Military Sponsored (including Champus
& Tricare) (Military Sponsored (including
CHAMPUS & TRICARE))
National Health Service (National Health
Service)
No Means Of Payment (no Insurance)
(No means of payment (no insurance))
Other (Other)
Private Insurance (Private Insurance)
Self Pay (no Insurance) (Self Pay (No
Insurance))
Unknown (Unknown)
Veterans Sponsored (Veterans
Sponsored)
Attending Physician
Institution contact
Registrar
Country of Residence
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Comments
Signature of treating physician (I have reviewed
the above data and agree the date are accurate
and correct)
Date (Note: Date must be on or before date of
registration)
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Colorectal Cancer NCT00217737 Eligibility - E5202
Registration Worksheet (step 1) - 2769142v1.0
E5202 Registration Worksheet (step 1)
Oxaliplatin, Leucovorin, and Fluorouracil With or Without
Bevacizumab in Treating Patients Who Have Undergone
Surgery for Stage II Colon Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=532CA5B1-
0290-07D2-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/8703
E5202 Registration Worksheet (step
1)
Eligibility
First initial
Last initial
Has the eligibility checklist been completed
Yes
No
In the opinion of the investigator, is the patient
eligible?
Yes
No
Has written informed consent been obtained
Yes
No
Date Informed Consent Signed
Has HIPAA authorization been obtained
Exempt - Non-usa Participant (Exempt -
non-USA participant)
No: C49487 (No)
Yes: C49488 (Yes)
HIPAA Authorization Date
Date of Resection
Will research tumor be submitted
Yes
No
I agree to participate in the protein and DNA
studies that are being done as part of this clinical
trial.
Yes
No
I agree to provide additional specimens for
research
Yes
1 / 4
No
My specimens may be kept for use in research to
learn about, prevent, treat, or cure cancer.
Yes
No
My specimens may be kept for research about
other health problems (for example: causes of
diabetes, Alzheimer's disease, and heart
disease)
Yes
No
Someone from this institution may contact me in
the future to ask me to take part in more
research.
Yes
No
Patient Demographics / Pre-treatment
Characteristics
Patient's Sex
Female (F)
Male (M)
Birthdate (mm/yy)
Patient Race (check all that applyU.S. and
Canada only)
A Person Having Origins In Any Of The
Original Peoples Of North And South
America (including Central America),
And Who Maintains Tribal Affiliation Or
Community Attachment. (American
Indian or Alaska Native)
A Person Having Origins In Any Of The
Original Peoples Of The Far East,
Southeast Asia, Or The Indian
Subcontinent Including, For Example,
Cambodia, China, India, Japan, Korea,
Malaysia, Pakistan, The Philippine
Islands, Thailand, And Vietnam. (Asian)
A Person Having Origins In Any Of The
Black Racial Groups Of Africa. Terms
Such As "haitian" Or "negro" Can Be
Used In Addition To "black Or African
American." (Black or African American)
A Person Having Origins In Any Of The
Original Peoples Of Hawaii, Guam,
Samoa, Or Other Pacific Islands. (Native
Hawaiian or other Pacific Islander)
Not Provided Or Available (Not
Reported)
Could Not Be Determined Or Unsure
(Unknown)
A Person Having Origins In Any Of The
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Original Peoples Of Europe, The Middle
East, Or North Africa. (White)
ZIP Code
Patient Ethnicity
A Person Of Mexican, Puerto Rican,
Cuban, Central Or South American Or
Other Spanish Culture Or Origin,
Regardless Of Race. (Hispanic or Latino)
A Person Not Meeting The Definition For
Hispanic Or Latino. (Not Hispanic or
Latino)
Not Provided Or Available (Not reported)
Could Not Be Determined Or Unsure
(Unknown)
Patient Hospital No.
Patient Social Security Number
Method of payment (check one)
Medicaid (Medicaid)
Medicaid And Medicare (Medicaid and
Medicare)
Medicare (Medicare)
Medicare And Private Insurance
(Medicare and Private Insurance)
Military Or Veterans Sponsored Nos
(Military or Veterans Sponsored, Not
Otherwise Specified (NOS))
Military Sponsored (including Champus
& Tricare) (Military Sponsored (including
CHAMPUS & TRICARE))
National Health Service (National Health
Service)
No Means Of Payment (no Insurance)
(No means of payment (no insurance))
Other (Other)
Private Insurance (Private Insurance)
Self Pay (no Insurance) (Self Pay (No
Insurance))
Unknown (Unknown)
Veterans Sponsored (Veterans
Sponsored)
Attending Physician
Institution contact
Registrar
Country of Residence
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Comments
Signature of treating physician (I have reviewed
the above data and agree the date are accurate
and correct)
Date (Note: Date must be on or before date of
registration)
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Colorectal Cancer NCT00268463 Registration - NSABP
PROTOCOL C-09: REGISTRATION FORM - 2319554v3.0
NSABP PROTOCOL C-09: REGISTRATION FORM
Oxaliplatin and Capecitabine With or Without an Hepatic
Arterial Infusion With Floxuridine in Treating Patients Who
Are Undergoing Surgery and/or Ablation for Liver
Metastases Due to Colorectal Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=FC7DB4A4-
172A-4E9B-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/8704
NSABP PROTOCOL C-09:
REGISTRATION FORM
Unnamed 1
(Physician to whom drug will be sent must have a
valid FDA Number.)
Patient Initials (Last First Middle)
NSABP Patient ID (other protocol)
Institution Name
Affiliate Name
Physician of Record
Date Informed Consent Signed (Month Day Year)
Person Completing Form Last Name
Person Completing Form First Name
Person Completing Form Phone
Person Completing Form Fax
Unnamed2
Patient's Date of Birth (Month Day Year)
Patient's Social Security Number (USA only)
Unnamed3
Race (more than one may be marked)
A Person Having Origins In Any Of The
Original Peoples Of North And South
America (including Central America),
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And Who Maintains Tribal Affiliation Or
Community Attachment. (American
Indian or Alaska Native)
A Person Having Origins In Any Of The
Original Peoples Of The Far East,
Southeast Asia, Or The Indian
Subcontinent Including, For Example,
Cambodia, China, India, Japan, Korea,
Malaysia, Pakistan, The Philippine
Islands, Thailand, And Vietnam. (Asian)
A Person Having Origins In Any Of The
Black Racial Groups Of Africa. Terms
Such As "haitian" Or "negro" Can Be
Used In Addition To "black Or African
American." (Black or African American)
A Person Having Origins In Any Of The
Original Peoples Of Hawaii, Guam,
Samoa, Or Other Pacific Islands. (Native
Hawaiian or Other Pacific Islander)
Could Not Be Determined Or Unsure
(Unknown)
A Person Having Origins In Any Of The
Original Peoples Of Europe, The Middle
East, Or North Africa. (White)
Method of Payment (mark primary method only)
Medicaid (Medicaid)
Medicaid And Medicare (Medicaid and
Medicare)
Medicare (Medicare)
Medicare And Private Insurance
(Medicare and Private Insurance)
Military Or Veterans Sponsored Nos
(Military or Veterans Sponsored NOS)
Military Sponsored (including Champus
& Tricare) (Military Sponsored)
No Means Of Payment (no Insurance)
(No means of payment)
Other (Other)
Private Insurance (Private Insurance)
Self Pay (no Insurance) (Self pay)
Unknown (Unknown)
Veterans Sponsored (Veterans
Sponsored)
Ethnicity
A Person Of Mexican, Puerto Rican,
Cuban, Central Or South American Or
Other Spanish Culture Or Origin,
Regardless Of Race. (Hispanic or Latino)
A Person Not Meeting The Definition For
Hispanic Or Latino. (Not Hispanic or
Latino)
Could Not Be Determined Or Unsure
(Unknown)
Country of Residence (if not USA)
Canada (Canada)
Mexico (Mexico)
Other (Other)
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Puerto Rico (Puerto Rico)
Other, specify
Patient Zip Code (USA)
Unnamed4
Your blood and tissues samples may be kept by
the NSABP for use in future research to learn
about, prevent, detect, or treat cancer.
Yes
No
Your blood and tissue samples may be used for
research about other health
problems (for example: causes of heart disease,
osteoporosis, diabetes)
Yes
No
Your study doctor may contact you in the future to
ask you to take part in more research. (or
someone he or she chooses)
Yes
No
Number of Hepatic Lesions on Pre-Entry
Evaluation
Stratification Factors
Intended Method for Removal of Hepatic
Metastases
Combination Of Resection And Ablation
(Combination of resection and ablation)
Cryoablation Or Radiofrequency Ablation
Alone (Cryoablation or radiofrequency
ablation alone)
Surgical Resection Alone (Surgical
resection alone)
Adjuvant Chemotherapy for Colorectal Cancer
Chemotherapy Regimen With Oxaliplatin
(Chemotherapy regimen with oxaliplatin)
Chemotherapy Regimen Without
Oxaliplatin (Chemotherapy regimen
without oxaliplatin)
No Chemotherapy (No chemotherapy)
Certification Of Eligibility
In the opinion of the investigator, is the patient
eligible
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Yes
No
Did patient complete the baseline QOL form
Yes
No
Unnamed5
Has the patient authorized the release of
Protected Health Information to the NSABP
Yes
No
Unnamed6
Was the primary colorectal tumor resected prior
to randomization (If yes, provide date of
resection.)
Yes
No
Date of Resection (if applicable)
Instructions
Investigator Number (NCI)
Investigator Name (Hepatic Surgeon)
Unnamed 8
Is the patient also enrolled in another NSABP
protocol?
Yes
No
NSABP Protocol Number (If yes, provide
information for the other protocol. - other
protocol)
NSABP Patient ID (other protocol)
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Head and Neck Cancer NCT00956007 Registration -
RTOG 0920 OPEN Registration Worksheet - 3219099v1.0
RTOG 0920 OPEN Registration Worksheet
Radiation Therapy With or Without Cetuximab in Treating
Patients Who Have Undergone Surgery for Locally
Advanced Head and Neck Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=9FDDB442-
DA44-C42C-E040-BB89AD432DB7
All rights reserved. Please visit https://medical-data-
models.org/forms/8705
RTOG 0920 OPEN Registration
Worksheet
Module 1
Institutional person randomizing case
Has the eligibility checklist been completed
Yes
No
In the opinion of the investigator, is the patient
eligible?
Yes
No
Date Informed Consent Signed
Patient Initials (First Middle Last)
Verifying physician
Patient ID
Date of Birth
Race
American Indian Or Alaska Native
(American Indian or Alaska Native)
Asian (Asian)
Black Or African American (Black or
African American)
More Than One Race (More than one
race)
Native Hawaiian Or Other Pacific
Islander (Native Hawaiian or other Pacific
Islander)
Unknown (Unknown)
White (White)
Demographics
Module 1
Any care at VA or military hospital
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No (No)
Unknown (Unknown)
Yes (Yes)
Calendar base date
Randomization Date
Medical oncologist's name
Have you obtained the patient's consent for his or
her tissue to be kept for use in research to learn
about, prevent, treat or cure cancer
Yes
No
Have you obtained the patient's consent for his or
her blood to be kept for use in research to learn
about, prevent, treat, or cure cancer?
Yes
No
Have you obtained the patient's consent for his or
her tissue to be kept for use research about other
health problems (for example: causes of
diabetes, Alzheimer's disease, and heart
disease)?
Yes
No
Have you obtained the patient's consent for his or
her blood to be kept for use research about other
health problems (for example: causes of
diabetes, Alzheimer's disease, and heart
disease)?
Yes
No
Have you obtained the patient's consent to allow
someone from this institution to contact him or
her in the future to take part in more research
Yes
No
Tissue sent for HPV analysis?
Yes
No
Disease Type
Larynx (Larynx)
Oral Cavity (Oral Cavity)
Oropharynx P16 Not Evaluable
(Oropharynx p16 not evaluable)
Oropharynx P16- (Oropharynx p16-)
Oropharynx P16+ (Oropharynx p16+)
If yes, have pre-registration credentialing
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requirements in Section 5.2 been met?
Yes
No
Module 2
Use of IGRT?
Yes
No
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Head and Neck Cancer NCT00956007 Registration - RTOG
0920 OPEN Registration Worksheet - Step 2 - 3219537v1.0
RTOG 0920 OPEN Registration Worksheet - Step 2
Radiation Therapy With or Without Cetuximab in Treating
Patients Who Have Undergone Surgery for Locally
Advanced Head and Neck Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=A0190014-
3FCB-4E42-E040-BB89AD43786E
All rights reserved. Please visit https://medical-data-
models.org/forms/8707
RTOG 0920 OPEN Registration
Worksheet - Step 2
Module 1
Institutional person randomizing case
Is the patient able to continue protocol treatment?
Yes
No
If no, specify the reason the patient cannot
continue to Step 2
Failure To Submit Tissue Assay (Failure
to submit tissue assay)
Other (Other)
Patient Refusal (Patient refusal)
Physician Preference (Physician
preference)
Progression Of Disease (Progression of
disease)
Specify the reason the patient cannot continue to
Step 2
Patient Initials (First Middle Last)
Verifying physician
Patient ID
Module 1
Calendar base date (for Step 2)
Randomization Date (for Step 2)
Patient has consented to take part in the Quality
of Life Study
Yes
No
If no, provide reason
Not Approved By Institutional Irb (Not
approved by institutional IRB)
Other, Specify (Other, specify)
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Patient Refused Due To Illness (Patient
refused due to illness)
Patient Refused For Other Reason
(Patient refused for other reason)
Tool Not Available In Patient's Language
(Tool not available in patient's language)
If response is "2) Patient refused for other
reason", specify the reason
If response is "5) Other reason", specify the
reason the patient will not participate in the
quality of life component of the study
If the patient agreed to participate in the quality of
life component, did the patient agree to
participate in Vision Tree?
Yes
No
Disease Type
Larynx (Larynx)
Oral Cavity (Oral Cavity)
Oropharynx P16 Not Evaluable
(Oropharynx p16 not evaluable)
Oropharynx P16- (Oropharynx p16-)
Oropharynx P16+ (Oropharynx p16+)
EGFR Expression
High (High)
Low (Low)
Not Evaluable (Not Evaluable)
Use of IGRT?
Yes
No
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Lung Cancer NCT00107172 Treatment -
Z4032 Brachytherapy Report - 2306538v3.0
Z4032 Brachytherapy Report
Surgery With or Without Internal Radiation Therapy in
Treating Patients With Stage I Non-Small Cell Lung Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=F21E5540-
6368-6874-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/8709
Z4032 Brachytherapy Report
Header Module
Visit
Day 0 (Day 0)
Patient ID
Patient Initials
Institution No.
Institution Name
Header
Date of Procedure (OR)
Not Done
Staple line length (CM)
Brachytherapy technique (check only one box)
Double Strand (Double strand)
Mesh (Mesh)
Mesh Width (Mesh only)
Mesh Length (cm)
Mesh type used
Mesh Pre-fabricated By Manufacturer
(Mesh pre-fabricated by manufacturer)
Mesh Seeds Manually Threaded (Mesh
seeds manually threaded)
Strand distance from resection margin (double
strand only)
Total number of strands
Strand
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Length (double strand only)
Seeds per strand
Activity per strand
Total activity
Total # Seeds
Total Activity (mCi)
Prescription (Gy)
Date of post-implant CT (mm/dd/yyyy)
Have the 3D dosimetry images, the post implant
planning CT, and Dose Volume Histograms for
CTV, PTV-1 and PTV-2 been sent to Quality
Assurance Review Center (copied or printed copy
QARC)
Yes
No
Footer Module
Completed by
Date Form Completed (mm/dd/yyyy)
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Lung Cancer NCT00533949 Registration - RTOG 0617
A0 OPEN Registration Worksheet - 3135441v1.0
RTOG 0617 A0 OPEN Registration Worksheet
High-Dose or Standard-Dose Radiation Therapy and
Chemotherapy With or Without Cetuximab in Treating
Patients With Newly Diagnosed Stage III Non-Small Cell
Lung Cancer That Cannot Be Removed by Surgery
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=8FD3C7E4-
20F0-2852-E040-BB89AD432AD1
All rights reserved. Please visit https://medical-data-
models.org/forms/8710
RTOG 0617 A0 OPEN Registration
Worksheet
Module 1
Institutional person randomizing case
Has the eligibility checklist been completed
Yes
No
In the opinion of the investigator, is the patient
eligible?
Yes
No
Date Informed Consent Signed
Participant Initials (FML)
Verifying physician
Patient ID
Date of Birth
Race
A Person Having Origins In Any Of The
Original Peoples Of North And South
America (including Central America),
And Who Maintains Tribal Affiliation Or
Community Attachment. (American
Indian or Alaska Native)
A Person Having Origins In Any Of The
Original Peoples Of The Far East,
Southeast Asia, Or The Indian
Subcontinent Including, For Example,
Cambodia, China, India, Japan, Korea,
Malaysia, Pakistan, The Philippine
Islands, Thailand, And Vietnam. (Asian)
A Person Having Origins In Any Of The
Black Racial Groups Of Africa. Terms
Such As "haitian" Or "negro" Can Be
Used In Addition To "black Or African
American." (Black or African American)
More Than One Race (More than one
race)
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A Person Having Origins In Any Of The
Original Peoples Of Hawaii, Guam,
Samoa, Or Other Pacific Islands. (Native
Hawaiian or other Pacific Islander)
Could Not Be Determined Or Unsure
(Unknown)
A Person Having Origins In Any Of The
Original Peoples Of Europe, The Middle
East, Or North Africa. (White)
Ethnicity
A Person Of Mexican, Puerto Rican,
Cuban, Central Or South American Or
Other Spanish Culture Or Origin,
Regardless Of Race. (Hispanic or Latino)
A Person Not Meeting The Definition For
Hispanic Or Latino. (Not Hispanic or
Latino)
Could Not Be Determined Or Unsure
(Unknown)
Gender
Female Gender (Female)
Male Gender (Male)
Country of residence
Canada (CA)
Other (Other)
Usa (US)
ZIP Code (U.S. Residents)
Method of Payment
Medicaid (Medicaid)
Medicare And Medicaid (Medicaid and
Medicare)
Medicare (Medicare)
Medicare And Private Insurance
(Medicare and Private Insurance)
Military Or Veterans Sponsored
Insurance, Not Otherwise Specified
(Military or Veterans Sponsored, NOS)
No Insurance (No Means of Payment
(No Insurance))
Other (Other)
Private Insurance (Private Insurance)
Self Payment (Self-Pay (No Insurance))
Unknown (Unknown)
Any care at VA or military hospital
No (No)
Unknown (Unknown)
Yes (Yes)
Calendar base date
Randomization Date
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Medical oncologist's name
PET staging
Yes
No
Performance Status (Zubrod)
Normal Activity (0)
Symptoms, But Nearly Fully Ambulatory
(1)
I attest that I am willing to treat this patient
according to the arm to which he/she is
randomized
Yes
No
Histologic Type
Non-squamous Cell Carcinoma (Non-
Squamous cell carcinoma)
Squamous Cell Carcinoma (Squamous
cell carcinoma)
Patient has consented to take part in the Quality
of Life Study
Yes
No
If no, provide reason
Not Approved By Institutional Irb (Not
approved by institutional IRB)
Other, Specify (Other, specify)
Patient Refused Due To Illness (Patient
refused due to illness)
Patient Refused For Other Reason
(Patient refused for other reason)
Tool Not Available In Patient's Language
(Tool not available in patient's language)
Other reason, specify ([other reason patient
refused])
Other, specify
Have you obtained the patient's consent for his or
her tissue to be kept for use in research to learn
about, prevent, treat or cure cancer
Yes
No
Have you obtained the patient's consent for his or
her urine to be kept for use in research to learn
about, prevent, treat, or cure cancer
Yes
No
Have you obtained the patient's consent for his or
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her blood to be kept for use in research to learn
about, prevent, treat, or cure cancer?
Yes
No
Have you obtained the patient's consent for his or
her tissue to be kept for use in research about
other health problems (for example: causes of
diabetes, Alzheimer's disease or heart disease)
Yes
No
Have you obtained the patient's consent for his or
her urine to be kept for use in research about
other health problems (for example: causes of
diabetes, Alzheimer's disease, and heart
disease)
Yes
No
Have you obtained the patient's consent for his or
her blood to be kept for use in research about
other health problems (for example: causes of
diabetes, Alzheimer's disease or heart disease)
Yes
No
Have you obtained the patient's consent to allow
someone from this institution to contact him or
her in the future to take part in more research
Yes
No
Module 2
Planned radiation therapy
3-dimensional Conformal Radiation
Therapy (3D-CRT)
Imrt (intensity Modulated Rt) (IMRT)
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Demographic - OPEN Demographic Form -
2800417v1.0
OPEN Demographic Form
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=5BA7C715-
E93A-3AEA-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/8711
OPEN Demographic Form
Header
Patient's Date of Birth
Race (check all that apply)
A Person Having Origins In Any Of The
Original Peoples Of North And South
America (including Central America),
And Who Maintains Tribal Affiliation Or
Community Attachment. (American
Indian or Alaska Native)
A Person Having Origins In Any Of The
Original Peoples Of The Far East,
Southeast Asia, Or The Indian
Subcontinent Including, For Example,
Cambodia, China, India, Japan, Korea,
Malaysia, Pakistan, The Philippine
Islands, Thailand, And Vietnam. (Asian)
A Person Having Origins In Any Of The
Black Racial Groups Of Africa. Terms
Such As "haitian" Or "negro" Can Be
Used In Addition To "black Or African
American." (Black or African American)
A Person Having Origins In Any Of The
Original Peoples Of Hawaii, Guam,
Samoa, Or Other Pacific Islands. (Native
Hawaiian or other Pacific Islander)
Could Not Be Determined Or Unsure
(Unknown)
A Person Having Origins In Any Of The
Original Peoples Of Europe, The Middle
East, Or North Africa. (White)
Ethnicity
A Person Of Mexican, Puerto Rican,
Cuban, Central Or South American Or
Other Spanish Culture Or Origin,
Regardless Of Race. (Hispanic or Latino)
A Person Not Meeting The Definition For
Hispanic Or Latino. (Not Hispanic or
Latino)
Could Not Be Determined Or Unsure
(Unknown)
Gender
Female (FEMALE)
Male (MALE)
Method of Payment
Medicaid (Medicaid)
Medicaid And Medicare (Medicaid and
Medicare)
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Medicare (Medicare)
Medicare And Private Insurance
(Medicare and Private Insurance)
Military Or Veterans Sponsored Nos
(Military or Veterans Sponsored, Not
Otherwise Specified (NOS))
Military Sponsored (including Champus
& Tricare) (Military Sponsored (including
CHAMPUS & TRICARE))
No Means Of Payment (no Insurance)
(No means of payment (no insurance))
Other (Other)
Private Insurance (Private Insurance)
Self Pay (no Insurance) (Self Pay (No
Insurance))
Unknown (Unknown)
Veterans Sponsored (Veterans
Sponsored)
Country of Residence
ZIP Code
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Colorectal Cancer NCT00321685 Eligibility - E3204
Registration Worksheet (step 1) - 2946577v1.0
E3204 Registration Worksheet (step 1)
Bevacizumab, Radiation Therapy, and Combination
Chemotherapy in Treating Patients Who Are Undergoing
Surgery for Locally Advanced Nonmetastatic Rectal Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=74A5ACCC-
D9EB-ED2D-E040-BB89AD4358DB
All rights reserved. Please visit https://medical-data-
models.org/forms/8712
E3204 Registration Worksheet (step
1)
Eligibility
First initial
Last initial
Has the eligibility checklist been completed
Yes
No
In the opinion of the investigator, is the patient
eligible?
Yes
No
Has written informed consent been obtained
Yes
No
Date Informed Consent Signed
Has HIPAA authorization been obtained
Exempt - Non-usa Participant (Exempt -
non-USA participant)
No: C49487 (No)
Yes: C49488 (Yes)
HIPAA Authorization Date
Primary T stage
Locally Advanced T3 Rectal
Adenocarcinoma (Locally advanced T3
rectal adenocarcinoma)
Locally Advanced T4 Rectal
Adenocarcinoma (Locally advanced T4
rectal adenocarcinoma)
If an ECOG patient is to receive radiation therapy,
will it be given at the registering institution
No (No)
Not Applicable - Not An Ecog Patient
(Not applicable - not an ECOG patient)
Unknown (Unknown)
Yes (Yes)
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Name of the institution that will administer the
radiation therapy
Race
Patient's Race
A Person Having Origins In Any Of The
Original Peoples Of North And South
America (including Central America),
And Who Maintains Tribal Affiliation Or
Community Attachment. (American
Indian or Alaska Native)
A Person Having Origins In Any Of The
Original Peoples Of The Far East,
Southeast Asia, Or The Indian
Subcontinent Including, For Example,
Cambodia, China, India, Japan, Korea,
Malaysia, Pakistan, The Philippine
Islands, Thailand, And Vietnam. (Asian)
A Person Having Origins In Any Of The
Black Racial Groups Of Africa. Terms
Such As "haitian" Or "negro" Can Be
Used In Addition To "black Or African
American." (Black or African American)
A Person Having Origins In Any Of The
Original Peoples Of Hawaii, Guam,
Samoa, Or Other Pacific Islands. (Native
Hawaiian or other Pacific Islander)
Not Provided Or Available (Not
Reported)
Could Not Be Determined Or Unsure
(Unknown)
A Person Having Origins In Any Of The
Original Peoples Of Europe, The Middle
East, Or North Africa. (White)
Patient Demographics / Pre-treatment
Characteristics
Patient's Sex
Female (F)
Male (M)
Birthdate (mm/yy)
ZIP Code
Patient Ethnicity
A Person Of Mexican, Puerto Rican,
Cuban, Central Or South American Or
Other Spanish Culture Or Origin,
Regardless Of Race. (Hispanic or Latino)
A Person Not Meeting The Definition For
Hispanic Or Latino. (Not Hispanic or
Latino)
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Not Provided Or Available (Not reported)
Could Not Be Determined Or Unsure
(Unknown)
Patient Hospital No.
Patient Social Security Number
Method of payment (check one)
Medicaid (Medicaid)
Medicaid And Medicare (Medicaid and
Medicare)
Medicare (Medicare)
Medicare And Private Insurance
(Medicare and Private Insurance)
Military Or Veterans Sponsored Nos
(Military or Veterans Sponsored, Not
Otherwise Specified (NOS))
Military Sponsored (including Champus
& Tricare) (Military Sponsored (including
CHAMPUS & TRICARE))
No Means Of Payment (no Insurance)
(No means of payment (no insurance))
Other (Other)
Private Insurance (Private Insurance)
Self Pay (no Insurance) (Self Pay (No
Insurance))
Unknown (Unknown)
Veterans Sponsored (Veterans
Sponsored)
Attending Physician
Institution contact
Registrar
Country of residence
Ascension Island (AC)
Andorra (AD)
United Arab Emirates (AE)
Afghanistan (AF)
Antigua And Barbuda (AG)
Anguilla (AI)
Albania (AL)
Armenia (AM)
Netherland Antilles (AN)
Angola (AO)
Antarctica (AQ)
Argentina (AR)
American Samoa (AS)
Austria (AT)
Australia (AU)
Aruba (AW)
Azerbaidjan (AZ)
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Bosnia-herzegovina (BA)
Barbados (BB)
Bangladesh (BD)
Belgium (BE)
Burkina Faso (BF)
Bulgaria (BG)
Bahrain (BH)
Burundi (BI)
Benin (BJ)
Bermuda (BM)
Brunei Darussalam (BN)
Bolivia (BO)
Brazil (BR)
Bahamas (BS)
Bhutan (BT)
Bouvet Island (BV)
Botswana (BW)
Belarus (BY)
Belize (BZ)
Canada (CA)
Cocos Isl. (CC)
Rep. Dem. Congo (CD)
Central African Rep. (CF)
Congo (CG)
Switzerland (CH)
Ivory Coast (CI)
Cook Islands (CK)
Chile (CL)
Cameroon (CM)
China (CN)
Colombia (CO)
Costa Rica (CR)
Cuba (CU)
Cape Verde (CV)
Christmas Island (CX)
Cyprus (CY)
Czech Republic (CZ)
Germany (DE)
Djibouti (DJ)
Denmark (DK)
Dominica (DM)
Dominican Republic (DO)
Algeria (DZ)
Ecuador (EC)
Estonia (EE)
Egypt (EG)
Western Sahara (EH)
Eritrea (ER)
Spain (ES)
Ethiopia (ET)
Finland (FI)
Fiji (FJ)
Falkland Isl. (FK)
Micronesia (FM)
Faroe Islands (FO)
France (FR)
France (european Ter.) (FX)
Gabon (GA)
Great Britain (GB)
Grenada (GD)
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Georgia (GE)
Guiana (fr.) (GF)
Guernsey (GG)
Ghana (GH)
Gibraltar (GI)
Greenland (GL)
Gambia (GM)
Guinea (GN)
Guadeloupe (fr.) (GP)
Equatorial Guinea (GQ)
Greece (GR)
South Georgia And South Sandwich
Islands (GS)
Guatemala (GT)
Guam (us) (GU)
Guinea Bissau (GW)
Guyana (GY)
Hong Kong (HK)
Heard & Mcdonald Isl. (HM)
Honduras (HN)
Croatia (HR)
Haiti (HT)
Hungary (HU)
Indonesia (ID)
Ireland (IE)
Israel (IL)
Isle Of Man (IM)
India (IN)
British Indian O. Ter. (IO)
Iraq (IQ)
Iran (IR)
Iceland (IS)
Italy (IT)
Jersey (JE)
Jamaica (JM)
Jordan (JO)
Japan (JP)
Kenya (KE)
Kyrgyz Republic (KG)
Cambodia (KH)
Kiribati (KI)
Comoros (KM)
St. Kitts Nevis Anguilla (KN)
Korea (north) (KP)
Korea (south) (KR)
Kuwait (KW)
Cayman Islands (KY)
Kazakstan (KZ)
Laos (LA)
Lebanon (LB)
Saint Lucia (LC)
Liechtenstein (LI)
Sri Lanka (LK)
Liberia (LR)
Lesotho (LS)
Lithuania (LT)
Luxembourg (LU)
Latvia (LV)
Libya (LY)
Morocco (MA)
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Monaco (MC)
Moldova (MD)
Madagascar (MG)
Marshall Islands (MH)
Macedonia (MK)
Mali (ML)
Myanmar (MM)
Mongolia (MN)
Macau (MO)
Northern Mariana Isl. (MP)
Martinique (fr.) (MQ)
Mauritania (MR)
Montserrat (MS)
Malta (MT)
Mauritius (MU)
Maldives (MV)
Malawi (MW)
Mexico (MX)
Malaysia (MY)
Mozambique (MZ)
Namibia (NA)
New Caledonia (fr.) (NC)
Niger (NE)
Norfolk Island (NF)
Nigeria (NG)
Nicaragua (NI)
Netherlands (NL)
Norway (NO)
Nepal (NP)
Nauru (NR)
Niue (NU)
New Zealand (NZ)
Oman (OM)
Other (Other)
Panama (PA)
Peru (PE)
Polynesia (fr.) (PF)
Papua New Guinea (PG)
Philippines (PH)
Pakistan (PK)
Poland (PL)
St. Pierre & Miquelon (PM)
Pitcairn (PN)
Puerto Rico (PR)
Portugal (PT)
Palau (PW)
Paraguay (PY)
Qatar (QA)
Reunion (fr.) (RE)
Romania (RO)
Russian Federation (RU)
Rwanda (RW)
Saudi Arabia (SA)
Solomon Islands (SB)
Seychelles (SC)
Sudan (SD)
Sweden (SE)
Singapore (SG)
St. Helena (SH)
Slovenia (SI)
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Svalbard & Jan Mayen Isl. (SJ)
Slovakia (SK)
Sierra Leone (SL)
San Marino (SM)
Senegal (SN)
Somalia (SO)
Suriname (SR)
St. Tome And Principe (ST)
Soviet Union (SU)
El Salvador (SV)
Syria (SY)
Swaziland (SZ)
Turks & Caicos Islands (TC)
Chad (TD)
French Southern Terr. (TF)
Togo (TG)
Thailand (TH)
Tadjikistan (TJ)
Tokelau (TK)
Turkmenistan (TM)
Tunisia (TN)
Tonga (TO)
East Timor (TP)
Turkey (TR)
Trinidad & Tobago (TT)
Tuvalu (TV)
Taiwan (TW)
Tanzania (TZ)
Ukraine (UA)
Uganda (UG)
United Kingdom (UK)
Us Minor Outlying Isl. (UM)
Usa (US)
Uruguay (UY)
Uzbekistan (UZ)
Vatican City State (VA)
St. Vincent & Grenadines (VC)
Venezuela (VE)
Virgin Islands (brit) (VG)
Virgin Islands (us) (VI)
Vietnam (VN)
Vanuatu (VU)
Wallis & Futuna Islands (WF)
Western Samoa (WS)
Yemen (YE)
Mayotte (YT)
Yugoslavia (YU)
South Africa (ZA)
Zambia (ZM)
Dem. Rep. Of Congo (ZR)
Zimbabwe (ZW)
Comments
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Lung Cancer NCT00107172 Treatment -
Z4032 Post-Operative Report - 2306479v3.0
Z4032 Post-Operative Report
Surgery With or Without Internal Radiation Therapy in
Treating Patients With Stage I Non-Small Cell Lung Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=F21CFBF9-
E8F9-6424-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/8713
Z4032 Post-Operative Report
Header Module
Visit
Month 1 (Month 1)
Patient ID
Patient Initials
Institution No.
Institution Name
Header
Post-Operative Events (Note: All post-operative
events with a grade of 3, 4 or 5 must also be
reported on the AE page.)
Air Leak > 5 Days Duration (Air leak > 5
days duration)
Chylothorax Requiring Drainage/medical
Treatment Only (Chylothorax requiring
drainage/medical treatment only)
Chylothorax Requiring Surgical
Intervention (Chylothorax requiring
surgical intervention)
Delerium Tremens (Delerium tremens)
Ileus (Ileus)
Initial Vent Support > 48 Hours (Initial
vent support > 48 hours)
New Central Neurological Event (New
central neurological event)
New Renal Failure Requiring Treatment
Or Worsening (New renal failure
requiring treatment or worsening)
None (None)
Recurrent Laryngeal Nerve Paresis Or
Paralysis (Recurrent laryngeal nerve
paresis or paralysis)
Reintubation (Reintubation)
Tracheostomy (Tracheostomy)
Urinary Tract Infection (Urinary tract
infection)
Final Pathological Stage
1 / 3
Pathologic T Stage
Tumor 3 Cm Or Less In Greatest
Dimension, Surrounded By Lung Or
Visceral Pleura, Invasion More Proximal
Than The Lobar Bronchus, (i.e., Not In
The Main Bronchus) (T1)
Tumor With Any Of The Following
Features Of Size Or Extent: More Than
3cm In Greatest Dimension; Invades The
Visceral Pleura; Associated With
Atelectasis Or Obstructive Pneumonitis
That Extends To The Hilar Region But
Does Not Involve The Entire Lung (T2)
Tumor Of Any Size That Directly Invades
Any Of The Following: Chest Wall
(including Superior Sulcus Tumors),
Diaphragm, Mediastinal Pleura, Parietal
Pericardium; Or Tumor In The Main
Bronchus Less Than 2 Cm Distal To The
Carina, But Without Involvement O* (T3)
Tumor Of Any Size That Invades Any Of
The Following: Mediastinum, Heart,
Great Vessels, Trachea, Esophagus,
Vertebral Body, Carina; Or Separate
Tumor Nodules In The Same Lobe; Or
Tumor With A Malignant Pleural Effusion
(T4)
Pathologic N Stage
No Regional Lymph Node Metastasis
(N0)
Metastasis To Ipsilateral Peribronchial
And/or Ipsilateral Hilar Lymph Nodes,
And Intrapulmonary Nodes Including
Involvement By Direct Extension Of The
Primary Tumor (N1)
Metastasis To Ipsilateral Mediastinal
And/or Subcarinal Lymph Node(s) (N2)
Metastasis To Contralateral Mediastinal,
Contralateral Hilar, Ipsilateral Or
Contralateral Scalene, Or
Supraclavicular Lymph Node(s) (N3)
Regional Lymph Nodes Cannot Be
Assessed (NX)
Pathologic M Stage
No Distant Metastasis (M0)
Distant Metastasis Present (M1)
Staple line Cytology
Negative (Negative)
Positive (Positive)
Staple line Histology
Negative (Negative)
Positive (Positive)
Pathologic Primary Tumor Size
> 4.0 Cm (> 4.0 cm)
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0 - 1.0 Cm (0 - 1.0 cm)
1.1 - 2.0 Cm (1.1 - 2.0 cm)
2.1 - 3.0 Cm (2.1 - 3.0 cm)
3.1 - 4.0 Cm (3.1 - 4.0 cm)
Histologic Type (Mixed histology should be
assigned to the group of the predominant cell
type)
Adenocarcinoma (Adenocarcinoma)
Non-small Cell Lung Cancer (nsclc), Nos
(Other non small cell)
Squamous Cell Carcinoma (Squamous)
Patient Vital Status
Alive (Alive)
Dead (Dead)
Date of Death
Discharge
Still hospitalized at form completion
Yes
No
Discharge Date
Date chest tube removed (CT)
Footer Module
Completed by
Date Form Completed
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Neoplasms, Breast NCT00490139 Follow-Up - BIG 2-06 /
NCCTG N063D / EGF106708 - Death Form - 2639215v1.0
BIG 2-06 / NCCTG N063D / EGF106708 - Death Form
ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment
Optimisation) Study; BIG 2-06/N063D
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=30B15E86-
F939-6F6F-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/8715
BIG 2-06 / NCCTG N063D /
EGF106708 - Death Form
Header Module
Centre No.
Subject No.
Header
Date of Death
Primary cause of death
Adverse Event During Study (Adverse
event during study)
Adverse Event During Treatment Given
After Recurrence (Adverse event during
treatment given after recurrence)
Breast Cancer Progression (Breast
cancer progression)
Malignant Disease Other Than Breast
Cancer (Malignant disease other than
breast cancer)
Other (Other)
Specify
Was autopsy performed
No (No)
Unknown (Unknown)
Yes (Yes)
Please summarize findings
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Prostate Cancer NCT01546987 Registration -
RTOG-1115 A0: Eligibility Checklist - 3295665v1.0
RTOG-1115 A0: Eligibility Checklist
Hormone Therapy, Radiation Therapy, and Steroid 17alpha-
monooxygenase TAK-700 in Treating Patients With High-
Risk Prostate Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=AFAD4201-
221B-BDB1-E040-BB89AD4317CC
All rights reserved. Please visit https://medical-data-
models.org/forms/8717
RTOG-1115 A0: Eligibility Checklist
Module 1
Institutional person randomizing case
Has the eligibility checklist been completed
Yes
No
In the opinion of the investigator, is the patient
eligible?
Yes
No
Date Informed Consent Signed
Patient Initials (First Middle Last)
Verifying physician
Patient ID
Date of Birth
Race
A Person Having Origins In Any Of The
Original Peoples Of North And South
America (including Central America),
And Who Maintains Tribal Affiliation Or
Community Attachment. (American
Indian or Alaska Native)
A Person Having Origins In Any Of The
Original Peoples Of The Far East,
Southeast Asia, Or The Indian
Subcontinent Including, For Example,
Cambodia, China, India, Japan, Korea,
Malaysia, Pakistan, The Philippine
Islands, Thailand, And Vietnam. (Asian)
A Person Having Origins In Any Of The
Black Racial Groups Of Africa. Terms
Such As "haitian" Or "negro" Can Be
Used In Addition To "black Or African
American." (Black or African American)
More Than One Race (More than one
race)
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A Person Having Origins In Any Of The
Original Peoples Of Hawaii, Guam,
Samoa, Or Other Pacific Islands. (Native
Hawaiian or other Pacific Islander)
Could Not Be Determined Or Unsure
(Unknown)
A Person Having Origins In Any Of The
Original Peoples Of Europe, The Middle
East, Or North Africa. (White)
Ethnicity
A Person Of Mexican, Puerto Rican,
Cuban, Central Or South American Or
Other Spanish Culture Or Origin,
Regardless Of Race. (Hispanic or Latino)
A Person Not Meeting The Definition For
Hispanic Or Latino. (Not Hispanic or
Latino)
Could Not Be Determined Or Unsure
(Unknown)
Gender
Female Gender (Female)
Male Gender (Male)
Country of residence
Canada (CA)
Other (Other)
Usa (US)
ZIP Code (U.S. Residents)
Method of Payment
Medicaid (Medicaid)
Medicare And Medicaid (Medicaid and
Medicare)
Medicare (Medicare)
Medicare And Private Insurance
(Medicare and Private Insurance)
Military Or Veterans Sponsored
Insurance, Not Otherwise Specified
(Military or Veterans Sponsored, NOS)
No Insurance (No Means of Payment
(No Insurance))
Other (Other)
Private Insurance (Private Insurance)
Self Payment (Self-Pay (No Insurance))
Unknown (Unknown)
Any care at VA or military hospital
No (No)
Unknown (Unknown)
Yes (Yes)
Calendar base date
Randomization Date
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Medical oncologist's name
Have you obtained the patient's consent for his or
her tissue to be kept for use in research to learn
about, prevent, treat or cure cancer
Yes
No
Have you obtained the patient's consent for his or
her blood to be kept for use in research to learn
about, prevent, treat, or cure cancer?
Yes
No
Have you obtained the patient's consent for his or
her tissue to be kept for use in research about
other health problems (for example: causes of
diabetes, Alzheimer's disease or heart disease)
Yes
No
Have you obtained the patient's consent for his or
her blood to be kept for use in research about
other health problems (for example: causes of
diabetes, Alzheimer's disease or heart disease)
Yes
No
Have you obtained the patient's consent to allow
someone from this institution to contact him or
her in the future to take part in more research
Yes
No
Did the patient agree to participant in the Quality
of Life component (mandatory participation for
the first 410 patients)
Yes
No
If no, provide reason (from the following)
Not Approved By Institutional Irb (Not
approved by institutional IRB)
Other, Specify (Other, specify)
Patient Refused Due To Illness (Patient
refused due to illness)
Patient Refused For Other Reason
(Patient refused for other reason)
Tool Not Available In Patient's Language
(Tool not available in patient's language)
If response is "2) Patient refused for other
reason", specify the reason ([other reason patient
refused])
If response is "5) Other reason", specify the
reason the patient will not participate in the
quality of life component of the study
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Risk group (Specify)
Gleason >=9, Psa < 150, Any T-stage
(Gleason >=9, PSA < 150, any T-stage)
Gleason 7, Psa >= 20-150, Any T-stage
(Gleason 7, PSA >= 20-150, any T-
stage)
Gleason 8, Psa < 20, And >= T2
(Gleason 8, PSA < 20, and >= T2)
Gleason 8, Psa >= 20-150, Any T-stage
(Gleason 8, PSA >= 20-150, any T-
stage)
RT modality for boost (Specify)
Hdr Boost (HDR Boost)
Imrt (IMRT)
Ldr Permanent Prostate Implant (ppi)
Boost (LDR Permanent Prostate Implant
(PPI) Boost)
Use of IMRT (Specify)
Yes
No
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Response - Multiple Myeloma - Follow-Up
Disease Assessment Form - 2274798v3.0
Multiple Myeloma - Follow-Up Disease Assessment Form
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=D6E34646-
3810-5812-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/8718
Multiple Myeloma - Follow-Up
Disease Assessment Form
Crf Header
Coordinating Group Protocol No.
Coordinating Group Code
Protocol Title
Patient Study ID
Institution/Affiliate
Other Patient ID
Participating Group Code
Patient Name (initials acceptable)
Myeloma: Form Administration
Person Completing Form
Are data amended (If data are amended, please
circle in red when using paper form)
Yes
No
Myeloma: Assessment Reporting Interval
Reporting Period Start Date
Reporting Period End Date
Performance Status (check one)
Fully Active, Able To Carry On All Pre-
disease Performance Without
Restriction. (0)
Restricted In Physically Strenuous
Activity But Ambulatory And Able To
Carry Out Work Of A Light Or Sedentary
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Nature, E.g., Light Housework, Office
Work. (1)
Ambulatory And Capable Of All Selfcare
But Unable To Carry Out Any Work
Activities. Up And About More Than 50%
Of Waking Hours. (2)
Capable Of Only Limited Selfcare,
Confined To Bed Or Chair More Than
50% Of Waking Hours. (3)
Completely Disabled. Cannot Carry On
Any Selfcare. Totally Confined To Bed Or
Chair. (4)
Myeloma: Protein Studies Response
Serum Total Protein (SPEP)
Serum M-Protein Spike (SPEP If immunofixation
is positive but M-spike is not quantifiable, enter
.01 or follow protocol guidelines for entering M-
spike.)
Unit of Measure
Grams Per Deciliter (g/dL)
Milligrams Per Deciliter (mg/dL)
Serum M-Protein by Immunofixation
Equivocal (Equivocal)
Negative (Negative)
Positive (Positive)
Unknown (Unknown)
Serum Heavy Chain (If positive or equivocal,
check all that apply)
A (A)
D (D)
E (E)
G (G)
M (M)
Unknown (Unknown)
Serum Light Chain (check all that apply)
Kappa (Kappa)
Lambda (Lambda)
Unknown (Unknown)
Biclonal
Yes
No
Yes specify
Oligoclonal
Yes
No
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Yes specify
IgG
IgA
IgM
IgD
IgE
Urine Total Protein (UPEP)
Urine M-Protein Light Chain Excretion (If
immunofixation is positive but M-protein is not
quantifiable, enter .01 or follow protocol
guidelines for entering M-protein.)
Units of Measure
Grams/24 Hours (g/24 hrs)
Milligrams/24 Hours (mg/24 hrs)
Units of Measure
Grams/24 Hours (g/24 hrs)
Milligrams/24 Hours (mg/24 hrs)
Urine M-Protein by Immunofixation
Equivocal (Equivocal)
Negative (Negative)
Positive (Positive)
Unknown (Unknown)
Urine Light Chain (If positive or equivocal,)
Kappa (Kappa)
Lambda (Lambda)
Unknown (Unknown)
Myeloma: Peripheral Blood
Hematology/chemistry
Date Hematology (Blood) Sample Obtained
Peripheral WBC Count (x 10^3/mcl)
Hemoglobin (g/dl)
Absolute Plasma Cell Count (x 10^3/mcl ** For
plasma cell leukemia, absolute plasma cell count
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>2000 x 10^3/mcl OR >20% of WBC)
Plasma Cells in blood (% ** For plasma cell
leukemia, absolute plasma cell count >2000 x
10^3/mcl OR >20% of WBC)
Creatinine (mg/dl)
Calcium (Ca, mg/dl)
C-reactive Protein (mg/dl)
Peripheral Platelet Count (x 10^3/mcl)
Absolute Neutrophil Count (x 10^3/mcl)
Albumin (serum, g/dl, mg/dl or g/L)
Lactate Dehydrogenase (LDH) (U/l)
Lactate Dehydrogenase ULN (LDH U/l * Note:
Record institutional upper limit of normal)
Beta-2 Microglobulin (mcg/ml)
Beta-2 Microglobulin ULN (mcg/ml * Note:
Record institutional upper limit of normal)
Myeloma: Bone And Marrow Response
Assessment
Was bone marrow biopsy done
Inadequate Sample (Inadequate sample)
No (No)
Unknown (Unknown)
Yes (Yes)
Plasma Cells on Biopsy (%) (If yes,)
Was bone marrow aspirate done
Inadequate Sample (Inadequate sample)
No (No)
Unknown (Unknown)
Yes (Yes)
Plasma Cells on Aspirate in Interpretation (%) (If
yes,)
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Plasma Cells on Differential (%)
Was any bone fracture reported
No (No)
Unknown (Unknown)
Yes (Yes)
Was bone evaluation done
No (No)
Unknown (Unknown)
Yes (Yes)
Were lytic bone lesions present at study entry (If
yes,)
No (No)
Unknown (Unknown)
Yes (Yes)
Was there distinct enlargement of existing lesions
(If yes,)
No (No)
Unknown (Unknown)
Yes (Yes)
Was the appearance of any new lesions
documented
No (No)
Unknown (Unknown)
Yes (Yes)
Was bone assessment done (by imaging or scan)
No (No)
Unknown (Unknown)
Yes (Yes)
Bone Assessment Method (If yes, check all that
apply)
Bone Scan (Bone Scan)
Ct Scan (CT scan)
Mri (nmr) (MRI (NMR))
Pet Scan (PET Scan)
Skeletal Survey (Skeletal survey)
Bone Assessment Result
Abnormal (Abnormal)
Equivocal (Equivocal)
Normal (Normal)
Myeloma: Soft Tissue Plasmacytoma
Response
Soft Tissue Plasmacytoma
No (No)
Not Done (Not done)
Unknown (Unknown)
Yes (Yes)
Number of Plasmacytomas (If yes,)
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Are plasmacytomas measurable
Yes
No
Site of Largest Plasmacytoma (If yes, or
Indicator)
Greatest measurement (Size of Largest or
Indicator Plasmacytoma diameter cm x)
Greatest perpendicular measurement (cm)
Were any new soft tissue plasmacytomas
documented
No (No)
Unknown (Unknown)
Yes (Yes)
Method of Evaluation (If yes,)
Biopsy (Biopsy)
Clinical Examination (pe) (Clinical
examination)
Ct Scan (CT scan)
Mri (MRI (NMR))
Other (Other)
Method of Evaluation (If yes,)
Biopsy (Biopsy)
Clinical Examination (pe) (Clinical
examination)
Ct Scan (CT scan)
Mri (MRI (NMR))
Other (Other)
Other specify
Other specify
Are new plasmacytomas measurable
Yes
No
Site of New Plasmacytoma (If yes,)
Size of New Plasmacytoma (Greatest
measurement or diameter cm)
Myeloma: Objective Response
Assessment
Objective Status at This Evaluation
Complete Response (Complete
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Response)
Minimal Response (Minimal Response)
Near Complete Response (Near
Complete Response)
No Response/stable Disease (No
response/Stable Disease)
Partial Response (Partial Response)
Progressive Disease (Progressive
Disease)
Unevaluable (Unevaluable)
Very Good Partial Response (Very Good
Partial Response)
Basis for Determination of Response (check all
that apply)
Change In Bone Marrow Plasma Cells
(Change in bone marrow plasma cells)
Change In Serum M-protein Level (spep,
Immunofixation, Or Quantitative
Immunoglobulin) (Change in serum M-
Protein level (SPEP, immunofixation, or
quantitative immunoglobulin))
Change In Soft Tissue Plasmacytoma
(Change in soft tissue plasmacytoma)
Change In Urine M-protein Level (upep
Or Immunofixation) (Change in urine M-
Protein level (UPEP or immunofixation))
Other (Other)
Other specify
Basis for Determination of Progression (or
Relapse check all that apply)
Change In Bone Marrow Plasma Cells
(Change in bone marrow plasma cells)
Change In Serum M-protein Level (spep,
Immunofixation, Or Quantitative
Immunoglobulin) (Change in serum M-
Protein level (SPEP, immunofixation, or
quantitative immunoglobulin))
Change In Size And/or Number Of Bone
Lesions (Change in size and/or number
of bone lesions)
Change In Soft Tissue Plasmacytoma
(Change in soft tissue plasmacytoma)
Change In Urine M-protein Level (upep
Or Immunofixation) (Change in urine M-
Protein level (UPEP or immunofixation))
Increase In Calcium (Increase in
calcium)
Other (Other)
Other specify
Comments
Comments
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Drug/Agent Toxicity by Tissue/Organ NCT00057811 On-Study
- COG: Diagnosis/Registry [ANHL01P1] - 2090320v3.0
COG: Diagnosis/Registry [ANHL01P1]
Rituximab, Rasburicase, and Combination Chemotherapy
in Treating Young Patients With Newly Diagnosed
Advanced B-Cell Leukemia or Lymphoma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=B9F47A18-
28A9-232C-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/8719
COG: Diagnosis/Registry
[ANHL01P1]
Header
Institution
Institution Personnel
Institution Patient Identifier
Institution Patient Identifier
Today's date
Date worksheet entered into RDE
Demographics
Patient's Last Name (PLEASE give the first initial
at a minimum.)
Patient's First Name (PLEASE give the first initial
at a minimum.)
Patient's Middle Name (PLEASE give the first
initial at a minimum.)
Birthdate (MM/DD/YYYY)
Zip Code (Mandatory)
Country of Residence (Mandatory)
Pt. Sex (Mandatory)
Female (Female)
Male (Male)
Unknown (Unknown)
NAACCR Race Code (Mandatory)
A Person Having Origins In Any Of The
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Original Peoples Of North And South
America (including Central America),
And Who Maintains Tribal Affiliation Or
Community Attachment (American
Indian, Aleutian, Eskimo)
A Person Having Origins In Any Of The
Original Peoples Of The Far East,
Southeast Asia, Or The Indian
Subcontinent Including, For Example,
Cambodia, China, India, Japan, Korea,
Malaysia, Pakistan, The Philippine
Islands, Thailand, And Vietnam. (Asian
Indian, Pakistani)
A Person Having Origins In Any Of The
Black Racial Groups Of Africa. Terms
Such As "haitian" Or "negro" Can Be
Used In Addition To "black Or African
American." (Black)
A Person Having Origins In Any Of The
Original Peoples Of Hawaii, Guam,
Samoa, Or Other Pacific Islands
(Chamorran)
A Person Having Origins In Any Of The
Original Peoples Of The Far East,
Southeast Asia, Or The Indian
Subcontinent Including, For Example,
Cambodia, China, India, Japan, Korea,
Malaysia, Pakistan, The Philippine
Islands, Thailand, And Vietnam.
(Chinese)
A Person Having Origins In Any Of The
Original Peoples Of Hawaii, Guam,
Samoa, Or Other Pacific Islands (Fiji
Islander)
A Person Having Origins In Any Of The
Original Peoples Of The Far East,
Southeast Asia, Or The Indian
Subcontinent Including, For Example,
Cambodia, China, India, Japan, Korea,
Malaysia, Pakistan, The Philippine
Islands, Thailand, And Vietnam. (Filipino)
A Person Having Origins In Any Of The
Original Peoples Of Hawaii, Guam,
Samoa, Or Other Pacific Islands
(Guamanian, NOS)
A Person Having Origins In Any Of The
Original Peoples Of Hawaii, Guam,
Samoa, Or Other Pacific Islands
(Hawaiian)
A Person Having Origins In Any Of The
Original Peoples Of The Far East,
Southeast Asia, Or The Indian
Subcontinent Including, For Example,
Cambodia, China, India, Japan, Korea,
Malaysia, Pakistan, The Philippine
Islands, Thailand, And Vietnam.
(Hmong)
A Person Having Origins In Any Of The
Original Peoples Of The Far East,
Southeast Asia, Or The Indian
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Subcontinent Including, For Example,
Cambodia, China, India, Japan, Korea,
Malaysia, Pakistan, The Philippine
Islands, Thailand, And Vietnam.
(Japanese)
A Person Having Origins In Any Of The
Original Peoples Of The Far East,
Southeast Asia, Or The Indian
Subcontinent Including, For Example,
Cambodia, China, India, Japan, Korea,
Malaysia, Pakistan, The Philippine
Islands, Thailand, And Vietnam.
(Kampuchean)
A Person Having Origins In Any Of The
Original Peoples Of The Far East,
Southeast Asia, Or The Indian
Subcontinent Including, For Example,
Cambodia, China, India, Japan, Korea,
Malaysia, Pakistan, The Philippine
Islands, Thailand, And Vietnam.
(Laotian)
A Person Having Origins In Any Of The
Original Peoples Of Hawaii, Guam,
Samoa, Or Other Pacific Islands
(Melanesian, NOS)
A Person Having Origins In Any Of The
Original Peoples Of Hawaii, Guam,
Samoa, Or Other Pacific Islands
(Micronesian, NOS)
A Person Having Origins In Any Of The
Original Peoples Of Hawaii, Guam,
Samoa, Or Other Pacific Islands (New
Guinean)
A Person Having Origins In Any Of The
Original Peoples Of The Far East,
Southeast Asia, Or The Indian
Subcontinent Including, For Example,
Cambodia, China, India, Japan, Korea,
Malaysia, Pakistan, The Philippine
Islands, Thailand, And Vietnam. (Other
Asian, incl Asian NOS and Oriental
NOS)
A Person Having Origins In Any Of The
Original Peoples Of The Far East,
Southeast Asia, Or The Indian
Subcontinent Including, For Example,
Cambodia, China, India, Japan, Korea,
Malaysia, Pakistan, The Philippine
Islands, Thailand, And Vietnam. (Other
Asian, incl Asian NOS and Oriental
NOS)
A Person Having Origins In Any Of The
Original Peoples Of Hawaii, Guam,
Samoa, Or Other Pacific Islands (Pacific
Islander, NOS)
A Person Having Origins In Any Of The
Original Peoples Of Hawaii, Guam,
Samoa, Or Other Pacific Islands
(Polynesian, NOS)
A Person Having Origins In Any Of The
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Original Peoples Of Hawaii, Guam,
Samoa, Or Other Pacific Islands
(Samoan)
A Person Having Origins In Any Of The
Original Peoples Of Hawaii, Guam,
Samoa, Or Other Pacific Islands
(Tahitian)
A Person Having Origins In Any Of The
Original Peoples Of The Far East,
Southeast Asia, Or The Indian
Subcontinent Including, For Example,
Cambodia, China, India, Japan, Korea,
Malaysia, Pakistan, The Philippine
Islands, Thailand, And Vietnam. (Thai)
A Person Having Origins In Any Of The
Original Peoples Of Hawaii, Guam,
Samoa, Or Other Pacific Islands
(Tongan)
Patient Is Unsure Of Their Race
(Unknown)
A Person Having Origins In Any Of The
Original Peoples Of The Far East,
Southeast Asia, Or The Indian
Subcontinent Including, For Example,
Cambodia, China, India, Japan, Korea,
Malaysia, Pakistan, The Philippine
Islands, Thailand, And Vietnam.
(Vietnamese)
A Person Having Origins In Any Of The
Original Peoples Of Europe, The Middle
East, Or North Africa. (White)
NAACCR Race Other (If an "OTHER" option is
selected in the NAACCR Race field, you must
provide additional details in this field.)
NAACCR Ethnicity Other (If an "OTHER" option
is selected in the NAACCR Ethnicity field, you
must provide additional details in this field.)
NAACCR Ethnicity Other (If an "OTHER" option
is selected in the NAACCR Ethnicity field, you
must provide additional details in this field.)
Primary Diagnosis
Date of Diagnosis (MM/DD/YYYY)
Primary Site (Topography) Description
(Mandatory)
Primary Site (Topography) ICD-O Code (Primary
Site is coded by central office personnel.)
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Diagnosis Description (Mandatory)
Diagnosis ICD-O Code (Diagnosis is coded by
central office personnel.)
Secondary Malignancy (If Applicable)
Date of Diagnosis (MM/DD/YYYY)
Primary Site (Topography) (Mandatory)
Primary Site (Topography) ICD-O Code
(Secondary Diagnosis is coded by central office
personnel)
Initial Diagnosis (Morphology) Description
(Mandatory)
Initial Diagnosis (Morphology) ICD-O Code
(Secondary Diagnosis is coded by central office
personnel.)
Registry Stage (Mandatory)
Distant (Distant)
Local (Local)
N/a (N/A)
Regional (Regional)
Registry Stage (Mandatory)
Distant (Distant)
Local (Local)
N/a (N/A)
Regional (Regional)
Ccrr Module For Cog: Diagnosis/registry
[anhl01p1]
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Eligibility - E6508 Lung Cancer Registration
Worksheet (step 2) - 2862658v1.0
E6508 Registration Worksheet (step 2)
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=683ADC5E-
C8AE-081D-E040-BB89AD4336AC
All rights reserved. Please visit https://medical-data-
models.org/forms/8722
E6508 Lung Cancer Registration
Worksheet (step 2)
Eligibility
First initial
Last initial
Has the eligibility checklist been completed
Yes
No
In the opinion of the investigator, is the patient
eligible?
Yes
No
Patient's ECOG sequence number
Race
Patient's Race
A Person Having Origins In Any Of The
Original Peoples Of North And South
America (including Central America),
And Who Maintains Tribal Affiliation Or
Community Attachment. (American
Indian or Alaska Native)
A Person Having Origins In Any Of The
Original Peoples Of The Far East,
Southeast Asia, Or The Indian
Subcontinent Including, For Example,
Cambodia, China, India, Japan, Korea,
Malaysia, Pakistan, The Philippine
Islands, Thailand, And Vietnam. (Asian)
A Person Having Origins In Any Of The
Black Racial Groups Of Africa. Terms
Such As "haitian" Or "negro" Can Be
Used In Addition To "black Or African
American." (Black or African American)
A Person Having Origins In Any Of The
Original Peoples Of Hawaii, Guam,
Samoa, Or Other Pacific Islands. (Native
Hawaiian or other Pacific Islander)
Not Provided Or Available (Not
Reported)
Could Not Be Determined Or Unsure
(Unknown)
A Person Having Origins In Any Of The
Original Peoples Of Europe, The Middle
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East, Or North Africa. (White)
Patient Demographics / Pre-treatment
Characteristics
Patient's Sex
Female (F)
Male (M)
Birthdate (mm/yy)
ZIP Code
Patient Ethnicity
A Person Of Mexican, Puerto Rican,
Cuban, Central Or South American Or
Other Spanish Culture Or Origin,
Regardless Of Race. (Hispanic or Latino)
A Person Not Meeting The Definition For
Hispanic Or Latino. (Not Hispanic or
Latino)
Not Provided Or Available (Not reported)
Could Not Be Determined Or Unsure
(Unknown)
Patient Hospital No.
Patient Social Security Number
Method of payment (check one)
Medicaid (Medicaid)
Medicaid And Medicare (Medicaid and
Medicare)
Medicare (Medicare)
Medicare And Private Insurance
(Medicare and Private Insurance)
Military Or Veterans Sponsored Nos
(Military or Veterans Sponsored, Not
Otherwise Specified (NOS))
Military Sponsored (including Champus
& Tricare) (Military Sponsored (including
CHAMPUS & TRICARE))
No Means Of Payment (no Insurance)
(No means of payment (no insurance))
Other (Other)
Private Insurance (Private Insurance)
Self Pay (no Insurance) (Self Pay (No
Insurance))
Unknown (Unknown)
Veterans Sponsored (Veterans
Sponsored)
Attending Physician
Institution contact
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Registrar
Country of residence
Ascension Island (AC)
Andorra (AD)
United Arab Emirates (AE)
Afghanistan (AF)
Antigua And Barbuda (AG)
Anguilla (AI)
Albania (AL)
Armenia (AM)
Netherland Antilles (AN)
Angola (AO)
Antarctica (AQ)
Argentina (AR)
American Samoa (AS)
Austria (AT)
Australia (AU)
Aruba (AW)
Azerbaidjan (AZ)
Bosnia-herzegovina (BA)
Barbados (BB)
Bangladesh (BD)
Belgium (BE)
Burkina Faso (BF)
Bulgaria (BG)
Bahrain (BH)
Burundi (BI)
Benin (BJ)
Bermuda (BM)
Brunei Darussalam (BN)
Bolivia (BO)
Brazil (BR)
Bahamas (BS)
Bhutan (BT)
Bouvet Island (BV)
Botswana (BW)
Belarus (BY)
Belize (BZ)
Canada (CA)
Cocos Isl. (CC)
Rep. Dem. Congo (CD)
Central African Rep. (CF)
Congo (CG)
Switzerland (CH)
Ivory Coast (CI)
Cook Islands (CK)
Chile (CL)
Cameroon (CM)
China (CN)
Colombia (CO)
Costa Rica (CR)
Cuba (CU)
Cape Verde (CV)
Christmas Island (CX)
Cyprus (CY)
Czech Republic (CZ)
Germany (DE)
Djibouti (DJ)
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Denmark (DK)
Dominica (DM)
Dominican Republic (DO)
Algeria (DZ)
Ecuador (EC)
Estonia (EE)
Egypt (EG)
Western Sahara (EH)
Eritrea (ER)
Spain (ES)
Ethiopia (ET)
Finland (FI)
Fiji (FJ)
Falkland Isl. (FK)
Micronesia (FM)
Faroe Islands (FO)
France (FR)
France (european Ter.) (FX)
Gabon (GA)
Great Britain (GB)
Grenada (GD)
Georgia (GE)
Guiana (fr.) (GF)
Guernsey (GG)
Ghana (GH)
Gibraltar (GI)
Greenland (GL)
Gambia (GM)
Guinea (GN)
Guadeloupe (fr.) (GP)
Equatorial Guinea (GQ)
Greece (GR)
South Georgia And South Sandwich
Islands (GS)
Guatemala (GT)
Guam (us) (GU)
Guinea Bissau (GW)
Guyana (GY)
Hong Kong (HK)
Heard & Mcdonald Isl. (HM)
Honduras (HN)
Croatia (HR)
Haiti (HT)
Hungary (HU)
Indonesia (ID)
Ireland (IE)
Israel (IL)
Isle Of Man (IM)
India (IN)
British Indian O. Ter. (IO)
Iraq (IQ)
Iran (IR)
Iceland (IS)
Italy (IT)
Jersey (JE)
Jamaica (JM)
Jordan (JO)
Japan (JP)
Kenya (KE)
Kyrgyz Republic (KG)
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Cambodia (KH)
Kiribati (KI)
Comoros (KM)
St. Kitts Nevis Anguilla (KN)
Korea (north) (KP)
Korea (south) (KR)
Kuwait (KW)
Cayman Islands (KY)
Kazakstan (KZ)
Laos (LA)
Lebanon (LB)
Saint Lucia (LC)
Liechtenstein (LI)
Sri Lanka (LK)
Liberia (LR)
Lesotho (LS)
Lithuania (LT)
Luxembourg (LU)
Latvia (LV)
Libya (LY)
Morocco (MA)
Monaco (MC)
Moldova (MD)
Madagascar (MG)
Marshall Islands (MH)
Macedonia (MK)
Mali (ML)
Myanmar (MM)
Mongolia (MN)
Macau (MO)
Northern Mariana Isl. (MP)
Martinique (fr.) (MQ)
Mauritania (MR)
Montserrat (MS)
Malta (MT)
Mauritius (MU)
Maldives (MV)
Malawi (MW)
Mexico (MX)
Malaysia (MY)
Mozambique (MZ)
Namibia (NA)
New Caledonia (fr.) (NC)
Niger (NE)
Norfolk Island (NF)
Nigeria (NG)
Nicaragua (NI)
Netherlands (NL)
Norway (NO)
Nepal (NP)
Nauru (NR)
Niue (NU)
New Zealand (NZ)
Oman (OM)
Other (Other)
Panama (PA)
Peru (PE)
Polynesia (fr.) (PF)
Papua New Guinea (PG)
Philippines (PH)
5 / 7
Eligibility - E6508 Lung Cancer Registration Worksheet (step 2) -
2862658v1.0
Pakistan (PK)
Poland (PL)
St. Pierre & Miquelon (PM)
Pitcairn (PN)
Puerto Rico (PR)
Portugal (PT)
Palau (PW)
Paraguay (PY)
Qatar (QA)
Reunion (fr.) (RE)
Romania (RO)
Russian Federation (RU)
Rwanda (RW)
Saudi Arabia (SA)
Solomon Islands (SB)
Seychelles (SC)
Sudan (SD)
Sweden (SE)
Singapore (SG)
St. Helena (SH)
Slovenia (SI)
Svalbard & Jan Mayen Isl. (SJ)
Slovakia (SK)
Sierra Leone (SL)
San Marino (SM)
Senegal (SN)
Somalia (SO)
Suriname (SR)
St. Tome And Principe (ST)
Soviet Union (SU)
El Salvador (SV)
Syria (SY)
Swaziland (SZ)
Turks & Caicos Islands (TC)
Chad (TD)
French Southern Terr. (TF)
Togo (TG)
Thailand (TH)
Tadjikistan (TJ)
Tokelau (TK)
Turkmenistan (TM)
Tunisia (TN)
Tonga (TO)
East Timor (TP)
Turkey (TR)
Trinidad & Tobago (TT)
Tuvalu (TV)
Taiwan (TW)
Tanzania (TZ)
Ukraine (UA)
Uganda (UG)
United Kingdom (UK)
Us Minor Outlying Isl. (UM)
Usa (US)
Uruguay (UY)
Uzbekistan (UZ)
Vatican City State (VA)
St. Vincent & Grenadines (VC)
Venezuela (VE)
Virgin Islands (brit) (VG)
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Virgin Islands (us) (VI)
Vietnam (VN)
Vanuatu (VU)
Wallis & Futuna Islands (WF)
Western Samoa (WS)
Yemen (YE)
Mayotte (YT)
Yugoslavia (YU)
South Africa (ZA)
Zambia (ZM)
Dem. Rep. Of Congo (ZR)
Zimbabwe (ZW)
Comments
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Breast Cancer NCT00513292 Follow-Up -
Z1041: Extended Follow-up Form - 2533635v1.0
Z1041: Extended Follow-up Form
Combination Chemotherapy and Paclitaxel Plus
Trastuzumab in Treating Women With Palpable Breast
Cancer That Can Be Removed by Surgery
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=211CBE88-
1531-5AB5-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/8723
Z1041: Extended Follow-up Form
Header Module
Visit
30 Days Post Surgery (30 Days post
surgery)
Mo12fu (Mo12FU)
Mo15fu (Mo15FU)
Mo18fu (Mo18FU)
Mo24fu (Mo24FU)
Mo30fu (Mo30FU)
Mo36fu (Mo36FU)
Mo3fu (Mo3FU)
Mo42fu (Mo42FU)
Mo48fu (Mo48FU)
Mo54fu (Mo54FU)
Mo6fu (Mo6FU)
Mo9fu (Mo9FU)
Unscheduled (Unscheduled)
Date
Patient ID (Patient ID issued during registration or
previously issued Patient ID.)
Patient Initials (F M L)
Institution No.
Institution Name
Header
Vital status
Alive (Alive)
Dead (Dead)
Date of Last Contact or Death (Year Month e.g.,
JAN Day)
Primary Cause of Death (If deceased,)
Due To Cardiovascular Disease (Due to
cardiovascular disease)
Due To Other Cause (Due to other
cause)
Due To Protocol Treatment (Due to
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protocol treatment)
Due To This Disease (Due to this
disease)
Describe cause of death
Was imaging done to assess for recurrence
Yes
No
Image date
Notice Of First Recurrence/progression
Has the patient developed a first progression (or
relapse) that has not been previously reported?
Yes
No
First recurrence/progression
Distant (Distant)
Local (Local)
Regional (Regional)
Date of first recurrence/progression
Site of first recurrence/progression
Bone (Bone)
Liver (Liver)
Ln (LN)
Lung/pleura (Lung/pleura)
Other (Other)
Other, specify
Notice Of New Primary
Has a new primary cancer or MDS been
diagnosed that has not been previously reported?
Yes
No
Date of diagnosis
New Primary, Histologic type
Footer Module
Completed by
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Form - 2533635v1.0
Date Form Completed
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Breast Cancer NCT00513292 Follow-Up - Z1041: Extended Follow-up
Form - 2533635v1.0
Response - Primary Amyloidosis - Baseline
Disease Assessment Form - 2275065v3.0
Primary Amyloidosis - Baseline Disease Assessment Form
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=D6E369F3-
B8C0-58EE-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/8725
Primary Amyloidosis - Baseline
Disease Assessment Form
Crf Header
Coordinating Group Protocol No.
Coordinating Group Code
Protocol Title
Patient Study ID
Institution/Affiliate
Other Patient ID
Participating Group Code
Patient Name (initials acceptable)
Amyloid: Form Administration
Person Completing Form
Are data amended (If data are amended, please
circle in red when using paper form)
Yes
No
Amyloid: Assessment Reporting Interval
Reporting Period Start Date
Reporting Period End Date
Performance Status (check one)
Fully Active, Able To Carry On All Pre-
disease Performance Without
Restriction. (0)
Restricted In Physically Strenuous
Activity But Ambulatory And Able To
Carry Out Work Of A Light Or Sedentary
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Nature, E.g., Light Housework, Office
Work. (1)
Ambulatory And Capable Of All Selfcare
But Unable To Carry Out Any Work
Activities. Up And About More Than 50%
Of Waking Hours. (2)
Capable Of Only Limited Selfcare,
Confined To Bed Or Chair More Than
50% Of Waking Hours. (3)
Completely Disabled. Cannot Carry On
Any Selfcare. Totally Confined To Bed Or
Chair. (4)
Amyloid: Protein Studies
Serum Total Protein (SPEP)
Serum M-Protein Spike (SPEP If immunofixation
is positive but M-spike is not quantifiable, enter
.01 or follow protocol guidelines for entering M-
spike.)
Serum M-Protein by Immunofixation
Equivocal (Equivocal)
Negative (Negative)
Positive (Positive)
Unknown (Unknown)
Serum Heavy Chain (If positive or equivocal,
check all that apply)
A (A)
D (D)
E (E)
G (G)
M (M)
Unknown (Unknown)
Serum Light Chain (check all that apply)
Kappa (Kappa)
Lambda (Lambda)
Unknown (Unknown)
Biclonal
Yes
No
Yes specify
Oligoclonal
Yes
No
Yes specify
IgG
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IgA
IgM
IgD
IgE
Urine Total Protein (UPEP)
Urine M-Protein Light Chain Excretion (If
immunofixation is positive but M-protein is not
quantifiable, enter .01 or follow protocol
guidelines for entering M-protein.)
Unit of Measure
Grams/24 Hours (g/24 hrs)
Milligrams/24 Hours (mg/24 hrs)
Unit of Measure
Grams/24 Hours (g/24 hrs)
Milligrams/24 Hours (mg/24 hrs)
Unit of Measure
Grams/24 Hours (g/24 hrs)
Milligrams/24 Hours (mg/24 hrs)
Urine M-Protein by Immunofixation
Equivocal (Equivocal)
Negative (Negative)
Positive (Positive)
Unknown (Unknown)
Urine Light Chain (If positive or equivocal,)
Kappa (Kappa)
Lambda (Lambda)
Unknown (Unknown)
Amyloid: Peripheral Blood
Hematology/chemistry
Date Hematology (Blood) Sample Obtained
Peripheral WBC Count (x 10^3/mcl)
Hemoglobin (g/dl)
Creatinine (mg/dl)
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Creatinine Clearance (24-hour, cc/min)
C-reactive Protein (mg/dl)
Total Bilirubin (mg/dl or mcmol/L)
Direct bilirubin (mg/dl or mcmol/L)
Calcium (Ca, mg/dl)
Carotene (mg/dl, mcg/dl or mcmol/L ** Carotene
should be collected if autonomic neuropathy or
small bowel involvement is present at diagnosis)
Peripheral Platelet Count (x 10^3/mcl)
Absolute Neutrophil Count (x 10^3/mcl)
Albumin (serum, g/dl, mg/dl or g/L)
Albumin, 24 hour urine (g/24 hrs)
Alkaline Phosphatase (U/l or mcKat/l)
Lactate Dehydrogenase (LDH) (U/l)
Lactate Dehydrogenase ULN (LDH U/l * Note:
Record institutional upper limit of normal)
Beta-2 Microglobulin (mcg/ml)
Beta-2 Microglobulin ULN (mcg/ml * Note:
Record institutional upper limit of normal)
International Normalization Ratio (INR)
Amyloid: Organ Assessment
Interventricular Septal Wall Thickness (mm)
Left Ventricular Ejection Fraction at Rest (%)
LVEF Institutional Lower Limit of Normal (%)
4 / 7
Response - Primary Amyloidosis - Baseline Disease Assessment Form -
2275065v3.0
New York Heart Association Classification (check
one)
Patients With Cardiac Disease But
Without Resulting Limitation Of Physical
Activity. Ordinary Physical Activity Does
Not Cause Undue Fatigue, Palpitation,
Dyspnea Or Anginal Pain. (Class I)
Patients With Cardiac Disease Resulting
In Slight Limitation Of Physical Activity.
They Are Comfortable At Rest. Ordinary
Physical Activity Results In Fatigue,
Palpitation, Dyspnea Or Anginal Pain.
(Class II)
Patients With Cardiac Disease Resulting
In Marked Limitation Of Physical Activity.
They Are Comfortable At Rest. Less
Than Ordinary Activity Causes Fatigue,
Palpitation, Dyspnea Or Anginal Pain.
(Class III)
Patients With Cardiac Disease Resulting
In Inability To Carry On Any Physical
Activity Without Discomfort. Symptoms
Of Heart Failure Or The Anginal
Syndrome May Be Present Even At
Rest. If Any Physical Activity Is
Undertaken, Discomfort Increases.
(Class IV)
Unknown (Unknown)
Is there hepatomegaly
No (No)
Not Examined (Not examined)
Unknown (Unknown)
Yes (Yes)
Liver Measurement (If yes, cm)
Liver Measurement Method
From Costal Margin (from costal margin)
From Total Span (from total span)
Method of Evaluation
Clinical Examination (pe) (Clinical
examination)
Ct Scan (CT Scan)
Gallium Scan (Gallium scan)
Mri (MRI (NMR))
Other (Other)
Pet Scan (PET scan)
Spiral Ct Scan (Spiral CT Scan)
Ultrasound (Ultrasound)
Other specify
Date of Liver Evaluation
If steatorrhea, is diarrhea present
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No (No)
Unknown (Unknown)
Yes (Yes)
Number of stools per day (If yes,)
48-hour Fecal Fat Excretion (g)
Evidence of peripheral neuropathy
No (No)
Unknown (Unknown)
Yes (Yes)
Symptomatic (If yes,)
Yes
No
Objective (physical exam)
Yes
No
EMG (Note: If yes, submit EMG report)
Yes
No
Amyloid: Bone Marrow Assessment
Was bone marrow biopsy done
Inadequate Sample (Inadequate sample)
No (No)
Unknown (Unknown)
Yes (Yes)
Plasma Cells on Biopsy (%) (If yes,)
Was bone marrow aspirate done
Inadequate Sample (Inadequate sample)
No (No)
Unknown (Unknown)
Yes (Yes)
Plasma Cells on Aspirate in Interpretation (%) (If
yes,)
Plasma Cells on Differential (%)
Plasma Cell Clonality
Kappa (Kappa)
Lambda (Lambda)
Not Tested (Not tested)
Polyclonal (Polyclonal)
Clonality Determined by (If done,)
Flow Cytometry (Flow cytometry)
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Immunohistochemical Stain
(Immunohistochemical stain)
Other (Other)
Plasma Cell Labeling Index (pcli)
(Plasma cell labeling index (PCLI))
Other specify
Amyloid: Amyloidoma
Amyloidoma
No (No)
Not Done (Not done)
Unknown (Unknown)
Yes (Yes)
Size of Largest Amyloidoma (If yes, cm)
Site of Amyloidoma
Comments
Comments
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Breast Cancer NCT00513292 Follow-Up -
Z1041: Missed Visit Form - 2533711v1.0
Z1041: Missed Visit Form
Combination Chemotherapy and Paclitaxel Plus
Trastuzumab in Treating Women With Palpable Breast
Cancer That Can Be Removed by Surgery
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=211E1232-
0FB6-645F-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/8726
Z1041: Missed Visit Form
Header Module
Visit
30 Days Post Surgery (30 Days post
surgery)
C1d21 (C1D21)
C2d21 (C2D21)
C3d21 (C3D21)
C4d21 (C4D21)
C5d21 (C5D21)
C6d21 (C6D21)
C7d21 (C7D21)
C8d21 (C8D21)
Mo12fu (Mo12FU)
Mo15fu (Mo15FU)
Mo18fu (Mo18FU)
Mo24fu (Mo24FU)
Mo30fu (Mo30FU)
Mo36fu (Mo36FU)
Mo3fu (Mo3FU)
Mo42fu (Mo42FU)
Mo48fu (Mo48FU)
Mo54fu (Mo54FU)
Mo6fu (Mo6FU)
Mo9fu (Mo9FU)
Patient ID (Pt. ID issued during registration or
previously issued patient ID)
Patient Initials (F M L)
Institution No.
Institution Name
Header
Missed Visit Date (Year Month e.g., JAN Day)
Reason patient missed visit (Mark only one.)
Distance From Home To Clinical Site
(Distance from home to clinical site)
Health Reasons (Health reasons)
Other (Other)
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Scheduling Difficulties (Scheduling
difficulties)
Other, specify
Footer Module
Completed by
Date Form Completed
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Breast Cancer NCT00513292 Follow-Up - Z1041:
Early Termination of Follow-up (ETFU) - 2533765v1.0
Z1041: Early Termination of Follow-up (ETFU)
Combination Chemotherapy and Paclitaxel Plus
Trastuzumab in Treating Women With Palpable Breast
Cancer That Can Be Removed by Surgery
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=211E6516-
FD7F-6E79-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/8728
Z1041: Early Termination of Follow-
up (ETFU)
Header Module
Visit
30 Days Post Surgery (30 Days post
surgery)
Baseline (Baseline)
C1d21 (C1D21)
C2d21 (C2D21)
C3d21 (C3D21)
C4d21 (C4D21)
C5d21 (C5D21)
C6d21 (C6D21)
C7d21 (C7D21)
C8d21 (C8D21)
Mo12fu (Mo12FU)
Mo15fu (Mo15FU)
Mo18fu (Mo18FU)
Mo24fu (Mo24FU)
Mo30fu (Mo30FU)
Mo36fu (Mo36FU)
Mo3fu (Mo3FU)
Mo42fu (Mo42FU)
Mo48fu (Mo48FU)
Mo54fu (Mo54FU)
Mo6fu (Mo6FU)
Mo9fu (Mo9FU)
Patient ID (Pt. ID issued during registration or
previously issued patient ID)
Patient Initials (F M L)
Institution No.
Institution Name
Header
Date of Early Termination of Follow-up
Reason for early termination of patient follow-up
(mark only one)
Lost Contact With Patient (Lost contact
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with patient)
Other (Other)
Patient Refusal For Further Study
Follow-up (Patient refusal for further
study follow-up)
Patient Withdrew Consent. (Patient
withdrew consent)
Other, specify
Footer Module
Completed by
Date Form Completed
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Esophageal Cancer NCT00551759 Eligibility - E2205
Registration Worksheet (step 1) - 2753343v1.0
E2205 Registration Worksheet (step 1)
Chemotherapy, Radiation Therapy, and Cetuximab
Followed by Surgery, Docetaxel, and Cetuximab in Treating
Patients With Esophageal Cancer or Gastroesophageal
Junction Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=4E4AEBDF-
A595-00B2-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/8729
E2205 Registration Worksheet (step
1)
Eligibility
First initial
Last initial
Has the eligibility checklist been completed
Yes
No
In the opinion of the investigator, is the patient
eligible?
Yes
No
Has written informed consent been obtained
Yes
No
Date Informed Consent Signed
Has HIPAA authorization been obtained
Exempt - Non-usa Participant (Exempt -
non-USA participant)
No: C49487 (No)
Yes: C49488 (Yes)
HIPAA Authorization Date
ECOG Performance Status
Fully Active, Able To Carry On All Pre-
disease Performance Without
Restriction. (0)
Restricted In Physically Strenuous
Activity But Ambulatory And Able To
Carry Out Work Of A Light Or Sedentary
Nature, E.g., Light Housework, Office
Work. (1)
Ambulatory And Capable Of All Selfcare
But Unable To Carry Out Any Work
Activities. Up And About More Than 50%
Of Waking Hours. (2)
Capable Of Only Limited Selfcare,
Confined To Bed Or Chair More Than
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50% Of Waking Hours. (3)
Completely Disabled. Cannot Carry On
Any Selfcare. Totally Confined To Bed Or
Chair. (4)
Dead (5)
Clinical Stage
T1-3n+m0 (T1-3N+M0)
T1-3n0-1m1a (T1-3N0-1M1A)
T2n0m0 (T2N0M0)
T3n0m0 (T3N0M0)
I agree to participate in the laboratory research
studies that are being done as part of this clinical
trial.
Yes
No
My specimens may be kept for use in research to
learn about, prevent, treat, or cure cancer.
Yes
No
My specimens may be kept for research about
other health problems (for example: causes of
diabetes, Alzheimer's disease, and heart
disease)
Yes
No
Someone may contact me in the future to ask me
to allow other uses of my specimens.
Yes
No
Name of the contact person responsible for
sample submission
Phone number of the contact person responsible
for sample submission
Fax number of the contact person responsible for
sample submission
E-mail address of the contact person responsible
for sample submission
If an ECOG patient is to receive radiation therapy,
will it be given at the registering institution
No (No)
Not Applicable - Not An Ecog Patient
(Not applicable - not an ECOG patient)
Unknown (Unknown)
Yes (Yes)
Name of the institution that will administered the
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radiation therapy
Patient Demographics / Pre-treatment
Characteristics
Patient's Sex
Female (F)
Male (M)
Birthdate (mm/yy)
Patient Race (check all that applyU.S. and
Canada only)
A Person Having Origins In Any Of The
Original Peoples Of North And South
America (including Central America),
And Who Maintains Tribal Affiliation Or
Community Attachment. (American
Indian or Alaska Native)
A Person Having Origins In Any Of The
Original Peoples Of The Far East,
Southeast Asia, Or The Indian
Subcontinent Including, For Example,
Cambodia, China, India, Japan, Korea,
Malaysia, Pakistan, The Philippine
Islands, Thailand, And Vietnam. (Asian)
A Person Having Origins In Any Of The
Black Racial Groups Of Africa. Terms
Such As "haitian" Or "negro" Can Be
Used In Addition To "black Or African
American." (Black or African American)
A Person Having Origins In Any Of The
Original Peoples Of Hawaii, Guam,
Samoa, Or Other Pacific Islands. (Native
Hawaiian or other Pacific Islander)
Not Provided Or Available (Not
Reported)
Could Not Be Determined Or Unsure
(Unknown)
A Person Having Origins In Any Of The
Original Peoples Of Europe, The Middle
East, Or North Africa. (White)
ZIP Code
Patient Hospital No.
Patient Social Security Number
Method of payment (check one)
Medicaid (Medicaid)
Medicaid And Medicare (Medicaid and
Medicare)
Medicare (Medicare)
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Medicare And Private Insurance
(Medicare and Private Insurance)
Military Or Veterans Sponsored Nos
(Military or Veterans Sponsored, Not
Otherwise Specified (NOS))
Military Sponsored (including Champus
& Tricare) (Military Sponsored (including
CHAMPUS & TRICARE))
National Health Service (National Health
Service)
No Means Of Payment (no Insurance)
(No means of payment (no insurance))
Other (Other)
Private Insurance (Private Insurance)
Self Pay (no Insurance) (Self Pay (No
Insurance))
Unknown (Unknown)
Veterans Sponsored (Veterans
Sponsored)
Attending Physician
Institution contact
Registrar
Country of Residence
Comments
Signature of treating physician (I have reviewed
the above data and agree the date are accurate
and correct)
Date (Note: Date must be on or before date of
registration)
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Response - Primary Amyloidosis - Follow-Up
Disease Assessment Form - 2275307v3.0
Primary Amyloidosis - Follow-Up Disease Assessment
Form
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=D6E37EC9-
1337-59D5-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/8730
Primary Amyloidosis - Follow-Up
Disease Assessment Form
Crf Header
Coordinating Group Protocol No.
Coordinating Group Code
Protocol Title
Patient Study ID
Institution/Affiliate
Other Patient ID
Participating Group Code
Patient Name (initials acceptable)
Amyloid: Form Administration
Person Completing Form
Are data amended (If data are amended, please
circle in red when using paper form)
Yes
No
Amyloid: Assessment Reporting Interval
Reporting Period Start Date
Reporting Period End Date
Performance Status (check one)
Fully Active, Able To Carry On All Pre-
disease Performance Without
Restriction. (0)
1 / 8
Restricted In Physically Strenuous
Activity But Ambulatory And Able To
Carry Out Work Of A Light Or Sedentary
Nature, E.g., Light Housework, Office
Work. (1)
Ambulatory And Capable Of All Selfcare
But Unable To Carry Out Any Work
Activities. Up And About More Than 50%
Of Waking Hours. (2)
Capable Of Only Limited Selfcare,
Confined To Bed Or Chair More Than
50% Of Waking Hours. (3)
Completely Disabled. Cannot Carry On
Any Selfcare. Totally Confined To Bed Or
Chair. (4)
Amyloid: Protein Studies
Serum Total Protein (SPEP)
Serum M-Protein Spike (SPEP If immunofixation
is positive but M-spike is not quantifiable, enter
.01 or follow protocol guidelines for entering M-
spike.)
Serum M-Protein by Immunofixation
Equivocal (Equivocal)
Negative (Negative)
Positive (Positive)
Unknown (Unknown)
Serum Heavy Chain (If positive or equivocal,
check all that apply)
A (A)
D (D)
E (E)
G (G)
M (M)
Unknown (Unknown)
Serum Light Chain (check all that apply)
Kappa (Kappa)
Lambda (Lambda)
Unknown (Unknown)
Biclonal
Yes
No
Yes specify
Oligoclonal
Yes
No
Yes specify
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IgG
IgA
IgM
IgD
IgE
Urine Total Protein (UPEP)
Urine M-Protein Light Chain Excretion (If
immunofixation is positive but M-protein is not
quantifiable, enter .01 or follow protocol
guidelines for entering M-protein.)
Unit of Measure
Grams/24 Hours (g/24 hrs)
Milligrams/24 Hours (mg/24 hrs)
Unit of Measure
Grams/24 Hours (g/24 hrs)
Milligrams/24 Hours (mg/24 hrs)
Unit of Measure
Grams/24 Hours (g/24 hrs)
Milligrams/24 Hours (mg/24 hrs)
Urine M-Protein by Immunofixation
Equivocal (Equivocal)
Negative (Negative)
Positive (Positive)
Unknown (Unknown)
Urine Light Chain (If positive or equivocal,)
Kappa (Kappa)
Lambda (Lambda)
Unknown (Unknown)
Amyloid: Peripheral Blood
Hematology/chemistry
Date Hematology (Blood) Sample Obtained
Peripheral WBC Count (x 10^3/mcl)
Hemoglobin (g/dl)
Creatinine (mg/dl)
3 / 8
Response - Primary Amyloidosis - Follow-Up Disease Assessment Form
- 2275307v3.0
Creatinine Clearance (24-hour, cc/min)
C-reactive Protein (mg/dl)
Total Bilirubin (mg/dl or mcmol/L)
Direct bilirubin (mg/dl or mcmol/L)
Calcium (Ca, mg/dl)
Carotene (mg/dl, mcg/dl or mcmol/L ** Carotene
should be collected if autonomic neuropathy or
small bowel involvement is present at diagnosis)
Peripheral Platelet Count (x 10^3/mcl)
Absolute Neutrophil Count (x 10^3/mcl)
Albumin (serum, g/dl, mg/dl or g/L)
Albumin, 24 hour urine (g/24 hrs)
Alkaline Phosphatase (U/l or mcKat/l)
Lactate Dehydrogenase (LDH) (U/l)
Lactate Dehydrogenase ULN (LDH U/l * Note:
Record institutional upper limit of normal)
Beta-2 Microglobulin (mcg/ml)
Beta-2 Microglobulin ULN (mcg/ml * Note:
Record institutional upper limit of normal)
International Normalization Ratio (INR)
Amyloid: Organ Assessment
Interventricular Septal Wall Thickness (mm)
Left Ventricular Ejection Fraction at Rest (%)
LVEF Institutional Lower Limit of Normal (%)
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New York Heart Association Classification (check
one)
Patients With Cardiac Disease But
Without Resulting Limitation Of Physical
Activity. Ordinary Physical Activity Does
Not Cause Undue Fatigue, Palpitation,
Dyspnea Or Anginal Pain. (Class I)
Patients With Cardiac Disease Resulting
In Slight Limitation Of Physical Activity.
They Are Comfortable At Rest. Ordinary
Physical Activity Results In Fatigue,
Palpitation, Dyspnea Or Anginal Pain.
(Class II)
Patients With Cardiac Disease Resulting
In Marked Limitation Of Physical Activity.
They Are Comfortable At Rest. Less
Than Ordinary Activity Causes Fatigue,
Palpitation, Dyspnea Or Anginal Pain.
(Class III)
Patients With Cardiac Disease Resulting
In Inability To Carry On Any Physical
Activity Without Discomfort. Symptoms
Of Heart Failure Or The Anginal
Syndrome May Be Present Even At
Rest. If Any Physical Activity Is
Undertaken, Discomfort Increases.
(Class IV)
Unknown (Unknown)
Is there hepatomegaly
No (No)
Not Examined (Not examined)
Unknown (Unknown)
Yes (Yes)
Liver Measurement (If yes, cm)
Liver Measurement Method
From Costal Margin (from costal margin)
From Total Span (from total span)
Method of Evaluation
Clinical Examination (pe) (Clinical
examination)
Ct Scan (CT Scan)
Gallium Scan (Gallium scan)
Mri (MRI (NMR))
Other (Other)
Pet Scan (PET scan)
Spiral Ct Scan (Spiral CT Scan)
Ultrasound (Ultrasound)
Other specify
Date of Liver Evaluation
If steatorrhea, is diarrhea present
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No (No)
Unknown (Unknown)
Yes (Yes)
Number of stools per day (If yes,)
48-hour Fecal Fat Excretion (g)
Evidence of peripheral neuropathy
No (No)
Unknown (Unknown)
Yes (Yes)
Symptomatic (If yes,)
Yes
No
Objective (physical exam)
Yes
No
EMG (Note: If yes, submit EMG report)
Yes
No
Amyloid: Bone Marrow Assessment
Was bone marrow biopsy done
Inadequate Sample (Inadequate sample)
No (No)
Unknown (Unknown)
Yes (Yes)
Plasma Cells on Biopsy (%) (If yes,)
Was bone marrow aspirate done
Inadequate Sample (Inadequate sample)
No (No)
Unknown (Unknown)
Yes (Yes)
Plasma Cells on Aspirate in Interpretation (%) (If
yes,)
Plasma Cells on Differential (%)
Plasma Cell Clonality
Kappa (Kappa)
Lambda (Lambda)
Not Tested (Not tested)
Polyclonal (Polyclonal)
Clonality Determined by (If done,)
Flow Cytometry (Flow cytometry)
6 / 8
Response - Primary Amyloidosis - Follow-Up Disease Assessment Form
- 2275307v3.0
Immunohistochemical Stain
(Immunohistochemical stain)
Other (Other)
Plasma Cell Labeling Index (pcli)
(Plasma cell labeling index (PCLI))
Other specify
Amyloid: Amyloidoma
Amyloidoma
No (No)
Not Done (Not done)
Unknown (Unknown)
Yes (Yes)
Size of Largest Amyloidoma (If yes, cm)
Site of Amyloidoma
Amyloid: Objective Response Assessment
Cardiac/Heart Response
Not Assessed (Not assessed)
Progressed (Progressed)
Response (Response)
Stable (Stable)
Hepatic/Liver Response
Not Assessed (Not assessed)
Progressed (Progressed)
Response (Response)
Stable (Stable)
Renal/Kidney Response (See UPEP)
Not Assessed (Not assessed)
Progressed (Progressed)
Response (Response)
Stable (Stable)
Gastrointestinal Tract Response
Not Assessed (Not assessed)
Progressed (Progressed)
Response (Response)
Stable (Stable)
Autonomic Neuropathy Response
Not Assessed (Not assessed)
Progressed (Progressed)
Response (Response)
Stable (Stable)
Peripheral Neuropathy Response
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Soft Tissue Response (tongue, muscle,
amyloidoma)
Not Assessed (Not assessed)
Progressed (Progressed)
Response (Response)
Stable (Stable)
Date of First Organ Response (If any response,)
Hematologic Response
Not Assessed (Not assessed)
Progressed (Progressed)
Response (Response)
Stable (Stable)
Date of First Hematologic Response (If any
response,)
Objective Status at This Evaluation
Major Response (Major Response)
Minor Response (Minor Response)
No Response/stable Disease (No
response/Stable Disease)
Progressive Disease (Progressive
Disease)
Unevaluable (Unevaluable)
Comments
Comments
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Fallopian Tube Cancer NCT00951496 Registration - Gynecologic
Oncology Group Registration Form (Form R) - 2758755v1.0
Gynecologic Oncology Group Registration Form (Form R)
Bevacizumab and Intravenous or Intraperitoneal
Chemotherapy in Treating Patients With Stage II, Stage III,
or Stage IV Ovarian Epithelial Cancer, Fallopian Tube
Cancer, or Primary Peritoneal Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=4F54A394-
F161-2250-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/8731
Gynecologic Oncology Group
Registration Form (Form R)
Header Module
Date form originally completed (m d y)
Date form amended (m d y)
Person amending form, last name
Patient Name, Last
Patient Name, First
Patient Study ID
Person Completing Form, Last Name
Tracking Information
Institution name (affiliate)
Treating physician
Patient medical record number
Patient's date of birth (m d y)
Patient Social Security Number
Patient Zip Code
Country of residence (if not USA)
Demographic Information
Patient race (mark all that apply)
1 / 3
A Person Having Origins In Any Of The
Original Peoples Of North And South
America (including Central America),
And Who Maintains Tribal Affiliation Or
Community Attachment. (American
Indian or Alaska Native)
A Person Having Origins In Any Of The
Original Peoples Of The Far East,
Southeast Asia, Or The Indian
Subcontinent Including, For Example,
Cambodia, China, India, Japan, Korea,
Malaysia, Pakistan, The Philippine
Islands, Thailand, And Vietnam. (Asian)
A Person Having Origins In Any Of The
Black Racial Groups Of Africa. Terms
Such As "haitian" Or "negro" Can Be
Used In Addition To "black Or African
American." (Black or African American)
A Person Having Origins In Any Of The
Original Peoples Of Hawaii, Guam,
Samoa, Or Other Pacific Islands. (Native
Hawaiian or other Pacific Islander)
Could Not Be Determined Or Unsure
(Unknown)
A Person Having Origins In Any Of The
Original Peoples Of Europe, The Middle
East, Or North Africa. (White)
Patient Ethnicity
A Person Of Mexican, Puerto Rican,
Cuban, Central Or South American Or
Other Spanish Culture Or Origin,
Regardless Of Race. (Hispanic or Latino)
A Person Not Meeting The Definition For
Hispanic Or Latino. (Not Hispanic or
Latino)
Could Not Be Determined Or Unsure
(Unknown)
Method of payment
Medicaid (Medicaid)
Medicaid And Medicare (Medicaid &
Medicare)
Medicare (Medicare)
Medicare And Private Insurance
(Medicare & Private Insurance)
Military Or Veterans Sponsored Nos
(Military or Veterans Sponsored NOS)
Military Sponsored (including Champus
& Tricare) (Military Sponsored (including
Champus & Tricare))
No Means Of Payment (no Insurance)
(No means of payment (no insurance))
Other (Other)
Private Insurance (Private Insurance)
Self Pay (no Insurance) (Self pay (no
insurance))
Unknown (Unknown)
Veterans Sponsored (Veterans
Sponsored)
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Patient Height
Patient weight (kg)
Performance status (Zubrod)
Fully Active, Able To Carry On All Pre-
disease Performance Without
Restriction. (0)
Restricted In Physically Strenuous
Activity But Ambulatory And Able To
Carry Out Work Of A Light Or Sedentary
Nature, E.g., Light Housework, Office
Work. (1)
Ambulatory And Capable Of All Selfcare
But Unable To Carry Out Any Work
Activities. Up And About More Than 50%
Of Waking Hours. (2)
Capable Of Only Limited Selfcare,
Confined To Bed Or Chair More Than
50% Of Waking Hours. (3)
Completely Disabled. Cannot Carry On
Any Selfcare. Totally Confined To Bed Or
Chair. (4)
Has the patient had any prior cancer diagnosed?
Yes
No
Prior cancer type
Prior cancer diagnosis date (m d y)
Comments
Brief clinical history
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Head and Neck Cancer NCT01084083 Eligibility -
Registration Worsksheet for E1308 (Step 0) - 2922435v1.0
Registration Worsksheet for E1308 (Step 0)
Paclitaxel, Cisplatin, and Cetuximab Followed By
Cetuximab and Intensity-Modulated Radiation Therapy in
Treating Patients With HPV-Associated Stage III or Stage
IV Cancer of the Oropharynx That Can Be Removed By
Surgery
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=6F7AB198-
2739-A0A1-E040-BB89AD43458F
All rights reserved. Please visit https://medical-data-
models.org/forms/8732
Registration Worsksheet for E1308
(Step 0)
Eligibility
First initial
Last initial
Has the eligibility checklist been completed
Yes
No
In the opinion of the investigator, is the patient
eligible?
Yes
No
Has written informed consent been obtained
Yes
No
Date Informed Consent Signed
Has HIPAA authorization been obtained
Exempt - Non-usa Participant (Exempt -
non-USA participant)
No: C49487 (No)
Yes: C49488 (Yes)
HIPAA Authorization Date (Note:  Mandatory
Submission of representative pathological
materials for central HPV assessments is
required following pre-registration - step 0.
Specimens submissions for the optional studies
should be submitted from eligible patients after
registration to treatment - step 1.)
I agree to participate in the laboratory research
studies that are being done as part of this clinical
trial.
Yes
No
I agree my tissue will be submitted for research.
Yes
No
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My specimens may be kept for use in research to
learn about, prevent, treat, or cure cancer.
Yes
No
My specimens may be kept for use in research
about other health problems (for example: causes
of heart disease, osteoporosis, diabetes)
Yes
No
Someone from this institution may contact me in
the future to ask me to take part in more
research.
Yes
No
Name of the contact person responsible for
sample submission
Phone number of the contact person responsible
for sample submission
Fax number of the contact person responsible for
sample submission
E-mail address of the contact person responsible
for sample submission
Patient Demographics / Pre-treatment
Characteristics
Patient's Sex
Female (F)
Male (M)
Birthdate (mm/yy)
Patient Race (check all that applyU.S. and
Canada only)
A Person Having Origins In Any Of The
Original Peoples Of North And South
America (including Central America),
And Who Maintains Tribal Affiliation Or
Community Attachment. (American
Indian or Alaska Native)
A Person Having Origins In Any Of The
Original Peoples Of The Far East,
Southeast Asia, Or The Indian
Subcontinent Including, For Example,
Cambodia, China, India, Japan, Korea,
Malaysia, Pakistan, The Philippine
Islands, Thailand, And Vietnam. (Asian)
A Person Having Origins In Any Of The
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Black Racial Groups Of Africa. Terms
Such As "haitian" Or "negro" Can Be
Used In Addition To "black Or African
American." (Black or African American)
A Person Having Origins In Any Of The
Original Peoples Of Hawaii, Guam,
Samoa, Or Other Pacific Islands. (Native
Hawaiian or other Pacific Islander)
Not Provided Or Available (Not
Reported)
Could Not Be Determined Or Unsure
(Unknown)
A Person Having Origins In Any Of The
Original Peoples Of Europe, The Middle
East, Or North Africa. (White)
ZIP Code
Patient Ethnicity
A Person Of Mexican, Puerto Rican,
Cuban, Central Or South American Or
Other Spanish Culture Or Origin,
Regardless Of Race. (Hispanic or Latino)
A Person Not Meeting The Definition For
Hispanic Or Latino. (Not Hispanic or
Latino)
Not Provided Or Available (Not reported)
Could Not Be Determined Or Unsure
(Unknown)
Patient Hospital No.
Patient Social Security Number
Method of payment (check one)
Medicaid (Medicaid)
Medicaid And Medicare (Medicaid and
Medicare)
Medicare (Medicare)
Medicare And Private Insurance
(Medicare and Private Insurance)
Military Or Veterans Sponsored Nos
(Military or Veterans Sponsored, Not
Otherwise Specified (NOS))
Military Sponsored (including Champus
& Tricare) (Military Sponsored (including
CHAMPUS & TRICARE))
National Health Service (National Health
Service)
No Means Of Payment (no Insurance)
(No means of payment (no insurance))
Other (Other)
Private Insurance (Private Insurance)
Self Pay (no Insurance) (Self Pay (No
Insurance))
Unknown (Unknown)
Veterans Sponsored (Veterans
Sponsored)
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Attending Physician
Institution contact
Registrar
Country of Residence
Comments
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Infection NCT00513526 Demographic - AMC-
052 Demographic Form (DEM) - 2676987v1.0
AMC-052 Demographic Form (DEM)
Human Papillomavirus Vaccine Therapy in Treating Men
With HIV-1 Infection
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=395422A0-
6091-42B3-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/8733
AMC-052 Demographic Form (DEM)
Header
Patient Initials (First, Last)
Patient's Date of Birth (mm/dd/yyyy)
Gender
Female (FEMALE)
Male (MALE)
Ethnicity
A Person Of Mexican, Puerto Rican,
Cuban, Central Or South American Or
Other Spanish Culture Or Origin,
Regardless Of Race. (Hispanic or Latino)
A Person Not Meeting The Definition For
Hispanic Or Latino. (Not Hispanic or
Latino)
Could Not Be Determined Or Unsure
(Unknown)
Race (check all that apply)
A Person Having Origins In Any Of The
Original Peoples Of North And South
America (including Central America),
And Who Maintains Tribal Affiliation Or
Community Attachment. (American
Indian or Alaska Native)
A Person Having Origins In Any Of The
Original Peoples Of The Far East,
Southeast Asia, Or The Indian
Subcontinent Including, For Example,
Cambodia, China, India, Japan, Korea,
Malaysia, Pakistan, The Philippine
Islands, Thailand, And Vietnam. (Asian)
A Person Having Origins In Any Of The
Black Racial Groups Of Africa. Terms
Such As "haitian" Or "negro" Can Be
Used In Addition To "black Or African
American." (Black or African American)
A Person Having Origins In Any Of The
Original Peoples Of Hawaii, Guam,
Samoa, Or Other Pacific Islands. (Native
Hawaiian or other Pacific Islander)
Could Not Be Determined Or Unsure
(Unknown)
A Person Having Origins In Any Of The
Original Peoples Of Europe, The Middle
East, Or North Africa. (White)
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Patient Zip Code (xxxxx)
Method of Payment
Medicaid (Medicaid)
Medicaid And Medicare (Medicaid and
Medicare)
Medicare (Medicare)
Medicare And Private Insurance
(Medicare and Private Insurance)
Military Or Veterans Sponsored Nos
(Military or Veterans Sponsored, Not
Otherwise Specified (NOS))
Military Sponsored (including Champus
& Tricare) (Military Sponsored (including
CHAMPUS & TRICARE))
No Means Of Payment (no Insurance)
(No means of payment (no insurance))
Other (Other)
Private Insurance (Private Insurance)
Self Pay (no Insurance) (Self Pay (No
Insurance))
Unknown (Unknown)
Veterans Sponsored (Veterans
Sponsored)
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Head and Neck Cancer NCT01084083 Eligibility -
Registration Worksheet for E1308 (Step 1) - 2924700v1.0
Registration Worksheet for E1308 (Step 1)
Paclitaxel, Cisplatin, and Cetuximab Followed By
Cetuximab and Intensity-Modulated Radiation Therapy in
Treating Patients With HPV-Associated Stage III or Stage
IV Cancer of the Oropharynx That Can Be Removed By
Surgery
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=6FCB8806-
CC72-7795-E040-BB89AD43466D
All rights reserved. Please visit https://medical-data-
models.org/forms/8734
Registration Worksheet for E1308
(Step 1)
Eligibility
First initial
Last initial
Has the HPV status been determined by central
review
Yes
No
Has the eligibility checklist been completed
Yes
No
In the opinion of the investigator, is the patient
eligible?
Yes
No
Patient's ECOG sequence number
QOL contact person
Phone
Email address
If an ECOG patient is to receive radiation therapy,
will it be given at the registering institution
No (No)
Not Applicable - Not An Ecog Patient
(Not applicable - not an ECOG patient)
Yes (Yes)
Name of the institution that will administered the
radiation therapy
Patient Demographics / Pre-treatment
Characteristics
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Patient's Sex
Female (F)
Male (M)
Birthdate (mm/yy)
Patient's Race
A Person Having Origins In Any Of The
Original Peoples Of North And South
America (including Central America),
And Who Maintains Tribal Affiliation Or
Community Attachment. (American
Indian or Alaska Native)
A Person Having Origins In Any Of The
Original Peoples Of The Far East,
Southeast Asia, Or The Indian
Subcontinent Including, For Example,
Cambodia, China, India, Japan, Korea,
Malaysia, Pakistan, The Philippine
Islands, Thailand, And Vietnam. (Asian)
A Person Having Origins In Any Of The
Black Racial Groups Of Africa. Terms
Such As "haitian" Or "negro" Can Be
Used In Addition To "black Or African
American." (Black or African American)
A Person Having Origins In Any Of The
Original Peoples Of Hawaii, Guam,
Samoa, Or Other Pacific Islands. (Native
Hawaiian or other Pacific Islander)
Not Provided Or Available (Not
Reported)
Could Not Be Determined Or Unsure
(Unknown)
A Person Having Origins In Any Of The
Original Peoples Of Europe, The Middle
East, Or North Africa. (White)
ZIP Code
Patient Hospital No.
Patient Social Security Number
Method of payment (check one)
Medicaid (Medicaid)
Medicaid And Medicare (Medicaid and
Medicare)
Medicare (Medicare)
Medicare And Private Insurance
(Medicare and Private Insurance)
Military Or Veterans Sponsored Nos
(Military or Veterans Sponsored, Not
Otherwise Specified (NOS))
Military Sponsored (including Champus
& Tricare) (Military Sponsored (including
CHAMPUS & TRICARE))
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No Means Of Payment (no Insurance)
(No means of payment (no insurance))
Other (Other)
Private Insurance (Private Insurance)
Self Pay (no Insurance) (Self Pay (No
Insurance))
Unknown (Unknown)
Veterans Sponsored (Veterans
Sponsored)
Attending Physician
Institution contact
Registrar
Country of residence
Ascension Island (AC)
Andorra (AD)
United Arab Emirates (AE)
Afghanistan (AF)
Antigua And Barbuda (AG)
Anguilla (AI)
Albania (AL)
Armenia (AM)
Netherland Antilles (AN)
Angola (AO)
Antarctica (AQ)
Argentina (AR)
American Samoa (AS)
Austria (AT)
Australia (AU)
Aruba (AW)
Azerbaidjan (AZ)
Bosnia-herzegovina (BA)
Barbados (BB)
Bangladesh (BD)
Belgium (BE)
Burkina Faso (BF)
Bulgaria (BG)
Bahrain (BH)
Burundi (BI)
Benin (BJ)
Bermuda (BM)
Brunei Darussalam (BN)
Bolivia (BO)
Brazil (BR)
Bahamas (BS)
Bhutan (BT)
Bouvet Island (BV)
Botswana (BW)
Belarus (BY)
Belize (BZ)
Canada (CA)
Cocos Isl. (CC)
Rep. Dem. Congo (CD)
Central African Rep. (CF)
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Congo (CG)
Switzerland (CH)
Ivory Coast (CI)
Cook Islands (CK)
Chile (CL)
Cameroon (CM)
China (CN)
Colombia (CO)
Costa Rica (CR)
Cuba (CU)
Cape Verde (CV)
Christmas Island (CX)
Cyprus (CY)
Czech Republic (CZ)
Germany (DE)
Djibouti (DJ)
Denmark (DK)
Dominica (DM)
Dominican Republic (DO)
Algeria (DZ)
Ecuador (EC)
Estonia (EE)
Egypt (EG)
Western Sahara (EH)
Eritrea (ER)
Spain (ES)
Ethiopia (ET)
Finland (FI)
Fiji (FJ)
Falkland Isl. (FK)
Micronesia (FM)
Faroe Islands (FO)
France (FR)
France (european Ter.) (FX)
Gabon (GA)
Great Britain (GB)
Grenada (GD)
Georgia (GE)
Guiana (fr.) (GF)
Guernsey (GG)
Ghana (GH)
Gibraltar (GI)
Greenland (GL)
Gambia (GM)
Guinea (GN)
Guadeloupe (fr.) (GP)
Equatorial Guinea (GQ)
Greece (GR)
South Georgia And South Sandwich
Islands (GS)
Guatemala (GT)
Guam (us) (GU)
Guinea Bissau (GW)
Guyana (GY)
Hong Kong (HK)
Heard & Mcdonald Isl. (HM)
Honduras (HN)
Croatia (HR)
Haiti (HT)
Hungary (HU)
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Indonesia (ID)
Ireland (IE)
Israel (IL)
Isle Of Man (IM)
India (IN)
British Indian O. Ter. (IO)
Iraq (IQ)
Iran (IR)
Iceland (IS)
Italy (IT)
Jersey (JE)
Jamaica (JM)
Jordan (JO)
Japan (JP)
Kenya (KE)
Kyrgyz Republic (KG)
Cambodia (KH)
Kiribati (KI)
Comoros (KM)
St. Kitts Nevis Anguilla (KN)
Korea (north) (KP)
Korea (south) (KR)
Kuwait (KW)
Cayman Islands (KY)
Kazakstan (KZ)
Laos (LA)
Lebanon (LB)
Saint Lucia (LC)
Liechtenstein (LI)
Sri Lanka (LK)
Liberia (LR)
Lesotho (LS)
Lithuania (LT)
Luxembourg (LU)
Latvia (LV)
Libya (LY)
Morocco (MA)
Monaco (MC)
Moldova (MD)
Madagascar (MG)
Marshall Islands (MH)
Macedonia (MK)
Mali (ML)
Myanmar (MM)
Mongolia (MN)
Macau (MO)
Northern Mariana Isl. (MP)
Martinique (fr.) (MQ)
Mauritania (MR)
Montserrat (MS)
Malta (MT)
Mauritius (MU)
Maldives (MV)
Malawi (MW)
Mexico (MX)
Malaysia (MY)
Mozambique (MZ)
Namibia (NA)
New Caledonia (fr.) (NC)
Niger (NE)
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Norfolk Island (NF)
Nigeria (NG)
Nicaragua (NI)
Netherlands (NL)
Norway (NO)
Nepal (NP)
Nauru (NR)
Niue (NU)
New Zealand (NZ)
Oman (OM)
Other (Other)
Panama (PA)
Peru (PE)
Polynesia (fr.) (PF)
Papua New Guinea (PG)
Philippines (PH)
Pakistan (PK)
Poland (PL)
St. Pierre & Miquelon (PM)
Pitcairn (PN)
Puerto Rico (PR)
Portugal (PT)
Palau (PW)
Paraguay (PY)
Qatar (QA)
Reunion (fr.) (RE)
Romania (RO)
Russian Federation (RU)
Rwanda (RW)
Saudi Arabia (SA)
Solomon Islands (SB)
Seychelles (SC)
Sudan (SD)
Sweden (SE)
Singapore (SG)
St. Helena (SH)
Slovenia (SI)
Svalbard & Jan Mayen Isl. (SJ)
Slovakia (SK)
Sierra Leone (SL)
San Marino (SM)
Senegal (SN)
Somalia (SO)
Suriname (SR)
St. Tome And Principe (ST)
Soviet Union (SU)
El Salvador (SV)
Syria (SY)
Swaziland (SZ)
Turks & Caicos Islands (TC)
Chad (TD)
French Southern Terr. (TF)
Togo (TG)
Thailand (TH)
Tadjikistan (TJ)
Tokelau (TK)
Turkmenistan (TM)
Tunisia (TN)
Tonga (TO)
East Timor (TP)
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Turkey (TR)
Trinidad & Tobago (TT)
Tuvalu (TV)
Taiwan (TW)
Tanzania (TZ)
Ukraine (UA)
Uganda (UG)
United Kingdom (UK)
Us Minor Outlying Isl. (UM)
Usa (US)
Uruguay (UY)
Uzbekistan (UZ)
Vatican City State (VA)
St. Vincent & Grenadines (VC)
Venezuela (VE)
Virgin Islands (brit) (VG)
Virgin Islands (us) (VI)
Vietnam (VN)
Vanuatu (VU)
Wallis & Futuna Islands (WF)
Western Samoa (WS)
Yemen (YE)
Mayotte (YT)
Yugoslavia (YU)
South Africa (ZA)
Zambia (ZM)
Dem. Rep. Of Congo (ZR)
Zimbabwe (ZW)
Comments
Footer
Signature of treating physician (I have reviewed
the above data and agree the data are accurate
and correct.)
Date (Note:  Date must be on or before date of
registration)
Footer
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Response - Waldenstroms Macroglobulinemia -
Follow-Up Disease Assessment Form - 2276095v3.0
Waldenstrom's Macroglobulinemia - Follow-Up Disease
Assessment Form
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=D6E2F0A5-
966B-5DD3-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/8735
Waldenstroms Macroglobulinemia -
Follow-Up Disease Assessment
Form
Crf Header
Coordinating Group Protocol No.
Coordinating Group Code
Protocol Title
Patient Study ID
Institution/Affiliate
Other Patient ID
Participating Group Code
Patient Name (initials acceptable)
Waldenstrom's: Form Administration
Person Completing Form
Are data amended (If data are amended, please
circle in red when using paper form)
Yes
No
Waldenstrom's: Assessment Reporting
Interval
Reporting Period Start Date
Reporting Period End Date
Waldenstrom's: Peripheral Blood
Hematology/chemistry
1 / 6
Date Hematology (Blood) Sample Obtained
Peripheral WBC Count (x 10^3/mcl)
Hemoglobin (g/dl)
Peripheral Platelet Count (x 10^3/mcl)
Absolute Lymphocyte Count
Creatinine (mg/dl age-adjusted)
Total Bilirubin (mg/dl or mcmol/L)
Albumin (serum, g/dl, mg/dl or g/L)
Lactate Dehydrogenase (LDH) (U/l)
Lactate Dehydrogenase ULN (LDH U/l * Note:
Record institutional upper limit of normal)
Beta-2 Microglobulin (mcg/ml)
Beta-2 Microglobulin ULN (mcg/ml * Note:
Record institutional upper limit of normal)
Serum Viscosity relative to Water (centipoise)
Waldenstrom's: Protein Studies
Serum Total Protein (SPEP)
Serum M-Protein Spike (SPEP If immunofixation
is positive but M-spike is not quantifiable, enter
.01 or follow protocol guidelines for entering M-
spike.)
Serum M-Protein by Immunofixation
Equivocal (Equivocal)
Negative (Negative)
Not Done (Not done)
Positive (Positive)
Unknown (Unknown)
Serum Heavy Chain (If positive or equivocal,)
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Assessment Form - 2276095v3.0
M (M)
Unknown (Unknown)
Serum Light Chain (check all that apply)
Kappa (Kappa)
Lambda (Lambda)
Unknown (Unknown)
Biclonal
Yes
No
Yes specify
Oligoclonal
Yes
No
Yes specify
IgM
Urine Total Protein (UPEP)
Urine M-Protein Light Chain Excretion (If
immunofixation is positive but M-protein is not
quantifiable, enter .01 or follow protocol
guidelines for entering M-protein.)
Unit of Measure
Grams/24 Hours (g/24 hrs)
Milligrams/24 Hours (mg/24 hrs)
Unit of Measure
Grams/24 Hours (g/24 hrs)
Milligrams/24 Hours (mg/24 hrs)
Unit of Measure
Grams/24 Hours (g/24 hrs)
Milligrams/24 Hours (mg/24 hrs)
Urine M-Protein by Immunofixation
Equivocal (Equivocal)
Negative (Negative)
Positive (Positive)
Unknown (Unknown)
Urine Light Chain (If positive or equivocal,)
Kappa (Kappa)
Lambda (Lambda)
Unknown (Unknown)
Waldenstrom's: Bone Marrow Assessment
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Assessment Form - 2276095v3.0
Is there bone marrow involvement
No (No)
Unknown (Unknown)
Yes (Yes)
Was bone marrow biopsy done (If yes,)
Inadequate Sample (Inadequate sample)
No (No)
Unknown (Unknown)
Yes (Yes)
Bone Marrow Biopsy Result (If yes,)
Equivocal (Equivocal)
Involved (Involved)
Not Involved (Not Involved)
Was bone marrow aspirate done
Inadequate Sample (Inadequate sample)
No (No)
Unknown (Unknown)
Yes (Yes)
Bone Marrow Aspirate Result (If yes,)
Equivocal (Equivocal)
Involved (Involved)
Not Involved (Not Involved)
Marrow Lymphocytes (%)
Marrow Plasma Cells (%)
Marrow Lymphoplasmacytes (%)
Method of Evaluation
Clinical Examination (pe) (Clinical
examination)
Ct Scan (CT Scan)
Gallium Scan (Gallium scan)
Mri (MRI (NMR))
Other (Other)
Pet Scan (PET scan)
Spiral Ct Scan (Spiral CT Scan)
Ultrasound (Ultrasound)
Waldenstrom's: Liver, Spleen, And Node
Assessment
Is there hepatomegaly
No (No)
Not Examined (Not examined)
Unknown (Unknown)
Yes (Yes)
Liver Measurement (If yes, cm)
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Liver Measurement Method
From Costal Margin (from costal margin)
From Total Span (from total span)
Date of Liver Evaluation
Is the spleen enlarged
No (No)
Not Examined (Not examined)
Surgically Absent (Surgically absent)
Unknown (Unknown)
Yes (Yes)
Method of Evaluation
Clinical Examination (pe) (Clinical
examination)
Ct Scan (CT Scan)
Gallium Scan (Gallium scan)
Mri (MRI (NMR))
Other (Other)
Pet Scan (PET scan)
Spiral Ct Scan (Spiral CT Scan)
Ultrasound (Ultrasound)
Spleen Measurement (If yes, cm)
Method of Evaluation
Clinical Examination (pe) (Clinical
examination)
Ct Scan (CT Scan)
Gallium Scan (Gallium scan)
Mri (MRI (NMR))
Other (Other)
Pet Scan (PET scan)
Spiral Ct Scan (Spiral CT Scan)
Ultrasound (Ultrasound)
Other specify
Other specify
Date of Spleen Evaluation
Is there lymph node involvement
No (No)
Unknown (Unknown)
Yes (Yes)
Palpable Lymphadenopathy (If yes,)
Examination Performed And
Lymphadenopathy Absent (No)
Examination Of Lymph Nodes Not
Performed (Not examined)
Examination Performed And
Lymphadenopathy Present (Yes)
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Assessment Form - 2276095v3.0
Lymphadenopathy by scan or x-ray
Examination Performed And
Lymphadenopathy Absent (No)
Examination Of Lymph Nodes Not
Performed (Not examined)
Examination Performed And
Lymphadenopathy Present (Yes)
Sites of Lymphadenopathy (If yes,)
Axillary/brachial (Axillary/Brachial)
Celiac Axis/retrocrural (Celiac
axis/Retrocrural)
Cervical (Cervical)
Common Pelvic (Common pelvic)
Epitrochlear (Epitrochlear)
External/internal Iliac (External/internal
iliac)
Hilar (Hilar)
Infraclavicular (Infraclavicular)
Inguinal/femoral (Inguinal/Femoral)
Mediastinal (Mediastinal)
Mesenteric (Mesenteric)
Occipital (Occipital)
Orbital (Orbital)
Other (Other)
Para-aortic (Para-aortic)
Paratracheal (Paratracheal)
Pectoral (Pectoral)
Popliteal (Popliteal)
Porta Caval (Porta caval)
Porta Hepatis (Porta hepatis)
Pre-auricular (Pre-auricular)
Splenic Hilar (Splenic hilar)
Supraclavicular (Supraclavicular)
Waldeyer's Ring (Waldeyer's ring)
Other specify
Waldenstrom's: Objective Response
Assessment
Objective Status at This Evaluation
Complete Response (Complete
Response)
Minor Response (Minor Response)
Objective Response (Objective
Response)
Partial Response (Partial Response)
Progressive Disease (Progressive
Disease)
Stable Disease (Stable Disease)
Unevaluable (Unevaluable)
Comments
Comments
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Response - Waldenstroms Macroglobulinemia -
Baseline Disease Assessment Form - 2275870v3.0
Waldenstrom's Macroglobulinemia - Baseline Disease
Assessment Form
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=D6E2C90E-
8775-5BFC-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/8736
Waldenstroms Macroglobulinemia -
Baseline Disease Assessment Form
Crf Header
Coordinating Group Protocol No.
Coordinating Group Code
Protocol Title
Patient Study ID
Institution/Affiliate
Other Patient ID
Participating Group Code
Patient Name (initials acceptable)
Waldenstrom's: Form Administration
Person Completing Form
Are data amended (If data are amended, please
circle in red when using paper form)
Yes
No
Waldenstrom's: Assessment Reporting
Interval
Reporting Period Start Date
Reporting Period End Date
Waldenstrom's: Peripheral Blood
Hematology/chemistry
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Date Hematology (Blood) Sample Obtained
Peripheral WBC Count (x 10^3/mcl)
Hemoglobin (g/dl)
Peripheral Platelet Count (x 10^3/mcl)
Absolute Lymphocyte Count
Creatinine (mg/dl age-adjusted)
Total Bilirubin (mg/dl or mcmol/L)
Albumin (serum, g/dl, mg/dl or g/L)
Lactate Dehydrogenase (LDH) (U/l)
Lactate Dehydrogenase ULN (LDH U/l * Note:
Record institutional upper limit of normal)
Beta-2 Microglobulin (mcg/ml)
Beta-2 Microglobulin ULN (mcg/ml * Note:
Record institutional upper limit of normal)
Serum Viscosity relative to Water (centipoise)
Waldenstrom's: Protein Studies
Serum Total Protein (SPEP)
Serum M-Protein Spike (SPEP If immunofixation
is positive but M-spike is not quantifiable, enter
.01 or follow protocol guidelines for entering M-
spike.)
Serum M-Protein by Immunofixation
Equivocal (Equivocal)
Negative (Negative)
Not Done (Not done)
Positive (Positive)
Unknown (Unknown)
Serum Heavy Chain (If positive or equivocal,)
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M (M)
Unknown (Unknown)
Serum Light Chain (check all that apply)
Kappa (Kappa)
Lambda (Lambda)
Unknown (Unknown)
Biclonal
Yes
No
Yes specify
Oligoclonal
Yes
No
Yes specify
IgM
Urine Total Protein (UPEP)
Urine M-Protein Light Chain Excretion (If
immunofixation is positive but M-protein is not
quantifiable, enter .01 or follow protocol
guidelines for entering M-protein.)
Unit of Measure
Grams/24 Hours (g/24 hrs)
Milligrams/24 Hours (mg/24 hrs)
Unit of Measure
Grams/24 Hours (g/24 hrs)
Milligrams/24 Hours (mg/24 hrs)
Unit of Measure
Grams/24 Hours (g/24 hrs)
Milligrams/24 Hours (mg/24 hrs)
Urine M-Protein by Immunofixation
Equivocal (Equivocal)
Negative (Negative)
Positive (Positive)
Unknown (Unknown)
Urine Light Chain (If positive or equivocal,)
Kappa (Kappa)
Lambda (Lambda)
Unknown (Unknown)
Waldenstrom's: Bone Marrow Assessment
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Assessment Form - 2275870v3.0
Is there bone marrow involvement
No (No)
Unknown (Unknown)
Yes (Yes)
Was bone marrow biopsy done (If yes,)
Inadequate Sample (Inadequate sample)
No (No)
Unknown (Unknown)
Yes (Yes)
Bone Marrow Biopsy Result (If yes,)
Equivocal (Equivocal)
Involved (Involved)
Not Involved (Not Involved)
Was bone marrow aspirate done
Inadequate Sample (Inadequate sample)
No (No)
Unknown (Unknown)
Yes (Yes)
Bone Marrow Aspirate Result (If yes,)
Equivocal (Equivocal)
Involved (Involved)
Not Involved (Not Involved)
Marrow Lymphocytes (%)
Marrow Plasma Cells (%)
Marrow Lymphoplasmacytes (%)
Method of Evaluation
Clinical Examination (pe) (Clinical
examination)
Ct Scan (CT Scan)
Gallium Scan (Gallium scan)
Mri (MRI (NMR))
Other (Other)
Pet Scan (PET scan)
Spiral Ct Scan (Spiral CT Scan)
Ultrasound (Ultrasound)
Waldenstrom's: Liver, Spleen, And Node
Assessment
Is there hepatomegaly
No (No)
Not Examined (Not examined)
Unknown (Unknown)
Yes (Yes)
Liver Measurement (If yes, cm)
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Liver Measurement Method
From Costal Margin (from costal margin)
From Total Span (from total span)
Date of Liver Evaluation
Is the spleen enlarged
No (No)
Not Examined (Not examined)
Surgically Absent (Surgically absent)
Unknown (Unknown)
Yes (Yes)
Method of Evaluation
Clinical Examination (pe) (Clinical
examination)
Ct Scan (CT Scan)
Gallium Scan (Gallium scan)
Mri (MRI (NMR))
Other (Other)
Pet Scan (PET scan)
Spiral Ct Scan (Spiral CT Scan)
Ultrasound (Ultrasound)
Spleen Measurement (If yes, cm)
Method of Evaluation
Clinical Examination (pe) (Clinical
examination)
Ct Scan (CT Scan)
Gallium Scan (Gallium scan)
Mri (MRI (NMR))
Other (Other)
Pet Scan (PET scan)
Spiral Ct Scan (Spiral CT Scan)
Ultrasound (Ultrasound)
Other specify
Other specify
Date of Spleen Evaluation
Is there lymph node involvement
No (No)
Unknown (Unknown)
Yes (Yes)
Palpable Lymphadenopathy (If yes,)
Examination Performed And
Lymphadenopathy Absent (No)
Examination Of Lymph Nodes Not
Performed (Not examined)
Examination Performed And
Lymphadenopathy Present (Yes)
5 / 6
Response - Waldenstroms Macroglobulinemia - Baseline Disease
Assessment Form - 2275870v3.0
Lymphadenopathy by scan or x-ray
Examination Performed And
Lymphadenopathy Absent (No)
Examination Of Lymph Nodes Not
Performed (Not examined)
Examination Performed And
Lymphadenopathy Present (Yes)
Sites of Lymphadenopathy (If yes,)
Axillary/brachial (Axillary/Brachial)
Celiac Axis/retrocrural (Celiac
axis/Retrocrural)
Cervical (Cervical)
Common Pelvic (Common pelvic)
Epitrochlear (Epitrochlear)
External/internal Iliac (External/internal
iliac)
Hilar (Hilar)
Infraclavicular (Infraclavicular)
Inguinal/femoral (Inguinal/Femoral)
Mediastinal (Mediastinal)
Mesenteric (Mesenteric)
Occipital (Occipital)
Orbital (Orbital)
Other (Other)
Para-aortic (Para-aortic)
Paratracheal (Paratracheal)
Pectoral (Pectoral)
Popliteal (Popliteal)
Porta Caval (Porta caval)
Porta Hepatis (Porta hepatis)
Pre-auricular (Pre-auricular)
Splenic Hilar (Splenic hilar)
Supraclavicular (Supraclavicular)
Waldeyer's Ring (Waldeyer's ring)
Other specify
Comments
Comments
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Kidney Cancer NCT00326898 Eligibility - E2805
Registration Worksheet (step 2) - 2766277v1.0
E2805 Registration Worksheet (step 2)
Sunitinib or Sorafenib in Treating Patients With Kidney
Cancer That Was Removed By Surgery
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=51FE4236-
C92E-577B-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/8737
E2805 Registration Worksheet (step
2)
Eligibility
First initial
Last initial
Has the eligibility checklist been completed
Yes
No
In the opinion of the investigator, is the patient
eligible?
Yes
No
Pathologic stage
Intermediate High Risk Group
(Intermediate high risk group)
Very High Risk Group (Very high risk
group)
Histologic Subtype
Clear Cell (Clear cell)
Other (Other)
ECOG Performance Status
Fully Active, Able To Carry On All Pre-
disease Performance Without
Restriction. (0)
Restricted In Physically Strenuous
Activity But Ambulatory And Able To
Carry Out Work Of A Light Or Sedentary
Nature, E.g., Light Housework, Office
Work. (1)
Ambulatory And Capable Of All Selfcare
But Unable To Carry Out Any Work
Activities. Up And About More Than 50%
Of Waking Hours. (2)
Capable Of Only Limited Selfcare,
Confined To Bed Or Chair More Than
50% Of Waking Hours. (3)
Completely Disabled. Cannot Carry On
Any Selfcare. Totally Confined To Bed Or
Chair. (4)
Dead (5)
Type of nephrectomy
Laparoscopic (Laparoscopic)
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Open Nephrectomy (Open
Nephrectomy)
Do you wish to use an express carrier to ship the
drugs (at your expense)?
Yes
No
Name of express carrier
Airborne Express (Airborne Express)
Dhl (DHL)
Federal Express (Federal Express)
Other (Other)
Purolator (Purolator)
Ups (UPS)
Express account number
Patient's ECOG sequence number
QOL contact person
Did the consent form signed by the patient
contain the mandatory Quality of Life study
Yes
No
Phone
Email address
Patient Demographics / Pre-treatment
Characteristics
Patient's Sex
Female (F)
Male (M)
Birthdate (mm/yy)
Patient Race (check all that applyU.S. and
Canada only)
A Person Having Origins In Any Of The
Original Peoples Of North And South
America (including Central America),
And Who Maintains Tribal Affiliation Or
Community Attachment. (American
Indian or Alaska Native)
A Person Having Origins In Any Of The
Original Peoples Of The Far East,
Southeast Asia, Or The Indian
Subcontinent Including, For Example,
Cambodia, China, India, Japan, Korea,
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Malaysia, Pakistan, The Philippine
Islands, Thailand, And Vietnam. (Asian)
A Person Having Origins In Any Of The
Black Racial Groups Of Africa. Terms
Such As "haitian" Or "negro" Can Be
Used In Addition To "black Or African
American." (Black or African American)
A Person Having Origins In Any Of The
Original Peoples Of Hawaii, Guam,
Samoa, Or Other Pacific Islands. (Native
Hawaiian or other Pacific Islander)
Not Provided Or Available (Not
Reported)
Could Not Be Determined Or Unsure
(Unknown)
A Person Having Origins In Any Of The
Original Peoples Of Europe, The Middle
East, Or North Africa. (White)
ZIP Code
Patient Ethnicity
A Person Of Mexican, Puerto Rican,
Cuban, Central Or South American Or
Other Spanish Culture Or Origin,
Regardless Of Race. (Hispanic or Latino)
A Person Not Meeting The Definition For
Hispanic Or Latino. (Not Hispanic or
Latino)
Not Provided Or Available (Not reported)
Could Not Be Determined Or Unsure
(Unknown)
Patient Hospital No.
Patient Social Security Number
Method of payment (check one)
Medicaid (Medicaid)
Medicaid And Medicare (Medicaid and
Medicare)
Medicare (Medicare)
Medicare And Private Insurance
(Medicare and Private Insurance)
Military Or Veterans Sponsored Nos
(Military or Veterans Sponsored, Not
Otherwise Specified (NOS))
Military Sponsored (including Champus
& Tricare) (Military Sponsored (including
CHAMPUS & TRICARE))
National Health Service (National Health
Service)
No Means Of Payment (no Insurance)
(No means of payment (no insurance))
Other (Other)
Private Insurance (Private Insurance)
Self Pay (no Insurance) (Self Pay (No
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Insurance))
Unknown (Unknown)
Veterans Sponsored (Veterans
Sponsored)
Attending Physician
Institution contact
Registrar
Country of Residence
Comments
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Response - Multiple Myeloma - Baseline
Disease Assessment Form - 2274587v3.0
Multiple Myeloma - Baseline Disease Assessment Form
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=D6E3244C-
90DF-56DA-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/8739
Multiple Myeloma - Baseline Disease
Assessment Form
Crf Header
Coordinating Group Protocol No.
Coordinating Group Code
Protocol Title
Patient Study ID
Institution/Affiliate
Other Patient ID
Participating Group Code
Patient Name (initials acceptable)
Myeloma: Form Administration
Person Completing Form
Are data amended (If data are amended, please
circle in red when using paper form)
Yes
No
Myeloma: Assessment Reporting Interval
Reporting Period Start Date
Reporting Period End Date
Performance Status (check one)
Fully Active, Able To Carry On All Pre-
disease Performance Without
Restriction. (0)
Restricted In Physically Strenuous
Activity But Ambulatory And Able To
Carry Out Work Of A Light Or Sedentary
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Nature, E.g., Light Housework, Office
Work. (1)
Ambulatory And Capable Of All Selfcare
But Unable To Carry Out Any Work
Activities. Up And About More Than 50%
Of Waking Hours. (2)
Capable Of Only Limited Selfcare,
Confined To Bed Or Chair More Than
50% Of Waking Hours. (3)
Completely Disabled. Cannot Carry On
Any Selfcare. Totally Confined To Bed Or
Chair. (4)
Myeloma: Protein Studies
Serum Total Protein (SPEP)
Serum M-Protein Spike (SPEP If immunofixation
is positive but M-spike is not quantifiable, enter
.01 or follow protocol guidelines for entering M-
spike.)
Serum M-Protein by Immunofixation
Equivocal (Equivocal)
Negative (Negative)
Positive (Positive)
Unknown (Unknown)
Serum Heavy Chain (If positive or equivocal,
check all that apply)
A (A)
D (D)
E (E)
G (G)
M (M)
Unknown (Unknown)
Serum Light Chain (check all that apply)
Kappa (Kappa)
Lambda (Lambda)
Unknown (Unknown)
Biclonal
Yes
No
Yes specify
Oligoclonal
Yes
No
Yes specify
IgG
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Response - Multiple Myeloma - Baseline Disease Assessment Form -
2274587v3.0
IgA
IgM
IgD
IgE
Urine Total Protein (UPEP)
Urine M-Protein Light Chain Excretion (If
immunofixation is positive but M-protein is not
quantifiable, enter .01 or follow protocol
guidelines for entering M-protein.)
Unit of Measure
Grams/24 Hours (g/24 hrs)
Milligrams/24 Hours (mg/24 hrs)
Unit of Measure
Grams/24 Hours (g/24 hrs)
Milligrams/24 Hours (mg/24 hrs)
Unit of Measure
Grams/24 Hours (g/24 hrs)
Milligrams/24 Hours (mg/24 hrs)
Urine M-Protein by Immunofixation
Equivocal (Equivocal)
Negative (Negative)
Positive (Positive)
Unknown (Unknown)
Urine Light Chain (If positive or equivocal,)
Kappa (Kappa)
Lambda (Lambda)
Unknown (Unknown)
Myeloma: Peripheral Blood
Hematology/chemistry
Date Hematology (Blood) Sample Obtained
Peripheral WBC Count (x 10^3/mcl)
Hemoglobin (g/dl)
Absolute Plasma Cell Count (x 10^3/mcl ** For
plasma cell leukemia, absolute plasma cell count
>2000 x 10^3/mcl OR >20% of WBC)
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Plasma Cells in blood (% ** For plasma cell
leukemia, absolute plasma cell count >2000 x
10^3/mcl OR >20% of WBC)
Creatinine (mg/dl)
Calcium (Ca, mg/dl)
C-reactive Protein (mg/dl)
Peripheral Platelet Count (x 10^3/mcl)
Absolute Neutrophil Count (x 10^3/mcl)
Albumin (serum, g/dl, mg/dl or g/L)
Lactate Dehydrogenase (LDH) (U/l)
Lactate Dehydrogenase ULN (LDH U/l * Note:
Record institutional upper limit of normal)
Beta-2 Microglobulin (mcg/ml)
Beta-2 Microglobulin ULN (mcg/ml * Note:
Record institutional upper limit of normal)
Myeloma: Bone And Marrow Assessment
Was bone marrow biopsy done
Inadequate Sample (Inadequate sample)
No (No)
Unknown (Unknown)
Yes (Yes)
Plasma Cells on Biopsy (%) (If yes,)
Was bone marrow aspirate done
Inadequate Sample (Inadequate sample)
No (No)
Unknown (Unknown)
Yes (Yes)
Plasma Cells on Aspirate in Interpretation (%) (If
yes,)
Plasma Cells on Differential (%)
Solitary bone plasmacytoma only
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No (No)
Unknown (Unknown)
Yes (Yes)
Osteopenia
No (No)
Unknown (Unknown)
Yes (Yes)
Number of bones with lytic lesions present
1-3 Bones (1-3 bones)
More Than 3 Bones (More than 3 bones)
None (None)
Unknown (Unknown)
Number of lytic lesions >2 cm in diameter
1-3 Lesions (1-3 lesions)
More Than 3 Lesions (More than 3
lesions)
None (None)
Unknown (Unknown)
Is severe osteoporosis present (If 3 or more
bones or lesions,)
No (No)
Unknown (Unknown)
Yes (Yes)
Was bone assessment done (by imaging or scan)
No (No)
Unknown (Unknown)
Yes (Yes)
Bone Assessment Method (If yes, check all that
apply)
Bone Scan (Bone Scan)
Ct Scan (CT scan)
Mri (nmr) (MRI (NMR))
Pet Scan (PET Scan)
Skeletal Survey (Skeletal survey)
Bone Assessment Result
Abnormal (Abnormal)
Equivocal (Equivocal)
Normal (Normal)
Myeloma: Soft Tissue Plasmacytoma
Soft Tissue Plasmacytoma
No (No)
Not Done (Not done)
Unknown (Unknown)
Yes (Yes)
Number of Plasmacytomas (If yes,)
Method of Evaluation
Biopsy (Biopsy)
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Clinical Examination (pe) (Clinical
examination)
Ct Scan (CT Scan)
Mri (MRI (NMR))
Other (Other)
Other specify
Are plasmacytomas measurable
Yes
No
Site of Largest Plasmacytoma (If yes, or
Indicator)
Greatest measurement (Size of Largest or
Indicator Plasmacytoma diameter cm x)
Greatest perpendicular measurement (cm)
Comments
Comments
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Treatment - Brain Cancer - Treatment by
Cycle Form - 2287531v3.0
Brain Cancer - Treatment by Cycle Form
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=E51F0AB1-
37FF-4133-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/8740
Brain Cancer - Treatment by Cycle
Form
Crf Header
Coordinating Group Protocol No.
Coordinating Group Code
Protocol Title
Patient Study ID
Institution/Affiliate
Other Patient ID
Participating Group Code
Patient Name (initials acceptable)
Brain: Treatment Reporting Interval
Reporting Period Start Date (MM DD YYYY)
Reporting Period End Date (MM DD YYYY)
Brain: Treatment Cycle Information -
Clinical Evaluation Follow-up
Performance Status (check one)
Fully Active, Able To Carry On All Pre-
disease Performance Without
Restriction. (0)
Restricted In Physically Strenuous
Activity But Ambulatory And Able To
Carry Out Work Of A Light Or Sedentary
Nature, E.g., Light Housework, Office
Work. (1)
Ambulatory And Capable Of All Selfcare
But Unable To Carry Out Any Work
Activities. Up And About More Than 50%
Of Waking Hours. (2)
Capable Of Only Limited Selfcare,
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Confined To Bed Or Chair More Than
50% Of Waking Hours. (3)
Completely Disabled. Cannot Carry On
Any Selfcare. Totally Confined To Bed Or
Chair. (4)
Dead (5)
Patient Height (cm)
Patient Weight (kg)
Body Surface Area (m^2)
Brain: Treatment Cycle Information -
Systemic Therapy
Cycle Start Date (MM DD YYYY)
Cycle End Date (MM DD YYYY)
Current Cycle Number
Agent Name (s)
Total Protocol Dose of Agents/Drugs for this
Cycle
Total Dose of Agents/Drugs for this Cycle
Total Actual Dose of Agents/Drugs for this Cycle
Agent Dose Units
Agent Dose Units
Agent Dose Units
Were there any dose modifications or
additions/omissions to protocol treatment? (check
one)
No (No)
Unknown (Unknown)
Yes, Planned (i.e., The Treatment Was
Changed According To Protocol
Guidelines) (Yes, planned)
Yes, Unplanned (i.e., The Treatment
Change Was Not Part Of Protocol
Guidelines) (Yes, unplanned)
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Name of Therapy (If yes,)
Reason for Therapy Modification
Brain: Treatment Cycle Information -
Concomitant Therapy
Treatment Start Date (MM DD YYYY)
Treatment End Date (MM/DD/YYYY)
Agent Dose
Agent Name (s)
Agent Dose Units
Brain: Treatment Schedule - Non-protocol
Therapy
Was any non-protocol therapy given during
protocol treatment?
Yes
No
Non-Protocol Chemotherapy
Yes
No
Yes specify
Non-Protocol Hormonal Therapy?
Yes
No
Yes specify
Non-Protocol Immunotherapy?
Yes
No
Yes specify
Non-Protocol Radiation Therapy?
Yes
No
Yes specify
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Non-Protocol Surgery?
Yes
No
Yes specify
Non-Protocol Radiosurgery?
Yes
No
Yes specify
Other Non-Protocol Therapy
Yes
No
Name of Other Non-Protocol Therapy (If yes,)
Comments
Comments
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Kidney Cancer NCT00378703 Eligibility -
E2804 Registration Worsksheet - 2680170v1.0
E2804 Registration Worsksheet
Bevacizumab, Sorafenib, and Temsirolimus in Treating
Patients With Metastatic Kidney Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=39DE83BC-
8CC5-21F3-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/8745
E2804 Registration Worsksheet
Eligibility
First initial
Last initial
Has the eligibility checklist been completed
Yes
No
In the opinion of the investigator, is the patient
eligible?
Yes
No
Has written informed consent been obtained
Yes
No
Date Informed Consent Signed
Has HIPAA authorization been obtained
Exempt - Non-usa Participant (Exempt -
non-USA participant)
No: C49487 (No)
Yes: C49488 (Yes)
HIPAA Authorization Date
Prior Therapy Type
No Prior Cytokine Or Vaccine (No prior
cytokine or vaccine)
Prior Cytokine Or Vaccine (Prior cytokine
or vaccine)
Motzer risk status
Second Of The Following Risk Factors:
Low Karnofsky Performance Status, High
Corrected Serum Calcium Level, Low
Hemoglobin Level (High risk, 2 or more
risk factors)
One Of The Following Risk Factors: Low
Karnofsky Performance Status, High
Corrected Serum Calcium Level, Low
Hemoglobin Level (Intermediate risk, 1
risk factor)
None Of The Following Risk Factors:
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Low Karnofsky Performance Status, High
Corrected Serum Calcium Level, Low
Hemoglobin Level (Low risk, 0 risk
factors)
My specimens may be kept for use in research to
learn about, prevent, treat, or cure cancer.
Yes
No
I agree to participate in the protein and DNA
studies that are being done as part of this clinical
trial.
Yes
No
I agree to participate in the drug level studies that
are being done as part of this clinical trial.
No (No)
Site Not Participating (Site not
participating)
Yes (Yes)
My specimens may be kept for use in research
about other health problems (for example: causes
of diabetes, Alzheimer's disease, or heart
disease)
Yes
No
Someone from this institution may contact me in
the future to ask me to take part in more
research.
Yes
No
Patient Demographics / Pre-treatment
Characteristics
Patient's Sex
Female (F)
Male (M)
Birthdate (mm/yy)
Patient's Race
A Person Having Origins In Any Of The
Original Peoples Of North And South
America (including Central America),
And Who Maintains Tribal Affiliation Or
Community Attachment. (American
Indian or Alaska Native)
A Person Having Origins In Any Of The
Original Peoples Of The Far East,
Southeast Asia, Or The Indian
Subcontinent Including, For Example,
Cambodia, China, India, Japan, Korea,
Malaysia, Pakistan, The Philippine
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Islands, Thailand, And Vietnam. (Asian)
A Person Having Origins In Any Of The
Black Racial Groups Of Africa. Terms
Such As "haitian" Or "negro" Can Be
Used In Addition To "black Or African
American." (Black or African American)
A Person Having Origins In Any Of The
Original Peoples Of Hawaii, Guam,
Samoa, Or Other Pacific Islands. (Native
Hawaiian or other Pacific Islander)
Not Provided Or Available (Not
Reported)
Could Not Be Determined Or Unsure
(Unknown)
A Person Having Origins In Any Of The
Original Peoples Of Europe, The Middle
East, Or North Africa. (White)
ZIP Code
Patient Ethnicity
A Person Of Mexican, Puerto Rican,
Cuban, Central Or South American Or
Other Spanish Culture Or Origin,
Regardless Of Race. (Hispanic or Latino)
A Person Not Meeting The Definition For
Hispanic Or Latino. (Not Hispanic or
Latino)
Not Provided Or Available (Not reported)
Could Not Be Determined Or Unsure
(Unknown)
Patient Hospital No.
Patient Social Security Number
Method of payment (check one)
Medicaid (Medicaid)
Medicaid And Medicare (Medicaid and
Medicare)
Medicare (Medicare)
Medicare And Private Insurance
(Medicare and Private Insurance)
Military Or Veterans Sponsored Nos
(Military or Veterans Sponsored, Not
Otherwise Specified (NOS))
Military Sponsored (including Champus
& Tricare) (Military Sponsored (including
CHAMPUS & TRICARE))
National Health Service (National Health
Service)
No Means Of Payment (no Insurance)
(No means of payment (no insurance))
Other (Other)
Private Insurance (Private Insurance)
Self Pay (no Insurance) (Self Pay (No
Insurance))
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Unknown (Unknown)
Veterans Sponsored (Veterans
Sponsored)
Country of Residence
Comments
I Have Reviewed The Above Data And
Agree The Date Are Accurate And Correct
Signature of treating physician
Date
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Kidney Cancer NCT00326898 Eligibility - E2805
Registration Worksheet (step 1) - 2766140v1.0
E2805 Registration Worksheet (step 1)
Sunitinib or Sorafenib in Treating Patients With Kidney
Cancer That Was Removed By Surgery
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=51FCB83B-
9355-3F89-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/8748
E2805 Registration Worksheet (step
1)
Eligibility
First initial
Last initial
Has the eligibility checklist been completed
Yes
No
In the opinion of the investigator, is the patient
eligible?
Yes
No
Has written informed consent been obtained
Yes
No
Date Informed Consent Signed
Has HIPAA authorization been obtained
Exempt - Non-usa Participant (Exempt -
non-USA participant)
No: C49487 (No)
Yes: C49488 (Yes)
HIPAA Authorization Date
Is the patient being entered pre- or post-surgery
(Enter '1' if this is a Pre-surgery registration. -
Enter '2' if this is a Post-surgery registration.)
Will you register the patient to the next step today
Yes
No
I agree to participate in the laboratory research
studies that are being done as part of this clinical
trial.
Yes
No
Have you contacted Zemotak International to
request kits to collect and ship the samples
No, Kit Will Not Be Requested (No, kit
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will not be requested)
Not Yet (Not yet)
Yes (Yes)
I agree to participate in the protein and DNA
studies that are being done as part of this clinical
trial.
Yes
No
I agree to participate in the drug level studies that
are being done as part of this clinical trial.
No (No)
Site Not Participating (Site not
participating)
Yes (Yes)
My specimens may be kept for use in research to
learn about, prevent, treat, or cure cancer.
Yes
No
My specimens may be kept for research about
other health problems (for example: diabetes,
Alzheimer's disease, and heart disease)
Yes
No
Someone from this institution may contact me in
the future to ask me to take part in more
research.
Yes
No
Name of the contact person responsible for
sample submission
Phone number of the contact person responsible
for sample submission
E-mail address of the contact person responsible
for sample submission
Patient Demographics / Pre-treatment
Characteristics
Patient's Sex
Female (F)
Male (M)
Birthdate (mm/yy)
Patient Race (check all that applyU.S. and
Canada only)
A Person Having Origins In Any Of The
2 / 4
Kidney Cancer NCT00326898 Eligibility - E2805 Registration Worksheet
(step 1) - 2766140v1.0
Original Peoples Of North And South
America (including Central America),
And Who Maintains Tribal Affiliation Or
Community Attachment. (American
Indian or Alaska Native)
A Person Having Origins In Any Of The
Original Peoples Of The Far East,
Southeast Asia, Or The Indian
Subcontinent Including, For Example,
Cambodia, China, India, Japan, Korea,
Malaysia, Pakistan, The Philippine
Islands, Thailand, And Vietnam. (Asian)
A Person Having Origins In Any Of The
Black Racial Groups Of Africa. Terms
Such As "haitian" Or "negro" Can Be
Used In Addition To "black Or African
American." (Black or African American)
A Person Having Origins In Any Of The
Original Peoples Of Hawaii, Guam,
Samoa, Or Other Pacific Islands. (Native
Hawaiian or other Pacific Islander)
Not Provided Or Available (Not
Reported)
Could Not Be Determined Or Unsure
(Unknown)
A Person Having Origins In Any Of The
Original Peoples Of Europe, The Middle
East, Or North Africa. (White)
ZIP Code
Patient Ethnicity
A Person Of Mexican, Puerto Rican,
Cuban, Central Or South American Or
Other Spanish Culture Or Origin,
Regardless Of Race. (Hispanic or Latino)
A Person Not Meeting The Definition For
Hispanic Or Latino. (Not Hispanic or
Latino)
Not Provided Or Available (Not reported)
Could Not Be Determined Or Unsure
(Unknown)
Patient Hospital No.
Patient Social Security Number
Method of payment (check one)
Medicaid (Medicaid)
Medicaid And Medicare (Medicaid and
Medicare)
Medicare (Medicare)
Medicare And Private Insurance
(Medicare and Private Insurance)
Military Or Veterans Sponsored Nos
(Military or Veterans Sponsored, Not
Otherwise Specified (NOS))
Military Sponsored (including Champus
& Tricare) (Military Sponsored (including
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CHAMPUS & TRICARE))
National Health Service (National Health
Service)
No Means Of Payment (no Insurance)
(No means of payment (no insurance))
Other (Other)
Private Insurance (Private Insurance)
Self Pay (no Insurance) (Self Pay (No
Insurance))
Unknown (Unknown)
Veterans Sponsored (Veterans
Sponsored)
Attending Physician
Institution contact
Registrar
Country of Residence
Comments
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Prostate Cancer NCT00079001 Lab - CALGB 90202:
Prostate Specific Antigen Form - 2085594v3.0
CALGB 90202: Prostate Specific Antigen Form
Zoledronate in Preventing Skeletal (Bone)-Related Events
in Patients Who Are Receiving Androgen Deprivation
Therapy For Prostate Cancer and Bone Metastases
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=B7BE06E0-
D405-6E46-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/8749
CALGB 90202: Prostate Specific
Antigen Form
Ccrr Module For Calgb 90202: Prostate
Specific Antigen Form
CALGB Form
CALGB Study No.
CALGB Patient ID
Amended data?
Yes (Yes)
Patient's Name
Patient Hospital Number
Main Member Institution/Adjunct
Participating Group
Participating Group Protocol No.
Participating Group Patient No
Date Obtained
PSA
Status
Baseline Value (baseline value)
Follow-up, Off Treatment Value (follow-
up, off treatment value)
Pre-study Value (pre-study value)
Protocol Treatment Value (protocol
treatment value)
Completed by
Date completed
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CALGB: 90202 Prior Therapy Form - 2075871v3.0
CALGB: 90202 Prior Therapy Form
Zoledronate in Preventing Skeletal (Bone)-Related Events
in Patients Who Are Receiving Androgen Deprivation
Therapy For Prostate Cancer and Bone Metastases
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=B4605CF5-
A50B-0515-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/8752
CALGB: 90202 Prior Therapy Form
Ccrr Module For Calgb: 90202 Prior
Therapy Form
CALGB Form
CALGB Study No.
CALGB Patient ID
Are data amended?
Yes (Yes)
Patient?s Name
Patient Hospital Number
Main Member Institution/Adjunct
Participating Group
Participating Group Protocol No.
Participating Group Patient No.
No prior cancer treatment
Chemotherapy single agent systemic
Chemotherapy multi-agent systemic
Chemotherapy not otherwise specified
Number of regimens, chemotherapy not
otherwise specified
Number of regimens, chemotherapy not
otherwise specified
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Number of regimens, chemotherapy not
otherwise specified
Immunotherapy
Hormonal therapy
Surgery
Radiotherapy not otherwise specified
Radiotherapy not otherwise specified
Radiotherapy not otherwise specified
Bone marrow transplant
Other prior therapy
Comments
Completed by
Date completed
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Prostate Cancer NCT00567580 Follow-Up - RTOG
0534 FO: Interim Follow-up Form - 2600263v1.0
RTOG 0534 FO: Interim Follow-up Form
Prostate Radiation Therapy or Short-Term Androgen
Deprivation Therapy and Pelvic Lymph Node Radiation
Therapy With or Without Prostate Radiation Therapy in
Treating Patients With a Rising PSA After Surgery for
Prostate Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=2A1468A9-
C70B-1202-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/8753
RTOG 0534 FO: Interim Follow-up
Form
Unnamed2
RTOG Study No.
Case #
Institution Name
Institution No.
Patient Initials
RTOG Patient ID
Header
Amended Data
Yes
No
Unnamed 3
Patient's Vital Status
Alive (Alive)
Dead (Dead)
Date of Last Contact or Death
Primary Cause of Death
Due To Other Cause (Due to other
cause)
Due To Protocol Treatment (Due to
protocol treatment)
Due To This Disease (Due to this
disease)
Not Applicable (Not applicable)
Unknown (Unknown)
Due to other cause, specify
Has the patient had a documented clinical
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assessment for this cancer (SINCE
SUBMISSION OF THE PREVIOUS FOLLOW-UP
FORM)
No (No)
Unknown (Unknown)
Yes (Yes)
Date
Performance Status (Zubrod 0-5)
Fully Active, Able To Carry On All Pre-
disease Performance Without
Restriction. (0)
Restricted In Physically Strenuous
Activity But Ambulatory And Able To
Carry Out Work Of A Light Or Sedentary
Nature, E.g., Light Housework, Office
Work. (1)
Ambulatory And Capable Of All Selfcare
But Unable To Carry Out Any Work
Activities. Up And About More Than 50%
Of Waking Hours. (2)
Capable Of Only Limited Selfcare,
Confined To Bed Or Chair More Than
50% Of Waking Hours. (3)
Completely Disabled. Cannot Carry On
Any Selfcare. Totally Confined To Bed Or
Chair. (4)
Dead (5)
Unnamed Module 5
Has the patient been diagnosed with biochemical
recurrence since submission of the last follow-up
form
No (NO)
Unknown (Unknown)
Yes (YES)
Has the patient been diagnosed with a first local
recurrence (SINCE SUBMISSION OF THE LAST
FOLLOW-UP FORM)
No (NO)
Unknown (Unknown)
Yes (YES)
Date
Has the patient been diagnosed with a first local-
regional progression (pelvic node - or progression
- SINCE SUBMISSION OF THE LAST FOLLOW-
UP FORM)
Yes
No
Date
Site of first regional recurrence
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External Iliac (External iliac)
Hypogastric (Hypogastric)
Internal Iliac (Internal iliac)
Other Specify (Other)
Other, specify
Other Specify
Other Specify
Other Specify
Has the patient been diagnosed with first distant
recurrence/progression? (SINCE SUBMISSION
OF THE LAST FOLLOW-UP FORM)
No (No)
Unknown (Unknown)
Yes (Yes)
Date
Site of first distant progression
Bone (Bone)
Brain (Brain)
Liver (Liver)
Lung (Lung)
Lymph Node (Lymph Node (outside
pelvis))
Other (Other)
Other, specify
Method of Evaluation (DISTANT
PROGRESSION)
Mri (MRI (NMR))
Not Applicable (Not applicable)
Other (Other)
Pathologic (Pathologic)
Physical Exam (Physical exam)
Radiographic (Radiographic)
Method of Evaluation (DISTANT
PROGRESSION)
Mri (MRI (NMR))
Not Applicable (Not applicable)
Other (Other)
Pathologic (Pathologic)
Physical Exam (Physical exam)
Radiographic (Radiographic)
Method of Evaluation (DISTANT
PROGRESSION)
Mri (MRI (NMR))
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Not Applicable (Not applicable)
Other (Other)
Pathologic (Pathologic)
Physical Exam (Physical exam)
Radiographic (Radiographic)
Unnamed Module 4a
PSA Date
PSA Value
Unit of Measure
Nanograms Per Deciliter (ng/dL)
Nanograms Per Milliliter (ng/mL)
Nanomoles Per Liter (nmol/l)
Not Otherwise Specified (NOS)
Method of Assay
Abbott Labs (Abbott)
Bayer (Bayer)
Dpc (DPC)
Hybritech (Hybritech)
Other (Other)
Unknown (Unknown)
Has the patient had a prostatic fossa biopsy
No (No)
Not Done (Not done)
Unknown (Unknown)
Yes, Negative (Yes, negative)
Yes, Positive (Yes, positive)
Yes, Results Unknown (Yes, results
unknown)
Date of Biopsy (If yes,)
Palpable prostatic fossa mass
Equivocal (Equivocal)
No (No)
Not Evaluated (Not evaluated)
Unknown (Unknown)
Yes (Yes)
Lab Values
Pre-RT
Abnormal (Abnormal)
Normal (Normal)
Not Done (Not done)
Unknown (Unknown)
Week 6 of RT
Abnormal (Abnormal)
Normal (Normal)
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Not Done (Not done)
Unknown (Unknown)
Week 6 Post RT
Abnormal (Abnormal)
Normal (Normal)
Not Done (Not done)
Unknown (Unknown)
Unit of Measure
Nanograms Per Deciliter (ng/dL)
Nanograms Per Milliliter (ng/mL)
Nanomoles Per Liter (nmol/l)
Not Otherwise Specified (NOS)
Testosterone
Date
Testosterone Lower Limit Normal
Testosterone Upper Limit Normal
Baseline Lab Values (hematologic)
Pre-RT
Abnormal (Abnormal)
Normal (Normal)
Not Done (Not done)
Unknown (Unknown)
Week 6 of RT
Abnormal (Abnormal)
Normal (Normal)
Not Done (Not done)
Unknown (Unknown)
Week 6 Post RT
Abnormal (Abnormal)
Normal (Normal)
Not Done (Not done)
Unknown (Unknown)
Test
Value
Date
Baseline Lab Values (hematologic)
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Pre-RT
Abnormal (Abnormal)
Normal (Normal)
Not Done (Not done)
Unknown (Unknown)
Week 6 of RT
Abnormal (Abnormal)
Normal (Normal)
Not Done (Not done)
Unknown (Unknown)
Week 6 Post RT
Abnormal (Abnormal)
Normal (Normal)
Not Done (Not done)
Unknown (Unknown)
WBC (mm^3)
Hemoglobin (g/dL)
Peripheral Platelet Count (x 10^3 U/L)
Date
Non-protocol Therapy
Is the patient receiving any non-protocol cancer
therapy not previously reported (PROSTATE If
yes, enter therapy type and date for each therapy
delivered during the follow-up period.)
No (No)
Unknown (Unknown)
Yes (Yes)
Non-Protocol Therapy Type
Chemotherapy (Chemotherapy)
Hormones (Hormones)
None (None)
Other Specify (Other, specify)
Radiation To Other Sites, Specify
(Radiation to other sites, specify)
Radiation To Pelvis (Radiation to pelvis)
Surgery (Surgery)
Date of First Non-Protocol Therapy
Specify
Unnamed Module 7
Has a new primary cancer or MDS been
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diagnosed that has not been previously reported?
(MYELODYSPLASTIC SYNDROME)
No (No)
Unknown (Unknown)
Yes (Yes)
Second Primary Tumor Site
Aml/mds (AML/MDS)
Bcc (BCC)
Bladder Is The Site Of Second Primary
Or Recurrent Tumor (bladder)
Brain Is The Site Of Second Primary Or
Recurrent Tumor (brain)
Colorectal (Colorectal)
Esophageal (Esophageal)
Gastric (Gastric)
Liver Is The Site Of Second Primary Or
Recurrent Tumor (liver)
Lung Is The Site Of Second Primary Or
Recurrent Tumor (lung)
Melanoma (Melanoma)
Nhl (NHL)
Other Hematologic (Other hematologic)
Other Solid (Other solid)
Pancreatic (Pancreatic)
Renal (Renal)
Squamous-skin (Squamous-skin)
Unknown Primary (Unknown primary)
Second Primary Cancer Date
Other specify
Treatment Schedule (lhrh Agonist)
Is patient on protocol hormone (ORAL
ANTIANDROGEN)
Yes
No
LHRH agonist
Eligard (Eligard)
Lupron (Lupron)
Other (Other)
Viadur (Viadur)
Zoladex (Zoladex)
Other, specify
LHRH agonist start date (IF STARTED IN THIS
FOLLOW-UP PERIOD)
LHRH agonist end date (IF TERMINATED IN
THIS FOLLOW-UP PERIOD)
Reason Treatment Ended (ORAL
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ANTIANDROGEN)
Adverse Event/side Effects/complications
(Adverse Event/Side
Effects/Complications)
Alternative Therapy (Alternative therapy)
Death On Study (Death on study)
Disease Progression, Relapse During
Active Treatment (Disease progression,
relapse during active treatment)
Other (Other)
Patient Off-treatment For Other
Complicating Disease (Patient off-
treatment for other complicating disease)
Patient Withdrawal Or Refusal After
Beginning Protocol Therapy (Patient
withdrawal/refusal after beginning
protocol therapy)
Patient Withdrawal Or Refusal Before
Beginning Protocol Therapy (Patient
withdrawal/refusal prior to beginning
protocol therapy)
Treatment Completed Per Protocol
Criteria (Treatment completed per
protocol criteria)
Alternative Therapy, Specify
Patient off-treatment for other complicating
disease, specify
Other specify
Total Dose (TO DATE)
Treatment Schedule (oral Antiandrogen)
Is patient on protocol hormone (ORAL
ANTIANDROGEN)
Yes
No
Oral antiandrogen taken
Casodex (Casodex)
Eulexin (Eulexin)
Other (Other)
Other, specify
Oral Antiandrogen Start Date (IF STARTED IN
THIS FOLLOW-UP PERIOD)
Oral Antiandrogen End Date (IF TERMINATED IN
THIS FOLLOW-UP PERIOD)
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Reason Treatment Ended (ORAL
ANTIANDROGEN)
Adverse Event/side Effects/complications
(Adverse Event/Side
Effects/Complications)
Alternative Therapy (Alternative therapy)
Death On Study (Death on study)
Disease Progression, Relapse During
Active Treatment (Disease progression,
relapse during active treatment)
Other (Other)
Patient Off-treatment For Other
Complicating Disease (Patient off-
treatment for other complicating disease)
Patient Withdrawal Or Refusal After
Beginning Protocol Therapy (Patient
withdrawal/refusal after beginning
protocol therapy)
Patient Withdrawal Or Refusal Before
Beginning Protocol Therapy (Patient
withdrawal/refusal prior to beginning
protocol therapy)
Treatment Completed Per Protocol
Criteria (Treatment completed per
protocol criteria)
Alternative Therapy, Specify
Patient off-treatment for other complicating
disease, specify
Other specify
Total Dose (TO DATE)
Report All Continuing Or New Adverse
Events
Any Treatment Related Adverse Events
No (No)
Unknown (Unknown)
Yes (Yes)
MedDRA Code (BASED ON CTC AE TERM)
CTC Adverse Event Term
Acidosis Nos (Acidosis (metabolic or
respiratory))
Capillary Leak Syndrome (Acute
vascular leak syndrome)
Adrenal Insufficiency (Adrenal
insufficiency)
Adult Respiratory Distress Syndrome
(Adult respiratory distress syndrome
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(ARDS))
Blood Albumin Decreased (Albumin,
serum-low (hypoalbuminemia))
Alcohol Intolerance Syndrome
(antabuse-like Syndrome) (Alcohol
intolerance syndrome (antabuse-like
syndrome))
Blood Alkaline Phosphatase Nos
Increased (Alkaline phosphatase)
Alkalosis Nos (Alkalosis (metabolic or
respiratory))
Hypersensitivity Nos (Allergic
reaction/hypersensitivity (including drug
fever))
Rhinitis Allergic Nos (Allergic rhinitis
(including sneezing, nasal stuffiness,
postnasal drip))
Allergy/immunology Other
(Allergy/Immunology-Other (Specify))
Alanine Aminotransferase Increased
(ALT, SGPT (serum glutamic pyruvic
transaminase))
Blood Amylase Increased (Amylase)
Anorexia (Anorexia)
Apnoea (Apnea)
Arachnoiditis
(Arachnoiditis/meningismus/radiculitis)
Arthritis Nos (Arthritis (non-septic))
Ascites (Ascites (non-malignant))
Aspiration (Aspiration)
Aspartate Aminotransferase Increased
(AST, SGOT (serum glutamic oxaloacetic
transaminase))
Ataxia Nec (Ataxia (incoordination))
Atelectasis (Atelectasis)
Atrophy, Skin (Atrophy, skin)
Atrophy, Subcutaneous Fat (Atrophy,
subcutaneous fat)
Auditory/ear Other (Auditory/Ear-Other
(Specify))
Autoimmune Disorder Nos (Autoimmune
reaction)
Blood Bicarbonate Decreased
(Bicarbonate, serum-low)
Blood Bilirubin Increased (Bilirubin
(hyperbilirubinemia))
Bladder Disorder Nos (Bladder spasms)
Blood/bone Marrow Other (Blood/Bone
Marrow-Other (Specify))
Bone Age (alteration In Bone Age) (Bone
age (alteration in bone age))
Bone Growth: Femoral Head; Slipped
Capital Femoral Epiphysis (Bone growth:
femoral head; slipped capital femoral
epiphysis)
Bone Growth: Limb Length Discrepancy
(Bone growth: limb length discrepancy)
Bone Growth: Spine Kyphosis/lordosis
(Bone growth: spine kyphosis/lordosis)
Bone Marrow Depression Nos (Bone
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marrow cellularity)
Bone: Spine-scoliosis (Bone: spine-
scoliosis)
Brachial Plexopathy (Brachial
plexopathy)
Breast Function/lactation (Breast
function/lactation)
Breast Nipple/areolar Deformity (Breast
nipple/areolar deformity)
Breast Volume/hypoplasia (Breast
volume/hypoplasia)
Bronchospasm, Wheezing
(Bronchospasm, wheezing)
Ecchymosis (Bruising (in absence of
grade 3 or 4 thrombocytopenia))
Burn (Burn)
Hypercalcaemia (Calcium, serum-high
(hypercalcemia))
Hypocalcaemia (Calcium, serum-low
(hypocalcemia))
Pulmonary Function Test Nos Decreased
(Carbon monoxide diffusion capacity
(DL(co)))
Arrhythmia Nos (Cardiac Arrhythmia-
Other (Specify))
Cardiac General Other (Cardiac
General-Other (Specify))
Myocardial Ischaemia (Cardiac
ischemia/infarction)
Cardiac Troponin I Increased (Cardiac
troponin I (cTnI))
Cardiac Troponin T Increased (Cardiac
troponin T (cTnT))
Cardiopulmonary Arrest, Cause
Unknown (non-fatal) (Cardiopulmonary
arrest, cause unknown (non-fatal))
Cataract Nec (Cataract)
Cd4 Lymphocytes Decreased (CD4
count)
Cervical Spine-range Of Motion (Cervical
spine-range of motion)
Chelitis (Cheilitis)
Cholecystitis (Cholecystitis)
Hypercholesteraemia (Cholesterol,
serum-high (hypercholesteremia))
Chyle Or Lymph Leakage (Chyle or
lymph leakage)
Chylothorax (Chylothorax)
Cerebral Ischaemia (CNS
cerebrovascular ischemia)
Cns Necrosis/cystic Progression (CNS
necrosis/cystic progression)
Coagulation Disorder Nos (Coagulation-
Other (Specify))
Learning Disorder Nos (Cognitive
disturbance)
Colitis Nos (Colitis)
Colitis, Infectious (e.g., Clostridium
Difficile) (Colitis, infectious (e.g.,
Clostridium difficile))
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Ventricular Asystole (Conduction
abnormality/Atrioventricular heart block -
Asystole)
Conduction Abnormality/atrioventricular
Heart Block (Conduction
abnormality/Atrioventricular heart block -
AV block-first degree)
Conduction Abnormality/atrioventricular
Heart Block - Av Block-second Degree
Mobitz Type I (wenckebach) (Conduction
abnormality/Atrioventricular heart block -
AV block-Second degree Mobitz Type I
(Wenckebach))
Conduction Abnormality/atrioventricular
Heart Block (Conduction
abnormality/Atrioventricular heart block -
AV block-second degree Mobitz Type II)
Conduction Abnormality/atrioventricular
Heart Block (Conduction
abnormality/Atrioventricular heart block -
AV block-third degree (complete AV
block))
Conduction Abnormality/atrioventricular
Heart Block (Conduction
abnormality/Atrioventricular heart block -
Conduction abnormality NOS)
Conduction Abnormality/atrioventricular
Heart Block (Conduction
abnormality/Atrioventricular heart block -
Sick sinus syndrome)
Conduction Abnormality/atrioventricular
Heart Block (Conduction
abnormality/Atrioventricular heart block -
Stokes-Adams syndrome)
Conduction Abnormality/atrioventricular
Heart Block (Conduction
abnormality/Atrioventricular heart block -
Wolff-Parkinson-White syndrome)
Confusion (Confusion)
Constipation (Constipation)
Constitutional Symptoms Other
(Constitutional Symptoms-Other
(Specify))
Cough (Cough)
Blood Creatine Phosphokinase
Increased (CPK (creatine
phosphokinase))
Blood Creatinine Increased (Creatinine)
Cushingoid (Cushingoid appearance
(e.g., moon face, buffalo hump,
centripetal obesity, cutaneous striae))
Cystitis (Cystitis)
Cytokine Release Syndrome/acute
Infusion Reaction (Cytokine release
syndrome/acute infusion reaction)
Death Not Associated With Ctcae Term
(Death not associated with CTCAE term
- Death NOS)
Death Not Associated With Ctcae Term
(Death not associated with CTCAE term
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- Disease progression NOS)
Death Not Associated With Ctcae Term
(Death not associated with CTCAE term
- Multi-organ failure)
Death Not Associated With Ctcae Term
(Death not associated with CTCAE term
- Sudden death)
Dehydration (Dehydration)
Dental: Dentures Or Prosthesis (Dental:
dentures or prosthesis)
Dental: Periodontal Disease (Dental:
periodontal disease)
Dental: Teeth (Dental: teeth)
Dental: Teeth Development (Dental:
teeth development)
Dermal Change Lymphedema,
Phlebolymphedema (Dermal change
lymphedema, phlebolymphedema)
Dermatology/skin Other
(Dermatology/Skin-Other (Specify))
Diarrhoea Nos (Diarrhea)
Disseminated Intravascular Coagulation
(DIC (disseminated intravascular
coagulation))
Distention/bloating, Abdominal
(Distention/bloating, abdominal)
Dizziness (exc Vertigo) (Dizziness)
Dry Eye Nec (Dry eye syndrome)
Dry Mouth (Dry mouth/salivary gland
(xerostomia))
Dry Skin (Dry skin)
Dysphagia (Dysphagia (difficulty
swallowing))
Dyspnoea Nos (Dyspnea (shortness of
breath))
Edema, Larynx (Edema, larynx)
Edema: Head And Neck (Edema: head
and neck)
Oedema Nos (Edema: limb)
Edema: Trunk/genital (Edema:
trunk/genital)
Edema: Viscera (Edema: viscera)
Ejaculatory Dysfunction (Ejaculatory
dysfunction)
Encephalopathy (Encephalopathy)
Endocrine Other (Endocrine-Other
(Specify))
Enteritis (inflammation Of The Small
Bowel) (Enteritis (inflammation of the
small bowel))
Impotence (Erectile dysfunction)
Oesophagitis Nos (Esophagitis)
Exostosis (Exostosis)
Extrapyramidal Disorder Nec
(Extrapyramidal/involuntary
movement/restlessness)
Extremity-lower (gait/walking) (Extremity-
lower (gait/walking))
Extremity-upper (function) (Extremity-
upper (function))
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Eyelid Dysfunction (Eyelid dysfunction)
Fatigue (Fatigue (asthenia, lethargy,
malaise))
Febrile Neutropenia (fever Of Unknown
Origin Without Clinically Or
Microbiologically Documented Infection)
(anc <1.0 X 10^9/l, Fever >=38.5
Degrees C) (Febrile neutropenia)
Feminization (Feminization of male)
Forced Expiratory Volume Decreased
(FEV(1))
Pyrexia (Fever (in the absence of
neutropenia, where neutropenia is
defined as ANC <1.0 x 10^9/L))
Blood Fibrinogen Decreased
(Fibrinogen)
Fibrosis-cosmesis (Fibrosis-cosmesis)
Fibrosis-deep Connective Tissue
(Fibrosis-deep connective tissue)
Fistula, Gi (Fistula, GI - Abdomen NOS)
Anal Fistula (Fistula, GI - Anus)
Fistula, Gi (Fistula, GI - Biliary tree)
Fistula, Gi (Fistula, GI -
Colon/cecum/appendix)
Intestinal Fistula (Fistula, GI -
Duodenum)
Tracheo-oesophageal Fistula Nos
(Fistula, GI - Esophagus)
Fistula, Gi (Fistula, GI - Gallbladder)
Fistula, Gi (Fistula, GI - Ileum)
Fistula, Gi (Fistula, GI - Jejunum)
Fistula, Gi (Fistula, GI - Oral cavity)
Fistula, Gi (Fistula, GI - Pancreas)
Fistula, Gi (Fistula, GI - Pharynx)
Fistula, Gi (Fistula, GI - Rectum)
Fistula, Gi (Fistula, GI - Salivary gland)
Fistula, Gi (Fistula, GI - Small bowel
NOS)
Fistula, Gi (Fistula, GI - Stomach)
Fistula, Gu (Fistula, GU - Bladder)
Fistula, Gu (Fistula, GU - Genital tract-
female)
Fistula, Gu (Fistula, GU - Kidney)
Fistula, Gu (Fistula, GU - Ureter)
Fistula, Gu (Fistula, GU - Urethra)
Fistula, Gu (Fistula, GU - Uterus)
Urogenital Fistula (Fistula, GU - Vagina)
Fistula, Pulmonary/upper Respiratory
(Fistula, pulmonary/upper respiratory -
Bronchus)
Fistula, Pulmonary/upper Respiratory
(Fistula, pulmonary/upper respiratory -
Larynx)
Fistula, Pulmonary/upper Respiratory
(Fistula, pulmonary/upper respiratory -
Lung)
Fistula, Pulmonary/upper Respiratory
(Fistula, pulmonary/upper respiratory -
Oral cavity)
Fistula, Pulmonary/upper Respiratory
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(Fistula, pulmonary/upper respiratory -
Pharynx)
Fistula, Pulmonary/upper Respiratory
(Fistula, pulmonary/upper respiratory -
Pleura)
Fistula, Pulmonary/upper Respiratory
(Fistula, pulmonary/upper respiratory -
Trachea)
Flatulence (Flatulence)
Flu-like Syndrome (Flu-like syndrome)
Flushing (Flushing)
Fracture (Fracture)
Gastritis Nos (Gastritis (including bile
reflux gastritis))
Gastrointestinal Other (Gastrointestinal-
Other (Specify))
Gamma-glutamyltransferase Increased
(GGT (gamma-glutamyl transpeptidase))
Glaucoma Nos (Glaucoma)
Glomerular Filtration Rate (Glomerular
filtration rate)
Hyperglycaemia Nos (Glucose, serum-
high (hyperglycemia))
Hypoglycaemia Nos (Glucose, serum-
low (hypoglycemia))
Growth And Development Other (Growth
and Development-Other (Specify))
Growth Velocity (reduction In Growth
Velocity) (Growth velocity (reduction in
growth velocity))
Gynaecomastia (Gynecomastia)
Alopecia (Hair loss/Alopecia (scalp or
body))
Haptoglobin Decreased (Haptoglobin)
Hearing: Patients With/without Baseline
Audiogram And Enrolled In A Monitoring
Program (Hearing: patients with/without
baseline audiogram and enrolled in a
monitoring program)
Hearing: Patients Without Baseline
Audiogram And Not Enrolled In A
Monitoring Program (Hearing: patients
without baseline audiogram and not
enrolled in a monitoring program)
Dyspepsia (Heartburn/dyspepsia)
Hematoma (Hematoma)
Haemoglobin Decreased (Hemoglobin)
Haemoglobinuria Present
(Hemoglobinuria)
Hemolysis Nos (Hemolysis (e.g.,
immune hemolytic anemia, drug related
hemolysis))
Haemorrhagic Stroke (Hemorrhage,
CNS)
Melaena (Hemorrhage, GI - Abdomen
NOS)
Hemorrhage, Gi (Hemorrhage, GI -
Anus)
Hemorrhage, Gi (Hemorrhage, GI -
Biliary tree)
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Hemorrhage, Gi (Hemorrhage, GI -
Cecum/appendix)
Hemorrhage, Gi (Hemorrhage, GI -
Colon)
Hemorrhage, Gi (Hemorrhage, GI -
Duodenum)
Hemorrhage, Gi (Hemorrhage, GI -
Esophagus)
Hemorrhage, Gi (Hemorrhage, GI -
Ileum)
Hemorrhage, Gi (Hemorrhage, GI -
Jejunum)
Hemorrhage, Gi (Hemorrhage, GI - Liver)
Hemorrhage, Gi (Hemorrhage, GI -
Lower GI NOS)
Hemorrhage, Gi (Hemorrhage, GI - Oral
cavity)
Hemorrhage, Gi (Hemorrhage, GI -
Pancreas)
Hemorrhage, Gi (Hemorrhage, GI -
Peritoneal cavity)
Rectal Bleeding (Hemorrhage, GI -
Rectum)
Hemorrhage, Gi (Hemorrhage, GI -
Stoma)
Haematemesis (Hemorrhage, GI -
Stomach)
Hemorrhage, Gi (Hemorrhage, GI -
Upper GI NOS)
Hemorrhage, Gi (Hemorrhage, GI -
Varices (esophageal))
Hemorrhage, Gi (Hemorrhage, GI -
Varices (rectal))
Hemorrhage, Gu (Hemorrhage, GU -
Bladder)
Hemorrhage, Gu (Hemorrhage, GU -
Fallopian tube)
Hemorrhage, Gu (Hemorrhage, GU -
Kidney)
Hemorrhage, Gu (Hemorrhage, GU -
Ovary)
Hemorrhage, Gu (Hemorrhage, GU -
Prostate)
Hemorrhage, Gu (Hemorrhage, GU -
Retroperitoneum)
Hemorrhage, Gu (Hemorrhage, GU -
Spermatic cord)
Hemorrhage, Gu (Hemorrhage, GU -
Stoma)
Hemorrhage, Gu (Hemorrhage, GU -
Testes)
Hemorrhage, Gu (Hemorrhage, GU -
Ureter)
Hemorrhage, Gu (Hemorrhage, GU -
Urethra)
Haematuria Present (Hemorrhage, GU -
Urinary NOS)
Hemorrhage, Gu (Hemorrhage, GU -
Uterus)
Vaginal Haemorrhage (Hemorrhage, GU
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- Vagina)
Hemorrhage, Gu (Hemorrhage, GU - Vas
deferens)
Hemorrhage, Pulmonary/upper
Respiratory (Hemorrhage,
pulmonary/upper respiratory -
Bronchopulmonary NOS)
Hemorrhage, Pulmonary/upper
Respiratory (Hemorrhage,
pulmonary/upper respiratory - Bronchus)
Hemorrhage, Pulmonary/upper
Respiratory (Hemorrhage,
pulmonary/upper respiratory - Larynx)
Hemorrhage, Pulmonary/upper
Respiratory (Hemorrhage,
pulmonary/upper respiratory - Lung)
Hemorrhage, Pulmonary/upper
Respiratory (Hemorrhage,
pulmonary/upper respiratory -
Mediastinum)
Epistaxis (Hemorrhage, pulmonary/upper
respiratory - Nose)
Hemorrhage, Pulmonary/upper
Respiratory (Hemorrhage,
pulmonary/upper respiratory - Pharynx)
Hemorrhage, Pulmonary/upper
Respiratory (Hemorrhage,
pulmonary/upper respiratory - Pleura)
Haemoptysis (Hemorrhage,
pulmonary/upper respiratory -
Respiratory tract NOS)
Hemorrhage, Pulmonary/upper
Respiratory (Hemorrhage,
pulmonary/upper respiratory - Stoma)
Hemorrhage, Pulmonary/upper
Respiratory (Hemorrhage,
pulmonary/upper respiratory - Trachea)
Post-operative Haemorrhage
(Hemorrhage/bleeding associated with
surgery, intra-operative or post-operative)
Hemorrhage/bleeding Other
(Hemorrhage/Bleeding-Other (Specify))
Hemorrhoids (Hemorrhoids)
Hepatobiliary/pancreas Other
(Hepatobiliary/Pancreas-Other (Specify))
Hiccups (Hiccoughs (hiccups, singultus))
Menopausal Symptoms (Hot
flashes/flushes)
Hydrocephalus (Hydrocephalus)
Skin Discolouration (Hyperpigmentation)
Hypertension Nos (Hypertension)
Hypopigmentation (Hypopigmentation)
Hypotension Nos (Hypotension)
Hypothermia (Hypothermia)
Hypoxia (Hypoxia)
Ileus (Ileus, GI (functional obstruction of
bowel, i.e., neuroconstipation))
Incontinence, Anal (Incontinence, anal)
Urinary Incontinence (Incontinence,
urinary)
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Induration/fibrosis (skin And
Subcutaneous Tissue)
(Induration/fibrosis (skin and
subcutaneous tissue))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Abdomen NOS)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Anal/perianal)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Appendix)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Artery)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Biliary tree)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Bladder (urinary))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Blood)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Bone (osteomyelitis))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Brain (encephalitis,
infectious))
Infection (documented Clinically Or
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Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Brain + Spinal cord
(encephalomyelitis))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Bronchus)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Catheter-related)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Cecum)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Cervix)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Colon)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Conjunctiva)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Cornea)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Dental-tooth)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Duodenum)
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Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Esophagus)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - External ear (otitis externa))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Eye NOS)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Fallopian tube)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Foreign body (e.g., graft,
implant, prosthesis, stent))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Gallbladder (cholecystitis))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Heart (endocarditis))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Ileum)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Jejunum)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
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neutrophils - Joint)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Kidney)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Larynx)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Lens)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Lip/perioral)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Liver)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Lung (pneumonia))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Lymphatic)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Mediastinum NOS)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Meninges (meningitis))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
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neutrophils - Middle ear (otitis media))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Mucosa)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Muscle (infection myositis))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Neck NOS)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Nerve-cranial)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Nerve-peripheral)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Nose)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Oral cavity-gums
(gingivitis))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Pancreas)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Paranasal)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
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microbiologically) with Grade 3 or 4
neutrophils - Pelvis NOS)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Penis)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Peristomal)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Peritoneal cavity)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Pharynx)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Pleura (empyema))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Prostate)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Rectum)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Salivary gland)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Scrotum)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
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microbiologically) with Grade 3 or 4
neutrophils - Sinus)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Skin (cellulitis))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Small bowel NOS)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Soft tissue NOS)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Spinal cord (myelitis))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Spleen)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Stomach)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Trachea)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Ungual (nails))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Upper aerodigestive NOS)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
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microbiologically) with Grade 3 or 4
neutrophils - Upper airway NOS)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Ureter)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Urethra)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Urinary tract NOS)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Uterus)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Vagina)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Vein)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Vulva)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Wound)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Abdomen
NOS)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils -
Anal/perianal)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
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or Grade 1 or 2 neutrophils - Appendix)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Artery)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Biliary tree)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Bladder
(urinary))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Blood)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Bone
(osteomyelitis))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Brain
(encephalitis, infectious))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Brain +
Spinal cord (encephalomyelitis))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Bronchus)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Catheter-
related)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Cecum)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Cervix)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Colon)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils -
Conjunctiva)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Cornea)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Dental-
tooth)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Duodenum)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Esophagus)
Infection With Normal Anc Or Grade 1 Or
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2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - External ear
(otitis externa))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Eye NOS)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Fallopian
tube)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Foreign
body (e.g., graft, implant, prosthesis,
stent))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Gallbladder
(cholecystitis))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Heart
(endocarditis))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Ileum)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Jejunum)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Joint)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Kidney)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Larynx)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Lens)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Lip/perioral)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Liver)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Lung
(pneumonia))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Lymphatic)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils -
Mediastinum NOS)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
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or Grade 1 or 2 neutrophils - Meninges
(meningitis))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Middle ear
(otitis media))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Mucosa)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Muscle
(infection myositis))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Neck NOS)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Nerve-
cranial)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Nerve-
peripheral)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Nose)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Oral cavity-
gums (gingivitis))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Pancreas)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Paranasal)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Pelvis NOS)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Penis)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Peristomal)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Peritoneal
cavity)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Pharynx)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Pleura
(empyema))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Prostate)
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Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Rectum)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Salivary
gland)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Scrotum)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Sinus)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Skin
(cellulitis))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Small bowel
NOS)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Soft tissue
NOS)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Spinal cord
(myelitis))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Spleen)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Stomach)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Trachea)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Ungual
(nails))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Upper
aerodigestive NOS)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Upper
airway NOS)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Ureter)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Urethra)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Urinary
tract NOS)
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Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Uterus)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Vagina)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Vein)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Vulva)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Wound)
Infection With Unknown Anc (Infection
with unknown ANC - Abdomen NOS)
Infection With Unknown Anc (Infection
with unknown ANC - Anal/perianal)
Infection With Unknown Anc (Infection
with unknown ANC - Appendix)
Infection With Unknown Anc (Infection
with unknown ANC - Artery)
Infection With Unknown Anc (Infection
with unknown ANC - Biliary tree)
Infection With Unknown Anc (Infection
with unknown ANC - Bladder (urinary))
Infection With Unknown Anc (Infection
with unknown ANC - Blood)
Infection With Unknown Anc (Infection
with unknown ANC - Bone
(osteomyelitis))
Infection With Unknown Anc (Infection
with unknown ANC - Brain (encephalitis,
infectious))
Infection With Unknown Anc (Infection
with unknown ANC - Brain + Spinal cord
(encephalomyelitis))
Infection With Unknown Anc (Infection
with unknown ANC - Bronchus)
Implant Infection (Infection with unknown
ANC - Catheter-related)
Infection With Unknown Anc (Infection
with unknown ANC - Cecum)
Infection With Unknown Anc (Infection
with unknown ANC - Cervix)
Infection With Unknown Anc (Infection
with unknown ANC - Colon)
Infection With Unknown Anc (Infection
with unknown ANC - Conjunctiva)
Infection With Unknown Anc (Infection
with unknown ANC - Cornea)
Infection With Unknown Anc (Infection
with unknown ANC - Dental-tooth)
Infection With Unknown Anc (Infection
with unknown ANC - Duodenum)
Infection With Unknown Anc (Infection
with unknown ANC - Esophagus)
Infection With Unknown Anc (Infection
with unknown ANC - External ear (otitis
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externa))
Infection With Unknown Anc (Infection
with unknown ANC - Eye NOS)
Infection With Unknown Anc (Infection
with unknown ANC - Fallopian tube)
Infection With Unknown Anc (Infection
with unknown ANC - Foreign body (e.g.,
graft, implant, prosthesis, stent))
Infection With Unknown Anc (Infection
with unknown ANC - Gallbladder
(cholecystitis))
Infection With Unknown Anc (Infection
with unknown ANC - Heart
(endocarditis))
Infection With Unknown Anc (Infection
with unknown ANC - Ileum)
Infection With Unknown Anc (Infection
with unknown ANC - Jejunum)
Infection With Unknown Anc (Infection
with unknown ANC - Joint)
Infection With Unknown Anc (Infection
with unknown ANC - Kidney)
Infection With Unknown Anc (Infection
with unknown ANC - Larynx)
Infection With Unknown Anc (Infection
with unknown ANC - Lens)
Infection With Unknown Anc (Infection
with unknown ANC - Lip/perioral)
Infection With Unknown Anc (Infection
with unknown ANC - Liver)
Infection With Unknown Anc (Infection
with unknown ANC - Lung (pneumonia))
Infection With Unknown Anc (Infection
with unknown ANC - Lymphatic)
Infection With Unknown Anc (Infection
with unknown ANC - Mediastinum NOS)
Infection With Unknown Anc (Infection
with unknown ANC - Meninges
(meningitis))
Infection With Unknown Anc (Infection
with unknown ANC - Middle ear (otitis
media))
Infection With Unknown Anc (Infection
with unknown ANC - Mucosa)
Infection With Unknown Anc (Infection
with unknown ANC - Muscle (infection
myositis))
Infection With Unknown Anc (Infection
with unknown ANC - Neck NOS)
Infection With Unknown Anc (Infection
with unknown ANC - Nerve-cranial)
Infection With Unknown Anc (Infection
with unknown ANC - Nerve-peripheral)
Infection With Unknown Anc (Infection
with unknown ANC - Nose)
Infection With Unknown Anc (Infection
with unknown ANC - Oral cavity-gums
(gingivitis))
Infection With Unknown Anc (Infection
with unknown ANC - Pancreas)
31 / 53
Prostate Cancer NCT00567580 Follow-Up - RTOG 0534 FO: Interim
Follow-up Form - 2600263v1.0
Infection With Unknown Anc (Infection
with unknown ANC - Paranasal)
Infection With Unknown Anc (Infection
with unknown ANC - Pelvis NOS)
Infection With Unknown Anc (Infection
with unknown ANC - Penis)
Infection With Unknown Anc (Infection
with unknown ANC - Peristomal)
Infection With Unknown Anc (Infection
with unknown ANC - Peritoneal cavity)
Infection With Unknown Anc (Infection
with unknown ANC - Pharynx)
Infection With Unknown Anc (Infection
with unknown ANC - Pleura (empyema))
Infection With Unknown Anc (Infection
with unknown ANC - Prostate)
Infection With Unknown Anc (Infection
with unknown ANC - Rectum)
Infection With Unknown Anc (Infection
with unknown ANC - Salivary gland)
Infection With Unknown Anc (Infection
with unknown ANC - Scrotum)
Infection With Unknown Anc (Infection
with unknown ANC - Sinus)
Infection With Unknown Anc (Infection
with unknown ANC - Skin (cellulitis))
Infection With Unknown Anc (Infection
with unknown ANC - Small bowel NOS)
Infection With Unknown Anc (Infection
with unknown ANC - Soft tissue NOS)
Infection With Unknown Anc (Infection
with unknown ANC - Spinal cord
(myelitis))
Infection With Unknown Anc (Infection
with unknown ANC - Spleen)
Infection With Unknown Anc (Infection
with unknown ANC - Stomach)
Infection With Unknown Anc (Infection
with unknown ANC - Trachea)
Infection With Unknown Anc (Infection
with unknown ANC - Ungual (nails))
Infection With Unknown Anc (Infection
with unknown ANC - Upper aerodigestive
NOS)
Infection With Unknown Anc (Infection
with unknown ANC - Upper airway NOS)
Infection With Unknown Anc (Infection
with unknown ANC - Ureter)
Infection With Unknown Anc (Infection
with unknown ANC - Urethra)
Infection With Unknown Anc (Infection
with unknown ANC - Urinary tract NOS)
Infection With Unknown Anc (Infection
with unknown ANC - Uterus)
Infection With Unknown Anc (Infection
with unknown ANC - Vagina)
Infection With Unknown Anc (Infection
with unknown ANC - Vein)
Infection With Unknown Anc (Infection
with unknown ANC - Vulva)
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Culture Wound Positive (Infection with
unknown ANC - Wound)
Infection Nos (Infection-Other (Specify))
Infertility/sterility (Infertility/sterility)
Injection Site Reaction Nos (Injection site
reaction/extravasation changes)
Prothrombin Time Prolonged (INR
(International Normalized Ratio of
prothrombin time))
Insomnia Nec (Insomnia)
Intra-operative Injury (Intra-operative
injury - Abdomen NOS)
Intra-operative Injury (Intra-operative
injury - Adrenal gland)
Intra-operative Injury (Intra-operative
injury - Anal sphincter)
Intra-operative Injury (Intra-operative
injury - Anus)
Intra-operative Injury (Intra-operative
injury - Appendix)
Intra-operative Injury (Intra-operative
injury - Artery NOS)
Intra-operative Injury (Intra-operative
injury - Artery-aorta)
Intra-operative Injury (Intra-operative
injury - Artery-carotid)
Intra-operative Injury (Intra-operative
injury - Artery-cerebral)
Intra-operative Injury (Intra-operative
injury - Artery-extremity (lower))
Intra-operative Injury (Intra-operative
injury - Artery-extremity (upper))
Intra-operative Injury (Intra-operative
injury - Artery-hepatic)
Intra-operative Injury (Intra-operative
injury - Artery-major visceral artery)
Intra-operative Injury (Intra-operative
injury - Artery-pulmonary)
Intra-operative Injury (Intra-operative
injury - Biliary tree NOS)
Intra-operative Injury (Intra-operative
injury - Biliary tree-common bile duct)
Intra-operative Injury (Intra-operative
injury - Biliary tree-common hepatic duct)
Intra-operative Injury (Intra-operative
injury - Biliary tree-left hepatic duct)
Intra-operative Injury (Intra-operative
injury - Biliary tree-right hepatic duct)
Bladder Perforation Postoperative (Intra-
operative injury - Bladder)
Intra-operative Injury (Intra-operative
injury - Bone)
Intra-operative Injury (Intra-operative
injury - Brachial plexus)
Intra-operative Injury (Intra-operative
injury - Brain)
Intra-operative Injury (Intra-operative
injury - Breast)
Intra-operative Injury (Intra-operative
injury - Bronchus)
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Intra-operative Injury (Intra-operative
injury - Cartilage)
Intra-operative Injury (Intra-operative
injury - Cecum)
Intra-operative Injury (Intra-operative
injury - Cervix)
Intra-operative Injury (Intra-operative
injury - CN I (olfactory))
Intra-operative Injury (Intra-operative
injury - CN II (optic))
Intra-operative Injury (Intra-operative
injury - CN III (oculomotor))
Intra-operative Injury (Intra-operative
injury - CN IV (trochlear))
Intra-operative Injury (Intra-operative
injury - CN IX (glossopharyngeal) motor
pharynx)
Intra-operative Injury (Intra-operative
injury - CN IX (glossopharyngeal)
sensory ear-pharynx-tongue)
Intra-operative Injury (Intra-operative
injury - CN V (trigeminal) motor)
Intra-operative Injury (Intra-operative
injury - CN V (trigeminal) sensory)
Intra-operative Injury (Intra-operative
injury - CN VI (abducens))
Intra-operative Injury (Intra-operative
injury - CN VII (facial) motor-face)
Intra-operative Injury (Intra-operative
injury - CN VII (facial) sensory-taste)
Intra-operative Injury (Intra-operative
injury - CN VIII (vestibulocochlear))
Intra-operative Injury (Intra-operative
injury - CN X (vagus))
Intra-operative Injury (Intra-operative
injury - CN XI (spinal accessory))
Intra-operative Injury (Intra-operative
injury - CN XII (hypoglossal))
Intra-operative Injury (Intra-operative
injury - Colon)
Intra-operative Injury (Intra-operative
injury - Conjunctiva)
Intra-operative Injury (Intra-operative
injury - Cornea)
Intra-operative Injury (Intra-operative
injury - Cranial nerve or branch NOS)
Intra-operative Injury (Intra-operative
injury - Duodenum)
Intra-operative Injury (Intra-operative
injury - Esophagus)
Intra-operative Injury (Intra-operative
injury - Extremity-lower)
Intra-operative Injury (Intra-operative
injury - Extremity-upper)
Intra-operative Injury (Intra-operative
injury - Eye NOS)
Intra-operative Injury (Intra-operative
injury - Face NOS)
Intra-operative Injury (Intra-operative
injury - Fallopian tube)
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Intra-operative Injury (Intra-operative
injury - Gallbladder)
Intra-operative Injury (Intra-operative
injury - Gingiva)
Intra-operative Injury (Intra-operative
injury - Heart)
Intra-operative Injury (Intra-operative
injury - Ileum)
Intra-operative Injury (Intra-operative
injury - Inner ear)
Intra-operative Injury (Intra-operative
injury - Jejunum)
Intra-operative Injury (Intra-operative
injury - Joint)
Intra-operative Injury (Intra-operative
injury - Kidney)
Intra-operative Injury (Intra-operative
injury - Larynx)
Intra-operative Injury (Intra-operative
injury - Lens)
Intra-operative Injury (Intra-operative
injury - Ligament)
Intra-operative Injury (Intra-operative
injury - Lingual)
Intra-operative Injury (Intra-operative
injury - Lip/perioral area)
Intra-operative Injury (Intra-operative
injury - Liver)
Intra-operative Injury (Intra-operative
injury - Lung)
Intra-operative Injury (Intra-operative
injury - Lung thoracic)
Intra-operative Injury (Intra-operative
injury - Mediastinum)
Intra-operative Injury (Intra-operative
injury - Meninges)
Intra-operative Injury (Intra-operative
injury - Middle ear)
Intra-operative Injury (Intra-operative
injury - Muscle)
Intra-operative Injury (Intra-operative
injury - Nails)
Intra-operative Injury (Intra-operative
injury - Nasal cavity)
Intra-operative Injury (Intra-operative
injury - Nasopharynx)
Intra-operative Injury (Intra-operative
injury - Neck NOS)
Intra-operative Injury (Intra-operative
injury - Nose)
Intra-operative Injury (Intra-operative
injury - Oral)
Intra-operative Injury (Intra-operative
injury - Oral cavity NOS)
Intra-operative Injury (Intra-operative
injury - Outer ear NOS)
Intra-operative Injury (Intra-operative
injury - Outer ear-pinna)
Intra-operative Injury (Intra-operative
injury - Ovary)
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Intra-operative Injury (Intra-operative
injury - Pancreas)
Intra-operative Injury (Intra-operative
injury - Pancreatic duct)
Intra-operative Injury (Intra-operative
injury - Parathyroid)
Intra-operative Injury (Intra-operative
injury - Parotid gland)
Intra-operative Injury (Intra-operative
injury - Pelvis NOS)
Intra-operative Injury (Intra-operative
injury - Penis)
Intra-operative Injury (Intra-operative
injury - Peripheral motor NOS)
Intra-operative Injury (Intra-operative
injury - Peripheral sensory NOS)
Intra-operative Injury (Intra-operative
injury - Peritoneal cavity)
Intra-operative Injury (Intra-operative
injury - Pharynx)
Intra-operative Injury (Intra-operative
injury - Pituitary)
Intra-operative Injury (Intra-operative
injury - Pleura)
Intra-operative Injury (Intra-operative
injury - Prostate)
Intra-operative Injury (Intra-operative
injury - Rectum)
Intra-operative Injury (Intra-operative
injury - Recurrent laryngeal)
Intra-operative Injury (Intra-operative
injury - Retina)
Intra-operative Injury (Intra-operative
injury - Sacral plexus)
Intra-operative Injury (Intra-operative
injury - Salivary duct)
Intra-operative Injury (Intra-operative
injury - Salivary gland)
Intra-operative Injury (Intra-operative
injury - Sciatic)
Intra-operative Injury (Intra-operative
injury - Scrotum)
Intra-operative Injury (Intra-operative
injury - Sinus)
Intra-operative Injury (Intra-operative
injury - Skin)
Intra-operative Injury (Intra-operative
injury - Small bowel NOS)
Intra-operative Injury (Intra-operative
injury - Soft tissue NOS)
Intra-operative Injury (Intra-operative
injury - Spinal cord)
Intra-operative Injury (Intra-operative
injury - Spleen)
Intra-operative Injury (Intra-operative
injury - Stoma (GI))
Intra-operative Injury (Intra-operative
injury - Stomach)
Intra-operative Injury (Intra-operative
injury - Teeth)
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Intra-operative Injury (Intra-operative
injury - Tendon)
Intra-operative Injury (Intra-operative
injury - Testis)
Intra-operative Injury (Intra-operative
injury - Thoracic duct)
Intra-operative Injury (Intra-operative
injury - Thoracodorsal)
Intra-operative Injury (Intra-operative
injury - Thyroid)
Intra-operative Injury (Intra-operative
injury - Tongue)
Intra-operative Injury (Intra-operative
injury - Trachea)
Intra-operative Injury (Intra-operative
injury - Upper aerodigestive NOS)
Intra-operative Injury (Intra-operative
injury - Upper airway NOS)
Intra-operative Injury (Intra-operative
injury - Ureter)
Intra-operative Injury (Intra-operative
injury - Urethra)
Intra-operative Injury (Intra-operative
injury - Urinary conduit)
Intra-operative Injury (Intra-operative
injury - Urinary tract NOS)
Intra-operative Injury (Intra-operative
injury - Uterus)
Intra-operative Injury (Intra-operative
injury - Vagina)
Intra-operative Injury - Vein (Intra-
operative injury - Vein NOS)
Intra-operative Injury (Intra-operative
injury - Vein-extremity (lower))
Intra-operative Injury (Intra-operative
injury - Vein-extremity (upper))
Intra-operative Injury (Intra-operative
injury - Vein-hepatic)
Intra-operative Injury (Intra-operative
injury - Vein-inferior vena cava)
Intra-operative Injury (Intra-operative
injury - Vein-jugular)
Intra-operative Injury (Intra-operative
injury - Vein-major visceral vein)
Intra-operative Injury (Intra-operative
injury - Vein-portal vein)
Intra-operative Injury (Intra-operative
injury - Vein-pulmonary)
Intra-operative Injury (Intra-operative
injury - Vein-superior vena cava)
Intra-operative Injury (Intra-operative
injury - Vulva)
Intra-operative Injury Other (Intra-
operative Injury-Other (Specify))
Iron Overload (Iron overload)
Menstruation Irregular (Irregular menses
(change from baseline))
Irritability (Irritability (children <3 years of
age))
Joint-effusion (Joint-effusion)
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Joint-effusion (Joint-function)
Keratitis Nec (Keratitis (corneal
inflammation/corneal ulceration))
Laryngeal Nerve Dysfunction (Laryngeal
nerve dysfunction)
Leak (including Anastomotic), Gi (Leak
(including anastomotic), GI - Biliary tree)
Leak (including Anastomotic), Gi (Leak
(including anastomotic), GI - Esophagus)
Leak (including Anastomotic), Gi (Leak
(including anastomotic), GI - Large
bowel)
Leak (including Anastomotic), Gi (Leak
(including anastomotic), GI - Leak NOS)
Leak (including Anastomotic), Gi (Leak
(including anastomotic), GI - Pancreas)
Leak (including Anastomotic), Gi (Leak
(including anastomotic), GI - Pharynx)
Leak (including Anastomotic), Gi (Leak
(including anastomotic), GI - Rectum)
Leak (including Anastomotic), Gi (Leak
(including anastomotic), GI - Small
bowel)
Leak (including Anastomotic), Gi (Leak
(including anastomotic), GI - Stoma)
Leak (including Anastomotic), Gi (Leak
(including anastomotic), GI - Stomach)
Leak (including Anastomotic), Gu (Leak
(including anastomotic), GU - Bladder)
Leak (including Anastomotic), Gu (Leak
(including anastomotic), GU - Fallopian
tube)
Leak (including Anastomotic), Gu (Leak
(including anastomotic), GU - Kidney)
Leak (including Anastomotic), Gu (Leak
(including anastomotic), GU - Spermatic
cord)
Leak (including Anastomotic), Gu (Leak
(including anastomotic), GU - Stoma)
Leak (including Anastomotic), Gu (Leak
(including anastomotic), GU - Ureter)
Leak (including Anastomotic), Gu (Leak
(including anastomotic), GU - Urethra)
Leak (including Anastomotic), Gu (Leak
(including anastomotic), GU - Uterus)
Leak (including Anastomotic), Gu (Leak
(including anastomotic), GU - Vagina)
Leak (including Anastomotic), Gu (Leak
(including anastomotic), GU - Vas
deferens)
Leak, Cerebrospinal Fluid (csf) (Leak,
cerebrospinal fluid (CSF))
Left Ventricular Diastolic Dysfunction
(Left ventricular diastolic dysfunction)
Left Ventricular Failure (Left ventricular
systolic dysfunction)
Leucopenia Nos (Leukocytes (total
WBC))
Encephalopathy Nos
(Leukoencephalopathy (radiolographic
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findings))
Libido Decreased (Libido)
Lipase Increased (Lipase)
Hepatic Failure (Liver dysfunction/failure
(clinical))
Local Complication - Device/prosthesis-
related (Local complication -
device/prosthesis-related)
Lumbar Spine-range Of Motion (Lumbar
spine-range of motion)
Lymphatics Other (Lymphatics-Other
(Specify))
Lymphedema-related Fibrosis
(Lymphedema-related fibrosis)
Lymphocele (Lymphocele)
Lymphopenia (Lymphopenia)
Hypermagnesaemia (Magnesium,
serum-high (hypermagnesemia))
Blood Magnesium Decreased
(Magnesium, serum-low
(hypomagnesemia))
Malabsorption (Malabsorption)
Virilism (Masculinization of female)
Amnesia Nec (Memory impairment)
Mental Status (Mental status)
Metabolic/laboratory Other
(Metabolic/Laboratory-Other (Specify))
Mood Alteration - Agitation (Mood
alteration - agitation)
Anxiety Nec (Mood alteration - anxiety)
Depression Nec (Mood alteration -
depression)
Euphoric Mood (Mood alteration -
euphoria)
Mucositis/stomatitis (clinical Exam)
(Mucositis/stomatitis (clinical exam) -
Anus)
Mucositis/stomatitis (clinical Exam)
(Mucositis/stomatitis (clinical exam) -
Esophagus)
Mucositis/stomatitis (clinical Exam)
(Mucositis/stomatitis (clinical exam) -
Large bowel)
Mucositis/stomatitis (clinical Exam)
(Mucositis/stomatitis (clinical exam) -
Larynx)
Mucositis/stomatitis (clinical Exam)
(Mucositis/stomatitis (clinical exam) -
Oral cavity)
Stomatitis (Mucositis/stomatitis (clinical
exam) - Pharynx)
Mucositis/stomatitis (clinical Exam)
(Mucositis/stomatitis (clinical exam) -
Rectum)
Mucositis/stomatitis (clinical Exam)
(Mucositis/stomatitis (clinical exam) -
Small bowel)
Mucositis/stomatitis (clinical Exam)
(Mucositis/stomatitis (clinical exam) -
Stomach)
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Mucositis/stomatitis (clinical Exam)
(Mucositis/stomatitis (clinical exam) -
Trachea)
Mucositis/stomatitis
(functional/symptomatic)
(Mucositis/stomatitis
(functional/symptomatic) - Anus)
Mucositis/stomatitis
(functional/symptomatic)
(Mucositis/stomatitis
(functional/symptomatic) - Esophagus)
Mucositis/stomatitis
(functional/symptomatic)
(Mucositis/stomatitis
(functional/symptomatic) - Large bowel)
Mucositis/stomatitis
(functional/symptomatic)
(Mucositis/stomatitis
(functional/symptomatic) - Larynx)
Mucositis/stomatitis
(functional/symptomatic)
(Mucositis/stomatitis
(functional/symptomatic) - Oral cavity)
Mucositis/stomatitis
(functional/symptomatic)
(Mucositis/stomatitis
(functional/symptomatic) - Pharynx)
Mucositis/stomatitis
(functional/symptomatic)
(Mucositis/stomatitis
(functional/symptomatic) - Rectum)
Mucositis/stomatitis
(functional/symptomatic)
(Mucositis/stomatitis
(functional/symptomatic) - Small bowel)
Mucositis/stomatitis
(functional/symptomatic)
(Mucositis/stomatitis
(functional/symptomatic) - Stomach)
Mucositis/stomatitis
(functional/symptomatic)
(Mucositis/stomatitis
(functional/symptomatic) - Trachea)
Muscle Weakness, Generalized Or
Specific Area (not Due To Neuropathy)
(Muscle weakness, generalized or
specific area (not due to neuropathy) -
Extraocular)
Muscle Weakness, Generalized Or
Specific Area (not Due To Neuropathy)
(Muscle weakness, generalized or
specific area (not due to neuropathy) -
Extremity-lower)
Muscle Weakness, Generalized Or
Specific Area (not Due To Neuropathy)
(Muscle weakness, generalized or
specific area (not due to neuropathy) -
Extremity-upper)
Muscle Weakness, Generalized Or
Specific Area (not Due To Neuropathy)
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(Muscle weakness, generalized or
specific area (not due to neuropathy) -
Facial)
Muscle Weakness, Generalized Or
Specific Area (not Due To Neuropathy)
(Muscle weakness, generalized or
specific area (not due to neuropathy) -
Left-sided)
Muscle Weakness, Generalized Or
Specific Area (not Due To Neuropathy)
(Muscle weakness, generalized or
specific area (not due to neuropathy) -
Ocular)
Muscle Weakness, Generalized Or
Specific Area (not Due To Neuropathy)
(Muscle weakness, generalized or
specific area (not due to neuropathy) -
Pelvic)
Muscle Weakness, Generalized Or
Specific Area (not Due To Neuropathy)
(Muscle weakness, generalized or
specific area (not due to neuropathy) -
Right-sided)
Muscle Weakness, Generalized Or
Specific Area (not Due To Neuropathy)
(Muscle weakness, generalized or
specific area (not due to neuropathy) -
Trunk)
Muscle Weakness Nos (Muscle
weakness, generalized or specific area
(not due to neuropathy) - Whole
body/generalized)
Muscular/skeletal Hypoplasia
(Muscular/skeletal hypoplasia)
Musculoskeletal/soft Tissue Other
(Musculoskeletal/Soft Tissue-Other
(Specify))
Myelitis (Myelitis)
Myelodysplasia (Myelodysplasia)
Myocarditis Nos (Myocarditis)
Myositis (Myositis (inflammation/damage
of muscle))
Nail Abnormality Nos (Nail changes)
Nasal Cavity/paranasal Sinus Reactions
(Nasal cavity/paranasal sinus reactions)
Nausea (Nausea)
Necrosis, Gi (Necrosis, GI - Anus)
Necrosis, Gi (Necrosis, GI -
Colon/cecum/appendix)
Necrosis, Gi (Necrosis, GI - Duodenum)
Necrosis, Gi (Necrosis, GI - Esophagus)
Necrosis, Gi (Necrosis, GI - Gallbladder)
Necrosis, Gi (Necrosis, GI - Hepatic)
Necrosis, Gi (Necrosis, GI - Ileum)
Necrosis, Gi (Necrosis, GI - Jejunum)
Necrosis, Gi (Necrosis, GI - Oral)
Necrosis, Gi (Necrosis, GI - Pancreas)
Necrosis, Gi (Necrosis, GI - Peritoneal
cavity)
Necrosis, Gi (Necrosis, GI - Pharynx)
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Necrosis, Gi (Necrosis, GI - Rectum)
Necrosis, Gi (Necrosis, GI - Small bowel
NOS)
Necrosis, Gi (Necrosis, GI - Stoma)
Necrosis, Gi (Necrosis, GI - Stomach)
Neuroendocrine: Acth Deficiency
(Neuroendocrine: ACTH deficiency)
Inappropriate Adh Secretion
(Neuroendocrine: ADH secretion
abnormality (e.g., SIADH or low ADH))
Neuroendocrine: Gonadotropin Secretion
Abnormality (Neuroendocrine:
gonadotropin secretion abnormality)
Neuroendocrine: Growth Hormone
Secretion Abnormality (Neuroendocrine:
growth hormone secretion abnormality)
Neuroendocrine: Prolactin Hormone
Secretion Abnormality (Neuroendocrine:
prolactin hormone secretion abnormality)
Neurology Other (Neurology-Other
(Specify))
Parosmia (Neuropathy: cranial - CN I
Smell)
Cranial Nerve Injury Nos (Neuropathy:
cranial - CN II Vision)
Neuropathy: Cranial (Neuropathy: cranial
- CN III Pupil, upper eyelid, extra ocular
movements)
Neuropathy: Cranial (Neuropathy: cranial
- CN IV Downward, inward movement of
eye)
Neuropathy: Cranial (Neuropathy: cranial
- CN IX Motor-pharynx; Sensory-ear,
pharynx, tongue)
Neuropathy: Cranial (Neuropathy: cranial
- CN V Motor-jaw muscles; Sensory-
facial)
Neuropathy: Cranial (Neuropathy: cranial
- CN VI Lateral deviation of eye)
Neuropathy: Cranial (Neuropathy: cranial
- CN VII Motor-face; Sensory-taste)
Neuropathy: Cranial (Neuropathy: cranial
- CN VIII Hearing and balance)
Neuropathy: Cranial (Neuropathy: cranial
- CN X Motor-palate; pharynx, larynx)
Neuropathy: Cranial (Neuropathy: cranial
- CN XI Motor-sternomastoid and
trapezius)
Neuropathy: Cranial (Neuropathy: cranial
- CN XII Motor-tongue)
Peripheral Motor Neuropathy
(Neuropathy: motor)
Peripheral Sensory Neuropathy
(Neuropathy: sensory)
Neutropenia (Neutrophils/granulocytes
(ANC/AGC))
Blindness Night (Night blindness
(nyctalopia))
Nystagmus Nos (Nystagmus)
Obesity (Obesity)
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Obstruction, Gi (Obstruction, GI -
Cecum)
Obstruction, Gi (Obstruction, GI - Colon)
Obstruction, Gi (Obstruction, GI -
Duodenum)
Obstruction, Gi (Obstruction, GI -
Esophagus)
Obstruction, Gi (Obstruction, GI -
Gallbladder)
Obstruction, Gi (Obstruction, GI - Ileum)
Obstruction, Gi (Obstruction, GI -
Jejunum)
Obstruction, Gi (Obstruction, GI -
Rectum)
Obstruction, Gi (Obstruction, GI - Small
bowel NOS)
Obstruction, Gi (Obstruction, GI - Stoma)
Obstruction, Gi (Obstruction, GI -
Stomach)
Obstruction, Gu (Obstruction, GU -
Bladder)
Obstruction, Gu (Obstruction, GU -
Fallopian tube)
Obstruction, Gu (Obstruction, GU -
Prostate)
Obstruction, Gu (Obstruction, GU -
Spermatic cord)
Obstruction, Gu (Obstruction, GU -
Stoma)
Obstruction, Gu (Obstruction, GU -
Testes)
Ureteric Obstruction (Obstruction, GU -
Ureter)
Obstruction, Gu (Obstruction, GU -
Urethra)
Obstruction, Gu (Obstruction, GU -
Uterus)
Obstruction, Gu (Obstruction, GU -
Vagina)
Obstruction, Gu (Obstruction, GU - Vas
deferens)
Obstruction/stenosis Of Airway
(Obstruction/stenosis of airway -
Bronchus)
Obstruction/stenosis Of Airway
(Obstruction/stenosis of airway - Larynx)
Obstruction/stenosis Of Airway
(Obstruction/stenosis of airway -
Pharynx)
Obstruction/stenosis Of Airway
(Obstruction/stenosis of airway -
Trachea)
Conjunctivitis Nec (Ocular surface
disease)
Ocular/visual Other (Ocular/Visual-Other
(Specify))
Odor (patient Odor) (Odor (patient odor))
Diplopia (Ophthalmoplegia/diplopia
(double vision))
Opportunistic Infection Associated With
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>=grade 2 Lymphopenia (Opportunistic
infection associated with >=Grade 2
lymphopenia)
Optic Disc Edema (Optic disc edema)
Orgasmic Dysfunction (Orgasmic
dysfunction)
Osteonecrosis (Osteonecrosis (avascular
necrosis))
Osteoporosis (Osteoporosis)
Otitis Externa (exc Boil Of Meatus) Nos
(Otitis, external ear (non-infectious))
Otitis Media Serous Nos (Otitis, middle
ear (non-infectious))
Abdominal Pain Nos (Pain - Abdomen
NOS)
Pain (Pain - Anus)
Pain (Pain - Back)
Pain (Pain - Bladder)
Bone Pain (Pain - Bone)
Pain (Pain - Breast)
Pain (Pain - Buttock)
Pain (Pain - Cardiac/heart)
Pain (Pain - Chest wall)
Chest Pain (Pain - Chest/thorax NOS)
Pain (Pain - Dental/teeth/peridontal)
Pain (Pain - Esophagus)
Earache (Pain - External ear)
Pain (Pain - Extremity-limb)
Pain (Pain - Eye)
Pain (Pain - Face)
Pain (Pain - Gallbladder)
Headache Nos (Pain - Head/headache)
Pain (Pain - Intestine)
Arthralgia (Pain - Joint)
Pain (Pain - Kidney)
Pain (Pain - Larynx)
Pain (Pain - Lip)
Hepatic Pain (Pain - Liver)
Pain (Pain - Lymph node)
Pain (Pain - Middle ear)
Myalgia (Pain - Muscle)
Pain (Pain - Neck)
Neuralgia Nos (Pain -
Neuralgia/peripheral nerve)
Pain (Pain - Oral cavity)
Pain (Pain - Oral-gums)
Pain (Pain - Ovulatory)
Pain (Pain - Pain NOS)
Pelvic Pain Nos (Pain - Pelvis)
Pain (Pain - Penis)
Pain (Pain - Pericardium)
Pain (Pain - Perineum)
Pain (Pain - Peritoneum)
Pain (Pain - Phantom (pain associated
with missing limb))
Pleuritic Pain (Pain - Pleura)
Pain (Pain - Prostate)
Proctalgia (Pain - Rectum)
Pain (Pain - Scalp)
Pain (Pain - Scrotum)
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Pain (Pain - Sinus)
Pain (Pain - Skin)
Pain (Pain - Stomach)
Pain (Pain - Testicle)
Pain (Pain - Throat/pharynx/larynx)
Tumour Pain (Pain - Tumor pain)
Dysuria (Pain - Urethra)
Dysmenorrhoea (Pain - Uterus)
Pain (Pain - Vagina)
Pain Other (Pain-Other (Specify))
Palpitations (Palpitations)
Pancreas, Exocrine Enzyme Deficiency
(Pancreas, exocrine enzyme deficiency)
Pancreatic Endocrine: Glucose
Intolerance (Pancreatic endocrine:
glucose intolerance)
Pancreatitis Nos (Pancreatitis)
Parathyroid Function, Low
(hypoparathyroidism) (Parathyroid
function, low (hypoparathyroidism))
Perforation, Gi (Perforation, GI -
Appendix)
Perforation, Gi (Perforation, GI - Biliary
tree)
Perforation, Gi (Perforation, GI - Cecum)
Perforation, Gi (Perforation, GI - Colon)
Perforation, Gi (Perforation, GI -
Duodenum)
Perforation, Gi (Perforation, GI -
Esophagus)
Perforation, Gi (Perforation, GI -
Gallbladder)
Perforation, Gi (Perforation, GI - Ileum)
Perforation, Gi (Perforation, GI -
Jejunum)
Perforation, Gi (Perforation, GI - Rectum)
Perforation, Gi (Perforation, GI - Small
bowel NOS)
Perforation, Gi (Perforation, GI -
Stomach)
Perforation, Gu (Perforation, GU -
Bladder)
Perforation, Gu (Perforation, GU -
Fallopian tube)
Perforation, Gu (Perforation, GU -
Kidney)
Perforation, Gu (Perforation, GU - Ovary)
Perforation, Gu (Perforation, GU -
Prostate)
Perforation, Gu (Perforation, GU -
Spermatic cord)
Perforation, Gu (Perforation, GU -
Stoma)
Perforation, Gu (Perforation, GU -
Testes)
Perforation, Gu (Perforation, GU - Ureter)
Perforation, Gu (Perforation, GU -
Urethra)
Perforation, Gu (Perforation, GU -
Uterus)
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Perforation, Gu (Perforation, GU -
Vagina)
Perforation, Gu (Perforation, GU - Vas
deferens)
Pericardial Effusion (Pericardial effusion
(non-malignant))
Pericarditis (Pericarditis)
Peripheral Ischaemia Nos (Peripheral
arterial ischemia)
Personality Change
(Personality/behavioral)
Petechiae (Petechiae/purpura
(hemorrhage/bleeding into skin or
mucosa))
Phlebitis Superficial (Phlebitis (including
superficial thrombosis))
Phlebolymphatic Cording
(Phlebolymphatic cording)
Hypophosphataemia (Phosphate, serum-
low (hypophosphatemia))
Photosensitivity Reaction Nos
(Photosensitivity)
Phrenic Nerve Dysfunction (Phrenic
nerve dysfunction)
Platelet Count Decreased (Platelets)
Pleural Effusion (Pleural effusion (non-
malignant))
Pneumonitis Nos
(Pneumonitis/pulmonary infiltrates)
Pneumothorax Nos (Pneumothorax)
Portal Hypertension (Portal vein flow)
Hyperkalaemia (Potassium, serum-high
(hyperkalemia))
Hypokalaemia (Potassium, serum-low
(hypokalemia))
Proctitis Nos (Proctitis)
Prolapse Of Stoma, Gi (Prolapse of
stoma, GI)
Prolapse Of Stoma, Gu (Prolapse of
stoma, GU)
Prolonged Chest Tube Drainage Or Air
Leak After Pulmonary Resection
(Prolonged chest tube drainage or air
leak after pulmonary resection)
Prolonged Intubation After Pulmonary
Resection (>24 Hrs After Surgery)
(Prolonged intubation after pulmonary
resection (>24 hrs after surgery))
Electrocardiogram Qt Prolonged
(Prolonged QTc interval)
Proptosis/enophthalmos
(Proptosis/enophthalmos)
Proteinuria Present (Proteinuria)
Pruritus Nos (Pruritus/itching)
Delusion Nos (Psychosis
(hallucinations/delusions))
Activated Partial Thromboplastin Time
Prolonged (PTT (Partial thromboplastin
time))
Puberty (delayed) (Puberty (delayed))
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Puberty (precocious) (Puberty
(precocious))
Pulmonary Fibrosis (Pulmonary fibrosis
(radiographic changes))
Pulmonary Hypertension (Pulmonary
hypertension)
Pulmonary/upper Respiratory Other
(Pulmonary/Upper Respiratory-Other
(Specify))
Upper Motor Neurone Lesion (Pyramidal
tract dysfunction (e.g., increased tone,
hyperreflexia, positive Babinski,
decreased fine motor coordination))
Rash: Acne/acneiform (Rash:
acne/acneiform)
Radiation Recall Syndrome (Rash:
dermatitis associated with radiation -
Chemoradiation)
Dermatitis Radiation Nos (Rash:
dermatitis associated with radiation -
Radiation)
Erythema Multiforme (Rash: erythema
multiforme (e.g., Stevens-Johnson
syndrome, toxic epidermal necrolysis))
Localised Exfoliation (Rash: hand-foot
skin reaction)
Dermatitis Exfoliative Nos
(Rash/desquamation)
Renal Failure Nos (Renal failure)
Renal/genitourinary Other
(Renal/Genitourinary-Other (Specify))
Restrictive Cardiomyopathy (Restrictive
cardiomyopathy)
Retinal Detachment (Retinal
detachment)
Retinoic Acid Syndrome (Retinoic acid
syndrome")
Retinopathy (Retinopathy)
Right Ventricular Dysfunction (cor
Pulmonale) (Right ventricular dysfunction
(cor pulmonale))
Rigors (Rigors/chills)
Salivary Gland Disorder Nos (Salivary
gland changes/saliva)
Scleral Necrosis/melt (Scleral
necrosis/melt)
Secondary Malignancy Possibly Related
To Cancer Treatment (Secondary
Malignancy-possibly related to cancer
treatment (Specify))
Convulsions Nos (Seizure)
Seroma (Seroma)
Serum Sickness (Serum sickness)
Sexual/reproductive Function Other
(Sexual/Reproductive Function-Other
(Specify))
Short Stature (Short stature)
Skin Breakdown/decubitus Ulcer (Skin
breakdown/decubitus ulcer)
Hypernatraemia (Sodium, serum-high
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(hypernatremia))
Hyponatraemia (Sodium, serum-low
(hyponatremia))
Soft Tissue Necrosis (Soft tissue
necrosis - Abdomen)
Soft Tissue Necrosis (Soft tissue
necrosis - Extremity-lower)
Soft Tissue Necrosis (Soft tissue
necrosis - Extremity-upper)
Soft Tissue Necrosis (Soft tissue
necrosis - Head)
Soft Tissue Necrosis (Soft tissue
necrosis - Neck)
Soft Tissue Necrosis (Soft tissue
necrosis - Pelvic)
Soft Tissue Necrosis (Soft tissue
necrosis - Thorax)
Depressed Level Of Consciousness
(Somnolence/depressed level of
consciousness)
Speech Disorder Nec (Speech
impairment (e.g., dysphasia or aphasia))
Splenic Function (Splenic function)
Striae (Striae)
Stricture/stenosis (including
Anastomotic), Gi (Stricture/stenosis
(including anastomotic), GI - Anus)
Stricture/stenosis (including
Anastomotic), Gi (Stricture/stenosis
(including anastomotic), GI - Biliary tree)
Stricture/stenosis (including
Anastomotic), Gi (Stricture/stenosis
(including anastomotic), GI - Cecum)
Stricture/stenosis (including
Anastomotic), Gi (Stricture/stenosis
(including anastomotic), GI - Colon)
Stricture/stenosis (including
Anastomotic), Gi (Stricture/stenosis
(including anastomotic), GI - Duodenum)
Stricture/stenosis (including
Anastomotic), Gi (Stricture/stenosis
(including anastomotic), GI - Esophagus)
Stricture/stenosis (including
Anastomotic), Gi (Stricture/stenosis
(including anastomotic), GI - Ileum)
Stricture/stenosis (including
Anastomotic), Gi (Stricture/stenosis
(including anastomotic), GI - Jejunum)
Stricture/stenosis (including
Anastomotic), Gi (Stricture/stenosis
(including anastomotic), GI -
Pancreas/pancreatic duct)
Stricture/stenosis (including
Anastomotic), Gi (Stricture/stenosis
(including anastomotic), GI - Pharynx)
Stricture/stenosis (including
Anastomotic), Gi (Stricture/stenosis
(including anastomotic), GI - Rectum)
Stricture/stenosis (including
Anastomotic), Gi (Stricture/stenosis
48 / 53
Prostate Cancer NCT00567580 Follow-Up - RTOG 0534 FO: Interim
Follow-up Form - 2600263v1.0
(including anastomotic), GI - Small bowel
NOS)
Stricture/stenosis (including
Anastomotic), Gi (Stricture/stenosis
(including anastomotic), GI - Stoma)
Stricture/stenosis (including
Anastomotic), Gi (Stricture/stenosis
(including anastomotic), GI - Stomach)
Stricture/stenosis (including
Anastomotic), Gu (Stricture/stenosis
(including anastomotic), GU - Bladder)
Stricture/stenosis (including
Anastomotic), Gu (Stricture/stenosis
(including anastomotic), GU - Fallopian
tube)
Stricture/stenosis (including
Anastomotic), Gu (Stricture/stenosis
(including anastomotic), GU - Prostate)
Stricture/stenosis (including
Anastomotic), Gu (Stricture/stenosis
(including anastomotic), GU - Spermatic
cord)
Stricture/stenosis (including
Anastomotic), Gu (Stricture/stenosis
(including anastomotic), GU - Stoma)
Stricture/stenosis (including
Anastomotic), Gu (Stricture/stenosis
(including anastomotic), GU - Testes)
Stricture/stenosis (including
Anastomotic), Gu (Stricture/stenosis
(including anastomotic), GU - Ureter)
Stricture/stenosis (including
Anastomotic), Gu (Stricture/stenosis
(including anastomotic), GU - Urethra)
Stricture/stenosis (including
Anastomotic), Gu (Stricture/stenosis
(including anastomotic), GU - Uterus)
Stricture/stenosis (including
Anastomotic), Gu (Stricture/stenosis
(including anastomotic), GU - Vagina)
Stricture/stenosis (including
Anastomotic), Gu (Stricture/stenosis
(including anastomotic), GU - Vas
deferens)
Supraventricular And Nodal Arrhythmia
(Supraventricular and nodal arrhythmia -
Atrial fibrillation)
Supraventricular And Nodal Arrhythmia
(Supraventricular and nodal arrhythmia -
Atrial flutter)
Supraventricular And Nodal Arrhythmia
(Supraventricular and nodal arrhythmia -
Atrial tachycardia/paroxysmal atrial
tachycardia)
Supraventricular And Nodal Arrhythmia
(Supraventricular and nodal arrhythmia -
Nodal/junctional)
Supraventricular And Nodal Arrhythmia
(Supraventricular and nodal arrhythmia -
Sinus arrhythmia)
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Sinus Bradycardia (Supraventricular and
nodal arrhythmia - Sinus bradycardia)
Sinus Tachycardia (Supraventricular and
nodal arrhythmia - Sinus tachycardia)
Supraventricular Arrhythmia Nos
(Supraventricular and nodal arrhythmia -
Supraventricular arrhythmia NOS)
Supraventricular And Nodal Arrhythmia -
Supraventricular Extrasystoles
(premature Atrial Contractions;
Premature Nodal/junctional
Contractions) (Supraventricular and
nodal arrhythmia - Supraventricular
extrasystoles (premature atrial
contractions; premature nodal/junctional
contractions))
Supraventricular And Nodal Arrhythmia
(Supraventricular and nodal arrhythmia -
Supraventricular tachycardia)
Sweating Increased (Sweating
(diaphoresis))
Syncope (Syncope (fainting))
Syndromes Other (Syndromes-Other
(Specify))
Taste Disturbance (Taste alteration
(dysgeusia))
Telangiectasia (Telangiectasia)
Thrombosis/embolism (vascular Access-
related) (Thrombosis/embolism (vascular
access-related))
Thrombosis Nos
(Thrombosis/thrombus/embolism)
Thrombotic Microangiopathy (e.g.,
Thrombotic Thrombocytopenic
Purpura[ttp] Or Hemolytic Uremic
Syndrome[hus]) (Thrombotic
microangiopathy (e.g., thrombotic
thrombocytopenic purpura or hemolytic
uremic syndrome))
Thyroid Function, High (hyperthyroidism,
Thyrotoxicosis) (Thyroid function, high
(hyperthyroidism, thyrotoxicosis))
Hypothyroidism (Thyroid function, low
(hypothyroidism))
Tinnitus (Tinnitus)
Tremor Nec (Tremor)
Hypertriglyceridaemia (Triglyceride,
serum-high (hypertriglyceridemia))
Trismus (difficulty, Restriction Or Pain
When Opening Mouth) (Trismus
(difficulty, restriction or pain when
opening mouth))
Tumour Flare (Tumor flare)
Tumour Lysis Syndrome (Tumor lysis
syndrome)
Caecitis (Typhlitis (cecal inflammation))
Ulcer, Gi (Ulcer, GI - Anus)
Ulcer, Gi (Ulcer, GI - Cecum)
Ulcer, Gi (Ulcer, GI - Colon)
Duodenal Ulcer (Ulcer, GI - Duodenum)
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Ulcer, Gi (Ulcer, GI - Esophagus)
Ulcer, Gi (Ulcer, GI - Ileum)
Ulcer, Gi (Ulcer, GI - Jejunum)
Ulcer, Gi (Ulcer, GI - Rectum)
Ulcer, Gi (Ulcer, GI - Small bowel NOS)
Ulcer, Gi (Ulcer, GI - Stoma)
Gastric Ulcer (Ulcer, GI - Stomach)
Ulceration (Ulceration)
Hyperuricaemia (Uric acid, serum-high
(hyperuricemia))
Fanconi Syndrome (Urinary electrolyte
wasting (e.g., Fanconi's syndrome, renal
tubular acidosis))
Urinary Frequency (Urinary
frequency/urgency)
Urinary Retention (Urinary retention
(including neurogenic bladder))
Urine Discolouration (Urine color
change)
Urticaria Nos (Urticaria (hives, welts,
wheals))
Uveitis (Uveitis)
Vaginal Discharge (non-infectious)
(Vaginal discharge (non-infectious))
Vulvovaginal Dryness (Vaginal dryness)
Vaginal Mucositis (Vaginal mucositis)
Vaginal Stenosis/length (Vaginal
stenosis/length)
Vaginitis (Vaginitis (not due to infection))
Valvular Heart Disease (Valvular heart
disease)
Vascular Other (Vascular-Other
(Specify))
Vasculitis Nos (Vasculitis)
Vasovagal Attack (Vasovagal episode)
Ventricular Arrhythmia (Ventricular
arrhythmia - Bigeminy)
Ventricular Arrhythmia (Ventricular
arrhythmia - Idioventricular rhythm)
Ventricular Arrhythmia (Ventricular
arrhythmia - PVCs)
Ventricular Arrhythmia (Ventricular
arrhythmia - Torsade de pointes)
Ventricular Arrhythmia (Ventricular
arrhythmia - Trigeminy)
Ventricular Arrhythmia Nos (Ventricular
arrhythmia - Ventricular arrhythmia NOS)
Ventricular Arrhythmia (Ventricular
arrhythmia - Ventricular fibrillation)
Ventricular Arrhythmia (Ventricular
arrhythmia - Ventricular flutter)
Ventricular Arrhythmia (Ventricular
arrhythmia - Ventricular tachycardia)
Vessel Injury-artery (Vessel injury-artery
- Aorta)
Vessel Injury-artery (Vessel injury-artery
- Carotid)
Vessel Injury-artery (Vessel injury-artery
- Extremity-lower)
Vessel Injury-artery (Vessel injury-artery
51 / 53
Prostate Cancer NCT00567580 Follow-Up - RTOG 0534 FO: Interim
Follow-up Form - 2600263v1.0
- Extremity-upper)
Vessel Injury-artery (Vessel injury-artery
- Other NOS)
Vessel Injury-artery (Vessel injury-artery
- Visceral)
Vessel Injury-vein (Vessel injury-vein -
Extremity-lower)
Vessel Injury-vein (Vessel injury-vein -
Extremity-upper)
Vessel Injury-vein (Vessel injury-vein -
IVC)
Vessel Injury-vein (Vessel injury-vein -
Jugular)
Vessel Injury-vein (Vessel injury-vein -
Other NOS)
Vessel Injury-vein (Vessel injury-vein -
SVC)
Vessel Injury-vein (Vessel injury-vein -
Viscera)
Viral Hepatitis (Viral hepatitis)
Visceral Arterial Ischaemia (Visceral
arterial ischemia (non-myocardial))
Vision Blurred (Vision-blurred vision)
Photopsia (Vision-flashing lights/floaters)
Photophobia (Vision-photophobia)
Vital Capacity (Vital capacity)
Vitreous Hemorrhage (Vitreous
hemorrhage)
Dysphonia (Voice changes/dysarthria
(e.g., hoarseness, loss or alteration in
voice, laryngitis))
Vomiting Nos (Vomiting)
Lacrimation Increased (Watery eye
(epiphora, tearing))
Weight Increased (Weight gain)
Weight Decreased (Weight loss)
Culture Wound Negative (Wound
complication, non-infectious)
CTC AE Grade
CTCAE Begin Date
CTC AE Attribution Code (Attribution to Protocol
Treatment See protocol sections 6 & 7 for
definition of "protocol treatment")
Definite (Definite)
Possible (Possible)
Probable (Probable)
Unlikely (Unlikely)
Unrelated (Unrelated)
Serious adverse event report submitted
No (No)
Unknown (Unknown)
Yes (Yes)
Other, specify
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Footer
Comments
Signature of Person Completing This Form
Date Form Originally Completed
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Prostate Cancer NCT00079001 Follow-Up -
CALGB: 90202 Notification of death - 2075975v3.0
CALGB: 90202 Notification of death
Zoledronate in Preventing Skeletal (Bone)-Related Events
in Patients Who Are Receiving Androgen Deprivation
Therapy For Prostate Cancer and Bone Metastases
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=B4605223-
F60D-04F8-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/8754
CALGB: 90202 Notification of death
Ccrr Module For Calgb: 90202 Notification
Of Death
CALGB Form
CALGB Study No.
CALGB Patient ID
Are data amended?
Yes (Yes)
Patient?s Name
Patient Hospital Number
Main Member Institution/Adjunct
Participating Group
Participating Group Protocol No.
Participating Group Patient No.
Date of Death (M D Y)
Cause of Death (mark only one with an X)
Due To Other Cause, Specify (Not
related to protocol treatment or protocol
disease)
Due To This Disease (Protocol disease
related)
Due To Protocol Treatment (Protocol
treatment related)
Cause of Death (specify)
Comments
Completed By (Print or Type Name)
1 / 2
Date Completed
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of death - 2075975v3.0
Prostate Cancer NCT00079001 Off Treatment - CALGB
90202 OFF TREATMENT NOTICE 2075955_v3_0
CALGB: 90202 OFF TREATMENT NOTICE
Zoledronate in Preventing Skeletal (Bone)-Related Events
in Patients Who Are Receiving Androgen Deprivation
Therapy For Prostate Cancer and Bone Metastases
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=B460546D-
46F1-0505-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/8756
CALGB: 90202 OFF TREATMENT
NOTICE
CCRR Modul Für CALGB : 90202 Off-
Behandlung Hinweis
CALGB Formular
CALGB Studiennummer
CALGB Patienten-ID
Geänderte Daten?
ja (Yes)
Patientenname
Teilnehmende Gruppe
Krankenhaus-Nummer des Patienten
Teilnehmende Gruppen Protokoll Nr.
Hauptmitglied Institution
Teilnehmende Patientengruppen Nr
Grund OFF BEHANDLUNG ( wählen Sie einen
einzigen Grund aus, indem Sie ein X in das
entsprechende Feld setzen)
Unerwünschte Ereignisse /
Nebenwirkungen / Komplikationen
(Adverse event)
andere (Other, specify)
Off- Patient für die Behandlung anderer
Krankheiten Komplizierende (Patient
developed other disease)
Patient sprach nicht auf die Therapie an
(Patient did not respond to therapy)
Tod durch Studie (Patient died during
treatment)
Krankheitsfortschritt, Rezidiv während
der aktiven Behandlung (Patient had
disease progression or relapse during
active treatment)
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Patient widerruft oder verweigert, bevor
Protokoll-Therapie anfängt (Patient
refused further protocol treatment, but
consented to be followed)
Lost to follow-up (Patient refused further
protocol treatment, withdrew consent to
be followed. Patient is lost to follow-up.)
Alternative Therapie (Patient taken off of
protocol treatment to receive non-
protocol therapy during active protocol
treatment)
Patient Entzug oder die Verweigerung
Vor Beginn der Protokoll-Therapie
(Patient withdrawal or refusal prior to
beginning protocol therapy)
Behandlung nach Protokollkriterien
abgeschlossen (Treatment completed
per protocol)
Patient Entzug oder die Verweigerung
Vor Beginn der Protokoll-Therapie
(Treatment never started)
Patient entwickelte eine andere Krankheit.
Erläutern
Grund, warum die Behandlung nicht begonnen
wurde
Geben Sie die Art der nicht-Protokoll Behandlung
an.
Andere, angeben (off Behandlung Grund )
Datum der letzten Protokoll Behandlung (M T J)
Kommentare
Ausgefüllt von
Abschlussdatum
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Prostate Cancer NCT00079001 Off Treatment - CALGB 90202 OFF
TREATMENT NOTICE 2075955_v3_0
Bladder Cancer NCT00014534 Follow-Up -
CALGB: 90104 Survival Data Form - 2169468v3.0
CALGB: 90104 Survival Data Form
Combination Chemotherapy in Treating Patients With
Bladder Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=BE1B54C8-
3A4E-70F6-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/8757
CALGB: 90104 Survival Data Form
Ccrr Module For Calgb: 90104 Survival
Data Form
CALGB Form
CALGB Study No
CALGB Patient ID
Amended data
Yes (Yes)
Patient's Name
Patient Hospital Number
Main Member Institution/Adjunct
Participating Group
Participating Group Protocol No.
Participating Group Patient No.
Date patient last known alive or date of death
Patient's surval status as of the above date
Alive (alive)
Consent For Survival Follow-up
Withdrawn (consent for survival follow-up
withdrawn)
Dead (dead)
Lost (lost)
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III-Multiple Brain Mets Quality of Life Cover Sheet - 2277042v3.0
Cover Sheet RTOG Phase III-Multiple Brain Mets Quality of
Life Cover Sheet
Radiation Therapy and Stereotactic Radiosurgery With or
Without Temozolomide or Erlotinib in Treating Patients With
Brain Metastases Secondary to Non-Small Cell Lung
Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=D7FA3BB6-
3594-636D-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/8759
Cover Sheet RTOG Phase III-
Multiple Brain Mets Quality of Life
Cover Sheet
Header
[RTOG Study No.]
RTOG Study 0320 (RTOG Study 0320)
Case #
Institution
Institution No.
Participant's Name
Participant's I.D. No.
Module 1
If this is a revised or corrected form, indicate by
checking box.
Module 2
Type of Quality of Life Form
Eq5d (EQ5D)
Fact Subscale (Fact Subscale)
Fact-g (Fact-G)
Patient refused, specify reason for refusal
Reason Questionnaire Was Not Completed
Institution Not Participating In Qol
(Institution not participating in QOL)
Not Applicable (Not applicable)
Other Reason (Other reason)
Patient Refused (Patient refused)
Patient Unable To Be Contacted (Patient
unable to be contacted)
Patient Too Ill (Patient was too ill)
1 / 2
Institution Error (Questionnaire not
completed due to institutional error)
Unknown (Unknown)
Reason
Who
Did the patient require assistance in completing
the radiotherapy questionnaire?
Yes
No
Other, specify
Time point of assessment of protocol treatment
18 Month Follow-up (Eighteen (18)
month follow-up)
9 Month Follow-up (Nine (9) month
follow-up)
Other, Specify (Other)
Baseline/pretreatment (Pretreatment)
6 Month Follow-up (Six (6) month follow-
up)
3 Month Follow-up (Three (3) month
follow-up)
12 Month Follow-up (Twelve (12) month
follow-up)
24 Month Follow-up (Twenty-four (24)
month follow-up)
Calendar Due Date
Was questionnaire completed?
Yes
No
Date Questionnaire Completed
Other reason, specify
Module 3
Comments
Signature of person completing cover page
Date
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Liver Cancer NCT01004978 Eligibility - E1208
Registration Worksheet/Step 1 - 2944998v1.0
E1208 Registration Worksheet/Step 1
Chemoembolization With or Without Sorafenib Tosylate in
Treating Patients With Liver Cancer That Cannot Be
Removed By Surgery
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=7454791C-
AC85-65C0-E040-BB89AD431786
All rights reserved. Please visit https://medical-data-
models.org/forms/8760
E1208 Registration Worksheet/Step
1
Eligibility
First initial
Last initial
Has the eligibility checklist been completed?
Yes
No
In the opinion of the investigator, is the patient
eligible?
Yes
No
Has written informed consent been obtained?
Yes
No
Date Informed Consent Signed
Has HIPAA authorization been obtained?
Exempt - Non-usa Participant (Exempt -
non-USA participant)
No: C49487 (No)
Yes: C49488 (Yes)
HIPAA Authorization Date
Macrovascular intrahepatic portal vein invasion
Absent (Absent)
Present (Present)
Child Pugh Score
Grade A (Class A)
Grade B7 (Class B7)
What method does institution plan to use to
administer TACE?
Conventional Method (Conventional
method)
Dc Beads (DC Beads)
Do you wish to use an express carrier to ship the
drugs (at your expense)?
1 / 8
Yes
No
I agree to participate in the drug level studies that
are being done as part of this clinical trial.
Yes
No
I agree to participate in the protein and DNA
studies that are being done as part of this clinical
trial.
Yes
No
My specimens may be kept for use in research to
learn about, prevent, treat, or cure cancer.
Yes
No
My specimens may be kept for use in research
about other health problems (for example: causes
of diabetes, Alzheimer's disease, or heart
disease) (for example: causes of diabetes,
Alzheimer's disease, and heart disease)
Yes
No
Someone from this institution may contact me in
the future to ask me to take part in more
research.
Yes
No
Patient Demographics / Pre-treatment
Characteristics
Patient's Sex
Female (F)
Male (M)
Birthdate (mm/yy)
Patient's Race
A Person Having Origins In Any Of The
Original Peoples Of North And South
America (including Central America),
And Who Maintains Tribal Affiliation Or
Community Attachment. (American
Indian or Alaska Native)
A Person Having Origins In Any Of The
Original Peoples Of The Far East,
Southeast Asia, Or The Indian
Subcontinent Including, For Example,
Cambodia, China, India, Japan, Korea,
Malaysia, Pakistan, The Philippine
Islands, Thailand, And Vietnam. (Asian)
A Person Having Origins In Any Of The
Black Racial Groups Of Africa. Terms
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Such As "haitian" Or "negro" Can Be
Used In Addition To "black Or African
American." (Black or African American)
A Person Having Origins In Any Of The
Original Peoples Of Hawaii, Guam,
Samoa, Or Other Pacific Islands. (Native
Hawaiian or other Pacific Islander)
Not Provided Or Available (Not
Reported)
Could Not Be Determined Or Unsure
(Unknown)
A Person Having Origins In Any Of The
Original Peoples Of Europe, The Middle
East, Or North Africa. (White)
ZIP Code
Patient Ethnicity
A Person Of Mexican, Puerto Rican,
Cuban, Central Or South American Or
Other Spanish Culture Or Origin,
Regardless Of Race. (Hispanic or Latino)
A Person Not Meeting The Definition For
Hispanic Or Latino. (Not Hispanic or
Latino)
Not Provided Or Available (Not reported)
Could Not Be Determined Or Unsure
(Unknown)
Patient Hospital No.
Patient Social Security Number
Method of payment (check one)
Medicaid (Medicaid)
Medicaid And Medicare (Medicaid and
Medicare)
Medicare (Medicare)
Medicare And Private Insurance
(Medicare and Private Insurance)
Military Or Veterans Sponsored Nos
(Military or Veterans Sponsored, Not
Otherwise Specified (NOS))
Military Sponsored (including Champus
& Tricare) (Military Sponsored (including
CHAMPUS & TRICARE))
No Means Of Payment (no Insurance)
(No means of payment (no insurance))
Other (Other)
Private Insurance (Private Insurance)
Self Pay (no Insurance) (Self Pay (No
Insurance))
Unknown (Unknown)
Veterans Sponsored (Veterans
Sponsored)
Country of residence
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Ascension Island (AC)
Andorra (AD)
United Arab Emirates (AE)
Afghanistan (AF)
Antigua And Barbuda (AG)
Anguilla (AI)
Albania (AL)
Armenia (AM)
Netherland Antilles (AN)
Angola (AO)
Antarctica (AQ)
Argentina (AR)
American Samoa (AS)
Austria (AT)
Australia (AU)
Aruba (AW)
Azerbaidjan (AZ)
Bosnia-herzegovina (BA)
Barbados (BB)
Bangladesh (BD)
Belgium (BE)
Burkina Faso (BF)
Bulgaria (BG)
Bahrain (BH)
Burundi (BI)
Benin (BJ)
Bermuda (BM)
Brunei Darussalam (BN)
Bolivia (BO)
Brazil (BR)
Bahamas (BS)
Bhutan (BT)
Bouvet Island (BV)
Botswana (BW)
Belarus (BY)
Belize (BZ)
Canada (CA)
Cocos Isl. (CC)
Rep. Dem. Congo (CD)
Central African Rep. (CF)
Congo (CG)
Switzerland (CH)
Ivory Coast (CI)
Cook Islands (CK)
Chile (CL)
Cameroon (CM)
China (CN)
Colombia (CO)
Costa Rica (CR)
Cuba (CU)
Cape Verde (CV)
Christmas Island (CX)
Cyprus (CY)
Czech Republic (CZ)
Germany (DE)
Djibouti (DJ)
Denmark (DK)
Dominica (DM)
Dominican Republic (DO)
Algeria (DZ)
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Ecuador (EC)
Estonia (EE)
Egypt (EG)
Western Sahara (EH)
Eritrea (ER)
Spain (ES)
Ethiopia (ET)
Finland (FI)
Fiji (FJ)
Falkland Isl. (FK)
Micronesia (FM)
Faroe Islands (FO)
France (FR)
France (european Ter.) (FX)
Gabon (GA)
Great Britain (GB)
Grenada (GD)
Georgia (GE)
Guiana (fr.) (GF)
Guernsey (GG)
Ghana (GH)
Gibraltar (GI)
Greenland (GL)
Gambia (GM)
Guinea (GN)
Guadeloupe (fr.) (GP)
Equatorial Guinea (GQ)
Greece (GR)
South Georgia And South Sandwich
Islands (GS)
Guatemala (GT)
Guam (us) (GU)
Guinea Bissau (GW)
Guyana (GY)
Hong Kong (HK)
Heard & Mcdonald Isl. (HM)
Honduras (HN)
Croatia (HR)
Haiti (HT)
Hungary (HU)
Indonesia (ID)
Ireland (IE)
Israel (IL)
Isle Of Man (IM)
India (IN)
British Indian O. Ter. (IO)
Iraq (IQ)
Iran (IR)
Iceland (IS)
Italy (IT)
Jersey (JE)
Jamaica (JM)
Jordan (JO)
Japan (JP)
Kenya (KE)
Kyrgyz Republic (KG)
Cambodia (KH)
Kiribati (KI)
Comoros (KM)
St. Kitts Nevis Anguilla (KN)
5 / 8
Liver Cancer NCT01004978 Eligibility - E1208 Registration
Worksheet/Step 1 - 2944998v1.0
Korea (north) (KP)
Korea (south) (KR)
Kuwait (KW)
Cayman Islands (KY)
Kazakstan (KZ)
Laos (LA)
Lebanon (LB)
Saint Lucia (LC)
Liechtenstein (LI)
Sri Lanka (LK)
Liberia (LR)
Lesotho (LS)
Lithuania (LT)
Luxembourg (LU)
Latvia (LV)
Libya (LY)
Morocco (MA)
Monaco (MC)
Moldova (MD)
Madagascar (MG)
Marshall Islands (MH)
Macedonia (MK)
Mali (ML)
Myanmar (MM)
Mongolia (MN)
Macau (MO)
Northern Mariana Isl. (MP)
Martinique (fr.) (MQ)
Mauritania (MR)
Montserrat (MS)
Malta (MT)
Mauritius (MU)
Maldives (MV)
Malawi (MW)
Mexico (MX)
Malaysia (MY)
Mozambique (MZ)
Namibia (NA)
New Caledonia (fr.) (NC)
Niger (NE)
Norfolk Island (NF)
Nigeria (NG)
Nicaragua (NI)
Netherlands (NL)
Norway (NO)
Nepal (NP)
Nauru (NR)
Niue (NU)
New Zealand (NZ)
Oman (OM)
Other (Other)
Panama (PA)
Peru (PE)
Polynesia (fr.) (PF)
Papua New Guinea (PG)
Philippines (PH)
Pakistan (PK)
Poland (PL)
St. Pierre & Miquelon (PM)
Pitcairn (PN)
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Puerto Rico (PR)
Portugal (PT)
Palau (PW)
Paraguay (PY)
Qatar (QA)
Reunion (fr.) (RE)
Romania (RO)
Russian Federation (RU)
Rwanda (RW)
Saudi Arabia (SA)
Solomon Islands (SB)
Seychelles (SC)
Sudan (SD)
Sweden (SE)
Singapore (SG)
St. Helena (SH)
Slovenia (SI)
Svalbard & Jan Mayen Isl. (SJ)
Slovakia (SK)
Sierra Leone (SL)
San Marino (SM)
Senegal (SN)
Somalia (SO)
Suriname (SR)
St. Tome And Principe (ST)
Soviet Union (SU)
El Salvador (SV)
Syria (SY)
Swaziland (SZ)
Turks & Caicos Islands (TC)
Chad (TD)
French Southern Terr. (TF)
Togo (TG)
Thailand (TH)
Tadjikistan (TJ)
Tokelau (TK)
Turkmenistan (TM)
Tunisia (TN)
Tonga (TO)
East Timor (TP)
Turkey (TR)
Trinidad & Tobago (TT)
Tuvalu (TV)
Taiwan (TW)
Tanzania (TZ)
Ukraine (UA)
Uganda (UG)
United Kingdom (UK)
Us Minor Outlying Isl. (UM)
Usa (US)
Uruguay (UY)
Uzbekistan (UZ)
Vatican City State (VA)
St. Vincent & Grenadines (VC)
Venezuela (VE)
Virgin Islands (brit) (VG)
Virgin Islands (us) (VI)
Vietnam (VN)
Vanuatu (VU)
Wallis & Futuna Islands (WF)
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Western Samoa (WS)
Yemen (YE)
Mayotte (YT)
Yugoslavia (YU)
South Africa (ZA)
Zambia (ZM)
Dem. Rep. Of Congo (ZR)
Zimbabwe (ZW)
Comments
I Have Reviewed The Above Data And
Agree The Date Are Accurate And Correct
Signature of treating physician
Date
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Leukemia NCT00843882 Eligibility - E2905
Registration Worksheet (step 2) - 2769504v1.0
E2905 Registration Worksheet (step 2)
Lenalidomide With or Without Epoetin Alfa in Treating
Patients With Myelodysplastic Syndrome and Anemia
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=532EF76D-
D605-140D-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/8761
E2905 Registration Worksheet (step
2)
Eligibility
First initial
Last initial
Has the eligibility checklist been completed
Yes
No
In the opinion of the investigator, is the patient
eligible?
Yes
No
Which treatment arm did the patient receive on
step 1 of treatment
A: Lenalidomide Monotherapy (A:
Lenalidomide Monotherapy)
B: Lenalidomide + Epoetin Alfa (B:
Lenalidomide + Epoetin Alfa)
Patient's ECOG sequence number
Patient Demographics / Pre-treatment
Characteristics
Patient's Sex
Female (F)
Male (M)
Birthdate (mm/yy)
Patient Race (check all that applyU.S. and
Canada only)
A Person Having Origins In Any Of The
Original Peoples Of North And South
America (including Central America),
And Who Maintains Tribal Affiliation Or
Community Attachment. (American
Indian or Alaska Native)
A Person Having Origins In Any Of The
Original Peoples Of The Far East,
Southeast Asia, Or The Indian
Subcontinent Including, For Example,
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Cambodia, China, India, Japan, Korea,
Malaysia, Pakistan, The Philippine
Islands, Thailand, And Vietnam. (Asian)
A Person Having Origins In Any Of The
Black Racial Groups Of Africa. Terms
Such As "haitian" Or "negro" Can Be
Used In Addition To "black Or African
American." (Black or African American)
A Person Having Origins In Any Of The
Original Peoples Of Hawaii, Guam,
Samoa, Or Other Pacific Islands. (Native
Hawaiian or other Pacific Islander)
Not Provided Or Available (Not
Reported)
Could Not Be Determined Or Unsure
(Unknown)
A Person Having Origins In Any Of The
Original Peoples Of Europe, The Middle
East, Or North Africa. (White)
ZIP Code
Patient Ethnicity
A Person Of Mexican, Puerto Rican,
Cuban, Central Or South American Or
Other Spanish Culture Or Origin,
Regardless Of Race. (Hispanic or Latino)
A Person Not Meeting The Definition For
Hispanic Or Latino. (Not Hispanic or
Latino)
Not Provided Or Available (Not reported)
Could Not Be Determined Or Unsure
(Unknown)
Patient Hospital No.
Patient Social Security Number
Method of payment (check one)
Medicaid (Medicaid)
Medicaid And Medicare (Medicaid and
Medicare)
Medicare (Medicare)
Medicare And Private Insurance
(Medicare and Private Insurance)
Military Or Veterans Sponsored Nos
(Military or Veterans Sponsored, Not
Otherwise Specified (NOS))
Military Sponsored (including Champus
& Tricare) (Military Sponsored (including
CHAMPUS & TRICARE))
National Health Service (National Health
Service)
No Means Of Payment (no Insurance)
(No means of payment (no insurance))
Other (Other)
Private Insurance (Private Insurance)
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Self Pay (no Insurance) (Self Pay (No
Insurance))
Unknown (Unknown)
Veterans Sponsored (Veterans
Sponsored)
Attending Physician
Institution contact
Registrar
Country of Residence
Comments
Signature of treating physician (I have reviewed
the above data and agree the date are accurate
and correct)
Date (Note: Date must be on or before date of
registration)
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Lung Cancer NCT00324805 Eligibility - E1505 TEST
Registration Worksheet (step 1) - 2935543v1.0
E1505 TEST Registration Worksheet (step 1)
Chemotherapy With or Without Bevacizumab in Treating
Patients With Stage IB, Stage II, or Stage IIIA Non-Small
Lung Cancer That Was Removed By Surgery
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=71F8ECE9-
1DD6-C56F-E040-BB89AD4342B9
All rights reserved. Please visit https://medical-data-
models.org/forms/8763
E1505 TEST Registration Worksheet
(step 1)
Eligibility
First initial
Last initial
Has the eligibility checklist been completed
Yes
No
In the opinion of the investigator, is the patient
eligible?
Yes
No
Has written informed consent been obtained
Yes
No
Date Informed Consent Signed
Has HIPAA authorization been obtained
Exempt - Non-usa Participant (Exempt -
non-USA participant)
No: C49487 (No)
Yes: C49488 (Yes)
HIPAA Authorization Date
Planned Chemotherapy Regimen
Cisplatin And Docetaxel (Cisplatin and
Docetaxel)
Cisplatin And Gemcitabine (Cisplatin and
Gemcitabine)
Cisplatin And Pemetrexed (Cisplatin and
pemetrexed)
Cisplatin And Vinorelbine (Cisplatin and
Vinorelbine)
What is the patient's stage of disease
Stage Ib >/= 4 Cm (Stage IB >/= 4 cm)
Stage Ii Lung Cancer (Stage II)
Stage Iiia-n2 Lung Cancer (Stage IIIA-
N2)
Stage Iiia-t3n1 Lung Cancer (Stage IIIA-
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T3N1)
Histology
Non-small Cell Lung Carcinoma (Other
Non-Small Cell Lung Cancer)
Squamous Cell Carcinoma (Squamous
cell carcinoma)
Patient Gender
Female (FEMALE)
Male (MALE)
Principal Investigator
Phone
Fax Number
Email address
Senior Clinical Research Associate/Data
Manager
Phone
Fax Number
Email address
I agree to donate additional blood for research.
Yes
No
My specimens may be kept for use in research to
learn about, prevent, treat, or cure cancer.
Yes
No
My specimens may be kept for research about
other health problems (for example: causes of
diabetes, Alzheimer's disease, and heart
disease) (for example: causes of diabetes,
Alzheimer's disease, and heart disease)
Yes
No
Someone may contact me in the future to ask me
to allow other uses of my specimens.
Yes
No
Name of the contact person responsible for
sample submission
2 / 8
Lung Cancer NCT00324805 Eligibility - E1505 TEST Registration
Worksheet (step 1) - 2935543v1.0
Phone
FAX
Email
Race
Patient's Race
A Person Having Origins In Any Of The
Original Peoples Of North And South
America (including Central America),
And Who Maintains Tribal Affiliation Or
Community Attachment. (American
Indian or Alaska Native)
A Person Having Origins In Any Of The
Original Peoples Of The Far East,
Southeast Asia, Or The Indian
Subcontinent Including, For Example,
Cambodia, China, India, Japan, Korea,
Malaysia, Pakistan, The Philippine
Islands, Thailand, And Vietnam. (Asian)
A Person Having Origins In Any Of The
Black Racial Groups Of Africa. Terms
Such As "haitian" Or "negro" Can Be
Used In Addition To "black Or African
American." (Black or African American)
A Person Having Origins In Any Of The
Original Peoples Of Hawaii, Guam,
Samoa, Or Other Pacific Islands. (Native
Hawaiian or other Pacific Islander)
Not Provided Or Available (Not
Reported)
Could Not Be Determined Or Unsure
(Unknown)
A Person Having Origins In Any Of The
Original Peoples Of Europe, The Middle
East, Or North Africa. (White)
Patient Demographics / Pre-treatment
Characteristics
Patient's Sex
Female (F)
Male (M)
Birthdate (mm/yy)
ZIP Code
Patient Ethnicity
A Person Of Mexican, Puerto Rican,
Cuban, Central Or South American Or
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Other Spanish Culture Or Origin,
Regardless Of Race. (Hispanic or Latino)
A Person Not Meeting The Definition For
Hispanic Or Latino. (Not Hispanic or
Latino)
Not Provided Or Available (Not reported)
Could Not Be Determined Or Unsure
(Unknown)
Patient Hospital No.
Patient Social Security Number
Method of payment (check one)
Medicaid (Medicaid)
Medicaid And Medicare (Medicaid and
Medicare)
Medicare (Medicare)
Medicare And Private Insurance
(Medicare and Private Insurance)
Military Or Veterans Sponsored Nos
(Military or Veterans Sponsored, Not
Otherwise Specified (NOS))
Military Sponsored (including Champus
& Tricare) (Military Sponsored (including
CHAMPUS & TRICARE))
No Means Of Payment (no Insurance)
(No means of payment (no insurance))
Other (Other)
Private Insurance (Private Insurance)
Self Pay (no Insurance) (Self Pay (No
Insurance))
Unknown (Unknown)
Veterans Sponsored (Veterans
Sponsored)
Attending Physician
Institution contact
Registrar
Country of residence
Ascension Island (AC)
Andorra (AD)
United Arab Emirates (AE)
Afghanistan (AF)
Antigua And Barbuda (AG)
Anguilla (AI)
Albania (AL)
Armenia (AM)
Netherland Antilles (AN)
Angola (AO)
Antarctica (AQ)
Argentina (AR)
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American Samoa (AS)
Austria (AT)
Australia (AU)
Aruba (AW)
Azerbaidjan (AZ)
Bosnia-herzegovina (BA)
Barbados (BB)
Bangladesh (BD)
Belgium (BE)
Burkina Faso (BF)
Bulgaria (BG)
Bahrain (BH)
Burundi (BI)
Benin (BJ)
Bermuda (BM)
Brunei Darussalam (BN)
Bolivia (BO)
Brazil (BR)
Bahamas (BS)
Bhutan (BT)
Bouvet Island (BV)
Botswana (BW)
Belarus (BY)
Belize (BZ)
Canada (CA)
Cocos Isl. (CC)
Rep. Dem. Congo (CD)
Central African Rep. (CF)
Congo (CG)
Switzerland (CH)
Ivory Coast (CI)
Cook Islands (CK)
Chile (CL)
Cameroon (CM)
China (CN)
Colombia (CO)
Costa Rica (CR)
Cuba (CU)
Cape Verde (CV)
Christmas Island (CX)
Cyprus (CY)
Czech Republic (CZ)
Germany (DE)
Djibouti (DJ)
Denmark (DK)
Dominica (DM)
Dominican Republic (DO)
Algeria (DZ)
Ecuador (EC)
Estonia (EE)
Egypt (EG)
Western Sahara (EH)
Eritrea (ER)
Spain (ES)
Ethiopia (ET)
Finland (FI)
Fiji (FJ)
Falkland Isl. (FK)
Micronesia (FM)
Faroe Islands (FO)
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France (FR)
France (european Ter.) (FX)
Gabon (GA)
Great Britain (GB)
Grenada (GD)
Georgia (GE)
Guiana (fr.) (GF)
Guernsey (GG)
Ghana (GH)
Gibraltar (GI)
Greenland (GL)
Gambia (GM)
Guinea (GN)
Guadeloupe (fr.) (GP)
Equatorial Guinea (GQ)
Greece (GR)
South Georgia And South Sandwich
Islands (GS)
Guatemala (GT)
Guam (us) (GU)
Guinea Bissau (GW)
Guyana (GY)
Hong Kong (HK)
Heard & Mcdonald Isl. (HM)
Honduras (HN)
Croatia (HR)
Haiti (HT)
Hungary (HU)
Indonesia (ID)
Ireland (IE)
Israel (IL)
Isle Of Man (IM)
India (IN)
British Indian O. Ter. (IO)
Iraq (IQ)
Iran (IR)
Iceland (IS)
Italy (IT)
Jersey (JE)
Jamaica (JM)
Jordan (JO)
Japan (JP)
Kenya (KE)
Kyrgyz Republic (KG)
Cambodia (KH)
Kiribati (KI)
Comoros (KM)
St. Kitts Nevis Anguilla (KN)
Korea (north) (KP)
Korea (south) (KR)
Kuwait (KW)
Cayman Islands (KY)
Kazakstan (KZ)
Laos (LA)
Lebanon (LB)
Saint Lucia (LC)
Liechtenstein (LI)
Sri Lanka (LK)
Liberia (LR)
Lesotho (LS)
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Lithuania (LT)
Luxembourg (LU)
Latvia (LV)
Libya (LY)
Morocco (MA)
Monaco (MC)
Moldova (MD)
Madagascar (MG)
Marshall Islands (MH)
Macedonia (MK)
Mali (ML)
Myanmar (MM)
Mongolia (MN)
Macau (MO)
Northern Mariana Isl. (MP)
Martinique (fr.) (MQ)
Mauritania (MR)
Montserrat (MS)
Malta (MT)
Mauritius (MU)
Maldives (MV)
Malawi (MW)
Mexico (MX)
Malaysia (MY)
Mozambique (MZ)
Namibia (NA)
New Caledonia (fr.) (NC)
Niger (NE)
Norfolk Island (NF)
Nigeria (NG)
Nicaragua (NI)
Netherlands (NL)
Norway (NO)
Nepal (NP)
Nauru (NR)
Niue (NU)
New Zealand (NZ)
Oman (OM)
Other (Other)
Panama (PA)
Peru (PE)
Polynesia (fr.) (PF)
Papua New Guinea (PG)
Philippines (PH)
Pakistan (PK)
Poland (PL)
St. Pierre & Miquelon (PM)
Pitcairn (PN)
Puerto Rico (PR)
Portugal (PT)
Palau (PW)
Paraguay (PY)
Qatar (QA)
Reunion (fr.) (RE)
Romania (RO)
Russian Federation (RU)
Rwanda (RW)
Saudi Arabia (SA)
Solomon Islands (SB)
Seychelles (SC)
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Sudan (SD)
Sweden (SE)
Singapore (SG)
St. Helena (SH)
Slovenia (SI)
Svalbard & Jan Mayen Isl. (SJ)
Slovakia (SK)
Sierra Leone (SL)
San Marino (SM)
Senegal (SN)
Somalia (SO)
Suriname (SR)
St. Tome And Principe (ST)
Soviet Union (SU)
El Salvador (SV)
Syria (SY)
Swaziland (SZ)
Turks & Caicos Islands (TC)
Chad (TD)
French Southern Terr. (TF)
Togo (TG)
Thailand (TH)
Tadjikistan (TJ)
Tokelau (TK)
Turkmenistan (TM)
Tunisia (TN)
Tonga (TO)
East Timor (TP)
Turkey (TR)
Trinidad & Tobago (TT)
Tuvalu (TV)
Taiwan (TW)
Tanzania (TZ)
Ukraine (UA)
Uganda (UG)
United Kingdom (UK)
Us Minor Outlying Isl. (UM)
Usa (US)
Uruguay (UY)
Uzbekistan (UZ)
Vatican City State (VA)
St. Vincent & Grenadines (VC)
Venezuela (VE)
Virgin Islands (brit) (VG)
Virgin Islands (us) (VI)
Vietnam (VN)
Vanuatu (VU)
Wallis & Futuna Islands (WF)
Western Samoa (WS)
Yemen (YE)
Mayotte (YT)
Yugoslavia (YU)
South Africa (ZA)
Zambia (ZM)
Dem. Rep. Of Congo (ZR)
Zimbabwe (ZW)
Comments
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Lung Cancer NCT00103207 Eligibility - E1504
Registration Worksheet (step 1) - 2779425v1.0
E1504 Registration Worksheet (step 1)
Cetuximab in Treating Patients With Recurrent or Stage IIIB
or Stage IV Lung Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=55EEB706-
F047-150C-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/8765
E1504 Registration Worksheet (step
1)
Eligibility
First initial
Last initial
Has the eligibility checklist been completed
Yes
No
In the opinion of the investigator, is the patient
eligible?
Yes
No
Has written informed consent been obtained
Yes
No
Date Informed Consent Signed
Has HIPAA authorization been obtained
Exempt (Exempt)
No: C49487 (No)
Yes: C49488 (Yes)
HIPAA Authorization Date
Are samples being submitted for central
pathology review?
Yes
No
Have regulatory documents been submitted as
outline in the Drug Formulation and Procurement
Section of the protocol
Yes
No
I agree to participate in the laboratory research
studies that are being done as part of this clinical
trial.
Yes
No
My specimens may be kept for use in research to
learn about, prevent, treat, or cure cancer.
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Yes
No
My specimens may be kept for research about
other health problems (for example: causes of
diabetes, Alzheimer's disease, and heart
disease)
Yes
No
Someone may contact me in the future to ask me
to allow other uses of my specimens.
Yes
No
Patient Demographics / Pre-treatment
Characteristics
Patient's Sex
Female (F)
Male (M)
Birthdate (mm/yy)
Patient Race (check all that applyU.S. and
Canada only)
A Person Having Origins In Any Of The
Original Peoples Of North And South
America (including Central America),
And Who Maintains Tribal Affiliation Or
Community Attachment. (American
Indian or Alaska Native)
A Person Having Origins In Any Of The
Original Peoples Of The Far East,
Southeast Asia, Or The Indian
Subcontinent Including, For Example,
Cambodia, China, India, Japan, Korea,
Malaysia, Pakistan, The Philippine
Islands, Thailand, And Vietnam. (Asian)
A Person Having Origins In Any Of The
Black Racial Groups Of Africa. Terms
Such As "haitian" Or "negro" Can Be
Used In Addition To "black Or African
American." (Black or African American)
A Person Having Origins In Any Of The
Original Peoples Of Hawaii, Guam,
Samoa, Or Other Pacific Islands. (Native
Hawaiian or other Pacific Islander)
Not Provided Or Available (Not
Reported)
Could Not Be Determined Or Unsure
(Unknown)
A Person Having Origins In Any Of The
Original Peoples Of Europe, The Middle
East, Or North Africa. (White)
ZIP Code
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Patient Ethnicity
A Person Of Mexican, Puerto Rican,
Cuban, Central Or South American Or
Other Spanish Culture Or Origin,
Regardless Of Race. (Hispanic or Latino)
A Person Not Meeting The Definition For
Hispanic Or Latino. (Not Hispanic or
Latino)
Not Provided Or Available (Not reported)
Could Not Be Determined Or Unsure
(Unknown)
Patient Hospital No.
Patient Social Security Number
Method of payment (check one)
Medicaid (Medicaid)
Medicaid And Medicare (Medicaid and
Medicare)
Medicare (Medicare)
Medicare And Private Insurance
(Medicare and Private Insurance)
Military Or Veterans Sponsored Nos
(Military or Veterans Sponsored, Not
Otherwise Specified (NOS))
Military Sponsored (including Champus
& Tricare) (Military Sponsored (including
CHAMPUS & TRICARE))
National Health Service (National Health
Service)
No Means Of Payment (no Insurance)
(No means of payment (no insurance))
Other (Other)
Private Insurance (Private Insurance)
Self Pay (no Insurance) (Self Pay (No
Insurance))
Unknown (Unknown)
Veterans Sponsored (Veterans
Sponsored)
Attending Physician
Institution contact
Registrar
Country of Residence (if not USA)
Ascension Island (AC)
Andorra (AD)
United Arab Emirates (AE)
Afghanistan (AF)
Antigua And Barbuda (AG)
Anguilla (AI)
Albania (AL)
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Armenia (AM)
Netherland Antilles (AN)
Angola (AO)
Antarctica (AQ)
Argentina (AR)
American Samoa (AS)
Austria (AT)
Australia (AU)
Aruba (AW)
Azerbaidjan (AZ)
Bosnia-herzegovina (BA)
Barbados (BB)
Bangladesh (BD)
Belgium (BE)
Burkina Faso (BF)
Bulgaria (BG)
Bahrain (BH)
Burundi (BI)
Benin (BJ)
Bermuda (BM)
Brunei Darussalam (BN)
Bolivia (BO)
Brazil (BR)
Bahamas (BS)
Bhutan (BT)
Bouvet Island (BV)
Botswana (BW)
Belarus (BY)
Belize (BZ)
Canada (CA)
Cocos Isl. (CC)
Rep. Dem. Congo (CD)
Central African Rep. (CF)
Congo (CG)
Switzerland (CH)
Ivory Coast (CI)
Cook Islands (CK)
Chile (CL)
Cameroon (CM)
China (CN)
Colombia (CO)
Costa Rica (CR)
Cuba (CU)
Cape Verde (CV)
Christmas Island (CX)
Cyprus (CY)
Czech Republic (CZ)
Germany (DE)
Djibouti (DJ)
Denmark (DK)
Dominica (DM)
Dominican Republic (DO)
Algeria (DZ)
Ecuador (EC)
Estonia (EE)
Egypt (EG)
Western Sahara (EH)
Eritrea (ER)
Spain (ES)
Ethiopia (ET)
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Finland (FI)
Fiji (FJ)
Falkland Isl. (FK)
Micronesia (FM)
Faroe Islands (FO)
France (FR)
France (european Ter.) (FX)
Gabon (GA)
Great Britain (GB)
Grenada (GD)
Georgia (GE)
Guiana (fr.) (GF)
Guernsey (GG)
Ghana (GH)
Gibraltar (GI)
Greenland (GL)
Gambia (GM)
Guinea (GN)
Guadeloupe (fr.) (GP)
Equatorial Guinea (GQ)
Greece (GR)
South Georgia And South Sandwich
Islands (GS)
Guatemala (GT)
Guam (us) (GU)
Guinea Bissau (GW)
Guyana (GY)
Hong Kong (HK)
Heard & Mcdonald Isl. (HM)
Honduras (HN)
Croatia (HR)
Haiti (HT)
Hungary (HU)
Indonesia (ID)
Ireland (IE)
Israel (IL)
Isle Of Man (IM)
India (IN)
British Indian O. Ter. (IO)
Iraq (IQ)
Iran (IR)
Iceland (IS)
Italy (IT)
Jersey (JE)
Jamaica (JM)
Jordan (JO)
Japan (JP)
Kenya (KE)
Kyrgyz Republic (KG)
Cambodia (KH)
Kiribati (KI)
Comoros (KM)
St. Kitts Nevis Anguilla (KN)
Korea (north) (KP)
Korea (south) (KR)
Kuwait (KW)
Cayman Islands (KY)
Kazakstan (KZ)
Laos (LA)
Lebanon (LB)
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Saint Lucia (LC)
Liechtenstein (LI)
Sri Lanka (LK)
Liberia (LR)
Lesotho (LS)
Lithuania (LT)
Luxembourg (LU)
Latvia (LV)
Libya (LY)
Morocco (MA)
Monaco (MC)
Moldova (MD)
Madagascar (MG)
Marshall Islands (MH)
Macedonia (MK)
Mali (ML)
Myanmar (MM)
Mongolia (MN)
Macau (MO)
Northern Mariana Isl. (MP)
Martinique (fr.) (MQ)
Mauritania (MR)
Montserrat (MS)
Malta (MT)
Mauritius (MU)
Maldives (MV)
Malawi (MW)
Mexico (MX)
Malaysia (MY)
Mozambique (MZ)
Namibia (NA)
New Caledonia (fr.) (NC)
Niger (NE)
Norfolk Island (NF)
Nigeria (NG)
Nicaragua (NI)
Netherlands (NL)
Norway (NO)
Nepal (NP)
Nauru (NR)
Niue (NU)
New Zealand (NZ)
Oman (OM)
Other (Other)
Panama (PA)
Peru (PE)
Polynesia (fr.) (PF)
Papua New Guinea (PG)
Philippines (PH)
Pakistan (PK)
Poland (PL)
St. Pierre & Miquelon (PM)
Pitcairn (PN)
Puerto Rico (PR)
Portugal (PT)
Palau (PW)
Paraguay (PY)
Qatar (QA)
Reunion (fr.) (RE)
Romania (RO)
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Russian Federation (RU)
Rwanda (RW)
Saudi Arabia (SA)
Solomon Islands (SB)
Seychelles (SC)
Sudan (SD)
Sweden (SE)
Singapore (SG)
St. Helena (SH)
Slovenia (SI)
Svalbard & Jan Mayen Isl. (SJ)
Slovakia (SK)
Sierra Leone (SL)
San Marino (SM)
Senegal (SN)
Somalia (SO)
Suriname (SR)
St. Tome And Principe (ST)
Soviet Union (SU)
El Salvador (SV)
Syria (SY)
Swaziland (SZ)
Turks & Caicos Islands (TC)
Chad (TD)
French Southern Terr. (TF)
Togo (TG)
Thailand (TH)
Tadjikistan (TJ)
Tokelau (TK)
Turkmenistan (TM)
Tunisia (TN)
Tonga (TO)
East Timor (TP)
Turkey (TR)
Trinidad & Tobago (TT)
Tuvalu (TV)
Taiwan (TW)
Tanzania (TZ)
Ukraine (UA)
Uganda (UG)
United Kingdom (UK)
Us Minor Outlying Isl. (UM)
Usa (US)
Uruguay (UY)
Uzbekistan (UZ)
Vatican City State (VA)
St. Vincent & Grenadines (VC)
Venezuela (VE)
Virgin Islands (brit) (VG)
Virgin Islands (us) (VI)
Vietnam (VN)
Vanuatu (VU)
Wallis & Futuna Islands (WF)
Western Samoa (WS)
Yemen (YE)
Mayotte (YT)
Yugoslavia (YU)
South Africa (ZA)
Zambia (ZM)
Dem. Rep. Of Congo (ZR)
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Zimbabwe (ZW)
Comments
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Lung Cancer NCT00828009 Eligibility - E6508
Registration Worksheet (step 1) - 2862322v1.0
E6508 Registration Worksheet (step 1)
BLP25 Liposome Vaccine and Bevacizumab After
Chemotherapy and Radiation Therapy in Treating Patients
With Newly Diagnosed Stage IIIA or Stage IIIB Non-Small
Cell Lung Cancer That Cannot Be Removed by Surgery
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=683ADC5E-
C609-081D-E040-BB89AD4336AC
All rights reserved. Please visit https://medical-data-
models.org/forms/8767
E6508 Registration Worksheet (step
1)
Eligibility
First initial
Last initial
Has the eligibility checklist been completed
Yes
No
In the opinion of the investigator, is the patient
eligible?
Yes
No
Has written informed consent been obtained
Yes
No
Date Informed Consent Signed
Has HIPAA authorization been obtained
Exempt - Non-usa Participant (Exempt -
non-USA participant)
No: C49487 (No)
Yes: C49488 (Yes)
HIPAA Authorization Date
I agree to participate in the laboratory research
studies that are being done as part of this clinical
trial.
Yes
No
I agree my tissue will be submitted for research.
Yes
No
My specimens may be kept for use in research to
learn about, prevent, treat, or cure cancer.
Yes
No
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My specimens may be kept for research about
other health problems (for example: causes of
diabetes, Alzheimer's disease, and heart
disease)
Yes
No
Someone may contact me in the future to ask me
to allow other uses of my specimens.
Yes
No
Name of the contact person responsible for
sample submission
Phone
FAX
Email
If an ECOG patient is to receive radiation therapy,
will it be given at the registering institution
Yes
No
Name of the institution that will administer the
radiation therapy
Race
Patient's Race
A Person Having Origins In Any Of The
Original Peoples Of North And South
America (including Central America),
And Who Maintains Tribal Affiliation Or
Community Attachment. (American
Indian or Alaska Native)
A Person Having Origins In Any Of The
Original Peoples Of The Far East,
Southeast Asia, Or The Indian
Subcontinent Including, For Example,
Cambodia, China, India, Japan, Korea,
Malaysia, Pakistan, The Philippine
Islands, Thailand, And Vietnam. (Asian)
A Person Having Origins In Any Of The
Black Racial Groups Of Africa. Terms
Such As "haitian" Or "negro" Can Be
Used In Addition To "black Or African
American." (Black or African American)
A Person Having Origins In Any Of The
Original Peoples Of Hawaii, Guam,
Samoa, Or Other Pacific Islands. (Native
Hawaiian or other Pacific Islander)
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Not Provided Or Available (Not
Reported)
Could Not Be Determined Or Unsure
(Unknown)
A Person Having Origins In Any Of The
Original Peoples Of Europe, The Middle
East, Or North Africa. (White)
Patient Demographics / Pre-treatment
Characteristics
Patient's Sex
Female (F)
Male (M)
Birthdate (mm/yy)
ZIP Code
Patient Ethnicity
A Person Of Mexican, Puerto Rican,
Cuban, Central Or South American Or
Other Spanish Culture Or Origin,
Regardless Of Race. (Hispanic or Latino)
A Person Not Meeting The Definition For
Hispanic Or Latino. (Not Hispanic or
Latino)
Not Provided Or Available (Not reported)
Could Not Be Determined Or Unsure
(Unknown)
Patient Hospital No.
Patient Social Security Number
Method of payment (check one)
Medicaid (Medicaid)
Medicaid And Medicare (Medicaid and
Medicare)
Medicare (Medicare)
Medicare And Private Insurance
(Medicare and Private Insurance)
Military Or Veterans Sponsored Nos
(Military or Veterans Sponsored, Not
Otherwise Specified (NOS))
Military Sponsored (including Champus
& Tricare) (Military Sponsored (including
CHAMPUS & TRICARE))
No Means Of Payment (no Insurance)
(No means of payment (no insurance))
Other (Other)
Private Insurance (Private Insurance)
Self Pay (no Insurance) (Self Pay (No
Insurance))
Unknown (Unknown)
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Veterans Sponsored (Veterans
Sponsored)
Attending Physician
Institution contact
Registrar
Country of residence
Ascension Island (AC)
Andorra (AD)
United Arab Emirates (AE)
Afghanistan (AF)
Antigua And Barbuda (AG)
Anguilla (AI)
Albania (AL)
Armenia (AM)
Netherland Antilles (AN)
Angola (AO)
Antarctica (AQ)
Argentina (AR)
American Samoa (AS)
Austria (AT)
Australia (AU)
Aruba (AW)
Azerbaidjan (AZ)
Bosnia-herzegovina (BA)
Barbados (BB)
Bangladesh (BD)
Belgium (BE)
Burkina Faso (BF)
Bulgaria (BG)
Bahrain (BH)
Burundi (BI)
Benin (BJ)
Bermuda (BM)
Brunei Darussalam (BN)
Bolivia (BO)
Brazil (BR)
Bahamas (BS)
Bhutan (BT)
Bouvet Island (BV)
Botswana (BW)
Belarus (BY)
Belize (BZ)
Canada (CA)
Cocos Isl. (CC)
Rep. Dem. Congo (CD)
Central African Rep. (CF)
Congo (CG)
Switzerland (CH)
Ivory Coast (CI)
Cook Islands (CK)
Chile (CL)
Cameroon (CM)
China (CN)
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Colombia (CO)
Costa Rica (CR)
Cuba (CU)
Cape Verde (CV)
Christmas Island (CX)
Cyprus (CY)
Czech Republic (CZ)
Germany (DE)
Djibouti (DJ)
Denmark (DK)
Dominica (DM)
Dominican Republic (DO)
Algeria (DZ)
Ecuador (EC)
Estonia (EE)
Egypt (EG)
Western Sahara (EH)
Eritrea (ER)
Spain (ES)
Ethiopia (ET)
Finland (FI)
Fiji (FJ)
Falkland Isl. (FK)
Micronesia (FM)
Faroe Islands (FO)
France (FR)
France (european Ter.) (FX)
Gabon (GA)
Great Britain (GB)
Grenada (GD)
Georgia (GE)
Guiana (fr.) (GF)
Guernsey (GG)
Ghana (GH)
Gibraltar (GI)
Greenland (GL)
Gambia (GM)
Guinea (GN)
Guadeloupe (fr.) (GP)
Equatorial Guinea (GQ)
Greece (GR)
South Georgia And South Sandwich
Islands (GS)
Guatemala (GT)
Guam (us) (GU)
Guinea Bissau (GW)
Guyana (GY)
Hong Kong (HK)
Heard & Mcdonald Isl. (HM)
Honduras (HN)
Croatia (HR)
Haiti (HT)
Hungary (HU)
Indonesia (ID)
Ireland (IE)
Israel (IL)
Isle Of Man (IM)
India (IN)
British Indian O. Ter. (IO)
Iraq (IQ)
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Iran (IR)
Iceland (IS)
Italy (IT)
Jersey (JE)
Jamaica (JM)
Jordan (JO)
Japan (JP)
Kenya (KE)
Kyrgyz Republic (KG)
Cambodia (KH)
Kiribati (KI)
Comoros (KM)
St. Kitts Nevis Anguilla (KN)
Korea (north) (KP)
Korea (south) (KR)
Kuwait (KW)
Cayman Islands (KY)
Kazakstan (KZ)
Laos (LA)
Lebanon (LB)
Saint Lucia (LC)
Liechtenstein (LI)
Sri Lanka (LK)
Liberia (LR)
Lesotho (LS)
Lithuania (LT)
Luxembourg (LU)
Latvia (LV)
Libya (LY)
Morocco (MA)
Monaco (MC)
Moldova (MD)
Madagascar (MG)
Marshall Islands (MH)
Macedonia (MK)
Mali (ML)
Myanmar (MM)
Mongolia (MN)
Macau (MO)
Northern Mariana Isl. (MP)
Martinique (fr.) (MQ)
Mauritania (MR)
Montserrat (MS)
Malta (MT)
Mauritius (MU)
Maldives (MV)
Malawi (MW)
Mexico (MX)
Malaysia (MY)
Mozambique (MZ)
Namibia (NA)
New Caledonia (fr.) (NC)
Niger (NE)
Norfolk Island (NF)
Nigeria (NG)
Nicaragua (NI)
Netherlands (NL)
Norway (NO)
Nepal (NP)
Nauru (NR)
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Niue (NU)
New Zealand (NZ)
Oman (OM)
Other (Other)
Panama (PA)
Peru (PE)
Polynesia (fr.) (PF)
Papua New Guinea (PG)
Philippines (PH)
Pakistan (PK)
Poland (PL)
St. Pierre & Miquelon (PM)
Pitcairn (PN)
Puerto Rico (PR)
Portugal (PT)
Palau (PW)
Paraguay (PY)
Qatar (QA)
Reunion (fr.) (RE)
Romania (RO)
Russian Federation (RU)
Rwanda (RW)
Saudi Arabia (SA)
Solomon Islands (SB)
Seychelles (SC)
Sudan (SD)
Sweden (SE)
Singapore (SG)
St. Helena (SH)
Slovenia (SI)
Svalbard & Jan Mayen Isl. (SJ)
Slovakia (SK)
Sierra Leone (SL)
San Marino (SM)
Senegal (SN)
Somalia (SO)
Suriname (SR)
St. Tome And Principe (ST)
Soviet Union (SU)
El Salvador (SV)
Syria (SY)
Swaziland (SZ)
Turks & Caicos Islands (TC)
Chad (TD)
French Southern Terr. (TF)
Togo (TG)
Thailand (TH)
Tadjikistan (TJ)
Tokelau (TK)
Turkmenistan (TM)
Tunisia (TN)
Tonga (TO)
East Timor (TP)
Turkey (TR)
Trinidad & Tobago (TT)
Tuvalu (TV)
Taiwan (TW)
Tanzania (TZ)
Ukraine (UA)
Uganda (UG)
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United Kingdom (UK)
Us Minor Outlying Isl. (UM)
Usa (US)
Uruguay (UY)
Uzbekistan (UZ)
Vatican City State (VA)
St. Vincent & Grenadines (VC)
Venezuela (VE)
Virgin Islands (brit) (VG)
Virgin Islands (us) (VI)
Vietnam (VN)
Vanuatu (VU)
Wallis & Futuna Islands (WF)
Western Samoa (WS)
Yemen (YE)
Mayotte (YT)
Yugoslavia (YU)
South Africa (ZA)
Zambia (ZM)
Dem. Rep. Of Congo (ZR)
Zimbabwe (ZW)
Comments
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Breast Cancer NCT00075764 Follow-Up - SOUTHWEST ONCOLOGY GROUP
S0226 Notice of First Post-Protocol Treatment Regimen - 2541770v1.0
SOUTHWEST ONCOLOGY GROUP S0226 Notice of First
Post-Protocol Treatment Regimen
S0226 Anastrozole With or Without Fulvestrant as First-
Line Therapy in Postmenopausal Women With Metastatic
Breast Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=22258139-
0B75-658A-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/8771
SOUTHWEST ONCOLOGY GROUP
S0226 Notice of First Post-Protocol
Treatment Regimen
Header
SWOG Patient ID
SWOG Study No.
Registration Step
Patient Initials (L, F M)
Institution/Affiliate
Physician (Groups other than SWOG)
Group Name
Study No.
Pt. ID
Status
Treatment Start Date
First treatment regimen received after off protocol
treatment (after off S0226 protocol treatment -
select all that apply)
Chemotherapy (Chemotherapy)
Hormonal Therapy (Hormonal Therapy)
Other Therapy (Other therapy)
Agent Name
Comments
1 / 1
Multiple Myeloma and Plasma Cell Neoplasm NCT00522392
Eligibility - E1A05 Registration Worksheet (step 1) - 2948474v1.0
E1A05 Registration Worksheet (step 1)
Bortezomib and Dexamethasone With or Without
Lenalidomide in Treating Patients With Multiple Myeloma
Previously Treated With Dexamethasone
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=74CCB3AB-
1EF3-A75A-E040-BB89AD431F27
All rights reserved. Please visit https://medical-data-
models.org/forms/8774
E1A05 Registration Worksheet (step
1)
Eligibility
First initial
Last initial
Has the eligibility checklist been completed
Yes
No
In the opinion of the investigator, is the patient
eligible?
Yes
No
Has written informed consent been obtained
Yes
No
Date Informed Consent Signed
Has HIPAA authorization been obtained
Exempt - Non-usa Participant (Exempt -
non-USA participant)
No: C49487 (No)
Yes: C49488 (Yes)
HIPAA Authorization Date
Prior induction therapy
No Prior Lenalidomide And
Dexamethasone (No prior lenalidomide
and dexamethasone)
Dexamethasone Lenalidomide (Prior
lenalidomide and dexamethasone)
Complete response
Yes
No
If the patient has been registered to E3A05,
please enter the ECOG patient ID assigned.
Others enter 'N/A'.
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My specimens may be kept for use in research to
learn about, prevent, treat, or cure cancer.
Yes
No
My specimens may be kept for use in research
about other health problems (for example: causes
of diabetes, Alzheimer's disease, or heart
disease)
Yes
No
Someone from this institution may contact me in
the future to ask me to take part in more
research.
Yes
No
Patient Demographics / Pre-treatment
Characteristics
Patient's Sex
Female (F)
Male (M)
Birthdate (mm/yy)
Patient's Race
A Person Having Origins In Any Of The
Original Peoples Of North And South
America (including Central America),
And Who Maintains Tribal Affiliation Or
Community Attachment. (American
Indian or Alaska Native)
A Person Having Origins In Any Of The
Original Peoples Of The Far East,
Southeast Asia, Or The Indian
Subcontinent Including, For Example,
Cambodia, China, India, Japan, Korea,
Malaysia, Pakistan, The Philippine
Islands, Thailand, And Vietnam. (Asian)
A Person Having Origins In Any Of The
Black Racial Groups Of Africa. Terms
Such As "haitian" Or "negro" Can Be
Used In Addition To "black Or African
American." (Black or African American)
A Person Having Origins In Any Of The
Original Peoples Of Hawaii, Guam,
Samoa, Or Other Pacific Islands. (Native
Hawaiian or other Pacific Islander)
Not Provided Or Available (Not
Reported)
Could Not Be Determined Or Unsure
(Unknown)
A Person Having Origins In Any Of The
Original Peoples Of Europe, The Middle
East, Or North Africa. (White)
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ZIP Code
Patient Ethnicity
A Person Of Mexican, Puerto Rican,
Cuban, Central Or South American Or
Other Spanish Culture Or Origin,
Regardless Of Race. (Hispanic or Latino)
A Person Not Meeting The Definition For
Hispanic Or Latino. (Not Hispanic or
Latino)
Not Provided Or Available (Not reported)
Could Not Be Determined Or Unsure
(Unknown)
Patient Hospital No.
Patient Social Security Number
Method of payment (check one)
Medicaid (Medicaid)
Medicaid And Medicare (Medicaid and
Medicare)
Medicare (Medicare)
Medicare And Private Insurance
(Medicare and Private Insurance)
Military Or Veterans Sponsored Nos
(Military or Veterans Sponsored, Not
Otherwise Specified (NOS))
Military Sponsored (including Champus
& Tricare) (Military Sponsored (including
CHAMPUS & TRICARE))
No Means Of Payment (no Insurance)
(No means of payment (no insurance))
Other (Other)
Private Insurance (Private Insurance)
Self Pay (no Insurance) (Self Pay (No
Insurance))
Unknown (Unknown)
Veterans Sponsored (Veterans
Sponsored)
Country of residence
Ascension Island (AC)
Andorra (AD)
United Arab Emirates (AE)
Afghanistan (AF)
Antigua And Barbuda (AG)
Anguilla (AI)
Albania (AL)
Armenia (AM)
Netherland Antilles (AN)
Angola (AO)
Antarctica (AQ)
Argentina (AR)
American Samoa (AS)
Austria (AT)
Australia (AU)
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Aruba (AW)
Azerbaidjan (AZ)
Bosnia-herzegovina (BA)
Barbados (BB)
Bangladesh (BD)
Belgium (BE)
Burkina Faso (BF)
Bulgaria (BG)
Bahrain (BH)
Burundi (BI)
Benin (BJ)
Bermuda (BM)
Brunei Darussalam (BN)
Bolivia (BO)
Brazil (BR)
Bahamas (BS)
Bhutan (BT)
Bouvet Island (BV)
Botswana (BW)
Belarus (BY)
Belize (BZ)
Canada (CA)
Cocos Isl. (CC)
Rep. Dem. Congo (CD)
Central African Rep. (CF)
Congo (CG)
Switzerland (CH)
Ivory Coast (CI)
Cook Islands (CK)
Chile (CL)
Cameroon (CM)
China (CN)
Colombia (CO)
Costa Rica (CR)
Cuba (CU)
Cape Verde (CV)
Christmas Island (CX)
Cyprus (CY)
Czech Republic (CZ)
Germany (DE)
Djibouti (DJ)
Denmark (DK)
Dominica (DM)
Dominican Republic (DO)
Algeria (DZ)
Ecuador (EC)
Estonia (EE)
Egypt (EG)
Western Sahara (EH)
Eritrea (ER)
Spain (ES)
Ethiopia (ET)
Finland (FI)
Fiji (FJ)
Falkland Isl. (FK)
Micronesia (FM)
Faroe Islands (FO)
France (FR)
France (european Ter.) (FX)
Gabon (GA)
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Great Britain (GB)
Grenada (GD)
Georgia (GE)
Guiana (fr.) (GF)
Guernsey (GG)
Ghana (GH)
Gibraltar (GI)
Greenland (GL)
Gambia (GM)
Guinea (GN)
Guadeloupe (fr.) (GP)
Equatorial Guinea (GQ)
Greece (GR)
South Georgia And South Sandwich
Islands (GS)
Guatemala (GT)
Guam (us) (GU)
Guinea Bissau (GW)
Guyana (GY)
Hong Kong (HK)
Heard & Mcdonald Isl. (HM)
Honduras (HN)
Croatia (HR)
Haiti (HT)
Hungary (HU)
Indonesia (ID)
Ireland (IE)
Israel (IL)
Isle Of Man (IM)
India (IN)
British Indian O. Ter. (IO)
Iraq (IQ)
Iran (IR)
Iceland (IS)
Italy (IT)
Jersey (JE)
Jamaica (JM)
Jordan (JO)
Japan (JP)
Kenya (KE)
Kyrgyz Republic (KG)
Cambodia (KH)
Kiribati (KI)
Comoros (KM)
St. Kitts Nevis Anguilla (KN)
Korea (north) (KP)
Korea (south) (KR)
Kuwait (KW)
Cayman Islands (KY)
Kazakstan (KZ)
Laos (LA)
Lebanon (LB)
Saint Lucia (LC)
Liechtenstein (LI)
Sri Lanka (LK)
Liberia (LR)
Lesotho (LS)
Lithuania (LT)
Luxembourg (LU)
Latvia (LV)
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Libya (LY)
Morocco (MA)
Monaco (MC)
Moldova (MD)
Madagascar (MG)
Marshall Islands (MH)
Macedonia (MK)
Mali (ML)
Myanmar (MM)
Mongolia (MN)
Macau (MO)
Northern Mariana Isl. (MP)
Martinique (fr.) (MQ)
Mauritania (MR)
Montserrat (MS)
Malta (MT)
Mauritius (MU)
Maldives (MV)
Malawi (MW)
Mexico (MX)
Malaysia (MY)
Mozambique (MZ)
Namibia (NA)
New Caledonia (fr.) (NC)
Niger (NE)
Norfolk Island (NF)
Nigeria (NG)
Nicaragua (NI)
Netherlands (NL)
Norway (NO)
Nepal (NP)
Nauru (NR)
Niue (NU)
New Zealand (NZ)
Oman (OM)
Other (Other)
Panama (PA)
Peru (PE)
Polynesia (fr.) (PF)
Papua New Guinea (PG)
Philippines (PH)
Pakistan (PK)
Poland (PL)
St. Pierre & Miquelon (PM)
Pitcairn (PN)
Puerto Rico (PR)
Portugal (PT)
Palau (PW)
Paraguay (PY)
Qatar (QA)
Reunion (fr.) (RE)
Romania (RO)
Russian Federation (RU)
Rwanda (RW)
Saudi Arabia (SA)
Solomon Islands (SB)
Seychelles (SC)
Sudan (SD)
Sweden (SE)
Singapore (SG)
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St. Helena (SH)
Slovenia (SI)
Svalbard & Jan Mayen Isl. (SJ)
Slovakia (SK)
Sierra Leone (SL)
San Marino (SM)
Senegal (SN)
Somalia (SO)
Suriname (SR)
St. Tome And Principe (ST)
Soviet Union (SU)
El Salvador (SV)
Syria (SY)
Swaziland (SZ)
Turks & Caicos Islands (TC)
Chad (TD)
French Southern Terr. (TF)
Togo (TG)
Thailand (TH)
Tadjikistan (TJ)
Tokelau (TK)
Turkmenistan (TM)
Tunisia (TN)
Tonga (TO)
East Timor (TP)
Turkey (TR)
Trinidad & Tobago (TT)
Tuvalu (TV)
Taiwan (TW)
Tanzania (TZ)
Ukraine (UA)
Uganda (UG)
United Kingdom (UK)
Us Minor Outlying Isl. (UM)
Usa (US)
Uruguay (UY)
Uzbekistan (UZ)
Vatican City State (VA)
St. Vincent & Grenadines (VC)
Venezuela (VE)
Virgin Islands (brit) (VG)
Virgin Islands (us) (VI)
Vietnam (VN)
Vanuatu (VU)
Wallis & Futuna Islands (WF)
Western Samoa (WS)
Yemen (YE)
Mayotte (YT)
Yugoslavia (YU)
South Africa (ZA)
Zambia (ZM)
Dem. Rep. Of Congo (ZR)
Zimbabwe (ZW)
Comments
I Have Reviewed The Above Data And
Agree The Date Are Accurate And Correct
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Signature of treating physician
Date
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Lymphoma NCT00598169 Demographic - AMC-
053 Demographic Form (DEM) - 3122339v1.0
AMC-053 Demographic Form (DEM)
Bortezomib, Ifosfamide, Carboplatin, and Etoposide, With
or Without Rituximab, in Treating Patients With Relapsed or
Refractory AIDS-Related Non-Hodgkin Lymphoma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=8B708D70-
684B-F9DE-E040-BB89AD43114E
All rights reserved. Please visit https://medical-data-
models.org/forms/8776
AMC-053 Demographic Form (DEM)
Header
Patient Initials (First, Last)
Patient's Date of Birth (mm/dd/yyyy)
Gender
Female (FEMALE)
Male (MALE)
Ethnicity
A Person Of Mexican, Puerto Rican,
Cuban, Central Or South American Or
Other Spanish Culture Or Origin,
Regardless Of Race. (Hispanic or Latino)
A Person Not Meeting The Definition For
Hispanic Or Latino. (Not Hispanic or
Latino)
Could Not Be Determined Or Unsure
(Unknown)
Race (check all that apply)
A Person Having Origins In Any Of The
Original Peoples Of North And South
America (including Central America),
And Who Maintains Tribal Affiliation Or
Community Attachment. (American
Indian or Alaska Native)
A Person Having Origins In Any Of The
Original Peoples Of The Far East,
Southeast Asia, Or The Indian
Subcontinent Including, For Example,
Cambodia, China, India, Japan, Korea,
Malaysia, Pakistan, The Philippine
Islands, Thailand, And Vietnam. (Asian)
A Person Having Origins In Any Of The
Black Racial Groups Of Africa. Terms
Such As "haitian" Or "negro" Can Be
Used In Addition To "black Or African
American." (Black or African American)
A Person Having Origins In Any Of The
Original Peoples Of Hawaii, Guam,
Samoa, Or Other Pacific Islands. (Native
Hawaiian or other Pacific Islander)
Could Not Be Determined Or Unsure
(Unknown)
A Person Having Origins In Any Of The
Original Peoples Of Europe, The Middle
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East, Or North Africa. (White)
Patient Zip Code (xxxxx)
Method of Payment
Medicaid (Medicaid)
Medicaid And Medicare (Medicaid and
Medicare)
Medicare (Medicare)
Medicare And Private Insurance
(Medicare and Private Insurance)
Military Or Veterans Sponsored Nos
(Military or Veterans Sponsored, Not
Otherwise Specified (NOS))
Military Sponsored (including Champus
& Tricare) (Military Sponsored (including
CHAMPUS & TRICARE))
No Means Of Payment (no Insurance)
(No means of payment (no insurance))
Other (Other)
Private Insurance (Private Insurance)
Self Pay (no Insurance) (Self Pay (No
Insurance))
Unknown (Unknown)
Veterans Sponsored (Veterans
Sponsored)
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Lymphoma NCT00598169 Demographic - AMC-053 Demographic Form
(DEM) - 3122339v1.0
Lymphoma NCT00981097 Demographic - AMC-
064 Demographic Form (DEM) - 2983192v1.0
AMC-064 Demographic Form (DEM)
Study of Blood and Tissue Samples From Patients With
Aggressive Non-Hodgkin B-Cell Lymphoma or Hodgkin
Lymphoma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=7C9955D9-
C344-BD2D-E040-BB89AD431FA0
All rights reserved. Please visit https://medical-data-
models.org/forms/8777
AMC-064 Demographic Form (DEM)
Header
Patient Initials (First, Last)
Patient's Date of Birth (mm/dd/yyyy)
Gender
Female (FEMALE)
Male (MALE)
Ethnicity
A Person Of Mexican, Puerto Rican,
Cuban, Central Or South American Or
Other Spanish Culture Or Origin,
Regardless Of Race. (Hispanic or Latino)
A Person Not Meeting The Definition For
Hispanic Or Latino. (Not Hispanic or
Latino)
Could Not Be Determined Or Unsure
(Unknown)
Race (check all that apply)
A Person Having Origins In Any Of The
Original Peoples Of North And South
America (including Central America),
And Who Maintains Tribal Affiliation Or
Community Attachment. (American
Indian or Alaska Native)
A Person Having Origins In Any Of The
Original Peoples Of The Far East,
Southeast Asia, Or The Indian
Subcontinent Including, For Example,
Cambodia, China, India, Japan, Korea,
Malaysia, Pakistan, The Philippine
Islands, Thailand, And Vietnam. (Asian)
A Person Having Origins In Any Of The
Black Racial Groups Of Africa. Terms
Such As "haitian" Or "negro" Can Be
Used In Addition To "black Or African
American." (Black or African American)
A Person Having Origins In Any Of The
Original Peoples Of Hawaii, Guam,
Samoa, Or Other Pacific Islands. (Native
Hawaiian or other Pacific Islander)
Could Not Be Determined Or Unsure
(Unknown)
A Person Having Origins In Any Of The
Original Peoples Of Europe, The Middle
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East, Or North Africa. (White)
Patient Zip Code (xxxxx)
Method of Payment
Medicaid (Medicaid)
Medicaid And Medicare (Medicaid and
Medicare)
Medicare (Medicare)
Medicare And Private Insurance
(Medicare and Private Insurance)
Military Or Veterans Sponsored Nos
(Military or Veterans Sponsored, Not
Otherwise Specified (NOS))
Military Sponsored (including Champus
& Tricare) (Military Sponsored (including
CHAMPUS & TRICARE))
No Means Of Payment (no Insurance)
(No means of payment (no insurance))
Other (Other)
Private Insurance (Private Insurance)
Self Pay (no Insurance) (Self Pay (No
Insurance))
Unknown (Unknown)
Veterans Sponsored (Veterans
Sponsored)
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Lymphoma NCT00981097 Demographic - AMC-064 Demographic Form
(DEM) - 2983192v1.0
Multiple Myeloma and Plasma Cell Neoplasm NCT00602641
Eligibility - E1A06 Registration Worksheet (Step 1) - 2762148v1.0
E1A06 Registration Worksheet (Step 1)
Melphalan, Prednisone, and Thalidomide or Lenalidomide
in Treating Patients With Newly Diagnosed Multiple
Myeloma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=510B294D-
430D-4275-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/8778
E1A06 Registration Worksheet (Step
1)
Eligibility
First initial
Last initial
Has the eligibility checklist been completed
Yes
No
In the opinion of the investigator, is the patient
eligible?
Yes
No
Has written informed consent been obtained
Yes
No
Date Informed Consent Signed
Has HIPAA authorization been obtained
Exempt - Non-usa Participant (Exempt -
non-USA participant)
No: C49487 (No)
Yes: C49488 (Yes)
HIPAA Authorization Date
Age at Registration
ISS stage
I (I)
Ii (II)
Iii (III)
If the patient has been registered to E3A05,
please enter the ECOG patient ID assigned.
Others enter 'N/A'.
I agree to participate in the laboratory research
studies that are being done as part of this clinical
trial.
1 / 8
Yes
No
My specimens may be kept for use in research to
learn about, prevent, treat, or cure cancer.
Yes
No
My specimens may be kept for use in research
about other health problems (for example: causes
of diabetes, Alzheimer's disease, or heart
disease)
Yes
No
Someone from this institution may contact me in
the future to ask me to take part in more
research.
Yes
No
Patient Demographics / Pre-treatment
Characteristics
Patient's Sex
Female (F)
Male (M)
Birthdate (mm/yy)
Patient's Race
A Person Having Origins In Any Of The
Original Peoples Of North And South
America (including Central America),
And Who Maintains Tribal Affiliation Or
Community Attachment. (American
Indian or Alaska Native)
A Person Having Origins In Any Of The
Original Peoples Of The Far East,
Southeast Asia, Or The Indian
Subcontinent Including, For Example,
Cambodia, China, India, Japan, Korea,
Malaysia, Pakistan, The Philippine
Islands, Thailand, And Vietnam. (Asian)
A Person Having Origins In Any Of The
Black Racial Groups Of Africa. Terms
Such As "haitian" Or "negro" Can Be
Used In Addition To "black Or African
American." (Black or African American)
A Person Having Origins In Any Of The
Original Peoples Of Hawaii, Guam,
Samoa, Or Other Pacific Islands. (Native
Hawaiian or other Pacific Islander)
Not Provided Or Available (Not
Reported)
Could Not Be Determined Or Unsure
(Unknown)
A Person Having Origins In Any Of The
Original Peoples Of Europe, The Middle
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East, Or North Africa. (White)
ZIP Code
Patient Ethnicity
A Person Of Mexican, Puerto Rican,
Cuban, Central Or South American Or
Other Spanish Culture Or Origin,
Regardless Of Race. (Hispanic or Latino)
A Person Not Meeting The Definition For
Hispanic Or Latino. (Not Hispanic or
Latino)
Not Provided Or Available (Not reported)
Could Not Be Determined Or Unsure
(Unknown)
Patient Hospital No.
Patient Social Security Number
Method of payment (check one)
Medicaid (Medicaid)
Medicaid And Medicare (Medicaid and
Medicare)
Medicare (Medicare)
Medicare And Private Insurance
(Medicare and Private Insurance)
Military Or Veterans Sponsored Nos
(Military or Veterans Sponsored, Not
Otherwise Specified (NOS))
Military Sponsored (including Champus
& Tricare) (Military Sponsored (including
CHAMPUS & TRICARE))
No Means Of Payment (no Insurance)
(No means of payment (no insurance))
Other (Other)
Private Insurance (Private Insurance)
Self Pay (no Insurance) (Self Pay (No
Insurance))
Unknown (Unknown)
Veterans Sponsored (Veterans
Sponsored)
Country of residence
Ascension Island (AC)
Andorra (AD)
United Arab Emirates (AE)
Afghanistan (AF)
Antigua And Barbuda (AG)
Anguilla (AI)
Albania (AL)
Armenia (AM)
Netherland Antilles (AN)
Angola (AO)
Antarctica (AQ)
Argentina (AR)
American Samoa (AS)
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Austria (AT)
Australia (AU)
Aruba (AW)
Azerbaidjan (AZ)
Bosnia-herzegovina (BA)
Barbados (BB)
Bangladesh (BD)
Belgium (BE)
Burkina Faso (BF)
Bulgaria (BG)
Bahrain (BH)
Burundi (BI)
Benin (BJ)
Bermuda (BM)
Brunei Darussalam (BN)
Bolivia (BO)
Brazil (BR)
Bahamas (BS)
Bhutan (BT)
Bouvet Island (BV)
Botswana (BW)
Belarus (BY)
Belize (BZ)
Canada (CA)
Cocos Isl. (CC)
Rep. Dem. Congo (CD)
Central African Rep. (CF)
Congo (CG)
Switzerland (CH)
Ivory Coast (CI)
Cook Islands (CK)
Chile (CL)
Cameroon (CM)
China (CN)
Colombia (CO)
Costa Rica (CR)
Cuba (CU)
Cape Verde (CV)
Christmas Island (CX)
Cyprus (CY)
Czech Republic (CZ)
Germany (DE)
Djibouti (DJ)
Denmark (DK)
Dominica (DM)
Dominican Republic (DO)
Algeria (DZ)
Ecuador (EC)
Estonia (EE)
Egypt (EG)
Western Sahara (EH)
Eritrea (ER)
Spain (ES)
Ethiopia (ET)
Finland (FI)
Fiji (FJ)
Falkland Isl. (FK)
Micronesia (FM)
Faroe Islands (FO)
France (FR)
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France (european Ter.) (FX)
Gabon (GA)
Great Britain (GB)
Grenada (GD)
Georgia (GE)
Guiana (fr.) (GF)
Guernsey (GG)
Ghana (GH)
Gibraltar (GI)
Greenland (GL)
Gambia (GM)
Guinea (GN)
Guadeloupe (fr.) (GP)
Equatorial Guinea (GQ)
Greece (GR)
South Georgia And South Sandwich
Islands (GS)
Guatemala (GT)
Guam (us) (GU)
Guinea Bissau (GW)
Guyana (GY)
Hong Kong (HK)
Heard & Mcdonald Isl. (HM)
Honduras (HN)
Croatia (HR)
Haiti (HT)
Hungary (HU)
Indonesia (ID)
Ireland (IE)
Israel (IL)
Isle Of Man (IM)
India (IN)
British Indian O. Ter. (IO)
Iraq (IQ)
Iran (IR)
Iceland (IS)
Italy (IT)
Jersey (JE)
Jamaica (JM)
Jordan (JO)
Japan (JP)
Kenya (KE)
Kyrgyz Republic (KG)
Cambodia (KH)
Kiribati (KI)
Comoros (KM)
St. Kitts Nevis Anguilla (KN)
Korea (north) (KP)
Korea (south) (KR)
Kuwait (KW)
Cayman Islands (KY)
Kazakstan (KZ)
Laos (LA)
Lebanon (LB)
Saint Lucia (LC)
Liechtenstein (LI)
Sri Lanka (LK)
Liberia (LR)
Lesotho (LS)
Lithuania (LT)
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Luxembourg (LU)
Latvia (LV)
Libya (LY)
Morocco (MA)
Monaco (MC)
Moldova (MD)
Madagascar (MG)
Marshall Islands (MH)
Macedonia (MK)
Mali (ML)
Myanmar (MM)
Mongolia (MN)
Macau (MO)
Northern Mariana Isl. (MP)
Martinique (fr.) (MQ)
Mauritania (MR)
Montserrat (MS)
Malta (MT)
Mauritius (MU)
Maldives (MV)
Malawi (MW)
Mexico (MX)
Malaysia (MY)
Mozambique (MZ)
Namibia (NA)
New Caledonia (fr.) (NC)
Niger (NE)
Norfolk Island (NF)
Nigeria (NG)
Nicaragua (NI)
Netherlands (NL)
Norway (NO)
Nepal (NP)
Nauru (NR)
Niue (NU)
New Zealand (NZ)
Oman (OM)
Other (Other)
Panama (PA)
Peru (PE)
Polynesia (fr.) (PF)
Papua New Guinea (PG)
Philippines (PH)
Pakistan (PK)
Poland (PL)
St. Pierre & Miquelon (PM)
Pitcairn (PN)
Puerto Rico (PR)
Portugal (PT)
Palau (PW)
Paraguay (PY)
Qatar (QA)
Reunion (fr.) (RE)
Romania (RO)
Russian Federation (RU)
Rwanda (RW)
Saudi Arabia (SA)
Solomon Islands (SB)
Seychelles (SC)
Sudan (SD)
6 / 8
Multiple Myeloma and Plasma Cell Neoplasm NCT00602641 Eligibility -
E1A06 Registration Worksheet (Step 1) - 2762148v1.0
Sweden (SE)
Singapore (SG)
St. Helena (SH)
Slovenia (SI)
Svalbard & Jan Mayen Isl. (SJ)
Slovakia (SK)
Sierra Leone (SL)
San Marino (SM)
Senegal (SN)
Somalia (SO)
Suriname (SR)
St. Tome And Principe (ST)
Soviet Union (SU)
El Salvador (SV)
Syria (SY)
Swaziland (SZ)
Turks & Caicos Islands (TC)
Chad (TD)
French Southern Terr. (TF)
Togo (TG)
Thailand (TH)
Tadjikistan (TJ)
Tokelau (TK)
Turkmenistan (TM)
Tunisia (TN)
Tonga (TO)
East Timor (TP)
Turkey (TR)
Trinidad & Tobago (TT)
Tuvalu (TV)
Taiwan (TW)
Tanzania (TZ)
Ukraine (UA)
Uganda (UG)
United Kingdom (UK)
Us Minor Outlying Isl. (UM)
Usa (US)
Uruguay (UY)
Uzbekistan (UZ)
Vatican City State (VA)
St. Vincent & Grenadines (VC)
Venezuela (VE)
Virgin Islands (brit) (VG)
Virgin Islands (us) (VI)
Vietnam (VN)
Vanuatu (VU)
Wallis & Futuna Islands (WF)
Western Samoa (WS)
Yemen (YE)
Mayotte (YT)
Yugoslavia (YU)
South Africa (ZA)
Zambia (ZM)
Dem. Rep. Of Congo (ZR)
Zimbabwe (ZW)
Comments
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I Have Reviewed The Above Data And
Agree The Date Are Accurate And Correct
Signature of treating physician
Date
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E1A06 Registration Worksheet (Step 1) - 2762148v1.0
Lung Cancer NCT00887159 Eligibility - E1508
Registration Worksheet (step 1) - 2898915v1.0
E1508 Registration Worksheet (step 1)
Cisplatin and Etoposide Phosphate With or Without GDC-
0449 or Cixutumumab in Treating Patients With Extensive-
Stage Small Cell Lung Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=6BDB8EBF-
0580-BA81-E040-BB89AD43079B
All rights reserved. Please visit https://medical-data-
models.org/forms/8781
E1508 Registration Worksheet (step
1)
Eligibility
First initial
Last initial
Has the eligibility checklist been completed
Yes
No
In the opinion of the investigator, is the patient
eligible?
Yes
No
Has written informed consent been obtained
Yes
No
Date Informed Consent Signed
Has HIPAA authorization been obtained
Exempt - Non-usa Participant (Exempt -
non-USA participant)
No: C49487 (No)
Yes: C49488 (Yes)
HIPAA Authorization Date
I agree to participate in the laboratory research
studies that are being done as part of this clinical
trial.
Yes
No
I agree my tissue will be submitted for research.
Yes
No
My specimens may be kept for use in research to
learn about, prevent, treat, or cure cancer.
Yes
No
My specimens may be kept for research about
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other health problems (for example: causes of
diabetes, Alzheimer's disease, and heart
disease)
Yes
No
Someone from this institution may contact me in
the future to ask me to take part in more
research.
Yes
No
Patient Demographics / Pre-treatment
Characteristics
Patient's Sex
Female (F)
Male (M)
Birthdate (mm/yy)
Patient's Race
A Person Having Origins In Any Of The
Original Peoples Of North And South
America (including Central America),
And Who Maintains Tribal Affiliation Or
Community Attachment. (American
Indian or Alaska Native)
A Person Having Origins In Any Of The
Original Peoples Of The Far East,
Southeast Asia, Or The Indian
Subcontinent Including, For Example,
Cambodia, China, India, Japan, Korea,
Malaysia, Pakistan, The Philippine
Islands, Thailand, And Vietnam. (Asian)
A Person Having Origins In Any Of The
Black Racial Groups Of Africa. Terms
Such As "haitian" Or "negro" Can Be
Used In Addition To "black Or African
American." (Black or African American)
A Person Having Origins In Any Of The
Original Peoples Of Hawaii, Guam,
Samoa, Or Other Pacific Islands. (Native
Hawaiian or other Pacific Islander)
Not Provided Or Available (Not
Reported)
Could Not Be Determined Or Unsure
(Unknown)
A Person Having Origins In Any Of The
Original Peoples Of Europe, The Middle
East, Or North Africa. (White)
ZIP Code
Patient Ethnicity
A Person Of Mexican, Puerto Rican,
Cuban, Central Or South American Or
2 / 7
Lung Cancer NCT00887159 Eligibility - E1508 Registration Worksheet
(step 1) - 2898915v1.0
Other Spanish Culture Or Origin,
Regardless Of Race. (Hispanic or Latino)
A Person Not Meeting The Definition For
Hispanic Or Latino. (Not Hispanic or
Latino)
Not Provided Or Available (Not reported)
Could Not Be Determined Or Unsure
(Unknown)
Patient Hospital No.
Patient Social Security Number
Method of payment (check one)
Medicaid (Medicaid)
Medicaid And Medicare (Medicaid and
Medicare)
Medicare (Medicare)
Medicare And Private Insurance
(Medicare and Private Insurance)
Military Or Veterans Sponsored Nos
(Military or Veterans Sponsored, Not
Otherwise Specified (NOS))
Military Sponsored (including Champus
& Tricare) (Military Sponsored (including
CHAMPUS & TRICARE))
No Means Of Payment (no Insurance)
(No means of payment (no insurance))
Other (Other)
Private Insurance (Private Insurance)
Self Pay (no Insurance) (Self Pay (No
Insurance))
Unknown (Unknown)
Veterans Sponsored (Veterans
Sponsored)
Country of residence
Ascension Island (AC)
Andorra (AD)
United Arab Emirates (AE)
Afghanistan (AF)
Antigua And Barbuda (AG)
Anguilla (AI)
Albania (AL)
Armenia (AM)
Netherland Antilles (AN)
Angola (AO)
Antarctica (AQ)
Argentina (AR)
American Samoa (AS)
Austria (AT)
Australia (AU)
Aruba (AW)
Azerbaidjan (AZ)
Bosnia-herzegovina (BA)
Barbados (BB)
Bangladesh (BD)
Belgium (BE)
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Burkina Faso (BF)
Bulgaria (BG)
Bahrain (BH)
Burundi (BI)
Benin (BJ)
Bermuda (BM)
Brunei Darussalam (BN)
Bolivia (BO)
Brazil (BR)
Bahamas (BS)
Bhutan (BT)
Bouvet Island (BV)
Botswana (BW)
Belarus (BY)
Belize (BZ)
Canada (CA)
Cocos Isl. (CC)
Rep. Dem. Congo (CD)
Central African Rep. (CF)
Congo (CG)
Switzerland (CH)
Ivory Coast (CI)
Cook Islands (CK)
Chile (CL)
Cameroon (CM)
China (CN)
Colombia (CO)
Costa Rica (CR)
Cuba (CU)
Cape Verde (CV)
Christmas Island (CX)
Cyprus (CY)
Czech Republic (CZ)
Germany (DE)
Djibouti (DJ)
Denmark (DK)
Dominica (DM)
Dominican Republic (DO)
Algeria (DZ)
Ecuador (EC)
Estonia (EE)
Egypt (EG)
Western Sahara (EH)
Eritrea (ER)
Spain (ES)
Ethiopia (ET)
Finland (FI)
Fiji (FJ)
Falkland Isl. (FK)
Micronesia (FM)
Faroe Islands (FO)
France (FR)
France (european Ter.) (FX)
Gabon (GA)
Great Britain (GB)
Grenada (GD)
Georgia (GE)
Guiana (fr.) (GF)
Guernsey (GG)
Ghana (GH)
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Gibraltar (GI)
Greenland (GL)
Gambia (GM)
Guinea (GN)
Guadeloupe (fr.) (GP)
Equatorial Guinea (GQ)
Greece (GR)
South Georgia And South Sandwich
Islands (GS)
Guatemala (GT)
Guam (us) (GU)
Guinea Bissau (GW)
Guyana (GY)
Hong Kong (HK)
Heard & Mcdonald Isl. (HM)
Honduras (HN)
Croatia (HR)
Haiti (HT)
Hungary (HU)
Indonesia (ID)
Ireland (IE)
Israel (IL)
Isle Of Man (IM)
India (IN)
British Indian O. Ter. (IO)
Iraq (IQ)
Iran (IR)
Iceland (IS)
Italy (IT)
Jersey (JE)
Jamaica (JM)
Jordan (JO)
Japan (JP)
Kenya (KE)
Kyrgyz Republic (KG)
Cambodia (KH)
Kiribati (KI)
Comoros (KM)
St. Kitts Nevis Anguilla (KN)
Korea (north) (KP)
Korea (south) (KR)
Kuwait (KW)
Cayman Islands (KY)
Kazakstan (KZ)
Laos (LA)
Lebanon (LB)
Saint Lucia (LC)
Liechtenstein (LI)
Sri Lanka (LK)
Liberia (LR)
Lesotho (LS)
Lithuania (LT)
Luxembourg (LU)
Latvia (LV)
Libya (LY)
Morocco (MA)
Monaco (MC)
Moldova (MD)
Madagascar (MG)
Marshall Islands (MH)
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Macedonia (MK)
Mali (ML)
Myanmar (MM)
Mongolia (MN)
Macau (MO)
Northern Mariana Isl. (MP)
Martinique (fr.) (MQ)
Mauritania (MR)
Montserrat (MS)
Malta (MT)
Mauritius (MU)
Maldives (MV)
Malawi (MW)
Mexico (MX)
Malaysia (MY)
Mozambique (MZ)
Namibia (NA)
New Caledonia (fr.) (NC)
Niger (NE)
Norfolk Island (NF)
Nigeria (NG)
Nicaragua (NI)
Netherlands (NL)
Norway (NO)
Nepal (NP)
Nauru (NR)
Niue (NU)
New Zealand (NZ)
Oman (OM)
Other (Other)
Panama (PA)
Peru (PE)
Polynesia (fr.) (PF)
Papua New Guinea (PG)
Philippines (PH)
Pakistan (PK)
Poland (PL)
St. Pierre & Miquelon (PM)
Pitcairn (PN)
Puerto Rico (PR)
Portugal (PT)
Palau (PW)
Paraguay (PY)
Qatar (QA)
Reunion (fr.) (RE)
Romania (RO)
Russian Federation (RU)
Rwanda (RW)
Saudi Arabia (SA)
Solomon Islands (SB)
Seychelles (SC)
Sudan (SD)
Sweden (SE)
Singapore (SG)
St. Helena (SH)
Slovenia (SI)
Svalbard & Jan Mayen Isl. (SJ)
Slovakia (SK)
Sierra Leone (SL)
San Marino (SM)
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Senegal (SN)
Somalia (SO)
Suriname (SR)
St. Tome And Principe (ST)
Soviet Union (SU)
El Salvador (SV)
Syria (SY)
Swaziland (SZ)
Turks & Caicos Islands (TC)
Chad (TD)
French Southern Terr. (TF)
Togo (TG)
Thailand (TH)
Tadjikistan (TJ)
Tokelau (TK)
Turkmenistan (TM)
Tunisia (TN)
Tonga (TO)
East Timor (TP)
Turkey (TR)
Trinidad & Tobago (TT)
Tuvalu (TV)
Taiwan (TW)
Tanzania (TZ)
Ukraine (UA)
Uganda (UG)
United Kingdom (UK)
Us Minor Outlying Isl. (UM)
Usa (US)
Uruguay (UY)
Uzbekistan (UZ)
Vatican City State (VA)
St. Vincent & Grenadines (VC)
Venezuela (VE)
Virgin Islands (brit) (VG)
Virgin Islands (us) (VI)
Vietnam (VN)
Vanuatu (VU)
Wallis & Futuna Islands (WF)
Western Samoa (WS)
Yemen (YE)
Mayotte (YT)
Yugoslavia (YU)
South Africa (ZA)
Zambia (ZM)
Dem. Rep. Of Congo (ZR)
Zimbabwe (ZW)
Comments
I Have Reviewed The Above Data And
Agree The Date Are Accurate And Correct
Signature of treating physician
Date
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Multiple Myeloma and Plasma Cell Neoplasm NCT01078454
Eligibility - E4A08 Registration Worksheet (step 1) - 2991676v1.0
E4A08 Registration Worksheet (step 1)
Melphalan and Dexamethasone With or Without
Bortezomib in Treating Patients With Previously Untreated
Systemic Light-Chain Amyloidosis
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=7DC3CF9B-
7994-514C-E040-BB89AD436D78
All rights reserved. Please visit https://medical-data-
models.org/forms/8782
E4A08 Registration Worksheet (step
1)
Eligibility
First initial
Last initial
Has the eligibility checklist been completed
Yes
No
In the opinion of the investigator, is the patient
eligible?
Yes
No
Has written informed consent been obtained
Yes
No
Date Informed Consent Signed
Has HIPAA authorization been obtained
Exempt - Non-usa Participant (Exempt -
non-USA participant)
No: C49487 (No)
Yes: C49488 (Yes)
HIPAA Authorization Date
Cardiac Stage
Cardiac Stage I (Cardiac Stage I)
Cardiac Stage Ii (Cardiac Stage II)
I agree to participate in the laboratory research
studies that are being done as part of this clinical
trial.
Yes
No
My specimens may be kept for use in research to
learn about, prevent, treat, or cure cancer.
Yes
No
My specimens may be kept for research about
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other health problems (for example: causes of
diabetes, Alzheimer's disease, and heart
disease)
Yes
No
Someone from this institution may contact me in
the future to ask me to take part in more
research.
Yes
No
Patient Demographics / Pre-treatment
Characteristics
Patient's Sex
Female (F)
Male (M)
Birthdate (mm/yy)
Patient Race (check all that applyU.S. and
Canada only)
A Person Having Origins In Any Of The
Original Peoples Of North And South
America (including Central America),
And Who Maintains Tribal Affiliation Or
Community Attachment. (American
Indian or Alaska Native)
A Person Having Origins In Any Of The
Original Peoples Of The Far East,
Southeast Asia, Or The Indian
Subcontinent Including, For Example,
Cambodia, China, India, Japan, Korea,
Malaysia, Pakistan, The Philippine
Islands, Thailand, And Vietnam. (Asian)
A Person Having Origins In Any Of The
Black Racial Groups Of Africa. Terms
Such As "haitian" Or "negro" Can Be
Used In Addition To "black Or African
American." (Black or African American)
A Person Having Origins In Any Of The
Original Peoples Of Hawaii, Guam,
Samoa, Or Other Pacific Islands. (Native
Hawaiian or other Pacific Islander)
Not Provided Or Available (Not
Reported)
Could Not Be Determined Or Unsure
(Unknown)
A Person Having Origins In Any Of The
Original Peoples Of Europe, The Middle
East, Or North Africa. (White)
ZIP Code
Patient Hospital No.
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Multiple Myeloma and Plasma Cell Neoplasm NCT01078454 Eligibility -
E4A08 Registration Worksheet (step 1) - 2991676v1.0
Patient Social Security Number
Method of payment (check one)
Medicaid (Medicaid)
Medicaid And Medicare (Medicaid and
Medicare)
Medicare (Medicare)
Medicare And Private Insurance
(Medicare and Private Insurance)
Military Or Veterans Sponsored Nos
(Military or Veterans Sponsored, Not
Otherwise Specified (NOS))
Military Sponsored (including Champus
& Tricare) (Military Sponsored (including
CHAMPUS & TRICARE))
National Health Service (National Health
Service)
No Means Of Payment (no Insurance)
(No means of payment (no insurance))
Other (Other)
Private Insurance (Private Insurance)
Self Pay (no Insurance) (Self Pay (No
Insurance))
Unknown (Unknown)
Veterans Sponsored (Veterans
Sponsored)
Attending Physician
Institution contact
Registrar
Country of Residence
Comments
Signature of treating physician (I have reviewed
the above data and agree the date are accurate
and correct)
Date (Note: Date must be on or before date of
registration)
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E4A08 Registration Worksheet (step 1) - 2991676v1.0
Lung Cancer NCT00986674 Eligibility - E4508
Registration Worksheet (Step 1) - 2922542v1.0
E4508 Registration Worksheet (Step 1)
Carboplatin and Paclitaxel Combined With Cetuximab
and/or Cixutumumab in Treating Patients With Stage IIIB or
Stage IV Non-Small Cell Lung Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=6F7AE42B-
9F67-B050-E040-BB89AD436438
All rights reserved. Please visit https://medical-data-
models.org/forms/8783
E4508 Registration Worksheet (Step
1)
Eligibility
First initial
Last initial
Has the eligibility checklist been completed
Yes
No
In the opinion of the investigator, is the patient
eligible?
Yes
No
Has written informed consent been obtained
Yes
No
Date Informed Consent Signed
Has HIPAA authorization been obtained
Exempt - Non-usa Participant (Exempt -
non-USA participant)
No: C49487 (No)
Yes: C49488 (Yes)
HIPAA Authorization Date
Histology
Non-squamous - Or Nsclc Nos (Non-
squamous - or NSCLC NOS)
Squamous Cell Carcinoma (Squamous
Cell Carcinoma)
I agree to participate in the laboratory research
studies that are being done as part of this clinical
trial.
Yes
No
My specimens may be kept for use in research to
learn about, prevent, treat, or cure cancer.
Yes
No
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My tissue and blood may be kept for research
about other health problems (for example: causes
of diabetes, Alzheimer's disease, and heart
disease)
Yes
No
Someone from this institution may contact me in
the future to ask me to take part in more
research.
Yes
No
Patient Demographics / Pre-treatment
Characteristics
Patient's Sex
Female (F)
Male (M)
Birthdate (mm/yy)
Patient's Race
A Person Having Origins In Any Of The
Original Peoples Of North And South
America (including Central America),
And Who Maintains Tribal Affiliation Or
Community Attachment. (American
Indian or Alaska Native)
A Person Having Origins In Any Of The
Original Peoples Of The Far East,
Southeast Asia, Or The Indian
Subcontinent Including, For Example,
Cambodia, China, India, Japan, Korea,
Malaysia, Pakistan, The Philippine
Islands, Thailand, And Vietnam. (Asian)
A Person Having Origins In Any Of The
Black Racial Groups Of Africa. Terms
Such As "haitian" Or "negro" Can Be
Used In Addition To "black Or African
American." (Black or African American)
A Person Having Origins In Any Of The
Original Peoples Of Hawaii, Guam,
Samoa, Or Other Pacific Islands. (Native
Hawaiian or other Pacific Islander)
Not Provided Or Available (Not
Reported)
Could Not Be Determined Or Unsure
(Unknown)
A Person Having Origins In Any Of The
Original Peoples Of Europe, The Middle
East, Or North Africa. (White)
ZIP Code
Patient Ethnicity
A Person Of Mexican, Puerto Rican,
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Cuban, Central Or South American Or
Other Spanish Culture Or Origin,
Regardless Of Race. (Hispanic or Latino)
A Person Not Meeting The Definition For
Hispanic Or Latino. (Not Hispanic or
Latino)
Not Provided Or Available (Not reported)
Could Not Be Determined Or Unsure
(Unknown)
Patient Hospital No.
Patient Social Security Number
Method of payment (check one)
Medicaid (Medicaid)
Medicaid And Medicare (Medicaid and
Medicare)
Medicare (Medicare)
Medicare And Private Insurance
(Medicare and Private Insurance)
Military Or Veterans Sponsored Nos
(Military or Veterans Sponsored, Not
Otherwise Specified (NOS))
Military Sponsored (including Champus
& Tricare) (Military Sponsored (including
CHAMPUS & TRICARE))
No Means Of Payment (no Insurance)
(No means of payment (no insurance))
Other (Other)
Private Insurance (Private Insurance)
Self Pay (no Insurance) (Self Pay (No
Insurance))
Unknown (Unknown)
Veterans Sponsored (Veterans
Sponsored)
Country of residence
Ascension Island (AC)
Andorra (AD)
United Arab Emirates (AE)
Afghanistan (AF)
Antigua And Barbuda (AG)
Anguilla (AI)
Albania (AL)
Armenia (AM)
Netherland Antilles (AN)
Angola (AO)
Antarctica (AQ)
Argentina (AR)
American Samoa (AS)
Austria (AT)
Australia (AU)
Aruba (AW)
Azerbaidjan (AZ)
Bosnia-herzegovina (BA)
Barbados (BB)
Bangladesh (BD)
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Belgium (BE)
Burkina Faso (BF)
Bulgaria (BG)
Bahrain (BH)
Burundi (BI)
Benin (BJ)
Bermuda (BM)
Brunei Darussalam (BN)
Bolivia (BO)
Brazil (BR)
Bahamas (BS)
Bhutan (BT)
Bouvet Island (BV)
Botswana (BW)
Belarus (BY)
Belize (BZ)
Canada (CA)
Cocos Isl. (CC)
Rep. Dem. Congo (CD)
Central African Rep. (CF)
Congo (CG)
Switzerland (CH)
Ivory Coast (CI)
Cook Islands (CK)
Chile (CL)
Cameroon (CM)
China (CN)
Colombia (CO)
Costa Rica (CR)
Cuba (CU)
Cape Verde (CV)
Christmas Island (CX)
Cyprus (CY)
Czech Republic (CZ)
Germany (DE)
Djibouti (DJ)
Denmark (DK)
Dominica (DM)
Dominican Republic (DO)
Algeria (DZ)
Ecuador (EC)
Estonia (EE)
Egypt (EG)
Western Sahara (EH)
Eritrea (ER)
Spain (ES)
Ethiopia (ET)
Finland (FI)
Fiji (FJ)
Falkland Isl. (FK)
Micronesia (FM)
Faroe Islands (FO)
France (FR)
France (european Ter.) (FX)
Gabon (GA)
Great Britain (GB)
Grenada (GD)
Georgia (GE)
Guiana (fr.) (GF)
Guernsey (GG)
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Ghana (GH)
Gibraltar (GI)
Greenland (GL)
Gambia (GM)
Guinea (GN)
Guadeloupe (fr.) (GP)
Equatorial Guinea (GQ)
Greece (GR)
South Georgia And South Sandwich
Islands (GS)
Guatemala (GT)
Guam (us) (GU)
Guinea Bissau (GW)
Guyana (GY)
Hong Kong (HK)
Heard & Mcdonald Isl. (HM)
Honduras (HN)
Croatia (HR)
Haiti (HT)
Hungary (HU)
Indonesia (ID)
Ireland (IE)
Israel (IL)
Isle Of Man (IM)
India (IN)
British Indian O. Ter. (IO)
Iraq (IQ)
Iran (IR)
Iceland (IS)
Italy (IT)
Jersey (JE)
Jamaica (JM)
Jordan (JO)
Japan (JP)
Kenya (KE)
Kyrgyz Republic (KG)
Cambodia (KH)
Kiribati (KI)
Comoros (KM)
St. Kitts Nevis Anguilla (KN)
Korea (north) (KP)
Korea (south) (KR)
Kuwait (KW)
Cayman Islands (KY)
Kazakstan (KZ)
Laos (LA)
Lebanon (LB)
Saint Lucia (LC)
Liechtenstein (LI)
Sri Lanka (LK)
Liberia (LR)
Lesotho (LS)
Lithuania (LT)
Luxembourg (LU)
Latvia (LV)
Libya (LY)
Morocco (MA)
Monaco (MC)
Moldova (MD)
Madagascar (MG)
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Marshall Islands (MH)
Macedonia (MK)
Mali (ML)
Myanmar (MM)
Mongolia (MN)
Macau (MO)
Northern Mariana Isl. (MP)
Martinique (fr.) (MQ)
Mauritania (MR)
Montserrat (MS)
Malta (MT)
Mauritius (MU)
Maldives (MV)
Malawi (MW)
Mexico (MX)
Malaysia (MY)
Mozambique (MZ)
Namibia (NA)
New Caledonia (fr.) (NC)
Niger (NE)
Norfolk Island (NF)
Nigeria (NG)
Nicaragua (NI)
Netherlands (NL)
Norway (NO)
Nepal (NP)
Nauru (NR)
Niue (NU)
New Zealand (NZ)
Oman (OM)
Other (Other)
Panama (PA)
Peru (PE)
Polynesia (fr.) (PF)
Papua New Guinea (PG)
Philippines (PH)
Pakistan (PK)
Poland (PL)
St. Pierre & Miquelon (PM)
Pitcairn (PN)
Puerto Rico (PR)
Portugal (PT)
Palau (PW)
Paraguay (PY)
Qatar (QA)
Reunion (fr.) (RE)
Romania (RO)
Russian Federation (RU)
Rwanda (RW)
Saudi Arabia (SA)
Solomon Islands (SB)
Seychelles (SC)
Sudan (SD)
Sweden (SE)
Singapore (SG)
St. Helena (SH)
Slovenia (SI)
Svalbard & Jan Mayen Isl. (SJ)
Slovakia (SK)
Sierra Leone (SL)
6 / 7
Lung Cancer NCT00986674 Eligibility - E4508 Registration Worksheet
(Step 1) - 2922542v1.0
San Marino (SM)
Senegal (SN)
Somalia (SO)
Suriname (SR)
St. Tome And Principe (ST)
Soviet Union (SU)
El Salvador (SV)
Syria (SY)
Swaziland (SZ)
Turks & Caicos Islands (TC)
Chad (TD)
French Southern Terr. (TF)
Togo (TG)
Thailand (TH)
Tadjikistan (TJ)
Tokelau (TK)
Turkmenistan (TM)
Tunisia (TN)
Tonga (TO)
East Timor (TP)
Turkey (TR)
Trinidad & Tobago (TT)
Tuvalu (TV)
Taiwan (TW)
Tanzania (TZ)
Ukraine (UA)
Uganda (UG)
United Kingdom (UK)
Us Minor Outlying Isl. (UM)
Usa (US)
Uruguay (UY)
Uzbekistan (UZ)
Vatican City State (VA)
St. Vincent & Grenadines (VC)
Venezuela (VE)
Virgin Islands (brit) (VG)
Virgin Islands (us) (VI)
Vietnam (VN)
Vanuatu (VU)
Wallis & Futuna Islands (WF)
Western Samoa (WS)
Yemen (YE)
Mayotte (YT)
Yugoslavia (YU)
South Africa (ZA)
Zambia (ZM)
Dem. Rep. Of Congo (ZR)
Zimbabwe (ZW)
Comments
I Have Reviewed The Above Data And
Agree The Date Are Accurate And Correct
Signature of treating physician
Date
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Lymphoma NCT00335140 Eligibility - E1F05
Registration Worksheet (step 1) - 2952523v1.0
E1F05 Registration Worksheet (step 1)
Rituximab and Combination Chemotherapy in Treating
Patients With Primary Central Nervous System Lymphoma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=75BE18CF-
8246-E1B5-E040-BB89AD4301D0
All rights reserved. Please visit https://medical-data-
models.org/forms/8784
E1F05 Registration Worksheet (step
1)
Eligibility
First initial
Last initial
Has the eligibility checklist been completed
Yes
No
In the opinion of the investigator, is the patient
eligible?
Yes
No
Has written informed consent been obtained
Yes
No
Date Informed Consent Signed
Has HIPAA authorization been obtained
Exempt - Non-usa Participant (Exempt -
non-USA participant)
No: C49487 (No)
Yes: C49488 (Yes)
HIPAA Authorization Date
I agree to participate in the laboratory research
studies that are being done as part of this clinical
trial.
Yes
No
My specimens may be kept for use in research to
learn about, prevent, treat, or cure cancer.
Yes
No
My specimens may be kept for use in research
about other health problems (for example:
diabetes, Alzheimer's disease, or heart disease).
Yes
No
Someone from this institution may contact me in
1 / 8
the future to ask me to take part in more
research.
Yes
No
Name of the contact person responsible for
sample submission
Phone number of the contact person responsible
for sample submission
E-mail address of the contact person responsible
for sample submission
Fax number of the contact person responsible for
sample submission
Race
Patient's Race
A Person Having Origins In Any Of The
Original Peoples Of North And South
America (including Central America),
And Who Maintains Tribal Affiliation Or
Community Attachment. (American
Indian or Alaska Native)
A Person Having Origins In Any Of The
Original Peoples Of The Far East,
Southeast Asia, Or The Indian
Subcontinent Including, For Example,
Cambodia, China, India, Japan, Korea,
Malaysia, Pakistan, The Philippine
Islands, Thailand, And Vietnam. (Asian)
A Person Having Origins In Any Of The
Black Racial Groups Of Africa. Terms
Such As "haitian" Or "negro" Can Be
Used In Addition To "black Or African
American." (Black or African American)
A Person Having Origins In Any Of The
Original Peoples Of Hawaii, Guam,
Samoa, Or Other Pacific Islands. (Native
Hawaiian or other Pacific Islander)
Not Provided Or Available (Not
Reported)
Could Not Be Determined Or Unsure
(Unknown)
A Person Having Origins In Any Of The
Original Peoples Of Europe, The Middle
East, Or North Africa. (White)
Patient Demographics / Pre-treatment
Characteristics
Patient's Sex
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Female (F)
Male (M)
Birthdate (mm/yy)
ZIP Code
Patient Ethnicity
A Person Of Mexican, Puerto Rican,
Cuban, Central Or South American Or
Other Spanish Culture Or Origin,
Regardless Of Race. (Hispanic or Latino)
A Person Not Meeting The Definition For
Hispanic Or Latino. (Not Hispanic or
Latino)
Not Provided Or Available (Not reported)
Could Not Be Determined Or Unsure
(Unknown)
Patient's simplified disease code
Acute Myeloid Leukemia (Acute Myeloid
Leukemia, NOS)
Chronic Myelomonocytic Leukemia
(Chronic Myelomonocytic Leukemia)
Mds (Myelodysplastic syndrome, NOS)
Patient Hospital No.
Patient Social Security Number
Method of payment (check one)
Medicaid (Medicaid)
Medicaid And Medicare (Medicaid and
Medicare)
Medicare (Medicare)
Medicare And Private Insurance
(Medicare and Private Insurance)
Military Or Veterans Sponsored Nos
(Military or Veterans Sponsored, Not
Otherwise Specified (NOS))
Military Sponsored (including Champus
& Tricare) (Military Sponsored (including
CHAMPUS & TRICARE))
No Means Of Payment (no Insurance)
(No means of payment (no insurance))
Other (Other)
Private Insurance (Private Insurance)
Self Pay (no Insurance) (Self Pay (No
Insurance))
Unknown (Unknown)
Veterans Sponsored (Veterans
Sponsored)
Attending Physician
Institution contact
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Registrar
Country of residence
Ascension Island (AC)
Andorra (AD)
United Arab Emirates (AE)
Afghanistan (AF)
Antigua And Barbuda (AG)
Anguilla (AI)
Albania (AL)
Armenia (AM)
Netherland Antilles (AN)
Angola (AO)
Antarctica (AQ)
Argentina (AR)
American Samoa (AS)
Austria (AT)
Australia (AU)
Aruba (AW)
Azerbaidjan (AZ)
Bosnia-herzegovina (BA)
Barbados (BB)
Bangladesh (BD)
Belgium (BE)
Burkina Faso (BF)
Bulgaria (BG)
Bahrain (BH)
Burundi (BI)
Benin (BJ)
Bermuda (BM)
Brunei Darussalam (BN)
Bolivia (BO)
Brazil (BR)
Bahamas (BS)
Bhutan (BT)
Bouvet Island (BV)
Botswana (BW)
Belarus (BY)
Belize (BZ)
Canada (CA)
Cocos Isl. (CC)
Rep. Dem. Congo (CD)
Central African Rep. (CF)
Congo (CG)
Switzerland (CH)
Ivory Coast (CI)
Cook Islands (CK)
Chile (CL)
Cameroon (CM)
China (CN)
Colombia (CO)
Costa Rica (CR)
Cuba (CU)
Cape Verde (CV)
Christmas Island (CX)
Cyprus (CY)
Czech Republic (CZ)
Germany (DE)
Djibouti (DJ)
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Denmark (DK)
Dominica (DM)
Dominican Republic (DO)
Algeria (DZ)
Ecuador (EC)
Estonia (EE)
Egypt (EG)
Western Sahara (EH)
Eritrea (ER)
Spain (ES)
Ethiopia (ET)
Finland (FI)
Fiji (FJ)
Falkland Isl. (FK)
Micronesia (FM)
Faroe Islands (FO)
France (FR)
France (european Ter.) (FX)
Gabon (GA)
Great Britain (GB)
Grenada (GD)
Georgia (GE)
Guiana (fr.) (GF)
Guernsey (GG)
Ghana (GH)
Gibraltar (GI)
Greenland (GL)
Gambia (GM)
Guinea (GN)
Guadeloupe (fr.) (GP)
Equatorial Guinea (GQ)
Greece (GR)
South Georgia And South Sandwich
Islands (GS)
Guatemala (GT)
Guam (us) (GU)
Guinea Bissau (GW)
Guyana (GY)
Hong Kong (HK)
Heard & Mcdonald Isl. (HM)
Honduras (HN)
Croatia (HR)
Haiti (HT)
Hungary (HU)
Indonesia (ID)
Ireland (IE)
Israel (IL)
Isle Of Man (IM)
India (IN)
British Indian O. Ter. (IO)
Iraq (IQ)
Iran (IR)
Iceland (IS)
Italy (IT)
Jersey (JE)
Jamaica (JM)
Jordan (JO)
Japan (JP)
Kenya (KE)
Kyrgyz Republic (KG)
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Cambodia (KH)
Kiribati (KI)
Comoros (KM)
St. Kitts Nevis Anguilla (KN)
Korea (north) (KP)
Korea (south) (KR)
Kuwait (KW)
Cayman Islands (KY)
Kazakstan (KZ)
Laos (LA)
Lebanon (LB)
Saint Lucia (LC)
Liechtenstein (LI)
Sri Lanka (LK)
Liberia (LR)
Lesotho (LS)
Lithuania (LT)
Luxembourg (LU)
Latvia (LV)
Libya (LY)
Morocco (MA)
Monaco (MC)
Moldova (MD)
Madagascar (MG)
Marshall Islands (MH)
Macedonia (MK)
Mali (ML)
Myanmar (MM)
Mongolia (MN)
Macau (MO)
Northern Mariana Isl. (MP)
Martinique (fr.) (MQ)
Mauritania (MR)
Montserrat (MS)
Malta (MT)
Mauritius (MU)
Maldives (MV)
Malawi (MW)
Mexico (MX)
Malaysia (MY)
Mozambique (MZ)
Namibia (NA)
New Caledonia (fr.) (NC)
Niger (NE)
Norfolk Island (NF)
Nigeria (NG)
Nicaragua (NI)
Netherlands (NL)
Norway (NO)
Nepal (NP)
Nauru (NR)
Niue (NU)
New Zealand (NZ)
Oman (OM)
Other (Other)
Panama (PA)
Peru (PE)
Polynesia (fr.) (PF)
Papua New Guinea (PG)
Philippines (PH)
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Pakistan (PK)
Poland (PL)
St. Pierre & Miquelon (PM)
Pitcairn (PN)
Puerto Rico (PR)
Portugal (PT)
Palau (PW)
Paraguay (PY)
Qatar (QA)
Reunion (fr.) (RE)
Romania (RO)
Russian Federation (RU)
Rwanda (RW)
Saudi Arabia (SA)
Solomon Islands (SB)
Seychelles (SC)
Sudan (SD)
Sweden (SE)
Singapore (SG)
St. Helena (SH)
Slovenia (SI)
Svalbard & Jan Mayen Isl. (SJ)
Slovakia (SK)
Sierra Leone (SL)
San Marino (SM)
Senegal (SN)
Somalia (SO)
Suriname (SR)
St. Tome And Principe (ST)
Soviet Union (SU)
El Salvador (SV)
Syria (SY)
Swaziland (SZ)
Turks & Caicos Islands (TC)
Chad (TD)
French Southern Terr. (TF)
Togo (TG)
Thailand (TH)
Tadjikistan (TJ)
Tokelau (TK)
Turkmenistan (TM)
Tunisia (TN)
Tonga (TO)
East Timor (TP)
Turkey (TR)
Trinidad & Tobago (TT)
Tuvalu (TV)
Taiwan (TW)
Tanzania (TZ)
Ukraine (UA)
Uganda (UG)
United Kingdom (UK)
Us Minor Outlying Isl. (UM)
Usa (US)
Uruguay (UY)
Uzbekistan (UZ)
Vatican City State (VA)
St. Vincent & Grenadines (VC)
Venezuela (VE)
Virgin Islands (brit) (VG)
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Virgin Islands (us) (VI)
Vietnam (VN)
Vanuatu (VU)
Wallis & Futuna Islands (WF)
Western Samoa (WS)
Yemen (YE)
Mayotte (YT)
Yugoslavia (YU)
South Africa (ZA)
Zambia (ZM)
Dem. Rep. Of Congo (ZR)
Zimbabwe (ZW)
Comments
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(step 1) - 2952523v1.0
Lymphoma NCT00389818 Demographic - AMC-
047 Demographic Form (DEM) - 2527628v1.0
AMC-047 Demographic Form (DEM)
Combination Chemotherapy and Rituximab in Treating
Patients With Newly Diagnosed AIDS-Related B-Cell Non-
Hodgkin's Lymphoma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=1FB0B27B-
7A4E-2BB7-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/8788
AMC-047 Demographic Form (DEM)
Header
Patient Initials
Patient's Date of Birth
Gender
Female (FEMALE)
Male (MALE)
Ethnicity
A Person Of Mexican, Puerto Rican,
Cuban, Central Or South American Or
Other Spanish Culture Or Origin,
Regardless Of Race. (Hispanic or Latino)
A Person Not Meeting The Definition For
Hispanic Or Latino. (Not Hispanic or
Latino)
Could Not Be Determined Or Unsure
(Unknown)
Race (check all that apply)
A Person Having Origins In Any Of The
Original Peoples Of North And South
America (including Central America),
And Who Maintains Tribal Affiliation Or
Community Attachment. (American
Indian or Alaska Native)
A Person Having Origins In Any Of The
Original Peoples Of The Far East,
Southeast Asia, Or The Indian
Subcontinent Including, For Example,
Cambodia, China, India, Japan, Korea,
Malaysia, Pakistan, The Philippine
Islands, Thailand, And Vietnam. (Asian)
A Person Having Origins In Any Of The
Black Racial Groups Of Africa. Terms
Such As "haitian" Or "negro" Can Be
Used In Addition To "black Or African
American." (Black or African American)
A Person Having Origins In Any Of The
Original Peoples Of Hawaii, Guam,
Samoa, Or Other Pacific Islands. (Native
Hawaiian or other Pacific Islander)
Could Not Be Determined Or Unsure
(Unknown)
A Person Having Origins In Any Of The
Original Peoples Of Europe, The Middle
1 / 2
East, Or North Africa. (White)
Patient Zip Code
Method of Payment
Medicaid (Medicaid)
Medicaid And Medicare (Medicaid and
Medicare)
Medicare (Medicare)
Medicare And Private Insurance
(Medicare and Private Insurance)
Military Or Veterans Sponsored Nos
(Military or Veterans Sponsored, Not
Otherwise Specified (NOS))
Military Sponsored (including Champus
& Tricare) (Military Sponsored (including
CHAMPUS & TRICARE))
No Means Of Payment (no Insurance)
(No means of payment (no insurance))
Other (Other)
Private Insurance (Private Insurance)
Self Pay (no Insurance) (Self Pay (No
Insurance))
Unknown (Unknown)
Veterans Sponsored (Veterans
Sponsored)
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Multiple Myeloma and Plasma Cell Neoplasm null Eligibility -
E3A05 Registration Worksheet (step 1) - 2951239v1.0
E3A05 Registration Worksheet (step 1)
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=7582EB75-
614C-2DBD-E040-BB89AD436AF2
All rights reserved. Please visit https://medical-data-
models.org/forms/8789
E3A05 Registration Worksheet (step
1)
Eligibility
First initial
Last initial
Has the eligibility checklist been completed
Yes
No
In the opinion of the investigator, is the patient
eligible?
Yes
No
Patient's simplified disease code
Monoclonal Gammopathy Of
Undetermined Significance (Monoclonal
gammopathy of undetermined
significance (MGUS))
Myeloma (Myeloma, NOS)
Solitary Plasmacytoma (Solitary
Plasmacytoma)
Is the patient being considered for enrollment into
one or more ECOG treatment trials for plasma
cell disorders
Yes
No
Enter the suspected clinical diagnoses
Enter the protocol number(s) of the treatment
protocol under consideration
Are the ECOG treatment protocol(s) that are
being considered active and accruing
Yes
No
Has the patient registered to or started treatment
on the respective treatment trial
No (No)
Registered Only (Registered only)
Started Treatment (Started treatment)
If the patient is registered to a treatment trial,
enter the treatment protocol number(s) followed
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by the ECOG patient ID on the treatment
protocol(s).  Others enter 'N/A'.
Has written informed consent been obtained
Yes
No
Date Informed Consent Signed
Has HIPAA authorization been obtained
Exempt - Non-usa Participant (Exempt -
non-USA participant)
No: C49487 (No)
Yes: C49488 (Yes)
HIPAA Authorization Date
My coded samples and related coded information
may be used for the optional scientific studies
defined in the Treatment Protocol in which I am
considering participation
Yes
No
My coded samples and related coded information
may be kept for use in research to learn about,
prevent, find or treat cancer?  This may also
include research on inherited traits (genes
passed on in families).
Yes
No
My coded samples and related coded information
may be kept for use in research to learn about,
prevent, find or treat other health problems (for
example: diabetes, Alzheimer's disease, or heart
disease)? This may also include research on
inherited traits (genes passed on in families).
Yes
No
Someone from my hospital or the Eastern
Cooperative Oncology Group may contact me in
the future to ask me to take part in more
research.
Yes
No
Name of local cytogenetics lab
Phone number
Race
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Multiple Myeloma and Plasma Cell Neoplasm null Eligibility - E3A05
Registration Worksheet (step 1) - 2951239v1.0
Patient's Race
A Person Having Origins In Any Of The
Original Peoples Of North And South
America (including Central America),
And Who Maintains Tribal Affiliation Or
Community Attachment. (American
Indian or Alaska Native)
A Person Having Origins In Any Of The
Original Peoples Of The Far East,
Southeast Asia, Or The Indian
Subcontinent Including, For Example,
Cambodia, China, India, Japan, Korea,
Malaysia, Pakistan, The Philippine
Islands, Thailand, And Vietnam. (Asian)
A Person Having Origins In Any Of The
Black Racial Groups Of Africa. Terms
Such As "haitian" Or "negro" Can Be
Used In Addition To "black Or African
American." (Black or African American)
A Person Having Origins In Any Of The
Original Peoples Of Hawaii, Guam,
Samoa, Or Other Pacific Islands. (Native
Hawaiian or other Pacific Islander)
Not Provided Or Available (Not
Reported)
Could Not Be Determined Or Unsure
(Unknown)
A Person Having Origins In Any Of The
Original Peoples Of Europe, The Middle
East, Or North Africa. (White)
Patient Demographics / Pre-treatment
Characteristics
Patient's Sex
Female (F)
Male (M)
Birthdate (mm/yy)
ZIP Code
Patient Ethnicity
A Person Of Mexican, Puerto Rican,
Cuban, Central Or South American Or
Other Spanish Culture Or Origin,
Regardless Of Race. (Hispanic or Latino)
A Person Not Meeting The Definition For
Hispanic Or Latino. (Not Hispanic or
Latino)
Not Provided Or Available (Not reported)
Could Not Be Determined Or Unsure
(Unknown)
Patient's simplified disease code
Monoclonal Gammopathy Of
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Multiple Myeloma and Plasma Cell Neoplasm null Eligibility - E3A05
Registration Worksheet (step 1) - 2951239v1.0
Undetermined Significance (Monoclonal
gammopathy of undetermined
significance (MGUS))
Myeloma (Myeloma, NOS)
Solitary Plasmacytoma (Solitary
Plasmacytoma)
Patient Hospital No.
Patient Social Security Number
Method of payment (check one)
Medicaid (Medicaid)
Medicaid And Medicare (Medicaid and
Medicare)
Medicare (Medicare)
Medicare And Private Insurance
(Medicare and Private Insurance)
Military Or Veterans Sponsored Nos
(Military or Veterans Sponsored, Not
Otherwise Specified (NOS))
Military Sponsored (including Champus
& Tricare) (Military Sponsored (including
CHAMPUS & TRICARE))
No Means Of Payment (no Insurance)
(No means of payment (no insurance))
Other (Other)
Private Insurance (Private Insurance)
Self Pay (no Insurance) (Self Pay (No
Insurance))
Unknown (Unknown)
Veterans Sponsored (Veterans
Sponsored)
Attending Physician
Institution contact
Registrar
Country of residence
Ascension Island (AC)
Andorra (AD)
United Arab Emirates (AE)
Afghanistan (AF)
Antigua And Barbuda (AG)
Anguilla (AI)
Albania (AL)
Armenia (AM)
Netherland Antilles (AN)
Angola (AO)
Antarctica (AQ)
Argentina (AR)
American Samoa (AS)
Austria (AT)
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Multiple Myeloma and Plasma Cell Neoplasm null Eligibility - E3A05
Registration Worksheet (step 1) - 2951239v1.0
Australia (AU)
Aruba (AW)
Azerbaidjan (AZ)
Bosnia-herzegovina (BA)
Barbados (BB)
Bangladesh (BD)
Belgium (BE)
Burkina Faso (BF)
Bulgaria (BG)
Bahrain (BH)
Burundi (BI)
Benin (BJ)
Bermuda (BM)
Brunei Darussalam (BN)
Bolivia (BO)
Brazil (BR)
Bahamas (BS)
Bhutan (BT)
Bouvet Island (BV)
Botswana (BW)
Belarus (BY)
Belize (BZ)
Canada (CA)
Cocos Isl. (CC)
Rep. Dem. Congo (CD)
Central African Rep. (CF)
Congo (CG)
Switzerland (CH)
Ivory Coast (CI)
Cook Islands (CK)
Chile (CL)
Cameroon (CM)
China (CN)
Colombia (CO)
Costa Rica (CR)
Cuba (CU)
Cape Verde (CV)
Christmas Island (CX)
Cyprus (CY)
Czech Republic (CZ)
Germany (DE)
Djibouti (DJ)
Denmark (DK)
Dominica (DM)
Dominican Republic (DO)
Algeria (DZ)
Ecuador (EC)
Estonia (EE)
Egypt (EG)
Western Sahara (EH)
Eritrea (ER)
Spain (ES)
Ethiopia (ET)
Finland (FI)
Fiji (FJ)
Falkland Isl. (FK)
Micronesia (FM)
Faroe Islands (FO)
France (FR)
France (european Ter.) (FX)
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Multiple Myeloma and Plasma Cell Neoplasm null Eligibility - E3A05
Registration Worksheet (step 1) - 2951239v1.0
Gabon (GA)
Great Britain (GB)
Grenada (GD)
Georgia (GE)
Guiana (fr.) (GF)
Guernsey (GG)
Ghana (GH)
Gibraltar (GI)
Greenland (GL)
Gambia (GM)
Guinea (GN)
Guadeloupe (fr.) (GP)
Equatorial Guinea (GQ)
Greece (GR)
South Georgia And South Sandwich
Islands (GS)
Guatemala (GT)
Guam (us) (GU)
Guinea Bissau (GW)
Guyana (GY)
Hong Kong (HK)
Heard & Mcdonald Isl. (HM)
Honduras (HN)
Croatia (HR)
Haiti (HT)
Hungary (HU)
Indonesia (ID)
Ireland (IE)
Israel (IL)
Isle Of Man (IM)
India (IN)
British Indian O. Ter. (IO)
Iraq (IQ)
Iran (IR)
Iceland (IS)
Italy (IT)
Jersey (JE)
Jamaica (JM)
Jordan (JO)
Japan (JP)
Kenya (KE)
Kyrgyz Republic (KG)
Cambodia (KH)
Kiribati (KI)
Comoros (KM)
St. Kitts Nevis Anguilla (KN)
Korea (north) (KP)
Korea (south) (KR)
Kuwait (KW)
Cayman Islands (KY)
Kazakstan (KZ)
Laos (LA)
Lebanon (LB)
Saint Lucia (LC)
Liechtenstein (LI)
Sri Lanka (LK)
Liberia (LR)
Lesotho (LS)
Lithuania (LT)
Luxembourg (LU)
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Multiple Myeloma and Plasma Cell Neoplasm null Eligibility - E3A05
Registration Worksheet (step 1) - 2951239v1.0
Latvia (LV)
Libya (LY)
Morocco (MA)
Monaco (MC)
Moldova (MD)
Madagascar (MG)
Marshall Islands (MH)
Macedonia (MK)
Mali (ML)
Myanmar (MM)
Mongolia (MN)
Macau (MO)
Northern Mariana Isl. (MP)
Martinique (fr.) (MQ)
Mauritania (MR)
Montserrat (MS)
Malta (MT)
Mauritius (MU)
Maldives (MV)
Malawi (MW)
Mexico (MX)
Malaysia (MY)
Mozambique (MZ)
Namibia (NA)
New Caledonia (fr.) (NC)
Niger (NE)
Norfolk Island (NF)
Nigeria (NG)
Nicaragua (NI)
Netherlands (NL)
Norway (NO)
Nepal (NP)
Nauru (NR)
Niue (NU)
New Zealand (NZ)
Oman (OM)
Other (Other)
Panama (PA)
Peru (PE)
Polynesia (fr.) (PF)
Papua New Guinea (PG)
Philippines (PH)
Pakistan (PK)
Poland (PL)
St. Pierre & Miquelon (PM)
Pitcairn (PN)
Puerto Rico (PR)
Portugal (PT)
Palau (PW)
Paraguay (PY)
Qatar (QA)
Reunion (fr.) (RE)
Romania (RO)
Russian Federation (RU)
Rwanda (RW)
Saudi Arabia (SA)
Solomon Islands (SB)
Seychelles (SC)
Sudan (SD)
Sweden (SE)
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Multiple Myeloma and Plasma Cell Neoplasm null Eligibility - E3A05
Registration Worksheet (step 1) - 2951239v1.0
Singapore (SG)
St. Helena (SH)
Slovenia (SI)
Svalbard & Jan Mayen Isl. (SJ)
Slovakia (SK)
Sierra Leone (SL)
San Marino (SM)
Senegal (SN)
Somalia (SO)
Suriname (SR)
St. Tome And Principe (ST)
Soviet Union (SU)
El Salvador (SV)
Syria (SY)
Swaziland (SZ)
Turks & Caicos Islands (TC)
Chad (TD)
French Southern Terr. (TF)
Togo (TG)
Thailand (TH)
Tadjikistan (TJ)
Tokelau (TK)
Turkmenistan (TM)
Tunisia (TN)
Tonga (TO)
East Timor (TP)
Turkey (TR)
Trinidad & Tobago (TT)
Tuvalu (TV)
Taiwan (TW)
Tanzania (TZ)
Ukraine (UA)
Uganda (UG)
United Kingdom (UK)
Us Minor Outlying Isl. (UM)
Usa (US)
Uruguay (UY)
Uzbekistan (UZ)
Vatican City State (VA)
St. Vincent & Grenadines (VC)
Venezuela (VE)
Virgin Islands (brit) (VG)
Virgin Islands (us) (VI)
Vietnam (VN)
Vanuatu (VU)
Wallis & Futuna Islands (WF)
Western Samoa (WS)
Yemen (YE)
Mayotte (YT)
Yugoslavia (YU)
South Africa (ZA)
Zambia (ZM)
Dem. Rep. Of Congo (ZR)
Zimbabwe (ZW)
Comments
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Multiple Myeloma and Plasma Cell Neoplasm null Eligibility - E3A05
Registration Worksheet (step 1) - 2951239v1.0
Neoplasms, Breast NCT00490139 Treatment - BIG 2-06 / NCCTG N063D /
EGF106708 - Investigational Product Compliance - 2646090v1.0
BIG 2-06 / NCCTG N063D / EGF106708 - Investigational
Product Compliance
ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment
Optimisation) Study; BIG 2-06/N063D
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=31D31784-
6D30-060F-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/8792
BIG 2-06 / NCCTG N063D /
EGF106708 - Investigational Product
Compliance
Header Module
Centre No.
Subject No.
Administration Of Paclitaxel Concomitantly
With Biological Therapy (design 2)
Agent Name
Date tablets dispensed
Number of tablets dispensed
Date tablets returned
Number of tablets returned
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Melanoma (Skin) NCT00003641 Eligibility - E1697
Registration Worksheet (step 1) - 2798257v1.0
E1697 Registration Worksheet (step 1)
Phase III Randomized Study of Four Weeks of High Dose
Interferon Alfa-2b in Stage TN ,TN, TN, and T, N
(Microscopic) Melanoma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=5B1B6E65-
B0DA-03C6-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/8794
E1697 Registration Worksheet (step
1)
Eligibility
First initial
Last initial
Has the eligibility checklist been completed
Yes
No
In the opinion of the investigator, is the patient
eligible?
Yes
No
Has written informed consent been obtained
Yes
No
Date Informed Consent Signed
Has HIPAA authorization been obtained
Exempt (Exempt)
No: C49487 (No)
Yes: C49488 (Yes)
HIPAA Authorization Date
Is this a COG group patient
Yes
No
QOL contact person
Phone
Email address
Pathologic Lymph Node Assessment
Known (Known)
Unknown (unknown)
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Lymph node staging procedure
Lymphadenectomy (Elective
lymphadenectomy)
No Lymphadenectomy (No
lymphadenectomy)
Sentinel Lymph Node Biopsy (Sentinel
lymph node procedure)
Breslow Thickness (mm)
Is there lymph node involvement
Yes
No
Lymph Node Involvement
Negative (negative)
Positive (positive)
Is the primary ulcerated
Yes
No
I agree to participate in the laboratory research
studies that are being done as part of this clinical
trial.
Yes
No
My specimens may be kept for use in research to
learn about, prevent, treat, or cure cancer.
Yes
No
My specimens may be kept for research about
other health problems (for example: causes of
diabetes, Alzheimer's disease, and heart
disease)
Yes
No
Someone may contact me in the future to ask me
to take part in more research.
Yes
No
Name of the contact person responsible for
sample submission
Phone number of the contact person responsible
for sample submission
Fax number of the contact person responsible for
sample submission
E-mail address of the contact person responsible
for sample submission
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Melanoma (Skin) NCT00003641 Eligibility - E1697 Registration
Worksheet (step 1) - 2798257v1.0
Patient Demographics / Pre-treatment
Characteristics
Patient's Sex
Female (F)
Male (M)
Birthdate (mm/yy)
Patient Race (check all that applyU.S. and
Canada only)
A Person Having Origins In Any Of The
Original Peoples Of North And South
America (including Central America),
And Who Maintains Tribal Affiliation Or
Community Attachment. (American
Indian or Alaska Native)
A Person Having Origins In Any Of The
Original Peoples Of The Far East,
Southeast Asia, Or The Indian
Subcontinent Including, For Example,
Cambodia, China, India, Japan, Korea,
Malaysia, Pakistan, The Philippine
Islands, Thailand, And Vietnam. (Asian)
A Person Having Origins In Any Of The
Black Racial Groups Of Africa. Terms
Such As "haitian" Or "negro" Can Be
Used In Addition To "black Or African
American." (Black or African American)
A Person Having Origins In Any Of The
Original Peoples Of Hawaii, Guam,
Samoa, Or Other Pacific Islands. (Native
Hawaiian or other Pacific Islander)
Not Provided Or Available (Not
Reported)
Could Not Be Determined Or Unsure
(Unknown)
A Person Having Origins In Any Of The
Original Peoples Of Europe, The Middle
East, Or North Africa. (White)
ZIP Code
Patient Ethnicity
A Person Of Mexican, Puerto Rican,
Cuban, Central Or South American Or
Other Spanish Culture Or Origin,
Regardless Of Race. (Hispanic or Latino)
A Person Not Meeting The Definition For
Hispanic Or Latino. (Not Hispanic or
Latino)
Not Provided Or Available (Not reported)
Could Not Be Determined Or Unsure
(Unknown)
Patient Hospital No.
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Melanoma (Skin) NCT00003641 Eligibility - E1697 Registration
Worksheet (step 1) - 2798257v1.0
Patient Social Security Number
Method of payment (check one)
Medicaid (Medicaid)
Medicaid And Medicare (Medicaid and
Medicare)
Medicare (Medicare)
Medicare And Private Insurance
(Medicare and Private Insurance)
Military Or Veterans Sponsored Nos
(Military or Veterans Sponsored, Not
Otherwise Specified (NOS))
Military Sponsored (including Champus
& Tricare) (Military Sponsored (including
CHAMPUS & TRICARE))
National Health Service (National Health
Service)
No Means Of Payment (no Insurance)
(No means of payment (no insurance))
Other (Other)
Private Insurance (Private Insurance)
Self Pay (no Insurance) (Self Pay (No
Insurance))
Unknown (Unknown)
Veterans Sponsored (Veterans
Sponsored)
Attending Physician
Institution contact
Registrar
Country of Residence (if not USA)
Ascension Island (AC)
Andorra (AD)
United Arab Emirates (AE)
Afghanistan (AF)
Antigua And Barbuda (AG)
Anguilla (AI)
Albania (AL)
Armenia (AM)
Netherland Antilles (AN)
Angola (AO)
Antarctica (AQ)
Argentina (AR)
American Samoa (AS)
Austria (AT)
Australia (AU)
Aruba (AW)
Azerbaidjan (AZ)
Bosnia-herzegovina (BA)
Barbados (BB)
Bangladesh (BD)
Belgium (BE)
Burkina Faso (BF)
Bulgaria (BG)
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Melanoma (Skin) NCT00003641 Eligibility - E1697 Registration
Worksheet (step 1) - 2798257v1.0
Bahrain (BH)
Burundi (BI)
Benin (BJ)
Bermuda (BM)
Brunei Darussalam (BN)
Bolivia (BO)
Brazil (BR)
Bahamas (BS)
Bhutan (BT)
Bouvet Island (BV)
Botswana (BW)
Belarus (BY)
Belize (BZ)
Canada (CA)
Cocos Isl. (CC)
Rep. Dem. Congo (CD)
Central African Rep. (CF)
Congo (CG)
Switzerland (CH)
Ivory Coast (CI)
Cook Islands (CK)
Chile (CL)
Cameroon (CM)
China (CN)
Colombia (CO)
Costa Rica (CR)
Cuba (CU)
Cape Verde (CV)
Christmas Island (CX)
Cyprus (CY)
Czech Republic (CZ)
Germany (DE)
Djibouti (DJ)
Denmark (DK)
Dominica (DM)
Dominican Republic (DO)
Algeria (DZ)
Ecuador (EC)
Estonia (EE)
Egypt (EG)
Western Sahara (EH)
Eritrea (ER)
Spain (ES)
Ethiopia (ET)
Finland (FI)
Fiji (FJ)
Falkland Isl. (FK)
Micronesia (FM)
Faroe Islands (FO)
France (FR)
France (european Ter.) (FX)
Gabon (GA)
Great Britain (GB)
Grenada (GD)
Georgia (GE)
Guiana (fr.) (GF)
Guernsey (GG)
Ghana (GH)
Gibraltar (GI)
Greenland (GL)
5 / 8
Melanoma (Skin) NCT00003641 Eligibility - E1697 Registration
Worksheet (step 1) - 2798257v1.0
Gambia (GM)
Guinea (GN)
Guadeloupe (fr.) (GP)
Equatorial Guinea (GQ)
Greece (GR)
South Georgia And South Sandwich
Islands (GS)
Guatemala (GT)
Guam (us) (GU)
Guinea Bissau (GW)
Guyana (GY)
Hong Kong (HK)
Heard & Mcdonald Isl. (HM)
Honduras (HN)
Croatia (HR)
Haiti (HT)
Hungary (HU)
Indonesia (ID)
Ireland (IE)
Israel (IL)
Isle Of Man (IM)
India (IN)
British Indian O. Ter. (IO)
Iraq (IQ)
Iran (IR)
Iceland (IS)
Italy (IT)
Jersey (JE)
Jamaica (JM)
Jordan (JO)
Japan (JP)
Kenya (KE)
Kyrgyz Republic (KG)
Cambodia (KH)
Kiribati (KI)
Comoros (KM)
St. Kitts Nevis Anguilla (KN)
Korea (north) (KP)
Korea (south) (KR)
Kuwait (KW)
Cayman Islands (KY)
Kazakstan (KZ)
Laos (LA)
Lebanon (LB)
Saint Lucia (LC)
Liechtenstein (LI)
Sri Lanka (LK)
Liberia (LR)
Lesotho (LS)
Lithuania (LT)
Luxembourg (LU)
Latvia (LV)
Libya (LY)
Morocco (MA)
Monaco (MC)
Moldova (MD)
Madagascar (MG)
Marshall Islands (MH)
Macedonia (MK)
Mali (ML)
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Melanoma (Skin) NCT00003641 Eligibility - E1697 Registration
Worksheet (step 1) - 2798257v1.0
Myanmar (MM)
Mongolia (MN)
Macau (MO)
Northern Mariana Isl. (MP)
Martinique (fr.) (MQ)
Mauritania (MR)
Montserrat (MS)
Malta (MT)
Mauritius (MU)
Maldives (MV)
Malawi (MW)
Mexico (MX)
Malaysia (MY)
Mozambique (MZ)
Namibia (NA)
New Caledonia (fr.) (NC)
Niger (NE)
Norfolk Island (NF)
Nigeria (NG)
Nicaragua (NI)
Netherlands (NL)
Norway (NO)
Nepal (NP)
Nauru (NR)
Niue (NU)
New Zealand (NZ)
Oman (OM)
Other (Other)
Panama (PA)
Peru (PE)
Polynesia (fr.) (PF)
Papua New Guinea (PG)
Philippines (PH)
Pakistan (PK)
Poland (PL)
St. Pierre & Miquelon (PM)
Pitcairn (PN)
Puerto Rico (PR)
Portugal (PT)
Palau (PW)
Paraguay (PY)
Qatar (QA)
Reunion (fr.) (RE)
Romania (RO)
Russian Federation (RU)
Rwanda (RW)
Saudi Arabia (SA)
Solomon Islands (SB)
Seychelles (SC)
Sudan (SD)
Sweden (SE)
Singapore (SG)
St. Helena (SH)
Slovenia (SI)
Svalbard & Jan Mayen Isl. (SJ)
Slovakia (SK)
Sierra Leone (SL)
San Marino (SM)
Senegal (SN)
Somalia (SO)
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Melanoma (Skin) NCT00003641 Eligibility - E1697 Registration
Worksheet (step 1) - 2798257v1.0
Suriname (SR)
St. Tome And Principe (ST)
Soviet Union (SU)
El Salvador (SV)
Syria (SY)
Swaziland (SZ)
Turks & Caicos Islands (TC)
Chad (TD)
French Southern Terr. (TF)
Togo (TG)
Thailand (TH)
Tadjikistan (TJ)
Tokelau (TK)
Turkmenistan (TM)
Tunisia (TN)
Tonga (TO)
East Timor (TP)
Turkey (TR)
Trinidad & Tobago (TT)
Tuvalu (TV)
Taiwan (TW)
Tanzania (TZ)
Ukraine (UA)
Uganda (UG)
United Kingdom (UK)
Us Minor Outlying Isl. (UM)
Usa (US)
Uruguay (UY)
Uzbekistan (UZ)
Vatican City State (VA)
St. Vincent & Grenadines (VC)
Venezuela (VE)
Virgin Islands (brit) (VG)
Virgin Islands (us) (VI)
Vietnam (VN)
Vanuatu (VU)
Wallis & Futuna Islands (WF)
Western Samoa (WS)
Yemen (YE)
Mayotte (YT)
Yugoslavia (YU)
South Africa (ZA)
Zambia (ZM)
Dem. Rep. Of Congo (ZR)
Zimbabwe (ZW)
Comments
8 / 8
Melanoma (Skin) NCT00003641 Eligibility - E1697 Registration
Worksheet (step 1) - 2798257v1.0
Sarcoma NCT01016730 Demographic - AMC-
063 Demographic Form (DEM) - 3020351v1.0
AMC-063 Demographic Form (DEM)
Bortezomib in Treating Patients With Relapsed or
Refractory AIDS-Related Kaposi Sarcoma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=81639FFD-
CB0E-371A-E040-BB89AD435082
All rights reserved. Please visit https://medical-data-
models.org/forms/8799
AMC-063 Demographic Form (DEM)
Header
Patient Initials (First, Last)
Patient's Date of Birth (mm/dd/yyyy)
Gender
Female (FEMALE)
Male (MALE)
Ethnicity
A Person Of Mexican, Puerto Rican,
Cuban, Central Or South American Or
Other Spanish Culture Or Origin,
Regardless Of Race. (Hispanic or Latino)
A Person Not Meeting The Definition For
Hispanic Or Latino. (Not Hispanic or
Latino)
Could Not Be Determined Or Unsure
(Unknown)
Race (check all that apply)
A Person Having Origins In Any Of The
Original Peoples Of North And South
America (including Central America),
And Who Maintains Tribal Affiliation Or
Community Attachment. (American
Indian or Alaska Native)
A Person Having Origins In Any Of The
Original Peoples Of The Far East,
Southeast Asia, Or The Indian
Subcontinent Including, For Example,
Cambodia, China, India, Japan, Korea,
Malaysia, Pakistan, The Philippine
Islands, Thailand, And Vietnam. (Asian)
A Person Having Origins In Any Of The
Black Racial Groups Of Africa. Terms
Such As "haitian" Or "negro" Can Be
Used In Addition To "black Or African
American." (Black or African American)
A Person Having Origins In Any Of The
Original Peoples Of Hawaii, Guam,
Samoa, Or Other Pacific Islands. (Native
Hawaiian or other Pacific Islander)
Could Not Be Determined Or Unsure
(Unknown)
A Person Having Origins In Any Of The
Original Peoples Of Europe, The Middle
East, Or North Africa. (White)
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Patient Zip Code (xxxxx)
Method of Payment
Medicaid (Medicaid)
Medicaid And Medicare (Medicaid and
Medicare)
Medicare (Medicare)
Medicare And Private Insurance
(Medicare and Private Insurance)
Military Or Veterans Sponsored Nos
(Military or Veterans Sponsored, Not
Otherwise Specified (NOS))
Military Sponsored (including Champus
& Tricare) (Military Sponsored (including
CHAMPUS & TRICARE))
No Means Of Payment (no Insurance)
(No means of payment (no insurance))
Other (Other)
Private Insurance (Private Insurance)
Self Pay (no Insurance) (Self Pay (No
Insurance))
Unknown (Unknown)
Veterans Sponsored (Veterans
Sponsored)
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Sarcoma NCT01016730 Demographic - AMC-063 Demographic Form
(DEM) - 3020351v1.0
Prostate Cancer NCT01145508 Pre-Study - E1809
Registration Worksheet (step 1) - 3110938v1.0
E1809 Registration Worksheet (step 1)
Docetaxel and Prednisone With or Without Vaccine
Therapy in Treating Patients With Metastatic Hormone-
Resistant Prostate Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=8940C069-
6B67-B37D-E040-BB89AD437E49
All rights reserved. Please visit https://medical-data-
models.org/forms/8801
E1809 Registration Worksheet (step
1)
Eligibility
First initial
Last initial
Has the eligibility checklist been completed
Yes
No
In the opinion of the investigator, is the patient
eligible?
Yes
No
Has written informed consent been obtained
Yes
No
Date Informed Consent Signed
Has HIPAA authorization been obtained
Exempt - Non-usa Participant (Exempt -
non-USA participant)
No: C49487 (No)
Yes: C49488 (Yes)
HIPAA Authorization Date
Disease progression
Psa (by PSA)
Radiograph (by radiographic criteria)
Extraskeletal metastases
Yes
No
Prior bisphosphonate therapy
Yes
No
I agree to participate in the laboratory research
studies that are being done as part of this clinical
trial.
Yes
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No
My specimens may be kept for use in research to
learn about, prevent, treat, or cure cancer.
Yes
No
My specimens may be kept for research about
other health problems (for example: causes of
diabetes, Alzheimer's disease, and heart
disease)
Yes
No
Someone from this institution may contact me in
the future to ask me to take part in more
research.
Yes
No
Patient Demographics / Pre-treatment
Characteristics
Patient's Sex
Female (F)
Male (M)
Birthdate
Patient's Race
A Person Having Origins In Any Of The
Original Peoples Of North And South
America (including Central America),
And Who Maintains Tribal Affiliation Or
Community Attachment. (American
Indian or Alaska Native)
A Person Having Origins In Any Of The
Original Peoples Of The Far East,
Southeast Asia, Or The Indian
Subcontinent Including, For Example,
Cambodia, China, India, Japan, Korea,
Malaysia, Pakistan, The Philippine
Islands, Thailand, And Vietnam. (Asian)
A Person Having Origins In Any Of The
Black Racial Groups Of Africa. Terms
Such As "haitian" Or "negro" Can Be
Used In Addition To "black Or African
American." (Black or African American)
A Person Having Origins In Any Of The
Original Peoples Of Hawaii, Guam,
Samoa, Or Other Pacific Islands. (Native
Hawaiian or other Pacific Islander)
Not Provided Or Available (Not
Reported)
Could Not Be Determined Or Unsure
(Unknown)
A Person Having Origins In Any Of The
Original Peoples Of Europe, The Middle
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Worksheet (step 1) - 3110938v1.0
East, Or North Africa. (White)
ZIP Code
Patient's simplified disease code
Bronchioloalveolar Carcinoma
(Bronchioloalveolar carcinoma)
Lung Adenocarcinoma (Lung
Adenocarcinoma)
Bronchioloalveolar Carcinoma Lung
Adenocarcinoma (Lung Adenocarcinoma
with bronchioloalveolar features)
Not Otherwise Specified Non-small Cell
Carcinoma (Non-small cell carcinoma,
NOS)
Patient Hospital No.
Patient Social Security Number
Method of payment (check one)
Medicaid (Medicaid)
Medicaid And Medicare (Medicaid and
Medicare)
Medicare (Medicare)
Medicare And Private Insurance
(Medicare and Private Insurance)
Military Or Veterans Sponsored Nos
(Military or Veterans Sponsored, Not
Otherwise Specified (NOS))
Military Sponsored (including Champus
& Tricare) (Military Sponsored (including
CHAMPUS & TRICARE))
No Means Of Payment (no Insurance)
(No means of payment (no insurance))
Other (Other)
Private Insurance (Private Insurance)
Self Pay (no Insurance) (Self Pay (No
Insurance))
Unknown (Unknown)
Veterans Sponsored (Veterans
Sponsored)
Country of residence
Ascension Island (AC)
Andorra (AD)
United Arab Emirates (AE)
Afghanistan (AF)
Antigua And Barbuda (AG)
Anguilla (AI)
Albania (AL)
Armenia (AM)
Netherland Antilles (AN)
Angola (AO)
Antarctica (AQ)
Argentina (AR)
American Samoa (AS)
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Austria (AT)
Australia (AU)
Aruba (AW)
Azerbaidjan (AZ)
Bosnia-herzegovina (BA)
Barbados (BB)
Bangladesh (BD)
Belgium (BE)
Burkina Faso (BF)
Bulgaria (BG)
Bahrain (BH)
Burundi (BI)
Benin (BJ)
Bermuda (BM)
Brunei Darussalam (BN)
Bolivia (BO)
Brazil (BR)
Bahamas (BS)
Bhutan (BT)
Bouvet Island (BV)
Botswana (BW)
Belarus (BY)
Belize (BZ)
Canada (CA)
Cocos Isl. (CC)
Rep. Dem. Congo (CD)
Central African Rep. (CF)
Congo (CG)
Switzerland (CH)
Ivory Coast (CI)
Cook Islands (CK)
Chile (CL)
Cameroon (CM)
China (CN)
Colombia (CO)
Costa Rica (CR)
Cuba (CU)
Cape Verde (CV)
Christmas Island (CX)
Cyprus (CY)
Czech Republic (CZ)
Germany (DE)
Djibouti (DJ)
Denmark (DK)
Dominica (DM)
Dominican Republic (DO)
Algeria (DZ)
Ecuador (EC)
Estonia (EE)
Egypt (EG)
Western Sahara (EH)
Eritrea (ER)
Spain (ES)
Ethiopia (ET)
Finland (FI)
Fiji (FJ)
Falkland Isl. (FK)
Micronesia (FM)
Faroe Islands (FO)
France (FR)
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Worksheet (step 1) - 3110938v1.0
France (european Ter.) (FX)
Gabon (GA)
Great Britain (GB)
Grenada (GD)
Georgia (GE)
Guiana (fr.) (GF)
Guernsey (GG)
Ghana (GH)
Gibraltar (GI)
Greenland (GL)
Gambia (GM)
Guinea (GN)
Guadeloupe (fr.) (GP)
Equatorial Guinea (GQ)
Greece (GR)
South Georgia And South Sandwich
Islands (GS)
Guatemala (GT)
Guam (us) (GU)
Guinea Bissau (GW)
Guyana (GY)
Hong Kong (HK)
Heard & Mcdonald Isl. (HM)
Honduras (HN)
Croatia (HR)
Haiti (HT)
Hungary (HU)
Indonesia (ID)
Ireland (IE)
Israel (IL)
Isle Of Man (IM)
India (IN)
British Indian O. Ter. (IO)
Iraq (IQ)
Iran (IR)
Iceland (IS)
Italy (IT)
Jersey (JE)
Jamaica (JM)
Jordan (JO)
Japan (JP)
Kenya (KE)
Kyrgyz Republic (KG)
Cambodia (KH)
Kiribati (KI)
Comoros (KM)
St. Kitts Nevis Anguilla (KN)
Korea (north) (KP)
Korea (south) (KR)
Kuwait (KW)
Cayman Islands (KY)
Kazakstan (KZ)
Laos (LA)
Lebanon (LB)
Saint Lucia (LC)
Liechtenstein (LI)
Sri Lanka (LK)
Liberia (LR)
Lesotho (LS)
Lithuania (LT)
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Luxembourg (LU)
Latvia (LV)
Libya (LY)
Morocco (MA)
Monaco (MC)
Moldova (MD)
Madagascar (MG)
Marshall Islands (MH)
Macedonia (MK)
Mali (ML)
Myanmar (MM)
Mongolia (MN)
Macau (MO)
Northern Mariana Isl. (MP)
Martinique (fr.) (MQ)
Mauritania (MR)
Montserrat (MS)
Malta (MT)
Mauritius (MU)
Maldives (MV)
Malawi (MW)
Mexico (MX)
Malaysia (MY)
Mozambique (MZ)
Namibia (NA)
New Caledonia (fr.) (NC)
Niger (NE)
Norfolk Island (NF)
Nigeria (NG)
Nicaragua (NI)
Netherlands (NL)
Norway (NO)
Nepal (NP)
Nauru (NR)
Niue (NU)
New Zealand (NZ)
Oman (OM)
Other (Other)
Panama (PA)
Peru (PE)
Polynesia (fr.) (PF)
Papua New Guinea (PG)
Philippines (PH)
Pakistan (PK)
Poland (PL)
St. Pierre & Miquelon (PM)
Pitcairn (PN)
Puerto Rico (PR)
Portugal (PT)
Palau (PW)
Paraguay (PY)
Qatar (QA)
Reunion (fr.) (RE)
Romania (RO)
Russian Federation (RU)
Rwanda (RW)
Saudi Arabia (SA)
Solomon Islands (SB)
Seychelles (SC)
Sudan (SD)
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Worksheet (step 1) - 3110938v1.0
Sweden (SE)
Singapore (SG)
St. Helena (SH)
Slovenia (SI)
Svalbard & Jan Mayen Isl. (SJ)
Slovakia (SK)
Sierra Leone (SL)
San Marino (SM)
Senegal (SN)
Somalia (SO)
Suriname (SR)
St. Tome And Principe (ST)
Soviet Union (SU)
El Salvador (SV)
Syria (SY)
Swaziland (SZ)
Turks & Caicos Islands (TC)
Chad (TD)
French Southern Terr. (TF)
Togo (TG)
Thailand (TH)
Tadjikistan (TJ)
Tokelau (TK)
Turkmenistan (TM)
Tunisia (TN)
Tonga (TO)
East Timor (TP)
Turkey (TR)
Trinidad & Tobago (TT)
Tuvalu (TV)
Taiwan (TW)
Tanzania (TZ)
Ukraine (UA)
Uganda (UG)
United Kingdom (UK)
Us Minor Outlying Isl. (UM)
Usa (US)
Uruguay (UY)
Uzbekistan (UZ)
Vatican City State (VA)
St. Vincent & Grenadines (VC)
Venezuela (VE)
Virgin Islands (brit) (VG)
Virgin Islands (us) (VI)
Vietnam (VN)
Vanuatu (VU)
Wallis & Futuna Islands (WF)
Western Samoa (WS)
Yemen (YE)
Mayotte (YT)
Yugoslavia (YU)
South Africa (ZA)
Zambia (ZM)
Dem. Rep. Of Congo (ZR)
Zimbabwe (ZW)
Comments
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I Have Reviewed The Above Data And
Agree The Date Are Accurate And Correct
Signature of treating physician
Date
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Worksheet (step 1) - 3110938v1.0
Sarcoma NCT01533207 Registration -
Registration Form (R) - 2843290v1.0
Registration Form (R)
Gemcitabine Hydrochloride and Docetaxel Followed by
Doxorubicin Hydrochloride or Observation in Treating
Patients With High-Risk Uterine Leiomyosarcoma
Previously Removed by Surgery
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=644E6D14-
3F75-95F3-E040-BB89AD4357FF
All rights reserved. Please visit https://medical-data-
models.org/forms/8803
Registration Form (R)
Header Module
Date form originally completed (m d y)
Date form amended (m d y)
Person amending form, last name
Patient Name, Last
Patient Name, First
Patient Study ID
Person Completing Form, Last Name
Tracking Information
Institution name (affiliate)
Treating physician
Patient medical record number
Patient's date of birth (m d y)
Patient Social Security Number
Patient Zip Code
Country of residence (if not USA)
Demographic Information
Patient race (mark all that apply)
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A Person Having Origins In Any Of The
Original Peoples Of North And South
America (including Central America),
And Who Maintains Tribal Affiliation Or
Community Attachment. (American
Indian or Alaska Native)
A Person Having Origins In Any Of The
Original Peoples Of The Far East,
Southeast Asia, Or The Indian
Subcontinent Including, For Example,
Cambodia, China, India, Japan, Korea,
Malaysia, Pakistan, The Philippine
Islands, Thailand, And Vietnam. (Asian)
A Person Having Origins In Any Of The
Black Racial Groups Of Africa. Terms
Such As "haitian" Or "negro" Can Be
Used In Addition To "black Or African
American." (Black or African American)
A Person Having Origins In Any Of The
Original Peoples Of Hawaii, Guam,
Samoa, Or Other Pacific Islands. (Native
Hawaiian or other Pacific Islander)
Could Not Be Determined Or Unsure
(Unknown)
A Person Having Origins In Any Of The
Original Peoples Of Europe, The Middle
East, Or North Africa. (White)
Patient Ethnicity
A Person Of Mexican, Puerto Rican,
Cuban, Central Or South American Or
Other Spanish Culture Or Origin,
Regardless Of Race. (Hispanic or Latino)
A Person Not Meeting The Definition For
Hispanic Or Latino. (Not Hispanic or
Latino)
Could Not Be Determined Or Unsure
(Unknown)
Method of payment
Medicaid (Medicaid)
Medicaid And Medicare (Medicaid &
Medicare)
Medicare (Medicare)
Medicare And Private Insurance
(Medicare & Private Insurance)
Military Or Veterans Sponsored Nos
(Military or Veterans Sponsored NOS)
Military Sponsored (including Champus
& Tricare) (Military Sponsored (including
Champus & Tricare))
No Means Of Payment (no Insurance)
(No means of payment (no insurance))
Other (Other)
Private Insurance (Private Insurance)
Self Pay (no Insurance) (Self pay (no
insurance))
Unknown (Unknown)
Veterans Sponsored (Veterans
Sponsored)
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Sarcoma NCT01533207 Registration - Registration Form (R) -
2843290v1.0
Patient Height
Patient weight (kg)
Performance status (Zubrod)
Fully Active, Able To Carry On All Pre-
disease Performance Without
Restriction. (0)
Restricted In Physically Strenuous
Activity But Ambulatory And Able To
Carry Out Work Of A Light Or Sedentary
Nature, E.g., Light Housework, Office
Work. (1)
Ambulatory And Capable Of All Selfcare
But Unable To Carry Out Any Work
Activities. Up And About More Than 50%
Of Waking Hours. (2)
Capable Of Only Limited Selfcare,
Confined To Bed Or Chair More Than
50% Of Waking Hours. (3)
Completely Disabled. Cannot Carry On
Any Selfcare. Totally Confined To Bed Or
Chair. (4)
Has the patient had any prior cancer diagnosed?
Yes
No
Prior cancer type
Prior cancer diagnosis date (m d y)
Comments
Brief clinical history
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Sarcoma NCT01533207 Registration - Registration Form (R) -
2843290v1.0
On-Study - Demo Enrollment -
2725838v1.0
Enrollment form Demo
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=4508911E-
AEC4-6A3B-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/8805
Demo Enrollment
Demographics
Patient Initials Name
Patient Registration Date
Patient Gender Category
Female (FEMALE)
Male (MALE)
Unknown (UNKNOWN)
Pregnant or Nursing
Yes
No
Patient Birth Date
Patient/Participant Age
Race
A Person Having Origins In Any Of The
Original Peoples Of North And South
America (including Central America),
And Who Maintains Tribal Affiliation Or
Community Attachment. (American
Indian or Alaska Native)
A Person Having Origins In Any Of The
Original Peoples Of The Far East,
Southeast Asia, Or The Indian
Subcontinent Including, For Example,
Cambodia, China, India, Japan, Korea,
Malaysia, Pakistan, The Philippine
Islands, Thailand, And Vietnam. (Asian)
A Person Having Origins In Any Of The
Black Racial Groups Of Africa. Terms
Such As "haitian" Or "negro" Can Be
Used In Addition To "black Or African
American." (Black or African American)
A Person Having Origins In Any Of The
Original Peoples Of Hawaii, Guam,
Samoa, Or Other Pacific Islands. (Native
Hawaiian or other Pacific Islander)
Not Provided Or Available (Not
Reported)
Could Not Be Determined Or Unsure
(Unknown)
A Person Having Origins In Any Of The
Original Peoples Of Europe, The Middle
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East, Or North Africa. (White)
Patient Ethnic Group Category
A Person Of Mexican, Puerto Rican,
Cuban, Central Or South American Or
Other Spanish Culture Or Origin,
Regardless Of Race. (HISPANIC OR
LATINO)
A Person Not Meeting The Definition For
Hispanic Or Latino. (NOT HISPANIC OR
LATINO)
Not Provided Or Available (Not reported)
Could Not Be Determined Or Unsure
(UNKNOWN)
Disease
Primary Site of Disease Name
Bile Duct (Bile Duct)
Breast (Breast)
Cervix (Cervix)
Fallopian Tube (Fallopian Tube)
Lung, Anterior Left Lower Lobe (Lung,
Ant-LLL)
Lung, Anterior Left Upper Lobe (Lung,
Ant-LUL)
Lung, Anterior Right Lower Lobe (Lung,
Ant-RLL)
Lung, Anterior Right Middle Lobe (Lung,
Ant-RML)
Lung, Anterior Right Upper Lobe (Lung,
Ant-RUL)
Lung, Posterior Left Lower Lobe (Lung,
Post-LLL)
Lung, Posterior Left Upper Lobe (Lung,
Post-LUL)
Lung, Posterior Right Lower Lobe (Lung,
Post-RLL)
Lung, Posterior Right Middle Lobe (Lung,
Post-RML)
Lung, Posterior Right Upper Lobe (Lung,
Post-RUL)
Ovary (Ovary)
Prostate (Prostate)
2 / 2
On-Study - Demo Enrollment - 2725838v1.0
Pancreatic Cancer NCT00733746 Registration -
Z5041 - OPEN Enrollment Form - 3013792v1.0
Z5041 - OPEN Enrollment Form
Gemcitabine and Erlotinib Before and After Surgery in
Treating Patients With Pancreatic Cancer That Can Be
Removed by Surgery
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=7FFA1514-
8347-A58F-E040-BB89AD4376E5
All rights reserved. Please visit https://medical-data-
models.org/forms/8806
Z5041 - OPEN Enrollment Form
Patient Information
Date of Birth (month day year)
Gender of a Person
Female Gender (Female Gender)
Male Gender (Male Gender)
Unknown (Unknown)
Ethnicity
A Person Of Mexican, Puerto Rican,
Cuban, Central Or South American Or
Other Spanish Culture Or Origin,
Regardless Of Race. (Hispanic or Latino)
A Person Not Meeting The Definition For
Hispanic Or Latino. (Not Hispanic or
Latino)
Not Provided Or Available (Not reported)
Country of Residence
Zip code
Race
A Person Having Origins In Any Of The
Original Peoples Of North And South
America (including Central America),
And Who Maintains Tribal Affiliation Or
Community Attachment. (American
Indian or Alaska Native)
A Person Having Origins In Any Of The
Original Peoples Of The Far East,
Southeast Asia, Or The Indian
Subcontinent Including, For Example,
Cambodia, China, India, Japan, Korea,
Malaysia, Pakistan, The Philippine
Islands, Thailand, And Vietnam. (Asian)
A Person Having Origins In Any Of The
Black Racial Groups Of Africa. Terms
Such As "haitian" Or "negro" Can Be
Used In Addition To "black Or African
American." (Black or African American)
A Person Having Origins In Any Of The
Original Peoples Of Hawaii, Guam,
Samoa, Or Other Pacific Islands. (Native
Hawaiian or other Pacific Islander)
Not Provided Or Available (Not
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Reported)
Could Not Be Determined Or Unsure
(Unknown)
A Person Having Origins In Any Of The
Original Peoples Of Europe, The Middle
East, Or North Africa. (White)
Method of Payment
Medicaid (Medicaid)
Medicaid And Medicare (Medicaid and
Medicare)
Medicare (Medicare)
Medicare And Private Insurance
(Medicare and Private Insurance)
Military Or Veterans Sponsored Nos
(Military or Veterans Sponsored, Not
Otherwise Specified (NOS))
Military Sponsored (including Champus
& Tricare) (Military Sponsored (including
CHAMPUS & TRICARE))
No Means Of Payment (no Insurance)
(No means of payment (no insurance))
Other (Other)
Private Insurance (Private Insurance)
Self Pay (no Insurance) (Self Pay (No
Insurance))
Unknown (Unknown)
Veterans Sponsored (Veterans
Sponsored)
General Information
Pt ID# (Local Patient Identifier)
Last (initial)
First (initial)
Middle (initial optional)
E-mail (for Registration Confirmation)
Date Informed Consent Signed (month day year)
Was HIPAA Authorization included in Study
Informed Consent (mark one)
Yes
No
HIPAA Authorization Date (If no month day year)
Eligibility Criteria
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Cytologic or histologic proof of adenocarcinoma
of the pancreatic head or uncinate process.
NOTE: Patients with tumors of the pancreatic
neck, body or tail are not eligible. Patients with
evidence of Neuroendocrine tumors, duodenal
adenocarcinoma, or ampullary adenocarcinoma
are not eligible.
Yes
No
Localized, potentially resectable tumors as
defined below. All patients must be staged with a
chest X-ray or CT, and abdominal CT (contrast-
enhanced, helical thin-cut) or MRI. Radiological
resectability is defined by the following criteria on
abdominal imaging: a) No evidence of tumor
extension to the celiac axis, hepatic artery or
superior mesenteric artery b) No evidence of
tumor encasement or occlusion of the superior
mesenteric vein (SMV) or the SMV/portal vein
confluence c) No evidence of visceral or
peritoneal metastases NOTE: Patients with
borderline resectable or marginally resectable
pancreatic cancer are not eligible. Patients must
meet all objective imaging criteria outlined above.
Yes
No
Age >= 18 years
Yes
No
ECOG performance status of 0 or 1 (Zubrod)
Yes
No
ECOG Performance Status (Zubrod 0 or 1)
Fully Active, Able To Carry On All Pre-
disease Performance Without
Restriction. (0)
Restricted In Physically Strenuous
Activity But Ambulatory And Able To
Carry Out Work Of A Light Or Sedentary
Nature, E.g., Light Housework, Office
Work. (1)
Baseline weight loss <=15% of premorbid weight
Yes
No
WBC >= 2,000/mm^3
Yes
No
WBC (>= 2000)
ANC >= 1,500/mm^3
Yes
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No
ANC (>= 1500)
Platelet count >= 100,000/mm^3
Yes
No
Platelet count (>= 100000)
Total bilirubin <= 2.5 mg/dL
Yes
No
Total Bilirubin (<= 2.5)
Creatinine <= 1.5 mg/dL or a calculated
creatinine clearance of >= 50 ml/min (24-hour
urine collection)
Yes
No
Creatinine (<= 1.5)
Calculated creatinine clearance (>= 50)
SGPT (ALT) < 2.5 times ULN
Yes
No
SGPT (ALT) (< 2.5 times ULN)
SGPT (ALT) ULN
SGOT (AST) < 2.5 times ULN
Yes
No
SGOT (AST) (< 2.5 times ULN)
SGOT (AST) ULN
Albumin >= 3.2 g/dL
Yes
No
Albumin (>= 3.2)
No history of the following: Prior EGFR targeted
therapy or therapy for pancreatic cancer 
Active infection requiring intravenous antibiotics
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at the time of registration
Yes
No
Non-pregnant and non-breast-feeding (Female
participants of child-bearing potential must have
a negative urine or serum pregnancy test prior to
registration. Perimenopausal participants must be
amenorrheic > 12 months to be considered not of
childbearing potential. All patients of reproductive
potential must agree to use an effective method
of birth-control while receiving study therapy. If
not a female of child-bearing potential or male
check NA)
N/a (N/A)
No (No)
Yes (Yes)
Negative urine or serum pregnancy test date (If
female of child-bearing potential mm/dd/yyyy)
No prior malignancy within 5 years of registration
(Exceptions: non-melanoma skin cancer, in-situ
cancers)
Yes
No
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Sarcoma NCT00450320 Demographic - AMC-
051 Demographic Form (DEM) - 2636010v1.0
AMC-051 Demographic Form (DEM)
Sirolimus in Treating Patients With HIV-Related Kaposi's
Sarcoma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=2FDFA89A-
0726-6018-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/8808
AMC-051 Demographic Form (DEM)
Header
Patient Initials
Patient's Date of Birth
Gender
Female (FEMALE)
Male (MALE)
Ethnicity
A Person Of Mexican, Puerto Rican,
Cuban, Central Or South American Or
Other Spanish Culture Or Origin,
Regardless Of Race. (Hispanic or Latino)
A Person Not Meeting The Definition For
Hispanic Or Latino. (Not Hispanic or
Latino)
Could Not Be Determined Or Unsure
(Unknown)
Race (check all that apply)
A Person Having Origins In Any Of The
Original Peoples Of North And South
America (including Central America),
And Who Maintains Tribal Affiliation Or
Community Attachment. (American
Indian or Alaska Native)
A Person Having Origins In Any Of The
Original Peoples Of The Far East,
Southeast Asia, Or The Indian
Subcontinent Including, For Example,
Cambodia, China, India, Japan, Korea,
Malaysia, Pakistan, The Philippine
Islands, Thailand, And Vietnam. (Asian)
A Person Having Origins In Any Of The
Black Racial Groups Of Africa. Terms
Such As "haitian" Or "negro" Can Be
Used In Addition To "black Or African
American." (Black or African American)
A Person Having Origins In Any Of The
Original Peoples Of Hawaii, Guam,
Samoa, Or Other Pacific Islands. (Native
Hawaiian or other Pacific Islander)
Could Not Be Determined Or Unsure
(Unknown)
A Person Having Origins In Any Of The
Original Peoples Of Europe, The Middle
East, Or North Africa. (White)
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Patient Zip Code
Method of Payment
Medicaid (Medicaid)
Medicaid And Medicare (Medicaid and
Medicare)
Medicare (Medicare)
Medicare And Private Insurance
(Medicare and Private Insurance)
Military Or Veterans Sponsored Nos
(Military or Veterans Sponsored, Not
Otherwise Specified (NOS))
Military Sponsored (including Champus
& Tricare) (Military Sponsored (including
CHAMPUS & TRICARE))
No Means Of Payment (no Insurance)
(No means of payment (no insurance))
Other (Other)
Private Insurance (Private Insurance)
Self Pay (no Insurance) (Self Pay (No
Insurance))
Unknown (Unknown)
Veterans Sponsored (Veterans
Sponsored)
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Infection NCT00513526 - Demographic - AMC-
052 Demographic Form (DEM) 2676987_v1_0
AMC-052 Demographic Form (DEM)
Human Papillomavirus Vaccine Therapy in Treating Men
With HIV-1 Infection
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=395422A0-
6091-42B3-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/8809
AMC-052 Demographic Form (DEM)
Demografie
Patienteninitialen (Vorname, Nachname)
Patienten Geburtsdatum ( mm / tt / jjjj)
Geschlecht
weiblich (FEMALE)
männlich (MALE)
Volkszugehörigkeit
Eine Person, von mexikanischer, Puerto
Rico, Kuba , Mittel-oder Südamerika
oder anderer spanischer Kultur oder
Herkunft, unabhängig von Rasse .
(Hispanic or Latino)
Eine Person, auf die nicht die Definition
für Spanier oder Lateinamerikaner passt.
(Not Hispanic or Latino)
Konnte nicht ermittelt werden oder
unsicher (Unknown)
Rasse (Zutreffendes bitte ankreuzen)
Eine Person, mit der Herkunft von
irgendeiner der ursprünglichen Völker
von Nord-und Südamerika
(einschließlich Mittelamerika ), und wer
Behält Stammeszugehörigkeit oder
gemeinschaftliche Anlage . (American
Indian or Alaska Native)
Eine Person, mit Ursprüngen in eines
der ursprünglichen Völker des Fernen
Osten, Südostasien , oder dem
indischen Subkontinent einschließlich
zum Beispiel , Kambodscha, China ,
Indien, Japan , Korea, Malaysia ,
Pakistan, die Philippinen, Thailand und
Vietnam . (Asian)
Eine Person, mit der Herkunft von
irgendeiner schwarzen Volksgruppe von
Afrika. (Black or African American)
Eine Person, mit der Herkunft von
irgendeiner der ursprünglichen Völker
von Hawaii, Guam, Samoa oder anderen
pazifischen Inseln . (Native Hawaiian or
other Pacific Islander)
Konnte nicht ermittelt werden oder
unsicher (Unknown)
Eine Person, mit der Herkunft von
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irgendeiner der ursprünglichen Völker
von Europa, den Nahen Osten oder
Nordafrika. (White)
Patient PLZ (xxxxx)
Zahlungsweise
Gesundheitsdienst für Bedüfrtige
(Medicaid)
Gesundheitsdienst für Bedüfrtige und
Gesetzliche Krankenversicherung
(Medicaid and Medicare)
Gesetzliche Krankenversicherung
(Medicare)
Gesetzliche und private Versicherungen
(Medicare and Private Insurance)
Militär- oder Veteranen Sponsored, nicht
näher bezeichnet (Military or Veterans
Sponsored, Not Otherwise Specified
(NOS))
Militärische Sponsored (einschließlich
Champus und Tricare ) (Military
Sponsored (including CHAMPUS &
TRICARE))
Keine Art der Zahlung ( keine
Versicherung ) (No means of payment
(no insurance))
andere (Other)
Privatversicherungen (Private Insurance)
Eigene Bezahlung (keine Versicherung)
(Self Pay (No Insurance))
unbekannt (Unknown)
Veteranen gesponsort (Veterans
Sponsored)
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E1902 Registration Worksheet (step 1)
Reduced-Intensity Regimen Before Donor Bone Marrow
Transplant in Treating Patients With Myelodysplastic
Syndromes
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=74FABE90-
2003-D4A5-E040-BB89AD43500C
All rights reserved. Please visit https://medical-data-
models.org/forms/8810
E1902 Registration Worksheet (step
1)
Eligibility
First initial
Last initial
Has the eligibility checklist been completed
Yes
No
In the opinion of the investigator, is the patient
eligible?
Yes
No
Has written informed consent been obtained
Yes
No
Date Informed Consent Signed
Has HIPAA authorization been obtained
Exempt - Non-usa Participant (Exempt -
non-USA participant)
No: C49487 (No)
Yes: C49488 (Yes)
HIPAA Authorization Date
Has donor and/or parent/guardian given signed
and dated informed consent as appropriate
No: C49487 (No)
Not Applicable (Not Applicable)
Yes: C49488 (Yes)
Date informed consent signed
Has HIPAA authorization been obtained
Exempt - Non-usa Participant (Exempt -
non-USA participant)
No: C49487 (No)
Yes: C49488 (Yes)
HIPAA authorization date
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Name of local cytogenetics lab
Phone number
Have/will center complete QARC TBI benchmark
prior to patients receiving TBI on this protocol
Yes
No
My specimens may be kept for use in research to
learn about, prevent, treat, or cure cancer.
Yes
No
My specimens may be kept for use in research
about other health problems (for example:
diabetes, Alzheimer's disease, or heart disease).
Yes
No
Someone from this institution may contact me in
the future to ask me to take part in more
research.
Yes
No
Name of the contact person responsible for
sample submission
Phone number of the contact person responsible
for sample submission
Fax number of the contact person responsible for
sample submission
E-mail address of the contact person responsible
for sample submission
Race
Patient's Race
A Person Having Origins In Any Of The
Original Peoples Of North And South
America (including Central America),
And Who Maintains Tribal Affiliation Or
Community Attachment. (American
Indian or Alaska Native)
A Person Having Origins In Any Of The
Original Peoples Of The Far East,
Southeast Asia, Or The Indian
Subcontinent Including, For Example,
Cambodia, China, India, Japan, Korea,
Malaysia, Pakistan, The Philippine
Islands, Thailand, And Vietnam. (Asian)
A Person Having Origins In Any Of The
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Black Racial Groups Of Africa. Terms
Such As "haitian" Or "negro" Can Be
Used In Addition To "black Or African
American." (Black or African American)
A Person Having Origins In Any Of The
Original Peoples Of Hawaii, Guam,
Samoa, Or Other Pacific Islands. (Native
Hawaiian or other Pacific Islander)
Not Provided Or Available (Not
Reported)
Could Not Be Determined Or Unsure
(Unknown)
A Person Having Origins In Any Of The
Original Peoples Of Europe, The Middle
East, Or North Africa. (White)
Patient Demographics / Pre-treatment
Characteristics
Patient's Sex
Female (F)
Male (M)
Birthdate (mm/yy)
ZIP Code
Patient Ethnicity
A Person Of Mexican, Puerto Rican,
Cuban, Central Or South American Or
Other Spanish Culture Or Origin,
Regardless Of Race. (Hispanic or Latino)
A Person Not Meeting The Definition For
Hispanic Or Latino. (Not Hispanic or
Latino)
Not Provided Or Available (Not reported)
Could Not Be Determined Or Unsure
(Unknown)
Patient Hospital No.
Patient Social Security Number
Method of payment (check one)
Medicaid (Medicaid)
Medicaid And Medicare (Medicaid and
Medicare)
Medicare (Medicare)
Medicare And Private Insurance
(Medicare and Private Insurance)
Military Or Veterans Sponsored Nos
(Military or Veterans Sponsored, Not
Otherwise Specified (NOS))
Military Sponsored (including Champus
& Tricare) (Military Sponsored (including
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CHAMPUS & TRICARE))
No Means Of Payment (no Insurance)
(No means of payment (no insurance))
Other (Other)
Private Insurance (Private Insurance)
Self Pay (no Insurance) (Self Pay (No
Insurance))
Unknown (Unknown)
Veterans Sponsored (Veterans
Sponsored)
Attending Physician
Institution contact
Registrar
Country of residence
Ascension Island (AC)
Andorra (AD)
United Arab Emirates (AE)
Afghanistan (AF)
Antigua And Barbuda (AG)
Anguilla (AI)
Albania (AL)
Armenia (AM)
Netherland Antilles (AN)
Angola (AO)
Antarctica (AQ)
Argentina (AR)
American Samoa (AS)
Austria (AT)
Australia (AU)
Aruba (AW)
Azerbaidjan (AZ)
Bosnia-herzegovina (BA)
Barbados (BB)
Bangladesh (BD)
Belgium (BE)
Burkina Faso (BF)
Bulgaria (BG)
Bahrain (BH)
Burundi (BI)
Benin (BJ)
Bermuda (BM)
Brunei Darussalam (BN)
Bolivia (BO)
Brazil (BR)
Bahamas (BS)
Bhutan (BT)
Bouvet Island (BV)
Botswana (BW)
Belarus (BY)
Belize (BZ)
Canada (CA)
Cocos Isl. (CC)
Rep. Dem. Congo (CD)
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Central African Rep. (CF)
Congo (CG)
Switzerland (CH)
Ivory Coast (CI)
Cook Islands (CK)
Chile (CL)
Cameroon (CM)
China (CN)
Colombia (CO)
Costa Rica (CR)
Cuba (CU)
Cape Verde (CV)
Christmas Island (CX)
Cyprus (CY)
Czech Republic (CZ)
Germany (DE)
Djibouti (DJ)
Denmark (DK)
Dominica (DM)
Dominican Republic (DO)
Algeria (DZ)
Ecuador (EC)
Estonia (EE)
Egypt (EG)
Western Sahara (EH)
Eritrea (ER)
Spain (ES)
Ethiopia (ET)
Finland (FI)
Fiji (FJ)
Falkland Isl. (FK)
Micronesia (FM)
Faroe Islands (FO)
France (FR)
France (european Ter.) (FX)
Gabon (GA)
Great Britain (GB)
Grenada (GD)
Georgia (GE)
Guiana (fr.) (GF)
Guernsey (GG)
Ghana (GH)
Gibraltar (GI)
Greenland (GL)
Gambia (GM)
Guinea (GN)
Guadeloupe (fr.) (GP)
Equatorial Guinea (GQ)
Greece (GR)
South Georgia And South Sandwich
Islands (GS)
Guatemala (GT)
Guam (us) (GU)
Guinea Bissau (GW)
Guyana (GY)
Hong Kong (HK)
Heard & Mcdonald Isl. (HM)
Honduras (HN)
Croatia (HR)
Haiti (HT)
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Hungary (HU)
Indonesia (ID)
Ireland (IE)
Israel (IL)
Isle Of Man (IM)
India (IN)
British Indian O. Ter. (IO)
Iraq (IQ)
Iran (IR)
Iceland (IS)
Italy (IT)
Jersey (JE)
Jamaica (JM)
Jordan (JO)
Japan (JP)
Kenya (KE)
Kyrgyz Republic (KG)
Cambodia (KH)
Kiribati (KI)
Comoros (KM)
St. Kitts Nevis Anguilla (KN)
Korea (north) (KP)
Korea (south) (KR)
Kuwait (KW)
Cayman Islands (KY)
Kazakstan (KZ)
Laos (LA)
Lebanon (LB)
Saint Lucia (LC)
Liechtenstein (LI)
Sri Lanka (LK)
Liberia (LR)
Lesotho (LS)
Lithuania (LT)
Luxembourg (LU)
Latvia (LV)
Libya (LY)
Morocco (MA)
Monaco (MC)
Moldova (MD)
Madagascar (MG)
Marshall Islands (MH)
Macedonia (MK)
Mali (ML)
Myanmar (MM)
Mongolia (MN)
Macau (MO)
Northern Mariana Isl. (MP)
Martinique (fr.) (MQ)
Mauritania (MR)
Montserrat (MS)
Malta (MT)
Mauritius (MU)
Maldives (MV)
Malawi (MW)
Mexico (MX)
Malaysia (MY)
Mozambique (MZ)
Namibia (NA)
New Caledonia (fr.) (NC)
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Niger (NE)
Norfolk Island (NF)
Nigeria (NG)
Nicaragua (NI)
Netherlands (NL)
Norway (NO)
Nepal (NP)
Nauru (NR)
Niue (NU)
New Zealand (NZ)
Oman (OM)
Other (Other)
Panama (PA)
Peru (PE)
Polynesia (fr.) (PF)
Papua New Guinea (PG)
Philippines (PH)
Pakistan (PK)
Poland (PL)
St. Pierre & Miquelon (PM)
Pitcairn (PN)
Puerto Rico (PR)
Portugal (PT)
Palau (PW)
Paraguay (PY)
Qatar (QA)
Reunion (fr.) (RE)
Romania (RO)
Russian Federation (RU)
Rwanda (RW)
Saudi Arabia (SA)
Solomon Islands (SB)
Seychelles (SC)
Sudan (SD)
Sweden (SE)
Singapore (SG)
St. Helena (SH)
Slovenia (SI)
Svalbard & Jan Mayen Isl. (SJ)
Slovakia (SK)
Sierra Leone (SL)
San Marino (SM)
Senegal (SN)
Somalia (SO)
Suriname (SR)
St. Tome And Principe (ST)
Soviet Union (SU)
El Salvador (SV)
Syria (SY)
Swaziland (SZ)
Turks & Caicos Islands (TC)
Chad (TD)
French Southern Terr. (TF)
Togo (TG)
Thailand (TH)
Tadjikistan (TJ)
Tokelau (TK)
Turkmenistan (TM)
Tunisia (TN)
Tonga (TO)
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East Timor (TP)
Turkey (TR)
Trinidad & Tobago (TT)
Tuvalu (TV)
Taiwan (TW)
Tanzania (TZ)
Ukraine (UA)
Uganda (UG)
United Kingdom (UK)
Us Minor Outlying Isl. (UM)
Usa (US)
Uruguay (UY)
Uzbekistan (UZ)
Vatican City State (VA)
St. Vincent & Grenadines (VC)
Venezuela (VE)
Virgin Islands (brit) (VG)
Virgin Islands (us) (VI)
Vietnam (VN)
Vanuatu (VU)
Wallis & Futuna Islands (WF)
Western Samoa (WS)
Yemen (YE)
Mayotte (YT)
Yugoslavia (YU)
South Africa (ZA)
Zambia (ZM)
Dem. Rep. Of Congo (ZR)
Zimbabwe (ZW)
Comments
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Lung Cancer NCT01336894 Toxicity - ACOSOG-
Z4099 Baseline Adverse Event Form - 3177833v1.0
ACOSOG-Z4099 Baseline Adverse Event Form
Surgery With or Without Internal Radiation Therapy
Compared With Stereotactic Body Radiation Therapy in
Treating Patients With High-Risk Stage I Non-Small Cell
Lung Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=9805AE2C-
90B9-70EF-E040-BB89AD431611
All rights reserved. Please visit https://medical-data-
models.org/forms/8814
ACOSOG-Z4099 Baseline Adverse
Event Form
Header Module
Protocol Number
Patient ID
Patient Initials (L F M)
Institution Number
Institution
Are data amended (check one if data amended,
please circle in red when using paper forms)
Yes
No
Visit
Visit
Registration (Registration)
Required Baseline Adverse Events From
Section 8 Of Protocol
CTC Adverse Event Term (CTCAE v.4.0)
Abdominal Distension (Abdominal
distension)
Abdominal Infection (Abdominal
infection)
Abdominal Pain (Abdominal pain)
Abdominal Soft Tissue Necrosis
(Abdominal soft tissue necrosis)
Abducens Nerve Disorder (Abducens
nerve disorder)
Accessory Nerve Disorder (Accessory
nerve disorder)
Acidosis (Acidosis)
Acoustic Nerve Disorder Nos (Acoustic
nerve disorder NOS)
Activated Partial Thromboplastin Time
Prolonged (Activated partial
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thromboplastin time prolonged)
Acute Coronary Syndrome (Acute
coronary syndrome)
Acute Kidney Injury (Acute kidney injury)
Adrenal Insufficiency (Adrenal
insufficiency)
Adult Respiratory Distress Syndrome
(Adult respiratory distress syndrome)
Agitation (Agitation)
Akathisia (Akathisia)
Alanine Aminotransferase Increased
(Alanine aminotransferase increased)
Alcohol Intolerance (Alcohol intolerance)
Alkaline Phosphatase Increased
(Alkaline phosphatase increased)
Alkalosis (Alkalosis)
Allergic Reaction (Allergic reaction)
Allergic Rhinitis (Allergic rhinitis)
Alopecia (Alopecia)
Amnesia (Amnesia)
Anal Fistula (Anal fistula)
Anal Hemorrhage (Anal hemorrhage)
Anal Mucositis (Anal mucositis)
Anal Necrosis (Anal necrosis)
Anal Pain (Anal pain)
Anal Stenosis (Anal stenosis)
Anal Ulcer (Anal ulcer)
Anaphylaxis (Anaphylaxis)
Anemia (Anemia)
Ankle Fracture (Ankle fracture)
Anorectal Infection (Anorectal infection)
Anorexia (Anorexia)
Anorgasmia (Anorgasmia)
Anxiety (Anxiety)
Aortic Injury (Aortic injury)
Aortic Valve Disease (Aortic valve
disease)
Aphonia (Aphonia)
Apnea (Apnea)
Appendicitis (Appendicitis)
Appendicitis Perforated (Appendicitis
perforated)
Arachnoiditis (Arachnoiditis)
Arterial Injury (Arterial injury)
Arteritis Infective (Arteritis infective)
Arthralgia (Arthralgia)
Arthritis (Arthritis)
Ascites (Ascites)
Aspartate Aminotransferase Increased
(Aspartate aminotransferase increased)
Aspiration (Aspiration)
Asystole (Asystole)
Ataxia (Ataxia)
Atelectasis (Atelectasis)
Atrial Fibrillation (Atrial fibrillation)
Atrial Flutter (Atrial flutter)
Atrioventricular Block Complete
(Atrioventricular block complete)
Atrioventricular Block First Degree
(Atrioventricular block first degree)
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Autoimmune Disorder (Autoimmune
disorder)
Avascular Necrosis (Avascular necrosis)
Azoospermia (Azoospermia)
Back Pain (Back pain)
Bile Duct Stenosis (Bile duct stenosis)
Biliary Anastomotic Leak (Biliary
anastomotic leak)
Biliary Fistula (Biliary fistula)
Biliary Tract Infection (Biliary tract
infection)
Bladder Anastomotic Leak (Bladder
anastomotic leak)
Bladder Infection (Bladder infection)
Bladder Perforation (Bladder perforation)
Bladder Spasm (Bladder spasm)
Bloating (Bloating)
Blood And Lymphatic System Disorders -
Other, Specify (Blood and lymphatic
system disorders - Other, Specify)
Blood Antidiuretic Hormone Abnormal
(Blood antidiuretic hormone abnormal)
Blood Bilirubin Increased (Blood bilirubin
increased)
Blood Corticotrophin Decreased (Blood
corticotrophin decreased)
Blood Gonadotrophin Abnormal (Blood
gonadotrophin abnormal)
Blood Prolactin Abnormal (Blood
prolactin abnormal)
Blurred Vision (Blurred vision)
Body Odor (Body odor)
Bone Infection (Bone infection)
Bone Marrow Hypocellular (Bone
marrow hypocellular)
Bone Pain (Bone pain)
Brachial Plexopathy (Brachial
plexopathy)
Breast Atrophy (Breast atrophy)
Breast Infection (Breast infection)
Breast Pain (Breast pain)
Bronchial Fistula (Bronchial fistula)
Bronchial Infection (Bronchial infection)
Bronchial Obstruction (Bronchial
obstruction)
Bronchial Stricture (Bronchial stricture)
Bronchopleural Fistula (Bronchopleural
fistula)
Bronchopulmonary Hemorrhage
(Bronchopulmonary hemorrhage)
Bronchospasm (Bronchospasm)
Bruising (Bruising)
Bullous Dermatitis (Bullous dermatitis)
Burn (Burn)
Buttock Pain (Buttock pain)
Capillary Leak Syndrome (Capillary leak
syndrome)
Carbon Monoxide Diffusing Capacity
Decreased (Carbon monoxide diffusing
capacity decreased)
3 / 21
Lung Cancer NCT01336894 Toxicity - ACOSOG-Z4099 Baseline Adverse
Event Form - 3177833v1.0
Cardiac Arrest (Cardiac arrest)
Cardiac Disorders - Other, Specify
(Cardiac disorders - Other, Specify)
Cardiac Troponin I Increased (Cardiac
troponin I increased)
Cardiac Troponin T Increased (Cardiac
troponin T increased)
Cataract (Cataract)
Catheter Related Infection (Catheter
related infection)
Cd4 Lymphocytes Decreased (CD4
lymphocytes decreased)
Cecal Hemorrhage (Cecal hemorrhage)
Cecal Infection (Cecal infection)
Central Nervous System Necrosis
(Central nervous system necrosis)
Cerebrospinal Fluid Leakage
(Cerebrospinal fluid leakage)
Cervicitis Infection (Cervicitis infection)
Cheilitis (Cheilitis)
Chest Pain - Cardiac (Chest pain -
cardiac)
Chest Wall Pain (Chest wall pain)
Chills (Chills)
Cholecystitis (Cholecystitis)
Cholesterol High (Cholesterol high)
Chronic Kidney Disease (Chronic kidney
disease)
Chylothorax (Chylothorax)
Cognitive Disturbance (Cognitive
disturbance)
Colitis (Colitis)
Colonic Fistula (Colonic fistula)
Colonic Hemorrhage (Colonic
hemorrhage)
Colonic Obstruction (Colonic obstruction)
Colonic Perforation (Colonic perforation)
Colonic Stenosis (Colonic stenosis)
Colonic Ulcer (Colonic ulcer)
Concentration Impairment
(Concentration impairment)
Conduction Disorder (Conduction
disorder)
Confusion (Confusion)
Congenital, Familial And Genetic
Disorders - Other, Specify (Congenital,
familial and genetic disorders - Other,
Specify)
Conjunctivitis (Conjunctivitis)
Conjunctivitis Infective (Conjunctivitis
infective)
Constipation (Constipation)
Constrictive Pericarditis (Constrictive
pericarditis)
Corneal Infection (Corneal infection)
Corneal Ulcer (Corneal ulcer)
Cough (Cough)
Cpk Increased (CPK increased)
Cranial Nerve Infection (Cranial nerve
infection)
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Creatinine Increased (Creatinine
increased)
Cushingoid (Cushingoid)
Cystitis Noninfective (Cystitis
noninfective)
Cytokine Release Syndrome (Cytokine
release syndrome)
Death Neonatal (Death neonatal)
Death Nos (Death NOS)
Dehydration (Dehydration)
Delayed Orgasm (Delayed orgasm)
Delayed Puberty (Delayed puberty)
Delirium (Delirium)
Delusions (Delusions)
Dental Caries (Dental caries)
Depressed Level Of Consciousness
(Depressed level of consciousness)
Depression (Depression)
Dermatitis Radiation (Dermatitis
radiation)
Device Related Infection (Device related
infection)
Diarrhea (Diarrhea)
Disseminated Intravascular Coagulation
(Disseminated intravascular coagulation)
Dizziness (Dizziness)
Dry Eye (Dry eye)
Dry Mouth (Dry mouth)
Dry Skin (Dry skin)
Duodenal Fistula (Duodenal fistula)
Duodenal Hemorrhage (Duodenal
hemorrhage)
Duodenal Infection (Duodenal infection)
Duodenal Obstruction (Duodenal
obstruction)
Duodenal Perforation (Duodenal
perforation)
Duodenal Stenosis (Duodenal stenosis)
Duodenal Ulcer (Duodenal ulcer)
Dysarthria (Dysarthria)
Dysesthesia (Dysesthesia)
Dysgeusia (Dysgeusia)
Dysmenorrhea (Dysmenorrhea)
Dyspareunia (Dyspareunia)
Dyspepsia (Dyspepsia)
Dysphagia (Dysphagia)
Dysphasia (Dysphasia)
Dyspnea (Dyspnea)
Ear And Labyrinth Disorders - Other,
Specify (Ear and labyrinth disorders -
Other, Specify)
Ear Pain (Ear pain)
Edema Cerebral (Edema cerebral)
Edema Face (Edema face)
Edema Limbs (Edema limbs)
Edema Trunk (Edema trunk)
Ejaculation Disorder (Ejaculation
disorder)
Ejection Fraction Decreased (Ejection
fraction decreased)
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Electrocardiogram Qt Corrected Interval
Prolonged (Electrocardiogram QT
corrected interval prolonged)
Encephalitis Infection (Encephalitis
infection)
Encephalomyelitis Infection
(Encephalomyelitis infection)
Encephalopathy (Encephalopathy)
Endocarditis Infective (Endocarditis
infective)
Endocrine Disorders - Other, Specify
(Endocrine disorders - Other, Specify)
Endophthalmitis (Endophthalmitis)
Enterocolitis (Enterocolitis)
Enterocolitis Infectious (Enterocolitis
infectious)
Enterovesical Fistula (Enterovesical
fistula)
Epistaxis (Epistaxis)
Erectile Dysfunction (Erectile
dysfunction)
Erythema Multiforme (Erythema
multiforme)
Erythroderma (Erythroderma)
Esophageal Anastomotic Leak
(Esophageal anastomotic leak)
Esophageal Fistula (Esophageal fistula)
Esophageal Hemorrhage (Esophageal
hemorrhage)
Esophageal Infection (Esophageal
infection)
Esophageal Necrosis (Esophageal
necrosis)
Esophageal Obstruction (Esophageal
obstruction)
Esophageal Pain (Esophageal pain)
Esophageal Perforation (Esophageal
perforation)
Esophageal Stenosis (Esophageal
stenosis)
Esophageal Ulcer (Esophageal ulcer)
Esophageal Varices Hemorrhage
(Esophageal varices hemorrhage)
Esophagitis (Esophagitis)
Euphoria (Euphoria)
Exostosis (Exostosis)
External Ear Inflammation (External ear
inflammation)
External Ear Pain (External ear pain)
Extraocular Muscle Paresis (Extraocular
muscle paresis)
Extrapyramidal Disorder (Extrapyramidal
disorder)
Eye Disorders - Other, Specify (Eye
disorders - Other, Specify)
Eye Infection (Eye infection)
Eye Pain (Eye pain)
Eyelid Function Disorder (Eyelid function
disorder)
Facial Muscle Weakness (Facial muscle
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weakness)
Facial Nerve Disorder (Facial nerve
disorder)
Facial Pain (Facial pain)
Fall (Fall)
Fallopian Tube Anastomotic Leak
(Fallopian tube anastomotic leak)
Fallopian Tube Obstruction (Fallopian
tube obstruction)
Fallopian Tube Perforation (Fallopian
tube perforation)
Fallopian Tube Stenosis (Fallopian tube
stenosis)
Fat Atrophy (Fat atrophy)
Fatigue (Fatigue)
Febrile Neutropenia (Febrile
neutropenia)
Fecal Incontinence (Fecal incontinence)
Female Genital Tract Fistula (Female
genital tract fistula)
Feminization Acquired (Feminization
acquired)
Fetal Death (Fetal death)
Fetal Growth Retardation (Fetal growth
retardation)
Fever (Fever)
Fibrinogen Decreased (Fibrinogen
decreased)
Fibrosis Deep Connective Tissue
(Fibrosis deep connective tissue)
Flank Pain (Flank pain)
Flashing Lights (Flashing lights)
Flatulence (Flatulence)
Floaters (Floaters)
Flu Like Symptoms (Flu like symptoms)
Flushing (Flushing)
Forced Expiratory Volume Decreased
(Forced expiratory volume decreased)
Fracture (Fracture)
Gait Disturbance (Gait disturbance)
Gallbladder Fistula (Gallbladder fistula)
Gallbladder Infection (Gallbladder
infection)
Gallbladder Necrosis (Gallbladder
necrosis)
Gallbladder Obstruction (Gallbladder
obstruction)
Gallbladder Pain (Gallbladder pain)
Gallbladder Perforation (Gallbladder
perforation)
Gastric Anastomotic Leak (Gastric
anastomotic leak)
Gastric Fistula (Gastric fistula)
Gastric Hemorrhage (Gastric
hemorrhage)
Gastric Necrosis (Gastric necrosis)
Gastric Perforation (Gastric perforation)
Gastric Stenosis (Gastric stenosis)
Gastric Ulcer (Gastric ulcer)
Gastritis (Gastritis)
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Gastroesophageal Reflux Disease
(Gastroesophageal reflux disease)
Gastrointestinal Anastomotic Leak
(Gastrointestinal anastomotic leak)
Gastrointestinal Disorders - Other,
Specify (Gastrointestinal disorders -
Other, Specify)
Gastrointestinal Fistula (Gastrointestinal
fistula)
Gastrointestinal Pain (Gastrointestinal
pain)
Gastrointestinal Stoma Necrosis
(Gastrointestinal stoma necrosis)
Gastroparesis (Gastroparesis)
General Disorders And Administration
Site Conditions - Other, Specify (General
disorders and administration site
conditions - Other, Specify)
Generalized Muscle Weakness
(Generalized muscle weakness)
Genital Edema (Genital edema)
Ggt Increased (GGT increased)
Gingival Pain (Gingival pain)
Glaucoma (Glaucoma)
Glossopharyngeal Nerve Disorder
(Glossopharyngeal nerve disorder)
Glucose Intolerance (Glucose
intolerance)
Growth Accelerated (Growth
accelerated)
Growth Hormone Abnormal (Growth
hormone abnormal)
Growth Suppression (Growth
suppression)
Gum Infection (Gum infection)
Gynecomastia (Gynecomastia)
Hallucinations (Hallucinations)
Haptoglobin Decreased (Haptoglobin
decreased)
Head Soft Tissue Necrosis (Head soft
tissue necrosis)
Headache (Headache)
Hearing Impaired (Hearing impaired)
Heart Failure (Heart failure)
Hematoma (Hematoma)
Hematosalpinx (Hematosalpinx)
Hematuria (Hematuria)
Hemoglobin Increased (Hemoglobin
increased)
Hemoglobinuria (Hemoglobinuria)
Hemolysis (Hemolysis)
Hemolytic Uremic Syndrome (Hemolytic
uremic syndrome)
Hemorrhoidal Hemorrhage
(Hemorrhoidal hemorrhage)
Hemorrhoids (Hemorrhoids)
Hepatic Failure (Hepatic failure)
Hepatic Hemorrhage (Hepatic
hemorrhage)
Hepatic Infection (Hepatic infection)
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Hepatic Necrosis (Hepatic necrosis)
Hepatic Pain (Hepatic pain)
Hepatitis Viral (Hepatitis viral)
Hepatobiliary Disorders - Other, Specify
(Hepatobiliary disorders - Other, Specify)
Hiccups (Hiccups)
Hip Fracture (Hip fracture)
Hirsutism (Hirsutism)
Hoarseness (Hoarseness)
Hot Flashes (Hot flashes)
Hydrocephalus (Hydrocephalus)
Hypercalcemia (Hypercalcemia)
Hyperglycemia (Hyperglycemia)
Hyperhidrosis (Hyperhidrosis)
Hyperkalemia (Hyperkalemia)
Hypermagnesemia (Hypermagnesemia)
Hypernatremia (Hypernatremia)
Hyperparathyroidism
(Hyperparathyroidism)
Hypersomnia (Hypersomnia)
Hypertension (Hypertension)
Hyperthyroidism (Hyperthyroidism)
Hypertrichosis (Hypertrichosis)
Hypertriglyceridemia
(Hypertriglyceridemia)
Hyperuricemia (Hyperuricemia)
Hypoalbuminemia (Hypoalbuminemia)
Hypocalcemia (Hypocalcemia)
Hypoglossal Nerve Disorder
(Hypoglossal nerve disorder)
Hypoglycemia (Hypoglycemia)
Hypohidrosis (Hypohidrosis)
Hypokalemia (Hypokalemia)
Hypomagnesemia (Hypomagnesemia)
Hyponatremia (Hyponatremia)
Hypoparathyroidism
(Hypoparathyroidism)
Hypophosphatemia (Hypophosphatemia)
Hypotension (Hypotension)
Hypothermia (Hypothermia)
Hypothyroidism (Hypothyroidism)
Hypoxia (Hypoxia)
Ileal Fistula (Ileal fistula)
Ileal Hemorrhage (Ileal hemorrhage)
Ileal Obstruction (Ileal obstruction)
Ileal Perforation (Ileal perforation)
Ileal Stenosis (Ileal stenosis)
Ileal Ulcer (Ileal ulcer)
Ileus (Ileus)
Immune System Disorders - Other,
Specify (Immune system disorders -
Other, Specify)
Infections And Infestations - Other,
Specify (Infections and infestations -
Other, Specify)
Infective Myositis (Infective myositis)
Infusion Related Reaction (Infusion
related reaction)
Infusion Site Extravasation (Infusion site
extravasation)
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Injection Site Reaction (Injection site
reaction)
Injury To Carotid Artery (Injury to carotid
artery)
Injury To Inferior Vena Cava (Injury to
inferior vena cava)
Injury To Jugular Vein (Injury to jugular
vein)
Injury To Superior Vena Cava (Injury to
superior vena cava)
Injury, Poisoning And Procedural
Complications - Other, Specify (Injury,
poisoning and procedural complications -
Other, Specify)
Inr Increased (INR increased)
Insomnia (Insomnia)
Intestinal Stoma Leak (Intestinal stoma
leak)
Intestinal Stoma Obstruction (Intestinal
stoma obstruction)
Intestinal Stoma Site Bleeding (Intestinal
stoma site bleeding)
Intra-abdominal Hemorrhage (Intra-
abdominal hemorrhage)
Intracranial Hemorrhage (Intracranial
hemorrhage)
Intraoperative Arterial Injury
(Intraoperative arterial injury)
Intraoperative Breast Injury
(Intraoperative breast injury)
Intraoperative Cardiac Injury
(Intraoperative cardiac injury)
Intraoperative Ear Injury (Intraoperative
ear injury)
Intraoperative Endocrine Injury
(Intraoperative endocrine injury)
Intraoperative Gastrointestinal Injury
(Intraoperative gastrointestinal injury)
Intraoperative Head And Neck Injury
(Intraoperative head and neck injury)
Intraoperative Hemorrhage
(Intraoperative hemorrhage)
Intraoperative Hepatobiliary Injury
(Intraoperative hepatobiliary injury)
Intraoperative Musculoskeletal Injury
(Intraoperative musculoskeletal injury)
Intraoperative Neurological Injury
(Intraoperative neurological injury)
Intraoperative Ocular Injury
(Intraoperative ocular injury)
Intraoperative Renal Injury
(Intraoperative renal injury)
Intraoperative Reproductive Tract Injury
(Intraoperative reproductive tract injury)
Intraoperative Respiratory Injury
(Intraoperative respiratory injury)
Intraoperative Skin Injury (Intraoperative
skin injury)
Intraoperative Splenic Injury
(Intraoperative splenic injury)
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Intraoperative Urinary Injury
(Intraoperative urinary injury)
Intraoperative Venous Injury
(Intraoperative venous injury)
Investigations - Other, Specify
(Investigations - Other, Specify)
Iron Overload (Iron overload)
Irregular Menstruation (Irregular
menstruation)
Irritability (Irritability)
Ischemia Cerebrovascular (Ischemia
cerebrovascular)
Ivth Nerve Disorder (IVth nerve disorder)
Jejunal Fistula (Jejunal fistula)
Jejunal Hemorrhage (Jejunal
hemorrhage)
Jejunal Obstruction (Jejunal obstruction)
Jejunal Perforation (Jejunal perforation)
Jejunal Stenosis (Jejunal stenosis)
Jejunal Ulcer (Jejunal ulcer)
Joint Effusion (Joint effusion)
Joint Infection (Joint infection)
Joint Range Of Motion Decreased (Joint
range of motion decreased)
Joint Range Of Motion Decreased
Cervical Spine (Joint range of motion
decreased cervical spine)
Joint Range Of Motion Decreased
Lumbar Spine (Joint range of motion
decreased lumbar spine)
Keratitis (Keratitis)
Kidney Anastomotic Leak (Kidney
anastomotic leak)
Kidney Infection (Kidney infection)
Kyphosis (Kyphosis)
Lactation Disorder (Lactation disorder)
Large Intestinal Anastomotic Leak (Large
intestinal anastomotic leak)
Laryngeal Edema (Laryngeal edema)
Laryngeal Fistula (Laryngeal fistula)
Laryngeal Hemorrhage (Laryngeal
hemorrhage)
Laryngeal Inflammation (Laryngeal
inflammation)
Laryngeal Mucositis (Laryngeal
mucositis)
Laryngeal Obstruction (Laryngeal
obstruction)
Laryngeal Stenosis (Laryngeal stenosis)
Laryngitis (Laryngitis)
Laryngopharyngeal Dysesthesia
(Laryngopharyngeal dysesthesia)
Laryngospasm (Laryngospasm)
Left Ventricular Systolic Dysfunction (Left
ventricular systolic dysfunction)
Lethargy (Lethargy)
Leukemia Secondary To Oncology
Chemotherapy (Leukemia secondary to
oncology chemotherapy)
Leukocytosis (Leukocytosis)
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Leukoencephalopathy
(Leukoencephalopathy)
Libido Decreased (Libido decreased)
Libido Increased (Libido increased)
Lip Infection (Lip infection)
Lip Pain (Lip pain)
Lipase Increased (Lipase increased)
Lipohypertrophy (Lipohypertrophy)
Localized Edema (Localized edema)
Lordosis (Lordosis)
Lower Gastrointestinal Hemorrhage
(Lower gastrointestinal hemorrhage)
Lung Infection (Lung infection)
Lymph Gland Infection (Lymph gland
infection)
Lymph Leakage (Lymph leakage)
Lymph Node Pain (Lymph node pain)
Lymphedema (Lymphedema)
Lymphocele (Lymphocele)
Lymphocyte Count Decreased
(Lymphocyte count decreased)
Lymphocyte Count Increased
(Lymphocyte count increased)
Malabsorption (Malabsorption)
Malaise (Malaise)
Mania (Mania)
Mediastinal Hemorrhage (Mediastinal
hemorrhage)
Mediastinal Infection (Mediastinal
infection)
Memory Impairment (Memory
impairment)
Meningismus (Meningismus)
Meningitis (Meningitis)
Menopause (Menopause)
Menorrhagia (Menorrhagia)
Metabolism And Nutrition Disorders -
Other, Specify (Metabolism and nutrition
disorders - Other, Specify)
Middle Ear Inflammation (Middle ear
inflammation)
Mitral Valve Disease (Mitral valve
disease)
Mobitz (type) Ii Atrioventricular Block
(Mobitz (type) II atrioventricular block)
Mobitz Type I (Mobitz type I)
Movements Involuntary (Movements
involuntary)
Mucosal Infection (Mucosal infection)
Mucositis Oral (Mucositis oral)
Multi-organ Failure (Multi-organ failure)
Muscle Weakness Left-sided (Muscle
weakness left-sided)
Muscle Weakness Lower Limb (Muscle
weakness lower limb)
Muscle Weakness Right-sided (Muscle
weakness right-sided)
Muscle Weakness Trunk (Muscle
weakness trunk)
Muscle Weakness Upper Limb (Muscle
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weakness upper limb)
Musculoskeletal And Connective Tissue
Disorder - Other, Specify
(Musculoskeletal and connective tissue
disorders - Other, Specify)
Musculoskeletal Deformity
(Musculoskeletal deformity)
Myalgia (Myalgia)
Myelitis (Myelitis)
Myelodysplastic Syndrome
(Myelodysplastic syndrome)
Myocardial Infarction (Myocardial
infarction)
Myocarditis (Myocarditis)
Myositis (Myositis)
Nail Discoloration (Nail discoloration)
Nail Infection (Nail infection)
Nail Loss (Nail loss)
Nail Ridging (Nail ridging)
Nasal Congestion (Nasal congestion)
Nausea (Nausea)
Neck Edema (Neck edema)
Neck Pain (Neck pain)
Neck Soft Tissue Necrosis (Neck soft
tissue necrosis)
Neoplasms Benign, Malignant And
Unspecified (incl Cysts And Polyps) -
Other, Specify (Neoplasms benign,
malignant and unspecified (incl cysts and
polyps) - Other, Specify)
Nervous System Disorders - Other,
Specify (Nervous system disorders -
Other, Specify)
Neuralgia (Neuralgia)
Neutrophil Count Decreased (Neutrophil
count decreased)
Night Blindness (Night blindness)
Nipple Deformity (Nipple deformity)
Non-cardiac Chest Pain (Non-cardiac
chest pain)
Nystagmus (Nystagmus)
Obesity (Obesity)
Obstruction Gastric (Obstruction gastric)
Oculomotor Nerve Disorder (Oculomotor
nerve disorder)
Olfactory Nerve Disorder (Olfactory
nerve disorder)
Oligospermia (Oligospermia)
Optic Nerve Disorder (Optic nerve
disorder)
Oral Cavity Fistula (Oral cavity fistula)
Oral Dysesthesia (Oral dysesthesia)
Oral Hemorrhage (Oral hemorrhage)
Oral Pain (Oral pain)
Osteonecrosis Of Jaw (Osteonecrosis of
jaw)
Osteoporosis (Osteoporosis)
Otitis Externa (Otitis externa)
Otitis Media (Otitis media)
Ovarian Hemorrhage (Ovarian
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hemorrhage)
Ovarian Infection (Ovarian infection)
Ovarian Rupture (Ovarian rupture)
Ovulation Pain (Ovulation pain)
Pain (Pain)
Pain In Extremity (Pain in extremity)
Pain Of Skin (Pain of skin)
Palmar-plantar Erythrodysesthesia
Syndrome (Palmar-plantar
erythrodysesthesia syndrome)
Palpitations (Palpitations)
Pancreas Infection (Pancreas infection)
Pancreatic Anastomotic Leak (Pancreatic
anastomotic leak)
Pancreatic Duct Stenosis (Pancreatic
duct stenosis)
Pancreatic Enzymes Decreased
(Pancreatic enzymes decreased)
Pancreatic Fistula (Pancreatic fistula)
Pancreatic Hemorrhage (Pancreatic
hemorrhage)
Pancreatic Necrosis (Pancreatic
necrosis)
Pancreatitis (Pancreatitis)
Papilledema (Papilledema)
Papulopustular Rash (Papulopustular
rash)
Paresthesia (Paresthesia)
Paronychia (Paronychia)
Paroxysmal Atrial Tachycardia
(Paroxysmal atrial tachycardia)
Pelvic Floor Muscle Weakness (Pelvic
floor muscle weakness)
Pelvic Infection (Pelvic infection)
Pelvic Pain (Pelvic pain)
Pelvic Soft Tissue Necrosis (Pelvic soft
tissue necrosis)
Penile Infection (Penile infection)
Penile Pain (Penile pain)
Perforation Bile Duct (Perforation bile
duct)
Pericardial Effusion (Pericardial effusion)
Pericardial Tamponade (Pericardial
tamponade)
Pericarditis (Pericarditis)
Perineal Pain (Perineal pain)
Periodontal Disease (Periodontal
disease)
Periorbital Edema (Periorbital edema)
Periorbital Infection (Periorbital infection)
Peripheral Ischemia (Peripheral
ischemia)
Peripheral Motor Neuropathy (Peripheral
motor neuropathy)
Peripheral Nerve Infection (Peripheral
nerve infection)
Peripheral Sensory Neuropathy
(Peripheral sensory neuropathy)
Peritoneal Infection (Peritoneal infection)
Peritoneal Necrosis (Peritoneal necrosis)
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Personality Change (Personality change)
Phantom Pain (Phantom pain)
Pharyngeal Anastomotic Leak
(Pharyngeal anastomotic leak)
Pharyngeal Fistula (Pharyngeal fistula)
Pharyngeal Hemorrhage (Pharyngeal
hemorrhage)
Pharyngeal Mucositis (Pharyngeal
mucositis)
Pharyngeal Necrosis (Pharyngeal
necrosis)
Pharyngeal Stenosis (Pharyngeal
stenosis)
Pharyngitis (Pharyngitis)
Pharyngolaryngeal Pain
(Pharyngolaryngeal pain)
Phlebitis (Phlebitis)
Phlebitis Infective (Phlebitis infective)
Photophobia (Photophobia)
Photosensitivity (Photosensitivity)
Platelet Count Decreased (Platelet count
decreased)
Pleural Effusion (Pleural effusion)
Pleural Hemorrhage (Pleural
hemorrhage)
Pleural Infection (Pleural infection)
Pleuritic Pain (Pleuritic pain)
Pneumonitis (Pneumonitis)
Pneumothorax (Pneumothorax)
Portal Hypertension (Portal
hypertension)
Portal Vein Thrombosis (Portal vein
thrombosis)
Postnasal Drip (Postnasal drip)
Postoperative Hemorrhage
(Postoperative hemorrhage)
Postoperative Thoracic Procedure
Complication (Postoperative thoracic
procedure complication)
Precocious Puberty (Precocious
puberty)
Pregnancy, Puerperium And Perinatal
Conditions - Other, Specify (Pregnancy,
puerperium and perinatal conditions -
Other, Specify)
Premature Delivery (Premature delivery)
Premature Menopause (Premature
menopause)
Presyncope (Presyncope)
Proctitis (Proctitis)
Productive Cough (Productive cough)
Prolapse Of Intestinal Stoma (Prolapse
of intestinal stoma)
Prolapse Of Urostomy (Prolapse of
urostomy)
Prostate Infection (Prostate infection)
Prostatic Hemorrhage (Prostatic
hemorrhage)
Prostatic Obstruction (Prostatic
obstruction)
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Prostatic Pain (Prostatic pain)
Proteinuria (Proteinuria)
Pruritus (Pruritus)
Psychiatric Disorders - Other, Specify
(Psychiatric disorders - Other, Specify)
Psychosis (Psychosis)
Pulmonary Edema (Pulmonary edema)
Pulmonary Fibrosis (Pulmonary fibrosis)
Pulmonary Fistula (Pulmonary fistula)
Pulmonary Hypertension (Pulmonary
hypertension)
Pulmonary Valve Disease (Pulmonary
valve disease)
Purpura (Purpura)
Pyramidal Tract Syndrome (Pyramidal
tract syndrome)
Radiation Recall Reaction (dermatologic)
(Radiation recall reaction (dermatologic))
Radiculitis (Radiculitis)
Rash Acneiform (Rash acneiform)
Rash Maculo-papular (Rash maculo-
papular)
Rash Pustular (Rash pustular)
Rectal Anastomotic Leak (Rectal
anastomotic leak)
Rectal Fistula (Rectal fistula)
Rectal Hemorrhage (Rectal hemorrhage)
Rectal Mucositis (Rectal mucositis)
Rectal Necrosis (Rectal necrosis)
Rectal Obstruction (Rectal obstruction)
Rectal Pain (Rectal pain)
Rectal Perforation (Rectal perforation)
Rectal Stenosis (Rectal stenosis)
Rectal Ulcer (Rectal ulcer)
Recurrent Laryngeal Nerve Palsy
(Recurrent laryngeal nerve palsy)
Renal And Urinary Disorders - Other,
Specify (Renal and urinary disorders -
Other, Specify)
Renal Calculi (Renal calculi)
Renal Colic (Renal colic)
Renal Hemorrhage (Renal hemorrhage)
Reproductive System And Breast
Disorders - Other, Specify (Reproductive
system and breast disorders - Other,
Specify)
Respiratory Failure (Respiratory failure)
Respiratory, Thoracic And Mediastinal
Disorders - Other, Specify (Respiratory,
thoracic and mediastinal disorders -
Other, Specify)
Restlessness (Restlessness)
Restrictive Cardiomyopathy (Restrictive
cardiomyopathy)
Retinal Detachment (Retinal
detachment)
Retinal Tear (Retinal tear)
Retinal Vascular Disorder (Retinal
vascular disorder)
Retinoic Acid Syndrome (Retinoic acid
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syndrome)
Retinopathy (Retinopathy)
Retroperitoneal Hemorrhage
(Retroperitoneal hemorrhage)
Reversible Posterior
Leukoencephalopathy Syndrome
(Reversible posterior
leukoencephalopathy syndrome)
Rhinitis Infective (Rhinitis infective)
Right Ventricular Dysfunction (Right
ventricular dysfunction)
Salivary Duct Inflammation (Salivary duct
inflammation)
Salivary Gland Fistula (Salivary gland
fistula)
Salivary Gland Infection (Salivary gland
infection)
Scalp Pain (Scalp pain)
Scleral Disorder (Scleral disorder)
Scoliosis (Scoliosis)
Scrotal Infection (Scrotal infection)
Scrotal Pain (Scrotal pain)
Seizure (Seizure)
Sepsis (Sepsis)
Seroma (Seroma)
Serum Amylase Increased (Serum
amylase increased)
Serum Sickness (Serum sickness)
Sick Sinus Syndrome (Sick sinus
syndrome)
Sinus Bradycardia (Sinus bradycardia)
Sinus Disorder (Sinus disorder)
Sinus Pain (Sinus pain)
Sinus Tachycardia (Sinus tachycardia)
Sinusitis (Sinusitis)
Skin And Subcutaneous Tissue
Disorders - Other, Specify (Skin and
subcutaneous tissue disorders - Other,
Specify)
Skin Atrophy (Skin atrophy)
Skin Hyperpigmentation (Skin
hyperpigmentation)
Skin Hypopigmentation (Skin
hypopigmentation)
Skin Induration (Skin induration)
Skin Infection (Skin infection)
Skin Ulceration (Skin ulceration)
Sleep Apnea (Sleep apnea)
Small Intestinal Anastomotic Leak (Small
intestinal anastomotic leak)
Small Intestinal Mucositis (Small
intestinal mucositis)
Small Intestinal Obstruction (Small
intestinal obstruction)
Small Intestinal Perforation (Small
intestinal perforation)
Small Intestinal Stenosis (Small intestinal
stenosis)
Small Intestine Infection (Small intestine
infection)
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Small Intestine Ulcer (Small intestine
ulcer)
Sneezing (Sneezing)
Social Circumstances - Other, Specify
(Social circumstances - Other, Specify)
Soft Tissue Infection (Soft tissue
infection)
Soft Tissue Necrosis Lower Limb (Soft
tissue necrosis lower limb)
Soft Tissue Necrosis Upper Limb (Soft
tissue necrosis upper limb)
Somnolence (Somnolence)
Sore Throat (Sore throat)
Spasticity (Spasticity)
Spermatic Cord Anastomotic Leak
(Spermatic cord anastomotic leak)
Spermatic Cord Hemorrhage (Spermatic
cord hemorrhage)
Spermatic Cord Obstruction (Spermatic
cord obstruction)
Spinal Fracture (Spinal fracture)
Spleen Disorder (Spleen disorder)
Splenic Infection (Splenic infection)
Stenosis Of Gastrointestinal Stoma
(Stenosis of gastrointestinal stoma)
Stevens-johnson Syndrome (Stevens-
Johnson syndrome)
Stoma Site Infection (Stoma site
infection)
Stomach Pain (Stomach pain)
Stomal Ulcer (Stomal ulcer)
Stridor (Stridor)
Stroke (Stroke)
Sudden Death Nos (Sudden death NOS)
Suicidal Ideation (Suicidal ideation)
Suicide Attempt (Suicide attempt)
Superficial Soft Tissue Fibrosis
(Superficial soft tissue fibrosis)
Superficial Thrombophlebitis (Superficial
thrombophlebitis)
Superior Vena Cava Syndrome (Superior
vena cava syndrome)
Supraventricular Tachycardia
(Supraventricular tachycardia)
Surgical And Medical Procedures -
Other, Specify (Surgical and medical
procedures - Other, Specify)
Syncope (Syncope)
Telangiectasia (Telangiectasia)
Testicular Disorder (Testicular disorder)
Testicular Hemorrhage (Testicular
hemorrhage)
Testicular Pain (Testicular pain)
Thromboembolic Event
(Thromboembolic event)
Thrombotic Thrombocytopenic Purpura
(Thrombotic thrombocytopenic purpura)
Tinnitus (Tinnitus)
Tooth Development Disorder (Tooth
development disorder)
18 / 21
Lung Cancer NCT01336894 Toxicity - ACOSOG-Z4099 Baseline Adverse
Event Form - 3177833v1.0
Tooth Discoloration (Tooth discoloration)
Tooth Infection (Tooth infection)
Toothache (Toothache)
Toxic Epidermal Necrolysis (Toxic
epidermal necrolysis)
Tracheal Fistula (Tracheal fistula)
Tracheal Hemorrhage (Tracheal
hemorrhage)
Tracheal Mucositis (Tracheal mucositis)
Tracheal Obstruction (Tracheal
obstruction)
Tracheal Stenosis (Tracheal stenosis)
Tracheitis (Tracheitis)
Tracheostomy Site Bleeding
(Tracheostomy site bleeding)
Transient Ischemic Attacks (Transient
ischemic attacks)
Treatment Related Secondary
Malignancy (Treatment related
secondary malignancy)
Tremor (Tremor)
Tricuspid Valve Disease (Tricuspid valve
disease)
Trigeminal Nerve Disorder (Trigeminal
nerve disorder)
Trismus (Trismus)
Tumor Lysis Syndrome (Tumor lysis
syndrome)
Tumor Pain (Tumor pain)
Typhlitis (Typhlitis)
Unequal Limb Length (Unequal limb
length)
Unintended Pregnancy (Unintended
pregnancy)
Upper Gastrointestinal Hemorrhage
(Upper gastrointestinal hemorrhage)
Upper Respiratory Infection (Upper
respiratory infection)
Ureteric Anastomotic Leak (Ureteric
anastomotic leak)
Urethral Anastomotic Leak (Urethral
anastomotic leak)
Urethral Infection (Urethral infection)
Urinary Fistula (Urinary fistula)
Urinary Frequency (Urinary frequency)
Urinary Incontinence (Urinary
incontinence)
Urinary Retention (Urinary retention)
Urinary Tract Infection (Urinary tract
infection)
Urinary Tract Obstruction (Urinary tract
obstruction)
Urinary Tract Pain (Urinary tract pain)
Urinary Urgency (Urinary urgency)
Urine Discoloration (Urine discoloration)
Urine Output Decreased (Urine output
decreased)
Urostomy Leak (Urostomy leak)
Urostomy Obstruction (Urostomy
obstruction)
19 / 21
Lung Cancer NCT01336894 Toxicity - ACOSOG-Z4099 Baseline Adverse
Event Form - 3177833v1.0
Urostomy Site Bleeding (Urostomy site
bleeding)
Urostomy Stenosis (Urostomy stenosis)
Urticaria (Urticaria)
Uterine Anastomotic Leak (Uterine
anastomotic leak)
Uterine Fistula (Uterine fistula)
Uterine Hemorrhage (Uterine
hemorrhage)
Uterine Infection (Uterine infection)
Uterine Obstruction (Uterine obstruction)
Uterine Pain (Uterine pain)
Uterine Perforation (Uterine perforation)
Uveitis (Uveitis)
Vaginal Anastomotic Leak (Vaginal
anastomotic leak)
Vaginal Discharge (Vaginal discharge)
Vaginal Dryness (Vaginal dryness)
Vaginal Fistula (Vaginal fistula)
Vaginal Hemorrhage (Vaginal
hemorrhage)
Vaginal Infection (Vaginal infection)
Vaginal Inflammation (Vaginal
inflammation)
Vaginal Obstruction (Vaginal obstruction)
Vaginal Pain (Vaginal pain)
Vaginal Perforation (Vaginal perforation)
Vaginal Stricture (Vaginal stricture)
Vaginismus (Vaginismus)
Vagus Nerve Disorder (Vagus nerve
disorder)
Vas Deferens Anastomotic Leak (Vas
deferens anastomotic leak)
Vascular Access Complication (Vascular
access complication)
Vascular Disorders - Other, Specify
(Vascular disorders - Other, Specify)
Vasculitis (Vasculitis)
Vasovagal Reaction (Vasovagal reaction)
Venous Injury (Venous injury)
Ventricular Arrhythmia (Ventricular
arrhythmia)
Ventricular Fibrillation (Ventricular
fibrillation)
Ventricular Tachycardia (Ventricular
tachycardia)
Vertigo (Vertigo)
Vestibular Disorder (Vestibular disorder)
Virilization (Virilization)
Visceral Arterial Ischemia (Visceral
arterial ischemia)
Vital Capacity Abnormal (Vital capacity
abnormal)
Vitreous Hemorrhage (Vitreous
hemorrhage)
Voice Alteration (Voice alteration)
Vomiting (Vomiting)
Vulval Infection (Vulval infection)
Watering Eyes (Watering eyes)
Weight Gain (Weight gain)
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Weight Loss (Weight loss)
Wheezing (Wheezing)
White Blood Cell Decreased (White
blood cell decreased)
Wolff-parkinson-white Syndrome (Wolff-
Parkinson-White syndrome)
Wound Complication (Wound
complication)
Wound Dehiscence (Wound dehiscence)
Wound Infection (Wound infection)
Wrist Fracture (Wrist fracture)
MedDRA Code (v.12.0)
CTC Adverse Event Grade
Absent Adverse Event (0)
Mild Adverse Event (1)
Moderate Adverse Event (2)
Severe Adverse Event (3)
Life Threatening Adverse Event (4)
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Aids-related Malignancies NCT00695422 Demographic -
AMC-058 Demographic Form (DEM) - 3063562v1.0
AMC-058 Demographic Form (DEM)
Detecting Anal and Genital Human Papillomavirus Infection
and Squamous Intraepithelial Lesions in HIV-Positive
Patients Enrolled in AIDS Cancer Clinical Trials
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=84984553-
E82F-C037-E040-BB89AD434F82
All rights reserved. Please visit https://medical-data-
models.org/forms/8816
AMC-058 Demographic Form (DEM)
Header
Patient Initials (First, Last example: JS)
Patient's Date of Birth (mm/dd/yyyy)
Gender
Female (FEMALE)
Male (MALE)
Ethnicity
A Person Of Mexican, Puerto Rican,
Cuban, Central Or South American Or
Other Spanish Culture Or Origin,
Regardless Of Race. (Hispanic or Latino)
A Person Not Meeting The Definition For
Hispanic Or Latino. (Not Hispanic or
Latino)
Could Not Be Determined Or Unsure
(Unknown)
Race (check all that apply)
A Person Having Origins In Any Of The
Original Peoples Of North And South
America (including Central America),
And Who Maintains Tribal Affiliation Or
Community Attachment. (American
Indian or Alaska Native)
A Person Having Origins In Any Of The
Original Peoples Of The Far East,
Southeast Asia, Or The Indian
Subcontinent Including, For Example,
Cambodia, China, India, Japan, Korea,
Malaysia, Pakistan, The Philippine
Islands, Thailand, And Vietnam. (Asian)
A Person Having Origins In Any Of The
Black Racial Groups Of Africa. Terms
Such As "haitian" Or "negro" Can Be
Used In Addition To "black Or African
American." (Black or African American)
A Person Having Origins In Any Of The
Original Peoples Of Hawaii, Guam,
Samoa, Or Other Pacific Islands. (Native
Hawaiian or other Pacific Islander)
Could Not Be Determined Or Unsure
(Unknown)
A Person Having Origins In Any Of The
Original Peoples Of Europe, The Middle
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East, Or North Africa. (White)
Patient Zip Code (xxxxx)
Method of Payment
Medicaid (Medicaid)
Medicaid And Medicare (Medicaid and
Medicare)
Medicare (Medicare)
Medicare And Private Insurance
(Medicare and Private Insurance)
Military Or Veterans Sponsored Nos
(Military or Veterans Sponsored, Not
Otherwise Specified (NOS))
Military Sponsored (including Champus
& Tricare) (Military Sponsored (including
CHAMPUS & TRICARE))
No Means Of Payment (no Insurance)
(No means of payment (no insurance))
Other (Other)
Private Insurance (Private Insurance)
Self Pay (no Insurance) (Self Pay (No
Insurance))
Unknown (Unknown)
Veterans Sponsored (Veterans
Sponsored)
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Anal Cancer NCT00550589 Demographic - AMC-046
Demographic Form (DEM) Segment A Segment B - 2989575v1.0
AMC-046 Demographic Form (DEM) Segment A Segment
B
Cidofovir in Treating HIV-Infected Patients With High-Grade
Squamous Intraepithelial Lesions of the Skin Near the Anus
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=7D8985E5-
2F98-08A5-E040-BB89AD434A3B
All rights reserved. Please visit https://medical-data-
models.org/forms/8817
AMC-046 Demographic Form (DEM)
Segment A Segment B
Header
Patient Initials (First, Last)
Patient's Date of Birth (mm/dd/yyyy)
Gender
Female (FEMALE)
Male (MALE)
Ethnicity
A Person Of Mexican, Puerto Rican,
Cuban, Central Or South American Or
Other Spanish Culture Or Origin,
Regardless Of Race. (Hispanic or Latino)
A Person Not Meeting The Definition For
Hispanic Or Latino. (Not Hispanic or
Latino)
Could Not Be Determined Or Unsure
(Unknown)
Race (check all that apply)
A Person Having Origins In Any Of The
Original Peoples Of North And South
America (including Central America),
And Who Maintains Tribal Affiliation Or
Community Attachment. (American
Indian or Alaska Native)
A Person Having Origins In Any Of The
Original Peoples Of The Far East,
Southeast Asia, Or The Indian
Subcontinent Including, For Example,
Cambodia, China, India, Japan, Korea,
Malaysia, Pakistan, The Philippine
Islands, Thailand, And Vietnam. (Asian)
A Person Having Origins In Any Of The
Black Racial Groups Of Africa. Terms
Such As "haitian" Or "negro" Can Be
Used In Addition To "black Or African
American." (Black or African American)
A Person Having Origins In Any Of The
Original Peoples Of Hawaii, Guam,
Samoa, Or Other Pacific Islands. (Native
Hawaiian or other Pacific Islander)
Could Not Be Determined Or Unsure
(Unknown)
A Person Having Origins In Any Of The
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Original Peoples Of Europe, The Middle
East, Or North Africa. (White)
Patient Zip Code (xxxxx)
Method of Payment
Medicaid (Medicaid)
Medicaid And Medicare (Medicaid and
Medicare)
Medicare (Medicare)
Medicare And Private Insurance
(Medicare and Private Insurance)
Military Or Veterans Sponsored Nos
(Military or Veterans Sponsored, Not
Otherwise Specified (NOS))
Military Sponsored (including Champus
& Tricare) (Military Sponsored (including
CHAMPUS & TRICARE))
No Means Of Payment (no Insurance)
(No means of payment (no insurance))
Other (Other)
Private Insurance (Private Insurance)
Self Pay (no Insurance) (Self Pay (No
Insurance))
Unknown (Unknown)
Veterans Sponsored (Veterans
Sponsored)
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Lung Cancer NCT01107626 Eligibility - E5508
Registration Worksheet (step 2) - 3078042v1.0
E5508 Registration Worksheet (step 2)
Bevacizumab or Pemetrexed Disodium Alone or In
Combination After Induction Therapy in Treating Patients
With Advanced Non-Squamous Non-Small Cell Lung
Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=8528E45F-
A327-F490-E040-BB89AD4356FC
All rights reserved. Please visit https://medical-data-
models.org/forms/8819
E5508 Registration Worksheet (step
2)
Eligibility
First initial
Last initial
Has the eligibility checklist been completed
Yes
No
In the opinion of the investigator, is the patient
eligible?
Yes
No
Stage
Iiib-t4nx/iv M1a (IIIB-T4Nx/IV M1a)
Iv M1b (IV M1b)
Recurrent Disease (Recurrent)
Best response to first line therapy
Cr/pr (CR/PR)
Sd (SD)
Smoking status
Ever-smoker (Ever-smoker)
Never Smoker (Never smoker)
Patient Demographics / Pre-treatment
Characteristics
Patient's Sex
Female (F)
Male (M)
Birthdate
Patient's Race
A Person Having Origins In Any Of The
Original Peoples Of North And South
America (including Central America),
And Who Maintains Tribal Affiliation Or
Community Attachment. (American
Indian or Alaska Native)
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A Person Having Origins In Any Of The
Original Peoples Of The Far East,
Southeast Asia, Or The Indian
Subcontinent Including, For Example,
Cambodia, China, India, Japan, Korea,
Malaysia, Pakistan, The Philippine
Islands, Thailand, And Vietnam. (Asian)
A Person Having Origins In Any Of The
Black Racial Groups Of Africa. Terms
Such As "haitian" Or "negro" Can Be
Used In Addition To "black Or African
American." (Black or African American)
A Person Having Origins In Any Of The
Original Peoples Of Hawaii, Guam,
Samoa, Or Other Pacific Islands. (Native
Hawaiian or other Pacific Islander)
Not Provided Or Available (Not
Reported)
Could Not Be Determined Or Unsure
(Unknown)
A Person Having Origins In Any Of The
Original Peoples Of Europe, The Middle
East, Or North Africa. (White)
ZIP Code
Patient's simplified disease code
Bronchioloalveolar Carcinoma
(Bronchioloalveolar carcinoma)
Lung Adenocarcinoma (Lung
Adenocarcinoma)
Bronchioloalveolar Carcinoma Lung
Adenocarcinoma (Lung Adenocarcinoma
with bronchioloalveolar features)
Not Otherwise Specified Nsclc (Non-
Small Cell Lung Cancer, NOS)
Not Otherwise Specified Nsclc (Non-
Small Cell Lung Cancer, NOS)
Patient Hospital No.
Patient Social Security Number
Method of payment
Medicaid (Medicaid)
Medicaid And Medicare (Medicaid and
Medicare)
Medicare (Medicare)
Medicare And Private Insurance
(Medicare and Private Insurance)
Military Or Veterans Sponsored Nos
(Military or Veterans Sponsored, Not
Otherwise Specified (NOS))
Military Sponsored (including Champus
& Tricare) (Military Sponsored (including
CHAMPUS & TRICARE))
No Means Of Payment (no Insurance)
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(No means of payment (no insurance))
Other (Other)
Private Insurance (Private Insurance)
Self Pay (no Insurance) (Self Pay (No
Insurance))
Unknown (Unknown)
Veterans Sponsored (Veterans
Sponsored)
Country of residence
Ascension Island (AC)
Andorra (AD)
United Arab Emirates (AE)
Afghanistan (AF)
Antigua And Barbuda (AG)
Anguilla (AI)
Albania (AL)
Armenia (AM)
Netherland Antilles (AN)
Angola (AO)
Antarctica (AQ)
Argentina (AR)
American Samoa (AS)
Austria (AT)
Australia (AU)
Aruba (AW)
Azerbaidjan (AZ)
Bosnia-herzegovina (BA)
Barbados (BB)
Bangladesh (BD)
Belgium (BE)
Burkina Faso (BF)
Bulgaria (BG)
Bahrain (BH)
Burundi (BI)
Benin (BJ)
Bermuda (BM)
Brunei Darussalam (BN)
Bolivia (BO)
Brazil (BR)
Bahamas (BS)
Bhutan (BT)
Bouvet Island (BV)
Botswana (BW)
Belarus (BY)
Belize (BZ)
Canada (CA)
Cocos Isl. (CC)
Rep. Dem. Congo (CD)
Central African Rep. (CF)
Congo (CG)
Switzerland (CH)
Ivory Coast (CI)
Cook Islands (CK)
Chile (CL)
Cameroon (CM)
China (CN)
Colombia (CO)
Costa Rica (CR)
Cuba (CU)
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Cape Verde (CV)
Christmas Island (CX)
Cyprus (CY)
Czech Republic (CZ)
Germany (DE)
Djibouti (DJ)
Denmark (DK)
Dominica (DM)
Dominican Republic (DO)
Algeria (DZ)
Ecuador (EC)
Estonia (EE)
Egypt (EG)
Western Sahara (EH)
Eritrea (ER)
Spain (ES)
Ethiopia (ET)
Finland (FI)
Fiji (FJ)
Falkland Isl. (FK)
Micronesia (FM)
Faroe Islands (FO)
France (FR)
France (european Ter.) (FX)
Gabon (GA)
Great Britain (GB)
Grenada (GD)
Georgia (GE)
Guiana (fr.) (GF)
Guernsey (GG)
Ghana (GH)
Gibraltar (GI)
Greenland (GL)
Gambia (GM)
Guinea (GN)
Guadeloupe (fr.) (GP)
Equatorial Guinea (GQ)
Greece (GR)
South Georgia And South Sandwich
Islands (GS)
Guatemala (GT)
Guam (us) (GU)
Guinea Bissau (GW)
Guyana (GY)
Hong Kong (HK)
Heard & Mcdonald Isl. (HM)
Honduras (HN)
Croatia (HR)
Haiti (HT)
Hungary (HU)
Indonesia (ID)
Ireland (IE)
Israel (IL)
Isle Of Man (IM)
India (IN)
British Indian O. Ter. (IO)
Iraq (IQ)
Iran (IR)
Iceland (IS)
Italy (IT)
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Jersey (JE)
Jamaica (JM)
Jordan (JO)
Japan (JP)
Kenya (KE)
Kyrgyz Republic (KG)
Cambodia (KH)
Kiribati (KI)
Comoros (KM)
St. Kitts Nevis Anguilla (KN)
Korea (north) (KP)
Korea (south) (KR)
Kuwait (KW)
Cayman Islands (KY)
Kazakstan (KZ)
Laos (LA)
Lebanon (LB)
Saint Lucia (LC)
Liechtenstein (LI)
Sri Lanka (LK)
Liberia (LR)
Lesotho (LS)
Lithuania (LT)
Luxembourg (LU)
Latvia (LV)
Libya (LY)
Morocco (MA)
Monaco (MC)
Moldova (MD)
Madagascar (MG)
Marshall Islands (MH)
Macedonia (MK)
Mali (ML)
Myanmar (MM)
Mongolia (MN)
Macau (MO)
Northern Mariana Isl. (MP)
Martinique (fr.) (MQ)
Mauritania (MR)
Montserrat (MS)
Malta (MT)
Mauritius (MU)
Maldives (MV)
Malawi (MW)
Mexico (MX)
Malaysia (MY)
Mozambique (MZ)
Namibia (NA)
New Caledonia (fr.) (NC)
Niger (NE)
Norfolk Island (NF)
Nigeria (NG)
Nicaragua (NI)
Netherlands (NL)
Norway (NO)
Nepal (NP)
Nauru (NR)
Niue (NU)
New Zealand (NZ)
Oman (OM)
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Other (Other)
Panama (PA)
Peru (PE)
Polynesia (fr.) (PF)
Papua New Guinea (PG)
Philippines (PH)
Pakistan (PK)
Poland (PL)
St. Pierre & Miquelon (PM)
Pitcairn (PN)
Puerto Rico (PR)
Portugal (PT)
Palau (PW)
Paraguay (PY)
Qatar (QA)
Reunion (fr.) (RE)
Romania (RO)
Russian Federation (RU)
Rwanda (RW)
Saudi Arabia (SA)
Solomon Islands (SB)
Seychelles (SC)
Sudan (SD)
Sweden (SE)
Singapore (SG)
St. Helena (SH)
Slovenia (SI)
Svalbard & Jan Mayen Isl. (SJ)
Slovakia (SK)
Sierra Leone (SL)
San Marino (SM)
Senegal (SN)
Somalia (SO)
Suriname (SR)
St. Tome And Principe (ST)
Soviet Union (SU)
El Salvador (SV)
Syria (SY)
Swaziland (SZ)
Turks & Caicos Islands (TC)
Chad (TD)
French Southern Terr. (TF)
Togo (TG)
Thailand (TH)
Tadjikistan (TJ)
Tokelau (TK)
Turkmenistan (TM)
Tunisia (TN)
Tonga (TO)
East Timor (TP)
Turkey (TR)
Trinidad & Tobago (TT)
Tuvalu (TV)
Taiwan (TW)
Tanzania (TZ)
Ukraine (UA)
Uganda (UG)
United Kingdom (UK)
Us Minor Outlying Isl. (UM)
Usa (US)
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Uruguay (UY)
Uzbekistan (UZ)
Vatican City State (VA)
St. Vincent & Grenadines (VC)
Venezuela (VE)
Virgin Islands (brit) (VG)
Virgin Islands (us) (VI)
Vietnam (VN)
Vanuatu (VU)
Wallis & Futuna Islands (WF)
Western Samoa (WS)
Yemen (YE)
Mayotte (YT)
Yugoslavia (YU)
South Africa (ZA)
Zambia (ZM)
Dem. Rep. Of Congo (ZR)
Zimbabwe (ZW)
Comments
I Have Reviewed The Above Data And
Agree The Date Are Accurate And Correct
Signature of treating physician
Date
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Leukemia NCT01041703 Lab - E2906
Hematology/Chemistry Form - 2950751v1.0
E2906 Hematology/Chemistry Form
Clofarabine or Daunorubicin Hydrochloride and Cytarabine
Followed By Decitabine or Observation in Treating Older
Patients With Newly Diagnosed Acute Myeloid Leukemia
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=755ADD70-
A207-B92C-E040-BB89AD435B07
All rights reserved. Please visit https://medical-data-
models.org/forms/8822
E2906 Hematology/Chemistry Form
Header
DCI Name
Registration Step (Place ID Label Here)
Patient Initials (Last, First)
ECOG Protocol Number
ECOG Protocol Number
ECOG Patient ID
ECOG Patient ID
Participating Group Protocol Number
Participating Group Patient ID
Institution/Affiliate
On Treatment
On Treatment Reporting Period (If this form
covers an On Treatment Report Period Choose
one)
At Transplant (At Transplant)
Cycle 1 - Consolidation (Cycle 1 -
Consolidation)
Cycle 1 - Induction (Cycle 1 - Induction)
Cycle 1 - Step 3 (Cycle 1 - Step 3)
Cycle 10 - Step 3 (Cycle 10 - Step 3)
Cycle 11 - Step 3 (Cycle 11 - Step 3)
Cycle 12 - Step 3 (Cycle 12 - Step 3)
Cycle 13 - Step 3 (Cycle 13 - Step 3)
Cycle 2 - Consolidation (Cycle 2 -
Consolidation)
Cycle 2 - Induction (Cycle 2 - Induction)
Cycle 2 - Step 3 (Cycle 2 - Step 3)
Cycle 3 - Step 3 (Cycle 3 - Step 3)
Cycle 4 - Step 3 (Cycle 4 - Step 3)
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Cycle 5 - Step 3 (Cycle 5 - Step 3)
Cycle 6 - Step 3 (Cycle 6 - Step 3)
Cycle 7 - Step 3 (Cycle 7 - Step 3)
Cycle 8 - Step 3 (Cycle 8 - Step 3)
Cycle 9 - Step 3 (Cycle 9 - Step 3)
Off Treatment
Off Treatment Reporting Period (If this form
covers an Off Treatment Report Period Choose
one since registration)
12 Months (12 Months Post Registration)
15 Months (15 Months Post Registration)
18 Months (18 Months Post Registration)
21 Months Post Registration (21 Months
Post Registration)
2 Years (24 Months Post Registration)
3 Months (3 Months Post Registration)
30 Months (30 Months Post Registration)
3 Years (36 Months Post Registration)
42 Months (42 Months Post Registration)
4 Years (48 Months Post Registration)
54 Months (54 Months Post Registration)
6 Months (6 Months Post Registration)
5 Years (60 Months Post Registration)
9 Months (9 Months Post Registration)
Unnamed2
Are data amended (If yes, please circle amended
items in red)
Yes
No
Hematology/chemistry
Date Obtained (M D Y)
Absolute granulocyte count LLN
Absolute Granulocyte Count (AGC/ANC)
Alkaline Phosphatase ULN (U/L)
Alkaline Phosphatase (U/L)
Creatinine ULN (mg/dl)
Creatinine (mg/dl)
Hematocrit LLN (%)
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Hematocrit (%)
Peripheral Blasts (%)
Platelets LLN (mm^3 x1000)
Platelets (mm^3 x1000)
SGOT (AST) ULN (U/L)
SGOT (AST) (U/L)
Total bilirubin (mg/dl), ULN (mg/dl)
Total Bilirubin (mg/dl)
WBC count (x1000), LLN (x1000)
WBC Count (x1000)
Hemoglobin (Hgb) (g/dl), LLN (g/dl)
Hemoglobin (g/dl)
CTC Adverse Event Term (v4)
Anemia (Anemia)
CTC AE Grade (v4.0)
Absent Adverse Event (0)
Mild Adverse Event (1)
Moderate Adverse Event (2)
Severe Adverse Event (3)
Life Threatening Adverse Event (4)
Death Related To Adverse Event (5)
Creatinine Clearance (mL/min)
Lactate Dehydrogenase ULN (U/L)
Lactate Dehydrogenase (LDH) (U/L)
Magnesium, LLN (mg/dL)
Magnesium, ULN (mg/dL)
Magnesium (mg/dL)
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SGPT (ALT) ULN (U/L)
SGPT (U/L)
Uric Acid ULN (mg/dL)
Uric acid (mg/dL)
CTC AE Attribution Code (v4.0)
Definite (Definite)
Possible (Possible)
Probable (Probable)
Unlikely (Unlikely)
Unrelated (Unrelated)
Comments
Investigator Signature
Investigator Signature Date (M D Y)
4 / 4
Leukemia NCT01041703 Lab - E2906 Hematology/Chemistry Form -
2950751v1.0
Breast Cancer NCT00914043 Registration - NSABP
B-45 Worksheet for Entry Form - 2846518v1.0
NSABP B-45 Worksheet for Entry Form
Studying Biological Markers of Fatigue in Women With
Residual Invasive Breast Cancer Enrolled on Clinical Trial
NSABP-B-45
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=6461E18A-
2104-98F1-E040-BB89AD4303E7
All rights reserved. Please visit https://medical-data-
models.org/forms/8823
NSABP B-45 Worksheet for Entry
Form
Header
Patient Initials (Last First Middle)
Site Name
Patient Birth Date (Month Day Year)
Treating physician
Patient Social Security Number (USA Only)
Patient Gender
Female Gender (FEMALE)
Male Gender (MALE)
Race
Race (more than one may be marked)
A Person Having Origins In Any Of The
Original Peoples Of North And South
America (including Central America),
And Who Maintains Tribal Affiliation Or
Community Attachment. (American
Indian or Alaska Native)
A Person Having Origins In Any Of The
Original Peoples Of The Far East,
Southeast Asia, Or The Indian
Subcontinent Including, For Example,
Cambodia, China, India, Japan, Korea,
Malaysia, Pakistan, The Philippine
Islands, Thailand, And Vietnam. (Asian)
A Person Having Origins In Any Of The
Black Racial Groups Of Africa. Terms
Such As "haitian" Or "negro" Can Be
Used In Addition To "black Or African
American." (Black or African American)
A Person Having Origins In Any Of The
Original Peoples Of Hawaii, Guam,
Samoa, Or Other Pacific Islands. (Native
Hawaiian or other Pacific Islander)
Could Not Be Determined Or Unsure
(Unknown)
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A Person Having Origins In Any Of The
Original Peoples Of Europe, The Middle
East, Or North Africa. (White)
Person Completing Form, Last Name
Method of Payment (mark primary method only)
Medicaid (Medicaid)
Medicaid And Medicare (Medicaid and
Medicare)
Medicare (Medicare)
Medicare And Private Insurance
(Medicare and Private Insurance)
Military Or Veterans Sponsored Nos
(Military or Veterans Sponsored, Not
Otherwise Specified (NOS))
Military Sponsored (including Champus
& Tricare) (Military Sponsored (including
CHAMPUS & TRICARE))
No Means Of Payment (no Insurance)
(No means of payment (no insurance))
Other (Other)
Private Insurance (Private Insurance)
Self Pay (no Insurance) (Self Pay (No
Insurance))
Unknown (Unknown)
Veterans Sponsored (Veterans
Sponsored)
Ethnicity
A Person Of Mexican, Puerto Rican,
Cuban, Central Or South American Or
Other Spanish Culture Or Origin,
Regardless Of Race. (HISPANIC OR
LATINO)
A Person Not Meeting The Definition For
Hispanic Or Latino. (NOT HISPANIC OR
LATINO)
Could Not Be Determined Or Unsure
(UNKNOWN)
Country of residence
Canada (CA)
Other (Other)
Puerto Rico (PR)
Usa (US)
Other
Patient Zip Code (USA)
Unnamed4
Date Informed Consent Signed (Month Day Year)
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Was this an IRB-approved consent form that
conforms to federal and institutional guidelines for
study treatment and release of required tumor
blocks
Yes
No
Did the patient consent to future contact about
more research
Yes
No
Did the pathology department agree to release
the required blocks
Yes
No
Did the patient agree to have a blood sample
collected before starting study drug
Yes
No
Has the patient authorized the release of
Protected Health Information to the NSABP?
Yes
No
Did the patient complete the Quality of Life
baseline form?
Yes
No
Date baseline QOL completed by patient (Month
Day Year)
Cardiac Conditions
Angina pectoris that requires the use of anti-
anginal medication
Yes
No
Serious cardiac arrythmia requiring medication?
Yes
No
Valvular disease with documented cardiac
function compromise?
Yes
No
Does the patient have a history of myocardial
infarction
Yes
No
History of documented congestive heart failure
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Yes
No
Severe conduction abnormality?
Yes
No
Uncontrolled hypertension defined as BP >
150/90 on antihypertensive therapy
Yes
No
Was there documentation of elevated cardiac
enzymes or persistent regional wall abnormalities
on assessment of LV function
Yes
No
Other Conditions
Has the patient had contralateral breast cancer
(including DCIS) at any time
Yes
No
Has the patient had any prior cancer diagnosed?
Yes
No
Is the patient deemed by her physician to be a
low risk for recurrence (If yes)
Yes
No
Has the patient been disease free for 5 years or
more
Yes
No
Does the patient have a history of hypertensive
crisis or hypertensive encephalopathy
Yes
No
Does the patient have a history of arterial
thrombotic event within the past 12 months
(including catheter-related thrombus)
Yes
No
Date of thrombotic event (MM DD YYYY)
Does the patient have a history of ipsilateral
breast cancer (including DCIS)
Yes
No
Has the patient had any prior malignancies in the
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past 5 years other than squamous or basal cell
carcinoma of the skin, melanoma in situ,
carcinoma in situ of the colon or rectum, or
carcinoma in situ of the cervix that has been
effectively treated? (If the patient has not been
disease free for 5 years or more)
Yes
No
Does the patient have a prior history of
documented cerebral vascular accident or
documented transient ischemic attack?
Yes
No
Has the patient had any significant non-traumatic
bleeding within 6 months before study entry
Yes
No
Date of bleeding event (MM DD YYYY)
Cardiac Risk Factors
Does the patient have any first degree relatives
who died from heart disease before the age of 55
(First degree relatives are parents, children,
brothers, and sisters)
Yes
No
Hypertension requiring medical therapy (If yes,
mark all categories that apply)
Yes
No
Diabetes requiring medical therapy
Yes
No
Hyperlipidemia requiring medical therapy
Yes
No
Smoking (Patient History)
Currently Smoking (Currently smoking)
Never Smoked (Never smoked)
Smoked In The Past (Smoked in the
past)
Section 2 - Diagnostic
Stage (Clinical)
T0, N1, M0 Or T1*, N1, M0 Or T2, N0,
M0 (IIA)
T2, N1, M0 Or T3, N0, M0 (IIB)
T0, N2, M0 Or T1*, N2, M0 Or T2, N2,
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M0 Or T3, N1, M0 Or T3, N2, M0 (IIIA)
T4, N0, M0 Or T4, N1, M0 Or T4, N2, M0
(IIIB)
Is estrogen receptor analysis result available
(from primary surgery)
Yes
No
Receptor Status, ER (If yes,)
Negative (Negative)
Positive (Positive)
Date of Diagnostic Core or Incisional Biopsy
(Month Day Year)
Was there any histologic evidence of invasive
tumor cells in the surgical breast specimen
Yes
No
Is progesterone receptor analysis result available
(from primary surgery)
Yes
No
Receptor Status, PgR
Negative (Negative)
Positive (Positive)
Was HER2 status assessed by IHC assay
Yes
No
Her2/neu expression status by
immunohistochemistry
0 (0)
1+ (1+)
2+ (2+)
3+ (3+)
Date of IHC Assay (Month Day Year A copy of the
report must be provided)
Was HER2 status assessed by ISH assay (FISH,
CISH, or other ISH)
Yes
No
HER2 Status by ISH Assay (If yes, If multiple ISH
assays were done, and at least one was positive,
the positive assay must be reported.)
Equivocal (Equivocal)
Negative (Negative)
Positive (Positive)
Was HER2-targeted therapy administered pre-
operatively or post-operatively prior to study entry
(If ISH assay is equivocal,)
6 / 17
Breast Cancer NCT00914043 Registration - NSABP B-45 Worksheet for
Entry Form - 2846518v1.0
Yes
No
Is there a plan to administer HER2-targeted
therapy
Yes
No
Date of ISH Assay (Month Day Year A copy of the
report must be provided.)
Nodal Status Assessments Prior To
Neoadjuvant Chemotherapy
Was nodal FNA performed
Yes
No
Was nodal FNA positive
Yes
No
Was nodal core biopsy performed
Yes
No
Was nodal core biopsy positive
Yes
No
Was sentinel node sampling performed
Yes
No
Were there any positive sentinel nodes
Yes
No
Section 3 - Neoadjuvant Chemotherapy
Date Prior Neoadjuvant Chemotherapy Started
(first neoadjuvant chemotherapy dose Month Day
Year)
Date Prior Neoadjuvant Chemotherapy Ended
(last neoadjuvant chemotherapy dose Month Day
Year)
Neoadjuvant Chemotherapy
Anthracycline (Anthracycline)
Cyclophosphamide (Cyclophosphamide)
Other Chemotherapy Agents (Other
Chemotherapy Agents)
Taxane (Taxane)
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Specify other chemotherapy agents (if applicable)
No. of Courses
Total number of cycles completed
Section 4 - Surgery After Neoadjuvant
Chemotherapy
Tumor Laterality
Left (Left)
Right (Right)
Margin Status (If mastectomy was performed,)
Grossly Negative And Microscopically
Negative (Grossly negative and
microscopically negative)
Grossly Negative And Microscopically
Positive (Grossly negative and
microscopically positive)
Grossly Positive (Grossly positive)
Is estrogen receptor analysis result available
(from primary surgery)
Yes
No
Receptor Status, ER (If yes,)
Negative (Negative)
Positive (Positive)
Does the pathology report from the breast
surgery indicate on H&E staining that residual
invasive in-breast disease was found in the
surgical specimen
Yes
No
Size of residual tumor (If yes, If > 0.5 cm, refer to
Protocol Table 3.)
<=0.5 Cm (<=0.5 cm)
>0.5 Cm (>0.5 cm)
Pathologic N Stage (If no,)
No Regional Lymph Node Metastasis
Histologically, Positive Ihc, No Ihc Cluster
>0.2 Mm (ypN0(i+))
No Regionally Lymph Node Metastasis
Histologically, Positive Molecular
Findings (rt-pcr) (ypN0(mol+))
Date of Last Surgery for staging or treatment
(including re-excision of margins and any axillary
staging procedures Month Day Year)
Has the patient recovered from surgery
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Yes
No
Section 4 - Surgery After Neoadjuvant
Chemotherapy1
Was lumpectomy performed
Yes
No
Date lumpectomy performed (If yes, Month Day
Year)
Was mastectomy performed
Yes
No
Date mastectomy performed (If yes, Month Day
Year)
Were lumpectomy margins histologically free of
invasive tumor and DCIS, either initially or after
one or more re-excisions (If mastectomy was not
performed,)
Yes
No
Is progesterone receptor analysis result available
(from primary surgery)
Yes
No
Receptor Status, PgR
Negative (Negative)
Positive (Positive)
Was axillary staging performed
Yes
No
Does the pathology report from the axillary
staging procedure indicate on H&E staining that
residual axillary nodal metastasis was found in
the surgical specimen
Yes
No
Size of largest focus of nodal metastasis (If yes, If
> 0.5 cm, refer to Protocol Table 3)
<=0.5 Cm (<=0.5 cm)
>0.5 Cm (>0.5 cm)
Will postoperative radiation therapy be
administered after the patient has been entered
on study
Yes
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No
Has the incision completely healed with no signs
of infection (If yes,)
Yes
No
Sentinel Node Biopsy Staging
Was sentinel node biopsy (SNB) performed after
neoadjuvant therapy
Yes
No
Sentinel Node Biopsy Date (Month Day Year)
Number of Sentinel Nodes Examined
(AXILLARY)
Number of Positive Sentinel Nodes (AXILLARY)
Other Axillary Staging
Number of axillary staging procedures (other than
SNB) performed after neoadjuvant therapy (If 1 or
2, list dates and nodal information)
1 (1)
2 (2)
None (None)
Date of procedure (Month Day Year)
Number of axillary nodes examined (Total Non-
Sentinel)
Number of positive axillary lymph nodes (Total
Non-Sentinel)
Number of Positive Lymph Nodes (Total of all
positive axillary and non-axillary nodes from all
nodal staging procedures, including sentinel node
biopsy)
Postoperative Chemotherapy
Postoperative Chemotherapy (If no, skip to B
Baseline Values)
Yes
No
10 / 17
Breast Cancer NCT00914043 Registration - NSABP B-45 Worksheet for
Entry Form - 2846518v1.0
Date Chemotherapy Began (first postoperative
chemotherapy dose Month Day Year)
Date Chemotherapy Ended (last postoperative
chemotherapy dose Month Day Year)
Types of Postoperative Chemotherapy (Mark all
that apply)
Anthracycline (Anthracycline)
Capecitabine (Capecitabine)
Cyclophosphamide (Cyclophosphamide)
Other (Other)
Taxane (Taxane)
Other, specify
Did the patient experience chemotherapy-related
toxicity (excluding alopecia, nail changes,
dysgeusia, hot flashes/flushes,
sexual/reproductive function)
Yes
No
Have these toxicities resolved to <= grade 1 (If
yes,)
Yes
No
Baseline Values
Blood Pressure, Systolic (most recent)
Blood pressure, Diastolic (most recent)
Hypertension requiring medical therapy (If yes,
mark all categories that apply)
Yes
No
Date of most recent blood pressure assessment
(Month Day Year)
Anti-Hypertensive Drugs (for management of
hypertension)
Ace Inhibitor (ACE inhibitors)
Alpha/beta Blocker (Alpha/beta blocker)
Beta Blocker (Beta blockers)
Calcium Channel Blocker (Calcium
channel blockers)
Diuretic (Diuretics)
Other (Other)
Other, specify
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Patient Characteristics
Patient Height
Patient Weight
Baseline Values1
QTc Interval (from ECG seconds)
Date of EKG (Month Day Year A copy of the ECG
report must be provided)
TSH (Patient Value microIU/mL)
TSH LLN (Lower Limit of Lab Normal
microIU/mL)
TSH ULN (Upper Limit of Lab Normal
microIU/mL)
Date of Assessment (Month Day Year)
LVEF (% At least 2 weeks after last dose of the
most recent chemotherapy regimen)
Date of LVEF (Month Day Year)
Assessment Type (A copy of the echocardiogram
or MUGA scan report must be provided. If this
document does not report LVEF as a whole
number, see Protocol Section 5.3 for rounding
instructions)
2-d Echocardiogram (2-D
Echocardiogram)
Muga Scan (MUGA scan)
Urine Protein
0 (0)
1+ (1+)
2+ (2+)
3+ (3+)
4+ (4+)
Was 24-hour urine specimen collected (If >= 2+,)
Yes
No
Protein from 24 hour Urine Collection (If yes, g
protein per 24 hours)
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Blood Counts
Absolute neutrophil count (ANC thousand/mm^3)
Platelet count (thousand/mm^3)
Hemoglobin (g/dL)
Alkaline Phosphatase (Patient Value units/L)
Alkaline Phosphatase ULN (Upper Limit of Lab
Normal units/L)
SGOT (AST) (Patient Value units/L)
SGOT (AST) ULN (Upper Limit of Lab Normal
units/L)
SGPT (ALT) (Patient Value units/L)
SGPT (ALT) ULN (Upper Limit of Lab Normal
units/L)
Total Bilirubin (Patient Value mg/dL)
Total Bilirubin ULN (Upper Limit of Lab Normal
mg/dL)
Phosphate (Patient Value mg/dL)
Phosphate LLN (Lower Limit of Lab Normal
mg/dL)
Does the patient require chronic supplementation
for serum phosphate levels
Yes
No
Creatinine (Patient Value mg/dL)
Creatinine ULN (Upper Limit of Lab Normal
mg/dL)
Does the patient have Gilbert's disease or a
similar syndrome due to slow conjugation of
bilirubin (If Total Bilirubin is > ULN and <= 1.5 x
ULN)
Yes
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No
Baseline Values2
Was liver imaging performed (If AST, ALT, or
alkaline phosphatase is higher than ULN)
Yes
No
Was gross extrahepatic disease identified (If yes,)
Yes
No
Does the patient have symptomatic pancreatitis
Yes
No
Does the patient have bone pain
Yes
No
Was at least one bone scan or PET scan
performed (If patient has skeletal pain or alkaline
phosphatase is higher than ULN)
Yes
No
Did any bone scan or PET scan demonstrate
metastatic disease (If yes,)
Yes
No
Were there suspicious findings on bone scan or
PET scan (If no,)
Yes
No
Were the suspicious findings confirmed as
benign by x-ray, MRI, or biopsy (If yes,)
Yes
No
Amylase (units/L)
Amylase ULN (units/L)
Lipase (units/L)
Lipase ULN (units/L)
Other
ECOG Performance Status (Patient)
Fully Active, Able To Carry On All Pre-
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disease Performance Without
Restriction. (0)
Restricted In Physically Strenuous
Activity But Ambulatory And Able To
Carry Out Work Of A Light Or Sedentary
Nature, E.g., Light Housework, Office
Work. (1)
Ambulatory And Capable Of All Selfcare
But Unable To Carry Out Any Work
Activities. Up And About More Than 50%
Of Waking Hours. (2)
Capable Of Only Limited Selfcare,
Confined To Bed Or Chair More Than
50% Of Waking Hours. (3)
Completely Disabled. Cannot Carry On
Any Selfcare. Totally Confined To Bed Or
Chair. (4)
Is metastatic breast cancer present
Yes
No
Has the patient had prior therapy with
angiogenesis inhibitors, for example bevacizumab
and sorafenib
Yes
No
Does the patient have the ability to swallow oral
medication
Yes
No
Has the patient had partial breast irradiation (PBI)
Yes
No
Is there a plan to administer PBI following
randomization
Yes
No
Other1
Does the patient require medication having
proarrhythmic potential, for example terfenadine,
quinidine, procainamide, disopyramide, sotalol,
probucol, bepridil, haloperidol, risperidone,
indapamide and flecainide
Yes
No
Does the patient have a history of symptomatic
peripheral vascular disease
Yes
No
Does the patient have active gastroduodenal
ulcer(s) determined by endoscopy to be active?
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Yes
No
Planned Date of Treatment Initiation (Month Day
Year)
Has the patient had a major surgical procedure,
open biopsy or significant traumatic injury within
28 days of entry, or is there anticipation of a need
for major surgical procedure during the course of
the study?
Yes
No
Date of last prior major surgery (If yes, Month
Day Year)
Is the patient having ongoing treatment with
therapeutic doses of warfarin
Yes
No
Is the patient on any sex hormonal therapy, e.g.,
birth control pills, ovarian hormone replacement
therapy, SERMS other than tamoxifen and
toremifene, systemic estrogen or progesterone
replacement therapy or contraceptive products
Yes
No
Will the medication(s) be discontinued prior to
randomization (If yes,)
Yes
No
Does the patient plan to have reconstructive
surgery or other major surgical procedures during
the course of the study
Yes
No
Other2
Has the patient had hyperthyroidism within 6
months prior to randomization
Yes
No
Date of most recent lab value indicating
hyperthyroidism (Month Day Year)
Does the patient have a non-healing wound, skin
ulcers, or incompletely healed bone fracture
Yes
No
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Does the patient have malabsorption syndrome,
ulcerative colitis, inflammatory bowel disease,
resection of the stomach or small bowel, or other
disease significantly affecting gastrointestinal
function
Yes
No
Does the patient have known bleeding diathesis
or coagulopathy
Yes
No
At the time of study entry, will the patient be
pregnant or lactating
Yes
No
Has the patient had any investigational agents
within 30 days before randomization
Yes
No
Agent End Date (If yes, Month Day Year)
Footer Module
Comments (optional)
Person Completing Form
Date Form Completed (MM DD YYYY)
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Lung Cancer null On-Study - Director's Challenge
Lung Study Clinical Data Form - 2193149v1.0
On-study data collection for Director's Challenge Lung
Study 2004.
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=E7FC921D-
AD85-346E-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/8828
Director's Challenge Lung Study
Clinical Data Form
Enrollment Requirements
Specimen ID
Date of Operation
Demographics
Age at diagnosis
Gender
Female (FEMALE)
Male (MALE)
Unknown (UNKNOWN)
Race
A Person Having Origins In Any Of The
Original Peoples Of North And South
America (including Central America),
And Who Maintains Tribal Affiliation Or
Community Attachment. (American
Indian or Alaska Native)
A Person Having Origins In Any Of The
Original Peoples Of The Far East,
Southeast Asia, Or The Indian
Subcontinent Including, For Example,
Cambodia, China, India, Japan, Korea,
Malaysia, Pakistan, The Philippine
Islands, Thailand, And Vietnam. (Asian)
A Person Having Origins In Any Of The
Black Racial Groups Of Africa. Terms
Such As "haitian" Or "negro" Can Be
Used In Addition To "black Or African
American." (Black or African American)
A Person Having Origins In Any Of The
Original Peoples Of Hawaii, Guam,
Samoa, Or Other Pacific Islands. (Native
Hawaiian or other Pacific Islander)
Not Provided Or Available (Not
Reported)
Could Not Be Determined Or Unsure
(Unknown)
A Person Having Origins In Any Of The
Original Peoples Of Europe, The Middle
East, Or North Africa. (White)
Ethnicity
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A Person Of Mexican, Puerto Rican,
Cuban, Central Or South American Or
Other Spanish Culture Or Origin,
Regardless Of Race (HISPANIC OR
LATINO)
A Person Not Meeting The Definition For
Hispanic Or Latino. (NOT HISPANIC OR
LATINO)
Not Provided Or Available (Not reported)
Could Not Be Determined Or Unsure
(UNKNOWN)
Performance Status
Performance Status
Ambulatory And Capable Of All Selfcare
But Unable To Carry Out Any Work
Activities (Ambulatory and capable of all
selfcare but unable to carry out any work
activities)
Capable Of Limited Selfcare, Confined
To Bed Or Chair More Than 50% Of
Waking Hours (Capable of limited
selfcare, confined to bed or chair more
than 50% of waking hours)
Completely Disabled (Completely
disabled)
Fully Active, Able To Carry On All Pre-
disease Performance Without Restriction
(Fully active, able to carry on all pre-
disease performance without restriction)
Restricted In Physically Strenuous
Activity But Ambulatory (Restricted in
physically strenuous activity but
ambulatory)
Smoking History
Does the patient have a history of smoking?
Currently Smoking (Currently smoking)
Never Smoked (Never smoked)
Smoked In The Past (Smoked in the
past)
Unknown (Unknown)
Specify time since patient stopped smoking
Less Than 6 Months (< 6 months)
More Than 20 Years (> 20 years)
1 To 5 Years (1-5 years)
10 To 20 Years (10-20 years)
5 To 10 Years (5-10 years)
6 To 12 Months (6-12 months)
Unknown (Unknown)
Average pack per day consumption over entire
smoking history (former and current smokers)
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Number of years smoked
Second Hand Smoke Exposure Indicator
No (No)
Unknown (Unknown)
Yes (Yes)
Number of years exposed to second hand smoke
Baseline Laboratory Studies
Units used by Lab
Imperial Units (Imperial)
Si Units (S/I)
Unknown (Unknown)
Lactate Dehydrogenase (LDH)
Lactate Dehydrogenase ULN
Lung Treatment
Adjuvant RT Administered Ind-3
No (No)
Unknown (Unknown)
Yes (Yes)
Has the patient received adjuvant systemic
chemotherapy?
No (No)
Unknown (Unknown)
Yes (Yes)
Lung Surgical Procedure
Side of Tumor Location
Both (Both)
Left (Left)
Right (Right)
Unknown (Unknown)
Surgical Approach
Bilateral Anterior Thoracotomies
W/transverse Sternotomy (Bilat ant
thoracotomies/sternotomy)
Median Sternotomy (Median sternotomy)
Other Approach (Other approach)
Partial Sternotomy (Partial sternotomy)
Thoracoscopy (Thoracoscopy)
Thoracotomy (Thoracotomy)
Unknown (Unknown)
Other, Specify
3 / 7
Lung Cancer null On-Study - Director's Challenge Lung Study Clinical
Data Form - 2193149v1.0
Primary Pulmonary Procedure
Bilobectomy (Bilobectomy)
Completion Pneumonectomy
(Completion pneumonectomy)
Lobectomy (Lobectomy)
Pneumonectomy (Pneumonectomy)
Segmentectomy (Segmentectomy)
Wedge Resection, Multiple (Wedge
Resection, Multiple)
Wedge Resection, Single (Wedge
Resection, Single)
Additional components of resection (Mark all that
apply)
Bronchial Sleeve Resection (Bronchial
sleeve resection)
Chest Wall Resection, No
Reconstruction (Chest wall resection, no
reconstruction)
Chest Wall Resection, With
Reconstruction (Chest wall resection,
with reconstruction)
Intrapericardial Reconstruction
(Intrapericardial reconstruction)
Major Vascular Resection, No
Reconstruction (Major vascular
resection, no reconstruction)
Other, Specify (Other, specify)
Vascular Sleeve Resection (Vascular
sleeve resection)
Additional Component of resection Other, Specify
Lymph Node Assessment
Lymph Node (Station)
Highest Mediastinal Lymph Node
(Highest Mediastinal LN)
Interlobar Lymph Node (Interlobar LN)
Left Hilar Lymph Node (Left Hilar LN)
Left Lobar Lymph Node (Left Lobar LN)
Left Lower Paratracheal Lymph Node
(Left Lower Paratracheal LN)
Left Segmental Lymph Node (Left
Segmental LN)
Left Subsegmental Lymph Node (Left
Subsegmental LN)
Left Upper Paratracheal Lymph Node
(Left Upper Paratracheal LN)
Para-aortic Lymph Node (Para-aortic LN)
Paraesophageal Lymph Node
(Paraesophageal LN)
Pre-paratracheal Lymph Node (Pre-
paratracheal LN)
Pulmonary Ligament Lymph Node
(Pulmonary Ligament LN)
Right Hilar Lymph Node (Right Hilar LN)
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Right Lobar Lymph Node (Right Lobar
LN)
Right Lower Paratracheal Lymph Node
(Right Lower Paratracheal LN)
Right Segmental Lymph Node (Right
Segmental LN)
Right Subsegmental Lymph Node (Right
Subsegmental LN)
Right Upper Paratracheal Lymph Node
(Right Upper Paratracheal LN)
Subaortic Lymph Node (Subaortic LN)
Subcarinal Lymph Node (Subcarinal LN)
Clinical Involvement
Equivocal (Equivocal)
Negative (Negative)
Positive (Positive)
Unknown (Unknown)
Pathologic Involvement
Equivocal (Equivocal)
Negative (Negative)
Positive (Positive)
Unknown (Unknown)
Vital Status
Patient's Vital Status
Alive (Alive)
Dead (Dead)
Unknown (Unknown)
Was death caused by lung cancer ?
No (No)
Unknown (Unknown)
Yes (Yes)
Describe cause of death
Date of Last Contact or Death
Follow-up Status
Has patient developed a first pogression or
relapse?
Yes
No
Date of first progression or relapse
Date of Last Clinical Assessment
Sites Of Progression Or Relapse
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Lung, Ipsilateral
No (No)
Unknown (Unknown)
Yes (Yes)
Regional lymph nodes
No (No)
Unknown (Unknown)
Yes (Yes)
Lung, Contralateral
No (No)
Unknown (Unknown)
Yes (Yes)
Liver
No (No)
Unknown (Unknown)
Yes (Yes)
Pleura
No (No)
Unknown (Unknown)
Yes (Yes)
CNS (Excluding brain)
No (No)
Unknown (Unknown)
Yes (Yes)
Brain
No (No)
Unknown (Unknown)
Yes (Yes)
Bone
No (No)
Unknown (Unknown)
Yes (Yes)
Adrenal
No (No)
Unknown (Unknown)
Yes (Yes)
Distant lymph nodes
No (No)
Unknown (Unknown)
Yes (Yes)
Distant skin/subcutaneous tissue
No (No)
Unknown (Unknown)
Yes (Yes)
Other Site(s)
No (No)
Unknown (Unknown)
Yes (Yes)
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If site(s) other than specified, indicate name
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Breast Cancer NCT01101438 Toxicity - NCIC MA.32
Serious Adverse Event Folder - 3027655v1.0
NCIC MA.32 Serious Adverse Event Folder
A Phase III Randomized Trial of Metformin vs Placebo in
Early Stage Breast Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=81E4E526-
5F38-E26A-E040-BB89AD43175C
All rights reserved. Please visit https://medical-data-
models.org/forms/8830
NCIC MA.32 Serious Adverse Event
Folder
Date Of Event/reporting Period
Start Date of Primary AE
SAE Reported to Investigator Date
Temporal relation to SAE to protocol treatment
During Protocol Treatment (during
protocol treatment)
More Than 30 Days After Completion Of
Protocol Treatment (more than 30 days
after completion of protocol treatment)
Within 30 Days After Completion Of
Protocol Treatment (within 30 days after
completion of protocol treatment)
Reporting period at which SAE occurred
Event Description
Event Description
Serious Adverse Events
CTC Adverse Event Term
Event Onset Time
Event End Time
Grade
Absent Adverse Event (0)
Mild Adverse Event (1)
Moderate Adverse Event (2)
Severe Adverse Event (3)
Life Threatening Adverse Event (4)
Death Related To Adverse Event (5)
Attribution (to Metformin/Placebo)
Definite (Definite)
Possible (Possible)
Probable (Probable)
Unlikely (Unlikely)
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Unrelated (Unrelated)
Action Taken at Time of Adverse Event
There Was No Action Taken Based On
The Adverse Event (none)
Protocol Treatment Was Delayed As A
Result Of The Adverse Event (protocol
treatment delayed)
Protocol Treatment Was Discontinued As
A Result Of The Adverse Event (protocol
treatment discontinued)
Study Dose Was Reduced As A Result
Of The Adverse Event (study dose
reduced)
AE Outcome
Fatal Or Died (Fatal/Died)
Not Recovered Or Not Resolved (Not
recovered/Not resolved)
Recovered Or Resolved With Sequelae
(Recovered/Resolved with Sequelae)
Recovered Or Resolved Without
Sequelae (Recovered/Resolved without
Sequelae)
Seriousness Attributed to Adverse Event
Congenital Anomaly (Congenital
anomaly)
Death (Death)
Disability (Disability/incapacity)
Hospitalized (Hospitalization, initial or
prolonged)
Life Threatening (Life threatening)
Not Serious (Not serious)
Intervention Required (Required
intervention to prevent permanent
impairment/damage)
Laboratory Tests - Question
Are there any relevant laboratory or physical
exam tests to report
Yes
No
Laboratory Test
Diagnostic Test
Activated Partial Thromboplastin Time
(Activated partial thromboplastin time
(APTT))
Albumin (Albumin - blood)
Alkaline Phosphatase (Alkaline
phosphatase NOS)
Alkaline Phosphatase (Alkaline
phosphates NOS)
Amylase (Amylase - blood)
Absolute Neutrophil Count (ANC)
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Bacterial Infection (Bacterial infection
NOS)
Direct Bilirubin (Bilirubin direct - blood)
Total Bilirubin (Bilirubin total - blood)
Blood Bicarbonate (Blood bicarbonate)
Blood Carbon Dioxide (Blood carbon
dioxide)
Anc (Blood neutrophils (ANC))
Bun (Blood urea nitrogen (BUN))
Bone Marrow Blasts (Bone Marrow
Blasts)
Bone Marrow Cellularity (Bone Marrow
Cellularity)
Calcium (Calcium - blood (Ca))
Blood Carbon Dioxide (Carbon dioxide -
blood (CO2))
Chloride (Chloride - blood)
Cholesterol (Cholesterol - blood)
Creatine Phosphokinase (Creatine
phosphokinase - blood (CK))
Creatinine (Creatinine - serum (Cr))
Creatinine Clearance (Creatinine
clearance (CrCl))
Fibrin D-dimer (Fibrin D-dimer)
Fibrin Degradation Products (Fibrin
degradation products (FDP))
Fibrinogen (Fibrinogen - blood)
Fungal Infection (Fungal infection NOS)
Glucose (Glucose - blood)
Glutamic-oxaloacetic Transferase (ast,
Sgot) (Glutamic-oxaloacetic transferase
(AST, SGOT))
Glutamic-pyruvate Transferase (alt, Sgpt)
(Glutamic-pyruvate transferase (ALT,
SGPT))
Hematocrit (Hematocrit (Hct))
Hemoglobin (hgb) (Hemoglobin (Hb))
International Normalized Ratio
(International normalised ratio (INR))
Ldh (Lactate dehydrogenase - blood
(LDH))
Lipase (Lipase)
Magnesium (Magnesium - blood (Mg))
Oxygen Saturation (Oxygen saturation)
Peripheral Blasts (Peripheral Blasts)
Ph Nos (pH NOS)
Phosphorus (Phosphorus)
Platelet Count (Platelet count (PLT))
Po2 (pO2)
Potassium (Potassium - blood (K))
Total Protein (Protein NOS (Total))
Prothrombin Time (Prothrombin time
(PT))
Sodium (Sodium - blood)
Triglycerides (Triglycerides)
Urinalysis (Urine analysis)
Viral Infection (Viral infection NOS)
Wbc (White blood cell count (WBC))
Specify
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Nadir/Worst Value
Nadir/Worst Date (at Time of SAE)
Nadir/Worst Unit of Measure
Percent (%)
1000 Per Cubic Millimiter (1000/mm3)
1000 Per Microliter (1000/uL)
Cubic Centimeters Per Minute (cc/min)
Cells Per Liter (cells/L)
Grams Per Deciliter (g/dL)
Grams Per Liter (g/L)
Gram (gm)
Grams Per Deciliter (gm/dl)
International Units Per Liter (iU/L)
Kilopascals (kPa)
Milliequivalents Per Liter (mEq/L)
Milligrams Per Deciliter (mg/dL)
Milligrams Per Liter (mg/L)
Minutes (min)
Ml/min/1.73m^2 (mL/min/1.73m2)
Cubic Millimeters (mm3)
Millimeters Of Mercury (mmHg)
Millimole Per Liter (mmol/L)
Not Applicable (n/a)
Number (number)
Seconds (seconds)
Units Per Liter (U/L)
Micrograms Per Milliliter (ug/mL)
Microliter (ul)
Micromole Per Liter (umol/L)
Volume Fraction (Vol Frac)
LLN
ULN
Has the patient recovered
Yes
No
Recovery or Latest Value
Date of Recovery or Death
Name of Laboratory (where tests were
completed)
Blood Pressure - Question
Are there any relevant blood pressure results to
report
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Yes
No
Blood Pressure
Nadir/Worst Date (at Time of SAE)
Blood Pressure, Systolic (mmHg, Recovery
Value)
Blood Pressure, Systolic (mmHg, Recovery
Value)
Blood pressure, Diastolic (mmHg, Recovery
Value)
Blood pressure, Diastolic (mmHg, Recovery
Value)
Has the patient recovered
Yes
No
Date of Recovery or Death
Other Investigations - Question
Are there any other relevant investigations to
report
Yes
No
Other Investigations - Question
Diagnostic Test
Activated Partial Thromboplastin Time
(Activated partial thromboplastin time
(APTT))
Albumin (Albumin - blood)
Alkaline Phosphatase (Alkaline
phosphatase NOS)
Alkaline Phosphatase (Alkaline
phosphates NOS)
Amylase (Amylase - blood)
Absolute Neutrophil Count (ANC)
Bacterial Infection (Bacterial infection
NOS)
Direct Bilirubin (Bilirubin direct - blood)
Total Bilirubin (Bilirubin total - blood)
Blood Bicarbonate (Blood bicarbonate)
Blood Carbon Dioxide (Blood carbon
dioxide)
Anc (Blood neutrophils (ANC))
Bun (Blood urea nitrogen (BUN))
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Bone Marrow Blasts (Bone Marrow
Blasts)
Bone Marrow Cellularity (Bone Marrow
Cellularity)
Calcium (Calcium - blood (Ca))
Blood Carbon Dioxide (Carbon dioxide -
blood (CO2))
Chloride (Chloride - blood)
Cholesterol (Cholesterol - blood)
Creatine Phosphokinase (Creatine
phosphokinase - blood (CK))
Creatinine (Creatinine - serum (Cr))
Creatinine Clearance (Creatinine
clearance (CrCl))
Fibrin D-dimer (Fibrin D-dimer)
Fibrin Degradation Products (Fibrin
degradation products (FDP))
Fibrinogen (Fibrinogen - blood)
Fungal Infection (Fungal infection NOS)
Glucose (Glucose - blood)
Glutamic-oxaloacetic Transferase (ast,
Sgot) (Glutamic-oxaloacetic transferase
(AST, SGOT))
Glutamic-pyruvate Transferase (alt, Sgpt)
(Glutamic-pyruvate transferase (ALT,
SGPT))
Hematocrit (Hematocrit (Hct))
Hemoglobin (hgb) (Hemoglobin (Hb))
International Normalized Ratio
(International normalised ratio (INR))
Ldh (Lactate dehydrogenase - blood
(LDH))
Lipase (Lipase)
Magnesium (Magnesium - blood (Mg))
Oxygen Saturation (Oxygen saturation)
Peripheral Blasts (Peripheral Blasts)
Ph Nos (pH NOS)
Phosphorus (Phosphorus)
Platelet Count (Platelet count (PLT))
Po2 (pO2)
Potassium (Potassium - blood (K))
Total Protein (Protein NOS (Total))
Prothrombin Time (Prothrombin time
(PT))
Sodium (Sodium - blood)
Triglycerides (Triglycerides)
Urinalysis (Urine analysis)
Viral Infection (Viral infection NOS)
Wbc (White blood cell count (WBC))
Specify
Date
Results
6 / 9
Breast Cancer NCT01101438 Toxicity - NCIC MA.32 Serious Adverse
Event Folder - 3027655v1.0
Protocol Treatment
Treatment Assignment Code
Actual dose
Units
Route of Administration
Oral Administration Of Drug (PO)
Schedule
Daily (Daily)
Randomization Date
Last Administered Date (Prior to SAE)
Agent Source
Patient rechallenged with agent
Decision Pending (Decision Pending)
No (No)
Yes (Yes)
Did event reoccur
Yes
No
Prior Systemic Therapy - Question
Has the patient received systemic therapy?
Yes
No
Prior Radiation Therapy - Question
Has the patient received adjuvant RT
Yes
No
Relevant Major Medical Problems -
Question
Significant Medical History, Concomitant
Diseases and/or Relevant Medical Conditions
Yes
No
Relevant Major Medical Problems
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Date Documented
Relevant major medical problems
Acquired Immunodeficiency Syndrome
(AIDS)
Immunology Hypersensitivity
(Allergy/Immunology)
Auditory (Auditory/Ear)
Bone Marrow Blood (Blood/Bone
Marrow)
Cardiac (Cardiac)
Coagulation (Coagulation)
Dermatologic (Dermatology/Skin)
Endocrine (Endocrine)
Gastrointestinal (Gastrointestinal)
Hepatobiliary System
(Hepatobiliary/Pancreas)
Infection (Infection)
Metabolic (Metabolic/Laboratory)
Soft Tissue Musculoskeletal
(Musculoskeletal/Soft Tissue)
Neurology (Neurology)
Ocular (Ocular)
Ocular (Ocular/Eye)
Other (Other)
Other Malignant Neoplasm (Other
Malignancy)
Pulmonary (Pulmonary/Upper
Respiratory)
Genitourinary Renal
(Renal/Genitourinary)
Surgical Procedure (Surgical Procedure)
Specify other disease/condition
Other Relevant Details
Concomitant Medications - Question
Did the participant report taking any concomitant
medication
Yes
No
Concomitant Medications
Concomitant Medication (335 permissible values)
Agent Type (116 permissible values not coded)
Was this medication used to treat the SAE
Yes
No
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Start date
Stop date
Sae Notification Form
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Enrollment form for C3D 3.12 Adopters
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=7D884695-
F5C5-C71D-E040-BB89AD437E63
All rights reserved. Please visit https://medical-data-
models.org/forms/8831
ENROLLMENT
Demographics
Gender of a Person
Female Gender (Female Gender)
Male Gender (Male Gender)
Unknown (Unknown)
Unspecified (Unspecified)
Patient's Date of Birth
Patient/Participant Age
Race
A Person Having Origins In Any Of The
Original Peoples Of North And South
America (including Central America),
And Who Maintains Tribal Affiliation Or
Community Attachment. (American
Indian or Alaska Native)
A Person Having Origins In Any Of The
Original Peoples Of The Far East,
Southeast Asia, Or The Indian
Subcontinent Including, For Example,
Cambodia, China, India, Japan, Korea,
Malaysia, Pakistan, The Philippine
Islands, Thailand, And Vietnam. (Asian)
A Person Having Origins In Any Of The
Black Racial Groups Of Africa. Terms
Such As "haitian" Or "negro" Can Be
Used In Addition To "black Or African
American." (Black or African American)
A Person Having Origins In Any Of The
Original Peoples Of Hawaii, Guam,
Samoa, Or Other Pacific Islands. (Native
Hawaiian or other Pacific Islander)
Not Provided Or Available (Not
Reported)
Could Not Be Determined Or Unsure
(Unknown)
A Person Having Origins In Any Of The
Original Peoples Of Europe, The Middle
East, Or North Africa. (White)
Ethnicity, other
Patient Initials Name
1 / 11
Patient Registration Date
Prestudy Lab Date
Patient Identifier
Registration
Patient Subgroup Assignment
Registering Group
Registering Institution Identification Code
Country Code
Ascension Island (AC)
Andorra (AD)
United Arab Emirates (AE)
Afghanistan (AF)
Antigua And Barbuda (AG)
Anguilla (AI)
Albania (AL)
Armenia (AM)
Netherland Antilles (AN)
Angola (AO)
Antarctica (AQ)
Argentina (AR)
American Samoa (AS)
Austria (AT)
Australia (AU)
Aruba (AW)
Azerbaidjan (AZ)
Bosnia-herzegovina (BA)
Barbados (BB)
Bangladesh (BD)
Belgium (BE)
Burkina Faso (BF)
Bulgaria (BG)
Bahrain (BH)
Burundi (BI)
Benin (BJ)
Bermuda (BM)
Brunei Darussalam (BN)
Bolivia (BO)
Brazil (BR)
Bahamas (BS)
Bhutan (BT)
Bouvet Island (BV)
Botswana (BW)
Belarus (BY)
Belize (BZ)
Canada (CA)
Cocos Isl. (CC)
Rep. Dem. Congo (CD)
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Central African Rep. (CF)
Congo (CG)
Switzerland (CH)
Ivory Coast (CI)
Cook Islands (CK)
Chile (CL)
Cameroon (CM)
China (CN)
Colombia (CO)
Costa Rica (CR)
Cuba (CU)
Cape Verde (CV)
Christmas Island (CX)
Cyprus (CY)
Czech Republic (CZ)
Germany (DE)
Djibouti (DJ)
Denmark (DK)
Dominica (DM)
Dominican Republic (DO)
Algeria (DZ)
Ecuador (EC)
Estonia (EE)
Egypt (EG)
Western Sahara (EH)
Eritrea (ER)
Spain (ES)
Ethiopia (ET)
Finland (FI)
Fiji (FJ)
Falkland Isl. (FK)
Micronesia (FM)
Faroe Islands (FO)
France (FR)
France (european Ter.) (FX)
Gabon (GA)
Great Britain (GB)
Grenada (GD)
Georgia (GE)
Guiana (fr.) (GF)
Guernsey (GG)
Ghana (GH)
Gibraltar (GI)
Greenland (GL)
Gambia (GM)
Guinea (GN)
Guadeloupe (fr.) (GP)
Equatorial Guinea (GQ)
Greece (GR)
South Georgia And South Sandwich
Islands (GS)
Guatemala (GT)
Guam (us) (GU)
Guinea Bissau (GW)
Guyana (GY)
Hong Kong (HK)
Heard & Mcdonald Isl. (HM)
Honduras (HN)
Croatia (HR)
Haiti (HT)
3 / 11
On-Study - ENROLLMENT - 2988652v1.0
Hungary (HU)
Indonesia (ID)
Ireland (IE)
Israel (IL)
Isle Of Man (IM)
India (IN)
British Indian O. Ter. (IO)
Iraq (IQ)
Iran (IR)
Iceland (IS)
Italy (IT)
Jersey (JE)
Jamaica (JM)
Jordan (JO)
Japan (JP)
Kenya (KE)
Kyrgyz Republic (KG)
Cambodia (KH)
Kiribati (KI)
Comoros (KM)
St. Kitts Nevis Anguilla (KN)
Korea (north) (KP)
Korea (south) (KR)
Kuwait (KW)
Cayman Islands (KY)
Kazakstan (KZ)
Laos (LA)
Lebanon (LB)
Saint Lucia (LC)
Liechtenstein (LI)
Sri Lanka (LK)
Liberia (LR)
Lesotho (LS)
Lithuania (LT)
Luxembourg (LU)
Latvia (LV)
Libya (LY)
Morocco (MA)
Monaco (MC)
Moldova (MD)
Madagascar (MG)
Marshall Islands (MH)
Macedonia (MK)
Mali (ML)
Myanmar (MM)
Mongolia (MN)
Macau (MO)
Northern Mariana Isl. (MP)
Martinique (fr.) (MQ)
Mauritania (MR)
Montserrat (MS)
Malta (MT)
Mauritius (MU)
Maldives (MV)
Malawi (MW)
Mexico (MX)
Malaysia (MY)
Mozambique (MZ)
Namibia (NA)
New Caledonia (fr.) (NC)
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Niger (NE)
Norfolk Island (NF)
Nigeria (NG)
Nicaragua (NI)
Netherlands (NL)
Norway (NO)
Nepal (NP)
Nauru (NR)
Niue (NU)
New Zealand (NZ)
Oman (OM)
Other (Other)
Panama (PA)
Peru (PE)
Polynesia (fr.) (PF)
Papua New Guinea (PG)
Philippines (PH)
Pakistan (PK)
Poland (PL)
St. Pierre & Miquelon (PM)
Pitcairn (PN)
Puerto Rico (PR)
Portugal (PT)
Palau (PW)
Paraguay (PY)
Qatar (QA)
Reunion (fr.) (RE)
Romania (RO)
Russian Federation (RU)
Rwanda (RW)
Saudi Arabia (SA)
Solomon Islands (SB)
Seychelles (SC)
Sudan (SD)
Sweden (SE)
Singapore (SG)
St. Helena (SH)
Slovenia (SI)
Svalbard & Jan Mayen Isl. (SJ)
Slovakia (SK)
Sierra Leone (SL)
San Marino (SM)
Senegal (SN)
Somalia (SO)
Suriname (SR)
St. Tome And Principe (ST)
Soviet Union (SU)
El Salvador (SV)
Syria (SY)
Swaziland (SZ)
Turks & Caicos Islands (TC)
Chad (TD)
French Southern Terr. (TF)
Togo (TG)
Thailand (TH)
Tadjikistan (TJ)
Tokelau (TK)
Turkmenistan (TM)
Tunisia (TN)
Tonga (TO)
5 / 11
On-Study - ENROLLMENT - 2988652v1.0
East Timor (TP)
Turkey (TR)
Trinidad & Tobago (TT)
Tuvalu (TV)
Taiwan (TW)
Tanzania (TZ)
Ukraine (UA)
Uganda (UG)
United Kingdom (UK)
Us Minor Outlying Isl. (UM)
Usa (US)
Uruguay (UY)
Uzbekistan (UZ)
Vatican City State (VA)
St. Vincent & Grenadines (VC)
Venezuela (VE)
Virgin Islands (brit) (VG)
Virgin Islands (us) (VI)
Vietnam (VN)
Vanuatu (VU)
Wallis & Futuna Islands (WF)
Western Samoa (WS)
Yemen (YE)
Mayotte (YT)
Yugoslavia (YU)
South Africa (ZA)
Zambia (ZM)
Dem. Rep. Of Congo (ZR)
Zimbabwe (ZW)
ZIP Code
City
Payment Method
Private Insurance (1)
Medicare (2)
Medicare And Private Insurance (3)
Medicaid (4)
Medicaid And Medicare (5)
Military Or Veterans Sponsored Nos (6)
Military Sponsored (including Champus
&tricare) (6a)
Veterans Sponsored (6b)
Self Pay (no Insurance) (7)
No Means Of Payment (no Insurance)
(8)
Other (98)
Unknown (99)
Disease
Primary Site of Disease Name
Adrenal Gland (Adrenal Gland)
Anus (Anus)
Appendix (Appendix)
Back (Back)
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Bile Duct (Bile Duct)
Bladder (Bladder)
Bone Marrow (Bone Marrow)
Brainstem (Brainstem)
Breast (Breast)
Cerebellum (Cerebellum)
Cerebrum (Cerebrum)
Cervix (Cervix)
Chest (Chest)
Colon (Colon)
Cerebrospinal Fluid (CSF)
Duodenum (Duodenum)
Ear, External (Ear, External)
Ear, Inner (Ear, Inner)
Ear, Mid (Ear, Mid)
Esophagus (Esophagus)
Eye, Globe (Eye, Globe)
Eye, Orbit (Eye, Orbit)
Fallopian Tube (Fallopian Tube)
Feet (Feet)
Femur (Femur)
Fibula (Fibula)
Hands (Hands)
Hilum, Thoracic (Hilum)
Humerus (Humerus)
Ileum (Ileum)
Iliac Bone (Iliac)
Jejunum (Jejunum)
Kidney (Kidney)
Liver (Liver)
Lymph Node (LN)
Lymph Node, Axilla (LN, Axilla)
Lymph Node, Brachial (LN, Brachial)
Lymph Node, Cervical (LN, Cervical)
Lymph Node, Epitrochlear (LN,
Epitrochlear)
Lymph Node, Femoral (LN, Femoral)
Lymph Node, Hilar (LN, Hilar)
Lymph Node, Iliac (LN, Iliac)
Lymph Node, Inguinal (LN, Inguinal)
Lymph Node, Internal Mammary (LN,
Internal Mammary)
Lymph Node, Mediastinal (LN,
Mediastinal)
Lymph Node, Mesenteric (LN,
Mesenteric)
Lymph Node, Mid-pelvis (LN, Mid Pelvis)
Lymph Node, Neck (LN, Neck)
Lymph Node, Occipital (LN, Occipital)
Lymph Node, Paraaortic (LN, Paraaortic)
Lymph Node, Pelvis (LN, Pelvis)
Lymph Node, Periauricular (LN,
Periauricular)
Lymph Node, Popliteal (LN, Popliteal)
Lymph Node, Retroperitoneal (LN,
Retroperitoneal)
Lymph Node(s), Subclavian (LN,
Subclavian)
Lymph Node, Submental (LN,
Submental)
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Lymph Node, Supraclavicular (LN,
Supraclavicular)
Lung (Lung)
Lung, Anterior Left Lower Lobe (Lung,
Ant-LLL)
Lung, Anterior Left Upper Lobe (Lung,
Ant-LUL)
Lung, Anterior Right Lower Lobe (Lung,
Ant-RLL)
Lung, Anterior Right Middle Lobe (Lung,
Ant-RML)
Lung, Anterior Right Upper Lobe (Lung,
Ant-RUL)
Lung, Posterior Left Lower Lobe (Lung,
Post-LLL)
Lung, Posterior Left Upper Lobe (Lung,
Post-LUL)
Lung, Posterior Right Lower Lobe (Lung,
Post-RLL)
Lung, Posterior Right Middle Lobe (Lung,
Post-RML)
Lung, Posterior Right Upper Lobe (Lung,
Post-RUL)
Mandible (Mandible)
Mediastinum (Mediastinum)
Mouth (Mouth)
Muscle, Lower Extremity Distal (Muscle,
LE DIstal)
Muscle, Lower Extremity Proximal
(Muscle, LE Proximal)
Muscle, Upper Extremity Distal (Muscle,
UE Distal)
Muscle, Upper Extremity Proximal
(Muscle, UE Proximal)
Nasopharynx (Nasopharynx)
Nose (Nose)
Other Site (Other Site)
Ovary (Ovary)
Pancreas (Pancreas)
Pelvis (Pelvis)
Penis (Penis)
Pericardium (Pericardium)
Peripheral Blood (Peripheral Blood)
Pharynx (Pharynx)
Pleura (Pleura)
Prostate (Prostate)
Radius (Radius)
Rectum (Rectum)
Ribs (Ribs)
Sigmoid Colon (Sigmoid Colon)
Sinuses (Sinuses)
Skin (Skin)
Skull (Skull)
Spine, Cervical (Spine-C)
Spine, Lumbar (Spine-L)
Spine, Sacral (Spine-S)
Spine, Thoracic (Spine-T)
Spleen (Spleen)
Sternum (Sternum)
Stomach (Stomach)
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Testicle (Testicle)
Throat (Throat)
Thyroid (Thyroid)
Tibia (Tibia)
Ulna (Ulna)
Ureter (Ureter)
Uterus (Uterus)
Vagina (Vagina)
Disease Term
Histology/Cytopathology Description
Disease Stage
Stage 0 (0)
Stage A (A)
Stage B (B)
Stage C (C)
Stage D (D)
Stage D0 (D0)
Stage D1 (D1)
Stage D2 (D2)
Stage D3 (D3)
Stage I (I)
Stage Ia (IA)
Stage Ib (IB)
Stage Ii (II)
Stage Iia (IIA)
Stage Iib (IIB)
Stage Iii (III)
Stage Iiia (IIIA)
Stage Iiib (IIIB)
Stage Iiic (IIIC)
Stage Iv (IV)
Stage Iva (IVA)
Stage Ivb (IVB)
Disease CDUS Code (This is a derived field and
may be displayed on the form, if needed.)
Consent
Histologic Confirmation Date
Diagnosis Date
ICF Signed Date
Informed Consent Version
Histopathologic Differentiation Text Grade
High Grade (High Grade)
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Low Grade (Low Grade)
Moderately Differentiated (Moderately)
Not Applicable (N/A)
Poorly Differentiated (Poorly)
Unknown (Unknown)
Well Differentiated (Well)
Treatment Assignment Code at Enrollment
Vital Signs
Evaluation Date
Lab Collection Time
Height (cm)
Body Weight in Kilograms
BSA
Zubrod Performance Status Score
Normal Activity (0)
Symptoms, But Nearly Fully Ambulatory
(1)
Some Bed Time, But Needs To Be In
Bed <50% Of Normal Daytime (2)
Needs To Be In Bed > 50% Of Normal
Daytime (3)
Unable To Get Out Of Bed (4)
Karnofsky Performance Status Score
Dead (0)
Moribund, Fatal Processes Progressing
Rapidly (10)
Normal, No Complaints, No Evidence Of
Disease (100)
Very Sick, Hospitalization Indicated.
Death Not Imminent (20)
Severely Disabled, Hospitalization
Indicated. Death Not Imminent (30)
Disabled, Requires Special Care And
Assistance (40)
Requires Considerable Assistance And
Frequent Medical Care (50)
Requires Occasional Assistance, But Is
Able To Care For Most Of His/her Needs
(60)
Cares For Self, Unable To Carry On
Normal Activity Or To Do Active Work
(70)
Normal Activity With Effort; Some Signs
Or Symptoms Of Disease (80)
Able To Carry On Normal Activity; Minor
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Signs Or Symptoms Of Disease (90)
Lansky Performance Status Score
Unresponsive (0)
No Play; Does Not Get Out Of Bed. (10)
Fully Active, Normal (100)
Often Sleeping; Play Entirely Limited To
Very Passive Activities. (20)
In Bed; Needs Assistance Even For
Quiet Play. (30)
Mostly In Bed; Participates In Quiet
Activities. (40)
Gets Dressed, But Lies Around Much Of
The Day; No Active Play, Able To
Participate In All Quiet Play And
Activities. (50)
Up And Around, But Minimal Active Play;
Keeps Busy With Quieter Activities. (60)
Both Greater Restriction Of And Less
Time Spent In Play Activity (70)
Active, But Tires More Quickly (80)
Minor Restrictions In Physically
Strenuous Activity (90)
Comments
Note Date
Research Comments Text
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Colorectal Cancer NCT00217737 Eligibility - E5202
Registration Worksheet (step 2) - 2769258v1.0
E5202 Registration Worksheet (step 2)
Oxaliplatin, Leucovorin, and Fluorouracil With or Without
Bevacizumab in Treating Patients Who Have Undergone
Surgery for Stage II Colon Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=532CA5B1-
037C-07D2-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/8835
E5202 Registration Worksheet (step
2)
Eligibility
First initial
Last initial
Has the eligibility checklist been completed
Yes
No
In the opinion of the investigator, is the patient
eligible?
Yes
No
Disease Risk Status (That was assigned to you
by MD Anderson)
Is the reported lab value/assessment correct on
the webpage
Yes
No
Disease stage
Stage Iia Colorectal Cancer (Stage IIA)
Stage Iib Colorectal Cancer (Stage IIB)
Patient's ECOG sequence number
Patient Demographics / Pre-treatment
Characteristics
Patient's Sex
Female (F)
Male (M)
Birthdate (mm/yy)
Patient Race (check all that applyU.S. and
Canada only)
A Person Having Origins In Any Of The
Original Peoples Of North And South
America (including Central America),
And Who Maintains Tribal Affiliation Or
Community Attachment. (American
1 / 3
Indian or Alaska Native)
A Person Having Origins In Any Of The
Original Peoples Of The Far East,
Southeast Asia, Or The Indian
Subcontinent Including, For Example,
Cambodia, China, India, Japan, Korea,
Malaysia, Pakistan, The Philippine
Islands, Thailand, And Vietnam. (Asian)
A Person Having Origins In Any Of The
Black Racial Groups Of Africa. Terms
Such As "haitian" Or "negro" Can Be
Used In Addition To "black Or African
American." (Black or African American)
A Person Having Origins In Any Of The
Original Peoples Of Hawaii, Guam,
Samoa, Or Other Pacific Islands. (Native
Hawaiian or other Pacific Islander)
Not Provided Or Available (Not
Reported)
Could Not Be Determined Or Unsure
(Unknown)
A Person Having Origins In Any Of The
Original Peoples Of Europe, The Middle
East, Or North Africa. (White)
ZIP Code
Patient Ethnicity
A Person Of Mexican, Puerto Rican,
Cuban, Central Or South American Or
Other Spanish Culture Or Origin,
Regardless Of Race. (Hispanic or Latino)
A Person Not Meeting The Definition For
Hispanic Or Latino. (Not Hispanic or
Latino)
Not Provided Or Available (Not reported)
Could Not Be Determined Or Unsure
(Unknown)
Patient Hospital No.
Patient Social Security Number
Method of payment (check one)
Medicaid (Medicaid)
Medicaid And Medicare (Medicaid and
Medicare)
Medicare (Medicare)
Medicare And Private Insurance
(Medicare and Private Insurance)
Military Or Veterans Sponsored Nos
(Military or Veterans Sponsored, Not
Otherwise Specified (NOS))
Military Sponsored (including Champus
& Tricare) (Military Sponsored (including
CHAMPUS & TRICARE))
National Health Service (National Health
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Service)
No Means Of Payment (no Insurance)
(No means of payment (no insurance))
Other (Other)
Private Insurance (Private Insurance)
Self Pay (no Insurance) (Self Pay (No
Insurance))
Unknown (Unknown)
Veterans Sponsored (Veterans
Sponsored)
Attending Physician
Institution contact
Registrar
Country of Residence
Comments
Signature of treating physician (I have reviewed
the above data and agree the date are accurate
and correct)
Date (Note: Date must be on or before date of
registration)
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Kidney Cancer NCT01164228 Eligibility - E1808
Registration Worksheet (step 1) - 3084118v1.0
E1808 Registration Worksheet (step 1)
Sunitinib Malate With or Without Gemcitabine
Hydrochloride in Treating Patients With Advanced Kidney
Cancer That Cannot Be Removed By Surgery
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=863E7AF9-
E486-FB2D-E040-BB89AD43214E
All rights reserved. Please visit https://medical-data-
models.org/forms/8836
E1808 Registration Worksheet (step
1)
Eligibility
First initial
Last initial
Has the eligibility checklist been completed
Yes
No
In the opinion of the investigator, is the patient
eligible?
Yes
No
Has written informed consent been obtained
Yes
No
Date Informed Consent Signed
Has HIPAA authorization been obtained
Exempt - Non-usa Participant (Exempt -
non-USA participant)
No: C49487 (No)
Yes: C49488 (Yes)
HIPAA Authorization Date
Risk category
Good Risk (Good risk)
Intermediate Risk (Intermediate risk)
Poor Risk (Poor risk)
My specimens may be kept for use in research to
learn about, prevent, treat, or cure cancer.
Yes
No
My specimens may be kept for use in research
about other health problems (for example: causes
of diabetes, Alzheimer's disease, or heart
disease)
Yes
No
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Someone from this institution may contact me in
the future to ask me to take part in more
research.
Yes
No
Patient Demographics / Pre-treatment
Characteristics
Patient's Sex
Female (F)
Male (M)
Birthdate (mm/yy)
Patient's Race
A Person Having Origins In Any Of The
Original Peoples Of North And South
America (including Central America),
And Who Maintains Tribal Affiliation Or
Community Attachment. (American
Indian or Alaska Native)
A Person Having Origins In Any Of The
Original Peoples Of The Far East,
Southeast Asia, Or The Indian
Subcontinent Including, For Example,
Cambodia, China, India, Japan, Korea,
Malaysia, Pakistan, The Philippine
Islands, Thailand, And Vietnam. (Asian)
A Person Having Origins In Any Of The
Black Racial Groups Of Africa. Terms
Such As "haitian" Or "negro" Can Be
Used In Addition To "black Or African
American." (Black or African American)
A Person Having Origins In Any Of The
Original Peoples Of Hawaii, Guam,
Samoa, Or Other Pacific Islands. (Native
Hawaiian or other Pacific Islander)
Not Provided Or Available (Not
Reported)
Could Not Be Determined Or Unsure
(Unknown)
A Person Having Origins In Any Of The
Original Peoples Of Europe, The Middle
East, Or North Africa. (White)
ZIP Code
Patient Ethnicity
A Person Of Mexican, Puerto Rican,
Cuban, Central Or South American Or
Other Spanish Culture Or Origin,
Regardless Of Race. (Hispanic or Latino)
A Person Not Meeting The Definition For
Hispanic Or Latino. (Not Hispanic or
Latino)
Not Provided Or Available (Not reported)
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Could Not Be Determined Or Unsure
(Unknown)
Patient Hospital No.
Patient Social Security Number
Method of payment (check one)
Medicaid (Medicaid)
Medicaid And Medicare (Medicaid and
Medicare)
Medicare (Medicare)
Medicare And Private Insurance
(Medicare and Private Insurance)
Military Or Veterans Sponsored Nos
(Military or Veterans Sponsored, Not
Otherwise Specified (NOS))
Military Sponsored (including Champus
& Tricare) (Military Sponsored (including
CHAMPUS & TRICARE))
No Means Of Payment (no Insurance)
(No means of payment (no insurance))
Other (Other)
Private Insurance (Private Insurance)
Self Pay (no Insurance) (Self Pay (No
Insurance))
Unknown (Unknown)
Veterans Sponsored (Veterans
Sponsored)
Country of residence
Ascension Island (AC)
Andorra (AD)
United Arab Emirates (AE)
Afghanistan (AF)
Antigua And Barbuda (AG)
Anguilla (AI)
Albania (AL)
Armenia (AM)
Netherland Antilles (AN)
Angola (AO)
Antarctica (AQ)
Argentina (AR)
American Samoa (AS)
Austria (AT)
Australia (AU)
Aruba (AW)
Azerbaidjan (AZ)
Bosnia-herzegovina (BA)
Barbados (BB)
Bangladesh (BD)
Belgium (BE)
Burkina Faso (BF)
Bulgaria (BG)
Bahrain (BH)
Burundi (BI)
Benin (BJ)
Bermuda (BM)
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Brunei Darussalam (BN)
Bolivia (BO)
Brazil (BR)
Bahamas (BS)
Bhutan (BT)
Bouvet Island (BV)
Botswana (BW)
Belarus (BY)
Belize (BZ)
Canada (CA)
Cocos Isl. (CC)
Rep. Dem. Congo (CD)
Central African Rep. (CF)
Congo (CG)
Switzerland (CH)
Ivory Coast (CI)
Cook Islands (CK)
Chile (CL)
Cameroon (CM)
China (CN)
Colombia (CO)
Costa Rica (CR)
Cuba (CU)
Cape Verde (CV)
Christmas Island (CX)
Cyprus (CY)
Czech Republic (CZ)
Germany (DE)
Djibouti (DJ)
Denmark (DK)
Dominica (DM)
Dominican Republic (DO)
Algeria (DZ)
Ecuador (EC)
Estonia (EE)
Egypt (EG)
Western Sahara (EH)
Eritrea (ER)
Spain (ES)
Ethiopia (ET)
Finland (FI)
Fiji (FJ)
Falkland Isl. (FK)
Micronesia (FM)
Faroe Islands (FO)
France (FR)
France (european Ter.) (FX)
Gabon (GA)
Great Britain (GB)
Grenada (GD)
Georgia (GE)
Guiana (fr.) (GF)
Guernsey (GG)
Ghana (GH)
Gibraltar (GI)
Greenland (GL)
Gambia (GM)
Guinea (GN)
Guadeloupe (fr.) (GP)
Equatorial Guinea (GQ)
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Greece (GR)
South Georgia And South Sandwich
Islands (GS)
Guatemala (GT)
Guam (us) (GU)
Guinea Bissau (GW)
Guyana (GY)
Hong Kong (HK)
Heard & Mcdonald Isl. (HM)
Honduras (HN)
Croatia (HR)
Haiti (HT)
Hungary (HU)
Indonesia (ID)
Ireland (IE)
Israel (IL)
Isle Of Man (IM)
India (IN)
British Indian O. Ter. (IO)
Iraq (IQ)
Iran (IR)
Iceland (IS)
Italy (IT)
Jersey (JE)
Jamaica (JM)
Jordan (JO)
Japan (JP)
Kenya (KE)
Kyrgyz Republic (KG)
Cambodia (KH)
Kiribati (KI)
Comoros (KM)
St. Kitts Nevis Anguilla (KN)
Korea (north) (KP)
Korea (south) (KR)
Kuwait (KW)
Cayman Islands (KY)
Kazakstan (KZ)
Laos (LA)
Lebanon (LB)
Saint Lucia (LC)
Liechtenstein (LI)
Sri Lanka (LK)
Liberia (LR)
Lesotho (LS)
Lithuania (LT)
Luxembourg (LU)
Latvia (LV)
Libya (LY)
Morocco (MA)
Monaco (MC)
Moldova (MD)
Madagascar (MG)
Marshall Islands (MH)
Macedonia (MK)
Mali (ML)
Myanmar (MM)
Mongolia (MN)
Macau (MO)
Northern Mariana Isl. (MP)
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Martinique (fr.) (MQ)
Mauritania (MR)
Montserrat (MS)
Malta (MT)
Mauritius (MU)
Maldives (MV)
Malawi (MW)
Mexico (MX)
Malaysia (MY)
Mozambique (MZ)
Namibia (NA)
New Caledonia (fr.) (NC)
Niger (NE)
Norfolk Island (NF)
Nigeria (NG)
Nicaragua (NI)
Netherlands (NL)
Norway (NO)
Nepal (NP)
Nauru (NR)
Niue (NU)
New Zealand (NZ)
Oman (OM)
Other (Other)
Panama (PA)
Peru (PE)
Polynesia (fr.) (PF)
Papua New Guinea (PG)
Philippines (PH)
Pakistan (PK)
Poland (PL)
St. Pierre & Miquelon (PM)
Pitcairn (PN)
Puerto Rico (PR)
Portugal (PT)
Palau (PW)
Paraguay (PY)
Qatar (QA)
Reunion (fr.) (RE)
Romania (RO)
Russian Federation (RU)
Rwanda (RW)
Saudi Arabia (SA)
Solomon Islands (SB)
Seychelles (SC)
Sudan (SD)
Sweden (SE)
Singapore (SG)
St. Helena (SH)
Slovenia (SI)
Svalbard & Jan Mayen Isl. (SJ)
Slovakia (SK)
Sierra Leone (SL)
San Marino (SM)
Senegal (SN)
Somalia (SO)
Suriname (SR)
St. Tome And Principe (ST)
Soviet Union (SU)
El Salvador (SV)
6 / 7
Kidney Cancer NCT01164228 Eligibility - E1808 Registration Worksheet
(step 1) - 3084118v1.0
Syria (SY)
Swaziland (SZ)
Turks & Caicos Islands (TC)
Chad (TD)
French Southern Terr. (TF)
Togo (TG)
Thailand (TH)
Tadjikistan (TJ)
Tokelau (TK)
Turkmenistan (TM)
Tunisia (TN)
Tonga (TO)
East Timor (TP)
Turkey (TR)
Trinidad & Tobago (TT)
Tuvalu (TV)
Taiwan (TW)
Tanzania (TZ)
Ukraine (UA)
Uganda (UG)
United Kingdom (UK)
Us Minor Outlying Isl. (UM)
Usa (US)
Uruguay (UY)
Uzbekistan (UZ)
Vatican City State (VA)
St. Vincent & Grenadines (VC)
Venezuela (VE)
Virgin Islands (brit) (VG)
Virgin Islands (us) (VI)
Vietnam (VN)
Vanuatu (VU)
Wallis & Futuna Islands (WF)
Western Samoa (WS)
Yemen (YE)
Mayotte (YT)
Yugoslavia (YU)
South Africa (ZA)
Zambia (ZM)
Dem. Rep. Of Congo (ZR)
Zimbabwe (ZW)
Comments
I Have Reviewed The Above Data And
Agree The Date Are Accurate And Correct
Signature of treating physician
Date
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Leukemia NCT00843882 Eligibility - E2905
Registration Worksheet (step 1) - 2769395v1.0
E2905 Registration Worksheet (step 1)
Lenalidomide With or Without Epoetin Alfa in Treating
Patients With Myelodysplastic Syndrome and Anemia
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=532F2F3F-
8CD5-5A3D-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/8837
E2905 Registration Worksheet (step
1)
Eligibility
First initial
Last initial
Has the eligibility checklist been completed
Yes
No
In the opinion of the investigator, is the patient
eligible?
Yes
No
Has written informed consent been obtained
Yes
No
Date Informed Consent Signed
Has HIPAA authorization been obtained
Exempt - Non-usa Participant (Exempt -
non-USA participant)
No: C49487 (No)
Yes: C49488 (Yes)
HIPAA Authorization Date
Serum EPO Level (mU/ml)
Prior erythropoietic growth factor
None (None)
Erythropoietin (Prior erythropoietin/DA)
Del 5131-33 karotype
Yes
No
I agree to participate in the laboratory research
studies that are being done as part of this clinical
trial.
Yes
No
My specimens may be kept for use in research to
1 / 4
learn about, prevent, treat, or cure cancer.
Yes
No
My specimens may be kept for research about
other health problems (for example: causes of
diabetes, Alzheimer's disease, and heart
disease)
Yes
No
Someone from this institution may contact me in
the future to ask me to take part in more
research.
Yes
No
Name of local cytogenetics lab
Phone number
Patient Demographics / Pre-treatment
Characteristics
Patient's Sex
Female (F)
Male (M)
Birthdate (mm/yy)
Patient Race (check all that applyU.S. and
Canada only)
A Person Having Origins In Any Of The
Original Peoples Of North And South
America (including Central America),
And Who Maintains Tribal Affiliation Or
Community Attachment. (American
Indian or Alaska Native)
A Person Having Origins In Any Of The
Original Peoples Of The Far East,
Southeast Asia, Or The Indian
Subcontinent Including, For Example,
Cambodia, China, India, Japan, Korea,
Malaysia, Pakistan, The Philippine
Islands, Thailand, And Vietnam. (Asian)
A Person Having Origins In Any Of The
Black Racial Groups Of Africa. Terms
Such As "haitian" Or "negro" Can Be
Used In Addition To "black Or African
American." (Black or African American)
A Person Having Origins In Any Of The
Original Peoples Of Hawaii, Guam,
Samoa, Or Other Pacific Islands. (Native
Hawaiian or other Pacific Islander)
Not Provided Or Available (Not
Reported)
Could Not Be Determined Or Unsure
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(Unknown)
A Person Having Origins In Any Of The
Original Peoples Of Europe, The Middle
East, Or North Africa. (White)
ZIP Code
Patient Ethnicity
A Person Of Mexican, Puerto Rican,
Cuban, Central Or South American Or
Other Spanish Culture Or Origin,
Regardless Of Race. (Hispanic or Latino)
A Person Not Meeting The Definition For
Hispanic Or Latino. (Not Hispanic or
Latino)
Not Provided Or Available (Not reported)
Could Not Be Determined Or Unsure
(Unknown)
Patient Hospital No.
Patient Social Security Number
Method of payment (check one)
Medicaid (Medicaid)
Medicaid And Medicare (Medicaid and
Medicare)
Medicare (Medicare)
Medicare And Private Insurance
(Medicare and Private Insurance)
Military Or Veterans Sponsored Nos
(Military or Veterans Sponsored, Not
Otherwise Specified (NOS))
Military Sponsored (including Champus
& Tricare) (Military Sponsored (including
CHAMPUS & TRICARE))
National Health Service (National Health
Service)
No Means Of Payment (no Insurance)
(No means of payment (no insurance))
Other (Other)
Private Insurance (Private Insurance)
Self Pay (no Insurance) (Self Pay (No
Insurance))
Unknown (Unknown)
Veterans Sponsored (Veterans
Sponsored)
Attending Physician
Institution contact
Registrar
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Country of Residence
Comments
Signature of treating physician (I have reviewed
the above data and agree the date are accurate
and correct)
Date (Note: Date must be on or before date of
registration)
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Lung Cancer NCT01107626 Eligibility - E5508
Registration Worksheet (step 1) - 3077720v1.0
E5508 Registration Worksheet (step 1)
Bevacizumab or Pemetrexed Disodium Alone or In
Combination After Induction Therapy in Treating Patients
With Advanced Non-Squamous Non-Small Cell Lung
Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=8528E45F-
A0A0-F490-E040-BB89AD4356FC
All rights reserved. Please visit https://medical-data-
models.org/forms/8838
E5508 Registration Worksheet (step
1)
Eligibility
First initial
Last initial
Has the eligibility checklist been completed
Yes
No
In the opinion of the investigator, is the patient
eligible?
Yes
No
Has written informed consent been obtained
Yes
No
Date Informed Consent Signed
Has HIPAA authorization been obtained
Exempt - Non-usa Participant (Exempt -
non-USA participant)
No: C49487 (No)
Yes: C49488 (Yes)
HIPAA Authorization Date
Patient's simplified disease code
Bronchioloalveolar Carcinoma
(Bronchioloalveolar carcinoma)
Lung Adenocarcinoma (Lung
Adenocarcinoma)
Bronchioloalveolar Carcinoma Lung
Adenocarcinoma (Lung Adenocarcinoma
with bronchioloalveolar features)
Not Otherwise Specified Nsclc (Non-
Small Cell Lung Cancer, NOS)
I agree to participate in the laboratory research
studies that are being done as part of this clinical
trial.
Yes
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No
I agree my tissue will be submitted for research.
Yes
No
My specimens may be kept for use in research to
learn about, prevent, treat, or cure cancer.
Yes
No
My specimens may be kept for use in research
about other health problems (for example: causes
of diabetes, Alzheimer's disease, or heart
disease)
Yes
No
Someone from this institution may contact me in
the future to ask me to take part in more
research.
Yes
No
Patient Demographics / Pre-treatment
Characteristics
Patient's Sex
Female (F)
Male (M)
Birthdate
Patient's Race
A Person Having Origins In Any Of The
Original Peoples Of North And South
America (including Central America),
And Who Maintains Tribal Affiliation Or
Community Attachment. (American
Indian or Alaska Native)
A Person Having Origins In Any Of The
Original Peoples Of The Far East,
Southeast Asia, Or The Indian
Subcontinent Including, For Example,
Cambodia, China, India, Japan, Korea,
Malaysia, Pakistan, The Philippine
Islands, Thailand, And Vietnam. (Asian)
A Person Having Origins In Any Of The
Black Racial Groups Of Africa. Terms
Such As "haitian" Or "negro" Can Be
Used In Addition To "black Or African
American." (Black or African American)
A Person Having Origins In Any Of The
Original Peoples Of Hawaii, Guam,
Samoa, Or Other Pacific Islands. (Native
Hawaiian or other Pacific Islander)
Not Provided Or Available (Not
Reported)
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Could Not Be Determined Or Unsure
(Unknown)
A Person Having Origins In Any Of The
Original Peoples Of Europe, The Middle
East, Or North Africa. (White)
ZIP Code
Patient Hospital No.
Patient's simplified disease code
Bronchioloalveolar Carcinoma
(Bronchioloalveolar carcinoma)
Lung Adenocarcinoma (Lung
Adenocarcinoma)
Bronchioloalveolar Carcinoma Lung
Adenocarcinoma (Lung Adenocarcinoma
with bronchioloalveolar features)
Not Otherwise Specified Nsclc (Non-
Small Cell Lung Cancer, NOS)
Patient Social Security Number
Method of payment (check one)
Medicaid (Medicaid)
Medicaid And Medicare (Medicaid and
Medicare)
Medicare (Medicare)
Medicare And Private Insurance
(Medicare and Private Insurance)
Military Or Veterans Sponsored Nos
(Military or Veterans Sponsored, Not
Otherwise Specified (NOS))
Military Sponsored (including Champus
& Tricare) (Military Sponsored (including
CHAMPUS & TRICARE))
No Means Of Payment (no Insurance)
(No means of payment (no insurance))
Other (Other)
Private Insurance (Private Insurance)
Self Pay (no Insurance) (Self Pay (No
Insurance))
Unknown (Unknown)
Veterans Sponsored (Veterans
Sponsored)
Country of residence
Ascension Island (AC)
Andorra (AD)
United Arab Emirates (AE)
Afghanistan (AF)
Antigua And Barbuda (AG)
Anguilla (AI)
Albania (AL)
Armenia (AM)
Netherland Antilles (AN)
Angola (AO)
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Antarctica (AQ)
Argentina (AR)
American Samoa (AS)
Austria (AT)
Australia (AU)
Aruba (AW)
Azerbaidjan (AZ)
Bosnia-herzegovina (BA)
Barbados (BB)
Bangladesh (BD)
Belgium (BE)
Burkina Faso (BF)
Bulgaria (BG)
Bahrain (BH)
Burundi (BI)
Benin (BJ)
Bermuda (BM)
Brunei Darussalam (BN)
Bolivia (BO)
Brazil (BR)
Bahamas (BS)
Bhutan (BT)
Bouvet Island (BV)
Botswana (BW)
Belarus (BY)
Belize (BZ)
Canada (CA)
Cocos Isl. (CC)
Rep. Dem. Congo (CD)
Central African Rep. (CF)
Congo (CG)
Switzerland (CH)
Ivory Coast (CI)
Cook Islands (CK)
Chile (CL)
Cameroon (CM)
China (CN)
Colombia (CO)
Costa Rica (CR)
Cuba (CU)
Cape Verde (CV)
Christmas Island (CX)
Cyprus (CY)
Czech Republic (CZ)
Germany (DE)
Djibouti (DJ)
Denmark (DK)
Dominica (DM)
Dominican Republic (DO)
Algeria (DZ)
Ecuador (EC)
Estonia (EE)
Egypt (EG)
Western Sahara (EH)
Eritrea (ER)
Spain (ES)
Ethiopia (ET)
Finland (FI)
Fiji (FJ)
Falkland Isl. (FK)
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Micronesia (FM)
Faroe Islands (FO)
France (FR)
France (european Ter.) (FX)
Gabon (GA)
Great Britain (GB)
Grenada (GD)
Georgia (GE)
Guiana (fr.) (GF)
Guernsey (GG)
Ghana (GH)
Gibraltar (GI)
Greenland (GL)
Gambia (GM)
Guinea (GN)
Guadeloupe (fr.) (GP)
Equatorial Guinea (GQ)
Greece (GR)
South Georgia And South Sandwich
Islands (GS)
Guatemala (GT)
Guam (us) (GU)
Guinea Bissau (GW)
Guyana (GY)
Hong Kong (HK)
Heard & Mcdonald Isl. (HM)
Honduras (HN)
Croatia (HR)
Haiti (HT)
Hungary (HU)
Indonesia (ID)
Ireland (IE)
Israel (IL)
Isle Of Man (IM)
India (IN)
British Indian O. Ter. (IO)
Iraq (IQ)
Iran (IR)
Iceland (IS)
Italy (IT)
Jersey (JE)
Jamaica (JM)
Jordan (JO)
Japan (JP)
Kenya (KE)
Kyrgyz Republic (KG)
Cambodia (KH)
Kiribati (KI)
Comoros (KM)
St. Kitts Nevis Anguilla (KN)
Korea (north) (KP)
Korea (south) (KR)
Kuwait (KW)
Cayman Islands (KY)
Kazakstan (KZ)
Laos (LA)
Lebanon (LB)
Saint Lucia (LC)
Liechtenstein (LI)
Sri Lanka (LK)
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Liberia (LR)
Lesotho (LS)
Lithuania (LT)
Luxembourg (LU)
Latvia (LV)
Libya (LY)
Morocco (MA)
Monaco (MC)
Moldova (MD)
Madagascar (MG)
Marshall Islands (MH)
Macedonia (MK)
Mali (ML)
Myanmar (MM)
Mongolia (MN)
Macau (MO)
Northern Mariana Isl. (MP)
Martinique (fr.) (MQ)
Mauritania (MR)
Montserrat (MS)
Malta (MT)
Mauritius (MU)
Maldives (MV)
Malawi (MW)
Mexico (MX)
Malaysia (MY)
Mozambique (MZ)
Namibia (NA)
New Caledonia (fr.) (NC)
Niger (NE)
Norfolk Island (NF)
Nigeria (NG)
Nicaragua (NI)
Netherlands (NL)
Norway (NO)
Nepal (NP)
Nauru (NR)
Niue (NU)
New Zealand (NZ)
Oman (OM)
Other (Other)
Panama (PA)
Peru (PE)
Polynesia (fr.) (PF)
Papua New Guinea (PG)
Philippines (PH)
Pakistan (PK)
Poland (PL)
St. Pierre & Miquelon (PM)
Pitcairn (PN)
Puerto Rico (PR)
Portugal (PT)
Palau (PW)
Paraguay (PY)
Qatar (QA)
Reunion (fr.) (RE)
Romania (RO)
Russian Federation (RU)
Rwanda (RW)
Saudi Arabia (SA)
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Solomon Islands (SB)
Seychelles (SC)
Sudan (SD)
Sweden (SE)
Singapore (SG)
St. Helena (SH)
Slovenia (SI)
Svalbard & Jan Mayen Isl. (SJ)
Slovakia (SK)
Sierra Leone (SL)
San Marino (SM)
Senegal (SN)
Somalia (SO)
Suriname (SR)
St. Tome And Principe (ST)
Soviet Union (SU)
El Salvador (SV)
Syria (SY)
Swaziland (SZ)
Turks & Caicos Islands (TC)
Chad (TD)
French Southern Terr. (TF)
Togo (TG)
Thailand (TH)
Tadjikistan (TJ)
Tokelau (TK)
Turkmenistan (TM)
Tunisia (TN)
Tonga (TO)
East Timor (TP)
Turkey (TR)
Trinidad & Tobago (TT)
Tuvalu (TV)
Taiwan (TW)
Tanzania (TZ)
Ukraine (UA)
Uganda (UG)
United Kingdom (UK)
Us Minor Outlying Isl. (UM)
Usa (US)
Uruguay (UY)
Uzbekistan (UZ)
Vatican City State (VA)
St. Vincent & Grenadines (VC)
Venezuela (VE)
Virgin Islands (brit) (VG)
Virgin Islands (us) (VI)
Vietnam (VN)
Vanuatu (VU)
Wallis & Futuna Islands (WF)
Western Samoa (WS)
Yemen (YE)
Mayotte (YT)
Yugoslavia (YU)
South Africa (ZA)
Zambia (ZM)
Dem. Rep. Of Congo (ZR)
Zimbabwe (ZW)
Comments
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I Have Reviewed The Above Data And
Agree The Date Are Accurate And Correct
Signature of treating physician
Date
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Treatment - 2400 - Pre-Transplant Essential
Data (TED) - 2492857v5.0
Pre-Transplant Essential Data (TED)
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=609D5967-
37B1-F25E-E040-BB89AD437F88
All rights reserved. Please visit https://medical-data-
models.org/forms/8839
2400 - Pre-Transplant Essential Data
(TED)
Cibmtr Use Only
Sequence number:
Date received:
Center Identification
CIBMTR Center Number:
EBMT Code (CIC) Number
Hospital:
Unit:
Adult Patient Department (Adult)
Hematology Patient Department
(Hematology)
Oncology Patient Department
(Oncology)
Other Department (Other unit)
Pediatric Patient Department (Pediatric)
Specify the other unit name:
Contact person:
Telephone number:
Fax number:
EMail Address
Today's date:
Recipient Identification
Universal Recipient ID:
1 / 51
What organization assigned the universal
recipient ID?
Center For International Blood And
Marrow Transplant Research (cibmtr)
(CIBMTR)
European Group For Blood And Marrow
Transplantation (ebmt) (EBMT)
Other (Other)
Specify the organization that assigned the
universal recipient ID:
Study Id Number
What was the study ID number?
Recipient Identification
Was the study affiliated with BMT-CTN?
Yes (Yes)
Was the study affiliated with NMDP?
Yes (Yes)
Was the study affiliated with RCI-BMT?
Yes (Yes)
Was the study affiliated with SCTOD?
Yes (Yes)
Consented for research?
Yes
No
Consented for CIBMTR related specimen
repository?
Yes
No
Gender
Female Gender (Female Gender)
Male Gender (Male Gender)
Patient's Date of Birth
Ethnicity (Optional for non-US centers)
A Person Of Mexican, Puerto Rican,
Cuban, Central Or South American Or
Other Spanish Culture Or Origin,
Regardless Of Race. (Hispanic or Latino)
A Person Not Meeting The Definition For
Hispanic Or Latino. (Not Hispanic or
Latino)
Recipient Race
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Race
A Person Having Origins In Any Of The
Original Peoples Of North And South
America (including Central America),
And Who Maintains Tribal Affiliation Or
Community Attachment. (American
Indian or Alaska Native)
A Person Having Origins In Any Of The
Original Peoples Of The Far East,
Southeast Asia, Or The Indian
Subcontinent Including, For Example,
Cambodia, China, India, Japan, Korea,
Malaysia, Pakistan, The Philippine
Islands, Thailand, And Vietnam. (Asian)
A Person Having Origins In Any Of The
Black Racial Groups Of Africa. Terms
Such As "haitian" Or "negro" Can Be
Used In Addition To "black Or African
American." (Black or African American)
A Person Having Origins In Any Of The
Original Peoples Of Hawaii, Guam,
Samoa, Or Other Pacific Islands. (Native
Hawaiian or other Pacific Islander)
A Person Having Origins In Any Of The
Original Peoples Of Europe, The Middle
East, Or North Africa. (White)
Disease Classification
What was the date of diagnosis of the primary
disease for which the hematopoietic stem cell
transplantation was performed?
Hematopoietic Stem Cell Transplant (hsct)
Date of hematopoietic stem cell transplantation
(HSCT) for which this form is being completed:
What is the chronological number of the current
hematopoietic stem cell transplantation?
Date of the most recent previous HSCT:
If there has been more than one hematopoietic
stem cell transplantation, what was the type of
the most recent previous hematopoietic stem cell
transplantation?
Allogeneic Hematopoietic Stem Cell
Transplantation (Allogeneic)
Autologous Stem Cell Transplantation
(Autologous)
If the institution where previous HSCT was
performed is different from the current HSCT,
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what is the name of the institution?
If the institution where previous HSCT was
performed is different from the current HSCT,
what is the city where the institution is located?
If the institution where previous HSCT was
performed is different from the current HSCT,
what is the state where the institution is located?
If the institution where previous HSCT was
performed is different from the current HSCT,
what is the country where the institution is
located?
Product Type
What type of hematopoietic stem cell transplant
was used?
Umbilical Cord Blood (Cord blood)
Bone Marrow (Marrow)
Other (Other)
Peripheral Blood Stem Cell (PBSC)
Was a particular hematopoietic stem cell
transplant type used?
Yes
No
Specify the other hematopoietic stem cell
transplant type: (Answer only if the value for
2730912 is "Other")
Hematopoietic Stem Cell Transplant (hsct)
For allogeneic HSCT, was the donor gender
male?
Yes
No
For allogeneic HSCT, was the donor gender
female?
Yes
No
Autologous HSCT?
Yes
No
Did the hematopoietic stem cell transplant consist
of multiple donors?
Yes
No
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Donor Information
What type of donor was used for this
hematopoietic stem cell transplant?
Mhc Class I Protein Mhc Class Ii Protein
Identical Sibling (HLA-identical sibling)
Mhc Class I Protein Mhc Class Ii Protein
Other Relative (HLA-matched other
relative)
Mhc Class I Protein Mhc Class Ii Protein
Mismatch Relative (HLA-mismatched
relative)
Syngeneic (Syngeneic)
Donor Unrelated (Unrelated donor)
For an HLA-mismatched related donor, what was
the degree of mismatch:
Integer::1 Mhc Class I Protein Antigen
Mismatch (1 HLA antigen mismatch)
Greater Than Integer::2 Mhc Class I
Protein Antigen Mismatch (greater than
or equal to 2 HLA antigen mismatch (full
haploidentical))
At what registry or cord blood bank was the
unrelated donor registered?
(a) Austrian Bone Marrow Donors (A)
(acb) Austrian Cord Blood Registry
(ACB)
(accb) Stemcyte, Inc. (ACCB)
(ae) Emirates Bone Marrow Donor
Registry (AE)
(am) Armenian Bone Marrow Donor
Registry Charitable Trust (AM)
(aocb) University Of Colorado Cord
Blood Bank (AOCB)
(ar) Argentine Cph Donors Registry (AR)
(arcb) Bancel - Argentina Cord Blood
Bank (ARCB)
(aucb) Australian Cord Blood Registry
(AUCB)
(aus) Australia / New Zealand Bone
Marrow Donor Registry (AUS)
(b) Marrow Donor Program Belgium (B)
(bcb) Belgium Cord Blood Registry
(BCB)
(bg) Bulgarian Bone Marrow Donor
Registry (BG)
(br) Inca/redomo (BR)
(bscb) British Bone Marrow Registry -
Cord Blood (BSCB)
(ch) Swiss Bloodstem Cells - Adult
Donors (CH)
(chcb) Swiss Blood Stem Cells - Cord
Blood (CHCB)
(ckcb) Celgene Cord Blood Bank
(CKCB)
(cn) China Marrow Donor Program
(cmdp) (CN)
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(cncb) Shan Dong Cord Blood Bank
(CNCB)
(cnd) Canadian Blood Services Bone
Marrow Donor Registry (CND)
(cs2) Czech National Marrow Donor
Registry (CS2)
(cscr) Czech Stem Cells Registry
(CSCR)
(cy) Cyprus Paraskevaidio Bone Marrow
Donor Registry (CY)
(cy2) The Cyprus Bone Marrow Donor
Registry (CY2)
(d) Zkrd - Zentrales
Knochenmarkspender - Register
Deutschland Adult Donors (D)
(dcb) Zkrd - Zentrales
Knochenmarkspender - Register
Deutschland Cord Blood (DCB)
(dk) The Danish Bone Marrow Donor
Registry (DK)
(dk2) Bone Marrow Donors Copenhagen
(bmdc) (DK2)
(ducb) German Branch Of The European
Cord Blood Bank (DUCB)
(e) Redmo (E)
(ecb) Spanish Cord Blood Registry
(ECB)
(f) France Greffe De Moelle - Adult
Donors (F)
(fcb) France Greffe De Moelle - Cord
Blood (FCB)
(fi) Finnish Bone Marrow Donor Registry
(FI)
(ficb) Finnish Cord Blood Registry (FICB)
(gb) The Anthony Nolan Trust (GB)
(gb3) Welsh Bone Marrow Donor
Registry (GB3)
(gb4) British Bone Marrow Registry
(GB4)
(gr) Unrelated Hematopoietic Stem Cell
Donor Registry Greece (GR)
(grcb) Michigan Community Blood
Centers Cord Blood Bank (GRCB)
(h) Hungarian Bone Marrow Donor
Registry (H)
(hk) Hong Kong Bone Marrow Donor
Registry (HK)
(hr) Croatian Bone Marrow Donor
Registry (HR)
(i) Italian Bone Marrow Donor Registry (I)
(i3cb) Sheba Medical Centre Cord Blood
Registry (I3CB)
(icb) Italian Cord Blood Bank Network
(ICB)
(il) Hadassah Bmdr (IL)
(il2) Ezer Mizion Bone Marrow Donor
Registry (IL2)
(il3) Sheba Medical Center Donor
Registry (IL3)
(ilcb) Isreal Cord Blood Bank (ILCB)
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(in) Asian Indian Donor Marrow Registry
(IN)
(in2) Dept. Of Transfusion Medicine (IN2)
International-unable To Answer
(INTL_UA)
(irl) The Irish Unrelated Bone Marrow
Panel (IRL)
(jp) Japan Marrow Donor Program (JP)
(kr) Korea Marrow Donor Program (KR)
(lt) Lithuanian National Bone Marrow
Donor Registry (LT)
(lvcb) Leuven Cord Blood Bank (LVCB)
(macb) Victoria Angel Registry Of Hope
(MACB)
(mx) Mexican Bone Marrow Donor
Registry (MX)
(n) The Norwegian Bone Marrow Donor
Registry (N)
(nl) Europdonor Foundation- Adult
Donors (NL)
(nlcb) Europdonor Foundation - Cord
Blood (NLCB)
(nycb) National Cord Blood Program,
New York Blood Center (NYCB)
(p) Portuguese Bone Marrow Donors
Registry (P)
(pl) National Polish Bone Marrow
Registry (PL)
(pl2) Unrelated Bone Marrow Donor
Registry -adult Donors (PL2)
(pl3) Against Leukemia Foundation
Marrow Donor Registry (PL3)
(pl4) Ursula Jaworska Foundation - Bone
Marrow Donor Registry (PL4)
(pl5) Polish Central Bone Marrow Donor
Registry - Adult Donors (PL5)
(pmcb) Elie Katz Umbilical Cord Blood
Program (PMCB)
(r) Russian Bone Marrow Donor Registry
(R)
(r2) Karelian Registry Of Unrelated
Donors Of Hematopoietic Stem Cells
(R2)
(s) Tobias Registry Of Swedish Bone
Marrow Donors (S)
(sg) Singapore Bone Marrow Donor
Programme (bmdp) (SG)
(sk) Slovak National Bone Marrow Donor
Registry (SK)
(skcb) Eurocord Slovakia / Slovak
Pacental Stem Cell Registry (SKCB)
(slo) Slovenia Donor (SLO)
(sm) San Marino Bone Marrow Donor
Registry (SM)
(t1cb) Tran - Cord Blood (T1CB)
(tacb) Stemcyte, Inc. Taiwan (TACB)
(tecb) Healthbanks Biotech, Co., Ltd
(TECB)
(th) Thai Stem Cell Donor Registry
(tscdr) (TH)
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(tocb) Tokyo Cord Blood Bank (TOCB)
(tpcb) Bionet / Babybanks (TPCB)
(tran) Tran - Adult Donors (TRAN)
(tris) Bone Marrow Bank Of Istanbul
Medical Faculty (TRIS)
(tw) Buddhist Tzu Chi Stem Cells Center
- Adult Donors (TW)
(twcb) Buddhist Tzu Chi Stem Cells
Center - Cord Blood (TWCB)
(u1cb) National Marrow Donor Program -
Cord Blood (U1CB)
(u3cb) Caitlin Raymond International
Registry - Cord Blood (U3CB)
(u4cb) Gift Of Life Bone Marrow
Foundation - Cord Blood (U4CB)
(usa1) National Marrow Donor Program -
Adult Donors (USA1)
(usa2) America Bone Marrow Donor
Registry (USA2)
(usa3) Caitlin Raymond International
Registry -adult Donors (USA3)
(usa4) Gift Of Life Bone Marrow
Foundation - Adult Donors (USA4)
(uy) Sindome (UY)
(w3cb) Polish Central Bone Marrow
Donor Registry - Cord Blood (W3CB)
(wacb) Unrelated Bone Marrow Donor
Registry - Cord Blood (WACB)
(za) South African Bone Marrow Registry
(ZA)
Specify the other registry or cord blood bank that
the unrelated donor was registered at:
How many mismatches were there for the HLA -
A antigenic test? (2 digits)
Match (0)
Integer::1 Mismatch (1)
Integer::2 Mismatch (2)
Without Evaluation (ND)
How many mismatches were there for the HLA -
B antigenic test? (2 digits)
Match (0)
Integer::1 Mismatch (1)
Integer::2 Mismatch (2)
Without Evaluation (ND)
How many mismatches were there for the HLA -
C antigenic test? (2 digits)
Match (0)
Integer::1 Mismatch (1)
Integer::2 Mismatch (2)
Without Evaluation (ND)
How many mismatches were there for the HLA -
DRB1 antigenic test? (2 digits)
Match (0)
Integer::1 Mismatch (1)
Integer::2 Mismatch (2)
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Without Evaluation (ND)
How many mismatches were there for the HLA -
DQB1 antigenic test? (2 digits)
Match (0)
Integer::1 Mismatch (1)
Integer::2 Mismatch (2)
Without Evaluation (ND)
How many mismatches were there for the HLA -
DPB1 antigenic test? (2 digits)
Match (0)
Integer::1 Mismatch (1)
Integer::2 Mismatch (2)
Without Evaluation (ND)
How many mismatches were there for the HLA -
A allelic test? (4 digits)
Match (0)
Integer::1 Mismatch (1)
Integer::2 Mismatch (2)
Without Evaluation (ND)
How many mismatches were there for the HLA -
B allelic test? (4 digits)
Match (0)
Integer::1 Mismatch (1)
Integer::2 Mismatch (2)
Without Evaluation (ND)
How many mismatches were there for the HLA -
C allelic test? (4 digits)
Match (0)
Integer::1 Mismatch (1)
Integer::2 Mismatch (2)
Without Evaluation (ND)
How many mismatches were there for the HLA -
DRB1 allelic test? (4 digits)
Match (0)
Integer::1 Mismatch (1)
Integer::2 Mismatch (2)
Without Evaluation (ND)
How many mismatches were there for the HLA -
DQB1 allelic test? (4 digits)
Match (0)
Integer::1 Mismatch (1)
Integer::2 Mismatch (2)
Without Evaluation (ND)
How many mismatches were there for the HLA -
DPB1 allelic test? (4 digits)
Match (0)
Integer::1 Mismatch (1)
Integer::2 Mismatch (2)
Without Evaluation (ND)
Hematopoietic Stem Cell Transplant (hsct)
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Was there ex vivo graft manipulation other than
for RBC removal or volume reduction?
Yes
No
Ex Vivo Graft Manipulation Type
What was the method of ex vivo graft
manipulation other than for RBC removal or
volume reduction? (Optional for non-U.S.
Centers)
Cd34 Selection (CD34 selection)
Ex Vivo Increase (Ex vivo expansion)
Other Ex Vivo Manipulation (Other)
Other Negative Selection (Other negative
selection)
T-cell Depletion (T-cell depletion)
Tumor Purging (Tumor purging)
Was a particular method of ex vivo graft
manipulation other than for RBC removal or
volume reduction performed?
Yes
No
Specify the ex vivo graft manipulation other than
for RBC removal or volume reduction: (Answer
this CDE only if the answer to CDE 2750679 is
"Other negative selection" or "other.")
Hematopoietic Stem Cell Transplant (hsct)
Which scale was used to measure/report the
functional status? (Prior to the start of the
preparative regimen)
Karnofsky Performance Status
(Karnofsky)
Lansky Play-performance Status
(Lansky)
Performance Status (Karnofsky) (Prior to the start
of the preparative regimen)
Moribund, Fatal Processes Progressing
Rapidly (10)
Normal, No Complaints, No Evidence Of
Disease (100)
Very Sick, Hospitalization Indicated.
Death Not Imminent (20)
Severely Disabled, Hospitalization
Indicated. Death Not Imminent (30)
Disabled, Requires Special Care And
Assistance (40)
Requires Considerable Assistance And
Frequent Medical Care (50)
Requires Occasional Assistance, But Is
Able To Care For Most Of His/her Needs
(60)
Cares For Self, Unable To Carry On
Normal Activity Or To Do Active Work
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(70)
Normal Activity With Effort; Some Signs
Or Symptoms Of Disease (80)
Able To Carry On Normal Activity; Minor
Signs Or Symptoms Of Disease (90)
Performance Status (Lansky) (Prior to the start of
the preparative regimen)
No Play; Does Not Get Out Of Bed. (10)
Fully Active, Normal (100)
Often Sleeping; Play Entirely Limited To
Very Passive Activities. (20)
In Bed; Needs Assistance Even For
Quiet Play. (30)
Mostly In Bed; Participates In Quiet
Activities. (40)
Gets Dressed, But Lies Around Much Of
The Day; No Active Play, Able To
Participate In All Quiet Play And
Activities. (50)
Up And Around, But Minimal Active Play;
Keeps Busy With Quieter Activities. (60)
Both Greater Restriction Of And Less
Time Spent In Play Activity (70)
Active, But Tires More Quickly (80)
Minor Restrictions In Physically
Strenuous Activity (90)
What was the recipient's test results for the
presence of CMV-antibodies? (IgG or Total )
Not Reaction (Non-reactive)
Not Done: C49484 (Not Done)
Reaction (Reactive)
Unknown (Unknown)
What was the donor test results for the presence
of CMV-antibodies? (allo onlyMultiple donors:
report any positive CMV test as reactive)
Not Reaction (Non-reactive)
Not Done: C49484 (Not Done)
Reaction (Reactive)
Unknown (Unknown)
Preparative Regimen
Was a preparatve regimen given?
Yes
No
Was total body irradiation given as a preparative
regimen? (TBI)
Yes
No
What was the total prescribed cumulative dose of
total body irradiation for the preparative regimen
(per the protocol)? (TBI)
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What was the unit of measure for the total
prescribed cumulative dose of total body
irradiation for the preparative regimen (per the
protocol)? (TBI)
Centigray (cGy)
Gray (Gy)
Was total nodal or total abdominal irradiation
given as a preparative regimen? (TLI, TNI, TAI)
Yes
No
What was the total prescribed cumulative dose of
total nodal or total abdominal irradiation for the
preparative regimen (per the protocol)? (TLI, TNI,
TAI)
What was the unit of measure for the total
prescribed cumulative dose of total nodal or total
abdominal irradiation for the preparative regimen
(per the protocol)? (TLI, TNI, TAI)
Centigray (cGy)
Gray (Gy)
Preparative Regimen - General
Medication
What was the type of preparative regimen
medication?
Antithymocyte Globulin Antilymphocyte
Serum (ALG, ALS, ATG, ATS (before
d0))
Anthracycline Antibiotic (Anthracycline)
Bleomycin (Bleomycin)
Busulfan (Busulfan)
Carboplatin (Carboplatin)
Carmustine (Carmustine (BCNU))
Cisplatin Medication (Cisplatin)
Corticosteroid Medication
(Corticosteriods)
Cyclophosphamide Medication
(Cyclophosphamide)
Cytosine Arabinoside (Cytarabine (Ara-
C))
Etoposide (Etoposide (VP-16))
Fludarabine (Fludarabine)
Ifosfamide (Ifosfamide)
Imatinib Mesylate (Imanitib mesylate
(Gleevec, Glivec))
Lomustine (Lomustine (CCNU))
Melphalan (Melphalan (L-PAM))
Mitoxantrone (Mitoxantrone)
Monoclonal Antibody (Monoclonal
Antibody)
Other (Other)
Paclitaxel (Paclitaxel (Taxol, Xyotax))
Radiolabeled Monoclonal Antibody
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(Radiolabeled MAb)
Teniposide (Teniposide (VM26))
Thiotepa (Thiotepa)
Was a particular preparative regimen medication
administered per the protocol?
Yes
No
What was the dose of the planned preparative
regimen per the protocol? (Do not answer if the
answer to CDE 2739625 is
"Anthracycline","Monoclonal Antibody",
"Radiolabled MAb".)
What was the unit of measure for the preparative
regimen dose per the protocol? (Do not answer if
the answer to CDE 2739625 is
"Anthracycline","Monoclonal Antibody" or
"Radiolabled MAb".)
Milligram Per Kilogram (mg/kg)
Milligram Per Meter Squared (mg/m2)
Specify the source of the preparative regimen
medication: (Answer this CDE only if the answer
to CDE 2739625 is ALG, ALS, ATG, ATS before
d0)
Horse (Horse)
Other Source (Other source)
Rabbit (Rabbit)
Specify the other source of the preparative
regimen medication: (Answer this CDE only if the
answer to CDE 2753241 is OTHER.)
What was the route of administration for the
planned preparative regimen medication?
(Answer this CDE only if the value to CDE
2739625 is "Busulfan.")
Oral Route Of Administration Intravenous
Route Of Administration (Both)
Intravenous Route Of Administration (IV)
Oral Route Of Administration (Oral)
Specify the other type of preparative regimen
medication: (Answer this CDE only if the answer
to CDE 2739625 is "Other.")
Preparative Regimen - Anthracyclines
What was the type of anthracycline preparative
regimen?
Daunorubicin (Daunorubicin)
Doxorubicin (Doxorubicin)
Idarubicin (Idarubicin)
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Was an anthracycline planned as a preparative
regimen?
Yes
No
What was the planned dosage of the
anthracycline preparative regimen?
What was the unit of measure for the planned
dosage of the anthracycline preparative regimen?
Milligram Per Kilogram (mg/kg)
Milligram Per Meter Squared (mg/m2)
Preparative Regimen - Monoclonal
Antibodies (mab)
What was the type of preparative regimen
monoclonal antibody (MAb)?
Alemtuzumab (Campath)
Gemtuzumab Ozogamicin (Gemtuzumab
(mylotarg, anti-CD33))
Other Monoclonal Antibody (Other MAb)
Rituximab (Rituximab (Rituxan, anti-
CD20))
Was a monoclonal antibody planned as a
preparative regimen?
Yes
No
What was the planned dosage of the monoclonal
antibody preparative regimen?
What was the unit of measure for the planned
dosage of the monoclonal antibody preparative
regimen?
Milligram Per Kilogram (mg/kg)
Milligram Per Meter Squared (mg/m2)
Specify the other type of the monoclonal antibody
preparative regimen: (Answer only if the answer
to CDE 2741209 is "Other MAb.")
Preparative Regimen - Radiolabeled Mab
What type of radiolabeled monoclonal antibody
was used as a   preparative regimen?
Ibritumomab Tiuxetan (Ibritumomab
(Zevalin))
Other Radiolabeled Monoclonal Antibody
(Other rMAb)
Tositumomab (Tositumomab (Bexxar))
Was a radiolabeled monoclonal antibody planned
as a preparative regimen?
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Yes
No
What was the planned dosage of the radiolabeled
monoclonal antibody preparative regimen?
What was the unit of measure for the planned
dosage of the radiolabeled monoclonal antibody
preparative regimen?
Millibecquerel (mBq)
Millicurie (mCi)
Specify the other type of the radiolabeled
monoclonal antibody preparative regimen:
(Answer only if the answer to CDE 2741552 is
"Other rMAb.")
Intent Of Preparative Regimen
Is the INTENT of the preparative regimen
MYELOABLATIVE (allogeneic only)?
Yes
No
Reason For Nst / Ric
What was the reason for the reduced intensity/
non-myeloablative preparative regimen?
Recipient Age (Age of recipient)
Comorbidity (Comorbid conditions)
Other (Other)
Prior Hematopoietic Stem Cell
Transplantation (Prior HSCT)
Protocol (Protocol-driven)
Did a particular reason for the non-myeloablative
/ reduced intensity preparative regimen occur?
Yes
No
Specify the other reason for the non-
myeloablative / reduced intensity (NST / RIC)
preparative regimen: (Answer only if the answer
to CDE 2737040 is "Other.")
Comorbid Conditions
Is there a history of mechanical ventilation?
Yes
No
Is there a history of proven invasive fungal
infection?
Yes
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No
Was there any involvement of clinically significant
co-existing diseases or organ impairment at any
time prior to preparative regimen?
Yes
No
Type Of Comorbid Condition
What was the clinically significant co-existing
disease or organ impairment?
Arrhythmia. (Arrhythmia)
Cardiac. (Cardiac)
Cerebrovascular Disease.
(Cerebrovascular disease)
Diabetes. (Diabetes)
Heart Valve Disease. (Heart valve
disease)
Hepatic, Mild. (Hepatic, mild)
Hepatic, Moderate / Severe. (Hepatic,
moderate / severe)
Infection. (Infection)
Inflammatory Bowel Disease.
(Inflammatory bowel disease)
Obesity. (Obesity)
Other (Other)
Peptic Ulcer. (Peptic ulcer)
Psychiatric Disturbance (Psychiatric
disturbance)
Pulmonary, Moderate. (Pulmonary,
moderate)
Pulmonary, Severe. (Pulmonary, severe)
Renal, Moderate / Severe. (Renal,
moderate / severe)
Rheumatologic (2) (Rheumatologic)
Solid Tumor, Prior. (Solid tumor, prior)
Was a particular clinically significant comorbidity
present before the start of the preparative
regimen?
No: C49487 (No)
Not Done: C49484 (Not Done)
Yes: C49488 (Yes)
Specify the other type of clinically significant
comorbidity: (Answer only if the answer to CDE
2737130 is "Other.")
Gvhd Prophylaxis (allo Only)
Was GVHD prophylaxis planned / given?
Yes
No
Was ALG, ALS, ATG, ATS (after d0) therapy used
after the start of the preparative regimen to
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prevent acute GVHD or graft rejection?
Yes
No
Was corticosteroid (systemic) therapy used after
the start of the preparative regimen to prevent
acute GVHD or graft rejection?
Yes
No
Was cyclosporine (CSA) (Sandimmune, Neoral)
therapy used after the start of the preparative
regimen to prevent acute GVHD or graft
rejection?
Yes
No
Was ECP (extra-corporeal photopheresis)
therapy used after the start of the preparative
regimen to prevent acute GVHD or graft
rejection?
Yes
No
Was FK 506 (Tacrolimus, Prograf) therapy used
after the start of the preparative regimen to
prevent acute GVHD or graft rejection?
Yes
No
Was methotrexate (MTX) (Amethopterin) used
after the start of the preparative regimen to
prevent acute GVHD or graft rejection?
Yes
No
Was an in vivo monoclonal antibody used after
the start of the preparative regimen to prevent
acute GVHD or graft rejection?
Yes
No
Was anti CD 25 (Zenapax, Daclizumab, AntiTAC)
the in vivo monoclonal antibody used after the
start of the preparative regimen to prevent acute
GVHD or graft rejection?
Yes
No
Was campath the in vivo monoclonal antibody
used after the start of the preparative regimen to
prevent acute GVHD or graft rejection?
Yes
No
Was etanercept (Enbrel) the in vivo monoclonal
antibody used after the start of the preparative
regimen to prevent acute GVHD or graft
rejection?
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Yes
No
Was infliximab (Remicade) the in vivo monoclonal
antibody used after the start of the preparative
regimen to prevent acute GVHD or graft
rejection?
Yes
No
Was some other in vivo monoclonal antibody
used after the start of the preparative regimen to
prevent acute GVHD or graft rejection?
Yes
No
Specify the other in vivo monoclonal antibody
used after the start of the preparative regimen to
prevent acute GVHD or graft rejection
Was mycophenolate mofetil (MMF) (CellCept)
used after the start of the preparative regimen to
prevent acute GVHD or graft rejection?
Yes
No
Was sirolimus (Rapamycin, Rapamune) used
after the start of the preparative regimen to
prevent acute GVHD or graft rejection?
Yes
No
Was some other agent used after the start of the
preparative regimen to prevent acute GVHD or
graft rejection?
Yes
No
Specify the other agent used after the start of the
preparative regimen to prevent acute GVHD or
graft rejection
Post-hsct Disease Therapy Planned As Of
Day 0
Is this HSCT part of a planned multiple
(sequential) graft / HSCT protocol?
Yes
No
Is additional post-HSCT therapy planned?
Yes
No
Type Of Additional Post-hsct Therapy
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What was the type of post-hematopoietic stem
cell transplantation (HSCT) therapy?
Bortezomib (Bortezomib (Velcade))
Cellular Therapy (Cellular therapy (e.g.
DCI, DLI))
Imatinib Mesylate (Imanitib mesylate
(Gleevec, Glivec))
Intrathecal Chemotherapy (Intrathecal
chemotherapy)
Lenalidomide (Lenalidomide (Revlimid))
Local Radiation Therapy (Local
radiotherapy)
Other (Other)
Rituximab (Rituximab (Rituxan,
Mabthera))
Thalidomide (Thalidomide (Thalomid))
Was a particular post-hematopoietic stem cell
transplantation (HSCT) therapy planned?
Yes
No
Specify the other planned post-HSCT therapy:
(Answer this CDE only if the answer to CDE
2738487 is "Other.")
Other Toxicity Modifying Regimen
Was KGF (palifermin, Kepivance) started or is
there a plan to use it?
Blinded Clinical Study (Masked trial)
No: C49487 (No)
Yes (Yes)
As part of a toxicity modifying regimen, was FGF
(velafermin) started or is there a plan to use it?
Blinded Clinical Study (Masked trial)
No: C49487 (No)
Yes (Yes)
Pre-transplant Essential Data Disease
Classification Sheet
What was the primary disease for which the
HSCT was performed?
All (Acute lymphoblastic leukemia (ALL))
Acute Myeloid Leukemia (Acute
myelogenous leukemia (AML or ANLL))
Anemia Hemoglobinopathy (Anemia /
hemoglobinopathy)
Autoimmune Disease (Autoimmune
Disorder)
Breast Carcinoma (Breast Cancer)
Chronic Myelogenous Leukemia
(Chronic myelogenous leukemia (CML))
Histiocytic Disorders (Histiocytic
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disorders)
Hodgkin's Lymphoma (Hodgkin
lymphoma)
Immunodeficiency Syndrome (Immune
deficiencies)
Congenital Metabolic Disorder
Osteopetrosis (Inherited disorders of
metabolism / osteopetrosis)
Plasma Cell Myeloma (Multiple myeloma
/ plasma cell disorder (PCD))
Myelodysplastic/myeloproliferative
Disease (Myelodysplastic (MDS) /
myeloproliferative (MPS) disorders)
Non-hodgkin's Lymphoma (Non-Hodgkin
lymphoma)
Other Acute Leukemia (Other acute
leukemia)
Other Diseases And Disorders (Other
disease)
Other Leukemia (Other leukemias)
Other Malignant Neoplasm (Other
malignancies)
Platelet Diseases And Disorders
(Platelet disorder)
Acute Leukemias
What was the W.H.O classification of the acute
myelogenous leukemia (AML) or acute
nonlymphocytic leukemia (ANLL)?
Acute Basophilic Leukemia (Acute
Basophilic Leukemia)
Acute Erythroid Leukemia (Acute
Erythroid Leukemia (erythroid / myeloid
and pure erythroleukemia) / {M6})
Acute Megakaryoblastic Leukemia
(Acute Megakaryoblastic Leukemia  /
{M7})
Acute Monoblastic Leukemia And Acute
Monocytic Leukemia (Acute Monoblastic
Leukemia / Acute Monocytic Leukemia /
{M5})
Not Otherwise Specified Acute Myeloid
Leukemia (Acute Myeloid Leukemia Not
Otherwise Specified)
Acute Myeloid Leukemia With Maturation
(Acute Myeloid Leukemia with Maturation
/ {M2})
Acute Myeloid Leukemia Without
Maturation (Acute Myeloid Leukemia
without Maturation / {M1})
Acute Myeloid Leukemia, Minimally
Differentiated (Acute Myeloid Leukemia,
Minimally Differentiated / {M0})
Acute Myelomonocytic Leukemia (Acute
Myelomonocytic Leukemia / {M4})
Acute Panmyelosis With Myelofibrosis
(Acute Panmyelosis with Myelofibrosis)
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Acute Myeloid Leukemia With 11q23
(mll) Abnormalities (AML with 11q23
(MLL) abnormalities)
Acute Myeloid Leukemia With Abnormal
Marrow Eosinophils (AML with abnormal
bone marrow eosinophils and
inv(16)(p13;q22) or t(16;16) (p13;q22),
(CBF beta/MYH11))
Acute Myeloid Leukemia With
Multilineage Dysplasia (AML with multi-
lineage dysplasia)
Acute Myeloid Leukemia With
T(8;21)(q22;q22)(aml1(cbfa)/eto) (AML
with t(8;21) (q22;q22) (AML1 / ETO))
Acute Promyelocytic Leukemia With
T(15;17)(q22;q12)(pml/rara) (APL with
t(15;17)(q22;q12),(PML/RAR alpha) and
variant /  {M3})
Myeloid Sarcoma (Myeloid Sarcoma)
Did AML transform from MDS / MPS? (Complete
entire MDS Section on Disease Classification on
page 10-11 - of PDF copy, questions 218-261
and entire AML Section page 7-8 of PDF copy,
questions 174-185, 2682630, 2494567, 2648560,
2675109, 2685090, 2674686, 2676456, 2676461,
2676467.)
Yes
No
Was AML therapy-related?
No (No)
Unknown (Unknown)
Yes (Yes)
Type Of Therapy Related Aml
What was the cause of the therapy related AML?
Alkylating Agent Radiation Therapy
Related (Alkylating agent / radiation-
related)
Topoisomerase-ii Inhibitor Related
(Topoisomerase II inhibitor-related)
Unknown (Unknown)
Did a particular cause of therapy-related AML
occur?
Yes
No
Acute Leukemias
Was imatinib mesylate given as pretransplant
therapy for the acute myeloid leukemia anytime
prior to start of preparative regimen?
No (No)
Unknown (Unknown)
Yes (Yes)
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What was the status of the acute myelogenous
leukemia (AML) or acute nonlymphocytic
leukemia (ANLL) at the time of transplantation?
Complete Remission (Complete
Remission)
Never Therapeutic Procedure (Never
treated)
Primary Induction Failure (Primary
Induction Failure (PIF))
Recurrent Disease (Relapse)
For patients with hematologic CR, was a
cytogenetic CR also achieved at the time of
transplantation?
No (No)
Unknown (Unknown)
Yes (Yes)
For patients with hematologic CR, was a
molecular CR also achieved at the time of
transplantation?
No (No)
Unknown (Unknown)
Yes (Yes)
At the time of transplantation, what was the
number of the complete remission of acute
myeloid leukemia?
First (First)
Second:c25666 (Second)
Greater Third (Third or higher)
At the time of transplantation, what was the
number of the relapse of acute myeloid
leukemia?
First (First)
Second:c25666 (Second)
Greater Third (Third or higher)
Acute Lymphoblastic Leukemia (all)
Specify the type of acute lymphoblastic leukemia
(ALL):
Not Otherwise Specified All (ALL, NOS)
Precursor B-lymphoblastic Leukemia
(Precursor B-cell ALL (L1/L2))
Precursor T-lymphoblastic Leukemia
(Precursor T-Cell ALL)
T(1;19)(q23;p13.3) (t(1;19)(q23;p13)
E2A/PBX1)
T(21;22)(q22;q12) (t(12;21)(p12;q22)
ETV / CBF-alpha)
T(9;22)(q34;q11) (t(9;22)(q34;q11);
BCR/ABL+)
T(v;11)(v;q23) (t(v;11q23); MLL
rearranged)
Was imatinib mesylate given as pretransplant
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therapy for acute lymphoblastic leukemia (ALL)
anytime prior to start of preparative regimen?
No (No)
Unknown (Unknown)
Yes (Yes)
What was the status of the acute lymphoblastic
leukemia (ALL) at the time of transplantation?
Complete Remission (Complete
Remission)
Never Therapeutic Procedure (Never
treated)
Primary Induction Failure (Primary
Induction Failure (PIF))
Recurrent Disease (Relapse)
At the time of transplantation, was the type of
hematologic complete remission of the acute
lymphoblastic leukemia (ALL) cytogenetic
remission?
No (No)
Unknown (Unknown)
Yes (Yes)
At the time of transplantation, was the type of
hematologic complete remission of the acute
lymphoblastic leukemia (ALL) molecular
remission?
No (No)
Unknown (Unknown)
Yes (Yes)
At the time of transplantation, what was the
number of the complete remission of acute
lymphoblastic leukemia (ALL)?
First (First)
Second:c25666 (Second)
Greater Third (Third or higher)
At the time of transplantation, what was the
number of the relapse of acute lymphoblastic
leukemia (ALL)?
First (First)
Second:c25666 (Second)
Greater Third (Third or higher)
Other Acute Leukemia
What was the W.H.O. classification of the other
acute leukemia?
Acute Mast Cell Leukemia (Acute  Mast
Cell Leukemia)
Acute Undifferentiated Leukemia (Acute
Undifferentiated Leukemia)
Acute Biphenotypic Leukemia
(biphenotypic, bilineage or hybrid
leukemia)
Other Acute Leukemia (Other  Acute
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Leukemia)
Specify the type of other acute leukemia:
Was imatinib mesylate given for pretransplant
therapy for the other acute leukemia anytime prior
to the start of the preparative regimen?
No (No)
Unknown (Unknown)
Yes (Yes)
What was the status of the other acute leukemia
at the time of transplantation?
Complete Remission (Complete
Remission)
Never Therapeutic Procedure (Never
treated)
Primary Induction Failure (Primary
Induction Failure (PIF))
Recurrent Disease (Relapse)
For patients with complete remission of the other
acute leukemia, was a cytogenetic complete
remission also achieved at the time of
transplantation?
No (No)
Unknown (Unknown)
Yes (Yes)
For patients with complete remission of the other
acute leukemia, was a molecular complete
remission also achieved at the time of
transplantation?
No (No)
Unknown (Unknown)
Yes (Yes)
At the time of transplantation, what was the
number of the complete remission of the other
acute leukemia?
First (First)
Second:c25666 (Second)
Greater Third (Third or higher)
At the time of transplantation, what was the
number of the relapse of the other acute
leukemia?
First (First)
Second:c25666 (Second)
Greater Third (Third or higher)
Chronic Myelogenous Leukemia (cml)
What was the classification of the chronic
myelogenous leukemia (Philadelphia
chromosome+, Ph+, t(9;22)(q34;q11), or variant
OR bcr/abl+)?
Ph Unknown/bcr+ (Ph Unknown/BCR+)
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Ph-/bcr+ (Ph-/BCR+)
Ph+/bcr Unknown (Ph+/BCR Unknown)
Ph+/bcr- (Ph+/BCR-)
Ph+/bcr+ (Ph+/BCR+)
Did the recipient receive treatment for chronic
myelogenous leukemia prior to this HSCT?
Yes
No
Cml Prior Hsct Treatment
What type of treatment did the recipient receive
prior to the hematopoietic stem cell
transplantation (HSCT)?
Combination Chemotherapy
(Combination chemotherapy)
Dasatinib (Dasatinib (Sprycel))
Hydroxyurea (Hydroxyurea (HU))
Imatinib Mesylate (Imatinib mesylate
(Gleevec, Glivec))
Interferon (Interferon)
Nilotinib (Nilotinib (Tasigna))
Other (Other)
Was a treatment administered prior to this
hematopoietic stem cell transplantation?
Yes
No
Specify the other type of therapy that the
recipient received prior to this hematopoietic stem
cell transplantation (HSCT): (Answer only if the
answer to CDE 2737666 is "Other.")
Chronic Myelogenous Leukemia (cml)
What was the phase of the CML at the time of
transplantation?
Accelerated Phase Chronic
Myelogenous Leukemia (Accelerated
Phase)
Blast Phase Chronic Myelogenous
Leukemia (Blast crisis)
Chronic Phase Chronic Myelogenous
Leukemia (Chronic phase)
Hematologic Cr (Hematologic complete
remission)
If the CML was in hematologic complete
remission, what was the disease status before
treatment?
Accelerated Phase Chronic
Myelogenous Leukemia (Accelerated
Phase)
Blast Phase Chronic Myelogenous
Leukemia (Blast crisis)
Chronic Phase Chronic Myelogenous
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Leukemia (Chronic phase)
At the time of transplantation, was the type of
hematologic complete remission of the chronic
myelogenous leukemia also a cytogenetic
remission?
Complete (Complete)
Cytogenetics Unknown (Cytogenetics
Unknown)
No (No)
At the time of transplantation, was the type of
hematologic complete remission of the chronic
myelogenous leukemia also molecular remission
(bcr/abl)?
Bcr-abl Oncoprotein Unknown (bcr/abl
unknown)
No (No)
Yes (Yes)
At the time of transplantation, was the type of
chronic phase of the chronic myelogenous
leukemia also a cytogenetic remission?
Complete (Complete)
Cytogenetics Unknown (Cytogenetics
Unknown)
No (No)
At the time of transplantation, was the type of
chronic phase of the chronic myelogenous
leukemia also a molecular remission (bcr/abl)?
Bcr-abl Oncoprotein Unknown (bcr/abl
unknown)
No (No)
Yes (Yes)
At the time of transplantation, what was the
number of the status of the CML?
First (First)
Second:c25666 (Second)
Greater Third (Third or higher)
Myelodysplastic Or Myeloproliferative
Disease Classification
What was the MDS or myeloproliferative disease
classification?
Myelodysplastic Syndrome Associated
With Isolated Del (5q) Chromosome
Abnormality (5q- syndrome)
Acute Myeloid Leukemia (AML)
Chronic Eosinophilic Leukemia (Chronic
eosinophilic leukemia (hypereosinophilic
syndrome))
Chronic Idiopathic Myelofibrosis (Chronic
idiopathic myelofibrosis (with extra-
medullary hematopoiesis), myelofibrosis
with myeloid metaplasia, acute
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myelofibrosis or myelosclerosis)
Chronic Myelomonocytic Leukemia
(Chronic myelomonocytic leukemia
(CMMol, CMML))
Not Otherwise Specified Chronic
Myeloproliferative Disorder (Chronic
myeloproliferative disease, unclassifiable
(MPS, NOS))
Chronic Neutrophilic Leukemia (Chronic
neutrophilic leukemia)
Essential Thrombocythemia (Essential
thrombocythemia (ET))
Juvenile Myelomonocytic Leukemia
(Juvenile myelomonocytic leukemia
(JMML, JCML, JCMML))
Not Otherwise Specified Mds (MDS
unclassifiable/NOS)
Polycythemia Vera (Polycythemia vera
(PCV))
Refractory Anemia (RA)
Raeb-1 (RAEB-1)
Raeb-2 (RAEB-2)
Refractory Anemia With Ringed
Sideroblasts (RARS)
Refractory Cytopenia With Multilineage
Dysplasia (RCMD)
Refractory Cytopenia With Multilineage
Dysplasia And Ringed Sideroblasts
(RCMD / RS)
Was the myelodysplastic/myeloproliferative
disease classification made at the time of
diagnosis?
Yes
No
Was the myelodysplastic/myeloproliferative
disease classification made at the time of
transplantation?
Yes
No
Myelodysplastic Or Myeloproliferative
Diseases
If the MDS sub type is AML, date of MDS
diagnosis:
Was Janus kinase 2 (jak2) gene mutation
positive?
No: C49487 (No)
Not Done: C49484 (Not Done)
Yes: C49488 (Yes)
Was MDS / MPS therapy-related?
No (No)
Unknown (Unknown)
Yes (Yes)
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Type Of Therapy Related Mds / Mps
What was the cause of the therapy-related
MDS/MPS?
Alkylating Agent Radiation Therapy
Related (Alkylating agent / radiation-
related)
Topoisomerase-ii Inhibitor Related
(Topoisomerase II inhibitor-related)
Unknown (Unknown)
Did a cause of the therapy related MDS / MPS
occur?
Yes
No
Myelodysplastic Or Myeloproliferative
Diseases
What was the status of MDS/MPS/CMML at
transplantation?
Relapse Cr (Relapse after complete
response)
Supportive Care Without Chemotherapy
(Supportive care or treatment without
chemotherapy)
Chemotherapy (Treated with
chemotherapy)
If the MDS/MPS/CMML was treated with
chemotherapy, what was the disease status at
the time of transplantation?
Complete Remission (CR)
No Cr Better (Improvement but no CR)
Without Response (NR - no response)
Progressive Disease (Prog / worse)
At the time of transplantation, what was the
number of the complete remission of the MDS /
MPS / CMML?
First (First)
Second:c25666 (Second)
Greater Third (Third or higher)
At the time of transplantation what was the
number of the relapse after complete response of
the MDS/MPS/CMML?
First (First)
Second:c25666 (Second)
Greater Third (Third or higher)
At the time of transplantation, what was the
status of the JMML?
Continued Complete Response (CCR -
Continued Complete Response)
Complete Remission (CR - Complete
Response)
Minimum Response (MR - Minimal
28 / 51
Treatment - 2400 - Pre-Transplant Essential Data (TED) - 2492857v5.0
Response)
Not Assessed (Not Assessed)
Progressive Disease (PD - Progressive
Disease)
Partial Remission (PR - Partial
Response)
Stable Disease (SD - Stable Disease)
Other Leukemias
What is the classification of the other leukemia?
Ph Unknown/bcr Unknown Atypical
Chronic Myeloid Leukemia (Atypical
chronic myeloid leukemia (CML, NOS),
Ph unknown/bcr unknown)
Ph Unknown/bcr- Atypical Chronic
Myeloid Leukemia (Atypical chronic
myeloid leukemia (CML, NOS), Ph
unknown/bcr-)
Ph-/bcr Unknown Atypical Chronic
Myeloid Leukemia (Atypical chronic
myeloid leukemia (CML, NOS), Ph-/bcr
unknown)
Ph -/bcr-abl- Atypical Chronic Myeloid
Leukemia (Atypical chronic myeloid
leukemia (CML, NOS), Ph-/bcr/abl-)
Small Lymphocytic Lymphoma Cll
(Chronic Lymphocytic Leukemia (CLL),
B-cell / Small Lymphocytic Lymphoma
(SLL))
Not Otherwise Specified Cll (Chronic
Lymphocytic Leukemia (CLL), NOS)
Cll, T-cell (CLL, T-cell)
Hairy Cell Leukemia (Hairy Cell
Leukemia)
Leukemia (Other Leukemia)
Not Otherwise Specified Leukemia
(Other Leukemia, NOS)
B-cell Prolymphocytic Leukemia (PLL, B-
Cell)
T-cell Prolymphocytic Leukemia (PLL, T-
Cell)
Not Otherwise Specified Prolymphocytic
Leukemia (Prolymphocytic Leukemia
(PLL), NOS)
Specify the other type of  leukemia:
What was the status of the other leukemia at the
time of transplantation?
Complete Remission (Complete
Remission (CR))
Never Therapeutic Procedure (Never
treated)
Stable Disease (No Response / Stable
(NR / SD))
Nodular Partial Remission (Nodular
partial remission (nPR))
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Partial Remission (Partial remission
(PR))
Progressive Disease (Progression)
Without Therapeutic Procedure
Recurrent Disease (Relapse (untreated))
Lymphomas
Specify the type of hodgkin lymphoma:
Not Otherwise Specified Hodgkin's
Lymphoma (Hodgkin Lymphoma, NOS)
Lymphocyte Depleted Hodgkin
Lymphoma (Lymphocyte Depleted)
Lymphocyte Rich Classical Hodgkin
Lymphoma (Lymphocyte-rich)
Mixed Cellularity Hodgkin Lymphoma
(Mixed Cellularity)
Nodular Lymphocyte Predominant
Hodgkin Lymphoma (Nodular
Lymphocyte Predominant Hodgkin
Lymphoma)
Nodular Sclerosis Hodgkin Lymphoma
(Nodular Sclerosis)
What was the status of the hodgkin lymphoma at
the time of transplantation?
Confirmed Cr (Complete Response
confirmed)
Not Confirmed Cr (CR unconfirmed
(CRU) (complete response with
persistent scan abnormalities of
unknown signifcance))
Never Therapeutic Procedure (Never
treated)
Partial Response (Partial response (PR))
Primary Refractory (less Than Partial
Response (pr) To Initial Therapy) /
Primary Induction Failure-resistant (pif
Res) (Primary refractory (less than
partial response (PR) to initial therapy) /
Primary induction failure-resistant (PIF
res))
Recurrent Disease (Relapse)
Specify the type of partial response of the
hodgkin lymphoma:
With Prior Cr (With prior complete
remission)
Without Prior Cr (Without prior complete
remission)
If there was a complete response of the hodgkin
lymphoma at the time of transplantation, what
was the number of the complete response?
First (First)
Second:c25666 (Second)
Greater Third (Third or higher)
If there was a relapse of hodgkin lymphoma at
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the time of transplantation, what was the number
of the relapse?
First (First)
Second:c25666 (Second)
Greater Third (Third or higher)
If there was a relapse of hodgkin lymphoma at
the time of transplantation, what was the
sensitivity to chemotherapy?
Resistance (Resistant)
Sensitivity (Sensitive)
Unknown (Unknown)
Without Therapeutic Procedure
(Untreated)
Non-hodgkin's Lymphoma
Specify the type of non-hodgkin lymphoma:
Acute Adult T-cell Lymphoma/leukemia
(Adult T-cell lymphoma / leukemia
(HTLV1+))
Aggressive Nk-cell Leukemia
(Aggressive NK-Cell Leukemia)
Cutaneous Angioimmunoblastic T-cell
Lymphoma (Anaplastic large cell
lymphoma, T / cell, primary cutaneous
type)
Systemic Anaplastic Large Cell
Lymphoma (Anaplastic large cell
lymphoma, T / cell, primary systemic
type)
Angioimmunoblastic T-cell Lymphoma
(Angioimmunoblastic T-Cell Lymphoma
(AILD))
Burkitt's Lymphoma Burkitt's Leukemia
(Burkitt's lymphoma / Burkitt cell
leukemia (ALL L3))
Diffuse Large B-cell Lymphoma (Diffuse
Large B-Cell Lymphoma)
Enteropathy-type T-cell Lymphoma
(Enteropathy-type T-Cell Lymphoma)
Extranodal Marginal Zone B-cell
Lymphoma Of Mucosa-associated
Lymphoid Tissue (Extranodal marginal
zone B-cell lymphoma of MALT type)
Nasal Type Extranodal Nk/t-cell
Lymphoma (Extranodal NK / T-cell
lymphoma, nasal type)
Grade 1 Follicular Lymphoma (Follicular
lymphoma (includes variants), Grade I)
Grade 2 Follicular Lymphoma (Follicular
lymphoma (includes variants), Grade II)
Grade 3 Follicular Lymphoma (Follicular
lymphoma (includes variants), Grade III)
Follicular Lymphoma (Follicular
lymphoma (includes variants), grade
unknown)
Hepatosplenic T-cell Lymphoma
(Hepatosplenic gamma-delta T-cell
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lymphoma)
High-grade B-cell Lymphoma, Burkitt-like
(provisional Entity) (High-grade B-cell
lymphoma, Burkitt-like (Provisional
entity))
T-cell Large Granular Lymphocyte
Leukemia (Large T-cell granular
lymphocytic leukemia)
Lymphoplasmacytic
Lymphoma/waldenstrom's
Macroglobulinemia (Lymphoplasmacytic
lymphoma)
Mantle Cell Lymphoma (Mantle Cell
Lymphoma)
Mycosis Fungoides (Mycosis Fungoides)
Nodal Marginal Zone B-cell Lymphoma
(Nodal marginal zone B-cell lymphoma
(+ /  -  monocytoid B-cells))
Other B-cell Non-hodgkin Lymphoma
(Other B-cell lymphoma)
Other T-cell Non-hodgkin Lymphoma
(Other T-cell / NK-cell lymphoma,)
Unspecified Peripheral T-cell Lymphoma
(Peripheral T-cell lymphoma, NOS)
Central Nervous System Lymphoma
(Primary CNS lymphoma)
Sezary Syndrome (Sezary Syndrome)
Splenic Marginal Zone B-cell Lymphoma
(Splenic marginal zone B-cell lymphoma)
Subcutaneous Panniculitis-like T-cell
Lymphoma (Subcutaneous Panniculitis-
Like T-Cell Lymphoma)
Lymphoplasmacytic
Lymphoma/waldenstrom's
Macroglobulinemia (Waldenstrom
macroglobulinemia)
What was the subtype of the non-hodgkin
lymphoma diffuse, large B-cell lymphoma?
Intravascular Large B-cell Lymphoma
(Intravascular large B-cell lymphoma)
Mediastinal (thymic) Large B-cell
Lymphoma (Mediastinal large B-cell
lymphoma)
Primary Effusion Lymphoma (Primary
effusion lymphoma)
Specify the type of other B-cell lymphoma:
Specify the other T / NK cell lymphoma:
What was the status of the non-hodgkin's
lymphoma at the time of transplantation?
Confirmed Cr (Complete Response
confirmed)
Not Confirmed Cr (CR unconfirmed
(CRU) (complete response with
persistent scan abnormalities of
32 / 51
Treatment - 2400 - Pre-Transplant Essential Data (TED) - 2492857v5.0
unknown signifcance))
Never Therapeutic Procedure (Never
treated)
Partial Response (Partial response (PR))
Primary Refractory (less Than Partial
Response (pr) To Initial Therapy) /
Primary Induction Failure-resistant (pif
Res) (Primary refractory (less than
partial response (PR) to initial therapy) /
Primary induction failure-resistant (PIF
res))
Recurrent Disease (Relapse)
Specify the type of partial response of the non-
hodgkin lymphoma:
With Prior Cr (With prior complete
remission)
Without Prior Cr (Without prior complete
remission)
If there was a complete response of the non-
hodgkin lymphoma at the time of transplantation,
what was the number?
First (First)
Second:c25666 (Second)
Greater Third (Third or higher)
If there was a relapse of non-hodgkin lymphoma
at the time of transplantation, what was the
number?
First (First)
Second:c25666 (Second)
Greater Third (Third or higher)
If there was a relapse of non-hodgkin lymphoma
at the time of transplantation, what was the
sensitivity to chemotherapy?
Resistance (Resistant)
Sensitivity (Sensitive)
Unknown (Unknown)
Without Therapeutic Procedure
(Untreated)
Plasma Cell Disorders
What was the classification of plasma cell
disorders?
Multiple Myeloma-iga (Multiple Myeloma-
IgA)
Multiple Myeloma-igd (Multiple Myeloma-
IgD)
Multiple Myeloma-ige (Multiple Myeloma-
IgE)
Multiple Myeloma-igg (Multiple Myeloma-
IgG)
Multiple Myeloma-igm (not Waldenstrom
Macroglobulinemia) (Multiple Myeloma-
IgM (not Waldenstrom
Macroglobulinemia))
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Multiple Myeloma-light Chain Only
(Multiple Myeloma-Light Chain Only)
Non-secretory Myeloma (Multiple
myeloma-non-secretory)
Other Plasma Cell Diseases And
Disorders (Other Plasma Cell Disorder)
Plasma Cell Leukemia (Plasma cell
leukemia)
Primary Amyloidosis (Primary
Amyloidosis)
Solitary Plasmacytoma (Solitary
plasmacytoma (no evidence of
myeloma))
Light Chain Involved
Kappa (kappa)
Lambda (lambda)
Durie-Salmon Stage
I - All Of The Following Must Be Present
(hemoglobin >10 G/dl; Serum Calcium
<12 Mg/dl; Urine Light Chains <4 G/24
Hrs; Normal Bones On Radiograph Or
Solitary Plasmacytoma; Igg <5 G/dl; Iga
<3 G/dl) (I - ALL of the following must be
present)
Ii - Fitting Neither Stage I Or Stage Iii (II -
Fitting neither Stage I or Stage III)
Iii - One Of The Following Must Be
Present (hemoglobin <8.5 G/dl; Serum
Calcium >12 Mg/dl; Urine Light Chains
>12 G/24 Hrs; Advanced Lytic Bone
Lesions (>3 Lytic Lesions); Igg >7 G/dl;
Iga >5 G/dl) (III - one of the following
must be present)
Durie-Salmon Sub-stage
A (relatively Normal Renal Function -
Serum Creatinine <2.0 Mg/dl) (A
(relatively normal renal function - serum
creatinine <2.0 mg/dl))
B (abnormal Renal Function - Serum
Creatinine >= 2.0 Mg/dl) (B (abnormal
renal function - serum creatinine >= 2.0
mg/dl))
Specify the serum beta2-microglobulin value:
Specify the unit of measure for the serum beta2-
microglobulin value:
Mg/l (mg/L)
Nanomole Per Liter (nmol/L)
Ug/dl (ug/dL)
Specify the serum albumin value:
Specify the unit of measure for the serum
albumin value:
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Gram Per Deciliter (g/dL)
Gram Per Liter (g/L)
What was the International Staging System for
Myeloma Stage?
Iss Stage I Plasma Cell Myeloma (Stage
1)
Iss Stage Ii Plasma Cell Myeloma (Stage
2)
Iss Stage Iii Plasma Cell Myeloma
(Stage 3)
Specify the other type of plasma cell disorder:
What was the plasma cell disorder status at
transplantation?
Complete Remission (Complete
Remission (CR))
Never Therapeutic Procedure (Never
treated)
Partial Response Of Multiple Myeloma
Or Plasma Cell Leukemia (Partial
Response (PR))
Progression Of Multiple Myeloma Or
Plasma Cell Leukemia (Progression)
Relapse From Complete Response Of
Multiple Myeloma Or Plasma Cell
Leukemia (Relapse from complete
remission (untreated))
Stable Multiple Myeloma Or Plasma Cell
Leukemia (Stable Disease (SD))
Stringent Complete Response (scr) Of
Multiple Myeloma Or Plasma Cell
Leukemia (Stringent Complete
Remission (sCR))
Very Good Partial Response (vgpr) Of
Multiple Myeloma Or Plasma Cell
Leukemia (Very Good Partial Response
(VGPR))
If the plasma cell disorder was treated, what was
the number of the response?
First (First)
Second:c25666 (Second)
Greater Third (Third or higher)
Breast Cancer
Was the breast cancer inflammatory or non-
inflammatory?
Inflammatory Breast Carcinoma
(Inflammatory)
Not Inflammatory Breast Carcinoma
(Non-inflammatory)
What was the stage of the breast cancer at
diagnosis?
Stage 0 Breast Cancer (0)
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Stage I Breast Cancer (I)
Stage Ii Breast Cancer (II)
Stage Iii Breast Cancer (III)
What was the metastases of the breast cancer?
Metastatic (Metastatic)
Without Distant Metastasis (No distant
metastases)
What was the status of the breast cancer at the
time of transplantation?
First Partial Remission (1st partial
response (PR1))
Adjuvant Therapy (Adjuvant (Stage II, III
only))
Complete Remission (Complete
Remission (CR))
Never Therapeutic Procedure (Never
treated)
Primary Refractory (Primary refractory)
Recurrent Disease (Relapse)
Specify the type of complete remission of the
breast cancer at the time of transplantation:
Confirmed Cr (CR confirmed)
Not Confirmed Cr (CR unconfirmed
(CRU)(complete response with persistent
scan abnormalities of unknown
significance))
What was the number of complete remission of
the breast cancer at the time of transplantation?
First (First)
Second:c25666 (Second)
Greater Third (Third or higher)
If the breast cancer was in the state of relapse at
the time of transplantation, was the cancer local
or metastatic?
Local (Local)
Metastatic (Metastatic)
If the breast cancer was in the state of relapse at
the time of transplantation, what was the number
of the relapse?
First (First)
Second:c25666 (Second)
Greater Third (Third or higher)
If the breast cancer was in the state of relapse at
the time of transplantation, what was the
sensitivity to chemotherapy?
Resistance (Resistant)
Sensitivity (Sensitive)
Unknown (Unknown)
Without Therapeutic Procedure
(Untreated)
Other Disease
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Specify other
Copy of pathology report submitted?
Yes
No
What was the indication for the alternative
hematopoietic cell transplantation (HCT)?
Cardiac Regeneration (Cardiac
regeneration)
Neurologic Regeneration (Neurologic
Regeneration)
Other (Other)
Tolerance Induction Pre-solid Organ
Transplant (Tolerance Induction Pre-Solid
Organ Transplant)
Specify the indication for the other alternative
HCT:
Other Malignancies
What was the classification of the other
malignancy?
Bone Sarcoma (Bone sarcoma,
excluding Ewing family tumors)
Central Nervous System Carcinoma
(Central nervous system tumor, including
CNS PNET)
Colorectal Carcinoma (Colorectal)
Ewing Sarcoma Of Bone (Ewing family
tumors of bone (includes PNET))
Extraosseous Ewing Sarcoma (Ewing
family tumors, extra-osseous (includes
PNET))
Extragonadal Germ Cell Tumor (Germ
cell tumor, extragonadal only)
Hepato-biliary Neoplasm (Hepatobiliary)
Non-small Cell Lung Carcinoma (Lung
cancer, non-small cell)
Sclc (Lung cancer, small cell)
Medulloblastoma (Medulloblastoma)
Melanoma (Melanoma)
Neuroblastoma (Neuroblastoma)
Other Solid Neoplasm (Other solid
tumor)
Ovarian Carcinoma (Ovary)
Pancreatic Carcinoma (Pancreas)
Prostate Carcinoma (Prostate)
Renal Cell Carcinoma (Renal Cell)
Retinoblastoma (Retinoblastoma)
Rhabdomyosarcoma
(Rhabdomyosarcoma)
Soft Tissue Sarcoma (Soft Tissue
Sarcoma)
Malignant Testicular Germ Cell Tumor
(Testicular)
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Thymoma (Thymoma)
Wilms Tumor (Wilms Tumor)
Specify the type of other solid tumor:
What was the status of the other malignancy at
the time of transplantation?
Adjuvant Therapy (Adjuvant)
Complete Remission (CR)
Never Therapeutic Procedure (Never
treated)
Stable Disease (NR / SD)
Progressive Disease (PD)
Partial Remission (PR)
Without Therapeutic Procedure
Recurrent Disease (Relapse (untreated))
Without Confirmed Cr (Unconfirmed
complete remission (CRU))
If the status of the other malignancy at the time of
transplantation is partial remission, what was the
type of partial remission
With Prior Cr (With prior complete
remission)
Without Prior Cr (Without prior complete
remission)
Was RECIST criteria used for evaluation of the
status of the other malignancy at the time of
transplantation?
Yes
No
What was the number of the complete response,
complete response with persistent imaging
abnormalities of unknown significance, or relapse
for the other malignancy at the time of
transplantation?
First (First)
Second:c25666 (Second)
Greater Third (Third or higher)
If there was a relapse of the other malignancy,
what was the sensitivity to chemotherapy?
(Complete only for relapse)
Resistance (Resistant)
Sensitive (Sensitive)
Unknown (Unknown)
Not Treatment (Untreated)
Anemia/hemoglobinopathy
What was the classification of the anemia /
hemoglobinopathy?
Not Genetic Amegakaryocytosis
(Acquired amegakaryocytosis (not
congenital))
Acquired Pure Red Cell Aplasia
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(Acquired Pure Red Cell Aplasia (PRCA)
(not congenital))
Aplastic Anemia Due To Hepatitis
(Acquired SAA, secondary to hepatitis)
Drug-induced Aplastic Anemia (Acquired
SAA, secondary to toxin / other drug)
Severe Aplastic Anemia Not Otherwise
Specified (Acquired Severe Aplastic
Anemia (SAA), NOS)
Diamond-blackfan Anemia (Diamond-
Blackfan anemia (congenital PRCA))
Fanconi Anemia (Fanconi Anemia)
Other Not Genetic Cytopenia (Other
acquired cytopenic syndrome)
Other Genetic Anemia (Other
constitutional anemia)
Other Hemoglobinopathy (Other
hemoglobinopathy)
Paroxysmal Nocturnal Hemoglobinuria
(Paroxysmal Nocturnal Hemogloblinuria
(PNH))
Schwachmann-diamond Syndrome
(Shwachman-Diamond)
Sickle Cell Disease (Sickle Cell Disease)
Sickle Cell-thalassemia (Sickle
thalassemia)
Not Otherwise Specified Thalassemia
(Thalassemia, NOS)
Specify the other acquired cytopenic syndrome:
Specify the other constitutional anemia:
Specify the other hemoglobinopathy:
Platelet Disorders
What was the classification of the platelet
disorder?
Thrombocytopenia Congenital
Abnormality Amegakaryocytosis
(Congenital amegakaryocytosis /
congenital thrombocytopenia)
Glanzmann Thrombasthenia
(Glanzmann Thrombasthenia)
Other Congenital Platelets Abnormality
(Other inherited platelet abnormality)
Specify the other inherited platelet abnormalities:
Histiocytic Disorders
What was the classification of the histiocytic
disorder?
Familiar Hemophagocytic
Lymphohistiocytosis (Familial erythro /
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hemophagocytic lymphohistiocytosis
(FELH))
Hemophagocytosis (Hemophagocytosis
(reactive or viral associated))
Not Otherwise Specified Histiocytic And
Dendritic Cell Neoplasms (Histiocytic
disorder, NOS)
Langerhans Cell Histiocytosis
(Langerhans cell histiocytosis
(histiocytosis-X))
Malignant Histiocytosis (Malignant
histiocytosis)
Other Histiocytic And Dendritic Cell
Neoplasms (Other histiocytic disorder)
Specify the other histiocytic disorder:
Inherited Disorders Of
Metabolism/osteopetrosis
What was the classification of the inherited
disorders of metabolism / osteopetrosis?
Adrenoleukodystrophy
(Adrenoleukodystrophy (ALD))
Aspartylglycosaminuria (Aspartyl
Glucosaminuria)
Beta Glucuronidase Deficiency (vii) (Beta
glucuronidase deficiency (VII))
Fucosidosis (Fucosidosis)
Gaucher Disease (Gaucher Disease)
Glucose Storage Disease (Glucose
storage disease)
Hunter Syndrome (Hunter syndrome (II))
Hurler Syndrome (Hurler syndrome (IH))
I-cell Disease (I-Cell Disease)
Not Otherwise Specified Congenital
Metabolic Disorder (Inherited Disorders
or Metabolism, NOS)
Krabbe Disease (Krabbe disease
(Globoid leukodystrophy))
Lesch-nyhan Syndrome (Lesch-Nyhan
(HGPRT deficiency))
Mannosidosis (Mannosidosis)
Maroteaux-lamy Syndrome (Maroteaux-
Lamy (VI))
Metachromatic Leukodystrophy
(Metachromatic leukodystrophy (MLD))
Morquio Syndrome (Morquio (IV))
Not Otherwise Specified Mucolipidosis
(Mucolipidoses, not otherwise specified)
Mucopolysaccharidosis
(Mucopolysaccharidosis (V))
Not Otherwise Specified
Mucopolysaccharidosis
(Mucopolysaccharidosis, not otherwise
specified)
Batten Disease (Neuronalceroid
lipofuscinosis (Batten disease))
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Niemann-pick Disease (Niemann-Pick
disease)
Osteopetrosis (Osteopetrosis (malignant
infantile osteopetrosis))
Other Congenital Metabolic Disorder
(Other inherited disorder of metabolism)
Polysaccharide Hydrolase Abnormalities,
Nos (Polysaccharide hydrolase
abnormalities, NOS)
Sanfilippo Syndrome (Sanfilippo (III))
Scheie Syndrome (Scheie syndrome
(IS))
Wolman Disease (Wolman disease)
Specify the other inherited disorder of
metabolism:
Immune Deficiencies
What was the classification of the immune
deficiency?
Adenosine Deaminase Deficiency
Severe Combined Immunodeficiency
(Adenosine deaminase (ADA) deficiency
/ severe combined immunodefiency
(SCID))
Ataxia Telangiectasia Syndrome (Ataxia
telangiectasia)
Bare Lymphocyte Syndrome (Bare
lymphocyte syndrome)
Cartilage Hair Hypoplasia (Cartilage Hair
Hypoplasia)
Cd40 Ligand Deficiency (CD40 ligand
deficiency)
Chediak-higashi Syndrome (Chediak-
Higashi Syndrome)
Chronic Granulomatous Disease
(Chronic Granulomatous Disease)
Common Variable Immunodeficiency
(Common Variable Immunodeficiency)
Digeorge's Syndrome (DiGeorge
anomaly)
Hiv Infection (HIV Infection)
Not Otherwise Specified
Immunodeficiency Syndrome (Immune
Deficiencies, NOS)
Congenital Neutropenia (Kostmann
agranulocytosis (congenital
neutropenia))
Leukocyte Adhesion Deficiency
(Leukocyte adhesion deficiencies)
Neutrophil Actin Defect (Neutrophil actin
deficiency)
Omenn Syndrome (Omenn Syndrome)
Other Immunodeficiency Syndrome
(Other immune deficiency)
Reticular Dysgenesis (Reticular
Dysgenesis)
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Not Otherwise Specified Severe
Combined Immunodeficiency (SCID, not
otherwise specified)
Severe Combined Immunodeficiency
(SCID, other)
Severe Combined Immunodeficiency
With Absence Of T And B Cells (Severe
Combined Immunodeficiency with
Absence of T and B Cells)
Severe Combined Immunodeficiency
With Absence Of T, Normal B Cells
(Severe Combined Immunodeficiency
with Absence of T, Normal B Cells)
Wiskott-aldrich Syndrome (Wiskott-
Aldrich Syndrome)
X-linked Lymphoproliferative Syndrome
(X-Linked Lymphoproliferative
Syndrome)
Specify the other SCID:
Specify the other immune deficiency:
Autoimmune Disorders
Specify the type of autoimmune disease:
Antiphospholipid Syndrome
(Antiphospholipid syndrome)
Behcet's Syndrome (Behcet's Syndrome)
Churg-strauss Syndrome (Churg-
Strauss)
Crohn's Disease (Crohn's disease)
Evan Syndrome (Evan Syndrome)
Temporal Arteritis (Giant cell arteritis)
Hemolytic Anemia (Hemolytic Anemia)
Idiopathic Thrombocytopenic Purpura
(Idiopathic thrombocytopenic purpura
(ITP))
Stills Disease (Juvenile idiopathic
arthritis (JIA): systemic (Stills disease))
Oligoarticular Stills Disease (Juvenile
idiopathic arthritis: Oligoarticular)
Other Pediatric Idiopathic Arthritis
(Juvenile idiopathic arthritis: other)
Polyarticular Stills Disease (Juvenile
idiopathic arthritis: Polyarticular)
Multiple Sclerosis (Multiple sclerosis
(MS))
Myasthenia Gravis (Myasthenia Gravis)
Other Arthritis (Other  Arthritis)
Other Vasculitis (Other  Vasculitis)
Bowel Autoimmune Other Diseases And
Disorders (Other autoimmune bowel
disorder)
Other Autoimmune Cytopenia (Other
autoimmune cytopenia)
Neurologic Other Autoimmune Disease
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(Other autoimmune neurological
disorder)
Other Connective Tissue Disorder (Other
connective tissue disease)
Overlap Necrotizing Arteritis (Overlap
Necrotizing Arteritis)
Polyarteritis Nodosa (Polyarteritis
nodosa, classical)
Microscopic Polyarteritis (Polyarteritis
nodosa, microscopic)
Polymyositis Dermatomyositis
(Polymyositis / dermatomyositis)
Psoriasis Psoriatic Arthritis (Psoriatic
Arthritis / Psoriasis)
Rheumatoid Arthritis (Rheumatoid
Arthritis)
Sjogren's Syndrome (Sjogren syndrome)
Systemic Lupus Erythematosus
(Systemic lupus erythematosis (SLE))
Systemic Sclerosis (Systemic sclerosis)
Takayasu's Arteritis (Takayasu)
Ulcerative Colitis (Ulcerative colitis)
Wegener's Granulomatosis (Wegener
granulomatosis)
Specify the type of other connective tissue
disease:
Specify the other vasculitis:
Specify the other juvenile idiopathic arthritis:
Specify the other arthritis:
Specify the other autoimmune neurological
disorder:
Specify the other autoimmune cytopenia:
Specify the other autoimmune bowel disorder:
Systemic Sclerosis Involvement
For the systemic sclerosis, what was the involved
organ or clinical problem?
Crest Syndrome (CREST)
Diffuse Cutaneous (Diffuse cutaneous)
Esophagus (Esophagus)
Local Cutaneous (Limited cutaneous)
Lung Tissue (Lung parenchyma)
Other (Other)
Other Gastrointestinal Tract (Other GI
tract)
Pulmonary Hypertension (Pulmonary
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hypertension)
Raynaud's Syndrome (Raynaud)
Renal (Renal)
Hypertension Systemic (Systemic
hypertension)
Did the systemic sclerosis have a particular
involvement?
Yes
No
Was the involvement associated with systemic
sclerosis the primary reason for transplantation?
Yes
No
What was the systemic sclerosis biopsy type?
(Answer only if the answer to CDE 2748902 is
renal)
Specify the other involvement of the systemic
sclerosis: (Answer only if the answer to CDE
2748902 is "Other.")
Systemic Sclerosis Laboratory
Procedures
For the systemic sclerosis, what was the
laboratory procedure type?
Centromere Antibody (ACA positive)
Antinuclear Antibody (ANA)
Topoisomerase I Antibody (Scl 70
positive)
For the systemic sclerosis, what was the result of
the laboratory procedure?
Elevated (Elevated)
Normal (Normal)
Not Done: C49484 (Not Done)
Systemic Lupus Erythematosus (sle)
Involvement
For the systemic lupus erythematosus (SLE),
what was the involved organ or clinical problem?
Arthritis (Arthritis)
Central Nervous System (CNS)
Hematologic (Hematological)
Lung (Lung)
Other (Other)
Peripheral Nervous System (PNS)
Renal (Renal)
Serositis (Serositis)
Skin (Skin)
Vasculitis (Vasculitis)
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Did the systemic lupus erythematosus (SLE)
have a particular involvement?
Yes
No
Was the involvement associated with systemic
lupus erythematosus (SLE) the primary reason
for transplantation?
Yes
No
What was the systemic lupus erythematosus
(SLE) biopsy type? (Answer only if the answer to
CDE 2749007 is "Renal.")
Specify the type of systemic lupus erythematosus
(SLE) involvement: (Answer only if the answer to
CDE 2749007 is "CNS", "PNS", "Skin",
"Hematological", "Vasculitis", or "Other.")
Systemic Lupus Erythematosus (sle)
Laboratory Procedures
For the systemic lupus erythematosus, what was
the ANA test result?
Elevated (Elevated)
Normal (Normal)
Not Done: C49484 (Not Done)
For the systemic lupus erythematosus, what was
the ds DNA test result?
Elevated (Elevated)
Normal (Normal)
Not Done: C49484 (Not Done)
For the systemic lupus erythematosus, what was
the C3 test result?
Low (Low)
Normal (Normal)
Not Done: C49484 (Not Done)
For the systemic lupus erythematosus (SLE),
what was the C4 test result?
Low (Low)
Normal (Normal)
Not Done: C49484 (Not Done)
For systemic lupus, erythematosus, what was the
total complement test result?
Low (Low)
Normal (Normal)
Not Done: C49484 (Not Done)
For the systemic lupus erythematosus, what was
the test results at diagnosis for the other
antibody?
Elevated (Elevated)
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Normal (Normal)
Not Done: C49484 (Not Done)
For the systemic lupus erythematosus, specify
the other antibody:
Sjogren Syndrome Involvement
For the sjogren syndrome, what was the involved
organ or clinical problem?
Swelling Exocrine Gland (Exocrine gland
swelling)
Paraproteinemia Lymphoma
(Lymphoma, paraproteinemia)
Other (Other)
Lymphocytic Infiltration Other (Other
organ lymphocytic infiltration)
Sicca Syndrome (SICCA)
Vasculitis (Vasculitis)
Did the sjogren syndrome have a particular
involvement?
Yes
No
Was the involvement associated with sjogren
syndrome the primary reason for transplantation?
Yes
No
Specify the other involvement for sjogren
syndrome: (Answer only if the answer to CDE
2749605 is "Other.")
Polymyositis / Dermatomyositis
Involvement
For the polymyositis-dermatomyositis, what was
the involved organ or clinical problem?
Generalized Muscle Weakness
(Generalized weakness (including
bulbar))
Malignant Neoplasm (Malignancy)
Other (Other)
Proximal Muscle Weakness (Proximal
weakness)
Pulmonary Fibrosis (Pulmonary fibrosis)
Vasculitis (Vasculitis)
Did the polymyositis-dermatomyositis have a
particular involvement?
Yes
No
Was the involvement associated with
polymyositis-dermatomyositis the primary reason
46 / 51
Treatment - 2400 - Pre-Transplant Essential Data (TED) - 2492857v5.0
for transplantation?
Yes
No
Specify the type of polymyositis-dermatomyositis
involvement: (Answer only if the answer to CDE
2749891 is "Vasculitis", "Malignancy", or "Other.")
Polymyositis / Dermatomyositis Laboratory
Procedure
What was the CPK test result?
Elevated (Elevated)
Normal (Normal)
Not Done: C49484 (Not Done)
For the polymyositis-dermatomyositis, were the
biopsy results typical of the disease?
Elevated (Elevated)
Normal (Normal)
Not Done: C49484 (Not Done)
For the polymyositis-dermatomyositis, were the
EMG results typical of the disease?
Elevated (Elevated)
Normal (Normal)
Not Done: C49484 (Not Done)
For the dermatomyositis, was there a rash
present that was typical of the disease?
Elevated (Elevated)
Normal (Normal)
Not Done: C49484 (Not Done)
Antiphospholipid Syndrome Involvement
For the antiphospholipid syndrome, what was the
involved organ or clinical problem?
Abortion (Abortion)
Central Nervous System (CNS)
Hematology (Hematological)
Other (Other)
Vasculitis (Skin (livedo, vasculitis))
Thrombosis (Thrombosis)
Did the antiphospholipid syndrome have a
particular involvement?
Yes
No
Was the involvement associated with
antiphospholipid syndrome the primary reason for
transplantation?
Yes
No
Specify the other type of antiphospholipid
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syndrome involvement: (Answer only if the
answer to CDE 2749918 is "Thrombosis," "CNS,"
"Hematological," or "Other.")
Antiphospholipid Syndrome Laboratory
Procedures
For the antiphospholipid syndrome, what was the
laboratory procedure type?
Anticardiolipin Igg Antibody
(Anticardiolipin IgG)
Anticardiolipin Igm Antibody
(Anticardiolipin IgM)
Lab Lupus Inhibitor (Lab lupus inhibitor)
Lupus Anticoagulant Antibody (Lupus
anticoagulant)
For the antiphospholipid syndrome, what was the
result of the laboratory procedure?
Elevated (Elevated)
Normal (Normal)
Not Done: C49484 (Not Done)
Wegener Granulomatosis Invovlement
For the wegener granulomatosis, what was the
involved organ or clinical problem?
Other (Other)
Pulmonary (Pulmonary)
Renal (Renal)
Skin (Skin)
Upper Respiratory System (Upper
respiratory tract)
Did the wegener granulomatosis have a particular
involvement?
Yes
No
Was the involvement associated with wegener
granulomatosis the primary reason for
transplantation?
Yes
No
Specify the type of wegener granulomatosis
involvement: (Answer only if the answer to CDE
2749969 is "Renal" or "Other.")
Wegener Granulomatosis Laboratory
Procedures
For the wegener granulomatosis, what was the
laboratory procedure type?
Elisa Myeloperoxidase Antibody (Anti
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MPO)
Elisa Proteinase 3 Antibody (Anti Pr3)
Fluorescent Antibody Technique
Proteinase 3 Antibody (c-ANCA IFA)
Unknown Laboratory Procedure
Proteinase 3 Antibody (c-ANCA positive)
Fluorescent Antibody Technique
Myeloperoxidase Antibody (p-ANCA IFA)
For the wegener granulomatosis, what was the
result of the laboratory procedure?
Elevated (Elevated)
Normal (Normal)
Not Done: C49484 (Not Done)
Polyarteritis Nodosa Involvement
For the polyarteritis nodosa, classical or
microscopic, what was the involved organ or
clinical problem?
Gastrointestinal Tract (GI tract)
Mononeuritis Multiplex (Mononeuritis
multiplex)
Other (Other)
Pulmonary Hemorrhage (Pulmonary
hemorrhage)
Renal (Renal)
Skin (Skin)
Did the polyarteritis nodosa, classical or
microscopic, have a particular involvement?
Yes
No
Was the involvement associated with polyarteritis
nodosa, classical or microscopic, the primary
reason for transplantation?
Yes
No
Specify the type of polyarteritis nodosa, classical
or microscopic, involvement: (Answer only if the
answer to CDE 2750113 is "Renal" or "Other.")
Polyarteritis Nodosa Laboratory
Procedures
For the polyarteritis nodosa, classical or
microscopic, what was the laboratory procedure
type?
Unknown Laboratory Procedure
Proteinase 3 Antibody (c-ANCA positive)
Hepatitis Serological (Hepatitis serology)
Unknown Laboratory Procedure
Myeloperoxidase Antibody (p-ANCA
positive)
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For the polyarteritis, classical or microscopic,
what was the result of the laboratory procedure?
Elevated (Elevated)
Normal (Normal)
Not Done: C49484 (Not Done)
Rheumatoid Arthritis Involvement
For the rheumatoid arthritis, what was the
involved organ or clinical problem?
Destructive Arthritis (Destructive
arthritis)
Extra-articular (Extra-articular)
Eye (Eye)
Necrotizing Vasculitis (Necrotizing
vasculitis)
Other (Other)
Pulmonary (Pulmonary)
Did the rheumatoid arthritis have a particular
involvement?
Yes
No
Was the involvement associated with rheumatoid
arthritis the primary reason for transplantation?
Yes
No
Specify the type of rheumatoid arthritis
involvement: (Answer only if the answer to CDE
2750141 is "Eye", "Extra-articular," or "Other.")
Psoriatic Arthritis / Psoriasis Involvement
For the psoriatic arthritis / psoriasis, what was the
involved organ or clinical problem?
Destructive Arthritis (Destructive
arthritis)
Other (Other)
Psoriasis (Psoriasis)
Did the psoriatic arthritis / psoriasis have a
particular involvement?
Yes
No
Was the involvement associated with psoriatic
arthritis / psoriasis the primary reason for
transplantation?
Yes
No
For the psoriatic arthritis / psoriasis specify the
other involvement: (Answer only if the answer to
CDE 2750535 is "Other.")
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Multiple Sclerosis (ms) Involvement
For the multiple sclerosis, what was the involved
organ or clinical problem?
Other (Other)
Primary Progressive (Primary
progressive)
Recurrent Disease (Relapsing/remitting)
Secondary Progressive (Secondary
progressive)
Did the multiple sclerosis have a particular
involvement?
Yes
No
Was the involvement associated with multiple
sclerosis the primary reason for transplantation?
Yes
No
For the multiple sclerosis, specify the other
involvement: (Answer only if the answer to CDE
2749910 is "Other.")
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All rights reserved. Please visit https://medical-data-
models.org/forms/8840
2400 Revision 2  -  Pre-Transplant
Essential Data (TED)
Cibmtr Use Only
Sequence number:
Date received:
Center Identification
CIBMTR Center Number:
EBMT Code (CIC) Number
Hospital:
Unit:
Adult Patient Department (Adult)
Hematology Patient Department
(Hematology)
Oncology Patient Department
(Oncology)
Other Department (Other unit)
Pediatric Patient Department (Pediatric)
Specify the other unit name:
First Name
Last Name
Today's date:
Recipient Identification
CIBMTR Recipient ID (CRID):
What organization assigned the universal
recipient ID?
Center For International Blood And
Marrow Transplant Research (cibmtr)
(CIBMTR)
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European Group For Blood And Marrow
Transplantation (ebmt) (EBMT)
Other (Other)
Specify the organization that assigned the
universal recipient ID:
Study Id Number
What was the study ID number?
Recipient Identification
Was the study affiliated with BMT-CTN?
Yes (Yes)
Was the study affiliated with NMDP?
Yes (Yes)
Was the study affiliated with RCI-BMT?
Yes (Yes)
Was the study affiliated with SCTOD?
Yes (Yes)
Consented for research?
Yes
No
Consented for CIBMTR related specimen
repository?
Yes
No
Gender
Female Gender (Female Gender)
Male Gender (Male Gender)
Date of Birth
Ethnicity (Optional for non-US centers)
A Person Of Mexican, Puerto Rican,
Cuban, Central Or South American Or
Other Spanish Culture Or Origin,
Regardless Of Race. (Hispanic or Latino)
A Person Not Meeting The Definition For
Hispanic Or Latino. (Not Hispanic or
Latino)
Recipient Race
Race
A Person Having Origins In Any Of The
Original Peoples Of North And South
2 / 52
Treatment - 2400 Revision 2  -  Pre-Transplant Essential Data (TED) -
3002012v2.0
America (including Central America),
And Who Maintains Tribal Affiliation Or
Community Attachment. (American
Indian or Alaska Native)
A Person Having Origins In Any Of The
Original Peoples Of The Far East,
Southeast Asia, Or The Indian
Subcontinent Including, For Example,
Cambodia, China, India, Japan, Korea,
Malaysia, Pakistan, The Philippine
Islands, Thailand, And Vietnam. (Asian)
A Person Having Origins In Any Of The
Black Racial Groups Of Africa. Terms
Such As "haitian" Or "negro" Can Be
Used In Addition To "black Or African
American." (Black or African American)
A Person Having Origins In Any Of The
Original Peoples Of Hawaii, Guam,
Samoa, Or Other Pacific Islands. (Native
Hawaiian or other Pacific Islander)
A Person Having Origins In Any Of The
Original Peoples Of Europe, The Middle
East, Or North Africa. (White)
Disease Classification
What was the primary disease for which the
HSCT was performed?
All (Acute lymphoblastic leukemia (ALL))
Acute Myeloid Leukemia (Acute
myelogenous leukemia (AML or ANLL))
Autoimmune Disease (Autoimmune
Disorder)
Breast Carcinoma (Breast Cancer)
Chronic Myelogenous Leukemia
(Chronic myelogenous leukemia (CML))
Histiocytic Disorders (Histiocytic
disorders)
Hodgkin's Lymphoma (Hodgkin
lymphoma)
Immunodeficiency Syndrome (Immune
deficiencies)
Congenital Abnormalities Of Erythrocyte
Differentiation Or Function (Inherited
abnormalities of erythrocyte
differentiation or function)
Congenital Metabolic Disorder
Osteopetrosis (Inherited disorders of
metabolism / osteopetrosis)
Plasma Cell Myeloma (Multiple myeloma
/ plasma cell disorder (PCD))
Myelodysplastic/myeloproliferative
Disease (Myelodysplastic (MDS) /
myeloproliferative (MPS) disorders)
Non-hodgkin's Lymphoma (Non-Hodgkin
lymphoma)
Other Acute Leukemia (Other acute
leukemia)
Other Diseases And Disorders (Other
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disease)
Other Leukemia (Other leukemias)
Other Malignant Neoplasm (Other
malignancies)
Platelet Diseases And Disorders
(Platelet disorder)
Severe Aplastic Anemia (Severe aplastic
anemia)
What was the date of diagnosis of the primary
disease for which the hematopoietic stem cell
transplantation was performed?
Hematopoietic Stem Cell Transplant (hsct)
Date of hematopoietic stem cell transplantation
(HSCT) for which this form is being completed:
What is the chronological number of the current
hematopoietic stem cell transplantation?
Date of the most recent previous HSCT:
If there has been more than one hematopoietic
stem cell transplantation, what was the type of
the most recent previous hematopoietic stem cell
transplantation?
Allogeneic Hematopoietic Stem Cell
Transplantation (Allogeneic)
Autologous Stem Cell Transplantation
(Autologous)
If the institution where previous HSCT was
performed is different from the current HSCT,
what is the name of the institution?
If the institution where previous HSCT was
performed is different from the current HSCT,
what is the city where the institution is located?
If the institution where previous HSCT was
performed is different from the current HSCT,
what is the state where the institution is located?
If the institution where previous HSCT was
performed is different from the current HSCT,
what is the country where the institution is
located?
Product Type
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What type of hematopoietic stem cell transplant
was used?
Umbilical Cord Blood (Cord blood)
Bone Marrow (Marrow)
Multiple Umbilical Cord Blood (Multiple
cord blood units infused)
Other (Other)
Peripheral Blood Stem Cell (PBSC)
Was a particular hematopoietic stem cell
transplant type used?
Yes
No
Specify the other hematopoietic stem cell
transplant type: (Answer only if the value for
2730912 is "Other")
Autologous Hsct
Autologous HSCT?
Yes
No
What is the number of hematopoietic stem cell
products that resulted from different collection
methods or episodes and or mobilization
techniques? (A series of collections should be
considered a single product when they are all
from the same donor and use the same collection
method and technique and mobilization, if
applicable, even if the collections are performed
on different days.)
Hematopoietic Stem Cell Transplant (hsct)
Did the hematopoietic stem cell transplant consist
of multiple donors?
Yes
No
Specify number of donors:
Donor Information
For allogeneic HSCT, was the donor gender
male?
Yes
No
For allogeneic HSCT, was the donor gender
female?
Yes
No
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What type of donor was used for this
hematopoietic stem cell transplant?
Mhc Class I Protein Mhc Class Ii Protein
Identical Sibling (HLA-identical sibling)
Mhc Class I Protein Mhc Class Ii Protein
Other Relative (HLA-matched other
relative)
Mhc Class I Protein Mhc Class Ii Protein
Mismatch Relative (HLA-mismatched
relative)
Syngeneic (Syngeneic)
Donor Unrelated (Unrelated donor)
For an HLA-mismatched related donor, what was
the degree of mismatch:
Integer::1 Mhc Class I Protein Antigen
Mismatch (1 HLA antigen mismatch)
Greater Than Integer::2 Mhc Class I
Protein Antigen Mismatch (greater than
or equal to 2 HLA antigen mismatch (full
haploidentical))
Registry or UCB Bank:
(a) Austrian Bone Marrow Donors (A)
(acb) Austrian Cord Blood Registry
(ACB)
(accb) Stemcyte, Inc. (ACCB)
(ae) Emirates Bone Marrow Donor
Registry (AE)
(am) Armenian Bone Marrow Donor
Registry Charitable Trust (AM)
(aocb) University Of Colorado Cord
Blood Bank (AOCB)
(ar) Argentine Cph Donors Registry (AR)
(arcb) Bancel - Argentina Cord Blood
Bank (ARCB)
(aucb) Australian Cord Blood Registry
(AUCB)
(aus) Australia / New Zealand Bone
Marrow Donor Registry (AUS)
(b) Marrow Donor Program Belgium (B)
(bcb) Belgium Cord Blood Registry
(BCB)
(bg) Bulgarian Bone Marrow Donor
Registry (BG)
(br) Inca/redomo (BR)
(bscb) British Bone Marrow Registry -
Cord Blood (BSCB)
(ch) Swiss Bloodstem Cells - Adult
Donors (CH)
(chcb) Swiss Blood Stem Cells - Cord
Blood (CHCB)
(ckcb) Celgene Cord Blood Bank
(CKCB)
(cn) China Marrow Donor Program
(cmdp) (CN)
(cncb) Shan Dong Cord Blood Bank
(CNCB)
(cnd) Canadian Blood Services Bone
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Marrow Donor Registry (CND)
(cs2) Czech National Marrow Donor
Registry (CS2)
(cscr) Czech Stem Cells Registry
(CSCR)
(cy) Cyprus Paraskevaidio Bone Marrow
Donor Registry (CY)
(cy2) The Cyprus Bone Marrow Donor
Registry (CY2)
(d) Zkrd - Zentrales
Knochenmarkspender - Register
Deutschland Adult Donors (D)
(dcb) Zkrd - Zentrales
Knochenmarkspender - Register
Deutschland Cord Blood (DCB)
(dk) The Danish Bone Marrow Donor
Registry (DK)
(dk2) Bone Marrow Donors Copenhagen
(bmdc) (DK2)
(ducb) German Branch Of The European
Cord Blood Bank (DUCB)
(e) Redmo (E)
(ecb) Spanish Cord Blood Registry
(ECB)
(f) France Greffe De Moelle - Adult
Donors (F)
(fcb) France Greffe De Moelle - Cord
Blood (FCB)
(fi) Finnish Bone Marrow Donor Registry
(FI)
(ficb) Finnish Cord Blood Registry (FICB)
(gb) The Anthony Nolan Trust (GB)
(gb3) Welsh Bone Marrow Donor
Registry (GB3)
(gb4) British Bone Marrow Registry
(GB4)
(gr) Unrelated Hematopoietic Stem Cell
Donor Registry Greece (GR)
(grcb) Michigan Community Blood
Centers Cord Blood Bank (GRCB)
(h) Hungarian Bone Marrow Donor
Registry (H)
(hk) Hong Kong Bone Marrow Donor
Registry (HK)
(hr) Croatian Bone Marrow Donor
Registry (HR)
(i) Italian Bone Marrow Donor Registry (I)
(i3cb) Sheba Medical Centre Cord Blood
Registry (I3CB)
(icb) Italian Cord Blood Bank Network
(ICB)
(il) Hadassah Bmdr (IL)
(il2) Ezer Mizion Bone Marrow Donor
Registry (IL2)
(il3) Sheba Medical Center Donor
Registry (IL3)
(ilcb) Isreal Cord Blood Bank (ILCB)
(in) Asian Indian Donor Marrow Registry
(IN)
(in2) Dept. Of Transfusion Medicine (IN2)
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International-unable To Answer
(INTL_UA)
(irl) The Irish Unrelated Bone Marrow
Panel (IRL)
(jp) Japan Marrow Donor Program (JP)
(kr) Korea Marrow Donor Program (KR)
(lt) Lithuanian National Bone Marrow
Donor Registry (LT)
(lvcb) Leuven Cord Blood Bank (LVCB)
(macb) Victoria Angel Registry Of Hope
(MACB)
(mx) Mexican Bone Marrow Donor
Registry (MX)
(n) The Norwegian Bone Marrow Donor
Registry (N)
(nl) Europdonor Foundation- Adult
Donors (NL)
(nlcb) Europdonor Foundation - Cord
Blood (NLCB)
(nycb) National Cord Blood Program,
New York Blood Center (NYCB)
(p) Portuguese Bone Marrow Donors
Registry (P)
(pl) National Polish Bone Marrow
Registry (PL)
(pl2) Unrelated Bone Marrow Donor
Registry -adult Donors (PL2)
(pl3) Against Leukemia Foundation
Marrow Donor Registry (PL3)
(pl4) Ursula Jaworska Foundation - Bone
Marrow Donor Registry (PL4)
(pl5) Polish Central Bone Marrow Donor
Registry - Adult Donors (PL5)
(pmcb) Elie Katz Umbilical Cord Blood
Program (PMCB)
(r) Russian Bone Marrow Donor Registry
(R)
(r2) Karelian Registry Of Unrelated
Donors Of Hematopoietic Stem Cells
(R2)
(s) Tobias Registry Of Swedish Bone
Marrow Donors (S)
(sg) Singapore Bone Marrow Donor
Programme (bmdp) (SG)
(sk) Slovak National Bone Marrow Donor
Registry (SK)
(skcb) Eurocord Slovakia / Slovak
Pacental Stem Cell Registry (SKCB)
(slo) Slovenia Donor (SLO)
(sm) San Marino Bone Marrow Donor
Registry (SM)
(t1cb) Tran - Cord Blood (T1CB)
(tacb) Stemcyte, Inc. Taiwan (TACB)
(tecb) Healthbanks Biotech, Co., Ltd
(TECB)
(th) Thai Stem Cell Donor Registry
(tscdr) (TH)
(tocb) Tokyo Cord Blood Bank (TOCB)
(tpcb) Bionet / Babybanks (TPCB)
(tran) Tran - Adult Donors (TRAN)
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(tris) Bone Marrow Bank Of Istanbul
Medical Faculty (TRIS)
(tw) Buddhist Tzu Chi Stem Cells Center
- Adult Donors (TW)
(twcb) Buddhist Tzu Chi Stem Cells
Center - Cord Blood (TWCB)
(u1cb) National Marrow Donor Program -
Cord Blood (U1CB)
(u3cb) Caitlin Raymond International
Registry - Cord Blood (U3CB)
(u4cb) Gift Of Life Bone Marrow
Foundation - Cord Blood (U4CB)
(usa1) National Marrow Donor Program -
Adult Donors (USA1)
(usa2) America Bone Marrow Donor
Registry (USA2)
(usa3) Caitlin Raymond International
Registry -adult Donors (USA3)
(usa4) Gift Of Life Bone Marrow
Foundation - Adult Donors (USA4)
(uy) Sindome (UY)
(w3cb) Polish Central Bone Marrow
Donor Registry - Cord Blood (W3CB)
(wacb) Unrelated Bone Marrow Donor
Registry - Cord Blood (WACB)
(za) South African Bone Marrow Registry
(ZA)
Specify other Registry or UCB Bank:
How many mismatches were there for the HLA -
A antigenic test? (2 digits)
Match (0)
Integer::1 Mismatch (1)
Integer::2 Mismatch (2)
Without Evaluation (ND)
How many mismatches were there for the HLA -
B antigenic test? (2 digits)
Match (0)
Integer::1 Mismatch (1)
Integer::2 Mismatch (2)
Without Evaluation (ND)
How many mismatches were there for the HLA -
C antigenic test? (2 digits)
Match (0)
Integer::1 Mismatch (1)
Integer::2 Mismatch (2)
Without Evaluation (ND)
How many mismatches were there for the HLA -
DRB1 antigenic test? (2 digits)
Match (0)
Integer::1 Mismatch (1)
Integer::2 Mismatch (2)
Without Evaluation (ND)
How many mismatches were there for the HLA -
DQB1 antigenic test? (2 digits)
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Match (0)
Integer::1 Mismatch (1)
Integer::2 Mismatch (2)
Without Evaluation (ND)
How many mismatches were there for the HLA -
DPB1 antigenic test? (2 digits)
Match (0)
Integer::1 Mismatch (1)
Integer::2 Mismatch (2)
Without Evaluation (ND)
How many mismatches were there for the HLA -
A allelic test? (4 digits)
Match (0)
Integer::1 Mismatch (1)
Integer::2 Mismatch (2)
Without Evaluation (ND)
How many mismatches were there for the HLA -
B allelic test? (4 digits)
Match (0)
Integer::1 Mismatch (1)
Integer::2 Mismatch (2)
Without Evaluation (ND)
How many mismatches were there for the HLA -
C allelic test? (4 digits)
Match (0)
Integer::1 Mismatch (1)
Integer::2 Mismatch (2)
Without Evaluation (ND)
How many mismatches were there for the HLA -
DRB1 allelic test? (4 digits)
Match (0)
Integer::1 Mismatch (1)
Integer::2 Mismatch (2)
Without Evaluation (ND)
How many mismatches were there for the HLA -
DQB1 allelic test? (4 digits)
Match (0)
Integer::1 Mismatch (1)
Integer::2 Mismatch (2)
Without Evaluation (ND)
How many mismatches were there for the HLA -
DPB1 allelic test? (4 digits)
Match (0)
Integer::1 Mismatch (1)
Integer::2 Mismatch (2)
Without Evaluation (ND)
Hematopoietic Stem Cell Transplant (hsct)
Was there ex vivo graft manipulation other than
for RBC removal or volume reduction?
Yes
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No
Ex Vivo Graft Manipulation Type
What was the method of ex vivo graft
manipulation other than for RBC removal or
volume reduction? (Optional for non-U.S.
Centers)
Cd34 Selection (CD34 selection)
Ex Vivo Increase (Ex vivo expansion)
Other Ex Vivo Manipulation (Other)
Other Negative Selection (Other negative
selection)
T-cell Depletion (T-cell depletion)
Tumor Purging (Tumor purging)
Was a particular method of ex vivo graft
manipulation other than for RBC removal or
volume reduction performed? (Optional for non-
U.S. centers)
Yes
No
Specify the ex vivo graft manipulation other than
for RBC removal or volume reduction: (Optional
for non-U.S. centers. Answer this CDE only if the
answer to CDE 2750679 is "Other negative
selection" or "other." )
Hematopoietic Stem Cell Transplant (hsct)
Which scale was used to measure/report the
functional status? (Prior to the start of the
preparative regimen)
Karnofsky Performance Status
(Karnofsky)
Lansky Play-performance Status
(Lansky)
Performance Status (Karnofsky) (Prior to the start
of the preparative regimen)
Moribund, Fatal Processes Progressing
Rapidly (10)
Normal, No Complaints, No Evidence Of
Disease (100)
Very Sick, Hospitalization Indicated.
Death Not Imminent (20)
Severely Disabled, Hospitalization
Indicated. Death Not Imminent (30)
Disabled, Requires Special Care And
Assistance (40)
Requires Considerable Assistance And
Frequent Medical Care (50)
Requires Occasional Assistance, But Is
Able To Care For Most Of His/her Needs
(60)
Cares For Self, Unable To Carry On
Normal Activity Or To Do Active Work
11 / 52
Treatment - 2400 Revision 2  -  Pre-Transplant Essential Data (TED) -
3002012v2.0
(70)
Normal Activity With Effort; Some Signs
Or Symptoms Of Disease (80)
Able To Carry On Normal Activity; Minor
Signs Or Symptoms Of Disease (90)
Performance Status (Lansky) (Prior to the start of
the preparative regimen)
No Play; Does Not Get Out Of Bed. (10)
Fully Active, Normal (100)
Often Sleeping; Play Entirely Limited To
Very Passive Activities. (20)
In Bed; Needs Assistance Even For
Quiet Play. (30)
Mostly In Bed; Participates In Quiet
Activities. (40)
Gets Dressed, But Lies Around Much Of
The Day; No Active Play, Able To
Participate In All Quiet Play And
Activities. (50)
Up And Around, But Minimal Active Play;
Keeps Busy With Quieter Activities. (60)
Both Greater Restriction Of And Less
Time Spent In Play Activity (70)
Active, But Tires More Quickly (80)
Minor Restrictions In Physically
Strenuous Activity (90)
What was the recipient's test results for the
presence of CMV-antibodies? (IgG or Total )
Not Reaction (Non-reactive)
Not Done: C49484 (Not Done)
Reaction (Reactive)
Unknown (Unknown)
What was the donor test results for the presence
of CMV-antibodies? (allo only Multiple donors:
report any positive CMV test as reactive, IgG or
Total)
Not Reaction (Non-reactive)
Not Done: C49484 (Not Done)
Reaction (Reactive)
Unknown (Unknown)
Preparative Regimen
Was a preparative regimen given?
Yes
No
Was total body irradiation given as a preparative
regimen? (TBI)
Yes
No
What was the total prescribed cumulative dose of
total body irradiation for the preparative regimen
(per the protocol)? (TBI)
12 / 52
Treatment - 2400 Revision 2  -  Pre-Transplant Essential Data (TED) -
3002012v2.0
What was the unit of measure for the total
prescribed cumulative dose of total body
irradiation for the preparative regimen (per the
protocol)? (TBI)
Centigray (cGy)
Gray (Gy)
Was total nodal or total abdominal irradiation
given as a preparative regimen? (TLI, TNI, TAI)
Yes
No
What was the total prescribed cumulative dose of
total nodal or total abdominal irradiation for the
preparative regimen (per the protocol)? (TLI, TNI,
TAI)
What was the unit of measure for the total
prescribed cumulative dose of total nodal or total
abdominal irradiation for the preparative regimen
(per the protocol)? (TLI, TNI, TAI)
Centigray (cGy)
Gray (Gy)
Preparative Regimen - General
Medication
What was the type of preparative regimen
medication?
Antithymocyte Globulin Antilymphocyte
Serum (ALG, ALS, ATG, ATS (before
d0))
Anthracycline Antibiotic (Anthracycline)
Bleomycin (Bleomycin)
Busulfan (Busulfan)
Carboplatin (Carboplatin)
Carmustine (Carmustine (BCNU))
Cisplatin Medication (Cisplatin)
Corticosteroid Medication
(Corticosteriods)
Cyclophosphamide Medication
(Cyclophosphamide)
Cytosine Arabinoside (Cytarabine (Ara-
C))
Etoposide (Etoposide (VP-16))
Fludarabine (Fludarabine)
Ifosfamide (Ifosfamide)
Imatinib Mesylate (Imanitib mesylate
(Gleevec, Glivec))
Lomustine (Lomustine (CCNU))
Melphalan (Melphalan (L-PAM))
Mitoxantrone (Mitoxantrone)
Monoclonal Antibody (Monoclonal
Antibody)
Other (Other)
Paclitaxel (Paclitaxel (Taxol, Xyotax))
Radiolabeled Monoclonal Antibody
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(Radiolabeled MAb)
Teniposide (Teniposide (VM26))
Thiotepa (Thiotepa)
Was a particular preparative regimen medication
administered per the protocol?
Yes
No
What was the total dose of the planned
preparative regimen per the protocol?
What was the unit of measure for the preparative
regimen dose per the protocol? (Do not answer if
the answer to CDE 2739625 is
"Anthracycline","Monoclonal Antibody" or
"Radiolabled MAb".)
Milligram Per Kilogram (mg/kg)
Milligram Per Meter Squared (mg/m2)
Specify the source of the preparative regimen
medication: (Answer this CDE only if the answer
to CDE 2739625 is ALG, ALS, ATG, ATS before
d0)
Horse (Horse)
Other Source (Other source)
Rabbit (Rabbit)
Specify the other source of the preparative
regimen medication: (Answer this CDE only if the
answer to CDE 2753241 is OTHER.)
What was the route of administration for the
planned preparative regimen medication?
(Answer this CDE only if the value to CDE
2739625 is "Busulfan.")
Oral Route Of Administration Intravenous
Route Of Administration (Both)
Intravenous Route Of Administration (IV)
Oral Route Of Administration (Oral)
Specify the other type of preparative regimen
medication: (Answer this CDE only if the answer
to CDE 2739625 is "Other.")
Preparative Regimen - Anthracyclines
What was the type of anthracycline preparative
regimen?
Daunorubicin (Daunorubicin)
Doxorubicin (Doxorubicin)
Idarubicin (Idarubicin)
Was an anthracycline planned as a preparative
regimen?
Yes
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No
What was the total dose of the planned
preparative regimen per the protocol?
What was the unit of measure for the planned
dosage of the anthracycline preparative regimen?
Milligram Per Kilogram (mg/kg)
Milligram Per Meter Squared (mg/m2)
Preparative Regimen - Monoclonal
Antibodies (mab)
What was the type of preparative regimen
monoclonal antibody (MAb)?
Alemtuzumab (Campath)
Gemtuzumab Ozogamicin (Gemtuzumab
(mylotarg, anti-CD33))
Other Monoclonal Antibody (Other MAb)
Rituximab (Rituximab (Rituxan, anti-
CD20))
Was a monoclonal antibody planned as a
preparative regimen?
Yes
No
What was the total dose of the planned
preparative regimen per the protocol?
What was the unit of measure for the planned
dosage of the monoclonal antibody preparative
regimen?
Milligram Per Kilogram (mg/kg)
Milligram Per Meter Squared (mg/m2)
Specify the other type of the monoclonal antibody
preparative regimen: (Answer only if the answer
to CDE 2741209 is "Other MAb.")
Preparative Regimen - Radiolabeled Mab
What type of radiolabeled monoclonal antibody
was used as a   preparative regimen?
Ibritumomab Tiuxetan (Ibritumomab
(Zevalin))
Other Radiolabeled Monoclonal Antibody
(Other rMAb)
Tositumomab (Tositumomab (Bexxar))
Was a radiolabeled monoclonal antibody planned
as a preparative regimen?
Yes
No
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What was the planned total dosage of the
radiolabeled monoclonal antibody preparative
regimen?
What was the unit of measure for the planned
dosage of the radiolabeled monoclonal antibody
preparative regimen?
Megabecquerel (MBq)
Millicurie (mCi)
Specify the other type of the radiolabeled
monoclonal antibody preparative regimen:
(Answer only if the answer to CDE 2741552 is
"Other rMAb.")
Intent Of Preparative Regimen
Is the INTENT of the preparative regimen
MYELOABLATIVE (allogeneic only)?
Yes
No
Reason For Nst / Ric
What was the reason for the reduced intensity/
non-myeloablative preparative regimen?
Recipient Age (Age of recipient)
Comorbidity (Comorbid conditions)
Other (Other)
Prior Hematopoietic Stem Cell
Transplantation (Prior HSCT)
Protocol (Protocol-driven)
Did a particular reason for the non-myeloablative
/ reduced intensity preparative regimen occur?
Yes
No
Specify the other reason for the non-
myeloablative / reduced intensity (NST / RIC)
preparative regimen: (Answer only if the answer
to CDE 2737040 is "Other.")
Comorbid Conditions
Is there a history of mechanical ventilation?
Yes
No
Is there a history of proven invasive fungal
infection?
Yes
No
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Was there any involvement of clinically significant
co-existing diseases or organ impairment at any
time prior to preparative regimen?
Yes
No
Type Of Comorbid Condition
What was the clinically significant co-existing
disease or organ impairment?
Arrhythmia. (Arrhythmia)
Cardiac. (Cardiac)
Cerebrovascular Disease.
(Cerebrovascular disease)
Diabetes. (Diabetes)
Heart Valve Disease. (Heart valve
disease)
Hepatic, Mild. (Hepatic, mild)
Hepatic, Moderate / Severe. (Hepatic,
moderate / severe)
Infection. (Infection)
Inflammatory Bowel Disease.
(Inflammatory bowel disease)
Obesity. (Obesity)
Other (Other)
Peptic Ulcer. (Peptic ulcer)
Psychiatric Disturbance (Psychiatric
disturbance)
Pulmonary, Moderate. (Pulmonary,
moderate)
Pulmonary, Severe. (Pulmonary, severe)
Renal, Moderate / Severe. (Renal,
moderate / severe)
Rheumatologic (2) (Rheumatologic)
Solid Tumor, Prior. (Solid tumor, prior)
Was a particular clinically significant comorbidity
present before the start of the preparative
regimen?
No: C49487 (No)
Not Done: C49484 (Not Done)
Yes: C49488 (Yes)
Specify the other type of clinically significant
comorbidity: (Answer only if the answer to CDE
2737130 is "Other.")
Gvhd Prophylaxis (allo Only)
Was GVHD prophylaxis planned / given?
Yes
No
Was ALG, ALS, ATG, ATS (after d0) therapy used
after the start of the preparative regimen to
prevent acute GVHD or graft rejection?
Yes
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No
Was corticosteroid (systemic) therapy used after
the start of the preparative regimen to prevent
acute GVHD or graft rejection?
Yes
No
Was cyclosporine (CSA) (Sandimmune, Neoral)
therapy used after the start of the preparative
regimen to prevent acute GVHD or graft
rejection?
Yes
No
Was ECP (extra-corporeal photopheresis)
therapy used after the start of the preparative
regimen to prevent acute GVHD or graft
rejection?
Yes
No
Was FK 506 (Tacrolimus, Prograf) therapy used
after the start of the preparative regimen to
prevent acute GVHD or graft rejection?
Yes
No
Was methotrexate (MTX) (Amethopterin) used
after the start of the preparative regimen to
prevent acute GVHD or graft rejection?
Yes
No
Was an in vivo monoclonal antibody used after
the start of the preparative regimen to prevent
acute GVHD or graft rejection?
Yes
No
Was anti CD 25 (Zenapax, Daclizumab, AntiTAC)
the in vivo monoclonal antibody used after the
start of the preparative regimen to prevent acute
GVHD or graft rejection?
Yes
No
Was campath the in vivo monoclonal antibody
used after the start of the preparative regimen to
prevent acute GVHD or graft rejection?
Yes
No
Was etanercept (Enbrel) the in vivo monoclonal
antibody used after the start of the preparative
regimen to prevent acute GVHD or graft
rejection?
Yes
No
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Was infliximab (Remicade) the in vivo monoclonal
antibody used after the start of the preparative
regimen to prevent acute GVHD or graft
rejection?
Yes
No
Was some other in vivo monoclonal antibody
used after the start of the preparative regimen to
prevent acute GVHD or graft rejection?
Yes
No
Specify the other in vivo monoclonal antibody
used after the start of the preparative regimen to
prevent acute GVHD or graft rejection
Was mycophenolate mofetil (MMF) (CellCept)
used after the start of the preparative regimen to
prevent acute GVHD or graft rejection?
Yes
No
Was sirolimus (Rapamycin, Rapamune) used
after the start of the preparative regimen to
prevent acute GVHD or graft rejection?
Yes
No
Was some other agent used after the start of the
preparative regimen to prevent acute GVHD or
graft rejection?
Yes
No
Specify the other agent used after the start of the
preparative regimen to prevent acute GVHD or
graft rejection
Post-hsct Disease Therapy Planned As Of
Day 0
Is this HSCT part of a planned multiple
(sequential) graft / HSCT protocol?
Yes
No
Is additional post-HSCT therapy planned?
Yes
No
Type Of Additional Post-hsct Therapy
What was the type of post-hematopoietic stem
cell transplantation (HSCT) therapy?
Bortezomib (Bortezomib (Velcade))
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Cellular Therapy (Cellular therapy (e.g.
DCI, DLI))
Imatinib Mesylate (Imanitib mesylate
(Gleevec, Glivec))
Intrathecal Chemotherapy (Intrathecal
chemotherapy)
Lenalidomide (Lenalidomide (Revlimid))
Local Radiation Therapy (Local
radiotherapy)
Other (Other)
Rituximab (Rituximab (Rituxan,
Mabthera))
Thalidomide (Thalidomide (Thalomid))
Was a particular post-hematopoietic stem cell
transplantation (HSCT) therapy planned?
Yes
No
Specify the other planned post-HSCT therapy:
(Answer this CDE only if the answer to CDE
2738487 is "Other.")
Other Toxicity Modifying Regimen
Was KGF (palifermin, Kepivance) started or is
there a plan to use it?
Blinded Clinical Study (Masked trial)
No: C49487 (No)
Yes (Yes)
As part of a toxicity modifying regimen, was FGF
(velafermin) started or is there a plan to use it?
Blinded Clinical Study (Masked trial)
No: C49487 (No)
Yes (Yes)
Pre-transplant Essential Data Disease
Classification Sheet
What was the primary disease for which the
HSCT was performed?
All (Acute lymphoblastic leukemia (ALL))
Acute Myeloid Leukemia (Acute
myelogenous leukemia (AML or ANLL))
Autoimmune Disease (Autoimmune
Disorder)
Breast Carcinoma (Breast Cancer)
Chronic Myelogenous Leukemia
(Chronic myelogenous leukemia (CML))
Histiocytic Disorders (Histiocytic
disorders)
Hodgkin's Lymphoma (Hodgkin
lymphoma)
Immunodeficiency Syndrome (Immune
deficiencies)
Congenital Abnormalities Of Erythrocyte
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Differentiation Or Function (Inherited
abnormalities of erythrocyte
differentiation or function)
Congenital Metabolic Disorder
Osteopetrosis (Inherited disorders of
metabolism / osteopetrosis)
Plasma Cell Myeloma (Multiple myeloma
/ plasma cell disorder (PCD))
Myelodysplastic/myeloproliferative
Disease (Myelodysplastic (MDS) /
myeloproliferative (MPS) disorders)
Non-hodgkin's Lymphoma (Non-Hodgkin
lymphoma)
Other Acute Leukemia (Other acute
leukemia)
Other Diseases And Disorders (Other
disease)
Other Leukemia (Other leukemias)
Other Malignant Neoplasm (Other
malignancies)
Platelet Diseases And Disorders
(Platelet disorder)
Severe Aplastic Anemia (Severe aplastic
anemia)
Acute Leukemias
What was the W.H.O classification of the acute
myelogenous leukemia (AML) or acute
nonlymphocytic leukemia (ANLL)?
Acute Basophilic Leukemia (Acute
Basophilic Leukemia)
Acute Erythroid Leukemia (Acute
Erythroid Leukemia (erythroid / myeloid
and pure erythroleukemia) / {M6})
Acute Megakaryoblastic Leukemia
(Acute Megakaryoblastic Leukemia  /
{M7})
Acute Monoblastic Leukemia And Acute
Monocytic Leukemia (Acute Monoblastic
Leukemia / Acute Monocytic Leukemia /
{M5})
Not Otherwise Specified Acute Myeloid
Leukemia (Acute Myeloid Leukemia Not
Otherwise Specified)
Acute Myeloid Leukemia With Maturation
(Acute Myeloid Leukemia with Maturation
/ {M2})
Acute Myeloid Leukemia Without
Maturation (Acute Myeloid Leukemia
without Maturation / {M1})
Acute Myeloid Leukemia, Minimally
Differentiated (Acute Myeloid Leukemia,
Minimally Differentiated / {M0})
Acute Myelomonocytic Leukemia (Acute
Myelomonocytic Leukemia / {M4})
Acute Panmyelosis With Myelofibrosis
(Acute Panmyelosis with Myelofibrosis)
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Acute Myeloid Leukemia With 11q23
(mll) Abnormalities (AML with 11q23
(MLL) abnormalities)
Acute Myeloid Leukemia With Abnormal
Marrow Eosinophils (AML with abnormal
bone marrow eosinophils and
inv(16)(p13;q22) or t(16;16) (p13;q22),
(CBF beta/MYH11))
Acute Myeloid Leukemia With
Multilineage Dysplasia (AML with multi-
lineage dysplasia)
Acute Myeloid Leukemia With
T(8;21)(q22;q22)(aml1(cbfa)/eto) (AML
with t(8;21) (q22;q22) (AML1 / ETO))
Acute Promyelocytic Leukemia With
T(15;17)(q22;q12)(pml/rara) (APL with
t(15;17)(q22;q12),(PML/RAR alpha) and
variant /  {M3})
Myeloid Sarcoma (Myeloid Sarcoma)
Did AML transform from MDS / MPS? (Complete
entire MDS Section on Disease Classification on
page 10-11 - of PDF copy, questions 222-234
and entire AML Section page 7-8 of PDF copy,
questions 178-189, 2682630, 2494567, 2648560,
2675109, 2685090, 2674686, 2676456, 2676461,
2676467,2737648,2737653,2738448,2738429,27
38414,2866534,2674563,2648566,2738465,2738
473,2674599,2686057,2686068,2686091,268882
4)
Yes
No
Was AML therapy-related?
No (No)
Unknown (Unknown)
Yes (Yes)
Type Of Therapy Related Aml
What was the cause of the therapy related AML?
Alkylating Agent Radiation Therapy
Related (Alkylating agent / radiation-
related)
Topoisomerase-ii Inhibitor Related
(Topoisomerase II inhibitor-related)
Unknown (Unknown)
Did a particular cause of therapy-related AML
occur?
Yes
No
Acute Leukemias
Was imatinib mesylate given as pretransplant
therapy for the acute myeloid leukemia anytime
prior to start of preparative regimen?
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No (No)
Unknown (Unknown)
Yes (Yes)
What was the status of the acute myelogenous
leukemia (AML) or acute nonlymphocytic
leukemia (ANLL) at the time of transplantation?
Complete Remission (Complete
Remission)
Never Therapeutic Procedure (Never
treated)
Primary Induction Failure (Primary
Induction Failure (PIF))
Recurrent Disease (Relapse)
For patients with hematologic CR, was a
cytogenetic CR also achieved at the time of
transplantation?
No (No)
Unknown (Unknown)
Yes (Yes)
For patients with hematologic CR, was a
molecular CR also achieved at the time of
transplantation?
No (No)
Unknown (Unknown)
Yes (Yes)
At the time of transplantation, what was the
number of the complete remission of acute
myeloid leukemia?
First (First)
Second:c25666 (Second)
Greater Third (Third or higher)
At the time of transplantation, what was the
number of the relapse of acute myeloid
leukemia?
First (First)
Second:c25666 (Second)
Greater Third (Third or higher)
Acute Lymphoblastic Leukemia (all)
Specify the type of acute lymphoblastic leukemia
(ALL):
Not Otherwise Specified All (ALL, NOS)
Precursor B-lymphoblastic Leukemia
(Precursor B-cell ALL (L1/L2))
Precursor T-lymphoblastic Leukemia
(Precursor T-Cell ALL)
T(1;19)(q23;p13.3) (t(1;19)(q23;p13)
E2A/PBX1)
T(21;22)(q22;q12) (t(12;21)(p12;q22)
ETV / CBF-alpha)
T(9;22)(q34;q11) (t(9;22)(q34;q11);
BCR/ABL+)
T(v;11)(v;q23) (t(v;11q23); MLL
23 / 52
Treatment - 2400 Revision 2  -  Pre-Transplant Essential Data (TED) -
3002012v2.0
rearranged)
Was imatinib mesylate given as pretransplant
therapy for acute lymphoblastic leukemia (ALL)
anytime prior to start of preparative regimen?
No (No)
Unknown (Unknown)
Yes (Yes)
What was the status of the acute lymphoblastic
leukemia (ALL) at the time of transplantation?
Complete Remission (Complete
Remission)
Never Therapeutic Procedure (Never
treated)
Primary Induction Failure (Primary
Induction Failure (PIF))
Recurrent Disease (Relapse)
At the time of transplantation, was the type of
hematologic complete remission of the acute
lymphoblastic leukemia (ALL) cytogenetic
remission?
No (No)
Unknown (Unknown)
Yes (Yes)
At the time of transplantation, was the type of
hematologic complete remission of the acute
lymphoblastic leukemia (ALL) molecular
remission?
No (No)
Unknown (Unknown)
Yes (Yes)
At the time of transplantation, what was the
number of the complete remission of acute
lymphoblastic leukemia (ALL)?
First (First)
Second:c25666 (Second)
Greater Third (Third or higher)
At the time of transplantation, what was the
number of the relapse of acute lymphoblastic
leukemia (ALL)?
First (First)
Second:c25666 (Second)
Greater Third (Third or higher)
Other Acute Leukemia
What was the W.H.O. classification of the other
acute leukemia?
Acute Mast Cell Leukemia (Acute  Mast
Cell Leukemia)
Acute Undifferentiated Leukemia (Acute
Undifferentiated Leukemia)
Acute Biphenotypic Leukemia
(biphenotypic, bilineage or hybrid
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leukemia)
Other Acute Leukemia (Other  Acute
Leukemia)
Specify the type of other acute leukemia:
Was imatinib mesylate given for pretransplant
therapy for the other acute leukemia anytime prior
to the start of the preparative regimen?
No (No)
Unknown (Unknown)
Yes (Yes)
What was the status of the other acute leukemia
at the time of transplantation?
Complete Remission (Complete
Remission)
Never Therapeutic Procedure (Never
treated)
Primary Induction Failure (Primary
Induction Failure (PIF))
Recurrent Disease (Relapse)
For patients with complete remission of the other
acute leukemia, was a cytogenetic complete
remission also achieved at the time of
transplantation?
No (No)
Unknown (Unknown)
Yes (Yes)
For patients with complete remission of the other
acute leukemia, was a molecular complete
remission also achieved at the time of
transplantation?
No (No)
Unknown (Unknown)
Yes (Yes)
At the time of transplantation, what was the
number of the complete remission of the other
acute leukemia?
First (First)
Second:c25666 (Second)
Greater Third (Third or higher)
At the time of transplantation, what was the
number of the relapse of the other acute
leukemia?
First (First)
Second:c25666 (Second)
Greater Third (Third or higher)
Chronic Myelogenous Leukemia (cml)
What was the classification of the chronic
myelogenous leukemia (Philadelphia
chromosome+, Ph+, t(9;22)(q34;q11), or variant
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OR bcr/abl+)?
Ph Unknown/bcr+ (Ph Unknown/BCR+)
Ph-/bcr+ (Ph-/BCR+)
Ph+/bcr Unknown (Ph+/BCR Unknown)
Ph+/bcr- (Ph+/BCR-)
Ph+/bcr+ (Ph+/BCR+)
Did the recipient receive treatment for chronic
myelogenous leukemia prior to this HSCT?
Yes
No
Cml Prior Hsct Treatment
What type of treatment did the recipient receive
prior to the hematopoietic stem cell
transplantation (HSCT)?
Combination Chemotherapy
(Combination chemotherapy)
Dasatinib (Dasatinib (Sprycel))
Hydroxyurea (Hydroxyurea (HU))
Imatinib Mesylate (Imatinib mesylate
(Gleevec, Glivec))
Interferon (Interferon)
Nilotinib (Nilotinib (Tasigna))
Other (Other)
Was a treatment administered prior to this
hematopoietic stem cell transplantation?
Yes
No
Specify the other type of therapy that the
recipient received prior to this hematopoietic stem
cell transplantation (HSCT): (Answer only if the
answer to CDE 2737666 is "Other.")
Chronic Myelogenous Leukemia (cml)
What was the phase of the CML at the time of
transplantation?
Accelerated Phase Chronic
Myelogenous Leukemia (Accelerated
Phase)
Blast Phase Chronic Myelogenous
Leukemia (Blast crisis)
Chronic Phase Chronic Myelogenous
Leukemia (Chronic phase)
Hematologic Cr (Hematologic complete
remission)
If the CML was in hematologic complete
remission, what was the disease status before
treatment?
Accelerated Phase Chronic
Myelogenous Leukemia (Accelerated
Phase)
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Blast Phase Chronic Myelogenous
Leukemia (Blast crisis)
Chronic Phase Chronic Myelogenous
Leukemia (Chronic phase)
At the time of transplantation, was the type of
hematologic complete remission of the chronic
myelogenous leukemia also a cytogenetic
remission?
Complete (Complete)
Cytogenetics Unknown (Cytogenetics
Unknown)
No (No)
At the time of transplantation, was the type of
hematologic complete remission of the chronic
myelogenous leukemia also molecular remission
(bcr/abl)?
Bcr-abl Oncoprotein Unknown (bcr/abl
unknown)
No (No)
Yes (Yes)
At the time of transplantation, was the type of
chronic phase of the chronic myelogenous
leukemia also a cytogenetic remission?
Complete (Complete)
Cytogenetics Unknown (Cytogenetics
Unknown)
No (No)
At the time of transplantation, was the type of
chronic phase of the chronic myelogenous
leukemia also a molecular remission (bcr/abl)?
Bcr-abl Oncoprotein Unknown (bcr/abl
unknown)
No (No)
Yes (Yes)
At the time of transplantation, what was the
number of the status of the CML?
First (First)
Second:c25666 (Second)
Greater Third (Third or higher)
Myelodysplastic Or Myeloproliferative
Disease Classification At Diagnosis
What was the MDS or myeloproliferative disease
classification?
Myelodysplastic Syndrome Associated
With Isolated Del (5q) Chromosome
Abnormality (5q- syndrome)
Acute Myeloid Leukemia (AML)
Chronic Eosinophilic Leukemia (Chronic
eosinophilic leukemia (hypereosinophilic
syndrome))
Chronic Idiopathic Myelofibrosis (Chronic
idiopathic myelofibrosis (with extra-
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medullary hematopoiesis), myelofibrosis
with myeloid metaplasia, acute
myelofibrosis or myelosclerosis)
Chronic Myelomonocytic Leukemia
(Chronic myelomonocytic leukemia
(CMMol, CMML))
Not Otherwise Specified Chronic
Myeloproliferative Disorder (Chronic
myeloproliferative disease, unclassifiable
(MPS, NOS))
Chronic Neutrophilic Leukemia (Chronic
neutrophilic leukemia)
Essential Thrombocythemia (Essential
thrombocythemia (ET))
Juvenile Myelomonocytic Leukemia
(Juvenile myelomonocytic leukemia
(JMML, JCML, JCMML))
Not Otherwise Specified Mds (MDS
unclassifiable/NOS)
Polycythemia Vera (Polycythemia vera
(PCV))
Refractory Anemia (RA)
Raeb-1 (RAEB-1)
Raeb-2 (RAEB-2)
Refractory Anemia With Ringed
Sideroblasts (RARS)
Refractory Cytopenia With Multilineage
Dysplasia (RCMD)
Refractory Cytopenia With Multilineage
Dysplasia And Ringed Sideroblasts
(RCMD / RS)
Myelodysplastic Or Myeloproliferative
Disease Status At Transplantation
What was the MDS or myeloproliferative disease
classification?
Myelodysplastic Syndrome Associated
With Isolated Del (5q) Chromosome
Abnormality (5q- syndrome)
Acute Myeloid Leukemia (AML)
Chronic Eosinophilic Leukemia (Chronic
eosinophilic leukemia (hypereosinophilic
syndrome))
Chronic Idiopathic Myelofibrosis (Chronic
idiopathic myelofibrosis (with extra-
medullary hematopoiesis), myelofibrosis
with myeloid metaplasia, acute
myelofibrosis or myelosclerosis)
Chronic Myelomonocytic Leukemia
(Chronic myelomonocytic leukemia
(CMMol, CMML))
Not Otherwise Specified Chronic
Myeloproliferative Disorder (Chronic
myeloproliferative disease, unclassifiable
(MPS, NOS))
Chronic Neutrophilic Leukemia (Chronic
neutrophilic leukemia)
Essential Thrombocythemia (Essential
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thrombocythemia (ET))
Juvenile Myelomonocytic Leukemia
(Juvenile myelomonocytic leukemia
(JMML, JCML, JCMML))
Not Otherwise Specified Mds (MDS
unclassifiable/NOS)
Polycythemia Vera (Polycythemia vera
(PCV))
Refractory Anemia (RA)
Raeb-1 (RAEB-1)
Raeb-2 (RAEB-2)
Refractory Anemia With Ringed
Sideroblasts (RARS)
Refractory Cytopenia With Multilineage
Dysplasia (RCMD)
Refractory Cytopenia With Multilineage
Dysplasia And Ringed Sideroblasts
(RCMD / RS)
If the MDS sub type is AML, date of MDS
diagnosis:
Myelodysplastic Or Myeloproliferative
Diseases
Was Janus kinase 2 (jak2) gene mutation
positive?
No: C49487 (No)
Not Done: C49484 (Not Done)
Yes: C49488 (Yes)
Was MDS / MPS therapy-related?
No (No)
Unknown (Unknown)
Yes (Yes)
Type Of Therapy Related Mds / Mps
What was the cause of the therapy-related
MDS/MPS?
Alkylating Agent Radiation Therapy
Related (Alkylating agent / radiation-
related)
Topoisomerase-ii Inhibitor Related
(Topoisomerase II inhibitor-related)
Unknown (Unknown)
Did a cause of the therapy related MDS / MPS
occur?
Yes
No
Myelodysplastic Or Myeloproliferative
Diseases
What was the status of MDS/MPS/CMML at
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transplantation?
Relapse Cr (Relapse after complete
response)
Supportive Care Without Chemotherapy
(Supportive care or treatment without
chemotherapy)
Chemotherapy (Treated with
chemotherapy)
If the MDS/MPS/CMML was treated with
chemotherapy, what was the disease status at
the time of transplantation?
Complete Remission (CR)
No Cr Better (Improvement but no CR)
Without Response (NR - no response)
Progressive Disease (Prog / worse)
At the time of transplantation, what was the
number of the complete remission of the MDS /
MPS / CMML?
First (First)
Second:c25666 (Second)
Greater Third (Third or higher)
At the time of transplantation what was the
number of the relapse after complete response of
the MDS/MPS/CMML?
First (First)
Second:c25666 (Second)
Greater Third (Third or higher)
At the time of transplantation, what was the
status of the JMML?
Continued Complete Response (CCR -
Continued Complete Response)
Complete Remission (CR - Complete
Response)
Minimum Response (MR - Minimal
Response)
Not Assessed (Not Assessed)
Progressive Disease (PD - Progressive
Disease)
Partial Remission (PR - Partial
Response)
Stable Disease (SD - Stable Disease)
Other Leukemias
What is the classification of the other leukemia?
Ph Unknown/bcr Unknown Atypical
Chronic Myeloid Leukemia (Atypical
chronic myeloid leukemia (CML, NOS),
Ph unknown/bcr unknown)
Ph Unknown/bcr- Atypical Chronic
Myeloid Leukemia (Atypical chronic
myeloid leukemia (CML, NOS), Ph
unknown/bcr-)
Ph-/bcr Unknown Atypical Chronic
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Myeloid Leukemia (Atypical chronic
myeloid leukemia (CML, NOS), Ph-/bcr
unknown)
Ph -/bcr-abl- Atypical Chronic Myeloid
Leukemia (Atypical chronic myeloid
leukemia (CML, NOS), Ph-/bcr/abl-)
Small Lymphocytic Lymphoma Cll
(Chronic Lymphocytic Leukemia (CLL),
B-cell / Small Lymphocytic Lymphoma
(SLL))
Not Otherwise Specified Cll (Chronic
Lymphocytic Leukemia (CLL), NOS)
Hairy Cell Leukemia (Hairy Cell
Leukemia)
Leukemia (Other Leukemia)
Not Otherwise Specified Leukemia
(Other Leukemia, NOS)
B-cell Prolymphocytic Leukemia (PLL, B-
Cell)
T-cell Prolymphocytic Leukemia (PLL, T-
Cell)
Not Otherwise Specified Prolymphocytic
Leukemia (Prolymphocytic Leukemia
(PLL), NOS)
Specify the other type of  leukemia:
What was the status of the other leukemia at the
time of transplantation?
Complete Remission (Complete
Remission (CR))
Never Therapeutic Procedure (Never
treated)
Stable Disease (No Response / Stable
(NR / SD))
Nodular Partial Remission (Nodular
partial remission (nPR))
Partial Remission (Partial remission
(PR))
Progressive Disease (Progression)
Without Therapeutic Procedure
Recurrent Disease (Relapse (untreated))
Lymphomas
Specify the type of hodgkin lymphoma:
Not Otherwise Specified Hodgkin's
Lymphoma (Hodgkin Lymphoma, NOS)
Lymphocyte Depleted Hodgkin
Lymphoma (Lymphocyte Depleted)
Lymphocyte Rich Classical Hodgkin
Lymphoma (Lymphocyte-rich)
Mixed Cellularity Hodgkin Lymphoma
(Mixed Cellularity)
Nodular Lymphocyte Predominant
Hodgkin Lymphoma (Nodular
Lymphocyte Predominant Hodgkin
Lymphoma)
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Nodular Sclerosis Hodgkin Lymphoma
(Nodular Sclerosis)
What was the status of the hodgkin lymphoma at
the time of transplantation?
Confirmed Cr (Complete Response
confirmed)
Not Confirmed Cr (CR unconfirmed
(CRU) (complete response with
persistent scan abnormalities of
unknown signifcance))
Never Therapeutic Procedure (Never
treated)
Partial Response (Partial response (PR))
Primary Refractory (less Than Partial
Response (pr) To Initial Therapy) /
Primary Induction Failure-resistant (pif
Res) (Primary refractory (less than
partial response (PR) to initial therapy) /
Primary induction failure-resistant (PIF
res))
Recurrent Disease (Relapse)
Specify the type of partial response of the
hodgkin lymphoma:
With Prior Cr (With prior complete
remission)
Without Prior Cr (Without prior complete
remission)
If there was a complete response of the hodgkin
lymphoma at the time of transplantation, what
was the number of the complete response?
First (First)
Second:c25666 (Second)
Greater Third (Third or higher)
If there was a relapse of hodgkin lymphoma at
the time of transplantation, what was the number
of the relapse?
First (First)
Second:c25666 (Second)
Greater Third (Third or higher)
If there was a relapse of hodgkin lymphoma at
the time of transplantation, what was the
sensitivity to chemotherapy?
Resistance (Resistant)
Sensitivity (Sensitive)
Unknown (Unknown)
Without Therapeutic Procedure
(Untreated)
Non-hodgkin's Lymphoma
Specify the type of non-hodgkin lymphoma:
Acute Adult T-cell Lymphoma/leukemia
(Adult T-cell lymphoma / leukemia
(HTLV1+))
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Aggressive Nk-cell Leukemia
(Aggressive NK-Cell Leukemia)
Cutaneous Angioimmunoblastic T-cell
Lymphoma (Anaplastic large cell
lymphoma, T / null cell, primary
cutaneous type)
Systemic Anaplastic Large Cell
Lymphoma (Anaplastic large cell
lymphoma, T / null cell, primary systemic
type)
Angioimmunoblastic T-cell Lymphoma
(Angioimmunoblastic T-Cell Lymphoma
(AILD))
Burkitt's Lymphoma Burkitt's Leukemia
(Burkitt's lymphoma / Burkitt cell
leukemia (ALL L3))
Diffuse Large B-cell Lymphoma (Diffuse
Large B-Cell Lymphoma)
Enteropathy-type T-cell Lymphoma
(Enteropathy-type T-Cell Lymphoma)
Extranodal Marginal Zone B-cell
Lymphoma Of Mucosa-associated
Lymphoid Tissue (Extranodal marginal
zone B-cell lymphoma of MALT type)
Nasal Type Extranodal Nk/t-cell
Lymphoma (Extranodal NK / T-cell
lymphoma, nasal type)
Grade 1 Follicular Lymphoma (Follicular
lymphoma (includes variants), Grade I)
Grade 2 Follicular Lymphoma (Follicular
lymphoma (includes variants), Grade II)
Grade 3 Follicular Lymphoma (Follicular
lymphoma (includes variants), Grade III)
Follicular Lymphoma (Follicular
lymphoma (includes variants), grade
unknown)
Hepatosplenic T-cell Lymphoma
(Hepatosplenic gamma-delta T-cell
lymphoma)
High-grade B-cell Lymphoma, Burkitt-like
(provisional Entity) (High-grade B-cell
lymphoma, Burkitt-like (Provisional
entity))
T-cell Large Granular Lymphocyte
Leukemia (Large T-cell granular
lymphocytic leukemia)
Lymphoplasmacytic Lymphoma
(Lymphoplasmacytic Lymphoma)
Mantle Cell Lymphoma (Mantle Cell
Lymphoma)
Mycosis Fungoides (Mycosis Fungoides)
Nodal Marginal Zone B-cell Lymphoma
(Nodal marginal zone B-cell lymphoma
(+ /  -  monocytoid B-cells))
Other B-cell Non-hodgkin Lymphoma
(Other B-cell lymphoma)
Other T-cell Non-hodgkin Lymphoma
(Other T-cell / NK-cell lymphoma,)
Unspecified Peripheral T-cell Lymphoma
(Peripheral T-cell lymphoma, NOS)
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Central Nervous System Lymphoma
(Primary CNS lymphoma)
Sezary Syndrome (Sezary Syndrome)
Splenic Marginal Zone B-cell Lymphoma
(Splenic marginal zone B-cell lymphoma)
Subcutaneous Panniculitis-like T-cell
Lymphoma (Subcutaneous Panniculitis-
Like T-Cell Lymphoma)
Waldenstrom Macroglobulinemia
(Waldenstrom Macroglobulinemia)
What was the subtype of the non-hodgkin
lymphoma diffuse, large B-cell lymphoma?
Intravascular Large B-cell Lymphoma
(Intravascular large B-cell lymphoma)
Mediastinal (thymic) Large B-cell
Lymphoma (Mediastinal large B-cell
lymphoma)
Primary Effusion Lymphoma (Primary
effusion lymphoma)
Specify the type of other B-cell lymphoma:
Specify the other T / NK cell lymphoma:
What was the status of the non-hodgkin's
lymphoma at the time of transplantation?
Confirmed Cr (Complete Response
confirmed)
Not Confirmed Cr (CR unconfirmed
(CRU) (complete response with
persistent scan abnormalities of
unknown signifcance))
Never Therapeutic Procedure (Never
treated)
Partial Response (Partial response (PR))
Primary Refractory (less Than Partial
Response (pr) To Initial Therapy) /
Primary Induction Failure-resistant (pif
Res) (Primary refractory (less than
partial response (PR) to initial therapy) /
Primary induction failure-resistant (PIF
res))
Recurrent Disease (Relapse)
Specify the type of partial response of the non-
hodgkin lymphoma:
With Prior Cr (With prior complete
remission)
Without Prior Cr (Without prior complete
remission)
If there was a complete response of the non-
hodgkin lymphoma at the time of transplantation,
what was the number?
First (First)
Second:c25666 (Second)
Greater Third (Third or higher)
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If there was a relapse of non-hodgkin lymphoma
at the time of transplantation, what was the
number?
First (First)
Second:c25666 (Second)
Greater Third (Third or higher)
If there was a relapse of non-hodgkin lymphoma
at the time of transplantation, what was the
sensitivity to chemotherapy?
Resistance (Resistant)
Sensitivity (Sensitive)
Unknown (Unknown)
Without Therapeutic Procedure
(Untreated)
Plasma Cell Disorders
What was the classification of plasma cell
disorders?
Multiple Myeloma-iga (Multiple Myeloma-
IgA)
Multiple Myeloma-igd (Multiple Myeloma-
IgD)
Multiple Myeloma-ige (Multiple Myeloma-
IgE)
Multiple Myeloma-igg (Multiple Myeloma-
IgG)
Multiple Myeloma-igm (not Waldenstrom
Macroglobulinemia) (Multiple Myeloma-
IgM (not Waldenstrom
Macroglobulinemia))
Multiple Myeloma-light Chain Only
(Multiple Myeloma-Light Chain Only)
Non-secretory Myeloma (Multiple
myeloma-non-secretory)
Other Plasma Cell Diseases And
Disorders (Other Plasma Cell Disorder)
Plasma Cell Leukemia (Plasma cell
leukemia)
Primary Amyloidosis (Primary
Amyloidosis)
Solitary Plasmacytoma (Solitary
plasmacytoma (no evidence of
myeloma))
Light Chain Involved
Kappa (kappa)
Lambda (lambda)
Durie-Salmon Stage
I - All Of The Following Must Be Present
(hemoglobin >10 G/dl; Serum Calcium
<12 Mg/dl; Urine Light Chains <4 G/24
Hrs; Normal Bones On Radiograph Or
Solitary Plasmacytoma; Igg <5 G/dl; Iga
<3 G/dl) (I - ALL of the following must be
present)
Ii - Fitting Neither Stage I Or Stage Iii (II -
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Fitting neither Stage I or Stage III)
Iii - One Of The Following Must Be
Present (hemoglobin <8.5 G/dl; Serum
Calcium >12 Mg/dl; Urine Light Chains
>12 G/24 Hrs; Advanced Lytic Bone
Lesions (>3 Lytic Lesions); Igg >7 G/dl;
Iga >5 G/dl) (III - one of the following
must be present)
Durie-Salmon Sub-stage
A (relatively Normal Renal Function -
Serum Creatinine <2.0 Mg/dl) (A
(relatively normal renal function - serum
creatinine <2.0 mg/dl))
B (abnormal Renal Function - Serum
Creatinine >= 2.0 Mg/dl) (B (abnormal
renal function - serum creatinine >= 2.0
mg/dl))
Serum beta 2 microglobulin value:
Serum beta 2-microglobulin unit of measure:
Microgram Per Deciliter (mcg/dL)
Milligram Per Liter (mg/L)
Nanomole Per Liter (nmol/L)
Serum albumin value:
What is the unit of measure for serum albumin?
Gram Per Deciliter (g/dL)
Gram Per Liter (g/L)
What was the International Staging System for
Myeloma Stage?
Iss Stage I Plasma Cell Myeloma (Stage
1)
Iss Stage Ii Plasma Cell Myeloma (Stage
2)
Iss Stage Iii Plasma Cell Myeloma
(Stage 3)
Specify the other type of plasma cell disorder:
What was the plasma cell disorder status at
transplantation?
Complete Remission (Complete
Remission (CR))
Never Therapeutic Procedure (Never
treated)
Partial Response Of Multiple Myeloma
Or Plasma Cell Leukemia (Partial
Response (PR))
Progression Of Multiple Myeloma Or
Plasma Cell Leukemia (Progression)
Relapse From Complete Response Of
Multiple Myeloma Or Plasma Cell
Leukemia (Relapse from complete
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remission (untreated))
Stable Multiple Myeloma Or Plasma Cell
Leukemia (Stable Disease (SD))
Stringent Complete Response (scr) Of
Multiple Myeloma Or Plasma Cell
Leukemia (Stringent Complete
Remission (sCR))
Very Good Partial Response (vgpr) Of
Multiple Myeloma Or Plasma Cell
Leukemia (Very Good Partial Response
(VGPR))
If the plasma cell disorder was treated, what was
the number of the response?
First (First)
Second:c25666 (Second)
Greater Third (Third or higher)
Breast Cancer
Was the breast cancer inflammatory or non-
inflammatory?
Inflammatory Breast Carcinoma
(Inflammatory)
Not Inflammatory Breast Carcinoma
(Non-inflammatory)
What was the stage of the breast cancer at
diagnosis?
Stage 0 Breast Cancer (0)
Stage I Breast Cancer (I)
Stage Ii Breast Cancer (II)
Stage Iii Breast Cancer (III)
What was the metastases of the breast cancer?
Metastatic (Metastatic)
Without Distant Metastasis (No distant
metastases)
What was the status of the breast cancer at the
time of transplantation?
First Partial Remission (1st partial
response (PR1))
Adjuvant Therapy (Adjuvant (Stage II, III
only))
Complete Remission (Complete
Remission (CR))
Never Therapeutic Procedure (Never
treated)
Primary Refractory (Primary refractory)
Recurrent Disease (Relapse)
Specify the type of complete remission of the
breast cancer at the time of transplantation:
Confirmed Cr (CR confirmed)
Not Confirmed Cr (CR unconfirmed
(CRU)(complete response with persistent
scan abnormalities of unknown
significance))
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What was the number of complete remission of
the breast cancer at the time of transplantation?
First (First)
Second:c25666 (Second)
Greater Third (Third or higher)
If the breast cancer was in the state of relapse at
the time of transplantation, was the cancer local
or metastatic?
Local (Local)
Metastatic (Metastatic)
If the breast cancer was in the state of relapse at
the time of transplantation, what was the number
of the relapse?
First (First)
Second:c25666 (Second)
Greater Third (Third or higher)
If the breast cancer was in the state of relapse at
the time of transplantation, what was the
sensitivity to chemotherapy?
Resistance (Resistant)
Sensitivity (Sensitive)
Unknown (Unknown)
Without Therapeutic Procedure
(Untreated)
Other Disease
Specify other
Copy of pathology report submitted?
Yes
No
What was the indication for the alternative
hematopoietic cell transplantation (HCT)?
Cardiac Regeneration (Cardiac
regeneration)
Neurologic Regeneration (Neurologic
Regeneration)
Other (Other)
Tolerance Induction Pre-solid Organ
Transplant (Tolerance Induction Pre-Solid
Organ Transplant)
Specify the indication for the other alternative
HCT:
Other Malignancies
What was the classification of the other
malignancy?
Bone Sarcoma (Bone sarcoma,
excluding Ewing family tumors)
Central Nervous System Carcinoma
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(Central nervous system tumor, including
CNS PNET)
Colorectal Carcinoma (Colorectal)
Ewing Sarcoma Of Bone (Ewing family
tumors of bone (includes PNET))
Extraosseous Ewing Sarcoma (Ewing
family tumors, extra-osseous (includes
PNET))
Extragonadal Germ Cell Tumor (Germ
cell tumor, extragonadal only)
Hepato-biliary Neoplasm (Hepatobiliary)
Non-small Cell Lung Carcinoma (Lung
cancer, non-small cell)
Sclc (Lung cancer, small cell)
Medulloblastoma (Medulloblastoma)
Melanoma (Melanoma)
Neuroblastoma (Neuroblastoma)
Other Solid Neoplasm (Other solid
tumor)
Ovarian Carcinoma (Ovary)
Pancreatic Carcinoma (Pancreas)
Prostate Carcinoma (Prostate)
Renal Cell Carcinoma (Renal Cell)
Retinoblastoma (Retinoblastoma)
Rhabdomyosarcoma
(Rhabdomyosarcoma)
Soft Tissue Sarcoma (Soft Tissue
Sarcoma)
Malignant Testicular Germ Cell Tumor
(Testicular)
Thymoma (Thymoma)
Wilms Tumor (Wilms Tumor)
Specify the type of other solid tumor:
What was the status of the other malignancy at
the time of transplantation?
Adjuvant Therapy (Adjuvant)
Complete Response (cr) (CR)
Cru (CRU)
Never Therapeutic Procedure (Never
treated)
Stable Disease (nr/sd) (NR/SD)
Progressive Disease (pd) (PD)
Partial Response (pr) (PR)
Without Therapeutic Procedure
Recurrent Disease (Relapse (untreated))
If the status of the other malignancy at the time of
transplantation is partial remission, what was the
type of partial remission
With Prior Cr (With prior complete
remission)
Without Prior Cr (Without prior complete
remission)
Was RECIST criteria used for evaluation of the
status of the other malignancy at the time of
transplantation?
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Yes
No
What was the number of the complete response,
complete response with persistent imaging
abnormalities of unknown significance, or relapse
for the other malignancy at the time of
transplantation?
First (First)
Second:c25666 (Second)
Greater Third (Third or higher)
If there was a relapse of the other malignancy,
what was the sensitivity to chemotherapy?
(Complete only for relapse)
Resistance (Resistant)
Sensitive (Sensitive)
Unknown (Unknown)
Not Treatment (Untreated)
Severe Aplastic Anemia
What was the classification of the aplastic
anemia?
Not Genetic Amegakaryocytosis
(Acquired amegakaryocytosis (not
congenital))
Acquired Pure Red Cell Aplasia
(Acquired Pure Red Cell Aplasia (PRCA)
(not congenital))
Aplastic Anemia Due To Hepatitis
(Acquired SAA, secondary to hepatitis)
Drug-induced Aplastic Anemia (Acquired
SAA, secondary to toxin / other drug)
Severe Aplastic Anemia Not Otherwise
Specified (Acquired Severe Aplastic
Anemia (SAA), NOS)
Other Not Genetic Cytopenia (Other
acquired cytopenic syndrome)
Paroxysmal Nocturnal Hemoglobinuria
(Paroxysmal Nocturnal Hemogloblinuria
(PNH))
Specify the other acquired cytopenic syndrome:
What was the classification of the congenital
abnormalities of erythrocyte differentiation or
function?
Diamond-blackfan Anemia (Diamond-
Blackfan anemia (congenital PRCA))
Fanconi Anemia (Fanconi Anemia)
Other Genetic Anemia (Other
constitutional anemia)
Other Hemoglobinopathy (Other
hemoglobinopathy)
Schwachmann-diamond Syndrome
(Shwachman-Diamond)
Sickle Cell Disease (Sickle Cell Disease)
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Sickle Cell-thalassemia (Sickle
thalassemia)
Not Otherwise Specified Thalassemia
(Thalassemia, NOS)
Specify the other constitutional anemia:
Specify the other hemoglobinopathy:
Platelet Disorders
What was the classification of the platelet
disorder?
Thrombocytopenia Congenital
Abnormality Amegakaryocytosis
(Congenital amegakaryocytosis /
congenital thrombocytopenia)
Glanzmann Thrombasthenia
(Glanzmann Thrombasthenia)
Other Congenital Platelets Abnormality
(Other inherited platelet abnormality)
Specify the other inherited platelet abnormalities:
Histiocytic Disorders
What was the classification of the histiocytic
disorder?
Familiar Hemophagocytic
Lymphohistiocytosis (Familial erythro /
hemophagocytic lymphohistiocytosis
(FELH))
Hemophagocytosis (Hemophagocytosis
(reactive or viral associated))
Not Otherwise Specified Histiocytic And
Dendritic Cell Neoplasms (Histiocytic
disorder, NOS)
Langerhans Cell Histiocytosis
(Langerhans cell histiocytosis
(histiocytosis-X))
Malignant Histiocytosis (Malignant
histiocytosis)
Other Histiocytic And Dendritic Cell
Neoplasms (Other histiocytic disorder)
Specify the other histiocytic disorder:
Inherited Disorders Of
Metabolism/osteopetrosis
What was the classification of the inherited
disorders of metabolism / osteopetrosis?
Adrenoleukodystrophy
(Adrenoleukodystrophy (ALD))
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Aspartylglycosaminuria (Aspartyl
Glucosaminuria)
Beta Glucuronidase Deficiency (vii) (Beta
glucuronidase deficiency (VII))
Fucosidosis (Fucosidosis)
Gaucher Disease (Gaucher Disease)
Glucose Storage Disease (Glucose
storage disease)
Hunter Syndrome (Hunter syndrome (II))
Hurler Syndrome (Hurler syndrome (IH))
I-cell Disease (I-Cell Disease)
Not Otherwise Specified Congenital
Metabolic Disorder (Inherited Disorders
or Metabolism, NOS)
Krabbe Disease (Krabbe disease
(Globoid leukodystrophy))
Lesch-nyhan Syndrome (Lesch-Nyhan
(HGPRT deficiency))
Mannosidosis (Mannosidosis)
Maroteaux-lamy Syndrome (Maroteaux-
Lamy (VI))
Metachromatic Leukodystrophy
(Metachromatic leukodystrophy (MLD))
Morquio Syndrome (Morquio (IV))
Not Otherwise Specified Mucolipidosis
(Mucolipidoses, not otherwise specified)
Mucopolysaccharidosis
(Mucopolysaccharidosis (V))
Not Otherwise Specified
Mucopolysaccharidosis
(Mucopolysaccharidosis, not otherwise
specified)
Batten Disease (Neuronalceroid
lipofuscinosis (Batten disease))
Niemann-pick Disease (Niemann-Pick
disease)
Osteopetrosis (Osteopetrosis (malignant
infantile osteopetrosis))
Other Congenital Metabolic Disorder
(Other inherited disorder of metabolism)
Sanfilippo Syndrome (Sanfilippo (III))
Scheie Syndrome (Scheie syndrome
(IS))
Wolman Disease (Wolman disease)
Specify the other inherited disorder of
metabolism:
Immune Deficiencies
What was the classification of the immune
deficiency?
Adenosine Deaminase Deficiency
Severe Combined Immunodeficiency
(Adenosine deaminase (ADA) deficiency
/ severe combined immunodefiency
(SCID))
Ataxia Telangiectasia Syndrome (Ataxia
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telangiectasia)
Bare Lymphocyte Syndrome (Bare
lymphocyte syndrome)
Cartilage Hair Hypoplasia (Cartilage Hair
Hypoplasia)
Cd40 Ligand Deficiency (CD40 ligand
deficiency)
Chediak-higashi Syndrome (Chediak-
Higashi Syndrome)
Chronic Granulomatous Disease
(Chronic Granulomatous Disease)
Common Variable Immunodeficiency
(Common Variable Immunodeficiency)
Digeorge's Syndrome (DiGeorge
anomaly)
Hiv Infection (HIV Infection)
Not Otherwise Specified
Immunodeficiency Syndrome (Immune
Deficiencies, NOS)
Congenital Neutropenia (Kostmann
agranulocytosis (congenital
neutropenia))
Leukocyte Adhesion Deficiency
(Leukocyte adhesion deficiencies)
Neutrophil Actin Defect (Neutrophil actin
deficiency)
Omenn Syndrome (Omenn Syndrome)
Other Immunodeficiency Syndrome
(Other immune deficiency)
Reticular Dysgenesis (Reticular
Dysgenesis)
Not Otherwise Specified Severe
Combined Immunodeficiency (SCID, not
otherwise specified)
Severe Combined Immunodeficiency
(SCID, other)
Severe Combined Immunodeficiency
With Absence Of T And B Cells (Severe
Combined Immunodeficiency with
Absence of T and B Cells)
Severe Combined Immunodeficiency
With Absence Of T, Normal B Cells
(Severe Combined Immunodeficiency
with Absence of T, Normal B Cells)
Wiskott-aldrich Syndrome (Wiskott-
Aldrich Syndrome)
X-linked Lymphoproliferative Syndrome
(X-Linked Lymphoproliferative
Syndrome)
Specify the other SCID:
Specify the other immune deficiency:
Autoimmune Disorders
Specify the type of autoimmune disease:
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Antiphospholipid Syndrome
(Antiphospholipid syndrome)
Behcet's Syndrome (Behcet's Syndrome)
Churg-strauss Syndrome (Churg-
Strauss)
Crohn's Disease (Crohn's disease)
Evan Syndrome (Evan Syndrome)
Temporal Arteritis (Giant cell arteritis)
Hemolytic Anemia (Hemolytic Anemia)
Idiopathic Thrombocytopenic Purpura
(Idiopathic thrombocytopenic purpura
(ITP))
Stills Disease (Juvenile idiopathic
arthritis (JIA): systemic (Stills disease))
Oligoarticular Stills Disease (Juvenile
idiopathic arthritis: Oligoarticular)
Other Pediatric Idiopathic Arthritis
(Juvenile idiopathic arthritis: other)
Polyarticular Stills Disease (Juvenile
idiopathic arthritis: Polyarticular)
Multiple Sclerosis (Multiple sclerosis
(MS))
Myasthenia Gravis (Myasthenia Gravis)
Other Arthritis (Other  Arthritis)
Other Vasculitis (Other  Vasculitis)
Bowel Autoimmune Other Diseases And
Disorders (Other autoimmune bowel
disorder)
Other Autoimmune Cytopenia (Other
autoimmune cytopenia)
Neurologic Other Autoimmune Disease
(Other autoimmune neurological
disorder)
Other Connective Tissue Disorder (Other
connective tissue disease)
Overlap Necrotizing Arteritis (Overlap
Necrotizing Arteritis)
Polyarteritis Nodosa (Polyarteritis
nodosa, classical)
Microscopic Polyarteritis (Polyarteritis
nodosa, microscopic)
Polymyositis Dermatomyositis
(Polymyositis / dermatomyositis)
Psoriasis Psoriatic Arthritis (Psoriatic
Arthritis / Psoriasis)
Rheumatoid Arthritis (Rheumatoid
Arthritis)
Sjogren's Syndrome (Sjogren syndrome)
Systemic Lupus Erythematosus
(Systemic lupus erythematosis (SLE))
Systemic Sclerosis (Systemic sclerosis)
Takayasu's Arteritis (Takayasu)
Ulcerative Colitis (Ulcerative colitis)
Wegener's Granulomatosis (Wegener
granulomatosis)
Specify the type of other connective tissue
disease:
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Specify the other vasculitis:
Specify the other juvenile idiopathic arthritis:
Specify the other arthritis:
Specify the other autoimmune neurological
disorder:
Specify the other autoimmune cytopenia:
Specify the other autoimmune bowel disorder:
Systemic Sclerosis Involvement
For the systemic sclerosis, what was the involved
organ or clinical problem?
Crest Syndrome (CREST)
Diffuse Cutaneous (Diffuse cutaneous)
Esophagus (Esophagus)
Local Cutaneous (Limited cutaneous)
Lung Tissue (Lung parenchyma)
Other (Other)
Other Gastrointestinal Tract (Other GI
tract)
Pulmonary Hypertension (Pulmonary
hypertension)
Raynaud's Syndrome (Raynaud)
Renal (Renal)
Hypertension Systemic (Systemic
hypertension)
Did the systemic sclerosis have a particular
involvement?
Yes
No
Was the involvement associated with systemic
sclerosis the primary reason for transplantation?
Yes
No
What was the systemic sclerosis biopsy type?
(Answer only if the answer to CDE 2748902 is
renal)
Specify the other involvement of the systemic
sclerosis: (Answer only if the answer to CDE
2748902 is "Other.")
Systemic Sclerosis Laboratory
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Procedures
For the systemic sclerosis, what was the
laboratory procedure type?
Centromere Antibody (ACA positive)
Antinuclear Antibody (ANA)
Topoisomerase I Antibody (Scl 70
positive)
For the systemic sclerosis, what was the result of
the laboratory procedure?
Elevated (Elevated)
Normal (Normal)
Not Done: C49484 (Not Done)
Systemic Lupus Erythematosus (sle)
Involvement
For the systemic lupus erythematosus (SLE),
what was the involved organ or clinical problem?
Arthritis (Arthritis)
Central Nervous System (CNS)
Hematologic (Hematological)
Lung (Lung)
Other (Other)
Peripheral Nervous System (PNS)
Renal (Renal)
Serositis (Serositis)
Skin (Skin)
Vasculitis (Vasculitis)
Did the systemic lupus erythematosus (SLE)
have a particular involvement?
Yes
No
Was the involvement associated with systemic
lupus erythematosus (SLE) the primary reason
for transplantation?
Yes
No
What was the systemic lupus erythematosus
(SLE) biopsy type? (Answer only if the answer to
CDE 2749007 is "Renal.")
Specify the type of systemic lupus erythematosus
(SLE) involvement: (Answer only if the answer to
CDE 2749007 is "CNS", "PNS", "Skin",
"Hematological", "Vasculitis", or "Other.")
Systemic Lupus Erythematosus (sle)
Laboratory Procedures
For the systemic lupus erythematosus, what was
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the ANA test result?
Elevated (Elevated)
Normal (Normal)
Not Done: C49484 (Not Done)
For the systemic lupus erythematosus, what was
the ds DNA test result?
Elevated (Elevated)
Normal (Normal)
Not Done: C49484 (Not Done)
For the systemic lupus erythematosus, what was
the C3 test result?
Low (Low)
Normal (Normal)
Not Done: C49484 (Not Done)
For the systemic lupus erythematosus (SLE),
what was the C4 test result?
Low (Low)
Normal (Normal)
Not Done: C49484 (Not Done)
For systemic lupus, erythematosus, what was the
total complement test result?
Low (Low)
Normal (Normal)
Not Done: C49484 (Not Done)
For the systemic lupus erythematosus, what was
the test results at diagnosis for the other
antibody?
Elevated (Elevated)
Normal (Normal)
Not Done: C49484 (Not Done)
For the systemic lupus erythematosus, specify
the other antibody:
Sjogren Syndrome Involvement
For the sjogren syndrome, what was the involved
organ or clinical problem?
Swelling Exocrine Gland (Exocrine gland
swelling)
Paraproteinemia Lymphoma
(Lymphoma, paraproteinemia)
Other (Other)
Lymphocytic Infiltration Other (Other
organ lymphocytic infiltration)
Sicca Syndrome (SICCA)
Vasculitis (Vasculitis)
Did the sjogren syndrome have a particular
involvement?
Yes
No
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Was the involvement associated with sjogren
syndrome the primary reason for transplantation?
Yes
No
Specify the other involvement for sjogren
syndrome: (Answer only if the answer to CDE
2749605 is "Other.")
Polymyositis / Dermatomyositis
Involvement
For the polymyositis-dermatomyositis, what was
the involved organ or clinical problem?
Generalized Muscle Weakness
(Generalized weakness (including
bulbar))
Malignant Neoplasm (Malignancy)
Other (Other)
Proximal Muscle Weakness (Proximal
weakness)
Pulmonary Fibrosis (Pulmonary fibrosis)
Vasculitis (Vasculitis)
Did the polymyositis-dermatomyositis have a
particular involvement?
Yes
No
Was the involvement associated with
polymyositis-dermatomyositis the primary reason
for transplantation?
Yes
No
Specify the type of polymyositis-dermatomyositis
involvement: (Answer only if the answer to CDE
2749891 is "Vasculitis", "Malignancy", or "Other.")
Polymyositis / Dermatomyositis Laboratory
Procedure
What was the CPK test result?
Elevated (Elevated)
Normal (Normal)
Not Done: C49484 (Not Done)
For the polymyositis-dermatomyositis, were the
biopsy results typical of the disease?
Elevated (Elevated)
Normal (Normal)
Not Done: C49484 (Not Done)
For the polymyositis-dermatomyositis, were the
EMG results typical of the disease?
Elevated (Elevated)
Normal (Normal)
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Not Done: C49484 (Not Done)
For the dermatomyositis, was there a rash
present that was typical of the disease?
Elevated (Elevated)
Normal (Normal)
Not Done: C49484 (Not Done)
Antiphospholipid Syndrome Involvement
For the antiphospholipid syndrome, what was the
involved organ or clinical problem?
Abortion (Abortion)
Central Nervous System (CNS)
Hematology (Hematological)
Other (Other)
Vasculitis (Skin (livedo, vasculitis))
Thrombosis (Thrombosis)
Did the antiphospholipid syndrome have a
particular involvement?
Yes
No
Was the involvement associated with
antiphospholipid syndrome the primary reason for
transplantation?
Yes
No
Specify the other type of antiphospholipid
syndrome involvement: (Answer only if the
answer to CDE 2749918 is "Thrombosis," "CNS,"
"Hematological," or "Other.")
Antiphospholipid Syndrome Laboratory
Procedures
For the antiphospholipid syndrome, what was the
laboratory procedure type?
Anticardiolipin Igg Antibody
(Anticardiolipin IgG)
Anticardiolipin Igm Antibody
(Anticardiolipin IgM)
Lupus Anticoagulant Antibody (Lupus
anticoagulant)
For the antiphospholipid syndrome, what was the
result of the laboratory procedure?
Elevated (Elevated)
Normal (Normal)
Not Done: C49484 (Not Done)
Wegener Granulomatosis Invovlement
For the wegener granulomatosis, what was the
involved organ or clinical problem?
49 / 52
Treatment - 2400 Revision 2  -  Pre-Transplant Essential Data (TED) -
3002012v2.0
Other (Other)
Pulmonary (Pulmonary)
Renal (Renal)
Skin (Skin)
Upper Respiratory System (Upper
respiratory tract)
Did the wegener granulomatosis have a particular
involvement?
Yes
No
Was the involvement associated with wegener
granulomatosis the primary reason for
transplantation?
Yes
No
Specify the type of wegener granulomatosis
involvement: (Answer only if the answer to CDE
2749969 is "Renal" or "Other.")
Wegener Granulomatosis Laboratory
Procedures
For the wegener granulomatosis, what was the
laboratory procedure type?
Elisa Myeloperoxidase Antibody (Anti
MPO)
Elisa Proteinase 3 Antibody (Anti Pr3)
Fluorescent Antibody Technique
Proteinase 3 Antibody (c-ANCA IFA)
Unknown Laboratory Procedure
Proteinase 3 Antibody (c-ANCA positive)
Fluorescent Antibody Technique
Myeloperoxidase Antibody (p-ANCA IFA)
For the wegener granulomatosis, what was the
result of the laboratory procedure?
Elevated (Elevated)
Normal (Normal)
Not Done: C49484 (Not Done)
Polyarteritis Nodosa Involvement
For the polyarteritis nodosa, classical or
microscopic, what was the involved organ or
clinical problem?
Gastrointestinal Tract (GI tract)
Mononeuritis Multiplex (Mononeuritis
multiplex)
Other (Other)
Pulmonary Hemorrhage (Pulmonary
hemorrhage)
Renal (Renal)
Skin (Skin)
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Did the polyarteritis nodosa, classical or
microscopic, have a particular involvement?
Yes
No
Was the involvement associated with polyarteritis
nodosa, classical or microscopic, the primary
reason for transplantation?
Yes
No
Specify the type of polyarteritis nodosa, classical
or microscopic, involvement: (Answer only if the
answer to CDE 2750113 is "Renal" or "Other.")
Polyarteritis Nodosa Laboratory
Procedures
For the polyarteritis nodosa, classical or
microscopic, what was the laboratory procedure
type?
Unknown Laboratory Procedure
Proteinase 3 Antibody (c-ANCA positive)
Hepatitis Serological (Hepatitis serology)
Unknown Laboratory Procedure
Myeloperoxidase Antibody (p-ANCA
positive)
For the polyarteritis, classical or microscopic,
what was the result of the laboratory procedure?
Elevated (Elevated)
Normal (Normal)
Not Done: C49484 (Not Done)
Rheumatoid Arthritis Involvement
For the rheumatoid arthritis, what was the
involved organ or clinical problem?
Destructive Arthritis (Destructive
arthritis)
Extra-articular (Extra-articular)
Eye (Eye)
Necrotizing Vasculitis (Necrotizing
vasculitis)
Other (Other)
Pulmonary (Pulmonary)
Did the rheumatoid arthritis have a particular
involvement?
Yes
No
Was the involvement associated with rheumatoid
arthritis the primary reason for transplantation?
Yes
No
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Specify the type of rheumatoid arthritis
involvement: (Answer only if the answer to CDE
2750141 is "Eye", "Extra-articular," or "Other.")
Psoriatic Arthritis / Psoriasis Involvement
For the psoriatic arthritis / psoriasis, what was the
involved organ or clinical problem?
Destructive Arthritis (Destructive
arthritis)
Other (Other)
Psoriasis (Psoriasis)
Did the psoriatic arthritis / psoriasis have a
particular involvement?
Yes
No
Was the involvement associated with psoriatic
arthritis / psoriasis the primary reason for
transplantation?
Yes
No
For the psoriatic arthritis / psoriasis specify the
other involvement: (Answer only if the answer to
CDE 2750535 is "Other.")
Multiple Sclerosis (ms) Involvement
For the multiple sclerosis, what was the involved
organ or clinical problem?
Other (Other)
Primary Progressive (Primary
progressive)
Recurrent Disease (Relapsing/remitting)
Secondary Progressive (Secondary
progressive)
Did the multiple sclerosis have a particular
involvement?
Yes
No
Was the involvement associated with multiple
sclerosis the primary reason for transplantation?
Yes
No
For the multiple sclerosis, specify the other
involvement: (Answer only if the answer to CDE
2749910 is "Other.")
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Data (TED) ISO Date Format - 2892485v2.0
Revision 1 of form 2400 - Pre-Transplant Essential Data
(TED) Uses The ISO Date Format
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=8331F8AF-
85A0-6ABF-E040-BB89AD437A3C
All rights reserved. Please visit https://medical-data-
models.org/forms/8841
2400 Revision 1 - Pre-Transplant
Essential Data (TED) ISO Date
Format
Cibmtr Use Only
Sequence number:
Date received:
Center Identification
CIBMTR Center Number:
EBMT Code (CIC) Number
Hospital:
Unit:
Adult Patient Department (Adult)
Hematology Patient Department
(Hematology)
Oncology Patient Department
(Oncology)
Other Department (Other unit)
Pediatric Patient Department (Pediatric)
Specify the other unit name:
Contact person:
Telephone number:
Fax number:
EMail Address
Today's date:
Recipient Identification
Universal Recipient ID:
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What organization assigned the universal
recipient ID?
Center For International Blood And
Marrow Transplant Research (cibmtr)
(CIBMTR)
European Group For Blood And Marrow
Transplantation (ebmt) (EBMT)
Other (Other)
Specify the organization that assigned the
universal recipient ID:
Study Id Number
What was the study ID number?
Recipient Identification
Was the study affiliated with BMT-CTN?
Yes (Yes)
Was the study affiliated with NMDP?
Yes (Yes)
Was the study affiliated with RCI-BMT?
Yes (Yes)
Was the study affiliated with SCTOD?
Yes (Yes)
Consented for research?
Yes
No
Consented for CIBMTR related specimen
repository?
Yes
No
Gender
Female Gender (Female Gender)
Male Gender (Male Gender)
Date of Birth
Ethnicity (Optional for non-US centers)
A Person Of Mexican, Puerto Rican,
Cuban, Central Or South American Or
Other Spanish Culture Or Origin,
Regardless Of Race. (Hispanic or Latino)
A Person Not Meeting The Definition For
Hispanic Or Latino. (Not Hispanic or
Latino)
Recipient Race
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Race
A Person Having Origins In Any Of The
Original Peoples Of North And South
America (including Central America),
And Who Maintains Tribal Affiliation Or
Community Attachment. (American
Indian or Alaska Native)
A Person Having Origins In Any Of The
Original Peoples Of The Far East,
Southeast Asia, Or The Indian
Subcontinent Including, For Example,
Cambodia, China, India, Japan, Korea,
Malaysia, Pakistan, The Philippine
Islands, Thailand, And Vietnam. (Asian)
A Person Having Origins In Any Of The
Black Racial Groups Of Africa. Terms
Such As "haitian" Or "negro" Can Be
Used In Addition To "black Or African
American." (Black or African American)
A Person Having Origins In Any Of The
Original Peoples Of Hawaii, Guam,
Samoa, Or Other Pacific Islands. (Native
Hawaiian or other Pacific Islander)
A Person Having Origins In Any Of The
Original Peoples Of Europe, The Middle
East, Or North Africa. (White)
Disease Classification
What was the date of diagnosis of the primary
disease for which the hematopoietic stem cell
transplantation was performed?
Hematopoietic Stem Cell Transplant (hsct)
Date of hematopoietic stem cell transplantation
(HSCT) for which this form is being completed:
What is the chronological number of the current
hematopoietic stem cell transplantation?
Date of the most recent previous HSCT:
If there has been more than one hematopoietic
stem cell transplantation, what was the type of
the most recent previous hematopoietic stem cell
transplantation?
Allogeneic Hematopoietic Stem Cell
Transplantation (Allogeneic)
Autologous Stem Cell Transplantation
(Autologous)
If the institution where previous HSCT was
performed is different from the current HSCT,
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what is the name of the institution?
If the institution where previous HSCT was
performed is different from the current HSCT,
what is the city where the institution is located?
If the institution where previous HSCT was
performed is different from the current HSCT,
what is the state where the institution is located?
If the institution where previous HSCT was
performed is different from the current HSCT,
what is the country where the institution is
located?
Product Type
What type of hematopoietic stem cell transplant
was used?
Umbilical Cord Blood (Cord blood)
Bone Marrow (Marrow)
Other (Other)
Peripheral Blood Stem Cell (PBSC)
Was a particular hematopoietic stem cell
transplant type used?
Yes
No
Specify the other hematopoietic stem cell
transplant type: (Answer only if the value for
2730912 is "Other")
Hematopoietic Stem Cell Transplant (hsct)
For allogeneic HSCT, was the donor gender
male?
Yes
No
For allogeneic HSCT, was the donor gender
female?
Yes
No
Autologous HSCT?
Yes
No
Did the hematopoietic stem cell transplant consist
of multiple donors?
Yes
No
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Donor Information
What type of donor was used for this
hematopoietic stem cell transplant?
Mhc Class I Protein Mhc Class Ii Protein
Identical Sibling (HLA-identical sibling)
Mhc Class I Protein Mhc Class Ii Protein
Other Relative (HLA-matched other
relative)
Mhc Class I Protein Mhc Class Ii Protein
Mismatch Relative (HLA-mismatched
relative)
Syngeneic (Syngeneic)
Donor Unrelated (Unrelated donor)
For an HLA-mismatched related donor, what was
the degree of mismatch:
Integer::1 Mhc Class I Protein Antigen
Mismatch (1 HLA antigen mismatch)
Greater Than Integer::2 Mhc Class I
Protein Antigen Mismatch (greater than
or equal to 2 HLA antigen mismatch (full
haploidentical))
At what registry or cord blood bank was the
unrelated donor registered?
(a) Austrian Bone Marrow Donors (A)
(acb) Austrian Cord Blood Registry
(ACB)
(accb) Stemcyte, Inc. (ACCB)
(ae) Emirates Bone Marrow Donor
Registry (AE)
(am) Armenian Bone Marrow Donor
Registry Charitable Trust (AM)
(aocb) University Of Colorado Cord
Blood Bank (AOCB)
(ar) Argentine Cph Donors Registry (AR)
(arcb) Bancel - Argentina Cord Blood
Bank (ARCB)
(aucb) Australian Cord Blood Registry
(AUCB)
(aus) Australia / New Zealand Bone
Marrow Donor Registry (AUS)
(b) Marrow Donor Program Belgium (B)
(bcb) Belgium Cord Blood Registry
(BCB)
(bg) Bulgarian Bone Marrow Donor
Registry (BG)
(br) Inca/redomo (BR)
(bscb) British Bone Marrow Registry -
Cord Blood (BSCB)
(ch) Swiss Bloodstem Cells - Adult
Donors (CH)
(chcb) Swiss Blood Stem Cells - Cord
Blood (CHCB)
(ckcb) Celgene Cord Blood Bank
(CKCB)
(cn) China Marrow Donor Program
(cmdp) (CN)
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(cncb) Shan Dong Cord Blood Bank
(CNCB)
(cnd) Canadian Blood Services Bone
Marrow Donor Registry (CND)
(cs2) Czech National Marrow Donor
Registry (CS2)
(cscr) Czech Stem Cells Registry
(CSCR)
(cy) Cyprus Paraskevaidio Bone Marrow
Donor Registry (CY)
(cy2) The Cyprus Bone Marrow Donor
Registry (CY2)
(d) Zkrd - Zentrales
Knochenmarkspender - Register
Deutschland Adult Donors (D)
(dcb) Zkrd - Zentrales
Knochenmarkspender - Register
Deutschland Cord Blood (DCB)
(dk) The Danish Bone Marrow Donor
Registry (DK)
(dk2) Bone Marrow Donors Copenhagen
(bmdc) (DK2)
(ducb) German Branch Of The European
Cord Blood Bank (DUCB)
(e) Redmo (E)
(ecb) Spanish Cord Blood Registry
(ECB)
(f) France Greffe De Moelle - Adult
Donors (F)
(fcb) France Greffe De Moelle - Cord
Blood (FCB)
(fi) Finnish Bone Marrow Donor Registry
(FI)
(ficb) Finnish Cord Blood Registry (FICB)
(gb) The Anthony Nolan Trust (GB)
(gb3) Welsh Bone Marrow Donor
Registry (GB3)
(gb4) British Bone Marrow Registry
(GB4)
(gr) Unrelated Hematopoietic Stem Cell
Donor Registry Greece (GR)
(grcb) Michigan Community Blood
Centers Cord Blood Bank (GRCB)
(h) Hungarian Bone Marrow Donor
Registry (H)
(hk) Hong Kong Bone Marrow Donor
Registry (HK)
(hr) Croatian Bone Marrow Donor
Registry (HR)
(i) Italian Bone Marrow Donor Registry (I)
(i3cb) Sheba Medical Centre Cord Blood
Registry (I3CB)
(icb) Italian Cord Blood Bank Network
(ICB)
(il) Hadassah Bmdr (IL)
(il2) Ezer Mizion Bone Marrow Donor
Registry (IL2)
(il3) Sheba Medical Center Donor
Registry (IL3)
(ilcb) Isreal Cord Blood Bank (ILCB)
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(in) Asian Indian Donor Marrow Registry
(IN)
(in2) Dept. Of Transfusion Medicine (IN2)
International-unable To Answer
(INTL_UA)
(irl) The Irish Unrelated Bone Marrow
Panel (IRL)
(jp) Japan Marrow Donor Program (JP)
(kr) Korea Marrow Donor Program (KR)
(lt) Lithuanian National Bone Marrow
Donor Registry (LT)
(lvcb) Leuven Cord Blood Bank (LVCB)
(macb) Victoria Angel Registry Of Hope
(MACB)
(mx) Mexican Bone Marrow Donor
Registry (MX)
(n) The Norwegian Bone Marrow Donor
Registry (N)
(nl) Europdonor Foundation- Adult
Donors (NL)
(nlcb) Europdonor Foundation - Cord
Blood (NLCB)
(nycb) National Cord Blood Program,
New York Blood Center (NYCB)
(p) Portuguese Bone Marrow Donors
Registry (P)
(pl) National Polish Bone Marrow
Registry (PL)
(pl2) Unrelated Bone Marrow Donor
Registry -adult Donors (PL2)
(pl3) Against Leukemia Foundation
Marrow Donor Registry (PL3)
(pl4) Ursula Jaworska Foundation - Bone
Marrow Donor Registry (PL4)
(pl5) Polish Central Bone Marrow Donor
Registry - Adult Donors (PL5)
(pmcb) Elie Katz Umbilical Cord Blood
Program (PMCB)
(r) Russian Bone Marrow Donor Registry
(R)
(r2) Karelian Registry Of Unrelated
Donors Of Hematopoietic Stem Cells
(R2)
(s) Tobias Registry Of Swedish Bone
Marrow Donors (S)
(sg) Singapore Bone Marrow Donor
Programme (bmdp) (SG)
(sk) Slovak National Bone Marrow Donor
Registry (SK)
(skcb) Eurocord Slovakia / Slovak
Pacental Stem Cell Registry (SKCB)
(slo) Slovenia Donor (SLO)
(sm) San Marino Bone Marrow Donor
Registry (SM)
(t1cb) Tran - Cord Blood (T1CB)
(tacb) Stemcyte, Inc. Taiwan (TACB)
(tecb) Healthbanks Biotech, Co., Ltd
(TECB)
(th) Thai Stem Cell Donor Registry
(tscdr) (TH)
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(tocb) Tokyo Cord Blood Bank (TOCB)
(tpcb) Bionet / Babybanks (TPCB)
(tran) Tran - Adult Donors (TRAN)
(tris) Bone Marrow Bank Of Istanbul
Medical Faculty (TRIS)
(tw) Buddhist Tzu Chi Stem Cells Center
- Adult Donors (TW)
(twcb) Buddhist Tzu Chi Stem Cells
Center - Cord Blood (TWCB)
(u1cb) National Marrow Donor Program -
Cord Blood (U1CB)
(u3cb) Caitlin Raymond International
Registry - Cord Blood (U3CB)
(u4cb) Gift Of Life Bone Marrow
Foundation - Cord Blood (U4CB)
(usa1) National Marrow Donor Program -
Adult Donors (USA1)
(usa2) America Bone Marrow Donor
Registry (USA2)
(usa3) Caitlin Raymond International
Registry -adult Donors (USA3)
(usa4) Gift Of Life Bone Marrow
Foundation - Adult Donors (USA4)
(uy) Sindome (UY)
(w3cb) Polish Central Bone Marrow
Donor Registry - Cord Blood (W3CB)
(wacb) Unrelated Bone Marrow Donor
Registry - Cord Blood (WACB)
(za) South African Bone Marrow Registry
(ZA)
Specify the other registry or cord blood bank that
the unrelated donor was registered at:
How many mismatches were there for the HLA -
A antigenic test? (2 digits)
Match (0)
Integer::1 Mismatch (1)
Integer::2 Mismatch (2)
Without Evaluation (ND)
How many mismatches were there for the HLA -
B antigenic test? (2 digits)
Match (0)
Integer::1 Mismatch (1)
Integer::2 Mismatch (2)
Without Evaluation (ND)
How many mismatches were there for the HLA -
C antigenic test? (2 digits)
Match (0)
Integer::1 Mismatch (1)
Integer::2 Mismatch (2)
Without Evaluation (ND)
How many mismatches were there for the HLA -
DRB1 antigenic test? (2 digits)
Match (0)
Integer::1 Mismatch (1)
Integer::2 Mismatch (2)
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Without Evaluation (ND)
How many mismatches were there for the HLA -
DQB1 antigenic test? (2 digits)
Match (0)
Integer::1 Mismatch (1)
Integer::2 Mismatch (2)
Without Evaluation (ND)
How many mismatches were there for the HLA -
DPB1 antigenic test? (2 digits)
Match (0)
Integer::1 Mismatch (1)
Integer::2 Mismatch (2)
Without Evaluation (ND)
How many mismatches were there for the HLA -
A allelic test? (4 digits)
Match (0)
Integer::1 Mismatch (1)
Integer::2 Mismatch (2)
Without Evaluation (ND)
How many mismatches were there for the HLA -
B allelic test? (4 digits)
Match (0)
Integer::1 Mismatch (1)
Integer::2 Mismatch (2)
Without Evaluation (ND)
How many mismatches were there for the HLA -
C allelic test? (4 digits)
Match (0)
Integer::1 Mismatch (1)
Integer::2 Mismatch (2)
Without Evaluation (ND)
How many mismatches were there for the HLA -
DRB1 allelic test? (4 digits)
Match (0)
Integer::1 Mismatch (1)
Integer::2 Mismatch (2)
Without Evaluation (ND)
How many mismatches were there for the HLA -
DQB1 allelic test? (4 digits)
Match (0)
Integer::1 Mismatch (1)
Integer::2 Mismatch (2)
Without Evaluation (ND)
How many mismatches were there for the HLA -
DPB1 allelic test? (4 digits)
Match (0)
Integer::1 Mismatch (1)
Integer::2 Mismatch (2)
Without Evaluation (ND)
Hematopoietic Stem Cell Transplant (hsct)
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Was there ex vivo graft manipulation other than
for RBC removal or volume reduction?
Yes
No
Ex Vivo Graft Manipulation Type
What was the method of ex vivo graft
manipulation other than for RBC removal or
volume reduction? (Optional for non-U.S.
Centers)
Cd34 Selection (CD34 selection)
Ex Vivo Increase (Ex vivo expansion)
Other Ex Vivo Manipulation (Other)
Other Negative Selection (Other negative
selection)
T-cell Depletion (T-cell depletion)
Tumor Purging (Tumor purging)
Was a particular method of ex vivo graft
manipulation other than for RBC removal or
volume reduction performed? (Optional for non-
U.S. centers)
Yes
No
Specify the ex vivo graft manipulation other than
for RBC removal or volume reduction: (Optional
for non-U.S. centers. Answer this CDE only if the
answer to CDE 2750679 is "Other negative
selection" or "other." )
Hematopoietic Stem Cell Transplant (hsct)
Which scale was used to measure/report the
functional status? (Prior to the start of the
preparative regimen)
Karnofsky Performance Status
(Karnofsky)
Lansky Play-performance Status
(Lansky)
Performance Status (Karnofsky) (Prior to the start
of the preparative regimen)
Moribund, Fatal Processes Progressing
Rapidly (10)
Normal, No Complaints, No Evidence Of
Disease (100)
Very Sick, Hospitalization Indicated.
Death Not Imminent (20)
Severely Disabled, Hospitalization
Indicated. Death Not Imminent (30)
Disabled, Requires Special Care And
Assistance (40)
Requires Considerable Assistance And
Frequent Medical Care (50)
Requires Occasional Assistance, But Is
10 / 51
Treatment - 2400 Revision 1 - Pre-Transplant Essential Data (TED) ISO
Date Format - 2892485v2.0
Able To Care For Most Of His/her Needs
(60)
Cares For Self, Unable To Carry On
Normal Activity Or To Do Active Work
(70)
Normal Activity With Effort; Some Signs
Or Symptoms Of Disease (80)
Able To Carry On Normal Activity; Minor
Signs Or Symptoms Of Disease (90)
Performance Status (Lansky) (Prior to the start of
the preparative regimen)
No Play; Does Not Get Out Of Bed. (10)
Fully Active, Normal (100)
Often Sleeping; Play Entirely Limited To
Very Passive Activities. (20)
In Bed; Needs Assistance Even For
Quiet Play. (30)
Mostly In Bed; Participates In Quiet
Activities. (40)
Gets Dressed, But Lies Around Much Of
The Day; No Active Play, Able To
Participate In All Quiet Play And
Activities. (50)
Up And Around, But Minimal Active Play;
Keeps Busy With Quieter Activities. (60)
Both Greater Restriction Of And Less
Time Spent In Play Activity (70)
Active, But Tires More Quickly (80)
Minor Restrictions In Physically
Strenuous Activity (90)
What was the recipient's test results for the
presence of CMV-antibodies? (IgG or Total )
Not Reaction (Non-reactive)
Not Done: C49484 (Not Done)
Reaction (Reactive)
Unknown (Unknown)
What was the donor test results for the presence
of CMV-antibodies? (allo only Multiple donors:
report any positive CMV test as reactive, IgG or
Total)
Not Reaction (Non-reactive)
Not Done: C49484 (Not Done)
Reaction (Reactive)
Unknown (Unknown)
Preparative Regimen
Was a preparatve regimen given?
Yes
No
Was total body irradiation given as a preparative
regimen? (TBI)
Yes
No
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What was the total prescribed cumulative dose of
total body irradiation for the preparative regimen
(per the protocol)? (TBI)
What was the unit of measure for the total
prescribed cumulative dose of total body
irradiation for the preparative regimen (per the
protocol)? (TBI)
Centigray (cGy)
Gray (Gy)
Was total nodal or total abdominal irradiation
given as a preparative regimen? (TLI, TNI, TAI)
Yes
No
What was the total prescribed cumulative dose of
total nodal or total abdominal irradiation for the
preparative regimen (per the protocol)? (TLI, TNI,
TAI)
What was the unit of measure for the total
prescribed cumulative dose of total nodal or total
abdominal irradiation for the preparative regimen
(per the protocol)? (TLI, TNI, TAI)
Centigray (cGy)
Gray (Gy)
Preparative Regimen - General
Medication
What was the type of preparative regimen
medication?
Antithymocyte Globulin Antilymphocyte
Serum (ALG, ALS, ATG, ATS (before
d0))
Anthracycline Antibiotic (Anthracycline)
Bleomycin (Bleomycin)
Busulfan (Busulfan)
Carboplatin (Carboplatin)
Carmustine (Carmustine (BCNU))
Cisplatin Medication (Cisplatin)
Corticosteroid Medication
(Corticosteriods)
Cyclophosphamide Medication
(Cyclophosphamide)
Cytosine Arabinoside (Cytarabine (Ara-
C))
Etoposide (Etoposide (VP-16))
Fludarabine (Fludarabine)
Ifosfamide (Ifosfamide)
Imatinib Mesylate (Imanitib mesylate
(Gleevec, Glivec))
Lomustine (Lomustine (CCNU))
Melphalan (Melphalan (L-PAM))
Mitoxantrone (Mitoxantrone)
Monoclonal Antibody (Monoclonal
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Antibody)
Other (Other)
Paclitaxel (Paclitaxel (Taxol, Xyotax))
Radiolabeled Monoclonal Antibody
(Radiolabeled MAb)
Teniposide (Teniposide (VM26))
Thiotepa (Thiotepa)
Was a particular preparative regimen medication
administered per the protocol?
Yes
No
What was the total dose of the planned
preparative regimen per the protocol?
What was the unit of measure for the preparative
regimen dose per the protocol? (Do not answer if
the answer to CDE 2739625 is
"Anthracycline","Monoclonal Antibody" or
"Radiolabled MAb".)
Milligram Per Kilogram (mg/kg)
Milligram Per Meter Squared (mg/m2)
Specify the source of the preparative regimen
medication: (Answer this CDE only if the answer
to CDE 2739625 is ALG, ALS, ATG, ATS before
d0)
Horse (Horse)
Other Source (Other source)
Rabbit (Rabbit)
Specify the other source of the preparative
regimen medication: (Answer this CDE only if the
answer to CDE 2753241 is OTHER.)
What was the route of administration for the
planned preparative regimen medication?
(Answer this CDE only if the value to CDE
2739625 is "Busulfan.")
Oral Route Of Administration Intravenous
Route Of Administration (Both)
Intravenous Route Of Administration (IV)
Oral Route Of Administration (Oral)
Specify the other type of preparative regimen
medication: (Answer this CDE only if the answer
to CDE 2739625 is "Other.")
Preparative Regimen - Anthracyclines
What was the type of anthracycline preparative
regimen?
Daunorubicin (Daunorubicin)
Doxorubicin (Doxorubicin)
Idarubicin (Idarubicin)
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Was an anthracycline planned as a preparative
regimen?
Yes
No
What was the total dose of the planned
preparative regimen per the protocol?
What was the unit of measure for the planned
dosage of the anthracycline preparative regimen?
Milligram Per Kilogram (mg/kg)
Milligram Per Meter Squared (mg/m2)
Preparative Regimen - Monoclonal
Antibodies (mab)
What was the type of preparative regimen
monoclonal antibody (MAb)?
Alemtuzumab (Campath)
Gemtuzumab Ozogamicin (Gemtuzumab
(mylotarg, anti-CD33))
Other Monoclonal Antibody (Other MAb)
Rituximab (Rituximab (Rituxan, anti-
CD20))
Was a monoclonal antibody planned as a
preparative regimen?
Yes
No
What was the total dose of the planned
preparative regimen per the protocol?
What was the unit of measure for the planned
dosage of the monoclonal antibody preparative
regimen?
Milligram Per Kilogram (mg/kg)
Milligram Per Meter Squared (mg/m2)
Specify the other type of the monoclonal antibody
preparative regimen: (Answer only if the answer
to CDE 2741209 is "Other MAb.")
Preparative Regimen - Radiolabeled Mab
What type of radiolabeled monoclonal antibody
was used as a   preparative regimen?
Ibritumomab Tiuxetan (Ibritumomab
(Zevalin))
Other Radiolabeled Monoclonal Antibody
(Other rMAb)
Tositumomab (Tositumomab (Bexxar))
Was a radiolabeled monoclonal antibody planned
as a preparative regimen?
14 / 51
Treatment - 2400 Revision 1 - Pre-Transplant Essential Data (TED) ISO
Date Format - 2892485v2.0
Yes
No
What was the planned total dosage of the
radiolabeled monoclonal antibody preparative
regimen?
What was the unit of measure for the planned
dosage of the radiolabeled monoclonal antibody
preparative regimen?
Millibecquerel (mBq)
Millicurie (mCi)
Specify the other type of the radiolabeled
monoclonal antibody preparative regimen:
(Answer only if the answer to CDE 2741552 is
"Other rMAb.")
Intent Of Preparative Regimen
Is the INTENT of the preparative regimen
MYELOABLATIVE (allogeneic only)?
Yes
No
Reason For Nst / Ric
What was the reason for the reduced intensity/
non-myeloablative preparative regimen?
Recipient Age (Age of recipient)
Comorbidity (Comorbid conditions)
Other (Other)
Prior Hematopoietic Stem Cell
Transplantation (Prior HSCT)
Protocol (Protocol-driven)
Did a particular reason for the non-myeloablative
/ reduced intensity preparative regimen occur?
Yes
No
Specify the other reason for the non-
myeloablative / reduced intensity (NST / RIC)
preparative regimen: (Answer only if the answer
to CDE 2737040 is "Other.")
Comorbid Conditions
Is there a history of mechanical ventilation?
Yes
No
Is there a history of proven invasive fungal
infection?
Yes
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No
Was there any involvement of clinically significant
co-existing diseases or organ impairment at any
time prior to preparative regimen?
Yes
No
Type Of Comorbid Condition
What was the clinically significant co-existing
disease or organ impairment?
Arrhythmia. (Arrhythmia)
Cardiac. (Cardiac)
Cerebrovascular Disease.
(Cerebrovascular disease)
Diabetes. (Diabetes)
Heart Valve Disease. (Heart valve
disease)
Hepatic, Mild. (Hepatic, mild)
Hepatic, Moderate / Severe. (Hepatic,
moderate / severe)
Infection. (Infection)
Inflammatory Bowel Disease.
(Inflammatory bowel disease)
Obesity. (Obesity)
Other (Other)
Peptic Ulcer. (Peptic ulcer)
Psychiatric Disturbance (Psychiatric
disturbance)
Pulmonary, Moderate. (Pulmonary,
moderate)
Pulmonary, Severe. (Pulmonary, severe)
Renal, Moderate / Severe. (Renal,
moderate / severe)
Rheumatologic (2) (Rheumatologic)
Solid Tumor, Prior. (Solid tumor, prior)
Was a particular clinically significant comorbidity
present before the start of the preparative
regimen?
No: C49487 (No)
Not Done: C49484 (Not Done)
Yes: C49488 (Yes)
Specify the other type of clinically significant
comorbidity: (Answer only if the answer to CDE
2737130 is "Other.")
Gvhd Prophylaxis (allo Only)
Was GVHD prophylaxis planned / given?
Yes
No
Was ALG, ALS, ATG, ATS (after d0) therapy used
after the start of the preparative regimen to
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prevent acute GVHD or graft rejection?
Yes
No
Was corticosteroid (systemic) therapy used after
the start of the preparative regimen to prevent
acute GVHD or graft rejection?
Yes
No
Was cyclosporine (CSA) (Sandimmune, Neoral)
therapy used after the start of the preparative
regimen to prevent acute GVHD or graft
rejection?
Yes
No
Was ECP (extra-corporeal photopheresis)
therapy used after the start of the preparative
regimen to prevent acute GVHD or graft
rejection?
Yes
No
Was FK 506 (Tacrolimus, Prograf) therapy used
after the start of the preparative regimen to
prevent acute GVHD or graft rejection?
Yes
No
Was methotrexate (MTX) (Amethopterin) used
after the start of the preparative regimen to
prevent acute GVHD or graft rejection?
Yes
No
Was an in vivo monoclonal antibody used after
the start of the preparative regimen to prevent
acute GVHD or graft rejection?
Yes
No
Was anti CD 25 (Zenapax, Daclizumab, AntiTAC)
the in vivo monoclonal antibody used after the
start of the preparative regimen to prevent acute
GVHD or graft rejection?
Yes
No
Was campath the in vivo monoclonal antibody
used after the start of the preparative regimen to
prevent acute GVHD or graft rejection?
Yes
No
Was etanercept (Enbrel) the in vivo monoclonal
antibody used after the start of the preparative
regimen to prevent acute GVHD or graft
rejection?
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Yes
No
Was infliximab (Remicade) the in vivo monoclonal
antibody used after the start of the preparative
regimen to prevent acute GVHD or graft
rejection?
Yes
No
Was some other in vivo monoclonal antibody
used after the start of the preparative regimen to
prevent acute GVHD or graft rejection?
Yes
No
Specify the other in vivo monoclonal antibody
used after the start of the preparative regimen to
prevent acute GVHD or graft rejection
Was mycophenolate mofetil (MMF) (CellCept)
used after the start of the preparative regimen to
prevent acute GVHD or graft rejection?
Yes
No
Was sirolimus (Rapamycin, Rapamune) used
after the start of the preparative regimen to
prevent acute GVHD or graft rejection?
Yes
No
Was some other agent used after the start of the
preparative regimen to prevent acute GVHD or
graft rejection?
Yes
No
Specify the other agent used after the start of the
preparative regimen to prevent acute GVHD or
graft rejection
Post-hsct Disease Therapy Planned As Of
Day 0
Is this HSCT part of a planned multiple
(sequential) graft / HSCT protocol?
Yes
No
Is additional post-HSCT therapy planned?
Yes
No
Type Of Additional Post-hsct Therapy
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What was the type of post-hematopoietic stem
cell transplantation (HSCT) therapy?
Bortezomib (Bortezomib (Velcade))
Cellular Therapy (Cellular therapy (e.g.
DCI, DLI))
Imatinib Mesylate (Imanitib mesylate
(Gleevec, Glivec))
Intrathecal Chemotherapy (Intrathecal
chemotherapy)
Lenalidomide (Lenalidomide (Revlimid))
Local Radiation Therapy (Local
radiotherapy)
Other (Other)
Rituximab (Rituximab (Rituxan,
Mabthera))
Thalidomide (Thalidomide (Thalomid))
Was a particular post-hematopoietic stem cell
transplantation (HSCT) therapy planned?
Yes
No
Specify the other planned post-HSCT therapy:
(Answer this CDE only if the answer to CDE
2738487 is "Other.")
Other Toxicity Modifying Regimen
Was KGF (palifermin, Kepivance) started or is
there a plan to use it?
Blinded Clinical Study (Masked trial)
No: C49487 (No)
Yes (Yes)
As part of a toxicity modifying regimen, was FGF
(velafermin) started or is there a plan to use it?
Blinded Clinical Study (Masked trial)
No: C49487 (No)
Yes (Yes)
Pre-transplant Essential Data Disease
Classification Sheet
What was the primary disease for which the
HSCT was performed?
All (Acute lymphoblastic leukemia (ALL))
Acute Myeloid Leukemia (Acute
myelogenous leukemia (AML or ANLL))
Anemia Hemoglobinopathy (Anemia /
hemoglobinopathy)
Autoimmune Disease (Autoimmune
Disorder)
Breast Carcinoma (Breast Cancer)
Chronic Myelogenous Leukemia
(Chronic myelogenous leukemia (CML))
Histiocytic Disorders (Histiocytic
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disorders)
Hodgkin's Lymphoma (Hodgkin
lymphoma)
Immunodeficiency Syndrome (Immune
deficiencies)
Congenital Metabolic Disorder
Osteopetrosis (Inherited disorders of
metabolism / osteopetrosis)
Plasma Cell Myeloma (Multiple myeloma
/ plasma cell disorder (PCD))
Myelodysplastic/myeloproliferative
Disease (Myelodysplastic (MDS) /
myeloproliferative (MPS) disorders)
Non-hodgkin's Lymphoma (Non-Hodgkin
lymphoma)
Other Acute Leukemia (Other acute
leukemia)
Other Diseases And Disorders (Other
disease)
Other Leukemia (Other leukemias)
Other Malignant Neoplasm (Other
malignancies)
Platelet Diseases And Disorders
(Platelet disorder)
Acute Leukemias
What was the W.H.O classification of the acute
myelogenous leukemia (AML) or acute
nonlymphocytic leukemia (ANLL)?
Acute Basophilic Leukemia (Acute
Basophilic Leukemia)
Acute Erythroid Leukemia (Acute
Erythroid Leukemia (erythroid / myeloid
and pure erythroleukemia) / {M6})
Acute Megakaryoblastic Leukemia
(Acute Megakaryoblastic Leukemia  /
{M7})
Acute Monoblastic Leukemia And Acute
Monocytic Leukemia (Acute Monoblastic
Leukemia / Acute Monocytic Leukemia /
{M5})
Not Otherwise Specified Acute Myeloid
Leukemia (Acute Myeloid Leukemia Not
Otherwise Specified)
Acute Myeloid Leukemia With Maturation
(Acute Myeloid Leukemia with Maturation
/ {M2})
Acute Myeloid Leukemia Without
Maturation (Acute Myeloid Leukemia
without Maturation / {M1})
Acute Myeloid Leukemia, Minimally
Differentiated (Acute Myeloid Leukemia,
Minimally Differentiated / {M0})
Acute Myelomonocytic Leukemia (Acute
Myelomonocytic Leukemia / {M4})
Acute Panmyelosis With Myelofibrosis
(Acute Panmyelosis with Myelofibrosis)
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Acute Myeloid Leukemia With 11q23
(mll) Abnormalities (AML with 11q23
(MLL) abnormalities)
Acute Myeloid Leukemia With Abnormal
Marrow Eosinophils (AML with abnormal
bone marrow eosinophils and
inv(16)(p13;q22) or t(16;16) (p13;q22),
(CBF beta/MYH11))
Acute Myeloid Leukemia With
Multilineage Dysplasia (AML with multi-
lineage dysplasia)
Acute Myeloid Leukemia With
T(8;21)(q22;q22)(aml1(cbfa)/eto) (AML
with t(8;21) (q22;q22) (AML1 / ETO))
Acute Promyelocytic Leukemia With
T(15;17)(q22;q12)(pml/rara) (APL with
t(15;17)(q22;q12),(PML/RAR alpha) and
variant /  {M3})
Myeloid Sarcoma (Myeloid Sarcoma)
Did AML transform from MDS / MPS? (Complete
entire MDS Section on Disease Classification on
page 10-11 - of PDF copy, questions 218-261
and entire AML Section page 7-8 of PDF copy,
questions 174-185, 2682630, 2494567, 2648560,
2675109, 2685090, 2674686, 2676456, 2676461,
2676467,2737648,2737653,2738448,2738429,27
38414,2866534,2674563,2648566,2738465,2738
473,2674599,2686057,2686068,2686091,268882
4)
Yes
No
Was AML therapy-related?
No (No)
Unknown (Unknown)
Yes (Yes)
Type Of Therapy Related Aml
What was the cause of the therapy related AML?
Alkylating Agent Radiation Therapy
Related (Alkylating agent / radiation-
related)
Topoisomerase-ii Inhibitor Related
(Topoisomerase II inhibitor-related)
Unknown (Unknown)
Did a particular cause of therapy-related AML
occur?
Yes
No
Acute Leukemias
Was imatinib mesylate given as pretransplant
therapy for the acute myeloid leukemia anytime
prior to start of preparative regimen?
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No (No)
Unknown (Unknown)
Yes (Yes)
What was the status of the acute myelogenous
leukemia (AML) or acute nonlymphocytic
leukemia (ANLL) at the time of transplantation?
Complete Remission (Complete
Remission)
Never Therapeutic Procedure (Never
treated)
Primary Induction Failure (Primary
Induction Failure (PIF))
Recurrent Disease (Relapse)
For patients with hematologic CR, was a
cytogenetic CR also achieved at the time of
transplantation?
No (No)
Unknown (Unknown)
Yes (Yes)
For patients with hematologic CR, was a
molecular CR also achieved at the time of
transplantation?
No (No)
Unknown (Unknown)
Yes (Yes)
At the time of transplantation, what was the
number of the complete remission of acute
myeloid leukemia?
First (First)
Second:c25666 (Second)
Greater Third (Third or higher)
At the time of transplantation, what was the
number of the relapse of acute myeloid
leukemia?
First (First)
Second:c25666 (Second)
Greater Third (Third or higher)
Acute Lymphoblastic Leukemia (all)
Specify the type of acute lymphoblastic leukemia
(ALL):
Not Otherwise Specified All (ALL, NOS)
Precursor B-lymphoblastic Leukemia
(Precursor B-cell ALL (L1/L2))
Precursor T-lymphoblastic Leukemia
(Precursor T-Cell ALL)
T(1;19)(q23;p13.3) (t(1;19)(q23;p13)
E2A/PBX1)
T(21;22)(q22;q12) (t(12;21)(p12;q22)
ETV / CBF-alpha)
T(9;22)(q34;q11) (t(9;22)(q34;q11);
BCR/ABL+)
T(v;11)(v;q23) (t(v;11q23); MLL
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rearranged)
Was imatinib mesylate given as pretransplant
therapy for acute lymphoblastic leukemia (ALL)
anytime prior to start of preparative regimen?
No (No)
Unknown (Unknown)
Yes (Yes)
What was the status of the acute lymphoblastic
leukemia (ALL) at the time of transplantation?
Complete Remission (Complete
Remission)
Never Therapeutic Procedure (Never
treated)
Primary Induction Failure (Primary
Induction Failure (PIF))
Recurrent Disease (Relapse)
At the time of transplantation, was the type of
hematologic complete remission of the acute
lymphoblastic leukemia (ALL) cytogenetic
remission?
No (No)
Unknown (Unknown)
Yes (Yes)
At the time of transplantation, was the type of
hematologic complete remission of the acute
lymphoblastic leukemia (ALL) molecular
remission?
No (No)
Unknown (Unknown)
Yes (Yes)
At the time of transplantation, what was the
number of the complete remission of acute
lymphoblastic leukemia (ALL)?
First (First)
Second:c25666 (Second)
Greater Third (Third or higher)
At the time of transplantation, what was the
number of the relapse of acute lymphoblastic
leukemia (ALL)?
First (First)
Second:c25666 (Second)
Greater Third (Third or higher)
Other Acute Leukemia
What was the W.H.O. classification of the other
acute leukemia?
Acute Mast Cell Leukemia (Acute  Mast
Cell Leukemia)
Acute Undifferentiated Leukemia (Acute
Undifferentiated Leukemia)
Acute Biphenotypic Leukemia
(biphenotypic, bilineage or hybrid
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leukemia)
Other Acute Leukemia (Other  Acute
Leukemia)
Specify the type of other acute leukemia:
Was imatinib mesylate given for pretransplant
therapy for the other acute leukemia anytime prior
to the start of the preparative regimen?
No (No)
Unknown (Unknown)
Yes (Yes)
What was the status of the other acute leukemia
at the time of transplantation?
Complete Remission (Complete
Remission)
Never Therapeutic Procedure (Never
treated)
Primary Induction Failure (Primary
Induction Failure (PIF))
Recurrent Disease (Relapse)
For patients with complete remission of the other
acute leukemia, was a cytogenetic complete
remission also achieved at the time of
transplantation?
No (No)
Unknown (Unknown)
Yes (Yes)
For patients with complete remission of the other
acute leukemia, was a molecular complete
remission also achieved at the time of
transplantation?
No (No)
Unknown (Unknown)
Yes (Yes)
At the time of transplantation, what was the
number of the complete remission of the other
acute leukemia?
First (First)
Second:c25666 (Second)
Greater Third (Third or higher)
At the time of transplantation, what was the
number of the relapse of the other acute
leukemia?
First (First)
Second:c25666 (Second)
Greater Third (Third or higher)
Chronic Myelogenous Leukemia (cml)
What was the classification of the chronic
myelogenous leukemia (Philadelphia
chromosome+, Ph+, t(9;22)(q34;q11), or variant
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OR bcr/abl+)?
Ph Unknown/bcr+ (Ph Unknown/BCR+)
Ph-/bcr+ (Ph-/BCR+)
Ph+/bcr Unknown (Ph+/BCR Unknown)
Ph+/bcr- (Ph+/BCR-)
Ph+/bcr+ (Ph+/BCR+)
Did the recipient receive treatment for chronic
myelogenous leukemia prior to this HSCT?
Yes
No
Cml Prior Hsct Treatment
What type of treatment did the recipient receive
prior to the hematopoietic stem cell
transplantation (HSCT)?
Combination Chemotherapy
(Combination chemotherapy)
Dasatinib (Dasatinib (Sprycel))
Hydroxyurea (Hydroxyurea (HU))
Imatinib Mesylate (Imatinib mesylate
(Gleevec, Glivec))
Interferon (Interferon)
Nilotinib (Nilotinib (Tasigna))
Other (Other)
Was a treatment administered prior to this
hematopoietic stem cell transplantation?
Yes
No
Specify the other type of therapy that the
recipient received prior to this hematopoietic stem
cell transplantation (HSCT): (Answer only if the
answer to CDE 2737666 is "Other.")
Chronic Myelogenous Leukemia (cml)
What was the phase of the CML at the time of
transplantation?
Accelerated Phase Chronic
Myelogenous Leukemia (Accelerated
Phase)
Blast Phase Chronic Myelogenous
Leukemia (Blast crisis)
Chronic Phase Chronic Myelogenous
Leukemia (Chronic phase)
Hematologic Cr (Hematologic complete
remission)
If the CML was in hematologic complete
remission, what was the disease status before
treatment?
Accelerated Phase Chronic
Myelogenous Leukemia (Accelerated
Phase)
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Blast Phase Chronic Myelogenous
Leukemia (Blast crisis)
Chronic Phase Chronic Myelogenous
Leukemia (Chronic phase)
At the time of transplantation, was the type of
hematologic complete remission of the chronic
myelogenous leukemia also a cytogenetic
remission?
Complete (Complete)
Cytogenetics Unknown (Cytogenetics
Unknown)
No (No)
At the time of transplantation, was the type of
hematologic complete remission of the chronic
myelogenous leukemia also molecular remission
(bcr/abl)?
Bcr-abl Oncoprotein Unknown (bcr/abl
unknown)
No (No)
Yes (Yes)
At the time of transplantation, was the type of
chronic phase of the chronic myelogenous
leukemia also a cytogenetic remission?
Complete (Complete)
Cytogenetics Unknown (Cytogenetics
Unknown)
No (No)
At the time of transplantation, was the type of
chronic phase of the chronic myelogenous
leukemia also a molecular remission (bcr/abl)?
Bcr-abl Oncoprotein Unknown (bcr/abl
unknown)
No (No)
Yes (Yes)
At the time of transplantation, what was the
number of the status of the CML?
First (First)
Second:c25666 (Second)
Greater Third (Third or higher)
Myelodysplastic Or Myeloproliferative
Disease Classification
What was the MDS or myeloproliferative disease
classification?
Myelodysplastic Syndrome Associated
With Isolated Del (5q) Chromosome
Abnormality (5q- syndrome)
Acute Myeloid Leukemia (AML)
Chronic Eosinophilic Leukemia (Chronic
eosinophilic leukemia (hypereosinophilic
syndrome))
Chronic Idiopathic Myelofibrosis (Chronic
idiopathic myelofibrosis (with extra-
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medullary hematopoiesis), myelofibrosis
with myeloid metaplasia, acute
myelofibrosis or myelosclerosis)
Chronic Myelomonocytic Leukemia
(Chronic myelomonocytic leukemia
(CMMol, CMML))
Not Otherwise Specified Chronic
Myeloproliferative Disorder (Chronic
myeloproliferative disease, unclassifiable
(MPS, NOS))
Chronic Neutrophilic Leukemia (Chronic
neutrophilic leukemia)
Essential Thrombocythemia (Essential
thrombocythemia (ET))
Juvenile Myelomonocytic Leukemia
(Juvenile myelomonocytic leukemia
(JMML, JCML, JCMML))
Not Otherwise Specified Mds (MDS
unclassifiable/NOS)
Polycythemia Vera (Polycythemia vera
(PCV))
Refractory Anemia (RA)
Raeb-1 (RAEB-1)
Raeb-2 (RAEB-2)
Refractory Anemia With Ringed
Sideroblasts (RARS)
Refractory Cytopenia With Multilineage
Dysplasia (RCMD)
Refractory Cytopenia With Multilineage
Dysplasia And Ringed Sideroblasts
(RCMD / RS)
Was the myelodysplastic/myeloproliferative
disease classification made at the time of
diagnosis? (Do not answer if the answer to CDE
2738448 is AML)
Yes
No
Was the myelodysplastic/myeloproliferative
disease classification made at the time of
transplantation?
Yes
No
Myelodysplastic Or Myeloproliferative
Diseases
If the MDS sub type is AML, date of MDS
diagnosis:
Was Janus kinase 2 (jak2) gene mutation
positive?
No: C49487 (No)
Not Done: C49484 (Not Done)
Yes: C49488 (Yes)
Was MDS / MPS therapy-related?
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No (No)
Unknown (Unknown)
Yes (Yes)
Type Of Therapy Related Mds / Mps
What was the cause of the therapy-related
MDS/MPS?
Alkylating Agent Radiation Therapy
Related (Alkylating agent / radiation-
related)
Topoisomerase-ii Inhibitor Related
(Topoisomerase II inhibitor-related)
Unknown (Unknown)
Did a cause of the therapy related MDS / MPS
occur?
Yes
No
Myelodysplastic Or Myeloproliferative
Diseases
What was the status of MDS/MPS/CMML at
transplantation?
Relapse Cr (Relapse after complete
response)
Supportive Care Without Chemotherapy
(Supportive care or treatment without
chemotherapy)
Chemotherapy (Treated with
chemotherapy)
If the MDS/MPS/CMML was treated with
chemotherapy, what was the disease status at
the time of transplantation?
Complete Remission (CR)
No Cr Better (Improvement but no CR)
Without Response (NR - no response)
Progressive Disease (Prog / worse)
At the time of transplantation, what was the
number of the complete remission of the MDS /
MPS / CMML?
First (First)
Second:c25666 (Second)
Greater Third (Third or higher)
At the time of transplantation what was the
number of the relapse after complete response of
the MDS/MPS/CMML?
First (First)
Second:c25666 (Second)
Greater Third (Third or higher)
At the time of transplantation, what was the
status of the JMML?
Continued Complete Response (CCR -
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Continued Complete Response)
Complete Remission (CR - Complete
Response)
Minimum Response (MR - Minimal
Response)
Not Assessed (Not Assessed)
Progressive Disease (PD - Progressive
Disease)
Partial Remission (PR - Partial
Response)
Stable Disease (SD - Stable Disease)
Other Leukemias
What is the classification of the other leukemia?
Ph Unknown/bcr Unknown Atypical
Chronic Myeloid Leukemia (Atypical
chronic myeloid leukemia (CML, NOS),
Ph unknown/bcr unknown)
Ph Unknown/bcr- Atypical Chronic
Myeloid Leukemia (Atypical chronic
myeloid leukemia (CML, NOS), Ph
unknown/bcr-)
Ph-/bcr Unknown Atypical Chronic
Myeloid Leukemia (Atypical chronic
myeloid leukemia (CML, NOS), Ph-/bcr
unknown)
Ph -/bcr-abl- Atypical Chronic Myeloid
Leukemia (Atypical chronic myeloid
leukemia (CML, NOS), Ph-/bcr/abl-)
Small Lymphocytic Lymphoma Cll
(Chronic Lymphocytic Leukemia (CLL),
B-cell / Small Lymphocytic Lymphoma
(SLL))
Not Otherwise Specified Cll (Chronic
Lymphocytic Leukemia (CLL), NOS)
Cll, T-cell (CLL, T-cell)
Hairy Cell Leukemia (Hairy Cell
Leukemia)
Leukemia (Other Leukemia)
Not Otherwise Specified Leukemia
(Other Leukemia, NOS)
B-cell Prolymphocytic Leukemia (PLL, B-
Cell)
T-cell Prolymphocytic Leukemia (PLL, T-
Cell)
Not Otherwise Specified Prolymphocytic
Leukemia (Prolymphocytic Leukemia
(PLL), NOS)
Specify the other type of  leukemia:
What was the status of the other leukemia at the
time of transplantation?
Complete Remission (Complete
Remission (CR))
Never Therapeutic Procedure (Never
treated)
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Stable Disease (No Response / Stable
(NR / SD))
Nodular Partial Remission (Nodular
partial remission (nPR))
Partial Remission (Partial remission
(PR))
Progressive Disease (Progression)
Without Therapeutic Procedure
Recurrent Disease (Relapse (untreated))
Lymphomas
Specify the type of hodgkin lymphoma:
Not Otherwise Specified Hodgkin's
Lymphoma (Hodgkin Lymphoma, NOS)
Lymphocyte Depleted Hodgkin
Lymphoma (Lymphocyte Depleted)
Lymphocyte Rich Classical Hodgkin
Lymphoma (Lymphocyte-rich)
Mixed Cellularity Hodgkin Lymphoma
(Mixed Cellularity)
Nodular Lymphocyte Predominant
Hodgkin Lymphoma (Nodular
Lymphocyte Predominant Hodgkin
Lymphoma)
Nodular Sclerosis Hodgkin Lymphoma
(Nodular Sclerosis)
What was the status of the hodgkin lymphoma at
the time of transplantation?
Confirmed Cr (Complete Response
confirmed)
Not Confirmed Cr (CR unconfirmed
(CRU) (complete response with
persistent scan abnormalities of
unknown signifcance))
Never Therapeutic Procedure (Never
treated)
Partial Response (Partial response (PR))
Primary Refractory (less Than Partial
Response (pr) To Initial Therapy) /
Primary Induction Failure-resistant (pif
Res) (Primary refractory (less than
partial response (PR) to initial therapy) /
Primary induction failure-resistant (PIF
res))
Recurrent Disease (Relapse)
Specify the type of partial response of the
hodgkin lymphoma:
With Prior Cr (With prior complete
remission)
Without Prior Cr (Without prior complete
remission)
If there was a complete response of the hodgkin
lymphoma at the time of transplantation, what
was the number of the complete response?
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First (First)
Second:c25666 (Second)
Greater Third (Third or higher)
If there was a relapse of hodgkin lymphoma at
the time of transplantation, what was the number
of the relapse?
First (First)
Second:c25666 (Second)
Greater Third (Third or higher)
If there was a relapse of hodgkin lymphoma at
the time of transplantation, what was the
sensitivity to chemotherapy?
Resistance (Resistant)
Sensitivity (Sensitive)
Unknown (Unknown)
Without Therapeutic Procedure
(Untreated)
Non-hodgkin's Lymphoma
Specify the type of non-hodgkin lymphoma:
Acute Adult T-cell Lymphoma/leukemia
(Adult T-cell lymphoma / leukemia
(HTLV1+))
Aggressive Nk-cell Leukemia
(Aggressive NK-Cell Leukemia)
Cutaneous Angioimmunoblastic T-cell
Lymphoma (Anaplastic large cell
lymphoma, T / null cell, primary
cutaneous type)
Systemic Anaplastic Large Cell
Lymphoma (Anaplastic large cell
lymphoma, T / null cell, primary systemic
type)
Angioimmunoblastic T-cell Lymphoma
(Angioimmunoblastic T-Cell Lymphoma
(AILD))
Burkitt's Lymphoma Burkitt's Leukemia
(Burkitt's lymphoma / Burkitt cell
leukemia (ALL L3))
Diffuse Large B-cell Lymphoma (Diffuse
Large B-Cell Lymphoma)
Enteropathy-type T-cell Lymphoma
(Enteropathy-type T-Cell Lymphoma)
Extranodal Marginal Zone B-cell
Lymphoma Of Mucosa-associated
Lymphoid Tissue (Extranodal marginal
zone B-cell lymphoma of MALT type)
Nasal Type Extranodal Nk/t-cell
Lymphoma (Extranodal NK / T-cell
lymphoma, nasal type)
Grade 1 Follicular Lymphoma (Follicular
lymphoma (includes variants), Grade I)
Grade 2 Follicular Lymphoma (Follicular
lymphoma (includes variants), Grade II)
Grade 3 Follicular Lymphoma (Follicular
lymphoma (includes variants), Grade III)
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Follicular Lymphoma (Follicular
lymphoma (includes variants), grade
unknown)
Hepatosplenic T-cell Lymphoma
(Hepatosplenic gamma-delta T-cell
lymphoma)
High-grade B-cell Lymphoma, Burkitt-like
(provisional Entity) (High-grade B-cell
lymphoma, Burkitt-like (Provisional
entity))
T-cell Large Granular Lymphocyte
Leukemia (Large T-cell granular
lymphocytic leukemia)
Lymphoplasmacytic Lymphoma
(Lymphoplasmacytic Lymphoma)
Mantle Cell Lymphoma (Mantle Cell
Lymphoma)
Mycosis Fungoides (Mycosis Fungoides)
Nodal Marginal Zone B-cell Lymphoma
(Nodal marginal zone B-cell lymphoma
(+ /  -  monocytoid B-cells))
Other B-cell Non-hodgkin Lymphoma
(Other B-cell lymphoma)
Other T-cell Non-hodgkin Lymphoma
(Other T-cell / NK-cell lymphoma,)
Unspecified Peripheral T-cell Lymphoma
(Peripheral T-cell lymphoma, NOS)
Central Nervous System Lymphoma
(Primary CNS lymphoma)
Sezary Syndrome (Sezary Syndrome)
Splenic Marginal Zone B-cell Lymphoma
(Splenic marginal zone B-cell lymphoma)
Subcutaneous Panniculitis-like T-cell
Lymphoma (Subcutaneous Panniculitis-
Like T-Cell Lymphoma)
Waldenstrom Macroglobulinemia
(Waldenstrom Macroglobulinemia)
What was the subtype of the non-hodgkin
lymphoma diffuse, large B-cell lymphoma?
Intravascular Large B-cell Lymphoma
(Intravascular large B-cell lymphoma)
Mediastinal (thymic) Large B-cell
Lymphoma (Mediastinal large B-cell
lymphoma)
Primary Effusion Lymphoma (Primary
effusion lymphoma)
Specify the type of other B-cell lymphoma:
Specify the other T / NK cell lymphoma:
What was the status of the non-hodgkin's
lymphoma at the time of transplantation?
Confirmed Cr (Complete Response
confirmed)
Not Confirmed Cr (CR unconfirmed
(CRU) (complete response with
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persistent scan abnormalities of
unknown signifcance))
Never Therapeutic Procedure (Never
treated)
Partial Response (Partial response (PR))
Primary Refractory (less Than Partial
Response (pr) To Initial Therapy) /
Primary Induction Failure-resistant (pif
Res) (Primary refractory (less than
partial response (PR) to initial therapy) /
Primary induction failure-resistant (PIF
res))
Recurrent Disease (Relapse)
Specify the type of partial response of the non-
hodgkin lymphoma:
With Prior Cr (With prior complete
remission)
Without Prior Cr (Without prior complete
remission)
If there was a complete response of the non-
hodgkin lymphoma at the time of transplantation,
what was the number?
First (First)
Second:c25666 (Second)
Greater Third (Third or higher)
If there was a relapse of non-hodgkin lymphoma
at the time of transplantation, what was the
number?
First (First)
Second:c25666 (Second)
Greater Third (Third or higher)
If there was a relapse of non-hodgkin lymphoma
at the time of transplantation, what was the
sensitivity to chemotherapy?
Resistance (Resistant)
Sensitivity (Sensitive)
Unknown (Unknown)
Without Therapeutic Procedure
(Untreated)
Plasma Cell Disorders
What was the classification of plasma cell
disorders?
Multiple Myeloma-iga (Multiple Myeloma-
IgA)
Multiple Myeloma-igd (Multiple Myeloma-
IgD)
Multiple Myeloma-ige (Multiple Myeloma-
IgE)
Multiple Myeloma-igg (Multiple Myeloma-
IgG)
Multiple Myeloma-igm (not Waldenstrom
Macroglobulinemia) (Multiple Myeloma-
IgM (not Waldenstrom
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Macroglobulinemia))
Multiple Myeloma-light Chain Only
(Multiple Myeloma-Light Chain Only)
Non-secretory Myeloma (Multiple
myeloma-non-secretory)
Other Plasma Cell Diseases And
Disorders (Other Plasma Cell Disorder)
Plasma Cell Leukemia (Plasma cell
leukemia)
Primary Amyloidosis (Primary
Amyloidosis)
Solitary Plasmacytoma (Solitary
plasmacytoma (no evidence of
myeloma))
Light Chain Involved
Kappa (kappa)
Lambda (lambda)
Durie-Salmon Stage
I - All Of The Following Must Be Present
(hemoglobin >10 G/dl; Serum Calcium
<12 Mg/dl; Urine Light Chains <4 G/24
Hrs; Normal Bones On Radiograph Or
Solitary Plasmacytoma; Igg <5 G/dl; Iga
<3 G/dl) (I - ALL of the following must be
present)
Ii - Fitting Neither Stage I Or Stage Iii (II -
Fitting neither Stage I or Stage III)
Iii - One Of The Following Must Be
Present (hemoglobin <8.5 G/dl; Serum
Calcium >12 Mg/dl; Urine Light Chains
>12 G/24 Hrs; Advanced Lytic Bone
Lesions (>3 Lytic Lesions); Igg >7 G/dl;
Iga >5 G/dl) (III - one of the following
must be present)
Durie-Salmon Sub-stage
A (relatively Normal Renal Function -
Serum Creatinine <2.0 Mg/dl) (A
(relatively normal renal function - serum
creatinine <2.0 mg/dl))
B (abnormal Renal Function - Serum
Creatinine >= 2.0 Mg/dl) (B (abnormal
renal function - serum creatinine >= 2.0
mg/dl))
Serum beta 2 microglobulin value:
Serum beta 2-microglobulin unit of measure:
Microgram Per Deciliter (mcg/dL)
Milligram Per Liter (mg/L)
Nanomole Per Liter (nmol/L)
Serum albumin value:
What is the unit of measure for serum albumin?
Gram Per Deciliter (g/dL)
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Gram Per Liter (g/L)
What was the International Staging System for
Myeloma Stage?
Iss Stage I Plasma Cell Myeloma (Stage
1)
Iss Stage Ii Plasma Cell Myeloma (Stage
2)
Iss Stage Iii Plasma Cell Myeloma
(Stage 3)
Specify the other type of plasma cell disorder:
What was the plasma cell disorder status at
transplantation?
Complete Remission (Complete
Remission (CR))
Never Therapeutic Procedure (Never
treated)
Partial Response Of Multiple Myeloma
Or Plasma Cell Leukemia (Partial
Response (PR))
Progression Of Multiple Myeloma Or
Plasma Cell Leukemia (Progression)
Relapse From Complete Response Of
Multiple Myeloma Or Plasma Cell
Leukemia (Relapse from complete
remission (untreated))
Stable Multiple Myeloma Or Plasma Cell
Leukemia (Stable Disease (SD))
Stringent Complete Response (scr) Of
Multiple Myeloma Or Plasma Cell
Leukemia (Stringent Complete
Remission (sCR))
Very Good Partial Response (vgpr) Of
Multiple Myeloma Or Plasma Cell
Leukemia (Very Good Partial Response
(VGPR))
If the plasma cell disorder was treated, what was
the number of the response?
First (First)
Second:c25666 (Second)
Greater Third (Third or higher)
Breast Cancer
Was the breast cancer inflammatory or non-
inflammatory?
Inflammatory Breast Carcinoma
(Inflammatory)
Not Inflammatory Breast Carcinoma
(Non-inflammatory)
What was the stage of the breast cancer at
diagnosis?
Stage 0 Breast Cancer (0)
Stage I Breast Cancer (I)
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Stage Ii Breast Cancer (II)
Stage Iii Breast Cancer (III)
What was the metastases of the breast cancer?
Metastatic (Metastatic)
Without Distant Metastasis (No distant
metastases)
What was the status of the breast cancer at the
time of transplantation?
First Partial Remission (1st partial
response (PR1))
Adjuvant Therapy (Adjuvant (Stage II, III
only))
Complete Remission (Complete
Remission (CR))
Never Therapeutic Procedure (Never
treated)
Primary Refractory (Primary refractory)
Recurrent Disease (Relapse)
Specify the type of complete remission of the
breast cancer at the time of transplantation:
Confirmed Cr (CR confirmed)
Not Confirmed Cr (CR unconfirmed
(CRU)(complete response with persistent
scan abnormalities of unknown
significance))
What was the number of complete remission of
the breast cancer at the time of transplantation?
First (First)
Second:c25666 (Second)
Greater Third (Third or higher)
If the breast cancer was in the state of relapse at
the time of transplantation, was the cancer local
or metastatic?
Local (Local)
Metastatic (Metastatic)
If the breast cancer was in the state of relapse at
the time of transplantation, what was the number
of the relapse?
First (First)
Second:c25666 (Second)
Greater Third (Third or higher)
If the breast cancer was in the state of relapse at
the time of transplantation, what was the
sensitivity to chemotherapy?
Resistance (Resistant)
Sensitivity (Sensitive)
Unknown (Unknown)
Without Therapeutic Procedure
(Untreated)
Other Disease
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Specify other
Copy of pathology report submitted?
Yes
No
What was the indication for the alternative
hematopoietic cell transplantation (HCT)?
Cardiac Regeneration (Cardiac
regeneration)
Neurologic Regeneration (Neurologic
Regeneration)
Other (Other)
Tolerance Induction Pre-solid Organ
Transplant (Tolerance Induction Pre-Solid
Organ Transplant)
Specify the indication for the other alternative
HCT:
Other Malignancies
What was the classification of the other
malignancy?
Bone Sarcoma (Bone sarcoma,
excluding Ewing family tumors)
Central Nervous System Carcinoma
(Central nervous system tumor, including
CNS PNET)
Colorectal Carcinoma (Colorectal)
Ewing Sarcoma Of Bone (Ewing family
tumors of bone (includes PNET))
Extraosseous Ewing Sarcoma (Ewing
family tumors, extra-osseous (includes
PNET))
Extragonadal Germ Cell Tumor (Germ
cell tumor, extragonadal only)
Hepato-biliary Neoplasm (Hepatobiliary)
Non-small Cell Lung Carcinoma (Lung
cancer, non-small cell)
Sclc (Lung cancer, small cell)
Medulloblastoma (Medulloblastoma)
Melanoma (Melanoma)
Neuroblastoma (Neuroblastoma)
Other Solid Neoplasm (Other solid
tumor)
Ovarian Carcinoma (Ovary)
Pancreatic Carcinoma (Pancreas)
Prostate Carcinoma (Prostate)
Renal Cell Carcinoma (Renal Cell)
Retinoblastoma (Retinoblastoma)
Rhabdomyosarcoma
(Rhabdomyosarcoma)
Soft Tissue Sarcoma (Soft Tissue
Sarcoma)
Malignant Testicular Germ Cell Tumor
(Testicular)
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Thymoma (Thymoma)
Wilms Tumor (Wilms Tumor)
Specify the type of other solid tumor:
What was the status of the other malignancy at
the time of transplantation?
Adjuvant Therapy (Adjuvant)
Complete Response (cr) (CR)
Cru (CRU)
Never Therapeutic Procedure (Never
treated)
Stable Disease (nr/sd) (NR/SD)
Progressive Disease (pd) (PD)
Partial Response (pr) (PR)
Without Therapeutic Procedure
Recurrent Disease (Relapse (untreated))
If the status of the other malignancy at the time of
transplantation is partial remission, what was the
type of partial remission
With Prior Cr (With prior complete
remission)
Without Prior Cr (Without prior complete
remission)
Was RECIST criteria used for evaluation of the
status of the other malignancy at the time of
transplantation?
Yes
No
What was the number of the complete response,
complete response with persistent imaging
abnormalities of unknown significance, or relapse
for the other malignancy at the time of
transplantation?
First (First)
Second:c25666 (Second)
Greater Third (Third or higher)
If there was a relapse of the other malignancy,
what was the sensitivity to chemotherapy?
(Complete only for relapse)
Resistance (Resistant)
Sensitive (Sensitive)
Unknown (Unknown)
Not Treatment (Untreated)
Anemia/hemoglobinopathy
What was the classification of the anemia /
hemoglobinopathy?
Not Genetic Amegakaryocytosis
(Acquired amegakaryocytosis (not
congenital))
Acquired Pure Red Cell Aplasia
(Acquired Pure Red Cell Aplasia (PRCA)
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(not congenital))
Aplastic Anemia Due To Hepatitis
(Acquired SAA, secondary to hepatitis)
Drug-induced Aplastic Anemia (Acquired
SAA, secondary to toxin / other drug)
Severe Aplastic Anemia Not Otherwise
Specified (Acquired Severe Aplastic
Anemia (SAA), NOS)
Diamond-blackfan Anemia (Diamond-
Blackfan anemia (congenital PRCA))
Fanconi Anemia (Fanconi Anemia)
Other Not Genetic Cytopenia (Other
acquired cytopenic syndrome)
Other Genetic Anemia (Other
constitutional anemia)
Other Hemoglobinopathy (Other
hemoglobinopathy)
Paroxysmal Nocturnal Hemoglobinuria
(Paroxysmal Nocturnal Hemogloblinuria
(PNH))
Schwachmann-diamond Syndrome
(Shwachman-Diamond)
Sickle Cell Disease (Sickle Cell Disease)
Sickle Cell-thalassemia (Sickle
thalassemia)
Not Otherwise Specified Thalassemia
(Thalassemia, NOS)
Specify the other acquired cytopenic syndrome:
Specify the other constitutional anemia:
Specify the other hemoglobinopathy:
Platelet Disorders
What was the classification of the platelet
disorder?
Thrombocytopenia Congenital
Abnormality Amegakaryocytosis
(Congenital amegakaryocytosis /
congenital thrombocytopenia)
Glanzmann Thrombasthenia
(Glanzmann Thrombasthenia)
Other Congenital Platelets Abnormality
(Other inherited platelet abnormality)
Specify the other inherited platelet abnormalities:
Histiocytic Disorders
What was the classification of the histiocytic
disorder?
Familiar Hemophagocytic
Lymphohistiocytosis (Familial erythro /
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hemophagocytic lymphohistiocytosis
(FELH))
Hemophagocytosis (Hemophagocytosis
(reactive or viral associated))
Not Otherwise Specified Histiocytic And
Dendritic Cell Neoplasms (Histiocytic
disorder, NOS)
Langerhans Cell Histiocytosis
(Langerhans cell histiocytosis
(histiocytosis-X))
Malignant Histiocytosis (Malignant
histiocytosis)
Other Histiocytic And Dendritic Cell
Neoplasms (Other histiocytic disorder)
Specify the other histiocytic disorder:
Inherited Disorders Of
Metabolism/osteopetrosis
What was the classification of the inherited
disorders of metabolism / osteopetrosis?
Adrenoleukodystrophy
(Adrenoleukodystrophy (ALD))
Aspartylglycosaminuria (Aspartyl
Glucosaminuria)
Beta Glucuronidase Deficiency (vii) (Beta
glucuronidase deficiency (VII))
Fucosidosis (Fucosidosis)
Gaucher Disease (Gaucher Disease)
Glucose Storage Disease (Glucose
storage disease)
Hunter Syndrome (Hunter syndrome (II))
Hurler Syndrome (Hurler syndrome (IH))
I-cell Disease (I-Cell Disease)
Not Otherwise Specified Congenital
Metabolic Disorder (Inherited Disorders
or Metabolism, NOS)
Krabbe Disease (Krabbe disease
(Globoid leukodystrophy))
Lesch-nyhan Syndrome (Lesch-Nyhan
(HGPRT deficiency))
Mannosidosis (Mannosidosis)
Maroteaux-lamy Syndrome (Maroteaux-
Lamy (VI))
Metachromatic Leukodystrophy
(Metachromatic leukodystrophy (MLD))
Morquio Syndrome (Morquio (IV))
Not Otherwise Specified Mucolipidosis
(Mucolipidoses, not otherwise specified)
Mucopolysaccharidosis
(Mucopolysaccharidosis (V))
Not Otherwise Specified
Mucopolysaccharidosis
(Mucopolysaccharidosis, not otherwise
specified)
Batten Disease (Neuronalceroid
lipofuscinosis (Batten disease))
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Niemann-pick Disease (Niemann-Pick
disease)
Osteopetrosis (Osteopetrosis (malignant
infantile osteopetrosis))
Other Congenital Metabolic Disorder
(Other inherited disorder of metabolism)
Polysaccharide Hydrolase Abnormalities,
Nos (Polysaccharide hydrolase
abnormalities, NOS)
Sanfilippo Syndrome (Sanfilippo (III))
Scheie Syndrome (Scheie syndrome
(IS))
Wolman Disease (Wolman disease)
Specify the other inherited disorder of
metabolism:
Immune Deficiencies
What was the classification of the immune
deficiency?
Adenosine Deaminase Deficiency
Severe Combined Immunodeficiency
(Adenosine deaminase (ADA) deficiency
/ severe combined immunodefiency
(SCID))
Ataxia Telangiectasia Syndrome (Ataxia
telangiectasia)
Bare Lymphocyte Syndrome (Bare
lymphocyte syndrome)
Cartilage Hair Hypoplasia (Cartilage Hair
Hypoplasia)
Cd40 Ligand Deficiency (CD40 ligand
deficiency)
Chediak-higashi Syndrome (Chediak-
Higashi Syndrome)
Chronic Granulomatous Disease
(Chronic Granulomatous Disease)
Common Variable Immunodeficiency
(Common Variable Immunodeficiency)
Digeorge's Syndrome (DiGeorge
anomaly)
Hiv Infection (HIV Infection)
Not Otherwise Specified
Immunodeficiency Syndrome (Immune
Deficiencies, NOS)
Congenital Neutropenia (Kostmann
agranulocytosis (congenital
neutropenia))
Leukocyte Adhesion Deficiency
(Leukocyte adhesion deficiencies)
Neutrophil Actin Defect (Neutrophil actin
deficiency)
Omenn Syndrome (Omenn Syndrome)
Other Immunodeficiency Syndrome
(Other immune deficiency)
Reticular Dysgenesis (Reticular
Dysgenesis)
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Not Otherwise Specified Severe
Combined Immunodeficiency (SCID, not
otherwise specified)
Severe Combined Immunodeficiency
(SCID, other)
Severe Combined Immunodeficiency
With Absence Of T And B Cells (Severe
Combined Immunodeficiency with
Absence of T and B Cells)
Severe Combined Immunodeficiency
With Absence Of T, Normal B Cells
(Severe Combined Immunodeficiency
with Absence of T, Normal B Cells)
Wiskott-aldrich Syndrome (Wiskott-
Aldrich Syndrome)
X-linked Lymphoproliferative Syndrome
(X-Linked Lymphoproliferative
Syndrome)
Specify the other SCID:
Specify the other immune deficiency:
Autoimmune Disorders
Specify the type of autoimmune disease:
Antiphospholipid Syndrome
(Antiphospholipid syndrome)
Behcet's Syndrome (Behcet's Syndrome)
Churg-strauss Syndrome (Churg-
Strauss)
Crohn's Disease (Crohn's disease)
Evan Syndrome (Evan Syndrome)
Temporal Arteritis (Giant cell arteritis)
Hemolytic Anemia (Hemolytic Anemia)
Idiopathic Thrombocytopenic Purpura
(Idiopathic thrombocytopenic purpura
(ITP))
Stills Disease (Juvenile idiopathic
arthritis (JIA): systemic (Stills disease))
Oligoarticular Stills Disease (Juvenile
idiopathic arthritis: Oligoarticular)
Other Pediatric Idiopathic Arthritis
(Juvenile idiopathic arthritis: other)
Polyarticular Stills Disease (Juvenile
idiopathic arthritis: Polyarticular)
Multiple Sclerosis (Multiple sclerosis
(MS))
Myasthenia Gravis (Myasthenia Gravis)
Other Arthritis (Other  Arthritis)
Other Vasculitis (Other  Vasculitis)
Bowel Autoimmune Other Diseases And
Disorders (Other autoimmune bowel
disorder)
Other Autoimmune Cytopenia (Other
autoimmune cytopenia)
Neurologic Other Autoimmune Disease
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(Other autoimmune neurological
disorder)
Other Connective Tissue Disorder (Other
connective tissue disease)
Overlap Necrotizing Arteritis (Overlap
Necrotizing Arteritis)
Polyarteritis Nodosa (Polyarteritis
nodosa, classical)
Microscopic Polyarteritis (Polyarteritis
nodosa, microscopic)
Polymyositis Dermatomyositis
(Polymyositis / dermatomyositis)
Psoriasis Psoriatic Arthritis (Psoriatic
Arthritis / Psoriasis)
Rheumatoid Arthritis (Rheumatoid
Arthritis)
Sjogren's Syndrome (Sjogren syndrome)
Systemic Lupus Erythematosus
(Systemic lupus erythematosis (SLE))
Systemic Sclerosis (Systemic sclerosis)
Takayasu's Arteritis (Takayasu)
Ulcerative Colitis (Ulcerative colitis)
Wegener's Granulomatosis (Wegener
granulomatosis)
Specify the type of other connective tissue
disease:
Specify the other vasculitis:
Specify the other juvenile idiopathic arthritis:
Specify the other arthritis:
Specify the other autoimmune neurological
disorder:
Specify the other autoimmune cytopenia:
Specify the other autoimmune bowel disorder:
Systemic Sclerosis Involvement
For the systemic sclerosis, what was the involved
organ or clinical problem?
Crest Syndrome (CREST)
Diffuse Cutaneous (Diffuse cutaneous)
Esophagus (Esophagus)
Local Cutaneous (Limited cutaneous)
Lung Tissue (Lung parenchyma)
Other (Other)
Other Gastrointestinal Tract (Other GI
tract)
Pulmonary Hypertension (Pulmonary
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hypertension)
Raynaud's Syndrome (Raynaud)
Renal (Renal)
Hypertension Systemic (Systemic
hypertension)
Did the systemic sclerosis have a particular
involvement?
Yes
No
Was the involvement associated with systemic
sclerosis the primary reason for transplantation?
Yes
No
What was the systemic sclerosis biopsy type?
(Answer only if the answer to CDE 2748902 is
renal)
Specify the other involvement of the systemic
sclerosis: (Answer only if the answer to CDE
2748902 is "Other.")
Systemic Sclerosis Laboratory
Procedures
For the systemic sclerosis, what was the
laboratory procedure type?
Centromere Antibody (ACA positive)
Antinuclear Antibody (ANA)
Topoisomerase I Antibody (Scl 70
positive)
For the systemic sclerosis, what was the result of
the laboratory procedure?
Elevated (Elevated)
Normal (Normal)
Not Done: C49484 (Not Done)
Systemic Lupus Erythematosus (sle)
Involvement
For the systemic lupus erythematosus (SLE),
what was the involved organ or clinical problem?
Arthritis (Arthritis)
Central Nervous System (CNS)
Hematologic (Hematological)
Lung (Lung)
Other (Other)
Peripheral Nervous System (PNS)
Renal (Renal)
Serositis (Serositis)
Skin (Skin)
Vasculitis (Vasculitis)
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Did the systemic lupus erythematosus (SLE)
have a particular involvement?
Yes
No
Was the involvement associated with systemic
lupus erythematosus (SLE) the primary reason
for transplantation?
Yes
No
What was the systemic lupus erythematosus
(SLE) biopsy type? (Answer only if the answer to
CDE 2749007 is "Renal.")
Specify the type of systemic lupus erythematosus
(SLE) involvement: (Answer only if the answer to
CDE 2749007 is "CNS", "PNS", "Skin",
"Hematological", "Vasculitis", or "Other.")
Systemic Lupus Erythematosus (sle)
Laboratory Procedures
For the systemic lupus erythematosus, what was
the ANA test result?
Elevated (Elevated)
Normal (Normal)
Not Done: C49484 (Not Done)
For the systemic lupus erythematosus, what was
the ds DNA test result?
Elevated (Elevated)
Normal (Normal)
Not Done: C49484 (Not Done)
For the systemic lupus erythematosus, what was
the C3 test result?
Low (Low)
Normal (Normal)
Not Done: C49484 (Not Done)
For the systemic lupus erythematosus (SLE),
what was the C4 test result?
Low (Low)
Normal (Normal)
Not Done: C49484 (Not Done)
For systemic lupus, erythematosus, what was the
total complement test result?
Low (Low)
Normal (Normal)
Not Done: C49484 (Not Done)
For the systemic lupus erythematosus, what was
the test results at diagnosis for the other
antibody?
Elevated (Elevated)
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Normal (Normal)
Not Done: C49484 (Not Done)
For the systemic lupus erythematosus, specify
the other antibody:
Sjogren Syndrome Involvement
For the sjogren syndrome, what was the involved
organ or clinical problem?
Swelling Exocrine Gland (Exocrine gland
swelling)
Paraproteinemia Lymphoma
(Lymphoma, paraproteinemia)
Other (Other)
Lymphocytic Infiltration Other (Other
organ lymphocytic infiltration)
Sicca Syndrome (SICCA)
Vasculitis (Vasculitis)
Did the sjogren syndrome have a particular
involvement?
Yes
No
Was the involvement associated with sjogren
syndrome the primary reason for transplantation?
Yes
No
Specify the other involvement for sjogren
syndrome: (Answer only if the answer to CDE
2749605 is "Other.")
Polymyositis / Dermatomyositis
Involvement
For the polymyositis-dermatomyositis, what was
the involved organ or clinical problem?
Generalized Muscle Weakness
(Generalized weakness (including
bulbar))
Malignant Neoplasm (Malignancy)
Other (Other)
Proximal Muscle Weakness (Proximal
weakness)
Pulmonary Fibrosis (Pulmonary fibrosis)
Vasculitis (Vasculitis)
Did the polymyositis-dermatomyositis have a
particular involvement?
Yes
No
Was the involvement associated with
polymyositis-dermatomyositis the primary reason
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for transplantation?
Yes
No
Specify the type of polymyositis-dermatomyositis
involvement: (Answer only if the answer to CDE
2749891 is "Vasculitis", "Malignancy", or "Other.")
Polymyositis / Dermatomyositis Laboratory
Procedure
What was the CPK test result?
Elevated (Elevated)
Normal (Normal)
Not Done: C49484 (Not Done)
For the polymyositis-dermatomyositis, were the
biopsy results typical of the disease?
Elevated (Elevated)
Normal (Normal)
Not Done: C49484 (Not Done)
For the polymyositis-dermatomyositis, were the
EMG results typical of the disease?
Elevated (Elevated)
Normal (Normal)
Not Done: C49484 (Not Done)
For the dermatomyositis, was there a rash
present that was typical of the disease?
Elevated (Elevated)
Normal (Normal)
Not Done: C49484 (Not Done)
Antiphospholipid Syndrome Involvement
For the antiphospholipid syndrome, what was the
involved organ or clinical problem?
Abortion (Abortion)
Central Nervous System (CNS)
Hematology (Hematological)
Other (Other)
Vasculitis (Skin (livedo, vasculitis))
Thrombosis (Thrombosis)
Did the antiphospholipid syndrome have a
particular involvement?
Yes
No
Was the involvement associated with
antiphospholipid syndrome the primary reason for
transplantation?
Yes
No
Specify the other type of antiphospholipid
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syndrome involvement: (Answer only if the
answer to CDE 2749918 is "Thrombosis," "CNS,"
"Hematological," or "Other.")
Antiphospholipid Syndrome Laboratory
Procedures
For the antiphospholipid syndrome, what was the
laboratory procedure type?
Anticardiolipin Igg Antibody
(Anticardiolipin IgG)
Anticardiolipin Igm Antibody
(Anticardiolipin IgM)
Lab Lupus Inhibitor (Lab lupus inhibitor)
Lupus Anticoagulant Antibody (Lupus
anticoagulant)
For the antiphospholipid syndrome, what was the
result of the laboratory procedure?
Elevated (Elevated)
Normal (Normal)
Not Done: C49484 (Not Done)
Wegener Granulomatosis Invovlement
For the wegener granulomatosis, what was the
involved organ or clinical problem?
Other (Other)
Pulmonary (Pulmonary)
Renal (Renal)
Skin (Skin)
Upper Respiratory System (Upper
respiratory tract)
Did the wegener granulomatosis have a particular
involvement?
Yes
No
Was the involvement associated with wegener
granulomatosis the primary reason for
transplantation?
Yes
No
Specify the type of wegener granulomatosis
involvement: (Answer only if the answer to CDE
2749969 is "Renal" or "Other.")
Wegener Granulomatosis Laboratory
Procedures
For the wegener granulomatosis, what was the
laboratory procedure type?
Elisa Myeloperoxidase Antibody (Anti
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MPO)
Elisa Proteinase 3 Antibody (Anti Pr3)
Fluorescent Antibody Technique
Proteinase 3 Antibody (c-ANCA IFA)
Unknown Laboratory Procedure
Proteinase 3 Antibody (c-ANCA positive)
Fluorescent Antibody Technique
Myeloperoxidase Antibody (p-ANCA IFA)
For the wegener granulomatosis, what was the
result of the laboratory procedure?
Elevated (Elevated)
Normal (Normal)
Not Done: C49484 (Not Done)
Polyarteritis Nodosa Involvement
For the polyarteritis nodosa, classical or
microscopic, what was the involved organ or
clinical problem?
Gastrointestinal Tract (GI tract)
Mononeuritis Multiplex (Mononeuritis
multiplex)
Other (Other)
Pulmonary Hemorrhage (Pulmonary
hemorrhage)
Renal (Renal)
Skin (Skin)
Did the polyarteritis nodosa, classical or
microscopic, have a particular involvement?
Yes
No
Was the involvement associated with polyarteritis
nodosa, classical or microscopic, the primary
reason for transplantation?
Yes
No
Specify the type of polyarteritis nodosa, classical
or microscopic, involvement: (Answer only if the
answer to CDE 2750113 is "Renal" or "Other.")
Polyarteritis Nodosa Laboratory
Procedures
For the polyarteritis nodosa, classical or
microscopic, what was the laboratory procedure
type?
Unknown Laboratory Procedure
Proteinase 3 Antibody (c-ANCA positive)
Hepatitis Serological (Hepatitis serology)
Unknown Laboratory Procedure
Myeloperoxidase Antibody (p-ANCA
positive)
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For the polyarteritis, classical or microscopic,
what was the result of the laboratory procedure?
Elevated (Elevated)
Normal (Normal)
Not Done: C49484 (Not Done)
Rheumatoid Arthritis Involvement
For the rheumatoid arthritis, what was the
involved organ or clinical problem?
Destructive Arthritis (Destructive
arthritis)
Extra-articular (Extra-articular)
Eye (Eye)
Necrotizing Vasculitis (Necrotizing
vasculitis)
Other (Other)
Pulmonary (Pulmonary)
Did the rheumatoid arthritis have a particular
involvement?
Yes
No
Was the involvement associated with rheumatoid
arthritis the primary reason for transplantation?
Yes
No
Specify the type of rheumatoid arthritis
involvement: (Answer only if the answer to CDE
2750141 is "Eye", "Extra-articular," or "Other.")
Psoriatic Arthritis / Psoriasis Involvement
For the psoriatic arthritis / psoriasis, what was the
involved organ or clinical problem?
Destructive Arthritis (Destructive
arthritis)
Other (Other)
Psoriasis (Psoriasis)
Did the psoriatic arthritis / psoriasis have a
particular involvement?
Yes
No
Was the involvement associated with psoriatic
arthritis / psoriasis the primary reason for
transplantation?
Yes
No
For the psoriatic arthritis / psoriasis specify the
other involvement: (Answer only if the answer to
CDE 2750535 is "Other.")
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Multiple Sclerosis (ms) Involvement
For the multiple sclerosis, what was the involved
organ or clinical problem?
Other (Other)
Primary Progressive (Primary
progressive)
Recurrent Disease (Relapsing/remitting)
Secondary Progressive (Secondary
progressive)
Did the multiple sclerosis have a particular
involvement?
Yes
No
Was the involvement associated with multiple
sclerosis the primary reason for transplantation?
Yes
No
For the multiple sclerosis, specify the other
involvement: (Answer only if the answer to CDE
2749910 is "Other.")
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E1905 Registration Worksheet (step 1)
E1905 Registration Worksheet (step 1)
Azacitidine With or Without Entinostat in Treating Patients
With Myelodysplastic Syndromes, Chronic Myelomonocytic
Leukemia, or Acute Myeloid Leukemia
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=74CCB3AB-
1C3F-A75A-E040-BB89AD431F27
All rights reserved. Please visit https://medical-data-
models.org/forms/8842
E1905 Registration Worksheet (step
1)
Eligibility
Patient Initials
Has the eligibility checklist been completed
Yes
No
In the opinion of the investigator, is the patient
eligible?
Yes
No
Patient's simplified disease code
Acute Myeloid Leukemia (Acute Myeloid
Leukemia, NOS)
Chronic Myelomonocytic Leukemia
(Chronic Myelomonocytic Leukemia)
Mds (Myelodysplastic syndrome, NOS)
Has written informed consent been obtained
Yes
No
Date Informed Consent Signed
Has HIPAA authorization been obtained
No: C49487 (0)
Yes: C49488 (1)
Exempt - Non-USA Participant (2)
HIPAA Authorization Date
Is the disease treatment-induced
Yes
No
Disease site/type
Acute Myeloid Leukemia (AML-TLD)
Chronic Myelomonocytic Leukemia
(CMMOL)
Mds High/int-2 (MDS High/Int-2)
Mds Low/int-1 (MDS Low/Int-1)
I agree biopsies may be done to obtain research
specimens.
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No (No)
Not Applicable (Not Applicable)
Yes (Yes)
I agree to participate in the laboratory research
studies that are being done as part of this clinical
trial.
Yes
No
I agree to provide additional specimens for
research
Yes
No
My specimens may be kept for use in research to
learn about, prevent, treat, or cure cancer.
Yes
No
My specimens may be kept for use in research
about other health problems (for example:
diabetes, Alzheimer's disease, or heart disease).
Yes
No
Someone from this institution may contact me in
the future to ask me to take part in more
research.
Yes
No
Name of local cytogenetics lab
Phone number
Race
Patient's Race
A Person Having Origins In Any Of The
Original Peoples Of North And South
America (including Central America),
And Who Maintains Tribal Affiliation Or
Community Attachment. (American
Indian or Alaska Native)
A Person Having Origins In Any Of The
Original Peoples Of The Far East,
Southeast Asia, Or The Indian
Subcontinent Including, For Example,
Cambodia, China, India, Japan, Korea,
Malaysia, Pakistan, The Philippine
Islands, Thailand, And Vietnam. (Asian)
A Person Having Origins In Any Of The
Black Racial Groups Of Africa. Terms
Such As "haitian" Or "negro" Can Be
Used In Addition To "black Or African
American." (Black or African American)
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A Person Having Origins In Any Of The
Original Peoples Of Hawaii, Guam,
Samoa, Or Other Pacific Islands. (Native
Hawaiian or other Pacific Islander)
Not Provided Or Available (Not
Reported)
Could Not Be Determined Or Unsure
(Unknown)
A Person Having Origins In Any Of The
Original Peoples Of Europe, The Middle
East, Or North Africa. (White)
Patient Demographics / Pre-treatment
Characteristics
Patient's Sex
Female (F)
Male (M)
Birthdate (mm/yy)
ZIP Code
Patient Ethnicity
A Person Of Mexican, Puerto Rican,
Cuban, Central Or South American Or
Other Spanish Culture Or Origin,
Regardless Of Race. (Hispanic or Latino)
A Person Not Meeting The Definition For
Hispanic Or Latino. (Not Hispanic or
Latino)
Not Provided Or Available (Not reported)
Could Not Be Determined Or Unsure
(Unknown)
Patient's simplified disease code
Acute Myeloid Leukemia (Acute Myeloid
Leukemia, NOS)
Chronic Myelomonocytic Leukemia
(Chronic Myelomonocytic Leukemia)
Mds (Myelodysplastic syndrome, NOS)
Patient Hospital No.
Patient Social Security Number
Method of payment (check one)
Medicaid (Medicaid)
Medicaid And Medicare (Medicaid and
Medicare)
Medicare (Medicare)
Medicare And Private Insurance
(Medicare and Private Insurance)
Military Or Veterans Sponsored Nos
(Military or Veterans Sponsored, Not
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Otherwise Specified (NOS))
Military Sponsored (including Champus
& Tricare) (Military Sponsored (including
CHAMPUS & TRICARE))
No Means Of Payment (no Insurance)
(No means of payment (no insurance))
Other (Other)
Private Insurance (Private Insurance)
Self Pay (no Insurance) (Self Pay (No
Insurance))
Unknown (Unknown)
Veterans Sponsored (Veterans
Sponsored)
Attending Physician
Institution contact
Registrar
Country of residence
Ascension Island (AC)
Andorra (AD)
United Arab Emirates (AE)
Afghanistan (AF)
Antigua And Barbuda (AG)
Anguilla (AI)
Albania (AL)
Armenia (AM)
Netherland Antilles (AN)
Angola (AO)
Antarctica (AQ)
Argentina (AR)
American Samoa (AS)
Austria (AT)
Australia (AU)
Aruba (AW)
Azerbaidjan (AZ)
Bosnia-herzegovina (BA)
Barbados (BB)
Bangladesh (BD)
Belgium (BE)
Burkina Faso (BF)
Bulgaria (BG)
Bahrain (BH)
Burundi (BI)
Benin (BJ)
Bermuda (BM)
Brunei Darussalam (BN)
Bolivia (BO)
Brazil (BR)
Bahamas (BS)
Bhutan (BT)
Bouvet Island (BV)
Botswana (BW)
Belarus (BY)
Belize (BZ)
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Canada (CA)
Cocos Isl. (CC)
Rep. Dem. Congo (CD)
Central African Rep. (CF)
Congo (CG)
Switzerland (CH)
Ivory Coast (CI)
Cook Islands (CK)
Chile (CL)
Cameroon (CM)
China (CN)
Colombia (CO)
Costa Rica (CR)
Cuba (CU)
Cape Verde (CV)
Christmas Island (CX)
Cyprus (CY)
Czech Republic (CZ)
Germany (DE)
Djibouti (DJ)
Denmark (DK)
Dominica (DM)
Dominican Republic (DO)
Algeria (DZ)
Ecuador (EC)
Estonia (EE)
Egypt (EG)
Western Sahara (EH)
Eritrea (ER)
Spain (ES)
Ethiopia (ET)
Finland (FI)
Fiji (FJ)
Falkland Isl. (FK)
Micronesia (FM)
Faroe Islands (FO)
France (FR)
France (european Ter.) (FX)
Gabon (GA)
Great Britain (GB)
Grenada (GD)
Georgia (GE)
Guiana (fr.) (GF)
Guernsey (GG)
Ghana (GH)
Gibraltar (GI)
Greenland (GL)
Gambia (GM)
Guinea (GN)
Guadeloupe (fr.) (GP)
Equatorial Guinea (GQ)
Greece (GR)
South Georgia And South Sandwich
Islands (GS)
Guatemala (GT)
Guam (us) (GU)
Guinea Bissau (GW)
Guyana (GY)
Hong Kong (HK)
Heard & Mcdonald Isl. (HM)
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Honduras (HN)
Croatia (HR)
Haiti (HT)
Hungary (HU)
Indonesia (ID)
Ireland (IE)
Israel (IL)
Isle Of Man (IM)
India (IN)
British Indian O. Ter. (IO)
Iraq (IQ)
Iran (IR)
Iceland (IS)
Italy (IT)
Jersey (JE)
Jamaica (JM)
Jordan (JO)
Japan (JP)
Kenya (KE)
Kyrgyz Republic (KG)
Cambodia (KH)
Kiribati (KI)
Comoros (KM)
St. Kitts Nevis Anguilla (KN)
Korea (north) (KP)
Korea (south) (KR)
Kuwait (KW)
Cayman Islands (KY)
Kazakstan (KZ)
Laos (LA)
Lebanon (LB)
Saint Lucia (LC)
Liechtenstein (LI)
Sri Lanka (LK)
Liberia (LR)
Lesotho (LS)
Lithuania (LT)
Luxembourg (LU)
Latvia (LV)
Libya (LY)
Morocco (MA)
Monaco (MC)
Moldova (MD)
Madagascar (MG)
Marshall Islands (MH)
Macedonia (MK)
Mali (ML)
Myanmar (MM)
Mongolia (MN)
Macau (MO)
Northern Mariana Isl. (MP)
Martinique (fr.) (MQ)
Mauritania (MR)
Montserrat (MS)
Malta (MT)
Mauritius (MU)
Maldives (MV)
Malawi (MW)
Mexico (MX)
Malaysia (MY)
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Mozambique (MZ)
Namibia (NA)
New Caledonia (fr.) (NC)
Niger (NE)
Norfolk Island (NF)
Nigeria (NG)
Nicaragua (NI)
Netherlands (NL)
Norway (NO)
Nepal (NP)
Nauru (NR)
Niue (NU)
New Zealand (NZ)
Oman (OM)
Other (Other)
Panama (PA)
Peru (PE)
Polynesia (fr.) (PF)
Papua New Guinea (PG)
Philippines (PH)
Pakistan (PK)
Poland (PL)
St. Pierre & Miquelon (PM)
Pitcairn (PN)
Puerto Rico (PR)
Portugal (PT)
Palau (PW)
Paraguay (PY)
Qatar (QA)
Reunion (fr.) (RE)
Romania (RO)
Russian Federation (RU)
Rwanda (RW)
Saudi Arabia (SA)
Solomon Islands (SB)
Seychelles (SC)
Sudan (SD)
Sweden (SE)
Singapore (SG)
St. Helena (SH)
Slovenia (SI)
Svalbard & Jan Mayen Isl. (SJ)
Slovakia (SK)
Sierra Leone (SL)
San Marino (SM)
Senegal (SN)
Somalia (SO)
Suriname (SR)
St. Tome And Principe (ST)
Soviet Union (SU)
El Salvador (SV)
Syria (SY)
Swaziland (SZ)
Turks & Caicos Islands (TC)
Chad (TD)
French Southern Terr. (TF)
Togo (TG)
Thailand (TH)
Tadjikistan (TJ)
Tokelau (TK)
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Turkmenistan (TM)
Tunisia (TN)
Tonga (TO)
East Timor (TP)
Turkey (TR)
Trinidad & Tobago (TT)
Tuvalu (TV)
Taiwan (TW)
Tanzania (TZ)
Ukraine (UA)
Uganda (UG)
United Kingdom (UK)
Us Minor Outlying Isl. (UM)
Usa (US)
Uruguay (UY)
Uzbekistan (UZ)
Vatican City State (VA)
St. Vincent & Grenadines (VC)
Venezuela (VE)
Virgin Islands (brit) (VG)
Virgin Islands (us) (VI)
Vietnam (VN)
Vanuatu (VU)
Wallis & Futuna Islands (WF)
Western Samoa (WS)
Yemen (YE)
Mayotte (YT)
Yugoslavia (YU)
South Africa (ZA)
Zambia (ZM)
Dem. Rep. Of Congo (ZR)
Zimbabwe (ZW)
Comments
I Have Reviewed The Above Data And
Agree The Date Are Accurate And Correct
Signature of treating physician
Date
8 / 8
E1905 Registration Worksheet (step 1)
Brain and Central Nervous System Tumors NCT00890747
Demographic - AMC-061 Demographic Form (DEM) - 2978032v1.0
AMC-061 Demographic Form (DEM)
Sunitinib Malate in Treating HIV-Positive Patients With
Cancer Undergoing Highly Active Antiretroviral Therapy
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=7C6E3CDA-
FFD3-B993-E040-BB89AD432712
All rights reserved. Please visit https://medical-data-
models.org/forms/8843
AMC-061 Demographic Form (DEM)
Header
Patient Initials (First, Last)
Patient's Date of Birth (mm/dd/yyyy)
Gender
Female (FEMALE)
Male (MALE)
Ethnicity
A Person Of Mexican, Puerto Rican,
Cuban, Central Or South American Or
Other Spanish Culture Or Origin,
Regardless Of Race. (Hispanic or Latino)
A Person Not Meeting The Definition For
Hispanic Or Latino. (Not Hispanic or
Latino)
Could Not Be Determined Or Unsure
(Unknown)
Race (check all that apply)
A Person Having Origins In Any Of The
Original Peoples Of North And South
America (including Central America),
And Who Maintains Tribal Affiliation Or
Community Attachment. (American
Indian or Alaska Native)
A Person Having Origins In Any Of The
Original Peoples Of The Far East,
Southeast Asia, Or The Indian
Subcontinent Including, For Example,
Cambodia, China, India, Japan, Korea,
Malaysia, Pakistan, The Philippine
Islands, Thailand, And Vietnam. (Asian)
A Person Having Origins In Any Of The
Black Racial Groups Of Africa. Terms
Such As "haitian" Or "negro" Can Be
Used In Addition To "black Or African
American." (Black or African American)
A Person Having Origins In Any Of The
Original Peoples Of Hawaii, Guam,
Samoa, Or Other Pacific Islands. (Native
Hawaiian or other Pacific Islander)
Could Not Be Determined Or Unsure
(Unknown)
A Person Having Origins In Any Of The
Original Peoples Of Europe, The Middle
East, Or North Africa. (White)
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Patient Zip Code (xxxxx)
Method of Payment
Medicaid (Medicaid)
Medicaid And Medicare (Medicaid and
Medicare)
Medicare (Medicare)
Medicare And Private Insurance
(Medicare and Private Insurance)
Military Or Veterans Sponsored Nos
(Military or Veterans Sponsored, Not
Otherwise Specified (NOS))
Military Sponsored (including Champus
& Tricare) (Military Sponsored (including
CHAMPUS & TRICARE))
No Means Of Payment (no Insurance)
(No means of payment (no insurance))
Other (Other)
Private Insurance (Private Insurance)
Self Pay (no Insurance) (Self Pay (No
Insurance))
Unknown (Unknown)
Veterans Sponsored (Veterans
Sponsored)
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Neoplasms, Breast NCT00490139 Registration - NCI Cooperative Group Pre-
Registration Eligibility Checklist - Cover Sheet/Demographics (N063D) -
2647820v1.0
NCI Cooperative Group Pre-Registration Eligibility Checklist
- Cover Sheet/Demographics (N063D)
ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment
Optimisation) Study; BIG 2-06/N063D
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=3244F15B-
EF86-5AF0-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/8844
NCI Cooperative Group Pre-
Registration Eligibility Checklist -
Cover Sheet/Demographics (N063D)
Header Module
NCCTG Study No.
Central Lab ID Number
Institution Number
Patient Initials
Institution Name
Registration Header
Coordinating Group Protocol Number (N063D)
Coordinating Group Code (NCCTG)
Protocol Title (ALTTO:  Adjuvant Lapatinib and/or
Trastuzumab Treatment Optimisation Trial)
Central Lab ID Number
Patient Initials
Patient Medical Record Number
Participating Group Code
Institution Name
Are data amended (check one  if data are
amended, please circle in red when using paper
form)
Yes
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No
Header
Eligibility Checklist
Both (Both)
Central Pathology Review (Central
Pathology Review)
Snap Frozen Tissue (Snap Frozen
Tissue)
Header
Second Submission
Eligibility Checklist (Eligibility Checklist)
Pre-registration Eligibility Checklist Cover
Sheet/demographics (Pre-Registration
Eligibility Checklist Cover
Sheet/Demographics)
Eligibility Checklist
Both (Both)
Central Pathology Review (Central
Pathology Review)
Snap Frozen Tissue (Snap Frozen
Tissue)
Contact Person For Pathology Results
Last Name
First Name
Phone
Fax
E-mail
Contact Person For Pathology Results
Last Name
First Name
Phone
Fax
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E-mail
Header
Second Submission
Eligibility Checklist (Eligibility Checklist)
Pre-registration Eligibility Checklist Cover
Sheet/demographics (Pre-Registration
Eligibility Checklist Cover
Sheet/Demographics)
Eligibility Checklist
Both (Both)
Central Pathology Review (Central
Pathology Review)
Snap Frozen Tissue (Snap Frozen
Tissue)
Contact Person For Pathology Results
Last Name
First Name
Phone
Fax
E-mail
Contact Person For Pathology Results
Last Name
First Name
Phone
Fax
E-mail
Patient Demographics/pre-treatment
Characteristics
Gender
Female (Female)
Male (Male)
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Unknown (UNKNOWN)
Date of Birth (mm dd yyyy)
ZIP Code
Country of Residence
Method of Payment (check one USA only)
Medicaid (Medicaid)
Medicaid And Medicare (Medicaid and
Medicare)
Medicare (Medicare)
Medicare And Private Insurance
(Medicare and Private Insurance)
Military Or Veterans Sponsored Nos
(Military or Veterans Sponsored, Not
Otherwise Specified (NOS))
Military Sponsored (including Champus
& Tricare) (Military Sponsored (including
CHAMPUS & TRICARE))
No Means Of Payment (no Insurance)
(No means of payment (no insurance))
Other (Other)
Private Insurance (Private Insurance)
Self Pay (no Insurance) (Self Pay (No
Insurance))
Unknown (Unknown)
Veterans Sponsored (Veterans
Sponsored)
Race (check all that apply U.S. and Canada only)
A Person Having Origins In Any Of The
Original Peoples Of North And South
America (including Central America),
And Who Maintains Tribal Affiliation Or
Community Attachment. (American
Indian or Alaska Native)
A Person Having Origins In Any Of The
Original Peoples Of The Far East,
Southeast Asia, Or The Indian
Subcontinent Including, For Example,
Cambodia, China, India, Japan, Korea,
Malaysia, Pakistan, The Philippine
Islands, Thailand, And Vietnam. (Asian)
A Person Having Origins In Any Of The
Black Racial Groups Of Africa. Terms
Such As "haitian" Or "negro" Can Be
Used In Addition To "black Or African
American." (Black or African American)
A Person Having Origins In Any Of The
Original Peoples Of Hawaii, Guam,
Samoa, Or Other Pacific Islands. (Native
Hawaiian or other Pacific Islander)
Not Provided Or Available (Not
Reported)
Could Not Be Determined Or Unsure
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(Unknown)
A Person Having Origins In Any Of The
Original Peoples Of Europe, The Middle
East, Or North Africa. (White)
Ethnicity (U.S. and Canada only)
A Person Of Mexican, Puerto Rican,
Cuban, Central Or South American Or
Other Spanish Culture Or Origin,
Regardless Of Race. (HISPANIC OR
LATINO)
A Person Not Meeting The Definition For
Hispanic Or Latino. (NOT HISPANIC OR
LATINO)
Not Provided Or Available (Not reported)
Could Not Be Determined Or Unsure
(UNKNOWN)
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Colorectal Cancer NCT00726622 Registration -
Z6051 - OPEN Enrollment Form - 2967118v1.0
Z6051 - OPEN Enrollment Form
Laparoscopic-Assisted Resection or Open Resection in
Treating Patients With Stage IIA, Stage IIIA, or Stage IIIB
Rectal Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=7AB13387-
079D-04A4-E040-BB89AD4319A7
All rights reserved. Please visit https://medical-data-
models.org/forms/8846
Z6051 - OPEN Enrollment Form
Header Module
Institution CTEP ID
Institution Name
Protocol Number
Protocol Title
Registration Step
Treating Investigator (Add persons associated
with this enrollment)
Specify Credits
Participating Group Code (Credit Specify
Cooperative Group to receive enrollment credit)
Other Group Investigator Name (Credit Note: The
Credit Investigator must be affiliated with the
credited Cooperative Group and will be
accountable for the patient and the site's
responsibilities during a Cooperative Group
Audit)
Comments (Enter case notes optional)
Patient Information
Date of Birth (month day year)
Gender of a Person
Female Gender (Female Gender)
Male Gender (Male Gender)
Unknown (Unknown)
Ethnicity
A Person Of Mexican, Puerto Rican,
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Cuban, Central Or South American Or
Other Spanish Culture Or Origin,
Regardless Of Race. (Hispanic or Latino)
A Person Not Meeting The Definition For
Hispanic Or Latino. (Not Hispanic or
Latino)
Not Provided Or Available (Not reported)
Country of Residence
Zip code
Race
A Person Having Origins In Any Of The
Original Peoples Of North And South
America (including Central America),
And Who Maintains Tribal Affiliation Or
Community Attachment. (American
Indian or Alaska Native)
A Person Having Origins In Any Of The
Original Peoples Of The Far East,
Southeast Asia, Or The Indian
Subcontinent Including, For Example,
Cambodia, China, India, Japan, Korea,
Malaysia, Pakistan, The Philippine
Islands, Thailand, And Vietnam. (Asian)
A Person Having Origins In Any Of The
Black Racial Groups Of Africa. Terms
Such As "haitian" Or "negro" Can Be
Used In Addition To "black Or African
American." (Black or African American)
A Person Having Origins In Any Of The
Original Peoples Of Hawaii, Guam,
Samoa, Or Other Pacific Islands. (Native
Hawaiian or other Pacific Islander)
Not Provided Or Available (Not
Reported)
Could Not Be Determined Or Unsure
(Unknown)
A Person Having Origins In Any Of The
Original Peoples Of Europe, The Middle
East, Or North Africa. (White)
Method of Payment
Medicaid (Medicaid)
Medicaid And Medicare (Medicaid and
Medicare)
Medicare (Medicare)
Medicare And Private Insurance
(Medicare and Private Insurance)
Military Or Veterans Sponsored Nos
(Military or Veterans Sponsored, Not
Otherwise Specified (NOS))
Military Sponsored (including Champus
& Tricare) (Military Sponsored (including
CHAMPUS & TRICARE))
No Means Of Payment (no Insurance)
(No means of payment (no insurance))
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Other (Other)
Private Insurance (Private Insurance)
Self Pay (no Insurance) (Self Pay (No
Insurance))
Unknown (Unknown)
Veterans Sponsored (Veterans
Sponsored)
General Information
Pt ID# (Local Patient Identifier)
Last (initial)
First (initial)
Middle (initial optional)
E-mail (for Registration Confirmation)
Date Informed Consent Signed (month day year)
Was HIPAA Authorization included in Study
Informed Consent (mark one)
Yes
No
HIPAA authorization date (If no, month day year)
Stratification Factors
Site of primary tumor
Z6051-f1-l1 (High rectum)
Z6051-f1-l3 (Low rectum)
Z6051-f1-l2 (Middle rectum)
Planned operative procedure
Z6051-f2-l2 (Abdominal perineal
resection)
Z6051-f2-l1 (Low anterior resection)
Eligibility Criteria
Histologic diagnosis of adenocarcinoma of the
rectum (<= 12cm from the anal verge)
Yes
No
T3N0M0, T1-3N1-2M0 disease as determined by
pre-neoadjuvant therapy CT scans and pelvic
MRI or transrectal ultrasound. Patients with T4
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disease are not eligible
Yes
No
Start Date of Neoadjuvant therapy
Date of CT Scan
Date of MRI/TRUS
End Date of Neoadjuvant therapy
Completion of pre-operative 5FU-based
chemotherapy and/or radiation therapy.
Capecitabine may be substituted for 5FU.
Yes
No
Age >= 18 years
Yes
No
ECOG (Zubrod) Performance Status <= 2
Yes
No
ECOG Performance Status (Zubrod)
Fully Active, Able To Carry On All Pre-
disease Performance Without
Restriction. (0)
Restricted In Physically Strenuous
Activity But Ambulatory And Able To
Carry Out Work Of A Light Or Sedentary
Nature, E.g., Light Housework, Office
Work. (1)
Ambulatory And Capable Of All Selfcare
But Unable To Carry Out Any Work
Activities. Up And About More Than 50%
Of Waking Hours. (2)
Body Mass Index <= 34 (NOTE: The same value
applies to both male and female patients)
Yes
No
Weight (kg)
Height (cm)
No evidence of conditions that would preclude
use of a laparoscopic approach (e.g., multiple
previous major laparotomies, severe adhesions).
Yes
No
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No systemic disease (cardiovascular, renal,
hepatic, etc.) that would preclude surgery. No
other severe incapacitating disease, i.e., ASA IV
(a patient with severe systemic disease that is a
constant threat to life) or ASA V (a moribund
patient who is not expected to survive without the
operation)
Yes
No
No concurrent or previous invasive pelvic
malignancy (cervical, uterine and rectal) within
five years prior to registration.
Yes
No
No history of psychiatric or addictive disorders or
other conditions that, in the opinion of the
investigator, would preclude the patient from
meeting the study requirements.
Yes
No
Amendment 4 Approval
Amendment 4 (dated August 15, 2011) IRB/REB
approved
Yes
No
Specimen Collection And Banking
Consent
Patient has given permission to keep tissue
sample(s) for use in future research to learn
about, prevent, or treat cancer.
Yes
No
Patient has given permission to keep tissue
sample(s) for use in research to learn about,
prevent or treat other health problems (for
example: diabetes, Alzheimer's disease, or heart
disease).
Yes
No
Patient has given permission to keep tissue
sample(s) for use in future genetic research.
Yes
No
Randomization
Randomization
Laparoscopic-assisted Rectal Resection
(Laparoscopic-assisted rectal resection)
Open Laparotomy And Rectal Resection
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(Open laparotomy and rectal resection)
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Endometrial Cancer NCT00265759 Registration - ACOSOG-
Z1031 OPEN Registration Worksheet - 3014513v1.0
ACOSOG-Z1031 OPEN Registration Worksheet
Exemestane, Letrozole, or Anastrozole in Treating
Postmenopausal Women Who Are Undergoing Surgery for
Stage II or Stage III Breast Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=8036B060-
D675-EB4B-E040-BB89AD434531
All rights reserved. Please visit https://medical-data-
models.org/forms/8847
ACOSOG-Z1031 OPEN Registration
Worksheet
Header Module
Institution CTEP ID
Institution Name
Protocol Number
Protocol Title
Registration Step
Treating Investigator
Site Registrar
Cooperative Group (Credit)
Investigator (Credit)
Comments (Enter case notes optional)
Patient Information
Date of Birth (month day year)
Gender of a Person
Female Gender (Female)
Male Gender (Male)
Unknown (Unknown)
Ethnicity
A Person Of Mexican, Puerto Rican,
Cuban, Central Or South American Or
Other Spanish Culture Or Origin,
Regardless Of Race. (Hispanic or Latino)
A Person Not Meeting The Definition For
Hispanic Or Latino. (Not Hispanic or
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Latino)
Not Provided Or Available (Not reported)
Country of Residence
Zip code
Race
A Person Having Origins In Any Of The
Original Peoples Of North And South
America (including Central America),
And Who Maintains Tribal Affiliation Or
Community Attachment. (American
Indian or Alaska Native)
A Person Having Origins In Any Of The
Original Peoples Of The Far East,
Southeast Asia, Or The Indian
Subcontinent Including, For Example,
Cambodia, China, India, Japan, Korea,
Malaysia, Pakistan, The Philippine
Islands, Thailand, And Vietnam. (Asian)
A Person Having Origins In Any Of The
Black Racial Groups Of Africa. Terms
Such As "haitian" Or "negro" Can Be
Used In Addition To "black Or African
American." (Black or African American)
A Person Having Origins In Any Of The
Original Peoples Of Hawaii, Guam,
Samoa, Or Other Pacific Islands. (Native
Hawaiian or other Pacific Islander)
Not Provided Or Available (Not
Reported)
Could Not Be Determined Or Unsure
(Unknown)
A Person Having Origins In Any Of The
Original Peoples Of Europe, The Middle
East, Or North Africa. (White)
Method of Payment
Medicaid (Medicaid)
Medicaid And Medicare (Medicaid and
Medicare)
Medicare (Medicare)
Medicare And Private Insurance
(Medicare and Private Insurance)
Military Or Veterans Sponsored Nos
(Military or Veterans Sponsored, Not
Otherwise Specified (NOS))
Military Sponsored (including Champus
& Tricare) (Military Sponsored (including
CHAMPUS & TRICARE))
No Means Of Payment (no Insurance)
(No means of payment (no insurance))
Other (Other)
Private Insurance (Private Insurance)
Self Pay (no Insurance) (Self Pay (No
Insurance))
Unknown (Unknown)
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Veterans Sponsored (Veterans
Sponsored)
General Information
Pt ID# (Local Patient Identifier)
Last (initial)
First (initial)
Middle (initial optional)
E-mail (for Registration Confirmation)
Has patient previously been registered to an
ACOSOG study
Yes
No
Coordinating Group Patient ID (if yes previously
issued ACOSOG Patient ID)
Date Informed Consent Signed (month day year)
Was HIPAA Authorization included in Study
Informed Consent (mark one)
Yes
No
HIPAA Authorization Date (If no month day year)
Inclusion Criteria
Patient must have an ECOG performance status
of <= 2 (Zubrod)
Yes
No
ECOG Performance Status (Zubrod 0, 1, 2)
Fully Active, Able To Carry On All Pre-
disease Performance Without
Restriction. (0)
Restricted In Physically Strenuous
Activity But Ambulatory And Able To
Carry Out Work Of A Light Or Sedentary
Nature, E.g., Light Housework, Office
Work. (1)
Ambulatory And Capable Of All Selfcare
But Unable To Carry Out Any Work
Activities. Up And About More Than 50%
Of Waking Hours. (2)
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Patient must have T2-T4c, any N, M0 breast
cancer, by clinical staging (NOTE: Primary tumor
must be palpable and measure >2 cm by tape,
ruler or caliper measurements in at least one
dimension)
Yes
No
Patient must be postmenopausal, verified by
bilateral surgical oophorectomy, no spontaneous
menses >= 1 year, or no menses for < 1 year with
FSH and estradiol levels in postmenopausal
range, according to institutional standards
Yes
No
Patient, as documented by the treating physician,
is clinically staged as one of the following T4 a-c
for whom modified radical mastectomy with
negative margins is the goal, T2 or T3 for whom
conversion from needing mastectomy to breast
conservation is the goal, T2 for whom
lumpectomy at first attempt is the goal
Yes
No
Patient has an ER+ tumor with an Allred score of
6, 7 or 8 (Note: Patients with >66.6% two-thirds of
cells staining positive have a minimum Allred
score of 6 and are eligible)
Yes
No
Patient must have mammogram and ultrasound
within 42 days prior to registration
Yes
No
Date of mammogram (<= 42 days prior to
registration mm/dd/yyyy)
Date of Ultrasound (<= 42 days prior to
registration mm/dd/yyyy)
If patient is a cancer survivor, all of the following
criteria must be met Patient has undergone
potentially curative therapy for all prior
malignancies, No evidence of any prior
malignancies for at least 5 years with no evidence
of recurrence (except for successfully treated
cervical carcinoma in situ, lobular carcinoma in
situ of the breast, contralateral DCIS treated with
mastectomy or lumpectomy and radiation but
without tamoxifen treatment, or non-melanoma
skin cancer with no evidence of recurrence), and
Patient is deemed by their treating physician to
be at low risk for recurrence from prior
malignancies
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Not Applicable (NA)
No (No)
Yes (Yes)
Exclusion Criteria
Inflammatory breast cancer defined as clinically
significant erythema of the breast and/or
documented dermal lymphatic invasion (not direct
skin invasion by tumor or peau d'orange without
erythema)
Yes
No
Prior treatment for invasive breast cancer,
including radiation, endocrine therapy,
chemotherapy or investigational agent (Patients
whose diagnosis was established by incisional
biopsy are not eligible)
Yes
No
Patient has received hormone replacement
therapy of any type, megestrol acetate, or
raloxifene within one week prior to registration
Yes
No
Patient has distant metastasis (M1), excluding
isolated ipsilateral supraclavicular node
involvement
Yes
No
Patient does not agree to undergo mastectomy or
lumpectomy after neoadjuvant aromatose
inhibitor therapy
Yes
No
Patient is enrolled in another neoadjuvant clinical
trial for treatment of the existing breast cancer
Yes
No
Patient has undergone prior sentinel lymph node
biopsy (Cohort B only)
Yes
No
Randomization
Treatment Arm
Patient Chosen Arm (Patient chosen
arm)
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Breast Cancer NCT00785291 Registration - CALGB-
40502 Registration Worksheet Form - 2765448v1.0
CALGB-40502 Registration Worksheet Form
Paclitaxel, Paclitaxel Albumin-Stabilized Nanoparticle
Formulation, or Ixabepilone With or Without Bevacizumab
in Treating Patients With Stage IIIC or Stage IV Breast
Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=51FACCD6-
7472-0406-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/8849
CALGB-40502 Registration
Worksheet Form
Protocol Administration
IRB Approval Date
Date Informed Consent Signed (MM DD YYYY)
HIPAA Authorization Date (MM DD YYYY)
Projected Start Date of Treatment (MM DD
YYYY)
Institution/Affiliate
NCI Investigator Number
Physician of Record
NCI Institution Number
Contact Person at Institution
Phone
Fax
Patient Demographics/pre-treatment
Characteristics
Patient Initials (Last, First Middle)
Patient's Date of Birth (MM DD YYYY)
Patient Social Security Number
Patient Hospital No.
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Gender
Female (FEMALE)
Male (MALE)
Patient Demographics/pre-treatment
Characteristics
Race (Mark all that apply)
A Person Having Origins In Any Of The
Original Peoples Of North And South
America (including Central America),
And Who Maintains Tribal Affiliation Or
Community Attachment. (American
Indian or Alaska Native)
A Person Having Origins In Any Of The
Original Peoples Of The Far East,
Southeast Asia, Or The Indian
Subcontinent Including, For Example,
Cambodia, China, India, Japan, Korea,
Malaysia, Pakistan, The Philippine
Islands, Thailand, And Vietnam. (Asian)
A Person Having Origins In Any Of The
Black Racial Groups Of Africa. Terms
Such As "haitian" Or "negro" Can Be
Used In Addition To "black Or African
American." (Black or African American)
A Person Having Origins In Any Of The
Original Peoples Of Hawaii, Guam,
Samoa, Or Other Pacific Islands. (Native
Hawaiian or other Pacific Islander)
Could Not Be Determined Or Unsure
(Unknown)
A Person Having Origins In Any Of The
Original Peoples Of Europe, The Middle
East, Or North Africa. (White)
Ethnicity (Mark one)
A Person Of Mexican, Puerto Rican,
Cuban, Central Or South American Or
Other Spanish Culture Or Origin,
Regardless Of Race. (Hispanic or Latino)
A Person Not Meeting The Definition For
Hispanic Or Latino. (Not Hispanic or
Latino)
Could Not Be Determined Or Unsure
(Unknown)
Patient Demographics/pre-treatment
Characteristics2
Patient Zip Code
Country of Residence (if not USA)
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Patient Demographics/pre-treatment
Characteristics2
Performance Status (ECOG/Zubrod scale)
Fully Active, Able To Carry On All Pre-
disease Performance Without
Restriction. (0)
Restricted In Physically Strenuous
Activity But Ambulatory And Able To
Carry Out Work Of A Light Or Sedentary
Nature, E.g., Light Housework, Office
Work. (1)
Height (cm)
Weight (kg)
Disease name
Breast Neoplasm Nos (Breast Neoplasm
NOS)
Stage
Any T, N3, M0 (IIIC)
Any T, Any N, M1 (IV)
Pathologic type
Certification Of Eligibility And Protocol
Design
In the opinion of the investigator, is the patient
eligible
Yes
No
Certification Of Eligibility And Protocol
Design
Prior Taxane as Adjuvant therapy or Neoadjuvant
therapy
Yes
No
Receptor Status (ER/PgR status)
Er And Pgr Negative (ER and PgR
negative)
Er Or Pgr Positive (ER or PgR positive)
Physician's decision to use bevacizumab
Yes
No
Assigned Treatment Arm
Arm A = Paclitaxel +/- Bevacizumab
(Arm A = Paclitaxel +/- Bevacizumab)
3 / 5
Breast Cancer NCT00785291 Registration - CALGB-40502 Registration
Worksheet Form - 2765448v1.0
Arm B = Nab-paclitaxel +/- Bevacizumab
(Arm B = Nab-Paclitaxel +/-
Bevacizumab)
Companion Study Calgb - 150714
Patient's Initial Consent given for specimen use
for research on the patient's cancer (150714 If a
patient answers "yes" to "My specimens may be
used for the research described above." question
#1 in the model consent, they have consented to
participate in the substudy described in Appendix
I. The patient should be registered to CALGB -
150714)
Yes
No
In the opinion of the investigator, is the patient
eligible
Yes
No
Initial Patient Consent For Specimen Use
Patient's initial consent given for blood specimen
use for genetic research on patient's cancer?
Yes
No
In the opinion of the investigator, is the patient
eligible
Yes
No
Patient's Initial Consent given for specimen kept
for future use in research to learn about, prevent,
or treat cancer (model consent question #3)
Yes
No
Patient's Initial Consent given for specimen use
for research unrelated to the patient's cancer?
(model consent question #4)
Yes
No
Patient's initial consent given for further contact
regarding specimen?
Yes
No
Companion Study Calgb - 70501
Did the patient consent to participate in 70501
Yes
No
In the opinion of the investigator, is the patient
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eligible
Yes
No
Registration Information
CALGB Patient ID (Assigned)
Registration Date
Participating Group Patient ID (Assigned)
Registrar's Signature
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Breast Cancer NCT00770809 Registration - CALGB
40601 REGISTRATION WORKSHEET - 2680365v1.0
CALGB 40601 REGISTRATION WORKSHEET
Paclitaxel and Trastuzumab With or Without Lapatinib in
Treating Patients With Stage II or Stage III Breast Cancer
That Can Be Removed by Surgery
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=39E131B2-
F4E4-13F1-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/8850
CALGB 40601 REGISTRATION
WORKSHEET
Header Module
Lead Institution
Institution/Affiliate
CALGB Patient ID (Assigned)
Physician of Record
Principal Investigator No.
Participating Group Name
Protocol Administration
IRB Approval Date
Date Informed Consent Signed
Projected Start Date of Treatment
HIPAA Authorization Date
Contact Person at Institution
Phone
Fax
Patient Demographics/pre-treatment
Characteristics
Patient Initials (Last, First Middle)
Date of Birth (MM DD YYYY)
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Patient Social Security Number
Patient Hospital No.
Gender
Female (FEMALE)
Male (MALE)
Race (Mark all that apply)
A Person Having Origins In Any Of The
Original Peoples Of North And South
America (including Central America),
And Who Maintains Tribal Affiliation Or
Community Attachment. (American
Indian or Alaska Native)
A Person Having Origins In Any Of The
Original Peoples Of The Far East,
Southeast Asia, Or The Indian
Subcontinent Including, For Example,
Cambodia, China, India, Japan, Korea,
Malaysia, Pakistan, The Philippine
Islands, Thailand, And Vietnam. (Asian)
A Person Having Origins In Any Of The
Black Racial Groups Of Africa. Terms
Such As "haitian" Or "negro" Can Be
Used In Addition To "black Or African
American." (Black or African American)
A Person Having Origins In Any Of The
Original Peoples Of Hawaii, Guam,
Samoa, Or Other Pacific Islands. (Native
Hawaiian or other Pacific Islander)
Not Provided Or Available (Not
Reported)
Could Not Be Determined Or Unsure
(Unknown)
A Person Having Origins In Any Of The
Original Peoples Of Europe, The Middle
East, Or North Africa. (White)
Ethnicity (Mark one)
A Person Of Mexican, Puerto Rican,
Cuban, Central Or South American Or
Other Spanish Culture Or Origin,
Regardless Of Race. (Hispanic or Latino)
A Person Not Meeting The Definition For
Hispanic Or Latino. (Not Hispanic or
Latino)
Could Not Be Determined Or Unsure
(Unknown)
Patient Demographics/pre-treatment
Characteristics2
Performance Status (ECOG/Zubrod scale)
Fully Active, Able To Carry On All Pre-
disease Performance Without
Restriction. (0)
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Breast Cancer NCT00770809 Registration - CALGB 40601
REGISTRATION WORKSHEET - 2680365v1.0
Restricted In Physically Strenuous
Activity But Ambulatory And Able To
Carry Out Work Of A Light Or Sedentary
Nature, E.g., Light Housework, Office
Work. (1)
Ambulatory And Capable Of All Selfcare
But Unable To Carry Out Any Work
Activities. Up And About More Than 50%
Of Waking Hours. (2)
Capable Of Only Limited Selfcare,
Confined To Bed Or Chair More Than
50% Of Waking Hours. (3)
Completely Disabled. Cannot Carry On
Any Selfcare. Totally Confined To Bed Or
Chair. (4)
Dead (5)
Height (cm)
Weight (kg)
Body Surface Area (m^2)
Method of Payment (USA only Mark one)
Medicaid (Medicaid)
Medicaid And Medicare (Medicaid and
Medicare)
Medicare (Medicare)
Medicare And Private Insurance
(Medicare and Private Insurance)
Military Sponsored (including Champus
& Tricare) (Military Sponsored (including
CHAMPUS & TRICARE))
No Means Of Payment (no Insurance)
(No means of payment (no insurance))
Other (Other)
Private Insurance (Private Insurance)
Self Pay (no Insurance) (Self Pay (No
Insurance))
Unknown (Unknown)
Veterans Sponsored (Veterans
Sponsored)
Disease
Stage
T0, N1, M0 Or T1*, N1, M0 Or T2, N0,
M0 Or T2, N1, M0 Or T3, N0, M0 (II)
T0, N2, M0 Or T1*, N2, M0 Or T2, N2,
M0 Or T3, N1, M0 Or T3, N2, M0 Or T4,
N0, M0 Or T4, N1, M0 Or T4, N2, M0 Or
Any T, N3, M0 (III)
Pathologic type
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Breast Cancer NCT00770809 Registration - CALGB 40601
REGISTRATION WORKSHEET - 2680365v1.0
Patient Zip Code
Country of Residence (if not USA)
Certification Of Eligibility And Protocol
Design
In the opinion of the investigator, is the patient
eligible?
Yes
No
Protocol Design
Stratification factors
Er And Pgr Negative (ER and PGR
negative)
Er And/or Pgr Positive (ER and/or PGR
positive)
Stage Ii Breast Cancer (Stage II)
Stage Iii Breast Cancer (Stage III)
Assigned Treatment Arm
Arm 1: Paclitaxel + Trastuzumab +
Lapatinib (Arm 1: Paclitaxel +
Trastuzumab + Lapatinib)
Arm 2: Paclitaxel + Trastuzumab (Arm 2:
Paclitaxel + Trastuzumab)
Initial Patient Consent For Specimen Use
Patient's Initial Consent given for specimen use
for research on the patient's cancer?
Yes
No
Patient's initial consent given for specimen use
for genetic research relating to the study
treatment
Yes
No
Patient's Initial Consent given for specimen kept
for future use in research to learn about, prevent,
or treat cancer
Yes
No
Patient's initial consent given for specimen(s)
may be kept for use in research to learn about,
prevent, or treat other health problems (for
example:
diabetes, Alzheimer's disease, or heart disease)
Yes
No
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REGISTRATION WORKSHEET - 2680365v1.0
Patient's initial consent given for further contact
regarding specimen?
Yes
No
Tissue Procurement Kit
Name
Institution
Shipping Address
Phone
FAX
Email
Registration Information
Registration Date
CALGB Patient ID (Assigned)
Participating Group Patient ID (Assigned)
Registrar's Signature
5 / 5
Breast Cancer NCT00770809 Registration - CALGB 40601
REGISTRATION WORKSHEET - 2680365v1.0
Colorectal Cancer NCT01150045 Registration - CALGB
80702 Registration Worksheet Form - 2969752v1.0
CALGB 80702 Registration Worksheet Form
Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or
Without Celecoxib in Treating Patients With Stage III Colon
Cancer Previously Treated With Surgery
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=7AD9533B-
3CE6-57A8-E040-BB89AD434546
All rights reserved. Please visit https://medical-data-
models.org/forms/8851
CALGB 80702 Registration
Worksheet Form
Header Module
Lead Institution
Institution/Affiliate
Participating Group Name
CALGB Patient ID
Physician
Principal Investigator No.
Protocol Administration
IRB Approval Date (MM DD YYYY)
Date Informed Consent Signed (MM DD YYYY)
Projected Start Date of Treatment (MM DD
YYYY)
HIPAA Authorization Date (MM DD YYYY)
Institution contact
Phone
Fax
Patient Demographics/pre-treatment
Characteristics
Patient Initials (Last, First Middle)
1 / 5
Date of Birth (MM DD YYYY)
Patient Social Security Number
Patient Hospital No.
Gender
Female (FEMALE)
Male (MALE)
Race (Mark all that apply)
A Person Having Origins In Any Of The
Original Peoples Of North And South
America (including Central America),
And Who Maintains Tribal Affiliation Or
Community Attachment. (American
Indian or Alaska Native)
A Person Having Origins In Any Of The
Original Peoples Of The Far East,
Southeast Asia, Or The Indian
Subcontinent Including, For Example,
Cambodia, China, India, Japan, Korea,
Malaysia, Pakistan, The Philippine
Islands, Thailand, And Vietnam. (Asian)
A Person Having Origins In Any Of The
Black Racial Groups Of Africa. Terms
Such As "haitian" Or "negro" Can Be
Used In Addition To "black Or African
American." (Black or African American)
A Person Having Origins In Any Of The
Original Peoples Of Hawaii, Guam,
Samoa, Or Other Pacific Islands. (Native
Hawaiian or other Pacific Islander)
Could Not Be Determined Or Unsure
(Unknown)
A Person Having Origins In Any Of The
Original Peoples Of Europe, The Middle
East, Or North Africa. (White)
Ethnicity (Mark one)
A Person Of Mexican, Puerto Rican,
Cuban, Central Or South American Or
Other Spanish Culture Or Origin,
Regardless Of Race. (Hispanic or Latino)
A Person Not Meeting The Definition For
Hispanic Or Latino. (Not Hispanic or
Latino)
Could Not Be Determined Or Unsure
(Unknown)
Patient Demographics/pre-treatment
Characteristics2
Performance Status (ECOG/Zubrod scale)
Fully Active, Able To Carry On All Pre-
disease Performance Without
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Colorectal Cancer NCT01150045 Registration - CALGB 80702
Registration Worksheet Form - 2969752v1.0
Restriction. (0)
Restricted In Physically Strenuous
Activity But Ambulatory And Able To
Carry Out Work Of A Light Or Sedentary
Nature, E.g., Light Housework, Office
Work. (1)
Ambulatory And Capable Of All Selfcare
But Unable To Carry Out Any Work
Activities. Up And About More Than 50%
Of Waking Hours. (2)
Capable Of Only Limited Selfcare,
Confined To Bed Or Chair More Than
50% Of Waking Hours. (3)
Completely Disabled. Cannot Carry On
Any Selfcare. Totally Confined To Bed Or
Chair. (4)
Dead (5)
Height (cm)
Weight (kg)
Body Surface Area (m^2)
Method of Payment (USA only Mark one)
Medicaid (Medicaid)
Medicaid And Medicare (Medicaid and
Medicare)
Medicare (Medicare)
Medicare And Private Insurance
(Medicare and Private Insurance)
Military Sponsored (including Champus
& Tricare) (Military Sponsored (including
CHAMPUS & TRICARE))
No Means Of Payment (no Insurance)
(No means of payment (no insurance))
Other (Other)
Private Insurance (Private Insurance)
Self Pay (no Insurance) (Self Pay (No
Insurance))
Unknown (Unknown)
Veterans Sponsored (Veterans
Sponsored)
Patient Demographics/pre-treatment
Characteristics3
Disease
Patient Zip Code
Country of Residence (If not USA)
3 / 5
Colorectal Cancer NCT01150045 Registration - CALGB 80702
Registration Worksheet Form - 2969752v1.0
Certification Of Eligibility And Protocol
Design
In the opinion of the investigator, is the patient
eligible for 80702
Yes
No
In the opinion of the investigator, is the patient
eligible for 150911
Yes
No
In the opinion of the investigator, is the patient
eligible for 60905
Yes
No
Protocol Design
Stratification Factors
Assigned Treatment Arm
Initial Patient Consent For Specimen Use
Did the patient agree to participate in the Diet
and Lifestyle study and complete the diet and
lifestyle questionnaire
Yes
No
Patient's Initial Consent given for specimen use
for research on the patient's cancer
Yes
No
Patient's initial consent given for blood specimen
use for genetic research on patient's cancer?
Yes
No
Patient's Initial Consent given for specimen kept
for future use in research to learn about, prevent,
or treat cancer
Yes
No
Patient's Initial Consent given for specimen use
for research unrelated to the patient's cancer?
Yes
No
Patient's initial consent given for further contact
regarding specimen?
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Registration Worksheet Form - 2969752v1.0
Yes
No
Notes
CRA Name
CRA e-mail
CRA mailing address
CRA Phone
Registration Information
Registration Date (MM DD YYYY)
Participating Group Patient ID
CALGB Patient ID
Registrar's Signature
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Registration Worksheet Form - 2969752v1.0
Leukemia NCT00513747 Registration - CALGB-10501
Pre-Registration Worksheet Form - 2660322v1.0
CALGB-10501 Pre-Registration Worksheet Form
Early or Delayed Fludarabine and Rituximab in Treating
Patients With Previously Untreated Chronic Lymphocytic
Leukemia
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=33E5BC11-
98AA-4A14-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/8852
CALGB-10501 Pre-Registration
Worksheet Form
Header Module
Lead Institution
Institution/Affiliate
CALGB Patient ID (Assigned)
Physician of Record
Participating Group
Protocol Administration
IRB Approval Date
Date Informed Consent Signed
Projected Start Date of Treatment
HIPAA Authorization Date
Contact Person at Institution
Phone
Fax
Patient Demographics/pre-treatment
Characteristics
Patient Initials (Last, First Middle)
Patient's Date of Birth (MM DD YYYY)
1 / 3
Patient Social Security Number
Patient Hospital No.
Gender
Female (FEMALE)
Male (MALE)
Race (Mark all that apply)
A Person Having Origins In Any Of The
Original Peoples Of North And South
America (including Central America),
And Who Maintains Tribal Affiliation Or
Community Attachment. (American
Indian or Alaska Native)
A Person Having Origins In Any Of The
Original Peoples Of The Far East,
Southeast Asia, Or The Indian
Subcontinent Including, For Example,
Cambodia, China, India, Japan, Korea,
Malaysia, Pakistan, The Philippine
Islands, Thailand, And Vietnam. (Asian)
A Person Having Origins In Any Of The
Black Racial Groups Of Africa. Terms
Such As "haitian" Or "negro" Can Be
Used In Addition To "black Or African
American." (Black or African American)
A Person Having Origins In Any Of The
Original Peoples Of Hawaii, Guam,
Samoa, Or Other Pacific Islands. (Native
Hawaiian or other Pacific Islander)
Could Not Be Determined Or Unsure
(Unknown)
A Person Having Origins In Any Of The
Original Peoples Of Europe, The Middle
East, Or North Africa. (White)
Ethnicity (Mark one)
A Person Of Mexican, Puerto Rican,
Cuban, Central Or South American Or
Other Spanish Culture Or Origin,
Regardless Of Race. (Hispanic or Latino)
A Person Not Meeting The Definition For
Hispanic Or Latino. (Not Hispanic or
Latino)
Could Not Be Determined Or Unsure
(Unknown)
Patient Demographics/pre-treatment
Characteristics2
Patient Zip Code
Country of Residence (if not USA)
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Leukemia NCT00513747 Registration - CALGB-10501 Pre-Registration
Worksheet Form - 2660322v1.0
Certification Of Eligibility And Protocol
Design
In the opinion of the investigator, is the patient
eligible?
Yes
No
Patient has consented to take part in the Quality
of Life Study
Yes
No
Initial Patient Consent For Specimen Use
Patient's Initial Consent given for specimen use
for research on the patient's cancer?
Yes
No
Patient's Initial Consent given for specimen use
for research unrelated to the patient's cancer?
No (No)
Unknown (Unknown)
Yes (Yes)
Patient's initial consent given for further contact
regarding specimen?
Yes
No
Registration Information
Date of Registration
CALGB Patient ID (Assigned)
Participating Group Patient ID (Assigned)
Registrar's Signature
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Leukemia NCT00513747 Registration - CALGB-10501 Pre-Registration
Worksheet Form - 2660322v1.0
Liver Cancer NCT01015833 Registration - CALGB
80802 Registration Worksheet Form - 2940585v1.0
CALGB 80802 Registration Worksheet Form
Sorafenib Tosylate With or Without Doxorubicin
Hydrochloride in Treating Patients With Locally Advanced
or Metastatic Liver Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=73B6D8AE-
48AF-7324-E040-BB89AD43648A
All rights reserved. Please visit https://medical-data-
models.org/forms/8853
CALGB 80802 Registration
Worksheet Form
Header Module
Lead Institution
CALGB Patient ID (Assigned)
Institution/Affiliate
Participating Group Name
Physician
Principal Investigator No.
Protocol Administration
IRB Approval Date (MM DD YYYY)
Date Informed Consent Signed (MM DD YYYY)
Projected Start Date of Treatment (MM DD
YYYY)
HIPAA Authorization Date (MM DD YYYY)
Institution contact
Phone
Fax
Patient Demographics/pre-treatment
Characteristics
Patient Initials (Last, First Middle)
1 / 5
Date of Birth (MM DD YYYY)
Patient Social Security Number
Patient Hospital No.
Gender
Female (FEMALE)
Male (MALE)
Patient Demographics/pre-treatment
Characteristics2
Race (Mark all that apply)
A Person Having Origins In Any Of The
Original Peoples Of North And South
America (including Central America),
And Who Maintains Tribal Affiliation Or
Community Attachment. (American
Indian or Alaska Native)
A Person Having Origins In Any Of The
Original Peoples Of The Far East,
Southeast Asia, Or The Indian
Subcontinent Including, For Example,
Cambodia, China, India, Japan, Korea,
Malaysia, Pakistan, The Philippine
Islands, Thailand, And Vietnam. (Asian)
A Person Having Origins In Any Of The
Black Racial Groups Of Africa. Terms
Such As "haitian" Or "negro" Can Be
Used In Addition To "black Or African
American." (Black or African American)
A Person Having Origins In Any Of The
Original Peoples Of Hawaii, Guam,
Samoa, Or Other Pacific Islands. (Native
Hawaiian or other Pacific Islander)
Could Not Be Determined Or Unsure
(Unknown)
A Person Having Origins In Any Of The
Original Peoples Of Europe, The Middle
East, Or North Africa. (White)
Ethnicity (Mark one)
A Person Of Mexican, Puerto Rican,
Cuban, Central Or South American Or
Other Spanish Culture Or Origin,
Regardless Of Race. (Hispanic or Latino)
A Person Not Meeting The Definition For
Hispanic Or Latino. (Not Hispanic or
Latino)
Could Not Be Determined Or Unsure
(Unknown)
Performance Status (ECOG/Zubrod scale)
Fully Active, Able To Carry On All Pre-
disease Performance Without
2 / 5
Liver Cancer NCT01015833 Registration - CALGB 80802 Registration
Worksheet Form - 2940585v1.0
Restriction. (0)
Restricted In Physically Strenuous
Activity But Ambulatory And Able To
Carry Out Work Of A Light Or Sedentary
Nature, E.g., Light Housework, Office
Work. (1)
Ambulatory And Capable Of All Selfcare
But Unable To Carry Out Any Work
Activities. Up And About More Than 50%
Of Waking Hours. (2)
Capable Of Only Limited Selfcare,
Confined To Bed Or Chair More Than
50% Of Waking Hours. (3)
Completely Disabled. Cannot Carry On
Any Selfcare. Totally Confined To Bed Or
Chair. (4)
Dead (5)
Height (cm)
Weight (kg)
BSA (m^2)
Method of Payment (USA only Mark one)
Medicaid (Medicaid)
Medicaid And Medicare (Medicaid and
Medicare)
Medicare (Medicare)
Medicare And Private Insurance
(Medicare and Private Insurance)
Military Sponsored (including Champus
& Tricare) (Military Sponsored (including
CHAMPUS & TRICARE))
No Means Of Payment (no Insurance)
(No means of payment (no insurance))
Other (Other)
Private Insurance (Private Insurance)
Self Pay (no Insurance) (Self Pay (No
Insurance))
Unknown (Unknown)
Veterans Sponsored (Veterans
Sponsored)
Patient Demographics/pre-treatment
Characteristics3
Disease
Patient Zip Code
Country of Residence (If not USA)
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Liver Cancer NCT01015833 Registration - CALGB 80802 Registration
Worksheet Form - 2940585v1.0
Certification Of Eligibility And Protocol
Design
In the opinion of the investigator, is the patient
eligible?
Yes
No
Protocol Design
Hepatitis status
Hepatitis B (Hepatitis B)
Hepatitis B And C (Hepatitis B and C)
Hepatitis C (Hepatitis C)
No Hepatitis (No hepatitis)
Extent of disease
Locally Advanced (Locally advanced)
Metastatic (Metastatic)
Assigned Treatment Arm
Arm A: Doxorubicin Plus Sorafenib (Arm
A: Doxorubicin plus Sorafenib)
Arm B: Sorafenib (Arm B: Sorafenib)
Protocol Design
Did the patient agree to participate in the CT
imaging study
Yes
No
Patient's Initial Consent given for specimen use
for research on the patient's cancer
Yes
No
Patient's initial consent given for blood specimen
use for genetic research on patient's cancer?
Yes
No
Patient's Initial Consent given for specimen kept
for future use in research to learn about, prevent,
or treat cancer
Yes
No
Patient's Initial Consent given for specimen use
for research unrelated to the patient's cancer?
Yes
No
Patient's initial consent given for further contact
regarding specimen?
Yes
No
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Worksheet Form - 2940585v1.0
Registration Information
CALGB Patient ID (Assigned)
Registration Date (MM DD YYYY)
Participating Group Patient ID (Assigned)
Registrar's Signature
Notes:
CRA Name
CRA e-mail
CRA Phone
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Worksheet Form - 2940585v1.0
Lung Cancer NCT00863512 Registration - CALGB
30506 Pre-Registration Worksheet Form - 2817249v1.0
CALGB 30506 Pre-Registration Worksheet Form
Chemotherapy or Observation in Treating Patients With
Early Stage Non-Small Cell Lung Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=5E92C67F-
D6E2-CFB0-E040-BB89AD432DA1
All rights reserved. Please visit https://medical-data-
models.org/forms/8854
CALGB 30506 Pre-Registration
Worksheet Form
Header Module
Lead Institution
Institution/Affiliate
CALGB Patient ID (Assigned)
Physician of Record
Participating Group Name
Protocol Administration
IRB Approval Date (MM DD YYYY)
Date Informed Consent Signed (MM DD YYYY)
Projected Start Date of Treatment (MM DD
YYYY)
HIPAA Authorization Date (MM DD YYYY)
Institution contact
Phone
Fax
Patient Demographics/pre-treatment
Characteristics
Patient Initials (Last, First Middle)
Date of Birth (MM DD YYYY)
1 / 4
Patient Social Security Number
Patient Hospital No.
Gender
Female (FEMALE)
Male (MALE)
Race (Mark all that apply)
A Person Having Origins In Any Of The
Original Peoples Of North And South
America (including Central America),
And Who Maintains Tribal Affiliation Or
Community Attachment. (American
Indian or Alaska Native)
A Person Having Origins In Any Of The
Original Peoples Of The Far East,
Southeast Asia, Or The Indian
Subcontinent Including, For Example,
Cambodia, China, India, Japan, Korea,
Malaysia, Pakistan, The Philippine
Islands, Thailand, And Vietnam. (Asian)
A Person Having Origins In Any Of The
Black Racial Groups Of Africa. Terms
Such As "haitian" Or "negro" Can Be
Used In Addition To "black Or African
American." (Black or African American)
A Person Having Origins In Any Of The
Original Peoples Of Hawaii, Guam,
Samoa, Or Other Pacific Islands. (Native
Hawaiian or other Pacific Islander)
Could Not Be Determined Or Unsure
(Unknown)
A Person Having Origins In Any Of The
Original Peoples Of Europe, The Middle
East, Or North Africa. (White)
Ethnicity (Mark one)
A Person Of Mexican, Puerto Rican,
Cuban, Central Or South American Or
Other Spanish Culture Or Origin,
Regardless Of Race. (Hispanic or Latino)
A Person Not Meeting The Definition For
Hispanic Or Latino. (Not Hispanic or
Latino)
Could Not Be Determined Or Unsure
(Unknown)
Patient Demographics/pre-treatment
Characteristics2
Performance Status (ECOG/Zubrod scale)
Fully Active, Able To Carry On All Pre-
disease Performance Without
Restriction. (0)
Restricted In Physically Strenuous
Activity But Ambulatory And Able To
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Lung Cancer NCT00863512 Registration - CALGB 30506 Pre-
Registration Worksheet Form - 2817249v1.0
Carry Out Work Of A Light Or Sedentary
Nature, E.g., Light Housework, Office
Work. (1)
Ambulatory And Capable Of All Selfcare
But Unable To Carry Out Any Work
Activities. Up And About More Than 50%
Of Waking Hours. (2)
Capable Of Only Limited Selfcare,
Confined To Bed Or Chair More Than
50% Of Waking Hours. (3)
Completely Disabled. Cannot Carry On
Any Selfcare. Totally Confined To Bed Or
Chair. (4)
Dead (5)
Method of Payment (USA only Mark one)
Medicaid (Medicaid)
Medicaid And Medicare (Medicaid and
Medicare)
Medicare (Medicare)
Medicare And Private Insurance
(Medicare and Private Insurance)
Military Sponsored (including Champus
& Tricare) (Military Sponsored (including
CHAMPUS & TRICARE))
No Means Of Payment (no Insurance)
(No means of payment (no insurance))
Other (Other)
Private Insurance (Private Insurance)
Self Pay (no Insurance) (Self Pay (No
Insurance))
Unknown (Unknown)
Veterans Sponsored (Veterans
Sponsored)
Patient Demographics/pre-treatment
Characteristics3
Disease
Patient Zip Code
Country of Residence (If not USA)
Certification Of Eligibility And Protocol
Design
In the opinion of the investigator, is the patient
eligible?
Yes
No
Protocol Design
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Registration Worksheet Form - 2817249v1.0
Responsible CRA
CRA phone number
CRA email
Registration Information
Registration Date (MM DD YYYY)
CALGB Patient ID (Assigned)
Participating Group Patient ID (Assigned)
Registrar's Signature
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Registration Worksheet Form - 2817249v1.0
Prostate Cancer NCT00079001 Registration - CALGB
90202 Registration Worksheet - 2078253v3.0
CALGB 90202 Registration Worksheet
Zoledronate in Preventing Skeletal (Bone)-Related Events
in Patients Who Are Receiving Androgen Deprivation
Therapy For Prostate Cancer and Bone Metastases
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=B4604912-
73F0-0497-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/8855
CALGB 90202 Registration
Worksheet
Registration
Main Member Institution
Assigned CALGB Patient ID
Physician of Record
Affiliate/Treating Institution
Participating Group Name (If the patient has
been on a previous CALGB protocol, specify)
Protocol Administration
IRB Approval Date
Date Informed Consent Signed
Projected Treatment Start Date
Responsible Contact
Phone
Fax
Patient Demographics / Pre-treatment
Characteristics
Patient Initials (last, first, middle)
Social Security Number
Birth Date
1 / 4
Patient Hospital No.
Gender
Female (Female)
Male (Male)
Race
A Person Having Origins In Any Of The
Original Peoples Of North And South
America (including Central America),
And Who Maintains Tribal Affiliation Or
Community Attachment (American Indian
or Alaskan Native)
A Person Having Origins In Any Of The
Original Peoples Of The Far East,
Southeast Asia, Or The Indian
Subcontinent Including, For Example,
Cambodia, China, India, Japan, Korea,
Malaysia, Pakistan, The Philippine
Islands, Thailand, And Vietnam. (Asian)
A Person Having Origins In Any Of The
Black Racial Groups Of Africa. Terms
Such As "haitian" Or "negro" Can Be
Used In Addition To "black Or African
American." (Black or African American)
A Person Having Origins In Any Of The
Original Peoples Of Hawaii, Guam,
Samoa, Or Other Pacific Islands (Native
Hawaiian or Other Pacific Islander)
Patient Is Unsure Of Their Race
(Unknown)
A Person Having Origins In Any Of The
Original Peoples Of Europe, The Middle
East, Or North Africa. (White)
Ethnicity
A Person Of Mexican, Puerto Rican,
Cuban, Central Or South American Or
Other Spanish Culture Or Origin,
Regardless Of Race (Hispanic or Latino)
A Person Not Meeting The Definition For
Hispanic Or Latino. (Non-Hispanic)
Patient Is Unsure Of Their Ethnicity
(Unknown)
Method of Payment
Medicaid (Medicaid)
Medicaid And Medicare (Medicaid and
Medicare)
Medicare (Medicare)
Medicare And Private Insurance
(Medicare and Private Insurance)
Military Sponsored (including Champus
& Tricare) (Military (including
CHAMPUS))
No Means Of Payment (no Insurance)
(No means of payment (no insurance))
Other (Other)
Private Insurance (Private Insurance)
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Prostate Cancer NCT00079001 Registration - CALGB 90202
Registration Worksheet - 2078253v3.0
Self Pay (no Insurance) (Self pay (no
insurance))
Unknown (Unknown)
Veterans Sponsored (Veterans
Administration Sponsored)
Patient's Zip Code
Country of Residence (if not USA)
Certification Of Eligibility
Is the patient eligible? (STRATIFICATION
FACTORS)
Yes
No
Protocol Design
Assigned Treatment Arm (Initial Patient Consent
Specimen Use)
Arm 1 (Arm 1)
Arm 2 (Arm 2)
Patient's Initial Consent given for specimen use
for research on the patient's cancer?
Yes
No
Patient's Initial Consent given for specimen use
for research unrelated to the patient's cancer?
Yes
No
Patient's Initial Consent given for further contact
regarding specimen?
Yes
No
Registration Information
Assigned CALGB Patient ID
Assigned Participating Group Patient ID
Registration Date
Registrar's Signature
Ccrr Module For Calgb 90202 Registration
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Registration Worksheet - 2078253v3.0
Worksheet
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Prostate Cancer NCT00079001 Registration - CALGB 90202
Registration Worksheet - 2078253v3.0
Bladder Cancer NCT00014534 Registration - CALGB
90104 Registration Worksheet-Rev - 2169333v3.0
CALGB 90104 Registration Worksheet-Rev
Combination Chemotherapy in Treating Patients With
Bladder Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=BE1B0F83-
6C73-6D73-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/8856
CALGB 90104 Registration
Worksheet-Rev
Initial Patient Consent For Specimen Use
Patient?s Initial Consent given for specimen use
for research on the patient?s cancer?
Yes
No
Patient?s Initial Consent given for specien use for
research unrelated to the patient?s cancer?
Yes
No
Patient?s Initial Consent given for further contact
regarding specimen?
Yes
No
CALGB Patient ID
Registration Date
Assigned Participating Group Patient ID
Registrar's Signature
Ccrr Module For Calgb 90104 Registration
Worksheet-rev
Institution Name
Affiliate Institution
Physician of Record
Participating Group Name
CALGB Patient ID
IRB Approval Date
1 / 3
Date Informed Consent Signed
Projected Treatment Start Date
HIPAA Authorization Date
Responsible contact
phone
fax
Patient Initials
Patient Social Security Number
Patient Birth Date
Patient Hospital No.
Gender
Female (Female)
Male (Male)
Race
A Person Having Origins In Any Of The
Original Peoples Of North And South
America (including Central America),
And Who Maintains Tribal Affiliation Or
Community Attachment (American Indian
or Alaskan Native)
A Person Having Origins In Any Of The
Original Peoples Of The Far East,
Southeast Asia, Or The Indian
Subcontinent Including, For Example,
Cambodia, China, India, Japan, Korea,
Malaysia, Pakistan, The Philippine
Islands, Thailand, And Vietnam. (Asian)
A Person Having Origins In Any Of The
Black Racial Groups Of Africa. Terms
Such As "haitian" Or "negro" Can Be
Used In Addition To "black Or African
American." (Black or African American)
Ethnicity (Ethnicity)
Hispanic or Latino (Hispanic or Latino)
A Person Having Origins In Any Of The
Original Peoples Of Hawaii, Guam,
Samoa, Or Other Pacific Islands (Native
Hawaiian or Other Pacific Islander)
Non-Hispanic (Non-Hispanic)
Patient Is Unsure Of Their Race
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(Unknown)
Unknown (Unknown)
A Person Having Origins In Any Of The
Original Peoples Of Europe, The Middle
East, Or North Africa. (White)
Performance Status (ECOG/Zubrod)
Height
Weight
Body Surface Area
Method of Payment
Medicaid (medicaid)
Medicaid And Medicare (medicaid and
medicare)
Medicare (medicare)
Medicare And Private Insurance
(medicare and private insurance)
Military Sponsored (including Champus
& Tricare) (military (including Champus
and Tricare))
No Means Of Payment (no Insurance)
(no means of payment (no insurance))
Other (other)
Private Insurance (private insurance)
Self Pay (no Insurance) (self pay (no
insurance))
Unknown (unknown)
Veterans Sponsored (veterans
administration sponsored)
Patient's zip code
Country of residence (if not USA)
T status
Tumor More Than 5 Cm In Greatest
Dimension (T3)
Tumor Of Any Size With Direct Extension
To (a) Chest Wall Or (b) Skin, Only As
Described Below (T4)
Lymph node involvement (check one)
1 To 5 Nodes Invovled By Tumor (1 to 5
nodes invovled by tumor)
A (A)
Absent (absent)
B (B)
Greater Than Or Equal To 6 Nodes
Involved By Tumor (greater than or equal
to 6 nodes involved by tumor)
3 / 3
Bladder Cancer NCT00014534 Registration - CALGB 90104 Registration
Worksheet-Rev - 2169333v3.0
Bladder Cancer NCT00942331 Registration - CALGB
90601 Registration Worksheet - 2848728v1.0
CALGB 90601 Registration Worksheet
Gemcitabine Hydrochloride and Cisplatin With or Without
Bevacizumab in Treating Patients With Advanced Urinary
Tract Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=653F1390-
699C-B455-E040-BB89AD4361B9
All rights reserved. Please visit https://medical-data-
models.org/forms/8857
CALGB 90601 Registration
Worksheet
Header Module
Lead Institution*
Institution/Affiliate*
Physician of Record*
Participating Group Name*
CALGB Patient ID (Assigned)*
Protocol Administration
IRB Approval Date (MM DD YYYY)*
Date Informed Consent Signed (MM DD YYYY)*
Projected Start Date of Treatment (MM DD
YYYY)*
HIPAA Authorization Date (MM DD YYYY)*
Institution contact*
Phone*
Fax*
Patient Demographics/pre-treatment
Characteristics
Patient Initials (Last, First Middle)*
Date of Birth (MM DD YYYY)*
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Patient Social Security Number*
Patient Hospital No.*
Gender*
Female (FEMALE)
Male (MALE)
Race (Mark all that apply)*
A Person Having Origins In Any Of The
Original Peoples Of North And South
America (including Central America),
And Who Maintains Tribal Affiliation Or
Community Attachment. (American
Indian or Alaska Native)
A Person Having Origins In Any Of The
Original Peoples Of The Far East,
Southeast Asia, Or The Indian
Subcontinent Including, For Example,
Cambodia, China, India, Japan, Korea,
Malaysia, Pakistan, The Philippine
Islands, Thailand, And Vietnam. (Asian)
A Person Having Origins In Any Of The
Black Racial Groups Of Africa. Terms
Such As "haitian" Or "negro" Can Be
Used In Addition To "black Or African
American." (Black or African American)
A Person Having Origins In Any Of The
Original Peoples Of Hawaii, Guam,
Samoa, Or Other Pacific Islands. (Native
Hawaiian or other Pacific Islander)
Could Not Be Determined Or Unsure
(Unknown)
A Person Having Origins In Any Of The
Original Peoples Of Europe, The Middle
East, Or North Africa. (White)
Ethnicity (Mark one)*
A Person Of Mexican, Puerto Rican,
Cuban, Central Or South American Or
Other Spanish Culture Or Origin,
Regardless Of Race. (Hispanic or Latino)
A Person Not Meeting The Definition For
Hispanic Or Latino. (Not Hispanic or
Latino)
Could Not Be Determined Or Unsure
(Unknown)
Patient Demographics/pre-treatment
Characteristics2
Performance Status (ECOG/Zubrod scale)*
Fully Active, Able To Carry On All Pre-
disease Performance Without
Restriction. (0)
Restricted In Physically Strenuous
Activity But Ambulatory And Able To
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Worksheet - 2848728v1.0
Carry Out Work Of A Light Or Sedentary
Nature, E.g., Light Housework, Office
Work. (1)
Ambulatory And Capable Of All Selfcare
But Unable To Carry Out Any Work
Activities. Up And About More Than 50%
Of Waking Hours. (2)
Capable Of Only Limited Selfcare,
Confined To Bed Or Chair More Than
50% Of Waking Hours. (3)
Completely Disabled. Cannot Carry On
Any Selfcare. Totally Confined To Bed Or
Chair. (4)
Dead (5)
Height (cm)*
Weight (kg)*
Body Surface Area (m^2)*
Method of Payment (USA only Mark one)*
Medicaid (Medicaid)
Medicaid And Medicare (Medicaid and
Medicare)
Medicare (Medicare)
Medicare And Private Insurance
(Medicare and Private Insurance)
Military Sponsored (including Champus
& Tricare) (Military Sponsored (including
CHAMPUS & TRICARE))
No Means Of Payment (no Insurance)
(No means of payment (no insurance))
Other (Other)
Private Insurance (Private Insurance)
Self Pay (no Insurance) (Self Pay (No
Insurance))
Unknown (Unknown)
Veterans Sponsored (Veterans
Sponsored)
Patient Demographics/pre-treatment
Characteristics3
Disease*
Stage*
Pathologic type*
Patient Zip Code*
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Worksheet - 2848728v1.0
Country of Residence (If not USA)*
Certification Of Eligibility And Protocol
Design
In the opinion of the investigator, is the patient
eligible?*
Yes
No
Protocol Design
Stratification Factors*
Presence of visceral metastasis*
Yes
No
Assigned Treatment Arm*
Kit number*
Initial Patient Consent For Specimen Use
Patient's Initial Consent given for specimen use
for research on the patient's cancer*
Yes
No
Patient's initial consent given for specimen use
for genetic research relating to the study
treatment*
Yes
No
My specimens may be kept for use in research to
learn about, prevent, treat, or cure cancer.*
Yes
No
My specimens may be kept for use in research
about other health problems (for example:
diabetes, Alzheimer's disease, or heart disease).*
Yes
No
My doctor or someone from CALGB may contact
me in the future to ask me to take part in more
research*
Yes
No
Prior Cancer Therapies
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Other Prior Therapy*
Yes
No
Prior therapy type*
Agents Administered To Control The
Replication And/or Spread Of Viruses
(Anti-retroviral therapy)
Treatment With An Agent That Prevents
Or Impairs The Translation Of The
Genetic Message For Production Of A
Specific Protein (Antisense)
High Dose Chemotherapy Combined
With Transplantation Of Bone Marrow
Cells (Bone marrow transplant)
Non-systemic Chemotherapy Treatment
Or Chemotherapy Not Described By
Chemotherapy Single Agent Systemic Or
Multi-agent Systemic (Chemotherapy
(NOS))
Systemic Chemotherapy With A
Regimen Containing Multiple Agents
(Chemotherapy multiple agents
systemic)
Prior Therapy With Agents That Are Not
Known To Cause Damage To Cycling
Cells (Chemotherapy non-cytotoxic)
Systemic Chemotherapy With A Single
Agent Regimen (Chemotherapy single
agent systemic)
Drug And/or Immunotherapy (Drug
and/or Immunotherapy)
Treatment Of Human Disease By Gene
Transfer (Gene transfer)
Cancer Therapy Which Incorporates
Hormonal Manipulation (Hormonal
therapy)
Anticancer Treatment With A Live,
Replication-competent Virus (Oncolytic
virotherapy)
Targeted Ionizing Radiation Therapy
Utilizing Radioactive Implants Or Seeds
(Radiation therapy)
Surgical Procedure, Or Operation, With
Therapeutic Intent (Surgery)
Therapy Nos (Therapy (NOS))
Substance Or Group Of Substances
Administered To Induce The Immune
System To Recognize And Destroy
Tumors Or Microorganisms (Vaccine)
Number of prior chemotherapy regimens*
Registration Information
CALGB Patient ID (Assigned)*
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Registration Date (MM DD YYYY)*
Participating Group Patient ID (Assigned)*
Registrar's Signature*
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Lung Cancer NCT01041781 Registration - CALGB-
30801 Pre-Registration Worksheet Form - 2891008v1.0
CALGB-30801 Pre-Registration Worksheet Form
Gemcitabine Hydrochloride or Pemetrexed Disodium and
Carboplatin With or Without Celecoxib in Treating Patients
With Advanced Non-Small Cell Lung Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=6AF269FD-
C8E5-3B6B-E040-BB89AD432A5C
All rights reserved. Please visit https://medical-data-
models.org/forms/8858
CALGB-30801 Pre-Registration
Worksheet Form
Header Module
Lead Institution
CALGB Patient ID
Institution/Affiliate
Physician
Principal Investigator No.
Participating Group Name
Protocol Administration
IRB Approval Date (MM DD YYYY)
Date Informed Consent Signed (MM DD YYYY)
HIPAA Authorization Date (MM DD YYYY)
Institution contact
Phone
Fax
Patient Demographics/pre-treatment
Characteristics
Patient Initials (Last, First Middle)
Date of Birth (MM DD YYYY)
Patient Social Security Number
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Patient Hospital No.
Gender
Female (FEMALE)
Male (MALE)
Race (Mark all that apply)
A Person Having Origins In Any Of The
Original Peoples Of North And South
America (including Central America),
And Who Maintains Tribal Affiliation Or
Community Attachment. (American
Indian or Alaska Native)
A Person Having Origins In Any Of The
Original Peoples Of The Far East,
Southeast Asia, Or The Indian
Subcontinent Including, For Example,
Cambodia, China, India, Japan, Korea,
Malaysia, Pakistan, The Philippine
Islands, Thailand, And Vietnam. (Asian)
A Person Having Origins In Any Of The
Black Racial Groups Of Africa. Terms
Such As "haitian" Or "negro" Can Be
Used In Addition To "black Or African
American." (Black or African American)
A Person Having Origins In Any Of The
Original Peoples Of Hawaii, Guam,
Samoa, Or Other Pacific Islands. (Native
Hawaiian or other Pacific Islander)
Could Not Be Determined Or Unsure
(Unknown)
A Person Having Origins In Any Of The
Original Peoples Of Europe, The Middle
East, Or North Africa. (White)
Ethnicity (Mark one)
A Person Of Mexican, Puerto Rican,
Cuban, Central Or South American Or
Other Spanish Culture Or Origin,
Regardless Of Race. (Hispanic or Latino)
A Person Not Meeting The Definition For
Hispanic Or Latino. (Not Hispanic or
Latino)
Could Not Be Determined Or Unsure
(Unknown)
Patient Demographics/pre-treatment
Characteristics3
Disease (NSCLC)
Stage (III IV)
Pathologic type (Squamous Carcinoma Non-
Squamous Carcinoma)
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Registration Worksheet Form - 2891008v1.0
Patient Zip Code
Country of Residence (If not USA)
Certification Of Eligibility And Protocol
Design
In the opinion of the investigator, is the patient
eligible?
Yes
No
Protocol Design
Patient's Initial Consent given for specimen use
for research on the patient's cancer
Yes
No
Patient's Initial Consent given for specimen kept
for future use in research to learn about, prevent,
or treat cancer
Yes
No
Patient's Initial Consent given for specimen use
for research unrelated to the patient's cancer?
Yes
No
Patient's initial consent given for further contact
regarding specimen?
Yes
No
Registration Information
CALGB Patient ID
Registration Date (MM DD YYYY)
Participating Group Patient ID
Registrar's Signature
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Registration Worksheet Form - 2891008v1.0
Multiple Myeloma and Plasma Cell Neoplasm NCT00644228 Registration -
Southwest Oncology Group S0777 Registration Worksheet - Not for OPEN -
2697089v1.0
Southwest Oncology Group S0777 Registration Worksheet
-  Not for OPEN
Lenalidomide and Dexamethasone With or Without
Bortezomib in Treating Patients With Previously Untreated
Multiple Myeloma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=3EFCA54F-
811F-2D21-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/8859
Southwest Oncology Group S0777
Registration Worksheet - Not for
OPEN
Header
Activation Date
Last Amended Date
Registration Step
Unnamed2
Registrar's SWOG Roster ID Number
SWOG Investigator Number
SWOG Treating Institution Number (Check that
IRB approval is current for this institution prior to
registering. Registrations are not allowed if the
IRB approval is expired.)
Unnamed2
Registering Group Name
Investigator Name
Institution Name
NCI Institution Number
IRB/REB  Approval Date
Participating Group Patient ID
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Unnamed5
SWOG Patient ID Status
New Patient (New patient)
Previous Patient (Previous patient)
SWOG Patient ID
Date Informed Consent Signed
Date HIPAA Authorization signed (Not required if
Country of Residence is not USA)
Projected Start Date of Treatment
Patient First Name
Patient Middle Name
Patient Last Name
Patient's Date of Birth
Country of Residence (if not USA)
Canada (CA)
Other (Other)
Usa (US)
Country of Residence
Patient Social Security Number (If a U.S.
resident)
ZIP Code
Social Insurance Number (If a resident of
Canada)
Postal code
Race
Race
A Person Having Origins In Any Of The
Original Peoples Of North And South
America (including Central America),
And Who Maintains Tribal Affiliation Or
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Southwest Oncology Group S0777 Registration Worksheet - Not for OPEN -
2697089v1.0
Community Attachment. (American
Indian or Alaska Native)
A Person Having Origins In Any Of The
Original Peoples Of The Far East,
Southeast Asia, Or The Indian
Subcontinent Including, For Example,
Cambodia, China, India, Japan, Korea,
Malaysia, Pakistan, The Philippine
Islands, Thailand, And Vietnam. (Asian)
A Person Having Origins In Any Of The
Black Racial Groups Of Africa. Terms
Such As "haitian" Or "negro" Can Be
Used In Addition To "black Or African
American." (Black or African American)
A Person Having Origins In Any Of The
Original Peoples Of Hawaii, Guam,
Samoa, Or Other Pacific Islands. (Native
Hawaiian or other Pacific Islander)
Not Provided Or Available (Not
Reported)
Could Not Be Determined Or Unsure
(Unknown)
A Person Having Origins In Any Of The
Original Peoples Of Europe, The Middle
East, Or North Africa. (White)
Unnamed5
Patient's Ethnicity
No (not Spanish) (No (not Spanish))
Unknown (Unknown)
Yes, Central American (Yes, Central
American)
Yes, Cuban (Yes, Cuban)
Yes, Mexican (Yes, Mexican)
Yes, Nos (Yes, NOS)
Yes, Other (Yes, Other)
Yes, Puerto Rican (Yes, Puerto Rican)
Yes, South American (Yes, South
American)
Hispanic other,specify
Method of Payment
Medicaid (Medicaid)
Medicaid And Medicare (Medicaid and
Medicare)
Medicare (Medicare)
Medicare And Private Insurance
(Medicare and Private Insurance)
Military Or Veterans Sponsored Nos
(Military or Veterans Sponsored, Not
Otherwise Specified (NOS))
No Means Of Payment (no Insurance)
(No means of payment (no insurance))
Other (Other)
Private Insurance (Private Insurance)
Self Pay (no Insurance) (Self Pay (No
3 / 5
Multiple Myeloma and Plasma Cell Neoplasm NCT00644228 Registration -
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Insurance))
Unknown (Unknown)
Veterans Sponsored (Veterans
Sponsored)
Other, specify
Gender
Female (female)
Male (male)
Stratification Questions
ISS stage
I (I)
Ii (II)
Iii (III)
Intent to transplant at relapse
Yes
No
Unnamed4
My specimens may be kept for use in research to
learn about, prevent, treat, or cure cancer.
Yes
No
My tissue and blood may be kept for research
about other health problems (for example: causes
of diabetes, Alzheimer's disease, and heart
disease)
Yes
No
Someone may contact me in the future to ask me
to allow other uses of my specimens.
Yes
No
I agree to allow my study doctor, or someone
approved by my study doctor, to contact me
regard future research involving my participation
in this study
Yes
No
Unnamed 7
Has the Southwest Oncology Group Registration
Worksheet been completed entirely and is the
patient eligible according to the current version of
protocol section 5.0
Yes
No
4 / 5
Multiple Myeloma and Plasma Cell Neoplasm NCT00644228 Registration -
Southwest Oncology Group S0777 Registration Worksheet - Not for OPEN -
2697089v1.0
Comments
SWOG Patient ID
Assigned Treatment Arm
Treatment name
Expectations Notes
Other Notes
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Registration - CALGB Step 1 Registration
Worksheet - 2795201v1.0
CALGB Step 1 Registration Worksheet
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=5A3D0AEA-
4662-364B-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/8860
CALGB Step 1 Registration
Worksheet
Header Module
Lead Institution
CALGB Patient ID (Assigned)
Institution/Affiliate
Physician
Principal Investigator No.
Participating Group Name
Protocol Administration
IRB Approval Date (MM DD YYYY)
Date Informed Consent Signed (MM DD YYYY)
Projected Start Date of Treatment (MM DD
YYYY)
HIPAA Authorization Date (MM DD YYYY)
Institution contact
Phone
Fax
Patient Demographics/pre-treatment
Characteristics
Patient Initials (Last, First Middle)
Date of Birth (MM DD YYYY)
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Patient Social Security Number
Patient Hospital No.
Gender
Female (FEMALE)
Male (MALE)
Race (Mark all that apply)
A Person Having Origins In Any Of The
Original Peoples Of North And South
America (including Central America),
And Who Maintains Tribal Affiliation Or
Community Attachment. (American
Indian or Alaska Native)
A Person Having Origins In Any Of The
Original Peoples Of The Far East,
Southeast Asia, Or The Indian
Subcontinent Including, For Example,
Cambodia, China, India, Japan, Korea,
Malaysia, Pakistan, The Philippine
Islands, Thailand, And Vietnam. (Asian)
A Person Having Origins In Any Of The
Black Racial Groups Of Africa. Terms
Such As "haitian" Or "negro" Can Be
Used In Addition To "black Or African
American." (Black or African American)
A Person Having Origins In Any Of The
Original Peoples Of Hawaii, Guam,
Samoa, Or Other Pacific Islands. (Native
Hawaiian or other Pacific Islander)
Could Not Be Determined Or Unsure
(Unknown)
A Person Having Origins In Any Of The
Original Peoples Of Europe, The Middle
East, Or North Africa. (White)
Ethnicity (Mark one)
A Person Of Mexican, Puerto Rican,
Cuban, Central Or South American Or
Other Spanish Culture Or Origin,
Regardless Of Race. (Hispanic or Latino)
A Person Not Meeting The Definition For
Hispanic Or Latino. (Not Hispanic or
Latino)
Could Not Be Determined Or Unsure
(Unknown)
Patient Demographics/pre-treatment
Characteristics2
Performance Status (ECOG/Zubrod scale)
Fully Active, Able To Carry On All Pre-
disease Performance Without
Restriction. (0)
Restricted In Physically Strenuous
Activity But Ambulatory And Able To
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Carry Out Work Of A Light Or Sedentary
Nature, E.g., Light Housework, Office
Work. (1)
Ambulatory And Capable Of All Selfcare
But Unable To Carry Out Any Work
Activities. Up And About More Than 50%
Of Waking Hours. (2)
Capable Of Only Limited Selfcare,
Confined To Bed Or Chair More Than
50% Of Waking Hours. (3)
Completely Disabled. Cannot Carry On
Any Selfcare. Totally Confined To Bed Or
Chair. (4)
Dead (5)
Height (cm)
Weight (kg)
Body Surface Area (m^2)
Method of Payment (USA only Mark one)
Medicaid (Medicaid)
Medicaid And Medicare (Medicaid and
Medicare)
Medicare (Medicare)
Medicare And Private Insurance
(Medicare and Private Insurance)
Military Sponsored (including Champus
& Tricare) (Military Sponsored (including
CHAMPUS & TRICARE))
No Means Of Payment (no Insurance)
(No means of payment (no insurance))
Other (Other)
Private Insurance (Private Insurance)
Self Pay (no Insurance) (Self Pay (No
Insurance))
Unknown (Unknown)
Veterans Sponsored (Veterans
Sponsored)
Patient Demographics/pre-treatment
Characteristics3
Disease
Stage
Pathologic type
Patient Zip Code
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Country of Residence (If not USA)
Certification Of Eligibility And Protocol
Design
In the opinion of the investigator, is the patient
eligible?
Yes
No
Protocol Design
Stratification Factors
Assigned Treatment Arm
Initial Patient Consent For Specimen Use
Patient's Initial Consent given for specimen use
for research on the patient's cancer
Yes
No
Patient's Initial Consent given for specimen use
for research unrelated to the patient's cancer?
Yes
No
Patient's initial consent given for further contact
regarding specimen?
Yes
No
Registration Information
CALGB Patient ID (Assigned)
Registration Date (MM DD YYYY)
Participating Group Patient ID (Assigned)
Registrar's Signature
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Registration - CALGB Registration
Worksheet - 2794582v1.0
CALGB Registration Worksheet
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=59FF920E-
736A-5FDA-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/8861
CALGB Registration Worksheet
Header Module
Lead Institution
Institution/Affiliate
Participating Group Name
CALGB Patient ID (Assigned)
Physician
Principal Investigator No.
Protocol Administration
IRB Approval Date (MM DD YYYY)
Date Informed Consent Signed (MM DD YYYY)
Projected Start Date of Treatment (MM DD
YYYY)
HIPAA Authorization Date (MM DD YYYY)
Institution contact
Phone
Fax
Patient Demographics/pre-treatment
Characteristics
Patient Initials (Last, First Middle)
Date of Birth (MM DD YYYY)
Patient Social Security Number
1 / 4
Patient Hospital No.
Gender
Female (FEMALE)
Male (MALE)
Race (Mark all that apply)
A Person Having Origins In Any Of The
Original Peoples Of North And South
America (including Central America),
And Who Maintains Tribal Affiliation Or
Community Attachment. (American
Indian or Alaska Native)
A Person Having Origins In Any Of The
Original Peoples Of The Far East,
Southeast Asia, Or The Indian
Subcontinent Including, For Example,
Cambodia, China, India, Japan, Korea,
Malaysia, Pakistan, The Philippine
Islands, Thailand, And Vietnam. (Asian)
A Person Having Origins In Any Of The
Black Racial Groups Of Africa. Terms
Such As "haitian" Or "negro" Can Be
Used In Addition To "black Or African
American." (Black or African American)
A Person Having Origins In Any Of The
Original Peoples Of Hawaii, Guam,
Samoa, Or Other Pacific Islands. (Native
Hawaiian or other Pacific Islander)
Could Not Be Determined Or Unsure
(Unknown)
A Person Having Origins In Any Of The
Original Peoples Of Europe, The Middle
East, Or North Africa. (White)
Ethnicity (Mark one)
A Person Of Mexican, Puerto Rican,
Cuban, Central Or South American Or
Other Spanish Culture Or Origin,
Regardless Of Race. (Hispanic or Latino)
A Person Not Meeting The Definition For
Hispanic Or Latino. (Not Hispanic or
Latino)
Could Not Be Determined Or Unsure
(Unknown)
Patient Demographics/pre-treatment
Characteristics2
Performance Status (ECOG/Zubrod scale)
Fully Active, Able To Carry On All Pre-
disease Performance Without
Restriction. (0)
Restricted In Physically Strenuous
Activity But Ambulatory And Able To
Carry Out Work Of A Light Or Sedentary
Nature, E.g., Light Housework, Office
Work. (1)
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Ambulatory And Capable Of All Selfcare
But Unable To Carry Out Any Work
Activities. Up And About More Than 50%
Of Waking Hours. (2)
Capable Of Only Limited Selfcare,
Confined To Bed Or Chair More Than
50% Of Waking Hours. (3)
Completely Disabled. Cannot Carry On
Any Selfcare. Totally Confined To Bed Or
Chair. (4)
Dead (5)
Height (cm)
Weight (kg)
Body Surface Area (m^2)
Method of Payment (USA only Mark one)
Medicaid (Medicaid)
Medicaid And Medicare (Medicaid and
Medicare)
Medicare (Medicare)
Medicare And Private Insurance
(Medicare and Private Insurance)
Military Sponsored (including Champus
& Tricare) (Military Sponsored (including
CHAMPUS & TRICARE))
No Means Of Payment (no Insurance)
(No means of payment (no insurance))
Other (Other)
Private Insurance (Private Insurance)
Self Pay (no Insurance) (Self Pay (No
Insurance))
Unknown (Unknown)
Veterans Sponsored (Veterans
Sponsored)
Patient Demographics/pre-treatment
Characteristics3
Disease
Stage
Pathologic type
Patient Zip Code
Country of Residence (If not USA)
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Registration - CALGB Registration Worksheet - 2794582v1.0
Certification Of Eligibility And Protocol
Design
In the opinion of the investigator, is the patient
eligible?
Yes
No
Protocol Design
Stratification Factors
Assigned Treatment Arm
Initial Patient Consent For Specimen Use
Patient's Initial Consent given for specimen use
for research on the patient's cancer
Yes
No
Patient's Initial Consent given for specimen use
for research unrelated to the patient's cancer?
Yes
No
Patient's initial consent given for further contact
regarding specimen?
Yes
No
Registration Information
Registration Date (MM DD YYYY)
Participating Group Patient ID (Assigned)
CALGB Patient ID (Assigned)
Registrar's Signature
4 / 4
Registration - CALGB Registration Worksheet - 2794582v1.0
Registration - CALGB Registration Prior
Therapy Worksheet - 2795306v1.0
CALGB Registration Prior Therapy Worksheet
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=5A3D0AEA-
474A-364B-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/8862
CALGB Registration Prior Therapy
Worksheet
Header Module
Lead Institution
Institution/Affiliate
Participating Group Name
CALGB Patient ID (Assigned)
Physician
Principal Investigator No.
Protocol Administration
IRB Approval Date (MM DD YYYY)
Date Informed Consent Signed (MM DD YYYY)
Projected Start Date of Treatment (MM DD
YYYY)
HIPAA Authorization Date (MM DD YYYY)
Institution contact
Phone
Fax
Patient Demographics/pre-treatment
Characteristics
Patient Initials (Last, First Middle)
Date of Birth (MM DD YYYY)
1 / 5
Patient Social Security Number
Patient Hospital No.
Gender
Female (FEMALE)
Male (MALE)
Race (Mark all that apply)
A Person Having Origins In Any Of The
Original Peoples Of North And South
America (including Central America),
And Who Maintains Tribal Affiliation Or
Community Attachment. (American
Indian or Alaska Native)
A Person Having Origins In Any Of The
Original Peoples Of The Far East,
Southeast Asia, Or The Indian
Subcontinent Including, For Example,
Cambodia, China, India, Japan, Korea,
Malaysia, Pakistan, The Philippine
Islands, Thailand, And Vietnam. (Asian)
A Person Having Origins In Any Of The
Black Racial Groups Of Africa. Terms
Such As "haitian" Or "negro" Can Be
Used In Addition To "black Or African
American." (Black or African American)
A Person Having Origins In Any Of The
Original Peoples Of Hawaii, Guam,
Samoa, Or Other Pacific Islands. (Native
Hawaiian or other Pacific Islander)
Could Not Be Determined Or Unsure
(Unknown)
A Person Having Origins In Any Of The
Original Peoples Of Europe, The Middle
East, Or North Africa. (White)
Ethnicity (Mark one)
A Person Of Mexican, Puerto Rican,
Cuban, Central Or South American Or
Other Spanish Culture Or Origin,
Regardless Of Race. (Hispanic or Latino)
A Person Not Meeting The Definition For
Hispanic Or Latino. (Not Hispanic or
Latino)
Could Not Be Determined Or Unsure
(Unknown)
Patient Demographics/pre-treatment
Characteristics2
Performance Status (ECOG/Zubrod scale)
Fully Active, Able To Carry On All Pre-
disease Performance Without
Restriction. (0)
Restricted In Physically Strenuous
Activity But Ambulatory And Able To
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Carry Out Work Of A Light Or Sedentary
Nature, E.g., Light Housework, Office
Work. (1)
Ambulatory And Capable Of All Selfcare
But Unable To Carry Out Any Work
Activities. Up And About More Than 50%
Of Waking Hours. (2)
Capable Of Only Limited Selfcare,
Confined To Bed Or Chair More Than
50% Of Waking Hours. (3)
Completely Disabled. Cannot Carry On
Any Selfcare. Totally Confined To Bed Or
Chair. (4)
Dead (5)
Height (cm)
Weight (kg)
Body Surface Area (m^2)
Method of Payment (USA only Mark one)
Medicaid (Medicaid)
Medicaid And Medicare (Medicaid and
Medicare)
Medicare (Medicare)
Medicare And Private Insurance
(Medicare and Private Insurance)
Military Sponsored (including Champus
& Tricare) (Military Sponsored (including
CHAMPUS & TRICARE))
No Means Of Payment (no Insurance)
(No means of payment (no insurance))
Other (Other)
Private Insurance (Private Insurance)
Self Pay (no Insurance) (Self Pay (No
Insurance))
Unknown (Unknown)
Veterans Sponsored (Veterans
Sponsored)
Patient Demographics/pre-treatment
Characteristics3
Disease
Stage
Pathologic type
Patient Zip Code
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Country of Residence (If not USA)
Certification Of Eligibility And Protocol
Design
In the opinion of the investigator, is the patient
eligible?
Yes
No
Protocol Design
Stratification Factors
Assigned Treatment Arm
Initial Patient Consent For Specimen Use
Patient's Initial Consent given for specimen use
for research on the patient's cancer
Yes
No
Patient's Initial Consent given for specimen use
for research unrelated to the patient's cancer?
Yes
No
Patient's initial consent given for further contact
regarding specimen?
Yes
No
Prior Cancer Therapies
Any Other Prior Therapy?
Yes
No
Prior therapy type
Agents Administered To Control The
Replication And/or Spread Of Viruses
(Anti-retroviral therapy)
Treatment With An Agent That Prevents
Or Impairs The Translation Of The
Genetic Message For Production Of A
Specific Protein (Antisense)
High Dose Chemotherapy Combined
With Transplantation Of Bone Marrow
Cells (Bone marrow transplant)
Non-systemic Chemotherapy Treatment
Or Chemotherapy Not Described By
Chemotherapy Single Agent Systemic Or
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Multi-agent Systemic (Chemotherapy
(NOS))
Systemic Chemotherapy With A
Regimen Containing Multiple Agents
(Chemotherapy multiple agents
systemic)
Prior Therapy With Agents That Are Not
Known To Cause Damage To Cycling
Cells (Chemotherapy non-cytotoxic)
Systemic Chemotherapy With A Single
Agent Regimen (Chemotherapy single
agent systemic)
Drug And/or Immunotherapy (Drug
and/or Immunotherapy)
Treatment Of Human Disease By Gene
Transfer (Gene transfer)
Cancer Therapy Which Incorporates
Hormonal Manipulation (Hormonal
therapy)
Anticancer Treatment With A Live,
Replication-competent Virus (Oncolytic
virotherapy)
Targeted Ionizing Radiation Therapy
Utilizing Radioactive Implants Or Seeds
(Radiation therapy)
Surgical Procedure, Or Operation, With
Therapeutic Intent (Surgery)
Therapy Nos (Therapy (NOS))
Substance Or Group Of Substances
Administered To Induce The Immune
System To Recognize And Destroy
Tumors Or Microorganisms (Vaccine)
Number of prior chemotherapy regimens
Registration Information
Registration Date (MM DD YYYY)
Participating Group Patient ID (Assigned)
CALGB Patient ID (Assigned)
Registrar's Signature
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Breast Cancer NCT00041119 Registration - CALGB
40101 REGISTRATION WORKSHEET - 2670720v1.0
Cyclophosphamide and Doxorubicin (CA x 4 cycles) versus
Paclitaxel (4 cycles) as Adjuvant Therapy for Breast Cancer
in Women with 0-3 Positive Axillary Lymph Nodes: A 2x2
Factorial Phase III Randomized Study
Four Versus Six Cycles of Cyclophosphamide/Doxorubicin
or Paclitaxel in Adjuvant Breast Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=36B8E5A6-
BC9A-573E-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/8863
CALGB 40101 REGISTRATION
WORKSHEET
Header Module
Lead Institution
CALGB Patient ID (Assigned)
Institution/Affiliate
Physician of Record
Participating Group Name
Protocol Administration
IRB/REB  Approval Date
Date Informed Consent Signed
Projected Treatment Begin Date
HIPAA Authorization Date
Contact Person at Institution
Phone
Fax
Patient Demographics/pre-treatment
Characteristics
Last
First
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Middle
Patient Social Security Number
Patient Birth Date (MM DD YYYY)
Patient Hospital No.
Gender
Female (FEMALE)
Male (MALE)
Race (Mark all that apply)
A Person Having Origins In Any Of The
Original Peoples Of North And South
America (including Central America),
And Who Maintains Tribal Affiliation Or
Community Attachment. (American
Indian or Alaska Native)
A Person Having Origins In Any Of The
Original Peoples Of The Far East,
Southeast Asia, Or The Indian
Subcontinent Including, For Example,
Cambodia, China, India, Japan, Korea,
Malaysia, Pakistan, The Philippine
Islands, Thailand, And Vietnam. (Asian)
A Person Having Origins In Any Of The
Black Racial Groups Of Africa. Terms
Such As "haitian" Or "negro" Can Be
Used In Addition To "black Or African
American." (Black or African American)
A Person Having Origins In Any Of The
Original Peoples Of Hawaii, Guam,
Samoa, Or Other Pacific Islands. (Native
Hawaiian or other Pacific Islander)
Could Not Be Determined Or Unsure
(Unknown)
A Person Having Origins In Any Of The
Original Peoples Of Europe, The Middle
East, Or North Africa. (White)
Ethnicity (Mark one)
A Person Of Mexican, Puerto Rican,
Cuban, Central Or South American Or
Other Spanish Culture Or Origin,
Regardless Of Race. (Hispanic or Latino)
A Person Not Meeting The Definition For
Hispanic Or Latino. (Not Hispanic or
Latino)
Could Not Be Determined Or Unsure
(Unknown)
ECOG Performance Status
Fully Active, Able To Carry On All Pre-
disease Performance Without
Restriction. (0)
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Restricted In Physically Strenuous
Activity But Ambulatory And Able To
Carry Out Work Of A Light Or Sedentary
Nature, E.g., Light Housework, Office
Work. (1)
Ambulatory And Capable Of All Selfcare
But Unable To Carry Out Any Work
Activities. Up And About More Than 50%
Of Waking Hours. (2)
Capable Of Only Limited Selfcare,
Confined To Bed Or Chair More Than
50% Of Waking Hours. (3)
Completely Disabled. Cannot Carry On
Any Selfcare. Totally Confined To Bed Or
Chair. (4)
Dead (5)
Height (cm)
Weight (kg)
BSA (m^2)
Method of Payment
Medicaid (Medicaid)
Medicaid And Medicare (Medicaid and
Medicare)
Medicare (Medicare)
Medicare And Private Insurance
(Medicare and Private Insurance)
Military Sponsored (including Champus
& Tricare) (Military Sponsored (including
CHAMPUS & TRICARE))
No Means Of Payment (no Insurance)
(No means of payment (no insurance))
Other (Other)
Private Insurance (Private Insurance)
Self Pay (no Insurance) (Self Pay (No
Insurance))
Unknown (Unknown)
Veterans Sponsored (Veterans
Sponsored)
Patient Zip Code
Country of Residence (if not USA)
Certification Of Eligibility And Protocol
Design
In the opinion of the investigator, is the patient
eligible?
Yes
No
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Menopausal status
Postmenopausal (Postmenopausal)
Premenopausal (Premenopausal)
ER/PgR
Both Negative (Both negative)
Both Or Either Positive Or Unknown
(Both or either positive or unknown)
HER-2/neu status
Negative (Negative)
Positive (Positive)
Unknown (Unknown)
Assigned Treatment Arm
Ca Therapy -- 4 Cycles (c-600 Mg/m2 A-
60 Mg/m2 Q-14 Days) (CA Therapy -- 4
cycles (C-600 mg/m2 A-60 mg/m2 q-14
days))
Paclitaxel -- 4 Cycles (175 Mg/m2 Q-14
Days) (Paclitaxel -- 4 cycles (175 mg/m2
q-14 days))
Initial Patient Consent For Specimen Use
Is the patient registering to the Pharmacogenetic
companion study 60202 (titled "Drug Metabolism
and Transport PG in Breast CA")?
Yes
No
Patient's initial consent given for blood specimen
use for genetic research on patient's cancer?
Yes
No
Did patient consent to DNA specimen use in
future research studies?
Yes
No
Patient's Initial Consent given for tissue specimen
use for research on the patient's cancer?
Yes
No
Patient's Initial Consent given for tissue specimen
use for research unrelated to the patient's
cancer?
Yes
No
Patient's initial consent given for further contact
regarding specimen?
Yes
No
Registration Information
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CALGB Patient ID (Assigned)
Date of Registration
Participating Group Patient ID (Assigned)
Registrar's Signature
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Endometrial Cancer NCT00063999 Eligibility - Fast Fact
Sheet for Protocol 0209 (endometrial) - 2770341v1.0
Fast Fact Sheet for Protocol 0209 (endometrial)
Combination Chemotherapy in Treating Patients With Stage
III, Stage IV, or Recurrent Endometrial Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=53CE53A6-
C7B5-2895-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/8865
Fast Fact Sheet for Protocol 0209
(endometrial)
Tracking Information
GOG Institution Code
GOG Affiliate Code
Previous GOG #
Treating physician
Other Physician
Patient Hospital No.
Date of Birth (m d y)
Patient Name, Last
Patient Name, First
Patient Name, Middle
Patient Social Security Number
Patient Zip Code
Country of residence (if not USA)
Ethnicity
A Person Of Mexican, Puerto Rican,
Cuban, Central Or South American Or
Other Spanish Culture Or Origin,
Regardless Of Race. (Hispanic or Latino)
A Person Not Meeting The Definition For
Hispanic Or Latino. (Not Hispanic or
Latino)
Not Provided Or Available (Not reported)
Could Not Be Determined Or Unsure
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(Unknown)
Method of Payment
Medicaid (Medicaid)
Medicaid And Medicare (Medicaid and
Medicare)
Medicare (Medicare)
Medicare And Private Insurance
(Medicare and Private Insurance)
Military Or Veterans Sponsored Nos
(Military or Veterans Sponsored, Not
Otherwise Specified (NOS))
Military Sponsored (including Champus
& Tricare) (Military Sponsored (including
CHAMPUS & TRICARE))
No Means Of Payment (no Insurance)
(No means of payment (no insurance))
Other (Other)
Private Insurance (Private Insurance)
Self Pay (no Insurance) (Self Pay (No
Insurance))
Unknown (Unknown)
Veterans Sponsored (Veterans
Sponsored)
Race
Race
A Person Having Origins In Any Of The
Original Peoples Of North And South
America (including Central America),
And Who Maintains Tribal Affiliation Or
Community Attachment. (American
Indian or Alaska Native)
A Person Having Origins In Any Of The
Original Peoples Of The Far East,
Southeast Asia, Or The Indian
Subcontinent Including, For Example,
Cambodia, China, India, Japan, Korea,
Malaysia, Pakistan, The Philippine
Islands, Thailand, And Vietnam. (Asian)
A Person Having Origins In Any Of The
Black Racial Groups Of Africa. Terms
Such As "haitian" Or "negro" Can Be
Used In Addition To "black Or African
American." (Black or African American)
A Person Having Origins In Any Of The
Original Peoples Of Hawaii, Guam,
Samoa, Or Other Pacific Islands. (Native
Hawaiian or other Pacific Islander)
Not Provided Or Available (Not
Reported)
Could Not Be Determined Or Unsure
(Unknown)
A Person Having Origins In Any Of The
Original Peoples Of Europe, The Middle
East, Or North Africa. (White)
2 / 9
Endometrial Cancer NCT00063999 Eligibility - Fast Fact Sheet for
Protocol 0209 (endometrial) - 2770341v1.0
Module 1
Patient signed consent
Yes
No
Has the patient provided written authorization
permitting release of personal health information
Yes
No
What is the site of the disease
Endometrium (Endometrium)
What is the cell type
Adenocarcinoma With Squamous
Differentiation (Adenocarcinoma with
Squamous Differentiation)
Adenocarcinoma, Unspecified
(Adenocarcinoma, unspecified)
Adenofibroma (Adenofibroma)
Adenosarcoma (Adenosarcoma)
Adenosquamous (Adenosquamous
carcinoma)
Benign (Benign NOS)
Brenner Tumor (benign) (Brenner tumor
(benign))
Brenner Tumor (malignant) (Brenner
tumor (malignant))
Brenner Tumor Of Low Malignant
Potential (Brenner tumor of LMP)
Cancer With Dermoid Cyst, Specify
Types (Cancer with dermoid cyst)
Carcinosarcoma/mesodermal (mullerian)
Mixed Tumor (Carcinosarcoma MMT)
Choriocarcinoma (Choriocarcinoma)
Clear Cell Carcinoma (Clear cell
carcinoma)
Clear Cell Cystadenofibroma (benign)
(Clear cell cystadenofibroma (benign))
Clear Cell Cystadenoma (benign) (Clear
cell cystadenoma (benign))
Clear Cell Tumor Of Low Malignant
Potential (Clear cell tumor of LMP)
Dysgerminoma (Dysgerminoma)
Embryonal Carcinoma (Embryonal
carcinoma)
Endodermal Sinus Tumor (yolk Sac
Tumor) (Endodermal sinus tumor)
Endometrial Carcinoma (Endometrial
carcinoma)
Endometrial Stromal Sarcoma
(Endometrial stromal sarcoma)
Endometrioid Adenocarcinoma
(Endometrioid adenocarcinoma)
Endometrioid Cystadenofibroma (benign)
(Endometrioid cystadenofibroma
(benign))
Endometrioid Cystadenoma (benign)
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(Endometrioid cystadenoma (benign))
Endometrioid Tumor Of Low Malignant
Potential (Endometrioid tumor of LMP)
Fibroma (Fibroma)
Germ Cell Tumor, Mixed (Germ cell
tumor, mixed)
Gestational Trophoblastic Disease
(Gestational trophoblastic disease)
Granulosa Cell Tumor (Granulosa cell
tumor)
Gynandroblastoma (Gynandroblastoma)
Leiomyosarcoma (Leiomyosarcoma)
Mixed Epithelial Carcinoma, Specify
Components (Mixed epithelial
carcinoma)
Mixed Malignant Germ Cell Tumor,
Specify Components (Mixed malignant
germ cell tumor)
Mucinous Adenocarcinoma (Mucinous
adenocarcinoma)
Mucinous Cystadenofibroma (benign)
(Mucinous cystadenofibroma (benign))
Mucinous Cystadenoma (benign)
(Mucinous cystadenoma (benign))
Mucinous Tumor Of Low Malignant
Potential (Mucinous tumor of LMP)
Normal Tissue (Normal Tissue)
Other, Specify (Other specify)
Ovarian Endometriosis (Ovarian
endometriosis)
Physiologic Cyst (corpus Luteum)
(Physiologic cyst (corpus luteum))
Physiologic Cyst (follicle) (Physiologic
cyst (follicle))
Polyembryoma (Polyembryoma)
Serous Adenocarcinoma (Serous
adenocarcinoma)
Serous Cystadenofibroma (benign)
(Serous cystadenofibroma (benign))
Serous Cystadenoma (benign) (Serous
cystadenoma (benign))
Serous Tumor Of Low Malignant
Potential (Serous tumor of LMP)
Sertoli-leydig Cell (androblastoma)
(Sertoli-Leydig cell (Androblastoma))
Sex-cord/stromal, Unclassified (Sex-
cord/stromal, unclassified)
Simple Cyst (Simple cyst)
Small Cell Carcinoma (Small cell
carcinoma)
Squamous Cell Carcinoma (Squamous
cell carcinoma)
Steroid/lipid Cell Tumor (Steroid/Lipid cell
tumor)
Teratoma, Immature, Specify
Components (Teratoma, immature)
Teratoma, Mature (Teratoma, mature)
Transitional Cell Carcinoma, Including
Brenner Tumor (Transitional cell
carcinoma (including Brenner))
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Undifferentiated Carcinoma
(Undifferentiated carcinoma)
Uterine Carcinosarcoma (Uterine
carcinosarcoma)
Uterine Leiomyosarcoma (Uterine
leiomyosarcoma)
Villoglandular Carcinoma (Villoglandular
carcinoma)
Primary Tumor Diagnosis Date
Histologic Grade (Differentiation)
Grade 1-well Differentiated (1)
Grade 2-moderately Differentiated (2)
Grade 3-poorly Differentiated (3)
Stage
Refer To Figo Staging For Specific
Gynecologic Cancer (III)
Refer To Figo Staging For Specific
Gynecologic Cancer (IV)
Recurrent (Recurrent)
Date of Recurrence
Was the recurrence diagnosed histologically
No (NO)
Not Applicable (Not Applicable)
Yes (YES)
Is there potential for cure by radiation and/or
surgery
Yes
No
Does the patient have measurable disease
Yes
No
Is the measurable disease >= 20 mm when
measured by conventional techniques, including
palpation, plain X-ray, CT and MRI or >=10mm
when measured by spiral CT
Not Applicable (Not Applicable)
Yes (Yes)
Is estrogen receptor and progesterone receptor
status of the primary tumor available
Yes
No
Lab Results
Prior Radiation Therapy
Yes
No
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Was external beam RT delivered to the pelvis
No (No)
Not Applicable (Not Applicable)
Yes (Yes)
Was external beam RT delivered to the peri-
aortic lymph node region or to the abdomen
No (No)
Not Applicable (Not Applicable)
Yes (Yes)
Did the patient have intracavitary radiation
therapy to the vagina
No (No)
Not Applicable (Not Applicable)
Yes (Yes)
Have at least 4 weeks elapsed since completion
of radiation therapy if it involved the whole pelvis
or more than 50% of the spine
No (No)
Not Applicable (Not Applicable)
Yes (Yes)
Lab Results:
Date
Platelets (PLT)
ANC
Is the Serum Creatinine less than or equal to
ULN
Yes
No
Creatinine Clearance
Is SGPT (ALT) less than or equal to 3 X Upper
Limits of Normal
Yes
No
Is Bilirubin less than or equal to institutional
upper limit of normal
Yes
No
Will the patient have the following paramenters
measured within 14 days prior to initiating
protocol therapy
Yes
No
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Will the patient have the following parameters
measured within 28 days prior to initiating
protocol therapy
Yes
No
Has the patient had an EKG
Yes
No
Performance Status
Fully Active, Able To Carry On All Pre-
disease Performance Without
Restriction. (0)
Restricted In Physically Strenuous
Activity But Ambulatory And Able To
Carry Out Work Of A Light Or Sedentary
Nature, E.g., Light Housework, Office
Work. (1)
Ambulatory And Capable Of All Selfcare
But Unable To Carry Out Any Work
Activities. Up And About More Than 50%
Of Waking Hours. (2)
Capable Of Only Limited Selfcare,
Confined To Bed Or Chair More Than
50% Of Waking Hours. (3)
Completely Disabled. Cannot Carry On
Any Selfcare. Totally Confined To Bed Or
Chair. (4)
Dead (5)
Has the patient met the pre-entry requirements
as specified in section 7.0
Yes
No
Does the patient have a concomitant malignancy
other than non-melanoma skin cancer
Yes
No
Has the patient had any prior cancer diagnosed?
Yes
No
Has the patient been disease-free for 5 or more
years and had no prior chemotherapy for
previous malignancy
Not Available (NA)
No (No)
Yes (Yes)
Unnamed2
Does the patient have third-degree or complete
heart block
Yes
No
7 / 9
Endometrial Cancer NCT00063999 Eligibility - Fast Fact Sheet for
Protocol 0209 (endometrial) - 2770341v1.0
Is a pacemaker in place
Not Available (NA)
No (No)
Yes (Yes)
Does the patient have a chronic disease
Yes
No
Does the patient have a history of myocardial
infarction within 6 months before enrollment, New
York Heart Association (NYHA) Class II or
greater heart failure or symptoms suspicious for
congestive heart failure
Yes
No
Has the patient had a left ventricular ejection
fraction in the past 6 months that is documented
to be 50% or greater
Not Applicable (Not Applicable)
Yes (Yes)
Left Ventricular Ejection Fraction at Rest
Has the patient had an LVEF of less than 50% in
the last 6months
Yes
No
Are there circumstances that will not permit
patient to complete therapy or adequate follow-up
Yes
No
Is the patient sensitive to E. Coli-derived drug
preparations
Yes
No
Is the patient age 18 years or older
Yes
No
Stratification
The Patient Has Either Measurable Or
Recurrent Disease (Stratum 1 - The
patient has either measurable or
recurrent disease)
The Patient Has Non-measurable Stage
Iii Or Iv Disease And Has Received
Radiation To The Pelvis (Stratum 2 - The
patient has non-measurable Stage III or
IV disease and HAS received radiation to
the pelvis)
The Patient Has Non-measurable Stage
Iii Or Iv Disease With No Previous
Radiation To The Pelvis (Stratum 3 - The
patient has non-measurable Stage III or
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IV disease with NO previous radiation to
the pelvis)
Anticipated date treatment will start
Comments
Comments
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Ovarian Cancer NCT00954174 Registration - GOG-0261: Fast Fact
Sheet for Protocol 0261 (Uterine Corpus, Ovary) - 2949744v1.0
GOG-0261: Fast Fact Sheet for Protocol 0261 (Uterine
Corpus, Ovary)
Paclitaxel and Carboplatin or Ifosfamide in Treating Patients
With Newly Diagnosed Persistent or Recurrent Uterine or
Ovarian Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=74E5BFDB-
0F29-45AE-E040-BB89AD432FB0
All rights reserved. Please visit https://medical-data-
models.org/forms/8866
GOG-0261: Fast Fact Sheet for
Protocol 0261 (Uterine Corpus,
Ovary)
Tracking Information
GOG Institution Code
GOG Affiliate Code
This Patient's Previous GOG #
Treating physician
Other Physician
Patient Hospital No.
Date of Birth
Patient Name, Last
Patient Name, First
Patient Name, Middle
Patient Social Security Number
Patient Zip Code
Country
Race
A Person Having Origins In Any Of The
Original Peoples Of North And South
America (including Central America),
And Who Maintains Tribal Affiliation Or
Community Attachment. (American
Indian or Alaska Native)
A Person Having Origins In Any Of The
Original Peoples Of The Far East,
Southeast Asia, Or The Indian
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Subcontinent Including, For Example,
Cambodia, China, India, Japan, Korea,
Malaysia, Pakistan, The Philippine
Islands, Thailand, And Vietnam. (Asian)
A Person Having Origins In Any Of The
Black Racial Groups Of Africa. Terms
Such As "haitian" Or "negro" Can Be
Used In Addition To "black Or African
American." (Black or African American)
A Person Having Origins In Any Of The
Original Peoples Of Hawaii, Guam,
Samoa, Or Other Pacific Islands. (Native
Hawaiian or other Pacific Islander)
Could Not Be Determined Or Unsure
(Unknown)
A Person Having Origins In Any Of The
Original Peoples Of Europe, The Middle
East, Or North Africa. (White)
Ethnicity
A Person Of Mexican, Puerto Rican,
Cuban, Central Or South American Or
Other Spanish Culture Or Origin,
Regardless Of Race. (Hispanic or Latino)
A Person Not Meeting The Definition For
Hispanic Or Latino. (Not Hispanic or
Latino)
Could Not Be Determined Or Unsure
(Unknown)
Method of Payment
Medicaid (Medicaid)
Medicaid And Medicare (Medicaid and
Medicare)
Medicare (Medicare)
Medicare And Private Insurance
(Medicare and Private Insurance)
Military Or Veterans Sponsored Nos
(Military or Veterans Sponsored, Not
Otherwise Specified (NOS))
Military Sponsored (including Champus
& Tricare) (Military Sponsored (including
CHAMPUS & TRICARE))
No Means Of Payment (no Insurance)
(No means of payment (no insurance))
Other (Other)
Private Insurance (Private Insurance)
Self Pay (no Insurance) (Self Pay (No
Insurance))
Unknown (Unknown)
Veterans Sponsored (Veterans
Sponsored)
Header
Did the patient sign an approved informed
consent
Yes
No
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Has the patient provided written authorization
permitting release of personal health information
Yes
No
Does the patient have newly diagnosed Stage I-
IV OR persistent OR recurrent (including
unstaged), pathologically confirmed uterine or
ovarian carcinosarcoma
Yes
No
Was the patient diagnosed with ovarian
carcinosarcoma or uterine carcinosarcoma
Ovarian (Ovarian)
Uterus (Uterine)
Has there been a review of the pathologic
specimen from the uterus or ovary
Yes
No
Is the patient chemotherapy naive as directed
against uterine or ovarian carcinosarcoma
Yes
No
Has the patient received prior adjuvant external
beam radiation therapy and/or vaginal
brachytherapy
Yes
No
Will the completion of the radiotherapy be at least
4 weeks prior to beginning protocol
chemotherapy (If yes,)
No (No)
Not Applicable (Not Applicable)
Yes (Yes)
Is the patient age 18 years or older
Yes
No
Performance Status
Fully Active, Able To Carry On All Pre-
disease Performance Without
Restriction. (0)
Restricted In Physically Strenuous
Activity But Ambulatory And Able To
Carry Out Work Of A Light Or Sedentary
Nature, E.g., Light Housework, Office
Work. (1)
Ambulatory And Capable Of All Selfcare
But Unable To Carry Out Any Work
Activities. Up And About More Than 50%
Of Waking Hours. (2)
Capable Of Only Limited Selfcare,
Confined To Bed Or Chair More Than
50% Of Waking Hours. (3)
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Completely Disabled. Cannot Carry On
Any Selfcare. Totally Confined To Bed Or
Chair. (4)
Dead (5)
Has the patient recovered from the effects of
recent surgery, radiotherapy or  chemotherapy
Yes
No
Is the patient free of active infection requiring
antibiotics
Yes
No
Unnamed2
Has the patient received/will the patient receive
any hormonal therapy directed at the malignant
tumor within one week of beginning protocol
chemotherapy (Continuation of hormone
replacement therapy is permitted.)
Yes
No
Date of Results (if more than one, enter earliest)
Platelets (must be 100,000/mcl or greater)
ANC (must be 1,500/mcl or greater)
Is the creatinine less than or equal to 1.5 X ULN
(CTCAE v3.0 Grade 1)
Yes
No
Is the bilirubin less than or equal to 1.5 X ULN
(CTCAE v3.0 Grade 1)
Yes
No
Are SGOT and Alkaline Phosphatase less than or
equal to 2.5 times institutional ULN
Yes
No
Is the albumin greater than or equal to 3 g/dl
Yes
No
Is sensory or motor neuropathy less than or
equal to CTCAE v 3.0 grade 1
Yes
No
If the patient is of childbearing potential, has she
had a negative serum pregnancy test within 72
hours prior to initiating protocol therapy and is
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she practicing an effective form of contraception
No (No)
Not Applicable (Not Applicable)
Yes (Yes)
Was the patient treated previously with pelvic or
extended field radiation
Yes
No
What best describes the patient's disease
status/stage at the time of study entry
Figo Clinical Stage I-ii (FIGO Clinical
Stage I-II)
Figo Surgical Or Clinical Stage Iii-iv
(FIGO Surgical or Clinical Stage III-IV)
Figo Surgical Stage I-ii, Pelvic Nodes Are
Surgically/pathologically Assessed
(FIGO Surgical Stage I-II, pelvic nodes
are surgically/pathologically assessed)
Figo Surgical Stage I-ii, Pelvic Nodes Not
Surgically/pathologically Assessed
(FIGO Surgical Stage I-II, pelvic nodes
not surgically/pathologically assessed)
Recurrence Or Disease That Persists
After A 1st Line Regimen Without
Chemo (Recurrence or disease that
persists after a 1st line regimen without
chemo)
Date recurrence or persistence was confirmed (If
applicable,)
How was recurrence or persistence established
for this study
Histologic (Histologic)
Non-histological Method (Non-
Histological Method)
Not Applicable (Not Applicable)
Does patient have measurable disease as
defined by GOG RECIST criteria (Section 8.0 of
the protocol)
Yes
No
Unnamed3
Has the patient received prior cytotoxic
chemotherapy for management of uterine or
ovarian sarcoma
Yes
No
Does the patient have a history of the presence
of other invasive malignancies, other than non-
melanoma skin cancer, within the past 5 years
Yes
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No
Has the patient had previous cancer treatment
which contraindicates this protocol therapy
Yes
No
Is radiotherapy planned after or during study
chemotherapy prior to progression of cancer
Yes
No
Does the patient have a known hypersensitivity to
E. Coli-derived drug preparation (Pegfilgrastim
and Filgrastim)
Yes
No
Does the patient have a known hypersensitivity to
mesna or other thiol compounds
Yes
No
Will the patient have the following parameters
measured within 14 days of initiating protocol
chemotherapy (CBC, Differential, Platelets,
Serum Creatinine, Urinanalysis, Bilirubin, DGOT,
Alkaline Phosphatase, Electrolytes, BUN,
Calcium, Magnesium, Phosphate and Albumin)
Yes
No
Will the patient have the following parameters
measured within 28 days prior to initiating
protocol therapy (History and Physical Exam,
Toxicity Assessment, CA-125, Imaging of chest,
pelvis and abdomen, EKG and Tumor
Measurements radiographic or clinical)
Yes
No
Anticipated date treatment will start
Comments
Provide comments about this Fast Fact Sheet
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Breast Cancer NCT00601900 Registration - CALGB
40503 RE-REGISTRATION WORKSHEET - 2551890v1.0
CALGB 40503 RE-REGISTRATION WORKSHEET
Tamoxifen or Letrozole With or Without Bevacizumab in
Treating Women With Stage III or Stage IV Breast Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=2408A042-
94BA-4908-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/8867
CALGB 40503 RE-REGISTRATION
WORKSHEET
Header Module
Lead Institution
Institution/Affiliate
Physician of Record (for drug shipment purposes)
Participating Group
Patient Initials (Last, First Middle)
Contact Person at Institution
Phone
Fax
CALGB Patient ID
Patient Hospital No.
HIPAA Authorization Date (MM DD YYYY)
Certification Of Eligibility/protocol Design
Is the patient eligible for open label Bevacizumab
(Progression and initially received Placebo)
Yes
No
Assigned Treatment Arm (Bevacizumab)
Physician of Record (for drug shipment purposes)
NCI Investigator ID
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Re-registration Information
Date of Re-Registration (DD MM YYYY)
Registrar's Signature
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Registration - Test B42 Breast Cancer
Protocol Entry Form - 2707497v1.0
NSABP Protocol B-42 - Protocol Entry Form Worksheet
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=40686242-
2F60-3DEF-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/8868
Test B42 Breast Cancer Protocol
Entry Form
Header
Last
First
Middle
Site Name
Patient Birth Date
Treating physician
Patient Social Security Number (USA Only)
Unnamed2
Eligibility Criteria
All Other Protocol Criteria Met (All other
protocol criteria met)
Disease-free From Initial Breast Cancer
Diagnosis (Disease-free from initial
breast cancer diagnosis)
Histologically-confirmed Invasive Breast
Carcinoma By Diagnostic Core Needle
Biopsy Or Final Pathologic Evaluation Of
Surgical Specimen (Histologically-
confirmed invasive breast carcinoma by
diagnostic core needle biopsy or final
pathologic evaluation of surgical
specimen)
No Diagnosis Of Bilateral Breast Cancer
Including Dcis (synchronous Or
Metachronous) (No diagnosis of bilateral
breast cancer including DCIS
(synchronous or metachronous))
No History Of Non-traumatic
Osteoporotic Bone Fractures (No history
of non-traumatic osteoporotic bone
fractures)
No Other Malignancies Within Past 5
Years (No other malignancies within past
5 years)
Not Currently On Sex Hormonal Therapy
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(Not currently on sex hormonal therapy)
Postmenopausal (Postmenopausal)
Primary Tumor Was Er-positive And/or
Pgr-positive (Primary tumor was ER-
positive and/or PgR-positive)
Race
Race
A Person Having Origins In Any Of The
Original Peoples Of North And South
America (including Central America),
And Who Maintains Tribal Affiliation Or
Community Attachment. (American
Indian or Alaska Native)
A Person Having Origins In Any Of The
Original Peoples Of The Far East,
Southeast Asia, Or The Indian
Subcontinent Including, For Example,
Cambodia, China, India, Japan, Korea,
Malaysia, Pakistan, The Philippine
Islands, Thailand, And Vietnam. (Asian)
A Person Having Origins In Any Of The
Black Racial Groups Of Africa. Terms
Such As "haitian" Or "negro" Can Be
Used In Addition To "black Or African
American." (Black or African American)
A Person Having Origins In Any Of The
Original Peoples Of Hawaii, Guam,
Samoa, Or Other Pacific Islands. (Native
Hawaiian or other Pacific Islander)
Not Provided Or Available (Not
Reported)
Could Not Be Determined Or Unsure
(Unknown)
A Person Having Origins In Any Of The
Original Peoples Of Europe, The Middle
East, Or North Africa. (White)
Person Completing Form, Last Name
Method of Payment (mark primary method only)
Medicaid (Medicaid)
Medicaid And Medicare (Medicaid and
Medicare)
Medicare (Medicare)
Medicare And Private Insurance
(Medicare and Private Insurance)
Military Or Veterans Sponsored Nos
(Military or Veterans Sponsored, Not
Otherwise Specified (NOS))
Military Sponsored (including Champus
& Tricare) (Military Sponsored (including
CHAMPUS & TRICARE))
No Means Of Payment (no Insurance)
(No means of payment (no insurance))
Other (Other)
Private Insurance (Private Insurance)
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Self Pay (no Insurance) (Self Pay (No
Insurance))
Unknown (Unknown)
Veterans Sponsored (Veterans
Sponsored)
Ethnicity
A Person Of Mexican, Puerto Rican,
Cuban, Central Or South American Or
Other Spanish Culture Or Origin,
Regardless Of Race. (HISPANIC OR
LATINO)
A Person Not Meeting The Definition For
Hispanic Or Latino. (NOT HISPANIC OR
LATINO)
Could Not Be Determined Or Unsure
(UNKNOWN)
Country of Residence (if not USA)
Canada (CA)
Other (Other)
Puerto Rico (PR)
Usa (US)
Country of Residence
Patient Zip Code (USA)
Unnamed4
Date Informed Consent Signed
Patient consents to
Future Cancer Research (Future Cancer
Research)
Future Contact (Future Contact)
Future Other Research (Future Other
Research)
Planned Date of Treatment Initiation (Should
begin within 30 days following randomization.
Allow 7+ days after randomization for drug
distribution.)
Has the patient authorized the release of
Protected Health Information to the NSABP?
Yes
No
Date of Pre-entry History & Physical Exam (must
be within 3 months prior to randomization)
Date of Most Recent Mammogram (must be
within 12 months prior to randomization)
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Check here if patient did have a bilateral
mastectomy
Date of Most Recent Bone Mineral Density Test
(BMDmust be within 12 months prior to
randomization)
Lumbar-Sacral Spine (T-Score Result)
Total Hip
Femoral Neck
Date of Protocol-Qualifying Lipid Profile
Date of Initial Breast Cancer Diagnosis
Date of Prior Primary Surgery
Type of surgery
Lumpectomy + Axillary Staging + Rt
(Lumpectomy + Axillary Staging + RT)
Total Mastectomy + Axillary Staging
(Total Mastectomy + Axillary Staging)
Pathologic Lymph Node Assessment
Negative (negative)
Positive (positive)
Receptor Status, ER
Negative (Negative)
Positive (Positive)
Unknown (Unknown)
Receptor Status, PgR
Negative (Negative)
Positive (Positive)
Unknown (Unknown)
Was HER2 testing performed
Yes
No
HER-2/neu status
Negative (Negative)
Positive (Positive)
Unknown (Unknown)
Therapy Status
Did this patient receive any tamoxifen?
Yes
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No
Total Duration (Must be =< 36 months)
Tamoxifen Treatment End Date
Cumulative Duration of AIs (# months)
Which aromatase inhibitor was most recently
being taken
Is the patient currently receiving an AI
Yes
No
Aromatase inhibitor treatment end date
Was the patient on the B-42 Letrozole
Registration Program
Yes
No
Registration number (If Yes,)
Unnamed4
In the opinion of the investigator, is the patient
eligible?
Yes
No
Has the patient participated in any other NSABP
trial
Yes
No
Patient ID# (If yes, provide)
Patient Characteristics
Height (cm)
Weight (kg)
Cardiac History
Medical Condition
Atrial Fibrillation: C50466 (Atrial
Arrhythmia)
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Congestive Heart Failure (Congestive
Heart Failure)
Diabetes (diabetes)
Elevated Fasting Lipid Profile (Elevated
Fasting Lipid Profile)
Hypertension (hypertension)
Ischemic Heart Disease (Ischemic Heart
Disease)
Ventricular Arrhythmia (Ventricular
Arrhythmia)
Medications (in the 12 months prior to study
entry)
Yes
No
Comments (Optional)
Cardiac History - Other
Has the patient smoked daily for at least 3
months at any time since her breast cancer
diagnosis
Yes
No
Does the patient have any first degree relatives
who died from heart disease before the age of 55
("First degree relatives" include parent, children,
brothers, and sisters)
Yes
No
Concomitant Medications
Agent Category
Bisphosphonate (Bisphosphonate)
Calcium (Calcium)
Cardiovascular Medication #1
(Cardiovascular Medication #1)
Cardiovascular Medication #2
(Cardiovascular Medication #2)
Cardiovascular Medication #3
(Cardiovascular Medication #3)
Lipid Lowering Drug (Lipid Lowering
Drug)
Other Medication For Bone Density
(Other Medication for Bone Density)
Agent Name
Taking at time of randomization?
Yes
No
Continuing after Randomization
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Yes
No
Footer Module
Completed by
Date
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Breast Cancer NCT00881361 Demographic
- Demographic Worksheet - 2932449v1.0
Demographic Worksheet
Surgery to Remove the Sentinel Lymph Node and Axillary
Lymph Nodes After Chemotherapy in Treating Women With
Stage II, Stage IIIA, or Stage IIIB Breast Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=70F88030-
783B-64C6-E040-BB89AD432159
All rights reserved. Please visit https://medical-data-
models.org/forms/8869
Demographic Worksheet
Patient Demographics
Patient Initials
Patient SSN
Patient Hospital No.
Patient's Date of Birth
Ethnicity
A Person Of Mexican, Puerto Rican,
Cuban, Central Or South American Or
Other Spanish Culture Or Origin,
Regardless Of Race. (Hispanic or Latino)
A Person Not Meeting The Definition For
Hispanic Or Latino. (Not Hispanic or
Latino)
Not Provided Or Available (Not reported)
Could Not Be Determined Or Unsure
(Unknown)
Gender of a Person
Female Gender (Female Gender)
Male Gender (Male Gender)
Unknown (Unknown)
Unspecified (Unspecified)
Country of Residence
ZIP Code
Race
A Person Having Origins In Any Of The
Original Peoples Of North And South
America (including Central America),
And Who Maintains Tribal Affiliation Or
Community Attachment. (American
Indian or Alaska Native)
A Person Having Origins In Any Of The
Original Peoples Of The Far East,
Southeast Asia, Or The Indian
Subcontinent Including, For Example,
Cambodia, China, India, Japan, Korea,
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Malaysia, Pakistan, The Philippine
Islands, Thailand, And Vietnam. (Asian)
A Person Having Origins In Any Of The
Black Racial Groups Of Africa. Terms
Such As "haitian" Or "negro" Can Be
Used In Addition To "black Or African
American." (Black or African American)
A Person Having Origins In Any Of The
Original Peoples Of Hawaii, Guam,
Samoa, Or Other Pacific Islands. (Native
Hawaiian or other Pacific Islander)
Not Provided Or Available (Not
Reported)
Could Not Be Determined Or Unsure
(Unknown)
A Person Having Origins In Any Of The
Original Peoples Of Europe, The Middle
East, Or North Africa. (White)
Method of Payment
Medicaid (Medicaid)
Medicaid And Medicare (Medicaid and
Medicare)
Medicare (Medicare)
Medicare And Private Insurance
(Medicare and Private Insurance)
Military Or Veterans Sponsored Nos
(Military or Veterans Sponsored, Not
Otherwise Specified (NOS))
Military Sponsored (including Champus
& Tricare) (Military Sponsored (including
CHAMPUS & TRICARE))
No Means Of Payment (no Insurance)
(No means of payment (no insurance))
Other (Other)
Private Insurance (Private Insurance)
Self Pay (no Insurance) (Self Pay (No
Insurance))
Unknown (Unknown)
Veterans Sponsored (Veterans
Sponsored)
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Cervical Cancer NCT01266460 Pre-Study - GOG-0265:
Fast Fact Sheet for Protocol 0265 (Cervix) - 3185379v1.0
GOG-0265: Fast Fact Sheet for Protocol 0265 (Cervix)
Vaccine Therapy in Treating Patients With Persistent or
Recurrent Cervical Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=9A9974A7-
54D8-82CF-E040-BB89AD431753
All rights reserved. Please visit https://medical-data-
models.org/forms/8870
GOG-0265: Fast Fact Sheet for
Protocol 0265 (Cervix)
Tracking Information
GOG Institution Code
GOG Affiliate Code
Previous GOG #
Treating physician
Other Physician
Patient Hospital No.
Date of Birth
Patient Last Name
Patient First Name
Patient Middle Name
Header
Did the patient sign an approved informed
consent
Yes
No
Has HIPAA authorization been obtained
Exempt - Non-usa Participant (Exempt -
non-USA participant)
Yes: C49488 (Yes)
Is the patient eligible for a higher priority GOG
protocol
Yes
No
1 / 7
Enter the Reservation ID #
What is the primary disease site
Cervix (Cervix)
What is the cell type?
Adenocarcinoma (Adenocarcinoma)
Adenosquamous Carcinoma
(Adenosquamous Carcinoma)
Squamous Cell Carcinoma (Squamous
Cell Carcinoma)
Date primary confirmed histologically
What was the grade of the primary tumor
Grade 1-well Differentiated (1)
Grade 2-moderately Differentiated (2)
Grade 3-poorly Differentiated (3)
Is the disease recurrent or persistent with
documented progression? Which one? (disease
not amenable to curative therapy)
Persistent Disease (Persistent)
Recurrent Disease (Recurrent)
How was it established to be recurrent or
persistent?
Biopsy (Biopsy)
Non-histologic Evaluation (Non-
Histologic)
Surgical Procedure (Surgery)
Date recurrence or persistence documented?
(NOTE: This should be the date of the most
recent progression or persistence that made the
patient eligible for this study.)
Does patient have measurable disease defined
as at least one lesion that can be accurately
measured in at least one dimension (longest
dimension to be recorded) using RECIST 1.1
criteria?
Yes
No
What method of evaluation is used to obtain
tumor measurements?
Caliper Measurement By Clinical Exam
(Caliper measurement by clinical exam)
Chest Radiography (Chest X-ray)
Computed Tomography (CT)
Magnetic Resonance Imaging (MRI)
Is the measurable disease > or = 10 mm when
measured by CT, MRI or caliper measurement by
clinical exam; or > or = 20 mm when measured
by chest x-ray or lymph nodes > or = 15 mm in
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short axis when measured by CT or MRI?
Yes
No
Does the patient have at least one target lesion to
be used to assess response on this protocol as
defined by RECIST 1.1?
Yes
No
Is the measurable disease in a previously
irradiated field?
Yes
No
If yes, does the patient have disease in an
irradiated field as the only site of measurable
disease and has progression been documented
or a biopsy obtained to confirm persistent
disease at least 90 days following completion of
radiation treatment?
No (No)
Not Applicable (Not Applicable)
Yes (Yes)
Has the patient recovered from the effects of
recent surgery, radiotherapy or chemotherapy?
Yes
No
Is the patient free of active infection requiring
antibiotics?
Yes
No
Has any hormonal therapy directed at the
malignant tumor been discontinued at least one
week prior to registration? (continuation of
hormone replacement therapy is permitted)
Yes
No
Has all prior therapy directed at the malignant
tumor, including immunologic agents, been
discontinued for at least three weeks prior to
registration?
Yes
No
How many prior cytotoxic chemotherapy
regimens has the patient received?
(Chemotherapy administered in conjunction with
primary radiation as a radio-sensitizer is not
counted as a systemic chemotherapy regimen)
One Chemotherapy Regimen (1
Regimen)
Two Chemotherapy Regimens (2
Regimens)
Drug Regimen 1:
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Start date for Regimen 1:
End date for Regimen 1:
Drug Regimen 2:
Start date for Regimen 2:
End date for Regimen 2:
Performance Status (Patients who have received
one prior regimen must have a performance
status of 0, 1 or 2 - patients who have received
two prior regimens must have a performance
status of 0 or 1)
Fully Active, Able To Carry On All Pre-
disease Performance Without
Restriction. (0)
Restricted In Physically Strenuous
Activity But Ambulatory And Able To
Carry Out Work Of A Light Or Sedentary
Nature, E.g., Light Housework, Office
Work. (1)
Ambulatory And Capable Of All Selfcare
But Unable To Carry Out Any Work
Activities. Up And About More Than 50%
Of Waking Hours. (2)
Has the patient received any non-cytotoxic
chemotherapy for management of recurrent or
persistent disease
Yes
No
Date of Results (if more than one, enter earliest:)
Platelets greater than or equal to 100,000/mcl?
Yes
No
ANC greater than or equal to 1,500/mcl?
Yes
No
Is the Lymphocyte count greater than or equal to
700/mcl?
Yes
No
Is the creatinine less than or equal to 1.5 X ULN
Yes
No
Is the bilirubin less than or equal to 1.5 x ULN
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Yes
No
Is the SGOT, SGPT, and GGT less than or equal
to 1.5 x ULN?
Yes
No
Is the alkaline phosphatase less than or equal to
2.5 x ULN?
Yes
No
Is Neuropathy (sensory and motor) less than or
equal to CTCAE grade 1?
Yes
No
Has the patient met the pre-entry requirements
as specified in section 7.0
Yes
No
Will the patient have the following parameters
measured within 28 days prior to initiating
protocol therapy (History and Physical,
Performance Status, Clinical Tumor
Measurements, Vital Signs, Chest Imaging and
Radiographic Tumor Measurement)
Yes
No
Will the patient have the following parameters
measured within 14 days prior to initiating
protocol therapy (Toxicity Assessment,
CBC/Differential/Platelets, Electolytes, BUN,
Creatinine, Calcium, Magnesium, Phosphates,
Urinalysis, Bilirubin, SGOT, SGPT, GGT and
Alkaline Phosphatase)
Yes
No
If the patient has childbearing potential, has she
had a negative serum pregnancy test performed
48 hours prior to study entry?
No (No)
Not Applicable (Not Applicable)
Yes (Yes)
Has the patient agreed to practice an effective
form of contraception during protocol therapy and
for at least two months following completion of
protocol therapy?
No (No)
Not Applicable (Not Applicable)
Yes (Yes)
Is the patient pregnant or nursing?
Yes
No
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Is the patient under age 18?
Yes
No
Does the patient have the ability to swallow oral
medication
Yes
No
Has the patient received prior therapy with
ADXS11-001?
Yes
No
Has the patient had another invasive malignancy
other than non-melanoma of the skin, localized
cancer of the breast, head and neck or skin
diagnosed, present or recur within the past 3
years?
Yes
No
Has the patient had previous cancer treatment
which contraindicates this protocol therapy
Yes
No
Has the patient received prior radiotherapy to any
portion of the abdominal cavity or pelvis other
than for the treatment of cervical cancer within
the last three years? (Prior radiation for localized
cancer of the breast, head and neck or skin is
permitted as long as it was completed more than
3 years prior to registration and the patient
remains free of recurrent or metastatic disease)
Yes
No
Has the patient received prior chemotherapy for
any abdominal or pelvic tumor other than for the
treatment of cervical cancer within the last three
years? (Prior adjuvant chemotherapy for localized
breast cancer is permitted provided it was
completed more than 3 years prior to registration
and the patient remains free of recurrent or
metastatic disease)
Yes
No
Is the patient allergic to both penicillin and
trimethoprim-sulfa (including history of rash or
anaphalaxis)?
Yes
No
Is the patient allergic to naproxen?
Yes
No
Is the patient currently receiving antibiotics?
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Yes
No
Is the patient currently receiving steroids or has
she received steroids within the past four weeks
(topical corticosteroids and occasional inhaled
corticosteroids are allowed)?
Yes
No
Has uncontrolled intercurrent illness including,
but not limited to, ongoing or active infection,
symptomatic congestive heart failure, unstable
angina pectoris, cardiac arrhythmia, or psychiatric
illness/social situations that would limit
compliance with study requirement?
Yes
No
Does the patient have liver cirrhosis or any other
impaired hepatic function as determined by
serum enzymes?
Yes
No
Is the patient known to be seropositive for HIV
even if liver function studies are in eligible range?
Yes
No
Is the patient known to be seropositive for active
hepatitis even if liver function studies are in the
eligible range?
Yes
No
Does the patient have a prior history of a
splenectomy and/or sickle cell trait/disease?
Yes
No
Anticipated date treatment will start
Comments
Provide comments about this Fast Fact Sheet
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Registration - NSABP Protocol B-42 - Breast Cancer
- Protocol Entry Form Worksheet - 2707314v1.0
NSABP Protocol B-42 - Protocol Entry Form Worksheet
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=40684EFF-
677F-3D01-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/8871
NSABP Protocol B-42 - Breast
Cancer - Protocol Entry Form
Worksheet
Header
Last
First
Middle
Site Name
Patient Birth Date
Treating physician
Patient Social Security Number (USA Only)
Unnamed2
Eligibility Criteria
All Other Protocol Criteria Met (All other
protocol criteria met)
Disease-free From Initial Breast Cancer
Diagnosis (Disease-free from initial
breast cancer diagnosis)
Histologically-confirmed Invasive Breast
Carcinoma By Diagnostic Core Needle
Biopsy Or Final Pathologic Evaluation Of
Surgical Specimen (Histologically-
confirmed invasive breast carcinoma by
diagnostic core needle biopsy or final
pathologic evaluation of surgical
specimen)
No Diagnosis Of Bilateral Breast Cancer
Including Dcis (synchronous Or
Metachronous) (No diagnosis of bilateral
breast cancer including DCIS
(synchronous or metachronous))
No History Of Non-traumatic
Osteoporotic Bone Fractures (No history
of non-traumatic osteoporotic bone
fractures)
No Other Malignancies Within Past 5
1 / 7
Years (No other malignancies within past
5 years)
Not Currently On Sex Hormonal Therapy
(Not currently on sex hormonal therapy)
Postmenopausal (Postmenopausal)
Primary Tumor Was Er-positive And/or
Pgr-positive (Primary tumor was ER-
positive and/or PgR-positive)
Race
Race
A Person Having Origins In Any Of The
Original Peoples Of North And South
America (including Central America),
And Who Maintains Tribal Affiliation Or
Community Attachment. (American
Indian or Alaska Native)
A Person Having Origins In Any Of The
Original Peoples Of The Far East,
Southeast Asia, Or The Indian
Subcontinent Including, For Example,
Cambodia, China, India, Japan, Korea,
Malaysia, Pakistan, The Philippine
Islands, Thailand, And Vietnam. (Asian)
A Person Having Origins In Any Of The
Black Racial Groups Of Africa. Terms
Such As "haitian" Or "negro" Can Be
Used In Addition To "black Or African
American." (Black or African American)
A Person Having Origins In Any Of The
Original Peoples Of Hawaii, Guam,
Samoa, Or Other Pacific Islands. (Native
Hawaiian or other Pacific Islander)
Not Provided Or Available (Not
Reported)
Could Not Be Determined Or Unsure
(Unknown)
A Person Having Origins In Any Of The
Original Peoples Of Europe, The Middle
East, Or North Africa. (White)
Person Completing Form, Last Name
Method of Payment (mark primary method only)
Medicaid (Medicaid)
Medicaid And Medicare (Medicaid and
Medicare)
Medicare (Medicare)
Medicare And Private Insurance
(Medicare and Private Insurance)
Military Or Veterans Sponsored Nos
(Military or Veterans Sponsored, Not
Otherwise Specified (NOS))
Military Sponsored (including Champus
& Tricare) (Military Sponsored (including
CHAMPUS & TRICARE))
No Means Of Payment (no Insurance)
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(No means of payment (no insurance))
Other (Other)
Private Insurance (Private Insurance)
Self Pay (no Insurance) (Self Pay (No
Insurance))
Unknown (Unknown)
Veterans Sponsored (Veterans
Sponsored)
Ethnicity
A Person Of Mexican, Puerto Rican,
Cuban, Central Or South American Or
Other Spanish Culture Or Origin,
Regardless Of Race. (HISPANIC OR
LATINO)
A Person Not Meeting The Definition For
Hispanic Or Latino. (NOT HISPANIC OR
LATINO)
Could Not Be Determined Or Unsure
(UNKNOWN)
Country of Residence (if not USA)
Canada (CA)
Other (Other)
Puerto Rico (PR)
Usa (US)
Country of Residence
Patient Zip Code (USA)
Unnamed4
Date Informed Consent Signed
Patient consents to
Future Cancer Research (Future Cancer
Research)
Future Contact (Future Contact)
Future Other Research (Future Other
Research)
Planned Date of Treatment Initiation (Should
begin within 30 days following randomization.
Allow 7+ days after randomization for drug
distribution.)
Has the patient authorized the release of
Protected Health Information to the NSABP?
Yes
No
Date of Pre-entry History & Physical Exam (must
be within 3 months prior to randomization)
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Date of Most Recent Mammogram (must be
within 12 months prior to randomization)
Check here if patient did have a bilateral
mastectomy
Date of Most Recent Bone Mineral Density Test
(BMDmust be within 12 months prior to
randomization)
Lumbar-Sacral Spine (T-Score Result)
Total Hip
Femoral Neck
Date of Protocol-Qualifying Lipid Profile
Date of Initial Breast Cancer Diagnosis
Date of Prior Primary Surgery
Type of surgery
Lumpectomy + Axillary Staging + Rt
(Lumpectomy + Axillary Staging + RT)
Total Mastectomy + Axillary Staging
(Total Mastectomy + Axillary Staging)
Pathologic Lymph Node Assessment
Negative (negative)
Positive (positive)
Receptor Status, ER
Negative (Negative)
Positive (Positive)
Unknown (Unknown)
Receptor Status, PgR
Negative (Negative)
Positive (Positive)
Unknown (Unknown)
Was HER2 testing performed
Yes
No
HER-2/neu status
Negative (Negative)
Positive (Positive)
Unknown (Unknown)
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Therapy Status
Did this patient receive any tamoxifen?
Yes
No
Total Duration (Must be =< 36 months)
Tamoxifen Treatment End Date
Cumulative Duration of AIs (# months)
Which aromatase inhibitor was most recently
being taken
Is the patient currently receiving an AI
Yes
No
Aromatase inhibitor treatment end date
Was the patient on the B-42 Letrozole
Registration Program
Yes
No
Registration number (If Yes,)
Unnamed4
In the opinion of the investigator, is the patient
eligible?
Yes
No
Has the patient participated in any other NSABP
trial
Yes
No
Patient ID# (If yes, provide)
Patient Characteristics
Height (cm)
Weight (kg)
Cardiac History
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Medical Condition
Atrial Fibrillation: C50466 (Atrial
Arrhythmia)
Congestive Heart Failure (Congestive
Heart Failure)
Diabetes (diabetes)
Elevated Fasting Lipid Profile (Elevated
Fasting Lipid Profile)
Hypertension (hypertension)
Ischemic Heart Disease (Ischemic Heart
Disease)
Ventricular Arrhythmia (Ventricular
Arrhythmia)
Medications (in the 12 months prior to study
entry)
Yes
No
Comments (Optional)
Cardiac History - Other
Has the patient smoked daily for at least 3
months at any time since her breast cancer
diagnosis
Yes
No
Does the patient have any first degree relatives
who died from heart disease before the age of 55
("First degree relatives" include parent, children,
brothers, and sisters)
Yes
No
Concomitant Medications
Agent Category
Bisphosphonate (Bisphosphonate)
Calcium (Calcium)
Cardiovascular Medication #1
(Cardiovascular Medication #1)
Cardiovascular Medication #2
(Cardiovascular Medication #2)
Cardiovascular Medication #3
(Cardiovascular Medication #3)
Lipid Lowering Drug (Lipid Lowering
Drug)
Other Medication For Bone Density
(Other Medication for Bone Density)
Agent Name
Taking at time of randomization?
Yes
No
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Continuing after Randomization
Yes
No
Footer Module
Completed by
Date
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Cervical Cancer NCT01267253 Pre-Study - GOG-0227G:
Fast Fact Sheet for Protocol 0227-G (Cervix) - 3181753v1.0
GOG-0227G: Fast Fact Sheet for Protocol 0227-G (Cervix)
Brivanib in Treating Patients With Persistent or Recurrent
Cervical Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=994603C2-
7E97-D813-E040-BB89AD432944
All rights reserved. Please visit https://medical-data-
models.org/forms/8872
GOG-0227G: Fast Fact Sheet for
Protocol 0227-G (Cervix)
Tracking Information
GOG Institution Code
GOG Affiliate Code
Previous GOG #
Treating physician
Other Physician
Patient Hospital No.
Date of Birth
Patient Last Name
Patient First Name
Patient Middle Name
Header
Did the patient sign an approved informed
consent
Yes
No
Has HIPAA authorization been obtained
Exempt - Non-usa Participant (Exempt -
non-USA participant)
Yes: C49488 (Yes)
Is the patient eligible for a higher priority GOG
protocol
Yes
No
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What is the primary disease site
Cervix (Cervix)
What is the cell type?
Unspecified Adenocarcinoma
(Adenocarcinoma, Unspecified)
Adenoid Cystic Carcinoma (Adenoid
Cystic Carcinoma)
Adenosquamous Carcinoma
(Adenosquamous Carcinoma)
Glass Cell Carcinoma (Glass Cell
Carcinoma)
Large Cell Carcinoma (Large Cell
Carcinoma)
Mixed Epithelial Carcinoma (Mixed
Epithelial Carcinoma)
Small Cell Carcinoma (Small Cell
Carcinoma)
Squamous Cell Carcinoma (Squamous
Cell Carcinoma)
Transitional Cell Carcinoma (Transitional
Cell Carcinoma)
Unclassified Carcinoma (Unclassified
Carcinoma)
Undifferentiated Carcinoma
(Undifferentiated Carcinoma)
Date of initial histologic diagnosis of malignancy
What was the grade of the primary tumor
Grade 1-well Differentiated (1)
Grade 2-moderately Differentiated (2)
Grade 3-poorly Differentiated (3)
Is the disease recurrent or persistent with
documented progression? Which one?
Persistent Disease (Persistent)
Recurrent Disease (Recurrent)
How was it established to be recurrent or
persistent?
Biopsy (Biopsy)
Non-histologic Evaluation (Non-
Histologic)
Surgical Procedure (Surgery)
Date recurrence or persistence documented?
(NOTE: This should be the date of the most
recent progression or persistence that made the
patient eligible for this study.)
Does patient have measurable disease defined
as at least one lesion that can be accurately
measured in at least one dimension (longest
dimension to be recorded) using RECIST 1.1
criteria?
Yes
No
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What method of evaluation is used to obtain
tumor measurements?
Caliper Measurement By Clinical Exam
(Caliper measurement by clinical exam)
Chest Radiography (Chest X-ray)
Computed Tomography (CT)
Magnetic Resonance Imaging (MRI)
Is the measurable disease > or = 10 mm when
measured by CT, MRI or caliper measurement by
clinical exam; or > or = 20 mm when measured
by chest x-ray or lymph nodes > or = 15 mm in
short axis when measured by CT or MRI?
Yes
No
Does the patient have at least one target lesion to
be used to assess response on this protocol as
defined by RECIST 1.1?
Yes
No
Is the measurable disease in a previously
irradiated field?
Yes
No
If yes, does the patient have disease in an
irradiated field as the only site of measurable
disease and has progression been documented
or a biopsy obtained to confirm persistent
disease at least 90 days following completion of
radiation treatment?
No (No)
Not Applicable (Not Applicable)
Yes (Yes)
Has the patient recovered from the effects of
recent surgery, radiotherapy or chemotherapy?
Yes
No
Is the patient free of active infection requiring
antibiotics with the exception of uncomplicated
urinary tract infection (UTI)?
Yes
No
Has any hormonal therapy directed at the
malignant tumor been discontinued at least one
week prior to registration?
Yes
No
Has all prior therapy directed at the malignant
tumor, including chemotherapy and immunologic
agents, been discontinued for at least three
weeks prior to registration?
Yes
3 / 10
Cervical Cancer NCT01267253 Pre-Study - GOG-0227G: Fast Fact
Sheet for Protocol 0227-G (Cervix) - 3181753v1.0
No
Has any prior radiation therapy been completed
at least 4 weeks prior to registration?
Yes
No
Has at least 4 weeks elapsed since the patient
underwent any major surgery
Yes
No
Has the patient received one prior systemic
chemotherapeutic regimen for management of
advanced, metastatic or recurrent carcinoma of
the cervix? (Chemotherapy administered
concurrent with primary radiation e.g.; weekly
cisplatin is not counted as a systemic
chemotherapy regimen.  Also, adjuvant
chemotherapy given following the completion of
radiation therapy or concurrent chemotherapy
and radiation therapy is not counted as a
systemic chemotherapy regimen.)
Yes
No
Drug Regimen 1:
Start date for Regimen 1:
End date for Regimen 1:
How many prior cytotoxic chemotherapy
regimens has the patient received?
No Chemotherapy Regimens (0
Regimens)
One Chemotherapy Regimen (1
Regimen)
Two Or More Chemotherapy Regimens
(2 or more Regimens)
Drug Regimen 2:
Start date for Regimen 2:
End date for Regimen 2:
Performance Status (Patients who have received
one prior regimen must have a performance
status of 0, 1 or 2 - patients who have received
two prior regimens must have a performance
status of 0 or 1)
Fully Active, Able To Carry On All Pre-
disease Performance Without
Restriction. (0)
Restricted In Physically Strenuous
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Activity But Ambulatory And Able To
Carry Out Work Of A Light Or Sedentary
Nature, E.g., Light Housework, Office
Work. (1)
Ambulatory And Capable Of All Selfcare
But Unable To Carry Out Any Work
Activities. Up And About More Than 50%
Of Waking Hours. (2)
Has the patient received any non-cytotoxic
(biologic or targeted) agents as part of their
primary treatment or for management of recurrent
or persistent disease? (Non-cytotoxic biologic or
targeted agents include but are not limited to
monoclonal antibodies, cytokines, and small-
molecule inhibitors of signal transduction)
Yes
No
Date of Results (if more than one, enter earliest:)
Platelets greater than or equal to 100,000/mcl?
Yes
No
ANC greater than or equal to 1,500/mcl?
Yes
No
Hemoglobin greater than or equal to 9 g/dL?
Yes
No
Is Serum Creatinine less than or equal to 1.5 X
ULN
Yes
No
Does the patient have a urine protein of less than
or equal to 2+ by dipstick or a 24-hour protein
level of less than or equal to 3.5 g/24 hours?
Yes
No
Is the bilirubin less than or equal to 1.5 x ULN
Yes
No
Is the AST and ALT less than or equal to 3.0 X
ULN
Yes
No
Is the alkaline phosphatase less than or equal to
2.5 x ULN?
Yes
No
Is the albumin greater than or equal to 2.5 g/dL?
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Yes
No
Is Neuropathy (sensory and motor) less than or
equal to CTCAE grade 1?
Yes
No
Is the prothrombin time such that the
International Normalized Ratio (INR) is less than
or equal to 1.5 X ULN?
Yes
No
Has the patient had a baseline electrocardiogram
completed within 28 days prior to study entry and
was the QTc found to be less than or equal to
450 msec?
Yes
No
Has the patient met the pre-entry requirements
as specified in section 7.0
Yes
No
If the patient has childbearing potential, has she
had a negative serum pregnancy test performed
48 hours prior to study entry?
No (No)
Not Applicable (Not Applicable)
Yes (Yes)
Has the patient agreed to practice an effective
form of contraception during the study and for at
least three months after receiving the final
treatment of Brivanib?
No (No)
Not Applicable (Not Applicable)
Yes (Yes)
Has the patient had prior therapy with Brivanib or
anti-vascular, anti-PDGFR (platelet-derived
growth factor receptor) or anti-FGFR (fibroblast
growth factor receptor) therapy?
Yes
No
Has the patient had another invasive malignancy
other than non-melanoma of the skin, localized
cancer of the breast, head and neck or skin
diagnosed, present or recur within the past 3
years?
Yes
No
Has the patient had previous cancer treatment
which contraindicates this protocol therapy
Yes
No
6 / 10
Cervical Cancer NCT01267253 Pre-Study - GOG-0227G: Fast Fact
Sheet for Protocol 0227-G (Cervix) - 3181753v1.0
Has the patient received prior radiotherapy to any
portion of the abdominal cavity or pelvis other
than for the treatment of cervical cancer within
the last three years?
Yes
No
Has the patient received prior radiation for
localized cancer of the breast, head and neck or
skin?
Yes
No
Was the prior radiation for localized cancer of the
breast, head and neck or skin completed more
than 3 years prior to registration and does the
patient remain free of recurrent or metastatic
disease?
No (No)
Not Applicable (Not Applicable)
Yes (Yes)
Has the patient received prior chemotherapy for
any abdominal or pelvic tumor other than for the
treatment of cervical cancer within the last three
years?
Yes
No
Has the patient received prior adjuvant
chemotherapy for localized breast cancer?
Yes
No
Was the prior adjuvant chemotherapy for
localized cancer of the breast completed more
than 3 years prior to registration and does the
patient remain free of recurrent or metastatic
disease?
No (No)
Not Applicable (Not Applicable)
Yes (Yes)
Does the patient require chronic anti-platelet
therapy? (aspirin >300 mg/day or clopidogrel
greater than or equal to 75 mg/day)
Yes
No
Has the patient experienced gastrointestinal
bleeding or any other hemorrhage/bleeding
event, Grade 3 or greater of the NCI CTCAE
within 30 days prior to today?
Yes
No
Does the patient have a history of poor wound
healing, non-healing ulcers or bone fractures
within the last three months?
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Yes
No
Has the patient had clinically significant
cardiovascular disease
Yes
No
Has the patient had a myocardial infarction within
12 months of today?
Yes
No
Has the patient experienced uncontrolled angina
within 12 months of today?
Yes
No
Using the New York Heart Association guidelines,
does the patient have Class III-IV congestive
heart failure?
Yes
No
Does the patient have uncontrolled hypertension
defined as systolic greater than 140 mm Hg or
diastolic greater than 90 mm Hg despite anti-
hypertensive therapy?
Yes
No
Does the patient experience cardiac arrhythmias
requiring anti-arrhythmic therapy other than beta
blockers or digoxin?
Yes
No
Does the patient require the use of calcium
channel blockers that are CYP3A4 inhibitors?
Yes
No
Does the patient have a history of stroke, TIA or
other CNS ischemic event?
Yes
No
Has the patient had Left Ventricle Ejection
Fraction (LVEF) testing done within 28 days of
study entry and is the ejection fraction less than
institutional LLN?
Yes
No
Does the patient have valvular heart disease
greater than or equal to Grade 2?
Yes
No
Does the patient have a serious uncontrolled
medical disorder or active infection which would
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impair the ability of the subject to receive protocol
therapy or whose control may be jeopardized by
the complications of this therapy?
Yes
No
Does the patient have a pre-existing thyroid
abnormality with thyroid function that cannot be
maintained in the normal range with medication?
Yes
No
Does the patient have hyponatremia (sodium less
than 130 mEq/L)?
Yes
No
Does patient have a history of hepatitis B or
hepatitis C infection
Yes
No
Does the patient have clinical evidence of brain
metastases
Yes
No
Is the patient under age 18?
Yes
No
Is the patient pregnant or nursing?
Yes
No
Does the patient have untreated malabsorption
syndrome?
Yes
No
Is the patient capable of taking and absorbing
oral medications
Yes
No
Does the patient have a baseline serum
potassium less than 3.5 mmol/L?
Yes
No
Is the patient receiving a stable dose of warfarin
and has an in-range INR or receiving a stable
dose of heparin
Yes
No
Anticipated date treatment will start
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Comments
Provide comments about this Fast Fact Sheet
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Breast Cancer NCT00382070 Registration - NSABP Protocol
B-42 - Protocol Entry Form Worksheet - 2494107v1.0
NSABP Protocol B-42 - Protocol Entry Form Worksheet
Letrozole in Treating Postmenopausal Women Who Have
Received Hormone Therapy for Hormone Receptor-Positive
Breast Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=17AF2627-
D64B-3BA6-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/8873
NSABP Protocol B-42 - Protocol
Entry Form Worksheet
Header
Last
First
Middle
Site Name
Patient Birth Date
Treating physician
Patient Social Security Number (USA Only)
Unnamed2
Eligibility Criteria
All Other Protocol Criteria Met (All other
protocol criteria met)
Disease-free From Initial Breast Cancer
Diagnosis (Disease-free from initial
breast cancer diagnosis)
Histologically-confirmed Invasive Breast
Carcinoma By Diagnostic Core Needle
Biopsy Or Final Pathologic Evaluation Of
Surgical Specimen (Histologically-
confirmed invasive breast carcinoma by
diagnostic core needle biopsy or final
pathologic evaluation of surgical
specimen)
No Diagnosis Of Bilateral Breast Cancer
Including Dcis (synchronous Or
Metachronous) (No diagnosis of bilateral
breast cancer including DCIS
(synchronous or metachronous))
No History Of Non-traumatic
Osteoporotic Bone Fractures (No history
of non-traumatic osteoporotic bone
fractures)
No Other Malignancies Within Past 5
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Years (No other malignancies within past
5 years)
Not Currently On Sex Hormonal Therapy
(Not currently on sex hormonal therapy)
Postmenopausal (Postmenopausal)
Primary Tumor Was Er-positive And/or
Pgr-positive (Primary tumor was ER-
positive and/or PgR-positive)
Race
Race
A Person Having Origins In Any Of The
Original Peoples Of North And South
America (including Central America),
And Who Maintains Tribal Affiliation Or
Community Attachment. (American
Indian or Alaska Native)
A Person Having Origins In Any Of The
Original Peoples Of The Far East,
Southeast Asia, Or The Indian
Subcontinent Including, For Example,
Cambodia, China, India, Japan, Korea,
Malaysia, Pakistan, The Philippine
Islands, Thailand, And Vietnam. (Asian)
A Person Having Origins In Any Of The
Black Racial Groups Of Africa. Terms
Such As "haitian" Or "negro" Can Be
Used In Addition To "black Or African
American." (Black or African American)
A Person Having Origins In Any Of The
Original Peoples Of Hawaii, Guam,
Samoa, Or Other Pacific Islands. (Native
Hawaiian or other Pacific Islander)
Could Not Be Determined Or Unsure
(Unknown)
A Person Having Origins In Any Of The
Original Peoples Of Europe, The Middle
East, Or North Africa. (White)
Person Completing Form, Last Name
Method of Payment (mark primary method only)
Medicaid (Medicaid)
Medicaid And Medicare (Medicaid and
Medicare)
Medicare (Medicare)
Medicare And Private Insurance
(Medicare and Private Insurance)
Military Or Veterans Sponsored Nos
(Military or Veterans Sponsored, Not
Otherwise Specified (NOS))
Military Sponsored (including Champus
& Tricare) (Military Sponsored (including
CHAMPUS & TRICARE))
No Means Of Payment (no Insurance)
(No means of payment (no insurance))
Other (Other)
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Private Insurance (Private Insurance)
Self Pay (no Insurance) (Self Pay (No
Insurance))
Unknown (Unknown)
Veterans Sponsored (Veterans
Sponsored)
Ethnicity
A Person Of Mexican, Puerto Rican,
Cuban, Central Or South American Or
Other Spanish Culture Or Origin,
Regardless Of Race. (HISPANIC OR
LATINO)
A Person Not Meeting The Definition For
Hispanic Or Latino. (NOT HISPANIC OR
LATINO)
Could Not Be Determined Or Unsure
(UNKNOWN)
Country of residence
Canada (CA)
Other (Other)
Puerto Rico (PR)
Usa (US)
Country of Residence (Other)
Patient Zip Code (USA)
Consent
Patient consents to
Future Cancer Research (Future Cancer
Research)
Future Contact (Future Contact)
Future Other Research (Future Other
Research)
Unnamed4
Date Informed Consent Signed
Planned Date of Treatment Initiation (Should
begin within 30 days following randomization.
Allow 7+ days after randomization for drug
distribution.)
Has the patient authorized the release of
Protected Health Information to the NSABP?
Yes
No
Date of Pre-entry History & Physical Exam (must
be within 3 months prior to randomization)
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Date of Most Recent Mammogram (must be
within 12 months prior to randomization)
Did the patient have a bilateral mastectomy
Yes
No
Date of Most Recent Bone Mineral Density Test
(BMDmust be within 12 months prior to
randomization)
Lumbar-Sacral Spine
Total Hip
Femoral Neck
Date of Protocol-Qualifying Lipid Profile
Date of Initial Breast Cancer Diagnosis
Date of Prior Primary Surgery
Type of surgery
Lumpectomy + Axillary Staging + Rt
(Lumpectomy + Axillary Staging + RT)
Total Mastectomy + Axillary Staging
(Total Mastectomy + Axillary Staging)
Pathologic Lymph Node Assessment
Negative (negative)
Positive (positive)
Receptor Status, ER
Negative (Negative)
Positive (Positive)
Unknown (Unknown)
Receptor Status, PgR
Negative (Negative)
Positive (Positive)
Unknown (Unknown)
Was HER2 testing performed
Yes
No
HER-2/neu status
Negative (Negative)
Positive (Positive)
Unknown (Unknown)
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Therapy Status
Did this patient receive any tamoxifen?
Yes
No
Total Duration (Must be =< 36 months)
Tamoxifen Treatment End Date
Cumulative Duration of AIs (# months)
Which aromatase inhibitor was most recently
being taken
Is the patient currently receiving an AI
Yes
No
Aromatase inhibitor treatment end date
Was the patient on the B-42 Letrozole
Registration Program
Yes
No
Registration number (If Yes,)
Unnamed4
In the opinion of the investigator, is the patient
eligible?
Yes
No
Has the patient participated in any other NSABP
trial
Yes
No
Patient ID#
Patient Characteristics
Height (cm)
Weight (kg)
Cardiac History
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Medical Condition
Atrial Fibrillation: C50466 (Atrial
Arrhythmia)
Congestive Heart Failure (Congestive
Heart Failure)
Diabetes (diabetes)
Elevated Fasting Lipid Profile (Elevated
Fasting Lipid Profile)
Hypertension (hypertension)
Ischemic Heart Disease (Ischemic Heart
Disease)
Ventricular Arrhythmia (Ventricular
Arrhythmia)
Medications (in the 12 months prior to study
entry)
Yes
No
Comments (Optional)
Cardiac History - Other
Has the patient smoked daily for at least 3
months at any time since her breast cancer
diagnosis
Yes
No
Does the patient have any first degree relatives
who died from heart disease before the age of 55
("First degree relatives" include parent, children,
brothers, and sisters)
Yes
No
Concomitant Medications
Agent Category
Bisphosphonate (Bisphosphonate)
Calcium (Calcium)
Cardiovascular Medication #1
(Cardiovascular Medication #1)
Cardiovascular Medication #2
(Cardiovascular Medication #2)
Cardiovascular Medication #3
(Cardiovascular Medication #3)
Lipid Lowering Drug (Lipid Lowering
Drug)
Other Medication For Bone Density
(Other Medication for Bone Density)
Agent Name
Taking at time of randomization?
Yes
No
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Continuing after Randomization
Yes
No
Footer Module
Completed by
Date
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Breast Cancer NCT00433589 Treatment -
Baseline information - 2499196v1.0
Baseline information
Genetic Testing or Clinical Assessment in Determining the
Need for Chemotherapy in Women With Breast Cancer
That Involves No More Than 3 Lymph Nodes
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=196BF5B8-
7A98-4811-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/8874
Baseline information
Header
Patient Birth Date
Patient Hospital Number
Institution Name
Institution No.
Physician of Record
Baseline Information
Date of Most Extensive Primary Surgery
Tumor Laterality
Bilateral (Bilateral)
Left (Left)
Right (Right)
Number of Positive Lymph Nodes
Histologic Type
Ductal (Ductal)
Lobular (Lobular (pure > or =90%))
Other Specify (Other)
Her2/neu expression status by
immunohistochemistry
0 (0)
1+ (1+)
2+ (2+)
3+ (3+)
Not Done: C49484 (not done)
FISH Result
Amplified (Amplified)
Not Amplified (Not amplified)
Not Done (Not done)
Menopausal Status
Postmenopausal (Postmenopausal)
Pre-menopausal (Pre-menopausal)
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Menopausal Status
Postmenopausal (Postmenopausal)
Pre-menopausal (Pre-menopausal)
Date of blood specimen collection
Chest X-Ray Result
Abnormal (Abnormal)
Normal (Normal)
Height
Is adjuvant breast/chest wall radiotherapy
planned, ongoing or completed?
Yes
No
Comments
Date
Investigator Signature
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Colorectal Cancer NCT00077233 Demographic - CALGB:
80203 BACKGROUND INFORMATION FORM - 2171121v3.0
CALGB: 80203 BACKGROUND INFORMATION FORM
Fluorouracil and Leucovorin Plus Either Irinotecan or
Oxaliplatin With or Without Cetuximab in Treating Patients
With Previously Untreated Metastatic Adenocarcinoma of
the Colon or Rectum
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=BFD5AAD1-
D500-39A2-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/8875
CALGB: 80203 BACKGROUND
INFORMATION FORM
Ccrr Module For Calgb: 80203
Background Information Form
Patient Initials
Other relative, specify
Other, specify
Other, specify
Participating Group
Patient Hospital No.
Institution/Affiliate
Participating Group Protocol No.
Participating Group Patient ID
Today's date
What is the highest grade you finished in school?
(Mark one with an X)
1-8 Grades (1-8 grades)
9-11 Grades (9-11 grades)
Advanced Degree (Advanced degree)
College Degree (b.a./b.s.) (College
degree (B.A./B.S.))
High School Graduate (High School
graduate)
Junior College Degree (Junior college
degree)
Some College (Some college)
Some Post-college Work (Some post-
college work)
What is your marital status? (Mark one with an X)
Divorced (Divorced)
Married (Married)
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Separated (Separated)
Single, Never Married (Single, never
married)
Widowed (Widowed)
With whom do you live? (Mark all that apply with
an X)
Children Aged 18 Years Or Younger
(Children aged 18 years or younger)
Children Aged 19 Years Or Older
(Children aged 19 years or older)
Live Alone (Live alone)
Other Relative, Specify (Other relative,
specify)
Other Relative, Specify (Other relative,
specify)
Other, Specify (Other, specify)
Parent(s)/parent(s)-in-law
(Parent(s)/Parent(s)-In-Law)
Spouse/partner (Spouse/Partner)
What is your current employment status? (Mark
all that apply with an X)
Disabled (Disabled)
Employed 32 Hours Or More Per Week
(Employed 32 hours or more per week)
Employed less than 32 hours per week
(Employed less than 32 hours per week)
Full-time Student (Full-time student)
Homemaker (Homemaker)
On Medical Leave (On medical leave)
Other, Specify (Other, specify)
Part-time Student (Part-time student)
Retired (Retired)
Unemployed (Unemployed)
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Breast Cancer NCT00433589 Treatment -
Chemotherapy - Anthracycline arm - 2499309v1.0
Chemotherapy - Anthracycline arm
Genetic Testing or Clinical Assessment in Determining the
Need for Chemotherapy in Women With Breast Cancer
That Involves No More Than 3 Lymph Nodes
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=196E25F6-
1F2F-6362-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/8876
Chemotherapy - Anthracycline arm
Header
Patient Birth Date
Patient Hospital Number
Institution Name
Institution No.
Physician of Record
Chemotherapy - Anthracycline Arm
Date Chemotherapy Began
Cycle Number
Performance Status
Fully Active, Able To Carry On All Pre-
disease Performance Without
Restriction. (0)
Restricted In Physically Strenuous
Activity But Ambulatory And Able To
Carry Out Work Of A Light Or Sedentary
Nature, E.g., Light Housework, Office
Work. (1)
Ambulatory And Capable Of All Selfcare
But Unable To Carry Out Any Work
Activities. Up And About More Than 50%
Of Waking Hours. (2)
Capable Of Only Limited Selfcare,
Confined To Bed Or Chair More Than
50% Of Waking Hours. (3)
Completely Disabled. Cannot Carry On
Any Selfcare. Totally Confined To Bed Or
Chair. (4)
Were there any dose modifications or
additions/omissions to protocol treatment?
No (No)
Yes, Both Planned And Unplanned (Yes,
both planned and unplanned)
What is the type of modification?  Select all that
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apply from list.
Agent Dose Decreased (Agent Dose
Decreased)
Regimen Interrupted (Regimen
Interrupted)
Reason for therapy modification
Hematologic Toxicity (Hematologic
toxicity)
Comments
Date
Investigator Signature
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Ovarian Cancer NCT00993655 Pre-Study - NCIC
OV 21 Initial Evaluation Form - 2874238v1.0
NCIC OV 21 Initial Evaluation Form
Comparing Three Combination Chemotherapy Regimens in
Treating Patients With Stage IIB, Stage IIC, Stage III, or
Stage IV Ovarian Epithelial Cancer, Primary Peritoneal
Cancer, or Fallopian Tube Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=69B8C40D-
B84F-E610-E040-BB89AD43211A
All rights reserved. Please visit https://medical-data-
models.org/forms/8877
NCIC OV 21 Initial Evaluation Form
Patient Information
NCIC Patient ID (NCIC CTG Patient Serial
Number issued at the time of randomization)
Patient Initials (first-middle-last)
Patient Hospital No. (if permitted by REB)
Investigator No.
Investigator First Name
Investigator Middle Name
Investigator Last Name
Patient Race/ethnicity
Patient Race (please check all that apply; the
patient is encouraged to self designate)
A Person Having Origins In Any Of The
Original Peoples Of North And South
America (including Central America),
And Who Maintains Tribal Affiliation Or
Community Attachment. (American
Indian or Alaska Native)
A Person Having Origins In Any Of The
Original Peoples Of The Far East,
Southeast Asia, Or The Indian
Subcontinent Including, For Example,
Cambodia, China, India, Japan, Korea,
Malaysia, Pakistan, The Philippine
Islands, Thailand, And Vietnam. (Asian)
A Person Having Origins In Any Of The
Black Racial Groups Of Africa. Terms
Such As "haitian" Or "negro" Can Be
Used In Addition To "black Or African
American." (Black or African American)
A Person Having Origins In Any Of The
Original Peoples Of Hawaii, Guam,
Samoa, Or Other Pacific Islands. (Native
Hawaiian or other Pacific Islander)
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Not Provided Or Available (Not
Reported)
Could Not Be Determined Or Unsure
(Unknown)
A Person Having Origins In Any Of The
Original Peoples Of Europe, The Middle
East, Or North Africa. (White)
Patient Ethnicity
A Person Of Mexican, Puerto Rican,
Cuban, Central Or South American Or
Other Spanish Culture Or Origin,
Regardless Of Race. (Hispanic or Latino)
A Person Not Meeting The Definition For
Hispanic Or Latino. (Not Hispanic or
Latino)
Could Not Be Determined Or Unsure
(Unknown)
Physical Exam
Date of Physical Exam (yyyy-mmm-dd)
Height (cm)
Weight (kg)
BSA (m^2)
Hematology
Date Specimen collected (for biochemical
investigations)
Lab ID
Hemoglobin
WBC
Other
Date of evaluation
Hematology
Date Specimen collected (for biochemical
investigations)
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Lab ID
CA125
Date of evaluation
Timing Of Randomization
Physical Exam
Date of Physical Exam (yyyy-mmm-dd)
Weight (kg)
BSA (m^2)
ECOG Performance Status
Fully Active, Able To Carry On All Pre-
disease Performance Without
Restriction. (0)
Restricted In Physically Strenuous
Activity But Ambulatory And Able To
Carry Out Work Of A Light Or Sedentary
Nature, E.g., Light Housework, Office
Work. (1)
Ambulatory And Capable Of All Selfcare
But Unable To Carry Out Any Work
Activities. Up And About More Than 50%
Of Waking Hours. (2)
Capable Of Only Limited Selfcare,
Confined To Bed Or Chair More Than
50% Of Waking Hours. (3)
Completely Disabled. Cannot Carry On
Any Selfcare. Totally Confined To Bed Or
Chair. (4)
Hematology
Date Specimen collected (for biochemical
investigations)
Lab ID
Hemoglobin
Peripheral Platelet Count
WBC
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Other
Absolute neutrophil count
Date of evaluation
Biochemistry
Date Specimen collected (for biochemical
investigations)
Lab ID
Serum Creatinine
Total Bilirubin
SGOT (AST)
Other
SGPT (ALT)
Date of evaluation
Radiology Investigations
Date of evaluation
Baseline Ecg
Date of EKG
Result (ECG)
Abnormal - Clinically Significant
(Abnormal - Clinically significant)
Abnormal - Not Clinically Significant
(Abnormal - Not clinically significant)
Normal (Normal)
Target Lesions
Target Lesion Site (e.g. pelvis)
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Method of Evaluation
Other Specify
Dimension 1 (End of Reporting Period
Measurements)
Date of evaluation
Dimension 2 (End of Reporting Period
Measurements)
Sum of Longest Diameters of All Target Lesions
Non- Target Lesions During Treatment
Nontarget Lesion Site (e.g. pelvis)
Method of Evaluation
Other Specify
Date of evaluation
Disease Status At/after Delayed Primary
Debulking
Date of cancer debulking surgery (delayed
primary)
Pathologic Lymph Node Assessment
Negative (negative)
Positive (positive)
Unknown (unknown)
Lymph Node Type (If positive)
Other Specify (other)
Para-aortic (para-aortic)
Pelvic (pelvic)
Other specify
Catheter Selection And Placement
Prior Neoadjuvant Systemic Therapy For
Ovarian Cancer
5 / 9
Ovarian Cancer NCT00993655 Pre-Study - NCIC OV 21 Initial Evaluation
Form - 2874238v1.0
Neoadjuvant Chemotherapy
Total Number of Cycles given
Start date
End date
Disease History At Initial Diagnosis
Date of Definitive Histologic Diagnosis of Primary
Tumor (before neoadjuvant chemotherapy)
FIGO staging (at initial Diagnosis by
clinical/radiological assessment)
Stage I Cervical Cancer (I)
Stage Iia Cervical Cancer (IIA)
Stage Iib Cervical Cancer (IIB)
Iic (IIC)
Stage Iiia Cervical Cancer (IIIA)
Stage Iiib Cervical Cancer (IIIB)
Iiic (IIIC)
Stage Iv Cervical Cancer (IV)
Primary Site
Fallopian Tube (Fallopian tube)
Other Specify (Other)
Ovary (Ovary)
Peritoneum (Peritoneum)
Other specify
Histologic Grade
Grade 1-well Differentiated (1)
Grade 2-moderately Differentiated (2)
Grade 3-poorly Differentiated (3)
Grade Unknown (Unknown)
Histologic Type
Adenocarcinoma, Unspecified
(Adenocarcinoma, unspecified)
Clear Cell Carcinoma (Clear cell
carcinoma)
Endometrioid Adenocarcinoma
(Endometrioid adenocarcinoma)
Mixed Epithelial Carcinoma, Specify
Components (Mixed epithelial
carcinoma)
Mucinous Adenocarcinoma (Mucinous
adenocarcinoma)
Other, Specify (Other specify)
Serous Adenocarcinoma (Serous
adenocarcinoma)
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Other specify
Initial Diagnostic Surgical Procedure(s)
Surgery Date
Procedure
Biopsy (Biopsy)
Cytology (Cytology)
Primary Debulking (Debulking)
Other (Other)
Other, specify
Findings
Prior Gynaecological Surgeries /
Diagnostic Procedures For Non-ovarian
Cancer - Question/table
Adverse Events / Intercurrent Illness
CTC Adverse Event Short Name
CTC Select AE
CTC AE Grade
Concomitant Measures/medications
Name of treatment
Reason for Administration
Ongoing? (from previous)
Yes
No
Start date
Stop date
Major Medical Problems
Have there been any major ongoing medical
problems? (at baseline)
Yes
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No
Date Documented (first)
Medical condition
Other Relevant Details
Quality Of Life Questionnaire
Was QoL Questionnaire completed?
Yes
No
Date Questionnaire Completed
Specify the reason the questionnaire was not
completed
Other Reason (Other reason)
Patient Could Not Be Contacted (Patient
could not be contacted)
Patient Did Not Keep Appointment
(Patient did not keep appointment)
Patient Kept Appointment For
Examination, But Could Not Complete
Questionnaire Due To Illness (Patient
kept appointment for examination, but
could not complete questionnaire due to
illness)
Patient Kept Appointment For
Examination, But Refused To Complete
Questionnaire For Reasons Other Than
Illness (Patient kept appointment for
examination, but refused to complete
questionnaire for reasons other)
Test Omitted Due To
Institution/investigator Error
(Questionnaire not administered due to
institutional error)
Specify other reason
Comments
Comments
Contact Information
CRA Name
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Phone number
Fax Number
Institution Name
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Endometrial Cancer NCT01210222 Pre-Study - GOG-0229L: Fast
Fact Sheet for Protocol 0229L (Endometrium) - 3184152v1.0
GOG-0229L: Fast Fact Sheet for Protocol 0229L
(Endometrium)
AMG 386 in Treating Patients With Persistent or Recurrent
Endometrial Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=9A223983-
7B94-E221-E040-BB89AD437E30
All rights reserved. Please visit https://medical-data-
models.org/forms/8880
GOG-0229L: Fast Fact Sheet for
Protocol 0229L (Endometrium)
Tracking Information
GOG Institution Code
GOG Affiliate Code
Previous GOG #
Treating physician
Other Physician
Patient Hospital No.
Date of Birth
Patient Last Name
Patient First Name
Patient Middle Name
Header
Did the patient sign an approved informed
consent
Yes
No
Has HIPAA authorization been obtained
Exempt - Non-usa Participant (Exempt -
non-USA participant)
Yes: C49488 (Yes)
Is the patient eligible for a higher priority GOG
protocol
Yes
No
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What is the primary disease site
Endometrium (Endometrium)
What is the cell type?
Unspecified Adenocarcinoma
(Adenocarcinoma, Unspecified)
Clear Cell Carcinoma (Clear cell
carcinoma)
Endometrioid Adenocarcinoma
(Endometrioid Adenocarcinoma)
Mixed Epithelial Carcinoma (Mixed
Epithelial Carcinoma)
Mucinous Adenocarcinoma (Mucinous
Adenocarcinoma)
Serous Adenocarcinoma (Serous
Adenocarcinoma)
Transitional Cell Carcinoma (Transitional
Cell Carcinoma)
Undifferentiated Carcinoma
(Undifferentiated Carcinoma)
Date of initial histologic diagnosis of malignancy
What was the grade of the primary tumor
Grade 1-well Differentiated (1)
Grade 2-moderately Differentiated (2)
Grade 3-poorly Differentiated (3)
Is the disease recurrent or persistent with
documented progression? Which one?
Persistent Disease (Persistent)
Recurrent Disease (Recurrent)
Is the cancer refractory to curative therapy or
established treatments?
Yes
No
How was it established to be recurrent or
persistent?
Biopsy (Biopsy)
Ca-125 Antigen (CA-125)
Non-histologic Evaluation (Non-
Histologic)
Not Applicable - No
Recurrence/progression During Most
Recent Course (Not applicable - no
recurrence/progression during most
recent course)
Surgical Procedure (Surgery)
Date recurrence or persistence documented?
(NOTE: This should be the date of the most
recent progression or persistence that made the
patient eligible for this study.)
Does patient have measurable disease defined
as at least one lesion that can be accurately
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measured in at least one dimension (longest
dimension to be recorded) using RECIST 1.1
criteria?
Yes
No
What method of evaluation is used to obtain
tumor measurements?
Caliper Measurement By Clinical Exam
(Caliper measurement by clinical exam)
Chest Radiography (Chest X-ray)
Computed Tomography (CT)
Magnetic Resonance Imaging (MRI)
Is the measurable disease > or = 10 mm when
measured by CT, MRI or caliper measurement by
clinical exam; or > or = 20 mm when measured
by chest x-ray or lymph nodes > or = 15 mm in
short axis when measured by CT or MRI?
Yes
No
Does the patient have at least one target lesion to
be used to assess response on this protocol as
defined by RECIST 1.1?
Yes
No
Is the measurable disease in a previously
irradiated field?
Yes
No
If yes, does the patient have disease in an
irradiated field as the only site of measurable
disease and has progression been documented
or a biopsy obtained to confirm persistent
disease at least 90 days following completion of
radiation treatment?
No (No)
Not Applicable (Not Applicable)
Yes (Yes)
Has the patient recovered from the effects of
recent surgery, radiotherapy or chemotherapy?
Yes
No
Is the patient free of active infection requiring
antibiotics with the exception of uncomplicated
urinary tract infection (UTI)?
Yes
No
Has any hormonal therapy directed at the
malignant tumor been discontinued at least one
week prior to registration?
Yes
No
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Has all prior therapy directed at the malignant
tumor, including chemotherapy and immunologic
agents, been discontinued for at least three
weeks prior to registration?
Yes
No
Has any prior radiation therapy been completed
at least 4 weeks prior to registration?
Yes
No
How many prior cytotoxic chemotherapy
regimens has the patient received? (NOTE:
Chemotherapy administered in conjunction with
primary radiation as a radio-sensitizer WILL be
counted as a chemotherapy regimen.)
One Chemotherapy Regimen (1
Regimen)
Two Chemotherapy Regimens (2
Regimens)
Drug Regimen 1:
Start date for Regimen 1:
End date for Regimen 1:
Drug Regimen 2:
Start date for Regimen 2:
End date for Regimen 2:
Performance Status (Patients who have received
one prior regimen must have performance status
of 0, 1 or 2 - patients who have received two prior
regimens must have performance status of 0 or
1)
Fully Active, Able To Carry On All Pre-
disease Performance Without
Restriction. (0)
Restricted In Physically Strenuous
Activity But Ambulatory And Able To
Carry Out Work Of A Light Or Sedentary
Nature, E.g., Light Housework, Office
Work. (1)
Ambulatory And Capable Of All Selfcare
But Unable To Carry Out Any Work
Activities. Up And About More Than 50%
Of Waking Hours. (2)
Has the patient received any non-cytotoxic
(biologic or targeted) agents as part of their
primary treatment or for management of recurrent
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or persistent disease?
Yes
No
Date of Results (if more than one, enter earliest:)
Platelets greater than or equal to 100,000/mcl?
Yes
No
ANC greater than or equal to 1,500/mcl?
Yes
No
Hemoglobin greater than or equal to 9 g/dL?
Yes
No
Is creatinine less than or equal to 1.5 X ULN or a
creatinine clearance greater than or equal to 60
ml/m2?
Yes
No
Is the bilirubin less than or equal to 1.5 x ULN
Yes
No
Is the AST and ALT less than or equal to 3.0 X
ULN
Yes
No
Is the alkaline phosphatase less than or equal to
2.5 x ULN?
Yes
No
Is Neuropathy (sensory or motor) less than or
equal to CTCAE grade 1?
Yes
No
Is the urine protein less than or equal to 1 on
dipstick (or if 2+ or higher, is urine protein less
than 1.0g/24 hours)?
Yes
No
Is the Prothrombin Time (PT) such that the
International Normalized Ratio (INR) is:
Between 2 And 3 And On A Stable Dose
Of Therapeutic Warfarin (Between 2 and
3 AND on a stable dose of therapeutic
warfarin)
Less Than Or Equal To 1.5 X Uln (Less
than or equal to 1.5 x ULN)
Is the PTT less than or equal to 1.5 times the
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institutional upper limit of normal?
Yes
No
Is the serum albumin greater than or equal to 2.8
mg/dL?
Yes
No
Has the patient met the pre-entry requirements
as specified in section 7.0
Yes
No
If the patient has childbearing potential, has she
had a negative serum pregnancy test performed
48 hours prior to study entry?
No (No)
Not Applicable (Not Applicable)
Yes (Yes)
If patient has the capacity to become pregnant,
has she agreed to use an accepted and effective
non-hormonal method of contraception i.e.,
double barrier method (eg. condom plus
diaphragm) from the time of signing the informed
consent through six months after the last dose of
study drug?
No (No)
Not Applicable (Not Applicable)
Yes (Yes)
Is the patient currently receiving or has she been
treated previously with AMG 386, or other
molecules that inhibit the angiopoietins or Tie2
receptor?
Yes
No
Has the patient had another invasive malignancy
other than non-melanoma of the skin, localized
cancer of the breast, head and neck or skin
diagnosed, present or recur within the past 3
years?
Yes
No
Has the patient received prior radiotherapy to any
portion of the abdominal cavity or pelvis other
than for the treatment of endometrial cancer
within the last three years? (Prior radiation for
localized cancer of the breast, head and neck or
skin is permitted as long as it was completed
more than 3 years prior to registration and the
patient remains free of recurrent or metastatic
disease)
Yes
No
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Has the patient received prior chemotherapy for
any abdominal or pelvic tumor other than for the
treatment of endometrial cancer within the last
three years? (Prior adjuvant chemotherapy for
localized breast cancer is permitted provided it
was completed more than 3 years prior to
registration and the patient remains free of
recurrent or metastatic disease)
Yes
No
Is the treatment of previous cancer a
contraindication to the current protocol therapy?
Yes
No
Does the patient have a serious non-healing
wound (including gastrointestinal), ulcer or bone
fracture
Yes
No
Does the patient have symptoms of partial or
complete bowel obstruction or a history of fistula,
intra-abdominal abscess or bowel perforation
within 6 months prior to first day of study therapy
Yes
No
Does the patient require total parenteral nutrition
or parenteral hydration
Yes
No
Has the patient had significant bleeding within 6
months of enrollment or any pathologic conditions
that carry high risk of bleeding, such as known
bleeding disorder, coagulopathy, or tumor
involving major vessels?
Yes
No
Does the patient have a history or evidence upon
physical examination of CNS disease, including
primary brain tumor, seizures not controlled with
standard medical therapy or any brain
metastases?
Yes
No
Has the patient had clinically significant
cardiovascular disease
Yes
No
Does the patient have uncontrolled hypertension
defined as systolic greater than 150 mm Hg or
diastolic greater than 90 mm Hg despite anti-
hypertensive therapy?
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Yes
No
Does the patient have a history of myocardial
infarction or unstable angina within the past 12
months
Yes
No
Using the New York Heart Association (NYHA)
guideline, does the patient have Class II or
greater congestive heart failure?
Yes
No
Does the patient have a history of serious
ventricular arrhythmia (ventricular tachycardia or
ventricular fibrillation) or arrhythmias requiring
anti-arrhythmic medications (except for atrial
fibrillation that is well controlled with anti-
arrhythmic medication)?
Yes
No
Does the patient have peripheral vascular
disease greater than or equal to Grade 2
Yes
No
Does the patient have a history of
cerebrovascular accident (CVA, stroke), transient
ischemic attack (TIA) or subarachnoid
hemorrhage within six months of the first date of
study therapy?
Yes
No
Does the patient have a history of arterial
ischemia or thrombus?
Yes
No
Has the patient undergone a major surgical
procedure, open biopsy or incurred a significant
traumatic injury within 28 days prior to the first
date of study therapy?
Yes
No
Is a major surgical procedure anticipated for this
patient during the course of this study
Yes
No
Has the patient had any minor surgical
procedures, fine needle aspirates or core
biopsies within 7 days prior to the first date of
study therapy? (Paracentesis and thoracentesis
are permitted prior to and while on study at the
discretion of the investigator and as clinically
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indicated.)
Yes
No
Is the patient under age 18?
Yes
No
Is the patient pregnant or nursing?
Yes
No
Has the patient been treated with immune
modulators such as systemic cyclosporine or
tacrolimus within 30 days prior to enrollment?
Yes
No
Does the patient have human immunodeficiency
virus (HIV), hepatitis C or chronic or active
hepatitis B
Yes
No
Does the patient have any condition which in the
investigator's opinion makes the patient
unsuitable for study participation?
Yes
No
Is the patient available for follow-up
assessments?
Yes
No
Does the patient have known sensitivity to any of
the products to be administered during dosing?
Yes
No
Does the patient have a history of allergic
reactions to bacterially produced proteins?
Yes
No
Anticipated date treatment will start
Comments
Provide comments about this Fast Fact Sheet
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Breast Cancer NCT00433589 Treatment -
Disease recurrence - 2498795v1.0
Disease recurrence
Genetic Testing or Clinical Assessment in Determining the
Need for Chemotherapy in Women With Breast Cancer
That Involves No More Than 3 Lymph Nodes
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=1966F1B5-
7BF7-3D46-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/8881
Disease recurrence
Header
Patient Birth Date
Patient Hospital Number
Institution Name
Institution No.
Physician of Record
Disease Recurrence
Date of Assessment
Metastasis Diagnosis Date
Loco-regional Recurrence
Site of first local-regional recurrence
At The Site Of The Primary Tumor (At
the site of the primary tumor)
Elsewhere In The Breast (Elsewhere in
the breast)
Ipsilateral Axillary Lymph Nodes And/or
Soft Tissue (Ipsilateral axillary lymph
nodes and/or soft tissue)
Ipsilateral Chest Wall (Ipsilateral chest
wall)
Ipsilateral Infraclavicular Nodes
(Ipsilateral infraclavicular nodes)
Ipsilateral Internal Mammary Nodes
(Ipsilateral internal mammary nodes)
Ipsilateral Supraclavicular Nodes
(Ipsilateral suparclavicular nodes)
Method of Evaluation
Autopsy (Autopsy)
Axillary Dissection (Axillary dissection)
Bilateral Mammogram (Bilateral
mammogram)
Bimanual Examination (Bimanual
examination)
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Biopsy (Biopsy)
Biopsy (Biopsy, other)
Bone Scan (Bone scan)
Chest X-ray (Chest x-ray)
Clinical (Clinical)
Clinical Examination (pe) (Clinical
examination)
Colposcopy (Colposcopy)
Contrast Enhanced Ct Scan (Contrast
enhanced CT scan/CT perfusion exam)
Ct Scan (CT scan)
Cystoscopy (Cystoscopy)
Cytologic Confirmation (Cytologic
confirmation)
Cytology (Cytology)
Cytoscopy (Cytoscopy)
Differential (Differential)
Direct Inspection (Direct inspection)
Ductal Lavage (Ductal lavage)
Ductoscopic Biopsy (Ductoscopic
biopsy)
Echocardiogram (Echocardiogram)
Ekg (EKG)
Endoscopy (Endoscopy)
Excisional Biopsy Or Lumpectomy
(Excisional biopsy or lumpectomy)
Lumpectomy, With Wire Localization
(Excisional biopsy or lumpectomy, with
wire localization)
Fine Needle Aspiration Biopsy (Fine
needle aspiration biopsy)
Fine Needle Aspiration Biopsy With Wire
Localization (Fine needle aspiration
biopsy, with wire localization)
Fluid Cytology, Ascites (Fluid cytology,
ascites)
Fluid Cytology, Cerebrospinal Fluid (Fluid
cytology, cerebrospinal fluid)
Fluid Cytology, Pleural (Fluid cytology,
pleural)
Gallium Scan (Gallium scan)
Histologic (Histologic)
Histologic Confirmation (Histologic
confirmation)
Histology (Histology)
Incisional Biopsy (Incisional biopsy)
Incisional Biopsy, With Wire Localization
(Incisional biopsy, with wire localization)
Intraoperative Ultrasound (Intraoperative
ultrasound)
Laparoscopy (Laparoscopy)
Laparotomy (Laparotomy)
Mammogram (Mammogram)
Mastectomy (Mastectomy)
Mri (MRI (NMR))
Mri Scan (MRI scan)
Nomograms (MSK Nomogram)
Muga Scan (MUGA)
Needle Biopsy (tru-cut Or Core) (Needle
biopsy (tru-cut or core))
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Needle Biopsy (tru-cut Or Core), With
Wire Localization (Needle biopsy (tru-cut
or core), with wire localization))
Nipple Fluid (Nipple fluid)
Not Applicable (Not applicable)
Not Done (Not done)
Not Evaluated (Not evaluated)
Other (Other)
Other, Specify (Other, specify)
Palpation (Palpation)
Pathologic (Pathologic)
Pet Scan (PET scan)
Physical Exam (Physical exam)
Plain Film/x-ray With Contrast (Plain
film/X-ray with contrast)
Plain Film/x-ray Without Contrast (Plain
film/X-ray without contrast)
Ct Scan (Preoperative CT scan)
Primary Surgery (Primary surgery)
Prophalactic Mastectomy (Prophalactic
mastectomy)
Radiograph (Radiograph)
Radiographic (Radiographic)
Radioisotope Scan (Radioisotope scan)
Resection/re-excision Of Lumpectomy
Margins (Resection/re-excision of
lumpectomy margins)
Sentinel Node Biopsy (Sentinel node
biopsy)
Spiral Ct Scan (Spiral CT scan)
Surgery (Surgery)
Tumor Marker (Tumor Marker)
Tumor Markers (Tumor markers)
Ultrasound (Ultrasound)
Unknown (Unknown)
Visual Assessment (Visual assessment)
Visualization (Visualization)
X-ray (X-ray)
Other Specify
Distant Metastasis
Metastatic Site
Bone (Bone)
Brain (Brain)
Distant Nodes (Distant nodes)
Distant Skin/subcutaneous Tissue
(Distant skin/subcutaneous tissue)
Liver (Liver)
Lung (Lung)
Other Specify (Other)
Other Cns (Other Central Nervous
System)
Pleura (Pleura)
Other specify
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Method of Evaluation
Autopsy (Autopsy)
Axillary Dissection (Axillary dissection)
Bilateral Mammogram (Bilateral
mammogram)
Bimanual Examination (Bimanual
examination)
Biopsy (Biopsy)
Biopsy (Biopsy, other)
Bone Scan (Bone scan)
Chest X-ray (Chest x-ray)
Clinical (Clinical)
Clinical Examination (pe) (Clinical
examination)
Colposcopy (Colposcopy)
Contrast Enhanced Ct Scan (Contrast
enhanced CT scan/CT perfusion exam)
Ct Scan (CT scan)
Cystoscopy (Cystoscopy)
Cytologic Confirmation (Cytologic
confirmation)
Cytology (Cytology)
Cytoscopy (Cytoscopy)
Differential (Differential)
Direct Inspection (Direct inspection)
Ductal Lavage (Ductal lavage)
Ductoscopic Biopsy (Ductoscopic
biopsy)
Echocardiogram (Echocardiogram)
Ekg (EKG)
Endoscopy (Endoscopy)
Excisional Biopsy Or Lumpectomy
(Excisional biopsy or lumpectomy)
Lumpectomy, With Wire Localization
(Excisional biopsy or lumpectomy, with
wire localization)
Fine Needle Aspiration Biopsy (Fine
needle aspiration biopsy)
Fine Needle Aspiration Biopsy With Wire
Localization (Fine needle aspiration
biopsy, with wire localization)
Fluid Cytology, Ascites (Fluid cytology,
ascites)
Fluid Cytology, Cerebrospinal Fluid (Fluid
cytology, cerebrospinal fluid)
Fluid Cytology, Pleural (Fluid cytology,
pleural)
Gallium Scan (Gallium scan)
Histologic (Histologic)
Histologic Confirmation (Histologic
confirmation)
Histology (Histology)
Incisional Biopsy (Incisional biopsy)
Incisional Biopsy, With Wire Localization
(Incisional biopsy, with wire localization)
Intraoperative Ultrasound (Intraoperative
ultrasound)
Laparoscopy (Laparoscopy)
Laparotomy (Laparotomy)
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Mammogram (Mammogram)
Mastectomy (Mastectomy)
Mri (MRI (NMR))
Mri Scan (MRI scan)
Nomograms (MSK Nomogram)
Muga Scan (MUGA)
Needle Biopsy (tru-cut Or Core) (Needle
biopsy (tru-cut or core))
Needle Biopsy (tru-cut Or Core), With
Wire Localization (Needle biopsy (tru-cut
or core), with wire localization))
Nipple Fluid (Nipple fluid)
Not Applicable (Not applicable)
Not Done (Not done)
Not Evaluated (Not evaluated)
Other (Other)
Other, Specify (Other, specify)
Palpation (Palpation)
Pathologic (Pathologic)
Pet Scan (PET scan)
Physical Exam (Physical exam)
Plain Film/x-ray With Contrast (Plain
film/X-ray with contrast)
Plain Film/x-ray Without Contrast (Plain
film/X-ray without contrast)
Ct Scan (Preoperative CT scan)
Primary Surgery (Primary surgery)
Prophalactic Mastectomy (Prophalactic
mastectomy)
Radiograph (Radiograph)
Radiographic (Radiographic)
Radioisotope Scan (Radioisotope scan)
Resection/re-excision Of Lumpectomy
Margins (Resection/re-excision of
lumpectomy margins)
Sentinel Node Biopsy (Sentinel node
biopsy)
Spiral Ct Scan (Spiral CT scan)
Surgery (Surgery)
Tumor Marker (Tumor Marker)
Tumor Markers (Tumor markers)
Ultrasound (Ultrasound)
Unknown (Unknown)
Visual Assessment (Visual assessment)
Visualization (Visualization)
X-ray (X-ray)
Other Specify
Comments
Date
Investigator Signature
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Prostate Cancer NCT00499174 On-Study - NCIC-
PR.11 Form 1- Initial Evaluation - 2457017v1.0
NCIC-PR.11 Form 1- Initial Evaluation
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=0EF80EFC-
B7A8-1C24-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/8882
NCIC-PR.11 Form 1- Initial
Evaluation
Patient Information
NCIC Patient ID (NCIC CTG Patient Serial
Number issued at the time of randomization)
Patient Initials (first-middle-last)
Patient Medical Record Number (if permitted by
IRB)
Intergroup Patient Serial No
Institution Name
NCI Institution Number (CTEP assigned)
Investigator First Name
Investigator Last Name
Patient's Date of Birth (yyyy - mmm - dd)
Investigator Number (NCI Investigator Number)
Date of Randomization
Patient Ethnicity (check one only)
A Person Of Mexican, Puerto Rican,
Cuban, Central Or South American Or
Other Spanish Culture Or Origin,
Regardless Of Race. (Hispanic or Latino)
A Person Not Meeting The Definition For
Hispanic Or Latino. (Not Hispanic or
Latino)
Not Provided Or Available (Not reported)
Could Not Be Determined Or Unsure
(Unknown)
Payment Method (check one USA only -  )
Medicaid (Medicaid)
Medicaid And Medicare (Medicaid and
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Medicare)
Medicare (Medicare)
Medicare And Private Insurance
(Medicare and Private Insurance)
Military Or Veterans Sponsored Nos
(Military or Veterans Sponsored, Not
Otherwise Specified (NOS))
Military Sponsored (including Champus
& Tricare) (Military Sponsored (including
CHAMPUS & TRICARE))
No Means Of Payment (no Insurance)
(No means of payment (no insurance))
Other (Other)
Private Insurance (Private Insurance)
Self Pay (no Insurance) (Self Pay (No
Insurance))
Unknown (Unknown)
Veterans Sponsored (Veterans
Sponsored)
ZIP Code
Race
Race
A Person Having Origins In Any Of The
Original Peoples Of North And South
America (including Central America),
And Who Maintains Tribal Affiliation Or
Community Attachment. (American
Indian or Alaska Native)
A Person Having Origins In Any Of The
Original Peoples Of The Far East,
Southeast Asia, Or The Indian
Subcontinent Including, For Example,
Cambodia, China, India, Japan, Korea,
Malaysia, Pakistan, The Philippine
Islands, Thailand, And Vietnam. (Asian)
A Person Having Origins In Any Of The
Black Racial Groups Of Africa. Terms
Such As "haitian" Or "negro" Can Be
Used In Addition To "black Or African
American." (Black or African American)
A Person Having Origins In Any Of The
Original Peoples Of Hawaii, Guam,
Samoa, Or Other Pacific Islands. (Native
Hawaiian or other Pacific Islander)
Not Provided Or Available (Not
Reported)
Could Not Be Determined Or Unsure
(Unknown)
A Person Having Origins In Any Of The
Original Peoples Of Europe, The Middle
East, Or North Africa. (White)
Physical Exam
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Date of Evaluation (yyyy - mmm - dd)
Performance Status (check one)
Fully Active, Able To Carry On All Pre-
disease Performance Without
Restriction. (0)
Restricted In Physically Strenuous
Activity But Ambulatory And Able To
Carry Out Work Of A Light Or Sedentary
Nature, E.g., Light Housework, Office
Work. (1)
Ambulatory And Capable Of All Selfcare
But Unable To Carry Out Any Work
Activities. Up And About More Than 50%
Of Waking Hours. (2)
Capable Of Only Limited Selfcare,
Confined To Bed Or Chair More Than
50% Of Waking Hours. (3)
Completely Disabled. Cannot Carry On
Any Selfcare. Totally Confined To Bed Or
Chair. (4)
Disease History
Date of Initial Diagnosis of Primary Tumor (yyyy
mmm dd date of initial pathologic diagnosis
submit a copy of the pathology report with the
Form 1)
Histologic Type
Adenocarcinoma (Adenocarcinoma)
Other Specify (Other)
Other specify
Date Baseline Surgical Gleason Score Obtained
(yyyy mmm dd)
Gleason Score Based on Specimen Type
Biopsy (Biopsy)
Fine Needle Aspiration Biopsy (Fine
Needle Aspirate)
Surgical Specimen (Surgical specimen)
Gleason Score, Primary Pattern (1-5)
Gleason Score, Secondary Pattern (1-5)
Gleason Score, Combined (sum of the primary
and secondary)
Any tertiary elements of Gleason 4 or 5 pattern?
No (No)
Unknown (Unknown)
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Yes (Yes)
Percent (%) (If yes,)
Prostate intraepithelial neoplasia (PIN), High
Grade
Yes
No
Atypical small acinar proliferation (ASAP)
Yes
No
Total number cores (Left side)
Total number cores (Left side)
Number cores positive (Left side)
Number cores positive (Left side)
Specimen/Core No. (CRF text recommended -
CRF only shows Specimen/Core #1, 2, 3, 4)
Percent involved Right side
Percent involved Left side
T Stage, Clinical
Tumor Incidental Histologic Finding In
5% Or Less Of Tissue Resected (T1a)
Tumor Incidental Histologic Finding In
More Than 5% Of Tissue Resected
(T1b)
Tumor Identified By Needle Biopsy (eg,
Because Of Elevated Psa) (T1c)
Tumor Involves One Lobe (T2a)
Tumor Involves Both Lobes (T2b)
Tumor Involves Both Lobes (T2c)
Untitled/disease History (continued)
Date of Transrectal Ultrasound (yyyy mmm dd)
Volume of gland/Prostate gland size (cubic
centimetres)
Hypoechoic area
Yes
No
Size (cm) (If yes,)
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Date of exam (yyyy mmm dd)
Was the nodule palpable (at baseline)
Yes
No
Nodule is (If yes, )
Highly Suspicious For Cancer (Highly
suspicious for prostate cancer)
Mildly Suspicious For Cancer (Mildly
suspicious for prostate cancer)
Moderately Suspicious For Cancer
(Moderately suspicious for prostate
cancer)
Maximum Diameter (cm)
Date of Baseline PSA (closest to randomization
yyyy mmm dd)
Baseline PSA Value
Date of PSA prior to androgen deprivation
therapy (if applicable yyyy mmm dd)
PSA Value prior to androgen deprivation therapy
(if applicable)
PSA Value (total)
Units (* ng/ml, mg/L)
Micrograms Per Liter (mcg/L)
Nanograms Per Milliliter (ng/mL)
Units (* ng/ml, mg/L)
Micrograms Per Liter (mcg/L)
Nanograms Per Milliliter (ng/mL)
Units (* ng/ml, mg/L)
Micrograms Per Liter (mcg/L)
Nanograms Per Milliliter (ng/mL)
Date of PSA Assessment (yyyy mmm dd)
Therapy For Lower Urinary Tract
Symptoms/prostate Cancer
Prevention/prostate Cancer
5 alpha-reductase inhibitor
Yes
No
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Reason for use
Agent (If yes,)
Non-steroidal antiandrogen
Yes
No
Agent (If yes,)
Date Agent Started (yyyy mmm dd)
Date Agent Started (yyyy mmm dd)
Date Agent Started (yyyy mmm dd)
Date Agent Started (yyyy mmm dd)
Date Agent Ended (yyyy mmm dd)
Date Agent Ended (yyyy mmm dd)
Date Agent Ended (yyyy mmm dd)
Date Agent Ended (yyyy mmm dd)
LHRH analogues
Yes
No
Agent (If yes,)
Prior Surgery (for prostate cancer other than
biopsy or TURP?)
Yes
No
Radiation Therapy (for prostate cancer?)
Yes
No
Complementary and alternative medicines (*e.g.
Saw palmetto, Vitamin B/E, Selenium, Lycopene)
Yes
No
Agent (If yes, )
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Adverse Event Status
Has the patient experienced any symptoms in the
14 days prior to randomization
Yes
No
CTC Adverse Event Term
Constipation (Constipation)
Impotence (Erectile dysfunction)
Fatigue (Fatigue)
Urinary Frequency (Urinary frequency)
Grade (Worst this time period - Consult grade
definitions in CTCAE version 4.0 handbook and
enter appropriate code below. - If event not
present, leave event grade field blank.)
Absent Adverse Event (0)
Mild Adverse Event (1)
Moderate Adverse Event (2)
Severe Adverse Event (3)
Life Threatening Adverse Event (4)
Death Related To Adverse Event (5)
Other Major Medical Problems
Have there been any major ongoing medical
problems? (If yes, please enter details below:)
Yes
No
Disease/Condition
Correlative Studies
Did the patient agree to allow tissue from tumor
to be collected for tumor banking?
Yes
No
Was tissue collected for tumor banking (If yes,)
Yes
No
Reason
Quality Of Life Questionnaire
Was QoL Questionnaire completed?
No: C49487 (No)
Not Applicable (Not Applicable)
Yes: C49488 (Yes)
Date Questionnaire Completed (yyyy mmm dd
Please submit quality of life questionnaires)
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Reason Questionnaire was not Completed (check
one)
Other Reason (Other reason)
Questionnaire Not Completed Due To
Institutional Error (Questionnaire not
completed due to institutional error)
Other reason, specify
Planned Therapeutic Action
Planned Therapeutic Action for this patient
(*Radical therapy must begin within 90 days of
the date of the randomization)
Radical Prostatectomy (Radical
prostatectomy)
Radical Radiation Therapy (Radical
radiation therapy)
Radiation Therapy Type
External Beam Radiation Therapy
(External beam)
High-dose Rate Brachytherapy (High
dose rate temporary brachytherapy)
Prostate Implant Brachytherapy
(Permanent prostate brachytherapy)
Comments
Comments
Supporting Documentation
Investigator Signature
Person Completing Form, Last Name
Person Completing Form, First Name
Date Form Originally Completed (yyyy - mmm -
dd)
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Breast Cancer NCT00433589 Treatment -
Radiotherapy - 2498060v1.0
Radiotherapy
Genetic Testing or Clinical Assessment in Determining the
Need for Chemotherapy in Women With Breast Cancer
That Involves No More Than 3 Lymph Nodes
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=1958C7F6-
3740-3647-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/8884
Radiotherapy
Header
Patient Birth Date
Patient Hospital Number
Institution Name
Institution No.
Physician of Record
Radiotherapy
Date Prior RT Started
Date Prior RT Ended
Were there any unscheduled interruptions in
radiation therapy?
No (No)
Unknown (Unknown)
Yes (Yes)
Yes Due To Adverse Event (Yes, due to
adverse event(s))
Yes Due To Local-regional Toxicity (yes,
due to local-regional toxicity)
Yes, Due To Other Reason (Yes, due to
other reasons)
Yes Due To Systemic Toxicity (yes, due
to systemic toxicity)
Yes, Due To Toxicity (Yes, due to toxicity)
Yes, For Other Reasons, Specify (Yes,
for other reasons)
Comments
Date
Investigator Signature
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Breast Cancer NCT00433589 Treatment -
Follow up - 2498181v1.0
Follow up
Genetic Testing or Clinical Assessment in Determining the
Need for Chemotherapy in Women With Breast Cancer
That Involves No More Than 3 Lymph Nodes
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=195A7E8D-
AE8F-464E-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/8885
Follow up
Header
Patient Birth Date
Patient Hospital Number
Institution Name
Institution No.
Physician of Record
Follow Up
Date of Assessment
Trastuzumad Therapy
Prior Trastuzumab Therapy
Yes
No
Date trastuzumab started
Date trastuzumab discontinued
Endocrine Therapy
Endocrine therapy
Yes
No
Disease Evaluation
Local recurrence?
Yes
No
Relapsed at regional site?
Yes
No
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Distant metastases present?
Yes
No
Treatment For Loco-regional Recurrence
Prior Radiation Therapy
Yes
No
Endocrine therapy
Yes
No
Prior Surgery
Yes
No
Did the patient receive chemotherapy?
Yes
No
Immunotherapy/BRM
Yes
No
Did the patient receive other therapy during this
reporting period?
Yes
No
Other, specify
Second Primary Tumors
Has patient had a suspicious or proven second
primary since submission of last Follow-up Form
Yes
No
Date of Diagnosis of Second Primary Cancer
Specify
Describe cause of death
Survival
Vital Status
Alive (Alive)
Dead (Dead)
Lost To Follow-up (Lost to follow-up)
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Date of Last Clinical Assessment
Primary Cause of Death
Due To Other Cause (Due to other
cause)
Due To Protocol Treatment (Due to
protocol treatment)
Due To Second Primary Or Other
Malignancy (Due to second primary or
other malignancy)
Due To This Disease (Due to this
disease)
Unknown (Unknown)
Specify
Due to other cause, specify
Comments
Date
Investigator Signature
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Fallopian Tube Cancer NCT01081262 Registration -
GOG-0241 Registration Form (R) - 3127136v1.0
GOG-0241 Registration Form (R)
Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine,
With or Without Bevacizumab, as First-Line Therapy in
Treating Patients With Newly Diagnosed Stage II, Stage III,
Stage IV, or Recurrent Stage I Epithelial Ovarian Cancer or
Fallopian Tube Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=8D17F7CB-
7296-90BC-E040-BB89AD435566
All rights reserved. Please visit https://medical-data-
models.org/forms/8886
GOG-0241 Registration Form (R)
Header Module
Date form originally completed (m d y)
Date form amended (m d y)
Person amending form, last name
Patient Name, Last
Patient Name, First
Patient Study ID
Person Completing Form, Last Name
Tracking Information
Institution name (affiliate)
Treating physician
Patient medical record number
Patient's Date of Birth (m d y)
Patient Social Security Number
Patient Zip Code (USA)
Country of Residence (if not USA)
Demographic Information
Patient Race (mark all that apply)
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A Person Having Origins In Any Of The
Original Peoples Of North And South
America (including Central America),
And Who Maintains Tribal Affiliation Or
Community Attachment. (American
Indian or Alaska Native)
A Person Having Origins In Any Of The
Original Peoples Of The Far East,
Southeast Asia, Or The Indian
Subcontinent Including, For Example,
Cambodia, China, India, Japan, Korea,
Malaysia, Pakistan, The Philippine
Islands, Thailand, And Vietnam. (Asian)
A Person Having Origins In Any Of The
Black Racial Groups Of Africa. Terms
Such As "haitian" Or "negro" Can Be
Used In Addition To "black Or African
American." (Black or African American)
A Person Having Origins In Any Of The
Original Peoples Of Hawaii, Guam,
Samoa, Or Other Pacific Islands. (Native
Hawaiian or other Pacific Islander)
Could Not Be Determined Or Unsure
(Unknown)
A Person Having Origins In Any Of The
Original Peoples Of Europe, The Middle
East, Or North Africa. (White)
Patient Ethnicity (check one)
A Person Of Mexican, Puerto Rican,
Cuban, Central Or South American Or
Other Spanish Culture Or Origin,
Regardless Of Race. (Hispanic or Latino)
A Person Not Meeting The Definition For
Hispanic Or Latino. (Not Hispanic or
Latino)
Could Not Be Determined Or Unsure
(Unknown)
Method of Payment
Medicaid (Medicaid)
Medicare And Medicaid (Medicaid and
Medicare)
Medicare (Medicare)
Medicare And Private Insurance
(Medicare and Private Insurance)
Military Or Veterans Sponsored
Insurance, Not Otherwise Specified
(Military or Veterans Sponsored, NOS)
Military Insurance (Military Sponsored
(Including CHAMPUS & TriCare))
No Insurance (No Means of Payment
(No Insurance))
Other (Other)
Private Insurance (Private Insurance)
Self Payment (Self-Pay (No Insurance))
Unknown (Unknown)
Veterans Administration Sponsor
Insurance (Veterans Sponsored)
2 / 3
Fallopian Tube Cancer NCT01081262 Registration - GOG-0241
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Patient Height (cm)
Patient weight (kg)
Performance status (Zubrod)
Fully Active, Able To Carry On All Pre-
disease Performance Without
Restriction. (0)
Restricted In Physically Strenuous
Activity But Ambulatory And Able To
Carry Out Work Of A Light Or Sedentary
Nature, E.g., Light Housework, Office
Work. (1)
Ambulatory And Capable Of All Selfcare
But Unable To Carry Out Any Work
Activities. Up And About More Than 50%
Of Waking Hours. (2)
Capable Of Only Limited Selfcare,
Confined To Bed Or Chair More Than
50% Of Waking Hours. (3)
Completely Disabled. Cannot Carry On
Any Selfcare. Totally Confined To Bed Or
Chair. (4)
Has the patient had any prior cancer diagnosed?
Yes
No
Prior cancer type
Prior cancer diagnosis date (m d y)
Comments
Brief clinical history
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Breast Cancer NCT00433589 Treatment -
Chemotherapy checklist - 2499056v1.0
Chemotherapy checklist
Genetic Testing or Clinical Assessment in Determining the
Need for Chemotherapy in Women With Breast Cancer
That Involves No More Than 3 Lymph Nodes
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=1968DCB8-
C8AB-7156-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/8887
Chemotherapy checklist
Header
Patient Birth Date
Patient Hospital Number
Institution Name
Institution No.
Physician of Record
Header
Date Chemotherapy Began
Chemotherapy
Not Planned (Not planned)
Planned (Planned)
Performance Status
Fully Active, Able To Carry On All Pre-
disease Performance Without
Restriction. (0)
Restricted In Physically Strenuous
Activity But Ambulatory And Able To
Carry Out Work Of A Light Or Sedentary
Nature, E.g., Light Housework, Office
Work. (1)
Ambulatory And Capable Of All Selfcare
But Unable To Carry Out Any Work
Activities. Up And About More Than 50%
Of Waking Hours. (2)
Capable Of Only Limited Selfcare,
Confined To Bed Or Chair More Than
50% Of Waking Hours. (3)
Completely Disabled. Cannot Carry On
Any Selfcare. Totally Confined To Bed Or
Chair. (4)
Dead (5)
Has the patient had a baseline LVEF measured
by MUGA scan or echocardiogram within the past
3 months?
Yes
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No
Left Ventricular Ejection Fraction at Rest (%)
Does the patient have swallowing problems
following treatment
Yes
No
Date Informed Consent Signed
Assigned Treatment Arm
Chemotherapy Type
Chemotherapy Regimen
3 Month Anthracycline Based (3 month
anthracycline based)
6 Month/cycle Anthracycline Based (6
month/cycle anthracycline based)
6 Month/cycle Non-anthracycline
Regimen (6 month/cycle non-
anthracycline regimen)
Carboplatin And Paclitaxel (Carboplatin
and Paclitaxel)
Cisplatin And Docetaxel (Cisplatin and
Docetaxel)
Cisplatin And Gemcitabine (Cisplatin and
Gemcitabine)
Cisplatin And Vinorelbine (Cisplatin and
Vinorelbine)
Dose Dense Anthracycline (doxorubicin)
And Cyclophosphamide (ac) Therapy
(dose dense AC)
Dose Dense Anthracycline (doxorubicin)
And Cyclophosphamide (ac) Followed By
A Taxane (dose dense AC followed by a
taxane)
5-fluorouracil, Epirubicin,
Cyclophosphamide (fec) (FEC)
Intravenous Cyclophosphamide,
Methotrexate, And Fluorouracil (cmf) (IV
CMF)
Oral Cyclophosphamide, Methotrexate
And 5-fluorouracil (cmf) (Oral CMF)
Other (Other)
Other Regimen Given As Part Of A Ctsu
Adjuvant Therapy Protocol (other
regimen given as part of a CTSU
adjuvant therapy protocol)
Standard Anthracycline And
Cyclophosphamide (ac) Therapy
(standard AC)
Standard Anthracycline (doxorubicin)
And Cyclophosphamide (ac) Followed By
A Taxane (standard AC followed by a
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taxane)
Doxorubicin, Cyclophosphamide, And
Docetaxel (tac) (TAC)
Other, specify
Comments
Date
Investigator Signature
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Breast Cancer NCT00659373 Treatment - Ovarian
Function Suppression Form (Form 24-OFS) - 2080631v3.0
Ovarian Function Suppression Form (Form 24-OFS)
Brain Function in Premenopausal Women Receiving
Tamoxifen With or Without Ovarian Function Suppression
for Early-Stage Breast Cancer on Clinical Trial IBCSG-2402
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=B70C65E9-
F1BA-21F5-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/8890
Ovarian Function Suppression Form
(Form 24-OFS)
Ccrr Module For Ovarian Function
Suppression Form-revised (form 24-ofs)
Patient ID No.
Patient Initials (f m fl sl)
Patient's Date of Birth (day)
Participating Center/Affiliate
Center Code
Did patient receive Ovarian Function Suppression
(OFS) during this follow-up period
No, Will Never Start. (No, will never
start.)
No, Will Start Later, Submit With Next
Follow-up Form (No, will start later)
Yes, But Stopped Early. (Yes, but
stopped early)
Yes, Completed Per Protocol (Yes,
completed per protocol)
Yes, Continuing (Yes, continuing)
If OFS will start later, reason
Adverse Event(s), Specify (Adverse
event(s), specify)
Error (Error)
Medical Decision, Specify (Medical
decision, specify)
Other, Specify (Other, specify)
Patient Refusal (Patient refusal)
Adverse event, specify
Other, specify (OFS later)
Adverse event, specify
If stopped early or never started, reason (select
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one and sign & date at the bottom of this form -
DataFax only page 1.)
Adverse Event(s), Specify (Adverse
event(s), specify)
Death On Study (Death on study)
Error (Error)
Gnrh Analogue Failed To Suppress
Ovarian Function (GnRH analogue failed
to suppress ovarian function)
Medical Decision, Specify (Medical
decision, specify)
Other, Specify (Other, specify)
Patient Refusal (Patient refusal)
Recurrence (Recurrence)
Medical decision, specify
Medical decision, specify
Other, specify
Which method(s) of OFS did patient receive?
Bilateral ovarian radiation therapy
(Bilateral ovarian radiation therapy)
Gnrh Analogue (GnRH analogue)
Surgical Oophorectomy (Surgical
oophorectomy)
Gnrh Analogue
Agent Name
Decapeptyl (Decapeptyl)
Goserelin (Goserelin)
Other (Other)
Trelstar Depot (Trelstar Depot)
Triptorelin (Triptorelin)
Other, specify
Route of Administration
Intramuscular (Intramuscular)
Subcutaneous (Subcutaneous)
Date Agent Administered
Administered by (initials)
Batch Number
Compliance Code
Delayed For At Least One Month
(Delayed for at least one month)
Not Taken At All (Not taken at all)
Other, Specify (Other, specify)
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Taken As Per Protocol (Taken as per
protocol)
Other, specify (compliance code)
Reason not taken code
Adverse Event, Specify (Adverse event,
specify)
Other, Specify (Other, specify)
Patient Refusal (Patient refusal)
Recurrence/relapse
(Recurrence/relapse)
Adverse event, specify
Other, specify (reason not taken)
Is this the final treatment
Yes
No
Surgical Oophorectomy
Date of surgical oophorectomy (day month year)
Was the oophorectomy bilateral
Yes
No
Reason
This oophorectomy is (Report oophorectomy for
reasons other than protocol-related ovarian
function suppression on Forms 24-E and 24-
GYN.)
Initial Attempt At Ovarian Function
Suppression (Initial attempt at ovarian
function suppression)
Surgical Oophorectomy After Receiving
Failed Ovarian Radiation (Surgical
oophorectomy after receiving failed
ovarian radiation)
Surgical Oophorectomy After Receiving
Gnrh Analogue (Surgical oophorectomy
after receiving GnRH analogue)
Reason
Gnrh Failed (GnRH failed)
Other (Other)
Bilateral Ovarian Radiation Therapy
Radiation Therapy Start Date (day month year)
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Radiation Therapy End Date (day month year)
Total Dose of Radiation Therapy (cGy)
Confirmation Of Biochemical Evidence Of
Cessation Of Ovarian Function After
Ovarian Radiotherapy Is Completed.
Estradiol pmol/L
Institutional lower limit for premenopausal
(pmol/L)
Institutional upper limit for postmenopausal
(pmol/L)
Date blood drawn for this estradiol level (day
month year)
This radiation therapy is
Bilateral Ovarian Radiation Therapy After
Receiving Gnrh Analogue (Bilateral
ovarian radiation therapy after receiving
GnRH analogue)
Initial Attempt At Ovarian Function
Suppression (Initial attempt at ovarian
function suppression)
Reason
Gnrh Failed (GnRH failed)
Other (Other)
Other, specify
Investigator Signature (Designee)
Date (day month year)
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Fallopian Tube Cancer NCT01305213 Pre-Study - Fast
Fact Sheet for Protocol 0186-I (Ovary) - 3190753v1.0
Fast Fact Sheet for Protocol 0186-I (Ovary)
Bevacizumab With or Without Fosbretabulin Tromethamine
in Patients With Recurrent or Persistent Ovarian Epithelial,
Fallopian Tube, or Peritoneal Cavity Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=9BF343E9-
48AD-0577-E040-BB89AD437EA3
All rights reserved. Please visit https://medical-data-
models.org/forms/8891
Fast Fact Sheet for Protocol 0186-I
(Ovary)
Tracking Information
GOG Institution Code
GOG Affiliate Code
Previous GOG #
Treating physician
Other Physician
Patient Hospital No.
Date of Birth
Patient Last Name
Patient First Name
Patient Middle Name
Header
Did the patient sign an approved informed
consent
Yes
No
Has HIPAA authorization been obtained
Exempt - Non-usa Participant (Exempt -
non-USA participant)
Yes: C49488 (Yes)
Is the patient eligible for a higher priority GOG
protocol
Yes
No
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Is the patient under age 18?
Yes
No
What is the primary disease site
Fallopian Tube (Fallopian tube)
Ovary (Ovary)
Peritoneum (Peritoneum)
What is the cell type?
Unspecified Adenocarcinoma
(Adenocarcinoma, Unspecified)
Clear Cell Carcinoma (Clear cell
carcinoma)
Endometrioid Adenocarcinoma
(Endometrioid Adenocarcinoma)
Malignant Ovarian Brenner Tumor
(Malignant Brenners Tumor)
Mixed Epithelial Carcinoma (Mixed
Epithelial Carcinoma)
Mucinous Adenocarcinoma (Mucinous
Adenocarcinoma)
Serous Adenocarcinoma (Serous
Adenocarcinoma)
Transitional Cell Carcinoma (Transitional
Cell Carcinoma)
Undifferentiated Carcinoma
(Undifferentiated Carcinoma)
Date primary confirmed histologically
What was the grade of the primary tumor
Grade 1-well Differentiated (1)
Grade 2-moderately Differentiated (2)
Grade 3-poorly Differentiated (3)
Is the disease recurrent or persistent with
documented progression? Which one?
Persistent Disease (Persistent)
Recurrent Disease (Recurrent)
How was it established to be recurrent or
persistent?
Biopsy (Biopsy)
Non-histologic Evaluation (Non-
Histologic)
Surgical Procedure (Surgery)
Date recurrence or persistence documented?
Does the patient have measurable disease or
detectable disease?
Detectable (Detectable)
Measurable_disease (Measurable)
Does patient have measurable disease defined
as at least one lesion that can be accurately
measured in at least one dimension (longest
dimension to be recorded) using RECIST 1.1
criteria?
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No (No)
Not Applicable (Not Applicable)
Yes (Yes)
What method of evaluation is used to obtain
tumor measurements?
Computed Tomography (CT)
Magnetic Resonance Imaging (MRI)
N/a- Detectable Disease (N/A -
Detectable Disease)
Palpation (Palpatation)
X-ray (Plain X-Ray)
Spiral Ct (Spiral CT)
Is the measurable disease > or = 10 mm when
measured by CT, MRI or caliper measurement by
clinical exam; or > or = 20 mm when measured
by chest x-ray or lymph nodes > or = 15 mm in
short axis when measured by CT or MRI?
No (No)
Not Applicable (Not Applicable)
Yes (Yes)
Does the patient have at least one target lesion to
be used to assess response on this protocol as
defined by RECIST 1.1?
No (No)
Not Applicable (Not Applicable)
Yes (Yes)
Is the measurable disease in a previously
irradiated field?
No (No)
Not Applicable (Not Applicable)
Yes (Yes)
If yes, does the patient have disease in an
irradiated field as the only site of measurable
disease and has progression been documented
or a biopsy obtained to confirm persistent
disease at least 90 days following completion of
radiation treatment?
No (No)
Not Applicable (Not Applicable)
Yes (Yes)
How was detectable disease determined?
Ascites And/or Pleural Effusion
Attributed To Tumor (Ascites and/or
pleural effusion attributed to tumor)
Baseline Values Of Ca-125 At Least 2x
Uln (Baseline values of CA-125 at least
2x ULN)
Not Applicable- Measurable Disease
(Not Applicable- Measurable Disease)
Solid/cystic Abnormalities On
Radiographic Imaging That Do Not Meet
Recist 1.1 (Solid/cystic abnormalities on
radiographic imaging that do not meet
3 / 11
Fallopian Tube Cancer NCT01305213 Pre-Study - Fast Fact Sheet for
Protocol 0186-I (Ovary) - 3190753v1.0
RECIST 1.1)
Has the patient recovered from the effects of
recent surgery, radiotherapy or chemotherapy?
Yes
No
Is the patient free of acute hepatitis and active
infection requiring parenteral antibiotics with the
exception of uncomplicated urinary tract infection
(UTI)?
Yes
No
Has any hormonal therapy directed at the
malignant tumor been discontinued at least one
week prior to registration?
Yes
No
Has all other prior therapy directed at the
malignant tumor, including chemotherapy,
biologic/targeted, and immunological agents,
been discontinued for at least three weeks prior
to today?
Yes
No
Have all chimeric or human or humanized
monoclonal antibodies (including Bevacizumab)
or VEGF receptor fusion proteins (including
VEGF Trap/aflibercept) been discontinued for at
least 12 weeks prior to today?
Yes
No
Will all investigational therapy be discontinued
within 30 days prior to start of study treatment?
Yes
No
Has prior radiation therapy been discontinued for
at least four weeks prior to registration?
Yes
No
Has the patient received one prior platinum-
based chemotherapeutic regimen for
management of primary disease containing
carboplatin, cisplatin or another organoplatinum
compound (may include intraperitoneal therapy,
consolidation, non-cytotoxic agents,
biologic/targeted agents, such as Bevacizumab)
or extended therapy administered after surgical or
non-surgical assessment?
Yes
No
How many cytotoxic regimens has the patient
received for management of recurrent or
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persistent disease?
Greater Than Two Regimens (>2
regimens)
No Chemotherapy Regimens (0
Regimens)
One Chemotherapy Regimen (1
Regimen)
Two Chemotherapy Regimens (2
Regimens)
How many non-platinum, non-taxane regimens
did the patient receive for recurrent or persistent
disease?
More Than One Regimen (>1 regimen)
Zero Or One Regimen (0-1 regimens)
Has the patient received any non-cytotoxic
chemotherapy (biologic/targeted agents) for
management of recurrent or persistent disease?
Yes
No
Performance Status (Patients who have received
one prior regimen must have GOG performance
status of 0, 1 or 2; patients who have received
two or three prior regimens must must have GOG
performance status of 0 or 1)
Fully Active, Able To Carry On All Pre-
disease Performance Without
Restriction. (0)
Restricted In Physically Strenuous
Activity But Ambulatory And Able To
Carry Out Work Of A Light Or Sedentary
Nature, E.g., Light Housework, Office
Work. (1)
Ambulatory And Capable Of All Selfcare
But Unable To Carry Out Any Work
Activities. Up And About More Than 50%
Of Waking Hours. (2)
Has the patient received Bevacizumab for
management of primary disease?
Yes
No
Is the platinum-free interval from the last platinum
containing regimen greater than 6 months?
Yes
No
Did the patient have a documented recurrence
(or disease progression) following (or during) her
most recent course of platinum-based
chemotherapy?
Yes
No
What was the PFI in months (period of time
between the last dose of platinum-based
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chemotherapy and the first date of recurrence or
progression)
Pfi > 12 (PFI > 12)
Pfi > 6 And Pfi <= 12 (PFI > 6 and PFI
<= 12)
Pfi Unknown (PFI Unknown)
What method of evaluation was used to
determine that recurrence or progression?
Biopsy (Biopsy)
Ca-125 Antigen (CA-125)
Non-histologic Evaluation (Non-
Histologic)
Not Applicable - No
Recurrence/progression During Most
Recent Course (Not applicable - no
recurrence/progression during most
recent course)
Surgical Procedure (Surgery)
Date of Results (if more than one, enter earliest:)
ANC (must be 1,500/mcl or greater)
Peripheral Platelet Count (must be 100,000/mcl
or greater)
Hemoglobin (Must be greater than or equal to 9
g/dl)
Is the creatinine less than or equal to 1.5 x ULN?
Yes
No
Is the potassium greater than or equal to 4.0
mEq/L (or mmol/L)?
Yes
No
Is the magnesium greater than or equal to 1.8
mmol/L?
No (No)
No (no)
Yes (Yes)
Yes (yes)
Is the calcium greater than or equal to 8.4 mg/dL
(or 2.0 mmol/L)?
Yes
No
Is the bilirubin less than or equal to 1.5 x ULN
Yes
No
Does the patient have a urine protein of less than
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2+ on dipstick or a 24-hour urine protein of <
1000 mg (<1.0 g/24hrs)
Yes
No
Is the SGOT less than or equal to 3 X ULN
Yes
No
Is the alkaline phosphatase less than or equal to
2.5 x ULN?
Yes
No
Is the Prothrombin Time (PT) such that the
International Normalized Ratio (INR) is:
Inr Between 2 And 3 X Uln And On A
Stable Dose Of Therapeutic Warfarin
(Between 2 and 3 x ULN AND on a
stable dose of therapeutic warfarin)
Inr Greater Than 3 X Uln (Greater than 3
x ULN)
Less Than Or Equal To 1.5 X Uln (Less
than or equal to 1.5 x ULN)
Is the PTT less than or equal to 1.5 times the
institutional upper limit of normal?
Yes
No
If the patient is of childbearing potential will she
have a serum pregnancy test within 72 hours of
starting protocol therapy and has she agreed to
practice an effective form of birth control during
study treatment and for six months after
completion of treatment?
No (No)
Not Applicable (Not Applicable)
Yes (Yes)
Has the patient met the pre-entry requirements
as specified in section 7.0
Yes
No
Has the patient had prior treatment with
fosbretabulin tromethamine or any other VDA?
Yes
No
Has the patient had another invasive malignancy
other than non-melanoma of the skin, localized
cancer of the breast, head and neck or skin
diagnosed, present or recur within the past 3
years?
Yes
No
Has the patient received prior radiotherapy to any
portion of the abdominal cavity or pelvis other
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than for the treatment of ovarian, fallopian tube or
primary peritoneal cancer within the last three
years? (Prior radiation for localized cancer of the
breast, head and neck or skin is permitted as
long as it was completed more than 3 years prior
to registration and the patient remains free of
recurrent or metastatic disease)
Yes
No
Has the patient received prior chemotherapy for
any abdominal or pelvic tumor other than for the
treatment of ovarian, fallopian tube or primary
peritoneal cancer within the last three years?
(Prior adjuvant chemotherapy for localized breast
cancer is permitted provided it was completed
more than 3 years prior to registration and the
patient remains free of recurrent or metastatic
disease)
Yes
No
Is the treatment of previous cancer a
contraindication to the current protocol therapy?
Yes
No
Does the patient have a serious non-healing
wound, ulcer or bone fracture?
Yes
No
Does the patient have a history of abdominal
fistula, gastrointestinal perforation or intra-
abdominal abscess?
Yes
No
Did the abdominal fistula, gastrointestinal
perforation or intra-abdominal abscess occur
within 90 days of the first date of the therapy on
this protocol?
No (No)
Not Applicable (Not Applicable)
Yes (Yes)
Does the patient have active bleeding or
pathologic conditions that carry high risk of
bleeding such as known bleeding disorder,
coagulopathy or tumor involving major vessels?
Yes
No
Does the patient have a history or evidence upon
physical examination of CNS disease, including
primary brain tumor, seizures not controlled with
standard medical therapy or any brain
metastases?
Yes
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No
Does the patient have a history of
cerebrovascular accident (CVA, stroke), transient
ischemic attack (TIA) or subarachnoid
hemorrhage within six months of the first date of
study therapy?
Yes
No
Does the patient have uncontrolled hypertension
defined as systolic greater than 150 mm Hg or
diastolic greater than 90 mm Hg despite anti-
hypertensive therapy?
Yes
No
Does the patient have a history of torsade de
pointes, ventricular tachycardia or fibrillation,
pathologic sinus bradycardia (<60 bpm), heart
block (1st degree block, being, PR interval
prolongation only), congenital long QT syndrome,
new ST segment elevation or depression or new
Q waves on ECG?
Yes
No
Does the patient require any drug known to
prolong QTc interval, including anti-arrhythmic
medication?
Yes
No
Is the QTc interval greater than or equal to 470
msec?
Yes
No
Has the patient had a myocardial infarction or
unstable angina within 6 months of the first date
of study therapy?
Yes
No
Using the New York Heart Association (NYHA)
guideline, does the patient have Class II or
greater congestive heart failure?
Yes
No
Has the patient had clinically significant
cardiovascular disease
Yes
No
Does patient have serious cardiac arrhythmia
requiring medication (except for asymptomatic
atrial fibrillation with controlled ventricular rate)?
Yes
No
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Has the patient received prior treatment with an
anthracycline? (including Doxorubicin or
Pegylated liposomal Doxorubicin [Doxil, PLD])
Yes
No
If yes, has the patient had an echocardiogram
assessment and is the LVEF less than 50%?
No (No)
Not Applicable (Not Applicable)
Yes (Yes)
Does the patient have CTCAE Grade 2 or greater
peripheral vascular disease? (Note: at least brief
less than 24 hours episodes of ischemia
managed non-surgically and without permanent
deficit.)
Yes
No
Does the patient have known hypersensitivity to
any components of fosbretabulin tromethamine or
bevacizumab?
Yes
No
Has the patient had a major surgical procedure
within 28 days prior to the first date of treatment
on this study?
Yes
No
Is a major surgical procedure anticipated for this
patient during the course of this study
Yes
No
Will a core biopsy be done within 7 days prior to
the start of study drug?
Yes
No
Does the patient have clinical symptoms or signs
of gastrointestinal obstruction and require
parenteral hydration and/or nutrition
Yes
No
Does the patient have any condition which in the
investigator's opinion makes the patient
unsuitable for study participation?
Yes
No
Is the patient pregnant or nursing?
Yes
No
Anticipated date treatment will start
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Comments
Provide comments about this Fast Fact Sheet
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Leukemia, Myelocytic, Acute null Treatment
- ENR - 2395563v3.0
ENR
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=FF19AF22-
C849-2763-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/8892
ENR
Aml T Cell Depletion - Segment A
Record date patient informed consent form was
signed
Record donor's birthdate
Record the proposed start date of conditioning
Patient Inclusion Criteria
Does the patient meet the World Health
Organizations (WHO) criteria for do novo AML
Yes
No
Is there any evidence of extramedullary leukemia
Yes
No
Is there any evidence of a persistently abnormal
leaukemia population by flow cytometry
Yes
No
If yes, is there any evidence of leukemia blasts in
the CSF
Yes
No
Indicate the number of cycles of infuction
chemotherapy (or in0induction for patients in 2nd
CR) the patient received to achieve first or
second complete remission
One prior cycle (One prior cycle)
Two prior cycles (Two prior cycles)
If an adequate bone marrow aspirate was not
perforned, was a bone marrow biopsy performed
within 4 weeks prior to the proposed conditioning
date
Yes
No
Does the patient have a history of CNS
involvement
Yes
No
Indicate the number of consolidation therapies
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the patient received prior to transplant (any
consolidation regimen that does not require
transplantation for hematopoetic recovery can be
used)
More than one cycle (More than one
cycle)
One cycle (One cycle)
Was an adequate bone marrow aspirate
performed within 4 weeks prior to the proposed
conditioning date
Yes
No
Record the date the most recent complete
remission
Record the patients most recent complete
remission stage
First morphologic CR (First morphologic
CR)
Second morphologic CR (Second
morphologic CR)
Were Auer rods present
Yes
No
Date of most recent bone marrow aspirate
If yes, record the percentage of blasts in most
recent biopsy
If yes, record the percentage of blasts in most
recent biopsy
Date of bone marrow biopsy
Record the patients Karnofsky performance
status
Moribund, Fatal Processes Progressing
Rapidly (10 (Moribund; completely
disabled))
Normal, No Complaints, No Evidence Of
Disease (100 (Normal; no
complaints/fully active_)
Very Sick, Hospitalization Indicated.
Death Not Imminent (20 (Very
sick/limited to very passive activity))
Severely Disabled, Hospitalization
Indicated. Death Not Imminent (30
(severely disabled/needs assistance for
quiet play))
Disabled, Requires Special Care And
Assistance (40 (Disabled/needs
assistance for quiet play))
Requires Considerable Assistance And
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Frequent Medical Care (50 (Requires
considerable assistance/no active play))
Requires Occasional Assistance, But Is
Able To Care For Most Of His/her Needs
(60 (Requires occasional
assistance/minimal active play))
Cares For Self, Unable To Carry On
Normal Activity Or To Do Active Work
(70 (Unable to carry on normal
activity/less time spent at play))
Normal Activity With Effort; Some Signs
Or Symptoms Of Disease (80 (Normal
activity with effort/restricted to strenuous
play))
Able To Carry On Normal Activity; Minor
Signs Or Symptoms Of Disease (90
(Normal activity/minor restrictions in
strenuous play))
Left Ventricular Ejection Fraction
ULN for your institution
Most recent value
Date of assessment
Bilirubin
Most recent value
ULN for your institution
Date of assessment
Alt
ULN for your institution
Most recent value
Date of assessment
Ast
Most recent value
ULN for your institution
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Date of assessment
Serum Creatinine
Most recent value
ULN for your institution
Date of assessment
Dlco (corrected For Hemoglobin)
ULN for your institution
Most recent value
Date of assessment
Patient Exclusion Criteria
Is the patient doagnosed with M3-AML (acute
promyelocytic leukemia and in first complete
remission)
Yes
No
Does the patient have a documented allergy to
iron dextran or murine proteins and rabbit
antithymocyte globulin
Yes
No
No
Does the patients have evidence of active
Hepatitis B or C infection or evidence of cirrhosis
Yes
No
Does the patient have a history of cytopenia
consistent with diagnoses of myelodysplastic
syndrome (MDS) for more then 3 months prior to
the diagnosis of Aml or does the patient have
reatments-related AML
Yes
No
Has the patient had a prior allogeneic or
autologous transplant
Yes
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No
Is the patient participating in other clinical trails
that involve investigational drugs or devices
No (No)
Yes (Yes)
Yes, approved by medical monitor (Yes,
approved by medical monitor)
Is the patient diagnosed with AML with t(8;21)
and in first complete remission
Yes
No
Is the patient diagnosed with acute leukemia
following blast transformation of prior chronic
myelogenous leukemia (CML) or other
myeloproliferative disease
Yes
No
Is the patient diagnosed with M4Eo-AML with inv
16 and in first complete remission
Yes
No
Date approved by medical monitor
Is the patient HIV seropositive
Yes
No
Does the patient have uncontrolled diabetes
mellitus
Yes
No
Is the patient diagnosed with an uncontrolled
viral, bacterial, or fungal infection
Yes (Yes)
Is the donor pregant (positive serum or unie B-
HCG) or breastfeeding
No, And Not Nursing (No)
Not applicable (Not applicable)
Yes (Yes)
Donor Inclusion Criteria
Is the donor seronegative for syphilis within 30
days fo apheresis collection
Yes
No
Does the donoe have any factors which place
him-her at increase rick for complications from
leukopharesis of G-CSF therapy (e.g.,
autoimmune disease, sickle cell trait,
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symptomatic coronary artery disease requiring
therapy)
Yes
No
Does the donor have evidence of active infection
(including urinary tract infection or respiratory
tract infection) or viral hepatitis exposure (on
screeninig), unless only HBs, AB+ and HBV DNA
negative
Yes
No
Does the donor have adequate veins for
leukapheresis or agress to placement fo a central
catheter
Yes
No
Is the donor agreeable to undergo general
anesthesia and bone marrow donation, if
necessary
Yes
No
Is the donor agreeable to second donation of
PBSC in the event of graft failure of EBV-related
lymphopropliferative diesase, if necessary
Yes
No
Record date donor centent was signed
Record donor's birthdate
Record donor's weight
Is the donor HIV seronegative within 30 days of
apheresis collection
Yes
No
Is the donor seronegative for hepatitis B surface
antigen within 30 days of apheresis collection
Yes
No
Is the donor seronegative for hepatitis C within 30
days of apheresis collection
Yes
No
Is the donor pregant (positive serum or unie B-
HCG) or breastfeeding
No, And Not Nursing (No)
Not applicable (Not applicable)
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Yes (Yes)
Hla Typing
Type of HLA Match required by this protocol
High level DNA (High level DNA)
Loci A, B: low level DNA, locus DRB1:
high level DNA (Loci A, B: low level DNA,
locus DRB1: high level DNA)
Loci A, B: serologic, locus DRB1, low
level DNA (Loci A, B: serologic, locus
DRB1, low level DNA)
Loci A, B: serologic; locus DRB1: high
level DNA (Loci A, B: serologic; locus
DRB1: high level DNA)
Low level DNA (Low level DNA)
Serologic (Serologic)
Recipient Hla Typing
Hla-a
Antigens/alleles provided
One (One)
Two (Two)
1st
2nd
Typing method
Dna (DNA technology)
Serology (Serology)
Hla-b
Antigens/alleles provided
One (One)
Two (Two)
1st
2nd
Typing method
Dna (DNA technology)
Serology (Serology)
Hla-c
1st
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2nd
Hla-drb1
Antigens/alleles provided
One (One)
Two (Two)
1st
2nd
Typing method
Dna (DNA technology)
Serology (Serology)
Donor Hla Typing
Hla-a
Antigens/alleles provided
One (One)
Two (Two)
1st
2nd
Typing method
Dna (DNA technology)
Serology (Serology)
Hla-b
Antigens/alleles provided
One (One)
Two (Two)
1st
2nd
Typing method
Dna (DNA technology)
Serology (Serology)
Hla-c
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1st
2nd
Hla-drb1
Locus-B calculated HLA Match score
Total calculated HLA Match score
Locus-DRB1 calculated HLA Match score
Indicate your institution's HLA Match score for
this participant
0/6 (0/6)
1/6 (1/6)
2/6 (2/6)
3/6 (3/6)
4/6 (4/6)
5/6 (5/6)
6/6 (6/6)
Locus-A calculated HLA Match score
HLA Match score required by this protocol
2nd
1st
Antigens/alleles provided
One (One)
Two (Two)
Do you agree with the calculated HLA Match
score
Yes
No
Typing method
Dna (DNA technology)
Serology (Serology)
Comments
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Adenocarcinoma of the Gastroesophageal Junction NCT01196390
Demographic - RTOG 1010 Demographic Data Form (A5) - 3085100v1.0
RTOG 1010 Demographic Data Form (A5)
Radiation Therapy, Paclitaxel, and Carboplatin With or
Without Trastuzumab in Treating Patients With Esophageal
Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=8666BB88-
BFD1-08B9-E040-BB89AD434AC6
All rights reserved. Please visit https://medical-data-
models.org/forms/8896
RTOG 1010 Demographic Data
Form (A5)
Header
RTOG Study No.
Case #
Institution Name
Institution No.
Patient Initials
RTOG Patient ID
Unnamed2
Date Completed (mm-dd-yyyy)
Amended Data
Yes
No
Who completed this form (Check one box)
Not Applicable, No Items Completed (Not
applicable, no items completed)
Other Person (Other person)
Self (Self)
Staff (Staff)
Patient Race Category (Check all that apply)
A Person Having Origins In Any Of The
Original Peoples Of North And South
America (including Central America),
And Who Maintains Tribal Affiliation Or
Community Attachment. (American
Indian or Alaska Native)
A Person Having Origins In Any Of The
Original Peoples Of The Far East,
Southeast Asia, Or The Indian
Subcontinent Including, For Example,
Cambodia, China, India, Japan, Korea,
Malaysia, Pakistan, The Philippine
Islands, Thailand, And Vietnam. (Asian)
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A Person Having Origins In Any Of The
Black Racial Groups Of Africa. Terms
Such As "haitian" Or "negro" Can Be
Used In Addition To "black Or African
American." (Black or African American)
A Person Having Origins In Any Of The
Original Peoples Of Hawaii, Guam,
Samoa, Or Other Pacific Islands. (Native
Hawaiian or other Pacific Islander)
Not Provided Or Available (Not
Reported)
Could Not Be Determined Or Unsure
(Unknown)
A Person Having Origins In Any Of The
Original Peoples Of Europe, The Middle
East, Or North Africa. (White)
Patient Ethnic Group Cateogy (Check one box)
A Person Of Mexican, Puerto Rican,
Cuban, Central Or South American Or
Other Spanish Culture Or Origin,
Regardless Of Race. (HISPANIC OR
LATINO)
A Person Not Meeting The Definition For
Hispanic Or Latino. (NOT HISPANIC OR
LATINO)
Not Provided Or Available (Not reported)
Could Not Be Determined Or Unsure
(UNKNOWN)
Highest school grade completed (Check one box)
8th Or Less (8th or less)
9 - 11th Grade (9 - 11th Grade)
Advanced Degree (Advanced degree)
Associate Degree / Some College
(Associate degree/some college)
Bachelor's Degree (Bachelor's degree)
High School Graduate / Ged (High
school graduate/GED)
I Prefer Not To Answer (I prefer not to
answer)
Other (Other)
Vocational / Technical School
(Vocational/technical school)
Other, specify
Religion during childhood (Check one box)
Catholic (Catholic)
I Prefer Not To Answer (I prefer not to
answer)
Jewish (Jewish)
Morman/latter Day Saints
(Morman/Latter Day Saints)
Muslim / Islam (Muslim/Islam)
None (None)
Other (Other)
Protestant (Protestant)
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Other, specify
Marital status (Check one box)
Divorced (Divorced)
Domestic Partnership (Domestic
Partnership)
I Prefer Not To Answer (I prefer not to
answer)
Married (Married)
Never Married (Never married)
Separated (Separated)
Widowed (Widowed)
Where were you born (Check one box Check the
box of the country where you were born)
Other Country (Other country)
Usa (USA)
USA, specify the 2 letter State code (eg NY)
Other country, specify
Where did you live the longest (Check one box)
Other Country (Other country)
Usa (USA)
USA, specify the 2 letter State code (eg NY)
Other country, specify
Cigarette History
Smoked at least 100 cigarette during lifetime (5
packs)
No (0)
Yes, But Quit (1)
Yes, Currently Smoke (2)
Age began smoking cigarettes
Number of years smoked cigarettes
Average number of cigarettes smoked per day
If quit, age stopped smoking completely
If you have had any of the illnesses listed below,
please check yes for those that apply (check =
Yes)
Heart Problems (1)
Thyroid Problems (10)
Seizure (11)
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Hiv/aids (12)
Frequent Infections (13)
Psychological Problems (14)
Other (15)
Lung Problems (2)
High Blood Pressure (3)
Bleeding Problems (4)
Circulation Problems (5)
Liver Problems (6)
Diabetes Or Sugar In Urine (7)
Kidney/urine Problems (8)
Stroke (9)
Specify other
Family History
How many brothers do you have (How many of
the following family members living and dead do
you have? Include only those who are blood-
related)
How many sisters do you have (How many of the
following family members living and dead do you
have? Include only those who are blood-related)
How many sons do you have (How many of the
following family members living and dead do you
have? Include only those who are blood-related)
How many daughters do you have (How many of
the following family members living and dead do
you have? Include only those who are blood-
related)
Are you adopted (Check one In 10C; complete
the question only for your children; omit mother,
father, sisters, brothers)
Yes
No
Blood relative with cancer (check = yes)
Brother #1 (Brother #1)
Brother #2 (Brother #2)
Brother #3 (Brother #3)
Brother #4 (Brother #4)
Child #1 (Child  #1)
Child #2 (Child  #2)
Child #3 (Child  #3)
Child #4 (Child  #4)
Father (Father)
Mother (Mother)
Sister #1 (Sister  #1)
Sister #2 (Sister  #2)
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Sister #3 (Sister  #3)
Sister #4 (Sister  #4)
Age when first cancer diagnosed
Type of Cancer (check = yes)
Breast (Breast)
Colon (Colon)
Head & Neck (Head & Neck)
Lung (Lung)
Non Melanoma Skin (Non Melanoma
Skin)
Other (Other)
Prostate (Prostate)
Specify
Have you ever heard of Cancer Prevention Trials
(Check one box By Cancer Prevention Trials we
mean studies in which healthy people, including
cured cancer patients, volunteer to take part in
experimental cancer prevention, such as the use
of special diets and new drugs. People volunteer
in order to obtain the newest prevention for
themselves and to help scientists learn how well
the new prevention methods work)
Yes
No
How likely would you be to volunteer to
participate in Cancer Prevention Trials (The
numbers below allow you to rate your answer
between 1 - never and 10 - extremely likely. Circle
the number below that best describes your
choice.)
1 (1)
10 (10)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
7 (7)
8 (8)
9 (9)
5 / 5
Adenocarcinoma of the Gastroesophageal Junction NCT01196390
Demographic - RTOG 1010 Demographic Data Form (A5) - 3085100v1.0
Registration - 2804 Revision 3 - CIBMTR
Recipient ID Assignment Form - 3113592v1.0
2804 Revision 3 - CIBMTR Recipient ID Assignment Form
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=89B7CC18-
3E3B-B38F-E040-BB89AD433571
All rights reserved. Please visit https://medical-data-
models.org/forms/8897
2804 Revision 3 - CIBMTR Recipient
ID Assignment Form
Identification Data
CIBMTR Center Number:
Today's date:
Recipient Date
What is the indication for CIBMTR recipient ID
(CRID) assignment?
Cellular Therapy Regenerative Medicine
(Cellular therapy for regenerative
medicine)
Hematopoietic Stem Cell Transplantation
(HSCT)
Mds Negation Hematopoietic Stem Cell
Transplantation Therapeutic Procedure
(Non-transplant therapy for MDS)
Other (Other)
Specify other indication for CRID assignment:
Recipient Data Part 2 Of 3
Is the recipient participating in any clinical trials?
(To facilitate FormsNet validation, this CDE is
included in the repeating module.)
Yes
No
Specify the group that is administering the clinical
trial:
Bmt Ctn (BMT CTN)
Other (Other)
Rci Bmt (RCI BMT)
 Specify other group:
Study ID number:
Recipient Data Part 3 Of 4
Has your center designated the CIBMTR to store
and create a data set? (For autologous HSCTs
only.)
1 / 12
Yes
No
Has the recipient given written consent to allow
his / her transplant data to be used for research?
(For autologous HSCTs only.)
Yes
No
First Name
Last Name
Recipient date of birth: (For autologous HSCTs at
centers that are not using the CIBMTR as their
data repository and the recipient has not given
consent to allow his / her transplant data to be
used for research, report year of birth only.)
City: (Recipient location of birth.)
State: (Recipient location of birth.)
Alabama (Alabama)
Alaska (Alaska)
Arizona (Arizona)
Arkansas (Arkansas)
California (California)
Colorado (Colorado)
Connecticut (Connecticut)
Delaware (Delaware)
District Of Columbia (District of
Columbia)
Florida (Florida)
Georgia (Georgia)
Hawaii (Hawaii)
Idaho (Idaho)
Illinois (Illinois)
Indiana (Indiana)
Iowa (Iowa)
Kansas (Kansas)
Kentucky (Kentucky)
Louisiana (Louisiana)
Maine (Maine)
Maryland (Maryland)
Massachusetts (Massachusetts)
Michigan (Michigan)
Minnesota (Minnesota)
Mississippi (Mississippi)
Missouri (Missouri)
Montana (Montana)
Nebraska (Nebraska)
Nevada (Nevada)
New Hampshire (New Hampshire)
New Jersey (New Jersey)
New Mexico (New Mexico)
New York (New York)
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North Carolina (North Carolina)
North Dakota (North Dakota)
Ohio (Ohio)
Oklahoma (Oklahoma)
Oregon (Oregon)
Pennsylvania (Pennsylvania)
Rhode Island (Rhode Island)
South Carolina (South Carolina)
South Dakota (South Dakota)
Tennessee (Tennessee)
Texas (Texas)
Utah (Utah)
Vermont (Vermont)
Virginia (Virginia)
Washington (Washington)
West Virginia (West Virginia)
Wisconsin (Wisconsin)
Wyoming (Wyoming)
Country: (Recipient location of birth.)
Afghanistan (Afghanistan)
Aland Islands (Aland Islands)
Albania (Albania)
Algeria (Algeria)
American Samoa (American Samoa)
Andorra (Andorra)
Angola (Angola)
Anguilla (Anguilla)
Antarctica (Antarctica)
Antigua And Barbuda (Antigua and
Barbuda)
Argentina (Argentina)
Armenia (Armenia)
Aruba (Aruba)
Australia (Australia)
Austria (Austria)
Azerbaijan (Azerbaijan)
Bahamas (Bahamas)
Bahrain (Bahrain)
Bangladesh (Bangladesh)
Barbados (Barbados)
Belarus (Belarus)
Belgium (Belgium)
Belize (Belize)
Benin Republic (Benin Republic)
Bermuda (Bermuda)
Bhutan (Bhutan)
Bolivia (Bolivia)
Bosnia-herzegovina (Bosnia and
Herzegovinia)
Botswana (Botswana)
Bouvet Island (Bouvet Island)
Brazil (Brazil)
British Indian Ocean Territory (British
Indian Ocean Territory)
British Virgin Islands (British Virgin
Islands)
Brunei Darussalam (Brunei Darussalam)
Bulgaria (Bulgaria)
Burkina Faso (Burkina Faso)
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Burundi (Burundi)
Cambodia (Cambodia)
Cameroon (Cameroon)
Canada (Canada)
Cape Verde (Cape Verde)
Cayman Islands (Cayman Islands)
Central African Republic (Central African
Republic)
Chad (Chad)
Chile (Chile)
China (China)
Christmas Island (Christmas Island)
Cocos (keeling) Islands (Cocos (Keeling)
Islands)
Colombia (Colombia)
Comoros (Comoros)
Congo (Congo)
Congo, The Democratic Republic Of The
(Congo, the Democratic Republic of the)
Cook Islands (Cook Islands)
Costa Rica (Costa Rica)
Cote D'ivoire (Cote d'Ivoire)
Croatia (Croatia)
Cuba (Cuba)
Cyprus (Cyprus)
Czech Republic (Czech Republic)
Denmark (Denmark)
Djibouti (Djibouti)
Dominica (Dominica)
Dominican Republic (Dominican
Republic)
Ecuador (Ecuador)
Egypt (Egypt)
El Salvador (El Salvador)
Equatorial Guinea (Equatorial Guinea)
Eritrea (Eritrea)
Estonia (Estonia)
Ethiopia (Ethiopia)
Falkland Islands (Falkland Islands)
Faroe Islands (Faroe Islands)
Fiji (Fiji)
Finland (Finland)
France (France)
French Guiana (French Guiana)
French Polynesia (French Polynesia)
French Southern Territories (French
Southern Territories)
Gabon (Gabon)
Gambia (Gambia)
Georgia (Georgia)
Germany (Germany)
Ghana (Ghana)
Gibraltar (Gibraltar)
Greece (Greece)
Greenland (Greenland)
Grenada (Grenada)
Guadeloupe (Guadeloupe)
Guam (Guam)
Guatemala (Guatemala)
Guernsey (Guernsey)
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Guinea (Guinea)
Guinea-bissau (Guinea-Bissau)
Guyana (Guyana)
Haiti (Haiti)
Heard Island And Mcdonald Islands
(Heard Island and McDonald Islands)
Holy See (Holy See)
Honduras (Honduras)
Hong Kong (Hong Kong)
Hungary (Hungary)
Iceland (Iceland)
India (India)
Indonesia (Indonesia)
Iran (Iran)
Iraq (Iraq)
Ireland (Ireland)
Isle Of Man (Isle of Man)
Israel (Israel)
Italy (Italy)
Jamaica (Jamaica)
Japan (Japan)
Jersey (Jersey)
Jordan (Jordan)
Kazakhstan (Kazakhstan)
Kenya (Kenya)
Kiribati (Kiribati)
Kuwait (Kuwait)
Kyrgyzstan (Kyrgyzstan)
Lao People's Democratic Republic (Lao
People's Democratic Republic)
Latvia (Latvia)
Lebanon (Lebanon)
Lesotho (Lesotho)
Liberia (Liberia)
Libyan Arab Jamahiriya (Libyan Arab
Jamahiriya)
Liechtenstein (Liechtenstein)
Lithuania (Lithuania)
Luxembourg (Luxembourg)
Macau (Macau)
Republic Of Macedonia (Macedonia)
Madagascar (Madagascar)
Malawi (Malawi)
Malaysia (Malaysia)
Maldives (Maldives)
Mali (Mali)
Malta (Malta)
Marshall Islands (Marshall Islands)
Martinique (Martinique)
Mauritania (Mauritania)
Mauritius (Mauritius)
Mayotte (Mayotte)
Mexico (Mexico)
Micronesia (Micronesia)
Moldova (Moldova)
Monaco (Monaco)
Mongolia (Mongolia)
Montenegro (Montenegro)
Montserrat (Montserrat)
Morocco (Morocco)
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Mozambique (Mozambique)
Myanmar (Myanmar)
Namibia (Namibia)
Nauru (Nauru)
Nepal (Nepal)
Netherlands (Netherlands)
Netherlands Antilles (Netherlands
Antilles)
New Caledonia (New Caledonia)
New Zealand (New Zealand)
Nicaragua (Nicaragua)
Niger (Niger)
Nigeria (Nigeria)
Niue (Niue)
Norfolk Island (Norfolk Island)
North Korea (North Korea)
Northern Mariana Islands (Northern
Mariana Islands)
Norway (Norway)
Oman (Oman)
Pakistan (Pakistan)
Palau (Palau)
Palestinian Territory, Occupied
(Palestinian Territory, Occupied)
Panama (Panama)
Papua New Guinea (Papua New Guinea)
Paraguay (Paraguay)
Peru (Peru)
Philippines (Philippines)
Pitcairn (Pitcairn)
Poland (Poland)
Portugal (Portugal)
Puerto Rico (Puerto Rico)
Qatar (Qatar)
Reunion (Reunion)
Romania (Romania)
Russia (Russia)
Rwanda (Rwanda)
Saint Barthelemy (Saint Barthelemy)
Saint Helena (Saint Helena)
Saint Kitts And Nevis (Saint Kitts and
Nevis)
Saint Lucia (Saint Lucia)
Saint Martin, French (Saint Martin,
French)
Saint Pierre And Miquelon (Saint Pierre
and Miquelon)
Saint Vincent And The Grenadines
(Saint Vincent and the Grenadines)
Samoa (Samoa)
San Marino (San Marino)
Sao Tome And Principe (Sao Tome and
Principe)
Saudi Arabia (Saudi Arabia)
Senegal (Senegal)
Serbia (Serbia)
Seychelles (Seychelles)
Sierra Leone (Sierra Leone)
Singapore (Singapore)
Slovakia (Slovak Republic)
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Slovenia (Slovenia)
Solomon Islands (Solomon Islands)
Somalia (Somalia)
South Africa (South Africa)
South Georgia And The South Sandwich
Islands (South Georgia and the South
Sandwich Islands)
South Korea (South Korea)
Spain (Spain)
Sri Lanka (Sri Lanka)
Sudan (Sudan)
Suriname (Suriname)
Svalbard And Jan Mayen (Svalbard and
Jan Mayen)
Swaziland (Swaziland)
Sweden (Sweden)
Switzerland (Switzerland)
Syria (Syrian Arab Republic)
Taiwan (Taiwan)
Tajikistan (Tajikistan)
Tanzania (Tanzania)
Thailand (Thailand)
East Timor (Timor-Leste)
Togo (Togo)
Tokelau (Tokelau)
Tonga (Tonga)
Trinidad And Tobago (Trinidad and
Tobago)
Tunisia (Tunisia)
Turkey (Turkey)
Turkmenistan (Turkmenistan)
Turks And Caicos Islands (Turks and
Caicos Islands)
Tuvalu (Tuvalu)
Uganda (Uganda)
Ukraine (Ukraine)
United Arab Emirates (United Arab
Emirates)
United Kingdom (United Kingdom
(England, Wales, Scotland, Northern
Ireland))
United States (United States)
United States Minor Outlying Islands
(United States Minor Outlying Islands)
United States Virgin Islands (United
States Virgin Islands)
Uruguay (Uruguay)
Uzbekistan (Uzbekistan)
Vanuatu (Vanuatu)
Venezuela (Venezuela)
Vietnam (Vietnam)
Wallis And Futuna Islands (Wallis and
Futuna Islands)
Western Sahara (Western Sahara)
Yemen (Yemen)
Zambia (Zambia)
Zimbabwe (Zimbabwe)
Recipient Gender:
Female (female)
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Male (male)
Recipient Social Security number:
If necessary, please validate the Social Security
number response:
Not Applicable (Not applicable)
Recipient NMDP ID:
If necessary, please validate patient identifier
response.
Not Applicable (Not applicable)
Recipient EBMT ID:
EBMT CIC:
If necessary, please validate the recipient
IUBMID and / or Team ID response.
Not Applicable (Not applicable)
Recipient Date
Recipient IUBMID: (Former CIBMTR #)
Team ID: (Former CIBMTR #)
Recipient's mother's maiden name: (Optional for
non-U.S. centers)
Tentative infusion date:
If necessary, please validate the recipient
IUBMID and / or Team ID response.
Not Applicable (Not applicable)
Recipient Date
Cell source for the HSCT: (Planned)
Related Allogenic (Allogeneic, related)
Unrelated Allogenic (Allogeneic,
unrelated)
Autologous (Autologous)
Syngeneic (Syngeneic (identical twin))
Was a particular hematopoietic stem cell source
used?
Yes
No
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Hematopoietic Stem Cell Transplant Date
Part 2 Of 4
Product type (Planned)
Umbilical Cord Blood (Cord blood)
Bone Marrow (Marrow)
Multiple Umbilical Cord Blood (Multiple
cord blood units infused)
Other (Other)
Peripheral Blood Stem Cell (PBSC)
Was a particular hematopoietic stem cell
transplant type used?
Yes
No
Specify other product: (Answer only if the
response to CDE 2730912 is "Other.")
Hematopoietic Stem Cell Transplant Part 3
Of 4
Primary disease for which the HSCT would be
performed:
All (Acute lymphoblastic leukemia (ALL))
Acute Myeloid Leukemia (Acute
myelogenous leukemia (AML or ANLL))
Autoimmune Disease (Autoimmune
Disorder)
Breast Carcinoma (Breast Cancer)
Chronic Myelogenous Leukemia
(Chronic myelogenous leukemia (CML))
Histiocytic Disorders (Histiocytic
disorders)
Hodgkin's Lymphoma (Hodgkin
lymphoma)
Immunodeficiency Syndrome (Immune
deficiencies)
Congenital Abnormalities Of Erythrocyte
Differentiation Or Function (Inherited
abnormalities of erythrocyte
differentiation or function)
Congenital Metabolic Disorder
Osteopetrosis (Inherited disorders of
metabolism / osteopetrosis)
Plasma Cell Myeloma (Multiple myeloma
/ plasma cell disorder (PCD))
Myelodysplastic/myeloproliferative
Disease (Myelodysplastic (MDS) /
myeloproliferative (MPS) disorders)
Non-hodgkin's Lymphoma (Non-Hodgkin
lymphoma)
Other Acute Leukemia (Other acute
leukemia)
Other Diseases And Disorders (Other
disease)
Other Leukemia (Other leukemias)
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Other Malignant Neoplasm (Other
malignancies)
Platelet Diseases And Disorders
(Platelet disorder)
Severe Aplastic Anemia (Severe aplastic
anemia)
Hematopoietic Stem Cell Transplant Part 4
Of 4
Is this the first HSCT for this recipient? (Do not
include donor cellular infusions. To facilitate
FormsNet validation, this CDE is included in the
repeating module.)
Yes
No
Date of previous HSCT:
Autologous (Cell sources for previous HSCT.)
Yes
No
Allogeneic, unrelated (Cell sources for previous
HSCT.)
Yes
No
Allogeneic, related (Cell sources for previous
HSCT.)
Yes
No
Syngeneic (Identical twin. Cell sources for
previous HSCT.)
Yes
No
Bone marrow (Product types for previous HSCT.)
Yes
No
Peripheral blood stem cells (PBSC. Product types
for previous HSCT.)
Yes
No
Umbilical cord blood (Product types for previous
HSCT.)
Yes
No
Recipient Data Part 4 Of 4
Indication for cellular therapy:
Autoimmune Disease (Autoimmune
disease)
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Cardiovascular And Peripheral Vascular
Disorder Disease Or Disorder (Cardio
and peripheral vascular disease)
Musculoskeletal Disease Or Disorder
(Musculoskeletal  disease)
Neurologic Disease Or Disorder
(Neurologic  disease)
Other (Other)
Specify other indication for cellular therapy:
Is this the first application of cellular therapy for
this indication?
Yes
No
Author Information
First Name
Telephone number:
Last Name
Fax number:
E-mail address:
Form Processing
CIBMTR Recipient ID (CRID):
Search result:
Exact Match (Exact match)
Mismatch (Inexact match)
Multiple Exact Match (Multiple exact
matches)
Negation Match (No match)
Not Applicable (Not applicable)
CRID processing result:
Identification Number Creation (CRID
created)
Negation Identification Number Creation
(No CRID created)
Not Applicable (Not applicable)
Form processing result :
2400 Already Started For Another Date
(2400 Already started for another date)
2400 Already Started For Requested
Date (2400 Already started for requested
date)
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2400 Made Due (2400 Made due)
Hematopoietic Stem Cell Transplantation
Date Revision (HSCT date updated)
Not Applicable (Not applicable)
Unable To Schedule Forms For Other
Transplant Center (Unable to schedule
forms for other Transplant Center)
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Lung Cancer NCT00049543 Off Treatment -
Emergency Unblinding Form - 2279706v3.0
Emergency Unblinding Form
Gefitinib in Treating Patients With Non-Small Cell Lung
Cancer That Has Been Surgically Removed
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=D98AA788-
C380-49AB-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/8898
Emergency Unblinding Form
1. Patient Information
Patient Study ID, Coordinating Group (NCIC CTG
Patient Serial Number)
Patient Initials
Patient Medical Record Number
Investigator Name
Institution Name
Registered Investigator (NCI Investigator #)
2. Unblinding Information
Was study treatment unblinded?
Yes
No
Date study treatment unblinded (If yes,)
Reason for unblinding
3. Signature
Investigator Signature
Date of Investigator Signature
Person Completing Form, Last Name
Person Completing Form, First Name
Form Completion Date, Original
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Ovarian Cancer NCT00993655 Eligibility - NCIC
OV 21 Eligibility Worksheet Form - 2888929v1.0
NCIC OV 21 Eligibility Worksheet Form
Comparing Three Combination Chemotherapy Regimens in
Treating Patients With Stage IIB, Stage IIC, Stage III, or
Stage IV Ovarian Epithelial Cancer, Primary Peritoneal
Cancer, or Fallopian Tube Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=6AC1EB4E-
A50F-6962-E040-BB89AD430850
All rights reserved. Please visit https://medical-data-
models.org/forms/8899
NCIC OV 21 Eligibility Worksheet
Form
Patient Information
NCIC Patient ID (NCIC CTG Patient Serial
Number issued at the time of randomization)
Patient Initials (first-middle-last)
Patient Hospital No. (if permitted by REB)
Investigator No.
Investigator First Name
Investigator Middle Name
Investigator Last Name
Eligibility Worksheet
Surgery Date
Date Prior Neoadjuvant Chemotherapy Ended
ECOG performance status (PS) 0, 1, or 2
Yes
No
Date of evaluation
ECOG Performance Status
Fully Active, Able To Carry On All Pre-
disease Performance Without
Restriction. (0)
Restricted In Physically Strenuous
Activity But Ambulatory And Able To
Carry Out Work Of A Light Or Sedentary
Nature, E.g., Light Housework, Office
Work. (1)
Ambulatory And Capable Of All Selfcare
But Unable To Carry Out Any Work
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Activities. Up And About More Than 50%
Of Waking Hours. (2)
Capable Of Only Limited Selfcare,
Confined To Bed Or Chair More Than
50% Of Waking Hours. (3)
Completely Disabled. Cannot Carry On
Any Selfcare. Totally Confined To Bed Or
Chair. (4)
Age >= 18 years
Yes
No
Life expectancy >3 months
Yes
No
Eligibility Labs
Were hematology and biochemistry done within 7
days prior to randomization
Yes
No
Absolute Granulocyte Count
Peripheral Platelet Count
Serum Creatinine
Date of evaluation
Creatinine Clearance (Measured)
Total Bilirubin
SGOT
SGPT
Units
Lab ID
Eligibility Worksheet1
Has the patient completed or does the patient
intend to complete the quality of life
questionnaires
Yes
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No
Date Questionnaire Completed
Does patient have history of any other
malignancy, except adequately treated non
melanoma skin cancer or curatively treated in situ
carcinoma of the cervix or other solid tumors
curatively treated with no evidence of disease for
> 5 years
Yes
No
Does patient have persistent peripheral
neuropathy or hearing loss >= Grade 2
Yes
No
Comments
Comments
Contact Information
CRA Name
Phone number
Fax Number
Institution Name
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Ovarian Cancer NCT00993655 Off Treatment -
NCIC OV 21 Death Report Form - 2874203v1.0
NCIC OV 21 Death Report Form
Comparing Three Combination Chemotherapy Regimens in
Treating Patients With Stage IIB, Stage IIC, Stage III, or
Stage IV Ovarian Epithelial Cancer, Primary Peritoneal
Cancer, or Fallopian Tube Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=69B794A7-
2EA4-1666-E040-BB89AD432FB9
All rights reserved. Please visit https://medical-data-
models.org/forms/8900
NCIC OV 21 Death Report Form
Patient Information
NCIC Patient ID (NCIC CTG Patient Serial
Number issued at the time of randomization)
Patient Initials (first-middle-last)
Patient Hospital No. (if permitted by REB)
Investigator No.
Investigator First Name
Investigator Middle Name
Investigator Last Name
Date/cause Of Death/autopsy
Date of Death (dd mmm yyyy)
Describe cause of death
Was autopsy performed
Yes
No
Comments
Comments
Contact Information
CRA Name
Phone number
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Fax Number
Institution Name
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Lung Cancer NCT00096265 Demographic - A5 RTOG Phase III - Multiple
Brain Mets Demographic Data Form - version 2 - 2277657v3.0
A5 RTOG Phase III - Multiple Brain Mets Demographic
Data Form - version 2
Radiation Therapy and Stereotactic Radiosurgery With or
Without Temozolomide or Erlotinib in Treating Patients With
Brain Metastases Secondary to Non-Small Cell Lung
Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=D81B5AB0-
2D5B-616A-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/8902
A5 RTOG Phase III - Multiple Brain
Mets Demographic Data Form -
version 2
Header
[RTOG Study No.]
RTOG Study 0320 (RTOG Study 0320)
Case #
Institution
Institution No.
Participant's Initials
Participant's I.D. No.
Module 1
Date Completed
If this is a revised or corrected form, indicate by
checking box.
Yes
No
Module 2
Who completed this form? (check one box)
Not Applicable, No Items Completed (Not
applicable, no items completed)
Other Person (Other person)
Self (Self)
Staff (Staff)
Other, specify
Additional Race/Ethnicity (If you consider yourself
multiracial, check all additional categories that
apply in this question Do not include what you
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reported in 2A.)
A Person Having Origins In Any Of The
Original Peoples Of The Far East,
Southeast Asia, Or The Indian
Subcontinent Including, For Example,
Cambodia, China, India, Japan, Korea,
Malaysia, Pakistan, The Philippine
Islands, Thailand, And Vietnam. (Asian)
Black, not Hispanic origin (Black, not
Hispanic origin)
Hispanic (Hispanic)
A Person Having Origins In Any Of The
Original Peoples Of North And South
America (including Central America),
And Who Maintains Tribal Affiliation Or
Community Attachment (Native
American/Alaskan Nation)
A Person Having Origins In Any Of The
Original Peoples Of Hawaii, Guam,
Samoa, Or Other Pacific Islands (Native
Hawaiian or other Pacific Islander)
Patient Is Unsure Of Their Race
(Unknown/I prefer not to answer)
A Person Having Origins In Any Of The
Original Peoples Of Europe, The Middle
East, Or North Africa. (White, not
Hispanic origin)
Additional Race/Ethnicity (If you consider yourself
multiracial, check all additional categories that
apply in this question Do not include what you
reported in 2A.)
A Person Having Origins In Any Of The
Original Peoples Of The Far East,
Southeast Asia, Or The Indian
Subcontinent Including, For Example,
Cambodia, China, India, Japan, Korea,
Malaysia, Pakistan, The Philippine
Islands, Thailand, And Vietnam. (Asian)
Black, not Hispanic origin (Black, not
Hispanic origin)
Hispanic (Hispanic)
A Person Having Origins In Any Of The
Original Peoples Of North And South
America (including Central America),
And Who Maintains Tribal Affiliation Or
Community Attachment (Native
American/Alaskan Nation)
A Person Having Origins In Any Of The
Original Peoples Of Hawaii, Guam,
Samoa, Or Other Pacific Islands (Native
Hawaiian or other Pacific Islander)
Patient Is Unsure Of Their Race
(Unknown/I prefer not to answer)
A Person Having Origins In Any Of The
Original Peoples Of Europe, The Middle
East, Or North Africa. (White, not
Hispanic origin)
Highest school grade completed (Check one box)
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8th Or Less (8th or less)
9 - 11th Grade (9-11th Grade)
Advanced Degree (Advanced degree)
Bachelor's Degree (Associate
degree/some college)
Bachelor's Degree (Bachelor's degree)
High School Graduate / Ged (High
school graduate/GED)
I Prefer Not To Answer (I prefer not to
answer)
Other, Specify (Other)
Vocational / Technical School
(Vocational/technical school)
Other, specify
Religion during childhood (check one box)
Catholic (Catholic)
I Prefer Not To Answer (I prefer not to
answer)
Jewish (Jewish)
Morman/latter Day Saints
(Morman/Latter Day Saints)
Muslim / Islam (Muslim/Islam)
None (None)
Other, Specify (Other)
Protestant (Protestant)
Other, specify
Marital status (check one box)
Divorced/separated
(Divorced/Separated)
I Prefer Not To Answer (I prefer not to
answer)
Living As Married (Living as married)
Married (Married)
Single (Single)
Widowed (Widowed)
Where were you born? (check one box Check the
box of the country where you were born.)
Other Country, Specify (Other country)
Usa, Specify The 2 Letter State Code,
Eg Ny (USA)
Other country, specify
Where did you live the longest (check one box)
Other Country, Specify (Other country)
Usa, Specify The 2 Letter State Code,
Eg Ny (USA)
specify the 2 letter State code, eg NY
specify the 2 letter State code, eg NY
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Other country, specify
Smoked at least 100 cigarette (5 packs) during
lifetime
No (No)
Yes, But Quit (Yes, but quit)
Yes, Currently Smoke (Yes, currently
smoke)
Age began smoking cigarettes
Number of years smoked cigarettes
Average number of cigarettes smoked per day
If quit, age stopped smoking completely
If you have had any of the illness listed below,
please check yes for those that apply. (check =
Yes 2)
Bleeding Problems (Bleeding problems)
Circulation Problems (Circulation
problems)
Diabetes Or Sugar In Urine (Diabetes or
sugar in urine)
Frequent Infections (Frequent infections)
Heart Problems (Heart problems)
High Blood Pressure (High blood
pressure)
Hiv/aids (HIV/AIDS)
Kidney/urine Problems (Kidney/urine
problems)
Liver Problems (Liver problems)
Lung Problems (Lung problems)
Other (Other)
Psychological Problems (Psychological
problems)
Seizure (Seizure)
Stroke (Stroke)
Thyroid Problems (Thyroid problems)
Specify other
Family History
Brothers
Sisters
Sons
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Daughters
Are you adopted?
Yes
No
Blood relative with cancer
Brother #1 (Brother #1)
Brother #2 (Brother #2)
Brother #3 (Brother #3)
Brother #4 (Brother #4)
Child #1 (Child #1)
Child #2 (Child #2)
Child #3 (Child #3)
Child #4 (Child #4)
Father (Father)
Mother (Mother)
Sister #1 (Sister #1)
Sister #2 (Sister #2)
Sister #3 (Sister #3)
Sister #4 (Sister #4)
Age when first cancer diagnosed
Type of Cancer
Breast (Breast)
Colon (Colon)
Head & Neck (Head & Neck)
Lung (Lung)
Non Melanoma Skin (Non Melanoma
Skin)
Other (Other)
Prostate (Prostate)
Specify
Have you ever heard of Cancer Prevention Trials?
Yes
No
How likely would you be to volunteer to
participate in Cancer Prevention Trials? (The
numbers below allow you to rate your answer
between 1 - never and 10 - extremely likely. Circle
the number below that best describes your
choice.)
1- Never Would Consider (1)
10 (10)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
7 (7)
8 (8)
9 (9)
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Registration - CALGB 40503 Breast Cancer RE-
REGISTRATION WORKSHEET - 2660178v1.0
CALGB 40503 RE-REGISTRATION WORKSHEET
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=33E5A9E8-
7063-4A74-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/8903
CALGB 40503 Breast Cancer RE-
REGISTRATION WORKSHEET
Header Module
Lead Institution
Institution/Affiliate
Physician of Record (for drug shipment purposes)
Participating Group
Patient Initials (Last, First Middle)
Contact Person at Institution
Phone
Fax
CALGB Patient ID
Patient Hospital No.
HIPAA Authorization Date (MM DD YYYY)
Certification Of Eligibility/protocol Design
Is the patient eligible for open label Bevacizumab
(Progression and initially received Placebo)
Yes
No
Assigned Treatment Arm (Bevacizumab)
Physician of Record (for drug shipment purposes)
NCI Investigator ID
Re-registration Information
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Date of Re-Registration (DD MM YYYY)
Registrar's Signature
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Registration - CALGB 40503 Breast Cancer RE-REGISTRATION
WORKSHEET - 2660178v1.0
Ovarian Cancer NCT00993655 Pathology - NCIC OV 21 Tumour
Tissue Banking Information Report Form - 2874201v1.0
NCIC OV 21 Tumour Tissue Banking Information Report
Form
Comparing Three Combination Chemotherapy Regimens in
Treating Patients With Stage IIB, Stage IIC, Stage III, or
Stage IV Ovarian Epithelial Cancer, Primary Peritoneal
Cancer, or Fallopian Tube Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=69B794A7-
2EA0-1666-E040-BB89AD432FB9
All rights reserved. Please visit https://medical-data-
models.org/forms/8904
NCIC OV 21 Tumour Tissue Banking
Information Report Form
Patient Information
NCIC Patient ID (NCIC CTG Patient Serial
Number issued at the time of randomization)
Patient Initials (first-middle-last)
Patient Hospital No. (if permitted by REB)
Investigator No.
Investigator First Name
Investigator Middle Name
Investigator Last Name
Tumour Tissue Banking Information
Date Specimen collected (Pathology dd-mmm-
yyyy)
Reviewing Pathologist (Name Diagnosing
Pathologist)
Specimen ID Number (or)
Specimen Accession Number (Pathology Use the
# applicable to the institution holding the tissue)
Pathology Institution Name (at which the
pathology specimens are held)
Address
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CRA Name (completing this form)
CRA Name (completing this form)
Phone number
Email address
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Banking Information Report Form - 2874201v1.0
Prostate Cancer NCT00499174 Follow-Up - NCIC-PR.11
Form 9 - Progressive Disease Report - 2457779v1.0
NCIC-PR.11 Form 9 - Progressive Disease Report
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=0EF825B9-
3741-1D8E-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/8905
NCIC-PR.11 Form 9 - Progressive
Disease Report
Patient Information
NCIC Patient ID (NCIC CTG Patient Serial
Number issued at the time of randomization)
Patient Initials (first-middle-last)
Patient Medical Record Number (if permitted by
IRB)
Intergroup Patient Serial No
Institution Name
NCI Institution Number (CTEP assigned)
Investigator First Name
Investigator Last Name
Investigator Number (NCI Investigator Number)
Month Of Report
Has the patient been diagnosed with first distant
progression?
Yes
No
Date of First Distant Progression (If yes, yyyy
mmm dd)
Site of First Distant Progression (s)
Method of Evaluation
Physical Exam
Imaging Site
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Date of Evaluation (yyyy-mmm-dd)
Method of Evaluation
Comments
Comments
Supporting Documentation
Investigator Signature
Person Completing Form, Last Name
Person Completing Form, First Name
Date Form Originally Completed (yyyy - mmm -
dd)
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Progressive Disease Report - 2457779v1.0
Brain and Central Nervous System Tumors NCT00884741 Demographic -
RTOG 0825 Phase III GBM Demographic Data Form (A5) - 2796060v1.0
RTOG 0825 Phase III GBM Demographic Data Form (A5)
Temozolomide and Radiation Therapy With or Without
Bevacizumab in Treating Patients With Newly Diagnosed
Glioblastoma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=5A7BB7B0-
E979-2DF8-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/8906
RTOG 0825 Phase III GBM
Demographic Data Form (A5)
Header
RTOG Study No.
Case #
Institution Name
Institution No.
Patient Initials
RTOG Patient ID
Unnamed2
Date Completed (mm-dd-yyyy)
Amended Data
Yes
No
Who completed this form (Check one box)
Not Applicable, No Items Completed (Not
applicable, no items completed)
Other Person (Other person)
Self (Self)
Staff (Staff)
Patient Race Category (Check all that apply)
A Person Having Origins In Any Of The
Original Peoples Of North And South
America (including Central America),
And Who Maintains Tribal Affiliation Or
Community Attachment. (American
Indian or Alaska Native)
A Person Having Origins In Any Of The
Original Peoples Of The Far East,
Southeast Asia, Or The Indian
Subcontinent Including, For Example,
Cambodia, China, India, Japan, Korea,
Malaysia, Pakistan, The Philippine
Islands, Thailand, And Vietnam. (Asian)
1 / 5
A Person Having Origins In Any Of The
Black Racial Groups Of Africa. Terms
Such As "haitian" Or "negro" Can Be
Used In Addition To "black Or African
American." (Black or African American)
A Person Having Origins In Any Of The
Original Peoples Of Hawaii, Guam,
Samoa, Or Other Pacific Islands. (Native
Hawaiian or other Pacific Islander)
Not Provided Or Available (Not
Reported)
Could Not Be Determined Or Unsure
(Unknown)
A Person Having Origins In Any Of The
Original Peoples Of Europe, The Middle
East, Or North Africa. (White)
Patient Ethnic Group Cateogy (If you consider
yourself multiracial, check all additional
categories that apply in this question Do not
include what you reported in 2A.)
A Person Of Mexican, Puerto Rican,
Cuban, Central Or South American Or
Other Spanish Culture Or Origin,
Regardless Of Race. (HISPANIC OR
LATINO)
A Person Not Meeting The Definition For
Hispanic Or Latino. (NOT HISPANIC OR
LATINO)
Not Provided Or Available (Not reported)
Could Not Be Determined Or Unsure
(UNKNOWN)
Highest school grade completed (Check one box)
8th Or Less (8th or less)
9 - 11th Grade (9 - 11th Grade)
Advanced Degree (Advanced degree)
Associate Degree / Some College
(Associate degree/some college)
Bachelor's Degree (Bachelor's degree)
High School Graduate / Ged (High
school graduate/GED)
I Prefer Not To Answer (I prefer not to
answer)
Other (Other)
Vocational / Technical School
(Vocational/technical school)
Other, specify
Religion during childhood (Check one box)
Catholic (Catholic)
I Prefer Not To Answer (I prefer not to
answer)
Jewish (Jewish)
Morman/latter Day Saints
(Morman/Latter Day Saints)
Muslim / Islam (Muslim/Islam)
None (None)
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Other (Other)
Protestant (Protestant)
Other, specify
Marital status (Check one box)
Divorced (Divorced)
Domestic Partnership (Domestic
Partnership)
I Prefer Not To Answer (I prefer not to
answer)
Married (Married)
Never Married (Never married)
Separated (Separated)
Widowed (Widowed)
Where were you born (Check one box)
Other Country (Other country)
Usa (USA)
USA, specify the 2 letter State code, eg NY (eg
NY)
Other country, specify
Where did you live the longest (Check one box)
Other Country (Other country)
Usa (USA)
USA, specify the 2 letter State code (eg NY)
Other country, specify
Cigarette History
Smoked at least 100 cigarette during lifetime (5
packs)
No (No)
Yes, But Quit (Yes, but quit)
Yes, Currently Smoke (Yes, currently
smoke)
Age began smoking cigarettes
Number of years smoked cigarettes
Average number of cigarettes smoked per day
If quit, age stopped smoking completely
If you have had any of the illnesses listed below,
3 / 5
Brain and Central Nervous System Tumors NCT00884741 Demographic -
RTOG 0825 Phase III GBM Demographic Data Form (A5) - 2796060v1.0
please check yes for those that apply (check =
Yes)
Bleeding Problems (Bleeding problems)
Circulation Problems (Circulation
problems)
Diabetes Or Sugar In Urine (Diabetes or
sugar in urine)
Frequent Infections (Frequent infections)
Heart Problems (Heart problems)
High Blood Pressure (High blood
pressure)
Hiv/aids (HIV/AIDS)
Kidney/urine Problems (Kidney/urine
problems)
Liver Problems (Liver problems)
Lung Problems (Lung problems)
Other (Other)
Psychological Problems (Psychological
problems)
Seizure (Seizure)
Stroke (Stroke)
Thyroid Problems (Thyroid problems)
Specify other
Family History
How many brothers do you have (How many of
the following family members do you have living
and dead Include only those who are blood-
related)
How many sisters do you have
How many sons do you have
How many daughters do you have
Are you adopted (Check one)
Yes
No
Blood relative with cancer (check = yes)
Brother #1 (Brother #1)
Brother #2 (Brother #2)
Brother #3 (Brother #3)
Brother #4 (Brother #4)
Child #1 (Child  #1)
Child #2 (Child  #2)
Child #3 (Child  #3)
Child #4 (Child  #4)
Father (Father)
Mother (Mother)
Sister #1 (Sister  #1)
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Sister #2 (Sister  #2)
Sister #3 (Sister  #3)
Sister #4 (Sister  #4)
Age when first cancer diagnosed
Type of Cancer (check = yes)
Breast (Breast)
Colon (Colon)
Head & Neck (Head & Neck)
Lung (Lung)
Non Melanoma Skin (Non Melanoma
Skin)
Other (Other)
Prostate (Prostate)
Specify
Have you ever heard of Cancer Prevention Trials
(Check one box)
Yes
No
How likely would you be to volunteer to
participate in Cancer Prevention Trials (The
numbers below allow you to rate your answer
between 1 - never and 10 - extremely likely. Circle
the number below that best describes your
choice.)
1 (1)
10 (10)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
7 (7)
8 (8)
9 (9)
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Ovarian Cancer NCT00993655 Follow-Up - NCIC
OV 21 Short Follow-Up Report Form - 2874233v1.0
NCIC OV 21 Short Follow-Up Report Form
Comparing Three Combination Chemotherapy Regimens in
Treating Patients With Stage IIB, Stage IIC, Stage III, or
Stage IV Ovarian Epithelial Cancer, Primary Peritoneal
Cancer, or Fallopian Tube Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=69B8C40D-
B845-E610-E040-BB89AD43211A
All rights reserved. Please visit https://medical-data-
models.org/forms/8907
NCIC OV 21 Short Follow-Up Report
Form
Patient Information
NCIC Patient ID (NCIC CTG Patient Serial
Number issued at the time of randomization)
Patient Initials (first-middle-last)
Patient Hospital No. (if permitted by REB)
Investigator No.
Investigator First Name
Investigator Middle Name
Investigator Last Name
Physical Exam
Date of Assessment (yyyy-mmm-dd)
Weight (kg)
Performance Status (ECOG)
Fully Active, Able To Carry On All Pre-
disease Performance Without
Restriction. (0)
Restricted In Physically Strenuous
Activity But Ambulatory And Able To
Carry Out Work Of A Light Or Sedentary
Nature, E.g., Light Housework, Office
Work. (1)
Ambulatory And Capable Of All Selfcare
But Unable To Carry Out Any Work
Activities. Up And About More Than 50%
Of Waking Hours. (2)
Capable Of Only Limited Selfcare,
Confined To Bed Or Chair More Than
50% Of Waking Hours. (3)
Completely Disabled. Cannot Carry On
Any Selfcare. Totally Confined To Bed Or
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Chair. (4)
Patient's Vital Status (check all that apply)
Alive (Alive)
Dead (Dead)
Comments
Comments
Contact Information
CRA Name
Phone number
Fax Number
Institution Name
2 / 2
Ovarian Cancer NCT00993655 Follow-Up - NCIC OV 21 Short Follow-Up
Report Form - 2874233v1.0
Sarcoma Pre-Study - GOG-0231D: Fast Fact
Sheet for Protocol 0231-D (Uterus) - 3307969v1.0
GOG-0231D: Fast Fact Sheet for Protocol 0231-D (Uterus)
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=B1F54BBE-
5B83-73AD-E040-BB89AD4338D5
All rights reserved. Please visit https://medical-data-
models.org/forms/8908
GOG-0231D: Fast Fact Sheet for
Protocol 0231-D (Uterus)
Tracking Information
GOG Institution Code
GOG Affiliate Code
Previous GOG #
Treating physician
Other Physician
Patient Hospital No.
Date of Birth
Patient Last Name
Patient First Name
Patient Middle Name
Eligibility
Did the patient sign an approved informed
consent
Yes
No
Has HIPAA authorization been obtained?
Exempt - Non-usa Participant (Exempt -
non-USA participant)
Yes: C49488 (Yes)
Does the patient have the ability to understand
the written informed consent?
Yes
No
Is the patient eligible for a higher priority GOG
protocol
Yes
1 / 7
No
What is the primary disease site
Uterus (Uterus)
What is the cell type
Uterine Leiomyosarcoma (Uterine
leiomyosarcoma)
Date the disease was documented histologically
Is the disease incurable recurrent or persistent?
Which one?
Persistent Disease (Persistent)
Recurrent Disease (Recurrent)
Date recurrence or persistence documented?
Does patient have measurable disease defined
as at least one lesion that can be accurately
measured in at least one dimension (longest
dimension to be recorded) using RECIST 1.1
criteria?
Yes
No
Is the measurable disease > or = 10 mm when
measured by CT, MRI or caliper measurement by
clinical exam; or > or = 20 mm when measured
by chest x-ray or lymph nodes > or = 15 mm in
short axis when measured by CT or MRI?
Yes
No
Does the patient have at least one target lesion to
be used to assess response on this protocol as
defined by RECIST 1.1?
Yes
No
Is the measurable disease in a previously
irradiated field?
Yes
No
If yes, does the patient have disease in an
irradiated field as the only site of measurable
disease and has progression been documented
or a biopsy obtained to confirm persistent
disease at least 90 days following completion of
radiation treatment?
No (No)
Not Applicable (Not Applicable)
Yes (Yes)
Has the patient recovered from the effects of
recent surgery, radiotherapy or  chemotherapy
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Yes
No
Is the patient free of active infection requiring
antibiotics with the exception of uncomplicated
urinary tract infection (UTI)?
Yes
No
Has any hormonal therapy directed at the
malignant tumor been discontinued at least one
week prior to registration?
Yes
No
Has all prior therapy directed at the malignant
tumor, including immunologic agents, been
discontinued for at least three weeks prior to
registration?
Yes
No
Has the patient had one prior chemotherapeutic
regimen for management of leiomyosarcoma?
Yes
No
Drug Regimen 1:
Start date for Regimen 1:
End date for Regimen 1:
How many additional cytotoxic chemotherapy
regimens has the patient received
No Chemotherapy Regimens (0
Regimens)
One Chemotherapy Regimen (1
Regimen)
Two Or More Chemotherapy Regimens
(2 or more Regimens)
Drug Regimen 2:
Start date for Regimen 2:
End date for Regimen 2:
Performance Status
Fully Active, Able To Carry On All Pre-
disease Performance Without
Restriction. (0)
Restricted In Physically Strenuous
Activity But Ambulatory And Able To
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Carry Out Work Of A Light Or Sedentary
Nature, E.g., Light Housework, Office
Work. (1)
Ambulatory And Capable Of All Selfcare
But Unable To Carry Out Any Work
Activities. Up And About More Than 50%
Of Waking Hours. (2)
Has the patient received prior therapy directed at
Aurora kinase for management of recurrent or
persistent disease?
Yes
No
Date of Results
Leukocytes greater than or equal to 3000/mcL?
Yes
No
ANC greater than or equal to 1,500/mcl?
Yes
No
Platelets greater than or equal to 100,000/mcl?
Yes
No
Is Bilirubin less than or equal to ULN?
Yes
No
Serum creatinine less than or equal to
Institutional ULN OR creatinine clearance greater
than or equal to 60 mL/min/1.73 m2 (calculated
or measured)
Yes
No
Is the AST and ALT less than or equal to 3.0 X
ULN
Yes
No
Is the alkaline phosphatase less than or equal to
2.5 x ULN?
Yes
No
Has the patient met the pre-entry requirements
as specified in section 7.0
Yes
No
If patient is of childbearing potential, has she had
a negative serum pregnancy test within 14 days
prior to study entry and agreed to practice an
effective means of contraception during study
treatment?
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No (No)
Not Applicable (Not Applicable)
Yes (Yes)
Is the patient age 18 years or older
Yes
No
Is the patient able to take oral medication and
maintain a fast for 2 hours before and 1 hour after
MLN8237 administration?
Yes
No
Will the patient take agents that effect gastric pH
within 4 days (any proton pump inhibitor) or 1 day
(any histamine-2 antagonist) of planned start of
therapy?
Yes
No
Is the patient able to avoid all other types of
antacids for 2 hours before and 2 hours after
each dose of MLN8237?
Yes
No
Has the patient had prior therapy with MLN8237
or taken part in a study of an investigational
compound or device within 4 weeks of entering
this study?
Yes
No
Has the patient had surgery (excluding biopsy),
radiotherapy, or chemotherapy within 4 weeks (6
weeks for nitrosoureas or mitomycin C) prior to
the planned start of protocol treatment?
Yes
No
Is the patient currently recovering from adverse
events due to agents administered more than 4
weeks earlier?
Yes
No
Has the patient had hormonal agents within 1
week of the planned start of protocol treatment?
Yes
No
Has the patient had another invasive malignancy
other than non-melanoma of the skin, carcinoma
in situ of the cervix, or ductal carcinoma in situ of
the breast present or recur within the past 3
years?
Yes
No
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Has the patient received prior radiotherapy to any
portion of the abdominal cavity or pelvis other
than for the treatment of uterine leiomyosarcoma
within the last 3 years? (Prior radiation for
localized cancer of the breast, head and neck or
skin is permitted as long as it was completed
more than 3 years prior to registration and the
patient remains free of recurrent or metastatic
disease.)
Yes
No
Has the patient received prior chemotherapy for
any abdominal or pelvic tumor other than for the
treatment of uterine leiomyosarcoma within the
last three years? (Prior adjuvant chemotherapy
for localized breast cancer is permitted provided it
was completed more than 3 years prior to
registration and the patient remains free of
recurrent or metastatic disease.)
Yes
No
Is patient nursing
Yes
No
Does the patient have a known history of Central
Nervous System metastases and/or
carcinomatous meningitis?
Yes
No
Does the patient have a history of allergic
reactions attributed to compounds of similar
chemical or biologic composition to MLN8237,
including but not limited to established allergic
reaction to benzodiazepines?
Yes
No
Has the patient had a prior allogeneic bone
marrow or organ transplant?
Yes
No
Does the patient have a known history of
uncontrolled sleep apnea syndrome or other
conditions that could result in excessive daytime
sleepiness, such as sever chronic obstructive
pulmonary disease; requirement for supplemental
oxygen; or any conditions that could result in
excessive toxicity associated with the
benzodiazepine-like effects of MLN8237?
Yes
No
Does the patient require constant administration
of proton pump inhibitor, H2 antagonist, or
pancreatic enzymes? (Intermittent uses of
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antacids or H2 antagonists are allowed.)
Yes
No
Does the patient have an inability to swallow oral
medication or maintain a fast?
Yes
No
Does the patient have any condition that would
modify small bowel absorption of oral
medications, including malabsorption or resection
of pancreas or upper bowel?
Yes
No
Will the patient receive treatment with clinically
significant enzyme inducers, such as the
enzyme-inducing antiepileptic drugs phenytoin,
carbamazepine, oxcarbazepine, primidone or
phenobarbital, or rifampin, rifabutin, rifapentine,
or St. John's wort within 14 days prior to the first
dose of MLN8237 or during the study?
Yes
No
Did the patient experience a myocardial infarction
within the past 6 months, New York Heart
Association (NYHA) Class III or IV heart failure,
uncontrolled angina, severe uncontrolled
ventricular arrhythmias, or electrocardiographic
evidence of acute ischemia or active conduction
system abnormalities
Yes
No
Is the patient HIV positive?
Yes
No
Is the patient unable to comply with restricting
alcohol consumption to no more than 1 standard
unit of alcohol [12 oz beer (350 mL), 1.5 oz (45
mL) of 80-proof alcohol, or one 6 oz (175 mL)
glass of wine] per day during the study and for 30
days from the last dose of MLN8237?
Yes
No
Anticipated date treatment will start
Comments
Provide comments about this Fast Fact Sheet
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Treatment - 2450 - Post-Transplant Essential Data
(TED) ISO Date Format Version 1 - 2888418v1.0
Post-Transplant Essential Data (TED) Uses The ISO Date
Format Version 1
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=6ABDA2AA-
191F-5CB2-E040-BB89AD431CF3
All rights reserved. Please visit https://medical-data-
models.org/forms/8910
2450 - Post-Transplant Essential
Data (TED) ISO Date Format Version
1
Registry Use Only
Sequence number:
Date received:
Center Identification
CIBMTR Center Number:
EBMT Code (CIC) Number
Hospital:
Unit:
Adult Patient Department (Adult)
Hematology Patient Department
(Hematology)
Oncology Patient Department
(Oncology)
Other Department (Other unit)
Pediatric Patient Department (Pediatric)
Specify the other unit name:
Contact person:
Telephone number:
Fax number:
EMail Address
Today's date: (Date of this report)
Follow-Up:
Integer::6 Month (6 Months)
Annual (Annual)
Integer::100 Day (Day 100)
1 / 10
annual, specify year:
Recipient Identification
CIBMTR Recipient ID:
Date of Birth
Gender
Female Gender (Female Gender)
Male Gender (Male Gender)
Disease:
Donor Type: Allogeneic
Yes (Yes)
Donor Type: Autologous
Yes (Yes)
Chronological # of this:  HSCT #:
Chronological # of this:  DCI #:
Date of HSCT for this follow - up:
Did the receipient receive a subsequent HSCT
since the date of contact from the last report?
Yes
No
100 Day Report Only
Is Date of HSCT same as date given on Pre-
TED?
Yes
No
Was HSCT Infusion given?
Yes
No
At least one dose of the preparative regimen was
given?
Yes
No
Patient died during prep regimen?
Yes
No
This HSCT is cancelled?
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Yes
No
This HSCT is postponed?
Yes
No
New estimated date:
Initial Anc Recovery
Was > = 0.5 x 10^9/L achieved for 3 consecutive
labs?
Never Less Than (Never below)
No (No)
Previous Report (Previously reported)
Unknown (Unknown)
Yes: C49488 (Yes)
First date of 3 consecutive labs:
Date of last assessment:
Did graft failure occur?
Yes
No
Initial Platelet Recovery
Initial platelet recovery
No (No)
Never Less Than Platelet Count 20000
(platelet count never dropped below 20 x
10^9/L)
Previous Report (Previously reported)
Unknown (Unknown)
Yes (Yes)
Date platelets >= 20 x 10^9/L:
Date of last assessment:
Graft Versus Host Disease
Maximum Grade of Acute GVHD
Agvhd Grade 0 (0)
Agvhd Grade I (I)
Agvhd Grade Ii (II)
Agvhd Grade Iii (III)
Agvhd Grade Iv (IV)
Agvhd Present, Grade Unknown
(Present, grade unknown)
Maximum extent of chronic GHVD during this
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period:
Extensive Gvhd Involvement (Extensive)
Limited Gvhd Involvement (Limited)
None (None)
Unknown (Unknown)
Date of diagnosis of chronic GVHD
Continued from last report (answer is only valid
on > d100 evaluation)
Yes
No
New Malignancy, Lymphoproliferative Or
Myeloproliferative Disorder
Did a new malignancy, lymphoproliferative or
myeloproliferative disorder occur? (Different from
the disease for which HSCT performed not
recurrence or transformation.)
No (No)
Unknown (Unknown)
Yes (Yes)
New Malignancy, Lymphoproliferative Or
Myeloproliferative Disorder
Date of diagnosis:
Specify:
Acute Myeloid Leukemia (Acute myeloid
leukemia (AML / ANLL))
Breast Carcinoma (Breast cancer)
Central Nervous System Neoplasm
(Central nervous system (CNS)
malignancy (glioblastoma, astrocytoma))
Malignant Gastrointestinal Neoplasm
(Gastrointestinal malignancy (colon,
rectum, stomach, pancreas, intestine))
Genitourinary System Malignant
Neoplasm (Genitourinary malignancy
(kidney, bladder, ovary, testicle, genitalia,
uterus, cervix))
Hodgkin's Lymphoma (Hodgkin disease)
Lung Carcinoma (Lung cancer)
Lymphoma Or Lymphoproliferative
Disorder (Lymphoma or
lymphoproliferative disease)
Melanoma (Melanoma)
Myelodysplastic/myeloproliferative
Disease (Myelodysplasia (MDS),
myeloproliferative (MPS) disorder)
Oropharyngeal Carcinoma
(Oropharyngeal cancer (tongue, buccal
mucosa))
Other Leukemia (Other leukemia
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including ALL)
Other Malignant Neoplasm (Other
malignancy)
Other Malignant Skin Neoplasm (Other
skin malignancy (basal cell, squamous))
Clonality Cytogenetic Abnormality
(Related by descent from clonal
cytogenetic abnormality without leukemia
or MDS)
Sarcoma (Sarcoma)
Thyroid Gland Carcinoma (Thyroid
cancer)
Please specify the new other leukemia disorder
that occurred.
Is the tumor EBV positive?
No (No)
Unknown (Unknown)
Yes (Yes)
Specify the other new malignancy,
lymphoproliferative or myeloproliferative disorder .
Copy of pathology report / documentation
attached?
Yes
No
Survival
Survival status at latest follow-up:
Life (Alive)
Death (Dead)
Negation Follow-up (Lost to Follow-
up(LTF))
Latest follow-up:
Date of death:
Last known date alive:
Day of the month is estimated
Yes (Yes)
Main cause of death: (check only one main
cause)
And/or Persistent Recurrent Disease
Disease Progression (Disease
progression and/or persistent relapse)
Transplantation Relationship
Hematopoietic Stem Cell (HSCT related
causes)
New Malignant Neoplasm (New
malignancy)
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Other (Other)
Unknown (Unknown)
Main cause of death: Other,specify
Survival
HSCT related causes
Cardiotoxicity (Cardiac toxicity)
Graft Versus Host Disease (GVHD)
Infection (Infection)
Other (Other)
Toxicity Pulmonary (Pulmonary toxicity)
Graft Rejection (Rejection / poor graft
function)
Hepatic Veno-occlusive Disease (VOD)
What is the main cause of HSCT related death?
Yes
No
Specify:
Post - Hsct Therapy
What was the type of post-hematopoietic stem
cell transplantation (HSCT) therapy?
Velafermin (FGF (velafermin))
Imatinib Mesylate (Imanitib mesylate
(Gleevec, Glivec))
Palifermin (KGF (palifermin, kepivance))
Was a particular post hematopoietic stem cell
transplant therapy administered?
Blinded Clinical Study (Masked trial)
No: C49487 (No)
Unknown (Unknown)
Yes (Yes)
Hsct For Non-malignant Disease Only
DCI given in this period?
Yes
No
Malignant Disease Evaluation For This
Hsct
Was a complete remission (CR) ever achieved in
response to the HSCT? (Including any therapy as
of Day 0, excluding any change in therapy in
response to disease assessment?)
Never Post Hematopoietic Stem Cell
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Transplantation Cr (No, CR was never
achieved post-HSCT)
Negation Evaluation (Not evaluated)
Begin Preparative Regimen Timepoint Cr
(Recipient was already in CR at the start
of the preparative regimen)
Yes Post Hematopoietic Stem Cell
Transplantation Cr (Yes, post-HSCT CR
was achieved)
Date:
First CR date reported previously. (Answer is only
valid on > d100 evaluation.)
Yes (Yes)
Date assessed:
First Relapse Or Progression After Hsct
First relapse or progression -after HSCT (If yes,
answer all 3 methods. If used, give the date used
and the results.)
Yes
No
Was the disease relapse or progression detected
by a molecular method?
No (No)
Not Done: C49484 (Not Done)
Previous Report (Previously reported)
Yes: C49488 (Yes)
Date first seen:
Date of assessment:
Was the disease relapse or progression detected
by a cytogenetic / FISH method?
No (No)
Not Done: C49484 (Not Done)
Previous Report (Previously reported)
Yes: C49488 (Yes)
Date first seen:
Date of assessment:
Was the disease relapse or progression detected
by a clinical / hematologic method?
No (No)
Not Done: C49484 (Not Done)
Previous Report (Previously reported)
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Yes: C49488 (Yes)
Date first seen:
Date of assessment:
Additional Treatment
Additional treatment
Yes
No
DCI (Allo Only. If yes, also complete "DCI"
section.)
Yes
No
Planned (given regardless of disease status /
assessment post HSCT)
Yes
No
Not planned (given for relapse, progression, or
persistent disease)
Yes
No
Method Of Latest Disease Assessment
Molecular
Yes
No
Disease detected?
No: C49487 (No)
Not Done: C49484 (Not Done)
Yes: C49488 (Yes)
If yes, was the status considered a disease
relapse or progression?
Yes
No
Date latest assessed:
Cytogenetic / FISH
Yes
No
Disease detected?
No: C49487 (No)
Not Done: C49484 (Not Done)
Yes: C49488 (Yes)
If yes, was the status considered a disease
relapse or progression?
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Yes
No
Date latest assessed:
Clinical / hematologic
Yes
No
Disease detected?
Yes (No)
No: C49487 (Not Done)
Not Done: C49484 (Yes)
Date latest assessed:
Was a previous HSCT performed for a different
disease than this HSCT?
Yes
No
Give status of original disease
Complete Remission (CR)
Not Cr (Not in CR)
Date determined:
Donor Cellular Infusion (dci)
Date of first DCI:
Total # DCI in 10 weeks
Lymphocytes
Yes
No
Fibroblasts
Yes
No
Dendritic cells
Yes
No
Mesenchymal
Yes
No
Other
Yes
No
Specify:
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Indication:
Loss Reduced Donor T-lymphocyte
Chimerism (Loss of / decreased donor T-
cell chimerism)
Other (Other)
Part First Hematopoietic Stem Cell
Transplantation Protocol Plan (Planned
as part of initial HSCT protocol)
Mixed Stable Chimerism (Stable, mixed
chimerism)
Therapeutic Procedure Graft Versus
Host Disease (Treatment for GVHD)
Post-transplant Lymphoproliferative
Disorder Epstein-barr Virus Therapeutic
Procedure (Treatment for PTLD, EBV
lymphoma)
Therapeutic Procedure Recurrent
Disease Persistent Pd Disease Or
Disorder (Treatment for relapsed,
persistent or progressive disease)
Therapeutic Procedure Viral Infection
(Viral infection)
Specify:
Maximum grade of acute graft versus host
disease:
Agvhd Grade 0 (0)
Agvhd Grade I (I)
Agvhd Grade Ii (II)
Agvhd Grade Iii (III)
Agvhd Grade Iv (IV)
Agvhd Grade Unknown (Unknown)
If another DCI was received in this reporting
period, disease status before next DCI:
Complete Remission (CR)
No Evaluation (Not evaluated)
Not Cr (Not in CR)
Donor Cellular Infustion (dci)
Were there more than 3 instances of DCI
infusions in this reporting period?
Yes
No
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Prostate Cancer NCT00499174 Pathology - NCIC-
PR.11 Pathology Submission Report - 2585611v1.0
NCIC-PR.11 Pathology Submission Report
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=26B1ED63-
8936-72F1-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/8911
NCIC-PR.11 Pathology Submission
Report
Patient Information
NCIC Patient ID (NCIC CTG Patient Serial
Number issued at the time of randomization)
Patient Initials (first-middle-last)
Patient Medical Record Number (if permitted by
IRB)
Intergroup Patient Serial No
Institution Name
NCI Institution Number (CTEP assigned)
Investigator First Name
Investigator Last Name
Investigator Number (NCI Investigator Number)
Frozen Tissue Information
Date Specimen collected (Specimen for frozen
tissue m/d/y)
Arm
Arm 2 (Arm 2)
Arm
Arm 2 (Arm 2)
Time point (RECOMMENDED TERM - Request
Adding to CRF not shown)
Other Specify (Other)
Randomization (Time of randomization)
Surgery (Time of surgery)
1 Year (Yr 1)
10 Years (Yr 10)
15 Years Post Registration (Yr 15)
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4 Years (Yr 4)
7 Years (Yr 7)
Time point (RECOMMENDED TERM - Request
Adding to CRF not shown)
Other Specify (Other)
Randomization (Time of randomization)
Surgery (Time of surgery)
1 Year (Yr 1)
10 Years (Yr 10)
15 Years Post Registration (Yr 15)
4 Years (Yr 4)
7 Years (Yr 7)
Other
Pathology Institution Name (at which frozen
tissue is held)
Dept/Building (Address:)
Street Name and Number
City
State/Province
Country
Postal Code
Reviewing Pathologist (Diagnosing Pathologists)
Specimen ID Number (Pathology Accession
Number #)
Comments
Comments
Investigator Signature
Person Completing Form, Last Name (*if different
from above)
Person Completing Form, First Name (*if different
from above)
Date Form Originally Completed (yyyy - mmm -
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dd)
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Ovarian Cancer NCT00993655 On-Study - NCIC OV
21 Relapse-Progression Report Form - 2874242v1.0
NCIC OV 21 Relapse-Progression Report Form
Comparing Three Combination Chemotherapy Regimens in
Treating Patients With Stage IIB, Stage IIC, Stage III, or
Stage IV Ovarian Epithelial Cancer, Primary Peritoneal
Cancer, or Fallopian Tube Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=69B8C40D-
B857-E610-E040-BB89AD43211A
All rights reserved. Please visit https://medical-data-
models.org/forms/8912
NCIC OV 21 Relapse-Progression
Report Form
Patient Information
NCIC Patient ID (NCIC CTG Patient Serial
Number issued at the time of randomization)
Patient Initials (first-middle-last)
Patient Hospital No. (if permitted by REB)
Investigator No.
Investigator First Name
Investigator Middle Name
Investigator Last Name
Type Of Progression
Date Of Ca125 Progression
Lab ID
Lab ID
Disease Status At Relapse-progression
Date of First Clinical Progression (yyyy-mmm-dd)
Target Lesions
Did the patient have any target lesions by
imaging or clinical exam on post-op baseline
report
Yes
No
Target Lesion Site (e.g. pelvis)
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Method of Evaluation
Other Specify
Date of evaluation (this reporting period)
Dimension 1 (End of Reporting Period
Measurements)
Dimension 2 (End of Reporting Period
Measurements)
Sum of Longest Diameters of All Target Lesions
Non- Target Lesions During Treatment
Were there any non-target lesions reported at
baseline
Yes
No
Nontarget Lesion Site (e.g. pelvis)
Method of Evaluation
Other Specify
Date of evaluation (this reporting period)
Follow-up status of nontarget lesion (End of
Reporting Period )
Absent (Absent)
Increase (Increase)
Increased To Pd (Increased to PD)
Present-no Change (Present-no change)
Unevaluable (Unevaluable)
New Lesions
Was the appearance of any new lesions
documented (since baseline i.e. previously or
current reporting periods Note: New Lesions
constitute objective disease progression)
Yes
No
New Lesion Site (e.g. pelvis)
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Method of Evaluation
Other Specify
Date of evaluation (this reporting period)
Comments
Comments
Contact Information
CRA Name
Phone number
Fax Number
Institution Name
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Cervical Cancer NCT00980954 Demographic - RTOG 0724 Phase III Cervix
Chemo RT (+)/(-) Adjuvant Chemotherapy: Demographic Data Form (A5) -
2806724v1.0
RTOG 0724 Phase III Cervix Chemo RT (+)/(-) Adjuvant
Chemotherapy: Demographic Data Form (A5)
Chemotherapy and Pelvic Radiation Therapy With or
Without Additional Chemotherapy in Treating Patients With
High-Risk Early-Stage Cervical Cancer After Radical
Hysterectomy
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=5CFDEE98-
0794-2FA7-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/8913
RTOG 0724 Phase III Cervix Chemo
RT (+)/(-) Adjuvant Chemotherapy:
Demographic Data Form (A5)
Header
RTOG Study No.
Case #
Institution Name
Institution No.
Patient Initials
RTOG Patient ID
Unnamed2
Date Completed (mm-dd-yyyy)
Amended Data
Yes
No
Who completed this form (Check one box)
Not Applicable, No Items Completed (Not
applicable, no items completed)
Other Person (Other person)
Self (Self)
Staff (Staff)
Patient Race Category (Check all that apply)
A Person Having Origins In Any Of The
Original Peoples Of North And South
America (including Central America),
And Who Maintains Tribal Affiliation Or
Community Attachment. (American
Indian or Alaska Native)
A Person Having Origins In Any Of The
Original Peoples Of The Far East,
Southeast Asia, Or The Indian
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Subcontinent Including, For Example,
Cambodia, China, India, Japan, Korea,
Malaysia, Pakistan, The Philippine
Islands, Thailand, And Vietnam. (Asian)
A Person Having Origins In Any Of The
Black Racial Groups Of Africa. Terms
Such As "haitian" Or "negro" Can Be
Used In Addition To "black Or African
American." (Black or African American)
A Person Having Origins In Any Of The
Original Peoples Of Hawaii, Guam,
Samoa, Or Other Pacific Islands. (Native
Hawaiian or other Pacific Islander)
Not Provided Or Available (Not
Reported)
Could Not Be Determined Or Unsure
(Unknown)
A Person Having Origins In Any Of The
Original Peoples Of Europe, The Middle
East, Or North Africa. (White)
Patient Ethnic Group Cateogy (If you consider
yourself multiracial, check all additional
categories that apply in this question Do not
include what you reported in 2A.)
A Person Of Mexican, Puerto Rican,
Cuban, Central Or South American Or
Other Spanish Culture Or Origin,
Regardless Of Race. (HISPANIC OR
LATINO)
A Person Not Meeting The Definition For
Hispanic Or Latino. (NOT HISPANIC OR
LATINO)
Not Provided Or Available (Not reported)
Could Not Be Determined Or Unsure
(UNKNOWN)
Highest school grade completed (Check one box)
8th Or Less (8th or less)
9 - 11th Grade (9 - 11th Grade)
Advanced Degree (Advanced degree)
Associate Degree / Some College
(Associate degree/some college)
Bachelor's Degree (Bachelor's degree)
High School Graduate / Ged (High
school graduate/GED)
I Prefer Not To Answer (I prefer not to
answer)
Other (Other)
Vocational / Technical School
(Vocational/technical school)
Other, specify
Religion during childhood (Check one box)
Catholic (Catholic)
I Prefer Not To Answer (I prefer not to
answer)
Jewish (Jewish)
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Morman/latter Day Saints
(Morman/Latter Day Saints)
Muslim / Islam (Muslim/Islam)
None (None)
Other (Other)
Protestant (Protestant)
Other, specify
Marital status (Check one box)
Divorced (Divorced)
Domestic Partnership (Domestic
Partnership)
I Prefer Not To Answer (I prefer not to
answer)
Married (Married)
Never Married (Never married)
Separated (Separated)
Widowed (Widowed)
Where were you born (Check one box)
Other Country (Other country)
Usa (USA)
USA, specify the 2 letter State code, eg NY (eg
NY)
Other country, specify
Where did you live the longest (Check one box)
Other Country (Other country)
Usa (USA)
USA, specify the 2 letter State code (eg NY)
Other country, specify
Cigarette History
Smoked at least 100 cigarette during lifetime (5
packs)
No (No)
Yes, But Quit (Yes, but quit)
Yes, Currently Smoke (Yes, currently
smoke)
Age began smoking cigarettes
Number of years smoked cigarettes
Average number of cigarettes smoked per day
If quit, age stopped smoking completely
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If you have had any of the illnesses listed below,
please check yes for those that apply (check =
Yes)
Bleeding Problems (Bleeding problems)
Circulation Problems (Circulation
problems)
Diabetes Or Sugar In Urine (Diabetes or
sugar in urine)
Frequent Infections (Frequent infections)
Heart Problems (Heart problems)
High Blood Pressure (High blood
pressure)
Hiv/aids (HIV/AIDS)
Kidney/urine Problems (Kidney/urine
problems)
Liver Problems (Liver problems)
Lung Problems (Lung problems)
Other (Other)
Psychological Problems (Psychological
problems)
Seizure (Seizure)
Stroke (Stroke)
Thyroid Problems (Thyroid problems)
Specify other
Family History
How many brothers do you have (How many of
the following family members do you have living
and dead Include only those who are blood-
related)
How many sisters do you have
How many sons do you have
How many daughters do you have
Are you adopted (Check one)
Yes
No
Blood relative with cancer (check = yes)
Brother #1 (Brother #1)
Brother #2 (Brother #2)
Brother #3 (Brother #3)
Brother #4 (Brother #4)
Child #1 (Child  #1)
Child #2 (Child  #2)
Child #3 (Child  #3)
Child #4 (Child  #4)
Father (Father)
Mother (Mother)
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Sister #1 (Sister  #1)
Sister #2 (Sister  #2)
Sister #3 (Sister  #3)
Sister #4 (Sister  #4)
Age when first cancer diagnosed
Type of Cancer (check = yes)
Breast (Breast)
Colon (Colon)
Head & Neck (Head & Neck)
Lung (Lung)
Non Melanoma Skin (Non Melanoma
Skin)
Other (Other)
Prostate (Prostate)
Specify
Have you ever heard of Cancer Prevention Trials
(Check one box)
Yes
No
How likely would you be to volunteer to
participate in Cancer Prevention Trials (The
numbers below allow you to rate your answer
between 1 - never and 10 - extremely likely. Circle
the number below that best describes your
choice.)
1 (1)
10 (10)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
7 (7)
8 (8)
9 (9)
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Endometrial Cancer NCT00942357 Pre-Study - Fast Fact
Sheet for Protocol 0258 (Endometrium) - 3244339v1.0
Fast Fact Sheet for Protocol 0258 (Endometrium)
Carboplatin and Paclitaxel With or Without Cisplatin and
Radiation Therapy in Treating Patients With Stage I, Stage
II, Stage III, or Stage IVA Endometrial Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=A5C0A0F9-
00AC-D53F-E040-BB89AD43271E
All rights reserved. Please visit https://medical-data-
models.org/forms/8914
Fast Fact Sheet for Protocol 0258
(Endometrium)
Tracking Information
GOG Institution Code
GOG Affiliate Code
Previous GOG #
Treating physician
Other Physician
Patient Hospital No.
Date of Birth
Patient Last Name
Patient First Name
Patient Middle Name
Header
Did the patient sign an approved informed
consent
Yes
No
Will the treatment plan for this first patient to be
treated at your institution be digitally submitted to
the ITC for processing in preparation for the rapid
review?
Not Applicable (Not Applicable)
Yes (Yes)
Is this the first patient to receive IMRT on this
study (GOG 0258) from your Institution?
No (No)
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Not Applicable (Not Applicable)
Yes (Yes)
Has HIPAA authorization been obtained
Exempt - Non-usa Participant (Exempt -
non-USA participant)
Yes: C49488 (Yes)
What is the site of the disease
Endometrium (Endometrium)
What is the cell type?
Adenocarcinoma W/ Squamous
Differentiation (Adenocarcinoma w/
Squamous Differentiation)
Unspecified Adenocarcinoma
(Adenocarcinoma, Unspecified)
Adenosquamous Carcinoma
(Adenosquamous Carcinoma)
Clear Cell Carcinoma (Clear cell
carcinoma)
Endometrioid Adenocarcinoma
(Endometrioid Adenocarcinoma)
Mixed Epithelial Carcinoma (Mixed
Epithelial Carcinoma)
Mucinous Adenocarcinoma (Mucinous
Adenocarcinoma)
Serous Adenocarcinoma (Serous
Adenocarcinoma)
Small Cell Carcinoma (Small Cell
Carcinoma)
Undifferentiated Carcinoma
(Undifferentiated Carcinoma)
Villoglandular Carcinoma (Villoglandular
carcinoma)
What is the grade of the primary tumor
Grade 1-well Differentiated (1)
Grade 2-moderately Differentiated (2)
Grade 3-poorly Differentiated (3)
Not Graded (Not Graded)
Stage
Stage I (I)
Stage Ii (II)
Stage Iii (III)
Stage Iva (IVA)
Positive Adnexa (For patients with Surgical Stage
III disease, please indicate the areas of
involvement at least one must be Yes - answer
Yes to all that apply:)
Not Applicable (Not Applicable)
Yes (Yes)
Tumor involves the serosa
Not Applicable (Not Applicable)
Yes (Yes)
Positive pelvic nodes
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Not Applicable (Not Applicable)
Yes (Yes)
Positive para-aortic nodes
Not Applicable (Not Applicable)
Yes (Yes)
Vaginal involvement
Not Applicable (Not Applicable)
Yes (Yes)
Parametrial involvement
Not Applicable (Not Applicable)
Yes (Yes)
Does the patient have FIGO 2009 Surgical Stage
I or II endometrial clear cell or serous carcinoma
with positive peritoneal cytology?
No (No)
Not Applicable (Not Applicable)
Yes (Yes)
Date primary confirmed (Please report date of
surgical staging. This date must be less than or
equal to 8 weeks from today)
Has the patient had a hysterectomy and bilateral
salpingo-oophorectomy?
Yes
No
Does the patient have residual tumor after
surgery (any single site) exceeding 2 cm in
maximum dimension?
Yes
No
Treating radiation oncologist (who has completed
a Knowledge Assessment Questionnaire)
What type of external beam radiation is planned
in the event that Regimen I is assigned to the
patient?
3-dimensional Conformal Radiation
Therapy (3D Conformal)
Imrt (IMRT)
Has the treating Institution been credentialed for
IMRT by the Radiological Physics Center (RPC)
at M.D. Anderson Cancer Center?
Not Applicable (Not Applicable)
Yes (Yes)
Date of Results (if more than one, enter earliest:)
WBC (must be 3,000 cells/mcl or greater)
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ANC (must be 1,500 cells/mcl or greater )
Platelet count (must be 100,000/mcl or greater)
Is the Serum Creatinine less than or equal to
institutional ULN?
Yes
No
Is the bilirubin less than or equal to 1.5 x ULN
Yes
No
Are the SGOT, SGPT and Alkaline Phosphatase
less than or equal to 2.5 X ULN?
Yes
No
Will the patient have the following parameters
measured within 14 days prior to initiating
protocol therapy (HGB or HCT, ANC, Differential,
Platelets, Creatinine, Bilirubin, SGOT, SGPT,
Alkaline Phosphatase, Urinalysis and Quality of
Life Assessment)
Yes
No
Will the patient have the following parameters
measured within 28 days prior to initiating
protocol therapy (History and Physical Exam,
Toxicity Assessment, Pelvic Examination, Chest
X-Ray, Abdominal/Pelvi CT and if required a
Chest CT scan)
Yes
No
Do the testing values/results meet the eligibility
criteria as specified in Section 3.1?
Yes
No
Has the patient met the pre-entry requirements
as specified in section 7.0
Yes
No
Performance Status
Fully Active, Able To Carry On All Pre-
disease Performance Without
Restriction. (0)
Restricted In Physically Strenuous
Activity But Ambulatory And Able To
Carry Out Work Of A Light Or Sedentary
Nature, E.g., Light Housework, Office
Work. (1)
Ambulatory And Capable Of All Selfcare
But Unable To Carry Out Any Work
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Activities. Up And About More Than 50%
Of Waking Hours. (2)
Is the patient age 18 years or older
Yes
No
Does the patient have a diagnosis of
carcinosarcoma?
Yes
No
Does the patient have recurrent endometrial
cancer
Yes
No
Has the patient received prior radiotherapy to any
portion of the abdominal cavity or pelvis
Yes
No
Does the patient have a history of invasive cancer
other than non-melanoma skin cancer that has
been active within the last 5 years?
Yes
No
Has the patient had previous cancer treatment
which contraindicates this protocol therapy
Yes
No
Does the patient have a history of serious co-
morbid illness or uncontrolled illnesses that would
preclude protocol therapy?
Yes
No
Does the patient have an estimated survival of
less than 3 months?
Yes
No
Does the patent have FIGO 2009 Stage IVB
endometrial cancer?
Yes
No
Does the patient have a history of myocardial
infarction, unstable angina or uncontrolled
arrythmia within 3 months of enrollment?
Yes
No
Does the patient have parenchymal liver
metastases?
Yes
No
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Has patient received prior chemotherapy for
endometrial cancer?
Yes
No
Anticipated date treatment will start
Comments
Provide comments about this Fast Fact Sheet
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Endometrial Cancer NCT01225887 Pre-Study - GOG-0229K: Fast
Fact Sheet for Protocol 0229-K (Endometrium) - 3183206v1.0
GOG-0229K: Fast Fact Sheet for Protocol 0229-K
(Endometrium)
BIBF 1120 in Treating Patients With Recurrent or Persistent
Endometrial Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=99D51BE9-
A450-39B5-E040-BB89AD43255D
All rights reserved. Please visit https://medical-data-
models.org/forms/8916
GOG-0229K: Fast Fact Sheet for
Protocol 0229-K (Endometrium)
Tracking Information
GOG Institution Code
GOG Affiliate Code
Previous GOG #
Treating physician
Other Physician
Patient Hospital No.
Date of Birth
Patient Last Name
Patient First Name
Patient Middle Name
Header
Did the patient sign an approved informed
consent
Yes
No
Is the SGOT less than or equal to 3 X ULN
(regardless of the presence of liver metastases)
Yes
No
Has HIPAA authorization been obtained
Exempt - Non-usa Participant (Exempt -
non-USA participant)
Yes: C49488 (Yes)
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Is the patient eligible for a higher priority GOG
protocol
Yes
No
What is the site of the disease
Endometrium (Endometrium)
What is the cell type?
Unspecified Adenocarcinoma
(Adenocarcinoma, Unspecified)
Clear Cell Carcinoma (Clear cell
carcinoma)
Endometrioid Adenocarcinoma
(Endometrioid Adenocarcinoma)
Mixed Epithelial Carcinoma (Mixed
Epithelial Carcinoma)
Mucinous Adenocarcinoma (Mucinous
Adenocarcinoma)
Serous Adenocarcinoma (Serous
Adenocarcinoma)
Squamous Cell Carcinoma (Squamous
Cell Carcinoma)
Transitional Cell Carcinoma (Transitional
Cell Carcinoma)
Undifferentiated Carcinoma
(Undifferentiated Carcinoma)
Date of initial histologic diagnosis of malignancy
What was the grade of the primary tumor
Grade 1-well Differentiated (1)
Grade 2-moderately Differentiated (2)
Grade 3-poorly Differentiated (3)
Is the disease recurrent or persistent with
documented progression? Which one?
Persistent Disease (Persistent)
Recurrent Disease (Recurrent)
Is the cancer refractory to curative therapy or
established treatment?
Yes
No
How was it established to be recurrent or
persistent?
Biopsy (Biopsy)
Non-histologic Evaluation (Non-
Histologic)
Surgical Procedure (Surgery)
Date recurrence or persistence documented?
(NOTE: This should be the date of the most
recent progression or persistence that made the
patient eligible for this study.)
Does patient have measurable disease defined
as at least one lesion that can be accurately
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measured in at least one dimension (longest
dimension to be recorded) using RECIST 1.1
criteria?
Yes
No
What method of evaluation is used to obtain
tumor measurements?
Caliper Measurement By Clinical Exam
(Caliper measurement by clinical exam)
Chest Radiography (Chest X-ray)
Computed Tomography (CT)
Magnetic Resonance Imaging (MRI)
Is the measurable disease > or = 10 mm when
measured by CT, MRI or caliper measurement by
clinical exam; or > or = 20 mm when measured
by chest x-ray or lymph nodes > or = 15 mm in
short axis when measured by CT or MRI?
Yes
No
Does the patient have at least one target lesion to
be used to assess response on this protocol as
defined by RECIST 1.1?
Yes
No
Is the measurable disease in a previously
irradiated field?
Yes
No
If yes, does the patient have disease in an
irradiated field as the only site of measurable
disease and has progression been documented
or a biopsy obtained to confirm persistent
disease at least 90 days following completion of
radiation treatment?
No (No)
Not Applicable (Not Applicable)
Yes (Yes)
Performance Status
Fully Active, Able To Carry On All Pre-
disease Performance Without
Restriction. (0)
Restricted In Physically Strenuous
Activity But Ambulatory And Able To
Carry Out Work Of A Light Or Sedentary
Nature, E.g., Light Housework, Office
Work. (1)
Ambulatory And Capable Of All Selfcare
But Unable To Carry Out Any Work
Activities. Up And About More Than 50%
Of Waking Hours. (2)
Does the patient have normal thyroid function?
Yes
No
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Has the patient recovered from the effects of
recent surgery, radiotherapy or chemotherapy?
Yes
No
Is the patient free of active infection requiring
antibiotics with the exception of uncomplicated
urinary tract infection (UTI)?
Yes
No
Has any hormonal therapy directed at the
malignant tumor been discontinued at least one
week prior to registration?
Yes
No
Has all prior therapy directed at the malignant
tumor, including immunologic agents, been
discontinued for at least three weeks prior to
registration?
Yes
No
Has the patient received one prior
chemotherapeutic regimen for management of
endometrial carcinoma?
Yes
No
Drug Regimen 1:
Start date for Regimen 1:
End date for Regimen 1:
How many prior cytotoxic chemotherapy
regimens has the patient received?
No Chemotherapy Regimens (0
Regimens)
One Chemotherapy Regimen (1
Regimen)
Two Or More Chemotherapy Regimens
(2 or more Regimens)
Drug Regimen 2:
Start date for Regimen 2:
End date for Regimen 2:
Has the patient received any non-cytotoxic
chemotherapy for management of recurrent or
persistent disease
Yes
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No
Date of Results (if more than one, enter earliest:)
Platelets greater than or equal to 100,000/mcl?
Yes
No
ANC greater than or equal to 1,500/mcl?
Yes
No
Is the creatinine less than or equal to 1.5 X ULN
Yes
No
Is the bilirubin less than or equal to 1.5 x ULN
(regardless of the presence of liver metastases)
Yes
No
Is SGPT (ALT) less than or equal to 3.0 X Upper
Limits of Normal
Yes
No
Is the alkaline phosphatase less than or equal to
2.5 x ULN? (regardless of the presence of liver
metastases)
Yes
No
Is her urine protein creatinine (UPC) ratio less
than 1 (or urinary protein less than 1.0g/24
hours)
Yes
No
Is the Prothrombin Time (PT) such that the
International Normalized Ratio (INR) is:
Between 2 And 3 And On A Stable Dose
Of Therapeutic Warfarin (Between 2 and
3 AND on a stable dose of therapeutic
warfarin)
Greater Than 3 (Greater than 3)
Less Than Or Equal To 1.5 X Uln (Less
than or equal to 1.5 x ULN)
Is the PTT less than or equal to 1.5 times the
institutional upper limit of normal?
Yes
No
Has the patient had a baseline electrocardiogram
completed within 28 days prior to study entry and
was the QTc found to be less than or equal to
450 msec? (ventricular tachycardia must be less
than 3 beats in a row or ventricular fibrillation)
Yes
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No
Has the patient met the pre-entry requirements
as specified in section 7.0
Yes
No
If the patient has childbearing potential, has she
had a negative serum pregnancy test within 14
days prior to initiation protocol therapy
No (No)
Not Applicable (Not Applicable)
Yes (Yes)
If patient has the capacity to become pregnant,
has she agreed to use adequate contraception
(two barrier methods of birth control) prior to
study entry and for the duration of the study and
up to three months after the final dose of
BIBF1120?
No (No)
Not Applicable (Not Applicable)
Yes (Yes)
Has the patient received prior therapy with
BIBF1120?
Yes
No
Has the patient had another invasive malignancy
other than non-melanoma of the skin, localized
cancer of the breast, head and neck or skin
diagnosed, present or recur within the past 3
years?
Yes
No
Has the patient received prior radiotherapy to any
portion of the abdominal cavity or pelvis other
than for the treatment of endometrial cancer
within the last three years?
Yes
No
Has the patient received prior radiation for
localized cancer of the breast, head and neck or
skin?
Yes
No
Was the prior radiation for localized cancer of the
breast, head and neck or skin completed more
than 3 years prior to registration and does the
patient remain free of recurrent or metastatic
disease?
No (No)
Not Applicable (Not Applicable)
Yes (Yes)
Has the patient received prior chemotherapy for
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any abdominal or pelvic tumor other than for the
treatment of endometrial cancer within the last
three years?
Yes
No
Has the patient received prior adjuvant
chemotherapy for localized breast cancer?
Yes
No
Was the prior adjuvant chemotherapy for
localized cancer of the breast completed more
than 3 years prior to registration and does the
patient remain free of recurrent or metastatic
disease?
No (No)
Not Applicable (Not Applicable)
Yes (Yes)
Is the treatment of previous cancer a
contraindication to the current protocol therapy?
Yes
No
Does the patient have a serious non-healing
wound, ulcer or bone fracture?
Yes
No
Does the patient have a history of abdominal
fistula, gastrointestinal perforation, intra-
abdominal abscess within 28 days prior to first
day of study therapy or an underlying lesion(s)
that caused the fistula or perforation in the past
that have not been corrected?
Yes
No
Does the patient have active bleeding or
pathologic conditions that carry high risk of
bleeding such as known bleeding disorder,
coagulopathy or tumor involving major vessels?
Yes
No
Does the patient have a history or evidence upon
physical examination of CNS disease, including
primary brain tumor, seizures not controlled with
standard medical therapy, any brain metastases,
or history of cerebrovascular accident (CVA,
stroke), transient ischemic attack (TIA) or
subarachnoid hemorrhage within six months of
the first date of treatment on this study
Yes
No
Does the patient have a history or evidence upon
physical examination of CNS disease, including
primary brain tumor, seizures not controlled with
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standard medical therapy, any brain metastases,
or history of cerebrovascular accident (CVA,
stroke), transient ischemic attack (TIA) or
subarachnoid hemorrhage within six months of
the first date of treatment on this study
Yes
No
Has the patient had clinically significant
cardiovascular disease
Yes
No
Does the patient have uncontrolled hypertension
defined as systolic greater than 140 mm Hg or
diastolic greater than 90 mm Hg despite anti-
hypertensive therapy?
Yes
No
Has the patient had a myocardial infarction or
unstable angina within 6 months of the first date
of study therapy?
Yes
No
Using the New York Heart Association (NYHA)
guideline, does the patient have Class II or
greater congestive heart failure?
Yes
No
Does the patient have an ejection fraction of less
than institutional LLN?
Yes
No
Does the patient have a history of serious
ventricular arrhythmia (ventricular tachycardia or
ventricular fibrillation) or arrhythmias requiring
anti-arrhythmic medications (except for atrial
fibrillation that is well controlled with anti-
arrhythmic medication)?
Yes
No
Does the patient have valvular heart disease
greater than or equal to Grade 2?
Yes
No
Has the patient undergone a major surgical
procedure, open biopsy or incurred a significant
traumatic injury within 28 days prior to the first
date of study therapy?
Yes
No
Is a major surgical procedure anticipated for this
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patient during the course of this study
Yes
No
Has the patient had any minor surgical
procedures, fine needle aspirates or core
biopsies within 7 days prior to the first date of
study therapy?
Yes
No
Is the patient under age 18?
Yes
No
Is the patient pregnant or nursing?
Yes
No
Does the patient have a history of major
thromboembolic event defined as: symptomatic
pulmonary embolism (PE), recurrent
asymptomatic PE, or recurrent deep vein
thrombosis?
Yes
No
Has the patient had prior thrombosis or
thromboembolic event due to a known inherited
coagulopathy? (ie, antithrombin-III deficiency,
Protein C or Protein S deficiency, Factor V Leiden
mutation presence, prothrombin G20210A
mutation )
Yes
No
Has the patient had serious infections requiring
systemic antibiotics or antiviral therapy including:
known active Hepatitis B or C infection; known
HIV infection?
Yes
No
Has the patient been treated with immune
modulators such as systemic cyclosporine or
tacrolimus within 30 days prior to enrollment?
Yes
No
Does the patient have a history of photosensitivity
or must she take agents which increase
photosensitivity?
Yes
No
Does the patient have the ability to swallow oral
medication
Yes
No
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Anticipated date treatment will start
Comments
Provide comments about this Fast Fact Sheet
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Treatment - 2450 Revision 2 - Post-Transplant
Essential Data (TED) - 2898108v1.0
Revision 2 of Form 2450 Post-Transplant Essential Data
(TED)
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=6B9E8DCD-
3CAF-40FC-E040-BB89AD434581
All rights reserved. Please visit https://medical-data-
models.org/forms/8917
2450 Revision 2 - Post-Transplant
Essential Data (TED)
Registry Use Only
Sequence number:
Date received:
Center Identification
CIBMTR Center Number:
EBMT Code (CIC) Number
Hospital:
Unit:
Adult Patient Department (Adult)
Hematology Patient Department
(Hematology)
Oncology Patient Department
(Oncology)
Other Department (Other unit)
Pediatric Patient Department (Pediatric)
Specify the other unit name:
First Name
Last Name
Date of this report:
Follow-Up:
Integer::6 Month (6 Months)
Annual (Annual)
Integer::100 Day (Day 100)
annual, specify year:
Recipient Identification
CIBMTR Recipient ID:
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Date of Birth
Gender
Female Gender (Female Gender)
Male Gender (Male Gender)
Disease:
Donor Type: Allogeneic
Yes (Yes)
Donor Type: Autologous
Yes (Yes)
What is the chronological number of the current
hematopoietic stem cell transplantation?
What is the chronological number of this donor
cell infusion?
Date of HSCT for this follow - up:
Did the receipient receive a subsequent HSCT
since the date of contact from the last report?
Yes
No
Date of subsequent HSCT:
Was the subsequent HSCT indication autologous
rescue?
Yes
No
100 Day Report Only
Is Date of HSCT same as date given on Pre-
TED?
Yes
No
Was HSCT Infusion given?
Yes
No
At least one dose of the preparative regimen was
given?
Yes
No
Patient died during prep regimen?
Yes
No
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This HSCT is cancelled?
Yes
No
This HSCT is postponed?
Yes
No
New estimated date:
Initial Anc Recovery
Was an ANC of equal to or greater than 0.5 x
10E9/L achieved for 3 consecutive labs?
Never Less Than (Never below)
No (No)
Previous Report (Previously reported)
Unknown (Unknown)
Yes: C49488 (Yes)
First date of 3 consecutive labs:
Date of last assessment:
Did graft failure occur?
Yes
No
Initial Platelet Recovery
Initial platelet recovery
No (No)
Never Less Than Platelet Count 20000
(platelet count never dropped below 20 x
10^9/L)
Previous Report (Previously reported)
Unknown (Unknown)
Yes (Yes)
Date platelet count greater than 20 x 10E9/L
Date of last assessment:
Graft Versus Host Disease
Maximum Grade of Acute GVHD
Agvhd Grade 0 (0)
Agvhd Grade I (I)
Agvhd Grade Ii (II)
Agvhd Grade Iii (III)
Agvhd Grade Iv (IV)
Agvhd Present, Grade Unknown
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(Present, grade unknown)
Maximum extent of chronic GHVD during this
period:
Extensive Gvhd Involvement (Extensive)
Limited Gvhd Involvement (Limited)
None (None)
Unknown (Unknown)
Date of diagnosis of chronic GVHD
Continued from last report (answer is only valid
on greater than d100 evaluation)
Yes
No
New Malignancy, Lymphoproliferative Or
Myeloproliferative Disorder
Did a new malignancy occur?
Yes
No
For all new malignancies except for "other skin
malignancy (basal cell, squamous)," was testing
performed to determine the cell of origin?
No (No)
Other Skin Malignant Neoplasm (The
only new malignancy in this reporting
period was "other skin malignancy(basal
cell, squamous)")
Yes (Yes)
Specify the cell origin of the new malignancy:
Donor (Donor)
Origin Unknown (Origin unknown)
Hematopoietic Stem Cell Graft Recipient
(Recipient)
Is a copy of the lab report attached? (Is a copy of
the cell origin evaluation VNTR, cytogenetics,
FISH attached?)
Yes
No
New Malignancy, Lymphoproliferative Or
Myeloproliferative Disorder
Specify which new disease(s) occurred:
Acute Myeloid Leukemia (Acute myeloid
leukemia (AML / ANLL))
Breast Carcinoma (Breast cancer)
Central Nervous System Neoplasm
(Central nervous system (CNS)
malignancy (glioblastoma, astrocytoma))
Malignant Gastrointestinal Neoplasm
(Gastrointestinal malignancy (colon,
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rectum, stomach, pancreas, intestine))
Genitourinary System Malignant
Neoplasm (Genitourinary malignancy
(kidney, bladder, ovary, testicle, genitalia,
uterus, cervix))
Hodgkin's Lymphoma (Hodgkin disease)
Lung Carcinoma (Lung cancer)
Lymphoma Or Lymphoproliferative
Disorder (Lymphoma or
lymphoproliferative disease)
Melanoma (Melanoma)
Myelodysplastic/myeloproliferative
Disease (Myelodysplasia (MDS),
myeloproliferative (MPS) disorder)
Oropharyngeal Carcinoma
(Oropharyngeal cancer (tongue, buccal
mucosa))
Other Leukemia (Other leukemia
including ALL)
Other Malignant Neoplasm (Other
malignancy)
Other Malignant Skin Neoplasm (Other
skin malignancy (basal cell, squamous))
Clonality Cytogenetic Abnormality
(Related by descent from clonal
cytogenetic abnormality without leukemia
or MDS)
Sarcoma (Sarcoma)
Thyroid Gland Carcinoma (Thyroid
cancer)
Did a new malignancy occur?
Yes
No
Date of diagnosis:
Is the tumor EBV positive? (Answer only if the
answer to CDE 2677021 is "Lymphoma or
lymphoproliferative disease".)
Yes
No
Specify the new malignancy, lymphoproliferative
or myeloproliferative disorder: (Answer only if the
answer to CDE 2677021 is "Other leukemia,
including ALL","Other skin malignancy basal cell,
squamous", or "Other new malignancy".)
New Malignancy, Lymphoproliferative Or
Myeloproliferative Disorder ¿ Part 3 Of 3
Copy of pathology report submitted? (Is a
pathology / autopsy report or other
documentation attached?)
Yes
No
5 / 11
Treatment - 2450 Revision 2 - Post-Transplant Essential Data (TED) -
2898108v1.0
Survival
Survival status at latest follow-up:
Life (Alive)
Death (Dead)
Latest follow-up:
Date of death:
Main cause of death: (check only one main
cause)
And/or Persistent Recurrent Disease
Disease Progression (Disease
progression and/or persistent relapse)
Transplantation Relationship
Hematopoietic Stem Cell (HSCT related
causes)
New Malignant Neoplasm (New
malignancy)
Other (Other)
Unknown (Unknown)
Main cause of death: Other,specify
Survival
HSCT related causes
Cardiotoxicity (Cardiac toxicity)
Graft Versus Host Disease (GVHD)
Infection (Infection)
Other (Other)
Toxicity Pulmonary (Pulmonary toxicity)
Graft Rejection (Rejection / poor graft
function)
Hepatic Veno-occlusive Disease (VOD)
What is the main cause of HSCT related death?
Yes
No
Specify: (Answer only if the answer to CDE
2677309 is "other".)
Post - Hsct Therapy
What was the type of post-hematopoietic stem
cell transplantation (HSCT) therapy?
Velafermin (FGF (velafermin))
Imatinib Mesylate (Imanitib mesylate
(Gleevec, Glivec))
Palifermin (KGF (palifermin, kepivance))
Was a particular post hematopoietic stem cell
transplant therapy administered?
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Blinded Clinical Study (Masked trial)
No: C49487 (No)
Unknown (Unknown)
Yes (Yes)
Hsct For Non-malignant Disease Only
DCI given in this period?
Yes
No
Malignant Disease Evaluation For This
Hsct
Was a complete remission (CR) ever achieved in
response to the HSCT? (Including any therapy as
of Day 0, excluding any change in therapy in
response to disease assessment?)
Never Post Hematopoietic Stem Cell
Transplantation Cr (No, CR was never
achieved post-HSCT)
Negation Evaluation (Not evaluated)
Begin Preparative Regimen Timepoint Cr
(Recipient was already in CR at the start
of the preparative regimen)
Yes Post Hematopoietic Stem Cell
Transplantation Cr (Yes, post-HSCT CR
was achieved)
Date:
First CR date reported previously. (Answer is only
valid on greater than d100 evaluation.)
Yes (Yes)
Date assessed:
If necessary, please validate the response for the
date the response was assessed. (Date of best
response was previously reported)
Date Previous Report (Date previously
reported)
First Relapse Or Progression After Hsct
First relapse or progression -after HSCT (If yes,
answer all 3 methods. If used, give the date used
and the results.)
Yes
No
Was the disease relapse or progression detected
by a molecular method?
No (No)
Not Done: C49484 (Not Done)
Previous Report (Previously reported)
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Yes: C49488 (Yes)
Date first seen:
Date of assessment:
Was the disease relapse or progression detected
by a cytogenetic / FISH method?
No (No)
Not Done: C49484 (Not Done)
Previous Report (Previously reported)
Yes: C49488 (Yes)
Date first seen:
Date of assessment:
Was the disease relapse or progression detected
by a clinical / hematologic method?
No (No)
Not Done: C49484 (Not Done)
Previous Report (Previously reported)
Yes: C49488 (Yes)
Date first seen:
Date of assessment:
Additional Treatment
Additional treatment
Yes
No
DCI (Allo Only. If yes, also complete "DCI"
section.)
Yes
No
Planned (given regardless of disease status /
assessment post HSCT)
Yes
No
Not planned (given for relapse, progression, or
persistent disease)
Yes
No
Method Of Latest Disease Assessment
Molecular
No Or Not Done (No / Not evaluated)
8 / 11
Treatment - 2450 Revision 2 - Post-Transplant Essential Data (TED) -
2898108v1.0
Yes (Yes)
Disease detected?
Yes
No
If yes, was the status considered a disease
relapse or progression?
Yes
No
Date latest assessed:
Was the method of latest disease assessment
cytogenetic / FISH?
No Or Not Done (No / Not evaluated)
Yes (Yes)
Disease detected?
Yes
No
If yes, was the status considered a disease
relapse or progression?
Yes
No
Date latest assessed:
Clinical/Hematologic
No Or Not Done (No / Not evaluated)
Yes (Yes)
Disease detected?
Yes
No
Date latest assessed:
Was a previous HSCT performed for a different
disease than this HSCT?
Yes
No
Give status of original disease
Complete Remission (CR)
Not Cr (Not in CR)
Date determined:
Donor Cellular Infusion (dci)
Date of DCI:
Total # DCI in 10 weeks
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Lymphocytes
Yes
No
Fibroblasts
Yes
No
Dendritic cells
Yes
No
Mesenchymal
Yes
No
Other
Yes
No
Specify:
Indication:
Loss Reduced Donor T-lymphocyte
Chimerism (Loss of / decreased donor T-
cell chimerism)
Other (Other)
Part First Hematopoietic Stem Cell
Transplantation Protocol Plan (Planned
as part of initial HSCT protocol)
Mixed Stable Chimerism (Stable, mixed
chimerism)
Therapeutic Procedure Graft Versus
Host Disease (Treatment for GVHD)
Post-transplant Lymphoproliferative
Disorder Epstein-barr Virus Therapeutic
Procedure (Treatment for PTLD, EBV
lymphoma)
Therapeutic Procedure Recurrent
Disease Persistent Pd Disease Or
Disorder (Treatment for relapsed,
persistent or progressive disease)
Therapeutic Procedure Viral Infection
(Viral infection)
Specify:
Maximum grade of acute graft versus host
disease:
Agvhd Grade 0 (0)
Agvhd Grade I (I)
Agvhd Grade Ii (II)
Agvhd Grade Iii (III)
Agvhd Grade Iv (IV)
Agvhd Grade Unknown (Unknown)
If another DCI was received in this reporting
period, disease status before next DCI:
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Complete Remission (CR)
No Evaluation (Not evaluated)
Not Cr (Not in CR)
Donor Cellular Infustion (dci)
Were there more than 3 instances of DCI
infusions in this reporting period?
Yes
No
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Breast Cancer NCT00310180 Eligibility - PACCT1
Registration Worksheet (step 1) - 2764542v1.0
PACCT1 Registration Worksheet (step 1)
Hormone Therapy With or Without Combination
Chemotherapy in Treating Women Who Have Undergone
Surgery for Node-Negative Breast Cancer (The TAILORx
Trial)
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=519E7791-
5644-1478-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/8925
PACCT1 Registration Worksheet
(step 1)
Eligibility
First initial
Last initial
Has the eligibility checklist been completed
Yes
No
In the opinion of the investigator, is the patient
eligible?
Yes
No
Has written informed consent been obtained
Yes
No
Date Informed Consent Signed
Has HIPAA authorization been obtained
Exempt - Non-usa Participant (Exempt -
non-USA participant)
No: C49487 (No)
Yes: C49488 (Yes)
HIPAA Authorization Date
Was an Oncotype DX assay performed
Yes
No
I agree my tissue will be submitted for research.
Yes
No
I agree to provide additional blood for research.
Yes
No
My specimens may be kept for research about
other health problems (for example: causes of
diabetes, Alzheimer's disease, and heart
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disease)
Yes
No
Someone may contact me in the future to ask me
to allow other uses of my specimens.
Yes
No
Race
Patient's Race
A Person Having Origins In Any Of The
Original Peoples Of North And South
America (including Central America),
And Who Maintains Tribal Affiliation Or
Community Attachment. (American
Indian or Alaska Native)
A Person Having Origins In Any Of The
Original Peoples Of The Far East,
Southeast Asia, Or The Indian
Subcontinent Including, For Example,
Cambodia, China, India, Japan, Korea,
Malaysia, Pakistan, The Philippine
Islands, Thailand, And Vietnam. (Asian)
A Person Having Origins In Any Of The
Black Racial Groups Of Africa. Terms
Such As "haitian" Or "negro" Can Be
Used In Addition To "black Or African
American." (Black or African American)
A Person Having Origins In Any Of The
Original Peoples Of Hawaii, Guam,
Samoa, Or Other Pacific Islands. (Native
Hawaiian or other Pacific Islander)
Not Provided Or Available (Not
Reported)
Could Not Be Determined Or Unsure
(Unknown)
A Person Having Origins In Any Of The
Original Peoples Of Europe, The Middle
East, Or North Africa. (White)
Patient Demographics / Pre-treatment
Characteristics
Patient's Sex
Female (F)
Male (M)
Birthdate (mm/yy)
ZIP Code
Patient Ethnicity
A Person Of Mexican, Puerto Rican,
Cuban, Central Or South American Or
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Other Spanish Culture Or Origin,
Regardless Of Race. (Hispanic or Latino)
A Person Not Meeting The Definition For
Hispanic Or Latino. (Not Hispanic or
Latino)
Not Provided Or Available (Not reported)
Could Not Be Determined Or Unsure
(Unknown)
Patient Hospital No.
Patient Social Security Number
Method of payment (check one)
Medicaid (Medicaid)
Medicaid And Medicare (Medicaid and
Medicare)
Medicare (Medicare)
Medicare And Private Insurance
(Medicare and Private Insurance)
Military Or Veterans Sponsored Nos
(Military or Veterans Sponsored, Not
Otherwise Specified (NOS))
Military Sponsored (including Champus
& Tricare) (Military Sponsored (including
CHAMPUS & TRICARE))
No Means Of Payment (no Insurance)
(No means of payment (no insurance))
Other (Other)
Private Insurance (Private Insurance)
Self Pay (no Insurance) (Self Pay (No
Insurance))
Unknown (Unknown)
Veterans Sponsored (Veterans
Sponsored)
Country of residence
Ascension Island (AC)
Andorra (AD)
United Arab Emirates (AE)
Afghanistan (AF)
Antigua And Barbuda (AG)
Anguilla (AI)
Albania (AL)
Armenia (AM)
Netherland Antilles (AN)
Angola (AO)
Antarctica (AQ)
Argentina (AR)
American Samoa (AS)
Austria (AT)
Australia (AU)
Aruba (AW)
Azerbaidjan (AZ)
Bosnia-herzegovina (BA)
Barbados (BB)
Bangladesh (BD)
Belgium (BE)
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Burkina Faso (BF)
Bulgaria (BG)
Bahrain (BH)
Burundi (BI)
Benin (BJ)
Bermuda (BM)
Brunei Darussalam (BN)
Bolivia (BO)
Brazil (BR)
Bahamas (BS)
Bhutan (BT)
Bouvet Island (BV)
Botswana (BW)
Belarus (BY)
Belize (BZ)
Canada (CA)
Cocos Isl. (CC)
Rep. Dem. Congo (CD)
Central African Rep. (CF)
Congo (CG)
Switzerland (CH)
Ivory Coast (CI)
Cook Islands (CK)
Chile (CL)
Cameroon (CM)
China (CN)
Colombia (CO)
Costa Rica (CR)
Cuba (CU)
Cape Verde (CV)
Christmas Island (CX)
Cyprus (CY)
Czech Republic (CZ)
Germany (DE)
Djibouti (DJ)
Denmark (DK)
Dominica (DM)
Dominican Republic (DO)
Algeria (DZ)
Ecuador (EC)
Estonia (EE)
Egypt (EG)
Western Sahara (EH)
Eritrea (ER)
Spain (ES)
Ethiopia (ET)
Finland (FI)
Fiji (FJ)
Falkland Isl. (FK)
Micronesia (FM)
Faroe Islands (FO)
France (FR)
France (european Ter.) (FX)
Gabon (GA)
Great Britain (GB)
Grenada (GD)
Georgia (GE)
Guiana (fr.) (GF)
Guernsey (GG)
Ghana (GH)
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Gibraltar (GI)
Greenland (GL)
Gambia (GM)
Guinea (GN)
Guadeloupe (fr.) (GP)
Equatorial Guinea (GQ)
Greece (GR)
South Georgia And South Sandwich
Islands (GS)
Guatemala (GT)
Guam (us) (GU)
Guinea Bissau (GW)
Guyana (GY)
Hong Kong (HK)
Heard & Mcdonald Isl. (HM)
Honduras (HN)
Croatia (HR)
Haiti (HT)
Hungary (HU)
Indonesia (ID)
Ireland (IE)
Israel (IL)
Isle Of Man (IM)
India (IN)
British Indian O. Ter. (IO)
Iraq (IQ)
Iran (IR)
Iceland (IS)
Italy (IT)
Jersey (JE)
Jamaica (JM)
Jordan (JO)
Japan (JP)
Kenya (KE)
Kyrgyz Republic (KG)
Cambodia (KH)
Kiribati (KI)
Comoros (KM)
St. Kitts Nevis Anguilla (KN)
Korea (north) (KP)
Korea (south) (KR)
Kuwait (KW)
Cayman Islands (KY)
Kazakstan (KZ)
Laos (LA)
Lebanon (LB)
Saint Lucia (LC)
Liechtenstein (LI)
Sri Lanka (LK)
Liberia (LR)
Lesotho (LS)
Lithuania (LT)
Luxembourg (LU)
Latvia (LV)
Libya (LY)
Morocco (MA)
Monaco (MC)
Moldova (MD)
Madagascar (MG)
Marshall Islands (MH)
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Macedonia (MK)
Mali (ML)
Myanmar (MM)
Mongolia (MN)
Macau (MO)
Northern Mariana Isl. (MP)
Martinique (fr.) (MQ)
Mauritania (MR)
Montserrat (MS)
Malta (MT)
Mauritius (MU)
Maldives (MV)
Malawi (MW)
Mexico (MX)
Malaysia (MY)
Mozambique (MZ)
Namibia (NA)
New Caledonia (fr.) (NC)
Niger (NE)
Norfolk Island (NF)
Nigeria (NG)
Nicaragua (NI)
Netherlands (NL)
Norway (NO)
Nepal (NP)
Nauru (NR)
Niue (NU)
New Zealand (NZ)
Oman (OM)
Other (Other)
Panama (PA)
Peru (PE)
Polynesia (fr.) (PF)
Papua New Guinea (PG)
Philippines (PH)
Pakistan (PK)
Poland (PL)
St. Pierre & Miquelon (PM)
Pitcairn (PN)
Puerto Rico (PR)
Portugal (PT)
Palau (PW)
Paraguay (PY)
Qatar (QA)
Reunion (fr.) (RE)
Romania (RO)
Russian Federation (RU)
Rwanda (RW)
Saudi Arabia (SA)
Solomon Islands (SB)
Seychelles (SC)
Sudan (SD)
Sweden (SE)
Singapore (SG)
St. Helena (SH)
Slovenia (SI)
Svalbard & Jan Mayen Isl. (SJ)
Slovakia (SK)
Sierra Leone (SL)
San Marino (SM)
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Senegal (SN)
Somalia (SO)
Suriname (SR)
St. Tome And Principe (ST)
Soviet Union (SU)
El Salvador (SV)
Syria (SY)
Swaziland (SZ)
Turks & Caicos Islands (TC)
Chad (TD)
French Southern Terr. (TF)
Togo (TG)
Thailand (TH)
Tadjikistan (TJ)
Tokelau (TK)
Turkmenistan (TM)
Tunisia (TN)
Tonga (TO)
East Timor (TP)
Turkey (TR)
Trinidad & Tobago (TT)
Tuvalu (TV)
Taiwan (TW)
Tanzania (TZ)
Ukraine (UA)
Uganda (UG)
United Kingdom (UK)
Us Minor Outlying Isl. (UM)
Usa (US)
Uruguay (UY)
Uzbekistan (UZ)
Vatican City State (VA)
St. Vincent & Grenadines (VC)
Venezuela (VE)
Virgin Islands (brit) (VG)
Virgin Islands (us) (VI)
Vietnam (VN)
Vanuatu (VU)
Wallis & Futuna Islands (WF)
Western Samoa (WS)
Yemen (YE)
Mayotte (YT)
Yugoslavia (YU)
South Africa (ZA)
Zambia (ZM)
Dem. Rep. Of Congo (ZR)
Zimbabwe (ZW)
Comments
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Treatment - 2450 - Post-Transplant
Essential Data (TED) - 2792764v3.0
Post-Transplant Essential Data (TED)
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=60000F98-
92BB-426C-E040-BB89AD43447C
All rights reserved. Please visit https://medical-data-
models.org/forms/8926
2450 - Post-Transplant Essential
Data (TED)
Registry Use Only
Sequence number:
Date received:
Center Identification
CIBMTR Center Number:
EBMT Code (CIC) Number
Hospital:
Unit:
Adult Patient Department (Adult)
Hematology Patient Department
(Hematology)
Oncology Patient Department
(Oncology)
Other Department (Other unit)
Pediatric Patient Department (Pediatric)
Specify the other unit name:
Contact person:
Telephone number:
Fax number:
EMail Address
Today's date:
Follow-Up:
Integer::6 Month (6 Months)
Annual (Annual)
Integer::100 Day (Day 100)
1 / 10
annual, specify year:
Recipient Identification
CIBMTR Recipient ID:
Patient's Date of Birth
Gender
Female Gender (Female Gender)
Male Gender (Male Gender)
Disease:
Donor Type: Allogeneic
Yes (Yes)
Donor Type: Autologous
Yes (Yes)
Chronological # of this:  HSCT #:
Chronological # of this:  DCI #:
Date of HSCT for this follow - up:
Did the receipient receive a subsequent HSCT
since the date of contact from the last report?
Yes
No
100 Day Report Only
Is Date of HSCT same as date given on Pre-
TED?
Yes
No
Was HSCT Infusion given?
Yes
No
At least one dose of the preparative regimen was
given?
Yes
No
Patient died during prep regimen?
Yes
No
This HSCT is cancelled?
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Yes
No
This HSCT is postponed?
Yes
No
New estimated date:
Initial Anc Recovery
Was > = 0.5 x 10^9/L achieved for 3 consecutive
labs?
Never Less Than (Never below)
No (No)
Previous Report (Previously reported)
Unknown (Unknown)
Yes: C49488 (Yes)
First date of 3 consecutive labs:
Date of last assessment:
Did graft failure occur?
Yes
No
Initial Platelet Recovery
Initial platelet recovery
No (No)
Never Less Than Platelet Count 20000
(platelet count never dropped below 20 x
10^9/L)
Previous Report (Previously reported)
Unknown (Unknown)
Yes (Yes)
Date Platelet > 20 x 10^9/L:
Date of last assessment:
Graft Versus Host Disease
Maximum Grade of Acute GVHD
Agvhd Grade 0 (0)
Agvhd Grade I (I)
Agvhd Grade Ii (II)
Agvhd Grade Iii (III)
Agvhd Grade Iv (IV)
Agvhd Present, Grade Unknown
(Present, grade unknown)
Maximum extent of chronic GHVD during this
3 / 10
Treatment - 2450 - Post-Transplant Essential Data (TED) - 2792764v3.0
period:
Extensive Gvhd Involvement (Extensive)
Limited Gvhd Involvement (Limited)
None (None)
Unknown (Unknown)
Date of diagnosis of chronic GVHD
Continued from last report (answer is only valid
on > d100 evaluation)
Yes
No
New Malignancy, Lymphoproliferative Or
Myeloproliferative Disorder
Did a new malignancy, lymphoproliferative or
myeloproliferative disorder occur? (Different from
the disease for which HSCT performed not
recurrence or transformation.)
No (No)
Unknown (Unknown)
Yes (Yes)
New Malignancy, Lymphoproliferative Or
Myeloproliferative Disorder
Date of diagnosis:
Specify:
Acute Myeloid Leukemia (Acute myeloid
leukemia (AML / ANLL))
Breast Carcinoma (Breast cancer)
Central Nervous System Neoplasm
(Central nervous system (CNS)
malignancy (glioblastoma, astrocytoma))
Malignant Gastrointestinal Neoplasm
(Gastrointestinal malignancy (colon,
rectum, stomach, pancreas, intestine))
Genitourinary System Malignant
Neoplasm (Genitourinary malignancy
(kidney, bladder, ovary, testicle, genitalia,
uterus, cervix))
Hodgkin's Lymphoma (Hodgkin disease)
Lung Carcinoma (Lung cancer)
Lymphoma Or Lymphoproliferative
Disorder (Lymphoma or
lymphoproliferative disease)
Melanoma (Melanoma)
Myelodysplastic/myeloproliferative
Disease (Myelodysplasia (MDS),
myeloproliferative (MPS) disorder)
Oropharyngeal Carcinoma
(Oropharyngeal cancer (tongue, buccal
mucosa))
Other Leukemia (Other leukemia
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including ALL)
Other Malignant Neoplasm (Other
malignancy)
Other Malignant Skin Neoplasm (Other
skin malignancy (basal cell, squamous))
Clonality Cytogenetic Abnormality
(Related by descent from clonal
cytogenetic abnormality without leukemia
or MDS)
Sarcoma (Sarcoma)
Thyroid Gland Carcinoma (Thyroid
cancer)
Please specify the new other leukemia disorder
that occurred.
Is the tumor EBV positive?
No (No)
Unknown (Unknown)
Yes (Yes)
Specify the other new malignancy,
lymphoproliferative or myeloproliferative disorder .
Copy of pathology report / documentation
attached?
Yes
No
Survival
Survival status at latest follow-up:
Life (Alive)
Death (Dead)
Negation Follow-up (Lost to Follow-
up(LTF))
Latest follow-up:
Date of death:
Last known date alive:
Day of the month is estimated
Yes (Yes)
Main cause of death: (check only one main
cause)
And/or Persistent Recurrent Disease
Disease Progression (Disease
progression and/or persistent relapse)
Transplantation Relationship
Hematopoietic Stem Cell (HSCT related
causes)
New Malignant Neoplasm (New
malignancy)
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Other (Other)
Unknown (Unknown)
Main cause of death: Other,specify
Survival
HSCT related causes
Cardiotoxicity (Cardiac toxicity)
Graft Versus Host Disease (GVHD)
Infection (Infection)
Other (Other)
Toxicity Pulmonary (Pulmonary toxicity)
Graft Rejection (Rejection / poor graft
function)
Hepatic Veno-occlusive Disease (VOD)
What is the main cause of HSCT related death?
Yes
No
Specify:
Post - Hsct Therapy
What was the type of post-hematopoietic stem
cell transplantation (HSCT) therapy?
Velafermin (FGF (velafermin))
Imatinib Mesylate (Imanitib mesylate
(Gleevec, Glivec))
Palifermin (KGF (palifermin, kepivance))
Was a particular post hematopoietic stem cell
transplant therapy administered?
Blinded Clinical Study (Masked trial)
No: C49487 (No)
Unknown (Unknown)
Yes (Yes)
Hsct For Non-malignant Disease Only
DCI given in this period?
Yes
No
Malignant Disease Evaluation For This
Hsct
Was a complete remission (CR) ever achieved in
response to the HSCT? (Including any therapy as
of Day 0, excluding any change in therapy in
response to disease assessment?)
Never Post Hematopoietic Stem Cell
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Transplantation Cr (No, CR was never
achieved post-HSCT)
Negation Evaluation (Not evaluated)
Begin Preparative Regimen Timepoint Cr
(Recipient was already in CR at the start
of the preparative regimen)
Yes Post Hematopoietic Stem Cell
Transplantation Cr (Yes, post-HSCT CR
was achieved)
Date:
First CR date reported previously. (Answer is only
valid on > d100 evaluation.)
Yes (Yes)
Date assessed:
First Relapse Or Progression After Hsct
First relapse or progression -after HSCT (If yes,
answer all 3 methods. If used, give the date used
and the results.)
Yes
No
Was the disease relapse or progression detected
by a molecular method?
No (No)
Not Done: C49484 (Not Done)
Previous Report (Previously reported)
Yes: C49488 (Yes)
Date first seen:
Date of assessment:
Was the disease relapse or progression detected
by a cytogenetic / FISH method?
No (No)
Not Done: C49484 (Not Done)
Previous Report (Previously reported)
Yes: C49488 (Yes)
Date first seen:
Date of assessment:
Was the disease relapse or progression detected
by a clinical / hematologic method?
No (No)
Not Done: C49484 (Not Done)
Previous Report (Previously reported)
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Yes: C49488 (Yes)
Date first seen:
Date of assessment:
Additional Treatment
Additional treatment
Yes
No
DCI (Allo Only. If yes, also complete "DCI"
section.)
Yes
No
Planned (given regardless of disease status /
assessment post HSCT)
Yes
No
Not planned (given for relapse, progression, or
persistent disease)
Yes
No
Method Of Latest Disease Assessment
Molecular
Yes
No
Disease detected?
No: C49487 (No)
Not Done: C49484 (Not Done)
Yes: C49488 (Yes)
If yes, was the status considered a disease
relapse or progression?
Yes
No
Date latest assessed:
Cytogenetic / FISH
Yes
No
Disease detected?
No: C49487 (No)
Not Done: C49484 (Not Done)
Yes: C49488 (Yes)
If yes, was the status considered a disease
relapse or progression?
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Yes
No
Date latest assessed:
Clinical / hematologic
Yes
No
Disease detected?
Yes (No)
No: C49487 (Not Done)
Not Done: C49484 (Yes)
Date latest assessed:
Was a previous HSCT performed for a different
disease than this HSCT?
Yes
No
Give status of original disease
Complete Remission (CR)
Not Cr (Not in CR)
Date determined:
Donor Cellular Infusion (dci)
Date of DCI:
Total # DCI in 10 weeks
Lymphocytes
Yes
No
Fibroblasts
Yes
No
Dendritic cells
Yes
No
Mesenchymal
Yes
No
Other
Yes
No
Specify:
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Indication:
Loss Reduced Donor T-lymphocyte
Chimerism (Loss of / decreased donor T-
cell chimerism)
Other (Other)
Part First Hematopoietic Stem Cell
Transplantation Protocol Plan (Planned
as part of initial HSCT protocol)
Mixed Stable Chimerism (Stable, mixed
chimerism)
Therapeutic Procedure Graft Versus
Host Disease (Treatment for GVHD)
Post-transplant Lymphoproliferative
Disorder Epstein-barr Virus Therapeutic
Procedure (Treatment for PTLD, EBV
lymphoma)
Therapeutic Procedure Recurrent
Disease Persistent Pd Disease Or
Disorder (Treatment for relapsed,
persistent or progressive disease)
Therapeutic Procedure Viral Infection
(Viral infection)
Specify:
Maximum grade of acute graft versus host
disease:
Agvhd Grade 0 (0)
Agvhd Grade I (I)
Agvhd Grade Ii (II)
Agvhd Grade Iii (III)
Agvhd Grade Iv (IV)
Agvhd Grade Unknown (Unknown)
If another DCI was received in this reporting
period, disease status before next DCI:
Complete Remission (CR)
No Evaluation (Not evaluated)
Not Cr (Not in CR)
Donor Cellular Infustion (dci)
Were there more than 3 instances of DCI
infusions in this reporting period?
Yes
No
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NCT00936390 Demographic - Radiation Therapy Oncology Group Phase III
Randomized Study of Dose- Escalated Radiotherapy With/Without STAD for
Intermediate-Risk Prostate Cancer Demographic Data Form (A5) - 2850682v1.0
Radiation Therapy Oncology Group Phase III Randomized
Study of Dose- Escalated Radiotherapy With/Without STAD
for Intermediate-Risk Prostate Cancer Demographic Data
Form (A5)
Radiation Therapy With or Without Androgen-Deprivation
Therapy in Treating Patients With Prostate Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=6551BC09-
9A2A-3EEB-E040-BB89AD430B43
All rights reserved. Please visit https://medical-data-
models.org/forms/8927
Radiation Therapy Oncology Group
Phase III Randomized Study of
Dose- Escalated Radiotherapy
With/Without STAD for Intermediate-
Risk Prostate Cancer Demographic
Data Form (A5)
Header
RTOG Study No.
Case #
Institution Name
Institution No.
Patient Initials
RTOG Patient ID
Unnamed2
Date Completed (mm-dd-yyyy)
Amended Data
Yes
No
Who completed this form (Check one box)
Not Applicable, No Items Completed (Not
applicable, no items completed)
Other Person (Other person)
Self (Self)
Staff (Staff)
Patient Race Category (Check all that apply)
A Person Having Origins In Any Of The
Original Peoples Of North And South
America (including Central America),
And Who Maintains Tribal Affiliation Or
Community Attachment. (American
Indian or Alaska Native)
1 / 5
A Person Having Origins In Any Of The
Original Peoples Of The Far East,
Southeast Asia, Or The Indian
Subcontinent Including, For Example,
Cambodia, China, India, Japan, Korea,
Malaysia, Pakistan, The Philippine
Islands, Thailand, And Vietnam. (Asian)
A Person Having Origins In Any Of The
Black Racial Groups Of Africa. Terms
Such As "haitian" Or "negro" Can Be
Used In Addition To "black Or African
American." (Black or African American)
A Person Having Origins In Any Of The
Original Peoples Of Hawaii, Guam,
Samoa, Or Other Pacific Islands. (Native
Hawaiian or other Pacific Islander)
Not Provided Or Available (Not
Reported)
Could Not Be Determined Or Unsure
(Unknown)
A Person Having Origins In Any Of The
Original Peoples Of Europe, The Middle
East, Or North Africa. (White)
Patient Ethnic Group Cateogy (If you consider
yourself multiracial, check all additional
categories that apply in this question Do not
include what you reported in 2A.)
A Person Of Mexican, Puerto Rican,
Cuban, Central Or South American Or
Other Spanish Culture Or Origin,
Regardless Of Race. (HISPANIC OR
LATINO)
A Person Not Meeting The Definition For
Hispanic Or Latino. (NOT HISPANIC OR
LATINO)
Not Provided Or Available (Not reported)
Could Not Be Determined Or Unsure
(UNKNOWN)
Highest school grade completed (Check one box)
8th Or Less (8th or less)
9 - 11th Grade (9 - 11th Grade)
Advanced Degree (Advanced degree)
Associate Degree / Some College
(Associate degree/some college)
Bachelor's Degree (Bachelor's degree)
High School Graduate / Ged (High
school graduate/GED)
I Prefer Not To Answer (I prefer not to
answer)
Other (Other)
Vocational / Technical School
(Vocational/technical school)
Other, specify
Religion during childhood (Check one box)
Catholic (Catholic)
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I Prefer Not To Answer (I prefer not to
answer)
Jewish (Jewish)
Morman/latter Day Saints
(Morman/Latter Day Saints)
Muslim / Islam (Muslim/Islam)
None (None)
Other (Other)
Protestant (Protestant)
Other, specify
Marital status (Check one box)
Divorced (Divorced)
Domestic Partnership (Domestic
Partnership)
I Prefer Not To Answer (I prefer not to
answer)
Married (Married)
Never Married (Never married)
Separated (Separated)
Widowed (Widowed)
Where were you born (Check one box)
Other Country (Other country)
Usa (USA)
USA, specify the 2 letter State code, eg NY (eg
NY)
Other country, specify
Where did you live the longest (Check one box)
Other Country (Other country)
Usa (USA)
USA, specify the 2 letter State code (eg NY)
Other country, specify
Cigarette History
Smoked at least 100 cigarette during lifetime (5
packs)
No (No)
Yes, But Quit (Yes, but quit)
Yes, Currently Smoke (Yes, currently
smoke)
Age began smoking cigarettes
Number of years smoked cigarettes
Average number of cigarettes smoked per day
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If quit, age stopped smoking completely
If you have had any of the illnesses listed below,
please check yes for those that apply (check =
Yes)
Bleeding Problems (Bleeding problems)
Circulation Problems (Circulation
problems)
Diabetes Or Sugar In Urine (Diabetes or
sugar in urine)
Frequent Infections (Frequent infections)
Heart Problems (Heart problems)
High Blood Pressure (High blood
pressure)
Hiv/aids (HIV/AIDS)
Kidney/urine Problems (Kidney/urine
problems)
Liver Problems (Liver problems)
Lung Problems (Lung problems)
Other (Other)
Psychological Problems (Psychological
problems)
Seizure (Seizure)
Stroke (Stroke)
Thyroid Problems (Thyroid problems)
Specify other
Family History
How many brothers do you have (How many of
the following family members do you have living
and dead Include only those who are blood-
related)
How many sisters do you have
How many sons do you have
How many daughters do you have
Are you adopted (Check one)
Yes
No
Blood relative with cancer (check = yes)
Brother #1 (Brother #1)
Brother #2 (Brother #2)
Brother #3 (Brother #3)
Brother #4 (Brother #4)
Child #1 (Child  #1)
Child #2 (Child  #2)
Child #3 (Child  #3)
Child #4 (Child  #4)
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Father (Father)
Mother (Mother)
Sister #1 (Sister  #1)
Sister #2 (Sister  #2)
Sister #3 (Sister  #3)
Sister #4 (Sister  #4)
Age when first cancer diagnosed
Type of Cancer (check = yes)
Breast (Breast)
Colon (Colon)
Head & Neck (Head & Neck)
Lung (Lung)
Non Melanoma Skin (Non Melanoma
Skin)
Other (Other)
Prostate (Prostate)
Specify
Have you ever heard of Cancer Prevention Trials
(Check one box)
Yes
No
How likely would you be to volunteer to
participate in Cancer Prevention Trials (The
numbers below allow you to rate your answer
between 1 - never and 10 - extremely likely. Circle
the number below that best describes your
choice.)
1 (1)
10 (10)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
7 (7)
8 (8)
9 (9)
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NCT00956007 Demographic - RTOG 0920 Phase III Head and
Neck Cancer Demographic Data Form (A5) - 2807575v1.0
RTOG 0920 Phase III Head and Neck Cancer
Demographic Data Form (A5)
Radiation Therapy With or Without Cetuximab in Treating
Patients Who Have Undergone Surgery for Locally
Advanced Head and Neck Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=5D112C65-
152C-09B2-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/8928
RTOG 0920 Phase III Head and
Neck Cancer Demographic Data
Form (A5)
Header
RTOG Study No.
Case #
Institution Name
Institution No.
Patient Initials
RTOG Patient ID
Unnamed2
Date Completed (mm-dd-yyyy)
Amended Data
Yes
No
Who completed this form (Check one box)
Not Applicable, No Items Completed (Not
applicable, no items completed)
Other Person (Other person)
Self (Self)
Staff (Staff)
Patient Race Category (Check all that apply)
A Person Having Origins In Any Of The
Original Peoples Of North And South
America (including Central America),
And Who Maintains Tribal Affiliation Or
Community Attachment. (American
Indian or Alaska Native)
A Person Having Origins In Any Of The
Original Peoples Of The Far East,
Southeast Asia, Or The Indian
Subcontinent Including, For Example,
Cambodia, China, India, Japan, Korea,
Malaysia, Pakistan, The Philippine
Islands, Thailand, And Vietnam. (Asian)
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A Person Having Origins In Any Of The
Black Racial Groups Of Africa. Terms
Such As "haitian" Or "negro" Can Be
Used In Addition To "black Or African
American." (Black or African American)
A Person Having Origins In Any Of The
Original Peoples Of Hawaii, Guam,
Samoa, Or Other Pacific Islands. (Native
Hawaiian or other Pacific Islander)
Not Provided Or Available (Not
Reported)
Could Not Be Determined Or Unsure
(Unknown)
A Person Having Origins In Any Of The
Original Peoples Of Europe, The Middle
East, Or North Africa. (White)
Patient Ethnic Group Cateogy (If you consider
yourself multiracial, check all additional
categories that apply in this question Do not
include what you reported in 2A.)
A Person Of Mexican, Puerto Rican,
Cuban, Central Or South American Or
Other Spanish Culture Or Origin,
Regardless Of Race. (HISPANIC OR
LATINO)
A Person Not Meeting The Definition For
Hispanic Or Latino. (NOT HISPANIC OR
LATINO)
Not Provided Or Available (Not reported)
Could Not Be Determined Or Unsure
(UNKNOWN)
Highest school grade completed (Check one box)
8th Or Less (8th or less)
9 - 11th Grade (9 - 11th Grade)
Advanced Degree (Advanced degree)
Associate Degree / Some College
(Associate degree/some college)
Bachelor's Degree (Bachelor's degree)
High School Graduate / Ged (High
school graduate/GED)
I Prefer Not To Answer (I prefer not to
answer)
Other (Other)
Vocational / Technical School
(Vocational/technical school)
Other, specify
Religion during childhood (Check one box)
Catholic (Catholic)
I Prefer Not To Answer (I prefer not to
answer)
Jewish (Jewish)
Morman/latter Day Saints
(Morman/Latter Day Saints)
Muslim / Islam (Muslim/Islam)
None (None)
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Other (Other)
Protestant (Protestant)
Other, specify
Marital status (Check one box)
Divorced (Divorced)
Domestic Partnership (Domestic
Partnership)
I Prefer Not To Answer (I prefer not to
answer)
Married (Married)
Never Married (Never married)
Separated (Separated)
Widowed (Widowed)
Where were you born (Check one box)
Other Country (Other country)
Usa (USA)
USA, specify the 2 letter State code, eg NY (eg
NY)
Other country, specify
Where did you live the longest (Check one box)
Other Country (Other country)
Usa (USA)
USA, specify the 2 letter State code (eg NY)
Other country, specify
Cigarette History
Smoked at least 100 cigarette during lifetime (5
packs)
No (No)
Yes, But Quit (Yes, but quit)
Yes, Currently Smoke (Yes, currently
smoke)
Age began smoking cigarettes
Number of years smoked cigarettes
Average number of cigarettes smoked per day
If quit, age stopped smoking completely
If you have had any of the illnesses listed below,
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please check yes for those that apply (check =
Yes)
Bleeding Problems (Bleeding problems)
Circulation Problems (Circulation
problems)
Diabetes Or Sugar In Urine (Diabetes or
sugar in urine)
Frequent Infections (Frequent infections)
Heart Problems (Heart problems)
High Blood Pressure (High blood
pressure)
Hiv/aids (HIV/AIDS)
Kidney/urine Problems (Kidney/urine
problems)
Liver Problems (Liver problems)
Lung Problems (Lung problems)
Other (Other)
Psychological Problems (Psychological
problems)
Seizure (Seizure)
Stroke (Stroke)
Thyroid Problems (Thyroid problems)
Specify other
Family History
How many brothers do you have (How many of
the following family members do you have living
and dead Include only those who are blood-
related)
How many sisters do you have
How many sons do you have
How many daughters do you have
Are you adopted (Check one)
Yes
No
Blood relative with cancer (check = yes)
Brother #1 (Brother #1)
Brother #2 (Brother #2)
Brother #3 (Brother #3)
Brother #4 (Brother #4)
Child #1 (Child  #1)
Child #2 (Child  #2)
Child #3 (Child  #3)
Child #4 (Child  #4)
Father (Father)
Mother (Mother)
Sister #1 (Sister  #1)
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Sister #2 (Sister  #2)
Sister #3 (Sister  #3)
Sister #4 (Sister  #4)
Age when first cancer diagnosed
Type of Cancer (check = yes)
Breast (Breast)
Colon (Colon)
Head & Neck (Head & Neck)
Lung (Lung)
Non Melanoma Skin (Non Melanoma
Skin)
Other (Other)
Prostate (Prostate)
Specify
Have you ever heard of Cancer Prevention Trials
(Check one box)
Yes
No
How likely would you be to volunteer to
participate in Cancer Prevention Trials (The
numbers below allow you to rate your answer
between 1 - never and 10 - extremely likely. Circle
the number below that best describes your
choice.)
1 (1)
10 (10)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
7 (7)
8 (8)
9 (9)
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Breast Cancer NCT00310180 Eligibility - PACCT1
Registration Worksheet (step 2) - 2764685v1.0
PACCT1 Registration Worksheet (step 2)
Hormone Therapy With or Without Combination
Chemotherapy in Treating Women Who Have Undergone
Surgery for Node-Negative Breast Cancer (The TAILORx
Trial)
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=519E7791-
5762-1478-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/8929
PACCT1 Registration Worksheet
(step 2)
Eligibility
First initial
Last initial
Has the eligibility checklist been completed
Yes
No
In the opinion of the investigator, is the patient
eligible?
Yes
No
Have you contacted Zemotak International to
request kits to collect and ship the samples
No, Kit Will Not Be Requested (No, kit
will not be requested)
Not Yet (Not yet)
Yes (Yes)
Date and time the Recurrence Score was faxed
to the ECOG Coordinating Center
Oncotype DX Recurrence Score
Is the reported lab value/assessment correct on
the webpage
Yes
No
Tumor size
>/= 2.1 Cm (Greater than or equal to 2.1
cm)
Less Than Or Equal To 2.0 Cm (Less
than or equal to 2.0 cm)
Menopausal status
Postmenopausal (Postmenopausal)
Premenopausal/perimenopausal
(Premenopausal/Perimenopausal)
Planned Chemotherapy regimen
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Non-taxane Containing (Non-taxane
containing)
Not Applicable (Not applicable)
Taxane-containing (Taxane-containing)
Planned radiation therapy
No Planned Radiation Therapy (No
planned radiation therapy)
Partial Breast Irradiation Planned (Partial
breast irradiation planned)
Whole Breast, Boost Planned (Whole
breast, boost planned)
Whole Breast, No Boost Planned (Whole
breast, no boost planned)
The ECOG Randomization will use the RS score
to stratify patients into the following ranges
Recurrence Score Of 11 To 15. (Eleven
to fifteen)
Not Applicable - Patient Is Being
Registered To Arm A Or Arm D (Not
applicable - patient is being registered to
Arm A or Arm D)
Recurrence Score Of 16 To 20. (Sixteen
to twenty)
Recurrence Score Of 21 To 25. (Twenty
one to twenty five)
Patient's ECOG sequence number
Did the consent form signed by the patient
contain the mandatory Quality of Life study
Yes
No
Race
Patient's Race
A Person Having Origins In Any Of The
Original Peoples Of North And South
America (including Central America),
And Who Maintains Tribal Affiliation Or
Community Attachment. (American
Indian or Alaska Native)
A Person Having Origins In Any Of The
Original Peoples Of The Far East,
Southeast Asia, Or The Indian
Subcontinent Including, For Example,
Cambodia, China, India, Japan, Korea,
Malaysia, Pakistan, The Philippine
Islands, Thailand, And Vietnam. (Asian)
A Person Having Origins In Any Of The
Black Racial Groups Of Africa. Terms
Such As "haitian" Or "negro" Can Be
Used In Addition To "black Or African
American." (Black or African American)
A Person Having Origins In Any Of The
Original Peoples Of Hawaii, Guam,
Samoa, Or Other Pacific Islands. (Native
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Hawaiian or other Pacific Islander)
Not Provided Or Available (Not
Reported)
Could Not Be Determined Or Unsure
(Unknown)
A Person Having Origins In Any Of The
Original Peoples Of Europe, The Middle
East, Or North Africa. (White)
Patient Demographics / Pre-treatment
Characteristics
Patient's Sex
Female (F)
Male (M)
Birthdate (mm/yy)
ZIP Code
Patient Ethnicity
A Person Of Mexican, Puerto Rican,
Cuban, Central Or South American Or
Other Spanish Culture Or Origin,
Regardless Of Race. (Hispanic or Latino)
A Person Not Meeting The Definition For
Hispanic Or Latino. (Not Hispanic or
Latino)
Not Provided Or Available (Not reported)
Could Not Be Determined Or Unsure
(Unknown)
Patient Hospital No.
Patient Social Security Number
Method of payment (check one)
Medicaid (Medicaid)
Medicaid And Medicare (Medicaid and
Medicare)
Medicare (Medicare)
Medicare And Private Insurance
(Medicare and Private Insurance)
Military Or Veterans Sponsored Nos
(Military or Veterans Sponsored, Not
Otherwise Specified (NOS))
Military Sponsored (including Champus
& Tricare) (Military Sponsored (including
CHAMPUS & TRICARE))
No Means Of Payment (no Insurance)
(No means of payment (no insurance))
Other (Other)
Private Insurance (Private Insurance)
Self Pay (no Insurance) (Self Pay (No
Insurance))
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Unknown (Unknown)
Veterans Sponsored (Veterans
Sponsored)
Country of residence
Ascension Island (AC)
Andorra (AD)
United Arab Emirates (AE)
Afghanistan (AF)
Antigua And Barbuda (AG)
Anguilla (AI)
Albania (AL)
Armenia (AM)
Netherland Antilles (AN)
Angola (AO)
Antarctica (AQ)
Argentina (AR)
American Samoa (AS)
Austria (AT)
Australia (AU)
Aruba (AW)
Azerbaidjan (AZ)
Bosnia-herzegovina (BA)
Barbados (BB)
Bangladesh (BD)
Belgium (BE)
Burkina Faso (BF)
Bulgaria (BG)
Bahrain (BH)
Burundi (BI)
Benin (BJ)
Bermuda (BM)
Brunei Darussalam (BN)
Bolivia (BO)
Brazil (BR)
Bahamas (BS)
Bhutan (BT)
Bouvet Island (BV)
Botswana (BW)
Belarus (BY)
Belize (BZ)
Canada (CA)
Cocos Isl. (CC)
Rep. Dem. Congo (CD)
Central African Rep. (CF)
Congo (CG)
Switzerland (CH)
Ivory Coast (CI)
Cook Islands (CK)
Chile (CL)
Cameroon (CM)
China (CN)
Colombia (CO)
Costa Rica (CR)
Cuba (CU)
Cape Verde (CV)
Christmas Island (CX)
Cyprus (CY)
Czech Republic (CZ)
Germany (DE)
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Djibouti (DJ)
Denmark (DK)
Dominica (DM)
Dominican Republic (DO)
Algeria (DZ)
Ecuador (EC)
Estonia (EE)
Egypt (EG)
Western Sahara (EH)
Eritrea (ER)
Spain (ES)
Ethiopia (ET)
Finland (FI)
Fiji (FJ)
Falkland Isl. (FK)
Micronesia (FM)
Faroe Islands (FO)
France (FR)
France (european Ter.) (FX)
Gabon (GA)
Great Britain (GB)
Grenada (GD)
Georgia (GE)
Guiana (fr.) (GF)
Guernsey (GG)
Ghana (GH)
Gibraltar (GI)
Greenland (GL)
Gambia (GM)
Guinea (GN)
Guadeloupe (fr.) (GP)
Equatorial Guinea (GQ)
Greece (GR)
South Georgia And South Sandwich
Islands (GS)
Guatemala (GT)
Guam (us) (GU)
Guinea Bissau (GW)
Guyana (GY)
Hong Kong (HK)
Heard & Mcdonald Isl. (HM)
Honduras (HN)
Croatia (HR)
Haiti (HT)
Hungary (HU)
Indonesia (ID)
Ireland (IE)
Israel (IL)
Isle Of Man (IM)
India (IN)
British Indian O. Ter. (IO)
Iraq (IQ)
Iran (IR)
Iceland (IS)
Italy (IT)
Jersey (JE)
Jamaica (JM)
Jordan (JO)
Japan (JP)
Kenya (KE)
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Kyrgyz Republic (KG)
Cambodia (KH)
Kiribati (KI)
Comoros (KM)
St. Kitts Nevis Anguilla (KN)
Korea (north) (KP)
Korea (south) (KR)
Kuwait (KW)
Cayman Islands (KY)
Kazakstan (KZ)
Laos (LA)
Lebanon (LB)
Saint Lucia (LC)
Liechtenstein (LI)
Sri Lanka (LK)
Liberia (LR)
Lesotho (LS)
Lithuania (LT)
Luxembourg (LU)
Latvia (LV)
Libya (LY)
Morocco (MA)
Monaco (MC)
Moldova (MD)
Madagascar (MG)
Marshall Islands (MH)
Macedonia (MK)
Mali (ML)
Myanmar (MM)
Mongolia (MN)
Macau (MO)
Northern Mariana Isl. (MP)
Martinique (fr.) (MQ)
Mauritania (MR)
Montserrat (MS)
Malta (MT)
Mauritius (MU)
Maldives (MV)
Malawi (MW)
Mexico (MX)
Malaysia (MY)
Mozambique (MZ)
Namibia (NA)
New Caledonia (fr.) (NC)
Niger (NE)
Norfolk Island (NF)
Nigeria (NG)
Nicaragua (NI)
Netherlands (NL)
Norway (NO)
Nepal (NP)
Nauru (NR)
Niue (NU)
New Zealand (NZ)
Oman (OM)
Other (Other)
Panama (PA)
Peru (PE)
Polynesia (fr.) (PF)
Papua New Guinea (PG)
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Philippines (PH)
Pakistan (PK)
Poland (PL)
St. Pierre & Miquelon (PM)
Pitcairn (PN)
Puerto Rico (PR)
Portugal (PT)
Palau (PW)
Paraguay (PY)
Qatar (QA)
Reunion (fr.) (RE)
Romania (RO)
Russian Federation (RU)
Rwanda (RW)
Saudi Arabia (SA)
Solomon Islands (SB)
Seychelles (SC)
Sudan (SD)
Sweden (SE)
Singapore (SG)
St. Helena (SH)
Slovenia (SI)
Svalbard & Jan Mayen Isl. (SJ)
Slovakia (SK)
Sierra Leone (SL)
San Marino (SM)
Senegal (SN)
Somalia (SO)
Suriname (SR)
St. Tome And Principe (ST)
Soviet Union (SU)
El Salvador (SV)
Syria (SY)
Swaziland (SZ)
Turks & Caicos Islands (TC)
Chad (TD)
French Southern Terr. (TF)
Togo (TG)
Thailand (TH)
Tadjikistan (TJ)
Tokelau (TK)
Turkmenistan (TM)
Tunisia (TN)
Tonga (TO)
East Timor (TP)
Turkey (TR)
Trinidad & Tobago (TT)
Tuvalu (TV)
Taiwan (TW)
Tanzania (TZ)
Ukraine (UA)
Uganda (UG)
United Kingdom (UK)
Us Minor Outlying Isl. (UM)
Usa (US)
Uruguay (UY)
Uzbekistan (UZ)
Vatican City State (VA)
St. Vincent & Grenadines (VC)
Venezuela (VE)
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Virgin Islands (brit) (VG)
Virgin Islands (us) (VI)
Vietnam (VN)
Vanuatu (VU)
Wallis & Futuna Islands (WF)
Western Samoa (WS)
Yemen (YE)
Mayotte (YT)
Yugoslavia (YU)
South Africa (ZA)
Zambia (ZM)
Dem. Rep. Of Congo (ZR)
Zimbabwe (ZW)
Comments
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Breast Cancer NCT00382070 Treatment - NSABP Protocol B-42 -
Optional Letrozole Registration Program Worksheet - 2494275v1.0
NSABP Protocol B-42 - Optional Letrozole Registration
Program Worksheet (See Protocol Appendix A)
Letrozole in Treating Postmenopausal Women Who Have
Received Hormone Therapy for Hormone Receptor-Positive
Breast Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=17AF72B9-
3E1D-4613-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/8930
NSABP Protocol B-42 - Optional
Letrozole Registration Program
Worksheet
Header
First
Middle
Last
Patient Birth Date
Site Name
Patient Social Security Number (USA only)
Treating physician
Unnamed2
Eligibility Criteria (All must be met)
All Other Protocol Criteria Met (All other
protocol criteria met)
Currently Taking An Aromatase Inhibitor
Or Tamoxifen With Cumulative Duration
Of 2 - 4.5 Years And With Tamoxifen
Duration Of 0-3 Years. (Currently taking
an aromatase inhibitor or tamoxifen, and
received a duration of 2 - 4.5 years
(regardless of missed doses). Total
tamoxifen duration must not exceed 3
years.)
Disease-free From Initial Breast Cancer
Diagnosis (Disease-free from initial
breast cancer diagnosis)
Histologically-confirmed Invasive Breast
Carcinoma By Diagnostic Core Needle
Biopsy Or Final Pathologic Evaluation Of
Surgical Specimen (Histologically-
confirmed invasive breast carcinoma by
diagnostic core needle biopsy or final
pathologic evaluation of surgical
specimen)
Lumpectomy + Axillary Staging +
1 / 3
Radiation Therapy Or Total Mastectomy
+ Axillary Staging (Lumpectomy +
Axillary Staging + Radiation Therapy OR
Total Mastectomy + Axillary Staging)
No Diagnosis Of Bilateral Breast Cancer
Including Dcis (synchronous Or
Metachronous) (No diagnosis of bilateral
breast cancer including DCIS
(synchronous or metachronous).)
No History Of Non-traumatic
Osteoporotic Bone Fractures (No history
of non-traumatic osteoporotic bone
fractures)
Not Currently On Any Other
Investigational Hormonal Therapy Or In
Any Other Hormonal Therapy Clinical
Trial (Not currently on any other
investigational hormonal therapy or in
any other hormonal therapy clinical trial)
Not Currently On Sex Hormonal Therapy
(Not currently on sex hormonal therapy)
Not On Any Hormonal Agent For
Osteoporosis (Not on any hormonal
agent for osteoporosis)
Postmenopausal (Postmenopausal)
Primary Tumor Was Er-positive And/or
Pgr-positive (Primary tumor was ER-
positive and/or PgR-positive)
Signed And Dated Consent (Signed and
Dated Consent)
Date Informed Consent Signed
Has the patient authorized the release of
Protected Health Information to the NSABP?
Yes
No
Adjuvant Hormonal Therapy History
Prior aromatase inhibitor therapy (Has patient
received AI)
Yes
No
Aromatase inhibitor treatment start date (If Yes,)
Cumulative Duration of AIs (# months)
Which aromatase inhibitor was most recently
being taken (AI)
Did this patient receive any tamoxifen?
Yes
No
2 / 3
Breast Cancer NCT00382070 Treatment - NSABP Protocol B-42 -
Optional Letrozole Registration Program Worksheet - 2494275v1.0
Beginning date (If Yes,)
Total Duration (# months)
Footer Module
Completed by
Date
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Breast Cancer NCT00066807 Registration - Confirmation
of Registration Form (Form 26-A) - 2167967v3.0
Confirmation of Registration Form (Form 26-A)
A Phase III Trial Evaluating the Role of Chemotherapy as
Adjuvant Therapy for Premenopausal Women With
Endocrine Responsive Breast Cancer Who Receive
Endocrine Therapy
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=BD162886-
D685-4FAB-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/8931
Confirmation of Registration Form
(Form 26-A)
Ccrr Module For Registration Form (form
26 A)
Patient ID No.
Patient Initials
Patient's Date of Birth
Participating Center/Affiliate
Center Code
PMD Code
Premenopausal
Yes
No
Suitable for adding chemotherapy to the adjuvant
systemic therapy
Yes
No
Randomized within 12 weeks after definite
surgery
Yes
No
To be selected by subsequent randomization to
the TEXT trial
Yes
No
Tamoxifen
Yes
No
Exemestane
Yes
No
Histologically proven, resected breast cancer
Yes
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No
Estrogen and/or progesterone receptor Postitive
tumor which is defined as > or = 10% of tumor
cells positive by immunohistochemical evaluation
Yes
No
The tumor must be confined to the breast and
axillary nodes without detected metastases
elsewhere, with the exception of tumor detected
in internal mammary chain nodes by sentinel
node procedure.
Yes
No
Total mastectomy OR breast-conserving
procedure with radiotherapy to the conserved
breast planned.  Margins must be clear of
invasive cancer and DCIS.  Documented clear
margins of resection in pathology report.
Yes
No
Either axillary lymph node dissection OR
negative axillary node biopsy and workup.
Yes
No
No locally advanced inoperable or inflammatory
breast cancer
Yes
No
no bilateral invasive breast cancer.
Yes
No
Final margins negative
Yes
No
No clinically detectable residual axillary disease.
Yes
No
No supraclavicular node invovlement, no
enlarged internal mammary nodes, no evidence
of distant metastatic disease.
Yes
No
No history of prior ipsilateral or contralateral
invasive breast cancer.
Yes
No
No previous or concomitant malignancy EXCEPT
adequately treated basal or squamous cell
carcinoma of the skin, or in situ carcinoma of the
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cervix or bladder, or contra- or ipsilateral in situ
breast carcinoma.
Yes
No
No non-malignant systemic diseases that would
prevent prolonged follow-up.
Yes
No
No prior bilateral oophorectomy or ovarian
reduction.
Yes
No
No history of noncompliance to medical regimens
and no considered potentially unreliable.
Yes
No
Not pregnant or lactating at the time of
randomization and does not desire pregnancy
within five years.
Yes
No
Not planning to use additional hormonal
treatment apart from randomized treatment
during the next five years, including all types of
hormonal contraception.
Yes
No
No endocrine therapy after breast cancer
diagnosis.
Yes
No
No Tamoxifen, other SERM, or HRT within 1 year
prior to diagnosis.  Prior oral contraceptives are
allowed.
Yes
No
Has not received neoadjuvant or adjuvant
chemotherapy.
Yes
No
No phychiatric, addictive, or other disorder which
compromises ability to give informed consent for
participation in study.
Yes
No
Accessible for follow-up.
Yes
No
Informed and agreed to data and tissue material
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transfer and handling, in accordance with national
data protection guidelines.
Yes
No
Are all answers to the Eligibility Checklist YES?
Yes
No
Has informed consent form been signed and
dated by the patient and investigator?
Yes
No
Date informed consent form signed by patient
Date informed consent form signed by
investigator
Is protocol-required pathology material available
Available Now (Available now)
Available Within 3 Months (Available
within 3 months)
Not Available (Not available)
give reason
Have baseline QL Core and module forms been
completed?
No, But We Intend To Present Baseline
Ql Forms To Be Completed By The
Patient Prior To Starting Theray (no, BUT
we intend to present baseline QL forms
to be completed by the patient prior to
starting theray)
No, Other Reason, Specify (no, other
reason, specify)
No, Patient Meets Exception Criterial
Listed In Protocol (no, patient meets
exception criterial listed in protocol)
Yes (yes)
Other reason, specify (QL forms not completed)
Date baseline QL forms were completed
Tumor Laterality
Bilateral (Bilateral)
Left (Left)
Right (Right)
Right Breast/Side
0 (0)
1 (1)
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Left Breast/Side
0 (0)
1 (1)
Intended method of ovarian function suppression
Ovarian Irradiation (ovarian irradiation)
Surgical Oophorectomy (surgical
oophorectomy)
Triptorelin For 5 Years (triptorelin for 5
years)
Intended chemotherapy
Containing Anthracycline Or Taxane
(containing anthracycline or taxane)
Not Containing Anthracycline Or Taxane
(not containing anthracycline or taxane)
Intended endocrine agent
Exemestane, Chosen By
Clinician/patient (Exemestane, chosen
by clinician/patient)
Selected By Randomization In The Text
Trial (selected by randomization in the
TEXT trial)
Tamoxifen, Chosen By Clinician/patient
(Tamoxifen, chosen by clinician/patient)
Projected Treatment Begin Date
Date of Most Extensive Primary Surgery (Left
breast/side)
Date of Most Extensive Primary Surgery (Left
breast/side)
Most Extensive Primary Surgery (Left
breast/side)
Less than mastectomy (Less than
mastectomy)
Mastectomy, Nos (Mastectomy)
Most Extensive Primary Surgery (Left
breast/side)
Less than mastectomy (Less than
mastectomy)
Mastectomy, Nos (Mastectomy)
Is adjuvant breast/chest wall radiotherapy
planned, ongoing or completed?
Yes
No
Specimen ID Number (Left breast/side)
Specimen ID Number (Left breast/side)
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Lab Facility Name
Pathology Institute Code
Full name of person randomizing at participating
center
Fax Number
Phone number
Full name of investigator responsible for
confirming eligibility
Treating physician
IBCSG Patient ID
Assigned Treatment Arm
Chemotherapy Plus Ofs Plus Tamoxifen
Or Exemestane For 5 Years
(Chemotherapy plus OFS plus Tamoxifen
or Exemestane for 5 years)
Ofs Plus Tamoxifen Or Exemestane For
5 Years (OFS plus Tamoxifen or
Exemestane for 5 years)
Randomization Date
Name of person who perfomed randomization at
Randomization Center
NCI Investigator Number Code
Investigator Signature
Date
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NCT01302834 Demographic - RTOG 1016 A5:  Radiation Therapy Oncology Group
Phase III Head and Neck Cancer Demographic Data Form - 3183922v1.0
RTOG 1016 A5:  Radiation Therapy Oncology Group
Phase III Head and Neck Cancer Demographic Data Form
Radiation Therapy With Cisplatin or Cetuximab in Treating
Patients With Oropharyngeal Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=9A132BA5-
91FC-FFE2-E040-BB89AD43727A
All rights reserved. Please visit https://medical-data-
models.org/forms/8932
RTOG 1016 A5:  Radiation Therapy
Oncology Group Phase III Head and
Neck Cancer Demographic Data
Form
Header
RTOG Study No.
Case #
Institution Name
Institution No.
Patient Initials
RTOG Patient ID
Unnamed2
Date Completed (mm-dd-yyyy)
Amended Data
Yes
No
Who completed this form (Check one box)
Not Applicable, No Items Completed (Not
applicable, no items completed)
Other Person (Other person)
Self (Self)
Staff (Staff)
Patient Race Category (Check all that apply)
A Person Having Origins In Any Of The
Original Peoples Of North And South
America (including Central America),
And Who Maintains Tribal Affiliation Or
Community Attachment. (American
Indian or Alaska Native)
A Person Having Origins In Any Of The
Original Peoples Of The Far East,
Southeast Asia, Or The Indian
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Subcontinent Including, For Example,
Cambodia, China, India, Japan, Korea,
Malaysia, Pakistan, The Philippine
Islands, Thailand, And Vietnam. (Asian)
A Person Having Origins In Any Of The
Black Racial Groups Of Africa. Terms
Such As "haitian" Or "negro" Can Be
Used In Addition To "black Or African
American." (Black or African American)
A Person Having Origins In Any Of The
Original Peoples Of Hawaii, Guam,
Samoa, Or Other Pacific Islands. (Native
Hawaiian or other Pacific Islander)
Not Provided Or Available (Not
Reported)
Could Not Be Determined Or Unsure
(Unknown)
A Person Having Origins In Any Of The
Original Peoples Of Europe, The Middle
East, Or North Africa. (White)
Patient Ethnic Group Cateogy (Check one box)
A Person Of Mexican, Puerto Rican,
Cuban, Central Or South American Or
Other Spanish Culture Or Origin,
Regardless Of Race. (HISPANIC OR
LATINO)
A Person Not Meeting The Definition For
Hispanic Or Latino. (NOT HISPANIC OR
LATINO)
Not Provided Or Available (Not reported)
Could Not Be Determined Or Unsure
(UNKNOWN)
Highest school grade completed (Check one box)
8th Or Less (8th or less)
9 - 11th Grade (9 - 11th Grade)
Advanced Degree (Advanced degree)
Associate Degree / Some College
(Associate degree/some college)
Bachelor's Degree (Bachelor's degree)
High School Graduate / Ged (High
school graduate/GED)
I Prefer Not To Answer (I prefer not to
answer)
Other (Other)
Vocational / Technical School
(Vocational/technical school)
Other, specify
Religion during childhood (Check one box)
Catholic (Catholic)
I Prefer Not To Answer (I prefer not to
answer)
Jewish (Jewish)
Morman/latter Day Saints
(Morman/Latter Day Saints)
Muslim / Islam (Muslim/Islam)
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None (None)
Other (Other)
Protestant (Protestant)
Other, specify
Marital status (Check one box)
Divorced (Divorced)
Domestic Partnership (Domestic
Partnership)
I Prefer Not To Answer (I prefer not to
answer)
Married (Married)
Never Married (Never married)
Separated (Separated)
Widowed (Widowed)
Where were you born (Check one box Check the
box of the country where you were born)
Other Country (Other country)
Usa (USA)
USA, specify the 2 letter State code (eg NY)
Other country, specify
Where did you live the longest (Check one box)
Other Country (Other country)
Usa (USA)
USA, specify the 2 letter State code (eg NY)
Other country, specify
Cigarette History
Smoked at least 100 cigarette during lifetime (5
packs)
No (No)
Yes, But Quit (Yes, but quit)
Yes, Currently Smoke (Yes, currently
smoke)
Age began smoking cigarettes
Number of years smoked cigarettes
Average number of cigarettes smoked per day
If quit, age stopped smoking completely
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If you have had any of the illnesses listed below,
please check yes for those that apply (check =
Yes)
Bleeding Problems (Bleeding problems)
Circulation Problems (Circulation
problems)
Diabetes Or Sugar In Urine (Diabetes or
sugar in urine)
Frequent Infections (Frequent infections)
Heart Problems (Heart problems)
High Blood Pressure (High blood
pressure)
Hiv/aids (HIV/AIDS)
Kidney/urine Problems (Kidney/urine
problems)
Liver Problems (Liver problems)
Lung Problems (Lung problems)
Other (Other)
Psychological Problems (Psychological
problems)
Seizure (Seizure)
Stroke (Stroke)
Thyroid Problems (Thyroid problems)
Specify other
Family History
How many brothers do you have (How many of
the following family members living and dead do
you have? Include only those who are blood-
related)
How many sisters do you have (How many of the
following family members living and dead do you
have? Include only those who are blood-related)
How many sons do you have (How many of the
following family members living and dead do you
have? Include only those who are blood-related)
How many daughters do you have (How many of
the following family members living and dead do
you have? Include only those who are blood-
related)
Are you adopted (Check one In 10C; complete
the question only for your children; omit mother,
father, sisters, brothers)
Yes
No
Blood relative with cancer (check = yes)
Brother #1 (Brother #1)
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Brother #2 (Brother #2)
Brother #3 (Brother #3)
Brother #4 (Brother #4)
Child #1 (Child  #1)
Child #2 (Child  #2)
Child #3 (Child  #3)
Child #4 (Child  #4)
Father (Father)
Mother (Mother)
Sister #1 (Sister  #1)
Sister #2 (Sister  #2)
Sister #3 (Sister  #3)
Sister #4 (Sister  #4)
Age when first cancer diagnosed
Type of Cancer (check = yes)
Breast (Breast)
Colon (Colon)
Head & Neck (Head & Neck)
Lung (Lung)
Non Melanoma Skin (Non Melanoma
Skin)
Other (Other)
Prostate (Prostate)
Specify
Have you ever heard of Cancer Prevention Trials
(Check one box By Cancer Prevention Trials we
mean studies in which healthy people, including
cured cancer patients, volunteer to take part in
experimental cancer prevention, such as the use
of special diets and new drugs. People volunteer
in order to obtain the newest prevention for
themselves and to help scientists learn how well
the new prevention methods work)
Yes
No
How likely would you be to volunteer to
participate in Cancer Prevention Trials (The
numbers below allow you to rate your answer
between 1 - never and 10 - extremely likely. Circle
the number below that best describes your
choice.)
1 (1)
10 (10)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
7 (7)
8 (8)
9 (9)
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Breast Cancer NCT00066703 Registration - Confirmation
of Registration Form (Form 25-A) - 2168101v3.0
Confirmation of Registration Form (Form 25-A)
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=BD163BF2-
874D-4FBE-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/8933
Confirmation of Registration Form
(Form 25-A)
Ccrr Module For Registration Form (form
25-a)
Patient ID No.
Patient Initials
Patient's Date of Birth
Participating Center/Affiliate
Center Code
PMD Code
Premenopausal
Yes
No
Randomized within 12 weeks after definite
surgery prior to commencing any adjuvant
systemic therapy
Yes
No
Histologically proven, resected breast cancer
Yes
No
Estrogen and/or progesterone receptor Postitive
tumor which is defined as > or = 10% of tumor
cells positive by immunohistochemical evaluation
Yes
No
The tumor must be confined to the breast and
axillary nodes without detected metastases
elsewhere, with the exception of tumor detected
in internal mammary chain nodes by sentinel
node procedure.
Yes
No
Total mastectomy OR breast-conserving
procedure with radiotherapy to the conserved
breast planned.  Margins must be clear of
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invasive cancer and DCIS.  Documented clear
margins of resection in pathology report.
Yes
No
Either axillary lymph node dissection OR
negative axillary node biopsy and workup.
Yes
No
No locally advanced inoperable or inflammatory
breast cancer
Yes
No
no bilateral invasive breast cancer.
Yes
No
Final margins negative
Yes
No
No clinically detectable residual axillary disease.
Yes
No
No supraclavicular node invovlement, no
enlarged internal mammary nodes, no evidence
of distant metastatic disease.
Yes
No
No history of prior ipsilateral or contralateral
invasive breast cancer.
Yes
No
No previous or concomitant malignancy EXCEPT
adequately treated basal or squamous cell
carcinoma of the skin, or in situ carcinoma of the
cervix or bladder, or contra- or ipsilateral in situ
breast carcinoma.
Yes
No
No non-malignant systemic diseases that would
prevent prolonged follow-up.
Yes
No
No prior bilateral oophorectomy or ovarian
reduction.
Yes
No
No history of noncompliance to medical regimens
and no considered potentially unreliable.
Yes
No
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Not pregnant or lactating at the time of
randomization and does not desire pregnancy
within five years.
Yes
No
Not planning to use additional hormonal
treatment apart from randomized treatment
during the next five years, including all types of
hormonal contraception.
Yes
No
No endocrine therapy after breast cancer
diagnosis.
Yes
No
No Tamoxifen, other SERM, or HRT within 1 year
prior to diagnosis.  Prior oral contraceptives are
allowed.
Yes
No
No neoadjuvant or adjuvant chemotherapy.
Yes
No
No phychiatric, addictive, or other disorder which
compromises ability to give informed consent for
participation in study.
Yes
No
Accessible for follow-up.
Yes
No
Informed and agreed to data and tissue material
transfer and handling, in accordance with national
data protection guidelines.
Yes
No
Are all answers to the Eligibility Checklist YES?
Yes
No
Has informed consent form been signed and
dated by the patient and investigator?
Yes
No
Date informed consent form signed by patient
Date informed consent form signed by
investigator
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Is protocol-required pathology material available
Available Now (Available now)
Available Within 3 Months (Available
within 3 months)
Not Available (Not available)
give reason
Have baseline QL Core and module forms been
completed?
No, But We Intend To Present Baseline
Ql Forms To Be Completed By The
Patient Prior To Starting Theray (no, BUT
we intend to present baseline QL forms
to be completed by the patient prior to
starting theray)
No, Other Reason, Specify (no, other
reason, specify)
No, Patient Meets Exception Criterial
Listed In Protocol (no, patient meets
exception criterial listed in protocol)
Yes (yes)
Other reason, specify (QL forms not completed)
Date baseline QL forms were completed
Was the patient randomized to Trial 26-02
Yes
No
Will adjuvant chemotherapy be given?
Yes
No
Projected Treatment Begin Date
Tumor Laterality
Bilateral (Bilateral)
Left (Left)
Right (Right)
Right Breast/Side
0 (0)
1 (1)
Left Breast/Side
0 (0)
1 (1)
Date of Most Extensive Primary Surgery (Left
breast/side)
Date of Most Extensive Primary Surgery (Left
breast/side)
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Most Extensive Primary Surgery (Right
breast/side)
Less Than Mastectomy (Less than
mastectomy)
Mastectomy (Mastectomy)
Most Extensive Primary Surgery (Right
breast/side)
Less Than Mastectomy (Less than
mastectomy)
Mastectomy (Mastectomy)
Is adjuvant breast/chest wall radiotherapy
planned, ongoing or completed?
Yes
No
Specimen ID Number (Right breast/side)
Specimen ID Number (Left breast/side)
Lab Facility Name
Pathology Institute Code
Full name of person randomizing at Participating
Center
Fax Number
Phone Number
Full name of investigator responsible for
confirming eligibility
Treating physician
IBCSG Patient ID
Assigned Treatment Arm
Triptorelin For 5 Years Plus Exemestane
For 5 Years (Triptorelin for 5 years plus
Exemestane for 5 years)
Triptorelin For 5 Years Plus Tamoxifen
For 5 Years (Triptorelin for 5 years plus
Tamoxifen for 5 years)
Randomization Date
Name of person who perfomed randomization at
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Randomization Center
NCI Investigator Number Code
Investigator Signature
Date
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Prostate Cancer NCT01546987 Demographic - RTOG 1115 A5: Phase III RT +
Standard ADT vs RT + Enhanced ADT + TAK-700 Demographic Data Form -
Version 2.2 - 3291043v1.0
RTOG 1115 A5: Phase III RT + Standard ADT vs RT +
Enhanced ADT + TAK-700 Demographic Data Form -
Version 2.2
Hormone Therapy, Radiation Therapy, and Steroid 17alpha-
monooxygenase TAK-700 in Treating Patients With High-
Risk Prostate Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=AEA3CD93-
B2AF-F7E1-E040-BB89AD43691D
All rights reserved. Please visit https://medical-data-
models.org/forms/8934
RTOG 1115 A5: Phase III RT +
Standard ADT vs RT + Enhanced
ADT + TAK-700 Demographic Data
Form - Version 2.2
Header
RTOG Study No.
Case #
Institution Name
Institution No.
Patient Initials
RTOG Patient ID
Unnamed2
Date Completed (mm-dd-yyyy)
Amended Data
Yes
No
Who completed this form (Check one box)
Not Applicable, No Items Completed (Not
applicable, no items completed)
Other Person (Other person)
Self (Self)
Staff (Staff)
Patient Race Category (Check all that apply)
A Person Having Origins In Any Of The
Original Peoples Of North And South
America (including Central America),
And Who Maintains Tribal Affiliation Or
Community Attachment. (American
Indian or Alaska Native)
A Person Having Origins In Any Of The
Original Peoples Of The Far East,
Southeast Asia, Or The Indian
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Subcontinent Including, For Example,
Cambodia, China, India, Japan, Korea,
Malaysia, Pakistan, The Philippine
Islands, Thailand, And Vietnam. (Asian)
A Person Having Origins In Any Of The
Black Racial Groups Of Africa. Terms
Such As "haitian" Or "negro" Can Be
Used In Addition To "black Or African
American." (Black or African American)
A Person Having Origins In Any Of The
Original Peoples Of Hawaii, Guam,
Samoa, Or Other Pacific Islands. (Native
Hawaiian or other Pacific Islander)
Not Provided Or Available (Not
Reported)
Could Not Be Determined Or Unsure
(Unknown)
A Person Having Origins In Any Of The
Original Peoples Of Europe, The Middle
East, Or North Africa. (White)
Patient Ethnic Group Cateogy (Check one box)
A Person Of Mexican, Puerto Rican,
Cuban, Central Or South American Or
Other Spanish Culture Or Origin,
Regardless Of Race. (HISPANIC OR
LATINO)
A Person Not Meeting The Definition For
Hispanic Or Latino. (NOT HISPANIC OR
LATINO)
Not Provided Or Available (Not reported)
Could Not Be Determined Or Unsure
(UNKNOWN)
Highest school grade completed (Check one box)
8th Or Less (8th or less)
9 - 11th Grade (9 - 11th Grade)
Advanced Degree (Advanced degree)
Associate Degree / Some College
(Associate degree/some college)
Bachelor's Degree (Bachelor's degree)
High School Graduate / Ged (High
school graduate/GED)
I Prefer Not To Answer (I prefer not to
answer)
Other (Other)
Vocational / Technical School
(Vocational/technical school)
Other, specify
Religion during childhood (Check one box)
Catholic (Catholic)
I Prefer Not To Answer (I prefer not to
answer)
Jewish (Jewish)
Morman/latter Day Saints
(Morman/Latter Day Saints)
Muslim / Islam (Muslim/Islam)
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None (None)
Other (Other)
Protestant (Protestant)
Other, specify
Marital status (Check one box)
Divorced (Divorced)
Domestic Partnership (Domestic
Partnership)
I Prefer Not To Answer (I prefer not to
answer)
Married (Married)
Never Married (Never married)
Separated (Separated)
Widowed (Widowed)
Where were you born (Check one box Check the
box of the country where you were born)
Other Country (Other country)
Usa (USA)
USA, specify the 2 letter State code (eg NY)
Where did you live the longest (Check one box)
Other Country (Other country)
Usa (USA)
USA, specify the 2 letter State code (eg NY)
Cigarette History
Smoked at least 100 cigarette during lifetime (5
packs)
No (No)
Yes, But Quit (Yes, but quit)
Yes, Currently Smoke (Yes, currently
smoke)
Age began smoking cigarettes
Number of years smoked cigarettes
Average number of cigarettes smoked per day
If quit, age stopped smoking completely
If you have had any of the illnesses listed below,
please check yes for those that apply (check =
Yes)
Bleeding Problems (Bleeding problems)
Circulation Problems (Circulation
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problems)
Diabetes Or Sugar In Urine (Diabetes or
sugar in urine)
Frequent Infections (Frequent infections)
Heart Problems (Heart problems)
High Blood Pressure (High blood
pressure)
Hiv/aids (HIV/AIDS)
Kidney/urine Problems (Kidney/urine
problems)
Liver Problems (Liver problems)
Lung Problems (Lung problems)
Other (Other)
Psychological Problems (Psychological
problems)
Seizure (Seizure)
Stroke (Stroke)
Thyroid Problems (Thyroid problems)
Family History
How many brothers do you have (How many of
the following family members living and dead do
you have? Include only those who are blood-
related)
How many sisters do you have (How many of the
following family members living and dead do you
have? Include only those who are blood-related)
How many sons do you have (How many of the
following family members living and dead do you
have? Include only those who are blood-related)
How many daughters do you have (How many of
the following family members living and dead do
you have? Include only those who are blood-
related)
Are you adopted (Check one In 10C; complete
the question only for your children; omit mother,
father, sisters, brothers)
Yes
No
Blood relative with cancer (check = yes)
Brother #1 (Brother #1)
Brother #2 (Brother #2)
Brother #3 (Brother #3)
Brother #4 (Brother #4)
Child #1 (Child  #1)
Child #2 (Child  #2)
Child #3 (Child  #3)
Child #4 (Child  #4)
Father (Father)
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Mother (Mother)
Sister #1 (Sister  #1)
Sister #2 (Sister  #2)
Sister #3 (Sister  #3)
Sister #4 (Sister  #4)
Age when first cancer diagnosed
Type of Cancer (check = yes)
Breast (Breast)
Colon (Colon)
Head & Neck (Head & Neck)
Lung (Lung)
Non Melanoma Skin (Non Melanoma
Skin)
Other (Other)
Prostate (Prostate)
Specify
Have you ever heard of Cancer Prevention Trials
(Check one box By Cancer Prevention Trials we
mean studies in which healthy people, including
cured cancer patients, volunteer to take part in
experimental cancer prevention, such as the use
of special diets and new drugs. People volunteer
in order to obtain the newest prevention for
themselves and to help scientists learn how well
the new prevention methods work)
Yes
No
How likely would you be to volunteer to
participate in Cancer Prevention Trials (The
numbers below allow you to rate your answer
between 1 - never and 10 - extremely likely. Circle
the number below that best describes your
choice.)
1 (1)
10 (10)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
7 (7)
8 (8)
9 (9)
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Breast Cancer NCT00382070 Registration -
NSABP Test B42 Entry Form - 2707680v1.0
Protocol Entry Form
Letrozole in Treating Postmenopausal Women Who Have
Received Hormone Therapy for Hormone Receptor-Positive
Breast Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=4068726B-
4FD9-3FB9-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/8939
NSABP Test B42 Entry Form
Test
Method of Payment (check all that apply)
Medicaid (Medicaid)
Medicaid And Medicare (Medicaid and
Medicare)
Medicare (Medicare)
Medicare And Private Insurance
(Medicare and Private Insurance)
Military Or Veterans Sponsored Nos
(Military or Veterans Sponsored, Not
Otherwise Specified (NOS))
Military Sponsored (including Champus
& Tricare) (Military Sponsored (including
CHAMPUS & TRICARE))
No Means Of Payment (no Insurance)
(No means of payment (no insurance))
Other (Other)
Private Insurance (Private Insurance)
Self Pay (no Insurance) (Self Pay (No
Insurance))
Unknown (Unknown)
Veterans Sponsored (Veterans
Sponsored)
Header
Race (Check all that apply)
A Person Having Origins In Any Of The
Original Peoples Of North And South
America (including Central America),
And Who Maintains Tribal Affiliation Or
Community Attachment. (American
Indian or Alaska Native)
A Person Having Origins In Any Of The
Original Peoples Of The Far East,
Southeast Asia, Or The Indian
Subcontinent Including, For Example,
Cambodia, China, India, Japan, Korea,
Malaysia, Pakistan, The Philippine
Islands, Thailand, And Vietnam. (Asian)
A Person Having Origins In Any Of The
Black Racial Groups Of Africa. Terms
Such As "haitian" Or "negro" Can Be
Used In Addition To "black Or African
American." (Black or African American)
A Person Having Origins In Any Of The
Original Peoples Of Hawaii, Guam,
Samoa, Or Other Pacific Islands. (Native
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Hawaiian or other Pacific Islander)
Could Not Be Determined Or Unsure
(Unknown)
A Person Having Origins In Any Of The
Original Peoples Of Europe, The Middle
East, Or North Africa. (White)
Last
First
Middle
Site Name
Patient Birth Date
Treating physician
Patient Social Security Number (USA Only)
Module 100
Race (Check all that apply)
A Person Having Origins In Any Of The
Original Peoples Of North And South
America (including Central America),
And Who Maintains Tribal Affiliation Or
Community Attachment. (American
Indian or Alaska Native)
A Person Having Origins In Any Of The
Original Peoples Of The Far East,
Southeast Asia, Or The Indian
Subcontinent Including, For Example,
Cambodia, China, India, Japan, Korea,
Malaysia, Pakistan, The Philippine
Islands, Thailand, And Vietnam. (Asian)
A Person Having Origins In Any Of The
Black Racial Groups Of Africa. Terms
Such As "haitian" Or "negro" Can Be
Used In Addition To "black Or African
American." (Black or African American)
A Person Having Origins In Any Of The
Original Peoples Of Hawaii, Guam,
Samoa, Or Other Pacific Islands. (Native
Hawaiian or other Pacific Islander)
Could Not Be Determined Or Unsure
(Unknown)
A Person Having Origins In Any Of The
Original Peoples Of Europe, The Middle
East, Or North Africa. (White)
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Race
Race (Check all that apply)
A Person Having Origins In Any Of The
Original Peoples Of North And South
America (including Central America),
And Who Maintains Tribal Affiliation Or
Community Attachment. (American
Indian or Alaska Native)
A Person Having Origins In Any Of The
Original Peoples Of The Far East,
Southeast Asia, Or The Indian
Subcontinent Including, For Example,
Cambodia, China, India, Japan, Korea,
Malaysia, Pakistan, The Philippine
Islands, Thailand, And Vietnam. (Asian)
A Person Having Origins In Any Of The
Black Racial Groups Of Africa. Terms
Such As "haitian" Or "negro" Can Be
Used In Addition To "black Or African
American." (Black or African American)
A Person Having Origins In Any Of The
Original Peoples Of Hawaii, Guam,
Samoa, Or Other Pacific Islands. (Native
Hawaiian or other Pacific Islander)
Could Not Be Determined Or Unsure
(Unknown)
A Person Having Origins In Any Of The
Original Peoples Of Europe, The Middle
East, Or North Africa. (White)
Race
Race (Check all that apply)
A Person Having Origins In Any Of The
Original Peoples Of North And South
America (including Central America),
And Who Maintains Tribal Affiliation Or
Community Attachment. (American
Indian or Alaska Native)
A Person Having Origins In Any Of The
Original Peoples Of The Far East,
Southeast Asia, Or The Indian
Subcontinent Including, For Example,
Cambodia, China, India, Japan, Korea,
Malaysia, Pakistan, The Philippine
Islands, Thailand, And Vietnam. (Asian)
A Person Having Origins In Any Of The
Black Racial Groups Of Africa. Terms
Such As "haitian" Or "negro" Can Be
Used In Addition To "black Or African
American." (Black or African American)
A Person Having Origins In Any Of The
Original Peoples Of Hawaii, Guam,
Samoa, Or Other Pacific Islands. (Native
Hawaiian or other Pacific Islander)
Could Not Be Determined Or Unsure
(Unknown)
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A Person Having Origins In Any Of The
Original Peoples Of Europe, The Middle
East, Or North Africa. (White)
Therapy Status
Did this patient receive any tamoxifen? (check all
that apply)
No (No)
Unknown (Unknown)
Yes (Yes)
Tamoxifen Treatment End Date (Cannot be within
past 24 months)
Cumulative Duration of AIs (# months)
Which aromatase inhibitor was most recently
being taken
Is the patient currently receiving an AI
Yes
No
Aromatase inhibitor treatment end date
Date Prior hormonal therapy Started (Total
Duration of Adjuvant Hormone Therapy including
AI: see Protocol Section 4.2.9)
Date Prior hormonal therapy Ended
Was the patient on the B-42 Letrozole
Registration Program
Yes
No
Registration number (If Yes,)
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Breast Cancer NCT00433589 Treatment - End
of chemotherapy treatment - 2497378v1.0
End of chemotherapy treatment
Genetic Testing or Clinical Assessment in Determining the
Need for Chemotherapy in Women With Breast Cancer
That Involves No More Than 3 Lymph Nodes
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=190698C3-
5CE2-7261-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/8940
End of chemotherapy treatment
Header
Patient Birth Date
Patient Hospital Number
Institution Name
Institution No.
Physician of Record
End Of Chemotherapy Treatment
Date Chemotherapy Ended
Total Number of Cycles given
Reason Treatment Ended
Adverse Event/side Effects/complications
(Adverse Event/Side
Effects/Complications)
Death On Study (Death on study)
Disease Progression, Relapse During
Active Treatment (Disease progression,
relapse during active treatment)
Lost To Follow-up (Lost to follow-up)
Other (Other)
Patient Off-treatment For Other
Complicating Disease (Patient off-
treatment for other complicating disease)
Patient Withdrawal Or Refusal After
Beginning Protocol Therapy (Patient
withdrawal/refusal after beginning
protocol therapy)
Treatment Completed Per Protocol
Criteria (Treatment completed per
protocol criteria)
Adverse event/side effects/complications specify
Other specify
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Further Treatment Planned
Endocrine therapy
Yes
No
Survival
Vital Status
Alive (Alive)
Dead (Dead)
Lost To Follow-up (Lost to follow-up)
Date of Last Clinical Assessment
Primary Cause of Death
Due To Other Cause (Due to other
cause)
Due To Protocol Treatment (Due to
protocol treatment)
Due To Second Primary Or Other
Malignancy (Due to second primary or
other malignancy)
Due To This Disease (Due to this
disease)
Unknown (Unknown)
Specify
Due to other cause, specify
Comments
Date
Investigator Signature
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Breast Cancer NCT00433589 Treatment -
Central pathology review - 2498947v1.0
Central pathology review
Genetic Testing or Clinical Assessment in Determining the
Need for Chemotherapy in Women With Breast Cancer
That Involves No More Than 3 Lymph Nodes
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=1967EFD8-
549F-5C8D-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/8941
Central pathology review
Header
Patient Birth Date
Patient Hospital Number
Institution Name
Institution No.
Physician of Record
Central Pathology Review
Date of Assessment
Histologic Type
Adenoid Cystic (Adenoid cystic (pure >
or =90%))
Atypical Lobular Hyperplasia (Atypical
lobular hyperplasia (ALH))
Cribriform (Cribriform)
Cribriform (Cribriform (pure > or =90%))
Ductal (Ductal)
Lobular (Lobular (pure > or =90%))
Medullary (Medullary (pure > or =90%))
Metaplastic Carcinoma (carcinoma With
Metaplasia) (Metaplastic carcinoma
(carcinoma with metaplasia))
Mucinous Adenocarcinoma (Mucinous
(pure > or =90%))
Other Specify (Other)
Tubular (Tubular (pure > or =90%))
Other specify
Histologic Grade
Well Differentiated (Grade I (low))
Moderately Differentiated (Grade II
(intermediate))
Poorly Differentiated (Grade III (high))
Is there vascular invasion
Yes
No
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ER % Positive
Allred score
PR % Positive
Her2/neu expression status by
immunohistochemistry
0 (0)
1+ (1+)
2+ (2+)
3+ (3+)
FISH Result
Amplified (Amplified)
Normal Copy Number (Normal copy
number)
Polysomic (Polysomic)
Comments
Date
Investigator Signature
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Breast Cancer NCT00433589 Treatment -
Endocrine therapy - 2498727v1.0
Endocrine therapy
Genetic Testing or Clinical Assessment in Determining the
Need for Chemotherapy in Women With Breast Cancer
That Involves No More Than 3 Lymph Nodes
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=19677A9A-
FFBD-2E6F-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/8942
Endocrine therapy
Header
Patient Birth Date
Patient Hospital Number
Institution Name
Institution No.
Physician of Record
Endocrine Therapy
Date of Assessment
Tamoxifen Treatment Start Date
Tamoxifen Treatment End Date
Reason Treatment Ended
Adverse Event/side Effects/complications
(Adverse Event/Side
Effects/Complications)
Death On Study (Death on study)
Disease Progression Before Active
Treatment (Disease Progression before
active treatment)
Disease Progression, Relapse During
Active Treatment (Disease progression,
relapse during active treatment)
Lost To Follow-up (Lost to follow-up)
Other (Other)
Patient Withdrawal Or Refusal After
Beginning Protocol Therapy (Patient
withdrawal/refusal after beginning
protocol therapy)
Patient Withdrawal Or Refusal Before
Beginning Protocol Therapy (Patient
withdrawal/refusal prior to beginning
protocol therapy)
Treatment Completed Per Protocol
Criteria (Treatment completed per
protocol criteria)
1 / 2
Adverse event/side effects/complications specify
Other specify
Did patient receive Ovarian Function Suppression
(OFS) during this follow-up period?
Comments
Date
Investigator Signature
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Breast Cancer NCT00659373 On-Study -
Clinical Form (Form 24-B) - 2074000v3.0
Clinical Form (Form 24-B)
Brain Function in Premenopausal Women Receiving
Tamoxifen With or Without Ovarian Function Suppression
for Early-Stage Breast Cancer on Clinical Trial IBCSG-2402
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=B121C37B-
513A-4BC8-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/8943
Clinical Form (Form 24-B)
Ccrr Module For Clinical Form (form 24-b)
Patient ID No. (Study No.)
Patient Initials (f m fl sl)
Patient's Date of Birth (day)
Participating Center/Affiliate
Center Code
Initial Data
Race (Non-North American) (Non-North
American Centers select one)
Asian (Asian)
Black (Black)
Other, Specify (Other, specify)
White / Caucasian (White / Caucasian)
Other, specify (race) (specify)
Race (Ethnicity)
Native_american_cdus (American Indian
or Alaska Native)
Asian_cdus (Asian)
Black_cdus (Black or African American)
Pacific_islander_cdus (Native Hawaiian
or other Pacific Islander)
Unknown (Unknown)
White_cdus (White)
Ethnicity
A Person Of Mexican, Puerto Rican,
Cuban, Central Or South American Or
Other Spanish Culture Or Origin,
Regardless Of Race. (HISPANIC OR
LATINO)
A Person Not Meeting The Definition For
Hispanic Or Latino. (NOT HISPANIC OR
LATINO)
Could Not Be Determined Or Unsure
(UNKNOWN)
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Weight (kg)
Height (cm)
Premenopausal determination
Estradiol Levels (Estradiol levels)
Patient Did Not Receive Chemotherapy,
Patient Menstruating Regularly And Has
Not Had Any Hormonal Contraception Or
Treatment During The 6 Months Before
Randomization (Patient did NOT receive
chemotherapy, patient menstruating
regularly and has not had any hormonal
contraception or treatment during the 6
months before randomization)
Estradiol value used to determine eligibility
(pmol/L)
Date blood drawn for this estradiol level
Institutional lower limit for premenopausal
(pmol/L)
Institutional upper limit for postmenopausal
(pmol/L)
Age at menarche
Date of start of the three recent menstrual cycles
prior to randomization, most recent first (most
recent)
Menstruation (select one)
Occasionally Irregular Or Lengthened
Interval, But Continuing Menstrual
Cycles (Irregular)
Normal (Normal)
Persistent Amenorrhea (Persistent
amenorrhea)
Has the patient had a hysterectomy? (D  M  Y )
No (No)
Yes (Yes, specify reason(s) performed)
Specify reason(s) performed
History of diabetes?
Yes
No
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2074000v3.0
Has patient ever been pregnant, regardless of
outcome?
Yes
No
Total number of pregnancies
Number of successful pregnancies which
resulted in at least 1 live birth
Number of early completions
Year of first pregnancy
Year of most recent pregnancy
Was patient pregnant at diagnosis?
Yes
No
Primary Disease
Tumor Laterality
Bilateral (Bilateral)
Left (Left)
Right (Right)
Predominant site of primary right breast/side
Lateral (Lateral)
Medial (Medial)
On The Vertical Central Line (On the
vertical central line)
Other, Specify (Other, specify)
Predominant site of primary left breast/side
Lateral (Lateral)
Medial (Medial)
On The Vertical Central Line (On the
vertical central line)
Other, Specify (Other, specify)
Other specify
Other specify
Required Clinical Investigations
Chest X-ray or chest CT
Abnormal (Abnormal)
Normal (Normal)
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Results
Right mammogram (PA and lateral views)
Abnormal (Abnormal)
Normal (Normal)
Results
Left mammogram (PA and lateral views)
Suspicious For Metastases (Abnormal)
No Metastases (Normal)
Results
Bone Scan
Abnormal (Abnormal)
Normal (Normal)
Not Done (Not Done)
Results
Additional test(s) to rule out bone metastasis
Bone densitometry
Below Normal (Below Normal)
Normal (Normal)
Not Done (Not Done)
Date performed
SGOT (AST)
Abnormal (Abnormal)
Normal (Normal)
Not Done (Not Done)
SGOT
SGPT (ALT)
Abnormal (Abnormal)
Normal (Normal)
Not Done (Not Done)
SGPT
Alkaline Phosphatase
Abnormal (Abnormal)
Normal (Normal)
Not Done (Not Done)
Alkaline Phosphatase
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Bilirubin
Abnormal (Abnormal)
Normal (Normal)
Not Done (Not Done)
Bilirubin
Peripheral WBC Count x 10^9/l
Abnormal (Abnormal)
Normal (Normal)
Not Done (Not Done)
Peripheral WBC Count
Peripheral Platelet Count x 10^9/l
Abnormal (Abnormal)
Normal (Normal)
Not Done (Not Done)
Peripheral Platelet Count
Hemoglobin g/l
Abnormal (Abnormal)
Normal (Normal)
Not Done (Not Done)
Hemoglobin
Performance status at randomization (Karnofsky
90-100)
2 (Ambulatory and capable of all selfcare
but unable to carry out any work
activities (K 50 - 60))
3 (Capable of only limited selfcare,
confined to bed or chair more than 50%
of waking hours (K 30 - 40))
4 (Completely disabled)
0 (Fully active, able to carry on all pre-
disease performance without restriction)
1 (Restricted in physically strenuous
activity, but ambulatory)
Family History
Any known female blood relative(s) diagnosed
with breast cancer or ovarian cancer?
No (No)
Patient Adopted (Patient adopted)
Yes (Yes)
Relative (unnamed)
Daughter(s) (Daughter(s))
Maternal Aunt(s) (Maternal aunt(s))
Maternal Grandmother (Maternal
grandmother)
Mother (Mother)
Paternal Aunt(s) (Paternal aunt(s))
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Paternal Grandmother (Paternal
grandmother)
Sister(s) (Sister(s))
Diagnosed with breast cancer
Yes
No
Diagnosed with ovarian cancer
Yes
No
Age diagnosed
Age diagnosed
Total number (of relatives)
Number with breast cancer
Number with ovarian cancer
Youngest age diagnosed
Youngest age diagnosed
Any known male blood relatives diagnosed with
breast cancer?
Yes
No
Specify family relationship.
Investigator Signature (/Designee)
Date
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2074000v3.0
Breast Cancer NCT01272037 Registration - S1007
Registration Worksheet Form - Step 1 - 3139482v1.0
S1007 Registration Worksheet Form - Step 1
Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane
With or Without Chemotherapy in Treating Patients With
Invasive RxPONDER Breast Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=90C7517A-
44AF-82BC-E040-BB89AD432492
All rights reserved. Please visit https://medical-data-
models.org/forms/8944
S1007 Registration Worksheet Form
- Step 1
Header
Activation Date (MM DD YYYY)
Last Amended Date (MM DD YYYY)
Registration Step
Swog Patient Id
SWOG Patient ID Status
New Patient (New patient)
Previous Patient (Previous patient)
SWOG Patient ID
Demography
Patient First Name
Patient Middle Name
Patient Last Name
Unnamed2
Registrar's SWOG Roster ID Number
SWOG Investigator Number
SWOG Treating Institution Number
Unnamed5
Date Informed Consent Signed (MM DD YYYY)
Date HIPAA Authorization signed (Not required if
Country of Residence is not USA MM DD YYYY)
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Projected Start Date of Treatment (MM DD
YYYY)
Auxiliary Question
Is the patient's Oncotype DX® Recurrence Score
already known to be 25 or less?
Yes
No
Unnamed4
I choose to take part in the Quality of Life and
Economic Analysis Study. I agree to fill out the
Quality of Life Questionnaires and to allow
information about my health insurance claims to
be sent to researchers.
Yes
No
I agree to allow my study doctor, or someone
approved by my study doctor, to contact me
regarding future research involving my
participation in this study.
Yes
No
Unnamed 7
Has the Southwest Oncology Group Registration
Worksheet been completed entirely and is the
patient eligible according to the current version of
protocol section 5.1 - 5.15?
Yes
No
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Breast Cancer NCT01272037 Registration - S1007 Registration
Worksheet Form - Step 1 - 3139482v1.0
Breast Cancer NCT00659373 Pathology - Bilateral
Surgery Form (Form 24-BC) - 2408466v1.0
Bilateral Surgery Form (Form 24-BC)
Brain Function in Premenopausal Women Receiving
Tamoxifen With or Without Ovarian Function Suppression
for Early-Stage Breast Cancer on Clinical Trial IBCSG-2402
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=01617880-
D901-0B38-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/8945
Bilateral Surgery Form (Form 24-BC)
Ccrr Module For Surgery Form (form 24-c)
Patient ID No. (CCRR MODULE FOR Surgery
Form Form 24-C)
Patient Initials (CCRR MODULE FOR Surgery
Form Form 24-C)
Patient's Date of Birth (CCRR MODULE FOR
Surgery Form Form 24-C)
Participating Center/Affiliate
Center Code
This form is being completed for
Left Breast/side (Left breast/side)
Right Breast/side (Right breast/side)
Date of Initial Pathologic Diagnosis (CCRR
MODULE FOR Surgery Form Form 24-C)
Type (LTM = less than mastectomy)
Core Biopsy (Core biopsy)
Fine Needle Aspiration (Fine needle
aspiration)
Ltm: Lump Excision/complete Local
Excision (LTM: lump excision/complete
local excision)
Ltm: Partial Mastectomy/quadrantectomy
(LTM: partial
mastectomy/quadrantectomy)
Ltm: Re-excision For Unclear Or Positive
Margins (LTM: re-excision for unclear or
positive margins)
Ltm: Subcutaneous Mastectomy (LTM:
subcutaneous mastectomy)
Ltm: Subtotal Mastectomy (LTM: subtotal
mastectomy)
Mastectomy (Mastectomy)
Other (Other)
Other Biopsy (Other biopsy)
Other, (CCRR MODULE FOR Surgery Form
Form 24-C)
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Surgery Date (CCRR MODULE FOR Surgery
Form Form 24-C)
PATHOLOGICAL FINDINGS (CCRR MODULE
FOR Surgery Form Form 24-C)
In Situ Without Invasion (IN SITU without
invasion)
Invasive Cancer (Invasive cancer)
Malignant Cells On Fna (Malignant cells
on FNA)
No Malignancy (No malignancy)
Suspicious For Malignancy (Suspicious
for malignancy)
Was sentinel node biopsy performed? (CCRR
MODULE FOR Surgery Form Form 24-C)
Yes
No
Sentinel Node Biopsy Date (CCRR MODULE
FOR Surgery Form Form 24-C)
Was axillary dissection performed? (CCRR
MODULE FOR Surgery Form Form 24-C)
Yes
No
Date of axillary dissection (CCRR MODULE FOR
Surgery Form Form 24-C)
Investigator Signature (/Designee)
Date
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24-BC) - 2408466v1.0
Breast Cancer NCT00856492 Registration - Southwest Oncology
Group S0800 Registration Worksheet Form - 3019867v1.0
Southwest Oncology Group S0800 Registration Worksheet
Form
Paclitaxel Albumin-Stabilized Nanoparticle Formulation,
Doxorubicin, Cyclophosphamide, and Pegfilgrastim With or
Without Bevacizumab in Treating Women With
Inflammatory or Locally Advanced Breast Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=814C8E57-
4D2D-39D5-E040-BB89AD43710A
All rights reserved. Please visit https://medical-data-
models.org/forms/8947
Southwest Oncology Group S0800
Registration Worksheet Form
Header
Activation Date (MM DD YYYY)
Last Amended Date (MM DD YYYY)
Registration Step
Swog Patient Id
SWOG Patient ID Status
New Patient (New patient)
Previous Patient (Previous patient)
SWOG Patient ID
Demography
Patient First Name
Patient Middle Name
Patient Last Name
Unnamed2
Registrar's SWOG Roster ID Number
SWOG Investigator Number
SWOG Treating Institution Number
Unnamed5
Date Informed Consent Signed (MM DD YYYY)
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Date HIPAA Authorization signed (Not required if
Country of Residence is not USA MM DD YYYY)
Projected Start Date of Treatment (MM DD
YYYY)
Stratification Questions
Disease
Receptor status
Unnamed4
My specimens may be kept for use in research to
learn about, prevent, treat, or cure cancer.
Yes
No
My specimens may be kept for use in research
about other health problems (for example:
diabetes, Alzheimer's disease, or heart disease).
Yes
No
Someone may contact me in the future to ask me
to allow other uses of my specimens.
Yes
No
I agree to allow my study doctor, or someone
approved by my study doctor, to contact me
regarding future research involving my
participation in this study
Yes
No
I agree to submit a blood specimen for genetic
expression studies to study what role the protocol
treatment is having on my disease
Yes
No
I agree to submit my tissue for additional follow-
up angiogenic and other biomarker studies to see
what role the treatment is having on my disease
No (No)
Post Chemo Specimens Only (Post
chemo specimens only)
Week 9 Specimens Only (Week 9
specimens only)
Yes (Yes)
Unnamed 7
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Breast Cancer NCT00856492 Registration - Southwest Oncology Group
S0800 Registration Worksheet Form - 3019867v1.0
Has the Southwest Oncology Group Registration
Worksheet been completed entirely and is the
patient eligible according to the current version of
protocol section 5.0
Yes
No
Auxiliary Question
Has the patient consented to participate in the
Diffusion MRI substudy
Yes
No
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Breast Cancer NCT00856492 Registration - Southwest Oncology Group
S0800 Registration Worksheet Form - 3019867v1.0
Breast Cancer NCT00659373 Pathology - Bilateral
Pathology Form (Form 24-BP) - 2414361v1.0
Bilateral Pathology Form (Form 24-BP)
Brain Function in Premenopausal Women Receiving
Tamoxifen With or Without Ovarian Function Suppression
for Early-Stage Breast Cancer on Clinical Trial IBCSG-2402
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=023F7058-
16FD-152E-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/8950
Bilateral Pathology Form (Form 24-
BP)
Ccrr Module For Pathology Form (form 24-
p)
Patient ID No. (CCRR MODULE FOR Pathology
Form Form 24-P)
Patient Initials (f m fl sl)
Patient's Date of Birth (CCRR MODULE FOR
Pathology Form Form 24-P)
Participating Center/Affiliate
Center Code
Header
Specimen ID Number
Adjacent normal tissue block specimen number
Primary tumor slide specimen number
Adjacent normal breast tissue slide specimen
number
This form is being completed for
Left Breast/side (Left breast/side)
Right Breast/side (Right breast/side)
Primary Tumor
Pathologic primary tumor size. Maximum
diameter of invasive component. (cm )
Histological type (PRIMARY TUMOR)
in situ lobular carcinoma (in situ lobular
carcinoma)
intraductal (in situ) carcinoma, high
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grade (intraductal (in situ) carcinoma,
high grade)
intraductal (in situ) carcinoma, low grade
(intraductal (in situ) carcinoma, low
grade)
intraductal (in situ) carcinoma, moderate
grade (intraductal (in situ) carcinoma,
moderate grade)
invasive cribriform, mixed (invasive
cribriform, mixed)
invasive cribriform, pure (invasive
cribriform, pure)
invasive ductal (NOS) (invasive ductal
(NOS))
invasive ductal with predominant
intraductal component (invasive ductal
with predominant intraductal component)
invasive lobular - classic type (invasive
lobular - classic type)
invasive lobular - variant type (invasive
lobular - variant type)
medullary (medullary)
medullary-atypical (medullary-atypical)
mucinous (colloid) (mucinous (colloid))
mucinous (colloid) - variant (mucinous
(colloid) - variant)
no cancer on slide (no cancer on slide)
other, specify (other, specify)
tubular (tubular)
tubular-variant (tubular-variant)
other,  (PRIMARY TUMOR)
Grade
Total points - Bloom, Richardson, Elston (Grade)
(GRADE)
Tubule formation (GRADE)
Nuclear pleomorphism (GRADE)
Mitoses (GRADE)
Differentiation (GRADE)
Tumor Is Moderately Differentiated
According To Who Grading System
(Moderately differentiated)
Tumor Is Poorly Differentiated According
To Who Grading System (Poorly
differentiated)
Tumor Is Well Differentiated According
To Who Grading System (Well
differentiated)
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Excision Margins
Invasive cancer
<= 1 Mm, But Not Involved (<= 1 mm,
but not involved)
> 1 And <= 10 Mm (> 1 and <= 10 mm)
> 10 Mm (> 10 mm)
Not Involved, But Distance Not
Assessable (Not involved, but distance
not assessable)
DCIS
<= 1 Mm, But Not Involved (<= 1 mm,
but not involved)
> 1 And <= 10 Mm (> 1 and <= 10 mm)
> 10 Mm (> 10 mm)
Not Involved, But Distance Not
Assessable (Not involved, but distance
not assessable)
Vessel Invasion
Was there invasion of vessels around primary
tumor?  (VESSEL INVASION)
No (No)
Not Able To Assess (Not able to assess)
Yes (Yes)
Her2/neu
Score by immunohistochemistry
0 (0)
1+ (1+)
2+ (2+)
3+ (3+)
Not Done (Not done)
Immunohistochemistry Kit or Test Type
Dako Herceptest [tm] (DAKO Herceptest
[TM])
Other, Specify (Other, specify)
Other, specify (assay) (HER2/NEU)
By FISH
Amplified (Amplified)
Normal Copy Number (Normal copy
number)
Not Done (Not done)
Polysomic (Polysomic)
Type of Assay
Dako (DAKO)
Oncor (Oncor)
Other, Specify (Other, specify)
Vysis (Vysis)
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Other, specify (assay) (HER2/NEU)
By other technique, (Her2/neu) (HER2/NEU)
Her2/neu status, (by other technique)
Negative (Negative)
Not Done (Not done)
Positive (Positive)
Nodal Involvement
Total number examined
Number of metastatic axillary lymph nodes
Extracapsular Extension (NODAL
INVOLVEMENT)
Yes
No
Isolated tumor cells only
Yes
No
Total number examined
Number of metastatic axillary sentinel lymph
nodes
Largest tumor deposit
Isolated Tumor Cells Alone (Isolated
tumor cells alone)
Macrometastases (Macrometastases)
Micrometastases (Micrometastases)
None Detected (None detected)
Largest tumor deposit
Isolated Tumor Cells Alone (Isolated
tumor cells alone)
Macrometastases (Macrometastases)
Micrometastases (Micrometastases)
None Detected (None detected)
Total number examined
Number of metastatic internal mammary sentinel
nodes
Form completed by (NODAL INVOLVEMENT)
Investigator (Investigator)
Pathologist (Pathologist)
Comments (NODAL INVOLVEMENT)
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(Form 24-BP) - 2414361v1.0
Investigator/Pathologist Signature
Date
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(Form 24-BP) - 2414361v1.0
Breast Cancer NCT01439711 Registration - CALGB-
40903 OPEN Registration Worksheet - 3302958v1.0
CALGB-40903 OPEN Registration Worksheet
Letrozole in Treating Postmenopausal Women With Ductal
Carcinoma in Situ
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=B163AFA0-
47EE-9956-E040-BB89AD4304B2
All rights reserved. Please visit https://medical-data-
models.org/forms/8951
CALGB-40903 OPEN Registration
Worksheet
Protocol Administration
Date Informed Consent Signed (MM DD YYYY)
HIPAA Authorization Date (MM DD YYYY)
Projected Start Date of Treatment (MM DD
YYYY)
Pre-treatment Characteristics
Performance Status
Fully Active, Able To Carry On All Pre-
disease Performance Without
Restriction. (0)
Restricted In Physically Strenuous
Activity But Ambulatory And Able To
Carry Out Work Of A Light Or Sedentary
Nature, E.g., Light Housework, Office
Work. (1)
Height (cm)
Weight (kg)
Disease code (breast)
Certification Of Eligibility
In the opinion of the investigator, is the patient
eligible
Yes
No
Protocol Design (stratification Factors)
Is the institution pre-qualified by ACRIN for breast
MRI acquisition
Yes
No
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Notes:
ACRIN qualification date (MM DD YYYY)
Name (ACRIN Contact Person responsible for
obtaining ACRIN pre-qualification, sending
images and responding to ACRIN queries:)
Email address
Phone
Fax
Companion Study Calgb - 150714
I choose to take part in the Quality of Life study
and agree to complete the QOL assessments
(consent question #1)
Yes
No
Initial Patient Consent For Specimen Use
I agree that my tissue may be used for the
research described in the protocol. (consent
question #2 - must be Yes for participation in
151008)
Yes
No
In the opinion of the investigator, is the patient
eligible
Yes
No
Initial Patient Consent For Specimen Use
Patient's initial consent given for specimen use
for genetic research relating to the study
treatment (consent question #3 - must be Yes for
participation in 61105)
Yes
No
In the opinion of the investigator, is the patient
eligible
Yes
No
Initial Patient Consent For Specimen Use
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Registration Worksheet - 3302958v1.0
My specimens may be kept for future unknown
use in research to learn about, prevent, treat, or
cure cancer (consent question #4)
Yes
No
My specimens may be kept for use in research
about other health problems (for example:
diabetes, Alzheimer's disease, or heart disease).
(consent question #5)
Yes
No
In the opinion of the investigator, is the patient
eligible
Yes
No
My doctor or someone may contact me in the
future to ask me to take part in more research
(consent question #6)
Yes
No
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Breast Cancer NCT01272037 Registration - S1007
Registration Worksheet Form - Step 2 - 3139539v1.0
S1007 Registration Worksheet Form - Step 2
Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane
With or Without Chemotherapy in Treating Patients With
Invasive RxPONDER Breast Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=90C7517A-
4524-82BC-E040-BB89AD432492
All rights reserved. Please visit https://medical-data-
models.org/forms/8952
S1007 Registration Worksheet Form
- Step 2
Header
Activation Date (MM DD YYYY)
Last Amended Date (MM DD YYYY)
Registration Step
Swog Patient Id
SWOG Patient ID
Unnamed2
Registrar's SWOG Roster ID Number
SWOG Investigator Number
SWOG Treating Institution Number
Unnamed5
Projected Start Date of Treatment (MM DD
YYYY)
Stratification Questions
Recurrence Score
Menopausal Status
Type of nodal dissection
Unnamed4
1 / 2
I choose to take part in the Quality of Life and
Economic Analysis Study. I agree to fill out the
Quality of Life Questionnaires and to allow
information about my health insurance claims to
be sent to researchers.
Yes
No
I agree to allow my study doctor, or someone
approved by my study doctor, to contact me
regarding future research involving my
participation in this study.
Yes
No
My specimens may be kept for use in research to
learn about, prevent, treat, or cure cancer.
Yes
No
My specimens may be kept for use in research
about other health problems (for example:
diabetes, Alzheimer's disease, or heart disease).
Yes
No
Someone may contact me in the future to ask me
to allow other uses of my specimens.
Yes
No
Unnamed 7
Has the Southwest Oncology Group Registration
Worksheet been completed entirely and is the
patient eligible according to the current version of
protocol section 5.16 - 5.20?
Yes
No
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Worksheet Form - Step 2 - 3139539v1.0
Breast Cancer NCT01124695 Eligibility - E3108
Registration Worksheet (step 1) - 3133390v1.0
E3108 Registration Worksheet (step 1)
Tamoxifen Citrate in Treating Patients With Metastatic or
Recurrent Breast Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=8EBE5DB9-
5474-798F-E040-BB89AD430AFF
All rights reserved. Please visit https://medical-data-
models.org/forms/8954
E3108 Registration Worksheet (step
1)
Eligibility
Has the eligibility checklist been completed
Yes
No
In the opinion of the investigator, is the patient
eligible?
Yes
No
Has written informed consent been obtained
Yes
No
Date Informed Consent Signed
Has HIPAA authorization been obtained
Exempt - Non-usa Participant (Exempt -
non-USA participant)
No: C49487 (No)
Yes: C49488 (Yes)
HIPAA Authorization Date
Patient's simplified disease code
Breast Carcinoma Not Otherwise
Specified (Breast cancer, NOS)
Invasive Breast Carcinoma (Invasive
breast carcinoma)
I agree to provide additional specimens for
research
Yes
No
May your coded samples and related coded
information be kept for use in research to learn
about, prevent, find or treat cancer?  This may
also include research on inherited traits (genes
passed on in families).
Yes
No
May your coded samples and related coded
information be kept for use in research to learn
about, prevent, find or treat other health problems
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(for example: diabetes, Alzheimer's disease, or
heart disease)?  This may also include research
on inherited traits (genes passed on in families).
Yes
No
Someone from my hospital or the Eastern
Cooperative Oncology Group may contact me in
the future to ask me to take part in more
research.
Yes
No
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(step 1) - 3133390v1.0
Breast Cancer NCT01275677 Follow-Up - NSABP-
B-47 Follow-Up Form (Form F) - 3161621v1.0
NSABP-B-47 Follow-Up Form (Form F)
A Randomized Phase III Trial of Adjuvant Therapy
Comparing Chemotherapy Alone (Six Cycles of Docetaxel
Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus
Cyclophosphamide Followed by Weekly Paclitaxel) to
Chemotherapy Plus Trastuzumab in Women With Node-
Positive or High-Risk Node-Negative HER2-Low Invasive
Breast Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=9556F723-
E4C3-09D5-E040-BB89AD433F36
All rights reserved. Please visit https://medical-data-
models.org/forms/8955
NSABP-B-47 Follow-Up Form (Form
F)
Header
Patient Initials (Last First Middle)
NSABP Patient ID
Vital Status
Patient's Vital Status
Alive (Alive)
Dead (Dead)
Date of Last Contact or Death (month day year)
Source of Survival Information (if alive)
Documentation Of Hospital Or Clinic Visit
(Documentation of hospital or clinic visit)
Other (Other)
Phone Contact To Patient (Phone
contact to patient)
Other,
Primary Cause of Death (if dead)
Due To Other Cause (Due to other
cause)
Due To Protocol Treatment (Due to
protocol treatment)
Due To This Disease (Due to this
disease)
Unknown (Unknown)
Describe Cause of Death (Provide
documentation)
Was there evidence of recurrence at the time of
death
No (No)
Unknown (Unknown)
Yes (Yes)
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First Recurrence
Has the patient been diagnosed with first
recurrence since submission of the last follow-up
form (excluding LCIS)
Yes
No
Was the First Recurrence DCIS Alone in the
ipsilateral breast following lumpectomy
Yes
No
Date of DCIS Alone in Ipsilateral Breast following
lumpectomy (If yes Month Day Year)
First Invasive Local Recurrence
Has the patient been diagnosed with first invasive
local recurrence since submission of the last
follow-up form
Yes
No
Date of First Invasive Local Recurrence (if
applicable Month Day Year)
Site of first recurrence/progression (s Mark all
that apply)
Ipsilateral Breast (Ipsilateral breast)
Ipsilateral Chest Wall (Ipsilateral chest
wall)
Skin Of Ipsilateral Breast (Skin of
ipsilateral breast)
Skin Of Ipsilateral Chest Wall (Skin of
ipsilateral chest wall)
First Local-regional Recurrence
Has the patient been diagnosed with first regional
recurrence since submission of the last follow-up
form
Yes
No
Date of first regional recurrence (if applicable
Month Day Year)
Site of First Regional Recurrence (s mark all
ipsilateral sites that apply)
Axilla (Axilla)
Axillary Nodes (Axillary nodes)
Infraclavicular Nodes (Infraclavicular
nodes)
Internal Mammary (Internal mammary
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nodes)
Supraclavicular Nodes (Supraclavicular
nodes)
First Central Nervous System Recurrence
Has the patient been diagnosed with first central
nervous system recurrence since submission of
the last follow-up form (CNS )
Yes
No
Date of First CNS Recurrence (if applicable
Month Day Year)
Site of First CNS Recurrence (s)
First Distant Recurrence
Has the patient been diagnosed with first distant
recurrence since submission of the last follow-up
form? (other than CNS recurrence)
Yes
No
Date of First Distant Recurrence (if applicable
Month Day Year)
Site(s) of First Distant Recurrence
New Primary Cancer Or Mds
Has a new primary cancer or MDS been
diagnosed that has not been previously reported?
Yes
No
Date of Diagnosis (if applicable Month Day Year)
Site(s) of New Primary
Patient Height And Weight
Was patient height measured since the previous
follow-up report
Yes
No
Height (If yes cm)
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Was patient weight measured since the previous
follow-up report
Yes
No
Weight (If yes kg)
Late Thrombotic Event
Has the patient been diagnosed with any of the
following cardiac events since submission of the
last follow-up form? (If yes, Indicate applicable
grade in the following table, and provide
supporting documentation. The online software
will provide a transmittal form that must be
printed. Fax this transmittal form with the
supporting documentation to 412-622-2111. A
Cardiac Report Form Form CR must be
submitted via Coordinator Online, and all required
documentation must be provided)
Yes
No
Adverse Event
Acute Coronary Syndrome (Acute
coronary syndrome)
Heart Failure (Heart failure)
Left Ventricular Systolic Dysfunction (Left
ventricular systolic dysfunction)
Myocardial Infarction (Myocardial
infarction)
Grade
Moderate Adverse Event (2)
Severe Adverse Event (3)
Life Threatening Adverse Event (4)
Death Related To Adverse Event (5)
Footer Module
Comments (Optional)
Person Completing Form
Date Form Completed (MM DD YYYY)
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Breast Cancer NCT00785291 Registration - CALGB-
40502 OPEN Registration Worksheet - 3057089v1.0
CALGB-40502 OPEN Registration Worksheet
Paclitaxel, Paclitaxel Albumin-Stabilized Nanoparticle
Formulation, or Ixabepilone With or Without Bevacizumab
in Treating Patients With Stage IIIC or Stage IV Breast
Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=83D2C45E-
345D-C493-E040-BB89AD4375BE
All rights reserved. Please visit https://medical-data-
models.org/forms/8956
CALGB-40502 OPEN Registration
Worksheet
Protocol Administration
Date Informed Consent Signed (MM DD YYYY)
HIPAA Authorization Date (MM DD YYYY)
Projected Start Date of Treatment (MM DD
YYYY)
Institution/Affiliate
Physician of Record
NCI Investigator Number
NCI Institution Number
Patient Demographics/pre-treatment
Characteristics2
Disease (Breast Neoplasm NOS)
Stage
Any T, N3, M0 (IIIC)
Any T, Any N, M1 (IV)
Pathologic type (Invasive)
Certification Of Eligibility
In the opinion of the investigator, is the patient
eligible
Yes
No
Certification Of Eligibility And Protocol
Design
Prior Taxane as Adjuvant therapy or Neoadjuvant
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therapy
Yes
No
Receptor Status (ER/PgR)
Er And Pgr Negative (ER and PgR
negative)
Er Or Pgr Positive (ER or PgR positive)
Assigned Treatment Arm
Arm A = Paclitaxel + Bevacizumab (Arm
A = Paclitaxel + Bevacizumab)
Arm B = Nab-paclitaxel + Bevacizumab
(Arm B = Nab-Paclitaxel + Bevacizumab)
Arm C = Ixabepilone + Bevacizumab
(Arm C = Ixabepilone + Bevacizumab)
Companion Study Calgb - 150714
Patient's initial consent given for specimen use
(150714 If a patient answers "yes" to "My
specimens may be used for the research
described above." question #1 in the model
consent, they have consented to participate in the
substudy described in Appendix I. The patient
should be registered to CALGB - 150714)
Yes
No
In the opinion of the investigator, is the patient
eligible
Yes
No
Companion Study Calgb - 60704
Patient's initial consent given for specimen use
for genetic research relating to the study
treatment (60704 If a patient answers "yes" to
"My blood specimen may be used for the genetic
research described above." question #2 in the
model consent, they have consented to
participate in the substudy described in Appendix
II.)
Yes
No
In the opinion of the investigator, is the patient
eligible
Yes
No
Initial Patient Consent For Specimen Use
Patient's Initial Consent given for specimen kept
for future use in research to learn about, prevent,
or treat cancer (model consent question #3)
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Yes
No
Patient's initial consent given for specimen(s)
may be kept for use in research to learn about,
prevent, or treat other health problems (for
example:
diabetes, Alzheimer's disease, or heart disease)
(model consent question #4)
Yes
No
Someone may contact me in the future to ask me
to take part in more research. (model consent
question #5)
Yes
No
Companion Study Calgb - 70501
Did the patient consent to participate in 70501
(approved CALGB institutions only If yes, register
the patient to 70501 during registration to CALGB
40502)
Yes
No
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Breast Cancer NCT00659373 Pathology - Bilateral
Hormone Receptor Form (Form 24-BF) - 2409866v1.0
Bilateral Hormone Receptor Form (Form 24-BF)
Brain Function in Premenopausal Women Receiving
Tamoxifen With or Without Ovarian Function Suppression
for Early-Stage Breast Cancer on Clinical Trial IBCSG-2402
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=01609FC5-
4143-11A6-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/8957
Bilateral Hormone Receptor Form
(Form 24-BF)
Ccrr Module For Hormone Receptor Form
(form 24-f)
Patient ID No. (CCRR MODULE FOR Hormone
Receptor Form Form 24-F)
Patient Initials (CCRR MODULE FOR Hormone
Receptor Form Form 24-F)
Patient's Date of Birth (CCRR MODULE FOR
Hormone Receptor Form Form 24-F)
Participating Center/Affiliate
Center Code
This form is being completed for
Left Breast/side (Left breast/side)
Right Breast/side (Right breast/side)
Specimen ID Number (CCRR MODULE FOR
Hormone Receptor Form Form 24-F)
Date Specimen Collected (CCRR MODULE FOR
Hormone Receptor Form Form 24-F)
ER % Positive (Results of immunohistochemistry
IHC: Percent of positive cells use 0-100)
PR % Positive (Results of immunohistochemistry
IHC: Percent of positive cells use 0-100)
ER status (CCRR MODULE FOR Hormone
Receptor Form Form 24-F)
Negative (Negative)
Positive (Positive)
Unknown (Unknown)
PgR status (CCRR MODULE FOR Hormone
Receptor Form Form 24-F)
Negative (Negative)
Positive (Positive)
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Unknown (Unknown)
Investigator Signature
Date
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Breast Cancer Registration - S1101
Registration Worksheet Step 1 - 3252541v1.0
S1101 Registration Worksheet Step 1
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=A7CED929-
76C4-7ED1-E040-BB89AD4359CF
All rights reserved. Please visit https://medical-data-
models.org/forms/8958
S1101 Registration Worksheet Step
1
Header
Activation Date (MM DD YYYY)
Last Amended Date (MM DD YYYY)
Registration Step
Swog Patient Id
SWOG Patient ID Status
New Patient (New patient)
Previous Patient (Previous patient)
SWOG Patient ID
Demography
Patient First Name
Patient Middle Name
Patient Last Name
Unnamed2
Registrar's SWOG Roster ID Number
SWOG Investigator Number
SWOG Treating Institution Number
Unnamed5
Date Informed Consent Signed (MM DD YYYY)
Date HIPAA Authorization signed (Not required if
Country of Residence is not USA MM DD YYYY)
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Projected Start Date of Treatment (MM DD
YYYY)
Unnamed4
My specimens may be kept for use in research to
learn about, prevent, treat, or cure cancer.
Yes
No
My specimens may be kept for use in research
about other health problems (for example:
diabetes, Alzheimer's disease, or heart disease).
Yes
No
Someone may contact me in the future to ask me
to allow other uses of my specimens.
Yes
No
I agree to allow my study doctor, or someone
approved by my study doctor, to contact me
regarding future research involving my
participation in this study
Yes
No
Unnamed 7
Has the SWOG Registration Worksheet been
completed entirely and is the patient eligible
according to the current version of protocol
section 5.0?
Yes
No
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Breast Cancer NCT00914043 Quality of Life - NSABP
B-45 Quality of Life Questionnaire Form - 2847215v1.0
NSABP B-45 Quality of Life Questionnaire Form
Studying Biological Markers of Fatigue in Women With
Residual Invasive Breast Cancer Enrolled on Clinical Trial
NSABP-B-45
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=64B2569C-
B533-2D46-E040-BB89AD432515
All rights reserved. Please visit https://medical-data-
models.org/forms/8959
NSABP B-45 Quality of Life
Questionnaire Form
Header
Patient Initials (Last First Middle)
NSABP Patient ID
Institution/Affiliate
Staff member administering form
Staff member administering form
Phone
Are data amended
Yes
No
Time Point
Time point (mark one)
12 Months After Randomization (12
months after randomization)
18 Months After Randomization (18
months after randomization)
24 Months After Randomization (24
months after randomization)
3 Months After Randomization (3 months
after randomization)
6 Months After Randomization (6 months
after randomization)
Within 2 Weeks Prior To Randomization
(Within 2 weeks prior to randomization)
This form is being filled out (mark one)
By Clinical Staff On Phone With
Participant (By clinical staff on phone
with participant)
By Patient In Doctor's Office (By
participant in doctor's office)
By Participant Not In Doctor's Office (By
participant not in doctor's office)
Other (Other)
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Date Questionnaire Completed (MM DD YYYY)
Qol
Nausea
Bothered A Little Bit (Bothered a little bit)
Bothered Quite A Bit (Bothered quite a
bit)
Bothered Very Much (Bothered very
much)
Not At All Bothered (Not at all bothered)
Somewhat Bothered (Somewhat
bothered)
vomiting
Bothered A Little Bit (Bothered a little bit)
Bothered Quite A Bit (Bothered quite a
bit)
Bothered Very Much (Bothered very
much)
Not At All Bothered (Not at all bothered)
Somewhat Bothered (Somewhat
bothered)
diarrhea
Bothered A Little Bit (Bothered a little bit)
Bothered Quite A Bit (Bothered quite a
bit)
Bothered Very Much (Bothered very
much)
Not At All Bothered (Not at all bothered)
Somewhat Bothered (Somewhat
bothered)
Difficulty with bladder control (when laughing or
crying)
Bothered A Little Bit (Bothered a little bit)
Bothered Quite A Bit (Bothered quite a
bit)
Bothered Very Much (Bothered very
much)
Not At All Bothered (Not at all bothered)
Somewhat Bothered (Somewhat
bothered)
Difficulty with bladder control (at other times)
Bothered A Little Bit (Bothered a little bit)
Bothered Quite A Bit (Bothered quite a
bit)
Bothered Very Much (Bothered very
much)
Not At All Bothered (Not at all bothered)
Somewhat Bothered (Somewhat
bothered)
Hot flashes
Bothered A Little Bit (Bothered a little bit)
Bothered Quite A Bit (Bothered quite a
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bit)
Bothered Very Much (Bothered very
much)
Not At All Bothered (Not at all bothered)
Somewhat Bothered (Somewhat
bothered)
genital itching or irritation
Bothered A Little Bit (Bothered a little bit)
Bothered Quite A Bit (Bothered quite a
bit)
Bothered Very Much (Bothered very
much)
Not At All Bothered (Not at all bothered)
Somewhat Bothered (Somewhat
bothered)
vaginal discharge
Bothered A Little Bit (Bothered a little bit)
Bothered Quite A Bit (Bothered quite a
bit)
Bothered Very Much (Bothered very
much)
Not At All Bothered (Not at all bothered)
Somewhat Bothered (Somewhat
bothered)
Vaginal bleeding or spotting
Bothered A Little Bit (Bothered a little bit)
Bothered Quite A Bit (Bothered quite a
bit)
Bothered Very Much (Bothered very
much)
Not At All Bothered (Not at all bothered)
Somewhat Bothered (Somewhat
bothered)
vaginal dryness
Bothered A Little Bit (Bothered a little bit)
Bothered Quite A Bit (Bothered quite a
bit)
Bothered Very Much (Bothered very
much)
Not At All Bothered (Not at all bothered)
Somewhat Bothered (Somewhat
bothered)
Pain with intercourse
Bothered A Little Bit (Bothered a little bit)
Bothered Quite A Bit (Bothered quite a
bit)
Bothered Very Much (Bothered very
much)
Not At All Bothered (Not at all bothered)
Somewhat Bothered (Somewhat
bothered)
Easily distracted
Bothered A Little Bit (Bothered a little bit)
Bothered Quite A Bit (Bothered quite a
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bit)
Bothered Very Much (Bothered very
much)
Not At All Bothered (Not at all bothered)
Somewhat Bothered (Somewhat
bothered)
General aches and pains
Bothered A Little Bit (Bothered a little bit)
Bothered Quite A Bit (Bothered quite a
bit)
Bothered Very Much (Bothered very
much)
Not At All Bothered (Not at all bothered)
Somewhat Bothered (Somewhat
bothered)
Joint pains
Bothered A Little Bit (Bothered a little bit)
Bothered Quite A Bit (Bothered quite a
bit)
Bothered Very Much (Bothered very
much)
Not At All Bothered (Not at all bothered)
Somewhat Bothered (Somewhat
bothered)
Muscle stiffness
Bothered A Little Bit (Bothered a little bit)
Bothered Quite A Bit (Bothered quite a
bit)
Bothered Very Much (Bothered very
much)
Not At All Bothered (Not at all bothered)
Somewhat Bothered (Somewhat
bothered)
Weight gain
Bothered A Little Bit (Bothered a little bit)
Bothered Quite A Bit (Bothered quite a
bit)
Bothered Very Much (Bothered very
much)
Not At All Bothered (Not at all bothered)
Somewhat Bothered (Somewhat
bothered)
Weight loss
Bothered A Little Bit (Bothered a little bit)
Bothered Quite A Bit (Bothered quite a
bit)
Bothered Very Much (Bothered very
much)
Not At All Bothered (Not at all bothered)
Somewhat Bothered (Somewhat
bothered)
Decreased appetite
Bothered A Little Bit (Bothered a little bit)
Bothered Quite A Bit (Bothered quite a
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bit)
Bothered Very Much (Bothered very
much)
Not At All Bothered (Not at all bothered)
Somewhat Bothered (Somewhat
bothered)
Unhappy with appearance of my body
Bothered A Little Bit (Bothered a little bit)
Bothered Quite A Bit (Bothered quite a
bit)
Bothered Very Much (Bothered very
much)
Not At All Bothered (Not at all bothered)
Somewhat Bothered (Somewhat
bothered)
Forgetfulness
Bothered A Little Bit (Bothered a little bit)
Bothered Quite A Bit (Bothered quite a
bit)
Bothered Very Much (Bothered very
much)
Not At All Bothered (Not at all bothered)
Somewhat Bothered (Somewhat
bothered)
Night sweats
Bothered A Little Bit (Bothered a little bit)
Bothered Quite A Bit (Bothered quite a
bit)
Bothered Very Much (Bothered very
much)
Not At All Bothered (Not at all bothered)
Somewhat Bothered (Somewhat
bothered)
Cold sweats
Bothered A Little Bit (Bothered a little bit)
Bothered Quite A Bit (Bothered quite a
bit)
Bothered Very Much (Bothered very
much)
Not At All Bothered (Not at all bothered)
Somewhat Bothered (Somewhat
bothered)
Difficulty concentrating
Bothered A Little Bit (Bothered a little bit)
Bothered Quite A Bit (Bothered quite a
bit)
Bothered Very Much (Bothered very
much)
Not At All Bothered (Not at all bothered)
Somewhat Bothered (Somewhat
bothered)
Abdominal pain or cramping
Bothered A Little Bit (Bothered a little bit)
Bothered Quite A Bit (Bothered quite a
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bit)
Bothered Very Much (Bothered very
much)
Not At All Bothered (Not at all bothered)
Somewhat Bothered (Somewhat
bothered)
mouth sores
Bothered A Little Bit (Bothered a little bit)
Bothered Quite A Bit (Bothered quite a
bit)
Bothered Very Much (Bothered very
much)
Not At All Bothered (Not at all bothered)
Somewhat Bothered (Somewhat
bothered)
Numbness or tingling in the hands or feet
Bothered A Little Bit (Bothered a little bit)
Bothered Quite A Bit (Bothered quite a
bit)
Bothered Very Much (Bothered very
much)
Not At All Bothered (Not at all bothered)
Somewhat Bothered (Somewhat
bothered)
Gas pain
Bothered A Little Bit (Bothered a little bit)
Bothered Quite A Bit (Bothered quite a
bit)
Bothered Very Much (Bothered very
much)
Not At All Bothered (Not at all bothered)
Somewhat Bothered (Somewhat
bothered)
constipation
Bothered A Little Bit (Bothered a little bit)
Bothered Quite A Bit (Bothered quite a
bit)
Bothered Very Much (Bothered very
much)
Not At All Bothered (Not at all bothered)
Somewhat Bothered (Somewhat
bothered)
skin problems (rash, irritation, redness)
Bothered A Little Bit (Bothered a little bit)
Bothered Quite A Bit (Bothered quite a
bit)
Bothered Very Much (Bothered very
much)
Not At All Bothered (Not at all bothered)
Somewhat Bothered (Somewhat
bothered)
Skin redness or peeling on hands and feet
Bothered A Little Bit (Bothered a little bit)
Bothered Quite A Bit (Bothered quite a
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bit)
Bothered Very Much (Bothered very
much)
Not At All Bothered (Not at all bothered)
Somewhat Bothered (Somewhat
bothered)
fever or shivering (shaking, chills)
Bothered A Little Bit (Bothered a little bit)
Bothered Quite A Bit (Bothered quite a
bit)
Bothered Very Much (Bothered very
much)
Not At All Bothered (Not at all bothered)
Somewhat Bothered (Somewhat
bothered)
Hair loss
Bothered A Little Bit (Bothered a little bit)
Bothered Quite A Bit (Bothered quite a
bit)
Bothered Very Much (Bothered very
much)
Not At All Bothered (Not at all bothered)
Somewhat Bothered (Somewhat
bothered)
Chest pain
Bothered A Little Bit (Bothered a little bit)
Bothered Quite A Bit (Bothered quite a
bit)
Bothered Very Much (Bothered very
much)
Not At All Bothered (Not at all bothered)
Somewhat Bothered (Somewhat
bothered)
Shortness of breath
Bothered A Little Bit (Bothered a little bit)
Bothered Quite A Bit (Bothered quite a
bit)
Bothered Very Much (Bothered very
much)
Not At All Bothered (Not at all bothered)
Somewhat Bothered (Somewhat
bothered)
Other problems
Bothered A Little Bit (Bothered a little bit)
Bothered Quite A Bit (Bothered quite a
bit)
Bothered Very Much (Bothered very
much)
Not At All Bothered (Not at all bothered)
Somewhat Bothered (Somewhat
bothered)
Please specify other problems
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Header
In general, would you say your health is
Excellent (Excellent)
Fair (Fair)
Good (Good)
Poor (Poor)
Very Good (Very good)
Compared to one year ago, how would you rate
your health in general now
About The Same As One Year Ago
(About the same as one year ago)
Much Better Now Than One Year Ago
(Much better now than one year ago)
Much Worse Now Than One Year Ago
(Much worse now than one year ago)
Somewhat Better Now Than One Year
Ago (Somewhat better now than one
year ago)
Somewhat Worse Now Than One Year
Ago (Somewhat worse now than one
year ago)
Module Question 3
Vigorous activities, such as running, lifting heavy
objects, participating in strenuous sports
No, Not Limited At All (No, not limited at
all)
Yes, Limited A Little (Yes, limited a little)
Yes, Limited A Lot (Yes, limited a lot)
Moderate activities, such as moving a table,
pushing a vacuum cleaner, bowling, or playing
golf
No, Not Limited At All (No, not limited at
all)
Yes, Limited A Little (Yes, limited a little)
Yes, Limited A Lot (Yes, limited a lot)
Lifting or carrying groceries
No, Not Limited At All (No, not limited at
all)
Yes, Limited A Little (Yes, limited a little)
Yes, Limited A Lot (Yes, limited a lot)
Climbing several flights of stairs
No, Not Limited At All (No, not limited at
all)
Yes, Limited A Little (Yes, limited a little)
Yes, Limited A Lot (Yes, limited a lot)
Climbing one flight of stairs
No, Not Limited At All (No, not limited at
all)
Yes, Limited A Little (Yes, limited a little)
Yes, Limited A Lot (Yes, limited a lot)
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Bending, kneeling or stooping
No, Not Limited At All (No, not limited at
all)
Yes, Limited A Little (Yes, limited a little)
Yes, Limited A Lot (Yes, limited a lot)
Walking more than a mile
No, Not Limited At All (No, not limited at
all)
Yes, Limited A Little (Yes, limited a little)
Yes, Limited A Lot (Yes, limited a lot)
Walking several hundred yards
No, Not Limited At All (No, not limited at
all)
Yes, Limited A Little (Yes, limited a little)
Yes, Limited A Lot (Yes, limited a lot)
Walking one hundred yards
No, Not Limited At All (No, not limited at
all)
Yes, Limited A Little (Yes, limited a little)
Yes, Limited A Lot (Yes, limited a lot)
Bathing or dressing yourself
No, Not Limited At All (No, not limited at
all)
Yes, Limited A Little (Yes, limited a little)
Yes, Limited A Lot (Yes, limited a lot)
Module Question 5
Cut down on the amount of time you spent on
work or other activities (as a result of any
emotional problems such as feeling depressed or
anxious)
A Little Of The Time (A little of the time)
All Of The Time (All of the time)
Most Of The Time (Most of the time)
None Of The Time (None of the time)
Some Of The Time (Some of the time)
Cut down on the amount of time you spent on
work or other activities (as a result of any
emotional problems such as feeling depressed or
anxious)
A Little Of The Time (A little of the time)
All Of The Time (All of the time)
Most Of The Time (Most of the time)
None Of The Time (None of the time)
Some Of The Time (Some of the time)
Accomplished less than you would like (as a
result of any emotional problems such as feeling
depressed or anxious)
A Little Of The Time (A little of the time)
All Of The Time (All of the time)
Most Of The Time (Most of the time)
None Of The Time (None of the time)
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Some Of The Time (Some of the time)
Accomplished less than you would like (as a
result of any emotional problems such as feeling
depressed or anxious)
A Little Of The Time (A little of the time)
All Of The Time (All of the time)
Most Of The Time (Most of the time)
None Of The Time (None of the time)
Some Of The Time (Some of the time)
Were limited in the kind of work or other activities
(as a result of your physical health)
A Little Of The Time (A little of the time)
All Of The Time (All of the time)
Most Of The Time (Most of the time)
None Of The Time (None of the time)
Some Of The Time (Some of the time)
Had difficulty performing the work or other
activities (as a result of your physical health)
A Little Of The Time (A little of the time)
All Of The Time (All of the time)
Most Of The Time (Most of the time)
None Of The Time (None of the time)
Some Of The Time (Some of the time)
Did work or other activities less carefully than
usual (as a result of any emotional problems such
as feeling depressed or anxious)
A Little Of The Time (A little of the time)
All Of The Time (All of the time)
Most Of The Time (Most of the time)
None Of The Time (None of the time)
Some Of The Time (Some of the time)
During the past 4 weeks, to what extent has your
physical health or emotional problems interfered
with your normal social activities with family,
friends, neighbors, or groups
Extremely (Extremely)
Moderately (Moderately)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Slightly (Slightly)
How much bodily pain have you had during the
past 4 weeks
Mild (Mild)
Moderate (Moderate)
None (None)
Severe (Severe)
Very Mild (Very mild)
Very Severe (Very severe)
During the past 4 weeks, how much did pain
interfere with your normal work (including both
work outside the home and housework)
A Little Bit (A little bit)
Extremely (Extremely)
10 / 13
Breast Cancer NCT00914043 Quality of Life - NSABP B-45 Quality of
Life Questionnaire Form - 2847215v1.0
Moderately (Moderately)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Module Question 9
Did you feel full of life
A Little Of The Time (A little of the time)
All Of The Time (All of the time)
Most Of The Time (Most of the time)
None Of The Time (None of the time)
Some Of The Time (Some of the time)
Have you been very nervous
A Little Of The Time (A little of the time)
All Of The Time (All of the time)
Most Of The Time (Most of the time)
None Of The Time (None of the time)
Some Of The Time (Some of the time)
Have you felt so down in the dumps that nothing
could cheer you up
A Little Of The Time (A little of the time)
All Of The Time (All of the time)
Most Of The Time (Most of the time)
None Of The Time (None of the time)
Some Of The Time (Some of the time)
Have you felt calm and peaceful
A Little Of The Time (A little of the time)
All Of The Time (All of the time)
Most Of The Time (Most of the time)
None Of The Time (None of the time)
Some Of The Time (Some of the time)
Did you have a lot of energy
A Little Of The Time (A little of the time)
All Of The Time (All of the time)
Most Of The Time (Most of the time)
None Of The Time (None of the time)
Some Of The Time (Some of the time)
Have you felt downhearted and depressed
A Little Of The Time (A little of the time)
All Of The Time (All of the time)
Most Of The Time (Most of the time)
None Of The Time (None of the time)
Some Of The Time (Some of the time)
Did you feel worn out
A Little Of The Time (A little of the time)
All Of The Time (All of the time)
Most Of The Time (Most of the time)
None Of The Time (None of the time)
Some Of The Time (Some of the time)
Have you been happy
A Little Of The Time (A little of the time)
All Of The Time (All of the time)
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Most Of The Time (Most of the time)
None Of The Time (None of the time)
Some Of The Time (Some of the time)
Did you feel tired
A Little Of The Time (A little of the time)
All Of The Time (All of the time)
Most Of The Time (Most of the time)
None Of The Time (None of the time)
Some Of The Time (Some of the time)
During the past 4 weeks, how much of the time
has your physical health or emotional problems
interfered with your social activities (like visiting
friends, relatives, etc.)
A Little Of The Time (A little of the time)
All Of The Time (All of the time)
Most Of The Time (Most of the time)
None Of The Time (None of the time)
Some Of The Time (Some of the time)
Module Question 11
I seem to get sick a little easier than other people
Definitely False (Definitely false)
Definitely True (Definitely true)
Don't Know (Don't know)
Mostly False (Mostly false)
Mostly True (Mostly true)
I am as healthy as anybody I know
Definitely False (Definitely false)
Definitely True (Definitely true)
Don't Know (Don't know)
Mostly False (Mostly false)
Mostly True (Mostly true)
I expect my health to get worse
Definitely False (Definitely false)
Definitely True (Definitely true)
Don't Know (Don't know)
Mostly False (Mostly false)
Mostly True (Mostly true)
My health is excellent
Definitely False (Definitely false)
Definitely True (Definitely true)
Don't Know (Don't know)
Mostly False (Mostly false)
Mostly True (Mostly true)
Qol2
Rate your level of fatigue on the day you felt most
fatigued during the past week
Rate your level of fatigue on the day you felt least
fatigued during the past week
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Rate your level of fatigue on the average during
the past week
Rate your level of fatigue right now
Rate how much, in the past week, fatigue
interfered with your general level of activity
Rate how much, in the past week, fatigue
interfered with your ability to bathe and dress
yourself
Rate how much, in the past week, fatigue
interfered with your normal work activity (includes
both work outside the home and housework)
Rate how much, in the past week, fatigue
interfered with your ability to concentrate
Rate how much, in the past week, fatigue
interfered with your relations with other people
Rate how much, in the past week, fatigue
interfered with your enjoyment of life
Rate how much, in the past week, fatigue
interfered with your mood
Indicate how many days, in the past week, you
felt fatigued for any part of the day
Rate how much of the day, on average, you felt
fatigued in the past week
Please score your overall quality of life as of
today on an 11-point scale where 0 indicates
being in the worst possible health and 10
indicates being in perfect health
0 (0)
1 (1)
10 (10)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
7 (7)
8 (8)
9 (9)
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Breast Cancer NCT01306032 Registration -
Eligibility/Pre-Registration Worksheet - 3158687v1.0
Eligibility/Pre-Registration Worksheet
ABT-888 With Cyclophosphamide in Refractory BRCA-
Positive Ovarian, Primary Peritoneal or Ovarian High-Grade
Serous Carcinoma, Fallopian Tube Cancer, Triple-Negative
Breast Cancer, and Low-Grade Non-Hodgkin's Lymphoma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=94CE0410-
6594-C0F7-E040-BB89AD4342BD
All rights reserved. Please visit https://medical-data-
models.org/forms/8960
Eligibility/Pre-Registration Worksheet
Standard Patient Identifier
First
Middle
Last
Standard Demographics (ii)
Informed Consent Date Signed
Projected Start Date of Treatment
Institution Name
Principal Investigator
Inclusion Criteria
Has histologically documented (confirmed by the
department of pathology at the enrolling
institution prior to patient registration) BRCA-
positive ovarian cancer, primary peritoneal or
ovarian high-grade serous carcinoma, fallopian
tube cancer, triple-negative breast cancer with
distant metastasis, or low-grade lymphoid
malignancies (NHL) as specified below:
Yes
No
Indicate Cancer histology:
Brca-positive Ovarian Cancer
(deleterious Brca1/2 Mutation Or A
Brcapro Score Of >= 30%.
Documentation Must Be Provided Prior
To Enrolling In The Study) (BRCA-
positive ovarian cancer (Deleterious
BRCA1/2 mutation or a BRCAPRO score
of >= 30%. Documentation must be
provided prior to enrolling in the study))
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Low-grade Lymphoid Malignancies (nhl)
(Low-grade lymphoid malignancies
(NHL))
Primary Peritoneal Or Ovarian High-
grade Serous Carcinoma Or Fallopian
Tube Cancer (no Requirement For Brca
Status) (Primary peritoneal or ovarian
high-grade serous carcinoma or fallopian
tube cancer (no requirement for BRCA
status))
Triple-negative Breast Cancer With Brca-
negative Or Brca-unknown Mutation And
With Metastasis To Distant Sites. (Triple-
negative breast cancer with BRCA-
negative or BRCA-unknown mutation
and with metastasis to distant sites.)
Triple-negative Breast Cancer With Brca-
positive Mutation And With Metastasis To
Distant Sites. (Triple-negative breast
cancer with BRCA-positive mutation and
with metastasis to distant sites.)
Has disease progressed following at least one
line of standard therapy?
Yes
No
Has measurable disease, defined as at least one
lesion that can be accurately measured in at least
one dimension (longest diameter to be recorded)
as >=20 mm with conventional techniques or as
>=10 mm with spiral CT scan?
Yes
No
Prior therapy completed >=4 weeks prior to
enrollment on protocol (at least six weeks out
from nitrosoureas and mitomycin C) and
associated toxicities resolved to eligibility levels.
Yes
No
Prior radiation completed >=4 weeks prior to
study enrollment, and associated toxicities
resolved to eligibility levels.
Not Applicable (NA)
No (No)
Yes (Yes)
At least 2 weeks since prior investigational agent
administered as part of a Phase 0 study, and
associated toxicities resolved to eligibility levels.
Not Applicable (NA)
No (No)
Yes (Yes)
Age >= 18 years
Yes
No
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Karnofsky Performance Status (>=70%, see
Appendix A site to complete box with actual
score)
Dead (0)
Moribund, Fatal Processes Progressing
Rapidly (10)
Normal, No Complaints, No Evidence Of
Disease (100)
Very Sick, Hospitalization Indicated.
Death Not Imminent (20)
Severely Disabled, Hospitalization
Indicated. Death Not Imminent (30)
Disabled, Requires Special Care And
Assistance (40)
Requires Considerable Assistance And
Frequent Medical Care (50)
Requires Occasional Assistance, But Is
Able To Care For Most Of His/her Needs
(60)
Cares For Self, Unable To Carry On
Normal Activity Or To Do Active Work
(70)
Normal Activity With Effort; Some Signs
Or Symptoms Of Disease (80)
Able To Carry On Normal Activity; Minor
Signs Or Symptoms Of Disease (90)
Life expectancy >3 months
Yes
No
Absolute neutrophil count (ANC) >=1,500/mm^3
Yes
No
ANC
Date
Platelet count >= 100,000/mm^3
Yes
No
Platelet count
Date
Total bilirubin <= 1.5 x ULN
Yes
No
Total Bilirubin
Total bilirubin ULN
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Date
AST (SGOT) and ALT (SGPT) <= 2.5x
institutional upper limits of normal
Yes
No
SGOT
SGOT (AST) ULN
Date
SGPT (ALT)
SGPT (ALT) ULN
Date
Creatinine < 1.5x institutional upper limits of
normal OR Creatinine clearance >=60 mL/min for
patients with creatinine levels >=1.5x institutional
upper limit of normal.
Yes
No
Creatinine
Creatinine ULN
Date
Creatinine Clearance
Date
Able to swallow whole capsule?
Yes
No
Exclusion Criteria
Has uncontrolled intercurrent illness including,
but not limited to, ongoing or active infection,
symptomatic congestive heart failure, unstable
angina pectoris, cardiac arrhythmia, or psychiatric
illness/social situations that would limit
compliance with study requirement?
4 / 6
Breast Cancer NCT01306032 Registration - Eligibility/Pre-Registration
Worksheet - 3158687v1.0
Yes
No
Pregnant? ([Note: women of childbearing
potential and men must agree to use adequate
contraception prior to study entry, for the duration
of study participation and for 3 months after
completion of study.])
Not Available (NA)
No (No)
Yes (Yes)
Date of most recent test
Breastfeeding?
Not Available (NA)
No (No)
Yes (Yes)
Has germ cell or borderline ovarian epithelial
tumors
Yes
No
Has had seizure within last 3 months while on
anti-seizure medication for CNS metastases
Not Available (NA)
No (No)
Yes (Yes)
Has ulcerative colitis, inflammatory bowel
disease, partial or complete small bowel
obstruction, or other gastrointestinal condition
that might predispose for drug intolerability or
poor drug absorption (e.g., inability to take oral
medication or a requirement for IV alimentation,
prior surgical procedures affecting absorption,
malabsorption syndrome, and active peptic ulcer
disease).
Yes
No
Has had prior treatment with any PARP inhibitors
that were administered in combination with
cyclophosphamide
Not Available (NA)
No (No)
Yes (Yes)
Is receiving other investigational agents
Yes
No
Pre Study Evaluations
History and Physical Exam (prior to starting study
drug)
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Height, Weight, vital signs (prior to starting study
drug)
EKG (prior to starting study drug)
Performance status (prior to starting study drug)
Does the patient have bone marrow involvement?
(for lymphoma patients only,  if "Yes" please
provide date in the following question, select "NA"
if patient is not a lymphoma patient)
Not Available (NA)
No (No)
Yes (Yes)
Bone marrow aspirate and biopsy for lymphoma
patients with known bone marrow involvement
(prior to starting study drug)
Laboratory Studies Will Be Conducted 1
Week Prior To Starting Study Drug Will
Include
CBC with Diff and Plts
Blood Chemistries: Na+, K+, Cl-, CO2,
Creatinine, BUN, calcium, glucose, albumin,
SGPT (ALT), SGOT (AST), LDH, Alkaline Phos,
and Bilirubin
Urinalysis
Date of CA125
CT scan chest/abd/pelvis (within 28 days)
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Colorectal Cancer NCT00098787 Eligibility - E4203
Registration Worksheet (step 2) - 3115210v1.0
E4203 Registration Worksheet (step 2)
Bevacizumab and Oxaliplatin Combined With Irinotecan or
Leucovorin and Fluorouracil in Treating Patients With
Metastatic or Recurrent Colorectal Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=8A2D12C3-
C08C-3EF0-E040-BB89AD436C14
All rights reserved. Please visit https://medical-data-
models.org/forms/8962
E4203 Registration Worksheet (step
2)
Eligibility
Has the eligibility checklist been completed
Yes
No
In the opinion of the investigator, is the patient
eligible?
Yes
No
Indicate the level/status that was determined
centrally and reported to you.
1 - High Ts Expression Status - Score Of
2 Or 3 (1 - High TS expression status -
score of 2 or 3)
2 - Low Ts Expression - Score Of 0 Or 1
(2 - Low TS expression - score of 0 or 1)
3 - Indeterminate Ts Expression Status
(3 - Indeterminate TS expression status)
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Colorectal Cancer NCT00098787 Eligibility - E4203
Registration Worksheet (step 1) - 3114884v1.0
E4203 Registration Worksheet (step 1)
Bevacizumab and Oxaliplatin Combined With Irinotecan or
Leucovorin and Fluorouracil in Treating Patients With
Metastatic or Recurrent Colorectal Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=8A2D12C3-
BDFE-3EF0-E040-BB89AD436C14
All rights reserved. Please visit https://medical-data-
models.org/forms/8963
E4203 Registration Worksheet (step
1)
Eligibility
Has the eligibility checklist been completed
Yes
No
In the opinion of the investigator, is the patient
eligible?
Yes
No
Has written informed consent been obtained
Yes
No
Date Informed Consent Signed
Has HIPAA authorization been obtained
Exempt - Non-usa Participant (Exempt -
non-USA participant)
No: C49487 (No)
Yes: C49488 (Yes)
HIPAA Authorization Date
I agree to participate in the scientific laboratory
research studies that are being done as part of
this clinical trial
Yes
No
My specimens may be kept for use in research to
learn about, prevent, treat, or cure cancer.
Yes
No
My specimens may be kept for use in research
about other health problems (for example: causes
of diabetes, Alzheimer's disease, or heart
disease)
Yes
No
Someone from this institution may contact me in
the future to ask me to take part in more
research.
Yes
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Colorectal Cancer NCT01079780 Eligibility - E7208
Registration Worksheet (step 1) - 3144427v1.0
E7208 Registration Worksheet (step 1)
Irinotecan Hydrochloride and Cetuximab With or Without
Ramucirumab in Treating Patients With Advanced
Colorectal Cancer With Progressive Disease After
Treatment With Bevacizumab-Containing Chemotherapy
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=917D26EA-
3F70-45A5-E040-BB89AD431DBE
All rights reserved. Please visit https://medical-data-
models.org/forms/8966
E7208 Registration Worksheet (step
1)
Eligibility
Has the eligibility checklist been completed
Yes
No
In the opinion of the investigator, is the patient
eligible?
Yes
No
Has written informed consent been obtained
Yes
No
Date Informed Consent Signed
Has HIPAA authorization been obtained
Exempt - Non-usa Participant (Exempt -
non-USA participant)
No: C49487 (No)
Yes: C49488 (Yes)
HIPAA Authorization Date
ECOG Performance Status
Fully Active, Able To Carry On All Pre-
disease Performance Without
Restriction. (0)
Restricted In Physically Strenuous
Activity But Ambulatory And Able To
Carry Out Work Of A Light Or Sedentary
Nature, E.g., Light Housework, Office
Work. (1)
Ambulatory And Capable Of All Selfcare
But Unable To Carry Out Any Work
Activities. Up And About More Than 50%
Of Waking Hours. (2)
Capable Of Only Limited Selfcare,
Confined To Bed Or Chair More Than
50% Of Waking Hours. (3)
Completely Disabled. Cannot Carry On
Any Selfcare. Totally Confined To Bed Or
Chair. (4)
Dead (5)
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Discontinuation of oxaliplatin first line therapy
before disease progression
Yes
No
Time frame of progression
Greater Than 6 Months Since Last
Treatment (Greater than 6 months since
last treatment)
Within 6 Months Of Last Treatment
(Within 6 months of last treatment)
Patient's simplified disease code
Adenocarcinoma Colon
(Adenocarcinoma of the colon)
Adenocarcinoma Rectum
(Adenocarcinoma of the rectum)
Colorectal Carcinoma Not Otherwise
Specified (Colorectal cancer, NOS)
May your coded samples and related coded
information be kept for use in research to learn
about, prevent, find or treat cancer?  This may
also include research on inherited traits (genes
passed on in families).
Yes
No
May your coded samples and related coded
information be kept for use in research to learn
about, prevent, find or treat other health problems
(for example: diabetes, Alzheimer's disease, or
heart disease)?  This may also include research
on inherited traits (genes passed on in families).
Yes
No
Someone from my hospital or the Eastern
Cooperative Oncology Group may contact me in
the future to ask me to take part in more
research.
Yes
No
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Extrahepatic Bile Duct Cancer NCT01093222 Registration - Southwest
Oncology Group S0941 Registration Worksheet Form - 3028434v1.0
Southwest Oncology Group S0941 Registration Worksheet
Form
Sorafenib Tosylate and Erlotinib Hydrochloride in Treating
Patients With Locally Advanced, Unresectable, or
Metastatic Gallbladder Cancer or Cholangiocarcinoma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=8229FCFE-
E5C8-63E1-E040-BB89AD43798D
All rights reserved. Please visit https://medical-data-
models.org/forms/8967
Southwest Oncology Group S0941
Registration Worksheet Form
Header
Activation Date (MM DD YYYY)
Last Amended Date (MM DD YYYY)
Registration Step
Swog Patient Id
SWOG Patient ID Status
New Patient (New patient)
Previous Patient (Previous patient)
SWOG Patient ID
Demography
Patient First Name
Patient Middle Name
Patient Last Name
Unnamed2
Registrar's SWOG Roster ID Number
SWOG Investigator Number
SWOG Treating Institution Number
Unnamed5
Date Informed Consent Signed (MM DD YYYY)
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Date HIPAA Authorization signed (Not required if
Country of Residence is not USA MM DD YYYY)
Projected Start Date of Treatment (MM DD
YYYY)
Unnamed4
My specimens may be kept for use in research to
learn about, prevent, treat, or cure cancer.
Yes
No
My specimens may be kept for use in research
about other health problems (for example:
diabetes, Alzheimer's disease, or heart disease).
Yes
No
Someone may contact me in the future to ask me
to allow other uses of my specimens.
Yes
No
I agree to allow my study doctor, or someone
approved by my study doctor, to contact me
regarding future research involving my
participation in this study
Yes
No
Unnamed 7
Has the Southwest Oncology Group Registration
Worksheet been completed entirely and is the
patient eligible according to the current version of
protocol section 5.0
Yes
No
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Colorectal Cancer NCT00058474 Treatment - NSABP
PROTOCOL R-04: SURGERY FORM - 2086952v3.0
NSABP PROTOCOL R-04: SURGERY FORM
Radiation Therapy and Either Capecitabine or Fluorouracil
With or Without Oxaliplatin Before Surgery in Treating
Patients With Resectable Rectal Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=B7ABE177-
6C54-3DC5-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/8968
NSABP PROTOCOL R-04:
SURGERY FORM
Ccrr Module For Nsabp Protocol R-04:
Surgery Form
Last
First
Middle
NSABP Patient ID
Person Completing Form, Last Name (Person
Completing Form, First Name)
Person Completing Form, First Name
Person Completing Form, Phone
Institution Name / Affiliate
Are data amended
Yes
No
Perioperative Tumor Assessment Of
Clinical Response
Method of Evaluation
Method of Evaluation
Date of Assessment
Date of Assessment
Clinical response
Not Done (Not done)
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Tumor Absent (Tumor absent)
Tumor Present (Tumor present)
Clinical response
Not Done (Not done)
Tumor Absent (Tumor absent)
Tumor Present (Tumor present)
Vascular Access Device
Date of placement
Type (MARK ONE)
Port-a-cath (Implanted port)
Percutaneous Catheter (Percutaneous
catheter)
Peripherally Inserted Central Venous
Catheter (PIC line)
Blood Transfusions
Blood transfusion
Intraoperative (Intraoperative)
Preoperative (Preoperative)
Within 30 Days Post-operative (Within 30
days post-operative)
Total units whole blood
Total number of units PRBC
Surgery
Did patient undergo surgical resection?
Yes
No
Date of Resection (month day year)
Reason for no resection
Death (Death)
Local Regional Tumor Growth (Local
regional tumor growth)
Metastatic Disease (Metastatic disease)
Other (Other)
Patient Refused (Patient refused)
Second Primary Cancer (Second
primary cancer)
Other, specify
Found on
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Intra-operatively (Intra-operatively)
Pre-op Diagnostic Testing (Pre-op
diagnostic testing)
Is there adherence to adjacent organs?
Yes
No
Was an "en bloc" resection performed?
Yes
No
Residual Primary Tumor
Yes
No
Was an abdominal exploration carried out?
Yes
No
Was there tumor spillage?
Yes
No
Was sphincter preserved
Yes
No
Was a total mesorectal excision performed?
Yes
No
Were all suspicious lymph nodes removed?
Yes
No
Were there any isolated distant or non-
contiguous intra-abdominal mets (other than peri-
rectal lymph node involvement)?
Yes
No
Metastasis completely resected
No (No)
Not Applicable (Not Applicable)
Yes (Yes)
Was there bowel perforation
Yes
No
Indicate the type (perforation)
Contained (Contained)
Free (Free)
Was there bowel obstruction
Yes
No
Indicate the type (tumor)
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Complete (Complete)
Partial (Partial)
Was an ostomy created at the time of resection?
No (No)
Yes, Colostomy (Yes, colostomy)
Yes, Ileostomy (Yes, ileostomy)
Number of primary tumors
Location of distal edge of tumor
Lower Rectum (0-5 Cm From The Anal
Verge) (Lower rectum (0-5 cm from the
anal verge))
Middle Rectum (6-10 Cm From The Anal
Verge) (Middle rectum (6-10 cm from the
anal verge))
Upper Rectum (11 Or More Cm From
The Anal Verge) (Upper rectum (11 or
more cm from the anal verge))
Were there any Post-operative and Early
Complications
Yes
No
Mark all that apply
Anastomotic Leak (Anastomotic leak)
Bowel Obstruction/ileus (Bowel
obstruction/ileus)
Cardiopulmonary Complication
(Cardiopulmonary complication)
Death (Death)
Heart/lung Bypass (heart/lung bypass)
Hemorrhage (HEMORRHAGE)
Intra-abdominal Abscess (Intra-
abdominal abscess)
Other, Specify (Other, Specify)
Pneumonia (PNEUMONIA)
Renal Failure (Renal failure)
Urinary Complication, Choose Type
(Urinary complication, choose type)
Wound Dehiscence/fistula (Wound
dehiscence/fistula)
Wound Infection (Wound infection)
Other, specify
Wound infection, mark type
Abdominal (Abdominal)
Perineal (Perineal)
Urinary complication, choose type
Infection (Infection)
Other (Other)
Retention (Retention)
Was a re-operation necessary?
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Yes
No
Pathology
Pathology Accession Number
Pathologic T Stage
No Evidence Of Primary Tumor (T0)
Tumor Invades Submucosa (T1)
Tumor Invades Muscularis Propria (T2)
Tumor Invades Through The Muscularis
Propria Into The Subserosa, Or Into
Nonperitonealized Pericolic Or Perirectal
Tissues (T3)
Tumor Directly Invades Other Organs Or
Structures, And/or Perforates Visceral
Peritoneum (T4)
Carcinoma In Situ: Intraepithelial Or
Invasion Of Lamina Propria (Tis)
Primary Tumor Cannot Be Assessed
(TX)
Number of Lymph Nodes Examined
Number of Positive Lymph Nodes
Pathologic response
Evidence Of Invasive Tumor Cells
(Evidence of invasive tumor cells)
No Evidence Of Invasive Tumor Cells
(No evidence of invasive tumor cells)
Longest Dimension of Tumor (cm)
Histologic Type (mark one)
Adenocarcinoma (Adenocarcinoma)
Adenosquamous carcinoma
(Adenosquamous carcinoma)
Medullary carcinoma (Medullary
carcinoma)
Mucinous (colloid) carcinoma (Mucinous
(colloid) carcinoma)
Other, specify (Other, specify)
Signet-ring cell adenocarcinoma (Signet-
ring cell adenocarcinoma)
Small cell carcinoma (oat cell) (Small cell
carcinoma (oat cell))
Squamous cell carcinoma (Squamous
cell carcinoma)
Undifferentiated or solid (Undifferentiated
or solid)
Other, specify (histologic type)
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Venous Invasion
Indeterminate (Indeterminate)
No (No)
Unknown (Unknown)
Yes (Yes)
Histologic Grade (Differentiation)
High Grade (poor Differentiation And/or
Undifferentiated) (High grade)
Low Grade (well And/or Moderate
Differentiation) (Low grade)
All surgical margins of resection are negative for
tumor
Yes
No
Which margin was involved?
Circumferential (Circumferential)
Distal (Distal)
Proximal (Proximal)
Distance from Primary Tumor to Distal Margin of
Resection
Distance from Primary Tumor to Proximal Margin
of Resection
Distance to Nearest Radial Margin
(Circumferential)
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Fallopian Tube Cancer NCT00872989 Registration - Southwest
Oncology Group S0904 Registration Worksheet - 2982652v1.0
Southwest Oncology Group S0904 Registration Worksheet
for OPEN Testing - Step 1
Docetaxel With or Without Vandetanib in Treating Patients
With Persistent or Recurrent Ovarian Epithelial Cancer,
Fallopian Tube Cancer, or Primary Peritoneal Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=7C965708-
991B-5904-E040-BB89AD432C8B
All rights reserved. Please visit https://medical-data-
models.org/forms/8969
Southwest Oncology Group S0904
Registration Worksheet
Unnamed2
SWOG Patient ID Status
New Patient (New patient)
Previous Patient (Previous patient)
SWOG Patient ID
Unnamed5
Patient First Name
Patient Middle Name
Patient Last Name
Unnamed4
Registrar's SWOG Roster ID Number
SWOG Investigator Number
SWOG Treating Institution Number
Patient Information
Date Informed Consent Signed
Date HIPAA Authorization signed (Not required if
Country of Residence is not USA)
Projected Start Date of Treatment
Unnamed5
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Has patient received prior treatment with an
antiangiogenesis agent (excluding Vandetanib)
Unnamed4
My specimens may be kept for use in research to
learn about, prevent, treat, or cure cancer.
Yes
No
My specimens may be kept for use in research
about other health problems (for example:
diabetes, Alzheimer's disease, or heart disease).
Yes
No
Someone may contact me in the future to ask me
to allow other uses of my specimens.
Yes
No
I agree to allow my study doctor, or someone
approved by my study doctor, to contact me
regarding future research involving my
participation in this study
Yes
No
Patient Eligibility
Has the Southwest Oncology Group Registration
Worksheet been completed entirely and is the
patient eligible according to the current version of
protocol section 5.0
Yes
No
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Group S0904 Registration Worksheet - 2982652v1.0
Head and Neck Cancer NCT00588770 Eligibility -
E1305 Registration Worksheet (step 1) - 2750715v1.0
E1305 Registration Worksheet (step 1)
Chemotherapy With or Without Bevacizumab in Treating
Patients With Recurrent or Metastatic Head and Neck
Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=4D9A0B72-
1D0D-5E28-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/8970
E1305 Registration Worksheet (step
1)
Eligibility
Has the eligibility checklist been completed
Yes
No
In the opinion of the investigator, is the patient
eligible?
Yes
No
Has written informed consent been obtained
Yes
No
Date Informed Consent Signed
Has HIPAA authorization been obtained
Exempt - Non-usa Participant (Exempt -
non-USA participant)
No: C49487 (No)
Yes: C49488 (Yes)
HIPAA Authorization Date
Planned Chemotherapy Regimen
Carboplatin And 5-fluorouracil
(Carboplatin and 5-Fluorouracil)
Carboplatin And Docetaxel (Carboplatin
and Docetaxel)
Cisplatin And 5-fluorouracil (Cisplatin
and 5-Fluorouracil)
Cisplatin And Docetaxel (Cisplatin and
Docetaxel)
ECOG Performance Status
Fully Active, Able To Carry On All Pre-
disease Performance Without
Restriction. (0)
Restricted In Physically Strenuous
Activity But Ambulatory And Able To
Carry Out Work Of A Light Or Sedentary
Nature, E.g., Light Housework, Office
Work. (1)
Ambulatory And Capable Of All Selfcare
But Unable To Carry Out Any Work
Activities. Up And About More Than 50%
1 / 2
Of Waking Hours. (2)
Capable Of Only Limited Selfcare,
Confined To Bed Or Chair More Than
50% Of Waking Hours. (3)
Completely Disabled. Cannot Carry On
Any Selfcare. Totally Confined To Bed Or
Chair. (4)
Dead (5)
Prior Radiation Therapy to head and neck
Yes
No
Weight Loss in Previous Six Months
Greater Than Or Equal To 5% Of Body
Weight (Greater than or equal to 5% of
body weight)
Less Than 5% Of Body Weight (Less
than 5% of body weight)
I agree to participate in the laboratory research
studies that are being done as part of this clinical
trial.
Yes
No
My specimens may be kept for use in research to
learn about, prevent, treat, or cure cancer.
Yes
No
My specimens may be kept for use in research
about other health problems (for example: causes
of diabetes, Alzheimer's disease, or heart
disease). (for example: causes of diabetes,
Alzheimer's disease, and heart disease)
Yes
No
Someone from this institution may contact me in
the future to ask me to take part in more
research.
Yes
No
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Head and Neck Cancer NCT00588770 Eligibility - E1305 Registration
Worksheet (step 1) - 2750715v1.0
Kidney Cancer NCT01120249 Registration - Southwest Oncology Group
S0931 Registration Worksheet Form (Form #62788) - 2992250v1.0
Southwest Oncology Group S0931 Registration Worksheet
Form (Form #62788)
Everolimus in Treating Patients With Kidney Cancer Who
Have Undergone Surgery
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=7DFFD6EC-
BC3B-4B34-E040-BB89AD4345BB
All rights reserved. Please visit https://medical-data-
models.org/forms/8971
Southwest Oncology Group S0931
Registration Worksheet Form (Form
#62788)
Header
Activation Date (MM DD YYYY)
Last Amended Date (MM DD YYYY)
Registration Step
Swog Patient Id
SWOG Patient ID Status
New Patient (New patient)
Previous Patient (Previous patient)
SWOG Patient ID
Demography
Patient First Name
Patient Middle Name
Patient Last Name
Unnamed2
Registrar's SWOG Roster ID Number
SWOG Investigator Number
SWOG Treating Institution Number
Unnamed5
Date Informed Consent Signed (MM DD YYYY)
1 / 2
Date HIPAA Authorization signed (Not required if
Country of Residence is not USA MM DD YYYY)
Projected Start Date of Treatment (MM DD
YYYY)
Stratification Questions
Risk group based on pathologic stage
Histology
Performance status
Unnamed4
My specimens may be kept for use in research to
learn about, prevent, treat, or cure cancer.
Yes
No
My specimens may be kept for use in research
about other health problems (for example:
diabetes, Alzheimer's disease, or heart disease).
Yes
No
Someone may contact me in the future to ask me
to allow other uses of my specimens.
Yes
No
I agree to allow my study doctor, or someone
approved by my study doctor, to contact me
regarding future research involving my
participation in this study
Yes
No
Unnamed 7
Has the Southwest Oncology Group Registration
Worksheet been completed entirely and is the
patient eligible according to the current version of
protocol section 5.0
Yes
No
Auxiliary Question
Pharmacy number (assigned by VA Pharmacy
Coordinating Center:)
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Kidney Cancer NCT01120249 Registration - Southwest Oncology Group
S0931 Registration Worksheet Form (Form #62788) - 2992250v1.0
Leukemia NCT00074282 Eligibility - E2903
Registration Worksheet (step 1) - 2787672v1.0
E2903 Registration Worksheet (step 1)
Pentostatin, Cyclophosphamide, and Rituximab Followed
By Alemtuzumab in Treating Patients With Relapsed or
Refractory B-Cell Chronic Lymphocytic Leukemia
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=57BCD093-
C3A2-3B7C-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/8972
E2903 Registration Worksheet (step
1)
Eligibility
Has the eligibility checklist been completed
Yes
No
In the opinion of the investigator, is the patient
eligible?
Yes
No
Has written informed consent been obtained
Yes
No
Date Informed Consent Signed
Has HIPAA authorization been obtained
Exempt - Non-usa Participant (Exempt -
non-USA participant)
No: C49487 (No)
Yes: C49488 (Yes)
HIPAA Authorization Date
I agree to participate in the laboratory research
studies that are being done as part of this clinical
trial.
Yes
No
I agree to provide additional blood for research.
Yes
No
My specimens may be kept for use in research to
learn about, prevent, treat, or cure cancer.
Yes
No
My specimens may be kept for use in research
about other health problems (for example: causes
of diabetes, Alzheimer's disease, or heart
disease)
Yes
No
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Someone from this institution may contact me in
the future to ask me to take part in more
research.
Yes
No
Name of local cytogenetics lab
Phone number
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Leukemia NCT00074282 Eligibility - E2903 Registration Worksheet (step
1) - 2787672v1.0
Leukemia NCT00074282 Eligibility - E2903
Registration Worksheet (step 2) - 2787779v1.0
E2903 Registration Worksheet (step 2)
Pentostatin, Cyclophosphamide, and Rituximab Followed
By Alemtuzumab in Treating Patients With Relapsed or
Refractory B-Cell Chronic Lymphocytic Leukemia
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=57BCF96C-
D19C-414F-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/8973
E2903 Registration Worksheet (step
2)
Eligibility
Has the eligibility checklist been completed
Yes
No
In the opinion of the investigator, is the patient
eligible?
Yes
No
CLL Response Assessment
Confirmed Cr (Confirmed CR)
Nodular Partial Remission (nPR)
Partial Response (PR)
Stable Disease Pd (SD or PD)
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Colorectal Cancer NCT00058474 On-Study - NSABP
PROTOCOL R-04: ON-STUDY FORM - 2086441v3.0
NSABP PROTOCOL R-04: ON-STUDY FORM
Radiation Therapy and Either Capecitabine or Fluorouracil
With or Without Oxaliplatin Before Surgery in Treating
Patients With Resectable Rectal Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=B7ABE8CD-
3652-3DD1-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/8974
NSABP PROTOCOL R-04: ON-
STUDY FORM
Ccrr Module For Nsabp Protocol R-04:
On-study Form
Last (Patient Initials)
First
Middle
Patient Study ID
Institution Name / Affiliate Name
Person Completing Form, Last Name
Person Completing Form, First Name
Person Completing Form, Phone
Are Data Amended?
Yes
No
Reports Provided
Biopsy Pathology Report (Biopsy
Pathology Report)
Biopsy (Biopsy Procedure Report)
Ct Scan (CT Scan of Abdomen/Pelvis
Report)
Full Colonoscopy Procedure Report (Full
Colonoscopy Procedure Report)
MRI of Abdomen/Pelvis Report (MRI of
Abdomen/Pelvis Report)
Proctoscopy/sigmoidoscopy
(Proctoscopy/sigmoidoscopy)
Date of Biopsy (month day year)
Date of CT Scan (month day year)
Date of MRI (month day year)
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Date of last colonoscopy
Date of Proctoscopy/Sigmoidoscopy
Procedure Used To Definitively Stage
Primary Tumor
Procedure Used to Definitively Stage Primary
Tumor
Ct/combined Pet/ct (CT/Combined
PET/CT)
Magnetic Resonance Imaging (MRI)
Ultrasound (Ultrasound)
Date
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Colorectal Cancer NCT00058474 On-Study - NSABP PROTOCOL R-04:
ON-STUDY FORM - 2086441v3.0
Leukemia NCT01041703 Eligibility - E2906
Registration Worksheet (step 3) - 3083677v1.0
E2906 Registration Worksheet (step 3)
Clofarabine or Daunorubicin Hydrochloride and Cytarabine
Followed By Decitabine or Observation in Treating Older
Patients With Newly Diagnosed Acute Myeloid Leukemia
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=860606B1-
A35A-DE3F-E040-BB89AD4345DE
All rights reserved. Please visit https://medical-data-
models.org/forms/8975
E2906 Registration Worksheet (step
3)
Eligibility
Has the eligibility checklist been completed
Yes
No
In the opinion of the investigator, is the patient
eligible?
Yes
No
Transplant donor
Hla Matching Donor (HLA Matched
Donor)
Not Applicable (Not applicable)
Cytogenetic results
Other (Other)
Unfavorable (Unfavorable)
Induction treatment
Arm A - Daunorubicin + Cytarabine (Arm
A - Daunorubicin + Cytarabine)
Arm B - Clofarbine (Arm B - Clofarbine)
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Leukemia NCT01013961 Eligibility - E1908
Registration Worksheet (step 1) - 2988263v1.0
E1908 Registration Worksheet (step 1)
Rituximab and Alemtuzumab in Treating Older Patients
With Progressive Chronic Lymphocytic Leukemia
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=7D742C85-
295F-A7C8-E040-BB89AD432037
All rights reserved. Please visit https://medical-data-
models.org/forms/8976
E1908 Registration Worksheet (step
1)
Eligibility
Has the eligibility checklist been completed
Yes
No
In the opinion of the investigator, is the patient
eligible?
Yes
No
Indicate the level/status that was determined
centrally and reported to you.
High Risk (1 - High Risk)
Intermediate Risk (2 - Intermediate Risk)
Low Risk (3 - Low Risk)
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Leukemia NCT01041703 Eligibility - E2906
Registration Worksheet (step 1) - 3082845v1.0
E2906 Registration Worksheet (step 1)
Clofarabine or Daunorubicin Hydrochloride and Cytarabine
Followed By Decitabine or Observation in Treating Older
Patients With Newly Diagnosed Acute Myeloid Leukemia
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=85FA2555-
1EC1-F884-E040-BB89AD432656
All rights reserved. Please visit https://medical-data-
models.org/forms/8977
E2906 Registration Worksheet (step
1)
Eligibility
Has the eligibility checklist been completed
Yes
No
In the opinion of the investigator, is the patient
eligible?
Yes
No
Has written informed consent been obtained
Yes
No
Date Informed Consent Signed
Has HIPAA authorization been obtained
Exempt - Non-usa Participant (Exempt -
non-USA participant)
No: C49487 (No)
Yes: C49488 (Yes)
HIPAA Authorization Date
Cytogenetic results
Other (Other)
Unfavorable (Unfavorable)
Therapy-related AML
Yes
No
Antecedent hematologic disorders
Yes
No
Patient has consented to take part in the Quality
of Life Study
Yes
No
If the patient has been registered to E3903,
please enter the ECOG patient ID assigned.
Others enter 'N/A'.
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I agree to participate in the laboratory research
studies that are being done as part of this clinical
trial.
Yes
No
I agree to provide additional blood for research.
Yes
No
May your coded samples and related coded
information be kept for use in research to learn
about, prevent, find or treat cancer?  This may
also include research on inherited traits (genes
passed on in families).
Yes
No
May your coded samples and related coded
information be kept for use in research to learn
about, prevent, find or treat other health problems
(for example: diabetes, Alzheimer's disease, or
heart disease)?  This may also include research
on inherited traits (genes passed on in families).
Yes
No
Someone from this institution may contact me in
the future to ask me to take part in more
research.
Yes
No
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Leukemia NCT01041703 Eligibility - E2906 Registration Worksheet (step
1) - 3082845v1.0
Colorectal Cancer NCT00499369 Registration - Southwest
Oncology Group S0600 Registration Worksheet - 2994609v1.0
Southwest Oncology Group S0600 Registration Worksheet
Irinotecan and Cetuximab With or Without Bevacizumab in
Treating Patients With Metastatic Colorectal Cancer That
Progressed During First-Line Therapy
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=7E16B1D7-
6F02-2C29-E040-BB89AD4317D7
All rights reserved. Please visit https://medical-data-
models.org/forms/8978
Southwest Oncology Group S0600
Registration Worksheet
Unnamed2
SWOG Patient ID Status
New Patient (New patient)
Previous Patient (Previous patient)
SWOG Patient ID
Unnamed5
Patient First Name
Patient Middle Name
Patient Last Name
Unnamed4
Registrar's SWOG Roster ID Number
SWOG Investigator Number
SWOG Treating Institution Number
Patient Information
Date Informed Consent Signed
Date HIPAA Authorization signed (Not required if
Country of Residence is not USA)
Projected Start Date of Treatment
Stratification Questions
Performance status
Discontinuation of oxaliplatin while on first line
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therapy
Planned concurrent chemotherapy
Irinotecan + 5-fluorouracil/leucovorin
Regimen (folfiri) (1)
Single Agent Irinotecan (2)
Time from last dose of bevacizumab
14-42 Days (1)
43 Days Or Higher (2)
Unnamed4
I agree to allow my study doctor, or someone
approved by my study doctor, to contact me
regarding future research involving my
participation in this study
Yes
No
Patient Eligibility
Has the Southwest Oncology Group Registration
Worksheet been completed entirely and is the
patient eligible according to the current version of
protocol section 5.0
Yes
No
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Colorectal Cancer NCT00499369 Registration - Southwest Oncology
Group S0600 Registration Worksheet - 2994609v1.0
Leukemia NCT01013961 Eligibility - E1908
Registration Worksheet (step 0) - 2987252v1.0
E1908 Registration Worksheet (step 0)
Rituximab and Alemtuzumab in Treating Older Patients
With Progressive Chronic Lymphocytic Leukemia
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=7D3B8954-
095E-A41C-E040-BB89AD430BDF
All rights reserved. Please visit https://medical-data-
models.org/forms/8979
E1908 Registration Worksheet (step
0)
Eligibility
Has the eligibility checklist been completed
Yes
No
In the opinion of the investigator, is the patient
eligible?
Yes
No
Has written informed consent been obtained
Yes
No
Date Informed Consent Signed
Has HIPAA authorization been obtained
Exempt - Non-usa Participant (Exempt -
non-USA participant)
No: C49487 (No)
Yes: C49488 (Yes)
HIPAA Authorization Date
I agree to participate in the laboratory research
studies that are being done as part of this clinical
trial.
Yes
No
May your coded samples and related coded
information be kept for use in research to learn
about, prevent, find or treat cancer?  This may
also include research on inherited traits (genes
passed on in families).
Yes
No
May your coded samples and related coded
information be kept for use in research to learn
about, prevent, find or treat other health problems
(for example: diabetes, Alzheimer's disease, or
heart disease)?  This may also include research
on inherited traits (genes passed on in families).
Yes
No
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Someone from my hospital or the Eastern
Cooperative Oncology Group may contact me in
the future to ask me to take part in more
research.
Yes
No
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Leukemia NCT01013961 Eligibility - E1908 Registration Worksheet (step
0) - 2987252v1.0
Colorectal Cancer NCT01416688 Registration -
S1013 Registration Worksheet Form - 3293938v1.0
S1013 Registration Worksheet Form
Validation of Cancer Questionnaire for Skin Toxicities in
Patients With Colorectal Cancer or Lung Cancer Receiving
Cetuximab, Panitumumab, or Erlotinib Hydrochloride
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=AF2FF709-
241B-4A47-E040-BB89AD4325B1
All rights reserved. Please visit https://medical-data-
models.org/forms/8980
S1013 Registration Worksheet Form
Header
Activation Date (MM DD YYYY)
Last Amended Date (MM DD YYYY)
Registration Step
Swog Patient Id
SWOG Patient ID Status
New Patient (New patient)
Previous Patient (Previous patient)
SWOG Patient ID
Demography
Patient First Name
Patient Middle Name
Patient Last Name
Unnamed2
Registrar's SWOG Roster ID Number
SWOG Investigator Number
SWOG Treating Institution Number
Unnamed5
Date Informed Consent Signed (MM DD YYYY)
Date HIPAA Authorization signed (Not required if
Country of Residence is not USA MM DD YYYY)
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Projected Start Date of Treatment (MM DD
YYYY)
Unnamed4
I agree to allow my study doctor, or someone
approved by my study doctor, to contact me
regarding future research involving my
participation in this study.
Yes
No
Unnamed 7
Has the SWOG Registration Worksheet been
completed entirely and is the patient eligible
according to the current version of protocol
section 5.0?
Yes
No
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Colorectal Cancer NCT01416688 Registration - S1013 Registration
Worksheet Form - 3293938v1.0
Breast Cancer NCT00659373 Treatment - Gynecologic
Procedures Form (Form 24-GYN) - 2074074v3.0
Gynecologic Procedures Form (Form 24-GYN)
Brain Function in Premenopausal Women Receiving
Tamoxifen With or Without Ovarian Function Suppression
for Early-Stage Breast Cancer on Clinical Trial IBCSG-2402
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=B12178AE-
C51B-4967-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/8982
Gynecologic Procedures Form (Form
24-GYN)
Report All Gynecologic Procedures Which
Apply:
Pathologic Diagnosis
Complex/adenomatous hyperplasia
without atypia (Complex/adenomatous
hyperplasia without atypia)
Complex/adenomatoushyperplasia with
atypia
(Complex/adenomatoushyperplasia with
atypia)
In situ cancer (In situ cancer)
Invasive cancer (Invasive cancer)
Negative (Negative)
Non-diagnostic (Non-diagnostic)
Simple cystic hyperplasia with atypia
(Simple cystic hyperplasia with atypia)
Simple cystic hyperplasia without atypia
(Simple cystic hyperplasia without
atypia)
Transvaginal ultrasound Date (D M Y)
Abdominal/pelvic ultrasound Date (D M Y)
Other imaging Date (D M Y)
Other imaging, specify site and type of image
Screening endometrial sampling Date (D M Y)
Hysterectomy (date) (D M Y)
Unilateral oophorectomy Date (D M Y)
Bilateral oophorectomy Date (D M Y)
Reason hysterectomy or oophorectomy was done
(select all that apply by marking your selection
with an ?X? in the appropriate boxes)
Benign Gynecologic Condition (Benign
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gynecologic condition)
Borderline Ovarian Tumor (Borderline
ovarian tumor)
Breast Cancer Prevention (Breast cancer
prevention)
Invasive Cancer (Invasive cancer)
Other, Specify (Other, specify)
Ovarian Cancer Prevention (Ovarian
cancer prevention)
Pre-malignancy (Pre-malignancy)
Other, specify (hysterectomy done)
Date (day month year)
Date (day month year)
Ccrr Module For Gynecologic Procedures
Form (form 24-gyn)
Patient ID Number (Study No.)
Patient Initials (f m fl sl)
Patient's Date of Birth (day)
Participating Center/Affiliate
Center Code
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Breast Cancer NCT00659373 Treatment - Gynecologic Procedures Form
(Form 24-GYN) - 2074074v3.0
Breast Cancer NCT00659373 Quality of Life - Quality of
Life Core Questionnaire (Form 24-QLC) - 2073639v3.0
Quality of Life Core Questionnaire (Form 24-QLC)
Brain Function in Premenopausal Women Receiving
Tamoxifen With or Without Ovarian Function Suppression
for Early-Stage Breast Cancer on Clinical Trial IBCSG-2402
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=B0EA521D-
9A9B-6310-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/8984
Quality of Life Core Questionnaire
(Form 24-QLC)
How Have You Been Within The Last Two
Weeks?
Physical Well-Being
Good (Good)
Lousy (Lousy)
Mood
Happy (Happy)
Miserable (Miserable)
Tiredness
A Lot (A lot)
None (None)
Appetite
Good (Good)
None (None)
Hot Flushes
A Lot (A lot)
None (None)
Feeling Sick (nausea/vomiting)
A Lot (A lot)
None (None)
How much effort does it cost you to cope with
your illness?
A Great Deal Of Effort (A great deal of
effort)
No Effort At All (No effort at all)
Do you feel supported by the people close to
you?
Not At All (Not at all)
Very Much (Very much)
Does the operation restrict the use of your arm?
A Lot (A lot)
Not At All (Not at all)
Imagine that you would have to live the rest of
your life in your current condition. Please indicate,
on the line below, how you would rate a life in
your current condition between perfect health and
worst health.Make a vertical mark according to
your est
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Perfect Health (Perfect health)
Worst Health (Worst health)
Ccrr Module For Quality Of Life Core
Questionnaire (form 24-qlc)
Patient ID Number (Study No.)
Patient Initials (f m fl sl)
Patient's Date of Birth (day)
Participating Center/Affiliate
Center Code
2 / 2
Breast Cancer NCT00659373 Quality of Life - Quality of Life Core
Questionnaire (Form 24-QLC) - 2073639v3.0
Leukemia NCT00558519 Registration - CALGB-
10403 OPEN Registration Worksheet - 3057212v1.0
CALGB-10403 OPEN Registration Worksheet
Combination Chemotherapy in Treating Young Patients
With Newly Diagnosed Acute Lymphoblastic Leukemia
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=83D35A37-
D0A0-FE1A-E040-BB89AD435D90
All rights reserved. Please visit https://medical-data-
models.org/forms/8985
CALGB-10403 OPEN Registration
Worksheet
Protocol Administration
Date Informed Consent Signed (MM DD YYYY)
HIPAA Authorization Date (MM DD YYYY)
Projected Start Date of Treatment (MM DD
YYYY)
Institution/Affiliate
Physician of Record
NCI Investigator Number
NCI Institution Number
Patient Demographics/pre-treatment
Characteristics2
Disease (ALL)
Certification Of Eligibility
In the opinion of the investigator, is the patient
eligible
Yes
No
Certification Of Eligibility And Protocol
Design
Assigned Treatment Arm
Sequential Chemotherapy (Sequential
Chemotherapy)
Initial Patient Consent For Specimen Use
Did the patient consent to participate in Study #
1 / 2
9665 (Study # 9665 CALGB Leukemia Tissue
Bank If yes, register the patient to Study # 9665
during registration to Study # 10403)
Yes
No
Did the patient consent to participate in Study #
9862 (Study # 9862 Molecular Genetic Features
of Acute Lymphoblastic Leukemia If yes, register
the patient to Study # 9862 during registration to
Study # 10403)
Yes
No
Did the patient agree to complete the Patient
Survey (Questionnaire)
Yes
No
Initial Patient Consent For Specimen Use
Did the patient consent to participate in Study #
S-9007 (Study # S-9007 Marrow and blood
samples Mandatory for SWOG institutions If yes,
register the patient to Study # S-9007 during
registration to Study #10403)
Yes
No
Did the patient consent to participate in Study #
S-9910 (Study # S-9910 Marrow aspirate, blood
and buccal smear Strongly encouraged for
SWOG institutions If yes, register the patient to
Study # S-9910 during registration to Study
#10403)
Yes
No
Notes:
CRA Name
CRA Phone
CRA email
Lead Institution (Treating if CTSU)
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Leukemia NCT00558519 Registration - CALGB-10403 OPEN
Registration Worksheet - 3057212v1.0
Breast Cancer NCT00769379 Follow-Up - NSABP
PROTOCOL B-43: FOLLOW-UP FORM - 2679283v1.0
NSABP PROTOCOL B-43: FOLLOW-UP FORM
Radiation Therapy With or Without Trastuzumab in Treating
Women With Ductal Carcinoma In Situ Who Have
Undergone Lumpectomy
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=3991DC1D-
88CC-388C-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/8986
NSABP PROTOCOL B-43:
FOLLOW-UP FORM
Header
NSABP Patient ID
Patient Initials (Last First Middle)
Vital Status
Patient's Vital Status
Alive (Alive)
Dead (Dead)
Date of Last Contact or Death (month day year)
Source of Survival Information (if alive)
Documentation Of Hospital Or Clinic Visit
(Documentation of hospital or clinic visit)
Other (Other)
Phone Contact To Patient (Phone
contact to patient)
Other,
Primary Cause of Death
Due To Other Cause (Due to other
cause)
Due To Protocol Treatment (Due to
protocol treatment)
Due To This Disease (Due to this
disease)
Unknown (Unknown)
Describe Cause of Death (attach documentation)
Was there evidence of recurrence at the time of
death
No (No)
Unknown (Unknown)
Yes (Yes)
Cancer Follow-up Status
1 / 4
Has the patient had a documented clinical
assessment for this cancer (since submission of
the last follow-up form)
Yes
No
Date of Last Clinical Assessment (if applicable)
Ipsilateral Breast Tumor Recurrence (ibtr)
Has the patient been diagnosed with an invasive
or non-invasive recurrence in the ipsilateral
breast that has not been previously reported (or
skin of the ipsilateral breast )
Yes
No
Date of IBTR
IBTR Type
Ipsilateral Dcis (post-lumpectomy)
(Ipsilateral DCIS (post-lumpectomy))
Ipsilateral Invasive Breast Cancer
(Ipsilateral invasive breast cancer)
Ipsilateral Skin Recurrence (Ipsilateral
skin recurrence)
First Local-regional Recurrence
Has the patient been diagnosed with first local-
regional recurrence (other than IBTR since
submission of the last follow-up form?)
Yes
No
Site(s) of First Local-Regional Recurrence (mark
all ipsilateral sites that apply)
Axilla (Axilla)
Axillary Nodes (Axillary nodes)
Chest Wall (Chest wall)
Infraclavicular Nodes (Infraclavicular
nodes)
Internal Mammary (Internal mammary)
Supraclavicular Nodes (Supraclavicular
nodes)
Date of First Local-Regional Recurrence (if
applicable)
First Distant Recurrence
Has the patient been diagnosed with first distant
recurrence/progression?
Yes
No
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Breast Cancer NCT00769379 Follow-Up - NSABP PROTOCOL B-43:
FOLLOW-UP FORM - 2679283v1.0
Date of First Distant Recurrence (if applicable)
Site(s) of First Distant Recurrence
New Primary Cancer Or Mds
Has a new primary cancer or MDS been
diagnosed that has not been previously reported?
Yes
No
Date of Diagnosis (if applicable)
Site(s) of New Primary
Mastectomy
Did the patient have total mastectomy?
Yes
No
Location of total mastectomy
Contralateral Breast (Contralateral
breast)
Ipsilateral Breast (Ipsilateral breast)
Total Mastectomy Date
Late Thrombotic Event
Has the patient been diagnosed with any of the
following cardiac events since submission of the
last follow-up form?
Yes
No
CTCAE Term
Acute Coronary Syndrome (Acute
coronary syndrome)
Heart Failure (Heart failure)
Left Ventricular Systolic Dysfunction (Left
ventricular systolic dysfunction)
Myocardial Infarction (Myocardial
infarction)
CTC AE Grade
Comments
Comments
3 / 4
Breast Cancer NCT00769379 Follow-Up - NSABP PROTOCOL B-43:
FOLLOW-UP FORM - 2679283v1.0
Footer Module
Completed by
Date
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Breast Cancer NCT00769379 Follow-Up - NSABP PROTOCOL B-43:
FOLLOW-UP FORM - 2679283v1.0
Leukemia NCT00897767 Eligibility - E3903
Registration Worksheet (step 1) - 2952105v1.0
E3903 Registration Worksheet (step 1)
Collecting Tissue Samples From Patients With Leukemia or
Other Blood Disorders Planning to Enroll in an ECOG
Leukemia Treatment Clinical Trial
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=7586FA81-
F57E-351C-E040-BB89AD43544C
All rights reserved. Please visit https://medical-data-
models.org/forms/8987
E3903 Registration Worksheet (step
1)
Eligibility
Enter the suspected clinical diagnoses
Enter the protocol number(s) of the treatment
protocol under consideration (Note:  Patients may
be entered simultaneously on this laboratory
protocol and a chosen treatment trial if immediate
treatment is medically indicated and a central
review is not mandatory to determine eligibility
prior to registration to the treatment trial.  The
requested materials must be submitted prior to
the start of therapy.  If a central diagnostic review
is performed and does not confirm the diagnosis,
treatment on the treatment protocol will be
discontinued if medically indicated.)
Has the patient registered to or started treatment
on the respective treatment trial
No (No)
Registered Only (Registered only)
Started Treatment (Started treatment)
If the patient is registered to a treatment trial,
enter the treatment protocol number(s) followed
by the ECOG patient ID on the treatment
protocol(s).  Others enter 'N/A'.
Has written informed consent been obtained
Yes
No
Date Informed Consent Signed
Has HIPAA authorization been obtained
Exempt - Non-usa Participant (Exempt -
non-USA participant)
No: C49487 (No)
Yes: C49488 (Yes)
HIPAA Authorization Date
My specimens may be kept for use in research to
learn about, prevent, treat, or cure cancer.
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Yes
No
My specimens may be kept for use in research
about other health problems (for example:
diabetes, Alzheimer's disease, or heart disease).
Yes
No
Someone from this institution may contact me in
the future to ask me to take part in more
research.
Yes
No
I agree research specimens may be collected
with a swab.
Yes
No
I agree to provide additional blood for research.
Yes
No
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Leukemia NCT00897767 Eligibility - E3903 Registration Worksheet (step
1) - 2952105v1.0
Leukemia NCT01041703 Eligibility - E2906
Registration Worksheet (step 2) - 3083300v1.0
E2906 Registration Worksheet (step 2)
Clofarabine or Daunorubicin Hydrochloride and Cytarabine
Followed By Decitabine or Observation in Treating Older
Patients With Newly Diagnosed Acute Myeloid Leukemia
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=8605B765-
B230-3E8A-E040-BB89AD4310BC
All rights reserved. Please visit https://medical-data-
models.org/forms/8988
E2906 Registration Worksheet (step
2)
Eligibility
Has the eligibility checklist been completed
Yes
No
In the opinion of the investigator, is the patient
eligible?
Yes
No
Induction treatment
Arm A - Daunorubicin + Cytarabine (Arm
A - Daunorubicin + Cytarabine)
Arm B - Clofarbine (Arm B - Clofarbine)
1 / 1
Leukemia NCT00792948 Registration - Southwest Oncology Group
S0805 Registration Worksheet Form (Step 1) - 3135175v1.0
Southwest Oncology Group S0805 Registration Worksheet
Form (Step 1)
Combination Chemotherapy With or Without Donor Stem
Cell Transplant in Treating Patients With Acute
Lymphoblastic Leukemia
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=8FB90D5C-
D5F7-9108-E040-BB89AD43238E
All rights reserved. Please visit https://medical-data-
models.org/forms/8989
Southwest Oncology Group S0805
Registration Worksheet Form (Step
1)
Header
Activation Date (MM DD YYYY)
Last Amended Date (MM DD YYYY)
Registration Step
Swog Patient Id
SWOG Patient ID Status
New Patient (New patient)
Previous Patient (Previous patient)
SWOG Patient ID
Demography
Patient First Name
Patient Middle Name
Patient Last Name
Unnamed2
Registrar's SWOG Roster ID Number
SWOG Investigator Number
SWOG Treating Institution Number
Unnamed5
Date Informed Consent Signed (MM DD YYYY)
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Date HIPAA Authorization signed (Not required if
Country of Residence is not USA MM DD YYYY)
Projected Start Date of Treatment (MM DD
YYYY)
Stratification Question
Prior treatment and disease status
Previously Untreated (1)
Achieved Remission (cr Or Cri) (2)
Refractory (previously Treated But Did
Not Achieve Cr Or Cri) (3)
Unnamed4
My specimens may be kept for use in research to
learn about, prevent, treat, or cure cancer.
Yes
No
My specimens may be kept for use in research
about other health problems (for example:
diabetes, Alzheimer's disease, or heart disease).
Yes
No
Someone may contact me in the future to ask me
to allow other uses of my specimens.
Yes
No
I agree to allow my study doctor, or someone
approved by my study doctor, to contact me
regarding future research involving my
participation in this study
Yes
No
Unnamed 7
Has the Southwest Oncology Group Registration
Worksheet been completed entirely and is the
patient eligible according to the current version of
protocol section 5.0
Yes
No
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Leukemia NCT00792948 Registration - Southwest Oncology Group
S0805 Registration Worksheet Form (Step 1) - 3135175v1.0
Leukemia NCT00945815 Registration - Southwest Oncology
Group S0910 Registration Worksheet Form - 3116464v1.0
Southwest Oncology Group S0910 Registration Worksheet
Form
Epratuzumab, Cytarabine, and Clofarabine in Treating
Patients With Relapsed or Refractory Acute Lymphoblastic
Leukemia
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=8A5A6B07-
2599-04D8-E040-BB89AD435E5E
All rights reserved. Please visit https://medical-data-
models.org/forms/8991
Southwest Oncology Group S0910
Registration Worksheet Form
Header
Activation Date (MM DD YYYY)
Last Amended Date (MM DD YYYY)
Registration Step
Swog Patient Id
SWOG Patient ID Status
New Patient (New patient)
Previous Patient (Previous patient)
SWOG Patient ID
Demography
Patient First Name
Patient Middle Name
Patient Last Name
Unnamed2
Registrar's SWOG Roster ID Number
SWOG Investigator Number
SWOG Treating Institution Number
Unnamed5
Date Informed Consent Signed (MM DD YYYY)
1 / 2
Date HIPAA Authorization signed (Not required if
Country of Residence is not USA MM DD YYYY)
Projected Start Date of Treatment (MM DD
YYYY)
Unnamed4
I agree to allow my study doctor, or someone
approved by my study doctor, to contact me
regarding future research involving my
participation in this study
Yes
No
I agree to have my specimens submitted for MRD
Testing.
Yes
No
Unnamed 7
Has the Southwest Oncology Group Registration
Worksheet been completed entirely and is the
patient eligible according to the current version of
protocol section 5.0
Yes
No
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Leukemia NCT00945815 Registration - Southwest Oncology Group
S0910 Registration Worksheet Form - 3116464v1.0
Breast Cancer NCT00914043 Treatment - NSABP B-45
Worksheet for Radiation Therapy (Form RT) - 2829524v1.0
NSABP B-45 Worksheet for Radiation Therapy (Form RT)
Studying Biological Markers of Fatigue in Women With
Residual Invasive Breast Cancer Enrolled on Clinical Trial
NSABP-B-45
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=612CCF23-
383A-C0A1-E040-BB89AD434751
All rights reserved. Please visit https://medical-data-
models.org/forms/8992
NSABP B-45 Worksheet for
Radiation Therapy (Form RT)
Header
Patient Initials (Last First Middle)
NSABP Patient ID
Section A - Radiation Therapy (rt) -- All
Patients
Did the patient receive radiation therapy? (If no,
the remaining questions do not apply. If yes,
continue)
Yes
No
RT begin date (first RT dose Month Day Year)
RT End Date (last RT dose Month Day Year)
Region irradiated (mark all that apply)
Chest Wall (Chest wall)
Internal Mammary Nodes (Internal
mammary nodes)
Regional Nodal (Regional nodal)
Whole Breast (Whole breast)
Total Dose Prior to Boost (Gy)
Total Number of Fractions Prior to Boost
Was a Boost given?
Yes
No
RT Total Dose to Boost Field (If boost was given
Gy)
Was brachytherapy used?
Yes
No
Total Number of Fractions to Boost Field (if no)
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Were there any unscheduled interruptions in
radiation therapy?
Yes
No
Was RT interruption possibly, probably, or
definitely due to RT toxicity? (if yes)
Yes
No
Assessment Of Rt Complications For
Patients Who Received Rt After
Randomization
Date of Assessment (RT Month Day Year)
CTC Adverse Event Short Name
(Dermatology/Skin v3.0)
Dermatitis (Dermatitis - Select)
CTCAE Select Term (v3.0)
Radiation (Radiation)
CTC AE Grade (v3.0)
Footer
Comments (optional)
Person Completing Form
Date Form Completed (MM DD YYYY)
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Breast Cancer NCT00914043 Treatment - NSABP B-45 Worksheet for
Radiation Therapy (Form RT) - 2829524v1.0
Lung Cancer NCT00693992 Registration - CALGB-
30607 OPEN Registration Worksheet - 3134278v1.0
CALGB-30607 OPEN Registration Worksheet
Sunitinib as Maintenance Therapy in Treating Patients With
Stage III or Stage IV Non-Small Cell Lung Cancer
Previously Treated With Combination Chemotherapy
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=8F3901A3-
899E-90D2-E040-BB89AD435A4E
All rights reserved. Please visit https://medical-data-
models.org/forms/8994
CALGB-30607 OPEN Registration
Worksheet
Protocol Administration
Date Informed Consent Signed (MM DD YYYY)
HIPAA Authorization Date (MM DD YYYY)
Projected Start Date of Treatment (MM DD
YYYY)
Pre-treatment Characteristics
Performance Status
Fully Active, Able To Carry On All Pre-
disease Performance Without
Restriction. (0)
Restricted In Physically Strenuous
Activity But Ambulatory And Able To
Carry Out Work Of A Light Or Sedentary
Nature, E.g., Light Housework, Office
Work. (1)
Height (cm)
Weight (kg)
Certification Of Eligibility
In the opinion of the investigator, is the patient
eligible
Yes
No
Certification Of Eligibility And Protocol
Design
Performance Status
Fully Active, Able To Carry On All Pre-
disease Performance Without
Restriction. (0)
Restricted In Physically Strenuous
Activity But Ambulatory And Able To
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Carry Out Work Of A Light Or Sedentary
Nature, E.g., Light Housework, Office
Work. (1)
Stage
Iiib (IIIB)
Iv (IV)
Prior treatment with Bevacizumab
Yes
No
Companion Study Calgb - 150714
In the opinion of the investigator, is the patient
eligible
Yes
No
Initial Patient Consent For Specimen Use
Patient's Initial Consent given for specimen use
for research on the patient's cancer (genomics
research - consent question #2)
Yes
No
Patient's Initial Consent given for specimen kept
for future use in research to learn about, prevent,
or treat cancer (consent question #3)
Yes
No
Patient's Initial Consent given for specimen use
for research unrelated to the patient's cancer?
(consent question #4)
Yes
No
Patient's initial consent given for further contact
regarding specimen? (consent question #5)
Yes
No
In the opinion of the investigator, is the patient
eligible
Yes
No
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Lung Cancer NCT00693992 Registration - CALGB-30607 OPEN
Registration Worksheet - 3134278v1.0
Breast Cancer NCT01275677 Lab - NSABP-B-47 Missing
Data Form for Blood Specimens (Form SMD) - 3166183v1.0
NSABP-B-47 Missing Data Form for Blood Specimens
(Form SMD)
A Randomized Phase III Trial of Adjuvant Therapy
Comparing Chemotherapy Alone (Six Cycles of Docetaxel
Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus
Cyclophosphamide Followed by Weekly Paclitaxel) to
Chemotherapy Plus Trastuzumab in Women With Node-
Positive or High-Risk Node-Negative HER2-Low Invasive
Breast Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=97608836-
5E24-648F-E040-BB89AD435D43
All rights reserved. Please visit https://medical-data-
models.org/forms/8996
NSABP-B-47 Missing Data Form for
Blood Specimens (Form SMD)
Header
Patient Initials (Last First Middle)
NSABP Patient ID
B-47 Study Blood Specimen
Is this form being submitted for a missed blood
specimen (B-47 study)
Yes
No
Time point (If yes)
12 Months Post Randomization (12
months post randomization)
After Randomization But Before Study
Therapy Begins (After randomization but
before study therapy begins)
Reason blood specimen was not collected
Other (Other)
Patient Missed Visit (Patient missed visit)
Patient Refused (Patient refused)
Specimen Collection Problem (Specimen
collection problem)
Specify
B-47 Study Blood Specimen
Is this form being submitted for a missed blood
specimen (B-47 study)
Yes
No
Time point (If yes)
12 Months Post Randomization (12
months post randomization)
After Randomization But Before Study
Therapy Begins (After randomization but
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before study therapy begins)
Reason blood specimen was not collected
Other (Other)
Patient Missed Visit (Patient missed visit)
Patient Refused (Patient refused)
Specimen Collection Problem (Specimen
collection problem)
Specify
Footer
Comments (optional)
Person Completing Form
Date Form Completed (MM DD YYYY)
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Breast Cancer NCT01275677 Lab - NSABP-B-47 Missing Data Form for
Blood Specimens (Form SMD) - 3166183v1.0
Lymphoma NCT01390584 Eligibility - E2410
Registration Worksheet (Step 1) - 3299675v1.0
E2410 Registration Worksheet (Step 1)
Chemotherapy Based on PET Scan in Treating Patients
With Stage I or Stage II Hodgkin Lymphoma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=B0DACA09-
2A81-1BE5-E040-BB89AD4318B8
All rights reserved. Please visit https://medical-data-
models.org/forms/8997
E2410 Registration Worksheet (Step
1)
Eligibility
Has the eligibility checklist been completed
Yes
No
In the opinion of the investigator, is the patient
eligible?
Yes
No
Has written informed consent been obtained
Yes
No
Date Informed Consent Signed
Has HIPAA authorization been obtained
Exempt - Non-usa Participant (Exempt -
non-USA participant)
No: C49487 (No)
Yes: C49488 (Yes)
HIPAA Authorization Date
I agree to participate in the laboratory research
studies that are being done as part of this clinical
trial.
Yes
No
I agree to provide additional blood for research.
Yes
No
I agree my tissue will be submitted for research.
Yes
No
May your coded samples and related coded
information be kept for use in research to learn
about, prevent, find or treat cancer?  This may
also include research on inherited traits (genes
passed on in families).
Yes
No
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My coded samples and related coded information
may be kept for use in research to learn about,
prevent, find or treat other health problems (for
example: diabetes, Alzheimer's disease, or heart
disease). This may also include research on
inherited traits (genes passed on in families).
Yes
No
Someone from my hospital or the Eastern
Cooperative Oncology Group may contact me in
the future to ask me to take part in more
research.
Yes
No
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Lymphoma NCT01390584 Eligibility - E2410 Registration Worksheet
(Step 1) - 3299675v1.0
Breast Cancer NCT00659373 Toxicity -
Exposure in Utero Form - 2073340v3.0
Exposure in Utero Form
Brain Function in Premenopausal Women Receiving
Tamoxifen With or Without Ovarian Function Suppression
for Early-Stage Breast Cancer on Clinical Trial IBCSG-2402
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=B0EA3F35-
AE5A-6303-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/8999
Exposure in Utero Form
Mother Information
First day of last menstrual period (D M Y)
Estimated date of conception (if available)
Relevant history (any maternal health problems
and medications, smoking, alcohol use during the
pregnancy, previous pregnancies and outcomes,
family history of congenital anomaly and genetic
diseases)
Patient's Date of Birth (day)
Estimated pregnancy age at beginning of
exposure to Tamoxifen/Exemestane (weeks)
First Trimester (First trimester)
Second Trimester (Second trimester)
Third Trimester (Third trimester)
Date of outcome of pregnancy (D M Y)
Estimated number of weeks of exposure (weeks)
Outcome of pregnancy (select only one)
Full Term Live Birth (Full term live birth)
Induced/elective Abortion
(Induced/elective abortion)
Miscarriage/spontaneous Abortion
(Miscarriage/spontaneous abortion)
Neonatal Death (Neonatal death)
Preterm Live Birth (Preterm live birth)
Stillbirth (Stillbirth)
Perinatal problems
No (No)
Yes (Yes, specify)
Yes,  (specify)
Newborn Information
Congenital Anomaly, Specify And Submit
Forms 24-sae-a And 24-sae-b
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(Congenital anomaly, specify and submit
Forms 24-SAE-A and 24-SAE-B)
Normal (Normal)
Gender (sex)
Female (Female)
Male (Male)
Weight at birth (OR, if weight in grams is
unknown)
Grams (grams)
Lbs. (lbs.)
Oz. (oz.)
Length at birth (select one unit of measure)
Cm (cm)
In. (in.)
Gestational age at birth (weeks)
Date (day month year)
Date (day month year)
Ccrr Module For Exposure In Utero Form
Patient ID Number (Study No.)
Patient Initials (f m fl sl)
Patient's Date of Birth (day)
Participating Center/Affiliate
Center Code (Ver.#1)
Type of report
Prospective (Prospective)
Retrospective (Retrospective)
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Breast Cancer NCT00659373 Toxicity - Exposure in Utero Form -
2073340v3.0
Lymphoma NCT01216683 Eligibility - E2408
Registration Worksheet (step 1) - 3131998v1.0
E2408 Registration Worksheet (step 1)
Bendamustine Hydrochloride and Rituximab With or
Without Bortezomib Followed by Rituximab With or Without
Lenalidomide in Treating Patients With High-Risk Stage II,
Stage III, or Stage IV Follicular Lymphoma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=8E947DC1-
E82C-2CCF-E040-BB89AD4309FC
All rights reserved. Please visit https://medical-data-
models.org/forms/9000
E2408 Registration Worksheet (step
1)
Eligibility
Has the eligibility checklist been completed
Yes
No
In the opinion of the investigator, is the patient
eligible?
Yes
No
Has written informed consent been obtained
Yes
No
Date Informed Consent Signed
Has HIPAA authorization been obtained
Exempt - Non-usa Participant (Exempt -
non-USA participant)
No: C49487 (No)
Yes: C49488 (Yes)
HIPAA Authorization Date
FLIPI-1 status and GELF criteria
Flipi-1 Score 1 Or 2 Or Unknown; Gelf
High (FLIPI-1 score 1 or 2 or unknown;
GELF high)
Flipi-1 Score 3; Gelf High (FLIPI-1 score
3; GELF high)
Flipi-1 Score 3; Gelf Low Or Unknown
(FLIPI-1 score 3; GELF low or unknown)
Flipi-1 Score 4-5; Gelf High (FLIPI-1
score 4-5; GELF high)
Flipi-1 Score 4-5; Gelf Low Or Unknown
(FLIPI-1 score 4-5; GELF low or
unknown)
Flipi-1 Score Unknown Or 1 Or 2; Gelf
Unknown Or Low (FLIPI-1 score
unknown or 1 or 2; GELF unknown or
low)
I agree to participate in the laboratory research
studies that are being done as part of this clinical
trial.
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Yes
No
I agree to provide additional samples for research
Yes
No
My coded samples and related coded information
may be kept for use in research to learn about,
prevent, find or treat cancer.  This may also
include research on inherited traits (genes
passed on in families).
Yes
No
My coded samples and related coded information
may be kept for use in research to learn about,
prevent, find or treat other health problems (for
example: diabetes, Alzheimer's disease, or heart
disease). This may also include research on
inherited traits (genes passed on in families).
Yes
No
Someone from my hospital or the Eastern
Cooperative Oncology Group may contact me in
the future to ask me to take part in more
research.
Yes
No
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Lymphoma NCT01216683 Eligibility - E2408 Registration Worksheet
(step 1) - 3131998v1.0
Malignant Mesothelioma NCT01064648 Registration - Southwest Oncology
Group S0905 Registration Worksheet - Registration Step 1 - 2987153v1.0
Southwest Oncology Group S0905 Registration Worksheet
- Registration Step 1
Pemetrexed Disodium and Cisplatin With or Without
Cediranib Maleate in Treating Patients With Malignant
Pleural Mesothelioma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=7D36D635-
C082-5CC0-E040-BB89AD4304B4
All rights reserved. Please visit https://medical-data-
models.org/forms/9001
Southwest Oncology Group S0905
Registration Worksheet -
Registration Step 1
Unnamed2
SWOG Patient ID Status
New Patient (New patient)
Previous Patient (Previous patient)
SWOG Patient ID
Unnamed5
Patient First Name
Patient Middle Name
Patient Last Name
Unnamed4
Registrar's SWOG Roster ID Number
SWOG Investigator Number
SWOG Treating Institution Number
Patient Information
Date Informed Consent Signed
Date HIPAA Authorization signed (Not required if
Country of Residence is not USA)
Projected Start Date of Treatment
Unnamed5
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Performance status
Histologic subtype
Unnamed4
My specimens may be kept for use in research to
learn about, prevent, treat, or cure cancer.
Yes
No
My specimens may be kept for use in research
about other health problems (for example:
diabetes, Alzheimer's disease, or heart disease).
Yes
No
Someone may contact me in the future to ask me
to allow other uses of my specimens.
Yes
No
I agree to allow my study doctor, or someone
approved by my study doctor, to contact me
regarding future research involving my
participation in this study
Yes
No
Patient Eligibility
Has the Southwest Oncology Group Registration
Worksheet been completed entirely and is the
patient eligible according to the current version of
protocol section 5.0
Yes
No
Auxiliary Questions
Courier Name (select one)
Federal Express (Federal Express)
U.s. Priority Mail (U.S. Priority Mail)
Ups (UPS)
Courier Account # (enter NA if not applicable)
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Malignant Mesothelioma NCT01064648 Registration - Southwest Oncology
Group S0905 Registration Worksheet - Registration Step 1 - 2987153v1.0
Lymphoma NCT01190449 On-Study - CALGB
50901 On-Study Form - 3211664v1.0
CALGB 50901 On-Study Form
Ofatumumab in Treating Patients With Previously Untreated
Stage II, Stage III, or Stage IV Follicular Non-Hodgkin
Lymphoma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=9F537ABA-
AB9F-8F8B-E040-BB89AD437472
All rights reserved. Please visit https://medical-data-
models.org/forms/9002
CALGB 50901 On-Study Form
Patient Information
Patient Height (cm)
Patient Weight (kg)
BSA (m^2)
Any lymph node or aggregate with a diameter >=
7 cm
No (No)
Unknown (Unknown)
Yes (Yes)
Disease Involvement Site (Regions of extranodal
involvement Mark all that apply with an X.)
Bone (Bone)
Bone Marrow (Bone marrow)
Effusion (Effusion)
Liver (Liver)
Lung (Lung)
Other Specify (Other)
Skin (Skin (cutaneous))
Spleen (Spleen)
Other specify
Are B-symptoms present
Yes
No
Unexplained, persistent fever >38 degrees C (or
>100 degrees F) in the previous month
Yes
No
Recurring, drenching night sweats during the
previous month
Yes
No
Unexplained weight loss >10% of body weight in
the previous 6 months
Yes
No
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Beta-2 Microglobulin (mcg/ml)
Beta-2 Microglobulin ULN (mcg/ml)
FLIPI2 score (Mark one with an X.)
>=3 (>=3)
0 (0)
1-2 (1-2)
Is the patient currently taking a statin
Yes
No
Statin, specify (If yes)
Daily dose prescribed (mg)
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Lymphoma NCT01190449 On-Study - CALGB 50901 On-Study Form -
3211664v1.0
Breast Cancer NCT00659373 Toxicity - Adverse
Event Form (Form 24-AE) - 2072124v3.0
Adverse Event Form (Form 24-AE)
Brain Function in Premenopausal Women Receiving
Tamoxifen With or Without Ovarian Function Suppression
for Early-Stage Breast Cancer on Clinical Trial IBCSG-2402
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=B0FAA5C4-
439E-0ACB-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/9003
Adverse Event Form (Form 24-AE)
Sexual/reproductive Function
Vaginal Dryness (CTC Grade) (CTC Grade select
one)
Relation to study treatment(s)
Cannot be classified (Cannot be
classified)
Definite (Definite)
Possible (Possible)
Probable (Probable)
Unlikely (Unlikely)
Unrelated (Unrelated)
Relation to study treatment(s)
Cannot be classified (Cannot be
classified)
Definite (Definite)
Possible (Possible)
Probable (Probable)
Unlikely (Unlikely)
Unrelated (Unrelated)
Relation to study treatment(s)
Cannot be classified (Cannot be
classified)
Definite (Definite)
Possible (Possible)
Probable (Probable)
Unlikely (Unlikely)
Unrelated (Unrelated)
Relation to study treatment(s)
Cannot be classified (Cannot be
classified)
Definite (Definite)
Possible (Possible)
Probable (Probable)
Unlikely (Unlikely)
Unrelated (Unrelated)
Dyspareunia (CTC Grade) (pain or discomfort
with intercourse)
Was the patient treated for vaginal dryness or
dyspareunia?
Yes
No
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Other topical estrogen, (specify)
Other,  (specify)
Other,  (specify)
Decreased Libido (CTC Grade) (sexual interest)
Urinary Incontinence (CTC Grade) (CTC Grade )
Vasomotor Menopausal
Hot Flashes/Night Sweats (CTC Grade) (CTC
Grade)
Relation to study treatment(s)
Cannot be classified (Cannot be
classified)
Definite (Definite)
Possible (Possible)
Probable (Probable)
Unlikely (Unlikely)
Unrelated (Unrelated)
Was patient treated for hot flashes/night sweats?
Yes
No
Musculoskeletal
Bone Mineral Densitometry Performed
Yes
No
Relation to study treatment(s)
Cannot be classified (Cannot be
classified)
Definite (Definite)
Possible (Possible)
Probable (Probable)
Unlikely (Unlikely)
Unrelated (Unrelated)
Relation to study treatment(s)
Cannot be classified (Cannot be
classified)
Definite (Definite)
Possible (Possible)
Probable (Probable)
Unlikely (Unlikely)
Unrelated (Unrelated)
If yes, was bone mineral density T-score at least
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Breast Cancer NCT00659373 Toxicity - Adverse Event Form (Form 24-
AE) - 2072124v3.0
1.5 standard deviations below the young adult
normal mean in at least one site?
Yes
No
Bone Fractures
Yes
No
Date of bone fracture (D M Y)
Main cause of bone fracture (select all that apply)
Metastasis (Metastasis)
Osteoporosis (Osteoporosis)
Other, Specify (Other, specify)
Trauma (Trauma)
Other,  (specify)
Site of bone fracture (select all that apply)
Hip (Hip)
Other, Specify (Other, specify)
Vertebra (Vertebra)
Wrist/forearm (Wrist/forearm)
Musculoskeletal symptoms (CTC Grade) (i.e.,
myalgia, arthralgia joint pain, stiffness - not
including bone fractures)
Psychological
Mood Alteration - Depression (CTC Grade) (CTC
Grade)
Relation to study treatment(s)
Cannot be classified (Cannot be
classified)
Definite (Definite)
Possible (Possible)
Probable (Probable)
Unlikely (Unlikely)
Unrelated (Unrelated)
Cardiovascular/cerebrovascular
Hypertension (treated?) (Treated?)
Acute Hypertensive Crisis (Acute
hypertensive crisis)
Increase Or Change In This Time Period
Because Of Inadequate Efficacy Of
Previous Antihypertensive (Increase or
change in this time period because of
inadequate efficacy of previous
antihypertensive)
New Start Of Antihypertensive
Medication (New start of
antihypertensive medication)
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None (None)
Treated With Same Antihypertensive
Medications As Reported On Previous
Form (Treated with same
antihypertensive medications as
reported on previous form)
Relation to study treatment(s)
Cannot be classified (Cannot be
classified)
Definite (Definite)
Possible (Possible)
Probable (Probable)
Unlikely (Unlikely)
Unrelated (Unrelated)
Relation to study treatment(s)
Cannot be classified (Cannot be
classified)
Definite (Definite)
Possible (Possible)
Probable (Probable)
Unlikely (Unlikely)
Unrelated (Unrelated)
Relation to study treatment(s)
Cannot be classified (Cannot be
classified)
Definite (Definite)
Possible (Possible)
Probable (Probable)
Unlikely (Unlikely)
Unrelated (Unrelated)
Relation to study treatment(s)
Cannot be classified (Cannot be
classified)
Definite (Definite)
Possible (Possible)
Probable (Probable)
Unlikely (Unlikely)
Unrelated (Unrelated)
Cardiac Ischemia/Infarction (CTC Grade) (CTC
Grade)
Thrombosis/Embolism (CTC Grade) (CTC Grade)
CNS Cerebrovascular Ischemia (CTC Grade)
(CTC Grade)
Constitutional Symptoms
Insomnia (CTC Grade) (CTC Grade)
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Relation to study treatment(s)
Cannot be classified (Cannot be
classified)
Definite (Definite)
Possible (Possible)
Probable (Probable)
Unlikely (Unlikely)
Unrelated (Unrelated)
Relation to study treatment(s)
Cannot be classified (Cannot be
classified)
Definite (Definite)
Possible (Possible)
Probable (Probable)
Unlikely (Unlikely)
Unrelated (Unrelated)
Relation to study treatment(s)
Cannot be classified (Cannot be
classified)
Definite (Definite)
Possible (Possible)
Probable (Probable)
Unlikely (Unlikely)
Unrelated (Unrelated)
Fatigue (CTC Grade) (CTC Grade)
Nausea (CTC Grade) (CTC Grade)
Allergic Reaction / Hypersensitivity /
Injection Site Reaction
Allergic Reaction/Hypersensitivity (CTC Grade)
(CTC Grade)
Relation to study treatment(s)
Cannot be classified (Cannot be
classified)
Definite (Definite)
Possible (Possible)
Probable (Probable)
Unlikely (Unlikely)
Unrelated (Unrelated)
Relation to study treatment(s)
Cannot be classified (Cannot be
classified)
Definite (Definite)
Possible (Possible)
Probable (Probable)
Unlikely (Unlikely)
Unrelated (Unrelated)
If possibly, probably or definitely related to study
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treatment, in the Investigator?s opinion, the event
was most likely due to: (select one)
Exemestane (Exemestane)
Goserelin (Goserelin)
Other, Specify (Other, specify)
Tamoxifen (Tamoxifen)
Triptorelin (Triptorelin)
Other, (specify)
Injection Site Reaction (CTC Grade) (CTC
Grade)
Other Adverse Events
Did the patient have other Grade 3 or higher
adverse event(s)? (Use terminology and grading
from CTC)
Grade 3 (Grade 3)
Grade 4 (Grade 4)
Grade 5 - Fatal (Grade 5 - Fatal)
Relation to study treatment(s)
Cannot be classified (Cannot be
classified)
Definite (Definite)
Possible (Possible)
Probable (Probable)
Unlikely (Unlikely)
Unrelated (Unrelated)
Investigator/Designee Signature
Date (day month year)
Ccrr Module For Adverse Event Form
(form 24-ae)
Month Number
Patient ID Number (Study No.)
Patient Initials (f m fl sl)
Patient's Date of Birth (day)
Participating Center/Affiliate
Center Code (Ver.#1)
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Lung Cancer NCT00946712 Registration - Southwest
Oncology Group S0819 Registration Worksheet - 2863483v1.0
Southwest Oncology Group S0819 Registration Worksheet
Carboplatin and Paclitaxel With or Without Bevacizumab
and/or Cetuximab in Treating Patients With Stage IV or
Recurrent Non-Small Cell Lung Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=684CF883-
65C9-1929-E040-BB89AD4373A3
All rights reserved. Please visit https://medical-data-
models.org/forms/9005
Southwest Oncology Group S0819
Registration Worksheet
Header
Activation Date (MM DD YYYY)
Last Amended Date (MM DD YYYY)
Registration Step
Unnamed5
SWOG Patient ID Status
New Patient (New patient)
Previous Patient (Previous patient)
SWOG Patient ID
Demography
Patient First Name
Patient Middle Name
Patient Last Name
Unnamed2
Registrar's SWOG Roster ID Number
SWOG Investigator Number
SWOG Treating Institution Number
Patient Information
Date Informed Consent Signed
Date HIPAA Authorization signed
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Projected Start Date of Treatment
Stratification Questions
Based on the definition in section 6.1 of the
protocol, classify the patient as bevacizumab-
appropriate or bevacizumab-inappropriate
Bevacizumab-inappropriate (1)
Bevacizumab-appropriate (2)
Smoking history
Current (1)
Former (2)
Never (3)
Stage
M1a (1)
M1b (2)
Unnamed4
My specimens may be kept for use in research to
learn about, prevent, treat, or cure cancer.
Yes
No
My specimens may be kept for use in research
about other health problems (for example:
diabetes, Alzheimer's disease, or heart disease).
Yes
No
Someone may contact me in the future to ask me
to allow other uses of my specimens.
Yes
No
I agree to allow my study doctor, or someone
approved by my study doctor, to contact me
regarding future research involving my
participation in this study
Yes
No
Unnamed 7
Has the Southwest Oncology Group Registration
Worksheet been completed entirely and is the
patient eligible according to the current version of
protocol section 5.0
Yes
No
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Lung Cancer NCT00946712 Registration - Southwest Oncology Group
S0819 Registration Worksheet - 2863483v1.0
Melanoma (Skin) NCT01134614 Eligibility - E1608
Registration Worksheet (step 1) - 3099018v1.0
E1608 Registration Worksheet (step 1)
Ipilimumab With or Without Sargramostim in Treating
Patients With Stage III or Stage IV Melanoma That Cannot
Be Removed By Surgery
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=876C3FE1-
1D5C-9E03-E040-BB89AD434EEA
All rights reserved. Please visit https://medical-data-
models.org/forms/9007
E1608 Registration Worksheet (step
1)
Eligibility
Has the eligibility checklist been completed?
Yes
No
In the opinion of the investigator, is the patient
eligible?
Yes
No
Has written informed consent been obtained?
Yes
No
Date Informed Consent Signed
Has HIPAA authorization been obtained?
Exempt - Non-usa Participant (Exempt -
non-USA participant)
No: C49487 (No)
Yes: C49488 (Yes)
HIPAA Authorization Date
AJCC Stage
M1a/1b (M1a/1b)
M1c (M1c)
Unresectable (Unresectable)
Prior therapy
Ifn (IFN)
None (None)
One Investigational Therapy Or One
Systemic Therapeutic Regimen (One
investigational therapy or one systemic
therapeutic regimen)
I agree to provide additional blood for research.
Yes
No
I agree my tissue will be submitted for research.
Yes
No
My specimens may be kept for use in research to
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learn about, prevent, treat, or cure cancer.
Yes
No
My specimens may be kept for research about
other health problems (for example: causes of
diabetes, Alzheimer's disease, and heart
disease).
Yes
No
Someone from this institution may contact me in
the future to ask me to take part in more
research.
Yes
No
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Melanoma (Skin) NCT01134614 Eligibility - E1608 Registration
Worksheet (step 1) - 3099018v1.0
Lymphoma NCT01216683 Eligibility - E2408
Registration Worksheet (step 2) - 3132466v1.0
E2408 Registration Worksheet (step 2)
Bendamustine Hydrochloride and Rituximab With or
Without Bortezomib Followed by Rituximab With or Without
Lenalidomide in Treating Patients With High-Risk Stage II,
Stage III, or Stage IV Follicular Lymphoma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=8E95E365-
24C3-A131-E040-BB89AD431C79
All rights reserved. Please visit https://medical-data-
models.org/forms/9010
E2408 Registration Worksheet (step
2)
Eligibility
Has the eligibility checklist been completed
Yes
No
In the opinion of the investigator, is the patient
eligible?
Yes
No
Note: The Ecog Registration Program
Uses This Field To Store The Induction
Treatment The Patient Was Assigned.
Patient Stratification Is Based On This
Value.
Note: The Ecog Registration Program
Uses This Field To Store The Ecog Patient
Id.
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Multiple Myeloma and Plasma Cell Neoplasm NCT01055301 Registration -
Southwest Oncology Group S0833 Registration Worksheet - 3189708v1.0
Southwest Oncology Group S0833 Registration Worksheet
Bortezomib, Thalidomide, Lenalidomide, Combination
Chemotherapy, and Autologous Stem Cell Transplant in
Treating Patients With Newly Diagnosed Multiple Myeloma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=9BB380AB-
89F9-FD3C-E040-BB89AD436314
All rights reserved. Please visit https://medical-data-
models.org/forms/9012
Southwest Oncology Group S0833
Registration Worksheet
Header
Activation Date (MM DD YYYY)
Last Amended Date (MM DD YYYY)
Registration Step
Swog Patient Id
SWOG Patient ID Status
New Patient (New patient)
Previous Patient (Previous patient)
SWOG Patient ID
Demography
Patient First Name
Patient Middle Name
Patient Last Name
Unnamed2
Registrar's SWOG Roster ID Number
SWOG Investigator Number
SWOG Treating Institution Number
Unnamed5
Date Informed Consent Signed (MM DD YYYY)
Date HIPAA Authorization signed (Not required if
Country of Residence is not USA MM DD YYYY)
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Projected Start Date of Treatment (MM DD
YYYY)
Unnamed4
My specimens may be kept for use in research to
learn about, prevent, treat, or cure cancer.
Yes
No
My specimens may be kept for use in research
about other health problems (for example:
diabetes, Alzheimer's disease, or heart disease).
Yes
No
Someone may contact me in the future to ask me
to allow other uses of my specimens.
Yes
No
I agree to allow my study doctor, or someone
approved by my study doctor, to contact me
regarding future research involving my
participation in this study.
Yes
No
I agree to have my bone marrow submitted for
this testing.
Yes
No
Unnamed 7
Has the Southwest Oncology Group Registration
Worksheet been completed entirely and is the
patient eligible according to the current version of
protocol section 5.0?
Yes
No
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Multiple Myeloma and Plasma Cell Neoplasm NCT01055301 Registration -
Southwest Oncology Group S0833 Registration Worksheet - 3189708v1.0
Breast Cancer NCT00659373 Treatment - Bilateral
Breast Radiotherapy Form (Form 24-BR) - 2411259v1.0
Bilateral Breast Radiotherapy Form (Form 24-BR)
Brain Function in Premenopausal Women Receiving
Tamoxifen With or Without Ovarian Function Suppression
for Early-Stage Breast Cancer on Clinical Trial IBCSG-2402
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=0162063B-
84EB-2286-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/9013
Bilateral Breast Radiotherapy Form
(Form 24-BR)
Ccrr Module For Breast Radiotherapy
Form (form 24-r)
Patient ID No. (CCRR MODULE FOR Breast
Radiotherapy Form Form 24-R)
Patient Initials (CCRR MODULE FOR Breast
Radiotherapy Form Form 24-R)
Patient's Date of Birth (CCRR MODULE FOR
Breast Radiotherapy Form Form 24-R)
Participating Center/Affiliate
Center Code
This form is being completed for
Left Breast/side (Left breast/side)
Right Breast/side (Right breast/side)
Did the patient receive intraoperative
radiotherapy (IORT)? (CCRR MODULE FOR
Breast Radiotherapy Form Form 24-R)
Yes
No
Did patient start adjuvant postoperative
radiotherapy? (CCRR MODULE FOR Breast
Radiotherapy Form Form 24-R)
Yes
No
Date postoperative radiotherapy started (CCRR
MODULE FOR Breast Radiotherapy Form Form
24-R)
Date postoperative radiotherapy ended (CCRR
MODULE FOR Breast Radiotherapy Form Form
24-R)
Total postoperative dose given without boost
(CCRR MODULE FOR Breast Radiotherapy
Form Form 24-R)
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Postoperative radiotherapy fields (CCRR
MODULE FOR Breast Radiotherapy Form Form
24-R)
Axilla (Axilla)
Breast (Breast)
Chest wall (Chest wall)
Internal mammary lymph nodes (Internal
mammary lymph nodes)
Other, please specify (Other, please
specify)
Supraclavicular lymph nodes
(Supraclavicular lymph nodes)
Other, (CCRR MODULE FOR Breast
Radiotherapy Form Form 24-R)
Was postoperative radiotherapy boost given?
(CCRR MODULE FOR Breast Radiotherapy
Form Form 24-R)
Yes
No
Total Dose to Boost Field(s) (CCRR MODULE
FOR Breast Radiotherapy Form Form 24-R)
For those patients who did not start adjuvant
radiotherapy, please give reason (CCRR
MODULE FOR Breast Radiotherapy Form Form
24-R)
Early Death (Early death)
Early Recurrence (Early recurrence)
Initially Planned, But Physician Later
Advised Against (Initially planned, but
physician later advised against)
Other, Please Specify (Other, please
specify)
Patient Refused (Patient refused)
Other, (CCRR MODULE FOR Breast
Radiotherapy Form Form 24-R)
Investigator Signature (/Designee)
Date
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Breast Cancer NCT00659373 Treatment - Bilateral Breast Radiotherapy
Form (Form 24-BR) - 2411259v1.0
Lung Cancer NCT00976677 Eligibility - E2508
Registration Worksheet (step 1) - 2938183v1.0
E2508 Registration Worksheet (step 1)
Carboplatin, Paclitaxel, and Bevacizumab With or Without
Erlotinib Hydrochloride in Treating Non-Smokers With
Advanced Non-Small Cell Lung Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=72ADEF6D-
FC71-9197-E040-BB89AD43667E
All rights reserved. Please visit https://medical-data-
models.org/forms/9015
E2508 Registration Worksheet (step
1)
Eligibility
Has the eligibility checklist been completed
Yes
No
In the opinion of the investigator, is the patient
eligible?
Yes
No
Has written informed consent been obtained
Yes
No
Date Informed Consent Signed
Has HIPAA authorization been obtained
Exempt - Non-usa Participant (Exempt -
non-USA participant)
No: C49487 (No)
Yes: C49488 (Yes)
HIPAA Authorization Date
Bevacizumab eligibility
Bevacizumab Eligible And Will Elect Not
To Receive Bevacizumab (Bevacizumab
eligible and will elect not to receive
bevacizumab)
Bevacizumab Eligible And Will Receive
Bevacizumab (Bevacizumab eligible and
will receive bevacizumab)
Bevacizumab Ineligible (Bevacizumab
ineligible)
Do you wish to use an express carrier to ship the
drugs (at your expense)?
Yes
No
I agree to participate in the laboratory research
studies that are being done as part of this clinical
trial.
Yes
No
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I agree to provide additional blood for research.
Yes
No
My specimens may be kept for use in research to
learn about, prevent, treat, or cure cancer.
Yes
No
My specimens may be kept for research about
other health problems (for example: causes of
diabetes, Alzheimer's disease, and heart
disease)
Yes
No
Someone from this institution may contact me in
the future to ask me to take part in more
research.
Yes
No
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Lung Cancer NCT00976677 Eligibility - E2508 Registration Worksheet
(step 1) - 2938183v1.0
Melanoma (Skin) NCT00700882 Eligibility - E2607
Registration Worksheet (step 0) - 2860488v1.0
E2607 Registration Worksheet (step 0)
Dasatinib in Treating Patients With Locally Advanced or
Metastatic Mucosal Melanoma, Acral Melanoma, or
Vulvovaginal Melanoma That Cannot Be Removed By
Surgery
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=677233B8-
A620-31B0-E040-BB89AD4363FD
All rights reserved. Please visit https://medical-data-
models.org/forms/9018
E2607 Registration Worksheet (step
0)
Eligibility
Has the eligibility checklist been completed
Yes
No
In the opinion of the investigator, is the patient
eligible?
Yes
No
Has written informed consent been obtained
Yes
No
Date Informed Consent Signed
Has HIPAA authorization been obtained
Exempt - Non-usa Participant (Exempt -
non-USA participant)
No: C49487 (No)
Yes: C49488 (Yes)
HIPAA Authorization Date
Please select C-KIT positive mutation status
Locally Determined Mutation In Exon 9,
11, 13, 17 Or 18 (1)
Locally Determined Other Or Uncertain
Mutation (2)
To Be Determined By Central Laboratory
(3)
I agree to participate in the laboratory research
studies that are being done as part of this clinical
trial.
Yes
No
My specimens may be kept for use in research to
learn about, prevent, treat, or cure cancer.
Yes
No
My specimens may be kept for research about
other health problems (for example: causes of
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diabetes, Alzheimer's disease, and heart
disease). (for example: causes of diabetes,
Alzheimer's disease, and heart disease)
Yes
No
Someone from this institution may contact me in
the future to ask me to take part in more
research.
Yes
No
2 / 2
Melanoma (Skin) NCT00700882 Eligibility - E2607 Registration
Worksheet (step 0) - 2860488v1.0
Breast Cancer NCT00659373 Treatment -
Surgery Form (Form 24-C) - 2074148v3.0
Surgery Form (Form 24-C)
Brain Function in Premenopausal Women Receiving
Tamoxifen With or Without Ovarian Function Suppression
for Early-Stage Breast Cancer on Clinical Trial IBCSG-2402
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=B0E98146-
9F96-636E-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/9020
Surgery Form (Form 24-C)
Ccrr Module For Surgery Form (form 24-c)
Patient ID No. (Study No.)
Patient Initials (f m fl sl)
Patient's Date of Birth (day)
Participating Center/Affiliate
Center Code (Ver.#1)
This form is being completed for
Left Breast/side (Left breast/side)
Right Breast/side (Right breast/side)
Date of Initial Pathologic Diagnosis (D M Y)
Type (LTM = less than mastectomy)
Core Biopsy (Core biopsy)
Fine Needle Aspiration (Fine needle
aspiration)
Ltm: Lump Excision/complete Local
Excision (LTM: lump excision/complete
local excision)
Ltm: Partial Mastectomy/quadrantectomy
(LTM: partial
mastectomy/quadrantectomy)
Ltm: Re-excision For Unclear Or Positive
Margins (LTM: re-excision for unclear or
positive margins)
Ltm: Subcutaneous Mastectomy (LTM:
subcutaneous mastectomy)
Ltm: Subtotal Mastectomy (LTM: subtotal
mastectomy)
Mastectomy (Mastectomy)
Other (Other)
Other Biopsy (Other biopsy)
Other,  (specify)
Surgery Date (D M Y)
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PATHOLOGIC FINDINGS
In Situ Without Invasion (IN SITU without
invasion)
Invasive Cancer (Invasive cancer)
Malignant Cells On Fna (Malignant cells
on FNA)
No Malignancy (No malignancy)
Suspicious For Malignancy (Suspicious
for malignancy)
Was sentinel node biopsy performed?
Yes
No
Sentinel Node Biopsy Date (D M Y)
Was axillary dissection performed?
Yes
No
Date of axillary dissection (D M Y)
Investigator Signature (/Designee)
Date
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Breast Cancer NCT00659373 Treatment - Surgery Form (Form 24-C) -
2074148v3.0
Melanoma (Skin) NCT01274338 Eligibility - E1609
Registration Worksheet (step 1) - 3229501v1.0
E1609 Registration Worksheet (step 1)
Ipilimumab or High-Dose Interferon Alfa-2b in Treating
Patients With High-Risk Stage III or Stage IV Melanoma
That Has Been Removed by Surgery
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=A1C001A9-
8344-A8EA-E040-BB89AD4301D2
All rights reserved. Please visit https://medical-data-
models.org/forms/9021
E1609 Registration Worksheet (step
1)
Eligibility
Has the eligibility checklist been completed
Yes
No
In the opinion of the investigator, is the patient
eligible?
Yes
No
Has written informed consent been obtained
Yes
No
Date Informed Consent Signed
Has HIPAA authorization been obtained
Exempt - Non-usa Participant (Exempt -
non-USA participant)
No: C49487 (No)
Yes: C49488 (Yes)
HIPAA Authorization Date
Surgically resected AJCC stage
Melanoma Stage Iiib (IIIB)
Melanoma Stage Iiic (IIIC)
Melanoma M1a (M1a)
Melanoma M1b (M1b)
Is the registering site a CCOP?
Yes
No
I agree to provide additional blood for research.
Yes
No
I agree my tissue will be submitted for research.
Yes
No
May your coded samples and related coded
information be kept for use in research to learn
about, prevent, find or treat cancer?  This may
also include research on inherited traits (genes
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passed on in families).
Yes
No
May your coded samples and related coded
information be kept for use in research to learn
about, prevent, find or treat other health problems
(for example: diabetes, Alzheimer's disease, or
heart disease)?  This may also include research
on inherited traits (genes passed on in families).
Yes
No
Someone from my hospital or the Eastern
Cooperative Oncology Group may contact me in
the future to ask me to take part in more
research.
Yes
No
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Melanoma (Skin) NCT01274338 Eligibility - E1609 Registration
Worksheet (step 1) - 3229501v1.0
Malignant Mesothelioma  Registration - CALGB-31004 OPEN
Registration/Randomization Worksheet (SPARE Phase IB) - 3342180v1.0
CALGB-31004 OPEN Registration/Randomization
Worksheet (SPARE Phase IB)
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=B5A21D41-
B9DA-D92A-E040-BB89AD4353CA
All rights reserved. Please visit https://medical-data-
models.org/forms/9023
CALGB-31004 OPEN
Registration/Randomization
Worksheet (SPARE Phase IB)
Protocol Administration
Date Informed Consent Signed (MM DD YYYY)
HIPAA Authorization Date (MM DD YYYY)
Projected Start Date of Treatment (MM DD
YYYY)
Pre-treatment Characteristics
Performance Status
Fully Active, Able To Carry On All Pre-
disease Performance Without
Restriction. (0)
Restricted In Physically Strenuous
Activity But Ambulatory And Able To
Carry Out Work Of A Light Or Sedentary
Nature, E.g., Light Housework, Office
Work. (1)
Height (cm)
Weight (kg)
Disease code (mesothelioma)
Certification Of Eligibility
In the opinion of the investigator, is the patient
eligible
Yes
No
Prior Therapy
Prior Cancer Therapies (Mark all that apply with
an X.)
Agents Administered To Control The
Replication And/or Spread Of Viruses
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(Anti-retroviral therapy)
Treatment With An Agent That Prevents
Or Impairs The Translation Of The
Genetic Message For Production Of A
Specific Protein (Antisense)
High Dose Chemotherapy Combined
With Transplantation Of Bone Marrow
Cells (Bone marrow transplant)
Non-systemic Chemotherapy Treatment
Or Chemotherapy Not Described By
Chemotherapy Single Agent Systemic Or
Multi-agent Systemic (Chemotherapy
(NOS))
Systemic Chemotherapy With A
Regimen Containing Multiple Agents
(Chemotherapy multiple agents
systemic)
Prior Therapy With Agents That Are Not
Known To Cause Damage To Cycling
Cells (Chemotherapy non-cytotoxic)
Systemic Chemotherapy With A Single
Agent Regimen (Chemotherapy single
agent systemic)
Drug And/or Immunotherapy (Drug
and/or Immunotherapy)
Treatment Of Human Disease By Gene
Transfer (Gene transfer)
Hematopoietic Stem Cell Transplantation
(Hematopoietic Stem Cell
Transplantation)
Cancer Therapy Which Incorporates
Hormonal Manipulation (Hormonal
therapy)
Image Directed Local Therapy (Image
Directed Local Therapy)
No Previous Exposure To Drug (nos) (No
prior therapy)
Anticancer Treatment With A Live,
Replication-competent Virus (Oncolytic
virotherapy)
Targeted Ionizing Radiation Therapy
Utilizing Radioactive Implants Or Seeds
(Radiation therapy)
Surgical Procedure, Or Operation, With
Therapeutic Intent (Surgery)
Therapy Nos (Therapy (NOS))
Substance Or Group Of Substances
Administered To Induce The Immune
System To Recognize And Destroy
Tumors Or Microorganisms (Vaccine)
Number of regimens (Chemotherapy multiple
agents systemic)
Number of regimens (Chemotherapy non-
cytotoxic)
Number of regimens (Chemotherapy - NOS)
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Malignant Mesothelioma  Registration - CALGB-31004 OPEN
Registration/Randomization Worksheet (SPARE Phase IB) - 3342180v1.0
Number of regimens (Chemotherapy single agent
systemic)
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Malignant Mesothelioma  Registration - CALGB-31004 OPEN
Registration/Randomization Worksheet (SPARE Phase IB) - 3342180v1.0
Breast Cancer NCT00659373 Registration - Confirmation
of Registration Form (Form 24-A) - 2072688v3.0
Confirmation of Registration Form (Form 24-A)
Brain Function in Premenopausal Women Receiving
Tamoxifen With or Without Ovarian Function Suppression
for Early-Stage Breast Cancer on Clinical Trial IBCSG-2402
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=B0EA065B-
0F5E-629F-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/9024
Confirmation of Registration Form
(Form 24-A)
Ccrr Module For Confirmation Of
Registration Form (form 24-a)
Patient ID No. (Study No.)
Patient Initials (f m fl sl)
Patient's Date of Birth (day)
Participating Center/Affiliate
Center Code
PMD Code  (Swiss centers ONLY)
Eligibility Checklist
Randomized within 12 weeks after definitive
surgery.
Yes
No
Premenopausal [estrodiol (E2) in premenopausal
range] following surgery.
Yes
No
Randomized after completing chemotherapy and
within 6 months of the final dose of chemotherapy
as soon as premenopausal status is confirmed.
Yes
No
Premenopausal [estrodiol (E2) in premenopausal
range] between 2 weeks and 6 months after
completing chemotherapy.
Yes
No
Histologically proven, resected breast cancer.
Yes
No
Estrogen and/or progesterone receptor
POSITIVE tumor which is defined as . Or = 10%
1 / 6
of the tumor cells positive by
immunohistochemical evaluation.
Yes
No
The tumor must be confined to the breast and
axillary nodes without detected metastases
elsewhere, with the exception of tumor detected
in internal mammary chain nodes by sentinel
node procedure.  Patients who received
neoadjuvant therapy must have had op
Yes
No
Total mastectomy (with or without radiotherapy
planned) OR breast-conserving procedure with
radiotherapy to the conserved breast planned.
Margins must be clear of invasive cancer and
DCIS.  Documented clear margins of resection in
pathology report.
Yes
No
Either axillary lymph node dissection OR
negative axillary sentinel node biopsy and
workup.  Patients with H&E positive axillary
nodes require axillary dissection, except for
patients with microscopically positive (pN1 mi:
micrometastasis < 2mm) axillary
Yes
No
Eligibility Checklist
No locally advanced inoperable or inflammatory
breast cancer.
Yes
No
No bilateral invasive breast cancer.
Yes
No
Final margins negative (referring to DCIS and
invasive cancer, not LCIS.)
Yes
No
No clinically detectable residual axillary disease.
Yes
No
No supraclavicular node involvement or evidence
of distant metastatic disease.
Yes
No
No history of prior ipsilateral or contralateral
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invasive breast cancer.
Yes
No
No previous or concomitant malignancy EXCEPT
adequately treated basal or squamous cell
carcinoma of the skin, or in situ carcinoma of the
cervix or bladder, or contra-or ipsilateral in situ
breast carcinoma.
Yes
No
No non-malignant systemic diseases that would
prevent prolonged follow-up.
Yes
No
No prior bilateral oophorectomy or ovarian
radiation, and no plan for oophorectomy within
five years
(except if randomized to OFS).
Yes
No
No history of noncompliance to medical regimens
and not considered potentially unreliable.
Yes
No
Not pregnant or lactating at the time of
randomization and does not desire pregnancy
within five years.
Yes
No
Not planning to use additional hormonal
treatment apart from randomized treatment
during the next five years, including all types of
hormonal contraception.
Yes
No
No more than six months of endocrine treatment
(adjuvant and neoadjuvant) after breast cancer
diagnosis.
Yes
No
No Tamoxifen, other SERM (e.g. Raloxifene), or
HRT within 1 year prior to diagnosis.
Yes
No
Has not taken GnRH analogue for breast cancer
treatment.
Yes
No
No psychiatric, addictive or other disorder which
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compromises ability to give informed consent for
participation in study.
Yes
No
Accessible for follow-up.
Yes
No
Informed and agreed to data and tissue material
transfer and handling, in accordance with national
data protection guidelines.
Yes
No
Are all the answers to the Eligibility Checklist
YES? (must be yes to randomize)
Yes
No
Has Informed Consent Form been signed and
dated by the patient and Investigator? (must be
yes to randomize)
Yes
No
Date Informed Consent Form signed by patient  (
must be entered to randomize)
Date Informed Consent Form signed by
Investigator (must be entered to randomize)
Is protocol-required pathology material available
Available Now (Available now)
Available Within 3 Months (Available
within 3 months)
Not Available (Not available)
give reason
Have baseline QL Core and module forms been
completed?
No, But We Intend To Present Baseline
Ql Forms To Be Completed By The
Patient Prior To Starting Theray (no, BUT
we intend to present baseline QL forms
to be completed by the patient prior to
starting theray)
No, Other Reason, Specify (no, other
reason, specify)
No, Patient Meets Exception Criterial
Listed In Protocol (no, patient meets
exception criterial listed in protocol)
Yes (yes)
Other reason, specify (QL forms not completed)
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Date baseline QL forms were completed
Stratification Factors
Prior adjuvant and/or neoadjuvant chemotherapy
Yes
No
Tumor Laterality
Bilateral (Bilateral)
Left (Left)
Right (Right)
Right Breast/Side
0 (0)
1 (1)
Left Breast/Side
0 (0)
1 (1)
Intended method of ovarian function suppression
if patient is randomized to OFS:
Gnrh Analogue X 5 Years (GnRH
analogue x 5 years)
Ovarian Irradiation (Ovarian irradiation)
Surgical Oophorectomy (Surgical
oophorectomy)
Date of the last dose of chemotherapy
Date of Most Extensive Primary Surgery (day
month year)
Date of Most Extensive Primary Surgery (day
month year)
Most Extensive Primary Surgery (Left
breast/side)
Less Than Mastectomy (Less than
mastectomy)
Mastectomy (Mastectomy)
Most Extensive Primary Surgery (Left
breast/side)
Less Than Mastectomy (Less than
mastectomy)
Mastectomy (Mastectomy)
Is adjuvant breast/chest wall radiotherapy
planned, ongoing or completed?
Yes
No
Specimen ID Number (Left breast/side)
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Specimen ID Number (Left breast/side)
Lab Facility Name
Pathology Institute Code
Full name of person randomizing at Participating
Center
Fax Number
Phone Number
Full name of investigator responsible for
confirming eligibility
Treating physician
IBCSG Patient ID
Assigned Treatment Arm
Exemestane For 5 Years With Ovarian
Function Suppression (Exemestane for 5
years with ovarian function suppression)
Tamoxifen For 5 Years (Tamoxifen for 5
years)
Tamoxifen For 5 Years With Ovarian
Function Suppression (Tamoxifen for 5
years with ovarian function suppression)
Randomization Date
Name of person who performed randomization at
Randomization Center
NCI Investigator Number Code
Investigator Signature
Date
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Breast Cancer NCT01275677 Treatment - NSABP-B-
47 Radiation Therapy Form (Form RT) - 3161989v1.0
NSABP-B-47 Radiation Therapy Form (Form RT)
A Randomized Phase III Trial of Adjuvant Therapy
Comparing Chemotherapy Alone (Six Cycles of Docetaxel
Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus
Cyclophosphamide Followed by Weekly Paclitaxel) to
Chemotherapy Plus Trastuzumab in Women With Node-
Positive or High-Risk Node-Negative HER2-Low Invasive
Breast Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=955B416B-
5B63-F8A3-E040-BB89AD43125A
All rights reserved. Please visit https://medical-data-
models.org/forms/9029
NSABP-B-47 Radiation Therapy
Form (Form RT)
Header
Patient Initials (Last First Middle)
NSABP Patient ID
Section A - Radiation Therapy (rt) -- All
Patients
Did the patient receive radiation therapy? (If no,
omit the remaining questions)
Yes
No
RT begin date (first RT dose Month Day Year)
RT End Date (last RT dose Month Day Year)
Region irradiated (mark all that apply)
Chest Wall (Chest wall)
Internal Mammary Nodes (Internal
mammary nodes)
Partial Breast (Partial breast)
Regional Nodal (Regional nodal)
Whole Breast (Whole breast)
Section A - Radiation Therapy (rt) -- All
Patients
Total Dose Prior to Boost (Gy)
Total Number of Fractions Prior to Boost
Was a Boost given?
Yes
No
RT Total Dose to Boost Field (If boost was given
Gy)
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Was brachytherapy used?
Yes
No
Total Number of Fractions to Boost Field
Were there any unscheduled interruptions in
radiation therapy?
Yes
No
Was RT interruption possibly, probably, or
definitely due to RT toxicity? (if yes)
Yes
No
Section A - Radiation Therapy (rt) -- All
Patients
Total Dose (Gy)
Total Number of Fractions
PBI Technique
3-dimensional Conformal Radiation
Therapy (3-D Conformal RT)
Brachytherapy (Brachytherapy)
Were there any unscheduled interruptions in
radiation therapy?
Yes
No
Was RT interruption possibly, probably, or
definitely due to RT toxicity? (if yes)
Yes
No
Section A - Radiation Therapy (rt) -- All
Patients
Total Dose Prior to Boost (Gy)
Total Number of Fractions Prior to Boost
Was a Boost given?
Yes
No
RT Total Dose to Boost Field (If boost was given
Gy)
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Total Number of Fractions to Boost Field
Were there any unscheduled interruptions in
radiation therapy?
Yes
No
Was RT interruption possibly, probably, or
definitely due to RT toxicity? (if yes)
Yes
No
Footer
Comments (optional)
Person Completing Form
Date Form Completed (MM DD YYYY)
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Multiple Myeloma and Plasma Cell Neoplasm NCT01169337
Eligibility - E3A06 Registration Worksheet (Step 1) - 3116584v1.0
E3A06 Registration Worksheet (Step 1)
Lenalidomide or Observation in Treating Patients With
Asymptomatic High-Risk Smoldering Multiple Myeloma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=8A5CBD48-
79FD-0A96-E040-BB89AD43430D
All rights reserved. Please visit https://medical-data-
models.org/forms/9030
E3A06 Registration Worksheet (Step
1)
Eligibility
Has the eligibility checklist been completed
Yes
No
In the opinion of the investigator, is the patient
eligible?
Yes
No
Has written informed consent been obtained
Yes
No
Date Informed Consent Signed
Has HIPAA authorization been obtained
Exempt - Non-usa Participant (Exempt -
non-USA participant)
No: C49487 (No)
Yes: C49488 (Yes)
HIPAA Authorization Date
If the patient has been registered to E3A05,
please enter the ECOG patient ID assigned.
Others enter 'N/A'.
I agree to participate in the laboratory research
studies that are being done as part of this clinical
trial.
Yes
No
I agree to provide additional blood for research.
Yes
No
My specimens may be kept for use in research to
learn about, prevent, treat, or cure cancer.
Yes
No
My specimens may be kept for use in research
about other health problems (for example: causes
1 / 2
of diabetes, Alzheimer's disease, or heart
disease)
Yes
No
Someone from this institution may contact me in
the future to ask me to take part in more
research.
Yes
No
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Lymphoma NCT01190449 Registration - CALGB
50901 OPEN Registration Worksheet - 3235818v1.0
CALGB 50901 OPEN Registration Worksheet
Ofatumumab in Treating Patients With Previously Untreated
Stage II, Stage III, or Stage IV Follicular Non-Hodgkin
Lymphoma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=A3A2758B-
379D-E1D2-E040-BB89AD432897
All rights reserved. Please visit https://medical-data-
models.org/forms/9031
CALGB 50901 OPEN Registration
Worksheet
Protocol Administration
Date Informed Consent Signed (MM DD YYYY)
HIPAA Authorization Date (MM DD YYYY)
Projected Start Date of Treatment (MM DD
YYYY)
Pre-treatment Characteristics
Disease
Nhl (NHL)
Stage
Iii, Iv, Or Bulky Stage Ii (III, IV, or bulky
stage II)
Pathologic Type
Follicular Lymphoma (Follicular
Lymphoma)
Certification Of Eligibility
In the opinion of the investigator, is the patient
eligible (150910)
Yes
No
Certification Of Eligibility And Protocol
Design
Assigned Treatment Arm
Ofatumumab 1000 Mg (Ofatumumab
1000 mg)
Ofatumumab 500 Mg (Ofatumumab 500
mg)
Initial Patient Consent For Specimen Use
Patient's initial consent given for specimen use
for genetic research relating to the study
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treatment (model consent question #1 If the
patient answered "Yes" to this question, register
the patient to 150910 during registration to
50901)
Yes
No
Patient's Initial Consent given for specimen use
for research on the patient's cancer (model
consent question #2 If the patient answered "Yes"
to this question, register the patient to 150910
during registration to 50901)
Yes
No
In the opinion of the investigator, is the patient
eligible (150910)
Yes
No
Initial Patient Consent For Specimen Use
Patient's Initial Consent given for specimen kept
for future use in research to learn about, prevent,
or treat cancer (model consent question #3)
Yes
No
Patient's initial consent given for specimen(s)
may be kept for use in research to learn about,
prevent, or treat other health problems (for
example:
diabetes, Alzheimer's disease, or heart disease)
(model consent question #4)
Yes
No
Patient's initial consent given for further contact to
participate in research on future studies (model
consent question #5)
Yes
No
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Lung Cancer NCT01336894 Registration - ACOSOG-
Z4099 OPEN Enrollment Form - 3167507v1.0
ACOSOG-Z4099 OPEN Enrollment Form
Surgery With or Without Internal Radiation Therapy
Compared With Stereotactic Body Radiation Therapy in
Treating Patients With High-Risk Stage I Non-Small Cell
Lung Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=977826FD-
FE23-332B-E040-BB89AD437C06
All rights reserved. Please visit https://medical-data-
models.org/forms/9032
ACOSOG-Z4099 OPEN Enrollment
Form
General Information
Pt ID# (Local Patient Identifier)
Last (initial)
First (initial)
Middle (initial optional)
Date Informed Consent Signed (month day year)
Was HIPAA Authorization included in Study
Informed Consent
Yes
No
HIPAA Authorization Date (If no month day year)
Stratification Factors
Institutional intent to use Brachytherapy
Yes
No
ECOG Performance Status (PS)
Fully Active, Able To Carry On All Pre-
disease Performance Without
Restriction. (0)
Restricted In Physically Strenuous
Activity But Ambulatory And Able To
Carry Out Work Of A Light Or Sedentary
Nature, E.g., Light Housework, Office
Work. (1)
Ambulatory And Capable Of All Selfcare
But Unable To Carry Out Any Work
Activities. Up And About More Than 50%
Of Waking Hours. (2)
Eligibility Checklist
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Age >= 18 years
Yes
No
Age (>= 18)
ECOG performance status (PS) 0, 1, or 2
Yes
No
Biopsy-proven non-small cell lung cancer
(NSCLC).
Yes
No
Tumor <=3 cm maximum diameter, clinical stage
Ia or selected Ib (i.e., with visceral pleural
involvement) by PET/CT scan of the chest and
upper abdomen performed within 60 days prior to
registration.
Yes
No
Date of PET/CT scan (chest and upper
abdomen)
All clinically suspicious mediastinal N1, N2, or N3
lymph nodes (> 1 cm short-axis dimension on CT
scan and/or positive on PET scan) confirmed
negative for involvement with NSCLC by one of
the following methods: mediastinoscopy, anterior
mediastinotomy, EUS/EBUS guided needle
aspiration, CT-guided, video-assisted
thoracoscopic or open lymph node biopsy.
Yes
No
Tumor verified by a thoracic surgeon to be in a
location that will permit sublobar resection.
Yes
No
Tumor located peripherally within the lung.
(NOTE: Peripheral is defined as not touching any
surface within 2 cm of the proximal bronchial tree
in all directions. See the diagram in Section 2.2.
Patients with non-peripheral central tumors are
NOT eligible.)
Yes
No
No evidence of distant metastases.
Yes
No
PFTs with DLCO within 90 days prior to
registration.
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Yes
No
Patient at high-risk for surgery by meeting a
minimum of one major criteria or two minor
criteria as described below:  Major Criteria:
FEV1 <= 50% predicted  DLCO <= 50%
predicted  Minor Criteria: Age >= 75 FEV1 51-
60% predicted  DLCO 51-60% predicted
Pulmonary hypertension (defined as a pulmonary
artery systolic pressure greater than 40mmHg)
as estimated by echocardiography or right heart
catheterization) Poor left ventricular function
(defined as an ejection fraction of 40% or less)
Resting or Exercise Arterial pO2 <= 55 mm Hg or
SpO2 <= 88%  pCO2 >45 mm Hg  Modified
Medical Research Council (MMRC) Dyspnea
Scale >= 3 (see table within Section 2.1)
Yes
No
No prior intra-thoracic radiation therapy. (Note:
Previous radiotherapy as part of treatment for
head and neck, breast, or other non-thoracic
cancer is permitted.  Previous chemotherapy or
surgical resection for the lung cancer being
treated on this protocol is NOT permitted.)
Yes
No
Non-pregnant and non-lactating.  Women of
childbearing potential must have a negative urine
or serum pregnancy test within 60 days prior to
registration.  Peri-menopausal women must be
amenorrheic >= 12 months prior to registration to
be considered not of childbearing potential. (If not
a female of child-bearing potential check NA)
N/a (N/A)
No (No)
Yes (Yes)
Negative urine or serum pregnancy test date (If
female of child-bearing potential)
No prior invasive malignancy, unless disease-free
for >= 3 years prior to registration (exceptions:
non-melanoma skin cancer, in-situ cancers).
Yes
No
Specimen Collection And Banking
Consent
Patient has given permission for blood specimen
collection for use in this study.
Yes
No
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Patient has given permission to keep blood
sample(s) for use in future research to learn
about, prevent, or treat cancer.
Yes
No
Patient has given permission to keep blood
sample(s) for use in future research to learn
about genetics and how they relate to cancer.
This may also include research on inherited traits
(genes passed on in families).
Yes
No
Patient has given permission to keep blood
sample(s) for use in future research to learn
about, prevent or treat other health problems (for
example: diabetes, Alzheimer's disease, or heart
disease). This may also include genetic research
on inherited traits (genes passed on in families).
Yes
No
Patient has given permission to keep tissue
sample(s) for use in future research to learn
about, prevent, or treat cancer.
Yes
No
Patient has given permission to keep tissue
sample(s) for use in future research to learn
about genetics and how they relate to cancer.
This may also include research on inherited traits
(genes passed on in families).
Yes
No
Patient has given permission to keep tissue
sample(s) for use in future research to learn
about, prevent or treat other health problems (for
example: diabetes, Alzheimer's disease, or heart
disease).  This may also include genetic research
on inherited traits (genes passed on in families).
Yes
No
Randomization
Randomization
Stereotactic Body Radiation Therapy
(Stereotactic body radiation therapy)
Sublobar Resection With Or Without
Brachytherapy (Sublobar resection with
or without brachytherapy)
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Melanoma (Skin) NCT01120275 Registration - Southwest Oncology
Group S0933 Registration Worksheet Form - 3010973v1.0
Southwest Oncology Group S0933 Registration Worksheet
Form
RO4929097 in Treating Patients With Stage IV Melanoma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=7FCD7236-
FF64-40A9-E040-BB89AD4378DB
All rights reserved. Please visit https://medical-data-
models.org/forms/9033
Southwest Oncology Group S0933
Registration Worksheet Form
Header
Activation Date (MM DD YYYY)
Last Amended Date (MM DD YYYY)
Registration Step
Swog Patient Id
SWOG Patient ID Status
New Patient (New patient)
Previous Patient (Previous patient)
SWOG Patient ID
Demography
Patient First Name
Patient Middle Name
Patient Last Name
Unnamed2
Registrar's SWOG Roster ID Number
SWOG Investigator Number
SWOG Treating Institution Number
Unnamed5
Date Informed Consent Signed (MM DD YYYY)
Date HIPAA Authorization signed (Not required if
Country of Residence is not USA MM DD YYYY)
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Projected Start Date of Treatment (MM DD
YYYY)
Unnamed4
My specimens may be kept for use in research to
learn about, prevent, treat, or cure cancer.
Yes
No
My specimens may be kept for use in research
about other health problems (for example:
diabetes, Alzheimer's disease, or heart disease).
Yes
No
Someone may contact me in the future to ask me
to allow other uses of my specimens.
Yes
No
I agree to allow my study doctor, or someone
approved by my study doctor, to contact me
regarding future research involving my
participation in this study.
Yes
No
My fresh tumor samples may be used for the
special testing described as part of this study.
Yes
No
Unnamed 7
Has the Southwest Oncology Group Registration
Worksheet been completed entirely and is the
patient eligible according to the current version of
protocol section 5.0
Yes
No
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Breast Cancer NCT00659373 Treatment -
Follow-up Form (Form 24-E) - 2072392v3.0
Follow-up Form (Form 24-E)
Brain Function in Premenopausal Women Receiving
Tamoxifen With or Without Ovarian Function Suppression
for Early-Stage Breast Cancer on Clinical Trial IBCSG-2402
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=B0FA982B-
ACAA-0AC1-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/9034
Follow-up Form (Form 24-E)
Ccrr Module For Follow-up Form (form 24-
e)
Patient ID No. (Study No.)
Patient Initials (f m fl sl)
Patient's Date of Birth (day)
Participating Center/Affiliate
Center Code (Ver.#1)
Reporting Period Start Date (if this is the first
follow-up period enter date of randomization)
Reporting Period End Date
Documentation of hospital or clinic visit
Other (Other)
Patient Seen (Patient seen)
Phone Contact To Patient (Phone
contact to patient)
Other, specify
Patient's Vital Status (select one)
Alive (Alive)
Dead (Dead)
Date of death (day month year)
Primary cause of death
Accident (Accident)
Cerebrovascular Accident
(Cerebrovascular accident)
Congestive Heart Failure (Congestive
heart failure)
Myocardial Infarction (Myocardial
infarction)
New Primary Diagnosis (New primary
diagnosis)
Other Cause (Other cause)
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Progression Of Underlying Breast
Cancer (Progression of underlying breast
cancer)
Sepsis / Infection (Sepsis / infection)
Suicide (Suicide)
Thromboembolic Event
(Thromboembolic event)
Other cause, specify
Autopsy
Yes
No
Bone densitometry
Below Normal (Below Normal)
Normal (Normal)
Not Done (Not Done)
Date performed
Performance status at date of this examination or
contact
2 (Ambulatory and capable of all selfcare
but unable to carry out any work
activities)
3 (Capable of limited selfcare, confined
to bed or chair more than 50% of waking
hours)
4 (Completely disabled)
0 (Fully active, able to carry on all pre-
disease performance without restriction)
1 (Restricted in physically strenuous
activity but ambulatory)
Weight (if measured in clinic)
Menstrual status during 3 months prior to follow-
up visit (select one)
Occasionally Irregular Or Lengthened
Interval, But Continuing Menstrual
Cycles (Irregular)
Normal (Normal)
Persistent Amenorrhea (Persistent
amenorrhea)
Was patient pregnant at any time during this
follow-up period? If more than one pregnancy,
indicate most recent episode. (If pregnant during
protocol treatment, complete Form 24-EIU for
each pregnancy.)
Full Term Live Birth (Full term live birth)
Induced / Elective Abortion (Induced /
elective abortion)
Miscarriage / Spontaneous Abortion
(Miscarriage / spontaneous abortion)
Neonatal Death (Neonatal death)
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No (No)
Preterm Live Birth (Preterm live birth)
Stillbirth (Stillbirth)
Yes, Currently Pregnant (Yes, currently
pregnant)
Did the patient have gynecologic surgery,
procedures and/or diagnostic imaging (excluding
PAP smear?)
No (No.)
Yes (Yes)
Has the patient attempted to become pregnant
during this follow-up period
Yes
No
Method
Assisted (Assisted)
Natural (Natural)
Has the patient had any clinically significant
cardiovascular and/or cerebrovascular events
after protocol treatment ended (Report on Form
24-AE if during protocol treatment or up to 12
months after protocol treatment has ended.)
Yes
No
Specify event
Specify date
Specify date
Did the patient have any bone fractures after
protocol treatment ended? (Report on Form 24-
AE if during protocol treatment or up to 12
months after protocol treatment has ended.)
Yes
No
Has patient experienced any other severe (>
grade 3) adverse event(s), (not reported in Q13-
16) after protocol treatment ended? (Report on
Form 24-AE during protocol treatment or up to 12
months after protocol treatment has ended.)
Yes
No
Describe
Was event related to protocol treatment
Definite (Definite)
Possible (Possible)
Probable (Probable)
Unlikely (Unlikely)
Unrelated (Unrelated)
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Was event related to protocol treatment
Definite (Definite)
Possible (Possible)
Probable (Probable)
Unlikely (Unlikely)
Unrelated (Unrelated)
Was event related to protocol treatment
Definite (Definite)
Possible (Possible)
Probable (Probable)
Unlikely (Unlikely)
Unrelated (Unrelated)
Has the patient been diagnosed with in situ
breast cancer, right side, since the submission of
the last Follow-up Form (select one)
No (No)
Yes, Both Ductal And Lobular Carcinoma
In Situ (Yes, both ductal and lobular
carcinoma in situ)
Yes, Ductal Carcinoma In Situ (Yes,
ductal carcinoma in situ)
Yes, Lobular Carcinoma In Situ (Yes,
lobular carcinoma in situ)
Has the patient been diagnosed with in situ
breast cancer, left side, since the submission of
the last Follow-up Form
No (No)
Yes, Both Ductal & Lobular Carcinoma In
Situ (Yes, both ductal & lobular
carcinoma in situ)
Yes, Ductal Carcinoma In Situ (Yes,
ductal carcinoma in situ)
Yes, Lobular Carcinoma In Situ (Yes,
lobular carcinoma in situ)
Specify treatment
Specify treatment
Has the patient been diagnosed with in situ
cervical cancer since the submission of the last
Follow-up Form?
Yes
No
Has the patient been diagnosed with basal cell or
squamous cell carcinoma of the skin since the
submission of the last Follow-up Form?
Yes
No
Date of Initial Pathologic Diagnosis (day month
year)
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Date of Initial Pathologic Diagnosis (day month
year)
Date of Initial Pathologic Diagnosis (day month
year)
Date of Initial Pathologic Diagnosis (day month
year)
Has patient had a suspicious or proven second
primary since submission of last Follow-up Form
Yes
No
Specify site below
Endometrial Cancer (Endometrial
cancer)
Mixed Mullerian Tumor (Mixed Mullerian
tumor)
Other (Other)
Uterine Sarcoma (Uterine sarcoma)
Other, specify type and site
Other, specify type and site
Date suspected
Date suspected
Date proven
Date proven
Specify treatment for first 2nd primary
Has patient had a suspicious or proven
recurrence/metastasis or contralateral invasive
breast cancer since submission of last Follow-up
Form?
Yes
No
Site
Breast Scar / Skin (Breast scar / skin)
Breast Tissue (Breast tissue)
Chest Wall (Chest wall)
Chest Wall / Outside Breast (Chest wall /
outside breast)
Contra Breast (Contra breast)
Ipsi Axilla (Ipsi axilla)
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Ipsi Axillary Nodes (Ipsi axillary nodes)
Ipsi Infraclavicular Nodes (Ipsi
infraclavicular nodes)
Ipsi Internal Mammary Nodes (Ipsi
internal mammary nodes)
Ipsi Supraclavicular Nodes (Ipsi
supraclavicular nodes)
Scar (Scar)
Specify Site (Specify site)
Specify
Investigation
Bone Scan (Bone scan)
Ct Scan (CT scan)
Cytology (Cytology)
Histology (Histology)
Mri (MRI (NMR))
Other (Other)
Pet Scan (PET scan)
Ultrasound (Ultrasound)
X-ray (X-ray)
Other, specify
Date 1st Performed
Date Repeated
Are there additional sites
Yes
No
Surgery
Yes
No
Specify procedure
Surgery Date (D M Y)
Radiation Therapy
Yes
No
Specify dose
Specify field
Chemotherapy
Yes
No
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Specify drug
Endocrine therapy
Yes
No
Specify
Other
Yes
No
Specify
Date started
Date started
Date started
Date started
Investigator Signature (/Designee)
Date (day month year)
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Lymphoma NCT01390584 Eligibility - E2410
Registration Worksheet (Step 2) - 3299717v1.0
E2410 Registration Worksheet (Step 2)
Chemotherapy Based on PET Scan in Treating Patients
With Stage I or Stage II Hodgkin Lymphoma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=B0DB2488-
DEEB-F2F5-E040-BB89AD430E38
All rights reserved. Please visit https://medical-data-
models.org/forms/9035
E2410 Registration Worksheet (Step
2)
Eligibility
Has the eligibility checklist been completed
Yes
No
In the opinion of the investigator, is the patient
eligible?
Yes
No
Indicate the PET-CT scan result that was
determined centrally and reported to you
Positron Emission Tomography Negative
Finding (PET Negative)
Positron Emission Tomography Positive
(PET Positive)
Radiation Oncology Facility (Enter response)
1 / 1
Multiple Myeloma and Plasma Cell Neoplasm NCT00644228 Registration -
Southwest Oncology Group S0777 Registration Worksheet - Step 1 - 2838964v1.0
Southwest Oncology Group S0777 Registration Worksheet
for OPEN - Step 1
Lenalidomide and Dexamethasone With or Without
Bortezomib in Treating Patients With Previously Untreated
Multiple Myeloma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=62BC6580-
A0D5-914B-E040-BB89AD432984
All rights reserved. Please visit https://medical-data-
models.org/forms/9037
Southwest Oncology Group S0777
Registration Worksheet - Step 1
Header
Activation Date
Last Amended Date
Registration Step
Unnamed2
SWOG Patient ID Status
New Patient (New patient)
Previous Patient (Previous patient)
SWOG Patient ID
Unnamed5
Patient First Name
Patient Middle Name
Patient Last Name
For All Institutions
Is registering institution a SWOG institution
Yes
No
Unnamed4
Registrar's SWOG Roster ID Number
SWOG Investigator Number
1 / 3
SWOG Treating Institution Number
Patient Information
Date Informed Consent Signed
Date HIPAA Authorization signed (Not required if
Country of Residence is not USA)
Projected Start Date of Treatment
Unnamed5
ISS stage
I (1)
Ii (2)
Iii (3)
Intent to transplant at relapse
Unnamed4
My specimens may be kept for use in research to
learn about, prevent, treat, or cure cancer.
Yes
No
My specimens may be kept for use in research
about other health problems (for example:
diabetes, Alzheimer's disease, or heart disease).
Yes
No
Someone may contact me in the future to ask me
to allow other uses of my specimens.
Yes
No
I agree to allow my study doctor, or someone
approved by my study doctor, to contact me
regarding future research involving my
participation in this study
Yes
No
I agree to submit bone marrow samples for
genetic studies related to this study
Yes
No
Patient Eligibility
2 / 3
Multiple Myeloma and Plasma Cell Neoplasm NCT00644228 Registration -
Southwest Oncology Group S0777 Registration Worksheet - Step 1 - 2838964v1.0
Has the Southwest Oncology Group Registration
Worksheet been completed entirely and is the
patient eligible according to the current version of
protocol section 5.0
Yes
No
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Multiple Myeloma and Plasma Cell Neoplasm NCT00644228 Registration -
Southwest Oncology Group S0777 Registration Worksheet - Step 1 - 2838964v1.0
Lymphoma NCT00972478 Registration - Southwest Oncology
Group S0806 Registration Worksheet - 3153147v1.0
Southwest Oncology Group S0806 Registration Worksheet
Vorinostat, Rituximab, and Combination Chemotherapy In
Treating Patients With Newly Diagnosed Stage II, Stage III,
or Stage IV Diffuse Large B-Cell Lymphoma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=93A47944-
A122-F633-E040-BB89AD435946
All rights reserved. Please visit https://medical-data-
models.org/forms/9039
Southwest Oncology Group S0806
Registration Worksheet
Header
Activation Date (MM DD YYYY)
Last Amended Date (MM DD YYYY)
Registration Step
Swog Patient Id
SWOG Patient ID Status
New Patient (New patient)
Previous Patient (Previous patient)
SWOG Patient ID
Demography
Patient First Name
Patient Middle Name
Patient Last Name
Unnamed2
Registrar's SWOG Roster ID Number
SWOG Investigator Number
SWOG Treating Institution Number
Unnamed5
Date Informed Consent Signed (MM DD YYYY)
Date HIPAA Authorization signed (Not required if
Country of Residence is not USA MM DD YYYY)
1 / 2
Projected Start Date of Treatment (MM DD
YYYY)
Unnamed4
My specimens may be kept for use in research to
learn about, prevent, treat, or cure cancer.
Yes
No
My specimens may be kept for use in research
about other health problems (for example:
diabetes, Alzheimer's disease, or heart disease).
Yes
No
Someone may contact me in the future to ask me
to allow other uses of my specimens.
Yes
No
I agree to allow my study doctor, or someone
approved by my study doctor, to contact me
regarding future research involving my
participation in this study.
Yes
No
I agree to have my blood submitted for the
evaluation of immune system proteins and cells.
Yes
No
I agree to have part of my original tumor biopsy
submitted for the evaluation of immune system
proteins and cells.
Yes
No
I agree to have tissue from an on-study biopsy
submitted for the evaluation of immune system
proteins and cells.
Yes
No
Unnamed 7
Has the Southwest Oncology Group Registration
Worksheet been completed entirely and is the
patient eligible according to the current version of
protocol section 5.0?
Yes
No
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Lymphoma NCT00972478 Registration - Southwest Oncology Group
S0806 Registration Worksheet - 3153147v1.0
Multiple Myeloma and Plasma Cell Neoplasm NCT01078441
Eligibility - E2A08 Registration Worksheet (step 1) - 2991593v1.0
E2A08 Registration Worksheet (step 1)
Bortezomib, Liposomal Doxorubicin Hydrochloride,
Dexamethasone, and Cyclophosphamide in Treating
Patients With Multiple Myeloma That Relapsed After
Autologous Stem Cell Transplant
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=7DC3B0B9-
ECC6-DFC6-E040-BB89AD432ED9
All rights reserved. Please visit https://medical-data-
models.org/forms/9041
E2A08 Registration Worksheet (step
1)
Eligibility
Has the eligibility checklist been completed
Yes
No
In the opinion of the investigator, is the patient
eligible?
Yes
No
Has written informed consent been obtained
Yes
No
Date Informed Consent Signed
Has HIPAA authorization been obtained
Exempt - Non-usa Participant (Exempt -
non-USA participant)
No: C49487 (No)
Yes: C49488 (Yes)
HIPAA Authorization Date
If the patient has been registered to E3A05,
please enter the ECOG patient ID assigned.
Others enter 'N/A'.
My coded samples and related coded information
may be kept for use in research to learn about,
prevent, find or treat cancer.  This may also
include research on inherited traits (genes
passed on in families).
Yes
No
My coded samples and related coded information
may be kept for use in research to learn about,
prevent, find or treat other health problems (for
example: diabetes, Alzheimer's disease, or heart
disease). This may also include research on
inherited traits (genes passed on in families).
Yes
No
1 / 2
Someone from my hospital or the Eastern
Cooperative Oncology Group may contact me in
the future to ask me to take part in more
research.
Yes
No
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Multiple Myeloma and Plasma Cell Neoplasm NCT01078441 Eligibility -
E2A08 Registration Worksheet (step 1) - 2991593v1.0
Breast Cancer NCT00659373 Toxicity - Serious
Adverse Event Form (Form 24-SAE_B) - 2074086v3.0
Serious Adverse Event Form (Form 24-SAE_B)
Brain Function in Premenopausal Women Receiving
Tamoxifen With or Without Ovarian Function Suppression
for Early-Stage Breast Cancer on Clinical Trial IBCSG-2402
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=B0EA7BE0-
EB0F-636A-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/9043
Serious Adverse Event Form (Form
24-SAE_B)
Section B - Follow-up Report
Date of onset: (day month year)
Date of this follow-up report: (day month year)
Action taken regarding protocol treatment: (select
all that apply)
Dose Reduced (Dose reduced)
None (None)
Other, Specify (Other, specify)
Treatment Delayed (Treatment delayed)
Treatment Permanently Discontinued
(Treatment permanently discontinued)
Treatment Temporarily Discontinued
(Treatment temporarily discontinued)
Other, (specify)
Treatments/procedures for SAE: (please
describe)
Were there changes in previous Concomitant
Therapy? (Complete ONLY if different from initial
report in Section A.)
Yes
No
Name of Medication
Admin. (e.g., i.v., p.o.)
Daily Dosage
Date Started (day month year)
Date Stopped (day month year)
Outcome (select one)
Death, date of death: (Death, date of
death:)
1 / 2
Not resolved/ongoing (Not
resolved/ongoing)
Resolved with Sequelae: (Resolved with
Sequelae:)
Resolved: (Resolved:)
Resolved with Sequelae: (please specify)
Cause of death:
Autopsy Report available?
No (No)
Yes (Yes.)
Investigator/Designee Signature
Investigator/Designee Signature
Phone number:
MD Name (please print:)
Fax number:
Date (day month year)
Ccrr Module For Serious Adverse Event
Form (form 24-sae_b)
Patient ID Number (Study No.)
Patient Initials (f m fl sl)
Patient's Date of Birth (day)
Participating Center/Affiliate
Center Code (Ver.#1)
2 / 2
Breast Cancer NCT00659373 Toxicity - Serious Adverse Event Form
(Form 24-SAE_B) - 2074086v3.0
Lung Cancer NCT00955305 Eligibility - E3508
Registration Worksheet (step 1) - 2938533v1.0
E3508 Registration Worksheet (step 1)
Paclitaxel, Carboplatin, and Bevacizumab With or Without
Cixutumumab in Treating Patients With Stage IV or
Recurrent Non-Small Cell Lung Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=72AE81D7-
07C1-6D88-E040-BB89AD437E80
All rights reserved. Please visit https://medical-data-
models.org/forms/9044
E3508 Registration Worksheet (step
1)
Eligibility
Has the eligibility checklist been completed
Yes
No
In the opinion of the investigator, is the patient
eligible?
Yes
No
Has written informed consent been obtained
Yes
No
Date Informed Consent Signed
Has HIPAA authorization been obtained
Exempt - Non-usa Participant (Exempt -
non-USA participant)
No: C49487 (No)
Yes: C49488 (Yes)
HIPAA Authorization Date
ECOG Performance Status
Fully Active, Able To Carry On All Pre-
disease Performance Without
Restriction. (0)
Restricted In Physically Strenuous
Activity But Ambulatory And Able To
Carry Out Work Of A Light Or Sedentary
Nature, E.g., Light Housework, Office
Work. (1)
Ambulatory And Capable Of All Selfcare
But Unable To Carry Out Any Work
Activities. Up And About More Than 50%
Of Waking Hours. (2)
Capable Of Only Limited Selfcare,
Confined To Bed Or Chair More Than
50% Of Waking Hours. (3)
Completely Disabled. Cannot Carry On
Any Selfcare. Totally Confined To Bed Or
Chair. (4)
Dead (5)
My specimens may be kept for use in research to
1 / 2
learn about, prevent, treat, or cure cancer.
Yes
No
My specimens may be kept for use in research
about other health problems (for example: causes
of diabetes, Alzheimer's disease, or heart
disease)
Yes
No
Someone from this institution may contact me in
the future to ask me to take part in more
research.
Yes
No
2 / 2
Lung Cancer NCT00955305 Eligibility - E3508 Registration Worksheet
(step 1) - 2938533v1.0
Prostate Cancer NCT00417040 Registration - CALGB-
70501 OPEN Registration Worksheet - 3109455v1.0
CALGB-70501 OPEN Registration Worksheet
Using the Internet to Collect Symptoms and the Ability to
Carry Out Daily Activities From Patients With Metastatic
Prostate Cancer That Has Not Responded to Hormone
Therapy
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=88FDC7BD-
6156-D30B-E040-BB89AD4371E0
All rights reserved. Please visit https://medical-data-
models.org/forms/9045
CALGB-70501 OPEN Registration
Worksheet
Header Module
CALGB Patient ID (Number - Enter the patient ID
number into OPEN to retrieve the patient's
administrative and demographic information from
the registration to the treatment study.  NOTE:
This form should only be used for patients for
whom registration to a treatment study has
already occurred.  If registration to the treatment
study has not already occurred, then use the
worksheet for the treatment study)
Protocol Administration
Date Informed Consent Signed (MM DD YYYY)
HIPAA Authorization Date (MM DD YYYY)
Projected Start Date of Treatment (MM DD
YYYY)
Certification Of Eligibility
In the opinion of the investigator, is the patient
eligible (If yes, register patient in 70501)
Yes
No
1 / 1
Pancreatic Cancer NCT01473303 Registration - CALGB-81003
OPEN Registration Worksheet (SPARE Phase Ib) - 3340712v1.0
CALGB-81003 OPEN Registration Worksheet (SPARE
Phase Ib)
Combination Chemotherapy With or Without Ganitumab in
Treating Patients With Previously Untreated Metastatic
Pancreatic Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=B5545048-
A6BC-B965-E040-BB89AD437802
All rights reserved. Please visit https://medical-data-
models.org/forms/9047
CALGB-81003 OPEN Registration
Worksheet (SPARE Phase Ib)
Protocol Administration
Date Informed Consent Signed (MM DD YYYY)
HIPAA Authorization Date (MM DD YYYY)
Projected Start Date of Treatment (MM DD
YYYY)
Pre-treatment Characteristics
ECOG Performance Status
Fully Active, Able To Carry On All Pre-
disease Performance Without
Restriction. (0)
Restricted In Physically Strenuous
Activity But Ambulatory And Able To
Carry Out Work Of A Light Or Sedentary
Nature, E.g., Light Housework, Office
Work. (1)
Height (cm)
Weight (kg)
Disease code (pancreas)
Certification Of Eligibility
In the opinion of the investigator, is the patient
eligible (for CALGB 61103)
Yes
No
Protocol Design
ECOG Performance Status
Fully Active, Able To Carry On All Pre-
disease Performance Without
1 / 4
Restriction. (0)
Restricted In Physically Strenuous
Activity But Ambulatory And Able To
Carry Out Work Of A Light Or Sedentary
Nature, E.g., Light Housework, Office
Work. (1)
Prior Therapy
Prior Cancer Therapies (If patient received prior
cancer therapy: Mark an X for each therapy
received. For chemotherapies, specify number of
regimens received. The number of regimens
refers to the number of treatment courses, not the
number of cycles received for a course of
treatment. For example, a patient who received 3
cycles while on Treatment A and 6 cycles while
on Treatment B has received 2 treatment
regimens - Treatment A and Treatment B.)
Agents Administered To Control The
Replication And/or Spread Of Viruses
(Anti-retroviral therapy)
Treatment With An Agent That Prevents
Or Impairs The Translation Of The
Genetic Message For Production Of A
Specific Protein (Antisense)
High Dose Chemotherapy Combined
With Transplantation Of Bone Marrow
Cells (Bone marrow transplant)
Non-systemic Chemotherapy Treatment
Or Chemotherapy Not Described By
Chemotherapy Single Agent Systemic Or
Multi-agent Systemic (Chemotherapy
(NOS))
Systemic Chemotherapy With A
Regimen Containing Multiple Agents
(Chemotherapy multiple agents
systemic)
Prior Therapy With Agents That Are Not
Known To Cause Damage To Cycling
Cells (Chemotherapy non-cytotoxic)
Systemic Chemotherapy With A Single
Agent Regimen (Chemotherapy single
agent systemic)
Drug And/or Immunotherapy (Drug
and/or Immunotherapy)
Treatment Of Human Disease By Gene
Transfer (Gene transfer)
Hematopoietic Stem Cell Transplantation
(Hematopoietic Stem Cell
Transplantation)
Cancer Therapy Which Incorporates
Hormonal Manipulation (Hormonal
therapy)
Image Directed Local Therapy (Image
Directed Local Therapy)
No Previous Exposure To Drug (nos) (No
prior therapy)
Anticancer Treatment With A Live,
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Pancreatic Cancer NCT01473303 Registration - CALGB-81003 OPEN
Registration Worksheet (SPARE Phase Ib) - 3340712v1.0
Replication-competent Virus (Oncolytic
virotherapy)
Targeted Ionizing Radiation Therapy
Utilizing Radioactive Implants Or Seeds
(Radiation therapy)
Surgical Procedure, Or Operation, With
Therapeutic Intent (Surgery)
Therapy Nos (Therapy (NOS))
Substance Or Group Of Substances
Administered To Induce The Immune
System To Recognize And Destroy
Tumors Or Microorganisms (Vaccine)
Number of regimens (Chemotherapy multiple
agents systemic)
Number of regimens (Chemotherapy non-
cytotoxic)
Number of regimens (Chemotherapy - NOS)
Number of regimens (Chemotherapy single agent
systemic)
Initial Patient Consent For Specimen Use
I choose to take part in the Patient-Reported
Outcomes Study and agree to complete the
questionnaire once per month (consent question
#1 - must be Yes for participation in 71102)
Yes
No
In the opinion of the investigator, is the patient
eligible (for CALGB 61103)
Yes
No
Initial Patient Consent For Specimen Use
My coded samples and related coded information
may be used to learn about, prevent, find or treat
my type of cancer. This may also include
research on inherited traits (genes passed on in
families) (consent question #2 - must be Yes for
participation in 151109 and 61103)
Yes
No
My coded samples and related coded information
may be kept for use in future research to learn
about, prevent, find or treat any type of cancer.
This may also include research on inherited traits
(genes passed on in families) (consent question
#3)
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Pancreatic Cancer NCT01473303 Registration - CALGB-81003 OPEN
Registration Worksheet (SPARE Phase Ib) - 3340712v1.0
Yes
No
In the opinion of the investigator, is the patient
eligible (for CALGB 61103)
Yes
No
My coded samples and related coded information
may be kept for use in future research to learn
about, prevent, find or treat other health problems
(for example: diabetes, Alzheimer's disease, or
heart disease). This may also include research
on inherited traits (genes passed on in families)
(consent question #4)
Yes
No
Someone from my hospital or CALGB may
contact me in the future to ask me to take part in
more research (consent question #5)
Yes
No
Certification Of Eligibility
In the opinion of the investigator, is the patient
eligible (for CALGB 61103)
Yes
No
4 / 4
Pancreatic Cancer NCT01473303 Registration - CALGB-81003 OPEN
Registration Worksheet (SPARE Phase Ib) - 3340712v1.0
Breast Cancer NCT00914043 On-Study - NSABP B-45
Worksheet for Thyroid Function Monitoring Form - 2847070v1.0
NSABP B-45 Worksheet for Thyroid Function Monitoring
Form
Studying Biological Markers of Fatigue in Women With
Residual Invasive Breast Cancer Enrolled on Clinical Trial
NSABP-B-45
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=64AFECAB-
BE8A-0357-E040-BB89AD431986
All rights reserved. Please visit https://medical-data-
models.org/forms/9048
NSABP B-45 Worksheet for Thyroid
Function Monitoring Form
Header
Patient Initials (Last First Middle)
NSABP Patient ID
Tsh Assessment
Time point (for this report)
12 Months After Randomization (12
months after randomization)
3 Months After Randomization (3 months
after randomization)
6 Months After Randomization (6 months
after randomization)
6 Weeks After Start Of Study Therapy (6
weeks after start of study therapy)
9 Months After Randomization (9 months
after randomization)
Other (Other)
Was TSH assessed at this time point
Yes
No
Tsh Assessment1
Was the patient being treated with
sunitinib/placebo at the time of this assessment
Yes
No
Was the patient being treated with levothyroxine
at the time of this assessment
Yes
No
Was levothyroxine initiated as a result of this
assessment (If no)
Yes
No
Levothyroxine Dose (if either question is marked
yes)
1 / 2
0.1 Mg Daily (0.1 mg daily)
0.125 Mg Daily (0.125 mg daily)
0.15 Mg Daily (0.15 mg daily)
Other (Other)
Other, specify (mg daily)
Tsh Assessment2
Date of Assessment (MM DD YYYY)
TSH (patient value microIU/mL)
TSH LLN (microIU/mL)
TSH ULN (microIU/mL)
Did the patient receive any systemic anticancer
treatment for documented invasive breast cancer
recurrence or second primary cancer prior to this
Time Point
Yes
No
Reason TSH was Assessed at Other Time Point
(When Other Time Point applies)
Evaluation Of Symptoms (Evaluation of
Symptoms)
Follow-up After Discontinuation Of
Levothyroxine (Follow-up after
Discontinuation of Levothyroxine)
Follow-up Of Previous Assessment
(Follow-up of Previous Assessment)
Other (Other)
Other, specify
Footer
Comments (optional)
Person Completing Form
Date Form Completed (MM DD YYYY)
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Breast Cancer NCT00914043 On-Study - NSABP B-45 Worksheet for
Thyroid Function Monitoring Form - 2847070v1.0
Breast Cancer NCT00659373 Quality of Life - Missing Quality
of Life Assessment Form (Form 24-MQL) - 2073685v3.0
Missing Quality of Life Assessment Form (Form 24-MQL)
Brain Function in Premenopausal Women Receiving
Tamoxifen With or Without Ovarian Function Suppression
for Early-Stage Breast Cancer on Clinical Trial IBCSG-2402
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=B0EA56FC-
31B5-6351-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/9049
Missing Quality of Life Assessment
Form (Form 24-MQL)
Ccrr Module For Missing Quality Of Life
Assessment Form (form 24-mql)
Patient ID Number (Study No.)
Patient Initials (f m fl sl)
Patient's Date of Birth (day)
*Scheduled Date of Quality of Life Form (day
month year)
Center Code
Participating Center Name/ Affiliate
Form(s) which were not completed at this
scheduled assessment  (select all that apply by
marking ?X? in the box)
Core Form (Core Form)
Module Form (Module Form)
Supplement Form (Supplement Form)
Reason patient did not complete the Quality of
Life Form(s) at this scheduled assessment
(please select one)
Form Not Presented Or Mailed To
Patient. (Form not presented or mailed to
patient.)
Other, Specify: (Other, specify:)
Patient Did Not Come To Clinic And
Mailed Form Was Not Returned. (Patient
did not come to clinic and mailed form
was not returned.)
Patient Felt Too Ill To Complete The
Quality Of Life Form At This
Assessment. (Patient felt too ill to
complete the Quality of Life Form at this
assessment.)
Patient Refused To Participate In Quality
Of Life Assessment. (Patient refused to
participate in Quality of Life
assessment.)
1 / 2
Patient Wishes To Withdraw From
Further Participation In The Quality Of
Life Study. (Patient wishes to withdraw
from further participation in the Quality of
Life Study.)
Other,  (specify:)
Reason patient missed this scheduled clinic
appointment: (please select one)
Patient In Hospital Or Nursing Home
(Patient in hospital or nursing home)
Patient On Holiday (Patient on holiday)
Unknown (Unknown)
Investigator/Designee Signature
Date (day month year)
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Breast Cancer NCT00659373 Quality of Life - Missing Quality of Life
Assessment Form (Form 24-MQL) - 2073685v3.0
Pancreatic Cancer NCT01473303 Registration - CALGB-
81003 OPEN Registration Worksheet (Phase II) - 3297544v1.0
CALGB-81003 OPEN Registration Worksheet (Phase II)
Combination Chemotherapy With or Without Ganitumab in
Treating Patients With Previously Untreated Metastatic
Pancreatic Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=B0263E2E-
A570-C223-E040-BB89AD4317AC
All rights reserved. Please visit https://medical-data-
models.org/forms/9051
CALGB-81003 OPEN Registration
Worksheet (Phase II)
Protocol Administration
Date Informed Consent Signed (MM DD YYYY)
HIPAA Authorization Date (MM DD YYYY)
Projected Start Date of Treatment (MM DD
YYYY)
Pre-treatment Characteristics
ECOG Performance Status
Fully Active, Able To Carry On All Pre-
disease Performance Without
Restriction. (0)
Restricted In Physically Strenuous
Activity But Ambulatory And Able To
Carry Out Work Of A Light Or Sedentary
Nature, E.g., Light Housework, Office
Work. (1)
Height (cm)
Weight (kg)
Disease code (pancreas)
Certification Of Eligibility
In the opinion of the investigator, is the patient
eligible (for CALGB 61103)
Yes
No
Protocol Design
ECOG Performance Status
Fully Active, Able To Carry On All Pre-
disease Performance Without
Restriction. (0)
1 / 4
Restricted In Physically Strenuous
Activity But Ambulatory And Able To
Carry Out Work Of A Light Or Sedentary
Nature, E.g., Light Housework, Office
Work. (1)
Prior Therapy
Prior Cancer Therapies (If patient received prior
cancer therapy: Mark an X for each therapy
received. For chemotherapies, specify number of
regimens received. The number of regimens
refers to the number of treatment courses, not the
number of cycles received for a course of
treatment. For example, a patient who received 3
cycles while on Treatment A and 6 cycles while
on Treatment B has received 2 treatment
regimens - Treatment A and Treatment B.)
Agents Administered To Control The
Replication And/or Spread Of Viruses
(Anti-retroviral therapy)
Treatment With An Agent That Prevents
Or Impairs The Translation Of The
Genetic Message For Production Of A
Specific Protein (Antisense)
High Dose Chemotherapy Combined
With Transplantation Of Bone Marrow
Cells (Bone marrow transplant)
Non-systemic Chemotherapy Treatment
Or Chemotherapy Not Described By
Chemotherapy Single Agent Systemic Or
Multi-agent Systemic (Chemotherapy
(NOS))
Systemic Chemotherapy With A
Regimen Containing Multiple Agents
(Chemotherapy multiple agents
systemic)
Prior Therapy With Agents That Are Not
Known To Cause Damage To Cycling
Cells (Chemotherapy non-cytotoxic)
Systemic Chemotherapy With A Single
Agent Regimen (Chemotherapy single
agent systemic)
Drug And/or Immunotherapy (Drug
and/or Immunotherapy)
Treatment Of Human Disease By Gene
Transfer (Gene transfer)
Hematopoietic Stem Cell Transplantation
(Hematopoietic Stem Cell
Transplantation)
Cancer Therapy Which Incorporates
Hormonal Manipulation (Hormonal
therapy)
Image Directed Local Therapy (Image
Directed Local Therapy)
No Previous Exposure To Drug (nos) (No
prior therapy)
Anticancer Treatment With A Live,
Replication-competent Virus (Oncolytic
2 / 4
Pancreatic Cancer NCT01473303 Registration - CALGB-81003 OPEN
Registration Worksheet (Phase II) - 3297544v1.0
virotherapy)
Targeted Ionizing Radiation Therapy
Utilizing Radioactive Implants Or Seeds
(Radiation therapy)
Surgical Procedure, Or Operation, With
Therapeutic Intent (Surgery)
Therapy Nos (Therapy (NOS))
Substance Or Group Of Substances
Administered To Induce The Immune
System To Recognize And Destroy
Tumors Or Microorganisms (Vaccine)
Number of regimens (Chemotherapy multiple
agents systemic)
Number of regimens (Chemotherapy non-
cytotoxic)
Number of regimens (Chemotherapy - NOS)
Number of regimens (Chemotherapy single agent
systemic)
Initial Patient Consent For Specimen Use
I choose to take part in the Patient-Reported
Outcomes Study and agree to complete the
questionnaire once per month (consent question
#1 - must be Yes for participation in 71102)
Yes
No
In the opinion of the investigator, is the patient
eligible (for CALGB 61103)
Yes
No
Initial Patient Consent For Specimen Use
My coded samples and related coded information
may be used to learn about, prevent, find or treat
my type of cancer. This may also include
research on inherited traits (genes passed on in
families) (consent question #2 - must be Yes for
participation in 151109 and 61103)
Yes
No
My coded samples and related coded information
may be kept for use in future research to learn
about, prevent, find or treat any type of cancer.
This may also include research on inherited traits
(genes passed on in families) (consent question
#3)
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Registration Worksheet (Phase II) - 3297544v1.0
Yes
No
In the opinion of the investigator, is the patient
eligible (for CALGB 61103)
Yes
No
My coded samples and related coded information
may be kept for use in future research to learn
about, prevent, find or treat other health problems
(for example: diabetes, Alzheimer's disease, or
heart disease). This may also include research
on inherited traits (genes passed on in families)
(consent question #4)
Yes
No
Someone from my hospital or CALGB may
contact me in the future to ask me to take part in
more research (consent question #5)
Yes
No
Certification Of Eligibility
In the opinion of the investigator, is the patient
eligible (for CALGB 61103)
Yes
No
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Pancreatic Cancer NCT01473303 Registration - CALGB-81003 OPEN
Registration Worksheet (Phase II) - 3297544v1.0
Breast Cancer NCT00659373 Pathology - Hormone
Receptor Form (Form 24-F) - 2073222v3.0
Hormone Receptor Form (Form 24-F)
Brain Function in Premenopausal Women Receiving
Tamoxifen With or Without Ovarian Function Suppression
for Early-Stage Breast Cancer on Clinical Trial IBCSG-2402
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=B0EA32D1-
99C1-62FB-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/9052
Hormone Receptor Form (Form 24-
F)
Ccrr Module For Hormone Receptor Form
(form 24-f)
Patient ID No. (Study No.)
Patient Initials (f m fl sl)
Patient's Date of Birth (day)
Participating Center/Affiliate
Center Code
This form is being completed for
Left Breast/side (Left breast/side)
Right Breast/side (Right breast/side)
Specimen ID Number
Date Specimen Collected (D M Y)
ER % Positive (Results of immunohistochemical
IHC: Percent of positive cells use 0-100)
PR % Positive (Results of immunohistochemical
IHC: Percent of positive cells use 0-100)
ER status (select one)
Negative (Negative)
Positive (Positive)
Unknown (Unknown)
PgR status (select one)
Negative (Negative)
Positive (Positive)
Unknown (Unknown)
Investigator Signature
Date
1 / 1
Breast Cancer NCT01275677 Treatment - NSABP-B-47
Concomitant Medications Form (Form MED) - 3162774v1.0
NSABP-B-47 Concomitant Medications Form (Form MED)
A Randomized Phase III Trial of Adjuvant Therapy
Comparing Chemotherapy Alone (Six Cycles of Docetaxel
Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus
Cyclophosphamide Followed by Weekly Paclitaxel) to
Chemotherapy Plus Trastuzumab in Women With Node-
Positive or High-Risk Node-Negative HER2-Low Invasive
Breast Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=95D01C7E-
6ACF-38AE-E040-BB89AD4351B3
All rights reserved. Please visit https://medical-data-
models.org/forms/9053
NSABP-B-47 Concomitant
Medications Form (Form MED)
Header
Patient Initials (Last First Middle)
NSABP Patient ID
Unnamed Module 1
Reporting Period
12 Months Post Randomization (12
Months Post Randomization)
24 Months Post Randomization (24
Months Post Randomization)
36 Months Post Randomization (36
Months Post Randomization)
48 Months Post Randomization (48
Months Post Randomization)
60 Months Post Randomization (60
Months Post Randomization)
Baseline (Baseline)
Concomitant Medication
Were concomitant medications used during this
reporting period? (metformin, NSAIDs, beta
blockers, ace inhibitors, ARBs, diabetes
medication, or hypertension medication)
Yes
No
Metformin
Yes
No
Aspirin
Yes
No
Specify (Medication names)
Specify (Medication names)
1 / 2
Agent Duration (Round up to the nearest month
months)
Has the patient taken any other medications
during this reporting period (If yes, report the
names trade name or generic name of both over
the counter and prescription medications the
patient has taken since submission of the
previous form. For the first time point, list all
medications taken within 4 weeks of
randomization. For patients taking more than 9
other medications, additional rows will be
available for entry online. Do not report vitamins
or herbal/dietary supplements on this form)
Yes
No
Footer
Comments (optional)
Person Completing Form
Date Form Completed
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Breast Cancer NCT01275677 Treatment - NSABP-B-47 Concomitant
Medications Form (Form MED) - 3162774v1.0
Prostate Cancer NCT01251861 Pre-Study - E2809
Registration Worksheet (step 1) - 3153226v1.0
E2809 Registration Worksheet (step 1)
Bicalutamide With or Without MK2206 in Treating Patients
With Previously Treated Prostate Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=93A7565E-
608E-32A1-E040-BB89AD436B02
All rights reserved. Please visit https://medical-data-
models.org/forms/9055
E2809 Registration Worksheet (step
1)
Eligibility
Has the eligibility checklist been completed?
Yes
No
In the opinion of the investigator, is the patient
eligible?
Yes
No
Has written informed consent been obtained?
Yes
No
Date Informed Consent Signed
Has HIPAA authorization been obtained?
Exempt - Non-usa Participant (Exempt -
non-USA participant)
No: C49487 (No)
Yes: C49488 (Yes)
HIPAA Authorization Date
Gleason Score
6 Or Less (6 or less)
7 (7)
8 To 10 (8 to 10)
Prior Hormonal Therapy
Yes
No
May your coded samples and related coded
information be kept for use in research to learn
about, prevent, find or treat cancer?  This may
also include research on inherited traits (genes
passed on in families).
Yes
No
May your coded samples and related coded
information be kept for use in research to learn
about, prevent, find or treat other health problems
(for example: diabetes, Alzheimer's disease, or
heart disease)?  This may also include research
1 / 2
on inherited traits (genes passed on in families).
Yes
No
Someone from this institution may contact me in
the future to ask me to take part in more
research.
Yes
No
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Prostate Cancer NCT01251861 Pre-Study - E2809 Registration
Worksheet (step 1) - 3153226v1.0
Breast Cancer NCT00659373 Pathology -
Pathology Form (Form 24-P) - 2074955v3.0
Pathology Form (Form 24-P)
Brain Function in Premenopausal Women Receiving
Tamoxifen With or Without Ovarian Function Suppression
for Early-Stage Breast Cancer on Clinical Trial IBCSG-2402
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=B126C787-
1E49-54D3-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/9056
Pathology Form (Form 24-P)
Ccrr Module For Pathology Form (form 24-
p)
Patient ID No. (Study No.)
Patient Initials (f m fl sl)
Patient's Date of Birth (day)
Participating Center/Affiliate
Center Code
Header
Specimen ID Number
Adjacent normal tissue block specimen number
Primary tumor slide specimen number
Adjacent normal breast tissue slide specimen
number
This form is being completed for
Left Breast/side (Left breast/side)
Right Breast/side (Right breast/side)
Primary Tumor
Pathologic primary tumor size. Maximum
diameter of invasive component. (cm )
Histological type (Dominant)
in situ lobular carcinoma (in situ lobular
carcinoma)
intraductal (in situ) carcinoma, high
grade (intraductal (in situ) carcinoma,
high grade)
1 / 5
intraductal (in situ) carcinoma, low grade
(intraductal (in situ) carcinoma, low
grade)
intraductal (in situ) carcinoma, moderate
grade (intraductal (in situ) carcinoma,
moderate grade)
invasive cribriform, mixed (invasive
cribriform, mixed)
invasive cribriform, pure (invasive
cribriform, pure)
invasive ductal (NOS) (invasive ductal
(NOS))
invasive ductal with predominant
intraductal component (invasive ductal
with predominant intraductal component)
invasive lobular - classic type (invasive
lobular - classic type)
invasive lobular - variant type (invasive
lobular - variant type)
medullary (medullary)
medullary-atypical (medullary-atypical)
mucinous (colloid) (mucinous (colloid))
mucinous (colloid) - variant (mucinous
(colloid) - variant)
no cancer on slide (no cancer on slide)
other, specify (other, specify)
tubular (tubular)
tubular-variant (tubular-variant)
other,  (specify)
Grade
Total points - Bloom, Richardson, Elston (Grade)
(If not available, complete Q4.)
Tubule formation
Nuclear pleomorphism
Mitoses
Differentiation (select one)
Tumor Is Moderately Differentiated
According To Who Grading System
(Moderately differentiated)
Tumor Is Poorly Differentiated According
To Who Grading System (Poorly
differentiated)
Tumor Is Well Differentiated According
To Who Grading System (Well
differentiated)
Excision Margins
Invasive cancer
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Breast Cancer NCT00659373 Pathology - Pathology Form (Form 24-P) -
2074955v3.0
<= 1 Mm, But Not Involved (<= 1 mm,
but not involved)
> 1 And <= 10 Mm (> 1 and <= 10 mm)
> 10 Mm (> 10 mm)
Not Involved, But Distance Not
Assessable (Not involved, but distance
not assessable)
DCIS
<= 1 Mm, But Not Involved (<= 1 mm,
but not involved)
> 1 And <= 10 Mm (> 1 and <= 10 mm)
> 10 Mm (> 10 mm)
Not Involved, But Distance Not
Assessable (Not involved, but distance
not assessable)
Vessel Invasion
Was there invasion of vessels around primary
tumor?  (select one)
No (No)
Not Able To Assess (Not able to assess)
Yes (Yes)
Her2/neu
Score by immunohistochemistry
0 (0)
1+ (1+)
2+ (2+)
3+ (3+)
Not Done (Not done)
Immunohistochemistry Kit or Test Type
Dako Herceptest [tm] (DAKO Herceptest
[TM])
Other, Specify (Other, specify)
Other, specify (assay)
By FISH
Amplified (Amplified)
Normal Copy Number (Normal copy
number)
Not Done (Not done)
Polysomic (Polysomic)
Type of Assay
Dako (DAKO)
Oncor (Oncor)
Other, Specify (Other, specify)
Vysis (Vysis)
Other, specify (assay)
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Breast Cancer NCT00659373 Pathology - Pathology Form (Form 24-P) -
2074955v3.0
By other technique, (Her2/neu)
Her2/neu status, (by other technique)
Negative (Negative)
Not Done (Not done)
Positive (Positive)
Nodal Involvement
Total number examined
Number of metastatic axillary lymph nodes
Extracapsular Extension
Yes
No
Isolated tumor cells only
Yes
No
Total number examined
Number of metastatic axillary sentinel lymph
nodes
Largest tumor deposit
Isolated Tumor Cells Alone (Isolated
tumor cells alone)
Macrometastases (Macrometastases)
Micrometastases (Micrometastases)
None Detected (None detected)
Largest tumor deposit
Isolated Tumor Cells Alone (Isolated
tumor cells alone)
Macrometastases (Macrometastases)
Micrometastases (Micrometastases)
None Detected (None detected)
Total number examined
Number of metastatic internal mammary sentinel
nodes
Form completed by (select one)
Investigator (Investigator)
Pathologist (Pathologist)
Comments
Investigator/Pathologist Signature
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Breast Cancer NCT00659373 Pathology - Pathology Form (Form 24-P) -
2074955v3.0
Date
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Breast Cancer NCT00659373 Pathology - Pathology Form (Form 24-P) -
2074955v3.0
Neoplasm Metastasis NCT01015560 Registration - Southwest
Oncology Group S0916 Registration Worksheet - 2992473v1.0
Southwest Oncology Group S0916 Registration Worksheet
MLN1202 in Treating Patients With Bone Metastases
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=7E132CE7-
168F-1F88-E040-BB89AD4321DB
All rights reserved. Please visit https://medical-data-
models.org/forms/9062
Southwest Oncology Group S0916
Registration Worksheet
Header
Activation Date (MM DD YYYY)
Last Amended Date (MM DD YYYY)
Registration Step
Unnamed2
SWOG Patient ID Status
New Patient (New patient)
Previous Patient (Previous patient)
SWOG Patient ID
Unnamed5
Patient First Name
Patient Middle Name
Patient Last Name
Unnamed4
Registrar's SWOG Roster ID Number
SWOG Investigator Number
SWOG Treating Institution Number
Patient Information
Date Informed Consent Signed
Date HIPAA Authorization signed (Not required if
Country of Residence is not USA)
1 / 2
Projected Start Date of Treatment
Unnamed4
My specimens may be kept for use in research to
learn about, prevent, treat, or cure cancer.
Yes
No
My specimens may be kept for use in research
about other health problems (for example:
diabetes, Alzheimer's disease, or heart disease).
Yes
No
Someone may contact me in the future to ask me
to allow other uses of my specimens.
Yes
No
I agree to allow my study doctor, or someone
approved by my study doctor, to contact me
regarding future research involving my
participation in this study
Yes
No
Patient Eligibility
Has the Southwest Oncology Group Registration
Worksheet been completed entirely and is the
patient eligible according to the current version of
protocol section 5.0
Yes
No
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Neoplasm Metastasis NCT01015560 Registration - Southwest Oncology
Group S0916 Registration Worksheet - 2992473v1.0
Breast Cancer NCT00914043 Pathology - NSABP B-45 Worksheet
for Calculation of Residual Cancer Burden - 2829593v1.0
NSABP B-45 Worksheet for Calculation of Residual Cancer
Burden
Studying Biological Markers of Fatigue in Women With
Residual Invasive Breast Cancer Enrolled on Clinical Trial
NSABP-B-45
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=612CCF23-
38C5-C0A1-E040-BB89AD434751
All rights reserved. Please visit https://medical-data-
models.org/forms/9065
NSABP B-45 Worksheet for
Calculation of Residual Cancer
Burden
Header
Patient Initials (Last First Middle)
NSABP Patient ID
Items Related To Calculation Of Residual
Cancer Burden
Primary Tumor Bed Area (Identification of cross-
sectional dimensions of residual bed, considering
gross and adjacent microscopic tumor. If no
residual tumor, measurements = 0. x.xx %)
Primary Tumor Bed Area (Identification of cross-
sectional dimensions of residual bed, considering
gross and adjacent microscopic tumor. If no
residual tumor, measurements = 0. x.xx %)
Overall Cancer Cellularity (as percentage of area
Estimate of percent of residual tumor bed area
that is involved by cancer invasive and/or in situ.
If no residual tumor, % = 0 x.xx %)
Percentage of Cancer that is in situ Disease
(Estimate of the proportion of residual tumor bed
area that is in situ component. If no residual
tumor, % = 0 x.xx %)
Number of Positive Lymph Nodes (Consider
axillary nodes from applicable post-neoadjuvant
procedures: sentinel node biopsy and/or surgical
evaluation of axilla. If no positive axillary nodes,
number = 0.)
Diameter of largest metastasis  (Consider axillary
nodes from applicable post-neoadjuvant
procedures: sentinel node biopsy and/or surgical
evaluation of axilla. If no positive axillary nodes,
largest metastasis = 0 x.xx %)
1 / 2
Units
Millimeters (mm)
Footer
Comments (optional)
Person Completing Form
Date Form Completed (MM DD YYYY)
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Breast Cancer NCT00914043 Pathology - NSABP B-45 Worksheet for
Calculation of Residual Cancer Burden - 2829593v1.0
Adenocarcinoma of the Gastroesophageal Junction NCT01333033 Registration -
CALGB-80803 OPEN Registration/Randomization Worksheet (Step 1) -
3287859v1.0
CALGB-80803 OPEN Registration/Randomization
Worksheet (Step 1)
PET Scan Imaging in Assessing Response in Patients With
Esophageal Cancer Receiving Combination Chemotherapy
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=AE28FF1D-
7C5B-BC14-E040-BB89AD43491A
All rights reserved. Please visit https://medical-data-
models.org/forms/9066
CALGB-80803 OPEN
Registration/Randomization
Worksheet (Step 1)
Protocol Administration
Date Informed Consent Signed (MM DD YYYY)
HIPAA Authorization Date (MM DD YYYY)
Projected Start Date of Treatment (MM DD
YYYY)
Pre-treatment Characteristics
Performance Status
Fully Active, Able To Carry On All Pre-
disease Performance Without
Restriction. (0)
Restricted In Physically Strenuous
Activity But Ambulatory And Able To
Carry Out Work Of A Light Or Sedentary
Nature, E.g., Light Housework, Office
Work. (1)
Height (cm)
Weight (kg)
Disease code (esophagus)
Certification Of Eligibility
In the opinion of the investigator, is the patient
eligible
Yes
No
Protocol Design (stratification Factors)
Initial Patient Consent For Specimen Use
1 / 2
I agree that my blood and tissue may be used for
the research described in the protocol (consent
question #1 - must be Yes for participation in
151007)
Yes
No
My specimens may be kept for future unknown
use in research to learn about, prevent, treat, or
cure cancer (consent question #2)
Yes
No
My specimens may be kept for use in research
about other health problems (for example:
diabetes, Alzheimer's disease, or heart disease).
(consent question #3)
Yes
No
My doctor or someone from CALGB may contact
me in the future to ask me to take part in more
research (consent question #4)
Yes
No
In the opinion of the investigator, is the patient
eligible
Yes
No
Companion Study Calgb - 150714
I choose to take part in the Quality of Life study
and agree to complete the QOL assessments
Yes
No
In the opinion of the investigator, is the patient
eligible
Yes
No
2 / 2
Adenocarcinoma of the Gastroesophageal Junction NCT01333033 Registration -
CALGB-80803 OPEN Registration/Randomization Worksheet (Step 1) -
3287859v1.0
Breast Cancer NCT01275677 Follow-Up - NSABP-B-47 Left
Ventricular Assessment Report Form (Form LVA) - 3161750v1.0
NSABP-B-47 Left Ventricular Assessment Report Form
(Form LVA)
A Randomized Phase III Trial of Adjuvant Therapy
Comparing Chemotherapy Alone (Six Cycles of Docetaxel
Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus
Cyclophosphamide Followed by Weekly Paclitaxel) to
Chemotherapy Plus Trastuzumab in Women With Node-
Positive or High-Risk Node-Negative HER2-Low Invasive
Breast Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=955926C1-
ED44-2CC7-E040-BB89AD436024
All rights reserved. Please visit https://medical-data-
models.org/forms/9067
NSABP-B-47 Left Ventricular
Assessment Report Form (Form
LVA)
Header
Patient Initials (Last First Middle)
NSABP Patient ID
Unnamed3
Time point of this assessment (for LVEF
Assessment)
A (A)
A-r (A-R)
B (B)
B-r (B-R)
C (C)
C-r (C-R)
D (D)
D-r (D-R)
E (E)
F (F)
G (G)
Was LVEF assessment performed at this time
point
Yes
No
Unnamed5
LVEF (%)
Date of Assessment (Month Day Year)
Assessment Type
2-d Echocardiogram (2-D
Echocardiogram)
Muga Scan (MUGA scan)
1 / 2
Footer
Comments (optional)
Person Completing Form
Date Form Completed
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Breast Cancer NCT01275677 Follow-Up - NSABP-B-47 Left Ventricular
Assessment Report Form (Form LVA) - 3161750v1.0
Adenocarcinoma of the Gastroesophageal Junction NCT01260701 Registration -
Southwest Oncology Group S1005 Registration Worksheet Form - 3163565v1.0
Southwest Oncology Group S1005 Registration Worksheet
Form
MK2206 in Treating Patients With Advanced Gastric or
Gastroesophageal Junction Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=966F7821-
708F-89E4-E040-BB89AD432062
All rights reserved. Please visit https://medical-data-
models.org/forms/9068
Southwest Oncology Group S1005
Registration Worksheet Form
Header
Activation Date (MM DD YYYY)
Last Amended Date (MM DD YYYY)
Registration Step
Swog Patient Id
SWOG Patient ID Status
New Patient (New patient)
Previous Patient (Previous patient)
SWOG Patient ID
Demography
Patient First Name
Patient Middle Name
Patient Last Name
Unnamed2
Registrar's SWOG Roster ID Number
SWOG Investigator Number
SWOG Treating Institution Number
Unnamed5
Date Informed Consent Signed (MM DD YYYY)
Date HIPAA Authorization signed (Not required if
Country of Residence is not USA MM DD YYYY)
1 / 2
Projected Start Date of Treatment (MM DD
YYYY)
Unnamed4
I agree to allow my study doctor, or someone
approved by my study doctor, to contact me
regarding future research involving my
participation in this study
Yes
No
Unnamed 7
Has the Southwest Oncology Group Registration
Worksheet been completed entirely and is the
patient eligible according to the current version of
protocol section 5.0?
Yes
No
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Adenocarcinoma of the Gastroesophageal Junction NCT01260701 Registration -
Southwest Oncology Group S1005 Registration Worksheet Form - 3163565v1.0
Adenocarcinoma of the Gastroesophageal Junction NCT01142388
Eligibility - E2208 Registration Worksheet (step 1) - 3131369v1.0
E2208 Registration Worksheet (step 1)
Paclitaxel With or Without Cixutumumab as Second-Line
Therapy in Treating Patients With Metastatic Esophageal
Cancer or Gastroesophageal Junction Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=8E830FA8-
C594-2081-E040-BB89AD43554F
All rights reserved. Please visit https://medical-data-
models.org/forms/9070
E2208 Registration Worksheet (step
1)
Eligibility
Has the eligibility checklist been completed
Yes
No
In the opinion of the investigator, is the patient
eligible?
Yes
No
Has written informed consent been obtained
Yes
No
Date Informed Consent Signed
Has HIPAA authorization been obtained
Exempt - Non-usa Participant (Exempt -
non-USA participant)
No: C49487 (No)
Yes: C49488 (Yes)
HIPAA Authorization Date
Tumor Location
Esophagus (Esophagus)
Gastroesophageal Junction
(Gastroesophageal Junction)
Histologic Type
Adenocarcinoma (Adenocarcinoma)
Squamous Cell Carcinoma (Squamous
Cell Carcinoma)
Patient's simplified disease code
Adenocarcinoma Of The Esophagus
(Adenocarcinoma of the esophagus)
Adenocarcinoma Of The
Gastroesophageal Junction
(Adenocarcinoma of the
gastroesophageal junction)
Esophageal Cancer, Nos (Esophageal
cancer, NOS)
Squamous Cell Carcinoma Of The
Esophagus (Squamous cell carcinoma of
the esophagus)
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I agree to participate in the laboratory research
studies that are being done as part of this clinical
trial.
Yes
No
May your coded samples and related coded
information be kept for use in research to learn
about, prevent, find or treat cancer?  This may
also include research on inherited traits (genes
passed on in families).
Yes
No
May your coded samples and related coded
information be kept for use in research to learn
about, prevent, find or treat other health problems
(for example: diabetes, Alzheimer's disease, or
heart disease)?  This may also include research
on inherited traits (genes passed on in families).
Yes
No
Someone from my hospital or the Eastern
Cooperative Oncology Group may contact me in
the future to ask me to take part in more
research.
Yes
No
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Adenocarcinoma of the Gastroesophageal Junction NCT01142388
Eligibility - E2208 Registration Worksheet (step 1) - 3131369v1.0
Breast Cancer NCT00769379 Treatment - NSABP Protocol B-43 Worksheet
Protocol Treatment Form (Radiation Therapy and Trastuzumab) - 2675912v1.0
NSABP Protocol B-43 Worksheet Protocol Treatment Form
(Radiation Therapy and Trastuzumab)
Radiation Therapy With or Without Trastuzumab in Treating
Women With Ductal Carcinoma In Situ Who Have
Undergone Lumpectomy
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=38EE2EF6-
D07E-1323-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/9071
NSABP Protocol B-43 Worksheet
Protocol Treatment Form (Radiation
Therapy and Trastuzumab)
Header
NSABP Patient ID
Patient Initials (Last First Middle)
Section A - Radiation Therapy (rt) -- All
Patients
Was RT administered
Yes
No
RT begin date
RT End Date
Was accelerated fractionation employed
Yes
No
Total Dose Prior to Boost
Total Number of Fractions Prior to Boost
Was a Boost given?
Yes
No
Was brachytherapy used?
No (No)
Unknown (Unknown)
Yes (Yes)
RT Total Dose to Boost Field
Total Number of Fractions to Boost Field
Were there any unscheduled interruptions in
radiation therapy?
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Yes
No
Was RT interruption possibly, probably, or
definitely due to RT toxicity?
Yes
No
Reason RT Treatment Ended
Adverse Event/side Effects/complications
(Adverse event/side
effects/complications)
Death (Death)
New Lesion (including Second Primary
Cancer) Or Other Sign Of Progression
(New lesion (including second primary
cancer) or other sign of progression)
Other (Other)
Patient Withdrawal Or Refusal (Patient
withdrawal or refusal)
Treatment Completed Per Protocol
Criteria (Treatment completed per
protocol criteria)
Section B Trastuzumab Administration --
Group 2 Patients Only
Was dose 1 of trastuzumab administered?
Yes
No
Date dose 1 administered
Dose administered (mg/kg)
Was dose 2 of trastuzumab administered?
Yes
No
Date dose 2 administered
Dose administered (mg/kg)
Primary reason trastuzumab treatment ended
Adverse Event/side Effects/complications
(Adverse event/side
effects/complications)
Death (Death)
New Lesion (including Second Primary
Cancer) Or Other Sign Of Progression
(New lesion (including second primary
cancer) or other sign of progression)
Other (Other)
Patient Withdrawal Or Refusal (Patient
withdrawal or refusal)
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Breast Cancer NCT00769379 Treatment - NSABP Protocol B-43 Worksheet
Protocol Treatment Form (Radiation Therapy and Trastuzumab) - 2675912v1.0
Treatment Completed Per Protocol
Criteria (Treatment completed per
protocol criteria)
Other, specify
Adverse Events/side Effects/complications
Adverse Event
Abdominal Distention (Abdominal
distension)
Abdominal Infection (Abdominal
infection)
Abdominal Pain (Abdominal pain)
Abdominal Soft Tissue Necrotic Lesion
(Abdominal soft tissue necrosis)
Abducens Nerve Disorder (Abducens
nerve disorder)
Accessory Nerve Disorder (Accessory
nerve disorder)
Acidosis (Acidosis)
Vestibulocochlear Nerve Disorder
(Acoustic nerve disorder NOS)
Prolonged Partial Thromboplastin Time
(Activated partial thromboplastin time
prolonged)
Acute Coronary Syndrome (Acute
coronary syndrome)
Acute Renal Failure (Acute kidney injury)
Adrenal Gland Insufficiency (Adrenal
insufficiency)
Adult Respiratory Distress Syndrome
(Adult respiratory distress syndrome)
Agitation (Agitation)
Akathisia (Akathisia)
Alanine Aminotransferase Increased
(Alanine aminotransferase increased)
Alcohol Intolerance (Alcohol intolerance)
Blood Alkaline Phosphatase Increased
(Alkaline phosphatase increased)
Alkalosis (Alkalosis)
Hypersensitivity (Allergic reaction)
Allergic Rhinitis (Allergic rhinitis)
Alopecia (Alopecia)
Amnesia (Amnesia)
Anorectal Fistula (Anal fistula)
Anal Hemorrhage (Anal hemorrhage)
Anal Mucositis (Anal mucositis)
Anal Necrotic Lesion (Anal necrosis)
Anal Pain (Anal pain)
Anal Stenosis (Anal stenosis)
Anal Ulcer (Anal ulcer)
Anaphylactic Shock (Anaphylaxis)
Anemia (Anemia)
Ankle Fracture (Ankle fracture)
Anorectal Infection (Anorectal infection)
Anorexia (Anorexia)
Anorgasmia (Anorgasmia)
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Breast Cancer NCT00769379 Treatment - NSABP Protocol B-43 Worksheet
Protocol Treatment Form (Radiation Therapy and Trastuzumab) - 2675912v1.0
Anxiety (Anxiety)
Aortic Injury (Aortic injury)
Aortic Valve Disorder (Aortic valve
disease)
Aphonia (Aphonia)
Apnea (Apnea)
Acute Appendicitis (Appendicitis)
Acute Perforated Appendicitis
(Appendicitis perforated)
Arachnoiditis (Arachnoiditis)
Arterial Injury (Arterial injury)
Arteritis (Arteritis infective)
Arthralgia (Arthralgia)
Arthritis (Arthritis)
Ascites (Ascites)
Aspartate Aminotransferase Increased
(Aspartate aminotransferase increased)
Aspiration (Aspiration)
Cardiac Arrest (Asystole)
Ataxia (Ataxia)
Atelectasis (Atelectasis)
Atrial Fibrillation (Atrial fibrillation)
Atrial Flutter (Atrial flutter)
Av Block Third Degree (Atrioventricular
block complete)
Av Block First Degree (Atrioventricular
block first degree)
Autoimmune Disease (Autoimmune
disorder)
Bone Necrosis (Avascular necrosis)
Azoospermia (Azoospermia)
Back Pain (Back pain)
Bile Duct Stenosis (Bile duct stenosis)
Biliary Anastomotic Leakage (Biliary
anastomotic leak)
Biliary Fistula (Biliary fistula)
Cholangitis (Biliary tract infection)
Bladder Anastomotic Leakage (Bladder
anastomotic leak)
Cystitis (Bladder infection)
Bladder Perforation (Bladder perforation)
Bladder Spasm (Bladder spasm)
Bloating (Bloating)
Hematopoietic And Lymphoid System
Disorder Other Specify (Blood and
lymphatic system disorders - Other,
specify)
Abnormal Blood Antidiuretic Hormone
(Blood antidiuretic hormone abnormal)
Elevated Bilirubin (Blood bilirubin
increased)
Blood Corticotrophin Decreased (Blood
corticotrophin decreased)
Abnormal Blood Gonadotrophin (Blood
gonadotrophin abnormal)
Abnormal Blood Prolactin (Blood
prolactin abnormal)
Blurred Vision (Blurred vision)
Body Odor (Body odor)
Bone Infection (Bone infection)
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Hypocellular Bone Marrow (Bone
marrow hypocellular)
Bone Pain (Bone pain)
Brachial Plexopathy (Brachial
plexopathy)
Breast Atrophy (Breast atrophy)
Mastitis (Breast infection)
Breast Pain (Breast pain)
Bronchial Fistula (Bronchial fistula)
Bronchitis (Bronchial infection)
Bronchial Obstruction (Bronchial
obstruction)
Bronchial Stricture (Bronchial stricture)
Bronchopleural Fistula (Bronchopleural
fistula)
Bronchial Hemorrhage
(Bronchopulmonary hemorrhage)
Bronchospasm (Bronchospasm)
Bruise (Bruising)
Bullous Dermatitis (Bullous dermatitis)
Burn (Burn)
Buttock Pain (Buttock pain)
Capillary Leak Syndrome Capillary Leak
Syndrome (Capillary leak syndrome)
Decreased Carbon Monoxide Diffusing
Capacity (Carbon monoxide diffusing
capacity decreased)
Cardiac Arrest (Cardiac arrest)
Heart Disorder Other Specify (Cardiac
disorders - Other, specify)
Blood Cardiac Troponin I Increased
(Cardiac troponin I increased)
Blood Cardiac Troponin T Increased
(Cardiac troponin T increased)
Cataract (Cataract)
Catheter-related Infection (Catheter
related infection)
Cd4 Lymphocytes Decreased (CD4
lymphocytes decreased)
Cecal Hemorrhage (Cecal hemorrhage)
Cecal Infection (Cecal infection)
Central Nervous System Necrotic Lesion
(Central nervous system necrosis)
Cerebrospinal Fluid Leakage
(Cerebrospinal fluid leakage)
Infectious Cervicitis (Cervicitis infection)
Cheilitis (Cheilitis)
Angina (Chest pain - cardiac)
Chest Wall Pain (Chest wall pain)
Chills (Chills)
Cholecystitis (Cholecystitis)
Hypercholesterolemia (Cholesterol high)
Chronic Kidney Disease (Chronic kidney
disease)
Chylothorax (Chylothorax)
Cognitive Disturbance (Cognitive
disturbance)
Colitis (Colitis)
Colonic Fistula (Colonic fistula)
Colonic Hemorrhage (Colonic
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hemorrhage)
Colonic Obstruction (Colonic obstruction)
Colonic Perforation (Colonic perforation)
Colonic Stenosis (Colonic stenosis)
Colonic Ulcer (Colonic ulcer)
Concentration Impairment
(Concentration impairment)
Heart Conduction Disorder (Conduction
disorder)
Confusion (Confusion)
Congenital, Familial And Genetic
Disorder Class Other Specify
(Congenital, familial and genetic
disorders - Other, specify)
Conjunctivitis (Conjunctivitis)
Acute Contagious Conjunctivitis
(Conjunctivitis infective)
Constipation (Constipation)
Constrictive Pericarditis (Constrictive
pericarditis)
Keratitis (Corneal infection)
Corneal Ulcer (Corneal ulcer)
Cough (Cough)
Creatine Phosphokinase Increased (CPK
increased)
Cranial Nerve Infection (Cranial nerve
infection)
Increased Creatinine (Creatinine
increased)
Cushingoid (Cushingoid)
Non-infectious Cystitis (Cystitis
noninfective)
Cytokine Release Syndrome (Cytokine
release syndrome)
Neonatal Death (Death neonatal)
Death (Death NOS)
Dehydration (Dehydration)
Delayed Orgasm (Delayed orgasm)
Delayed Puberty (Delayed puberty)
Delirium (Delirium)
Delusion (Delusions)
Caries (Dental caries)
Depressed Level Of Consciousness
(Depressed level of consciousness)
Depression (Depression)
Radiation-induced Dermatitis (Dermatitis
radiation)
Prosthesis-related Infection (Device
related infection)
Diarrhea (Diarrhea)
Disseminated Intravascular Coagulation
(Disseminated intravascular coagulation)
Dizziness (Dizziness)
Dry Eye Syndrome (Dry eye)
Xerostomia (Dry mouth)
Dry Skin (Dry Skin)
Duodenal Fistula (Duodenal fistula)
Duodenal Hemorrhage (Duodenal
hemorrhage)
Duodenal Infection (Duodenal infection)
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Duodenal Obstruction (Duodenal
obstruction)
Duodenal Perforation (Duodenal
perforation)
Duodenal Stenosis (Duodenal stenosis)
Duodenal Ulcer (Duodenal ulcer)
Dysarthria (Dysarthria)
Dysesthesia (Dysesthesia)
Dysgeusia (Dysgeusia)
Dysmenorrhea (Dysmenorrhea)
Dyspareunia (Dyspareunia)
Dyspepsia (Dyspepsia)
Dysphagia (Dysphagia)
Dysphasia (Dysphasia)
Dyspnea (Dyspnea)
Ear And Labyrinth Disorder Class Other
Specify (Ear and labyrinth disorders -
Other, specify)
Earache (Ear pain)
Cerebral Edema (Edema cerebral)
Face Edema (Edema face)
Edema Limbs (Edema limbs)
Edema Trunk (Edema trunk)
Ejaculation Disorder (Ejaculation
disorder)
Ejection Fraction Decreased (Ejection
fraction decreased)
Prolonged Qt Interval (Electrocardiogram
QT corrected interval prolonged)
Infectious Encephalitis (Encephalitis
infection)
Infectious Encephalomyelitis
(Encephalomyelitis infection)
Encephalopathy (Encephalopathy)
Infective Endocarditis (Endocarditis
infective)
Endocrine Disorder Other Specify
(Endocrine disorders - Other, specify)
Endophthalmitis (Endophthalmitis)
Enterocolitis (Enterocolitis)
Infectious Enterocolitis (Enterocolitis
infectious)
Enterovesical Fistula (Enterovesical
fistula)
Epistaxis (Epistaxis)
Impotence (Erectile dysfunction)
Erythema Multiforme (Erythema
multiforme)
Erythroderma (Erythroderma)
Esophageal Anastomotic Leakage
(Esophageal anastomotic leak)
Esophageal Fistula (Esophageal fistula)
Esophageal Hemorrhage (Esophageal
hemorrhage)
Esophageal Infection (Esophageal
infection)
Esophageal Necrotic Lesion
(Esophageal necrosis)
Esophageal Obstruction (Esophageal
obstruction)
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Esophageal Pain (Esophageal pain)
Perforation Of Esophagus (Esophageal
perforation)
Esophageal Stricture (Esophageal
stenosis)
Esophageal Ulcer (Esophageal ulcer)
Esophageal Varices Hemorrhage
(Esophageal varices hemorrhage)
Esophagitis (Esophagitis)
Euphoria (Euphoria)
Exostosis (Exostosis)
External Ear Inflammation (External ear
inflammation)
External Ear Pain (External ear pain)
Extraocular Muscle Paresis (Extraocular
muscle paresis)
Extrapyramidal Disorder (Extrapyramidal
disorder)
Eye Disorder Other Specify (Eye
disorders - Other, specify)
Eye Infection (Eye infection)
Eye Pain (Eye pain)
Eyelid Function Disorder (Eyelid function
disorder)
Facial Muscle Weakness (Facial muscle
weakness)
Facial Nerve Disorder (Facial nerve
disorder)
Facial Pain (Facial pain)
Fall (Fall)
Fallopian Tube Anastomotic Leakage
(Fallopian tube anastomotic leak)
Fallopian Tube Obstruction (Fallopian
tube obstruction)
Fallopian Tube Perforation (Fallopian
tube perforation)
Fallopian Tube Stenosis (Fallopian tube
stenosis)
Adipose Tissue Atrophy (Fat atrophy)
Fatigue (Fatigue)
Neutropenic Fever (Febrile neutropenia)
Fecal Incontinence (Fecal incontinence)
Female Genital Tract Fistula (Female
genital tract fistula)
Acquired Feminization (Feminization
acquired)
Intrauterine Fetal Death (Fetal death)
Fetal Growth Retardation (Fetal growth
retardation)
Fever (Fever)
Fibrinogen Decreased (Fibrinogen
decreased)
Deep Connective Tissue Fibrosis
(Fibrosis deep connective tissue)
Flank Pain (Flank pain)
Flasher (Flashing lights)
Flatulence (Flatulence)
Floaters (Floaters)
Flu-like Symptoms (Flu like symptoms)
Flushing (Flushing)
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Decreased Forced Expiratory Volume
(Forced expiratory volume decreased)
Fracture (Fracture)
Gait Disturbance (Gait disturbance)
Gallbladder Fistula (Gallbladder fistula)
Gallbladder Infection (Gallbladder
infection)
Gallbladder Necrotic Lesion (Gallbladder
necrosis)
Gallbladder Obstruction (Gallbladder
obstruction)
Gallbladder Pain (Gallbladder pain)
Gallbladder Perforation (Gallbladder
perforation)
Gastric Anastomotic Leakage (Gastric
anastomotic leak)
Gastric Fistula (Gastric fistula)
Gastric Hemorrhage (Gastric
hemorrhage)
Gastric Necrotic Lesion (Gastric
necrosis)
Gastric Perforation (Gastric perforation)
Gastric Stenosis (Gastric stenosis)
Gastric Ulcer (Gastric ulcer)
Gastritis (Gastritis)
Gastroesophageal Reflux Disease
(Gastroesophageal reflux disease)
Gastrointestinal System Anastomotic
Leakage (Gastrointestinal anastomotic
leak)
Gastrointestinal Disorder Other Specify
(Gastrointestinal disorders - Other,
specify)
Gastrointestinal Fistula (Gastrointestinal
fistula)
Gastrointestinal Pain (Gastrointestinal
pain)
Gastrointestinal Stoma Necrotic Lesion
(Gastrointestinal stoma necrosis)
Gastroparesis (Gastroparesis)
General Disorders And Administration
Site Conditions Class Other Specify
(General disorders and administration
site conditions - Other, specify)
Generalized Muscle Weakness
(Generalized muscle weakness)
Genital Edema (Genital edema)
Gamma-glutamyltransferase Increased
(GGT increased)
Gingival Pain (Gingival pain)
Glaucoma (Glaucoma)
Glossopharyngeal Nerve Disorder
(Glossopharyngeal nerve disorder)
Glucose Intolerance (Glucose
intolerance)
Accelerated Growth (Growth
accelerated)
Abnormal Growth Hormone (Growth
hormone abnormal)
Growth Retardation (Growth
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suppression)
Gum Infection (Gum infection)
Gynecomastia (Gynecomastia)
Hallucination (Hallucinations)
Haptoglobin Decreased (Haptoglobin
decreased)
Head Soft Tissue Necrotic Lesion (Head
soft tissue necrosis)
Headache (Headache)
Hearing Impairment (Hearing impaired)
Heart Failure (Heart failure)
Hematoma (Hematoma)
Hematosalpinx (Hematosalpinx)
Hematuria (Hematuria)
Hemoglobin Increased (Hemoglobin
increased)
Hemoglobinuria (Hemoglobinuria)
Hemolysis (Hemolysis)
Hemolytic Uremic Syndrome (Hemolytic
uremic syndrome)
Hemorrhoidal Hemorrhage
(Hemorrhoidal hemorrhage)
Hemorrhoid (Hemorrhoids)
Hepatic Failure (Hepatic failure)
Hepatic Hemorrhage (Hepatic
hemorrhage)
Hepatic Infection (Hepatic infection)
Hepatic Necrotic Lesion (Hepatic
necrosis)
Hepatic Pain (Hepatic pain)
Viral Hepatitis (Hepatitis viral)
Liver And Biliary Tract Disorder Other
Specify (Hepatobiliary disorders - Other,
specify)
Hiccough (Hiccups)
Hip Fracture (Hip fracture)
Hirsutism (Hirsutism)
Hoarseness (Hoarseness)
Hot Flashes (Hot flashes)
Hydrocephalus (Hydrocephalus)
Hypercalcemia (Hypercalcemia)
Hyperglycemia (Hyperglycemia)
Hyperhidrosis (Hyperhidrosis)
Hyperkalemia (Hyperkalemia)
Hypermagnesemia (Hypermagnesemia)
Hypernatremia (Hypernatremia)
Hyperparathyroidism
(Hyperparathyroidism)
Hypersomnia (Hypersomnia)
Hypertension (Hypertension)
Hyperthyroidism (Hyperthyroidism)
Hypertrichosis (Hypertrichosis)
Hypertriglyceridemia
(Hypertriglyceridemia)
Hyperuricemia (Hyperuricemia)
Hypoalbuminemia (Hypoalbuminemia)
Hypocalcemia (Hypocalcemia)
Hypoglossal Nerve Disorder
(Hypoglossal nerve disorder)
Hypoglycemia (Hypoglycemia)
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Hypohidrosis (Hypohidrosis)
Hypokalemia (Hypokalemia)
Hypomagnesemia (Hypomagnesemia)
Hyponatremia (Hyponatremia)
Hypoparathyroidism
(Hypoparathyroidism)
Hypophosphatemia (Hypophosphatemia)
Hypotension (Hypotension)
Hypothermia (Hypothermia)
Hypothyroidism (Hypothyroidism)
Hypoxia (Hypoxia)
Ileal Fistula (Ileal fistula)
Ileal Hemorrhage (Ileal hemorrhage)
Ileal Obstruction (Ileal obstruction)
Ileal Perforation (Ileal perforation)
Ileal Stenosis (Ileal stenosis)
Ileal Ulcer (Ileal ulcer)
Ileus (Ileus)
Immune System Disorder Other Specify
(Immune system disorders - Other,
specify)
Infection Other Specify (Infections and
infestations - Other, specify)
Infectious Myositis (Infective myositis)
Infusion-related Reaction (Infusion
related reaction)
Infusion Site Extravasation (Infusion site
extravasation)
Injection Site Reaction (Injection site
reaction)
Injury To Carotid Artery (Injury to carotid
artery)
Injury To Inferior Vena Cava (Injury to
inferior vena cava)
Injury To Jugular Vein (Injury to jugular
vein)
Injury To Superior Vena Cava (Injury to
superior vena cava)
Injury, Poisoning And Procedural
Complication Class Other Specify (Injury,
poisoning and procedural complications -
Other, specify)
Inr Increased (INR increased)
Insomnia (Insomnia)
Intestinal Stoma Leakage (Intestinal
stoma leak)
Intestinal Stoma Obstruction (Intestinal
stoma obstruction)
Intestinal Stoma Site Hemorrhage
(Intestinal stoma site bleeding)
Intra-abdominal Hemorrhage (Intra-
abdominal hemorrhage)
Intracranial Hemorrhage (Intracranial
hemorrhage)
Intraoperative Arterial Injury
(Intraoperative arterial injury)
Intraoperative Breast Injury
(Intraoperative breast injury)
Intraoperative Cardiac Injury
(Intraoperative cardiac injury)
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Intraoperative Ear Injury (Intraoperative
ear injury)
Intraoperative Endocrine Injury
(Intraoperative endocrine injury)
Intraoperative Gastrointestinal Injury
(Intraoperative gastrointestinal injury)
Intraoperative Head And Neck Injury
(Intraoperative head and neck injury)
Intraoperative Hemorrhage
(Intraoperative hemorrhage)
Intraoperative Hepatobiliary Injury
(Intraoperative hepatobiliary injury)
Intraoperative Musculoskeletal Injury
(Intraoperative musculoskeletal injury)
Intraoperative Neurological Injury
(Intraoperative neurological injury)
Intraoperative Ocular Injury
(Intraoperative ocular injury)
Intraoperative Renal Injury
(Intraoperative renal injury)
Intraoperative Reproductive System
Injury (Intraoperative reproductive tract
injury)
Intraoperative Respiratory Injury
(Intraoperative respiratory injury)
Intraoperative Skin Injury (Intraoperative
skin injury)
Intraoperative Splenic Injury
(Intraoperative splenic injury)
Intraoperative Urinary System Injury
(Intraoperative urinary injury)
Intraoperative Venous Injury
(Intraoperative venous injury)
Investigation Other Specify
(Investigations - Other, specify)
Iron Overload (Iron overload)
Irregular Menstruation (Irregular
menstruation)
Irritability (Irritability)
Cerebrovascular Ischemia (Ischemia
cerebrovascular)
Trochlear Nerve Disorder (IVth nerve
disorder)
Jejunal Fistula (Jejunal fistula)
Jejunal Hemorrhage (Jejunal
hemorrhage)
Jejunal Obstruction (Jejunal obstruction)
Jejunal Perforation (Jejunal perforation)
Jejunal Stenosis (Jejunal stenosis)
Jejunal Ulcer (Jejunal ulcer)
Joint Effusion (Joint effusion)
Joint Infection (Joint infection)
Joint Range Of Motion Decreased (Joint
range of motion decreased)
Cervical Spine Joint Range Of Motion
Decreased (Joint range of motion
decreased cervical spine)
Lumbar Spine Joint Range Of Motion
Decreased (Joint range of motion
decreased lumbar spine)
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Keratitis (Keratitis)
Kidney Anastomotic Leakage (Kidney
anastomotic leak)
Pyelonephritis (Kidney infection)
Kyphosis (Kyphosis)
Lactation Disorder (Lactation disorder)
Large Intestinal Anastomotic Leakage
(Large intestinal anastomotic leak)
Laryngeal Edema (Laryngeal edema)
Laryngeal Fistula (Laryngeal fistula)
Laryngeal Hemorrhage (Laryngeal
hemorrhage)
Laryngitis (Laryngeal inflammation)
Laryngeal Mucositis (Laryngeal
mucositis)
Laryngeal Obstruction (Laryngeal
obstruction)
Laryngeal Stenosis (Laryngeal stenosis)
Laryngitis (Laryngitis)
Laryngopharyngeal Dysesthesia
(Laryngopharyngeal dysesthesia)
Laryngospasm (Laryngospasm)
Left Ventricular Systolic Dysfunction (Left
ventricular systolic dysfunction)
Lethargy (Lethargy)
Chemotherapy-related Leukemia
(Leukemia secondary to oncology
chemotherapy)
Leukocytosis (Leukocytosis)
Leukoencephalopathy
(Leukoencephalopathy)
Decreased Libido (Libido decreased)
Increased Libido (Libido increased)
Lip Infection (Lip infection)
Lip Pain (Lip pain)
Lipase Increased (Lipase increased)
Lipohypertrophy (Lipohypertrophy)
Localized Edema (Localized edema)
Lordosis (Lordosis)
Lower Gastrointestinal Hemorrhage
(Lower gastrointestinal hemorrhage)
Infectious Lung Disorder (Lung infection)
Lymphadenitis (Lymph gland infection)
Lymph Leakage (Lymph leakage)
Lymph Node Pain (Lymph node pain)
Lymphedema (Lymphedema)
Lymphocele (Lymphocele)
Lymphopenia (Lymphocyte count
decreased)
Lymphocytosis (Lymphocyte count
increased)
Malabsorption Syndrome
(Malabsorption)
Malaise (Malaise)
Mania (Mania)
Mediastinal Hemorrhage (Mediastinal
hemorrhage)
Mediastinitis (Mediastinal infection)
Memory Impairment (Memory
impairment)
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Meningismus (Meningismus)
Meningitis (Meningitis)
Menopause (Menopause)
Menorrhagia (Menorrhagia)
Metabolism And Nutrition Disorder Class
Other Specify (Metabolism and nutrition
disorders - Other, specify)
Otitis Media (Middle ear inflammation)
Mitral Valve Disorder (Mitral valve
disease)
Av Block Second Degree Mobitz Type Ii
(Mobitz (type) II atrioventricular block)
Av Block Second Degree Mobitz Type I
(Mobitz type I)
Involuntary Movements (Movements
involuntary)
Mucosal Infection (Mucosal infection)
Stomatitis (Mucositis oral)
Multiple Organ Failure (Multi-organ
failure)
Muscle Weakness Left-sided (Muscle
weakness left-sided)
Muscle Weakness Lower Limb (Muscle
weakness lower limb)
Muscle Weakness Right-sided (Muscle
weakness right-sided)
Muscle Weakness Trunk (Muscle
weakness trunk)
Muscle Weakness Upper Limb (Muscle
weakness upper limb)
Connective And Soft Tissue Disorder
Other Specify (Musculoskeletal and
connective tissue disorder -  Other,
specify)
Musculoskeletal Deformity
(Musculoskeletal deformity)
Myalgia (Myalgia)
Myelitis (Myelitis)
Mds (Myelodysplastic syndrome)
Myocardial Infarction (Myocardial
infarction)
Myocarditis (Myocarditis)
Myositis (Myositis)
Nail Discoloration (Nail discoloration)
Nail Infection (Nail infection)
Nail Loss (Nail loss)
Nail Ridging (Nail ridging)
Nasal Congestion (Nasal congestion)
Nausea (Nausea)
Neck Edema (Neck edema)
Neck Pain (Neck pain)
Neck Soft Tissue Necrotic Lesion (Neck
soft tissue necrosis)
Neoplasm Other Specify (Neoplasms
benign, malignant and unspecified (incl
cysts and polyps) - Other, specify)
Nervous System Disorder Other Specify
(Nervous system disorders - Other,
specify)
Neuralgia (Neuralgia)
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Neutrophil Count Decreased (Neutrophil
count decreased)
Night Blindness (Night blindness)
Nipple Deformity (Nipple deformity)
Non-cardiac Chest Pain (Non-cardiac
chest pain)
Nystagmus (Nystagmus)
Obesity (Obesity)
Gastric Obstruction (Obstruction gastric)
Oculomotor Nerve Disorder (Oculomotor
nerve disorder)
Olfactory Nerve Disorder (Olfactory
nerve disorder)
Oligospermia (Oligospermia)
Optic Nerve Disorder (Optic nerve
disorder)
Oral Cavity Fistula (Oral cavity fistula)
Burning Mouth Syndrome (Oral
dysesthesia)
Oral Hemorrhage (Oral hemorrhage)
Oral Pain (Oral pain)
Osteonecrosis Of Jaw (Osteonecrosis of
jaw)
Osteoporosis (Osteoporosis)
External Ear Infection (Otitis externa)
Otitis Media (Otitis media)
Ovarian Hemorrhage (Ovarian
hemorrhage)
Ovarian Infection (Ovarian infection)
Ovarian Rupture (Ovarian rupture)
Ovulatory Pain (Ovulation pain)
Pain (Pain)
Pain In Extremity (Pain in extremity)
Skin Pain (Pain of skin)
Palmar-plantar Erythodysthesia (Palmar-
plantar erythrodysesthesia syndrome)
Palpitation (Palpitations)
Pancreatic Infection (Pancreas infection)
Pancreatic Anastomotic Leakage
(Pancreatic anastomotic leak)
Pancreatic Duct Stenosis (Pancreatic
duct stenosis)
Pancreatic Enzymes Decreased
(Pancreatic enzymes decreased)
Pancreatic Fistula (Pancreatic fistula)
Pancreatic Hemorrhage (Pancreatic
hemorrhage)
Pancreatic Necrotic Lesion (Pancreatic
necrosis)
Pancreatitis (Pancreatitis)
Papilledema (Papilledema)
Papulopustular Rash (Papulopustular
rash)
Paresthesia (Paresthesia)
Paronychia (Paronychia)
Paroxysmal Atrial Tachycardia
(Paroxysmal atrial tachycardia)
Pelvic Floor Muscle Weakness (Pelvic
floor muscle weakness)
Pelvic Inflammatory Disease (Pelvic
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infection)
Pelvic Pain (Pelvic pain)
Pelvic Soft Tissue Necrotic Lesion
(Pelvic soft tissue necrosis)
Penile Infection (Penile infection)
Penile Pain (Penile pain)
Bile Duct Perforation (Perforation bile
duct)
Pericardial Effusion (Pericardial effusion)
Cardiac Tamponade (Pericardial
tamponade)
Pericarditis (Pericarditis)
Perineal Pain (Perineal pain)
Periodontal Disorder (Periodontal
disease)
Periorbital Edema (Periorbital edema)
Periorbital Infection (Periorbital infection)
Peripheral Ischemia (Peripheral
ischemia)
Peripheral Motor Neuropathy (Peripheral
motor neuropathy)
Peripheral Nervous System Infectious
Disorder (Peripheral nerve infection)
Peripheral Sensory Neuropathy
(Peripheral sensory neuropathy)
Peritoneal Infection (Peritoneal infection)
Peritoneal Necrotic Lesion (Peritoneal
necrosis)
Personality Change (Personality change)
Phantom Pain (Phantom pain)
Pharyngeal Anastomotic Leakage
(Pharyngeal anastomotic leak)
Pharyngeal Fistula (Pharyngeal fistula)
Pharyngeal Hemorrhage (Pharyngeal
hemorrhage)
Pharyngeal Mucositis (Pharyngeal
mucositis)
Pharyngeal Necrotic Lesion (Pharyngeal
necrosis)
Pharyngeal Stenosis (Pharyngeal
stenosis)
Pharyngitis (Pharyngitis)
Pharyngolaryngeal Pain
(Pharyngolaryngeal pain)
Phlebitis (Phlebitis)
Infective Phlebitis (Phlebitis infective)
Photophobia (Photophobia)
Photosensitivity (Photosensitivity)
Thrombocytopenia (Platelet count
decreased)
Pleural Effusion (Pleural effusion)
Hemothorax (Pleural hemorrhage)
Pleural Infection (Pleural infection)
Pleuritic Pain (Pleuritic pain)
Pneumonia (Pneumonitis)
Pneumothorax (Pneumothorax)
Portal Hypertension (Portal
Hypertension)
Portal Vein Thrombosis (Portal vein
thrombosis)
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Post-nasal Drip (Postnasal drip)
Postoperative Bleeding (Postoperative
hemorrhage)
Thoracic Procedure Postoperative
Complication (Postoperative thoracic
procedure complication)
Precocious Puberty (Precocious
puberty)
Pregnancy, Puerperium And Perinatal
Condition Class Other Specify
(Pregnancy, puerperium and perinatal
conditions - Other, specify)
Premature Labor (Premature delivery)
Premature Menopause (Premature
menopause)
Presyncope (Presyncope)
Proctitis (Proctitis)
Productive Cough (Productive cough)
Intestinal Stoma Prolapse (Prolapse of
intestinal stoma)
Urostomy Prolapse (Prolapse of
urostomy)
Prostatic Infection (Prostate infection)
Prostatic Hemorrhage (Prostatic
hemorrhage)
Prostatic Obstruction (Prostatic
obstruction)
Prostatic Pain (Prostatic pain)
Proteinuria (Proteinuria)
Pruritus (Pruritus)
Psychiatric Disorder Other Specify
(Psychiatric disorders - Other, specify)
Psychosis (Psychosis)
Pulmonary Edema (Pulmonary edema)
Pulmonary Fibrosis (Pulmonary fibrosis)
Pulmonary Fistula (Pulmonary fistula)
Pulmonary Hypertension (Pulmonary
hypertension)
Pulmonary Valve Disorder (Pulmonary
valve disease)
Purpura (Purpura)
Pyramidal Tract Dysfunction (Pyramidal
tract syndrome)
Radiation-recall Dermatitis (Radiation
recall reaction (dermatologic))
Radiculitis (Radiculitis)
Acneiform Dermatitis (Rash acneiform)
Maculopapular Lesion (Rash maculo-
papular)
Papulopustular Rash (Rash pustular)
Rectal Anastomotic Leakage (Rectal
anastomotic leak)
Rectal Fistula (Rectal fistula)
Rectal Hemorrhage (Rectal hemorrhage)
Rectal Mucositis (Rectal mucositis)
Rectal Necrotic Lesion (Rectal necrosis)
Rectal Obstruction (Rectal obstruction)
Rectal Pain (Rectal pain)
Rectal Perforation (Rectal perforation)
Rectal Stenosis (Rectal stenosis)
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Rectal Ulcer (Rectal ulcer)
Recurrent Laryngeal Nerve Paralysis
(Recurrent laryngeal nerve palsy)
Urinary Tract Disorder Other Specify
(Renal and urinary disorders - Other,
specify)
Renal Stone (Renal calculi)
Renal Colic (Renal colic)
Renal Hemorrhage (Renal hemorrhage)
Reproductive System And Breast
Disorder Class Other Specify
(Reproductive system and breast
disorders - Other, specify)
Respiratory Failure (Respiratory failure)
Respiratory And Thoracic Disorder Other
Specify (Respiratory, thoracic and
mediastinal disorders - Other, specify)
Restlessness (Restlessness)
Restrictive Cardiomyopathy (Restrictive
cardiomyopathy)
Retinal Detachment (Retinal
detachment)
Retinal Tear (Retinal tear)
Retinal Vascular Disorder (Retinal
vascular disorder)
Retinoic Acid Syndrome (Retinoic acid
syndrome)
Retinopathy (Retinopathy)
Retroperitoneal Hemorrhage
(Retroperitoneal hemorrhage)
Reversible Posterior
Leukoencephalopathy Syndrome
(Reversible posterior
leukoencephalopathy syndrome)
Infectious Rhinitis (Rhinitis infective)
Right Ventricular Dysfunction (Right
ventricular dysfunction)
Salivary Duct Inflammation (Salivary duct
inflammation)
Salivary Gland Fistula (Salivary gland
fistula)
Salivary Gland Infection (Salivary gland
infection)
Scalp Pain (Scalp pain)
Sclera Disorder (Scleral disorder)
Scoliosis (Scoliosis)
Scrotal Infection (Scrotal infection)
Scrotal Pain (Scrotal pain)
Seizure (Seizure)
Septicemia (Sepsis)
Seroma (Seroma)
Serum Amylase Increased (Serum
amylase increased)
Serum Sickness (Serum sickness)
Sick Sinus Syndrome (Sick sinus
syndrome)
Sinus Bradycardia (Sinus bradycardia)
Paranasal Sinus Disorder (Sinus
disorder)
Sinus Pain (Sinus pain)
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Sinus Tachycardia (Sinus tachycardia)
Sinusitis (Sinusitis)
Skin Disorder Other Specify (Skin and
subcutaneous tissue disorders - Other,
specify)
Skin Atrophy (Skin atrophy)
Skin Hyperpigmentation (Skin
hyperpigmentation)
Skin Hypopigmentation (Skin
hypopigmentation)
Skin Induration (Skin induration)
Skin Infection (Skin infection)
Skin Ulcer (Skin ulceration)
Sleep Apnea (Sleep apnea)
Small Intestinal Anastomotic Leakage
(Small intestinal anastomotic leak)
Small Intestinal Mucositis (Small
intestinal mucositis)
Small Intestinal Obstruction (Small
intestinal obstruction)
Small Intestinal Perforation (Small
intestinal perforation)
Small Intestinal Stenosis (Small intestinal
stenosis)
Small Intestinal Infection (Small intestine
infection)
Small Intestinal Ulcer (Small intestine
ulcer)
Sneezing (Sneezing)
Social Circumstances Other Specify
(Social circumstances - Other, specify)
Soft Tissue Infection (Soft tissue
infection)
Lower Limb Soft Tissue Necrotic Lesion
(Soft tissue necrosis lower limb)
Upper Limb Soft Tissue Necrotic Lesion
(Soft tissue necrosis upper limb)
Somnolence (Somnolence)
Sore Throat (Sore throat)
Spasticity (Spasticity)
Spermatic Cord Anastomotic Leakage
(Spermatic cord anastomotic leak)
Spermatic Cord Hemorrhage (Spermatic
cord hemorrhage)
Spermatic Cord Obstruction (Spermatic
cord obstruction)
Vertebral Fracture (Spinal fracture)
Splenic Disorder (Spleen disorder)
Splenic Infection (Splenic infection)
Gastrointestinal Stoma Stenosis
(Stenosis of gastrointestinal stoma)
Stevens-johnson Syndrome (Stevens-
Johnson syndrome)
Stoma Site Infection (Stoma site
infection)
Stomach Pain (Stomach pain)
Stomal Ulcer (Stomal ulcer)
Stridor (Stridor)
Cerebrovascular Accident (Stroke)
Sudden Cardiac Death (Sudden death
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NOS)
Suicidal Ideation (Suicidal ideation)
Suicide Attempt (Suicide attempt)
Superficial Soft Tissue Fibrosis
(Superficial soft tissue fibrosis)
Superficial Thrombophlebitis (Superficial
thrombophlebitis)
Superior Vena Cava Syndrome (Superior
vena cava syndrome)
Supraventricular Tachycardia
(Supraventricular tachycardia)
Intervention Or Procedure Other Specify
(Surgical and medical procedures -
Other, specify)
Syncope (Syncope)
Telangiectasia (Telangiectasia)
Testicular Disorder (Testicular disorder)
Testicular Hemorrhage (Testicular
hemorrhage)
Testicular Pain (Testicular pain)
Thromboembolism (Thromboembolic
event)
Thrombotic Thrombocytopenic Purpura
(Thrombotic thrombocytopenic purpura)
Tinnitus (Tinnitus)
Dental Developmental Disorder (Tooth
development disorder)
Tooth Discoloration (Tooth discoloration)
Tooth Infection (Tooth infection)
Toothache (Toothache)
Toxic Epidermal Necrolysis (Toxic
epidermal necrolysis)
Tracheal Fistula (Tracheal fistula)
Tracheal Hemorrhage (Tracheal
hemorrhage)
Tracheal Mucositis (Tracheal mucositis)
Tracheal Obstruction (Tracheal
obstruction)
Tracheal Stenosis (Tracheal stenosis)
Tracheitis (Tracheitis)
Tracheostomy Site Bleeding
(Tracheostomy site bleeding)
Transient Ischemic Attack (Transient
ischemic attacks)
Therapy-related Malignant Neoplasm
(Treatment related secondary
malignancy)
Tremor (Tremor)
Tricuspid Valve Disorder (Tricuspid valve
disease)
Trigeminal Nerve Disorder (Trigeminal
nerve disorder)
Trismus (Trismus)
Tumor Lysis Syndrome (Tumor lysis
syndrome)
Tumor Pain (Tumor pain)
Typhlitis (Typhlitis)
Unequal Limb Length (Unequal limb
length)
Unintended Pregnancy (Unintended
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pregnancy)
Upper Gastrointestinal Hemorrhage
(Upper gastrointestinal hemorrhage)
Upper Respiratory Tract Infection (Upper
respiratory infection)
Ureteric Anastomotic Leakage (Ureteric
anastomotic leak)
Urethral Anastomotic Leakage (Urethral
anastomotic leak)
Urethral Infection (Urethral infection)
Urinary Tract Fistula (Urinary fistula)
Urinary Frequency (Urinary frequency)
Urinary Incontinence (Urinary
incontinence)
Urinary Retention (Urinary retention)
Urinary Tract Infection (Urinary tract
infection)
Urinary Tract Obstruction (Urinary tract
obstruction)
Urinary Tract Pain (Urinary tract pain)
Urinary Urgency (Urinary urgency)
Urine Discoloration (Urine discoloration)
Urine Output Decreased (Urine output
decreased)
Urostomy Leakage (Urostomy leak)
Urostomy Obstruction (Urostomy
obstruction)
Urostomy Site Bleeding (Urostomy site
bleeding)
Urostomy Stenosis (Urostomy stenosis)
Urticaria (Urticaria)
Uterine Anastomotic Leakage (Uterine
anastomotic leak)
Uterine Fistula (Uterine fistula)
Uterine Hemorrhage (Uterine
hemorrhage)
Endometritis (Uterine infection)
Uterine Obstruction (Uterine obstruction)
Uterine Pain (Uterine pain)
Uterine Perforation (Uterine perforation)
Uveitis (Uveitis)
Vaginal Anastomotic Leakage (Vaginal
anastomotic leak)
Vaginal Discharge (Vaginal discharge)
Vaginal Dryness (Vaginal dryness)
Vaginal Fistula (Vaginal fistula)
Vaginal Hemorrhage (Vaginal
hemorrhage)
Vaginitis (Vaginal infection)
Vaginitis (Vaginal inflammation)
Vaginal Obstruction (Vaginal obstruction)
Vaginal Pain (Vaginal pain)
Vaginal Perforation (Vaginal perforation)
Vaginal Stricture (Vaginal stricture)
Vaginismus (Vaginismus)
Vagus Nerve Disorder (Vagus nerve
disorder)
Vas Deferens Anastomotic Leakage (Vas
deferens anastomotic leak)
Vascular Access Complication (Vascular
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access complication)
Vascular Disorder Other Specify
(Vascular disorders - Other, specify)
Vasculitis (Vasculitis)
Vasovagal Reaction (Vasovagal reaction)
Venous Injury (Venous injury)
Ventricular Arrhythmia (Ventricular
arrhythmia)
Ventricular Fibrillation (Ventricular
fibrillation)
Ventricular Tachycardia (Ventricular
tachycardia)
Vertigo (Vertigo)
Internal Ear Disorder (Vestibular
disorder)
Virilization (Virilization)
Visceral Artery Ischemia (Visceral
arterial ischemia)
Abnormal Vital Capacity (Vital capacity
abnormal)
Vitreous Hemorrhage (Vitreous
hemorrhage)
Voice Alternation (Voice alteration)
Vomiting (Vomiting)
Vulval Infection (Vulval infection)
Watering Eyes (Watering eyes)
Weight Gain (Weight gain)
Weight Loss (Weight loss)
Wheezing (Wheezing)
Leukopenia (White blood cell decreased)
Wolff-parkinson-white Syndrome (Wolff-
Parkinson-White Syndrome)
Wound Complication (Wound
complication)
Wound Dehiscence (Wound dehiscence)
Wound Infection (Wound infection)
Wrist Fracture (Wrist fracture)
Grade
Absent Adverse Event (0)
Mild Adverse Event (1)
Moderate Adverse Event (2)
Severe Adverse Event (3)
Life Threatening Adverse Event (4)
Death Related To Adverse Event (5)
Footer
Comments
Person Completing Form
Date Form Completed
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Adenocarcinoma of the Gastroesophageal Junction NCT01498289
Registration - SWOG S1201 Registration Worksheet Form - 3341218v1.0
SWOG S1201 Registration Worksheet Form
Combination Chemotherapy in Treating Patients With
Advanced or Metastatic Esophageal Cancer, Gastric
Cancer, or Gastroesophageal Junction Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=B5907598-
58E9-643E-E040-BB89AD4312F7
All rights reserved. Please visit https://medical-data-
models.org/forms/9073
SWOG S1201 Registration
Worksheet Form
Header
Activation Date (MM DD YYYY)
Last Amended Date (MM DD YYYY)
Registration Step
Swog Patient Id
SWOG Patient ID Status
New Patient (New patient)
Previous Patient (Previous patient)
SWOG Patient ID
Demography
Patient First Name
Patient Middle Name
Patient Last Name
Unnamed2
Registrar's SWOG Roster ID Number
SWOG Investigator Number
SWOG Treating Institution Number
Unnamed5
Date Informed Consent Signed (MM DD YYYY)
Date HIPAA Authorization signed (Not required if
Country of Residence is not USA MM DD YYYY)
1 / 2
Projected Start Date of Treatment (MM DD
YYYY)
Stratification Question
Primary Disease Site
Unnamed4
My specimens may be kept for use in research to
learn about, prevent, treat, or cure cancer.
Yes
No
My specimens may be kept for use in research
about other health problems (for example:
diabetes, Alzheimer's disease, or heart disease).
Yes
No
Someone may contact me in the future to ask me
to allow other uses of my specimens.
Yes
No
I agree to allow my study doctor, or someone
approved by my study doctor, to contact me
regarding future research involving my
participation in this study
Yes
No
Unnamed 7
Has the SWOG Registration Worksheet been
completed entirely and is the patient eligible
according to the current version of protocol
section 5.0?
Yes
No
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Breast Cancer NCT01275677 Registration - NSABP
Protocol B-47 Worksheet for Form Entry - 3155372v1.0
NSABP Protocol B-47 Worksheet for Form Entry
A Randomized Phase III Trial of Adjuvant Therapy
Comparing Chemotherapy Alone (Six Cycles of Docetaxel
Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus
Cyclophosphamide Followed by Weekly Paclitaxel) to
Chemotherapy Plus Trastuzumab in Women With Node-
Positive or High-Risk Node-Negative HER2-Low Invasive
Breast Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=942D0C00-
2D04-589C-E040-BB89AD433FFB
All rights reserved. Please visit https://medical-data-
models.org/forms/9076
NSABP Protocol B-47 Worksheet for
Form Entry
Header
Patient Initials (Last, First Middle)
Patient Social Security Number (USA only)
Unnamed4
Site Name
Treating physician
Intended chemotherapy regimen
Ac - Wp: Doxorubicin 60 Mg/m2 And
Cyclophosphamide 600 Mg/m2 (iv)
Followed By Paclitaxel 80 Mg/m2 (iv) (AC
- WP: doxorubicin 60 mg/m2 and
cyclophosphamide 600 mg/m2 (IV)
followed by paclitaxel 80 mg/m2 (IV))
Tc: Docetaxel 75 Mg/m2 And
Cyclophosphamide 600 Mg/m2 (iv) (TC:
docetaxel 75 mg/m2 and
cyclophosphamide 600 mg/m2 (IV))
Date Informed Consent Signed (Month Day Year)
Has the patient authorized the release of
Protected Health Information to the NSABP?
Yes
No
Did the patient consent to use of blood samples
for research related to this study?
Yes
No
Did the patient consent to use of blood samples
for the B-47 Menstrual History study?
No: C49487 (No)
Not Applicable (Not Applicable)
Yes: C49488 (Yes)
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Did the patient consent to future contact about
more research?
Yes
No
Section 2 - Diagnostic
IHC Staining Score (If multiple IHC assays were
performed, report the one with the highest
staining intensity score. Please refer to Protocol -
Section 4.2.7 for more information. - A copy of
the IHC report must be provided.)
0 (0)
1+ (1+)
2+ (2+)
3+ (3+)
HER2 gene copy number (If multiple assay
results were performed, report the assay result
with the highest HER2 gene copy number.)
Was HER2 status assessed by ISH assay
Yes
No
Was HER2 to CEP17 ratio performed?
Yes
No
HER2 to CEP17 ratio (If multiple HER2 to CEP17
ratios were performed, report the highest one.)
Section 4 - Surgery After Neoadjuvant
Chemotherapy1
Does the patient have unilateral invasive
adenocarcinoma of the breast on histologic
examination?
Yes
No
Tumor Laterality
Left Breast (Left breast)
Right Breast (Right breast)
Was lumpectomy performed?
Yes
No
Date lumpectomy performed
Was total mastectomy performed?
Yes
No
Date Total Mastectomy Performed
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Were mastectomy margins free of gross residual
tumor?
Yes
No
Were mastectomy margins microscopically
positive?
Yes
No
Will post-mastectomy RT of the chest wall be
administered?
Yes
No
Were lumpectomy margins histologically free of
invasive tumor and DCIS, either initially or after
one or more re-excisions?
Yes
No
Was estrogen receptor status determined from
the primary tumor?
Yes
No
Receptor Status, ER
Negative (Negative)
Positive (Positive)
Was progesterone receptor status determined
from the primary tumor?
Yes
No
Receptor Status, PgR
Negative (Negative)
Positive (Positive)
Histologic Type (Mark predominant tumor type.)
Ductal (Ductal)
Lobular (Lobular)
Other Specify (Other)
Other specify
Histologic Grade (Use combined histologic grade
classification.)
High (High)
Intermediate (Intermediate)
Low (Low)
Was Oncotype DX Recurrence Score
determined?
Yes
No
Oncotype DX Recurrence Score (A copy of the
report must be provided.)
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Was sentinel lymphadenectomy performed?
Yes
No
Date of Sentinel Lymphadenectomy
Number of Sentinel Nodes Examined
Number of Positive Sentinel Nodes
Total Number of Positive Nodes (Pathologic; all
procedures)
Surgical Procedure for Evaluation of Pathological
Nodal Status
Axillary Lymph Node Dissection (Axillary
lymphadenectomy with or without SN
isolation procedure)
Regional Lymph Node Dissection
Sentinel Lymph Node (Sentinel
lymphadenectomy alone)
Sentinel Lymph Node Biopsy With
Axillary Lymph Node Dissection
(Sentinel lymphadenectomy followed by
removal of additional non-sentinel lymph
nodes)
Date of Last Surgery for Breast Cancer Treatment
or Staging
Pathologic T Stage
Tumor More Than 0.1 Cm But Not More
Than 0.5 Cm In Greatest Dimension
(pT1a)
Tumor More Than 0.5 Cm But Not More
Than 1 Cm In Greatest Dimension
(pT1b)
Tumor More Than 1 Cm But Not More
Than 2 Cm In Greatest Dimension
(pT1c)
Microinvasion 0.1 Cm Or Less In
Greatest Dimension (pT1mi)
Tumor More Than 2 Cm But Not More
Than 5 Cm In Greatest Dimension (pT2)
Tumor More Than 5 Cm In Greatest
Dimension (pT3)
Pathologic N Stage (pathologic evaluation of
ipsilateral nodes)
No Regional Lymph Node Metastasis
Histologically, No Additional Examination
For Isolated Tumor Cells (itc) (pN0)
Metastasis In 1 To 3 Axillary Lymph
Nodes (pN1a)
Metastasis In Internal Mammary Nodes
With Microscopic Disease Detected By
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Sln Dissection But Not Clinically
Apparent (pN1b)
Metastasis In 1 To 3 Axillary Lymph
Nodes And In Internal Mammary Lymph
Nodes With Microscopic Disease
Detected By Sln Dissection But Not
Clinically Apparent. (pN1c)
Micrometastasis (>0.2 Mm But <=2.0
Mm) (pN1mi)
Metastasis In 4 To 9 Axillary Lymph
Nodes (at Least 1 Tumor Deposit >2.0
Mm) (pN2a)
Metastasis In Clinically Apparent*
Internal Mammary Lymph Nodes In The
Absence Of Axillary Lymph Node
Metastasis (pN2b)
Metastasis In >=10 Axillary Lymph
Nodes (at Least 1 Tumor Deposit >2.0
Mm); Or, Metastasis To The
Infraclavicular Lymph Nodes (pN3a)
Metastasis In Clinically Apparent*
Ipsilateral Internal Mammary Lymph
Nodes In The Presence Of >=1 Positive
Axillary Lymph Node(s); Or, In >3
Axillary Lymph Nodes And In Internal
Mammary Lymph Nodes With
Microscopic Disease Detected By
Sentinel Lymph Node (pN3b)
Patient Characteristics
Patient Height (cm)
Patient Weight (kg)
Date of Assessment
Date of Assessment
Blood Pressure, Systolic (most recent)
Blood pressure, Diastolic (most recent)
Date of most recent blood pressure assessment
Are anti-hypertensive medication(s) needed to
sustain systolic BP <= 150 mmHg and diastolic
BP <= 90 mmHg?
Yes
No
LVEF (%)
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Date LVEF performed
Assessment Type
2-d Echocardiogram (2-D
Echocardiogram)
Muga Scan (MUGA scan)
Section 3 (continued)
ANC
Yes
No
ANC (thousand/mm^3)
Date of Collection
Platelet Count
Yes
No
Platelet count (thousand/mm^3)
Date of Collection
Hemoglobin
Yes
No
Hemoglobin (g/dL)
Date of Collection
Section 3 (continued)
AST
Yes
No
AST (units/L)
AST ULN (units/L)
Date of Collection
ALT (required only when SGOT AST is not
available)
Yes
No
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ALT (units/L)
ALT ULN (units/L)
Date of Collection
Alkaline Phosphatase
Yes
No
Alkaline Phosphatase (units/L)
Alkaline Phosphatase ULN (units/L)
Date of Collection
Total Bilirubin
Yes
No
Total Bilirubin
Total bilirubin ULN (mg/dL)
Date of Collection
Serum Creatinine
Yes
No
Serum creatinine (mg/dL)
Serum Creatinine ULN (mg/dL)
Date of Collection
Baseline Values2
Was liver imaging performed? (CT, MRI, PET
scan, or PET-CT)
Yes
No
Does liver imaging demonstrate metastatic
disease?
Yes
No
Date of Assessment
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Does the patient have unexplained bone pain?
Yes
No
Was bone scan, PET-CT scan, or PET scan
performed?
Yes
No
Does bone scan, PET-CT scan, or PET scan
demonstrate metastatic disease?
Yes
No
Date of Assessment (if applicable)
Is bilirubin elevation due to Gilbert's disease or
similar syndrome involving slow conjugation of
bilirubin?
Yes
No
Was chest imaging performed?
Yes
No
Did chest imaging demonstrate metastatic
disease?
Yes
No
Date chest imaging performed
Section 4 - Patient History
Was the breast cancer staged as T4, including
inflammatory breast cancer?
Yes
No
Is there definitive clinical or radiologic evidence of
metastatic disease for this patient?
Yes
No
Did the patient have synchronous or previous
contralateral invasive breast cancer?
Yes
No
Does the patient have a history of ipsilateral
invasive breast cancer or ipsilateral DCIS?
Yes
No
Does the patient have a history of non-breast
malignancies within the past 5 years?
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Yes
No
Were the other malignancies limited to one or
more of the following: in situ cancers treated only
by local excision, and basal and squamous cell
carcinomas of the skin?
Yes
No
Has the patient had previous therapy with
anthracyclines, taxanes, or trastuzumab for any
malignancy?
Yes
No
Has the patient had chemotherapy or HER2-
targeted therapy administered for the currently
diagnosed breast cancer?
Yes
No
Has the patient had whole breast RT prior to
randomization or partial breast RT that cannot be
completed on or before the date of
randomization?
Yes
No
Will the patient receive continued endocrine
therapy with any hormonal agent such as
raloxifene or tamoxifen (or other SERM) or an
aromatase inhibitor after randomization?
Yes
No
Will the patient receive continued sex hormonal
therapy, e.g., birth control pills, ovarian hormone
replacement therapy after randomization?
Yes
No
Does the patient have angina pectoris that
requires the use of anti-anginal medication?
Yes
No
Does the patient have ventricular arrhythmias
except for benign premature ventricular
contractions?
Yes
No
Does the patient have supraventricular or nodal
arrhythmias requiring a pacemaker or not
controlled with medication?
Yes
No
Does the patient have a conduction abnormality
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requiring a pacemaker?
Yes
No
Does the patient have valvular disease with
documented compromise in cardiac function?
Yes
No
Does the patient have symptomatic pericarditis?
Yes
No
Does the patient have a history of documented
CHF?
Yes
No
Does the patient have a history of documented
cardiomyopathy?
Yes
No
Does the patient have a history of myocardial
infarction documented by elevated cardiac
enzymes or persistent regional wall abnormalities
on assessment of LV function?
Yes
No
Does the patient have any other cardiac disease
(history of and/or active disease) that would
preclude the use of drugs included in the
treatment regimen?
Yes
No
Does the patient have active hepatitis B or
hepatitis C with abnormal liver function tests?
Yes
No
Does the patient have intrinsic lung disease
resulting in dyspnea?
Yes
No
Does the patient have poorly controlled diabetes
mellitus?
Yes
No
Does the patient have active infection or chronic
infection requiring chronic suppressive
antibiotics?
Yes
No
Does the patient have a nervous system disorder
(paresthesia, peripheral motor neuropathy, or
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peripheral sensory neuropathy) >= grade 2, per
the CTCAE v4.0?
Yes
No
Does the patient have any conditions that would
prohibit administration of corticosteroids?
Yes
No
Does the patient have known hypersensitivity
reaction to any of the study drugs or excipients,
e.g. polysorbate 80 and Cremophor EL?
Yes
No
Does the patient have chronic daily treatment
with corticosteroids with a dose >= 10 mg/day
methylprednisolone equivalent (excluding inhaled
steroids)?
Yes
No
Does the patient have other non-malignant
systemic disease that would preclude the patient
from receiving study treatment or would prevent
required follow-up?
Yes
No
Does the patient have psychiatric or addictive
disorders or other condition that, in the opinion of
the investigator, would preclude the patient from
meeting the study requirements?
Yes
No
Has the patient used any investigational product
within the past 30 days?
Yes
No
Is patient a woman of childbearing potential?
Yes
No
Was a pregnancy test performed?
Yes
No
Date of pregnancy test
Is the patient pregnant or lactating at time of
study entry?
Yes
No
Does the patient have an ECOG performance
status of 0 or 1?
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Yes
No
Section 5 - Menapausal Status
Has the patient had a hysterectomy?
Yes
No
Date of Hysterectomy (Please provide surgical
report.)
Has the patient had any spontaneous menses in
the past 12 months?
Yes
No
Date of last menstrual period (If unsure of the
date, please provide a close approximation.)
Has the patient had both ovaries removed?
No (No)
Unknown (Unknown)
Yes (Yes)
Date both (or second) ovaries were removed
(Please provide all surgical reports related to
oophorectomies. If unsure of the date, please
report a close approximation.)
Has the patient had a documented estradiol level
in the postmenopausal range according to local
institutional/laboratory standard? (If yes, please
provide documentation of estradiol level.)
Yes
No
Footer
Comments (optional)
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Bladder Cancer NCT01224665 Registration - S1011
Registration Worksheet Step 1 (#23645) - 3152651v1.0
S1011 Registration Worksheet Step 1 (#23645)
Standard or Extended Pelvic Lymphadenectomy in Treating
Patients Undergoing Surgery for Invasive Bladder Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=9386ADF9-
F927-860A-E040-BB89AD4354A2
All rights reserved. Please visit https://medical-data-
models.org/forms/9077
S1011 Registration Worksheet Step
1 (#23645)
Header
Activation Date (MM DD YYYY)
Last Amended Date (MM DD YYYY)
Registration Step
Swog Patient Id
SWOG Patient ID Status
New Patient (New patient)
Previous Patient (Previous patient)
SWOG Patient ID
Demography
Patient First Name
Patient Middle Name
Patient Last Name
Unnamed2
Registrar's SWOG Roster ID Number
SWOG Investigator Number
SWOG Treating Institution Number
Unnamed5
Date Informed Consent Signed (MM DD YYYY)
Date HIPAA Authorization signed (Not required if
Country of Residence is not USA MM DD YYYY)
1 / 2
Projected Start Date of Treatment (MM DD
YYYY)
Unnamed4
I agree to allow my study doctor, or someone
approved by my study doctor, to contact me
regarding future research involving my
participation in this study
Yes
No
My specimens may be kept for use in research to
learn about, prevent, treat, or cure cancer.
Yes
No
My specimens may be kept for use in research
about other health problems (for example:
diabetes, Alzheimer's disease, or heart disease).
Yes
No
Someone may contact me in the future to ask me
to allow other uses of my specimens.
Yes
No
Unnamed 7
Has the SWOG Registration Worksheet been
completed entirely and is the patient eligible
according to the current version of protocol
section 5.0?
Yes
No
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Arthralgia NCT01385137 Registration - S0927
REGISTRATION WORKSHEET - 3303246v1.0
S0927 REGISTRATION WORKSHEET
Omega-3-Fatty Acid Supplements in Treating Muscle and
Bone Pain and Stiffness in Patients With Stage I, Stage II,
or Stage III Breast Cancer Receiving Hormone Therapy
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=B1B9094A-
B2F6-CBEC-E040-BB89AD435D64
All rights reserved. Please visit https://medical-data-
models.org/forms/9078
S0927 REGISTRATION
WORKSHEET
Header
Activation Date (MM DD YYYY)
Last Amended Date (MM DD YYYY)
Registration Step
Swog Patient Id
SWOG Patient ID Status
New Patient (New patient)
Previous Patient (Previous patient)
SWOG Patient ID
Demography
Patient First Name
Patient Middle Name
Patient Last Name
Unnamed2
Registrar's SWOG Roster ID Number
SWOG Investigator Number
SWOG Treating Institution Number
Unnamed5
Date Informed Consent Signed (MM DD YYYY)
Date HIPAA Authorization signed (Not required if
Country of Residence is not USA MM DD YYYY)
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Projected Start Date of Treatment (MM DD
YYYY)
Stratification Question
Prior history of diagnosed osteoarthritis
Prior taxane
Unnamed4
My specimens may be kept for use in research to
learn about, prevent, treat, or cure cancer.
Yes
No
My specimens may be kept for use in research
about other health problems (for example:
diabetes, Alzheimer's disease, or heart disease).
Yes
No
Someone may contact me in the future to ask me
to allow other uses of my specimens.
Yes
No
I agree to allow my study doctor, or someone
approved by my study doctor, to contact me
regarding future research involving my
participation in this study
Yes
No
I agree for my blood to be used in the additional
studies.
Yes
No
Unnamed 7
Has the SWOG Registration Worksheet been
completed entirely and is the patient eligible
according to the current version of protocol
section 5.0?
Yes
No
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Arthralgia NCT01385137 Registration - S0927 REGISTRATION
WORKSHEET - 3303246v1.0
Infection NCT00513526 On-Study - AMC-
052 Vital Signs Form (F20) - 2676717v1.0
AMC-052 Vital Signs Form (F20)
Human Papillomavirus Vaccine Therapy in Treating Men
With HIV-1 Infection
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=3952E724-
4180-361E-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/9079
AMC-052 Vital Signs Form (F20)
Header Module
Visit number
Header
Date of evaluation (mm/dd/yyyy)
Time Test Completed (hh:mm)
Unnamed2
Height (cm in)
Weight (kg lb)
Body Surface Area (m^2)
Blood Pressure (mmHg)
Blood pressure (mmHg)
Heart Rate (beats/min)
Respiratory Rate (/min)
Body Temperature (C F)
Karnofsky Performance Status (%)
Dead (0)
Moribund, Fatal Processes Progressing
Rapidly (10)
Normal, No Complaints, No Evidence Of
Disease (100)
Very Sick, Hospitalization Indicated.
Death Not Imminent (20)
Severely Disabled, Hospitalization
Indicated. Death Not Imminent (30)
Disabled, Requires Special Care And
Assistance (40)
Requires Considerable Assistance And
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Frequent Medical Care (50)
Requires Occasional Assistance, But Is
Able To Care For Most Of His/her Needs
(60)
Cares For Self, Unable To Carry On
Normal Activity Or To Do Active Work
(70)
Normal Activity With Effort; Some Signs
Or Symptoms Of Disease (80)
Able To Carry On Normal Activity; Minor
Signs Or Symptoms Of Disease (90)
Units (SI=International System of Units &
CU=Conventional Units)
Percentage (%)
Beats Per Minute:c49673 (beats/min)
Breaths Per Minute:c49674 (breaths/min)
Degree Celsius (C)
Centimeter (cm)
Degree Fahrenheit (F)
Inch (in)
Kilogram (kg)
Pound (lb)
Square Meter (m^2)
Millimeter Of Mercury:c49670 (mmHg)
Footer Module
Comments
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Infection NCT00513526 On-Study - AMC-052 Vital Signs Form (F20) -
2676717v1.0
Sarcoma NCT00450320 On-Study - AMC-
051 Vital Signs Form (F20) - 2636818v1.0
AMC-051 Vital Signs Form (F20)
Sirolimus in Treating Patients With HIV-Related Kaposi's
Sarcoma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=2FF95103-
FC90-6437-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/9081
AMC-051 Vital Signs Form (F20)
Header Module
Visit number
Header
Date of evaluation
Time Test Completed
Unnamed2
Height (cm in)
Weight (kg lb)
Body Surface Area (m^2)
Blood Pressure (mmHg)
Blood pressure (mmHg)
Heart Rate (beats/min)
Respiratory Rate (breaths/min)
Body Temperature (C F)
Karnofsky Performance Status Score (%)
Dead (0)
Moribund, Fatal Processes Progressing
Rapidly (10)
Normal, No Complaints, No Evidence Of
Disease (100)
Very Sick, Hospitalization Indicated.
Death Not Imminent (20)
Severely Disabled, Hospitalization
Indicated. Death Not Imminent (30)
Disabled, Requires Special Care And
Assistance (40)
Requires Considerable Assistance And
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Frequent Medical Care (50)
Requires Occasional Assistance, But Is
Able To Care For Most Of His/her Needs
(60)
Cares For Self, Unable To Carry On
Normal Activity Or To Do Active Work
(70)
Normal Activity With Effort; Some Signs
Or Symptoms Of Disease (80)
Able To Carry On Normal Activity; Minor
Signs Or Symptoms Of Disease (90)
Units
Percentage (%)
Beats Per Minute:c49673 (beats/min)
Breaths Per Minute:c49674 (breaths/min)
Degree Celsius (C)
Centimeter (cm)
Degree Fahrenheit (F)
Inch (in)
Kilogram (kg)
Pound (lb)
Square Meter (m^2)
Millimeter Of Mercury:c49670 (mmHg)
Footer Module
Comments
2 / 2
Sarcoma NCT00450320 On-Study - AMC-051 Vital Signs Form (F20) -
2636818v1.0
Cervical Cancer NCT01101451 Quality of Life - Gynecologic Oncology
Group Smoking History Questionnaire (Form SHQ) - 2785914v1.0
Gynecologic Oncology Group Smoking History
Questionnaire (Form SHQ)
Radiation Therapy With or Without Chemotherapy in
Patients With Stage I or Stage II Cervical Cancer Who
Previously Underwent Surgery
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=572CCDFB-
3AD6-1370-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/9082
Gynecologic Oncology Group
Smoking History Questionnaire
(Form SHQ)
Header Module
Date form originally completed (m d y)
Date form amended (m d y)
Person amending form, last name
Patient Name, Last
Patient Name, First
Patient Study ID
Person Completing Form, Last Name
Smoking History Questionnaire
Have you ever smoked tobacco products?
Yes
No
Personal Smoking Section
Have you smoked at least 100 cigarette during
your lifetime
No (No)
Yes, But Quit (Yes, but quit)
Yes, Currently Smoke (Yes, currently
smoke)
Are you currently using nicotine skin patches or
gum
Yes
No
How old were you when you smoked your first
cigarette
On average, how many cigarettes do/did you
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smoke per day
Are you still smoking at least one cigarette per
week
Yes
No
If you are no longer smoking, how old were you
when you stopped smoking (years old)
Household Smoking Section
Have you ever lived for at least a year in the
same household with someone who smoked
cigarettes regularly
Yes
No
For about how many years, in total, have you
lived with someone who smoked cigarettes
regularly at the time (years)
Do you now live in the same household with
someone who smokes cigarettes regularly
Yes
No
On average, how many cigarettes per day are
smoked by other people while you are at home
(cigarettes/day)
Second Hand Smoking Section
Are you exposed to smoke from another person's
cigarettes at least once per week when you are
outside of your household
Yes
No
On average, how many hours per week are you
exposed to smoke from other person's cigarettes
outside of your household (hours/week)
Comments
COMMENTS
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Cervical Cancer NCT01101451 Quality of Life - Gynecologic Oncology
Group Smoking History Questionnaire (Form SHQ) - 2785914v1.0
Brain and Central Nervous System Tumors NCT00978458
Eligibility - E3F05 Registration Worksheet (step 0) - 2828702v1.0
E3F05 Registration Worksheet (step 0)
Radiation Therapy With or Without Temozolomide in
Treating Patients With Low-Grade Glioma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=6129B720-
53B3-074C-E040-BB89AD436AFD
All rights reserved. Please visit https://medical-data-
models.org/forms/9085
E3F05 Registration Worksheet (step
0)
Eligibility
First initial
Fax number of the contact person responsible for
sample submission
Phone number of the contact person responsible
for sample submission
Name of the contact person responsible for
sample submission
E-mail address of the contact person responsible
for sample submission
Last initial
Has the eligibility checklist been completed
Yes
No
In the opinion of the investigator, is the patient
eligible?
Yes
No
Has written informed consent been obtained
Yes
No
Date Informed Consent Signed
Has HIPAA authorization been obtained
Exempt (Exempt)
No: C49487 (No)
Yes: C49488 (Yes)
HIPAA Authorization Date
I agree to donate additional blood for research.
Yes
No
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My specimens may be kept for use in research to
learn about, prevent, treat, or cure cancer.
Yes
No
My specimens may be kept for research about
other health problems (for example: causes of
diabetes, Alzheimer's disease, and heart
disease)
Yes
No
Someone may contact me in the future to ask me
to allow other uses of my specimens.
Yes
No
Race
Race (check all that apply)
A Person Having Origins In Any Of The
Original Peoples Of North And South
America (including Central America),
And Who Maintains Tribal Affiliation Or
Community Attachment. (American
Indian or Alaska Native)
A Person Having Origins In Any Of The
Original Peoples Of The Far East,
Southeast Asia, Or The Indian
Subcontinent Including, For Example,
Cambodia, China, India, Japan, Korea,
Malaysia, Pakistan, The Philippine
Islands, Thailand, And Vietnam. (Asian)
A Person Having Origins In Any Of The
Black Racial Groups Of Africa. Terms
Such As "haitian" Or "negro" Can Be
Used In Addition To "black Or African
American." (Black or African American)
A Person Having Origins In Any Of The
Original Peoples Of Hawaii, Guam,
Samoa, Or Other Pacific Islands. (Native
Hawaiian or other Pacific Islander)
Not Provided Or Available (Not
Reported)
Could Not Be Determined Or Unsure
(Unknown)
A Person Having Origins In Any Of The
Original Peoples Of Europe, The Middle
East, Or North Africa. (White)
Patient Demographics / Pre-treatment
Characteristics
Patient's Sex
Female (F)
Male (M)
Country of Residence (if not USA)
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Brain and Central Nervous System Tumors NCT00978458 Eligibility -
E3F05 Registration Worksheet (step 0) - 2828702v1.0
Ascension Island (AC)
Andorra (AD)
United Arab Emirates (AE)
Afghanistan (AF)
Antigua And Barbuda (AG)
Anguilla (AI)
Albania (AL)
Armenia (AM)
Netherland Antilles (AN)
Angola (AO)
Antarctica (AQ)
Argentina (AR)
American Samoa (AS)
Austria (AT)
Australia (AU)
Aruba (AW)
Azerbaidjan (AZ)
Bosnia-herzegovina (BA)
Barbados (BB)
Bangladesh (BD)
Belgium (BE)
Burkina Faso (BF)
Bulgaria (BG)
Bahrain (BH)
Burundi (BI)
Benin (BJ)
Bermuda (BM)
Brunei Darussalam (BN)
Bolivia (BO)
Brazil (BR)
Bahamas (BS)
Bhutan (BT)
Bouvet Island (BV)
Botswana (BW)
Belarus (BY)
Belize (BZ)
Canada (CA)
Cocos Isl. (CC)
Rep. Dem. Congo (CD)
Central African Rep. (CF)
Congo (CG)
Switzerland (CH)
Ivory Coast (CI)
Cook Islands (CK)
Chile (CL)
Cameroon (CM)
China (CN)
Colombia (CO)
Costa Rica (CR)
Cuba (CU)
Cape Verde (CV)
Christmas Island (CX)
Cyprus (CY)
Czech Republic (CZ)
Germany (DE)
Djibouti (DJ)
Denmark (DK)
Dominica (DM)
Dominican Republic (DO)
Algeria (DZ)
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Brain and Central Nervous System Tumors NCT00978458 Eligibility -
E3F05 Registration Worksheet (step 0) - 2828702v1.0
Ecuador (EC)
Estonia (EE)
Egypt (EG)
Western Sahara (EH)
Eritrea (ER)
Spain (ES)
Ethiopia (ET)
Finland (FI)
Fiji (FJ)
Falkland Isl. (FK)
Micronesia (FM)
Faroe Islands (FO)
France (FR)
France (european Ter.) (FX)
Gabon (GA)
Great Britain (GB)
Grenada (GD)
Georgia (GE)
Guiana (fr.) (GF)
Guernsey (GG)
Ghana (GH)
Gibraltar (GI)
Greenland (GL)
Gambia (GM)
Guinea (GN)
Guadeloupe (fr.) (GP)
Equatorial Guinea (GQ)
Greece (GR)
South Georgia And South Sandwich
Islands (GS)
Guatemala (GT)
Guam (us) (GU)
Guinea Bissau (GW)
Guyana (GY)
Hong Kong (HK)
Heard & Mcdonald Isl. (HM)
Honduras (HN)
Croatia (HR)
Haiti (HT)
Hungary (HU)
Indonesia (ID)
Ireland (IE)
Israel (IL)
Isle Of Man (IM)
India (IN)
British Indian O. Ter. (IO)
Iraq (IQ)
Iran (IR)
Iceland (IS)
Italy (IT)
Jersey (JE)
Jamaica (JM)
Jordan (JO)
Japan (JP)
Kenya (KE)
Kyrgyz Republic (KG)
Cambodia (KH)
Kiribati (KI)
Comoros (KM)
St. Kitts Nevis Anguilla (KN)
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Brain and Central Nervous System Tumors NCT00978458 Eligibility -
E3F05 Registration Worksheet (step 0) - 2828702v1.0
Korea (north) (KP)
Korea (south) (KR)
Kuwait (KW)
Cayman Islands (KY)
Kazakstan (KZ)
Laos (LA)
Lebanon (LB)
Saint Lucia (LC)
Liechtenstein (LI)
Sri Lanka (LK)
Liberia (LR)
Lesotho (LS)
Lithuania (LT)
Luxembourg (LU)
Latvia (LV)
Libya (LY)
Morocco (MA)
Monaco (MC)
Moldova (MD)
Madagascar (MG)
Marshall Islands (MH)
Macedonia (MK)
Mali (ML)
Myanmar (MM)
Mongolia (MN)
Macau (MO)
Northern Mariana Isl. (MP)
Martinique (fr.) (MQ)
Mauritania (MR)
Montserrat (MS)
Malta (MT)
Mauritius (MU)
Maldives (MV)
Malawi (MW)
Mexico (MX)
Malaysia (MY)
Mozambique (MZ)
Namibia (NA)
New Caledonia (fr.) (NC)
Niger (NE)
Norfolk Island (NF)
Nigeria (NG)
Nicaragua (NI)
Netherlands (NL)
Norway (NO)
Nepal (NP)
Nauru (NR)
Niue (NU)
New Zealand (NZ)
Oman (OM)
Other (Other)
Panama (PA)
Peru (PE)
Polynesia (fr.) (PF)
Papua New Guinea (PG)
Philippines (PH)
Pakistan (PK)
Poland (PL)
St. Pierre & Miquelon (PM)
Pitcairn (PN)
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Brain and Central Nervous System Tumors NCT00978458 Eligibility -
E3F05 Registration Worksheet (step 0) - 2828702v1.0
Puerto Rico (PR)
Portugal (PT)
Palau (PW)
Paraguay (PY)
Qatar (QA)
Reunion (fr.) (RE)
Romania (RO)
Russian Federation (RU)
Rwanda (RW)
Saudi Arabia (SA)
Solomon Islands (SB)
Seychelles (SC)
Sudan (SD)
Sweden (SE)
Singapore (SG)
St. Helena (SH)
Slovenia (SI)
Svalbard & Jan Mayen Isl. (SJ)
Slovakia (SK)
Sierra Leone (SL)
San Marino (SM)
Senegal (SN)
Somalia (SO)
Suriname (SR)
St. Tome And Principe (ST)
Soviet Union (SU)
El Salvador (SV)
Syria (SY)
Swaziland (SZ)
Turks & Caicos Islands (TC)
Chad (TD)
French Southern Terr. (TF)
Togo (TG)
Thailand (TH)
Tadjikistan (TJ)
Tokelau (TK)
Turkmenistan (TM)
Tunisia (TN)
Tonga (TO)
East Timor (TP)
Turkey (TR)
Trinidad & Tobago (TT)
Tuvalu (TV)
Taiwan (TW)
Tanzania (TZ)
Ukraine (UA)
Uganda (UG)
United Kingdom (UK)
Us Minor Outlying Isl. (UM)
Usa (US)
Uruguay (UY)
Uzbekistan (UZ)
Vatican City State (VA)
St. Vincent & Grenadines (VC)
Venezuela (VE)
Virgin Islands (brit) (VG)
Virgin Islands (us) (VI)
Vietnam (VN)
Vanuatu (VU)
Wallis & Futuna Islands (WF)
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Brain and Central Nervous System Tumors NCT00978458 Eligibility -
E3F05 Registration Worksheet (step 0) - 2828702v1.0
Western Samoa (WS)
Yemen (YE)
Mayotte (YT)
Yugoslavia (YU)
South Africa (ZA)
Zambia (ZM)
Dem. Rep. Of Congo (ZR)
Zimbabwe (ZW)
Registrar
Institution contact
Attending Physician
Method of payment (check one)
Medicaid (Medicaid)
Medicaid And Medicare (Medicaid and
Medicare)
Medicare (Medicare)
Medicare And Private Insurance
(Medicare and Private Insurance)
Military Or Veterans Sponsored Nos
(Military or Veterans Sponsored, Not
Otherwise Specified (NOS))
Military Sponsored (including Champus
& Tricare) (Military Sponsored (including
CHAMPUS & TRICARE))
No Means Of Payment (no Insurance)
(No means of payment (no insurance))
Other (Other)
Private Insurance (Private Insurance)
Self Pay (no Insurance) (Self Pay (No
Insurance))
Unknown (Unknown)
Veterans Sponsored (Veterans
Sponsored)
Patient Social Security Number
Patient Hospital No.
Patient Ethnicity
A Person Of Mexican, Puerto Rican,
Cuban, Central Or South American Or
Other Spanish Culture Or Origin,
Regardless Of Race. (Hispanic or Latino)
A Person Not Meeting The Definition For
Hispanic Or Latino. (Not Hispanic or
Latino)
Not Provided Or Available (Not reported)
Could Not Be Determined Or Unsure
(Unknown)
ZIP Code
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Brain and Central Nervous System Tumors NCT00978458 Eligibility -
E3F05 Registration Worksheet (step 0) - 2828702v1.0
Birthdate (mm/yy)
Comments
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Brain and Central Nervous System Tumors NCT00978458 Eligibility -
E3F05 Registration Worksheet (step 0) - 2828702v1.0
Lung Cancer NCT00324805 Eligibility - E1505
Registration Worksheet (step 1) - 2555093v1.0
E1505 Registration Worksheet (step 1)
Chemotherapy With or Without Bevacizumab in Treating
Patients With Stage IB, Stage II, or Stage IIIA Non-Small
Lung Cancer That Was Removed By Surgery
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=24E23D06-
7E57-43FF-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/9086
E1505 Registration Worksheet (step
1)
Eligibility
First initial
Last initial
Has the eligibility checklist been completed
Yes
No
In the opinion of the investigator, is the patient
eligible?
Yes
No
Has written informed consent been obtained
Yes
No
Date Informed Consent Signed
Has HIPAA authorization been obtained
Exempt - Non-usa Participant (Exempt -
non-USA participant)
No: C49487 (No)
Yes: C49488 (Yes)
HIPAA Authorization Date
Planned Chemotherapy Regimen
Cisplatin And Docetaxel (Cisplatin and
Docetaxel)
Cisplatin And Gemcitabine (Cisplatin and
Gemcitabine)
Cisplatin And Pemetrexed (Cisplatin and
pemetrexed)
Cisplatin And Vinorelbine (Cisplatin and
Vinorelbine)
What is the patient's stage of disease
Stage Ib >/= 4 Cm (Stage IB >/= 4 cm)
Stage Ii Lung Cancer (Stage II)
Stage Iiia-n2 Lung Cancer (Stage IIIA-
N2)
Stage Iiia-t3n1 Lung Cancer (Stage IIIA-
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T3N1)
Histology
Non-small Cell Lung Carcinoma (Other
Non-Small Cell Lung Cancer)
Squamous Cell Carcinoma (Squamous
cell carcinoma)
Patient Gender
Female (FEMALE)
Male (MALE)
I agree to donate additional blood for research.
Yes
No
My specimens may be kept for use in research to
learn about, prevent, treat, or cure cancer.
Yes
No
My specimens may be kept for research about
other health problems (for example: causes of
diabetes, Alzheimer's disease, and heart
disease) (for example: causes of diabetes,
Alzheimer's disease, and heart disease)
Yes
No
Someone may contact me in the future to ask me
to allow other uses of my specimens.
Yes
No
Race
Patient's Race
A Person Having Origins In Any Of The
Original Peoples Of North And South
America (including Central America),
And Who Maintains Tribal Affiliation Or
Community Attachment. (American
Indian or Alaska Native)
A Person Having Origins In Any Of The
Original Peoples Of The Far East,
Southeast Asia, Or The Indian
Subcontinent Including, For Example,
Cambodia, China, India, Japan, Korea,
Malaysia, Pakistan, The Philippine
Islands, Thailand, And Vietnam. (Asian)
A Person Having Origins In Any Of The
Black Racial Groups Of Africa. Terms
Such As "haitian" Or "negro" Can Be
Used In Addition To "black Or African
American." (Black or African American)
A Person Having Origins In Any Of The
Original Peoples Of Hawaii, Guam,
Samoa, Or Other Pacific Islands. (Native
Hawaiian or other Pacific Islander)
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Lung Cancer NCT00324805 Eligibility - E1505 Registration Worksheet
(step 1) - 2555093v1.0
Not Provided Or Available (Not
Reported)
Could Not Be Determined Or Unsure
(Unknown)
A Person Having Origins In Any Of The
Original Peoples Of Europe, The Middle
East, Or North Africa. (White)
Patient Demographics / Pre-treatment
Characteristics
Patient's Sex
Female (F)
Male (M)
Country of residence
Ascension Island (AC)
Andorra (AD)
United Arab Emirates (AE)
Afghanistan (AF)
Antigua And Barbuda (AG)
Anguilla (AI)
Albania (AL)
Armenia (AM)
Netherland Antilles (AN)
Angola (AO)
Antarctica (AQ)
Argentina (AR)
American Samoa (AS)
Austria (AT)
Australia (AU)
Aruba (AW)
Azerbaidjan (AZ)
Bosnia-herzegovina (BA)
Barbados (BB)
Bangladesh (BD)
Belgium (BE)
Burkina Faso (BF)
Bulgaria (BG)
Bahrain (BH)
Burundi (BI)
Benin (BJ)
Bermuda (BM)
Brunei Darussalam (BN)
Bolivia (BO)
Brazil (BR)
Bahamas (BS)
Bhutan (BT)
Bouvet Island (BV)
Botswana (BW)
Belarus (BY)
Belize (BZ)
Canada (CA)
Cocos Isl. (CC)
Rep. Dem. Congo (CD)
Central African Rep. (CF)
Congo (CG)
Switzerland (CH)
Ivory Coast (CI)
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Lung Cancer NCT00324805 Eligibility - E1505 Registration Worksheet
(step 1) - 2555093v1.0
Cook Islands (CK)
Chile (CL)
Cameroon (CM)
China (CN)
Colombia (CO)
Costa Rica (CR)
Cuba (CU)
Cape Verde (CV)
Christmas Island (CX)
Cyprus (CY)
Czech Republic (CZ)
Germany (DE)
Djibouti (DJ)
Denmark (DK)
Dominica (DM)
Dominican Republic (DO)
Algeria (DZ)
Ecuador (EC)
Estonia (EE)
Egypt (EG)
Western Sahara (EH)
Eritrea (ER)
Spain (ES)
Ethiopia (ET)
Finland (FI)
Fiji (FJ)
Falkland Isl. (FK)
Micronesia (FM)
Faroe Islands (FO)
France (FR)
France (european Ter.) (FX)
Gabon (GA)
Great Britain (GB)
Grenada (GD)
Georgia (GE)
Guiana (fr.) (GF)
Guernsey (GG)
Ghana (GH)
Gibraltar (GI)
Greenland (GL)
Gambia (GM)
Guinea (GN)
Guadeloupe (fr.) (GP)
Equatorial Guinea (GQ)
Greece (GR)
South Georgia And South Sandwich
Islands (GS)
Guatemala (GT)
Guam (us) (GU)
Guinea Bissau (GW)
Guyana (GY)
Hong Kong (HK)
Heard & Mcdonald Isl. (HM)
Honduras (HN)
Croatia (HR)
Haiti (HT)
Hungary (HU)
Indonesia (ID)
Ireland (IE)
Israel (IL)
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Lung Cancer NCT00324805 Eligibility - E1505 Registration Worksheet
(step 1) - 2555093v1.0
Isle Of Man (IM)
India (IN)
British Indian O. Ter. (IO)
Iraq (IQ)
Iran (IR)
Iceland (IS)
Italy (IT)
Jersey (JE)
Jamaica (JM)
Jordan (JO)
Japan (JP)
Kenya (KE)
Kyrgyz Republic (KG)
Cambodia (KH)
Kiribati (KI)
Comoros (KM)
St. Kitts Nevis Anguilla (KN)
Korea (north) (KP)
Korea (south) (KR)
Kuwait (KW)
Cayman Islands (KY)
Kazakstan (KZ)
Laos (LA)
Lebanon (LB)
Saint Lucia (LC)
Liechtenstein (LI)
Sri Lanka (LK)
Liberia (LR)
Lesotho (LS)
Lithuania (LT)
Luxembourg (LU)
Latvia (LV)
Libya (LY)
Morocco (MA)
Monaco (MC)
Moldova (MD)
Madagascar (MG)
Marshall Islands (MH)
Macedonia (MK)
Mali (ML)
Myanmar (MM)
Mongolia (MN)
Macau (MO)
Northern Mariana Isl. (MP)
Martinique (fr.) (MQ)
Mauritania (MR)
Montserrat (MS)
Malta (MT)
Mauritius (MU)
Maldives (MV)
Malawi (MW)
Mexico (MX)
Malaysia (MY)
Mozambique (MZ)
Namibia (NA)
New Caledonia (fr.) (NC)
Niger (NE)
Norfolk Island (NF)
Nigeria (NG)
Nicaragua (NI)
5 / 8
Lung Cancer NCT00324805 Eligibility - E1505 Registration Worksheet
(step 1) - 2555093v1.0
Netherlands (NL)
Norway (NO)
Nepal (NP)
Nauru (NR)
Niue (NU)
New Zealand (NZ)
Oman (OM)
Other (Other)
Panama (PA)
Peru (PE)
Polynesia (fr.) (PF)
Papua New Guinea (PG)
Philippines (PH)
Pakistan (PK)
Poland (PL)
St. Pierre & Miquelon (PM)
Pitcairn (PN)
Puerto Rico (PR)
Portugal (PT)
Palau (PW)
Paraguay (PY)
Qatar (QA)
Reunion (fr.) (RE)
Romania (RO)
Russian Federation (RU)
Rwanda (RW)
Saudi Arabia (SA)
Solomon Islands (SB)
Seychelles (SC)
Sudan (SD)
Sweden (SE)
Singapore (SG)
St. Helena (SH)
Slovenia (SI)
Svalbard & Jan Mayen Isl. (SJ)
Slovakia (SK)
Sierra Leone (SL)
San Marino (SM)
Senegal (SN)
Somalia (SO)
Suriname (SR)
St. Tome And Principe (ST)
Soviet Union (SU)
El Salvador (SV)
Syria (SY)
Swaziland (SZ)
Turks & Caicos Islands (TC)
Chad (TD)
French Southern Terr. (TF)
Togo (TG)
Thailand (TH)
Tadjikistan (TJ)
Tokelau (TK)
Turkmenistan (TM)
Tunisia (TN)
Tonga (TO)
East Timor (TP)
Turkey (TR)
Trinidad & Tobago (TT)
Tuvalu (TV)
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Taiwan (TW)
Tanzania (TZ)
Ukraine (UA)
Uganda (UG)
United Kingdom (UK)
Us Minor Outlying Isl. (UM)
Usa (US)
Uruguay (UY)
Uzbekistan (UZ)
Vatican City State (VA)
St. Vincent & Grenadines (VC)
Venezuela (VE)
Virgin Islands (brit) (VG)
Virgin Islands (us) (VI)
Vietnam (VN)
Vanuatu (VU)
Wallis & Futuna Islands (WF)
Western Samoa (WS)
Yemen (YE)
Mayotte (YT)
Yugoslavia (YU)
South Africa (ZA)
Zambia (ZM)
Dem. Rep. Of Congo (ZR)
Zimbabwe (ZW)
Registrar
Institution contact
Attending Physician
Method of payment (check one)
Medicaid (Medicaid)
Medicaid And Medicare (Medicaid and
Medicare)
Medicare (Medicare)
Medicare And Private Insurance
(Medicare and Private Insurance)
Military Or Veterans Sponsored Nos
(Military or Veterans Sponsored, Not
Otherwise Specified (NOS))
Military Sponsored (including Champus
& Tricare) (Military Sponsored (including
CHAMPUS & TRICARE))
No Means Of Payment (no Insurance)
(No means of payment (no insurance))
Other (Other)
Private Insurance (Private Insurance)
Self Pay (no Insurance) (Self Pay (No
Insurance))
Unknown (Unknown)
Veterans Sponsored (Veterans
Sponsored)
Patient Social Security Number
Patient Hospital No.
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Patient Ethnicity
A Person Of Mexican, Puerto Rican,
Cuban, Central Or South American Or
Other Spanish Culture Or Origin,
Regardless Of Race. (Hispanic or Latino)
A Person Not Meeting The Definition For
Hispanic Or Latino. (Not Hispanic or
Latino)
Not Provided Or Available (Not reported)
Could Not Be Determined Or Unsure
(Unknown)
ZIP Code
Birthdate (mm/yy)
Comments
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Breast Cancer NCT01275677 Follow-Up - NSABP-B-47
Cardiac Report Follow-Up Form (Form CR-F) - 3162754v1.0
NSABP-B-47 Cardiac Report Follow-Up Form (Form CR-F)
A Randomized Phase III Trial of Adjuvant Therapy
Comparing Chemotherapy Alone (Six Cycles of Docetaxel
Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus
Cyclophosphamide Followed by Weekly Paclitaxel) to
Chemotherapy Plus Trastuzumab in Women With Node-
Positive or High-Risk Node-Negative HER2-Low Invasive
Breast Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=95D01C7E-
6A9D-38AE-E040-BB89AD4351B3
All rights reserved. Please visit https://medical-data-
models.org/forms/9087
NSABP-B-47 Cardiac Report Follow-
Up Form (Form CR-F)
Header
Patient Initials (Last First Middle)
NSABP Patient ID
Reporting Period
Reporting Period
First Cardiac Follow-up (First cardiac
follow-up)
Fourth Cardiac Follow-up (Fourth cardiac
follow-up)
Second Cardiac Follow-up (Second
cardiac follow-up)
Third Cardiac Follow-up (Third cardiac
follow-up)
Reporting Period End Date (Month Day Year)
Cardiac Information
Has the patient had symptoms of CHF since the
previous report (Previous report will be Form CR
if this is the first CR-F form submitted.)
Yes
No
How would you classify the symptoms of
congestive heart failure (If yes)
Asymptomatic At Rest, But Less Than
Ordinary Physical Activity Results In
Fatigue, Palpitation, Dyspnea Or Anginal
Pain (Asymptomatic at rest, but less than
ordinary physical activity results in
fatigue, palpitation, dyspnea or anginal
pain)
Asymptomatic At Rest, But Ordinary
Physical Activity Results In Fatigue,
Palpitation, Dyspnea Or Anginal Pain
(Asymptomatic at rest, but ordinary
1 / 2
physical activity results in fatigue,
palpitation, dyspnea or anginal pain)
Ordinary Physical Activity Does Not
Cause Undue Fatigue, Palpitation,
Dyspnea Or Anginal Pain (Ordinary
physical activity does not cause undue
fatigue, palpitation, dyspnea or anginal
pain)
Symptomatic At Rest, Or Any Physical
Activity Results In Fatigue, Palpitation,
Dyspnea Or Anginal Pain (Symptomatic
at rest, or any physical activity results in
fatigue, palpitation, dyspnea or anginal
pain)
Has the patient had one or more LVEF
assessments since the previous report (Form LVA
should be submitted any time through 10 years
following randomization when a non-protocol
specified LVEF assessment has been performed
because the patient has signs or symptoms of
CHF see Protocol Section 5.3. Please submit all
LVEF assessments since the previous report)
Yes
No
Has the patient received medications for heart
failure and/or hypertension since the previous
report
Yes
No
Medications (Mark all that apply)
Ace Inhibitor (ACE inhibitors)
Alpha/beta Blocker (Alpha/beta blocker)
Arb (ARB)
Beta Blocker (Beta blockers)
Cardiac Glycoside (Cardiac glycoside)
Diuretic (Diuretics)
Other (Other)
Other, specify
Medication Reason (Mark all reasons that apply)
Heart Failure (Heart Failure)
Hypertension (hypertension)
Footer
Comments (optional)
Person Completing Form
Date Form Completed
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Breast Cancer NCT00769379 Toxicity - NSABP PROTOCOL
B-43 Worksheet for Reporting Adverse Events - 2675165v1.0
NSABP PROTOCOL B-43 Worksheet for Reporting
Adverse Events
Radiation Therapy With or Without Trastuzumab in Treating
Women With Ductal Carcinoma In Situ Who Have
Undergone Lumpectomy
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=38ED3BE3-
2DBE-50EF-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/9088
NSABP PROTOCOL B-43
Worksheet for Reporting Adverse
Events
Header
NSABP Patient ID
Patient Initials (Last First Middle)
Treatment Group
Radiation Therapy Start Date
30 Days After Study Therapy Completed
Was the patient hospitalized for 24 hours or
more?
Yes
No
Adverse Events
CTCAE Term
Abdominal Distention (Abdominal
distension)
Abdominal Infection (Abdominal
infection)
Abdominal Pain (Abdominal pain)
Abdominal Soft Tissue Necrotic Lesion
(Abdominal soft tissue necrosis)
Abducens Nerve Disorder (Abducens
nerve disorder)
Accessory Nerve Disorder (Accessory
nerve disorder)
Acidosis (Acidosis)
Vestibulocochlear Nerve Disorder
(Acoustic nerve disorder NOS)
Prolonged Partial Thromboplastin Time
(Activated partial thromboplastin time
prolonged)
Acute Coronary Syndrome (Acute
coronary syndrome)
Acute Renal Failure (Acute kidney injury)
Adrenal Gland Insufficiency (Adrenal
1 / 41
insufficiency)
Adult Respiratory Distress Syndrome
(Adult respiratory distress syndrome)
Agitation (Agitation)
Akathisia (Akathisia)
Alanine Aminotransferase Increased
(Alanine aminotransferase increased)
Alcohol Intolerance (Alcohol intolerance)
Blood Alkaline Phosphatase Increased
(Alkaline phosphatase increased)
Alkalosis (Alkalosis)
Hypersensitivity (Allergic reaction)
Allergic Rhinitis (Allergic rhinitis)
Alopecia (Alopecia)
Amnesia (Amnesia)
Anorectal Fistula (Anal fistula)
Anal Hemorrhage (Anal hemorrhage)
Anal Mucositis (Anal mucositis)
Anal Necrotic Lesion (Anal necrosis)
Anal Pain (Anal pain)
Anal Stenosis (Anal stenosis)
Anal Ulcer (Anal ulcer)
Anaphylactic Shock (Anaphylaxis)
Anemia (Anemia)
Ankle Fracture (Ankle fracture)
Anorectal Infection (Anorectal infection)
Anorexia (Anorexia)
Anorgasmia (Anorgasmia)
Anxiety (Anxiety)
Aortic Injury (Aortic injury)
Aortic Valve Disorder (Aortic valve
disease)
Aphonia (Aphonia)
Apnea (Apnea)
Acute Appendicitis (Appendicitis)
Acute Perforated Appendicitis
(Appendicitis perforated)
Arachnoiditis (Arachnoiditis)
Arterial Injury (Arterial injury)
Arteritis (Arteritis infective)
Arthralgia (Arthralgia)
Arthritis (Arthritis)
Ascites (Ascites)
Aspartate Aminotransferase Increased
(Aspartate aminotransferase increased)
Aspiration (Aspiration)
Cardiac Arrest (Asystole)
Ataxia (Ataxia)
Atelectasis (Atelectasis)
Atrial Fibrillation (Atrial fibrillation)
Atrial Flutter (Atrial flutter)
Av Block Third Degree (Atrioventricular
block complete)
Av Block First Degree (Atrioventricular
block first degree)
Autoimmune Disease (Autoimmune
disorder)
Bone Necrosis (Avascular necrosis)
Azoospermia (Azoospermia)
Back Pain (Back pain)
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Bile Duct Stenosis (Bile duct stenosis)
Biliary Anastomotic Leakage (Biliary
anastomotic leak)
Biliary Fistula (Biliary fistula)
Cholangitis (Biliary tract infection)
Bladder Anastomotic Leakage (Bladder
anastomotic leak)
Cystitis (Bladder infection)
Bladder Perforation (Bladder perforation)
Bladder Spasm (Bladder spasm)
Bloating (Bloating)
Hematopoietic And Lymphoid System
Disorder Other Specify (Blood and
lymphatic system disorders - Other,
specify)
Abnormal Blood Antidiuretic Hormone
(Blood antidiuretic hormone abnormal)
Elevated Bilirubin (Blood bilirubin
increased)
Blood Corticotrophin Decreased (Blood
corticotrophin decreased)
Abnormal Blood Gonadotrophin (Blood
gonadotrophin abnormal)
Abnormal Blood Prolactin (Blood
prolactin abnormal)
Blurred Vision (Blurred vision)
Body Odor (Body odor)
Bone Infection (Bone infection)
Hypocellular Bone Marrow (Bone
marrow hypocellular)
Bone Pain (Bone pain)
Brachial Plexopathy (Brachial
plexopathy)
Breast Atrophy (Breast atrophy)
Mastitis (Breast infection)
Breast Pain (Breast pain)
Bronchial Fistula (Bronchial fistula)
Bronchitis (Bronchial infection)
Bronchial Obstruction (Bronchial
obstruction)
Bronchial Stricture (Bronchial stricture)
Bronchopleural Fistula (Bronchopleural
fistula)
Bronchial Hemorrhage
(Bronchopulmonary hemorrhage)
Bronchospasm (Bronchospasm)
Bruise (Bruising)
Bullous Dermatitis (Bullous dermatitis)
Burn (Burn)
Buttock Pain (Buttock pain)
Capillary Leak Syndrome Capillary Leak
Syndrome (Capillary leak syndrome)
Decreased Carbon Monoxide Diffusing
Capacity (Carbon monoxide diffusing
capacity decreased)
Cardiac Arrest (Cardiac arrest)
Heart Disorder Other Specify (Cardiac
disorders - Other, specify)
Blood Cardiac Troponin I Increased
(Cardiac troponin I increased)
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Blood Cardiac Troponin T Increased
(Cardiac troponin T increased)
Cataract (Cataract)
Catheter-related Infection (Catheter
related infection)
Cd4 Lymphocytes Decreased (CD4
lymphocytes decreased)
Cecal Hemorrhage (Cecal hemorrhage)
Cecal Infection (Cecal infection)
Central Nervous System Necrotic Lesion
(Central nervous system necrosis)
Cerebrospinal Fluid Leakage
(Cerebrospinal fluid leakage)
Infectious Cervicitis (Cervicitis infection)
Cheilitis (Cheilitis)
Angina (Chest pain - cardiac)
Chest Wall Pain (Chest wall pain)
Chills (Chills)
Cholecystitis (Cholecystitis)
Hypercholesterolemia (Cholesterol high)
Chronic Kidney Disease (Chronic kidney
disease)
Chylothorax (Chylothorax)
Cognitive Disturbance (Cognitive
disturbance)
Colitis (Colitis)
Colonic Fistula (Colonic fistula)
Colonic Hemorrhage (Colonic
hemorrhage)
Colonic Obstruction (Colonic obstruction)
Colonic Perforation (Colonic perforation)
Colonic Stenosis (Colonic stenosis)
Colonic Ulcer (Colonic ulcer)
Concentration Impairment
(Concentration impairment)
Heart Conduction Disorder (Conduction
disorder)
Confusion (Confusion)
Congenital, Familial And Genetic
Disorder Class Other Specify
(Congenital, familial and genetic
disorders - Other, specify)
Conjunctivitis (Conjunctivitis)
Acute Contagious Conjunctivitis
(Conjunctivitis infective)
Constipation (Constipation)
Constrictive Pericarditis (Constrictive
pericarditis)
Keratitis (Corneal infection)
Corneal Ulcer (Corneal ulcer)
Cough (Cough)
Creatine Phosphokinase Increased (CPK
increased)
Cranial Nerve Infection (Cranial nerve
infection)
Increased Creatinine (Creatinine
increased)
Cushingoid (Cushingoid)
Non-infectious Cystitis (Cystitis
noninfective)
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Cytokine Release Syndrome (Cytokine
release syndrome)
Neonatal Death (Death neonatal)
Death (Death NOS)
Dehydration (Dehydration)
Delayed Orgasm (Delayed orgasm)
Delayed Puberty (Delayed puberty)
Delirium (Delirium)
Delusion (Delusions)
Caries (Dental caries)
Depressed Level Of Consciousness
(Depressed level of consciousness)
Depression (Depression)
Radiation-induced Dermatitis (Dermatitis
radiation)
Prosthesis-related Infection (Device
related infection)
Diarrhea (Diarrhea)
Disseminated Intravascular Coagulation
(Disseminated intravascular coagulation)
Dizziness (Dizziness)
Dry Eye Syndrome (Dry eye)
Xerostomia (Dry mouth)
Dry Skin (Dry Skin)
Duodenal Fistula (Duodenal fistula)
Duodenal Hemorrhage (Duodenal
hemorrhage)
Duodenal Infection (Duodenal infection)
Duodenal Obstruction (Duodenal
obstruction)
Duodenal Perforation (Duodenal
perforation)
Duodenal Stenosis (Duodenal stenosis)
Duodenal Ulcer (Duodenal ulcer)
Dysarthria (Dysarthria)
Dysesthesia (Dysesthesia)
Dysgeusia (Dysgeusia)
Dysmenorrhea (Dysmenorrhea)
Dyspareunia (Dyspareunia)
Dyspepsia (Dyspepsia)
Dysphagia (Dysphagia)
Dysphasia (Dysphasia)
Dyspnea (Dyspnea)
Ear And Labyrinth Disorder Class Other
Specify (Ear and labyrinth disorders -
Other, specify)
Earache (Ear pain)
Cerebral Edema (Edema cerebral)
Face Edema (Edema face)
Edema Limbs (Edema limbs)
Edema Trunk (Edema trunk)
Ejaculation Disorder (Ejaculation
disorder)
Ejection Fraction Decreased (Ejection
fraction decreased)
Prolonged Qt Interval (Electrocardiogram
QT corrected interval prolonged)
Infectious Encephalitis (Encephalitis
infection)
Infectious Encephalomyelitis
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(Encephalomyelitis infection)
Encephalopathy (Encephalopathy)
Infective Endocarditis (Endocarditis
infective)
Endocrine Disorder Other Specify
(Endocrine disorders - Other, specify)
Endophthalmitis (Endophthalmitis)
Enterocolitis (Enterocolitis)
Infectious Enterocolitis (Enterocolitis
infectious)
Enterovesical Fistula (Enterovesical
fistula)
Epistaxis (Epistaxis)
Impotence (Erectile dysfunction)
Erythema Multiforme (Erythema
multiforme)
Erythroderma (Erythroderma)
Esophageal Anastomotic Leakage
(Esophageal anastomotic leak)
Esophageal Fistula (Esophageal fistula)
Esophageal Hemorrhage (Esophageal
hemorrhage)
Esophageal Infection (Esophageal
infection)
Esophageal Necrotic Lesion
(Esophageal necrosis)
Esophageal Obstruction (Esophageal
obstruction)
Esophageal Pain (Esophageal pain)
Perforation Of Esophagus (Esophageal
perforation)
Esophageal Stricture (Esophageal
stenosis)
Esophageal Ulcer (Esophageal ulcer)
Esophageal Varices Hemorrhage
(Esophageal varices hemorrhage)
Esophagitis (Esophagitis)
Euphoria (Euphoria)
Exostosis (Exostosis)
External Ear Inflammation (External ear
inflammation)
External Ear Pain (External ear pain)
Extraocular Muscle Paresis (Extraocular
muscle paresis)
Extrapyramidal Disorder (Extrapyramidal
disorder)
Eye Disorder Other Specify (Eye
disorders - Other, specify)
Eye Infection (Eye infection)
Eye Pain (Eye pain)
Eyelid Function Disorder (Eyelid function
disorder)
Facial Muscle Weakness (Facial muscle
weakness)
Facial Nerve Disorder (Facial nerve
disorder)
Facial Pain (Facial pain)
Fall (Fall)
Fallopian Tube Anastomotic Leakage
(Fallopian tube anastomotic leak)
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Fallopian Tube Obstruction (Fallopian
tube obstruction)
Fallopian Tube Perforation (Fallopian
tube perforation)
Fallopian Tube Stenosis (Fallopian tube
stenosis)
Adipose Tissue Atrophy (Fat atrophy)
Fatigue (Fatigue)
Neutropenic Fever (Febrile neutropenia)
Fecal Incontinence (Fecal incontinence)
Female Genital Tract Fistula (Female
genital tract fistula)
Acquired Feminization (Feminization
acquired)
Intrauterine Fetal Death (Fetal death)
Fetal Growth Retardation (Fetal growth
retardation)
Fever (Fever)
Fibrinogen Decreased (Fibrinogen
decreased)
Deep Connective Tissue Fibrosis
(Fibrosis deep connective tissue)
Flank Pain (Flank pain)
Flasher (Flashing lights)
Flatulence (Flatulence)
Floaters (Floaters)
Flu-like Symptoms (Flu like symptoms)
Flushing (Flushing)
Decreased Forced Expiratory Volume
(Forced expiratory volume decreased)
Fracture (Fracture)
Gait Disturbance (Gait disturbance)
Gallbladder Fistula (Gallbladder fistula)
Gallbladder Infection (Gallbladder
infection)
Gallbladder Necrotic Lesion (Gallbladder
necrosis)
Gallbladder Obstruction (Gallbladder
obstruction)
Gallbladder Pain (Gallbladder pain)
Gallbladder Perforation (Gallbladder
perforation)
Gastric Anastomotic Leakage (Gastric
anastomotic leak)
Gastric Fistula (Gastric fistula)
Gastric Hemorrhage (Gastric
hemorrhage)
Gastric Necrotic Lesion (Gastric
necrosis)
Gastric Perforation (Gastric perforation)
Gastric Stenosis (Gastric stenosis)
Gastric Ulcer (Gastric ulcer)
Gastritis (Gastritis)
Gastroesophageal Reflux Disease
(Gastroesophageal reflux disease)
Gastrointestinal System Anastomotic
Leakage (Gastrointestinal anastomotic
leak)
Gastrointestinal Disorder Other Specify
(Gastrointestinal disorders - Other,
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specify)
Gastrointestinal Fistula (Gastrointestinal
fistula)
Gastrointestinal Pain (Gastrointestinal
pain)
Gastrointestinal Stoma Necrotic Lesion
(Gastrointestinal stoma necrosis)
Gastroparesis (Gastroparesis)
General Disorders And Administration
Site Conditions Class Other Specify
(General disorders and administration
site conditions - Other, specify)
Generalized Muscle Weakness
(Generalized muscle weakness)
Genital Edema (Genital edema)
Gamma-glutamyltransferase Increased
(GGT increased)
Gingival Pain (Gingival pain)
Glaucoma (Glaucoma)
Glossopharyngeal Nerve Disorder
(Glossopharyngeal nerve disorder)
Glucose Intolerance (Glucose
intolerance)
Accelerated Growth (Growth
accelerated)
Abnormal Growth Hormone (Growth
hormone abnormal)
Growth Retardation (Growth
suppression)
Gum Infection (Gum infection)
Gynecomastia (Gynecomastia)
Hallucination (Hallucinations)
Haptoglobin Decreased (Haptoglobin
decreased)
Head Soft Tissue Necrotic Lesion (Head
soft tissue necrosis)
Headache (Headache)
Hearing Impairment (Hearing impaired)
Heart Failure (Heart failure)
Hematoma (Hematoma)
Hematosalpinx (Hematosalpinx)
Hematuria (Hematuria)
Hemoglobin Increased (Hemoglobin
increased)
Hemoglobinuria (Hemoglobinuria)
Hemolysis (Hemolysis)
Hemolytic Uremic Syndrome (Hemolytic
uremic syndrome)
Hemorrhoidal Hemorrhage
(Hemorrhoidal hemorrhage)
Hemorrhoid (Hemorrhoids)
Hepatic Failure (Hepatic failure)
Hepatic Hemorrhage (Hepatic
hemorrhage)
Hepatic Infection (Hepatic infection)
Hepatic Necrotic Lesion (Hepatic
necrosis)
Hepatic Pain (Hepatic pain)
Viral Hepatitis (Hepatitis viral)
Liver And Biliary Tract Disorder Other
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Specify (Hepatobiliary disorders - Other,
specify)
Hiccough (Hiccups)
Hip Fracture (Hip fracture)
Hirsutism (Hirsutism)
Hoarseness (Hoarseness)
Hot Flashes (Hot flashes)
Hydrocephalus (Hydrocephalus)
Hypercalcemia (Hypercalcemia)
Hyperglycemia (Hyperglycemia)
Hyperhidrosis (Hyperhidrosis)
Hyperkalemia (Hyperkalemia)
Hypermagnesemia (Hypermagnesemia)
Hypernatremia (Hypernatremia)
Hyperparathyroidism
(Hyperparathyroidism)
Hypersomnia (Hypersomnia)
Hypertension (Hypertension)
Hyperthyroidism (Hyperthyroidism)
Hypertrichosis (Hypertrichosis)
Hypertriglyceridemia
(Hypertriglyceridemia)
Hyperuricemia (Hyperuricemia)
Hypoalbuminemia (Hypoalbuminemia)
Hypocalcemia (Hypocalcemia)
Hypoglossal Nerve Disorder
(Hypoglossal nerve disorder)
Hypoglycemia (Hypoglycemia)
Hypohidrosis (Hypohidrosis)
Hypokalemia (Hypokalemia)
Hypomagnesemia (Hypomagnesemia)
Hyponatremia (Hyponatremia)
Hypoparathyroidism
(Hypoparathyroidism)
Hypophosphatemia (Hypophosphatemia)
Hypotension (Hypotension)
Hypothermia (Hypothermia)
Hypothyroidism (Hypothyroidism)
Hypoxia (Hypoxia)
Ileal Fistula (Ileal fistula)
Ileal Hemorrhage (Ileal hemorrhage)
Ileal Obstruction (Ileal obstruction)
Ileal Perforation (Ileal perforation)
Ileal Stenosis (Ileal stenosis)
Ileal Ulcer (Ileal ulcer)
Ileus (Ileus)
Immune System Disorder Other Specify
(Immune system disorders - Other,
specify)
Infection Other Specify (Infections and
infestations - Other, specify)
Infectious Myositis (Infective myositis)
Infusion-related Reaction (Infusion
related reaction)
Infusion Site Extravasation (Infusion site
extravasation)
Injection Site Reaction (Injection site
reaction)
Injury To Carotid Artery (Injury to carotid
artery)
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Injury To Inferior Vena Cava (Injury to
inferior vena cava)
Injury To Jugular Vein (Injury to jugular
vein)
Injury To Superior Vena Cava (Injury to
superior vena cava)
Injury, Poisoning And Procedural
Complication Class Other Specify (Injury,
poisoning and procedural complications -
Other, specify)
Inr Increased (INR increased)
Insomnia (Insomnia)
Intestinal Stoma Leakage (Intestinal
stoma leak)
Intestinal Stoma Obstruction (Intestinal
stoma obstruction)
Intestinal Stoma Site Hemorrhage
(Intestinal stoma site bleeding)
Intra-abdominal Hemorrhage (Intra-
abdominal hemorrhage)
Intracranial Hemorrhage (Intracranial
hemorrhage)
Intraoperative Arterial Injury
(Intraoperative arterial injury)
Intraoperative Breast Injury
(Intraoperative breast injury)
Intraoperative Cardiac Injury
(Intraoperative cardiac injury)
Intraoperative Ear Injury (Intraoperative
ear injury)
Intraoperative Endocrine Injury
(Intraoperative endocrine injury)
Intraoperative Gastrointestinal Injury
(Intraoperative gastrointestinal injury)
Intraoperative Head And Neck Injury
(Intraoperative head and neck injury)
Intraoperative Hemorrhage
(Intraoperative hemorrhage)
Intraoperative Hepatobiliary Injury
(Intraoperative hepatobiliary injury)
Intraoperative Musculoskeletal Injury
(Intraoperative musculoskeletal injury)
Intraoperative Neurological Injury
(Intraoperative neurological injury)
Intraoperative Ocular Injury
(Intraoperative ocular injury)
Intraoperative Renal Injury
(Intraoperative renal injury)
Intraoperative Reproductive System
Injury (Intraoperative reproductive tract
injury)
Intraoperative Respiratory Injury
(Intraoperative respiratory injury)
Intraoperative Skin Injury (Intraoperative
skin injury)
Intraoperative Splenic Injury
(Intraoperative splenic injury)
Intraoperative Urinary System Injury
(Intraoperative urinary injury)
Intraoperative Venous Injury
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(Intraoperative venous injury)
Investigation Other Specify
(Investigations - Other, specify)
Iron Overload (Iron overload)
Irregular Menstruation (Irregular
menstruation)
Irritability (Irritability)
Cerebrovascular Ischemia (Ischemia
cerebrovascular)
Trochlear Nerve Disorder (IVth nerve
disorder)
Jejunal Fistula (Jejunal fistula)
Jejunal Hemorrhage (Jejunal
hemorrhage)
Jejunal Obstruction (Jejunal obstruction)
Jejunal Perforation (Jejunal perforation)
Jejunal Stenosis (Jejunal stenosis)
Jejunal Ulcer (Jejunal ulcer)
Joint Effusion (Joint effusion)
Joint Infection (Joint infection)
Joint Range Of Motion Decreased (Joint
range of motion decreased)
Cervical Spine Joint Range Of Motion
Decreased (Joint range of motion
decreased cervical spine)
Lumbar Spine Joint Range Of Motion
Decreased (Joint range of motion
decreased lumbar spine)
Keratitis (Keratitis)
Kidney Anastomotic Leakage (Kidney
anastomotic leak)
Pyelonephritis (Kidney infection)
Kyphosis (Kyphosis)
Lactation Disorder (Lactation disorder)
Large Intestinal Anastomotic Leakage
(Large intestinal anastomotic leak)
Laryngeal Edema (Laryngeal edema)
Laryngeal Fistula (Laryngeal fistula)
Laryngeal Hemorrhage (Laryngeal
hemorrhage)
Laryngitis (Laryngeal inflammation)
Laryngeal Mucositis (Laryngeal
mucositis)
Laryngeal Obstruction (Laryngeal
obstruction)
Laryngeal Stenosis (Laryngeal stenosis)
Laryngitis (Laryngitis)
Laryngopharyngeal Dysesthesia
(Laryngopharyngeal dysesthesia)
Laryngospasm (Laryngospasm)
Left Ventricular Systolic Dysfunction (Left
ventricular systolic dysfunction)
Lethargy (Lethargy)
Chemotherapy-related Leukemia
(Leukemia secondary to oncology
chemotherapy)
Leukocytosis (Leukocytosis)
Leukoencephalopathy
(Leukoencephalopathy)
Decreased Libido (Libido decreased)
11 / 41
Breast Cancer NCT00769379 Toxicity - NSABP PROTOCOL B-43
Worksheet for Reporting Adverse Events - 2675165v1.0
Increased Libido (Libido increased)
Lip Infection (Lip infection)
Lip Pain (Lip pain)
Lipase Increased (Lipase increased)
Lipohypertrophy (Lipohypertrophy)
Localized Edema (Localized edema)
Lordosis (Lordosis)
Lower Gastrointestinal Hemorrhage
(Lower gastrointestinal hemorrhage)
Infectious Lung Disorder (Lung infection)
Lymphadenitis (Lymph gland infection)
Lymph Leakage (Lymph leakage)
Lymph Node Pain (Lymph node pain)
Lymphedema (Lymphedema)
Lymphocele (Lymphocele)
Lymphopenia (Lymphocyte count
decreased)
Lymphocytosis (Lymphocyte count
increased)
Malabsorption Syndrome
(Malabsorption)
Malaise (Malaise)
Mania (Mania)
Mediastinal Hemorrhage (Mediastinal
hemorrhage)
Mediastinitis (Mediastinal infection)
Memory Impairment (Memory
impairment)
Meningismus (Meningismus)
Meningitis (Meningitis)
Menopause (Menopause)
Menorrhagia (Menorrhagia)
Metabolism And Nutrition Disorder Class
Other Specify (Metabolism and nutrition
disorders - Other, specify)
Otitis Media (Middle ear inflammation)
Mitral Valve Disorder (Mitral valve
disease)
Av Block Second Degree Mobitz Type Ii
(Mobitz (type) II atrioventricular block)
Av Block Second Degree Mobitz Type I
(Mobitz type I)
Involuntary Movements (Movements
involuntary)
Mucosal Infection (Mucosal infection)
Stomatitis (Mucositis oral)
Multiple Organ Failure (Multi-organ
failure)
Muscle Weakness Left-sided (Muscle
weakness left-sided)
Muscle Weakness Lower Limb (Muscle
weakness lower limb)
Muscle Weakness Right-sided (Muscle
weakness right-sided)
Muscle Weakness Trunk (Muscle
weakness trunk)
Muscle Weakness Upper Limb (Muscle
weakness upper limb)
Connective And Soft Tissue Disorder
Other Specify (Musculoskeletal and
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connective tissue disorder -  Other,
specify)
Musculoskeletal Deformity
(Musculoskeletal deformity)
Myalgia (Myalgia)
Myelitis (Myelitis)
Mds (Myelodysplastic syndrome)
Myocardial Infarction (Myocardial
infarction)
Myocarditis (Myocarditis)
Myositis (Myositis)
Nail Discoloration (Nail discoloration)
Nail Infection (Nail infection)
Nail Loss (Nail loss)
Nail Ridging (Nail ridging)
Nasal Congestion (Nasal congestion)
Nausea (Nausea)
Neck Edema (Neck edema)
Neck Pain (Neck pain)
Neck Soft Tissue Necrotic Lesion (Neck
soft tissue necrosis)
Neoplasm Other Specify (Neoplasms
benign, malignant and unspecified (incl
cysts and polyps) - Other, specify)
Nervous System Disorder Other Specify
(Nervous system disorders - Other,
specify)
Neuralgia (Neuralgia)
Neutrophil Count Decreased (Neutrophil
count decreased)
Night Blindness (Night blindness)
Nipple Deformity (Nipple deformity)
Non-cardiac Chest Pain (Non-cardiac
chest pain)
Nystagmus (Nystagmus)
Obesity (Obesity)
Gastric Obstruction (Obstruction gastric)
Oculomotor Nerve Disorder (Oculomotor
nerve disorder)
Olfactory Nerve Disorder (Olfactory
nerve disorder)
Oligospermia (Oligospermia)
Optic Nerve Disorder (Optic nerve
disorder)
Oral Cavity Fistula (Oral cavity fistula)
Burning Mouth Syndrome (Oral
dysesthesia)
Oral Hemorrhage (Oral hemorrhage)
Oral Pain (Oral pain)
Osteonecrosis Of Jaw (Osteonecrosis of
jaw)
Osteoporosis (Osteoporosis)
External Ear Infection (Otitis externa)
Otitis Media (Otitis media)
Ovarian Hemorrhage (Ovarian
hemorrhage)
Ovarian Infection (Ovarian infection)
Ovarian Rupture (Ovarian rupture)
Ovulatory Pain (Ovulation pain)
Pain (Pain)
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Pain In Extremity (Pain in extremity)
Skin Pain (Pain of skin)
Palmar-plantar Erythodysthesia (Palmar-
plantar erythrodysesthesia syndrome)
Palpitation (Palpitations)
Pancreatic Infection (Pancreas infection)
Pancreatic Anastomotic Leakage
(Pancreatic anastomotic leak)
Pancreatic Duct Stenosis (Pancreatic
duct stenosis)
Pancreatic Enzymes Decreased
(Pancreatic enzymes decreased)
Pancreatic Fistula (Pancreatic fistula)
Pancreatic Hemorrhage (Pancreatic
hemorrhage)
Pancreatic Necrotic Lesion (Pancreatic
necrosis)
Pancreatitis (Pancreatitis)
Papilledema (Papilledema)
Papulopustular Rash (Papulopustular
rash)
Paresthesia (Paresthesia)
Paronychia (Paronychia)
Paroxysmal Atrial Tachycardia
(Paroxysmal atrial tachycardia)
Pelvic Floor Muscle Weakness (Pelvic
floor muscle weakness)
Pelvic Inflammatory Disease (Pelvic
infection)
Pelvic Pain (Pelvic pain)
Pelvic Soft Tissue Necrotic Lesion
(Pelvic soft tissue necrosis)
Penile Infection (Penile infection)
Penile Pain (Penile pain)
Bile Duct Perforation (Perforation bile
duct)
Pericardial Effusion (Pericardial effusion)
Cardiac Tamponade (Pericardial
tamponade)
Pericarditis (Pericarditis)
Perineal Pain (Perineal pain)
Periodontal Disorder (Periodontal
disease)
Periorbital Edema (Periorbital edema)
Periorbital Infection (Periorbital infection)
Peripheral Ischemia (Peripheral
ischemia)
Peripheral Motor Neuropathy (Peripheral
motor neuropathy)
Peripheral Nervous System Infectious
Disorder (Peripheral nerve infection)
Peripheral Sensory Neuropathy
(Peripheral sensory neuropathy)
Peritoneal Infection (Peritoneal infection)
Peritoneal Necrotic Lesion (Peritoneal
necrosis)
Personality Change (Personality change)
Phantom Pain (Phantom pain)
Pharyngeal Anastomotic Leakage
(Pharyngeal anastomotic leak)
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Pharyngeal Fistula (Pharyngeal fistula)
Pharyngeal Hemorrhage (Pharyngeal
hemorrhage)
Pharyngeal Mucositis (Pharyngeal
mucositis)
Pharyngeal Necrotic Lesion (Pharyngeal
necrosis)
Pharyngeal Stenosis (Pharyngeal
stenosis)
Pharyngitis (Pharyngitis)
Pharyngolaryngeal Pain
(Pharyngolaryngeal pain)
Phlebitis (Phlebitis)
Infective Phlebitis (Phlebitis infective)
Photophobia (Photophobia)
Photosensitivity (Photosensitivity)
Thrombocytopenia (Platelet count
decreased)
Pleural Effusion (Pleural effusion)
Hemothorax (Pleural hemorrhage)
Pleural Infection (Pleural infection)
Pleuritic Pain (Pleuritic pain)
Pneumonia (Pneumonitis)
Pneumothorax (Pneumothorax)
Portal Hypertension (Portal
Hypertension)
Portal Vein Thrombosis (Portal vein
thrombosis)
Post-nasal Drip (Postnasal drip)
Postoperative Bleeding (Postoperative
hemorrhage)
Thoracic Procedure Postoperative
Complication (Postoperative thoracic
procedure complication)
Precocious Puberty (Precocious
puberty)
Pregnancy, Puerperium And Perinatal
Condition Class Other Specify
(Pregnancy, puerperium and perinatal
conditions - Other, specify)
Premature Labor (Premature delivery)
Premature Menopause (Premature
menopause)
Presyncope (Presyncope)
Proctitis (Proctitis)
Productive Cough (Productive cough)
Intestinal Stoma Prolapse (Prolapse of
intestinal stoma)
Urostomy Prolapse (Prolapse of
urostomy)
Prostatic Infection (Prostate infection)
Prostatic Hemorrhage (Prostatic
hemorrhage)
Prostatic Obstruction (Prostatic
obstruction)
Prostatic Pain (Prostatic pain)
Proteinuria (Proteinuria)
Pruritus (Pruritus)
Psychiatric Disorder Other Specify
(Psychiatric disorders - Other, specify)
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Psychosis (Psychosis)
Pulmonary Edema (Pulmonary edema)
Pulmonary Fibrosis (Pulmonary fibrosis)
Pulmonary Fistula (Pulmonary fistula)
Pulmonary Hypertension (Pulmonary
hypertension)
Pulmonary Valve Disorder (Pulmonary
valve disease)
Purpura (Purpura)
Pyramidal Tract Dysfunction (Pyramidal
tract syndrome)
Radiation-recall Dermatitis (Radiation
recall reaction (dermatologic))
Radiculitis (Radiculitis)
Acneiform Dermatitis (Rash acneiform)
Maculopapular Lesion (Rash maculo-
papular)
Papulopustular Rash (Rash pustular)
Rectal Anastomotic Leakage (Rectal
anastomotic leak)
Rectal Fistula (Rectal fistula)
Rectal Hemorrhage (Rectal hemorrhage)
Rectal Mucositis (Rectal mucositis)
Rectal Necrotic Lesion (Rectal necrosis)
Rectal Obstruction (Rectal obstruction)
Rectal Pain (Rectal pain)
Rectal Perforation (Rectal perforation)
Rectal Stenosis (Rectal stenosis)
Rectal Ulcer (Rectal ulcer)
Recurrent Laryngeal Nerve Paralysis
(Recurrent laryngeal nerve palsy)
Urinary Tract Disorder Other Specify
(Renal and urinary disorders - Other,
specify)
Renal Stone (Renal calculi)
Renal Colic (Renal colic)
Renal Hemorrhage (Renal hemorrhage)
Reproductive System And Breast
Disorder Class Other Specify
(Reproductive system and breast
disorders - Other, specify)
Respiratory Failure (Respiratory failure)
Respiratory And Thoracic Disorder Other
Specify (Respiratory, thoracic and
mediastinal disorders - Other, specify)
Restlessness (Restlessness)
Restrictive Cardiomyopathy (Restrictive
cardiomyopathy)
Retinal Detachment (Retinal
detachment)
Retinal Tear (Retinal tear)
Retinal Vascular Disorder (Retinal
vascular disorder)
Retinoic Acid Syndrome (Retinoic acid
syndrome)
Retinopathy (Retinopathy)
Retroperitoneal Hemorrhage
(Retroperitoneal hemorrhage)
Reversible Posterior
Leukoencephalopathy Syndrome
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(Reversible posterior
leukoencephalopathy syndrome)
Infectious Rhinitis (Rhinitis infective)
Right Ventricular Dysfunction (Right
ventricular dysfunction)
Salivary Duct Inflammation (Salivary duct
inflammation)
Salivary Gland Fistula (Salivary gland
fistula)
Salivary Gland Infection (Salivary gland
infection)
Scalp Pain (Scalp pain)
Sclera Disorder (Scleral disorder)
Scoliosis (Scoliosis)
Scrotal Infection (Scrotal infection)
Scrotal Pain (Scrotal pain)
Seizure (Seizure)
Septicemia (Sepsis)
Seroma (Seroma)
Serum Amylase Increased (Serum
amylase increased)
Serum Sickness (Serum sickness)
Sick Sinus Syndrome (Sick sinus
syndrome)
Sinus Bradycardia (Sinus bradycardia)
Paranasal Sinus Disorder (Sinus
disorder)
Sinus Pain (Sinus pain)
Sinus Tachycardia (Sinus tachycardia)
Sinusitis (Sinusitis)
Skin Disorder Other Specify (Skin and
subcutaneous tissue disorders - Other,
specify)
Skin Atrophy (Skin atrophy)
Skin Hyperpigmentation (Skin
hyperpigmentation)
Skin Hypopigmentation (Skin
hypopigmentation)
Skin Induration (Skin induration)
Skin Infection (Skin infection)
Skin Ulcer (Skin ulceration)
Sleep Apnea (Sleep apnea)
Small Intestinal Anastomotic Leakage
(Small intestinal anastomotic leak)
Small Intestinal Mucositis (Small
intestinal mucositis)
Small Intestinal Obstruction (Small
intestinal obstruction)
Small Intestinal Perforation (Small
intestinal perforation)
Small Intestinal Stenosis (Small intestinal
stenosis)
Small Intestinal Infection (Small intestine
infection)
Small Intestinal Ulcer (Small intestine
ulcer)
Sneezing (Sneezing)
Social Circumstances Other Specify
(Social circumstances - Other, specify)
Soft Tissue Infection (Soft tissue
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infection)
Lower Limb Soft Tissue Necrotic Lesion
(Soft tissue necrosis lower limb)
Upper Limb Soft Tissue Necrotic Lesion
(Soft tissue necrosis upper limb)
Somnolence (Somnolence)
Sore Throat (Sore throat)
Spasticity (Spasticity)
Spermatic Cord Anastomotic Leakage
(Spermatic cord anastomotic leak)
Spermatic Cord Hemorrhage (Spermatic
cord hemorrhage)
Spermatic Cord Obstruction (Spermatic
cord obstruction)
Vertebral Fracture (Spinal fracture)
Splenic Disorder (Spleen disorder)
Splenic Infection (Splenic infection)
Gastrointestinal Stoma Stenosis
(Stenosis of gastrointestinal stoma)
Stevens-johnson Syndrome (Stevens-
Johnson syndrome)
Stoma Site Infection (Stoma site
infection)
Stomach Pain (Stomach pain)
Stomal Ulcer (Stomal ulcer)
Stridor (Stridor)
Cerebrovascular Accident (Stroke)
Sudden Cardiac Death (Sudden death
NOS)
Suicidal Ideation (Suicidal ideation)
Suicide Attempt (Suicide attempt)
Superficial Soft Tissue Fibrosis
(Superficial soft tissue fibrosis)
Superficial Thrombophlebitis (Superficial
thrombophlebitis)
Superior Vena Cava Syndrome (Superior
vena cava syndrome)
Supraventricular Tachycardia
(Supraventricular tachycardia)
Intervention Or Procedure Other Specify
(Surgical and medical procedures -
Other, specify)
Syncope (Syncope)
Telangiectasia (Telangiectasia)
Testicular Disorder (Testicular disorder)
Testicular Hemorrhage (Testicular
hemorrhage)
Testicular Pain (Testicular pain)
Thromboembolism (Thromboembolic
event)
Thrombotic Thrombocytopenic Purpura
(Thrombotic thrombocytopenic purpura)
Tinnitus (Tinnitus)
Dental Developmental Disorder (Tooth
development disorder)
Tooth Discoloration (Tooth discoloration)
Tooth Infection (Tooth infection)
Toothache (Toothache)
Toxic Epidermal Necrolysis (Toxic
epidermal necrolysis)
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Tracheal Fistula (Tracheal fistula)
Tracheal Hemorrhage (Tracheal
hemorrhage)
Tracheal Mucositis (Tracheal mucositis)
Tracheal Obstruction (Tracheal
obstruction)
Tracheal Stenosis (Tracheal stenosis)
Tracheitis (Tracheitis)
Tracheostomy Site Bleeding
(Tracheostomy site bleeding)
Transient Ischemic Attack (Transient
ischemic attacks)
Therapy-related Malignant Neoplasm
(Treatment related secondary
malignancy)
Tremor (Tremor)
Tricuspid Valve Disorder (Tricuspid valve
disease)
Trigeminal Nerve Disorder (Trigeminal
nerve disorder)
Trismus (Trismus)
Tumor Lysis Syndrome (Tumor lysis
syndrome)
Tumor Pain (Tumor pain)
Typhlitis (Typhlitis)
Unequal Limb Length (Unequal limb
length)
Unintended Pregnancy (Unintended
pregnancy)
Upper Gastrointestinal Hemorrhage
(Upper gastrointestinal hemorrhage)
Upper Respiratory Tract Infection (Upper
respiratory infection)
Ureteric Anastomotic Leakage (Ureteric
anastomotic leak)
Urethral Anastomotic Leakage (Urethral
anastomotic leak)
Urethral Infection (Urethral infection)
Urinary Tract Fistula (Urinary fistula)
Urinary Frequency (Urinary frequency)
Urinary Incontinence (Urinary
incontinence)
Urinary Retention (Urinary retention)
Urinary Tract Infection (Urinary tract
infection)
Urinary Tract Obstruction (Urinary tract
obstruction)
Urinary Tract Pain (Urinary tract pain)
Urinary Urgency (Urinary urgency)
Urine Discoloration (Urine discoloration)
Urine Output Decreased (Urine output
decreased)
Urostomy Leakage (Urostomy leak)
Urostomy Obstruction (Urostomy
obstruction)
Urostomy Site Bleeding (Urostomy site
bleeding)
Urostomy Stenosis (Urostomy stenosis)
Urticaria (Urticaria)
Uterine Anastomotic Leakage (Uterine
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anastomotic leak)
Uterine Fistula (Uterine fistula)
Uterine Hemorrhage (Uterine
hemorrhage)
Endometritis (Uterine infection)
Uterine Obstruction (Uterine obstruction)
Uterine Pain (Uterine pain)
Uterine Perforation (Uterine perforation)
Uveitis (Uveitis)
Vaginal Anastomotic Leakage (Vaginal
anastomotic leak)
Vaginal Discharge (Vaginal discharge)
Vaginal Dryness (Vaginal dryness)
Vaginal Fistula (Vaginal fistula)
Vaginal Hemorrhage (Vaginal
hemorrhage)
Vaginitis (Vaginal infection)
Vaginitis (Vaginal inflammation)
Vaginal Obstruction (Vaginal obstruction)
Vaginal Pain (Vaginal pain)
Vaginal Perforation (Vaginal perforation)
Vaginal Stricture (Vaginal stricture)
Vaginismus (Vaginismus)
Vagus Nerve Disorder (Vagus nerve
disorder)
Vas Deferens Anastomotic Leakage (Vas
deferens anastomotic leak)
Vascular Access Complication (Vascular
access complication)
Vascular Disorder Other Specify
(Vascular disorders - Other, specify)
Vasculitis (Vasculitis)
Vasovagal Reaction (Vasovagal reaction)
Venous Injury (Venous injury)
Ventricular Arrhythmia (Ventricular
arrhythmia)
Ventricular Fibrillation (Ventricular
fibrillation)
Ventricular Tachycardia (Ventricular
tachycardia)
Vertigo (Vertigo)
Internal Ear Disorder (Vestibular
disorder)
Virilization (Virilization)
Visceral Artery Ischemia (Visceral
arterial ischemia)
Abnormal Vital Capacity (Vital capacity
abnormal)
Vitreous Hemorrhage (Vitreous
hemorrhage)
Voice Alternation (Voice alteration)
Vomiting (Vomiting)
Vulval Infection (Vulval infection)
Watering Eyes (Watering eyes)
Weight Gain (Weight gain)
Weight Loss (Weight loss)
Wheezing (Wheezing)
Leukopenia (White blood cell decreased)
Wolff-parkinson-white Syndrome (Wolff-
Parkinson-White Syndrome)
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Wound Complication (Wound
complication)
Wound Dehiscence (Wound dehiscence)
Wound Infection (Wound infection)
Wrist Fracture (Wrist fracture)
Grade
Absent Adverse Event (0)
Mild Adverse Event (1)
Moderate Adverse Event (2)
Severe Adverse Event (3)
Life Threatening Adverse Event (4)
Death Related To Adverse Event (5)
Other Aes
CTCAE Term
Abdominal Distention (Abdominal
distension)
Abdominal Infection (Abdominal
infection)
Abdominal Pain (Abdominal pain)
Abdominal Soft Tissue Necrotic Lesion
(Abdominal soft tissue necrosis)
Abducens Nerve Disorder (Abducens
nerve disorder)
Accessory Nerve Disorder (Accessory
nerve disorder)
Acidosis (Acidosis)
Vestibulocochlear Nerve Disorder
(Acoustic nerve disorder NOS)
Prolonged Partial Thromboplastin Time
(Activated partial thromboplastin time
prolonged)
Acute Coronary Syndrome (Acute
coronary syndrome)
Acute Renal Failure (Acute kidney injury)
Adrenal Gland Insufficiency (Adrenal
insufficiency)
Adult Respiratory Distress Syndrome
(Adult respiratory distress syndrome)
Agitation (Agitation)
Akathisia (Akathisia)
Alanine Aminotransferase Increased
(Alanine aminotransferase increased)
Alcohol Intolerance (Alcohol intolerance)
Blood Alkaline Phosphatase Increased
(Alkaline phosphatase increased)
Alkalosis (Alkalosis)
Hypersensitivity (Allergic reaction)
Allergic Rhinitis (Allergic rhinitis)
Alopecia (Alopecia)
Amnesia (Amnesia)
Anorectal Fistula (Anal fistula)
Anal Hemorrhage (Anal hemorrhage)
Anal Mucositis (Anal mucositis)
Anal Necrotic Lesion (Anal necrosis)
Anal Pain (Anal pain)
Anal Stenosis (Anal stenosis)
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Anal Ulcer (Anal ulcer)
Anaphylactic Shock (Anaphylaxis)
Anemia (Anemia)
Ankle Fracture (Ankle fracture)
Anorectal Infection (Anorectal infection)
Anorexia (Anorexia)
Anorgasmia (Anorgasmia)
Anxiety (Anxiety)
Aortic Injury (Aortic injury)
Aortic Valve Disorder (Aortic valve
disease)
Aphonia (Aphonia)
Apnea (Apnea)
Acute Appendicitis (Appendicitis)
Acute Perforated Appendicitis
(Appendicitis perforated)
Arachnoiditis (Arachnoiditis)
Arterial Injury (Arterial injury)
Arteritis (Arteritis infective)
Arthralgia (Arthralgia)
Arthritis (Arthritis)
Ascites (Ascites)
Aspartate Aminotransferase Increased
(Aspartate aminotransferase increased)
Aspiration (Aspiration)
Cardiac Arrest (Asystole)
Ataxia (Ataxia)
Atelectasis (Atelectasis)
Atrial Fibrillation (Atrial fibrillation)
Atrial Flutter (Atrial flutter)
Av Block Third Degree (Atrioventricular
block complete)
Av Block First Degree (Atrioventricular
block first degree)
Autoimmune Disease (Autoimmune
disorder)
Bone Necrosis (Avascular necrosis)
Azoospermia (Azoospermia)
Back Pain (Back pain)
Bile Duct Stenosis (Bile duct stenosis)
Biliary Anastomotic Leakage (Biliary
anastomotic leak)
Biliary Fistula (Biliary fistula)
Cholangitis (Biliary tract infection)
Bladder Anastomotic Leakage (Bladder
anastomotic leak)
Cystitis (Bladder infection)
Bladder Perforation (Bladder perforation)
Bladder Spasm (Bladder spasm)
Bloating (Bloating)
Hematopoietic And Lymphoid System
Disorder Other Specify (Blood and
lymphatic system disorders - Other,
specify)
Abnormal Blood Antidiuretic Hormone
(Blood antidiuretic hormone abnormal)
Elevated Bilirubin (Blood bilirubin
increased)
Blood Corticotrophin Decreased (Blood
corticotrophin decreased)
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Abnormal Blood Gonadotrophin (Blood
gonadotrophin abnormal)
Abnormal Blood Prolactin (Blood
prolactin abnormal)
Blurred Vision (Blurred vision)
Body Odor (Body odor)
Bone Infection (Bone infection)
Hypocellular Bone Marrow (Bone
marrow hypocellular)
Bone Pain (Bone pain)
Brachial Plexopathy (Brachial
plexopathy)
Breast Atrophy (Breast atrophy)
Mastitis (Breast infection)
Breast Pain (Breast pain)
Bronchial Fistula (Bronchial fistula)
Bronchitis (Bronchial infection)
Bronchial Obstruction (Bronchial
obstruction)
Bronchial Stricture (Bronchial stricture)
Bronchopleural Fistula (Bronchopleural
fistula)
Bronchial Hemorrhage
(Bronchopulmonary hemorrhage)
Bronchospasm (Bronchospasm)
Bruise (Bruising)
Bullous Dermatitis (Bullous dermatitis)
Burn (Burn)
Buttock Pain (Buttock pain)
Capillary Leak Syndrome Capillary Leak
Syndrome (Capillary leak syndrome)
Decreased Carbon Monoxide Diffusing
Capacity (Carbon monoxide diffusing
capacity decreased)
Cardiac Arrest (Cardiac arrest)
Heart Disorder Other Specify (Cardiac
disorders - Other, specify)
Blood Cardiac Troponin I Increased
(Cardiac troponin I increased)
Blood Cardiac Troponin T Increased
(Cardiac troponin T increased)
Cataract (Cataract)
Catheter-related Infection (Catheter
related infection)
Cd4 Lymphocytes Decreased (CD4
lymphocytes decreased)
Cecal Hemorrhage (Cecal hemorrhage)
Cecal Infection (Cecal infection)
Central Nervous System Necrotic Lesion
(Central nervous system necrosis)
Cerebrospinal Fluid Leakage
(Cerebrospinal fluid leakage)
Infectious Cervicitis (Cervicitis infection)
Cheilitis (Cheilitis)
Angina (Chest pain - cardiac)
Chest Wall Pain (Chest wall pain)
Chills (Chills)
Cholecystitis (Cholecystitis)
Hypercholesterolemia (Cholesterol high)
Chronic Kidney Disease (Chronic kidney
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disease)
Chylothorax (Chylothorax)
Cognitive Disturbance (Cognitive
disturbance)
Colitis (Colitis)
Colonic Fistula (Colonic fistula)
Colonic Hemorrhage (Colonic
hemorrhage)
Colonic Obstruction (Colonic obstruction)
Colonic Perforation (Colonic perforation)
Colonic Stenosis (Colonic stenosis)
Colonic Ulcer (Colonic ulcer)
Concentration Impairment
(Concentration impairment)
Heart Conduction Disorder (Conduction
disorder)
Confusion (Confusion)
Congenital, Familial And Genetic
Disorder Class Other Specify
(Congenital, familial and genetic
disorders - Other, specify)
Conjunctivitis (Conjunctivitis)
Acute Contagious Conjunctivitis
(Conjunctivitis infective)
Constipation (Constipation)
Constrictive Pericarditis (Constrictive
pericarditis)
Keratitis (Corneal infection)
Corneal Ulcer (Corneal ulcer)
Cough (Cough)
Creatine Phosphokinase Increased (CPK
increased)
Cranial Nerve Infection (Cranial nerve
infection)
Increased Creatinine (Creatinine
increased)
Cushingoid (Cushingoid)
Non-infectious Cystitis (Cystitis
noninfective)
Cytokine Release Syndrome (Cytokine
release syndrome)
Neonatal Death (Death neonatal)
Death (Death NOS)
Dehydration (Dehydration)
Delayed Orgasm (Delayed orgasm)
Delayed Puberty (Delayed puberty)
Delirium (Delirium)
Delusion (Delusions)
Caries (Dental caries)
Depressed Level Of Consciousness
(Depressed level of consciousness)
Depression (Depression)
Radiation-induced Dermatitis (Dermatitis
radiation)
Prosthesis-related Infection (Device
related infection)
Diarrhea (Diarrhea)
Disseminated Intravascular Coagulation
(Disseminated intravascular coagulation)
Dizziness (Dizziness)
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Dry Eye Syndrome (Dry eye)
Xerostomia (Dry mouth)
Dry Skin (Dry Skin)
Duodenal Fistula (Duodenal fistula)
Duodenal Hemorrhage (Duodenal
hemorrhage)
Duodenal Infection (Duodenal infection)
Duodenal Obstruction (Duodenal
obstruction)
Duodenal Perforation (Duodenal
perforation)
Duodenal Stenosis (Duodenal stenosis)
Duodenal Ulcer (Duodenal ulcer)
Dysarthria (Dysarthria)
Dysesthesia (Dysesthesia)
Dysgeusia (Dysgeusia)
Dysmenorrhea (Dysmenorrhea)
Dyspareunia (Dyspareunia)
Dyspepsia (Dyspepsia)
Dysphagia (Dysphagia)
Dysphasia (Dysphasia)
Dyspnea (Dyspnea)
Ear And Labyrinth Disorder Class Other
Specify (Ear and labyrinth disorders -
Other, specify)
Earache (Ear pain)
Cerebral Edema (Edema cerebral)
Face Edema (Edema face)
Edema Limbs (Edema limbs)
Edema Trunk (Edema trunk)
Ejaculation Disorder (Ejaculation
disorder)
Ejection Fraction Decreased (Ejection
fraction decreased)
Prolonged Qt Interval (Electrocardiogram
QT corrected interval prolonged)
Infectious Encephalitis (Encephalitis
infection)
Infectious Encephalomyelitis
(Encephalomyelitis infection)
Encephalopathy (Encephalopathy)
Infective Endocarditis (Endocarditis
infective)
Endocrine Disorder Other Specify
(Endocrine disorders - Other, specify)
Endophthalmitis (Endophthalmitis)
Enterocolitis (Enterocolitis)
Infectious Enterocolitis (Enterocolitis
infectious)
Enterovesical Fistula (Enterovesical
fistula)
Epistaxis (Epistaxis)
Impotence (Erectile dysfunction)
Erythema Multiforme (Erythema
multiforme)
Erythroderma (Erythroderma)
Esophageal Anastomotic Leakage
(Esophageal anastomotic leak)
Esophageal Fistula (Esophageal fistula)
Esophageal Hemorrhage (Esophageal
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hemorrhage)
Esophageal Infection (Esophageal
infection)
Esophageal Necrotic Lesion
(Esophageal necrosis)
Esophageal Obstruction (Esophageal
obstruction)
Esophageal Pain (Esophageal pain)
Perforation Of Esophagus (Esophageal
perforation)
Esophageal Stricture (Esophageal
stenosis)
Esophageal Ulcer (Esophageal ulcer)
Esophageal Varices Hemorrhage
(Esophageal varices hemorrhage)
Esophagitis (Esophagitis)
Euphoria (Euphoria)
Exostosis (Exostosis)
External Ear Inflammation (External ear
inflammation)
External Ear Pain (External ear pain)
Extraocular Muscle Paresis (Extraocular
muscle paresis)
Extrapyramidal Disorder (Extrapyramidal
disorder)
Eye Disorder Other Specify (Eye
disorders - Other, specify)
Eye Infection (Eye infection)
Eye Pain (Eye pain)
Eyelid Function Disorder (Eyelid function
disorder)
Facial Muscle Weakness (Facial muscle
weakness)
Facial Nerve Disorder (Facial nerve
disorder)
Facial Pain (Facial pain)
Fall (Fall)
Fallopian Tube Anastomotic Leakage
(Fallopian tube anastomotic leak)
Fallopian Tube Obstruction (Fallopian
tube obstruction)
Fallopian Tube Perforation (Fallopian
tube perforation)
Fallopian Tube Stenosis (Fallopian tube
stenosis)
Adipose Tissue Atrophy (Fat atrophy)
Fatigue (Fatigue)
Neutropenic Fever (Febrile neutropenia)
Fecal Incontinence (Fecal incontinence)
Female Genital Tract Fistula (Female
genital tract fistula)
Acquired Feminization (Feminization
acquired)
Intrauterine Fetal Death (Fetal death)
Fetal Growth Retardation (Fetal growth
retardation)
Fever (Fever)
Fibrinogen Decreased (Fibrinogen
decreased)
Deep Connective Tissue Fibrosis
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(Fibrosis deep connective tissue)
Flank Pain (Flank pain)
Flasher (Flashing lights)
Flatulence (Flatulence)
Floaters (Floaters)
Flu-like Symptoms (Flu like symptoms)
Flushing (Flushing)
Decreased Forced Expiratory Volume
(Forced expiratory volume decreased)
Fracture (Fracture)
Gait Disturbance (Gait disturbance)
Gallbladder Fistula (Gallbladder fistula)
Gallbladder Infection (Gallbladder
infection)
Gallbladder Necrotic Lesion (Gallbladder
necrosis)
Gallbladder Obstruction (Gallbladder
obstruction)
Gallbladder Pain (Gallbladder pain)
Gallbladder Perforation (Gallbladder
perforation)
Gastric Anastomotic Leakage (Gastric
anastomotic leak)
Gastric Fistula (Gastric fistula)
Gastric Hemorrhage (Gastric
hemorrhage)
Gastric Necrotic Lesion (Gastric
necrosis)
Gastric Perforation (Gastric perforation)
Gastric Stenosis (Gastric stenosis)
Gastric Ulcer (Gastric ulcer)
Gastritis (Gastritis)
Gastroesophageal Reflux Disease
(Gastroesophageal reflux disease)
Gastrointestinal System Anastomotic
Leakage (Gastrointestinal anastomotic
leak)
Gastrointestinal Disorder Other Specify
(Gastrointestinal disorders - Other,
specify)
Gastrointestinal Fistula (Gastrointestinal
fistula)
Gastrointestinal Pain (Gastrointestinal
pain)
Gastrointestinal Stoma Necrotic Lesion
(Gastrointestinal stoma necrosis)
Gastroparesis (Gastroparesis)
General Disorders And Administration
Site Conditions Class Other Specify
(General disorders and administration
site conditions - Other, specify)
Generalized Muscle Weakness
(Generalized muscle weakness)
Genital Edema (Genital edema)
Gamma-glutamyltransferase Increased
(GGT increased)
Gingival Pain (Gingival pain)
Glaucoma (Glaucoma)
Glossopharyngeal Nerve Disorder
(Glossopharyngeal nerve disorder)
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Glucose Intolerance (Glucose
intolerance)
Accelerated Growth (Growth
accelerated)
Abnormal Growth Hormone (Growth
hormone abnormal)
Growth Retardation (Growth
suppression)
Gum Infection (Gum infection)
Gynecomastia (Gynecomastia)
Hallucination (Hallucinations)
Haptoglobin Decreased (Haptoglobin
decreased)
Head Soft Tissue Necrotic Lesion (Head
soft tissue necrosis)
Headache (Headache)
Hearing Impairment (Hearing impaired)
Heart Failure (Heart failure)
Hematoma (Hematoma)
Hematosalpinx (Hematosalpinx)
Hematuria (Hematuria)
Hemoglobin Increased (Hemoglobin
increased)
Hemoglobinuria (Hemoglobinuria)
Hemolysis (Hemolysis)
Hemolytic Uremic Syndrome (Hemolytic
uremic syndrome)
Hemorrhoidal Hemorrhage
(Hemorrhoidal hemorrhage)
Hemorrhoid (Hemorrhoids)
Hepatic Failure (Hepatic failure)
Hepatic Hemorrhage (Hepatic
hemorrhage)
Hepatic Infection (Hepatic infection)
Hepatic Necrotic Lesion (Hepatic
necrosis)
Hepatic Pain (Hepatic pain)
Viral Hepatitis (Hepatitis viral)
Liver And Biliary Tract Disorder Other
Specify (Hepatobiliary disorders - Other,
specify)
Hiccough (Hiccups)
Hip Fracture (Hip fracture)
Hirsutism (Hirsutism)
Hoarseness (Hoarseness)
Hot Flashes (Hot flashes)
Hydrocephalus (Hydrocephalus)
Hypercalcemia (Hypercalcemia)
Hyperglycemia (Hyperglycemia)
Hyperhidrosis (Hyperhidrosis)
Hyperkalemia (Hyperkalemia)
Hypermagnesemia (Hypermagnesemia)
Hypernatremia (Hypernatremia)
Hyperparathyroidism
(Hyperparathyroidism)
Hypersomnia (Hypersomnia)
Hypertension (Hypertension)
Hyperthyroidism (Hyperthyroidism)
Hypertrichosis (Hypertrichosis)
Hypertriglyceridemia
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(Hypertriglyceridemia)
Hyperuricemia (Hyperuricemia)
Hypoalbuminemia (Hypoalbuminemia)
Hypocalcemia (Hypocalcemia)
Hypoglossal Nerve Disorder
(Hypoglossal nerve disorder)
Hypoglycemia (Hypoglycemia)
Hypohidrosis (Hypohidrosis)
Hypokalemia (Hypokalemia)
Hypomagnesemia (Hypomagnesemia)
Hyponatremia (Hyponatremia)
Hypoparathyroidism
(Hypoparathyroidism)
Hypophosphatemia (Hypophosphatemia)
Hypotension (Hypotension)
Hypothermia (Hypothermia)
Hypothyroidism (Hypothyroidism)
Hypoxia (Hypoxia)
Ileal Fistula (Ileal fistula)
Ileal Hemorrhage (Ileal hemorrhage)
Ileal Obstruction (Ileal obstruction)
Ileal Perforation (Ileal perforation)
Ileal Stenosis (Ileal stenosis)
Ileal Ulcer (Ileal ulcer)
Ileus (Ileus)
Immune System Disorder Other Specify
(Immune system disorders - Other,
specify)
Infection Other Specify (Infections and
infestations - Other, specify)
Infectious Myositis (Infective myositis)
Infusion-related Reaction (Infusion
related reaction)
Infusion Site Extravasation (Infusion site
extravasation)
Injection Site Reaction (Injection site
reaction)
Injury To Carotid Artery (Injury to carotid
artery)
Injury To Inferior Vena Cava (Injury to
inferior vena cava)
Injury To Jugular Vein (Injury to jugular
vein)
Injury To Superior Vena Cava (Injury to
superior vena cava)
Injury, Poisoning And Procedural
Complication Class Other Specify (Injury,
poisoning and procedural complications -
Other, specify)
Inr Increased (INR increased)
Insomnia (Insomnia)
Intestinal Stoma Leakage (Intestinal
stoma leak)
Intestinal Stoma Obstruction (Intestinal
stoma obstruction)
Intestinal Stoma Site Hemorrhage
(Intestinal stoma site bleeding)
Intra-abdominal Hemorrhage (Intra-
abdominal hemorrhage)
Intracranial Hemorrhage (Intracranial
29 / 41
Breast Cancer NCT00769379 Toxicity - NSABP PROTOCOL B-43
Worksheet for Reporting Adverse Events - 2675165v1.0
hemorrhage)
Intraoperative Arterial Injury
(Intraoperative arterial injury)
Intraoperative Breast Injury
(Intraoperative breast injury)
Intraoperative Cardiac Injury
(Intraoperative cardiac injury)
Intraoperative Ear Injury (Intraoperative
ear injury)
Intraoperative Endocrine Injury
(Intraoperative endocrine injury)
Intraoperative Gastrointestinal Injury
(Intraoperative gastrointestinal injury)
Intraoperative Head And Neck Injury
(Intraoperative head and neck injury)
Intraoperative Hemorrhage
(Intraoperative hemorrhage)
Intraoperative Hepatobiliary Injury
(Intraoperative hepatobiliary injury)
Intraoperative Musculoskeletal Injury
(Intraoperative musculoskeletal injury)
Intraoperative Neurological Injury
(Intraoperative neurological injury)
Intraoperative Ocular Injury
(Intraoperative ocular injury)
Intraoperative Renal Injury
(Intraoperative renal injury)
Intraoperative Reproductive System
Injury (Intraoperative reproductive tract
injury)
Intraoperative Respiratory Injury
(Intraoperative respiratory injury)
Intraoperative Skin Injury (Intraoperative
skin injury)
Intraoperative Splenic Injury
(Intraoperative splenic injury)
Intraoperative Urinary System Injury
(Intraoperative urinary injury)
Intraoperative Venous Injury
(Intraoperative venous injury)
Investigation Other Specify
(Investigations - Other, specify)
Iron Overload (Iron overload)
Irregular Menstruation (Irregular
menstruation)
Irritability (Irritability)
Cerebrovascular Ischemia (Ischemia
cerebrovascular)
Trochlear Nerve Disorder (IVth nerve
disorder)
Jejunal Fistula (Jejunal fistula)
Jejunal Hemorrhage (Jejunal
hemorrhage)
Jejunal Obstruction (Jejunal obstruction)
Jejunal Perforation (Jejunal perforation)
Jejunal Stenosis (Jejunal stenosis)
Jejunal Ulcer (Jejunal ulcer)
Joint Effusion (Joint effusion)
Joint Infection (Joint infection)
Joint Range Of Motion Decreased (Joint
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range of motion decreased)
Cervical Spine Joint Range Of Motion
Decreased (Joint range of motion
decreased cervical spine)
Lumbar Spine Joint Range Of Motion
Decreased (Joint range of motion
decreased lumbar spine)
Keratitis (Keratitis)
Kidney Anastomotic Leakage (Kidney
anastomotic leak)
Pyelonephritis (Kidney infection)
Kyphosis (Kyphosis)
Lactation Disorder (Lactation disorder)
Large Intestinal Anastomotic Leakage
(Large intestinal anastomotic leak)
Laryngeal Edema (Laryngeal edema)
Laryngeal Fistula (Laryngeal fistula)
Laryngeal Hemorrhage (Laryngeal
hemorrhage)
Laryngitis (Laryngeal inflammation)
Laryngeal Mucositis (Laryngeal
mucositis)
Laryngeal Obstruction (Laryngeal
obstruction)
Laryngeal Stenosis (Laryngeal stenosis)
Laryngitis (Laryngitis)
Laryngopharyngeal Dysesthesia
(Laryngopharyngeal dysesthesia)
Laryngospasm (Laryngospasm)
Left Ventricular Systolic Dysfunction (Left
ventricular systolic dysfunction)
Lethargy (Lethargy)
Chemotherapy-related Leukemia
(Leukemia secondary to oncology
chemotherapy)
Leukocytosis (Leukocytosis)
Leukoencephalopathy
(Leukoencephalopathy)
Decreased Libido (Libido decreased)
Increased Libido (Libido increased)
Lip Infection (Lip infection)
Lip Pain (Lip pain)
Lipase Increased (Lipase increased)
Lipohypertrophy (Lipohypertrophy)
Localized Edema (Localized edema)
Lordosis (Lordosis)
Lower Gastrointestinal Hemorrhage
(Lower gastrointestinal hemorrhage)
Infectious Lung Disorder (Lung infection)
Lymphadenitis (Lymph gland infection)
Lymph Leakage (Lymph leakage)
Lymph Node Pain (Lymph node pain)
Lymphedema (Lymphedema)
Lymphocele (Lymphocele)
Lymphopenia (Lymphocyte count
decreased)
Lymphocytosis (Lymphocyte count
increased)
Malabsorption Syndrome
(Malabsorption)
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Malaise (Malaise)
Mania (Mania)
Mediastinal Hemorrhage (Mediastinal
hemorrhage)
Mediastinitis (Mediastinal infection)
Memory Impairment (Memory
impairment)
Meningismus (Meningismus)
Meningitis (Meningitis)
Menopause (Menopause)
Menorrhagia (Menorrhagia)
Metabolism And Nutrition Disorder Class
Other Specify (Metabolism and nutrition
disorders - Other, specify)
Otitis Media (Middle ear inflammation)
Mitral Valve Disorder (Mitral valve
disease)
Av Block Second Degree Mobitz Type Ii
(Mobitz (type) II atrioventricular block)
Av Block Second Degree Mobitz Type I
(Mobitz type I)
Involuntary Movements (Movements
involuntary)
Mucosal Infection (Mucosal infection)
Stomatitis (Mucositis oral)
Multiple Organ Failure (Multi-organ
failure)
Muscle Weakness Left-sided (Muscle
weakness left-sided)
Muscle Weakness Lower Limb (Muscle
weakness lower limb)
Muscle Weakness Right-sided (Muscle
weakness right-sided)
Muscle Weakness Trunk (Muscle
weakness trunk)
Muscle Weakness Upper Limb (Muscle
weakness upper limb)
Connective And Soft Tissue Disorder
Other Specify (Musculoskeletal and
connective tissue disorder -  Other,
specify)
Musculoskeletal Deformity
(Musculoskeletal deformity)
Myalgia (Myalgia)
Myelitis (Myelitis)
Mds (Myelodysplastic syndrome)
Myocardial Infarction (Myocardial
infarction)
Myocarditis (Myocarditis)
Myositis (Myositis)
Nail Discoloration (Nail discoloration)
Nail Infection (Nail infection)
Nail Loss (Nail loss)
Nail Ridging (Nail ridging)
Nasal Congestion (Nasal congestion)
Nausea (Nausea)
Neck Edema (Neck edema)
Neck Pain (Neck pain)
Neck Soft Tissue Necrotic Lesion (Neck
soft tissue necrosis)
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Neoplasm Other Specify (Neoplasms
benign, malignant and unspecified (incl
cysts and polyps) - Other, specify)
Nervous System Disorder Other Specify
(Nervous system disorders - Other,
specify)
Neuralgia (Neuralgia)
Neutrophil Count Decreased (Neutrophil
count decreased)
Night Blindness (Night blindness)
Nipple Deformity (Nipple deformity)
Non-cardiac Chest Pain (Non-cardiac
chest pain)
Nystagmus (Nystagmus)
Obesity (Obesity)
Gastric Obstruction (Obstruction gastric)
Oculomotor Nerve Disorder (Oculomotor
nerve disorder)
Olfactory Nerve Disorder (Olfactory
nerve disorder)
Oligospermia (Oligospermia)
Optic Nerve Disorder (Optic nerve
disorder)
Oral Cavity Fistula (Oral cavity fistula)
Burning Mouth Syndrome (Oral
dysesthesia)
Oral Hemorrhage (Oral hemorrhage)
Oral Pain (Oral pain)
Osteonecrosis Of Jaw (Osteonecrosis of
jaw)
Osteoporosis (Osteoporosis)
External Ear Infection (Otitis externa)
Otitis Media (Otitis media)
Ovarian Hemorrhage (Ovarian
hemorrhage)
Ovarian Infection (Ovarian infection)
Ovarian Rupture (Ovarian rupture)
Ovulatory Pain (Ovulation pain)
Pain (Pain)
Pain In Extremity (Pain in extremity)
Skin Pain (Pain of skin)
Palmar-plantar Erythodysthesia (Palmar-
plantar erythrodysesthesia syndrome)
Palpitation (Palpitations)
Pancreatic Infection (Pancreas infection)
Pancreatic Anastomotic Leakage
(Pancreatic anastomotic leak)
Pancreatic Duct Stenosis (Pancreatic
duct stenosis)
Pancreatic Enzymes Decreased
(Pancreatic enzymes decreased)
Pancreatic Fistula (Pancreatic fistula)
Pancreatic Hemorrhage (Pancreatic
hemorrhage)
Pancreatic Necrotic Lesion (Pancreatic
necrosis)
Pancreatitis (Pancreatitis)
Papilledema (Papilledema)
Papulopustular Rash (Papulopustular
rash)
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Paresthesia (Paresthesia)
Paronychia (Paronychia)
Paroxysmal Atrial Tachycardia
(Paroxysmal atrial tachycardia)
Pelvic Floor Muscle Weakness (Pelvic
floor muscle weakness)
Pelvic Inflammatory Disease (Pelvic
infection)
Pelvic Pain (Pelvic pain)
Pelvic Soft Tissue Necrotic Lesion
(Pelvic soft tissue necrosis)
Penile Infection (Penile infection)
Penile Pain (Penile pain)
Bile Duct Perforation (Perforation bile
duct)
Pericardial Effusion (Pericardial effusion)
Cardiac Tamponade (Pericardial
tamponade)
Pericarditis (Pericarditis)
Perineal Pain (Perineal pain)
Periodontal Disorder (Periodontal
disease)
Periorbital Edema (Periorbital edema)
Periorbital Infection (Periorbital infection)
Peripheral Ischemia (Peripheral
ischemia)
Peripheral Motor Neuropathy (Peripheral
motor neuropathy)
Peripheral Nervous System Infectious
Disorder (Peripheral nerve infection)
Peripheral Sensory Neuropathy
(Peripheral sensory neuropathy)
Peritoneal Infection (Peritoneal infection)
Peritoneal Necrotic Lesion (Peritoneal
necrosis)
Personality Change (Personality change)
Phantom Pain (Phantom pain)
Pharyngeal Anastomotic Leakage
(Pharyngeal anastomotic leak)
Pharyngeal Fistula (Pharyngeal fistula)
Pharyngeal Hemorrhage (Pharyngeal
hemorrhage)
Pharyngeal Mucositis (Pharyngeal
mucositis)
Pharyngeal Necrotic Lesion (Pharyngeal
necrosis)
Pharyngeal Stenosis (Pharyngeal
stenosis)
Pharyngitis (Pharyngitis)
Pharyngolaryngeal Pain
(Pharyngolaryngeal pain)
Phlebitis (Phlebitis)
Infective Phlebitis (Phlebitis infective)
Photophobia (Photophobia)
Photosensitivity (Photosensitivity)
Thrombocytopenia (Platelet count
decreased)
Pleural Effusion (Pleural effusion)
Hemothorax (Pleural hemorrhage)
Pleural Infection (Pleural infection)
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Pleuritic Pain (Pleuritic pain)
Pneumonia (Pneumonitis)
Pneumothorax (Pneumothorax)
Portal Hypertension (Portal
Hypertension)
Portal Vein Thrombosis (Portal vein
thrombosis)
Post-nasal Drip (Postnasal drip)
Postoperative Bleeding (Postoperative
hemorrhage)
Thoracic Procedure Postoperative
Complication (Postoperative thoracic
procedure complication)
Precocious Puberty (Precocious
puberty)
Pregnancy, Puerperium And Perinatal
Condition Class Other Specify
(Pregnancy, puerperium and perinatal
conditions - Other, specify)
Premature Labor (Premature delivery)
Premature Menopause (Premature
menopause)
Presyncope (Presyncope)
Proctitis (Proctitis)
Productive Cough (Productive cough)
Intestinal Stoma Prolapse (Prolapse of
intestinal stoma)
Urostomy Prolapse (Prolapse of
urostomy)
Prostatic Infection (Prostate infection)
Prostatic Hemorrhage (Prostatic
hemorrhage)
Prostatic Obstruction (Prostatic
obstruction)
Prostatic Pain (Prostatic pain)
Proteinuria (Proteinuria)
Pruritus (Pruritus)
Psychiatric Disorder Other Specify
(Psychiatric disorders - Other, specify)
Psychosis (Psychosis)
Pulmonary Edema (Pulmonary edema)
Pulmonary Fibrosis (Pulmonary fibrosis)
Pulmonary Fistula (Pulmonary fistula)
Pulmonary Hypertension (Pulmonary
hypertension)
Pulmonary Valve Disorder (Pulmonary
valve disease)
Purpura (Purpura)
Pyramidal Tract Dysfunction (Pyramidal
tract syndrome)
Radiation-recall Dermatitis (Radiation
recall reaction (dermatologic))
Radiculitis (Radiculitis)
Acneiform Dermatitis (Rash acneiform)
Maculopapular Lesion (Rash maculo-
papular)
Papulopustular Rash (Rash pustular)
Rectal Anastomotic Leakage (Rectal
anastomotic leak)
Rectal Fistula (Rectal fistula)
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Rectal Hemorrhage (Rectal hemorrhage)
Rectal Mucositis (Rectal mucositis)
Rectal Necrotic Lesion (Rectal necrosis)
Rectal Obstruction (Rectal obstruction)
Rectal Pain (Rectal pain)
Rectal Perforation (Rectal perforation)
Rectal Stenosis (Rectal stenosis)
Rectal Ulcer (Rectal ulcer)
Recurrent Laryngeal Nerve Paralysis
(Recurrent laryngeal nerve palsy)
Urinary Tract Disorder Other Specify
(Renal and urinary disorders - Other,
specify)
Renal Stone (Renal calculi)
Renal Colic (Renal colic)
Renal Hemorrhage (Renal hemorrhage)
Reproductive System And Breast
Disorder Class Other Specify
(Reproductive system and breast
disorders - Other, specify)
Respiratory Failure (Respiratory failure)
Respiratory And Thoracic Disorder Other
Specify (Respiratory, thoracic and
mediastinal disorders - Other, specify)
Restlessness (Restlessness)
Restrictive Cardiomyopathy (Restrictive
cardiomyopathy)
Retinal Detachment (Retinal
detachment)
Retinal Tear (Retinal tear)
Retinal Vascular Disorder (Retinal
vascular disorder)
Retinoic Acid Syndrome (Retinoic acid
syndrome)
Retinopathy (Retinopathy)
Retroperitoneal Hemorrhage
(Retroperitoneal hemorrhage)
Reversible Posterior
Leukoencephalopathy Syndrome
(Reversible posterior
leukoencephalopathy syndrome)
Infectious Rhinitis (Rhinitis infective)
Right Ventricular Dysfunction (Right
ventricular dysfunction)
Salivary Duct Inflammation (Salivary duct
inflammation)
Salivary Gland Fistula (Salivary gland
fistula)
Salivary Gland Infection (Salivary gland
infection)
Scalp Pain (Scalp pain)
Sclera Disorder (Scleral disorder)
Scoliosis (Scoliosis)
Scrotal Infection (Scrotal infection)
Scrotal Pain (Scrotal pain)
Seizure (Seizure)
Septicemia (Sepsis)
Seroma (Seroma)
Serum Amylase Increased (Serum
amylase increased)
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Serum Sickness (Serum sickness)
Sick Sinus Syndrome (Sick sinus
syndrome)
Sinus Bradycardia (Sinus bradycardia)
Paranasal Sinus Disorder (Sinus
disorder)
Sinus Pain (Sinus pain)
Sinus Tachycardia (Sinus tachycardia)
Sinusitis (Sinusitis)
Skin Disorder Other Specify (Skin and
subcutaneous tissue disorders - Other,
specify)
Skin Atrophy (Skin atrophy)
Skin Hyperpigmentation (Skin
hyperpigmentation)
Skin Hypopigmentation (Skin
hypopigmentation)
Skin Induration (Skin induration)
Skin Infection (Skin infection)
Skin Ulcer (Skin ulceration)
Sleep Apnea (Sleep apnea)
Small Intestinal Anastomotic Leakage
(Small intestinal anastomotic leak)
Small Intestinal Mucositis (Small
intestinal mucositis)
Small Intestinal Obstruction (Small
intestinal obstruction)
Small Intestinal Perforation (Small
intestinal perforation)
Small Intestinal Stenosis (Small intestinal
stenosis)
Small Intestinal Infection (Small intestine
infection)
Small Intestinal Ulcer (Small intestine
ulcer)
Sneezing (Sneezing)
Social Circumstances Other Specify
(Social circumstances - Other, specify)
Soft Tissue Infection (Soft tissue
infection)
Lower Limb Soft Tissue Necrotic Lesion
(Soft tissue necrosis lower limb)
Upper Limb Soft Tissue Necrotic Lesion
(Soft tissue necrosis upper limb)
Somnolence (Somnolence)
Sore Throat (Sore throat)
Spasticity (Spasticity)
Spermatic Cord Anastomotic Leakage
(Spermatic cord anastomotic leak)
Spermatic Cord Hemorrhage (Spermatic
cord hemorrhage)
Spermatic Cord Obstruction (Spermatic
cord obstruction)
Vertebral Fracture (Spinal fracture)
Splenic Disorder (Spleen disorder)
Splenic Infection (Splenic infection)
Gastrointestinal Stoma Stenosis
(Stenosis of gastrointestinal stoma)
Stevens-johnson Syndrome (Stevens-
Johnson syndrome)
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Stoma Site Infection (Stoma site
infection)
Stomach Pain (Stomach pain)
Stomal Ulcer (Stomal ulcer)
Stridor (Stridor)
Cerebrovascular Accident (Stroke)
Sudden Cardiac Death (Sudden death
NOS)
Suicidal Ideation (Suicidal ideation)
Suicide Attempt (Suicide attempt)
Superficial Soft Tissue Fibrosis
(Superficial soft tissue fibrosis)
Superficial Thrombophlebitis (Superficial
thrombophlebitis)
Superior Vena Cava Syndrome (Superior
vena cava syndrome)
Supraventricular Tachycardia
(Supraventricular tachycardia)
Intervention Or Procedure Other Specify
(Surgical and medical procedures -
Other, specify)
Syncope (Syncope)
Telangiectasia (Telangiectasia)
Testicular Disorder (Testicular disorder)
Testicular Hemorrhage (Testicular
hemorrhage)
Testicular Pain (Testicular pain)
Thromboembolism (Thromboembolic
event)
Thrombotic Thrombocytopenic Purpura
(Thrombotic thrombocytopenic purpura)
Tinnitus (Tinnitus)
Dental Developmental Disorder (Tooth
development disorder)
Tooth Discoloration (Tooth discoloration)
Tooth Infection (Tooth infection)
Toothache (Toothache)
Toxic Epidermal Necrolysis (Toxic
epidermal necrolysis)
Tracheal Fistula (Tracheal fistula)
Tracheal Hemorrhage (Tracheal
hemorrhage)
Tracheal Mucositis (Tracheal mucositis)
Tracheal Obstruction (Tracheal
obstruction)
Tracheal Stenosis (Tracheal stenosis)
Tracheitis (Tracheitis)
Tracheostomy Site Bleeding
(Tracheostomy site bleeding)
Transient Ischemic Attack (Transient
ischemic attacks)
Therapy-related Malignant Neoplasm
(Treatment related secondary
malignancy)
Tremor (Tremor)
Tricuspid Valve Disorder (Tricuspid valve
disease)
Trigeminal Nerve Disorder (Trigeminal
nerve disorder)
Trismus (Trismus)
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Tumor Lysis Syndrome (Tumor lysis
syndrome)
Tumor Pain (Tumor pain)
Typhlitis (Typhlitis)
Unequal Limb Length (Unequal limb
length)
Unintended Pregnancy (Unintended
pregnancy)
Upper Gastrointestinal Hemorrhage
(Upper gastrointestinal hemorrhage)
Upper Respiratory Tract Infection (Upper
respiratory infection)
Ureteric Anastomotic Leakage (Ureteric
anastomotic leak)
Urethral Anastomotic Leakage (Urethral
anastomotic leak)
Urethral Infection (Urethral infection)
Urinary Tract Fistula (Urinary fistula)
Urinary Frequency (Urinary frequency)
Urinary Incontinence (Urinary
incontinence)
Urinary Retention (Urinary retention)
Urinary Tract Infection (Urinary tract
infection)
Urinary Tract Obstruction (Urinary tract
obstruction)
Urinary Tract Pain (Urinary tract pain)
Urinary Urgency (Urinary urgency)
Urine Discoloration (Urine discoloration)
Urine Output Decreased (Urine output
decreased)
Urostomy Leakage (Urostomy leak)
Urostomy Obstruction (Urostomy
obstruction)
Urostomy Site Bleeding (Urostomy site
bleeding)
Urostomy Stenosis (Urostomy stenosis)
Urticaria (Urticaria)
Uterine Anastomotic Leakage (Uterine
anastomotic leak)
Uterine Fistula (Uterine fistula)
Uterine Hemorrhage (Uterine
hemorrhage)
Endometritis (Uterine infection)
Uterine Obstruction (Uterine obstruction)
Uterine Pain (Uterine pain)
Uterine Perforation (Uterine perforation)
Uveitis (Uveitis)
Vaginal Anastomotic Leakage (Vaginal
anastomotic leak)
Vaginal Discharge (Vaginal discharge)
Vaginal Dryness (Vaginal dryness)
Vaginal Fistula (Vaginal fistula)
Vaginal Hemorrhage (Vaginal
hemorrhage)
Vaginitis (Vaginal infection)
Vaginitis (Vaginal inflammation)
Vaginal Obstruction (Vaginal obstruction)
Vaginal Pain (Vaginal pain)
Vaginal Perforation (Vaginal perforation)
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Vaginal Stricture (Vaginal stricture)
Vaginismus (Vaginismus)
Vagus Nerve Disorder (Vagus nerve
disorder)
Vas Deferens Anastomotic Leakage (Vas
deferens anastomotic leak)
Vascular Access Complication (Vascular
access complication)
Vascular Disorder Other Specify
(Vascular disorders - Other, specify)
Vasculitis (Vasculitis)
Vasovagal Reaction (Vasovagal reaction)
Venous Injury (Venous injury)
Ventricular Arrhythmia (Ventricular
arrhythmia)
Ventricular Fibrillation (Ventricular
fibrillation)
Ventricular Tachycardia (Ventricular
tachycardia)
Vertigo (Vertigo)
Internal Ear Disorder (Vestibular
disorder)
Virilization (Virilization)
Visceral Artery Ischemia (Visceral
arterial ischemia)
Abnormal Vital Capacity (Vital capacity
abnormal)
Vitreous Hemorrhage (Vitreous
hemorrhage)
Voice Alternation (Voice alteration)
Vomiting (Vomiting)
Vulval Infection (Vulval infection)
Watering Eyes (Watering eyes)
Weight Gain (Weight gain)
Weight Loss (Weight loss)
Wheezing (Wheezing)
Leukopenia (White blood cell decreased)
Wolff-parkinson-white Syndrome (Wolff-
Parkinson-White Syndrome)
Wound Complication (Wound
complication)
Wound Dehiscence (Wound dehiscence)
Wound Infection (Wound infection)
Wrist Fracture (Wrist fracture)
Grade
Absent Adverse Event (0)
Mild Adverse Event (1)
Moderate Adverse Event (2)
Severe Adverse Event (3)
Life Threatening Adverse Event (4)
Death Related To Adverse Event (5)
Comments
Comments
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Footer
Person Completing Form
Date Form Completed
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Cycle Dose Drug Form D2R Endometrial
Cancer (NCT00063999)
Cycle Dose Drug Form, GOG-0209, Form D2R
Combination Chemotherapy in Treating Patients With Stage
III, Stage IV, or Recurrent Endometrial Cancer
NCT00063999
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=B2402FA9-
5BBE-0F62-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/9090
Cycle Dose Drug Form D2R
Endometrial Cancer (NCT00063999)
Header Module
Date form originally completed (m d y)
Date form amended (m d y)
Person amending form, last name
Patient Name, Last
Patient Name, First
Patient Study ID
Participating Group Code
Participating Group Protocol Number
Patient Study ID, Participating Group
Person Completing Form, Last Name
Treatment Cycle And Modification
Cycle start date (Day 1 m d y)
Current cycle number
Cycle delayed
Yes
No
Number of days treatment course was delayed
Agent name (Drug)
1 / 3
Agent Dose level
Were there any dose modifications or
additions/omissions to protocol treatment (* 1
=Yes, planned, 2 =Yes, unplanned, 3 =No)
No (No)
Yes, Planned (i.e., The Treatment Was
Changed According To Protocol
Guidelines) (Yes, planned)
Yes, Unplanned (i.e., The Treatment
Change Was Not Part Of Protocol
Guidelines) (Yes, unplanned)
Total dose of agents/drugs for this cycle
Units
Patient weight (kg)
Body surface area (m2)
Performance status (Zubrod)
Fully Active, Able To Carry On All Pre-
disease Performance Without Restriction
(karnofsky 90 - 100) (ecog - 0
Asymptomatic) (0 = Fully active, able to
carry on all pre-disease performance
without restriction (Kamofsky 90-100))
Restricted In Physically Strenuous
Activity But Ambulatory (k70 - 80) (ecog -
1 Symptomatic - Fully Ambulatory) (1 =
Restricted in physically strenuous
activity, but ambulatory (K 70-80))
Ambulatory And Capable Of All Selfcare
But Unable To Carry Out Any Work
Activities (k 50 - 60) (ecog - 2
Symptomatic; In Bed , 50% Of The Day)
(2 = Ambulatory and capable of all
selfcare but unable to carry out any work
activities (K 50-60))
Capable Of Limited Selfcare, Confined
To Bed Or Chair More Than 50% Of
Waking Hours. (k 30 - 40) (ecog - 3
Symptomatic; In Bed > 50% Of The Day
But Not Bedridden) (3 = Capable of only
limited selfcare, confined to bed or chair
for more than 50% of waking hours (K
30-40))
Completely Disabled (k10 - 20) (ecog - 4
Bedridden) (4 = Completely disabled (K
10-20))
Assessment date (m d y Pretreatment
hematology and chemistry values Specify
individual dates when assessment dates differ)
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Hemoglobin
Peripheral hematocrit count (1000/L)
Peripheral WBC count (mm3)
Peripheral granulocytes count (mm3)
Peripheral platelet count (mm3)
BUN (mg/dl)
Creatinine (mg/dl)
Creatinine Clearance (ml/min)
SGOT (IU/ml)
Bilirubin (mg %)
Result of CA125 (IU/ml)
Other, specify (test) 1
Other, specify (value) 1
Other, specify (test) 2
Other, specify (value) 2
COMMENTS
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Endometrial Cancer NCT00063999 Treatment - Treatment
Completion Form, GOG-0209, Form Q0 - 2077501v3.0
Treatment Completion Form, GOG-0209, Form Q0
Combination Chemotherapy in Treating Patients With Stage
III, Stage IV, or Recurrent Endometrial Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=B2403C63-
772C-0F6D-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/9091
Treatment Completion Form, GOG-
0209, Form Q0
Header Module
Date form originally completed (m d y)
Date form amended (m d y)
Person amending form, last name
Patient Name, Last
Patient Name, First
Patient Study ID
Person Completing Form, Last Name
Treatment Schedule
Total number of cycles given
Last date (any modality of) protocol therapy was
given (m d y)
Off-treatment Reason
Reason treatment ended (check only one)
Death Of Patient Occurred After The
Patient Began Protocol Therapy (Death
after beginning protocol therapy)
Disease Progression, Relapse During
Active Treatment (Disease progression,
relapse during active treatment)
Other (Other)
Patient Off-treatment For Other
Complicating Disease (Patient off-
treatment for other complicating disease)
Patient Withdrawal Or Refusal For
Reason Other Than Toxicity (Patient
withdrawal or refusal for reason other
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than toxicity)
Routine Completion Of Planned Protocol
Treatment (Routine completion of
planned protocol treatment)
Adverse Event/side Effects/complications
(Toxicity/side effects/complications)
Toxicity/side effects/complications specify
Patient withdrawal or refusal for reason other
than toxicity specify
Complicating disease
Other (Off Treatment Reason)
Will patient receive further treatment?
Yes
No
Yes, specify (further treatment)
COMMENTS
Footer Module
Participating Group Code
Participating Group Protocol Number
Patient Study ID, Participating Group
Ccrr Module For Treatment Completion
Form, Gog-0209, Form Q0
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Colorectal Cancer NCT01167725 Eligibility - 8214:
Registration Information Form - 2829956v1.0
8214:  Registration Information Form
Standard Therapy With or Without Surgery and Mitomycin
C in Treating Patients With Advanced Limited Peritoneal
Dissemination of Colon Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=618EF2EF-
0953-F882-E040-BB89AD434C20
All rights reserved. Please visit https://medical-data-
models.org/forms/9093
8214:  Registration Information Form
Header Module
Institution CTEP ID
Institution Name
Protocol Number
Protocol Title
Registration Step
Treating Investigator
Credited Group or Organization
Investigator (Credit - Note: The Credit
Investigator must be affiliated with the credited
Group or Organization and will be accountable for
the patient and the site¿s responsibilities during
Audit.)
Comments (Enter case notes optional)
Demography Section
Date of Birth
Gender of a Person
Female Gender (Female)
Male Gender (Male)
Unknown (Unknown)
Ethnicity
A Person Of Mexican, Puerto Rican,
Cuban, Central Or South American Or
Other Spanish Culture Or Origin,
Regardless Of Race. (Hispanic or Latino)
A Person Not Meeting The Definition For
Hispanic Or Latino. (Not Hispanic or
Latino)
Not Provided Or Available (Not reported)
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Country of Residence
Zip code
Race
A Person Having Origins In Any Of The
Original Peoples Of North And South
America (including Central America),
And Who Maintains Tribal Affiliation Or
Community Attachment. (American
Indian or Alaska Native)
A Person Having Origins In Any Of The
Original Peoples Of The Far East,
Southeast Asia, Or The Indian
Subcontinent Including, For Example,
Cambodia, China, India, Japan, Korea,
Malaysia, Pakistan, The Philippine
Islands, Thailand, And Vietnam. (Asian)
A Person Having Origins In Any Of The
Black Racial Groups Of Africa. Terms
Such As "haitian" Or "negro" Can Be
Used In Addition To "black Or African
American." (Black or African American)
A Person Having Origins In Any Of The
Original Peoples Of Hawaii, Guam,
Samoa, Or Other Pacific Islands. (Native
Hawaiian or other Pacific Islander)
Not Provided Or Available (Not
Reported)
Could Not Be Determined Or Unsure
(Unknown)
A Person Having Origins In Any Of The
Original Peoples Of Europe, The Middle
East, Or North Africa. (White)
Method of Payment
Medicaid (Medicaid)
Medicaid And Medicare (Medicaid and
Medicare)
Medicare (Medicare)
Medicare And Private Insurance
(Medicare and Private Insurance)
Military Or Veterans Sponsored Nos
(Military or Veterans Sponsored, Not
Otherwise Specified (NOS))
Military Sponsored (including Champus
& Tricare) (Military Sponsored (including
CHAMPUS & TRICARE))
No Means Of Payment (no Insurance)
(No means of payment (no insurance))
Other (Other)
Private Insurance (Private Insurance)
Self Pay (no Insurance) (Self Pay (No
Insurance))
Unknown (Unknown)
Veterans Sponsored (Veterans
Sponsored)
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General Information
Pt ID#
Last
First
Middle
Email
Date Informed Consent Signed
Was HIPAA Authorization included in Study
Informed Consent
Yes
No
HIPAA Authorization Date
Eligibility Checklist
Mode of presentation of peritoneal surface
dissemination of colon adenocarcinoma
Metachronous (Metachronous)
Synchronous (Synchronous)
ECOG Performance Status
Fully Active, Able To Carry On All Pre-
disease Performance Without
Restriction. (0)
Restricted In Physically Strenuous
Activity But Ambulatory And Able To
Carry Out Work Of A Light Or Sedentary
Nature, E.g., Light Housework, Office
Work. (1)
Ability to measure peritoneal surface disease
Measurable: Peritoneal Surface Disease
Apparent On Cross Sectional Imaging
(Measurable: peritoneal surface disease
apparent on cross sectional imaging)
Non-measurable: Peritoneal Surface
Disease Unapparent On Cross Sectional
Imaging (Non-measurable: peritoneal
surface disease unapparent on cross
sectional imaging)
Planned chemotherapy
5-fu/lv-capecitabine Alone (5-FU/LV-
capecitabine alone)
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Irinotecan-based Therapy (Irinotecan-
based therapy)
Oxaliplatin Based Therapy (Oxaliplatin
based therapy)
Planned biologic therapy
Bevacizumab (Bevacizumab)
Cetuximab (Cetuximab)
No Biologic Therapy (No biologic
therapy)
Prior first-line therapy for advanced disease
Chemo Naive (Chemo Naive)
Prior First-line Therapy (Prior First-Line
Therapy)
Eligibility Criteria
Age >= 18 years
Yes
No
Capable of providing informed consent
Yes
No
The patient must have newly diagnosed,
previously untreated, histopathologically or
cytologically confirmed colon (not appendiceal or
rectal) adenocarcinoma (not signet ring cell type)
with synchronous or metachronous document
limited peritoneal disease dissemination
Yes
No
Peritoneal Cancer Index (PCI) of 20 or less
determined by helical CT scan +/- staging
laparoscopy
Yes
No
PCI score
No parenchymal hepatic metastases
Yes
No
No evidence of clinical (jaundice), biochemical
(abnormally elevated serum bilirubin and/or
alkaline phosphatase) or radiological (ultrasound,
CT, or MR) biliary obstruction
Yes
No
No evidence of symptomatic malignant ascites
requiring palliative paracentesis
Yes
No
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Small volume of disease in the gastro-hepatic
ligament defined by a <5 cm mass in the
epigastric region on cross-sectional imaging
Yes
No
No cross sectional imaging findings indicative of
multi-segmental (>1 site) small bowel obstruction,
or small bowel loops matted together, or gross
disease of the small bowel mesentery
characterized by distortion, thickening or loss of
mesenteric vascular clarity
Yes
No
No clinical or radiological evidence of
hematogenous or distant nodal (retroperitoneal,
pelvic, mediastinal, peri-portal or peri-aortic)
metastasis
Yes
No
ECOG (Zubrod) performance status of 1 or less
(Zubrod)
Yes
No
Absolute neutrophil count (ANC) >1200/mm3,
white blood cell count (WBC) >4000/mm3 and
platelet count >150,000/mm3
Yes
No
ANC
WBC
Platelet count
An international normalized ratio (INR) <= 1.5
(patients who are therapeutically anti-coagulated
for unrelated medical conditions such as atrial
fibrillation and whose anti-thrombotic treatment
can be withheld for operation will be eligible)
Yes
No
INR
Adequate hepatic function must be met as
evidenced by total serum bilirubin <= 1.5 mg/dL
(patients with total bilirubin >1.5 mg/dL eligible
only with Gilbert's syndrome); alkaline
phosphatase <2.5 times the upper limit of normal;
and/or, SGOT (AST) <1.5 times upper limit of
normal [alkaline phosphatase and SGOT (AST)
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cannot both exceed the upper limit of normal]
Yes
No
Is total bilirubin >1.5 mg/dL due to Gilbert's
syndrome?
Yes
No
Total Bilirubin
Alkaline phosphatase and AST cannot both
exceed the upper limit of normal; select the test
that does not exceed the upper limit of normal
(check one)
Alkaline Phosphatase (Alkaline
Phosphatase)
Both Alkaline Phosphatase And Sgot
(ast) (Both Alkaline Phosphatase and
SGOT (AST))
Sgot (ast) (SGOT (AST))
Alkaline Phosphatase
Alkaline Phosphatase ULN
SGOT (AST)
SGOT (AST) ULN
Serum renal functional parameters, BUN and
creatinine are within normal limits
Yes
No
BUN
BUN LNL
BUN ULN
Creatinine
Creatinine LLN
Creatinine ULN
Satisfactory cardiopulmonary function (no history
of severe congestive heart failure or severe
pulmonary disease, as indicated by clinically
acceptable risks to undergo major abdominal-
cytoreductive surgery).
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Yes
No
No clinical history of acute myocardial infarction
within six months of registration  Patients who are
status post revascularization procedures with
satisfactory cardiac function are eligible
Yes
No
No significant history of a medical problem or co-
morbidity that would preclude the patient from
undergoing a major abdominal operation such as
a history of severe congestive heart failure or
active ischemic heart disease
Yes
No
No concurrent second malignancy requiring
systemic therapy
Yes
No
Non-pregnant and non-lactating.  Women of
reproductive age must be willing to use
contraception during study therapy.  If not a
woman of reproductive age (or male) (check NA)
N/a (N/A)
No (No)
Yes (Yes)
No psychiatric or addictive disorders or other
conditions that would preclude the patient from
meeting the study requirements
Yes
No
No prior second-line systemic treatment for
metastatic colon adenocarcinoma. Patients who
received prior adjuvant therapy for colon
adenocarcinoma and/or prior first-line systemic
therapy for metastatic colon adenocarcinoma are
eligible
Yes
No
Instructions
Patient has given permission to complete the
Quality of Life questionnaires at the time points
indicated
Yes
No
Your tissue, from surgery and intra-peritoneal
chemotherapy (HIPEC), may be collected and
used for the research study
Yes
No
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Your blood may be collected and used for the
research study
Yes
No
Your tissue samples may be kept by the USMCI
Biospecimen Network for use in future research
to learn about, prevent, detect, treat cancer
Yes
No
Your tissue samples may be used for research
about other diseases
Yes
No
Your blood samples may be kept by the USMCI
Biospecimen Network for use in future research
to learn about, prevent, detect, treat cancer
Yes
No
Your blood samples may be used for research
about other diseases
Yes
No
Your study doctor (or someone he or she
chooses) may contact you in the future to ask you
to take part in more research
Yes
No
Randomization
Randomization
Crs/hipec & System Therapy
(CRS/HIPEC & System Therapy)
Systemic Therapy (Systemic Therapy)
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Cervical Cancer NCT01101451 Pre-Study - GOG-0263:
Fast Fact Sheet for Protocol 0263 (Cervix) - 3206071v1.0
GOG-0263: Fast Fact Sheet for Protocol 0263 (Cervix)
Radiation Therapy With or Without Chemotherapy in
Patients With Stage I or Stage II Cervical Cancer Who
Previously Underwent Surgery
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=9F0539D1-
8FD7-03D5-E040-BB89AD4378BD
All rights reserved. Please visit https://medical-data-
models.org/forms/9094
GOG-0263: Fast Fact Sheet for
Protocol 0263 (Cervix)
Tracking Information
GOG Institution Code
GOG Affiliate Code
Previous GOG #
Treating physician
Other Physician
Patient Hospital No.
Date of Birth
Patient Last Name
Patient First Name
Patient Middle Name
Header
Did the patient sign an approved informed
consent
Yes
No
Has HIPAA authorization been obtained
Exempt - Non-usa Participant (Exempt -
non-USA participant)
Yes: C49488 (Yes)
Is the patient age 18 years or older
Yes
No
Does the patient have pathologically proven
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primary cervical cancer I-IIA with squamous cell
carcinoma, adenosquamous carcinoma or
adenocarcinoma initially treated with a standard
radical hysterectomy with pelvic
lymphadenectomy?
Yes
No
Treating radiation oncologist
Stage
Stage Ia (IA)
Stage Ia1 (IA1)
Stage Ia2 (IA2)
Stage Ib1 (IB1)
Stage Ib2 (IB2)
Stage Iia1 (IIA1)
Stage Iia2 (IIA2)
What is the cell type?
Adenocarcinoma (Adenocarcinoma)
Adenosquamous Carcinoma
(Adenosquamous Carcinoma)
Squamous Cell Carcinoma (Squamous
Cell Carcinoma)
Date primary confirmed histologically
What was the grade of the primary tumor
Grade 1-well Differentiated (1)
Grade 2-moderately Differentiated (2)
Grade 3-poorly Differentiated (3)
Not Graded (Not Graded)
Performance Status
Fully Active, Able To Carry On All Pre-
disease Performance Without
Restriction. (0)
Restricted In Physically Strenuous
Activity But Ambulatory And Able To
Carry Out Work Of A Light Or Sedentary
Nature, E.g., Light Housework, Office
Work. (1)
Ambulatory And Capable Of All Selfcare
But Unable To Carry Out Any Work
Activities. Up And About More Than 50%
Of Waking Hours. (2)
Surgery Date
Please select the option which best describes the
patient's disease characteristics:
Negative Capillary-lymphatic Space
Involvement, Deep Third Penetration,
Clinical Tumor >= 4 Cm (Negative
capillary-lymphatic space involvement,
deep third penetration, Clinical tumor >=
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4 cm)
Negative Capillary-lymphatic Space
Involvement, Middle Third Penetration,
Clinical Tumor >= 4 Cm (Negative
capillary-lymphatic space involvement,
Middle third penetration, Clinical tumor
>= 4 cm)
Positive Capillary-lymphovascular Space
Involvement And Deep Third Penetration
(Positive capillary-lymphovascular space
involvement and deep third penetration)
Positive Capillary-lymphovascular Space
Involvement, Middle Third Penetration,
Clinical Tumor >= 2 Cm (Positive
capillary-lymphovascular space
involvement, Middle third penetration,
clinical tumor >= 2 cm)
Positive Capillary-lymphovascular Space
Involvement, Superficial Third
Penetration, Clinical Tumor >= 5 Cm
(Positive capillary-lymphovascular space
involvement, Superficial third
penetration, clinical tumor >= 5 cm)
Will the patient receive standard 4-field External
Beam Radiotherapy or Intensity Modulated
Radiation Therapy (IMRT)?
Intensity-modulated Radiotherapy
(Intensity Modulated Radiation Therapy)
Standard 4-field External Beam
Radiotherapy (Standard 4-field External
Beam Radiotherapy)
If IMRT is planned, has the treating Institution
been credentialed for IMRT by the Radiological
Physics Center (RPC) at M.D. Anderson Cancer
Center?
Not Applicable (Not Applicable)
Yes (Yes)
Date of Results (if more than one, enter earliest:)
ANC (must be 1,500/mcl or greater)
Platelets (must be 100,000/mcl or greater)
Is the Serum Creatinine less than or equal to
ULN
Yes
No
If no, is calculated creatinine clearance greater
than 60 mL/min?
No (No)
Not Applicable (Not Applicable)
Yes (Yes)
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Is the bilirubin less than or equal to 1.5 x ULN
Yes
No
Are SGOT and Alkaline Phosphatase less than or
equal to 3 X institutional upper limits of normal?
Yes
No
Has the patient met the pre-entry requirements
as specified in section 7.0
Yes
No
Will the patient have the following parameters
measured within 14 days prior to initiating
protocol therapy (CBC, Differential, Platelets,
Bilirubin, SGOT, Alkaline Phosphatase and
Creatinine)
Yes
No
Will the patient have the following parameters
measured within 28 days prior to initiating
protocol therapy (Physical Exam, Pelvic Exam
and Chest X-Ray)
Yes
No
Does the patient have tumor in the parametria,
pelvic lymph nodes or any other extra uterine site
or with positive surgical margins?
Yes
No
Does the patient have septicemia or severe
infection?
Yes
No
Does the patient have intestinal obstruction or GI
bleeding?
Yes
No
Does that patient have a post-operative fistula?
Yes
No
Has the patient received prior
chemotherapy/radiation therapy treatment?
Yes
No
Are there circumstances that will not permit
completion of study therapy or the required
follow-up
Yes
No
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Does the patient have any renal abnormalities
that would require modification of radiation fields?
Yes
No
Does the patient have a history of the presence
of other invasive malignancies, other than non-
melanoma skin cancer, within the past 5 years?
Yes
No
Has the patient had previous cancer treatment
which contraindicates this protocol therapy
Yes
No
Anticipated date treatment will start
Comments
Provide comments about this Fast Fact Sheet
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Eligibility - ELIGIBILITY CHECKLIST -
2411490v1.0
Eligibility form for C3D 3.12 Adopters
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=0175F239-
AE1E-6771-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/9095
ELIGIBILITY CHECKLIST
Eligibility
Checklist Number
Effective Date
Waiver Number
Question Display Sequence
Eligibility Criteria Text
Eligibility Criteria Indicator
Not Applicable (N/A)
No (No)
Yes (Yes)
Eligibility (exclusion)
Question Display Sequence
Patient Eligibility Indicator
No (No)
Unknown (Unknown)
Yes (Yes)
Eligibility Criteria Text
Eligibility Waiver Reason
Eligibility Criteria Indicator
Not Applicable (N/A)
No (No)
Yes (Yes)
Comments
Note Date
Research Comments Text
Header Module
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NCCTG Study No.
Central Lab ID Number
Patient Initials
Institution Number
Institution
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Pathology - Leukemia Pathology Form -
Cytogenetics - 2019350v3.0
Leukemia Pathology Form - Cytogenetics
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=1B4D83AE-
8665-6A50-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/9096
Leukemia Pathology Form -
Cytogenetics
Crf Header
Coordinating Group Protocol No.
Coordinating Group Code
Protocol Title
Patient Study ID
Institution/Affiliate
Other Patient ID
Participating Group Code
Patient Initials
Leukemia/mds: Form Administration
Person Completing Form
Are data amended (If data are amended, please
circle in red when using paper form)
Yes
No
Pathology: Cytogenetic Assessment
Patient Gender
Female (FEMALE)
Male (MALE)
Date of Initial Pathologic Diagnosis (mm dd yyyy
enter test date for first diagnosis of leukemia)
Date Specimen collected (s mm dd yyyy)
Date of Receipt of Specimens ( mm dd yyyy)
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Source of Cells used for Analysis
Bone Biopsy (Bone biopsy)
Bone Marrow (Bone marrow)
Cerebrospinal Fluid (Cerebrospinal fluid)
Lymph Node (Lymph node)
Other Specify (Other)
Peripheral Blood (Peripheral blood)
Peritoneal Fluid (Peritoneal fluid)
Pleural Fluid (Pleural fluid)
Soft Tissue Mass (Soft tissue mass)
Other specify
Specimen Condition
Damaged Or Unusable (Damaged or
unusable)
No Specimen Received (No specimen
received)
Usable (Usable)
Was cytogenetic analysis successful?
(Cytogenetic Results Note: Repeat this module
for each processing method and banding method
used for analysis.)
Yes
No
Reason(s) (If unsuccessful,)
Inadequate Banding (Inadequate
banding)
Other (Other)
Poor Sample (Poor sample)
Too Few Dividing Cells (Too few dividing
cells)
Other specify
Culture Method and Duration
Mitogen
No (not Used) (No (not used))
Yes (Yes)
Specify Type
Method Used for Banding
Gtg (GTG)
Gtw (GTW)
Other Specify (Other)
Qfq (QFQ)
Other specify
No. of Normal Cells Obtained (Cell Karyotype
Descriptions)
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No. of Clonal Cells Obtained (add more lines as
needed)
No. of Abnormal Nonclonal Cells Obtained (add
more lines as needed)
Complete ISCN Karyotype Description (2005)
Complete ISCN Karyotype Description (2005)
Complete ISCN Karyotype Description (2005)
Banding Level, based on Chromosome 10
Were FISH studies performed (Fluorescence in
Situ Hybridization FISH)
Yes
No
FISH probe(s) specify (If yes,)
Total Number of Interphase Nuclei (Results of
Interphase and Metaphase FISH)
Total Number of Abnormal Interphases
Total Number of Metaphases
Total Number of Abnormal Metaphases
Other specify
Result of FISH
Indeterminate (Indeterminate)
Negative (Negative)
Positive (Positive)
Specific Abnormalities Detected by FISH
Aneuploidy (Aneuploidy)
Specific Abnormalities Detected by FISH
Aneuploidy (Aneuploidy)
Result of FISH for Aneuploidy
Gain (Gain)
Indeterminate (Indeterminate)
Loss (Loss)
Negative (Negative)
Specify Probes ()
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FISH Lab Normal Range for Losses/Interphase
FISH Lab Normal Range for Gains/Interphase
FISH Lab Normal Range for Rearrangement
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Leukemia NCT00651261 Registration - CALGB: 10603 Registration
Worksheet For Non-North American Sites - 2945236v1.0
CALGB: 10603 Registration Worksheet For Non-North
American Sites
Daunorubicin, Cytarabine, and Midostaurin in Treating
Patients With Newly Diagnosed Acute Myeloid Leukemia
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=7456F79A-
F2F6-BFB6-E040-BB89AD436544
All rights reserved. Please visit https://medical-data-
models.org/forms/9098
CALGB: 10603 Registration
Worksheet For Non-North American
Sites
Header Module
Lead Institution
CALGB Patient ID (Assigned)
Institution/Affiliate
Physician of Record
Participating Group (Country name for
International Sites)
Protocol Administration
IRB Approval Date (MM DD YYYY)
Date Informed Consent Signed (MM DD YYYY)
Projected Treatment Begin Date (MM DD YYYY)
HIPAA Authorization Date (MM DD YYYY)
Institution contact
Phone
Fax
Patient Demographics/pre-treatment
Characteristics
Patient Initials (Last, First Middle)
Date of Birth
1 / 4
Patient Social Security Number
Patient Hospital No.
Gender
Female (FEMALE)
Male (MALE)
Patient Demographics/pre-treatment
Characteristics2
Performance Status (ECOG/Zubrod scale)
Fully Active, Able To Carry On All Pre-
disease Performance Without
Restriction. (0)
Restricted In Physically Strenuous
Activity But Ambulatory And Able To
Carry Out Work Of A Light Or Sedentary
Nature, E.g., Light Housework, Office
Work. (1)
Ambulatory And Capable Of All Selfcare
But Unable To Carry Out Any Work
Activities. Up And About More Than 50%
Of Waking Hours. (2)
Capable Of Only Limited Selfcare,
Confined To Bed Or Chair More Than
50% Of Waking Hours. (3)
Completely Disabled. Cannot Carry On
Any Selfcare. Totally Confined To Bed Or
Chair. (4)
Dead (5)
Height (cm)
Weight (kg)
BSA (m^2)
Disease (AML)
Patient Postal Code
Country of Residence (If not USA)
Method of Payment (USA only Mark one)
Medicaid (Medicaid)
Medicaid And Medicare (Medicaid and
Medicare)
Medicare (Medicare)
Medicare And Private Insurance
(Medicare and Private Insurance)
Military Sponsored (including Champus
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& Tricare) (Military Sponsored (including
CHAMPUS & TRICARE))
No Means Of Payment (no Insurance)
(No means of payment (no insurance))
Other (Other)
Private Insurance (Private Insurance)
Self Pay (no Insurance) (Self Pay (No
Insurance))
Unknown (Unknown)
Veterans Sponsored (Veterans
Sponsored)
Certification Of Eligibility And Protocol
Design
In the opinion of the investigator, is the patient
eligible?
Yes
No
Protocol Design
Stratification factors
Flt3 Tkd (no Itd) (FLT3 TKD (No ITD))
Itd Allelic Ratio < 0.7 (with Or Without
Flt3 Tkd) (ITD Allelic ratio < 0.7 (with or
without FLT3 TKD))
Itd Allelic Ratio >= 0.7 (with Or Without
Flt3 Tkd) (ITD Allelic ratio >= 0.7 (with or
without FLT3 TKD))
Randomization Number/Kit Number
Initial Patient Consent For Specimen Use
Patient's Initial Consent given for specimen use
for research on the patient's cancer
Yes
No
Patient's Initial Consent given for specimen kept
for future use in research to learn about, prevent,
or treat cancer
Yes
No
Patient's Initial Consent given for tissue specimen
use for research unrelated to the patient's
cancer?
Yes
No
My doctor or someone from CALGB may contact
me in the future to ask me to take part in more
research
Yes
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No
My doctor or someone from CALGB may contact
me in the future to ask me to take part in more
research
Yes
No
Registration Information
CALGB Patient ID (Assigned)
Registration Date (MM DD YYYY)
Participating Group Patient ID (Assigned)
Registrar's Signature
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Fallopian Tube Cancer NCT01081262 Eligibility - GOG-0241: Fast
Fact Sheet for Protocol 0241 (Ovary, Fallopian Tube) - 3128347v1.0
GOG-0241: Fast Fact Sheet for Protocol 0241 (Ovary,
Fallopian Tube)
Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine,
With or Without Bevacizumab, as First-Line Therapy in
Treating Patients With Newly Diagnosed Stage II, Stage III,
Stage IV, or Recurrent Stage I Epithelial Ovarian Cancer or
Fallopian Tube Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=8DA7C30C-
FD52-1F06-E040-BB89AD430C14
All rights reserved. Please visit https://medical-data-
models.org/forms/9099
GOG-0241: Fast Fact Sheet for
Protocol 0241 (Ovary, Fallopian
Tube)
Tracking Information
GOG Institution Code
GOG Affiliate Code
Previous GOG #
Treating physician
Other Physician
Patient Hospital No.
Date of Birth
Patient Name, Last
Patient Name, First
Patient Name, Middle
Patient Social Security Number
Patient Zip Code
Country
Race
A Person Having Origins In Any Of The
Original Peoples Of North And South
America (including Central America),
And Who Maintains Tribal Affiliation Or
Community Attachment. (American
Indian or Alaska Native)
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A Person Having Origins In Any Of The
Original Peoples Of The Far East,
Southeast Asia, Or The Indian
Subcontinent Including, For Example,
Cambodia, China, India, Japan, Korea,
Malaysia, Pakistan, The Philippine
Islands, Thailand, And Vietnam. (Asian)
A Person Having Origins In Any Of The
Black Racial Groups Of Africa. Terms
Such As "haitian" Or "negro" Can Be
Used In Addition To "black Or African
American." (Black or African American)
Could Not Be Determined Or Unsure
(Unknown)
A Person Having Origins In Any Of The
Original Peoples Of Europe, The Middle
East, Or North Africa. (White)
Ethnicity
A Person Of Mexican, Puerto Rican,
Cuban, Central Or South American Or
Other Spanish Culture Or Origin,
Regardless Of Race. (Hispanic or Latino)
A Person Not Meeting The Definition For
Hispanic Or Latino. (Not Hispanic or
Latino)
Could Not Be Determined Or Unsure
(Unknown)
Method of Payment
Medicaid (Medicaid)
Medicaid And Medicare (Medicaid and
Medicare)
Medicare (Medicare)
Medicare And Private Insurance
(Medicare and Private Insurance)
Military Or Veterans Sponsored Nos
(Military or Veterans Sponsored, Not
Otherwise Specified (NOS))
Military Sponsored (including Champus
& Tricare) (Military Sponsored (including
CHAMPUS & TRICARE))
No Means Of Payment (no Insurance)
(No means of payment (no insurance))
Other (Other)
Private Insurance (Private Insurance)
Self Pay (no Insurance) (Self Pay (No
Insurance))
Unknown (Unknown)
Veterans Sponsored (Veterans
Sponsored)
Header
Did the patient sign an approved informed
consent
Yes
No
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Has HIPAA authorization been obtained?
Yes
No
Does the patient have a histologic diagnosis of
mucinous adenocarcinoma of the ovary or
Fallopian tube
Yes
No
What is the site of the disease
Fallopian Tube (Fallopian tube)
Ovary (Ovary)
Does the patient have either Stage II-IV disease
(no brain metastasis) or recurrent Stage I disease
(chemonaive)?
Recurrent (Recurrent (chemonaive))
Stage Ii (Stage II)
Stage Iii (Stage III)
Stage Iv (Stage IV)
If the patient is newly diagnosed, will protocol
therapy begin within 6 weeks of primary
debulking?
No (No)
Recurrent Disease Not Applicable (Not
Applicable - Recurrent disease)
Yes (Yes)
If the patient is stage I (Recurrent), will protocol
therapy begin within 14 days of randomization?
No (No)
Primary Disease Or Disorder Not
Applicable (Not Applicable - Primary
disease)
Yes (Yes)
Has the patient had appropriate surgery including
appendectomy (unless patient has history of prior
appendectomy) for ovarian or fallopian tube
carcinoma with appropriate tissue available for
histologic evaluation to confirm diagnosis and
stage?
Yes
No
Does this patient have measurable disease as
defined by RECIST 1.1 criteria for assessing
clinical response to treatment OR non-
measurable disease? (see Section 8.0 in the
protocol)
Measurable Disease (Measurable)
Non-measurable (Non-measurable)
Does the patient have measurable disease
defined as any tumor lesion that can be
accurately measured in at least one dimension
with a minimum size of 1.0 cm by CT scan (CT
scan slice thickness < 0.5 cm), 1.0 cm caliper
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measurement by clinical exam, 2.0 cm by chest
X-ray, or 1.5 cm malignant, pathologically
enlarged lymph node by CT scan?
No (No)
Non-measurable (Not applicable - Non-
Measurable)
Yes (Yes)
What method of evaluation is used to obtain
tumor measurements?
Vernier Caliper Measurement Physical
Examination (Caliper measurement by
clinical exam)
Chest X-ray (Chest x-ray)
Ct Scan (CT scan)
Mri (MRI (NMR))
What is the size of the largest residual lesion?
>1.0 Cm, Suboptimal Gross Residual
Disease (>1.0 cm, suboptimal gross
residual disease)
0.1 - 1.0cm, Optimal Gross Residual
Disease (0.1 - 1.0cm, optimal gross
residual disease)
Less Than 0.1 Cm, No Gross Residual
Disease (Less than 0.1 cm, no gross
residual disease)
Has the patient had a negative colonoscopy
within one year of today?
Yes
No
Unnamed2
Date of Results (if more than one, enter earliest)
ANC (must be 1,500/mcl or greater)
WBC (must be 3,000 cells/mcl or greater)
Platelets (must be 100,000/mcl or greater)
Hemoglobin (Must be greater than or equal to 10
g/dl)
Is Serum Creatinine less than or equal to 1.5 X
ULN
Yes
No
Is the Creatinine Clearance greater than 50
cc/min?
Yes
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No
Is the bilirubin less than or equal to 1.5 X ULN
Yes
No
Are SGOT and Alkaline Phosphatase less than or
equal to 2.5 times institutional ULN
Yes
No
Are sensory or motor neuropathy less than or
equal to CTC Grade 1
Yes
No
Does the patient have one of the following: a
urine dipstick for proteinuria less then 2+ OR If
urine dipstick for proteinuria is greater then 2+,
does the 24 hour urine demonstrate less then or
equal to 1 g protein in 24 hours OR a urine
protein-to-creatinine ratio (UPCR) less then or
equal to 1.0 mg/dL?
Yes
No
Are PT and APTT less than or equal to 1.5 X
ULN?
Yes
No
CA125 Laboratory upper limit of normal
Unnamed3
Will the patient have the following paramenters
measured within 14 days prior to initiating
protocol therapy (Toxicity Assessment,
Coagulation parameters PT, APTT, CBC,
Differential, Platelets, Electrolytes, BUN,
Creatinine, Calcium, Magnesium, Phosphorus,
UPCR or Urinalysis, Bilirubin, SGOT, Alkaline
Phosphatase, Total protein albumin, CA-125)
Yes
No
Will the patient have the following parameters
measured within 28 days prior to initiating
protocol therapy (History and Physical Exam,
EKG, Radiographic tumor Measurement, Chest
Imaging and Blood Pressure Measurement)
Yes
No
Has the patient met the pre-entry requirements
as specified in section 7.0
Yes
No
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Performance Status
Fully Active, Able To Carry On All Pre-
disease Performance Without
Restriction. (0)
Restricted In Physically Strenuous
Activity But Ambulatory And Able To
Carry Out Work Of A Light Or Sedentary
Nature, E.g., Light Housework, Office
Work. (1)
Ambulatory And Capable Of All Selfcare
But Unable To Carry Out Any Work
Activities. Up And About More Than 50%
Of Waking Hours. (2)
Is the patient age 18 years or older
Yes
No
Does the patient have a life expectancy of greater
than 3 months?
Yes
No
Does the patient have colon cancer or a history of
colon cancer?
Yes
No
Does the patient have primary peritoneal
carcinoma?
Yes
No
If the patient has had a prior invasive malignancy
(except non-melanoma skin cancer), has she had
any evidence of disease within the last 5 years or
does the prior malignancy treatment
contraindicate the current protocol therapy
Yes
No
Has the patient ever received chemotherapy or
radiotherapy for any gynecologic or colorectal
cancer prior to enrollment?
Yes
No
Does the treating physician anticipate the need
for major surgical procedure during the course of
the study? (See Section 3.25)
Yes
No
Will the patient have any minor surgical
procedures, fine needle aspirates or core
biopsies within 7 days prior to the first date of
Bevacizumab therapy?
Yes
No
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Has the patient had surgery (including open
biopsy) within 4 weeks prior to anticipated first
dose of bevacizumab (allowing for the fact that
bevacizumab can be omitted from first cycle of
chemotherapy)?
Yes
No
Does the patient have any evidence of wound
disruption or impaired healing?
Yes
No
Does the patient have a history of abdominal
fistula or perforation within the past 12 months?
Yes
No
Does the patient have a serious non-healing
wound, ulcer, or bone fracture? (Patients with
granulating incisions healing by secondary
intention with no evidence of fascial dehiscence
or infection are eligible but require weekly wound
re-examinations - See Section 7.1 in the
protocol.)
Yes
No
Does the patient have known hypersensitivity to
Chinese hamster ovary cell products or other
recombinant human or humanized antibodies
Yes
No
Does the patient have mixed epithelial ovarian
cancer histology?
Yes
No
Does the patient have a tumor of low malignant
potential?
Yes
No
Does the patient have a history or evidence upon
physical examination of CNS disease, including
brain tumor, seizures not controlled with standard
medical therapy or any brain metastases?
No (No)
Not Applicable (Not Applicable)
Yes (Yes)
Does the patient have uncontrolled hypertension
defined as systolic pressure greater than 150mm
Hg or diastolic greater than 100mm Hg?
Yes
No
Has the patient had myocardial infarction or
unstable angina within 12 months of the first date
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of Bevacizumab therapy?
Yes
No
Using New York Heart Association (NYHA)
guidelines, does the patient have Grade II or
greater congestive heart failure or serious cardiac
arrhythmia requiring medication?
Yes
No
Does the patient have Grade 1, Category 2 or
greater, peripheral vascular disease?
Yes
No
Does the patient have a history of
cerebrovascular accident (CVA, stroke), transient
ischemic attack (TIA) or subarachnoid
hemorrhage within six months of the first date of
Bevacizumab therapy?
Yes
No
Does the patient have a history of pulmonary
embolism or deep vein thrombosis within the past
6 months?
Yes
No
Does the patient have a history of malabsorption
or other conditions preventing oral treatment?
Yes
No
If the patient is of childbearing potential will she
have a serum pregnancy test within 72 hours of
starting protocol therapy and has she agreed to
practice an effective form of birth control during
study treatment and for six months after
completion of treatment?
No (No)
Not Applicable (Not Applicable)
Yes (Yes)
Is the patient pregnant or nursing
Yes
No
Does the patient have acute hepatitis or active
infection requiring parenteral antibiotics
Yes
No
Does the patient have active bleeding or
pathologic conditions that carry high risk of
bleeding such as known bleeding disorder,
coagulopathy or tumor involving major vessels?
Yes
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No
Is the patient taking warfarin?
Yes
No
Anticipated date treatment will start
Comments
Provide comments about this Fast Fact Sheet
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Leukemia NCT00513747 Registration - CALGB-
10501 Registration Worksheet Form - 2660208v1.0
CALGB-10501 Registration Worksheet Form
Early or Delayed Fludarabine and Rituximab in Treating
Patients With Previously Untreated Chronic Lymphocytic
Leukemia
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=33E5ACDE-
FDD4-48D4-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/9100
CALGB-10501 Registration
Worksheet Form
Header Module
Lead Institution
CALGB Patient ID (Assigned)
Institution/Affiliate
Physician of Record
Participating Group
Protocol Administration
IRB Approval Date
Date Informed Consent Signed
Projected Start Date of Treatment
HIPAA Authorization Date
Contact Person at Institution
Phone
Fax
Patient Demographics/pre-treatment
Characteristics
Patient Initials (Last, First Middle)
Patient's Date of Birth (MM DD YYYY)
1 / 3
Patient Social Security Number
Patient Hospital No.
Gender
Female (FEMALE)
Male (MALE)
Patient Demographics/pre-treatment
Characteristics2
Performance Status (ECOG/Zubrod scale)
Fully Active, Able To Carry On All Pre-
disease Performance Without
Restriction. (0)
Restricted In Physically Strenuous
Activity But Ambulatory And Able To
Carry Out Work Of A Light Or Sedentary
Nature, E.g., Light Housework, Office
Work. (1)
Ambulatory And Capable Of All Selfcare
But Unable To Carry Out Any Work
Activities. Up And About More Than 50%
Of Waking Hours. (2)
Capable Of Only Limited Selfcare,
Confined To Bed Or Chair More Than
50% Of Waking Hours. (3)
Completely Disabled. Cannot Carry On
Any Selfcare. Totally Confined To Bed Or
Chair. (4)
Dead (5)
Height (cm)
Weight (kg)
Body Surface Area (m^2)
Disease name
Chronic Lymphocytic Leukemia Nos
(Chronic Lymphocytic Leukemia NOS)
Tumor Stage
No Evidence Of Disease (0)
I (1)
Certification Of Eligibility And Protocol
Design
In the opinion of the investigator, is the patient
eligible?
Yes
No
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Stratification Factors
Age group
< 50 Years Of Age (< 50 years of age)
> 70 Years Of Age (> 70 years of age)
50-70 Years Of Age (50-70 years of age)
Assigned Treatment Arm
Arm A: Early Treatment With Rituximab +
Fludarabine (Arm A: Early treatment with
Rituximab + Fludarabine)
Arm B: Observation With Later
Treatment With Rituximab + Fludarabine
(Arm B: Observation with later treatment
with Rituximab + Fludarabine)
Arm C: Follow Up Until Nc196 Criteria
Met; The Patient Receives Rituximab +
Fludarabine Or Other Alternative
Treatment Per Physician (Arm C: Follow
up until NC196 criteria met; the patient
receives Rituximab + Fludarabine or
other alternative treatment per physician)
Registration Information
CALGB Patient ID (Assigned)
Date of Registration
Participating Group Patient ID (Assigned)
Registrar's Signature
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Lung Cancer NCT01041781 Registration - CALGB-
30801 Registration Worksheet Form - 2891095v1.0
CALGB-30801 Registration Worksheet Form
Gemcitabine Hydrochloride or Pemetrexed Disodium and
Carboplatin With or Without Celecoxib in Treating Patients
With Advanced Non-Small Cell Lung Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=6AF26CA3-
DB68-EEE0-E040-BB89AD436D54
All rights reserved. Please visit https://medical-data-
models.org/forms/9101
CALGB-30801 Registration
Worksheet Form
Header Module
Lead Institution
CALGB Patient ID
Institution/Affiliate
Physician
Principal Investigator No.
Participating Group Name
Protocol Administration
IRB Approval Date (MM DD YYYY)
Date Informed Consent Signed (MM DD YYYY)
Projected Start Date of Treatment (MM DD
YYYY)
HIPAA Authorization Date (MM DD YYYY)
Institution contact
Phone
Fax
Patient Demographics/pre-treatment
Characteristics
Patient Initials (Last, First Middle)
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Date of Birth (MM DD YYYY)
Patient Social Security Number
Patient Hospital No.
Gender
Female (FEMALE)
Male (MALE)
Patient Demographics/pre-treatment
Characteristics2
Performance Status (ECOG/Zubrod scale)
Fully Active, Able To Carry On All Pre-
disease Performance Without
Restriction. (0)
Restricted In Physically Strenuous
Activity But Ambulatory And Able To
Carry Out Work Of A Light Or Sedentary
Nature, E.g., Light Housework, Office
Work. (1)
Ambulatory And Capable Of All Selfcare
But Unable To Carry Out Any Work
Activities. Up And About More Than 50%
Of Waking Hours. (2)
Capable Of Only Limited Selfcare,
Confined To Bed Or Chair More Than
50% Of Waking Hours. (3)
Completely Disabled. Cannot Carry On
Any Selfcare. Totally Confined To Bed Or
Chair. (4)
Dead (5)
Method of Payment (USA only Mark one)
Medicaid (Medicaid)
Medicaid And Medicare (Medicaid and
Medicare)
Medicare (Medicare)
Medicare And Private Insurance
(Medicare and Private Insurance)
Military Sponsored (including Champus
& Tricare) (Military Sponsored (including
CHAMPUS & TRICARE))
No Means Of Payment (no Insurance)
(No means of payment (no insurance))
Other (Other)
Private Insurance (Private Insurance)
Self Pay (no Insurance) (Self Pay (No
Insurance))
Unknown (Unknown)
Veterans Sponsored (Veterans
Sponsored)
Patient Demographics/pre-treatment
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Characteristics3
Disease (NSCLC)
Patient Zip Code
Country of Residence (If not USA)
Certification Of Eligibility And Protocol
Design
In the opinion of the investigator, is the patient
eligible?
Yes
No
Protocol Design
Stratification Factors
Pathologic type (Squamous Carcinoma Non-
Squamous Carcinoma)
Stage (IIIB IV)
Smoking History (Never/Light smoker is a patient
who smoked <= 10 pack years AND quit >= 1
year ago.)
Never/light Smoker (Never/Light Smoker)
Smoker (Smoker)
Initial Patient Consent For Specimen Use
Patient's Initial Consent given for specimen use
for research on the patient's cancer
Yes
No
Patient's Initial Consent given for specimen kept
for future use in research to learn about, prevent,
or treat cancer
Yes
No
Patient's Initial Consent given for specimen use
for research unrelated to the patient's cancer?
Yes
No
Patient's initial consent given for further contact
regarding specimen?
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Yes
No
Registration Information
CALGB Patient ID
Registration Date (MM DD YYYY)
Participating Group Patient ID
Registrar's Signature
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Kidney Cancer NCT01198158 Registration - CALGB
90802 Registration Worksheet Form - 3103555v1.0
CALGB 90802 Registration Worksheet Form
Everolimus With or Without Bevacizumab in Treating
Patients With Advanced Kidney Cancer That Progressed
After First-Line Therapy
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=879626AD-
DB8C-4AF2-E040-BB89AD4364E1
All rights reserved. Please visit https://medical-data-
models.org/forms/9103
CALGB 90802 Registration
Worksheet Form
Header Module
Lead Institution
Institution/Affiliate
Participating Group Name
CALGB Patient ID
Physician
Principal Investigator No.
Protocol Administration
IRB Approval Date (MM DD YYYY)
Date Informed Consent Signed (MM DD YYYY)
Projected Start Date of Treatment (MM DD
YYYY)
HIPAA Authorization Date (MM DD YYYY)
Institution contact
Phone
Fax
Patient Demographics/pre-treatment
Characteristics
Patient Initials (Last, First Middle)
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Date of Birth (MM DD YYYY)
Patient Social Security Number
Patient Hospital No.
Gender
Female Gender (Female)
Male Gender (Male)
Race (Mark all that apply)
A Person Having Origins In Any Of The
Original Peoples Of North And South
America (including Central America),
And Who Maintains Tribal Affiliation Or
Community Attachment. (American
Indian or Alaska Native)
A Person Having Origins In Any Of The
Original Peoples Of The Far East,
Southeast Asia, Or The Indian
Subcontinent Including, For Example,
Cambodia, China, India, Japan, Korea,
Malaysia, Pakistan, The Philippine
Islands, Thailand, And Vietnam. (Asian)
A Person Having Origins In Any Of The
Black Racial Groups Of Africa. Terms
Such As "haitian" Or "negro" Can Be
Used In Addition To "black Or African
American." (Black or African American)
A Person Having Origins In Any Of The
Original Peoples Of Hawaii, Guam,
Samoa, Or Other Pacific Islands. (Native
Hawaiian or other Pacific Islander)
Could Not Be Determined Or Unsure
(Unknown)
A Person Having Origins In Any Of The
Original Peoples Of Europe, The Middle
East, Or North Africa. (White)
Ethnicity (Mark one)
A Person Of Mexican, Puerto Rican,
Cuban, Central Or South American Or
Other Spanish Culture Or Origin,
Regardless Of Race. (Hispanic or Latino)
A Person Not Meeting The Definition For
Hispanic Or Latino. (Not Hispanic or
Latino)
Could Not Be Determined Or Unsure
(Unknown)
Patient Demographics/pre-treatment
Characteristics2
Performance Status (ECOG/Zubrod scale)
Fully Active, Able To Carry On All Pre-
disease Performance Without
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Restriction. (0)
Restricted In Physically Strenuous
Activity But Ambulatory And Able To
Carry Out Work Of A Light Or Sedentary
Nature, E.g., Light Housework, Office
Work. (1)
Ambulatory And Capable Of All Selfcare
But Unable To Carry Out Any Work
Activities. Up And About More Than 50%
Of Waking Hours. (2)
Capable Of Only Limited Selfcare,
Confined To Bed Or Chair More Than
50% Of Waking Hours. (3)
Completely Disabled. Cannot Carry On
Any Selfcare. Totally Confined To Bed Or
Chair. (4)
Dead (5)
Height (cm)
Weight (kg)
Body Surface Area (m^2)
Method of Payment (USA only Mark one)
Medicaid (Medicaid)
Medicare And Medicaid (Medicaid and
Medicare)
Medicare (Medicare)
Medicare And Private Insurance
(Medicare and Private Insurance)
Military Insurance (Military Sponsored
(Including CHAMPUS & TriCare))
No Insurance (No Means of Payment
(No Insurance))
Other (Other)
Private Insurance (Private Insurance)
Self Payment (Self-Pay (No Insurance))
Unknown (Unknown)
Veterans Administration Sponsor
Insurance (Veterans Sponsored)
Patient Demographics/pre-treatment
Characteristics3
Disease (Renal cell carcinoma)
Stage (IV)
Pathologic type (Clear cell component)
Patient Zip Code
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Country of Residence (If not USA)
Certification Of Eligibility And Protocol
Design
In the opinion of the investigator, is the patient
eligible?
Yes
No
Protocol Design
Stratification Factors (Number of risk factors
present: The risk factors are: Karnofsky
performance status <80%; Corrected serum
calcium >10mg/dL; and Hb <13 for males and
<11.5 for females. Mark one with an X. Zero risk
factors One risk factor Two or three risk factors
Total duration of prior VEGFR TKI Therapy Mark
one with an X. <12 weeks of therapy >=12 weeks
of therapy)
Assigned Treatment Arm
Kit number
Initial Patient Consent For Specimen Use
Patient's Initial Consent given for specimen use
for research on the patient's cancer
Yes
No
Patient's initial consent given for specimen use
for genetic research relating to the study
treatment
Yes
No
Patient's Initial Consent given for specimen kept
for future use in research to learn about, prevent,
or treat cancer
Yes
No
Patient's initial consent given for specimen(s)
may be kept for use in research to learn about,
prevent, or treat other health problems (for
example:
diabetes, Alzheimer's disease, or heart disease)
Yes
No
My doctor or someone from CALGB may contact
me in the future to ask me to take part in more
research
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Yes
No
Calgb 580902
Was the patient registered to CALGB 580902 (a
companion to CALGB 90802)
Yes
No
Registration Information
Registration Date (MM DD YYYY)
Participating Group Patient ID
CALGB Patient ID
Registrar's Signature
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Fallopian Tube Cancer NCT01167712 Pre-Study - GOG-0262: Fast Fact Sheet
for Protocol 0262 (Ovary, Fallopian Tube, Primary Peritoneal) - 3110638v1.0
GOG-0262: Fast Fact Sheet for Protocol 0262 (Ovary,
Fallopian Tube, Primary Peritoneal)
Paclitaxel and Carboplatin With or Without Bevacizumab in
Treating Patients With Stage II, Stage III, or Stage IV
Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or
Fallopian Tube Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=893B4E4E-
209D-97F3-E040-BB89AD4371DB
All rights reserved. Please visit https://medical-data-
models.org/forms/9104
GOG-0262: Fast Fact Sheet for
Protocol 0262 (Ovary, Fallopian
Tube, Primary Peritoneal)
Tracking Information
GOG Institution Code
GOG Affiliate Code
Previous GOG #
Treating physician
Other Physician
Patient Hospital No.
Date of Birth
Patient Name, Last
Patient Name, First
Patient Name, Middle
Patient Social Security Number
Patient Zip Code
Country
Race
A Person Having Origins In Any Of The
Original Peoples Of North And South
America (including Central America),
And Who Maintains Tribal Affiliation Or
Community Attachment. (American
Indian or Alaska Native)
1 / 10
A Person Having Origins In Any Of The
Original Peoples Of The Far East,
Southeast Asia, Or The Indian
Subcontinent Including, For Example,
Cambodia, China, India, Japan, Korea,
Malaysia, Pakistan, The Philippine
Islands, Thailand, And Vietnam. (Asian)
A Person Having Origins In Any Of The
Black Racial Groups Of Africa. Terms
Such As "haitian" Or "negro" Can Be
Used In Addition To "black Or African
American." (Black or African American)
Could Not Be Determined Or Unsure
(Unknown)
A Person Having Origins In Any Of The
Original Peoples Of Europe, The Middle
East, Or North Africa. (White)
Ethnicity
A Person Of Mexican, Puerto Rican,
Cuban, Central Or South American Or
Other Spanish Culture Or Origin,
Regardless Of Race. (Hispanic or Latino)
A Person Not Meeting The Definition For
Hispanic Or Latino. (Not Hispanic or
Latino)
Could Not Be Determined Or Unsure
(Unknown)
Method of Payment
Medicaid (Medicaid)
Medicaid And Medicare (Medicaid and
Medicare)
Medicare (Medicare)
Medicare And Private Insurance
(Medicare and Private Insurance)
Military Or Veterans Sponsored Nos
(Military or Veterans Sponsored, Not
Otherwise Specified (NOS))
Military Sponsored (including Champus
& Tricare) (Military Sponsored (including
CHAMPUS & TRICARE))
No Means Of Payment (no Insurance)
(No means of payment (no insurance))
Other (Other)
Private Insurance (Private Insurance)
Self Pay (no Insurance) (Self Pay (No
Insurance))
Unknown (Unknown)
Veterans Sponsored (Veterans
Sponsored)
Header
Did the patient sign an approved informed
consent
Yes
No
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Has HIPAA authorization been obtained?
Exempt - Non-usa Participant (Exempt -
non-USA participant)
Yes: C49488 (Yes)
What is the site of the disease
Fallopian Tube (Fallopian tube)
Ovary (Ovary)
Peritoneum (Peritoneum)
What is the stage/residual disease status
Stage Ii (Stage II)
Stage Iii (neo-adjuvant Therapy Planned)
(Stage III (Neo-Adjuvant therapy
planned))
Stage Iii Less Than Or Equal To 1.0cm
(Stage III less than or equal to 1.0cm)
Residual Disease Or Disorder Stage Iii
(Stage III, Max Residual disease > 1cm)
Stage Iv (Stage IV)
If Stage IV, how was the stage documented
Histologic (Histological)
Non-histological Method (Non-
Histological Method)
Not Applicable (Not Applicable)
Is the patient eligible for a higher priority GOG
protocol (for example GOG-0252)
Yes
No
What was the grade of the primary tumor
Grade 1-well Differentiated (1)
Grade 2-moderately Differentiated (2)
Grade 3-poorly Differentiated (3)
Not Graded (Not Graded)
Does this patient have measurable disease as
defined by RECIST criteria for assessing clinical
response to treatment OR non-measurable
disease (see Section 8.0 in the protocol)
Measurable Disease (Measurable)
Non-measurable (Non-measurable)
What is the cell type
Not Otherwise Specified
Adenocarcinoma (Adenocarcinoma,
NOS)
Clear Cell Carcinoma (Clear cell
carcinoma)
Endometrioid Adenocarcinoma
(Endometrioid adenocarcinoma)
Malignant Ovarian Brenner Tumor
(Malignant Brenner's tumor)
Mixed Epithelial Carcinoma, Specify
Components (Mixed epithelial
carcinoma)
Mucinous Adenocarcinoma (Mucinous
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adenocarcinoma)
Serous Adenocarcinoma (Serous
adenocarcinoma)
Transitional Cell Carcinoma (Transitional
Cell Carcinoma)
Undifferentiated Carcinoma
(Undifferentiated carcinoma)
Does the patient have a current diagnosis of
borderline epithelial ovarian tumor or recurrent
invasive epithelial ovarian, primary peritoneal or
fallopian tube cancer treated with surgery only
Yes
No
Is the patient going to receive neo-adjuvant
chemotherapy with interval cytoreductive surgery
Yes
No
Was the required core biopsy done
No (No)
Not Applicable (Not Applicable)
Yes (Yes)
If done, what was the date the core biopsy was
done
Does the patient have documentation of at least
stage II disease acquired via imaging or surgery
(without attempt at cytoreduction)
No (No)
Not Applicable (Not Applicable)
Yes (Yes)
Has the patient had abdominal surgery with
appropriate tissue available for histologic
evaluation and maximum tumor debulking
Yes
No
If surgery done, what is the date of surgery
Has the patient had another invasive malignancy
(other than non-melanoma of the skin, localized
cancer of the breast, head and neck or skin)
diagnosed, present or recur within the past 5
years
Yes
No
Has the patient received prior radiotherapy to any
portion of the abdominal cavity or pelvis (Prior
radiation for localized cancer of the breast, head
and neck or skin is permitted as long as it was
completed more than 3 years prior to registration
and the patient remains free of recurrent or
metastatic disease )
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Yes
No
Has the patient received prior chemotherapy for
any abdominal or pelvic tumor including neo-
adjuvant chemotherapy for their ovarian, primary
peritoneal or Fallopian tube cancer (Prior
adjuvant chemotherapy for localized breast
cancer is permitted provided it was completed
more than 3 years prior to registration and the
patient remains free of recurrent or metastatic
disease.)
Yes
No
Has the patient had previous cancer treatment
which contraindicates this protocol therapy
Yes
No
If the patient has a synchronous primary
endometrial cancer or past history of endometrial
cancer, is it more advanced than Stage I-B OR
with greater than superficial myometrial invasion
with vascular or lymphatic invasion OR poorly
differentiated subtypes including papillary serous,
clear cell or other FIGO Grade 3 lesions
No (No)
Not Applicable (Not Applicable)
Yes (Yes)
Has the patient received any targeted therapy
(including, but not limited to vaccines, antibodies
or tyrosine kinase inhibitors) or hormonal therapy
for management of their ovarian, Fallopian tube
or peritoneal primary carcinoma
Yes
No
Performance Status
Fully Active, Able To Carry On All Pre-
disease Performance Without
Restriction. (0)
Restricted In Physically Strenuous
Activity But Ambulatory And Able To
Carry Out Work Of A Light Or Sedentary
Nature, E.g., Light Housework, Office
Work. (1)
Ambulatory And Capable Of All Selfcare
But Unable To Carry Out Any Work
Activities. Up And About More Than 50%
Of Waking Hours. (2)
Unnamed2
Date of Results (if more than one, enter earliest)
ANC (must be 1,500/mcl or greater and not
induced or supported by GCSFs)
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Platelets (must be 100,000/mcl or greater)
Is the bilirubin less than or equal to 1.5 X ULN
Yes
No
Is the SGOT less than or equal to 3 X ULN
Yes
No
Is the alkaline phosphatase less than or equal to
2.5 X ULN
Yes
No
Is Serum Creatinine less than or equal to 1.5 X
ULN
Yes
No
Are sensory or motor neuropathy less than or
equal to CTC Grade 1
Yes
No
Unnamed3
Will the patient have the following paramenters
measured within 14 days prior to initiating
protocol therapy (CBC, Differential, Platelets,
Serum Creatinine, Bilirubin, SGOT, Alkaline
Phosphatase, Calcium, Phosphorus, Magnesium,
Urinalysis, Toxicity Assessment, Serum
Pregnancy test if childbearing potential exists)
Yes
No
Will the patient have the following parameters
measured within 28 days prior to initiating
protocol therapy (History and Physical Exam, CA-
125, Chest X-Ray, EKG and Radiographic
Disease Assessment)
Yes
No
If the patient has a history of hearing loss, has an
audiogram been performed
No (No)
Not Applicable (Not Applicable)
Yes (Yes)
Does the patient have acute hepatitis or active
infection requiring parenteral antibiotics
No (No)
Not Applicable (Not Applicable)
Yes (Yes)
Has the patient had a myocardial infarction,
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unstable angina or a history of CVA within the last
six months
Yes
No
Does the patient have New York Heart
Association Grade II or greater congestive heart
failure
Yes
No
Does the patient have serious cardiac arrhythmia
requiring medication (This does not include
asymptomatic, atrial fibrillation with controlled
ventricular rate)
Yes
No
Is the patient pregnant or breastfeeding
Yes
No
Is the patient age 18 years or older
Yes
No
Has the patient received prior therapy with any
anti-VEGF drug, including Bevacizumab
Yes
No
Does the patient have a medical history or
condition not otherwise previously specified
which in the opinion of the investigator should
exclude her from participating in this study
Yes
No
Eligibility 4
Has the patient elected to receive concurrent or
consolidation bevacizumab?
Yes
No
Has the pre-treatment blood pressure been
recorded
No (No)
Not Applicable (Not Applicable)
Yes (Yes)
Are the pre-treatment Urine Protein-Creatine
Ratio (UPCR) results available
No (No)
Not Applicable (Not Applicable)
Yes (Yes)
Is the urine protein-creatinine ratio (UPCR) less
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than 1.0
No (No)
Not Applicable (Not Applicable)
Yes (Yes)
Are the pre-treatment PT/PT INR/PTT results
available
No (No)
Not Applicable (Not Applicable)
Yes (Yes)
Is the PT INR less than or equal to 1.5 (or an in-
range INR, usually between 2 and 3, if a patient
is on a stable dose of therapeutic warfarin) and
the PTT less than 1.2 times the Upper Limit of
Normal
No (No)
Not Applicable (Not Applicable)
Yes (Yes)
Will the patient have the following parameters
measured within 28 days prior to initiating
protocol therapy: Blood Pressure
No (No)
Not Applicable (Not Applicable)
Yes (Yes)
Does the patient have active bleeding or
pathologic conditions that carry high risk of
bleeding such as known bleeding disorder,
coagulopathy or tumor involving major vessels?
No (No)
Not Applicable (Not Applicable)
Yes (Yes)
Does the patient have a serious non-healing
wound, ulcer or bone fracture? (This includes
history of abdominal fistula, gastrointestinal
perforation or intra-abdominal abscess within 28
days. Patients with granulating incisions healing
by secondary intention with no evidence of fascial
dehiscence or infection are eligible but require
weekly wound re-examinations - See Section 7.1
in the protocol.)
No (No)
Not Applicable (Not Applicable)
Yes (Yes)
Does the patient have a history or evidence upon
physical examination of CNS disease, including
primary brain tumor, seizures not controlled with
standard medical therapy, any brain metastases,
or history of cerebrovascular accident (CVA,
stroke), transient ischemic attack (TIA) or
subarachnoid hemorrhage within six months of
the first date of treatment on this study?
No (No)
Not Applicable (Not Applicable)
Yes (Yes)
8 / 10
Fallopian Tube Cancer NCT01167712 Pre-Study - GOG-0262: Fast Fact Sheet
for Protocol 0262 (Ovary, Fallopian Tube, Primary Peritoneal) - 3110638v1.0
Does the patient have CTCAE Grade 2 or greater
peripheral vascular disease
No (No)
Not Applicable (Not Applicable)
Yes (Yes)
Does the patient have known hypersensitivity to
Chinese hamster ovary cell products or other
recombinant human or humanized antibodies or a
known allergy to cremophor or Polysorbate 80?
No (No)
Not Applicable (Not Applicable)
Yes (Yes)
Has the patient had a major surgical procedure,
open biopsy or significant traumatic injury within
28 days of treatment start date of Bevacizumab
therapy (cycle 2)?
No (No)
Not Applicable (Not Applicable)
Yes (Yes)
Is a major surgical procedure anticipated for this
patient during the course of this study
No (No)
Not Applicable (Not Applicable)
Yes (Yes)
Will the patient have any tissue biopsy, such as a
core biopsy, within 7 days prior to treatment start
date of Bevacizumab therapy (cycle 2)?
No (No)
Not Applicable (Not Applicable)
Yes (Yes)
Does the patient have clinical symptoms or signs
of gastrointestinal obstruction and require
parenteral hydration or nutrition?
No (No)
Not Applicable (Not Applicable)
Yes (Yes)
Does the patient have metastatic tumor in the
parenchyma of the liver or lungs with proximity to
large vessels which could make the patient at
high risk of lethal hemorrhage during treatment
with Bevacizumab (i.e. hemoptysis, liver rupture)?
No (No)
Not Applicable (Not Applicable)
Yes (Yes)
If patient is of childbearing potential, has she
agreed to use contraceptive measures during
study therapy and for at least 6 months after
completion of Bevacizumab therapy
No (No)
Not Applicable (Not Applicable)
Yes (Yes)
Has the pre-treatment incision check been
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completed?
No (No)
Not Applicable (Not Applicable)
Yes (Yes)
Is your site accredited to participate in the
imaging component of this study, ACRIN 6695
Yes
No
If your site is accredited, did the patient consent
to participate in the imaging component of this
study, ACRIN 6695
No (No)
Not Applicable (Not Applicable)
Yes (Yes)
Anticipated date treatment will start
Comments
Provide comments about this Fast Fact Sheet
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brca1 Mutation Carrier NCT01097278 Registration - Southwest Oncology
Group S0812 Registration Worksheet Form (Step 1) - 3289182v1.0
Southwest Oncology Group S0812 Registration Worksheet
Form (Step 1)
High Dose Cholecalciferol in Premenopausal Women at
High-Risk for Breast Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=AE8F0868-
7F44-FEC9-E040-BB89AD4357E7
All rights reserved. Please visit https://medical-data-
models.org/forms/9105
Southwest Oncology Group S0812
Registration Worksheet Form (Step
1)
Header
Activation Date (MM DD YYYY)
Last Amended Date (MM DD YYYY)
Registration Step
Swog Patient Id
SWOG Patient ID Status
New Patient (New patient)
Previous Patient (Previous patient)
SWOG Patient ID
Demography
Patient First Name
Patient Middle Name
Patient Last Name
Unnamed2
Registrar's SWOG Roster ID Number
SWOG Investigator Number
SWOG Treating Institution Number
Unnamed5
Date Informed Consent Signed (MM DD YYYY)
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Date HIPAA Authorization signed (Not required if
Country of Residence is not USA MM DD YYYY)
Projected Start Date of Treatment (MM DD
YYYY)
Stratification Question
Baseline serum 25(OH)D level
< 20 Ng/ml (1)
20-32 Ng/ml (2)
Baseline mammographic density
11-50% (1)
> 50% (2)
Designated biopsy site
Yes (1)
No (2)
Unnamed4
My blood may be kept for use in research to learn
about, prevent, treat, or cure cancer
Yes
No
My blood may be kept for use in research about
other health problems (for example: diabetes,
Alzheimer's disease, or heart disease)
Yes
No
Someone may contact me in the future to ask me
to allow other uses of my blood
Yes
No
My tissue may be kept for use in research to
learn about, prevent, treat, or cure cancer
Yes
No
My tissue may be kept for use in research about
other health problems (for example: diabetes,
Alzheimer's disease, or heart disease)
Yes
No
Someone may contact me in the future to ask me
to allow other uses of my tissue
Yes
No
My mammogram may be kept for use in research
to learn about, prevent, treat, or cure cancer
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Yes
No
My mammogram may be kept for use in research
about other health problems (for example:
diabetes, Alzheimer's disease, or heart disease)
Yes
No
Someone may contact me in the future to ask me
to allow other uses of my mammogram
Yes
No
I agree to allow my study doctor, or someone
approved by my study doctor, to contact me
regarding future research involving my
participation in this study
Yes
No
Unnamed 7
Has the SWOG Registration Worksheet been
completed entirely and is the patient eligible
according to the current version of protocol
section 5.0?
Yes
No
Auxiliary Questions
Does the participant have a known deleterious
mutation in BRCA1, BRCA2, PTEN or TP53
Yes
No
Does the participant have a history of resected
DCIS or LCIS
Yes
No
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Sarcoma NCT01247571 Pre-Study - GOG-0230: Fast
Fact Sheet for Protocol 0230-D (Uterus) - 3174263v1.0
GOG-0230: Fast Fact Sheet for Protocol 0230-D (Uterus)
Pazopanib Hydrochloride in Treating Patients With
Recurrent or Persistent Uterine Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=97F2A353-
AB36-7B12-E040-BB89AD432C3D
All rights reserved. Please visit https://medical-data-
models.org/forms/9106
GOG-0230: Fast Fact Sheet for
Protocol 0230-D (Uterus)
Tracking Information
GOG Institution Code
GOG Affiliate Code
Previous GOG #
Treating physician
Other Physician
Patient Hospital No.
Date of Birth
Patient Last Name
Patient First Name
Patient Middle Name
Header
Did the patient sign an approved informed
consent
Yes
No
Has HIPAA authorization been obtained
Exempt - Non-usa Participant (Exempt -
non-USA participant)
Yes: C49488 (Yes)
Is the patient eligible for a higher priority GOG
protocol (this includes any active GOG Phase III
protocol or Rare Tumor protocol for the same
population)
Yes
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No
What is the site of the disease
Uterus (Uterus)
What is the cell type?
Carcinosarcoma - Heterologous
(Carcinosarcoma - heterologous)
Carcinosarcoma - Homologous
(Carcinosarcoma - homologous)
Carcinosarcoma, Type Unspecified
(Carcinosarcoma, type unspecified)
Date primary confirmed histologically (if more
than one, enter earliest)
Is the disease recurrent or persistent with
documented progression? Which one?
Persistent Disease (Persistent)
Recurrent Disease (Recurrent)
How was it established to be recurrent or
persistent?
Biopsy (Biopsy)
Non-histologic Evaluation (Non-
Histologic)
Surgical Procedure (Surgery)
Date recurrence or persistence documented?
(NOTE: This should be the date of the most
recent progression or persistence that made the
patient eligible for this study.)
Does patient have measurable disease defined
as at least one lesion that can be accurately
measured in at least one dimension (longest
dimension to be recorded) using RECIST 1.1
criteria?
Yes
No
What method of evaluation is used to obtain
tumor measurements?
Caliper Measurement By Clinical Exam
(Caliper measurement by clinical exam)
Chest Radiography (Chest X-ray)
Computed Tomography (CT)
Magnetic Resonance Imaging (MRI)
Is the measurable disease > or = 10 mm when
measured by CT, MRI or caliper measurement by
clinical exam; or > or = 20 mm when measured
by chest x-ray or lymph nodes > or = 15 mm in
short axis when measured by CT or MRI?
Yes
No
Does the patient have at least one target lesion to
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be used to assess response on this protocol as
defined by RECIST 1.1? (Tumors within a
previously irradiated field will be designated as
non-target lesions unless progression is
documented or a biopsy is obtained to confirm
persistence at least 90 days following completion
of radiation therapy.)
Yes
No
Performance Status
Fully Active, Able To Carry On All Pre-
disease Performance Without
Restriction. (0)
Restricted In Physically Strenuous
Activity But Ambulatory And Able To
Carry Out Work Of A Light Or Sedentary
Nature, E.g., Light Housework, Office
Work. (1)
Ambulatory And Capable Of All Selfcare
But Unable To Carry Out Any Work
Activities. Up And About More Than 50%
Of Waking Hours. (2)
Has at least 4 weeks elapsed since the patient
underwent any major surgery (e.g., major:
hysterectomy, resection of a lung nodule - minor:
a central venous access catheter placement)
Yes
No
Has the patient recovered from the effects of
recent surgery, radiotherapy or chemotherapy?
Yes
No
Is the patient free of active infection requiring
antibiotics with the exception of uncomplicated
urinary tract infection (UTI)?
Yes
No
Has any hormonal therapy directed at the
malignant tumor been discontinued at least one
week prior to registration?
Yes
No
Has all prior therapy (chemotherapy) directed at
the malignant tumor been discontinued for at
least three weeks prior to registration
Yes
No
Has prior radiation therapy been discontinued for
at least four weeks prior to registration?
Yes
No
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How many prior cytotoxic chemotherapy
regimens has the patient received?
One Chemotherapy Regimen (1
Regimen)
Two Chemotherapy Regimens (2
Regimens)
Drug Regimen 1:
Start date for Regimen 1:
End date for Regimen 1:
Drug Regimen 2:
Start date for Regimen 2:
End date for Regimen 2:
Has the patient received any non-cytotoxic
chemotherapy for management of recurrent or
persistent disease (Prior hormonal therapy is
permitted)
Yes
No
Date of Results (if more than one, enter earliest:)
ANC (must be 1,500/mcl or greater)
Platelets (must be 100,000/mcl or greater:)
Hemoglobin (must be 9 g/dL 5.6 mmol/L or
greater:)
Is Serum Creatinine less than or equal to 1.5 X
ULN
Yes
No
Is her urine protein creatinine (UPC) ratio less
than 1 (or urinary protein less than 1.0g/24
hours)
Yes
No
Is the bilirubin less than or equal to 1.5 x ULN
(subjects with Gilbert's syndrome and elevations
of indirect bilirubin only are eligible)
Yes
No
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Are the AST, ALT and alkaline phosphatase less
than or equal to 2.5 x ULN
Yes
No
Does the patient have both bilirubin and AST/ALT
greater than ULN?
Yes
No
Is the PT INR less than or equal to 1.5 x ULN (or
an in range INR, usually between 2 and 3, if a
patient is on a stable dose of therapeutic
warfarin) and the PTT less than 1.5 x ULN?
Yes
No
Does the patient have normal baseline thyroid
function tests (TSH. T3, T4)
Yes
No
If the patient has a history of
hypothyroidism/hyperthyroidism, has the patient
had stable well-controlled thyroid function for a
minimum of 2 months
No (No)
Not Applicable (Not Applicable)
Yes (Yes)
Has the patient met the pre-entry requirements
as specified in section 7.0
Yes
No
If the patient has childbearing potential, has she
had a negative serum pregnancy test within 14
days prior to initiation protocol therapy
No (No)
Not Applicable (Not Applicable)
Yes (Yes)
Has patient agreed to use contraception during
protocol?
No (No)
Not Applicable (Not Applicable)
Yes (Yes)
Is the patient capable of taking and absorbing
oral medications
Yes
No
Does the patient have any lesion, whether
induced by tumor, radiation or other conditions
which makes it difficult to swallow tablets
Yes
No
Has the patient had a prior surgical procedure
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affecting absorption including, but not limited to
major resection of stomach or small bowel
Yes
No
Does the patient have active peptic ulcer disease
Yes
No
Does the patient have malabsorption syndrome
Yes
No
Does the patient take any concomitant
medications that are associated with a risk of
QTc prolongation and/or Torsades de Pointes? (If
possible, these medications should be
discontinued or replaced with drugs that do not
carry these risks. See Appendix III for a list of
concomitant medications associated. )
Yes
No
Does the patient have a history or family history
of congenital long QTc syndrome
Yes
No
Is the patient on medications classified as strong
inducers or inhibitors of CYP3A4? (Grapefruit
juice is considered an inhibitor and should not be
taken with pazopanib, see section 4.111.
Additional information for drug interactions with
cytochrome P450 isoenzymes may be found at
http://medicine.iupui.edu/flockhart/ )
Yes
No
Has the patient had prior therapy with
pazopanib?
Yes
No
Has the patient had another invasive malignancy
other than non-melanoma skin cancer present or
recur within the past 3 years?
Yes
No
Has the patient received prior radiotherapy to any
portion of the abdominal cavity or pelvis other
than for the treatment of uterine carcinoma within
the last 3 years? (Prior radiation for localized
cancer of the breast, head and neck or skin is
permitted as long as it was completed more than
3 years prior to registration and the patient
remains free of recurrent or metastatic disease)
Yes
No
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Has the patient received prior chemotherapy for
any abdominal or pelvic tumor other than for the
treatment of uterine carcinosarcoma within the
last three years? (Prior adjuvant chemotherapy of
localized breast cancer is permitted as long as it
was completed more than 3 years prior to
registration, and the patient remains free of
recurrent or metastatic disease)
Yes
No
Has the patient had previous cancer treatment
which contraindicates this protocol therapy
Yes
No
Has the patient had clinically significant
cardiovascular disease
Yes
No
Does the patient have a blood pressure (BP)
greater than 140 mmHg (systolic) and 90 mmHg
(diastolic)
Yes
No
Has the patient had myocardial infarction or
unstable angina within 6 months of the first date
of pazopanib therapy?
Yes
No
Using the New York Heart Association (NYHA)
guideline, does the patient have Class II or
greater congestive heart failure?
Yes
No
Does the patient have a history of serious
ventricular arrhythmia (ventricular tachycardia or
ventricular fibrillation) or arrhythmias requiring
anti-arrhythmic medications (This does not
include asymptomatic atrial fibrillation with
controlled ventricular rate)
Yes
No
Has she ever received prior treatment with an
anthracycline (including doxorubicin and/or
liposomal doxorubicin) and have an ejection
fraction less than the institutional lower limit of
normal?
Yes
No
Has she received a life time exposure to
doxorubicin (or liposomal doxorubicin) greater
than 300 mg/m2?
Yes
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No
Does the patient have CTCAE Grade 2 or greater
peripheral vascular disease
Yes
No
Does she have a history of cerebrovascular
accident (CVA, stroke), transient ischemic attack
(TIA) or subarachnoid hemorrhage within 6
months of starting pazopanib?
Yes
No
Does she have a baseline QTc greater than or
equal to 480 milliseconds?
Yes
No
Does she have a history of cardiac angioplasty or
stenting within 6 months prior to registration
Yes
No
Has the patient had coronary artery bypass graft
surgery within 6 months prior to registration
Yes
No
Has the patient had arterial thrombosis within 6
months prior to enrollment?
Yes
No
Does the patient have a history or evidence upon
physical examination of CNS disease, including
primary brain tumor, seizures not controlled with
standard medical therapy or any brain
metastases?
Yes
No
Does the patient have active bleeding or
pathologic conditions that carry high risk of
bleeding such as known bleeding disorder,
coagulopathy or tumor involving major vessels?
Yes
No
Does the patient have a serious non-healing
wound, ulcer or bone fracture? (This includes
history of abdominal fistual, gastrointestinal
perforation or intra-abdominal abscess within 28
days prior to the first date of pazopanib therapy)
Yes
No
Does the patient have a history of allergic
reactions attributed to compounds of similar
chemical or biologic composition to pazopanib?
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Yes
No
Is the patient HIV positive on combination
antiretroviral therapy?
Yes
No
Is the patient under age 18?
Yes
No
Is patient currently breastfeeding (Patients who
are lactating should discontinue nursing prior to
the first dose of study drug and should refrain
from nursing throughout the treatment period and
for 14 days following the last dose of study drug. )
Yes
No
Does the patient have any condition that may
increase the risk of gastrointestinal bleeding or
gastrointestinal perforation, including the
following: Active peptic ulcer disease Known
gastrointestinal intraluminal metastatic lesions
(gastrointestinal serosa metastatic lesion are
permitted) Inflammatory bowel disease (e.g.,
ulcerative colitis, Crohn's disease)
Yes
No
Does the patient have a history of hemoptysis in
excess of 2.5 mL (1/2 teaspoon) within 8 weeks
prior to first dose of pazopanib?
Yes
No
Has uncontrolled intercurrent illness including,
but not limited to, ongoing or active infection,
symptomatic congestive heart failure, unstable
angina pectoris, cardiac arrhythmia, or psychiatric
illness/social situations that would limit
compliance with study requirement?
Yes
No
Anticipated date treatment will start
Comments
Provide comments about this Fast Fact Sheet
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Ovarian Cancer NCT01196429 Eligibility - GOG-0268:
Fast Fact Sheet for Protocol 0268 (Ovary) - 3148320v1.0
GOG-0268: Fast Fact Sheet for Protocol 0268 (Ovary)
Temsirolimus, Carboplatin, and Paclitaxel as First-Line
Therapy in Treating Patients With Newly Diagnosed Stage
III or Stage IV Clear Cell Ovarian Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=926D80CE-
376C-A9F6-E040-BB89AD43312D
All rights reserved. Please visit https://medical-data-
models.org/forms/9108
GOG-0268: Fast Fact Sheet for
Protocol 0268 (Ovary)
Tracking Information
GOG Institution Code
GOG Affiliate Code
Previous GOG #
Treating physician
Other Physician
Patient Hospital No.
Date of Birth
Patient Name, Last
Patient Name, First
Patient Name, Middle
Patient Social Security Number
Patient Zip Code
Country
Race
A Person Having Origins In Any Of The
Original Peoples Of North And South
America (including Central America),
And Who Maintains Tribal Affiliation Or
Community Attachment. (American
Indian or Alaska Native)
A Person Having Origins In Any Of The
Original Peoples Of The Far East,
Southeast Asia, Or The Indian
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Subcontinent Including, For Example,
Cambodia, China, India, Japan, Korea,
Malaysia, Pakistan, The Philippine
Islands, Thailand, And Vietnam. (Asian)
A Person Having Origins In Any Of The
Black Racial Groups Of Africa. Terms
Such As "haitian" Or "negro" Can Be
Used In Addition To "black Or African
American." (Black or African American)
A Person Having Origins In Any Of The
Original Peoples Of Hawaii, Guam,
Samoa, Or Other Pacific Islands. (Native
Hawaiian or other Pacific Islander)
Not Provided Or Available (Not
Reported)
Could Not Be Determined Or Unsure
(Unknown)
A Person Having Origins In Any Of The
Original Peoples Of Europe, The Middle
East, Or North Africa. (White)
Ethnicity
A Person Of Mexican, Puerto Rican,
Cuban, Central Or South American Or
Other Spanish Culture Or Origin,
Regardless Of Race. (Hispanic or Latino)
A Person Not Meeting The Definition For
Hispanic Or Latino. (Not Hispanic or
Latino)
Not Provided Or Available (Not reported)
Could Not Be Determined Or Unsure
(Unknown)
Method of Payment
Medicaid (Medicaid)
Medicaid And Medicare (Medicaid and
Medicare)
Medicare (Medicare)
Medicare And Private Insurance
(Medicare and Private Insurance)
Military Or Veterans Sponsored Nos
(Military or Veterans Sponsored, Not
Otherwise Specified (NOS))
Military Sponsored (including Champus
& Tricare) (Military Sponsored (including
CHAMPUS & TRICARE))
No Means Of Payment (no Insurance)
(No means of payment (no insurance))
Other (Other)
Private Insurance (Private Insurance)
Self Pay (no Insurance) (Self Pay (No
Insurance))
Unknown (Unknown)
Veterans Sponsored (Veterans
Sponsored)
Header
Did the patient sign an approved informed
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consent
Yes
No
Has HIPAA authorization been obtained
Yes
No
Does the patient have stage III or IV clear cell
ovarian cancer with the tumor having at least
50% clear cell histomorphology
Yes
No
Are there representative stained slides available
from the primary tumor showing lack of
immunoreactivity or negative for expression of
WT-1 antigen and Estrogen Receptor (ER)
antigen by immunohistochemistry?
Yes
No
What stage is the disease?
Stage Iii (Stage III)
Stage Iv (Stage IV)
Date primary confirmed
Performance Status
Fully Active, Able To Carry On All Pre-
disease Performance Without
Restriction. (0)
Restricted In Physically Strenuous
Activity But Ambulatory And Able To
Carry Out Work Of A Light Or Sedentary
Nature, E.g., Light Housework, Office
Work. (1)
Ambulatory And Capable Of All Selfcare
But Unable To Carry Out Any Work
Activities. Up And About More Than 50%
Of Waking Hours. (2)
Has it been at least 2 weeks but not more than 12
weeks after initial surgery performed for the
combined purpose of diagnosis, staging and
cytoreduction?
Yes
No
Is the patient age 18 years or older
Yes
No
Is residual disease optimal (<= 1 cm residual
disease) or suboptimal?
Optimal (Optimal)
Suboptimal (Suboptimal)
Is the patient free of active infection requiring
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antibiotics with exception of uncomplicated
urinary tract infection (UTI)?
Yes
No
Unnamed2
Date of Results (if more than one, enter earliest)
ANC (must be 1,000/mcl or greater)
Platelets (must be 100,000/mcl or greater)
Is Total Bilirubin within normal institutional limits?
Yes
No
Are the AST (SGOT) and alkaline phosphatase
less than or equal to 2.5 times the institutional
upper limit of normal?
Yes
No
Is creatinine <=1.5 x institutional upper limit of
normal, grade 1 per CTCAE Version 4.0?
Yes
No
Is Cholesterol <=350 mg/dL (fasting) and
Triglycerides <=400 mg/dL (fasting)?
Yes
No
Is albumin >=3.0 mg/dL?
Yes
No
Is the PT INR less than or equal to 1.5 (or an in-
range INR, usually between 2 and 3, if a patient
is on a stable dose of therapeutic warfarin for
management of venous thrombosis including
pulmonary thrombo-embolus) and the PTT less
than 1.2 times the Upper Limit of Normal?
Yes
No
Is Neuropathy (sensory or motor) less than or
equal to CTCAE grade 1?
Yes
No
Unnamed3
Will the patient have the following paramenters
measured within 14 days prior to initiating
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protocol therapy (Toxicity Assessment, CBC/Diff/
platelets, Electrolytes Na, K, Cl, BUN, creatinine,
Ca, Mg, PO4, Urine Protein Creatinine Ratio,
Bilirubin, SGOT, Alkaline Phosphatase, Albumin,
Fasting Glucose, Cholesterol, Fasting
Triglycerides, PT/PTT/INR, Blood Pressure
measurement, DLCO, Serum CA-125 Level)
Yes
No
Will the patient have the following parameters
measured within 28 days prior to initiating
protocol therapy (History & Physical, Clinical
tumor measurement, EKG, Chest imaging X-ray
or CT scan of the chest and Radiographic tumor
measurement)
Yes
No
Has the patient met the pre-entry requirements
as specified in section 7.0
Yes
No
If the patient has had a prior invasive malignancy
(except non-melanoma skin cancer), has she had
any evidence of disease within the last 5 years or
does the prior malignancy treatment
contraindicate the current protocol therapy
No (No)
No Prior Malignant Neoplasm (No prior
malignancy)
Yes (Yes)
Has the patient received prior radiotherapy to any
portion of the abdominal cavity or pelvis (Prior
radiation for localized cancer of the breast, head
and neck or skin is permitted as long as it was
completed more than 5 years prior to registration
and the patient remains free of recurrent or
metastatic disease)
Yes
No
Has the patient received prior chemotherapy for
any abdominal or pelvic tumor including neo-
adjuvant chemotherapy for their clear cell ovarian
cancer?
Yes
No
Does the patient have peritoneal or fallopian
carcinoma?
Yes
No
Has the patient had previous treatment with an
mTOR inhibitor (sirolimus, temsirolimus,
everolimus), paclitaxel, or carboplatin?
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Yes
No
Is the patient on medications classified as
CYP3A4 inducers? (See Appendix II)
Yes
No
Is the patient receiving enzyme-inducing
antiepileptic drugs (EIAEDs; e.g., phenytoin,
carbamazepine, phenobarbital) or any other
CYP3A4 inducer such as rifampin or St. John's
Wort, as these may decrease temsirolimus
levels?
Yes
No
Is the patient receiving any Strong CYP3A4
inhibitors? (See Appendix II)
Yes
No
Is the patient receiving any investigational
agents?
Yes
No
Does the patient have severely impaired lung
function defined as a diffusion lung capacity for
carbon monoxide (DLCO) <= 50% of the normal
predicted value and/or O2 saturation <= 88% at
rest on room air?
Yes
No
Does the patient have a history with symptomatic
congestive heart failure of New York Heart
Association Class III or IV (See Appendix III),
unstable angina pectoris, symptomatic
congestive heart failure, myocardial infarction <=6
months of start of study drug, serious
uncontrolled cardiac arrhythmia or any other
clinically significant disease?
Yes
No
Does the patient have active bleeding or
pathologic conditions that carry high risk of
bleeding such as known bleeding disorder,
coagulopathy or tumor involving major vessels?
Yes
No
Does the patient have a baseline requirement for
oxygen?
Yes
No
Is the patient on maintenance corticosteriods?
(Any treatment longer than 5 days.)
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Yes
No
Does the patient have a serious concomitant
illness which, in the opinion of the treating
physician, will place patient at unreasonable risk
from therapy on this protocol?
Yes
No
If the patient is of childbearing potential will she
have a serum pregnancy test within 72 hours of
starting protocol therapy and has she agreed to
practice an effective form of birth control during
study treatment and for six months after
completion of treatment?
No (No)
Not Applicable (Not Applicable)
Yes (Yes)
Is the patient pregnant or nursing
Yes
No
Does the patient have poorly controlled diabetes?
Yes
No
Anticipated date treatment will start
Comments
Provide comments about this Fast Fact Sheet
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Colorectal Cancer NCT01189227 Registration - NSABP
C-11 OPEN Worksheet for Form Entry - 3105627v1.0
NSABP C-11 OPEN Worksheet for Form Entry
Combination Chemotherapy Before or After Surgery in
Treating Patients With Colorectal Cancer With Liver
Metastases That Could Be Removed By Surgery
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=8836C32C-
ED52-3A5B-E040-BB89AD436D98
All rights reserved. Please visit https://medical-data-
models.org/forms/9109
NSABP C-11 OPEN Worksheet for
Form Entry
Header
Patient Initials
Site Name
Patient Birth Date (Month Day Year)
Treating physician
Race
Race
A Person Having Origins In Any Of The
Original Peoples Of North And South
America (including Central America),
And Who Maintains Tribal Affiliation Or
Community Attachment. (American
Indian or Alaska Native)
A Person Having Origins In Any Of The
Original Peoples Of The Far East,
Southeast Asia, Or The Indian
Subcontinent Including, For Example,
Cambodia, China, India, Japan, Korea,
Malaysia, Pakistan, The Philippine
Islands, Thailand, And Vietnam. (Asian)
A Person Having Origins In Any Of The
Black Racial Groups Of Africa. Terms
Such As "haitian" Or "negro" Can Be
Used In Addition To "black Or African
American." (Black or African American)
A Person Having Origins In Any Of The
Original Peoples Of Hawaii, Guam,
Samoa, Or Other Pacific Islands. (Native
Hawaiian or other Pacific Islander)
Could Not Be Determined Or Unsure
(Unknown)
A Person Having Origins In Any Of The
Original Peoples Of Europe, The Middle
East, Or North Africa. (White)
Person Completing Form, Last Name
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Method of Payment (mark primary method only)
Medicaid (Medicaid)
Medicaid And Medicare (Medicaid and
Medicare)
Medicare (Medicare)
Medicare And Private Insurance
(Medicare and Private Insurance)
Military Or Veterans Sponsored Nos
(Military or Veterans Sponsored, Not
Otherwise Specified (NOS))
Military Sponsored (including Champus
& Tricare) (Military Sponsored (including
CHAMPUS & TRICARE))
No Means Of Payment (no Insurance)
(No means of payment (no insurance))
Other (Other)
Private Insurance (Private Insurance)
Self Pay (no Insurance) (Self Pay (No
Insurance))
Unknown (Unknown)
Veterans Sponsored (Veterans
Sponsored)
Ethnicity
A Person Of Mexican, Puerto Rican,
Cuban, Central Or South American Or
Other Spanish Culture Or Origin,
Regardless Of Race. (HISPANIC OR
LATINO)
A Person Not Meeting The Definition For
Hispanic Or Latino. (NOT HISPANIC OR
LATINO)
Could Not Be Determined Or Unsure
(UNKNOWN)
Country of residence
Canada (CA)
Other (Other)
Puerto Rico (PR)
Usa (US)
Other
Patient Zip Code (USA)
Patient Social Security Number (USA only)
Patient gender
Female Gender (Female)
Male Gender (Male)
Unnamed4
Did the patient consent to use of blood samples
for testing related to C-11?
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Yes
No
Did the patient consent to use of tissue and blood
samples for future research to learn about,
prevent, or treat cancer?
Yes
No
Did the patient consent to use of tissue and blood
samples for research about other problems?
Yes
No
Did the patient consent to future contact about
more research?
Yes
No
Has the patient authorized the release of
Protected Health Information to the NSABP?
Yes
No
Date Informed Consent Signed (Month Day Year)
Number of liver metastases on pre-entry
evaluation
Has the patient received prior oxaliplatin therapy?
Yes
No
Page Headers
Patient Initials
NSABP Patient ID
Surgery For Primary Colorectal Tumor
Was a diagnosis of colorectal adenocarcinoma
confirmed histologically?
Yes
No
Date of Report (A copy of the pathology report
must be provided.)
When were suspicious liver metastases first
detected on imaging?
Have the primary tumor and regional nodes been
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resected?
Yes
No
Is there a plan to resect the primary tumor and
the liver metastases in a single surgical
procedure?
Yes
No
Were the surgical margins clear?
Yes
No
Was there evidence of extrahepatic disease?
Yes
No
Did the patient have chemotherapy for the
primary colorectal disease?
Yes
No
Approximately when was the last dose of
chemotherapy?
>24 Months Ago (>24 months ago)
0-6 Months Ago (0-6 months ago)
13-24 Months Ago (13-24 months ago)
7-12 Months Ago (7-12 months ago)
In the past four weeks, has a hepatic surgeon
determined that the patient's liver metastases are
resectable based on the following criteria? (- A
complete resection can be performed in a single
operation AND - There are at least two
uninvolved contiguous segments of the liver)
Yes
No
Date of Assessment (Month Day Year)
Section 2
List of Imaging Evaluations Performed
Contrast Abdominal Cavity Computed
Tomography (CT scan with contrast,
abdomen)
Contrast Chest Computed Tomography
(CT scan with contrast, chest)
Contrast Pelvis Computed Tomography
(CT scan with contrast, pelvis)
Contrast Abdominal Cavity Magnetic
Resonance Imaging (MRI with contrast,
abdomen)
Contrast Pelvis Magnetic Resonance
Imaging (MRI with contrast, pelvis)
Positron Emission Tomography (PET
scan)
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Computed Tomography Contrast
Positron Emission Tomography (PET-CT
scan with contrast)
Computed Tomography No Contrast
Positron Emission Tomography (PET-CT
scan without contrast)
Evaluation Performed?
Yes
No
Date of Assessment (Month Day Year)
Section 2 (continued)
Were hepatic metastases evident on one or more
scans?
Yes
No
Were extrahepatic metastases evident on one or
more scans?
Yes
No
Patient Characteristics
Patient Height (cm)
Patient Weight (kg)
ECOG Performance Status
Fully Active, Able To Carry On All Pre-
disease Performance Without
Restriction. (0)
Restricted In Physically Strenuous
Activity But Ambulatory And Able To
Carry Out Work Of A Light Or Sedentary
Nature, E.g., Light Housework, Office
Work. (1)
Ambulatory And Capable Of All Selfcare
But Unable To Carry Out Any Work
Activities. Up And About More Than 50%
Of Waking Hours. (2)
Capable Of Only Limited Selfcare,
Confined To Bed Or Chair More Than
50% Of Waking Hours. (3)
Completely Disabled. Cannot Carry On
Any Selfcare. Totally Confined To Bed Or
Chair. (4)
Blood Pressure, Systolic
Blood pressure, Diastolic
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Section 3 (continued)
AST
Yes
No
SGOT (AST) (Patient Value units/L)
SGOT (AST) ULN
Date of Collection (Month   Day   Year)
Alkaline Phosphatase
Yes
No
Alkaline Phosphatase (Patient Value units/L)
Alkaline Phosphatase ULN
Date of Collection (Month   Day   Year)
Total Bilirubin
Yes
No
Total Bilirubin (Patient Value mg/dL)
Total bilirubin ULN
Date of Collection (Month   Day   Year)
Serum Creatinine
Yes
No
Serum creatinine (Patient Value mg/dL)
Serum Creatinine ULN
Date of Collection (Month Day Year )
Section 3 (continued)
ANC
Yes
No
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ANC (Patient Value thousand/mm^3)
Date of Collection (Month Day Year )
Platelet Count
Yes
No
Platelet count (Patient Value thousand/mm^3)
Date of Collection (Month Day Year )
Hemoglobin
Yes
No
Hemoglobin (Patient Value g/dL)
Date of Collection (Month Day Year )
CEA
Yes
No
CEA (Patient Value ng/mL)
Date of Collection (Month Day Year )
Calculated Creatinine Clearance
Yes
No
Calculated creatinine clearance (Patient Value
mL/min)
Date of Collection (Month Day Year )
Section 4
Does the patient have a history of diabetes
mellitus?
Yes
No
Does the patient have a diagnosis of anal, small
bowel or appendiceal carcinoma?
Yes
No
Has the patient been diagnosed with colorectal
malignant diseases other than adenocarcinoma,
e.g., sarcoma, lymphoma, carcinoid?
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Yes
No
Does the patient have an unresected primary
tumor in the colon or rectum with significant
symptoms related to obstruction or that will
require radiation therapy?
Yes
No
Does the patient have a history of or current
evidence of extrahepatic metastases? (Exclude
regional nodes that are suspicious on imaging
and associated with the primary colorectal cancer
if the nodes will be resected with the primary
tumor after randomization.)
Yes
No
Does the patient's disease demonstrate
radiographic evidence of metastases to portal
lymph nodes (node > 1 cm in diameter) not
proven by biopsy to be negative?
Yes
No
Has the patient received previous hepatic-
directed therapy including hepatic resection
and/or ablation, hepatic arterial infusion therapy,
or hepatic radiation therapy (exluding incisional or
excisional biopsy)?
Yes
No
Has the patient received previous chemotherapy
or any other systemic therapy for metastatic
colorectal cancer?
Yes
No
Has the patient had a portal vein embolization
(PVE) or other hepatic preconditioning
techniques already performed or are
preconditioning techniques such as PVE planned
for this patient?
Yes
No
Is there intent to use ablation to treat any hepatic
lesion for this patient?
Yes
No
Does the patient have pre-existing chronic
hepatic disease (e.g., chronic active hepatitis,
cirrhosis) that, in the opinion of the investigator
and hepatic surgeon, would limit the patient's
ability to undergo hepatic metastasectomy?
Yes
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No
Does the patient have grade 3 or 4 anorexia,
grade 3 nausea, or >= grade 2 vomiting (per
CTCAE v4.0) related to metastatic disease?
Yes
No
Does the patient have paresthesias, peripheral
sensory neuropathy, or peripheral motor
neuropathy >= grade 2 per CTCAE v4.0 (Exclude
grade 2 neuropathy in patients who will receive
FOLFIRI in this study)?
Yes
No
Does the patient have a documented history of
congestive heart failure requiring chronic medical
therapy?
Yes
No
Does the patient require therapeutic doses of
coumadin or equivalent?
Yes
No
Does the patient have active inflammatory bowel
disease?
Yes
No
Does the patient have an active infection or
chronic infection requiring chronic suppressive
antibiotics?
Yes
No
Does the patient have any known bleeding
diathesis or coagulopathy?
Yes
No
Does the patient have symptomatic interstitial
pneumonitis or is the patient asymptomatic with
definitive evidence of interstitial pneumonitis
described on CT scan, MRI, or chest x-ray?
Yes
No
Has the patient had other malignancies (other
than carcinoma in situ of the cervix, colorectal
carcinoma in situ, melanoma in situ, or basal cell
or squamous cell carcinoma of the skin that has
been treated)?
Yes
No
Is patient considered to be disease-free?
Yes
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No
Did the patient complete therapy for the
malignancies >= 1 year ago?
Yes
No
Is the patient known to have Gilbert's Syndrome?
Yes
No
Is the patient known to be homozygous for the
UGT1A1 28 allele?
Yes
No
Has the patient experienced a previous serious
hypersensitivity reaction to any of the agents the
patient will receive as part of the C-11 trial?
Yes
No
Does the patient have any other serious
concomitant medical condition that, in the opinion
of the investigator, would compromise the safety
of the patient, compromise the patient's ability to
participate in the study, or cause a delay in the
initiation of therapy (surgery or chemotherapy)
longer than 4 weeks following randomization?
Yes
No
Does the patient have psychiatric or addictive
disorders or other condition that, in the opinion of
the investigator, would preclude the patient from
meeting the study requirements?
Yes
No
Has the patient taken any investigational product
within the past 30 days?
Yes
No
Is the patient a woman of child-bearing potential?
(The following questions are to be completed for
female patients only.)
Yes
No
Was a pregnancy test performed?
Yes
No
Date of pregnancy test
Is the patient pregnant or lactating at time of
study entry?
Yes
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Breast Cancer NCT00914043 On-Study - NSABP B-45 Worksheet
for Cardiac Safety Monitoring Report Form - 2847086v1.0
NSABP B-45 Worksheet for Cardiac Safety Monitoring
Report Form
Studying Biological Markers of Fatigue in Women With
Residual Invasive Breast Cancer Enrolled on Clinical Trial
NSABP-B-45
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=64AFECAB-
BEAA-0357-E040-BB89AD431986
All rights reserved. Please visit https://medical-data-
models.org/forms/9110
NSABP B-45 Worksheet for Cardiac
Safety Monitoring Report Form
Header
Patient Initials (Last First Middle)
NSABP Patient ID
Report Period
Time point (for this report)
12 Months After Randomization (12
months after randomization)
3 Months After Randomization (3 months
after randomization)
6 Months After Randomization (6 months
after randomization)
9 Months After Randomization (9 months
after randomization)
Other Specify (Other)
Did the patient receive any systemic anticancer
treatment for documented invasive breast cancer
recurrence or second primary cancer prior to this
Time Point
Yes
No
Section A: Lvef Assessment
Reason LVEF was Assessed at Other Time Point
(If Time Point is Other mark one)
Evaluation Of Symptoms (Evaluation of
Symptoms)
Follow-up Of Previous Assessment
(Follow-up of Previous Assessment)
Other (Other)
Other, specify
Was LVEF assessment performed at this time
point (If Time Point is not Other)
Yes
No
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LVEF (%)
Date of LVEF (MM DD YYYY)
Assessment Type
2-d Echocardiogram (2-D
Echocardiogram)
Muga Scan (MUGA scan)
Section B: Ecg With Qtc Assessment
Has the patient had an EKG (this time point Note:
not required 9 months after randomization)
Yes
No
Was QTc assessed
Yes
No
QTc Interval
Date of EKG (MM DD YYYY)
Section C: Cardiac Events
Did the patient experience any of the following
cardiac events at the specified time point (mark
all that apply)
Definite Cardiac Death (Definite cardiac
death)
Probable Cardiac Death (Probable
cardiac death)
Signs Or Symptoms Of Chf With
Documented Decrease In Lvef To < 50 %
(Signs or symptoms of CHF with
documented decrease in LVEF to < 50
%)
Date of Symptom/Event Assessment (if
applicable Month Day Year)
Date of Definite or Probable Cardiac Death (if
applicable Month Day Year)
Footer
Comments (optional)
Person Completing Form
2 / 3
Breast Cancer NCT00914043 On-Study - NSABP B-45 Worksheet for
Cardiac Safety Monitoring Report Form - 2847086v1.0
Date Form Completed (MM DD YYYY)
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Breast Cancer NCT01272037 Off Treatment
- S1007 Notice of Death Form - 3140582v1.0
S1007 Notice of Death Form (49467)
Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane
With or Without Chemotherapy in Treating Patients With
Invasive RxPONDER Breast Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=90D9C2DE-
6ACF-8071-E040-BB89AD430CF6
All rights reserved. Please visit https://medical-data-
models.org/forms/9113
S1007 Notice of Death Form
Header
SWOG Patient ID
Most Recent SWOG Study No.
Patient Initials (L, F, M)
Institution/Affiliate
Physician
Participating Group Name
Participating Group Study No.
Participating Group Patient ID
Unnamed2
Date of Death (month / day / year)
Causes Of Death
Any cancer (select one)
Contributory (Contributory)
No (No)
Possible (Possible)
Primary Cause (Primary Cause)
Unknown (Unknown)
If cancer was the primary cause or if cancer
possibly or definitely contributed to death, and the
patient had had multiple tumor types, specify
those which were causes of death
Cancer Of Most Recent Swog Study
(Cancer of most recent SWOG study)
Cancer Of Other Swog Study (Cancer of
other SWOG study)
Other Cancer (Other cancer)
Cancer of most recent SWOG study, specify
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cancer
Cancer of other SWOG study, specify cancer
Other cancer, specify
Toxicity from disease related treatment (select
one)
Contributory (Contributory)
No (No)
Possible (Possible)
Primary Cause (Primary Cause)
Unknown (Unknown)
If Primary Cause, Contributory or Possible,
specify treatment and toxicity
Non-cancer and non-treatment related causes
(select one)
Contributory (Contributory)
No (No)
Possible (Possible)
Primary Cause (Primary Cause)
Unknown (Unknown)
If Primary Cause, Contributory or Possible,
specify
Autopsy?
No (No)
Unknown (Unknown)
Yes (Yes)
Source of death information (s)
Autopsy Report (Autopsy report)
Medical Record / Death Certificate
(Medical record / Death certificate)
Other (Other)
Physician (Physician)
Relative Or Friend (Relative or friend)
Other, specify
Comments
Comments
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Breast Cancer NCT00659373 Toxicity - Serious
Adverse Event Form (Form 24-SAE-A) - 2072974v3.0
Serious Adverse Event Form (Form 24-SAE-A)
Brain Function in Premenopausal Women Receiving
Tamoxifen With or Without Ovarian Function Suppression
for Early-Stage Breast Cancer on Clinical Trial IBCSG-2402
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=B111F21A-
A960-319C-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/9115
Serious Adverse Event Form (Form
24-SAE-A)
Section A - Serious Adverse Event Onset
Date of onset (day month year)
Date Section A filled in (date) (within 24 hours of
SAE)
Main Event
Brief Description
Daily Dosage
Admin. (e.g., i.v., p.o.)
Trial Phase (select all that apply)
On Chemotherapy (On chemotherapy)
On Endocrine Therapy (On endocrine
therapy)
On Follow-up Phase (On follow-up
phase)
On Immunotherapy (On immunotherapy)
On Radiation Therapy (On radiation
therapy)
Other, Specify (Other, specify)
Trial Phase, Other specify
Start date of first cycle (chemotheraphy) (day
month year)
Date Started (day month year)
Date Started (day month year)
Date Started (day month year)
Date Started (day month year)
Date Started (day month year)
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Trial Therapy
Date of Last Administration prior to SAE (day
month year)
Concomitant Therapy:
Type of Therapy
Antibiotics (Antibiotics)
Anticoagulants (Anticoagulants)
Antidepressants (Antidepressants)
Antihypertensives (Antihypertensives)
Oral Hypoglycemic / Insulin (Oral
Hypoglycemic / Insulin)
Other(s) (Other(s))
Radiotherapy (Radiotherapy)
Name of Medication
Daily Dosage
Admin. (e.g., i.v., p.o.)
Date Started
Significant Medical History, Concomitant
Diseases and/or Relevant Medical Conditions
Reason for seriousness (select one only)
Congenital Anomaly (Congenital
anomaly)
Fatal. (Fatal.)
Life-threatening (Life-threatening)
Other, Specify (Other, specify)
Overdose (Overdose)
Required Or Prolonged Hospitalization
(Required or prolonged hospitalization)
Resulted In Severe Or Permanent
Disability (Resulted in severe or
permanent disability)
Second Primary Cancer (Second
primary cancer)
Unexpected Grade 4 Toxicity
(Unexpected grade 4 toxicity)
Other specify (seriousness)
Causality assessment regarding protocol
treatment:
Cannot be classified (Cannot be
classified)
Definite (Definite)
Possible (Possible)
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Probable (Probable)
Unrelated (Unrelated)
Toxicity Grade for Events thought to be at least
possibly related
In the Investigator?s opinion, the Event was most
likely due to:
Investigator/Designee Signature
Investigator/Designee Signature
MD Name (please print:)
Phone number
Fax number
Date (day month year)
Ccrr Module For Serious Adverse Event
Form (form 24-sae-a)
Patient ID Number (Study No.)
Patient Initials (f m fl sl)
Patient's Date of Birth (day)
Participating Center/Affiliate
Center Code (Ver.#1)
Date of initial report (within 24 hours of SAE:)
Date of follow-up report (within 15 days of initial
report:)
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Breast Cancer NCT00659373 Toxicity - Serious Adverse Event Form
(Form 24-SAE-A) - 2072974v3.0
Breast Cancer NCT00659373 Pre-Study - Prior
Treatment History Form (Form 24-H) - 2074666v3.0
Prior Treatment History Form (Form 24-H)
Brain Function in Premenopausal Women Receiving
Tamoxifen With or Without Ovarian Function Suppression
for Early-Stage Breast Cancer on Clinical Trial IBCSG-2402
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=B1274765-
836E-53AF-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/9118
Prior Treatment History Form (Form
24-H)
Before Diagnosis: Chemoprevention For
Breast Cancer
Indicate which chemoprevention agents the
patient received BEFORE DIAGNOSIS and
indicate the number of months patient received
these agents. (select all that apply by marking an
?X? in the appropriate Therapy.)
Other, specify (therapy)
Other, specify (therapy)
MONTHS
DATE STOPPED (If continuing, use -1)
Prior Chemotherapy Regimen For Breast
Cancer
Did patient receive adjuvant and/or neoadjuvant
chemotherapy for breast cancer? (Mark your
selection with an ?X? in the appropriate boxes.)
Adjuvant Only (Adjuvant only)
Both Adjuvant And Neoadjuvant (Both
adjuvant and neoadjuvant)
Neoadjuvant Only (Neoadjuvant only)
No (No)
Date of first dose of chemotherapy (day month
year)
Other, specify (therapy)
Other, specify (therapy)
Other, specify (therapy)
Neoadjuvant Total Number of Cycles
1 / 2
Neoadjuvant Total Number of Cycles
DATE STOPPED (If continuing, use -1)
Agent Dose
Agent Dose
Route
Other SERM,  (specify)
DATE STARTED (D M Y)
Investigator/Designee Signature
Date (day month year)
Ccrr Module For Prior Treatment History
Form (form 24-h)
Patient ID Number (Study No.)
Patient Initials (f m fl sl)
Patient's Date of Birth (day)
Participating Center/Affiliate
Center Code (Ver.#1)
2 / 2
Breast Cancer NCT00659373 Pre-Study - Prior Treatment History Form
(Form 24-H) - 2074666v3.0
Breast Cancer NCT00914043 Follow-Up - NSABP
B-45 Worksheet for Follow-up Form - 2829422v1.0
NSABP B-45 Worksheet for Follow-up Form
Studying Biological Markers of Fatigue in Women With
Residual Invasive Breast Cancer Enrolled on Clinical Trial
NSABP-B-45
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=612CCF23-
375D-C0A1-E040-BB89AD434751
All rights reserved. Please visit https://medical-data-
models.org/forms/9119
NSABP B-45 Worksheet for Follow-
up Form
Header
Patient Initials (Last First Middle)
NSABP Patient ID
Vital Status
Patient's Vital Status
Alive (Alive)
Dead (Dead)
Date of Last Contact or Death (month day year)
Source of Survival Information (if alive)
Documentation Of Hospital Or Clinic Visit
(Documentation of hospital or clinic visit)
Other (Other)
Phone Contact To Patient (Phone
contact to patient)
Other,
Primary Cause of Death (if dead)
Due To Other Cause (Due to other
cause)
Due To Protocol Treatment (Due to
protocol treatment)
Due To This Disease (Due to this
disease)
Unknown (Unknown)
Describe Cause of Death (Provide
documentation)
Was there evidence of recurrence at the time of
death
No (No)
Unknown (Unknown)
Yes (Yes)
Cancer Follow-up Status
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Has the patient had a documented clinical
assessment for this cancer (since submission of
the last follow-up form)
Yes
No
Date of Last Clinical Assessment (if applicable
Month Day Year)
First Local-regional Recurrence
Has the patient been diagnosed with first local-
regional recurrence (since submission of the last
follow-up form)
Yes
No
Date of First Local-Regional Recurrence (if
applicable Month Day Year)
Site(s) of First Local-Regional Recurrence (mark
all ipsilateral sites that apply)
Axilla (Axilla)
Axillary Nodes (Axillary nodes)
Chest Wall (Chest wall)
Infraclavicular Nodes (Infraclavicular
nodes)
Internal Mammary (Internal mammary
nodes)
Supraclavicular Nodes (Supraclavicular
nodes)
First Distant Recurrence
Has the patient been diagnosed with first distant
recurrence/progression?
Yes
No
Date of First Distant Recurrence (if applicable
Month Day Year`)
Site(s) of First Distant Recurrence
New Primary Cancer Or Mds
Has a new primary cancer or MDS been
diagnosed that has not been previously reported?
Yes
No
Date of Diagnosis (if applicable Month Day Year)
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Breast Cancer NCT00914043 Follow-Up - NSABP B-45 Worksheet for
Follow-up Form - 2829422v1.0
Site(s) of New Primary
Footer Module
Comments (Optional)
Person Completing Form
Date Form Completed (MM DD YYYY)
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Breast Cancer NCT00914043 Follow-Up - NSABP B-45 Worksheet for
Follow-up Form - 2829422v1.0
Breast Cancer NCT00659373 Treatment - Breast
Radiotherapy Form (Form 24-R) - 2073924v3.0
Breast Radiotherapy Form (Form 24-R)
Brain Function in Premenopausal Women Receiving
Tamoxifen With or Without Ovarian Function Suppression
for Early-Stage Breast Cancer on Clinical Trial IBCSG-2402
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=B0EA70C7-
465E-6363-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/9123
Breast Radiotherapy Form (Form 24-
R)
Ccrr Module For Breast Radiotherapy
Form (form 24-r)
Patient ID No. (Study No.)
Patient Initials (f m fl sl)
Patient's Date of Birth (day)
Participating Center/Affiliate
Center Code
This form is being completed for
Left Breast/side (Left breast/side)
Right Breast/side (Right breast/side)
Did the patient receive intraoperative
radiotherapy (IORT)?
Yes
No
Did patient start adjuvant postoperative
radiotherapy?
Yes
No
Date postoperative radiotherapy started (day
month year)
Date postoperative radiotherapy ended (day
month year)
Total postoperative dose given without boost
(cGy)
Postoperative radiotherapy fields (select all areas
that apply)
Axilla (Axilla)
Breast (Breast)
Chest wall (Chest wall)
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Internal mammary lymph nodes (Internal
mammary lymph nodes)
Other, please specify (Other, please
specify)
Supraclavicular lymph nodes
(Supraclavicular lymph nodes)
Other, ( please specify)
Was postoperative radiotherapy boost given?
Yes
No
Total Dose to Boost Field(s) (cGy)
For those patients who did not start adjuvant
radiotherapy, please give reason (select one box
only)
Early Death (Early death)
Early Recurrence (Early recurrence)
Initially Planned, But Physician Later
Advised Against (Initially planned, but
physician later advised against)
Other, Please Specify (Other, please
specify)
Patient Refused (Patient refused)
Other, (please specify)
Investigator Signature (/Designee)
Date
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Breast Cancer NCT00659373 Treatment - Breast Radiotherapy Form
(Form 24-R) - 2073924v3.0
Breast Cancer NCT00769379 Follow-Up - NSABP Protocol
B-43 Worksheet for Menopausal Status Form - 2677537v1.0
NSABP Protocol B-43 Worksheet for Menopausal Status
Form
Radiation Therapy With or Without Trastuzumab in Treating
Women With Ductal Carcinoma In Situ Who Have
Undergone Lumpectomy
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=39688272-
F98B-5199-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/9124
NSABP Protocol B-43 Worksheet for
Menopausal Status Form
Header
NSABP Patient ID
Patient Initials (Last First Middle)
Menopausal Assessment
Date of Assessment (menopausal status)
Date of Onset of Most Recent Menstrual Period
(since study entry)
Menstrual period within the last 12 months?
Yes
No
Hysterectomy since being entered on study?
Yes
No
Date of Hysterectomy (If yes,)
Does patient have at least one ovary?
Yes
No
Date Second Ovary Removed (If no,)
Tamoxifen treatment since being entered on
study?
Yes
No
Tamoxifen Treatment Start Date
Date of Most Recent Treatment
Aromatase inhibitor treatment since being
entered on study?
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Yes
No
Aromatase inhibitor treatment start date
Date of most recent treatment
LHRH agonist treatment since being entered on
study?
Yes
No
LHRH agonist start date
Date of Most Recent Treatment
Pregnant at any time during last 12 months?
Yes
No
Comments
Comments
Footer
Person Completing Form
Date Form Completed
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Breast Cancer NCT00769379 Follow-Up - NSABP Protocol B-43
Worksheet for Menopausal Status Form - 2677537v1.0
Endometrial Cancer NCT00063999 Toxicity - Common
Toxicity Reporting Form, GOG-0209, Form T - 2075711v3.0
Common Toxicity Reporting Form, GOG-0209, Form T
Combination Chemotherapy in Treating Patients With Stage
III, Stage IV, or Recurrent Endometrial Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=B27B3670-
3E5E-21DA-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/9125
Common Toxicity Reporting Form,
GOG-0209, Form T
Header Module
Date form originally completed (m d y)
Date form amended (m d y)
Person amending form, last name
Patient Name, Last
Patient Name, First
Patient Study ID
Person Completing Form, Last Name
Adverse Events - Section 1
Current course number (The toxicities listed
below occurred following this course of therapy)
Has the patient received any transfusions during
this course of therapy?
No Transfusion (No)
Transfusion With Platelets (Yes,
platelets)
Transfusion With Red Blood Cells (Yes,
red blood cells)
Was patient hospitalized as a result of reported
adverse events?
Yes
No
Were cytokines administered this course?
No (No)
Yes (Yes, specify)
Yes, specify (cytokines)
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Has an Adverse Drug Reaction Report been
filed?
Yes
No
Adverse Events - Section 2
Peripheral WBC count done?
Yes
No
Peripheral WBC count (1000/mm3 Nadir)
CTC Adverse Event Grade
CTC Adverse Event Attribution Code (*
Attribution Codes for Relationship of Event to
Treatment: 1 =Unrelated, 2 =Unlikely, 3 =Possibly,
4 =Probably, 5 =Definitely)
Definite (Definitely)
Possible (Possibly)
Probable (Probably)
Unlikely (Unlikely)
Unrelated (Unrelated)
Peripheral WBC count, Date (m d y)
Peripheral Granulocytes count done?
Yes
No
Peripheral Granulocytes count (ANC, 1000/mm3
Nadir)
Peripheral Granulocytes count, Date
Peripheral Platelet count done?
Yes
No
Peripheral Platelet count (mm3 Nadir)
Peripheral Platelet count, Date
Hemoglobin done?
Yes
No
Hemoglobin (G/DL Nadir)
Hemoglobin, Date
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Endometrial Cancer NCT00063999 Toxicity - Common Toxicity Reporting
Form, GOG-0209, Form T - 2075711v3.0
Adverse Events - Section 3
CTC Adverse Event Term
CTC Adverse Event Grade
CTC Adverse Event Attribution Code (*
Attribution Codes for Relationship of Event to
Treatment: 1 =Unrelated, 2 =Unlikely, 3 =Possibly,
4 =Probably, 5 =Definitely)
Definite (Definitely)
Possible (Possibly)
Probable (Probably)
Unlikely (Unlikely)
Unrelated (Unrelated)
COMMENTS
Footer Module
Participating Group Code
Participating Group Protocol Number
Patient Study ID, Participating Group
Ccrr Module For Common Toxicity
Reporting Form, Gog-0209, Form T
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Endometrial Cancer NCT00063999 Toxicity - Common Toxicity Reporting
Form, GOG-0209, Form T - 2075711v3.0
Breast Cancer NCT00659373 Quality of Life - Quality
of Life Supplement (Form 24-QLS) - 2073782v3.0
Quality of Life Supplement (Form 24-QLS)
Brain Function in Premenopausal Women Receiving
Tamoxifen With or Without Ovarian Function Suppression
for Early-Stage Breast Cancer on Clinical Trial IBCSG-2402
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=B0EA67FC-
7593-635E-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/9126
Quality of Life Supplement (Form 24-
QLS)
Ccrr Module For Quality Of Life
Supplement (form 24-qls)
Patient ID Number (Study No.)
Patient Initials (f m fl sl)
Patient's Date of Birth (day)
Participating Center/Affiliate
Center Code (During the past week:)
I was bothered by things that usually don?t
bother me
Most Of The Time (Most or all of the time
(5-7 days))
Moderate (Occasionally or a moderate
amount of the time (3-4 days))
None Of The Time (Rarely or none of the
time (less than 1 day))
Some Of The Time (Some or a little of
the time (1-2 days))
I did not feel like eating; my appetite was poor
Most Of The Time (Most or all of the time
(5-7 days))
Moderate (Occasionally or a moderate
amount of the time (3-4 days))
None Of The Time (Rarely or none of the
time (less than 1 day))
Some Of The Time (Some or a little of
the time (1-2 days))
I felt that I could not shake off the blues even with
the help of my family and friends
Most Of The Time (Most or all of the time
(5-7 days))
Moderate (Occasionally or a moderate
amount of the time (3-4 days))
None Of The Time (Rarely or none of the
time (less than 1 day))
Some Of The Time (Some or a little of
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the time (1-2 days))
I felt that I was just as good as other people
Most Of The Time (Most or all of the time
(5-7 days))
Moderate (Occasionally or a moderate
amount of the time (3-4 days))
None Of The Time (Rarely or none of the
time (less than 1 day))
Some Of The Time (Some or a little of
the time (1-2 days))
I had trouble keeping my mind on what I was
doing
Most Of The Time (Most or all of the time
(5-7 days))
Moderate (Occasionally or a moderate
amount of the time (3-4 days))
None Of The Time (Rarely or none of the
time (less than 1 day))
Some Of The Time (Some or a little of
the time (1-2 days))
I felt depressed
Most Of The Time (Most or all of the time
(5-7 days))
Moderate (Occasionally or a moderate
amount of the time (3-4 days))
None Of The Time (Rarely or none of the
time (less than 1 day))
Some Of The Time (Some or a little of
the time (1-2 days))
I felt that everything I did was an effort
Most Of The Time (Most or all of the time
(5-7 days))
Moderate (Occasionally or a moderate
amount of the time (3-4 days))
None Of The Time (Rarely or none of the
time (less than 1 day))
Some Of The Time (Some or a little of
the time (1-2 days))
I felt hopeful about the future
Most Of The Time (Most or all of the time
(5-7 days))
Moderate (Occasionally or a moderate
amount of the time (3-4 days))
None Of The Time (Rarely or none of the
time (less than 1 day))
Some Of The Time (Some or a little of
the time (1-2 days))
I thought my life had been a failure
Most Of The Time (Most or all of the time
(5-7 days))
Moderate (Occasionally or a moderate
amount of the time (3-4 days))
None Of The Time (Rarely or none of the
time (less than 1 day))
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Breast Cancer NCT00659373 Quality of Life - Quality of Life Supplement
(Form 24-QLS) - 2073782v3.0
Some Of The Time (Some or a little of
the time (1-2 days))
I felt fearful
Most Of The Time (Most or all of the time
(5-7 days))
Moderate (Occasionally or a moderate
amount of the time (3-4 days))
None Of The Time (Rarely or none of the
time (less than 1 day))
Some Of The Time (Some or a little of
the time (1-2 days))
My sleep was restless
Most Of The Time (Most or all of the time
(5-7 days))
Moderate (Occasionally or a moderate
amount of the time (3-4 days))
None Of The Time (Rarely or none of the
time (less than 1 day))
Some Of The Time (Some or a little of
the time (1-2 days))
I was happy
Most Of The Time (Most or all of the time
(5-7 days))
Moderate (Occasionally or a moderate
amount of the time (3-4 days))
None Of The Time (Rarely or none of the
time (less than 1 day))
Some Of The Time (Some or a little of
the time (1-2 days))
I talked less than usual
Most Of The Time (Most or all of the time
(5-7 days))
Moderate (Occasionally or a moderate
amount of the time (3-4 days))
None Of The Time (Rarely or none of the
time (less than 1 day))
Some Of The Time (Some or a little of
the time (1-2 days))
I felt lonely
Most Of The Time (Most or all of the time
(5-7 days))
Moderate (Occasionally or a moderate
amount of the time (3-4 days))
None Of The Time (Rarely or none of the
time (less than 1 day))
Some Of The Time (Some or a little of
the time (1-2 days))
People were unfriendly
Most Of The Time (Most or all of the time
(5-7 days))
Moderate (Occasionally or a moderate
amount of the time (3-4 days))
None Of The Time (Rarely or none of the
time (less than 1 day))
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Some Of The Time (Some or a little of
the time (1-2 days))
I enjoyed life
Most Of The Time (Most or all of the time
(5-7 days))
Moderate (Occasionally or a moderate
amount of the time (3-4 days))
None Of The Time (Rarely or none of the
time (less than 1 day))
Some Of The Time (Some or a little of
the time (1-2 days))
I had crying spells
Most Of The Time (Most or all of the time
(5-7 days))
Moderate (Occasionally or a moderate
amount of the time (3-4 days))
None Of The Time (Rarely or none of the
time (less than 1 day))
Some Of The Time (Some or a little of
the time (1-2 days))
I felt sad
Most Of The Time (Most or all of the time
(5-7 days))
Moderate (Occasionally or a moderate
amount of the time (3-4 days))
None Of The Time (Rarely or none of the
time (less than 1 day))
Some Of The Time (Some or a little of
the time (1-2 days))
I felt that people disliked me
Most Of The Time (Most or all of the time
(5-7 days))
Moderate (Occasionally or a moderate
amount of the time (3-4 days))
None Of The Time (Rarely or none of the
time (less than 1 day))
Some Of The Time (Some or a little of
the time (1-2 days))
I could not get ?going?
Most Of The Time (Most or all of the time
(5-7 days))
Moderate (Occasionally or a moderate
amount of the time (3-4 days))
None Of The Time (Rarely or none of the
time (less than 1 day))
Some Of The Time (Some or a little of
the time (1-2 days))
How much of a problem was each of the following
during the past four (4) weeks?
Lack of sexual interest
A Little (Little of a problem)
Not At All (Not a problem)
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Not applicable (Not applicable)
Somewhat (Somewhat of a problem)
Very Much (Very much of a problem)
Unable to relax and enjoy sex
A Little (Little of a problem)
Not At All (Not a problem)
Not applicable (Not applicable)
Somewhat (Somewhat of a problem)
Very Much (Very much of a problem)
Difficulty in becoming aroused
A Little (Little of a problem)
Not At All (Not a problem)
Not applicable (Not applicable)
Somewhat (Somewhat of a problem)
Very Much (Very much of a problem)
Difficulty in having an orgasm
A Little (Little of a problem)
Not At All (Not a problem)
Not applicable (Not applicable)
Somewhat (Somewhat of a problem)
Very Much (Very much of a problem)
Pain or discomfort with intercourse
A Little (Little of a problem)
Not At All (Not a problem)
Not applicable (Not applicable)
Somewhat (Somewhat of a problem)
Very Much (Very much of a problem)
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Cervical Cancer NCT00262821 Follow-Up - Follow-
Up Form, Form Q, GOG-0219 - 2302696v3.0
Follow-Up Form, Form Q, GOG-0219
Cisplatin and Radiation Therapy With or Without
Tirapazamine in Treating Patients With Cervical Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=EF89B25C-
6E10-0ECD-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/9127
Follow-Up Form, Form Q, GOG-0219
Header Module
Date form originally completed (m d y)
Date form amended (m d y)
Person amending form, last name
Patient Name, Last
Patient Name, First
Patient Study ID
Person Completing Form, Last Name
Vital Status
Patient's vital status
Alive (Alive)
Dead (Dead)
Last contact date/Death date (m d y)
Primary cause of death
Due To Other Cause (Due to other
cause)
Due To Protocol Treatment (Due to
protocol treatment)
Due To This Disease (Due to this
disease)
Unknown (Unknown)
Describe Cause of Death
Is the patient lost to follow-up?
Yes
No
Notice Of Progression
Has the patient been diagnosed with a new
progression?
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Yes
No
Date of progression (/recurrence)
Site(s) of progression
What was the method used to determine
progression?
Histologic (Histologic)
Physical Exam (Physical exam)
Radiographic (Radiographic)
Tumor Marker (Tumor marker)
Ca125 And Other Biomarkers
Marker Name (s)
Marker Value (s)
Date of CA125 (s or other biomarkers)
Notice Of New Primary
Has a new primary cancer or MDS been
diagnosed that has not been previously reported?
(myelodysplastic syndrome)
Yes
No
Date of diagnosis (m d y)
Site(s) of new primary
Late Adverse Event
Has the patient experienced (prior to diagnosis of
recurrence or second primary) any severe (Grade
>=3), long term toxicity that has not been
previously reported?
Yes
No
Late adverse event term
Late adverse event grade
Late Adverse Event Onset Date (m d y)
2 / 3
Cervical Cancer NCT00262821 Follow-Up - Follow-Up Form, Form Q,
GOG-0219 - 2302696v3.0
CTC adverse event attribution code (Adverse
Event Attribution Codes 1=Unrelated, 2=Unlikely,
3=Possibly, 4=Probably, 5=Definitely)
Definite (Definitely)
Possible (Possibly)
Probable (Probably)
Unlikely (Unlikely)
Unrelated (Unrelated)
Non-protocol Therapy
Is the patient receiving any non-protocol cancer
therapy not previously reported?
Yes
No
Name of other non-protocol therapy
Date of first non-protocol therapy (m d y)
Additional therapy reason
Comments
COMMENTS
Footer Module
Participating Group Code
Participating Group Protocol Number
Participating Group Patient ID
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Endometrial Cancer NCT00063999 Follow-Up -
Follow-Up Form, GOG-0209, Form Q - 2077545v3.0
Follow-Up Form, GOG-0209, Form Q
Combination Chemotherapy in Treating Patients With Stage
III, Stage IV, or Recurrent Endometrial Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=B240426A-
8527-0F73-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/9128
Follow-Up Form, GOG-0209, Form Q
Header Module
Date form originally completed (m d y)
Date form amended (m d y)
Person amending form, last name
Patient Name, Last
Patient Name, First
Patient Study ID
Person Completing Form, Last Name
Vital Status
Patient's vital status
Alive (Alive)
Dead (Dead)
Primary cause of death
Due To Other Cause, Specify (Due to
other cause)
Due To Protocol Treatment (Due to
protocol treatment)
Due To This Disease (Due to this
disease)
Unknown (Unknown)
Describe Cause of Death
Death date / last contact date (m d y)
Was patient unable to be contacted for current
scheduled follow-up?
Yes
No
Notice Of Progression
Has the patient been diagnosed with a new
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progression?
Yes
No
Date of progression (recurrence m d y)
Site(s) of progression
What was the method used to determine
progression?
Histology (Histologic)
Physical Exam (Physical exam)
Radiographic (Radiographic)
Tumor Markers (Tumor marker)
Ca125 And Other Biomarkers
Marker Name (s)
Marker Value (s)
Date of CA125 (or other biomarkers  m d y)
Notice Of New Primary
Has a new primary cancer or MDS been
diagnosed that has not been previously reported?
(myelodysplastic syndrome)
Yes
No
Date of diagnosis (m d y)
Site(s) of new primary
Late Adverse Event
Has the patient experienced (prior to diagnosis of
recurrence or second primary) any severe (Grade
>/= 3), long term toxicity that has not been
previously reported?
Yes
No
Late adverse event term
Late adverse event grade
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0209, Form Q - 2077545v3.0
Late Adverse Event Onset Date (m d y)
CTC adverse event attribution code (*Adverse
Event Attribution Codes 1=Unrelated, 2=Unlikely,
3=Possibly, 4=Probably, 5=Definitely)
Definite (Definitely)
Possible (Possibly)
Probable (Probably)
Unlikely (Unlikely)
Unrelated (Unrelated)
Non-protocol Therapy
Is the patient receiving any non-protocol cancer
therapy not previously reported?
Yes
No
Name of other non-protocol therapy
Date of first non-protocol therapy (m d y)
Additional therapy reason
COMMENTS
Footer Module
Participating Group Code
Participating Group Protocol Number
Patient Study ID, Participating Group
Ccrr Module For Follow-up Form, Gog-
0209, Form Q
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Neoplasms, Breast NCT00490139 On-Study - BIG 2-06 /
NCCTG N063D / EGF106708 - Screening - 2646496v1.0
BIG 2-06 / NCCTG N063D / EGF106708 - Screening
ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment
Optimisation) Study; BIG 2-06/N063D
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=320F58CD-
66A7-57B6-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/9129
BIG 2-06 / NCCTG N063D /
EGF106708 - Screening
Header Module
Centre No.
Subject No.
Eligibility Screening Form
Inclusion Criteria
>= 18 Years Of Age (Age >= 18 years)
Baseline Lvef > 50% Measured By
Echocardiography Or Muga Scan After
Completion Of All Anthracycline-based
(neo-) Adjuvant Chemotherapy And Prior
To The Targeted Therapy(ies) (Baseline
LVEF > 50% measured by
echocardiography or MUGA scan after
completion of all anthracycline-based
(neo-) adjuvant chemotherapy and prior
to the targeted therapy(ies))
Completion Of All Necessary Baseline
Laboratory And Radiological
Investigations (Completion of all
necessary baseline laboratory and
radiological investigations)
Eastern Cooperative Oncology Group
(ecog) Performance Status < 1 (Eastern
Cooperative Oncology Group (ECOG)
performance status < 1)
Known Hormone Receptor Status (er/pgr
Or Er Alone) (Known hormone receptor
status (ER/PgR or ER alone))
Must Have Received At Least Four
Cycles Of An Approved Anthracycline-
based (neo-) Adjuvant Chemotherapy
Regimen (Must have received at least
four cycles of an approved anthracycline-
based (neo-) adjuvant chemotherapy
regimen)
Non-metastatic Operable Primary
Invasive Adenocarcinoma Of The Breast
(Non-metastatic operable primary
invasive adenocarcinoma of the breast)
Overexpression And/or Amplification Of
Her2 In The Invasive Component Of The
Primary Tumor (Overexpression and/or
amplification of HER2 in the invasive
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component of the primary tumor)
Signed Written Informed Consent
(Signed written informed consent)
Exclusion Criteria
(neo-) Or Adjuvant Chemotherapy Using
Peripheral Stem Cell Or Bone Marrow
Stem Cell Support ((Neo-) or adjuvant
chemotherapy using peripheral stem cell
or bone marrow stem cell support)
Any Clinically Staged T4 Tumor,
Including Inflammatory Breast Cancer
(Any clinically staged T4 tumor, including
inflammatory breast cancer)
Any Of The Following Abnormal
Laboratory Tests Immediately Prior To
Randomization (Any of the following
abnormal laboratory tests immediately
prior to randomization (see list in
instructions))
Any Prior Mediastinal Irradiation Except
Internal Mammary Node Irradiation For
The Present Breast Cancer (Any prior
mediastinal irradiation except internal
mammary node irradiation for the
present)
Bilateral Tumors (Bilateral tumors)
Concomitant Use Of Cyp3a4 Inhibitors
Or Inducers (Concomitant use of
CYP3A4 inhibitors or inducers)
Concurrent Anti-cancer Treatment In
Another Investigational Trial With
Hormone Therapy Or Immunotherapy
(Concurrent anti-cancer treatment in
another investigational trial with hormone
therapy or immunotherapy)
Concurrent Anti-cancer Treatment,
Except Hormonal Therapy (Concurrent
anti-cancer treatment, except hormonal
therapy)
History Of Any Prior (ipsi- And/or
Contralateral) Invasive Breast Carcinoma
(History of any prior (ipsi- and/or
contralateral) invasive breast carcinoma)
Malabsorption Syndrome, Disease
Significantly Affecting Gastrointestinal
Function, Or Resection Of The Stomach
Or Small Bowel, Or Person Unable To
Swallow Oral Medication (Malabsorption
syndrome, disease significantly affecting
gastrointestinal function, or resection of
the stomach or small bowel, or person
unable to swallow oral medication)
Maximum Cumulative Dose Of
Doxorubicin >360mg/m2 Or Maximum
Cumulative Dose Of Epirubicin
>720mg/m2 Or Any Prior Anthracyclines
Unrelated To The Present Breast Cancer
(Maximum cumulative dose of
doxorubicin >360mg/m2 or maximum
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cumulative dose of epirubicin
>720mg/m2 or any prior anthracyclines
unrelated to the present breast cancer)
Multifocal Tumors (Multifocal tumors)
Other Concurrent Serious Diseases That
May Interfere With Planned Treatment
Including Severe Pulmonary
Conditions/illness (Other concurrent
serious diseases that may interfere with
planned treatment including severe
pulmonary conditions/illness)
Past Or Current History Of Malignant
Neoplasms, Except For Curatively
Treated Basal And Squamous Cell
Carcinoma Of The Skin Or Carcinoma In
Situ Of The Cervix (Past or current
history of malignant neoplasms, except
for curatively treated basal and
squamous cell carcinoma of the skin or
carcinoma in situ of the cervix)
Patients With Positive Or Suspicious
Internal Mammary Nodes Identified By
Sentinel Node Technique Which Have
Not Been Irradiated Or Will Not Be
Irradiated, Or Patients With
Supraclavicular Lymph Node
Involvement (Patients with positive or
suspicious internal mammary nodes
identified by sentinel node technique
which have not been irradiated or will not
be irradiated, or patients with
supraclavicular lymph node involvement)
Pregnant Or Lactating Women (Pregnant
or lactating women)
Prior Use Of Anti-her2 Therapy For Any
Reason Or Other Prior Biologic Or
Immunotherapy For Breast Cancer (Prior
use of anti-HER2 therapy for any reason
or other prior biologic or immunotherapy
for breast cancer)
Serious Cardiac Illness Or Medical
Conditions (Serious cardiac illness or
medical conditions (including...))
Unresolved Or Unstable Serious Adverse
Event From Prior Adjuvant
Chemotherapy Or Radiotherapy
(Unresolved or unstable serious adverse
event from prior adjuvant chemotherapy
or radiotherapy)
Women Of Childbearing Potential
Including Women Whose Last Menstrual
Period Was <1 Year Ago Who Are
Unable Or Unwilling To Use Adequate
Contraceptive Measures During Study
Treatment (Women of childbearing
potential including women whose last
menstrual period was <1 year ago who
are unable or unwilling to use adequate
contraceptive measures during study
treatment)
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Randomization
Date of Randomization
Assigned Treatment Arm
Lapatinib (Lapatinib alone)
Lapatinib In Combination With
Trastuzumab (Lapatinib in combination
with Trastuzumab)
Trastuzumab (Trastuzumab alone)
Trastuzumab Followed By Lapatinib
(Trastuzumab followed by Lapatinib)
Informed Consent
Date Informed Consent Signed
Date of consent [for] pharmacogenetic research
Did the patient consent to donate blood sample
Yes
No
Did the patient consent to tumor tissue
Yes
No
Did the patient consent to donate additional blood
sample
Yes
No
Did the patient consent to donate fresh/frozen
tissue
Yes
No
Header
Date of Birth
Patient Gender
Female Gender (FEMALE)
Male Gender (MALE)
Race
American Indian Or Alaska Native
(American Indian or Alaska Native)
Asian - Central/south Asian Heritage
(Asian)
Asian: East Asian Heritage (Asian)
Asian: Japanese Heritage (Asian)
Asian: South East Asia Heritage (Asian)
African American (Black or African
American/African Heritage)
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Native Hawaiian Or Other Pacific
Islander (Native Hawaiian or Other
Pacific Islander)
Other (Other)
White: Arabic/north African Heritage
(White)
White: White/caucasian European
Heritage (White)
Other specify
Ethnicity
A Person Of Mexican, Puerto Rican,
Cuban, Central Or South American Or
Other Spanish Culture Or Origin,
Regardless Of Race. (Hispanic or Latino)
A Person Not Meeting The Definition For
Hispanic Or Latino. (Not Hispanic or
Latino)
Menopausal Status
Above Categories Not Applicable And
Age <50 (Above categories not
applicable AND Age < 50)
Above Categories Not Applicable And
Age >= 50 (Above categories not
applicable AND Age >= 50)
Post (prior Bilateral Ovariectomy Or >12
Mo Since Lmp With No Prior
Hysterectomy) (Post (prior bilateral
ovariectomy OR >12 mo since LMP with
no prior hysterectomy))
Pre (<6 Mo Since Lmp And No Prior
Bilateral Ovariectomy And Not On
Estrogen Replacement) (Pre (<6 mo
since LMP AND no prior bilateral
ovariectomy AND not on estrogen
replacement))
Date of last menstrual cycle
Date of pregnancy test
Pregnancy test
Negative (negative)
Not Applicable, Not Female Of Child-
bearing Potential (not applicable, not
female of child-bearing potential)
Positive (positive)
Has the patient had a hysterectomy?
Yes
No
Hysterectomy (date)
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Unilateral ovariectomy/oophorectomy
Yes
No
Specify side
Left (Left)
Right (Right)
Unilateral oophorectomy Date
Patient Status
Date of Physical Exam
Physical exam
Abnormal - Clinically Significant
(Abnormal - Clinically significant)
Abnormal - Not Clinically Significant
(Abnormal - Not clinically significant)
Normal (Normal)
Height (cm)
Weight (Kg)
BSA (m^2)
Blood Pressure, Systolic
Blood pressure, Diastolic
Heart Rate (beats/min)
ECOG Performance Status
Fully Active, Able To Carry On All Pre-
disease Performance Without
Restriction. (0)
Restricted In Physically Strenuous
Activity But Ambulatory And Able To
Carry Out Work Of A Light Or Sedentary
Nature, E.g., Light Housework, Office
Work. (1)
Ambulatory And Capable Of All Selfcare
But Unable To Carry Out Any Work
Activities. Up And About More Than 50%
Of Waking Hours. (2)
Capable Of Only Limited Selfcare,
Confined To Bed Or Chair More Than
50% Of Waking Hours. (3)
Completely Disabled. Cannot Carry On
Any Selfcare. Totally Confined To Bed Or
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Chair. (4)
Dead (5)
Ecg
Date of EKG
Result
Abnormal - Clinically Significant
(Abnormal - Clinically significant)
Abnormal - Not Clinically Significant
(Abnormal - Not clinically significant)
Normal (Normal)
Cardiac Monitoring
Date of LVEF
LVEF
Method of Evaluation
Echocardiogram (Echocardiogram)
Muga Scan (MUGA scan)
Result
Abnormal - Clinically Significant
(Abnormal - Clinically significant)
Abnormal - Not Clinically Significant
(Abnormal - Not clinically significant)
Normal (Normal)
Symptomatic CHF
Yes
No
NYHA classification
Patients With Cardiac Disease But
Without Resulting Limitation Of Physical
Activity. Ordinary Physical Activity Does
Not Cause Undue Fatigue, Palpitation,
Dyspnea Or Anginal Pain. (Class I)
Patients With Cardiac Disease Resulting
In Slight Limitation Of Physical Activity.
They Are Comfortable At Rest. Ordinary
Physical Activity Results In Fatigue,
Palpitation, Dyspnea Or Anginal Pain.
(Class II)
Patients With Cardiac Disease Resulting
In Marked Limitation Of Physical Activity.
They Are Comfortable At Rest. Less
Than Ordinary Activity Causes Fatigue,
Palpitation, Dyspnea Or Anginal Pain.
(Class III)
Patients With Cardiac Disease Resulting
In Inability To Carry On Any Physical
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Activity Without Discomfort. Symptoms
Of Heart Failure Or The Anginal
Syndrome May Be Present Even At
Rest. If Any Physical Activity Is
Undertaken, Discomfort Increases.
(Class IV)
Local Her2 Results
Staining Antibody
Cb-11/ventana Kit (CB-11/Ventana Kit)
Dako A0485 (DAKO A0485)
Dako Herceptest [tm] (DAKO Herceptest
[TM])
Ncl-c-erbb2-316 (NCL-c-erbB2-316)
Other Specify (Other)
Tab-250 (TAB-250)
Other specify
IHC Result
Equivocal (Equivocal)
Negative (Negative)
Non-interpretable (Non-interpretable)
Positive (Positive)
Percentage of invasive tumor cells with complete
membrane staining
FISH Kit or Test Type
Other Specify (Other)
Vysis/path Vysion[tm] (Vysis/PathVysion)
Other specify
FISH Result
Amplified (Amplified)
Equivocal (Equivocal)
Non-interpretable (Non-interpretable)
Not Amplified (Not amplified)
FISH HER2/neu chromosome 17 Ratio
Chromosome 17 copy number
Monosomy (Monosomy)
Normal (Normal)
Polysomy (Polysomy)
Sample test date
Sample test date
Sample test date
8 / 17
Neoplasms, Breast NCT00490139 On-Study - BIG 2-06 / NCCTG N063D
/ EGF106708 - Screening - 2646496v1.0
Not done
Not done
Not done
CISH Kit or Test Type
Other Specify (Other)
Ventana Inform (Ventana INFORM)
Other specify
CISH Result
Amplification (Amplified)
Equivocal (Equivocal)
Not Amplified (Not amplified)
Chromosome 17 copy number
Monosomy (Monosomy)
Normal (Normal)
Polysomy (Polysomy)
Local Her2 Results
Central Lab ID Number
IHC Result
Equivocal (Equivocal)
Negative (Negative)
Non-interpretable (Non-interpretable)
Positive (Positive)
Percentage of invasive tumor cells with complete
membrane staining
FISH Result
Amplified (Amplified)
Equivocal (Equivocal)
Non-interpretable (Non-interpretable)
Not Amplified (Not amplified)
FISH HER2/neu chromosome 17 Ratio
Sample test date
Sample test date
Hormonal Receptor Status
ER % cells stained positive
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PgR % cells stained positive
History Of Primary Breast Cancer
Date of Initial Pathologic Diagnosis
Tumor Laterality
Left (Left)
Right (Right)
Clinical Size of Tumor
Clinical N Stage
No Regional Lymph Node Metastasis
(N0)
Metastasis To Movable Ipsilateral Axillary
Lymph Node(s) (N1)
Metastasis To Ipsilateral Axillary Lymph
Node(s) Fixed Or Matted, Or In Clinically
Apparent* Ipsilateral Internal Mammary
Nodes In The Absence Of Clinically
Evident Lymph Node Metastasis (N2)
Metastasis In Ipsilateral Infraclavicular
Lymph Node(s) With Or Without Axillary
Lymph Node Involvement, Or In Clinically
Apparent* Ipsilateral Internal Mammary
Lymph Node(s) And In The Presence Of
Clinically Evident Axillary Lymph Node
Metastasis; Or, Me (N3)
Pathologic Primary Tumor Size
Margin involvement
Yes
No
Margin involvement
Non-resectable Deep Margins (Non-
resectable deep margins)
Other (Other)
Histologic Type
Apocrine (Apocrine)
Cribriform (Cribriform)
Ductal Nos (Ductal NOS)
Invasive Nos (Invasive NOS)
Lobular (Lobular)
Medullary Carcinoma (Medullary)
Micropapillary (Micropapillary)
Mixed Ductal And Lobular (Mixed ductal
and lobular)
Mucinous Adenocarcinoma (Mucinous)
Other Specify (Other)
Tubulolobular (Tubulolobular)
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Other specify
Is carcinoma in situ present
Yes
No
Histologic type
Ductal Breast Carcinoma In Situ (DCIS)
Lobular Carcinoma In Situ (LCIS)
Mixed Ductal And Lobular (Mixed DCIS
& LCIS)
Is Paget's disease of the nipple present?
Yes
No
Histologic Grade
G1 Low Combined Histologic Grade
(favorable) (G1)
G2 Intermediate Combined Histologic
Grade (moderately Favorable) (G2)
G3 High Combined Histologic Grade
(unfavorable) (G3)
Gx Grade Cannot Be Assessed (GX)
Lymph node involvement
>= 4 Positive Nodes, No Neoadjuvant
Chemotherapy (>= 4 positive nodes, no
neoadjuvant chemotherapy)
1-3 Positive Nodes, No Neoadjuvant
Chemotherapy (1-3 positive nodes, no
neoadjuvant chemotherapy)
Node Negative, No Neoadjuvant
Chemotherapy (Node negative, no
neoadjuvant chemotherapy)
Not Applicable (Not applicable)
Timing of chemotherapy
Concurrent (Concurrently with targeted
therapy)
Sequential (Sequentially)
Hematology And Biochemistry
Date Collected
Result
Abnormal - Clinically Significant
(Abnormal - Clinically significant)
Abnormal - Not Clinically Significant
(Abnormal - Not clinically significant)
Normal (Normal)
History Of Primary Cancer (continued)
Laboratory Name
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ER % cells stained positive
PgR % cells stained positive
City
Postal Code
ER Status
Negative (Negative)
Positive (Positive)
Unknown (Unknown)
Is estrogen receptor analysis result available
Yes
No
Estrogen receptor value
H-score
Allred score
Remmele score
Other
Method
Range
PgR Status
Negative (Negative)
Positive (Positive)
Unknown (Unknown)
Is progesterone receptor analysis result available
Yes
No
Progesterone receptor value
H-score
Allred score
Remmele score
Other
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Method
Range
Sentinel Nodes Sampling
Was sentinel node sampling performed
Yes
No
Sentinel Node Biopsy Date
Laterality
Left (left)
Right (right)
Axillary sentinel node biopsy
Negative (negative)
Positive (positive)
Internal sentinel mammary nodes biopsy
Negative (negative)
Positive (positive)
Not done
Not done
Most Extensive Primary Surgery
Primary breast cancer surgery
Lumpectomy (Lumpectomy)
Modified Radical Mastectomy (Modified
radical mastectomy)
Other (Other)
Partial Mastectomy (Partial Mastectomy)
Quandrantectomy / Segmentectomy
(Quandrantectomy / Segmentectomy)
Radical Mastectomy (Radical
Mastectomy)
Specify
Laterality
Left (left)
Right (right)
Primary Surgery Date
Axillary Node Dissection
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Date of Axillary Dissection
Laterality
Left (left)
Right (right)
Number of Lymph Nodes Examined
Number of Positive Lymph Nodes
Largest tumor deposit
Isolated Tumor Cells Alone (Isolated
tumor cells alone)
Macrometastases (Macrometastases)
Micromets (Micrometastases)
None Detected (None detected)
Not Measured (Not measured)
Not done
Chemotherapy
Agent Name
Total Dose
Initial Dose
Total No. of Cycles
Prior Treatment Regimen Type
Adjuvant (Adjuvant)
Neoadjuvant Therapy (Neoadjuvant)
Date Started
Date Stopped
Previous Or Current Cardiovascular
Disease
Has the patient suffered cardiovascular disease?
Yes
No
Medical condition
Medical condition
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Current (Current)
Resolved (Resolved)
CTC Adverse Event Grade
Treatment Required
Yes
No
Previous Or Current Cardiovascular
Disease
Has the patient been assessed for systemic
disease
Yes
No
Medical condition
Medical condition
Current (Current)
Resolved (Resolved)
CTC Adverse Event Grade
Treatment Required
Yes
No
Ecg
Type of radiological examination
Abdominal Ct-scan (Abdominal CT-scan)
Bilateral Mammogram (Bilateral
mammogram)
Bone Scan (Bone scan (scintigraphy))
Bone X-ray (Bone X-ray)
Ct Scan Of Chest (Chest CT-scan)
Chest X-ray (Chest X-Ray)
Left Mammogram, Only (Left
mammogram, only)
Right Mammogram, Only (Right
mammogram, only)
Type of radiological examination (Other
examinations)
Bone Scan (Bone scan)
Computed Tomography (CT scan)
Endoscopy (Endoscopy)
Lymphangiogram (Lymphangiogram)
Mammography (Mammography)
Magnetic Resonance Imaging (MRI)
Nuclear Scan (Nuclear scan)
Other (Other)
Positron Emission Tomography (PET
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scan)
Pet/ct Scan (PET/CT scan)
Transvaginal Ultrasound (Transvaginal
Ultrasound)
Ultrasound (Ultrasound)
X-ray (X-ray)
Specify
Anatomical site
Abdomen (Abdomen)
Abdomen/abdominal Wall
(Abdomen/abdominal wall)
Bladder (Bladder)
Bone (Bone)
Breast (Breast)
Cervix Uteri (Cervix)
Chest (Chest)
Central Nervous System (CNS)
Colon (Colon)
Colorectal (Colorectal)
Esophagus (Esophagus/Oesophagus)
Head And Neck (Head and Neck)
Heart (Heart)
Kidney (Kidney)
Liver (Liver)
Lung (Lung)
Lymph Node (Lymph Node)
Mouth (Oral Cavity)
Other (Other)
Ovary (Ovary)
Pancreas (Pancreas)
Pelvis (Pelvis)
Peritoneum (Peritoneum)
Pleura (Pleura)
Prostate Gland (Prostate)
Rectum (Rectum)
Skin (Skin)
Small Intestine (Small Intestine)
Spleen (Spleen)
Stomach (Stomach)
Testis (Testicle)
Thyroid Gland (Thyroid)
Date of test
Date of test
Are there any clinically significant abnormalities
Yes
No
Are there any clinically significant abnormalities
Yes
No
Specify
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Specify
Not done
Translational Research (appendix 5)
Type of tissue
Additional Blood Sample For Ctc
(circulating Tumor Cells) (Additional
blood sample for CTC (circulating tumor
cells))
Additional Blood Sample For Proteomics
(Additional blood sample for Proteomics)
Additional Fresh Frozen Tumor Samples
(Additional fresh frozen tumor samples)
Blood Sample For Pgx (Blood sample for
PGx)
Ffpe Tumor Block (FFPE tumor block)
Tumor Tissue For Pgx (Tumor tissue for
PGx)
Date Collected
Was sample obtained
Yes
No
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Cervical Cancer NCT00057928 Pre-Study - SOUTHWEST ONCOLOGY GROUP
S0227 ADVANCED CERVICAL CARCINOMA PRESTUDY FORM - 2056878v3.0
SOUTHWEST ONCOLOGY GROUP S0227 ADVANCED
CERVICAL CARCINOMA PRESTUDY FORM
S0227 Comparison of Cisplatin Combined With Either
Paclitaxel or Gemcitabine in Treating Patients With
Recurrent, Persistent, or Metastatic Cervical Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=A9C2988B-
9167-372F-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/9130
SOUTHWEST ONCOLOGY GROUP
S0227 ADVANCED CERVICAL
CARCINOMA PRESTUDY FORM
Header
SWOG Patient ID
SWOG Study No.
Registration Step
Patient Initials (L, F M)
Institution / Affiliate
Physician (Groups Other than SWOG)
Group Name
Study No.
Pt. ID (Instructions: All dates are MONTH, DAY,
YEAR. Explain any blank fields or blank dates in
the Comments section at the end of the form.
Place an X in appropriate boxes. Circle
AMENDED items in red.)
Disease Description At Diagnosis
Date of definitive histologic diagnosis of primary
tumor
Stage at diagnosis (FIGO, select one)
Refer To Figo Staging For Specific
Gynecologic Cancer (IA)
Refer To Figo Staging For Specific
Gynecologic Cancer (IB)
Refer To Figo Staging For Specific
Gynecologic Cancer (IIA)
Refer To Figo Staging For Specific
Gynecologic Cancer (IIB)
Refer To Figo Staging For Specific
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Gynecologic Cancer (IIIA)
Refer To Figo Staging For Specific
Gynecologic Cancer (IIIB)
Refer To Figo Staging For Specific
Gynecologic Cancer (IVA)
Refer To Figo Staging For Specific
Gynecologic Cancer (IVB)
Histologic grade at diagnosis (check highest
grade)
Grade 1-well Differentiated (1)
Grade 2-moderately Differentiated (2)
Grade 3-poorly Differentiated (3)
Grade Unknown (unknown)
Histologic type at diagnosis (check all that apply)
Adenocarcinoma, Unspecified
(Adenocarcinoma, unspecified)
Adenosquamous (Adenosquamous)
Other, Specify (Other, specify)
Squamous Cell Carcinoma (Squamous
cell carcinoma)
Other, specify
Prior Treatment Related To This Cancer
Primary Surgery
Yes
No
Primary Surgery Date
Radiation therapy
Yes
No
Persistent disease after radiation therapy
Yes
No
Persistent disease after radiation therapy
Yes
No
Prior Chemotherapy
No (No)
Yes (Yes, specify agents)
Yes, specify agents
Other treatment, specify
Disease Description At Study Entry
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Disease status at study entry (If recurrent
disease)
Metastatic disease at presentation
(Metastatic disease at presentation)
Primary Gyn Disease Continues To Be
Present Following Initial Treatment
(Persistent disease despite primary
surgery and/or RT)
Recurrent disease following complete
response to primary surgery and/or RT
(Recurrent disease following complete
response to primary surgery and/or RT)
date of first recurrence
Site of disease at study entry (check all that
apply)
Ascites (Ascites)
Bladder (Bladder)
Bone (Bone)
Cervix (Cervix)
Cns/brain (CNS/Brain)
Colon (Colon)
Endometrium (Endometrium)
Liver (Liver)
Lung (Lung)
Lymph Nodes, Specify (Lymph nodes,
specify)
Other, Specify (Other, specify)
Ovary (Ovary)
Parametrial Involvement (Parametrial
involvement)
Peritoneum (Peritoneum)
Pleura (Pleura)
Pleural Effusion (Pleural effusion)
Skin (Skin)
Uterus (Uterus)
Lymph nodes, specify
Other, specify
Clinical size of tumor at study entry (if
microscopic, enter 0)
Comments
Comments
Ccrr Module For Southwest Oncology
Group S0227 Advanced Cervical
Carcinoma Prestudy Form
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Fallopian Tube Cancer NCT00262847 Follow-
Up - GOG-0218 Follow-Up Form - 2303387v3.0
GOG-0218 Follow-Up Form
Carboplatin and Paclitaxel With or Without Bevacizumab in
Treating Patients With Stage III or Stage IV Ovarian
Epithelial, Primary Peritoneal Cancer, or Fallopian Tube
Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=F0E07E6F-
7EF7-42B7-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/9131
GOG-0218 Follow-Up Form
Header Module
Date form originally completed
Date form amended
Person amending form, last name
Patient Name, Last
Patient Name, First
Patient Study ID
Person Completing Form, Last Name
Vital Status
Patient's vital status
Alive (Alive)
Dead (Dead)
Last contact date/Death date
Primary cause of death
Due To Other Cause (Due to other
cause)
Due To Protocol Treatment (Due to
protocol treatment)
Due To This Disease (Due to this
disease)
Unknown (Unknown)
Describe Cause of Death
Is the patient lost to follow-up
Yes
No
1 / 4
Disease Follow-up Status
Has the patient had a documented clinical
assessment for this cancer since submission of
the previous follow-up form
Yes
No
Date of assessment
Method of assessment (s)
Histologic (Histologic)
Physical Exam (Physical exam)
Radiographic (Radiographic)
Tumor Marker (Tumor marker)
Notice Of Progression/recurrence
Has the patient been diagnosed with a new
progression
Yes
No
Date of progression (/recurrence)
Site of progression (s)
What was the method used to determine
progression
Histologic (Histologic)
Physical Exam (Physical exam)
Radiographic (Radiographic)
Tumor Marker (Tumor marker)
Ca125 And Other Biomarkers
Marker Name (s)
Beta-hcg (beta-HCG)
Ca125 (CA125)
Other (Other)
Marker Value (s)
Date of CA125 (s or other biomarkers)
Notice Of New Primary
Has a new primary cancer or MDS been
diagnosed that has not been previously reported
(myelodysplastic syndrome)
Yes
No
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Fallopian Tube Cancer NCT00262847 Follow-Up - GOG-0218 Follow-Up
Form - 2303387v3.0
Date of diagnosis
Site of new primary (s)
Late Adverse Event
Has the patient experienced any toxicity that has
not been previously reported (prior to diagnosis
of recurrence or second primary)
Yes
No
Late adverse event term
Late adverse event grade
Late Adverse Event Onset Date
CTC adverse event attribution code (*)
Definite (Definitely)
Possible (Possibly)
Probable (Probably)
Unlikely (Unlikely)
Unrelated (Unrelated)
Non-protocol Therapy
Is the patient receiving any non-protocol cancer
therapy not previously reported
Yes
No
Name of other non-protocol therapy
Date of first non-protocol therapy
Additional therapy reason
Comments
COMMENTS
Footer Module
Participating Group Code
Participating Group Protocol Number
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Fallopian Tube Cancer NCT00262847 Follow-Up - GOG-0218 Follow-Up
Form - 2303387v3.0
Participating Group Patient ID
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Fallopian Tube Cancer NCT00262847 Follow-Up - GOG-0218 Follow-Up
Form - 2303387v3.0
Cervical Cancer NCT00803062 On-Study - GOG-0240 Solid
Tumor Evaluation Form (Form D2MV2) - 2728202v1.0
GOG-0240 Solid Tumor Evaluation Form (Form D2MV2)
Paclitaxel and Cisplatin or Topotecan With or Without
Bevacizumab in Treating Patients With Stage IVB,
Recurrent, or Persistent Cervical Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=45826B4E-
823F-4F57-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/9132
GOG-0240 Solid Tumor Evaluation
Form (Form D2MV2)
Header Module
Date form originally completed (m d y)
Date form amended (m d y)
Person amending form, last name
Patient Initials (First, Middle, Last)
Patient Study ID
Person completing form, last name
Target Lesion(s) Evaluation
Did the patient have measurable disease at
baseline
Yes
No
Site of lesion or site of evaluation
Method of Evaluation (*)
Chest X-ray (Chest X-ray)
Clinical Examination (pe) (Clinical
examination)
Ct Scan (CT scan)
Mri (MRI)
Not Evaluated (Not evaluated)
Other (Other)
Spiral Ct Scan (Spiral CT scan)
Ultrasound (Ultrasound)
If Other Specify
Date of evaluation (m d y)
Longest diameter (s)
1 / 3
Sum of Longest Diameters of All Target Lesions
Non-target Lesion(s) Evaluation
Were there any non-target lesions reported at
baseline (If no, skip to the next section)
Yes
No
Site of Lesion
Method of Evaluation (*)
Chest X-ray (Chest X-ray)
Clinical Examination (pe) (Clinical
examination)
Ct Scan (CT scan)
Mri (MRI)
Not Evaluated (Not evaluated)
Other (Other)
Spiral Ct Scan (Spiral CT scan)
Ultrasound (Ultrasound)
If Other Specify
Date of evaluation (m d y)
Follow-Up Status of Lesion (^Follow-up status of
lesion)
New Target Lesion(s) At Follow-up
Evaluation
Was the appearance of any new lesions
documented (If no, skip to the Overall Response
section below.)
Yes
No
Site of Lesion
Method of Evaluation (*)
Chest X-ray (Chest X-ray)
Clinical Examination (pe) (Clinical
examination)
Ct Scan (CT scan)
Mri (MRI)
Not Evaluated (Not evaluated)
Other (Other)
Spiral Ct Scan (Spiral CT scan)
Ultrasound (Ultrasound)
If Other Specify
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Cervical Cancer NCT00803062 On-Study - GOG-0240 Solid Tumor
Evaluation Form (Form D2MV2) - 2728202v1.0
Date of evaluation (m d y)
Overall Response
Disease status at this assessment
Biologic Progression Only (Biologic
progression only)
Complete Remission (Complete
Remission)
Insufficient Evaluation To Determine
Response Status (Insufficient
Evaluation)
Not Applicable - Baseline (N/A -
Baseline)
Not Evaluable (Not evaluable)
Partial Response (Partial Response)
Pd (Progressive Disease)
Stable Disease (Stable Disease)
Overall best confirmed response
Complete Remission (Complete
Remission)
Disease Progression (Disease
progression)
Increasing Disease (Increasing disease)
Insufficient Evaluation To Determine
Response Status (Insufficient
Evaluation)
Not Applicable - Baseline (N/A -
Baseline)
No Disease Progression (No disease
progression)
Non-measurable Disease At Baseline
(Non-measurable disease at baseline)
Stable Disease (Stable Disease)
PR First Observed Date (m d y)
Response Confirmed Date, PR (m d y)
CR First Observed Date (m d y)
Response Confirmed Date, CR (m d y)
Comments
Comments
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Cervical Cancer NCT00803062 On-Study - GOG-0240 Solid Tumor
Evaluation Form (Form D2MV2) - 2728202v1.0
Endometrial Cancer NCT00942357 Follow-
Up - Follow-Up Form (Q) - 2843361v1.0
Follow-Up Form (Q)
Carboplatin and Paclitaxel With or Without Cisplatin and
Radiation Therapy in Treating Patients With Stage I, Stage
II, Stage III, or Stage IVA Endometrial Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=644E86D7-
D4D5-D7C8-E040-BB89AD4321CC
All rights reserved. Please visit https://medical-data-
models.org/forms/9133
Follow-Up Form (Q)
Header Module
Date form originally completed (m d y)
Date form amended (m d y)
Person amending form, last name
Patient Name, Last
Patient Name, First
Patient Study ID
Person Completing Form, Last Name
Vital Status
Patient's vital status
Alive (Alive)
Dead (Dead)
Date of Last Contact or Death (m d y)
Primary Cause of Death
Due To Other Cause (Due to other
cause)
Due To Protocol Treatment (Due to
protocol treatment)
Due To This Disease (Due to this
disease)
Unknown (Unknown)
Describe Cause of Death
Is the patient lost to follow-Up
Yes
No
Notice Of Progression
Has the patient been diagnosed with a new
progression?
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Yes
No
Date of progression (m d y)
Sites of Progression
What was the method used to determine
progression
Histologic (Histologic)
Physical Exam (Physical Exam)
Radiographic (Radiographic)
Tumor Marker (Tumor Marker)
Ca125 And Other Biomarkers
Marker Name (s)
Marker Value (s)
Date of CA125 (s or other biomarkers)
Notice Of New Primary
Has a new primary cancer or MDS been
diagnosed that has not been previously reported?
(myelodysplastic syndrome)
Yes
No
Date of diagnosis (m d y)
Site of New Primary (s)
Late Adverse Event
Has the patient experienced (prior to diagnosis of
recurrence or second primary) any severe (Grade
>=3), long term toxicity that has not been
previously reported
Yes
No
Late adverse event term
Late adverse event grade
Late Adverse Event Onset Date (m d y)
2 / 3
Endometrial Cancer NCT00942357 Follow-Up - Follow-Up Form (Q) -
2843361v1.0
CTC adverse event attribution code (Adverse
Event Attribution Codes 1=Unrelated, 2=Unlikely,
3=Possibly, 4=Probably, 5=Definitely)
Definite (Definite)
Possible (Possible)
Probable (Probable)
Unlikely (Unlikely)
Unrelated (Unrelated)
Non-protocol Therapy
Is the patient receiving any non-protocol cancer
therapy not previously reported?
Yes
No
Name of Other Non-Protocol Therapy
Date of First Non-Protocol Therapy (m d y)
Additional therapy reason
Comments
COMMENTS
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Endometrial Cancer NCT00942357 Follow-Up - Follow-Up Form (Q) -
2843361v1.0
Cervical Cancer NCT01414608 Pre-Study -
ANZGOG-0902 Radiotherapy Form - 3143029v1.0
ANZGOG-0902 Radiotherapy Form
Cisplatin and Radiation Therapy With or Without
Carboplatin and Paclitaxel in Patients With Locally
Advanced Cervical Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=910A7DEE-
7F67-4FA7-E040-BB89AD4352F8
All rights reserved. Please visit https://medical-data-
models.org/forms/9134
ANZGOG-0902 Radiotherapy Form
Header
Institution Code
Patient Initials
External Beam Radiotherapy (ebrt)
RT Dose per Fraction
Total Number of Fractions
Daily RT Dose administered to each field
Radiation Therapy Start Date
Was brachytherapy used?
Yes
No
Brachytherapy Start Date
Brachytherapy End Date
Brachytherapy Total Dose, Boost
Total Number of Brachytherapy Applications
Radiation Therapy End Date
Dose to point A - Left
Total Dose to point A - Left
Dose to point B - Left
Total Dose to point B - Left
1 / 2
Footer Module
Investigator Name
Date
Investigator's signature
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Cervical Cancer NCT01414608 Pre-Study - ANZGOG-0902
Radiotherapy Form - 3143029v1.0
Endometrial Cancer NCT00807768 Follow-Up
- GOG-0249 Follow-Up Form - 2758826v1.0
GOG-0249 Follow-Up Form
Pelvic Radiation Therapy or Vaginal Implant Radiation
Therapy, Paclitaxel, and Carboplatin in Treating Patients
With High-Risk Stage I or Stage II Endometrial Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=4F54A57A-
175D-1F59-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/9135
GOG-0249 Follow-Up Form
Header Module
Date form originally completed (m d y)
Date form amended (m d y)
Person amending form, last name
Patient Name, Last
Patient Name, First
Patient Study ID
Person Completing Form, Last Name
Vital Status
Patient's vital status
Alive (Alive)
Dead (Dead)
Date of Last Contact or Death (m d y)
Primary Cause of Death
Due To Other Cause (Due to other
cause)
Due To Protocol Treatment (Due to
protocol treatment)
Due To This Disease (Due to this
disease)
Unknown (Unknown)
Describe Cause of Death
Is the patient lost to follow-Up
Yes
No
Notice Of Progression
Has the patient been diagnosed with a new
progression?
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Yes
No
Date of progression (m d y)
Sites of Progression
What was the method used to determine
progression
Histologic (Histologic)
Physical Exam (Physical Exam)
Radiographic (Radiographic)
Tumor Marker (Tumor Marker)
Ca125 And Other Biomarkers
Marker Name (s)
Marker Value (s)
Date of CA125 (s or other biomarkers)
Notice Of New Primary
Has a new primary cancer or MDS been
diagnosed that has not been previously reported?
(myelodysplastic syndrome)
Yes
No
Date of diagnosis (m d y)
Site of New Primary (s)
Late Adverse Event
Has the patient experienced (prior to diagnosis of
recurrence or second primary) any severe (Grade
>=3), long term toxicity that has not been
previously reported
Yes
No
Late adverse event term
Late adverse event grade
Late Adverse Event Onset Date (m d y)
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Endometrial Cancer NCT00807768 Follow-Up - GOG-0249 Follow-Up
Form - 2758826v1.0
CTC adverse event attribution code (Adverse
Event Attribution Codes 1=Unrelated, 2=Unlikely,
3=Possibly, 4=Probably, 5=Definitely)
Definite (Definite)
Possible (Possible)
Probable (Probable)
Unlikely (Unlikely)
Unrelated (Unrelated)
Non-protocol Therapy
Is the patient receiving any non-protocol cancer
therapy not previously reported?
Yes
No
Name of Other Non-Protocol Therapy
Date of First Non-Protocol Therapy (m d y)
Additional therapy reason
Comments
COMMENTS
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Endometrial Cancer NCT00807768 Follow-Up - GOG-0249 Follow-Up
Form - 2758826v1.0
Fallopian Tube Cancer NCT00108745 Follow-Up -
Follow-Up Form, GOG-0212, Form Q - 2296326v3.0
Follow-Up Form, GOG-0212, Form Q
Paclitaxel or Polyglutamate Paclitaxel or Observation in
Treating Patients With Stage III or Stage IV Ovarian
Epithelial or Peritoneal Cancer or Fallopian Tube Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=E7488E3D-
0DD6-4AC5-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/9137
Follow-Up Form, GOG-0212, Form Q
Header Module
Date form originally completed (m d y)
Date form amended (m d y)
Person amending form, last name
Patient Name, Last
Patient Name, First
Patient Study ID
Person Completing Form, Last Name
Vital Status
Patient's vital status
Alive (Alive)
Dead (Dead)
Last contact date/Death date (m d y)
Primary cause of death
Due To Other Cause (Due to other
cause)
Due To Protocol Treatment (Due to
protocol treatment)
Due To This Disease (Due to this
disease)
Unknown (Unknown)
Describe Cause of Death
Is the patient lost to follow-up?
Yes
No
Disease Follow-up Status
Has the patient had a documented clinical
assessment for this cancer (since submission of
1 / 3
the previous follow-up form)
Yes
No
Date of Assessment (m d y)
Method of assessment (s)
Histologic (Histologic)
Physical Exam (Physical exam)
Radiographic (Radiographic)
Tumor Marker (Tumor marker)
Notice Of Progression/recurrence
Has the patient been diagnosed with a new
progression?
Yes
No
Date of progression (recurrence)
Site(s) of progression
What was the method used to determine
progression?
Histologic (Histologic)
Physical Exam (Physical exam)
Radiographic (Radiographic)
Tumor Marker (Tumor marker)
Ca125 And Other Biomarkers
Marker Name (s)
Marker Value (s)
Date of CA125 (s or other biomarkers)
Notice Of New Primary
Has a new primary cancer or MDS been
diagnosed that has not been previously reported?
(myelodysplastic syndrome)
Yes
No
Date of diagnosis (m d y)
Site(s) of new primary
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Fallopian Tube Cancer NCT00108745 Follow-Up - Follow-Up Form,
GOG-0212, Form Q - 2296326v3.0
Late Adverse Event
Has the patient experienced (prior to diagnosis of
recurrence or second primary) any toxicity that
has not been previously reported?
Yes
No
Late adverse event term
Late adverse event grade
Late Adverse Event Onset Date (m d y)
CTC adverse event attribution code (Adverse
Event Attribution Codes 1=Unrelated, 2=Unlikely,
3=Possibly, 4=Probably, 5=Definitely)
Definite (Definitely)
Possible (Possibly)
Probable (Probably)
Unlikely (Unlikely)
Unrelated (Unrelated)
Non-protocol Therapy
Is the patient receiving any non-protocol cancer
therapy not previously reported?
Yes
No
Name of other non-protocol therapy
Date of first non-protocol therapy (m d y)
Additional therapy reason
Comments
COMMENTS
Footer Module
Participating Group Code
Participating Group Protocol Number
Participating Group Patient ID
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Fallopian Tube Cancer NCT00108745 Follow-Up - Follow-Up Form,
GOG-0212, Form Q - 2296326v3.0
Cervical Cancer NCT00057928 Follow-Up - SOUTHWEST ONCOLOGY
GROUP FOLLOW-UP TUMOR ASSESSMENT FORM - 2056737v3.0
SOUTHWEST ONCOLOGY GROUP FOLLOW-UP
TUMOR ASSESSMENT FORM
S0227 Comparison of Cisplatin Combined With Either
Paclitaxel or Gemcitabine in Treating Patients With
Recurrent, Persistent, or Metastatic Cervical Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=A9C28ABD-
653E-36E3-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/9139
SOUTHWEST ONCOLOGY GROUP
FOLLOW-UP TUMOR
ASSESSMENT FORM
Header
SWOG Patient ID
SWOG Study No.
Registration Step
Patient Initials (L, F M)
Date form completed
Institution / Affiliate
Physician (Groups Other than SWOG)
Group Name
Study No.
Pt. ID (Instructions: Record the requested
information for all target lesions and all sites of
other disease. Lesion and site numbers L1, S1,
etc. should correspond to the same lesions and
sites of disease as indicated on the baseline
tumor assessment form. If a target lesion was
assessed but measurements were not
obtainable, complete assessment type and
assessment date, and state lesion number and
reason measurement was not obtained in
Comments section on page 2. Record site of any
new lesions since baseline in the New Lesions
section. Place an X in appropriate boxes.)
Target Lesions
Unnamed2 (Lesion number)
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Unnamed3 (Lesion site)
Longest Diameter (cm)
Assessment Type
Laparoscopy (Colposcopy)
Ct Scan (CT scan)
Cytology (Cytologic confirmation)
Laparoscopy (Endoscopy)
Histology (Histologic confirmation)
Mri (MRI scan)
Other (Other)
Clinical Examination (Palpation)
PET scan (PET scan)
Plain film/X-ray with contrast (Plain
film/X-ray with contrast)
Plain film/X-ray without contrast (Plain
film/X-ray without contrast)
Radiograph (Radioisotope scan)
Spiral Ct Scan (Spiral CT scan)
Ultrasound (Ultrasound)
Laparotomy (Visualization)
Assessment Date
Non-target Disease
Unnamed2 (Lesion number)
Unnamed3 (Lesion site)
Extent
Clear increase (Clear increase)
Complete disappearance (Complete
disappearance)
Not assessed (Not assessed)
Present (Present)
Assessment Type
Laparoscopy (Colposcopy)
Ct Scan (CT scan)
Cytology (Cytologic confirmation)
Laparoscopy (Endoscopy)
Histology (Histologic confirmation)
Mri (MRI scan)
Other (Other)
Clinical Examination (Palpation)
PET scan (PET scan)
Plain film/X-ray with contrast (Plain
film/X-ray with contrast)
Plain film/X-ray without contrast (Plain
film/X-ray without contrast)
Radiograph (Radioisotope scan)
Spiral Ct Scan (Spiral CT scan)
Ultrasound (Ultrasound)
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Cervical Cancer NCT00057928 Follow-Up - SOUTHWEST ONCOLOGY
GROUP FOLLOW-UP TUMOR ASSESSMENT FORM - 2056737v3.0
Laparotomy (Visualization)
Assessment Date
New Lesions
Unnamed2 (Lesion number)
Unnamed3 (Lesion site)
Assessment Type
Laparoscopy (Colposcopy)
Ct Scan (CT scan)
Cytology (Cytologic confirmation)
Laparoscopy (Endoscopy)
Histology (Histologic confirmation)
Mri (MRI scan)
Other (Other)
Clinical Examination (Palpation)
PET scan (PET scan)
Plain film/X-ray with contrast (Plain
film/X-ray with contrast)
Plain film/X-ray without contrast (Plain
film/X-ray without contrast)
Radiograph (Radioisotope scan)
Spiral Ct Scan (Spiral CT scan)
Ultrasound (Ultrasound)
Laparotomy (Visualization)
Assessment Date
Assessment Date
Symptomatic deterioration
Yes
No
Comments
Comments
Ccrr Module For Southwest Oncology
Group Follow-up Tumor Assessment Form
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Cervical Cancer NCT00057928 Follow-Up - SOUTHWEST ONCOLOGY
GROUP FOLLOW-UP TUMOR ASSESSMENT FORM - 2056737v3.0
Fallopian Tube Cancer NCT01081262 Follow-Up
- GOG-0241 Follow-Up Form (Q) - 3126299v1.0
GOG-0241 Follow-Up Form (Q)
Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine,
With or Without Bevacizumab, as First-Line Therapy in
Treating Patients With Newly Diagnosed Stage II, Stage III,
Stage IV, or Recurrent Stage I Epithelial Ovarian Cancer or
Fallopian Tube Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=8D161DC6-
F374-44EE-E040-BB89AD431853
All rights reserved. Please visit https://medical-data-
models.org/forms/9142
GOG-0241 Follow-Up Form (Q)
Header Module
Date form originally completed (m d y)
Date form amended (m d y)
Person amending form, last name
Patient Name, Last
Patient Name, First
Patient Study ID
Person Completing Form, Last Name
Vital Status
Patient's vital status
Alive (Alive)
Dead (Dead)
Date of Last Contact or Death (m d y)
Primary Cause of Death
Due To Other Cause (Due to other
cause)
Due To Protocol Treatment (Due to
protocol treatment)
Due To This Disease (Due to this
disease)
Unknown (Unknown)
Describe Cause of Death
Is the patient lost to follow-Up
Yes
No
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Notice Of Progression
Has the patient been diagnosed with a new
progression?
Yes
No
Date of progression (recurrence m d y)
Sites of Progression
What was the method used to determine
progression
Histologic (Histologic)
Physical Exam (Physical Exam)
Radiographic (Radiographic)
Tumor Marker (Tumor Marker)
Ca125 And Other Biomarkers
Marker Name (s)
Marker Value (s)
Date of CA125 (s or other biomarkers)
Notice Of New Primary
Has a new primary cancer or MDS been
diagnosed that has not been previously reported?
(myelodysplastic syndrome)
Yes
No
Date of diagnosis (m d y)
Site of New Primary (s)
Late Adverse Event
Has the patient experienced (prior to diagnosis of
recurrence or second primary) any severe (Grade
>=3), long term toxicity that has not been
previously reported
Yes
No
Late adverse event term
Late adverse event grade
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Fallopian Tube Cancer NCT01081262 Follow-Up - GOG-0241 Follow-Up
Form (Q) - 3126299v1.0
Late Adverse Event Onset Date (m d y)
CTC adverse event attribution code (Adverse
Event Attribution Codes 1=Unrelated, 2=Unlikely,
3=Possibly, 4=Probably, 5=Definitely)
Definite (Definite)
Possible (Possible)
Probable (Probable)
Unlikely (Unlikely)
Unrelated (Unrelated)
Non-protocol Therapy
Is the patient receiving any non-protocol cancer
therapy not previously reported?
Yes
No
Name of Other Non-Protocol Therapy
Date of First Non-Protocol Therapy (m d y)
Additional therapy reason
Comments
Comments
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Fallopian Tube Cancer NCT01081262 Follow-Up - GOG-0241 Follow-Up
Form (Q) - 3126299v1.0
Cervical Cancer NCT01101451 Pre-Study - Gynecologic Oncology
Group Pretreatment Summary Form (Form DR) - 2728315v1.0
Gynecologic Oncology Group Pretreatment Summary Form
(Form DR)
Radiation Therapy With or Without Chemotherapy in
Patients With Stage I or Stage II Cervical Cancer Who
Previously Underwent Surgery
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=45832E79-
C605-72FC-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/9143
Gynecologic Oncology Group
Pretreatment Summary Form (Form
DR)
Header Module
Date form originally completed (m d y)
Date form amended (m d y)
Person amending form, last name
Patient Initials (First, Middle, Last)
Patient Study ID
Person completing form, last name
Non-invasive Diagnostic Procedures
Chest X-Ray Result
Abnormal (Abnormal)
Normal (Normal)
Not Done (Not done)
Date of Chest X-Ray (m d y)
EKG Result
Abnormal (Abnormal)
Normal (Normal)
Not Done (Not done)
Date of EKG (m d y)
MRI Result
Abnormal (Abnormal)
Normal (Normal)
Not Done (Not done)
Date of MRI (m d y)
CT Result
Abnormal (Abnormal)
Normal (Normal)
Not Done (Not done)
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Abnormal specify
Abnormal specify
Abnormal specify
Abnormal specify
Abnormal specify
Date of CT Scan (m d y)
Other Procedure Performed
Abnormal (Abnormal)
Normal (Normal)
Not Done (Not done)
Specify
Procedure Date (m d y)
Are there any target lesions?
Yes
No
Comments
Comments
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Cervical Cancer NCT01101451 Pre-Study - Gynecologic Oncology
Group Pretreatment Summary Form (Form DR) - 2728315v1.0
Sarcoma NCT01533207 Follow-Up - Gynecologic
Oncology Group Follow-Up Form (Form Q) - 2727848v1.0
Gynecologic Oncology Group Follow-Up Form (Form Q)
Gemcitabine Hydrochloride and Docetaxel Followed by
Doxorubicin Hydrochloride or Observation in Treating
Patients With High-Risk Uterine Leiomyosarcoma
Previously Removed by Surgery
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=45808A16-
A3A1-20DA-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/9145
Gynecologic Oncology Group
Follow-Up Form (Form Q)
Header Module
Date form originally completed (m d y)
Date form amended (m d y)
Person amending form, last name
Patient Name, Last
Patient Name, First
Patient Study ID
Person Completing Form, Last Name
Vital Status
Patient's vital status
Alive (Alive)
Dead (Dead)
Date of Last Contact or Death (m d y)
Primary Cause of Death
Due To Other Cause (Due to other
cause)
Due To Protocol Treatment (Due to
protocol treatment)
Due To This Disease (Due to this
disease)
Unknown (Unknown)
Describe Cause of Death
Is the patient lost to follow-Up
Yes
No
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Notice Of Progression
Has the patient been diagnosed with a new
progression?
Yes
No
Date of progression (m d y)
Sites of Progression
What was the method used to determine
progression
Histologic (Histologic)
Physical Exam (Physical Exam)
Radiographic (Radiographic)
Tumor Marker (Tumor Marker)
Ca125 And Other Biomarkers
Marker Name (s)
Marker Value (s)
Date of CA125 (s or other biomarkers)
Notice Of New Primary
Has a new primary cancer or MDS been
diagnosed that has not been previously reported?
(myelodysplastic syndrome)
Yes
No
Date of diagnosis (m d y)
Site of New Primary (s)
Late Adverse Event
Has the patient experienced (prior to diagnosis of
recurrence or second primary) any severe (Grade
>=3), long term toxicity that has not been
previously reported
Yes
No
Late adverse event term
Late adverse event grade
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Sarcoma NCT01533207 Follow-Up - Gynecologic Oncology Group
Follow-Up Form (Form Q) - 2727848v1.0
Late Adverse Event Onset Date (m d y)
CTC adverse event attribution code (Adverse
Event Attribution Codes 1=Unrelated, 2=Unlikely,
3=Possibly, 4=Probably, 5=Definitely)
Definite (Definite)
Possible (Possible)
Probable (Probable)
Unlikely (Unlikely)
Unrelated (Unrelated)
Non-protocol Therapy
Is the patient receiving any non-protocol cancer
therapy not previously reported?
Yes
No
Name of Other Non-Protocol Therapy
Date of First Non-Protocol Therapy (m d y)
Additional therapy reason
Comments
COMMENTS
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Sarcoma NCT01533207 Follow-Up - Gynecologic Oncology Group
Follow-Up Form (Form Q) - 2727848v1.0
Breast Cancer NCT00723294 Registration - ACOSOG-
Z1072 Registration Worksheet - 2919301v1.0
ACOSOG-Z1072 Registration Worksheet
Cryoablation Therapy in Treating Patients With Invasive
Ductal Breast Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=6EC42FC0-
2010-95F5-E040-BB89AD432658
All rights reserved. Please visit https://medical-data-
models.org/forms/9146
ACOSOG-Z1072 Registration
Worksheet
Header Module
Protocol Number
Patient ID
Patient Initials (L F M)
Institution Number
Institution
Are data amended (if data are amended, please
circle in red when using paper form)
Yes
No
Eligibility Criteria
Unifocal primary invasive ductal breast carcinoma
diagnosed by core needle biopsy (NOTE:
Patients with multifocal and/or multicentric
ipsilateral breast cancer, multifocal calcifications,
or DCIS with microinvasion are NOT eligible.
Patients with contralateral disease will remain
eligible. NOTE: Results of ER, PR, HER-2/neu
and Oncotye DX if needed must be obtained on
pre-registration needle core biopsy material. See
Testing Guidelines Section 3.1)
Not Applicable (NA)
No (No)
Yes (Yes)
No history of rotational vacuum assisted core
biopsies; en bloc open surgical biopsy and/or
lumpectomy for diagnosis/treatment of the index
breast cancer
Not Applicable (NA)
No (No)
Yes (Yes)
Tumor size <= 2.0 cm in greatest diameter
(Specifically, the tumor must measure <=2.0 cm
in the axis parallel to the treatment probe and
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<=1.5 cm in the axis anti-parallel to the treatment
probe. Largest size measured by mammogram,
ultrasound or MRI will be used to determine
eligibility)
Not Applicable (NA)
No (No)
Yes (Yes)
Tumor enhancement on pre-study MRI
Not Applicable (NA)
No (No)
Yes (Yes)
Tumor with < 25% intraductal components in the
aggregate
Not Applicable (NA)
No (No)
Yes (Yes)
No prior or planned neoadjuvant chemotherapy
for breast cancer
Not Applicable (NA)
No (No)
Yes (Yes)
Non-pregnant and non-lactating (Patients of
childbearing potential must have a negative
serum or urine pregnancy test. Note: Peri-
menopausal women must be mernorrheic for >12
months to be considered not of childbearing
potential)
N/a (N/A)
No (No)
Yes (Yes)
Adequate breast size for safe cryoablation (Male
breast cancer patients and female breast cancer
patients with breasts too small to allow safe
cryoablation are not eligible as the minimal
thickness of the breast tissue does not lend itself
to cryoablation)
Not Applicable (NA)
No (No)
Yes (Yes)
Instructions
Patient consented to optional blood sample
collection
Yes
No
Patient's Initial Consent given for blood specimen
use for research on the patient's cancer?
Yes
No
Patient's Initial Consent given for blood specimen
use for research unrelated to the patient's
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cancer?
Yes
No
Patient's Initial Consent given for tissue specimen
use for research on the patient's cancer?
Yes
No
Patient's Initial Consent given for tissue specimen
use for research unrelated to the patient's
cancer?
Yes
No
Patient consented to allow an ACOSOG
representative to contact patient in the future to
take part in more research
Yes
No
Description Of Primary Disease
MedDRA Code (10006285 [Breast cancer, NOS])
Primary Site (Tumor Breast)
Histologic Type (check one)
Infiltrating Ductal Carcinoma (Infiltrating
ductal)
Other Specify (Other)
Other specify
Nuclear Grade (check one)
High (High)
Intermediate (Intermediate)
Low (Low)
Biopsy Data
Date of core needle biopsy (mm/dd/yyyy)
Needle gauge
Biopsy clip placed at time of biopsy (check one)
Yes
No
Name of biopsy clip
% Intraductal component (DCIS %)
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HER2 results/IHC (check one)
0 (0)
1+ (1+)
2+ (2+)
3+ (3+)
Not Done: C49484 (not done)
HER2 results/FISH (check one)
Amplified (Amplified)
Not Amplified (Not amplified)
Not Done (Not done)
Date (mm/dd/yyyy)
Date (mm/dd/yyyy)
Estrogen/progesterone Data
ER Status (check one)
Negative (Negative)
Positive (Positive)
Unknown (Unknown)
PgR Status (check one)
Negative (Negative)
Positive (Positive)
Unknown (Unknown)
Pregnancy test done (check one)
Yes
No
Reason pregnancy test not performed (If no
check one)
Other (Other)
Patient Is Female But Is Not Of
Childbearing Potential (Patient is female
but is not of childbearing potential)
Other, specify
Date of Onset of Most Recent Menstrual Period
(mm/dd/yyyy)
Date (mm/dd/yyyy)
Date (mm/dd/yyyy)
Not Applicable (Patient is post-menopausal)
Ultrasound/mammogram
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Is oncotype analysis planned (check one)
Yes
No
Is adequate tumor volume present (If yes check
one)
Cannot Undergo Cryoablation (Cannot
undergo cryoablation)
Need Additional Cores (Need additional
cores)
No (No)
Yes (Yes)
Date of Ultrasound (mm/dd/yyyy)
Dimension 2 (Tumor size width cm)
Dimension 2 (Tumor size width cm)
Dimension 3 (Tumor size depth cm)
Dimension 3 (Tumor size depth cm)
Date of mammogram (mm/dd/yyyy)
Dimension 1 (Tumor size length cm)
Dimension 1 (Tumor size length cm)
Calcifications (check one)
Absent (Absent)
Present (Present)
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Breast Cancer NCT00382070 Registration - NSABP
Protocol B-42 Follow-Up Form Worksheet - 2494051v1.0
NSABP Protocol B-42 Follow-Up Form Worksheet
Letrozole in Treating Postmenopausal Women Who Have
Received Hormone Therapy for Hormone Receptor-Positive
Breast Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=17ADCB3C-
0478-2F7E-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/9148
NSABP Protocol B-42 Follow-Up
Form Worksheet
Header
NSABP Patient ID
Patient Initials (Last First Middle)
Vital Status
Patient's Vital Status
Alive (Alive)
Dead (Dead)
Date of Last Contact or Death (month day year)
Source of Survival Information (if alive)
Documentation Of Hospital Or Clinic Visit
(Documentation of hospital or clinic visit)
Other (Other)
Phone Contact To Patient (Phone
contact to patient)
Other,
Describe Cause of Death (attach documentation)
Primary Cause of Death
Due To Other Cause (Due to other
cause)
Due To Protocol Treatment (Due to
protocol treatment)
Due To This Disease (Due to this
disease)
Unknown (Unknown)
Was there evidence of recurrence at the time of
death
No (No)
Unknown (Unknown)
Yes (Yes)
Cancer Follow-up Status
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Has the patient had a documented clinical
assessment for this cancer (since submission of
the last follow-up form)
Yes
No
Date of Last Clinical Assessment (if applicable)
First Local-regional Recurrence
Has the patient been diagnosed with first local-
regional recurrence
Yes
No
Date of First Local-Regional Recurrence (if
applicable)
Site(s) of First Local-Regional Recurrence (mark
all ipsilateral sites that apply)
Axilla (Axilla)
Axillary Nodes (Axillary nodes)
Chest Wall (Chest wall)
Infraclavicular Nodes (Infraclavicular
nodes)
Internal Mammary (Internal mammary)
Ipsilateral Breast (Ipsilateral breast)
Supraclavicular Nodes (Supraclavicular
nodes)
First Distant Recurrence
Has the patient been diagnosed with first distant
recurrence/progression?
Yes
No
Date of First Distant Recurrence (if applicable)
Site(s) of First Distant Recurrence
New Primary Cancer Or Contralateral
Breast Cancer (cbc)
Has a new primary cancer or contralateral breast
cancer been diagnosed that has not been
previously reported (CBC)
Yes
No
Has a new primary cancer or contralateral breast
cancer been diagnosed that has not been
previously reported (CBC)
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Yes
No
Date of diagnosis
Site of New Primary/Contralateral Breast Cancer
(s - CBC)
Site of New Primary/Contralateral Breast Cancer
(s - CBC)
Osteoporosis Evaluation
Was height and weight measured
Yes
No
Height (If yes, complete)
Weight (kg)
Site
Hip (Hip)
Spine (Spine)
Wrist (Wrist)
Occurrence
Yes
No
Date of diagnosis (If yes,)
Has the patient had a Bone Mineral Density test
(since the previous follow-up report)
Yes
No
Date of Most Recent Bone Mineral Density Test
(If Yes,)
Lumbar-Sacral Spine (T-Score Results)
Total Hip
Femoral Neck
Has the patient begun any new prescribed bone
density medication
Yes
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No
What drug
Biphosphonate (Biphosphonate)
Other (Other)
Specify
Late Thrombotic Event
Adverse Event
Acute Coronary Syndrome (Acute
coronary syndrome)
Ischemia Cerebrovascular (Ischemia
cerebrovascular)
Myocardial Infarction (Myocardial
infarction)
Peripheral Ischemia (Peripheral
ischemia)
Stroke (Stroke)
Thromboembolic Event
(Thromboembolic event)
Transient Ischemic Attacks (Transient
ischemic attacks)
Visceral Arterial Ischemia (Visceral
arterial ischemia)
Grade
Absent Adverse Event (0)
Mild Adverse Event (1)
Moderate Adverse Event (2)
Severe Adverse Event (3)
Life Threatening Adverse Event (4)
Death Related To Adverse Event (5)
Patient Compliance
What percentage of the patient study pills did she
take (Select the item that best describes her
compliance during the latest 6-month period)
About Half (approximately 50%) (About
half (approximately 50%))
About One-fourth (approximately 25%)
(About one-fourth (approximately 25%))
About Three-fourths (approximately
75%) (About three-fourths
(approximately 75%))
All (100%) (All (100%))
Almost All (approximately 90%) (Almost
all (approximately 90%))
None (None)
Only A Few (less Than 25%) (Only a few
(less than 25%))
How was this percentage determined?
Both (Both)
Patient Estimate (Patient Estimate)
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Pill Count (Pill Count)
Footer Module
Completed by
Date
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Colorectal Cancer NCT00096278 Follow-Up - NSABP
PROTOCOL C-08: FOLLOW-UP FORM - 2276708v3.0
NSABP PROTOCOL C-08: FOLLOW-UP FORM
Fluorouracil, Leucovorin, and Oxaliplatin With or Without
Bevacizumab in Treating Patients Who Have Undergone
Surgery for Stage II or Stage III Colon Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=D7F78B7A-
6547-4FB6-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/9150
NSABP PROTOCOL C-08:
FOLLOW-UP FORM
Header
Patient Initials (Last, First Middle)
NSABP Patient ID
Institution Name
Affiliate Name
Person Completing Form Last Name
Person Completing Form First Name
Person Completing Form Phone
Are data amended? (check box if yes, and circle
amended items)
Yes
No
Vital Status
Patient's Vital Status
Alive (Alive)
Dead (Dead)
Date of Last Contact or Death (month day year)
Source of Survival Information (if alive)
Documentation Of Hospital Or Clinic Visit
(Documentation of hospital or clinic visit)
Other (Other)
Phone Contact To Patient (Phone
contact to patient)
Other
Primary Cause of Death (if dead)
Due To Other Cause, Specify (Due to
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other cause)
Due To Protocol Treatment (Due to
protocol treatment)
Due To This Disease (Due to this
disease)
Unknown (Unknown)
Describe Cause of Death (attach documentation)
Was there evidence of recurrence at the time of
death?
No (No)
Unknown (Unknown)
Yes, Autopsy (Yes, autopsy)
Yes, Clinical (Yes, clinical)
Cancer Follow-up Status
Has the patient had a documented clinical
assessment for this cancer (since submission of
the last follow-up form)?
Yes
No
Date of Last Clinical Assessment (if applicable)
First Recurrence
Has the patient been diagnosed with first
recurrence (since submission of the last follow-up
form)? (See "Diagnosis of Colon Cancer
Recurrence" in protocol.)
Yes
No
Recurrence Date (if applicable)
Site(s) of Recurrence
New Primary Cancer Or Mds
Has a new primary cancer or MDS been
diagnosed that has not been previously reported?
Yes
No
Date of Diagnosis (if applicable)
Site(s) of New Primary
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Colorectal Cancer NCT00268463 Treatment - NSABP PROTOCOL
C-09: Report of Arterial Catheter Flow Form - 2319723v3.0
NSABP PROTOCOL C-09: Report of Arterial Catheter Flow
Form
Oxaliplatin and Capecitabine With or Without an Hepatic
Arterial Infusion With Floxuridine in Treating Patients Who
Are Undergoing Surgery and/or Ablation for Liver
Metastases Due to Colorectal Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=FC806838-
F009-67DB-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/9151
NSABP PROTOCOL C-09: Report of
Arterial Catheter Flow Form
Header
Patient Initials (Last First Middle)
NSABP Patient ID
Institution Name
Affiliate Name
Person Completing Form Last Name
Person Completing Form First Name
Person Completing Form Phone
Are data amended (check box if yes, and circle
amended items)
Yes
No
Reason for MAA-HAI Scan
Other (Other reason)
Post-operative Scan (Post-operative
scan)
Technical Problems Are Suspected
Based On The Volume Of Fluid
Administered By The Infusion Pump
During Courses Of Fudr (Technical
problems are suspected based on the
volume of fluid administered by the
infusion pump during courses of FUDR)
To Determine Adequacy Of Hepatic
Perfusion For Possible Further Fudr
Administration At The Time Of
Recurrence Of Hepatic Metastases (To
determine adequacy of hepatic perfusion
for possible further FUDR administration
at the time of recurrence of hepatic
metastases)
To Evaluate For Inadvertent Extrahepatic
Perfusion In The Event Of Severe
Chemical Gastritis And/or Upper
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Gastrointestinal Ulceration (To evaluate
for inadvertent extrahepatic perfusion in
the event of severe chemical gastritis
and/or upper gastrointestinal ulceration)
Other, specify
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Esophageal Cancer NCT00757172 Registration -
ACOSOG-Z4051 Registration Worksheet - 2921081v1.0
ACOSOG-Z4051 Registration Worksheet
Panitumumab, Docetaxel, Cisplatin, Radiation Therapy, and
Surgery in Treating Patients With Newly Diagnosed, Locally
Advanced Esophageal Cancer or Cancer of the
Gastroesophageal Junction
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=6F3CD617-
2357-8015-E040-BB89AD43783A
All rights reserved. Please visit https://medical-data-
models.org/forms/9153
ACOSOG-Z4051 Registration
Worksheet
Header Module
Protocol Number
Patient ID
Patient Initials (L F M)
Institution Number
Institution
Are data amended (if data are amended, please
circle in red when using paper form)
Yes
No
Eligibility Criteria
Age >= 18 years
Yes
No
ECOG Performance Status 0-1 (Zubrod)
Yes
No
Biopsy-proven resectable primary (nonrecurrent)
adenocarcinoma of the distal esophagus or GE
junction (Siewert Type I or II) (Siewert Type
definitions: Siewert Type I: adenocarcinoma of
the distal esophagus Siewert Type II:
adenocarcinoma of the esophago-gastric
junction/real cardia)
Yes
No
Pre-registration EUS, CT of chest and upper
abdomen, and PET must support a clinical stage
of T3N0M0, T2-3N1M0 or T2-3N0-1M1a (celiac
adenopathy must be <=2 cm by EUS) (Clinically
staged T1 tumors and T2N0M0 tumors are not
eligible. N1 does not require biopsy/FNA)
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Yes
No
No definitive radiological evidence of distant
metastases
Yes
No
No pre-existing grade 2 or greater peripheral
neuropathy of any etiology
Yes
No
Adequate bone marrow, hepatic and renal
function prior to registration (WBC >= 3000/mm^3
ANC >= 1,500/mm^3 Hemoglobin >= 9.5 g/dL
Platelet count >= 100,000/mm^3 Creatinine <=
1.5 mg/dL Total bilirubin <= 3 mg/dL AST SGOT
<= 2.0 times ULN ALT SGPT <= 2.0 times ULN
Alkaline phosphatase <= 2.0 times ULN Albumin
>= 2.0 g/dL or prealbumin >= 15 mg/dL
Magnesium >= LLN)
Yes
No
Patient must be evaluated before registration by
medical oncologist, radiation oncologist and
surgeon and deemed fit for protocol therapy and
surgery
No (No)
Unknown (Unknown)
Yes (Yes)
No prior invasive malignancy, unless disease-free
for >= 5 years (Exceptions: non-melanoma skin
cancer, in-situ cancers)
Yes
No
Non-pregnant and non-breast-feeding (Female
participants of childbearing potential must have a
negative urine or serum pregnancy test <= 14
days prior to registration. Perimenopausal
participants must be amenorrheic >= 12 months
to be considered not of childbearing potential. All
patients of reproductive potential must agree to
use an effective method of birth-control while
receiving study therapy and for six months after
completion of therapy)
Yes
No
No history of prior EGFR targeted therapy or
therapy for pancreatic cancer or active infection
requiring intravenous antibiotics at the time of
registration
Yes
No
No uncontrolled intercurrent illness including, but
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not limited to, ongoing or active infection,
symptomatic congestive heart failure, unstable
angina pectoris, cardiac arrhythmia, or psychiatric
illness/social situations
Yes
No
No history of interstitial lung disease e.g.
pneumonitis or pulmonary fibrosis or any
evidence of interstitial lung disease on baseline
chest CT scan
Yes
No
No history of any medical or psychiatric condition
or laboratory abnormality that in the opinion of
the investigator may increase the risks
associated with the study participation or
investigational product(s) administration
Yes
No
Smoking Status
Have you smoked at least 100 cigarettes in your
entire life? (check one)
No (No)
Unknown (Unknown)
Yes (Yes)
How old were you when you first started to
smoke regularly? (Age)
On average, how many cigarettes do/did you
smoke per day
Do you now smoke cigarettes? (smoked in the
past 30 days check one)
Yes
No
Number of years smoked cigarettes (If No)
Date Patient Stopped Smoking (cigarettes
mm/dd/yyyy)
Cigar (Have you used any other tobacco products
at least 100 times in your lifetime)
Yes
No
Pipe (Have you used any other tobacco products
at least 100 times in your lifetime)
Yes
No
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Snuff (Have you used any other tobacco products
at least 100 times in your lifetime)
Yes
No
Chewing tobacco (Have you used any other
tobacco products at least 100 times in your
lifetime)
Yes
No
Other (Have you used any other tobacco
products at least 100 times in your lifetime)
Yes
No
Other, specify
For how many years (If Yes, years)
Laboratory Values
WBC (cells/mm^3)
ANC (cells/mm^3)
Hemoglobin (g/dL)
Platelet count (cells/mm^3)
Serum Creatinine (mg/dL)
Total Bilirubin (mg/dL)
SGOT (AST) (U/L)
SGOT (AST) ULN (U/L)
SGPT (ALT) (U/L)
SGPT (ALT) ULN (U/L)
Alkaline Phosphatase (U/L)
Alkaline Phosphatase ULN (U/L)
Albumin (g/dL or)
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Prealbumin (mg/dL)
Magnesium (mg/dL)
Magnesium, LLN (mg/dL)
Date of collection (mm/dd/yyyy)
Pregnancy Test
Pregnancy test done (check one)
Yes
No
Reason pregnancy test not performed (If No,
check one)
Other (Other)
Patient Is Female But Is Not Of
Childbearing Potential (Patient is female
but is not of childbearing potential)
Patient Is Male (Patient is male)
Other, specify
Pregnancy Test Date (If Yes, Negative
mm/dd/yyyy)
Pre-treatment Staging
Date of endoscopy (mm/dd/yyyy)
Proximal tumor extent (cm from incisors)
Distal tumor extent (cm from incisors)
Siewert Type (check one)
Type I (Type I)
Type Ii (Type II)
Date of CT chest/upper abdomen (mm/dd/yyyy)
CT evidence of tumor invasion into adjacent
structures (check one)
Yes
No
CT suspicious for pulmonary metastases (check
one)
5 / 7
Esophageal Cancer NCT00757172 Registration - ACOSOG-Z4051
Registration Worksheet - 2921081v1.0
Yes
No
CT suspicious for liver metastases (check one)
Yes
No
Biopsy done (If Yes, check one)
Yes
No
CT nodal enlargement (check one)
Yes
No
Nodal Sites (If Yes, indicate check all that apply)
Celiac (Celiac)
Perigastric (Perigastric)
Peritumoral (Peritumoral)
Pre-treatment Staging1
Date of FDG-PET (mm/dd/yyyy)
Maximum SUV
Uptake in LN or other sites (check one)
Yes
No
Date of EUS (mm/dd/yyyy)
Maximum depth of tumor invasion (check one)
Into Adventitia (t3) (Into adventitia (T3))
Into Mucosa/submucosa (t1) (Into
mucosa/submucosa (T1))
Into Muscularis Propria (t2) (Into
muscularis propria (T2))
EUS T stage
EUS N stage
Biopsy done (If Yes, check one)
Yes
No
EUS M stage
Nodes biopsied (check one)
Yes
No
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Biopsy Result (If Yes, indicate)
Negative (negative)
Positive (positive)
LN Site
Pre-treatment Staging2
Clinical T Stage
Tumor Invades Lamina Propria Or
Submucosa (T1)
Tumor Invades Muscularis Propria (T2)
Tumor Invades Adventitia (T3)
Clinical N Stage
No Regional Lymph Node Metastasis
(N0)
Regional Lymph Node Metastasis (N1)
Clinical M Stage
No Distant Metastasis (M0)
Metastases Present - See Figo And Ajcc
Staging For Complete Details (M1a)
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Colorectal Cancer NCT00268463 Follow-Up - NSABP
PROTOCOL C-09: FOLLOW-UP FORM - 2319472v3.0
NSABP PROTOCOL C-09: FOLLOW-UP FORM
Oxaliplatin and Capecitabine With or Without an Hepatic
Arterial Infusion With Floxuridine in Treating Patients Who
Are Undergoing Surgery and/or Ablation for Liver
Metastases Due to Colorectal Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=FC7DA612-
18CD-4443-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/9163
NSABP PROTOCOL C-09:
FOLLOW-UP FORM
Header
Patient Initials (Last First Middle)
NSABP Patient ID
Institution Name
Affiliate Name
Person Completing Form Last Name
Person Completing Form First Name
Person Completing Form Phone
Are data amended (check box if yes, and circle
amended items)
Yes
No
Vital Status
Patient's Vital Status
Alive (Alive)
Dead (Dead)
Date of Last Contact or Death (month day year)
Source of Survival Information (if alive)
Documentation Of Hospital Or Clinic Visit
(Documentation of hospital or clinic visit)
Other (Other)
Phone Contact To Patient (Phone
contact to patient)
Other, specify
Primary Cause of Death (if dead)
Due To Other Cause (Due to other
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cause)
Due To Protocol Treatment (Due to
protocol treatment)
Due To This Disease (Due to this
disease)
Unknown (Unknown)
Describe Cause of Death (attach documentation)
Was there evidence of recurrence at the time of
death
No (No)
Unknown (Unknown)
Yes (Yes)
Type of Evidence (if yes,)
Autopsy (Autopsy)
Clinical (Clinical)
Cancer Follow-up Status
Has the patient had a documented clinical
assessment for this cancer (since submission of
the last follow-up form)
Yes
No
Date of Last Clinical Assessment (if applicable)
First Hepatic Recurrence Since
Randomization
Has the patient been diagnosed with first
HEPATIC recurrence that has not been previously
reported (since randomization)
Yes
No
Recurrence Date (Non-Hepatic if applicable)
First Non-hepatic Recurrence
Has the patient been diagnosed with first non-
hepatic recurrence that has not been previously
reported? (See protocol, "Diagnosis of New
Colorectal Cancer Recurrence.")
Yes
No
Recurrence Date (Non-Hepatic if applicable)
Site of Recurrence (s Non-Hepatic)
New Primary Cancer Or Mds
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Has a new primary cancer or MDS been
diagnosed that has not been previously reported
Yes
No
Date of Diagnosis (if applicable)
Site of New Primary (s)
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Sarcoma, Kaposi xxx Eligibility - Eligibility Form
for Protocol #040 - PR4001 - 2266387v3.0
Eligibility Form for Protocol #040 - PR4001
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=CCE1F242-
913A-4391-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/9164
Eligibility Form for Protocol #040 -
PR4001
Ccrr Module For Eligibility Form For
Protocol #040 - Pr4001
Does the patient have evidence of a prior MI or
cardiac ischemia?
Yes
No
If female capable of childbearing, has the patient
had a negative serum B-HCG within 72 hours
prior to study entry?
N/A (N/A)
No (No)
Yes (Yes)
If female capable of childbearing, does the
patient agree to practice adequate birth control to
prevent pregnancy while receiving treatment and
for three months after treatment is discontinued?
N/A (N/A)
No (No)
Yes (Yes)
If female, is the patient breast feeding?
N/A (N/A)
No (No)
Yes (Yes)
If male of child fathering potential, does the
patient agree to practice adequate birth control?
N/A (N/A)
No (No)
Yes (Yes)
In the opinion of the investigator, is the patient
capable of complying with the protocol?
Yes
No
If patient is receiving antiretroviral therapy, is the
patient on a stable regimen for at least 4 weeks
prior to study entry?
Yes
No
Does the patient have concurrent, acute, active
opportunistic infection other than oral thrush or
genital herpes within 14 days of enrollment?
Yes
No
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Does the patient have symptomatic visceral
Kaposi's Sarcoma requiring cytotoxic therapy
unless the patient has already been shown to be
refractory to or intolerant of all currently approved
agents for visceral Kaposi's Sarcoma?
Yes
No
Does the patient have concurrent neoplasia
requiring cytotoxic therapy?
Yes
No
Has the patient had acute treatment for an
infection (other than oral thrush or genital herpes)
or other serious medical illness within 14 days of
study entry?
Yes
No
Has the patient had anti-neoplastic treatment for
Kaposi's Sarcoma (including chemotherapy,
radiation therapy, local therapy, biological therapy,
or investigational therapy) within two weeks of
study entry?
Yes
No
Has the patient had previous local therapy of any
KS-indicator lesion within 60 days unless the
lesion has clearly progressed since treatment?
Yes
No
Has the patient used of investigational drugs
other than IND-available anti-retroviral agents?
Yes
No
Does the patient have ability and willingness to
give informed consent?
Yes
No
Is the patient age of 18 or older?
Yes
No
Does the patient have biopsy proven KS involving
the skin, lymph nodes, oral cavity, gastrointestinal
(GI) tract and/or lungs?
Yes
No
Does the patient have Serologic documentation
of HIV infection 21 days prior to study entry, as
evidenced by positive ELISA, positive Western
Blot, or other federally approved licensed HIV
test?
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Yes
No
Is patient's baseline Karnofsky performance
status >60%?
Yes
No
Is patient's hemoglobin > 8 g/dl within 7 days of
study entry?
Yes
No
Is patient's absolute neutrophil count > 1500
cells/mm3 and platelets > 100,000 cells/mm3
within 7 days of study entry?
Yes
No
Is patient's creatinine < 1.5 times the upper limit
of normal within 7 days of study entry?
Yes
No
Is patient's total bilirubin <1.5x ULN within 7 days
of study entry?
Yes
No
Is patient's AST (SGOT) and ALT (SGPT) < 3 x
the upper limit of normal within 7 days of study
entry?
Yes
No
Is patient's life expectancy > 3 months?
Yes
No
Patient Initials
Study#
Site#
ID#
Visit Date
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Colorectal Cancer NCT01189227 Follow-Up - NSABP
C-11 Worksheet for Follow-up Form - 3107456v1.0
NSABP C-11 Worksheet for Follow-up Form
Combination Chemotherapy Before or After Surgery in
Treating Patients With Colorectal Cancer With Liver
Metastases That Could Be Removed By Surgery
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=8872BD9C-
FAAE-BB88-E040-BB89AD432025
All rights reserved. Please visit https://medical-data-
models.org/forms/9168
NSABP C-11 Worksheet for Follow-
up Form
Header
NSABP Patient ID
Patient Initials (Last First Middle)
Vital Status
Patient's Vital Status
Alive (Alive)
Dead (Dead)
Date of Last Contact or Death (month day year)
Source of Survival Information (if alive)
Documentation Of Hospital Or Clinic Visit
(Documentation of hospital or clinic visit)
Other (Other)
Phone Contact To Patient (Phone
contact to patient)
Other,
Primary Cause of Death (if dead)
Due To Other Cause (Due to other
cause)
Due To Protocol Treatment (Due to
protocol treatment)
Due To This Disease (Due to this
disease)
Unknown (Unknown)
Describe Cause of Death (submit documentation)
Was there evidence of recurrence at the time of
death
No (No)
Unknown (Unknown)
Yes (Yes)
Diagnostic Imaging
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Did the patient have diagnostic imaging
Yes
No
Date of most recent diagnostic imaging
Type of imaging
Computed Tomography (CT scan)
Magnetic Resonance Imaging (MRI)
Positron Emission Tomography (PET
scan)
Pet/ct Scan (PET/CT scan)
First Distant Recurrence
Has the patient been diagnosed with first
recurrence
Not Applicable (N/A)
No (No)
Yes (Yes)
Recurrence Date
Site(s) of Recurrence
New Primary Cancer Or Mds
Has a new primary cancer or MDS/AML/ALL
been diagnosed that has not been previously
reported
Yes
No
Date of Diagnosis (if applicable Month Day Year)
Site(s) of New Primary
Cea Level
Has the CEA level of the patient been determined
Yes
No
Date of most recent CEA
CEA Level
Footer Module
2 / 3
Colorectal Cancer NCT01189227 Follow-Up - NSABP C-11 Worksheet
for Follow-up Form - 3107456v1.0
Comments (Optional)
Person Completing Form
Date Form Completed (MM DD YYYY)
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Colorectal Cancer NCT01189227 On-Study - NSABP
C-11 Worksheet for Surgery Form - 3108323v1.0
NSABP C-11 Worksheet for Surgery Form
Combination Chemotherapy Before or After Surgery in
Treating Patients With Colorectal Cancer With Liver
Metastases That Could Be Removed By Surgery
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=88886A5F-
48CD-CEEC-E040-BB89AD4347C8
All rights reserved. Please visit https://medical-data-
models.org/forms/9169
NSABP C-11 Worksheet for Surgery
Form
Header
Patient Initials (Last First Middle)
NSABP Patient ID
Section 1
Was the patient's primary tumor resected
Yes
No
Reason resection was not performed (If no,)
Toxicity Adverse Event (Adverse
event/toxicity)
Death (Death)
Local Regional Tumor Growth (Local
regional tumor growth)
Metastatic Disease (Metastatic disease)
Other (Other)
Patient Refused (Patient refused)
Second Primary Cancer (Second
primary cancer)
Other, specify
Date of Resection
Number of Lymph Nodes Examined
Number of Positive Lymph Nodes
Are all surgical margins of resection negative for
tumor
Yes
No
Tumor Location
Appendix (Appendix)
Ascending Colon (Ascending colon)
Cecum (Cecum)
Descending Colon (Descending colon)
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Hepatic Flexure (Hepatic flexure)
Rectum (Rectum)
Sigmoid Colon (Sigmoid colon)
Splenic Flexure (Splenic flexure)
Transverse Colon (Transverse colon)
Unknown (Unknown)
Primary tumor surgical procedure
Abdominal Perineal Resection
(Abdominal perineal resection)
Anterior Resection (Anterior resection)
Colonoscopic Polypectomy
(Colonoscopic polypectomy)
Colectomy Extension Left
Hemicolectomy (Extended left
hemicolectomy/colectomy)
Colectomy Right Extension
Hemicolectomy (Extended right
hemicolectomy/colectomy)
Colectomy Left Hemicolectomy (Left
hemicolectomy/colectomy)
Local Excision Of Rectal Cancer (Local
excision of rectal cancer)
Anterior Low Excision (Low anterior
resection)
Unknown Other (Other/Unknown)
Right Colectomy Hemicolectomy (Right
hemicolectomy/colectomy)
Sigmoid Colectomy (Sigmoid colectomy)
Subtotal Colectomy (Subtotal colectomy)
Total Proctocolectomy (Total
proctocolectomy)
Transverse Colectomy (Transverse
colectomy)
Pathologic T Stage
No Evidence Of Primary Tumor (T0)
Tumor Invades Submucosa (T1)
Tumor Invades Muscularis Propria (T2)
Tumor Invades Through The Muscularis
Propria Into The Pericolorectal Tissues
(T3)
Tumor Penetrates To The Surfaces Of
The Visceral Peritoneum (T4a)
Tumor Directly Invades Or Is Adherent To
Other Organs Or Structures (T4b)
Carcinoma In Situ: Intraepithelial Or
Invasion Of Lamina Propria (Tis)
Primary Tumor Cannot Be Assessed
(TX)
Section 2
Were extrahepatic metastases identified after
randomization and prior to initial surgery
Yes
No
Was hepatic surgery initiated?
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Yes
No
Reason surgery was not initiated
Toxicity Adverse Event (Adverse
event/toxicity)
Death (Death)
Metastatic Disease (Metastatic disease)
Other (Other)
Patient Refused (Patient refused)
Hepatic Progression Metastasis
(Progression of hepatic metastases)
Second Primary Cancer (Second
primary cancer)
Number of hepatic metastases
Other, specify
Date of first hepatic surgery
Were extrahepatic metastases identified during
initial surgery
Yes
No
Outcome of surgery
Laproscopic Exploration, No Resection
(Laproscopic exploration, no resection)
Open Laparotomy (Open laparotomy, no
resection)
Margin Negative Finding (R0 - Margin-
negative)
R1 - Microscopically Positive Margin Of
Any Of The Resected Tumor Nodules
(R1 - Microscopically positive margin of
any of the resected tumor nodules)
Margin Positive Finding (R2 - Unresected
gross residual disease at any margin or
elsewhere in the liver)
What was the estimated percentage of the
remnant volume of liver (i.e., percentage of liver
that remains after surgery)
Were at least two adjacent liver segments spared
Yes
No
Section 2 (continued)
Liver procedure
Caudate Resection (Caudate resection)
Center Hepatectomy (Central
hepatectomy)
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Hepatic Segmentectomy, Other (Hepatic
segmentectomy, other)
Left Hepatectomy (Left hepatectomy)
Left Lateral Sectionectomy (Left lateral
sectionectomy)
Unknown Other (Other/Unknown)
Partial Hepatectomy, Multiple (Partial
hepatectomy, multiple)
Partial Hepatectomy, Single (Partial
hepatectomy, single)
Right Anterior Sectionectomy (Right
anterior sectionectomy)
Right Hepatectomy (Right hepatectomy)
Right Posterior Sectionectomy (Right
posterior sectionectomy)
Were ablative techniques used to eliminate gross
disease
Yes
No
Number of hepatic metastases
Longest Diameter of Lesion(s)
Number of hepatic metastases with viable tumor
cells
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Colorectal Cancer NCT01189227 Toxicity - NSABP C-11
Worksheet for Surgical Complications Form - 3107700v1.0
NSABP C-11 Worksheet for Surgical Complications Form
Combination Chemotherapy Before or After Surgery in
Treating Patients With Colorectal Cancer With Liver
Metastases That Could Be Removed By Surgery
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=8875CBD2-
E809-4D15-E040-BB89AD43751B
All rights reserved. Please visit https://medical-data-
models.org/forms/9170
NSABP C-11 Worksheet for Surgical
Complications Form
Header
Patient Initials (Last First Middle)
NSABP Patient ID
Header
How many units of RBC were given
intraoperatively and postoperatively
On postoperative day
On postoperative day
What was the maximum postoperative bilirubin
level (from post-op day 31 to the day before the
start of postoperative therapy [or postoperative
day 84, if postoperative therapy will not be
initiated] - mg/dL)
Need for reoperation within the 30-day
postoperative period (Did the patient experience:)
Yes
No
Any grade 5 event (Did the patient experience:)
Yes
No
Blood bilirubin > 10 mg/dL for > 3 consecutive
days? (Hepatectomy-specific morbidity)
Yes
No
Biliary fistula with drain output > 100 mL/day for >
10 days (Hepatectomy-specific morbidity)
Yes
No
Adverse Event
Abdominal Infection (Abdominal
infection)
Acute Coronary Syndrome (Acute
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coronary syndrome)
Acute Renal Failure (Acute kidney injury)
Ascites (Ascites)
Infectious Lung Disorder (Lung infection)
Myocardial Infarction (Myocardial
infarction)
Septicemia (Sepsis)
Cerebrovascular Accident (Stroke)
Thromboembolism (Thromboembolic
event)
Transient Ischemic Attack (Transient
ischemic attacks)
Wound Dehiscence (Wound dehiscence)
Grade
Absent Adverse Event (0)
Mild Adverse Event (1)
Moderate Adverse Event (2)
Severe Adverse Event (3)
Life Threatening Adverse Event (4)
Death Related To Adverse Event (5)
None of the listed grades (Mark response in
column below when an adverse event occurred
with a grade lower than those listed, or when an
adverse event did not occur.)
Selected Surgical Complications
Did the patient start postoperative therapy on or
before postoperative day 31 (If postoperative
therapy will not start after surgery, report surgical
complications through postoperative day 84 in
this section.)
Yes
No
On postoperative day
What was the maximum postoperative bilirubin
level (from post-op day 31 to the day before the
start of postoperative therapy [or postoperative
day 84, if postoperative therapy will not be
initiated] - mg/dL)
Any grade 5 event (Did the patient experience:)
Yes
No
Did the patient initiate postoperative therapy
Yes
No
Adverse Event
Abdominal Infection (Abdominal
infection)
Acute Coronary Syndrome (Acute
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coronary syndrome)
Acute Renal Failure (Acute kidney injury)
Ascites (Ascites)
Infectious Lung Disorder (Lung infection)
Myocardial Infarction (Myocardial
infarction)
Septicemia (Sepsis)
Cerebrovascular Accident (Stroke)
Thromboembolism (Thromboembolic
event)
Transient Ischemic Attack (Transient
ischemic attacks)
Wound Dehiscence (Wound dehiscence)
Grade
Absent Adverse Event (0)
Mild Adverse Event (1)
Moderate Adverse Event (2)
Severe Adverse Event (3)
Life Threatening Adverse Event (4)
Death Related To Adverse Event (5)
None of the listed grades (Mark response in
column below when an adverse event occurred
with a grade lower than those listed, or when an
adverse event did not occur.)
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Endometrial Cancer NCT00807768 On-Study - GOG-
0249 Uterine Cancer - On Study Form - 2760084v1.0
GOG-0249 Uterine Cancer - On Study Form
Pelvic Radiation Therapy or Vaginal Implant Radiation
Therapy, Paclitaxel, and Carboplatin in Treating Patients
With High-Risk Stage I or Stage II Endometrial Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=4FF32E53-
FBDF-394B-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/9173
GOG-0249 Uterine Cancer - On
Study Form
Header Module
Date form originally completed (m d y)
Date form amended (m d y)
Person amending form, last name
Patient Initials
Patient Study ID
Person Completing Form, Last Name
Uterine Cancer: Disease Description
Date of Definitive Histologic Diagnosis of Primary
Tumor (m d y)
Primary Surgery Type (s check all that apply)
Bilateral Salpingo-oophorectomy
(bilateral salpingo-oophorectomy)
Biopsy Only (Biopsy only)
Other, Specify (other specify)
Para-aortic Node Sampling/dissection
(para-aortic node sampling/dissection)
Pelvic Node Sampling/dissection (pelvic
node sampling/dissection)
Total Hysterectomy (total hysterectomy)
Unilateral Salpingo-oophorectomy
(unilateral salpingo-oophorectomy)
Other specify
Stage (at diagnosis)
Staging System (FIGO)
1988 (1988)
2009 (2009)
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Lymph Node Metastasis
Lymph Nodes Type
Other Specify (other)
Para-aortic (para-aortic)
Pelvic (pelvic)
Other specify
Method of Evaluation
Pathologic (Pathologic)
Method of Evaluation
Pathologic (Pathologic)
Lymph Node Involvement
Equivocal (equivocal)
Negative (negative)
Not Evaluated (not evaluated)
Positive (positive)
Unknown (unknown)
Lymph Node Involvement
Equivocal (equivocal)
Negative (negative)
Not Evaluated (not evaluated)
Positive (positive)
Unknown (unknown)
Number of Lymph Nodes Examined
(pathologically)
Histologic Type (of primary tumor)
Endometrial Carcinoma (Endometrial
carcinoma)
Uterine Carcinosarcoma (Uterine
carcinosarcoma)
Uterine Leiomyosarcoma (Uterine
leiomyosarcoma)
Depth of Tumor Penetration into Myometrial
Tissue
<50% Thickness (<50% thickness)
> Or = 50% Thickness (> or = 50%
thickness)
None (None)
Unknown (Unknown)
Vascular Lymphatic Invasion
No (NO)
Unknown (UNKNOWN)
Yes (YES)
Size of Residual Disease (Maximum size after
resection is complete. For microscopic enter 0.0)
Radiation therapy (prior to study entry check all
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that apply)
Brachytherapy (Brachytherapy)
Extended Field External Beam
(Extended field external beam)
None (None)
Other (Other)
Pelvic External Beam (Pelvic external
beam)
Other, specify
Is measurable disease present? (at study entry)
No (No)
Unknown (Unknown)
Yes (Yes)
Comments
COMMENTS
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Endometrial Cancer NCT00942357 Treatment - Gynecologic
Oncology Group Radiation Treatment Form (Form G) - 2844087v1.0
Gynecologic Oncology Group Radiation Treatment Form
(Form G)
Carboplatin and Paclitaxel With or Without Cisplatin and
Radiation Therapy in Treating Patients With Stage I, Stage
II, Stage III, or Stage IVA Endometrial Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=644E86D7-
DA90-D7C8-E040-BB89AD4321CC
All rights reserved. Please visit https://medical-data-
models.org/forms/9174
Gynecologic Oncology Group
Radiation Treatment Form (Form G)
Header Module
Date form originally completed (m d y)
Date form amended (m d y)
Person amending form, last name
Patient Initials (First, Middle, Last)
Patient Study ID
Person Completing Form, Last Name
Radiation Location
Radiation oncologist's name (Treating)
Radiation Oncologist's phone number (Treating)
City
State
Radiation Oncology Facility
Country
Radiation Treatment Summary
Radiation therapy field
Boost Field(s) treated by Radiation Therapy
Total number of fractions
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Total number of fractions
Radiation Therapy start date (m d y)
Radiation Therapy start date (m d y)
Radiation Therapy end date (m d y)
Radiation Therapy end date (m d y)
Total dose of radiation therapy (Gy)
Total dose of radiation therapy (Gy)
Reason for delays (of >4 days) or reduced
fractional dose (Use form Q0 for reporting reason
for discontinuing therapy)
No Delays Or Reduction Of Fractional
Doses (N/A)
Other (Other)
Patient Non-compliant (non-medical
Reason) (Patient non-compliant (non-
medical reason))
Technical Or Scheduling Problem
(Technical or scheduling problem)
Adverse Event (Toxicity)
Treating Physician Modified For Other
Medical Condition (Treating physician
modified for other medical condition)
Treating physician modified for other medical
condition
Other specify
Comments
COMMENTS
2 / 2
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Group Radiation Treatment Form (Form G) - 2844087v1.0
Endometrial Cancer NCT00807768 On-Study - GOG-
0249 Comorbid Illness Reporting Form - 2760082v1.0
GOG-0249 Comorbid Illness Reporting Form
Pelvic Radiation Therapy or Vaginal Implant Radiation
Therapy, Paclitaxel, and Carboplatin in Treating Patients
With High-Risk Stage I or Stage II Endometrial Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=4FF32E53-
FBDB-394B-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/9175
GOG-0249 Comorbid Illness
Reporting Form
Header Module
Date form originally completed (m d y)
Date form amended (m d y)
Person amending form, last name
Patient Initials (first, middle, last)
Patient Study ID
Person Completing Form, Last Name
Personal Medical History
Current Medical Conditions
Angina (Angina)
Cerebral Vascular Accident (Cerebral
vascular accident)
Coronary Artery Disease (Coronary
artery disease)
Diabetes (diabetes)
Drug Treatment For Decreasing Hdl-c
Level (Drug treatment for decreasing
HDL-C level)
Drug Treatment For Hypertension (Drug
treatment for hypertension)
Drug Treatment For Increasing Glucose
Level (Drug treatment for increasing
glucose level)
Drug Treatment For Increasing
Triglycerides (Drug treatment for
increasing triglycerides)
Hypertension (hypertension)
Myocardial Infarction (Myocardial
Infarction)
Peripheral Vascular Disease (peripheral
vascular disease)
Transient Ischemic Attack (Transient
Ischemic Attack)
Waist Circumference >= 35 Inches
(Waist circumference >= 35 inches)
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History of comorbid condition
No (No)
Unknown (Unknown)
Yes (Yes)
Is the patient currently taking medication for this
illness or has the patient had a surgical
intervention for this illness within the last 12
months
No (No)
Unknown (Unknown)
Yes (Yes)
Comments
COMMENTS
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Endometrial Cancer NCT00942357 Pre-Study - GOG-
0258 Pre-Treatment Summary Form (DR) - 2843236v1.0
GOG-0258 Pre-Treatment Summary Form (DR)
Carboplatin and Paclitaxel With or Without Cisplatin and
Radiation Therapy in Treating Patients With Stage I, Stage
II, Stage III, or Stage IVA Endometrial Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=644E6D14-
3F06-95F3-E040-BB89AD4357FF
All rights reserved. Please visit https://medical-data-
models.org/forms/9176
GOG-0258 Pre-Treatment Summary
Form (DR)
Header Module
Date form originally completed (m d y)
Date form amended (m d y)
Person amending form, last name
Patient Initials (First, Middle, Last)
Patient Study ID
Person completing form, last name
Non-invasive Diagnostic Procedures
Chest X-Ray Result
Abnormal (Abnormal)
Normal (Normal)
Not Done (Not done)
Date of Chest X-Ray (m d y)
EKG Result
Abnormal (Abnormal)
Normal (Normal)
Not Done (Not done)
Date of EKG (m d y)
MRI Result
Abnormal (Abnormal)
Normal (Normal)
Not Done (Not done)
Date of MRI (m d y)
CT Result
Abnormal (Abnormal)
Normal (Normal)
Not Done (Not done)
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Abnormal specify
Abnormal specify
Abnormal specify
Abnormal specify
Abnormal specify
Date of CT Scan (m d y)
Other Procedure Performed
Abnormal (Abnormal)
Normal (Normal)
Not Done (Not done)
Specify
Procedure Date (m d y)
Are there any target lesions?
Yes
No
Comments
Comments
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Treatment Summary Form (DR) - 2843236v1.0
Endometrial Cancer NCT00807768 Treatment -
GOG-0249 Radiation Treatment Form - 2759357v1.0
GOG-0249 Radiation Treatment Form
Pelvic Radiation Therapy or Vaginal Implant Radiation
Therapy, Paclitaxel, and Carboplatin in Treating Patients
With High-Risk Stage I or Stage II Endometrial Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=4F8BA90A-
2B2C-2C01-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/9178
GOG-0249 Radiation Treatment
Form
Header Module
Date form originally completed (m d y)
Date form amended (m d y)
Person amending form, last name
Patient Initials (First, Middle, Last)
Patient Study ID
Person Completing Form, Last Name
Radiation Location
Radiation oncologist's name (Treating)
Radiation Oncologist's phone number (Treating)
City
State
Radiation Oncology Facility
Country
Radiation Treatment Summary
Radiation Therapy Site
Pelvic Region (Pelvis)
Boost Field(s) treated by Radiation Therapy
Total number of fractions
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Total number of fractions
Radiation Therapy start date (m d y)
Radiation Therapy start date (m d y)
Radiation Therapy end date (m d y)
Radiation Therapy end date (m d y)
Total dose of radiation therapy (Gy)
Total dose of radiation therapy (Gy)
Reason for delays (of >4 days) or reduced
fractional dose (Use form Q0 for reporting reason
for discontinuing therapy)
No Delays Or Reduction Of Fractional
Doses (N/A)
Other (Other)
Patient Non-compliant (non-medical
Reason) (Patient non-compliant (non-
medical reason))
Technical Or Scheduling Problem
(Technical or scheduling problem)
Adverse Event (Toxicity)
Treating Physician Modified For Other
Medical Condition (Treating physician
modified for other medical condition)
Treating physician modified for other medical
condition
Other specify
Comments
COMMENTS
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Endometrial Cancer NCT00807768 Treatment - GOG-0249 Radiation
Treatment Form - 2759357v1.0
Endometrial Cancer NCT00942357 Quality of Life -
GOG-0258 Quality of Life Survey Form - 2844576v1.0
GOG-0258 Quality of Life Survey Form
Carboplatin and Paclitaxel With or Without Cisplatin and
Radiation Therapy in Treating Patients With Stage I, Stage
II, Stage III, or Stage IVA Endometrial Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=644E86D7-
DE63-D7C8-E040-BB89AD4321CC
All rights reserved. Please visit https://medical-data-
models.org/forms/9179
GOG-0258 Quality of Life Survey
Form
Header Module
Patient Initials
Date
Patient Study ID
Scheduled time to obtain Quality of Life
Questionnaire
18 Weeks After Starting Study Therapy
(18 weeks after starting study therapy)
70 Weeks After Starting Study Therapy
(70 weeks after starting study therapy)
Prior To Starting Study Therapy (Prior to
starting study therapy)
Regimen I: 1 Week After Completion Of
Radiation Therapy Or Regimen Ii: Prior
To Cycle 3 (Regimen I:  1 week  after
completion of radiation therapy or
Regimen II:  Prior to cycle 3)
Physical Well-being
I have a lack of energy.
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have nausea.
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
Because of my physical condition, I have trouble
meeting the needs of my family.
2 (A little bit)
1 (Not at all)
4 (Quite a bit)
3 (Somewhat)
5 (Very much)
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I have pain.
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am bothered by side effects of treatment.
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I feel ill
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am forced to spend time in bed
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
Functional Wellbeing
I am able to work (include work at home)
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
My work (include work at home) is fulfilling
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am able to enjoy life.
2 (A little bit)
1 (Not at all)
4 (Quite a bit)
3 (Somewhat)
5 (Very much)
I have accepted my illness
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am sleeping well
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A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am enjoying the things I usually do for fun
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am content with the quality of my life right now
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
Additional Concerns
I have swelling in my stomach area
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have cramps in my stomach area
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have discomfort or pain in my stomach area
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have vaginal bleeding or spotting
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have vaginal discharge
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am unhappy about a change in my appearance
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A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have hot flashes
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have cold sweats
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have night sweats
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I feel fatigued
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have pain or discomfort with intercourse
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have trouble digesting food
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have been short of breath
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am bothered by constipation
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
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Very Much (Very much)
I urinate more frequently than usual
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have discomfort or pain in my pelvic area
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have control of my bowels
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have diarrhea
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
Ntx4 Subscale
I have numbness or tingling in my hands
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have numbness or tingling in my feet
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I feel discomfort in my hands
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I feel discomfort in my feet
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
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To Be Completed By Clinical Staff
QOL contact person
Status of the QOL assessment
Other (Other)
Patient Died (Patient died)
Patient Kept Appointment, But Could Not
Complete Questionnaire Due To Illness
(Patient kept appointment, but could not
complete questionnaire due to illness)
Patient Kept Appointment, But Refused
To Complete Questionnaire For Reasons
Other Than Illness (Patient kept
appointment, but refused to complete
questionnaire for reasons other than
illness)
Patient Off Study Treatment And Cannot
Be Contacted For Follow-up (Patient off
study treatment and cannot be contacted
for follow-up)
Questionnaire Not Administered Due To
Clinical Staff Error (Questionnaire not
administered due to clinical staff error)
The Questionnaire Is Complete (The
questionnaire is complete)
Specify reason
Other, specify
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Endometrial Cancer NCT00807768 Pathology
- GOG-0249 Pathology Form - 2759208v1.0
GOG-0249 Pathology Form
Pelvic Radiation Therapy or Vaginal Implant Radiation
Therapy, Paclitaxel, and Carboplatin in Treating Patients
With High-Risk Stage I or Stage II Endometrial Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=4F8BA90A-
2A00-2C01-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/9180
GOG-0249 Pathology Form
Header Module
Date form originally completed
Date form amended
Person amending form, last name
Patient Initials
Patient Study ID
Person Completing Form, Last Name
Primary Disease Assessment
Primary Site
Cervix (Cervix)
Endometrium (Endometrium)
Fallopian Tube (Fallopian tube)
Gestational Trophoblastic Disease (GTD)
Other Specify (Other)
Ovary (Ovary)
Peritoneum (Peritoneum)
Uterine Sarcoma (Uterine Sarcoma)
Vagina (Vagina)
Vulva (Vulva)
Method of evaluation
Biopsy (Biopsy)
Cytology (Cytology)
Other (Other)
Surgery (Surgery)
Other specify
Other, specify
Histologic Type (check one)
Adenocarcinoma With Squamous
Differentiation (Adenocarcinoma with
Squamous Differentiation)
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Adenocarcinoma, Unspecified
(Adenocarcinoma, unspecified)
Adenosquamous (Adenosquamous
carcinoma)
Benign (Benign NOS)
Carcinosarcoma/mesodermal (mullerian)
Mixed Tumor (Carcinosarcoma MMT)
Clear Cell Carcinoma (Clear cell
carcinoma)
Dysgerminoma (Dysgerminoma)
Endodermal Sinus Tumor (yolk Sac
Tumor) (Endodermal sinus tumor)
Endometrial Stromal Sarcoma
(Endometrial stromal sarcoma)
Endometrioid Adenocarcinoma
(Endometrioid adenocarcinoma)
Fibroma (Fibroma)
Germ Cell Tumor, Mixed (Germ cell
tumor, mixed)
Granulosa Cell Tumor (Granulosa cell
tumor)
Leiomyosarcoma (Leiomyosarcoma)
Mixed Epithelial Carcinoma, Specify
Components (Mixed epithelial
carcinoma)
Mucinous Adenocarcinoma (Mucinous
adenocarcinoma)
Mucinous Cystadenoma (benign)
(Mucinous cystadenoma (benign))
Mucinous Tumor Of Low Malignant
Potential (Mucinous tumor of LMP)
Normal Tissue (Normal Tissue)
Other, Specify (Other specify)
Serous Adenocarcinoma (Serous
adenocarcinoma)
Serous Cystadenoma (benign) (Serous
cystadenoma (benign))
Serous Tumor Of Low Malignant
Potential (Serous tumor of LMP)
Sex-cord/stromal, Unclassified (Sex-
cord/stromal, unclassified)
Small Cell Carcinoma (Small cell
carcinoma)
Squamous Cell Carcinoma (Squamous
cell carcinoma)
Teratoma, Immature, Specify
Components (Teratoma, immature)
Teratoma, Mature (Teratoma, mature)
Transitional Cell Carcinoma, Including
Brenner Tumor (Transitional cell
carcinoma (including Brenner))
Undifferentiated Carcinoma
(Undifferentiated carcinoma)
Villoglandular Carcinoma (Villoglandular
carcinoma)
Other, specify
Date of evaluation
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Histologic grade (Differentiation)
Grade 1-well Differentiated (1)
Grade 2-moderately Differentiated (2)
Grade 3-poorly Differentiated (3)
Indeterminate (Indeterminate)
Not Applicable (Not applicable)
Grade Unknown (Unknown)
Specimen Site
Bladder Peritoneum (Bladder
peritoneum)
Bowel Peritoneum/serosa (Bowel
peritoneum/serosa)
Cervix (Cervix)
Corpus (Corpus)
Cul-de-sac (Cul-de-sac)
Diaphragm (Diaphragm)
Endometrium (Endometrium)
Fallopian Tube (Fallopian tube)
Lymph Node(s) (Lymph node(s))
Metastatic Site (Metastatic site)
Omentum (Omentum)
Other Specify (Other)
Ovary (Ovary)
Paracolic Gutter Left (Paracolic gutter
left)
Paracolic Gutter Right (Paracolic gutter
right)
Pelvic Wall Left (Pelvic wall left)
Pelvic Wall Right (Pelvic wall right)
Peritoneum/uterine Serosa
(Peritoneum/uterine serosa)
Lymph nodes specify
Metastatic site specify
Other specify
Specimen ID (of the blocks/slides)
Secondary Disease Assessment
Method of evaluation
Biopsy (Biopsy)
Cytology (Cytology)
Other (Other)
Surgery (Surgery)
Other specify
Disease Status
Disease Continues To Be Present
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Following Initial Treatment (Persistent)
Progression (Progression)
Recurrence/relapse (Recurrence)
Date of evaluation
Specimen Site
Bladder Peritoneum (Bladder
peritoneum)
Bowel Peritoneum/serosa (Bowel
peritoneum/serosa)
Cervix (Cervix)
Corpus (Corpus)
Cul-de-sac (Cul-de-sac)
Diaphragm (Diaphragm)
Endometrium (Endometrium)
Fallopian Tube (Fallopian tube)
Lymph Node(s) (Lymph node(s))
Metastatic Site (Metastatic site)
Omentum (Omentum)
Other Specify (Other)
Ovary (Ovary)
Paracolic Gutter Left (Paracolic gutter
left)
Paracolic Gutter Right (Paracolic gutter
right)
Pelvic Wall Left (Pelvic wall left)
Pelvic Wall Right (Pelvic wall right)
Peritoneum/uterine Serosa
(Peritoneum/uterine serosa)
Lymph nodes specify
Metastatic site specify
Other specify
Specimen ID (of the blocks/slides)
4 / 4
Endometrial Cancer NCT00807768 Pathology - GOG-0249 Pathology
Form - 2759208v1.0
Endometrial Cancer NCT00942357 Pathology
- Pathology Form (F) - 2843620v1.0
Pathology Form (F)
Carboplatin and Paclitaxel With or Without Cisplatin and
Radiation Therapy in Treating Patients With Stage I, Stage
II, Stage III, or Stage IVA Endometrial Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=644E86D7-
D6E1-D7C8-E040-BB89AD4321CC
All rights reserved. Please visit https://medical-data-
models.org/forms/9181
Pathology Form (F)
Header Module
Date form originally completed
Date form amended
Person amending form, last name
Patient Initials
Patient Study ID
Person Completing Form, Last Name
Primary Disease Assessment
Primary Site
Cervix (Cervix)
Endometrium (Endometrium)
Fallopian Tube (Fallopian tube)
Gestational Trophoblastic Disease (GTD)
Other Specify (Other)
Ovary (Ovary)
Peritoneum (Peritoneum)
Uterine Sarcoma (Uterine Sarcoma)
Vagina (Vagina)
Vulva (Vulva)
Method of evaluation
Biopsy (Biopsy)
Cytology (Cytology)
Other (Other)
Surgery (Surgery)
Other specify
Other, specify
Histologic Type (check one)
Adenocarcinoma With Squamous
Differentiation (Adenocarcinoma with
Squamous Differentiation)
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Adenocarcinoma, Unspecified
(Adenocarcinoma, unspecified)
Adenosquamous (Adenosquamous
carcinoma)
Benign (Benign NOS)
Carcinosarcoma/mesodermal (mullerian)
Mixed Tumor (Carcinosarcoma MMT)
Clear Cell Carcinoma (Clear cell
carcinoma)
Dysgerminoma (Dysgerminoma)
Endodermal Sinus Tumor (yolk Sac
Tumor) (Endodermal sinus tumor)
Endometrial Stromal Sarcoma
(Endometrial stromal sarcoma)
Endometrioid Adenocarcinoma
(Endometrioid adenocarcinoma)
Fibroma (Fibroma)
Germ Cell Tumor, Mixed (Germ cell
tumor, mixed)
Granulosa Cell Tumor (Granulosa cell
tumor)
Leiomyosarcoma (Leiomyosarcoma)
Mixed Epithelial Carcinoma, Specify
Components (Mixed epithelial
carcinoma)
Mucinous Adenocarcinoma (Mucinous
adenocarcinoma)
Mucinous Cystadenoma (benign)
(Mucinous cystadenoma (benign))
Mucinous Tumor Of Low Malignant
Potential (Mucinous tumor of LMP)
Normal Tissue (Normal Tissue)
Other, Specify (Other specify)
Serous Adenocarcinoma (Serous
adenocarcinoma)
Serous Cystadenoma (benign) (Serous
cystadenoma (benign))
Serous Tumor Of Low Malignant
Potential (Serous tumor of LMP)
Sex-cord/stromal, Unclassified (Sex-
cord/stromal, unclassified)
Small Cell Carcinoma (Small cell
carcinoma)
Squamous Cell Carcinoma (Squamous
cell carcinoma)
Teratoma, Immature, Specify
Components (Teratoma, immature)
Teratoma, Mature (Teratoma, mature)
Transitional Cell Carcinoma, Including
Brenner Tumor (Transitional cell
carcinoma (including Brenner))
Undifferentiated Carcinoma
(Undifferentiated carcinoma)
Villoglandular Carcinoma (Villoglandular
carcinoma)
Other, specify
Date of evaluation
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Histologic grade (Differentiation)
Grade 1-well Differentiated (1)
Grade 2-moderately Differentiated (2)
Grade 3-poorly Differentiated (3)
Indeterminate (Indeterminate)
Not Applicable (Not applicable)
Grade Unknown (Unknown)
Specimen Site
Bladder Peritoneum (Bladder
peritoneum)
Bowel Peritoneum/serosa (Bowel
peritoneum/serosa)
Cervix (Cervix)
Corpus (Corpus)
Cul-de-sac (Cul-de-sac)
Diaphragm (Diaphragm)
Endometrium (Endometrium)
Fallopian Tube (Fallopian tube)
Lymph Node(s) (Lymph node(s))
Metastatic Site (Metastatic site)
Omentum (Omentum)
Other Specify (Other)
Ovary (Ovary)
Paracolic Gutter Left (Paracolic gutter
left)
Paracolic Gutter Right (Paracolic gutter
right)
Pelvic Wall Left (Pelvic wall left)
Pelvic Wall Right (Pelvic wall right)
Peritoneum/uterine Serosa
(Peritoneum/uterine serosa)
Lymph nodes specify
Metastatic site specify
Other specify
Specimen ID (of the blocks/slides)
Secondary Disease Assessment
Method of evaluation
Biopsy (Biopsy)
Cytology (Cytology)
Other (Other)
Surgery (Surgery)
Other specify
Disease Status
Disease Continues To Be Present
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Following Initial Treatment (Persistent)
Progression (Progression)
Recurrence/relapse (Recurrence)
Date of evaluation
Specimen Site
Bladder Peritoneum (Bladder
peritoneum)
Bowel Peritoneum/serosa (Bowel
peritoneum/serosa)
Cervix (Cervix)
Corpus (Corpus)
Cul-de-sac (Cul-de-sac)
Diaphragm (Diaphragm)
Endometrium (Endometrium)
Fallopian Tube (Fallopian tube)
Lymph Node(s) (Lymph node(s))
Metastatic Site (Metastatic site)
Omentum (Omentum)
Other Specify (Other)
Ovary (Ovary)
Paracolic Gutter Left (Paracolic gutter
left)
Paracolic Gutter Right (Paracolic gutter
right)
Pelvic Wall Left (Pelvic wall left)
Pelvic Wall Right (Pelvic wall right)
Peritoneum/uterine Serosa
(Peritoneum/uterine serosa)
Lymph nodes specify
Metastatic site specify
Other specify
Specimen ID (of the blocks/slides)
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Endometrial Cancer NCT00942357 On-Study -
Solid Tumor Evaluation Form (D2M) - 2843034v1.0
Solid Tumor Evaluation Form (D2M)
Carboplatin and Paclitaxel With or Without Cisplatin and
Radiation Therapy in Treating Patients With Stage I, Stage
II, Stage III, or Stage IVA Endometrial Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=644E6D14-
3D6E-95F3-E040-BB89AD4357FF
All rights reserved. Please visit https://medical-data-
models.org/forms/9182
Solid Tumor Evaluation Form (D2M)
Header Module
Date form originally completed (m d y)
Date form amended (m d y)
Person amending form, last name
Patient Initials (First, Middle, Last)
Patient Study ID
Person completing form, last name
Target Lesion(s) Evaluation
Did the patient have measurable disease at
baseline
No (No)
Unknown (Unknown)
Yes (Yes)
Site of lesion or site of evaluation
Method of Evaluation (*)
Chest X-ray (Chest X-ray)
Clinical Examination (pe) (Clinical
examination)
Ct Scan (CT scan)
Mri (MRI)
Not Evaluated (Not evaluated)
Other (Other)
Spiral Ct Scan (Spiral CT scan)
Ultrasound (Ultrasound)
If Other Specify
Date of evaluation (m d y)
Longest diameter (s)
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Sum of Longest Diameters of All Target Lesions
Non-target Lesion(s) Evaluation
Were there any non-target lesions reported at
baseline
Yes
No
Site of Lesion
Method of Evaluation (*)
Chest X-ray (Chest X-ray)
Clinical Examination (pe) (Clinical
examination)
Ct Scan (CT scan)
Mri (MRI)
Not Evaluated (Not evaluated)
Other (Other)
Spiral Ct Scan (Spiral CT scan)
Ultrasound (Ultrasound)
If Other Specify
Date of evaluation (m d y)
Follow-Up Status of Lesion (^Follow-up status of
lesion)
Complete Response (Complete
Response)
Progressive Disease (Progressive
Disease)
Stable Disease Or Unchanged (Stable)
New Target Lesion(s) At Follow-up
Evaluation
Was the appearance of any new lesions
documented (If no, skip to the Overall Response
section below.)
Yes
No
Site of Lesion
Method of Evaluation (*)
Chest X-ray (Chest X-ray)
Clinical Examination (pe) (Clinical
examination)
Ct Scan (CT scan)
Mri (MRI)
Not Evaluated (Not evaluated)
Other (Other)
Spiral Ct Scan (Spiral CT scan)
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Ultrasound (Ultrasound)
If Other Specify
Date of evaluation (m d y)
Overall Response
Disease status at this assessment
Biologic Progression Only (Biologic
progression only)
Complete Remission (Complete
Remission)
Disease Progression (Disease
progression)
Increasing Disease (Increasing disease)
Insufficient Evaluation To Determine
Response Status (Insufficient
Evaluation)
Not Applicable - Baseline (N/A -
Baseline)
No Disease Progression (No disease
progression)
Non-measurable Disease At Baseline
(Non-measurable disease at baseline)
Not Evaluable (Not evaluable)
Partial Response (Partial Response)
Pd (Progressive Disease)
Stable Disease (Stable Disease)
Overall best confirmed response
Biologic Progression Only (Biologic
progression only)
Complete Remission (Complete
Remission)
Disease Progression (Disease
progression)
Increasing Disease (Increasing disease)
Insufficient Evaluation To Determine
Response Status (Insufficient
Evaluation)
Not Applicable - Baseline (N/A -
Baseline)
No Disease Progression (No disease
progression)
Non-measurable Disease At Baseline
(Non-measurable disease at baseline)
Not Evaluable (Not evaluable)
Partial Response (Partial Response)
Pd (Progressive Disease)
Stable Disease (Stable Disease)
PR First Observed Date
Response Confirmed Date, PR
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CR First Observed Date
Response Confirmed Date, CR
Comments
Comments
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Fallopian Tube Cancer NCT01167712 On-Study - GOG-
0262: Body Diagram Form (Form BDR) - 2918951v1.0
GOG-0262: Body Diagram Form (Form BDR)
Paclitaxel and Carboplatin With or Without Bevacizumab in
Treating Patients With Stage II, Stage III, or Stage IV
Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or
Fallopian Tube Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=6EAC48CD-
A2C2-DA34-E040-BB89AD4341C1
All rights reserved. Please visit https://medical-data-
models.org/forms/9184
GOG-0262: Body Diagram Form
(Form BDR)
Header Module
Date form originally completed (m d y)
Date form amended (m d y)
Person amending form, last name
Patient Initials (First, Middle, Last)
Patient Study ID
Person completing form, last name
Body Diagram
Date of examination
Comments
Comments
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Fallopian Tube Cancer NCT01081262 Pathology
- GOG-0241 Pathology Form (F) - 3126918v1.0
GOG-0241 Pathology Form (F)
Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine,
With or Without Bevacizumab, as First-Line Therapy in
Treating Patients With Newly Diagnosed Stage II, Stage III,
Stage IV, or Recurrent Stage I Epithelial Ovarian Cancer or
Fallopian Tube Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=8D17F7CB-
70DF-90BC-E040-BB89AD435566
All rights reserved. Please visit https://medical-data-
models.org/forms/9185
GOG-0241 Pathology Form (F)
Header Module
Date form originally completed
Date form amended
Person amending form, last name
Patient Initials
Patient Study ID
Person Completing Form, Last Name
Primary Disease Assessment
Primary Site
Cervix (Cervix)
Endometrium (Endometrium)
Fallopian Tube (Fallopian tube)
Gestational Trophoblastic Disease (GTD)
Other Specify (Other)
Ovary (Ovary)
Peritoneum (Peritoneum)
Uterine Sarcoma (Uterine Sarcoma)
Vagina (Vagina)
Vulva (Vulva)
Method of evaluation
Biopsy (Biopsy)
Cytology (Cytology)
Other (Other)
Surgery (Surgery)
Other specify
Other, specify
Histologic Type (check one)
Adenocarcinoma With Squamous
Differentiation (Adenocarcinoma with
Squamous Differentiation)
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Adenocarcinoma, Unspecified
(Adenocarcinoma, unspecified)
Adenosquamous (Adenosquamous
carcinoma)
Benign (Benign NOS)
Carcinosarcoma/mesodermal (mullerian)
Mixed Tumor (Carcinosarcoma MMT)
Clear Cell Carcinoma (Clear cell
carcinoma)
Dysgerminoma (Dysgerminoma)
Endodermal Sinus Tumor (yolk Sac
Tumor) (Endodermal sinus tumor)
Endometrial Stromal Sarcoma
(Endometrial stromal sarcoma)
Endometrioid Adenocarcinoma
(Endometrioid adenocarcinoma)
Fibroma (Fibroma)
Germ Cell Tumor, Mixed (Germ cell
tumor, mixed)
Granulosa Cell Tumor (Granulosa cell
tumor)
Leiomyosarcoma (Leiomyosarcoma)
Mixed Epithelial Carcinoma, Specify
Components (Mixed epithelial
carcinoma)
Mucinous Adenocarcinoma (Mucinous
adenocarcinoma)
Mucinous Cystadenoma (benign)
(Mucinous cystadenoma (benign))
Mucinous Tumor Of Low Malignant
Potential (Mucinous tumor of LMP)
Normal Tissue (Normal Tissue)
Other, Specify (Other specify)
Serous Adenocarcinoma (Serous
adenocarcinoma)
Serous Cystadenoma (benign) (Serous
cystadenoma (benign))
Serous Tumor Of Low Malignant
Potential (Serous tumor of LMP)
Sex-cord/stromal, Unclassified (Sex-
cord/stromal, unclassified)
Small Cell Carcinoma (Small cell
carcinoma)
Squamous Cell Carcinoma (Squamous
cell carcinoma)
Teratoma, Immature, Specify
Components (Teratoma, immature)
Teratoma, Mature (Teratoma, mature)
Transitional Cell Carcinoma, Including
Brenner Tumor (Transitional cell
carcinoma (including Brenner))
Undifferentiated Carcinoma
(Undifferentiated carcinoma)
Villoglandular Carcinoma (Villoglandular
carcinoma)
Other, specify
Date of evaluation (m d y)
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Histologic grade (Differentiation)
Grade 1-well Differentiated (1)
Grade 2-moderately Differentiated (2)
Grade 3-poorly Differentiated (3)
Indeterminate (Indeterminate)
Not Applicable (Not applicable)
Grade Unknown (Unknown)
Specimen Site
Bladder Peritoneum (Bladder
peritoneum)
Bowel Peritoneum/serosa (Bowel
peritoneum/serosa)
Cervix (Cervix)
Corpus (Corpus)
Cul-de-sac (Cul-de-sac)
Diaphragm (Diaphragm)
Endometrium (Endometrium)
Fallopian Tube (Fallopian tube)
Lymph Node(s) (Lymph node(s))
Metastatic Site (Metastatic site)
Omentum (Omentum)
Other Specify (Other)
Ovary (Ovary)
Paracolic Gutter Left (Paracolic gutter
left)
Paracolic Gutter Right (Paracolic gutter
right)
Pelvic Wall Left (Pelvic wall left)
Pelvic Wall Right (Pelvic wall right)
Peritoneum/uterine Serosa
(Peritoneum/uterine serosa)
Lymph nodes specify
Metastatic site specify
Other specify
Specimen ID (of the blocks/slides)
Secondary Disease Assessment
Method of evaluation
Biopsy (Biopsy)
Cytology (Cytology)
Other (Other)
Surgery (Surgery)
Other specify
Disease Status
Disease Continues To Be Present
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Following Initial Treatment (Persistent)
Progression (Progression)
Recurrence/relapse (Recurrence)
Date of evaluation (m d y)
Specimen Site
Bladder Peritoneum (Bladder
peritoneum)
Bowel Peritoneum/serosa (Bowel
peritoneum/serosa)
Cervix (Cervix)
Corpus (Corpus)
Cul-de-sac (Cul-de-sac)
Diaphragm (Diaphragm)
Endometrium (Endometrium)
Fallopian Tube (Fallopian tube)
Lymph Node(s) (Lymph node(s))
Metastatic Site (Metastatic site)
Omentum (Omentum)
Other Specify (Other)
Ovary (Ovary)
Paracolic Gutter Left (Paracolic gutter
left)
Paracolic Gutter Right (Paracolic gutter
right)
Pelvic Wall Left (Pelvic wall left)
Pelvic Wall Right (Pelvic wall right)
Peritoneum/uterine Serosa
(Peritoneum/uterine serosa)
Lymph nodes specify
Metastatic site specify
Other specify
Specimen ID (of the blocks/slides)
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Fallopian Tube Cancer NCT01081262 On-Study - GOG-0241
Recurrent Gynecologic Cancer - On Study Form (OSR) - 3127560v1.0
GOG-0241 Recurrent Gynecologic Cancer - On Study
Form (OSR)
Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine,
With or Without Bevacizumab, as First-Line Therapy in
Treating Patients With Newly Diagnosed Stage II, Stage III,
Stage IV, or Recurrent Stage I Epithelial Ovarian Cancer or
Fallopian Tube Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=8D189316-
59D5-8D82-E040-BB89AD433C8E
All rights reserved. Please visit https://medical-data-
models.org/forms/9187
GOG-0241 Recurrent Gynecologic
Cancer - On Study Form (OSR)
Header Module
Date form originally completed (m d y)
Date form amended (m d y)
Person amending form, last name
Patient Initials (First, Middle, Last)
Patient Study ID
Person Completing Form, Last Name
Disease Description - Prior History
Date of Definitive Histologic Diagnosis of Primary
Tumor (m d y)
Stage (at diagnosis FIGO)
Stage I Cervical Cancer (I)
Stage Ii Cervical Cancer (II)
Stage Iii Cervical Cancer (III)
Stage Iv Cervical Cancer (IV)
Primary surgery date (m d y)
Primary Surgery Type (check all that apply)
Bilateral Salpingo-oophorectomy
(bilateral salpingo-oophorectomy)
Cervical Conization (cervical conization)
Omentectomy (omentectomy)
Other, Specify (other specify)
Para-aortic Node Sampling/dissection
(para-aortic node sampling/dissection)
Partial Hysterectomy (partial
hysterectomy)
Pelvic Node Sampling/dissection (pelvic
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node sampling/dissection)
Radical Hysterectomy (radical
hysterectomy)
Radical Trachelectomy (radical
trachelectomy)
Total Hysterectomy (total hysterectomy)
Unilateral Salpingo-oophorectomy
(unilateral salpingo-oophorectomy)
Other specify
Date of First Recurrence or Progression (m d y)
Disease Description - Current History
Current Status of Disease
Disease Continues To Be Present
Following Initial Treatment (Persistent)
Primary Tumor (Primary (Advanced))
Progression (Progression)
Recurrence/relapse (Recurrence)
Date of most recent recurrence or progression (m
d y)
What was the method used to determine
recurrence or progression
Clinical Examination (Clinical)
Histologic (Histologic)
Radiographic (Radiographic)
Tumor Marker (Tumor Marker)
Site(s) of disease at study entry (check all that
apply)
Ascites (Ascites)
Bladder (Bladder)
Bone (Bone)
Cervix (Cervix)
Cns/brain (CNS/Brain)
Colon (Colon)
Endometrium (Endometrium)
Liver (Liver)
Lung (Lung)
Lymph Nodes (Lymph nodes)
Other (Other)
Ovary (Ovary)
Parametrial Involvement (Parametrial
involvement)
Peritoneum (Peritoneum)
Pleura (Pleura)
Pleural Effusion (Pleural effusion)
Skin (Skin)
Uterus (Uterus)
Lymph Nodes Specify
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Fallopian Tube Cancer NCT01081262 On-Study - GOG-0241 Recurrent
Gynecologic Cancer - On Study Form (OSR) - 3127560v1.0
Other specify
Prior Treatment For Gynecologic Cancer
Prior Systemic Chemotherapy
Yes
No
Date Prior Chemotherapy Started (m d y)
Date Prior Chemotherapy Ended (m d y)
Chemotherapy Regimen
First Line Agent (First line)
Other Specify (Other)
Second Line Agent (Second line)
Specify agent (s)
No. of Courses
Prior Hormonal Therapy
Yes
No
Yes, specify
Non-protocol biologic response modifier?
Yes
No
Specify
Prior Radiation Therapy
Yes
No
Yes specify
Is the site of recurrence within the field previously
treated by radiation therapy?
Yes
No
Comments Module
Comments
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Fallopian Tube Cancer NCT01081262 On-Study - GOG-0241 Recurrent
Gynecologic Cancer - On Study Form (OSR) - 3127560v1.0
Fallopian Tube Cancer NCT00951496 Pre-Study - Gynecologic Oncology
Group Pre-Treatment Summary Form (Form DR) - 2757969v1.0
Gynecologic Oncology Group Pre-Treatment Summary
Form (Form DR)
Bevacizumab and Intravenous or Intraperitoneal
Chemotherapy in Treating Patients With Stage II, Stage III,
or Stage IV Ovarian Epithelial Cancer, Fallopian Tube
Cancer, or Primary Peritoneal Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=4F539833-
2C57-6522-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/9188
Gynecologic Oncology Group Pre-
Treatment Summary Form (Form
DR)
Header Module
Date form originally completed (m d y)
Date form amended (m d y)
Person amending form, last name
Patient Initials (First, Middle, Last)
Patient Study ID
Person completing form, last name
Non-invasive Diagnostic Procedures
Chest X-Ray Result
Abnormal (Abnormal)
Normal (Normal)
Not Done (Not done)
Date of Chest X-Ray (m d y)
EKG Result
Abnormal (Abnormal)
Normal (Normal)
Not Done (Not done)
Date of EKG (m d y)
MRI Result
Abnormal (Abnormal)
Normal (Normal)
Not Done (Not done)
Date of MRI (m d y)
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CT Result
Abnormal (Abnormal)
Normal (Normal)
Not Done (Not done)
Date of CT Scan (m d y)
Other Procedure Performed
Abnormal (Abnormal)
Normal (Normal)
Not Done (Not done)
Abnormal specify
Abnormal specify
Abnormal specify
Abnormal specify
Abnormal specify
Procedure Date (m d y)
Are there any target lesions? (RECOMMENDED
TERM: Are there any target lesions?)
Yes
No
Comments
Comments
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Fallopian Tube Cancer NCT00951496 Pre-Study - Gynecologic Oncology
Group Pre-Treatment Summary Form (Form DR) - 2757969v1.0
Fallopian Tube Cancer NCT01167712 On-Study - GOG-0262:
Biomarker Reporting Form (Form BMR) - 2917747v1.0
GOG-0262:  Biomarker Reporting Form (Form BMR)
Paclitaxel and Carboplatin With or Without Bevacizumab in
Treating Patients With Stage II, Stage III, or Stage IV
Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or
Fallopian Tube Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=6E5EDF6F-
88D2-E23E-E040-BB89AD435A10
All rights reserved. Please visit https://medical-data-
models.org/forms/9189
GOG-0262:  Biomarker Reporting
Form (Form BMR)
Header Module
Date form originally completed (m d y)
Date form amended (m d y)
Person amending form, last name
Patient Initials (First, Middle, Last)
Patient Study ID
Person Completing Form, Last Name
Biomarker Information
Reporting Period
Were biomarkers assessed during this reporting
period
Yes
No
Biomarker Name
Biomarker Value
Biomarker ULN
Date of Biomarker Assessment Result
Comments
COMMENTS
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Fallopian Tube Cancer NCT00951496 Pathology - Gynecologic
Oncology Group Pathology Form (Form F) - 2834756v1.0
Gynecologic Oncology Group Pathology Form (Form F)
Bevacizumab and Intravenous or Intraperitoneal
Chemotherapy in Treating Patients With Stage II, Stage III,
or Stage IV Ovarian Epithelial Cancer, Fallopian Tube
Cancer, or Primary Peritoneal Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=624516DD-
721D-10AB-E040-BB89AD434B50
All rights reserved. Please visit https://medical-data-
models.org/forms/9190
Gynecologic Oncology Group
Pathology Form (Form F)
Header Module
Date form originally completed
Date form amended
Person amending form, last name
Patient Initials
Patient Study ID
Person Completing Form, Last Name
Primary Disease Assessment
Primary Site
Cervix (Cervix)
Endometrium (Endometrium)
Fallopian Tube (Fallopian tube)
Gestational Trophoblastic Disease (GTD)
Other Specify (Other)
Ovary (Ovary)
Peritoneum (Peritoneum)
Uterine Sarcoma (Uterine Sarcoma)
Vagina (Vagina)
Vulva (Vulva)
Method of evaluation
Biopsy (Biopsy)
Cytology (Cytology)
Other (Other)
Surgery (Surgery)
Other specify
Other, specify
Histologic Type (check one)
Adenocarcinoma With Squamous
Differentiation (Adenocarcinoma with
Squamous Differentiation)
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Adenocarcinoma, Unspecified
(Adenocarcinoma, unspecified)
Adenosquamous (Adenosquamous
carcinoma)
Benign (Benign NOS)
Carcinosarcoma/mesodermal (mullerian)
Mixed Tumor (Carcinosarcoma MMT)
Clear Cell Carcinoma (Clear cell
carcinoma)
Dysgerminoma (Dysgerminoma)
Endodermal Sinus Tumor (yolk Sac
Tumor) (Endodermal sinus tumor)
Endometrial Stromal Sarcoma
(Endometrial stromal sarcoma)
Endometrioid Adenocarcinoma
(Endometrioid adenocarcinoma)
Fibroma (Fibroma)
Germ Cell Tumor, Mixed (Germ cell
tumor, mixed)
Granulosa Cell Tumor (Granulosa cell
tumor)
Leiomyosarcoma (Leiomyosarcoma)
Mixed Epithelial Carcinoma, Specify
Components (Mixed epithelial
carcinoma)
Mucinous Adenocarcinoma (Mucinous
adenocarcinoma)
Mucinous Cystadenoma (benign)
(Mucinous cystadenoma (benign))
Mucinous Tumor Of Low Malignant
Potential (Mucinous tumor of LMP)
Normal Tissue (Normal Tissue)
Other, Specify (Other specify)
Serous Adenocarcinoma (Serous
adenocarcinoma)
Serous Cystadenoma (benign) (Serous
cystadenoma (benign))
Serous Tumor Of Low Malignant
Potential (Serous tumor of LMP)
Sex-cord/stromal, Unclassified (Sex-
cord/stromal, unclassified)
Small Cell Carcinoma (Small cell
carcinoma)
Squamous Cell Carcinoma (Squamous
cell carcinoma)
Teratoma, Immature, Specify
Components (Teratoma, immature)
Teratoma, Mature (Teratoma, mature)
Transitional Cell Carcinoma, Including
Brenner Tumor (Transitional cell
carcinoma (including Brenner))
Undifferentiated Carcinoma
(Undifferentiated carcinoma)
Villoglandular Carcinoma (Villoglandular
carcinoma)
Other, specify
Date of evaluation
2 / 4
Fallopian Tube Cancer NCT00951496 Pathology - Gynecologic Oncology
Group Pathology Form (Form F) - 2834756v1.0
Histologic grade (Differentiation)
Grade 1-well Differentiated (1)
Grade 2-moderately Differentiated (2)
Grade 3-poorly Differentiated (3)
Indeterminate (Indeterminate)
Not Applicable (Not applicable)
Grade Unknown (Unknown)
Specimen Site
Bladder Peritoneum (Bladder
peritoneum)
Bowel Peritoneum/serosa (Bowel
peritoneum/serosa)
Cervix (Cervix)
Corpus (Corpus)
Cul-de-sac (Cul-de-sac)
Diaphragm (Diaphragm)
Endometrium (Endometrium)
Fallopian Tube (Fallopian tube)
Lymph Node(s) (Lymph node(s))
Metastatic Site (Metastatic site)
Omentum (Omentum)
Other Specify (Other)
Ovary (Ovary)
Paracolic Gutter Left (Paracolic gutter
left)
Paracolic Gutter Right (Paracolic gutter
right)
Pelvic Wall Left (Pelvic wall left)
Pelvic Wall Right (Pelvic wall right)
Peritoneum/uterine Serosa
(Peritoneum/uterine serosa)
Lymph nodes specify
Metastatic site specify
Other specify
Specimen ID (of the blocks/slides)
Secondary Disease Assessment
Method of evaluation
Biopsy (Biopsy)
Cytology (Cytology)
Other (Other)
Surgery (Surgery)
Other specify
Disease Status
Disease Continues To Be Present
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Fallopian Tube Cancer NCT00951496 Pathology - Gynecologic Oncology
Group Pathology Form (Form F) - 2834756v1.0
Following Initial Treatment (Persistent)
Progression (Progression)
Recurrence/relapse (Recurrence)
Date of evaluation
Specimen Site
Bladder Peritoneum (Bladder
peritoneum)
Bowel Peritoneum/serosa (Bowel
peritoneum/serosa)
Cervix (Cervix)
Corpus (Corpus)
Cul-de-sac (Cul-de-sac)
Diaphragm (Diaphragm)
Endometrium (Endometrium)
Fallopian Tube (Fallopian tube)
Lymph Node(s) (Lymph node(s))
Metastatic Site (Metastatic site)
Omentum (Omentum)
Other Specify (Other)
Ovary (Ovary)
Paracolic Gutter Left (Paracolic gutter
left)
Paracolic Gutter Right (Paracolic gutter
right)
Pelvic Wall Left (Pelvic wall left)
Pelvic Wall Right (Pelvic wall right)
Peritoneum/uterine Serosa
(Peritoneum/uterine serosa)
Lymph nodes specify
Metastatic site specify
Other specify
Specimen ID (of the blocks/slides)
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Fallopian Tube Cancer NCT00951496 Pathology - Gynecologic Oncology
Group Pathology Form (Form F) - 2834756v1.0
Fallopian Tube Cancer NCT00951496 Lab - Gynecologic Oncology
Group Biomarker Reporting Form (Form BMR) - 2760081v1.0
Gynecologic Oncology Group Biomarker Reporting Form
(Form BMR)
Bevacizumab and Intravenous or Intraperitoneal
Chemotherapy in Treating Patients With Stage II, Stage III,
or Stage IV Ovarian Epithelial Cancer, Fallopian Tube
Cancer, or Primary Peritoneal Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=4FF32823-
727F-27D4-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/9191
Gynecologic Oncology Group
Biomarker Reporting Form (Form
BMR)
Header Module
Date form originally completed (m d y)
Date form amended (m d y)
Person amending form, last name
Patient Initials
Patient Study ID
Person Completing Form, Last Name
Biomarker Information
Reporting Period
Were biomarkers assessed during this reporting
period
Yes
No
Biomarker Name
Biomarker Value
Biomarker ULN
Date of Biomarker Assessment Result
Comments
COMMENTS
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Leukemia NCT00085124 Treatment - CALGB:
10201 Treatment FORM - 2031608v3.0
CALGB: 10201 Treatment FORM
Daunorubicin and Cytarabine With or Without Oblimersen
in Treating Older Patients With Previously Untreated Acute
Myeloid Leukemia
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=AD83D624-
B33F-3003-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/9194
CALGB: 10201 Treatment FORM
Calgb Form
CALGB Study No.
CALGB Patient ID
Are data amended?
Patient's Initials (Last, First, Middle)
Participating Group
Patient Hospital No.
Participating Group Protocol No.
Institution/Affiliate
Participating Group Patient ID:
Reporting period Start Date
Reporting period Start Date
Reporting period End Date (MM DD YYYY)
Reporting period End Date (MM DD YYYY)
Treatment Phase Information
Treatment Phase (Mark one with an X)
Current Phase Of Leukemia Treatment
For Patient Is Consolidation
(Consolidation)
Current Phase Of Leukemia Treatment
For Patient Is Follow-up, Or Patient Is Off
Therapy (Follow-Up/Off Therapy)
Current Phase Of Leukemia Treatment
For Patient Is Induction (Induction)
Current Phase Of Leukemia Treatment
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For Patient Is Specified Other Phase
(Other, specify)
Other, specify (treatment phase)
Leukemia Treatment Plan
Did the patient receive any protocol treatment?
Yes
No
Date of first dose for this reporting period (MM
DD YYYY)
Number of courses or cycles given this reporting
period
Date of last dose for this reporting period (MM
DD YYYY)
G3139 (dose) (mg)
G3139 (dose) (mg)
G3139 (dose) (mg)
If the treatment ended this period, reason
treatment ended or not given (Mark one with an
X)
Alternative Therapy (Alternative therapy)
Death Of Patient Occurred After The
Patient Began Protocol Therapy (Death
after beginning protocol therapy)
Death Prior To Beginning Protocol
Therapy (Death prior to beginning
protocol therapy)
Disease Progression, Relapse During
Active Treatment (Disease progression,
relapse during active treatment)
Progression Of Disease Occurred Prior
To The Patient Beginning Protocol
Therapy (Disease progression, relapse
prior to beginning protocol therapy)
Other (Other complicating disease)
Other, Specify (Other, specify)
Patient Withdrawal Or Refusal After
Beginning Protocol Therapy (Patient
withdraw or refusal after beginning
protocol therapy)
Patient Withdrawal Or Refusal Prior To
Beginning Protocol Therapy (Patient
withdraw or refusal before beginning
protocol therapy)
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Leukemia NCT00085124 Treatment - CALGB: 10201 Treatment FORM -
2031608v3.0
Toxicity/side Effects/complications
(Toxicity/side effects/complications)
Treatment Completed Per Protocol
Criteria (Treatment completed per
protocol criteria)
Other, specify (reason treatment ended)
Were there any dose modifications or
additions/omissions to protocol treatment (Mark
one with an X)
No (No)
(i.e., The Treatment Was Changed
According To Protocol Guidelines) (Yes,
planned)
(i.e., The Treatment Change Was Not
Part Of Protocol Guidelines) (Yes,
unplanned)
If yes, unplanned, specify change
Completed by (First Name, Last Name)
Ccrr Module For Calgb: 10201 Treatment
Form
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Leukemia NCT00085124 Treatment - CALGB: 10201 Treatment FORM -
2031608v3.0
Leukemia NCT00085124 Follow-Up - CALGB:
10201 FOLLOW-UP FORM - 2031846v3.0
CALGB: 10201 FOLLOW-UP FORM
Daunorubicin and Cytarabine With or Without Oblimersen
in Treating Older Patients With Previously Untreated Acute
Myeloid Leukemia
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=AD85E4FA-
DE35-3551-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/9197
CALGB: 10201 FOLLOW-UP FORM
Calgb Form
CALGB Study No.
CALGB Patient ID
Reporting period Start Date
Reporting period End Date
MM DD YYYY
Are data amended?
Patient's Initials (Last, First, Middle)
Participating Group
Patient Hospital No.
Participating Group Protocol No.
Main Member Institution/Adjunct
Participating Group Patient ID:
Vital Status
Patient's vital status
Alive (Alive)
Dead (Dead)
Cause of Death (if dead)
Due To Other Cause (Due to other
cause)
Due To Protocol Treatment (Due to
protocol treatment)
Due To This Disease (Due to this
disease)
Unknown (Unknown)
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Describe Cause of Death
Disease Follow-up Status
Has the patient had a documented clinical
assessment for this cancer during this reporting
period?
No (No)
Unknown (Unknown)
Yes (Yes)
Date of last clinical assessment (mm dd yyyy)
Did the patient achieve a complete response
according to clinical/hematologic criteria during
this reporting period?
Null (No)
Null (Unknown)
Null (Yes)
date of complete response
Notice Of Progression
Has the patient developed a first progression or
relapse that has not been previously reported?
No (No)
Unknown (Uncertain)
Yes (Yes)
Date of bone marrow relapse (mm dd yyyy)
Date of non-marrow relapse (mm dd yyyy)
Type of non-marrow relapse (mark all that apply
with an X)
Cns (CNS)
Gonadal (Gonadal)
Other, Specify (Other, specify)
Peripheral Blood (Peripheral blood)
Skin (Skin)
Other, specify (Type of non-marrow relapse)
Recovery
Was the patient hospitalized other than for
chemotherapy administration? (If yes, )
Yes
No
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Leukemia NCT00085124 Follow-Up - CALGB: 10201 FOLLOW-UP
FORM - 2031846v3.0
number of extra days hospitalized
Did the patient require IV antibiotics/antifungals
(in or out patient)?
Yes
No
Number of days on IV antibiotics/antifungals
Did the patient require platlet transfusions?
Yes
No
Did the patient require red blood cell (RBC)
transfusions? (If yes, )
Yes
No
number of units given
First date of ANC dropped below 500 (mm dd
yyyy)
First date of ANC recovery over 500 (mm dd
yyyy)
First date platelets dropped below 20,000 (mm dd
yyyy)
First date platelets recovery over 20,000 (non-
transfused) (mm dd yyyy)
Transplant Treatment Plan
Did the patient receive a transplant?
Yes
No
Date of first bone marrow or peripheral blood
stem cell infusion (mm dd yyyy)
Type of bone marrow or peripheral blood stem
cell (PBSC) transplant (mark one with X)
Bone Marrow Stem Cells Used For
Transplant Obtained From Recipient
Him/herself (Autologous bone marrow)
Peripheral Blood Stem Cells Used For
Transplant Obtained From Recipient
Him/herself (Autologous PBSC)
Bone Marrow Stem Cells Used For
Transplant Obtained From Antigen-
matched Sibling Or Family Member Of
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Leukemia NCT00085124 Follow-Up - CALGB: 10201 FOLLOW-UP
FORM - 2031846v3.0
Recipient (Bone marrow from matched
sibling)
Bone Marrow Stem Cells Used For
Transplant Obtained From Antigen-
matched Individual Unrelated To
Recipient (Bone marrow from matched
unrelated donor)
Specified Other Source, Type, And Form
Of Transplanted Material (Other, specify)
Peripheral Blood Stem Cells Used For
Transplant Obtained From Antigen-
matched Sibling Or Family Member Of
Recipient (PBSC from matched sibling)
Peripheral Blood Stem Cells Used For
Transplant Obtained From Antigen-
matched Individual Unrelated To
Recipient (PBSC from matched
unrelated donor)
Other, specify (type of bone marrow transplant)
Ccrr Module For Calgb: 10201 Follow-up
Form
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Leukemia NCT00085124 Follow-Up - CALGB: 10201 FOLLOW-UP
FORM - 2031846v3.0
Leukemia NCT00085124 On-Study - CALGB:
10201On-Study Form - 2057573v3.0
CALGB: 10201On-Study Form
Daunorubicin and Cytarabine With or Without Oblimersen
in Treating Older Patients With Previously Untreated Acute
Myeloid Leukemia
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=AD838530-
D422-2F4D-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/9198
CALGB: 10201On-Study Form
Calgb Form
CALGB Study No.
CALGB Patient ID
Are data amended?
Patient's Initials (Last, First, Middle)
Participating Group
Patient Hospital Number
Participating Group Protocol No.
Main Member Institution/Adjunct
Participating Group Patient No.
Patient Description
Date of initial Pathologic Diagnosis (Enter test
date for first diagnosis of AML)
Date of first abnormal bone marrow for
antecedent myelodysplasia (MM DD YYYY)
Leukemia
Disease Classified As Acute
Erythroblastic Leukemia (fab M6) (Acute
erythroblastic leukemia)
Acute megakaryoblastic leukemia (Acute
megakaryoblastic leukemia)
Disease Classified As Acute Myeloid
Leukemia W/o Maturation (fab M1)
(Acute meyloid leukemia without
maturation)
Disease Classified As Acute Monocytic
Leukemia (fab M5) (Acute monocytic
leukemia)
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Disease Classified As Acute
Myelomonocytic Leukemia (fab M4)
(Acute myelomonocytic leukemia)
Disease Classified As Acute
Promyelocytic Leukemia (fab M3) (Acute
promyelocytic leukemia)
Disease Classified As Acute
Undifferentiated Leukemia (aul) (Acute
undifferentiated leukemia)
Disease Classified As Aml, Not
Otherwise Specified (nos) (AML, not
otherwise specified)
Disease Is A Mixed Lineage Acute
Leukemia (Mixed lineage acute
leukemia)
Disease Classified As Specified Other
Leukemia (Other, specify)
Disease Is An Unclassifiable Acute
Leukemia (Unclassifiable acute
leukemia)
Disease Classified As Undifferentiated
Acute Myeloid Leukemia (fab M0)
(Undifferentiated acute myeloid
leukemia)
Other, specify (leukemia)
Clinical Onset of AML
Aml Without Prior Clinical History Of Mds
Or Potentially Leukemogenic Treatment
(de novo)
Aml Related To/associated With Prior
Clinical History Of Mds (Following
primary MDS)
Aml Related To/associated With Prior
Clinical History Of Potentially
Leukemogenic Treatment (Therapy
related)
Extramedullary Disease Involvement (mark all
that apply)
Pathology Or Disease Involving The
Central Nervous System Present
(Central Nervous System)
Gingival Hypertrophy Present (Gingival
Hypertrophy)
Mediastinal Mass Present (Mediastinal
Mass)
Other (Other)
Pathology Or Disease Involving The
Peripheral Nervous System Present
(Peripheral Nervous System)
Skin (Skin)
Other, specify
Are Auer Rods present?
Yes
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2057573v3.0
No
Organ Involvement
Palpable Splenomegaly
Palpation Performed And Splenomegaly
Absent (No)
Palpation Of Spleen Not Performed (Not
examined)
Surgically absent (Surgically absent)
Palpation Performed And Splenomegaly
Present (Yes)
Splenomegaly by scan or x-ray
Imaging Performed And Splenomegaly
Absent (No)
Imaging Of Spleen Not Performed (Not
examined)
Spleen Removed Via Prior Surgery
(Surgically absent)
Imaging Performed And Splenomegaly
Present (Yes)
Palpable Heptomegaly
No (No)
Not examined (Not examined)
Yes (Yes)
Hepatomegaly by scan or x-ray
No (No)
Not examined (Not examined)
Yes (Yes)
Palpable Lymphadenopathy
No (No)
Not examined (Not examined)
Yes (Yes)
Lymphadenopathy by scan or x-ray
No (No)
Not examined (Not examined)
Yes (Yes)
Current Symptoms
Current Infection (mark one with an X)
Life-threatening (Life-threatening)
Mild (Mild)
Moderate (Moderate)
None (None)
Severe (Severe)
Bleeding/Hemorrage (mark one with an X)
Active, Requiring Transfusion (Active,
requiring transfusion)
Mild, Not Requiring Transfusion (Mild,
not requiring transfusion)
None (None)
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Leukemia NCT00085124 On-Study - CALGB: 10201On-Study Form -
2057573v3.0
Lab Data At Study Entry
% LVEF by ECHO
Creatinine
Bilirubin
Lacate Dehyrogenase (LDH)
Upper Limit of Normal (LDH)
SGOT
Upper Limit of Normal (SGOT)
SGPT
Upper Limit of Normal (SGPT)
Alkaline Phosphatase
Upper Limit of Normal (Alkaline Phosphatase)
%LVEF by MUGA
Completed by (Print or Type name)
Date completed (MM DD YYYY)
Ccrr Module For Calgb: 10201on-study
Form
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Leukemia NCT00085124 On-Study - CALGB: 10201On-Study Form -
2057573v3.0
Leukemia NCT00085124 Toxicity - CALGB:
10201 ADVERSE EVENT FORM - 2070578v3.0
CALGB: 10201 ADVERSE EVENT FORM
Daunorubicin and Cytarabine With or Without Oblimersen
in Treating Older Patients With Previously Untreated Acute
Myeloid Leukemia
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=AD846683-
4685-2F05-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/9199
CALGB: 10201 ADVERSE EVENT
FORM
Calgb Form
CALGB Study No.
CALGB Patient ID
From
To (MM DD YYYY)
Are data Amended?
Yes (Yes)
Patient's Initials (Last, First, Middle)
Participating Group
Patient Hospital Number
Participating Group Protocol No.
Main Member Institution/Adjunct
Participating Group Patient No.
Current Course/Cycle No.
Treatment Phase
Current Phase Of Leukemia Treatment
For Patient Is Consolidation
(Consolidation)
Current Phase Of Leukemia Treatment
For Patient Is Induction (Induction)
Current Phase Of Leukemia Treatment
For Patient Is Specified Other Phase
(Other, specify)
Was an AER/ADR filed with Central Office based
on an event reported below?
Yes
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No
Expected Adverse Events
MedDRA Code
MedDRA Code
CTC Adverse Event Term
CTC Adverse Event Term
Were there any other events (Hematologic grade
4-5 only or Non-Hematologic grade 3-5 only)
noted during this time period?
Yes
No
CTC Grade
CTC Grade
Attribution
Definite (definitely related to treatment)
Possible (possibly related to treatment)
Probable (probably related to treatment)
Unlikely (unlikely to be related to
treatment)
Unrelated (unrelated to treatment)
Attribution
Definite (definitely related to treatment)
Possible (possibly related to treatment)
Probable (probably related to treatment)
Unlikely (unlikely to be related to
treatment)
Unrelated (unrelated to treatment)
Completed by (Print or Type Name)
Date Completed (MM DD YYYY)
Ccrr Module For Calgb: 10201 Adverse
Event Form
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Leukemia NCT00085124 Toxicity - CALGB: 10201 ADVERSE EVENT
FORM - 2070578v3.0
Leukemia NCT00085124 Lab - CALGB: 10201 PERIPHERAL
BLOOD AND BONE MARROW REPORT FORM - 2031273v3.0
CALGB: 10201 PERIPHERAL BLOOD AND BONE
MARROW REPORT FORM
Daunorubicin and Cytarabine With or Without Oblimersen
in Treating Older Patients With Previously Untreated Acute
Myeloid Leukemia
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=AD85FF2B-
39F3-35D3-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/9200
CALGB: 10201 PERIPHERAL
BLOOD AND BONE MARROW
REPORT FORM
Calgb Form
CALGB Study No.
CALGB Patient ID
From
To (MM DD YYYY)
Are data Amended?
Yes (Yes)
Patient's Initials (Last, First, Middle)
Participating Group
Patient Hospital Number
Participating Group Protocol No.
Main Member Institution/Adjunct
Participating Group Patient No.
Current Course or Cycle No. (MM DD YYYY)
Bone Marrow
Marrow Cellularity (0-100%)
Bone Marrow Differential
% Marrow neutrophils
1 / 3
% Marrow Metamyeocytes and Marrow
Myelocytes
Marrow Promyelocytes (%)
Marrow Blasts (%)
Marrow Lymphocytes (%)
Marrow Monocytes (%)
Marrow Monoblasts (%)
Marrow Eosinophils (%)
Marrow Basophils (%)
Total Marrow Erythroid Cells (%)
Marrow Plasma Cells (%)
Megakaryocyte Status (MM DD YYYY)
Decreased (Decreased)
Increased (Increased)
None (None)
Normal (Normal)
Unknown (Unknown)
Peripheral Blood Differential
Date Specimen Collected
Hemaglobin (gm/dl)
Peripheral Platelet Count (1000/ml)
Peripheral WBC count
Peripheral neutrophils (%) (bands, segs)
Peripheral Metamyelocytes and Myelocytes (%)
Peripheral Promyelocytes (%)
2 / 3
Leukemia NCT00085124 Lab - CALGB: 10201 PERIPHERAL BLOOD
AND BONE MARROW REPORT FORM - 2031273v3.0
Peripheral Blasts (%)
Peripheral Lymphocytes (%)
Peripheral Monocytes (%)
Peripheral Monoblasts (%)
Peripheral Eosinophils (%)
Peripheral Basophils (%)
Degree Of Dyspoiesis Present
Myleopoiesis
Absent (Absent)
Marked (Marked)
Minimal (Minimal)
Moderate (Moderate)
Rare (Rare)
Erythropoiesis
Absent (Absent)
Marked (Marked)
Minimal (Minimal)
Moderate (Moderate)
Rare (Rare)
Megakaryopoiesis
Absent (Absent)
Marked (Marked)
Minimal (Minimal)
Moderate (Moderate)
Rare (Rare)
Completed by (Print or Type Name)
Date Completed (MM DD YYYY)
Ccrr Module For Calgb: 10201 Peripheral
Blood And Bone Marrow Report Form
3 / 3
Leukemia NCT00085124 Lab - CALGB: 10201 PERIPHERAL BLOOD
AND BONE MARROW REPORT FORM - 2031273v3.0
Lung Cancer NCT00049543 Off Treatment -
Off Treatment Form - 2034390v3.0
Off Treatment Form
Gefitinib in Treating Patients With Non-Small Cell Lung
Cancer That Has Been Surgically Removed
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=A069F1F1-
C7BA-50DA-E034-080020C9C0E0
All rights reserved. Please visit https://medical-data-
models.org/forms/9204
Off Treatment Form
1. Patient Information
Pt. Serial #
Hospital #
Pt. Initials
Intergroup Patient Serial #
Site #
Patient's Social Security # (USA only)
Institution
Investigator
2. Off Protocol Therapy
Date final dose of Iressa/placebo given
Please indicate the reason study treatment
stopped:
Death On Study ((D) death)
Patient Off-treatment For Other
Complicating Disease ((II) intercurrent
illness)
Other, Specify ((OT/PV) other: specify)
Disease Progression, Relapse During
Active Treatment ((PD) progressive
disease)
Toxicity/side Effects/complications ((PT)
toxicity to protocol therapy)
Patient Withdrawl Or Refusal After
Beginning Protocol Therapy ((RT) patient
refusal)
Treatment Completed Per Protocol
Criteria ((TC) treatment completed)
(UU) unknown ((UU) unknown)
Patient Withdrawl Or Refusal Prior To
Beginning Protocol Therapy (Patient
withdrawal or refusal prior to beginning
1 / 3
protocol therapy)
other
Toxicity(s)
NCIC CTG Code
Grade* (* Grade according to NCIC CTG
Expanded Common Toxicity Criteria)
Relation to Protocol Therapy (** 1=unrelated
2=unlikely 3=possible 4=probably 5=definite)
Unrelated (1=unrelated)
Unlikely (2=unlikely)
Possibly (3=possible)
Probably (4=probable)
Definitely (5=definite)
Ncic Ctg Use Only2
Date protocol therapy stopped:
Off protocol therapy code
Protocol Violation (PV)
Yes
No
Coord
Phy
Ncic Ctg Use Only
Logged
Header
Study Coord
Unnamed2
Phy
Data Ent'd
2 / 3
Lung Cancer NCT00049543 Off Treatment - Off Treatment Form -
2034390v3.0
Verified
Header
Pt. Serial #
Pt. Initials
3. Unblinding
Was study treatment unblinded?
Yes
No
Date unblinded (If yes,)
4. Comments
4. COMMENTS
5. Investigator Signature
Signature of Responsible Investigator
Name of Clinical Research Associate
Date
Ccrr Module For Off Treatment Form
Person Completing Form, First Name
3 / 3
Lung Cancer NCT00049543 Off Treatment - Off Treatment Form -
2034390v3.0
Lung Cancer NCT00049543 Lab - Supplemental
Laboratory Report Form - 2036656v3.0
Supplemental Laboratory Report Form
Gefitinib in Treating Patients With Non-Small Cell Lung
Cancer That Has Been Surgically Removed
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=A7039E38-
F4C1-1898-E034-0003BA0B1A09
All rights reserved. Please visit https://medical-data-
models.org/forms/9207
Supplemental Laboratory Report
Form
Patient Information
Patient Study ID, Coordinating Group
Patient Initials (first - middle - last)
Patient Medical Record Number
Institution Name
Registered Investigator (NCI Investigator #)
Month Of Report
Month of report (circle one)
1 (1)
12 (12)
15 (15)
18 (18)
21 (21)
24 (24)
27 Months (27)
3 (3)
30 (30)
36 (36)
42 (42)
48 (48)
54 (54)
6 (6)
60 (60)
9 (9)
Other Month (Other)
Other
Biochemistry
Specimen Collection Date (Biochemistry, yyyy
mmm dd)
Lab Unit of Measure (circle unit used)
1 / 4
% (%)
X10^9/l (10 9/L)
1000/ul (1000/uL)
G/dl (g/dl)
G/l (g/L)
Bilirubin (uL or 10 9/L)
Bilirubin ULN
SGOT (AST) (U/L; * If alkaline phosphatase is
greater than ULN but < 2.5 X ULN, ultrasound or
CT scan of abdomen and bone scan MUST be
done prior to randomization)
SGOT (AST) ULN
SGPT (ALT) (U/L; * If alkaline phosphatase is
greater than ULN but < 2.5 X ULN, ultrasound or
CT scan of abdomen and bone scan MUST be
done prior to randomization)
SGPT (ALT) ULN
Alkaline Phosphatase (U/L; ** If AST SGOT or
ALT SGPT is greater than ULN but < 2.5 X ULN,
ultrasound, CT or MRI or abdomen MUST be
done prior to randomization.)
Alkaline Phosphatase ULN
Lactate Dehydrogenase (LDH) (U/L)
Lactate Dehydrogenase ULN
Creatinine (mg/dl or umol/L)
Creatinine ULN
BUN (mg/dl or umol/L)
BUN ULN
Potassium (K) (mEq/L)
Potassium LLN
2 / 4
Lung Cancer NCT00049543 Lab - Supplemental Laboratory Report Form
- 2036656v3.0
Potassium ULN
Sodium (Na) (mmol/L)
Sodium LLN
Sodium ULN
Chloride (Cl) (mEq/L)
Chloride LLN
Chloride ULN
Calcium (Ca) (mg/dL or umol/L)
Calcium LLN
Calcium ULN
Albumin (g/dl or g/L)
Albumin LLN
Albumin ULN
Ncic Ctg Use Only
Logged
Unnamed (Logged Date)
RA
Unnamed (RA Date)
Study Coord
Unnamed (Coord Date)
Phy
Data Ent'd
3 / 4
Lung Cancer NCT00049543 Lab - Supplemental Laboratory Report Form
- 2036656v3.0
Verified
Header
Patient Study ID, Coordinating Group
Patient Initials (first - middle - last)
Hematology
Date Hematology (Blood) Sample Obtained (yyyy
mmm dd)
Lab Unit of Measure (circle unit used)
% (%)
X10^9/l (10 9/L)
1000/ul (1000/uL)
G/dl (g/dl)
G/l (g/L)
Hemoglobin (g/dl or g/L)
Peripheral Platelet Count (1000/uL or x 10 9/L)
Peripheral WBC Count (1000/uL or x 10 9/L)
Peripheral Neutrophils (%)
Comments
COMMENTS
Investigator Signature
Investigator Signature
Person Completing Form, Last Name
Person Completing Form, First Name
Form Completion Date, Original (yyyy mmm dd)
Ccrr Module For Supplemental Laboratory
Report Form
4 / 4
Lung Cancer NCT00049543 Lab - Supplemental Laboratory Report Form
- 2036656v3.0
Lung Cancer NCT00049543 Pathology -
Pathology Submission Report - 2034358v3.0
Pathology Submission Report
Gefitinib in Treating Patients With Non-Small Cell Lung
Cancer That Has Been Surgically Removed
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=A069EFF3-
E6C4-50D8-E034-080020C9C0E0
All rights reserved. Please visit https://medical-data-
models.org/forms/9210
Pathology Submission Report
1. Patient Information
NCIC CTG Patient Serial #
Hospital #
Patient Initials (first-middle-last)
Intergroup Patient Serial #
Site #
Patient's Social Security # (USA only)
Institution
Investigator
2. Pathology Submission
Date tissue obtained for diagnosis
Name of Institution
Address
Contact Pathologist Name
Pathology specimen number(s)
3. Comments
3. COMMENTS
4. Investigator Signature
Signature of Responsible Investigator
1 / 2
Name of Clinical Research Associate
Date
Ncic Ctg Use Only
Logged
Header
Study Coord
Unnamed2
Phy
Data Ent'd
Verified
Ccrr Module For Pathology Submission
Report
State
Person Completing Form, First Name
Address, Department
Address, Street
Address Postal Code
Address Province
Address Country
Address City
2 / 2
Lung Cancer NCT00049543 Pathology - Pathology Submission Report -
2034358v3.0
Lung Cancer NCT00049543 Follow-Up - Form
5M - Minimal Follow-Up Report - 2050474v3.0
Form 5M - Minimal Follow-Up Report
Gefitinib in Treating Patients With Non-Small Cell Lung
Cancer That Has Been Surgically Removed
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=A6FFB989-
6864-715F-E034-0003BA0B1A09
All rights reserved. Please visit https://medical-data-
models.org/forms/9212
Form 5M - Minimal Follow-Up Report
Patient Information
Patient Study ID, Coordinating Group
Patient Initials (first - middle - last)
Patient Medical Record Number
Institution Name
Registered Investigator (NCI Investigator #)
Status
Patient's Vital Status
Alive (Alive)
Dead (Dead)
Primary Cause of Death
Due To Other Cause, Specify (Due to
other cause)
Due To This Disease (Due to this
disease)
Unknown (Unknown)
Describe cause of death
Date of Last Contact or Death (yyyy mmm dd)
Has the patient had a documented clinical
assessment for this cancer (since submission of
the previous follow-up form)
No (No)
Unknown (Unknown)
Yes (Yes)
Date of Last Clinical Assessment (yyyy mmm dd)
Has the patient developed a first progression (or
relapse) that has not been previously reported? (*
submit Form 9 Relapse Report if this is the first
evidence of recurrence)
1 / 3
Yes
No
Date of Progression (yyyy mmm dd)
Other Malignancies Or Myelodysplastic
Syndrome
Has a new primary cancer or MDS been
diagnosed that was not previously reported?
Yes
No
Date of diagnosis (yyyy mmm dd)
Malignancy Type
Site(s) of New Primary
Describe
Ncic Ctg Use Only
Logged
Unnamed (Logged Date)
RA
Unnamed (RA Date)
Study Coord
Unnamed (Coord Date)
Phy
Data Ent'd
Verified
Header
Patient Study ID, Coordinating Group
Patient Initials (first - middle - last)
2 / 3
Lung Cancer NCT00049543 Follow-Up - Form 5M - Minimal Follow-Up
Report - 2050474v3.0
Comments
COMMENTS
Investigator Signature
Investigator Signature
Person Completing Form, Last Name
Person Completing Form, First Name
Form Completion Date, Original (yyyy mmm dd)
Ccrr Module For Form 5m - Minimal
Follow-up Report
3 / 3
Lung Cancer NCT00049543 Follow-Up - Form 5M - Minimal Follow-Up
Report - 2050474v3.0
Melanoma (Skin) null Registration - Imaging
Report Shuttle (ORS) - 2074563v3.0
Imaging Report Shuttle (ORS)
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=B123395A-
8E0C-4C8B-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/9214
Imaging Report Shuttle (ORS)
Ccrr Module For Imaging Report Shuttle
(ors)
Patient ID (Pt. ID issued during registration or
previously issued patient ID)
Institution ID:
Patient Initials: (F ML)
Institution:
1 / 1
Melanoma (Skin) null Follow-Up -
Recurrence Information (RI) - 2074747v3.0
Recurrence Information (RI)
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=B122D931-
FF39-4DDE-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/9215
Recurrence Information (RI)
Ccrr Module For Recurrence Information
(ri)
Notice of Initial Recurrence
Patient ID (Pt. ID issued during registration or
previously issued patient ID)
Institution ID:
Patient Initials: (F ML)
Institution:
Date of Assessment: (Year Month Day)
Has the patient had an initial recurrence of this
cancer that has not been previously reported?
Distant: (Distant:)
Intransit: (Intransit:)
Local: (Local:)
Notice Of Initial Recurrence (Notice of
Initial Recurrence)
Regional/nodal (Regional/Nodal)
Type Of Recurrence(s): (Type of
Recurrence(s):)
Yes (Yes)
Date of Recurrence: (Year Month Day)
Completed by:
Date: (Year Month Day)
1 / 1
Melanoma (Skin) Follow-Up - Extended
Follow-up (EFU) - 2074771v3.0
Extended Follow-up (EFU)
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=B122E5B0-
F30F-4DE5-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/9216
Extended Follow-up (EFU)
Ccrr Module For Extended Follow-up (efu)
Year Month Day
Patient ID (Pt. ID issued during registration or
previously issued patient ID)
Institution ID:
Patient Initials: (F ML)
Institution:
Date of Contact:
Vital Status:
Alive (Alive)
Dead (Dead)
Date of death:
1 / 1
Melanoma (Skin) null Registration - Chest
X-ray Report Shuttle (CXRS) - 2074545v3.0
Chest X-ray Report Shuttle (CXRS)
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=B1232AA1-
F528-4C83-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/9217
Chest X-ray Report Shuttle (CXRS)
Ccrr Module For Chest X-ray Report
Shuttle (cxrs)
Patient ID (Pt. ID issued during registration or
previously issued patient ID)
Institution ID:
Patient Initials: (F ML)
Institution:
1 / 1
Melanoma (Skin) null Follow-Up - Termination
of Patient Follow-up (TPFU) - 2074808v3.0
Termination of Patient Follow-up (TPFU)
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=B1243BAC-
D9BC-4E9B-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/9219
Termination of Patient Follow-up
(TPFU)
Ccrr Module For Termination Of Patient
Follow-up (tpfu)
Year Month Day
Patient ID (Pt. ID issued during registration or
previously issued patient ID)
Institution ID:
Patient Initials: (F ML)
Institution:
Date of Study Completion or Early Follow-up
Terminiation (Year Month Day)
Did the Patient complete the study per protocol
Yes
No
Reason for early termination of patient follow-up
(mark x only one:)
Adverse Event (Adverse event, specify)
Death (Death)
Other (Other, specify)
Patient Declared Ineligible (Patient
declared ineligible, specify)
Patient Follow-up Terminated For Other
Complicating Disease. (Patient follow-up
terminated for other complicating
disease.)
Patient Withdrew Consent. (Patient
withdrew consent.)
Adverse event,  (specify)
Patient declared ineligible (specify)
Other, (specify)
Early follow-up termination authorization number:
1 / 2
Completed by:
Date:
2 / 2
Melanoma (Skin) null Follow-Up - Termination of Patient Follow-up
(TPFU) - 2074808v3.0
Melanoma (Skin) null Registration - Operative
Report Shuttle (ORS) - 2074554v3.0
Operative Report Shuttle (ORS)
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=B1233053-
3400-4C86-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/9221
Operative Report Shuttle (ORS)
Ccrr Module For Operative Report Shuttle
(ors)
Patient ID (Pt. ID issued during registration or
previously issued patient ID)
Institution ID:
Patient Initials: (F ML)
Institution:
1 / 1
Melanoma (Skin) Follow-Up - Miscellaneous
Pages Shuttle (MPS) - 2074799v3.0
Miscellaneous Pages Shuttle (MPS)
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=B12410D0-
2110-4E41-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/9224
Miscellaneous Pages Shuttle (MPS)
Ccrr Module For Miscellaneous Pages
Shuttle (mps)
Patient ID (Pt. ID issued during registration or
previously issued patient ID)
Institution ID:
Patient Initials: (F ML)
Institution:
1 / 1
Melanoma (Skin) null Treatment - Surgical
Report (SR) - 2074581v3.0
Surgical Report (SR)
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=B1229F05-
2708-4D58-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/9225
Surgical Report (SR)
Type Of Procedure
Excision/Sentinel Node Biopsy
Yes
No
Completion Lymphadenectomy
Yes
No
Location(s) of basin(s):
Re-excision
Yes
No
Indication:
In Situ Tumor Present At Any Margin (In
Situ tumor present at any margin)
Invasive Primary Tumor Present Within 1
Mm Of Any Margin (Invasive primary
tumor present within 1 mm of any
margin)
Microsatellite Tumor Present Within 1mm
Of Any Margin (Microsatellite tumor
present within 1mm of any margin)
Other, Specify (Other, specify)
Other, specify (Other, specify)
Adjunctive Procedure: (Mark only one)
Primary Closure With Or Without
Undermining (Primary closure with or
without undermining)
Reconstructive Flap And/or Skin Graft
(Reconstructive flap and/or skin graft)
Name of surgeon responsible for case:
Signature of surgeon/PI:
Completed by:
Date: (Year Month Day)
Date: (Year Month Day)
1 / 2
Ccrr Module For Surgical Report (sr)
Type of Surgery:
Patient ID (Pt. ID issued during registration or
previously issued patient ID)
Institution ID:
Patient Initials: (F ML)
Institution:
Date of Surgery: (within 30 days of
randomization)
2 / 2
Melanoma (Skin) null Treatment - Surgical Report (SR) - 2074581v3.0
Melanoma (Skin) null Follow-Up - Request to
Terminate Patient Follow-up (RTPFU) - 2074785v3.0
Request to Terminate Patient Follow-up (RTPFU)
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=B12401BA-
52F9-4E39-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/9227
Request to Terminate Patient Follow-
up (RTPFU)
Ccrr Module For Request To Terminate
Patient Follow-up (rtpfu)
Patient ID (Pt. ID issued during registration or
previously issued patient ID)
Institution ID:
Patient Initials: (F ML)
Institution:
Date of site request to terminate patient follow-
up: (Month Day Year)
Reason for request:
Completed by:
Date: (Year Month Day)
1 / 1
Melanoma (Skin) null Toxicity - S0201 Observation
Arm Assessment Form - 2055704v3.0
S0201 Observation Arm Assessment Form
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=A93268F8-
DF07-6139-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/9229
S0201 Observation Arm Assessment
Form
Header
SWOG Patient ID
SWOG Study No.
Registration Step
Patient Initials (L, F M)
Reporting interval number
If reporting interval #1, then Indicate week
number for this submission
Week 12 (Week 12)
Week 27 (week 27)
Institution/Affiliate
Physician
Group Name
Study No.
Pt. ID
Disease Status
Date of Last Contact or Death
Vital Status
Alive (Alive)
Dead (Dead)
Reporting interval start date
Reporting interval end date
1 / 2
Adverse Events
Were adverse events assessed during this time
period?
Yes
No
Date of most recent toxicity assessment
Unnamed3
Mark Box If Toxicities Were Assessed
But None Were Seen. (Mark box if
toxicities were assessed but none were
seen.)
Code
Adverse Event
CTC 2.0 Grade (0-5)
0 (0)
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
Other Toxicities (specify)
Comments
Comments
Ccrr Module For S0201 Observation Arm
Assessment Form
2 / 2
Melanoma (Skin) null Toxicity - S0201 Observation Arm Assessment
Form - 2055704v3.0
Melanoma (Skin) null Toxicity - Adverse
Events (AE) - 2074863v3.0
Adverse Events (AE)
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=B1267264-
7F67-522F-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/9230
Adverse Events (AE)
Ccrr Module For Adverse Events (ae)
Month Year Day
Patient ID (Pt. ID issued during registration or
previously issued patient ID)
Institution ID
Patient Initials (F ML)
Institution:
Date of patient evaluation (Month Year Day)
Has the patient experienced any adverse events
since the last visit (Adverse Event Text)
Yes
No
Grade
Fatal (Fatal)
Life-threatening or disabling (Life-
threatening or disabling)
Mild (Mild)
Moderate (Moderate)
Severe (Severe)
Serious (If AE is serious, also report through
AdEERS)
Yes
No
Relationship to Study Intervention
Definitely (Definitely)
Possibly (Possibly)
Probably (Probably)
Unknown/Not Applicable (Unknown/Not
Applicable)
Unlikely (Unlikely)
Unrelated (Unrelated)
Present Status
Adverse Event Was Fatal (Fatal/Died)
Adverse Event Is Ongoing (Intervention
for AE continues)
Adverse Event Is Unchanged (Not
recovered/Not resolved)
1 / 2
Other (specify in Comments) (Other
(specify in Comments))
Adverse Event Is Resolved With
Sequelae (Recovered/Resolved with
sequelae)
Adverse Event Is Resolved
(Recovered/Resolved without sequelae)
Adverse Event Has Improved
(Recovering/Resolving)
Other (specify in Comments)
Action Taken:
Concomitant medications (Concomitant
medications)
Protocol Treatment Was Discontinued As
A Result Of The Adverse Event (Early
termination)
Hospitalization (Hospitalization)
There Was No Action Taken Based On
The Adverse Event (None)
Other (specify in Comments) (Other
(specify in Comments))
Other  (specify in Comments)
MedDRA Code
Onset (DATE):
Resolution (DATE):
Onset Date reported at a prior visit
still present at this visit (Month Year Day)
Comments:
Completed by:
Date:
2 / 2
Melanoma (Skin) null Toxicity - Adverse Events (AE) - 2074863v3.0
Melanoma (Skin) null Toxicity - S0201 Melacine Arm
Cycle-Specific Toxicity and Dosage Form - 2055710v3.0
S0201 Melacine Arm Cycle-Specific Toxicity and Dosage
Form
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=A93417EC-
7384-694A-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/9235
S0201 Melacine Arm Cycle-Specific
Toxicity and Dosage Form
Header
SWOG Patient ID
SWOG Study No.
Registration Step
Patient Initials (L, F M)
Cycle Number
If cycle #1, then Indicate week number for this
submission
Week 12 (Week 12)
Week 27 (week 27)
Institution/Affiliate
Physician
Group Name
Study No.
Pt. ID
Disease Status
Date of Last Contact or Death
Vital Status
Alive (Alive)
Dead (Dead)
Treatment Status
Is patient still on protocol treatment?
Yes
No
1 / 3
Were there any additions, adjustments or
omissions to protocol treatment?
No (No)
(i.e., The Treatment Was Changed
According To Protocol Guidelines) (Yes,
planned (per protocol guidelines))
(i.e., The Treatment Change Was Not
Part Of Protocol Guidelines) (Yes,
unplanned (not per protocol guidelines))
If yes, specify amount and reason
Number of Melacine injections
First date of treatment during this cycle
Last date of treatment during this cycle
Toxicity
Were toxicities assessed during this time period?
Yes
No
Date of most recent toxicity assessment
Unnamed3
Mark Box If Toxicities Were Assessed
But None Were Seen. (Mark box if
toxicities were assessed but none were
seen.)
Code
Toxicity
CTC 2.0 Grade (0-5)
0 (0)
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
Treatment Relation
Definitely (definite)
Possibly (possible)
Probably (probable)
Unlikely (unlikely)
Unrelated (unrelated)
Other Toxicities (specify)
2 / 3
Melanoma (Skin) null Toxicity - S0201 Melacine Arm Cycle-Specific
Toxicity and Dosage Form - 2055710v3.0
Comments
Comments
Ccrr Module For S0201 Melacine Arm
Cycle-specific Toxicity And Dosage Form
3 / 3
Melanoma (Skin) null Toxicity - S0201 Melacine Arm Cycle-Specific
Toxicity and Dosage Form - 2055710v3.0
Melanoma (Skin) Follow-Up - Follow-up
Assessment (FA) - 2074729v3.0
Follow-up Assessment (FA)
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=B122D2BC-
9A32-4DD0-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/9239
Follow-up Assessment (FA)
Ccrr Module For Follow-up Assessment
(fa)
Patient ID (Pt. ID issued during registration or
previously issued patient ID)
Institution ID:
Patient Initials: (F ML)
Institution:
Date of History and Physical:
Date of P/A and Lateral Chest X-ray
Date of LDH: (Year Month Day)
Is LDH greater than upper limit of institutional
norm:
Yes
No
Completed by:
Date: (Year Month Day)
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Melanoma (Skin) null Registration - Pathology
Report Shuttle (PRS) - 2074572v3.0
Pathology Report Shuttle (PRS)
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=B1233DE1-
C318-4C8E-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/9243
Pathology Report Shuttle (PRS)
Ccrr Module For Pathology Report Shuttle
(prs)
Patient ID (Pt. ID issued during registration or
previously issued patient ID)
Institution ID:
Patient Initials: (F ML)
Institution:
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Melanoma (Skin) null Follow-Up - Missed
Visit (MV) - 2074838v3.0
Missed Visit (MV)
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=B12440AB-
9301-4E9E-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/9244
Missed Visit (MV)
Ccrr Module For Missed Visit (mv)
Year Month Day
Patient ID (Pt. ID issued during registration or
previously issued patient ID)
Institution ID:
Patient Initials: (F ML)
Institution:
Missed Visit Date: (originally scheduled date)
Reason patient missed visit: (Mark only one.)
Distance From Home To Clinical Site
(Distance from home to clinical site)
Health Reasons (Health reasons)
Other (Other, specify:)
Scheduling Difficulties (Scheduling
difficulties)
Other, (specify:)
Completed by:
Date:
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Melanoma (Skin) null Registration -
Histopathologic Evaluation (HE) - 2073503v3.0
Histopathologic Evaluation (HE)
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=B122BFC7-
B32C-4DBD-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/9245
Histopathologic Evaluation (HE)
Histopathologic Stage:
Tumor:
Tumor Invades Subepithelial Connective
Tissue (T1)
T2 (T2)
T3 (T3)
Inflammatory Carcinoma (T4)
Nodes
N0 (N0)
Metastasis In A Single Lymph Node, 2
Cm Or Less In Greatest Dimension (N1)
Metastasis In A Single Lymph Node,
More Than 2 Cm But Not More Than 5
Cm In Greatest Dimension; Or Multiple
Lymph Nodes, None More Than 5 Cm In
Greatest Dimension (N2)
Metastasis In A Lymph Node More Than
5 Cm In Greatest Dimension (N3)
Metastisis
M0, According To Ajcc Staging
Definitions (M0)
M1, According To Ajcc Staging
Definitions (M1)
Completed by:
Date: (Year Month Day)
Ccrr Module For Histopathologic
Evaluation (he)
Patient ID (Pt. ID issued during registration or
previously issued patient ID)
Institution ID:
Patient Initials: (F ML)
Institution:
Date of Histopathologic Evaluation (Year Month
Day)
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Source of Specimen (Mark all that apply)
Completion Lymphadenectomy
(Completion Lymphadenectomy)
Excision/Sentinel Node Biopsy
(Excision/Sentinel Node Biopsy)
Re-excision (Re-excision)
If residual tumor present, indicate tumor
thickness: (mm)
Total # of tumor-positive sentinel nodes (SNs)
identified by pathologist (total for all basins):
Basin location(s) of tumor-positive Sentinel
Nodes:
Total # of tumor-positive lymph nodes (LNs)
identified by pathologist (total for all basins):
Final margin after re-excision:
Negative (Negative)
Positive (Positive)
Final margin after re-excision:
Negative (Negative)
Positive (Positive)
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Melanoma (Skin) null Registration - Histopathologic Evaluation (HE) -
2073503v3.0
NCT00049517 Follow-Up - E1900 Cover Page for Acute
Leukemia Disease Assessment Form - 2075100v3.0
E1900 Cover Page for Acute Leukemia Disease
Assessment Form
Combination Chemotherapy With or Without Monoclonal
Antibody Therapy Followed by Stem Cell Transplant in
Treating Patients With Acute Myeloid Leukemia
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=B19AB05D-
F815-25DE-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/9246
E1900 Cover Page for Acute
Leukemia Disease Assessment
Form
Header
DCI Name
Patient Initials
ECOG Protocol Number
ECOG Protocol Number
ECOG Protocol Number
ECOG Patient ID
ECOG Patient ID
Participating Group Protocol No.
Participating Group Patient ID
Institution/Affiliate
On Treatment
On Treatment Time Period
Consolidation (Consolidation)
Induction (Induction)
Induction, Additional Forms (Induction,
additional Forms)
Post-transplant (Post-Transplant)
Off Treatment
Off Treatment Time Period
10 Years (10 years)
12 Months (12 months)
15 Months (15 months)
18 Months (18 months)
1 / 2
2 Years (2 years)
24 Months (24 months)
3 Months (3 months)
3 Years (3 years)
30 Months (30 months)
36 Months (36 months)
4 Years (4 years)
42 Months (42 months)
48 Months (48 months)
5 Years (5 years)
54 Months (54 months)
6 Months (6 months)
6 Years (6 years)
60 Months (60 months)
7 Years (7 years)
8 Years (8 years)
9 Months (9 months)
9 Years (9 years)
Ccrr Module For E1900 Cover Page For
Acute Leukemia Disease Assessment
Form
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NCT00049517 Follow-Up - E1900 Cover Page for Acute Leukemia
Disease Assessment Form - 2075100v3.0
Pancreatic Cancer NCT00058149 Response - E6201
Cover Page for Supplemental Form - 2075318v3.0
E6201 Cover Page for Supplemental Form
A Phase III, Randomized Study of Gemcitabine (Fixed-
Dose Rate Infusion) and Oxaliplatin (NSC 266046) Versus
Gemcitabine (Fixed-Dose Rate Infusion) Versus
Gemcitabine (30-Minute Infusion) in Pancreatic Carcinoma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=B1B0ADEE-
BA19-4B20-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/9248
E6201 Cover Page for Supplemental
Form
Header
DCI Name
Patient Initials
ECOG Protocol Number
ECOG Protocol Number
ECOG Patient ID
ECOG Patient ID
Participating Group Protocol No.
Participating Group Patient ID
Institution/Affiliate
On Treatment
On Treatment Time Period
> 48 weeks (> 48 weeks)
16 weeks (16 weeks)
24 weeks (24 weeks)
32 weeks (32 weeks)
40 weeks (40 weeks)
48 weeks (48 weeks)
8 weeks (8 weeks)
Baseline (Baseline)
Specify weeks
Off Treatment
Off Treatment Time Period
12 Months (12 months)
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15 Months (15 months)
18 Months (18 months)
2 Years (2 years)
24 Months (24 months)
3 Months (3 months)
3 Years (3 years)
30 Months (30 months)
36 Months (36 months)
42 Months (42 months)
48 Months (48 months)
54 Months (54 months)
6 Months (6 months)
60 Months (60 months)
9 Months (9 months)
Ccrr Module For E6201 Cover Page For
Supplemental Form
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Pancreatic Cancer NCT00058149 Response - E6201 Cover Page for
Supplemental Form - 2075318v3.0
Sarcoma NCT01533207 On-Study - Uterine
Cancer - On Study Form (OSU) - 2845059v1.0
Uterine Cancer - On Study Form (OSU)
Gemcitabine Hydrochloride and Docetaxel Followed by
Doxorubicin Hydrochloride or Observation in Treating
Patients With High-Risk Uterine Leiomyosarcoma
Previously Removed by Surgery
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=644E86D7-
E229-D7C8-E040-BB89AD4321CC
All rights reserved. Please visit https://medical-data-
models.org/forms/9249
Uterine Cancer - On Study Form
(OSU)
Header Module
Date form originally completed (m d y)
Date form amended (m d y)
Person amending form, last name
Patient Initials
Patient Study ID
Person Completing Form, Last Name
Uterine Cancer: Disease Description
Date of Definitive Histologic Diagnosis of Primary
Tumor (m d y)
Primary Surgery Type (s check all that apply)
Bilateral Salpingo-oophorectomy
(bilateral salpingo-oophorectomy)
Biopsy Only (Biopsy only)
Other, Specify (other specify)
Para-aortic Node Sampling/dissection
(para-aortic node sampling/dissection)
Pelvic Node Sampling/dissection (pelvic
node sampling/dissection)
Total Hysterectomy (total hysterectomy)
Unilateral Salpingo-oophorectomy
(unilateral salpingo-oophorectomy)
Other specify
Stage
Stage I (I)
Stage Ia (IA)
Stage Ib (IB)
Stage Ic (IC)
Stage Ii (II)
Stage Iia (IIA)
Stage Iib (IIB)
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Stage Iii (III)
Stage Iiia (IIIA)
Stage Iiib (IIIB)
Stage Iiic (IIIC)
Stage Iv (IV)
Stage Iva (IVA)
Stage Ivb (IVB)
Staging System (FIGO)
1988 (1988)
2009 (2009)
Lymph Node Metastasis
Lymph Nodes Type
Other Specify (other)
Para-aortic (para-aortic)
Pelvic (pelvic)
Other specify
Method of Evaluation
Pathologic (Pathologic)
Method of Evaluation
Pathologic (Pathologic)
Lymph Node Involvement
Equivocal (equivocal)
Negative (negative)
Not Evaluated (not evaluated)
Positive (positive)
Unknown (unknown)
Lymph Node Involvement
Equivocal (equivocal)
Negative (negative)
Not Evaluated (not evaluated)
Positive (positive)
Unknown (unknown)
Number of Lymph Nodes Examined
(pathologically)
Histologic Type (of primary tumor)
Endometrial Carcinoma (Endometrial
carcinoma)
Uterine Carcinosarcoma (Uterine
carcinosarcoma)
Uterine Leiomyosarcoma (Uterine
leiomyosarcoma)
Depth of Tumor Penetration into Myometrial
Tissue
<50% Thickness (<50% thickness)
> Or = 50% Thickness (>= 50%
thickness)
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None (None)
Unknown (Unknown)
Vascular Lymphatic Invasion (Are malignant cells
present in the vascular lymphatic space)
No (NO)
Unknown (UNKNOWN)
Yes (YES)
Size of Residual Disease (Maximum size after
resection is complete. For microscopic enter 0.0
cm)
Radiation therapy (prior to study entry check all
that apply)
Brachytherapy (Brachytherapy)
Extended Field External Beam
(Extended field external beam)
None (None)
Other (Other)
Pelvic External Beam (Pelvic external
beam)
Other, specify
Is measurable disease present? (at study entry)
No (No)
Unknown (Unknown)
Yes (Yes)
Comments
COMMENTS
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Sarcoma NCT01533207 On-Study - Uterine Cancer - On Study Form
(OSU) - 2845059v1.0
Pancreatic Cancer NCT00075686 Pre-Study - S0205
Advanced GI Carcinoma Prestudy Form - 2035482v3.0
S0205 Advanced GI Carcinoma Prestudy Form
S0205 Gemcitabine With or Without Cetuximab as First-
Line Therapy in Treating Patients With Locally Advanced
Unresectable or Metastatic Adenocarcinoma of the
Pancreas
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=A11A5640-
9768-6C93-E034-080020C9C0E0
All rights reserved. Please visit https://medical-data-
models.org/forms/9251
S0205 Advanced GI Carcinoma
Prestudy Form
Header
SWOG Patient ID
SWOG Study No.
Registration Step
Patient Initials (L, F M)
Institution
Affiliate
Physician
Description Of Disease
Date of initial diagnosis of pancreatic cancer
Stage of disease at initial diagnosis
The Cancer Is No Bigger Than 2
Centimeters (about 1 Inch) And Has Not
Spread Outside The Breast. (I)
Iia (II)
Iib (IIB)
Defined By Either Of The Following: The
Cancer Is Smaller Than 5 Centimeters
And Has Spread To The Lymh Nodes
Under The Arm, Which Have Grown Into
Each Other Or Into Other Structures And
Are Attached To Them. The Cancer Is
Bigger Than 5 Cm And Has Spre* (III)
Defined By Either Of The Following.: The
Cancer Has Spread To Tissues Near
The Breast (skin, Chest Wall, Including
The Ribs And The Muscles In The
Chest). The Cancer Has Spread To
Lymph Nodes Inside The Chest Wall
Along The Breast Bone. (IIIB)
The Cancer Has Spread To Other
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Organs Of The Body, Most Often The
Bones, Lungs, Liver, Or Brain. Or, Tumor
Has Spread Locally To The Skin And
Lymph Nodes Inside The Neck, Near
The Collarbone. (IVA)
IVB (IVB)
Current Disease Status
Locally Advanced Unresectable (Locally
advanced unresectable)
Metastatic (Metastatic)
Height (cm)
Performance Status
Current Disease Sites (select all that apply)
Bone (Bone)
Distant Lymph Nodes (Distant Nodes)
Liver (Liver)
Lung (Lung/Pleura)
Other abdominal (Other abdominal)
Other, Specify (Other, specify)
Primary Site/Direct Extension (Primary
Site/Direct Extension)
Regional Lymph Nodes (Regional
Nodes)
Other, specify
Prior Treatment Related To This Cancer
Prior Systemic Therapy
Yes
No
Prior Radiation Therapy
Yes
No
Prior Surgery
Yes
No
Prior Immunotherapy
Yes
No
Comments
Comments
Ccrr Module For S0205 Advanced Gi
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Pancreatic Cancer NCT00075686 Pre-Study - S0205 Advanced GI
Carcinoma Prestudy Form - 2035482v3.0
Carcinoma Prestudy Form
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Pancreatic Cancer NCT00075686 Pre-Study - S0205 Advanced GI
Carcinoma Prestudy Form - 2035482v3.0
Ovarian Cancer NCT00954174 On-Study - Gynecologic Oncology Group
Recurrent Gynecologic Cancer - On Study Form (Form OSR) - 2728090v1.0
Gynecologic Oncology Group Recurrent Gynecologic
Cancer - On Study Form (Form OSR)
Paclitaxel and Carboplatin or Ifosfamide in Treating Patients
With Newly Diagnosed Persistent or Recurrent Uterine or
Ovarian Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=4582476E-
F7EA-478B-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/9252
Gynecologic Oncology Group
Recurrent Gynecologic Cancer - On
Study Form (Form OSR)
Header Module
Date form originally completed (m d y)
Date form amended (m d y)
Person amending form, last name
Patient Initials (First, Middle, Last)
Patient Study ID
Person Completing Form, Last Name
Disease Description - Prior History
Date of Definitive Histologic Diagnosis of Primary
Tumor
Stage (at diagnosis FIGO)
Refer To Figo Staging For Specific
Gynecologic Cancer (I)
Refer To Figo Staging For Specific
Gynecologic Cancer (II)
Refer To Figo Staging For Specific
Gynecologic Cancer (III)
Refer To Figo Staging For Specific
Gynecologic Cancer (IV)
Primary surgery date (m d y)
Primary Surgery Type
Bilateral Salpingo-oophorectomy
(bilateral salpingo-oophorectomy)
Cervical Conization (cervical conization)
Omentectomy (omentectomy)
Other, Specify (other specify)
Para-aortic Node Sampling/dissection
(para-aortic node sampling/dissection)
Partial Hysterectomy (partial
hysterectomy)
Pelvic Node Sampling/dissection (pelvic
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node sampling/dissection)
Radical Hysterectomy (radical
hysterectomy)
Radical Trachelectomy (radical
trachelectomy)
Total Hysterectomy (total hysterectomy)
Unilateral Salpingo-oophorectomy
(unilateral salpingo-oophorectomy)
Other specify
Date of First Recurrence or Progression
Disease Description - Current History
Current Status of Disease
Disease Continues To Be Present
Following Initial Treatment (Persistent)
Primary Tumor (Primary (Advanced))
Progression (Progression)
Recurrence/relapse (Recurrence)
Date of most recent recurrence or progression (or
progression)
What was the method used to determine
recurrence or progression
Clinical Examination (Clinical)
Histologic (Histologic)
Radiographic (Radiographic)
Tumor Marker (Tumor Marker)
Site(s) of disease at study entry
Ascites (Ascites)
Bladder (Bladder)
Bone (Bone)
Cervix (Cervix)
Cns/brain (CNS/Brain)
Colon (Colon)
Endometrium (Endometrium)
Liver (Liver)
Lung (Lung)
Lymph Nodes (Lymph nodes)
Other (Other)
Ovary (Ovary)
Parametrial Involvement (Parametrial
involvement)
Peritoneum (Peritoneum)
Pleura (Pleura)
Pleural Effusion (Pleural effusion)
Skin (Skin)
Uterus (Uterus)
Lymph Nodes Specify
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Other specify
Prior Treatment For Gynecologic Cancer
Prior Systemic Chemotherapy
Yes
No
Date Prior Chemotherapy Started
Date Prior Chemotherapy Ended
Chemotherapy Regimen
First Line Agent (First line)
Other Specify (Other)
Second Line Agent (Second line)
Specify agent (s)
No. of Courses
Prior Hormonal Therapy
No (No)
Yes (Yes, specify)
Yes, specify
Non-protocol biologic response modifier?
No (No)
Yes (Yes, specify)
Specify
Prior Radiation Therapy
No (No)
Yes (Yes, specify)
Yes specify
Is the site of recurrence within the field previously
treated by radiation therapy?
Yes
No
Comments Module
Comments
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Ovarian Cancer NCT00954174 On-Study - Gynecologic Oncology Group
Recurrent Gynecologic Cancer - On Study Form (Form OSR) - 2728090v1.0
Pancreatic Cancer NCT00058149 Response - E6201
Cover Page for RECIST Forms - 2075205v3.0
E6201 Cover Page for RECIST Forms
A Phase III, Randomized Study of Gemcitabine (Fixed-
Dose Rate Infusion) and Oxaliplatin (NSC 266046) Versus
Gemcitabine (Fixed-Dose Rate Infusion) Versus
Gemcitabine (30-Minute Infusion) in Pancreatic Carcinoma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=B1B164EC-
ED7F-4A7F-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/9254
E6201 Cover Page for RECIST
Forms
Header
DCI Name
Patient Initials
ECOG Protocol Number
ECOG Protocol Number
ECOG Patient ID
ECOG Patient ID
Participating Group Protocol No.
Participating Group Patient ID
Institution/Affiliate
Select Form
Ecog Follow-up Disease Evaluation
Form (ECOG Follow-up Disease
Evaluation Form)
Ecog Nontarget Lesions Supplemental
Form (ECOG Nontarget Lesions
Supplemental Form)
On Treatment
On Treatment Time Period
> 48 weeks (> 48 weeks)
16 weeks (16 weeks)
24 weeks (24 weeks)
32 weeks (32 weeks)
40 weeks (40 weeks)
48 weeks (48 weeks)
8 weeks (8 weeks)
Baseline (Baseline)
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Specify weeks
Off Treatment
Off Treatment Time Period
12 Months (12 months)
15 Months (15 months)
18 Months (18 months)
2 Years (2 years)
24 Months (24 months)
3 Months (3 months)
3 Years (3 years)
30 Months (30 months)
36 Months (36 months)
42 Months (42 months)
48 Months (48 months)
54 Months (54 months)
6 Months (6 months)
60 Months (60 months)
9 Months (9 months)
Ccrr Module For E6201 Cover Page For
Recist Forms
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Pancreatic Cancer NCT00058149 Response - E6201 Cover Page for
RECIST Forms - 2075205v3.0
Ovarian Cancer NCT00954174 Quality of Life - GOG
0261:  Quality of Life Survey Form - 2847538v1.0
GOG 0261:  Quality of Life Survey Form
Paclitaxel and Carboplatin or Ifosfamide in Treating Patients
With Newly Diagnosed Persistent or Recurrent Uterine or
Ovarian Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=64F255EF-
4DA9-30CE-E040-BB89AD436169
All rights reserved. Please visit https://medical-data-
models.org/forms/9255
GOG 0261:  Quality of Life Survey
Form
Header Module
Patient Initials
Date
Patient Study ID
Scheduled time to obtain Quality of Life
Questionnaire
26 Weeks After Starting Study Therapy
(26 weeks after starting study therapy)
Prior To Cycle 3 (Prior to cycle 3)
Prior To Cycle 6 (Prior to cycle 6)
Prior To Starting Study Therapy (Prior to
starting study therapy)
Physical Well-being
I have a lack of energy.
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have nausea.
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
Because of my physical condition, I have trouble
meeting the needs of my family.
2 (A little bit)
1 (Not at all)
4 (Quite a bit)
3 (Somewhat)
5 (Very much)
I have pain.
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
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Very Much (Very much)
I am bothered by side effects of treatment.
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I feel ill
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am forced to spend time in bed
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
Functional Wellbeing
I am able to work (include work at home)
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
My work (include work at home) is fulfilling
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am able to enjoy life.
2 (A little bit)
1 (Not at all)
4 (Quite a bit)
3 (Somewhat)
5 (Very much)
I have accepted my illness
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am sleeping well
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
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Life Survey Form - 2847538v1.0
I am enjoying the things I usually do for fun
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am content with the quality of my life right now
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
Additional Concerns
I have swelling in my stomach area
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have cramps in my stomach area
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have discomfort or pain in my stomach area
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have vaginal bleeding or spotting
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have vaginal discharge
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am unhappy about a change in my appearance
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have hot flashes
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A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have cold sweats
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have night sweats
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I feel fatigued
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have pain or discomfort with intercourse
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have trouble digesting food
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have been short of breath
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am bothered by constipation
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I urinate more frequently than usual
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
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Very Much (Very much)
I have discomfort or pain in my pelvic area
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
Ntx4 Subscale
I have numbness or tingling in my hands
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have numbness or tingling in my feet
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I feel discomfort in my hands
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I feel discomfort in my feet
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have joint pain or muscle cramps
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I feel weak all over
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have trouble hearing
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
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I get a ringing or buzzing in my ears
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have trouble buttoning buttons
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have trouble feeling the shape of small objects
when they are in my hand
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have trouble walking
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
To Be Completed By Clinical Staff
QOL contact person
Status of the QOL assessment
Other (Other)
Patient Died (Patient died)
Patient Kept Appointment, But Could Not
Complete Questionnaire Due To Illness
(Patient kept appointment, but could not
complete questionnaire due to illness)
Patient Kept Appointment, But Refused
To Complete Questionnaire For Reasons
Other Than Illness (Patient kept
appointment, but refused to complete
questionnaire for reasons other than
illness)
Patient Off Study Treatment And Cannot
Be Contacted For Follow-up (Patient off
study treatment and cannot be contacted
for follow-up)
Questionnaire Not Administered Due To
Clinical Staff Error (Questionnaire not
administered due to clinical staff error)
The Questionnaire Is Complete (The
questionnaire is complete)
Specify reason
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Other, specify
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Sarcoma NCT01533207 Pre-Study - Gynecologic Oncology
Group Pre-Treatment Summary Form (Form DR) - 3127082v1.0
Gynecologic Oncology Group Pre-Treatment Summary
Form (Form DR)
Gemcitabine Hydrochloride and Docetaxel Followed by
Doxorubicin Hydrochloride or Observation in Treating
Patients With High-Risk Uterine Leiomyosarcoma
Previously Removed by Surgery
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=8D17F7CB-
7227-90BC-E040-BB89AD435566
All rights reserved. Please visit https://medical-data-
models.org/forms/9259
Gynecologic Oncology Group Pre-
Treatment Summary Form (Form
DR)
Header Module
Date form originally completed (m d y)
Date form amended (m d y)
Person amending form, last name
Patient Initials (First, Middle, Last)
Patient Study ID
Person completing form, last name
Non-invasive Diagnostic Procedures
Chest X-Ray Result
Abnormal (Abnormal)
Normal (Normal)
Not Done (Not done)
Date of Chest X-Ray (m d y)
EKG Result
Abnormal (Abnormal)
Normal (Normal)
Not Done (Not done)
Date of EKG (m d y)
MRI Result
Abnormal (Abnormal)
Normal (Normal)
Not Done (Not done)
Date of MRI (m d y)
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CT Result
Abnormal (Abnormal)
Normal (Normal)
Not Done (Not done)
Abnormal specify
Abnormal specify
Abnormal specify
Abnormal specify
Abnormal specify
Date of CT Scan (m d y)
Other Procedure Performed
Abnormal (Abnormal)
Normal (Normal)
Not Done (Not done)
Specify
Procedure Date (m d y)
Are there any target lesions?
Yes
No
Comments
Comments
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Registration - CALGB Step 2 Registration
Worksheet - 2794818v1.0
CALGB Step 2 Registration Worksheet
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=59FF920E-
757A-5FDA-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/9261
CALGB Step 2 Registration
Worksheet
Header Module
Lead Institution
Institution/Affiliate
Physician
Principal Investigator No.
Participating Group Name
Protocol Administration
Patient Initials (Last First Middle)
CALGB Patient ID (If the patient has been on a
previous CALGB study, specify)
Institution contact
Phone
Fax
Protocol Design
Stratification Factors
Assigned Treatment Arm
Registration Information
Registration Date (MM DD YYYY)
Registrar's Signature
1 / 1
Pancreatic Cancer NCT00058149 Quality of
Life - Brief Pain Inventory - 2031356v3.0
Brief Pain Inventory
A Phase III, Randomized Study of Gemcitabine (Fixed-
Dose Rate Infusion) and Oxaliplatin (NSC 266046) Versus
Gemcitabine (Fixed-Dose Rate Infusion) Versus
Gemcitabine (30-Minute Infusion) in Pancreatic Carcinoma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=AE65F8E1-
704E-30A0-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/9263
Brief Pain Inventory
Header
Registration Step
Patient Initials
ECOG Protocol Number
ECOG Protocol Number
ECOG Patient ID
ECOG Patient ID
Participating Group Protocol No.
Participating Group Patient ID
Institution/Affiliate
Throughout our lives, most of us have had pain
from time to time (such as minor headaches,
sprains, and toothaches). Have you had pain
other than these everyday kinds of pain today?
Yes
No
Please rate your pain by circling the one number
that best describes your pain at its worst in the
last 24 hours.
0 (0)
1 (1)
10 (10)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
7 (7)
8 (8)
9 (9)
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Please rate your pain by circling the one number
that best describes your pain at its least in the
last 24 hours.
0 (0)
1 (1)
10 (10)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
7 (7)
8 (8)
9 (9)
Please rate your pain by circling the one number
that best describes your pain on the average.
0 (0)
1 (1)
10 (10)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
7 (7)
8 (8)
9 (9)
Please rate your pain by circling the one number
that tells how much pain you have right now.
0 (0)
1 (1)
10 (10)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
7 (7)
8 (8)
9 (9)
What treatments or medications are you receiving
for your pain?
In the last 24 hours, how much relief have pain
treatments or medications provided? (Please
circle the one percentage that most shows how
much relief you have received.)
0.3 (0.3)
0.4 (0.4)
0.9 (0.9)
10% (10%)
100% (100%)
20% (20%)
50% (50%)
60% (60%)
70% (70%)
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80% (80%)
Circle the one number that describes, during the
past 24 hours, pain has interfered with your
general activity.
0 (0)
1 (1)
10 (10)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
7 (7)
8 (8)
9 (9)
Circle the one number that describes, during the
past 24 hours, pain has interfered with your
mood.
0 (0)
1 (1)
10 (10)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
7 (7)
8 (8)
9 (9)
Circle the one number that describes, during the
past 24 hours, pain has interfered with your
walking ability.
0 (0)
1 (1)
10 (10)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
7 (7)
8 (8)
9 (9)
Circle the one number that describes, during the
past 24 hours, pain has interfered with your
normal walk.
0 (0)
1 (1)
10 (10)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
7 (7)
8 (8)
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9 (9)
Circle the one number that describes, during the
past 24 hours, pain has interfered with your
relations with other people.
0 (0)
1 (1)
10 (10)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
7 (7)
8 (8)
9 (9)
Circle the one number that describes, during the
past 24 hours, pain has interfered with your
sleep.
0 (0)
1 (1)
10 (10)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
7 (7)
8 (8)
9 (9)
Circle the one number that describes, during the
past 24 hours, pain has interfered with your
enjoyment of life.
0 (0)
1 (1)
10 (10)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
7 (7)
8 (8)
9 (9)
Ccrr Module For Brief Pain Inventory
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Pancreatic Cancer NCT00058149 Response - E6201
Cover Page for Adverse Event Form - 2075284v3.0
E6201 Cover Page for Adverse Event Form
A Phase III, Randomized Study of Gemcitabine (Fixed-
Dose Rate Infusion) and Oxaliplatin (NSC 266046) Versus
Gemcitabine (Fixed-Dose Rate Infusion) Versus
Gemcitabine (30-Minute Infusion) in Pancreatic Carcinoma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=B1B0ABAE-
0BB9-4B1E-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/9264
E6201 Cover Page for Adverse
Event Form
Header
DCI Name
Patient Initials
ECOG Protocol Number
ECOG Protocol Number
ECOG Patient ID
ECOG Patient ID
Participating Group Protocol No.
Participating Group Patient ID
Institution/Affiliate
On Treatment
On Treatment Time Period
> 48 weeks (> 48 weeks)
16 weeks (16 weeks)
24 weeks (24 weeks)
32 weeks (32 weeks)
40 weeks (40 weeks)
48 weeks (48 weeks)
8 weeks (8 weeks)
Baseline (Baseline)
Specify weeks
Off Treatment
Off Treatment Time Period
12 Months (12 months)
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15 Months (15 months)
18 Months (18 months)
2 Years (2 years)
24 Months (24 months)
3 Months (3 months)
3 Years (3 years)
30 Months (30 months)
36 Months (36 months)
42 Months (42 months)
48 Months (48 months)
54 Months (54 months)
6 Months (6 months)
60 Months (60 months)
9 Months (9 months)
Ccrr Module For E6201 Cover Page For
Adverse Event Form
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Adverse Event Form - 2075284v3.0
Sarcoma NCT01533207 On-Study - Gynecologic Oncology Group
Solid Tumor Evaluation Form (D2M version 3) - 3127207v1.0
Gynecologic Oncology Group Solid Tumor Evaluation Form
(D2M version 3)
Gemcitabine Hydrochloride and Docetaxel Followed by
Doxorubicin Hydrochloride or Observation in Treating
Patients With High-Risk Uterine Leiomyosarcoma
Previously Removed by Surgery
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=8D1826DA-
E799-F792-E040-BB89AD433BF7
All rights reserved. Please visit https://medical-data-
models.org/forms/9271
Gynecologic Oncology Group Solid
Tumor Evaluation Form (D2M version
3)
Header Module
Date form originally completed (m d y)
Date form amended (m d y)
Person amending form, last name
Patient Initials (First, Middle, Last)
Patient Study ID
Person completing form, last name
Target Lesion(s) Evaluation
Did the patient have measurable disease at
baseline
Yes
No
Assessment
Site of Lesion
Method of Evaluation (Method of evaluation *)
Chest X-ray (Chest X-ray)
Clinical Examination (pe) (Clinical
examination)
Ct Scan (CT scan)
Positron Emission Tomography (FDG-
PET)
Mri (MRI (NMR))
Not Evaluated (Not evaluated)
Other (Other)
Pet/ct Scan (PET/CT scan)
Lymph node
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Yes
No
Date of evaluation (m d y)
Tumor Size (cm) (Please report the longest
diameter for non-nodal target lesions. The short
axis should be reported for nodal target lesions)
Sum of diameters (cm)
Non-target Lesion(s) Evaluation
Were there any non-target lesions reported at
baseline
Yes
No
Site of Lesion
Method of Evaluation (Method of evaluation *)
Chest X-ray (Chest X-ray)
Clinical Examination (pe) (Clinical
examination)
Ct Scan (CT scan)
Positron Emission Tomography (FDG-
PET)
Mri (MRI (NMR))
Not Evaluated (Not evaluated)
Other (Other)
Pet/ct Scan (PET/CT scan)
Date of evaluation (m d y)
Follow-up status of lesion
Complete Response (Complete
response)
N/a - Baseline (N/A - Baseline)
Non Cr/ Non Pd (Non-CR/ Non-PD)
Unequivocal Pd (Unequivocal PD)
New Target Lesion(s) At Follow-up
Evaluation
Was the appearance of any new lesions
documented (since the baseline evaluation)
Yes
No
Site of Lesion
Method of Evaluation (Method of evaluation *)
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Chest X-ray (Chest X-ray)
Clinical Examination (pe) (Clinical
examination)
Ct Scan (CT scan)
Positron Emission Tomography (FDG-
PET)
Mri (MRI (NMR))
Not Evaluated (Not evaluated)
Other (Other)
Pet/ct Scan (PET/CT scan)
Date of evaluation (m d y)
Overall Response
Time point response
Biologic Progression Only (Biologic
progression only)
Complete Response (Complete
response)
Not Applicable - Baseline (N/A -
Baseline)
Not Evaluable (Not evaluable)
Partial Response (Partial Response)
Pd (Progressive Disease)
Stable Disease (Stable Disease)
Overall best confirmed response
Complete Response (Complete
response)
Not Applicable - Baseline (N/A -
Baseline)
Non-measurable Disease At Baseline
(Non-measurable disease at baseline)
Not Evaluable (Not evaluable)
Partial Response (Partial Response)
Pd (Progressive Disease)
Stable Disease (Stable Disease)
Overall best response (unconfirmed)
Complete Response (CR)
N/a - Baseline (N/A - Baseline)
Not Evaluable (ne) (NE)
Non-measurable Disease At Baseline
(Non-measurable disease at baseline)
Progressive Disease (PD)
Partial Response (PR)
Stable Disease (SD)
PR First Observed Date (m d y)
Response Confirmed Date, PR (m d y)
CR First Observed Date (m d y)
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Response Confirmed Date, CR (m d y)
Comments
Comments
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Pancreatic Cancer NCT00058149 Response - E6201 Cover
Page for Hematology/Chemistry Forms - 2075247v3.0
E6201 Cover Page for Hematology/Chemistry Forms
A Phase III, Randomized Study of Gemcitabine (Fixed-
Dose Rate Infusion) and Oxaliplatin (NSC 266046) Versus
Gemcitabine (Fixed-Dose Rate Infusion) Versus
Gemcitabine (30-Minute Infusion) in Pancreatic Carcinoma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=B1B0A8C1-
ED1A-4B19-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/9273
E6201 Cover Page for
Hematology/Chemistry Forms
Header
DCI Name
Patient Initials
ECOG Protocol Number
ECOG Protocol Number
ECOG Patient ID
ECOG Patient ID
Participating Group Protocol No.
Participating Group Patient ID
Institution/Affiliate
On Treatment
On Treatment Time Period
> 48 weeks (> 48 weeks)
16 weeks (16 weeks)
24 weeks (24 weeks)
32 weeks (32 weeks)
40 weeks (40 weeks)
48 weeks (48 weeks)
8 weeks (8 weeks)
Baseline (Baseline)
Specify weeks
Off Treatment
Off Treatment Time Period
12 Months (12 months)
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15 Months (15 months)
18 Months (18 months)
2 Years (2 years)
24 Months (24 months)
3 Months (3 months)
3 Years (3 years)
30 Months (30 months)
36 Months (36 months)
42 Months (42 months)
48 Months (48 months)
54 Months (54 months)
6 Months (6 months)
60 Months (60 months)
9 Months (9 months)
Ccrr Module For E6201 Cover Page For
Hematology/chemistry Forms
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Pancreatic Cancer NCT00058149 Response - E6201 Cover Page for
Hematology/Chemistry Forms - 2075247v3.0
Nonneoplastic Condition NCT01057121 Demographic
- AMC-070 Demographic Form (DEM) - 3146420v1.0
AMC-070 Demographic Form (DEM)
Lenalidomide in Treating Patients With AIDS-Related
Kaposi Sarcoma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=91E333A1-
42F8-701C-E040-BB89AD433C30
All rights reserved. Please visit https://medical-data-
models.org/forms/9274
AMC-070 Demographic Form (DEM)
Header
Patient Initials (First, Last example: JS)
Patient's Date of Birth (mm/dd/yyyy)
Gender
Female Gender (Female)
Male Gender (Male)
Ethnicity
A Person Of Mexican, Puerto Rican,
Cuban, Central Or South American Or
Other Spanish Culture Or Origin,
Regardless Of Race. (Hispanic or Latino)
A Person Not Meeting The Definition For
Hispanic Or Latino. (Not Hispanic or
Latino)
Could Not Be Determined Or Unsure
(Unknown)
Race (check all that apply)
A Person Having Origins In Any Of The
Original Peoples Of North And South
America (including Central America),
And Who Maintains Tribal Affiliation Or
Community Attachment. (American
Indian or Alaska Native)
A Person Having Origins In Any Of The
Original Peoples Of The Far East,
Southeast Asia, Or The Indian
Subcontinent Including, For Example,
Cambodia, China, India, Japan, Korea,
Malaysia, Pakistan, The Philippine
Islands, Thailand, And Vietnam. (Asian)
A Person Having Origins In Any Of The
Black Racial Groups Of Africa. Terms
Such As "haitian" Or "negro" Can Be
Used In Addition To "black Or African
American." (Black or African American)
A Person Having Origins In Any Of The
Original Peoples Of Hawaii, Guam,
Samoa, Or Other Pacific Islands. (Native
Hawaiian or other Pacific Islander)
Could Not Be Determined Or Unsure
(Unknown)
A Person Having Origins In Any Of The
Original Peoples Of Europe, The Middle
East, Or North Africa. (White)
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Patient Zip Code (xxxxx)
Method of Payment
Medicaid (Medicaid)
Medicare And Medicaid (Medicaid and
Medicare)
Medicare (Medicare)
Medicare And Private Insurance
(Medicare and Private Insurance)
Military Or Veterans Sponsored
Insurance, Not Otherwise Specified
(Military or Veterans Sponsored, NOS)
Military Insurance (Military Sponsored
(Including CHAMPUS & TriCare))
No Insurance (No Means of Payment
(No Insurance))
Other (Other)
Private Insurance (Private Insurance)
Self Payment (Self-Pay (No Insurance))
Unknown (Unknown)
Veterans Administration Sponsor
Insurance (Veterans Sponsored)
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Endometrial Cancer NCT00942357 - Pre-Study - GOG-
0258 Pre-Treatment Summary Form (DR) 2843236_v1_0
GOG-0258 Pre-Treatment Summary Form (DR)
Carboplatin and Paclitaxel With or Without Cisplatin and
Radiation Therapy in Treating Patients With Stage I, Stage
II, Stage III, or Stage IVA Endometrial Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=644E6D14-
3F06-95F3-E040-BB89AD4357FF
All rights reserved. Please visit https://medical-data-
models.org/forms/9275
GOG-0258 Pre-Treatment Summary
Form (DR)
Kopfmodul
Ursprüngliches Abschlussdatum (m t j)
Datum: Formularänderungen (m t j)
Person der Formularänderung, Nachname
Patienteninitialen ( Vorname, zweiter Vorname ,
Nachname)
Studienpatienten-ID
Ausfüllende Person, Nachname
Nicht-invasive Diagnostik
Brust Röntgenergebnis
Unregelmäßig (Abnormal)
normal (Normal)
nicht durchgeführt (Not done)
Datum des Bruströntgen (m t j)
EKG-Ergebnis
Unregelmäßig (Abnormal)
normal (Normal)
nicht durchgeführt (Not done)
Datum der EKG-Untersuchung (m t j)
MRT-Ergebnis
Unregelmäßig (Abnormal)
normal (Normal)
nicht durchgeführt (Not done)
Datum der MRT-Untersuchung (m t j)
CT-Ergebnis
Unregelmäßig (Abnormal)
normal (Normal)
nicht durchgeführt (Not done)
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Unregelmäßig, angeben
Unregelmäßig, angeben
Unregelmäßig, angeben
Unregelmäßig, angeben
Unregelmäßig, angeben
Datum des CT-Scans (m t j)
Andere Verfahren durchgeführt
Unregelmäßig (Abnormal)
normal (Normal)
nicht durchgeführt (Not done)
angeben
Untersuchungsdatum ( m d y)
Gibt es irgendwelche Zielläsionen?
Ja
Nein
Kommentare
Kommentare
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Treatment Summary Form (DR) 2843236_v1_0
Pre-Study - NCI Standard Participant
Identification Template - 2729615v1.0
The collection of CDEs used in the Participant ID module.
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=46716FCE-
3AD1-70D5-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/9277
NCI Standard Participant
Identification Template
Mandatory Participant Id Questions
Participant Last Name
Participant First Name
Optional Participant Id Questions
Participant Middle Name
Person Name Suffix
First (I)
Second: C49463 (II)
Third (III)
Fourth (IV)
Junior (Jr.)
Senior (Sr.)
Participant Home Street Address
Participant City
Participant State
Aguascalientes (Aguascalientes)
Alabama (Alabama)
Alaska (Alaska)
Alberta (Alberta)
American Samoa (American Samoa)
Arizona (Arizona)
Arkansas (Arkansas)
Baja California (Baja California)
Baja California Sur (Baja California Sur)
British Columbia (British Columbia)
California (California)
Campeche (Campeche)
Chiapas (Chiapas)
Chihuahua (Chihuahua)
Coahuila De Zaragoza (Coahuila de
Zaragoza)
Colima (Colima)
Colorado (Colorado)
Connecticut (Connecticut)
Delaware (Delaware)
District Of Columbia (District of
Columbia)
Distrito Federal (Distrito Federal)
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Durango (Durango)
Florida (Florida)
Georgia (Georgia)
Guam (Guam)
Guanajuato (Guanajuato)
Guerrero (Guerrero)
Hawaii (Hawaii)
Hildalgo (Hildalgo)
Idaho (Idaho)
Illinois (Illinois)
Indiana (Indiana)
Iowa (Iowa)
Jalisco (Jalisco)
Kansas (Kansas)
Kentucky (Kentucky)
Louisiana (Louisiana)
Maine (Maine)
Manitoba (Manitoba)
Marshall Islands (Marshall Islands)
Maryland (Maryland)
Massachusetts (Massachusetts)
Mexico (Mexico)
Michigan (Michigan)
Michoacan De Ocampo (Michoacan de
Ocampo)
Micronesia (Micronesia)
Minnesota (Minnesota)
Mississippi (Mississippi)
Missouri (Missouri)
Montana (Montana)
Morelos (Morelos)
Nayarit (Nayarit)
Nebraska (Nebraska)
Nevada (Nevada)
New Brunswick (New Brunswick)
New Hampshire (New Hampshire)
New Jersey (New Jersey)
New Mexico (New Mexico)
New York (New York)
Newfoundland (Newfoundland)
North Carolina (North Carolina)
North Dakota (North Dakota)
Northern Mariana Islands (Northern
Mariana Islands)
Northwest Territories (Northwest
Territories)
Nova Scotia (Nova Scotia)
Nuevo Leon (Nuevo Leon)
Nunavut (Nunavut)
Oaxaca (Oaxaca)
Ohio (Ohio)
Oklahoma (Oklahoma)
Ontario (Ontario)
Oregon (Oregon)
Palau (Palau)
Pennsylvania (Pennsylvania)
Prince Edward Island (Prince Edward
Island)
Puebla (Puebla)
Puerto Rico (Puerto Rico)
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Quebec (Quebec)
Queretaro De Arteaga (Queretaro de
Arteaga)
Quintana Roo (Quintana Roo)
Rhode Island (Rhode Island)
San Luis Potosi (San Luis Potosi)
Saskatchewan (Saskatchewan)
Sinaloa (Sinaloa)
Sonora (Sonora)
South Carolina (South Carolina)
South Dakota (South Dakota)
Tabasco (Tabasco)
Tamaulipas (Tamaulipas)
Tennessee (Tennessee)
Texas (Texas)
Tlaxcala (Tlaxcala)
Us Minor Outlying Islands (US Minor
Outlying Islands)
Utah (Utah)
Veracruz-llave (Veracruz-Llave)
Vermont (Vermont)
Virgin Islands Of The Us (Virgin Islands
of the US)
Virginia (Virginia)
Washington (Washington)
West Virginia (West Virginia)
Wisconsin (Wisconsin)
Wyoming (Wyoming)
Yucatan (Yucatan)
Yukon Territory (Yukon Territory)
Zacatecas (Zacatecas)
Participant Postal Code
Telephone Number Type
Cellular Telephone (Cellular)
Facsimile Machine (Facsimile)
Home (Home)
Mobile Telephone (Mobile Telephone)
Modem Device Component (Modem)
Pager (Pager)
Worksite: C17556 (Work)
Participant Phone
Participant Initials
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Sarcoma NCT01012297 On-Study - Gynecologic Oncology
Group Solid Tumor Evaluation Form - D2M - 2838219v1.0
Gynecologic Oncology Group Solid Tumor Evaluation Form
- D2M
Gemcitabine Hydrochloride and Docetaxel With or Without
Bevacizumab in Treating Patients With Advanced or
Recurrent Uterine Leiomyosarcoma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=6295AE97-
F579-6F8E-E040-BB89AD430F75
All rights reserved. Please visit https://medical-data-
models.org/forms/9279
Gynecologic Oncology Group Solid
Tumor Evaluation Form - D2M
Header Module
Date form originally completed (m d y)
Date form amended (m d y)
Person amending form, last name
Patient Initials (First, Middle, Last)
Patient Study ID
Person completing form, last name
Target Lesion(s) Evaluation
Site of Lesion
Date of evaluation (m d y)
Method of Evaluation (*)
Chest X-ray (Chest X-ray)
Clinical Examination (pe) (Clinical
examination)
Ct Scan (CT scan)
Mri (MRI)
Not Evaluated (Not evaluated)
Other (Other)
Spiral Ct Scan (Spiral CT scan)
Ultrasound (Ultrasound)
If Other Specify
Longest diameter (s)
Sum of Longest Diameters of All Target Lesions
Non-target Lesion(s) Evaluation
1 / 3
Are there any nontarget lesions?
Yes
No
Site of Lesion
Date of evaluation (m d y)
Method of Evaluation (*)
Chest X-ray (Chest X-ray)
Clinical Examination (pe) (Clinical
examination)
Ct Scan (CT scan)
Mri (MRI)
Not Evaluated (Not evaluated)
Other (Other)
Spiral Ct Scan (Spiral CT scan)
Ultrasound (Ultrasound)
If Other Specify
Follow-Up Status of Lesion (^Follow-up status of
lesion)
Complete Response (Complete
Response)
Progressive Disease (Progressive
Disease)
Stable Disease Or Unchanged (Stable)
New Target Lesion(s) At Follow-up
Evaluation
Was the appearance of any new lesions
documented (If no, skip to the Overall Response
section below.)
Yes
No
Site of Lesion
Date of evaluation (m d y)
Method of Evaluation (*)
Chest X-ray (Chest X-ray)
Clinical Examination (pe) (Clinical
examination)
Ct Scan (CT scan)
Mri (MRI)
Not Evaluated (Not evaluated)
Other (Other)
Spiral Ct Scan (Spiral CT scan)
Ultrasound (Ultrasound)
If Other Specify
2 / 3
Sarcoma NCT01012297 On-Study - Gynecologic Oncology Group Solid
Tumor Evaluation Form - D2M - 2838219v1.0
Overall Response
Overall response status at this assessment
(check one)
Complete Response (CR)
Insufficient Evaluation (Insufficient
evaluation to determine response status)
Progressive Disease (PD)
Partial Response (PR)
Stable Disease (SD)
Response confirmed date (m/d/y)
Comments
Comments
3 / 3
Sarcoma NCT01012297 On-Study - Gynecologic Oncology Group Solid
Tumor Evaluation Form - D2M - 2838219v1.0
Ovarian Cancer NCT00954174 Pre-Study - Pre-
Treatment Summary Form (DR) - 2847792v1.0
Pre-Treatment Summary Form (DR)
Paclitaxel and Carboplatin or Ifosfamide in Treating Patients
With Newly Diagnosed Persistent or Recurrent Uterine or
Ovarian Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=64F29740-
03E8-692F-E040-BB89AD432164
All rights reserved. Please visit https://medical-data-
models.org/forms/9280
Pre-Treatment Summary Form (DR)
Header Module
Date form originally completed (m d y)
Date form amended (m d y)
Person amending form, last name
Patient Initials (First, Middle, Last)
Patient Study ID
Person completing form, last name
Non-invasive Diagnostic Procedures
Chest X-Ray Result
Abnormal (Abnormal)
Normal (Normal)
Not Done (Not done)
Date of Chest X-Ray (m d y)
EKG Result
Abnormal (Abnormal)
Normal (Normal)
Not Done (Not done)
Date of EKG (m d y)
MRI Result
Abnormal (Abnormal)
Normal (Normal)
Not Done (Not done)
Date of MRI (m d y)
CT Result
Abnormal (Abnormal)
Normal (Normal)
Not Done (Not done)
1 / 2
Abnormal specify
Abnormal specify
Abnormal specify
Abnormal specify
Abnormal specify
Date of CT Scan (m d y)
Other Procedure Performed
Abnormal (Abnormal)
Normal (Normal)
Not Done (Not done)
Specify
Procedure Date (m d y)
Are there any target lesions?
Yes
No
Comments
Comments
2 / 2
Ovarian Cancer NCT00954174 Pre-Study - Pre-Treatment Summary
Form (DR) - 2847792v1.0
Leukemia NCT00085124 Follow-Up - CALGB:
10201 Notification of death - 2076956v3.0
CALGB: 10201 Notification of death
Daunorubicin and Cytarabine With or Without Oblimersen
in Treating Older Patients With Previously Untreated Acute
Myeloid Leukemia
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=B22B0174-
18C2-5157-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/9285
CALGB: 10201 Notification of death
Ccrr Module For Calgb: 10201 Notification
Of Death
Patient?s Name
Patient Hospital Number
Main Member Institution/Adjunct
Participating Group
Participating Group Protocol No.
Participating Group Patient No.
CALGB Form
CALGB Study No.
CALGB Patient ID
Are data amended?
Yes (Yes)
Date of Death (M D Y)
Cause of Death (mark only one with an X)
Due To Other Cause, Specify (Not
related to protocol treatment or protocol
disease)
Due To This Disease (Protocol disease
related)
Due To Protocol Treatment (Protocol
treatment related)
Cause of Death (specify)
Comments
Completed By (Print or Type Name)
1 / 2
Date Completed
2 / 2
Leukemia NCT00085124 Follow-Up - CALGB: 10201 Notification of
death - 2076956v3.0
Pancreatic Cancer NCT00075686 Toxicity - S0205
CETUXIMAB SKIN TOXICITIES FORM - 2049859v3.0
S0205 CETUXIMAB SKIN TOXICITIES FORM
S0205 Gemcitabine With or Without Cetuximab as First-
Line Therapy in Treating Patients With Locally Advanced
Unresectable or Metastatic Adenocarcinoma of the
Pancreas
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=A66332D9-
9FC0-48D9-E034-0003BA0B1A09
All rights reserved. Please visit https://medical-data-
models.org/forms/9289
S0205 CETUXIMAB SKIN
TOXICITIES FORM
Header
SWOG Patient ID
SWOG Study No.
Registration Step
Patient Initials (L, F M)
Institution
Affiliate
Physician
Cetuximab Skin Toxicities
For Stat Center Use
Sk11 (SK11)
Sk16 (SK16)
Sk20 (SK20)
Sk80 (SK80)
Toxicity
Dry skin (Dry skin)
Erythema multiforme (Erythema
multiforme)
Other, specify (Other, specify)
Pruritus (Pruritus)
Rash/desquamation
(Rash/desquamation)
Other, specify
Grade (0-5)
0 (0)
1 (1)
2 (2)
3 (3)
4 (4)
1 / 2
5 (5)
Cetuximab Action Required (*1-3)
Dose Discontinued (dose discontinued)
Dose Held (dose held)
Dose Reduced (dose reduced)
Onset
Resolved
If ongoing, check box
Concurrent Therapy/procedures For
Cetuximab Skin Toxicities
Check box if there are none
Drug/Procedure
Started
Completed
If ongoing, check box
Comments
Comments
Ccrr Module For S0205 Cetuximab Skin
Toxicities Form
Ccrr Module For S0205 Cetuximab Skin
Toxicities Form
2 / 2
Pancreatic Cancer NCT00075686 Toxicity - S0205 CETUXIMAB SKIN
TOXICITIES FORM - 2049859v3.0
Leukemia NCT00049517 Lab - E1900 Cover
Page for Hematology Form - 2075140v3.0
E1900 Cover Page for Hematology Form
Combination Chemotherapy With or Without Monoclonal
Antibody Therapy Followed by Stem Cell Transplant in
Treating Patients With Acute Myeloid Leukemia
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=B19AB29D-
AC61-25E1-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/9291
E1900 Cover Page for Hematology
Form
Header
DCI Name
Patient Initials
ECOG Protocol Number
ECOG Protocol Number
ECOG Protocol Number
ECOG Patient ID
ECOG Patient ID
Participating Group Protocol No.
Participating Group Patient ID
Institution/Affiliate
On Treatment
On Treatment Time Period
Consolidation (Consolidation)
Induction (Induction)
Induction, Additional Forms (Induction,
additional Forms)
Post-transplant (Post-Transplant)
Off Treatment
Off Treatment Time Period
10 Years (10 years)
12 Months (12 months)
15 Months (15 months)
18 Months (18 months)
1 / 2
2 Years (2 years)
24 Months (24 months)
3 Months (3 months)
3 Years (3 years)
30 Months (30 months)
36 Months (36 months)
4 Years (4 years)
42 Months (42 months)
48 Months (48 months)
5 Years (5 years)
54 Months (54 months)
6 Months (6 months)
6 Years (6 years)
60 Months (60 months)
7 Years (7 years)
8 Years (8 years)
9 Months (9 months)
9 Years (9 years)
Ccrr Module For E1900 Cover Page For
Hematology Form
2 / 2
Leukemia NCT00049517 Lab - E1900 Cover Page for Hematology Form
- 2075140v3.0
Leukemia NCT00049517 Toxicity - E1900 Cover
Page for Adverse Event Form - 2075062v3.0
E1900 Cover Page for Adverse Event Form
Combination Chemotherapy With or Without Monoclonal
Antibody Therapy Followed by Stem Cell Transplant in
Treating Patients With Acute Myeloid Leukemia
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=B19AAD35-
91C7-25DB-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/9294
E1900 Cover Page for Adverse
Event Form
Header
DCI Name
Patient Initials
ECOG Protocol Number
ECOG Protocol Number
ECOG Protocol Number
ECOG Patient ID
ECOG Patient ID
Participating Group Protocol No.
Participating Group Patient ID
Institution/Affiliate
On Treatment
On Treatment Time Period
Consolidation (Consolidation)
Induction (Induction)
Induction, Additional Forms (Induction,
additional Forms)
Post-transplant (Post-Transplant)
Off Treatment
Off Treatment Time Period
10 Years (10 years)
12 Months (12 months)
15 Months (15 months)
18 Months (18 months)
1 / 2
2 Years (2 years)
24 Months (24 months)
3 Months (3 months)
3 Years (3 years)
30 Months (30 months)
36 Months (36 months)
4 Years (4 years)
42 Months (42 months)
48 Months (48 months)
5 Years (5 years)
54 Months (54 months)
6 Months (6 months)
6 Years (6 years)
60 Months (60 months)
7 Years (7 years)
8 Years (8 years)
9 Months (9 months)
9 Years (9 years)
Ccrr Module For E1900 Cover Page For
Adverse Event Form
2 / 2
Leukemia NCT00049517 Toxicity - E1900 Cover Page for Adverse Event
Form - 2075062v3.0
Leukemia NCT00898079 Follow-Up - Off Protocol Therapy
Follow-up (OPTF) Report [ABTR01B1] - 2172125v3.0
Off Protocol Therapy Follow-up (OPTF) Report
[ABTR01B1]
Collecting and Storing Malignant, Borderline Malignant
Neoplasms, and Related Samples From Young Patients
With Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=C0DB9E9B-
20A9-68CC-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/9295
Off Protocol Therapy Follow-up
(OPTF) Report [ABTR01B1]
Header
CRA Name
COG Number
Study Number
Study Number
Today's date
Date worksheet entered into RDE
Patient Status Information
Date of Previous Contact
date of previous contact according to the patient's
records
Please provide some text to explain the possible
nature of the disagreement.
Date of Last Contact
Life Status at the Date of Last Contact
Alive (Alive)
Dead (Dead)
Disease Status at the end of the reporting period
Disease Present (Disease present)
No Disease Present (No disease present
(remission))
Unknown (Unknown)
Has patient received anti-cancer therapy since
the last OPTF report submission?
Yes
No
1 / 2
select the type of treatment from this list
Chemotherapy (Chemotherapy)
Other Therapy (other)
Surgery (Surgery)
Transplant (Transplant)
External Beam Radiation (XRT)
describe [anti-cancer therapy]
Events Of Interest.
Did the patient relapse or experience disease
progression during the reporting period?
No (No)
Unknown (Unknown)
Yes (Yes)
date of relapse or progression
Did the patient experience a second malignant
neoplasm during the reporting period?
No (No)
Unknown (Unknown)
Yes (Yes)
date of second malignant neoplasm
Did the patient withdraw consent for follow-up at
the end of the reporting period?
Yes
No
Was the patient confirmed lost to follow-up at the
end of the reporting period?
Yes
No
Was the patient enrolled on another COG
therapeutic study at the end of the reporting
period?
Yes
No
COMMENT
Ccrr Module For Off Protocol Therapy
Follow-up (optf) Report [abtr01b1]
2 / 2
Leukemia NCT00898079 Follow-Up - Off Protocol Therapy Follow-up
(OPTF) Report [ABTR01B1] - 2172125v3.0
Breast Cancer NCT00070564 Follow-Up - SOUTHWEST
ONCOLOGY GROUP S0221 FOLLOW UP FORM - 2050216v3.0
SOUTHWEST ONCOLOGY GROUP S0221 FOLLOW UP
FORM
Adjuvant Doxorubicin, Cyclophosphamide, and Paclitaxel in
Treating Patients With Breast Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=A678C302-
20D3-50A8-E034-0003BA0B1A09
All rights reserved. Please visit https://medical-data-
models.org/forms/9296
SWOG S0221 FOLLOW UP FORM
Administrative documentation
SWOG Patient ID
SWOG Study No.
Registration Step
Patient Initials (L, F M)
Institution / Affiliate
Physician
Participating Group Name
Participating Group Study No.
Participating Group Patient ID
Vital Status
Vital Status
Dead (0)
Alive (1)
Date of last contact or death
Disease Follow Up Status
Has the patient had a documented clinical
assessment for this cancer since submission of
the previous follow-up form?
Yes
No
Date of Last Clinical Assessment
Notice Of Progression - Adjuvant
1 / 2
Has the patient developed a first relapse or
progression that has not been previously
reported
Yes
No
If Yes, Date of Relapse or Progression:
Site(s) of relapse or progression
Notice Of New Primary
Has a new primary cancer, opposite breast
cancer, or myelodysplastic syndrome (MDS)
been diagnosed that has not been previously
reported?
Yes
No
Date of Diagnosis
New Primary Site
Non-protocol Treatment
Has the patient received any non-protocol cancer
therapy (prior to progression/relapse) not
previously reported?
Yes
No
Date of First Non-Protocol Therapy (If Yes,)
Agent
Long Term Toxicity
Has the patient experienced any severe long
term toxicity that has not been previously
reported?
Yes
No
Toxicities and Grades
Comments
Comments
2 / 2
Breast Cancer NCT00070564 Follow-Up - SOUTHWEST ONCOLOGY
GROUP S0221 FOLLOW UP FORM - 2050216v3.0
NCT00392834 Follow-Up - AMC-048
Lymphoma Follow-Up Form - 2684532v1.0
AMC-048 Lymphoma Follow-Up Form
Rituximab and Combination Chemotherapy in Treating
Patients With Newly Diagnosed, HIV-Associated Burkitt's
Lymphoma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=3AF716DF-
4BFC-67AB-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/9297
AMC-048 Lymphoma Follow-Up
Form
Patient Status
Vital Status
Alive (Alive)
Dead (Dead)
Lost To Follow-up (Lost to follow-up)
Date of Last Contact or Death (MM DD YYYY If
patient status is dead, complete Death Form)
Header
Is the patient receiving any non-protocol cancer
therapy not previously reported?
Yes
No
Name of Other Non-Protocol Therapy (If yes)
Date of First Non-Protocol Therapy (MM DD
YYYY)
Comments
Comments
1 / 1
NCT00598169 Follow-Up - AMC-053 Lymphoma
Follow-Up Form (LFU) - 3127857v1.0
AMC-053 Lymphoma Follow-Up Form (LFU)
Bortezomib, Ifosfamide, Carboplatin, and Etoposide, With
or Without Rituximab, in Treating Patients With Relapsed or
Refractory AIDS-Related Non-Hodgkin Lymphoma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=8D6577D4-
E51D-6AD1-E040-BB89AD432F6C
All rights reserved. Please visit https://medical-data-
models.org/forms/9299
AMC-053 Lymphoma Follow-Up
Form (LFU)
Header
Visit number
Patient Status
Vital Status
Alive (Alive)
Dead (Dead)
Lost To Follow-up (Lost to follow-up)
Date of Last Contact or Death (mm/dd/yyyy If
participant's status is dead, complete Death
Form)
Header
Is the patient receiving any non-protocol cancer
therapy not previously reported? (i.e. other than
this protocol)
Yes
No
Name of Other Non-Protocol Therapy (If "Yes")
Date of First Non-Protocol Therapy (mm/dd/yyyy)
Comments
Comments
1 / 1
NCT00324415 Follow-Up - AMC-045 Anal
Cancer Follow-Up Form (FOL) - 2516531v1.0
AMC-045 Anal Cancer Follow-Up Form (FOL)
Cisplatin, Fluorouracil, Cetuximab, and Radiation Therapy
in Treating Patients With HIV and Stage I, Stage II, or
Stage III Anal Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=1C146777-
FBAB-57F8-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/9300
AMC-045 Anal Cancer Follow-Up
Form (FOL)
Header
Visit number
Patient Status
Vital Status
Alive (Alive)
Dead (Dead)
Lost To Follow-up (Lost to follow-up)
Date of Last Contact or Death (mm/dd/yyyy)
Clinical Data
Fecal Continence
Gas Incontinence Only; Able To Control
Stool Movements But Not Gas (Gas
incontinence only; able to control stool
movements but not gas)
Minor Spotting Or Leakage Of Stool (up
To Coin Size) About Once Per Week
(Minor spotting or leakage of stool (up to
coin size) about once per week)
Minor Spotting Or Leakage Of Stool (up
To Coin Size) More Than Once Per
Week (Minor spotting or leakage of stool
(up to coin size) more than once per
week)
Normal Continence; Able To Control
Stool Movements At All Times (Normal
continence; able to control stool
movements at all times)
Not Applicable (Not applicable)
Significant Leakage Of Stool (larger
Than Coin Size) About Once Per Week
(Significant leakage of stool (larger than
coin size) about once per week)
Significant Leakage Of Stool (larger
Than Coin Size) More Than Once Per
Week (Significant leakage of stool (larger
than coin size) more than once per
week)
Unknown (Unknown)
1 / 2
Has the patient required a colostomy bag since
being enrolled on this protocol
Yes
No
Indicate reason for colostomy bag (If "Yes")
Both (Both)
Control Of Disease (Control of disease)
Management Of Toxicity (Management of
toxicity)
Other (Other)
Other, specify
Date colostomy performed (mm/dd/yyyy)
Is the patient receiving any non-protocol cancer
therapy not previously reported?
Yes
No
Name of Other Non-Protocol Therapy
Date of First Non-Protocol Therapy (mm/dd/yyyy)
Are there any treatment toxicities unrelated to
radiation (continuing or new)
No (No)
Unknown (Unknown)
Yes (Yes)
Comments
Comments
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NCT00324415 Follow-Up - AMC-045 Anal Cancer Follow-Up Form (FOL)
- 2516531v1.0
Lymphoma NCT01190449 Follow-Up - CALGB 50901
Confirmation of Lost to Follow-Up Form - 3211940v1.0
CALGB 50901 Confirmation of Lost to Follow-Up Form
Ofatumumab in Treating Patients With Previously Untreated
Stage II, Stage III, or Stage IV Follicular Non-Hodgkin
Lymphoma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=9F9012C3-
FDE7-DB91-E040-BB89AD432434
All rights reserved. Please visit https://medical-data-
models.org/forms/9301
CALGB 50901 Confirmation of Lost
to Follow-Up Form
Criteria For Lost To Follow-up Status
Has it been at least 2 years since you were last
able to contact the patient
Yes
No
Date of Last Contact (prior to this confirmation)
Contact Type (Please indicate when steps were
taken to contact the patient.  Both Social Security
Death Index and Certified/Registered Letter
methods must be attempted without success after
2 years without contact before a patient can be
declared lost)
Mail Contact With Patient/participant
(Mail contact with Patient/Participant)
Contact Type (Please indicate when steps were
taken to contact the patient.  Both Social Security
Death Index and Certified/Registered Letter
methods must be attempted without success after
2 years without contact before a patient can be
declared lost)
Mail Contact With Patient/participant
(Mail contact with Patient/Participant)
Specify most recent date
Specify most recent date
Patient Contact Status
Letter Returned Unclaimed Or Marked
Addressee Unknown (Letter returned
unclaimed or marked addressee
unknown)
No Response 1 Month After Confirmed
Receipt Of Letter (No response 1 month
after confirmed receipt of letter)
Investigator Signature (Required for patients who
have been lost for 2 years: I verify that the above
information is correct and that all attempts to
contact this patient have failed)
1 / 2
Date
Patient No Longer Lost To Follow-up
New information for this patient is now available
for
Clinical And Survival Status (Clinical and
survival status)
Survival Status Only (Survival status
only)
Vital Status (based on new data)
Alive (Alive)
Dead (Dead)
Date of Last Contact or Death
2 / 2
Lymphoma NCT01190449 Follow-Up - CALGB 50901 Confirmation of
Lost to Follow-Up Form - 3211940v1.0
NCT00389818 Follow-Up - AMC-047 Lymphoma
Follow-Up Form (LFU) - 2684487v1.0
AMC-047 Lymphoma Follow-Up Form (LFU)
Combination Chemotherapy and Rituximab in Treating
Patients With Newly Diagnosed AIDS-Related B-Cell Non-
Hodgkin's Lymphoma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=3AF6579E-
81FA-3EE8-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/9302
AMC-047 Lymphoma Follow-Up
Form (LFU)
Patient Status
Vital Status
Alive (Alive)
Dead (Dead)
Lost To Follow-up (Lost to follow-up)
Date of Last Contact or Death (MM DD YYYY If
patient status is dead, complete Death Form)
Header
Is the patient receiving any non-protocol cancer
therapy not previously reported?
Yes
No
Name of Other Non-Protocol Therapy (If yes)
Date of First Non-Protocol Therapy (MM DD
YYYY)
Comments
Comments
1 / 1
Neuroblastoma NCT00053326 Off Treatment - ANBL0321 Off
Protocol Therapy Follow-up (OPTF) Report (Master) - 2089607v3.0
ANBL0321 Off Protocol Therapy Follow-up (OPTF) Report
(Master)
Fenretinide in Treating Children With Recurrent or
Resistant Neuroblastoma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=B9B484F8-
51DB-1EF7-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/9303
ANBL0321 Off Protocol Therapy
Follow-up (OPTF) Report (Master)
Header
CRA Name
COG Number
Study Number (All studies for which the patient
has registered will appear on the RDE Screen.)
Study Number (All studies for which the patient
has registered will appear on the RDE Screen.)
Today's date
Date worksheet entered into RDE
Patient Status Information
Date of Previous Contact (1. Calculate the
previous contact date from the date of the last
reporting period submitted or the date of the last
OPTF report submitted.)
enter the date of previous contact according to
the patient's records (1. If a date is entered, send
an email to the RC with heading "OPTF Date
Disagreement" providing the patient and study
identifiers in the body along with the explanation
below.)
Please provide some text to explain the possible
nature of the disagreement. (2. This must be
answered if a date was provided for the previous
question.)
Date of Last Contact (Enter the date of last
confirmed patient contact.  'Contact' includes, but
is not limited to, an office visit, a letter from the
family or phone contact.)
1 / 4
Life Status at the Date of Last Contact (1.
Required.)
Alive (Alive)
Dead (Dead)
Disease Status at the end of the reporting period
(Select one)
Eradicated But Recurred Locally And
Distantly (Disease present)
Residual Disease After Prior Therapy
(No disease present)
Unknown (Unknown)
Has patient received anti-cancer therapy since
the last OPTF report submission? (1. Required.)
Yes
No
select the type of treatment from this list (1. If 'TX'
is answered 'Yes', this must be answered.)
Anti-retroviral Therapy (Anti-retroviral
Therapy)
Antisense (Antisense)
Chemotherapy (Chemotherapy)
Chemotherapy Non-cytotoxic
(Chemotherapy Non-cytotoxic)
Extensive Radiation (Extensive
Radiation)
Gene Therapy (Gene Therapy)
Immunotherapy (Immunotherapy)
Limited Radiation (Limited Radiation)
No Prior Therapy (No Prior Therapy)
Oncolytic Virotherapy (Oncolytic
Virotherapy)
Other Therapy (Other)
Prior Therapy (nos) (Prior Therapy
(NOS))
Radiation (nos) (Radiation (NOS))
Stem Cell Transplant (Stem Cell
Transplant)
Surgery (Surgery)
Transplant (Transplant)
Vaccine (Vaccine)
External Beam Radiation (XRT)
describe [anti-cancer therapy] (3. If 'TX' is
answered 'Yes', this must be answered.)
Events Of Interest
Did the patient relapse or experience disease
progression during the reporting period? (1.
Required.)
No (No)
Unknown (Unknown)
Yes (Yes)
2 / 4
Neuroblastoma NCT00053326 Off Treatment - ANBL0321 Off Protocol
Therapy Follow-up (OPTF) Report (Master) - 2089607v3.0
date of relapse or progression (4. If RLPS is
coded 'Yes', this field must be completed.)
Did the patient experience a second malignant
neoplasm during the reporting period? (1.
Required.)
No (No)
Unknown (Unknown)
Yes (Yes)
date of second malignant neoplasm (5. If SMN is
coded 'Yes', this field must be completed.)
Did the patient withdraw consent for follow-up at
the end of the reporting period? (Note:
Withdrawal of consent is to be coded only when
the patient no longer wants to participate in the
study and asks data no longer be submitted.)
Yes
No
Was the patient confirmed lost to follow-up at the
end of the reporting period? (1. Required.)
Yes
No
Was the patient enrolled on another COG
therapeutic study at the end of the reporting
period? (1. Required.)
Yes
No
Check all that apply:
Bone Marrow Immunocytology (Bone
marrow immunocytology)
Bone Marrow Morphology (Bone marrow
morphology)
Bone Scan (Bone scan)
Ct Scan (CT)
Mibg (MIBG)
Mri (MRI)
Other, Specify (Other, specify)
Urine Hva/vma (Urine HVA/VMA)
Check all that apply:
Bone Marrow Immunocytology (Bone
marrow immunocytology)
Bone Marrow Morphology (Bone marrow
morphology)
Bone Scan (Bone scan)
Ct Scan (CT)
Mibg (MIBG)
Mri (MRI)
Other, Specify (Other, specify)
Urine Hva/vma (Urine HVA/VMA)
Other, specify [tests done to document response]
3 / 4
Neuroblastoma NCT00053326 Off Treatment - ANBL0321 Off Protocol
Therapy Follow-up (OPTF) Report (Master) - 2089607v3.0
COMMENTS
Ccrr Module For Anbl0321 Off Protocol
Therapy Follow-up (optf) Report (master)
4 / 4
Neuroblastoma NCT00053326 Off Treatment - ANBL0321 Off Protocol
Therapy Follow-up (OPTF) Report (Master) - 2089607v3.0
NCT01193842 Follow-Up - AMC-075 Lymphoma
Follow-Up Form (LFU) - 3253296v1.0
AMC-075 Lymphoma Follow-Up Form (LFU)
Vorinostat and Combination Chemotherapy With Rituximab
in Treating Patients With Previously Untreated HIV-Related
Diffuse Large B-Cell Non-Hodgkin Lymphoma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=A80B878E-
8818-EF45-E040-BB89AD4353A5
All rights reserved. Please visit https://medical-data-
models.org/forms/9306
AMC-075 Lymphoma Follow-Up
Form (LFU)
Header
Visit number
Patient Status
Vital Status
Alive (Alive)
Dead (Dead)
Lost To Follow-up (Lost to follow-up)
Date of Last Contact or Death (mm/dd/yyyy If
participant's status is dead, complete Death
Form)
Header
Is the patient receiving any non-protocol cancer
therapy not previously reported? (i.e. other than
this protocol)
Yes
No
Name of Other Non-Protocol Therapy (If "Yes")
Date of First Non-Protocol Therapy (mm/dd/yyyy)
Has the patient been diagnosed with a new
progression? (If the participant has been
diagnosed with new progression, please update
the Lymphoma Response Form)
Yes
No
Comments
Comments
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Anal Cancer NCT00324415 Toxicity - AMC-045
Delayed Toxicity Form (TOX) - 2514820v1.0
AMC-045 Delayed Toxicity Form (TOX)
Cisplatin, Fluorouracil, Cetuximab, and Radiation Therapy
in Treating Patients With HIV and Stage I, Stage II, or
Stage III Anal Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=1BB3598F-
7655-640C-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/9307
AMC-045 Delayed Toxicity Form
(TOX)
Header
Visit number
Unnamed2
CTC Select AE
Bladder (Bladder)
Bone (Bone)
Brain (Brain)
Esophagus (Esophagus)
Eye (Eye)
Heart (Heart)
Joint (Joint)
Kidney (Kidney)
Large Bowel (Large bowel)
Larynx (Larynx)
Liver (Liver)
Lung (Lung)
Mucosa (Mucosa)
Other (Other NOS)
Radiation (Radiation)
Salivary Gland (Salivary gland)
Skin (Skin)
Small Bowel (Small bowel)
Spinal Cord (Spinal cord)
Other, specify
CTC Adverse Event Grade
Comments
Comments
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Prostate Cancer NCT00499174 Registration - NCIC-
PR.11 Eligibility Worksheet Form - 2897735v1.0
NCIC-PR.11 Eligibility Worksheet Form
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=6B77A6FA-
9AF8-CC7A-E040-BB89AD434302
All rights reserved. Please visit https://medical-data-
models.org/forms/9308
NCIC-PR.11 Eligibility Worksheet
Form
Eligibility Criteria
Patient has histologically confirmed
adenocarcinoma of the prostate diagnosed within
6 months prior to randomization
Yes
No
Date of diagnosis (MM DD YYYY)
Clinical T Stage
Tumor Incidental Histologic Finding In
More Than 5% Of Tissue Resected
(T1b)
Tumor Identified By Needle Biopsy (eg,
Because Of Elevated Psa) (T1c)
Tumor Involves One Lobe (T2a)
Tumor Involves Both Lobes (T2b)
Gleason Grade, Score (sum)
PSA <=10.0 ng/ml (ug/L Note: for patients who
have received prior treatment with 5-alpha
reductase inhibitors 5ARI must adhere to the
following criteria: Duration of 5ARI exposure prior
to date of  baseline PSA Eligible PSA value ng/ml
or ug/L < 2 months <= 10.0 2 months-6 months
<= 7.0 > 6 months <= 5.0)
Yes
No
PSA Value (total) (ng/ml ug/L)
Physical examination, rectal examination and
transrectal ultrasound have been done within 6
months prior to randomization and radiographic
studies, if indicated, are negative for metastasis
Yes
No
Patient is a suitable candidate for radical
prostatectomy or radiotherapy
Yes
No
No previous treatment for prostate cancer
including surgery (excluding biopsy), radiation
therapy
Yes
No
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No previous androgen deprivation therapy for
prostate cancer for greater than 3 months
Yes
No
ECOG Performance Status
Fully Active, Able To Carry On All Pre-
disease Performance Without
Restriction. (0)
Restricted In Physically Strenuous
Activity But Ambulatory And Able To
Carry Out Work Of A Light Or Sedentary
Nature, E.g., Light Housework, Office
Work. (1)
Ambulatory And Capable Of All Selfcare
But Unable To Carry Out Any Work
Activities. Up And About More Than 50%
Of Waking Hours. (2)
Patient has a minimum life expectancy of > 10
years
Yes
No
Patient has completed the prerandomization
quality of life assessment, and is willing to
complete future assessments
No: C49487 (No)
Not Applicable (Not Applicable)
Yes: C49488 (Yes)
Reason Questionnaire was not Completed
Centre Is Not Participating In The Quality
Of Life Component Of The Trial (Centre
is not participating in the Quality of Life
component of the trial)
Unable To Accomodate Disability Or
Language Needs (Unable to accomodate
disability or language needs)
Patient accessible for treatment and follow-up.
Yes
No
Protocol treatment is to begin within 90 days of
randomization
Yes
No
Planned Date of Treatment Initiation (MM DD
YYYY)
Ineligibility Criteria
Patient has a history of other malignancies
except: adequately treated non-melanoma skin
cancer or adequately treated superficial bladder
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Worksheet Form - 2897735v1.0
cancer or other solid tumours curatively treated
with no evidence of disease for >= 5 years from
randomization
Yes
No
Androgen therapy is planned for this patient
except in the context of radical therapy
Yes
No
For U.s. Patients
Has HIPAA authorization been obtained?
Yes
No
Date HIPAA Authorization signed (YYYY MMM
DD)
Stratification Factors
ECOG Performance status
0 (0)
1 Or 2 (1 or 2)
Stage
T1 (T1)
T2 (T2)
Baseline PSA Value (ng/ml or ug/l)
< 5.0 (< 5.0)
>= 5.0 And <= 10.0 (>= 5.0 and <= 10.0)
Age
< 65 (< 65)
>= 65 (>= 65)
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Worksheet Form - 2897735v1.0
Bladder Cancer NCT01224665 Off Treatment -
S1011 Notice of Death Form (#49467) - 3152396v1.0
S1011 Notice of Death Form (#49467)
Standard or Extended Pelvic Lymphadenectomy in Treating
Patients Undergoing Surgery for Invasive Bladder Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=9339E952-
BBCA-996A-E040-BB89AD43480C
All rights reserved. Please visit https://medical-data-
models.org/forms/9309
S1011 Notice of Death Form
(#49467)
Header
SWOG Patient ID
Most Recent SWOG Study No.
Patient Initials (L, F, M)
Institution/Affiliate
Physician
Participating Group Name
Participating Group Study No.
Participating Group Patient ID
Unnamed2
Date of Death (month / day / year)
Causes Of Death
Any cancer (select one)
Contributory (Contributory)
No (No)
Possible (Possible)
Primary Cause (Primary Cause)
Unknown (Unknown)
If cancer was the primary cause or if cancer
possibly or definitely contributed to death, and the
patient had had multiple tumor types, specify
those which were causes of death
Cancer Of Most Recent Swog Study
(Cancer of most recent SWOG study)
Cancer Of Other Swog Study (Cancer of
other SWOG study)
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Other Cancer (Other cancer)
Cancer of most recent SWOG study, specify
cancer
Cancer of other SWOG study, specify cancer
Other cancer, specify
Toxicity from disease related treatment (select
one)
Contributory (Contributory)
No (No)
Possible (Possible)
Primary Cause (Primary Cause)
Unknown (Unknown)
If Primary Cause, Contributory or Possible,
specify treatment and toxicity
Non-cancer and non-treatment related causes
(select one)
Contributory (Contributory)
No (No)
Possible (Possible)
Primary Cause (Primary Cause)
Unknown (Unknown)
If Primary Cause, Contributory or Possible,
specify
Autopsy?
No (No)
Unknown (Unknown)
Yes (Yes)
Source of death information (s)
Autopsy Report (Autopsy report)
Medical Record / Death Certificate
(Medical record / Death certificate)
Other (Other)
Physician (Physician)
Relative Or Friend (Relative or friend)
Other, specify
Comments
Comments
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Form (#49467) - 3152396v1.0
Follow-Up Form Chronic Lymphocytic
Leukemia (CLL) (NCT00513747)
CALGB-10501 Chronic Lymphocytic Leukemia (CLL) -
Follow-Up Form
Early or Delayed Fludarabine and Rituximab in Treating
Patients With Previously Untreated Chronic Lymphocytic
Leukemia
NCT00513747
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=33F8D5BA-
3FDA-71CF-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/9310
Follow-Up Form Chronic
Lymphocytic Leukemia (CLL)
(NCT00513747)
Header
CALGB Form
CALGB Study No
CALGB Patient ID
Reporting Period Start Date
Reporting Period End Date
Patient Initials (Last, First Middle)
Patient Hospital No.
Institution/Affiliate
Participating Group
Participating Group Study No.
Participating Group Patient ID
Are data amended
Yes
No
Completed by (Last name, First name)
Date Form Completed
Aml/all/apl: Vital Status
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Patient's Vital Status (Mark one with an X)
Alive (Alive)
Dead (Dead)
Lost To Follow-up (Lost to follow-up)
Primary Cause of Death (Mark one with an X)
Due To Other Cause (Due to other
cause)
Due To Protocol Treatment (Due to
protocol treatment)
Due To This Disease (Due to this
disease)
Unknown (Unknown)
Describe cause of death
Date of Last Contact or Death (mm dd yyyy)
Aml/all/apl: Disease Follow-up Status
Treatment Status
First Treatment (First treatment)
First Treatment Follow-up (First
treatment follow-up)
Pretreatment Observation (Pretreatment
observation)
Restaging (Restaging)
Second Treatment (Second treatment)
Second Treatment Follow-up (Second
treatment follow-up)
Has the patient had a documented clinical
assessment for this cancer? (during this reporting
period)
No (No)
Unknown (Unknown)
Yes (Yes)
Date of Last Clinical Assessment (mm dd yyyy
only provide date if assessment during this
reporting period)
Cll: Notice Of Progression
Has the patient developed a first progression (or
relapse) that has not been previously reported?
(Mark one with an X.)
No (No)
Unknown (Unknown)
Yes (Yes)
Liver Assessment (If yes, indicate all evidence of
progression from the following: refer to protocol
criteria for guidelines on organ assessment)
No (NO)
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Unknown (Unknown)
Yes (YES)
Spleen Assessment
No (NO)
Unknown (Unknown)
Yes (YES)
Lymph Node Assessment
No (NO)
Unknown (Unknown)
Yes (YES)
Lymphocytes (> or = 50% increase in absolute
number of circulating lymphocytes to at least
5000/mcL)
No (NO)
Unknown (Unknown)
Yes (YES)
Date of Progression (If yes, Earliest  mm dd yyyy
only provide date if progression occurred during
this reporting period)
Notice Of Progression2
Prior bone marrow or peripheral blood stem cell
transplant? (during this period)
Yes
No
Date of First Bone Marrow or Peripheral Blood
Stem Cell (PBSC) Infusion
Type of Transplant (Mark one with an X.)
Autologous (autologous)
Cord Blood (cord blood)
Hla Identical (sibling) (HLA identical
(sibling))
Hla Identical (unrelated) (HLA identical
(unrelated))
Other (other)
Partially Hla Matched, Family Member
(Partially HLA matched, family member)
Other specify
Allogeneic Transplant Type (Mark one with an X.)
Myeloablative (myeloablative)
Non-myeloablative (Non-myeloablative)
Has the patient received any non-protocol cancer
therapy during this reporting period?
Yes
No
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Non-Protocol Therapy Type (If yes)
Long Term Adverse Event/other Long
Term Toxicity
Has the patient experienced (prior to diagnosis of
recurrence or second primary) any severe (Grade
>=3), long term toxicity that has not been
previously reported (treatment related)
Yes
No
MedDRA Code
CTC Adverse Event Term
CTC Adverse Event Grade (only 3,4,5)
Adverse Event Onset Date
Notice Of New Primary
Has a new primary cancer or MDS been
diagnosed that has not been previously reported?
(complete the following)
Yes
No
Date of diagnosis (MM DD YYYY)
Site of New Primary (s If new primary site is
AML/MDS, submit NCI AML/MDS form to CALGB
Central Office)
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Sarcoma, Kaposi xxx Follow-Up - Death
Form - RF04 - 2266270v3.0
Death Form - RF04
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=CCE1DDEF-
292E-4323-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/9321
Death Form - RF04
Ccrr Module For Death Form - Rf04
Patient Initials
Study#
Site#
ID#
Cycle #
Date of Death
Status at the time of death
No (Off Study)
No (On Study, off protocol treatment)
Yes (On Study, on protocol treatment)
Date of last protocol treatment if status at time of
death = 2 or 3
What was the primary cause of death
Due To Other Cause, Specify (Non-
malignancy complications of HIV
disease)
Due To Other Cause, Specify (Other)
Due To Second Primary Or Other
Malignancy (Other Malignancy)
Due To This Disease (Primary
Malignancy)
Due To Protocol Treatment (Treatment
Toxicity)
What are the contributing causes of death, if any
Due To Other Cause, Specify (Non-
malignancy complications of HIV
disease)
Due To Other Cause, Specify (Other)
Due To Second Primary Or Other
Malignancy (Other Malignancy)
Due To This Disease (Primary
Malignancy)
Due To Protocol Treatment (Treatment
Toxicity)
Describe
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Describe
Source(s) of cause of death information (check all
that apply)
Autopsy Was The Source Of Information
On The Patient's Death (Autopsy)
Clinical Evidence Was The Source Of
Information On The Patient's Death
(Clinical Records)
Clinical Evidence Was The Source Of
Information On The Patient's Death
(Contact with Physician)
Death Certificate Was The Source Of
Information On The Patient's Death
(Death Certificate)
The Source Of Information On The
Patient's Death Is Not On This List,
Specify Other (Information from Friends
and Relatives)
The Source Of Information On The
Patient's Death Is Not On This List,
Specify Other (Other Source)
Histological Evidence Was The Source
Of Information On The Patient's Death
(Pathologic Confirmation)
Specify
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Cervical Cancer NCT01101451 Quality of Life - GOG-
0263: Quality of Life Questionnaire - 2933853v1.0
GOG-0263: Quality of Life Questionnaire
Radiation Therapy With or Without Chemotherapy in
Patients With Stage I or Stage II Cervical Cancer Who
Previously Underwent Surgery
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=7170934C-
5F81-20E2-E040-BB89AD434964
All rights reserved. Please visit https://medical-data-
models.org/forms/9323
GOG-0263: Quality of Life
Questionnaire
Header Module
Patient Initials
Date Questionnaire Completed
Patient Study ID
Physical Well-being
I have a lack of energy.
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have nausea.
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
Because of my physical condition, I have trouble
meeting the needs of my family.
2 (A little bit)
1 (Not at all)
4 (Quite a bit)
3 (Somewhat)
5 (Very much)
I have pain.
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am bothered by side effects of treatment.
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
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I feel ill
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am forced to spend time in bed
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
Social/family Well-being
I feel close to my friends
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I get emotional support from my family
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I get support from my friends
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
My family has accepted my illness
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am satisfied with family communication about
my illness
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I feel close to my partner (or the person who is
my main support)
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
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Regardless of your current level of sexual activity,
please answer the following question.  If you
prefer not to answer it, please check this box and
go to the next section.
I am satisfied with my sex life
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
Emotional Well-being
I feel sad
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am satisfied with how I am coping with my
illness
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am losing hope in the fight against my illness
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I feel nervous
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I worry about dying
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I worry that my condition will get worse
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
Functional Well-being
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I am able to work (include work at home)
2 (A little bit)
1 (Not at all)
4 (Quite a bit)
3 (Somewhat)
5 (Very much)
My work is fulfilling (include work at home)
2 (A little bit)
1 (Not at all)
4 (Quite a bit)
3 (Somewhat)
5 (Very much)
I am able to enjoy life
2 (A little bit)
1 (Not at all)
4 (Quite a bit)
3 (Somewhat)
5 (Very much)
I have accepted my illness
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am sleeping well
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am enjoying the things I usually do for fun
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am content with the quality of my life right now
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
Additional Concerns
I am bothered by discharge or bleeding from my
vagina
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
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I am bothered by odor coming from my vagina
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am afraid to have sex
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I feel sexually attractive.
2 (A little bit)
1 (Not at all)
4 (Quite a bit)
3 (Somewhat)
5 (Very much)
My vagina feels too narrow or short
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have concerns about my ability to have children
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am afraid the treatment may harm my body
A Little Bit (A little bit)
Not At All (Not at all)
Somewhat (Somewhat)
Very Much (Very much)
I am interested in sex
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I like the appearance of my body
2 (A little bit)
1 (Not at all)
4 (Quite a bit)
3 (Somewhat)
5 (Very much)
I am bothered by constipation
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
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Somewhat (Somewhat)
Very Much (Very much)
I have a good appetite
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have trouble controlling my urine
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
It burns when I urinate
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have discomfort when I urinate
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am able to eat the foods that I like
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have numbness or tingling in my hands
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have numbness or tingling in my feet
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I feel discomfort in my hands
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I feel discomfort in my feet
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A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I urinate more frequently than usual
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have control of my bowels
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have cramps in my stomach area
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have diarrhea
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
Please rate your pain by selecting the one
number that best describes your pain at its
WORST in the past 24 hours.
Whole Number (0)
Whole Number (1)
Whole Number (10)
Whole Number (2)
Whole Number (3)
Whole Number (4)
Whole Number (5)
Whole Number (6)
Whole Number (7)
Whole Number (8)
Whole Number (9)
To Be Completed By Clinical Staff
QOL contact person
Status of the QOL assessment
Other (Other)
Patient Died (Patient died)
Patient Kept Appointment, But Could Not
Complete Questionnaire Due To Illness
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(Patient kept appointment, but could not
complete questionnaire due to illness)
Patient Kept Appointment, But Refused
To Complete Questionnaire For Reasons
Other Than Illness (Patient kept
appointment, but refused to complete
questionnaire for reasons other than
illness)
Patient Off Study Treatment And Cannot
Be Contacted For Follow-up (Patient off
study treatment and cannot be contacted
for follow-up)
Questionnaire Not Administered Due To
Clinical Staff Error (Questionnaire not
administered due to clinical staff error)
The Questionnaire Is Complete (The
questionnaire is complete)
Specify reason
Other, specify
8 / 8
Cervical Cancer NCT01101451 Quality of Life - GOG-0263: Quality of
Life Questionnaire - 2933853v1.0
Fallopian Tube Cancer NCT01167712 Quality of Life -
GOG-0262: Quality of Life Survey Form - 2917772v1.0
GOG-0262: Quality of Life Survey Form
Paclitaxel and Carboplatin With or Without Bevacizumab in
Treating Patients With Stage II, Stage III, or Stage IV
Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or
Fallopian Tube Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=6E5EDF6F-
8906-E23E-E040-BB89AD435A10
All rights reserved. Please visit https://medical-data-
models.org/forms/9328
GOG-0262: Quality of Life Survey
Form
Header Module
Patient Initials
Date Questionnaire Completed
GOG Patient ID
Physical Well-being
I have a lack of energy.
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have nausea.
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
Because of my physical condition, I have trouble
meeting the needs of my family.
2 (A little bit)
1 (Not at all)
4 (Quite a bit)
3 (Somewhat)
5 (Very much)
I have pain.
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am bothered by side effects of treatment.
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
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Very Much (Very much)
I feel ill
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am forced to spend time in bed
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
Functional Wellbeing
I am able to work (include work at home)
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
My work (include work at home) is fulfilling
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am able to enjoy life.
2 (A little bit)
1 (Not at all)
4 (Quite a bit)
3 (Somewhat)
5 (Very much)
I have accepted my illness
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am sleeping well
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am enjoying the things I usually do for fun
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
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I am content with the quality of my life right now
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
Additional Concerns
I have swelling in my stomach area
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am losing weight
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have control of my bowels
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have been vomiting
2 (A little bit)
1 (Not at all)
4 (Quite a bit)
3 (Somewhat)
5 (Very much)
I am bothered by hair loss.
2 (A little bit)
1 (Not at all)
4 (Quite a bit)
3 (Somewhat)
5 (Very much)
I have a good appetite
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I like the appearance of my body
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am able to get around by myself
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A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am able to feel like a woman.
2 (A little bit)
1 (Not at all)
4 (Quite a bit)
3 (Somewhat)
5 (Very much)
I have cramps in my stomach area
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am interested in sex
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have concerns about my ability to have children
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
Ntx4 Subscale
I have numbness or tingling in my hands
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have numbness or tingling in my feet
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I feel discomfort in my hands
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I feel discomfort in my feet
A Little Bit (A little bit)
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Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
To Be Completed By Clinical Staff
QOL contact person
Status of the QOL assessment
Other (Other)
Patient Died (Patient died)
Patient Kept Appointment, But Could Not
Complete Questionnaire Due To Illness
(Patient kept appointment, but could not
complete questionnaire due to illness)
Patient Kept Appointment, But Refused
To Complete Questionnaire For Reasons
Other Than Illness (Patient kept
appointment, but refused to complete
questionnaire for reasons other than
illness)
Patient Off Study Treatment And Cannot
Be Contacted For Follow-up (Patient off
study treatment and cannot be contacted
for follow-up)
Questionnaire Not Administered Due To
Clinical Staff Error (Questionnaire not
administered due to clinical staff error)
The Questionnaire Is Complete (The
questionnaire is complete)
Specify reason
Other, specify
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Fallopian Tube Cancer NCT01081262 Quality of Life -
GOG-0241 Quality of Life Survey Form - 3126513v1.0
GOG-0241 Quality of Life Survey Form
Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine,
With or Without Bevacizumab, as First-Line Therapy in
Treating Patients With Newly Diagnosed Stage II, Stage III,
Stage IV, or Recurrent Stage I Epithelial Ovarian Cancer or
Fallopian Tube Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=8D16EFA4-
532E-082B-E040-BB89AD434B01
All rights reserved. Please visit https://medical-data-
models.org/forms/9329
GOG-0241 Quality of Life Survey
Form
Header Module
Patient Initials (First, Middle, Last)
Date Questionnaire Completed (M D Y)
GOG Patient ID
Qol Questionnaire Administration
Scheduled time to obtain Quality of Life
Questionnaire (Mark one)
2 Years From Date-on Study (2 years
from date-on study)
3 Years From Date-on Study (3 years
from date-on study)
4 Years From Date-on Study (4 years
from date-on study)
5 Years From Date-on Study (5 years
from date-on study)
6 Months After Bevacizumab
Maintenance (6 months after
bevacizumab maintenance)
6 Months Post-chemo (6 months post-
chemo)
After Bevacizumab Maintenance (After
bevacizumab maintenance)
Post-cycle 6 (Post-cycle 6)
Pre-cycle 4 (Pre-cycle 4)
Prior To Treatment (Prior to treatment)
Physical Well-being
I have a lack of energy.
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have nausea.
A Little Bit (A little bit)
Not At All (Not at all)
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Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
Because of my physical condition, I have trouble
meeting the needs of my family.
2 (A little bit)
1 (Not at all)
4 (Quite a bit)
3 (Somewhat)
5 (Very much)
I have pain.
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am bothered by side effects of treatment.
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I feel ill
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am forced to spend time in bed
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
Functional Wellbeing
I am able to work (include work at home)
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
My work (include work at home) is fulfilling
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am able to enjoy life.
2 (A little bit)
1 (Not at all)
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4 (Quite a bit)
3 (Somewhat)
5 (Very much)
I have accepted my illness
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am sleeping well
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am enjoying the things I usually do for fun
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am content with the quality of my life right now
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
Additional Concerns
I have swelling in my stomach area
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am losing weight
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have control of my bowels
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have been vomiting
2 (A little bit)
1 (Not at all)
4 (Quite a bit)
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3 (Somewhat)
5 (Very much)
I am bothered by hair loss.
2 (A little bit)
1 (Not at all)
4 (Quite a bit)
3 (Somewhat)
5 (Very much)
I have a good appetite
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I like the appearance of my body
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am able to get around by myself
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am able to feel like a woman.
2 (A little bit)
1 (Not at all)
4 (Quite a bit)
3 (Somewhat)
5 (Very much)
I have cramps in my stomach area
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am interested in sex
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have concerns about my ability to have children
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
Ntx4 Subscale
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I have numbness or tingling in my hands
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have numbness or tingling in my feet
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I feel discomfort in my hands
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I feel discomfort in my feet
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
Unamed Module 2
Mobility
I Am Confined To Bed (I am confined to
bed)
I Have No Problems In Walking About (I
have no problems in walking about)
I Have Some Problems In Walking About
(I have some problems in walking about)
Self care
I Am Unable To Wash Or Dress Myself (I
am unable to wash or dress myself)
I Have No Problems With Self Care (I
have no problems with self care)
I Have Some Problems Washing Or
Dressing Myself (I have some problems
washing or dressing myself)
Usual activities (e.g. work, study, housework,
family, or leisure activities)
I Am Unable To Perform My Usual
Activities (I am unable to perform my
usual activities)
I Have No Problems With Performing My
Usual Activities (I have no problems with
performing my usual activities)
I Have Some Problems With Performing
My Usual Activities (I have some
problems with performing my usual
activities)
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Pain/discomfort
I Have Extreme Pain Or Discomfort (I
have extreme pain or discomfort)
I Have Moderate Pain Or Discomfort (I
have moderate pain or discomfort)
I Have No Pain Or Discomfort (I have no
pain or discomfort)
Anxiety/depression
I Am Extremely Anxious Or Depressed (I
am extremely anxious or depressed)
I Am Moderately Anxious Or Depressed
(I am moderately anxious or depressed)
I Am Not Anxious Or Depressed (I am
not anxious or depressed)
Unnamed Module 3
Your own health state today
To Be Completed By Clinical Staff
QOL contact person
Status of the QOL assessment
Other (Other)
Patient Died (Patient died)
Patient Kept Appointment, But Could Not
Complete Questionnaire Due To Illness
(Patient kept appointment, but could not
complete questionnaire due to illness)
Patient Kept Appointment, But Refused
To Complete Questionnaire For Reasons
Other Than Illness (Patient kept
appointment, but refused to complete
questionnaire for reasons other than
illness)
Patient Off Study Treatment And Cannot
Be Contacted For Follow-up (Patient off
study treatment and cannot be contacted
for follow-up)
Questionnaire Not Administered Due To
Clinical Staff Error (Questionnaire not
administered due to clinical staff error)
The Questionnaire Is Complete (The
questionnaire is complete)
Specify reason
Other, specify
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Breast Cancer NCT01275677 Quality of Life - NSABP-B-47 Medical Conditions
and Lifestyle Questionnaire Form - Follow-up (Form MCL-F) - 3165236v1.0
NSABP-B-47 Medical Conditions and Lifestyle
Questionnaire Form - Follow-up (Form MCL-F)
A Randomized Phase III Trial of Adjuvant Therapy
Comparing Chemotherapy Alone (Six Cycles of Docetaxel
Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus
Cyclophosphamide Followed by Weekly Paclitaxel) to
Chemotherapy Plus Trastuzumab in Women With Node-
Positive or High-Risk Node-Negative HER2-Low Invasive
Breast Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=96C1751F-
BD70-2B10-E040-BB89AD433A9B
All rights reserved. Please visit https://medical-data-
models.org/forms/9331
NSABP-B-47 Medical Conditions
and Lifestyle Questionnaire Form -
Follow-up (Form MCL-F)
Header
Patient Initials (Last First Middle)
NSABP Patient ID
Institution/Affiliate
Institution Number
Staff member administering form, Last Name
Staff member administering form, first name
Staff Member Administering Form, Phone
Are data amended (If yes, check the box and
circle amended items)
Yes
No
Time Point
This form is being filled out (mark one)
By Clinical Staff On Phone With
Participant (By clinical staff on phone
with participant)
By Patient In Doctor's Office (By
participant in doctor's office)
By Participant Not In Doctor's Office (By
participant not in doctor's office)
Other (Other)
Time point
12 Months Post Randomization (12
months post randomization)
24 Months Post Randomization (24
months post randomization)
36 Months Post Randomization (36
1 / 3
months post randomization)
48 Months Post Randomization (48
months post randomization)
60 Months Post Randomization (60
months post randomization)
Date Questionnaire Completed (Month Day Year)
Section 1 - Lifetime Medical Conditions
New problem
Anemia (Anemia or other blood disease)
Atrial Fibrillation (Atrial fibrillation)
Back Pain (Back pain)
Osteoporosis (Bone loss or
osteoporosis)
Malignant Neoplasm (Cancer (other than
breast or non-melanoma skin cancer))
Congestive Heart Failure (Congestive
Heart Failure)
Depression (Depression)
Diabetes Mellitus (Diabetes)
Myocardial Infarction (Heart attack
(myocardial infarction))
Coronary Disease (Heart disease)
Hypertension (High blood pressure)
Disease Or Disorder Kidney (Kidney
disease)
Disease Or Disorder Liver (Liver
disease)
Disease Or Disorder Pulmonary (Lung
disease)
Osteoarthritis (Osteoarthritis,
degenerative arthritis)
Arrhythmia (Other heart rhythm problem)
Rheumatoid Arthritis (Rheumatoid
Arthritis)
Stroke (Stroke)
Disease Or Disorder Thyroid Gland
(Thyroid disease)
Ulcer (Ulcer or stomach disease)
Is this a problem for which you have seen a
doctor?
Yes
No
Do you currently receive treatment for it?
Yes
No
Does it currently limit your activities?
Yes
No
Section 2 - Alcohol And Tobacco Usage
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How many drinks of any kind of alcoholic
beverage have you had in the last month
Did you use tobacco (In the past month)
No, Not At All (No, not at all)
Yes, Every Day (Yes, every day)
Yes, Some Days (Yes, some days)
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Breast Cancer NCT01275677 Quality of Life - NSABP-B-47 Medical Conditions
and Lifestyle Questionnaire Form - Baseline (Form MCL-B) - 3165170v1.0
NSABP-B-47 Medical Conditions and Lifestyle
Questionnaire Form - Baseline (Form MCL-B)
A Randomized Phase III Trial of Adjuvant Therapy
Comparing Chemotherapy Alone (Six Cycles of Docetaxel
Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus
Cyclophosphamide Followed by Weekly Paclitaxel) to
Chemotherapy Plus Trastuzumab in Women With Node-
Positive or High-Risk Node-Negative HER2-Low Invasive
Breast Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=96C1751F-
BCDC-2B10-E040-BB89AD433A9B
All rights reserved. Please visit https://medical-data-
models.org/forms/9332
NSABP-B-47 Medical Conditions
and Lifestyle Questionnaire Form -
Baseline (Form MCL-B)
Header
Patient Initials (Last First Middle)
NSABP Patient ID
Institution/Affiliate
Institution Number
Staff member administering form, Last Name
Staff member administering form, first name
Staff Member Administering Form, Phone
Are data amended (If yes, check the box and
circle amended items)
Yes
No
Time Point
This form is being filled out (mark one)
By Clinical Staff On Phone With
Participant (By clinical staff on phone
with participant)
By Patient In Doctor's Office (By
participant in doctor's office)
By Participant Not In Doctor's Office (By
participant not in doctor's office)
Other (Other)
Date Questionnaire Completed (Month Day Year)
Section 1 - Lifetime Medical Conditions
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Problem
Anemia (Anemia or other blood disease)
Atrial Fibrillation (Atrial fibrillation)
Back Pain (Back pain)
Osteoporosis (Bone loss or
osteoporosis)
Malignant Neoplasm (Cancer (other than
breast or non-melanoma skin cancer))
Congestive Heart Failure (Congestive
Heart Failure)
Depression (Depression)
Diabetes Mellitus (Diabetes)
Myocardial Infarction (Heart attack
(myocardial infarction))
Coronary Disease (Heart disease)
Hypertension (High blood pressure)
Disease Or Disorder Kidney (Kidney
disease)
Disease Or Disorder Liver (Liver
disease)
Disease Or Disorder Pulmonary (Lung
disease)
Osteoarthritis (Osteoarthritis,
degenerative arthritis)
Arrhythmia (Other heart rhythm problem)
Rheumatoid Arthritis (Rheumatoid
Arthritis)
Stroke (Stroke)
Disease Or Disorder Thyroid Gland
(Thyroid disease)
Ulcer (Ulcer or stomach disease)
Have you ever seen a doctor for the problem?
Yes
No
Do you currently receive treatment for it?
Yes
No
Does it now limit your activities?
Yes
No
Section 2 - Tobacco Usage
Have you smoked at least 100 cigarettes in your
entire life? (100 cigarettes = 5 packs)
Yes
No
Have you used other forms of tobacco regularly
Yes
No
Have you used other forms of tobacco regularly
(Check all that apply)
Chew Tobacco (Chew tobacco)
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Cigar (Cigar)
Other, Specify (Other, specify)
Pipe (Pipe)
How old were you when you started using
tobacco (In years)
Did you use tobacco (In the past week)
No, Not At All (No, not at all)
Yes, Every Day (Yes, every day)
Yes, Some Days (Yes, some days)
On about how many days did you use tobacco
(During the period of your life when you used
tobacco, think about a typical month)
1 - 2 Days (1 - 2 days)
10 - 19 Days (10 - 19 days)
20 - 29 Days (20 - 29 days)
3 - 5 Days (3 - 5 days)
6 - 9 Days (6 - 9 days)
Every Day (Every day)
On the days you did smoke, what was the
average number of cigarettes you smoked per
day (Think about a typical month when you
smoked cigarettes)
10 To 20 Cigarettes (10 to 20 cigarettes)
Fewer Than 10 Cigarettes (Fewer than
10 cigarettes)
More Than 20 Cigarettes (More than 20
cigarettes)
Section 3 - Alcohol Consumption
During your entire life, have you had at least 12
drinks of any kind of alcoholic beverage? ([this
includes beer 1 bottle/can, wine 1 glass, and hard
liquor 1 cocktail or 1 shot of liquor])
Yes
No
In any one year have you had at least 12 drinks
of any kind of alcoholic beverage (this includes
beer, wine, and hard liquor)
Yes
No
In the last 12 months have you had at least 12
drinks of any kind of alcoholic beverage (this
includes beer, wine, and hard liquor)
Yes
No
On about how many days did you have at least
one drink of alcohol (In the last 12 months when
you drank alcohol, think about a typical month)
1 - 2 Days (1 - 2 days)
10 - 19 Days (10 - 19 days)
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20 - 29 Days (20 - 29 days)
3 - 5 Days (3 - 5 days)
6 - 9 Days (6 - 9 days)
Every Day (Every day)
On the days when you drank, about how many
drinks did you have on average
1 - 2 Per Day (1 - 2 per day)
3 - 5 Per Day (3 - 5 per day)
6+ Per Day (6+ per day)
Less Than 1 Drink Per Day (Less than 1
drink per day)
How many drinks of any kind of alcoholic
beverage have you had in the last week
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Registration - Enrollment - 3276705v1.0
The patient's enrollment information at the time of study
entry.
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=ACFCC8EF-
1679-775F-E040-BB89AD4328A6
All rights reserved. Please visit https://medical-data-
models.org/forms/9333
Enrollment
Enrollment
Visit Date (Enter the patient's registration date.)
Gender (Select the patient's gender:)
Female Gender (Female)
Male Gender (Male)
Unknown (Unknown)
Date of Birth (Enter the patient's date of birth.)
Age at Entry
Patient Initials (Enter the patient's initials.)
Date from which to Start Including labs (Enter the
date indicating when lab results data should be
start being loaded from the centralized lab.)
Race (Select Yes or No for the following OMB
race categories when subject is multi-racial,
answer YES to all the apply and No to the other
race categories:)
American Indian Or Alaska Native
(American Indian or Alaska Native)
Asian (Asian)
Black Or African American (Black or
African American)
Native Hawaiian Or Other Pacific
Islander (Native Hawaiian or other Pacific
Islander)
Not Reported (Not Reported)
Unknown (Unknown)
White (White)
Ethnicity (Select one of the following OMB
ethnicity categories:)
Hispanic Or Latino (Hispanic or Latino)
Not Hispanic Or Latino (Not Hispanic or
Latino)
Not Reported (Not reported)
Unknown (Unknown)
Registering Institution (Enter the unique CTEP
institution code where the patient was originally
registered on study e.g., institution where the
patient signed the informed consent form.)
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Primary ID
Patient Subgroup (Select the appropriate unique
code for identification of uniform groups of
patients for separate analysis or treatment as
defined in the Clinical Data System CDS.)
Registering Group (Note: This is required for
Inter-Group trials only ¿ otherwise leave blank.)
Country Code
Ascension Island (AC)
Andorra (AD)
United Arab Emirates (AE)
Afghanistan (AF)
Antigua And Barbuda (AG)
Anguilla (AI)
Albania (AL)
Armenia (AM)
Netherland Antilles (AN)
Angola (AO)
Antarctica (AQ)
Argentina (AR)
American Samoa (AS)
Austria (AT)
Australia (AU)
Aruba (AW)
Azerbaidjan (AZ)
Bosnia-herzegovina (BA)
Barbados (BB)
Bangladesh (BD)
Belgium (BE)
Burkina Faso (BF)
Bulgaria (BG)
Bahrain (BH)
Burundi (BI)
Benin (BJ)
Bermuda (BM)
Brunei Darussalam (BN)
Bolivia (BO)
Brazil (BR)
Bahamas (BS)
Bhutan (BT)
Bouvet Island (BV)
Botswana (BW)
Belarus (BY)
Belize (BZ)
Canada (CA)
Cocos Isl. (CC)
Rep. Dem. Congo (CD)
Central African Rep. (CF)
Congo (CG)
Switzerland (CH)
Ivory Coast (CI)
Cook Islands (CK)
Chile (CL)
Cameroon (CM)
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China (CN)
Colombia (CO)
Costa Rica (CR)
Cuba (CU)
Cape Verde (CV)
Christmas Island (CX)
Cyprus (CY)
Czech Republic (CZ)
Germany (DE)
Djibouti (DJ)
Denmark (DK)
Dominica (DM)
Dominican Republic (DO)
Algeria (DZ)
Ecuador (EC)
Estonia (EE)
Egypt (EG)
Western Sahara (EH)
Eritrea (ER)
Spain (ES)
Ethiopia (ET)
Finland (FI)
Fiji (FJ)
Falkland Isl. (FK)
Micronesia (FM)
Faroe Islands (FO)
France (FR)
France (european Ter.) (FX)
Gabon (GA)
Great Britain (GB)
Grenada (GD)
Georgia (GE)
Guiana (fr.) (GF)
Guernsey (GG)
Ghana (GH)
Gibraltar (GI)
Greenland (GL)
Gambia (GM)
Guinea (GN)
Guadeloupe (fr.) (GP)
Equatorial Guinea (GQ)
Greece (GR)
South Georgia And South Sandwich
Islands (GS)
Guatemala (GT)
Guam (us) (GU)
Guinea Bissau (GW)
Guyana (GY)
Hong Kong (HK)
Heard & Mcdonald Isl. (HM)
Honduras (HN)
Croatia (HR)
Haiti (HT)
Hungary (HU)
Indonesia (ID)
Ireland (IE)
Israel (IL)
Isle Of Man (IM)
India (IN)
British Indian O. Ter. (IO)
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Iraq (IQ)
Iran (IR)
Iceland (IS)
Italy (IT)
Jersey (JE)
Jamaica (JM)
Jordan (JO)
Japan (JP)
Kenya (KE)
Kyrgyz Republic (KG)
Cambodia (KH)
Kiribati (KI)
Comoros (KM)
St. Kitts Nevis Anguilla (KN)
Korea (north) (KP)
Korea (south) (KR)
Kuwait (KW)
Cayman Islands (KY)
Kazakstan (KZ)
Laos (LA)
Lebanon (LB)
Saint Lucia (LC)
Liechtenstein (LI)
Sri Lanka (LK)
Liberia (LR)
Lesotho (LS)
Lithuania (LT)
Luxembourg (LU)
Latvia (LV)
Libya (LY)
Morocco (MA)
Monaco (MC)
Moldova (MD)
Madagascar (MG)
Marshall Islands (MH)
Macedonia (MK)
Mali (ML)
Myanmar (MM)
Mongolia (MN)
Macau (MO)
Northern Mariana Isl. (MP)
Martinique (fr.) (MQ)
Mauritania (MR)
Montserrat (MS)
Malta (MT)
Mauritius (MU)
Maldives (MV)
Malawi (MW)
Mexico (MX)
Malaysia (MY)
Mozambique (MZ)
Namibia (NA)
New Caledonia (fr.) (NC)
Niger (NE)
Norfolk Island (NF)
Nigeria (NG)
Nicaragua (NI)
Netherlands (NL)
Norway (NO)
Nepal (NP)
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Nauru (NR)
Niue (NU)
New Zealand (NZ)
Oman (OM)
Other (Other)
Panama (PA)
Peru (PE)
Polynesia (fr.) (PF)
Papua New Guinea (PG)
Philippines (PH)
Pakistan (PK)
Poland (PL)
St. Pierre & Miquelon (PM)
Pitcairn (PN)
Puerto Rico (PR)
Portugal (PT)
Palau (PW)
Paraguay (PY)
Qatar (QA)
Reunion (fr.) (RE)
Romania (RO)
Russian Federation (RU)
Rwanda (RW)
Saudi Arabia (SA)
Solomon Islands (SB)
Seychelles (SC)
Sudan (SD)
Sweden (SE)
Singapore (SG)
St. Helena (SH)
Slovenia (SI)
Svalbard & Jan Mayen Isl. (SJ)
Slovakia (SK)
Sierra Leone (SL)
San Marino (SM)
Senegal (SN)
Somalia (SO)
Suriname (SR)
St. Tome And Principe (ST)
Soviet Union (SU)
El Salvador (SV)
Syria (SY)
Swaziland (SZ)
Turks & Caicos Islands (TC)
Chad (TD)
French Southern Terr. (TF)
Togo (TG)
Thailand (TH)
Tadjikistan (TJ)
Tokelau (TK)
Turkmenistan (TM)
Tunisia (TN)
Tonga (TO)
East Timor (TP)
Turkey (TR)
Trinidad & Tobago (TT)
Tuvalu (TV)
Taiwan (TW)
Tanzania (TZ)
Ukraine (UA)
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Uganda (UG)
United Kingdom (UK)
Us Minor Outlying Isl. (UM)
Usa (US)
Uruguay (UY)
Uzbekistan (UZ)
Vatican City State (VA)
St. Vincent & Grenadines (VC)
Venezuela (VE)
Virgin Islands (brit) (VG)
Virgin Islands (us) (VI)
Vietnam (VN)
Vanuatu (VU)
Wallis & Futuna Islands (WF)
Western Samoa (WS)
Yemen (YE)
Mayotte (YT)
Yugoslavia (YU)
South Africa (ZA)
Zambia (ZM)
Dem. Rep. Of Congo (ZR)
Zimbabwe (ZW)
Postal Code (For U.S. residents, enter the
patient's home 5 digit zip code. Do not enter the
last 4 digits of the complete zip code to assure
patient confidentiality. Also do not enter the
dash.)
Method of Payment (Select the patient's primary
method of payment using the following codes:)
Private Insurance (1)
Medicare (2)
Medicare And Private Insurance (3)
Medicaid (4)
Medicaid And Medicare (5)
Military Or Veterans Sponsored Nos (6)
Military Sponsored (including Champus
&tricare) (6a)
Veterans Sponsored (6b)
Self Pay (no Insurance) (7)
No Means Of Payment (no Insurance)
(8)
Other (98)
Unknown (99)
Primary Disease Site (Select the primary disease
site of the malignancy from the pick list.)
Abdomen (Abdomen)
Abdomen/pelvis (Abdomen/Pelvis)
Abdominal Wall (Abdominal wall)
Acetabulum (Acetabulum)
Pharyngeal Tonsil (Adenoid)
Adipose Tissue (Adipose)
Adrenal Gland (Adrenal gland)
Alveolar Ridge (Alveolar Ridge)
Amniotic Fluid (Amniotic Fluid)
Ampulla Of Vater (Ampulla of Vater)
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Anal Canal (Anal canal)
Anal Sphincter (Anal sphincter)
Ankle (Ankle)
Anorectum (Anorectum)
Antecubital Fossa (Antecubital fossa)
Antrum Pylori (Antrum)
Anus (Anus)
Aorta (Aorta)
Aortic Body (Aortic Body)
Appendix (Appendix)
Aqueous Fluid (Aqueous Fluid)
Arm (Arm)
Artery (Artery)
Ascending Colon (Ascending colon)
Ascending Colon Hepatic Flexure
(Ascending Colon Hepatic Flexure)
Auditory Canal (Auditory canal)
Autonomic Nervous System (Autonomic
nervous system)
Axilla (Axilla)
Back (Back)
Bile Duct (Bile duct)
Bladder (Bladder)
Blood (Blood)
Blood Vessel (Blood vessel)
Bone (Bone)
Bone Marrow (Bone marrow)
Bowel (Bowel)
Brain (Brain)
Brain Stem (Brain stem)
Breast (Breast)
Broad Ligament (Broad ligament)
Bronchiole (Bronchiole)
Bronchus (Bronchus)
Bronchus And Lung (Bronchus and
Lung)
Brow (Brow)
Buccal Cavity (Buccal cavity)
Buccal Mucosa (Buccal mucosa)
Buttock (Buttock)
Calf (Calf)
Capillary (Capillary)
Gastric Cardia (Cardia)
Carina (Carina)
Carotid Artery (Carotid artery)
Carotid Body (Carotid body)
Cartilage (Cartilage)
Cecum (Cecum)
Central Line Catheter (Central Line
Catheter)
Central Nervous System (Central
nervous system)
Cerebellum (Cerebellum)
Cerebral Cortex (Cerebral cortex)
Cerebrospinal Fluid (Cerebrospinal fluid)
Cerebrum (Cerebrum)
Cervical Spine (Cervical spine)
Cervical/thoracic/lumbar Spine
(Cervical/Thoracic/Lumbar spine)
Cervix (Cervix)
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Chest (Chest)
Chest Wall (Chest wall)
Chest/abdomen/pelvis
(Chest/Abdomen/Pelvis)
Chest/pelvis (Chest/Pelvis)
Chin (Chin)
Clavicle (Clavicle)
Clitoris (Clitoris)
Colon (Colon)
Colon And Rectum (Colon and rectum)
Colon Mucosa (Colon, mucosa only)
Common Duct (Common duct)
Conjunctiva (Conjunctiva)
Connective Tissue (Connective tissue)
Descending Colon (Descending colon)
Diaphragm (Diaphragm)
Duodenum (Duodenum)
Ear (Ear)
Ear Canal (Ear canal)
External Ear (Ear, Pinna (External))
Effusion (Effusion)
Elbow (Elbow)
Endocrine Gland (Endocrine gland)
Epididymis (Epididymis)
Epidural Spinal Canal Space (Epidural
space)
Esophagogastric Junction
(Esophagogastric junction)
Esophagus (Esophagus)
Esophageal Mucosa (Esophagus,
Mucosa only)
Extremities (Extremities)
Eye (Eye)
Fallopian Tube (Fallopian tube)
Femur (Femur)
Fibula (Fibula)
Finger (Finger)
Floor Of Mouth (Floor of Mouth)
Body Fluid Or Substance (Fluid)
Foot (Foot)
Forearm (Forearm)
Forehead (Forehead)
Foreskin (Foreskin)
Frontal Lobe (Frontal lobe)
Fundus Of Stomach (Fundus of
stomach)
Gallbladder (Gallbladder)
Ganglion (Ganglia)
Gastroesophageal Junction
(Gastroesophageal Junction)
Gastrointestinal Tract (Gastrointestinal
tract)
Genitourinary (Genitourinary)
Groin (Groin)
Gum (Gum)
Hand (Hand)
Hard Palate (Hard palate)
Head - Face Or Neck, Nos (Head - face
or neck, NOS)
Head/neck (Head/Neck)
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Head/neck/chest/adb/pelvis
(Head/Neck/Chest/Adb/Pelvis)
Heart (Heart)
Hepatic Duct (Hepatic duct)
Hip (Hip)
Humerus (Humerus)
Hypopharynx (Hypopharynx)
Ileum (Ileum)
Ilium (Ilium)
Intestine (Intestine)
Ischium (Ischium)
Jaw (Jaw)
Jejunum (Jejunum)
Joints (Joints)
Kidney (Kidney)
Knee (Knee)
Lacrimal Gland (Lacrimal Gland)
Large Bowel (Large bowel)
Laryngopharynx (Laryngopharynx)
Larynx (Larynx)
Leg (Leg)
Ligament (Ligament)
Lip (Lip)
Liver (Liver)
Liver And Intrahepatic Duct (Liver and
intrahepatic duct)
Liver/spleen (Liver/Spleen)
Lumbar Spine (Lumbar spine)
Lung (Lung)
Lymph Node (Lymph node)
Lymph Node(s) Axilla (Lymph Node(s)
Axilla)
Lymph Node(s) Cervical (Lymph Node(s)
Cervical)
Distant Lymph Node (Lymph node(s)
Distant)
Lymph Node(s) Hilar (Lymph Node(s)
Hilar)
Lymph Node(s) Inguinal (Lymph Node(s)
Inguinal)
Lymph Node(s) Int Mammary (Lymph
Node(s) Int Mammary)
Lymph Node(s) Mammary (Lymph
Node(s) Mammary)
Paraaortic Region Lymph Node (Lymph
node(s) Para aortic)
Lymph Node(s) Pelvic (Lymph Node(s)
Pelvic)
Regional Lymph Node (Lymph node(s)
Regional)
Scalene Lymph Node (Lymph node(s)
Scalene)
Lymph Node(s) Subclavicular (Lymph
Node(s) Subclavicular)
Lymph Node(s) Supraclav (Lymph
Node(s) Supraclav)
Lymph Nodes (Lymph nodes)
Mediastinal Lymph Node (Lymph
nodes(s) Mediastinal)
Lymphoma (Lymphoma)
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Mammary Gland (Mammary Gland)
Mandible (Mandible)
Maxilla (Maxilla)
Mediastinum (Mediastinum)
Mesentery (Mesentery)
Mesothelium (Mesothelium)
Mini Mantle (Mini Mantle)
Mouth (Mouth)
Muscle (Muscle)
Nail (Nails)
Nasal Cavity (Nasal Cavity)
Nasopharynx (Nasopharynx)
Neck (Neck)
Neck Chest (Neck/Chest)
Neck/chest/abdomen/pelvis
(Neck/Chest/Abdomen/Pelvis)
Nerve (Nerve)
Cranial Nerve (Nerve(s) Cranial)
Not Applicable (Not Applicable)
Ocular Orbits (Ocular Orbits)
Omentum (Omentum)
Oral Cavity (Oral cavity)
Oral Cavity Mucosa (Oral Cavity, Mucosa
only)
Oropharynx (Oropharynx)
Other (Other)
Ovary (Ovary)
Posterior Anterior/lateral (PA/Lat)
Palate (Palate)
Pancreas (Pancreas)
Paraspinal Ganglion (Paraspinal
Ganglion)
Parathyroid Gland (Parathyroid)
Parotid Gland (Parotid gland)
Patella (Patella)
Pelvis (Pelvis)
Penis (Penis)
Perianus (Perianus)
Pericardium (Pericardium)
Peritoneal Cavity (Peritoneal cavity)
Peritoneum (Peritoneum)
Pharynx (Pharynx)
Pineal Gland (Pineal Gland)
Pituitary Gland (Pituitary gland)
Placenta (Placenta)
Pleura (Pleura)
Popliteal Fossa (Popliteal fossa)
Prostate (Prostate)
Pylorus (Pylorus)
Rectosigmoid Junction (Rectosigmoid
Junction)
Rectum (Rectum)
Retina (Retina)
Retro-orbital Area (Retro-orbital Area)
Retroperitoneum (Retroperitoneum)
Ribs (Ribs)
Round Ligament (Round ligament)
Sacrum (Sacrum)
Salivary Gland (Salivary gland)
Scalp (Scalp)
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Scapula (Scapula)
Scrotum (Scrotum)
Shoulder Joint (Shoulder)
Sigmoid Colon (Sigmoid colon)
Sinus(es) (Sinus(es))
Sinus(es), Maxillary (Sinus(es),
Maxillary)
Skeletal Muscle Tissue (Skeletal Muscle)
Skin (Skin)
Skull (Skull)
Small Bowel Mucosa (Small Bowel,
Mucosa only)
Small Intestine (Small intestine)
Soft Tissue (Soft Tissue)
Spinal Cord (Spinal Cord)
Spine (Spine)
Spine/femur (Spine/Femur)
Spine/femur/radius
(Spine/Femur/Radius)
Spleen (Spleen)
Splenic Flexure (Splenic Flexure)
Sternum (Sternum)
Stomach (Stomach)
Stomach Mucosa (Stomach, Mucosa
only)
Subcutaneous Tissue (Subcutaneous
tissue)
Synovial Membrane (Synovium)
Tendon (Tendon)
Testis (Testicle)
Testicle (Testicle)
Thigh (Thigh)
Thoracic Spine (Thoracic spine)
Thoracic/lumbar Spine (Thoracic/Lumbar
spine)
Thorax (Thorax)
Throat (Throat)
Thymus (Thymus)
Thyroid Gland (Thyroid gland)
Tibia (Tibia)
Tongue (Tongue)
Tongue, Base Of Tongue (Tongue, Base
of tongue)
Tonsil (Tonsil)
Pharyngeal Tonsil (Tonsil, Pharyngeal)
Trachea (Trachea)
Trachea Main Bronchus (Trachea/Major
Bronchi)
Transverse Colon (Transverse Colon)
Trunk (Trunk)
Superficial Trunk (Trunk, Superficial)
Umbilical Cord (Umbilical Cord)
Upper Extremity (Upper extremity)
Ureter (Ureter)
Urethra (Urethra)
Urinary Tract (Urinary tract)
Uterus (Uterus)
Uvula (Uvula)
Vagina (Vagina)
Vas Deferens (Vas Deferens)
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Vein (Vein)
Vena Cava (Vena Cava,
Inferior/Superior)
Vertebra (Vertebra)
Vertebral Column (Vertebral column)
Vulva (Vulva)
Whole Body (Whole body)
Wrist (Wrist)
Disease Term (Select a disease term. Use the list
of Disease Terms "MedDRA" as listed on the
CTEP Web site.)
Disease Stage of Entry (Select the stage of the
disease at the time of study entry if appropriate.
Otherwise, leave it blank.)
Stage 0 (0)
Stage A (A)
Stage B (B)
Stage C (C)
Stage D (D)
Stage D0 (D0)
Stage D1 (D1)
Stage D2 (D2)
Stage D3 (D3)
Stage I (I)
Stage Ia (IA)
Stage Ib (IB)
Stage Ic (IC)
Stage Ie (extranodal) (IE)
Stage Ii (II)
Stage Iia (IIA)
Stage Iib (IIB)
Stage Iic (IIC)
Stage Iie (extranodal) (IIE)
Stage Iii (III)
Stage Iiia (IIIA)
Stage Iiib (IIIB)
Iiic (IIIC)
Stage Iv (IV)
Stage Iva (IVA)
Stage Ivb (IVB)
Disease T Stage (Select the stage of disease
based on the primary tumor.)
Disease N Stage (Select the stage of disease
based on the nodes present.)
Disease M Stage (Select the stage of disease
based on the metastases present.)
Histology/Cytopathology (State briefly the type of
histology or cytopathology found at the time of
original diagnosis.)
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Date of Confirmation of Histology (Enter the date
when the patient's disease status was confirmed,
at the treating institution, prior to study entry if
required by the protocol.)
Grade of Histology (Enter the grade of histology
at study entry, if appropriate. Leave it blank
otherwise.)
High Grade (High Grade)
Low Grade (Low Grade)
Moderately Differentiated (Moderately)
Not Applicable (N/A)
Not Otherwise Specified (NOS)
Not Done (Not Done)
Poorly Differentiated (Poorly)
Undifferentiated (Undifferentiated)
Unknown (Unknown)
Well Differentiated (Well)
Date of Diagnosis (Enter the first date of original
diagnosis e.g., when a positive biopsy or surgical
result was obtained. Do not give the start date of
symptoms as the date of diagnosis.)
Treatment Assignment Code (Select the
appropriate code for the patient's treatment
assignment as specified.)
Date Informed Consent Signed (Enter the date
the patient signed the informed consent form.)
Date of Informed Consent Version (Enter the date
of the informed consent version of the IRB-
approved informed consent form that was signed
by the patient at the time of study entry.)
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On-Study - ENROLLMENT - 2393048v1.2
Enrollment form for C3D 3.12 Adopters
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=790C39AF-
C663-A8ED-E040-BB89AD435AB1
All rights reserved. Please visit https://medical-data-
models.org/forms/9334
ENROLLMENT
Demographics
Gender of a Person
Female Gender (Female Gender)
Male Gender (Male Gender)
Unknown (Unknown)
Unspecified (Unspecified)
Patient's Date of Birth
Patient/Participant Age
Race
A Person Having Origins In Any Of The
Original Peoples Of North And South
America (including Central America),
And Who Maintains Tribal Affiliation Or
Community Attachment. (American
Indian or Alaska Native)
A Person Having Origins In Any Of The
Original Peoples Of The Far East,
Southeast Asia, Or The Indian
Subcontinent Including, For Example,
Cambodia, China, India, Japan, Korea,
Malaysia, Pakistan, The Philippine
Islands, Thailand, And Vietnam. (Asian)
A Person Having Origins In Any Of The
Black Racial Groups Of Africa. Terms
Such As "haitian" Or "negro" Can Be
Used In Addition To "black Or African
American." (Black or African American)
A Person Having Origins In Any Of The
Original Peoples Of Hawaii, Guam,
Samoa, Or Other Pacific Islands. (Native
Hawaiian or other Pacific Islander)
Not Provided Or Available (Not
Reported)
Could Not Be Determined Or Unsure
(Unknown)
A Person Having Origins In Any Of The
Original Peoples Of Europe, The Middle
East, Or North Africa. (White)
Ethnicity
A Person Of Mexican, Puerto Rican,
Cuban, Central Or South American Or
Other Spanish Culture Or Origin,
Regardless Of Race. (Hispanic or Latino)
A Person Not Meeting The Definition For
Hispanic Or Latino. (Not Hispanic or
Latino)
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Not Provided Or Available (Not reported)
Could Not Be Determined Or Unsure
(Unknown)
Patient Initials Name
Patient Registration Date
Prestudy Lab Date
Patient Identifier
Registration
Patient Subgroup Assignment
Registering Group
Registering Institution Identification Code
Country Code
Ascension Island (AC)
Andorra (AD)
United Arab Emirates (AE)
Afghanistan (AF)
Antigua And Barbuda (AG)
Anguilla (AI)
Albania (AL)
Armenia (AM)
Netherland Antilles (AN)
Angola (AO)
Antarctica (AQ)
Argentina (AR)
American Samoa (AS)
Austria (AT)
Australia (AU)
Aruba (AW)
Azerbaidjan (AZ)
Bosnia-herzegovina (BA)
Barbados (BB)
Bangladesh (BD)
Belgium (BE)
Burkina Faso (BF)
Bulgaria (BG)
Bahrain (BH)
Burundi (BI)
Benin (BJ)
Bermuda (BM)
Brunei Darussalam (BN)
Bolivia (BO)
Brazil (BR)
Bahamas (BS)
Bhutan (BT)
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Bouvet Island (BV)
Botswana (BW)
Belarus (BY)
Belize (BZ)
Canada (CA)
Cocos Isl. (CC)
Rep. Dem. Congo (CD)
Central African Rep. (CF)
Congo (CG)
Switzerland (CH)
Ivory Coast (CI)
Cook Islands (CK)
Chile (CL)
Cameroon (CM)
China (CN)
Colombia (CO)
Costa Rica (CR)
Cuba (CU)
Cape Verde (CV)
Christmas Island (CX)
Cyprus (CY)
Czech Republic (CZ)
Germany (DE)
Djibouti (DJ)
Denmark (DK)
Dominica (DM)
Dominican Republic (DO)
Algeria (DZ)
Ecuador (EC)
Estonia (EE)
Egypt (EG)
Western Sahara (EH)
Eritrea (ER)
Spain (ES)
Ethiopia (ET)
Finland (FI)
Fiji (FJ)
Falkland Isl. (FK)
Micronesia (FM)
Faroe Islands (FO)
France (FR)
France (european Ter.) (FX)
Gabon (GA)
Great Britain (GB)
Grenada (GD)
Georgia (GE)
Guiana (fr.) (GF)
Guernsey (GG)
Ghana (GH)
Gibraltar (GI)
Greenland (GL)
Gambia (GM)
Guinea (GN)
Guadeloupe (fr.) (GP)
Equatorial Guinea (GQ)
Greece (GR)
South Georgia And South Sandwich
Islands (GS)
Guatemala (GT)
Guam (us) (GU)
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Guinea Bissau (GW)
Guyana (GY)
Hong Kong (HK)
Heard & Mcdonald Isl. (HM)
Honduras (HN)
Croatia (HR)
Haiti (HT)
Hungary (HU)
Indonesia (ID)
Ireland (IE)
Israel (IL)
Isle Of Man (IM)
India (IN)
British Indian O. Ter. (IO)
Iraq (IQ)
Iran (IR)
Iceland (IS)
Italy (IT)
Jersey (JE)
Jamaica (JM)
Jordan (JO)
Japan (JP)
Kenya (KE)
Kyrgyz Republic (KG)
Cambodia (KH)
Kiribati (KI)
Comoros (KM)
St. Kitts Nevis Anguilla (KN)
Korea (north) (KP)
Korea (south) (KR)
Kuwait (KW)
Cayman Islands (KY)
Kazakstan (KZ)
Laos (LA)
Lebanon (LB)
Saint Lucia (LC)
Liechtenstein (LI)
Sri Lanka (LK)
Liberia (LR)
Lesotho (LS)
Lithuania (LT)
Luxembourg (LU)
Latvia (LV)
Libya (LY)
Morocco (MA)
Monaco (MC)
Moldova (MD)
Madagascar (MG)
Marshall Islands (MH)
Macedonia (MK)
Mali (ML)
Myanmar (MM)
Mongolia (MN)
Macau (MO)
Northern Mariana Isl. (MP)
Martinique (fr.) (MQ)
Mauritania (MR)
Montserrat (MS)
Malta (MT)
Mauritius (MU)
4 / 11
On-Study - ENROLLMENT - 2393048v1.2
Maldives (MV)
Malawi (MW)
Mexico (MX)
Malaysia (MY)
Mozambique (MZ)
Namibia (NA)
New Caledonia (fr.) (NC)
Niger (NE)
Norfolk Island (NF)
Nigeria (NG)
Nicaragua (NI)
Netherlands (NL)
Norway (NO)
Nepal (NP)
Nauru (NR)
Niue (NU)
New Zealand (NZ)
Oman (OM)
Other (Other)
Panama (PA)
Peru (PE)
Polynesia (fr.) (PF)
Papua New Guinea (PG)
Philippines (PH)
Pakistan (PK)
Poland (PL)
St. Pierre & Miquelon (PM)
Pitcairn (PN)
Puerto Rico (PR)
Portugal (PT)
Palau (PW)
Paraguay (PY)
Qatar (QA)
Reunion (fr.) (RE)
Romania (RO)
Russian Federation (RU)
Rwanda (RW)
Saudi Arabia (SA)
Solomon Islands (SB)
Seychelles (SC)
Sudan (SD)
Sweden (SE)
Singapore (SG)
St. Helena (SH)
Slovenia (SI)
Svalbard & Jan Mayen Isl. (SJ)
Slovakia (SK)
Sierra Leone (SL)
San Marino (SM)
Senegal (SN)
Somalia (SO)
Suriname (SR)
St. Tome And Principe (ST)
Soviet Union (SU)
El Salvador (SV)
Syria (SY)
Swaziland (SZ)
Turks & Caicos Islands (TC)
Chad (TD)
French Southern Terr. (TF)
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Togo (TG)
Thailand (TH)
Tadjikistan (TJ)
Tokelau (TK)
Turkmenistan (TM)
Tunisia (TN)
Tonga (TO)
East Timor (TP)
Turkey (TR)
Trinidad & Tobago (TT)
Tuvalu (TV)
Taiwan (TW)
Tanzania (TZ)
Ukraine (UA)
Uganda (UG)
United Kingdom (UK)
Us Minor Outlying Isl. (UM)
Usa (US)
Uruguay (UY)
Uzbekistan (UZ)
Vatican City State (VA)
St. Vincent & Grenadines (VC)
Venezuela (VE)
Virgin Islands (brit) (VG)
Virgin Islands (us) (VI)
Vietnam (VN)
Vanuatu (VU)
Wallis & Futuna Islands (WF)
Western Samoa (WS)
Yemen (YE)
Mayotte (YT)
Yugoslavia (YU)
South Africa (ZA)
Zambia (ZM)
Dem. Rep. Of Congo (ZR)
Zimbabwe (ZW)
ZIP Code
Payment Method
Private Insurance (1)
Medicare (2)
Medicare And Private Insurance (3)
Medicaid (4)
Medicaid And Medicare (5)
Military Or Veterans Sponsored Nos (6)
Military Sponsored (including Champus
&tricare) (6a)
Veterans Sponsored (6b)
Self Pay (no Insurance) (7)
No Means Of Payment (no Insurance)
(8)
Other (98)
Unknown (99)
Disease
Primary Site of Disease Name
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Adrenal Gland (Adrenal Gland)
Anus (Anus)
Appendix (Appendix)
Back (Back)
Bile Duct (Bile Duct)
Bladder (Bladder)
Bone Marrow (Bone Marrow)
Brainstem (Brainstem)
Breast (Breast)
Cerebellum (Cerebellum)
Cerebrum (Cerebrum)
Cervix (Cervix)
Chest (Chest)
Colon (Colon)
Cerebrospinal Fluid (CSF)
Duodenum (Duodenum)
Ear, External (Ear, External)
Ear, Inner (Ear, Inner)
Ear, Mid (Ear, Mid)
Esophagus (Esophagus)
Eye, Globe (Eye, Globe)
Eye, Orbit (Eye, Orbit)
Fallopian Tube (Fallopian Tube)
Feet (Feet)
Femur (Femur)
Fibula (Fibula)
Hands (Hands)
Hilum, Thoracic (Hilum)
Humerus (Humerus)
Ileum (Ileum)
Iliac Bone (Iliac)
Jejunum (Jejunum)
Kidney (Kidney)
Liver (Liver)
Lymph Node (LN)
Lymph Node, Axilla (LN, Axilla)
Lymph Node, Brachial (LN, Brachial)
Lymph Node, Cervical (LN, Cervical)
Lymph Node, Epitrochlear (LN,
Epitrochlear)
Lymph Node, Femoral (LN, Femoral)
Lymph Node, Hilar (LN, Hilar)
Lymph Node, Iliac (LN, Iliac)
Lymph Node, Inguinal (LN, Inguinal)
Lymph Node, Internal Mammary (LN,
Internal Mammary)
Lymph Node, Mediastinal (LN,
Mediastinal)
Lymph Node, Mesenteric (LN,
Mesenteric)
Lymph Node, Mid-pelvis (LN, Mid Pelvis)
Lymph Node, Neck (LN, Neck)
Lymph Node, Occipital (LN, Occipital)
Lymph Node, Paraaortic (LN, Paraaortic)
Lymph Node, Pelvis (LN, Pelvis)
Lymph Node, Periauricular (LN,
Periauricular)
Lymph Node, Popliteal (LN, Popliteal)
Lymph Node, Retroperitoneal (LN,
Retroperitoneal)
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Lymph Node(s), Subclavian (LN,
Subclavian)
Lymph Node, Submental (LN,
Submental)
Lymph Node, Supraclavicular (LN,
Supraclavicular)
Lung (Lung)
Lung, Anterior Left Lower Lobe (Lung,
Ant-LLL)
Lung, Anterior Left Upper Lobe (Lung,
Ant-LUL)
Lung, Anterior Right Lower Lobe (Lung,
Ant-RLL)
Lung, Anterior Right Middle Lobe (Lung,
Ant-RML)
Lung, Anterior Right Upper Lobe (Lung,
Ant-RUL)
Lung, Posterior Left Lower Lobe (Lung,
Post-LLL)
Lung, Posterior Left Upper Lobe (Lung,
Post-LUL)
Lung, Posterior Right Lower Lobe (Lung,
Post-RLL)
Lung, Posterior Right Middle Lobe (Lung,
Post-RML)
Lung, Posterior Right Upper Lobe (Lung,
Post-RUL)
Mandible (Mandible)
Mediastinum (Mediastinum)
Mouth (Mouth)
Muscle, Lower Extremity Distal (Muscle,
LE DIstal)
Muscle, Lower Extremity Proximal
(Muscle, LE Proximal)
Muscle, Upper Extremity Distal (Muscle,
UE Distal)
Muscle, Upper Extremity Proximal
(Muscle, UE Proximal)
Nasopharynx (Nasopharynx)
Nose (Nose)
Other Site (Other Site)
Ovary (Ovary)
Pancreas (Pancreas)
Pelvis (Pelvis)
Penis (Penis)
Pericardium (Pericardium)
Peripheral Blood (Peripheral Blood)
Pharynx (Pharynx)
Pleura (Pleura)
Prostate (Prostate)
Radius (Radius)
Rectum (Rectum)
Ribs (Ribs)
Sigmoid Colon (Sigmoid Colon)
Sinuses (Sinuses)
Skin (Skin)
Skull (Skull)
Spine, Cervical (Spine-C)
Spine, Lumbar (Spine-L)
Spine, Sacral (Spine-S)
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On-Study - ENROLLMENT - 2393048v1.2
Spine, Thoracic (Spine-T)
Spleen (Spleen)
Sternum (Sternum)
Stomach (Stomach)
Testicle (Testicle)
Throat (Throat)
Thyroid (Thyroid)
Tibia (Tibia)
Ulna (Ulna)
Ureter (Ureter)
Uterus (Uterus)
Vagina (Vagina)
Disease Term
Histology/Cytopathology Description
Disease Stage
Stage 0 (0)
Stage A (A)
Stage B (B)
Stage C (C)
Stage D (D)
Stage D0 (D0)
Stage D1 (D1)
Stage D2 (D2)
Stage D3 (D3)
Stage I (I)
Stage Ia (IA)
Stage Ib (IB)
Stage Ii (II)
Stage Iia (IIA)
Stage Iib (IIB)
Stage Iii (III)
Stage Iiia (IIIA)
Stage Iiib (IIIB)
Stage Iiic (IIIC)
Stage Iv (IV)
Stage Iva (IVA)
Stage Ivb (IVB)
Disease CDUS Code (This is a derived field and
may be displayed on the form, if needed.)
Consent
Histologic Confirmation Date
Diagnosis Date
ICF Signed Date
Informed Consent Version
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Histopathologic Differentiation Text Grade
High Grade (High Grade)
Low Grade (Low Grade)
Moderately Differentiated (Moderately)
Not Applicable (N/A)
Poorly Differentiated (Poorly)
Unknown (Unknown)
Well Differentiated (Well)
Treatment Assignment Code at Enrollment
Vital Signs
Evaluation Date
Lab Collection Time
Height (cm)
Body Weight in Kilograms
BSA
Zubrod Performance Status Score
Normal Activity (0)
Symptoms, But Nearly Fully Ambulatory
(1)
Some Bed Time, But Needs To Be In
Bed <50% Of Normal Daytime (2)
Needs To Be In Bed > 50% Of Normal
Daytime (3)
Unable To Get Out Of Bed (4)
Karnofsky Performance Status Score
Dead (0)
Moribund, Fatal Processes Progressing
Rapidly (10)
Normal, No Complaints, No Evidence Of
Disease (100)
Very Sick, Hospitalization Indicated.
Death Not Imminent (20)
Severely Disabled, Hospitalization
Indicated. Death Not Imminent (30)
Disabled, Requires Special Care And
Assistance (40)
Requires Considerable Assistance And
Frequent Medical Care (50)
Requires Occasional Assistance, But Is
Able To Care For Most Of His/her Needs
(60)
Cares For Self, Unable To Carry On
Normal Activity Or To Do Active Work
(70)
Normal Activity With Effort; Some Signs
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Or Symptoms Of Disease (80)
Able To Carry On Normal Activity; Minor
Signs Or Symptoms Of Disease (90)
Lansky Performance Status Score
Unresponsive (0)
No Play; Does Not Get Out Of Bed. (10)
Fully Active, Normal (100)
Often Sleeping; Play Entirely Limited To
Very Passive Activities. (20)
In Bed; Needs Assistance Even For
Quiet Play. (30)
Mostly In Bed; Participates In Quiet
Activities. (40)
Gets Dressed, But Lies Around Much Of
The Day; No Active Play, Able To
Participate In All Quiet Play And
Activities. (50)
Up And Around, But Minimal Active Play;
Keeps Busy With Quieter Activities. (60)
Both Greater Restriction Of And Less
Time Spent In Play Activity (70)
Active, But Tires More Quickly (80)
Minor Restrictions In Physically
Strenuous Activity (90)
Comments
Note Date
Research Comments Text
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Breast Cancer Follow-Up - IBCSG Long Term Follow-
Up Adverse Event Form (18-LTF-AE) - 3108519v1.0
IBCSG Long Term Follow-Up Adverse Event Form (18-LTF-
AE)
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=889C3F60-
2C61-8540-E040-BB89AD4303DD
All rights reserved. Please visit https://medical-data-
models.org/forms/9339
IBCSG Long Term Follow-Up
Adverse Event Form (18-LTF-AE)
Header Module
Visit number
IBCSG Patient ID
IBCSG Study No.
Randomization No.
Institution Code Number
Institution Name
Protocol Specific Adverse Event
Evaluation
CTC Adverse Event Term
Heart Disorder Other Specify (Cardiac
disorders - Other, specify)
Angina (Chest pain - cardiac)
Myocardial Infarction (Myocardial
infarction)
Cerebrovascular Accident (Stroke)
Thromboembolism (Thromboembolic
event)
Transient Ischemic Attack (Transient
ischemic attacks)
CTCAE Begin Date (MM DD YYYY)
CTC AE Grade
Mild Adverse Event (1)
Moderate Adverse Event (2)
Severe Adverse Event (3)
Life Threatening Adverse Event (4)
Death Related To Adverse Event (5)
Date of Assessment (day month year)
Method of Evaluation
Scan, Dual-energy X-ray Absorpitometry
(DEXA scan)
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Other (Other)
X-ray (X-ray)
Other Specify
Bone Events
Did the patient have any bone fractures during
this follow-up period (If yes, specify below)
Yes
No
Date of Fracture (month year)
Treatment required
Present, Not Requiring Surgery
(Present, not requiring surgery)
Requiring Surgery (Requiring surgery)
Site
Ankle (Ankle)
Cervical Spine (Cervical spine)
Clavicle (Clavicle)
Femur (Femur)
Humerus (Humerus)
Lumbar Spine (Lumbar spine)
Other (Other)
Pelvis (Pelvis)
Radius (Radius)
Rib (Rib)
Thoracic Spine (Thoracic spine)
Tibia (Tibia)
Ulna (Ulna)
Wrist (Wrist)
Other, specify
Primary Cause
Metastases (Metastases)
Osteoporosis (Osteoporosis)
Other (Other)
Trauma (Trauma)
Other, specify
Other, specify
Secondary Cause
Metastases (Metastases)
Osteoporosis (Osteoporosis)
Other (Other)
Trauma (Trauma)
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Breast Cancer Follow-Up - IBCSG Long Term Follow-Up Adverse Event
Form (18-LTF-AE) - 3108519v1.0
Protocol Specific Adverse Event
Evaluation
CTC Adverse Event Term
Heart Disorder Other Specify (Cardiac
disorders - Other, specify)
Angina (Chest pain - cardiac)
Myocardial Infarction (Myocardial
infarction)
Cerebrovascular Accident (Stroke)
Thromboembolism (Thromboembolic
event)
Transient Ischemic Attack (Transient
ischemic attacks)
Other, specify
CTCAE Begin Date (MM DD YYYY)
CTC AE Grade
Mild Adverse Event (1)
Moderate Adverse Event (2)
Severe Adverse Event (3)
Life Threatening Adverse Event (4)
Death Related To Adverse Event (5)
Angina requiring percutaneous transluminal
coronary angioplasty (PTCA)
Yes
No
Angina requiring coronary bypass graft (CABG)
Yes
No
Footer Module
Investigator/Designee Signature
Date (day month year)
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Breast Cancer Follow-Up - IBCSG Long Term Follow-Up Adverse Event
Form (18-LTF-AE) - 3108519v1.0
Lung Cancer NCT00020709 Treatment - SOUTHWEST ONCOLOGY
GROUP S0023 ZD1839/PLACEBO TREATMENT FORM - 2291323v3.0
SOUTHWEST ONCOLOGY GROUP S0023
ZD1839/PLACEBO TREATMENT FORM
S0023: Combination Chemo Plus RT With or Without
Gefitinib in Treating Patients With Unresectable Stage III
NSCLC
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=E1C7F123-
3963-7126-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/9342
SOUTHWEST ONCOLOGY GROUP
S0023 ZD1839/PLACEBO
TREATMENT FORM
Header
SWOG Patient ID
SWOG Study No.
Registration Step
Submission time
12 Week Submission (12 week
submission)
P4_week_first_submissio2005312 (4
week submission)
P8_week_second_submissi2005313 (8
week submission)
Other2005314 (Other)
Patient Initials
Institution/Affiliate
Physician
Participating Group Name
Participating Group Study No.
Participating Group Patient ID
Status
Date of last contact or death
Vital status
Alive (Alive)
Dead (Dead)
1 / 2
Has the patient progressed per the definition of
Section 10.0 of the protocol?
Yes
No
Treatment
Reporting Begin Date
Reporting End Date
Were there any dose modifications or
additions/deletions to protocol treatment (If yes,
specify amount and reason in the comments
section.)
No2005326 (No)
Yes_planned_per_prot_gu2005327 (Yes,
planned)
Yes_unplanned_not_per_p2005328 (Yes,
unplanned)
Delay
Yes
No
Dose reduction
Yes
No
Total dose for this reporting period
Comments
Comments
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Lung Cancer NCT00020709 Treatment - SOUTHWEST ONCOLOGY
GROUP S0023 ZD1839/PLACEBO TREATMENT FORM - 2291323v3.0
Neoplasms, Breast NCT00490139 Follow-Up - North Central Cancer Treatment
Group - Patient Questionnaire Booklet Compliance Form - 2648090v1.0
North Central Cancer Treatment Group - Patient
Questionnaire Booklet Compliance Form
ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment
Optimisation) Study; BIG 2-06/N063D
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=324F19A9-
67ED-1E08-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/9346
North Central Cancer Treatment
Group - Patient Questionnaire
Booklet Compliance Form
Header Module
NCCTG Study No.
Patient Study ID
Patient Initials
Institution Number
Institution
Are data amended
Yes
No
Header
Date Form Completed
Reporting Period
Approximately 12 Weeks Post
Randomization (Approximately 12 weeks
post randomization)
Approximately 3 Years Post
Randomization (Approximately 3 years
post randomization)
Approximately 5 Years Post
Randomization (Approximately 5 years
post randomization)
Approximately 52 Weeks Post
Randomization (Approximately 52 weeks
post randomization)
Baseline (Baseline)
Reason Questionnaire was not Completed
Death (Death)
Other Reason (Other reason)
Patient Not Given Booklet By Staff
(Patient not given booklet by staff)
Patient Refused (Patient refused)
1 / 2
Staff Unavailable (Staff unavailable)
Unable To Accomodate Disability Or
Language Needs (Unable to accomodate
disability or language needs)
Other reason, specify
Future booklet(s) expected from this patient
Yes
No
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Neoplasms, Breast NCT00490139 Follow-Up - North Central Cancer Treatment
Group - Patient Questionnaire Booklet Compliance Form - 2648090v1.0
Brain and Central Nervous System Tumors NCT00887146 Follow-Up - North
Central Cancer Treatment Group N0577 - Patient Questionnaire Booklet
Compliance Form - 2745216v1.0
North Central Cancer Treatment Group N0577 - Patient
Questionnaire Booklet Compliance Form
Radiation Therapy or Radiation Therapy and Temozolomide
or Temozolomide Alone in Treating Patients With Newly
Diagnosed Anaplastic Glioma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=4C07E8C3-
3298-293D-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/9347
North Central Cancer Treatment
Group N0577 - Patient Questionnaire
Booklet Compliance Form
Header
Protocol Number
Patient ID
Patient Initials (L F M)
Institution Number
Institution
Are data amended (If yes, highlight amended
areas)
Yes
No
Header
Reporting Period
Baseline (Baseline)
Current Cycle Number
Date Form Completed
Reason Questionnaire was not Completed
Other Reason (Other reason)
Patient Not Given Form By Staff (Patient
not given form by staff)
Patient Refused (Patient refused)
Staff Unavailable (Staff unavailable)
Unable To Accomodate Disability Or
Language Needs (Unable to accomodate
disability or language needs)
Other reason, specify
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Breast Cancer NCT00914043 Quality of Life - NSABP B-45 Missing
Data Worksheet for Quality of Life Questionnaire Form - 2847103v1.0
NSABP B-45 Missing Data Worksheet for Quality of Life
Questionnaire Form
Studying Biological Markers of Fatigue in Women With
Residual Invasive Breast Cancer Enrolled on Clinical Trial
NSABP-B-45
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=64AFECAB-
BECC-0357-E040-BB89AD431986
All rights reserved. Please visit https://medical-data-
models.org/forms/9351
NSABP B-45 Missing Data
Worksheet for Quality of Life
Questionnaire Form
Header
Patient Initials (Last First Middle)
NSABP Patient ID
Institution/Affiliate
Person Completing Form (Last Name First
Name)
Person Completing Form, Phone
Date Form Completed (MM DD YYYY)
Are data amended
Yes
No
Reason Qol Not Assessed
Time point (for this form mark one)
12 Months After Randomization (12
months after randomization)
18 Months After Randomization (18
months after randomization)
24 Months After Randomization (24
months after randomization)
3 Months After Randomization (3 months
after randomization)
6 Months After Randomization (6 months
after randomization)
Reason QOL was Not Assessed During Clinic
Visit (Mark the main reason and add comments
below)
Patient Refused To Complete
Questionnaire For Reason Other Than
Illness Or Upset (Patient refused to
complete questionnaire for reason other
than illness or upset)
1 / 2
Patient Stated That She Was Too Ill Or
Upset To Complete Questionnaire
(Patient stated that she was too ill or
upset to complete questionnaire)
Patient Was Unavailable (e.g.,
Scheduling Or Transportation Difficulties)
(Patient was unavailable)
Staff Concerned For Patient's Medical Or
Emotional Condition (Staff concerned for
patient's medical or emotional condition)
Staff Oversight Or Understaffing (Staff
oversight or understaffing)
Reason QOL was Not Obtained by Phone or Mail
(Mark the main reason and add comments
below)
Patient Refused To Complete
Questionnaire (Patient refused to
complete questionnaire)
Patient's Medical Or Emotional Condition
(Patient's medical or emotional condition)
Questionnaire Was Mailed To Patient,
But She Did Not Return It (for Unknown
Reasons) (QUESTIONNAIRE WAS
MAILED TO PATIENT, BUT SHE DID
NOT RETURN IT)
Staff Oversight Or Understaffing (STAFF
OVERSIGHT OR UNDERSTAFFING)
Staff Was Unable To Contact Patient By
Phone (STAFF WAS UNABLE TO
CONTACT PATIENT BY PHONE)
Comments
Comments
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Breast Cancer NCT00914043 Quality of Life - NSABP B-45 Missing Data
Worksheet for Quality of Life Questionnaire Form - 2847103v1.0
Breast Cancer NCT01275677 Quality of Life - NSABP-B-47 Missing Data form
for Medical Conditions and Lifestyle Questionnaire (Form QMD) - 3161696v1.0
NSABP-B-47 Missing Data form for Medical Conditions and
Lifestyle Questionnaire (Form QMD)
A Randomized Phase III Trial of Adjuvant Therapy
Comparing Chemotherapy Alone (Six Cycles of Docetaxel
Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus
Cyclophosphamide Followed by Weekly Paclitaxel) to
Chemotherapy Plus Trastuzumab in Women With Node-
Positive or High-Risk Node-Negative HER2-Low Invasive
Breast Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=9556F723-
E572-09D5-E040-BB89AD433F36
All rights reserved. Please visit https://medical-data-
models.org/forms/9353
NSABP-B-47 Missing Data form for
Medical Conditions and Lifestyle
Questionnaire (Form QMD)
Header
Patient Initials (Last First Middle)
NSABP Patient ID
Reason Qol Not Assessed
Time point
12 Months Post Randomization (12
months post randomization)
24 Months Post Randomization (24
months post randomization)
36 Months Post Randomization (36
months post randomization)
48 Months Post Randomization (48
months post randomization)
60 Months Post Randomization (60
months post randomization)
Reason MCL-F was Not Assessed During Clinic
Visit (Mark the main reason and add comments
below)
Other, Specify (Other)
Patient Refused To Complete
Questionnaire For Reason Other Than
Illness Or Upset (Patient refused to
complete questionnaire for reason other
than illness or upset)
Patient Stated That She Was Too Ill Or
Upset To Complete Questionnaire
(Patient stated that she was too ill or
upset to complete questionnaire)
Patient Was Unavailable (e.g.,
Scheduling Or Transportation Difficulties)
(Patient was unavailable)
Staff Concerned For Patient's Medical Or
Emotional Condition (Staff concerned for
patient's medical or emotional condition)
Staff Oversight Or Understaffing (Staff
oversight or understaffing)
1 / 2
Reason MCL-F was Not Assessed by Phone or
Mail (Mark the main reason and add comments
below)
Other (Other)
Patient Refused To Complete
Questionnaire (Patient refused to
complete questionnaire)
Questionnaire Was Mailed To Patient,
But She Did Not Return It (for Unknown
Reasons) (QUESTIONNAIRE WAS
MAILED TO PATIENT, BUT SHE DID
NOT RETURN IT)
Staff Oversight Or Understaffing (STAFF
OVERSIGHT OR UNDERSTAFFING)
Staff Was Unable To Contact Patient By
Phone (STAFF WAS UNABLE TO
CONTACT PATIENT BY PHONE)
Other, specify
Other, specify
Footer
Comments (optional)
Person Completing Form
Date Form Completed
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Breast Cancer NCT01275677 Quality of Life - NSABP-B-47 Missing Data form
for Medical Conditions and Lifestyle Questionnaire (Form QMD) - 3161696v1.0
Breast Cancer NCT01275677 Treatment - NSABP-B-47
Hormonal/Endocrine Therapy Form (Form HT) - 3161813v1.0
NSABP-B-47 Hormonal/Endocrine Therapy Form (Form
HT)
A Randomized Phase III Trial of Adjuvant Therapy
Comparing Chemotherapy Alone (Six Cycles of Docetaxel
Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus
Cyclophosphamide Followed by Weekly Paclitaxel) to
Chemotherapy Plus Trastuzumab in Women With Node-
Positive or High-Risk Node-Negative HER2-Low Invasive
Breast Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=95594CE0-
B466-936E-E040-BB89AD43333F
All rights reserved. Please visit https://medical-data-
models.org/forms/9354
NSABP-B-47 Hormonal/Endocrine
Therapy Form (Form HT)
Header
Patient Initials (Last First Middle)
NSABP Patient ID
Unnamed Module 1
Reporting Period
12 Months Post Randomization (12
Months Post Randomization)
24 Months Post Randomization (24
Months Post Randomization)
36 Months Post Randomization (36
Months Post Randomization)
48 Months Post Randomization (48
Months Post Randomization)
60 Months Post Randomization (60
Months Post Randomization)
72 Months Post Randomization (72
Months Post Randomization)
Since being entered on study, has the patient
received any postoperative adjuvant hormonal
treatment? (If no, omit all remaining questions)
Yes
No
Was endocrine therapy use assessed at the
specified time point (If yes, complete the following
table)
Yes
No
Unnamed3
Agent Name
Other, specify
1 / 2
Was agent administered
Yes
No
Cumulative Agent Duration (Round up to the
nearest month months)
Footer
Comments (optional)
Person Completing Form
Date Form Completed (MM DD YYYY)
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Breast Cancer NCT01275677 Treatment - NSABP-B-47
Hormonal/Endocrine Therapy Form (Form HT) - 3161813v1.0
Breast Cancer NCT01272037 Quality of Life - S1007 Cover Sheet for
Patient-Completed Questionnaires Form (QLCS1007) - 3140796v1.0
S1007 Cover Sheet for Patient-Completed Questionnaires
Form (QLCS1007)
Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane
With or Without Chemotherapy in Treating Patients With
Invasive RxPONDER Breast Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=90DA93B9-
5312-5D33-E040-BB89AD434FA6
All rights reserved. Please visit https://medical-data-
models.org/forms/9355
S1007 Cover Sheet for Patient-
Completed Questionnaires Form
(QLCS1007)
Unnamed 1
SWOG Patient ID
SWOG Study No.
Registration Step
Patient Initials (L, F M)
Date form completed (MM DD YYYY)
Institution/Affiliate
Physician
Participating Group Name
Participating Study No.
Participating Patient ID
Planned Assessment
Month 12 (Month 12)
Month 36 (Month 36)
Month 6 (Month 6)
Randomization (Randomization)
Unnamed 1
Was the S1007 Health-Related Quality of Life
Questionnaire Randomized Study form
completed
Yes
No
Did the patient require any assistance in
completing the questionnaire? (If yes,)
Yes
1 / 2
No
Describe (If yes,)
Method of questionnaire administration
By Telephone (by telephone)
In The Clinic (in the clinic)
Other (other)
Other (please specify)
If Not Completed, please give reason (select one)
Death (Death)
Illness/deteriorating Health
(Illness/deteriorating health)
Institution Error (Institutional error)
Not Illness Related (Not illness related)
Other (Other)
Unnamed 3
Person completing form, last name
Person completing form, phone
Comments
Comments
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Breast Cancer NCT01272037 Quality of Life - S1007 Cover Sheet for
Patient-Completed Questionnaires Form (QLCS1007) - 3140796v1.0
Cervical Cancer NCT00057928 Treatment - SOUTHWEST ONCOLOGY
GROUP S0227 TREATMENT SUMMARY FORM (S0227) - 2057355v3.0
SOUTHWEST ONCOLOGY GROUP S0227 TREATMENT
SUMMARY FORM (S0227)
S0227 Comparison of Cisplatin Combined With Either
Paclitaxel or Gemcitabine in Treating Patients With
Recurrent, Persistent, or Metastatic Cervical Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=A9C46950-
C286-3B4D-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/9356
SOUTHWEST ONCOLOGY GROUP
S0227 TREATMENT SUMMARY
FORM (S0227)
Header
SWOG Patient ID
SWOG Study No.
Registration Step
Patient Initials (L, F M)
Institution / Affiliate
Physician (Groups other than SWOG)
Group Name
Study No.
Pt. ID
Status
Date of Last Contact or Death
Vital Status
Alive (Alive)
Dead (Dead)
Treatment For Cycles 2-6
Were there any dose modifications or
additions/omissions to protocol treatment
No (No)
(i.e., The Treatment Was Changed
According To Protocol Guidelines) (Yes,
planned, specify in comments)
(i.e., The Treatment Change Was Not
Part Of Protocol Guidelines) (Yes,
1 / 4
unplanned, specify in comments)
Cycle 2
Cycle Start Date
Cycle Stop Date
Weight (First day of this cycle)
BSA (First day of this cycle)
Total dose for this cycle: gemcitabine (Arm 2
only)
Total dose for this cycle: gemcitabine (Arm 2
only)
Total dose for this cycle: gemcitabine (Arm 2
only)
Cycle 3
Cycle Start Date
Cycle Stop Date
Weight (First day of this cycle)
BSA (First day of this cycle)
Total dose for this cycle: gemcitabine (Arm 2
only)
Total dose for this cycle: gemcitabine (Arm 2
only)
Total dose for this cycle: gemcitabine (Arm 2
only)
Comments
Comments
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Cervical Cancer NCT00057928 Treatment - SOUTHWEST ONCOLOGY
GROUP S0227 TREATMENT SUMMARY FORM (S0227) - 2057355v3.0
Cycle 4
Cycle Start Date
Cycle Stop Date
Weight (First day of this cycle)
BSA (First day of this cycle)
Total dose for this cycle: gemcitabine (Arm 2
only)
Total dose for this cycle: gemcitabine (Arm 2
only)
Total dose for this cycle: gemcitabine (Arm 2
only)
Cycle 5
Cycle Start Date
Cycle Stop Date
Weight (First day of this cycle)
BSA (First day of this cycle)
Total dose for this cycle: gemcitabine (Arm 2
only)
Total dose for this cycle: gemcitabine (Arm 2
only)
Total dose for this cycle: gemcitabine (Arm 2
only)
Cycle 6
Cycle Start Date
Cycle Stop Date
Weight (First day of this cycle)
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Cervical Cancer NCT00057928 Treatment - SOUTHWEST ONCOLOGY
GROUP S0227 TREATMENT SUMMARY FORM (S0227) - 2057355v3.0
BSA (First day of this cycle)
Total dose for this cycle: gemcitabine (Arm 2
only)
Total dose for this cycle: gemcitabine (Arm 2
only)
Total dose for this cycle: gemcitabine (Arm 2
only)
Others, specify
Others, specify
Others, specify
Others, specify
Comments
Comments
Ccrr Module For Southwest Oncology
Group S0227 Treatment Summary Form
(s0227)
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Cervical Cancer NCT00057928 Treatment - SOUTHWEST ONCOLOGY
GROUP S0227 TREATMENT SUMMARY FORM (S0227) - 2057355v3.0
Colorectal Cancer NCT00070122 Treatment - SOUTHWEST
ONCOLOGY GROUP S0303 Treatment Form - Arm 2 - 2167010v3.0
SOUTHWEST ONCOLOGY GROUP S0303 Treatment
Form - Arm 2
Combination Chemotherapy and Bevacizumab in Treating
Patients With Locally Advanced, Metastatic, or Recurrent
Colorectal Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=BC630599-
2A8A-10C7-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/9357
SOUTHWEST ONCOLOGY GROUP
S0303 Treatment Form - Arm 2
Header
SWOG Patient ID
SWOG Study No.
Registration Step
Patient Initials (L, F M)
Institution/Affiliate
Physician (Groups other than SWOG)
Group Name
Study No.
Pt. ID
Status
Date of Last Contact or Death
Vital Status
Alive (Alive)
Dead (Dead)
Has the patient progressed per the definition of
Section 10.0 of the protocol?
Yes
No
Were there any dose modifications or
additions/omissions to protocol treatment
No (No)
Yes, Planned (i.e., The Treatment Was
Changed According To Protocol
Guidelines) (Yes, planned)
1 / 2
Yes, Unplanned (i.e., The Treatment
Change Was Not Part Of Protocol
Guidelines) (Yes, unplanned)
Cycle Number
Treatment start date
Date of last treatment
Did the patient receive Oxaliplatin this cycle?
Yes
No
Did the patient receive Capecitabine this cycle?
Yes
No
Total dose of Leucovorin for this cycle
Total dose of Leucovorin for this cycle
Dispensed Pills
Returned Pills
Patient Estimate Remaining Pills
Dide the patient received G-CSF?
Yes
No
Comments
Ccrr Module For Southwest Oncology
Group S0303 Treatment Form - Arm 2
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Colorectal Cancer NCT00070122 Treatment - SOUTHWEST
ONCOLOGY GROUP S0303 Treatment Form - Arm 2 - 2167010v3.0
Cervical Cancer NCT00057928 Treatment - SOUTHWEST ONCOLOGY GROUP
S0227 TREATMENT FORM FOR FIRST CYCLE (S0227) - 2057464v3.0
SOUTHWEST ONCOLOGY GROUP S0227 TREATMENT
FORM FOR FIRST CYCLE (S0227)
S0227 Comparison of Cisplatin Combined With Either
Paclitaxel or Gemcitabine in Treating Patients With
Recurrent, Persistent, or Metastatic Cervical Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=A9C3C405-
9249-3D84-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/9358
SOUTHWEST ONCOLOGY GROUP
S0227 TREATMENT FORM FOR
FIRST CYCLE (S0227)
Header
SWOG Patient ID
SWOG Study No.
Registration Step
Patient Initials (L, F M)
Institution / Affiliate
Physician (Groups other than SWOG)
Group Name
Study No.
Pt. ID
Status
Date of Last Contact or Death
Vital Status
Alive (Alive)
Dead (Dead)
First Cycle Of Treatment
Cycle start date (same as treatment start date)
Cycle end date (Date immediately prior to the
date next cycle begins, or date decision made to
discontinue patient from protocol treatment if last
cycle.)
1 / 2
Weight first day this cycle (kg)
BSA first day this cycle
Were there any dose modifications or
additions/omissions to protocol treatment
No (No)
(i.e., The Treatment Was Changed
According To Protocol Guidelines) (Yes,
planned, specify in comments)
(i.e., The Treatment Change Was Not
Part Of Protocol Guidelines) (Yes,
unplanned, specify in comments)
Total dose of gemcitabine for this cycle (Arm 2
only)
Total dose of gemcitabine for this cycle (Arm 2
only)
Total dose of gemcitabine for this cycle (Arm 2
only)
Concomitant Medications / Medical
Interventions
Start Date
Stop Date
Others, specify
Others, specify
Comments
Comments
Ccrr Module For Southwest Oncology
Group S0227 Treatment Form For First
Cycle (s0227)
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Cervical Cancer NCT00057928 Treatment - SOUTHWEST ONCOLOGY GROUP
S0227 TREATMENT FORM FOR FIRST CYCLE (S0227) - 2057464v3.0
Endometrial Cancer NCT00807768 Treatment - GOG-0249 Vaginal
LDR Intracavitary Radiation Oncology Form - 2759711v1.0
GOG-0249 Vaginal LDR Intracavitary Radiation Oncology
Form
Pelvic Radiation Therapy or Vaginal Implant Radiation
Therapy, Paclitaxel, and Carboplatin in Treating Patients
With High-Risk Stage I or Stage II Endometrial Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=4FB4ED77-
E1A6-4A26-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/9363
GOG-0249 Vaginal LDR Intracavitary
Radiation Oncology Form
Header Module
Date form originally completed (m d y)
Date form amended (m d y)
Person amending form, last name
Patient Initials (First, Middle, Last)
Patient Study ID
Person Completing Form, Last Name
Radiation Description
Total Number of Brachytherapy Applications (high
dose rate intracavitary applications delivered to
patient)
Reason treatment ended (intracavitary )
Radiation
Application
Application #1 (Application #1)
Application #2 (Application #2)
Brachytherapy Start Date (m d y)
Elapsed days
Total hours
Isotope Type
Applicator type
1 / 3
Diameter of ovoid/cylinder (cm)
Activity of isotope (Ci)
Number of radioactive sources
Vaginal surface dose at apex (Gy)
Vaginal dose at 0.5 cm (Gy)
Isodose length along axis of vagina (Gy)
ICRU Bladder dose (Gy)
ICRU Rectal dose (Gy)
RT Total Dose
Magnification Factor
AP
Lateral
Totals
Physicist's name
Physicist's E-mail address
Radiation Oncologist's name
Radiation Oncologist's E-mail address
Radiation Oncologist's phone number
RT Facility Code
Completed by
Brachytherapy facility
2 / 3
Endometrial Cancer NCT00807768 Treatment - GOG-0249 Vaginal LDR
Intracavitary Radiation Oncology Form - 2759711v1.0
Comments
COMMENTS
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Endometrial Cancer NCT00807768 Treatment - GOG-0249 Vaginal LDR
Intracavitary Radiation Oncology Form - 2759711v1.0
Colorectal Cancer NCT00070122 Treatment - SOUTHWEST
ONCOLOGY GROUP S0303 Treatment Form - Arm 1 - 2166964v3.0
SOUTHWEST ONCOLOGY GROUP S0303 Treatment
Form - Arm 1
Combination Chemotherapy and Bevacizumab in Treating
Patients With Locally Advanced, Metastatic, or Recurrent
Colorectal Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=BC6300AF-
35F5-10B8-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/9364
SOUTHWEST ONCOLOGY GROUP
S0303 Treatment Form - Arm 1
Header
SWOG Patient ID
SWOG Study No.
Registration Step
Patient Initials (L, F M)
Institution/Affiliate
Physician (Groups other than SWOG)
Group Name
Study No.
Pt. ID
Status
Date of Last Contact or Death
Vital Status
Alive (Alive)
Dead (Dead)
Has the patient progressed per the definition of
Section 10.0 of the protocol?
Yes
No
Were there any dose modifications or
additions/omissions to protocol treatment
No (No)
Yes, Planned (i.e., The Treatment Was
Changed According To Protocol
Guidelines) (Yes, planned)
1 / 2
Yes, Unplanned (i.e., The Treatment
Change Was Not Part Of Protocol
Guidelines) (Yes, unplanned)
Cycle Number
Treatment start date
Date of last treatment
Did the patient receive Oxaliplatin this cycle?
Yes
No
Did the patient receive Leucovorin this cycle?
Yes
No
Did the patient receive bolus 5-Fluorouracil this
cycle?
Yes
No
Did the patient receive infusional 5-fluorouracil
this cycle?
Yes
No
Total dose of infusional 5-fluorouracil for this
cycle
Total dose of infusional 5-fluorouracil for this
cycle
Total dose of infusional 5-fluorouracil for this
cycle
Total dose of infusional 5-fluorouracil for this
cycle
Did the patient receive G-CSF?
Yes
No
Comments
Ccrr Module For Southwest Oncology
Group S0303 Treatment Form - Arm 1
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Colorectal Cancer NCT00070122 Treatment - SOUTHWEST
ONCOLOGY GROUP S0303 Treatment Form - Arm 1 - 2166964v3.0
Endometrial Cancer NCT00942357 Treatment - GOG-0258 Vaginal
LDR Intracavitary Radiation Oncology Form (LDRV) - 2843844v1.0
GOG-0258 Vaginal LDR Intracavitary Radiation Oncology
Form (LDRV)
Carboplatin and Paclitaxel With or Without Cisplatin and
Radiation Therapy in Treating Patients With Stage I, Stage
II, Stage III, or Stage IVA Endometrial Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=644E86D7-
D8A5-D7C8-E040-BB89AD4321CC
All rights reserved. Please visit https://medical-data-
models.org/forms/9365
GOG-0258 Vaginal LDR Intracavitary
Radiation Oncology Form (LDRV)
Header Module
Date form originally completed (m d y)
Date form amended (m d y)
Person amending form, last name
Patient Initials (First, Middle, Last)
Patient Study ID
Person Completing Form, Last Name
Radiation Description
Total Number of Brachytherapy Applications (low
dose rate)
Reason treatment ended (low dose rate
brachytherapy)
Radiation
Application
Application #1 (Application #1)
Application #2 (Application #2)
Brachytherapy Start Date (m d y)
Elapsed days
Total hours
Isotope Type
Applicator type
1 / 3
Diameter of ovoid/cylinder (cm)
Activity of isotope (Ci)
Number of radioactive sources
Vaginal surface dose at apex (Gy)
Vaginal dose at 0.5 cm (Gy)
Isodose length along axis of vagina (Gy)
ICRU Rectal dose (Gy)
ICRU Bladder dose (Gy)
RT Total Dose
Magnification Factor
AP
Lateral
Totals
Physicist's name
Physicist's E-mail address
Radiation Oncologist's name
Radiation Oncologist's E-mail address
Radiation Oncologist's phone number
RT Facility Code
Completed by
Brachytherapy facility
2 / 3
Endometrial Cancer NCT00942357 Treatment - GOG-0258 Vaginal LDR
Intracavitary Radiation Oncology Form (LDRV) - 2843844v1.0
Comments
COMMENTS
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Endometrial Cancer NCT00942357 Treatment - GOG-0258 Vaginal LDR
Intracavitary Radiation Oncology Form (LDRV) - 2843844v1.0
Endometrial Cancer NCT00942357 Treatment - GOG-0258 Vaginal
HDR Intracavitary Radiation Oncology Form (HDRV) - 2843783v1.0
GOG-0258 Vaginal HDR Intracavitary Radiation Oncology
Form (HDRV)
Carboplatin and Paclitaxel With or Without Cisplatin and
Radiation Therapy in Treating Patients With Stage I, Stage
II, Stage III, or Stage IVA Endometrial Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=644E86D7-
D829-D7C8-E040-BB89AD4321CC
All rights reserved. Please visit https://medical-data-
models.org/forms/9367
GOG-0258 Vaginal HDR
Intracavitary Radiation Oncology
Form (HDRV)
Header Module
Date form originally completed (m d y)
Date form amended (m d y)
Person amending form, last name
Patient Initials (First, Middle, Last)
Patient Study ID
Person Completing Form, Last Name
Radiation Description
Total Number of Brachytherapy Applications (high
dose rate intracavitary applications delivered to
patient)
Reason treatment ended (intracavitary )
Radiation
Application
Application #1 (Application #1)
Application #2 (Application #2)
Application #3 (Application #3)
Brachytherapy Start Date (m d y)
Isotope Type
Applicator type
Diameter of ovoid/cylinder (cm)
Activity of isotope (Ci)
1 / 2
Number of active dwell positions
Total dwell time (sec)
Vaginal surface dose at apex (Gy)
Vaginal dose at 0.5 cm (Gy)
Isodose length along axis of vagina (Gy)
ICRU Bladder dose (Gy)
ICRU Rectal dose (Gy)
RT Total Dose
Magnification Factor
AP
Lateral
Totals
Physicist's name
Physicist's E-mail address
Radiation Oncologist's name
Radiation Oncologist's E-mail address
Radiation Oncologist's phone number
RT Facility Code
Completed by
Brachytherapy facility
Comments
COMMENTS
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Endometrial Cancer NCT00942357 Treatment - GOG-0258 Vaginal HDR
Intracavitary Radiation Oncology Form (HDRV) - 2843783v1.0
Endometrial Cancer NCT00807768 Treatment - GOG-0249 Vaginal
HDR Intracavitary Radiation Oncology Form - 2759637v1.0
GOG-0249 Vaginal HDR Intracavitary Radiation Oncology
Form
Pelvic Radiation Therapy or Vaginal Implant Radiation
Therapy, Paclitaxel, and Carboplatin in Treating Patients
With High-Risk Stage I or Stage II Endometrial Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=4FB4E3CF-
D77D-4890-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/9369
GOG-0249 Vaginal HDR
Intracavitary Radiation Oncology
Form
Header Module
Date form originally completed (m d y)
Date form amended (m d y)
Person amending form, last name
Patient Initials (First, Middle, Last)
Patient Study ID
Person Completing Form, Last Name
Radiation Description
Total Number of Brachytherapy Applications (high
dose rate intracavitary applications delivered to
patient)
Reason treatment ended (intracavitary )
Radiation
Application
Application #1 (Application #1)
Application #2 (Application #2)
Application #3 (Application #3)
Brachytherapy Start Date (m d y)
Isotope Type
Applicator type
Diameter of ovoid/cylinder (cm)
Activity of isotope (Ci)
1 / 2
Number of active dwell positions
Total dwell time (sec)
Vaginal surface dose at apex (Gy)
Vaginal dose at 0.5 cm (Gy)
Isodose length along axis of vagina (Gy)
ICRU Bladder dose (Gy)
ICRU Rectal dose (Gy)
RT Total Dose
Magnification Factor
AP
Lateral
Totals
Physicist's name
Physicist's E-mail address
Radiation Oncologist's name
Radiation Oncologist's E-mail address
Radiation Oncologist's phone number
RT Facility Code
Completed by
Brachytherapy facility
Comments
COMMENTS
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Endometrial Cancer NCT00807768 Treatment - GOG-0249 Vaginal HDR
Intracavitary Radiation Oncology Form - 2759637v1.0
Fallopian Tube Cancer NCT01167712 On-Study - GOG-0262:
Solid Tumor Evaluation Form (D2M version 3) - 2918350v1.0
GOG-0262: Solid Tumor Evaluation Form (D2M version 3)
Paclitaxel and Carboplatin With or Without Bevacizumab in
Treating Patients With Stage II, Stage III, or Stage IV
Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or
Fallopian Tube Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=6E6221CA-
7BE9-32FA-E040-BB89AD43071B
All rights reserved. Please visit https://medical-data-
models.org/forms/9371
GOG-0262: Solid Tumor Evaluation
Form (D2M version 3)
Header Module
Date form originally completed (m d y)
Date form amended (m d y)
Person amending form, last name
Patient Initials (First, Middle, Last)
Patient Study ID
Person completing form, last name
Target Lesion(s) Evaluation
Did the patient have measurable disease at
baseline
Yes
No
Site of Lesion
Lymph node
Yes
No
Method of Evaluation (*)
Chest X-ray (Chest X-ray)
Clinical Examination (pe) (Clinical
examination)
Ct Scan (CT scan)
Positron Emission Tomography (FDG-
PET)
Mri (MRI (NMR))
Not Evaluated (Not evaluated)
Other (Other)
Pet/ct Scan (PET/CT scan)
Date of evaluation (m d y)
Tumor Size (cm)
1 / 4
Sum of diameters (cm)
Non-target Lesion(s) Evaluation
Were there any non-target lesions reported at
baseline
Yes
No
Site of Lesion
Method of Evaluation (*)
Chest X-ray (Chest X-ray)
Clinical Examination (pe) (Clinical
examination)
Ct Scan (CT scan)
Positron Emission Tomography (FDG-
PET)
Mri (MRI (NMR))
Not Evaluated (Not evaluated)
Other (Other)
Pet/ct Scan (PET/CT scan)
Date of evaluation (m d y)
Follow-up status of lesion
Complete Response (Complete
response)
N/a - Baseline (N/A - Baseline)
Non Cr/ Non Pd (Non-CR/ Non-PD)
Unequivocal Pd (Unequivocal PD)
New Target Lesion(s) At Follow-up
Evaluation
Was the appearance of any new lesions
documented (If no, skip to the Overall Response
section below.)
Yes
No
Site of Lesion
Method of Evaluation (*)
Chest X-ray (Chest X-ray)
Clinical Examination (pe) (Clinical
examination)
Ct Scan (CT scan)
Positron Emission Tomography (FDG-
PET)
Mri (MRI (NMR))
Not Evaluated (Not evaluated)
Other (Other)
Pet/ct Scan (PET/CT scan)
2 / 4
Fallopian Tube Cancer NCT01167712 On-Study - GOG-0262: Solid
Tumor Evaluation Form (D2M version 3) - 2918350v1.0
Date of evaluation (m d y)
Overall Response
Time point response (If q1=N and q8=N)
Biologic Progression Only (Biologic
progression only)
Disease Progression (Disease
progression)
Not Applicable - Baseline (N/A -
Baseline)
No Disease Progression (No disease
progression)
Time point response (If q1=N and q8=N)
Biologic Progression Only (Biologic
progression only)
Disease Progression (Disease
progression)
Not Applicable - Baseline (N/A -
Baseline)
No Disease Progression (No disease
progression)
Time point response (If q1=N and q8=N)
Biologic Progression Only (Biologic
progression only)
Disease Progression (Disease
progression)
Not Applicable - Baseline (N/A -
Baseline)
No Disease Progression (No disease
progression)
Overall best response
Complete Response (CR)
N/a - Baseline (N/A - Baseline)
Not Evaluable (ne) (NE)
Non-measurable Disease At Baseline
(Non-measurable disease at baseline)
Progressive Disease (PD)
Partial Response (PR)
Stable Disease (SD)
Overall best confirmed response
Complete Response (Complete
response)
Not Applicable - Baseline (N/A -
Baseline)
Non-measurable Disease At Baseline
(Non-measurable disease at baseline)
Not Evaluable (Not evaluable)
Partial Response (Partial Response)
Pd (Progressive Disease)
Stable Disease (Stable Disease)
PR First Observed Date
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Fallopian Tube Cancer NCT01167712 On-Study - GOG-0262: Solid
Tumor Evaluation Form (D2M version 3) - 2918350v1.0
Response Confirmed Date, PR
CR First Observed Date
Response Confirmed Date, CR
Comments
Comments
4 / 4
Fallopian Tube Cancer NCT01167712 On-Study - GOG-0262: Solid
Tumor Evaluation Form (D2M version 3) - 2918350v1.0
Leukemia NCT00085124 Registration - CALGB 10201
REGISTRATION WORKSHEET - 2076520v3.0
CALGB 10201 REGISTRATION WORKSHEET
Daunorubicin and Cytarabine With or Without Oblimersen
in Treating Older Patients With Previously Untreated Acute
Myeloid Leukemia
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=B228B8A4-
E2DC-4D1A-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/9372
CALGB 10201 REGISTRATION
WORKSHEET
Protocol Administration
IRB Approval Date (M M DD YYYY)
Responsible Contact
Date Informed Consent Signed (M M DD YYYY)
Phone
Projected Treatment Start Date (M M DD YYYY)
FAX
Patient Demographics/pre-treatment
Characteristics
Patient Initials (Last , First Middle)
Social Security Number
Birth Date (M M DD YYYY)
Patient Hospital No.
Gender
Female (Female)
Male (Male)
Race (Mark all that apply)
American Indian or Alaskan Native
(American Indian or Alaskan Native)
Asian_cdus (Asian)
Black_cdus (Black or African American)
Pacific_islander_cdus (Native Hawaiian
or Other Pacific Islander)
Unknown (Unknown)
White_cdus (White)
Ethnicity (Mark one)
1 / 3
Hispanic_or_latino (Hispanic or Latino)
Non_hispanic (Non-Hispanic)
Unknown (Unknown)
Performance Status (ECOG/Zubrod scale)
Height (cm)
Weight (kg)
Body Surface Area (2 m)
Method of Payment (USA only)
Medicaid (Medicaid)
Medicaid And Medicare (Medicaid and
Medicare)
Medicare (Medicare)
Medicare And Private Insurance
(Medicare and Private Insurance)
Military Sponsored (including Champus
& Tricare) (Military)
No Means Of Payment (no Insurance)
(No means of payment)
Other (Other)
Private Insurance (Private Insurance)
Self Pay (no Insurance) (Self Pay)
Unknown (Unknown)
Military Or Veterans Sponsored Nos
(Veterans Administration Sponsored)
Patient's Zip Code
Country Of Residence (If not USA)
Certification Of Eligibility
Is the patient eligible? (Stratification Factors)
Yes
No
Protocol Design
Type of AML
Aml With Antecedent Mds (AML with
antecedent MDS)
De Novo Aml (de novo AML)
Assigned Treatment Arm
Cytarabine and Daunorubicin
(Cytarabine and Daunorubicin)
G3139 and Cytarabine and Daunorubicin
(G3139 and Cytarabine and
2 / 3
Leukemia NCT00085124 Registration - CALGB 10201 REGISTRATION
WORKSHEET - 2076520v3.0
Daunorubicin)
Initial Patient Consent For Specimen Use
Patient's Initial Consent given for Specimen use
for research on the patient's cancer?
Yes
No
Patient's Initial Consent given for specimen use
for research unrelated to the patient's cancer?
Yes
No
Patient's Initial Consent given for further contact
regarding specimen?
Yes
No
Registration Information
Assigned Participating Group Patient ID
CALGB Patient ID
Registration Date (MM DD YYYY)
Registrar's Signature
Ccrr Module For Calgb 10201 Registration
Worksheet
Main Member Institution
Affiliate/Treating Institution
CALGB Patient ID
Physician of Record
Participating Group Name
3 / 3
Leukemia NCT00085124 Registration - CALGB 10201 REGISTRATION
WORKSHEET - 2076520v3.0
Central Pathology Review Form (NCCTG
Pre-Registration Eligibility Checklist)
NCCTG Pre-Registration Eligibility Checklist - Central
Pathology Review Form
ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment
Optimisation) Study; BIG 2-06/N063D
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=36179FE2-
B4A6-4988-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/9374
Central Pathology Review Form
(NCCTG Pre-Registration Eligibility
Checklist)
Header Module
NCCTG Study No.
Central Lab ID Number*
Patient Initials*
Institution Number*
Institution*
Are data amended*
Yes
No
Person Registering*
CTSU Random. specialist*
Investigator Signature*
Date of Investigator Signature*
I. Snap Frozen Tissue
Assigned Treatment Arm*
Inclusion Criteria*
Adequately Excised (Adequately
excised)
Axilla Dissected (Axilla dissected)
T1c) according to TNM (Axillary node
positive patient OR node negative patient
with a tumour greater than or equal to
1.0 cm in greatest diameter (>)
Blood Draw Kit Availability Checked
1 / 4
(Blood draw kit availability checked)
1 (Eastern Cooperative Oncology Group
(ECOG) performance status <)
Existence Of A Signed Consent Form
(Existence of a signed consent form)
Histologically Confirmed (Histologically
confirmed)
Informed Consent Has Been Signed And
Dated By The Patient And Person
Obtaining Consent (Informed Consent
has been signed and dated by the
patient and person obtaining consent)
Irb Approval At The Registering
Institution (IRB approval at the
registering institution)
Known Hormone Receptor Status (er/pgr
Or Er Alone) (Known hormone receptor
status (ER/PgR or ER alone))
Non-metastatic Operable Primary
Invasive Adenocarcinoma Of The Breast
(Non-metastatic operable primary
invasive adenocarcinoma of the breast)
Overexpression And/or Amplification Of
Her2 In The Invasive Component Of The
Primary Tumor (Overexpression and/or
amplification of HER2 in the invasive
component of the primary tumor)
Patient Has Agreed By Signature Of
Consent Form To Allow Tissue And
Blood Samples To Be Used For
Correlative Science Studies Associated
With This Study (Patient has agreed by
signature of consent form to allow tissue
and blood samples to be used for
correlative science studies associated
with this study)
Patient Questionnaire Booklet Availability
Checked (Patient Questionnaire booklet
availability checked)
Patient Registered In The Mandatory
Translational Research Component Of
This Study At The Time Of Pre-
registration (Patient registered in the
mandatory translational research
component of this study at the time of
pre-registration)
Tissue Portion Of The Consent Form Is
Complete (Tissue portion of the consent
form is complete)
18 years of age, diagnosed with primary,
invasive breast cancer (Woman or man
>)
Age
Performance Status
Fully Active, Able To Carry On All Pre-
disease Performance Without
Restriction. (0)
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Central Pathology Review Form (NCCTG Pre-Registration Eligibility
Checklist)
Restricted In Physically Strenuous
Activity But Ambulatory And Able To
Carry Out Work Of A Light Or Sedentary
Nature, E.g., Light Housework, Office
Work. (1)
Ambulatory And Capable Of All Selfcare
But Unable To Carry Out Any Work
Activities. Up And About More Than 50%
Of Waking Hours. (2)
Capable Of Only Limited Selfcare,
Confined To Bed Or Chair More Than
50% Of Waking Hours. (3)
Completely Disabled. Cannot Carry On
Any Selfcare. Totally Confined To Bed Or
Chair. (4)
Dead (5)
Authorization for use and disclosure of protected
health information signed and dated*
Yes
No
Date of authorization*
Patient has consented to take part in the Quality
of Life Study*
Yes
No
Patient has given permission for
pharmacogenetic testing on her/his blood
samples*
Yes
No
Patient has given permission for
pharmacogenetic testing on her/his tissue
samples*
Yes
No
Patient has consented provide recurrence blood
(if available) samples*
Yes
No
Patient has consented to provide recurrence
tissue (if available) samples*
Yes
No
Patient's Initial Consent given for specimen use
for research unrelated to the patient's cancer?
Yes
No
Patient's initial consent for sharing specimen(s)
with outside researchers.*
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Central Pathology Review Form (NCCTG Pre-Registration Eligibility
Checklist)
Yes
No
4 / 4
Central Pathology Review Form (NCCTG Pre-Registration Eligibility
Checklist)
Pancreatic Cancer NCT00075686 Toxicity -
S0205 Toxicity and Dosage Form - 2035853v3.0
S0205 Toxicity and Dosage Form
S0205 Gemcitabine With or Without Cetuximab as First-
Line Therapy in Treating Patients With Locally Advanced
Unresectable or Metastatic Adenocarcinoma of the
Pancreas
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=A1204548-
9EF3-3AA5-E034-080020C9C0E0
All rights reserved. Please visit https://medical-data-
models.org/forms/9375
S0205 Toxicity and Dosage Form
Header
SWOG Patient ID*
SWOG Study No.*
Registration Step*
Patient Initials (L, F M)
Institution
Affiliate
Physician*
Was patient hospitalized during this reporting
interval?
Yes
No
Disease Status
Date of Last Contact or Death*
Vital Status*
Alive (Alive)
Dead (Dead)
Treatment
Is patient still on protocol treatment?
Yes
No
Reporting interval start date (Reporting interval
start date should be the day after the last full
toxicity assessment date.)*
1 / 5
Reporting interval stop date (First Day of
Reporting Interval)*
Weight
BSA (m?)
Performance Status
Were there any additions, adjustments or
omissions to protocol treatment based on
previous cycle toxicities?*
No (No)
(i.e., The Treatment Was Changed
According To Protocol Guidelines) (Yes,
planned (per protocol guidelines))
(i.e., The Treatment Change Was Not
Part Of Protocol Guidelines) (Yes,
unplanned (not per protocol guidelines))
If Yes, unplanned, Specify therapy, amount and
reason on line below*
Number of weeks treatment given in reports
interval*
Total dose gemcitabine given this reporting
interval (mg)*
Total dose gemcitabine given this reporting
interval (mg)*
Comments
Comments*
Toxicity
Were toxicities assessed for this reporting
interval?*
Yes
No
Date of most recent toxicity assessment*
Toxicity assessed but none were seen*
Yes
No
For Stat Center Use*
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Ca02 (CA02)
Ca20 (CA20)
Ca30 (CA30)
Ca53 (CA53)
Ey01 (EY01)
Ey02 (EY02)
Ey99 (EY99)
Fl01 (FL01)
Fl10 (FL10)
Fl40 (FL40)
Gi00 (GI00)
Gi01 (GI01)
Gi10 (GI10)
Gi20 (GI20)
Gi30 (GI30)
Gi41 (GI41)
Gi60 (GI60)
Gu50 (GU50)
He00 (HE00)
He10 (HE10)
He20 (HE20)
He30 (HE30)
Hm40 (HM40)
Im00 (IM00)
Li00 (LI00)
Li11 (LI11)
Li12 (LI12)
Li20 (LI20)
Li30 (LI30)
Lu00 (LU00)
Lu50 (LU50)
Lu51 (LU51)
Ms00 (MS00)
Nr30 (NR30)
Nr60 (NR60)
Nr92 (NR92)
Pa00 (PA00)
Pa21 (PA21)
Pa22 (PA22)
Pa40 (PA40)
Pa70 (PA70)
Pa80 (PA80)
Pa99 (PA99)
Sk11 (SK11)
Sk16 (SK16)
Sk20 (SK20)
Sk80 (SK80)
Sk90 (SK90)
Toxicity*
Alkaline phosphatase (Alkaline
phosphatase)
Allergy/hypersensitivity
(Allergy/hypersensitivity)
Alopecia (Alopecia)
Anemia (Anemia)
Anorexia (Anorexia)
Arthralgia (Arthralgia)
Bilirubin (Bilirubin)
Cardiac ischemia/infarction (Cardiac
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ischemia/infarction)
Chest pain (Chest pain)
Conjunctivitis (Conjunctivitis)
Constipation (Constipation)
Creatinine (Creatinine)
Diarrhea (Diarrhea)
Dry skin (Dry skin)
Dyspnea (Dyspnea)
Edema (Edema)
Erythema multiforme (Erythema
multiforme)
Eye - other (Eye - other)
Fatigue (Fatigue)
Fever without neutropenia (Fever without
neutropenia)
Headache (Headache)
Hematuria (Hematuria)
Insomnia (Insomnia)
Keratitis (Keratitis)
Leukopenia (Leukopenia)
Liver - clinical (Liver - clinical)
Mouth dryness (Mouth dryness)
Muscle weakness (Muscle weakness)
Myalgia (Myalgia)
Nausea (Nausea)
Neuropathic pain (Neuropathic pain)
Neuropathy - sensory (Neuropathy -
sensory)
Neutropenia (ANC) (Neutropenia (ANC))
Nodal / junctional dysrhythmia (Nodal /
junctional dysrhythmia)
Pain - other, specify below (Pain - other,
specify below)
Pericardial effusion/pericarditis
(Pericardial effusion/pericarditis)
Plural effusion (Plural effusion)
Pneumonitis/infiltrates
(Pneumonitis/infiltrates)
Pruritus (Pruritus)
Rash/desquamation
(Rash/desquamation)
Rigors/chills (Rigors/chills)
Seizure(s) (Seizure(s))
SGOT (AST) (SGOT (AST))
SGPT (ALT) (SGPT (ALT))
Stomatitis/pharyngitis
(Stomatitis/pharyngitis)
Thrombocytopenia (Thrombocytopenia)
Tumor pain (Tumor pain)
Vomiting (Vomiting)
CTC Adverse Event Grade (0-5)
0 (0)
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
Pain - other, specify below*
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Other Toxicities (specify)*
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Breast Cancer NCT00070564 Pre-Study - SOUTHWEST ONCOLOGY
GROUP S0221 BREAST CANCER PRESTUDY FORM - 2046547v3.0
SOUTHWEST ONCOLOGY GROUP S0221 BREAST
CANCER PRESTUDY FORM
Adjuvant Doxorubicin, Cyclophosphamide, and Paclitaxel in
Treating Patients With Breast Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=A6788C86-
182E-5088-E034-0003BA0B1A09
All rights reserved. Please visit https://medical-data-
models.org/forms/9376
SOUTHWEST ONCOLOGY GROUP
S0221 BREAST CANCER
PRESTUDY FORM
Header
SWOG Patient ID
SWOG Study No.
Registration Step
Patient Initials (L, F M)
Institution / Affiliate
Physician
Participating Group Name
Participating Group Study No.
Participating Group Patient ID
Patient Characteristics
Menopausal status (select one)
Above Categories Not Applicable And
Age < 50 (Above not applicable AND age
< 50)
Above Categories Not Applicable And
Age => 50 (Above not applicable AND
age >= 50)
NA-male (NA-male)
Post (prior Bilateral Ovariectomy Or >12
Mo Since Lmp With No Prior
Hysterectomy) (Post)
Pre (<6 Mo Since Lmp And No Prior
Bilateral Ovariectomy And Not On
Estrogen Replacement) (Pre)
Negative urine or serum pregnancy test date
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Height (cm)
Weight (kg)
BSA (m2)
Performance Status
Fully Active, Able To Carry On All Pre-
disease Performance Without
Restriction. (0)
Restricted In Physically Strenuous
Activity But Ambulatory And Able To
Carry Out Work Of A Light Or Sedentary
Nature, E.g., Light Housework, Office
Work. (1)
Ambulatory And Capable Of All Selfcare
But Unable To Carry Out Any Work
Activities. Up And About More Than 50%
Of Waking Hours. (2)
Disease Description
Date of Initial Diagnosis of Primary Tumor
Stage
T1*, N0, M0 (I)
T0, N1, M0 Or T1*, N1, M0 Or T2, N0,
M0 Or T2, N1, M0 Or T3, N0, M0 (II)
T0, N2, M0 Or T1*, N2, M0 Or T2, N2,
M0 Or T3, N1, M0 Or T3, N2, M0 Or T4,
N0, M0 Or T4, N1, M0 Or T4, N2, M0 Or
Any T, N3, M0 (III)
Tumor Laterality (select one)
Bilateral (Bilateral)
Left (Left)
Right (Right)
Pathologic Primary Tumor Size (Maximum
diameter of the invasive component; if multiple
lesions, use longest lesion)
Number of Positive Lymph Nodes (If sentinel
node biopsy and axillary node dissection were
performed, enter the sum of positive nodes.)
ER Status
Negative (ER-)
Positive (ER+)
PgR Status
Negative (PgR-)
Positive (PgR+)
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Was HER-2/neu status determined?
Yes
No
HER2/neu final diagnosis
Equivocal (Equivocal)
Negative (Negative)
Positive (Positive)
Was an Oncotype DX assay performed
Yes
No
Oncotype DX Recurrence Score (If yes)
Laboratory Values
ANC (mcl)
Peripheral Platelet Count (mcl)
Total Bilirubin (mg/dL)
Total Bilirubin ULN (mg/dL)
SGOT (AST) (U/L)
SGOT (AST) ULN (U/L)
SGPT (ALT) (U/L)
SGPT (ALT) ULN (U/L)
Alkaline Phosphatase (U/L)
Serum creatinine (mg/dL)
Creatinine ULN
Ejection fraction
Echocardiogram (Echocardiogram)
Radionuclide Ventriculogram Scan
(Multiple Gated Acquisition (MUGA))
LVEF (%)
LLN
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Collection Date
Collection Date
Collection Date
Collection Date
Collection Date
Collection Date
Collection Date
Prior Treatment Related To This Cancer
Most Extensive Primary Surgery (select one)
Mastectomy, Nos (Mastectomy, NOS)
Partial
Mastectomy/lumpectomy/excisional
Biopsy (Partial
mastectomy/lumpectomy/excisional
biopsy)
Date of Most Extensive Primary Surgery (If
required, use last re-excision date)
Was sentinel node sampling performed?
Yes
No
Sentinal Node Biopsy Date
Sentinel Node Biopsy Results
Negative (Negative)
Positive (Positive)
Was axillary dissection performed?
Yes
No
Date of Axillary Dissection
Number of Lymph Nodes Examined (If sentinal
node biopsy and axillary node dissection were
performed, enter the sum of positive nodes
examined.)
Prior cytotoxic chemotherapy for this breast
cancer?
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Yes
No
Prior anthracycline chemotherapy
Yes
No
Prior taxane chemotherapy?
Yes
No
Prior Radiation Therapy
Yes
No
Date of completion (If yes,)
Ccrr Module For Southwest Oncology
Group S0221 Breast Cancer Prestudy
Form
Comments
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Neuroendocrine Carcinoma NCT00569127 Toxicity - Southwest
Oncology Group S0518 Baseline Abnormalities Form - 2460372v1.0
Southwest Oncology Group S0518 Baseline Abnormalities
Form
Octreotide and Interferon Alfa-2b or Bevacizumab in
Treating Patients With Metastatic or Locally Advanced,
High-Risk Neuroendocrine Tumor
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=0F2473B5-
5A04-6D8C-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/9384
Southwest Oncology Group S0518
Baseline Abnormalities Form
Header
SWOG Patient ID
SWOG Study No.
Registration Step
Patient Initials (L, F M)
Institution/Affiliate
Physician
Participating Group Name
Participating Group Study No.
Participating Group Patient ID
Adverse Events
CTC Adverse Event Term (pre-treatment)
Blood Alkaline Phosphatase Nos
Increased (Alkaline phosphatase)
Hypersensitivity Nos (Allergic
reaction/hypersensitivity (including drug
fever))
Alanine Aminotransferase Increased
(ALT, SGPT (serum glutamic pyruvic
transaminase))
Anorexia (Anorexia)
Aspartate Aminotransferase Increased
(AST, SGOT (serum glutamic oxaloacetic
transaminase))
Blood Bilirubin Increased (Bilirubin
(hyperbilirubinemia))
Bronchospasm, Wheezing
(Bronchospasm, wheezing)
Myocardial Ischaemia (Cardiac
1 / 3
ischemia/infarction)
Cerebral Ischaemia (CNS
cerebrovascular ischemia)
Cough (Cough)
Blood Creatinine Increased (Creatinine)
Cytokine Release Syndrome/acute
Infusion Reaction (Cytokine release
syndrome/acute infusion reaction)
Dehydration (Dehydration)
Diarrhoea Nos (Diarrhea)
Dyspnoea Nos (Dyspnea (shortness of
breath))
Fatigue (Fatigue (asthenia, lethargy,
malaise))
Pyrexia (Fever (in the absence of
neutropenia, where neutropenia is
defined as ANC <1.0 x 10^9/L))
Flatulence (Flatulence)
Hyperglycaemia Nos (Glucose, serum-
high (hyperglycemia))
Hypoglycaemia Nos (Glucose, serum-
low (hypoglycemia))
Dyspepsia (Heartburn/dyspepsia)
Haemorrhagic Stroke (Hemorrhage,
CNS)
Melaena (Hemorrhage, GI - Abdomen
NOS)
Hemorrhage, Gi (Hemorrhage, GI -
Anus)
Hemorrhage, Gi (Hemorrhage, GI -
Colon)
Hemorrhage, Gi (Hemorrhage, GI -
Ileum)
Hemorrhage, Gi (Hemorrhage, GI -
Jejunum)
Hemorrhage, Gi (Hemorrhage, GI - Liver)
Rectal Bleeding (Hemorrhage, GI -
Rectum)
Haematemesis (Hemorrhage, GI -
Stomach)
Hemorrhage, Gi (Hemorrhage, GI -
Upper GI NOS)
Vaginal Haemorrhage (Hemorrhage, GU
- Vagina)
Hemorrhage, Pulmonary/upper
Respiratory (Hemorrhage,
pulmonary/upper respiratory - Lung)
Epistaxis (Hemorrhage, pulmonary/upper
respiratory - Nose)
Hypertension Nos (Hypertension)
Hypotension Nos (Hypotension)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Colon)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Upper
aerodigestive NOS)
Leak (including Anastomotic), Gi (Leak
(including anastomotic), GI - Large
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bowel)
Leucopenia Nos (Leukocytes (total
WBC))
Mucositis/stomatitis (clinical Exam)
(Mucositis/stomatitis (clinical exam) -
Oral cavity)
Stomatitis (Mucositis/stomatitis (clinical
exam) - Pharynx)
Mucositis/stomatitis
(functional/symptomatic)
(Mucositis/stomatitis
(functional/symptomatic) - Oral cavity)
Mucositis/stomatitis
(functional/symptomatic)
(Mucositis/stomatitis
(functional/symptomatic) - Pharynx)
Nasal Cavity/paranasal Sinus Reactions
(Nasal cavity/paranasal sinus reactions)
Nausea (Nausea)
Neutropenia (Neutrophils/granulocytes
(ANC/AGC))
Abdominal Pain Nos (Pain - Abdomen
NOS)
Chest Pain (Pain - Chest/thorax NOS)
Headache Nos (Pain - Head/headache)
Arthralgia (Pain - Joint)
Myalgia (Pain - Muscle)
Platelet Count Decreased (Platelets)
Proteinuria Present (Proteinuria)
Dermatitis Exfoliative Nos
(Rash/desquamation)
Rigors (Rigors/chills)
Thrombosis Nos
(Thrombosis/thrombus/embolism)
Ulceration (Ulceration)
Urticaria Nos (Urticaria (hives, welts,
wheals))
Visceral Arterial Ischaemia (Visceral
arterial ischemia (non-myocardial))
Dysphonia (Voice changes/dysarthria
(e.g., hoarseness, loss or alteration in
voice, laryngitis))
Vomiting Nos (Vomiting)
Weight Decreased (Weight loss)
Culture Wound Negative (Wound
complication, non-infectious)
CTC AE Grade (3.0 1-5)
CTC Adverse Event Term Other (specify using
CTCAE 3.0 terminology)
Comments
Comments
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Lung Cancer NCT00049543 Response - Form 9 -
Relapse/ Progressive Disease Report - 2034459v3.0
Form 9 - Relapse/ Progressive Disease Report
Gefitinib in Treating Patients With Non-Small Cell Lung
Cancer That Has Been Surgically Removed
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=A06B0201-
DAB9-5179-E034-080020C9C0E0
All rights reserved. Please visit https://medical-data-
models.org/forms/9391
Form 9 - Relapse/ Progressive
Disease Report
1. PATIENT INFORMATION
PatientStudyID,CoordinatingGroup*
PatientMedicalRecordNumber*
Patient Initials*
PatientStudyID,ParticipatingGroup*
NCIInstitutionNumber*
PatientSocialSecurityNumber*
InstitutionName*
RegisteredInvestigator*
VisitReportMonthSpecify*
Radiologie
Röntgen Thorax*
Nicht durchgeführt (0)
Negativ (1)
Auffällig, nicht maligne (2)
Positiv (3)
CT/MR/Ultraschall oberes Abdomen*
Nicht durchgeführt (0)
Negativ (1)
Auffällig, nicht maligne (2)
Positiv (3)
Art der Untersuchung*
Ultraschall (1)
CT (2)
MR (3)
Knochen Scan*
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Nicht durchgeführt (0)
Negativ (1)
Auffällig, nicht maligne (2)
Positiv (3)
CT Kopf*
CT Kopf nicht durchgeführt (0)
CT Kopf negativ (1)
CT Kopf auffällig, nicht maligne (2)
CT Kopf positiv (3)
Andere radiologische Untersuchung*
Nicht durchgeführt (0)
Negativ (1)
Auffällig, nicht maligne (2)
Positiv (3)
Art der Untersuchung*
Untersuchungsdatum*
3. DISEASE STATUS
ProgressionDate*
TreatmentAssignmentCode*
NCIC CTG use only
LoggedEntryInitials*
LoggedEntryDate*
CoordinatorReviewInitials*
CoordinatorReviewDate*
PhysicianReviewInitials*
DataEntryInitials*
DataVerificationInitials*
4. RECURRENCE TABLE
Lung (* Local recurrence in the area of tumour
bed or Hilum.)*
Ja
Nein
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Liver*
Ja
Nein
Pleura (to be discussed)*
Ja
Nein
CNS (excluding brain)*
Ja
Nein
Brain*
Ja
Nein
Bone*
Ja
Nein
Opposite Lung*
Ja
Nein
Regional Lymph nodes (** Mediastinal lymph
nodes)*
Ja
Nein
Distant Lymph Nodes (*** Spread of disease
beyond limits specified as same lung or regional
lymph)*
Ja
Nein
Distant Skin or Subcutaneous tissue*
Ja
Nein
Distant Lung Site Ind*
Ja
Nein
Ascites*
Ja
Nein
Pleural Effusion*
Ja
Nein
Local Lung Site Ind*
Ja
Nein
Other*
Ja
Nein
OtherSiteName*
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ProgressionSuspectedBeginDate*
ProgressionDefiniteBeginDate*
ProgressionCriteria*
5. TREATMENT PLAN
6. COMMENTS
Have You attached copies of*
chest x-ray (1)
CT of abdomen/pelvis (2)
pathology/cytology report(s) (3)
other radiology (4)
MRI (5)
Other: specify (6)
8. INVESTIGATOR SIGNATURE
PersonCompletingForm,FirstName*
InvestigatorSignature*
PersonCompletingForm,LastName*
FormCompletionDate,Original*
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Breast Cancer NCT00068601 Pre-Study - Southwest Oncology
Group Ovarian Function Assessment (S0230) - 2170708v3.0
Southwest Oncology Group Ovarian Function Assessment
(S0230)
Goserelin in Preventing Ovarian Failure in Women
Receiving Chemotherapy for Breast Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=BEA6A9CC-
6D74-0D93-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/9397
Southwest Oncology Group Ovarian
Function Assessment (S0230)
Menstrual Cycle
First day of the most current or most recent
menstrual cycle
Have the patient's menstrual periods been absent
for the entire preceding 6 months?
Yes
No
If no, have the patient's menstrual periods been
absent for the entire preceding 3 months?
Yes
No
Laboratory Test
Laboratory lower limit for postmenopausal FSH
Laboratory upper limit for postmenopausal
estradiol
Laboratory upper limit for postmenopausal inhibin
B
FSH level
FSH date
Estradiol level
Estradiol date
Inhibin B level
Inhibin B date (For women with Regular Menses)
Were these hormone levels measured on days 2,
3, or 4 of the menstrual cycle?
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Yes
No
Specify reason
Comments
Ccrr Module For Southwest Oncology
Group Ovarian Function Assessment
(s0230)
SWOG Patient ID
Patient Initials (L, F, M)
Insitution/Affiliate
Physician
Group Name
Group Name
Study NO.
Pt. ID
Date of Assessment
Assessment Time
1 Year (1 Year)
2 Year (2 Year)
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Breast Cancer NCT00068601 Pre-Study - Southwest Oncology
Group BASELINE ASSESSMENT FORM (S0230) - 2170664v3.0
Southwest Oncology Group BASELINE ASSESSMENT
FORM (S0230)
Goserelin in Preventing Ovarian Failure in Women
Receiving Chemotherapy for Breast Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=BEA4E960-
6745-0470-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/9400
Southwest Oncology Group
BASELINE ASSESSMENT FORM
(S0230)
Baseline Conditions
Assessment Date
Conditions
Anxiety Nec (Anxiety/agitation)
Depression Nec (Depression)
Headache Nos (Headache)
Menopausal Symptoms (Hot Flashes)
Libido Decreased (Libido loss)
Sweating Increased (Sweating)
Vulvovaginal Dryness (Vaginal dryness)
CTC GRADE
Other conditions (specify using CTC Terminology
Does the patient have bone mineral loss?
No (No)
Unknown (Unknown)
Yes, Specify Grade (Yes, specify Grade)
Yes, specify Grade
Comments
Ccrr Module For Southwest Oncology
Group Baseline Assessment Form
(s0230)
SWOG Patient ID
Patient Initials (L, F, M)
Insitution/Affiliate
Physician
Group Name
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Study No.
Pt. ID
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BASELINE ASSESSMENT FORM (S0230) - 2170664v3.0
Breast Cancer NCT00090974 Off Treatment -
OFF TREATMENT FORM (OPT) - 2058934v3.0
OFF TREATMENT FORM (OPT)
Quality Of Life Companion Study For JMA27 (NCIC-
MA.27): A Randomized Phase III Trial Of Exemestane
Versus Anastrozole With Or Without Celecoxib In
Postmenopausal Women With Receptor Positive Primary
Breast Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=ABE19FE8-
ADA4-53BD-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/9402
OFF TREATMENT FORM (OPT)
Patient Information
Patient Study ID, Coordinating Group
Patient Initials (first - middle - last)
Patient Medical Record Number
Investigator Name
Institution Name
Registered Investigator (NCI Investigator #)
Off Protocol Therapy
Treatment End Date (yyyy mmm dd)
Reason treatment ended (both components of
study)
Death On Study (Death on-study)
Disease Progression, Relapse During
Active Treatment (Disease progression,
relapse during active treatment)
Other, Specify (Other specify)
Patient Off-treatment For Other
Complicating Disease (Patient off
treatment for other complicating disease)
Patient Withdrawal Or Refusal After
Beginning Protocol Therapy (Patient
withdrawal or refusal after beginning
protocol therapy)
Patient Withdrawal Or Refusal Prior To
Beginning Protocol Therapy (Patient
withdrawal or refusal prior to beginning
protocol therapy)
Toxicity/side Effects/complications
(Toxicity/side effects/complications)
Treatment Completed Per Protocol
Criteria (Treatment completed per
protocol criteria)
Other specify (Reason treatment ended)
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CTC Adverse Event Term
CTC Adverse Event Category
CTC Adverse Event Grade (Grade according to
NCI Common Toxicity Criteria, Version 2.0)
CTC Adverse Event Attribution Code
Definitely (definite)
Possibly (possible)
Probably (probable)
Unlikely (unlikely)
Unrelated (unrelated)
Unblinding
Was study treatment unblinded?
Yes
No
Date study treatment unblinded (yyyy mmm dd)
Header
Patient Study ID, Coordinating Group
Patient Initials (first - middle - last)
Comments
COMMENTS
Investigator Signature
Investigator Signature
Person Completing Form, Last Name
Person Completing Form, First Name
Form Completion Date, Original (yyyy mmm dd)
Ccrr Module For Off Treatment Form (opt)
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Breast Cancer NCT00090974 Transmittal -
PATHOLOGY SUBMISSION REPORT - 2059549v3.0
PATHOLOGY SUBMISSION REPORT
Quality Of Life Companion Study For JMA27 (NCIC-
MA.27): A Randomized Phase III Trial Of Exemestane
Versus Anastrozole With Or Without Celecoxib In
Postmenopausal Women With Receptor Positive Primary
Breast Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=ABE248E1-
B493-53AD-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/9403
PATHOLOGY SUBMISSION
REPORT
Patient Information
Patient Study ID, Coordinating Group (NCIC CTG
Patient Serial Number)
Patient Initials (first - middle - last)
Patient Medical Record Number
Investigator Name
Institution Name
Registered Investigator (NCI Investigator #)
Pathology Submission
Specimen Collection Date - Pathology (yyyy
mmm dd)
Pathology Institution Name (at which the
pathology specimens are held)
Address: Dept./Building
Street name and Number
City
State/Province
Country
Postal Code
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Reviewing Pathologist (Diagnosing Pathologists)
Specimen ID number (Pathology accession
number #)
Comments
COMMENTS
Investigator Signature
Investigator Signature
Person Completing Form, Last Name
Person Completing Form, First Name
Form Completion Date, Original (yyyy mmm dd)
Ccrr Module For Pathology Submission
Report
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Breast Cancer NCT00103181 Treatment - NSABP
PROTOCOL B-39: Chemotherapy Report - 2295346v3.0
NSABP PROTOCOL B-39: Chemotherapy Report
Radiation Therapy in Treating Women Who Have
Undergone Surgery For Ductal Carcinoma In Situ or Stage
I or Stage II Breast Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=E6F98A67-
4163-1881-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/9404
NSABP PROTOCOL B-39:
Chemotherapy Report
Part 1. Patient Treatment Plan Based On
Information Provided At Patient
Registration
NSABP Patient ID
Patient Initials
Date of Registration
Intention to Administer Chemotherapy
Yes
No
Assigned Treatment
Group 1: Whole Breast Irradiation
(Group 1: Whole Breast Irradiation)
Group 2: Partial Breast Irradiation
(Group 2: Partial Breast Irradiation)
Treatment Plan
Chemotherapy Followed By Wbi
(Chemotherapy followed by WBI)
Pbi Followed By Chemotherapy (PBI
followed by chemotherapy)
Pbi Without Chemotherapy (PBI without
chemotherapy)
Wbi Without Chemotherapy (WBI without
chemotherapy)
Part 2. To Be Completed By Institution
Did patient receive adjuvant chemotherapy? (If
no, remaining questions do not apply.)
Yes
No
Chemotherapy Treatment Start Date
Chemotherapy Treatment End Date (date of last
dose)
Adjuvant Chemotherapy (mark all types of
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chemotherapy patient received)
Anthracyclines (Anthracyclines)
Other (Other)
Taxanes (Taxanes)
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Bladder Cancer NCT01224665 Treatment - S1011 Surgeon's Post-Op
Data Form Standard Versus Extended LND (#19886) - 3153895v1.0
S1011 Surgeon's Post-Op Data Form Standard Versus
Extended LND (#19886)
Standard or Extended Pelvic Lymphadenectomy in Treating
Patients Undergoing Surgery for Invasive Bladder Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=940453E3-
437B-BBC7-E040-BB89AD431F9F
All rights reserved. Please visit https://medical-data-
models.org/forms/9409
S1011 Surgeon's Post-Op Data
Form Standard Versus Extended
LND (#19886)
Header Module
SWOG Patient ID
SWOG Study No.
Registration Step
Patient Initials (L, F M)
Date of completion (MM DD YYYY)
Institution/Affiliate
Physician
Participating Group Name
Participating Group Study No.
Participating Group Patient ID
Hospitalization
Protocol Surgery Date (MM DD YYYY)
Discharge Date (MM DD YYYY)
Number of days in ICU
Did patient require an unplanned admission to
ICU at any time
Length of hospital stay (ICU and acute care)
1 / 4
Was TPN used postoperatively (Central/Total
Parenteral Nutrition)
Were enteral tube feedings used postoperatively
Disease Description
Pathologic T Stage
Tumor Invades Superficial Muscularis
Propria (inner Half) (pT2a)
Tumor Invades Deep Muscularis Propria
(outer Half) (pT2b)
Tumor Invades Perivesical Tissue
Microscopically (pT3a)
Tumor Invades Perivesical Tissue
Macroscopically (extravesical Mass)
(pT3b)
Tumor Invades Prostatic Stroma, Uterus,
Vagina (pT4a)
Pathologic N Stage
No Lymph Node Metastasis (pN0)
Single Regional Lymph Node Metastasis
In The True Pelvis (hypogastric,
Obturator, External Iliac Or Presacral
Lymph Node) (pN1)
Multiple Regional Lymph Node
Metastasis In The True Pelvis
(hypogastric, Obturator, External Iliac Or
Presacral Lymph Node Metastasis)
(pN2)
Lymph Node Metastasis To The
Common Iliac Lymph Nodes (pN3)
Lymph Nodes Cannot Be Assessed
(pNX)
Histologic Type (select all that apply)
Adenocarcinoma (Adenocarcinoma)
Micropapillary Transitional Cell
Carcinoma (Micropapillary carcinoma)
Other Specify (Other, specify)
Squamous Cell Carcinoma (Squamous
cell carcinoma)
Urothelial Carcinoma (Urothelial cell
carcinoma)
Other specify
Type of Variant Histology (if selected please
specify)
Adenocarcinoma (< 50%
Adenocarcinoma)
Micropapillary Transitional Cell
Carcinoma (< 50% Micropapillary
carcinoma)
Squamous Cell Carcinoma (< 50%
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Squamous cell carcinoma)
Urothelial Carcinoma (< 50% Urothelial
cell carcinoma)
Adenocarcinoma (>= 50%
Adenocarcinoma)
Micropapillary Transitional Cell
Carcinoma (>= 50% Micropapillary
carcinoma)
Squamous Cell Carcinoma (>= 50%
Squamous cell carcinoma)
Urothelial Carcinoma (>= 50% Urothelial
cell carcinoma)
Complications
Was the assessment done
Other, specify
Other, specify
Start date (MM DD YYYY should be the date of
surgery)
Stop date (MM DD YYYY should be the date of
hospital discharge)
Surgical Complications
Acute Renal Failure (Acute renal failure)
Anastomotic Bowel Leak (Anastomotic
bowel leak)
Hemorrhage Postoperative (Bleeding > 4
units postoperative)
Bowel Obstruction (Bowel obstruction)
Cardiac Event With Cpr (Cardiac event
with CPR)
Cerebrovascular Accident Stroke
(CVA/stroke)
Death Prior To Hospital Discharge
(Death prior to hospital discharge)
Death Within 30 Days Of Cystectomy
(Death within 30 days of cystectomy)
Deep Vein Thrombosis (Deep venous
thrombosis)
Deep Wound Infection (Deep wound
infection)
Failure To Wean From Ventilator Within
48 Hours (Failure to wean from ventilator
within 48 hours)
Ileus (Ileus)
Lymph Leakage/lymphocele Requiring
Intervention (Lymph leakage/lymphocele
requiring intervention)
Myocardial Infarction (Myocardial
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infarction)
Other, Specify (Other, Specify)
Pneumonia (PNEUMONIA)
Pulmonary Embolism (Pulmonary
Embolism)
Intubation (Re-intubation)
Renal Insufficiency Dialysis (Renal
insufficiency requiring dialysis)
Sepsis (Sepsis)
Superficial Wound Infection (Superficial
wound infection)
Symptomatic Lymph
Leakage/lymphocele (Symptomatic
lymph leakage/lymphocele)
Urinary Tract Infection (Urinary tract
infection)
Wound Disruption (Wound disruption)
Surgical Complication Grade
Death (Death of patient)
Interventional Radiology, Therapeutic
Endoscopy, Intubation, Angiography, Or
Operation (Interventional radiology,
therapeutic endoscopy, intubation,
angiography, or operation)
Residual Lasting Disability Requiring
Major Rehabilitation Or Organ Resection
(Residual lasting disability requiring
major rehabilitation or organ resection)
Use Of Intravenous Medication, Total
Parenteral Nutrition (tpn), Enteral
Nutrition, Or Blood Transfusion (Use of
intravenous medication, total parenteral
nutrition (TPN), enteral nutrition, or blood
transfusion)
Use Of Oral Medications Or Bedside
Intervention (Use of oral medications or
bedside intervention)
Transfusions
Total units whole blood
Total units fresh frozen plasma
Total units PRBC
Total units platelets
Comments
Comments
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Breast Cancer NCT00090974 Follow-Up - FORM 9 - RECURRENCE
AND CONTRALATERAL BREAST CANCER REPORT - 2058833v3.0
FORM 9 - RECURRENCE AND CONTRALATERAL
BREAST CANCER REPORT
Quality Of Life Companion Study For JMA27 (NCIC-
MA.27): A Randomized Phase III Trial Of Exemestane
Versus Anastrozole With Or Without Celecoxib In
Postmenopausal Women With Receptor Positive Primary
Breast Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=ABE31B86-
C179-5457-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/9410
FORM 9 - RECURRENCE AND
CONTRALATERAL BREAST
CANCER REPORT
Patient Information
Patient Study ID, Coordinating Group
Patient Initials (first - middle - last)
Patient Medical Record Number
Investigator Name
Institution Name
Registered Investigator (NCI Investigator #)
Disease Status
Has the patient been diagnosed with first local-
regional recurrence?
Yes
No
Date of First Local-Regional Progression (yyyy
mmm dd)
Has the patient been diagnosed with first distant
recurrence/progression?
Yes
No
Date of First Distant Progression (yyyy mmm dd)
Has the patient been diagnosed with contralateral
breast cancer? (since submission of the last
follow-up form)
Yes
No
Date of Diagnosis of Contralateral Breast Cancer
1 / 4
(yyyy mmm dd)
Supporting Documentation
Comments
COMMENTS
Investigator Signature
Investigator Signature
Person Completing Form, Last Name
Person Completing Form, First Name
Form Completion Date, Original (yyyy mmm dd)
Header
Patient Study ID, Coordinating Group
Patient Initials (first - middle - last)
Recurrence Table
Site(s) Local-Regional, Ipsilateral Breast (Check)
Yes
No
Definite Date (yyyy-mmm-dd)
Site(s) Local-Regional, Chest Wall (Check)
Yes
No
Site(s) Local-Regional, Regional Nodes/axilla
(Check)
Yes
No
Site(s) Distant, Lung (Check)
Yes
No
Site(s) Distant, Liver (Check)
Yes
No
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Site(s) Distant, Bone (Check)
Yes
No
Site(s) Distant, Central Nervous System (Check)
Yes
No
Site(s) Distant, Bone Marrow (Check)
Yes
No
Site(s) Distant, Ascites (Check)
Yes
No
Site(s) Distant, Pleural Effusion (Check)
Yes
No
Site(s) Distant, First Other, Specify (Check)
Yes
No
Site(s) Distant, Second Other, Specify (Check)
Yes
No
Site(s) Distant, Second Other, Specify
Site(s) Distant, Second Other, Specify
Suspected Date (yyyy-mmm-dd)
Suspected Date (yyyy-mmm-dd)
Suspected Date (yyyy-mmm-dd)
Suspected Date (yyyy-mmm-dd)
Suspected Date (yyyy-mmm-dd)
Suspected Date (yyyy-mmm-dd)
Suspected Date (yyyy-mmm-dd)
Suspected Date (yyyy-mmm-dd)
Suspected Date (yyyy-mmm-dd)
Suspected Date (yyyy-mmm-dd)
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Suspected Date (yyyy-mmm-dd)
Suspected Date (yyyy-mmm-dd)
Definite Date (yyyy-mmm-dd)
Definite Date (yyyy-mmm-dd)
Definite Date (yyyy-mmm-dd)
Definite Date (yyyy-mmm-dd)
Definite Date (yyyy-mmm-dd)
Definite Date (yyyy-mmm-dd)
Definite Date (yyyy-mmm-dd)
Definite Date (yyyy-mmm-dd)
Definite Date (yyyy-mmm-dd)
Definite Date (yyyy-mmm-dd)
Definite Date (yyyy-mmm-dd)
Ccrr Module For Form 9 - Recurrence And
Contralateral Breast Cancer Report
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Breast Cancer NCT00090974 Follow-Up - FORM 9 - RECURRENCE
AND CONTRALATERAL BREAST CANCER REPORT - 2058833v3.0
Breast Cancer NCT00127205 Follow-Up - SOUTHWEST
ONCOLOGY GROUP S0307 FOLLOW UP FORM - 2286366v3.0
SOUTHWEST ONCOLOGY GROUP S0307 FOLLOW UP
FORM
Zoledronate, Clodronate, or Ibandronate in Treating Women
Who Have Undergone Surgery for Stage I, Stage II, or
Stage III Breast
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=DE914057-
9DF7-6A08-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/9416
SOUTHWEST ONCOLOGY GROUP
S0307 FOLLOW UP FORM
Header
SWOG Patient ID
SWOG Study No.
Registration Step
Patient Initials (L, F M)
Institution/Affiliate
Physician
Participating Group Name
Participating Group Study No.
Participating Group Patient ID
Vital Status
Vital Status
Alive (Alive)
Dead (Dead)
Date of last contact or death
Has the patient had a documented clinical
assessment for this cancer (since submission of
the previous follow-up form?)
Yes
No
Date of Last Clinical Assessment (If Yes,)
Has the patient developed a first relapse or
progression that has not been previously
1 / 2
reported?
Yes
No
Date of Relapse or Progression (If Yes,)
Site(s) of Relapse or Progression
Has a new primary cancer or MDS been
diagnosed that has not been previously reported?
(myelodysplastic syndrome)
Yes
No
Date of Diagnosis (If Yes,)
New Primary Site
Has the patient received any non-protocol cancer
therapy (prior to progression/relapse) not
previously reported?
Yes
No
Date of First Non-Protocol Therapy (If yes,)
Agent Name (s:)
Has the patient experienced (prior to treatment
for progression or relapse or a second primary,
and prior to
non-protocol treatment) any severe (grade >=3)
long term toxicity that has not been previously
reported?
Yes
No
Adverse Events and Grades (If Yes,)
Comments
Comments
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Breast Cancer NCT00127205 Follow-Up - SOUTHWEST ONCOLOGY
GROUP S0307 FOLLOW UP FORM - 2286366v3.0
Breast Cancer NCT00090974 Follow-Up - FORM 5M
- MINIMAL FOLLOW-UP REPORT - 2064122v3.0
FORM 5M - MINIMAL FOLLOW-UP REPORT
Quality Of Life Companion Study For JMA27 (NCIC-
MA.27): A Randomized Phase III Trial Of Exemestane
Versus Anastrozole With Or Without Celecoxib In
Postmenopausal Women With Receptor Positive Primary
Breast Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=ABF3BD71-
F788-63E3-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/9417
FORM 5M - MINIMAL FOLLOW-UP
REPORT
Patient Information
Patient Study ID, Coordinating Group
Patient Initials (first - middle - last)
Patient Medical Record Number
Investigator Name
Institution Name
Registered Investigator (NCI Investigator #)
Status
Date of Last Contact or Death (yyyy mmm dd)
Patient's Vital Status
Alive (Alive)
Dead (Dead)
Primary Cause of Death
Cardiovascular death (specify)
(Cardiovascular death (specify))
Due To Other Cause, Specify (Due to
other cause, describe primary cause of
death)
Due To Protocol Treatment (Due to
protocol treatment)
Due To This Disease (Due to this
disease)
Due to other cause, describe primary cause of
death
Due to other cause, describe primary cause of
death
Has the patient been diagnosed with first local-
regional recurrence? (since submission of the
1 / 3
last follow-up form)
Yes
No
Date of First Local-Regional Progression (yyyy
mmm dd)
Has the patient been diagnosed with first distant
recurrence/progression?
Yes
No
Date of First Distant Progression (yyyy mmm dd)
Has the patient been diagnosed with contralateral
breast cancer? (since submission of the last
follow-up form)
Yes
No
Date of Diagnosis of Contralateral Breast Cancer
(yyyy mmm dd)
Other Malignancies Or Myelodysplastic
Syndrome
Has a new primary cancer or MDS been
diagnosed that has not been previously reported?
Yes
No
Date of diagnosis (yyyy mmm dd)
Malignancy Type
Site(s) of New Primary
Describe (new primary cancer or MDS)
Header
Patient Study ID, Coordinating Group
Patient Initials (first - middle - last)
Comments
COMMENTS
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Investigator Signature
Investigator Signature
Person Completing Form, Last Name
Person Completing Form, First Name
Form Completion Date, Original (yyyy mmm dd)
Ccrr Module For Form 5m - Minimal
Follow-up Report
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Breast Cancer NCT00090974 Follow-Up - FORM 5M - MINIMAL
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Breast Cancer NCT00075764 Treatment - SOUTHWEST ONCOLOGY
GROUP  TREATMENT SUMMARY FORM (S0226) - 2174161v3.0
SOUTHWEST ONCOLOGY GROUP  TREATMENT
SUMMARY FORM (S0226)
S0226 Anastrozole With or Without Fulvestrant as First-
Line Therapy in Postmenopausal Women With Metastatic
Breast Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=C3227788-
83F0-2769-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/9418
SOUTHWEST ONCOLOGY GROUP
TREATMENT SUMMARY FORM
(S0226)
Header
SWOG Patient ID
SWOG Study No.
Registration Step
Patient Initials (L, F M)
Institution/Affiliate
Physician (Groups other than SWOG)
Group Name
Study No.
Pt. ID
Status
Date of Last Contact or Death
Vital Status
Alive (Alive)
Dead (Dead)
Has the patient progressed per the definition in
Section 10.0 of the protocol? (Submit Follow-up
Form and Follow-up Tumor Assessment Form)
No (no)
Unknown (Unknown)
Yes (yes)
Which treatment did the patient receive?
Arm 1 (Arm 1)
Arm 2 (Arm 2)
1 / 2
Were there any dose modifications or
additions/omissions to protocol treatment since
last form?
No (No)
Yes, Planned (i.e., The Treatment Was
Changed According To Protocol
Guidelines) (Yes, planned)
Yes, Unplanned (i.e., The Treatment
Change Was Not Part Of Protocol
Guidelines) (Yes, unplanned)
Cycle Number
Treatment Start Date
Did the patient receive fulvestrant this cycle?
(Arm 2 only)
Yes
No
Did the patient receive fulvestrant this cycle?
(Arm 2 only)
Yes
No
Comments
Ccrr Module For Southwest Oncology
Group Treatment Summary Form (s0226)
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Breast Cancer NCT00093795 Pathology - NSABP
Worksheet for Pregnancy Event Form - 3006894v1.0
NSABP Worksheet for Pregnancy Event Form
Combination Chemotherapy in Treating Women Who Have
Undergone Surgery for Node-Positive Breast Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=7EDC1E5D-
3817-778E-E040-BB89AD432648
All rights reserved. Please visit https://medical-data-
models.org/forms/9419
NSABP Worksheet for Pregnancy
Event Form
Header
Patient Initials
NSABP Patient ID
Unnamed 1
Patient Initials
NSABP Patient ID
Treating Investigator
Person Completing Form (Reporter)
Phone (Reporter)
Fax (Reporter)
E-mail (Reporter)
Date Form Completed
Cancer Treatment Prior To Pregnancy
Diagnosis
Classification of NSABP Protocol Patient
Male Partner Of Pregnant Or Post-
partum Woman (Male partner of
pregnant or post-partum woman)
Pregnant Or Post-partum Woman
(Pregnant or post-partum woman)
Cancer Treatment Prior to Pregnancy Diagnosis
(Describe most recent cancer treatment prior to
pregnancy diagnosis; please include dates of
treatment)
1 / 3
Relevant Past Medical History of Pregnant
Individual (e.g., diabetes, surgery, concomitant
medications)
Tests & Procedures Relevant To
Pregnancy
Has the patient had any tests or procedures
performed relevant to pregnancy
Yes
No
Tests/Procedure (Specify)
Date of test
Result of test
Abnormal (Abnormal)
Normal (Normal)
Abnormal (If abnormal, specify)
Pregnancy Information
Pregnancy prevention measures
Yes
No
If yes, specify
Date of last menstrual period
Weeks of gestation when pregnancy first
confirmed
Estimated delivery
Pregnancy Status/pregnancy Outcome
Pregnancy Status
Pregnancy Ongoing (Pregnancy
ongoing)
Unknown (Unknown)
Pregnancy Outcome
Delivery (Delivery)
Ectopic Pregnancy (Ectopic Pregnancy)
Induced Abortion (Induced abortion)
Spontaneous Abortion (Spontaneous
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Pregnancy Event Form - 3006894v1.0
Abortion)
Date (Provide date of selected outcome)
Fetal/baby Outcome
Fetal/Baby Outcome
Footer Module
Comments
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Breast Cancer NCT00103233 Treatment - SOUTHWEST
ONCOLOGY GROUP S0347 TREATMENT FORM - 2285534v3.0
SOUTHWEST ONCOLOGY GROUP S0347 TREATMENT
FORM
Vinorelbine With or Without Trastuzumab in Treating
Women With Progressive Metastatic Breast Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=DDB236B7-
9161-179E-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/9420
SOUTHWEST ONCOLOGY GROUP
S0347 TREATMENT FORM
Header
SWOG Patient ID
SWOG Study No.
Registration Step
Cycle Number (see instructions)
Patient Initials (L, F M)
Institution/Affiliate
Physician
Participating Group Name
Participating Study No.
Participating Patient ID (Instructions: Please
complete this form after each cycle 1 cycle = 4
weeks. All dates are MONTH, DAY, YEAR.
Explain any blank dates or fields in a Comments
section. Place an X in appropriate boxes. Circle
AMENDED items in red and write AMENDED
across top of form.)
Status
Date of Last Contact or Death
Vital Status
Alive (Alive)
Dead (Dead)
Has the patient progressed per the definition in
Section 10.0 of the protocol?
1 / 2
Yes
No
Treatment For This Cycle
Assigned Treatment Arm
Arm 1 (Arm 1)
Arm 2 (Arm 2)
Cycle start date
Weight first day this cycle
Date of last treatment for this cycle
BSA first day this cycle
Were there any dose modifications or
additions/omissions to protocol treatment?
No (No)
Yes, Planned (i.e., The Treatment Was
Changed According To Protocol
Guidelines) (Yes, planned)
Yes, Unplanned (i.e., The Treatment
Change Was Not Part Of Protocol
Guidelines) (Yes, unplanned)
Unnamed question 2
Day 1 (Day 1)
Day 15 (Day 15)
Day 22 (Day 22)
Day 8 (Day 8)
Unnamed question 3
Trastuzumab (Trastuzumab)
Vinorelbine (Vinorelbine)
Dose
Comments
Comments
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Breast Cancer NCT00103233 Follow-Up - SOUTHWEST
ONCOLOGY GROUP S0347 FOLLOW UP FORM - 2285690v3.0
SOUTHWEST ONCOLOGY GROUP S0347 FOLLOW UP
FORM
Vinorelbine With or Without Trastuzumab in Treating
Women With Progressive Metastatic Breast Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=DDEE7C0B-
FD5A-6513-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/9423
SOUTHWEST ONCOLOGY GROUP
S0347 FOLLOW UP FORM
Header
SWOG Patient ID
SWOG Study No.
Registration Step
Patient Initials (L, F M)
Institution/Affiliate
Physician (Participating Group Name)
Participating Group Study No.
Participating Group Patient ID
Vital Status
Vital Status
Alive (Alive)
Dead (Dead)
Date of last contact or death
Has the patient had a documented clinical
assessment for this cancer (since submission of
the previous follow-up form)
Yes
No
Date of Last Clinical Assessment: (If Yes,)
Has the patient developed a first relapse or
progression that has not been previously
reported?
Yes
No
1 / 2
Date of Relapse or Progression: (If Yes,)
Site(s) of relapse or progression
Has a new primary cancer or MDS been
diagnosed that has not been previously reported?
(myelodysplastic syndrome)
Yes
No
Date of Diagnosis (If Yes,)
New Primary Site
Has the patient received any non-protocol cancer
therapy (prior to progression/relapse) not
previously reported?
Yes
No
Date of First Non-Protocol Therapy (If Yes,)
Agent Name (s:)
Has the patient experienced (prior to treatment
for progression or relapse or a second primary,
and prior to non-protocol treatment) any severe
(grade >=3) long term toxicity that has not been
previously reported?
Yes
No
Adverse Events and Grades (If Yes,)
Comments
Comments
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Breast Cancer NCT00103233 Follow-Up - SOUTHWEST ONCOLOGY
GROUP S0347 FOLLOW UP FORM - 2285690v3.0
Breast Cancer NCT00090974 Transmittal - WHOLE BLOOD for
SERUM/DNA BANKING SUBMISSION REPORT - 2058882v3.0
WHOLE BLOOD for SERUM/DNA BANKING
SUBMISSION REPORT
Quality Of Life Companion Study For JMA27 (NCIC-
MA.27): A Randomized Phase III Trial Of Exemestane
Versus Anastrozole With Or Without Celecoxib In
Postmenopausal Women With Receptor Positive Primary
Breast Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=ABE25A45-
A7B6-53B4-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/9430
WHOLE BLOOD for SERUM/DNA
BANKING SUBMISSION REPORT
Patient Information
Patient Study ID, Coordinating Group (NCIC CTG
Patient Serial Number)
Patient Initials (first - middle - last)
Patient Medical Record Number
Investigator Name
Institution Name
Registered Investigator (NCI Investigator #)
Whole Blood Submission
Specimen Collection Date (Whole Blood in EDTA)
Unnamed question (specimen type) (check one)
6-month Specimen (6-month Specimen)
Baseline Specimen (Baseline Specimen)
Comments
COMMENTS
Investigator Signature
Investigator Signature
Person Completing Form, Last Name
Person Completing Form, First Name
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Form Completion Date, Original (yyyy mmm dd)
Ccrr Module For Whole Blood For
Serum/dna Banking Submission Report
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Breast Cancer NCT00090974 Transmittal - WHOLE BLOOD for
SERUM/DNA BANKING SUBMISSION REPORT - 2058882v3.0
Drug/Agent Toxicity by Tissue/Organ NCT00057811 Follow-Up -
ANHL01P1 Off Protocol Therapy Follow-Up Form - 2090921v3.0
ANHL01P1 Off Protocol Therapy Follow-Up Form
Rituximab, Rasburicase, and Combination Chemotherapy
in Treating Young Patients With Newly Diagnosed
Advanced B-Cell Leukemia or Lymphoma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=B9F521CB-
5F88-2558-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/9431
ANHL01P1 Off Protocol Therapy
Follow-Up Form
Header
Institution
CRA Name
COG Number
Study Number
Today's date
Date worksheet entered into RDE
Patient Status Information
Date of Previous Contact (1. Calculate the
previous contact date from the date of the last
reporting period submitted or the date of the last
OPTF report submitted.)
date of previous contact according to the patient's
records (If the patient's records reflect a date of
last contact which disagrees with the displayed
date of previous contact, enter the)
Please provide text to explain the possible nature
of the disagreement. (2. This must be answered if
a date was provided for the previous question.)
Date of Last Contact (Enter the date of last
confirmed patient contact. 'Contact' includes, but
is not limited to, an office visit, a letter from the
family or phone contact.)
Life Status (at the Date of Last Contact)
Alive (Alive)
Dead (Dead)
Disease Status at the end of the reporting period
1 / 3
(Select one)
Disease Present (Disease present)
No Disease Present (No disease
present)
Unknown (Unknown)
Has patient received anti-cancer therapy since
the last OPTF report submission? (1. Required.)
Yes
No
select the type of treatment from this list (1. If 'TX'
is answered 'Yes', this must be answered.)
Chemotherapy (Chemotherapy)
Other Therapy (Other)
Surgery (Surgery)
Transplant (Transplant)
External Beam Radiation (XRT)
describe [anti-cancer therapy] (If the patient
received anti-cancer therapy during this reporting
period,)
Events Of Interest
Did the patient relapse or experience disease
progression during the reporting period? (1.
Required.)
No (No)
Unknown (Unknown)
Yes (Yes)
date of relapse or progression (If yes,)
Did the patient experience a second malignant
neoplasm during the reporting period? (1.
Required.)
No (No)
Unknown (Unknown)
Yes (Yes)
date of second malignant neoplasm (If yes,)
Did the patient withdraw consent for follow-up at
the end of the reporting period? (Note:
Withdrawal of consent is to be coded only when
the patient no longer wants to participate in the
study and asks that data no longer be submitted.)
Yes
No
Was the patient confirmed lost to follow-up at the
end of the reporting period? (1. Required.)
Yes
No
2 / 3
Drug/Agent Toxicity by Tissue/Organ NCT00057811 Follow-Up -
ANHL01P1 Off Protocol Therapy Follow-Up Form - 2090921v3.0
Was the patient enrolled on another COG
therapeutic study at the end of the reporting
period? (1. Required.)
Yes
No
COMMENT (Please enter any data, regarding
your patient, you think would be helpful for the
Study Chair.)
Ccrr Module For Anhl01p1 Off Protocol
Therapy Follow-up Form
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Drug/Agent Toxicity by Tissue/Organ NCT00057811 Follow-Up -
ANHL01P1 Off Protocol Therapy Follow-Up Form - 2090921v3.0
Brain and Central Nervous System Tumors NCT00053963 Off Treatment - Off
Protocol Therapy Follow-up (OPTF) Report (Master) [ADVL0212] - 2077867v3.0
Off Protocol Therapy Follow-up (OPTF) Report (Master)
[ADVL0212]
FR901228 in Treating Children With Refractory or
Recurrent Solid Tumors or Leukemia
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=B24316ED-
D5DA-16A3-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/9433
Off Protocol Therapy Follow-up
(OPTF) Report (Master) [ADVL0212]
Header
Institution
CRA Name
COG Number
Study Number (All studies for which the patient
has registered will appear on the RDE Screen.)
Today's date
Date worksheet entered into RDE
Patient Status Information
Date of Previous Contact (If the patient's records
reflect a date of last contact which disagrees with
the displayed date of previous contact,)
enter the date of previous contact according to
the patient's records (mm/dd/yyyy)
Please provide some text to explain the possible
nature of the disagrement.
Date of Last Contact (mm/dd/yyyy)
Life Status at the Date of Last Contact
Alive (Alive)
Dead (Dead)
Disease Status at the end of the reporting period
(Select one)
Eradicated But Recurred Locally And
Distantly (Disease present)
Residual Disease After Prior Therapy
(No disease present)
Unknown (Unknown)
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Has patient received anti-cancer therapy since
the last OPTF report submission? (If the patient
received anti-cancer therapy during this reporting
period,)
Yes
No
select the type of treatment from this list (If the
patient received anti-cancer therapy during this
reporting period,)
Anti-retroviral Therapy (Anti-retroviral
Therapy)
Antisense (Antisense)
Bone Marrow Transplant (Bone Marrow
Transplant)
Chemotherapy (Chemotherapy)
Chemotherapy Non-cytotoxic
(Chemotherapy Non-cytotoxic)
Extensive Radiation (Extensive
Radiation)
Gene Therapy (Gene Therapy)
Immunotherapy (Immunotherapy)
Limited Radiation (Limited Radiation)
No Prior Therapy (No Prior Therapy)
Oncolytic Virotherapy (Oncolytic
Virotherapy)
Other Therapy (Other)
Prior Therapy (nos) (Prior Therapy
(NOS))
Radiation (nos) (Radiation (NOS))
Stem Cell Transplant (Stem Cell
Transplant)
Surgery (Surgery)
Transplant (Transplant)
Vaccine (Vaccine)
External Beam Radiation (XRT)
describe [anti-cancer therapy]
Events Of Interest
Did the patient relapse or experience disease
progression during the reporting period? (If yes,)
No (No)
Unknown (Unknown)
Yes (Yes)
date of relapse or progression (mm/dd/ccyy)
Did the patient experience a second malignant
neoplasm during the reporting period? (If yes,)
No (No)
Unknown (Unknown)
Yes (Yes)
date of second malignant neoplasm
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(mm/dd/ccyy)
Did the patient withdraw consent for follow-up at
the end of the reporting period? (Note:
Withdrawal of consent is to be coded only when
the patient no longer wants to participate in the
study and asks data no longer be submitted.)
Yes
No
Was the patient confirmed lost to follow-up at the
end of the reporting period?
Yes
No
Was the patient enrolled on another COG
therapeutic study at the end of the reporting
period? (If disease status was evaluated during
this interval,)
Yes
No
what was the patient's response?
Complete Response (Complete
Response)
Death Prior To Completion Of Protocol
Criteria (Early death)
Insufficient Evaluation (Not Evaluable)
Partial Response (Partial Response)
Progressive Disease (PD)
Partial Response (Progressive Disease)
Stable Disease (Stable Disease)
Did patient receive radiation therapy during this
reporting period? (If yes,)
Yes
No
specify sites [radiation therapy]
Did patient receive PBSC transfusion? (If yes,)
Yes
No
what date(s) did the transfusion(s) take place?
COMMENT
Ccrr Module For Off Protocol Therapy
Follow-up (optf) Report (master)
[advl0212]
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Brain and Central Nervous System Tumors NCT00053963 Off Treatment - Off
Protocol Therapy Follow-up (OPTF) Report (Master) [ADVL0212] - 2077867v3.0
Lung Cancer NCT01336894 Quality of Life - ACOSOG-
Z4099 Patient Questionnaire Form - 3180120v1.0
ACOSOG-Z4099 Patient Questionnaire Form
Surgery With or Without Internal Radiation Therapy
Compared With Stereotactic Body Radiation Therapy in
Treating Patients With High-Risk Stage I Non-Small Cell
Lung Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=98F70399-
A5F3-0EAF-E040-BB89AD430DD7
All rights reserved. Please visit https://medical-data-
models.org/forms/9437
ACOSOG-Z4099 Patient
Questionnaire Form
Header Module
Protocol Number
Patient ID
Patient Initials (L F M)
Institution Number
Institution
Are data amended (check one if data amended,
please circle in red when using paper forms)
Yes
No
Visit
Visit (check one)
12 Months After Surgery/completion Of
Stereotactic Body Radiation Therapy (12
months after surgery/completion of
SBRT)
24 Months After Surgery/completion Of
Stereotactic Body Radiation Therapy (24
months after surgery/completion of
SBRT)
3 Months After Surgery/completion Of
Stereotactic Body Radiation Therapy (3
months after surgery/completion of
SBRT)
4 Weeks After Surgery/completion Of
Stereotactic Body Radiation Therapy (4
weeks after surgery/completion of SBRT)
6 Months After Surgery/completion Of
Stereotactic Body Radiation Therapy (6
months after surgery/completion of
SBRT)
Registration (Registration)
Quality Of Life Information
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Were any of the Patient Questionnaires
completed (check one)
Yes
No
Questionnaire (If yes check all that were
completed)
Eq-5d (EQ-5D)
Linear Analogue Self Assessment
(LASA)
Lung Cancer Symptom Scale (LCSS)
Ucsd Shortness Of Breath (UCSD
Shortness of Breath)
Reason Questionnaire was not Completed (If no
check one)
Other (Other)
Patient Not Given Booklet By Staff
(Patient not given booklet by staff)
Patient Refused (Patient refused)
Unable To Accomodate Disability Or
Language Needs (Unable to accomodate
disability or language needs)
Please explain (End Form)
Specify
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Lung Cancer NCT01336894 Quality of Life - ACOSOG-Z4099 Patient
Questionnaire Form - 3180120v1.0
Breast Cancer NCT00408408 Follow-Up - NSABP
Protocol B-40: Follow-Up Form - 2511785v1.0
NSABP Protocol B-40: Follow-Up Form
A Randomized Phase III Trial of Neoadjuvant Therapy in
Patients With Palpable and Operable Breast Cancer
Evaluating the Effect on Pathologic Complete Response
(pCR) of Adding Capecitabine or Gemcitabine to Docetaxel
When Administered Before AC With or Without
Bevacizumab and Correlative Science Studies Attempting
to Identify Predictors of High Likelihood for pCR With Each
of the Regimens
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=1B7E56A5-
1088-1102-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/9440
NSABP Protocol B-40: Follow-Up
Form
Header
Patient Initials (Last First Middle)
NSABP Patient ID
Vital Status
Patient's Vital Status
Alive (Alive)
Dead (Dead)
Date of Last Contact or Death (month day year)
Source of Survival Information (if alive)
Documentation Of Hospital Or Clinic Visit
(Documentation of hospital or clinic visit)
Other (Other)
Phone Contact To Patient (Phone
contact to patient)
Other,
Primary Cause of Death (if dead)
Due To Other Cause (Due to other
cause)
Due To Protocol Treatment (Due to
protocol treatment)
Due To This Disease (Due to this
disease)
Unknown (Unknown)
Describe Cause of Death (attach documentation)
Was there evidence of recurrence at the time of
death
No (No)
Unknown (Unknown)
Yes (Yes)
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Type of Evidence (if yes)
Autopsy (Autopsy)
Clinical (Clinical)
Cancer Follow-up Status
Has the patient had a documented clinical
assessment for this cancer (since submission of
the last follow-up form)
Yes
No
Date of Last Clinical Assessment (if applicable)
First Local-regional Recurrence
Has the patient been diagnosed with first local-
regional recurrence
Yes
No
Date of First Local-Regional Recurrence (if
applicable)
Site(s) of First Local-Regional Recurrence (mark
all ipsilateral sites that apply)
Axilla (Axilla)
Axillary Nodes (Axillary nodes)
Chest Wall (Chest wall)
Infraclavicular Nodes (Infraclavicular
nodes)
Internal Mammary (Internal mammary)
Ipsilateral Breast (Ipsilateral breast)
Supraclavicular Nodes (Supraclavicular
nodes)
First Distant Recurrence
Has the patient been diagnosed with first distant
recurrence/progression? (since submission of the
last follow-up form)
Yes
No
Date of First Distant Recurrence (if applicable)
Site(s) of First Distant Recurrence
New Primary Cancer Or Mds
Has a new primary cancer or MDS been
diagnosed that has not been previously reported?
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Yes
No
Date of Diagnosis (if applicable)
Site(s) of New Primary
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Breast Cancer NCT00408408 Pathology - NSABP Protocol B-40 -
Worksheet for Calculation of Residual Cancer Burden - 2734029v1.0
NSABP Protocol B-40 - Worksheet for Calculation of
Residual Cancer Burden
A Randomized Phase III Trial of Neoadjuvant Therapy in
Patients With Palpable and Operable Breast Cancer
Evaluating the Effect on Pathologic Complete Response
(pCR) of Adding Capecitabine or Gemcitabine to Docetaxel
When Administered Before AC With or Without
Bevacizumab and Correlative Science Studies Attempting
to Identify Predictors of High Likelihood for pCR With Each
of the Regimens
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=47C6C52F-
D25C-1865-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/9443
NSABP Protocol B-40 - Worksheet
for Calculation of Residual Cancer
Burden
Header
Patient Initials (Last First Middle)
NSABP Patient ID
Items Related To Calculation Of Residual
Cancer Burden
Primary Tumor Bed Area (Identification of cross-
sectional dimensions of residual bed, considering
gross and adjacent microscopic tumor. If no
residual tumor, measurements = 0.)
Primary Tumor Bed Area
Overall Cancer Cellularity (Estimate of proportion
of residual tumor bed area that is involved by
cancer. If no residual tumor, % = 0)
Percentage of Cancer that is in situ Disease
(Estimate of the proportion of residual tumor bed
area that is in situ component. If no residual
tumor, % = 0)
Number of Positive Lymph Nodes (Consider
axillary nodes from applicable post-neoadjuvant
procedures: sentinel node biopsy and/or surgical
evaluation of axilla. If no positive axillary nodes,
number = 0.)
Diameter of largest metastasis  (Consider axillary
nodes from applicable post-neoadjuvant
procedures: sentinel node biopsy and/or surgical
evaluation of axilla. If no positive axillary nodes,
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largest metastasis = 0)
Units
Millimeters (mm)
Footer
Comments
Person Completing Form
Date Form Completed
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Breast Cancer NCT00408408 Pathology - NSABP Protocol B-40 -
Worksheet for Calculation of Residual Cancer Burden - 2734029v1.0
Bladder Cancer NCT00014534 Treatment - CALGB:
90104 Treatment and Follow-up Form - 2169531v3.0
CALGB: 90104 Treatment and Follow-up Form
Combination Chemotherapy in Treating Patients With
Bladder Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=BE1B6072-
F2CE-7116-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/9449
CALGB: 90104 Treatment and
Follow-up Form
Ccrr Module For Calgb: 90104 Treatment
And Follow-up Form
CALGB Form
CALGB Study No
CALGB Patient ID
From
To
Amended data?
Yes (Yes)
Patient Initials
Participating Group
Patient Medical Record Number
Participating Group Protocol Number
Institute/Affiliate
Patient's vital status
Alive (Alive with disease)
Alive (Alive-NED)
Dead (Dead)
Primary cause of death
Due To Other Cause, Specify (due to
other cause)
Due To Protocol Treatment (due to
protocol treatment)
Due To This Disease (due to this
disease)
Unknown (unknown)
Due to other cause, specify
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Date of last contact or death
GCSF administered?
Yes
No
If yes, specify why (GCSF administered)
Treatment
Arm A (Arm A)
Arm B (Arm B)
Reason treatment ended
Alternative Therapy (alternative therapy)
Death After Beginning Protocol Therapy
(death after beginning protocol therapy)
Death Prior To Beginning Protocol
Therapy (death prior to beginning
protocol therapy)
Disease Progression, Relapse During
Active Treatment (Disease progression,
relapse during active treatment)
Disease Progression, Relapse Prior To
Beginning Protocol Therapy (Disease
progression, relapse prior to beginning
protocol therapy)
disease recurrence (disease recurrence)
Other (other complicating disease)
Other (Other, specify)
Patient Withdrawal Or Refusal After
Beginning Protocol Therapy (Patient
withdrawal or refusal after beginning
protocol therapy)
Patient Withdrawal Or Refusal Prior To
Beginning Protocol Therapy (Patient
withdrawal or refusal prior to beginning
protocol therapy)
Toxicity/side Effects/complications
(Toxicity/side effects/complications)
Treatment Completed Per Protocol
Criteria (Treatment completed per
protocol)
Other, specify (off treatment reason)
Were there any dose modifications or
additions/omissions to protocol treatment?
No (no)
Unknown (unknown)
Yes, Planned (i.e., The Treatment Was
Changed According To Protocol
Guidelines) (yes, planned)
Yes, Unplanned (i.e., The Treatment
Change Was Not Part Of Protocol
Guidelines) (yes, unplanned)
If yes, specify (modification)
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Calculated creatinine clearance
WBC
ANC
AST
Platelet count
BUN
BUN, ULN
Bilirubin
Bilirubin, ULN
Serum creatinine
alkaline phosphatase
Alkaline phlosphatase, ULN
Has the patient had a documented clinical
assessment for this cancer?
Yes
No
Date of last clinical assessment
chest x-ray assessment date
Chest x-ray result
Equivocal (equivocal)
Negative (negative)
Positive (positive)
abdominal/pelvic CT assessment date
Abdominal/pelvic CT result
Abnormal-disease Related (abnormal-
disease related)
Abnormal-not Disease Related
(abnormal-not disease related)
Equivocal (equivocal)
Normal (normal)
Not Done (not done)
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Unknown (unknown)
Has the patient been diagnosed with a local
recurrence that has not been previously
reported?
Yes
No
Date of first local progression
Site(s) of first local progression
Local Progression To The Abdominal
Wall (abdominal wall)
Progression To Another Site, Specify
Site (other, specify)
Progression To Another Site, Specify
Site (Other, specify)
Local Progression To The Pelvic Wall
(pelvic wall)
Local Spread To Peritoneal Tissue
(peritoneum)
Spread Of Cancer To Skin Or
Subcutaneous Tissue Near To The
Bladder (skin)
Local Spread To The Urethra (urethra)
Local Spread To The Vagina (vagina)
Has the patient been diagnosed with a local-
regional lymph node recurrence that has not
been previously reported?
Yes
No
Date of first local-regional lymph node
progression
Site(s) of first local-regional lymph node
progression
Disease Is Present In The Common Iliac
Lymph Nodes (common iliac)
Disease Is Present In The External Iliac
Lymph Nodes (external iliac)
Disease Is Present In The Hypogastric
Lymph Nodes (hypogastric)
Disease Is Present In The Internal Iliac
Lymph Nodes (internal iliac)
Disease Is Present In Another Local-
regional Lymph Nodes, Specify (other,
specify)
Disease Is Present In Another Local-
regional Lymph Nodes, Specify (Other,
specify)
Disease Is Present In The Para-aortic
Lymph Nodes (para-aortic)
Has the patient been diagnosed with a distant
metastatic progression that has not been
previously reported?
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Yes
No
Date of first distant progression
Site(s) of first local (distant) progression
Bone (bone)
Central Nervous System Or Brain
(central nervous system/brain)
Distant Lymph Nodes (distant nodes)
Liver (liver)
Lung (lung)
Other, Specify (other)
Peritoneum (peritoneum)
Pleura (pleura)
Skin (skin)
distant nodes, specify
other, specify
Has a new primary cancer or myelodysplatsic
syndrome been diagnosed that has not been
previously reported?
Yes
No
Date of first local progression (new primary)
Site(s) of new primary
Has the patient experienced any severe, long-
term toxicity that has not been previously
reported?
Yes
No
late adverse event term
late adverse event grade
date of onset of long-term toxicity
comments
completed by
date form completed
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Lung Cancer NCT00096265 Follow-Up - F1 RTOG Phase
III - Multiple Brain Mets Follow-Up Form - 2278053v3.0
F1 RTOG Phase III - Multiple Brain Mets Follow-Up Form
Radiation Therapy and Stereotactic Radiosurgery With or
Without Temozolomide or Erlotinib in Treating Patients With
Brain Metastases Secondary to Non-Small Cell Lung
Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=D81E0CAD-
FB8C-12F8-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/9452
F1 RTOG Phase III - Multiple Brain
Mets Follow-Up Form
Header
RTOG Study No.
Case #
Institution
Institution No.
Participant's Initials
Participant's I.D. No.
Amended
Yes
No
Date of last clinical assessment
Patient Vital Status
Alive (Alive)
Dead (Dead)
Date of last contact or Death
Primary Cause of Death
Due To Brain Mets (Due to brain mets)
Due To Lung Disease Treatment (Due to
lung disease treatment)
Due To Lung Primary (Due to lung
primary)
Due To Other Cause (Due to other
cause)
Due To Protocol Treatment (Due to
protocol treatment)
Due To Second Primary Or Other
Malignancy (Due to second primary or
other malignancy)
Not Applicable (Not applicable)
Unknown (Unknown)
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Specify (primary cause of death)
Performance Status
Fully Active, Able To Carry On All Pre-
disease Performance Without
Restriction. (0)
Restricted In Physically Strenuous
Activity But Ambulatory And Able To
Carry Out Work Of A Light Or Sedentary
Nature, E.g., Light Housework, Office
Work. (1)
Ambulatory And Capable Of All Selfcare
But Unable To Carry Out Any Work
Activities. Up And About More Than 50%
Of Waking Hours. (2)
Capable Of Only Limited Selfcare,
Confined To Bed Or Chair More Than
50% Of Waking Hours. (3)
Completely Disabled. Cannot Carry On
Any Selfcare. Totally Confined To Bed Or
Chair. (4)
Dead (5)
Neurological Function Status
Minor Neurologic Symptoms, Fully Active
At Home/work Without Assistance (Minor
neurologic symptoms, fully active at
home/work without assistance)
Moderate Neurologic Symptoms, Fully
Active At Home/work But Requires
Assistance (Moderate neurologic
symptoms, fully active at home/work but
requires assistance)
Moderate Neurologic Symptoms, Less
Than Fully Active At Home/work And
Requires Assitance (Moderate
neurologic symptoms, less than fully
active at home/work and requires
assistance)
No Neurologic Symptoms, Fully Active At
Home/work Without Assistance (No
neurologic symptoms, fully active at
home/work without assistance)
Severe Neurologic Symptoms, Totally
Inactive Requiring Complete Assistance
At Home Or Institution, Unable To Work
(Severe neurologic symptoms, totally
inactive requiring complete assistance at
home or institution, unable to work)
Appearance of new mets
Growth of previously known mets
No (NO)
Unknown (UNKNOWN)
Yes (YES)
Assessment type
2 / 5
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Ct Scan (CT scan)
Mri (MRI (NMR))
Not Applicable (not applicable)
Pet Scan (PET scan)
Date of Evaluation
Dexamethasone Concomitant Medication Day
Dose Administered Amount
< 4 Mg (< 4 mg)
>= 12 Mg (>= 12 mg)
4 To 8 Mg (4 to 8 mg)
8 To 12 Mg (8 to 12 mg)
None (None)
Is the patient receiving corticosteroids?
No (no)
Unknown (unknown)
Yes (yes)
Specify drug
Total Daily Dose of Agent (or Drug)
Units
Date of MRI
Lesion number
CM Largest diameter
CM Perpendicular
Non protocol surgery
Biopsy Only (Biopsy only)
None (None)
Other (Other)
Partial Resection (Partial resection)
Shunt Plus Partial Resection (Shunt plus
partial resection)
Shunt Plus Total Resection (Shunt plus
total resection)
Surgery Done, Details Unavailable
(Surgery done, details unavailable)
Total Tumor Resection (Total tumor
resection)
Unknown (Unknown)
Other, specify
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Date of surgery
Was there gross evidence of tumor?
No (no)
Undetermined (not aplicable)
Unknown (unknown)
Yes (yes)
Was RT necrosis present
No (No)
Undetermined (Undetermined)
Unknown (Unknown)
Yes (Yes)
Was there evidence of tumor and necrosis
No (No)
Undetermined (Undetermined)
Unknown (Unknown)
Yes (Yes)
Non-protocol RT
No (no)
Unknown (unknown)
Yes (yes)
RT Begin Date
Non-protocol radiosurgery
No (no)
Unknown (unknown)
Yes (yes)
Radiosurgery date
Total Dose of Radiation Therapy
Total Dose of Radiation Therapy
Non-protocol TMZ
No (No)
Unknown (Unknown)
Yes (Yes)
Date TMZ started
Total dose of TMZ
Non-Protocol Erlotinib Agent Administered Ind-3
No (No)
Unknown (Unknown)
Yes (Yes)
Non-Protocol Erlotinib Agent Administered Begin
Date
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Non-Protocol Erlotinib Agent Administered Total
Dose
Non-Protocol Chemotherapy
No (No)
Unknown (Unknown)
Yes (Yes)
Non-protocol Chemotherapy Name
New or continuing adverse events
Yes
No
Comments
Completed by
Date Form Originally Completed
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Breast Cancer NCT00066703 Treatment -
Chemotherapy Form (Form 25/26-CT) - 2167893v3.0
Chemotherapy Form (Form 25/26-CT)
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=BD161F67-
0591-4F92-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/9457
Chemotherapy Form (Form 25/26-
CT)
Ccrr Module For Chemotherapy Form
(form 25/26-ct)
IBCSG Patient ID
Patient Initials
Patient's Date of Birth
Participating Center/Affiliate
Center Code
Did the patient complete chemotherapy?
No, Started But Stopped Early (no,
started but stopped early)
No, Will Never Start (no, will never start)
Yes, Completed As Planned (yes,
completed as planned)
Yes, Completed With Modifications Or
Delays Of One Week Or More (yes,
completed with modifications or delays of
one week or more)
Reason code, specify (reason treatment ended)
Adverse Event (adverse event)
Death On Study (death on study)
Error (error)
Medical Decision (medical decision)
Other, Specify (other, specify)
Patient Refused (patient refused)
Recurrence (recurrence)
adverse event, specify
medical decision, specify
other, specify
Reasons chemotherapy was delayed or modified
Hematologic Toxicity (hematologic
toxicity)
Other Toxicity, Specify (other toxicity,
specify)
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Reason Other Than Toxicity, Specify
(reason other than toxicity, specify)
other toxicity, specify
reason other than toxicity, specify
Date of first dose of chemotherapy
Date of last dose of chemotherapy
Total number of cycles of the regimen of
chemotherapy given
Investigator Signature
Date
Agent Name
Agent Dose
Route of Administration
Schedule & Frequency
Leukocytes CTCAE Grade
Platelets CTCAE Grade
Hemoglobin CTCAE Grade
Mucositis/Stomatis CTCAE Grade
Fatigue CTCAE Grade
Dizziness/lightheadedness CTCAE Grade
Somnolence/Depressed level of consciousness
CTCAE Grade
Memory impairment CTCAE Grade
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25/26-CT) - 2167893v3.0
Mood alternation-depression CTCAE Grade
Neuropathy-sensory CTCAE Grade
Did the patient have other Grade 3 or higher
adverse event(s)?
Yes
No
If yes, specify other CTCAE terms not listed
CTCAE Grade
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25/26-CT) - 2167893v3.0
Ovarian Cancer NCT00993655 Treatment - NCIC
OV 21 Treatment Report Form - 2874225v1.0
NCIC OV 21 Treatment Report Form
Comparing Three Combination Chemotherapy Regimens in
Treating Patients With Stage IIB, Stage IIC, Stage III, or
Stage IV Ovarian Epithelial Cancer, Primary Peritoneal
Cancer, or Fallopian Tube Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=69B8C40D-
B835-E610-E040-BB89AD43211A
All rights reserved. Please visit https://medical-data-
models.org/forms/9462
NCIC OV 21 Treatment Report Form
Patient Information
NCIC Patient ID (NCIC CTG Patient Serial
Number issued at the time of randomization)
Patient Initials (first-middle-last)
Patient Hospital No. (if permitted by REB)
Investigator No.
Investigator First Name
Investigator Middle Name
Investigator Last Name
Timing Of Report
Cycle Number
1 (1)
2 (2)
3 (3)
Other (Other)
Other, specify
Day 1 of this cycle (yyyy-mmm-dd)
Physical Exam
Date of Physical Exam (yyyy-mmm-dd)
Weight (kg)
ECOG Performance Status
Fully Active, Able To Carry On All Pre-
disease Performance Without
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Restriction. (0)
Restricted In Physically Strenuous
Activity But Ambulatory And Able To
Carry Out Work Of A Light Or Sedentary
Nature, E.g., Light Housework, Office
Work. (1)
Ambulatory And Capable Of All Selfcare
But Unable To Carry Out Any Work
Activities. Up And About More Than 50%
Of Waking Hours. (2)
Capable Of Only Limited Selfcare,
Confined To Bed Or Chair More Than
50% Of Waking Hours. (3)
Completely Disabled. Cannot Carry On
Any Selfcare. Totally Confined To Bed Or
Chair. (4)
Systemic Therapy Report
Was the agent Paclitaxel administered during this
reporting period
Yes
No
Was the agent Carboplatin administered during
this reporting period
Yes
No
Was the agent Cisplatin administered during this
reporting period
Yes
No
Study Drug Administration - Paclitaxel
Day of cycle
Day 1 (Day 1)
Other (Other)
Other, specify
Date (yyyy-mmm-dd)
Route
Intraperitoneal Route Of Administration
(IP)
Intravenous (IV)
Total Actual Dose of Agents/Drugs for this cycle
(mg)
Was dose modified due to weight loss (from the
previous cycle due to a change in weight BSA
during this reporting period)
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Yes
No
Dose Modification Table - Paclitaxel
Date of dose modifications (yyyy-mmm-dd)
Dose modification (Type of)
Change Of Route (Change of route)
Dose Delayed (Dose delayed)
Dose Omitted (Dose omitted)
Dose Reduced (Dose reduced)
Other (Other)
Other, specify
Protocol mandated
Yes
No
Gfr For Carboplatin Dose Calculation
Date
Units
Milliliters Per Minute (ml/min)
Milliliters Per Second (ml/sec)
Study Drug Administration - Paclitaxel
Day of cycle
Day 1 (Day 1)
Other (Other)
Other, specify
Date (yyyy-mmm-dd)
Route
Intraperitoneal Route Of Administration
(IP)
Intravenous (IV)
Total Actual Dose of Agents/Drugs for this cycle
(mg)
Was dose modified due to weight loss (from the
previous cycle due to a change in weight BSA
during this reporting period)
Yes
No
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Dose Modification Table - Paclitaxel
Date of dose modifications (yyyy-mmm-dd)
Dose modification (Type of)
Change Of Route (Change of route)
Dose Delayed (Dose delayed)
Dose Omitted (Dose omitted)
Dose Reduced (Dose reduced)
Other (Other)
Other, specify
Protocol mandated
Yes
No
Study Drug Administration - Paclitaxel
Day of cycle
Day 1 (Day 1)
Other (Other)
Other, specify
Date (yyyy-mmm-dd)
Route
Intraperitoneal Route Of Administration
(IP)
Intravenous (IV)
Total Actual Dose of Agents/Drugs for this cycle
(mg)
Was dose modified due to weight loss (from the
previous cycle due to a change in weight BSA
during this reporting period)
Yes
No
Dose Modification Table - Paclitaxel
Date of dose modifications (yyyy-mmm-dd)
Dose modification (Type of)
Change Of Route (Change of route)
Dose Delayed (Dose delayed)
Dose Omitted (Dose omitted)
Dose Reduced (Dose reduced)
Other (Other)
Other, specify
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Ovarian Cancer NCT00993655 Treatment - NCIC OV 21 Treatment
Report Form - 2874225v1.0
Protocol mandated
Yes
No
Hospitalization
Reason for hospitalization
Admission Date (yyyy-mmm-dd)
Discharge Date (yyyy-mmm-dd)
Growth Factors
Was growth factor administered? (e.g. GCSF,
erythropoietin, etc. during this reporting period)
Yes
No
Growth factor
Epoetin Alfa (Epoetin)
Granulocyte-macrophage Colony-
stimulating Factor (G-CSF)
Other (Other)
Other, specify (If)
Start Date (yyyy-mmm-dd)
Stop Date (yyyy-mmm-dd)
Surgery
Surgery Date (dd-mmm-yyyy)
Anti-cancer Treatment
Non-Protocol Therapy Type
Chemotherapy (Chemotherapy)
Hormonal Therapy (Hormonal Therapy)
Immunotherapy (Immunotherapy)
Other Specify (Other)
Radiation Therapy (Radiation therapy)
Other, specify
Name of non-protocol cancer therapy (eg. 2nd
look surgery, tamoxifen)
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Ovarian Cancer NCT00993655 Treatment - NCIC OV 21 Treatment
Report Form - 2874225v1.0
Ongoing from previous reporting period
Yes
No
Treatment Start Date (yyyy-mmm-dd)
Continuing at end of this reporting period
Yes
No
Treatment Stop Date (yyyy-mmm-dd)
Hematology
Date Specimen collected (for biochemical
investigations)
Date
Lab ID
Hemoglobin
Peripheral Platelet Count
WBC
Absolute neutrophil count
Other
Biochemistry
Date Specimen collected (for biochemical
investigations)
Date
Lab ID
Serum Creatinine
Total Bilirubin
SGOT (AST)
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SGPT (ALT)
CA125
Other
Magnesium
Calcium
Response Assessment - Question 2
Were disease assessment results obtained this
report period?
Yes
No
Reason evaluation not done
Institution Error (Institution error)
Not Required Per Protocol (Not required
per protocol)
Other (Other)
Patient Noncompliance (Patient
noncompliance)
Specify
Was there evidence of objective disease
progression at this assessment
Yes
No
Target Lesions
Did the patient have any target lesions by
imaging or clinical exam on post-op baseline
report
Yes
No
Date
Target Lesion Site (e.g. pelvis)
Method of Evaluation
Other Specify
Dimension 1 (End of Reporting Period
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Measurements)
Dimension 2 (End of Reporting Period
Measurements)
Sum of Longest Diameters of All Target Lesions
Non- Target Lesions During Treatment
Were there any non-target lesions reported at
baseline
Yes
No
Date
Nontarget Lesion Site (e.g. pelvis)
Method of Evaluation
Other Specify
Follow-up status of nontarget lesion (End of
Reporting Period )
Absent (Absent)
Increase (Increase)
Increased To Pd (Increased to PD)
Present-no Change (Present-no change)
Unevaluable (Unevaluable)
New Lesions
Was the appearance of any new lesions
documented (since baseline i.e. previously or
current reporting periods Note: New Lesions
constitute objective disease progression)
Yes
No
Date
New Lesion Site (e.g. pelvis)
Method of Evaluation
Other Specify
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Other Radiology
Date
Adverse Events / Intercurrent Illness
Has the patient experienced any symptoms or
adverse events since the last report
No (No)
Not Assessed (Not assessed)
Yes (Yes)
CTC Adverse Event Short Name
CTC Select AE
CTC AE Attribution Code
Definite (Definite)
Possible (Possible)
Probable (Probable)
Unlikely (Unlikely)
Unrelated (Unrelated)
Seriousness Attributed to Adverse Event
Congenital Anomaly (Congenital
anomaly)
Death (Death)
Disability (Disability/incapacity)
Hospitalized (Hospitalization, initial or
prolonged)
Life Threatening (Life threatening)
Not Serious (Not serious)
Other (Other)
Ip Administration -- Questions
Day 1 Ip Administration
Concomitant Measures/medications
Name of treatment
Reason for Administration
Ongoing? (from previous)
Yes
No
Start date
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Ovarian Cancer NCT00993655 Treatment - NCIC OV 21 Treatment
Report Form - 2874225v1.0
Stop date
Major Medical Problems
Date Documented (first)
Medical condition
Other Relevant Details
Quality Of Life Questionnaire
Was QoL Questionnaire completed?
Yes
No
Date Questionnaire Completed
Specify the reason the questionnaire was not
completed
Other Reason (Other reason)
Patient Could Not Be Contacted (Patient
could not be contacted)
Patient Did Not Keep Appointment
(Patient did not keep appointment)
Patient Kept Appointment For
Examination, But Could Not Complete
Questionnaire Due To Illness (Patient
kept appointment for examination, but
could not complete questionnaire due to
illness)
Patient Kept Appointment For
Examination, But Refused To Complete
Questionnaire For Reasons Other Than
Illness (Patient kept appointment for
examination, but refused to complete
questionnaire for reasons other)
Test Omitted Due To
Institution/investigator Error
(Questionnaire not administered due to
institutional error)
Specify other reason
Comments
Comments
Contact Information
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CRA Name
Phone number
Fax Number
Institution Name
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Breast Cancer NCT00068601 Treatment - Southwest
Oncology Group Treatment Form (S0230) - 2170362v3.0
Southwest Oncology Group Treatment Form (S0230)
Goserelin in Preventing Ovarian Failure in Women
Receiving Chemotherapy for Breast Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=BEA57D29-
C362-02E5-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/9463
Southwest Oncology Group
Treatment Form (S0230)
Status
Date of last contact or death
Vital Status
Alive (Alive)
Dead (Dead)
Has the patient progressed per the definition in
Section 10.0 of the protocol?
Yes
No
Chemotherapy
Date of start of chemotherapy
Date of end of chemotherapy
Number of chemotherapy courses planned
Number of chemotherapy courses given
Goserelin-for Arm 2 Patients Only
Were there any dose modifications or
additions/omissions to goserelin?
No (No)
Yes, Planned (i.e., The Treatment Was
Changed According To Protocol
Guidelines) (Yes)
Yes, Unplanned (i.e., The Treatment
Change Was Not Part Of Protocol
Guidelines) (Yes)
start date
dose (mg)
dose (mg)
1 / 2
Ccrr Module For Southwest Oncology
Group Treatment Form (s0230)
SWOG Patient ID
Patient Initials (L, F, M)
Insitution/Affiliate
Physician
Group Name
Group Name
Study No.
Pt. ID
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Breast Cancer NCT00068601 Treatment - Southwest Oncology Group
Treatment Form (S0230) - 2170362v3.0
Bladder Cancer NCT00014534 Toxicity - CALGB
90104 Adverse Event Form 2 2169496_v3_0
CALGB: 90104 Adverse Event Form 2
Combination Chemotherapy in Treating Patients With
Bladder Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=BE1B5A58-
F45B-70FF-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/9464
CALGB: 90104 Adverse Event Form
2
CCRR Modul für CALGB : 90104 Adverse
Event Formular 2
CALGB Formular
CALGB Studiennummer
CALGB Patienten-ID
CTC AE Bericht Anfangsdatum
CTC AE Bericht Enddatum
Wurden Daten geändert?
ja (Yes)
Patienteninitialen
Teilnehmende Gruppe
Patientaktennummer
Teilnehmende Gruppenprotokoll Nr
Institut / Einrichtung
Teilnehmende Patientengruppen-ID
Wurde ein AdEERS-Bericht der Zentralstelle
berichtet, basierend auf einem Event?
Ja
Nein
MedDRA Code
CTC AE Laufzeit
Bradykardie (bradycardia)
Erhöhtes Kreatinin im Blut (creatinine)
Müdigkeit (fatigue)
neutropenisches Fieber (fever
1 / 2
neutropenic)
Hypotonie, nicht näher angegeben
(hypotension)
Übelkeit (nausea)
Neutropenie (neutropenia)
peripheren motorneuropathy (peripheral
motorneuropathy)
Thrombozytenzahl vermindert (platelets)
Pneumonitis (pneumonitis)
Stomatitis (Mukositis) (stomatitis
(mucositis))
Erbrechen, nicht näher angegeben
(vomiting NOS)
CTC-Grad
Zuordnungscode
bestimmt (definite)
möglich (possible)
wahrscheinlich (probable)
unwahrscheinlich (unlikely)
ohne Bezug (unrelated)
Vervollständigt durch
Datum: Formular ausgefüllt
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Bladder Cancer NCT00014534 Toxicity - CALGB 90104 Adverse Event
Form 2 2169496_v3_0
Colorectal Cancer NCT01150045 Toxicity - CALGB 80702
Adverse Event (AE) Form (CTCAE v.4) - 2969642v1.0
CALGB 80702 Adverse Event (AE) Form (CTCAE v.4)
Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or
Without Celecoxib in Treating Patients With Stage III Colon
Cancer Previously Treated With Surgery
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=7ACBD923-
90EA-A7A3-E040-BB89AD436248
All rights reserved. Please visit https://medical-data-
models.org/forms/9471
CALGB 80702 Adverse Event (AE)
Form (CTCAE v.4)
Header
CALGB Form
CALGB Study No
CALGB Patient ID
CTC Adverse Event Report Begin Date (MM DD
YYYY)
CTC Adverse Event Report End Date (MM DD
YYYY)
Are data amended
Yes
No
Unnamed2
Patient Initials (Last, First Middle)
Patient Hospital No.
Institution/Affiliate
Participating Group
Participating Group Study No.
Participating Group Patient ID
Unnamed3
Has an AdEERS been filed (with Central Office
based on an event reported below)
Yes
1 / 2
No
Expected Adverse Events
CTC AE Attribution Code (AE is defined as
adverse event)
Definite (definite)
Possible (possible)
Probable (probable)
Unlikely (unlikely)
Unrelated (unrelated)
CTC AE Attribution Code (AE is defined as
adverse event)
Definite (definite)
Possible (possible)
Probable (probable)
Unlikely (unlikely)
Unrelated (unrelated)
MedDRA Code (Specify any other events, grade
3 or higher that occurred during this time period.
Report secondary malignancies other than
AML/MDS here and on Form C-1001)
MedDRA Code (Specify any other events, grade
3 or higher that occurred during this time period.
Report secondary malignancies other than
AML/MDS here and on Form C-1001)
CTC Adverse Event Term
CTC Adverse Event Term
CTC AE Grade
Severe Adverse Event (3)
Life Threatening Adverse Event (4)
Death Related To Adverse Event (5)
CTC AE Grade
Severe Adverse Event (3)
Life Threatening Adverse Event (4)
Death Related To Adverse Event (5)
Completed by (Last name, First name)
Date Form Completed (MM DD YYYY)
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Colorectal Cancer NCT01150045 Toxicity - CALGB 80702 Adverse Event
(AE) Form (CTCAE v.4) - 2969642v1.0
Esophageal Cancer NCT00052910 Toxicity - CALGB:
80101 Late RT Morbidity Report Form - 2078927v3.0
CALGB: 80101 Late RT Morbidity Report Form
Chemotherapy and Radiation Therapy After Surgery in
Treating Patients With Stomach or Esophageal Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=B4D51146-
81F5-2F1A-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/9472
CALGB: 80101 Late RT Morbidity
Report Form
Ccrr Module For Calgb: 80101 Late Rt
Morbidity Report Form
Site
Bladder (Bladder)
Bone (Bone)
Brain (Brain)
Esophagus (Esophagus)
Eye (Eye)
Heart (Heart)
Joint (Joint)
Kidney (Kidney)
Larynx (Larynx)
Liver (Liver)
Lung (Lung)
Mucous membrane (Mucous membrane)
RT other, specify (RT other, specify)
Salivary glands (Salivary glands)
Skin (Skin)
Small/Large intestine (Small/Large
intestine)
Spinal cord (Spinal cord)
Subcutaneous tissue (Subcutaneous
tissue)
CALGB Form
CALGB Study
CALGB Patient ID
Ameded data?
Yes (Yes)
Patient Initials
Participating Group
Patient Hospital Number
Participating Group Protocol No
Main Member Institution/Adjunct
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Participating Group Patient No
From
To
Was an Adverse Drug Reaction Report filed
based on an event reported below?
Yes
No
Site, other
MedDRA Code
Grade
Treatment Relation
Definite (definitely related to treatment)
Completed by
Date completed
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Esophageal Cancer NCT00052910 Toxicity - CALGB: 80101 Late RT
Morbidity Report Form - 2078927v3.0
Kidney Cancer NCT01198158 Toxicity - CALGB
90802 Adverse Event (AE) Form - 3103307v1.0
CALGB 90802 Adverse Event (AE) Form
Everolimus With or Without Bevacizumab in Treating
Patients With Advanced Kidney Cancer That Progressed
After First-Line Therapy
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=87856A36-
E968-CA3E-E040-BB89AD431C27
All rights reserved. Please visit https://medical-data-
models.org/forms/9473
CALGB 90802 Adverse Event (AE)
Form
Header
CALGB Form
CALGB Study No
CALGB Patient ID
CTC Adverse Event Report Begin Date (MM DD
YYYY)
CTC Adverse Event Report End Date (MM DD
YYYY)
Are data amended
Yes
No
Unnamed2
Patient Initials (Last, First Middle)
Patient Hospital No.
Institution/Affiliate
Participating Group
Participating Group Study No.
Participating Group Patient ID
Unnamed3
Has an AdEERS been filed (with Central Office
based on an event reported below)
Yes
1 / 2
No
Expected Adverse Events
CTC AE Attribution Code (^3)
Definite (definite)
Possible (possible)
Probable (probable)
Unlikely (unlikely)
Unrelated (unrelated)
CTC AE Attribution Code (^3)
Definite (definite)
Possible (possible)
Probable (probable)
Unlikely (unlikely)
Unrelated (unrelated)
MedDRA Code (Specify any other events, grade
3 or higher that occurred during this time period.
Report secondary malignancies other than
AML/MDS here and on Form C-1001)
MedDRA Code (Specify any other events, grade
3 or higher that occurred during this time period.
Report secondary malignancies other than
AML/MDS here and on Form C-1001)
CTC Adverse Event Term
CTC Adverse Event Term
CTC AE Grade
Severe Adverse Event (3)
Life Threatening Adverse Event (4)
Death Related To Adverse Event (5)
CTC AE Grade
Severe Adverse Event (3)
Life Threatening Adverse Event (4)
Death Related To Adverse Event (5)
Completed by (Last name, First name)
Date Form Completed (MM DD YYYY)
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Kidney Cancer NCT01198158 Toxicity - CALGB 90802 Adverse Event
(AE) Form - 3103307v1.0
Adenocarcinoma of the Gastroesophageal Junction NCT01196390
Follow-Up - RTOG 1010 Initial Follow-up Form (FS) - 3088118v1.0
RTOG 1010 Initial Follow-up Form (FS)
Radiation Therapy, Paclitaxel, and Carboplatin With or
Without Trastuzumab in Treating Patients With Esophageal
Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=86E1F1DA-
E438-F1B2-E040-BB89AD43175C
All rights reserved. Please visit https://medical-data-
models.org/forms/9480
RTOG 1010 Initial Follow-up Form
(FS)
Unnamed Module 1
RTOG Study No.
Case #
Institution Name
Institution No.
Patient Initials
RTOG Patient ID
Amended Data
Yes
No
Assessment
Date of Last Contact or Death (MM/DD/YYYY)
Vital Status
Alive (Alive)
Dead (Dead)
Primary Cause of Death
Due To Other Cause (Due to other
cause)
Due To Protocol Treatment (Due to
protocol treatment)
Due To Second Primary Or Other
Malignancy (Due to second primary or
other malignancy)
Due To This Disease (Due to this
disease)
Not Applicable (Not applicable)
Unknown (Unknown)
Describe cause of death
1 / 4
Has the patient had a documented clinical
assessment for this cancer?
No (No)
Unknown (Unknown)
Yes (Yes)
Date of clinical assessment (MM/DD/YYYY)
Current Disease Status
Primary Tumor
Disease Absent (Disease absent)
Disease Present (Disease present)
Unknown (Unknown)
Regional lymph nodes
Disease Absent (Disease absent)
Disease Present (Disease present)
Unknown (Unknown)
Distant metastasis
Disease Absent (Disease absent)
Disease Present (Disease present)
Unknown (Unknown)
Second primary
Disease Absent (Disease absent)
Disease Present (Disease present)
Unknown (Unknown)
Method of Evaluation
Ct Scan (CT scan)
Other (Other)
Pet/ct Scan (PET/CT scan)
Other Specify
LVEF (Value)
Date LVEF performed (MM DD YYYY)
LVEF LLN (Institutions lower limit of normal)
Events
Event
Appearance Of Distant Nodes
(Appearance of distant nodes)
Appearance Of Liver Metastasis
(Appearance of liver metastasis)
Appearance Of Lung Metastasis
(Appearance of lung metastasis)
Appearance Of Other Metastasis
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Adenocarcinoma of the Gastroesophageal Junction NCT01196390
Follow-Up - RTOG 1010 Initial Follow-up Form (FS) - 3088118v1.0
(Appearance of other metastasis)
Appearance Of Peritoneal Metastasis
(Appearance of peritoneal metastasis)
Appearance Of Second Primary
(Appearance of second primary)
Clearance Of Metastasis (Clearance of
metastasis)
Clearance Of Second Primary
(Clearance of second primary)
Complete Response (Complete
response)
Nodal Progression (Nodal progression)
Progression Of Local Disease
(Progression of local disease)
Recurrence (Recurrence)
Recurrence Of Nodal Disease
(Recurrence of nodal disease)
Recurrence Of Second Primary
(Recurrence of second primary)
Date (mm-dd-yyyy)
Specify
Toxicities
Grade 3 or 4 Restrictive Cardiomyopathy
Yes
No
Toxicities
Was a MUGA/Echocardiogram Performed During
This Report Period
Yes
No
Incipient CHF (If yes, did the patient experience
defined as asymptomatic >20% decrease in
LVEF or a decrease of LVEF >10% below the
institutions lower limit of normal and required
treatment according to institutional guidelines)
Yes
No
LVEF Status (If a MUGA/echocardiogram was
performed during this report period)
Decrease Of <10% From Baseline And
>=6% Below Lln (Decrease of <10%
from baseline and >=6% below LLN)
Decrease Of <10% From Baseline And
1-5% Below Lln (Decrease of <10% from
baseline and 1-5% below LLN)
Decrease Of >=16% From Baseline And
>=6% Below Lln (Decrease of >=16%
from baseline and >=6% below LLN)
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Decrease Of >=16% From Baseline And
1-5% Below Lln (Decrease of >=16%
from baseline and 1-5% below LLN)
Decrease Of 10-15% From Baseline And
>=6% Below Lln (Decrease of 10-15%
from baseline and >=6% below LLN)
Decrease Of 10-15% From Baseline And
1-5% Below Lln (Decrease of 10-15%
from baseline and 1-5% below LLN)
Within Normal Limits (Within normal
limits)
Protocol Specific Adverse Event
Evaluation
Any adverse events
No (No)
Unknown (Unknown)
Yes (Yes)
MedDRA Code
CTC Adverse Event Term
CTC AE Grade
Mild Adverse Event (1)
Moderate Adverse Event (2)
Severe Adverse Event (3)
Life Threatening Adverse Event (4)
Death Related To Adverse Event (5)
CTCAE Begin Date (MM DD YYYY)
CTC AE Attribution Code
Definite (Definite)
Possible (Possible)
Probable (Probable)
Unlikely (Unlikely)
Unrelated (Unrelated)
SAE report submitted
No (No)
Unknown (Unknown)
Yes (Yes)
Footer Module
Comments
Investigator Signature
Date
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Adenocarcinoma of the Gastroesophageal Junction NCT01196390
Follow-Up - RTOG 1010 Initial Follow-up Form (FS) - 3088118v1.0
Toxicity - CALGB Adverse Event (AE) Form
(CTCAE v4) - Phase III, Specify - 2956281v1.0
CALGB Adverse Event (AE) Form (CTCAE v4) - Phase III,
Specify
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=77004C80-
3180-DC10-E040-BB89AD430A30
All rights reserved. Please visit https://medical-data-
models.org/forms/9483
CALGB Adverse Event (AE) Form
(CTCAE v4) - Phase III, Specify
Header
CALGB Form
CALGB Study No
CALGB Patient ID
CTC Adverse Event Report Begin Date (MM DD
YYYY)
CTC Adverse Event Report End Date (MM DD
YYYY)
Are data amended
Yes
No
Unnamed2
Patient Initials (Last, First Middle)
Patient Hospital No.
Institution/Affiliate
Participating Group
Participating Group Study No.
Participating Group Patient ID
Unnamed3
Has an AdEERS been filed (with Central Office
based on an event reported below)
Yes
No
1 / 2
Expected Adverse Events
CTC AE Attribution Code (AE is defined as
adverse event)
Definite (definite)
Possible (possible)
Probable (probable)
Unlikely (unlikely)
Unrelated (unrelated)
CTC AE Attribution Code (AE is defined as
adverse event)
Definite (definite)
Possible (possible)
Probable (probable)
Unlikely (unlikely)
Unrelated (unrelated)
Specify (Specify adverse events in right column, if
Grade 1 or higher, using MedDRA code
corresponding to the specific adverse event. If
more than one adverse event is present, report
each separately)
MedDRA Code (Specify any other events, grade
3 or higher that occurred during this time period.
Report secondary malignancies other than
AML/MDS here and on Form C-1001)
MedDRA Code (Specify any other events, grade
3 or higher that occurred during this time period.
Report secondary malignancies other than
AML/MDS here and on Form C-1001)
CTC Adverse Event Term
CTC Adverse Event Term
CTC AE Grade
Severe Adverse Event (3)
Life Threatening Adverse Event (4)
Death Related To Adverse Event (5)
CTC AE Grade
Severe Adverse Event (3)
Life Threatening Adverse Event (4)
Death Related To Adverse Event (5)
Completed by (Last name, First name)
Date Form Completed (MM DD YYYY)
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Toxicity - CALGB Adverse Event (AE) Form (CTCAE v4) - Phase III,
Specify - 2956281v1.0
Toxicity - CALGB Adverse Event (AE) Form
(CTCAE v4) - Phase I, II, Solicited - 2956553v1.0
CALGB Adverse Event (AE) Form (CTCAE v4) - Phase I, II,
Solicited
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=77004C80-
3307-DC10-E040-BB89AD430A30
All rights reserved. Please visit https://medical-data-
models.org/forms/9486
CALGB Adverse Event (AE) Form
(CTCAE v4) - Phase I, II, Solicited
Header
CALGB Form
CALGB Study No
CALGB Patient ID
CTC Adverse Event Report Begin Date (MM DD
YYYY)
CTC Adverse Event Report End Date (MM DD
YYYY)
Are data amended
Yes
No
Unnamed2
Patient Initials (Last, First Middle)
Patient Hospital No.
Institution/Affiliate
Participating Group
Participating Group Study No.
Participating Group Patient ID
Unnamed3
Has an AdEERS been filed (with Central Office
based on an event reported below)
Yes
No
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Expected Adverse Events
CTC AE Attribution Code (AE is defined as
adverse event)
Definite (definite)
Possible (possible)
Probable (probable)
Unlikely (unlikely)
Unrelated (unrelated)
CTC AE Attribution Code (AE is defined as
adverse event)
Definite (definite)
Possible (possible)
Probable (probable)
Unlikely (unlikely)
Unrelated (unrelated)
MedDRA Code (Specify any other events, grade
3 or higher that occurred during this time period.
Report secondary malignancies other than
AML/MDS here and on Form C-1001)
MedDRA Code (Specify any other events, grade
3 or higher that occurred during this time period.
Report secondary malignancies other than
AML/MDS here and on Form C-1001)
CTC Adverse Event Term
CTC Adverse Event Term
CTC AE Grade
Severe Adverse Event (3)
Life Threatening Adverse Event (4)
Death Related To Adverse Event (5)
CTC AE Grade
Severe Adverse Event (3)
Life Threatening Adverse Event (4)
Death Related To Adverse Event (5)
Completed by (Last name, First name)
Date Form Completed (MM DD YYYY)
2 / 2
Toxicity - CALGB Adverse Event (AE) Form (CTCAE v4) - Phase I, II,
Solicited - 2956553v1.0
Toxicity - CALGB Adverse Event (AE) Form
(CTCAE v4) - Phase III, Solicited - 2956475v1.0
CALGB Adverse Event (AE) Form (CTCAE v4) - Phase III,
Solicited
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=77009E30-
35A2-7478-E040-BB89AD434232
All rights reserved. Please visit https://medical-data-
models.org/forms/9488
CALGB Adverse Event (AE) Form
(CTCAE v4) - Phase III, Solicited
Header
CALGB Form
CALGB Study No
CALGB Patient ID
CTC Adverse Event Report Begin Date (MM DD
YYYY)
CTC Adverse Event Report End Date (MM DD
YYYY)
Are data amended
Yes
No
Unnamed2
Patient Initials (Last, First Middle)
Patient Hospital No.
Institution/Affiliate
Participating Group
Participating Group Study No.
Participating Group Patient ID
Unnamed3
Has an AdEERS been filed (with Central Office
based on an event reported below)
Yes
No
1 / 2
Expected Adverse Events
CTC AE Attribution Code (AE is defined as
adverse event)
Definite (definite)
Possible (possible)
Probable (probable)
Unlikely (unlikely)
Unrelated (unrelated)
CTC AE Attribution Code (AE is defined as
adverse event)
Definite (definite)
Possible (possible)
Probable (probable)
Unlikely (unlikely)
Unrelated (unrelated)
MedDRA Code (Specify any other events, grade
3 or higher that occurred during this time period.
Report secondary malignancies other than
AML/MDS here and on Form C-1001)
MedDRA Code (Specify any other events, grade
3 or higher that occurred during this time period.
Report secondary malignancies other than
AML/MDS here and on Form C-1001)
CTC Adverse Event Term
CTC Adverse Event Term
CTC AE Grade
Severe Adverse Event (3)
Life Threatening Adverse Event (4)
Death Related To Adverse Event (5)
CTC AE Grade
Severe Adverse Event (3)
Life Threatening Adverse Event (4)
Death Related To Adverse Event (5)
Completed by (Last name, First name)
Date Form Completed (MM DD YYYY)
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Toxicity - CALGB Adverse Event (AE) Form (CTCAE v4) - Phase III,
Solicited - 2956475v1.0
Toxicity - CALGB Adverse Event (AE) Form
(CTCAE v4) - Phase I, II, Specify - 2956397v1.0
CALGB Adverse Event (AE) Form (CTCAE v4) - Phase I, II,
Specify
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=77004C80-
3268-DC10-E040-BB89AD430A30
All rights reserved. Please visit https://medical-data-
models.org/forms/9490
CALGB Adverse Event (AE) Form
(CTCAE v4) - Phase I, II, Specify
Header
CALGB Form
CALGB Study No
CALGB Patient ID
CTC Adverse Event Report Begin Date (MM DD
YYYY)
CTC Adverse Event Report End Date (MM DD
YYYY)
Are data amended
Yes
No
Unnamed2
Patient Initials (Last, First Middle)
Patient Hospital No.
Institution/Affiliate
Participating Group
Participating Group Study No.
Participating Group Patient ID
Unnamed3
Has an AdEERS been filed (with Central Office
based on an event reported below)
Yes
No
1 / 2
Expected Adverse Events
CTC AE Attribution Code (AE is defined as
adverse event)
Definite (definite)
Possible (possible)
Probable (probable)
Unlikely (unlikely)
Unrelated (unrelated)
CTC AE Attribution Code (AE is defined as
adverse event)
Definite (definite)
Possible (possible)
Probable (probable)
Unlikely (unlikely)
Unrelated (unrelated)
Specify (Specify adverse events in right column, if
Grade 1 or higher, using MedDRA code
corresponding to the specific adverse event. If
more than one adverse event is present, report
each separately)
MedDRA Code (Specify any other events, grade
3 or higher that occurred during this time period.
Report secondary malignancies other than
AML/MDS here and on Form C-1001)
MedDRA Code (Specify any other events, grade
3 or higher that occurred during this time period.
Report secondary malignancies other than
AML/MDS here and on Form C-1001)
CTC Adverse Event Term
CTC Adverse Event Term
CTC AE Grade
Severe Adverse Event (3)
Life Threatening Adverse Event (4)
Death Related To Adverse Event (5)
CTC AE Grade
Severe Adverse Event (3)
Life Threatening Adverse Event (4)
Death Related To Adverse Event (5)
Completed by (Last name, First name)
Date Form Completed (MM DD YYYY)
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Toxicity - CALGB Adverse Event (AE) Form (CTCAE v4) - Phase I, II,
Specify - 2956397v1.0
Toxicity - CALGB 40502 Breast Cancer
Adverse Event (AE) Form - 3102480v1.0
CALGB 40502 Adverse Event (AE) Form
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=8771560A-
044E-E3B6-E040-BB89AD431BF6
All rights reserved. Please visit https://medical-data-
models.org/forms/9492
CALGB 40502 Breast Cancer
Adverse Event (AE) Form
Header
CALGB Form
CALGB Study No
CALGB Patient ID
CTC Adverse Event Report Begin Date (MM DD
YYYY)
CTC Adverse Event Report End Date (MM DD
YYYY)
Are data amended
Yes
No
Unnamed2
Patient Initials (Last, First Middle)
Patient Hospital No.
Institution/Affiliate
Participating Group
Participating Group Study No.
Participating Group Patient ID
Unnamed3
Has an AdEERS been filed (with Central Office
based on an event reported below)
Yes
No
1 / 2
Expected Adverse Events
CTC AE Attribution Code (AE is defined as
adverse event)
Definite (definite)
Possible (possible)
Probable (probable)
Unlikely (unlikely)
Unrelated (unrelated)
CTC AE Attribution Code (AE is defined as
adverse event)
Definite (definite)
Possible (possible)
Probable (probable)
Unlikely (unlikely)
Unrelated (unrelated)
Specify (Specify adverse events in right column, if
Grade 1 or higher, using MedDRA code
corresponding to the specific adverse event. If
more than one adverse event is present, report
each separately)
MedDRA Code (Specify any other events, grade
3 or higher that occurred during this time period.
Report secondary malignancies other than
AML/MDS here and on Form C-1001)
MedDRA Code (Specify any other events, grade
3 or higher that occurred during this time period.
Report secondary malignancies other than
AML/MDS here and on Form C-1001)
CTC Adverse Event Term
CTC Adverse Event Term
CTC AE Grade
Severe Adverse Event (3)
Life Threatening Adverse Event (4)
Death Related To Adverse Event (5)
CTC AE Grade
Severe Adverse Event (3)
Life Threatening Adverse Event (4)
Death Related To Adverse Event (5)
Completed by (Last name, First name)
Date Form Completed (MM DD YYYY)
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Toxicity - CALGB 40502 Breast Cancer Adverse Event (AE) Form -
3102480v1.0
Cervical Cancer NCT00980954 Quality of Life - RTOG 0724 Phase III Cervix
Chemo RT (+)/(-) Adjuvant Chemotherapy:  Quality of Life Form - 2807448v1.0
RTOG 0724 Phase III Cervix Chemo RT (+)/(-) Adjuvant
Chemotherapy:  Quality of Life Form
Chemotherapy and Pelvic Radiation Therapy With or
Without Additional Chemotherapy in Treating Patients With
High-Risk Early-Stage Cervical Cancer After Radical
Hysterectomy
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=5D0320C5-
F603-076A-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/9494
RTOG 0724 Phase III Cervix Chemo
RT (+)/(-) Adjuvant Chemotherapy:
Quality of Life Form
Unnamed Module 1
RTOG Study No.
Case #
Institution Name
Institution No.
Patient Initials
RTOG Patient ID
Amended Data
Yes
No
Unamed Module 2
Time point
12 Months (12 months)
24 Months (24 months)
6 Months (6 months)
Pretreatment (Pretreatment)
Treatment Start Date
Was patient questionnaire completed
Yes
No
Date Questionnaire Completed (MM DD YYYY)
Reason Questionnaire was not Completed
Institution Error (Institutional error)
Not Applicable, Questionnaire Was
Completed (Not applicable,
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questionnaire was completed)
Other Reason (Other reason)
Patient Refused Due To Illness (Patient
refused due to illness)
Patient Refused For Other Reason
(Patient refused for other reason)
Patient Unable To Be Contacted (Patient
unable to be contacted)
Tool Not Availalble In Patient's Language
(Tool not available in patient's language)
Unknown (Unknown)
Patient refused for other reason, specify
Other reason, specify
Specify method of completion
At Appointment (At appointment)
By Mail (By mail)
By Telephone (By telephone)
Not Applicable (Not applicable)
Unknown (Unknown)
Did the patient require any assistance in
completing the questionnaire?
No (No)
Not Applicable (Not applicable)
Unknown If Assistance Given (Unknown
if assistance given)
Yes (Yes)
Specify the person who assisted the patient
Family (Family)
Not Applicable (Not applicable)
Other (Other)
Staff Member (Staff member)
Unknown (Unknown)
Other, specify
Extent of assistance given
Combination Of Above (Combination of
above)
Interpreted Items For Patient (Interpreted
items for patient)
Marked Items Per Patient's Response
(Marked items per patient's response)
Not Applicable (Not applicable)
Other (Other)
Read Items To Patient (Read items to
patient)
Unknown (Unknown)
Combination of above, specify
Other, specify
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Signature of Person Completing This Form
Date Form Completed
Physical Well-being
I have a lack of energy
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have nausea
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
Because of my physical condition, I have trouble
meeting the needs of my family
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have pain
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am bothered by side effects of treatment
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I feel ill
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am forced to spend time in bed
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
Social/family Well-being
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I feel close to my friends
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I get emotional support from my family
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I get support from my friends
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
My family has accepted my illness
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am satisfied with family communication about
my illness
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I feel close to my partner (or the person who is
my main support)
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am satisfied with my sex life
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
Emotional Well-being
I feel sad
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
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I am satisfied with how I am coping with my
illness
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am losing hope in the fight against my illness
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I feel nervous
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I worry about dying
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I worry that my condition will get worse
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
Functional Well-being
I am able to work (include work at home)
2 (A little bit)
1 (Not at all)
4 (Quite a bit)
3 (Somewhat)
5 (Very much)
My work is fulfilling (include work at home)
2 (A little bit)
1 (Not at all)
4 (Quite a bit)
3 (Somewhat)
5 (Very much)
I am able to enjoy life
2 (A little bit)
1 (Not at all)
4 (Quite a bit)
3 (Somewhat)
5 (Very much)
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I have accepted my illness
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am sleeping well
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am enjoying the things I usually do for fun
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am content with the quality of my life right now
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
Additional Concerns
I have control of my bowels
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I move my bowels more frequently than usual
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am afraid to be far from a toliet
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have to limit my social activity because of
diarrhea
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have to limit my physical activity because of
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diarrhea
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have to limit my sexual activity because of
diarrhea
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am embarrassed by having diarrhea
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have abdominal cramps or discomfort due to my
diarrhea
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
My problem with diarrhea keeps/wakes me up at
night
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I must move my bowels frequently to avoid
accidents
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I wear protection for soiling of stool
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
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Bladder Cancer NCT00014534 Toxicity - CALGB:
90104 Adverse Event Form 2 - 2169496v3.0
CALGB: 90104 Adverse Event Form 2
Combination Chemotherapy in Treating Patients With
Bladder Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=BE1B5A58-
F45B-70FF-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/9498
CALGB: 90104 Adverse Event Form
2
Ccrr Module For Calgb: 90104 Adverse
Event Form 2
CALGB Form
CALGB Study No
CALGB Patient ID
CTC AE report begin date
CTC AE report end date
Are data amended?
Yes (Yes)
Patient Initials
Participating Group
Patient Medical Record Number
Participating Group Protocol Number
Institute/Affiliate
Participating Group Patient ID
Was an AdEERS report filed with Central Office
based on an event reported below?
Yes
No
MedDRA code
CTC AE Term
bradycardia (bradycardia)
Blood Creatinine Increased (creatinine)
fatigue (fatigue)
fever neutropenic (fever neutropenic)
1 / 2
Hypotension Nos (hypotension)
Nausea (nausea)
neutropenia (neutropenia)
peripheral motorneuropathy (peripheral
motorneuropathy)
Platelet Count Decreased (platelets)
pneumonitis (pneumonitis)
stomatitis (mucositis) (stomatitis
(mucositis))
Vomiting Nos (vomiting NOS)
CTC Grade
Attribution Code
Definite (definite)
Possible (possible)
Probable (probable)
Unlikely (unlikely)
Unrelated (unrelated)
Completed by
Date form completed
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Bladder Cancer NCT00014534 Toxicity - CALGB: 90104 Adverse Event
Form 2 - 2169496v3.0
Esophageal Cancer NCT00655876 Treatment - CS: Radiation Therapy
Oncology Group Phase III Esophagus Cover Sheet - 2620609v1.0
CS: Radiation Therapy Oncology Group Phase III
Esophagus Cover Sheet
Paclitaxel, Cisplatin, and Radiation Therapy With or Without
Cetuximab in Treating Patients With Locally Advanced
Esophageal Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=2CD0D9D5-
DF0D-1CE5-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/9499
CS: Radiation Therapy Oncology
Group Phase III Esophagus Cover
Sheet
Module 1
RTOG Study No.
Case #
Institution Name
Institution No.
Patient Initials
RTOG Patient ID
AMENDED DATA
Yes
No
Unnamed 1
Time point of this assessment
1 Year From Start Of Treatment (1 year
from start of treatment)
2 Years From Start Of Treatment (2 years
from start of treatment)
3 Months From Start Of Treatment (3
months from start of treatment)
Pretreatment (Pretreatment)
Treatment Start Date
Was patient questionnaire completed
Yes
No
Date patient questionnaire completed
Reason Questionnaire was not Completed
Institution Error (Institutional error)
Not Applicable, Questionnaire Was
Completed (Not applicable,
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questionnaire was completed)
Other Reason (Other reason)
Patient Refused Due To Illness (Patient
refused due to illness)
Patient Refused For Other Reason
(Patient refused for other reason)
Patient Unable To Be Contacted (Patient
unable to be contacted)
Tool Not Availalble In Patient's Language
(Tool not availalble in patient's language)
Unknown (Unknown)
Other reason, specify
Specify method of completion
At Appointment (At appointment)
By Mail (By mail)
By Telephone (By telephone)
Not Applicable (Not applicable)
Unknown (Unknown)
Did the patient require any assistance in
completing the questionnaire?
No (No)
Not Applicable (Not applicable)
Unknown If Assistance Given (Unknown
if assistance given)
Yes (Yes)
Specify the person who assisted the patient
Family (Family)
Not Applicable (Not applicable)
Other (Other)
Staff Member (Staff member)
Unknown (Unknown)
Other, specify
Extent of assistance given
Combination Of Above (Combination of
above)
Interpreted Items For Patient (Interpreted
items for patient)
Marked Items Per Patient's Response
(Marked items per patient's response)
Not Applicable (Not applicable)
Other (Other)
Read Items To Patient (Read items to
patient)
Unknown (Unknown)
Combination of above, specify
Other, specify
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Footer Module
Comments
Signature
Date
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Esophageal Cancer NCT00655876 Quality of Life - RTOG-0436: Radiation Therapy
Oncology Group Phase III Esophagus FACT-E (Version 4) - 2617850v1.0
RTOG-0436: Radiation Therapy Oncology Group Phase III
Esophagus FACT-E (Version 4)
Paclitaxel, Cisplatin, and Radiation Therapy With or Without
Cetuximab in Treating Patients With Locally Advanced
Esophageal Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=2CAEEF21-
9D12-21F1-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/9503
RTOG-0436: Radiation Therapy
Oncology Group Phase III
Esophagus FACT-E (Version 4)
Header
RTOG Study No.
Case #
Institution Name
Institution No.
Patient Initials
RTOG Patient ID
Amended Data
Yes
No
Unnamed 1
Time point of this assessment
1 Year From Start Of Treatment (1 year
from start of treatment)
2 Years From Start Of Treatment (2 years
from start of treatment)
3 Months From Start Of Treatment (3
months from start of treatment)
Pretreatment (Pretreatment)
Treatment Start Date
Was patient questionnaire completed
Yes
No
Date patient questionnaire completed
Reason Questionnaire was not Completed
Institution Error (Institutional error)
Not Applicable, Questionnaire Was
Completed (Not applicable,
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questionnaire was completed)
Other Reason (Other reason)
Patient Refused Due To Illness (Patient
refused due to illness)
Patient Refused For Other Reason
(Patient refused for other reason)
Patient Unable To Be Contacted (Patient
unable to be contacted)
Tool Not Availalble In Patient's Language
(Tool not availalble in patient's language)
Unknown (Unknown)
Other reason, specify
Specify method of completion
At Appointment (At appointment)
By Mail (By mail)
By Telephone (By telephone)
Not Applicable (Not applicable)
Unknown (Unknown)
Did the patient require any assistance in
completing the questionnaire?
No (No)
Not Applicable (Not applicable)
Unknown If Assistance Given (Unknown
if assistance given)
Yes (Yes)
Specify the person who assisted the patient
Family (Family)
Not Applicable (Not applicable)
Other (Other)
Staff Member (Staff member)
Unknown (Unknown)
Other, specify
Extent of assistance given
Combination Of Above (Combination of
above)
Interpreted Items For Patient (Interpreted
items for patient)
Marked Items Per Patient's Response
(Marked items per patient's response)
Not Applicable (Not applicable)
Other (Other)
Read Items To Patient (Read items to
patient)
Unknown (Unknown)
Combination of above, specify
Other, specify
Signature of Person Completing This Form
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Date Form Completed
Physical Well-being
I have a lack of energy
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have nausea
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
Because of my physical condition, I have trouble
meeting the needs of my family
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have pain
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am bothered by side effects of treatment
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I feel ill
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am forced to spend time in bed
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
Social/family Well-being
I feel close to my friends
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A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I get emotional support from my family
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I get support from my friends
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
My family has accepted my illness
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am satisfied with family communication about
my illness
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I feel close to my partner (or the person who is
my main support)
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am satisfied with my sex life
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
Emotional Well-being
I feel sad
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
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I am satisfied with how I am coping with my
illness
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am losing hope in the fight against my illness
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I feel nervous
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I worry about dying
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I worry that my condition will get worse
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
Functional Well-being
I am able to work (include work at home)
2 (A little bit)
1 (Not at all)
4 (Quite a bit)
3 (Somewhat)
5 (Very much)
My work is fulfilling (include work at home)
2 (A little bit)
1 (Not at all)
4 (Quite a bit)
3 (Somewhat)
5 (Very much)
I am able to enjoy life
2 (A little bit)
1 (Not at all)
4 (Quite a bit)
3 (Somewhat)
5 (Very much)
5 / 8
Esophageal Cancer NCT00655876 Quality of Life - RTOG-0436: Radiation Therapy
Oncology Group Phase III Esophagus FACT-E (Version 4) - 2617850v1.0
I have accepted my illness
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am sleeping well
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am enjoying the things I usually do for fun
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am content with the quality of my life right now
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
Additional Concerns
I am able to eat the foods that I like
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
My mouth is dry
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have trouble breathing
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
My voice has its usual quality and strength
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am able to eat as much food as I want
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A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am unhappy with how my face and neck look
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I can swallow naturally and easily
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I smoke cigarettes or other tobacco products
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I drink alcohol (e.g. beer, wine, etc.)
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am able to communicate with others
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I can eat solid foods
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have pain in my mouth, throat or neck
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
COMMENTS
Person completing form
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Form completion date, original
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Lung Cancer NCT00113386 Follow-Up - RTOG-0412
FO: Post Induction Follow-Up Form - 2292884v3.0
RTOG-0412 FO: Post Induction Follow-Up Form
Cisplatin and Docetaxel With or Without Radiation Therapy
in Treating Patients Who Are Undergoing Surgery for Newly
Diagnosed Stage III Non-Small Cell Lung Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=E4C29E9F-
1120-040D-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/9509
RTOG-0412 FO: Post Induction
Follow-Up Form
Module 1
RTOG Study
Case #
Institution
Institution No.
Participant's Initials
Participant's I.D. No.
AMENDED DATA
Yes
No
Module 2
DATE OF LAST CLINICAL ASSESSMENT
PATIENT'S VITAL STATUS
Alive (Alive)
Dead (Dead)
Lost To Follow-up (Unknown)
DEATH DATE/LAST CONTACT DATE
PRIMARY CAUSE OF DEATH
Due To Other Cause, Specify (Due to
other cause)
Due To Protocol Treatment (Due to
protocol treatment)
Due To This Disease (Due to this
disease)
Related to or probably related to
complications of other treatment
(Related to or probably related to
complications of other treatment)
Due To Second Primary Or Other
1 / 3
Malignancy (Related to or probably
related to a second primary tumor)
Unknown (Unknown)
Describe cause of death
PERFORMANCE STATUS (ZUBROD)
Ambulatory And Capable Of All Selfcare
But Unable To Carry Out Any Work
Activities (Ambulatory and capable of all
selfcare but unable to carry out any work
activities)
Capable Of Limited Selfcare, Confined
To Bed Or Chair More Than 50% Of
Waking Hours (Capable of limited
selfcare, confined to bed or chair more
than 50% of waking hours)
Completely Disabled (Completely
disabled)
Fully Active, Able To Carry On All Pre-
disease Performance Without Restriction
(Fully active, able to carry on all pre-
disease performance without restriction)
Restricted In Physically Strenuous
Activity But Ambulatory (Restricted in
physically strenuous activity but
ambulatory)
HAS THE PATIENT ACHIEVED A RESPONSE?
Complete Response (Complete
Response)
Partial Response (Partial Response)
Partial Response (Progressive Disease)
Stable Disease (Stable Response)
Progressive Disease Documentation
SITE OF PROGRESSION
Bone (Bone)
Brain (Brain)
Cns (CNS)
Contralateral Lung (Contralateral lung)
Distant Lymph Nodes (Distant lymph
nodes)
Ipsilateral Lung (Ipsilateral lung)
Liver (Liver)
Lung (primary Site) (Lung)
Lung (primary, Margin Or Stump) (Lung)
Other (Other site)
Pleura (Pleura)
Regional Lymph Nodes (Regional lymph
nodes)
Skin Or Subcutaneous (Skin or
subcutaneous)
Distant lymph nodes, specify
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Skin or subcutaneous, specify
Other site, specify
PROGRESSION (#1)
No (No)
Not Evaluated (Not evaluated)
Unknown (Unknown)
Yes (Yes)
METHOD OF EVALUATION (#2)
Ct Scan (CT/MRI Scan)
Mri Scan (MRI scan)
Not Applicable (Not applicable)
Pathologic (Pathologic)
Pet Scan (PET Scan)
Physical Exam (Physical Exam)
DATE  RESPONSE LAST DOCUMENTED
IS THERE SYMPTOMATIC DETERIORATION
OF THE PATIENT'S HEALTH STATUS
REQUIRING DISCONTINUATION OF
TREATMENT?
No (No)
Unknown (Not  applicable)
Yes (Yes)
COMMENTS
Name of person completing this form
Form completion date, original
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Lung Cancer NCT00113386 Follow-Up - RTOG-
0412 F1: Follow-Up Form - 2293590v3.0
RTOG-0412 F1: Follow-Up Form
Cisplatin and Docetaxel With or Without Radiation Therapy
in Treating Patients Who Are Undergoing Surgery for Newly
Diagnosed Stage III Non-Small Cell Lung Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=E4DB4C4B-
28BD-1A62-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/9510
RTOG-0412 F1: Follow-Up Form
Module 1
RTOG Study
Case #
Institution
Institution No.
Participant's Initials
Participant's I.D. No.
AMENDED DATA
Yes
No
Module 2
DATE OF LAST CLINICAL ASSESSMENT
PATIENT'S VITAL STATUS
Alive (Alive)
Dead (Dead)
Lost To Follow-up (Unknown)
DEATH DATE/LAST CONTACT DATE
PRIMARY CAUSE OF DEATH
Due To Other Cause, Specify (Due to
other cause)
Due To Protocol Treatment (Due to
protocol treatment)
Due To This Disease (Due to this
disease)
Related to or probably related to
complications of other treatment
(Related to or probably related to
complications of other treatment)
Due To Second Primary Or Other
Malignancy (Related to or probably
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related to a second primary tumor)
Unknown (Unknown)
Describe cause of death
PERFORMANCE STATUS (ZUBROD)
Ambulatory And Capable Of All Selfcare
But Unable To Carry Out Any Work
Activities (Ambulatory and capable of all
selfcare but unable to carry out any work
activities)
Capable Of Limited Selfcare, Confined
To Bed Or Chair More Than 50% Of
Waking Hours (Capable of limited
selfcare, confined to bed or chair more
than 50% of waking hours)
Completely Disabled (Completely
disabled)
Fully Active, Able To Carry On All Pre-
disease Performance Without Restriction
(Fully active, able to carry on all pre-
disease performance without restriction)
Restricted In Physically Strenuous
Activity But Ambulatory (Restricted in
physically strenuous activity but
ambulatory)
Response Status at this Assessment
Complete Response (Complete
Response)
Partial Response (Partial Response)
Progressive Disease (Progressive
Disease)
Stable Disease (Stable Disease)
Has Patient Been Diagnosed With A New
Progression?
SITE OF PROGRESSION
Bone (Bone)
Brain (Brain)
Cns (CNS)
Contralateral Lung (Contralateral lung)
Distant Lymph Nodes (Distant lymph
nodes)
Ipsilateral Lung (Ipsilateral lung)
Liver (Liver)
Lung (primary Site) (Lung)
Lung (Lung)
Other (Other site)
Pleura (Pleura)
Regional Lymph Nodes (Regional lymph
nodes)
Skin Or Subcutaneous (Skin or
subcutaneous)
Distant lymph nodes, specify
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Skin or subcutaneous, specify
Other site, specify
PROGRESSION (#1)
No (No)
Not Evaluated (Not evaluated)
Unknown (Unknown)
Yes (Yes)
METHOD OF EVALUATION (#2)
Ct Scan (CT/MRI Scan)
Mri Scan (MRI scan)
Not Applicable (Not applicable)
Pathologic (Pathologic)
Pet Scan (PET Scan)
Physical Exam (Physical Exam)
PROGRESSION OBSERVED DATE
IS THE PATIENT RECEIVING ANY NON-
PROTOCOL CANCER THERAPY NOT
PREVIOUSLY REPORTED?
No (No)
Unknown (Unknown)
Yes (Yes)
Non-Protocol Radiation Therapy
No (No)
Unknown (Unknown)
Yes (Yes)
Non-Protocol Surgery
No (No)
Unknown (Unknown)
Yes (Yes)
Non-Protocol Chemotherapy
No (No)
Unknown (Unknown)
Yes (Yes)
Other Non-Protocol therapy
No (No)
Unknown (Unknown)
Yes (Yes)
Other Non-Protocol therapy (specify)
NEW OR CONTINUING ADVERSE EVENTS
Yes
No
COMMENTS
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Name of person completing this form
Form completion date, original
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Lung Cancer NCT00533949 Follow-Up - RTOG-0617 F1: Radiation Therapy
Oncology Group Phase III Lung Pre-Op Chemotherapy vs. Pre-Op Concurrent
Chemoradiation for NSCLC Follow-up Form - 2556229v1.0
RTOG-0617 F1: Radiation Therapy Oncology Group Phase
III Lung Pre-Op Chemotherapy vs. Pre-Op Concurrent
Chemoradiation for NSCLC Follow-up Form
High-Dose or Standard-Dose Radiation Therapy and
Chemotherapy With or Without Cetuximab in Treating
Patients With Newly Diagnosed Stage III Non-Small Cell
Lung Cancer That Cannot Be Removed by Surgery
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=24F6F134-
391D-15F5-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/9512
RTOG-0617 F1: Radiation Therapy
Oncology Group Phase III Lung Pre-
Op Chemotherapy vs. Pre-Op
Concurrent Chemoradiation for
NSCLC Follow-up Form
Module 1
RTOG Study No.
Case #
Institution
Institution No.
Patient Initials
RTOG Patient ID
AMENDED DATA
Yes
No
Module 2
Date of Last Clinical Assessment
Patient's Vital Status
Alive (Alive)
Dead (Dead)
Death Date/Last Contact Date
Primary Cause of Death
Due To Other Cause (Due to other
cause)
Due To Protocol Treatment (Due to
protocol treatment)
Due To Second Primary Or Other
Malignancy (Due to second primary or
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other malignancy)
Due To This Disease (Due to this
disease)
Unknown (Unknown)
Describe cause of death
Performance Status (Zubrod)
Fully Active, Able To Carry On All Pre-
disease Performance Without
Restriction. (0)
Restricted In Physically Strenuous
Activity But Ambulatory And Able To
Carry Out Work Of A Light Or Sedentary
Nature, E.g., Light Housework, Office
Work. (1)
Ambulatory And Capable Of All Selfcare
But Unable To Carry Out Any Work
Activities. Up And About More Than 50%
Of Waking Hours. (2)
Capable Of Only Limited Selfcare,
Confined To Bed Or Chair More Than
50% Of Waking Hours. (3)
Completely Disabled. Cannot Carry On
Any Selfcare. Totally Confined To Bed Or
Chair. (4)
Dead (5)
Response Status at This Assessment
Complete Response (CR)
Not Reported (Not reported)
Progressive Disease (PD)
Partial Response (PR)
Stable Disease (SD)
Response Confirmed Date
Has Patient Been Diagnosed With A New
Progression?
Site of progression
Bone (Bone)
Brain (Brain)
Cns (CNS)
Contralateral Lung (Contralateral lung)
Distant Lymph Nodes (Distant lymph
nodes)
Ipsilateral Lung (Ipsilateral lung)
Liver (Liver)
Lung (primary Site) (Lung)
Lung (Lung)
Other (Other site)
Pleura (Pleura)
Regional Lymph Nodes (Regional lymph
nodes)
Skin Or Subcutaneous (Skin or
subcutaneous)
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Distant lymph nodes, specify
Skin or subcutaneous, specify
Other site, specify
Progression (#1)
No (No)
Not Evaluated (Not evaluated)
Unknown (Unknown)
Yes (Yes)
Date Response Last Documented
Has a new primary cancer or MDS been
diagnosed that has not been previously reported?
No (No)
Unknown (Unknown)
Yes (Yes)
Date of diagnosis
Site(s) of new primary
Aml/mds (AML/MDS)
Bcc (BCC)
Bladder (Bladder)
Brain (Brain)
Colorectal (Colorectal)
Esophageal (Esophageal)
Gastric (Gastric)
Hypopharynx (Hypopharynx)
Larynx (Larynx)
Liver (Liver)
Lung (Lung)
Melanoma (Melanoma)
Nasopharynx (Nasopharynx)
Nhl (NHL)
None (None)
Oral Cavity (Oral cavity)
Oropharynx (Oropharynx)
Other H + N (Other H + N)
Other Hematologic (Other Hematologic)
Other Solid (Other solid)
Pancreatic (Pancreatic)
Prostate (Prostate)
Renal (Renal)
Squamous-skin (Squamous-Skin)
Unknown Primary (Unknown primary)
Method of Evaluation
Chest X-ray (Chest x-ray)
Ct Scan (CT scan)
Mri Scan (MRI scan)
Not Applicable (Not applicable)
Pathologic (Pathologic)
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Pet Scan (PET scan)
Physical Exam (Physical exam)
Method of Evaluation
Chest X-ray (Chest x-ray)
Ct Scan (CT scan)
Mri Scan (MRI scan)
Not Applicable (Not applicable)
Pathologic (Pathologic)
Pet Scan (PET scan)
Physical Exam (Physical exam)
Pulmonary function tests
Yes
No
Forced Expiratory Volume 1 (FEV1)
Is the patient receiving any non-protocol cancer
therapy not previously reported?
No (No)
Unknown (Unknown)
Yes (Yes)
Non-Protocol Radiation Therapy
No (No)
Unknown (Unknown)
Yes (Yes)
Non-Protocol Surgery
No (No)
Unknown (Unknown)
Yes (Yes)
Non-Protocol Chemotherapy
No (No)
Unknown (Unknown)
Yes (Yes)
Other Non-Protocol therapy
No (No)
Unknown (Unknown)
Yes (Yes)
Other Non-Protocol therapy (specify)
Report All Continuing Or New Adverse
Events
New or continuing adverse events
No (No)
Unknown (Unknown)
Yes (Yes)
MedDRA Code
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CTC Adverse Event Term
Acidosis Nos (Acidosis (metabolic or
respiratory))
Capillary Leak Syndrome (Acute
vascular leak syndrome)
Adrenal Insufficiency (Adrenal
insufficiency)
Adult Respiratory Distress Syndrome
(Adult respiratory distress syndrome
(ARDS))
Blood Albumin Decreased (Albumin,
serum-low (hypoalbuminemia))
Alcohol Intolerance Syndrome
(antabuse-like Syndrome) (Alcohol
intolerance syndrome (antabuse-like
syndrome))
Blood Alkaline Phosphatase Nos
Increased (Alkaline phosphatase)
Alkalosis Nos (Alkalosis (metabolic or
respiratory))
Hypersensitivity Nos (Allergic
reaction/hypersensitivity (including drug
fever))
Rhinitis Allergic Nos (Allergic rhinitis
(including sneezing, nasal stuffiness,
postnasal drip))
Allergy/immunology Other
(Allergy/Immunology-Other (Specify))
Alanine Aminotransferase Increased
(ALT, SGPT (serum glutamic pyruvic
transaminase))
Blood Amylase Increased (Amylase)
Anorexia (Anorexia)
Apnoea (Apnea)
Arachnoiditis
(Arachnoiditis/meningismus/radiculitis)
Arthritis Nos (Arthritis (non-septic))
Ascites (Ascites (non-malignant))
Aspiration (Aspiration)
Aspartate Aminotransferase Increased
(AST, SGOT (serum glutamic oxaloacetic
transaminase))
Ataxia Nec (Ataxia (incoordination))
Atelectasis (Atelectasis)
Atrophy, Skin (Atrophy, skin)
Atrophy, Subcutaneous Fat (Atrophy,
subcutaneous fat)
Auditory/ear Other (Auditory/Ear-Other
(Specify))
Autoimmune Disorder Nos (Autoimmune
reaction)
Blood Bicarbonate Decreased
(Bicarbonate, serum-low)
Blood Bilirubin Increased (Bilirubin
(hyperbilirubinemia))
Bladder Disorder Nos (Bladder spasms)
Blood/bone Marrow Other (Blood/Bone
Marrow-Other (Specify))
Bone Age (alteration In Bone Age) (Bone
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age (alteration in bone age))
Bone Growth: Femoral Head; Slipped
Capital Femoral Epiphysis (Bone growth:
femoral head; slipped capital femoral
epiphysis)
Bone Growth: Limb Length Discrepancy
(Bone growth: limb length discrepancy)
Bone Growth: Spine Kyphosis/lordosis
(Bone growth: spine kyphosis/lordosis)
Bone Marrow Depression Nos (Bone
marrow cellularity)
Bone: Spine-scoliosis (Bone: spine-
scoliosis)
Brachial Plexopathy (Brachial
plexopathy)
Breast Function/lactation (Breast
function/lactation)
Breast Nipple/areolar Deformity (Breast
nipple/areolar deformity)
Breast Volume/hypoplasia (Breast
volume/hypoplasia)
Bronchospasm, Wheezing
(Bronchospasm, wheezing)
Ecchymosis (Bruising (in absence of
grade 3 or 4 thrombocytopenia))
Burn (Burn)
Hypercalcaemia (Calcium, serum-high
(hypercalcemia))
Hypocalcaemia (Calcium, serum-low
(hypocalcemia))
Pulmonary Function Test Nos Decreased
(Carbon monoxide diffusion capacity
(DL(co)))
Arrhythmia Nos (Cardiac Arrhythmia-
Other (Specify))
Cardiac General Other (Cardiac
General-Other (Specify))
Myocardial Ischaemia (Cardiac
ischemia/infarction)
Cardiac Troponin I Increased (Cardiac
troponin I (cTnI))
Cardiac Troponin T Increased (Cardiac
troponin T (cTnT))
Cardiopulmonary Arrest, Cause
Unknown (non-fatal) (Cardiopulmonary
arrest, cause unknown (non-fatal))
Cataract Nec (Cataract)
Cd4 Lymphocytes Decreased (CD4
count)
Cervical Spine-range Of Motion (Cervical
spine-range of motion)
Chelitis (Cheilitis)
Cholecystitis (Cholecystitis)
Hypercholesteraemia (Cholesterol,
serum-high (hypercholesteremia))
Chyle Or Lymph Leakage (Chyle or
lymph leakage)
Chylothorax (Chylothorax)
Cerebral Ischaemia (CNS
cerebrovascular ischemia)
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Cns Necrosis/cystic Progression (CNS
necrosis/cystic progression)
Coagulation Disorder Nos (Coagulation-
Other (Specify))
Learning Disorder Nos (Cognitive
disturbance)
Colitis Nos (Colitis)
Colitis, Infectious (e.g., Clostridium
Difficile) (Colitis, infectious (e.g.,
Clostridium difficile))
Ventricular Asystole (Conduction
abnormality/Atrioventricular heart block -
Asystole)
Conduction Abnormality/atrioventricular
Heart Block (Conduction
abnormality/Atrioventricular heart block -
AV block-first degree)
Conduction Abnormality/atrioventricular
Heart Block - Av Block-second Degree
Mobitz Type I (wenckebach) (Conduction
abnormality/Atrioventricular heart block -
AV block-Second degree Mobitz Type I
(Wenckebach))
Conduction Abnormality/atrioventricular
Heart Block (Conduction
abnormality/Atrioventricular heart block -
AV block-second degree Mobitz Type II)
Conduction Abnormality/atrioventricular
Heart Block (Conduction
abnormality/Atrioventricular heart block -
AV block-third degree (complete AV
block))
Conduction Abnormality/atrioventricular
Heart Block (Conduction
abnormality/Atrioventricular heart block -
Conduction abnormality NOS)
Conduction Abnormality/atrioventricular
Heart Block (Conduction
abnormality/Atrioventricular heart block -
Sick sinus syndrome)
Conduction Abnormality/atrioventricular
Heart Block (Conduction
abnormality/Atrioventricular heart block -
Stokes-Adams syndrome)
Conduction Abnormality/atrioventricular
Heart Block (Conduction
abnormality/Atrioventricular heart block -
Wolff-Parkinson-White syndrome)
Confusion (Confusion)
Constipation (Constipation)
Constitutional Symptoms Other
(Constitutional Symptoms-Other
(Specify))
Cough (Cough)
Blood Creatine Phosphokinase
Increased (CPK (creatine
phosphokinase))
Blood Creatinine Increased (Creatinine)
Cushingoid (Cushingoid appearance
(e.g., moon face, buffalo hump,
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centripetal obesity, cutaneous striae))
Cystitis (Cystitis)
Cytokine Release Syndrome/acute
Infusion Reaction (Cytokine release
syndrome/acute infusion reaction)
Death Not Associated With Ctcae Term
(Death not associated with CTCAE term
- Death NOS)
Death Not Associated With Ctcae Term
(Death not associated with CTCAE term
- Disease progression NOS)
Death Not Associated With Ctcae Term
(Death not associated with CTCAE term
- Multi-organ failure)
Death Not Associated With Ctcae Term
(Death not associated with CTCAE term
- Sudden death)
Dehydration (Dehydration)
Dental: Dentures Or Prosthesis (Dental:
dentures or prosthesis)
Dental: Periodontal Disease (Dental:
periodontal disease)
Dental: Teeth (Dental: teeth)
Dental: Teeth Development (Dental:
teeth development)
Dermal Change Lymphedema,
Phlebolymphedema (Dermal change
lymphedema, phlebolymphedema)
Dermatology/skin Other
(Dermatology/Skin-Other (Specify))
Diarrhoea Nos (Diarrhea)
Disseminated Intravascular Coagulation
(DIC (disseminated intravascular
coagulation))
Distention/bloating, Abdominal
(Distention/bloating, abdominal)
Dizziness (exc Vertigo) (Dizziness)
Dry Eye Nec (Dry eye syndrome)
Dry Mouth (Dry mouth/salivary gland
(xerostomia))
Dry Skin (Dry skin)
Dysphagia (Dysphagia (difficulty
swallowing))
Dyspnoea Nos (Dyspnea (shortness of
breath))
Edema, Larynx (Edema, larynx)
Edema: Head And Neck (Edema: head
and neck)
Oedema Nos (Edema: limb)
Edema: Trunk/genital (Edema:
trunk/genital)
Edema: Viscera (Edema: viscera)
Ejaculatory Dysfunction (Ejaculatory
dysfunction)
Encephalopathy (Encephalopathy)
Endocrine Other (Endocrine-Other
(Specify))
Enteritis (inflammation Of The Small
Bowel) (Enteritis (inflammation of the
small bowel))
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Impotence (Erectile dysfunction)
Oesophagitis Nos (Esophagitis)
Exostosis (Exostosis)
Extrapyramidal Disorder Nec
(Extrapyramidal/involuntary
movement/restlessness)
Extremity-lower (gait/walking) (Extremity-
lower (gait/walking))
Extremity-upper (function) (Extremity-
upper (function))
Eyelid Dysfunction (Eyelid dysfunction)
Fatigue (Fatigue (asthenia, lethargy,
malaise))
Febrile Neutropenia (fever Of Unknown
Origin Without Clinically Or
Microbiologically Documented Infection)
(anc <1.0 X 10^9/l, Fever >=38.5
Degrees C) (Febrile neutropenia)
Feminization (Feminization of male)
Forced Expiratory Volume Decreased
(FEV(1))
Pyrexia (Fever (in the absence of
neutropenia, where neutropenia is
defined as ANC <1.0 x 10^9/L))
Blood Fibrinogen Decreased
(Fibrinogen)
Fibrosis-cosmesis (Fibrosis-cosmesis)
Fibrosis-deep Connective Tissue
(Fibrosis-deep connective tissue)
Fistula, Gi (Fistula, GI - Abdomen NOS)
Anal Fistula (Fistula, GI - Anus)
Fistula, Gi (Fistula, GI - Biliary tree)
Fistula, Gi (Fistula, GI -
Colon/cecum/appendix)
Intestinal Fistula (Fistula, GI -
Duodenum)
Tracheo-oesophageal Fistula Nos
(Fistula, GI - Esophagus)
Fistula, Gi (Fistula, GI - Gallbladder)
Fistula, Gi (Fistula, GI - Ileum)
Fistula, Gi (Fistula, GI - Jejunum)
Fistula, Gi (Fistula, GI - Oral cavity)
Fistula, Gi (Fistula, GI - Pancreas)
Fistula, Gi (Fistula, GI - Pharynx)
Fistula, Gi (Fistula, GI - Rectum)
Fistula, Gi (Fistula, GI - Salivary gland)
Fistula, Gi (Fistula, GI - Small bowel
NOS)
Fistula, Gi (Fistula, GI - Stomach)
Fistula, Gu (Fistula, GU - Bladder)
Fistula, Gu (Fistula, GU - Genital tract-
female)
Fistula, Gu (Fistula, GU - Kidney)
Fistula, Gu (Fistula, GU - Ureter)
Fistula, Gu (Fistula, GU - Urethra)
Fistula, Gu (Fistula, GU - Uterus)
Urogenital Fistula (Fistula, GU - Vagina)
Fistula, Pulmonary/upper Respiratory
(Fistula, pulmonary/upper respiratory -
Bronchus)
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Fistula, Pulmonary/upper Respiratory
(Fistula, pulmonary/upper respiratory -
Larynx)
Fistula, Pulmonary/upper Respiratory
(Fistula, pulmonary/upper respiratory -
Lung)
Fistula, Pulmonary/upper Respiratory
(Fistula, pulmonary/upper respiratory -
Oral cavity)
Fistula, Pulmonary/upper Respiratory
(Fistula, pulmonary/upper respiratory -
Pharynx)
Fistula, Pulmonary/upper Respiratory
(Fistula, pulmonary/upper respiratory -
Pleura)
Fistula, Pulmonary/upper Respiratory
(Fistula, pulmonary/upper respiratory -
Trachea)
Flatulence (Flatulence)
Flu-like Syndrome (Flu-like syndrome)
Flushing (Flushing)
Fracture (Fracture)
Gastritis Nos (Gastritis (including bile
reflux gastritis))
Gastrointestinal Other (Gastrointestinal-
Other (Specify))
Gamma-glutamyltransferase Increased
(GGT (gamma-glutamyl transpeptidase))
Glaucoma Nos (Glaucoma)
Glomerular Filtration Rate (Glomerular
filtration rate)
Hyperglycaemia Nos (Glucose, serum-
high (hyperglycemia))
Hypoglycaemia Nos (Glucose, serum-
low (hypoglycemia))
Growth And Development Other (Growth
and Development-Other (Specify))
Growth Velocity (reduction In Growth
Velocity) (Growth velocity (reduction in
growth velocity))
Gynaecomastia (Gynecomastia)
Alopecia (Hair loss/Alopecia (scalp or
body))
Haptoglobin Decreased (Haptoglobin)
Hearing: Patients With/without Baseline
Audiogram And Enrolled In A Monitoring
Program (Hearing: patients with/without
baseline audiogram and enrolled in a
monitoring program)
Hearing: Patients Without Baseline
Audiogram And Not Enrolled In A
Monitoring Program (Hearing: patients
without baseline audiogram and not
enrolled in a monitoring program)
Dyspepsia (Heartburn/dyspepsia)
Hematoma (Hematoma)
Haemoglobin Decreased (Hemoglobin)
Haemoglobinuria Present
(Hemoglobinuria)
Hemolysis Nos (Hemolysis (e.g.,
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immune hemolytic anemia, drug related
hemolysis))
Haemorrhagic Stroke (Hemorrhage,
CNS)
Melaena (Hemorrhage, GI - Abdomen
NOS)
Hemorrhage, Gi (Hemorrhage, GI -
Anus)
Hemorrhage, Gi (Hemorrhage, GI -
Biliary tree)
Hemorrhage, Gi (Hemorrhage, GI -
Cecum/appendix)
Hemorrhage, Gi (Hemorrhage, GI -
Colon)
Hemorrhage, Gi (Hemorrhage, GI -
Duodenum)
Hemorrhage, Gi (Hemorrhage, GI -
Esophagus)
Hemorrhage, Gi (Hemorrhage, GI -
Ileum)
Hemorrhage, Gi (Hemorrhage, GI -
Jejunum)
Hemorrhage, Gi (Hemorrhage, GI - Liver)
Hemorrhage, Gi (Hemorrhage, GI -
Lower GI NOS)
Hemorrhage, Gi (Hemorrhage, GI - Oral
cavity)
Hemorrhage, Gi (Hemorrhage, GI -
Pancreas)
Hemorrhage, Gi (Hemorrhage, GI -
Peritoneal cavity)
Rectal Bleeding (Hemorrhage, GI -
Rectum)
Hemorrhage, Gi (Hemorrhage, GI -
Stoma)
Haematemesis (Hemorrhage, GI -
Stomach)
Hemorrhage, Gi (Hemorrhage, GI -
Upper GI NOS)
Hemorrhage, Gi (Hemorrhage, GI -
Varices (esophageal))
Hemorrhage, Gi (Hemorrhage, GI -
Varices (rectal))
Hemorrhage, Gu (Hemorrhage, GU -
Bladder)
Hemorrhage, Gu (Hemorrhage, GU -
Fallopian tube)
Hemorrhage, Gu (Hemorrhage, GU -
Kidney)
Hemorrhage, Gu (Hemorrhage, GU -
Ovary)
Hemorrhage, Gu (Hemorrhage, GU -
Prostate)
Hemorrhage, Gu (Hemorrhage, GU -
Retroperitoneum)
Hemorrhage, Gu (Hemorrhage, GU -
Spermatic cord)
Hemorrhage, Gu (Hemorrhage, GU -
Stoma)
Hemorrhage, Gu (Hemorrhage, GU -
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Testes)
Hemorrhage, Gu (Hemorrhage, GU -
Ureter)
Hemorrhage, Gu (Hemorrhage, GU -
Urethra)
Haematuria Present (Hemorrhage, GU -
Urinary NOS)
Hemorrhage, Gu (Hemorrhage, GU -
Uterus)
Vaginal Haemorrhage (Hemorrhage, GU
- Vagina)
Hemorrhage, Gu (Hemorrhage, GU - Vas
deferens)
Hemorrhage, Pulmonary/upper
Respiratory (Hemorrhage,
pulmonary/upper respiratory -
Bronchopulmonary NOS)
Hemorrhage, Pulmonary/upper
Respiratory (Hemorrhage,
pulmonary/upper respiratory - Bronchus)
Hemorrhage, Pulmonary/upper
Respiratory (Hemorrhage,
pulmonary/upper respiratory - Larynx)
Hemorrhage, Pulmonary/upper
Respiratory (Hemorrhage,
pulmonary/upper respiratory - Lung)
Hemorrhage, Pulmonary/upper
Respiratory (Hemorrhage,
pulmonary/upper respiratory -
Mediastinum)
Epistaxis (Hemorrhage, pulmonary/upper
respiratory - Nose)
Hemorrhage, Pulmonary/upper
Respiratory (Hemorrhage,
pulmonary/upper respiratory - Pharynx)
Hemorrhage, Pulmonary/upper
Respiratory (Hemorrhage,
pulmonary/upper respiratory - Pleura)
Haemoptysis (Hemorrhage,
pulmonary/upper respiratory -
Respiratory tract NOS)
Hemorrhage, Pulmonary/upper
Respiratory (Hemorrhage,
pulmonary/upper respiratory - Stoma)
Hemorrhage, Pulmonary/upper
Respiratory (Hemorrhage,
pulmonary/upper respiratory - Trachea)
Post-operative Haemorrhage
(Hemorrhage/bleeding associated with
surgery, intra-operative or post-operative)
Hemorrhage/bleeding Other
(Hemorrhage/Bleeding-Other (Specify))
Hemorrhoids (Hemorrhoids)
Hepatobiliary/pancreas Other
(Hepatobiliary/Pancreas-Other (Specify))
Hiccups (Hiccoughs (hiccups, singultus))
Menopausal Symptoms (Hot
flashes/flushes)
Hydrocephalus (Hydrocephalus)
Skin Discolouration (Hyperpigmentation)
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Hypertension Nos (Hypertension)
Hypopigmentation (Hypopigmentation)
Hypotension Nos (Hypotension)
Hypothermia (Hypothermia)
Hypoxia (Hypoxia)
Ileus (Ileus, GI (functional obstruction of
bowel, i.e., neuroconstipation))
Incontinence, Anal (Incontinence, anal)
Urinary Incontinence (Incontinence,
urinary)
Induration/fibrosis (skin And
Subcutaneous Tissue)
(Induration/fibrosis (skin and
subcutaneous tissue))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Abdomen NOS)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Anal/perianal)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Appendix)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Artery)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Biliary tree)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Bladder (urinary))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Blood)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
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microbiologically) with Grade 3 or 4
neutrophils - Bone (osteomyelitis))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Brain (encephalitis,
infectious))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Brain + Spinal cord
(encephalomyelitis))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Bronchus)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Catheter-related)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Cecum)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Cervix)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Colon)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Conjunctiva)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Cornea)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
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Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Dental-tooth)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Duodenum)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Esophagus)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - External ear (otitis externa))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Eye NOS)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Fallopian tube)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Foreign body (e.g., graft,
implant, prosthesis, stent))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Gallbladder (cholecystitis))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Heart (endocarditis))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Ileum)
Infection (documented Clinically Or
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Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Jejunum)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Joint)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Kidney)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Larynx)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Lens)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Lip/perioral)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Liver)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Lung (pneumonia))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Lymphatic)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Mediastinum NOS)
Infection (documented Clinically Or
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Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Meninges (meningitis))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Middle ear (otitis media))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Mucosa)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Muscle (infection myositis))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Neck NOS)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Nerve-cranial)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Nerve-peripheral)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Nose)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Oral cavity-gums
(gingivitis))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Pancreas)
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Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Paranasal)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Pelvis NOS)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Penis)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Peristomal)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Peritoneal cavity)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Pharynx)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Pleura (empyema))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Prostate)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Rectum)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Salivary gland)
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Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Scrotum)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Sinus)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Skin (cellulitis))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Small bowel NOS)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Soft tissue NOS)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Spinal cord (myelitis))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Spleen)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Stomach)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Trachea)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Ungual (nails))
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Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Upper aerodigestive NOS)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Upper airway NOS)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Ureter)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Urethra)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Urinary tract NOS)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Uterus)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Vagina)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Vein)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Vulva)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Wound)
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Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Abdomen
NOS)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils -
Anal/perianal)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Appendix)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Artery)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Biliary tree)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Bladder
(urinary))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Blood)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Bone
(osteomyelitis))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Brain
(encephalitis, infectious))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Brain +
Spinal cord (encephalomyelitis))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Bronchus)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Catheter-
related)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Cecum)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Cervix)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Colon)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils -
Conjunctiva)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Cornea)
Infection With Normal Anc Or Grade 1 Or
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2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Dental-
tooth)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Duodenum)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Esophagus)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - External ear
(otitis externa))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Eye NOS)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Fallopian
tube)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Foreign
body (e.g., graft, implant, prosthesis,
stent))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Gallbladder
(cholecystitis))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Heart
(endocarditis))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Ileum)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Jejunum)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Joint)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Kidney)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Larynx)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Lens)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Lip/perioral)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Liver)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Lung
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(pneumonia))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Lymphatic)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils -
Mediastinum NOS)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Meninges
(meningitis))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Middle ear
(otitis media))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Mucosa)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Muscle
(infection myositis))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Neck NOS)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Nerve-
cranial)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Nerve-
peripheral)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Nose)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Oral cavity-
gums (gingivitis))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Pancreas)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Paranasal)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Pelvis NOS)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Penis)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Peristomal)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Peritoneal
cavity)
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Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Pharynx)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Pleura
(empyema))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Prostate)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Rectum)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Salivary
gland)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Scrotum)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Sinus)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Skin
(cellulitis))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Small bowel
NOS)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Soft tissue
NOS)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Spinal cord
(myelitis))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Spleen)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Stomach)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Trachea)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Ungual
(nails))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Upper
aerodigestive NOS)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Upper
airway NOS)
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Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Ureter)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Urethra)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Urinary
tract NOS)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Uterus)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Vagina)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Vein)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Vulva)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Wound)
Infection With Unknown Anc (Infection
with unknown ANC - Abdomen NOS)
Infection With Unknown Anc (Infection
with unknown ANC - Anal/perianal)
Infection With Unknown Anc (Infection
with unknown ANC - Appendix)
Infection With Unknown Anc (Infection
with unknown ANC - Artery)
Infection With Unknown Anc (Infection
with unknown ANC - Biliary tree)
Infection With Unknown Anc (Infection
with unknown ANC - Bladder (urinary))
Infection With Unknown Anc (Infection
with unknown ANC - Blood)
Infection With Unknown Anc (Infection
with unknown ANC - Bone
(osteomyelitis))
Infection With Unknown Anc (Infection
with unknown ANC - Brain (encephalitis,
infectious))
Infection With Unknown Anc (Infection
with unknown ANC - Brain + Spinal cord
(encephalomyelitis))
Infection With Unknown Anc (Infection
with unknown ANC - Bronchus)
Implant Infection (Infection with unknown
ANC - Catheter-related)
Infection With Unknown Anc (Infection
with unknown ANC - Cecum)
Infection With Unknown Anc (Infection
with unknown ANC - Cervix)
Infection With Unknown Anc (Infection
with unknown ANC - Colon)
Infection With Unknown Anc (Infection
with unknown ANC - Conjunctiva)
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Infection With Unknown Anc (Infection
with unknown ANC - Cornea)
Infection With Unknown Anc (Infection
with unknown ANC - Dental-tooth)
Infection With Unknown Anc (Infection
with unknown ANC - Duodenum)
Infection With Unknown Anc (Infection
with unknown ANC - Esophagus)
Infection With Unknown Anc (Infection
with unknown ANC - External ear (otitis
externa))
Infection With Unknown Anc (Infection
with unknown ANC - Eye NOS)
Infection With Unknown Anc (Infection
with unknown ANC - Fallopian tube)
Infection With Unknown Anc (Infection
with unknown ANC - Foreign body (e.g.,
graft, implant, prosthesis, stent))
Infection With Unknown Anc (Infection
with unknown ANC - Gallbladder
(cholecystitis))
Infection With Unknown Anc (Infection
with unknown ANC - Heart
(endocarditis))
Infection With Unknown Anc (Infection
with unknown ANC - Ileum)
Infection With Unknown Anc (Infection
with unknown ANC - Jejunum)
Infection With Unknown Anc (Infection
with unknown ANC - Joint)
Infection With Unknown Anc (Infection
with unknown ANC - Kidney)
Infection With Unknown Anc (Infection
with unknown ANC - Larynx)
Infection With Unknown Anc (Infection
with unknown ANC - Lens)
Infection With Unknown Anc (Infection
with unknown ANC - Lip/perioral)
Infection With Unknown Anc (Infection
with unknown ANC - Liver)
Infection With Unknown Anc (Infection
with unknown ANC - Lung (pneumonia))
Infection With Unknown Anc (Infection
with unknown ANC - Lymphatic)
Infection With Unknown Anc (Infection
with unknown ANC - Mediastinum NOS)
Infection With Unknown Anc (Infection
with unknown ANC - Meninges
(meningitis))
Infection With Unknown Anc (Infection
with unknown ANC - Middle ear (otitis
media))
Infection With Unknown Anc (Infection
with unknown ANC - Mucosa)
Infection With Unknown Anc (Infection
with unknown ANC - Muscle (infection
myositis))
Infection With Unknown Anc (Infection
with unknown ANC - Neck NOS)
Infection With Unknown Anc (Infection
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with unknown ANC - Nerve-cranial)
Infection With Unknown Anc (Infection
with unknown ANC - Nerve-peripheral)
Infection With Unknown Anc (Infection
with unknown ANC - Nose)
Infection With Unknown Anc (Infection
with unknown ANC - Oral cavity-gums
(gingivitis))
Infection With Unknown Anc (Infection
with unknown ANC - Pancreas)
Infection With Unknown Anc (Infection
with unknown ANC - Paranasal)
Infection With Unknown Anc (Infection
with unknown ANC - Pelvis NOS)
Infection With Unknown Anc (Infection
with unknown ANC - Penis)
Infection With Unknown Anc (Infection
with unknown ANC - Peristomal)
Infection With Unknown Anc (Infection
with unknown ANC - Peritoneal cavity)
Infection With Unknown Anc (Infection
with unknown ANC - Pharynx)
Infection With Unknown Anc (Infection
with unknown ANC - Pleura (empyema))
Infection With Unknown Anc (Infection
with unknown ANC - Prostate)
Infection With Unknown Anc (Infection
with unknown ANC - Rectum)
Infection With Unknown Anc (Infection
with unknown ANC - Salivary gland)
Infection With Unknown Anc (Infection
with unknown ANC - Scrotum)
Infection With Unknown Anc (Infection
with unknown ANC - Sinus)
Infection With Unknown Anc (Infection
with unknown ANC - Skin (cellulitis))
Infection With Unknown Anc (Infection
with unknown ANC - Small bowel NOS)
Infection With Unknown Anc (Infection
with unknown ANC - Soft tissue NOS)
Infection With Unknown Anc (Infection
with unknown ANC - Spinal cord
(myelitis))
Infection With Unknown Anc (Infection
with unknown ANC - Spleen)
Infection With Unknown Anc (Infection
with unknown ANC - Stomach)
Infection With Unknown Anc (Infection
with unknown ANC - Trachea)
Infection With Unknown Anc (Infection
with unknown ANC - Ungual (nails))
Infection With Unknown Anc (Infection
with unknown ANC - Upper aerodigestive
NOS)
Infection With Unknown Anc (Infection
with unknown ANC - Upper airway NOS)
Infection With Unknown Anc (Infection
with unknown ANC - Ureter)
Infection With Unknown Anc (Infection
with unknown ANC - Urethra)
27 / 48
Lung Cancer NCT00533949 Follow-Up - RTOG-0617 F1: Radiation Therapy
Oncology Group Phase III Lung Pre-Op Chemotherapy vs. Pre-Op Concurrent
Chemoradiation for NSCLC Follow-up Form - 2556229v1.0
Infection With Unknown Anc (Infection
with unknown ANC - Urinary tract NOS)
Infection With Unknown Anc (Infection
with unknown ANC - Uterus)
Infection With Unknown Anc (Infection
with unknown ANC - Vagina)
Infection With Unknown Anc (Infection
with unknown ANC - Vein)
Infection With Unknown Anc (Infection
with unknown ANC - Vulva)
Culture Wound Positive (Infection with
unknown ANC - Wound)
Infection Nos (Infection-Other (Specify))
Infertility/sterility (Infertility/sterility)
Injection Site Reaction Nos (Injection site
reaction/extravasation changes)
Prothrombin Time Prolonged (INR
(International Normalized Ratio of
prothrombin time))
Insomnia Nec (Insomnia)
Intra-operative Injury (Intra-operative
injury - Abdomen NOS)
Intra-operative Injury (Intra-operative
injury - Adrenal gland)
Intra-operative Injury (Intra-operative
injury - Anal sphincter)
Intra-operative Injury (Intra-operative
injury - Anus)
Intra-operative Injury (Intra-operative
injury - Appendix)
Intra-operative Injury (Intra-operative
injury - Artery NOS)
Intra-operative Injury (Intra-operative
injury - Artery-aorta)
Intra-operative Injury (Intra-operative
injury - Artery-carotid)
Intra-operative Injury (Intra-operative
injury - Artery-cerebral)
Intra-operative Injury (Intra-operative
injury - Artery-extremity (lower))
Intra-operative Injury (Intra-operative
injury - Artery-extremity (upper))
Intra-operative Injury (Intra-operative
injury - Artery-hepatic)
Intra-operative Injury (Intra-operative
injury - Artery-major visceral artery)
Intra-operative Injury (Intra-operative
injury - Artery-pulmonary)
Intra-operative Injury (Intra-operative
injury - Biliary tree NOS)
Intra-operative Injury (Intra-operative
injury - Biliary tree-common bile duct)
Intra-operative Injury (Intra-operative
injury - Biliary tree-common hepatic duct)
Intra-operative Injury (Intra-operative
injury - Biliary tree-left hepatic duct)
Intra-operative Injury (Intra-operative
injury - Biliary tree-right hepatic duct)
Bladder Perforation Postoperative (Intra-
operative injury - Bladder)
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Intra-operative Injury (Intra-operative
injury - Bone)
Intra-operative Injury (Intra-operative
injury - Brachial plexus)
Intra-operative Injury (Intra-operative
injury - Brain)
Intra-operative Injury (Intra-operative
injury - Breast)
Intra-operative Injury (Intra-operative
injury - Bronchus)
Intra-operative Injury (Intra-operative
injury - Cartilage)
Intra-operative Injury (Intra-operative
injury - Cecum)
Intra-operative Injury (Intra-operative
injury - Cervix)
Intra-operative Injury (Intra-operative
injury - CN I (olfactory))
Intra-operative Injury (Intra-operative
injury - CN II (optic))
Intra-operative Injury (Intra-operative
injury - CN III (oculomotor))
Intra-operative Injury (Intra-operative
injury - CN IV (trochlear))
Intra-operative Injury (Intra-operative
injury - CN IX (glossopharyngeal) motor
pharynx)
Intra-operative Injury (Intra-operative
injury - CN IX (glossopharyngeal)
sensory ear-pharynx-tongue)
Intra-operative Injury (Intra-operative
injury - CN V (trigeminal) motor)
Intra-operative Injury (Intra-operative
injury - CN V (trigeminal) sensory)
Intra-operative Injury (Intra-operative
injury - CN VI (abducens))
Intra-operative Injury (Intra-operative
injury - CN VII (facial) motor-face)
Intra-operative Injury (Intra-operative
injury - CN VII (facial) sensory-taste)
Intra-operative Injury (Intra-operative
injury - CN VIII (vestibulocochlear))
Intra-operative Injury (Intra-operative
injury - CN X (vagus))
Intra-operative Injury (Intra-operative
injury - CN XI (spinal accessory))
Intra-operative Injury (Intra-operative
injury - CN XII (hypoglossal))
Intra-operative Injury (Intra-operative
injury - Colon)
Intra-operative Injury (Intra-operative
injury - Conjunctiva)
Intra-operative Injury (Intra-operative
injury - Cornea)
Intra-operative Injury (Intra-operative
injury - Cranial nerve or branch NOS)
Intra-operative Injury (Intra-operative
injury - Duodenum)
Intra-operative Injury (Intra-operative
injury - Esophagus)
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Intra-operative Injury (Intra-operative
injury - Extremity-lower)
Intra-operative Injury (Intra-operative
injury - Extremity-upper)
Intra-operative Injury (Intra-operative
injury - Eye NOS)
Intra-operative Injury (Intra-operative
injury - Face NOS)
Intra-operative Injury (Intra-operative
injury - Fallopian tube)
Intra-operative Injury (Intra-operative
injury - Gallbladder)
Intra-operative Injury (Intra-operative
injury - Gingiva)
Intra-operative Injury (Intra-operative
injury - Heart)
Intra-operative Injury (Intra-operative
injury - Ileum)
Intra-operative Injury (Intra-operative
injury - Inner ear)
Intra-operative Injury (Intra-operative
injury - Jejunum)
Intra-operative Injury (Intra-operative
injury - Joint)
Intra-operative Injury (Intra-operative
injury - Kidney)
Intra-operative Injury (Intra-operative
injury - Larynx)
Intra-operative Injury (Intra-operative
injury - Lens)
Intra-operative Injury (Intra-operative
injury - Ligament)
Intra-operative Injury (Intra-operative
injury - Lingual)
Intra-operative Injury (Intra-operative
injury - Lip/perioral area)
Intra-operative Injury (Intra-operative
injury - Liver)
Intra-operative Injury (Intra-operative
injury - Lung)
Intra-operative Injury (Intra-operative
injury - Lung thoracic)
Intra-operative Injury (Intra-operative
injury - Mediastinum)
Intra-operative Injury (Intra-operative
injury - Meninges)
Intra-operative Injury (Intra-operative
injury - Middle ear)
Intra-operative Injury (Intra-operative
injury - Muscle)
Intra-operative Injury (Intra-operative
injury - Nails)
Intra-operative Injury (Intra-operative
injury - Nasal cavity)
Intra-operative Injury (Intra-operative
injury - Nasopharynx)
Intra-operative Injury (Intra-operative
injury - Neck NOS)
Intra-operative Injury (Intra-operative
injury - Nose)
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Intra-operative Injury (Intra-operative
injury - Oral)
Intra-operative Injury (Intra-operative
injury - Oral cavity NOS)
Intra-operative Injury (Intra-operative
injury - Outer ear NOS)
Intra-operative Injury (Intra-operative
injury - Outer ear-pinna)
Intra-operative Injury (Intra-operative
injury - Ovary)
Intra-operative Injury (Intra-operative
injury - Pancreas)
Intra-operative Injury (Intra-operative
injury - Pancreatic duct)
Intra-operative Injury (Intra-operative
injury - Parathyroid)
Intra-operative Injury (Intra-operative
injury - Parotid gland)
Intra-operative Injury (Intra-operative
injury - Pelvis NOS)
Intra-operative Injury (Intra-operative
injury - Penis)
Intra-operative Injury (Intra-operative
injury - Peripheral motor NOS)
Intra-operative Injury (Intra-operative
injury - Peripheral sensory NOS)
Intra-operative Injury (Intra-operative
injury - Peritoneal cavity)
Intra-operative Injury (Intra-operative
injury - Pharynx)
Intra-operative Injury (Intra-operative
injury - Pituitary)
Intra-operative Injury (Intra-operative
injury - Pleura)
Intra-operative Injury (Intra-operative
injury - Prostate)
Intra-operative Injury (Intra-operative
injury - Rectum)
Intra-operative Injury (Intra-operative
injury - Recurrent laryngeal)
Intra-operative Injury (Intra-operative
injury - Retina)
Intra-operative Injury (Intra-operative
injury - Sacral plexus)
Intra-operative Injury (Intra-operative
injury - Salivary duct)
Intra-operative Injury (Intra-operative
injury - Salivary gland)
Intra-operative Injury (Intra-operative
injury - Sciatic)
Intra-operative Injury (Intra-operative
injury - Scrotum)
Intra-operative Injury (Intra-operative
injury - Sinus)
Intra-operative Injury (Intra-operative
injury - Skin)
Intra-operative Injury (Intra-operative
injury - Small bowel NOS)
Intra-operative Injury (Intra-operative
injury - Soft tissue NOS)
31 / 48
Lung Cancer NCT00533949 Follow-Up - RTOG-0617 F1: Radiation Therapy
Oncology Group Phase III Lung Pre-Op Chemotherapy vs. Pre-Op Concurrent
Chemoradiation for NSCLC Follow-up Form - 2556229v1.0
Intra-operative Injury (Intra-operative
injury - Spinal cord)
Intra-operative Injury (Intra-operative
injury - Spleen)
Intra-operative Injury (Intra-operative
injury - Stoma (GI))
Intra-operative Injury (Intra-operative
injury - Stomach)
Intra-operative Injury (Intra-operative
injury - Teeth)
Intra-operative Injury (Intra-operative
injury - Tendon)
Intra-operative Injury (Intra-operative
injury - Testis)
Intra-operative Injury (Intra-operative
injury - Thoracic duct)
Intra-operative Injury (Intra-operative
injury - Thoracodorsal)
Intra-operative Injury (Intra-operative
injury - Thyroid)
Intra-operative Injury (Intra-operative
injury - Tongue)
Intra-operative Injury (Intra-operative
injury - Trachea)
Intra-operative Injury (Intra-operative
injury - Upper aerodigestive NOS)
Intra-operative Injury (Intra-operative
injury - Upper airway NOS)
Intra-operative Injury (Intra-operative
injury - Ureter)
Intra-operative Injury (Intra-operative
injury - Urethra)
Intra-operative Injury (Intra-operative
injury - Urinary conduit)
Intra-operative Injury (Intra-operative
injury - Urinary tract NOS)
Intra-operative Injury (Intra-operative
injury - Uterus)
Intra-operative Injury (Intra-operative
injury - Vagina)
Intra-operative Injury - Vein (Intra-
operative injury - Vein NOS)
Intra-operative Injury (Intra-operative
injury - Vein-extremity (lower))
Intra-operative Injury (Intra-operative
injury - Vein-extremity (upper))
Intra-operative Injury (Intra-operative
injury - Vein-hepatic)
Intra-operative Injury (Intra-operative
injury - Vein-inferior vena cava)
Intra-operative Injury (Intra-operative
injury - Vein-jugular)
Intra-operative Injury (Intra-operative
injury - Vein-major visceral vein)
Intra-operative Injury (Intra-operative
injury - Vein-portal vein)
Intra-operative Injury (Intra-operative
injury - Vein-pulmonary)
Intra-operative Injury (Intra-operative
injury - Vein-superior vena cava)
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Intra-operative Injury (Intra-operative
injury - Vulva)
Intra-operative Injury Other (Intra-
operative Injury-Other (Specify))
Iron Overload (Iron overload)
Menstruation Irregular (Irregular menses
(change from baseline))
Irritability (Irritability (children <3 years of
age))
Joint-effusion (Joint-effusion)
Joint-effusion (Joint-function)
Keratitis Nec (Keratitis (corneal
inflammation/corneal ulceration))
Laryngeal Nerve Dysfunction (Laryngeal
nerve dysfunction)
Leak (including Anastomotic), Gi (Leak
(including anastomotic), GI - Biliary tree)
Leak (including Anastomotic), Gi (Leak
(including anastomotic), GI - Esophagus)
Leak (including Anastomotic), Gi (Leak
(including anastomotic), GI - Large
bowel)
Leak (including Anastomotic), Gi (Leak
(including anastomotic), GI - Leak NOS)
Leak (including Anastomotic), Gi (Leak
(including anastomotic), GI - Pancreas)
Leak (including Anastomotic), Gi (Leak
(including anastomotic), GI - Pharynx)
Leak (including Anastomotic), Gi (Leak
(including anastomotic), GI - Rectum)
Leak (including Anastomotic), Gi (Leak
(including anastomotic), GI - Small
bowel)
Leak (including Anastomotic), Gi (Leak
(including anastomotic), GI - Stoma)
Leak (including Anastomotic), Gi (Leak
(including anastomotic), GI - Stomach)
Leak (including Anastomotic), Gu (Leak
(including anastomotic), GU - Bladder)
Leak (including Anastomotic), Gu (Leak
(including anastomotic), GU - Fallopian
tube)
Leak (including Anastomotic), Gu (Leak
(including anastomotic), GU - Kidney)
Leak (including Anastomotic), Gu (Leak
(including anastomotic), GU - Spermatic
cord)
Leak (including Anastomotic), Gu (Leak
(including anastomotic), GU - Stoma)
Leak (including Anastomotic), Gu (Leak
(including anastomotic), GU - Ureter)
Leak (including Anastomotic), Gu (Leak
(including anastomotic), GU - Urethra)
Leak (including Anastomotic), Gu (Leak
(including anastomotic), GU - Uterus)
Leak (including Anastomotic), Gu (Leak
(including anastomotic), GU - Vagina)
Leak (including Anastomotic), Gu (Leak
(including anastomotic), GU - Vas
deferens)
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Leak, Cerebrospinal Fluid (csf) (Leak,
cerebrospinal fluid (CSF))
Left Ventricular Diastolic Dysfunction
(Left ventricular diastolic dysfunction)
Left Ventricular Failure (Left ventricular
systolic dysfunction)
Leucopenia Nos (Leukocytes (total
WBC))
Encephalopathy Nos
(Leukoencephalopathy (radiolographic
findings))
Libido Decreased (Libido)
Lipase Increased (Lipase)
Hepatic Failure (Liver dysfunction/failure
(clinical))
Local Complication - Device/prosthesis-
related (Local complication -
device/prosthesis-related)
Lumbar Spine-range Of Motion (Lumbar
spine-range of motion)
Lymphatics Other (Lymphatics-Other
(Specify))
Lymphedema-related Fibrosis
(Lymphedema-related fibrosis)
Lymphocele (Lymphocele)
Lymphopenia (Lymphopenia)
Hypermagnesaemia (Magnesium,
serum-high (hypermagnesemia))
Blood Magnesium Decreased
(Magnesium, serum-low
(hypomagnesemia))
Malabsorption (Malabsorption)
Virilism (Masculinization of female)
Amnesia Nec (Memory impairment)
Mental Status (Mental status)
Metabolic/laboratory Other
(Metabolic/Laboratory-Other (Specify))
Mood Alteration - Agitation (Mood
alteration - agitation)
Anxiety Nec (Mood alteration - anxiety)
Depression Nec (Mood alteration -
depression)
Euphoric Mood (Mood alteration -
euphoria)
Mucositis/stomatitis (clinical Exam)
(Mucositis/stomatitis (clinical exam) -
Anus)
Mucositis/stomatitis (clinical Exam)
(Mucositis/stomatitis (clinical exam) -
Esophagus)
Mucositis/stomatitis (clinical Exam)
(Mucositis/stomatitis (clinical exam) -
Large bowel)
Mucositis/stomatitis (clinical Exam)
(Mucositis/stomatitis (clinical exam) -
Larynx)
Mucositis/stomatitis (clinical Exam)
(Mucositis/stomatitis (clinical exam) -
Oral cavity)
Stomatitis (Mucositis/stomatitis (clinical
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exam) - Pharynx)
Mucositis/stomatitis (clinical Exam)
(Mucositis/stomatitis (clinical exam) -
Rectum)
Mucositis/stomatitis (clinical Exam)
(Mucositis/stomatitis (clinical exam) -
Small bowel)
Mucositis/stomatitis (clinical Exam)
(Mucositis/stomatitis (clinical exam) -
Stomach)
Mucositis/stomatitis (clinical Exam)
(Mucositis/stomatitis (clinical exam) -
Trachea)
Mucositis/stomatitis
(functional/symptomatic)
(Mucositis/stomatitis
(functional/symptomatic) - Anus)
Mucositis/stomatitis
(functional/symptomatic)
(Mucositis/stomatitis
(functional/symptomatic) - Esophagus)
Mucositis/stomatitis
(functional/symptomatic)
(Mucositis/stomatitis
(functional/symptomatic) - Large bowel)
Mucositis/stomatitis
(functional/symptomatic)
(Mucositis/stomatitis
(functional/symptomatic) - Larynx)
Mucositis/stomatitis
(functional/symptomatic)
(Mucositis/stomatitis
(functional/symptomatic) - Oral cavity)
Mucositis/stomatitis
(functional/symptomatic)
(Mucositis/stomatitis
(functional/symptomatic) - Pharynx)
Mucositis/stomatitis
(functional/symptomatic)
(Mucositis/stomatitis
(functional/symptomatic) - Rectum)
Mucositis/stomatitis
(functional/symptomatic)
(Mucositis/stomatitis
(functional/symptomatic) - Small bowel)
Mucositis/stomatitis
(functional/symptomatic)
(Mucositis/stomatitis
(functional/symptomatic) - Stomach)
Mucositis/stomatitis
(functional/symptomatic)
(Mucositis/stomatitis
(functional/symptomatic) - Trachea)
Muscle Weakness, Generalized Or
Specific Area (not Due To Neuropathy)
(Muscle weakness, generalized or
specific area (not due to neuropathy) -
Extraocular)
Muscle Weakness, Generalized Or
Specific Area (not Due To Neuropathy)
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(Muscle weakness, generalized or
specific area (not due to neuropathy) -
Extremity-lower)
Muscle Weakness, Generalized Or
Specific Area (not Due To Neuropathy)
(Muscle weakness, generalized or
specific area (not due to neuropathy) -
Extremity-upper)
Muscle Weakness, Generalized Or
Specific Area (not Due To Neuropathy)
(Muscle weakness, generalized or
specific area (not due to neuropathy) -
Facial)
Muscle Weakness, Generalized Or
Specific Area (not Due To Neuropathy)
(Muscle weakness, generalized or
specific area (not due to neuropathy) -
Left-sided)
Muscle Weakness, Generalized Or
Specific Area (not Due To Neuropathy)
(Muscle weakness, generalized or
specific area (not due to neuropathy) -
Ocular)
Muscle Weakness, Generalized Or
Specific Area (not Due To Neuropathy)
(Muscle weakness, generalized or
specific area (not due to neuropathy) -
Pelvic)
Muscle Weakness, Generalized Or
Specific Area (not Due To Neuropathy)
(Muscle weakness, generalized or
specific area (not due to neuropathy) -
Right-sided)
Muscle Weakness, Generalized Or
Specific Area (not Due To Neuropathy)
(Muscle weakness, generalized or
specific area (not due to neuropathy) -
Trunk)
Muscle Weakness Nos (Muscle
weakness, generalized or specific area
(not due to neuropathy) - Whole
body/generalized)
Muscular/skeletal Hypoplasia
(Muscular/skeletal hypoplasia)
Musculoskeletal/soft Tissue Other
(Musculoskeletal/Soft Tissue-Other
(Specify))
Myelitis (Myelitis)
Myelodysplasia (Myelodysplasia)
Myocarditis Nos (Myocarditis)
Myositis (Myositis (inflammation/damage
of muscle))
Nail Abnormality Nos (Nail changes)
Nasal Cavity/paranasal Sinus Reactions
(Nasal cavity/paranasal sinus reactions)
Nausea (Nausea)
Necrosis, Gi (Necrosis, GI - Anus)
Necrosis, Gi (Necrosis, GI -
Colon/cecum/appendix)
Necrosis, Gi (Necrosis, GI - Duodenum)
36 / 48
Lung Cancer NCT00533949 Follow-Up - RTOG-0617 F1: Radiation Therapy
Oncology Group Phase III Lung Pre-Op Chemotherapy vs. Pre-Op Concurrent
Chemoradiation for NSCLC Follow-up Form - 2556229v1.0
Necrosis, Gi (Necrosis, GI - Esophagus)
Necrosis, Gi (Necrosis, GI - Gallbladder)
Necrosis, Gi (Necrosis, GI - Hepatic)
Necrosis, Gi (Necrosis, GI - Ileum)
Necrosis, Gi (Necrosis, GI - Jejunum)
Necrosis, Gi (Necrosis, GI - Oral)
Necrosis, Gi (Necrosis, GI - Pancreas)
Necrosis, Gi (Necrosis, GI - Peritoneal
cavity)
Necrosis, Gi (Necrosis, GI - Pharynx)
Necrosis, Gi (Necrosis, GI - Rectum)
Necrosis, Gi (Necrosis, GI - Small bowel
NOS)
Necrosis, Gi (Necrosis, GI - Stoma)
Necrosis, Gi (Necrosis, GI - Stomach)
Neuroendocrine: Acth Deficiency
(Neuroendocrine: ACTH deficiency)
Inappropriate Adh Secretion
(Neuroendocrine: ADH secretion
abnormality (e.g., SIADH or low ADH))
Neuroendocrine: Gonadotropin Secretion
Abnormality (Neuroendocrine:
gonadotropin secretion abnormality)
Neuroendocrine: Growth Hormone
Secretion Abnormality (Neuroendocrine:
growth hormone secretion abnormality)
Neuroendocrine: Prolactin Hormone
Secretion Abnormality (Neuroendocrine:
prolactin hormone secretion abnormality)
Neurology Other (Neurology-Other
(Specify))
Parosmia (Neuropathy: cranial - CN I
Smell)
Cranial Nerve Injury Nos (Neuropathy:
cranial - CN II Vision)
Neuropathy: Cranial (Neuropathy: cranial
- CN III Pupil, upper eyelid, extra ocular
movements)
Neuropathy: Cranial (Neuropathy: cranial
- CN IV Downward, inward movement of
eye)
Neuropathy: Cranial (Neuropathy: cranial
- CN IX Motor-pharynx; Sensory-ear,
pharynx, tongue)
Neuropathy: Cranial (Neuropathy: cranial
- CN V Motor-jaw muscles; Sensory-
facial)
Neuropathy: Cranial (Neuropathy: cranial
- CN VI Lateral deviation of eye)
Neuropathy: Cranial (Neuropathy: cranial
- CN VII Motor-face; Sensory-taste)
Neuropathy: Cranial (Neuropathy: cranial
- CN VIII Hearing and balance)
Neuropathy: Cranial (Neuropathy: cranial
- CN X Motor-palate; pharynx, larynx)
Neuropathy: Cranial (Neuropathy: cranial
- CN XI Motor-sternomastoid and
trapezius)
Neuropathy: Cranial (Neuropathy: cranial
- CN XII Motor-tongue)
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Peripheral Motor Neuropathy
(Neuropathy: motor)
Peripheral Sensory Neuropathy
(Neuropathy: sensory)
Neutropenia (Neutrophils/granulocytes
(ANC/AGC))
Blindness Night (Night blindness
(nyctalopia))
Nystagmus Nos (Nystagmus)
Obesity (Obesity)
Obstruction, Gi (Obstruction, GI -
Cecum)
Obstruction, Gi (Obstruction, GI - Colon)
Obstruction, Gi (Obstruction, GI -
Duodenum)
Obstruction, Gi (Obstruction, GI -
Esophagus)
Obstruction, Gi (Obstruction, GI -
Gallbladder)
Obstruction, Gi (Obstruction, GI - Ileum)
Obstruction, Gi (Obstruction, GI -
Jejunum)
Obstruction, Gi (Obstruction, GI -
Rectum)
Obstruction, Gi (Obstruction, GI - Small
bowel NOS)
Obstruction, Gi (Obstruction, GI - Stoma)
Obstruction, Gi (Obstruction, GI -
Stomach)
Obstruction, Gu (Obstruction, GU -
Bladder)
Obstruction, Gu (Obstruction, GU -
Fallopian tube)
Obstruction, Gu (Obstruction, GU -
Prostate)
Obstruction, Gu (Obstruction, GU -
Spermatic cord)
Obstruction, Gu (Obstruction, GU -
Stoma)
Obstruction, Gu (Obstruction, GU -
Testes)
Ureteric Obstruction (Obstruction, GU -
Ureter)
Obstruction, Gu (Obstruction, GU -
Urethra)
Obstruction, Gu (Obstruction, GU -
Uterus)
Obstruction, Gu (Obstruction, GU -
Vagina)
Obstruction, Gu (Obstruction, GU - Vas
deferens)
Obstruction/stenosis Of Airway
(Obstruction/stenosis of airway -
Bronchus)
Obstruction/stenosis Of Airway
(Obstruction/stenosis of airway - Larynx)
Obstruction/stenosis Of Airway
(Obstruction/stenosis of airway -
Pharynx)
Obstruction/stenosis Of Airway
38 / 48
Lung Cancer NCT00533949 Follow-Up - RTOG-0617 F1: Radiation Therapy
Oncology Group Phase III Lung Pre-Op Chemotherapy vs. Pre-Op Concurrent
Chemoradiation for NSCLC Follow-up Form - 2556229v1.0
(Obstruction/stenosis of airway -
Trachea)
Conjunctivitis Nec (Ocular surface
disease)
Ocular/visual Other (Ocular/Visual-Other
(Specify))
Odor (patient Odor) (Odor (patient odor))
Diplopia (Ophthalmoplegia/diplopia
(double vision))
Opportunistic Infection Associated With
>=grade 2 Lymphopenia (Opportunistic
infection associated with >=Grade 2
lymphopenia)
Optic Disc Edema (Optic disc edema)
Orgasmic Dysfunction (Orgasmic
dysfunction)
Osteonecrosis (Osteonecrosis (avascular
necrosis))
Osteoporosis (Osteoporosis)
Otitis Externa (exc Boil Of Meatus) Nos
(Otitis, external ear (non-infectious))
Otitis Media Serous Nos (Otitis, middle
ear (non-infectious))
Abdominal Pain Nos (Pain - Abdomen
NOS)
Pain (Pain - Anus)
Pain (Pain - Back)
Pain (Pain - Bladder)
Bone Pain (Pain - Bone)
Pain (Pain - Breast)
Pain (Pain - Buttock)
Pain (Pain - Cardiac/heart)
Pain (Pain - Chest wall)
Chest Pain (Pain - Chest/thorax NOS)
Pain (Pain - Dental/teeth/peridontal)
Pain (Pain - Esophagus)
Earache (Pain - External ear)
Pain (Pain - Extremity-limb)
Pain (Pain - Eye)
Pain (Pain - Face)
Pain (Pain - Gallbladder)
Headache Nos (Pain - Head/headache)
Pain (Pain - Intestine)
Arthralgia (Pain - Joint)
Pain (Pain - Kidney)
Pain (Pain - Larynx)
Pain (Pain - Lip)
Hepatic Pain (Pain - Liver)
Pain (Pain - Lymph node)
Pain (Pain - Middle ear)
Myalgia (Pain - Muscle)
Pain (Pain - Neck)
Neuralgia Nos (Pain -
Neuralgia/peripheral nerve)
Pain (Pain - Oral cavity)
Pain (Pain - Oral-gums)
Pain (Pain - Ovulatory)
Pain (Pain - Pain NOS)
Pelvic Pain Nos (Pain - Pelvis)
Pain (Pain - Penis)
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Pain (Pain - Pericardium)
Pain (Pain - Perineum)
Pain (Pain - Peritoneum)
Pain (Pain - Phantom (pain associated
with missing limb))
Pleuritic Pain (Pain - Pleura)
Pain (Pain - Prostate)
Proctalgia (Pain - Rectum)
Pain (Pain - Scalp)
Pain (Pain - Scrotum)
Pain (Pain - Sinus)
Pain (Pain - Skin)
Pain (Pain - Stomach)
Pain (Pain - Testicle)
Pain (Pain - Throat/pharynx/larynx)
Tumour Pain (Pain - Tumor pain)
Dysuria (Pain - Urethra)
Dysmenorrhoea (Pain - Uterus)
Pain (Pain - Vagina)
Pain Other (Pain-Other (Specify))
Palpitations (Palpitations)
Pancreas, Exocrine Enzyme Deficiency
(Pancreas, exocrine enzyme deficiency)
Pancreatic Endocrine: Glucose
Intolerance (Pancreatic endocrine:
glucose intolerance)
Pancreatitis Nos (Pancreatitis)
Parathyroid Function, Low
(hypoparathyroidism) (Parathyroid
function, low (hypoparathyroidism))
Perforation, Gi (Perforation, GI -
Appendix)
Perforation, Gi (Perforation, GI - Biliary
tree)
Perforation, Gi (Perforation, GI - Cecum)
Perforation, Gi (Perforation, GI - Colon)
Perforation, Gi (Perforation, GI -
Duodenum)
Perforation, Gi (Perforation, GI -
Esophagus)
Perforation, Gi (Perforation, GI -
Gallbladder)
Perforation, Gi (Perforation, GI - Ileum)
Perforation, Gi (Perforation, GI -
Jejunum)
Perforation, Gi (Perforation, GI - Rectum)
Perforation, Gi (Perforation, GI - Small
bowel NOS)
Perforation, Gi (Perforation, GI -
Stomach)
Perforation, Gu (Perforation, GU -
Bladder)
Perforation, Gu (Perforation, GU -
Fallopian tube)
Perforation, Gu (Perforation, GU -
Kidney)
Perforation, Gu (Perforation, GU - Ovary)
Perforation, Gu (Perforation, GU -
Prostate)
Perforation, Gu (Perforation, GU -
40 / 48
Lung Cancer NCT00533949 Follow-Up - RTOG-0617 F1: Radiation Therapy
Oncology Group Phase III Lung Pre-Op Chemotherapy vs. Pre-Op Concurrent
Chemoradiation for NSCLC Follow-up Form - 2556229v1.0
Spermatic cord)
Perforation, Gu (Perforation, GU -
Stoma)
Perforation, Gu (Perforation, GU -
Testes)
Perforation, Gu (Perforation, GU - Ureter)
Perforation, Gu (Perforation, GU -
Urethra)
Perforation, Gu (Perforation, GU -
Uterus)
Perforation, Gu (Perforation, GU -
Vagina)
Perforation, Gu (Perforation, GU - Vas
deferens)
Pericardial Effusion (Pericardial effusion
(non-malignant))
Pericarditis (Pericarditis)
Peripheral Ischaemia Nos (Peripheral
arterial ischemia)
Personality Change
(Personality/behavioral)
Petechiae (Petechiae/purpura
(hemorrhage/bleeding into skin or
mucosa))
Phlebitis Superficial (Phlebitis (including
superficial thrombosis))
Phlebolymphatic Cording
(Phlebolymphatic cording)
Hypophosphataemia (Phosphate, serum-
low (hypophosphatemia))
Photosensitivity Reaction Nos
(Photosensitivity)
Phrenic Nerve Dysfunction (Phrenic
nerve dysfunction)
Platelet Count Decreased (Platelets)
Pleural Effusion (Pleural effusion (non-
malignant))
Pneumonitis Nos
(Pneumonitis/pulmonary infiltrates)
Pneumothorax Nos (Pneumothorax)
Portal Hypertension (Portal vein flow)
Hyperkalaemia (Potassium, serum-high
(hyperkalemia))
Hypokalaemia (Potassium, serum-low
(hypokalemia))
Proctitis Nos (Proctitis)
Prolapse Of Stoma, Gi (Prolapse of
stoma, GI)
Prolapse Of Stoma, Gu (Prolapse of
stoma, GU)
Prolonged Chest Tube Drainage Or Air
Leak After Pulmonary Resection
(Prolonged chest tube drainage or air
leak after pulmonary resection)
Prolonged Intubation After Pulmonary
Resection (>24 Hrs After Surgery)
(Prolonged intubation after pulmonary
resection (>24 hrs after surgery))
Electrocardiogram Qt Prolonged
(Prolonged QTc interval)
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Proptosis/enophthalmos
(Proptosis/enophthalmos)
Proteinuria Present (Proteinuria)
Pruritus Nos (Pruritus/itching)
Delusion Nos (Psychosis
(hallucinations/delusions))
Activated Partial Thromboplastin Time
Prolonged (PTT (Partial thromboplastin
time))
Puberty (delayed) (Puberty (delayed))
Puberty (precocious) (Puberty
(precocious))
Pulmonary Fibrosis (Pulmonary fibrosis
(radiographic changes))
Pulmonary Hypertension (Pulmonary
hypertension)
Pulmonary/upper Respiratory Other
(Pulmonary/Upper Respiratory-Other
(Specify))
Upper Motor Neurone Lesion (Pyramidal
tract dysfunction (e.g., increased tone,
hyperreflexia, positive Babinski,
decreased fine motor coordination))
Rash: Acne/acneiform (Rash:
acne/acneiform)
Radiation Recall Syndrome (Rash:
dermatitis associated with radiation -
Chemoradiation)
Dermatitis Radiation Nos (Rash:
dermatitis associated with radiation -
Radiation)
Erythema Multiforme (Rash: erythema
multiforme (e.g., Stevens-Johnson
syndrome, toxic epidermal necrolysis))
Localised Exfoliation (Rash: hand-foot
skin reaction)
Dermatitis Exfoliative Nos
(Rash/desquamation)
Renal Failure Nos (Renal failure)
Renal/genitourinary Other
(Renal/Genitourinary-Other (Specify))
Restrictive Cardiomyopathy (Restrictive
cardiomyopathy)
Retinal Detachment (Retinal
detachment)
Retinoic Acid Syndrome (Retinoic acid
syndrome")
Retinopathy (Retinopathy)
Right Ventricular Dysfunction (cor
Pulmonale) (Right ventricular dysfunction
(cor pulmonale))
Rigors (Rigors/chills)
Salivary Gland Disorder Nos (Salivary
gland changes/saliva)
Scleral Necrosis/melt (Scleral
necrosis/melt)
Secondary Malignancy Possibly Related
To Cancer Treatment (Secondary
Malignancy-possibly related to cancer
treatment (Specify))
42 / 48
Lung Cancer NCT00533949 Follow-Up - RTOG-0617 F1: Radiation Therapy
Oncology Group Phase III Lung Pre-Op Chemotherapy vs. Pre-Op Concurrent
Chemoradiation for NSCLC Follow-up Form - 2556229v1.0
Convulsions Nos (Seizure)
Seroma (Seroma)
Serum Sickness (Serum sickness)
Sexual/reproductive Function Other
(Sexual/Reproductive Function-Other
(Specify))
Short Stature (Short stature)
Skin Breakdown/decubitus Ulcer (Skin
breakdown/decubitus ulcer)
Hypernatraemia (Sodium, serum-high
(hypernatremia))
Hyponatraemia (Sodium, serum-low
(hyponatremia))
Soft Tissue Necrosis (Soft tissue
necrosis - Abdomen)
Soft Tissue Necrosis (Soft tissue
necrosis - Extremity-lower)
Soft Tissue Necrosis (Soft tissue
necrosis - Extremity-upper)
Soft Tissue Necrosis (Soft tissue
necrosis - Head)
Soft Tissue Necrosis (Soft tissue
necrosis - Neck)
Soft Tissue Necrosis (Soft tissue
necrosis - Pelvic)
Soft Tissue Necrosis (Soft tissue
necrosis - Thorax)
Depressed Level Of Consciousness
(Somnolence/depressed level of
consciousness)
Speech Disorder Nec (Speech
impairment (e.g., dysphasia or aphasia))
Splenic Function (Splenic function)
Striae (Striae)
Stricture/stenosis (including
Anastomotic), Gi (Stricture/stenosis
(including anastomotic), GI - Anus)
Stricture/stenosis (including
Anastomotic), Gi (Stricture/stenosis
(including anastomotic), GI - Biliary tree)
Stricture/stenosis (including
Anastomotic), Gi (Stricture/stenosis
(including anastomotic), GI - Cecum)
Stricture/stenosis (including
Anastomotic), Gi (Stricture/stenosis
(including anastomotic), GI - Colon)
Stricture/stenosis (including
Anastomotic), Gi (Stricture/stenosis
(including anastomotic), GI - Duodenum)
Stricture/stenosis (including
Anastomotic), Gi (Stricture/stenosis
(including anastomotic), GI - Esophagus)
Stricture/stenosis (including
Anastomotic), Gi (Stricture/stenosis
(including anastomotic), GI - Ileum)
Stricture/stenosis (including
Anastomotic), Gi (Stricture/stenosis
(including anastomotic), GI - Jejunum)
Stricture/stenosis (including
Anastomotic), Gi (Stricture/stenosis
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(including anastomotic), GI -
Pancreas/pancreatic duct)
Stricture/stenosis (including
Anastomotic), Gi (Stricture/stenosis
(including anastomotic), GI - Pharynx)
Stricture/stenosis (including
Anastomotic), Gi (Stricture/stenosis
(including anastomotic), GI - Rectum)
Stricture/stenosis (including
Anastomotic), Gi (Stricture/stenosis
(including anastomotic), GI - Small bowel
NOS)
Stricture/stenosis (including
Anastomotic), Gi (Stricture/stenosis
(including anastomotic), GI - Stoma)
Stricture/stenosis (including
Anastomotic), Gi (Stricture/stenosis
(including anastomotic), GI - Stomach)
Stricture/stenosis (including
Anastomotic), Gu (Stricture/stenosis
(including anastomotic), GU - Bladder)
Stricture/stenosis (including
Anastomotic), Gu (Stricture/stenosis
(including anastomotic), GU - Fallopian
tube)
Stricture/stenosis (including
Anastomotic), Gu (Stricture/stenosis
(including anastomotic), GU - Prostate)
Stricture/stenosis (including
Anastomotic), Gu (Stricture/stenosis
(including anastomotic), GU - Spermatic
cord)
Stricture/stenosis (including
Anastomotic), Gu (Stricture/stenosis
(including anastomotic), GU - Stoma)
Stricture/stenosis (including
Anastomotic), Gu (Stricture/stenosis
(including anastomotic), GU - Testes)
Stricture/stenosis (including
Anastomotic), Gu (Stricture/stenosis
(including anastomotic), GU - Ureter)
Stricture/stenosis (including
Anastomotic), Gu (Stricture/stenosis
(including anastomotic), GU - Urethra)
Stricture/stenosis (including
Anastomotic), Gu (Stricture/stenosis
(including anastomotic), GU - Uterus)
Stricture/stenosis (including
Anastomotic), Gu (Stricture/stenosis
(including anastomotic), GU - Vagina)
Stricture/stenosis (including
Anastomotic), Gu (Stricture/stenosis
(including anastomotic), GU - Vas
deferens)
Supraventricular And Nodal Arrhythmia
(Supraventricular and nodal arrhythmia -
Atrial fibrillation)
Supraventricular And Nodal Arrhythmia
(Supraventricular and nodal arrhythmia -
Atrial flutter)
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Supraventricular And Nodal Arrhythmia
(Supraventricular and nodal arrhythmia -
Atrial tachycardia/paroxysmal atrial
tachycardia)
Supraventricular And Nodal Arrhythmia
(Supraventricular and nodal arrhythmia -
Nodal/junctional)
Supraventricular And Nodal Arrhythmia
(Supraventricular and nodal arrhythmia -
Sinus arrhythmia)
Sinus Bradycardia (Supraventricular and
nodal arrhythmia - Sinus bradycardia)
Sinus Tachycardia (Supraventricular and
nodal arrhythmia - Sinus tachycardia)
Supraventricular Arrhythmia Nos
(Supraventricular and nodal arrhythmia -
Supraventricular arrhythmia NOS)
Supraventricular And Nodal Arrhythmia -
Supraventricular Extrasystoles
(premature Atrial Contractions;
Premature Nodal/junctional
Contractions) (Supraventricular and
nodal arrhythmia - Supraventricular
extrasystoles (premature atrial
contractions; premature nodal/junctional
contractions))
Supraventricular And Nodal Arrhythmia
(Supraventricular and nodal arrhythmia -
Supraventricular tachycardia)
Sweating Increased (Sweating
(diaphoresis))
Syncope (Syncope (fainting))
Syndromes Other (Syndromes-Other
(Specify))
Taste Disturbance (Taste alteration
(dysgeusia))
Telangiectasia (Telangiectasia)
Thrombosis/embolism (vascular Access-
related) (Thrombosis/embolism (vascular
access-related))
Thrombosis Nos
(Thrombosis/thrombus/embolism)
Thrombotic Microangiopathy (e.g.,
Thrombotic Thrombocytopenic
Purpura[ttp] Or Hemolytic Uremic
Syndrome[hus]) (Thrombotic
microangiopathy (e.g., thrombotic
thrombocytopenic purpura or hemolytic
uremic syndrome))
Thyroid Function, High (hyperthyroidism,
Thyrotoxicosis) (Thyroid function, high
(hyperthyroidism, thyrotoxicosis))
Hypothyroidism (Thyroid function, low
(hypothyroidism))
Tinnitus (Tinnitus)
Tremor Nec (Tremor)
Hypertriglyceridaemia (Triglyceride,
serum-high (hypertriglyceridemia))
Trismus (difficulty, Restriction Or Pain
When Opening Mouth) (Trismus
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(difficulty, restriction or pain when
opening mouth))
Tumour Flare (Tumor flare)
Tumour Lysis Syndrome (Tumor lysis
syndrome)
Caecitis (Typhlitis (cecal inflammation))
Ulcer, Gi (Ulcer, GI - Anus)
Ulcer, Gi (Ulcer, GI - Cecum)
Ulcer, Gi (Ulcer, GI - Colon)
Duodenal Ulcer (Ulcer, GI - Duodenum)
Ulcer, Gi (Ulcer, GI - Esophagus)
Ulcer, Gi (Ulcer, GI - Ileum)
Ulcer, Gi (Ulcer, GI - Jejunum)
Ulcer, Gi (Ulcer, GI - Rectum)
Ulcer, Gi (Ulcer, GI - Small bowel NOS)
Ulcer, Gi (Ulcer, GI - Stoma)
Gastric Ulcer (Ulcer, GI - Stomach)
Ulceration (Ulceration)
Hyperuricaemia (Uric acid, serum-high
(hyperuricemia))
Fanconi Syndrome (Urinary electrolyte
wasting (e.g., Fanconi's syndrome, renal
tubular acidosis))
Urinary Frequency (Urinary
frequency/urgency)
Urinary Retention (Urinary retention
(including neurogenic bladder))
Urine Discolouration (Urine color
change)
Urticaria Nos (Urticaria (hives, welts,
wheals))
Uveitis (Uveitis)
Vaginal Discharge (non-infectious)
(Vaginal discharge (non-infectious))
Vulvovaginal Dryness (Vaginal dryness)
Vaginal Mucositis (Vaginal mucositis)
Vaginal Stenosis/length (Vaginal
stenosis/length)
Vaginitis (Vaginitis (not due to infection))
Valvular Heart Disease (Valvular heart
disease)
Vascular Other (Vascular-Other
(Specify))
Vasculitis Nos (Vasculitis)
Vasovagal Attack (Vasovagal episode)
Ventricular Arrhythmia (Ventricular
arrhythmia - Bigeminy)
Ventricular Arrhythmia (Ventricular
arrhythmia - Idioventricular rhythm)
Ventricular Arrhythmia (Ventricular
arrhythmia - PVCs)
Ventricular Arrhythmia (Ventricular
arrhythmia - Torsade de pointes)
Ventricular Arrhythmia (Ventricular
arrhythmia - Trigeminy)
Ventricular Arrhythmia Nos (Ventricular
arrhythmia - Ventricular arrhythmia NOS)
Ventricular Arrhythmia (Ventricular
arrhythmia - Ventricular fibrillation)
Ventricular Arrhythmia (Ventricular
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arrhythmia - Ventricular flutter)
Ventricular Arrhythmia (Ventricular
arrhythmia - Ventricular tachycardia)
Vessel Injury-artery (Vessel injury-artery
- Aorta)
Vessel Injury-artery (Vessel injury-artery
- Carotid)
Vessel Injury-artery (Vessel injury-artery
- Extremity-lower)
Vessel Injury-artery (Vessel injury-artery
- Extremity-upper)
Vessel Injury-artery (Vessel injury-artery
- Other NOS)
Vessel Injury-artery (Vessel injury-artery
- Visceral)
Vessel Injury-vein (Vessel injury-vein -
Extremity-lower)
Vessel Injury-vein (Vessel injury-vein -
Extremity-upper)
Vessel Injury-vein (Vessel injury-vein -
IVC)
Vessel Injury-vein (Vessel injury-vein -
Jugular)
Vessel Injury-vein (Vessel injury-vein -
Other NOS)
Vessel Injury-vein (Vessel injury-vein -
SVC)
Vessel Injury-vein (Vessel injury-vein -
Viscera)
Viral Hepatitis (Viral hepatitis)
Visceral Arterial Ischaemia (Visceral
arterial ischemia (non-myocardial))
Vision Blurred (Vision-blurred vision)
Photopsia (Vision-flashing lights/floaters)
Photophobia (Vision-photophobia)
Vital Capacity (Vital capacity)
Vitreous Hemorrhage (Vitreous
hemorrhage)
Dysphonia (Voice changes/dysarthria
(e.g., hoarseness, loss or alteration in
voice, laryngitis))
Vomiting Nos (Vomiting)
Lacrimation Increased (Watery eye
(epiphora, tearing))
Weight Increased (Weight gain)
Weight Decreased (Weight loss)
Culture Wound Negative (Wound
complication, non-infectious)
CTC AE Grade
CTCAE Begin Date
Attribution (Attribution to Protocol Treatment See
protocol sections 6 & 7 for definition of "protocol
treatment")
Definite (Definite)
Possible (Possible)
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Probable (Probable)
Unlikely (Unlikely)
Unrelated (Unrelated)
Has an Adverse Event Expedited Report been
submitted? (AdEERS)
No (No)
Unknown (Unknown)
Yes (Yes)
CTC Adverse Event Term Specify
Comments
Person completing form
Date Form Completed
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NCT00936390 Quality of Life - RTOG 0815 FA:  Radiation Therapy Oncology Group
Phase III Randomized Study of Dose- Escalated Radiotherapy With/Without STAD
for Intermediate-Risk Prostate Cancer EPIC - 2851501v1.0
RTOG 0815 FA:  Radiation Therapy Oncology Group
Phase III Randomized Study of Dose- Escalated
Radiotherapy With/Without STAD for Intermediate-Risk
Prostate Cancer EPIC
Radiation Therapy With or Without Androgen-Deprivation
Therapy in Treating Patients With Prostate Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=6552F996-
36F6-40F6-E040-BB89AD436CB2
All rights reserved. Please visit https://medical-data-
models.org/forms/9513
RTOG 0815 FA:  Radiation Therapy
Oncology Group Phase III
Randomized Study of Dose-
Escalated Radiotherapy
With/Without STAD for Intermediate-
Risk Prostate Cancer EPIC
Unnamed Module 1
RTOG Study No.
Case #
Institution Name
Institution No.
Patient Initials
RTOG Patient ID
Amended data
Yes
No
Unamed Module 2
Time point of this assessment
12 Months After Radiation Therapy (12
months after RT)
6 Months Of Radiation Therapy (6
months after RT)
60 Months After Radiation Therapy (60
months after RT)
Last Week Of Radiation Therapy (Last
week of RT)
Other (Other)
Pretreatment (Pretreatment)
Third Week Of Radiation Therapy (Third
week of RT)
Other specify
1 / 3
Was patient questionnaire completed
Yes
No
Date patient questionnaire completed
Reason Questionnaire was not Completed
Institution Error (Institutional error)
Not Applicable, Questionnaire Was
Completed (Not applicable,
questionnaire was completed)
Other Reason (Other reason)
Patient Refused Due To Illness (Patient
refused due to illness)
Patient Refused For Other Reason
(Patient refused for other reason)
Patient Unable To Be Contacted (Patient
unable to be contacted)
Tool Not Availalble In Patient's Language
(Tool not availalble in patient's language)
Unknown (Unknown)
Patient refused for other reason, specify
Other reason, specify
Specify method of completion
At Appointment (At appointment)
By Mail (By mail)
By Telephone (By telephone)
Not Applicable (Not applicable)
Unknown (Unknown)
Did the patient require any assistance in
completing the questionnaire?
No (No)
Not Applicable (Not applicable)
Unknown If Assistance Given (Unknown
if assistance given)
Yes (Yes)
Specify the person who assisted the patient
Family (Family)
Not Applicable (Not applicable)
Other (Other)
Staff Member (Staff member)
Unknown (Unknown)
Extent of the assistance
Combination Of Above (Combination of
above)
Interpreted Items For Patient (Interpreted
items for patient)
Marked Items Per Patient's Response
(Marked items per patient's response)
Not Applicable (Not applicable)
Other (Other)
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Read Items To Patient (Read items to
patient)
Unknown (Unknown)
Combination of above, specify
Other, specify
Comments
Signature of Person Completing This Form
Date Form Originally Completed
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NCT00936390 Quality of Life - RTOG 0815 HP:  Radiation Therapy Oncology
Group Phase III Randomized Study of Dose- Escalated Radiotherapy With/Without
STAD for Intermediate-Risk Prostate Cancer PROMIS - 2851789v1.0
RTOG 0815 HP:  Radiation Therapy Oncology Group
Phase III Randomized Study of Dose- Escalated
Radiotherapy With/Without STAD for Intermediate-Risk
Prostate Cancer PROMIS
Radiation Therapy With or Without Androgen-Deprivation
Therapy in Treating Patients With Prostate Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=655504A8-
A72D-9C38-E040-BB89AD430197
All rights reserved. Please visit https://medical-data-
models.org/forms/9514
RTOG 0815 HP:  Radiation Therapy
Oncology Group Phase III
Randomized Study of Dose-
Escalated Radiotherapy
With/Without STAD for Intermediate-
Risk Prostate Cancer PROMIS
Unnamed Module 1
RTOG Study No.
Case #
Institution Name
Institution No.
Patient Initials
RTOG Patient ID
Amended data
Yes
No
Unamed Module 2
Time point of this assessment
12 Months After Radiation Therapy (12
months after RT)
6 Months Of Radiation Therapy (6
months after RT)
60 Months After Radiation Therapy (60
months after RT)
Last Week Of Radiation Therapy (Last
week of RT)
Other (Other)
Pretreatment (Pretreatment)
Third Week Of Radiation Therapy (Third
week of RT)
Other specify
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Was patient questionnaire completed
Yes
No
Date patient questionnaire completed
Reason Questionnaire was not Completed
Institution Error (Institutional error)
Not Applicable, Questionnaire Was
Completed (Not applicable,
questionnaire was completed)
Other Reason (Other reason)
Patient Refused Due To Illness (Patient
refused due to illness)
Patient Refused For Other Reason
(Patient refused for other reason)
Patient Unable To Be Contacted (Patient
unable to be contacted)
Tool Not Availalble In Patient's Language
(Tool not availalble in patient's language)
Unknown (Unknown)
Patient refused for other reason, specify
Other reason, specify
Specify method of completion
At Appointment (At appointment)
By Mail (By mail)
By Telephone (By telephone)
Not Applicable (Not applicable)
Unknown (Unknown)
Did the patient require any assistance in
completing the questionnaire?
No (No)
Not Applicable (Not applicable)
Unknown If Assistance Given (Unknown
if assistance given)
Yes (Yes)
Specify the person who assisted the patient
Family (Family)
Not Applicable (Not applicable)
Other (Other)
Staff Member (Staff member)
Unknown (Unknown)
Extent of the assistance
Combination Of Above (Combination of
above)
Interpreted Items For Patient (Interpreted
items for patient)
Marked Items Per Patient's Response
(Marked items per patient's response)
Not Applicable (Not applicable)
Other (Other)
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Group Phase III Randomized Study of Dose- Escalated Radiotherapy With/Without
STAD for Intermediate-Risk Prostate Cancer PROMIS - 2851789v1.0
Read Items To Patient (Read items to
patient)
Unknown (Unknown)
Combination of above, specify
Other, specify
Comments
Signature of Person Completing This Form
Date Form Originally Completed
Fatigue - Short Form
How often did you feel tired
Always (Always)
Never (Never)
Often (Often)
Rarely (Rarely)
Sometimes (Sometimes)
How often did you experience extreme
exhaustion
Always (Always)
Never (Never)
Often (Often)
Rarely (Rarely)
Sometimes (Sometimes)
How often did you run out of energy
Always (Always)
Never (Never)
Often (Often)
Rarely (Rarely)
Sometimes (Sometimes)
How often did your fatigue limit you at work
(include work at home)
Always (Always)
Never (Never)
Often (Often)
Rarely (Rarely)
Sometimes (Sometimes)
How often were you too tired to think clearly
Always (Always)
Never (Never)
Often (Often)
Rarely (Rarely)
Sometimes (Sometimes)
How often were you too tired to take a bath or
shower
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Always (Always)
Never (Never)
Often (Often)
Rarely (Rarely)
Sometimes (Sometimes)
How often did you have enough energy to
exercise strenuously
Always (Always)
Never (Never)
Often (Often)
Rarely (Rarely)
Sometimes (Sometimes)
4 / 4
NCT00936390 Quality of Life - RTOG 0815 HP:  Radiation Therapy Oncology
Group Phase III Randomized Study of Dose- Escalated Radiotherapy With/Without
STAD for Intermediate-Risk Prostate Cancer PROMIS - 2851789v1.0
NCT00936390 Quality of Life - RTOG 0815 QL:  Radiation Therapy Oncology
Group Phase III Randomized Study of Dose- Escalated Radiotherapy With/Without
STAD for Intermediate-Risk Prostate Cancer - 2852436v1.0
RTOG 0815 QL:  Radiation Therapy Oncology Group
Phase III Randomized Study of Dose- Escalated
Radiotherapy With/Without STAD for Intermediate-Risk
Prostate Cancer
Radiation Therapy With or Without Androgen-Deprivation
Therapy in Treating Patients With Prostate Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=65665DF7-
C5B9-73E9-E040-BB89AD433B06
All rights reserved. Please visit https://medical-data-
models.org/forms/9516
RTOG 0815 QL:  Radiation Therapy
Oncology Group Phase III
Randomized Study of Dose-
Escalated Radiotherapy
With/Without STAD for Intermediate-
Risk Prostate Cancer
Unnamed Module 1
RTOG Study No.
Case #
Institution Name
Institution No.
Patient Initials
RTOG Patient ID
Amended data
Yes
No
Unamed Module 2
Time point of this assessment
12 Months After Radiation Therapy (12
months after RT)
6 Months Of Radiation Therapy (6
months after RT)
60 Months After Radiation Therapy (60
months after RT)
Last Week Of Radiation Therapy (Last
week of RT)
Other (Other)
Pretreatment (Pretreatment)
Third Week Of Radiation Therapy (Third
week of RT)
Other specify
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Calendar Due Date
Was patient questionnaire completed
Yes
No
Date patient questionnaire completed
Reason Questionnaire was not Completed
Institution Error (Institutional error)
Not Applicable, Questionnaire Was
Completed (Not applicable,
questionnaire was completed)
Other Reason (Other reason)
Patient Refused Due To Illness (Patient
refused due to illness)
Patient Refused For Other Reason
(Patient refused for other reason)
Patient Unable To Be Contacted (Patient
unable to be contacted)
Tool Not Availalble In Patient's Language
(Tool not availalble in patient's language)
Unknown (Unknown)
Patient refused for other reason, specify
Other reason, specify
Specify method of completion
At Appointment (At appointment)
By Mail (By mail)
By Telephone (By telephone)
Not Applicable (Not applicable)
Unknown (Unknown)
Did the patient require any assistance in
completing the questionnaire?
No (No)
Not Applicable (Not applicable)
Unknown If Assistance Given (Unknown
if assistance given)
Yes (Yes)
Specify the person who assisted the patient
Family (Family)
Not Applicable (Not applicable)
Other (Other)
Staff Member (Staff member)
Unknown (Unknown)
Extent of the assistance
Combination Of Above (Combination of
above)
Interpreted Items For Patient (Interpreted
items for patient)
Marked Items Per Patient's Response
(Marked items per patient's response)
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Not Applicable (Not applicable)
Other (Other)
Read Items To Patient (Read items to
patient)
Unknown (Unknown)
Combination of above, specify
Other, specify
Comments
Signature of Person Completing This Form
Date Form Originally Completed
Exercise
Times per week
Average duration
Times per week
Average duration
Times per week
Average duration
I have been experiencing generalized muscle
weakness over the last week
0 (0)
1 (1)
2 (2)
3 (3)
During the past week, how would you rate your
sleep quality overall
0 (0)
1 (1)
2 (2)
3 (3)
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NCT00936390 Quality of Life - RTOG 0815 QF:  Radiation Therapy Oncology
Group Phase III Randomized Study of Dose- Escalated Radiotherapy With/Without
STAD for Intermediate-Risk Prostate Cancer EQ-5D - 2852003v1.0
RTOG 0815 QF:  Radiation Therapy Oncology Group
Phase III Randomized Study of Dose- Escalated
Radiotherapy With/Without STAD for Intermediate-Risk
Prostate Cancer EQ-5D
Radiation Therapy With or Without Androgen-Deprivation
Therapy in Treating Patients With Prostate Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=65578C81-
9FE2-2CB0-E040-BB89AD433402
All rights reserved. Please visit https://medical-data-
models.org/forms/9517
RTOG 0815 QF:  Radiation Therapy
Oncology Group Phase III
Randomized Study of Dose-
Escalated Radiotherapy
With/Without STAD for Intermediate-
Risk Prostate Cancer EQ-5D
Unnamed Module 1
RTOG Study No.
Case #
Institution Name
Institution No.
Patient Initials
RTOG Patient ID
Amended data
Yes
No
Unamed Module 2
Time point of this assessment
12 Months After Radiation Therapy (12
months after RT)
6 Months Of Radiation Therapy (6
months after RT)
60 Months After Radiation Therapy (60
months after RT)
Last Week Of Radiation Therapy (Last
week of RT)
Other (Other)
Pretreatment (Pretreatment)
Third Week Of Radiation Therapy (Third
week of RT)
Other specify
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Calendar Due Date
Was patient questionnaire completed
Yes
No
Date patient questionnaire completed
Reason Questionnaire was not Completed
Institution Error (Institutional error)
Not Applicable, Questionnaire Was
Completed (Not applicable,
questionnaire was completed)
Other Reason (Other reason)
Patient Refused Due To Illness (Patient
refused due to illness)
Patient Refused For Other Reason
(Patient refused for other reason)
Patient Unable To Be Contacted (Patient
unable to be contacted)
Tool Not Availalble In Patient's Language
(Tool not availalble in patient's language)
Unknown (Unknown)
Patient refused for other reason, specify
Other reason, specify
Specify method of completion
At Appointment (At appointment)
By Mail (By mail)
By Telephone (By telephone)
Not Applicable (Not applicable)
Unknown (Unknown)
Did the patient require any assistance in
completing the questionnaire?
No (No)
Not Applicable (Not applicable)
Unknown If Assistance Given (Unknown
if assistance given)
Yes (Yes)
Specify the person who assisted the patient
Family (Family)
Not Applicable (Not applicable)
Other (Other)
Staff Member (Staff member)
Unknown (Unknown)
Extent of the assistance
Combination Of Above (Combination of
above)
Interpreted Items For Patient (Interpreted
items for patient)
Marked Items Per Patient's Response
(Marked items per patient's response)
2 / 4
NCT00936390 Quality of Life - RTOG 0815 QF:  Radiation Therapy Oncology
Group Phase III Randomized Study of Dose- Escalated Radiotherapy With/Without
STAD for Intermediate-Risk Prostate Cancer EQ-5D - 2852003v1.0
Not Applicable (Not applicable)
Other (Other)
Read Items To Patient (Read items to
patient)
Unknown (Unknown)
Combination of above, specify
Other, specify
Your own health state today
Comments
Signature of Person Completing This Form
Date Form Originally Completed
Unamed Module 2
MOBILITY
I Am Confined To Bed (I am confined to
bed)
I Have No Problems In Walking About (I
have no problem in walking about)
I Have Some Problems In Walking About
(I have some problem in walking about)
SELF CARE
I Am Unable To Wash Or Dress Myself (I
am able to wash or dress myself)
I Have No Problem With Self Care (I
have no problem with self care)
I Have Some Problem Washing Or
Dressing Myself (I have some problem
washing or dressing myself)
USUAL ACTIVITIES (e.g. work, study,
housework, family, or leisure activities)
I Am Unable To Perform My Usual
Activities (I am unable to perform my
usual activities)
I Have No Problems With Performing My
Usual Activities (I have no problem with
performing my usual activities)
I Have Some Problems With Performing
My Usual Activities (I have some
problem with performing my usual
activities)
PAIN/DISCOMFORT
I Have Extreme Pain Or Discomfort (I
have extreme pain or discomfort)
I Have Moderate Pain Or Discomfort (I
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have moderate pain or discomfort)
I Have No Pain Or Discomfort (I have no
pain or discomfort)
ANXIETY/DEPRESSION (TO THE PATIENT: To
help people say how good or bad a health state
is, we have drawn a scale rather like a
thermometer on which the best state you can
imagine is marked 100 and the worst state you
can imagine is marked 0.)
I Am Extremely Anxious Or Depressed (I
am extremely anxious or depressed)
I Am Moderately Anxious Or Depressed
(I am moderately anxious or depressed)
I Am Not Anxious Or Depressed (I am
not anxious or depressed)
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Prostate Cancer NCT00567580 Quality of Life - RTOG 0534 QF:  Radiation
Therapy Oncology Group Phase III Pelvic LN RT with STAD for Rising PSA after
Radical Prostatectomy EQ-5D - 3010272v1.0
RTOG 0534 QF:  Radiation Therapy Oncology Group
Phase III Pelvic LN RT with STAD for Rising PSA after
Radical Prostatectomy EQ-5D
Prostate Radiation Therapy or Short-Term Androgen
Deprivation Therapy and Pelvic Lymph Node Radiation
Therapy With or Without Prostate Radiation Therapy in
Treating Patients With a Rising PSA After Surgery for
Prostate Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=7FBA387E-
8D9C-D87A-E040-BB89AD431B32
All rights reserved. Please visit https://medical-data-
models.org/forms/9518
RTOG 0534 QF:  Radiation Therapy
Oncology Group Phase III Pelvic LN
RT with STAD for Rising PSA after
Radical Prostatectomy EQ-5D
Unnamed Module 1
RTOG Study No.
Case #
Institution Name
Institution No.
Patient Initials
RTOG Patient ID
Amended data
Yes
No
Unamed Module 2
Time point of this assessment
Five Year Follow-up (Five year follow-up)
One Year Follow-up (One year follow-up)
Other (Other)
Pretreatment (Pretreatment)
Week 6 Of Rt (Week 6 of RT)
Other specify
Calendar Due Date
Date patient questionnaire completed
Reason Questionnaire was not Completed
1 / 4
Institution Error (Institutional error)
Not Applicable, Questionnaire Was
Completed (Not applicable,
questionnaire was completed)
Other Reason (Other reason)
Patient Refused Due To Illness (Patient
refused due to illness)
Patient Refused For Other Reason
(Patient refused for other reason)
Patient Unable To Be Contacted (Patient
unable to be contacted)
Tool Not Availalble In Patient's Language
(Tool not availalble in patient's language)
Unknown (Unknown)
Patient refused for other reason, specify
Other reason, specify
Did the patient require any assistance in
completing the questionnaire?
No (No)
Not Applicable (Not applicable)
Unknown If Assistance Given (Unknown
if assistance given)
Yes (Yes)
Extent of the assistance
Combination Of Above (Combination of
above)
Interpreted Items For Patient (Interpreted
items for patient)
Marked Items Per Patient's Response
(Marked items per patient's response)
Not Applicable (Not applicable)
Other (Other)
Read Items To Patient (Read items to
patient)
Unknown (Unknown)
Combination of above, specify
Other, specify
Specify the person who assisted the patient
Family (Family)
Not Applicable (Not applicable)
Other (Other)
Staff Member (Staff member)
Unknown (Unknown)
Specify method of completion
At Appointment (At appointment)
By Mail (By mail)
By Telephone (By telephone)
Unknown (Unknown)
2 / 4
Prostate Cancer NCT00567580 Quality of Life - RTOG 0534 QF:  Radiation
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Health score
Comments
Signature of Person Completing This Form
Date Form Originally Completed
Unamed Module 2
MOBILITY
I Am Confined To Bed (I am confined to
bed)
I Have No Problems In Walking About (I
have no problem in walking about)
I Have Some Problems In Walking About
(I have some problem in walking about)
SELF CARE
I Am Unable To Wash Or Dress Myself (I
am able to wash or dress myself)
I Have No Problem With Self Care (I
have no problem with self care)
I Have Some Problem Washing Or
Dressing Myself (I have some problem
washing or dressing myself)
USUAL ACTIVITIES (e.g. work, study,
housework, family, or leisure activities)
I Am Unable To Perform My Usual
Activities (I am unable to perform my
usual activities)
I Have No Problems With Performing My
Usual Activities (I have no problem with
performing my usual activities)
I Have Some Problems With Performing
My Usual Activities (I have some
problem with performing my usual
activities)
PAIN/DISCOMFORT
I Have Extreme Pain Or Discomfort (I
have extreme pain or discomfort)
I Have Moderate Pain Or Discomfort (I
have moderate pain or discomfort)
I Have No Pain Or Discomfort (I have no
pain or discomfort)
ANXIETY/DEPRESSION (TO THE PATIENT: To
help people say how good or bad a health state
is, we have drawn a scale rather like a
thermometer on which the best state you can
imagine is marked 100 and the worst state you
can imagine is marked 0.)
I Am Extremely Anxious Or Depressed (I
3 / 4
Prostate Cancer NCT00567580 Quality of Life - RTOG 0534 QF:  Radiation
Therapy Oncology Group Phase III Pelvic LN RT with STAD for Rising PSA after
Radical Prostatectomy EQ-5D - 3010272v1.0
am extremely anxious or depressed)
I Am Moderately Anxious Or Depressed
(I am moderately anxious or depressed)
I Am Not Anxious Or Depressed (I am
not anxious or depressed)
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Cervical Cancer NCT01414608 Follow-Up - ANZGOG-
0902 Serious Adverse Events - 3142795v1.0
ANZGOG-0902 Serious Adverse Events
Cisplatin and Radiation Therapy With or Without
Carboplatin and Paclitaxel in Patients With Locally
Advanced Cervical Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=91063CBD-
3BCB-F457-E040-BB89AD43096D
All rights reserved. Please visit https://medical-data-
models.org/forms/9520
ANZGOG-0902 Serious Adverse
Events
Header
Patient Initials
Patient ID
Institution Code
SAE Onset Date
SAE Report Type
Follow-up # (Follow-up #)
Initial (Initial)
Serious Adverse Event
Primary Site
Have any serious adverse events been reported?
Yes
No
SAE Onset Date
Seriousness Attributed to Adverse Event
Congenital Anomaly (Congenital
anomaly)
Death (Death)
Disability (Disability/incapacity)
Hospitalized (Hospitalization, initial or
prolonged)
Life Threatening (Life threatening)
Other (Other)
Did the patient require hospitalization
Yes
No
Admission Date
Discharge Date
1 / 3
Severity of Adverse Event
Mild Adverse Event (1)
Moderate Adverse Event (2)
Severe Adverse Event (3)
Life Threatening Adverse Event (4)
Death Related To Adverse Event (5)
CTC Adverse Event Attribution
Definite (Definite)
Possible (Possible)
Probable (Probable)
Unlikely (Unlikely)
Unrelated (Unrelated)
Was this event expected or anticipated
Yes
No
Action Taken
There Was No Action Taken Based On
The Adverse Event (none)
Protocol Treatment Was Delayed As A
Result Of The Adverse Event (protocol
treatment delayed)
Protocol Treatment Was Discontinued As
A Result Of The Adverse Event (protocol
treatment discontinued)
Study Dose Was Reduced As A Result
Of The Adverse Event (study dose
reduced)
AE Outcome
Fatal Or Died (Fatal/Died)
Not Recovered Or Not Resolved (Not
recovered/Not resolved)
Recovered Or Resolved With Sequelae
(Recovered/Resolved with Sequelae)
Recovered Or Resolved Without
Sequelae (Recovered/Resolved without
Sequelae)
If Resolved with sequelae, please specify
"Sequelae"
Adverse Event Reporting to Date
Date of Death
Other Relevant Details
Footer Module
Investigator Name
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Cervical Cancer NCT01414608 Follow-Up - ANZGOG-0902 Serious
Adverse Events - 3142795v1.0
Date
Investigator's signature
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Adverse Events - 3142795v1.0
Colorectal Cancer NCT00058474 Toxicity - NSABP
PROTOCOL R-04: ADVERSE EVENT FORM - 2082776v3.0
NSABP PROTOCOL R-04: ADVERSE EVENT FORM
Radiation Therapy and Either Capecitabine or Fluorouracil
With or Without Oxaliplatin Before Surgery in Treating
Patients With Resectable Rectal Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=B7822175-
F6A3-24E0-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/9521
NSABP PROTOCOL R-04:
ADVERSE EVENT FORM
Ccrr Module For Nsabp Protocol R-04:
Adverse Event Form
First Three Letters of Patients Last Name
Patient Study ID
Institution Name / Affiliate Name
Person Completing Form, Last Name
Person Completing Form, First Name
Person Completing Form, Phone
Are Data Amended?
Yes
No
AE report date
Any grade 2, 3, 4, or 5 adverse event?
Yes
No
Was the patient hospitalized for 24 hours or
more?
Yes
No
CTC Adverse Event Term
Other CTC Adverse Event Term(s) not listed
4-Character NSABP Code
CTC Adverse Event Grade
CTC Adverse Event Grade
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Attirubtion
Definite (related)
Unrelated (unrelated)
Attirubtion
Definite (related)
Unrelated (unrelated)
Did the patient experience an episode of Grade 3
or greater diarrhea with Grade 4
granulocytopenia (neutropenia)?
Yes
No
Was the patient hospitalized for the management
of diarrhea or dehydration, with radiographic or
colonoscopic evidence of bowel wall injury?
Yes
No
Comments
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Colorectal Cancer NCT00058474 Toxicity - NSABP PROTOCOL R-04:
ADVERSE EVENT FORM - 2082776v3.0
Pancreatic Cancer NCT01013649 Quality of Life - RTOG 0848 Phase III Pancreas-
Resected + Adjuvant Treatment PROMIS Fatigue Short Form-1 Cover Sheet (PR) -
2865750v1.0
RTOG 0848 Phase III Pancreas-Resected + Adjuvant
Treatment PROMIS Fatigue Short Form-1 Cover Sheet
(PR)
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=68B36F4B-
6CF7-CD4B-E040-BB89AD4309CF
All rights reserved. Please visit https://medical-data-
models.org/forms/9524
RTOG 0848 Phase III Pancreas-
Resected + Adjuvant Treatment
PROMIS Fatigue Short Form-1
Cover Sheet (PR)
Header
RTOG Study No.
Case #
Institution Name
Institution No.
Patient Initials
RTOG Patient ID
Unnamed2
Amended Data (This sheet is the cover page
used for submission of the FACT H&N -
questionnaire. This page must be completed by
the medical staff nurse, data manager, physician,
etc.)
Yes
No
Unamed Module 2
Time point
12 Months From Start Of Arm 1 Or Arm
2 Therapy (12 months from start of ARM
1 or ARM 2 therapy)
24 Months From Start Of Arm 1 Or Arm
2 Therapy (24 months from start of ARM
1 or ARM 2 therapy)
9 Months From Start Of Arm 1 Or Arm 2
Therapy (9 months from start of ARM 1
or ARM 2 therapy)
Post Arm 1 Or Arm 2 Systemic Therapy
(Post ARM 1 or ARM 2 systemic therapy)
Pretreatment (Pretreatment)
Treatment Start Date
1 / 4
Was patient questionnaire completed
Yes
No
Date patient questionnaire completed (MM DD
YYYY)
Reason Questionnaire was not Completed
Institution Error (Institutional error)
Not Applicable, Questionnaire Was
Completed (Not applicable,
questionnaire was completed)
Other Reason (Other reason)
Patient Refused Due To Illness (Patient
refused due to illness)
Patient Refused For Other Reason
(Patient refused for other reason)
Patient Unable To Be Contacted (Patient
unable to be contacted)
Tool Not Availalble In Patient's Language
(Tool not available in patient's language)
Unknown (Unknown)
Patient refused for other reason, specify
Other reason, specify
Specify method of completion
At Appointment (At appointment)
By Mail (By mail)
By Telephone (By telephone)
Not Applicable (Not applicable)
Unknown (Unknown)
Did the patient require any assistance in
completing the questionnaire?
No (No)
Not Applicable (Not applicable)
Unknown If Assistance Given (Unknown
if assistance given)
Yes (Yes)
Specify the person who assisted the patient
Family (Family)
Not Applicable (Not applicable)
Other (Other)
Staff Member (Staff member)
Unknown (Unknown)
Other, specify
Extent of assistance given
Combination Of Above (Combination of
above)
Interpreted Items For Patient (Interpreted
items for patient)
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Pancreatic Cancer NCT01013649 Quality of Life - RTOG 0848 Phase III Pancreas-
Resected + Adjuvant Treatment PROMIS Fatigue Short Form-1 Cover Sheet (PR) -
2865750v1.0
Marked Items Per Patient's Response
(Marked items per patient's response)
Not Applicable (Not applicable)
Other (Other)
Read Items To Patient (Read items to
patient)
Unknown (Unknown)
Combination of above, specify
Other, specify
Signature of Person Completing This Form
Date Form Completed (MM DD YYYY)
Promis Fatigue Short Form 1
How often did you feel tired
Always (Always)
Never (Never)
Often (Often)
Rarely (Rarely)
Sometimes (Sometimes)
How often did you experience extreme
exhaustion
Always (Always)
Never (Never)
Often (Often)
Rarely (Rarely)
Sometimes (Sometimes)
How often did you run out of energy
Always (Always)
Never (Never)
Often (Often)
Rarely (Rarely)
Sometimes (Sometimes)
How often did your fatigue limit you at work
(include work at home)
Always (Always)
Never (Never)
Often (Often)
Rarely (Rarely)
Sometimes (Sometimes)
How often were you too tired to think clearly
Always (Always)
Never (Never)
Often (Often)
Rarely (Rarely)
Sometimes (Sometimes)
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Pancreatic Cancer NCT01013649 Quality of Life - RTOG 0848 Phase III Pancreas-
Resected + Adjuvant Treatment PROMIS Fatigue Short Form-1 Cover Sheet (PR) -
2865750v1.0
How often were you too tired to take a bath or
shower
Always (Always)
Never (Never)
Often (Often)
Rarely (Rarely)
Sometimes (Sometimes)
How often did you have enough energy to
exercise strenuously
Always (Always)
Never (Never)
Often (Often)
Rarely (Rarely)
Sometimes (Sometimes)
4 / 4
Pancreatic Cancer NCT01013649 Quality of Life - RTOG 0848 Phase III Pancreas-
Resected + Adjuvant Treatment PROMIS Fatigue Short Form-1 Cover Sheet (PR) -
2865750v1.0
Colorectal Cancer NCT01167725 Follow-Up - USMCI
8214/Z6091:  Follow Up Form - 2832822v1.0
USMCI 8214/Z6091:  Follow Up Form
Standard Therapy With or Without Surgery and Mitomycin
C in Treating Patients With Advanced Limited Peritoneal
Dissemination of Colon Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=620B3C7C-
4FFC-9435-E040-BB89AD430464
All rights reserved. Please visit https://medical-data-
models.org/forms/9525
USMCI 8214/Z6091:  Follow Up
Form
Header Module
Visit
Follow-up (Follow-Up)
Patient ID
Institution No.
Institution Name
Visit time point
Month 12 (Month 12)
Month 15 (Month 15)
Month 18 (Month 18)
Month 21 (Month 21)
Month 24 (Month 24)
Month 27 (Month 27)
Month 3 (Month 3)
Month 30 (Month 30)
Month 33 (Month 33)
Month 36 (Month 36)
Month 42 (Month 42)
Month 48 (Month 48)
Month 54 (Month 54)
Month 6 (Month 6)
Month 60 (Month 60)
Month 9 (Month 9)
Vital Status
Were you able to obtain any information about
the patient since the last report
Yes
No
Date of last attempt to contact person
Vital Status
Alive (Alive)
Dead (Dead)
Date of Last Contact or Death (month day year)
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Primary Cause of Death
Due To Other Cause (Due to other
cause)
Due To Protocol Treatment (Due to
protocol treatment)
Due To This Disease (Due to this
disease)
Due to this disease
Due to other cause specify
Cancer Follow-up Status
Has the patient had a documented clinical
assessment for this cancer?
Yes
No
Cancer Follow-up Status Date
First Peritoneal Surface Recurrence
Has the patient been diagnosed with first
peritoneal surface recurrence/progression
Yes
No
Date of first peritoneal surface recurrence
Method of Evaluation
Clinical (Clinical)
Laparoscopy (Laparoscopy)
Radiology (Radiological)
Serology (Serological)
CEA
CA 19-9
Was CT done
Yes
No
CT-PCI at time of recurrence
Anatomic region
Central (Central)
Epigastric (Epigastrium)
Left Flank (Left flank)
Left Lower (Left Lower)
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Colorectal Cancer NCT01167725 Follow-Up - USMCI 8214/Z6091:
Follow Up Form - 2832822v1.0
Llq (Left Lower)
Left Upper (Left Upper)
Lower Ileum (Lower ileum)
Lower Jejunum (Lower jejunum)
Pelvis (Pelvis)
Right Flank (Right flank)
Right Lower (Right Lower)
Right Upper (Right Upper)
Upper Ileum (Upper ileum)
Upper Jejunum (Upper jejunum)
First Distant Recurrence
Has the patient been diagnosed with first distant
recurrence/progression? (since submission of the
last follow-up form)
Yes
No
Date of First Distant Recurrence (if applicable)
Site of First Distant Recurrence
Bone Marrow (Bone Marrow)
Central Nervous System (Central
Nervous System (e.g., brain, meninges))
Liver (Liver)
Lung (Lung(s))
Other (Other)
Skin, Soft Tissue, Distant Nodal (Skin,
soft tissue, distant nodal)
Other specify
Notice Of First Subsequent Treatment
Has the patient received subsequent treatment
for this cancer that has not been previously
reported
No (No)
Unknown (Unknown)
Yes (Yes)
Date of Subsequent Treatment
Subsequent Treatment Type
Ablation (Ablation)
Other (Other)
Palliative Hipec Metastesectomy
(Palliative HIPEC metastesectomy)
Radiation (Radiation)
Regional Chemotherapy (Regional
chemotherapy)
Systemic Chemotherapy (Systemic
chemotherapy)
Targeted Systemic Therapy (Targeted
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Follow Up Form - 2832822v1.0
systemic therapy)
Other, specify
Notice Of New Primary
Has a new primary cancer or MDS been
diagnosed that has not been previously reported?
No (No)
Unknown (Unknown)
Yes (Yes)
New Primary Cancer Date
Site of New Primary
Late Adverse Event
Has the patient experienced (prior to treatment
for progression or relapse or a second primary,
and prior to non-protocol treatment) any severe
(grade >=3) long term toxicity that has not been
previously reported?
No (No)
Unknown (Unknown)
Yes (Yes)
Late Adverse Event Reporting
Late Adverse Event Onset Date
CTC Adverse Event Term
Other, specify
CTC Adverse Event Grade
Severe Adverse Event (3)
Life Threatening Adverse Event (4)
Death Related To Adverse Event (5)
CTC AE Attribution Code
Definite (Definite)
Possible (Possible)
Probable (Probable)
Unlikely (Unlikely)
Unrelated (Unrelated)
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Follow Up Form - 2832822v1.0
Prostate Cancer NCT01546987 Quality of Life - RTOG 1115 HP: Phase III RT +
Standard ADT vs RT + Enhanced ADT + TAK-700 PROMIS Form - 3289372v1.0
RTOG 1115 HP: Phase III RT + Standard ADT vs RT +
Enhanced ADT + TAK-700 PROMIS Form
Hormone Therapy, Radiation Therapy, and Steroid 17alpha-
monooxygenase TAK-700 in Treating Patients With High-
Risk Prostate Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=AE8F0868-
80F7-FEC9-E040-BB89AD4357E7
All rights reserved. Please visit https://medical-data-
models.org/forms/9526
RTOG 1115 HP: Phase III RT +
Standard ADT vs RT + Enhanced
ADT + TAK-700 PROMIS Form
Unnamed Module 1
RTOG Study No.
Case #
Institution Name
Institution No.
Patient Initials
RTOG Patient ID
Amended data
Yes
No
Unamed Module 2
Time point
12 Months From Start Of Treatment (12
months from start of treatment)
30 Months From Start Of Treatment (30
months from start of treatment)
Baseline (baseline)
Last Week Of Radiation Therapy (Last
week of RT)
Other (Other)
Pretreatment (Pretreatment)
Other specify
Did the patient complete any items on the
questionnaire?
Yes
No
Date Questionnaire Completed
Reason Questionnaire was not Completed
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Institution Error (Institutional error)
Not Applicable, Questionnaire Was
Completed (Not applicable,
questionnaire was completed)
Other Reason (Other reason)
Patient Refused Due To Illness (Patient
refused due to illness)
Patient Refused For Other Reason
(Patient refused for other reason)
Patient Unable To Be Contacted (Patient
unable to be contacted)
Tool Not Availalble In Patient's Language
(Tool not available in patient's language)
Patient refused for other reason, specify
Other reason, specify
Did the patient require any assistance in
completing the questionnaire?
No (No)
Not Applicable (Not applicable)
Unknown If Assistance Given (Unknown
if assistance given)
Yes (Yes)
Extent of assistance given
Combination Of Above (Combination of
above)
Interpreted Items For Patient (Interpreted
items for patient)
Marked Items Per Patient's Response
(Marked items per patient's response)
Not Applicable (Not applicable)
Other (Other)
Read Items To Patient (Read items to
patient)
Combination of above, specify
Other, specify
Specify the person who assisted the patient
Family (Family)
Not Applicable (Not applicable)
Other (Other)
Staff Member (Staff member)
Unknown (Unknown)
Specify method of completion
At Appointment (At appointment)
By Mail (By mail)
By Telephone (By telephone)
Unknown (Unknown)
Comments
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Prostate Cancer NCT01546987 Quality of Life - RTOG 1115 HP: Phase III RT +
Standard ADT vs RT + Enhanced ADT + TAK-700 PROMIS Form - 3289372v1.0
Signature of Person Completing This Form
Date Form Originally Completed
Fatigue - Short Form
How often did you feel tired
Always (Always)
Never (Never)
Often (Often)
Rarely (Rarely)
Sometimes (Sometimes)
How often did you experience extreme
exhaustion
Always (Always)
Never (Never)
Often (Often)
Rarely (Rarely)
Sometimes (Sometimes)
How often did you run out of energy
Always (Always)
Never (Never)
Often (Often)
Rarely (Rarely)
Sometimes (Sometimes)
How often did your fatigue limit you at work
(include work at home)
Always (Always)
Never (Never)
Often (Often)
Rarely (Rarely)
Sometimes (Sometimes)
How often were you too tired to think clearly
Always (Always)
Never (Never)
Often (Often)
Rarely (Rarely)
Sometimes (Sometimes)
How often were you too tired to take a bath or
shower
Always (Always)
Never (Never)
Often (Often)
Rarely (Rarely)
Sometimes (Sometimes)
How often did you have enough energy to
exercise strenuously
Always (Always)
Never (Never)
Often (Often)
Rarely (Rarely)
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Sometimes (Sometimes)
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Colorectal Cancer NCT01167725 Toxicity - USMCI
8214/Z6091:  Adverse Event Form - Surgical - 2877874v1.0
USMCI 8214/Z6091:  Adverse Event Form - Surgical
Standard Therapy With or Without Surgery and Mitomycin
C in Treating Patients With Advanced Limited Peritoneal
Dissemination of Colon Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=6A35E76B-
55B0-7B8C-E040-BB89AD437142
All rights reserved. Please visit https://medical-data-
models.org/forms/9527
USMCI 8214/Z6091:  Adverse Event
Form - Surgical
Header Module
Patient ID
Institution No.
Institution Name
Visit
Post Surgery (Post Surgery)
Visit time point
Post Surgery (Post Surgery)
Post Surgery (6 Wks) (Post Surgery (6
wks))
Date
Surgical Complication
Were there any surgical complications?
Yes
No
AE Onset Date
CTC Adverse Event Term
Other, specify
Not Assessed
Not Present
CTC Adverse Event Grade
Severe Adverse Event (3)
Life Threatening Adverse Event (4)
Death Related To Adverse Event (5)
CTC AE Attribution Code
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Definite (Definite)
Possible (Possible)
Probable (Probable)
Unlikely (Unlikely)
Unrelated (Unrelated)
Surgical Complication
Were there any additional surgical complications?
Yes
No
CTC Adverse Event Term
CTC Adverse Event Grade
Severe Adverse Event (3)
Life Threatening Adverse Event (4)
Death Related To Adverse Event (5)
CTC AE Attribution Code
Definite (Definite)
Possible (Possible)
Probable (Probable)
Unlikely (Unlikely)
Unrelated (Unrelated)
Footer Module
Completed by
Date of completion
Phone
Fax
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Colorectal Cancer NCT01167725 Toxicity - USMCI 8214/Z6091:
Adverse Event Form - Surgical - 2877874v1.0
Prostate Cancer NCT01546987 Quality of Life - RTOG 1115 QL: Phase III RT +
Standard ADT vs RT + Enhanced ADT + TAK-700  PSQI/GLTEQ Form -
3288970v1.0
RTOG 1115 QL: Phase III RT + Standard ADT vs RT +
Enhanced ADT + TAK-700  PSQI/GLTEQ Form
Hormone Therapy, Radiation Therapy, and Steroid 17alpha-
monooxygenase TAK-700 in Treating Patients With High-
Risk Prostate Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=AE8E92E1-
C6E3-6523-E040-BB89AD436A37
All rights reserved. Please visit https://medical-data-
models.org/forms/9528
RTOG 1115 QL: Phase III RT +
Standard ADT vs RT + Enhanced
ADT + TAK-700  PSQI/GLTEQ Form
Unnamed Module 1
RTOG Study No.
Case #
Institution Name
Institution No.
Patient Initials
RTOG Patient ID
Amended data
Yes
No
Unamed Module 2
Time point
12 Months From Start Of Treatment (12
months from start of treatment)
30 Months From Start Of Treatment (30
months from start of treatment)
Baseline (baseline)
Last Week Of Radiation Therapy (Last
week of RT)
Other (Other)
Pretreatment (Pretreatment)
Other specify
Did the patient complete any items on the
questionnaire?
Yes
No
Date Questionnaire Completed
Reason Questionnaire was not Completed
1 / 4
Institution Error (Institutional error)
Not Applicable, Questionnaire Was
Completed (Not applicable,
questionnaire was completed)
Other Reason (Other reason)
Patient Refused Due To Illness (Patient
refused due to illness)
Patient Refused For Other Reason
(Patient refused for other reason)
Patient Unable To Be Contacted (Patient
unable to be contacted)
Tool Not Availalble In Patient's Language
(Tool not available in patient's language)
Patient refused for other reason, specify
Other reason, specify
Did the patient require any assistance in
completing the questionnaire?
No (No)
Not Applicable (Not applicable)
Unknown If Assistance Given (Unknown
if assistance given)
Yes (Yes)
Extent of assistance given
Combination Of Above (Combination of
above)
Interpreted Items For Patient (Interpreted
items for patient)
Marked Items Per Patient's Response
(Marked items per patient's response)
Not Applicable (Not applicable)
Other (Other)
Read Items To Patient (Read items to
patient)
Combination of above, specify
Other, specify
Specify the person who assisted the patient
Family (Family)
Not Applicable (Not applicable)
Other (Other)
Staff Member (Staff member)
Unknown (Unknown)
Specify method of completion
At Appointment (At appointment)
By Mail (By mail)
By Telephone (By telephone)
Unknown (Unknown)
Comments
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Prostate Cancer NCT01546987 Quality of Life - RTOG 1115 QL: Phase III RT +
Standard ADT vs RT + Enhanced ADT + TAK-700  PSQI/GLTEQ Form -
3288970v1.0
Signature of Person Completing This Form
Date Form Originally Completed
Exercise
Times per week (Mild exercise - that is, minimal
effort exercise that did not make you perspire,
such as easy walking, yoga, bowling, lawn
bowling, shuffleboard, or golf)
Average duration (Mild exercise - that is, minimal
effort exercise that did not make you perspire,
such as easy walking, yoga, bowling, lawn
bowling, shuffleboard, or golf mins.)
Times per week (Moderate exercise - that is,
exercise that is not exhausting and which made
you perspire lightly, such as fast walking, tennis,
easy bicycling, easy swimming, or popular and
folk dancing)
Average duration (Moderate exercise - that is,
exercise that is not exhausting and which made
you perspire lightly, such as fast walking, tennis,
easy bicycling, easy swimming, or popular and
folk dancing mins.)
Times per week (Strenuous exercise - that is,
exercise that made your heart beat rapidly and
made you sweat, such as running, aerobics
classes, cross country skiing, vigorous swimming,
or vigorous bicycling)
Average duration (Strenuous exercise - that is,
exercise that made your heart beat rapidly and
made you sweat, such as running, aerobics
classes, cross country skiing, vigorous swimming,
or vigorous bicycling mins.)
I have been experiencing generalized muscle
weakness over the last week
0 (0)
1 (1)
2 (2)
3 (3)
During the past month, how would you rate your
sleep quality overall
0 (0)
1 (1)
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2 (2)
3 (3)
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Endometrial Cancer NCT00265759 Toxicity -
Z1031: Adverse Events Form - 2316417v3.0
Z1031: Adverse Events Form
Exemestane, Letrozole, or Anastrozole in Treating
Postmenopausal Women Who Are Undergoing Surgery for
Stage II or Stage III Breast Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=FAD7AE3C-
C9A3-1CD3-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/9529
Z1031: Adverse Events Form
Header Module
Visit
30 Days Post Surgery (30 days post
surgery)
Day 1 (Day 1)
Surgery (Surgery)
Week 12 (Week 12)
Week 15 (Week 15)
Week 16 (Week 16)
Week 4 (Week 4)
Week 8 (Week 8)
Patient ID (Pt. ID issued during registration or
previously issued Patient ID)
Institution No.
Patient Initials (F M L)
Institution Name
Instructions
Date of Symptom/Event Assessment
Was patient hospitalized during this reporting
interval
Yes
No
Has an Adverse Event Expedited (AdEERS)
Report been submitted
Yes
No
Ae Module
Common Toxicity Criteria Adverse Event Term
Type
Dyspnoea Nos (Dyspnea (shortness of
breath))
Fatigue (Fatigue (asthenia, lethargy,
1 / 3
malaise))
Menopausal Symptoms (Hot
flashes/flushes)
Mood Alteration - Agitation (Mood
alteration - agitation)
Anxiety Nec (Mood alteration - anxiety)
Depression Nec (Mood alteration -
depression)
Euphoric Mood (Mood alteration -
euphoria)
Muscle Weakness Nos (Muscle
weakness, generalized or specific area
(not due to neuropathy) - Whole
body/generalized)
Nausea (Nausea)
Pain (Pain - Back)
Headache Nos (Pain - Head/headache)
Arthralgia (Pain - Joint)
Myalgia (Pain - Muscle)
Vomiting Nos (Vomiting)
Not Assessed
CTC Adverse Event Grade (1-5)
Not present
CTC AE Attribution Code (see above)
Definite (definite)
Possible (possible)
Probable (probable)
Unlikely (unlikely)
Unrelated (unrelated)
Header
Check box if no additional adverse events were
experienced by patient
Other Ae Module
CTC Adverse Event Term Specify
CTC Adverse Event Grade (1-5)
CTC AE Attribution Code (see above)
Definite (definite)
Possible (possible)
Probable (probable)
Unlikely (unlikely)
Unrelated (unrelated)
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Endometrial Cancer NCT00265759 Toxicity - Z1031: Adverse Events
Form - 2316417v3.0
Completed by
Date Form Completed
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Endometrial Cancer NCT00265759 Toxicity - Z1031: Adverse Events
Form - 2316417v3.0
Prostate Cancer NCT01368588 Quality of Life -
RTOG-0924 QF: EQ-5D Form - 3196564v1.0
RTOG-0924 QF: EQ-5D Form
Androgen-Deprivation Therapy and Radiation Therapy in
Treating Patients With Prostate Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=9D86210A-
A35F-FC8E-E040-BB89AD432CB7
All rights reserved. Please visit https://medical-data-
models.org/forms/9532
RTOG-0924 QF: EQ-5D Form
Unnamed Module 1
RTOG Study No.
Case #
Institution Name
Institution No.
Patient Initials
RTOG Patient ID
Amended data
Yes
No
Unamed Module 2
Time point
12 Months After Radiation Therapy (12
months after RT)
6 Months Of Radiation Therapy (6
months after RT)
60 Months After Radiation Therapy (60
months after RT)
Baseline (baseline)
Other (Other)
Pretreatment (Pretreatment)
Your own health state today
Other specify
Did the patient complete any items on the
questionnaire?
Yes
No
Date Questionnaire Completed
1 / 4
Reason Questionnaire was not Completed
Institution Error (Institutional error)
Not Applicable, Questionnaire Was
Completed (Not applicable,
questionnaire was completed)
Other Reason (Other reason)
Patient Refused Due To Illness (Patient
refused due to illness)
Patient Refused For Other Reason
(Patient refused for other reason)
Patient Unable To Be Contacted (Patient
unable to be contacted)
Tool Not Availalble In Patient's Language
(Tool not available in patient's language)
Patient refused for other reason, specify
Other reason, specify
Did the patient require any assistance in
completing the questionnaire?
No (No)
Not Applicable (Not applicable)
Unknown If Assistance Given (Unknown
if assistance given)
Yes (Yes)
Extent of assistance given
Combination Of Above (Combination of
above)
Interpreted Items For Patient (Interpreted
items for patient)
Marked Items Per Patient's Response
(Marked items per patient's response)
Not Applicable (Not applicable)
Other (Other)
Read Items To Patient (Read items to
patient)
Combination of above, specify
Other, specify
Specify the person who assisted the patient
Family (Family)
Not Applicable (Not applicable)
Other (Other)
Staff Member (Staff member)
Unknown (Unknown)
Specify method of completion
At Appointment (At appointment)
By Mail (By mail)
By Telephone (By telephone)
Unknown (Unknown)
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Prostate Cancer NCT01368588 Quality of Life - RTOG-0924 QF: EQ-5D
Form - 3196564v1.0
Comments
Signature of Person Completing This Form
Date Form Originally Completed
Unamed Module 2
Mobility (Please circle one statement in each
group below which best describes your health
today)
I Am Confined To Bed (I am confined to
bed)
I Have No Problems In Walking About (I
have no problems in walking about)
I Have Some Problems In Walking About
(I have some problems in walking about)
Self care (Please circle one statement in each
group below which best describes your health
today)
I Am Unable To Wash Or Dress Myself (I
am unable to wash or dress myself)
I Have No Problems With Self Care (I
have no problems with self care)
I Have Some Problems Washing Or
Dressing Myself (I have some problems
washing or dressing myself)
Usual activities (Please circle one statement in
each group below which best describes your
health today)
I Am Unable To Perform My Usual
Activities (I am unable to perform my
usual activities)
I Have No Problems With Performing My
Usual Activities (I have no problems with
performing my usual activities)
I Have Some Problems With Performing
My Usual Activities (I have some
problems with performing my usual
activities)
Pain/discomfort (Please circle one statement in
each group below which best describes your
health today)
I Have Extreme Pain Or Discomfort (I
have extreme pain or discomfort)
I Have Moderate Pain Or Discomfort (I
have moderate pain or discomfort)
I Have No Pain Or Discomfort (I have no
pain or discomfort)
Anxiety/depression (Please circle one statement
in each group below which best describes your
health today)
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I Am Extremely Anxious Or Depressed (I
am extremely anxious or depressed)
I Am Moderately Anxious Or Depressed
(I am moderately anxious or depressed)
I Am Not Anxious Or Depressed (I am
not anxious or depressed)
Your Own Health State Today
Your own health state today
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Pancreatic Cancer NCT01013649 Quality of Life - RTOG 0848 Phase III Pancreas-
Resected + Adjuvant Treatment FACIT - Fatigue Cover Sheet (FA) - 2865273v1.0
RTOG 0848 Phase III Pancreas-Resected + Adjuvant
Treatment FACIT - Fatigue Cover Sheet (FA)
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=68B33AD0-
8068-FF39-E040-BB89AD430ECB
All rights reserved. Please visit https://medical-data-
models.org/forms/9533
RTOG 0848 Phase III Pancreas-
Resected + Adjuvant Treatment
FACIT - Fatigue Cover Sheet (FA)
Header
RTOG Study No.
Case #
Institution Name
Institution No.
Patient Initials
RTOG Patient ID
Unnamed2
Amended Data (This sheet is the cover page
used for submission of the FACT H&N -
questionnaire. This page must be completed by
the medical staff nurse, data manager, physician,
etc.)
Yes
No
Unamed Module 2
Time point
12 Months From Start Of Arm 1 Or Arm
2 Therapy (12 months from start of ARM
1 or ARM 2 therapy)
24 Months From Start Of Arm 1 Or Arm
2 Therapy (24 months from start of ARM
1 or ARM 2 therapy)
9 Months From Start Of Arm 1 Or Arm 2
Therapy (9 months from start of ARM 1
or ARM 2 therapy)
Post Arm 1 Or Arm 2 Systemic Therapy
(Post ARM 1 or ARM 2 systemic therapy)
Pretreatment (Pretreatment)
Treatment Start Date
1 / 4
Was patient questionnaire completed
Yes
No
Date patient questionnaire completed (MM DD
YYYY)
Reason Questionnaire was not Completed
Institution Error (Institutional error)
Not Applicable, Questionnaire Was
Completed (Not applicable,
questionnaire was completed)
Other Reason (Other reason)
Patient Refused Due To Illness (Patient
refused due to illness)
Patient Refused For Other Reason
(Patient refused for other reason)
Patient Unable To Be Contacted (Patient
unable to be contacted)
Tool Not Availalble In Patient's Language
(Tool not available in patient's language)
Unknown (Unknown)
Patient refused for other reason, specify
Other reason, specify
Specify method of completion
At Appointment (At appointment)
By Mail (By mail)
By Telephone (By telephone)
Not Applicable (Not applicable)
Unknown (Unknown)
Did the patient require any assistance in
completing the questionnaire?
No (No)
Not Applicable (Not applicable)
Unknown If Assistance Given (Unknown
if assistance given)
Yes (Yes)
Specify the person who assisted the patient
Family (Family)
Not Applicable (Not applicable)
Other (Other)
Staff Member (Staff member)
Unknown (Unknown)
Other, specify
Extent of the assistance
Combination Of Above (Combination of
above)
Interpreted Items For Patient (Interpreted
items for patient)
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Marked Items Per Patient's Response
(Marked items per patient's response)
Not Applicable (Not applicable)
Other (Other)
Read Items To Patient (Read items to
patient)
Unknown (Unknown)
Combination of above, specify
Other, specify
Signature of Person Completing This Form
Date Form Completed (MM DD YYYY)
Additional Concerns
I feel fatigued
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I feel weak all over
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I feel listless ("washed out")
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I feel tired
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have trouble starting things because I am tired
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have trouble finishing things because I am tired
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A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have energy
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am able to do my usual activities
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I need to sleep during the day
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am too tired to eat
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I need help doing my usual activities
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am frustrated by being too tired to do the things
I want to do
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have to limit my social activity because I am
tired
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
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Prostate Cancer NCT00567580 Quality of Life - RTOG-0534
SA:  Utilization of Sexual Medications/Devices - 2712499v1.0
RTOG-0534 SA: Utilization of Sexual Medications/Devices
Prostate Radiation Therapy or Short-Term Androgen
Deprivation Therapy and Pelvic Lymph Node Radiation
Therapy With or Without Prostate Radiation Therapy in
Treating Patients With a Rising PSA After Surgery for
Prostate Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=40B59D19-
DE4D-46C2-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/9534
RTOG-0534 SA:  Utilization of
Sexual Medications/Devices
Unnamed Module 1
RTOG Study No.
Case #
Institution Name
Institution No.
Patient Initials
RTOG Patient ID
Amended data
Yes
No
Unamed Module 2
Time point
Five Year Follow-up (Five year follow-up)
One Year Follow-up (One year follow-up)
Pretreatment (Pretreatment)
Week 6 Of Rt (Week 6 of RT)
Was patient questionnaire completed
Yes
No
Date patient questionnaire completed
Reason Questionnaire was not Completed
Institution Error (Institutional error)
Not Applicable, Questionnaire Was
Completed (Not applicable,
questionnaire was completed)
Other Reason (Other reason)
Patient Refused Due To Illness (Patient
refused due to illness)
Patient Refused For Other Reason
(Patient refused for other reason)
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Patient Unable To Be Contacted (Patient
unable to be contacted)
Tool Not Availalble In Patient's Language
(Tool not availalble in patient's language)
Unknown (Unknown)
Patient refused for other reason, specify
Other reason, specify
Specify method of completion
At Appointment (At appointment)
By Mail (By mail)
By Telephone (By telephone)
Not Applicable (Not applicable)
Unknown (Unknown)
Did the patient require any assistance in
completing the questionnaire?
No (No)
Not Applicable (Not applicable)
Unknown If Assistance Given (Unknown
if assistance given)
Yes (Yes)
Specify the person who assisted the patient
Family (Family)
Not Applicable (Not applicable)
Other (Other)
Staff Member (Staff member)
Unknown (Unknown)
Extent of assistance given
Combination Of Above (Combination of
above)
Interpreted Items For Patient (Interpreted
items for patient)
Marked Items Per Patient's Response
(Marked items per patient's response)
Not Applicable (Not applicable)
Other (Other)
Read Items To Patient (Read items to
patient)
Unknown (Unknown)
Combination of above, specify
Other, specify
Comments
Signature of Person Completing This Form
Date Form Originally Completed
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NCT00956007 Quality of Life - RTOG 0920 Phase III Head and Neck
Cancer Dermatology Life Quality Index Form (DL) - 2815438v1.0
RTOG 0920 Phase III Head and Neck Cancer Dermatology
Life Quality Index Form (DL)
Radiation Therapy With or Without Cetuximab in Treating
Patients Who Have Undergone Surgery for Locally
Advanced Head and Neck Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=5DDB9090-
D79C-C15F-E040-BB89A6435310
All rights reserved. Please visit https://medical-data-
models.org/forms/9535
RTOG 0920 Phase III Head and
Neck Cancer Dermatology Life
Quality Index Form (DL)
Header
RTOG Study No.
Case #
Institution Name
Institution No.
Patient Initials
RTOG Patient ID
Unnamed2
Amended Data (This sheet is the cover page
used for submission of the DLQ - questionnaire.
This page must be completed by the medical staff
nurse, data manager, physician, etc.)
Yes
No
Unamed Module 2
Time point
1 Year From Start Of Treatment (1 year
from start of treatment)
18 Months From Start Of Treatment (18
months from start of treatment)
2 Years From Start Of Treatment (2 years
from start of treatment)
Baseline (baseline)
Was patient questionnaire completed
Yes
No
Date patient questionnaire completed (MM DD
YYYY)
Reason Questionnaire was not Completed
1 / 4
Institution Error (Institutional error)
Not Applicable, Questionnaire Was
Completed (Not applicable,
questionnaire was completed)
Other Reason (Other reason)
Patient Refused Due To Illness (Patient
refused due to illness)
Patient Refused For Other Reason
(Patient refused for other reason)
Patient Unable To Be Contacted (Patient
unable to be contacted)
Tool Not Availalble In Patient's Language
(Tool not available in patient's language)
Unknown (Unknown)
Patient refused for other reason, specify
Other reason, specify
Specify method of completion
At Appointment (At appointment)
By Mail (By mail)
By Telephone (By telephone)
Not Applicable (Not applicable)
Unknown (Unknown)
Did the patient require any assistance in
completing the questionnaire?
No (No)
Not Applicable (Not applicable)
Unknown If Assistance Given (Unknown
if assistance given)
Yes (Yes)
Specify the person who assisted the patient
Family (Family)
Not Applicable (Not applicable)
Other (Other)
Staff Member (Staff member)
Unknown (Unknown)
Other, specify
Extent of assistance given
Combination Of Above (Combination of
above)
Interpreted Items For Patient (Interpreted
items for patient)
Marked Items Per Patient's Response
(Marked items per patient's response)
Not Applicable (Not applicable)
Other (Other)
Read Items To Patient (Read items to
patient)
Unknown (Unknown)
Combination of above, specify
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Other, specify
Signature of Person Completing This Form
Date Form Completed (MM DD YYYY)
Dermatology Life Quality Index
Over the last week, how itchy, sore, painful or
stinging has your skin been
A Little (A little)
A Lot (A lot)
Not At All (Not at all)
Very Much (Very much)
Over the last week, how embarrassed or self
conscious have you been because of your skin
A Little (A little)
A Lot (A lot)
Not At All (Not at all)
Very Much (Very much)
Over the last week, how much has your skin
interfered with you going shopping or looking
after your home or garden
A Little (A little)
A Lot (A lot)
Not At All (Not at all)
Not Relevant (Not relevant)
Very Much (Very much)
Over the last week, how much has your skin
influenced the clothes you wear
A Little (A little)
A Lot (A lot)
Not At All (Not at all)
Not Relevant (Not relevant)
Very Much (Very much)
Over the last week, how much has your skin
affected any social or leisure activities
A Little (A little)
A Lot (A lot)
Not At All (Not at all)
Not Relevant (Not relevant)
Very Much (Very much)
Over the last week, how much has your skin
made it difficult for you to do any sport
A Little (A little)
A Lot (A lot)
Not At All (Not at all)
Not Relevant (Not relevant)
Very Much (Very much)
Over the last week, has your skin prevented you
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from working or studying
No (No)
Not Relevant (Not relevant)
Yes (Yes)
Over the last week how much has your skin been
a problem at work or studying
A Little (A little)
A Lot (A lot)
Not At All (Not at all)
Over the last week, how much has your skin
created problems with your partner or any of your
close friends or relatives
A Little (A little)
A Lot (A lot)
Not At All (Not at all)
Not Relevant (Not relevant)
Very Much (Very much)
Over the last week, how much has your skin
caused any sexual difficulties
A Little (A little)
A Lot (A lot)
Not At All (Not at all)
Not Relevant (Not relevant)
Very Much (Very much)
Over the last week, how much of a problem has
the treatment for your skin been, for example by
making your home messy, or by taking up time
A Little (A little)
A Lot (A lot)
Not At All (Not at all)
Not Relevant (Not relevant)
Very Much (Very much)
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NCT00956007 Quality of Life - RTOG 0920 Phase III Head and Neck Cancer
University of Michigan Xerostomia-Related Quality of Life Scale (Xe QOLS) Form
(L4) - 2815347v1.0
RTOG 0920 Phase III Head and Neck Cancer University of
Michigan Xerostomia-Related Quality of Life Scale (Xe
QOLS) Form (L4)
Radiation Therapy With or Without Cetuximab in Treating
Patients Who Have Undergone Surgery for Locally
Advanced Head and Neck Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=5DDB9090-
D6EA-C15F-E040-BB89A6435310
All rights reserved. Please visit https://medical-data-
models.org/forms/9536
RTOG 0920 Phase III Head and
Neck Cancer University of Michigan
Xerostomia-Related Quality of Life
Scale (Xe QOLS) Form (L4)
Header
RTOG Study No.
Case #
Institution Name
Institution No.
Patient Initials
RTOG Patient ID
Unnamed2
Amended Data (This sheet is the cover page
used for submission of the Xe-QOLS -
questionnaire. This page must be completed by
the medical staff nurse, data manager, physician,
etc.)
Yes
No
Unamed Module 2
Time point
1 Year From Start Of Treatment (1 year
from start of treatment)
3 Months From Start Of Treatment (3
months from start of treatment)
Baseline (baseline)
Was patient questionnaire completed
Yes
No
Date patient questionnaire completed (MM DD
YYYY)
1 / 5
Reason Questionnaire was not Completed
Institution Error (Institutional error)
Not Applicable, Questionnaire Was
Completed (Not applicable,
questionnaire was completed)
Other Reason (Other reason)
Patient Refused Due To Illness (Patient
refused due to illness)
Patient Refused For Other Reason
(Patient refused for other reason)
Patient Unable To Be Contacted (Patient
unable to be contacted)
Tool Not Availalble In Patient's Language
(Tool not available in patient's language)
Unknown (Unknown)
Patient refused for other reason, specify
Other reason, specify
Specify method of completion
At Appointment (At appointment)
By Mail (By mail)
By Telephone (By telephone)
Not Applicable (Not applicable)
Unknown (Unknown)
Did the patient require any assistance in
completing the questionnaire?
No (No)
Not Applicable (Not applicable)
Unknown If Assistance Given (Unknown
if assistance given)
Yes (Yes)
Specify the person who assisted the patient
Family (Family)
Not Applicable (Not applicable)
Other (Other)
Staff Member (Staff member)
Unknown (Unknown)
Other, specify
Extent of assistance given
Combination Of Above (Combination of
above)
Interpreted Items For Patient (Interpreted
items for patient)
Marked Items Per Patient's Response
(Marked items per patient's response)
Not Applicable (Not applicable)
Other (Other)
Read Items To Patient (Read items to
patient)
Unknown (Unknown)
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Combination of above, specify
Other, specify
Signature of Person Completing This Form
Date Form Completed (MM DD YYYY)
Xerostomia-related Quality Of Life Scale
My mouth/throat dryness limits the kinds or
amounts of food I eat
A Little (A little)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
My mouth/throat dryness causes discomfort
A Little (A little)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
My mouth/throat dryness causes a lot of worry or
concern
A Little (A little)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
My mouth/throat dryness keeps me from
socializing (going out)
A Little (A little)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
My mouth/throat dryness makes me
uncomfortable when eating in front of other
people
A Little (A little)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
My mouth/throat dryness makes me
uncomfortable speaking in front of other people
A Little (A little)
Not At All (Not at all)
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Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
My mouth/throat dryness makes me nervous
A Little (A little)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
My mouth/throat dryness makes me concerned
about the looks of my teeth and mouth
A Little (A little)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
My mouth/throat dryness keeps me from enjoying
life
A Little (A little)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
My mouth/throat dryness interferes with my daily
activities
A Little (A little)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
My mouth/throat dryness interferes with my
intimate relationships
A Little (A little)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
My mouth/throat dryness has a bad effect on
tasting food
A Little (A little)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
My mouth/throat dryness reduces my general
happiness with life
A Little (A little)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
My mouth/throat dryness affects all aspects of my
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life
A Little (A little)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
If you were to spend the rest of your life with your
mouth/throat dryness just the way it is now, how
would you feel about this
Delighted (Delighted)
Mixed: Equally Satisfied/dissatisfied
(Mixed: equally satisfied/dissatisfied)
Mostly Dissatisfied (Mostly dissatisfied)
Mostly Satisfied (Mostly satisfied)
Terrible (Terrible)
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NCT00956007 Quality of Life - RTOG 0920 Phase III Head and Neck
Cancer Therapy General Form FACT-H&N (FA) - 2810973v1.0
RTOG 0920 Phase III Head and Neck Cancer Therapy
General Form FACT-H&N (FA)
Radiation Therapy With or Without Cetuximab in Treating
Patients Who Have Undergone Surgery for Locally
Advanced Head and Neck Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=5D3C2575-
89D6-1D1F-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/9539
RTOG 0920 Phase III Head and
Neck Cancer Therapy General Form
FACT-H&N (FA)
Header
RTOG Study No.
Case #
Institution Name
Institution No.
Patient Initials
RTOG Patient ID
Unnamed2
Amended Data (This sheet is the cover page
used for submission of the FACT H&N -
questionnaire. This page must be completed by
the medical staff nurse, data manager, physician,
etc.)
Yes
No
Unamed Module 2
Time point
1 Year From Start Of Treatment (1 year
from start of treatment)
3 Months From Start Of Treatment (3
months from start of treatment)
Baseline (baseline)
Was patient questionnaire completed
Yes
No
Date patient questionnaire completed (MM DD
YYYY)
Reason Questionnaire was not Completed
Institution Error (Institutional error)
1 / 8
Not Applicable, Questionnaire Was
Completed (Not applicable,
questionnaire was completed)
Other Reason (Other reason)
Patient Refused Due To Illness (Patient
refused due to illness)
Patient Refused For Other Reason
(Patient refused for other reason)
Patient Unable To Be Contacted (Patient
unable to be contacted)
Tool Not Availalble In Patient's Language
(Tool not available in patient's language)
Unknown (Unknown)
Patient refused for other reason, specify
Other reason, specify
Specify method of completion
At Appointment (At appointment)
By Mail (By mail)
By Telephone (By telephone)
Not Applicable (Not applicable)
Unknown (Unknown)
Did the patient require any assistance in
completing the questionnaire?
No (No)
Not Applicable (Not applicable)
Unknown If Assistance Given (Unknown
if assistance given)
Yes (Yes)
Specify the person who assisted the patient
Family (Family)
Not Applicable (Not applicable)
Other (Other)
Staff Member (Staff member)
Unknown (Unknown)
Other, specify
Extent of assistance given
Combination Of Above (Combination of
above)
Interpreted Items For Patient (Interpreted
items for patient)
Marked Items Per Patient's Response
(Marked items per patient's response)
Not Applicable (Not applicable)
Other (Other)
Read Items To Patient (Read items to
patient)
Unknown (Unknown)
Combination of above, specify
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Other, specify
Signature of Person Completing This Form
Date Form Completed (MM DD YYYY)
Physical Well-being
I have a lack of energy
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have nausea
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
Because of my physical condition, I have trouble
meeting the needs of my family
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have pain
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am bothered by side effects of treatment
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I feel ill
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am forced to spend time in bed
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
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Very Much (Very much)
Social/family Well-being
I feel close to my friends
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I get emotional support from my family
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I get support from my friends
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
My family has accepted my illness
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am satisfied with family communication about
my illness
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I feel close to my partner (or the person who is
my main support)
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am satisfied with my sex life
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
Emotional Well-being
I feel sad
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A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am satisfied with how I am coping with my
illness
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am losing hope in the fight against my illness
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I feel nervous
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I worry about dying
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I worry that my condition will get worse
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
Functional Well-being
I am able to work (include work at home)
2 (A little bit)
1 (Not at all)
4 (Quite a bit)
3 (Somewhat)
5 (Very much)
My work is fulfilling (include work at home)
2 (A little bit)
1 (Not at all)
4 (Quite a bit)
3 (Somewhat)
5 (Very much)
I am able to enjoy life
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2 (A little bit)
1 (Not at all)
4 (Quite a bit)
3 (Somewhat)
5 (Very much)
I have accepted my illness
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am sleeping well
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am enjoying the things I usually do for fun
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am content with the quality of my life right now
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
Additional Concerns
I am able to eat the foods that I like
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
My mouth is dry
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have trouble breathing
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
My voice has its usual quality and strength
A Little Bit (A little bit)
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Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am able to eat as much food as I want
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am unhappy with how my face and neck look
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I can swallow naturally and easily
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I smoke cigarettes or other tobacco products
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I drink alcohol (e.g. beer, wine, etc.)
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am able to communicate with others
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I can eat solid foods
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have pain in my mouth, throat or neck
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
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NCI Standard Adverse Event/Serious Adverse
Event CTCAE v4 Template - 3265657v1.0
The collection of CDEs used in the Adverse Events/Serious
Adverse Events module.
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=ABE71DA5-
84B4-501B-E040-BB89AD430D93
All rights reserved. Please visit https://medical-data-
models.org/forms/9540
NCI Standard Adverse Event/Serious
Adverse Event CTCAE v4 Template
Mandatory Adverse Event Data Elements
Adverse Event Term (v4.0) (Code used to identify
the adverse event using a standard mechanism
that facilitates analysis. CTEP's code list and
associated Category/Term is currently a
standard.)
Abdominal Distension (Abdominal
distension)
Abdominal Infection (Abdominal
infection)
Abdominal Pain (Abdominal pain)
Abdominal Soft Tissue Necrosis
(Abdominal soft tissue necrosis)
Abducens Nerve Disorder (Abducens
nerve disorder)
Accessory Nerve Disorder (Accessory
nerve disorder)
Acidosis (Acidosis)
Acoustic Nerve Disorder Nos (Acoustic
nerve disorder NOS)
Activated Partial Thromboplastin Time
Prolonged (Activated partial
thromboplastin time prolonged)
Acute Coronary Syndrome (Acute
coronary syndrome)
Acute Kidney Injury (Acute kidney injury)
Adrenal Insufficiency (Adrenal
insufficiency)
Adult Respiratory Distress Syndrome
(Adult respiratory distress syndrome)
Agitation (Agitation)
Akathisia (Akathisia)
Alanine Aminotransferase Increased
(Alanine aminotransferase increased)
Alcohol Intolerance (Alcohol intolerance)
Alkaline Phosphatase Increased
(Alkaline phosphatase increased)
Alkalosis (Alkalosis)
Allergic Reaction (Allergic reaction)
Allergic Rhinitis (Allergic rhinitis)
Alopecia (Alopecia)
Amnesia (Amnesia)
Anal Fistula (Anal fistula)
Anal Hemorrhage (Anal hemorrhage)
Anal Mucositis (Anal mucositis)
Anal Necrosis (Anal necrosis)
Anal Pain (Anal pain)
Anal Stenosis (Anal stenosis)
Anal Ulcer (Anal ulcer)
Anaphylaxis (Anaphylaxis)
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Anemia (Anemia)
Ankle Fracture (Ankle fracture)
Anorectal Infection (Anorectal infection)
Anorexia (Anorexia)
Anorgasmia (Anorgasmia)
Anxiety (Anxiety)
Aortic Injury (Aortic injury)
Aortic Valve Disease (Aortic valve
disease)
Aphonia (Aphonia)
Apnea (Apnea)
Appendicitis (Appendicitis)
Appendicitis Perforated (Appendicitis
perforated)
Arachnoiditis (Arachnoiditis)
Arterial Injury (Arterial injury)
Arteritis Infective (Arteritis infective)
Arthralgia (Arthralgia)
Arthritis (Arthritis)
Ascites (Ascites)
Aspartate Aminotransferase Increased
(Aspartate aminotransferase increased)
Aspiration (Aspiration)
Asystole (Asystole)
Ataxia (Ataxia)
Atelectasis (Atelectasis)
Atrial Fibrillation (Atrial fibrillation)
Atrial Flutter (Atrial flutter)
Atrioventricular Block Complete
(Atrioventricular block complete)
Atrioventricular Block First Degree
(Atrioventricular block first degree)
Autoimmune Disorder (Autoimmune
disorder)
Avascular Necrosis (Avascular necrosis)
Azoospermia (Azoospermia)
Back Pain (Back pain)
Bile Duct Stenosis (Bile duct stenosis)
Biliary Anastomotic Leak (Biliary
anastomotic leak)
Biliary Fistula (Biliary fistula)
Biliary Tract Infection (Biliary tract
infection)
Bladder Anastomotic Leak (Bladder
anastomotic leak)
Bladder Infection (Bladder infection)
Bladder Perforation (Bladder perforation)
Bladder Spasm (Bladder spasm)
Bloating (Bloating)
Blood And Lymphatic System Disorders -
Other, Specify (Blood and lymphatic
system disorders - Other, Specify)
Blood Antidiuretic Hormone Abnormal
(Blood antidiuretic hormone abnormal)
Blood Bilirubin Increased (Blood bilirubin
increased)
Blood Corticotrophin Decreased (Blood
corticotrophin decreased)
Blood Gonadotrophin Abnormal (Blood
gonadotrophin abnormal)
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Blood Prolactin Abnormal (Blood
prolactin abnormal)
Blurred Vision (Blurred vision)
Body Odor (Body odor)
Bone Infection (Bone infection)
Bone Marrow Hypocellular (Bone
marrow hypocellular)
Bone Pain (Bone pain)
Brachial Plexopathy (Brachial
plexopathy)
Breast Atrophy (Breast atrophy)
Breast Infection (Breast infection)
Breast Pain (Breast pain)
Bronchial Fistula (Bronchial fistula)
Bronchial Infection (Bronchial infection)
Bronchial Obstruction (Bronchial
obstruction)
Bronchial Stricture (Bronchial stricture)
Bronchopleural Fistula (Bronchopleural
fistula)
Bronchopulmonary Hemorrhage
(Bronchopulmonary hemorrhage)
Bronchospasm (Bronchospasm)
Bruising (Bruising)
Bullous Dermatitis (Bullous dermatitis)
Burn (Burn)
Buttock Pain (Buttock pain)
Capillary Leak Syndrome (Capillary leak
syndrome)
Carbon Monoxide Diffusing Capacity
Decreased (Carbon monoxide diffusing
capacity decreased)
Cardiac Arrest (Cardiac arrest)
Cardiac Disorders - Other, Specify
(Cardiac disorders - Other, Specify)
Cardiac Troponin I Increased (Cardiac
troponin I increased)
Cardiac Troponin T Increased (Cardiac
troponin T increased)
Cataract (Cataract)
Catheter Related Infection (Catheter
related infection)
Cd4 Lymphocytes Decreased (CD4
lymphocytes decreased)
Cecal Hemorrhage (Cecal hemorrhage)
Cecal Infection (Cecal infection)
Central Nervous System Necrosis
(Central nervous system necrosis)
Cerebrospinal Fluid Leakage
(Cerebrospinal fluid leakage)
Cervicitis Infection (Cervicitis infection)
Cheilitis (Cheilitis)
Chest Pain - Cardiac (Chest pain -
cardiac)
Chest Wall Pain (Chest wall pain)
Chills (Chills)
Cholecystitis (Cholecystitis)
Cholesterol High (Cholesterol high)
Chronic Kidney Disease (Chronic kidney
disease)
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Chylothorax (Chylothorax)
Cognitive Disturbance (Cognitive
disturbance)
Colitis (Colitis)
Colonic Fistula (Colonic fistula)
Colonic Hemorrhage (Colonic
hemorrhage)
Colonic Obstruction (Colonic obstruction)
Colonic Perforation (Colonic perforation)
Colonic Stenosis (Colonic stenosis)
Colonic Ulcer (Colonic ulcer)
Concentration Impairment
(Concentration impairment)
Conduction Disorder (Conduction
disorder)
Confusion (Confusion)
Congenital, Familial And Genetic
Disorders - Other, Specify (Congenital,
familial and genetic disorders - Other,
Specify)
Conjunctivitis (Conjunctivitis)
Conjunctivitis Infective (Conjunctivitis
infective)
Constipation (Constipation)
Constrictive Pericarditis (Constrictive
pericarditis)
Corneal Infection (Corneal infection)
Corneal Ulcer (Corneal ulcer)
Cough (Cough)
Cpk Increased (CPK increased)
Cranial Nerve Infection (Cranial nerve
infection)
Creatinine Increased (Creatinine
increased)
Cushingoid (Cushingoid)
Cystitis Noninfective (Cystitis
noninfective)
Cytokine Release Syndrome (Cytokine
release syndrome)
Death Neonatal (Death neonatal)
Death Nos (Death NOS)
Dehydration (Dehydration)
Delayed Orgasm (Delayed orgasm)
Delayed Puberty (Delayed puberty)
Delirium (Delirium)
Delusions (Delusions)
Dental Caries (Dental caries)
Depressed Level Of Consciousness
(Depressed level of consciousness)
Depression (Depression)
Dermatitis Radiation (Dermatitis
radiation)
Device Related Infection (Device related
infection)
Diarrhea (Diarrhea)
Disseminated Intravascular Coagulation
(Disseminated intravascular coagulation)
Dizziness (Dizziness)
Dry Eye (Dry eye)
Dry Mouth (Dry mouth)
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Dry Skin (Dry skin)
Duodenal Fistula (Duodenal fistula)
Duodenal Hemorrhage (Duodenal
hemorrhage)
Duodenal Infection (Duodenal infection)
Duodenal Obstruction (Duodenal
obstruction)
Duodenal Perforation (Duodenal
perforation)
Duodenal Stenosis (Duodenal stenosis)
Duodenal Ulcer (Duodenal ulcer)
Dysarthria (Dysarthria)
Dysesthesia (Dysesthesia)
Dysgeusia (Dysgeusia)
Dysmenorrhea (Dysmenorrhea)
Dyspareunia (Dyspareunia)
Dyspepsia (Dyspepsia)
Dysphagia (Dysphagia)
Dysphasia (Dysphasia)
Dyspnea (Dyspnea)
Ear And Labyrinth Disorders - Other,
Specify (Ear and labyrinth disorders -
Other, Specify)
Ear Pain (Ear pain)
Edema Cerebral (Edema cerebral)
Edema Face (Edema face)
Edema Limbs (Edema limbs)
Edema Trunk (Edema trunk)
Ejaculation Disorder (Ejaculation
disorder)
Ejection Fraction Decreased (Ejection
fraction decreased)
Electrocardiogram Qt Corrected Interval
Prolonged (Electrocardiogram QT
corrected interval prolonged)
Encephalitis Infection (Encephalitis
infection)
Encephalomyelitis Infection
(Encephalomyelitis infection)
Encephalopathy (Encephalopathy)
Endocarditis Infective (Endocarditis
infective)
Endocrine Disorders - Other, Specify
(Endocrine disorders - Other, Specify)
Endophthalmitis (Endophthalmitis)
Enterocolitis (Enterocolitis)
Enterocolitis Infectious (Enterocolitis
infectious)
Enterovesical Fistula (Enterovesical
fistula)
Epistaxis (Epistaxis)
Erectile Dysfunction (Erectile
dysfunction)
Erythema Multiforme (Erythema
multiforme)
Erythroderma (Erythroderma)
Esophageal Anastomotic Leak
(Esophageal anastomotic leak)
Esophageal Fistula (Esophageal fistula)
Esophageal Hemorrhage (Esophageal
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hemorrhage)
Esophageal Infection (Esophageal
infection)
Esophageal Necrosis (Esophageal
necrosis)
Esophageal Obstruction (Esophageal
obstruction)
Esophageal Pain (Esophageal pain)
Esophageal Perforation (Esophageal
perforation)
Esophageal Stenosis (Esophageal
stenosis)
Esophageal Ulcer (Esophageal ulcer)
Esophageal Varices Hemorrhage
(Esophageal varices hemorrhage)
Esophagitis (Esophagitis)
Euphoria (Euphoria)
Exostosis (Exostosis)
External Ear Inflammation (External ear
inflammation)
External Ear Pain (External ear pain)
Extraocular Muscle Paresis (Extraocular
muscle paresis)
Extrapyramidal Disorder (Extrapyramidal
disorder)
Eye Disorders - Other, Specify (Eye
disorders - Other, Specify)
Eye Infection (Eye infection)
Eye Pain (Eye pain)
Eyelid Function Disorder (Eyelid function
disorder)
Facial Muscle Weakness (Facial muscle
weakness)
Facial Nerve Disorder (Facial nerve
disorder)
Facial Pain (Facial pain)
Fall (Fall)
Fallopian Tube Anastomotic Leak
(Fallopian tube anastomotic leak)
Fallopian Tube Obstruction (Fallopian
tube obstruction)
Fallopian Tube Perforation (Fallopian
tube perforation)
Fallopian Tube Stenosis (Fallopian tube
stenosis)
Fat Atrophy (Fat atrophy)
Fatigue (Fatigue)
Febrile Neutropenia (Febrile
neutropenia)
Fecal Incontinence (Fecal incontinence)
Female Genital Tract Fistula (Female
genital tract fistula)
Feminization Acquired (Feminization
acquired)
Fetal Death (Fetal death)
Fetal Growth Retardation (Fetal growth
retardation)
Fever (Fever)
Fibrinogen Decreased (Fibrinogen
decreased)
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Fibrosis Deep Connective Tissue
(Fibrosis deep connective tissue)
Flank Pain (Flank pain)
Flashing Lights (Flashing lights)
Flatulence (Flatulence)
Floaters (Floaters)
Flu Like Symptoms (Flu like symptoms)
Flushing (Flushing)
Forced Expiratory Volume Decreased
(Forced expiratory volume decreased)
Fracture (Fracture)
Gait Disturbance (Gait disturbance)
Gallbladder Fistula (Gallbladder fistula)
Gallbladder Infection (Gallbladder
infection)
Gallbladder Necrosis (Gallbladder
necrosis)
Gallbladder Obstruction (Gallbladder
obstruction)
Gallbladder Pain (Gallbladder pain)
Gallbladder Perforation (Gallbladder
perforation)
Gastric Anastomotic Leak (Gastric
anastomotic leak)
Gastric Fistula (Gastric fistula)
Gastric Hemorrhage (Gastric
hemorrhage)
Gastric Necrosis (Gastric necrosis)
Gastric Perforation (Gastric perforation)
Gastric Stenosis (Gastric stenosis)
Gastric Ulcer (Gastric ulcer)
Gastritis (Gastritis)
Gastroesophageal Reflux Disease
(Gastroesophageal reflux disease)
Gastrointestinal Anastomotic Leak
(Gastrointestinal anastomotic leak)
Gastrointestinal Disorders - Other,
Specify (Gastrointestinal disorders -
Other, Specify)
Gastrointestinal Fistula (Gastrointestinal
fistula)
Gastrointestinal Pain (Gastrointestinal
pain)
Gastrointestinal Stoma Necrosis
(Gastrointestinal stoma necrosis)
Gastroparesis (Gastroparesis)
General Disorders And Administration
Site Conditions - Other, Specify (General
disorders and administration site
conditions - Other, Specify)
Generalized Muscle Weakness
(Generalized muscle weakness)
Genital Edema (Genital edema)
Ggt Increased (GGT increased)
Gingival Pain (Gingival pain)
Glaucoma (Glaucoma)
Glossopharyngeal Nerve Disorder
(Glossopharyngeal nerve disorder)
Glucose Intolerance (Glucose
intolerance)
7 / 39
NCI Standard Adverse Event/Serious Adverse Event CTCAE v4
Template - 3265657v1.0
Growth Accelerated (Growth
accelerated)
Growth Hormone Abnormal (Growth
hormone abnormal)
Growth Suppression (Growth
suppression)
Gum Infection (Gum infection)
Gynecomastia (Gynecomastia)
Hallucinations (Hallucinations)
Haptoglobin Decreased (Haptoglobin
decreased)
Head Soft Tissue Necrosis (Head soft
tissue necrosis)
Headache (Headache)
Hearing Impaired (Hearing impaired)
Heart Failure (Heart failure)
Hematoma (Hematoma)
Hematosalpinx (Hematosalpinx)
Hematuria (Hematuria)
Hemoglobin Increased (Hemoglobin
increased)
Hemoglobinuria (Hemoglobinuria)
Hemolysis (Hemolysis)
Hemolytic Uremic Syndrome (Hemolytic
uremic syndrome)
Hemorrhoidal Hemorrhage
(Hemorrhoidal hemorrhage)
Hemorrhoids (Hemorrhoids)
Hepatic Failure (Hepatic failure)
Hepatic Hemorrhage (Hepatic
hemorrhage)
Hepatic Infection (Hepatic infection)
Hepatic Necrosis (Hepatic necrosis)
Hepatic Pain (Hepatic pain)
Hepatitis Viral (Hepatitis viral)
Hepatobiliary Disorders - Other, Specify
(Hepatobiliary disorders - Other, Specify)
Hiccups (Hiccups)
Hip Fracture (Hip fracture)
Hirsutism (Hirsutism)
Hoarseness (Hoarseness)
Hot Flashes (Hot flashes)
Hydrocephalus (Hydrocephalus)
Hypercalcemia (Hypercalcemia)
Hyperglycemia (Hyperglycemia)
Hyperhidrosis (Hyperhidrosis)
Hyperkalemia (Hyperkalemia)
Hypermagnesemia (Hypermagnesemia)
Hypernatremia (Hypernatremia)
Hyperparathyroidism
(Hyperparathyroidism)
Hypersomnia (Hypersomnia)
Hypertension (Hypertension)
Hyperthyroidism (Hyperthyroidism)
Hypertrichosis (Hypertrichosis)
Hypertriglyceridemia
(Hypertriglyceridemia)
Hyperuricemia (Hyperuricemia)
Hypoalbuminemia (Hypoalbuminemia)
Hypocalcemia (Hypocalcemia)
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Hypoglossal Nerve Disorder
(Hypoglossal nerve disorder)
Hypoglycemia (Hypoglycemia)
Hypohidrosis (Hypohidrosis)
Hypokalemia (Hypokalemia)
Hypomagnesemia (Hypomagnesemia)
Hyponatremia (Hyponatremia)
Hypoparathyroidism
(Hypoparathyroidism)
Hypophosphatemia (Hypophosphatemia)
Hypotension (Hypotension)
Hypothermia (Hypothermia)
Hypothyroidism (Hypothyroidism)
Hypoxia (Hypoxia)
Ileal Fistula (Ileal fistula)
Ileal Hemorrhage (Ileal hemorrhage)
Ileal Obstruction (Ileal obstruction)
Ileal Perforation (Ileal perforation)
Ileal Stenosis (Ileal stenosis)
Ileal Ulcer (Ileal ulcer)
Ileus (Ileus)
Immune System Disorders - Other,
Specify (Immune system disorders -
Other, Specify)
Infections And Infestations - Other,
Specify (Infections and infestations -
Other, Specify)
Infective Myositis (Infective myositis)
Infusion Related Reaction (Infusion
related reaction)
Infusion Site Extravasation (Infusion site
extravasation)
Injection Site Reaction (Injection site
reaction)
Injury To Carotid Artery (Injury to carotid
artery)
Injury To Inferior Vena Cava (Injury to
inferior vena cava)
Injury To Jugular Vein (Injury to jugular
vein)
Injury To Superior Vena Cava (Injury to
superior vena cava)
Injury, Poisoning And Procedural
Complications - Other, Specify (Injury,
poisoning and procedural complications -
Other, Specify)
Inr Increased (INR increased)
Insomnia (Insomnia)
Intestinal Stoma Leak (Intestinal stoma
leak)
Intestinal Stoma Obstruction (Intestinal
stoma obstruction)
Intestinal Stoma Site Bleeding (Intestinal
stoma site bleeding)
Intra-abdominal Hemorrhage (Intra-
abdominal hemorrhage)
Intracranial Hemorrhage (Intracranial
hemorrhage)
Intraoperative Arterial Injury
(Intraoperative arterial injury)
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Intraoperative Breast Injury
(Intraoperative breast injury)
Intraoperative Cardiac Injury
(Intraoperative cardiac injury)
Intraoperative Ear Injury (Intraoperative
ear injury)
Intraoperative Endocrine Injury
(Intraoperative endocrine injury)
Intraoperative Gastrointestinal Injury
(Intraoperative gastrointestinal injury)
Intraoperative Head And Neck Injury
(Intraoperative head and neck injury)
Intraoperative Hemorrhage
(Intraoperative hemorrhage)
Intraoperative Hepatobiliary Injury
(Intraoperative hepatobiliary injury)
Intraoperative Musculoskeletal Injury
(Intraoperative musculoskeletal injury)
Intraoperative Neurological Injury
(Intraoperative neurological injury)
Intraoperative Ocular Injury
(Intraoperative ocular injury)
Intraoperative Renal Injury
(Intraoperative renal injury)
Intraoperative Reproductive Tract Injury
(Intraoperative reproductive tract injury)
Intraoperative Respiratory Injury
(Intraoperative respiratory injury)
Intraoperative Skin Injury (Intraoperative
skin injury)
Intraoperative Splenic Injury
(Intraoperative splenic injury)
Intraoperative Urinary Injury
(Intraoperative urinary injury)
Intraoperative Venous Injury
(Intraoperative venous injury)
Investigations - Other, Specify
(Investigations - Other, Specify)
Iron Overload (Iron overload)
Irregular Menstruation (Irregular
menstruation)
Irritability (Irritability)
Ischemia Cerebrovascular (Ischemia
cerebrovascular)
Ivth Nerve Disorder (IVth nerve disorder)
Jejunal Fistula (Jejunal fistula)
Jejunal Hemorrhage (Jejunal
hemorrhage)
Jejunal Obstruction (Jejunal obstruction)
Jejunal Perforation (Jejunal perforation)
Jejunal Stenosis (Jejunal stenosis)
Jejunal Ulcer (Jejunal ulcer)
Joint Effusion (Joint effusion)
Joint Infection (Joint infection)
Joint Range Of Motion Decreased (Joint
range of motion decreased)
Joint Range Of Motion Decreased
Cervical Spine (Joint range of motion
decreased cervical spine)
Joint Range Of Motion Decreased
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Lumbar Spine (Joint range of motion
decreased lumbar spine)
Keratitis (Keratitis)
Kidney Anastomotic Leak (Kidney
anastomotic leak)
Kidney Infection (Kidney infection)
Kyphosis (Kyphosis)
Lactation Disorder (Lactation disorder)
Large Intestinal Anastomotic Leak (Large
intestinal anastomotic leak)
Laryngeal Edema (Laryngeal edema)
Laryngeal Fistula (Laryngeal fistula)
Laryngeal Hemorrhage (Laryngeal
hemorrhage)
Laryngeal Inflammation (Laryngeal
inflammation)
Laryngeal Mucositis (Laryngeal
mucositis)
Laryngeal Obstruction (Laryngeal
obstruction)
Laryngeal Stenosis (Laryngeal stenosis)
Laryngitis (Laryngitis)
Laryngopharyngeal Dysesthesia
(Laryngopharyngeal dysesthesia)
Laryngospasm (Laryngospasm)
Left Ventricular Systolic Dysfunction (Left
ventricular systolic dysfunction)
Lethargy (Lethargy)
Leukemia Secondary To Oncology
Chemotherapy (Leukemia secondary to
oncology chemotherapy)
Leukocytosis (Leukocytosis)
Leukoencephalopathy
(Leukoencephalopathy)
Libido Decreased (Libido decreased)
Libido Increased (Libido increased)
Lip Infection (Lip infection)
Lip Pain (Lip pain)
Lipase Increased (Lipase increased)
Lipohypertrophy (Lipohypertrophy)
Localized Edema (Localized edema)
Lordosis (Lordosis)
Lower Gastrointestinal Hemorrhage
(Lower gastrointestinal hemorrhage)
Lung Infection (Lung infection)
Lymph Gland Infection (Lymph gland
infection)
Lymph Leakage (Lymph leakage)
Lymph Node Pain (Lymph node pain)
Lymphedema (Lymphedema)
Lymphocele (Lymphocele)
Lymphocyte Count Decreased
(Lymphocyte count decreased)
Lymphocyte Count Increased
(Lymphocyte count increased)
Malabsorption (Malabsorption)
Malaise (Malaise)
Mania (Mania)
Mediastinal Hemorrhage (Mediastinal
hemorrhage)
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Mediastinal Infection (Mediastinal
infection)
Memory Impairment (Memory
impairment)
Meningismus (Meningismus)
Meningitis (Meningitis)
Menopause (Menopause)
Menorrhagia (Menorrhagia)
Metabolism And Nutrition Disorders -
Other, Specify (Metabolism and nutrition
disorders - Other, Specify)
Middle Ear Inflammation (Middle ear
inflammation)
Mitral Valve Disease (Mitral valve
disease)
Mobitz (type) Ii Atrioventricular Block
(Mobitz (type) II atrioventricular block)
Mobitz Type I (Mobitz type I)
Movements Involuntary (Movements
involuntary)
Mucosal Infection (Mucosal infection)
Mucositis Oral (Mucositis oral)
Multi-organ Failure (Multi-organ failure)
Muscle Weakness Left-sided (Muscle
weakness left-sided)
Muscle Weakness Lower Limb (Muscle
weakness lower limb)
Muscle Weakness Right-sided (Muscle
weakness right-sided)
Muscle Weakness Trunk (Muscle
weakness trunk)
Muscle Weakness Upper Limb (Muscle
weakness upper limb)
Musculoskeletal And Connective Tissue
Disorder - Other, Specify
(Musculoskeletal and connective tissue
disorders - Other, Specify)
Musculoskeletal Deformity
(Musculoskeletal deformity)
Myalgia (Myalgia)
Myelitis (Myelitis)
Myelodysplastic Syndrome
(Myelodysplastic syndrome)
Myocardial Infarction (Myocardial
infarction)
Myocarditis (Myocarditis)
Myositis (Myositis)
Nail Discoloration (Nail discoloration)
Nail Infection (Nail infection)
Nail Loss (Nail loss)
Nail Ridging (Nail ridging)
Nasal Congestion (Nasal congestion)
Nausea (Nausea)
Neck Edema (Neck edema)
Neck Pain (Neck pain)
Neck Soft Tissue Necrosis (Neck soft
tissue necrosis)
Neoplasms Benign, Malignant And
Unspecified (incl Cysts And Polyps) -
Other, Specify (Neoplasms benign,
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malignant and unspecified (incl cysts and
polyps) - Other, Specify)
Nervous System Disorders - Other,
Specify (Nervous system disorders -
Other, Specify)
Neuralgia (Neuralgia)
Neutrophil Count Decreased (Neutrophil
count decreased)
Night Blindness (Night blindness)
Nipple Deformity (Nipple deformity)
Non-cardiac Chest Pain (Non-cardiac
chest pain)
Nystagmus (Nystagmus)
Obesity (Obesity)
Obstruction Gastric (Obstruction gastric)
Oculomotor Nerve Disorder (Oculomotor
nerve disorder)
Olfactory Nerve Disorder (Olfactory
nerve disorder)
Oligospermia (Oligospermia)
Optic Nerve Disorder (Optic nerve
disorder)
Oral Cavity Fistula (Oral cavity fistula)
Oral Dysesthesia (Oral dysesthesia)
Oral Hemorrhage (Oral hemorrhage)
Oral Pain (Oral pain)
Osteonecrosis Of Jaw (Osteonecrosis of
jaw)
Osteoporosis (Osteoporosis)
Otitis Externa (Otitis externa)
Otitis Media (Otitis media)
Ovarian Hemorrhage (Ovarian
hemorrhage)
Ovarian Infection (Ovarian infection)
Ovarian Rupture (Ovarian rupture)
Ovulation Pain (Ovulation pain)
Pain (Pain)
Pain In Extremity (Pain in extremity)
Pain Of Skin (Pain of skin)
Palmar-plantar Erythrodysesthesia
Syndrome (Palmar-plantar
erythrodysesthesia syndrome)
Palpitations (Palpitations)
Pancreas Infection (Pancreas infection)
Pancreatic Anastomotic Leak (Pancreatic
anastomotic leak)
Pancreatic Duct Stenosis (Pancreatic
duct stenosis)
Pancreatic Enzymes Decreased
(Pancreatic enzymes decreased)
Pancreatic Fistula (Pancreatic fistula)
Pancreatic Hemorrhage (Pancreatic
hemorrhage)
Pancreatic Necrosis (Pancreatic
necrosis)
Pancreatitis (Pancreatitis)
Papilledema (Papilledema)
Papulopustular Rash (Papulopustular
rash)
Paresthesia (Paresthesia)
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Paronychia (Paronychia)
Paroxysmal Atrial Tachycardia
(Paroxysmal atrial tachycardia)
Pelvic Floor Muscle Weakness (Pelvic
floor muscle weakness)
Pelvic Infection (Pelvic infection)
Pelvic Pain (Pelvic pain)
Pelvic Soft Tissue Necrosis (Pelvic soft
tissue necrosis)
Penile Infection (Penile infection)
Penile Pain (Penile pain)
Perforation Bile Duct (Perforation bile
duct)
Pericardial Effusion (Pericardial effusion)
Pericardial Tamponade (Pericardial
tamponade)
Pericarditis (Pericarditis)
Perineal Pain (Perineal pain)
Periodontal Disease (Periodontal
disease)
Periorbital Edema (Periorbital edema)
Periorbital Infection (Periorbital infection)
Peripheral Ischemia (Peripheral
ischemia)
Peripheral Motor Neuropathy (Peripheral
motor neuropathy)
Peripheral Nerve Infection (Peripheral
nerve infection)
Peripheral Sensory Neuropathy
(Peripheral sensory neuropathy)
Peritoneal Infection (Peritoneal infection)
Peritoneal Necrosis (Peritoneal necrosis)
Personality Change (Personality change)
Phantom Pain (Phantom pain)
Pharyngeal Anastomotic Leak
(Pharyngeal anastomotic leak)
Pharyngeal Fistula (Pharyngeal fistula)
Pharyngeal Hemorrhage (Pharyngeal
hemorrhage)
Pharyngeal Mucositis (Pharyngeal
mucositis)
Pharyngeal Necrosis (Pharyngeal
necrosis)
Pharyngeal Stenosis (Pharyngeal
stenosis)
Pharyngitis (Pharyngitis)
Pharyngolaryngeal Pain
(Pharyngolaryngeal pain)
Phlebitis (Phlebitis)
Phlebitis Infective (Phlebitis infective)
Photophobia (Photophobia)
Photosensitivity (Photosensitivity)
Platelet Count Decreased (Platelet count
decreased)
Pleural Effusion (Pleural effusion)
Pleural Hemorrhage (Pleural
hemorrhage)
Pleural Infection (Pleural infection)
Pleuritic Pain (Pleuritic pain)
Pneumonitis (Pneumonitis)
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Pneumothorax (Pneumothorax)
Portal Hypertension (Portal
hypertension)
Portal Vein Thrombosis (Portal vein
thrombosis)
Postnasal Drip (Postnasal drip)
Postoperative Hemorrhage
(Postoperative hemorrhage)
Postoperative Thoracic Procedure
Complication (Postoperative thoracic
procedure complication)
Precocious Puberty (Precocious
puberty)
Pregnancy, Puerperium And Perinatal
Conditions - Other, Specify (Pregnancy,
puerperium and perinatal conditions -
Other, Specify)
Premature Delivery (Premature delivery)
Premature Menopause (Premature
menopause)
Presyncope (Presyncope)
Proctitis (Proctitis)
Productive Cough (Productive cough)
Prolapse Of Intestinal Stoma (Prolapse
of intestinal stoma)
Prolapse Of Urostomy (Prolapse of
urostomy)
Prostate Infection (Prostate infection)
Prostatic Hemorrhage (Prostatic
hemorrhage)
Prostatic Obstruction (Prostatic
obstruction)
Prostatic Pain (Prostatic pain)
Proteinuria (Proteinuria)
Pruritus (Pruritus)
Psychiatric Disorders - Other, Specify
(Psychiatric disorders - Other, Specify)
Psychosis (Psychosis)
Pulmonary Edema (Pulmonary edema)
Pulmonary Fibrosis (Pulmonary fibrosis)
Pulmonary Fistula (Pulmonary fistula)
Pulmonary Hypertension (Pulmonary
hypertension)
Pulmonary Valve Disease (Pulmonary
valve disease)
Purpura (Purpura)
Pyramidal Tract Syndrome (Pyramidal
tract syndrome)
Radiation Recall Reaction (dermatologic)
(Radiation recall reaction (dermatologic))
Radiculitis (Radiculitis)
Rash Acneiform (Rash acneiform)
Rash Maculo-papular (Rash maculo-
papular)
Rash Pustular (Rash pustular)
Rectal Anastomotic Leak (Rectal
anastomotic leak)
Rectal Fistula (Rectal fistula)
Rectal Hemorrhage (Rectal hemorrhage)
Rectal Mucositis (Rectal mucositis)
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Rectal Necrosis (Rectal necrosis)
Rectal Obstruction (Rectal obstruction)
Rectal Pain (Rectal pain)
Rectal Perforation (Rectal perforation)
Rectal Stenosis (Rectal stenosis)
Rectal Ulcer (Rectal ulcer)
Recurrent Laryngeal Nerve Palsy
(Recurrent laryngeal nerve palsy)
Renal And Urinary Disorders - Other,
Specify (Renal and urinary disorders -
Other, Specify)
Renal Calculi (Renal calculi)
Renal Colic (Renal colic)
Renal Hemorrhage (Renal hemorrhage)
Reproductive System And Breast
Disorders - Other, Specify (Reproductive
system and breast disorders - Other,
Specify)
Respiratory Failure (Respiratory failure)
Respiratory, Thoracic And Mediastinal
Disorders - Other, Specify (Respiratory,
thoracic and mediastinal disorders -
Other, Specify)
Restlessness (Restlessness)
Restrictive Cardiomyopathy (Restrictive
cardiomyopathy)
Retinal Detachment (Retinal
detachment)
Retinal Tear (Retinal tear)
Retinal Vascular Disorder (Retinal
vascular disorder)
Retinoic Acid Syndrome (Retinoic acid
syndrome)
Retinopathy (Retinopathy)
Retroperitoneal Hemorrhage
(Retroperitoneal hemorrhage)
Reversible Posterior
Leukoencephalopathy Syndrome
(Reversible posterior
leukoencephalopathy syndrome)
Rhinitis Infective (Rhinitis infective)
Right Ventricular Dysfunction (Right
ventricular dysfunction)
Salivary Duct Inflammation (Salivary duct
inflammation)
Salivary Gland Fistula (Salivary gland
fistula)
Salivary Gland Infection (Salivary gland
infection)
Scalp Pain (Scalp pain)
Scleral Disorder (Scleral disorder)
Scoliosis (Scoliosis)
Scrotal Infection (Scrotal infection)
Scrotal Pain (Scrotal pain)
Seizure (Seizure)
Sepsis (Sepsis)
Seroma (Seroma)
Serum Amylase Increased (Serum
amylase increased)
Serum Sickness (Serum sickness)
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Sick Sinus Syndrome (Sick sinus
syndrome)
Sinus Bradycardia (Sinus bradycardia)
Sinus Disorder (Sinus disorder)
Sinus Pain (Sinus pain)
Sinus Tachycardia (Sinus tachycardia)
Sinusitis (Sinusitis)
Skin And Subcutaneous Tissue
Disorders - Other, Specify (Skin and
subcutaneous tissue disorders - Other,
Specify)
Skin Atrophy (Skin atrophy)
Skin Hyperpigmentation (Skin
hyperpigmentation)
Skin Hypopigmentation (Skin
hypopigmentation)
Skin Induration (Skin induration)
Skin Infection (Skin infection)
Skin Ulceration (Skin ulceration)
Sleep Apnea (Sleep apnea)
Small Intestinal Anastomotic Leak (Small
intestinal anastomotic leak)
Small Intestinal Mucositis (Small
intestinal mucositis)
Small Intestinal Obstruction (Small
intestinal obstruction)
Small Intestinal Perforation (Small
intestinal perforation)
Small Intestinal Stenosis (Small intestinal
stenosis)
Small Intestine Infection (Small intestine
infection)
Small Intestine Ulcer (Small intestine
ulcer)
Sneezing (Sneezing)
Social Circumstances - Other, Specify
(Social circumstances - Other, Specify)
Soft Tissue Infection (Soft tissue
infection)
Soft Tissue Necrosis Lower Limb (Soft
tissue necrosis lower limb)
Soft Tissue Necrosis Upper Limb (Soft
tissue necrosis upper limb)
Somnolence (Somnolence)
Sore Throat (Sore throat)
Spasticity (Spasticity)
Spermatic Cord Anastomotic Leak
(Spermatic cord anastomotic leak)
Spermatic Cord Hemorrhage (Spermatic
cord hemorrhage)
Spermatic Cord Obstruction (Spermatic
cord obstruction)
Spinal Fracture (Spinal fracture)
Spleen Disorder (Spleen disorder)
Splenic Infection (Splenic infection)
Stenosis Of Gastrointestinal Stoma
(Stenosis of gastrointestinal stoma)
Stevens-johnson Syndrome (Stevens-
Johnson syndrome)
Stoma Site Infection (Stoma site
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infection)
Stomach Pain (Stomach pain)
Stomal Ulcer (Stomal ulcer)
Stridor (Stridor)
Stroke (Stroke)
Sudden Death Nos (Sudden death NOS)
Suicidal Ideation (Suicidal ideation)
Suicide Attempt (Suicide attempt)
Superficial Soft Tissue Fibrosis
(Superficial soft tissue fibrosis)
Superficial Thrombophlebitis (Superficial
thrombophlebitis)
Superior Vena Cava Syndrome (Superior
vena cava syndrome)
Supraventricular Tachycardia
(Supraventricular tachycardia)
Surgical And Medical Procedures -
Other, Specify (Surgical and medical
procedures - Other, Specify)
Syncope (Syncope)
Telangiectasia (Telangiectasia)
Testicular Disorder (Testicular disorder)
Testicular Hemorrhage (Testicular
hemorrhage)
Testicular Pain (Testicular pain)
Thromboembolic Event
(Thromboembolic event)
Thrombotic Thrombocytopenic Purpura
(Thrombotic thrombocytopenic purpura)
Tinnitus (Tinnitus)
Tooth Development Disorder (Tooth
development disorder)
Tooth Discoloration (Tooth discoloration)
Tooth Infection (Tooth infection)
Toothache (Toothache)
Toxic Epidermal Necrolysis (Toxic
epidermal necrolysis)
Tracheal Fistula (Tracheal fistula)
Tracheal Hemorrhage (Tracheal
hemorrhage)
Tracheal Mucositis (Tracheal mucositis)
Tracheal Obstruction (Tracheal
obstruction)
Tracheal Stenosis (Tracheal stenosis)
Tracheitis (Tracheitis)
Tracheostomy Site Bleeding
(Tracheostomy site bleeding)
Transient Ischemic Attacks (Transient
ischemic attacks)
Treatment Related Secondary
Malignancy (Treatment related
secondary malignancy)
Tremor (Tremor)
Tricuspid Valve Disease (Tricuspid valve
disease)
Trigeminal Nerve Disorder (Trigeminal
nerve disorder)
Trismus (Trismus)
Tumor Lysis Syndrome (Tumor lysis
syndrome)
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Tumor Pain (Tumor pain)
Typhlitis (Typhlitis)
Unequal Limb Length (Unequal limb
length)
Unintended Pregnancy (Unintended
pregnancy)
Upper Gastrointestinal Hemorrhage
(Upper gastrointestinal hemorrhage)
Upper Respiratory Infection (Upper
respiratory infection)
Ureteric Anastomotic Leak (Ureteric
anastomotic leak)
Urethral Anastomotic Leak (Urethral
anastomotic leak)
Urethral Infection (Urethral infection)
Urinary Fistula (Urinary fistula)
Urinary Frequency (Urinary frequency)
Urinary Incontinence (Urinary
incontinence)
Urinary Retention (Urinary retention)
Urinary Tract Infection (Urinary tract
infection)
Urinary Tract Obstruction (Urinary tract
obstruction)
Urinary Tract Pain (Urinary tract pain)
Urinary Urgency (Urinary urgency)
Urine Discoloration (Urine discoloration)
Urine Output Decreased (Urine output
decreased)
Urostomy Leak (Urostomy leak)
Urostomy Obstruction (Urostomy
obstruction)
Urostomy Site Bleeding (Urostomy site
bleeding)
Urostomy Stenosis (Urostomy stenosis)
Urticaria (Urticaria)
Uterine Anastomotic Leak (Uterine
anastomotic leak)
Uterine Fistula (Uterine fistula)
Uterine Hemorrhage (Uterine
hemorrhage)
Uterine Infection (Uterine infection)
Uterine Obstruction (Uterine obstruction)
Uterine Pain (Uterine pain)
Uterine Perforation (Uterine perforation)
Uveitis (Uveitis)
Vaginal Anastomotic Leak (Vaginal
anastomotic leak)
Vaginal Discharge (Vaginal discharge)
Vaginal Dryness (Vaginal dryness)
Vaginal Fistula (Vaginal fistula)
Vaginal Hemorrhage (Vaginal
hemorrhage)
Vaginal Infection (Vaginal infection)
Vaginal Inflammation (Vaginal
inflammation)
Vaginal Obstruction (Vaginal obstruction)
Vaginal Pain (Vaginal pain)
Vaginal Perforation (Vaginal perforation)
Vaginal Stricture (Vaginal stricture)
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Vaginismus (Vaginismus)
Vagus Nerve Disorder (Vagus nerve
disorder)
Vas Deferens Anastomotic Leak (Vas
deferens anastomotic leak)
Vascular Access Complication (Vascular
access complication)
Vascular Disorders - Other, Specify
(Vascular disorders - Other, Specify)
Vasculitis (Vasculitis)
Vasovagal Reaction (Vasovagal reaction)
Venous Injury (Venous injury)
Ventricular Arrhythmia (Ventricular
arrhythmia)
Ventricular Fibrillation (Ventricular
fibrillation)
Ventricular Tachycardia (Ventricular
tachycardia)
Vertigo (Vertigo)
Vestibular Disorder (Vestibular disorder)
Virilization (Virilization)
Visceral Arterial Ischemia (Visceral
arterial ischemia)
Vital Capacity Abnormal (Vital capacity
abnormal)
Vitreous Hemorrhage (Vitreous
hemorrhage)
Voice Alteration (Voice alteration)
Vomiting (Vomiting)
Vulval Infection (Vulval infection)
Watering Eyes (Watering eyes)
Weight Gain (Weight gain)
Weight Loss (Weight loss)
Wheezing (Wheezing)
White Blood Cell Decreased (White
blood cell decreased)
Wolff-parkinson-white Syndrome (Wolff-
Parkinson-White syndrome)
Wound Complication (Wound
complication)
Wound Dehiscence (Wound dehiscence)
Wound Infection (Wound infection)
Wrist Fracture (Wrist fracture)
Describe 'Other' Adverse Event (Verbatim AE
Description used to 'reinforce' selected AE Type -
Code.)
Adverse Event Grade (A coded value to identify
the severity of the AE.)
Mild Adverse Event (1)
Moderate Adverse Event (2)
Severe Adverse Event (3)
Life Threatening Adverse Event (4)
Death Related To Adverse Event (5)
Conditional Adverse Event Data Elements
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AE Start Date (Date on which the AE was first
evident.)
Unknown (Unknown)
Was patient hospitalized for toxicity? (Normally
required only if AE is deemed 'serious'.)
Yes
No
Cycle # (A repeating period of activity involving
treatment and rest.  Several cycles can make up
a course.)
Optional Adverse Event Data Elements
To what is the AE attributed? (List of other
therapies surgery, radiation, etc, disease,
concomitant meds, other. Select MOST likely.)
Biological Therapy (Biological Therapy)
Chemotherapy (Chemotherapy)
Combined Modality (Combined modality)
Concomitant Agent (Concomitant
medication)
Medical_device (Device)
Disease (Disease)
Endocrine Therapy (Endocrine Therapy)
Immunotherapy (Immunotherapy)
Investigational Agent (Investigational
agent)
Other (Other)
Radiation Therapy (Radiation therapy)
Surgery (Surgery)
Other Attribution, Specify (If 'other' selected in
data element above, must provide a - description
of the presumed cause.)
AE Stop Date (Date on which the AE resolved.)
Event/occurrence Is Ongoing (Ongoing)
Unknown Date (Unknown)
MedDRA System Organ Class (SOC)
Hematopoietic And Lymphoid System
Disorder (Blood and lymphatic system
disorders)
Cardiac Disorders (Cardiac disorders)
Congenital, Familial And Genetic
Disorder Class (Congenital, familial and
genetic disorders)
Ear And Labyrinth Disorder Class (Ear
and labyrinth disorders)
Endocrine Disorder (Endocrine
disorders)
Eye Disorder (Eye disorders)
Gastrointestinal Disorder
(Gastrointestinal disorders)
General Disorders And Administration
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Site Conditions Class (General disorders
and administration site conditions)
Liver And Biliary Tract Disorder
(Hepatobiliary disorders)
Immune System Disorder (Immune
system disorders)
Infection And Infestation (Infections and
infestations)
Injury, Poisoning And Procedural
Complication Class (Injury, poisoning
and procedural complications)
Investigation (Investigations)
Metabolism And Nutrition Disorder Class
(Metabolism and nutrition disorders)
Connective And Soft Tissue Disorder
(Musculoskeletal and connective tissue
disorders)
Neoplasm (Neoplasms benign,
malignant and unspecified (incl cysts and
polyps))
Nervous System Disorder (Nervous
system disorders)
Pregnancy, Puerperium And Perinatal
Condition Class (Pregnancy, puerperium
and perinatal conditions)
Psychiatric Disorder (Psychiatric
disorders)
Urinary Tract Disorder (Renal and
urinary disorders)
Reproductive System And Breast
Disorder Class (Reproductive system
and breast disorders)
Respiratory And Thoracic Disorder
(Respiratory, thoracic and mediastinal
disorders)
Skin Disorder (Skin and subcutaneous
tissue disorders)
Social Circumstances (Social
circumstances)
Intervention Or Procedure (Surgical and
medical procedures)
Vascular Disorder (Vascular disorders)
MedDRA AE Code (CTCAE v4.0) (Code used to
identify the adverse event using a standard
mechanism that facilitates analysis. CTEP's code
list and associated Category/Term is currently a
standard.)
Abdominal Distension (10000060)
Abdominal Pain (10000081)
Acidosis (10000486)
Acoustic Nerve Disorder Nos (10000521)
Activated Partial Thromboplastin Time
Prolonged (10000636)
Adrenal Insufficiency (10001367)
Adult Respiratory Distress Syndrome
(10001409)
Agitation (10001497)
Akathisia (10001540)
Alanine Aminotransferase Increased
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(10001551)
Alcohol Intolerance (10001598)
Alkaline Phosphatase Increased
(10001675)
Alkalosis (10001680)
Allergic Reaction (10001718)
Allergic Rhinitis (10001723)
Alopecia (10001760)
Amnesia (10001949)
Anal Fistula (10002156)
Anal Pain (10002167)
Anal Stenosis (10002176)
Anal Ulcer (10002180)
Anaphylaxis (10002218)
Anemia (10002272)
Ankle Fracture (10002544)
Anorexia (10002646)
Anorgasmia (10002652)
Anxiety (10002855)
Aortic Injury (10002899)
Aphonia (10002953)
Apnea (10002972)
Appendicitis (10003011)
Appendicitis Perforated (10003012)
Arachnoiditis (10003074)
Arterial Injury (10003162)
Arthralgia (10003239)
Arthritis (10003246)
Ascites (10003445)
Aspartate Aminotransferase Increased
(10003481)
Aspiration (10003504)
Asystole (10003586)
Ataxia (10003591)
Atelectasis (10003598)
Atrial Fibrillation (10003658)
Atrial Flutter (10003662)
Atrioventricular Block Complete
(10003673)
Atrioventricular Block First Degree
(10003674)
Azoospermia (10003883)
Back Pain (10003988)
Biliary Fistula (10004665)
Bladder Infection (10005047)
Bloating (10005265)
Blood And Lymphatic System Disorders -
Other, Specify (10005329)
Blood Antidiuretic Hormone Abnormal
(10005332)
Blood Bilirubin Increased (10005364)
Blood Corticotrophin Decreased
(10005452)
Blood Gonadotrophin Abnormal
(10005561)
Blood Prolactin Abnormal (10005778)
Blurred Vision (10005886)
Body Odor (10005901)
Bone Pain (10006002)
Breast Atrophy (10006179)
23 / 39
NCI Standard Adverse Event/Serious Adverse Event CTCAE v4
Template - 3265657v1.0
Breast Infection (10006259)
Breast Pain (10006298)
Bronchial Fistula (10006437)
Bronchial Obstruction (10006440)
Bronchospasm (10006482)
Bruising (10006504)
Bullous Dermatitis (10006556)
Burn (10006634)
Capillary Leak Syndrome (10007196)
Cardiac Arrest (10007515)
Cardiac Disorders - Other, Specify
(10007541)
Cardiac Troponin I Increased (10007612)
Cardiac Troponin T Increased
(10007613)
Cataract (10007739)
Catheter Related Infection (10007810)
Cd4 Lymphocytes Decreased
(10007839)
Cerebrospinal Fluid Leakage (10008164)
Cervicitis Infection (10008330)
Cheilitis (10008417)
Chest Pain - Cardiac (10008481)
Chest Wall Pain (10008496)
Chills (10008531)
Cholecystitis (10008612)
Cholesterol High (10008661)
Cognitive Disturbance (10009845)
Colitis (10009887)
Colonic Fistula (10009995)
Colonic Hemorrhage (10009998)
Colonic Obstruction (10010000)
Colonic Perforation (10010001)
Colonic Stenosis (10010004)
Colonic Ulcer (10010006)
Concentration Impairment (10010250)
Conduction Disorder (10010276)
Confusion (10010300)
Congenital, Familial And Genetic
Disorders - Other, Specify (10010331)
Conjunctivitis (10010741)
Conjunctivitis Infective (10010742)
Constipation (10010774)
Constrictive Pericarditis (10010783)
Cough (10011224)
Cpk Increased (10011268)
Creatinine Increased (10011368)
Cushingoid (10011655)
Death Neonatal (10011912)
Death Nos (10011914)
Dehydration (10012174)
Delayed Puberty (10012205)
Delirium (10012218)
Delusions (10012260)
Dental Caries (10012318)
Depressed Level Of Consciousness
(10012373)
Depression (10012378)
Diarrhea (10012727)
Disseminated Intravascular Coagulation
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(10013442)
Dizziness (10013573)
Dry Eye (10013774)
Dry Mouth (10013781)
Dry Skin (10013786)
Duodenal Fistula (10013828)
Duodenal Obstruction (10013830)
Duodenal Perforation (10013832)
Duodenal Ulcer (10013836)
Dysarthria (10013887)
Dysgeusia (10013911)
Dysmenorrhea (10013934)
Dyspareunia (10013941)
Dyspepsia (10013946)
Dysphagia (10013950)
Dysphasia (10013951)
Dyspnea (10013963)
Ear And Labyrinth Disorders - Other,
Specify (10013993)
Ear Pain (10014020)
Edema Cerebral (10014217)
Edema Face (10014222)
Ejaculation Disorder (10014326)
Electrocardiogram Qt Corrected Interval
Prolonged (10014383)
Encephalitis Infection (10014594)
Encephalomyelitis Infection (10014621)
Encephalopathy (10014625)
Endocarditis Infective (10014678)
Endocrine Disorders - Other, Specify
(10014698)
Endophthalmitis (10014801)
Enterocolitis (10014893)
Epistaxis (10015090)
Erythema Multiforme (10015218)
Erythroderma (10015277)
Esophageal Hemorrhage (10015384)
Esophageal Obstruction (10015387)
Esophageal Pain (10015388)
Esophageal Stenosis (10015448)
Esophageal Ulcer (10015451)
Esophageal Varices Hemorrhage
(10015453)
Esophagitis (10015461)
Euphoria (10015533)
Exostosis (10015688)
Extraocular Muscle Paresis (10015829)
Extrapyramidal Disorder (10015832)
Eye Disorders - Other, Specify
(10015919)
Eye Infection (10015929)
Eye Pain (10015958)
Facial Pain (10016059)
Fall (10016173)
Fat Atrophy (10016241)
Fatigue (10016256)
Febrile Neutropenia (10016288)
Fecal Incontinence (10016296)
Fetal Death (10016479)
Fever (10016558)
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Fibrinogen Decreased (10016596)
Flank Pain (10016750)
Flashing Lights (10016757)
Flatulence (10016766)
Floaters (10016778)
Flu Like Symptoms (10016791)
Flushing (10016825)
Forced Expiratory Volume Decreased
(10016987)
Fracture (10017076)
Gait Disturbance (10017577)
Gallbladder Fistula (10017631)
Gallbladder Obstruction (10017636)
Gallbladder Pain (10017638)
Gallbladder Perforation (10017639)
Gastric Hemorrhage (10017789)
Gastric Perforation (10017815)
Gastric Ulcer (10017822)
Gastritis (10017853)
Gastrointestinal Fistula (10017877)
Gastrointestinal Disorders - Other,
Specify (10017947)
Gastrointestinal Pain (10017999)
Gastroparesis (10018043)
General Disorders And Administration
Site Conditions - Other, Specify
(10018065)
Genital Edema (10018146)
Gingival Pain (10018286)
Glaucoma (10018304)
Growth Accelerated (10018746)
Growth Hormone Abnormal (10018748)
Growth Suppression (10018761)
Gum Infection (10018784)
Gynecomastia (10018801)
Hallucinations (10019077)
Haptoglobin Decreased (10019150)
Headache (10019211)
Hearing Impaired (10019245)
Heart Failure (10019279)
Hematoma (10019428)
Hematuria (10019450)
Hemoglobinuria (10019489)
Hemolysis (10019491)
Hemolytic Uremic Syndrome (10019515)
Hemorrhoids (10019611)
Hepatic Failure (10019663)
Hepatic Hemorrhage (10019678)
Hepatic Necrosis (10019692)
Hepatic Pain (10019705)
Hepatitis Viral (10019799)
Hepatobiliary Disorders - Other, Specify
(10019805)
Hiccups (10020039)
Hip Fracture (10020100)
Hirsutism (10020112)
Hoarseness (10020201)
Hot Flashes (10020407)
Hydrocephalus (10020508)
Hypercalcemia (10020587)
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Hyperglycemia (10020639)
Hyperhidrosis (10020642)
Hyperkalemia (10020647)
Hypermagnesemia (10020670)
Hypernatremia (10020680)
Hyperparathyroidism (10020705)
Hypersomnia (10020765)
Hypertension (10020772)
Hyperthyroidism (10020850)
Hypertrichosis (10020864)
Hypertriglyceridemia (10020870)
Hyperuricemia (10020907)
Hypoalbuminemia (10020943)
Hypocalcemia (10020949)
Hypoglycemia (10021005)
Hypohidrosis (10021013)
Hypokalemia (10021018)
Hypomagnesemia (10021028)
Hyponatremia (10021038)
Hypoparathyroidism (10021041)
Hypophosphatemia (10021059)
Hypotension (10021097)
Hypothermia (10021113)
Hypothyroidism (10021114)
Hypoxia (10021143)
Ileal Perforation (10021305)
Ileal Stenosis (10021307)
Ileal Ulcer (10021309)
Ileus (10021328)
Immune System Disorders - Other,
Specify (10021428)
Infections And Infestations - Other,
Specify (10021881)
Infective Myositis (10021918)
Injection Site Reaction (10022095)
Injury, Poisoning And Procedural
Complications - Other, Specify
(10022117)
Injury To Carotid Artery (10022161)
Injury To Inferior Vena Cava (10022213)
Injury To Superior Vena Cava
(10022356)
Inr Increased (10022402)
Insomnia (10022437)
Intracranial Hemorrhage (10022763)
Investigations - Other, Specify
(10022891)
Irregular Menstruation (10022992)
Irritability (10022998)
Ischemia Cerebrovascular (10023030)
Jejunal Perforation (10023174)
Jejunal Stenosis (10023176)
Jejunal Ulcer (10023177)
Joint Effusion (10023215)
Joint Infection (10023216)
Keratitis (10023332)
Kidney Infection (10023424)
Kyphosis (10023509)
Laryngeal Edema (10023838)
Laryngeal Stenosis (10023862)
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Laryngitis (10023874)
Laryngospasm (10023891)
Lethargy (10024264)
Leukocytosis (10024378)
Leukoencephalopathy (10024382)
Libido Decreased (10024419)
Libido Increased (10024421)
Lip Pain (10024561)
Lipase Increased (10024574)
Lordosis (10024842)
Lymph Node Pain (10025182)
Lymphedema (10025233)
Lymphocyte Count Decreased
(10025256)
Lymphocyte Count Increased
(10025258)
Malabsorption (10025476)
Malaise (10025482)
Mania (10026749)
Memory Impairment (10027175)
Meningismus (10027198)
Meningitis (10027199)
Menopause (10027308)
Menorrhagia (10027313)
Metabolism And Nutrition Disorders -
Other, Specify (10027433)
Mobitz (type) Ii Atrioventricular Block
(10027786)
Mobitz Type I (10027787)
Movements Involuntary (10028041)
Mucositis Oral (10028130)
Multi-organ Failure (10028154)
Musculoskeletal And Connective Tissue
Disorder - Other, Specify (10028395)
Myalgia (10028411)
Myelitis (10028524)
Myelodysplastic Syndrome (10028533)
Myocardial Infarction (10028596)
Myocarditis (10028606)
Myositis (10028653)
Nail Discoloration (10028691)
Nasal Congestion (10028735)
Nausea (10028813)
Neck Pain (10028836)
Neoplasms Benign, Malignant And
Unspecified (incl Cysts And Polyps) -
Other, Specify (10029104)
Nervous System Disorders - Other,
Specify (10029205)
Neuralgia (10029223)
Neutrophil Count Decreased (10029366)
Night Blindness (10029404)
Nystagmus (10029864)
Obesity (10029883)
Obstruction Gastric (10029957)
Oligospermia (10030300)
Oral Hemorrhage (10030980)
Oral Pain (10031009)
Osteoporosis (10031282)
Otitis Externa (10033072)
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Otitis Media (10033078)
Ovarian Rupture (10033279)
Ovulation Pain (10033314)
Pain (10033371)
Pain In Extremity (10033425)
Pain Of Skin (10033474)
Palpitations (10033557)
Pancreatic Hemorrhage (10033626)
Pancreatitis (10033645)
Papilledema (10033703)
Paresthesia (10033987)
Paronychia (10034016)
Paroxysmal Atrial Tachycardia
(10034040)
Pelvic Pain (10034263)
Penile Pain (10034310)
Perforation Bile Duct (10034405)
Pericardial Effusion (10034474)
Pericarditis (10034484)
Periodontal Disease (10034536)
Peripheral Ischemia (10034578)
Peripheral Motor Neuropathy (10034580)
Peripheral Sensory Neuropathy
(10034620)
Personality Change (10034719)
Pharyngeal Fistula (10034825)
Pharyngitis (10034835)
Pharyngolaryngeal Pain (10034844)
Phlebitis (10034879)
Photophobia (10034960)
Photosensitivity (10034966)
Platelet Count Decreased (10035528)
Pleural Effusion (10035598)
Pleuritic Pain (10035623)
Pneumonitis (10035742)
Pneumothorax (10035759)
Portal Hypertension (10036200)
Portal Vein Thrombosis (10036206)
Postnasal Drip (10036402)
Pregnancy, Puerperium And Perinatal
Conditions - Other, Specify (10036585)
Premature Delivery (10036595)
Premature Menopause (10036601)
Presyncope (10036653)
Proctitis (10036774)
Productive Cough (10036790)
Prostatic Pain (10036968)
Proteinuria (10037032)
Pruritus (10037087)
Psychiatric Disorders - Other, Specify
(10037175)
Psychosis (10037234)
Pulmonary Edema (10037375)
Pulmonary Fibrosis (10037383)
Pulmonary Hypertension (10037400)
Purpura (10037549)
Radiation Recall Reaction (dermatologic)
(10037767)
Rash Acneiform (10037847)
Rash Maculo-papular (10037868)
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Rash Pustular (10037888)
Rectal Fistula (10038062)
Rectal Hemorrhage (10038064)
Rectal Pain (10038072)
Rectal Perforation (10038073)
Rectal Stenosis (10038079)
Rectal Ulcer (10038080)
Recurrent Laryngeal Nerve Palsy
(10038130)
Renal And Urinary Disorders - Other,
Specify (10038359)
Renal Calculi (10038385)
Renal Colic (10038419)
Renal Hemorrhage (10038463)
Reproductive System And Breast
Disorders - Other, Specify (10038604)
Respiratory Failure (10038695)
Respiratory, Thoracic And Mediastinal
Disorders - Other, Specify (10038738)
Restlessness (10038743)
Restrictive Cardiomyopathy (10038748)
Retinal Detachment (10038848)
Retinal Tear (10038897)
Retinal Vascular Disorder (10038901)
Retinoic Acid Syndrome (10038921)
Retinopathy (10038923)
Retroperitoneal Hemorrhage (10038981)
Salivary Gland Fistula (10039411)
Salivary Gland Infection (10039413)
Scoliosis (10039722)
Scrotal Pain (10039757)
Seizure (10039906)
Sepsis (10040047)
Seroma (10040102)
Serum Amylase Increased (10040139)
Serum Sickness (10040400)
Sick Sinus Syndrome (10040639)
Sinus Bradycardia (10040741)
Sinus Pain (10040747)
Sinus Tachycardia (10040752)
Sinusitis (10040753)
Skin And Subcutaneous Tissue
Disorders - Other, Specify (10040785)
Skin Atrophy (10040799)
Skin Hyperpigmentation (10040865)
Skin Hypopigmentation (10040868)
Skin Infection (10040872)
Skin Ulceration (10040947)
Sleep Apnea (10040975)
Small Intestinal Obstruction (10041101)
Small Intestinal Perforation (10041103)
Small Intestine Ulcer (10041133)
Sneezing (10041232)
Social Circumstances - Other, Specify
(10041244)
Somnolence (10041349)
Sore Throat (10041367)
Spasticity (10041416)
Spinal Fracture (10041569)
Spleen Disorder (10041633)
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Stevens-johnson Syndrome (10042033)
Stomach Pain (10042112)
Stomal Ulcer (10042127)
Stridor (10042241)
Stroke (10042244)
Sudden Death Nos (10042435)
Suicidal Ideation (10042458)
Suicide Attempt (10042464)
Superficial Thrombophlebitis (10042554)
Superior Vena Cava Syndrome
(10042569)
Supraventricular Tachycardia (10042604)
Surgical And Medical Procedures -
Other, Specify (10042613)
Syncope (10042772)
Telangiectasia (10043189)
Testicular Disorder (10043306)
Testicular Pain (10043345)
Thromboembolic Event (10043565)
Thrombotic Thrombocytopenic Purpura
(10043648)
Tinnitus (10043882)
Tooth Development Disorder (10044030)
Tooth Discoloration (10044031)
Toothache (10044055)
Toxic Epidermal Necrolysis (10044223)
Tracheal Obstruction (10044291)
Tracheitis (10044302)
Transient Ischemic Attacks (10044391)
Tremor (10044565)
Trismus (10044684)
Tumor Lysis Syndrome (10045152)
Tumor Pain (10045158)
Typhlitis (10045271)
Unintended Pregnancy (10045542)
Upper Respiratory Infection (10046300)
Urinary Frequency (10046539)
Urinary Incontinence (10046543)
Urinary Retention (10046555)
Urinary Tract Infection (10046571)
Urinary Urgency (10046593)
Urine Discoloration (10046628)
Urticaria (10046735)
Uterine Hemorrhage (10046789)
Uterine Pain (10046809)
Uterine Perforation (10046810)
Uveitis (10046851)
Vaginal Discharge (10046901)
Vaginal Dryness (10046904)
Vaginal Hemorrhage (10046912)
Vaginal Infection (10046914)
Vaginal Inflammation (10046916)
Vaginal Pain (10046937)
Vaginismus (10046947)
Vascular Disorders - Other, Specify
(10047065)
Vasculitis (10047115)
Vasovagal Reaction (10047166)
Venous Injury (10047228)
Ventricular Arrhythmia (10047281)
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Ventricular Fibrillation (10047290)
Ventricular Tachycardia (10047302)
Vertigo (10047340)
Vestibular Disorder (10047386)
Virilization (10047488)
Vital Capacity Abnormal (10047580)
Vitreous Hemorrhage (10047656)
Voice Alteration (10047681)
Vomiting (10047700)
Watering Eyes (10047848)
Weight Gain (10047896)
Weight Loss (10047900)
Wheezing (10047924)
Wolff-parkinson-white Syndrome
(10048015)
Wound Dehiscence (10048031)
Wound Infection (10048038)
Wrist Fracture (10048049)
Leukemia Secondary To Oncology
Chemotherapy (10048293)
Corneal Ulcer (10048492)
Bone Marrow Hypocellular (10048580)
Lymphocele (10048642)
Buttock Pain (10048677)
Joint Range Of Motion Decreased
(10048706)
Tooth Infection (10048762)
Bladder Spasm (10048994)
Scalp Pain (10049120)
White Blood Cell Decreased (10049182)
Pancreatic Fistula (10049192)
Nail Loss (10049281)
Intestinal Stoma Site Bleeding
(10049468)
Treatment Related Secondary
Malignancy (10049737)
Pharyngeal Stenosis (10050028)
Edema Limbs (10050068)
Duodenal Stenosis (10050094)
Pancreatic Anastomotic Leak
(10050457)
Biliary Anastomotic Leak (10050458)
Ejection Fraction Decreased (10050528)
Prostate Infection (10050662)
Tracheal Stenosis (10050816)
Lymph Gland Infection (10050823)
Chylothorax (10051228)
Facial Muscle Weakness (10051272)
Bile Duct Stenosis (10051341)
Periorbital Infection (10051472)
Acute Coronary Syndrome (10051592)
Pancreas Infection (10051741)
Lower Gastrointestinal Hemorrhage
(10051746)
Infusion Related Reaction (10051792)
Skin Induration (10051837)
Gastric Necrosis (10051886)
Cytokine Release Syndrome (10052015)
Urethral Infection (10052298)
Glucose Intolerance (10052426)
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Bronchopleural Fistula (10053481)
Vaginal Stricture (10053496)
Pericardial Tamponade (10053565)
Oculomotor Nerve Disorder (10053661)
Abducens Nerve Disorder (10053662)
Wound Complication (10053692)
Feminization Acquired (10054382)
Neck Edema (10054482)
Oral Dysesthesia (10054520)
Palmar-plantar Erythrodysesthesia
Syndrome (10054524)
Periorbital Edema (10054541)
Visceral Arterial Ischemia (10054692)
Fetal Growth Retardation (10054746)
Ovarian Infection (10055005)
Prostatic Obstruction (10055026)
Bronchial Infection (10055078)
Anal Hemorrhage (10055226)
Duodenal Hemorrhage (10055242)
Ileal Hemorrhage (10055287)
Intra-abdominal Hemorrhage (10055291)
Intraoperative Hemorrhage (10055298)
Jejunal Hemorrhage (10055300)
Pharyngeal Hemorrhage (10055315)
Pleural Hemorrhage (10055319)
Postoperative Hemorrhage (10055322)
Prostatic Hemorrhage (10055325)
Testicular Hemorrhage (10055347)
Upper Gastrointestinal Hemorrhage
(10055356)
Esophageal Perforation (10055472)
Hemoglobin Increased (10055599)
Phantom Pain (10056238)
Mediastinal Hemorrhage (10056356)
Olfactory Nerve Disorder (10056388)
Abdominal Infection (10056519)
Hepatic Infection (10056522)
Phlebitis Infective (10056627)
Salivary Duct Inflammation (10056681)
Postoperative Thoracic Procedure
Complication (10056745)
Ggt Increased (10056910)
Delayed Orgasm (10057066)
Peritoneal Infection (10057262)
Mediastinal Infection (10057483)
Precocious Puberty (10058084)
Pancreatic Necrosis (10058096)
Right Ventricular Dysfunction (10058597)
Pelvic Infection (10058674)
Edema Trunk (10058720)
Esophageal Infection (10058804)
Enterocolitis Infectious (10058838)
Intestinal Stoma Obstruction (10059094)
Intestinal Stoma Leak (10059095)
Gallbladder Necrosis (10059446)
Laryngeal Obstruction (10059639)
Rhinitis Infective (10059827)
Urine Output Decreased (10059895)
Hematosalpinx (10060602)
Hemorrhoidal Hemorrhage (10060640)
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Trigeminal Nerve Disorder (10060890)
Accessory Nerve Disorder (10060929)
Bone Infection (10061017)
Dermatitis Radiation (10061103)
Eyelid Function Disorder (10061145)
Female Genital Tract Fistula (10061149)
Glossopharyngeal Nerve Disorder
(10061185)
Hypoglossal Nerve Disorder (10061212)
Lung Infection (10061229)
Lactation Disorder (10061261)
Nail Infection (10061304)
Optic Nerve Disorder (10061322)
Perineal Pain (10061339)
Pleural Infection (10061351)
Tricuspid Valve Disease (10061389)
Vagus Nerve Disorder (10061403)
Facial Nerve Disorder (10061457)
Erectile Dysfunction (10061461)
Scleral Disorder (10061510)
Mitral Valve Disease (10061532)
Pulmonary Valve Disease (10061541)
Urinary Tract Obstruction (10061574)
Aortic Valve Disease (10061589)
Anorectal Infection (10061640)
Autoimmune Disorder (10061664)
Biliary Tract Infection (10061695)
Corneal Infection (10061788)
Penile Infection (10061912)
Radiculitis (10061928)
Gastric Stenosis (10061970)
Splenic Infection (10062112)
Scrotal Infection (10062156)
Vascular Access Complication
(10062169)
Urinary Tract Pain (10062225)
Uterine Infection (10062233)
Sinus Disorder (10062244)
Soft Tissue Infection (10062255)
Small Intestinal Stenosis (10062263)
Nail Ridging (10062283)
Lipohypertrophy (10062315)
Localized Edema (10062466)
Non-cardiac Chest Pain (10062501)
Tracheal Hemorrhage (10062548)
Enterovesical Fistula (10062570)
Generalized Muscle Weakness
(10062572)
Gallbladder Infection (10062632)
Pancreatic Enzymes Decreased
(10062646)
Laryngopharyngeal Dysesthesia
(10062667)
Dysesthesia (10062872)
Cystitis Noninfective (10063057)
Rectal Mucositis (10063190)
Bronchial Stricture (10063524)
Bladder Perforation (10063575)
Pyramidal Tract Syndrome (10063636)
Reversible Posterior
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Leukoencephalopathy Syndrome
(10063761)
Pelvic Floor Muscle Weakness
(10064026)
Stoma Site Infection (10064505)
Osteonecrosis Of Jaw (10064658)
Device Related Infection (10064687)
Infusion Site Extravasation (10064774)
Chronic Kidney Disease (10064848)
Urinary Fistula (10065368)
Brachial Plexopathy (10065417)
Pancreatic Duct Stenosis (10065703)
Peritoneal Necrosis (10065704)
Pharyngeal Anastomotic Leak
(10065705)
Pharyngeal Necrosis (10065706)
Rectal Obstruction (10065707)
Rectal Necrosis (10065709)
Small Intestinal Mucositis (10065710)
Gastrointestinal Stoma Necrosis
(10065712)
Gastric Fistula (10065713)
Jejunal Fistula (10065719)
Oral Cavity Fistula (10065720)
Anal Mucositis (10065721)
Anal Necrosis (10065722)
Esophageal Necrosis (10065727)
Ileal Fistula (10065728)
Ileal Obstruction (10065730)
Jejunal Obstruction (10065732)
Laryngeal Inflammation (10065735)
Unequal Limb Length (10065738)
Arteritis Infective (10065744)
Prolapse Of Intestinal Stoma (10065745)
Bronchopulmonary Hemorrhage
(10065746)
Cecal Hemorrhage (10065747)
Urostomy Site Bleeding (10065748)
Tracheostomy Site Bleeding (10065749)
Duodenal Infection (10065752)
Lip Infection (10065755)
Laryngeal Hemorrhage (10065759)
Cecal Infection (10065761)
Spermatic Cord Hemorrhage (10065762)
Ovarian Hemorrhage (10065763)
Mucosal Infection (10065764)
Cranial Nerve Infection (10065765)
Peripheral Nerve Infection (10065766)
Small Intestine Infection (10065771)
Vulval Infection (10065772)
Lymph Leakage (10065773)
Abdominal Soft Tissue Necrosis
(10065775)
Muscle Weakness Lower Limb
(10065776)
Soft Tissue Necrosis Lower Limb
(10065777)
Soft Tissue Necrosis Upper Limb
(10065778)
Head Soft Tissue Necrosis (10065779)
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Muscle Weakness Left-sided (10065780)
Neck Soft Tissue Necrosis (10065781)
Musculoskeletal Deformity (10065783)
Central Nervous System Necrosis
(10065784)
External Ear Pain (10065785)
Laryngeal Fistula (10065786)
Tracheal Fistula (10065787)
Fallopian Tube Anastomotic Leak
(10065788)
Fallopian Tube Obstruction (10065789)
Fallopian Tube Perforation (10065790)
Fallopian Tube Stenosis (10065791)
Pelvic Soft Tissue Necrosis (10065793)
Muscle Weakness Right-sided
(10065794)
Muscle Weakness Trunk (10065795)
Joint Range Of Motion Decreased
Cervical Spine (10065796)
Superficial Soft Tissue Fibrosis
(10065798)
Fibrosis Deep Connective Tissue
(10065799)
Joint Range Of Motion Decreased
Lumbar Spine (10065800)
Bladder Anastomotic Leak (10065802)
Kidney Anastomotic Leak (10065803)
Spermatic Cord Obstruction (10065805)
Uterine Fistula (10065811)
Vaginal Fistula (10065813)
Ureteric Anastomotic Leak (10065814)
Urethral Anastomotic Leak (10065815)
Vaginal Obstruction (10065817)
Vaginal Perforation (10065818)
Prolapse Of Urostomy (10065822)
Nipple Deformity (10065823)
Intraoperative Gastrointestinal Injury
(10065825)
Intraoperative Arterial Injury (10065826)
Intraoperative Hepatobiliary Injury
(10065827)
Intraoperative Urinary Injury (10065828)
Intraoperative Musculoskeletal Injury
(10065829)
Intraoperative Neurological Injury
(10065830)
Intraoperative Breast Injury (10065831)
Intraoperative Respiratory Injury
(10065832)
Intraoperative Endocrine Injury
(10065834)
Ivth Nerve Disorder (10065836)
External Ear Inflammation (10065837)
Middle Ear Inflammation (10065838)
Intraoperative Reproductive Tract Injury
(10065840)
Intraoperative Ocular Injury (10065841)
Intraoperative Head And Neck Injury
(10065842)
Intraoperative Cardiac Injury (10065843)
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Intraoperative Ear Injury (10065844)
Intraoperative Renal Injury (10065845)
Intraoperative Skin Injury (10065846)
Intraoperative Splenic Injury (10065847)
Intraoperative Venous Injury (10065848)
Injury To Jugular Vein (10065849)
Esophageal Fistula (10065851)
Pulmonary Fistula (10065873)
Gastrointestinal Anastomotic Leak
(10065879)
Laryngeal Mucositis (10065880)
Pharyngeal Mucositis (10065881)
Urostomy Leak (10065882)
Urostomy Obstruction (10065883)
Urostomy Stenosis (10065885)
Uterine Anastomotic Leak (10065886)
Vaginal Anastomotic Leak (10065887)
Vas Deferens Anastomotic Leak
(10065888)
Large Intestinal Anastomotic Leak
(10065891)
Small Intestinal Anastomotic Leak
(10065892)
Gastric Anastomotic Leak (10065893)
Rectal Anastomotic Leak (10065894)
Muscle Weakness Upper Limb
(10065895)
Spermatic Cord Anastomotic Leak
(10065897)
Stenosis Of Gastrointestinal Stoma
(10065898)
Tracheal Mucositis (10065900)
Carbon Monoxide Diffusing Capacity
Decreased (10065906)
Uterine Obstruction (10065928)
Esophageal Anastomotic Leak
(10065961)
Iron Overload (10065973)
Avascular Necrosis (10066480)
Gastroesophageal Reflux Disease
(10066874)
Papulopustular Rash (10069138)
Acute Kidney Injury (10069339)
Left Ventricular Systolic Dysfunction
(10069501)
AE Attribution (This question is not asked for
baseline assessments. Question should be asked
mandatory for all studies that involve drug
therapy.)
Definite (Definite)
Possible (Possible)
Probable (Probable)
Unlikely (Unlikely)
Unrelated (Unrelated)
Reporting Period End Date (End of the
assessment period.)
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Were adverse events assessed during most
recent period (Indicator to clarify whether any
AEs were identified during the - reporting period.
This is confirmation that the remainder of the
form was intentionally left blank.)
No (No)
Unknown (Unknown)
Yes (Yes)
Expected? (Yes/No)
Yes
No
Serious? (If a 'yes' response is entered, complete
the SAE section for - this AE.)
Yes
No
Event Onset Time (Enter the time of day when
AE was first evident.  Used when Date of Onset
is insufficient.)
Course (May be used during protocol therapy
period to automatically - set the evaluation
start/end dates to the period of the course of
treatment e.g. user supplies course# and
evaluation period derived.)
AE Evaluation Period Start Date (Date of the
beginning start of the assessment period.)
Pre-existing AE? (Should be derivable if you
capture AEs for specified periods; not needed if
you track an AE until it resolves including
worseningrather than for a defined assessment
period.)
Yes
No
AE Resolved Time (Enter the time of day when
AE was resolved.)
AE Ongoing? (Flag to indicate whether AE has
resolved or not. This ensures that leaving 'Stop
Date' blank was not done inadvertently.)
Yes
No
Participant Status/Outcome
Death (Fatal)
Not Recovered Or Not Resolved (Not
Recovered/Not Resolved)
Recovered Or Resolved
(Recovered/Resolved)
Recovered Or Resolved With Sequelae
(Recovered/Resolved with Sequelae)
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Recovering Or Resolving
(Recovering/Resolving)
Unknown (Unknown)
Adverse Event Condition Pattern (This should be
derivable from a review of AEs over time.)
Single Episode (1)
Intermittent (2)
Continuous (3)
Did event reappear after study agent was
reintroduced? (Enter response from choice list.)
Not Applicable (N/A)
No (No)
Yes (Yes)
Comments (A general comment that should not
be specific to a single AE.)
Optional Serious Adverse Event
Questions
Why serious? (Select the appropriate response.)
Results In Death (1)
Is Life-threatening (2)
Requires Inpatient Hospitalization Or
Prolongation Of Existing Hospitalization
(3)
Results In Persistent Or Significant
Disability/incapacity (4)
Is A Congenital Anomaly/birth Defect (5)
In The Medical Judgment Of The
Treating Physician And/or Investigator, It
May Jeopardize The Participant Or
Require Intervention To Prevent One Of
These Outcomes (6)
Other, Specify (7)
Meets Criteria Per Protocol But Does Not
Meet Other Criterion (above) (8)
Dose-Limiting Toxicity? (Select the appropriate
response.)
No (N)
Yes (Y)
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Prostate Cancer NCT01546987 Quality of Life - RTOG 1115 QF: Phase III RT +
Standard ADT vs RT + Enhanced ADT + TAK-700  EQ-5D Form - 3289234v1.0
RTOG 1115 QF: Phase III RT + Standard ADT vs RT +
Enhanced ADT + TAK-700  EQ-5D Form
Hormone Therapy, Radiation Therapy, and Steroid 17alpha-
monooxygenase TAK-700 in Treating Patients With High-
Risk Prostate Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=AE8F0868-
7FC2-FEC9-E040-BB89AD4357E7
All rights reserved. Please visit https://medical-data-
models.org/forms/9541
RTOG 1115 QF: Phase III RT +
Standard ADT vs RT + Enhanced
ADT + TAK-700  EQ-5D Form
Unnamed Module 1
RTOG Study No.
Case #
Institution Name
Institution No.
Patient Initials
RTOG Patient ID
Amended data
Yes
No
Unamed Module 2
Time point
12 Months From Start Of Treatment (12
months from start of treatment)
30 Months From Start Of Treatment (30
months from start of treatment)
Baseline (baseline)
Last Week Of Radiation Therapy (Last
week of RT)
Other (Other)
Pretreatment (Pretreatment)
Your own health state today
Other specify
Did the patient complete any items on the
questionnaire?
Yes
No
Date Questionnaire Completed
1 / 4
Reason Questionnaire was not Completed
Institution Error (Institutional error)
Not Applicable, Questionnaire Was
Completed (Not applicable,
questionnaire was completed)
Other Reason (Other reason)
Patient Refused Due To Illness (Patient
refused due to illness)
Patient Refused For Other Reason
(Patient refused for other reason)
Patient Unable To Be Contacted (Patient
unable to be contacted)
Tool Not Availalble In Patient's Language
(Tool not available in patient's language)
Patient refused for other reason, specify
Other reason, specify
Did the patient require any assistance in
completing the questionnaire?
No (No)
Not Applicable (Not applicable)
Unknown If Assistance Given (Unknown
if assistance given)
Yes (Yes)
Extent of assistance given
Combination Of Above (Combination of
above)
Interpreted Items For Patient (Interpreted
items for patient)
Marked Items Per Patient's Response
(Marked items per patient's response)
Not Applicable (Not applicable)
Other (Other)
Read Items To Patient (Read items to
patient)
Combination of above, specify
Other, specify
Specify the person who assisted the patient
Family (Family)
Not Applicable (Not applicable)
Other (Other)
Staff Member (Staff member)
Unknown (Unknown)
Specify method of completion
At Appointment (At appointment)
By Mail (By mail)
By Telephone (By telephone)
Unknown (Unknown)
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Comments
Signature of Person Completing This Form
Date Form Originally Completed
Unamed Module 2
Mobility (Please circle one statement in each
group below which best describes your health
today)
I Am Confined To Bed (I am confined to
bed)
I Have No Problems In Walking About (I
have no problems in walking about)
I Have Some Problems In Walking About
(I have some problems in walking about)
Self care (Please circle one statement in each
group below which best describes your health
today)
I Am Unable To Wash Or Dress Myself (I
am unable to wash or dress myself)
I Have No Problems With Self Care (I
have no problems with self care)
I Have Some Problems Washing Or
Dressing Myself (I have some problems
washing or dressing myself)
Usual activities (Please circle one statement in
each group below which best describes your
health today)
I Am Unable To Perform My Usual
Activities (I am unable to perform my
usual activities)
I Have No Problems With Performing My
Usual Activities (I have no problems with
performing my usual activities)
I Have Some Problems With Performing
My Usual Activities (I have some
problems with performing my usual
activities)
Pain/discomfort (Please circle one statement in
each group below which best describes your
health today)
I Have Extreme Pain Or Discomfort (I
have extreme pain or discomfort)
I Have Moderate Pain Or Discomfort (I
have moderate pain or discomfort)
I Have No Pain Or Discomfort (I have no
pain or discomfort)
Anxiety/depression (Please circle one statement
in each group below which best describes your
health today)
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I Am Extremely Anxious Or Depressed (I
am extremely anxious or depressed)
I Am Moderately Anxious Or Depressed
(I am moderately anxious or depressed)
I Am Not Anxious Or Depressed (I am
not anxious or depressed)
Your Own Health State Today
Your own health state today
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Prostate Cancer NCT01368588 Quality of Life -
RTOG-0924 HP: PROMIS Form - 3196389v1.0
RTOG-0924 HP: PROMIS Form
Androgen-Deprivation Therapy and Radiation Therapy in
Treating Patients With Prostate Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=9D86210A-
A227-FC8E-E040-BB89AD432CB7
All rights reserved. Please visit https://medical-data-
models.org/forms/9542
RTOG-0924 HP: PROMIS Form
Unnamed Module 1
RTOG Study No.
Case #
Institution Name
Institution No.
Patient Initials
RTOG Patient ID
Amended data
Yes
No
Unamed Module 2
Time point
12 Months After Radiation Therapy (12
months after RT)
3 Months After Rt (3 months after RT)
6 Months Of Radiation Therapy (6
months after RT)
60 Months After Radiation Therapy (60
months after RT)
Baseline (baseline)
Last Week Of Radiation Therapy (Last
week of RT)
Other (Other)
Other specify
Did the patient complete any items on the
questionnaire?
Yes
No
Date Questionnaire Completed
1 / 4
Reason Questionnaire was not Completed
Institution Error (Institutional error)
Not Applicable, Questionnaire Was
Completed (Not applicable,
questionnaire was completed)
Other Reason (Other reason)
Patient Refused Due To Illness (Patient
refused due to illness)
Patient Refused For Other Reason
(Patient refused for other reason)
Patient Unable To Be Contacted (Patient
unable to be contacted)
Tool Not Availalble In Patient's Language
(Tool not available in patient's language)
Patient refused for other reason, specify
Other reason, specify
Did the patient require any assistance in
completing the questionnaire?
No (No)
Not Applicable (Not applicable)
Unknown If Assistance Given (Unknown
if assistance given)
Yes (Yes)
Extent of assistance given
Combination Of Above (Combination of
above)
Interpreted Items For Patient (Interpreted
items for patient)
Marked Items Per Patient's Response
(Marked items per patient's response)
Not Applicable (Not applicable)
Other (Other)
Read Items To Patient (Read items to
patient)
Combination of above, specify
Other, specify
Specify the person who assisted the patient
Family (Family)
Not Applicable (Not applicable)
Other (Other)
Staff Member (Staff member)
Unknown (Unknown)
Specify method of completion
At Appointment (At appointment)
By Mail (By mail)
By Telephone (By telephone)
Unknown (Unknown)
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Comments
Signature of Person Completing This Form
Date Form Originally Completed
Fatigue - Short Form
How often did you feel tired
Always (Always)
Never (Never)
Often (Often)
Rarely (Rarely)
Sometimes (Sometimes)
How often did you experience extreme
exhaustion
Always (Always)
Never (Never)
Often (Often)
Rarely (Rarely)
Sometimes (Sometimes)
How often did you run out of energy
Always (Always)
Never (Never)
Often (Often)
Rarely (Rarely)
Sometimes (Sometimes)
How often did your fatigue limit you at work
(include work at home)
Always (Always)
Never (Never)
Often (Often)
Rarely (Rarely)
Sometimes (Sometimes)
How often were you too tired to think clearly
Always (Always)
Never (Never)
Often (Often)
Rarely (Rarely)
Sometimes (Sometimes)
How often were you too tired to take a bath or
shower
Always (Always)
Never (Never)
Often (Often)
Rarely (Rarely)
Sometimes (Sometimes)
How often did you have enough energy to
exercise strenuously
Always (Always)
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Never (Never)
Often (Often)
Rarely (Rarely)
Sometimes (Sometimes)
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Prostate Cancer NCT01368588 Quality of Life -
RTOG-0924 QL: PSQI/GLTEQ Form - 3196710v1.0
RTOG-0924 QL: PSQI/GLTEQ Form
Androgen-Deprivation Therapy and Radiation Therapy in
Treating Patients With Prostate Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=9D869ED1-
F271-8812-E040-BB89AD432EA8
All rights reserved. Please visit https://medical-data-
models.org/forms/9545
RTOG-0924 QL: PSQI/GLTEQ Form
Unnamed Module 1
RTOG Study No.
Case #
Institution Name
Institution No.
Patient Initials
RTOG Patient ID
Amended data
Yes
No
Unamed Module 2
Time point
12 Months After Radiation Therapy (12
months after RT)
3 Months After Rt (3 months after RT)
6 Months Of Radiation Therapy (6
months after RT)
60 Months After Radiation Therapy (60
months after RT)
Baseline (baseline)
Last Week Of Radiation Therapy (Last
week of RT)
Other (Other)
Other specify
Did the patient complete any items on the
questionnaire?
Yes
No
Date Questionnaire Completed
1 / 4
Reason Questionnaire was not Completed
Institution Error (Institutional error)
Not Applicable, Questionnaire Was
Completed (Not applicable,
questionnaire was completed)
Other Reason (Other reason)
Patient Refused Due To Illness (Patient
refused due to illness)
Patient Refused For Other Reason
(Patient refused for other reason)
Patient Unable To Be Contacted (Patient
unable to be contacted)
Tool Not Availalble In Patient's Language
(Tool not available in patient's language)
Patient refused for other reason, specify
Other reason, specify
Did the patient require any assistance in
completing the questionnaire?
No (No)
Not Applicable (Not applicable)
Unknown If Assistance Given (Unknown
if assistance given)
Yes (Yes)
Extent of assistance given
Combination Of Above (Combination of
above)
Interpreted Items For Patient (Interpreted
items for patient)
Marked Items Per Patient's Response
(Marked items per patient's response)
Not Applicable (Not applicable)
Other (Other)
Read Items To Patient (Read items to
patient)
Combination of above, specify
Other, specify
Specify the person who assisted the patient
Family (Family)
Not Applicable (Not applicable)
Other (Other)
Staff Member (Staff member)
Unknown (Unknown)
Specify method of completion
At Appointment (At appointment)
By Mail (By mail)
By Telephone (By telephone)
Unknown (Unknown)
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Comments
Signature of Person Completing This Form
Date Form Originally Completed
Exercise
Times per week (Mild exercise - that is, minimal
effort exercise that did not make you perspire,
such as easy walking, yoga, bowling, lawn
bowling, shuffleboard, or golf)
Average duration (Mild exercise - that is, minimal
effort exercise that did not make you perspire,
such as easy walking, yoga, bowling, lawn
bowling, shuffleboard, or golf mins.)
Times per week (Moderate exercise - that is,
exercise that is not exhausting and which made
you perspire lightly, such as fast walking, tennis,
easy bicycling, easy swimming, or popular and
folk dancing)
Average duration (Moderate exercise - that is,
exercise that is not exhausting and which made
you perspire lightly, such as fast walking, tennis,
easy bicycling, easy swimming, or popular and
folk dancing mins.)
Times per week (Strenuous exercise - that is,
exercise that made your heart beat rapidly and
made you sweat, such as running, aerobics
classes, cross country skiing, vigorous swimming,
or vigorous bicycling)
Average duration (Strenuous exercise - that is,
exercise that made your heart beat rapidly and
made you sweat, such as running, aerobics
classes, cross country skiing, vigorous swimming,
or vigorous bicycling mins.)
I have been experiencing generalized muscle
weakness over the last week
0 (0)
1 (1)
2 (2)
3 (3)
During the past month, how would you rate your
sleep quality overall
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0 (0)
1 (1)
2 (2)
3 (3)
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Prostate Cancer NCT00567580 Quality of Life
- RTOG-0534 HP:  HSCL-25 - 2712777v1.0
RTOG-0534 HP: HSCL-25
Prostate Radiation Therapy or Short-Term Androgen
Deprivation Therapy and Pelvic Lymph Node Radiation
Therapy With or Without Prostate Radiation Therapy in
Treating Patients With a Rising PSA After Surgery for
Prostate Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=40EFE507-
C9EC-031B-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/9546
RTOG-0534 HP:  HSCL-25
Module 1
RTOG Study No.
Case #
Institution Name
Institution No.
Patient Initials
RTOG Patient ID
Amended data
Yes
No
Module 2
Time point
Pretreatment (1)
Week 6 Of Rt (2)
One Year Follow-up (3)
Five Year Follow-up (4)
Was patient questionnaire completed
No (0)
Yes (1)
Date patient questionnaire completed
Reason Questionnaire was not Completed
Not Applicable, Questionnaire Was
Completed (0)
Patient Refused Due To Illness (1)
Patient Refused For Other Reason (2)
Patient Unable To Be Contacted (3)
Institution Error (4)
Tool Not Availalble In Patient's Language
(5)
Other Reason (6)
1 / 2
Unknown (7)
Patient refused for other reason, specify
Other reason, specify
Specify method of completion
Not Applicable (0)
At Appointment (1)
By Mail (2)
By Telephone (3)
Unknown (4)
Did the patient require any assistance in
completing the questionnaire?
Not Applicable (0)
No (1)
Yes (2)
Unknown If Assistance Given (3)
Specify the person who assisted the patient
Not Applicable (0)
Staff Member (1)
Family (2)
Other (3)
Unknown (4)
Extent of assistance given
Not Applicable (0)
Read Items To Patient (1)
Interpreted Items For Patient (2)
Marked Items Per Patient's Response (3)
Combination Of Above (4)
Other (5)
Unknown (6)
Combination of above, specify
Other, specify
Comments
Signature of Person Completing This Form
Date Form Completed
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Adenocarcinoma of the Gastroesophageal Junction NCT01196390
Follow-Up - RTOG 1010 Follow-up Form (F1) - 3085847v1.0
RTOG 1010 Follow-up Form (F1)
Radiation Therapy, Paclitaxel, and Carboplatin With or
Without Trastuzumab in Treating Patients With Esophageal
Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=867B6E62-
3E34-C9D2-E040-BB89AD4349E3
All rights reserved. Please visit https://medical-data-
models.org/forms/9547
RTOG 1010 Follow-up Form (F1)
Unnamed Module 1
RTOG Study No.
Case #
Institution Name
Institution No.
Patient Initials
RTOG Patient ID
Amended Data
Yes
No
Assessment
Date of Last Contact or Death (MM/DD/YYYY)
Vital Status
Alive (Alive)
Dead (Dead)
Primary Cause of Death
Due To Other Cause (Due to other
cause)
Due To Protocol Treatment (Due to
protocol treatment)
Due To Second Primary Or Other
Malignancy (Due to second primary or
other malignancy)
Due To This Disease (Due to this
disease)
Not Applicable (Not applicable)
Unknown (Unknown)
Describe cause of death
Has the patient had a documented clinical
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assessment for this cancer? (since submission of
the previous follow-up form)
No (No)
Unknown (Unknown)
Yes (Yes)
Date of Last Clinical Assessment (MM/DD/YYYY)
Current Disease Status
Primary Tumor
Disease Absent (Disease absent)
Disease Present (Disease present)
Unknown (Unknown)
Regional lymph nodes
Disease Absent (Disease absent)
Disease Present (Disease present)
Unknown (Unknown)
Distant metastasis
Disease Absent (Disease absent)
Disease Present (Disease present)
Unknown (Unknown)
Second primary
Disease Absent (Disease absent)
Disease Present (Disease present)
Unknown (Unknown)
Method of Evaluation
Ct Scan (CT scan)
Other (Other)
Pet/ct Scan (PET/CT scan)
Other Specify
Events
Event
Appearance Of Distant Nodes
(Appearance of distant nodes)
Appearance Of Liver Metastasis
(Appearance of liver metastasis)
Appearance Of Lung Metastasis
(Appearance of lung metastasis)
Appearance Of Other Metastasis
(Appearance of other metastasis)
Appearance Of Peritoneal Metastasis
(Appearance of peritoneal metastasis)
Appearance Of Second Primary
(Appearance of second primary)
Clearance Of Metastasis (Clearance of
metastasis)
Clearance Of Second Primary
(Clearance of second primary)
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Complete Response (Complete
response)
Nodal Progression (Nodal progression)
Progression Of Local Disease
(Progression of local disease)
Recurrence (Recurrence)
Recurrence Of Nodal Disease
(Recurrence of nodal disease)
Recurrence Of Second Primary
(Recurrence of second primary)
Date (mm-dd-yyyy)
Specify
Performance Status
Fully Active, Able To Carry On All Pre-
disease Performance Without
Restriction. (0)
Restricted In Physically Strenuous
Activity But Ambulatory And Able To
Carry Out Work Of A Light Or Sedentary
Nature, E.g., Light Housework, Office
Work. (1)
Ambulatory And Capable Of All Selfcare
But Unable To Carry Out Any Work
Activities. Up And About More Than 50%
Of Waking Hours. (2)
Capable Of Only Limited Selfcare,
Confined To Bed Or Chair More Than
50% Of Waking Hours. (3)
Completely Disabled. Cannot Carry On
Any Selfcare. Totally Confined To Bed Or
Chair. (4)
Dead (5)
Unnamed2
Has a new primary cancer or MDS been
diagnosed that has not been previously reported?
(MYELODYSPLASTIC SYNDROME)
No (No)
Unknown (Unknown)
Yes (Yes)
New Primary Site
Aml/mds (AML/MDS)
Bcc (BCC)
Bladder (Bladder)
Brain (Brain)
Colorectal (Colorectal)
Esophageal (Esophageal)
Gastric (Gastric)
Liver (Liver)
Lung (Lung)
Melanoma (Melanoma)
Nhl (NHL)
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None (None)
Other Hematologic, Specify (Other
Hematologic, specify)
Other Solid, Specify (Other solid,
specify)
Pancreatic (Pancreatic)
Prostate (Prostate)
Renal (Renal)
Squamous-skin (Squamous-Skin)
Unknown Primary (Unknown primary)
New Primary Cancer Date (MM/DD/YYYY)
Specify
Unnamed5
Non-Protocol Therapy Type
Chemotherapy (Chemotherapy)
None (None)
Other Non-protocol Therapy (Other non-
protocol therapy)
Radiation Therapy (Radiation therapy)
Radiation To Other Sites, Specify
(Radiation to other sites)
Surgery (Surgery)
Unknown (Unknown)
Date of Non-protocol therapy (MM/DD/YYYY)
Specify
Toxicities
Grade 3 or 4 Restrictive Cardiomyopathy
Yes
No
Incipient CHF (Defined as asymptomatic >20%
decrease in LVEF or a decrease of LVEF >10%
below the institutions lower limit of normal who
are judged to require treatment according to
institutional guidelines)
Yes
No
Protocol Specific Adverse Event
Evaluation
Any adverse events
No (No)
Unknown (Unknown)
Yes (Yes)
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MedDRA Code
CTC Adverse Event Term
CTC AE Grade
Mild Adverse Event (1)
Moderate Adverse Event (2)
Severe Adverse Event (3)
Life Threatening Adverse Event (4)
Death Related To Adverse Event (5)
CTCAE Begin Date (MM DD YYYY)
CTC AE Attribution Code
Definite (Definite)
Possible (Possible)
Probable (Probable)
Unlikely (Unlikely)
Unrelated (Unrelated)
SAE report submitted
No (No)
Unknown (Unknown)
Yes (Yes)
Footer Module
Comments
Investigator Signature
Date
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Adenocarcinoma of the Gastroesophageal Junction NCT01196390 Quality of Life -
RTOG 1010 FACT-E Form (Version 4) and Cover Sheet (FA) - 3085308v1.0
RTOG 1010 FACT-E Form (Version 4) and Cover Sheet
(FA)
Radiation Therapy, Paclitaxel, and Carboplatin With or
Without Trastuzumab in Treating Patients With Esophageal
Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=8666F883-
A510-1716-E040-BB89AD436FC4
All rights reserved. Please visit https://medical-data-
models.org/forms/9548
RTOG 1010 FACT-E Form (Version
4) and Cover Sheet (FA)
Header
RTOG Study No.
Case #
Institution Name
Institution No.
Patient Initials
RTOG Patient ID
Amended Data
Yes
No
Unnamed 1
Time point
1 Year From Start Of Treatment (1 year
from start of treatment)
2 Years From Start Of Treatment (2 years
from start of treatment)
6-8 Weeks Post Chemo/rt (6-8 weeks
post chemo/RT)
Pretreatment (Pretreatment)
Treatment Start Date
Was patient questionnaire completed
Yes
No
Date patient questionnaire completed
Reason Questionnaire was not Completed
(PATIENT)
Institution Error (Institutional error)
Not Applicable, Questionnaire Was
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Completed (Not applicable,
questionnaire was completed)
Other Reason (Other reason)
Patient Refused Due To Illness (Patient
refused due to illness)
Patient Refused For Other Reason
(Patient refused for other reason)
Patient Unable To Be Contacted (Patient
unable to be contacted)
Tool Not Availalble In Patient's Language
(Tool not availalble in patient's language)
Unknown (Unknown)
Patient refused for other reason, specify
Other reason, specify
Specify method of completion
At Appointment (At appointment)
By Mail (By mail)
By Telephone (By telephone)
Not Applicable (Not applicable)
Unknown (Unknown)
Did the patient require any assistance in
completing the questionnaire?
No (No)
Not Applicable (Not applicable)
Unknown If Assistance Given (Unknown
if assistance given)
Yes (Yes)
Specify the person who assisted the patient
Family (Family)
Not Applicable (Not applicable)
Other (Other)
Staff Member (Staff member)
Unknown (Unknown)
Other, specify
Extent of the assistance
Combination Of Above (Combination of
above)
Interpreted Items For Patient (Interpreted
items for patient)
Marked Items Per Patient's Response
(Marked items per patient's response)
Not Applicable (Not applicable)
Other (Other)
Read Items To Patient (Read items to
patient)
Unknown (Unknown)
Combination of above, specify
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Other, specify
Signature of Person Completing This Form
Date Form Completed
Physical Well-being
I have a lack of energy
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have nausea
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
Because of my physical condition, I have trouble
meeting the needs of my family
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have pain
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am bothered by side effects of treatment
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I feel ill
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am forced to spend time in bed
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
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Very Much (Very much)
Social/family Well-being
I feel close to my friends
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I get emotional support from my family
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I get support from my friends
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
My family has accepted my illness
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am satisfied with family communication about
my illness
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I feel close to my partner (or the person who is
my main support)
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
Regardless of your current level of sexual activity,
please answer the following question.  If you
prefer not to answer it, please check this box and
go to the next section.
I am satisfied with my sex life
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
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Very Much (Very much)
Emotional Well-being
I feel sad
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am satisfied with how I am coping with my
illness
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am losing hope in the fight against my illness
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I feel nervous
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I worry about dying
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I worry that my condition will get worse
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
Functional Well-being
I am able to work (include work at home)
2 (A little bit)
1 (Not at all)
4 (Quite a bit)
3 (Somewhat)
5 (Very much)
My work is fulfilling (include work at home)
2 (A little bit)
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1 (Not at all)
4 (Quite a bit)
3 (Somewhat)
5 (Very much)
I am able to enjoy life
2 (A little bit)
1 (Not at all)
4 (Quite a bit)
3 (Somewhat)
5 (Very much)
I have accepted my illness
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am sleeping well
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am enjoying the things I usually do for fun
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am content with the quality of my life right now
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
Additional Concerns
I am able to eat the foods that I like
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
My mouth is dry
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have trouble breathing
A Little Bit (A little bit)
Not At All (Not at all)
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Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
My voice has its usual quality and strength
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am able to eat as much food as I want
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am able to communicate with others
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I can swallow naturally and easily
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have difficulty swallowing solid foods
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have difficulty swallowing soft or mashed foods
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have difficulty swallowing liquids
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have pain in my chest when I swallow
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
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I choke when I swallow
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am able to enjoy meals with family or friends
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have a good appetite
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I wake at night because of coughing
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have pain in my stomach area
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am losing weight
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
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Adenocarcinoma of the Gastroesophageal Junction NCT01196390
Treatment - RTOG 1010 Radiotherapy Form (T1) - 3104516v1.0
RTOG 1010 Radiotherapy Form (T1)
Radiation Therapy, Paclitaxel, and Carboplatin With or
Without Trastuzumab in Treating Patients With Esophageal
Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=87FCE11A-
1B67-F5BF-E040-BB89AD432516
All rights reserved. Please visit https://medical-data-
models.org/forms/9549
RTOG 1010 Radiotherapy Form (T1)
Module 1
RTOG Study No.
Case #
Institution Name
Institution No.
Patient Initials
RTOG Patient ID
Amended Data
Yes
No
Radiation Therapy Start Date (MM DD YYYY)
Radiation Therapy End Date (MM DD YYYY)
Elapsed days
RT Total Fraction Count
RT Total Dose  (to PTV Gy)
Number Of Days Radiotherapy Interrupted Due
To Toxicity (Do not include weekends or days on
which patient would not be treated)
Number Of Days Radiotherapy Interrupted Due
To Other Reasons (Do not include weekends or
days on which patient would not be treated)
Reason Treatment Ended
Adverse Event/side Effects/complications
(Adverse Event/Side
1 / 2
Effects/Complications)
Alternative Therapy (Alternative therapy)
Death On Study (Death on study)
Disease Progression, Relapse During
Active Treatment (Disease progression,
relapse during active treatment)
Other (Other)
Patient Off-treatment For Other
Complicating Disease (Patient off-
treatment for other complicating disease)
Patient Withdrawal Or Refusal After
Beginning Protocol Therapy (Patient
withdrawal/refusal after beginning
protocol therapy)
Patient Withdrawal Or Refusal Before
Beginning Protocol Therapy (Patient
withdrawal/refusal prior to beginning
protocol therapy)
Treatment Completed Per Protocol
Criteria (Treatment completed per
protocol criteria)
Alternative therapy, specify
Other specify
Comments
Person Completing Form
Date Form Originally Completed (MM DD YYYY)
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Adenocarcinoma of the Gastroesophageal Junction NCT01196390 Quality
of Life - RTOG 1010 EQ-5D Form and Cover Sheet (HP) - 3085654v1.0
RTOG 1010 EQ-5D Form and Cover Sheet (HP)
Radiation Therapy, Paclitaxel, and Carboplatin With or
Without Trastuzumab in Treating Patients With Esophageal
Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=8669CDC0-
3163-DDAC-E040-BB89AD431147
All rights reserved. Please visit https://medical-data-
models.org/forms/9550
RTOG 1010 EQ-5D Form and Cover
Sheet (HP)
Unnamed Module 1
RTOG Study No.
Case #
Institution Name
Institution No.
Patient Initials
RTOG Patient ID
Amended data
Yes
No
Unamed Module 2
Time point
1 Year From Start Of Treatment (1 year
from start of treatment)
2 Years From Start Of Treatment (2 years
from start of treatment)
Pretreatment (Pretreatment)
Treatment Start Date
Was patient questionnaire completed
Yes
No
Date patient questionnaire completed
Reason Questionnaire was not Completed
(PATIENT)
Institution Error (Institutional error)
Not Applicable, Questionnaire Was
Completed (Not applicable,
questionnaire was completed)
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Other Reason (Other reason)
Patient Refused Due To Illness (Patient
refused due to illness)
Patient Refused For Other Reason
(Patient refused for other reason)
Patient Unable To Be Contacted (Patient
unable to be contacted)
Tool Not Availalble In Patient's Language
(Tool not available in patient's language)
Unknown (Unknown)
Patient refused for other reason, specify
Other reason, specify
Specify method of completion
At Appointment (At appointment)
By Mail (By mail)
By Telephone (By telephone)
Not Applicable (Not applicable)
Unknown (Unknown)
Did the patient require any assistance in
completing the questionnaire?
No (No)
Not Applicable (Not applicable)
Unknown If Assistance Given (Unknown
if assistance given)
Yes (Yes)
Specify the person who assisted the patient
Family (Family)
Not Applicable (Not applicable)
Other (Other)
Staff Member (Staff member)
Unknown (Unknown)
Other, specify
Extent of the assistance
Combination Of Above (Combination of
above)
Interpreted Items For Patient (Interpreted
items for patient)
Marked Items Per Patient's Response
(Marked items per patient's response)
Not Applicable (Not applicable)
Other (Other)
Read Items To Patient (Read items to
patient)
Unknown (Unknown)
Combination of above, specify
Other, specify
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Signature of Person Completing This Form
Date Form Completed (MM DD YYYY)
Unamed Module 2
Mobility
I Am Confined To Bed (I am confined to
bed)
I Have No Problems In Walking About (I
have no problems in walking about)
I Have Some Problems In Walking About
(I have some problems in walking about)
Self care
I Am Unable To Wash Or Dress Myself (I
am unable to wash or dress myself)
I Have No Problems With Self Care (I
have no problems with self care)
I Have Some Problems Washing Or
Dressing Myself (I have some problems
washing or dressing myself)
Usual activities (e.g. work, study, housework,
family, or leisure activities)
I Am Unable To Perform My Usual
Activities (I am unable to perform my
usual activities)
I Have No Problems With Performing My
Usual Activities (I have no problems with
performing my usual activities)
I Have Some Problems With Performing
My Usual Activities (I have some
problems with performing my usual
activities)
Pain/discomfort
I Have Extreme Pain Or Discomfort (I
have extreme pain or discomfort)
I Have Moderate Pain Or Discomfort (I
have moderate pain or discomfort)
I Have No Pain Or Discomfort (I have no
pain or discomfort)
Anxiety/depression
I Am Extremely Anxious Or Depressed (I
am extremely anxious or depressed)
I Am Moderately Anxious Or Depressed
(I am moderately anxious or depressed)
I Am Not Anxious Or Depressed (I am
not anxious or depressed)
Unnamed Module 3
Your own health state today
3 / 3
Adenocarcinoma of the Gastroesophageal Junction NCT01196390 Quality
of Life - RTOG 1010 EQ-5D Form and Cover Sheet (HP) - 3085654v1.0
Prostate Cancer NCT00499174 Follow-Up - NCIC-PR.11 Form
5 - Follow-Up after Radical Intervention Form - 2457271v1.0
NCIC-PR.11 Form 5 - Follow-Up after Radical Intervention
Form
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=0EF815F1-
49C3-1C6E-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/9551
NCIC-PR.11 Form 5 - Follow-Up
after Radical Intervention Form
Patient Information
NCIC Patient ID (NCIC CTG Patient Serial
Number issued at the time of randomization)
Patient Initials (first-middle-last)
Patient Medical Record Number (if permitted by
REB)
Intergroup Patient Serial No
Institution Name
NCI Institution Number (CTEP assigned, North
American sites only)
Investigator First Name
Investigator Last Name
Investigator Number (NCI Investigator Number,
North American sites only)
Month Of Report
Month of report (circle one)
12 (12)
18 (18)
24 (24)
36 (36)
48 (48)
6 (6)
60 (60)
Other Month (OTHER)
Other (please circle one)
Physical Exam
Date of Last Clinical Assessment (yyyy - mmm -
1 / 8
dd)
ECOG Performance Status (check one)
Fully Active, Able To Carry On All Pre-
disease Performance Without
Restriction. (0)
Restricted In Physically Strenuous
Activity But Ambulatory And Able To
Carry Out Work Of A Light Or Sedentary
Nature, E.g., Light Housework, Office
Work. (1)
Ambulatory And Capable Of All Selfcare
But Unable To Carry Out Any Work
Activities. Up And About More Than 50%
Of Waking Hours. (2)
Capable Of Only Limited Selfcare,
Confined To Bed Or Chair More Than
50% Of Waking Hours. (3)
Completely Disabled. Cannot Carry On
Any Selfcare. Totally Confined To Bed Or
Chair. (4)
Digital Rectal Exam
Date of exam (yyyy mmm dd date of digital rectal
exam)
Was the nodule palpable
Yes
No
Nodule is (If yes,)
Highly Suspicious For Cancer (Highly
suspicious for prostate cancer)
Mildly Suspicious For Cancer (Mildly
suspicious for prostate cancer)
Moderately Suspicious For Cancer
(Moderately suspicious for prostate
cancer)
Maximum Diameter (cm)
Psa Measurements
PSA Value (total)
Units
Micrograms Per Liter (mcg/L)
Nanograms Per Milliliter (ng/mL)
Date of PSA Assessment (yyyy mmm dd)
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Notice Of Biochemical/distant
Relapse/progression After Radical
Intervention
Has the patient been diagnosed with a first
biochemical progression? (or relapse after radical
intervention)
Yes
No
Date of First Biochemical Progression (If yes, or
relapse* after radical intervention yyyy mmm dd)
Units
Micrograms Per Liter (mcg/L)
Nanograms Per Milliliter (ng/mL)
PSA Value at Progression (or relapse)
Has the patient been diagnosed with first distant
progression?
Yes
No
Adverse Event Status
Has the patient experienced any new or
continuing symptoms or adverse events since the
last report? (possibly, probably or definitely
related to protocol therapy)
Yes
No
CTC Adverse Event Term (CTCAE Version 4.0)
Abdominal Pain (Abdominal pain)
Alopecia (Alopecia)
Non-infectious Cystitis (Cystitis
noninfective)
Diarrhea (Diarrhea)
Impotence (Erectile dysfunction)
Fatigue (Fatigue)
Proctitis (Proctitis)
Urinary Frequency (Urinary frequency)
Urinary Incontinence (Urinary
incontinence)
Urinary Retention (Urinary retention)
Grade (Worst this time period If event no present,
leave this field blank.)
Absent Adverse Event (0)
Mild Adverse Event (1)
Moderate Adverse Event (2)
Severe Adverse Event (3)
Life Threatening Adverse Event (4)
Death Related To Adverse Event (5)
CTC Adverse Event Attribution Code (*Serious
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Adverse Event form required only if malignancy is
thought to be possibly, probably, or definitely
related to protocol therapy. See protocol...)
Definite (Definite)
Possible (Possible)
Probable (Probable)
Unlikely (Unlikely)
Unrelated (Unrelated)
Seriousness Attributed to Adverse Event (Enter
appropriate code as follows: 0=not serious;
1=death; 2=life threatening; 3=hospitalization,
initial or prolonged; 4=disability...)
Congenital Anomaly (Congenital
anomaly)
Death (Death)
Disability (Disability/incapacity)
Hospitalized (Hospitalization, initial or
prolonged)
Life Threatening (Life threatening)
Not Serious (Not serious)
Other (Other)
Intervention Required (Required
intervention to prevent permanent
impairment/damage)
SAE report submitted (NCIC CTG use only
Default=N enter Y only for adverse events
recorded on SAE report)
Yes
No
Therapy For Lower Urinary Tract
Symptoms/prostate Cancer Since The
Last Report
Non-protocol 5 alpha reductase inhibitors
Yes
No
Agent
Reason for use
Non-protocol non-steroidal antiandrogen therapy
Yes
No
Agent
Non-protocol LHRH analogues
Yes
No
Agent
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Non-Protocol Surgery? (for prostate cancer)
Yes
No
Date of Non-protocol therapy (If yes, Date of Non-
protocol surgery yyyy-mmm-dd)
Non-Protocol Surgery Type
Non-Protocol Radiation Therapy? (for prostate
cancer)
Yes
No
Non-protocol Radiation Therapy start date (If yes,
yyyy-mmm-dd)
Non-Protocol RT Type
Complementary and alternative medicines (for
lower urinary tract symptoms or prostate cancer?
CRF: Complementary and Alternative Medicines)
Yes
No
Agent (If yes, *e.g. Saw Palmetto, Vitamin B/E,
Selenium, Lycopene  CRF: Agent)
Other Non-Protocol Therapy (for prostate
cancer?)
Yes
No
Name of Other Non-Protocol Therapy (If yes, for
Prostate Cancer)
Date of First Non-Protocol Therapy (for Prostate
Cancer yyyy-mmm-dd)
Date of First Non-Protocol Therapy (for Prostate
Cancer yyyy-mmm-dd)
Date of First Non-Protocol Therapy (for Prostate
Cancer yyyy-mmm-dd)
Date of First Non-Protocol Therapy (for Prostate
Cancer yyyy-mmm-dd)
Adjuvant radiation therapy after radical
prostatectomy for prostate cancer?
Not Applicable (N/A)
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No (No)
Yes (Yes)
Name of adjuvant radiation therapy after radical
prostatectomy (If yes,)
Date Adjuvant Radiation Therapy Started (yyyy
mmm dd RECOMMENDED TERM for "Date of
first adjuvant radiation therapy after radical
prostatectomy")
Other Malignancies Or Marrow Dysplasia
Has a new primary cancer or MDS been
diagnosed that has not been previously reported?
(myelodysplastic syndrome)
Yes
No
Date of Diagnosis (yyyy-mmm-dd)
Malignancy Type (e.g., bladder)
New Primary Diagnosis
(Histology/Cytopathology)
CTC Adverse Event Attribution Code (*Serious
Adverse Event form required only if malignancy is
thought to be possibly, probably, or definitely
related to protocol therapy. See protocol...)
Definite (Definite)
Possible (Possible)
Probable (Probable)
Unlikely (Unlikely)
Unrelated (Unrelated)
Quality Of Life
Was QoL Questionnaire completed?
No: C49487 (No)
Not Applicable (Not Applicable)
Yes: C49488 (Yes)
Date Questionnaire Completed (yyyy mmm dd
Please submit Quality of Life questionnaires)
Reason Questionnaire was not Completed (check
one)
Other Reason (Other reason)
Patient Refused (Patient refused)
Patient Refused Due To Illness (Patient
refused due to illness)
Patient Unable To Be Contacted (Patient
unable to be contacted)
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Questionnaire Not Completed Due To
Institutional Error (Questionnaire not
completed due to institutional error)
Other reason, specify
Quality Of Life
Was QoL Questionnaire completed?
No: C49487 (No)
Not Applicable (Not Applicable)
Yes: C49488 (Yes)
Date Questionnaire Completed (yyyy mmm dd
Please submit Quality of Life questionnaires)
Reason Questionnaire was not Completed (check
one)
Other Reason (Other reason)
Patient Refused (Patient refused)
Patient Refused Due To Illness (Patient
refused due to illness)
Patient Unable To Be Contacted (Patient
unable to be contacted)
Questionnaire Not Completed Due To
Institutional Error (Questionnaire not
completed due to institutional error)
Other reason, specify
Quality Of Life
Was QoL Questionnaire completed?
No: C49487 (No)
Not Applicable (Not Applicable)
Yes: C49488 (Yes)
Date Questionnaire Completed (yyyy mmm dd
Please submit Quality of Life questionnaires)
Reason Questionnaire was not Completed (check
one)
Other Reason (Other reason)
Patient Refused (Patient refused)
Patient Refused Due To Illness (Patient
refused due to illness)
Patient Unable To Be Contacted (Patient
unable to be contacted)
Questionnaire Not Completed Due To
Institutional Error (Questionnaire not
completed due to institutional error)
Other reason, specify
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Comments
Comments
Supporting Documentation
Investigator Signature
Person Completing Form, Last Name
Person Completing Form, First Name
Date Form Originally Completed (yyyy - mmm -
dd)
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NCT01546987 Quality of Life - RTOG 1115 FA: Phase III RT + Standard ADT vs RT
+ Enhanced ADT + TAK-700 Expanded Prostate Cancer Index Composite (EPIC)
Form - 3288539v1.0
RTOG 1115 FA: Phase III RT + Standard ADT vs RT +
Enhanced ADT + TAK-700  Expanded Prostate Cancer
Index Composite (EPIC) Form
Hormone Therapy, Radiation Therapy, and Steroid 17alpha-
monooxygenase TAK-700 in Treating Patients With High-
Risk Prostate Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=AE8E7874-
4C98-11A5-E040-BB89AD43766D
All rights reserved. Please visit https://medical-data-
models.org/forms/9552
RTOG 1115 FA: Phase III RT +
Standard ADT vs RT + Enhanced
ADT + TAK-700 Expanded Prostate
Cancer Index Composite (EPIC)
Form
Unnamed Module 1
RTOG Study No.
Case #
Institution Name
Institution No.
Patient Initials
RTOG Patient ID
Amended data
Yes
No
Unamed Module 2
Time point
12 Months From Start Of Treatment (12
months from start of treatment)
30 Months From Start Of Treatment (30
months from start of treatment)
Baseline (baseline)
Last Week Of Radiation Therapy (Last
week of RT)
Other (Other)
Pretreatment (Pretreatment)
Other specify
Did the patient complete any items on the
questionnaire?
Yes
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No
Date Questionnaire Completed
Reason Questionnaire was not Completed
Institution Error (Institutional error)
Not Applicable, Questionnaire Was
Completed (Not applicable,
questionnaire was completed)
Other Reason (Other reason)
Patient Refused Due To Illness (Patient
refused due to illness)
Patient Refused For Other Reason
(Patient refused for other reason)
Patient Unable To Be Contacted (Patient
unable to be contacted)
Tool Not Availalble In Patient's Language
(Tool not available in patient's language)
Patient refused for other reason, specify
Other reason, specify
Did the patient require any assistance in
completing the questionnaire?
No (No)
Not Applicable (Not applicable)
Unknown If Assistance Given (Unknown
if assistance given)
Yes (Yes)
Extent of assistance given
Combination Of Above (Combination of
above)
Interpreted Items For Patient (Interpreted
items for patient)
Marked Items Per Patient's Response
(Marked items per patient's response)
Not Applicable (Not applicable)
Other (Other)
Read Items To Patient (Read items to
patient)
Combination of above, specify
Other, specify
Specify the person who assisted the patient
Family (Family)
Not Applicable (Not applicable)
Other (Other)
Staff Member (Staff member)
Unknown (Unknown)
Specify method of completion
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At Appointment (At appointment)
By Mail (By mail)
By Telephone (By telephone)
Unknown (Unknown)
Comments
Signature of Person Completing This Form
Date Form Completed
Epic: The Expanded Prostate Cancer
Index Composite
Today's date (please enter date when survey
completed Month Day Year)
Name (optional)
Date of Birth (optional Month Day Year)
Quality Of Life Module
Over the past 4 weeks how often have you leaked
urine (Circle one number)
Once A Day (About once a day)
About Once A Week (About once a
week)
More Than Once A Day (More than once
a day)
More Than Once A Week (More than
once a week)
Rarely (Rarely or never)
Over the past 4 weeks, how often have you
urinated blood (Circle one number)
Once A Day (About once a day)
About Once A Week (About once a
week)
More Than Once A Day (More than once
a day)
More Than Once A Week (More than
once a week)
Rarely (Rarely or never)
Over the past 4 weeks, how often have you had
pain or burning with urination (Circle one number)
Once A Day (About once a day)
About Once A Week (About once a
week)
More Than Once A Day (More than once
a day)
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More Than Once A Week (More than
once a week)
Rarely (Rarely or never)
Which of the following best describes your
urinary control during the last 4 weeks (Circle
one number)
Frequent Dribbling (Frequent dribbling)
No Urinary Control (No urinary control
whatsoever)
Occasional Dribbling (Occasional
dribbling)
Normal Urinary Control (Total control)
How many pads or adult diapers per day did you
usually use to control leakage during the last 4
weeks
1 Per Day (1 pad per day)
2 Per Day (2 pads per day)
3+ Per Day (3 or more pads per day)
None (None)
Dripping or leaking urine (How big a problem, if
any, has each of the following been for you during
the last 4 weeks? Circle one number on each
line)
Severe Problem (Big problem)
Moderate Problem (Moderate problem)
No Problem (No problem)
Mild To Moderate Problem (Small
problem)
Mild Problem (Very small problem)
Pain or burning on urination
Severe Problem (Big problem)
Moderate Problem (Moderate problem)
No Problem (No problem)
Mild To Moderate Problem (Small
problem)
Mild Problem (Very small problem)
Bleeding with urination
Severe Problem (Big problem)
Moderate Problem (Moderate problem)
No Problem (No problem)
Mild To Moderate Problem (Small
problem)
Mild Problem (Very small problem)
Weak urine stream or incomplete emptying
Severe Problem (Big problem)
Moderate Problem (Moderate problem)
No Problem (No problem)
Mild To Moderate Problem (Small
problem)
Mild Problem (Very small problem)
Waking up to urinate
Severe Problem (Big problem)
Moderate Problem (Moderate problem)
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No Problem (No problem)
Mild To Moderate Problem (Small
problem)
Mild Problem (Very small problem)
Need to urinate frequently during the day
Severe Problem (Big problem)
Moderate Problem (Moderate problem)
No Problem (No problem)
Mild To Moderate Problem (Small
problem)
Mild Problem (Very small problem)
Overall, how big a problem has your urinary
function been for you during the last 4 weeks
(Circle one number)
Severe Problem (Big problem)
Moderate Problem (Moderate problem)
No Problem (No problem)
Mild To Moderate Problem (Small
problem)
Mild Problem (Very small problem)
Quality Of Life Module
How often have you had rectal urgency (felt like I
had to pass stool, but did not) during the last 4
weeks (Circle one number)
Once A Day (About once a day)
About Once A Week (About once a
week)
More Than Once A Day (More than once
a day)
More Than Once A Week (More than
once a week)
Rarely (Rarely or never)
How often have you had uncontrolled leakage of
stool or feces (Circle one number)
Once A Day (About once a day)
About Once A Week (About once a
week)
More Than Once A Day (More than once
a day)
More Than Once A Week (More than
once a week)
Rarely (Rarely or never)
How often have you had stools (bowel
movements) that were loose or liquid (no form,
watery, mushy) during the last 4 weeks (Circle
one number)
About Half The Time (About half the
time)
Always (Always)
Never (Never)
Rarely (Rarely)
Usually (Usually)
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How often have you had bloody stools during the
last 4 weeks (Circle one number)
About Half The Time (About half the
time)
Always (Always)
Never (Never)
Rarely (Rarely)
Usually (Usually)
How often have your bowel movements been
painful during the last 4 weeks (Circle one
number)
About Half The Time (About half the
time)
Always (Always)
Never (Never)
Rarely (Rarely)
Usually (Usually)
How many bowel movements have you had on a
typical day during the last 4 weeks (Circle one
number)
Five Or More (Five or more)
Three To Four (Three to four)
Two Or Less (Two or less)
How often have you had crampy pain in your
abdomen, pelvis or rectum during the last 4
weeks (Circle one number)
Once A Day (About once a day)
About Once A Week (About once a
week)
More Than Once A Day (More than once
a day)
More Than Once A Week (More than
once a week)
Rarely (Rarely or never)
Urgency to have a bowel movement (How big a
problem, if any, has each of the following been for
you? Circle one number on each line)
Severe Problem (Big problem)
Moderate Problem (Moderate problem)
No Problem (No problem)
Mild To Moderate Problem (Small
problem)
Mild Problem (Very small problem)
Increased frequency of bowel movements
Severe Problem (Big problem)
Moderate Problem (Moderate problem)
No Problem (No problem)
Mild To Moderate Problem (Small
problem)
Mild Problem (Very small problem)
Watery bowel movements
Severe Problem (Big problem)
No Problem (No problem)
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Mild To Moderate Problem (Small
problem)
Mild Problem (Very small problem)
Losing control of your stools
Severe Problem (Big problem)
Moderate Problem (Moderate problem)
No Problem (No problem)
Mild To Moderate Problem (Small
problem)
Mild Problem (Very small problem)
Bloody stools
Severe Problem (Big problem)
Moderate Problem (Moderate problem)
No Problem (No problem)
Mild To Moderate Problem (Small
problem)
Mild Problem (Very small problem)
Abdominal/pelvic/rectal pain
Severe Problem (Big problem)
Moderate Problem (Moderate problem)
No Problem (No problem)
Mild To Moderate Problem (Small
problem)
Mild Problem (Very small problem)
Overall, how big a problem have your bowel
habits been for you during the last 4 weeks
(Circle one number)
Severe Problem (Big problem)
Moderate Problem (Moderate problem)
No Problem (No problem)
Mild To Moderate Problem (Small
problem)
Mild Problem (Very small problem)
Quality Of Life Module
Your level of sexual desire (How would you rate
each of the following during the last 4 weeks?
Circle one number on each line)
Fair (Fair)
Good (Good)
Poor (Poor)
Very Good (Very Good)
Very Poor To None (Very Poor to None)
Your ability to have an erection
Fair (Fair)
Good (Good)
Poor (Poor)
Very Good (Very Good)
None (Very poor to None)
Your ability to reach orgasm (climax)
Fair (Fair)
Good (Good)
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Poor (Poor)
Very Good (Very Good)
None (Very poor to None)
How would you describe the usual QUALITY of
your erections during the last 4 weeks (Circle one
number)
Firm Enough For Intercourse (Firm
enough for intercourse)
Firm Enough For Masturbation And
Foreplay Only (Firm enough for
masturbation and foreplay only)
None (None at all)
Not Firm Enough For Any Sexual Activity
(Not firm enough for any sexual activity)
How would you describe the FREQUENCY of
your erections during the last 4 weeks (Circle one
number)
About Half (approximately 50%) (I had
an erection ABOUT HALF the time I
wanted one)
Less Than Half (I had an erection LESS
THAN HALF the time I wanted one)
More Than Half (I had an erection MORE
THAN HALF the time I wanted one)
Normal (I had an erection WHENEVER I
wanted one)
Never (I NEVER had an erection when I
wanted one)
How often have you awakened in the morning or
night with an erection during the last 4 weeks
(Circle one number)
About Once A Week (About once a
week)
Daily (Daily)
Less Than Once A Week (Less than
once a week)
Never (Never)
Several Times A Week (Several times a
week)
During the last 4 weeks, how often did you have
any sexual activity (Circle one number)
About Once A Week (About once a
week)
Daily (Daily)
Less Than Once A Week (Less than
once a week)
Not At All (Not at all)
Several Times A Week (Several times a
week)
During the last 4 weeks, how often did you have
sexual intercourse (Circle one number)
About Once A Week (About once a
week)
Daily (Daily)
Less Than Once A Week (Less than
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once a week)
Not At All (Not at all)
Several Times A Week (Several times a
week)
Overall, how would you rate your ability to
function sexually during the last 4 weeks
Fair (Fair)
Good (Good)
Poor (Poor)
Very Good (Very Good)
Very Poor (Very poor)
Your level of sexual desire (How big a problem
during the last 4 weeks, if any, has each of the
following been for you? Circle one number on
each line)
Severe Problem (Big problem)
Moderate Problem (Moderate problem)
No Problem (No problem)
Mild To Moderate Problem (Small
problem)
Mild Problem (Very small problem)
Your ability to have an erection
Severe Problem (Big problem)
Moderate Problem (Moderate problem)
No Problem (No problem)
Mild To Moderate Problem (Small
problem)
Mild Problem (Very small problem)
Your ability to reach an orgasm
Severe Problem (Big problem)
Moderate Problem (Moderate problem)
No Problem (No problem)
Mild To Moderate Problem (Small
problem)
Mild Problem (Very small problem)
Overall, how big a problem has your sexual
function or lack of sexual function been for you
during the last 4 weeks
Severe Problem (Big problem)
Moderate Problem (Moderate problem)
No Problem (No problem)
Mild To Moderate Problem (Small
problem)
Mild Problem (Very small problem)
Quality Of Life Module
Over the last 4 weeks, how often have you
experienced hot flashes (Circle one number)
Once A Day (About once a day)
About Once A Week (About once a
week)
More Than Once A Day (More than once
a day)
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More Than Once A Week (More than
once a week)
Rarely (Rarely or never)
How often have you had breast tenderness
during the last 4 weeks (Circle one number)
Once A Day (About once a day)
About Once A Week (About once a
week)
More Than Once A Day (More than once
a day)
More Than Once A Week (More than
once a week)
Rarely (Rarely or never)
During the last 4 weeks, how often have you felt
depressed (Circle one number)
Once A Day (About once a day)
About Once A Week (About once a
week)
More Than Once A Day (More than once
a day)
More Than Once A Week (More than
once a week)
Rarely (Rarely or never)
During the last 4 weeks, how often have you felt a
lack of energy (Circle one number)
Once A Day (About once a day)
About Once A Week (About once a
week)
More Than Once A Day (More than once
a day)
More Than Once A Week (More than
once a week)
Rarely (Rarely or never)
How much change in your weight have you
experienced during the last 4 weeks, if any
(Circle one number)
Gained 10 Pounds Or More (Gained 10
pounds or more)
Gained Less Than 10 Pounds (Gained
less than 10 pounds)
Lost 10 Pounds Or More (Lost 10
pounds or more)
Lost Less Than 10 Pounds (Lost less
than 10 pounds)
No Change In Weight (No change in
weight)
Hot flashes (How big a problem during the last 4
weeks, if any, has each of the following been for
you? Circle one number on each line)
Severe Problem (Big problem)
Moderate Problem (Moderate problem)
No Problem (No problem)
Mild To Moderate Problem (Small
problem)
Mild Problem (Very small problem)
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Breast tenderness/enlargement
Severe Problem (Big problem)
Moderate Problem (Moderate problem)
No Problem (No problem)
Mild To Moderate Problem (Small
problem)
Mild Problem (Very small problem)
Loss of Body Hair
Big Problem (Big problem)
Moderate Problem (Moderate problem)
No Problem (No problem)
Small Problem (Small problem)
Very Small Problem (Very small problem)
Feeling depressed
Severe Problem (Big problem)
Moderate Problem (Moderate problem)
No Problem (No problem)
Mild To Moderate Problem (Small
problem)
Mild Problem (Very small problem)
Lack of energy
Severe Problem (Big problem)
Moderate Problem (Moderate problem)
No Problem (No problem)
Mild To Moderate Problem (Small
problem)
Mild Problem (Very small problem)
Change in body weight
Severe Problem (Big problem)
Moderate Problem (Moderate problem)
No Problem (No problem)
Mild To Moderate Problem (Small
problem)
Mild Problem (Very small problem)
Overall Satisfaction
Overall, how satisfied are you with the treatment
you received for your prostate cancer (Circle one
number)
Dissatisfied (Dissatisfied)
Extremely Dissatisfied (Extremely
dissatisfied)
Extremely Satisfied (Extremely satisfied)
Satisfied (Satisfied)
Uncertain (Uncertain)
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Prostate Cancer NCT00499174 Follow-Up - NCIC-PR.11
Form 5AS - Active Surveillance Form - 2457525v1.0
NCIC-PR.11 Form 5AS - Active Surveillance Form
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=0EF81D84-
2928-1CED-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/9553
NCIC-PR.11 Form 5AS - Active
Surveillance Form
Patient Information
NCIC Patient ID (NCIC CTG Patient Serial
Number issued at the time of randomization)
Patient Initials (first-middle-last)
Patient Medical Record Number (if permitted by
IRB)
Intergroup Patient Serial No
Institution Name
NCI Institution Number (CTEP assigned)
Investigator First Name
Investigator Last Name
Investigator Number (NCI Investigator Number)
Month Of Report
Month of report (circle one)
12 (12)
15 (15)
18 (18)
21 (21)
24 (24)
3 (3)
30 (30)
36 (36)
42 (42)
48 (48)
54 (54)
6 (6)
60 (60)
9 (9)
Other Month (OTHER)
Other
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Physical Exam
Date of Last Clinical Assessment (yyyy - mmm -
dd)
ECOG Performance Status (check one)
Fully Active, Able To Carry On All Pre-
disease Performance Without
Restriction. (0)
Restricted In Physically Strenuous
Activity But Ambulatory And Able To
Carry Out Work Of A Light Or Sedentary
Nature, E.g., Light Housework, Office
Work. (1)
Ambulatory And Capable Of All Selfcare
But Unable To Carry Out Any Work
Activities. Up And About More Than 50%
Of Waking Hours. (2)
Capable Of Only Limited Selfcare,
Confined To Bed Or Chair More Than
50% Of Waking Hours. (3)
Completely Disabled. Cannot Carry On
Any Selfcare. Totally Confined To Bed Or
Chair. (4)
Digital Rectal Exam
Date of exam (yyyy mmm dd)
Was the nodule palpable
Yes
No
Nodule is (If yes,  CRF: Nodule is)
Highly Suspicious For Cancer (Highly
suspicious for prostate cancer)
Mildly Suspicious For Cancer (Mildly
suspicious for prostate cancer)
Moderately Suspicious For Cancer
(Moderately suspicious for prostate
cancer)
Maximum Diameter (cm)
Psa Measurements
PSA Value (total) (The biologic variation in PSA is
substantial. To minimize the impact of a non-
significant rise in PSA reflecting random
fluctuation, patients should have a minimum of
5...)
Units (* ng/mL, ug/L)
Micrograms Per Liter (mcg/L)
Nanograms Per Milliliter (ng/mL)
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Date of PSA Assessment (yyyy mmm dd)
PSA Doubling Time (CRF: PSA Doubling-time
years)
Method
Nomograms (MSK Nomogram)
Other (Other)
Other Specify
Has the patient been diagnosed with a first
biochemical progression?
Yes
No
Date of First Biochemical Progression (If yes,
yyyy mmm dd)
Histology/grade
Date Surgical Gleason Score Obtained (yyyy
mmm dd  CRF: Date Surgical Gleason Score
Obtained)
Gleason Score Based on Specimen Type
Biopsy (Biopsy)
Fine Needle Aspiration Biopsy (Fine
Needle Aspirate)
Surgical Specimen (Surgical specimen)
Gleason Score, Primary Pattern (1-5)
Gleason Score, Secondary Pattern (1-5)
Gleason Score, Combined (sum of the primary
and secondary)
Has the patient developed a first histologic
progression (Histologic progression is defined as
Gleason pattern of predominant 4 or higher i.e.,
Gleason 7 4+3 or higher in the re-biopsy of
prostate)
Yes
No
Date of First Histologic Progression (If yes, yyyy
mmm dd  CRF: Date of First Histologic
Progression)
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Clinical Progression
Has the patient developed a first local
progression
Yes
No
Date of First Local Progression (If yes, yyyy
mmm dd)
Has the patient been diagnosed with first distant
progression?
Yes
No
Date of First Distant Progression (If yes, yyyy
mmm dd)
Adverse Event Status
Has the patient experienced any new or
continuing symptoms or adverse events since the
last report? (possibly, probably or definitely
related to protocol therapy)
Yes
No
CTC Adverse Event Attribution Code (**
1=unrelated, 2=unlikely, 3=possible, 4=probable,
5=definite)
Definite (Definite)
Possible (Possible)
Probable (Probable)
Unlikely (Unlikely)
Unrelated (Unrelated)
Seriousness Attributed to Adverse Event (Enter
appropriate code as follows: 0=not serious;
1=death; 2=life threatening; 3=hospitalization,
initial or prolonged; 4=disability...)
Congenital Anomaly (Congenital
anomaly)
Death (Death)
Disability (Disability/incapacity)
Hospitalized (Hospitalization, initial or
prolonged)
Life Threatening (Life threatening)
Not Serious (Not serious)
Other (Other)
Intervention Required (Required
intervention to prevent permanent
impairment/damage)
SAE report submitted (NCIC CTG use only
Default=N enter Y only for adverse events
recorded on SAE report)
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Yes
No
CTC Adverse Event Term
Grade (Grade according to NCI CTCAE, Version
4.0)
Absent Adverse Event (0)
Mild Adverse Event (1)
Moderate Adverse Event (2)
Severe Adverse Event (3)
Life Threatening Adverse Event (4)
Death Related To Adverse Event (5)
Therapy For Lower Urinary Tract
Symptoms/prostate Cancer Since The
Last Report
Non-protocol 5 alpha reductase inhibitors
Yes
No
Agent
Reason for use
Non-protocol non-steroidal antiandrogen therapy
Yes
No
Agent
Non-protocol LHRH analogues
Yes
No
Agent
Non-Protocol Surgery? (for prostate cancer)
Yes
No
Date of Non-protocol therapy (If yes, Date of Non-
protocol surgery yyyy-mmm-dd)
Non-Protocol Surgery Type
Non-Protocol Radiation Therapy? (for prostate
cancer)
Yes
No
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Non-Protocol Radiation Therapy Start Date (If
yes, yyyy-mmm-dd)
Non-Protocol RT Type
Complementary and alternative medicines (for
lower urinary tract symptoms or prostate cancer?
CRF: Complementary and Alternative Medicines)
Yes
No
Agent (If yes, *e.g. Saw Palmetto, Vitamin B/E,
Selenium, Lycopene  CRF: Agent)
Other Non-Protocol Therapy (for prostate
cancer?)
Yes
No
Name of Other Non-Protocol Therapy (If yes, for
prostate cancer)
Date of First Non-Protocol Therapy (for Prostate
Cancer yyyy-mmm-dd)
Date of First Non-Protocol Therapy (for Prostate
Cancer yyyy-mmm-dd)
Date of First Non-Protocol Therapy (for Prostate
Cancer yyyy-mmm-dd)
Date of First Non-Protocol Therapy (for Prostate
Cancer yyyy-mmm-dd)
Other Malignancies Or Marrow Dysplasia
Has a new primary cancer or MDS been
diagnosed that has not been previously reported?
(myelodysplastic syndrome)
Yes
No
Date of Diagnosis (yyyy-mmm-dd)
Malignancy Type (e.g., bladder)
New Primary Diagnosis
(Histology/Cytopathology)
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CTC Adverse Event Attribution Code (**
1=unrelated, 2=unlikely, 3=possible, 4=probable,
5=definite)
Definite (Definite)
Possible (Possible)
Probable (Probable)
Unlikely (Unlikely)
Unrelated (Unrelated)
End Of Active Surveillance
Will this patient continue on active surveillance
Yes
No
Date of the decision to stop active surveillance (If
no, yyyy mmm dd  CRF: Date of the decision to
stop active surveillance)
Reason active surveillance was stopped
Biochemical/psa Doubling-time
(Biochemical/PSA doubling-time)
Clinical Judgement (Clinical judgement)
Clinical Progression (Clinical progression
(local/distant))
Histologic/grade Progression
(Histologic/Grade progression)
Other (Other)
Patient Choice (Patient choice)
Other specify
Patient choice Reason
CTC Adverse Event Attribution Code (**
1=unrelated, 2=unlikely, 3=possible, 4=probable,
5=definite)
Definite (Definite)
Possible (Possible)
Probable (Probable)
Unlikely (Unlikely)
Unrelated (Unrelated)
Clinical judgement Reason
Will the patient receive radical prostatectomy or
radiation therapy
Yes
No
Radiation Therapy Type (**Please complete the
Patient Specific Radiotherapy Facility
Questionnaire, a Form 4 and follow the schedule
of investigations listed in protocol section 9.2.)
External Beam Radiation Therapy
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(External beam)
High-dose Rate Brachytherapy (High
dose rate temporary brachytherapy)
Prostate Implant Brachytherapy
(Permanent prostate brachytherapy)
Date of the decision that the patient will not
receive radical prostatectomy or radiation therapy
(If no, yyyy mmm dd)
Reason patient will not receive radical
prostatectomy or radiation therapy
Adverse Event/side Effects/complications
(Adverse events/side
effects/complications)
Death (Death on-study)
Disease Progression (Distant
progression during active surveillance)
Other (Other)
Patient Off-treatment For Other
Complicating Disease (Patient off
treatment for other complicating disease)
Patient Withdrawal Or Refusal Before
Beginning Protocol Therapy (Patient
withdrawal/refusal of radical intervention)
Other specify
CTC Adverse Event Term
Grade (Grade according to NCI CTCAE, Version
4.0)
Absent Adverse Event (0)
Mild Adverse Event (1)
Moderate Adverse Event (2)
Severe Adverse Event (3)
Life Threatening Adverse Event (4)
Death Related To Adverse Event (5)
Planned Therapeutic Action for this patient
(Please complete a Form 5 and follow the
schedule of investigations listed in protocol
section 9.2)
Planned Therapeutic Action for this patient
(Please complete a Form 5 and follow the
schedule of investigations listed in protocol
section 9.2)
Correlative Studies
Was tissue collected for tumor banking (at the
time of randomization)
Yes
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No
This tissue was collected for
Year (1 year)
10 Years (10 years)
15 Years Post Registration (15 years)
4 Years (4 years)
7 Years (7 years)
Other (Other)
Other
Reason (Please provide)
Quality Of Life Questionnaire
Was QoL Questionnaire completed?
No: C49487 (No)
Not Applicable (Not Applicable)
Yes: C49488 (Yes)
Date Questionnaire Completed (yyyy mmm dd
Please submit quality of life questionnaires)
Reason Questionnaire was not Completed (check
one)
Other Reason (Other reason)
Patient Refused (Patient refused)
Patient Refused Due To Illness (Patient
refused due to illness)
Patient Unable To Be Contacted (Patient
unable to be contacted)
Questionnaire Not Completed Due To
Institutional Error (Questionnaire not
completed due to institutional error)
Other reason, specify
Comments
Comments
Supporting Documentation
Investigator Signature
Person Completing Form, Last Name
Person Completing Form, First Name
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Date Form Originally Completed (yyyy - mmm -
dd)
10 / 10
Prostate Cancer NCT00499174 Follow-Up - NCIC-PR.11 Form 5AS -
Active Surveillance Form - 2457525v1.0
NCT01368588 Quality of Life - RTOG-0924 FA: Expanded
Prostate Cancer Index Composite (EPIC) Form - 3197349v1.0
RTOG-0924 FA: Expanded Prostate Cancer Index
Composite (EPIC) Form
Androgen-Deprivation Therapy and Radiation Therapy in
Treating Patients With Prostate Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=9D96A377-
765A-275E-E040-BB89AD437DB1
All rights reserved. Please visit https://medical-data-
models.org/forms/9554
RTOG-0924 FA: Expanded Prostate
Cancer Index Composite (EPIC)
Form
Unnamed Module 1
RTOG Study No.
Case #
Institution Name
Institution No.
Patient Initials
RTOG Patient ID
Amended data
Yes
No
Unamed Module 2
Time point
12 Months After Radiation Therapy (12
months after RT)
6 Months Of Radiation Therapy (6
months after RT)
60 Months After Radiation Therapy (60
months after RT)
Baseline (baseline)
Other (Other)
Pretreatment (Pretreatment)
Other specify
Did the patient complete any items on the
questionnaire?
Yes
No
Date Questionnaire Completed
Reason Questionnaire was not Completed
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Institution Error (Institutional error)
Not Applicable, Questionnaire Was
Completed (Not applicable,
questionnaire was completed)
Other Reason (Other reason)
Patient Refused Due To Illness (Patient
refused due to illness)
Patient Refused For Other Reason
(Patient refused for other reason)
Patient Unable To Be Contacted (Patient
unable to be contacted)
Tool Not Availalble In Patient's Language
(Tool not available in patient's language)
Patient refused for other reason, specify
Other reason, specify
Did the patient require any assistance in
completing the questionnaire?
No (No)
Not Applicable (Not applicable)
Unknown If Assistance Given (Unknown
if assistance given)
Yes (Yes)
Extent of assistance given
Combination Of Above (Combination of
above)
Interpreted Items For Patient (Interpreted
items for patient)
Marked Items Per Patient's Response
(Marked items per patient's response)
Not Applicable (Not applicable)
Other (Other)
Read Items To Patient (Read items to
patient)
Combination of above, specify
Other, specify
Specify the person who assisted the patient
Family (Family)
Not Applicable (Not applicable)
Other (Other)
Staff Member (Staff member)
Unknown (Unknown)
Specify method of completion
At Appointment (At appointment)
By Mail (By mail)
By Telephone (By telephone)
Unknown (Unknown)
Comments
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Signature of Person Completing This Form
Date Form Originally Completed
Epic: The Expanded Prostate Cancer
Index Composite
Today's date (please enter date when survey
completed Month Day Year)
Name (optional)
Date of Birth (optional Month Day Year)
Quality Of Life Module
Over the past 4 weeks how often have you leaked
urine (Circle one number)
Once A Day (About once a day)
About Once A Week (About once a
week)
More Than Once A Day (More than once
a day)
More Than Once A Week (More than
once a week)
Rarely (Rarely or never)
Over the past 4 weeks, how often have you
urinated blood (Circle one number)
Once A Day (About once a day)
About Once A Week (About once a
week)
More Than Once A Day (More than once
a day)
More Than Once A Week (More than
once a week)
Rarely (Rarely or never)
Over the past 4 weeks, how often have you had
pain or burning with urination (Circle one number)
Once A Day (About once a day)
About Once A Week (About once a
week)
More Than Once A Day (More than once
a day)
More Than Once A Week (More than
once a week)
Rarely (Rarely or never)
Which of the following best describes your
urinary control during the last 4 weeks (Circle
one number)
Frequent Dribbling (Frequent dribbling)
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No Urinary Control (No urinary control
whatsoever)
Occasional Dribbling (Occasional
dribbling)
Normal Urinary Control (Total control)
How many pads or adult diapers per day did you
usually use to control leakage during the last 4
weeks
1 Per Day (1 pad per day)
2 Per Day (2 pads per day)
3+ Per Day (3 or more pads per day)
None (None)
Dripping or leaking urine (How big a problem, if
any, has each of the following been for you during
the last 4 weeks? Circle one number on each
line)
Severe Problem (Big problem)
Moderate Problem (Moderate problem)
No Problem (No problem)
Mild To Moderate Problem (Small
problem)
Mild Problem (Very small problem)
Pain or burning on urination
Severe Problem (Big problem)
Moderate Problem (Moderate problem)
No Problem (No problem)
Mild To Moderate Problem (Small
problem)
Mild Problem (Very small problem)
Bleeding with urination
Severe Problem (Big problem)
Moderate Problem (Moderate problem)
No Problem (No problem)
Mild To Moderate Problem (Small
problem)
Mild Problem (Very small problem)
Weak urine stream or incomplete emptying
Severe Problem (Big problem)
Moderate Problem (Moderate problem)
No Problem (No problem)
Mild To Moderate Problem (Small
problem)
Mild Problem (Very small problem)
Waking up to urinate
Severe Problem (Big problem)
Moderate Problem (Moderate problem)
No Problem (No problem)
Mild To Moderate Problem (Small
problem)
Mild Problem (Very small problem)
Need to urinate frequently during the day
Severe Problem (Big problem)
Moderate Problem (Moderate problem)
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No Problem (No problem)
Mild To Moderate Problem (Small
problem)
Mild Problem (Very small problem)
Overall, how big a problem has your urinary
function been for you during the last 4 weeks
(Circle one number)
Severe Problem (Big problem)
Moderate Problem (Moderate problem)
No Problem (No problem)
Mild To Moderate Problem (Small
problem)
Mild Problem (Very small problem)
Quality Of Life Module
How often have you had rectal urgency (felt like I
had to pass stool, but did not) during the last 4
weeks (Circle one number)
Once A Day (About once a day)
About Once A Week (About once a
week)
More Than Once A Day (More than once
a day)
More Than Once A Week (More than
once a week)
Rarely (Rarely or never)
How often have you had uncontrolled leakage of
stool or feces (Circle one number)
Once A Day (About once a day)
About Once A Week (About once a
week)
More Than Once A Day (More than once
a day)
More Than Once A Week (More than
once a week)
Rarely (Rarely or never)
How often have you had stools (bowel
movements) that were loose or liquid (no form,
watery, mushy) during the last 4 weeks (Circle
one number)
About Half The Time (About half the
time)
Always (Always)
Never (Never)
Rarely (Rarely)
Usually (Usually)
How often have you had bloody stools during the
last 4 weeks (Circle one number)
About Half The Time (About half the
time)
Always (Always)
Never (Never)
Rarely (Rarely)
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Usually (Usually)
How often have your bowel movements been
painful during the last 4 weeks (Circle one
number)
About Half The Time (About half the
time)
Always (Always)
Never (Never)
Rarely (Rarely)
Usually (Usually)
How many bowel movements have you had on a
typical day during the last 4 weeks (Circle one
number)
Five Or More (Five or more)
Three To Four (Three to four)
Two Or Less (Two or less)
How often have you had crampy pain in your
abdomen, pelvis or rectum during the last 4
weeks (Circle one number)
Once A Day (About once a day)
About Once A Week (About once a
week)
More Than Once A Day (More than once
a day)
More Than Once A Week (More than
once a week)
Rarely (Rarely or never)
Urgency to have a bowel movement (How big a
problem, if any, has each of the following been for
you? Circle one number on each line)
Severe Problem (Big problem)
Moderate Problem (Moderate problem)
No Problem (No problem)
Mild To Moderate Problem (Small
problem)
Mild Problem (Very small problem)
Increased frequency of bowel movements
Severe Problem (Big problem)
Moderate Problem (Moderate problem)
No Problem (No problem)
Mild To Moderate Problem (Small
problem)
Mild Problem (Very small problem)
Watery bowel movements
Severe Problem (Big problem)
No Problem (No problem)
Mild To Moderate Problem (Small
problem)
Mild Problem (Very small problem)
Losing control of your stools
Severe Problem (Big problem)
Moderate Problem (Moderate problem)
No Problem (No problem)
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Mild To Moderate Problem (Small
problem)
Mild Problem (Very small problem)
Bloody stools
Severe Problem (Big problem)
Moderate Problem (Moderate problem)
No Problem (No problem)
Mild To Moderate Problem (Small
problem)
Mild Problem (Very small problem)
Abdominal/pelvic/rectal pain
Severe Problem (Big problem)
Moderate Problem (Moderate problem)
No Problem (No problem)
Mild To Moderate Problem (Small
problem)
Mild Problem (Very small problem)
Overall, how big a problem have your bowel
habits been for you during the last 4 weeks
(Circle one number)
Severe Problem (Big problem)
Moderate Problem (Moderate problem)
No Problem (No problem)
Mild To Moderate Problem (Small
problem)
Mild Problem (Very small problem)
Quality Of Life Module
Your level of sexual desire (How would you rate
each of the following during the last 4 weeks?
Circle one number on each line)
Fair (Fair)
Good (Good)
Poor (Poor)
Very Good (Very Good)
Very Poor To None (Very Poor to None)
Your ability to have an erection
Fair (Fair)
Good (Good)
Poor (Poor)
Very Good (Very Good)
None (Very poor to None)
Your ability to reach orgasm (climax)
Fair (Fair)
Good (Good)
Poor (Poor)
Very Good (Very Good)
None (Very poor to None)
How would you describe the usual QUALITY of
your erections during the last 4 weeks (Circle one
number)
Firm Enough For Intercourse (Firm
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enough for intercourse)
Firm Enough For Masturbation And
Foreplay Only (Firm enough for
masturbation and foreplay only)
None (None at all)
Not Firm Enough For Any Sexual Activity
(Not firm enough for any sexual activity)
How would you describe the FREQUENCY of
your erections during the last 4 weeks (Circle one
number)
About Half (approximately 50%) (I had
an erection ABOUT HALF the time I
wanted one)
Less Than Half (I had an erection LESS
THAN HALF the time I wanted one)
More Than Half (I had an erection MORE
THAN HALF the time I wanted one)
Normal (I had an erection WHENEVER I
wanted one)
Never (I NEVER had an erection when I
wanted one)
How often have you awakened in the morning or
night with an erection during the last 4 weeks
(Circle one number)
About Once A Week (About once a
week)
Daily (Daily)
Less Than Once A Week (Less than
once a week)
Never (Never)
Several Times A Week (Several times a
week)
During the last 4 weeks, how often did you have
any sexual activity (Circle one number)
About Once A Week (About once a
week)
Daily (Daily)
Less Than Once A Week (Less than
once a week)
Not At All (Not at all)
Several Times A Week (Several times a
week)
During the last 4 weeks, how often did you have
sexual intercourse (Circle one number)
About Once A Week (About once a
week)
Daily (Daily)
Less Than Once A Week (Less than
once a week)
Not At All (Not at all)
Several Times A Week (Several times a
week)
Overall, how would you rate your ability to
function sexually during the last 4 weeks
Fair (Fair)
8 / 11
NCT01368588 Quality of Life - RTOG-0924 FA: Expanded Prostate
Cancer Index Composite (EPIC) Form - 3197349v1.0
Good (Good)
Poor (Poor)
Very Good (Very Good)
Very Poor (Very poor)
Your level of sexual desire (How big a problem
during the last 4 weeks, if any, has each of the
following been for you? Circle one number on
each line)
Severe Problem (Big problem)
Moderate Problem (Moderate problem)
No Problem (No problem)
Mild To Moderate Problem (Small
problem)
Mild Problem (Very small problem)
Your ability to have an erection
Severe Problem (Big problem)
Moderate Problem (Moderate problem)
No Problem (No problem)
Mild To Moderate Problem (Small
problem)
Mild Problem (Very small problem)
Your ability to reach an orgasm
Severe Problem (Big problem)
Moderate Problem (Moderate problem)
No Problem (No problem)
Mild To Moderate Problem (Small
problem)
Mild Problem (Very small problem)
Overall, how big a problem has your sexual
function or lack of sexual function been for you
during the last 4 weeks
Severe Problem (Big problem)
Moderate Problem (Moderate problem)
No Problem (No problem)
Mild To Moderate Problem (Small
problem)
Mild Problem (Very small problem)
Quality Of Life Module
Over the last 4 weeks, how often have you
experienced hot flashes (Circle one number)
Once A Day (About once a day)
About Once A Week (About once a
week)
More Than Once A Day (More than once
a day)
More Than Once A Week (More than
once a week)
Rarely (Rarely or never)
How often have you had breast tenderness
during the last 4 weeks (Circle one number)
Once A Day (About once a day)
About Once A Week (About once a
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week)
More Than Once A Day (More than once
a day)
More Than Once A Week (More than
once a week)
Rarely (Rarely or never)
During the last 4 weeks, how often have you felt
depressed (Circle one number)
Once A Day (About once a day)
About Once A Week (About once a
week)
More Than Once A Day (More than once
a day)
More Than Once A Week (More than
once a week)
Rarely (Rarely or never)
During the last 4 weeks, how often have you felt a
lack of energy (Circle one number)
Once A Day (About once a day)
About Once A Week (About once a
week)
More Than Once A Day (More than once
a day)
More Than Once A Week (More than
once a week)
Rarely (Rarely or never)
How much change in your weight have you
experienced during the last 4 weeks, if any
(Circle one number)
Gained 10 Pounds Or More (Gained 10
pounds or more)
Gained Less Than 10 Pounds (Gained
less than 10 pounds)
Lost 10 Pounds Or More (Lost 10
pounds or more)
Lost Less Than 10 Pounds (Lost less
than 10 pounds)
No Change In Weight (No change in
weight)
Hot flashes (How big a problem during the last 4
weeks, if any, has each of the following been for
you? Circle one number on each line)
Severe Problem (Big problem)
Moderate Problem (Moderate problem)
No Problem (No problem)
Mild To Moderate Problem (Small
problem)
Mild Problem (Very small problem)
Breast tenderness/enlargement
Severe Problem (Big problem)
Moderate Problem (Moderate problem)
No Problem (No problem)
Mild To Moderate Problem (Small
problem)
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Mild Problem (Very small problem)
Loss of Body Hair
Big Problem (Big problem)
Moderate Problem (Moderate problem)
No Problem (No problem)
Small Problem (Small problem)
Very Small Problem (Very small problem)
Feeling depressed
Severe Problem (Big problem)
Moderate Problem (Moderate problem)
No Problem (No problem)
Mild To Moderate Problem (Small
problem)
Mild Problem (Very small problem)
Lack of energy
Severe Problem (Big problem)
Moderate Problem (Moderate problem)
No Problem (No problem)
Mild To Moderate Problem (Small
problem)
Mild Problem (Very small problem)
Change in body weight
Severe Problem (Big problem)
Moderate Problem (Moderate problem)
No Problem (No problem)
Mild To Moderate Problem (Small
problem)
Mild Problem (Very small problem)
Overall Satisfaction
Overall, how satisfied are you with the treatment
you received for your prostate cancer (Circle one
number)
Dissatisfied (Dissatisfied)
Extremely Dissatisfied (Extremely
dissatisfied)
Extremely Satisfied (Extremely satisfied)
Satisfied (Satisfied)
Uncertain (Uncertain)
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Sarcoma, Kaposi xxx On-Study - Reported
Adverse Events Form - RF28B - 2267256v3.0
Reported Adverse Events Form - RF28B
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=CCE3B728-
C8B8-5047-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/9555
Reported Adverse Events Form -
RF28B
Ccrr Module For Reported Adverse Events
Form - Rf28b
Patient Initials
Cycle#
Study#
Site#
ID#
First Day of Cycle
Has the patient experienced an adverse event
during this cycle
Yes
No
MedDRA Code
Description
Date of onset
Date Ended
Ongoing
No (No)
Not Applicable (Not applicable)
Yes (Yes)
Grade
Relationship to Therapy
Definite (Definate)
Possible (Possible)
Probable (Probable)
Unlikely (Unlikely)
Unrelated (Unrelated)
1 / 2
Effect on Study
Protocol Treatment Was Discontinued As
A Result Of The Adverse Event
(Discontinued)
Protocol Treatment Was Delayed As A
Result Of The Adverse Event
(Interrupted)
There Was No Action Taken Based On
The Adverse Event (None)
Other Treatment Was Required As A
Result Of The Adverse Event (other
treatment required)
Study Dose Was Reduced As A Result
Of The Adverse Event (Reduced)
Indicate
Phys. Initiated (Phys. Initiated)
Pt. Initiated (Pt. Initiated)
Additional Action Taken
Yes (Hospitalization)
No (None)
OTC/non-RX (OTC/non-RX)
Prescription (Prescription)
Has an AdEERs report been filed for this adverse
event
Yes
No
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Ovarian Cancer NCT00993655 Off Treatment -
NCIC OV 21 End of Treatment Form - 2874223v1.0
NCIC OV 21 End of Treatment Form
Comparing Three Combination Chemotherapy Regimens in
Treating Patients With Stage IIB, Stage IIC, Stage III, or
Stage IV Ovarian Epithelial Cancer, Primary Peritoneal
Cancer, or Fallopian Tube Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=69B8C40D-
B831-E610-E040-BB89AD43211A
All rights reserved. Please visit https://medical-data-
models.org/forms/9558
NCIC OV 21 End of Treatment Form
Patient Information
NCIC Patient ID (NCIC CTG Patient Serial
Number issued at the time of randomization)
Patient Initials (first-middle-last)
Patient Hospital No. (if permitted by REB)
Investigator No.
Investigator First Name
Investigator Middle Name
Investigator Last Name
Off Protocol Therapy
Last date protocol therapy was given (Date off
protocol therapy is 21 days from day 1 of last
cycle yyyy-mmm-dd)
Total Number of Cycles given (of protocol
therapy)
Reason Treatment Ended (protocol permanently)
Adverse Event/side Effects/complications
(Adverse Event/Side
Effects/Complications)
Death On Study (Death on study)
Disease Progression, Relapse During
Active Treatment (Disease progression,
relapse during active treatment)
Other (Other)
Patient Off-treatment For Other
Complicating Disease (Patient off-
treatment for other complicating disease)
Patient Withdrawal Or Refusal After
Beginning Protocol Therapy (Patient
withdrawal/refusal after beginning
1 / 2
protocol therapy)
Treatment Completed Per Protocol
Criteria (Treatment completed per
protocol criteria)
Other specify
CTC Adverse Event Short Name
CTCAE Select Term (if applicable)
CTC Adverse Event Grade
CTC AE Attribution Code
Definite (Definite)
Possible (Possible)
Probable (Probable)
Unlikely (Unlikely)
Unrelated (Unrelated)
Ca 125 At The End Of Protocol Treatment
Date of CA125 (yyyy-mmm-dd)
Result of CA125 (U/ml)
Comments
Comments
Contact Information
CRA Name
Phone number
Fax Number
Institution Name
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Aids-related Malignancies NCT00695422 Toxicity -
AMC-058 Adverse Events Form (ADV) - 3072852v1.0
AMC-058 Adverse Events Form (ADV)
Detecting Anal and Genital Human Papillomavirus Infection
and Squamous Intraepithelial Lesions in HIV-Positive
Patients Enrolled in AIDS Cancer Clinical Trials
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=84C08E62-
5708-47AE-E040-BB89AD433E0F
All rights reserved. Please visit https://medical-data-
models.org/forms/9559
AMC-058 Adverse Events Form
(ADV)
Header
CTC Adverse Event Term
CTC Adverse Event Grade
Adverse Event Onset Date
Unnamed2
MedDRA Code
If other CTC event selected, please provide
description of event
Was this event expected or anticipated
Yes
No
Procedure Name (Biopsy procedure)
CTC Adverse Event Attribution Code
Definite (Definite)
Possible (Possible)
Probable (Probable)
Unlikely (Unlikely)
Unrelated (Unrelated)
Alternative etiology
Accident, Trauma, Or External Factors
(Accident, trauma, or external factors)
Concurrent Illness/condition (not Pre-
existing) (Concurrent illness/condition
(not pre-existing))
None Apparent (None apparent)
Other Pre-existing Disease Or Condition
(Other pre-existing disease or condition)
Study Disease (Study disease)
Action Taken at Time of Adverse Event
Hospitalization For Ae (Hospitalization)
Otc/non-rx (OTC/non-Rx)
Other (Other)
Prescription (Prescription)
1 / 3
Protocol Treatment Was Delayed As A
Result Of The Adverse Event (protocol
treatment delayed)
Protocol Treatment Was Discontinued As
A Result Of The Adverse Event (protocol
treatment discontinued)
Study Dose Was Reduced As A Result
Of The Adverse Event (study dose
reduced)
Other, specify
If modification was made to study therapy, who
initiated modification
Patient Initiated (Patient initiated)
Physician Initiated (Physician initiated)
Unnamed3
Outcome of Adverse Event
Adverse Event Is Resolved (Resolved)
Adverse Event Is Resolved With
Sequelae (Resolved with sequelae)
Unresolved At Protocol Completion
(Unresolved at protocol completion)
Unresolved, Protocol Ongoing
(Unresolved, protocol ongoing)
AE Resolution Date (If "Resolved" mm/dd/yyyy)
If resolved with sequelae, specify
Was this considered a Serious Adverse Event
Yes
No
Seriousness Attributed to Adverse Event (If "Yes"
check "Yes" for all that apply Please note that
checking "Yes" to any of the events below will
require SAE notification according to protocol
requirements.)
Congenital Anomaly (Congenital
anomaly)
Death (Death)
Disability (Disability/incapacity)
Hospitalized (Hospitalization, initial or
prolonged)
Life Threatening (Life threatening)
Other (Other)
Intervention Required (Required
intervention to prevent permanent
impairment/damage)
Comments
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Comments
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Anal Cancer NCT01164722 Toxicity - AMC-076
Adverse Events Form (ADV) - 3184612v1.0
AMC-076 Adverse Events Form (ADV)
Infrared Coagulator Ablation or Observation in Preventing
Anal Cancer in HIV-Positive Patients With Anal Neoplasia
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=9A357A24-
852A-31A4-E040-BB89AD4314CA
All rights reserved. Please visit https://medical-data-
models.org/forms/9560
AMC-076 Adverse Events Form
(ADV)
Header
System Organ Class (SOC)
CTC Adverse Event Term
CTC Adverse Event Grade
Adverse Event Onset Date (mm/dd/yyyy)
Unnamed2
MedDRA Code
If other CTC event selected, please provide
description of event
Was this event expected or anticipated
Yes
No
Procedure Name (Infrared coagulation IRC)
CTC Adverse Event Attribution Code
Definite (Definite)
Possible (Possible)
Probable (Probable)
Unlikely (Unlikely)
Unrelated (Unrelated)
Alternative etiology
Accident, Trauma, Or External Factors
(Accident, trauma, or external factors)
Concurrent Illness/condition (not Pre-
existing) (Concurrent illness/condition
(not pre-existing))
None Apparent (None apparent)
Other Pre-existing Disease Or Condition
(Other pre-existing disease or condition)
Study Disease (Study disease)
Action Taken at Time of Adverse Event (check
1 / 3
"Yes" for all that apply)
Hospitalization For Ae (Hospitalization)
Otc/non-rx (OTC/non-Rx)
Other (Other)
Prescription (Prescription)
Protocol Treatment Was Delayed As A
Result Of The Adverse Event (protocol
treatment delayed)
Protocol Treatment Was Discontinued As
A Result Of The Adverse Event (protocol
treatment discontinued)
Study Dose Was Reduced As A Result
Of The Adverse Event (study dose
reduced)
Other, specify
If modification was made to study therapy, who
initiated modification
Patient Initiated (Patient initiated)
Physician Initiated (Physician initiated)
Unnamed3
Outcome of Adverse Event
Adverse Event Is Resolved (Resolved)
Adverse Event Is Resolved With
Sequelae (Resolved with sequelae)
Unresolved At Protocol Completion
(Unresolved at protocol completion)
Unresolved, Protocol Ongoing
(Unresolved, protocol ongoing)
AE Resolution Date (If "Resolved" mm/dd/yyyy)
If resolved with sequelae, specify
Was this considered a Serious Adverse Event
Yes
No
Seriousness Attributed to Adverse Event (If "Yes"
check "Yes" for all that apply Please note that
checking "Yes" to any of the events below will
require SAE notification according to protocol
requirements.)
Congenital Anomaly (Congenital
anomaly)
Death (Death)
Disability (Disability/incapacity)
Hospitalized (Hospitalization, initial or
prolonged)
Life Threatening (Life threatening)
Other (Other)
Intervention Required (Required
intervention to prevent permanent
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impairment/damage)
Comments
Comments
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Lymphoma NCT00981097 Toxicity - AMC-064
Adverse Events Form (ADV) - 2983108v1.0
AMC-064 Adverse Events Form (ADV)
Study of Blood and Tissue Samples From Patients With
Aggressive Non-Hodgkin B-Cell Lymphoma or Hodgkin
Lymphoma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=7C9955D9-
C2B3-BD2D-E040-BB89AD431FA0
All rights reserved. Please visit https://medical-data-
models.org/forms/9561
AMC-064 Adverse Events Form
(ADV)
Header
CTC Adverse Event Term
CTC Adverse Event Grade
Adverse Event Onset Date
Unnamed2
MedDRA Code
If other CTC event selected, please provide
description of event
Was this event expected or anticipated
Yes
No
Procedure Name (Biopsy procedure
Venipuncture)
CTC Adverse Event Attribution Code
Definite (Definite)
Possible (Possible)
Probable (Probable)
Unlikely (Unlikely)
Unrelated (Unrelated)
Alternative etiology
Accident, Trauma, Or External Factors
(Accident, trauma, or external factors)
Concurrent Illness/condition (not Pre-
existing) (Concurrent illness/condition
(not pre-existing))
None Apparent (None apparent)
Other Pre-existing Disease Or Condition
(Other pre-existing disease or condition)
Study Disease (Study disease)
Action Taken at Time of Adverse Event
Hospitalization For Ae (Hospitalization)
Otc/non-rx (OTC/non-Rx)
Other (Other)
1 / 3
Prescription (Prescription)
Protocol Treatment Was Delayed As A
Result Of The Adverse Event (protocol
treatment delayed)
Protocol Treatment Was Discontinued As
A Result Of The Adverse Event (protocol
treatment discontinued)
Study Dose Was Reduced As A Result
Of The Adverse Event (study dose
reduced)
Other, specify
If modification was made to study therapy, who
initiated modification
Patient Initiated (Patient initiated)
Physician Initiated (Physician initiated)
Unnamed3
Outcome of Adverse Event
Adverse Event Is Resolved (Resolved)
Adverse Event Is Resolved With
Sequelae (Resolved with sequelae)
Unresolved At Protocol Completion
(Unresolved at protocol completion)
Unresolved, Protocol Ongoing
(Unresolved, protocol ongoing)
AE Resolution Date (If "Resolved" mm/dd/yyyy)
If resolved with sequelae, specify
Was this considered a Serious Adverse Event
Yes
No
Seriousness Attributed to Adverse Event (If "Yes"
check "Yes" for all that apply Please note that
checking "Yes" to any of the events below will
require SAE notification according to protocol
requirements. Was required intervention
performed to prevent any of the above
conditions? Is this SAE considered an SAE for
another reason?)
Congenital Anomaly (Congenital
anomaly)
Death (Death)
Disability (Disability/incapacity)
Hospitalized (Hospitalization, initial or
prolonged)
Life Threatening (Life threatening)
Other (Other)
Intervention Required (Required
intervention to prevent permanent
impairment/damage)
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Comments
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Ovarian Cancer NCT00993655 Follow-Up - NCIC
OV 21 Follow-Up Report Form - 2874229v1.0
NCIC OV 21 Follow-Up Report Form
Comparing Three Combination Chemotherapy Regimens in
Treating Patients With Stage IIB, Stage IIC, Stage III, or
Stage IV Ovarian Epithelial Cancer, Primary Peritoneal
Cancer, or Fallopian Tube Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=69B8C40D-
B83D-E610-E040-BB89AD43211A
All rights reserved. Please visit https://medical-data-
models.org/forms/9562
NCIC OV 21 Follow-Up Report Form
Patient Information
NCIC Patient ID (NCIC CTG Patient Serial
Number issued at the time of randomization)
Patient Initials (first-middle-last)
Patient Hospital No. (if permitted by REB)
Investigator No.
Investigator First Name
Investigator Middle Name
Investigator Last Name
Timing Of Report
Month of report (Off-treatment)
12 (12)
15 (15)
18 (18)
21 (21)
24 (24)
3 (3)
30 (30)
36 (36)
42 (42)
48 (48)
6 (6)
60 (60)
72 (72)
9 (9)
Other Month (OTHER)
Other specify
Physical Exam
Weight (kg)
1 / 6
Performance Status (ECOG)
Fully Active, Able To Carry On All Pre-
disease Performance Without
Restriction. (0)
Restricted In Physically Strenuous
Activity But Ambulatory And Able To
Carry Out Work Of A Light Or Sedentary
Nature, E.g., Light Housework, Office
Work. (1)
Ambulatory And Capable Of All Selfcare
But Unable To Carry Out Any Work
Activities. Up And About More Than 50%
Of Waking Hours. (2)
Capable Of Only Limited Selfcare,
Confined To Bed Or Chair More Than
50% Of Waking Hours. (3)
Completely Disabled. Cannot Carry On
Any Selfcare. Totally Confined To Bed Or
Chair. (4)
Date
Response Assessment - Question 2
Were disease assessment results obtained this
report period?
Yes
No
Reason evaluation not done
Institution Error (Institution error)
Not Required Per Protocol (Not required
per protocol)
Other (Other)
Patient Noncompliance (Patient
noncompliance)
Specify
Target Lesions
Did the patient have any target lesions by
imaging or clinical exam on post-op baseline
report
Yes
No
Target Lesion Site (e.g. pelvis)
Method of Evaluation
Other Specify
Date
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Dimension 1 (End of Reporting Period
Measurements)
Dimension 2 (End of Reporting Period
Measurements)
Sum of Longest Diameters of All Target Lesions
Non- Target Lesions During Treatment
Were there any non-target lesions reported at
baseline
Yes
No
Nontarget Lesion Site (e.g. pelvis)
Method of Evaluation
Other Specify
Date
Follow-up status of nontarget lesion (End of
Reporting Period )
Absent (Absent)
Increase (Increase)
Increased To Pd (Increased to PD)
Present-no Change (Present-no change)
Unevaluable (Unevaluable)
New Lesions
Was the appearance of any new lesions
documented (since baseline i.e. previously or
current reporting periods Note: New Lesions
constitute objective disease progression)
Yes
No
New Lesion Site (e.g. pelvis)
Method of Evaluation
Other Specify
Date
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Other Radiology
Date
Ca 125 - Table
Date of CA125
CA125
Lab ID (Upper Normal Limit)
Adverse Events / Intercurrent Illness
Were there any study-specific adverse events
during this report period (ONGOING or NEW
relations 3, 4 or 5)
Yes
No
Not Assessed
CTC Adverse Event Short Name
CTC Select AE
CTC AE Attribution Code
Definite (Definite)
Possible (Possible)
Probable (Probable)
Unlikely (Unlikely)
Unrelated (Unrelated)
Seriousness Attributed to Adverse Event
Congenital Anomaly (Congenital
anomaly)
Death (Death)
Disability (Disability/incapacity)
Hospitalized (Hospitalization, initial or
prolonged)
Life Threatening (Life threatening)
Not Serious (Not serious)
Other (Other)
Anti-cancer Treatment
Non-Protocol Therapy Type
Chemotherapy (Chemotherapy)
Hormonal Therapy (Hormonal Therapy)
Immunotherapy (Immunotherapy)
Other Specify (Other)
Radiation Therapy (Radiation therapy)
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Other, specify
Name of non-protocol cancer therapy (eg. 2nd
look surgery, tamoxifen)
Ongoing from previous reporting period
Yes
No
Treatment Start Date (yyyy-mmm-dd)
Continuing at end of this reporting period
Yes
No
Treatment Stop Date (yyyy-mmm-dd)
Quality Of Life Questionnaire
Was QoL Questionnaire completed?
Yes
No
Date Questionnaire Completed
Specify the reason the questionnaire was not
completed
Other Reason (Other reason)
Patient Could Not Be Contacted (Patient
could not be contacted)
Patient Did Not Keep Appointment
(Patient did not keep appointment)
Patient Kept Appointment For
Examination, But Could Not Complete
Questionnaire Due To Illness (Patient
kept appointment for examination, but
could not complete questionnaire due to
illness)
Patient Kept Appointment For
Examination, But Refused To Complete
Questionnaire For Reasons Other Than
Illness (Patient kept appointment for
examination, but refused to complete
questionnaire for reasons other)
Test Omitted Due To
Institution/investigator Error
(Questionnaire not administered due to
institutional error)
Specify other reason
Comments
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Comments
Contact Information
CRA Name
Phone number
Fax Number
Institution Name
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NCT00956007 Quality of Life - RTOG 0920 Phase III Head and Neck Cancer
Health Utility Measurement Euro QOL (EQ-5D) Form (HP) - 2811233v1.0
RTOG 0920 Phase III Head and Neck Cancer Health Utility
Measurement Euro QOL (EQ-5D) Form (HP)
Radiation Therapy With or Without Cetuximab in Treating
Patients Who Have Undergone Surgery for Locally
Advanced Head and Neck Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=5D3C3F4A-
8C30-21E8-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/9565
RTOG 0920 Phase III Head and
Neck Cancer Health Utility
Measurement Euro QOL (EQ-5D)
Form (HP)
Unnamed Module 1
RTOG Study No.
Case #
Institution Name
Institution No.
Patient Initials
RTOG Patient ID
Amended data (The EQ-5D questionnaire should
be completed by the patient with or without
assistance)
Yes
No
Unamed Module 2
Time point
1 Year From Start Of Treatment (1 year
from start of treatment)
3 Months From Start Of Treatment (3
months from start of treatment)
Baseline (baseline)
Was patient questionnaire completed
Yes
No
Date patient questionnaire completed
Reason Questionnaire was not Completed
Institution Error (Institutional error)
Not Applicable, Questionnaire Was
Completed (Not applicable,
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questionnaire was completed)
Other Reason (Other reason)
Patient Refused Due To Illness (Patient
refused due to illness)
Patient Refused For Other Reason
(Patient refused for other reason)
Patient Unable To Be Contacted (Patient
unable to be contacted)
Tool Not Availalble In Patient's Language
(Tool not available in patient's language)
Unknown (Unknown)
Patient refused for other reason, specify
Other reason, specify
Specify method of completion
At Appointment (At appointment)
By Mail (By mail)
By Telephone (By telephone)
Not Applicable (Not applicable)
Unknown (Unknown)
Did the patient require any assistance in
completing the questionnaire?
No (No)
Not Applicable (Not applicable)
Unknown If Assistance Given (Unknown
if assistance given)
Yes (Yes)
Specify the person who assisted the patient
Family (Family)
Not Applicable (Not applicable)
Other (Other)
Staff Member (Staff member)
Unknown (Unknown)
Other, specify
Extent of assistance given
Combination Of Above (Combination of
above)
Interpreted Items For Patient (Interpreted
items for patient)
Marked Items Per Patient's Response
(Marked items per patient's response)
Not Applicable (Not applicable)
Other (Other)
Read Items To Patient (Read items to
patient)
Combination of above, specify
Other, specify
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Health Utility Measurement Euro QOL (EQ-5D) Form (HP) - 2811233v1.0
Signature of Person Completing This Form
Date Form Completed (MM DD YYYY)
Unamed Module 2
Mobility
I Am Confined To Bed (I am confined to
bed)
I Have No Problems In Walking About (I
have no problems in walking about)
I Have Some Problems In Walking About
(I have some problems in walking about)
Self care
I Am Unable To Wash Or Dress Myself (I
am unable to wash or dress myself)
I Have No Problems With Self Care (I
have no problems with self care)
I Have Some Problems Washing Or
Dressing Myself (I have some problems
washing or dressing myself)
Usual activities (e.g. work, study, housework,
family, or leisure activities)
I Am Unable To Perform My Usual
Activities (I am unable to perform my
usual activities)
I Have No Problems With Performing My
Usual Activities (I have no problems with
performing my usual activities)
I Have Some Problems With Performing
My Usual Activities (I have some
problems with performing my usual
activities)
Pain/discomfort
I Have Extreme Pain Or Discomfort (I
have extreme pain or discomfort)
I Have Moderate Pain Or Discomfort (I
have moderate pain or discomfort)
I Have No Pain Or Discomfort (I have no
pain or discomfort)
Anxiety/depression (We would like you to indicate
on this scale how good or bad your own health is
today, in your opinion. Please do this by drawing
a line from the box below to whichever point on
the scale indicates how good or bad your health
state is today.)
I Am Extremely Anxious Or Depressed (I
am extremely anxious or depressed)
I Am Moderately Anxious Or Depressed
(I am moderately anxious or depressed)
I Am Not Anxious Or Depressed (I am
not anxious or depressed)
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Unnamed Module 3
Your own health state today
Have you experienced serious illness in yourself?
(PLEASE CHECK APPROPRIATE BOXES)
Yes
No
Have you experienced serious illness in your
family? (PLEASE CHECK APPROPRIATE
BOXES)
Yes
No
Have you experienced serious illness in caring for
others? (PLEASE CHECK APPROPRIATE
BOXES)
Yes
No
What is your age in years?
Are you (PLEASE CHECK APPROPRIATE
BOXES)
Female Gender (FEMALE)
Male Gender (MALE)
Are you a current smoker  (PLEASE CHECK
APPROPRIATE BOXES)
Yes
No
Are you an ex-smoker (PLEASE CHECK
APPROPRIATE BOXES)
Yes
No
Are you a never smoker (PLEASE CHECK
APPROPRIATE BOXES)
Yes
No
Do you now, or did you ever, work in health or
social services? (PLEASE CHECK
APPROPRIATE BOXES)
Yes
No
If so, in what capacity?
WHICH OF THE FOLLOWING BEST
DESCRIBES YOUR MAIN ACTIVITY? (PLEASE
CHECK APPROPRIATE BOXES)
Employed (Employed)
Keeping House (Keeping house)
Other (Other)
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Retired (Retired)
Unemployed (Seeking work)
Student (Student)
Other
Highest school grade completed
College Degree (College degree)
High School Graduate Or Ged (High
school graduate or GED)
Professional Or Graduate Degree
(Professional or graduate degree)
Some High School Or Less (Some high
school or less)
Vocational College Or Some College
(Vocational college or some college)
If you know your zipcode, please write it here
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Neuroblastoma NCT00053326 Transmittal - Immunocytology
Specimen Shipping Form [ANBL0321] - 2174356v3.0
Immunocytology Specimen Shipping Form [ANBL0321]
Fenretinide in Treating Children With Recurrent or
Resistant Neuroblastoma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=C427B2DA-
BD65-633A-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/9566
Immunocytology Specimen Shipping
Form [ANBL0321]
Header
Institution Name
COG Study Number
COG Study Number
COG Number
Date form originally completed
Date worksheet entered into RDE
Patient Initials
Patient Name
Patient Information
Medical Record Number
Institution Name
Accession Number
TYPE OF SPECIMEN
Bone Marrow (BONE MARROW)
COG Number
Date specimen obtained
Time specimen obtained
Timepoint specimen obtained
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At the end of each course (1 - 30) (At the
end of each course (1 - 30))
Death (Death)
Diagnosis Of Primary (Diagnosis of
primary)
Second Malignancy (Diagnosis of
second malignancy)
After Study Entry (On study)
Other Specify (Other, specify)
Sample Or Specimen Collected After
Patient Received Treatment For Cancer
(Post completion of protocol therapy)
Sample Or Specimen Collected Before
Patient Was Diagnosed With Cancer
(Pre-diagnosis)
Sample Or Specimen Collected Before
Patient Received Treatment For Cancer
(Pre-treatment)
Progression Or Relapse
(Progression/Relapse)
Second-look Surgery (Second-look
surgery)
At the end of each course (1 - 30)
Specimen is being shipped to
Seeger Lab (Seeger Lab)
Carrier
Account Number
Carrier Tracking Number
Date Shipped
Estimated date and time of arrival
Treating Physician Phone
Treating Physician FAX
Treating Physician Email
Other Physician Phone
Other Physician FAX
Other Physician Email
Contact Person Phone
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Contact Person FAX
Contact Person Email
Address [Institution]
Ccrr Module For Immunocytology
Specimen Shipping Form [anbl0321]
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Brain and Central Nervous System Tumors NCT00884741 On-Study -
RTOG 0825: QOL M.D. Anderson Symptom Inventory - 2800871v1.0
RTOG 0825: QOL M.D. Anderson Symptom Inventory
Temozolomide and Radiation Therapy With or Without
Bevacizumab in Treating Patients With Newly Diagnosed
Glioblastoma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=5BABD9A9-
3DF8-0152-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/9567
RTOG 0825: QOL M.D. Anderson
Symptom Inventory
Unnamed Module 1
RTOG Study No.
Case #
Institution Name
Institution No.
Patient Initials
RTOG Patient ID
Amended Data
Yes
No
Unamed Module 2
Time point of this assessment (please check box
that applies to this assessment)
Other Followup (Other follow-ups)
Registration (Registration)
Week 10 (Week 10)
Week 22 (Week 22)
Week 34 (Week 34)
Week 46 (Week 46)
Week 6 (week 6)
Week 46 (Week 62)
Was patient questionnaire completed
Yes
No
Date Questionnaire Completed (MM DD YYYY)
Reason Questionnaire was not Completed
Other Reason (Other reason)
Patient Refused Due To Illness (Patient
refused due to illness)
Patient Refused For Other Reason
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(Patient refused for other reason)
Patient Unable To Be Contacted (Patient
unable to be contacted)
Questionnaire Not Completed Due To
Institutional Error (Questionnaire not
completed due to institutional error)
Tool Not Availalble In Patient's Language
(Tool not available in patient's language)
Unknown (Unknown)
Patient refused for other reason, specify
Other reason, specify
Specify method of completion
At Appointment (At appointment)
By Mail (By mail)
By Telephone (By telephone)
Unknown (Unknown)
Did the patient require any assistance in
completing the questionnaire?
No (No)
Unknown If Assistance Given (Unknown
if assistance given)
Yes (Yes)
Specify the person who assisted the patient
Family (Family)
Other (Other)
Staff Member (Staff member)
Unknown (Unknown)
Other, specify
Extent of assistance given
Combination Of Above (Combination of
above)
Marked Items Per Patient's Response
(Marked items per patient's response)
Read Items To Patient (Read items to
patient)
Unknown (Unknown)
Combination of above, specify
Comments
Signature of Person Completing This Form
Form Completion Date, Original (MM DD YYYY)
M.d. Anderson Symptom Inventory
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Brain and Central Nervous System Tumors NCT00884741 On-Study -
RTOG 0825: QOL M.D. Anderson Symptom Inventory - 2800871v1.0
(mdasi-bt)
Your pain at its worst
Your fatigue at its worst
Your nausea at its worst
Your disturbed sleep at its worst
Your feeling of being distressed at its worst
Your shortness of breath at its worst
Your problem with remembering things at its
worst
Your problem with lack of appetite at its worst
Your feeling drowsy at its worst
Your having a dry mouth at its worst
Your feeling sad at its worst
Your vomiting at its worst
Your numbness or tingling at its worst
Your weakness on one side of body at its worst
Your difficulty understanding at its worst
Your difficulty speaking at its worst
Your seizures at its worst
Your difficulty concentrating at its worst
Your vision at its worst
Your change in appearance at its worst
Your change in bowel pattern at its worst
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Your irritability at its worst
Part Ii
General activity
Mood
Work
Relations with other people
Walking
Enjoyment of life
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Cervical Cancer NCT00262821 Pathology -
Pathology Form, Form F, GOG-0219 - 2302165v3.0
Pathology Form, Form F, GOG-0219
Cisplatin and Radiation Therapy With or Without
Tirapazamine in Treating Patients With Cervical Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=EF8A6794-
4194-0A02-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/9570
Pathology Form, Form F, GOG-0219
Header Module
Date form originally completed (m d y)
Date form amended (m d y)
Person amending form, last name
Patient Initials (First, Middle, Last)
Patient Study ID
Person Completing Form, Last Name
Primary Disease Assessment
Primary site
Cervix (Cervix)
Endometrium (Endometrium)
Fallopian Tube (Fallopian tube)
Gestational Trophoblastic Disease (GTD)
Other, Specify (Other specify)
Ovary (Ovary)
Peritoneum (Peritoneum)
Uterine Sarcoma (Uterine sarcoma)
Vagina (Vagina)
Vulva (Vulva)
Other specify
Histologic type (check one)
Adenocarcinoma With Squamous
Differentiation (Adenocarcinoma with
squamous differentiation)
Adenocarcinoma, Unspecified
(Adenocarcinoma, unspecified)
Adenosquamous (Adenosquamous
carcinoma)
Benign (Benign NOS)
Carcinosarcoma/mesodermal (mullerian)
Mixed Tumor (Carcinosarcoma MMT)
Clear Cell Carcinoma (Clear cell
carcinoma)
Dysgerminoma (Dysgerminoma)
Endodermal Sinus Tumor (yolk Sac
1 / 4
Tumor) (Endodermal sinus tumor)
Endometrial Stromal Sarcoma
(Endometrial stromal sarcoma)
Endometrioid Adenocarcinoma
(Endometrioid adenocarcinoma)
Fibroma (Fibroma)
Germ Cell Tumor, Mixed (Germ cell
tumor, mixed)
Granulosa Cell Tumor (Granulosa cell
tumor)
Leiomyosarcoma (Leiomyosarcoma)
Mixed Epithelial Carcinoma, Specify
Components (Mixed epithelial
carcinoma)
Mucinous Adenocarcinoma (Mucinous
adenocarcinoma)
Mucinous Cystadenoma (benign)
(Mucinous cystadenoma (benign))
Mucinous Tumor Of Low Malignant
Potential (Mucinous tumor of LMP)
Normal Tissue (Normal tissue)
Other, Specify (Other specify)
Serous Adenocarcinoma (Serous
adenocarcinoma)
Serous Cystadenoma (benign) (Serous
cystadenoma (benign))
Serous Tumor Of Low Malignant
Potential (Serous tumor of LMP)
Sex-cord/stromal, Unclassified (Sex
cord/stromal, unclassified)
Small Cell Carcinoma (Small cell
carcinoma)
Squamous Cell Carcinoma (Squamous
cell carcinoma invasive)
Teratoma, Immature, Specify
Components (Teratoma, immature)
Teratoma, Mature (Teratoma, mature)
Transitional Cell Carcinoma, Including
Brenner Tumor (Transitional cell
carcinoma (including Brenner))
Undifferentiated Carcinoma
(Undifferentiated carcinoma)
Villoglandular Carcinoma (Villoglandular
carcinoma)
Other specify
Histologic grade (Differentiation)
Grade 1-well Differentiated (1)
Grade 2-moderately Differentiated (2)
Grade 3-poorly Differentiated (3)
Indeterminate (Indeterminate)
Not Applicable (Not applicable)
Grade Unknown (Unknown)
Method of evaluation
Biopsy (Biopsy)
Cytology (Cytology)
Other (Other specify)
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GOG-0219 - 2302165v3.0
Surgery (Surgery)
Other specify
Date of evaluation (m d y)
Specimen ID (of the blocks/slides)
Specimen site
Bladder Peritoneum (Bladder
peritoneum)
Bowel Peritoneum/serosa (Bowel
peritoneum/serosa)
Cervix (Cervix)
Corpus (Corpus)
Cul-de-sac (Cul-de-sac)
Diaphragm (Diaphragm)
Endometrium (Endometrium)
Fallopian Tube (Fallopian tube)
Lymph Node(s) (Lymph node(s))
Metastatic Site (Metastatic site)
Omentum (Omentum)
Other (Other)
Ovary (Ovary)
Paracolic Gutter Left (Paracolic gutter
left)
Paracolic Gutter Right (Paracolic gutter
right)
Pelvic Wall Left (Pelvic wall left)
Pelvic Wall Right (Pelvic wall right)
Peritoneum/uterine Serosa
(Peritoneum/uterine serosa)
Lymph nodes specify
Metastatic site specify
Other specify
Secondary Disease Assessment
Disease Status
Disease Continues To Be Present
Following Initial Treatment (Persistent)
Progression (Progression)
Recurrence/relapse (Recurrence)
Method of evaluation
Biopsy (Biopsy)
Cytology (Cytology)
Other (Other specify)
Surgery (Surgery)
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Other specify
Date of evaluation (m d y)
Specimen ID (of the blocks/slides)
Specimen site
Bladder Peritoneum (Bladder
peritoneum)
Bowel Peritoneum/serosa (Bowel
peritoneum/serosa)
Cervix (Cervix)
Corpus (Corpus)
Cul-de-sac (Cul-de-sac)
Diaphragm (Diaphragm)
Endometrium (Endometrium)
Fallopian Tube (Fallopian tube)
Lymph Node(s) (Lymph node(s))
Metastatic Site (Metastatic site)
Omentum (Omentum)
Other (Other)
Ovary (Ovary)
Paracolic Gutter Left (Paracolic gutter
left)
Paracolic Gutter Right (Paracolic gutter
right)
Pelvic Wall Left (Pelvic wall left)
Pelvic Wall Right (Pelvic wall right)
Peritoneum/uterine Serosa
(Peritoneum/uterine serosa)
Lymph nodes specify
Metastatic site specify
Other specify
Footer Module
Participating Group Code
Participating Group Protocol Number
Participating Group Patient ID
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Bladder Cancer NCT00445601 Toxicity - S0337
Adverse Event Summary Form - 2389159v1.0
S0337 Adverse Event Summary Form
Gemcitabine After Surgery in Treating Patients With Newly
Diagnosed or Recurrent Bladder Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=FE262249-
B6AB-4D54-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/9571
S0337 Adverse Event Summary
Form
Header
SWOG Patient ID
SWOG Study No.
Registration Step
Patient Initials (L, F M)
Institution/Affiliate
Physician
Participating Group Name
Participating Group Study No.
Participating Group Patient ID
Adverse Events
Reporting Period Start Date (Day 1 of this cycle)
Last Date of Adverse Event Assessment (Day
one of next cycle. If final cycle, date of first visit or
contact after resolution of acute adverse events.)
Were adverse events assessed during this report
period
No (No)
Yes, And Reportable Adverse Events
Occurred (Yes, and reportable adverse
events occurred)
Yes, But No Reportable Adverse Events
Occurred (Yes, but no reportable adverse
events occurred)
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CTC Adverse Event Term
Bladder Disorder Nos (Bladder spasms)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Bladder (urinary))
Neutropenia (Neutrophils/granulocytes
(ANC/AGC))
Pain (Pain - Bladder)
Perforation, Gu (Perforation, GU -
Bladder)
Platelet Count Decreased (Platelets)
Urinary Frequency (Urinary
frequency/urgency)
Urinary Retention (Urinary retention
(including neurogenic bladder))
Urine Discolouration (Urine color
change)
CTC AE Grade (3.0 1-5)
CTC Adverse Event Attribution Code (*
Attribution codes: 1-unrelated 2-unlikely 3-
possible 4-probably 5-definite)
Definite (Definite)
Possible (Possible)
Probable (Probable)
Unlikely (Unlikely)
Unrelated (Unrelated)
CTC Adverse Event Term Other (specify using
CTCAE 3.0 terminology)
Comments
Comments
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Bladder Cancer NCT00445601 Toxicity - S0337 Adverse Event Summary
Form - 2389159v1.0
Bladder Cancer NCT01224665 Toxicity - S1011
Adverse Event Form (#10184) - 3244012v1.0
S1011 Adverse Event Form (#10184)
Standard or Extended Pelvic Lymphadenectomy in Treating
Patients Undergoing Surgery for Invasive Bladder Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=A5B1CE1B-
FD09-92A4-E040-BB89AD432AC8
All rights reserved. Please visit https://medical-data-
models.org/forms/9573
S1011 Adverse Event Form
(#10184)
Header
SWOG Patient ID
SWOG Study No.
Registration Step
Patient Initials (L, F M)
Reporting Period (see instructions)
Institution/Affiliate
Physician
Participating Group Name
Participating Group Study No.
Participating Group Patient ID
Adverse Events
Reporting Period Start Date (MM DD YYYY For
first reporting period, these dates should be the
date of surgery and the date of hospital
discharge, respectively. For second reporting
period, these dates should be the date of hospital
discharge and 90 days post surgery.)
Reporting Period End Date (MM DD YYYY For
first reporting period, these dates should be the
date of surgery and the date of hospital
discharge, respectively. For second reporting
period, these dates should be the date of hospital
discharge and 90 days post surgery.)
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Were adverse events assessed during this time
period?
No (No)
Yes, And Reportable Adverse Events
Occurred (Yes, and reportable adverse
events occurred)
Yes, But No Reportable Adverse Events
Occurred (Yes, but no reportable adverse
events occurred)
Date of Most Recent Adverse Event Assessment
(MM DD YYYY)
CTC Adverse Event Term
Acute Kidney Injury (Acute kidney injury)
Cardiac Arrest (Cardiac arrest)
Colonic Obstruction (Colonic obstruction)
Gastroesophageal Reflux Disease
(Gastroesophageal reflux disease)
Ileal Obstruction (Ileal obstruction)
Intra-abdominal Hemorrhage (Intra-
abdominal hemorrhage)
Intraoperative Cardiac Injury
(Intraoperative cardiac injury)
Lymph Leakage (Lymph leakage)
Lymphocele (Lymphocele)
Myocardial Infarction (Myocardial
infarction)
Postoperative Thoracic Procedure
Complication (Postoperative thoracic
procedure complication)
Rectal Obstruction (Rectal obstruction)
Sepsis (Sepsis)
Surgical And Medical Procedures -
Other, Specify (Surgical and medical
procedures - Other, Specify)
Thromboembolic Event
(Thromboembolic event)
Urinary Tract Infection (Urinary tract
infection)
Wound Complication (Wound
complication)
Wound Infection (Wound infection)
CTC Adverse Event Term Other (specify using
CTCAE 4.0 terminology)
CTC AE Grade (4.0 1-5)
Mild Adverse Event (1)
Moderate Adverse Event (2)
Severe Adverse Event (3)
Life Threatening Adverse Event (4)
Death Related To Adverse Event (5)
CTC Adverse Event Attribution Code
Definite (Definite)
Possible (Possible)
Probable (Probable)
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Unlikely (Unlikely)
Unrelated (Unrelated)
Hospitalization (at least 24 hours)
Comments
Comments
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Breast Cancer NCT00068601 Toxicity - Southwest Oncology
Group Adverse Event Form (S0230) - 2170566v3.0
Southwest Oncology Group Adverse Event Form (S0230)
Goserelin in Preventing Ovarian Failure in Women
Receiving Chemotherapy for Breast Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=BEA4BC29-
7B1B-03E5-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/9574
Southwest Oncology Group Adverse
Event Form (S0230)
Toxicity
Reporting period start date
Were adverse events assessed during this time
period?
Yes
No
Date of most recent adverse event assessment
CTC Adverse Event Term
Anxiety Nec (Anxiety/agitation)
Depression Nec (Depression)
Headache Nos (Headache)
Menopausal Symptoms (Hot flashes)
Libido Decreased (Libido loss)
Sweating Increased (Sweating)
Vulvovaginal Dryness (Vaginal dryness)
CTC Adverse Event Grade
CTC Adverse Event Attribution Code
Definite (definite)
Possible (possible)
Probable (probable)
Unlikely (unlikely)
Unrelated (unrelated)
Has the patient experienced bone mineral loss?
No (No)
Unknown (Unknown)
Yes, Specify Grade (Yes, specify Grade)
Yes, specify Grade
Ccrr Module For Southwest Oncology
Group Adverse Event Form (s0230)
SWOG Patient ID
Patient Initials (L, F, M)
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Insitution/Affiliate
Physician
Group Name/Study No./Pt. ID
Study No.
Pt. ID
Weight (kg)
Date of Last Menses
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Breast Cancer NCT00068601 Toxicity - Southwest Oncology Group
Adverse Event Form (S0230) - 2170566v3.0
Breast Cancer NCT00103233 Toxicity - SOUTHWEST ONCOLOGY
GROUP S0347 ADVERSE EVENT FORM - 2291400v3.0
SOUTHWEST ONCOLOGY GROUP S0347 ADVERSE
EVENT FORM
Vinorelbine With or Without Trastuzumab in Treating
Women With Progressive Metastatic Breast Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=E1F2198E-
7C5B-3F6A-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/9575
SOUTHWEST ONCOLOGY GROUP
S0347 ADVERSE EVENT FORM
Header
SWOG Patient ID
SWOG Study No.
Registration Step
Cycle Number (see instructions)
Patient Initials
Institution/Affiliate
Physician
Participating Group Name (Participating Group)
Participating Study No.
Participating Patient ID
Adverse Events
Reporting period start date (Day 1 of this Cycle)
Reporting period end date (Day one of next cycle.
If final cycle, date of first visit or contact after
resolution of acute adverse events.)
Were adverse events assessed during this time
period?
No (No)
Yes, And Reportable Adverse Events
Occurred (Yes, and reportable adverse
events occurred)
Yes, But No Reportable Adverse Events
Occurred (Yes, but no reportable adverse
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events occurred)
CTC Adverse Event Term
Hypersensitivity Nos (Allergic
reaction/hypersensitivity)
Constipation (Constipation)
Cough (Cough)
Diarrhoea Nos (Diarrhea)
Dizziness (exc Vertigo) (Dizziness)
Dyspnoea Nos (Dyspnea)
Oedema Nos (Edema: limb)
Fatigue (Fatigue)
Pyrexia (Fever)
Hypotension Nos (Hypotension)
Injection Site Reaction Nos (Injection site
reaction/extravasation changes)
Insomnia Nec (Insomnia)
Left Ventricular Diastolic Dysfunction
(Left ventricular diastolic dysfunction)
Left Ventricular Failure (Left ventricular
systolic dysfunction)
Leucopenia Nos (Leukocytes)
Muscle Weakness Nos (Muscle
weakness, generalized or specific area -
whole body/generalized)
Nausea (Nausea)
Peripheral Motor Neuropathy
(Neuropathy - motor)
Peripheral Sensory Neuropathy
(Neuropathy - sensory)
Neutropenia (Neutrophils/granulocytes)
Chest Pain (Pain - Chest/thorax NOS)
Headache Nos (Pain - Head/headache)
Tumour Pain (Pain - Tumor pain)
Platelet Count Decreased (Platelets)
Pleural Effusion (Pleural effusion (non-
malignant))
Pneumonitis Nos
(Pneumonitis/pulmonary infiltrates)
Dermatitis Exfoliative Nos
(Rash/desquamation)
Rigors (Rigors/chills)
Vomiting Nos (Vomiting)
Adverse Event Status Code (**)
Continues At Same Or Lower Grade
(continues at same or lower grade)
Increased Grade Or Improved Then
Worsened (increased grade OR
improved then worsened)
New (new)
Adverse Event Status Code (**)
Continues At Same Or Lower Grade
(continues at same or lower grade)
Increased Grade Or Improved Then
Worsened (increased grade OR
improved then worsened)
New (new)
2 / 3
Breast Cancer NCT00103233 Toxicity - SOUTHWEST ONCOLOGY
GROUP S0347 ADVERSE EVENT FORM - 2291400v3.0
CTC Adverse Event Term, Other (specify using
CTCAE 3.0 terminology)
CTCAE (3.0) Grade (1 - 5)
CTCAE (3.0) Grade (1 - 5)
CTC Adverse Event Attribution Code
Definite (definite)
Possible (possible)
Probable (probable)
Unlikely (unlikely)
Unrelated (unrelated)
CTC Adverse Event Attribution Code
Definite (definite)
Possible (possible)
Probable (probable)
Unlikely (unlikely)
Unrelated (unrelated)
Comments
Comments
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Breast Cancer NCT01272037 Toxicity - S1007
Adverse Event Summary Form - 3140849v1.0
S1007 Adverse Event Summary Form
Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane
With or Without Chemotherapy in Treating Patients With
Invasive RxPONDER Breast Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=90DA93B9-
537E-5D33-E040-BB89AD434FA6
All rights reserved. Please visit https://medical-data-
models.org/forms/9577
S1007 Adverse Event Summary
Form
Header
SWOG Patient ID
SWOG Study No.
Registration Step
Patient Initials (L, F M)
Reporting Period
0-6 Months (0-6 months)
24 Months (24 months)
36 Months (36 months)
6 Mo-1 Yr (6 mo-1 yr)
Institution/Affiliate
Physician
Participating Group Name
Participating Group Study No.
Participating Group Patient ID
Adverse Events
Reporting Period Start Date (MM DD YYYY Day
1 of this reporting period)
Reporting Period End Date (MM DD YYYY Day
one of next reporting period. If final reporting
period, date of first visit or contact after resolution
of acute adverse events.)
Were adverse events assessed during this time
period?
No (No)
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Yes, And Reportable Adverse Events
Occurred (Yes, and reportable adverse
events occurred)
Yes, But No Reportable Adverse Events
Occurred (Yes, but no reportable adverse
events occurred)
CTC Adverse Event Term
Abdominal Pain (Abdominal pain)
Allergic Reaction (Allergic reaction)
Anemia (Anemia)
Anorexia (Anorexia)
Arthralgia (Arthralgia)
Aspartate Aminotransferase Increased
(Aspartate aminotransferase increased)
Ataxia (Ataxia)
Atrial Fibrillation (Atrial fibrillation)
Blood Bilirubin Increased (Blood bilirubin
increased)
Blurred Vision (Blurred vision)
Bone Pain (Bone pain)
Cardiac Troponin T Increased (Cardiac
troponin T increased)
Chills (Chills)
Constipation (Constipation)
Diarrhea (Diarrhea)
Dry Mouth (Dry mouth)
Dysgeusia (Dysgeusia)
Dyspareunia (Dyspareunia)
Dysphagia (Dysphagia)
Dyspnea (Dyspnea)
Esophagitis (Esophagitis)
Fatigue (Fatigue)
Febrile Neutropenia (Febrile
neutropenia)
Fever (Fever)
Fracture (Fracture)
General Disorders And Administration
Site Conditions - Other, Specify (General
disorders and administration site
conditions - Other, Specify)
Heart Failure (Heart failure)
Hot Flashes (Hot flashes)
Hyperhidrosis (Hyperhidrosis)
Hypertension (Hypertension)
Injection Site Reaction (Injection site
reaction)
Insomnia (Insomnia)
Left Ventricular Systolic Dysfunction (Left
ventricular systolic dysfunction)
Lung Infection (Lung infection)
Mucositis Oral (Mucositis oral)
Myalgia (Myalgia)
Nausea (Nausea)
Neutrophil Count Decreased (Neutrophil
count decreased)
Palmar-plantar Erythrodysesthesia
Syndrome (Palmar-plantar
erythrodysesthesia syndrome)
Peripheral Sensory Neuropathy
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(Peripheral sensory neuropathy)
Pharyngeal Mucositis (Pharyngeal
mucositis)
Platelet Count Decreased (Platelet count
decreased)
Pneumonitis (Pneumonitis)
Pruritus (Pruritus)
Rash Maculo-papular (Rash maculo-
papular)
Seizure (Seizure)
Thromboembolic Event
(Thromboembolic event)
Typhlitis (Typhlitis)
Urinary Tract Infection (Urinary tract
infection)
Vaginal Hemorrhage (Vaginal
hemorrhage)
Vascular Access Complication (Vascular
access complication)
Ventricular Tachycardia (Ventricular
tachycardia)
Vomiting (Vomiting)
Weight Gain (Weight gain)
White Blood Cell Decreased (White
blood cell decreased)
CTC Adverse Event Term Other (specify using
CTCAE 4.0 terminology)
CTC AE Grade (4.0 3-5)
Severe Adverse Event (3)
Life Threatening Adverse Event (4)
Death Related To Adverse Event (5)
CTC Adverse Event Attribution Code
Definite (Definite)
Possible (Possible)
Probable (Probable)
Unlikely (Unlikely)
Unrelated (Unrelated)
Comments
Comments
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Breast Cancer NCT00382018 Toxicity - SOUTHWEST ONCOLOGY
GROUP S0500 ADVERSE EVENT FORM - 2437392v1.0
SOUTHWEST ONCOLOGY GROUP S0500 ADVERSE
EVENT FORM
Treatment Decision Making Based on Blood Levels of
Tumor Cells in Women With Metastatic Breast Cancer
Receiving Chemotherapy
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=07D2F966-
246D-1836-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/9578
SOUTHWEST ONCOLOGY GROUP
S0500 ADVERSE EVENT FORM
Header
SWOG Patient ID
SWOG Study No.
Registration Step
Patient Initials
Reporting Period
3-6 Weeks (3-6 weeks)
6 Weeks Onward (6 weeks onward)
Registration To 3 Weeks (Registration to
3 weeks)
Institution/Affiliate
Physician
Participating Group Name
Participating Study No.
Participating Patient ID (Do not code a condition
existing prior to registration as an adverse event
unless it worsens. Category lists may not include
all adverse events from that category. Record any
observed adverse events not listed on the blank
lines at the end.)
Adverse Events
Reporting period start date
Date of most revent adverse event assessment
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Were adverse events assessed during this time
period?
No (No)
Yes, And Reportable Adverse Events
Occurred (Yes, and reportable adverse
events occurred)
Yes, But No Reportable Adverse Events
Occurred (Yes, but no reportable adverse
events occurred)
CTC Adverse Event Term
Blood Bilirubin Increased (Bilirubin
(hyperbilirubinemia))
Myocardial Ischaemia (Cardiac
ischemia/infarction)
Blood Creatinine Increased (Creatinine)
Dehydration (Dehydration)
Diarrhoea Nos (Diarrhea)
Dyspnoea Nos (Dyspnea (shortness of
breath))
Febrile Neutropenia (fever Of Unknown
Origin Without Clinically Or
Microbiologically Documented Infection)
(anc <1.0 X 10^9/l, Fever >=38.5
Degrees C) (Febrile neutropenia)
Haemoglobin Decreased (Hemoglobin)
Neutropenia (Neutrophils/granulocytes
(ANC/AGC))
Bone Pain (Pain - Bone)
Platelet Count Decreased (Platelets)
Pneumonitis Nos
(Pneumonitis/pulmonary infiltrates)
Vomiting Nos (Vomiting)
CTC Adverse Event Term, Other (specify using
CTCAE 3.0 terminology)
CTCAE (3.0) Grade (1 - 5)
CTCAE (3.0) Grade (1 - 5)
CTC Adverse Event Attribution Code
Definite (definite)
Possible (possible)
Probable (probable)
Unlikely (unlikely)
Unrelated (unrelated)
CTC Adverse Event Attribution Code
Definite (definite)
Possible (possible)
Probable (probable)
Unlikely (unlikely)
Unrelated (unrelated)
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Comments
Comments
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Breast Cancer NCT00127205 Toxicity - SOUTHWEST ONCOLOGY
GROUP S0307 ADVERSE EVENT SUMMARY FORM - 2286223v3.0
SOUTHWEST ONCOLOGY GROUP S0307 ADVERSE
EVENT SUMMARY FORM
Zoledronate, Clodronate, or Ibandronate in Treating Women
Who Have Undergone Surgery for Stage I, Stage II, or
Stage III Breast
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=DE8CE952-
3942-3EB0-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/9579
SOUTHWEST ONCOLOGY GROUP
S0307 ADVERSE EVENT
SUMMARY FORM
Header
SWOG Patient ID
SWOG Study No.
Registration Step
Patient Initials (L, F M)
Institution/Affiliate
Physician
Participating Group Name
Participating Group Study No.
Participating Group Patient ID
Adverse Events
Reporting period start date (Day 1 of this period)
Reporting period end date (Day one of next
period. If final period, date of first visit or contact
after resolution of acute adverse events.)
Were adverse events assessed during this time
period?
No (No)
Yes (Yes)
Yes, And Reportable Adverse Events
Occurred (Yes, and reportable adverse
events occurred)
Yes, But No Reportable Adverse Events
Occurred (Yes, but no reportable adverse
events occurred)
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CTC Adverse Event Term
Alanine Aminotransferase Increased
(ALT, SGPT (serum glutamic pyruvic
transaminase))
Arthritis Nos (Arthritis)
Aspartate Aminotransferase Increased
(AST, SGOT (serum glutamic oxaloacetic
transaminase))
Blood Bilirubin Increased (Bilirubin)
Hypocalcaemia (Calcium, serum-low
(hypocalcemia))
Blood Creatinine Increased (Creatinine)
Dental: Periodontal Disease (Dental:
periodontal disease)
Diarrhoea Nos (Diarrhea)
Oesophagitis Nos (Esophagitis)
Pyrexia (Fever)
Fracture (Fracture)
Nausea (Nausea)
Osteonecrosis (Osteonecrosis (avascular
necrosis))
Bone Pain (Pain - Bone)
Arthralgia (Pain - Joint)
Proteinuria Present (Proteinuria)
Dermatitis Exfoliative Nos
(Rash/desquamation)
Renal Failure Nos (Renal Failure)
Convulsions Nos (Seizure)
Vomiting Nos (Vomiting)
CTC Adverse Event Term, Other (specify using
CTCAE 3.0 terminology)
CTCAE (3.0) Grade (1 - 5)
CTCAE (3.0) Grade (1 - 5)
CTC Adverse Event Attribution Code (*)
Definite (definite)
Possible (possible)
Probable (probable)
Unlikely (unlikely)
Unrelated (unrelated)
CTC Adverse Event Attribution Code (*)
Definite (definite)
Possible (possible)
Probable (probable)
Unlikely (unlikely)
Unrelated (unrelated)
Comments
Comments
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Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getForm
Details&formIdSeq=19804734-1DD7-0F92-E044-0003BA3F9857
Prostate Cancer - Pathology Form - Biopsy
All rights reserved. Please visit https://medical-data-
models.org/forms/9581
Prostate Cancer - Pathology Form -
Biopsy
Crf Header
Coordinating Group Protocol No.
Coordinating Group Code
Protocol Title
Patient Study ID
Institution/Affiliate
Other Patient ID
Participating Group Code
Patient Name (initials acceptable)
Brain: Form Administration
Person Completing Form
Are data amended (If data are amended, please
circle in red when using paper form)
Yes
No
Pathology: Prostatic Biopsy
Data Source
Does analysis of tissue show evidence of
therapeutic effects?
No (No)
Unknown (Unknown)
Yes (Yes)
Type of Therapy (If yes.)
Hormonal Therapy (Hormonal therapy)
Other (Other)
Radiation Therapy (Radiation therapy)
Other specify
1 / 4
Type of Procedure
Fine Needle Aspiration (Fine needle
aspiration)
Needle Biopsy (Needle biopsy)
Other Specify (Other)
Other specify
Biopsy Date
Tumor Location, Side
Left (Left)
Left Lateral (Left lateral)
Midline (Midline)
Other, Specify (Other, specify)
Right (Right)
Right Lateral (Right lateral)
Unknown (Unknown)
Tumor Location, Other Side
Tumor Location, Area
Apex (Apex)
Base (Base)
Middle (Middle)
Other, Specify (Other, specify)
Seminal Vesicle (Seminal vesicle)
Tumor Location, Other Area
Tumor Location, Zone
Not Specified (Not specified)
Peripheral/central (Peripheral/central)
Transition (Transition)
Unknown (Unknown)
Biopsy, Core Length
Biopsy, Cancer Present Measurement
Biopsy, Cancer Present Percentage
Biopsy, Measurement of Gleason 4-5
PIN Ind, High Grade
No (No)
Unknown (Unknown)
Yes (Yes)
Extraprostatic Extension Ind
No (No)
Unknown (Unknown)
Yes (Yes)
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Extraprostatic Extension Type
Established (Established)
Focal </= 2 Hpf (Focal </= 2 hpf)
Unknown (Unknown)
Extraprostatic Extension Laterality
Bilateral (Bilateral)
Unilateral (Unilateral)
Unknown (Unknown)
Extraprostatic Extension Extent, Vertical
Extraprostatic Extension Extent, Horizontal
Gleason Score, Primary Pattern
Gleason Score, Secondary Pattern
Gleason Score, Combined
Gleason Score, Worst Pattern
Pathology: Disease Assessment - Biopsy
Histologic Type
Adenocarcinoma, Conventional, Not
Otherwise Specified (Adenocarcinoma,
conventional, NOS)
Adenocarcinoma/acinar
(Adenocarcinoma/Acinar)
Adenosquamous Carcinoma
(Adenosquamous carcinoma)
Basaloid And Adenoid Cystic Carcinoma
(Basaloid and adenoid cystic carcinoma)
Lymphoepithelioma-like Carcinoma
(Lymphoepithelioma-like carcinoma)
Mucinous (colloid) Adenocarcinoma
(Mucinous (colloid) adenocarcinoma)
Other (Other, specify)
Prostatic Duct Adenocarcinoma
(Prostatic duct adenocarcinoma)
Sarcomatoid Carcinoma (Sarcomatoid
carcinoma)
Signet Ring Cell Carcinoma (Signet ring
cell carcinoma)
Small Cell Carcinoma (Small cell
carcinoma)
Squamous Cell Carcinoma (Squamous
cell carcinoma)
Transitional Cell Carcinoma (Transitional
cell carcinoma)
Undifferentiated Carcinoma, Not
Otherwise Specified (Undifferentiated
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carcinoma, NOS)
Urothelial Primary In Prostate (Urothelial
primary in prostate)
Histologic Type, Other Name
Histologic Type, Variant
Adenosquamous Carcinoma
(Adenosquamous carcinoma)
Prostatic Duct Adenocarcinoma (Ductal
carcinoma)
Mucinous (colloid) Adenocarcinoma
(Mucinous adenocarcinoma)
Other, Specify (Other, specify)
Sarcomatoid Carcinoma (Sarcomatoid
carcinoma)
Signet Ring Cell Carcinoma (Signet ring
cell carcinoma)
Small Cell Carcinoma (Small cell
carcinoma)
Squamous Cell Carcinoma (Squamous
cell carcinoma)
Histologic Type, Other Variant
Histologic Type, Variant Percent
Histologic Type, Variant Percent
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Colorectal Cancer NCT00499369 Toxicity - Southwest
Oncology Group S0600 Adverse Event Form - 2813352v1.0
Southwest Oncology Group S0600 Adverse Event Form
Irinotecan and Cetuximab With or Without Bevacizumab in
Treating Patients With Metastatic Colorectal Cancer That
Progressed During First-Line Therapy
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=5DA30D89-
6264-0FC6-E040-BB89A643170F
All rights reserved. Please visit https://medical-data-
models.org/forms/9582
Southwest Oncology Group S0600
Adverse Event Form
Header
SWOG Patient ID
SWOG Study No.
Patient Initials (L, F M)
Registration Step
Current Cycle Number
Institution/Affiliate
Physician
Participating Group Name
Participating Group Study No.
Participating Group Patient ID
Adverse Events
Reporting Period Start Date (Day 1 of this cycle)
Reporting Period End Date (Day one of next
cycle. If final cycle, date of first visit or contact
after resolution of acute adverse events.)
Were adverse events assessed during this time
period?
No (No)
Yes, And Reportable Adverse Events
Occurred (Yes, and reportable adverse
events occurred)
Yes, But No Reportable Adverse Events
Occurred (Yes, but no reportable adverse
1 / 5
events occurred)
CTC Adverse Event Term
Blood Alkaline Phosphatase Nos
Increased (Alkaline phosphatase)
Hypersensitivity Nos (Allergic
reaction/hypersensitivity (including drug
fever))
Rhinitis Allergic Nos (Allergic rhinitis
(including sneezing, nasal stuffiness,
postnasal drip))
Alanine Aminotransferase Increased
(ALT, SGPT (serum glutamic pyruvic
transaminase))
Anorexia (Anorexia)
Aspartate Aminotransferase Increased
(AST, SGOT (serum glutamic oxaloacetic
transaminase))
Ataxia Nec (Ataxia (incoordination))
Blood Bilirubin Increased (Bilirubin
(hyperbilirubinemia))
Bronchospasm, Wheezing
(Bronchospasm, wheezing)
Myocardial Ischaemia (Cardiac
ischemia/infarction)
Cardiac Troponin I Increased (Cardiac
troponin I (cTnI))
Cerebral Ischaemia (CNS
cerebrovascular ischemia)
Colitis Nos (Colitis)
Constipation (Constipation)
Cough (Cough)
Blood Creatinine Increased (Creatinine)
Cytokine Release Syndrome/acute
Infusion Reaction (Cytokine release
syndrome/acute infusion reaction)
Dehydration (Dehydration)
Diarrhoea Nos (Diarrhea)
Dizziness (exc Vertigo) (Dizziness)
Dyspnoea Nos (Dyspnea (shortness of
breath))
Fatigue (Fatigue (asthenia, lethargy,
malaise))
Pyrexia (Fever (in the absence of
neutropenia, where neutropenia is
defined as ANC <1.0 x 10^9/L))
Fistula, Gi (Fistula, GI - Abdomen NOS)
Alopecia (Hair loss/Alopecia (scalp or
body))
Dyspepsia (Heartburn/dyspepsia)
Haemoglobin Decreased (Hemoglobin)
Haemorrhagic Stroke (Hemorrhage,
CNS)
Melaena (Hemorrhage, GI - Abdomen
NOS)
Hemorrhage, Gi (Hemorrhage, GI -
Colon)
Hemorrhage, Gi (Hemorrhage, GI -
Lower GI NOS)
Rectal Bleeding (Hemorrhage, GI -
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Rectum)
Hemorrhage, Gi (Hemorrhage, GI -
Upper GI NOS)
Hemorrhage, Pulmonary/upper
Respiratory (Hemorrhage,
pulmonary/upper respiratory - Lung)
Epistaxis (Hemorrhage, pulmonary/upper
respiratory - Nose)
Skin Discolouration (Hyperpigmentation)
Hypertension Nos (Hypertension)
Hypotension Nos (Hypotension)
Hypoxia (Hypoxia)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Abdomen
NOS)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Colon)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Lung
(pneumonia))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Pleura
(empyema))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Rectum)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Small bowel
NOS)
Leak (including Anastomotic), Gi (Leak
(including anastomotic), GI - Large
bowel)
Left Ventricular Diastolic Dysfunction
(Left ventricular diastolic dysfunction)
Left Ventricular Failure (Left ventricular
systolic dysfunction)
Leucopenia Nos (Leukocytes (total
WBC))
Blood Magnesium Decreased
(Magnesium, serum-low
(hypomagnesemia))
Mucositis/stomatitis (clinical Exam)
(Mucositis/stomatitis (clinical exam) -
Large bowel)
Mucositis/stomatitis (clinical Exam)
(Mucositis/stomatitis (clinical exam) -
Small bowel)
Mucositis/stomatitis
(functional/symptomatic)
(Mucositis/stomatitis
(functional/symptomatic) - Large bowel)
Mucositis/stomatitis
(functional/symptomatic)
(Mucositis/stomatitis
(functional/symptomatic) - Oral cavity)
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Mucositis/stomatitis
(functional/symptomatic)
(Mucositis/stomatitis
(functional/symptomatic) - Small bowel)
Nail Abnormality Nos (Nail changes)
Nasal Cavity/paranasal Sinus Reactions
(Nasal cavity/paranasal sinus reactions)
Nausea (Nausea)
Necrosis, Gi (Necrosis, GI - Rectum)
Peripheral Sensory Neuropathy
(Neuropathy: sensory)
Neutropenia (Neutrophils/granulocytes
(ANC/AGC))
Obstruction, Gi (Obstruction, GI - Colon)
Obstruction, Gi (Obstruction, GI - Small
bowel NOS)
Abdominal Pain Nos (Pain - Abdomen
NOS)
Pain (Pain - Back)
Chest Pain (Pain - Chest/thorax NOS)
Headache Nos (Pain - Head/headache)
Arthralgia (Pain - Joint)
Myalgia (Pain - Muscle)
Perforation, Gi (Perforation, GI - Colon)
Perforation, Gi (Perforation, GI - Small
bowel NOS)
Perforation, Gi (Perforation, GI -
Stomach)
Pneumonitis Nos
(Pneumonitis/pulmonary infiltrates)
Proteinuria Present (Proteinuria)
Pruritus Nos (Pruritus/itching)
Dermatitis Exfoliative Nos
(Rash/desquamation)
Renal Failure Nos (Renal failure)
Rigors (Rigors/chills)
Speech Disorder Nec (Speech
impairment (e.g., dysphasia or aphasia))
Supraventricular Arrhythmia Nos
(Supraventricular and nodal arrhythmia -
Supraventricular arrhythmia NOS)
Thrombosis Nos
(Thrombosis/thrombus/embolism)
Urticaria Nos (Urticaria (hives, welts,
wheals))
Ventricular Arrhythmia (Ventricular
arrhythmia - Ventricular fibrillation)
Visceral Arterial Ischaemia (Visceral
arterial ischemia (non-myocardial))
Vision Blurred (Vision-blurred vision)
Dysphonia (Voice changes/dysarthria
(e.g., hoarseness, loss or alteration in
voice, laryngitis))
Vomiting Nos (Vomiting)
Weight Decreased (Weight loss)
CTC AE Grade (3.0 1-5)
CTC Adverse Event Attribution Code (*
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Attribution codes: 1-unrelated 2-unlikely 3-
possible 4-probably 5-definite)
Definite (Definite)
Possible (Possible)
Probable (Probable)
Unlikely (Unlikely)
Unrelated (Unrelated)
Adverse event status code (** Status codes since
baseline or last cycle: 1-new 2-continues at same
or lower grade 3-increased grade OR improved
then worsened)
Continues At Same Or Lower Grade
(Continues at same or lower grade)
Increased Grade Or Improved Then
Worsened (Increased grade or improved
then worsened)
New (New)
CTC Adverse Event Term Other (specify using
CTCAE 3.0 terminology)
Comments
Comments
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Gastrointestinal Stromal Tumor NCT00324987
Toxicity - S0502 Adverse Event Form - 2320351v1.0
S0502 Adverse Event Form
S0502 Imatinib Mesylate With or Without Bevacizumab in
Treating Patients With Metastatic or Unresectable
Gastrointestinal Stromal Tumor
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=FCBF7FD7-
A1A5-7312-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/9583
S0502 Adverse Event Form
Header
SWOG Patient ID
SWOG Study No.
Registration Step
Patient Initials (L, F M)
Current Cycle Number
Institution/Affiliate
Physician
Participating Group Name
Participating Group Study No.
Participating Group Patient ID
Adverse Events
Reporting Period Start Date (Day 1 of this cycle)
Reporting Period End Date (Day one of next
cycle. If final cycle, date of first visit or contact
after resolution of acute adverse events.)
Were adverse events assessed during this time
period?
No (No)
Yes, And Reportable Adverse Events
Occurred (Yes, and reportable adverse
events occurred)
Yes, But No Reportable Adverse Events
Occurred (Yes, but no reportable adverse
events occurred)
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CTC Adverse Event Term
Blood Alkaline Phosphatase Nos
Increased (Alkaline phosphatase)
Alanine Aminotransferase Increased
(ALT, SGPT (serum glutamic pyruvic
transaminase))
Anorexia (Anorexia)
Aspartate Aminotransferase Increased
(AST, SGOT (serum glutamic oxaloacetic
transaminase))
Blood Bilirubin Increased (Bilirubin
(hyperbilirubinemia))
Blood Creatinine Increased (Creatinine)
Diarrhoea Nos (Diarrhea)
Fatigue (Fatigue (asthenia, lethargy,
malaise))
Febrile Neutropenia (fever Of Unknown
Origin Without Clinically Or
Microbiologically Documented Infection)
(anc <1.0 X 10^9/l, Fever >=38.5
Degrees C) (Febrile neutropenia)
Pyrexia (Fever (in the absence of
neutropenia, where neutropenia is
defined as ANC <1.0 x 10^9/L))
Flatulence (Flatulence)
Dyspepsia (Heartburn/dyspepsia)
Haemoglobin Decreased (Hemoglobin)
Haemorrhagic Stroke (Hemorrhage,
CNS)
Hemorrhage, Gi (Hemorrhage, GI - Liver)
Hemorrhage, Gi (Hemorrhage, GI -
Lower GI NOS)
Haematemesis (Hemorrhage, GI -
Stomach)
Hemorrhage, Gi (Hemorrhage, GI -
Upper GI NOS)
Haemoptysis (Hemorrhage,
pulmonary/upper respiratory -
Respiratory tract NOS)
Hemorrhage, Pulmonary/upper
Respiratory (Hemorrhage,
pulmonary/upper respiratory - Trachea)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Bladder (urinary))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Bronchus)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
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neutrophils - Colon)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Esophagus)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Lung (pneumonia))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Oral cavity-gums
(gingivitis))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Sinus)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Abdomen
NOS)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils -
Anal/perianal)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Bladder
(urinary))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Cecum)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Colon)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Duodenum)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Esophagus)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Ileum)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Jejunum)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Kidney)
Infection With Normal Anc Or Grade 1 Or
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2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Larynx)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Liver)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Lung
(pneumonia))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils -
Mediastinum NOS)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Mucosa)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Oral cavity-
gums (gingivitis))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Peritoneal
cavity)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Small bowel
NOS)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Soft tissue
NOS)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Stomach)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Trachea)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Upper
aerodigestive NOS)
Infection With Unknown Anc (Infection
with unknown ANC - Bladder (urinary))
Infection With Unknown Anc (Infection
with unknown ANC - Bronchus)
Infection With Unknown Anc (Infection
with unknown ANC - Colon)
Infection With Unknown Anc (Infection
with unknown ANC - Esophagus)
Infection With Unknown Anc (Infection
with unknown ANC - Lung (pneumonia))
Infection With Unknown Anc (Infection
with unknown ANC - Oral cavity-gums
(gingivitis))
Infection With Unknown Anc (Infection
with unknown ANC - Sinus)
Leucopenia Nos (Leukocytes (total
WBC))
Lymphopenia (Lymphopenia)
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Mucositis/stomatitis (clinical Exam)
(Mucositis/stomatitis (clinical exam) -
Oral cavity)
Nausea (Nausea)
Neutropenia (Neutrophils/granulocytes
(ANC/AGC))
Headache Nos (Pain - Head/headache)
Myalgia (Pain - Muscle)
Platelet Count Decreased (Platelets)
Proteinuria Present (Proteinuria)
Dermatitis Exfoliative Nos
(Rash/desquamation)
Rigors (Rigors/chills)
Thrombosis Nos
(Thrombosis/thrombus/embolism)
Vomiting Nos (Vomiting)
Weight Increased (Weight gain)
CTC AE Grade (3.0 1-5)
CTC Adverse Event Attribution Code (*
Attribution codes: 1-unrelated 2-unlikely 3-
possible 4-probably 5-definite)
Definite (Definite)
Possible (Possible)
Probable (Probable)
Unlikely (Unlikely)
Unrelated (Unrelated)
Adverse event status code (** Status codes since
baseline or last cycle: 1-new 2-continues at same
or lower grade 3-increased grade OR improved
then worsened)
Continues At Same Or Lower Grade
(Continues at same or lower grade)
Increased Grade Or Improved Then
Worsened (Increased grade or improved
then worsened)
New (New)
CTC Adverse Event Term Other (specify using
CTCAE 3.0 terminology)
Comments
Comments
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Leukemia NCT00492856 Toxicity - SOUTHWEST ONCOLOGY GROUP
Induction Adverse Event Summary Form (S0521) - 2415259v1.0
SOUTHWEST ONCOLOGY GROUP Induction Adverse
Event Summary Form (S0521)
Combination Chemotherapy With or Without Gemtuzumab
Followed By Tretinoin, Mercaptopurine, and Methotrexate
or Observation in Treating Patients With Acute
Promyelocytic Leukemia
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=02C81B59-
5981-2968-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/9584
SOUTHWEST ONCOLOGY GROUP
Induction Adverse Event Summary
Form (S0521)
Header
SWOG Patient ID
SWOG Study No.
Registration Step
Patient Initials (L, F M)
Reporting Period Start Date
Institution/Affiliate
Physician (Participating Group:)
Participating Group Name
American College Of Surgeons
Oncology Group (ACOSOG)
American College Of Radiology
Oncologic Imaging Network (ACRIN)
Aids-associated Malignancies Clinical
Trials Consortium (AMC)
Cancer And Leukemia Group B (CALGB)
Children's Oncology Group (COG)
Eastern Cooperative Oncology Group
(ECOG)
European Organization For Research
And Treatment Of Cancer (EORTC)
Gynecologic Oncology Group (GOG)
International Breast Cancer Study Group
(IBCSG)
North American Brain Tumor Consortium
(NABTC)
Nabtt Brain Tumor Consortium (NABTT)
North Central Cancer Treatment Group
(NCCTG)
National Cancer Institute Of Canada
Clinical Trials Group (NCIC)
National Surgical Adjuvant Breast And
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Bowel Project (NSABP)
Radiation Therapy Oncology Group
(RTOG)
Southwest Oncology Group (SWOG)
Participating Group Study No.
Participating Group Patient ID (Instructions: All
dates are MONTH, DAY, YEAR. Explain any
blank fields or blank dates in the Comments
section. Place an X in appropriate boxes. Circle
AMENDED items in red and write AMENDED
across the top of the form.)
Adverse Events
Date of Most Recent Adverse Event Assessment
Were adverse events assessed during this report
period?
No (No)
Yes, And Reportable Adverse Events
Occurred (Yes, and reportable adverse
events occurred)
Yes, But No Reportable Adverse Events
Occurred (Yes, but no reportable adverse
events occurred)
CTC Adverse Event Term
Retinoic Acid Syndrome (aaRetinoic acid
syndrome")
Hypersensitivity Nos (Allergic
reaction/hypersensitivity (including drug
fever))
Alanine Aminotransferase Increased
(ALT, SGPT (serum glutamic pyruvic
transaminase))
Anorexia (Anorexia)
Aspartate Aminotransferase Increased
(AST, SGOT (serum glutamic oxaloacetic
transaminase))
Blood Bilirubin Increased (Bilirubin
(hyperbilirubinemia))
Chelitis (Cheilitis)
Hypercholesteraemia (Cholesterol,
serum-high (hypercholesteremia))
Diarrhoea Nos (Diarrhea)
Disseminated Intravascular Coagulation
(DIC (disseminated intravascular
coagulation))
Dry Skin (Dry skin)
Dyspnoea Nos (Dyspnea (shortness of
breath))
Fatigue (Fatigue (asthenia, lethargy,
malaise))
Febrile Neutropenia (fever Of Unknown
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Origin Without Clinically Or
Microbiologically Documented Infection)
(anc <1.0 X 10^9/l, Fever >=38.5
Degrees C) (Febrile neutropenia)
Pyrexia (Fever (in the absence of
neutropenia, where neutropenia is
defined as ANC <1.0 x 10^9/L))
Alopecia (Hair loss/Alopecia (scalp or
body))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Blood)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Lung (pneumonia))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Blood)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Lung
(pneumonia))
Hepatic Failure (Liver dysfunction/failure
(clinical))
Mucositis/stomatitis (clinical Exam)
(Mucositis/stomatitis (clinical exam) -
Oral cavity)
Mucositis/stomatitis (clinical Exam)
(Mucositis/stomatitis (clinical exam) -
Rectum)
Nausea (Nausea)
Headache Nos (Pain - Head/headache)
Myalgia (Pain - Muscle)
Petechiae (Petechiae/purpura
(hemorrhage/bleeding into skin or
mucosa))
Pruritus Nos (Pruritus/itching)
Dermatitis Exfoliative Nos
(Rash/desquamation)
Renal Failure Nos (Renal failure)
Rigors (Rigors/chills)
Hypertriglyceridaemia (Triglyceride,
serum-high (hypertriglyceridemia))
Vomiting Nos (Vomiting)
CTC Adverse Event Term Other
CTC Adverse Event Grade
CTC AE Attribution Code
Definite (Definite)
Possible (Possible)
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Probable (Probable)
Unlikely (Unlikely)
Unrelated (Unrelated)
Comments
Comments
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Leukemia NCT00492856 Toxicity - SOUTHWEST ONCOLOGY GROUP Post-
Consolidation Adverse Event Summary Form: Gemtuzumab Ozogamicin (S0521) -
2466569v1.0
SOUTHWEST ONCOLOGY GROUP Post-Consolidation
Adverse Event Summary Form: Gemtuzumab Ozogamicin
(S0521)
Combination Chemotherapy With or Without Gemtuzumab
Followed By Tretinoin, Mercaptopurine, and Methotrexate
or Observation in Treating Patients With Acute
Promyelocytic Leukemia
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=10260116-
E797-475F-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/9585
SOUTHWEST ONCOLOGY GROUP
Post-Consolidation Adverse Event
Summary Form: Gemtuzumab
Ozogamicin (S0521)
Header
SWOG Patient ID
SWOG Study No.
Registration Step
Reporting Period Start Date
Patient Initials (L, F M)
Institution/Affiliate
Physician (Participating Group:)
Participating Group Name
American College Of Surgeons
Oncology Group (ACOSOG)
American College Of Radiology
Oncologic Imaging Network (ACRIN)
Aids-associated Malignancies Clinical
Trials Consortium (AMC)
Cancer And Leukemia Group B (CALGB)
Children's Oncology Group (COG)
Eastern Cooperative Oncology Group
(ECOG)
European Organization For Research
And Treatment Of Cancer (EORTC)
Gynecologic Oncology Group (GOG)
International Breast Cancer Study Group
(IBCSG)
North American Brain Tumor Consortium
(NABTC)
Nabtt Brain Tumor Consortium (NABTT)
North Central Cancer Treatment Group
(NCCTG)
National Cancer Institute Of Canada
Clinical Trials Group (NCIC)
National Surgical Adjuvant Breast And
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Bowel Project (NSABP)
Radiation Therapy Oncology Group
(RTOG)
Southwest Oncology Group (SWOG)
Participating Group Study No.
Participating Group Patient ID (Instructions: All
dates are MONTH, DAY, YEAR. Explain any
blank fields or blank dates in the Comments
section. Place an X in appropriate boxes. Circle
AMENDED items in red and write AMENDED
across the top of the form.)
Adverse Events
Date of Most Recent Adverse Event Assessment
Were adverse events assessed during this report
period?
No (No)
Yes, And Reportable Adverse Events
Occurred (Yes, and reportable adverse
events occurred)
Yes, But No Reportable Adverse Events
Occurred (Yes, but no reportable adverse
events occurred)
CTC Adverse Event Term
Hypersensitivity Nos (Allergic
reaction/hypersensitivity (including drug
fever))
Alanine Aminotransferase Increased
(ALT, SGPT (serum glutamic pyruvic
transaminase))
Anorexia (Anorexia)
Aspartate Aminotransferase Increased
(AST, SGOT (serum glutamic oxaloacetic
transaminase))
Blood Bilirubin Increased (Bilirubin
(hyperbilirubinemia))
Cough (Cough)
Diarrhoea Nos (Diarrhea)
Disseminated Intravascular Coagulation
(DIC (disseminated intravascular
coagulation))
Distention/bloating, Abdominal
(Distention/bloating, abdominal)
Dyspnoea Nos (Dyspnea (shortness of
breath))
Oedema Nos (Edema: limb)
Fatigue (Fatigue (asthenia, lethargy,
malaise))
Febrile Neutropenia (fever Of Unknown
Origin Without Clinically Or
Microbiologically Documented Infection)
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(anc <1.0 X 10^9/l, Fever >=38.5
Degrees C) (Febrile neutropenia)
Pyrexia (Fever (in the absence of
neutropenia, where neutropenia is
defined as ANC <1.0 x 10^9/L))
Hypoglycaemia Nos (Glucose, serum-
low (hypoglycemia))
Haemorrhagic Stroke (Hemorrhage,
CNS)
Hypertension Nos (Hypertension)
Hypotension Nos (Hypotension)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Blood)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Lung (pneumonia))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Blood)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Lung
(pneumonia))
Hepatic Failure (Liver dysfunction/failure
(clinical))
Nausea (Nausea)
Abdominal Pain Nos (Pain - Abdomen
NOS)
Pain (Pain - Back)
Headache Nos (Pain - Head/headache)
Petechiae (Petechiae/purpura
(hemorrhage/bleeding into skin or
mucosa))
Hyperkalaemia (Potassium, serum-high
(hyperkalemia))
Hypokalaemia (Potassium, serum-low
(hypokalemia))
Dermatitis Exfoliative Nos
(Rash/desquamation)
Rigors (Rigors/chills)
Vomiting Nos (Vomiting)
CTC Adverse Event Term Other
CTC Adverse Event Grade
CTC AE Attribution Code
Definite (Definite)
Possible (Possible)
Probable (Probable)
Unlikely (Unlikely)
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Unrelated (Unrelated)
Comments
Comments
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Leukemia NCT00492856 Toxicity - SOUTHWEST ONCOLOGY GROUP Post-
Consolidation Adverse Event Summary Form: Maintenance Chemotherapy (S0521)
- 2416541v1.0
SOUTHWEST ONCOLOGY GROUP Post-Consolidation
Adverse Event Summary Form: Maintenance
Chemotherapy (S0521)
Combination Chemotherapy With or Without Gemtuzumab
Followed By Tretinoin, Mercaptopurine, and Methotrexate
or Observation in Treating Patients With Acute
Promyelocytic Leukemia
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=02DFCC65-
BC50-09BA-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/9586
SOUTHWEST ONCOLOGY GROUP
Post-Consolidation Adverse Event
Summary Form: Maintenance
Chemotherapy (S0521)
Header
SWOG Patient ID
SWOG Study No.
Registration Step
Reporting Period Start Date
Patient Initials (L, F M)
Institution/Affiliate
Physician (Participating Group:)
Participating Group Name
American College Of Surgeons
Oncology Group (ACOSOG)
American College Of Radiology
Oncologic Imaging Network (ACRIN)
Aids-associated Malignancies Clinical
Trials Consortium (AMC)
Cancer And Leukemia Group B (CALGB)
Children's Oncology Group (COG)
Eastern Cooperative Oncology Group
(ECOG)
European Organization For Research
And Treatment Of Cancer (EORTC)
Gynecologic Oncology Group (GOG)
International Breast Cancer Study Group
(IBCSG)
North American Brain Tumor Consortium
(NABTC)
Nabtt Brain Tumor Consortium (NABTT)
North Central Cancer Treatment Group
(NCCTG)
National Cancer Institute Of Canada
Clinical Trials Group (NCIC)
National Surgical Adjuvant Breast And
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Bowel Project (NSABP)
Radiation Therapy Oncology Group
(RTOG)
Southwest Oncology Group (SWOG)
Participating Group Study No.
Participating Group Patient ID (Instructions: All
dates are MONTH, DAY, YEAR. Explain any
blank fields or blank dates in the Comments
section. Place an X in appropriate boxes. Circle
AMENDED items in red and write AMENDED
across the top of the form.)
Adverse Events
Date of Most Recent Adverse Event Assessment
Were adverse events assessed during this report
period?
No (No)
Yes, And Reportable Adverse Events
Occurred (Yes, and reportable adverse
events occurred)
Yes, But No Reportable Adverse Events
Occurred (Yes, but no reportable adverse
events occurred)
CTC Adverse Event Term
Hypersensitivity Nos (Allergic
reaction/hypersensitivity (including drug
fever))
Alanine Aminotransferase Increased
(ALT, SGPT (serum glutamic pyruvic
transaminase))
Anorexia (Anorexia)
Aspartate Aminotransferase Increased
(AST, SGOT (serum glutamic oxaloacetic
transaminase))
Blood Bilirubin Increased (Bilirubin
(hyperbilirubinemia))
Chelitis (Cheilitis)
Hypercholesteraemia (Cholesterol,
serum-high (hypercholesteremia))
Diarrhoea Nos (Diarrhea)
Dry Skin (Dry skin)
Fatigue (Fatigue (asthenia, lethargy,
malaise))
Febrile Neutropenia (fever Of Unknown
Origin Without Clinically Or
Microbiologically Documented Infection)
(anc <1.0 X 10^9/l, Fever >=38.5
Degrees C) (Febrile neutropenia)
Pyrexia (Fever (in the absence of
neutropenia, where neutropenia is
defined as ANC <1.0 x 10^9/L))
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Alopecia (Hair loss/Alopecia (scalp or
body))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Blood)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Lung (pneumonia))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Blood)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Lung
(pneumonia))
Mucositis/stomatitis (clinical Exam)
(Mucositis/stomatitis (clinical exam) -
Oral cavity)
Mucositis/stomatitis
(functional/symptomatic)
(Mucositis/stomatitis
(functional/symptomatic) - Oral cavity)
Nausea (Nausea)
Peripheral Sensory Neuropathy
(Neuropathy: sensory)
Headache Nos (Pain - Head/headache)
Myalgia (Pain - Muscle)
Pruritus Nos (Pruritus/itching)
Rash: Acne/acneiform (Rash:
acne/acneiform)
Dermatitis Exfoliative Nos
(Rash/desquamation)
Vomiting Nos (Vomiting)
CTC Adverse Event Term Other
CTC Adverse Event Grade
CTC AE Attribution Code
Definite (Definite)
Possible (Possible)
Probable (Probable)
Unlikely (Unlikely)
Unrelated (Unrelated)
Comments
Comments
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Consolidation Adverse Event Summary Form: Maintenance Chemotherapy (S0521)
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Metastatic Cancer NCT00134056 Toxicity - SOUTHWEST ONCOLOGY GROUP
S0421 ADVERSE EVENT SUMMARY FORM: Step 2 Post-Chemo Form -
2464820v1.0
SOUTHWEST ONCOLOGY GROUP S0421 ADVERSE
EVENT SUMMARY FORM: Step 2 Post-Chemo Form
Docetaxel and Prednisone With or Without Atrasentan in
Treating Patients With Stage IV Prostate Cancer and Bone
Metastases That Did Not Respond to Previous Hormone
Therapy
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=0F9D4F4F-
BA23-2F60-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/9587
SOUTHWEST ONCOLOGY GROUP
S0421 ADVERSE EVENT
SUMMARY FORM: Step 2 Post-
Chemo Form
Header
SWOG Patient ID
SWOG Study No.
Registration Step
Current Cycle Number
Patient Initials
Institution/Affiliate
Physician
Participating Group Name
Participating Study No.
Participating Patient ID (Instructions: Please
complete this form after first cycle, then send
every 3 cycles. Report all adverse events
observed. Document the worst Grade seen
during the reporting period.)
Adverse Events
Reporting period start date
Date of Most Recent Adverse Event Assessment
Were adverse events assessed during this time
period?
No (No)
1 / 2
Yes, And Reportable Adverse Events
Occurred (Yes, and reportable adverse
events occurred)
Yes, But No Reportable Adverse Events
Occurred (Yes, but no reportable adverse
events occurred)
CTC Adverse Event Term
Constipation (Constipation)
Dizziness (exc Vertigo) (Dizziness)
Oedema Nos (Edema: limb)
Nasal Cavity/paranasal Sinus Reactions
(Nasal cavity/paranasal sinus reactions)
Nausea (Nausea)
Headache Nos (Pain - Head/headache)
CTCAE (3.0) Grade (1 - 5)
CTCAE (3.0) Grade (1 - 5)
CTC Adverse Event Term, Other (specify using
CTCAE 3.0 terminology)
CTC Adverse Event Attribution Code
Definite (definite)
Possible (possible)
Probable (probable)
Unlikely (unlikely)
Unrelated (unrelated)
CTC Adverse Event Attribution Code
Definite (definite)
Possible (possible)
Probable (probable)
Unlikely (unlikely)
Unrelated (unrelated)
Comments
Comments
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S0421 ADVERSE EVENT SUMMARY FORM: Step 2 Post-Chemo Form -
2464820v1.0
Metastatic Cancer NCT00134056 Toxicity - SOUTHWEST ONCOLOGY GROUP
S0421 ADVERSE EVENT FORM: Step 1 Randomization - 2305232v3.0
SOUTHWEST ONCOLOGY GROUP S0421 ADVERSE
EVENT FORM: Step 1 Randomization
Docetaxel and Prednisone With or Without Atrasentan in
Treating Patients With Stage IV Prostate Cancer and Bone
Metastases That Did Not Respond to Previous Hormone
Therapy
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=F15B0C64-
8BEB-3314-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/9588
SOUTHWEST ONCOLOGY GROUP
S0421 ADVERSE EVENT FORM:
Step 1 Randomization
Header
SWOG Patient ID
SWOG Study No.
Registration Step
Current Cycle Number
Patient Initials
Institution/Affiliate
Physician
Participating Group Name
Participating Study No.
Participating Patient ID (Instructions: Please
complete this form after first cycle, then send
every 3 cycles. Report all adverse events
observed. Document the worst Grade seen
during the reporting period.)
Adverse Events
Reporting period start date
Date of Most Recent Adverse Event Assessment
Were adverse events assessed during this time
period?
No (No)
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Yes, And Reportable Adverse Events
Occurred (Yes, and reportable adverse
events occurred)
Yes, But No Reportable Adverse Events
Occurred (Yes, but no reportable adverse
events occurred)
CTC Adverse Event Term
Hypersensitivity Nos (Allergic
reaction/hypersensitivity)
Rhinitis Allergic Nos (Allergic rhinitis)
Aspartate Aminotransferase Increased
(AST, SGOT)
Blood Bilirubin Increased (Bilirubin)
Constipation (Constipation)
Dizziness (exc Vertigo) (Dizziness)
Dyspnoea Nos (Dyspnea)
Oedema Nos (Edema: limb)
Haemoglobin Decreased (Hemoglobin)
Leucopenia Nos (Leukocytes)
Nail Abnormality Nos (Nail changes)
Nasal Cavity/paranasal Sinus Reactions
(Nasal cavity/paranasal sinus reactions)
Nausea (Nausea)
Neutropenia (Neutophils/granulocytes)
Bone Pain (Pain - Bone)
Headache Nos (Pain - Head/headache)
Arthralgia (Pain - Joint)
Myalgia (Pain - Muscle)
Platelet Count Decreased (Platelets)
Dermatitis Exfoliative Nos
(Rash/desquamation)
Taste Disturbance (Taste alteration)
CTC Adverse Event Term, Other (specify using
CTCAE 3.0 terminology)
CTCAE (3.0) Grade (1 - 5)
CTCAE (3.0) Grade (1 - 5)
CTC Adverse Event Attribution Code
Definite (definite)
Possible (possible)
Probable (probable)
Unlikely (unlikely)
Unrelated (unrelated)
CTC Adverse Event Attribution Code
Definite (definite)
Possible (possible)
Probable (probable)
Unlikely (unlikely)
Unrelated (unrelated)
Comments
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Comments
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S0421 ADVERSE EVENT FORM: Step 1 Randomization - 2305232v3.0
Lung Cancer NCT00946712 Toxicity - Southwest Oncology
Group S0819 Adverse Event Form - 2863599v1.0
Southwest Oncology Group S0819 Adverse Event Form
Carboplatin and Paclitaxel With or Without Bevacizumab
and/or Cetuximab in Treating Patients With Stage IV or
Recurrent Non-Small Cell Lung Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=684CF883-
66AE-1929-E040-BB89AD4373A3
All rights reserved. Please visit https://medical-data-
models.org/forms/9589
Southwest Oncology Group S0819
Adverse Event Form
Header
SWOG Patient ID
SWOG Study No.
Patient Initials (L, F M)
Registration Step
Current Cycle Number
Institution/Affiliate
Physician
Participating Group Name
Participating Group Study No.
Participating Group Patient ID
Adverse Events
Reporting Period Start Date (MM DD YYYY Day
1 of this Cycle)
Reporting Period End Date (MM DD YYYY Day
one of next cycle. If final cycle, date of first visit or
contact after resolution of acute adverse events.)
Were adverse events assessed during this time
period?
No (No)
Yes, And Reportable Adverse Events
Occurred (Yes, and reportable adverse
events occurred)
Yes, But No Reportable Adverse Events
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Occurred (Yes, but no reportable adverse
events occurred)
CTC Adverse Event Term
Blood Albumin Decreased (Albumin,
serum-low (hypoalbuminemia))
Blood Alkaline Phosphatase Nos
Increased (Alkaline phosphatase)
Hypersensitivity Nos (Allergic
reaction/hypersensitivity (including drug
fever))
Alanine Aminotransferase Increased
(ALT, SGPT (serum glutamic pyruvic
transaminase))
Anorexia (Anorexia)
Aspartate Aminotransferase Increased
(AST, SGOT (serum glutamic oxaloacetic
transaminase))
Hypocalcaemia (Calcium, serum-low
(hypocalcemia))
Constipation (Constipation)
Cytokine Release Syndrome/acute
Infusion Reaction (Cytokine release
syndrome/acute infusion reaction)
Dehydration (Dehydration)
Diarrhoea Nos (Diarrhea)
Dry Skin (Dry skin)
Dyspnoea Nos (Dyspnea (shortness of
breath))
Fatigue (Fatigue (asthenia, lethargy,
malaise))
Febrile Neutropenia (fever Of Unknown
Origin Without Clinically Or
Microbiologically Documented Infection)
(anc <1.0 X 10^9/l, Fever >=38.5
Degrees C) (Febrile neutropenia)
Hyperglycaemia Nos (Glucose, serum-
high (hyperglycemia))
Alopecia (Hair loss/Alopecia (scalp or
body))
Haemoglobin Decreased (Hemoglobin)
Hemorrhage, Pulmonary/upper
Respiratory (Hemorrhage,
pulmonary/upper respiratory - Lung)
Epistaxis (Hemorrhage, pulmonary/upper
respiratory - Nose)
Hypertension Nos (Hypertension)
Hypoxia (Hypoxia)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Blood)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Lung (pneumonia))
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Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Sinus)
Leucopenia Nos (Leukocytes (total
WBC))
Lymphopenia (Lymphopenia)
Blood Magnesium Decreased
(Magnesium, serum-low
(hypomagnesemia))
Mucositis/stomatitis (clinical Exam)
(Mucositis/stomatitis (clinical exam) -
Oral cavity)
Muscle Weakness, Generalized Or
Specific Area (not Due To Neuropathy)
(Muscle weakness, generalized or
specific area (not due to neuropathy) -
Extremity-lower)
Muscle Weakness, Generalized Or
Specific Area (not Due To Neuropathy)
(Muscle weakness, generalized or
specific area (not due to neuropathy) -
Extremity-upper)
Muscle Weakness Nos (Muscle
weakness, generalized or specific area
(not due to neuropathy) - Whole
body/generalized)
Nausea (Nausea)
Peripheral Motor Neuropathy
(Neuropathy: motor)
Peripheral Sensory Neuropathy
(Neuropathy: sensory)
Neutropenia (Neutrophils/granulocytes
(ANC/AGC))
Pain (Pain - Extremity-limb)
Arthralgia (Pain - Joint)
Myalgia (Pain - Muscle)
Platelet Count Decreased (Platelets)
Pneumonitis Nos
(Pneumonitis/pulmonary infiltrates)
Hypokalaemia (Potassium, serum-low
(hypokalemia))
Pruritus Nos (Pruritus/itching)
Rash: Acne/acneiform (Rash:
acne/acneiform)
Erythema Multiforme (Rash: erythema
multiforme (e.g., Stevens-Johnson
syndrome, toxic epidermal necrolysis))
Localised Exfoliation (Rash: hand-foot
skin reaction)
Dermatitis Exfoliative Nos
(Rash/desquamation)
Hyponatraemia (Sodium, serum-low
(hyponatremia))
Supraventricular And Nodal Arrhythmia
(Supraventricular and nodal arrhythmia -
Atrial fibrillation)
Taste Disturbance (Taste alteration
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(dysgeusia))
Thrombosis/embolism (vascular Access-
related) (Thrombosis/embolism (vascular
access-related))
Ventricular Arrhythmia (Ventricular
arrhythmia - Ventricular tachycardia)
Vomiting Nos (Vomiting)
Weight Decreased (Weight loss)
CTC Adverse Event Term Other (specify using
CTCAE 3.0 terminology)
CTC AE Grade (3.0 1-5)
CTC Adverse Event Attribution Code
Definite (Definite)
Possible (Possible)
Probable (Probable)
Unlikely (Unlikely)
Unrelated (Unrelated)
Comments
Comments
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Multiple Myeloma and Plasma Cell Neoplasm null Toxicity - S0522
PBSC Collection Adverse Event Summary Form - 2456604v1.0
S0522 PBSC Collection Adverse Event Summary Form
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=0EE5EBB8-
3410-04D2-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/9590
S0522 PBSC Collection Adverse
Event Summary Form
Header
SWOG Patient ID
SWOG Study No.
Registration Step
Patient Initials (L, F M)
Institution/Affiliate
Physician
Participating Group Name
Participating Group Study No.
Participating Group Patient ID
Adverse Events
Reporting Period Start Date
Date of Most Recent Adverse Event Assessment
Were adverse events assessed during this time
period
No (No)
Yes, And Reportable Adverse Events
Occurred (Yes, and reportable adverse
events occurred)
Yes, But No Reportable Adverse Events
Occurred (Yes, but no reportable adverse
events occurred)
Ctc Adverse Event Term
CTC Adverse Event Term
Blood Alkaline Phosphatase Nos
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Increased (Alkaline phosphatase)
Hypersensitivity Nos (Allergic
reaction/hypersensitivity (including drug
fever))
Anorexia (Anorexia)
Blood Bilirubin Increased (Bilirubin
(hyperbilirubinemia))
Blood Creatinine Increased (Creatinine)
Diarrhoea Nos (Diarrhea)
Dizziness (exc Vertigo) (Dizziness)
Dyspnoea Nos (Dyspnea (shortness of
breath))
Fatigue (Fatigue (asthenia, lethargy,
malaise))
Pyrexia (Fever (in the absence of
neutropenia, where neutropenia is
defined as ANC <1.0 x 10^9/L))
Alopecia (Hair loss/Alopecia (scalp or
body))
Dyspepsia (Heartburn/dyspepsia)
Haemoglobin Decreased (Hemoglobin)
Skin Discolouration (Hyperpigmentation)
Hypopigmentation (Hypopigmentation)
Hypotension Nos (Hypotension)
Injection Site Reaction Nos (Injection site
reaction/extravasation changes)
Left Ventricular Diastolic Dysfunction
(Left ventricular diastolic dysfunction)
Left Ventricular Failure (Left ventricular
systolic dysfunction)
Leucopenia Nos (Leukocytes (total
WBC))
Myocarditis Nos (Myocarditis)
Nausea (Nausea)
Neutropenia (Neutrophils/granulocytes
(ANC/AGC))
Bone Pain (Pain - Bone)
Arthralgia (Pain - Joint)
Myalgia (Pain - Muscle)
Platelet Count Decreased (Platelets)
Pleural Effusion (Pleural effusion (non-
malignant))
Dermatitis Exfoliative Nos
(Rash/desquamation)
Rigors (Rigors/chills)
Sinus Bradycardia (Supraventricular and
nodal arrhythmia - Sinus bradycardia)
Supraventricular Arrhythmia Nos
(Supraventricular and nodal arrhythmia -
Supraventricular arrhythmia NOS)
Hyperuricaemia (Uric acid, serum-high
(hyperuricemia))
Urticaria Nos (Urticaria (hives, welts,
wheals))
Vomiting Nos (Vomiting)
Adverse Events
CTC Adverse Event Term, Other (specify using
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Collection Adverse Event Summary Form - 2456604v1.0
CTCAE 3.0 terminology)
CTCAE (3.0) Grade (1 - 5)
CTCAE (3.0) Grade (1 - 5)
CTC Adverse Event Attribution Code (*)
Definite (definite)
Possible (possible)
Probable (probable)
Unlikely (unlikely)
Unrelated (unrelated)
CTC Adverse Event Attribution Code (*)
Definite (definite)
Possible (possible)
Probable (probable)
Unlikely (unlikely)
Unrelated (unrelated)
Comments
Comments
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Collection Adverse Event Summary Form - 2456604v1.0
Pancreatic Cancer NCT00075686 Toxicity - SOUTHWEST ONCOLOGY
GROUP S0205 ADVERSE EVENT FORM - 2307412v3.0
SOUTHWEST ONCOLOGY GROUP S0205 ADVERSE
EVENT FORM
S0205 Gemcitabine With or Without Cetuximab as First-
Line Therapy in Treating Patients With Locally Advanced
Unresectable or Metastatic Adenocarcinoma of the
Pancreas
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=F2FD2A6F-
B0D0-6409-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/9591
SOUTHWEST ONCOLOGY GROUP
S0205 ADVERSE EVENT FORM
Header
SWOG Patient ID
SWOG Study No.
Registration Step
Cycle Number
Patient Initials
Institution/Affiliate
Physician (Instructions: Please complete this
form after first cycle, then send every 3 cycles.
Report all adverse events observed. Document
the worst Grade seen during the reporting
period.)
Toxicity
Was a physical exam performed during this
cycle?
Yes
No
Select box if adverse event were assessed but
none were seen
Date physical exam performed (if yes,)
Reporting period start date (Day after adverse
event assessment date from previous form)
Reporting Period End Date
Were adverse events assessed during this time
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period?
No (No)
Yes (Yes)
Yes, And Reportable Adverse Events
Occurred (Yes, and reportable adverse
events occurred)
Yes, But No Reportable Adverse Events
Occurred (Yes, but no reportable adverse
events occurred)
Date of most recent adverse event assessment
CTC Adverse Event Term
Blood Alkaline Phosphatase Nos
Increased (Alkaline phosphatase)
Hypersensitivity Nos (Allergic
reaction/hypersensitivity)
Alanine Aminotransferase Increased
(ALT, SGPT)
Anorexia (Anorexia)
Aspartate Aminotransferase Increased
(AST, SGOT)
Blood Bilirubin Increased (Bilirubin)
Constipation (Constipation)
Blood Creatinine Increased (Creatinine)
Diarrhoea Nos (Diarrhea)
Dry Mouth (Dry mouth/salivary gland)
Dry Skin (Dry skin)
Dyspnoea Nos (Dyspnea)
Fatigue (Fatigue)
Pyrexia (Fever)
Alopecia (Hair loss/alopecia)
Haemoglobin Decreased (Hemoglobin)
Hemorrhage, Gu (Hemorrhage, GU -
bladder)
Haematuria Present (Hemorrhage, GU -
urinary NOS)
Hemorrhage, Gu (Hemorrhage, GU -
uterus)
Insomnia Nec (Insomnia)
Keratitis Nec (Keratitis)
Leucopenia Nos (Leukocytes)
Mucositis/stomatitis (clinical Exam)
(Mucositis/stomatitis (clinical exam) - oral
cavity)
Stomatitis (Mucositis/stomatitis (clinical
exam) - pharynx)
Mucositis/stomatitis
(functional/symptomatic)
(Mucositis/stomatitis
(functional/symptomatic) - oral cavity)
Mucositis/stomatitis
(functional/symptomatic)
(Mucositis/stomatitis
(functional/symptomatic) - pharynx)
Muscle Weakness, Generalized Or
Specific Area (not Due To Neuropathy)
(Muscle weakness, generalized or
specific area - extremity-lower)
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Muscle Weakness, Generalized Or
Specific Area (not Due To Neuropathy)
(Muscle weakness, generalized or
specific area - extremity-upper)
Muscle Weakness, Generalized Or
Specific Area (not Due To Neuropathy)
(Muscle weakness, generalized or
specific area - whole body/generalized)
Nail Abnormality Nos (Nail changes)
Nausea (Nausea)
Peripheral Sensory Neuropathy
(Neuropathy - sensory)
Neutropenia (Neutrophils/granulocytes)
Conjunctivitis Nec (Ocular surface
disease)
Ocular/visual Other (Ocular/visual -
other)
Chest Pain (Pain - chest/thorax NOS)
Headache Nos (Pain - head/headache)
Arthralgia (Pain - Joint)
Myalgia (Pain - muscle)
Pain Other (Pain - other)
Tumour Pain (Pain - tumor pain)
Pericardial Effusion (Pericardial effusion)
Pericarditis (Pericarditis)
Platelet Count Decreased (Platelets)
Pleural Effusion (Pleural effusion)
Pneumonitis Nos
(Pneumonitis/pulmonary infiltrates)
Pruritus Nos (Pruritus/itching)
Erythema Multiforme (Rash: erythema
multiforme)
Dermatitis Exfoliative Nos
(Rash/desquamation)
Rigors (Rigors/chills)
Convulsions Nos (Seizure)
Supraventricular And Nodal Arrhythmia
(Supraventricular and nodal arrhythmia -
nodal/junction)
Vomiting Nos (Vomiting)
CTC Adverse Event Term, Other (specify using
CTCAE 3.0 terminology)
CTC adverse event Grade (1 - 5)
CTC adverse event Grade (1 - 5)
CTC Adverse Event Attribution Code
Definite (definite)
Possible (possible)
Probable (probable)
Unlikely (unlikely)
Unrelated (unrelated)
CTC Adverse Event Attribution Code
Definite (definite)
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Possible (possible)
Probable (probable)
Unlikely (unlikely)
Unrelated (unrelated)
Adverse event onset date
Adverse event onset date
Adverse event end date
Adverse event end date
AE status code
Continues At Same Or Lower Grade
(Continues at same or lower grade)
Increased Grade Or Improved Then
Worsened (Increased grade or improved
then worsened)
New (New)
AE status code
Continues At Same Or Lower Grade
(Continues at same or lower grade)
Increased Grade Or Improved Then
Worsened (Increased grade or improved
then worsened)
New (New)
Comments
Comments
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Neuroendocrine Carcinoma NCT00569127 Toxicity - Southwest
Oncology Group S0518 Adverse Event Form - 2460009v1.0
Southwest Oncology Group S0518 Adverse Event Form
Octreotide and Interferon Alfa-2b or Bevacizumab in
Treating Patients With Metastatic or Locally Advanced,
High-Risk Neuroendocrine Tumor
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=0F2281F3-
1D20-61F7-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/9592
Southwest Oncology Group S0518
Adverse Event Form
Header
SWOG Patient ID
SWOG Study No.
Registration Step
Patient Initials (L, F M)
Current Cycle Number
Institution/Affiliate
Physician
Participating Group Name
Participating Group Study No.
Participating Group Patient ID
Adverse Events
Reporting Period Start Date (Day 1 of this cycle)
Reporting Period End Date (Day one of next
cycle. If final cycle, date of first visit or contact
after resolution of acute adverse events.)
Were adverse events assessed during this time
period?
No (No)
Yes, And Reportable Adverse Events
Occurred (Yes, and reportable adverse
events occurred)
Yes, But No Reportable Adverse Events
Occurred (Yes, but no reportable adverse
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events occurred)
CTC Adverse Event Term
Blood Alkaline Phosphatase Nos
Increased (Alkaline phosphatase)
Hypersensitivity Nos (Allergic
reaction/hypersensitivity (including drug
fever))
Alanine Aminotransferase Increased
(ALT, SGPT (serum glutamic pyruvic
transaminase))
Anorexia (Anorexia)
Aspartate Aminotransferase Increased
(AST, SGOT (serum glutamic oxaloacetic
transaminase))
Blood Bilirubin Increased (Bilirubin
(hyperbilirubinemia))
Bronchospasm, Wheezing
(Bronchospasm, wheezing)
Myocardial Ischaemia (Cardiac
ischemia/infarction)
Cerebral Ischaemia (CNS
cerebrovascular ischemia)
Cough (Cough)
Blood Creatinine Increased (Creatinine)
Cytokine Release Syndrome/acute
Infusion Reaction (Cytokine release
syndrome/acute infusion reaction)
Dehydration (Dehydration)
Diarrhoea Nos (Diarrhea)
Dyspnoea Nos (Dyspnea (shortness of
breath))
Fatigue (Fatigue (asthenia, lethargy,
malaise))
Pyrexia (Fever (in the absence of
neutropenia, where neutropenia is
defined as ANC <1.0 x 10^9/L))
Flatulence (Flatulence)
Hyperglycaemia Nos (Glucose, serum-
high (hyperglycemia))
Hypoglycaemia Nos (Glucose, serum-
low (hypoglycemia))
Dyspepsia (Heartburn/dyspepsia)
Haemorrhagic Stroke (Hemorrhage,
CNS)
Melaena (Hemorrhage, GI - Abdomen
NOS)
Hemorrhage, Gi (Hemorrhage, GI -
Anus)
Hemorrhage, Gi (Hemorrhage, GI -
Colon)
Hemorrhage, Gi (Hemorrhage, GI -
Ileum)
Hemorrhage, Gi (Hemorrhage, GI -
Jejunum)
Hemorrhage, Gi (Hemorrhage, GI - Liver)
Rectal Bleeding (Hemorrhage, GI -
Rectum)
Haematemesis (Hemorrhage, GI -
Stomach)
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Hemorrhage, Gi (Hemorrhage, GI -
Upper GI NOS)
Vaginal Haemorrhage (Hemorrhage, GU
- Vagina)
Hemorrhage, Pulmonary/upper
Respiratory (Hemorrhage,
pulmonary/upper respiratory - Lung)
Epistaxis (Hemorrhage, pulmonary/upper
respiratory - Nose)
Hypertension Nos (Hypertension)
Hypotension Nos (Hypotension)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Colon)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Upper
aerodigestive NOS)
Leak (including Anastomotic), Gi (Leak
(including anastomotic), GI - Large
bowel)
Leucopenia Nos (Leukocytes (total
WBC))
Mucositis/stomatitis (clinical Exam)
(Mucositis/stomatitis (clinical exam) -
Oral cavity)
Stomatitis (Mucositis/stomatitis (clinical
exam) - Pharynx)
Mucositis/stomatitis
(functional/symptomatic)
(Mucositis/stomatitis
(functional/symptomatic) - Oral cavity)
Mucositis/stomatitis
(functional/symptomatic)
(Mucositis/stomatitis
(functional/symptomatic) - Pharynx)
Nasal Cavity/paranasal Sinus Reactions
(Nasal cavity/paranasal sinus reactions)
Nausea (Nausea)
Neutropenia (Neutrophils/granulocytes
(ANC/AGC))
Abdominal Pain Nos (Pain - Abdomen
NOS)
Chest Pain (Pain - Chest/thorax NOS)
Headache Nos (Pain - Head/headache)
Arthralgia (Pain - Joint)
Myalgia (Pain - Muscle)
Platelet Count Decreased (Platelets)
Proteinuria Present (Proteinuria)
Dermatitis Exfoliative Nos
(Rash/desquamation)
Rigors (Rigors/chills)
Thrombosis Nos
(Thrombosis/thrombus/embolism)
Ulceration (Ulceration)
Urticaria Nos (Urticaria (hives, welts,
wheals))
Visceral Arterial Ischaemia (Visceral
arterial ischemia (non-myocardial))
Dysphonia (Voice changes/dysarthria
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(e.g., hoarseness, loss or alteration in
voice, laryngitis))
Vomiting Nos (Vomiting)
Weight Decreased (Weight loss)
Culture Wound Negative (Wound
complication, non-infectious)
CTC AE Grade (3.0 1-5)
CTC Adverse Event Attribution Code (*
Attribution codes: 1-unrelated 2-unlikely 3-
possible 4-probably 5-definite)
Definite (Definite)
Possible (Possible)
Probable (Probable)
Unlikely (Unlikely)
Unrelated (Unrelated)
Adverse event status code (** Status codes since
baseline or last cycle: 1-new 2-continues at same
or lower grade 3-increased grade OR improved
then worsened)
Continues At Same Or Lower Grade
(Continues at same or lower grade)
Increased Grade Or Improved Then
Worsened (Increased grade or improved
then worsened)
New (New)
CTC Adverse Event Term Other (specify using
CTCAE 3.0 terminology)
Comments
Comments
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Leukemia NCT00492856 Toxicity - SOUTHWEST ONCOLOGY GROUP
Consolidation #1 and #2 Adverse Event Summary Form (S0521) - 2415914v1.0
SOUTHWEST ONCOLOGY GROUP Consolidation #1 and
#2 Adverse Event Summary Form (S0521)
Combination Chemotherapy With or Without Gemtuzumab
Followed By Tretinoin, Mercaptopurine, and Methotrexate
or Observation in Treating Patients With Acute
Promyelocytic Leukemia
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=02DAA575-
2A50-6603-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/9593
SOUTHWEST ONCOLOGY GROUP
Consolidation #1 and #2 Adverse
Event Summary Form (S0521)
Header
SWOG Patient ID
SWOG Study No.
Registration Step
Cycle completed
First Arsenic Consolidation (First arsenic
consolidation)
Second Arsenic Consolidation (Second
arsenic consolidation)
Patient Initials (L, F M)
Institution/Affiliate
Physician (Participating Group:)
Participating Group Name
American College Of Surgeons
Oncology Group (ACOSOG)
American College Of Radiology
Oncologic Imaging Network (ACRIN)
Aids-associated Malignancies Clinical
Trials Consortium (AMC)
Cancer And Leukemia Group B (CALGB)
Children's Oncology Group (COG)
Eastern Cooperative Oncology Group
(ECOG)
European Organization For Research
And Treatment Of Cancer (EORTC)
Gynecologic Oncology Group (GOG)
International Breast Cancer Study Group
(IBCSG)
North American Brain Tumor Consortium
(NABTC)
Nabtt Brain Tumor Consortium (NABTT)
North Central Cancer Treatment Group
(NCCTG)
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National Cancer Institute Of Canada
Clinical Trials Group (NCIC)
National Surgical Adjuvant Breast And
Bowel Project (NSABP)
Radiation Therapy Oncology Group
(RTOG)
Southwest Oncology Group (SWOG)
Participating Group Study No.
Participating Group Patient ID (Instructions: All
dates are MONTH, DAY, YEAR. Explain any
blank fields or blank dates in the Comments
section. Place an X in appropriate boxes. Circle
AMENDED items in red and write AMENDED
across the top of the form.)
Adverse Events
Reporting Period Start Date
Date of Most Recent Adverse Event Assessment
Were adverse events assessed during this report
period?
No (No)
Yes, And Reportable Adverse Events
Occurred (Yes, and reportable adverse
events occurred)
Yes, But No Reportable Adverse Events
Occurred (Yes, but no reportable adverse
events occurred)
CTC Adverse Event Term
Alanine Aminotransferase Increased
(ALT, SGPT (serum glutamic pyruvic
transaminase))
Anorexia (Anorexia)
Aspartate Aminotransferase Increased
(AST, SGOT (serum glutamic oxaloacetic
transaminase))
Blood Bilirubin Increased (Bilirubin
(hyperbilirubinemia))
Hypocalcaemia (Calcium, serum-low
(hypocalcemia))
Blood Creatinine Increased (Creatinine)
Diarrhoea Nos (Diarrhea)
Dry Skin (Dry skin)
Dyspnoea Nos (Dyspnea (shortness of
breath))
Fatigue (Fatigue (asthenia, lethargy,
malaise))
Febrile Neutropenia (fever Of Unknown
Origin Without Clinically Or
Microbiologically Documented Infection)
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(anc <1.0 X 10^9/l, Fever >=38.5
Degrees C) (Febrile neutropenia)
Pyrexia (Fever (in the absence of
neutropenia, where neutropenia is
defined as ANC <1.0 x 10^9/L))
Skin Discolouration (Hyperpigmentation)
Hypopigmentation (Hypopigmentation)
Hypotension Nos (Hypotension)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Blood)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Lung (pneumonia))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Blood)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Lung
(pneumonia))
Blood Magnesium Decreased
(Magnesium, serum-low
(hypomagnesemia))
Mucositis/stomatitis (clinical Exam)
(Mucositis/stomatitis (clinical exam) -
Oral cavity)
Mucositis/stomatitis
(functional/symptomatic)
(Mucositis/stomatitis
(functional/symptomatic) - Oral cavity)
Nausea (Nausea)
Peripheral Sensory Neuropathy
(Neuropathy: sensory)
Headache Nos (Pain - Head/headache)
Arthralgia (Pain - Joint)
Myalgia (Pain - Muscle)
Petechiae (Petechiae/purpura
(hemorrhage/bleeding into skin or
mucosa))
Electrocardiogram Qt Prolonged
(Prolonged QTc interval)
Renal Failure Nos (Renal failure)
Ventricular Arrhythmia (Ventricular
arrhythmia - Bigeminy)
Ventricular Arrhythmia (Ventricular
arrhythmia - PVCs)
Ventricular Arrhythmia (Ventricular
arrhythmia - Ventricular tachycardia)
Vomiting Nos (Vomiting)
CTC Adverse Event Term Other
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Consolidation #1 and #2 Adverse Event Summary Form (S0521) - 2415914v1.0
CTC Adverse Event Grade
CTC AE Attribution Code
Definite (Definite)
Possible (Possible)
Probable (Probable)
Unlikely (Unlikely)
Unrelated (Unrelated)
Comments
Comments
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Leukemia NCT00492856 Toxicity - SOUTHWEST ONCOLOGY GROUP
Consolidation #1 and #2 Adverse Event Summary Form (S0521) - 2415914v1.0
Multiple Myeloma and Plasma Cell Neoplasm null Toxicity - S0522 Bone
Marrow Transplant Adverse Event Summary Form - 2456515v1.0
S0522 Bone Marrow Transplant Adverse Event Summary
Form
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=0EE5E0CE-
44A3-0483-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/9594
S0522 Bone Marrow Transplant
Adverse Event Summary Form
Header
SWOG Patient ID
SWOG Study No.
Registration Step
Patient Initials (L, F M)
Cycle completed
First Transplant (First transplant)
Second Transplant (Second transplant)
Institution/Affiliate
Physician
Participating Group Name
Participating Group Study No.
Participating Group Patient ID
Adverse Events
Reporting Period Start Date
Date of Most Recent Adverse Event Assessment
Were adverse events assessed during this time
period
No (No)
Yes, And Reportable Adverse Events
Occurred (Yes, and reportable adverse
events occurred)
Yes, But No Reportable Adverse Events
Occurred (Yes, but no reportable adverse
events occurred)
Adverse Events1
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CTC Adverse Event Term
Blood Alkaline Phosphatase Nos
Increased (Alkaline phosphatase)
Hypersensitivity Nos (Allergic
reaction/hypersensitivity (including drug
fever))
Blood Bilirubin Increased (Bilirubin
(hyperbilirubinemia))
Blood Creatinine Increased (Creatinine)
Diarrhoea Nos (Diarrhea)
Dizziness (exc Vertigo) (Dizziness)
Dyspnoea Nos (Dyspnea (shortness of
breath))
Oesophagitis Nos (Esophagitis)
Fatigue (Fatigue (asthenia, lethargy,
malaise))
Febrile Neutropenia (fever Of Unknown
Origin Without Clinically Or
Microbiologically Documented Infection)
(anc <1.0 X 10^9/l, Fever >=38.5
Degrees C) (Febrile neutropenia)
Pyrexia (Fever (in the absence of
neutropenia, where neutropenia is
defined as ANC <1.0 x 10^9/L))
Alopecia (Hair loss/Alopecia (scalp or
body))
Dyspepsia (Heartburn/dyspepsia)
Haemoglobin Decreased (Hemoglobin)
Hypotension Nos (Hypotension)
Injection Site Reaction Nos (Injection site
reaction/extravasation changes)
Leucopenia Nos (Leukocytes (total
WBC))
Nausea (Nausea)
Peripheral Sensory Neuropathy
(Neuropathy: sensory)
Neutropenia (Neutrophils/granulocytes
(ANC/AGC))
Bone Pain (Pain - Bone)
Headache Nos (Pain - Head/headache)
Arthralgia (Pain - Joint)
Myalgia (Pain - Muscle)
Platelet Count Decreased (Platelets)
Pleural Effusion (Pleural effusion (non-
malignant))
Pruritus Nos (Pruritus/itching)
Dermatitis Exfoliative Nos
(Rash/desquamation)
Rigors (Rigors/chills)
Thrombosis/embolism (vascular Access-
related) (Thrombosis/embolism (vascular
access-related))
Urticaria Nos (Urticaria (hives, welts,
wheals))
Vomiting Nos (Vomiting)
Adverse Events
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Multiple Myeloma and Plasma Cell Neoplasm null Toxicity - S0522 Bone
Marrow Transplant Adverse Event Summary Form - 2456515v1.0
CTC Adverse Event Attribution Code (*)
Definite (definite)
Possible (possible)
Probable (probable)
Unlikely (unlikely)
Unrelated (unrelated)
CTC Adverse Event Attribution Code (*)
Definite (definite)
Possible (possible)
Probable (probable)
Unlikely (unlikely)
Unrelated (unrelated)
CTC Adverse Event Term, Other (specify using
CTCAE 3.0 terminology)
CTCAE (3.0) Grade (1 - 5)
CTCAE (3.0) Grade (1 - 5)
Comments
Comments
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Multiple Myeloma and Plasma Cell Neoplasm null Toxicity - S0522 Bone
Marrow Transplant Adverse Event Summary Form - 2456515v1.0
Multiple Myeloma and Plasma Cell Neoplasm null Toxicity - S0522 Induction
and Consolidation Adverse Event Summary Form - 2463018v1.0
S0522 Induction and Consolidation Adverse Event
Summary Form
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=0F6E276E-
AFFB-31C9-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/9595
S0522 Induction and Consolidation
Adverse Event Summary Form
Header
SWOG Patient ID
SWOG Study No.
Registration Step
Patient Initials (L, F M)
Cycle completed
Consolidation (Consolidation)
Induction (Induction)
Institution/Affiliate
Physician
Participating Group Name
Participating Group Study No.
Participating Group Patient ID
Adverse Events1
Reporting Period Start Date
Date of Most Recent Adverse Event Assessment
Were adverse events assessed during this time
period
No (No)
Yes, And Reportable Adverse Events
Occurred (Yes, and reportable adverse
events occurred)
Yes, But No Reportable Adverse Events
Occurred (Yes, but no reportable adverse
events occurred)
Ctc Adverse Event Term
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CTC Adverse Event Term
Blood Alkaline Phosphatase Nos
Increased (Alkaline phosphatase)
Rhinitis Allergic Nos (Allergic rhinitis
(including sneezing, nasal stuffiness,
postnasal drip))
Alanine Aminotransferase Increased
(ALT, SGPT (serum glutamic pyruvic
transaminase))
Anorexia (Anorexia)
Aspartate Aminotransferase Increased
(AST, SGOT (serum glutamic oxaloacetic
transaminase))
Hypercalcaemia (Calcium, serum-high
(hypercalcemia))
Hypocalcaemia (Calcium, serum-low
(hypocalcemia))
Cerebral Ischaemia (CNS
cerebrovascular ischemia)
Confusion (Confusion)
Constipation (Constipation)
Cough (Cough)
Blood Creatinine Increased (Creatinine)
Dehydration (Dehydration)
Diarrhoea Nos (Diarrhea)
Dizziness (exc Vertigo) (Dizziness)
Dry Eye Nec (Dry eye syndrome)
Dry Mouth (Dry mouth/salivary gland
(xerostomia))
Dry Skin (Dry skin)
Dyspnoea Nos (Dyspnea (shortness of
breath))
Edema: Head And Neck (Edema: head
and neck)
Oedema Nos (Edema: limb)
Oesophagitis Nos (Esophagitis)
Extremity-lower (gait/walking) (Extremity-
lower (gait/walking))
Fatigue (Fatigue (asthenia, lethargy,
malaise))
Pyrexia (Fever (in the absence of
neutropenia, where neutropenia is
defined as ANC <1.0 x 10^9/L))
Flatulence (Flatulence)
Flushing (Flushing)
Gamma-glutamyltransferase Increased
(GGT (gamma-glutamyl transpeptidase))
Hyperglycaemia Nos (Glucose, serum-
high (hyperglycemia))
Hypoglycaemia Nos (Glucose, serum-
low (hypoglycemia))
Dyspepsia (Heartburn/dyspepsia)
Haemoglobin Decreased (Hemoglobin)
Haemorrhagic Stroke (Hemorrhage,
CNS)
Hypertension Nos (Hypertension)
Hypotension Nos (Hypotension)
Ileus (Ileus, GI (functional obstruction of
bowel, i.e., neuroconstipation))
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Multiple Myeloma and Plasma Cell Neoplasm null Toxicity - S0522 Induction
and Consolidation Adverse Event Summary Form - 2463018v1.0
Injection Site Reaction Nos (Injection site
reaction/extravasation changes)
Insomnia Nec (Insomnia)
Leucopenia Nos (Leukocytes (total
WBC))
Blood Magnesium Decreased
(Magnesium, serum-low
(hypomagnesemia))
Anxiety Nec (Mood alteration - anxiety)
Depression Nec (Mood alteration -
depression)
Euphoric Mood (Mood alteration -
euphoria)
Muscle Weakness Nos (Muscle
weakness, generalized or specific area
(not due to neuropathy) - Whole
body/generalized)
Nasal Cavity/paranasal Sinus Reactions
(Nasal cavity/paranasal sinus reactions)
Nausea (Nausea)
Peripheral Motor Neuropathy
(Neuropathy: motor)
Peripheral Sensory Neuropathy
(Neuropathy: sensory)
Neutropenia (Neutrophils/granulocytes
(ANC/AGC))
Diplopia (Ophthalmoplegia/diplopia
(double vision))
Osteonecrosis (Osteonecrosis (avascular
necrosis))
Osteoporosis (Osteoporosis)
Pancreatitis Nos (Pancreatitis)
Pericardial Effusion (Pericardial effusion
(non-malignant))
Peripheral Ischaemia Nos (Peripheral
arterial ischemia)
Hypophosphataemia (Phosphate, serum-
low (hypophosphatemia))
Platelet Count Decreased (Platelets)
Pleural Effusion (Pleural effusion (non-
malignant))
Pruritus Nos (Pruritus/itching)
Delusion Nos (Psychosis
(hallucinations/delusions))
Erythema Multiforme (Rash: erythema
multiforme (e.g., Stevens-Johnson
syndrome, toxic epidermal necrolysis))
Dermatitis Exfoliative Nos
(Rash/desquamation)
Rigors (Rigors/chills)
Convulsions Nos (Seizure)
Sexual/reproductive Function Other
(Sexual/Reproductive Function-Other
(Specify))
Depressed Level Of Consciousness
(Somnolence/depressed level of
consciousness)
Sinus Bradycardia (Supraventricular and
nodal arrhythmia - Sinus bradycardia)
Syncope (Syncope (fainting))
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Multiple Myeloma and Plasma Cell Neoplasm null Toxicity - S0522 Induction
and Consolidation Adverse Event Summary Form - 2463018v1.0
Taste Disturbance (Taste alteration
(dysgeusia))
Thrombosis/embolism (vascular Access-
related) (Thrombosis/embolism (vascular
access-related))
Hypothyroidism (Thyroid function, low
(hypothyroidism))
Tinnitus (Tinnitus)
Tremor Nec (Tremor)
Urticaria Nos (Urticaria (hives, welts,
wheals))
Vasculitis Nos (Vasculitis)
Vision Blurred (Vision-blurred vision)
Vomiting Nos (Vomiting)
Weight Decreased (Weight loss)
Other Specify
Adverse Events
CTC Adverse Event Term, Other (specify using
CTCAE 3.0 terminology)
CTCAE (3.0) Grade (1 - 5)
CTCAE (3.0) Grade (1 - 5)
CTC Adverse Event Attribution Code (*)
Definite (definite)
Possible (possible)
Probable (probable)
Unlikely (unlikely)
Unrelated (unrelated)
CTC Adverse Event Attribution Code (*)
Definite (definite)
Possible (possible)
Probable (probable)
Unlikely (unlikely)
Unrelated (unrelated)
Comments
Comments
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Multiple Myeloma and Plasma Cell Neoplasm null Toxicity - S0522 Induction
and Consolidation Adverse Event Summary Form - 2463018v1.0
Multiple Myeloma and Plasma Cell Neoplasm NCT00644228 Toxicity - Southwest
Oncology Group S0777 Induction and Maintenance Adverse Event Summary Form
- 2657103v1.0
Southwest Oncology Group S0777 Induction and
Maintenance Adverse Event Summary Form
Lenalidomide and Dexamethasone With or Without
Bortezomib in Treating Patients With Previously Untreated
Multiple Myeloma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=3345A7C2-
9422-3C66-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/9596
Southwest Oncology Group S0777
Induction and Maintenance Adverse
Event Summary Form
Header
SWOG Patient ID
SWOG Study No.
Patient Initials (L, F M)
Registration Step
Cycle completed
Induction (Induction)
Maintenance Therapy (Maintenance)
Institution/Affiliate
Physician
Participating Group Name
Participating Group Study No.
Participating Group Patient ID
Adverse Events
Reporting Period Start Date
Date of Most Recent Adverse Event Assessment
Were adverse events assessed during this time
period?
No (No)
Yes, And Reportable Adverse Events
Occurred (Yes, and reportable adverse
events occurred)
Yes, But No Reportable Adverse Events
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Occurred (Yes, but no reportable adverse
events occurred)
CTC Adverse Event Term
Blood Alkaline Phosphatase Nos
Increased (Alkaline phosphatase)
Rhinitis Allergic Nos (Allergic rhinitis
(including sneezing, nasal stuffiness,
postnasal drip))
Alanine Aminotransferase Increased
(ALT, SGPT (serum glutamic pyruvic
transaminase))
Anorexia (Anorexia)
Aspartate Aminotransferase Increased
(AST, SGOT (serum glutamic oxaloacetic
transaminase))
Hypercalcaemia (Calcium, serum-high
(hypercalcemia))
Hypocalcaemia (Calcium, serum-low
(hypocalcemia))
Cerebral Ischaemia (CNS
cerebrovascular ischemia)
Confusion (Confusion)
Constipation (Constipation)
Cough (Cough)
Blood Creatinine Increased (Creatinine)
Dehydration (Dehydration)
Diarrhoea Nos (Diarrhea)
Dizziness (exc Vertigo) (Dizziness)
Dry Eye Nec (Dry eye syndrome)
Dry Mouth (Dry mouth/salivary gland
(xerostomia))
Dry Skin (Dry skin)
Dyspnoea Nos (Dyspnea (shortness of
breath))
Edema: Head And Neck (Edema: head
and neck)
Oedema Nos (Edema: limb)
Oesophagitis Nos (Esophagitis)
Extremity-lower (gait/walking) (Extremity-
lower (gait/walking))
Fatigue (Fatigue (asthenia, lethargy,
malaise))
Pyrexia (Fever (in the absence of
neutropenia, where neutropenia is
defined as ANC <1.0 x 10^9/L))
Flatulence (Flatulence)
Flushing (Flushing)
Gamma-glutamyltransferase Increased
(GGT (gamma-glutamyl transpeptidase))
Hyperglycaemia Nos (Glucose, serum-
high (hyperglycemia))
Hypoglycaemia Nos (Glucose, serum-
low (hypoglycemia))
Dyspepsia (Heartburn/dyspepsia)
Haemoglobin Decreased (Hemoglobin)
Haemorrhagic Stroke (Hemorrhage,
CNS)
Hypertension Nos (Hypertension)
Hypotension Nos (Hypotension)
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Multiple Myeloma and Plasma Cell Neoplasm NCT00644228 Toxicity - Southwest
Oncology Group S0777 Induction and Maintenance Adverse Event Summary Form
- 2657103v1.0
Ileus (Ileus, GI (functional obstruction of
bowel, i.e., neuroconstipation))
Injection Site Reaction Nos (Injection site
reaction/extravasation changes)
Insomnia Nec (Insomnia)
Leucopenia Nos (Leukocytes (total
WBC))
Lipase Increased (Lipase)
Blood Magnesium Decreased
(Magnesium, serum-low
(hypomagnesemia))
Anxiety Nec (Mood alteration - anxiety)
Depression Nec (Mood alteration -
depression)
Euphoric Mood (Mood alteration -
euphoria)
Muscle Weakness Nos (Muscle
weakness, generalized or specific area
(not due to neuropathy) - Whole
body/generalized)
Nasal Cavity/paranasal Sinus Reactions
(Nasal cavity/paranasal sinus reactions)
Nausea (Nausea)
Peripheral Motor Neuropathy
(Neuropathy: motor)
Peripheral Sensory Neuropathy
(Neuropathy: sensory)
Neutropenia (Neutrophils/granulocytes
(ANC/AGC))
Diplopia (Ophthalmoplegia/diplopia
(double vision))
Osteonecrosis (Osteonecrosis (avascular
necrosis))
Osteoporosis (Osteoporosis)
Pancreatitis Nos (Pancreatitis)
Pericardial Effusion (Pericardial effusion
(non-malignant))
Peripheral Ischaemia Nos (Peripheral
arterial ischemia)
Hypophosphataemia (Phosphate, serum-
low (hypophosphatemia))
Platelet Count Decreased (Platelets)
Pleural Effusion (Pleural effusion (non-
malignant))
Pruritus Nos (Pruritus/itching)
Delusion Nos (Psychosis
(hallucinations/delusions))
Erythema Multiforme (Rash: erythema
multiforme (e.g., Stevens-Johnson
syndrome, toxic epidermal necrolysis))
Dermatitis Exfoliative Nos
(Rash/desquamation)
Rigors (Rigors/chills)
Convulsions Nos (Seizure)
Sexual/reproductive Function Other
(Sexual/Reproductive Function-Other
(Specify))
Depressed Level Of Consciousness
(Somnolence/depressed level of
consciousness)
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Multiple Myeloma and Plasma Cell Neoplasm NCT00644228 Toxicity - Southwest
Oncology Group S0777 Induction and Maintenance Adverse Event Summary Form
- 2657103v1.0
Sinus Bradycardia (Supraventricular and
nodal arrhythmia - Sinus bradycardia)
Syncope (Syncope (fainting))
Taste Disturbance (Taste alteration
(dysgeusia))
Thrombosis/embolism (vascular Access-
related) (Thrombosis/embolism (vascular
access-related))
Hypothyroidism (Thyroid function, low
(hypothyroidism))
Tinnitus (Tinnitus)
Tremor Nec (Tremor)
Urticaria Nos (Urticaria (hives, welts,
wheals))
Vasculitis Nos (Vasculitis)
Vision Blurred (Vision-blurred vision)
Vomiting Nos (Vomiting)
Weight Decreased (Weight loss)
CTC AE Grade (3.0 1-5)
CTC Adverse Event Attribution Code (*
Attribution codes: 1-unrelated 2-unlikely 3-
possible 4-probably 5-definite)
Definite (Definite)
Possible (Possible)
Probable (Probable)
Unlikely (Unlikely)
Unrelated (Unrelated)
CTC Adverse Event Term Other (specify using
CTCAE 3.0 terminology)
Comments
Comments
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Multiple Myeloma and Plasma Cell Neoplasm NCT00644228 Toxicity - Southwest
Oncology Group S0777 Induction and Maintenance Adverse Event Summary Form
- 2657103v1.0
Toxicity - Sarcoma - Adverse Event Form -
2286753v3.0
Sarcoma - Adverse Event Form
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=DE953EB7-
2CB8-2814-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/9605
Sarcoma - Adverse Event Form
Crf Header
Coordinating Group Protocol No.
Coordinating Group Code
Protocol Title
Patient Study ID
Institution/Affiliate
Other Patient ID
Participating Group Code
Patient Name (initials acceptable)
Sarcoma: Form Administration
Person Completing Form
Are data amended (If data are amended, please
circle in red when using paper form)
Yes
No
Sarcoma: Adverse Events
Adverse Event Reporting From Date (MM DD
YYYY)
Adverse Event Reporting To Date (MM DD
YYYY)
CTC Adverse Event Term (Non-Hematologic)
Anorexia (Anorexia)
Diarrhoea Nos (Diarrhea)
Nausea (Nausea)
Dermatitis Exfoliative Nos
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(Rash/desquamation)
Vomiting Nos (Vomiting)
CTC Adverse Event Term (Non-Hematologic)
Anorexia (Anorexia)
Diarrhoea Nos (Diarrhea)
Nausea (Nausea)
Dermatitis Exfoliative Nos
(Rash/desquamation)
Vomiting Nos (Vomiting)
Other CTC Adverse Event Term not listed
Other CTC Adverse Event Term not listed
CTC Adverse Event Grade (Only report Grade 3-
5 for non-hematologic)
CTC Adverse Event Grade (Only report Grade 3-
5 for non-hematologic)
CTC Adverse Event Attribution Code (Attribution
Codes for Relationship of Event to Treatment)
Definite (Definite)
Possible (Possible)
Probable (Probable)
Unlikely (Unlikely)
Unrelated (Unrelated)
CTC Adverse Event Attribution Code (Attribution
Codes for Relationship of Event to Treatment)
Definite (Definite)
Possible (Possible)
Probable (Probable)
Unlikely (Unlikely)
Unrelated (Unrelated)
Comments
Comments
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Toxicity - Sarcoma - Adverse Event Form - 2286753v3.0
Toxicity - Colorectal Cancer - Adverse Event
Form - 2282298v3.0
Colorectal Cancer - Adverse Event Form
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=DB757EA4-
1F12-2F0E-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/9609
Colorectal Cancer - Adverse Event
Form
Crf Header
Coordinating Group Protocol No.
Coordinating Group Code
Protocol Title
Patient Study ID
Institution/Affiliate
Other Patient ID
Participating Group Code
Patient Name (initials acceptable)
Colorectal: Adverse Events
CTC Adverse Event Term (Non-Hematologic
examples only)
Anorexia (Anorexia)
Diarrhoea Nos (Diarrhea)
Nausea (Nausea)
Dermatitis Exfoliative Nos
(Rash/desquamation)
Vomiting Nos (Vomiting)
CTC Adverse Event Term (Non-Hematologic
examples only)
Anorexia (Anorexia)
Diarrhoea Nos (Diarrhea)
Nausea (Nausea)
Dermatitis Exfoliative Nos
(Rash/desquamation)
Vomiting Nos (Vomiting)
Other CTC Adverse Event Term not listed (s)
Other CTC Adverse Event Term not listed (s)
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CTC Adverse Event Grade (Only report Grade 3-
5 for non-hematologic)
CTC Adverse Event Grade (Only report Grade 3-
5 for non-hematologic)
Comments
Comments
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Toxicity - Colorectal Cancer - Adverse Event Form - 2282298v3.0
Toxicity - Lymphoma - Adverse Event Form
- 2269456v3.0
Lymphoma - Adverse Event Form
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=D4C1196B-
9707-1215-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/9613
Lymphoma - Adverse Event Form
Crf Header
Coordinating Group Protocol No.
Coordinating Group Code
Protocol Title
Patient Study ID
Institution/Affiliate
Other Patient ID
Participating Group Code
Patient Name (initials acceptable)
Lymphoma: Form Administration
Person Completing Form
Are data amended? (If data are amended, please
circle in red when using paper form)
Yes
No
Lymphoma: Adverse Events
Adverse Event Reporting From Date
Adverse Event Reporting To Date
CTC Adverse Event Term (Non-Hematologic
examples only)
Anorexia (Anorexia)
Diarrhoea Nos (Diarrhea)
Nausea (Nausea)
Dermatitis Exfoliative Nos
(Rash/desquamation)
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Vomiting Nos (Vomiting)
CTC Adverse Event Term (Non-Hematologic
examples only)
Anorexia (Anorexia)
Diarrhoea Nos (Diarrhea)
Nausea (Nausea)
Dermatitis Exfoliative Nos
(Rash/desquamation)
Vomiting Nos (Vomiting)
Other CTC Adverse Event Term not listed (s)
Other CTC Adverse Event Term not listed (s)
CTC Adverse Event Grade
CTC Adverse Event Grade
CTC Adverse Event Attribution Code (*
Attribution Codes for Relationship of Event to
Treatment:)
Definite (Definite)
Possible (Possible)
Probable (Probable)
Unlikely (Unlikely)
Unrelated (Unrelated)
CTC Adverse Event Attribution Code (*
Attribution Codes for Relationship of Event to
Treatment:)
Definite (Definite)
Possible (Possible)
Probable (Probable)
Unlikely (Unlikely)
Unrelated (Unrelated)
Comments
Comments
2 / 2
Toxicity - Lymphoma - Adverse Event Form - 2269456v3.0
Toxicity - Breast Cancer - Advanced Disease
Adverse Event Form - 2262463v3.0
Breast Cancer - Advanced Disease Adverse Event Form
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=DA18CE28-
6794-07E6-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/9614
Breast Cancer - Advanced Disease
Adverse Event Form
Crf Header
Coordinating Group Protocol No.
Coordinating Group Code
Protocol Title
Patient Study ID
Institution/Affiliate
Other Patient ID
Participating Group Code
Patient Name (initials acceptable)
Breast: Form Administration
Person Completing Form
Are data amended? (If data are amended, please
circle in red when using paper form)
Yes
No
Breast: Advanced Adverse Events
Adverse Event Reporting From Date
Adverse Event Reporting To Date
Other CTC Adverse Event Term not listed (s)
Other CTC Adverse Event Term not listed (s)
CTC Adverse Event Grade (Only report Grade 3-
5 for non-hematologic)
1 / 2
CTC Adverse Event Grade (Only report Grade 3-
5 for non-hematologic)
CTC Adverse Event Term (Non-Hematologic
examples only)
Anorexia (Anorexia)
Diarrhoea Nos (Diarrhea)
Nausea (Nausea)
Dermatitis Exfoliative Nos
(Rash/desquamation)
Vomiting Nos (Vomiting)
CTC Adverse Event Term (Non-Hematologic
examples only)
Anorexia (Anorexia)
Diarrhoea Nos (Diarrhea)
Nausea (Nausea)
Dermatitis Exfoliative Nos
(Rash/desquamation)
Vomiting Nos (Vomiting)
Comments
Comments
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Toxicity - Breast Cancer - Advanced Disease Adverse Event Form -
2262463v3.0
Toxicity - Multiple Myeloma - Adverse Event
Form - 2273748v3.0
Multiple Myeloma - Adverse Event Form
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=D6793013-
9D52-0B5E-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/9615
Multiple Myeloma - Adverse Event
Form
Crf Header
Coordinating Group Protocol No.
Coordinating Group Code
Protocol Title
Patient Study ID
Institution/Affiliate
Other Patient ID
Participating Group Code
Patient Name (initials acceptable)
Myeloma: Form Administration
Person Completing Form
Are data amended? (If data are amended, please
circle in red when using paper form)
Yes
No
Myeloma: Adverse Events
Adverse Event Reporting From Date
Adverse Event Reporting To Date
CTC Adverse Event Term (Non-Hematologic
examples only)
Anorexia (Anorexia)
Diarrhoea Nos (Diarrhea)
Nausea (Nausea)
Dermatitis Exfoliative Nos
(Rash/desquamation)
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Vomiting Nos (Vomiting)
CTC Adverse Event Term (Non-Hematologic
examples only)
Anorexia (Anorexia)
Diarrhoea Nos (Diarrhea)
Nausea (Nausea)
Dermatitis Exfoliative Nos
(Rash/desquamation)
Vomiting Nos (Vomiting)
Other CTC Adverse Event Term not listed (s)
Other CTC Adverse Event Term not listed (s)
CTC Adverse Event Grade
CTC Adverse Event Grade
CTC Adverse Event Attribution Code (*
Attribution Codes for Relationship of Event to
Treatment:)
Definite (Definite)
Possible (Possible)
Probable (Probable)
Unlikely (Unlikely)
Unrelated (Unrelated)
CTC Adverse Event Attribution Code (*
Attribution Codes for Relationship of Event to
Treatment:)
Definite (Definite)
Possible (Possible)
Probable (Probable)
Unlikely (Unlikely)
Unrelated (Unrelated)
Comments
Comments
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Toxicity - Multiple Myeloma - Adverse Event Form - 2273748v3.0
Adverse Events Form Toxicity Breast
Cancer (NCT00513292)
Z1041: Adverse Events Form
Combination Chemotherapy and Paclitaxel Plus
Trastuzumab in Treating Women With Palpable Breast
Cancer That Can Be Removed by Surgery
NCT00513292
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=20CBBAAC-
DEE9-0764-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/9616
Adverse Events Form Toxicity Breast
Cancer (NCT00513292)
Header Module
Visit
30 Days Post Surgery (30 days post
surgery)
C1d21 (C1D21)
C2d21 (C2D21)
C3d21 (C3D21)
C4d21 (C4D21)
C5d21 (C5D21)
C6d21 (C6D21)
C7d21 (C7D21)
C8d21 (C8D21)
Mo3fu (Mo3FU)
Mo6fu (Mo6FU)
Unscheduled (Unscheduled)
Date
Patient ID (Pt. ID issued during registration or
previously issued Patient ID)
Patient Initials (F M L)
Institution No.
Institution Name
Completed by
Date Form Completed
Instructions
Date of Symptom/Event Assessment
Was patient hospitalized during this reporting
interval
Yes
No
Has an Adverse Event Expedited (AdEERS)
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Report been submitted
Yes
No
Ae Module
CTC Adverse Event Term
Acidosis Nos (Acidosis (metabolic or
respiratory))
Capillary Leak Syndrome (Acute
vascular leak syndrome)
Adrenal Insufficiency (Adrenal
insufficiency)
Adult Respiratory Distress Syndrome
(Adult respiratory distress syndrome
(ARDS))
Blood Albumin Decreased (Albumin,
serum-low (hypoalbuminemia))
Alcohol Intolerance Syndrome
(antabuse-like Syndrome) (Alcohol
intolerance syndrome (antabuse-like
syndrome))
Blood Alkaline Phosphatase Nos
Increased (Alkaline phosphatase)
Alkalosis Nos (Alkalosis (metabolic or
respiratory))
Hypersensitivity Nos (Allergic
reaction/hypersensitivity (including drug
fever))
Rhinitis Allergic Nos (Allergic rhinitis
(including sneezing, nasal stuffiness,
postnasal drip))
Allergy/immunology Other
(Allergy/Immunology-Other (Specify))
Alanine Aminotransferase Increased
(ALT, SGPT (serum glutamic pyruvic
transaminase))
Blood Amylase Increased (Amylase)
Anorexia (Anorexia)
Apnoea (Apnea)
Arachnoiditis
(Arachnoiditis/meningismus/radiculitis)
Arthritis Nos (Arthritis (non-septic))
Ascites (Ascites (non-malignant))
Aspiration (Aspiration)
Aspartate Aminotransferase Increased
(AST, SGOT (serum glutamic oxaloacetic
transaminase))
Ataxia Nec (Ataxia (incoordination))
Atelectasis (Atelectasis)
Atrophy, Skin (Atrophy, skin)
Atrophy, Subcutaneous Fat (Atrophy,
subcutaneous fat)
Auditory/ear Other (Auditory/Ear-Other
(Specify))
Autoimmune Disorder Nos (Autoimmune
reaction)
Blood Bicarbonate Decreased
(Bicarbonate, serum-low)
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Blood Bilirubin Increased (Bilirubin
(hyperbilirubinemia))
Bladder Disorder Nos (Bladder spasms)
Blood/bone Marrow Other (Blood/Bone
Marrow-Other (Specify))
Bone Age (alteration In Bone Age) (Bone
age (alteration in bone age))
Bone Growth: Femoral Head; Slipped
Capital Femoral Epiphysis (Bone growth:
femoral head; slipped capital femoral
epiphysis)
Bone Growth: Limb Length Discrepancy
(Bone growth: limb length discrepancy)
Bone Growth: Spine Kyphosis/lordosis
(Bone growth: spine kyphosis/lordosis)
Bone Marrow Depression Nos (Bone
marrow cellularity)
Bone: Spine-scoliosis (Bone: spine-
scoliosis)
Brachial Plexopathy (Brachial
plexopathy)
Breast Function/lactation (Breast
function/lactation)
Breast Nipple/areolar Deformity (Breast
nipple/areolar deformity)
Breast Volume/hypoplasia (Breast
volume/hypoplasia)
Bronchospasm, Wheezing
(Bronchospasm, wheezing)
Ecchymosis (Bruising (in absence of
grade 3 or 4 thrombocytopenia))
Burn (Burn)
Hypercalcaemia (Calcium, serum-high
(hypercalcemia))
Hypocalcaemia (Calcium, serum-low
(hypocalcemia))
Pulmonary Function Test Nos Decreased
(Carbon monoxide diffusion capacity
(DL(co)))
Arrhythmia Nos (Cardiac Arrhythmia-
Other (Specify))
Cardiac General Other (Cardiac
General-Other (Specify))
Myocardial Ischaemia (Cardiac
ischemia/infarction)
Cardiac Troponin I Increased (Cardiac
troponin I (cTnI))
Cardiac Troponin T Increased (Cardiac
troponin T (cTnT))
Cardiopulmonary Arrest, Cause
Unknown (non-fatal) (Cardiopulmonary
arrest, cause unknown (non-fatal))
Cataract Nec (Cataract)
Cd4 Lymphocytes Decreased (CD4
count)
Cervical Spine-range Of Motion (Cervical
spine-range of motion)
Chelitis (Cheilitis)
Cholecystitis (Cholecystitis)
Hypercholesteraemia (Cholesterol,
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serum-high (hypercholesteremia))
Chyle Or Lymph Leakage (Chyle or
lymph leakage)
Chylothorax (Chylothorax)
Cerebral Ischaemia (CNS
cerebrovascular ischemia)
Cns Necrosis/cystic Progression (CNS
necrosis/cystic progression)
Coagulation Disorder Nos (Coagulation-
Other (Specify))
Learning Disorder Nos (Cognitive
disturbance)
Colitis Nos (Colitis)
Colitis, Infectious (e.g., Clostridium
Difficile) (Colitis, infectious (e.g.,
Clostridium difficile))
Ventricular Asystole (Conduction
abnormality/Atrioventricular heart block -
Asystole)
Conduction Abnormality/atrioventricular
Heart Block (Conduction
abnormality/Atrioventricular heart block -
AV block-first degree)
Conduction Abnormality/atrioventricular
Heart Block - Av Block-second Degree
Mobitz Type I (wenckebach) (Conduction
abnormality/Atrioventricular heart block -
AV block-Second degree Mobitz Type I
(Wenckebach))
Conduction Abnormality/atrioventricular
Heart Block (Conduction
abnormality/Atrioventricular heart block -
AV block-second degree Mobitz Type II)
Conduction Abnormality/atrioventricular
Heart Block (Conduction
abnormality/Atrioventricular heart block -
AV block-third degree (complete AV
block))
Conduction Abnormality/atrioventricular
Heart Block (Conduction
abnormality/Atrioventricular heart block -
Conduction abnormality NOS)
Conduction Abnormality/atrioventricular
Heart Block (Conduction
abnormality/Atrioventricular heart block -
Sick sinus syndrome)
Conduction Abnormality/atrioventricular
Heart Block (Conduction
abnormality/Atrioventricular heart block -
Stokes-Adams syndrome)
Conduction Abnormality/atrioventricular
Heart Block (Conduction
abnormality/Atrioventricular heart block -
Wolff-Parkinson-White syndrome)
Confusion (Confusion)
Constipation (Constipation)
Constitutional Symptoms Other
(Constitutional Symptoms-Other
(Specify))
Cough (Cough)
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Blood Creatine Phosphokinase
Increased (CPK (creatine
phosphokinase))
Blood Creatinine Increased (Creatinine)
Cushingoid (Cushingoid appearance
(e.g., moon face, buffalo hump,
centripetal obesity, cutaneous striae))
Cystitis (Cystitis)
Cytokine Release Syndrome/acute
Infusion Reaction (Cytokine release
syndrome/acute infusion reaction)
Death Not Associated With Ctcae Term
(Death not associated with CTCAE term
- Death NOS)
Death Not Associated With Ctcae Term
(Death not associated with CTCAE term
- Disease progression NOS)
Death Not Associated With Ctcae Term
(Death not associated with CTCAE term
- Multi-organ failure)
Death Not Associated With Ctcae Term
(Death not associated with CTCAE term
- Sudden death)
Dehydration (Dehydration)
Dental: Dentures Or Prosthesis (Dental:
dentures or prosthesis)
Dental: Periodontal Disease (Dental:
periodontal disease)
Dental: Teeth (Dental: teeth)
Dental: Teeth Development (Dental:
teeth development)
Dermal Change Lymphedema,
Phlebolymphedema (Dermal change
lymphedema, phlebolymphedema)
Dermatology/skin Other
(Dermatology/Skin-Other (Specify))
Diarrhoea Nos (Diarrhea)
Disseminated Intravascular Coagulation
(DIC (disseminated intravascular
coagulation))
Distention/bloating, Abdominal
(Distention/bloating, abdominal)
Dizziness (exc Vertigo) (Dizziness)
Dry Eye Nec (Dry eye syndrome)
Dry Mouth (Dry mouth/salivary gland
(xerostomia))
Dry Skin (Dry skin)
Dysphagia (Dysphagia (difficulty
swallowing))
Dyspnoea Nos (Dyspnea (shortness of
breath))
Edema, Larynx (Edema, larynx)
Edema: Head And Neck (Edema: head
and neck)
Oedema Nos (Edema: limb)
Edema: Trunk/genital (Edema:
trunk/genital)
Edema: Viscera (Edema: viscera)
Ejaculatory Dysfunction (Ejaculatory
dysfunction)
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Encephalopathy (Encephalopathy)
Endocrine Other (Endocrine-Other
(Specify))
Enteritis (inflammation Of The Small
Bowel) (Enteritis (inflammation of the
small bowel))
Impotence (Erectile dysfunction)
Oesophagitis Nos (Esophagitis)
Exostosis (Exostosis)
Extrapyramidal Disorder Nec
(Extrapyramidal/involuntary
movement/restlessness)
Extremity-lower (gait/walking) (Extremity-
lower (gait/walking))
Extremity-upper (function) (Extremity-
upper (function))
Eyelid Dysfunction (Eyelid dysfunction)
Fatigue (Fatigue (asthenia, lethargy,
malaise))
Febrile Neutropenia (fever Of Unknown
Origin Without Clinically Or
Microbiologically Documented Infection)
(anc <1.0 X 10^9/l, Fever >=38.5
Degrees C) (Febrile neutropenia)
Feminization (Feminization of male)
Forced Expiratory Volume Decreased
(FEV(1))
Pyrexia (Fever (in the absence of
neutropenia, where neutropenia is
defined as ANC <1.0 x 10^9/L))
Blood Fibrinogen Decreased
(Fibrinogen)
Fibrosis-cosmesis (Fibrosis-cosmesis)
Fibrosis-deep Connective Tissue
(Fibrosis-deep connective tissue)
Fistula, Gi (Fistula, GI - Abdomen NOS)
Anal Fistula (Fistula, GI - Anus)
Fistula, Gi (Fistula, GI - Biliary tree)
Fistula, Gi (Fistula, GI -
Colon/cecum/appendix)
Intestinal Fistula (Fistula, GI -
Duodenum)
Tracheo-oesophageal Fistula Nos
(Fistula, GI - Esophagus)
Fistula, Gi (Fistula, GI - Gallbladder)
Fistula, Gi (Fistula, GI - Ileum)
Fistula, Gi (Fistula, GI - Jejunum)
Fistula, Gi (Fistula, GI - Oral cavity)
Fistula, Gi (Fistula, GI - Pancreas)
Fistula, Gi (Fistula, GI - Pharynx)
Fistula, Gi (Fistula, GI - Rectum)
Fistula, Gi (Fistula, GI - Salivary gland)
Fistula, Gi (Fistula, GI - Small bowel
NOS)
Fistula, Gi (Fistula, GI - Stomach)
Fistula, Gu (Fistula, GU - Bladder)
Fistula, Gu (Fistula, GU - Genital tract-
female)
Fistula, Gu (Fistula, GU - Kidney)
Fistula, Gu (Fistula, GU - Ureter)
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Fistula, Gu (Fistula, GU - Urethra)
Fistula, Gu (Fistula, GU - Uterus)
Urogenital Fistula (Fistula, GU - Vagina)
Fistula, Pulmonary/upper Respiratory
(Fistula, pulmonary/upper respiratory -
Bronchus)
Fistula, Pulmonary/upper Respiratory
(Fistula, pulmonary/upper respiratory -
Larynx)
Fistula, Pulmonary/upper Respiratory
(Fistula, pulmonary/upper respiratory -
Lung)
Fistula, Pulmonary/upper Respiratory
(Fistula, pulmonary/upper respiratory -
Oral cavity)
Fistula, Pulmonary/upper Respiratory
(Fistula, pulmonary/upper respiratory -
Pharynx)
Fistula, Pulmonary/upper Respiratory
(Fistula, pulmonary/upper respiratory -
Pleura)
Fistula, Pulmonary/upper Respiratory
(Fistula, pulmonary/upper respiratory -
Trachea)
Flatulence (Flatulence)
Flu-like Syndrome (Flu-like syndrome)
Flushing (Flushing)
Fracture (Fracture)
Gastritis Nos (Gastritis (including bile
reflux gastritis))
Gastrointestinal Other (Gastrointestinal-
Other (Specify))
Gamma-glutamyltransferase Increased
(GGT (gamma-glutamyl transpeptidase))
Glaucoma Nos (Glaucoma)
Glomerular Filtration Rate (Glomerular
filtration rate)
Hyperglycaemia Nos (Glucose, serum-
high (hyperglycemia))
Hypoglycaemia Nos (Glucose, serum-
low (hypoglycemia))
Growth And Development Other (Growth
and Development-Other (Specify))
Growth Velocity (reduction In Growth
Velocity) (Growth velocity (reduction in
growth velocity))
Gynaecomastia (Gynecomastia)
Alopecia (Hair loss/Alopecia (scalp or
body))
Haptoglobin Decreased (Haptoglobin)
Hearing: Patients With/without Baseline
Audiogram And Enrolled In A Monitoring
Program (Hearing: patients with/without
baseline audiogram and enrolled in a
monitoring program)
Hearing: Patients Without Baseline
Audiogram And Not Enrolled In A
Monitoring Program (Hearing: patients
without baseline audiogram and not
enrolled in a monitoring program)
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Dyspepsia (Heartburn/dyspepsia)
Hematoma (Hematoma)
Haemoglobin Decreased (Hemoglobin)
Haemoglobinuria Present
(Hemoglobinuria)
Hemolysis Nos (Hemolysis (e.g.,
immune hemolytic anemia, drug related
hemolysis))
Haemorrhagic Stroke (Hemorrhage,
CNS)
Melaena (Hemorrhage, GI - Abdomen
NOS)
Hemorrhage, Gi (Hemorrhage, GI -
Anus)
Hemorrhage, Gi (Hemorrhage, GI -
Biliary tree)
Hemorrhage, Gi (Hemorrhage, GI -
Cecum/appendix)
Hemorrhage, Gi (Hemorrhage, GI -
Colon)
Hemorrhage, Gi (Hemorrhage, GI -
Duodenum)
Hemorrhage, Gi (Hemorrhage, GI -
Esophagus)
Hemorrhage, Gi (Hemorrhage, GI -
Ileum)
Hemorrhage, Gi (Hemorrhage, GI -
Jejunum)
Hemorrhage, Gi (Hemorrhage, GI - Liver)
Hemorrhage, Gi (Hemorrhage, GI -
Lower GI NOS)
Hemorrhage, Gi (Hemorrhage, GI - Oral
cavity)
Hemorrhage, Gi (Hemorrhage, GI -
Pancreas)
Hemorrhage, Gi (Hemorrhage, GI -
Peritoneal cavity)
Rectal Bleeding (Hemorrhage, GI -
Rectum)
Hemorrhage, Gi (Hemorrhage, GI -
Stoma)
Haematemesis (Hemorrhage, GI -
Stomach)
Hemorrhage, Gi (Hemorrhage, GI -
Upper GI NOS)
Hemorrhage, Gi (Hemorrhage, GI -
Varices (esophageal))
Hemorrhage, Gi (Hemorrhage, GI -
Varices (rectal))
Hemorrhage, Gu (Hemorrhage, GU -
Bladder)
Hemorrhage, Gu (Hemorrhage, GU -
Fallopian tube)
Hemorrhage, Gu (Hemorrhage, GU -
Kidney)
Hemorrhage, Gu (Hemorrhage, GU -
Ovary)
Hemorrhage, Gu (Hemorrhage, GU -
Prostate)
Hemorrhage, Gu (Hemorrhage, GU -
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Retroperitoneum)
Hemorrhage, Gu (Hemorrhage, GU -
Spermatic cord)
Hemorrhage, Gu (Hemorrhage, GU -
Stoma)
Hemorrhage, Gu (Hemorrhage, GU -
Testes)
Hemorrhage, Gu (Hemorrhage, GU -
Ureter)
Hemorrhage, Gu (Hemorrhage, GU -
Urethra)
Haematuria Present (Hemorrhage, GU -
Urinary NOS)
Hemorrhage, Gu (Hemorrhage, GU -
Uterus)
Vaginal Haemorrhage (Hemorrhage, GU
- Vagina)
Hemorrhage, Gu (Hemorrhage, GU - Vas
deferens)
Hemorrhage, Pulmonary/upper
Respiratory (Hemorrhage,
pulmonary/upper respiratory -
Bronchopulmonary NOS)
Hemorrhage, Pulmonary/upper
Respiratory (Hemorrhage,
pulmonary/upper respiratory - Bronchus)
Hemorrhage, Pulmonary/upper
Respiratory (Hemorrhage,
pulmonary/upper respiratory - Larynx)
Hemorrhage, Pulmonary/upper
Respiratory (Hemorrhage,
pulmonary/upper respiratory - Lung)
Hemorrhage, Pulmonary/upper
Respiratory (Hemorrhage,
pulmonary/upper respiratory -
Mediastinum)
Epistaxis (Hemorrhage, pulmonary/upper
respiratory - Nose)
Hemorrhage, Pulmonary/upper
Respiratory (Hemorrhage,
pulmonary/upper respiratory - Pharynx)
Hemorrhage, Pulmonary/upper
Respiratory (Hemorrhage,
pulmonary/upper respiratory - Pleura)
Haemoptysis (Hemorrhage,
pulmonary/upper respiratory -
Respiratory tract NOS)
Hemorrhage, Pulmonary/upper
Respiratory (Hemorrhage,
pulmonary/upper respiratory - Stoma)
Hemorrhage, Pulmonary/upper
Respiratory (Hemorrhage,
pulmonary/upper respiratory - Trachea)
Post-operative Haemorrhage
(Hemorrhage/bleeding associated with
surgery, intra-operative or post-operative)
Hemorrhage/bleeding Other
(Hemorrhage/Bleeding-Other (Specify))
Hemorrhoids (Hemorrhoids)
Hepatobiliary/pancreas Other
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(Hepatobiliary/Pancreas-Other (Specify))
Hiccups (Hiccoughs (hiccups, singultus))
Menopausal Symptoms (Hot
flashes/flushes)
Hydrocephalus (Hydrocephalus)
Skin Discolouration (Hyperpigmentation)
Hypertension Nos (Hypertension)
Hypopigmentation (Hypopigmentation)
Hypotension Nos (Hypotension)
Hypothermia (Hypothermia)
Hypoxia (Hypoxia)
Ileus (Ileus, GI (functional obstruction of
bowel, i.e., neuroconstipation))
Incontinence, Anal (Incontinence, anal)
Urinary Incontinence (Incontinence,
urinary)
Induration/fibrosis (skin And
Subcutaneous Tissue)
(Induration/fibrosis (skin and
subcutaneous tissue))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Abdomen NOS)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Anal/perianal)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Appendix)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Artery)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Biliary tree)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Bladder (urinary))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
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microbiologically) with Grade 3 or 4
neutrophils - Blood)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Bone (osteomyelitis))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Brain (encephalitis,
infectious))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Brain + Spinal cord
(encephalomyelitis))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Bronchus)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Catheter-related)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Cecum)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Cervix)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Colon)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Conjunctiva)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
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Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Cornea)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Dental-tooth)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Duodenum)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Esophagus)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - External ear (otitis externa))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Eye NOS)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Fallopian tube)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Foreign body (e.g., graft,
implant, prosthesis, stent))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Gallbladder (cholecystitis))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Heart (endocarditis))
Infection (documented Clinically Or
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Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Ileum)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Jejunum)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Joint)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Kidney)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Larynx)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Lens)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Lip/perioral)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Liver)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Lung (pneumonia))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Lymphatic)
Infection (documented Clinically Or
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Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Mediastinum NOS)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Meninges (meningitis))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Middle ear (otitis media))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Mucosa)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Muscle (infection myositis))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Neck NOS)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Nerve-cranial)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Nerve-peripheral)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Nose)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Oral cavity-gums
(gingivitis))
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Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Pancreas)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Paranasal)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Pelvis NOS)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Penis)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Peristomal)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Peritoneal cavity)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Pharynx)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Pleura (empyema))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Prostate)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Rectum)
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Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Salivary gland)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Scrotum)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Sinus)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Skin (cellulitis))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Small bowel NOS)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Soft tissue NOS)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Spinal cord (myelitis))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Spleen)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Stomach)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Trachea)
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Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Ungual (nails))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Upper aerodigestive NOS)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Upper airway NOS)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Ureter)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Urethra)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Urinary tract NOS)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Uterus)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Vagina)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Vein)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Vulva)
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Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Wound)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Abdomen
NOS)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils -
Anal/perianal)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Appendix)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Artery)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Biliary tree)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Bladder
(urinary))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Blood)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Bone
(osteomyelitis))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Brain
(encephalitis, infectious))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Brain +
Spinal cord (encephalomyelitis))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Bronchus)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Catheter-
related)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Cecum)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Cervix)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Colon)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
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or Grade 1 or 2 neutrophils -
Conjunctiva)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Cornea)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Dental-
tooth)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Duodenum)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Esophagus)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - External ear
(otitis externa))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Eye NOS)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Fallopian
tube)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Foreign
body (e.g., graft, implant, prosthesis,
stent))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Gallbladder
(cholecystitis))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Heart
(endocarditis))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Ileum)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Jejunum)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Joint)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Kidney)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Larynx)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Lens)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Lip/perioral)
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Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Liver)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Lung
(pneumonia))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Lymphatic)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils -
Mediastinum NOS)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Meninges
(meningitis))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Middle ear
(otitis media))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Mucosa)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Muscle
(infection myositis))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Neck NOS)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Nerve-
cranial)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Nerve-
peripheral)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Nose)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Oral cavity-
gums (gingivitis))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Pancreas)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Paranasal)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Pelvis NOS)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Penis)
Infection With Normal Anc Or Grade 1 Or
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2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Peristomal)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Peritoneal
cavity)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Pharynx)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Pleura
(empyema))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Prostate)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Rectum)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Salivary
gland)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Scrotum)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Sinus)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Skin
(cellulitis))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Small bowel
NOS)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Soft tissue
NOS)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Spinal cord
(myelitis))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Spleen)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Stomach)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Trachea)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Ungual
(nails))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
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or Grade 1 or 2 neutrophils - Upper
aerodigestive NOS)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Upper
airway NOS)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Ureter)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Urethra)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Urinary
tract NOS)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Uterus)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Vagina)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Vein)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Vulva)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Wound)
Infection With Unknown Anc (Infection
with unknown ANC - Abdomen NOS)
Infection With Unknown Anc (Infection
with unknown ANC - Anal/perianal)
Infection With Unknown Anc (Infection
with unknown ANC - Appendix)
Infection With Unknown Anc (Infection
with unknown ANC - Artery)
Infection With Unknown Anc (Infection
with unknown ANC - Biliary tree)
Infection With Unknown Anc (Infection
with unknown ANC - Bladder (urinary))
Infection With Unknown Anc (Infection
with unknown ANC - Blood)
Infection With Unknown Anc (Infection
with unknown ANC - Bone
(osteomyelitis))
Infection With Unknown Anc (Infection
with unknown ANC - Brain (encephalitis,
infectious))
Infection With Unknown Anc (Infection
with unknown ANC - Brain + Spinal cord
(encephalomyelitis))
Infection With Unknown Anc (Infection
with unknown ANC - Bronchus)
Implant Infection (Infection with unknown
ANC - Catheter-related)
Infection With Unknown Anc (Infection
with unknown ANC - Cecum)
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Infection With Unknown Anc (Infection
with unknown ANC - Cervix)
Infection With Unknown Anc (Infection
with unknown ANC - Colon)
Infection With Unknown Anc (Infection
with unknown ANC - Conjunctiva)
Infection With Unknown Anc (Infection
with unknown ANC - Cornea)
Infection With Unknown Anc (Infection
with unknown ANC - Dental-tooth)
Infection With Unknown Anc (Infection
with unknown ANC - Duodenum)
Infection With Unknown Anc (Infection
with unknown ANC - Esophagus)
Infection With Unknown Anc (Infection
with unknown ANC - External ear (otitis
externa))
Infection With Unknown Anc (Infection
with unknown ANC - Eye NOS)
Infection With Unknown Anc (Infection
with unknown ANC - Fallopian tube)
Infection With Unknown Anc (Infection
with unknown ANC - Foreign body (e.g.,
graft, implant, prosthesis, stent))
Infection With Unknown Anc (Infection
with unknown ANC - Gallbladder
(cholecystitis))
Infection With Unknown Anc (Infection
with unknown ANC - Heart
(endocarditis))
Infection With Unknown Anc (Infection
with unknown ANC - Ileum)
Infection With Unknown Anc (Infection
with unknown ANC - Jejunum)
Infection With Unknown Anc (Infection
with unknown ANC - Joint)
Infection With Unknown Anc (Infection
with unknown ANC - Kidney)
Infection With Unknown Anc (Infection
with unknown ANC - Larynx)
Infection With Unknown Anc (Infection
with unknown ANC - Lens)
Infection With Unknown Anc (Infection
with unknown ANC - Lip/perioral)
Infection With Unknown Anc (Infection
with unknown ANC - Liver)
Infection With Unknown Anc (Infection
with unknown ANC - Lung (pneumonia))
Infection With Unknown Anc (Infection
with unknown ANC - Lymphatic)
Infection With Unknown Anc (Infection
with unknown ANC - Mediastinum NOS)
Infection With Unknown Anc (Infection
with unknown ANC - Meninges
(meningitis))
Infection With Unknown Anc (Infection
with unknown ANC - Middle ear (otitis
media))
Infection With Unknown Anc (Infection
with unknown ANC - Mucosa)
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Infection With Unknown Anc (Infection
with unknown ANC - Muscle (infection
myositis))
Infection With Unknown Anc (Infection
with unknown ANC - Neck NOS)
Infection With Unknown Anc (Infection
with unknown ANC - Nerve-cranial)
Infection With Unknown Anc (Infection
with unknown ANC - Nerve-peripheral)
Infection With Unknown Anc (Infection
with unknown ANC - Nose)
Infection With Unknown Anc (Infection
with unknown ANC - Oral cavity-gums
(gingivitis))
Infection With Unknown Anc (Infection
with unknown ANC - Pancreas)
Infection With Unknown Anc (Infection
with unknown ANC - Paranasal)
Infection With Unknown Anc (Infection
with unknown ANC - Pelvis NOS)
Infection With Unknown Anc (Infection
with unknown ANC - Penis)
Infection With Unknown Anc (Infection
with unknown ANC - Peristomal)
Infection With Unknown Anc (Infection
with unknown ANC - Peritoneal cavity)
Infection With Unknown Anc (Infection
with unknown ANC - Pharynx)
Infection With Unknown Anc (Infection
with unknown ANC - Pleura (empyema))
Infection With Unknown Anc (Infection
with unknown ANC - Prostate)
Infection With Unknown Anc (Infection
with unknown ANC - Rectum)
Infection With Unknown Anc (Infection
with unknown ANC - Salivary gland)
Infection With Unknown Anc (Infection
with unknown ANC - Scrotum)
Infection With Unknown Anc (Infection
with unknown ANC - Sinus)
Infection With Unknown Anc (Infection
with unknown ANC - Skin (cellulitis))
Infection With Unknown Anc (Infection
with unknown ANC - Small bowel NOS)
Infection With Unknown Anc (Infection
with unknown ANC - Soft tissue NOS)
Infection With Unknown Anc (Infection
with unknown ANC - Spinal cord
(myelitis))
Infection With Unknown Anc (Infection
with unknown ANC - Spleen)
Infection With Unknown Anc (Infection
with unknown ANC - Stomach)
Infection With Unknown Anc (Infection
with unknown ANC - Trachea)
Infection With Unknown Anc (Infection
with unknown ANC - Ungual (nails))
Infection With Unknown Anc (Infection
with unknown ANC - Upper aerodigestive
NOS)
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Infection With Unknown Anc (Infection
with unknown ANC - Upper airway NOS)
Infection With Unknown Anc (Infection
with unknown ANC - Ureter)
Infection With Unknown Anc (Infection
with unknown ANC - Urethra)
Infection With Unknown Anc (Infection
with unknown ANC - Urinary tract NOS)
Infection With Unknown Anc (Infection
with unknown ANC - Uterus)
Infection With Unknown Anc (Infection
with unknown ANC - Vagina)
Infection With Unknown Anc (Infection
with unknown ANC - Vein)
Infection With Unknown Anc (Infection
with unknown ANC - Vulva)
Culture Wound Positive (Infection with
unknown ANC - Wound)
Infection Nos (Infection-Other (Specify))
Infertility/sterility (Infertility/sterility)
Injection Site Reaction Nos (Injection site
reaction/extravasation changes)
Prothrombin Time Prolonged (INR
(International Normalized Ratio of
prothrombin time))
Insomnia Nec (Insomnia)
Intra-operative Injury (Intra-operative
injury - Abdomen NOS)
Intra-operative Injury (Intra-operative
injury - Adrenal gland)
Intra-operative Injury (Intra-operative
injury - Anal sphincter)
Intra-operative Injury (Intra-operative
injury - Anus)
Intra-operative Injury (Intra-operative
injury - Appendix)
Intra-operative Injury (Intra-operative
injury - Artery NOS)
Intra-operative Injury (Intra-operative
injury - Artery-aorta)
Intra-operative Injury (Intra-operative
injury - Artery-carotid)
Intra-operative Injury (Intra-operative
injury - Artery-cerebral)
Intra-operative Injury (Intra-operative
injury - Artery-extremity (lower))
Intra-operative Injury (Intra-operative
injury - Artery-extremity (upper))
Intra-operative Injury (Intra-operative
injury - Artery-hepatic)
Intra-operative Injury (Intra-operative
injury - Artery-major visceral artery)
Intra-operative Injury (Intra-operative
injury - Artery-pulmonary)
Intra-operative Injury (Intra-operative
injury - Biliary tree NOS)
Intra-operative Injury (Intra-operative
injury - Biliary tree-common bile duct)
Intra-operative Injury (Intra-operative
injury - Biliary tree-common hepatic duct)
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Intra-operative Injury (Intra-operative
injury - Biliary tree-left hepatic duct)
Intra-operative Injury (Intra-operative
injury - Biliary tree-right hepatic duct)
Bladder Perforation Postoperative (Intra-
operative injury - Bladder)
Intra-operative Injury (Intra-operative
injury - Bone)
Intra-operative Injury (Intra-operative
injury - Brachial plexus)
Intra-operative Injury (Intra-operative
injury - Brain)
Intra-operative Injury (Intra-operative
injury - Breast)
Intra-operative Injury (Intra-operative
injury - Bronchus)
Intra-operative Injury (Intra-operative
injury - Cartilage)
Intra-operative Injury (Intra-operative
injury - Cecum)
Intra-operative Injury (Intra-operative
injury - Cervix)
Intra-operative Injury (Intra-operative
injury - CN I (olfactory))
Intra-operative Injury (Intra-operative
injury - CN II (optic))
Intra-operative Injury (Intra-operative
injury - CN III (oculomotor))
Intra-operative Injury (Intra-operative
injury - CN IV (trochlear))
Intra-operative Injury (Intra-operative
injury - CN IX (glossopharyngeal) motor
pharynx)
Intra-operative Injury (Intra-operative
injury - CN IX (glossopharyngeal)
sensory ear-pharynx-tongue)
Intra-operative Injury (Intra-operative
injury - CN V (trigeminal) motor)
Intra-operative Injury (Intra-operative
injury - CN V (trigeminal) sensory)
Intra-operative Injury (Intra-operative
injury - CN VI (abducens))
Intra-operative Injury (Intra-operative
injury - CN VII (facial) motor-face)
Intra-operative Injury (Intra-operative
injury - CN VII (facial) sensory-taste)
Intra-operative Injury (Intra-operative
injury - CN VIII (vestibulocochlear))
Intra-operative Injury (Intra-operative
injury - CN X (vagus))
Intra-operative Injury (Intra-operative
injury - CN XI (spinal accessory))
Intra-operative Injury (Intra-operative
injury - CN XII (hypoglossal))
Intra-operative Injury (Intra-operative
injury - Colon)
Intra-operative Injury (Intra-operative
injury - Conjunctiva)
Intra-operative Injury (Intra-operative
injury - Cornea)
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Intra-operative Injury (Intra-operative
injury - Cranial nerve or branch NOS)
Intra-operative Injury (Intra-operative
injury - Duodenum)
Intra-operative Injury (Intra-operative
injury - Esophagus)
Intra-operative Injury (Intra-operative
injury - Extremity-lower)
Intra-operative Injury (Intra-operative
injury - Extremity-upper)
Intra-operative Injury (Intra-operative
injury - Eye NOS)
Intra-operative Injury (Intra-operative
injury - Face NOS)
Intra-operative Injury (Intra-operative
injury - Fallopian tube)
Intra-operative Injury (Intra-operative
injury - Gallbladder)
Intra-operative Injury (Intra-operative
injury - Gingiva)
Intra-operative Injury (Intra-operative
injury - Heart)
Intra-operative Injury (Intra-operative
injury - Ileum)
Intra-operative Injury (Intra-operative
injury - Inner ear)
Intra-operative Injury (Intra-operative
injury - Jejunum)
Intra-operative Injury (Intra-operative
injury - Joint)
Intra-operative Injury (Intra-operative
injury - Kidney)
Intra-operative Injury (Intra-operative
injury - Larynx)
Intra-operative Injury (Intra-operative
injury - Lens)
Intra-operative Injury (Intra-operative
injury - Ligament)
Intra-operative Injury (Intra-operative
injury - Lingual)
Intra-operative Injury (Intra-operative
injury - Lip/perioral area)
Intra-operative Injury (Intra-operative
injury - Liver)
Intra-operative Injury (Intra-operative
injury - Lung)
Intra-operative Injury (Intra-operative
injury - Lung thoracic)
Intra-operative Injury (Intra-operative
injury - Mediastinum)
Intra-operative Injury (Intra-operative
injury - Meninges)
Intra-operative Injury (Intra-operative
injury - Middle ear)
Intra-operative Injury (Intra-operative
injury - Muscle)
Intra-operative Injury (Intra-operative
injury - Nails)
Intra-operative Injury (Intra-operative
injury - Nasal cavity)
27 / 45
Adverse Events Form Toxicity Breast Cancer (NCT00513292)
Intra-operative Injury (Intra-operative
injury - Nasopharynx)
Intra-operative Injury (Intra-operative
injury - Neck NOS)
Intra-operative Injury (Intra-operative
injury - Nose)
Intra-operative Injury (Intra-operative
injury - Oral)
Intra-operative Injury (Intra-operative
injury - Oral cavity NOS)
Intra-operative Injury (Intra-operative
injury - Outer ear NOS)
Intra-operative Injury (Intra-operative
injury - Outer ear-pinna)
Intra-operative Injury (Intra-operative
injury - Ovary)
Intra-operative Injury (Intra-operative
injury - Pancreas)
Intra-operative Injury (Intra-operative
injury - Pancreatic duct)
Intra-operative Injury (Intra-operative
injury - Parathyroid)
Intra-operative Injury (Intra-operative
injury - Parotid gland)
Intra-operative Injury (Intra-operative
injury - Pelvis NOS)
Intra-operative Injury (Intra-operative
injury - Penis)
Intra-operative Injury (Intra-operative
injury - Peripheral motor NOS)
Intra-operative Injury (Intra-operative
injury - Peripheral sensory NOS)
Intra-operative Injury (Intra-operative
injury - Peritoneal cavity)
Intra-operative Injury (Intra-operative
injury - Pharynx)
Intra-operative Injury (Intra-operative
injury - Pituitary)
Intra-operative Injury (Intra-operative
injury - Pleura)
Intra-operative Injury (Intra-operative
injury - Prostate)
Intra-operative Injury (Intra-operative
injury - Rectum)
Intra-operative Injury (Intra-operative
injury - Recurrent laryngeal)
Intra-operative Injury (Intra-operative
injury - Retina)
Intra-operative Injury (Intra-operative
injury - Sacral plexus)
Intra-operative Injury (Intra-operative
injury - Salivary duct)
Intra-operative Injury (Intra-operative
injury - Salivary gland)
Intra-operative Injury (Intra-operative
injury - Sciatic)
Intra-operative Injury (Intra-operative
injury - Scrotum)
Intra-operative Injury (Intra-operative
injury - Sinus)
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Intra-operative Injury (Intra-operative
injury - Skin)
Intra-operative Injury (Intra-operative
injury - Small bowel NOS)
Intra-operative Injury (Intra-operative
injury - Soft tissue NOS)
Intra-operative Injury (Intra-operative
injury - Spinal cord)
Intra-operative Injury (Intra-operative
injury - Spleen)
Intra-operative Injury (Intra-operative
injury - Stoma (GI))
Intra-operative Injury (Intra-operative
injury - Stomach)
Intra-operative Injury (Intra-operative
injury - Teeth)
Intra-operative Injury (Intra-operative
injury - Tendon)
Intra-operative Injury (Intra-operative
injury - Testis)
Intra-operative Injury (Intra-operative
injury - Thoracic duct)
Intra-operative Injury (Intra-operative
injury - Thoracodorsal)
Intra-operative Injury (Intra-operative
injury - Thyroid)
Intra-operative Injury (Intra-operative
injury - Tongue)
Intra-operative Injury (Intra-operative
injury - Trachea)
Intra-operative Injury (Intra-operative
injury - Upper aerodigestive NOS)
Intra-operative Injury (Intra-operative
injury - Upper airway NOS)
Intra-operative Injury (Intra-operative
injury - Ureter)
Intra-operative Injury (Intra-operative
injury - Urethra)
Intra-operative Injury (Intra-operative
injury - Urinary conduit)
Intra-operative Injury (Intra-operative
injury - Urinary tract NOS)
Intra-operative Injury (Intra-operative
injury - Uterus)
Intra-operative Injury (Intra-operative
injury - Vagina)
Intra-operative Injury - Vein (Intra-
operative injury - Vein NOS)
Intra-operative Injury (Intra-operative
injury - Vein-extremity (lower))
Intra-operative Injury (Intra-operative
injury - Vein-extremity (upper))
Intra-operative Injury (Intra-operative
injury - Vein-hepatic)
Intra-operative Injury (Intra-operative
injury - Vein-inferior vena cava)
Intra-operative Injury (Intra-operative
injury - Vein-jugular)
Intra-operative Injury (Intra-operative
injury - Vein-major visceral vein)
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Intra-operative Injury (Intra-operative
injury - Vein-portal vein)
Intra-operative Injury (Intra-operative
injury - Vein-pulmonary)
Intra-operative Injury (Intra-operative
injury - Vein-superior vena cava)
Intra-operative Injury (Intra-operative
injury - Vulva)
Intra-operative Injury Other (Intra-
operative Injury-Other (Specify))
Iron Overload (Iron overload)
Menstruation Irregular (Irregular menses
(change from baseline))
Irritability (Irritability (children <3 years of
age))
Joint-effusion (Joint-effusion)
Joint-effusion (Joint-function)
Keratitis Nec (Keratitis (corneal
inflammation/corneal ulceration))
Laryngeal Nerve Dysfunction (Laryngeal
nerve dysfunction)
Leak (including Anastomotic), Gi (Leak
(including anastomotic), GI - Biliary tree)
Leak (including Anastomotic), Gi (Leak
(including anastomotic), GI - Esophagus)
Leak (including Anastomotic), Gi (Leak
(including anastomotic), GI - Large
bowel)
Leak (including Anastomotic), Gi (Leak
(including anastomotic), GI - Leak NOS)
Leak (including Anastomotic), Gi (Leak
(including anastomotic), GI - Pancreas)
Leak (including Anastomotic), Gi (Leak
(including anastomotic), GI - Pharynx)
Leak (including Anastomotic), Gi (Leak
(including anastomotic), GI - Rectum)
Leak (including Anastomotic), Gi (Leak
(including anastomotic), GI - Small
bowel)
Leak (including Anastomotic), Gi (Leak
(including anastomotic), GI - Stoma)
Leak (including Anastomotic), Gi (Leak
(including anastomotic), GI - Stomach)
Leak (including Anastomotic), Gu (Leak
(including anastomotic), GU - Bladder)
Leak (including Anastomotic), Gu (Leak
(including anastomotic), GU - Fallopian
tube)
Leak (including Anastomotic), Gu (Leak
(including anastomotic), GU - Kidney)
Leak (including Anastomotic), Gu (Leak
(including anastomotic), GU - Spermatic
cord)
Leak (including Anastomotic), Gu (Leak
(including anastomotic), GU - Stoma)
Leak (including Anastomotic), Gu (Leak
(including anastomotic), GU - Ureter)
Leak (including Anastomotic), Gu (Leak
(including anastomotic), GU - Urethra)
Leak (including Anastomotic), Gu (Leak
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(including anastomotic), GU - Uterus)
Leak (including Anastomotic), Gu (Leak
(including anastomotic), GU - Vagina)
Leak (including Anastomotic), Gu (Leak
(including anastomotic), GU - Vas
deferens)
Leak, Cerebrospinal Fluid (csf) (Leak,
cerebrospinal fluid (CSF))
Left Ventricular Diastolic Dysfunction
(Left ventricular diastolic dysfunction)
Left Ventricular Failure (Left ventricular
systolic dysfunction)
Leucopenia Nos (Leukocytes (total
WBC))
Encephalopathy Nos
(Leukoencephalopathy (radiolographic
findings))
Libido Decreased (Libido)
Lipase Increased (Lipase)
Hepatic Failure (Liver dysfunction/failure
(clinical))
Local Complication - Device/prosthesis-
related (Local complication -
device/prosthesis-related)
Lumbar Spine-range Of Motion (Lumbar
spine-range of motion)
Lymphatics Other (Lymphatics-Other
(Specify))
Lymphedema-related Fibrosis
(Lymphedema-related fibrosis)
Lymphocele (Lymphocele)
Lymphopenia (Lymphopenia)
Hypermagnesaemia (Magnesium,
serum-high (hypermagnesemia))
Blood Magnesium Decreased
(Magnesium, serum-low
(hypomagnesemia))
Malabsorption (Malabsorption)
Virilism (Masculinization of female)
Amnesia Nec (Memory impairment)
Mental Status (Mental status)
Metabolic/laboratory Other
(Metabolic/Laboratory-Other (Specify))
Mood Alteration - Agitation (Mood
alteration - agitation)
Anxiety Nec (Mood alteration - anxiety)
Depression Nec (Mood alteration -
depression)
Euphoric Mood (Mood alteration -
euphoria)
Mucositis/stomatitis (clinical Exam)
(Mucositis/stomatitis (clinical exam) -
Anus)
Mucositis/stomatitis (clinical Exam)
(Mucositis/stomatitis (clinical exam) -
Esophagus)
Mucositis/stomatitis (clinical Exam)
(Mucositis/stomatitis (clinical exam) -
Large bowel)
Mucositis/stomatitis (clinical Exam)
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(Mucositis/stomatitis (clinical exam) -
Larynx)
Mucositis/stomatitis (clinical Exam)
(Mucositis/stomatitis (clinical exam) -
Oral cavity)
Stomatitis (Mucositis/stomatitis (clinical
exam) - Pharynx)
Mucositis/stomatitis (clinical Exam)
(Mucositis/stomatitis (clinical exam) -
Rectum)
Mucositis/stomatitis (clinical Exam)
(Mucositis/stomatitis (clinical exam) -
Small bowel)
Mucositis/stomatitis (clinical Exam)
(Mucositis/stomatitis (clinical exam) -
Stomach)
Mucositis/stomatitis (clinical Exam)
(Mucositis/stomatitis (clinical exam) -
Trachea)
Mucositis/stomatitis
(functional/symptomatic)
(Mucositis/stomatitis
(functional/symptomatic) - Anus)
Mucositis/stomatitis
(functional/symptomatic)
(Mucositis/stomatitis
(functional/symptomatic) - Esophagus)
Mucositis/stomatitis
(functional/symptomatic)
(Mucositis/stomatitis
(functional/symptomatic) - Large bowel)
Mucositis/stomatitis
(functional/symptomatic)
(Mucositis/stomatitis
(functional/symptomatic) - Larynx)
Mucositis/stomatitis
(functional/symptomatic)
(Mucositis/stomatitis
(functional/symptomatic) - Oral cavity)
Mucositis/stomatitis
(functional/symptomatic)
(Mucositis/stomatitis
(functional/symptomatic) - Pharynx)
Mucositis/stomatitis
(functional/symptomatic)
(Mucositis/stomatitis
(functional/symptomatic) - Rectum)
Mucositis/stomatitis
(functional/symptomatic)
(Mucositis/stomatitis
(functional/symptomatic) - Small bowel)
Mucositis/stomatitis
(functional/symptomatic)
(Mucositis/stomatitis
(functional/symptomatic) - Stomach)
Mucositis/stomatitis
(functional/symptomatic)
(Mucositis/stomatitis
(functional/symptomatic) - Trachea)
Muscle Weakness, Generalized Or
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Specific Area (not Due To Neuropathy)
(Muscle weakness, generalized or
specific area (not due to neuropathy) -
Extraocular)
Muscle Weakness, Generalized Or
Specific Area (not Due To Neuropathy)
(Muscle weakness, generalized or
specific area (not due to neuropathy) -
Extremity-lower)
Muscle Weakness, Generalized Or
Specific Area (not Due To Neuropathy)
(Muscle weakness, generalized or
specific area (not due to neuropathy) -
Extremity-upper)
Muscle Weakness, Generalized Or
Specific Area (not Due To Neuropathy)
(Muscle weakness, generalized or
specific area (not due to neuropathy) -
Facial)
Muscle Weakness, Generalized Or
Specific Area (not Due To Neuropathy)
(Muscle weakness, generalized or
specific area (not due to neuropathy) -
Left-sided)
Muscle Weakness, Generalized Or
Specific Area (not Due To Neuropathy)
(Muscle weakness, generalized or
specific area (not due to neuropathy) -
Ocular)
Muscle Weakness, Generalized Or
Specific Area (not Due To Neuropathy)
(Muscle weakness, generalized or
specific area (not due to neuropathy) -
Pelvic)
Muscle Weakness, Generalized Or
Specific Area (not Due To Neuropathy)
(Muscle weakness, generalized or
specific area (not due to neuropathy) -
Right-sided)
Muscle Weakness, Generalized Or
Specific Area (not Due To Neuropathy)
(Muscle weakness, generalized or
specific area (not due to neuropathy) -
Trunk)
Muscle Weakness Nos (Muscle
weakness, generalized or specific area
(not due to neuropathy) - Whole
body/generalized)
Muscular/skeletal Hypoplasia
(Muscular/skeletal hypoplasia)
Musculoskeletal/soft Tissue Other
(Musculoskeletal/Soft Tissue-Other
(Specify))
Myelitis (Myelitis)
Myelodysplasia (Myelodysplasia)
Myocarditis Nos (Myocarditis)
Myositis (Myositis (inflammation/damage
of muscle))
Nail Abnormality Nos (Nail changes)
Nasal Cavity/paranasal Sinus Reactions
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(Nasal cavity/paranasal sinus reactions)
Nausea (Nausea)
Necrosis, Gi (Necrosis, GI - Anus)
Necrosis, Gi (Necrosis, GI -
Colon/cecum/appendix)
Necrosis, Gi (Necrosis, GI - Duodenum)
Necrosis, Gi (Necrosis, GI - Esophagus)
Necrosis, Gi (Necrosis, GI - Gallbladder)
Necrosis, Gi (Necrosis, GI - Hepatic)
Necrosis, Gi (Necrosis, GI - Ileum)
Necrosis, Gi (Necrosis, GI - Jejunum)
Necrosis, Gi (Necrosis, GI - Oral)
Necrosis, Gi (Necrosis, GI - Pancreas)
Necrosis, Gi (Necrosis, GI - Peritoneal
cavity)
Necrosis, Gi (Necrosis, GI - Pharynx)
Necrosis, Gi (Necrosis, GI - Rectum)
Necrosis, Gi (Necrosis, GI - Small bowel
NOS)
Necrosis, Gi (Necrosis, GI - Stoma)
Necrosis, Gi (Necrosis, GI - Stomach)
Neuroendocrine: Acth Deficiency
(Neuroendocrine: ACTH deficiency)
Inappropriate Adh Secretion
(Neuroendocrine: ADH secretion
abnormality (e.g., SIADH or low ADH))
Neuroendocrine: Gonadotropin Secretion
Abnormality (Neuroendocrine:
gonadotropin secretion abnormality)
Neuroendocrine: Growth Hormone
Secretion Abnormality (Neuroendocrine:
growth hormone secretion abnormality)
Neuroendocrine: Prolactin Hormone
Secretion Abnormality (Neuroendocrine:
prolactin hormone secretion abnormality)
Neurology Other (Neurology-Other
(Specify))
Parosmia (Neuropathy: cranial - CN I
Smell)
Cranial Nerve Injury Nos (Neuropathy:
cranial - CN II Vision)
Neuropathy: Cranial (Neuropathy: cranial
- CN III Pupil, upper eyelid, extra ocular
movements)
Neuropathy: Cranial (Neuropathy: cranial
- CN IV Downward, inward movement of
eye)
Neuropathy: Cranial (Neuropathy: cranial
- CN IX Motor-pharynx; Sensory-ear,
pharynx, tongue)
Neuropathy: Cranial (Neuropathy: cranial
- CN V Motor-jaw muscles; Sensory-
facial)
Neuropathy: Cranial (Neuropathy: cranial
- CN VI Lateral deviation of eye)
Neuropathy: Cranial (Neuropathy: cranial
- CN VII Motor-face; Sensory-taste)
Neuropathy: Cranial (Neuropathy: cranial
- CN VIII Hearing and balance)
Neuropathy: Cranial (Neuropathy: cranial
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- CN X Motor-palate; pharynx, larynx)
Neuropathy: Cranial (Neuropathy: cranial
- CN XI Motor-sternomastoid and
trapezius)
Neuropathy: Cranial (Neuropathy: cranial
- CN XII Motor-tongue)
Peripheral Motor Neuropathy
(Neuropathy: motor)
Peripheral Sensory Neuropathy
(Neuropathy: sensory)
Neutropenia (Neutrophils/granulocytes
(ANC/AGC))
Blindness Night (Night blindness
(nyctalopia))
Nystagmus Nos (Nystagmus)
Obesity (Obesity)
Obstruction, Gi (Obstruction, GI -
Cecum)
Obstruction, Gi (Obstruction, GI - Colon)
Obstruction, Gi (Obstruction, GI -
Duodenum)
Obstruction, Gi (Obstruction, GI -
Esophagus)
Obstruction, Gi (Obstruction, GI -
Gallbladder)
Obstruction, Gi (Obstruction, GI - Ileum)
Obstruction, Gi (Obstruction, GI -
Jejunum)
Obstruction, Gi (Obstruction, GI -
Rectum)
Obstruction, Gi (Obstruction, GI - Small
bowel NOS)
Obstruction, Gi (Obstruction, GI - Stoma)
Obstruction, Gi (Obstruction, GI -
Stomach)
Obstruction, Gu (Obstruction, GU -
Bladder)
Obstruction, Gu (Obstruction, GU -
Fallopian tube)
Obstruction, Gu (Obstruction, GU -
Prostate)
Obstruction, Gu (Obstruction, GU -
Spermatic cord)
Obstruction, Gu (Obstruction, GU -
Stoma)
Obstruction, Gu (Obstruction, GU -
Testes)
Ureteric Obstruction (Obstruction, GU -
Ureter)
Obstruction, Gu (Obstruction, GU -
Urethra)
Obstruction, Gu (Obstruction, GU -
Uterus)
Obstruction, Gu (Obstruction, GU -
Vagina)
Obstruction, Gu (Obstruction, GU - Vas
deferens)
Obstruction/stenosis Of Airway
(Obstruction/stenosis of airway -
Bronchus)
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Obstruction/stenosis Of Airway
(Obstruction/stenosis of airway - Larynx)
Obstruction/stenosis Of Airway
(Obstruction/stenosis of airway -
Pharynx)
Obstruction/stenosis Of Airway
(Obstruction/stenosis of airway -
Trachea)
Conjunctivitis Nec (Ocular surface
disease)
Ocular/visual Other (Ocular/Visual-Other
(Specify))
Odor (patient Odor) (Odor (patient odor))
Diplopia (Ophthalmoplegia/diplopia
(double vision))
Opportunistic Infection Associated With
>=grade 2 Lymphopenia (Opportunistic
infection associated with >=Grade 2
lymphopenia)
Optic Disc Edema (Optic disc edema)
Orgasmic Dysfunction (Orgasmic
dysfunction)
Osteonecrosis (Osteonecrosis (avascular
necrosis))
Osteoporosis (Osteoporosis)
Otitis Externa (exc Boil Of Meatus) Nos
(Otitis, external ear (non-infectious))
Otitis Media Serous Nos (Otitis, middle
ear (non-infectious))
Abdominal Pain Nos (Pain - Abdomen
NOS)
Pain (Pain - Anus)
Pain (Pain - Back)
Pain (Pain - Bladder)
Bone Pain (Pain - Bone)
Pain (Pain - Breast)
Pain (Pain - Buttock)
Pain (Pain - Cardiac/heart)
Pain (Pain - Chest wall)
Chest Pain (Pain - Chest/thorax NOS)
Pain (Pain - Dental/teeth/peridontal)
Pain (Pain - Esophagus)
Earache (Pain - External ear)
Pain (Pain - Extremity-limb)
Pain (Pain - Eye)
Pain (Pain - Face)
Pain (Pain - Gallbladder)
Headache Nos (Pain - Head/headache)
Pain (Pain - Intestine)
Arthralgia (Pain - Joint)
Pain (Pain - Kidney)
Pain (Pain - Larynx)
Pain (Pain - Lip)
Hepatic Pain (Pain - Liver)
Pain (Pain - Lymph node)
Pain (Pain - Middle ear)
Myalgia (Pain - Muscle)
Pain (Pain - Neck)
Neuralgia Nos (Pain -
Neuralgia/peripheral nerve)
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Pain (Pain - Oral cavity)
Pain (Pain - Oral-gums)
Pain (Pain - Ovulatory)
Pain (Pain - Pain NOS)
Pelvic Pain Nos (Pain - Pelvis)
Pain (Pain - Penis)
Pain (Pain - Pericardium)
Pain (Pain - Perineum)
Pain (Pain - Peritoneum)
Pain (Pain - Phantom (pain associated
with missing limb))
Pleuritic Pain (Pain - Pleura)
Pain (Pain - Prostate)
Proctalgia (Pain - Rectum)
Pain (Pain - Scalp)
Pain (Pain - Scrotum)
Pain (Pain - Sinus)
Pain (Pain - Skin)
Pain (Pain - Stomach)
Pain (Pain - Testicle)
Pain (Pain - Throat/pharynx/larynx)
Tumour Pain (Pain - Tumor pain)
Dysuria (Pain - Urethra)
Dysmenorrhoea (Pain - Uterus)
Pain (Pain - Vagina)
Pain Other (Pain-Other (Specify))
Palpitations (Palpitations)
Pancreas, Exocrine Enzyme Deficiency
(Pancreas, exocrine enzyme deficiency)
Pancreatic Endocrine: Glucose
Intolerance (Pancreatic endocrine:
glucose intolerance)
Pancreatitis Nos (Pancreatitis)
Parathyroid Function, Low
(hypoparathyroidism) (Parathyroid
function, low (hypoparathyroidism))
Perforation, Gi (Perforation, GI -
Appendix)
Perforation, Gi (Perforation, GI - Biliary
tree)
Perforation, Gi (Perforation, GI - Cecum)
Perforation, Gi (Perforation, GI - Colon)
Perforation, Gi (Perforation, GI -
Duodenum)
Perforation, Gi (Perforation, GI -
Esophagus)
Perforation, Gi (Perforation, GI -
Gallbladder)
Perforation, Gi (Perforation, GI - Ileum)
Perforation, Gi (Perforation, GI -
Jejunum)
Perforation, Gi (Perforation, GI - Rectum)
Perforation, Gi (Perforation, GI - Small
bowel NOS)
Perforation, Gi (Perforation, GI -
Stomach)
Perforation, Gu (Perforation, GU -
Bladder)
Perforation, Gu (Perforation, GU -
Fallopian tube)
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Perforation, Gu (Perforation, GU -
Kidney)
Perforation, Gu (Perforation, GU - Ovary)
Perforation, Gu (Perforation, GU -
Prostate)
Perforation, Gu (Perforation, GU -
Spermatic cord)
Perforation, Gu (Perforation, GU -
Stoma)
Perforation, Gu (Perforation, GU -
Testes)
Perforation, Gu (Perforation, GU - Ureter)
Perforation, Gu (Perforation, GU -
Urethra)
Perforation, Gu (Perforation, GU -
Uterus)
Perforation, Gu (Perforation, GU -
Vagina)
Perforation, Gu (Perforation, GU - Vas
deferens)
Pericardial Effusion (Pericardial effusion
(non-malignant))
Pericarditis (Pericarditis)
Peripheral Ischaemia Nos (Peripheral
arterial ischemia)
Personality Change
(Personality/behavioral)
Petechiae (Petechiae/purpura
(hemorrhage/bleeding into skin or
mucosa))
Phlebitis Superficial (Phlebitis (including
superficial thrombosis))
Phlebolymphatic Cording
(Phlebolymphatic cording)
Hypophosphataemia (Phosphate, serum-
low (hypophosphatemia))
Photosensitivity Reaction Nos
(Photosensitivity)
Phrenic Nerve Dysfunction (Phrenic
nerve dysfunction)
Platelet Count Decreased (Platelets)
Pleural Effusion (Pleural effusion (non-
malignant))
Pneumonitis Nos
(Pneumonitis/pulmonary infiltrates)
Pneumothorax Nos (Pneumothorax)
Portal Hypertension (Portal vein flow)
Hyperkalaemia (Potassium, serum-high
(hyperkalemia))
Hypokalaemia (Potassium, serum-low
(hypokalemia))
Proctitis Nos (Proctitis)
Prolapse Of Stoma, Gi (Prolapse of
stoma, GI)
Prolapse Of Stoma, Gu (Prolapse of
stoma, GU)
Prolonged Chest Tube Drainage Or Air
Leak After Pulmonary Resection
(Prolonged chest tube drainage or air
leak after pulmonary resection)
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Prolonged Intubation After Pulmonary
Resection (>24 Hrs After Surgery)
(Prolonged intubation after pulmonary
resection (>24 hrs after surgery))
Electrocardiogram Qt Prolonged
(Prolonged QTc interval)
Proptosis/enophthalmos
(Proptosis/enophthalmos)
Proteinuria Present (Proteinuria)
Pruritus Nos (Pruritus/itching)
Delusion Nos (Psychosis
(hallucinations/delusions))
Activated Partial Thromboplastin Time
Prolonged (PTT (Partial thromboplastin
time))
Puberty (delayed) (Puberty (delayed))
Puberty (precocious) (Puberty
(precocious))
Pulmonary Fibrosis (Pulmonary fibrosis
(radiographic changes))
Pulmonary Hypertension (Pulmonary
hypertension)
Pulmonary/upper Respiratory Other
(Pulmonary/Upper Respiratory-Other
(Specify))
Upper Motor Neurone Lesion (Pyramidal
tract dysfunction (e.g., increased tone,
hyperreflexia, positive Babinski,
decreased fine motor coordination))
Rash: Acne/acneiform (Rash:
acne/acneiform)
Radiation Recall Syndrome (Rash:
dermatitis associated with radiation -
Chemoradiation)
Dermatitis Radiation Nos (Rash:
dermatitis associated with radiation -
Radiation)
Erythema Multiforme (Rash: erythema
multiforme (e.g., Stevens-Johnson
syndrome, toxic epidermal necrolysis))
Localised Exfoliation (Rash: hand-foot
skin reaction)
Dermatitis Exfoliative Nos
(Rash/desquamation)
Renal Failure Nos (Renal failure)
Renal/genitourinary Other
(Renal/Genitourinary-Other (Specify))
Restrictive Cardiomyopathy (Restrictive
cardiomyopathy)
Retinal Detachment (Retinal
detachment)
Retinoic Acid Syndrome (Retinoic acid
syndrome")
Retinopathy (Retinopathy)
Right Ventricular Dysfunction (cor
Pulmonale) (Right ventricular dysfunction
(cor pulmonale))
Rigors (Rigors/chills)
Salivary Gland Disorder Nos (Salivary
gland changes/saliva)
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Scleral Necrosis/melt (Scleral
necrosis/melt)
Secondary Malignancy Possibly Related
To Cancer Treatment (Secondary
Malignancy-possibly related to cancer
treatment (Specify))
Convulsions Nos (Seizure)
Seroma (Seroma)
Serum Sickness (Serum sickness)
Sexual/reproductive Function Other
(Sexual/Reproductive Function-Other
(Specify))
Short Stature (Short stature)
Skin Breakdown/decubitus Ulcer (Skin
breakdown/decubitus ulcer)
Hypernatraemia (Sodium, serum-high
(hypernatremia))
Hyponatraemia (Sodium, serum-low
(hyponatremia))
Soft Tissue Necrosis (Soft tissue
necrosis - Abdomen)
Soft Tissue Necrosis (Soft tissue
necrosis - Extremity-lower)
Soft Tissue Necrosis (Soft tissue
necrosis - Extremity-upper)
Soft Tissue Necrosis (Soft tissue
necrosis - Head)
Soft Tissue Necrosis (Soft tissue
necrosis - Neck)
Soft Tissue Necrosis (Soft tissue
necrosis - Pelvic)
Soft Tissue Necrosis (Soft tissue
necrosis - Thorax)
Depressed Level Of Consciousness
(Somnolence/depressed level of
consciousness)
Speech Disorder Nec (Speech
impairment (e.g., dysphasia or aphasia))
Splenic Function (Splenic function)
Striae (Striae)
Stricture/stenosis (including
Anastomotic), Gi (Stricture/stenosis
(including anastomotic), GI - Anus)
Stricture/stenosis (including
Anastomotic), Gi (Stricture/stenosis
(including anastomotic), GI - Biliary tree)
Stricture/stenosis (including
Anastomotic), Gi (Stricture/stenosis
(including anastomotic), GI - Cecum)
Stricture/stenosis (including
Anastomotic), Gi (Stricture/stenosis
(including anastomotic), GI - Colon)
Stricture/stenosis (including
Anastomotic), Gi (Stricture/stenosis
(including anastomotic), GI - Duodenum)
Stricture/stenosis (including
Anastomotic), Gi (Stricture/stenosis
(including anastomotic), GI - Esophagus)
Stricture/stenosis (including
Anastomotic), Gi (Stricture/stenosis
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(including anastomotic), GI - Ileum)
Stricture/stenosis (including
Anastomotic), Gi (Stricture/stenosis
(including anastomotic), GI - Jejunum)
Stricture/stenosis (including
Anastomotic), Gi (Stricture/stenosis
(including anastomotic), GI -
Pancreas/pancreatic duct)
Stricture/stenosis (including
Anastomotic), Gi (Stricture/stenosis
(including anastomotic), GI - Pharynx)
Stricture/stenosis (including
Anastomotic), Gi (Stricture/stenosis
(including anastomotic), GI - Rectum)
Stricture/stenosis (including
Anastomotic), Gi (Stricture/stenosis
(including anastomotic), GI - Small bowel
NOS)
Stricture/stenosis (including
Anastomotic), Gi (Stricture/stenosis
(including anastomotic), GI - Stoma)
Stricture/stenosis (including
Anastomotic), Gi (Stricture/stenosis
(including anastomotic), GI - Stomach)
Stricture/stenosis (including
Anastomotic), Gu (Stricture/stenosis
(including anastomotic), GU - Bladder)
Stricture/stenosis (including
Anastomotic), Gu (Stricture/stenosis
(including anastomotic), GU - Fallopian
tube)
Stricture/stenosis (including
Anastomotic), Gu (Stricture/stenosis
(including anastomotic), GU - Prostate)
Stricture/stenosis (including
Anastomotic), Gu (Stricture/stenosis
(including anastomotic), GU - Spermatic
cord)
Stricture/stenosis (including
Anastomotic), Gu (Stricture/stenosis
(including anastomotic), GU - Stoma)
Stricture/stenosis (including
Anastomotic), Gu (Stricture/stenosis
(including anastomotic), GU - Testes)
Stricture/stenosis (including
Anastomotic), Gu (Stricture/stenosis
(including anastomotic), GU - Ureter)
Stricture/stenosis (including
Anastomotic), Gu (Stricture/stenosis
(including anastomotic), GU - Urethra)
Stricture/stenosis (including
Anastomotic), Gu (Stricture/stenosis
(including anastomotic), GU - Uterus)
Stricture/stenosis (including
Anastomotic), Gu (Stricture/stenosis
(including anastomotic), GU - Vagina)
Stricture/stenosis (including
Anastomotic), Gu (Stricture/stenosis
(including anastomotic), GU - Vas
deferens)
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Supraventricular And Nodal Arrhythmia
(Supraventricular and nodal arrhythmia -
Atrial fibrillation)
Supraventricular And Nodal Arrhythmia
(Supraventricular and nodal arrhythmia -
Atrial flutter)
Supraventricular And Nodal Arrhythmia
(Supraventricular and nodal arrhythmia -
Atrial tachycardia/paroxysmal atrial
tachycardia)
Supraventricular And Nodal Arrhythmia
(Supraventricular and nodal arrhythmia -
Nodal/junctional)
Supraventricular And Nodal Arrhythmia
(Supraventricular and nodal arrhythmia -
Sinus arrhythmia)
Sinus Bradycardia (Supraventricular and
nodal arrhythmia - Sinus bradycardia)
Sinus Tachycardia (Supraventricular and
nodal arrhythmia - Sinus tachycardia)
Supraventricular Arrhythmia Nos
(Supraventricular and nodal arrhythmia -
Supraventricular arrhythmia NOS)
Supraventricular And Nodal Arrhythmia -
Supraventricular Extrasystoles
(premature Atrial Contractions;
Premature Nodal/junctional
Contractions) (Supraventricular and
nodal arrhythmia - Supraventricular
extrasystoles (premature atrial
contractions; premature nodal/junctional
contractions))
Supraventricular And Nodal Arrhythmia
(Supraventricular and nodal arrhythmia -
Supraventricular tachycardia)
Sweating Increased (Sweating
(diaphoresis))
Syncope (Syncope (fainting))
Syndromes Other (Syndromes-Other
(Specify))
Taste Disturbance (Taste alteration
(dysgeusia))
Telangiectasia (Telangiectasia)
Thrombosis/embolism (vascular Access-
related) (Thrombosis/embolism (vascular
access-related))
Thrombosis Nos
(Thrombosis/thrombus/embolism)
Thrombotic Microangiopathy (e.g.,
Thrombotic Thrombocytopenic
Purpura[ttp] Or Hemolytic Uremic
Syndrome[hus]) (Thrombotic
microangiopathy (e.g., thrombotic
thrombocytopenic purpura or hemolytic
uremic syndrome))
Thyroid Function, High (hyperthyroidism,
Thyrotoxicosis) (Thyroid function, high
(hyperthyroidism, thyrotoxicosis))
Hypothyroidism (Thyroid function, low
(hypothyroidism))
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Tinnitus (Tinnitus)
Tremor Nec (Tremor)
Hypertriglyceridaemia (Triglyceride,
serum-high (hypertriglyceridemia))
Trismus (difficulty, Restriction Or Pain
When Opening Mouth) (Trismus
(difficulty, restriction or pain when
opening mouth))
Tumour Flare (Tumor flare)
Tumour Lysis Syndrome (Tumor lysis
syndrome)
Caecitis (Typhlitis (cecal inflammation))
Ulcer, Gi (Ulcer, GI - Anus)
Ulcer, Gi (Ulcer, GI - Cecum)
Ulcer, Gi (Ulcer, GI - Colon)
Duodenal Ulcer (Ulcer, GI - Duodenum)
Ulcer, Gi (Ulcer, GI - Esophagus)
Ulcer, Gi (Ulcer, GI - Ileum)
Ulcer, Gi (Ulcer, GI - Jejunum)
Ulcer, Gi (Ulcer, GI - Rectum)
Ulcer, Gi (Ulcer, GI - Small bowel NOS)
Ulcer, Gi (Ulcer, GI - Stoma)
Gastric Ulcer (Ulcer, GI - Stomach)
Ulceration (Ulceration)
Hyperuricaemia (Uric acid, serum-high
(hyperuricemia))
Fanconi Syndrome (Urinary electrolyte
wasting (e.g., Fanconi's syndrome, renal
tubular acidosis))
Urinary Frequency (Urinary
frequency/urgency)
Urinary Retention (Urinary retention
(including neurogenic bladder))
Urine Discolouration (Urine color
change)
Urticaria Nos (Urticaria (hives, welts,
wheals))
Uveitis (Uveitis)
Vaginal Discharge (non-infectious)
(Vaginal discharge (non-infectious))
Vulvovaginal Dryness (Vaginal dryness)
Vaginal Mucositis (Vaginal mucositis)
Vaginal Stenosis/length (Vaginal
stenosis/length)
Vaginitis (Vaginitis (not due to infection))
Valvular Heart Disease (Valvular heart
disease)
Vascular Other (Vascular-Other
(Specify))
Vasculitis Nos (Vasculitis)
Vasovagal Attack (Vasovagal episode)
Ventricular Arrhythmia (Ventricular
arrhythmia - Bigeminy)
Ventricular Arrhythmia (Ventricular
arrhythmia - Idioventricular rhythm)
Ventricular Arrhythmia (Ventricular
arrhythmia - PVCs)
Ventricular Arrhythmia (Ventricular
arrhythmia - Torsade de pointes)
Ventricular Arrhythmia (Ventricular
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arrhythmia - Trigeminy)
Ventricular Arrhythmia Nos (Ventricular
arrhythmia - Ventricular arrhythmia NOS)
Ventricular Arrhythmia (Ventricular
arrhythmia - Ventricular fibrillation)
Ventricular Arrhythmia (Ventricular
arrhythmia - Ventricular flutter)
Ventricular Arrhythmia (Ventricular
arrhythmia - Ventricular tachycardia)
Vessel Injury-artery (Vessel injury-artery
- Aorta)
Vessel Injury-artery (Vessel injury-artery
- Carotid)
Vessel Injury-artery (Vessel injury-artery
- Extremity-lower)
Vessel Injury-artery (Vessel injury-artery
- Extremity-upper)
Vessel Injury-artery (Vessel injury-artery
- Other NOS)
Vessel Injury-artery (Vessel injury-artery
- Visceral)
Vessel Injury-vein (Vessel injury-vein -
Extremity-lower)
Vessel Injury-vein (Vessel injury-vein -
Extremity-upper)
Vessel Injury-vein (Vessel injury-vein -
IVC)
Vessel Injury-vein (Vessel injury-vein -
Jugular)
Vessel Injury-vein (Vessel injury-vein -
Other NOS)
Vessel Injury-vein (Vessel injury-vein -
SVC)
Vessel Injury-vein (Vessel injury-vein -
Viscera)
Viral Hepatitis (Viral hepatitis)
Visceral Arterial Ischaemia (Visceral
arterial ischemia (non-myocardial))
Vision Blurred (Vision-blurred vision)
Photopsia (Vision-flashing lights/floaters)
Photophobia (Vision-photophobia)
Vital Capacity (Vital capacity)
Vitreous Hemorrhage (Vitreous
hemorrhage)
Dysphonia (Voice changes/dysarthria
(e.g., hoarseness, loss or alteration in
voice, laryngitis))
Vomiting Nos (Vomiting)
Lacrimation Increased (Watery eye
(epiphora, tearing))
Weight Increased (Weight gain)
Weight Decreased (Weight loss)
Culture Wound Negative (Wound
complication, non-infectious)
Not Assessed
Not present
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CTC Adverse Event Grade (1-5)
CTC AE Attribution Code (see above)
Definite (definite)
Possible (possible)
Probable (probable)
Unlikely (unlikely)
Unrelated (unrelated)
Were any additional adverse events experienced
by the patient
Yes
No
CTC Adverse Event Term Other
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Toxicity - Breast Cancer - Adjuvant Adverse
Event Form - 2280079v3.0
Breast Cancer - Adjuvant Adverse Event Form
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=DA18B3BC-
1877-0671-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/9617
Breast Cancer - Adjuvant Adverse
Event Form
Crf Header
Coordinating Group Protocol No.
Coordinating Group Code
Protocol Title
Patient Study ID
Institution/Affiliate
Other Patient ID
Participating Group Code
Patient Name (initials acceptable)
Breast: Form Administration
Person Completing Form
Are data amended? (If data are amended, please
circle in red when using paper form)
Yes
No
Breast: Adverse Events
CTC Adverse Event Term (Non-Hematologic
examples only)
Anorexia (Anorexia)
Diarrhoea Nos (Diarrhea)
Nausea (Nausea)
Dermatitis Exfoliative Nos
(Rash/desquamation)
Vomiting Nos (Vomiting)
CTC Adverse Event Term (Non-Hematologic
examples only)
Anorexia (Anorexia)
Diarrhoea Nos (Diarrhea)
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Nausea (Nausea)
Dermatitis Exfoliative Nos
(Rash/desquamation)
Vomiting Nos (Vomiting)
Other CTC Adverse Event Term not listed (s)
Other CTC Adverse Event Term not listed (s)
CTC Adverse Event Grade (Only report Grade 3-
5 for non-hematologic)
CTC Adverse Event Grade (Only report Grade 3-
5 for non-hematologic)
Comments
Comments
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Toxicity - Breast Cancer - Adjuvant Adverse Event Form - 2280079v3.0
Toxicity - Lung Cancer - Adverse Event
Form - 2262800v3.0
Lung Cancer - Adverse Event Form
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=DE33598D-
A1FD-3B22-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/9621
Lung Cancer - Adverse Event Form
Crf Header
Coordinating Group Protocol No.
Coordinating Group Code
Protocol Title
Patient Study ID
Institution/Affiliate
Other Patient ID
Participating Group Code
Patient Name (initials acceptable)
Lung: Adverse Events
Other CTC Adverse Event Term not listed (s)
Other CTC Adverse Event Term not listed (s)
CTC Adverse Event Grade (Only report Grade 3-
5 for non-hematologic)
CTC Adverse Event Grade (Only report Grade 3-
5 for non-hematologic)
CTC Adverse Event Term (Non-Hematologic
examples only)
Anorexia (Anorexia)
Diarrhoea Nos (Diarrhea)
Nausea (Nausea)
Dermatitis Exfoliative Nos
(Rash/desquamation)
Vomiting Nos (Vomiting)
CTC Adverse Event Term (Non-Hematologic
1 / 2
examples only)
Anorexia (Anorexia)
Diarrhoea Nos (Diarrhea)
Nausea (Nausea)
Dermatitis Exfoliative Nos
(Rash/desquamation)
Vomiting Nos (Vomiting)
Comments
Comments
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Toxicity - Lung Cancer - Adverse Event Form - 2262800v3.0
Toxicity - Brain Cancer - Adverse Event
Form - 2263172v3.0
Brain Cancer - Adverse Event Form
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=DE93FBC6-
0592-249A-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/9626
Brain Cancer - Adverse Event Form
Crf Header
Coordinating Group Protocol No.
Coordinating Group Code
Protocol Title
Patient Study ID
Institution/Affiliate
Other Patient ID
Participating Group Code
Patient Name (initials acceptable)
Brain: Form Administration
Person Completing Form
Are data amended (If data are amended, please
circle in red when using paper form)
Yes
No
Brain: Adverse Events
Adverse Event Reporting From Date (MM DD
YYYY)
Adverse Event Reporting To Date (MM DD
YYYY)
CTC Adverse Event Term (Non-hematologic)
Anorexia (Anorexia)
Diarrhoea Nos (Diarrhea)
Nausea (Nausea)
Dermatitis Exfoliative Nos
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(Rash/desquamation)
Vomiting Nos (Vomiting)
CTC Adverse Event Term (Non-hematologic)
Anorexia (Anorexia)
Diarrhoea Nos (Diarrhea)
Nausea (Nausea)
Dermatitis Exfoliative Nos
(Rash/desquamation)
Vomiting Nos (Vomiting)
Other CTC Adverse Event Term not listed
Other CTC Adverse Event Term not listed
Other CTC Adverse Event Term not listed
Other CTC Adverse Event Term not listed
CTC Adverse Event Grade (Only report Grade 3-
5 for non-hematologic)
CTC Adverse Event Grade (Only report Grade 3-
5 for non-hematologic)
CTC Adverse Event Attribution Code
Definite (Definite)
Possible (Possible)
Probable (Probable)
Unlikely (Unlikely)
Unrelated (Unrelated)
CTC Adverse Event Attribution Code
Definite (Definite)
Possible (Possible)
Probable (Probable)
Unlikely (Unlikely)
Unrelated (Unrelated)
Comments
Comments
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Neoplasms, Breast NCT00490139 Toxicity - BIG 2-06 / NCCTG
N063D / EGF106708 - Adverse Event (AE) - 2640617v1.0
BIG 2-06 / NCCTG N063D / EGF106708 - Adverse Event
(AE)
ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment
Optimisation) Study; BIG 2-06/N063D
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=31129CA6-
A46E-2394-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/9627
BIG 2-06 / NCCTG N063D /
EGF106708 - Adverse Event (AE)
Header Module
Centre No.
Subject No.
Adverse Event (ae)
AE Name
Acidosis Nos (Acidosis (metabolic or
respiratory))
Capillary Leak Syndrome (Acute
vascular leak syndrome)
Adrenal Insufficiency (Adrenal
insufficiency)
Adult Respiratory Distress Syndrome
(Adult respiratory distress syndrome
(ARDS))
Blood Albumin Decreased (Albumin,
serum-low (hypoalbuminemia))
Alcohol Intolerance Syndrome
(antabuse-like Syndrome) (Alcohol
intolerance syndrome (antabuse-like
syndrome))
Blood Alkaline Phosphatase Nos
Increased (Alkaline phosphatase)
Alkalosis Nos (Alkalosis (metabolic or
respiratory))
Hypersensitivity Nos (Allergic
reaction/hypersensitivity (including drug
fever))
Rhinitis Allergic Nos (Allergic rhinitis
(including sneezing, nasal stuffiness,
postnasal drip))
Allergy/immunology Other
(Allergy/Immunology-Other (Specify))
Alanine Aminotransferase Increased
(ALT, SGPT (serum glutamic pyruvic
transaminase))
Blood Amylase Increased (Amylase)
Anorexia (Anorexia)
Apnoea (Apnea)
Arachnoiditis
(Arachnoiditis/meningismus/radiculitis)
Arthritis Nos (Arthritis (non-septic))
Ascites (Ascites (non-malignant))
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Aspiration (Aspiration)
Aspartate Aminotransferase Increased
(AST, SGOT (serum glutamic oxaloacetic
transaminase))
Ataxia Nec (Ataxia (incoordination))
Atelectasis (Atelectasis)
Atrophy, Skin (Atrophy, skin)
Atrophy, Subcutaneous Fat (Atrophy,
subcutaneous fat)
Auditory/ear Other (Auditory/Ear-Other
(Specify))
Autoimmune Disorder Nos (Autoimmune
reaction)
Blood Bicarbonate Decreased
(Bicarbonate, serum-low)
Blood Bilirubin Increased (Bilirubin
(hyperbilirubinemia))
Bladder Disorder Nos (Bladder spasms)
Blood/bone Marrow Other (Blood/Bone
Marrow-Other (Specify))
Bone Age (alteration In Bone Age) (Bone
age (alteration in bone age))
Bone Growth: Femoral Head; Slipped
Capital Femoral Epiphysis (Bone growth:
femoral head; slipped capital femoral
epiphysis)
Bone Growth: Limb Length Discrepancy
(Bone growth: limb length discrepancy)
Bone Growth: Spine Kyphosis/lordosis
(Bone growth: spine kyphosis/lordosis)
Bone Marrow Depression Nos (Bone
marrow cellularity)
Bone: Spine-scoliosis (Bone: spine-
scoliosis)
Brachial Plexopathy (Brachial
plexopathy)
Breast Function/lactation (Breast
function/lactation)
Breast Nipple/areolar Deformity (Breast
nipple/areolar deformity)
Breast Volume/hypoplasia (Breast
volume/hypoplasia)
Bronchospasm, Wheezing
(Bronchospasm, wheezing)
Ecchymosis (Bruising (in absence of
grade 3 or 4 thrombocytopenia))
Burn (Burn)
Hypercalcaemia (Calcium, serum-high
(hypercalcemia))
Hypocalcaemia (Calcium, serum-low
(hypocalcemia))
Pulmonary Function Test Nos Decreased
(Carbon monoxide diffusion capacity
(DL(co)))
Arrhythmia Nos (Cardiac Arrhythmia-
Other (Specify))
Cardiac General Other (Cardiac
General-Other (Specify))
Myocardial Ischaemia (Cardiac
ischemia/infarction)
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Cardiac Troponin I Increased (Cardiac
troponin I (cTnI))
Cardiac Troponin T Increased (Cardiac
troponin T (cTnT))
Cardiopulmonary Arrest, Cause
Unknown (non-fatal) (Cardiopulmonary
arrest, cause unknown (non-fatal))
Cataract Nec (Cataract)
Cd4 Lymphocytes Decreased (CD4
count)
Cervical Spine-range Of Motion (Cervical
spine-range of motion)
Chelitis (Cheilitis)
Cholecystitis (Cholecystitis)
Hypercholesteraemia (Cholesterol,
serum-high (hypercholesteremia))
Chyle Or Lymph Leakage (Chyle or
lymph leakage)
Chylothorax (Chylothorax)
Cerebral Ischaemia (CNS
cerebrovascular ischemia)
Cns Necrosis/cystic Progression (CNS
necrosis/cystic progression)
Coagulation Disorder Nos (Coagulation-
Other (Specify))
Learning Disorder Nos (Cognitive
disturbance)
Colitis Nos (Colitis)
Colitis, Infectious (e.g., Clostridium
Difficile) (Colitis, infectious (e.g.,
Clostridium difficile))
Ventricular Asystole (Conduction
abnormality/Atrioventricular heart block -
Asystole)
Conduction Abnormality/atrioventricular
Heart Block (Conduction
abnormality/Atrioventricular heart block -
AV block-first degree)
Conduction Abnormality/atrioventricular
Heart Block - Av Block-second Degree
Mobitz Type I (wenckebach) (Conduction
abnormality/Atrioventricular heart block -
AV block-Second degree Mobitz Type I
(Wenckebach))
Conduction Abnormality/atrioventricular
Heart Block (Conduction
abnormality/Atrioventricular heart block -
AV block-second degree Mobitz Type II)
Conduction Abnormality/atrioventricular
Heart Block (Conduction
abnormality/Atrioventricular heart block -
AV block-third degree (complete AV
block))
Conduction Abnormality/atrioventricular
Heart Block (Conduction
abnormality/Atrioventricular heart block -
Conduction abnormality NOS)
Conduction Abnormality/atrioventricular
Heart Block (Conduction
abnormality/Atrioventricular heart block -
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Sick sinus syndrome)
Conduction Abnormality/atrioventricular
Heart Block (Conduction
abnormality/Atrioventricular heart block -
Stokes-Adams syndrome)
Conduction Abnormality/atrioventricular
Heart Block (Conduction
abnormality/Atrioventricular heart block -
Wolff-Parkinson-White syndrome)
Confusion (Confusion)
Constipation (Constipation)
Constitutional Symptoms Other
(Constitutional Symptoms-Other
(Specify))
Cough (Cough)
Blood Creatine Phosphokinase
Increased (CPK (creatine
phosphokinase))
Blood Creatinine Increased (Creatinine)
Cushingoid (Cushingoid appearance
(e.g., moon face, buffalo hump,
centripetal obesity, cutaneous striae))
Cystitis (Cystitis)
Cytokine Release Syndrome/acute
Infusion Reaction (Cytokine release
syndrome/acute infusion reaction)
Death Not Associated With Ctcae Term
(Death not associated with CTCAE term
- Death NOS)
Death Not Associated With Ctcae Term
(Death not associated with CTCAE term
- Disease progression NOS)
Death Not Associated With Ctcae Term
(Death not associated with CTCAE term
- Multi-organ failure)
Death Not Associated With Ctcae Term
(Death not associated with CTCAE term
- Sudden death)
Dehydration (Dehydration)
Dental: Dentures Or Prosthesis (Dental:
dentures or prosthesis)
Dental: Periodontal Disease (Dental:
periodontal disease)
Dental: Teeth (Dental: teeth)
Dental: Teeth Development (Dental:
teeth development)
Dermal Change Lymphedema,
Phlebolymphedema (Dermal change
lymphedema, phlebolymphedema)
Dermatology/skin Other
(Dermatology/Skin-Other (Specify))
Diarrhoea Nos (Diarrhea)
Disseminated Intravascular Coagulation
(DIC (disseminated intravascular
coagulation))
Distention/bloating, Abdominal
(Distention/bloating, abdominal)
Dizziness (exc Vertigo) (Dizziness)
Dry Eye Nec (Dry eye syndrome)
Dry Mouth (Dry mouth/salivary gland
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(xerostomia))
Dry Skin (Dry skin)
Dysphagia (Dysphagia (difficulty
swallowing))
Dyspnoea Nos (Dyspnea (shortness of
breath))
Edema, Larynx (Edema, larynx)
Edema: Head And Neck (Edema: head
and neck)
Oedema Nos (Edema: limb)
Edema: Trunk/genital (Edema:
trunk/genital)
Edema: Viscera (Edema: viscera)
Ejaculatory Dysfunction (Ejaculatory
dysfunction)
Encephalopathy (Encephalopathy)
Endocrine Other (Endocrine-Other
(Specify))
Enteritis (inflammation Of The Small
Bowel) (Enteritis (inflammation of the
small bowel))
Impotence (Erectile dysfunction)
Oesophagitis Nos (Esophagitis)
Exostosis (Exostosis)
Extrapyramidal Disorder Nec
(Extrapyramidal/involuntary
movement/restlessness)
Extremity-lower (gait/walking) (Extremity-
lower (gait/walking))
Extremity-upper (function) (Extremity-
upper (function))
Eyelid Dysfunction (Eyelid dysfunction)
Fatigue (Fatigue (asthenia, lethargy,
malaise))
Febrile Neutropenia (fever Of Unknown
Origin Without Clinically Or
Microbiologically Documented Infection)
(anc <1.0 X 10^9/l, Fever >=38.5
Degrees C) (Febrile neutropenia)
Feminization (Feminization of male)
Forced Expiratory Volume Decreased
(FEV(1))
Pyrexia (Fever (in the absence of
neutropenia, where neutropenia is
defined as ANC <1.0 x 10^9/L))
Blood Fibrinogen Decreased
(Fibrinogen)
Fibrosis-cosmesis (Fibrosis-cosmesis)
Fibrosis-deep Connective Tissue
(Fibrosis-deep connective tissue)
Fistula, Gi (Fistula, GI - Abdomen NOS)
Anal Fistula (Fistula, GI - Anus)
Fistula, Gi (Fistula, GI - Biliary tree)
Fistula, Gi (Fistula, GI -
Colon/cecum/appendix)
Intestinal Fistula (Fistula, GI -
Duodenum)
Tracheo-oesophageal Fistula Nos
(Fistula, GI - Esophagus)
Fistula, Gi (Fistula, GI - Gallbladder)
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Fistula, Gi (Fistula, GI - Ileum)
Fistula, Gi (Fistula, GI - Jejunum)
Fistula, Gi (Fistula, GI - Oral cavity)
Fistula, Gi (Fistula, GI - Pancreas)
Fistula, Gi (Fistula, GI - Pharynx)
Fistula, Gi (Fistula, GI - Rectum)
Fistula, Gi (Fistula, GI - Salivary gland)
Fistula, Gi (Fistula, GI - Small bowel
NOS)
Fistula, Gi (Fistula, GI - Stomach)
Fistula, Gu (Fistula, GU - Bladder)
Fistula, Gu (Fistula, GU - Genital tract-
female)
Fistula, Gu (Fistula, GU - Kidney)
Fistula, Gu (Fistula, GU - Ureter)
Fistula, Gu (Fistula, GU - Urethra)
Fistula, Gu (Fistula, GU - Uterus)
Urogenital Fistula (Fistula, GU - Vagina)
Fistula, Pulmonary/upper Respiratory
(Fistula, pulmonary/upper respiratory -
Bronchus)
Fistula, Pulmonary/upper Respiratory
(Fistula, pulmonary/upper respiratory -
Larynx)
Fistula, Pulmonary/upper Respiratory
(Fistula, pulmonary/upper respiratory -
Lung)
Fistula, Pulmonary/upper Respiratory
(Fistula, pulmonary/upper respiratory -
Oral cavity)
Fistula, Pulmonary/upper Respiratory
(Fistula, pulmonary/upper respiratory -
Pharynx)
Fistula, Pulmonary/upper Respiratory
(Fistula, pulmonary/upper respiratory -
Pleura)
Fistula, Pulmonary/upper Respiratory
(Fistula, pulmonary/upper respiratory -
Trachea)
Flatulence (Flatulence)
Flu-like Syndrome (Flu-like syndrome)
Flushing (Flushing)
Fracture (Fracture)
Gastritis Nos (Gastritis (including bile
reflux gastritis))
Gastrointestinal Other (Gastrointestinal-
Other (Specify))
Gamma-glutamyltransferase Increased
(GGT (gamma-glutamyl transpeptidase))
Glaucoma Nos (Glaucoma)
Glomerular Filtration Rate (Glomerular
filtration rate)
Hyperglycaemia Nos (Glucose, serum-
high (hyperglycemia))
Hypoglycaemia Nos (Glucose, serum-
low (hypoglycemia))
Growth And Development Other (Growth
and Development-Other (Specify))
Growth Velocity (reduction In Growth
Velocity) (Growth velocity (reduction in
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growth velocity))
Gynaecomastia (Gynecomastia)
Alopecia (Hair loss/Alopecia (scalp or
body))
Haptoglobin Decreased (Haptoglobin)
Hearing: Patients With/without Baseline
Audiogram And Enrolled In A Monitoring
Program (Hearing: patients with/without
baseline audiogram and enrolled in a
monitoring program)
Hearing: Patients Without Baseline
Audiogram And Not Enrolled In A
Monitoring Program (Hearing: patients
without baseline audiogram and not
enrolled in a monitoring program)
Dyspepsia (Heartburn/dyspepsia)
Hematoma (Hematoma)
Haemoglobin Decreased (Hemoglobin)
Haemoglobinuria Present
(Hemoglobinuria)
Hemolysis Nos (Hemolysis (e.g.,
immune hemolytic anemia, drug related
hemolysis))
Haemorrhagic Stroke (Hemorrhage,
CNS)
Melaena (Hemorrhage, GI - Abdomen
NOS)
Hemorrhage, Gi (Hemorrhage, GI -
Anus)
Hemorrhage, Gi (Hemorrhage, GI -
Biliary tree)
Hemorrhage, Gi (Hemorrhage, GI -
Cecum/appendix)
Hemorrhage, Gi (Hemorrhage, GI -
Colon)
Hemorrhage, Gi (Hemorrhage, GI -
Duodenum)
Hemorrhage, Gi (Hemorrhage, GI -
Esophagus)
Hemorrhage, Gi (Hemorrhage, GI -
Ileum)
Hemorrhage, Gi (Hemorrhage, GI -
Jejunum)
Hemorrhage, Gi (Hemorrhage, GI - Liver)
Hemorrhage, Gi (Hemorrhage, GI -
Lower GI NOS)
Hemorrhage, Gi (Hemorrhage, GI - Oral
cavity)
Hemorrhage, Gi (Hemorrhage, GI -
Pancreas)
Hemorrhage, Gi (Hemorrhage, GI -
Peritoneal cavity)
Rectal Bleeding (Hemorrhage, GI -
Rectum)
Hemorrhage, Gi (Hemorrhage, GI -
Stoma)
Haematemesis (Hemorrhage, GI -
Stomach)
Hemorrhage, Gi (Hemorrhage, GI -
Upper GI NOS)
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Hemorrhage, Gi (Hemorrhage, GI -
Varices (esophageal))
Hemorrhage, Gi (Hemorrhage, GI -
Varices (rectal))
Hemorrhage, Gu (Hemorrhage, GU -
Bladder)
Hemorrhage, Gu (Hemorrhage, GU -
Fallopian tube)
Hemorrhage, Gu (Hemorrhage, GU -
Kidney)
Hemorrhage, Gu (Hemorrhage, GU -
Ovary)
Hemorrhage, Gu (Hemorrhage, GU -
Prostate)
Hemorrhage, Gu (Hemorrhage, GU -
Retroperitoneum)
Hemorrhage, Gu (Hemorrhage, GU -
Spermatic cord)
Hemorrhage, Gu (Hemorrhage, GU -
Stoma)
Hemorrhage, Gu (Hemorrhage, GU -
Testes)
Hemorrhage, Gu (Hemorrhage, GU -
Ureter)
Hemorrhage, Gu (Hemorrhage, GU -
Urethra)
Haematuria Present (Hemorrhage, GU -
Urinary NOS)
Hemorrhage, Gu (Hemorrhage, GU -
Uterus)
Vaginal Haemorrhage (Hemorrhage, GU
- Vagina)
Hemorrhage, Gu (Hemorrhage, GU - Vas
deferens)
Hemorrhage, Pulmonary/upper
Respiratory (Hemorrhage,
pulmonary/upper respiratory -
Bronchopulmonary NOS)
Hemorrhage, Pulmonary/upper
Respiratory (Hemorrhage,
pulmonary/upper respiratory - Bronchus)
Hemorrhage, Pulmonary/upper
Respiratory (Hemorrhage,
pulmonary/upper respiratory - Larynx)
Hemorrhage, Pulmonary/upper
Respiratory (Hemorrhage,
pulmonary/upper respiratory - Lung)
Hemorrhage, Pulmonary/upper
Respiratory (Hemorrhage,
pulmonary/upper respiratory -
Mediastinum)
Epistaxis (Hemorrhage, pulmonary/upper
respiratory - Nose)
Hemorrhage, Pulmonary/upper
Respiratory (Hemorrhage,
pulmonary/upper respiratory - Pharynx)
Hemorrhage, Pulmonary/upper
Respiratory (Hemorrhage,
pulmonary/upper respiratory - Pleura)
Haemoptysis (Hemorrhage,
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pulmonary/upper respiratory -
Respiratory tract NOS)
Hemorrhage, Pulmonary/upper
Respiratory (Hemorrhage,
pulmonary/upper respiratory - Stoma)
Hemorrhage, Pulmonary/upper
Respiratory (Hemorrhage,
pulmonary/upper respiratory - Trachea)
Post-operative Haemorrhage
(Hemorrhage/bleeding associated with
surgery, intra-operative or post-operative)
Hemorrhage/bleeding Other
(Hemorrhage/Bleeding-Other (Specify))
Hemorrhoids (Hemorrhoids)
Hepatobiliary/pancreas Other
(Hepatobiliary/Pancreas-Other (Specify))
Hiccups (Hiccoughs (hiccups, singultus))
Menopausal Symptoms (Hot
flashes/flushes)
Hydrocephalus (Hydrocephalus)
Skin Discolouration (Hyperpigmentation)
Hypertension Nos (Hypertension)
Hypopigmentation (Hypopigmentation)
Hypotension Nos (Hypotension)
Hypothermia (Hypothermia)
Hypoxia (Hypoxia)
Ileus (Ileus, GI (functional obstruction of
bowel, i.e., neuroconstipation))
Incontinence, Anal (Incontinence, anal)
Urinary Incontinence (Incontinence,
urinary)
Induration/fibrosis (skin And
Subcutaneous Tissue)
(Induration/fibrosis (skin and
subcutaneous tissue))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Abdomen NOS)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Anal/perianal)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Appendix)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Artery)
Infection (documented Clinically Or
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Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Biliary tree)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Bladder (urinary))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Blood)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Bone (osteomyelitis))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Brain (encephalitis,
infectious))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Brain + Spinal cord
(encephalomyelitis))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Bronchus)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Catheter-related)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Cecum)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
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neutrophils - Cervix)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Colon)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Conjunctiva)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Cornea)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Dental-tooth)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Duodenum)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Esophagus)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - External ear (otitis externa))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Eye NOS)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Fallopian tube)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
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neutrophils - Foreign body (e.g., graft,
implant, prosthesis, stent))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Gallbladder (cholecystitis))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Heart (endocarditis))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Ileum)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Jejunum)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Joint)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Kidney)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Larynx)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Lens)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Lip/perioral)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
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microbiologically) with Grade 3 or 4
neutrophils - Liver)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Lung (pneumonia))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Lymphatic)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Mediastinum NOS)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Meninges (meningitis))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Middle ear (otitis media))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Mucosa)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Muscle (infection myositis))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Neck NOS)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Nerve-cranial)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
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microbiologically) with Grade 3 or 4
neutrophils - Nerve-peripheral)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Nose)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Oral cavity-gums
(gingivitis))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Pancreas)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Paranasal)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Pelvis NOS)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Penis)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Peristomal)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Peritoneal cavity)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Pharynx)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
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(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Pleura (empyema))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Prostate)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Rectum)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Salivary gland)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Scrotum)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Sinus)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Skin (cellulitis))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Small bowel NOS)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Soft tissue NOS)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Spinal cord (myelitis))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
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(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Spleen)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Stomach)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Trachea)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Ungual (nails))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Upper aerodigestive NOS)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Upper airway NOS)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Ureter)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Urethra)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Urinary tract NOS)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Uterus)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
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(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Vagina)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Vein)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Vulva)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Wound)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Abdomen
NOS)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils -
Anal/perianal)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Appendix)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Artery)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Biliary tree)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Bladder
(urinary))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Blood)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Bone
(osteomyelitis))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Brain
(encephalitis, infectious))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Brain +
Spinal cord (encephalomyelitis))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Bronchus)
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Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Catheter-
related)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Cecum)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Cervix)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Colon)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils -
Conjunctiva)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Cornea)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Dental-
tooth)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Duodenum)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Esophagus)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - External ear
(otitis externa))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Eye NOS)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Fallopian
tube)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Foreign
body (e.g., graft, implant, prosthesis,
stent))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Gallbladder
(cholecystitis))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Heart
(endocarditis))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Ileum)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Jejunum)
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Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Joint)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Kidney)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Larynx)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Lens)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Lip/perioral)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Liver)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Lung
(pneumonia))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Lymphatic)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils -
Mediastinum NOS)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Meninges
(meningitis))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Middle ear
(otitis media))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Mucosa)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Muscle
(infection myositis))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Neck NOS)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Nerve-
cranial)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Nerve-
peripheral)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Nose)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
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or Grade 1 or 2 neutrophils - Oral cavity-
gums (gingivitis))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Pancreas)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Paranasal)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Pelvis NOS)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Penis)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Peristomal)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Peritoneal
cavity)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Pharynx)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Pleura
(empyema))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Prostate)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Rectum)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Salivary
gland)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Scrotum)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Sinus)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Skin
(cellulitis))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Small bowel
NOS)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Soft tissue
NOS)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Spinal cord
(myelitis))
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Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Spleen)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Stomach)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Trachea)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Ungual
(nails))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Upper
aerodigestive NOS)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Upper
airway NOS)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Ureter)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Urethra)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Urinary
tract NOS)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Uterus)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Vagina)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Vein)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Vulva)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Wound)
Infection With Unknown Anc (Infection
with unknown ANC - Abdomen NOS)
Infection With Unknown Anc (Infection
with unknown ANC - Anal/perianal)
Infection With Unknown Anc (Infection
with unknown ANC - Appendix)
Infection With Unknown Anc (Infection
with unknown ANC - Artery)
Infection With Unknown Anc (Infection
with unknown ANC - Biliary tree)
Infection With Unknown Anc (Infection
with unknown ANC - Bladder (urinary))
Infection With Unknown Anc (Infection
with unknown ANC - Blood)
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Infection With Unknown Anc (Infection
with unknown ANC - Bone
(osteomyelitis))
Infection With Unknown Anc (Infection
with unknown ANC - Brain (encephalitis,
infectious))
Infection With Unknown Anc (Infection
with unknown ANC - Brain + Spinal cord
(encephalomyelitis))
Infection With Unknown Anc (Infection
with unknown ANC - Bronchus)
Implant Infection (Infection with unknown
ANC - Catheter-related)
Infection With Unknown Anc (Infection
with unknown ANC - Cecum)
Infection With Unknown Anc (Infection
with unknown ANC - Cervix)
Infection With Unknown Anc (Infection
with unknown ANC - Colon)
Infection With Unknown Anc (Infection
with unknown ANC - Conjunctiva)
Infection With Unknown Anc (Infection
with unknown ANC - Cornea)
Infection With Unknown Anc (Infection
with unknown ANC - Dental-tooth)
Infection With Unknown Anc (Infection
with unknown ANC - Duodenum)
Infection With Unknown Anc (Infection
with unknown ANC - Esophagus)
Infection With Unknown Anc (Infection
with unknown ANC - External ear (otitis
externa))
Infection With Unknown Anc (Infection
with unknown ANC - Eye NOS)
Infection With Unknown Anc (Infection
with unknown ANC - Fallopian tube)
Infection With Unknown Anc (Infection
with unknown ANC - Foreign body (e.g.,
graft, implant, prosthesis, stent))
Infection With Unknown Anc (Infection
with unknown ANC - Gallbladder
(cholecystitis))
Infection With Unknown Anc (Infection
with unknown ANC - Heart
(endocarditis))
Infection With Unknown Anc (Infection
with unknown ANC - Ileum)
Infection With Unknown Anc (Infection
with unknown ANC - Jejunum)
Infection With Unknown Anc (Infection
with unknown ANC - Joint)
Infection With Unknown Anc (Infection
with unknown ANC - Kidney)
Infection With Unknown Anc (Infection
with unknown ANC - Larynx)
Infection With Unknown Anc (Infection
with unknown ANC - Lens)
Infection With Unknown Anc (Infection
with unknown ANC - Lip/perioral)
Infection With Unknown Anc (Infection
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with unknown ANC - Liver)
Infection With Unknown Anc (Infection
with unknown ANC - Lung (pneumonia))
Infection With Unknown Anc (Infection
with unknown ANC - Lymphatic)
Infection With Unknown Anc (Infection
with unknown ANC - Mediastinum NOS)
Infection With Unknown Anc (Infection
with unknown ANC - Meninges
(meningitis))
Infection With Unknown Anc (Infection
with unknown ANC - Middle ear (otitis
media))
Infection With Unknown Anc (Infection
with unknown ANC - Mucosa)
Infection With Unknown Anc (Infection
with unknown ANC - Muscle (infection
myositis))
Infection With Unknown Anc (Infection
with unknown ANC - Neck NOS)
Infection With Unknown Anc (Infection
with unknown ANC - Nerve-cranial)
Infection With Unknown Anc (Infection
with unknown ANC - Nerve-peripheral)
Infection With Unknown Anc (Infection
with unknown ANC - Nose)
Infection With Unknown Anc (Infection
with unknown ANC - Oral cavity-gums
(gingivitis))
Infection With Unknown Anc (Infection
with unknown ANC - Pancreas)
Infection With Unknown Anc (Infection
with unknown ANC - Paranasal)
Infection With Unknown Anc (Infection
with unknown ANC - Pelvis NOS)
Infection With Unknown Anc (Infection
with unknown ANC - Penis)
Infection With Unknown Anc (Infection
with unknown ANC - Peristomal)
Infection With Unknown Anc (Infection
with unknown ANC - Peritoneal cavity)
Infection With Unknown Anc (Infection
with unknown ANC - Pharynx)
Infection With Unknown Anc (Infection
with unknown ANC - Pleura (empyema))
Infection With Unknown Anc (Infection
with unknown ANC - Prostate)
Infection With Unknown Anc (Infection
with unknown ANC - Rectum)
Infection With Unknown Anc (Infection
with unknown ANC - Salivary gland)
Infection With Unknown Anc (Infection
with unknown ANC - Scrotum)
Infection With Unknown Anc (Infection
with unknown ANC - Sinus)
Infection With Unknown Anc (Infection
with unknown ANC - Skin (cellulitis))
Infection With Unknown Anc (Infection
with unknown ANC - Small bowel NOS)
Infection With Unknown Anc (Infection
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with unknown ANC - Soft tissue NOS)
Infection With Unknown Anc (Infection
with unknown ANC - Spinal cord
(myelitis))
Infection With Unknown Anc (Infection
with unknown ANC - Spleen)
Infection With Unknown Anc (Infection
with unknown ANC - Stomach)
Infection With Unknown Anc (Infection
with unknown ANC - Trachea)
Infection With Unknown Anc (Infection
with unknown ANC - Ungual (nails))
Infection With Unknown Anc (Infection
with unknown ANC - Upper aerodigestive
NOS)
Infection With Unknown Anc (Infection
with unknown ANC - Upper airway NOS)
Infection With Unknown Anc (Infection
with unknown ANC - Ureter)
Infection With Unknown Anc (Infection
with unknown ANC - Urethra)
Infection With Unknown Anc (Infection
with unknown ANC - Urinary tract NOS)
Infection With Unknown Anc (Infection
with unknown ANC - Uterus)
Infection With Unknown Anc (Infection
with unknown ANC - Vagina)
Infection With Unknown Anc (Infection
with unknown ANC - Vein)
Infection With Unknown Anc (Infection
with unknown ANC - Vulva)
Culture Wound Positive (Infection with
unknown ANC - Wound)
Infection Nos (Infection-Other (Specify))
Infertility/sterility (Infertility/sterility)
Injection Site Reaction Nos (Injection site
reaction/extravasation changes)
Prothrombin Time Prolonged (INR
(International Normalized Ratio of
prothrombin time))
Insomnia Nec (Insomnia)
Intra-operative Injury (Intra-operative
injury - Abdomen NOS)
Intra-operative Injury (Intra-operative
injury - Adrenal gland)
Intra-operative Injury (Intra-operative
injury - Anal sphincter)
Intra-operative Injury (Intra-operative
injury - Anus)
Intra-operative Injury (Intra-operative
injury - Appendix)
Intra-operative Injury (Intra-operative
injury - Artery NOS)
Intra-operative Injury (Intra-operative
injury - Artery-aorta)
Intra-operative Injury (Intra-operative
injury - Artery-carotid)
Intra-operative Injury (Intra-operative
injury - Artery-cerebral)
Intra-operative Injury (Intra-operative
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injury - Artery-extremity (lower))
Intra-operative Injury (Intra-operative
injury - Artery-extremity (upper))
Intra-operative Injury (Intra-operative
injury - Artery-hepatic)
Intra-operative Injury (Intra-operative
injury - Artery-major visceral artery)
Intra-operative Injury (Intra-operative
injury - Artery-pulmonary)
Intra-operative Injury (Intra-operative
injury - Biliary tree NOS)
Intra-operative Injury (Intra-operative
injury - Biliary tree-common bile duct)
Intra-operative Injury (Intra-operative
injury - Biliary tree-common hepatic duct)
Intra-operative Injury (Intra-operative
injury - Biliary tree-left hepatic duct)
Intra-operative Injury (Intra-operative
injury - Biliary tree-right hepatic duct)
Bladder Perforation Postoperative (Intra-
operative injury - Bladder)
Intra-operative Injury (Intra-operative
injury - Bone)
Intra-operative Injury (Intra-operative
injury - Brachial plexus)
Intra-operative Injury (Intra-operative
injury - Brain)
Intra-operative Injury (Intra-operative
injury - Breast)
Intra-operative Injury (Intra-operative
injury - Bronchus)
Intra-operative Injury (Intra-operative
injury - Cartilage)
Intra-operative Injury (Intra-operative
injury - Cecum)
Intra-operative Injury (Intra-operative
injury - Cervix)
Intra-operative Injury (Intra-operative
injury - CN I (olfactory))
Intra-operative Injury (Intra-operative
injury - CN II (optic))
Intra-operative Injury (Intra-operative
injury - CN III (oculomotor))
Intra-operative Injury (Intra-operative
injury - CN IV (trochlear))
Intra-operative Injury (Intra-operative
injury - CN IX (glossopharyngeal) motor
pharynx)
Intra-operative Injury (Intra-operative
injury - CN IX (glossopharyngeal)
sensory ear-pharynx-tongue)
Intra-operative Injury (Intra-operative
injury - CN V (trigeminal) motor)
Intra-operative Injury (Intra-operative
injury - CN V (trigeminal) sensory)
Intra-operative Injury (Intra-operative
injury - CN VI (abducens))
Intra-operative Injury (Intra-operative
injury - CN VII (facial) motor-face)
Intra-operative Injury (Intra-operative
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injury - CN VII (facial) sensory-taste)
Intra-operative Injury (Intra-operative
injury - CN VIII (vestibulocochlear))
Intra-operative Injury (Intra-operative
injury - CN X (vagus))
Intra-operative Injury (Intra-operative
injury - CN XI (spinal accessory))
Intra-operative Injury (Intra-operative
injury - CN XII (hypoglossal))
Intra-operative Injury (Intra-operative
injury - Colon)
Intra-operative Injury (Intra-operative
injury - Conjunctiva)
Intra-operative Injury (Intra-operative
injury - Cornea)
Intra-operative Injury (Intra-operative
injury - Cranial nerve or branch NOS)
Intra-operative Injury (Intra-operative
injury - Duodenum)
Intra-operative Injury (Intra-operative
injury - Esophagus)
Intra-operative Injury (Intra-operative
injury - Extremity-lower)
Intra-operative Injury (Intra-operative
injury - Extremity-upper)
Intra-operative Injury (Intra-operative
injury - Eye NOS)
Intra-operative Injury (Intra-operative
injury - Face NOS)
Intra-operative Injury (Intra-operative
injury - Fallopian tube)
Intra-operative Injury (Intra-operative
injury - Gallbladder)
Intra-operative Injury (Intra-operative
injury - Gingiva)
Intra-operative Injury (Intra-operative
injury - Heart)
Intra-operative Injury (Intra-operative
injury - Ileum)
Intra-operative Injury (Intra-operative
injury - Inner ear)
Intra-operative Injury (Intra-operative
injury - Jejunum)
Intra-operative Injury (Intra-operative
injury - Joint)
Intra-operative Injury (Intra-operative
injury - Kidney)
Intra-operative Injury (Intra-operative
injury - Larynx)
Intra-operative Injury (Intra-operative
injury - Lens)
Intra-operative Injury (Intra-operative
injury - Ligament)
Intra-operative Injury (Intra-operative
injury - Lingual)
Intra-operative Injury (Intra-operative
injury - Lip/perioral area)
Intra-operative Injury (Intra-operative
injury - Liver)
Intra-operative Injury (Intra-operative
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injury - Lung)
Intra-operative Injury (Intra-operative
injury - Lung thoracic)
Intra-operative Injury (Intra-operative
injury - Mediastinum)
Intra-operative Injury (Intra-operative
injury - Meninges)
Intra-operative Injury (Intra-operative
injury - Middle ear)
Intra-operative Injury (Intra-operative
injury - Muscle)
Intra-operative Injury (Intra-operative
injury - Nails)
Intra-operative Injury (Intra-operative
injury - Nasal cavity)
Intra-operative Injury (Intra-operative
injury - Nasopharynx)
Intra-operative Injury (Intra-operative
injury - Neck NOS)
Intra-operative Injury (Intra-operative
injury - Nose)
Intra-operative Injury (Intra-operative
injury - Oral)
Intra-operative Injury (Intra-operative
injury - Oral cavity NOS)
Intra-operative Injury (Intra-operative
injury - Outer ear NOS)
Intra-operative Injury (Intra-operative
injury - Outer ear-pinna)
Intra-operative Injury (Intra-operative
injury - Ovary)
Intra-operative Injury (Intra-operative
injury - Pancreas)
Intra-operative Injury (Intra-operative
injury - Pancreatic duct)
Intra-operative Injury (Intra-operative
injury - Parathyroid)
Intra-operative Injury (Intra-operative
injury - Parotid gland)
Intra-operative Injury (Intra-operative
injury - Pelvis NOS)
Intra-operative Injury (Intra-operative
injury - Penis)
Intra-operative Injury (Intra-operative
injury - Peripheral motor NOS)
Intra-operative Injury (Intra-operative
injury - Peripheral sensory NOS)
Intra-operative Injury (Intra-operative
injury - Peritoneal cavity)
Intra-operative Injury (Intra-operative
injury - Pharynx)
Intra-operative Injury (Intra-operative
injury - Pituitary)
Intra-operative Injury (Intra-operative
injury - Pleura)
Intra-operative Injury (Intra-operative
injury - Prostate)
Intra-operative Injury (Intra-operative
injury - Rectum)
Intra-operative Injury (Intra-operative
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injury - Recurrent laryngeal)
Intra-operative Injury (Intra-operative
injury - Retina)
Intra-operative Injury (Intra-operative
injury - Sacral plexus)
Intra-operative Injury (Intra-operative
injury - Salivary duct)
Intra-operative Injury (Intra-operative
injury - Salivary gland)
Intra-operative Injury (Intra-operative
injury - Sciatic)
Intra-operative Injury (Intra-operative
injury - Scrotum)
Intra-operative Injury (Intra-operative
injury - Sinus)
Intra-operative Injury (Intra-operative
injury - Skin)
Intra-operative Injury (Intra-operative
injury - Small bowel NOS)
Intra-operative Injury (Intra-operative
injury - Soft tissue NOS)
Intra-operative Injury (Intra-operative
injury - Spinal cord)
Intra-operative Injury (Intra-operative
injury - Spleen)
Intra-operative Injury (Intra-operative
injury - Stoma (GI))
Intra-operative Injury (Intra-operative
injury - Stomach)
Intra-operative Injury (Intra-operative
injury - Teeth)
Intra-operative Injury (Intra-operative
injury - Tendon)
Intra-operative Injury (Intra-operative
injury - Testis)
Intra-operative Injury (Intra-operative
injury - Thoracic duct)
Intra-operative Injury (Intra-operative
injury - Thoracodorsal)
Intra-operative Injury (Intra-operative
injury - Thyroid)
Intra-operative Injury (Intra-operative
injury - Tongue)
Intra-operative Injury (Intra-operative
injury - Trachea)
Intra-operative Injury (Intra-operative
injury - Upper aerodigestive NOS)
Intra-operative Injury (Intra-operative
injury - Upper airway NOS)
Intra-operative Injury (Intra-operative
injury - Ureter)
Intra-operative Injury (Intra-operative
injury - Urethra)
Intra-operative Injury (Intra-operative
injury - Urinary conduit)
Intra-operative Injury (Intra-operative
injury - Urinary tract NOS)
Intra-operative Injury (Intra-operative
injury - Uterus)
Intra-operative Injury (Intra-operative
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injury - Vagina)
Intra-operative Injury - Vein (Intra-
operative injury - Vein NOS)
Intra-operative Injury (Intra-operative
injury - Vein-extremity (lower))
Intra-operative Injury (Intra-operative
injury - Vein-extremity (upper))
Intra-operative Injury (Intra-operative
injury - Vein-hepatic)
Intra-operative Injury (Intra-operative
injury - Vein-inferior vena cava)
Intra-operative Injury (Intra-operative
injury - Vein-jugular)
Intra-operative Injury (Intra-operative
injury - Vein-major visceral vein)
Intra-operative Injury (Intra-operative
injury - Vein-portal vein)
Intra-operative Injury (Intra-operative
injury - Vein-pulmonary)
Intra-operative Injury (Intra-operative
injury - Vein-superior vena cava)
Intra-operative Injury (Intra-operative
injury - Vulva)
Intra-operative Injury Other (Intra-
operative Injury-Other (Specify))
Iron Overload (Iron overload)
Menstruation Irregular (Irregular menses
(change from baseline))
Irritability (Irritability (children <3 years of
age))
Joint-effusion (Joint-effusion)
Joint-effusion (Joint-function)
Keratitis Nec (Keratitis (corneal
inflammation/corneal ulceration))
Laryngeal Nerve Dysfunction (Laryngeal
nerve dysfunction)
Leak (including Anastomotic), Gi (Leak
(including anastomotic), GI - Biliary tree)
Leak (including Anastomotic), Gi (Leak
(including anastomotic), GI - Esophagus)
Leak (including Anastomotic), Gi (Leak
(including anastomotic), GI - Large
bowel)
Leak (including Anastomotic), Gi (Leak
(including anastomotic), GI - Leak NOS)
Leak (including Anastomotic), Gi (Leak
(including anastomotic), GI - Pancreas)
Leak (including Anastomotic), Gi (Leak
(including anastomotic), GI - Pharynx)
Leak (including Anastomotic), Gi (Leak
(including anastomotic), GI - Rectum)
Leak (including Anastomotic), Gi (Leak
(including anastomotic), GI - Small
bowel)
Leak (including Anastomotic), Gi (Leak
(including anastomotic), GI - Stoma)
Leak (including Anastomotic), Gi (Leak
(including anastomotic), GI - Stomach)
Leak (including Anastomotic), Gu (Leak
(including anastomotic), GU - Bladder)
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Leak (including Anastomotic), Gu (Leak
(including anastomotic), GU - Fallopian
tube)
Leak (including Anastomotic), Gu (Leak
(including anastomotic), GU - Kidney)
Leak (including Anastomotic), Gu (Leak
(including anastomotic), GU - Spermatic
cord)
Leak (including Anastomotic), Gu (Leak
(including anastomotic), GU - Stoma)
Leak (including Anastomotic), Gu (Leak
(including anastomotic), GU - Ureter)
Leak (including Anastomotic), Gu (Leak
(including anastomotic), GU - Urethra)
Leak (including Anastomotic), Gu (Leak
(including anastomotic), GU - Uterus)
Leak (including Anastomotic), Gu (Leak
(including anastomotic), GU - Vagina)
Leak (including Anastomotic), Gu (Leak
(including anastomotic), GU - Vas
deferens)
Leak, Cerebrospinal Fluid (csf) (Leak,
cerebrospinal fluid (CSF))
Left Ventricular Diastolic Dysfunction
(Left ventricular diastolic dysfunction)
Left Ventricular Failure (Left ventricular
systolic dysfunction)
Leucopenia Nos (Leukocytes (total
WBC))
Encephalopathy Nos
(Leukoencephalopathy (radiolographic
findings))
Libido Decreased (Libido)
Lipase Increased (Lipase)
Hepatic Failure (Liver dysfunction/failure
(clinical))
Local Complication - Device/prosthesis-
related (Local complication -
device/prosthesis-related)
Lumbar Spine-range Of Motion (Lumbar
spine-range of motion)
Lymphatics Other (Lymphatics-Other
(Specify))
Lymphedema-related Fibrosis
(Lymphedema-related fibrosis)
Lymphocele (Lymphocele)
Lymphopenia (Lymphopenia)
Hypermagnesaemia (Magnesium,
serum-high (hypermagnesemia))
Blood Magnesium Decreased
(Magnesium, serum-low
(hypomagnesemia))
Malabsorption (Malabsorption)
Virilism (Masculinization of female)
Amnesia Nec (Memory impairment)
Mental Status (Mental status)
Metabolic/laboratory Other
(Metabolic/Laboratory-Other (Specify))
Mood Alteration - Agitation (Mood
alteration - agitation)
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Anxiety Nec (Mood alteration - anxiety)
Depression Nec (Mood alteration -
depression)
Euphoric Mood (Mood alteration -
euphoria)
Mucositis/stomatitis (clinical Exam)
(Mucositis/stomatitis (clinical exam) -
Anus)
Mucositis/stomatitis (clinical Exam)
(Mucositis/stomatitis (clinical exam) -
Esophagus)
Mucositis/stomatitis (clinical Exam)
(Mucositis/stomatitis (clinical exam) -
Large bowel)
Mucositis/stomatitis (clinical Exam)
(Mucositis/stomatitis (clinical exam) -
Larynx)
Mucositis/stomatitis (clinical Exam)
(Mucositis/stomatitis (clinical exam) -
Oral cavity)
Stomatitis (Mucositis/stomatitis (clinical
exam) - Pharynx)
Mucositis/stomatitis (clinical Exam)
(Mucositis/stomatitis (clinical exam) -
Rectum)
Mucositis/stomatitis (clinical Exam)
(Mucositis/stomatitis (clinical exam) -
Small bowel)
Mucositis/stomatitis (clinical Exam)
(Mucositis/stomatitis (clinical exam) -
Stomach)
Mucositis/stomatitis (clinical Exam)
(Mucositis/stomatitis (clinical exam) -
Trachea)
Mucositis/stomatitis
(functional/symptomatic)
(Mucositis/stomatitis
(functional/symptomatic) - Anus)
Mucositis/stomatitis
(functional/symptomatic)
(Mucositis/stomatitis
(functional/symptomatic) - Esophagus)
Mucositis/stomatitis
(functional/symptomatic)
(Mucositis/stomatitis
(functional/symptomatic) - Large bowel)
Mucositis/stomatitis
(functional/symptomatic)
(Mucositis/stomatitis
(functional/symptomatic) - Larynx)
Mucositis/stomatitis
(functional/symptomatic)
(Mucositis/stomatitis
(functional/symptomatic) - Oral cavity)
Mucositis/stomatitis
(functional/symptomatic)
(Mucositis/stomatitis
(functional/symptomatic) - Pharynx)
Mucositis/stomatitis
(functional/symptomatic)
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(Mucositis/stomatitis
(functional/symptomatic) - Rectum)
Mucositis/stomatitis
(functional/symptomatic)
(Mucositis/stomatitis
(functional/symptomatic) - Small bowel)
Mucositis/stomatitis
(functional/symptomatic)
(Mucositis/stomatitis
(functional/symptomatic) - Stomach)
Mucositis/stomatitis
(functional/symptomatic)
(Mucositis/stomatitis
(functional/symptomatic) - Trachea)
Muscle Weakness, Generalized Or
Specific Area (not Due To Neuropathy)
(Muscle weakness, generalized or
specific area (not due to neuropathy) -
Extraocular)
Muscle Weakness, Generalized Or
Specific Area (not Due To Neuropathy)
(Muscle weakness, generalized or
specific area (not due to neuropathy) -
Extremity-lower)
Muscle Weakness, Generalized Or
Specific Area (not Due To Neuropathy)
(Muscle weakness, generalized or
specific area (not due to neuropathy) -
Extremity-upper)
Muscle Weakness, Generalized Or
Specific Area (not Due To Neuropathy)
(Muscle weakness, generalized or
specific area (not due to neuropathy) -
Facial)
Muscle Weakness, Generalized Or
Specific Area (not Due To Neuropathy)
(Muscle weakness, generalized or
specific area (not due to neuropathy) -
Left-sided)
Muscle Weakness, Generalized Or
Specific Area (not Due To Neuropathy)
(Muscle weakness, generalized or
specific area (not due to neuropathy) -
Ocular)
Muscle Weakness, Generalized Or
Specific Area (not Due To Neuropathy)
(Muscle weakness, generalized or
specific area (not due to neuropathy) -
Pelvic)
Muscle Weakness, Generalized Or
Specific Area (not Due To Neuropathy)
(Muscle weakness, generalized or
specific area (not due to neuropathy) -
Right-sided)
Muscle Weakness, Generalized Or
Specific Area (not Due To Neuropathy)
(Muscle weakness, generalized or
specific area (not due to neuropathy) -
Trunk)
Muscle Weakness Nos (Muscle
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weakness, generalized or specific area
(not due to neuropathy) - Whole
body/generalized)
Muscular/skeletal Hypoplasia
(Muscular/skeletal hypoplasia)
Musculoskeletal/soft Tissue Other
(Musculoskeletal/Soft Tissue-Other
(Specify))
Myelitis (Myelitis)
Myelodysplasia (Myelodysplasia)
Myocarditis Nos (Myocarditis)
Myositis (Myositis (inflammation/damage
of muscle))
Nail Abnormality Nos (Nail changes)
Nasal Cavity/paranasal Sinus Reactions
(Nasal cavity/paranasal sinus reactions)
Nausea (Nausea)
Necrosis, Gi (Necrosis, GI - Anus)
Necrosis, Gi (Necrosis, GI -
Colon/cecum/appendix)
Necrosis, Gi (Necrosis, GI - Duodenum)
Necrosis, Gi (Necrosis, GI - Esophagus)
Necrosis, Gi (Necrosis, GI - Gallbladder)
Necrosis, Gi (Necrosis, GI - Hepatic)
Necrosis, Gi (Necrosis, GI - Ileum)
Necrosis, Gi (Necrosis, GI - Jejunum)
Necrosis, Gi (Necrosis, GI - Oral)
Necrosis, Gi (Necrosis, GI - Pancreas)
Necrosis, Gi (Necrosis, GI - Peritoneal
cavity)
Necrosis, Gi (Necrosis, GI - Pharynx)
Necrosis, Gi (Necrosis, GI - Rectum)
Necrosis, Gi (Necrosis, GI - Small bowel
NOS)
Necrosis, Gi (Necrosis, GI - Stoma)
Necrosis, Gi (Necrosis, GI - Stomach)
Neuroendocrine: Acth Deficiency
(Neuroendocrine: ACTH deficiency)
Inappropriate Adh Secretion
(Neuroendocrine: ADH secretion
abnormality (e.g., SIADH or low ADH))
Neuroendocrine: Gonadotropin Secretion
Abnormality (Neuroendocrine:
gonadotropin secretion abnormality)
Neuroendocrine: Growth Hormone
Secretion Abnormality (Neuroendocrine:
growth hormone secretion abnormality)
Neuroendocrine: Prolactin Hormone
Secretion Abnormality (Neuroendocrine:
prolactin hormone secretion abnormality)
Neurology Other (Neurology-Other
(Specify))
Parosmia (Neuropathy: cranial - CN I
Smell)
Cranial Nerve Injury Nos (Neuropathy:
cranial - CN II Vision)
Neuropathy: Cranial (Neuropathy: cranial
- CN III Pupil, upper eyelid, extra ocular
movements)
Neuropathy: Cranial (Neuropathy: cranial
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- CN IV Downward, inward movement of
eye)
Neuropathy: Cranial (Neuropathy: cranial
- CN IX Motor-pharynx; Sensory-ear,
pharynx, tongue)
Neuropathy: Cranial (Neuropathy: cranial
- CN V Motor-jaw muscles; Sensory-
facial)
Neuropathy: Cranial (Neuropathy: cranial
- CN VI Lateral deviation of eye)
Neuropathy: Cranial (Neuropathy: cranial
- CN VII Motor-face; Sensory-taste)
Neuropathy: Cranial (Neuropathy: cranial
- CN VIII Hearing and balance)
Neuropathy: Cranial (Neuropathy: cranial
- CN X Motor-palate; pharynx, larynx)
Neuropathy: Cranial (Neuropathy: cranial
- CN XI Motor-sternomastoid and
trapezius)
Neuropathy: Cranial (Neuropathy: cranial
- CN XII Motor-tongue)
Peripheral Motor Neuropathy
(Neuropathy: motor)
Peripheral Sensory Neuropathy
(Neuropathy: sensory)
Neutropenia (Neutrophils/granulocytes
(ANC/AGC))
Blindness Night (Night blindness
(nyctalopia))
Nystagmus Nos (Nystagmus)
Obesity (Obesity)
Obstruction, Gi (Obstruction, GI -
Cecum)
Obstruction, Gi (Obstruction, GI - Colon)
Obstruction, Gi (Obstruction, GI -
Duodenum)
Obstruction, Gi (Obstruction, GI -
Esophagus)
Obstruction, Gi (Obstruction, GI -
Gallbladder)
Obstruction, Gi (Obstruction, GI - Ileum)
Obstruction, Gi (Obstruction, GI -
Jejunum)
Obstruction, Gi (Obstruction, GI -
Rectum)
Obstruction, Gi (Obstruction, GI - Small
bowel NOS)
Obstruction, Gi (Obstruction, GI - Stoma)
Obstruction, Gi (Obstruction, GI -
Stomach)
Obstruction, Gu (Obstruction, GU -
Bladder)
Obstruction, Gu (Obstruction, GU -
Fallopian tube)
Obstruction, Gu (Obstruction, GU -
Prostate)
Obstruction, Gu (Obstruction, GU -
Spermatic cord)
Obstruction, Gu (Obstruction, GU -
Stoma)
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Obstruction, Gu (Obstruction, GU -
Testes)
Ureteric Obstruction (Obstruction, GU -
Ureter)
Obstruction, Gu (Obstruction, GU -
Urethra)
Obstruction, Gu (Obstruction, GU -
Uterus)
Obstruction, Gu (Obstruction, GU -
Vagina)
Obstruction, Gu (Obstruction, GU - Vas
deferens)
Obstruction/stenosis Of Airway
(Obstruction/stenosis of airway -
Bronchus)
Obstruction/stenosis Of Airway
(Obstruction/stenosis of airway - Larynx)
Obstruction/stenosis Of Airway
(Obstruction/stenosis of airway -
Pharynx)
Obstruction/stenosis Of Airway
(Obstruction/stenosis of airway -
Trachea)
Conjunctivitis Nec (Ocular surface
disease)
Ocular/visual Other (Ocular/Visual-Other
(Specify))
Odor (patient Odor) (Odor (patient odor))
Diplopia (Ophthalmoplegia/diplopia
(double vision))
Opportunistic Infection Associated With
>=grade 2 Lymphopenia (Opportunistic
infection associated with >=Grade 2
lymphopenia)
Optic Disc Edema (Optic disc edema)
Orgasmic Dysfunction (Orgasmic
dysfunction)
Osteonecrosis (Osteonecrosis (avascular
necrosis))
Osteoporosis (Osteoporosis)
Otitis Externa (exc Boil Of Meatus) Nos
(Otitis, external ear (non-infectious))
Otitis Media Serous Nos (Otitis, middle
ear (non-infectious))
Abdominal Pain Nos (Pain - Abdomen
NOS)
Pain (Pain - Anus)
Pain (Pain - Back)
Pain (Pain - Bladder)
Bone Pain (Pain - Bone)
Pain (Pain - Breast)
Pain (Pain - Buttock)
Pain (Pain - Cardiac/heart)
Pain (Pain - Chest wall)
Chest Pain (Pain - Chest/thorax NOS)
Pain (Pain - Dental/teeth/peridontal)
Pain (Pain - Esophagus)
Earache (Pain - External ear)
Pain (Pain - Extremity-limb)
Pain (Pain - Eye)
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Pain (Pain - Face)
Pain (Pain - Gallbladder)
Headache Nos (Pain - Head/headache)
Pain (Pain - Intestine)
Arthralgia (Pain - Joint)
Pain (Pain - Kidney)
Pain (Pain - Larynx)
Pain (Pain - Lip)
Hepatic Pain (Pain - Liver)
Pain (Pain - Lymph node)
Pain (Pain - Middle ear)
Myalgia (Pain - Muscle)
Pain (Pain - Neck)
Neuralgia Nos (Pain -
Neuralgia/peripheral nerve)
Pain (Pain - Oral cavity)
Pain (Pain - Oral-gums)
Pain (Pain - Ovulatory)
Pain (Pain - Pain NOS)
Pelvic Pain Nos (Pain - Pelvis)
Pain (Pain - Penis)
Pain (Pain - Pericardium)
Pain (Pain - Perineum)
Pain (Pain - Peritoneum)
Pain (Pain - Phantom (pain associated
with missing limb))
Pleuritic Pain (Pain - Pleura)
Pain (Pain - Prostate)
Proctalgia (Pain - Rectum)
Pain (Pain - Scalp)
Pain (Pain - Scrotum)
Pain (Pain - Sinus)
Pain (Pain - Skin)
Pain (Pain - Stomach)
Pain (Pain - Testicle)
Pain (Pain - Throat/pharynx/larynx)
Tumour Pain (Pain - Tumor pain)
Dysuria (Pain - Urethra)
Dysmenorrhoea (Pain - Uterus)
Pain (Pain - Vagina)
Pain Other (Pain-Other (Specify))
Palpitations (Palpitations)
Pancreas, Exocrine Enzyme Deficiency
(Pancreas, exocrine enzyme deficiency)
Pancreatic Endocrine: Glucose
Intolerance (Pancreatic endocrine:
glucose intolerance)
Pancreatitis Nos (Pancreatitis)
Parathyroid Function, Low
(hypoparathyroidism) (Parathyroid
function, low (hypoparathyroidism))
Perforation, Gi (Perforation, GI -
Appendix)
Perforation, Gi (Perforation, GI - Biliary
tree)
Perforation, Gi (Perforation, GI - Cecum)
Perforation, Gi (Perforation, GI - Colon)
Perforation, Gi (Perforation, GI -
Duodenum)
Perforation, Gi (Perforation, GI -
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Esophagus)
Perforation, Gi (Perforation, GI -
Gallbladder)
Perforation, Gi (Perforation, GI - Ileum)
Perforation, Gi (Perforation, GI -
Jejunum)
Perforation, Gi (Perforation, GI - Rectum)
Perforation, Gi (Perforation, GI - Small
bowel NOS)
Perforation, Gi (Perforation, GI -
Stomach)
Perforation, Gu (Perforation, GU -
Bladder)
Perforation, Gu (Perforation, GU -
Fallopian tube)
Perforation, Gu (Perforation, GU -
Kidney)
Perforation, Gu (Perforation, GU - Ovary)
Perforation, Gu (Perforation, GU -
Prostate)
Perforation, Gu (Perforation, GU -
Spermatic cord)
Perforation, Gu (Perforation, GU -
Stoma)
Perforation, Gu (Perforation, GU -
Testes)
Perforation, Gu (Perforation, GU - Ureter)
Perforation, Gu (Perforation, GU -
Urethra)
Perforation, Gu (Perforation, GU -
Uterus)
Perforation, Gu (Perforation, GU -
Vagina)
Perforation, Gu (Perforation, GU - Vas
deferens)
Pericardial Effusion (Pericardial effusion
(non-malignant))
Pericarditis (Pericarditis)
Peripheral Ischaemia Nos (Peripheral
arterial ischemia)
Personality Change
(Personality/behavioral)
Petechiae (Petechiae/purpura
(hemorrhage/bleeding into skin or
mucosa))
Phlebitis Superficial (Phlebitis (including
superficial thrombosis))
Phlebolymphatic Cording
(Phlebolymphatic cording)
Hypophosphataemia (Phosphate, serum-
low (hypophosphatemia))
Photosensitivity Reaction Nos
(Photosensitivity)
Phrenic Nerve Dysfunction (Phrenic
nerve dysfunction)
Platelet Count Decreased (Platelets)
Pleural Effusion (Pleural effusion (non-
malignant))
Pneumonitis Nos
(Pneumonitis/pulmonary infiltrates)
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Pneumothorax Nos (Pneumothorax)
Portal Hypertension (Portal vein flow)
Hyperkalaemia (Potassium, serum-high
(hyperkalemia))
Hypokalaemia (Potassium, serum-low
(hypokalemia))
Proctitis Nos (Proctitis)
Prolapse Of Stoma, Gi (Prolapse of
stoma, GI)
Prolapse Of Stoma, Gu (Prolapse of
stoma, GU)
Prolonged Chest Tube Drainage Or Air
Leak After Pulmonary Resection
(Prolonged chest tube drainage or air
leak after pulmonary resection)
Prolonged Intubation After Pulmonary
Resection (>24 Hrs After Surgery)
(Prolonged intubation after pulmonary
resection (>24 hrs after surgery))
Electrocardiogram Qt Prolonged
(Prolonged QTc interval)
Proptosis/enophthalmos
(Proptosis/enophthalmos)
Proteinuria Present (Proteinuria)
Pruritus Nos (Pruritus/itching)
Delusion Nos (Psychosis
(hallucinations/delusions))
Activated Partial Thromboplastin Time
Prolonged (PTT (Partial thromboplastin
time))
Puberty (delayed) (Puberty (delayed))
Puberty (precocious) (Puberty
(precocious))
Pulmonary Fibrosis (Pulmonary fibrosis
(radiographic changes))
Pulmonary Hypertension (Pulmonary
hypertension)
Pulmonary/upper Respiratory Other
(Pulmonary/Upper Respiratory-Other
(Specify))
Upper Motor Neurone Lesion (Pyramidal
tract dysfunction (e.g., increased tone,
hyperreflexia, positive Babinski,
decreased fine motor coordination))
Rash: Acne/acneiform (Rash:
acne/acneiform)
Radiation Recall Syndrome (Rash:
dermatitis associated with radiation -
Chemoradiation)
Dermatitis Radiation Nos (Rash:
dermatitis associated with radiation -
Radiation)
Erythema Multiforme (Rash: erythema
multiforme (e.g., Stevens-Johnson
syndrome, toxic epidermal necrolysis))
Localised Exfoliation (Rash: hand-foot
skin reaction)
Dermatitis Exfoliative Nos
(Rash/desquamation)
Renal Failure Nos (Renal failure)
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Renal/genitourinary Other
(Renal/Genitourinary-Other (Specify))
Restrictive Cardiomyopathy (Restrictive
cardiomyopathy)
Retinal Detachment (Retinal
detachment)
Retinoic Acid Syndrome (Retinoic acid
syndrome")
Retinopathy (Retinopathy)
Right Ventricular Dysfunction (cor
Pulmonale) (Right ventricular dysfunction
(cor pulmonale))
Rigors (Rigors/chills)
Salivary Gland Disorder Nos (Salivary
gland changes/saliva)
Scleral Necrosis/melt (Scleral
necrosis/melt)
Secondary Malignancy Possibly Related
To Cancer Treatment (Secondary
Malignancy-possibly related to cancer
treatment (Specify))
Convulsions Nos (Seizure)
Seroma (Seroma)
Serum Sickness (Serum sickness)
Sexual/reproductive Function Other
(Sexual/Reproductive Function-Other
(Specify))
Short Stature (Short stature)
Skin Breakdown/decubitus Ulcer (Skin
breakdown/decubitus ulcer)
Hypernatraemia (Sodium, serum-high
(hypernatremia))
Hyponatraemia (Sodium, serum-low
(hyponatremia))
Soft Tissue Necrosis (Soft tissue
necrosis - Abdomen)
Soft Tissue Necrosis (Soft tissue
necrosis - Extremity-lower)
Soft Tissue Necrosis (Soft tissue
necrosis - Extremity-upper)
Soft Tissue Necrosis (Soft tissue
necrosis - Head)
Soft Tissue Necrosis (Soft tissue
necrosis - Neck)
Soft Tissue Necrosis (Soft tissue
necrosis - Pelvic)
Soft Tissue Necrosis (Soft tissue
necrosis - Thorax)
Depressed Level Of Consciousness
(Somnolence/depressed level of
consciousness)
Speech Disorder Nec (Speech
impairment (e.g., dysphasia or aphasia))
Splenic Function (Splenic function)
Striae (Striae)
Stricture/stenosis (including
Anastomotic), Gi (Stricture/stenosis
(including anastomotic), GI - Anus)
Stricture/stenosis (including
Anastomotic), Gi (Stricture/stenosis
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(including anastomotic), GI - Biliary tree)
Stricture/stenosis (including
Anastomotic), Gi (Stricture/stenosis
(including anastomotic), GI - Cecum)
Stricture/stenosis (including
Anastomotic), Gi (Stricture/stenosis
(including anastomotic), GI - Colon)
Stricture/stenosis (including
Anastomotic), Gi (Stricture/stenosis
(including anastomotic), GI - Duodenum)
Stricture/stenosis (including
Anastomotic), Gi (Stricture/stenosis
(including anastomotic), GI - Esophagus)
Stricture/stenosis (including
Anastomotic), Gi (Stricture/stenosis
(including anastomotic), GI - Ileum)
Stricture/stenosis (including
Anastomotic), Gi (Stricture/stenosis
(including anastomotic), GI - Jejunum)
Stricture/stenosis (including
Anastomotic), Gi (Stricture/stenosis
(including anastomotic), GI -
Pancreas/pancreatic duct)
Stricture/stenosis (including
Anastomotic), Gi (Stricture/stenosis
(including anastomotic), GI - Pharynx)
Stricture/stenosis (including
Anastomotic), Gi (Stricture/stenosis
(including anastomotic), GI - Rectum)
Stricture/stenosis (including
Anastomotic), Gi (Stricture/stenosis
(including anastomotic), GI - Small bowel
NOS)
Stricture/stenosis (including
Anastomotic), Gi (Stricture/stenosis
(including anastomotic), GI - Stoma)
Stricture/stenosis (including
Anastomotic), Gi (Stricture/stenosis
(including anastomotic), GI - Stomach)
Stricture/stenosis (including
Anastomotic), Gu (Stricture/stenosis
(including anastomotic), GU - Bladder)
Stricture/stenosis (including
Anastomotic), Gu (Stricture/stenosis
(including anastomotic), GU - Fallopian
tube)
Stricture/stenosis (including
Anastomotic), Gu (Stricture/stenosis
(including anastomotic), GU - Prostate)
Stricture/stenosis (including
Anastomotic), Gu (Stricture/stenosis
(including anastomotic), GU - Spermatic
cord)
Stricture/stenosis (including
Anastomotic), Gu (Stricture/stenosis
(including anastomotic), GU - Stoma)
Stricture/stenosis (including
Anastomotic), Gu (Stricture/stenosis
(including anastomotic), GU - Testes)
Stricture/stenosis (including
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Anastomotic), Gu (Stricture/stenosis
(including anastomotic), GU - Ureter)
Stricture/stenosis (including
Anastomotic), Gu (Stricture/stenosis
(including anastomotic), GU - Urethra)
Stricture/stenosis (including
Anastomotic), Gu (Stricture/stenosis
(including anastomotic), GU - Uterus)
Stricture/stenosis (including
Anastomotic), Gu (Stricture/stenosis
(including anastomotic), GU - Vagina)
Stricture/stenosis (including
Anastomotic), Gu (Stricture/stenosis
(including anastomotic), GU - Vas
deferens)
Supraventricular And Nodal Arrhythmia
(Supraventricular and nodal arrhythmia -
Atrial fibrillation)
Supraventricular And Nodal Arrhythmia
(Supraventricular and nodal arrhythmia -
Atrial flutter)
Supraventricular And Nodal Arrhythmia
(Supraventricular and nodal arrhythmia -
Atrial tachycardia/paroxysmal atrial
tachycardia)
Supraventricular And Nodal Arrhythmia
(Supraventricular and nodal arrhythmia -
Nodal/junctional)
Supraventricular And Nodal Arrhythmia
(Supraventricular and nodal arrhythmia -
Sinus arrhythmia)
Sinus Bradycardia (Supraventricular and
nodal arrhythmia - Sinus bradycardia)
Sinus Tachycardia (Supraventricular and
nodal arrhythmia - Sinus tachycardia)
Supraventricular Arrhythmia Nos
(Supraventricular and nodal arrhythmia -
Supraventricular arrhythmia NOS)
Supraventricular And Nodal Arrhythmia -
Supraventricular Extrasystoles
(premature Atrial Contractions;
Premature Nodal/junctional
Contractions) (Supraventricular and
nodal arrhythmia - Supraventricular
extrasystoles (premature atrial
contractions; premature nodal/junctional
contractions))
Supraventricular And Nodal Arrhythmia
(Supraventricular and nodal arrhythmia -
Supraventricular tachycardia)
Sweating Increased (Sweating
(diaphoresis))
Syncope (Syncope (fainting))
Syndromes Other (Syndromes-Other
(Specify))
Taste Disturbance (Taste alteration
(dysgeusia))
Telangiectasia (Telangiectasia)
Thrombosis/embolism (vascular Access-
related) (Thrombosis/embolism (vascular
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access-related))
Thrombosis Nos
(Thrombosis/thrombus/embolism)
Thrombotic Microangiopathy (e.g.,
Thrombotic Thrombocytopenic
Purpura[ttp] Or Hemolytic Uremic
Syndrome[hus]) (Thrombotic
microangiopathy (e.g., thrombotic
thrombocytopenic purpura or hemolytic
uremic syndrome))
Thyroid Function, High (hyperthyroidism,
Thyrotoxicosis) (Thyroid function, high
(hyperthyroidism, thyrotoxicosis))
Hypothyroidism (Thyroid function, low
(hypothyroidism))
Tinnitus (Tinnitus)
Tremor Nec (Tremor)
Hypertriglyceridaemia (Triglyceride,
serum-high (hypertriglyceridemia))
Trismus (difficulty, Restriction Or Pain
When Opening Mouth) (Trismus
(difficulty, restriction or pain when
opening mouth))
Tumour Flare (Tumor flare)
Tumour Lysis Syndrome (Tumor lysis
syndrome)
Caecitis (Typhlitis (cecal inflammation))
Ulcer, Gi (Ulcer, GI - Anus)
Ulcer, Gi (Ulcer, GI - Cecum)
Ulcer, Gi (Ulcer, GI - Colon)
Duodenal Ulcer (Ulcer, GI - Duodenum)
Ulcer, Gi (Ulcer, GI - Esophagus)
Ulcer, Gi (Ulcer, GI - Ileum)
Ulcer, Gi (Ulcer, GI - Jejunum)
Ulcer, Gi (Ulcer, GI - Rectum)
Ulcer, Gi (Ulcer, GI - Small bowel NOS)
Ulcer, Gi (Ulcer, GI - Stoma)
Gastric Ulcer (Ulcer, GI - Stomach)
Ulceration (Ulceration)
Hyperuricaemia (Uric acid, serum-high
(hyperuricemia))
Fanconi Syndrome (Urinary electrolyte
wasting (e.g., Fanconi's syndrome, renal
tubular acidosis))
Urinary Frequency (Urinary
frequency/urgency)
Urinary Retention (Urinary retention
(including neurogenic bladder))
Urine Discolouration (Urine color
change)
Urticaria Nos (Urticaria (hives, welts,
wheals))
Uveitis (Uveitis)
Vaginal Discharge (non-infectious)
(Vaginal discharge (non-infectious))
Vulvovaginal Dryness (Vaginal dryness)
Vaginal Mucositis (Vaginal mucositis)
Vaginal Stenosis/length (Vaginal
stenosis/length)
Vaginitis (Vaginitis (not due to infection))
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Valvular Heart Disease (Valvular heart
disease)
Vascular Other (Vascular-Other
(Specify))
Vasculitis Nos (Vasculitis)
Vasovagal Attack (Vasovagal episode)
Ventricular Arrhythmia (Ventricular
arrhythmia - Bigeminy)
Ventricular Arrhythmia (Ventricular
arrhythmia - Idioventricular rhythm)
Ventricular Arrhythmia (Ventricular
arrhythmia - PVCs)
Ventricular Arrhythmia (Ventricular
arrhythmia - Torsade de pointes)
Ventricular Arrhythmia (Ventricular
arrhythmia - Trigeminy)
Ventricular Arrhythmia Nos (Ventricular
arrhythmia - Ventricular arrhythmia NOS)
Ventricular Arrhythmia (Ventricular
arrhythmia - Ventricular fibrillation)
Ventricular Arrhythmia (Ventricular
arrhythmia - Ventricular flutter)
Ventricular Arrhythmia (Ventricular
arrhythmia - Ventricular tachycardia)
Vessel Injury-artery (Vessel injury-artery
- Aorta)
Vessel Injury-artery (Vessel injury-artery
- Carotid)
Vessel Injury-artery (Vessel injury-artery
- Extremity-lower)
Vessel Injury-artery (Vessel injury-artery
- Extremity-upper)
Vessel Injury-artery (Vessel injury-artery
- Other NOS)
Vessel Injury-artery (Vessel injury-artery
- Visceral)
Vessel Injury-vein (Vessel injury-vein -
Extremity-lower)
Vessel Injury-vein (Vessel injury-vein -
Extremity-upper)
Vessel Injury-vein (Vessel injury-vein -
IVC)
Vessel Injury-vein (Vessel injury-vein -
Jugular)
Vessel Injury-vein (Vessel injury-vein -
Other NOS)
Vessel Injury-vein (Vessel injury-vein -
SVC)
Vessel Injury-vein (Vessel injury-vein -
Viscera)
Viral Hepatitis (Viral hepatitis)
Visceral Arterial Ischaemia (Visceral
arterial ischemia (non-myocardial))
Vision Blurred (Vision-blurred vision)
Photopsia (Vision-flashing lights/floaters)
Photophobia (Vision-photophobia)
Vital Capacity (Vital capacity)
Vitreous Hemorrhage (Vitreous
hemorrhage)
Dysphonia (Voice changes/dysarthria
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Neoplasms, Breast NCT00490139 Toxicity - BIG 2-06 / NCCTG N063D /
EGF106708 - Adverse Event (AE) - 2640617v1.0
(e.g., hoarseness, loss or alteration in
voice, laryngitis))
Vomiting Nos (Vomiting)
Lacrimation Increased (Watery eye
(epiphora, tearing))
Weight Increased (Weight gain)
Weight Decreased (Weight loss)
Culture Wound Negative (Wound
complication, non-infectious)
SAE reported
Yes
No
CTCAE Begin Date
CTCAE End Date
CTC Adverse Event Grade
CTC Adverse Event Outcome
Adverse Event Was Fatal (fatal)
Adverse Event Has Improved (improved)
Adverse Event Is Ongoing (ongoing)
Adverse Event Is Resolved (resolved)
Adverse Event Is Resolved With
Sequelae (resolved with sequelae)
Action Taken at Time of Adverse Event
There Was No Action Taken Based On
The Adverse Event (none)
Other Treatment Was Required As A
Result Of The Adverse Event (other
treatment required)
Protocol Treatment Was Delayed As A
Result Of The Adverse Event (protocol
treatment delayed)
Protocol Treatment Was Discontinued As
A Result Of The Adverse Event (protocol
treatment discontinued)
Study Dose Was Reduced As A Result
Of The Adverse Event (study dose
reduced)
Relation to study drug
Yes
No
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Neoplasms, Breast NCT00490139 Toxicity - BIG 2-06 / NCCTG N063D /
EGF106708 - Adverse Event (AE) - 2640617v1.0
Brain and Central Nervous System Tumors NCT00887146 Toxicity - North Central
Cancer Treatment Group N0577 - Late Effects of Radiation Therapy - 2747295v1.0
North Central Cancer Treatment Group N0577 - Late
Effects of Radiation Therapy
Radiation Therapy or Radiation Therapy and Temozolomide
or Temozolomide Alone in Treating Patients With Newly
Diagnosed Anaplastic Glioma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=4C93C0B6-
85C4-1ECA-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/9628
North Central Cancer Treatment
Group N0577 - Late Effects of
Radiation Therapy
Header
Protocol Number
Patient ID
Patient Initials (L F M)
Institution Number
Institution
Are data amended (If yes, highlight amended
areas)
Yes
No
Header
Current Cycle Number
Date of evaluation
Description Of Primary Disease
CTC Adverse Event Term
Cns Necrosis/cystic Progression (CNS
necrosis/cystic progression)
Learning Disorder Nos (Cognitive
disturbance)
Amnesia Nec (Memory impairment)
MedDRA Code (primary tumor site: Metastases
to brain parenchyma)
CTC Adverse Event Grade (highest grade this
cycle)
1 / 2
CTC AE Attribution Code (If Grade > 0)
Definite (Definite)
Possible (Possible)
Probable (Probable)
Unlikely (Unlikely)
Unrelated (Unrelated)
Has an Adverse Event Expedited Report been
submitted? (Enter 1 for Yes or 2 for No)
Yes
No
Description Of Primary Disease
Current Cycle Number
Were adverse events assessed during this report
period
No (No)
Yes, And Reportable Adverse Events
Occurred (Yes, and reportable adverse
events occurred)
Yes, But No Reportable Adverse Events
Occurred (Yes, but no reportable adverse
events occurred)
MedDRA Code (primary tumor site: Metastases
to brain parenchyma)
Other CTC Adverse Event Term not listed
CTC Adverse Event Grade (highest grade this
cycle)
CTC AE Attribution Code (If Grade > 0)
Definite (Definite)
Possible (Possible)
Probable (Probable)
Unlikely (Unlikely)
Unrelated (Unrelated)
Has an Adverse Event Expedited Report been
submitted? (Enter 1 for Yes or 2 for No)
Yes
No
2 / 2
Brain and Central Nervous System Tumors NCT00887146 Toxicity - North Central
Cancer Treatment Group N0577 - Late Effects of Radiation Therapy - 2747295v1.0
Breast Cancer NCT00377156 Toxicity - North Central
Cancer Treatment Group Adverse Events Log - 2469808v1.0
North Central Cancer Treatment Group Adverse Events
Log
Stereotactic Radiation Therapy With or Without Whole-
Brain Radiation Therapy in Treating Patients With Brain
Metastases
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=10B44AAB-
1A9A-0E7A-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/9629
North Central Cancer Treatment
Group Adverse Events Log
Header
NCCTG Protocol Number
NCCTG Patient ID
Patient Initials (L F M)
Institution
Institution Number
Are data amended (If yes, highlight amended
areas)
Yes
No
Description Of Primary Disease
Cycle Number (Adverse events associated with)
Were adverse events assessed during this report
period
No (No)
Yes, And Reportable Adverse Events
Occurred (Yes, and reportable adverse
events occurred)
Yes, But No Reportable Adverse Events
Occurred (Yes, but no reportable adverse
events occurred)
Assessment Date
CTC Adverse Event Term
Cns Necrosis/cystic Progression (CNS
necrosis/cystic progression)
Learning Disorder Nos (Cognitive
disturbance)
Alopecia (Hair loss/Alopecia (scalp or
body))
Hearing: Patients With/without Baseline
1 / 2
Audiogram And Enrolled In A Monitoring
Program (Hearing: patients with/without
baseline audiogram and enrolled in a
monitoring program)
Nausea (Nausea)
Peripheral Motor Neuropathy
(Neuropathy: motor)
Otitis Externa (exc Boil Of Meatus) Nos
(Otitis, external ear (non-infectious))
Dermatitis Radiation Nos (Rash:
dermatitis associated with radiation -
Radiation)
Retinopathy (Retinopathy)
Vomiting Nos (Vomiting)
MedDRA Code (primary tumor site: Metastases
to brain parenchyma)
CTC Adverse Event Grade
CTC AE Attribution Code
Definite (Definite)
Possible (Possible)
Probable (Probable)
Unlikely (Unlikely)
Unrelated (Unrelated)
Has an Adverse Event Expedited Report been
submitted?
Yes
No
Description Of Primary Disease
Other CTC Adverse Event Term not listed
MedDRA Code (primary tumor site: Metastases
to brain parenchyma)
CTC Adverse Event Grade
CTC AE Attribution Code
Definite (Definite)
Possible (Possible)
Probable (Probable)
Unlikely (Unlikely)
Unrelated (Unrelated)
Has an Adverse Event Expedited Report been
submitted?
Yes
No
2 / 2
Breast Cancer NCT00377156 Toxicity - North Central Cancer Treatment
Group Adverse Events Log - 2469808v1.0
Toxicity - Acute Leukemia (ALL, AML)/Myelodysplastic
Syndrome (MDS) - Adverse Event Form - 2019363v3.0
Acute Leukemia (ALL, AML)/Myelodysplastic Syndrome
(MDS) - Adverse Event Form
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=1A9C4726-
156D-4A08-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/9631
Acute Leukemia (ALL,
AML)/Myelodysplastic Syndrome
(MDS) - Adverse Event Form
Crf Header
Coordinating Group Protocol No.
Coordinating Group Code
Protocol Title
Patient Study ID
Institution/Affiliate
Other Patient ID
Participating Group Code
Patient Initials
Registration Type
Leukemia/mds: Form Administration
Person Completing Form
Are data amended (If data are amended, please
circle in red when using paper form)
Yes
No
Adverse Event Reporting from Date (mm dd
yyyy)
Adverse Event Reporting to Date (mm dd yyyy)
All/aml/mds: Adverse Events
Treatment Phase
1 / 3
Consolidation (Consolidation)
Current Phase Of Leukemia Treatment
For Patient Is Crossover (Crossover)
Current Phase Of Leukemia Treatment
For Patient Is Follow-up, Or Patient Is Off
Therapy (Follow-up/Off Therapy)
Induction (Induction)
Current Phase Of Leukemia Treatment
For Patient Is Intensification
(Intensification)
Maintenance (Maintenance)
Other Specify (Other)
Current Phase Of Leukemia Treatment
For Patient Is Post-induction (Post-
Induction)
Current Phase Of Leukemia Treatment
For Patient Is Post-remission (Post-
Remission)
Other specify
Current Course Number (or Cycle refer to
treatment plan in protocol Note: Indicate Current
Course or Cycle Number only for treatment
phases that include multiple courses)
CTC Adverse Event Term (- Non-Hematologic list
below gives examples only - see note)
Anorexia (Anorexia)
Diarrhoea Nos (Diarrhea)
Nausea (Nausea)
Vomiting Nos (Vomiting)
CTC Adverse Event Term (- Non-Hematologic list
below gives examples only - see note)
Anorexia (Anorexia)
Diarrhoea Nos (Diarrhea)
Nausea (Nausea)
Vomiting Nos (Vomiting)
Other CTC Adverse Event Term not listed
Other CTC Adverse Event Term not listed
CTC Adverse Event Grade (Only report Grade 3-
5 for non-hematologic)
CTC Adverse Event Grade (Only report Grade 3-
5 for non-hematologic)
CTC Adverse Event Attribution Code (*
Attribution Codes for Relationship of Event to
Treatment: 1= Unrelated,...)
Definite (Definite)
2 / 3
Toxicity - Acute Leukemia (ALL, AML)/Myelodysplastic Syndrome (MDS)
- Adverse Event Form - 2019363v3.0
Possible (Possible)
Probable (Probable)
Unlikely (Unlikely)
Unrelated (Unrelated)
CTC Adverse Event Attribution Code (*
Attribution Codes for Relationship of Event to
Treatment: 1= Unrelated,...)
Definite (Definite)
Possible (Possible)
Probable (Probable)
Unlikely (Unlikely)
Unrelated (Unrelated)
Allows Documentation Of Any Additional
Cooments
Comments
3 / 3
Toxicity - Acute Leukemia (ALL, AML)/Myelodysplastic Syndrome (MDS)
- Adverse Event Form - 2019363v3.0
Toxicity - Chronic Myelogenous Leukemia
(CML) - Adverse Event Form - 2019367v3.0
Chronic Myelogenous Leukemia (CML) - Adverse Event
Form
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=1A9D318C-
7E11-6C12-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/9632
Chronic Myelogenous Leukemia
(CML) - Adverse Event Form
Crf Header
Coordinating Group Protocol No.
Coordinating Group Code
Protocol Title
Patient Study ID
Institution/Affiliate
Other Patient ID
Participating Group Code
Patient Initials
Registration Type
Leukemia/mds: Form Administration
Person Completing Form
Are data amended (If data are amended, please
circle in red when using paper form)
Yes
No
Adverse Event Reporting from Date (mm dd
yyyy)
Adverse Event Reporting to Date (mm dd yyyy)
All/aml/mds: Adverse Events
Treatment Phase
1 / 3
Consolidation (Consolidation)
Current Phase Of Leukemia Treatment
For Patient Is Crossover (Crossover)
Current Phase Of Leukemia Treatment
For Patient Is Follow-up, Or Patient Is Off
Therapy (Follow-up/Off Therapy)
Induction (Induction)
Current Phase Of Leukemia Treatment
For Patient Is Intensification
(Intensification)
Maintenance (Maintenance)
Other Specify (Other)
Current Phase Of Leukemia Treatment
For Patient Is Post-induction (Post-
Induction)
Current Phase Of Leukemia Treatment
For Patient Is Post-remission (Post-
Remission)
Other specify
Current Course Number (or Cycle refer to
treatment plan in protocol Note: Indicate Current
Course or Cycle Number only for treatment
phases that include multiple courses)
CTC Adverse Event Term (- Non-Hematologic list
below gives examples only - see note)
Anorexia (Anorexia)
Diarrhoea Nos (Diarrhea)
Nausea (Nausea)
Vomiting Nos (Vomiting)
CTC Adverse Event Term (- Non-Hematologic list
below gives examples only - see note)
Anorexia (Anorexia)
Diarrhoea Nos (Diarrhea)
Nausea (Nausea)
Vomiting Nos (Vomiting)
Other CTC Adverse Event Term not listed
Other CTC Adverse Event Term not listed
CTC Adverse Event Grade (Only report Grade 3-
5 for non-hematologic)
CTC Adverse Event Grade (Only report Grade 3-
5 for non-hematologic)
CTC Adverse Event Attribution Code (*
Attribution Codes for Relationship of Event to
Treatment: 1= Unrelated,...)
Definite (Definite)
2 / 3
Toxicity - Chronic Myelogenous Leukemia (CML) - Adverse Event Form -
2019367v3.0
Possible (Possible)
Probable (Probable)
Unlikely (Unlikely)
Unrelated (Unrelated)
CTC Adverse Event Attribution Code (*
Attribution Codes for Relationship of Event to
Treatment: 1= Unrelated,...)
Definite (Definite)
Possible (Possible)
Probable (Probable)
Unlikely (Unlikely)
Unrelated (Unrelated)
Allows Documentation Of Any Additional
Cooments
Comments
3 / 3
Toxicity - Chronic Myelogenous Leukemia (CML) - Adverse Event Form -
2019367v3.0
Toxicity - Hairy Cell Leukemia (HCL) -
Adverse Event Form - 2019371v3.0
Hairy Cell Leukemia (HCL) - Adverse Event Form
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=1A9D318C-
7E76-6C12-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/9633
Hairy Cell Leukemia (HCL) - Adverse
Event Form
Crf Header
Coordinating Group Protocol No.
Coordinating Group Code
Protocol Title
Patient Study ID
Institution/Affiliate
Other Patient ID
Participating Group Code
Patient Initials
Registration Type
Leukemia/mds: Form Administration
Person Completing Form
Are data amended (If data are amended, please
circle in red when using paper form)
Yes
No
Adverse Event Reporting from Date (mm dd
yyyy)
Adverse Event Reporting to Date (mm dd yyyy)
All/aml/mds: Adverse Events
Treatment Phase
Consolidation (Consolidation)
Current Phase Of Leukemia Treatment
1 / 3
For Patient Is Crossover (Crossover)
Current Phase Of Leukemia Treatment
For Patient Is Follow-up, Or Patient Is Off
Therapy (Follow-up/Off Therapy)
Induction (Induction)
Current Phase Of Leukemia Treatment
For Patient Is Intensification
(Intensification)
Maintenance (Maintenance)
Other Specify (Other)
Current Phase Of Leukemia Treatment
For Patient Is Post-induction (Post-
Induction)
Current Phase Of Leukemia Treatment
For Patient Is Post-remission (Post-
Remission)
Other specify
Current Course Number (or Cycle refer to
treatment plan in protocol Note: Indicate Current
Course or Cycle Number only for treatment
phases that include multiple courses)
CTC Adverse Event Term (- Non-Hematologic list
below gives examples only - see note)
Anorexia (Anorexia)
Diarrhoea Nos (Diarrhea)
Nausea (Nausea)
Vomiting Nos (Vomiting)
CTC Adverse Event Term (- Non-Hematologic list
below gives examples only - see note)
Anorexia (Anorexia)
Diarrhoea Nos (Diarrhea)
Nausea (Nausea)
Vomiting Nos (Vomiting)
Other CTC Adverse Event Term not listed
Other CTC Adverse Event Term not listed
CTC Adverse Event Grade (Only report Grade 3-
5 for non-hematologic)
CTC Adverse Event Grade (Only report Grade 3-
5 for non-hematologic)
CTC Adverse Event Attribution Code (*
Attribution Codes for Relationship of Event to
Treatment: 1= Unrelated,...)
Definite (Definite)
Possible (Possible)
Probable (Probable)
2 / 3
Toxicity - Hairy Cell Leukemia (HCL) - Adverse Event Form -
2019371v3.0
Unlikely (Unlikely)
Unrelated (Unrelated)
CTC Adverse Event Attribution Code (*
Attribution Codes for Relationship of Event to
Treatment: 1= Unrelated,...)
Definite (Definite)
Possible (Possible)
Probable (Probable)
Unlikely (Unlikely)
Unrelated (Unrelated)
Allows Documentation Of Any Additional
Cooments
Comments
3 / 3
Toxicity - Hairy Cell Leukemia (HCL) - Adverse Event Form -
2019371v3.0
Toxicity - Prostate Cancer - Adverse Event
Form - 2283646v3.0
Prostate Cancer - Adverse Event Form
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=DC4FB6C8-
2D4F-5BF6-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/9634
Prostate Cancer - Adverse Event
Form
Crf Header
Coordinating Group Protocol No.
Coordinating Group Code
Protocol Title
Patient Study ID
Institution/Affiliate
Other Patient ID
Participating Group Code
Patient Name (initials acceptable)
Prostate: Adverse Events
Adverse Event Reporting From Date
Adverse Event Reporting To Date
CTC Adverse Event Term (Non-Hematologic
examples only)
Anorexia (Anorexia)
Diarrhoea Nos (Diarrhea)
Nausea (Nausea)
Dermatitis Exfoliative Nos
(Rash/desquamation)
Vomiting Nos (Vomiting)
CTC Adverse Event Term (Non-Hematologic
examples only)
Anorexia (Anorexia)
Diarrhoea Nos (Diarrhea)
Nausea (Nausea)
Dermatitis Exfoliative Nos
(Rash/desquamation)
Vomiting Nos (Vomiting)
1 / 2
Other CTC Adverse Event Term not listed (s)
Other CTC Adverse Event Term not listed (s)
CTC Adverse Event Grade (Only report Grade 3-
5 for non-hematologic)
CTC Adverse Event Grade (Only report Grade 3-
5 for non-hematologic)
Comments
Comments
2 / 2
Toxicity - Prostate Cancer - Adverse Event Form - 2283646v3.0
Toxicity - Phase II Breast Cancer - Adverse
Event Form - 2550581v1.0
Phase II Breast Cancer - Adverse Event Form
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=23E61A19-
618F-6176-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/9635
Phase II Breast Cancer - Adverse
Event Form
Crf Header
Coordinating Group Protocol No.
Coordinating Group Code
Protocol Title
Patient Study ID
Institution/Affiliate
Registering Group Code
Registering Institution Code
Patient Initials
Lung: Adverse Events
Cycle Number
Were adverse events assessed during most
recent period
Yes
No
Adverse Event Reporting from Date
Adverse Event Reporting to Date
Has an Adverse Event Expedited Report been
submitted?
Yes
No
MedDRA Code
MedDRA Code
1 / 3
CTC Adverse Event Term (Non-hematologic
examples only)
Anorexia (Anorexia)
Diarrhoea Nos (Diarrhea)
Nausea (Nausea)
Dermatitis Exfoliative Nos
(Rash/desquamation)
CTC Adverse Event Term (Non-hematologic
examples only)
Anorexia (Anorexia)
Diarrhoea Nos (Diarrhea)
Nausea (Nausea)
Dermatitis Exfoliative Nos
(Rash/desquamation)
Other CTC Adverse Event Term not listed
Other CTC Adverse Event Term not listed
CTC Adverse Event Grade
CTC Adverse Event Grade
CTC AE Attribution Code
Definite (Definite)
Possible (Possible)
Probable (Probable)
Unlikely (Unlikely)
Unrelated (Unrelated)
CTC AE Attribution Code
Definite (Definite)
Possible (Possible)
Probable (Probable)
Unlikely (Unlikely)
Unrelated (Unrelated)
Lung: Nadir
Lab
Nadir/Worst Date
Nadir/Worst Value
Nadir/Worst Unit of Measure
Is nadir below LLN?
Yes
No
2 / 3
Toxicity - Phase II Breast Cancer - Adverse Event Form - 2550581v1.0
Comments
Comments
3 / 3
Toxicity - Phase II Breast Cancer - Adverse Event Form - 2550581v1.0
Toxicity - Chronic Lymphocytic Leukemia
(CLL) - Adverse Event Form - 2019369v3.0
Chronic Lymphocytic Leukemia (CLL) - Adverse Event
Form
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=1A9D2FC5-
015F-6BF7-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/9636
Chronic Lymphocytic Leukemia
(CLL) - Adverse Event Form
Crf Header
Coordinating Group Protocol No.
Coordinating Group Code
Protocol Title
Patient Study ID
Institution/Affiliate
Other Patient ID
Participating Group Code
Patient Initials
Registration Type
Leukemia/mds: Form Administration
Person Completing Form
Are data amended (If data are amended, please
circle in red when using paper form)
Yes
No
Adverse Event Reporting from Date (mm dd
yyyy)
Adverse Event Reporting to Date (mm dd yyyy)
All/aml/mds: Adverse Events
Treatment Phase
1 / 3
Consolidation (Consolidation)
Current Phase Of Leukemia Treatment
For Patient Is Crossover (Crossover)
Current Phase Of Leukemia Treatment
For Patient Is Follow-up, Or Patient Is Off
Therapy (Follow-up/Off Therapy)
Induction (Induction)
Current Phase Of Leukemia Treatment
For Patient Is Intensification
(Intensification)
Maintenance (Maintenance)
Other Specify (Other)
Current Phase Of Leukemia Treatment
For Patient Is Post-induction (Post-
Induction)
Current Phase Of Leukemia Treatment
For Patient Is Post-remission (Post-
Remission)
Other specify
Current Course Number (or Cycle refer to
treatment plan in protocol Note: Indicate Current
Course or Cycle Number only for treatment
phases that include multiple courses)
CTC Adverse Event Term (- Non-Hematologic list
below gives examples only - see note)
Anorexia (Anorexia)
Diarrhoea Nos (Diarrhea)
Nausea (Nausea)
Vomiting Nos (Vomiting)
CTC Adverse Event Term (- Non-Hematologic list
below gives examples only - see note)
Anorexia (Anorexia)
Diarrhoea Nos (Diarrhea)
Nausea (Nausea)
Vomiting Nos (Vomiting)
Other CTC Adverse Event Term not listed
Other CTC Adverse Event Term not listed
CTC Adverse Event Grade (Only report Grade 3-
5 for non-hematologic)
CTC Adverse Event Grade (Only report Grade 3-
5 for non-hematologic)
CTC Adverse Event Attribution Code (*
Attribution Codes for Relationship of Event to
Treatment: 1= Unrelated,...)
Definite (Definite)
2 / 3
Toxicity - Chronic Lymphocytic Leukemia (CLL) - Adverse Event Form -
2019369v3.0
Possible (Possible)
Probable (Probable)
Unlikely (Unlikely)
Unrelated (Unrelated)
CTC Adverse Event Attribution Code (*
Attribution Codes for Relationship of Event to
Treatment: 1= Unrelated,...)
Definite (Definite)
Possible (Possible)
Probable (Probable)
Unlikely (Unlikely)
Unrelated (Unrelated)
Allows Documentation Of Any Additional
Cooments
Comments
3 / 3
Toxicity - Chronic Lymphocytic Leukemia (CLL) - Adverse Event Form -
2019369v3.0
Toxicity - PHASE II ¿ ADVERSE EVENT
FORM - 2400548v1.0
Phase II Consortium PHASE II ¿ ADVERSE EVENT FORM
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=FFA66CD3-
4843-5338-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/9637
PHASE II ¿ ADVERSE EVENT
FORM
Crf Header
Coordinating Group Protocol No.
Coordinating Group Code
Protocol Title
Patient Study ID
Registering Group Code
Patient Medical Record Number
Other Patient ID
Institution/Affiliate
Registering Institution Code
Physician of Record
Lung: Adverse Events
Were adverse events assessed during most
recent period
Yes
No
Adverse Event Reporting from Date
Adverse Event Reporting to Date
Has an Adverse Event Expedited Report been
submitted?
No (No)
Unknown (Unknown)
Yes (Yes)
MedDRA Code
1 / 3
MedDRA Code
CTC Adverse Event Term (Non-hematologic
examples only)
Anorexia (Anorexia)
Diarrhoea Nos (Diarrhea)
Nausea (Nausea)
Dermatitis Exfoliative Nos
(Rash/desquamation)
CTC Adverse Event Term (Non-hematologic
examples only)
Anorexia (Anorexia)
Diarrhoea Nos (Diarrhea)
Nausea (Nausea)
Dermatitis Exfoliative Nos
(Rash/desquamation)
Other CTC Adverse Event Term not listed
Other CTC Adverse Event Term not listed
CTC Adverse Event Grade
CTC Adverse Event Grade
CTC AE Attribution Code
Definite (Definite)
Possible (Possible)
Probable (Probable)
Unlikely (Unlikely)
Unrelated (Unrelated)
CTC AE Attribution Code
Definite (Definite)
Possible (Possible)
Probable (Probable)
Unlikely (Unlikely)
Unrelated (Unrelated)
Lung: Nadir
Lab
Nadir/Worst Date
Nadir/Worst Value
Nadir/Worst Unit of Measure
Is nadir below LLN?
2 / 3
Toxicity - PHASE II ¿ ADVERSE EVENT FORM - 2400548v1.0
Yes
No
Comments
Comments
3 / 3
Toxicity - PHASE II ¿ ADVERSE EVENT FORM - 2400548v1.0
Toxicity - Head and Neck Cancers -
Adverse Event Form - 2267639v3.0
Head and Neck Cancers - Adverse Event Form
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=1DE87740-
5099-4043-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/9638
Head and Neck Cancers - Adverse
Event Form
Crf Header
Coordinating Group Protocol No.
Coordinating Group Code
Protocol Title
Patient Study ID
Institution/Affiliate
Other Patient ID
Participating Group Code
Patient Initials
Head & Neck: Form Administration
Person Completing Form
Are data amended? (If data are amended, please
circle in red when using paper form)
Yes
No
Adverse Event Reporting from Date (mm dd
yyyy)
Adverse Event Reporting to Date (mm dd yyyy)
Head & Neck: Adverse Events
Have any serious adverse events been reported?
(to regulatory body per protocol)
Yes
No
CTC Adverse Event Term (Non-Hematologic
1 / 2
examples only)
Anorexia (Anorexia)
Diarrhoea Nos (Diarrhea)
Nausea (Nausea)
Dermatitis Exfoliative Nos
(Rash/desquamation)
Vomiting Nos (Vomiting)
CTC Adverse Event Term (Non-Hematologic
examples only)
Anorexia (Anorexia)
Diarrhoea Nos (Diarrhea)
Nausea (Nausea)
Dermatitis Exfoliative Nos
(Rash/desquamation)
Vomiting Nos (Vomiting)
Other CTC Adverse Event Term not listed
Other CTC Adverse Event Term not listed
CTC Adverse Event Grade
CTC Adverse Event Grade
CTC Adverse Event Attribution Code (*
Attribution Codes for Relationship of Event to
Treatment:)
Definite (Definite)
Possible (Possible)
Probable (Probable)
Unlikely (Unlikely)
Unrelated (Unrelated)
CTC Adverse Event Attribution Code (*
Attribution Codes for Relationship of Event to
Treatment:)
Definite (Definite)
Possible (Possible)
Probable (Probable)
Unlikely (Unlikely)
Unrelated (Unrelated)
Comments
Comments
2 / 2
Toxicity - Head and Neck Cancers - Adverse Event Form - 2267639v3.0
Toxicity - Acute Promyelocytic Leukemia
(APL) - Adverse Event Form - 2019365v3.0
Acute Promyelocytic Leukemia (APL) - Adverse Event Form
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=1A9D2CEE-
0772-6B83-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/9639
Acute Promyelocytic Leukemia (APL)
- Adverse Event Form
Crf Header
Coordinating Group Protocol No.
Coordinating Group Code
Protocol Title
Patient Study ID
Institution/Affiliate
Other Patient ID
Participating Group Code
Patient Initials
Registration Type
Leukemia/mds: Form Administration
Person Completing Form
Are data amended (If data are amended, please
circle in red when using paper form)
Yes
No
Adverse Event Reporting from Date (mm dd
yyyy)
Adverse Event Reporting to Date (mm dd yyyy)
All/aml/mds: Adverse Events
Treatment Phase
Consolidation (Consolidation)
Current Phase Of Leukemia Treatment
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For Patient Is Crossover (Crossover)
Current Phase Of Leukemia Treatment
For Patient Is Follow-up, Or Patient Is Off
Therapy (Follow-up/Off Therapy)
Induction (Induction)
Current Phase Of Leukemia Treatment
For Patient Is Intensification
(Intensification)
Maintenance (Maintenance)
Other Specify (Other)
Current Phase Of Leukemia Treatment
For Patient Is Post-induction (Post-
Induction)
Current Phase Of Leukemia Treatment
For Patient Is Post-remission (Post-
Remission)
Other specify
Current Course Number (or Cycle refer to
treatment plan in protocol Note: Indicate Current
Course or Cycle Number only for treatment
phases that include multiple courses)
CTC Adverse Event Term (- Non-Hematologic list
below gives examples only - see note)
Anorexia (Anorexia)
Diarrhoea Nos (Diarrhea)
Nausea (Nausea)
Vomiting Nos (Vomiting)
CTC Adverse Event Term (- Non-Hematologic list
below gives examples only - see note)
Anorexia (Anorexia)
Diarrhoea Nos (Diarrhea)
Nausea (Nausea)
Vomiting Nos (Vomiting)
Other CTC Adverse Event Term not listed
Other CTC Adverse Event Term not listed
CTC Adverse Event Grade (Only report Grade 3-
5 for non-hematologic)
CTC Adverse Event Grade (Only report Grade 3-
5 for non-hematologic)
CTC Adverse Event Attribution Code (*
Attribution Codes for Relationship of Event to
Treatment: 1= Unrelated,...)
Definite (Definite)
Possible (Possible)
Probable (Probable)
2 / 3
Toxicity - Acute Promyelocytic Leukemia (APL) - Adverse Event Form -
2019365v3.0
Unlikely (Unlikely)
Unrelated (Unrelated)
CTC Adverse Event Attribution Code (*
Attribution Codes for Relationship of Event to
Treatment: 1= Unrelated,...)
Definite (Definite)
Possible (Possible)
Probable (Probable)
Unlikely (Unlikely)
Unrelated (Unrelated)
Allows Documentation Of Any Additional
Cooments
Comments
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2019365v3.0
Lung Cancer NCT00096265 Toxicity - AE RTOG Phase III Multiple
Brain Metastases Adverse Event Evaluation Form - 2277984v3.0
AE RTOG Phase III Multiple Brain Metastases Adverse
Event Evaluation Form
Radiation Therapy and Stereotactic Radiosurgery With or
Without Temozolomide or Erlotinib in Treating Patients With
Brain Metastases Secondary to Non-Small Cell Lung
Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=D81D6073-
C669-0831-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/9644
AE RTOG Phase III Multiple Brain
Metastases Adverse Event
Evaluation Form
Header
Type of corresponding gorm
F1 (F1)
TF (TF)
Total Protein (gm%), Normal Range
Uric Acid (mg%), Normal Range
Other, Normal Range
Hct (%), Normal Range
Calc. Creatinine Clearance, Normal Range
If unrelated to protocl treatment, specify cause
Treatment Cause Factor Attribution
Combined modality (Combined modality)
Other cause (Other cause)
Study drug only (Study drug only)
Unknown (Unknown)
XRT only (XRT only)
Due date of corresponding form
[RTOG Study No.]
RTOG Study 0320 (RTOG Study 0320)
Case #
Institution
Institution No.
Participant's Initials
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Participant's I.D. No.
Date of last clinical assessment
MedDRA Code
CTCAE Term
CTCAE Grade
CTCAE Begin Date
Attribution to Protocol Treatment
Definite (Definite)
Possible (Possible)
Probable (Probable)
Unlikely (Unlikely)
Unrelated (Unrelated)
Attribution to Protocol Treatment
Definite (Definite)
Possible (Possible)
Probable (Probable)
Unlikely (Unlikely)
Unrelated (Unrelated)
Adverse Event Report Submitted
No (no)
Unknown (unknown)
Yes (yes)
Hgb (gms)
Hgb (gms), Normal Range
Hct (%)
WBC (x1000)
WBC (x1000), Normal Range
Platelets (x1000)
platelets (x1000), Normal Range
Neutrophils/gran (%)
neutrophils/gran (%), Normal Range
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ANC
ANC, Normal Range
BUN
BUN, Normal Range
Creatinine (mg%)
Creatinine (mg%), Normal Range
Calc. Creatinine Clearance
Bilirubin (total (Mg%)
bilirubin (total (Mg%), Normal Range
Aklaline Phosphotase
aklaline Phosphotase, Normal Range
LDH
LDH, Normal Range
SGOT
SGOT, Normal Range
SGPT
SGPT, Normal Range
Total Protein (gm%)
Uric Acid (mg%)
Albumin (gm%)
Albumin (gm%), Normal Range
Potassium (mg/L)
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potassium (mg/L), Normal Range
Calcium (mg/d)
calcium (mg/d), Normal Range
Glucose
glucose, Normal Range
Sodium (meq/L)
sodium (meq/L), Normal Range
Other
Comments
Signature
Date
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Kidney Cancer NCT00357760 Eligibility - E4805
Registration Worsksheet - Step 1 - 3056754v1.0
E4805 Registration Worsksheet - Step 1
VEGF Trap in Treating Patients With Metastatic or
Unresectable Kidney Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=83D1F61D-
EFC6-FE74-E040-BB89AD436539
All rights reserved. Please visit https://medical-data-
models.org/forms/9648
E4805 Registration Worsksheet -
Step 1
Eligibility
First initial
Last initial
Has the eligibility checklist been completed?
Yes
No
In the opinion of the investigator, is the patient
eligible?
Yes
No
Has written informed consent been obtained?
Yes
No
Date Informed Consent Signed
Has HIPAA authorization been obtained?
Exempt - Non-usa Participant (Exempt -
non-USA participant)
No: C49487 (No)
Yes: C49488 (Yes)
HIPAA Authorization Date
MSKCC risk status
High Risk (High risk)
Intermediate Risk (Intermediate risk)
Low Risk (Low risk)
Prior cytokine therapy (interleukin 2 and
interferon alpha only)
Yes
No
I agree to participate in the laboratory research
studies that are being done as part of this clinical
trial.
Yes
No
My specimens may be kept for use in research to
learn about, prevent, treat, or cure cancer.
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Yes
No
My specimens may be kept for use in research
about other health problems (for example: causes
of diabetes, Alzheimer's disease, or heart
disease)
Yes
No
Someone from this institution may contact me in
the future to ask me to take part in more
research.
Yes
No
Patient Demographics / Pre-treatment
Characteristics
Patient's Sex
Female (F)
Male (M)
Birthdate (mm/yy)
Patient's Race
A Person Having Origins In Any Of The
Original Peoples Of North And South
America (including Central America),
And Who Maintains Tribal Affiliation Or
Community Attachment. (American
Indian or Alaska Native)
A Person Having Origins In Any Of The
Original Peoples Of The Far East,
Southeast Asia, Or The Indian
Subcontinent Including, For Example,
Cambodia, China, India, Japan, Korea,
Malaysia, Pakistan, The Philippine
Islands, Thailand, And Vietnam. (Asian)
A Person Having Origins In Any Of The
Black Racial Groups Of Africa. Terms
Such As "haitian" Or "negro" Can Be
Used In Addition To "black Or African
American." (Black or African American)
A Person Having Origins In Any Of The
Original Peoples Of Hawaii, Guam,
Samoa, Or Other Pacific Islands. (Native
Hawaiian or other Pacific Islander)
Not Provided Or Available (Not
Reported)
Could Not Be Determined Or Unsure
(Unknown)
A Person Having Origins In Any Of The
Original Peoples Of Europe, The Middle
East, Or North Africa. (White)
ZIP Code
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Patient Ethnicity
A Person Of Mexican, Puerto Rican,
Cuban, Central Or South American Or
Other Spanish Culture Or Origin,
Regardless Of Race. (Hispanic or Latino)
A Person Not Meeting The Definition For
Hispanic Or Latino. (Not Hispanic or
Latino)
Not Provided Or Available (Not reported)
Could Not Be Determined Or Unsure
(Unknown)
Patient Hospital No.
Patient Social Security Number
Method of payment (check one)
Medicaid (Medicaid)
Medicaid And Medicare (Medicaid and
Medicare)
Medicare (Medicare)
Medicare And Private Insurance
(Medicare and Private Insurance)
Military Or Veterans Sponsored Nos
(Military or Veterans Sponsored, Not
Otherwise Specified (NOS))
Military Sponsored (including Champus
& Tricare) (Military Sponsored (including
CHAMPUS & TRICARE))
No Means Of Payment (no Insurance)
(No means of payment (no insurance))
Other (Other)
Private Insurance (Private Insurance)
Self Pay (no Insurance) (Self Pay (No
Insurance))
Unknown (Unknown)
Veterans Sponsored (Veterans
Sponsored)
Country of residence
Ascension Island (AC)
Andorra (AD)
United Arab Emirates (AE)
Afghanistan (AF)
Antigua And Barbuda (AG)
Anguilla (AI)
Albania (AL)
Armenia (AM)
Netherland Antilles (AN)
Angola (AO)
Antarctica (AQ)
Argentina (AR)
American Samoa (AS)
Austria (AT)
Australia (AU)
Aruba (AW)
Azerbaidjan (AZ)
Bosnia-herzegovina (BA)
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Barbados (BB)
Bangladesh (BD)
Belgium (BE)
Burkina Faso (BF)
Bulgaria (BG)
Bahrain (BH)
Burundi (BI)
Benin (BJ)
Bermuda (BM)
Brunei Darussalam (BN)
Bolivia (BO)
Brazil (BR)
Bahamas (BS)
Bhutan (BT)
Bouvet Island (BV)
Botswana (BW)
Belarus (BY)
Belize (BZ)
Canada (CA)
Cocos Isl. (CC)
Rep. Dem. Congo (CD)
Central African Rep. (CF)
Congo (CG)
Switzerland (CH)
Ivory Coast (CI)
Cook Islands (CK)
Chile (CL)
Cameroon (CM)
China (CN)
Colombia (CO)
Costa Rica (CR)
Cuba (CU)
Cape Verde (CV)
Christmas Island (CX)
Cyprus (CY)
Czech Republic (CZ)
Germany (DE)
Djibouti (DJ)
Denmark (DK)
Dominica (DM)
Dominican Republic (DO)
Algeria (DZ)
Ecuador (EC)
Estonia (EE)
Egypt (EG)
Western Sahara (EH)
Eritrea (ER)
Spain (ES)
Ethiopia (ET)
Finland (FI)
Fiji (FJ)
Falkland Isl. (FK)
Micronesia (FM)
Faroe Islands (FO)
France (FR)
France (european Ter.) (FX)
Gabon (GA)
Great Britain (GB)
Grenada (GD)
Georgia (GE)
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Guiana (fr.) (GF)
Guernsey (GG)
Ghana (GH)
Gibraltar (GI)
Greenland (GL)
Gambia (GM)
Guinea (GN)
Guadeloupe (fr.) (GP)
Equatorial Guinea (GQ)
Greece (GR)
South Georgia And South Sandwich
Islands (GS)
Guatemala (GT)
Guam (us) (GU)
Guinea Bissau (GW)
Guyana (GY)
Hong Kong (HK)
Heard & Mcdonald Isl. (HM)
Honduras (HN)
Croatia (HR)
Haiti (HT)
Hungary (HU)
Indonesia (ID)
Ireland (IE)
Israel (IL)
Isle Of Man (IM)
India (IN)
British Indian O. Ter. (IO)
Iraq (IQ)
Iran (IR)
Iceland (IS)
Italy (IT)
Jersey (JE)
Jamaica (JM)
Jordan (JO)
Japan (JP)
Kenya (KE)
Kyrgyz Republic (KG)
Cambodia (KH)
Kiribati (KI)
Comoros (KM)
St. Kitts Nevis Anguilla (KN)
Korea (north) (KP)
Korea (south) (KR)
Kuwait (KW)
Cayman Islands (KY)
Kazakstan (KZ)
Laos (LA)
Lebanon (LB)
Saint Lucia (LC)
Liechtenstein (LI)
Sri Lanka (LK)
Liberia (LR)
Lesotho (LS)
Lithuania (LT)
Luxembourg (LU)
Latvia (LV)
Libya (LY)
Morocco (MA)
Monaco (MC)
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Moldova (MD)
Madagascar (MG)
Marshall Islands (MH)
Macedonia (MK)
Mali (ML)
Myanmar (MM)
Mongolia (MN)
Macau (MO)
Northern Mariana Isl. (MP)
Martinique (fr.) (MQ)
Mauritania (MR)
Montserrat (MS)
Malta (MT)
Mauritius (MU)
Maldives (MV)
Malawi (MW)
Mexico (MX)
Malaysia (MY)
Mozambique (MZ)
Namibia (NA)
New Caledonia (fr.) (NC)
Niger (NE)
Norfolk Island (NF)
Nigeria (NG)
Nicaragua (NI)
Netherlands (NL)
Norway (NO)
Nepal (NP)
Nauru (NR)
Niue (NU)
New Zealand (NZ)
Oman (OM)
Other (Other)
Panama (PA)
Peru (PE)
Polynesia (fr.) (PF)
Papua New Guinea (PG)
Philippines (PH)
Pakistan (PK)
Poland (PL)
St. Pierre & Miquelon (PM)
Pitcairn (PN)
Puerto Rico (PR)
Portugal (PT)
Palau (PW)
Paraguay (PY)
Qatar (QA)
Reunion (fr.) (RE)
Romania (RO)
Russian Federation (RU)
Rwanda (RW)
Saudi Arabia (SA)
Solomon Islands (SB)
Seychelles (SC)
Sudan (SD)
Sweden (SE)
Singapore (SG)
St. Helena (SH)
Slovenia (SI)
Svalbard & Jan Mayen Isl. (SJ)
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Slovakia (SK)
Sierra Leone (SL)
San Marino (SM)
Senegal (SN)
Somalia (SO)
Suriname (SR)
St. Tome And Principe (ST)
Soviet Union (SU)
El Salvador (SV)
Syria (SY)
Swaziland (SZ)
Turks & Caicos Islands (TC)
Chad (TD)
French Southern Terr. (TF)
Togo (TG)
Thailand (TH)
Tadjikistan (TJ)
Tokelau (TK)
Turkmenistan (TM)
Tunisia (TN)
Tonga (TO)
East Timor (TP)
Turkey (TR)
Trinidad & Tobago (TT)
Tuvalu (TV)
Taiwan (TW)
Tanzania (TZ)
Ukraine (UA)
Uganda (UG)
United Kingdom (UK)
Us Minor Outlying Isl. (UM)
Usa (US)
Uruguay (UY)
Uzbekistan (UZ)
Vatican City State (VA)
St. Vincent & Grenadines (VC)
Venezuela (VE)
Virgin Islands (brit) (VG)
Virgin Islands (us) (VI)
Vietnam (VN)
Vanuatu (VU)
Wallis & Futuna Islands (WF)
Western Samoa (WS)
Yemen (YE)
Mayotte (YT)
Yugoslavia (YU)
South Africa (ZA)
Zambia (ZM)
Dem. Rep. Of Congo (ZR)
Zimbabwe (ZW)
Comments
I Have Reviewed The Above Data And
Agree The Date Are Accurate And Correct
Signature of treating physician
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Lymphoma NCT00392834 Demographic - AMC-
048 Demographic Form (DEM) - 2655243v1.0
AMC-048 Demographic Form (DEM)
Rituximab and Combination Chemotherapy in Treating
Patients With Newly Diagnosed, HIV-Associated Burkitt's
Lymphoma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=32E18FA2-
33B5-4AF2-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/9650
AMC-048 Demographic Form (DEM)
Header
Patient Initials
Patient's Date of Birth
Gender
Female (FEMALE)
Male (MALE)
Ethnicity
A Person Of Mexican, Puerto Rican,
Cuban, Central Or South American Or
Other Spanish Culture Or Origin,
Regardless Of Race. (Hispanic or Latino)
A Person Not Meeting The Definition For
Hispanic Or Latino. (Not Hispanic or
Latino)
Could Not Be Determined Or Unsure
(Unknown)
Race (check all that apply)
A Person Having Origins In Any Of The
Original Peoples Of North And South
America (including Central America),
And Who Maintains Tribal Affiliation Or
Community Attachment. (American
Indian or Alaska Native)
A Person Having Origins In Any Of The
Original Peoples Of The Far East,
Southeast Asia, Or The Indian
Subcontinent Including, For Example,
Cambodia, China, India, Japan, Korea,
Malaysia, Pakistan, The Philippine
Islands, Thailand, And Vietnam. (Asian)
A Person Having Origins In Any Of The
Black Racial Groups Of Africa. Terms
Such As "haitian" Or "negro" Can Be
Used In Addition To "black Or African
American." (Black or African American)
A Person Having Origins In Any Of The
Original Peoples Of Hawaii, Guam,
Samoa, Or Other Pacific Islands. (Native
Hawaiian or other Pacific Islander)
Could Not Be Determined Or Unsure
(Unknown)
A Person Having Origins In Any Of The
Original Peoples Of Europe, The Middle
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East, Or North Africa. (White)
Patient Zip Code
Method of Payment
Medicaid (Medicaid)
Medicaid And Medicare (Medicaid and
Medicare)
Medicare (Medicare)
Medicare And Private Insurance
(Medicare and Private Insurance)
Military Or Veterans Sponsored Nos
(Military or Veterans Sponsored, Not
Otherwise Specified (NOS))
Military Sponsored (including Champus
& Tricare) (Military Sponsored (including
CHAMPUS & TRICARE))
No Means Of Payment (no Insurance)
(No means of payment (no insurance))
Other (Other)
Private Insurance (Private Insurance)
Self Pay (no Insurance) (Self Pay (No
Insurance))
Unknown (Unknown)
Veterans Sponsored (Veterans
Sponsored)
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Breast Cancer NCT00075764 Treatment - SOUTHWEST ONCOLOGY
GROUP S0226 Treatment Form for First Cycle - 2174131v3.0
SOUTHWEST ONCOLOGY GROUP S0226 Treatment
Form for First Cycle
S0226 Anastrozole With or Without Fulvestrant as First-
Line Therapy in Postmenopausal Women With Metastatic
Breast Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=C32272D8-
3E9A-2761-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/9652
SOUTHWEST ONCOLOGY GROUP
S0226 Treatment Form for First
Cycle
General information
SWOG Patient ID
SWOG Study No.
Registration Step
Patient Initials (L, F M)
Institution/Affiliate
Physician (Groups other than SWOG)
Group Name
Study No.
Pt. ID
Status
Date of Last Contact or Death
Vital Status
Dead (0)
Alive (1)
Has the patient progressed per the definition of
Section 10.0 of the protocol?
Yes
No
Assigned Treatment Arm
Arm 1: Anastrozole Only (Arm 1:
Anastrozole only)
Arm 2: Anastrozole And Fulvestrant (Arm
2: Anastrozole and fulvestrant)
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Cycle Start Date
Last Treatment Date (for this cycle)
Were there any dose modifications or
additions/omissions to protocol treatment?
No (No)
Yes, Planned (i.e., The Treatment Was
Changed According To Protocol
Guidelines) (Yes, planned)
Yes, Unplanned (i.e., The Treatment
Change Was Not Part Of Protocol
Guidelines) (Yes, unplanned)
Agent Name
Agent Total Dose
Comments
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Leukemia NCT00492856 Toxicity - SOUTHWEST ONCOLOGY GROUP
Consolidation #3 and #4 Adverse Event Summary Form (S0521) - 2416199v1.0
SOUTHWEST ONCOLOGY GROUP Consolidation #3 and
#4 Adverse Event Summary Form (S0521)
Combination Chemotherapy With or Without Gemtuzumab
Followed By Tretinoin, Mercaptopurine, and Methotrexate
or Observation in Treating Patients With Acute
Promyelocytic Leukemia
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=02DF0EAC-
60B5-4B6D-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/9653
SOUTHWEST ONCOLOGY GROUP
Consolidation #3 and #4 Adverse
Event Summary Form (S0521)
Header
SWOG Patient ID
SWOG Study No.
Registration Step
Cycle completed
First Atra/daunorubicin Consolidation
(First ATRA/daunorubicin consolidation)
Second Atra/daunorubicin Consolidation
(Second ATRA/daunorubicin
consolidation)
Patient Initials (L, F M)
Institution/Affiliate
Physician (Participating Group:)
Participating Group Name
American College Of Surgeons
Oncology Group (ACOSOG)
American College Of Radiology
Oncologic Imaging Network (ACRIN)
Aids-associated Malignancies Clinical
Trials Consortium (AMC)
Cancer And Leukemia Group B (CALGB)
Children's Oncology Group (COG)
Eastern Cooperative Oncology Group
(ECOG)
European Organization For Research
And Treatment Of Cancer (EORTC)
Gynecologic Oncology Group (GOG)
International Breast Cancer Study Group
(IBCSG)
North American Brain Tumor Consortium
(NABTC)
Nabtt Brain Tumor Consortium (NABTT)
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North Central Cancer Treatment Group
(NCCTG)
National Cancer Institute Of Canada
Clinical Trials Group (NCIC)
National Surgical Adjuvant Breast And
Bowel Project (NSABP)
Radiation Therapy Oncology Group
(RTOG)
Southwest Oncology Group (SWOG)
Participating Group Study No.
Participating Group Patient ID (Instructions: All
dates are MONTH, DAY, YEAR. Explain any
blank fields or blank dates in the Comments
section. Place an X in appropriate boxes. Circle
AMENDED items in red and write AMENDED
across the top of the form.)
Adverse Events
Date of Most Recent Adverse Event Assessment
Were adverse events assessed during this report
period?
No (No)
Yes, And Reportable Adverse Events
Occurred (Yes, and reportable adverse
events occurred)
Yes, But No Reportable Adverse Events
Occurred (Yes, but no reportable adverse
events occurred)
CTC Adverse Event Term
Alanine Aminotransferase Increased
(ALT, SGPT (serum glutamic pyruvic
transaminase))
Anorexia (Anorexia)
Aspartate Aminotransferase Increased
(AST, SGOT (serum glutamic oxaloacetic
transaminase))
Blood Bilirubin Increased (Bilirubin
(hyperbilirubinemia))
Chelitis (Cheilitis)
Hypercholesteraemia (Cholesterol,
serum-high (hypercholesteremia))
Diarrhoea Nos (Diarrhea)
Dry Skin (Dry skin)
Fatigue (Fatigue (asthenia, lethargy,
malaise))
Febrile Neutropenia (fever Of Unknown
Origin Without Clinically Or
Microbiologically Documented Infection)
(anc <1.0 X 10^9/l, Fever >=38.5
Degrees C) (Febrile neutropenia)
Pyrexia (Fever (in the absence of
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neutropenia, where neutropenia is
defined as ANC <1.0 x 10^9/L))
Alopecia (Hair loss/Alopecia (scalp or
body))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Blood)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Lung (pneumonia))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Blood)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Lung
(pneumonia))
Mucositis/stomatitis (clinical Exam)
(Mucositis/stomatitis (clinical exam) -
Oral cavity)
Mucositis/stomatitis (clinical Exam)
(Mucositis/stomatitis (clinical exam) -
Rectum)
Nausea (Nausea)
Headache Nos (Pain - Head/headache)
Myalgia (Pain - Muscle)
Pruritus Nos (Pruritus/itching)
Dermatitis Exfoliative Nos
(Rash/desquamation)
Renal Failure Nos (Renal failure)
Rigors (Rigors/chills)
Vomiting Nos (Vomiting)
CTC Adverse Event Term Other
CTC Adverse Event Grade
CTC AE Attribution Code
Definite (Definite)
Possible (Possible)
Probable (Probable)
Unlikely (Unlikely)
Unrelated (Unrelated)
Comments
Comments
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Breast Cancer NCT00070564 Toxicity - SOUTHWEST ONCOLOGY
GROUP S0221 PACLITAXEL ADVERSE EVENT FORM - 2101286v3.0
SOUTHWEST ONCOLOGY GROUP S0221 PACLITAXEL
ADVERSE EVENT FORM
Adjuvant Doxorubicin, Cyclophosphamide, and Paclitaxel in
Treating Patients With Breast Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=BACD4035-
5205-6831-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/9654
SOUTHWEST ONCOLOGY GROUP
S0221 PACLITAXEL ADVERSE
EVENT FORM
Header
SWOG Patient ID
SWOG Study No.
Registration Step
Patient Initials (L, F M)
Institution/Affiliate
Physician
Participating Group Name
Participating Group Study No.
Participating Group Patient ID
Adverse Events
Adverse Event Final Assessment Date
Common Toxicity Criteria Adverse Event Term
Type
Hypersensitivity Nos (Allergic
reaction/hypersensitivity (including drug
fever))
Aspartate Aminotransferase Increased
(AST, SGOT (serum glutamic oxaloacetic
transaminase))
Ataxia Nec (Ataxia (incoordination))
Blood Bilirubin Increased (Bilirubin
(hyperbilirubinemia))
Cardiac Troponin T Increased (Cardiac
troponin T (cTnT))
Diarrhoea Nos (Diarrhea)
Haemoglobin Decreased (Hemoglobin)
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Hypertension Nos (Hypertension)
Leucopenia Nos (Leukocytes (total
WBC))
Mucositis/stomatitis (clinical Exam)
(Mucositis/stomatitis (clinical exam) -
Oral cavity)
Stomatitis (Mucositis/stomatitis (clinical
exam) - Pharynx)
Mucositis/stomatitis
(functional/symptomatic)
(Mucositis/stomatitis
(functional/symptomatic) - Oral cavity)
Mucositis/stomatitis
(functional/symptomatic)
(Mucositis/stomatitis
(functional/symptomatic) - Pharynx)
Nausea (Nausea)
Peripheral Sensory Neuropathy
(Neuropathy: sensory)
Arthralgia (Pain - Joint)
Myalgia (Pain - Muscle)
Platelet Count Decreased (Platelets)
Convulsions Nos (Seizure)
Taste Disturbance (Taste alteration
(dysgeusia))
Thrombosis Nos
(Thrombosis/thrombus/embolism)
Caecitis (Typhlitis (cecal inflammation))
Vision Blurred (Vision-blurred vision)
Vomiting Nos (Vomiting)
Common Toxicity Criteria Adverse Event Grade
CTC Adverse Event Attribution Scale
Definite (Definite)
Possible (Possible)
Probable (Probable)
Unlikely (Unlikely)
Unrelated (Unrelated)
CTC Adverse Event Term Other (specify using
CTCAE 3.0 terminology)
Comments
Comments
Ccrr Module For Southwest Oncology
Group S0221 Paclitaxel Adverse Event
Form
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Breast Cancer NCT00070564 Toxicity - SOUTHWEST ONCOLOGY
GROUP S0221 AC or AC+G ADVERSE EVENT FORM - 2264763v3.0
SOUTHWEST ONCOLOGY GROUP S0221 AC or AC+G
ADVERSE EVENT FORM
Adjuvant Doxorubicin, Cyclophosphamide, and Paclitaxel in
Treating Patients With Breast Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=E92CA885-
2823-1D56-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/9655
SOUTHWEST ONCOLOGY GROUP
S0221 AC or AC+G ADVERSE
EVENT FORM
Header
SWOG Patient ID
SWOG Study No.
Registration Step
Patient Initials (L, F M)
Institution / Affiliate
Physician
Participating Group Name
Participating Group Study No.
Participating Group Patient ID (Instructions:
Submit this form only once, after patient has
completed AC or AC + G chemotherapy and has
recovered from acute adverse events. Report
Grades 3-5 adverse events only.)
Adverse Events
Date of Last Adverse Event Assessment
Select box if adverse events were assessed but
not seen. (Otherwise complete information
below.)
Yes
No
CTC Adverse Event Term
Diarrhoea Nos (Diarrhea)
Dysphagia (Dysphagia)
Dyspnoea Nos (Dyspnea)
Oesophagitis Nos (Esophagitis)
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Fatigue (Fatigue)
Febrile Neutropenia (fever Of Unknown
Origin Without Clinically Or
Microbiologically Documented Infection)
(anc <1.0 X 10^9/l, Fever >=38.5
Degrees C) (Febrile Neutropenia)
Localised Exfoliation (Hand-Foot)
Haemoglobin Decreased (Hemoglobin)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
with grade 3-4 ANC - Lung)
Left Ventricular Diastolic Dysfunction
(Left ventricular diastolic dysfunction)
Left Ventricular Failure (Left ventricular
systolic dysfunction)
Leucopenia Nos (Leukocytes)
Mucositis/stomatitis (clinical Exam)
(Mucositis (clinical exam) - esophagus)
Mucositis/stomatitis (clinical Exam)
(Mucositis (clinical exam) - oral cavity)
Stomatitis (Mucositis (clinical exam) -
pharynx)
Mucositis/stomatitis
(functional/symptomatic) (Mucositis
(functional/symptomatic) - esophagus)
Mucositis/stomatitis
(functional/symptomatic) (Mucositis
(functional/symptomatic) - oral cavity)
Mucositis/stomatitis
(functional/symptomatic) (Mucositis
(functional/symptomatic) - pharynx)
Nausea (Nausea)
Neutropenia (Neutrophils)
Abdominal Pain Nos (Pain - abdomen)
Bone Pain (Pain - bone)
Arthralgia (Pain - joint)
Platelet Count Decreased (Platelets)
Pneumonitis Nos (Pneumonitis)
Supraventricular And Nodal Arrhythmia
(Supraventricular arrythmia - atrial
fibrillation)
Ventricular Arrhythmia (Ventricular
arrythmia - ventricular tachycardia)
Vomiting Nos (Vomiting)
CTC Adverse Event Term Other
CTC Adverse Event Grade
CTC Attribution Code
Definite (definte)
Possible (possible)
Probable (probable)
Unlikely (unlikely)
Unrelated (unrelated)
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Comments
Comments
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Lymphoma NCT00598169 Toxicity - AMC-053
Adverse Events Form (ADV) - 3122012v1.0
AMC-053 Adverse Events Form (ADV)
Bortezomib, Ifosfamide, Carboplatin, and Etoposide, With
or Without Rituximab, in Treating Patients With Relapsed or
Refractory AIDS-Related Non-Hodgkin Lymphoma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=8B7087AC-
4210-0CD3-E040-BB89AD431A82
All rights reserved. Please visit https://medical-data-
models.org/forms/9657
AMC-053 Adverse Events Form
(ADV)
Header
CTC AE Category
CTC Adverse Event Term
CTC Adverse Event Grade
Adverse Event Onset Date (mm/dd/yyyy)
Unnamed2
MedDRA Code
If other CTC event selected, please provide
description of event
Was this event expected or anticipated
Yes
No
Agent Name
CTC Adverse Event Attribution Code
Definite (Definite)
Possible (Possible)
Probable (Probable)
Unlikely (Unlikely)
Unrelated (Unrelated)
Alternative etiology
Accident, Trauma, Or External Factors
(Accident, trauma, or external factors)
Concurrent Illness/condition (not Pre-
existing) (Concurrent illness/condition
(not pre-existing))
None Apparent (None apparent)
Other Pre-existing Disease Or Condition
(Other pre-existing disease or condition)
Study Disease (Study disease)
Action Taken at Time of Adverse Event (check
1 / 3
"Yes" for all that apply)
Hospitalization For Ae (Hospitalization)
Otc/non-rx (OTC/non-Rx)
Other (Other)
Prescription (Prescription)
Protocol Treatment Was Delayed As A
Result Of The Adverse Event (protocol
treatment delayed)
Protocol Treatment Was Discontinued As
A Result Of The Adverse Event (protocol
treatment discontinued)
Study Dose Was Reduced As A Result
Of The Adverse Event (study dose
reduced)
Other, specify
If modification was made to study therapy, who
initiated modification
Patient Initiated (Patient initiated)
Physician Initiated (Physician initiated)
Unnamed3
Outcome of Adverse Event
Adverse Event Is Resolved (Resolved)
Adverse Event Is Resolved With
Sequelae (Resolved with sequelae)
Unresolved At Protocol Completion
(Unresolved at protocol completion)
Unresolved, Protocol Ongoing
(Unresolved, protocol ongoing)
AE Resolution Date (If "Resolved" mm/dd/yyyy)
If resolved with sequelae, specify
Was this considered a Serious Adverse Event
Yes
No
Seriousness Attributed to Adverse Event (If "Yes"
check "Yes" for all that apply Please note that
checking "Yes" to any of the events below will
require SAE notification according to protocol
requirements.)
Congenital Anomaly (Congenital
anomaly)
Death (Death)
Disability (Disability/incapacity)
Hospitalized (Hospitalization, initial or
prolonged)
Life Threatening (Life threatening)
Other (Other)
Intervention Required (Required
intervention to prevent permanent
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impairment/damage)
Comments
Comments
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Prostate Cancer NCT01368588 Follow-Up - RTOG-
0924 F0: Interim Follow-Up Form - 3197931v1.0
RTOG-0924 F0: Interim Follow-Up Form
Androgen-Deprivation Therapy and Radiation Therapy in
Treating Patients With Prostate Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=9D96A377-
7B59-275E-E040-BB89AD437DB1
All rights reserved. Please visit https://medical-data-
models.org/forms/9658
RTOG-0924 F0: Interim Follow-Up
Form
Unnamed2
RTOG Study No.
Case #
Institution Name
Institution No.
Patient Initials
RTOG Patient ID
Header
Amended Data
Yes
No
Unnamed 3
Patient's Vital Status
Alive (Alive)
Dead (Dead)
Date of Last Contact or Death
Primary Cause of Death
Due To Other Cause (Due to other
cause)
Due To Protocol Treatment (Due to
protocol treatment)
Due To This Disease (Due to this
disease)
Not Applicable (Not applicable)
Unknown (Unknown)
Due to other cause, specify
Has the patient had a documented clinical
1 / 28
assessment for this cancer (SINCE
SUBMISSION OF THE PREVIOUS FOLLOW-UP
FORM)
No (No)
Unknown (Unknown)
Yes (Yes)
Date
Performance Status (ZUBROD 0-5, 9-
UNKNOWN)
Fully Active, Able To Carry On All Pre-
disease Performance Without
Restriction. (0)
Restricted In Physically Strenuous
Activity But Ambulatory And Able To
Carry Out Work Of A Light Or Sedentary
Nature, E.g., Light Housework, Office
Work. (1)
Ambulatory And Capable Of All Selfcare
But Unable To Carry Out Any Work
Activities. Up And About More Than 50%
Of Waking Hours. (2)
Capable Of Only Limited Selfcare,
Confined To Bed Or Chair More Than
50% Of Waking Hours. (3)
Completely Disabled. Cannot Carry On
Any Selfcare. Totally Confined To Bed Or
Chair. (4)
Dead (5)
Unnamed Module 6
Has the patient had a prostate biopsy (SINCE
SUBMISSION OF THE LAST FOLLOW-UP
FORM)
No (No)
Unknown (Unknown)
Yes, Negative (Yes, negative)
Yes, Positive (Yes, positive)
Yes, Results Unknown (Yes, results
unknown)
Biopsy Date
Is the tumor palpable
Equivocal (Equivocal)
No (No)
Not Evaluated (Not evaluated)
Unknown (Unknown)
Yes (Yes)
Unnamed Module 5
Has the patient been diagnosed with biochemical
recurrence since submission of the last follow-up
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form
No (NO)
Unknown (Unknown)
Yes (YES)
Has the patient been diagnosed with a first local
recurrence (SINCE SUBMISSION OF LAST
FOLLOW-UP FORM See Protocol Section 11)
No (NO)
Unknown (Unknown)
Yes (YES)
Date
Other Specify
Other Specify
Has the patient been diagnosed with first distant
progression (SINCE SUBMISSION OF THE
LAST FOLLOW-UP FORM)
No (No)
Unknown (Unknown)
Yes (Yes)
Date
Sites of Progression (First distant)
Method of Evaluation (DISTANT
PROGRESSION)
Mri (MRI (NMR))
Not Applicable (Not applicable)
Other (Other)
Pathologic (Pathologic)
Physical Exam (Physical exam)
Radiographic (Radiographic)
Method of Evaluation (DISTANT
PROGRESSION)
Mri (MRI (NMR))
Not Applicable (Not applicable)
Other (Other)
Pathologic (Pathologic)
Physical Exam (Physical exam)
Radiographic (Radiographic)
Unnamed Module 4a
PSA Date (s)
PSA Value (s)
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Units
Micrograms Per Liter (mcg/L)
N/milligram (n/mg)
Nanograms Per Deciliter (ng/dL)
Nanograms Per Milliliter (ng/mL)
Not Otherwise Specified (NOS)
Units Per Liter (U/L)
Method of Assay
Abbott Labs (Abbott)
Bayer (Bayer)
Dpc (DPC)
Hybritech (Hybritech)
Other (Other)
Unknown (Unknown)
Treatment Schedule (lhrh Agonist)
Is patient on protocol hormone (ORAL
ANTIANDROGEN)
Yes
No
LHRH agonist (OR ANTAGONIST)
Eligard (Eligard)
Lupron (Lupron)
Other (Other)
Viadur (Viadur)
Zoladex (Zoladex)
Other, specify
LHRH agonist start date (OR ANTAGONIST IF
STARTED IN THIS FOLLOW-UP PERIOD)
LHRH agonist end date (OR ANTAGONIST IF
TERMINATED IN THIS FOLLOW-UP PERIOD)
Reason Treatment Ended (ORAL
ANTIANDROGEN)
Adverse Event/side Effects/complications
(Adverse Event/Side
Effects/Complications)
Alternative Therapy (Alternative therapy)
Death On Study (Death on study)
Disease Progression, Relapse During
Active Treatment (Disease progression,
relapse during active treatment)
Other (Other)
Patient Off-treatment For Other
Complicating Disease (Patient off-
treatment for other complicating disease)
Patient Withdrawal Or Refusal After
Beginning Protocol Therapy (Patient
withdrawal/refusal after beginning
protocol therapy)
Patient Withdrawal Or Refusal Before
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Beginning Protocol Therapy (Patient
withdrawal/refusal prior to beginning
protocol therapy)
Treatment Completed Per Protocol
Criteria (Treatment completed per
protocol criteria)
Alternative Therapy, Specify
Patient off-treatment for other complicating
disease, specify
Other specify
Total Dose (TO DATE)
Treatment Schedule (oral Antiandrogen)
Is patient on protocol hormone (ORAL
ANTIANDROGEN)
Yes
No
Oral antiandrogen taken
Casodex (Casodex)
Eulexin (Eulexin)
Other (Other)
Other, specify
Oral Antiandrogen Start Date (IF STARTED IN
THIS FOLLOW-UP PERIOD)
Oral Antiandrogen End Date (IF TERMINATED IN
THIS FOLLOW-UP PERIOD)
Reason Treatment Ended (ORAL
ANTIANDROGEN)
Adverse Event/side Effects/complications
(Adverse Event/Side
Effects/Complications)
Alternative Therapy (Alternative therapy)
Death On Study (Death on study)
Disease Progression, Relapse During
Active Treatment (Disease progression,
relapse during active treatment)
Other (Other)
Patient Off-treatment For Other
Complicating Disease (Patient off-
treatment for other complicating disease)
Patient Withdrawal Or Refusal After
Beginning Protocol Therapy (Patient
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withdrawal/refusal after beginning
protocol therapy)
Patient Withdrawal Or Refusal Before
Beginning Protocol Therapy (Patient
withdrawal/refusal prior to beginning
protocol therapy)
Treatment Completed Per Protocol
Criteria (Treatment completed per
protocol criteria)
Alternative Therapy, Specify
Patient off-treatment for other complicating
disease, specify
Other specify
Total Dose (TO DATE)
Non-protocol Therapy
Is the patient receiving any non-protocol cancer
therapy not previously reported (PROSTATE If
yes, enter therapy type and date for each therapy
delivered during the follow-up period.)
No (No)
Unknown (Unknown)
Yes (Yes)
Non-Protocol Therapy Type
Chemotherapy (Chemotherapy)
Hormones (Hormones)
Other Specify (Other)
Radiation To Other Sites, Specify
(Radiation to other sites)
Radiation To Pelvis (Radiation to pelvis)
Surgery (Surgery)
Date of First Non-Protocol Therapy
Specify
Unnamed Module 7
Has a new primary cancer or MDS been
diagnosed that has not been previously reported?
(MYELODYSPLASTIC SYNDROME)
No (No)
Unknown (Unknown)
Yes (Yes)
Second Primary Tumor Site
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Aml/mds (AML/MDS)
Bcc (BCC)
Bladder Is The Site Of Second Primary
Or Recurrent Tumor (bladder)
Brain Is The Site Of Second Primary Or
Recurrent Tumor (brain)
Colorectal (Colorectal)
Esophageal (Esophageal)
Gastric (Gastric)
Liver Is The Site Of Second Primary Or
Recurrent Tumor (liver)
Lung Is The Site Of Second Primary Or
Recurrent Tumor (lung)
Melanoma (Melanoma)
Nhl (NHL)
Other Hematologic (Other hematologic)
Other Solid (Other solid)
Pancreatic (Pancreatic)
Renal (Renal)
Squamous-skin (Squamous-skin)
Unknown Primary (Unknown primary)
Second Primary Cancer Date
Other specify
Baseline Lab Values (hematologic)
Date (s)
Date (s)
Date (s)
Date (s)
WBC (mm^3)
Hemoglobin (g/dL)
Peripheral Platelet Count (mm^3)
ANC (mm^3)
Protocol Specific Adverse Event
Evaluation
Any Treatment Related Adverse Events
No (No)
Unknown (Unknown)
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Yes (Yes)
MedDRA Disease Code
CTC Adverse Event Term (OTHER CTC
ADVERSE EVENT NOT LISTED)
Abdominal Distension (Abdominal
distension)
Abdominal Infection (Abdominal
infection)
Abdominal Pain (Abdominal pain)
Abdominal Soft Tissue Necrosis
(Abdominal soft tissue necrosis)
Abducens Nerve Disorder (Abducens
nerve disorder)
Accessory Nerve Disorder (Accessory
nerve disorder)
Acidosis (Acidosis)
Acoustic Nerve Disorder Nos (Acoustic
nerve disorder NOS)
Activated Partial Thromboplastin Time
Prolonged (Activated partial
thromboplastin time prolonged)
Acute Coronary Syndrome (Acute
coronary syndrome)
Acute Kidney Injury (Acute kidney injury)
Adrenal Insufficiency (Adrenal
insufficiency)
Adult Respiratory Distress Syndrome
(Adult respiratory distress syndrome)
Agitation (Agitation)
Akathisia (Akathisia)
Alanine Aminotransferase Increased
(Alanine aminotransferase increased)
Alcohol Intolerance (Alcohol intolerance)
Alkaline Phosphatase Increased
(Alkaline phosphatase increased)
Alkalosis (Alkalosis)
Allergic Reaction (Allergic reaction)
Allergic Rhinitis (Allergic rhinitis)
Alopecia (Alopecia)
Amnesia (Amnesia)
Anal Fistula (Anal fistula)
Anal Hemorrhage (Anal hemorrhage)
Anal Mucositis (Anal mucositis)
Anal Necrosis (Anal necrosis)
Anal Pain (Anal pain)
Anal Stenosis (Anal stenosis)
Anal Ulcer (Anal ulcer)
Anaphylaxis (Anaphylaxis)
Anemia (Anemia)
Ankle Fracture (Ankle fracture)
Anorectal Infection (Anorectal infection)
Anorexia (Anorexia)
Anorgasmia (Anorgasmia)
Anxiety (Anxiety)
Aortic Injury (Aortic injury)
Aortic Valve Disease (Aortic valve
disease)
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Aphonia (Aphonia)
Apnea (Apnea)
Appendicitis (Appendicitis)
Appendicitis Perforated (Appendicitis
perforated)
Arachnoiditis (Arachnoiditis)
Arterial Injury (Arterial injury)
Arteritis Infective (Arteritis infective)
Arthralgia (Arthralgia)
Arthritis (Arthritis)
Ascites (Ascites)
Aspartate Aminotransferase Increased
(Aspartate aminotransferase increased)
Aspiration (Aspiration)
Asystole (Asystole)
Ataxia (Ataxia)
Atelectasis (Atelectasis)
Atrial Fibrillation (Atrial fibrillation)
Atrial Flutter (Atrial flutter)
Atrioventricular Block Complete
(Atrioventricular block complete)
Atrioventricular Block First Degree
(Atrioventricular block first degree)
Autoimmune Disorder (Autoimmune
disorder)
Avascular Necrosis (Avascular necrosis)
Azoospermia (Azoospermia)
Back Pain (Back pain)
Bile Duct Stenosis (Bile duct stenosis)
Biliary Anastomotic Leak (Biliary
anastomotic leak)
Biliary Fistula (Biliary fistula)
Biliary Tract Infection (Biliary tract
infection)
Bladder Anastomotic Leak (Bladder
anastomotic leak)
Bladder Infection (Bladder infection)
Bladder Perforation (Bladder perforation)
Bladder Spasm (Bladder spasm)
Bloating (Bloating)
Blood And Lymphatic System Disorders -
Other, Specify (Blood and lymphatic
system disorders - Other, Specify)
Blood Antidiuretic Hormone Abnormal
(Blood antidiuretic hormone abnormal)
Blood Bilirubin Increased (Blood bilirubin
increased)
Blood Corticotrophin Decreased (Blood
corticotrophin decreased)
Blood Gonadotrophin Abnormal (Blood
gonadotrophin abnormal)
Blood Prolactin Abnormal (Blood
prolactin abnormal)
Blurred Vision (Blurred vision)
Body Odor (Body odor)
Bone Infection (Bone infection)
Bone Marrow Hypocellular (Bone
marrow hypocellular)
Bone Pain (Bone pain)
Brachial Plexopathy (Brachial
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plexopathy)
Breast Atrophy (Breast atrophy)
Breast Infection (Breast infection)
Breast Pain (Breast pain)
Bronchial Fistula (Bronchial fistula)
Bronchial Infection (Bronchial infection)
Bronchial Obstruction (Bronchial
obstruction)
Bronchial Stricture (Bronchial stricture)
Bronchopleural Fistula (Bronchopleural
fistula)
Bronchopulmonary Hemorrhage
(Bronchopulmonary hemorrhage)
Bronchospasm (Bronchospasm)
Bruising (Bruising)
Bullous Dermatitis (Bullous dermatitis)
Burn (Burn)
Buttock Pain (Buttock pain)
Capillary Leak Syndrome (Capillary leak
syndrome)
Carbon Monoxide Diffusing Capacity
Decreased (Carbon monoxide diffusing
capacity decreased)
Cardiac Arrest (Cardiac arrest)
Cardiac Disorders - Other, Specify
(Cardiac disorders - Other, Specify)
Cardiac Troponin I Increased (Cardiac
troponin I increased)
Cardiac Troponin T Increased (Cardiac
troponin T increased)
Cataract (Cataract)
Catheter Related Infection (Catheter
related infection)
Cd4 Lymphocytes Decreased (CD4
lymphocytes decreased)
Cecal Hemorrhage (Cecal hemorrhage)
Cecal Infection (Cecal infection)
Central Nervous System Necrosis
(Central nervous system necrosis)
Cerebrospinal Fluid Leakage
(Cerebrospinal fluid leakage)
Cervicitis Infection (Cervicitis infection)
Cheilitis (Cheilitis)
Chest Pain - Cardiac (Chest pain -
cardiac)
Chest Wall Pain (Chest wall pain)
Chills (Chills)
Cholecystitis (Cholecystitis)
Cholesterol High (Cholesterol high)
Chronic Kidney Disease (Chronic kidney
disease)
Chylothorax (Chylothorax)
Cognitive Disturbance (Cognitive
disturbance)
Colitis (Colitis)
Colonic Fistula (Colonic fistula)
Colonic Hemorrhage (Colonic
hemorrhage)
Colonic Obstruction (Colonic obstruction)
Colonic Perforation (Colonic perforation)
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Colonic Stenosis (Colonic stenosis)
Colonic Ulcer (Colonic ulcer)
Concentration Impairment
(Concentration impairment)
Conduction Disorder (Conduction
disorder)
Confusion (Confusion)
Congenital, Familial And Genetic
Disorders - Other, Specify (Congenital,
familial and genetic disorders - Other,
Specify)
Conjunctivitis (Conjunctivitis)
Conjunctivitis Infective (Conjunctivitis
infective)
Constipation (Constipation)
Constrictive Pericarditis (Constrictive
pericarditis)
Corneal Infection (Corneal infection)
Corneal Ulcer (Corneal ulcer)
Cough (Cough)
Cpk Increased (CPK increased)
Cranial Nerve Infection (Cranial nerve
infection)
Creatinine Increased (Creatinine
increased)
Cushingoid (Cushingoid)
Cystitis Noninfective (Cystitis
noninfective)
Cytokine Release Syndrome (Cytokine
release syndrome)
Death Neonatal (Death neonatal)
Death Nos (Death NOS)
Dehydration (Dehydration)
Delayed Orgasm (Delayed orgasm)
Delayed Puberty (Delayed puberty)
Delirium (Delirium)
Delusions (Delusions)
Dental Caries (Dental caries)
Depressed Level Of Consciousness
(Depressed level of consciousness)
Depression (Depression)
Dermatitis Radiation (Dermatitis
radiation)
Device Related Infection (Device related
infection)
Diarrhea (Diarrhea)
Disseminated Intravascular Coagulation
(Disseminated intravascular coagulation)
Dizziness (Dizziness)
Dry Eye (Dry eye)
Dry Mouth (Dry mouth)
Dry Skin (Dry skin)
Duodenal Fistula (Duodenal fistula)
Duodenal Hemorrhage (Duodenal
hemorrhage)
Duodenal Infection (Duodenal infection)
Duodenal Obstruction (Duodenal
obstruction)
Duodenal Perforation (Duodenal
perforation)
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Duodenal Stenosis (Duodenal stenosis)
Duodenal Ulcer (Duodenal ulcer)
Dysarthria (Dysarthria)
Dysesthesia (Dysesthesia)
Dysgeusia (Dysgeusia)
Dysmenorrhea (Dysmenorrhea)
Dyspareunia (Dyspareunia)
Dyspepsia (Dyspepsia)
Dysphagia (Dysphagia)
Dysphasia (Dysphasia)
Dyspnea (Dyspnea)
Ear And Labyrinth Disorders - Other,
Specify (Ear and labyrinth disorders -
Other, Specify)
Ear Pain (Ear pain)
Edema Cerebral (Edema cerebral)
Edema Face (Edema face)
Edema Limbs (Edema limbs)
Edema Trunk (Edema trunk)
Ejaculation Disorder (Ejaculation
disorder)
Ejection Fraction Decreased (Ejection
fraction decreased)
Electrocardiogram Qt Corrected Interval
Prolonged (Electrocardiogram QT
corrected interval prolonged)
Encephalitis Infection (Encephalitis
infection)
Encephalomyelitis Infection
(Encephalomyelitis infection)
Encephalopathy (Encephalopathy)
Endocarditis Infective (Endocarditis
infective)
Endocrine Disorders - Other, Specify
(Endocrine disorders - Other, Specify)
Endophthalmitis (Endophthalmitis)
Enterocolitis (Enterocolitis)
Enterocolitis Infectious (Enterocolitis
infectious)
Enterovesical Fistula (Enterovesical
fistula)
Epistaxis (Epistaxis)
Erectile Dysfunction (Erectile
dysfunction)
Erythema Multiforme (Erythema
multiforme)
Erythroderma (Erythroderma)
Esophageal Anastomotic Leak
(Esophageal anastomotic leak)
Esophageal Fistula (Esophageal fistula)
Esophageal Hemorrhage (Esophageal
hemorrhage)
Esophageal Infection (Esophageal
infection)
Esophageal Necrosis (Esophageal
necrosis)
Esophageal Obstruction (Esophageal
obstruction)
Esophageal Pain (Esophageal pain)
Esophageal Perforation (Esophageal
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perforation)
Esophageal Stenosis (Esophageal
stenosis)
Esophageal Ulcer (Esophageal ulcer)
Esophageal Varices Hemorrhage
(Esophageal varices hemorrhage)
Esophagitis (Esophagitis)
Euphoria (Euphoria)
Exostosis (Exostosis)
External Ear Inflammation (External ear
inflammation)
External Ear Pain (External ear pain)
Extraocular Muscle Paresis (Extraocular
muscle paresis)
Extrapyramidal Disorder (Extrapyramidal
disorder)
Eye Disorders - Other, Specify (Eye
disorders - Other, Specify)
Eye Infection (Eye infection)
Eye Pain (Eye pain)
Eyelid Function Disorder (Eyelid function
disorder)
Facial Muscle Weakness (Facial muscle
weakness)
Facial Nerve Disorder (Facial nerve
disorder)
Facial Pain (Facial pain)
Fall (Fall)
Fallopian Tube Anastomotic Leak
(Fallopian tube anastomotic leak)
Fallopian Tube Obstruction (Fallopian
tube obstruction)
Fallopian Tube Perforation (Fallopian
tube perforation)
Fallopian Tube Stenosis (Fallopian tube
stenosis)
Fat Atrophy (Fat atrophy)
Fatigue (Fatigue)
Febrile Neutropenia (Febrile
neutropenia)
Fecal Incontinence (Fecal incontinence)
Female Genital Tract Fistula (Female
genital tract fistula)
Feminization Acquired (Feminization
acquired)
Fetal Death (Fetal death)
Fetal Growth Retardation (Fetal growth
retardation)
Fever (Fever)
Fibrinogen Decreased (Fibrinogen
decreased)
Fibrosis Deep Connective Tissue
(Fibrosis deep connective tissue)
Flank Pain (Flank pain)
Flashing Lights (Flashing lights)
Flatulence (Flatulence)
Floaters (Floaters)
Flu Like Symptoms (Flu like symptoms)
Flushing (Flushing)
Forced Expiratory Volume Decreased
13 / 28
Prostate Cancer NCT01368588 Follow-Up - RTOG-0924 F0: Interim
Follow-Up Form - 3197931v1.0
(Forced expiratory volume decreased)
Fracture (Fracture)
Gait Disturbance (Gait disturbance)
Gallbladder Fistula (Gallbladder fistula)
Gallbladder Infection (Gallbladder
infection)
Gallbladder Necrosis (Gallbladder
necrosis)
Gallbladder Obstruction (Gallbladder
obstruction)
Gallbladder Pain (Gallbladder pain)
Gallbladder Perforation (Gallbladder
perforation)
Gastric Anastomotic Leak (Gastric
anastomotic leak)
Gastric Fistula (Gastric fistula)
Gastric Hemorrhage (Gastric
hemorrhage)
Gastric Necrosis (Gastric necrosis)
Gastric Perforation (Gastric perforation)
Gastric Stenosis (Gastric stenosis)
Gastric Ulcer (Gastric ulcer)
Gastritis (Gastritis)
Gastroesophageal Reflux Disease
(Gastroesophageal reflux disease)
Gastrointestinal Anastomotic Leak
(Gastrointestinal anastomotic leak)
Gastrointestinal Disorders - Other,
Specify (Gastrointestinal disorders -
Other, Specify)
Gastrointestinal Fistula (Gastrointestinal
fistula)
Gastrointestinal Pain (Gastrointestinal
pain)
Gastrointestinal Stoma Necrosis
(Gastrointestinal stoma necrosis)
Gastroparesis (Gastroparesis)
General Disorders And Administration
Site Conditions - Other, Specify (General
disorders and administration site
conditions - Other, Specify)
Generalized Muscle Weakness
(Generalized muscle weakness)
Genital Edema (Genital edema)
Ggt Increased (GGT increased)
Gingival Pain (Gingival pain)
Glaucoma (Glaucoma)
Glossopharyngeal Nerve Disorder
(Glossopharyngeal nerve disorder)
Glucose Intolerance (Glucose
intolerance)
Growth Accelerated (Growth
accelerated)
Growth Hormone Abnormal (Growth
hormone abnormal)
Growth Suppression (Growth
suppression)
Gum Infection (Gum infection)
Gynecomastia (Gynecomastia)
Hallucinations (Hallucinations)
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Haptoglobin Decreased (Haptoglobin
decreased)
Head Soft Tissue Necrosis (Head soft
tissue necrosis)
Headache (Headache)
Hearing Impaired (Hearing impaired)
Heart Failure (Heart failure)
Hematoma (Hematoma)
Hematosalpinx (Hematosalpinx)
Hematuria (Hematuria)
Hemoglobin Increased (Hemoglobin
increased)
Hemoglobinuria (Hemoglobinuria)
Hemolysis (Hemolysis)
Hemolytic Uremic Syndrome (Hemolytic
uremic syndrome)
Hemorrhoidal Hemorrhage
(Hemorrhoidal hemorrhage)
Hemorrhoids (Hemorrhoids)
Hepatic Failure (Hepatic failure)
Hepatic Hemorrhage (Hepatic
hemorrhage)
Hepatic Infection (Hepatic infection)
Hepatic Necrosis (Hepatic necrosis)
Hepatic Pain (Hepatic pain)
Hepatitis Viral (Hepatitis viral)
Hepatobiliary Disorders - Other, Specify
(Hepatobiliary disorders - Other, Specify)
Hiccups (Hiccups)
Hip Fracture (Hip fracture)
Hirsutism (Hirsutism)
Hoarseness (Hoarseness)
Hot Flashes (Hot flashes)
Hydrocephalus (Hydrocephalus)
Hypercalcemia (Hypercalcemia)
Hyperglycemia (Hyperglycemia)
Hyperhidrosis (Hyperhidrosis)
Hyperkalemia (Hyperkalemia)
Hypermagnesemia (Hypermagnesemia)
Hypernatremia (Hypernatremia)
Hyperparathyroidism
(Hyperparathyroidism)
Hypersomnia (Hypersomnia)
Hypertension (Hypertension)
Hyperthyroidism (Hyperthyroidism)
Hypertrichosis (Hypertrichosis)
Hypertriglyceridemia
(Hypertriglyceridemia)
Hyperuricemia (Hyperuricemia)
Hypoalbuminemia (Hypoalbuminemia)
Hypocalcemia (Hypocalcemia)
Hypoglossal Nerve Disorder
(Hypoglossal nerve disorder)
Hypoglycemia (Hypoglycemia)
Hypohidrosis (Hypohidrosis)
Hypokalemia (Hypokalemia)
Hypomagnesemia (Hypomagnesemia)
Hyponatremia (Hyponatremia)
Hypoparathyroidism
(Hypoparathyroidism)
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Hypophosphatemia (Hypophosphatemia)
Hypotension (Hypotension)
Hypothermia (Hypothermia)
Hypothyroidism (Hypothyroidism)
Hypoxia (Hypoxia)
Ileal Fistula (Ileal fistula)
Ileal Hemorrhage (Ileal hemorrhage)
Ileal Obstruction (Ileal obstruction)
Ileal Perforation (Ileal perforation)
Ileal Stenosis (Ileal stenosis)
Ileal Ulcer (Ileal ulcer)
Ileus (Ileus)
Immune System Disorders - Other,
Specify (Immune system disorders -
Other, Specify)
Infections And Infestations - Other,
Specify (Infections and infestations -
Other, Specify)
Infective Myositis (Infective myositis)
Infusion Related Reaction (Infusion
related reaction)
Infusion Site Extravasation (Infusion site
extravasation)
Injection Site Reaction (Injection site
reaction)
Injury To Carotid Artery (Injury to carotid
artery)
Injury To Inferior Vena Cava (Injury to
inferior vena cava)
Injury To Jugular Vein (Injury to jugular
vein)
Injury To Superior Vena Cava (Injury to
superior vena cava)
Injury, Poisoning And Procedural
Complications - Other, Specify (Injury,
poisoning and procedural complications -
Other, Specify)
Inr Increased (INR increased)
Insomnia (Insomnia)
Intestinal Stoma Leak (Intestinal stoma
leak)
Intestinal Stoma Obstruction (Intestinal
stoma obstruction)
Intestinal Stoma Site Bleeding (Intestinal
stoma site bleeding)
Intra-abdominal Hemorrhage (Intra-
abdominal hemorrhage)
Intracranial Hemorrhage (Intracranial
hemorrhage)
Intraoperative Arterial Injury
(Intraoperative arterial injury)
Intraoperative Breast Injury
(Intraoperative breast injury)
Intraoperative Cardiac Injury
(Intraoperative cardiac injury)
Intraoperative Ear Injury (Intraoperative
ear injury)
Intraoperative Endocrine Injury
(Intraoperative endocrine injury)
Intraoperative Gastrointestinal Injury
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(Intraoperative gastrointestinal injury)
Intraoperative Head And Neck Injury
(Intraoperative head and neck injury)
Intraoperative Hemorrhage
(Intraoperative hemorrhage)
Intraoperative Hepatobiliary Injury
(Intraoperative hepatobiliary injury)
Intraoperative Musculoskeletal Injury
(Intraoperative musculoskeletal injury)
Intraoperative Neurological Injury
(Intraoperative neurological injury)
Intraoperative Ocular Injury
(Intraoperative ocular injury)
Intraoperative Renal Injury
(Intraoperative renal injury)
Intraoperative Reproductive Tract Injury
(Intraoperative reproductive tract injury)
Intraoperative Respiratory Injury
(Intraoperative respiratory injury)
Intraoperative Skin Injury (Intraoperative
skin injury)
Intraoperative Splenic Injury
(Intraoperative splenic injury)
Intraoperative Urinary Injury
(Intraoperative urinary injury)
Intraoperative Venous Injury
(Intraoperative venous injury)
Investigations - Other, Specify
(Investigations - Other, Specify)
Iron Overload (Iron overload)
Irregular Menstruation (Irregular
menstruation)
Irritability (Irritability)
Ischemia Cerebrovascular (Ischemia
cerebrovascular)
Ivth Nerve Disorder (IVth nerve disorder)
Jejunal Fistula (Jejunal fistula)
Jejunal Hemorrhage (Jejunal
hemorrhage)
Jejunal Obstruction (Jejunal obstruction)
Jejunal Perforation (Jejunal perforation)
Jejunal Stenosis (Jejunal stenosis)
Jejunal Ulcer (Jejunal ulcer)
Joint Effusion (Joint effusion)
Joint Infection (Joint infection)
Joint Range Of Motion Decreased (Joint
range of motion decreased)
Joint Range Of Motion Decreased
Cervical Spine (Joint range of motion
decreased cervical spine)
Joint Range Of Motion Decreased
Lumbar Spine (Joint range of motion
decreased lumbar spine)
Keratitis (Keratitis)
Kidney Anastomotic Leak (Kidney
anastomotic leak)
Kidney Infection (Kidney infection)
Kyphosis (Kyphosis)
Lactation Disorder (Lactation disorder)
Large Intestinal Anastomotic Leak (Large
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intestinal anastomotic leak)
Laryngeal Edema (Laryngeal edema)
Laryngeal Fistula (Laryngeal fistula)
Laryngeal Hemorrhage (Laryngeal
hemorrhage)
Laryngeal Inflammation (Laryngeal
inflammation)
Laryngeal Mucositis (Laryngeal
mucositis)
Laryngeal Obstruction (Laryngeal
obstruction)
Laryngeal Stenosis (Laryngeal stenosis)
Laryngitis (Laryngitis)
Laryngopharyngeal Dysesthesia
(Laryngopharyngeal dysesthesia)
Laryngospasm (Laryngospasm)
Left Ventricular Systolic Dysfunction (Left
ventricular systolic dysfunction)
Lethargy (Lethargy)
Leukemia Secondary To Oncology
Chemotherapy (Leukemia secondary to
oncology chemotherapy)
Leukocytosis (Leukocytosis)
Leukoencephalopathy
(Leukoencephalopathy)
Libido Decreased (Libido decreased)
Libido Increased (Libido increased)
Lip Infection (Lip infection)
Lip Pain (Lip pain)
Lipase Increased (Lipase increased)
Lipohypertrophy (Lipohypertrophy)
Localized Edema (Localized edema)
Lordosis (Lordosis)
Lower Gastrointestinal Hemorrhage
(Lower gastrointestinal hemorrhage)
Lung Infection (Lung infection)
Lymph Gland Infection (Lymph gland
infection)
Lymph Leakage (Lymph leakage)
Lymph Node Pain (Lymph node pain)
Lymphedema (Lymphedema)
Lymphocele (Lymphocele)
Lymphocyte Count Decreased
(Lymphocyte count decreased)
Lymphocyte Count Increased
(Lymphocyte count increased)
Malabsorption (Malabsorption)
Malaise (Malaise)
Mania (Mania)
Mediastinal Hemorrhage (Mediastinal
hemorrhage)
Mediastinal Infection (Mediastinal
infection)
Memory Impairment (Memory
impairment)
Meningismus (Meningismus)
Meningitis (Meningitis)
Menopause (Menopause)
Menorrhagia (Menorrhagia)
Metabolism And Nutrition Disorders -
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Other, Specify (Metabolism and nutrition
disorders - Other, Specify)
Middle Ear Inflammation (Middle ear
inflammation)
Mitral Valve Disease (Mitral valve
disease)
Mobitz (type) Ii Atrioventricular Block
(Mobitz (type) II atrioventricular block)
Mobitz Type I (Mobitz type I)
Movements Involuntary (Movements
involuntary)
Mucosal Infection (Mucosal infection)
Mucositis Oral (Mucositis oral)
Multi-organ Failure (Multi-organ failure)
Muscle Weakness Left-sided (Muscle
weakness left-sided)
Muscle Weakness Lower Limb (Muscle
weakness lower limb)
Muscle Weakness Right-sided (Muscle
weakness right-sided)
Muscle Weakness Trunk (Muscle
weakness trunk)
Muscle Weakness Upper Limb (Muscle
weakness upper limb)
Musculoskeletal And Connective Tissue
Disorder - Other, Specify
(Musculoskeletal and connective tissue
disorders - Other, Specify)
Musculoskeletal Deformity
(Musculoskeletal deformity)
Myalgia (Myalgia)
Myelitis (Myelitis)
Myelodysplastic Syndrome
(Myelodysplastic syndrome)
Myocardial Infarction (Myocardial
infarction)
Myocarditis (Myocarditis)
Myositis (Myositis)
Nail Discoloration (Nail discoloration)
Nail Infection (Nail infection)
Nail Loss (Nail loss)
Nail Ridging (Nail ridging)
Nasal Congestion (Nasal congestion)
Nausea (Nausea)
Neck Edema (Neck edema)
Neck Pain (Neck pain)
Neck Soft Tissue Necrosis (Neck soft
tissue necrosis)
Neoplasms Benign, Malignant And
Unspecified (incl Cysts And Polyps) -
Other, Specify (Neoplasms benign,
malignant and unspecified (incl cysts and
polyps) - Other, Specify)
Nervous System Disorders - Other,
Specify (Nervous system disorders -
Other, Specify)
Neuralgia (Neuralgia)
Neutrophil Count Decreased (Neutrophil
count decreased)
Night Blindness (Night blindness)
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Nipple Deformity (Nipple deformity)
Non-cardiac Chest Pain (Non-cardiac
chest pain)
Nystagmus (Nystagmus)
Obesity (Obesity)
Obstruction Gastric (Obstruction gastric)
Oculomotor Nerve Disorder (Oculomotor
nerve disorder)
Olfactory Nerve Disorder (Olfactory
nerve disorder)
Oligospermia (Oligospermia)
Optic Nerve Disorder (Optic nerve
disorder)
Oral Cavity Fistula (Oral cavity fistula)
Oral Dysesthesia (Oral dysesthesia)
Oral Hemorrhage (Oral hemorrhage)
Oral Pain (Oral pain)
Osteonecrosis Of Jaw (Osteonecrosis of
jaw)
Osteoporosis (Osteoporosis)
Otitis Externa (Otitis externa)
Otitis Media (Otitis media)
Ovarian Hemorrhage (Ovarian
hemorrhage)
Ovarian Infection (Ovarian infection)
Ovarian Rupture (Ovarian rupture)
Ovulation Pain (Ovulation pain)
Pain (Pain)
Pain In Extremity (Pain in extremity)
Pain Of Skin (Pain of skin)
Palmar-plantar Erythrodysesthesia
Syndrome (Palmar-plantar
erythrodysesthesia syndrome)
Palpitations (Palpitations)
Pancreas Infection (Pancreas infection)
Pancreatic Anastomotic Leak (Pancreatic
anastomotic leak)
Pancreatic Duct Stenosis (Pancreatic
duct stenosis)
Pancreatic Enzymes Decreased
(Pancreatic enzymes decreased)
Pancreatic Fistula (Pancreatic fistula)
Pancreatic Hemorrhage (Pancreatic
hemorrhage)
Pancreatic Necrosis (Pancreatic
necrosis)
Pancreatitis (Pancreatitis)
Papilledema (Papilledema)
Papulopustular Rash (Papulopustular
rash)
Paresthesia (Paresthesia)
Paronychia (Paronychia)
Paroxysmal Atrial Tachycardia
(Paroxysmal atrial tachycardia)
Pelvic Floor Muscle Weakness (Pelvic
floor muscle weakness)
Pelvic Infection (Pelvic infection)
Pelvic Pain (Pelvic pain)
Pelvic Soft Tissue Necrosis (Pelvic soft
tissue necrosis)
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Penile Infection (Penile infection)
Penile Pain (Penile pain)
Perforation Bile Duct (Perforation bile
duct)
Pericardial Effusion (Pericardial effusion)
Pericardial Tamponade (Pericardial
tamponade)
Pericarditis (Pericarditis)
Perineal Pain (Perineal pain)
Periodontal Disease (Periodontal
disease)
Periorbital Edema (Periorbital edema)
Periorbital Infection (Periorbital infection)
Peripheral Ischemia (Peripheral
ischemia)
Peripheral Motor Neuropathy (Peripheral
motor neuropathy)
Peripheral Nerve Infection (Peripheral
nerve infection)
Peripheral Sensory Neuropathy
(Peripheral sensory neuropathy)
Peritoneal Infection (Peritoneal infection)
Peritoneal Necrosis (Peritoneal necrosis)
Personality Change (Personality change)
Phantom Pain (Phantom pain)
Pharyngeal Anastomotic Leak
(Pharyngeal anastomotic leak)
Pharyngeal Fistula (Pharyngeal fistula)
Pharyngeal Hemorrhage (Pharyngeal
hemorrhage)
Pharyngeal Mucositis (Pharyngeal
mucositis)
Pharyngeal Necrosis (Pharyngeal
necrosis)
Pharyngeal Stenosis (Pharyngeal
stenosis)
Pharyngitis (Pharyngitis)
Pharyngolaryngeal Pain
(Pharyngolaryngeal pain)
Phlebitis (Phlebitis)
Phlebitis Infective (Phlebitis infective)
Photophobia (Photophobia)
Photosensitivity (Photosensitivity)
Platelet Count Decreased (Platelet count
decreased)
Pleural Effusion (Pleural effusion)
Pleural Hemorrhage (Pleural
hemorrhage)
Pleural Infection (Pleural infection)
Pleuritic Pain (Pleuritic pain)
Pneumonitis (Pneumonitis)
Pneumothorax (Pneumothorax)
Portal Hypertension (Portal
hypertension)
Portal Vein Thrombosis (Portal vein
thrombosis)
Postnasal Drip (Postnasal drip)
Postoperative Hemorrhage
(Postoperative hemorrhage)
Postoperative Thoracic Procedure
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Complication (Postoperative thoracic
procedure complication)
Precocious Puberty (Precocious
puberty)
Pregnancy, Puerperium And Perinatal
Conditions - Other, Specify (Pregnancy,
puerperium and perinatal conditions -
Other, Specify)
Premature Delivery (Premature delivery)
Premature Menopause (Premature
menopause)
Presyncope (Presyncope)
Proctitis (Proctitis)
Productive Cough (Productive cough)
Prolapse Of Intestinal Stoma (Prolapse
of intestinal stoma)
Prolapse Of Urostomy (Prolapse of
urostomy)
Prostate Infection (Prostate infection)
Prostatic Hemorrhage (Prostatic
hemorrhage)
Prostatic Obstruction (Prostatic
obstruction)
Prostatic Pain (Prostatic pain)
Proteinuria (Proteinuria)
Pruritus (Pruritus)
Psychiatric Disorders - Other, Specify
(Psychiatric disorders - Other, Specify)
Psychosis (Psychosis)
Pulmonary Edema (Pulmonary edema)
Pulmonary Fibrosis (Pulmonary fibrosis)
Pulmonary Fistula (Pulmonary fistula)
Pulmonary Hypertension (Pulmonary
hypertension)
Pulmonary Valve Disease (Pulmonary
valve disease)
Purpura (Purpura)
Pyramidal Tract Syndrome (Pyramidal
tract syndrome)
Radiation Recall Reaction (dermatologic)
(Radiation recall reaction (dermatologic))
Radiculitis (Radiculitis)
Rash Acneiform (Rash acneiform)
Rash Maculo-papular (Rash maculo-
papular)
Rash Pustular (Rash pustular)
Rectal Anastomotic Leak (Rectal
anastomotic leak)
Rectal Fistula (Rectal fistula)
Rectal Hemorrhage (Rectal hemorrhage)
Rectal Mucositis (Rectal mucositis)
Rectal Necrosis (Rectal necrosis)
Rectal Obstruction (Rectal obstruction)
Rectal Pain (Rectal pain)
Rectal Perforation (Rectal perforation)
Rectal Stenosis (Rectal stenosis)
Rectal Ulcer (Rectal ulcer)
Recurrent Laryngeal Nerve Palsy
(Recurrent laryngeal nerve palsy)
Renal And Urinary Disorders - Other,
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Specify (Renal and urinary disorders -
Other, Specify)
Renal Calculi (Renal calculi)
Renal Colic (Renal colic)
Renal Hemorrhage (Renal hemorrhage)
Reproductive System And Breast
Disorders - Other, Specify (Reproductive
system and breast disorders - Other,
Specify)
Respiratory Failure (Respiratory failure)
Respiratory, Thoracic And Mediastinal
Disorders - Other, Specify (Respiratory,
thoracic and mediastinal disorders -
Other, Specify)
Restlessness (Restlessness)
Restrictive Cardiomyopathy (Restrictive
cardiomyopathy)
Retinal Detachment (Retinal
detachment)
Retinal Tear (Retinal tear)
Retinal Vascular Disorder (Retinal
vascular disorder)
Retinoic Acid Syndrome (Retinoic acid
syndrome)
Retinopathy (Retinopathy)
Retroperitoneal Hemorrhage
(Retroperitoneal hemorrhage)
Reversible Posterior
Leukoencephalopathy Syndrome
(Reversible posterior
leukoencephalopathy syndrome)
Rhinitis Infective (Rhinitis infective)
Right Ventricular Dysfunction (Right
ventricular dysfunction)
Salivary Duct Inflammation (Salivary duct
inflammation)
Salivary Gland Fistula (Salivary gland
fistula)
Salivary Gland Infection (Salivary gland
infection)
Scalp Pain (Scalp pain)
Scleral Disorder (Scleral disorder)
Scoliosis (Scoliosis)
Scrotal Infection (Scrotal infection)
Scrotal Pain (Scrotal pain)
Seizure (Seizure)
Sepsis (Sepsis)
Seroma (Seroma)
Serum Amylase Increased (Serum
amylase increased)
Serum Sickness (Serum sickness)
Sick Sinus Syndrome (Sick sinus
syndrome)
Sinus Bradycardia (Sinus bradycardia)
Sinus Disorder (Sinus disorder)
Sinus Pain (Sinus pain)
Sinus Tachycardia (Sinus tachycardia)
Sinusitis (Sinusitis)
Skin And Subcutaneous Tissue
Disorders - Other, Specify (Skin and
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subcutaneous tissue disorders - Other,
Specify)
Skin Atrophy (Skin atrophy)
Skin Hyperpigmentation (Skin
hyperpigmentation)
Skin Hypopigmentation (Skin
hypopigmentation)
Skin Induration (Skin induration)
Skin Infection (Skin infection)
Skin Ulceration (Skin ulceration)
Sleep Apnea (Sleep apnea)
Small Intestinal Anastomotic Leak (Small
intestinal anastomotic leak)
Small Intestinal Mucositis (Small
intestinal mucositis)
Small Intestinal Obstruction (Small
intestinal obstruction)
Small Intestinal Perforation (Small
intestinal perforation)
Small Intestinal Stenosis (Small intestinal
stenosis)
Small Intestine Infection (Small intestine
infection)
Small Intestine Ulcer (Small intestine
ulcer)
Sneezing (Sneezing)
Social Circumstances - Other, Specify
(Social circumstances - Other, Specify)
Soft Tissue Infection (Soft tissue
infection)
Soft Tissue Necrosis Lower Limb (Soft
tissue necrosis lower limb)
Soft Tissue Necrosis Upper Limb (Soft
tissue necrosis upper limb)
Somnolence (Somnolence)
Sore Throat (Sore throat)
Spasticity (Spasticity)
Spermatic Cord Anastomotic Leak
(Spermatic cord anastomotic leak)
Spermatic Cord Hemorrhage (Spermatic
cord hemorrhage)
Spermatic Cord Obstruction (Spermatic
cord obstruction)
Spinal Fracture (Spinal fracture)
Spleen Disorder (Spleen disorder)
Splenic Infection (Splenic infection)
Stenosis Of Gastrointestinal Stoma
(Stenosis of gastrointestinal stoma)
Stevens-johnson Syndrome (Stevens-
Johnson syndrome)
Stoma Site Infection (Stoma site
infection)
Stomach Pain (Stomach pain)
Stomal Ulcer (Stomal ulcer)
Stridor (Stridor)
Stroke (Stroke)
Sudden Death Nos (Sudden death NOS)
Suicidal Ideation (Suicidal ideation)
Suicide Attempt (Suicide attempt)
Superficial Soft Tissue Fibrosis
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(Superficial soft tissue fibrosis)
Superficial Thrombophlebitis (Superficial
thrombophlebitis)
Superior Vena Cava Syndrome (Superior
vena cava syndrome)
Supraventricular Tachycardia
(Supraventricular tachycardia)
Surgical And Medical Procedures -
Other, Specify (Surgical and medical
procedures - Other, Specify)
Syncope (Syncope)
Telangiectasia (Telangiectasia)
Testicular Disorder (Testicular disorder)
Testicular Hemorrhage (Testicular
hemorrhage)
Testicular Pain (Testicular pain)
Thromboembolic Event
(Thromboembolic event)
Thrombotic Thrombocytopenic Purpura
(Thrombotic thrombocytopenic purpura)
Tinnitus (Tinnitus)
Tooth Development Disorder (Tooth
development disorder)
Tooth Discoloration (Tooth discoloration)
Tooth Infection (Tooth infection)
Toothache (Toothache)
Toxic Epidermal Necrolysis (Toxic
epidermal necrolysis)
Tracheal Fistula (Tracheal fistula)
Tracheal Hemorrhage (Tracheal
hemorrhage)
Tracheal Mucositis (Tracheal mucositis)
Tracheal Obstruction (Tracheal
obstruction)
Tracheal Stenosis (Tracheal stenosis)
Tracheitis (Tracheitis)
Tracheostomy Site Bleeding
(Tracheostomy site bleeding)
Transient Ischemic Attacks (Transient
ischemic attacks)
Treatment Related Secondary
Malignancy (Treatment related
secondary malignancy)
Tremor (Tremor)
Tricuspid Valve Disease (Tricuspid valve
disease)
Trigeminal Nerve Disorder (Trigeminal
nerve disorder)
Trismus (Trismus)
Tumor Lysis Syndrome (Tumor lysis
syndrome)
Tumor Pain (Tumor pain)
Typhlitis (Typhlitis)
Unequal Limb Length (Unequal limb
length)
Unintended Pregnancy (Unintended
pregnancy)
Upper Gastrointestinal Hemorrhage
(Upper gastrointestinal hemorrhage)
Upper Respiratory Infection (Upper
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respiratory infection)
Ureteric Anastomotic Leak (Ureteric
anastomotic leak)
Urethral Anastomotic Leak (Urethral
anastomotic leak)
Urethral Infection (Urethral infection)
Urinary Fistula (Urinary fistula)
Urinary Frequency (Urinary frequency)
Urinary Incontinence (Urinary
incontinence)
Urinary Retention (Urinary retention)
Urinary Tract Infection (Urinary tract
infection)
Urinary Tract Obstruction (Urinary tract
obstruction)
Urinary Tract Pain (Urinary tract pain)
Urinary Urgency (Urinary urgency)
Urine Discoloration (Urine discoloration)
Urine Output Decreased (Urine output
decreased)
Urostomy Leak (Urostomy leak)
Urostomy Obstruction (Urostomy
obstruction)
Urostomy Site Bleeding (Urostomy site
bleeding)
Urostomy Stenosis (Urostomy stenosis)
Urticaria (Urticaria)
Uterine Anastomotic Leak (Uterine
anastomotic leak)
Uterine Fistula (Uterine fistula)
Uterine Hemorrhage (Uterine
hemorrhage)
Uterine Infection (Uterine infection)
Uterine Obstruction (Uterine obstruction)
Uterine Pain (Uterine pain)
Uterine Perforation (Uterine perforation)
Uveitis (Uveitis)
Vaginal Anastomotic Leak (Vaginal
anastomotic leak)
Vaginal Discharge (Vaginal discharge)
Vaginal Dryness (Vaginal dryness)
Vaginal Fistula (Vaginal fistula)
Vaginal Hemorrhage (Vaginal
hemorrhage)
Vaginal Infection (Vaginal infection)
Vaginal Inflammation (Vaginal
inflammation)
Vaginal Obstruction (Vaginal obstruction)
Vaginal Pain (Vaginal pain)
Vaginal Perforation (Vaginal perforation)
Vaginal Stricture (Vaginal stricture)
Vaginismus (Vaginismus)
Vagus Nerve Disorder (Vagus nerve
disorder)
Vas Deferens Anastomotic Leak (Vas
deferens anastomotic leak)
Vascular Access Complication (Vascular
access complication)
Vascular Disorders - Other, Specify
(Vascular disorders - Other, Specify)
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Vasculitis (Vasculitis)
Vasovagal Reaction (Vasovagal reaction)
Venous Injury (Venous injury)
Ventricular Arrhythmia (Ventricular
arrhythmia)
Ventricular Fibrillation (Ventricular
fibrillation)
Ventricular Tachycardia (Ventricular
tachycardia)
Vertigo (Vertigo)
Vestibular Disorder (Vestibular disorder)
Virilization (Virilization)
Visceral Arterial Ischemia (Visceral
arterial ischemia)
Vital Capacity Abnormal (Vital capacity
abnormal)
Vitreous Hemorrhage (Vitreous
hemorrhage)
Voice Alteration (Voice alteration)
Vomiting (Vomiting)
Vulval Infection (Vulval infection)
Watering Eyes (Watering eyes)
Weight Gain (Weight gain)
Weight Loss (Weight loss)
Wheezing (Wheezing)
White Blood Cell Decreased (White
blood cell decreased)
Wolff-parkinson-white Syndrome (Wolff-
Parkinson-White syndrome)
Wound Complication (Wound
complication)
Wound Dehiscence (Wound dehiscence)
Wound Infection (Wound infection)
Wrist Fracture (Wrist fracture)
CTC AE Grade
Absent Adverse Event (0)
Mild Adverse Event (1)
Moderate Adverse Event (2)
Severe Adverse Event (3)
Life Threatening Adverse Event (4)
Death Related To Adverse Event (5)
CTCAE Begin Date
CTC AE Attribution Code
Definite (Definite)
Possible (Possible)
Probable (Probable)
Unlikely (Unlikely)
Unrelated (Unrelated)
SAE report submitted
No (No)
Unknown (Unknown)
Yes (Yes)
Footer
27 / 28
Prostate Cancer NCT01368588 Follow-Up - RTOG-0924 F0: Interim
Follow-Up Form - 3197931v1.0
Comments
Signature of Person Completing This Form
Date Form Originally Completed
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Prostate Cancer NCT01368588 Follow-Up - RTOG-0924 F0: Interim
Follow-Up Form - 3197931v1.0
Lymphoma NCT01193842 Toxicity - AMC-075
Adverse Events Form (ADV) - 3184458v1.0
AMC-075 Adverse Events Form (ADV)
Vorinostat and Combination Chemotherapy With Rituximab
in Treating Patients With Previously Untreated HIV-Related
Diffuse Large B-Cell Non-Hodgkin Lymphoma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=9A357A24-
8422-31A4-E040-BB89AD4314CA
All rights reserved. Please visit https://medical-data-
models.org/forms/9659
AMC-075 Adverse Events Form
(ADV)
Header
System Organ Class (SOC)
CTC Adverse Event Term
CTC Adverse Event Grade
Adverse Event Onset Date (mm/dd/yyyy)
Unnamed2
MedDRA Code
If other CTC event selected, please provide
description of event
Was this event expected or anticipated
Yes
No
Agent Name
CTC Adverse Event Attribution Code
Definite (Definite)
Possible (Possible)
Probable (Probable)
Unlikely (Unlikely)
Unrelated (Unrelated)
Alternative etiology
Accident, Trauma, Or External Factors
(Accident, trauma, or external factors)
Concurrent Illness/condition (not Pre-
existing) (Concurrent illness/condition
(not pre-existing))
None Apparent (None apparent)
Other Pre-existing Disease Or Condition
(Other pre-existing disease or condition)
Study Disease (Study disease)
Action Taken at Time of Adverse Event (check
1 / 3
"Yes" for all that apply)
Hospitalization For Ae (Hospitalization)
Otc/non-rx (OTC/non-Rx)
Other (Other)
Prescription (Prescription)
Protocol Treatment Was Delayed As A
Result Of The Adverse Event (protocol
treatment delayed)
Protocol Treatment Was Discontinued As
A Result Of The Adverse Event (protocol
treatment discontinued)
Study Dose Was Reduced As A Result
Of The Adverse Event (study dose
reduced)
Other, specify
If modification was made to study therapy, who
initiated modification
Patient Initiated (Patient initiated)
Physician Initiated (Physician initiated)
Unnamed3
Outcome of Adverse Event
Adverse Event Is Resolved (Resolved)
Adverse Event Is Resolved With
Sequelae (Resolved with sequelae)
Unresolved At Protocol Completion
(Unresolved at protocol completion)
Unresolved, Protocol Ongoing
(Unresolved, protocol ongoing)
AE Resolution Date (If "Resolved" mm/dd/yyyy)
If resolved with sequelae, specify
Was this considered a Serious Adverse Event
Yes
No
Seriousness Attributed to Adverse Event (If "Yes"
check "Yes" for all that apply Please note that
checking "Yes" to any of the events below will
require SAE notification according to protocol
requirements.)
Congenital Anomaly (Congenital
anomaly)
Death (Death)
Disability (Disability/incapacity)
Hospitalized (Hospitalization, initial or
prolonged)
Life Threatening (Life threatening)
Other (Other)
Intervention Required (Required
intervention to prevent permanent
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Lymphoma NCT01193842 Toxicity - AMC-075 Adverse Events Form
(ADV) - 3184458v1.0
impairment/damage)
Comments
Comments
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Lymphoma NCT01193842 Toxicity - AMC-075 Adverse Events Form
(ADV) - 3184458v1.0
Sarcoma NCT01016730 Toxicity - AMC-063
Adverse Events Form (ADV) - 3020269v1.0
AMC-063 Adverse Events Form (ADV)
Bortezomib in Treating Patients With Relapsed or
Refractory AIDS-Related Kaposi Sarcoma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=815FD9FC-
2465-4365-E040-BB89AD437E9F
All rights reserved. Please visit https://medical-data-
models.org/forms/9664
AMC-063 Adverse Events Form
(ADV)
Header
CTC Adverse Event Term
CTC Adverse Event Grade
Adverse Event Onset Date (mm/dd/yyyy)
Unnamed2
MedDRA Code
If other CTC event selected, please provide
description of event
Was this event expected or anticipated
Yes
No
Agent Name
CTC Adverse Event Attribution Code
Definite (Definite)
Possible (Possible)
Probable (Probable)
Unlikely (Unlikely)
Unrelated (Unrelated)
Alternative etiology
Accident, Trauma, Or External Factors
(Accident, trauma, or external factors)
Concurrent Illness/condition (not Pre-
existing) (Concurrent illness/condition
(not pre-existing))
None Apparent (None apparent)
Other Pre-existing Disease Or Condition
(Other pre-existing disease or condition)
Study Disease (Study disease)
Action Taken at Time of Adverse Event (check
"Yes" for all that apply)
Hospitalization For Ae (Hospitalization)
Otc/non-rx (OTC/non-Rx)
Other (Other)
1 / 3
Prescription (Prescription)
Protocol Treatment Was Delayed As A
Result Of The Adverse Event (protocol
treatment delayed)
Protocol Treatment Was Discontinued As
A Result Of The Adverse Event (protocol
treatment discontinued)
Study Dose Was Reduced As A Result
Of The Adverse Event (study dose
reduced)
Other, specify
If modification was made to study therapy, who
initiated modification
Patient Initiated (Patient initiated)
Physician Initiated (Physician initiated)
Unnamed3
Outcome of Adverse Event
Adverse Event Is Resolved (Resolved)
Adverse Event Is Resolved With
Sequelae (Resolved with sequelae)
Unresolved At Protocol Completion
(Unresolved at protocol completion)
Unresolved, Protocol Ongoing
(Unresolved, protocol ongoing)
AE Resolution Date (If "Resolved" mm/dd/yyyy)
If resolved with sequelae, specify
Was this considered a Serious Adverse Event
Yes
No
Seriousness Attributed to Adverse Event (If "Yes"
check "Yes" for all that apply Please note that
checking "Yes" to any of the events below will
require SAE notification according to protocol
requirements.)
Congenital Anomaly (Congenital
anomaly)
Death (Death)
Disability (Disability/incapacity)
Hospitalized (Hospitalization, initial or
prolonged)
Life Threatening (Life threatening)
Other (Other)
Intervention Required (Required
intervention to prevent permanent
impairment/damage)
Comments
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Sarcoma NCT01016730 Toxicity - AMC-063 Adverse Events Form (ADV)
- 3020269v1.0
Comments
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Sarcoma NCT01016730 Toxicity - AMC-063 Adverse Events Form (ADV)
- 3020269v1.0
Pancreatic Cancer NCT01013649 Treatment - RTOG 0848: Phase III Pancreas-
Resected + Adjuvant Treatment Additional Systemic Treatment Summary Form (AT)
- 2891794v1.0
RTOG 0848: Phase III Pancreas-Resected + Adjuvant
Treatment Additional Systemic Treatment Summary Form
(AT)
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=6AFC2AE9-
5C38-1FC0-E040-BB89AD4334D1
All rights reserved. Please visit https://medical-data-
models.org/forms/9665
RTOG 0848: Phase III Pancreas-
Resected + Adjuvant Treatment
Additional Systemic Treatment
Summary Form (AT)
Module 1
RTOG Study No.
Case #
Institution Name
Institution No.
Patient Initials
RTOG Patient ID
Amended Data (INSTRUCTIONS: Complete form
on web to unblind the protocol treatment arm)
Yes
No
Header
Assigned Treatment Arm First Randomization
Arm 1 (Arm 1)
Arm 2 (Arm 2)
Assessment
Height (CM)
Weight (CM)
BSA
Unnamed 3
Agent Name
1 / 3
Date Agent Started (MM DD YYYY)
Date Agent Ended (MM DD YYYY)
Total Dose
Dose Modification (Change)
No (No)
Yes, Planned (i.e., The Treatment Was
Changed According To Protocol
Guidelines) (Yes, planned)
Yes, Unplanned (i.e., The Treatment
Change Was Not Part Of Protocol
Guidelines) (Yes, unplanned)
Reason Treatment Ended
Adverse Event/side Effects/complications
(Adverse Event/Side
Effects/Complications)
Alternative Therapy (Alternative therapy)
Death On Study (Death on study)
Disease Progression, Relapse During
Active Treatment (Disease progression,
relapse during active treatment)
Other (Other)
Patient Off-treatment For Other
Complicating Disease (Patient off-
treatment for other complicating disease)
Patient Withdrawal Or Refusal After
Beginning Protocol Therapy (Patient
withdrawal/refusal after beginning
protocol therapy)
Patient Withdrawal Or Refusal Before
Beginning Protocol Therapy (Patient
withdrawal/refusal prior to beginning
protocol therapy)
Treatment Completed Per Protocol
Criteria (Treatment completed per
protocol criteria)
Alternative therapy, specify
Other Complicating Disease specify
Other specify
Details of any treatment modification
Dose modification
Dose Held (Dose held)
No Dose Modification (No dose
modification)
Non-permanent Reduction (Non-
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Pancreatic Cancer NCT01013649 Treatment - RTOG 0848: Phase III Pancreas-
Resected + Adjuvant Treatment Additional Systemic Treatment Summary Form (AT)
- 2891794v1.0
Permanent Reduction)
Other (Other)
Permanent Reduction (Permanent
Reduction)
Dose Re-escalated (Re-escalated)
Other, specify
Protocol Specific Adverse Event
Evaluation
Any adverse events
No (No)
Unknown (Unknown)
Yes (Yes)
MedDRA disease code
CTC AE Term
CTC AE Grade
CTCAE Begin Date (MM DD YYYY)
CTC Adverse Event Attribution Code
Definite (Definite)
Possible (Possible)
Probable (Probable)
Unlikely (Unlikely)
Unrelated (Unrelated)
SAE report submitted
No (No)
Unknown (Unknown)
Yes (Yes)
Unnamed Module 4
Comments
Investigator Signature
Date
3 / 3
Pancreatic Cancer NCT01013649 Treatment - RTOG 0848: Phase III Pancreas-
Resected + Adjuvant Treatment Additional Systemic Treatment Summary Form (AT)
- 2891794v1.0
Pancreatic Cancer NCT01013649 Treatment - RTOG 0848: Phase III Pancreas-
Resected + Adjuvant Treatment Systemic Treatment Summary Form (SF) -
2867004v1.0
RTOG 0848: Phase III Pancreas-Resected + Adjuvant
Treatment Systemic Treatment Summary Form (SF)
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=690785CE-
F693-0044-E040-BB89AD432A23
All rights reserved. Please visit https://medical-data-
models.org/forms/9666
RTOG 0848: Phase III Pancreas-
Resected + Adjuvant Treatment
Systemic Treatment Summary Form
(SF)
Module 1
RTOG Study No.
Case #
Institution Name
Institution No.
Patient Initials
RTOG Patient ID
Amended Data (INSTRUCTIONS: Complete form
on web to unblind the protocol treatment arm)
Yes
No
Header
Assigned Treatment Arm First Randomization
Arm 1 (Arm 1)
Arm 2 (Arm 2)
Assessment
Height (CM)
Weight (CM)
BSA
Which drug will be administered
Fluorouracil (5-FU)
Capecitabine (Capecitabine)
Not Applicable, No Drug Administered
(Not applicable, no drug administered)
1 / 3
Unnamed 3
Agent Name
Date Agent Started (MM DD YYYY)
Date Agent Ended (MM DD YYYY)
Total number of doses
Total Dose
Dose Modification (Change)
No (No)
Yes, Planned (i.e., The Treatment Was
Changed According To Protocol
Guidelines) (Yes, planned)
Yes, Unplanned (i.e., The Treatment
Change Was Not Part Of Protocol
Guidelines) (Yes, unplanned)
Reason Treatment Ended
Adverse Event/side Effects/complications
(Adverse Event/Side
Effects/Complications)
Alternative Therapy (Alternative therapy)
Death On Study (Death on study)
Disease Progression, Relapse During
Active Treatment (Disease progression,
relapse during active treatment)
Other (Other)
Patient Off-treatment For Other
Complicating Disease (Patient off-
treatment for other complicating disease)
Patient Withdrawal Or Refusal After
Beginning Protocol Therapy (Patient
withdrawal/refusal after beginning
protocol therapy)
Patient Withdrawal Or Refusal Before
Beginning Protocol Therapy (Patient
withdrawal/refusal prior to beginning
protocol therapy)
Treatment Completed Per Protocol
Criteria (Treatment completed per
protocol criteria)
Alternative therapy, specify
Other Complicating Disease specify
Other specify
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2867004v1.0
Details of any treatment modification
Protocol Specific Adverse Event
Evaluation
Any adverse events
No (No)
Unknown (Unknown)
Yes (Yes)
MedDRA disease code
CTC AE Term
CTC AE Grade
CTCAE Begin Date (MM DD YYYY)
CTC Adverse Event Attribution Code
Definite (Definite)
Possible (Possible)
Probable (Probable)
Unlikely (Unlikely)
Unrelated (Unrelated)
SAE report submitted
No (No)
Unknown (Unknown)
Yes (Yes)
Unnamed Module 4
Comments
Investigator Signature
Date
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Pancreatic Cancer NCT01013649 Treatment - RTOG 0848: Phase III Pancreas-
Resected + Adjuvant Treatment Systemic Treatment Summary Form (SF) -
2867004v1.0
Nonneoplastic Condition NCT01057121 Toxicity -
AMC-070 Adverse Events Form (ADV) - 3146259v1.0
AMC-070 Adverse Events Form (ADV)
Lenalidomide in Treating Patients With AIDS-Related
Kaposi Sarcoma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=91E30571-
CADC-D55E-E040-BB89AD43622F
All rights reserved. Please visit https://medical-data-
models.org/forms/9667
AMC-070 Adverse Events Form
(ADV)
Header
System Organ Class (SOC)
CTC Adverse Event Term
CTC Adverse Event Grade
Adverse Event Onset Date (mm/dd/yyyy)
Unnamed2
MedDRA Code
If other CTC event selected, please provide
description of event
Was this event expected or anticipated
Yes
No
Agent Name
CTC Adverse Event Attribution Code
Definite (Definite)
Possible (Possible)
Probable (Probable)
Unlikely (Unlikely)
Unrelated (Unrelated)
Alternative etiology
Accident, Trauma, Or External Factors
(Accident, trauma, or external factors)
Concurrent Illness/condition (not Pre-
existing) (Concurrent illness/condition
(not pre-existing))
None Apparent (None apparent)
Other Pre-existing Disease Or Condition
(Other pre-existing disease or condition)
Study Disease (Study disease)
Action Taken at Time of Adverse Event (check
1 / 3
"Yes" for all that apply)
Hospitalization For Ae (Hospitalization)
Otc/non-rx (OTC/non-Rx)
Other (Other)
Prescription (Prescription)
Protocol Treatment Was Delayed As A
Result Of The Adverse Event (protocol
treatment delayed)
Protocol Treatment Was Discontinued As
A Result Of The Adverse Event (protocol
treatment discontinued)
Study Dose Was Reduced As A Result
Of The Adverse Event (study dose
reduced)
Other, specify
If modification was made to study therapy, who
initiated modification
Patient Initiated (Patient initiated)
Physician Initiated (Physician initiated)
Unnamed3
Outcome of Adverse Event
Adverse Event Is Resolved (Resolved)
Adverse Event Is Resolved With
Sequelae (Resolved with sequelae)
Unresolved At Protocol Completion
(Unresolved at protocol completion)
Unresolved, Protocol Ongoing
(Unresolved, protocol ongoing)
AE Resolution Date (If "Resolved" mm/dd/yyyy)
If resolved with sequelae, specify
Was this considered a Serious Adverse Event
Yes
No
Seriousness Attributed to Adverse Event (If "Yes"
check "Yes" for all that apply Please note that
checking "Yes" to any of the events below will
require SAE notification according to protocol
requirements.)
Congenital Anomaly (Congenital
anomaly)
Death (Death)
Disability (Disability/incapacity)
Hospitalized (Hospitalization, initial or
prolonged)
Life Threatening (Life threatening)
Other (Other)
Intervention Required (Required
intervention to prevent permanent
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Nonneoplastic Condition NCT01057121 Toxicity - AMC-070 Adverse
Events Form (ADV) - 3146259v1.0
impairment/damage)
Comments
Comments
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Nonneoplastic Condition NCT01057121 Toxicity - AMC-070 Adverse
Events Form (ADV) - 3146259v1.0
Anal Cancer NCT00324415 Toxicity - AMC-045
Adverse Events Form (ADV) - 2936750v1.0
AMC-045 Adverse Events Form (ADV)
Cisplatin, Fluorouracil, Cetuximab, and Radiation Therapy
in Treating Patients With HIV and Stage I, Stage II, or
Stage III Anal Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=72844558-6106-
0B0B-E040-BB89AD4314AD
All rights reserved. Please visit https://medical-data-
models.org/forms/9668
AMC-045 Adverse Events Form
(ADV)
Header
CTC AE Category
CTC Adverse Event Term
CTC Adverse Event Grade
Adverse Event Onset Date (mm/dd/yyyy)
Unnamed2
MedDRA Code
If other CTC event selected, please provide
description of event
Was this event expected or anticipated
Yes
No
Agent Name (Relation of event to)
Therapy Name
Radiation Therapy (Radiation therapy)
CTC Adverse Event Attribution Code
Definite (Definite)
Possible (Possible)
Probable (Probable)
Unlikely (Unlikely)
Unrelated (Unrelated)
CTC Adverse Event Attribution Code
Definite (Definite)
Possible (Possible)
Probable (Probable)
Unlikely (Unlikely)
Unrelated (Unrelated)
Alternative etiology
Accident, Trauma, Or External Factors
1 / 3
(Accident, trauma, or external factors)
Concurrent Illness/condition (not Pre-
existing) (Concurrent illness/condition
(not pre-existing))
None Apparent (None apparent)
Other Pre-existing Disease Or Condition
(Other pre-existing disease or condition)
Study Disease (Study disease)
Action Taken at Time of Adverse Event (check
"Yes" for all that apply)
Hospitalization For Ae (Hospitalization)
Otc/non-rx (OTC/non-Rx)
Other (Other)
Prescription (Prescription)
Protocol Treatment Was Delayed As A
Result Of The Adverse Event (protocol
treatment delayed)
Protocol Treatment Was Discontinued As
A Result Of The Adverse Event (protocol
treatment discontinued)
Study Dose Was Reduced As A Result
Of The Adverse Event (study dose
reduced)
Other, specify
If modification was made to study therapy, who
initiated modification
Patient Initiated (Patient initiated)
Physician Initiated (Physician initiated)
Unnamed3
Outcome of Adverse Event
Adverse Event Is Resolved (Resolved)
Adverse Event Is Resolved With
Sequelae (Resolved with sequelae)
Unresolved At Protocol Completion
(Unresolved at protocol completion)
Unresolved, Protocol Ongoing
(Unresolved, protocol ongoing)
AE Resolution Date (If "Resolved" mm/dd/yyyy)
If resolved with sequelae, specify
Was this considered a Serious Adverse Event
Yes
No
Seriousness Attributed to Adverse Event (If "Yes"
check "Yes" for all that apply Please note that
checking "Yes" to any of the events below will
require SAE notification according to protocol
requirements.)
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(ADV) - 2936750v1.0
Congenital Anomaly (Congenital
anomaly)
Death (Death)
Disability (Disability/incapacity)
Hospitalized (Hospitalization, initial or
prolonged)
Life Threatening (Life threatening)
Other (Other)
Intervention Required (Required
intervention to prevent permanent
impairment/damage)
Comments
Comments
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Anal Cancer NCT00324415 Toxicity - AMC-045 Adverse Events Form
(ADV) - 2936750v1.0
Brain and Central Nervous System Tumors NCT00884741 Treatment -
RTOG 0825 Phase III GBM Treatment Summary Form (TF) - 2796514v1.0
RTOG 0825 Phase III GBM Treatment Summary Form (TF)
Temozolomide and Radiation Therapy With or Without
Bevacizumab in Treating Patients With Newly Diagnosed
Glioblastoma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=5A7D3B0F-
8D23-492E-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/9670
RTOG 0825 Phase III GBM
Treatment Summary Form (TF)
Unnamed Module 1
RTOG Study No.
Case #
Institution Name
Institution No.
Patient Initials
RTOG Patient ID
Amended Data
Yes
No
Assessment
Height (CM)
Weight (CM)
BSA (M2)
Karnofsky Performance Status (Use 9 if
unknown)
Dead (0)
Moribund, Fatal Processes Progressing
Rapidly (10)
Normal, No Complaints, No Evidence Of
Disease (100)
Very Sick, Hospitalization Indicated.
Death Not Imminent (20)
Severely Disabled, Hospitalization
Indicated. Death Not Imminent (30)
Disabled, Requires Special Care And
Assistance (40)
Requires Considerable Assistance And
1 / 6
Frequent Medical Care (50)
Requires Occasional Assistance, But Is
Able To Care For Most Of His/her Needs
(60)
Cares For Self, Unable To Carry On
Normal Activity Or To Do Active Work
(70)
Normal Activity With Effort; Some Signs
Or Symptoms Of Disease (80)
Able To Carry On Normal Activity; Minor
Signs Or Symptoms Of Disease (90)
Neurologic function
Minor Neurologic Symptoms, Fully Active
At Home/work Without Assistance (Minor
neurologic symptoms, fully active at
home/work without assistance)
Moderate Neurologic Symptoms, Fully
Active At Home/work But Requires
Assistance (Moderate neurologic
symptoms, fully active at home/work but
requires assistance)
Moderate Neurologic Symptoms, Less
Than Fully Active At Home/work And
Requires Assitance (Moderate
neurologic symptoms, less than fully
active at home/work and requires
assistance)
No Neurologic Symptoms, Fully Active At
Home/work Without Assistance (No
neurologic symptoms, fully active at
home/work without assistance)
Severe Neurologic Symptoms, Totally
Inactive Requiring Complete Assistance
At Home Or Institution, Unable To Work
(Severe neurologic symptoms, totally
inactive requiring complete assistance at
home or institution, unable to work)
Unknown (Unknown)
Disease Progression
Agent treatment being reported
Adjuvant Tmz And Bev / Placebo
(Adjuvant TMZ and BEV / placebo)
Concurrent Rt And Tmz (Concurrent RT
and TMZ)
Concurrent Rt, Tmz, And Bev / Placebo
(Concurrent RT, TMZ, and BEV /
placebo)
Is protocol chemotherapy continuing?
Yes
No
Unnamed 3
Agent Name
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Brain and Central Nervous System Tumors NCT00884741 Treatment -
RTOG 0825 Phase III GBM Treatment Summary Form (TF) - 2796514v1.0
Agent Start Date (MM DD YYYY)
Agent End Date (MM DD YYYY)
Agent Total Dose (MG)
Total number of doses
Was dose reduced more than 20%
Yes
No
Reason for Treatment Modification
Adverse Event/side Effects/complications
(Adverse event/side
effects/complications)
Alternative Therapy (Alternative therapy)
Death On Study (Death on study)
Disease Progression, Relapse During
Active Treatment (Disease progression,
relapse during active treatment)
No Modification (No modification)
Other (Other)
Patient Withdrawal Or Refusal After
Beginning Protocol Therapy (Patient
withdrawal/refusal after beginning
protocol therapy)
Patient Withdrawal Or Refusal Prior To
Beginning Protocol Therapy (Patient
withdrawal/refusal prior to beginning
protocol therapy)
Reason Treatment Ended
Adverse Event/side Effects/complications
(Adverse Event/Side
Effects/Complications)
Alternative Therapy (Alternative therapy)
Death On Study (Death on study)
Disease Progression, Relapse During
Active Treatment (Disease progression,
relapse during active treatment)
Other (Other)
Patient Off-treatment For Other
Complicating Disease (Patient off-
treatment for other complicating disease)
Patient Withdrawal Or Refusal After
Beginning Protocol Therapy (Patient
withdrawal/refusal after beginning
protocol therapy)
Patient Withdrawal Or Refusal Before
Beginning Protocol Therapy (Patient
withdrawal/refusal prior to beginning
protocol therapy)
Treatment Completed Per Protocol
Criteria (Treatment completed per
protocol criteria)
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Alternative therapy, specify
Other specify
Protocol Specific Adverse Event
Evaluation
Were there any hemorrhage events during this
report period
Yes
No
MedDRA Code
CTC Adverse Event Term
CTC Adverse Event Term
CTC AE Grade
CTC AE Grade
CTCAE Begin Date (MM DD YYYY)
CTCAE Begin Date (MM DD YYYY)
CTC AE Attribution Code
Definite (Definite)
Possible (Possible)
Probable (Probable)
Unlikely (Unlikely)
Unrelated (Unrelated)
CTC AE Attribution Code
Definite (Definite)
Possible (Possible)
Probable (Probable)
Unlikely (Unlikely)
Unrelated (Unrelated)
SAE report submitted
No (No)
Unknown (Unknown)
Yes (Yes)
SAE report submitted
No (No)
Unknown (Unknown)
Yes (Yes)
INR (International Normalized Ratio of
prothrombin time Value)
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RTOG 0825 Phase III GBM Treatment Summary Form (TF) - 2796514v1.0
INR LLN (Institution)
INR ULN (Institution)
PTT (sec) (Partial Thromboplastin Time Value)
PTT LLN (Institution)
PTT ULN (Institution)
PT (Prothrombin Time Value)
PT LLN (Institution)
PT ULN (Institution)
Platelets (PLT) (Platelets x 1000 cmm Value)
PLT LLN (Institution)
PLT ULN (Institution)
Date (MM DD YYYY)
Date (MM DD YYYY)
Date (MM DD YYYY)
Date (MM DD YYYY)
Protocol Specific Adverse Event
Evaluation
Were there any study-specific adverse events
during this report period
Yes
No
CTC Adverse Event Term
CTC AE Grade
CTCAE Begin Date (MM DD YYYY)
CTC AE Attribution Code
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Definite (Definite)
Possible (Possible)
Probable (Probable)
Unlikely (Unlikely)
Unrelated (Unrelated)
SAE report submitted
No (No)
Unknown (Unknown)
Yes (Yes)
Protocol Specific Adverse Event
Evaluation
Any Treatment Related Adverse Events
No (No)
Unknown (Unknown)
Yes (Yes)
MedDRA Code
CTC Adverse Event Term
CTC AE Grade
CTCAE Begin Date (MM DD YYYY)
CTC AE Attribution Code
Definite (Definite)
Possible (Possible)
Probable (Probable)
Unlikely (Unlikely)
Unrelated (Unrelated)
SAE report submitted
No (No)
Unknown (Unknown)
Yes (Yes)
Footer
Comments
Signature of Person Completing This Form
Date Form Originally Completed
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Brain and Central Nervous System Tumors NCT00884741 Treatment -
RTOG 0825 Phase III GBM Treatment Summary Form (TF) - 2796514v1.0
Anal Cancer NCT01249443 Toxicity - AMC-078
Adverse Events Form (ADV) - 3184680v1.0
AMC-078 Adverse Events Form (ADV)
Vorinostat in Combination With Paclitaxel and Carboplatin
in Treating Patients With Metastatic or Recurrent Solid
Tumors and HIV Infection
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=9A357A24-
85C8-31A4-E040-BB89AD4314CA
All rights reserved. Please visit https://medical-data-
models.org/forms/9671
AMC-078 Adverse Events Form
(ADV)
Header
System Organ Class (SOC)
CTC Adverse Event Term
CTC Adverse Event Grade
Adverse Event Onset Date (mm/dd/yyyy)
Unnamed2
MedDRA Code
If other CTC event selected, please provide
description of event
Was this event expected or anticipated
Yes
No
Agent Name
CTC Adverse Event Attribution Code
Definite (Definite)
Possible (Possible)
Probable (Probable)
Unlikely (Unlikely)
Unrelated (Unrelated)
Alternative etiology
Accident, Trauma, Or External Factors
(Accident, trauma, or external factors)
Concurrent Illness/condition (not Pre-
existing) (Concurrent illness/condition
(not pre-existing))
None Apparent (None apparent)
Other Pre-existing Disease Or Condition
(Other pre-existing disease or condition)
Study Disease (Study disease)
Action Taken at Time of Adverse Event (check
1 / 3
"Yes" for all that apply)
Hospitalization For Ae (Hospitalization)
Otc/non-rx (OTC/non-Rx)
Other (Other)
Prescription (Prescription)
Protocol Treatment Was Delayed As A
Result Of The Adverse Event (protocol
treatment delayed)
Protocol Treatment Was Discontinued As
A Result Of The Adverse Event (protocol
treatment discontinued)
Study Dose Was Reduced As A Result
Of The Adverse Event (study dose
reduced)
Other, specify
If modification was made to study therapy, who
initiated modification
Patient Initiated (Patient initiated)
Physician Initiated (Physician initiated)
Unnamed3
Outcome of Adverse Event
Adverse Event Is Resolved (Resolved)
Adverse Event Is Resolved With
Sequelae (Resolved with sequelae)
Unresolved At Protocol Completion
(Unresolved at protocol completion)
Unresolved, Protocol Ongoing
(Unresolved, protocol ongoing)
AE Resolution Date (If "Resolved" mm/dd/yyyy)
If resolved with sequelae, specify
Was this considered a Serious Adverse Event
Yes
No
Seriousness Attributed to Adverse Event (If "Yes"
check "Yes" for all that apply Please note that
checking "Yes" to any of the events below will
require SAE notification according to protocol
requirements.)
Congenital Anomaly (Congenital
anomaly)
Death (Death)
Disability (Disability/incapacity)
Hospitalized (Hospitalization, initial or
prolonged)
Life Threatening (Life threatening)
Other (Other)
Intervention Required (Required
intervention to prevent permanent
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impairment/damage)
Comments
Comments
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Brain and Central Nervous System Tumors NCT00884741 Treatment - RTOG
0825 Phase III GBM Salvage Treatment Summary Form (SF) - 2797440v1.0
RTOG 0825 Phase III GBM Salvage Treatment Summary
Form (SF)
Temozolomide and Radiation Therapy With or Without
Bevacizumab in Treating Patients With Newly Diagnosed
Glioblastoma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=5AE2A23C-
8AF1-6A8B-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/9672
RTOG 0825 Phase III GBM Salvage
Treatment Summary Form (SF)
Module 1
RTOG Study No.
Case #
Institution Name
Institution No.
Patient Initials
RTOG Patient ID
Amended Data (INSTRUCTIONS: Complete form
on web to unblind the protocol treatment arm)
Yes
No
Assessment
Height (CM)
Weight (CM)
BSA (M2)
Karnofsky Performance Status (Use 9 if
unknown)
Dead (0)
Moribund, Fatal Processes Progressing
Rapidly (10)
Normal, No Complaints, No Evidence Of
Disease (100)
Very Sick, Hospitalization Indicated.
Death Not Imminent (20)
Severely Disabled, Hospitalization
Indicated. Death Not Imminent (30)
Disabled, Requires Special Care And
Assistance (40)
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Requires Considerable Assistance And
Frequent Medical Care (50)
Requires Occasional Assistance, But Is
Able To Care For Most Of His/her Needs
(60)
Cares For Self, Unable To Carry On
Normal Activity Or To Do Active Work
(70)
Normal Activity With Effort; Some Signs
Or Symptoms Of Disease (80)
Able To Carry On Normal Activity; Minor
Signs Or Symptoms Of Disease (90)
Neurologic function
Minor Neurologic Symptoms, Fully Active
At Home/work Without Assistance (Minor
neurologic symptoms, fully active at
home/work without assistance)
Moderate Neurologic Symptoms, Fully
Active At Home/work But Requires
Assistance (Moderate neurologic
symptoms, fully active at home/work but
requires assistance)
Moderate Neurologic Symptoms, Less
Than Fully Active At Home/work And
Requires Assitance (Moderate
neurologic symptoms, less than fully
active at home/work and requires
assistance)
No Neurologic Symptoms, Fully Active At
Home/work Without Assistance (No
neurologic symptoms, fully active at
home/work without assistance)
Severe Neurologic Symptoms, Totally
Inactive Requiring Complete Assistance
At Home Or Institution, Unable To Work
(Severe neurologic symptoms, totally
inactive requiring complete assistance at
home or institution, unable to work)
Unknown (Unknown)
Disease Progression
Salvage treatment being reported
Bevacizumab Alone (Bevacizumab
alone)
Bevacizumab And Irinotecan
(Bevacizumab and Irinotecan)
Bevacizumab And Tmz Salvage
(Bevacizumab and TMZ salvage)
Is protocol chemotherapy continuing?
Yes
No
Unnamed 3
Agent Name
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Agent Start Date (MM DD YYYY)
Agent End Date (MM DD YYYY)
Agent Total Dose (MG)
Total number of doses
Was dose reduced more than 20%
Yes
No
Reason for Treatment Modification
Adverse Event/side Effects/complications
(Adverse event/side
effects/complications)
Alternative Therapy (Alternative therapy)
Death On Study (Death on study)
Disease Progression, Relapse During
Active Treatment (Disease progression,
relapse during active treatment)
No Modification (No modification)
Other (Other)
Patient Withdrawal Or Refusal After
Beginning Protocol Therapy (Patient
withdrawal/refusal after beginning
protocol therapy)
Patient Withdrawal Or Refusal Prior To
Beginning Protocol Therapy (Patient
withdrawal/refusal prior to beginning
protocol therapy)
Reason Treatment Ended
Adverse Event/side Effects/complications
(Adverse Event/Side
Effects/Complications)
Alternative Therapy (Alternative therapy)
Death On Study (Death on study)
Disease Progression, Relapse During
Active Treatment (Disease progression,
relapse during active treatment)
Other (Other)
Patient Off-treatment For Other
Complicating Disease (Patient off-
treatment for other complicating disease)
Patient Withdrawal Or Refusal After
Beginning Protocol Therapy (Patient
withdrawal/refusal after beginning
protocol therapy)
Patient Withdrawal Or Refusal Before
Beginning Protocol Therapy (Patient
withdrawal/refusal prior to beginning
protocol therapy)
Treatment Completed Per Protocol
Criteria (Treatment completed per
protocol criteria)
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Alternative therapy, specify
Other specify
Protocol Specific Adverse Event
Evaluation
Were there any hemorrhage events during this
report period
Yes
No
MedDRA Code
CTC Adverse Event Term
CTC Adverse Event Term
CTC AE Grade
CTC AE Grade
CTCAE Begin Date (MM DD YYYY)
CTCAE Begin Date (MM DD YYYY)
CTC AE Attribution Code
Definite (Definite)
Possible (Possible)
Probable (Probable)
Unlikely (Unlikely)
Unrelated (Unrelated)
CTC AE Attribution Code
Definite (Definite)
Possible (Possible)
Probable (Probable)
Unlikely (Unlikely)
Unrelated (Unrelated)
SAE report submitted
No (No)
Unknown (Unknown)
Yes (Yes)
SAE report submitted
No (No)
Unknown (Unknown)
Yes (Yes)
INR (International Normalized Ratio of
prothrombin time Value)
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INR LLN (Institution)
INR ULN (Institution)
PTT (sec) (Partial Thromboplastin Time Value)
PTT LLN (Institution)
PTT ULN (Institution)
PT (Prothrombin Time Value)
PT LLN (Institution)
PT ULN (Institution)
Platelets (PLT) (Platelets x 1000 cmm Value)
PLT LLN (Institution)
PLT ULN (Institution)
Date (MM DD YYYY)
Date (MM DD YYYY)
Date (MM DD YYYY)
Date (MM DD YYYY)
Protocol Specific Adverse Event
Evaluation
Were there any study-specific adverse events
during this report period
Yes
No
CTC Adverse Event Term
CTC AE Grade
CTCAE Begin Date (MM DD YYYY)
CTC AE Attribution Code
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Definite (Definite)
Possible (Possible)
Probable (Probable)
Unlikely (Unlikely)
Unrelated (Unrelated)
SAE report submitted
No (No)
Unknown (Unknown)
Yes (Yes)
Protocol Specific Adverse Event
Evaluation
Any Treatment Related Adverse Events
No (No)
Unknown (Unknown)
Yes (Yes)
MedDRA Code
CTC Adverse Event Term
CTC AE Grade
CTCAE Begin Date (MM DD YYYY)
CTC AE Attribution Code
Definite (Definite)
Possible (Possible)
Probable (Probable)
Unlikely (Unlikely)
Unrelated (Unrelated)
SAE report submitted
No (No)
Unknown (Unknown)
Yes (Yes)
Footer Module
Comments
Signature of Person Completing This Form
Form Completion Date, Original
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Anal Cancer NCT00550589 Toxicity - AMC-046
Adverse Events Form (ADV) - 2989394v1.0
AMC-046 Adverse Events Form (ADV)
Cidofovir in Treating HIV-Infected Patients With High-Grade
Squamous Intraepithelial Lesions of the Skin Near the Anus
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=7D8985E5-
2E37-08A5-E040-BB89AD434A3B
All rights reserved. Please visit https://medical-data-
models.org/forms/9673
AMC-046 Adverse Events Form
(ADV)
Header
CTC AE Category
CTC Adverse Event Term
CTC Adverse Event Grade
Adverse Event Onset Date (mm/dd/yyyy)
Unnamed2
MedDRA Code
If other CTC event selected, please provide
description of event
Was this event expected or anticipated
Yes
No
Agent Name
CTC Adverse Event Attribution Code
Definite (Definite)
Possible (Possible)
Probable (Probable)
Unlikely (Unlikely)
Unrelated (Unrelated)
Alternative etiology
Accident, Trauma, Or External Factors
(Accident, trauma, or external factors)
Concurrent Illness/condition (not Pre-
existing) (Concurrent illness/condition
(not pre-existing))
None Apparent (None apparent)
Other Pre-existing Disease Or Condition
(Other pre-existing disease or condition)
Study Disease (Study disease)
Action Taken at Time of Adverse Event
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Hospitalization For Ae (Hospitalization)
Otc/non-rx (OTC/non-Rx)
Other (Other)
Prescription (Prescription)
Protocol Treatment Was Delayed As A
Result Of The Adverse Event (protocol
treatment delayed)
Protocol Treatment Was Discontinued As
A Result Of The Adverse Event (protocol
treatment discontinued)
Study Dose Was Reduced As A Result
Of The Adverse Event (study dose
reduced)
Other, specify
If modification was made to study therapy, who
initiated modification
Patient Initiated (Patient initiated)
Physician Initiated (Physician initiated)
Unnamed3
Outcome of Adverse Event
Adverse Event Is Resolved (Resolved)
Adverse Event Is Resolved With
Sequelae (Resolved with sequelae)
Unresolved At Protocol Completion
(Unresolved at protocol completion)
Unresolved, Protocol Ongoing
(Unresolved, protocol ongoing)
AE Resolution Date (If "Resolved" mm/dd/yyyy)
If resolved with sequelae, specify
Was this considered a Serious Adverse Event
Yes
No
Seriousness Attributed to Adverse Event (If "Yes"
check "Yes" for all that apply Please note that
checking "Yes" to any of the events below will
require SAE notification according to protocol
requirements.)
Congenital Anomaly (Congenital
anomaly)
Death (Death)
Disability (Disability/incapacity)
Hospitalized (Hospitalization, initial or
prolonged)
Life Threatening (Life threatening)
Other (Other)
Intervention Required (Required
intervention to prevent permanent
impairment/damage)
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Comments
Comments
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Colorectal Cancer NCT00058474 Toxicity - NSABP
PROTOCOL R-04: FORM ALERT - 2082606v3.0
NSABP PROTOCOL R-04: FORM ALERT
Radiation Therapy and Either Capecitabine or Fluorouracil
With or Without Oxaliplatin Before Surgery in Treating
Patients With Resectable Rectal Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=B7822CF5-
8853-24F1-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/9674
NSABP PROTOCOL R-04: FORM
ALERT
Ccrr Module For Nsabp Protocol R-04:
Form Alert
First Three Letters of Patient's Last Name
Patient Study ID
Institution Name / Affiliate Name
Treating MD, Last Name
Treating MD, First Name
Treating MD, Phone
Person Completing Form, Last Name
Person Completing Form, First Name
Phone
Phone
Are data amended?
Yes
No
Date of this Report (Month Day Year)
Patient's Age at Time of AE
Notify Local IRB?
Yes
No
Was the patient hospitalized for 24 hours or
more?
Yes
No
1 / 2
CTC Adverse Event Type
Grade 3 Unexpected* (Grade 3
unexpected*)
Grade 4 Expected (Grade 4 expected)
Grade 4 Unexpected* (Grade 4
unexpected*)
Grade 5** Expected (Grade 5**
expected)
Grade 5**unexpected* (Grade
5**unexpected*)
CTC Adverse Event Term
4-Character NSABP Code
CTC Adverse Event Date (Month Day Year)
Protocol Therapy
5FU (5FU)
Capecitabine (Capecitabine)
Epoetin Alfa (Epoetin Alfa)
Date of Most Recent Treatment (Month Day Year)
CTC Adverse Event Attribution Code
Definite (Definitely)
Possible (Possibly)
Probable (Probably)
Unlikely (Unlikely)
Unrelated (Unrelated)
Briefly describe the AE  (provide supporting
documentation)
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Lung Cancer NCT00738881 Toxicity - North Central Cancer
Treatment Group N0723 Nadir/Adverse Event Form - 2731512v1.0
North Central Cancer Treatment Group N0723
Nadir/Adverse Event Form
Pemetrexed or Erlotinib as Second-Line Therapy in Treating
Patients With Advanced Non-Small Cell Lung Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=46FBB039-
1871-1A6C-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/9677
North Central Cancer Treatment
Group N0723 Nadir/Adverse Event
Form
Header
Protocol Number
Patient ID
Patient Initials (L F M)
Institution Number
Institution
Are data amended (If yes, highlight amended
areas)
Yes
No
Header
Current Cycle Number (nadir/adverse events
associated with this cycle)
Date of evaluation (mm/dd/yyyy)
Platelets (PLT) (K/uL or 10^9/L)
Leukocytes (WBC) (K/uL or 10^9/L)
CTC AE Attribution Code (If Grade > 0)
Definite (Definite)
Possible (Possible)
Probable (Probable)
Unlikely (Unlikely)
Unrelated (Unrelated)
Has an Adverse Event Expedited Report been
submitted? (Enter 1 for Yes or 2 for No)
Yes
1 / 4
No
Hemoglobin (g/dL)
Absolute Neutrophil Count (K/uL or 10^9/L)
Nadir/Worst Date (Date of lab test mm/dd/yyyy)
Nadir/Worst Value (The nadir is the lowest value
of counts occurring between two treatments)
Is nadir below LLN? (check one)
Yes
No
Description Of Primary Disease
CTC Adverse Event Term
Alanine Aminotransferase Increased
(ALT, SGPT (serum glutamic pyruvic
transaminase))
Anorexia (Anorexia)
Aspartate Aminotransferase Increased
(AST, SGOT (serum glutamic oxaloacetic
transaminase))
Blood Bilirubin Increased (Bilirubin
(hyperbilirubinemia))
Blood Creatinine Increased (Creatinine)
Diarrhoea Nos (Diarrhea)
Dyspnoea Nos (Dyspnea (shortness of
breath))
Fatigue (Fatigue (asthenia, lethargy,
malaise))
Febrile Neutropenia (fever Of Unknown
Origin Without Clinically Or
Microbiologically Documented Infection)
(anc <1.0 X 10^9/l, Fever >=38.5
Degrees C) (Febrile neutropenia)
Pyrexia (Fever (in the absence of
neutropenia, where neutropenia is
defined as ANC <1.0 x 10^9/L))
Infection With Unknown Anc (Infection
with unknown ANC - Abdomen NOS)
Infection With Unknown Anc (Infection
with unknown ANC - Lung (pneumonia))
Keratitis Nec (Keratitis (corneal
inflammation/corneal ulceration))
Mucositis/stomatitis (clinical Exam)
(Mucositis/stomatitis (clinical exam) -
Oral cavity)
Stomatitis (Mucositis/stomatitis (clinical
exam) - Pharynx)
Mucositis/stomatitis
(functional/symptomatic)
(Mucositis/stomatitis
2 / 4
Lung Cancer NCT00738881 Toxicity - North Central Cancer Treatment
Group N0723 Nadir/Adverse Event Form - 2731512v1.0
(functional/symptomatic) - Oral cavity)
Mucositis/stomatitis
(functional/symptomatic)
(Mucositis/stomatitis
(functional/symptomatic) - Pharynx)
Nausea (Nausea)
Abdominal Pain Nos (Pain - Abdomen
NOS)
Rash: Acne/acneiform (Rash:
acne/acneiform)
Dermatitis Exfoliative Nos
(Rash/desquamation)
Vomiting Nos (Vomiting)
Weight Decreased (Weight loss)
MedDRA Code (primary tumor site: Metastases
to brain parenchyma)
CTC Adverse Event Grade (highest grade this
cycle)
CTC AE Attribution Code (If Grade > 0)
Definite (Definite)
Possible (Possible)
Probable (Probable)
Unlikely (Unlikely)
Unrelated (Unrelated)
Has an Adverse Event Expedited Report been
submitted? (Enter 1 for Yes or 2 for No)
Yes
No
Were adverse events assessed during this report
period (other)
No (No)
Yes, And Reportable Adverse Events
Occurred (Yes, and reportable adverse
events occurred)
Yes, But No Reportable Adverse Events
Occurred (Yes, but no reportable adverse
events occurred)
Description Of Primary Disease
Other CTC Adverse Event Term not listed
MedDRA Code (primary tumor site: Metastases
to brain parenchyma)
CTC Adverse Event Grade (highest grade this
cycle)
CTC AE Attribution Code (If Grade > 0)
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Definite (Definite)
Possible (Possible)
Probable (Probable)
Unlikely (Unlikely)
Unrelated (Unrelated)
Has an Adverse Event Expedited Report been
submitted? (Enter 1 for Yes or 2 for No)
Yes
No
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Brain and Central Nervous System Tumors NCT00887146 Toxicity - North Central
Cancer Treatment Group N0577 Nadir/Adverse Event Form - 2745613v1.0
North Central Cancer Treatment Group N0577
Nadir/Adverse Event Form
Radiation Therapy or Radiation Therapy and Temozolomide
or Temozolomide Alone in Treating Patients With Newly
Diagnosed Anaplastic Glioma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=4C094A66-
12E0-40DD-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/9678
North Central Cancer Treatment
Group N0577 Nadir/Adverse Event
Form
Header
Protocol Number
Patient ID
Patient Initials (L F M)
Institution Number
Institution
Are data amended (If yes, highlight amended
areas)
Yes
No
Header
Date of evaluation (mm/dd/yyyy)
Platelets (PLT) (K/uL or 10^9/L)
Leukocytes (WBC) (K/uL or 10^9/L)
CTC AE Attribution Code (If Grade > 0)
Definite (Definite)
Possible (Possible)
Probable (Probable)
Unlikely (Unlikely)
Unrelated (Unrelated)
Has an Adverse Event Expedited Report been
submitted? (Enter 1 for Yes or 2 for No)
Yes
No
Hemoglobin (g/dL)
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Absolute Neutrophil Count (K/uL or 10^9/L)
Current Cycle Number
Nadir/Worst Date (Date of lab test mm/dd/yyyy)
Nadir/Worst Value (The nadir is the lowest value
of counts occurring between two treatments)
Is nadir below LLN? (check one)
Yes
No
Description Of Primary Disease
CTC Adverse Event Term
Cough (Cough)
Diarrhoea Nos (Diarrhea)
Dyspnoea Nos (Dyspnea (shortness of
breath))
Keratitis Nec (Keratitis (corneal
inflammation/corneal ulceration))
Nausea (Nausea)
Dermatitis Exfoliative Nos
(Rash/desquamation)
MedDRA Code (primary tumor site: Metastases
to brain parenchyma)
CTC Adverse Event Grade (highest grade this
cycle)
CTC AE Attribution Code (If Grade > 0)
Definite (Definite)
Possible (Possible)
Probable (Probable)
Unlikely (Unlikely)
Unrelated (Unrelated)
Has an Adverse Event Expedited Report been
submitted? (Enter 1 for Yes or 2 for No)
Yes
No
Current Cycle Number
Were adverse events assessed during this report
period (other)
No (No)
Yes, And Reportable Adverse Events
Occurred (Yes, and reportable adverse
events occurred)
Yes, But No Reportable Adverse Events
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Occurred (Yes, but no reportable adverse
events occurred)
Description Of Primary Disease
Other CTC Adverse Event Term not listed
MedDRA Code (primary tumor site: Metastases
to brain parenchyma)
CTC Adverse Event Grade (highest grade this
cycle)
CTC AE Attribution Code (If Grade > 0)
Definite (Definite)
Possible (Possible)
Probable (Probable)
Unlikely (Unlikely)
Unrelated (Unrelated)
Has an Adverse Event Expedited Report been
submitted? (Enter 1 for Yes or 2 for No)
Yes
No
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FORM ALERT Colorectal Cancer
(NCT00096278)
NSABP PROTOCOL C-08: FORM ALERT
Fluorouracil, Leucovorin, and Oxaliplatin With or Without
Bevacizumab in Treating Patients Who Have Undergone
Surgery for Stage II or Stage III Colon Cancer
NCT00096278
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=D7FA5174-
1580-6420-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/9680
FORM ALERT Colorectal Cancer
(NCT00096278)
Header
Date of this Report (Month Day Year)
Patient Initials (Last, First Middle)
NSABP Patient ID
Institution Name
Affiliate Name
Treating MD Last Name
Treating MD First Name
Treating MD Phone
Person Completing Form Last Name
Person Completing Form First Name
Person Completing Form Phone
Are data amended? (check box if yes, and circle
amended items)
Yes
No
Adverse event
Patient's Age at Time of AE
Notify Local IRB?
Yes
No
Was the patient hospitalized for 24 hours or
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more?
Yes
No
Specify Type of AE
Grade 4 Unexpected (Grade 4
unexpected)
Grade 5 (Grade 5)
CTCAE v3.0 Short Name
"Select" Term (when applicable)
Adverse Event Onset Date (Month Day Year)
Protocol Therapy
5FU (5FU)
Bevacizumab (Bevacizumab)
Leucovorin (Leucovorin)
Oxaliplatin (Oxaliplatin)
Date of Most Recent Treatment
CTC Adverse Event Attribution Code
Definite (Definite)
Possible (Possible)
Probable (Probable)
Unlikely (Unlikely)
Unrelated (Unrelated)
Briefly describe the AE
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Long-Term Follow-up Form Leukemia
(NCT00049517)
E1900 Long-Term Follow-up Form
Combination Chemotherapy With or Without Monoclonal
Antibody Therapy Followed by Stem Cell Transplant in
Treating Patients With Acute Myeloid Leukemia
NCT00049517
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=A7294868-
3C8F-2FCA-E034-0003BA0B1A09
All rights reserved. Please visit https://medical-data-
models.org/forms/9681
Long-Term Follow-up Form
Leukemia (NCT00049517)
Header
ECOG Protocol No.
ECOG Patient ID
Registration Step
Patient's Name
Participating Group Protocol No.
Participating Group Patient ID
Institution/Affiliate
Are data amended?
Yes
No
Reporting Period Start Date
Reporting Period End Date
Comments
Investigator Signature
Investigator Signature Date
Vital Status
Patient's Vital Status
Alive (Alive)
Dead (Dead)
Date of Last Contact or Death
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Primary Cause of Death
Due To Other Cause, Specify (Due to
other cause)
Due To Protocol Treatment (Due to
protocol treatment)
Due To This Disease (Due to this
disease)
Unknown (Unknown)
Describe cause of death
Disease Follow-up Status
Has the patient had a documented clinical
assessment for this cancer (since submission of
the previous follow-up form)?
Yes
No
Date of last clinical cancer assessment (If yes)
Notice Of Relapse
Has the patient developed a first relapse that has
not been previously reported?
Yes
No
Date of relapse
Did a physician make a formal diagnosis of
relapse? (If no or unknown, specify basis of PD in
Comments)
Yes
No
Notice Of New Primary
Has a new primary cancer or MDS been
diagnosed that has not been previously reported?
Yes
No
Site(s) of new primary
Toxicity
Has the patient experienced any severe (Grade
>= 3) long term toxicity that has not been
previously reported?
Yes
No
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Non-protocol Therapy
Has the patient received any non-protocol cancer
therapy prior to first relapse (not previously
reported)?
Yes
No
Transfusions
Number of platlet transfusions (this reporting
period)
Date of most recent platelet transfusion
Number of RBC transfusions (this reporting
period)
Date of most recent RBC transfusion
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Eligibility NCT00190047 Stroke
ODM derived from
http://clinicaltrials.gov/show/NCT00190047
All rights reserved. Please visit https://medical-data-
models.org/forms/9686
Eligibility
Inclusion Criteria
18 Years to 85 Years*
yes (1)
no (2)
Patients with ischemic stroke, (that is, stroke that
results from a blockage of blood flow to part of
the brain), which is accompanied by language
dysfunction (e.g. inability to understand speech),
visual field defect or inattention to one side of the
body or the space around the patient*
yes (1)
no (2)
Patients in whom the study treatment can start no
less than 1 and not more than 9 hours after the
stroke's onset*
Yes
No
Patients with moderate-severe degree of
neurological deficit in the 9 hours after stroke
onset (defined as NIHSS score of 7 to 20)*
yes (1)
no (2)
Patients that can understand the requirements of
the study and are willing to provide written
informed consent (If the subject is incapacitated,
informed consent will be sought from a legally
acceptable representative.)*
yes (1)
no (2)
Exclusion Criteria
Patients with a brain (intracerebral or
subarachnoid) hemorrhage per screening
computed tomography scan*
yes (1)
no (2)
candidates for thrombolytic therapy for the current
stroke*
yes (1)
no (2)
patients having a mental impairment that renders
them incapable to understand the study's
requirements*
yes (1)
no (2)
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patients with other diseases that in the
investigator's opinion may lead, independently of
the current stroke, to further deterioration in the
subject's neurological status during the trial
period, or may confuse the evaluation of the
present stroke*
yes (1)
no (2)
Patients likely to undergo a procedure involving
cardiopulmonary bypass during the study period*
yes (1)
no (2)
Patients with medical conditions that may not
enable them to complete the study (e.g life-
threatening diseases,)*
yes (1)
no (2)
Patients whose condition improves already during
the screening period*
yes (1)
no (2)
Patients who already have functional limitations
before the present study (retrospective Modified
Rankin Scale score of >3)*
yes (1)
no (2)
Patients who suffered a stroke within the past 90
days that seems to have been in the same brain
region as the current acute stroke*
Yes
No
Patients with severe hypertension (systolic BP
>210 mm Hg or diastolic BP >120 mm Hg) or
hypotension (systolic BP <90 mm Hg),*
yes (1)
no (2)
Patients with significant history of renal or liver
disease(s) (serum creatinine of > 2.0 mg/dL,
alanine aminotransferase, aspartate
aminotransferase, or gamma-glutamyl transferase
values of > threefold the upper normal limit)*
yes (1)
no (2)
Patients with a platelet count of <100,000/mm3*
yes (1)
no (2)
Female patients of childbearing potential who are
not using adequate and effective birth control
measures or who are pregnant or lactating (the
screening evaluation of female subjects of
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childbearing potential will include a serum
pregnancy test.)*
yes (1)
no (2)
Patients who are users of addictive agents, or
alcoholics*
yes (1)
no (2)
Patients who have received an investigational
drug within the 90 days before the present stroke
or such that are past recipients of DP-b99*
yes (1)
no (2)
Medical concepts
Age*
Diagnosis*
Ischemic stroke*
Disorder of language*
Visual field defect*
Hemi-inattention*
Onset*
NIH-SS*
Neurologic deficit*
Informed Consent*
Compliance*
Brain hemorrhage*
Therapeutic procedure*
Medication*
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Mental impairment disorders*
Cardiopulmonary bypass operation*
Life expectancy*
Rankin score*
Hypertensive disease*
Hypotension*
Creatinine*
GPT (Serum)*
GOT (Serum)*
Gamma Glutamyl Transpeptidase Measurement*
Platelet count - finding*
pregnant*
Breast feeding, Nursing*
Contraception*
Alcohol abuse*
Drug abuse*
Enrollment*
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Ersterhebung CRF AML2003 AML
Prospektive, randomisierte, multizentrische Therapie
optimierungsstudie - Studienprotokoll AML2003
All rights reserved. Please visit https://medical-data-
models.org/forms/9696
Ersterhebung
Allgemeine Angaben
Klinik-Nr.:*
Patienten-Nr.: 2-*
Patienten-Initialen: (Nachname/Vorname)*
Patientendaten
Name:*
Geburtsdatum:*
Vorname:*
Geschlecht:*
männlich (1)
weiblich (2)
Anamnesestatus (Bitte tragen Sie die
entsprechende Ziffer in das Kästchen ein.)*
de novo AML                           1 (1)
AML nach MDS                        2 (2)
AML nach Chemo- bzw. Strahlentherapie
3 (3)
de novo MDS RAEB-2           4 (4)
MDS RAEB-2 nach Chemo- bzw.
Strahlentherapie         5 (5)
FAB-Klassifikation für Patienten mit Status 1 bis 3
[Bitte tragen Sie die entsprechende Ziffer in das
Kästchen ein. (Wenn FAB-Typ unbekannt = 0)]*
M0 (1)
RAEB-T (10)
M1 (2)
M2 t(8,21) AML1/ETO (3a)
M2baso t(6,9) DEK/CAN (3b)
FAB M4 (4)
M4Eo - Akute myelomonozytäre
Leukämie mit abnormen Eosinophilen
(5)
FAB M5a (6a)
FAB M5b (6b)
FAB M6 (7)
FAB M7 (8)
RAEB (9)
WHO-Klassifikation*
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unbekannt (0)
t(8,21), AML1/ETO (1a)
inv(16), t(16,16), CBFbeta/MYH11 (1b)
abnl(11q23) (1c)
Mehrliniendysplasie mit
vorangegangenem MDS (2a)
Mehrliniendysplasie ohne
vorangegangenem MDS (2b)
therapieinduziert nach alkylierenden
Substanzen (3a)
therapieinduziert nach
Epipodophyllotoxinen (3b)
nicht anders klassifizierbar - minimal-
differenziert (4a)
ohne Ausreifung (4b)
mit Ausreifung (4c)
myelomonozytär (4d)
monoblastär oder monozytär (4e)
Monoblast (4f)
Monozyt (4g)
Erythrozytenleukämie (4h)
Megakaryoblastenleukämie (4i)
Basophilenleukämie (4j)
akute Myelofibrose (4k)
Myeloides Sarkom (Chlorom) (4l)
RAEB-2 (5)
Klinischer Befund
ECOG-Status bei Aufnahme*
0 (0)
1 (1)
2 (2)
3 (3)
4 (4)
Death (5)
Blutung*
Ja
Nein
Infektionen*
Ja
Nein
Temperatur > 38°C*
Ja
Nein
Gingivahyperplasie*
Ja
Nein
Lymphome*
Ja
Nein
Lebergröße (in MCL sonographisch) [cm]*
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Milzgröße (Länge sonographisch) [cm]*
Extramedulläre Manifestation, Lokalisation:*
andere Symptome:*
Randomisierung
Der Patient wurde in folgenden Therapiearm
randomisiert (Bitte tragen Sie den
entsprechenden Buchstaben in das Kästchen
ein.):*
A (nicht intensiviert; Standard-
Postremission mit 3xAra-C) (1)
B (intensiviert; Standard-Postremission
mit 3xAra-C) (2)
C (nicht intensiviert; Standard-
Postremission mit MAC/MAMAC/MAC)
(3)
D (intensiviert; Standard-Postremission
mit MAC/MAMAC/MAC) (4)
Unterschrift
Datum*
Name des Studienarztes/Unterschrift*
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Diagnostic ECG
The patient's ECG.
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=ACFB66E7-
BCB1-6D16-E040-BB89AD4363C3
All rights reserved. Please visit https://medical-data-
models.org/forms/9698
Diagnostic ECG
Diagnostic ECG
Visit Date
Course #
Day in Course (Cycle)
Date of Examination (Enter the date the ECG
was performed.)
Time (Enter the time the ECG was performed.)
QRSD Interval (Enter the QRS duration QRSD
interval in milliseconds.)
QT Interval (Enter the QT interval in
milliseconds.)
QTC (corrected) Interval (Enter the QTC interval
in milliseconds.)
PR Interval (Enter the PR interval in
milliseconds.)
ECG Impression (Select one of the following
summary finding:)
Abnormal (A)
Borderline (B)
Normal (N)
Rate (Enter the patients pulse rate.)
Rhythm (Select one of the following rhythm
finding:)
Abnormal (A)
Normal (N)
Arrhythmia type (Select the patients arrhythmia
type.)
Asystole (Asystole)
Atrial Fibrillation (Atrial fibrillation)
Atrial Flutter (Atrial flutter)
Atrial Tachycardia/paroxysmal Atrial
Tachycardia (pat) (Atrial
tachycardia/Paroxysmal Atrial
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Tachycardia (PAT))
Atrioventricular Block: First Degree Block
(AV block: First degree block)
Atrioventricular Block: Second Degree
Motitz Type I (wenckebach) (AV block:
Second degree Motitz Type I
(Wenckebach))
Atrioventricular Block: Second Degree
Motitz Type II (AV block: Second degree
Motitz Type II)
Atrioventricular Block: Third Degree
(complete Av Bloc (AV block: Third
degree (Complete AV block))
Bigeminy (Bigeminy)
Bundle Branch Block (Bundle branch
block)
Conduction Abnormality, Not Otherwise
Specified (Conduction abnormality NOS)
Idioventricular Rhythm (Idioventricular
rhythm)
Nodal/junctional Arrhythmia
(Nodal/Junctional arrhythmia)
Sinus Rhythm (Normal Sinus rhythm)
Paced Rhythm (Paced Rhythm)
Premature Ventricular Contractions
(pvcs) (Premature ventricular
contractions (PVCs))
Prolonged Qtc Interval (Prolonged QTc
interval)
Sick Sinus Syndrome (Sick Sinus
Syndrome)
Sinus Bradycardia (Sinus bradycardia)
Sinus Tachycardia (Sinus tachycardia)
Stokes-adams Syndrome (Stokes-
Adams Syndrome)
Supraventricular Arrhythmia, Not
Otherwise Specified (Supraventricular
arrhythmia NOS)
Supraventricular Extrasystoles
(Supraventricular extrasystoles)
Supraventricular Tachycardia (svt)
(Supraventricular tachycardia (SVT))
Torsade De Pointes (Torsade de pointes)
Trigeminy (Trigeminy)
Ventricular Arrhythmia, Not Otherwise
Specified (Ventricular arrhythmia NOS)
Ventricular Fibrillation (Ventricular
fibrillation)
Ventricular Flutter (Ventricular flutter)
Ventricular Tachycardia (Ventricular
tachycardia)
Wolff-parkinson-white Syndrome (Wolff-
Parkinson-White Syndrome)
P Wave (Select one of the following P Wave
finding:)
Abnormal (A)
Normal (N)
QRS Complex (Select one of the following QRS
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Complex finding:)
Abnormal (A)
Normal (N)
ST Segment (Select one of the following ST
Segment finding:)
Abnormal (A)
Normal (N)
Comments (Enter comments applicable to the
ECG.)
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Vaccine Administration Form
(NCT00513526)
AMC-052 Vaccine Administration Form
Human Papillomavirus Vaccine Therapy in Treating Men
With HIV-1 Infection
NCT00513526
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=39520C70-
99B3-4542-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/9699
Vaccine Administration Form
(NCT00513526)
Vaccine Module
Date of vaccination
Vaccination Site
Dominant Arm (Dominant arm)
Left Thigh (Left thigh)
Nondominant Arm (Nondominant arm)
Right Thigh (Right thigh)
Amount of vaccine administered
Time vaccine administered
Were there any delays in dose administration (If
yes,)
Yes
No
Duration Delay (If dose delay was due to an
adverse event, submit an Adverse Event AE
form)
Did the participant experience syncope following
vaccination
Yes
No
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HPV Antibody Collection and Shipping
Form (NCT00513526)
AMC-052 Serum HPV Antibody Collection and Shipping
Form
Human Papillomavirus Vaccine Therapy in Treating Men
With HIV-1 Infection
NCT00513526
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=546E2EAC-
07C0-32E8-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/9701
HPV Antibody Collection and
Shipping Form (NCT00513526)
Probe
Proben ID
Hospital Admission Ordinal Number
Specimen collected
Ja
Nein
Specimen collection date
Specimen Count
Specimen shipped
Ja
Nein
Additional Specimen submitted
Ja
Nein
Specimen Destination Site
Acsr (ACSR)
Merck And Co., Inc. (Merck)
Versanddatum
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Hematology form for C3D 3.12 Adopters
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=FF067363-
11AF-63F6-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/9702
HEMATOLOGY
Hematology lab
Course Number
Course Day Number
Sample Collection Date
Time
Lab Test
Absolute Neutrophil Count (Absolute
Neutrophil Count (ANC), Blood)
Atypical Lymphocytes, #, Blood (Atypical
Lymphocytes, #, Blood)
Basophils, %, Blood (Basophils, %,
Blood)
Blasts, #, Blood (Blasts, #, Blood)
Eosinophils, %, Blood (Eosinophils, %,
Blood)
Erythrocyte Sedimentation Rate (esr),
Blood (Erythrocyte Sedimentation Rate
(ESR), Blood)
Hematocrit, %, Blood (Hematocrit, %,
Blood)
Hemoglobin, Blood (Hemoglobin, Blood)
Lymphocytes, %, Blood (Lymphocytes,
%, Blood)
Monocytes, %, Blood (Monocytes, %,
Blood)
Neutrophil Bands, %, Blood (Neutrophil
Bands, %, Blood)
Neutrophils, %, Blood (Neutrophils, %,
Blood)
Partial Thromboplastin Time (Partial
Prothromboplastin Time (PTT), Blood)
Blood Platelets (Platelets, Blood)
Prothrombin Time (Prothrombin Time
(PT), Blood)
Red Blood Cells (rbc), #, Blood (Red
Blood Cells (RBC), #, Blood)
Reticulocytes, %, Red Blood Cells
(Reticulocytes, %, Red Blood Cells)
Blood Leukocyte Count (White Blood
Cells (WBC), #, Blood)
White Blood Cells (wbc), Other, % Blood
(White Blood Cells (WBC), Other, %
Blood)
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Laboratory Test Finding
Lab Unit of Measure Name
Per 100 Identifiable White Blood Cells
(/100 WBC)
Per Millimeter Cubed (/mm3)
Percent (%)
Percent Per 100 Wbc (%/100 WBC)
10e12 Cells Per Liter (10E12 Cells/L)
10e3 Cells Per Microliter (10E3
Cells/microL)
10e6 Cells (10E6 Cells)
10e6 Cells Per Microliter (10E6
Cells/microL)
10e6 Cells Per Millimeter Cubed (10E6
Cells/mm3)
10e7 Cells Per Kilogram (10E7 Cells/kg)
10e8 Cells (10E8 Cells)
10e9 Cells (10E9 Cells)
10e9 Cells Per Liter (10E9 Cells/L)
Complement Activity Enzyme Unit (CAE
Unit)
Cells Per Microliter (Cells/microL)
Copies (Copies)
Cubic Microns (cubic microns)
Enzyme Unit (EU)
Enzyme Units Per Deciliter (EU/dL)
Enzyme Units Per Milliliter (EU/mL)
Femtoliter (fL)
Grams (g) (g)
Gram Per 24 Hours (g/24hr)
Gram Per Deciliter (g/dL)
Gram Per Liter (g/L)
Gram Per Microliter (g/microL)
Per High Power Field (HPF)
International Unit (Iunit)
International Unit Per Liter (IUnit/L)
International Unit Per Meter Squared
(IUnit/m2)
Iu/ml (IUnit/mL)
Iu/ml (IUnit/mL)
Kilounit Per Liter (kU/L)
Liter (L)
Liters Per Minute (L/min)
Per Low Power Field (LPF)
Microgram Per 24 Hours (mcg/24hr)
Microgram Per Deciliter (mcg/dL)
Microgram Per Liter (mcg/L)
Microgram Per Milliliter (mcg/mL)
Microgram Per Specimen (mcg/spec)
Milliequivalent (mEq)
Milliequivalents Per 24 Hours (mEq/24hr)
Milliequivalent Per Deciliter (mEq/dL)
Milliequivalent Per Kilogram (mEq/kg)
Milliequivalent Per Liter (mEq/L)
Milligram (mg)
Milligram Per 24 Hours (mg/24hr)
Milligram Per Deciliter (mg/dL)
Milligram Per Kilogram (mg/kg)
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Milligram Per Liter (mg/L)
Milligram Per Milliliter (mg/mL)
Milligram Per Milliliter Per Minute
(mg/mL/min)
Micro International Unit Per Milliliter
(microIU/mL)
Microliter (microL)
Micromole Per 24 Hours (micromol/24hr)
Micromole Per Deciliter (micromol/dL)
Micromole Per Liter (micromol/L)
Million Plaque Forming Units (mill PFU)
Million (Million)
Million Per Microliter (Million/microL)
Million Per Millimeter Cubed
(Million/mm3)
Milliinternational Unit (miu)
Milliinternational Units Per Meter
Squared (miu/m2)
Milliinternational Unit Per Milliliter
(miu/mL)
Milliter (mL)
Milliliter Per Minute (mL/min)
Milliliter Per Minute Times 1.73 Times
Bsa (mL/min/1.73/BSA)
Milliter Per Minute Per Millimeters Of
Mercury (mL/minute/mmHg)
Millimeter Per Hour (mm/hr)
Millimeter Cubed (mm3)
Millimeter Of Mercury (mmHg)
Millimole (mmol)
Millimole Per 24 Hours (mmol/24hr)
Millimole Per Liter (mmol/L)
Milliosmole Per Kilogram (mosmol/kg)
Million Units Per Milliliter (MU/mL)
Not Applicable; No Uom Required (NA)
Nanogram Per Deciliter (ng/dL)
Nanograms Per Milliliter (ng/mL)
Nanogram Per Milliliter Per Hour
(ng/mL/hr)
Nanomole Per Liter (nmol/L)
Nanomole Per Milligram Of Protein
(nMol/mg protein)
Nanomole Per Milliliter (nmol/mL)
No Source Data (No Srce)
Picograms (pg)
Picogram Per Deciliter (pg/dL)
Picrogram Per Milliliter (pg/mL)
Pgpge2/mg Protein (pgPGE2/mg
protein)
Picomole Per Liter (pmol/L)
Ratio (Ratio)
Rna Copies Per Milliliter (RNA
copies/mL)
Seconds (sec)
Thousand (Thousand)
Thousand Per Microliter
(Thousand/microL)
Thousand Per Millimeter Squared
(Thousand/mm2)
Thousand Per Millimeter Cubed
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(Thousand/mm3)
Titer (Titer)
Unit (Unit)
Unit Per 24 Hours (Unit/24hr)
Unit Per Liter (Unit/L)
Unit Per Meter Squared (Unit/m2)
Unit Per Millilliter (Unit/mL)
Unit Per Millimeters Cubed (Unit/mm3)
Unknown (Unknown)
Test Result Significance Indicator
Yes
No
Laboratory Test Normal Reference Range Text
Laboratory Test Normal Range Indicator
High (High)
Low (Low)
Nonnumeric (Nonnum)
No Range (Norang)
Normal (Normal)
Common Toxicity Criteria Adverse Event Grade
No Adverse Event Or Within Normal
Limits (0)
Mild Adverse Event (1)
Moderate Adverse Event (2)
Severe And Undesirable Adverse Event
(3)
Life-threatening Or Disabling Adverse
Event (4)
Death Related To Adverse Event (5)
Comments
Note Date
Research Comments Text
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Multiple Sclerosis - Current treatment and
status (REGIMS)
Aktuelle verlaufsmodifizierende MS-Therapie
http://epi.uni-muenster.de
All rights reserved. Please visit https://medical-data-
models.org/forms/9706
Multiple Sclerosis - Current
treatment and status (REGIMS)
Kortisontherapie
Erfolgt zurzeit eine zusätzliche Therapie mit
Kortison?*
Ja
Nein
Dosis in (mg) pro Darreichung*
Kortison Therapiebeginn*
Wenn zurzeit Therapie mit Kortison, bitte Grund
dafür angeben*
aktuelle Schubtherapie (1)
Erhaltungstherapie (2)
sonstige (3)
Erläuterung Indikation Kortison-Therapie*
Initiale Darreichungsform*
IV (1)
Oral (2)
Intrathekal (3)
Ambulant oder stationär durchgeführt*
Ambulant (1)
Stationär (2)
MRT
Wurde jemals aufgrund der MS ein MRT
durchgeführt?*
Nein (0)
Unbekannt (1)
Ja, 1 mal (2)
Ja, mehr als 1 mal (3)
Datum des letzten bekannten MRTs
MRT Datum unbekannt
Ja
Nein
Was für ein MRT wurde durchgeführt?
kranial (1)
spinal (2)
kranial + spinal (3)
Wurde bei diesem/r Patient/in jemals eine
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der folgenden Erkrankungen ärztlich
diagnostiziert?
Diagnose*
Diabetes mellitus (1)
Hepatitis B oder C (10)
Herpes Infektion (11)
Medikamentenallergien (12)
Andere Allergien (13)
Autoimmunerkrankungen (z.B.
Goodpasture-Syndrom) (14)
HIV-Infektion (15)
PML (Progressive multifokale
Leukenzephalopathie) (16)
Lungenentzündung (17)
Wiederkehrende Harnwegsinfekte (>3/3
Jahren) (18)
Infektion durch Pilze (z.B. in
Oesophagus, Lunge) (19)
Bluthochdruck (2)
Andere opportunistische Infektionen (z
B. Toxoplasmose) (20)
Haarausfall (21)
Tuberkulose (22)
Retinopathie, Makulaödem oder Diplopie
(23)
Hautsymptome bei s.c. oder i.v.
verabreichten Medikamenten (z.B.
Entzündungen,Nekrosen an der
Injektionsstelle) (24)
Veränderungen des Blutes (z.B. Anämie,
Thrombopenie, Lymphopenie) (25)
Migräne und / oder
Spannungskopfschmerzen (26)
Diarrhoe (>3 Tage Durchfall) (27)
Arthralgien, Muskelspastiken (28)
Gewichtsverlust oder -zunahme (>5 kg)
(29)
Herzschwäche/-insuffizienz (3)
Krebserkrankungen (30)
Andere Begleiterkrankung (31)
Herzrhythmusstörung (4)
Depression (5)
Schilddrüsenunter- od. überfunktion (6)
Nierenfunktionseinschränkung (7)
Bauchspeicheldrüsenentzündung (8)
Leberzirrhose (9)
Diagnosedatum*
Details zur Diagnose (Ort der Diagnose, Art der
Allergie oder Infektion etc.)
Medikamentöse Behandlung?
Ja
Nein
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Details der medikamentösen Behandlung (z.B.
Chemotherapie-Substanzen)
Therapie aufgrund von Krebserkrankung
Operation (1)
Bestrahlung (2)
Chemotherapie (3)
Pregnancy
Liegt aktuell eine Schwangerschaft vor? Falls ja,
bitte Meldebogen Schwangerschaft ausfüllen
Ja
Nein
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Quality assurance cardiac pacemaker
Implantation (AQUA)
Documentation form for quality assurance in German
Health Care by the Institute for Applied Quality
Improvement and Research in Health Care (Aqua),
https://www.aqua-institut.de/en/home. Internal Aqua form
version: 09-1 Specification 2015 V02".
All rights reserved. Please visit https://medical-data-
models.org/forms/9707
Quality assurance cardiac
pacemaker (AQUA)
Art der Versicherung
Institutionskennzeichen der Krankenkasse der
Versichertenkarte (http://www.arge-ik.de)*
Patientenidentifizierende Daten
eGK-Versichertennummer*
Basisdokumentation
Institutionskennzeichen*
PLZ Entlassender Standort*
Betriebsstätten-Nummer*
Fachabteilung*
Innere Medizin (0100)
Innere Medizin/Schwerpunkt Geriatrie
(0102)
Innere Medizin/Schwerpunkt Kardiologie
(0103)
Innere Medizin/Schwerpunkt
Nephrologie (0104)
Innere Medizin/Schwerpunkt
Hämatologie und internistische
Onkologie (0105)
Innere Medizin/Schwerpunkt
Endokrinologie (0106)
Innere Medizin/Schwerpunkt
Gastroenterologie (0107)
Innere Medizin/Schwerpunkt
Pneumologie (0108)
Innere Medizin/Schwerpunkt
Rheumatologie (0109)
Innere Medizin/Schwerpunkt Lungen-
und Bronchialheilkunde (0114)
Innere Medizin/Tumorforschung (0150)
Innere Medizin/Schwerpunkt
Coloproktologie (0151)
Innere Medizin/Schwerpunkt
Infektionskrankheiten (0152)
Innere Medizin/Schwerpunkt Diabetes
(0153)
Innere Medizin/Schwerpunkt
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Naturheilkunde (0154)
Innere Medizin/Schwerpunkt
Schlaganfallpatienten (Stroke units,
Artikel 7 § 1 Abs. 3 (0156)
Innere Medizin (0190)
Geriatrie (0200)
Geriatrie/Schwerpunkt Frauenheilkunde
(0224)
Geriatrie/Tagesklinik (für teilstationäre
Pflegesätze) (0260)
Geriatrie/Nachtklinik (für teilstationäre
Pflegesätze) (0261)
Geriatrie (0290)
Kardiologie (0300)
Nephrologie (0400)
Nephrologie/Schwerpunkt Pädiatrie
(0410)
Nephrologie/Intensivmedizin (0436)
Nephrologie (0490)
Hämatologie und internistische
Onkologie (0500)
Hämatologie und internistische
Onkologie/Schwerpunkt Pädiatrie (0510)
Hämatologie und internistische
Onkologie/Schwerpunkt Frauenheilkunde
(0524)
Hämatologie und internistische
Onkologie/Schwerpunkt
Strahlenheilkunde (0533)
Hämatologie und internistische
Onkologie (0590)
Endokrinologie (0600)
Endokrinologie/Schwerpunkt
Gastroenterologie (0607)
Endokrinologie/Schwerpunkt Pädiatrie
(0610)
Endokrinologie (0690)
Gastroenterologie (0700)
Gastroenterologie/Schwerpunkt
Endokrinologie (0706)
Gastroenterologie/Schwerpunkt Pädiatrie
(0710)
Gastroenterologie (0790)
Pneumologie (0800)
Rheumatologie (0900)
Rheumatologie/Schwerpunkt Pädiatrie
(0910)
Rheumatologie (0990)
Pädiatrie (1000)
Pädiatrie/Schwerpunkt Nephrologie
(1004)
Pädiatrie/Schwerpunkt Hämatologie und
internistische Onkologie (1005)
Pädiatrie/Schwerpunkt Endokrinologie
(1006)
Pädiatrie/Schwerpunkt Gastroenterologie
(1007)
Pädiatrie/Schwerpunkt Rheumatologie
(1009)
Pädiatrie/Schwerpunkt Kinderkardiologie
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(1011)
Pädiatrie/Schwerpunkt Neonatologie
(1012)
Pädiatrie/Schwerpunkt Lungen- und
Bronchialheilkunde (1014)
Pädiatrie/Schwerpunkt Kinderneurologie
(1028)
Pädiatrie/Schwerpunkt Perinatalmedizin
(1050)
Langzeitbereich Kinder (1051)
Pädiatrie (1090)
Kinderkardiologie (1100)
Kinderkardiologie/Schwerpunkt
Intensivmedizin (1136)
Kinderkardiologie (1190)
Neonatologie (1200)
Kinderchirurgie (1300)
Lungen- und Bronchialheilkunde (1400)
Lungen- und
Bronchialheilkunde/Schwerpunkt
Pädiatrie (1410)
Lungen- und Bronchialheilkunde (1490)
Allgemeine Chirurgie (1500)
Allgemeine Chirurgie/Schwerpunkt
Kinderchirurgie (1513)
Allgemeine Chirurgie/Schwerpunkt
Unfallchirurgie (1516)
Allgemeine Chirurgie/Schwerpunkt
Gefäßchirurgie (1518)
Allgemeine Chirurgie/Schwerpunkt
Plastische Chirurgie (1519)
Allgemeine Chirurgie/Schwerpunkt
Thoraxchirurgie (1520)
Chirurgie/Schwerpunkt Orthopädie
(1523)
Allgemeine Chirurgie/Intensivmedizin (§
13 Abs. 2 Satz 3, 2. Halbsatz BPflV in
der am 31.12.2003 geltenden Fassung)
(1536)
Allgemeine Chirurgie/Schwerpunkt
Abdominal- und Gefäßchirurgie (1550)
Allgemeine Chirurgie/Schwerpunkt
Handchirurgie (1551)
Allgemeine Chirurgie (1590)
Unfallchirurgie (1600)
Neurochirurgie (1700)
Gefäßchirurgie (1800)
Plastische Chirurgie (1900)
Thoraxchirurgie (2000)
Thoraxchirurgie/Schwerpunkt
Herzchirurgie (2021)
Thoraxchirurgie/Intensivmedizin (2036)
Thoraxchirurgie/Schwerpunkt
Herzchirurgie Intensivmedizin (2050)
Thoraxchirurgie (2090)
Herzchirurgie (2100)
Herzchirurgie/Schwerpunkt
Gefäßchirurgie (2118)
Herzchirurgie/Schwerpunkt
Thoraxchirurgie (2120)
3 / 14
Quality assurance cardiac pacemaker Implantation (AQUA)
Herzchirurgie/Intensivmedizin (§ 13 Abs.
2 Satz 3 2. Halbsatz BPflV in der am
31.12.2003 geltenden Fassung) (2136)
Herzchirurgie/Schwerpunkt
Thoraxchirurgie Intensivmedizin (2150)
Herzchirurgie (2190)
Urologie (2200)
Orthopädie (2300)
Orthopädie/Schwerpunkt Rheumatologie
(2309)
Orthopädie/Schwerpunkt Chirurgie
(2315)
Orthopädie und Unfallchirurgie (2316)
Orthopädie (2390)
Frauenheilkunde und Geburtshilfe (2400)
Frauenheilkunde/Schwerpunkt Geriatrie
(2402)
Frauenheilkunde/Schwerpunkt
Hämatologie und internistische
Onkologie (2405)
Frauenheilkunde/Schwerpunkt
Endokrinologie (2406)
Frauenheilkunde (2425)
Frauenheilkunde und Geburtshilfe (2490)
Geburtshilfe (2500)
Hals-, Nasen-, Ohrenheilkunde (2600)
Augenheilkunde (2700)
Neurologie (2800)
Neurologie/Schwerpunkt Pädiatrie
(2810)
Neurologie/Schwerpunkt
Schlaganfallpatienten (Stroke units,
Artikel 7 § 1 Abs. 3 GKV-SolG) (2856)
Neurologie (2890)
Allgemeine Psychiatrie (2900)
Allgemeine Psychiatrie/Schwerpunkt
Neurologie (2928)
Allgemeine Psychiatrie/Schwerpunkt
Kinder- und Jugendpsychiatrie (2930)
Allgemeine Psychiatrie/Schwerpunkt
Psychosomatik/Psychotherapie (2931)
Allgemeine Psychiatrie/Schwerpunkt
Suchtbehandlung (2950)
Allgemeine Psychiatrie/Schwerpunkt
Gerontopsychiatrie (2951)
Allgemeine Psychiatrie/Schwerpunkt
Forensische Behandlung (2952)
Allgemeine Psychiatrie/Schwerpunkt
Suchtbehandlung, Tagesklinik (2953)
Allgemeine Psychiatrie/Schwerpunkt
Suchtbehandlung, Nachtklinik (2954)
Allgemeine Psychiatrie/Schwerpunkt
Gerontopsychiatrie, Tagesklinik (2955)
Allgemeine Psychiatrie/Schwerpunkt
Gerontopsychiatrie, Nachtklinik (2956)
Allgemeine Psychiatrie/Tagesklinik (für
teilstationäre Pflegesätze) (2960)
Allgemeine Psychiatrie/Nachtklinik (für
teilstationäre Pflegesätze) (2961)
Allgemeine Psychiatrie (2990)
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Kinder- und Jugendpsychiatrie (3000)
Kinder- und
Jugendpsychiatrie/Tagesklinik (für
teilstationäre Pflegesätze) (3060)
Kinder- und
Jugendpsychiatrie/Nachtklinik (für
teilstationäre Pflegesätze) (3061)
Kinder- und Jugendpsychiatrie (3090)
Psychosomatik/Psychotherapie (3100)
Psychosomatik/Psychotherapie/Schwerp
unkt Kinder- und Jugendpsychosomatik
(3110)
Psychosomatik/Psychotherapie/Tageskli
nik (für teilstationäre Pflegesätze) (3160)
Psychosomatik/Psychotherapie/Nachtkli
nik (für teilstationäre Pflegesätze) (3161)
Psychosomatik/Psychotherapie (3190)
Nuklearmedizin (3200)
Nuklearmedizin/Schwerpunkt
Strahlenheilkunde (3233)
Nuklearmedizin (3290)
Strahlenheilkunde (3300)
Strahlenheilkunde/Schwerpunkt
Hämatologie und internistische
Onkologie (3305)
Strahlenheilkunde/Schwerpunkt
Radiologie (3350)
Strahlenheilkunde (3390)
Dermatologie (3400)
Dermatologie/Tagesklinik (für
teilstationäre Pflegesätze) (3460)
Dermatologie (3490)
Zahn- und Kieferheilkunde, Mund- und
Kieferchirurgie (3500)
Intensivmedizin (3600)
Intensivmedizin/Schwerpunkt Innere
Medizin (3601)
Intensivmedizin/Schwerpunkt Kardiologie
(3603)
Intensivmedizin/Schwerpunkt Pädiatrie
(3610)
Intensivmedizin/Schwerpunkt
Neurochirurgie (3617)
Intensivmedizin/Schwerpunkt Chirurgie
(3618)
Intensivmedizin/Herzchirurgie (3621)
Intensivmedizin/Schwerpunkt Urologie
(3622)
Intensivmedizin/Schwerpunkt
Frauenheilkunde und Geburtshilfe (3624)
Intensivmedizin/Schwerpunkt Hals-,
Nasen-, Ohrenheilkunde (3626)
Intensivmedizin/Schwerpunkt Neurologie
(3628)
Operative Intensivmedizin/Schwerpunkt
Chirurgie (3650)
Intensivmedizin/Thorax-Herzchirurgie
(3651)
Intensivmedizin/Herz-Thoraxchirurgie
(3652)
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Intensivmedizin (3690)
sonstige Fachabteilung (3700)
Angiologie (3750)
Radiologie (3751)
Palliativmedizin (3752)
Schmerztherapie (3753)
Heiltherapeutische Abteilung (3754)
Wirbelsäulenchirurgie (3755)
Suchtmedizin (3756)
Visceralchirurgie (3757)
Sonstige Fachabteilung (3790)
Identifikationsnummer des Patienten*
Geburtsdatum*
Geschlecht*
männlich (1)
weiblich (2)
Aufnahmedatum Krankenhaus*
ASA-Klassifikation*
normaler, gesunder Patient (1)
Patient mit leichter Allgemeinerkrankung
(2)
Patient mit schwerer
Allgemeinerkrankung (3)
Patient mit schwerer
Allgemeinerkrankung, die eine ständige
Lebensbedrohung darstellt (4)
moribunder Patient, von dem nicht
erwartet wird, dass er ohne Operation
überlebt (5)
Führendes Symptom*
keines (asymptomatisch) (0)
Präsynkope/Schwindel (1)
Synkope einmalig (2)
Synkope rezidivierend (3)
synkopenbedingte Verletzung (4)
Herzinsuffizienz NYHA II (5)
Herzinsuffizienz NYHA III (6)
Herzinsuffizienz NYHA IV (7)
Symptome einer Vorhofpfropfung:
spontan oder infolge
Schrittmachersyndrom (8)
asymptomatisch unter externer
Stimulation (9)
sonstiges (99)
Führende Indikation zur
Schrittmacherimplantation*
AV-Block I (1)
kardiale Resynchronisationstherapie
(CRT) (10)
AV-Block II Wenckebach (2)
6 / 14
Quality assurance cardiac pacemaker Implantation (AQUA)
AV-Block II Mobitz (3)
AV-Block III (4)
Schenkelblock (5)
Sinusknotensyndrom (SSS) inklusive
BTS (bei paroxysmalem/persistierendem
Vorhofflimmern) (6)
Bradykardie bei permanentem
Vorhofflimmern (7)
Karotis-Sinus-Syndrom (CSS) (8)
Vasovagales Syndrom (VVS) (9)
sonstiges (99)
Ätiologie*
angeboren (1)
neuromuskulär (2)
infarktbedingt (3)
AV-Knoten-Ablation durchgeführt/geplant
(4)
sonstige Ablationsbehandlung (5)
Zustand nach herzchirurgischem Eingriff
(6)
Zustand nach Transkatheter-
Aortenklappenimplantation (TAVI) (7)
sonstige/unbekannt (9)
erwarteter Anteil ventrikulärer Stimulation*
>= 95% (1)
40% bis < 95% (2)
< 40% (3)
Diabetes mellitus*
nein (0)
ja, nicht insulinpflichtig (1)
ja, insulinpflichtig (2)
Nierenfunktion/Serum Kreatinin*
< (1)
> 1,5 mg/dl (> 133 µmol/l) bis < (2)
> 2,5 mg/dl (> 221 µmol/l), nicht
dialysepflichtig (3)
> 2,5 mg/dl (> 221 µmol/l),
dialysepflichtig (4)
unbekannt (8)
Präoperative Diagnostik
Vorhofrhythmus*
normofrequenter Sinusrhythmus (1)
Sinusbradykardie/SA-Blockierungen (2)
paroxysmales/ persistierendes
Vorhofflimmern/-flattern (3)
permanentes Vorhofflimmern (4)
Wechsel zwischen Sinusbradykardie und
Vorhofflimmern (BTS) (5)
sonstige (9)
AV-Block*
keiner (0)
AV-Block I. Grades, Überleitung < (1)
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AV-Block I. Grades, Überleitung > 300
ms (2)
AV-Block II. Grades, Typ Wenckebach
(3)
AV-Block II. Grades, Typ Mobitz (4)
AV-Block III. Grades (5)
nicht beurteilbar wegen Vorhofflimmerns
(6)
AV-Block nach HIS-Bündel-Ablation (7)
intraventrikuläre Leitungsstörungen*
keine (0)
Rechtsschenkelblock (RSB) (1)
Linksanteriorer Hemiblock (LAH) + RSB
(2)
Linksposteriorer Hemiblock (LPH) + RSB
(3)
Linksschenkelblock (4)
alternierender Schenkelblock (5)
sonstige (9)
QRS-Komplex*
< 120 ms (1)
120 bis < 150 ms (2)
> (3)
Pausen außerhalb von Schlafphasen*
keine Pause (0)
<= 3 s (1)
> 3 s bis <= 6 s (2)
> 6 s (3)
nicht bekannt (4)
Zusammenhang zwischen Symptomatik und
Bradykardie/Pausen*
kein Zusammenhang (0)
wahrscheinlicher Zusammenhang (1)
EKG-dokumentierter Zusammenhang (2)
keine Bradykardie / keine Pausen (3)
Spontanfrequenz außerhalb von Schlafphasen*
< 40/min (1)
40 bis unter 50/min (2)
>= 50/min (3)
nicht bekannt (4)
Ejektionsfraktion (EF)*
EF nicht bekannt*
Ja
Nein
AV-Knotendiagnostik (wenn führende Indikation
zur
Schrittmacherimplantation 1,2,3,4,5)*
keine (0)
Nachweis spontaner infrahisärer AV-
Blockierungen in EPU (1)
HV-Zeit >= 70 ms oder Provokation von
8 / 14
Quality assurance cardiac pacemaker Implantation (AQUA)
infrahisären Blockierungen in EPU (2)
positiver Adenosin-Test (3)
mehrere der vorgenannten Punkte (1, 2
oder 3) (4)
neurokardiogene Diagnostik  (wenn führende
Indikation zur
Schrittmacherimplantation 6,8,9)*
keine (0)
Karotissinusmassage mit synkopaler
Pause > 6 s (1)
Kipptisch positiv (2)
beides (3)
Kammerfrequenz regelmäßig  (wenn führende
Indikation zur
Schrittmacherimplantation 7)*
Ja
Nein
Chronotrope Inkompetenz bei Erkrankung des
Sinusknotens (wenn führende Indikation zur
Schrittmacherimplantation 1,2,3,4,5,6)*
Ja
Nein
konservative Therapie ineffektiv/ unzureichend
(wenn führende Indikation zur
Schrittmacherimplantation 9,10)*
Ja
Nein
Operation
OP-Datum*
Operationskodes (OPS-Schluessel) *
Zugang des implantierten Systems: Vena
cephalica*
Ja
Nein
Zugang des implantierten Systems: Vena
subclavia*
Ja
Nein
Zugang des implantierten Systems: andere*
Ja
Nein
Dauer des Eingriffs (Schnitt-Nahtzeit)*
Flächendosisprodukt*
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Flächendosisprodukt nicht bekannt*
Ja
Nein
Implantiertes System (postoperativ
funktionell aktive Anteile)
Schrittmacher-System*
VVI (1)
AAI (2)
DDD (3)
VDD (4)
CRT-System mit einer Vorhofsonde (5)
CRT-System ohne Vorhofsonde (6)
sonstiges (9)
Schrittmacher-Aggregat Hersteller*
Biotronik (1)
Vitatron (11)
St. Jude Medical (18)
Boston
Scientific/CPI/Guidant/Intermedics (3)
Medtronic (7)
Osypka (8)
nicht bekannt (89)
Sorin Biomedica/ELA Medical (9)
sonstiger (99)
Schrittmachersonden Vorhof: NBL-Code 1. Ziffer
(wenn System mit Vorhofsonde oder VDD oder
sonstiges System)*
bipolar (B)
multipolar (M)
unipolar (U)
Schrittmachersonden Vorhof: NBL-Code 2. Ziffer
(wenn System mit Vorhofsonde oder VDD oder
sonstiges System)*
keine Fixation (0)
aktive Fixation, z.B. Schraubsonde (A)
passive Fixation, z.B. Ankersonde (P)
Schrittmachersonden Vorhof: Hersteller*
Biotronik (1)
Vitatron (11)
St. Jude Medical (18)
Boston
Scientific/CPI/Guidant/Intermedics (3)
Medtronic (7)
Osypka (8)
nicht bekannt (89)
Sorin Biomedica/ELA Medical (9)
sonstiger (99)
Reizschwelle Vorhofsonde (intraoperativ, bei 0,5
ms)*
Reizschwelle Vorhofsonde nicht gemessen
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(intraoperativ, bei 0,5 ms)*
wegen Vorhofflimmerns (1)
aus anderen Gründen (9)
P-Wellen-Amplitude (intraoperativ)*
P-Wellen-Amplitude (intraoperativ) nicht
gemessen*
wegen Vorhofflimmerns (1)
fehlender Vorhofeigenrhythmus (2)
aus anderen Gründen (9)
Schrittmachersonden Ventrikel NBL-Code 1.
Ziffer (wenn System mit Ventrikelsonde oder
sonstiges System)*
bipolar (B)
multipolar (M)
unipolar (U)
Schrittmachersonden Ventrikel NBL-Code 2.
Ziffer (wenn System mit Ventrikelsonde oder
sonstiges System)*
keine Fixation (0)
aktive Fixation, z.B. Schraubsonde (A)
passive Fixation, z.B. Ankersonde (P)
Schrittmachersonden Ventrikel: Hersteller*
Biotronik (1)
Vitatron (11)
St. Jude Medical (18)
Boston
Scientific/CPI/Guidant/Intermedics (3)
Medtronic (7)
Osypka (8)
nicht bekannt (89)
Sorin Biomedica/ELA Medical (9)
sonstiger (99)
Reizschwelle Ventrikelsonde (intraoperativ, bei
0,5 ms)*
Reizschwelle Ventrikelsonde nicht gemessen
(intraoperativ, bei 0,5 ms)*
Ja
Nein
R-Amplitude (intraoperativ)*
R-Amplitude (intraoperativ) nicht gemessen*
kein Eigenrhythmus (1)
aus anderen Gründen (9)
Ventrikel (2. Sonde) NBL-Code 1. Ziffer*
bipolar (B)
multipolar (M)
unipolar (U)
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Ventrikel (2. Sonde) NBL-Code 2. Ziffer*
keine Fixation (0)
aktive Fixation, z.B. Schraubsonde (A)
passive Fixation, z.B. Ankersonde (P)
Hersteller*
Biotronik (1)
Vitatron (11)
St. Jude Medical (18)
Boston
Scientific/CPI/Guidant/Intermedics (3)
Medtronic (7)
Osypka (8)
nicht bekannt (89)
Sorin Biomedica/ELA Medical (9)
sonstiger (99)
Reizschwelle 2. Ventrikelsonde (intraoperativ, bei
0,5 ms)*
Reizschwelle 2. Ventrikelsonde nicht gemessen
(intraoperativ, bei 0,5 ms)*
Ja
Nein
R-Amplitude (intraoperativ)*
R-Amplitude nicht gemessen (intraoperativ)*
kein Eigenrhythmus (1)
aus anderen Gründen (9)
peri- bzw. postoperative Komplikation(en)*
Ja
Nein
Asystolie*
Ja
Nein
Kammerflimmern*
Ja
Nein
interventionspflichtiger Pneumothorax*
Ja
Nein
interventionspflichtiger Hämatothorax*
Ja
Nein
interventionspflichtiger Perikarderguss*
Ja
Nein
interventionspflichtiges Taschenhämatom*
Ja
Nein
12 / 14
Quality assurance cardiac pacemaker Implantation (AQUA)
Sondendislokation*
Ja
Nein
Sondendislokation Vorhof*
Ja
Nein
Sondendislokation Ventrikel*
keine (0)
1. Ventrikelsonde (1)
2. Ventrikelsonde (2)
beide (3)
Sondendysfunktion*
Ja
Nein
Sondendysfunktion Vorhof*
Ja
Nein
Sondendysfunktion Ventrikel*
keine (0)
1. Ventrikelsonde (1)
2. Ventrikelsonde (2)
beide (3)
postoperative Wundinfektion (nach Definition der
CDC)*
Ja
Nein
CDC-Klassifikation*
keine Infektion (0)
A1 (oberflächliche Infektion) (1)
A2 (tiefe Infektion) (2)
A3 (Räume/Organe) (3)
Sonstige interventionspflichtige Komplikation*
Ja
Nein
Entlassung
Entlassungsdatum Krankenhaus*
Entlassungsgrund*
Behandlung regulär beendet (1)
Entlassung in eine Pflegeeinrichtung (10)
Entlassung in ein Hospiz (11)
externe Verlegung zur psychiatrischen
Behandlung (13)
Behandlung aus sonstigen Gründen
beendet, nachstationäre Behandlung
vorgesehen (14)
Behandlung gegen ärztlichen Rat
beendet, nachstationäre Behandlung
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vorgesehen (15)
interne Verlegung mit Wechsel zwischen
den Entgeltbereichen der DRG-
Fallpauschalen, (17)
Behandlung regulär beendet,
nachstationäre Behandlung vorgesehen
(2)
Fallabschluss (interne Verlegung) bei
Wechsel zwischen voll- und
teilstationärer Behandlung (22)
Entlassung zum Jahresende bei
Aufnahme im Vorjahr (für Zwecke der
Abrechnung - PEPP, § 4 PEPPV 2013)
(25)
Behandlung aus sonstigen Gründen
beendet (3)
Behandlung gegen ärztlichen Rat
beendet (4)
Zuständigkeitswechsel des
Kostenträgers (5)
Verlegung in ein anderes Krankenhaus
(6)
Tod (7)
Verlegung in ein anderes Krankenhaus
im Rahmen einer Zusammenarbeit (§ 14
Abs. 5 Satz 2 BPflV in der am
31.12.2003 geltenden Fassung) (8)
Entlassung in eine
Rehabilitationseinrichtung (9)
1. Entlassungsdiagnose (ICD-10-GM)*
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Multiple Sclerosis - Base Sheet (REGIMS)
Medizinischer Basisbogen Multiple Sklerose
http://epi.uni-muenster.de
All rights reserved. Please visit https://medical-data-
models.org/forms/9713
Multiple Sclerosis - Base Sheet
(REGIMS)
Allgemeine Informationen
Identifikationsnummer*
Visitendatum*
Schriftliches Einverständnis vorliegend?*
Ja
Nein
Zentrums ID*
Geschlecht*
männlich (1)
weiblich (2)
Geburtsjahr*
Krankheitsspezifische Angaben
Datum der ersten MS-Symptomatik*
Datum der MS-Diagnosestellung*
Verlaufsform der Multiplen Sklerose*
noch nicht bestimmbar (1)
Klinisch isoliertes Syndrom (KIS) (2)
Schubförmige remittierende MS (RRMS)
(3)
Sekundär progrediente MS (SPMS) (4)
Primär progrediente MS (PPMS) (5)
Anzahl der Schübe in den letzten 24 Monaten*
>10 (>10)
0 (0)
1 (1)
10 (10)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
7 (7)
8 (8)
9 (9)
Heutiger EDSS-Score basierend auf
neurologischer Untersuchung*
1 / 5
EDSS vor 12 Monaten
Aktuelle MS bedingte Symptome
Symptom der MS
Spastik (1)
Dysarthrie/Dysphonie (10)
Dysphagie (11)
Epileptische Anfälle (12)
Sonst. Paroxysmen (13)
Müdigkeit (Fatigue) (2)
Schmerzen (3)
Miktion gestört (4)
Defäkation gestört (5)
Sexuelle Störung (6)
Ataxie/Tremor (7)
Kognitive Störung (8)
Okulomot. Störung (9)
Frühere MS-Therapie
Bisher keine verlaufsmodifizierende MS-
Therapie*
Ja
Nein
Medikation*
Interferon beta-1a Injectable Solution
(Avonex) (1)
Cyclophosphamid (10)
Rituximab (11)
Immunglobuline (12)
Medikation aus einer MS-Studie (13)
Alemtuzumab (Lemtrada) (14)
Teriflunomide (Aubagio) (15)
Fumarat (BG-12) (Tecfidera) (16)
Andere (17)
Interferon beta-1a SC (Rebif 22μg, Rebif
44 μg) (2)
Interferon beta-1b SC (Betaferon,
Extavia) (3)
Glatirameracetat (Copaxone) (4)
Natalizumab (Tysabri) (5)
Fingolimod (Gilenya) (6)
Azathioprin (7)
Methotrexat (8)
Mitoxantron (9)
Andere Medikation*
Medikation Beginn Monat /Jahr*
Medikation Ende Monat /Jahr*
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Grund für Therapieende (Bitte ALLE Gründe
ankreuzen)*
Nebenwirkungen, z.B. Übelkeit,
Zunahme der Spastik (1)
Fehlende Wirksamkeit - Schübe unter
Therapie/Progression (2)
Anderer Grund bitte angeben (3)
wenn anderer Grund, bitte angeben*
Aktuelle MS-Therapie
Medikation*
Interferon beta-1a Injectable Solution
(Avonex) (1)
Cyclophosphamid (10)
Rituximab (11)
Immunglobuline (12)
Medikation aus einer MS-Studie (13)
Alemtuzumab (Lemtrada) (14)
Teriflunomide (Aubagio) (15)
Fumarat (BG-12) (Tecfidera) (16)
Andere (17)
Interferon beta-1a SC (Rebif 22μg, Rebif
44 μg) (2)
Interferon beta-1b SC (Betaferon,
Extavia) (3)
Glatirameracetat (Copaxone) (4)
Natalizumab (Tysabri) (5)
Fingolimod (Gilenya) (6)
Azathioprin (7)
Methotrexat (8)
Mitoxantron (9)
Andere Medikation*
Medikation Beginn Monat /Jahr*
Dosis pro Infusion / Einnahme
Einheit
mg (mg)
µg (µg)
Wie oft wird die aktuelle Therapie
infundiert/eingenommen?
pro
Zeiteinheit
Tag (1)
Woche (2)
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Monat (3)
Jahr (4)
Andere (5)
Andere Art der Verabreichung
Kortisontherapie
Erfolgt zurzeit eine zusätzliche Schubtherapie mit
Kortison?
Ja
Nein
MRT
Wurde in den letzten 12 Monaten aufgrund der
MS Erkrankung ein MRT durchgeführt?
Unbekannt (0)
Nein (1)
kraniales MRT (2)
spinales MRT (3)
kraniales und spinales MRT (4)
Wurde bei diesem/r Patient/in jemals eine
der folgenden Erkrankungen ärztlich
diagnostiziert?
Diagnose*
Diabetes mellitus (1)
Hepatitis B oder C (10)
Herpes Infektion (11)
Medikamentenallergien (12)
Andere Allergien (13)
Autoimmunerkrankungen (z.B.
Goodpasture-Syndrom) (14)
HIV-Infektion (15)
PML (Progressive multifokale
Leukenzephalopathie) (16)
Lungenentzündung (17)
Wiederkehrende Harnwegsinfekte (>3/3
Jahren) (18)
Infektion durch Pilze (z.B. in
Oesophagus, Lunge) (19)
Bluthochdruck (2)
Andere opportunistische Infektionen (z
B. Toxoplasmose) (20)
Haarausfall (21)
Tuberkulose (22)
Retinopathie, Makulaödem oder Diplopie
(23)
Hautsymptome bei s.c. oder i.v.
verabreichten Medikamenten (z.B.
Entzündungen,Nekrosen an der
Injektionsstelle) (24)
Veränderungen des Blutes (z.B. Anämie,
Thrombopenie, Lymphopenie) (25)
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Migräne und / oder
Spannungskopfschmerzen (26)
Diarrhoe (>3 Tage Durchfall) (27)
Arthralgien, Muskelspastiken (28)
Gewichtsverlust oder -zunahme (>5 kg)
(29)
Herzschwäche/-insuffizienz (3)
Krebserkrankungen (30)
Andere Begleiterkrankung (31)
Herzrhythmusstörung (4)
Depression (5)
Schilddrüsenunter- od. überfunktion (6)
Nierenfunktionseinschränkung (7)
Bauchspeicheldrüsenentzündung (8)
Leberzirrhose (9)
Diagnosedatum*
Details zur Diagnose (Ort der Diagnose, Art der
Allergie oder Infektion etc.)
Medikamentöse Behandlung?
Ja
Nein
Details der medikamentösen Behandlung (z.B.
Chemotherapie-Substanzen)
Therapie aufgrund von Krebserkrankung
Operation (1)
Bestrahlung (2)
Chemotherapie (3)
Schwangerschaft, aktuell
Patientin schwanger
Ja
Nein
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Quality assurance Coronary
Angiography and Percuteanous
Intervention (PCI) -Procedure
(AQUA)
Procedure
number of procedure during this stay?*
Procedure date (TT.MM.JJJJ)*
Clinical severity of heart failure (NYHA-
Classifikation)*
no (0)
yes, NYHA I (1)
yes, NYHA II (2)
yes, NYHA III (3)
yes, NYHA IV (4)
Cardiogenic shock
no (0)
yes, stabilized at the start procedure (1)
yes, hemodynamically unstable at the
start procedure (2)
Type of procedure*
diagnostic coronary angiography (1)
PCI (2)
one-stage coronary angiography and
PCI (3)
Urgency type of that procedure*
elective (1)
urgently (2)
emergency basis (3)
Renal function measured*
Yes
No
Procedure details
known Dose Area product ?*
Yes
No
Dose Area product (cGy)* cm²)
Applied X-ray contrast media dose (in ml)*
1 / 2
Events during procedure
intraprocedural occuring events*
yes (1)
coronary occlusion
yes (1)
postprocedural TIA/Stroke
yes (1)
Patient death in cardiac catheter lab
yes (1)
other
yes (1)
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(PCI) -Procedure (AQUA)
Quality assurance Coronary Angiography and
Percuteanous Intervention (PCI) -PCI (AQUA)
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Quality assurance Coronary
Angiography and Percuteanous
Intervention (PCI) -PCI (AQUA)
PCI
number of PCIs during this stay? (1 ... 99)*
Major intervention goal reached? According to
angiography examiner: Less than 50% of original
occlusion in dilated segement
no (0)
yes (1)
questionable (2)
Are Stents implanted?*
Yes
No
special condition
PCI of complete vessel occlusion (1)
PCI of coronary bypass (2)
PCI of the unprotected main stem (3)
PCI of LAD Ostiumstenose / RCX / RCA
(4)
PCI of the last remaining vessel (5)
PCI to an in-stent stenosis (6)
other (9)
PCI under special coronary conditions (e.g.
existing coronary bypass, ostium stenosis,
stenosis of whole vessel)*
Yes
No
PCI at RCA
yes (1)
PCI at RCX
yes (1)
PCI at LAD
yes (1)
PCI at LCA
yes (1)
Procedure codes *
Fibrinolysis before procedure
no (0)
yes (1)
unknown (9)
1 / 2
Balloon-Time (time) (hh:mm)
Balloon-Time (date) (TT.MM.JJJJ)
Door-Time (time) (hh:mm)
Door-Time (date) (TT.MM.JJJJ)
Known Door to Balloon Time ?
Yes
No
Is STEMI the main diagnosis?
Yes
No
Indication of PCI*
stable angina pectoris (by CCS) (1)
acute coronary syndrome (rest angina)
without myocardial infarction (without
STEMI or NSTEMI) (2)
acute coronary syndrome with non-ST-
segment elevation myocardial infarction
(NSTEMI) (3)
acute coronary syndrome with ST-
segment elevation (( (4)
acute coronary syndrome with ST-
segment elevation (( (5)
prognostic indication or silent ischaemia
(6)
other (9)
Major intervention goal reached in case of
STEMI/NSTEMI (according to TIMI)
CodelistItem 576971 (0)
CodelistItem 576972 (1)
CodelistItem 576973 (2)
CodelistItem 576974 (3)
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(PCI) -PCI (AQUA)
Quality assurance Carotid
Revascularization - Basic  (AQUA)
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Quality assurance Carotid
Revascularization - Basic  (AQUA)
Basic documentation
Healthcare Facility Identifier *
Zip Code of Discharge*
Facility's Section Identifier
Medical specialty*
internal medicine (0100)
internal medicine: geriatrics (0102)
internal medicine: cardiology (0103)
internal medicine: nephrology (0104)
internal medicine: hematology and
internal oncology  (0105)
internal medicine: endocrinology (0106)
internal medicine: gastroenterology
(0107)
internal medicine: pneumonology (0108)
internal medicine: rheumatology (0109)
internal medicine: pulmonology (0114)
internal medicine: tumor research (0150)
internal medicine: coloproctology (0151)
internal medicine: infectiology (0152)
internal medicine: diabetes (0153)
internal medicine: naturopathy (0154)
internal medicine: stroke unit (0156)
internal medicine (0190)
geriatry (0200)
geriatry: gynecology  (0224)
geriatry: day unit (for semi-residential
care)   (0260)
geriaty: night unit (for semi-residential
care) (0261)
geriatry (0290)
cardiology (0300)
nephrology (0400)
nephrology: pediatrics (0410)
nephrology: intensive care (0436)
nephrology (0490)
hematology and internal oncology
(0500)
hematology and internal oncology:
pediatrics (0510)
hematology and internal oncology:
gynacology (0524)
hematology and internal oncology:
radiation therapy (0533)
hematology and internal oncology
(0590)
1 / 9
endocrinology (0600)
endicrinology: gastroenterology (0607)
endocrinology: pediatrics (0610)
endocrinology (0690)
gastroenterology (0700)
gastroenterology: endocrinology (0706)
gastroenterology: pediatrics (0710)
gastroenterology (0790)
pneumology (0800)
rheumatology (0900)
rheumatology: pediatrics (0910)
rheumatology (0990)
pediatrics (1000)
pediatrics: nephrology (1004)
pediatrics: hematology and internal
oncology  (1005)
pediatrics: endocrinology (1006)
pediatrics: gastroenterology (1007)
pediatrics: rheumatology (1009)
pediatrics: pediatric cardiology (1011)
pediatrics: nephrology (1012)
pediatrics: pulmonology (1014)
pediatrics: pediatric neurology (1028)
pediatrics: perinatal medicine (1050)
continuing care for children (1051)
pediatrics (1090)
pediatric cardiology (1100)
pediatric cardiology: intensive care
(1136)
pediatric cardiology (1190)
neonatology (1200)
pediatric surgery (1300)
pulmonology (1400)
pulmonology: pediatrics (1410)
pulmonology (1490)
general surgery (1500)
general surgery: pediatric surgery (1513)
general surgery: trauma surgery (1516)
general surgery: vascular surgery (1518)
general surgery: plastic surgery (1519)
general surgery: thoracic surgery (1520)
general surgery: orthopedics (1523)
general surgery: intensive care (1536)
general surgery: abdominal- and
vascular surgery (1550)
Allgemeine Chirurgie: hand surgery
(1551)
general surgery (1590)
trauma surgery (1600)
neurosurgery (1700)
vascular surgery (1800)
plastic surgery (1900)
thoracic surgery (2000)
thoracic surgery: cardiac surgery (2021)
thoracic surgery: intensive care (2036)
thoracic surgery: cardiac surgery
intensive care (2050)
thoracic surgery (2090)
cardiac surgery (2100)
cardiac surgery: vascular surgery (2118)
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cardiac surgery: thoracic surgery (2120)
cardiac surgery: intensive care (2136)
cardiac surgery: thoracic surgery and
intensive care (2150)
cardiac surgery (2190)
urology (2200)
orthopedics (2300)
orthopedics: rheumatology (2309)
orthopedics: surgery (2315)
orthopedics and trauma surgery (2316)
orthopedics (2390)
gynecology and obstetrics (2400)
gynecology: geriatry (2402)
gynecology: hematology and internal
oncology  (2405)
gynecology: endocrinology (2406)
gynecology (2425)
gynecology and obstetrics (2490)
obstetrics (2500)
otolaryngology (2600)
ophthalmology (2700)
neurology: (2800)
neurology: pediatrics (2810)
neurology: stroke units (2856)
neurology (2890)
general psychiatry: (2900)
general psychiatry: neurology (2928)
general psychiatry: child and adolescent
psychiatry (2930)
general psychiatry: psychosomatics and
psychotherapy (2931)
general psychiatry: addiction treatment
(2950)
general psychiatry: geropsychiatry
(2951)
general psychiatry: forensic treatment
(2952)
general psychiatry: addiction treatment
(day unit) (2953)
general psychiatry: addiction treatment
(night unit) (2954)
general psychiatry: geropsychiatry (day
unit) (2955)
general psychiatry: geropsychiatry (night
unit) (2956)
general psychiatry: day unit (for semi-
residential care) (2960)
general psychiatry: night unit (for semi-
residential care) (2961)
general psychiatry (2990)
child and adolescent psychiatry (3000)
child and adolescent psychiatry: day unit
(for semi-residential care) (3060)
child and adolescent psychiatry: night
unit (for semi-residential care) (3061)
child and adolescent psychiatry (3090)
psychosomatic/psychotherapy (3100)
psychosomatic/psychotherapy: child and
adolescent psychiatry (3110)
psychosomatic/psychotherapy: day unit
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(for semi-residential care) (3160)
psychosomatic/psychotherapy: night unit
(for semi-residential care) (3161)
psychosomatic/psychotherapy (3190)
nuclear medicine (3200)
nuclear medicine: radiation therapy
(3233)
nuclear medicine (3290)
radiation therapy (3300)
radiation therapy: hematology and
internal oncology  (3305)
radiation therapy: radiology (3350)
radiation therapy (3390)
dermatology (3400)
dermatology: day unit (for semi-
residential care) (3460)
dermatology (3490)
dentistry, orthodontics, maxillofacial
surgery (3500)
intensive-care medicine (3600)
intensive-care medicine: internal
medicine (3601)
intensive-care medicine: cardiology
(3603)
intensive-care medicine: pediatrics
(3610)
intensive-care medicine: neurosurgery
(3617)
intensive-care medicine: surgery (3618)
intensive-care medicine: cardiac surgery
(3621)
intensive-care medicine: urology (3622)
intensive-care medicine: gynecology and
obstetrics (3624)
intensive-care medicine: otolaryngology
(3626)
intensive-care medicine: neurology
(3628)
operative intensive-care medicine:
surgery (3650)
intensive-care medicine: thorax-heart
surgery (3651)
intensive-care medicine: heart-thorax
surgery (3652)
intensive-care medicine (3690)
other medical specialty (3700)
angiology (3750)
radiology (3751)
palliative care (3752)
pain therapy (3753)
section for alternative health practice
(3754)
spinal surgery (3755)
addiction medicine (3756)
visceral surgery (3757)
other medical specialty (3790)
Patient identification number*
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Date of Birth (DD.MM.YYYY)*
Gender*
male (1)
female (2)
Hospital admission date (DD.MM.YYYY)*
Clinical diagnostics
Carotid lesion/stenosis, right side*
no, no lesion on the right (0)
yes, asymptomatic lesion on the right (1)
yes, symptomatic lesion on the right (2)
symptomatic carotid lesion/stenosis right side
(elective)
amaurosis fugax ipsilateral (1)
hemispheres ipsilateral TIA (2)
stroke with rankin 0-5 (3)
other (9)
Time passed after the last event that caused  the
stenosis of the right carotid artery till procude is
applied during this stay (in days)
symptomatic carotid lesion/stenosis right side
(emergency)
crescendo TIA (relapsing occurring,
transient, focal neurological deficit in the
supply area of internal carotid artery with
increasing frequency, several episodes
on one or more days with increasing
duration and increasing severity) (1)
acute/progressive stroke (2)
other (9)
Carotid lesion/stenosis, left side*
no, no lesion on the left (0)
yes, asymptomatic lesion on the left (1)
yes, symptomatic lesion left (2)
symptomatic carotid lesion/stenosis right side
(elective)
amaurosis fugax ipsilateral (1)
hemispheres ipsilateral TIA (2)
stroke with rankin 0-5 (3)
other (9)
Time passed after the last event that caused  the
stenosis of the left carotid artery till procude is
applied during this stay (in days)
symptomatic carotid lesion/stenosis left side
(emergency)
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crescendo TIA (relapsing occurring,
transient, focal neurological deficit in the
supply area of internal carotid artery with
increasing frequency, several episodes
on one or more days with increasing
duration and increasing severity) (1)
acute/progressive stroke (2)
other (9)
Severity of Disability (at admission), Rankin
Scale*
rankin 0: no detectable neurological
deficit (0)
rankin 1: apoplexy with functionally
irrelevant neurological deficit (1)
rankin 2: slight stroke with functionally
low grading deficit and/or mild aphasia
(2)
rankin 3: moderate stroke with a
significant deficit with preserved ability to
walk and/or moderate aphasia (3)
rankin 4: severe stroke, walking possible
only with help and/or complete aphasia
(4)
rankin 5: invalid by stroke: patient is
bedridden or wheelchair-bound (5)
Apparatus-based diagnostics
Duplex ultrasonography*
Yes
No
other Carotid lesions, right side*
Yes
No
Ulcerating plaque
yes (1)
Aneurysm
yes (1)
Symptomatic Coiling
yes (1)
Multilevel lesions of artery
yes (1)
other lesions
yes (1)
other Carotid lesions, left side*
Yes
No
Ulcerating plaque
yes (1)
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Aneurysm
yes (1)
Symptomatic Coiling
yes (1)
Multilevel lesions of artery
yes (1)
other lesions
yes (1)
Change of severity od disability till first
procedure?*
Yes
No
Degree of Stenosis left (according to NASCET
method) (in percent)*
Degree of Stenosis right (according to NASCET
method) (in percent)*
Territorial infarction
yes (1)
Transcranial Doppler -or Duplex ultrasonography*
Yes
No
intra-arterial digital subtraction angiography*
Yes
No
Spiral-CT-Angiography*
Yes
No
Magnetic resonance angiography*
Yes
No
Computed tomography of head*
Yes
No
Magnetic resonance imaging of head*
Yes
No
Morphologic finding of right hemesphere is
normal
Yes
No
Lacunar infarction/Microangiopathy
yes (1)
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Hemodynamic stroke
yes (1)
Territorial infarction
yes (1)
Morphologic finding of right hemesphere is
normal
Yes
No
Lacunar infarction/Microangiopathy
yes (1)
Hemodynamic stroke
yes (1)
Severity of disability imediately before procedure?
rankin 0: no detectable neurological
deficit (0)
rankin 1: apoplexy with functionally
irrelevant neurological deficit (1)
rankin 2: slight stroke with functionally
low grade deficit and/or mild aphasia (2)
rankin 3: moderate stroke with a
significant deficit with preserved ability to
walk and/or moderate aphasia (3)
rankin 4: severe stroke, walking possible
only with help and/or complete aphasia
(4)
rankin 5: invalid by stroke: patient is
bedridden or wheelchair-bound (5)
Discharge
Hostpital discharge date  (DD.MM.YYYY)*
Discharge diagnoses - ICD codes*
Reason for Discharge*
treatment finished as planned (1)
transferral to nursing facility (10)
discharge to hospice (11)
external transferral to psychiatric
treatment (13)
treatment finished because of other
reasons, postdischarge treatment is
planned (14)
treatment aborted against medical
advice, postdischarge treatment is
planned (15)
internal transferral with change of DRG
payment areas (17)
treatment finished as planned,
postdischarge treatment is planned (2)
case termination (internal transferral)
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with change between full- and partial
stationary care (22)
discharge at the end of the year with
admission in previous year (25)
treatment finished because of other
reasons (3)
treatment aborted against medical
advice (4)
change of jurisdiction of insurer or other
payer (5)
transferral to another hospital (6)
death (7)
transferral to another hospital within
cooperative and governmental policies
(8)
transferral to rehabilitation facility (9)
Death connected to documented carotid
revascularization or connected to underlying
disease
Yes
No
Autopsy carried out
Yes
No
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Quality assurance Coronary Angiography and Percuteanous
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Quality assurance Coronary
Angiography and Percuteanous
Intervention (PCI) - Coronary
Angiography (AQUA)
Coronary angiography
Number of times coronary angiography has been
applied during this stay?  (1 ... 99)*
Leading indication of coronary angiography -
according to angiography examiner before
procedure*
suspicion of CHD or CHD exclusion (1)
known CHD (2)
acute coronary syndrome (rest angina)
without myocardial infarction (without
STEMI or NSTEMI) (3)
acute coronary syndrome with non-ST-
segment elevation myocardial infarction
(NSTEMI) (4)
acute coronary syndrome with ST-
segment Elevation ( (5)
acute coronary syndrome with ST-
segment elevation (( (6)
elective control after coronary
intervention (7)
myocardial disease with impaired
ventricular function (ejection fraction
<40%) (8)
vitium (9)
other (99)
Procedure codes *
Leading diagnosis after coronary angiography*
no CHD (0)
CHD with luminal narrowing less than
50% (1)
CHD with luminal narrowing greater than
50% (excluding bypass grafts) (2)
cardiomyopathy (3)
heart valves vitium (4)
aortic aneurysm (5)
hypertensive heart disease (6)
other cardiac disease (9)
Treatment suggestion after coronary
angiography*
no (0)
only medication (1)
interventional (2)
cardiac surgery (3)
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Quality assurance Carotid
Revascularization - Open Surgery
(AQUA)
Carotid Revascularization - Open Surgery
Number of open-surgery  carotid
revascularization during this stay*
others
yes (1)
intraoperative Lysis
yes (1)
Stent
yes (1)
Angioplasty
yes (1)
additional intraoperative procedures/actions*
Yes
No
other operative procedures*
no (0)
external plastic (1)
carotid-carotid bypass (2)
other (9)
Carotid artery interposition graft*
no (0)
vein (1)
PTFE (2)
dacron (3)
other (9)
Eversion carotid endarterectomy (eCEA)*
Yes
No
Thromboendarterectomy*
no (0)
with vein patch (1)
PTFE patch (2)
with polyurethane patch (3)
with dacron patch (4)
direct suture (5)
with xenogen material (6)
other (9)
Creation of shunt*
Yes
1 / 2
No
Local Anesthesia*
Yes
No
General Anesthesia*
Yes
No
Duration of artery clamping (in minutes)
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Quality assurance Carotid
Revascularization -
Interventional/Catheter-assisted
(PTA and/or Stent) (AQUA)
Carotid Revascularization -
Interventional/Catheter-assisted (PTA
and/or Stent)
Number of times of catheteral interventional
carotid revaskularization during this stay? (1 ...
99)*
Number of implanted Stents - at Target artery
Drug-Eluting  Stent
not drug-released (1)
drug-released (2)
Stent design 2
tapered (1)
non-tapered (2)
combination of tapered and non-tapered
(3)
Stent design 1
open-cell design (1)
closed-cell design (2)
semi-closed-cell design (3)
other (9)
Type of Stent
nitinol (1)
stainless steel (2)
other (9)
Type of protection system
filter (1)
proximal occlusion (2)
distal occlusion (3)
other (9)
Protection system*
Yes
No
Type of intervetion*
PTA (1)
stent (2)
PTA plus stent (3)
intraprocedural Lysis/Thrombectomy*
Yes
1 / 2
No
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assisted (PTA and/or Stent) (AQUA)
Hematology Form AML (E1900,
NCT00049517)
E1900 Hematology Form
Combination Chemotherapy With or Without Monoclonal
Antibody Therapy Followed by Stem Cell Transplant in
Treating Patients With Acute Myeloid Leukemia
NCT00049517
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=A729522D-
1C90-2FD4-E034-0003BA0B1A09
All rights reserved. Please visit https://medical-data-
models.org/forms/9741
Hematology Form AML (E1900,
NCT00049517)
Header
ECOG Protocol No.
ECOG Patient ID
Registration Step
Reporting period
Current Phase Of Leukemia Treatment
For Patient Is Consolidation
(consolidation)
Current Phase Of Leukemia Treatment
For Patient Is Induction (induction)
post transplant (post transplant)
Patient's Name
Participating Group Protocol No.
Participating Group Patient ID
Institution/Affiliate
Are data amended? (If yes, please circle
amended items in red)
Yes
No
Comments
Investigator Signature
Date
Hematology lab
Laboratory Name
1 / 2
Date obtained
Peripheral WBC count (x1000), LLN
Peripheral WBC count (x1000), Value
Granulocyte count AGC/ANC
Peripheral Platelet count (x1000), LLN
(Peripheral Platelet count x1000, Value)
Platelets
Hemoglobin LLN
Hemoglobin Value
Blasts
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Pancreatic Cancer NCT00058149 Follow-Up -
Hematology/Chemistry Form - 2048132v3.0
Hematology/Chemistry Form
A Phase III, Randomized Study of Gemcitabine (Fixed-
Dose Rate Infusion) and Oxaliplatin (NSC 266046) Versus
Gemcitabine (Fixed-Dose Rate Infusion) Versus
Gemcitabine (30-Minute Infusion) in Pancreatic Carcinoma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=A65D4877-
9B57-427A-E034-0003BA0B1A09
All rights reserved. Please visit https://medical-data-
models.org/forms/9749
Hematology/Chemistry Form
Header
ECOG Protocol No.
ECOG Patient ID
Registration Step
Cycle Number
Patient?s Name
Participating Group Protocol No.
Participating Group Patient ID
Institution/Affiliate
Comments
Are data amended? (If yes, please circle
amended items in red)
Yes
No
Investigator Signature
Date
Laboratory Name:
Date obtained (M D Y)
WBC count (x1000), LLN
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WBC count (x1000), Value
Granulocyte count (AGC/ANC), Value (Do not
report % granulocytes/neutrophils; report
absolute count without decimal.)
Platelet count (x1000), LLN
Platelet count (x1000), Value
Hemoglobin (g/dl), LLN
Hemoglobin (g/dl), Value
Total bilirubin (mg/dl), ULN
Total bilirubin (mg/dl), Value
SGOT (AST) (U/L), ULN
SGOT (AST) (U/L), Value
Creatinine (mg/dl), ULN
Creatinine (mg/dl), Value
Albumin (g/dl), LLN
Albumin (g/dl)
CTC Adverse Event Attribution Code
Definitely (definite)
Possibly (possible)
Probably (probable)
Unlikely (unlikely)
Unrelated (unrelated)
Bilirubin ULN
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Hematology Laboratory Test Form Bladder
Cancer (NCT00014534)
NCI Cooperative Group Hematology Laboratory Test Form
(CALGB-90104)
Combination Chemotherapy in Treating Patients With
Bladder Cancer
NCT00014534
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=A9C02B5C-
8C97-26B5-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/9759
Hematology Laboratory Test Form
Bladder Cancer (NCT00014534)
Administrative documentation
Coordinating Group Protocol Number*
Coordinating Group Code
Protocol Title*
Patient Study ID, Coordinating Group*
Patient Study ID, Participating Group
Participating Group Code
Institution Name*
Affiliate*
Patient Last Name (initials acceptable)
Patient First Name (initials acceptable)
Patient Middle Name (initials acceptable)
Person Completing Form, Last Name
Person Completing Form, First Name
Are data amended?
Yes
No
Hematology Laboratory Tests
Peripheral WBC Count*
1 / 2
Hemoglobin*
Peripheral Hematocrit Count*
Peripheral Platelet Count*
Peripheral Neutrophils*
Peripheral Neutrophil Count*
Unit (Normal Range)*
% (%)
G/dl (g/dL)
K/uL (K/uL)
Normal Range-Peripheral WBC Count*
Normal Range-Hemoglobin*
Normal Range-Peripheral Hematocrit Count (%)*
Normal Range-Peripheral Platelet Count*
Normal Range-Peripheral Neutrophils*
Normal Range-Peripheral Neutrophil Count*
Date*
Comments*
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Leukemia Follow-Up - S0100 CNS
LEUKEMIA EVALUATION FORM
S0100 CNS LEUKEMIA EVALUATION FORM
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=AEB474AE-
AD1A-426C-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/9762
S0100 CNS LEUKEMIA
EVALUATION FORM
Header
SWOG Patient ID
SWOG Study No.
Registration Step
Patient Initials (L, F, M)
Institution/Affiliate
Physician
Lumbar Puncture
Date of Lumbar Puncture
CNS disease
Absent (Absent)
Indeterminate (Indeterminate)
Present (Present)
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ECOG Long-Term Follow-up Form (E2100)
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=AC32795E-
CBE0-2328-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/9764
Long-Term Follow-up Form (ECOG
E2100)
ECOG Protocol No.
ECOG Patient ID
Registration Step
Patient's Name
Participating Group Protocol No.
Participating Group Patient ID
Institution/Affiliate
Are data amended?
Yes
No
Reporting Period Start Date (M D Y)
Reporting Period End Date (M D Y)
Comments
Investigator Signature
Date
Vital Status
Patient's Vital Status
Alive (Alive)
Dead (Dead)
Date of Last Contact or Death (M D Y)
Primary Cause of Death (if applicable)
Due To Other Cause (Due to other
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cause)
Due To Protocol Treatment (Due to
protocol treatment)
Due To This Disease (Due to this
disease)
Unknown (Unknown)
Describe cause of death
Disease Follow-up Status
Has the patient had a documented clinical
assessment for this cancer? (since submission of
the previous follow-up form)
No (No)
Unknown (Unknown)
Yes (Yes)
Date of last clinical assessment (M D Y)
Notice Of Progression
Has the patient developed a first progression that
has not been previously reported?
No (No)
Unknown (Unknown)
Yes (Yes)
Date of progression (M D Y)
Site(s) of progression
Did a physician make a formal diagnosis of
progressive disease?
No (No)
Unknown (Unknown)
Yes (Yes)
Notice Of New Primary
Has a new primary cancer or MDS been
diagnosed that has not been previously reported?
Yes
No
Site(s) of new primary (If new primary site is
AML/MDS, please submit NCI AML/MDS form)
Toxicity
Has the patient experienced (prior to diagnosis of
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recurrence or second primary) any severe (Grade
>= 3) long term toxicity that has not been
previously reported? (NOTE: Do not report
toxicities occurring after start of non-protocol
therapy.)
Yes
No
Non-protocol Therapy
Has the patient received any non-protocol cancer
therapy prior to first progression (not previously
reported)?
Yes
No
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Lung Cancer NCT00113386 Quality of Life - RTOG-0412 FA: Funcation
Assessment Cancer Therapy - Lung Trial Outcome Index (TOI) - 2288075v3.0
RTOG-0412 FA: Funcation Assessment Cancer Therapy -
Lung Trial Outcome Index (TOI)
Cisplatin and Docetaxel With or Without Radiation Therapy
in Treating Patients Who Are Undergoing Surgery for Newly
Diagnosed Stage III Non-Small Cell Lung Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=E48B0FD8-
0824-0529-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/9765
RTOG-0412 FA: Funcation
Assessment Cancer Therapy - Lung
Trial Outcome Index (TOI)
Module 1
RTOG Study 0412
Case #
Institution
Institution No.
Participant's I.D. No.
PATIENTS INITIALS
PATIENTS INITIALS
DATE COMPLETED (INSTRUCTIONS: Below is
a list of statements that other people with your
illness have said are important. By selecting one
1 box per line, please indicate how true each
statement has been for you during the past 7
days. Please select a box by marking an X  in it.)
Physical Well-being
I have a lack of energy
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have nausea
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
Because of my physical condition, I have trouble
meeting the needs of my family
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A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have pain
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am bothered by side effects of treatment
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I feel ill
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am forced to spend time in bed
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
Functional Well-being
I am able to work (include work at home)
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
My work (including work at home) is fulfilling
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am able to enjoy life
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have accepted my illness
A Little Bit (A little bit)
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Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am sleeping well
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am enjoying the things I usually do for fun
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am content with the quality of my life right now
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
Additional Concerns
I have been short of breath
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am losing weight
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
My thinking is clear
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have been coughing
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have a good appetite
A Little Bit (A little bit)
Not At All (Not at all)
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Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I feel tightness in my chest
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
Breathing is easy for me
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
COMMENTS
Completed by
Date form originally completed
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FOLLOW UP FORM (S0100)
S0100 FOLLOW UP FORM
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=AEB52E43-
75AF-43F2-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/9770
FOLLOW UP FORM (S0100)
Vital Status
Vital Status
Alive (Alive)
Dead (Dead)
Date of last contact or death
Disease Follow Up Status
Has the patient had a documented clinical
assessment for this cancer since submission of
the previous follow-up form? (If Yes, )
Yes
No
Date of Last Clinical Assessment
Notice Of First Relapse Or Progression
Has the patient developed a first relapse or
progression that has not been previously
reported? (If Yes)
Yes
No
Date of Relapse or Progression
Site(s) of Relapse or Progression
Notice Of New Primary
Has a new primary cancer or myelodysplastic
syndrome (MDS) been diagnosed that has not
been previously reported? (If Yes,)
Yes
No
New Primary Site
Non-protocol Treatment
Has the patient received any non-protocol cancer
therapy (prior to progression/relapse) not
previously reported? (If Yes)
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Yes
No
Date of First Non-Protocol Therapy
Agents
Long Term Toxicity
Has the patient experienced (prior to treatment
for progression or relapse or a second primary,
and prior to non-protocol treatment) any severe
(grade 3) long term toxicity that has not been
previously reported?
(If Yes,)
Yes
No
Toxicities and Grades
Notes
Ccrr Module For S0100 Follow Up Form
SWOG Patient ID
SWOG Study No.
Registration Step
Patient Initials (L, F, M)
Institution/Affiliate
Physician
Group Name
Study No.
Pt. ID
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FOLLOW UP FORM (S0100)
Registration Worksheet (step 1) AML
(NCT00634244)
E1906 Registration Worksheet (step 1)
Comparing Three Different Combination Chemotherapy
Regimens in Treating Patients With Relapsed or Refractory
Acute Myeloid Leukemia
NCT00634244
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=580BE65D-
2E90-52E8-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/9773
Registration Worksheet (step 1) AML
(NCT00634244)
Eligibility
First initial
Last initial
Has the eligibility checklist been completed?
Yes
No
In the opinion of the investigator, is the patient
eligible?
Yes
No
Has written informed consent been obtained?
Yes
No
Date Informed Consent Signed
Has HIPAA authorization been obtained?
No (0)
Yes (1)
Exempt - Non-USA Participant (2)
HIPAA Authorization Date
Duration of first remission
Relapse < (1)
Relapse Between 6-12 Months After
First CR (2)
Refractory to Coventional Initial Induction
Chemotherapy (< (3)
ECOG Patient ID (if available)
I agree biopsies may be done to obtain research
specimens.
Yes
No
I agree to provide additional specimens for
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research
Yes
No
My specimens may be kept for use in research to
learn about, prevent, treat, or cure cancer.
Yes
No
My specimens may be kept for use in research
about other health problems (for example: causes
of diabetes, Alzheimer's disease, or heart
disease)
Yes
No
Someone from this institution may contact me in
the future to ask me to take part in more
research.
Yes
No
Name of local cytogenetics lab
Phone number Cytogenetics Laboratory
Patient Demographics / Pre-treatment
Characteristics
Patient's Sex
Female (F)
Male (M)
Birthdate
Patient's Race
A Person Having Origins In Any Of The
Original Peoples Of North And South
America (including Central America),
And Who Maintains Tribal Affiliation Or
Community Attachment. (American
Indian or Alaska Native)
A Person Having Origins In Any Of The
Original Peoples Of The Far East,
Southeast Asia, Or The Indian
Subcontinent Including, For Example,
Cambodia, China, India, Japan, Korea,
Malaysia, Pakistan, The Philippine
Islands, Thailand, And Vietnam. (Asian)
A Person Having Origins In Any Of The
Black Racial Groups Of Africa. Terms
Such As "haitian" Or "negro" Can Be
Used In Addition To "black Or African
American." (Black or African American)
A Person Having Origins In Any Of The
Original Peoples Of Hawaii, Guam,
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Samoa, Or Other Pacific Islands. (Native
Hawaiian or other Pacific Islander)
Not Provided Or Available (Not
Reported)
Could Not Be Determined Or Unsure
(Unknown)
A Person Having Origins In Any Of The
Original Peoples Of Europe, The Middle
East, Or North Africa. (White)
ZIP Code
Patient Ethnicity
A Person Of Mexican, Puerto Rican,
Cuban, Central Or South American Or
Other Spanish Culture Or Origin,
Regardless Of Race. (Hispanic or Latino)
A Person Not Meeting The Definition For
Hispanic Or Latino. (Not Hispanic or
Latino)
Not Provided Or Available (Not reported)
Could Not Be Determined Or Unsure
(Unknown)
Patient Hospital No.
Patient Social Security Number
Method of payment (check one)
Medicaid (Medicaid)
Medicaid And Medicare (Medicaid and
Medicare)
Medicare (Medicare)
Medicare And Private Insurance
(Medicare and Private Insurance)
Military Or Veterans Sponsored Nos
(Military or Veterans Sponsored, Not
Otherwise Specified (NOS))
Military Sponsored (including Champus
& Tricare) (Military Sponsored (including
CHAMPUS & TRICARE))
No Means Of Payment (no Insurance)
(No means of payment (no insurance))
Other (Other)
Private Insurance (Private Insurance)
Self Pay (no Insurance) (Self Pay (No
Insurance))
Unknown (Unknown)
Veterans Sponsored (Veterans
Sponsored)
Country of residence
Ascension Island (AC)
Andorra (AD)
United Arab Emirates (AE)
Afghanistan (AF)
Antigua And Barbuda (AG)
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Anguilla (AI)
Albania (AL)
Armenia (AM)
Netherland Antilles (AN)
Angola (AO)
Antarctica (AQ)
Argentina (AR)
American Samoa (AS)
Austria (AT)
Australia (AU)
Aruba (AW)
Azerbaidjan (AZ)
Bosnia-herzegovina (BA)
Barbados (BB)
Bangladesh (BD)
Belgium (BE)
Burkina Faso (BF)
Bulgaria (BG)
Bahrain (BH)
Burundi (BI)
Benin (BJ)
Bermuda (BM)
Brunei Darussalam (BN)
Bolivia (BO)
Brazil (BR)
Bahamas (BS)
Bhutan (BT)
Bouvet Island (BV)
Botswana (BW)
Belarus (BY)
Belize (BZ)
Canada (CA)
Cocos Isl. (CC)
Rep. Dem. Congo (CD)
Central African Rep. (CF)
Congo (CG)
Switzerland (CH)
Ivory Coast (CI)
Cook Islands (CK)
Chile (CL)
Cameroon (CM)
China (CN)
Colombia (CO)
Costa Rica (CR)
Cuba (CU)
Cape Verde (CV)
Christmas Island (CX)
Cyprus (CY)
Czech Republic (CZ)
Germany (DE)
Djibouti (DJ)
Denmark (DK)
Dominica (DM)
Dominican Republic (DO)
Algeria (DZ)
Ecuador (EC)
Estonia (EE)
Egypt (EG)
Western Sahara (EH)
Eritrea (ER)
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Spain (ES)
Ethiopia (ET)
Finland (FI)
Fiji (FJ)
Falkland Isl. (FK)
Micronesia (FM)
Faroe Islands (FO)
France (FR)
France (european Ter.) (FX)
Gabon (GA)
Great Britain (GB)
Grenada (GD)
Georgia (GE)
Guiana (fr.) (GF)
Guernsey (GG)
Ghana (GH)
Gibraltar (GI)
Greenland (GL)
Gambia (GM)
Guinea (GN)
Guadeloupe (fr.) (GP)
Equatorial Guinea (GQ)
Greece (GR)
South Georgia And South Sandwich
Islands (GS)
Guatemala (GT)
Guam (us) (GU)
Guinea Bissau (GW)
Guyana (GY)
Hong Kong (HK)
Heard & Mcdonald Isl. (HM)
Honduras (HN)
Croatia (HR)
Haiti (HT)
Hungary (HU)
Indonesia (ID)
Ireland (IE)
Israel (IL)
Isle Of Man (IM)
India (IN)
British Indian O. Ter. (IO)
Iraq (IQ)
Iran (IR)
Iceland (IS)
Italy (IT)
Jersey (JE)
Jamaica (JM)
Jordan (JO)
Japan (JP)
Kenya (KE)
Kyrgyz Republic (KG)
Cambodia (KH)
Kiribati (KI)
Comoros (KM)
St. Kitts Nevis Anguilla (KN)
Korea (north) (KP)
Korea (south) (KR)
Kuwait (KW)
Cayman Islands (KY)
Kazakstan (KZ)
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Laos (LA)
Lebanon (LB)
Saint Lucia (LC)
Liechtenstein (LI)
Sri Lanka (LK)
Liberia (LR)
Lesotho (LS)
Lithuania (LT)
Luxembourg (LU)
Latvia (LV)
Libya (LY)
Morocco (MA)
Monaco (MC)
Moldova (MD)
Madagascar (MG)
Marshall Islands (MH)
Macedonia (MK)
Mali (ML)
Myanmar (MM)
Mongolia (MN)
Macau (MO)
Northern Mariana Isl. (MP)
Martinique (fr.) (MQ)
Mauritania (MR)
Montserrat (MS)
Malta (MT)
Mauritius (MU)
Maldives (MV)
Malawi (MW)
Mexico (MX)
Malaysia (MY)
Mozambique (MZ)
Namibia (NA)
New Caledonia (fr.) (NC)
Niger (NE)
Norfolk Island (NF)
Nigeria (NG)
Nicaragua (NI)
Netherlands (NL)
Norway (NO)
Nepal (NP)
Nauru (NR)
Niue (NU)
New Zealand (NZ)
Oman (OM)
Other (Other)
Panama (PA)
Peru (PE)
Polynesia (fr.) (PF)
Papua New Guinea (PG)
Philippines (PH)
Pakistan (PK)
Poland (PL)
St. Pierre & Miquelon (PM)
Pitcairn (PN)
Puerto Rico (PR)
Portugal (PT)
Palau (PW)
Paraguay (PY)
Qatar (QA)
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Reunion (fr.) (RE)
Romania (RO)
Russian Federation (RU)
Rwanda (RW)
Saudi Arabia (SA)
Solomon Islands (SB)
Seychelles (SC)
Sudan (SD)
Sweden (SE)
Singapore (SG)
St. Helena (SH)
Slovenia (SI)
Svalbard & Jan Mayen Isl. (SJ)
Slovakia (SK)
Sierra Leone (SL)
San Marino (SM)
Senegal (SN)
Somalia (SO)
Suriname (SR)
St. Tome And Principe (ST)
Soviet Union (SU)
El Salvador (SV)
Syria (SY)
Swaziland (SZ)
Turks & Caicos Islands (TC)
Chad (TD)
French Southern Terr. (TF)
Togo (TG)
Thailand (TH)
Tadjikistan (TJ)
Tokelau (TK)
Turkmenistan (TM)
Tunisia (TN)
Tonga (TO)
East Timor (TP)
Turkey (TR)
Trinidad & Tobago (TT)
Tuvalu (TV)
Taiwan (TW)
Tanzania (TZ)
Ukraine (UA)
Uganda (UG)
United Kingdom (UK)
Us Minor Outlying Isl. (UM)
Usa (US)
Uruguay (UY)
Uzbekistan (UZ)
Vatican City State (VA)
St. Vincent & Grenadines (VC)
Venezuela (VE)
Virgin Islands (brit) (VG)
Virgin Islands (us) (VI)
Vietnam (VN)
Vanuatu (VU)
Wallis & Futuna Islands (WF)
Western Samoa (WS)
Yemen (YE)
Mayotte (YT)
Yugoslavia (YU)
South Africa (ZA)
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Zambia (ZM)
Dem. Rep. Of Congo (ZR)
Zimbabwe (ZW)
Comments
I Have Reviewed The Above Data And
Agree The Date Are Accurate And Correct
Signature of treating physician
Treating Physician Signature Date
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Follow Up Disease Evaluation Form (E2905
NCT00843882)
E2905 Follow Up Disease Evaluation Form
Lenalidomide With or Without Epoetin Alfa in Treating
Patients With Myelodysplastic Syndrome and Anemia
NCT00843882
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=0F12A9EE-
8D74-6165-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/9795
Follow Up Disease Evaluation Form
(E2905 NCT00843882)
Header
ECOG Protocol Number
ECOG Patient ID
DCI Name
Registration Step
Patient Initials (Last, First)
Participating Group Protocol Number
Participating Group Patient ID
Institution/Affiliate
Please mark an 'X' if data have been amended.
(Please circle amended items in red)
Date data amended (MM/DD/YYYY)
Investigator Signature
Investigator Signature Date
On Treatment
On Treatment Report Period (Step 2 - Choose
one x)
>cycle 13-step 2 (>Cycle 13-Step 2)
Cycle 1 Step 2 (Cycle 1 Step 2)
Cycle 10 Step 2 (Cycle 10 Step 2)
Cycle 11 Step 2 (Cycle 11 Step 2)
Cycle 12 Step 2 (Cycle 12 Step 2)
Cycle 13-step 2 (Cycle 13-Step 2)
Cycle 2 Step 2 (Cycle 2 Step 2)
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Cycle 3 Step 2 (Cycle 3 Step 2)
Cycle 4 Step 2 (Cycle 4 Step 2)
Cycle 5 Step 2 (Cycle 5 Step 2)
Cycle 6 Step 2 (Cycle 6 Step 2)
Cycle 7 Step 2 (Cycle 7 Step 2)
Cycle 8 Step 2 (Cycle 8 Step 2)
Cycle 9 Step 2 (Cycle 9 Step 2)
Specify Cycle
Off Treatment
Off Treatment Report Period (since registration -
Choose one x)
3 Months Post End Of Treatment (3
months post end of treatment)
6 Months Post End Of Treatment (6
months post end of treatment)
Unnamed5
MDS classification
Chronic Myelomonocytic Leukemia
(CMML)
Myelodysplastic Syndrome Associated
With Isolated Del (5q) Chromosome
Abnormality (MDS associated with
isolated del(5q))
Myelodysplastic Syndrome,
Unclassifiable (MDS unclassified)
No Evidence Of Disease (No evidence of
disease)
Refractory Anemia (RA)
Refractory Anemia With Ringed
Sideroblasts (RA with Ringed
Sideroblasts)
Refractory anemia with excess blasts-1
(Raeb-1)
Refractory anemia with excess blasts-2
(Raeb-2)
Refractory Cytopenia With Multilineage
Dysplasia (Refractory Cytopenia with
Multilineage Dysplasia)
Refractory Cytopenia With Multilineage
Dysplasia And Ringed Sideroblasts
(Refractory Cytopenia with Multilineage
Dysplasia and Ringed Sideroblasts)
Was bone marrow biopsy done
Yes
No
Date of Bone Marrow Biopsy (Aspirate)
Marrow Blasts
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Marrow Cellularity
Reason bone marrow cellularity was not recorded
Cellularity Status Of Bone Marrow
Unknown, Procedure Resulted In No
Material To Analyze (Dry Tap or
inaspirable)
Local Pathologist Did Not Quantify
Cellularity (Local pathologist did not
quantify cellularity)
Dysplasia
No (No)
Unknown (Unknown)
Yes (Yes)
Dysplasia type
Erythroid (1)
Megakaryocyte (2)
Myeloid (3)
Is cytogenetic abnormality present now
Inevaluable (Inevaluable)
No (No)
Yes (Yes)
Section Ii
Did the patient require packed red blood cell
(PRBC) transfusions (in the last 8 weeks)
No (No)
Unknown (Unknown)
Yes (Yes)
Total number of units PRBC (transfused in the
last 8 weeks)
Date of First Transfusion (in the last 8 weeks)
Date of most recent  PRBC transfusion
Mds Response
Best response to date
Complete Remission (CR)
Better Hematologic (HI)
Progressive Disease (PD)
Partial Remission (PR)
Stable Disease (SD)
Transformation To Aml (Transformation to
AML)
First observed date
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First Confirmed Date
Relapse
Yes
No
Date of relapse
If Hematologic improvement
Major Erythroid Response (Major
erythroid response)
Minor Erythroid Response (Minor
erythroid response)
Relapse Major Erythroid Response
(Relaspe MER)
First observed date (HI)
First confirmed date (HI)
Cytogenetic Response
Complete Cytogenetic Response
(Complete Cytogenetic Response)
Partial Cytogenetic Response (Partial
Cytogenetic Response)
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Quality assurance Follow-up Heart
Transplant (AQUA)
Documentation form for quality assurance in German
Health Care by the Institute for Applied Quality
Improvement and Research in Health Care (Aqua),
https://www.aqua-institut.de/en/home. Internal Aqua form
version: HTXFU Specification 2015 V02
All rights reserved. Please visit https://medical-data-
models.org/forms/9816
Quality assurance Follow-up Heart
Transplant (AQUA)
Follow-up(to be filled out after 1, 2 and 3
years)
Health Insurance Identifier*
treated graft reactions since last follow-up year*
no (0)
yes, known number (1)
yes, number unknown (2)
unknown (9)
Follow-up: Year(s) after transplant ((1, 2, 3))*
Type of follow-up inquiry*
patient was personally in hospital (1)
telephone contact with patient  (2)
telephone contact with doctor further
treatment (3)
written information from the doctor
further treatment (4)
information about relatives/carers of
patients  (5)
no contact with patient, doctor further
treatment or relatives/carers of patients
(6)
Date of Follow-up examination (dd.mm.yyyy)*
Date of last transplant (dd.mm.yyyy)*
Gender*
male (1)
female (2)
Date of Birth (DD.MM.YYYY)*
Recipient ID (ET-Number)*
Medical specialty*
internal medicine (0100)
internal medicine: geriatrics (0102)
internal medicine: cardiology (0103)
internal medicine: nephrology (0104)
internal medicine: hematology and
internal oncology  (0105)
internal medicine: endocrinology (0106)
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internal medicine: gastroenterology
(0107)
internal medicine: pneumonology (0108)
internal medicine: rheumatology (0109)
internal medicine: pulmonology (0114)
internal medicine: tumor research (0150)
internal medicine: coloproctology (0151)
internal medicine: infectiology (0152)
internal medicine: diabetes (0153)
internal medicine: naturopathy (0154)
internal medicine: stroke unit (0156)
internal medicine (0190)
geriatry (0200)
geriatry: gynecology  (0224)
geriatry: day unit (for semi-residential
care)   (0260)
geriaty: night unit (for semi-residential
care) (0261)
geriatry (0290)
cardiology (0300)
nephrology (0400)
nephrology: pediatrics (0410)
nephrology: intensive care (0436)
nephrology (0490)
hematology and internal oncology
(0500)
hematology and internal oncology:
pediatrics (0510)
hematology and internal oncology:
gynacology (0524)
hematology and internal oncology:
radiation therapy (0533)
hematology and internal oncology
(0590)
endocrinology (0600)
endicrinology: gastroenterology (0607)
endocrinology: pediatrics (0610)
endocrinology (0690)
gastroenterology (0700)
gastroenterology: endocrinology (0706)
gastroenterology: pediatrics (0710)
gastroenterology (0790)
pneumology (0800)
rheumatology (0900)
rheumatology: pediatrics (0910)
rheumatology (0990)
pediatrics (1000)
pediatrics: nephrology (1004)
pediatrics: hematology and internal
oncology  (1005)
pediatrics: endocrinology (1006)
pediatrics: gastroenterology (1007)
pediatrics: rheumatology (1009)
pediatrics: pediatric cardiology (1011)
pediatrics: nephrology (1012)
pediatrics: pulmonology (1014)
pediatrics: pediatric neurology (1028)
pediatrics: perinatal medicine (1050)
continuing care for children (1051)
pediatrics (1090)
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pediatric cardiology (1100)
pediatric cardiology: intensive care
(1136)
pediatric cardiology (1190)
neonatology (1200)
pediatric surgery (1300)
pulmonology (1400)
pulmonology: pediatrics (1410)
pulmonology (1490)
general surgery (1500)
general surgery: pediatric surgery (1513)
general surgery: trauma surgery (1516)
general surgery: vascular surgery (1518)
general surgery: plastic surgery (1519)
general surgery: thoracic surgery (1520)
general surgery: orthopedics (1523)
general surgery: intensive care (1536)
general surgery: abdominal- and
vascular surgery (1550)
Allgemeine Chirurgie: hand surgery
(1551)
general surgery (1590)
trauma surgery (1600)
neurosurgery (1700)
vascular surgery (1800)
plastic surgery (1900)
thoracic surgery (2000)
thoracic surgery: cardiac surgery (2021)
thoracic surgery: intensive care (2036)
thoracic surgery: cardiac surgery
intensive care (2050)
thoracic surgery (2090)
cardiac surgery (2100)
cardiac surgery: vascular surgery (2118)
cardiac surgery: thoracic surgery (2120)
cardiac surgery: intensive care (2136)
cardiac surgery: thoracic surgery and
intensive care (2150)
cardiac surgery (2190)
urology (2200)
orthopedics (2300)
orthopedics: rheumatology (2309)
orthopedics: surgery (2315)
orthopedics and trauma surgery (2316)
orthopedics (2390)
gynecology and obstetrics (2400)
gynecology: geriatry (2402)
gynecology: hematology and internal
oncology  (2405)
gynecology: endocrinology (2406)
gynecology (2425)
gynecology and obstetrics (2490)
obstetrics (2500)
otolaryngology (2600)
ophthalmology (2700)
neurology: (2800)
neurology: pediatrics (2810)
neurology: stroke units (2856)
neurology (2890)
general psychiatry: (2900)
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general psychiatry: neurology (2928)
general psychiatry: child and adolescent
psychiatry (2930)
general psychiatry: psychosomatics and
psychotherapy (2931)
general psychiatry: addiction treatment
(2950)
general psychiatry: geropsychiatry
(2951)
general psychiatry: forensic treatment
(2952)
general psychiatry: addiction treatment
(day unit) (2953)
general psychiatry: addiction treatment
(night unit) (2954)
general psychiatry: geropsychiatry (day
unit) (2955)
general psychiatry: geropsychiatry (night
unit) (2956)
general psychiatry: day unit (for semi-
residential care) (2960)
general psychiatry: night unit (for semi-
residential care) (2961)
general psychiatry (2990)
child and adolescent psychiatry (3000)
child and adolescent psychiatry: day unit
(for semi-residential care) (3060)
child and adolescent psychiatry: night
unit (for semi-residential care) (3061)
child and adolescent psychiatry (3090)
psychosomatic/psychotherapy (3100)
psychosomatic/psychotherapy: child and
adolescent psychiatry (3110)
psychosomatic/psychotherapy: day unit
(for semi-residential care) (3160)
psychosomatic/psychotherapy: night unit
(for semi-residential care) (3161)
psychosomatic/psychotherapy (3190)
nuclear medicine (3200)
nuclear medicine: radiation therapy
(3233)
nuclear medicine (3290)
radiation therapy (3300)
radiation therapy: hematology and
internal oncology  (3305)
radiation therapy: radiology (3350)
radiation therapy (3390)
dermatology (3400)
dermatology: day unit (for semi-
residential care) (3460)
dermatology (3490)
dentistry, orthodontics, maxillofacial
surgery (3500)
intensive-care medicine (3600)
intensive-care medicine: internal
medicine (3601)
intensive-care medicine: cardiology
(3603)
intensive-care medicine: pediatrics
(3610)
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intensive-care medicine: neurosurgery
(3617)
intensive-care medicine: surgery (3618)
intensive-care medicine: cardiac surgery
(3621)
intensive-care medicine: urology (3622)
intensive-care medicine: gynecology and
obstetrics (3624)
intensive-care medicine: otolaryngology
(3626)
intensive-care medicine: neurology
(3628)
operative intensive-care medicine:
surgery (3650)
intensive-care medicine: thorax-heart
surgery (3651)
intensive-care medicine: heart-thorax
surgery (3652)
intensive-care medicine (3690)
other medical specialty (3700)
angiology (3750)
radiology (3751)
palliative care (3752)
pain therapy (3753)
section for alternative health practice
(3754)
spinal surgery (3755)
addiction medicine (3756)
visceral surgery (3757)
other medical specialty (3790)
Facility's Section Identifier
Zip Code of Discharge*
Number of treated rejection episodes since last
follow-up year
Survival status of recipient
Deceased patient*
no (0)
yes (1)
unknown (9)
Date of death (dd.mm.yyyy)
Causes of death in the course
1: cause of death: uncertain - not
determined (701)
11: myocardial ischemia / infarction (711)
12: hyperkalemia (712)
13: hemorrhagic pericarditis (713)
14: causes of cardiac failure / other (714)
15: cardiac arrest - sudden death (715)
16: hypertensive cardiac failure (716)
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17: hypokalemia (717)
18: fluid overload (718)
21: pulmonary embolus (721)
22: cerebrovascular accident (AVC)
(722)
23: gastrointestinal hemorrhage (723)
24: hemorrhage from graft site (724)
25: hemorrhage from vascular access or
dialysis circuit (725)
26: hemorrhage from ruptured vascular
aneurysm (AAA / etc) (726)
27: hemorrhage from surgery (727)
28: hemorrhage / other / specify (728)
29: mesenteric infarction (729)
30: infection (730)
31: pulmonary infection ( bacterial ) (731)
32: pulmonary infection ( viral ) (732)
33: pulmonary infection ( fungal or
protozoal ) (733)
34: infections elsewhere (except viral
hepatitis) (734)
35: septicemia / MOF (735)
36: tuberculosis ( lung ) (736)
37: tuberculosis ( not lung ) (737)
38: viral infection / generalized (738)
39: peritonitis (739)
41: liver disease due to hepatitis B virus
(741)
42: liver disease due to other viral
hepatitis (742)
43: liver disease due to drug toxicity
(743)
44: cirrhosis - not viral (744)
45: cystic liver disease (745)
46: liver failure / cause unknown (746)
51: patient refused further dialysis
treatment (751)
52: suicide (752)
53: dialysis ceased for any other reason
(753)
61: renal failure (761)
62: pancreatitis (762)
63: bone marrow depression (763)
64: cachexia (764)
66: malignant disease -
lymphoproliferative disorder / specify
(766)
67: malignant disease - other / specify
(767)
69: dementia (769)
70: sclerosing peritoneal disease (770)
71: perforation of peptic ulcer (771)
72: perforation of colon (772)
80: accident / all causes / specify (780)
81: accident related to dialysis treatment
(781)
82: accident unrelated to dialysis
treatment (782)
90: gastrointestinal / other / specify (790)
99: other / specify (799)
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101: failure of transplant (801)
102: surgical complications (802)
103: pulmonary embolus (803)
104: malignant disease -
lymfoproliferative disorder (804)
105: malignant disease - other (805)
106: infection (806)
107: cerebrovascular accident (CVA)
(807)
108: hemorrhage / other (808)
109: other (809)
Current immunosuppression
Cyclosporine
no (0)
yes (1)
unknown (9)
Tacrolimus
no (0)
yes (1)
unknown (9)
Azathioprine
no (0)
yes (1)
unknown (9)
Mycophenolat
no (0)
yes (1)
unknown (9)
Steroids
no (0)
yes (1)
unknown (9)
m-ToR-Inhibitor
no (0)
yes (1)
unknown (9)
other
no (0)
yes (1)
unknown (9)
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Quality assurance Heart Transplant Heart
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Documentation form for quality assurance in German
Health Care by the Institute for Applied Quality
Improvement and Research in Health Care (Aqua),
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models.org/forms/9817
Quality assurance Heart Transplant
Heart Assist Devices Artificial Heart -
Basic (AQUA)
Basic documentation recipient
Health Insurance Identifier*
Received any thoracic surgical procedures before
admission ?*
Yes
No
Heart Transplantation
Yes
No
Assist Device/TAH
Yes
No
Coronary surgery
Yes
No
Operation on heart valve
Yes
No
Repair of cardiac defects
Yes
No
other
Yes
No
Number of previous cardiac operations
Number of previous cardiac operations unknown
Yes
No
Date of last thoracic surgery (TT.MM.JJJJ)
Was a Heart transplantation performed during
this stay ?*
Yes
No
Was an Assist Device/TAH implanted during this
stay?*
Yes
1 / 14
No
Rhesus phenotype*
positive (1)
negative (2)
not determined (9)
Blood group (AB)*
A (1)
B (2)
0 (3)
AB (4)
not determined (9)
Zip Code of Discharge*
Facility's Section Identifier
Hospital admission date (DD.MM.YYYY)*
Medical specialty*
internal medicine (0100)
internal medicine: geriatrics (0102)
internal medicine: cardiology (0103)
internal medicine: nephrology (0104)
internal medicine: hematology and
internal oncology  (0105)
internal medicine: endocrinology (0106)
internal medicine: gastroenterology
(0107)
internal medicine: pneumonology (0108)
internal medicine: rheumatology (0109)
internal medicine: pulmonology (0114)
internal medicine: tumor research (0150)
internal medicine: coloproctology (0151)
internal medicine: infectiology (0152)
internal medicine: diabetes (0153)
internal medicine: naturopathy (0154)
internal medicine: stroke unit (0156)
internal medicine (0190)
geriatry (0200)
geriatry: gynecology  (0224)
geriatry: day unit (for semi-residential
care)   (0260)
geriaty: night unit (for semi-residential
care) (0261)
geriatry (0290)
cardiology (0300)
nephrology (0400)
nephrology: pediatrics (0410)
nephrology: intensive care (0436)
nephrology (0490)
hematology and internal oncology
(0500)
hematology and internal oncology:
pediatrics (0510)
hematology and internal oncology:
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gynacology (0524)
hematology and internal oncology:
radiation therapy (0533)
hematology and internal oncology
(0590)
endocrinology (0600)
endicrinology: gastroenterology (0607)
endocrinology: pediatrics (0610)
endocrinology (0690)
gastroenterology (0700)
gastroenterology: endocrinology (0706)
gastroenterology: pediatrics (0710)
gastroenterology (0790)
pneumology (0800)
rheumatology (0900)
rheumatology: pediatrics (0910)
rheumatology (0990)
pediatrics (1000)
pediatrics: nephrology (1004)
pediatrics: hematology and internal
oncology  (1005)
pediatrics: endocrinology (1006)
pediatrics: gastroenterology (1007)
pediatrics: rheumatology (1009)
pediatrics: pediatric cardiology (1011)
pediatrics: nephrology (1012)
pediatrics: pulmonology (1014)
pediatrics: pediatric neurology (1028)
pediatrics: perinatal medicine (1050)
continuing care for children (1051)
pediatrics (1090)
pediatric cardiology (1100)
pediatric cardiology: intensive care
(1136)
pediatric cardiology (1190)
neonatology (1200)
pediatric surgery (1300)
pulmonology (1400)
pulmonology: pediatrics (1410)
pulmonology (1490)
general surgery (1500)
general surgery: pediatric surgery (1513)
general surgery: trauma surgery (1516)
general surgery: vascular surgery (1518)
general surgery: plastic surgery (1519)
general surgery: thoracic surgery (1520)
general surgery: orthopedics (1523)
general surgery: intensive care (1536)
general surgery: abdominal- and
vascular surgery (1550)
Allgemeine Chirurgie: hand surgery
(1551)
general surgery (1590)
trauma surgery (1600)
neurosurgery (1700)
vascular surgery (1800)
plastic surgery (1900)
thoracic surgery (2000)
thoracic surgery: cardiac surgery (2021)
thoracic surgery: intensive care (2036)
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thoracic surgery: cardiac surgery
intensive care (2050)
thoracic surgery (2090)
cardiac surgery (2100)
cardiac surgery: vascular surgery (2118)
cardiac surgery: thoracic surgery (2120)
cardiac surgery: intensive care (2136)
cardiac surgery: thoracic surgery and
intensive care (2150)
cardiac surgery (2190)
urology (2200)
orthopedics (2300)
orthopedics: rheumatology (2309)
orthopedics: surgery (2315)
orthopedics and trauma surgery (2316)
orthopedics (2390)
gynecology and obstetrics (2400)
gynecology: geriatry (2402)
gynecology: hematology and internal
oncology  (2405)
gynecology: endocrinology (2406)
gynecology (2425)
gynecology and obstetrics (2490)
obstetrics (2500)
otolaryngology (2600)
ophthalmology (2700)
neurology: (2800)
neurology: pediatrics (2810)
neurology: stroke units (2856)
neurology (2890)
general psychiatry: (2900)
general psychiatry: neurology (2928)
general psychiatry: child and adolescent
psychiatry (2930)
general psychiatry: psychosomatics and
psychotherapy (2931)
general psychiatry: addiction treatment
(2950)
general psychiatry: geropsychiatry
(2951)
general psychiatry: forensic treatment
(2952)
general psychiatry: addiction treatment
(day unit) (2953)
general psychiatry: addiction treatment
(night unit) (2954)
general psychiatry: geropsychiatry (day
unit) (2955)
general psychiatry: geropsychiatry (night
unit) (2956)
general psychiatry: day unit (for semi-
residential care) (2960)
general psychiatry: night unit (for semi-
residential care) (2961)
general psychiatry (2990)
child and adolescent psychiatry (3000)
child and adolescent psychiatry: day unit
(for semi-residential care) (3060)
child and adolescent psychiatry: night
unit (for semi-residential care) (3061)
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child and adolescent psychiatry (3090)
psychosomatic/psychotherapy (3100)
psychosomatic/psychotherapy: child and
adolescent psychiatry (3110)
psychosomatic/psychotherapy: day unit
(for semi-residential care) (3160)
psychosomatic/psychotherapy: night unit
(for semi-residential care) (3161)
psychosomatic/psychotherapy (3190)
nuclear medicine (3200)
nuclear medicine: radiation therapy
(3233)
nuclear medicine (3290)
radiation therapy (3300)
radiation therapy: hematology and
internal oncology  (3305)
radiation therapy: radiology (3350)
radiation therapy (3390)
dermatology (3400)
dermatology: day unit (for semi-
residential care) (3460)
dermatology (3490)
dentistry, orthodontics, maxillofacial
surgery (3500)
intensive-care medicine (3600)
intensive-care medicine: internal
medicine (3601)
intensive-care medicine: cardiology
(3603)
intensive-care medicine: pediatrics
(3610)
intensive-care medicine: neurosurgery
(3617)
intensive-care medicine: surgery (3618)
intensive-care medicine: cardiac surgery
(3621)
intensive-care medicine: urology (3622)
intensive-care medicine: gynecology and
obstetrics (3624)
intensive-care medicine: otolaryngology
(3626)
intensive-care medicine: neurology
(3628)
operative intensive-care medicine:
surgery (3650)
intensive-care medicine: thorax-heart
surgery (3651)
intensive-care medicine: heart-thorax
surgery (3652)
intensive-care medicine (3690)
other medical specialty (3700)
angiology (3750)
radiology (3751)
palliative care (3752)
pain therapy (3753)
section for alternative health practice
(3754)
spinal surgery (3755)
addiction medicine (3756)
visceral surgery (3757)
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other medical specialty (3790)
Date of Birth (DD.MM.YYYY)*
Gender*
male (1)
female (2)
Body Height (in cm)
Body weight at admission time (in kg)
Primary disease*
cardiomyopathy, idiopathic dilated (1000)
cardiomyopathy, dilated, not idiopathic
(1009)
cardiomyopathy, idiopathic restrictive
(1050)
cardiomyopathy, not idiopathic restrictive
(1059)
coronary heart disease (1200)
hypertrophic cardiomyopathy (1201)
heart valve disease (1202)
congenital heart disease (1203)
heart neoplasm (1204)
other heart diseases (1497)
Diabetes mellitus*
no (0)
yes, only set dietary (1)
yes, medical controlled (2)
yes, insulin dependent (3)
Hepatitis B*
Yes
No
Hepatitis C*
Yes
No
Patient was registered on a waiting list für Heart
Transplantation befor or during this stay?
Yes
No
Discharge
Recipient ID (ET-Number)
Hostpital discharge date  (DD.MM.YYYY)*
Discharge diagnosis according to ICD-10*
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Reason of Discharge*
treatment finished as planned (1)
transferral to nursing facility (10)
discharge to hospice (11)
external transferral to psychiatric
treatment (13)
treatment finished because of other
reasons, postdischarge treatment is
planned (14)
treatment aborted against medical
advice, postdischarge treatment is
planned (15)
internal transferral with change of DRG
payment Areas (17)
treatment finished as planned,
postdischarge treatment is planned (2)
case termination (internal transferral)
with change between full- and partial
stationary  care (22)
discharge at the end of the year with
admission in previous year  (25)
treatment finished because of other
reasons (3)
treatment aborted against medical
advice (4)
change of jurisdiction of insurer or other
payer (5)
transferral to another hospital (6)
death (7)
transferral to another hospital within
cooperative and governmental policies
(8)
transferral to rehabilitation facility (9)
Causes death (acute)
graft failure (1)
other causes deaths (10)
Malfunction of the heart assist system
(2)
thromboembolism (3)
Right heart failure (4)
respiratory failure (5)
infection (6)
rejection (7)
hemorrhage (8)
multiple organ failure (9)
Was patient discharged with an Assist
Device/TAH that has been implanted during this
stay?
Yes
No
Basic documentation recipient
Health Insurance Identifier*
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Received any thoracic surgical procedures before
admission ?*
Yes
No
Heart Transplantation
Yes
No
Assist Device/TAH
Yes
No
Coronary surgery
Yes
No
Operation on heart valve
Yes
No
Repair of cardiac defects
Yes
No
other
Yes
No
Number of previous cardiac operations
Number of previous cardiac operations unknown
Yes
No
Date of last thoracic surgery (TT.MM.JJJJ)
Was a Heart transplantation performed during
this stay ?*
Yes
No
Was an Assist Device/TAH implanted during this
stay?*
Yes
No
Rhesus phenotype*
positive (1)
negative (2)
not determined (9)
Blood group (AB)*
A (1)
B (2)
0 (3)
AB (4)
not determined (9)
Zip Code of Discharge*
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Facility's Section Identifier
Hospital admission date (DD.MM.YYYY)*
Medical specialty*
internal medicine (0100)
internal medicine: geriatrics (0102)
internal medicine: cardiology (0103)
internal medicine: nephrology (0104)
internal medicine: hematology and
internal oncology  (0105)
internal medicine: endocrinology (0106)
internal medicine: gastroenterology
(0107)
internal medicine: pneumonology (0108)
internal medicine: rheumatology (0109)
internal medicine: pulmonology (0114)
internal medicine: tumor research (0150)
internal medicine: coloproctology (0151)
internal medicine: infectiology (0152)
internal medicine: diabetes (0153)
internal medicine: naturopathy (0154)
internal medicine: stroke unit (0156)
internal medicine (0190)
geriatry (0200)
geriatry: gynecology  (0224)
geriatry: day unit (for semi-residential
care)   (0260)
geriaty: night unit (for semi-residential
care) (0261)
geriatry (0290)
cardiology (0300)
nephrology (0400)
nephrology: pediatrics (0410)
nephrology: intensive care (0436)
nephrology (0490)
hematology and internal oncology
(0500)
hematology and internal oncology:
pediatrics (0510)
hematology and internal oncology:
gynacology (0524)
hematology and internal oncology:
radiation therapy (0533)
hematology and internal oncology
(0590)
endocrinology (0600)
endicrinology: gastroenterology (0607)
endocrinology: pediatrics (0610)
endocrinology (0690)
gastroenterology (0700)
gastroenterology: endocrinology (0706)
gastroenterology: pediatrics (0710)
gastroenterology (0790)
pneumology (0800)
rheumatology (0900)
rheumatology: pediatrics (0910)
rheumatology (0990)
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pediatrics (1000)
pediatrics: nephrology (1004)
pediatrics: hematology and internal
oncology  (1005)
pediatrics: endocrinology (1006)
pediatrics: gastroenterology (1007)
pediatrics: rheumatology (1009)
pediatrics: pediatric cardiology (1011)
pediatrics: nephrology (1012)
pediatrics: pulmonology (1014)
pediatrics: pediatric neurology (1028)
pediatrics: perinatal medicine (1050)
continuing care for children (1051)
pediatrics (1090)
pediatric cardiology (1100)
pediatric cardiology: intensive care
(1136)
pediatric cardiology (1190)
neonatology (1200)
pediatric surgery (1300)
pulmonology (1400)
pulmonology: pediatrics (1410)
pulmonology (1490)
general surgery (1500)
general surgery: pediatric surgery (1513)
general surgery: trauma surgery (1516)
general surgery: vascular surgery (1518)
general surgery: plastic surgery (1519)
general surgery: thoracic surgery (1520)
general surgery: orthopedics (1523)
general surgery: intensive care (1536)
general surgery: abdominal- and
vascular surgery (1550)
Allgemeine Chirurgie: hand surgery
(1551)
general surgery (1590)
trauma surgery (1600)
neurosurgery (1700)
vascular surgery (1800)
plastic surgery (1900)
thoracic surgery (2000)
thoracic surgery: cardiac surgery (2021)
thoracic surgery: intensive care (2036)
thoracic surgery: cardiac surgery
intensive care (2050)
thoracic surgery (2090)
cardiac surgery (2100)
cardiac surgery: vascular surgery (2118)
cardiac surgery: thoracic surgery (2120)
cardiac surgery: intensive care (2136)
cardiac surgery: thoracic surgery and
intensive care (2150)
cardiac surgery (2190)
urology (2200)
orthopedics (2300)
orthopedics: rheumatology (2309)
orthopedics: surgery (2315)
orthopedics and trauma surgery (2316)
orthopedics (2390)
gynecology and obstetrics (2400)
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gynecology: geriatry (2402)
gynecology: hematology and internal
oncology  (2405)
gynecology: endocrinology (2406)
gynecology (2425)
gynecology and obstetrics (2490)
obstetrics (2500)
otolaryngology (2600)
ophthalmology (2700)
neurology: (2800)
neurology: pediatrics (2810)
neurology: stroke units (2856)
neurology (2890)
general psychiatry: (2900)
general psychiatry: neurology (2928)
general psychiatry: child and adolescent
psychiatry (2930)
general psychiatry: psychosomatics and
psychotherapy (2931)
general psychiatry: addiction treatment
(2950)
general psychiatry: geropsychiatry
(2951)
general psychiatry: forensic treatment
(2952)
general psychiatry: addiction treatment
(day unit) (2953)
general psychiatry: addiction treatment
(night unit) (2954)
general psychiatry: geropsychiatry (day
unit) (2955)
general psychiatry: geropsychiatry (night
unit) (2956)
general psychiatry: day unit (for semi-
residential care) (2960)
general psychiatry: night unit (for semi-
residential care) (2961)
general psychiatry (2990)
child and adolescent psychiatry (3000)
child and adolescent psychiatry: day unit
(for semi-residential care) (3060)
child and adolescent psychiatry: night
unit (for semi-residential care) (3061)
child and adolescent psychiatry (3090)
psychosomatic/psychotherapy (3100)
psychosomatic/psychotherapy: child and
adolescent psychiatry (3110)
psychosomatic/psychotherapy: day unit
(for semi-residential care) (3160)
psychosomatic/psychotherapy: night unit
(for semi-residential care) (3161)
psychosomatic/psychotherapy (3190)
nuclear medicine (3200)
nuclear medicine: radiation therapy
(3233)
nuclear medicine (3290)
radiation therapy (3300)
radiation therapy: hematology and
internal oncology  (3305)
radiation therapy: radiology (3350)
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radiation therapy (3390)
dermatology (3400)
dermatology: day unit (for semi-
residential care) (3460)
dermatology (3490)
dentistry, orthodontics, maxillofacial
surgery (3500)
intensive-care medicine (3600)
intensive-care medicine: internal
medicine (3601)
intensive-care medicine: cardiology
(3603)
intensive-care medicine: pediatrics
(3610)
intensive-care medicine: neurosurgery
(3617)
intensive-care medicine: surgery (3618)
intensive-care medicine: cardiac surgery
(3621)
intensive-care medicine: urology (3622)
intensive-care medicine: gynecology and
obstetrics (3624)
intensive-care medicine: otolaryngology
(3626)
intensive-care medicine: neurology
(3628)
operative intensive-care medicine:
surgery (3650)
intensive-care medicine: thorax-heart
surgery (3651)
intensive-care medicine: heart-thorax
surgery (3652)
intensive-care medicine (3690)
other medical specialty (3700)
angiology (3750)
radiology (3751)
palliative care (3752)
pain therapy (3753)
section for alternative health practice
(3754)
spinal surgery (3755)
addiction medicine (3756)
visceral surgery (3757)
other medical specialty (3790)
Date of Birth (DD.MM.YYYY)*
Gender*
male (1)
female (2)
Body Height (in cm)
Body weight at admission time (in kg)
Primary disease*
cardiomyopathy, idiopathic dilated (1000)
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cardiomyopathy, dilated, not idiopathic
(1009)
cardiomyopathy, idiopathic restrictive
(1050)
cardiomyopathy, not idiopathic restrictive
(1059)
coronary heart disease (1200)
hypertrophic cardiomyopathy (1201)
heart valve disease (1202)
congenital heart disease (1203)
heart neoplasm (1204)
other heart diseases (1497)
Diabetes mellitus*
no (0)
yes, only set dietary (1)
yes, medical controlled (2)
yes, insulin dependent (3)
Hepatitis B*
Yes
No
Hepatitis C*
Yes
No
Patient was registered on a waiting list für Heart
Transplantation befor or during this stay?
Yes
No
Discharge
Recipient ID (ET-Number)
Hostpital discharge date  (DD.MM.YYYY)*
Discharge diagnosis according to ICD-10*
Reason of Discharge*
treatment finished as planned (1)
transferral to nursing facility (10)
discharge to hospice (11)
external transferral to psychiatric
treatment (13)
treatment finished because of other
reasons, postdischarge treatment is
planned (14)
treatment aborted against medical
advice, postdischarge treatment is
planned (15)
internal transferral with change of DRG
payment Areas (17)
treatment finished as planned,
postdischarge treatment is planned (2)
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case termination (internal transferral)
with change between full- and partial
stationary  care (22)
discharge at the end of the year with
admission in previous year  (25)
treatment finished because of other
reasons (3)
treatment aborted against medical
advice (4)
change of jurisdiction of insurer or other
payer (5)
transferral to another hospital (6)
death (7)
transferral to another hospital within
cooperative and governmental policies
(8)
transferral to rehabilitation facility (9)
Causes death (acute)
graft failure (1)
other causes deaths (10)
Malfunction of the heart assist system
(2)
thromboembolism (3)
Right heart failure (4)
respiratory failure (5)
infection (6)
rejection (7)
hemorrhage (8)
multiple organ failure (9)
Was patient discharged with an Assist
Device/TAH that has been implanted during this
stay?
Yes
No
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Quality assurance Follow-up  Living
Donor Liver Transplant (AQUA)
Follow-up(to be filled out after 1, 2 and 3
years)
Health Insurance Identifier*
Bilirubin i. S. in µmol/l
Bilirubin in Serum unknown
yes (1)
Gamma-GT(in U/l)
Gamma-GT unknown
yes (1)
procedure-specific complication
no (0)
yes (1)
unknown (9)
Complications of biliary ducts
yes (1)
Incisional hernia
yes (1)
Complication related to liver
yes (1)
intraabdominal complications
yes (1)
other procedure-specific complications
yes (1)
Patient (Living donor) requires liver
transplantation?
no (0)
yes (1)
unknown (9)
Bilirubin Serum (in mg/dl)
Date of death (dd.mm.yyyy)
Zip Code of Discharge*
1 / 6
Facility's Section Identifier
Medical specialty*
internal medicine (0100)
internal medicine: geriatrics (0102)
internal medicine: cardiology (0103)
internal medicine: nephrology (0104)
internal medicine: hematology and
internal oncology  (0105)
internal medicine: endocrinology (0106)
internal medicine: gastroenterology
(0107)
internal medicine: pneumonology (0108)
internal medicine: rheumatology (0109)
internal medicine: pulmonology (0114)
internal medicine: tumor research (0150)
internal medicine: coloproctology (0151)
internal medicine: infectiology (0152)
internal medicine: diabetes (0153)
internal medicine: naturopathy (0154)
internal medicine: stroke unit (0156)
internal medicine (0190)
geriatry (0200)
geriatry: gynecology  (0224)
geriatry: day unit (for semi-residential
care)   (0260)
geriaty: night unit (for semi-residential
care) (0261)
geriatry (0290)
cardiology (0300)
nephrology (0400)
nephrology: pediatrics (0410)
nephrology: intensive care (0436)
nephrology (0490)
hematology and internal oncology
(0500)
hematology and internal oncology:
pediatrics (0510)
hematology and internal oncology:
gynacology (0524)
hematology and internal oncology:
radiation therapy (0533)
hematology and internal oncology
(0590)
endocrinology (0600)
endicrinology: gastroenterology (0607)
endocrinology: pediatrics (0610)
endocrinology (0690)
gastroenterology (0700)
gastroenterology: endocrinology (0706)
gastroenterology: pediatrics (0710)
gastroenterology (0790)
pneumology (0800)
rheumatology (0900)
rheumatology: pediatrics (0910)
rheumatology (0990)
pediatrics (1000)
pediatrics: nephrology (1004)
pediatrics: hematology and internal
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oncology  (1005)
pediatrics: endocrinology (1006)
pediatrics: gastroenterology (1007)
pediatrics: rheumatology (1009)
pediatrics: pediatric cardiology (1011)
pediatrics: nephrology (1012)
pediatrics: pulmonology (1014)
pediatrics: pediatric neurology (1028)
pediatrics: perinatal medicine (1050)
continuing care for children (1051)
pediatrics (1090)
pediatric cardiology (1100)
pediatric cardiology: intensive care
(1136)
pediatric cardiology (1190)
neonatology (1200)
pediatric surgery (1300)
pulmonology (1400)
pulmonology: pediatrics (1410)
pulmonology (1490)
general surgery (1500)
general surgery: pediatric surgery (1513)
general surgery: trauma surgery (1516)
general surgery: vascular surgery (1518)
general surgery: plastic surgery (1519)
general surgery: thoracic surgery (1520)
general surgery: orthopedics (1523)
general surgery: intensive care (1536)
general surgery: abdominal- and
vascular surgery (1550)
Allgemeine Chirurgie: hand surgery
(1551)
general surgery (1590)
trauma surgery (1600)
neurosurgery (1700)
vascular surgery (1800)
plastic surgery (1900)
thoracic surgery (2000)
thoracic surgery: cardiac surgery (2021)
thoracic surgery: intensive care (2036)
thoracic surgery: cardiac surgery
intensive care (2050)
thoracic surgery (2090)
cardiac surgery (2100)
cardiac surgery: vascular surgery (2118)
cardiac surgery: thoracic surgery (2120)
cardiac surgery: intensive care (2136)
cardiac surgery: thoracic surgery and
intensive care (2150)
cardiac surgery (2190)
urology (2200)
orthopedics (2300)
orthopedics: rheumatology (2309)
orthopedics: surgery (2315)
orthopedics and trauma surgery (2316)
orthopedics (2390)
gynecology and obstetrics (2400)
gynecology: geriatry (2402)
gynecology: hematology and internal
oncology  (2405)
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gynecology: endocrinology (2406)
gynecology (2425)
gynecology and obstetrics (2490)
obstetrics (2500)
otolaryngology (2600)
ophthalmology (2700)
neurology: (2800)
neurology: pediatrics (2810)
neurology: stroke units (2856)
neurology (2890)
general psychiatry: (2900)
general psychiatry: neurology (2928)
general psychiatry: child and adolescent
psychiatry (2930)
general psychiatry: psychosomatics and
psychotherapy (2931)
general psychiatry: addiction treatment
(2950)
general psychiatry: geropsychiatry
(2951)
general psychiatry: forensic treatment
(2952)
general psychiatry: addiction treatment
(day unit) (2953)
general psychiatry: addiction treatment
(night unit) (2954)
general psychiatry: geropsychiatry (day
unit) (2955)
general psychiatry: geropsychiatry (night
unit) (2956)
general psychiatry: day unit (for semi-
residential care) (2960)
general psychiatry: night unit (for semi-
residential care) (2961)
general psychiatry (2990)
child and adolescent psychiatry (3000)
child and adolescent psychiatry: day unit
(for semi-residential care) (3060)
child and adolescent psychiatry: night
unit (for semi-residential care) (3061)
child and adolescent psychiatry (3090)
psychosomatic/psychotherapy (3100)
psychosomatic/psychotherapy: child and
adolescent psychiatry (3110)
psychosomatic/psychotherapy: day unit
(for semi-residential care) (3160)
psychosomatic/psychotherapy: night unit
(for semi-residential care) (3161)
psychosomatic/psychotherapy (3190)
nuclear medicine (3200)
nuclear medicine: radiation therapy
(3233)
nuclear medicine (3290)
radiation therapy (3300)
radiation therapy: hematology and
internal oncology  (3305)
radiation therapy: radiology (3350)
radiation therapy (3390)
dermatology (3400)
dermatology: day unit (for semi-
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residential care) (3460)
dermatology (3490)
dentistry, orthodontics, maxillofacial
surgery (3500)
intensive-care medicine (3600)
intensive-care medicine: internal
medicine (3601)
intensive-care medicine: cardiology
(3603)
intensive-care medicine: pediatrics
(3610)
intensive-care medicine: neurosurgery
(3617)
intensive-care medicine: surgery (3618)
intensive-care medicine: cardiac surgery
(3621)
intensive-care medicine: urology (3622)
intensive-care medicine: gynecology and
obstetrics (3624)
intensive-care medicine: otolaryngology
(3626)
intensive-care medicine: neurology
(3628)
operative intensive-care medicine:
surgery (3650)
intensive-care medicine: thorax-heart
surgery (3651)
intensive-care medicine: heart-thorax
surgery (3652)
intensive-care medicine (3690)
other medical specialty (3700)
angiology (3750)
radiology (3751)
palliative care (3752)
pain therapy (3753)
section for alternative health practice
(3754)
spinal surgery (3755)
addiction medicine (3756)
visceral surgery (3757)
other medical specialty (3790)
Donor ID (ET-Number)*
Date of Birth (DD.MM.YYYY)*
Gender*
male (1)
female (2)
Date of living donor transplantation
(dd.mm.yyyy)*
Date of Follow-up examination (dd.mm.yyyy)*
Type of follow-up inquiry*
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patient was personally in hospital (1)
telephone contact with patient  (2)
telephone contact with doctor further
treatment (3)
written information from the doctor
further treatment (4)
information about relatives/carers of
patients  (5)
no contact with patient, doctor further
treatment or relatives/carers of patients
(6)
Follow-up: Years after living donor transplant: ((1,
2, 3))*
Deceased patient*
no (0)
yes (1)
unknown (9)
Date of last transplant (dd.mm.yyyy)
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Quality assurance Heart and Lung
Transplantation - Basic (AQUA)
Basic documentation Recipient
Healthcare Facility Identifier *
Primary disease*
obstructive lung disease (1)
restrictive lung disease (2)
pulmonary hypertension (3)
cystic fibrosis (4)
other primary disease (9)
Body weight at admission time (in kg)
Body Height (in cm)
Gender*
male (1)
female (2)
Date of Birth (DD.MM.YYYY)*
Recipient ID (ET-Number)*
Medical specialty*
internal medicine (0100)
internal medicine: geriatrics (0102)
internal medicine: cardiology (0103)
internal medicine: nephrology (0104)
internal medicine: hematology and
internal oncology  (0105)
internal medicine: endocrinology (0106)
internal medicine: gastroenterology
(0107)
internal medicine: pneumonology (0108)
internal medicine: rheumatology (0109)
internal medicine: pulmonology (0114)
internal medicine: tumor research (0150)
internal medicine: coloproctology (0151)
internal medicine: infectiology (0152)
internal medicine: diabetes (0153)
internal medicine: naturopathy (0154)
internal medicine: stroke unit (0156)
internal medicine (0190)
geriatry (0200)
geriatry: gynecology  (0224)
geriatry: day unit (for semi-residential
care)   (0260)
geriaty: night unit (for semi-residential
care) (0261)
geriatry (0290)
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cardiology (0300)
nephrology (0400)
nephrology: pediatrics (0410)
nephrology: intensive care (0436)
nephrology (0490)
hematology and internal oncology
(0500)
hematology and internal oncology:
pediatrics (0510)
hematology and internal oncology:
gynacology (0524)
hematology and internal oncology:
radiation therapy (0533)
hematology and internal oncology
(0590)
endocrinology (0600)
endicrinology: gastroenterology (0607)
endocrinology: pediatrics (0610)
endocrinology (0690)
gastroenterology (0700)
gastroenterology: endocrinology (0706)
gastroenterology: pediatrics (0710)
gastroenterology (0790)
pneumology (0800)
rheumatology (0900)
rheumatology: pediatrics (0910)
rheumatology (0990)
pediatrics (1000)
pediatrics: nephrology (1004)
pediatrics: hematology and internal
oncology  (1005)
pediatrics: endocrinology (1006)
pediatrics: gastroenterology (1007)
pediatrics: rheumatology (1009)
pediatrics: pediatric cardiology (1011)
pediatrics: nephrology (1012)
pediatrics: pulmonology (1014)
pediatrics: pediatric neurology (1028)
pediatrics: perinatal medicine (1050)
continuing care for children (1051)
pediatrics (1090)
pediatric cardiology (1100)
pediatric cardiology: intensive care
(1136)
pediatric cardiology (1190)
neonatology (1200)
pediatric surgery (1300)
pulmonology (1400)
pulmonology: pediatrics (1410)
pulmonology (1490)
general surgery (1500)
general surgery: pediatric surgery (1513)
general surgery: trauma surgery (1516)
general surgery: vascular surgery (1518)
general surgery: plastic surgery (1519)
general surgery: thoracic surgery (1520)
general surgery: orthopedics (1523)
general surgery: intensive care (1536)
general surgery: abdominal- and
vascular surgery (1550)
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Allgemeine Chirurgie: hand surgery
(1551)
general surgery (1590)
trauma surgery (1600)
neurosurgery (1700)
vascular surgery (1800)
plastic surgery (1900)
thoracic surgery (2000)
thoracic surgery: cardiac surgery (2021)
thoracic surgery: intensive care (2036)
thoracic surgery: cardiac surgery
intensive care (2050)
thoracic surgery (2090)
cardiac surgery (2100)
cardiac surgery: vascular surgery (2118)
cardiac surgery: thoracic surgery (2120)
cardiac surgery: intensive care (2136)
cardiac surgery: thoracic surgery and
intensive care (2150)
cardiac surgery (2190)
urology (2200)
orthopedics (2300)
orthopedics: rheumatology (2309)
orthopedics: surgery (2315)
orthopedics and trauma surgery (2316)
orthopedics (2390)
gynecology and obstetrics (2400)
gynecology: geriatry (2402)
gynecology: hematology and internal
oncology  (2405)
gynecology: endocrinology (2406)
gynecology (2425)
gynecology and obstetrics (2490)
obstetrics (2500)
otolaryngology (2600)
ophthalmology (2700)
neurology: (2800)
neurology: pediatrics (2810)
neurology: stroke units (2856)
neurology (2890)
general psychiatry: (2900)
general psychiatry: neurology (2928)
general psychiatry: child and adolescent
psychiatry (2930)
general psychiatry: psychosomatics and
psychotherapy (2931)
general psychiatry: addiction treatment
(2950)
general psychiatry: geropsychiatry
(2951)
general psychiatry: forensic treatment
(2952)
general psychiatry: addiction treatment
(day unit) (2953)
general psychiatry: addiction treatment
(night unit) (2954)
general psychiatry: geropsychiatry (day
unit) (2955)
general psychiatry: geropsychiatry (night
unit) (2956)
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general psychiatry: day unit (for semi-
residential care) (2960)
general psychiatry: night unit (for semi-
residential care) (2961)
general psychiatry (2990)
child and adolescent psychiatry (3000)
child and adolescent psychiatry: day unit
(for semi-residential care) (3060)
child and adolescent psychiatry: night
unit (for semi-residential care) (3061)
child and adolescent psychiatry (3090)
psychosomatic/psychotherapy (3100)
psychosomatic/psychotherapy: child and
adolescent psychiatry (3110)
psychosomatic/psychotherapy: day unit
(for semi-residential care) (3160)
psychosomatic/psychotherapy: night unit
(for semi-residential care) (3161)
psychosomatic/psychotherapy (3190)
nuclear medicine (3200)
nuclear medicine: radiation therapy
(3233)
nuclear medicine (3290)
radiation therapy (3300)
radiation therapy: hematology and
internal oncology  (3305)
radiation therapy: radiology (3350)
radiation therapy (3390)
dermatology (3400)
dermatology: day unit (for semi-
residential care) (3460)
dermatology (3490)
dentistry, orthodontics, maxillofacial
surgery (3500)
intensive-care medicine (3600)
intensive-care medicine: internal
medicine (3601)
intensive-care medicine: cardiology
(3603)
intensive-care medicine: pediatrics
(3610)
intensive-care medicine: neurosurgery
(3617)
intensive-care medicine: surgery (3618)
intensive-care medicine: cardiac surgery
(3621)
intensive-care medicine: urology (3622)
intensive-care medicine: gynecology and
obstetrics (3624)
intensive-care medicine: otolaryngology
(3626)
intensive-care medicine: neurology
(3628)
operative intensive-care medicine:
surgery (3650)
intensive-care medicine: thorax-heart
surgery (3651)
intensive-care medicine: heart-thorax
surgery (3652)
intensive-care medicine (3690)
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other medical specialty (3700)
angiology (3750)
radiology (3751)
palliative care (3752)
pain therapy (3753)
section for alternative health practice
(3754)
spinal surgery (3755)
addiction medicine (3756)
visceral surgery (3757)
other medical specialty (3790)
Hospital admission date (DD.MM.YYYY)*
Facility's Section Identifier
Zip Code of Discharge*
Blood group*
CodelistItem 587908 (1)
CodelistItem 587909 (2)
CodelistItem 587910 (3)
CodelistItem 587912 (4)
Immunsuppression at time of discharge
Cyclosporine
Yes
No
Tacrolimus
Yes
No
Azathioprine
Yes
No
Mycophenolat
Yes
No
Steroids
Yes
No
m-ToR-Inhibitor
Yes
No
other
Yes
No
Patient received tracheotomy at time of discharge
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Yes
No
FEV 1 (predictive value)(in %)
Discharge recipient
Hostpital discharge date  (DD.MM.YYYY)*
Discharge diagnosis according to ICD-10-GM*
Reason of Discharge*
treatment finished as planned (1)
transferral to nursing facility (10)
discharge to hospice (11)
external transferral to psychiatric
treatment (13)
treatment finished because of other
reasons, postdischarge treatment is
planned (14)
treatment aborted against medical
advice, postdischarge treatment is
planned (15)
internal transferral with change of DRG
payment areas (17)
treatment finished as planned,
postdischarge treatment is planned (2)
case termination (internal transferral)
with change between full- and partial
stationary  care (22)
discharge at the end of the year with
admission in previous year (25)
treatment finished because of other
reasons (3)
treatment aborted against medical
advice (4)
change of jurisdiction of insurer or other
payer (5)
transferral to another hospital (6)
death (7)
transferral to another hospital within
cooperative and governmental policies
(8)
transferral to rehabilitation facility (9)
Causes deaths (acute)
non specific graft failure (1)
infection (2)
cardiovascular (3)
technical complications (4)
rejection (5)
multiple organ failure (6)
other causes deaths (9)
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Quality assurance Liver Transplant:
Basic (AQUA)
Basic documentation of organ recipient
Health Insurance Identifier*
Body Height (in cm)
Gender*
male (1)
female (2)
Date of Birth (dd.mm.yyyy)*
Recipient ID (ET-Number)*
Medical specialty*
internal medicine (0100)
internal medicine: geriatrics (0102)
internal medicine: cardiology (0103)
internal medicine: nephrology (0104)
internal medicine: hematology and
internal oncology  (0105)
internal medicine: endocrinology (0106)
internal medicine: gastroenterology
(0107)
internal medicine: pneumonology (0108)
internal medicine: rheumatology (0109)
internal medicine: pulmonology (0114)
internal medicine: tumor research (0150)
internal medicine: coloproctology (0151)
internal medicine: infectiology (0152)
internal medicine: diabetes (0153)
internal medicine: naturopathy (0154)
internal medicine: stroke unit (0156)
internal medicine (0190)
geriatry (0200)
geriatry: gynecology  (0224)
geriatry: day unit (for semi-residential
care)   (0260)
geriaty: night unit (for semi-residential
care) (0261)
geriatry (0290)
cardiology (0300)
nephrology (0400)
nephrology: pediatrics (0410)
nephrology: intensive care (0436)
nephrology (0490)
hematology and internal oncology
(0500)
hematology and internal oncology:
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pediatrics (0510)
hematology and internal oncology:
gynacology (0524)
hematology and internal oncology:
radiation therapy (0533)
hematology and internal oncology
(0590)
endocrinology (0600)
endicrinology: gastroenterology (0607)
endocrinology: pediatrics (0610)
endocrinology (0690)
gastroenterology (0700)
gastroenterology: endocrinology (0706)
gastroenterology: pediatrics (0710)
gastroenterology (0790)
pneumology (0800)
rheumatology (0900)
rheumatology: pediatrics (0910)
rheumatology (0990)
pediatrics (1000)
pediatrics: nephrology (1004)
pediatrics: hematology and internal
oncology  (1005)
pediatrics: endocrinology (1006)
pediatrics: gastroenterology (1007)
pediatrics: rheumatology (1009)
pediatrics: pediatric cardiology (1011)
pediatrics: nephrology (1012)
pediatrics: pulmonology (1014)
pediatrics: pediatric neurology (1028)
pediatrics: perinatal medicine (1050)
continuing care for children (1051)
pediatrics (1090)
pediatric cardiology (1100)
pediatric cardiology: intensive care
(1136)
pediatric cardiology (1190)
neonatology (1200)
pediatric surgery (1300)
pulmonology (1400)
pulmonology: pediatrics (1410)
pulmonology (1490)
general surgery (1500)
general surgery: pediatric surgery (1513)
general surgery: trauma surgery (1516)
general surgery: vascular surgery (1518)
general surgery: plastic surgery (1519)
general surgery: thoracic surgery (1520)
general surgery: orthopedics (1523)
general surgery: intensive care (1536)
general surgery: abdominal- and
vascular surgery (1550)
Allgemeine Chirurgie: hand surgery
(1551)
general surgery (1590)
trauma surgery (1600)
neurosurgery (1700)
vascular surgery (1800)
plastic surgery (1900)
thoracic surgery (2000)
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thoracic surgery: cardiac surgery (2021)
thoracic surgery: intensive care (2036)
thoracic surgery: cardiac surgery
intensive care (2050)
thoracic surgery (2090)
cardiac surgery (2100)
cardiac surgery: vascular surgery (2118)
cardiac surgery: thoracic surgery (2120)
cardiac surgery: intensive care (2136)
cardiac surgery: thoracic surgery and
intensive care (2150)
cardiac surgery (2190)
urology (2200)
orthopedics (2300)
orthopedics: rheumatology (2309)
orthopedics: surgery (2315)
orthopedics and trauma surgery (2316)
orthopedics (2390)
gynecology and obstetrics (2400)
gynecology: geriatry (2402)
gynecology: hematology and internal
oncology  (2405)
gynecology: endocrinology (2406)
gynecology (2425)
gynecology and obstetrics (2490)
obstetrics (2500)
otolaryngology (2600)
ophthalmology (2700)
neurology: (2800)
neurology: pediatrics (2810)
neurology: stroke units (2856)
neurology (2890)
general psychiatry: (2900)
general psychiatry: neurology (2928)
general psychiatry: child and adolescent
psychiatry (2930)
general psychiatry: psychosomatics and
psychotherapy (2931)
general psychiatry: addiction treatment
(2950)
general psychiatry: geropsychiatry
(2951)
general psychiatry: forensic treatment
(2952)
general psychiatry: addiction treatment
(day unit) (2953)
general psychiatry: addiction treatment
(night unit) (2954)
general psychiatry: geropsychiatry (day
unit) (2955)
general psychiatry: geropsychiatry (night
unit) (2956)
general psychiatry: day unit (for semi-
residential care) (2960)
general psychiatry: night unit (for semi-
residential care) (2961)
general psychiatry (2990)
child and adolescent psychiatry (3000)
child and adolescent psychiatry: day unit
(for semi-residential care) (3060)
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child and adolescent psychiatry: night
unit (for semi-residential care) (3061)
child and adolescent psychiatry (3090)
psychosomatic/psychotherapy (3100)
psychosomatic/psychotherapy: child and
adolescent psychiatry (3110)
psychosomatic/psychotherapy: day unit
(for semi-residential care) (3160)
psychosomatic/psychotherapy: night unit
(for semi-residential care) (3161)
psychosomatic/psychotherapy (3190)
nuclear medicine (3200)
nuclear medicine: radiation therapy
(3233)
nuclear medicine (3290)
radiation therapy (3300)
radiation therapy: hematology and
internal oncology  (3305)
radiation therapy: radiology (3350)
radiation therapy (3390)
dermatology (3400)
dermatology: day unit (for semi-
residential care) (3460)
dermatology (3490)
dentistry, orthodontics, maxillofacial
surgery (3500)
intensive-care medicine (3600)
intensive-care medicine: internal
medicine (3601)
intensive-care medicine: cardiology
(3603)
intensive-care medicine: pediatrics
(3610)
intensive-care medicine: neurosurgery
(3617)
intensive-care medicine: surgery (3618)
intensive-care medicine: cardiac surgery
(3621)
intensive-care medicine: urology (3622)
intensive-care medicine: gynecology and
obstetrics (3624)
intensive-care medicine: otolaryngology
(3626)
intensive-care medicine: neurology
(3628)
operative intensive-care medicine:
surgery (3650)
intensive-care medicine: thorax-heart
surgery (3651)
intensive-care medicine: heart-thorax
surgery (3652)
intensive-care medicine (3690)
other medical specialty (3700)
angiology (3750)
radiology (3751)
palliative care (3752)
pain therapy (3753)
section for alternative health practice
(3754)
spinal surgery (3755)
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addiction medicine (3756)
visceral surgery (3757)
other medical specialty (3790)
Admission date (dd.mm.yyyy)*
Facility's Section Identifier
Zip Code of Discharge*
Body weight at admission time (in kg)*
Discharge organ recipient
Hostpital discharge date  (dd.mm.yyyy)*
Discharge diagnosis/es*
Discharge diagnosis according to European Liver
Transplant Registry
Acute hepatic failure-Fulminant or
Subfulm hepatitis-Virus A (A1)
Acute hepatic failure-Post operative
(A10)
Acute hepatic failure-Post traumatic
(A11)
Acute hepatic failure-Others (A12)
Subacute hepatitis-Virus A (A13)
Subacute hepatitis-Virus B (A14)
Subacute hepatitis-Virus C (A15)
Subacute hepatitis-Virus D (A16)
Subacute hepatitis-Other known (A17)
Subacute hepatitis-Other unknown (A18)
Subacute hepatitis-Paracetamol (A19)
Acute hepatic failure-Fulminant or
Subfulm hepatitis-Virus B (A2)
Subacute hepatitis-Other drug related
(A20)
Subacute hepatitis-Toxic (non drug)
(A21)
Acute hepatic failure-Fulminant or
Subfulm hepatitis-Virus C (A3)
Acute hepatic failure-Fulminant or
Subfulm hepatitis-Virus D (A4)
Acute hepatic failure-Fulminant or
Subfulm hepatitis-Other known (A5)
Acute hepatic failure-Fulminant or
Subfulm hepatitis-Other unknown (A6)
Acute hepatic failure-Fulminant or
Subfulm hepatitis-Paracetamol (A7)
Acute hepatic failure-Fulm or Subfulm
hep-Other drug related (A8)
Acute hepatic failure-Fulminant or
Subfulm hepatitis-Toxic (non drug) (A9)
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Cholestatic disease-Secondary biliary
cirrhosis (B1)
Cholestatic disease-Primary biliary
cirrhosis (B2)
Cholestatic disease-Primary sclerosing
cholangitis (B3)
Cholestatic disease-Others (B4)
Congenital biliary disease-Caroli disease
(C1)
Congenital biliary disease-Extrahepatic
biliary atresia (C2)
Congenital biliary disease-Congenital
biliary fibrosis (C4)
Congenital biliary disease-Choledochal
cyst (C5)
Congenital biliary disease-Alagille
syndrome (C6)
Congenital biliary disease-Others (C7)
Cirrhosis-Alcoholic cirrhosis (D1)
Cirrhosis-Other cirrhosis (D10)
Cirrhosis-Cryptogenic (unknown)
cirrhosis (D11)
Cirrhosis-Autoimmune Cirrhosis (D2)
Cirrhosis-Virus B related cirrhosis (D3)
Cirrhosis-Virus C related cirrhosis (D4)
Cirrhosis-Virus BD related cirrhosis (D5)
Cirrhosis-Virus BC related cirrhosis (D6)
Cirrhosis-Virus BCD related cirrhosis
(D7)
Cirrhosis-Virus related cirrhosis - Other
viruses (D8)
Cirrhosis-Post hepatitic cirrhosis - Drug
related (D9)
Cancers-Hepatocellular carcinoma and
cirrhosis (E1)
Cancers-Secondary liver tumors - Other
neuroendocrine (E10)
Cancers-Secondary liver tumors -
Colorectal (E11)
Cancers-Secondary liver tumors - GI non
colorectal (E12)
Cancers-Secondary liver tumors - Non
gastrointestinal (E13)
Cancers-Other liver malignancies (E14)
Cancers-Hepatocellular carcinoma and
non cirrhotic liver (E2)
Cancers-Hepatocellular carcinoma -
Fibrolamellar (E3)
Cancers-Biliary tract carcinoma
(Klatskin) (E4)
Cancers-Hepatic cholangiocellular
carcinoma (E5)
Cancers-Hepatoblastoma (E6)
Cancers-Epithelioid
hemangioendothelioma (E7)
Cancers-Angiosarcoma (E8)
Cancers-Secondary liver tumors -
Carcinoid (E9)
Metabolic diseases-Wilson disease (F1)
Metabolic diseases-Other porphyria
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(F10)
Metabolic diseases-Crigler-Najjar (F11)
Metabolic diseases-Cystic fibrosis (F12)
Metabolic diseases-Byler disease (F13)
Metabolic diseases-Others (F14)
Metabolic diseases-Hemochromatosis
(F2)
Metabolic dis-Alpha-1 - Antitrypsin
deficiency (F3)
Metabolic diseases-Glycogen storage
disease (F4)
Metabolic dis-Homozygous
Hypercholesterolemia (F5)
Metabolic diseases-Tyrosinemia (F6)
Metabolic diseases-Familial amyloïdotic
polyneuropathy (F7)
Metabolic diseases-Primary
hyperoxaluria (F8)
Metabolic diseases-Protoporphyria (F9)
Budd Chiari (G)
Benign liver tumors or Polycystic dis-
Hepatic adenoma (H1)
Benign liver tumors or Polycystic dis-
Adenomatosis (H2)
Benign liver tumors or Polycystic dis-
Hemangioma (H3)
Benign liver tumors or Polycystic dis-
Focal nodular hyperplasia (H4)
Benign liver tumors or Polycystic dis-
Polycystic disease (H5)
Benign liver tumors or Polycystic dis-
Nodular regenerative hyperplasia (H6)
Benign liver tumors or Polycystic dis-
Other benign tumors (H7)
Parasitic disease-Schistosomia
(Bilharzia) (I1)
Parasitic disease-Alveolar
echinococcosis (I2)
Parasitic disease-Cystic hydatidosis (I3)
Parasitic disease-Others (I4)
Other liver diseases (J)
Not available (K)
Primary Nonfunction (L)
Reason for discharge*
treatment finished as planned (1)
transferral to nursing facility (10)
discharge to hospice (11)
external transferral to psychiatric
treatment (13)
treatment finished because of other
reasons, postdischarge treatment is
planned (14)
treatment aborted against medical
advice, postdischarge treatment is
planned (15)
internal transferral with change of DRG
payment Areas (17)
treatment finished as planned,
postdischarge treatment is planned (2)
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case termination (internal transferral)
with change between full- and partial
stationary  care (22)
discharge at the end of the year with
admission in previous year  (25)
treatment finished because of other
reasons (3)
treatment aborted against medical
advice (4)
change of jurisdiction of insurer or other
payer (5)
transferral to another hospital (6)
death (7)
transferral to another hospital within
cooperative and governmental policies
(8)
transferral to rehabilitation facility (9)
Cause of death
Intraoperative death (death on table)
(A1)
Infection-Bacterial infection (B1)
Infection-Viral infection (B2)
Infection-HIV (B3)
Infection-Fungal infection (B4)
Infection-Parasitic infection (B5)
Infection-Other known infect (B6)
Liver complications-Acute rejection (C1)
Liv complic-Recurrence of original dis
(C10)
Liv complic-Recurrence of original dis
(C11)
Liv complic-Recurrence of original dis
(C12)
Liv complic-Recurrence of original dis
(C13)
Liv complic-Recurrence of original dis
(C14)
Liv complic-Recurrence of original dis
(C15)
Liv complic-Recurrence of original dis
(C16)
Liv complic-Recur of orig dis (C17)
Liver complic-De novo hepatitis B virus
(C18)
Liver complications-De novo hepatitis C
virus (C19)
Liver complications-Chronic rejection
(C2)
Liver complications-De novo hepatitis D
virus (C20)
Liver complic-Massive hemorrhagic
necrosis (C21)
Liver complications-Other viral hepatitis
(C22)
Liver complications-Infection (C23)
Liver complications-Other (C24)
Liver complications-Arterial thrombosis
(C3)
Liver complic-Hepatic vein thrombosis
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(C4)
Liver complic-Primary N-function (Retx
or death < (C5)
Liv complic-Primary dysfunction (Retx or
death > 7d) (C6)
Liver complic-Anastomotic biliary complic
(C7)
Liver complic-Non anastomotic biliary
complic (C8)
Liver complic-Recurrence of original dis
(C9)
Gastrointestinal complications-GI
haemorrhage (D1)
Gastrointestinal complications-
Pancreatitis (D2)
Gastrointestinal complic-Visceral
perforation (D3)
Gastrointestinal complications-Other
(D4)
Cardiovascular complications-Myocardial
infarction (E1)
Cardiovascular complications-Other
cause (E2)
Cerebrovascular complications-
Intracranial haemorrhage (F1)
Cerebrovascular complications-Ischemic
stroke (F2)
Cerebrovascular complications-Cerebral
oedema (F3)
Cerebrovascular complications-Cerebral
infection (F4)
Tumor-Recurrence of original tumor (G1)
Tumor-Recurrence of previously
unrelated tumor (G2)
Tumor-De novo solid organ tumor (G3)
Tumor-Donor transmitted tumor (G4)
Tumor-Lympho proliferation disease (G5)
Kidney failure (H1)
Urinary tract infection (H2)
Pulmonary complications-Embolism (I1)
Pulmonary complications-Infection (I2)
Social complic-Non compliance
immunosup therapy (J1)
Social complications-Suicide (J2)
Social complications-Trauma (Motor,
Vehicle,..) (J3)
Bone marrow depression (K1)
Other cause (L1)
Not available (M1)
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Liver Transplant : Transplantation
Number of transplantations during this stay?*
Organ recipient
Urgency of transplantation according to  Medical
Urgency Code ET-Status*
HU (High Urgency ) (1)
ACO (Approved Combined Organ) (2)
T (Transplantable) (3)
Reason for exceptional MELD
non-standard-exception (0)
standard-exception (1)
exceptional MELD
Exceptional MELD score assigned?*
Yes
No
Dialysis or hemofiltration*
Yes
No
INR (International Normalized Ratio)*
Creatinine Serum (in µmol/l)
Creatinine Serum(in mg/dl)
Bilirubin i. S. in µmol/l(in µmol/l)
Bilirubin Serum (in mg/dl)
Standard exception
hepatocellular carcinoma (HCC) (1)
urea cycle disorders (10)
Morbus Osler (11)
hepatic hemangioendothelioma (12)
biliary sepsis (13)
primary sclerosing cholangitis (PSC) (14)
cholangiocarcinoma (15)
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non-metastatic hepatoblastoma (2)
adult polycystic degeneration of the liver
(APDL) (3)
primary hyperoxaluria type 1 (PH 1) (4)
small for size liver with indication for
retransplantation (5)
cystic fibrosis  (6)
familial amyloid neuropathy (FAP) (7)
hepatopulmonary syndrome (8)
portopulmonary hypertension (9)
Organ donor
Donor type*
brain-dead (1)
domino (2)
living (3)
Age of donor (years)*
Operation
Indication for liver transplantation*
Acute hepatic failure-Fulminant or
Subfulm hepatitis-Virus A (A1)
Acute hepatic failure-Post operative
(A10)
Acute hepatic failure-Post traumatic
(A11)
Acute hepatic failure-Others (A12)
Subacute hepatitis-Virus A (A13)
Subacute hepatitis-Virus B (A14)
Subacute hepatitis-Virus C (A15)
Subacute hepatitis-Virus D (A16)
Subacute hepatitis-Other known (A17)
Subacute hepatitis-Other unknown (A18)
Subacute hepatitis-Paracetamol (A19)
Acute hepatic failure-Fulminant or
Subfulm hepatitis-Virus B (A2)
Subacute hepatitis-Other drug related
(A20)
Subacute hepatitis-Toxic (non drug)
(A21)
Acute hepatic failure-Fulminant or
Subfulm hepatitis-Virus C (A3)
Acute hepatic failure-Fulminant or
Subfulm hepatitis-Virus D (A4)
Acute hepatic failure-Fulminant or
Subfulm hepatitis-Other known (A5)
Acute hepatic failure-Fulminant or
Subfulm hepatitis-Other unknown (A6)
Acute hepatic failure-Fulminant or
Subfulm hepatitis-Paracetamol (A7)
Acute hepatic failure-Fulm or Subfulm
hep-Other drug related (A8)
Acute hepatic failure-Fulminant or
Subfulm hepatitis-Toxic (non drug) (A9)
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Cholestatic disease-Secondary biliary
cirrhosis (B1)
Cholestatic disease-Primary biliary
cirrhosis (B2)
Cholestatic disease-Primary sclerosing
cholangitis (B3)
Cholestatic disease-Others (B4)
Congenital biliary disease-Caroli disease
(C1)
Congenital biliary disease-Extrahepatic
biliary atresia (C2)
Congenital biliary disease-Congenital
biliary fibrosis (C4)
Congenital biliary disease-Choledochal
cyst (C5)
Congenital biliary disease-Alagille
syndrome (C6)
Congenital biliary disease-Others (C7)
Cirrhosis-Alcoholic cirrhosis (D1)
Cirrhosis-Other cirrhosis (D10)
Cirrhosis-Cryptogenic (unknown)
cirrhosis (D11)
Cirrhosis-Autoimmune Cirrhosis (D2)
Cirrhosis-Virus B related cirrhosis (D3)
Cirrhosis-Virus C related cirrhosis (D4)
Cirrhosis-Virus BD related cirrhosis (D5)
Cirrhosis-Virus BC related cirrhosis (D6)
Cirrhosis-Virus BCD related cirrhosis
(D7)
Cirrhosis-Virus related cirrhosis - Other
viruses (D8)
Cirrhosis-Post hepatitic cirrhosis - Drug
related (D9)
Cancers-Hepatocellular carcinoma and
cirrhosis (E1)
Cancers-Secondary liver tumors - Other
neuroendocrine (E10)
Cancers-Secondary liver tumors -
Colorectal (E11)
Cancers-Secondary liver tumors - GI non
colorectal (E12)
Cancers-Secondary liver tumors - Non
gastrointestinal (E13)
Cancers-Other liver malignancies (E14)
Cancers-Hepatocellular carcinoma and
non cirrhotic liver (E2)
Cancers-Hepatocellular carcinoma -
Fibrolamellar (E3)
Cancers-Biliary tract carcinoma
(Klatskin) (E4)
Cancers-Hepatic cholangiocellular
carcinoma (E5)
Cancers-Hepatoblastoma (E6)
Cancers-Epithelioid
hemangioendothelioma (E7)
Cancers-Angiosarcoma (E8)
Cancers-Secondary liver tumors -
Carcinoid (E9)
Metabolic diseases-Wilson disease (F1)
Metabolic diseases-Other porphyria
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(F10)
Metabolic diseases-Crigler-Najjar (F11)
Metabolic diseases-Cystic fibrosis (F12)
Metabolic diseases-Byler disease (F13)
Metabolic diseases-Others (F14)
Metabolic diseases-Hemochromatosis
(F2)
Metabolic dis-Alpha-1 - Antitrypsin
deficiency (F3)
Metabolic diseases-Glycogen storage
disease (F4)
Metabolic dis-Homozygous
Hypercholesterolemia (F5)
Metabolic diseases-Tyrosinemia (F6)
Metabolic diseases-Familial amyloïdotic
polyneuropathy (F7)
Metabolic diseases-Primary
hyperoxaluria (F8)
Metabolic diseases-Protoporphyria (F9)
Budd Chiari (G)
Benign liver tumors or Polycystic dis-
Hepatic adenoma (H1)
Benign liver tumors or Polycystic dis-
Adenomatosis (H2)
Benign liver tumors or Polycystic dis-
Hemangioma (H3)
Benign liver tumors or Polycystic dis-
Focal nodular hyperplasia (H4)
Benign liver tumors or Polycystic dis-
Polycystic disease (H5)
Benign liver tumors or Polycystic dis-
Nodular regenerative hyperplasia (H6)
Benign liver tumors or Polycystic dis-
Other benign tumors (H7)
Parasitic disease-Schistosomia
(Bilharzia) (I1)
Parasitic disease-Alveolar
echinococcosis (I2)
Parasitic disease-Cystic hydatidosis (I3)
Parasitic disease-Others (I4)
Other liver diseases (J)
Not available (K)
Primary Nonfunction (L)
Operation date (dd.mm.yyyy)*
Operation *
Abortion of transplantation?*
Yes
No
Donor organ (type of transplantation)*
full size (1)
reduced size left lateral (2)
reduced size left (3)
reduced size right (4)
reduced size extended right (5)
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true split (6)
left lateral split (7)
extended right split (8)
Cold ischemia time (in hours)*
Cold ischemia time (additional minutes)*
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Quality assurance Follow-up Living
Donor Renal Transplant (AQUA)
Follow-up (to be completed after 1, 2 and
3 years)
Healthcare facility Identifier*
Date of death
Donor dependent on renal dialysis?
no (0)
yes (1)
unknown (9)
Serum creatinine level (in mg/dl)
Serum creatinine level(in µmol/l)
Serum creatinine Level unknown?
yes (1)
Urine albumin Level (in mg/l)
Urine albumin Level unknown
yes (1)
Urine albumin/creatinine ratio measurement (in
mg/g)
Urine albumin/creatinine ratio unknown
yes (1)
deceased donor*
no (0)
yes (1)
unknown or follow-up is not possible (9)
Follow-up: Year (s) after living donation*
Zip Code of Discharge*
Facility's Section Identifier
Medical specialty*
internal medicine (0100)
internal medicine: geriatrics (0102)
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internal medicine: cardiology (0103)
internal medicine: nephrology (0104)
internal medicine: hematology and
internal oncology  (0105)
internal medicine: endocrinology (0106)
internal medicine: gastroenterology
(0107)
internal medicine: pneumonology (0108)
internal medicine: rheumatology (0109)
internal medicine: pulmonology (0114)
internal medicine: tumor research (0150)
internal medicine: coloproctology (0151)
internal medicine: infectiology (0152)
internal medicine: diabetes (0153)
internal medicine: naturopathy (0154)
internal medicine: stroke unit (0156)
internal medicine (0190)
geriatry (0200)
geriatry: gynecology  (0224)
geriatry: day unit (for semi-residential
care)   (0260)
geriaty: night unit (for semi-residential
care) (0261)
geriatry (0290)
cardiology (0300)
nephrology (0400)
nephrology: pediatrics (0410)
nephrology: intensive care (0436)
nephrology (0490)
hematology and internal oncology
(0500)
hematology and internal oncology:
pediatrics (0510)
hematology and internal oncology:
gynacology (0524)
hematology and internal oncology:
radiation therapy (0533)
hematology and internal oncology
(0590)
endocrinology (0600)
endicrinology: gastroenterology (0607)
endocrinology: pediatrics (0610)
endocrinology (0690)
gastroenterology (0700)
gastroenterology: endocrinology (0706)
gastroenterology: pediatrics (0710)
gastroenterology (0790)
pneumology (0800)
rheumatology (0900)
rheumatology: pediatrics (0910)
rheumatology (0990)
pediatrics (1000)
pediatrics: nephrology (1004)
pediatrics: hematology and internal
oncology  (1005)
pediatrics: endocrinology (1006)
pediatrics: gastroenterology (1007)
pediatrics: rheumatology (1009)
pediatrics: pediatric cardiology (1011)
pediatrics: nephrology (1012)
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pediatrics: pulmonology (1014)
pediatrics: pediatric neurology (1028)
pediatrics: perinatal medicine (1050)
continuing care for children (1051)
pediatrics (1090)
pediatric cardiology (1100)
pediatric cardiology: intensive care
(1136)
pediatric cardiology (1190)
neonatology (1200)
pediatric surgery (1300)
pulmonology (1400)
pulmonology: pediatrics (1410)
pulmonology (1490)
general surgery (1500)
general surgery: pediatric surgery (1513)
general surgery: trauma surgery (1516)
general surgery: vascular surgery (1518)
general surgery: plastic surgery (1519)
general surgery: thoracic surgery (1520)
general surgery: orthopedics (1523)
general surgery: intensive care (1536)
general surgery: abdominal- and
vascular surgery (1550)
Allgemeine Chirurgie: hand surgery
(1551)
general surgery (1590)
trauma surgery (1600)
neurosurgery (1700)
vascular surgery (1800)
plastic surgery (1900)
thoracic surgery (2000)
thoracic surgery: cardiac surgery (2021)
thoracic surgery: intensive care (2036)
thoracic surgery: cardiac surgery
intensive care (2050)
thoracic surgery (2090)
cardiac surgery (2100)
cardiac surgery: vascular surgery (2118)
cardiac surgery: thoracic surgery (2120)
cardiac surgery: intensive care (2136)
cardiac surgery: thoracic surgery and
intensive care (2150)
cardiac surgery (2190)
urology (2200)
orthopedics (2300)
orthopedics: rheumatology (2309)
orthopedics: surgery (2315)
orthopedics and trauma surgery (2316)
orthopedics (2390)
gynecology and obstetrics (2400)
gynecology: geriatry (2402)
gynecology: hematology and internal
oncology  (2405)
gynecology: endocrinology (2406)
gynecology (2425)
gynecology and obstetrics (2490)
obstetrics (2500)
otolaryngology (2600)
ophthalmology (2700)
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neurology: (2800)
neurology: pediatrics (2810)
neurology: stroke units (2856)
neurology (2890)
general psychiatry: (2900)
general psychiatry: neurology (2928)
general psychiatry: child and adolescent
psychiatry (2930)
general psychiatry: psychosomatics and
psychotherapy (2931)
general psychiatry: addiction treatment
(2950)
general psychiatry: geropsychiatry
(2951)
general psychiatry: forensic treatment
(2952)
general psychiatry: addiction treatment
(day unit) (2953)
general psychiatry: addiction treatment
(night unit) (2954)
general psychiatry: geropsychiatry (day
unit) (2955)
general psychiatry: geropsychiatry (night
unit) (2956)
general psychiatry: day unit (for semi-
residential care) (2960)
general psychiatry: night unit (for semi-
residential care) (2961)
general psychiatry (2990)
child and adolescent psychiatry (3000)
child and adolescent psychiatry: day unit
(for semi-residential care) (3060)
child and adolescent psychiatry: night
unit (for semi-residential care) (3061)
child and adolescent psychiatry (3090)
psychosomatic/psychotherapy (3100)
psychosomatic/psychotherapy: child and
adolescent psychiatry (3110)
psychosomatic/psychotherapy: day unit
(for semi-residential care) (3160)
psychosomatic/psychotherapy: night unit
(for semi-residential care) (3161)
psychosomatic/psychotherapy (3190)
nuclear medicine (3200)
nuclear medicine: radiation therapy
(3233)
nuclear medicine (3290)
radiation therapy (3300)
radiation therapy: hematology and
internal oncology  (3305)
radiation therapy: radiology (3350)
radiation therapy (3390)
dermatology (3400)
dermatology: day unit (for semi-
residential care) (3460)
dermatology (3490)
dentistry, orthodontics, maxillofacial
surgery (3500)
intensive-care medicine (3600)
intensive-care medicine: internal
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medicine (3601)
intensive-care medicine: cardiology
(3603)
intensive-care medicine: pediatrics
(3610)
intensive-care medicine: neurosurgery
(3617)
intensive-care medicine: surgery (3618)
intensive-care medicine: cardiac surgery
(3621)
intensive-care medicine: urology (3622)
intensive-care medicine: gynecology and
obstetrics (3624)
intensive-care medicine: otolaryngology
(3626)
intensive-care medicine: neurology
(3628)
operative intensive-care medicine:
surgery (3650)
intensive-care medicine: thorax-heart
surgery (3651)
intensive-care medicine: heart-thorax
surgery (3652)
intensive-care medicine (3690)
other medical specialty (3700)
angiology (3750)
radiology (3751)
palliative care (3752)
pain therapy (3753)
section for alternative health practice
(3754)
spinal surgery (3755)
addiction medicine (3756)
visceral surgery (3757)
other medical specialty (3790)
Donor ID (ET-Number)*
Date of Birth (DD.MM.YYYY)*
Gender*
male (1)
female (2)
Date of living donor renal transplant*
Follow-up (referred to) program, appointment
date*
Type of Follow-Up Report*
patient was personally in hospital (1)
telephone contact with patient  (2)
telephone contact with doctor further
treatment (3)
written information from the doctor
further treatment (4)
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information about relatives/carers of
patients  (5)
no contact with patient, doctor further
treatment or relatives/carers of patients
(6)
Arterial hypertension
no (0)
yes (1)
unknown (9)
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Basic data recipient
Healthcare facility Identifier*
Body Height (in cm)*
Gender*
male (1)
female (2)
Date of Birth (DD.MM.YYYY)*
Receiver ID (ET-Number)*
Medical specialty*
internal medicine (0100)
internal medicine: geriatrics (0102)
internal medicine: cardiology (0103)
internal medicine: nephrology (0104)
internal medicine: hematology and
internal oncology  (0105)
internal medicine: endocrinology (0106)
internal medicine: gastroenterology
(0107)
internal medicine: pneumonology (0108)
internal medicine: rheumatology (0109)
internal medicine: pulmonology (0114)
internal medicine: tumor research (0150)
internal medicine: coloproctology (0151)
internal medicine: infectiology (0152)
internal medicine: diabetes (0153)
internal medicine: naturopathy (0154)
internal medicine: stroke unit (0156)
internal medicine (0190)
geriatry (0200)
geriatry: gynecology  (0224)
geriatry: day unit (for semi-residential
care)   (0260)
geriaty: night unit (for semi-residential
care) (0261)
geriatry (0290)
cardiology (0300)
nephrology (0400)
nephrology: pediatrics (0410)
nephrology: intensive care (0436)
nephrology (0490)
hematology and internal oncology
(0500)
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hematology and internal oncology:
pediatrics (0510)
hematology and internal oncology:
gynacology (0524)
hematology and internal oncology:
radiation therapy (0533)
hematology and internal oncology
(0590)
endocrinology (0600)
endicrinology: gastroenterology (0607)
endocrinology: pediatrics (0610)
endocrinology (0690)
gastroenterology (0700)
gastroenterology: endocrinology (0706)
gastroenterology: pediatrics (0710)
gastroenterology (0790)
pneumology (0800)
rheumatology (0900)
rheumatology: pediatrics (0910)
rheumatology (0990)
pediatrics (1000)
pediatrics: nephrology (1004)
pediatrics: hematology and internal
oncology  (1005)
pediatrics: endocrinology (1006)
pediatrics: gastroenterology (1007)
pediatrics: rheumatology (1009)
pediatrics: pediatric cardiology (1011)
pediatrics: nephrology (1012)
pediatrics: pulmonology (1014)
pediatrics: pediatric neurology (1028)
pediatrics: perinatal medicine (1050)
continuing care for children (1051)
pediatrics (1090)
pediatric cardiology (1100)
pediatric cardiology: intensive care
(1136)
pediatric cardiology (1190)
neonatology (1200)
pediatric surgery (1300)
pulmonology (1400)
pulmonology: pediatrics (1410)
pulmonology (1490)
general surgery (1500)
general surgery: pediatric surgery (1513)
general surgery: trauma surgery (1516)
general surgery: vascular surgery (1518)
general surgery: plastic surgery (1519)
general surgery: thoracic surgery (1520)
general surgery: orthopedics (1523)
general surgery: intensive care (1536)
general surgery: abdominal- and
vascular surgery (1550)
Allgemeine Chirurgie: hand surgery
(1551)
general surgery (1590)
trauma surgery (1600)
neurosurgery (1700)
vascular surgery (1800)
plastic surgery (1900)
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thoracic surgery (2000)
thoracic surgery: cardiac surgery (2021)
thoracic surgery: intensive care (2036)
thoracic surgery: cardiac surgery
intensive care (2050)
thoracic surgery (2090)
cardiac surgery (2100)
cardiac surgery: vascular surgery (2118)
cardiac surgery: thoracic surgery (2120)
cardiac surgery: intensive care (2136)
cardiac surgery: thoracic surgery and
intensive care (2150)
cardiac surgery (2190)
urology (2200)
orthopedics (2300)
orthopedics: rheumatology (2309)
orthopedics: surgery (2315)
orthopedics and trauma surgery (2316)
orthopedics (2390)
gynecology and obstetrics (2400)
gynecology: geriatry (2402)
gynecology: hematology and internal
oncology  (2405)
gynecology: endocrinology (2406)
gynecology (2425)
gynecology and obstetrics (2490)
obstetrics (2500)
otolaryngology (2600)
ophthalmology (2700)
neurology: (2800)
neurology: pediatrics (2810)
neurology: stroke units (2856)
neurology (2890)
general psychiatry: (2900)
general psychiatry: neurology (2928)
general psychiatry: child and adolescent
psychiatry (2930)
general psychiatry: psychosomatics and
psychotherapy (2931)
general psychiatry: addiction treatment
(2950)
general psychiatry: geropsychiatry
(2951)
general psychiatry: forensic treatment
(2952)
general psychiatry: addiction treatment
(day unit) (2953)
general psychiatry: addiction treatment
(night unit) (2954)
general psychiatry: geropsychiatry (day
unit) (2955)
general psychiatry: geropsychiatry (night
unit) (2956)
general psychiatry: day unit (for semi-
residential care) (2960)
general psychiatry: night unit (for semi-
residential care) (2961)
general psychiatry (2990)
child and adolescent psychiatry (3000)
child and adolescent psychiatry: day unit
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(for semi-residential care) (3060)
child and adolescent psychiatry: night
unit (for semi-residential care) (3061)
child and adolescent psychiatry (3090)
psychosomatic/psychotherapy (3100)
psychosomatic/psychotherapy: child and
adolescent psychiatry (3110)
psychosomatic/psychotherapy: day unit
(for semi-residential care) (3160)
psychosomatic/psychotherapy: night unit
(for semi-residential care) (3161)
psychosomatic/psychotherapy (3190)
nuclear medicine (3200)
nuclear medicine: radiation therapy
(3233)
nuclear medicine (3290)
radiation therapy (3300)
radiation therapy: hematology and
internal oncology  (3305)
radiation therapy: radiology (3350)
radiation therapy (3390)
dermatology (3400)
dermatology: day unit (for semi-
residential care) (3460)
dermatology (3490)
dentistry, orthodontics, maxillofacial
surgery (3500)
intensive-care medicine (3600)
intensive-care medicine: internal
medicine (3601)
intensive-care medicine: cardiology
(3603)
intensive-care medicine: pediatrics
(3610)
intensive-care medicine: neurosurgery
(3617)
intensive-care medicine: surgery (3618)
intensive-care medicine: cardiac surgery
(3621)
intensive-care medicine: urology (3622)
intensive-care medicine: gynecology and
obstetrics (3624)
intensive-care medicine: otolaryngology
(3626)
intensive-care medicine: neurology
(3628)
operative intensive-care medicine:
surgery (3650)
intensive-care medicine: thorax-heart
surgery (3651)
intensive-care medicine: heart-thorax
surgery (3652)
intensive-care medicine (3690)
other medical specialty (3700)
angiology (3750)
radiology (3751)
palliative care (3752)
pain therapy (3753)
section for alternative health practice
(3754)
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spinal surgery (3755)
addiction medicine (3756)
visceral surgery (3757)
other medical specialty (3790)
Admission date (dd.mm.yyyy)*
Facility's Section Identifier
Zip Code of Discharge*
Body weight at admission time (in kg)*
Recipient data
Kidney Diseases
Chronic renal failure, etiology uncertain
(1)
Glomerulonephritis, histologically NOT
examined (10)
Focal segmental glomerulosclerosis with
nephrotic syndrome in children (11)
IgA nephropathy (proven by
immunofluorescence, not code 76 and
not code 85) (12)
Dense deposit disease membrano-
proliferative GN, type II (proven by
immunofluorescence and/or electron
microscopy) (13)
Membranous nephropathy (14)
Membrano-proliferative GN, type I
(proven by immunofluorescence and/or
electron microscopy - not code 84 or 89)
(15)
Rapidly progressive GN without systemic
disease (crescentic, histologically
confirmed, not coded elsewhere) (16)
Focal segmental glomerulosclerosis with
nephrotic syndrome in adults (17)
Glomerulonephritis, histologically
examined (19)
Pyelonephritis/Interstitial nephritis-cause
not specified (20)
Pyelonephritis/interstitial nephritis
associated with neurogenic bladder (21)
Pyelonephritis/interstitial nephritis due to
congenital obstructive uropathy with or
without vesico-ureteric reflux (22)
Pyelonephritis/interstitial nephritis due to
acquired obstructive uropathy (23)
Pyelonephritis/interstitial nephritis due to
vesico-ureteric reflux without obstruction
(24)
Pyelonephritis/interstitial nephritis due to
urolithiasis (25)
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Pyelonephritis/interstitial nephritis due to
other cause (29)
Tubulo interstitial nephritis (not
pyelonephritis) (30)
Nephropathy due to analgesic drugs (31)
Nephropathy due to cisplatinum (32)
Nephropathy due to cyclosporin A (33)
Lead induced interstitial nephropathy
(34)
Nephropathy caused by other specific
drug (39)
Cystic kidney disease-type unspecified
(40)
Polycystic kidneys, adult type (dominant)
(41)
Polycystic kidneys, infantile (recessive)
(42)
Medullary cystic disease, including
nephronophthisis (43)
Cystic kidney disease-other specified
type (49)
Hereditary/Familial nephropathy-type
unspecified (50)
Hereditary nephritis with nerve deafness
(Alport's syndrome) (51)
Cystinosis (52)
Primary oxalosis (53)
Fabry's disease (54)
Hereditary nephropathy-other (59)
Congenital renal hypoplasia-type
unspecified (60)
Oligomeganephronic hypoplasia (61)
Congenital renal dysplasia with or
without urinary tract malformation (63)
Syndrome of agenesis of abdominal
muscles (Prune Belly syndrome) (66)
Renal vascular disease-type unspecified
(70)
Renal vascular disease due to malignant
hypertension (NO primary renal disease)
(71)
Renal vascular disease due to
hypertension (NO primary renal disease)
(72)
Renal vascular disease due to
polyarteritis (73)
Wegener's granulomatosis (74)
Ischemic renal disease / cholesterol
embolism (75)
Glomerulonephritis related to liver
cirrhosis (76)
Cryoglobulinemic glomerulonephrititis
(78)
Renal vascular disease-classified (79)
Diabetes Type I (80)
Diabetes Type II (81)
Myelomatosis/light chain deposit disease
(82)
Amyloidosis (83)
Lupus erythematosus (84)
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Henoch-Schönlein purpura (85)
Goodpasture's syndrome (86)
Systemic sclerosis (scleroderma) (87)
Hemolytic Uremic syndrome including
Moschcowitz syndrome (88)
Multisystem disease-other specified type
(89)
Cortical or tubular necrosis (90)
Tuberculosis (91)
Gout (92)
Nephrocalcinosis and hypercalcemic
nephropathy (93)
Balkan nephropathy (94)
Kidney tumor (95)
Traumatic or surgical loss of kidney (96)
Other identified renal disorders (99)
Pre-existing condition*
Yes
No
Diabetes mellitus
yes, treated dietetic (1)
yes, oral medication (2)
yes, treated with insulin (3)
yes, untreated (4)
Duration of diabetes (in years)
Renal replacement therapy
Yes
No
Start of renal replacement therapy
(DD.MM.YYYY)
Blood group*
A (1)
B (2)
0 (3)
AB (4)
Discharge of recipient
Serum creatinine level (in mg/dl)
Serum creatinine level(in µmol/l)
Patient insulin-free at discharge?
Yes
No
Hostpital discharge date  (DD.MM.YYYY)*
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Discharge diagnosis/es according to ICD-10*
Reason for patient discharge*
treatment finished as planned (1)
transferral to nursing facility (10)
discharge to hospice (11)
external transferral to psychiatric
treatment (13)
treatment finished because of other
reasons, postdischarge treatment is
planned (14)
treatment aborted against medical
advice, postdischarge treatment is
planned (15)
internal transferral with change of DRG
payment areas (17)
treatment finished as planned,
postdischarge treatment is planned (2)
case termination (internal transferral)
with change between full- and partial
stationary care (22)
discharge at the end of the year with
admission in previous year (25)
treatment finished because of other
reasons (3)
treatment aborted against medical
advice (4)
change of jurisdiction of insurer or other
payer (5)
transferral to another hospital (6)
death (7)
transferral to another hospital within
cooperative and governmental policies
(8)
transferral to rehabilitation facility (9)
cause of death
infection (1)
cardiovascular (2)
cerebrovascular (3)
malignancy (4)
other (5)
unknown (9)
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Pancreatic-(Renal-) Transplant (AQUA)
Documentation form for quality assurance in German
Health Care by the institute forapplied quality Improvement
and Research in Health Care (Aqua), https://www.aqua-
institut.de/en/home. Internal Aqua form version: PNTXFU
Specification 2015 V02
All rights reserved. Please visit https://medical-data-
models.org/forms/9833
Quality assurance Follow-up Renal
And Pancreatic-(Renal-) Transplant
(AQUA)
Follow-up (to be completed after 1, 2 and
3 years)
Healthcare facility Identifier*
Cause of death
infection (1)
cardiovascular (2)
cerebrovascular (3)
malignancy (4)
other (5)
unknown (9)
Kidney transplant failure
no (0)
yes (1)
unknown (9)
Date of kidney transplant failure (DD.MM.YYYY)
Cause of kidney transplant failure
rejection (1)
vascular occlusion (2)
bleeding (3)
infection in surgical area (4)
recurrence of the underlying disease (5)
de novo kidney disease (6)
primary non-function (7)
other (9)
Serum creatinine level (in mg/dl)
Serum creatinine level(in µmol/l)
Serum creatinine Level unknown?
yes (1)
Acute kidney rejection requiring treatment
Yes
No
Patient insulin-free at follow-up-examination?
no (0)
yes (1)
unknown (9)
Beginning date of insulin therapy (dd.mm.yyyy)
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Cause of pancreas transplant failure
rejection (1)
vascular occlusion (2)
bleeding (3)
infection in the surgical area (4)
primary non-function (5)
chronic graft failure (6)
other (9)
Date of death
Deceased donor*
no (0)
yes (1)
unknown or follow-up is not possible (9)
Zip Code of Discharge*
Facility's Section Identifier
Medical specialty*
internal medicine (0100)
internal medicine: geriatrics (0102)
internal medicine: cardiology (0103)
internal medicine: nephrology (0104)
internal medicine: hematology and
internal oncology  (0105)
internal medicine: endocrinology (0106)
internal medicine: gastroenterology
(0107)
internal medicine: pneumonology (0108)
internal medicine: rheumatology (0109)
internal medicine: pulmonology (0114)
internal medicine: tumor research (0150)
internal medicine: coloproctology (0151)
internal medicine: infectiology (0152)
internal medicine: diabetes (0153)
internal medicine: naturopathy (0154)
internal medicine: stroke unit (0156)
internal medicine (0190)
geriatry (0200)
geriatry: gynecology  (0224)
geriatry: day unit (for semi-residential
care)   (0260)
geriaty: night unit (for semi-residential
care) (0261)
geriatry (0290)
cardiology (0300)
nephrology (0400)
nephrology: pediatrics (0410)
nephrology: intensive care (0436)
nephrology (0490)
hematology and internal oncology
(0500)
hematology and internal oncology:
pediatrics (0510)
hematology and internal oncology:
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gynacology (0524)
hematology and internal oncology:
radiation therapy (0533)
hematology and internal oncology
(0590)
endocrinology (0600)
endicrinology: gastroenterology (0607)
endocrinology: pediatrics (0610)
endocrinology (0690)
gastroenterology (0700)
gastroenterology: endocrinology (0706)
gastroenterology: pediatrics (0710)
gastroenterology (0790)
pneumology (0800)
rheumatology (0900)
rheumatology: pediatrics (0910)
rheumatology (0990)
pediatrics (1000)
pediatrics: nephrology (1004)
pediatrics: hematology and internal
oncology  (1005)
pediatrics: endocrinology (1006)
pediatrics: gastroenterology (1007)
pediatrics: rheumatology (1009)
pediatrics: pediatric cardiology (1011)
pediatrics: nephrology (1012)
pediatrics: pulmonology (1014)
pediatrics: pediatric neurology (1028)
pediatrics: perinatal medicine (1050)
continuing care for children (1051)
pediatrics (1090)
pediatric cardiology (1100)
pediatric cardiology: intensive care
(1136)
pediatric cardiology (1190)
neonatology (1200)
pediatric surgery (1300)
pulmonology (1400)
pulmonology: pediatrics (1410)
pulmonology (1490)
general surgery (1500)
general surgery: pediatric surgery (1513)
general surgery: trauma surgery (1516)
general surgery: vascular surgery (1518)
general surgery: plastic surgery (1519)
general surgery: thoracic surgery (1520)
general surgery: orthopedics (1523)
general surgery: intensive care (1536)
general surgery: abdominal- and
vascular surgery (1550)
Allgemeine Chirurgie: hand surgery
(1551)
general surgery (1590)
trauma surgery (1600)
neurosurgery (1700)
vascular surgery (1800)
plastic surgery (1900)
thoracic surgery (2000)
thoracic surgery: cardiac surgery (2021)
thoracic surgery: intensive care (2036)
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thoracic surgery: cardiac surgery
intensive care (2050)
thoracic surgery (2090)
cardiac surgery (2100)
cardiac surgery: vascular surgery (2118)
cardiac surgery: thoracic surgery (2120)
cardiac surgery: intensive care (2136)
cardiac surgery: thoracic surgery and
intensive care (2150)
cardiac surgery (2190)
urology (2200)
orthopedics (2300)
orthopedics: rheumatology (2309)
orthopedics: surgery (2315)
orthopedics and trauma surgery (2316)
orthopedics (2390)
gynecology and obstetrics (2400)
gynecology: geriatry (2402)
gynecology: hematology and internal
oncology  (2405)
gynecology: endocrinology (2406)
gynecology (2425)
gynecology and obstetrics (2490)
obstetrics (2500)
otolaryngology (2600)
ophthalmology (2700)
neurology: (2800)
neurology: pediatrics (2810)
neurology: stroke units (2856)
neurology (2890)
general psychiatry: (2900)
general psychiatry: neurology (2928)
general psychiatry: child and adolescent
psychiatry (2930)
general psychiatry: psychosomatics and
psychotherapy (2931)
general psychiatry: addiction treatment
(2950)
general psychiatry: geropsychiatry
(2951)
general psychiatry: forensic treatment
(2952)
general psychiatry: addiction treatment
(day unit) (2953)
general psychiatry: addiction treatment
(night unit) (2954)
general psychiatry: geropsychiatry (day
unit) (2955)
general psychiatry: geropsychiatry (night
unit) (2956)
general psychiatry: day unit (for semi-
residential care) (2960)
general psychiatry: night unit (for semi-
residential care) (2961)
general psychiatry (2990)
child and adolescent psychiatry (3000)
child and adolescent psychiatry: day unit
(for semi-residential care) (3060)
child and adolescent psychiatry: night
unit (for semi-residential care) (3061)
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child and adolescent psychiatry (3090)
psychosomatic/psychotherapy (3100)
psychosomatic/psychotherapy: child and
adolescent psychiatry (3110)
psychosomatic/psychotherapy: day unit
(for semi-residential care) (3160)
psychosomatic/psychotherapy: night unit
(for semi-residential care) (3161)
psychosomatic/psychotherapy (3190)
nuclear medicine (3200)
nuclear medicine: radiation therapy
(3233)
nuclear medicine (3290)
radiation therapy (3300)
radiation therapy: hematology and
internal oncology  (3305)
radiation therapy: radiology (3350)
radiation therapy (3390)
dermatology (3400)
dermatology: day unit (for semi-
residential care) (3460)
dermatology (3490)
dentistry, orthodontics, maxillofacial
surgery (3500)
intensive-care medicine (3600)
intensive-care medicine: internal
medicine (3601)
intensive-care medicine: cardiology
(3603)
intensive-care medicine: pediatrics
(3610)
intensive-care medicine: neurosurgery
(3617)
intensive-care medicine: surgery (3618)
intensive-care medicine: cardiac surgery
(3621)
intensive-care medicine: urology (3622)
intensive-care medicine: gynecology and
obstetrics (3624)
intensive-care medicine: otolaryngology
(3626)
intensive-care medicine: neurology
(3628)
operative intensive-care medicine:
surgery (3650)
intensive-care medicine: thorax-heart
surgery (3651)
intensive-care medicine: heart-thorax
surgery (3652)
intensive-care medicine (3690)
other medical specialty (3700)
angiology (3750)
radiology (3751)
palliative care (3752)
pain therapy (3753)
section for alternative health practice
(3754)
spinal surgery (3755)
addiction medicine (3756)
visceral surgery (3757)
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other medical specialty (3790)
Receiver ID (ET-Number)*
Date of Birth (dd.mm.yyyy)*
Gender*
male (1)
female (2)
Type of Organ transplantation accomplished*
isolated kidney transplant (1)
simultaneous pancreas-kidney (SPK) (2)
pancreas after kidney transplantation
(PAK) (3)
isolated pancreas transplantation (4)
kidney combination with other organs (5)
pancreas combination with other organs
(6)
Date of last transplantation (DD.MM.YYYY)*
Follow-up (referred to) program, appointment
date*
Type of Follow-Up Report*
patient was personally in hospital (1)
telephone contact with patient  (2)
telephone contact with doctor further
treatment (3)
written information from the doctor
further treatment (4)
information about relatives/carers of
patients  (5)
no contact with patient, doctor further
treatment or relatives/carers of patients
(6)
Follow-up: Year (s) after transplantation*
Removal of the pancreas graft required
Yes
No
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Baseline Lymphoma Disease Activity
and Assessment
Lymphoma disease activity
Visit Number
Modified Ann Arbor Stage
I (I)
Ie (IE)
Ii (II)
Iie (IIE)
Iii (III)
Iiie (IIIE)
Iiie+s (IIIE+S)
Iiis (IIIS)
Iv (IV)
Recurring, drenching night sweats during the
previous month
Yes
No
Unexplained, persistent fever >38 degrees C (or
>100 degrees F) in the previous month
Yes
No
Unexplained weight loss above 10% of body
weight in the previous 6 months
Yes
No
Hematopoietic Diagnosis
Other (0)
Burkitt Lymphoma/leukemia (1)
Diffuse Large B-cell Lymphoma (2)
KSHV+ Plasmablastic Lymphoma-lymph
Node (3)
Plasma Lymphoma Of Oral Cavity (4)
Polymorphic B Cell Lymphoma-PTLD
Type (5)
Primary Effusion Lymphoma (6)
Other specify
If diffuse large B-cell lymphoma, specify
morphologic type
Centroblastic (Centroblastic)
Immunoblastic (Immunoblastic)
If Burkitt lymphoma/leukemia, specify
morphologic type
Atypical (Atypical)
Classical (Classical)
Plasmacytoid Differentiation
(Plasmacytoid differentiation)
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Date of Initial Pathologic Diagnosis
Method of Evaluation
Biopsy (Biopsy)
Cytology (Cytology)
Other (Other)
Other Specify
Is the participant >60 years of age
Yes
No
Does the participant have Stage III or IV disease
Yes
No
Is the serum LDH elevated
Yes
No
Is the ECOG Performance Status 2, 3, or 4
Yes
No
Does the participant have two or more extranodal
disease sites
Yes
No
International Prognostic Index
IPI Risk Category
Low Risk (1)
Low-intermediate Risk (2)
High-intermediate Risk (3)
High Risk (4)
Comments
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Registration Enrollment Form (ENR AMC-
053 )
Form imported via medical-data-models.org API-version 1
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models.org/forms/9838
Registration Enrollment Form (ENR
AMC-053 )
Header Module
Principal Investigator
Projected Start Date of Treatment
Karnofsky Performance Status
Date Informed Consent Signed
Comments
Inclusion Criteria
Inclusion Criteria
Exclusion Criteria
Active hepatitis B infection
Yes
No
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NCI Standard Adverse Event/Serious Adverse
Event CTCAE v3 Template - 2748814v1.0
The collection of CDEs used in the Adverse Events/Serious
Adverse Events module.
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=4D0BC7DD-
57DD-63BE-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/9840
NCI Standard Adverse Event/Serious
Adverse Event CTCAE v3 Template
Mandatory Adverse Event Data Elements
Adverse Event Name (v3.0) (Code used to
identify the adverse event using a standard
mechanism that facilitates analysis. CTEP's code
list and associated Category/Term is currently a
standard. )
Acidosis NOS (Acidosis (metabolic or
respiratory))
Capillary Leak Syndrome (Acute
vascular leak syndrome)
Adrenal Insufficiency (Adrenal
insufficiency)
Adult Respiratory Distress Syndrome
(Adult respiratory distress syndrome
(ARDS))
Blood Albumin Decreased (Albumin,
serum-low (hypoalbuminemia))
Alcohol Intolerance Syndrome
(antabuse-like Syndrome) (Alcohol
intolerance syndrome)
Blood Alkaline Phosphatase Nos
Increased (Alkaline phosphatase)
Alkalosis Nos (Alkalosis (metabolic or
respiratory))
Hypersensitivity Nos (Allergic
reaction/hypersensitivity (including drug
fever))
Rhinitis Allergic Nos (Allergic rhinitis
(including sneezing, nasal stuffiness,
postnasal drip))
Allergy/immunology Other
(Allergy/Immunology-Other (Specify))
Alanine Aminotransferase Increased
(ALT, SGPT (serum glutamic pyruvic
transaminase))
Blood Amylase Increased (Amylase)
Anorexia (Anorexia)
Apnoea (Apnea)
Arachnoiditis
(Arachnoiditis/meningismus/radiculitis)
Arthritis Nos (Arthritis (non-septic))
Ascites (Ascites (non-malignant))
Aspiration (Aspiration)
Aspartate Aminotransferase Increased
(AST, SGOT (serum glutamic oxaloacetic
transaminase))
Ataxia Nec (Ataxia (incoordination))
Atelectasis (Atelectasis)
Atrophy, Skin (Atrophy, skin)
Atrophy, Subcutaneous Fat (Atrophy,
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subcutaneous fat)
Auditory/ear Other (Auditory/Ear-Other
(Specify))
Autoimmune Disorder Nos (Autoimmune
reaction)
Blood Bicarbonate Decreased
(Bicarbonate, serum-low)
Blood Bilirubin Increased (Bilirubin
(hyperbilirubinemia))
Bladder Disorder Nos (Bladder spasms)
Blood/bone Marrow Other (Blood/Bone
Marrow-Other (Specify))
Bone Age (alteration In Bone Age) (Bone
age (alteration in bone age))
Bone Growth: Femoral Head; Slipped
Capital Femoral Epiphysis (Bone growth:
femoral head; slipped capital femoral
epiphysis)
Bone Growth: Limb Length Discrepancy
(Bone growth: limb length discrepancy)
Bone Growth: Spine Kyphosis/lordosis
(Bone growth: spine kyphosis/lordosis)
Bone Marrow Depression Nos (Bone
marrow cellularity)
Bone: Spine-scoliosis (Bone: spine-
scoliosis)
Brachial Plexopathy (Brachial
plexopathy)
Breast Function/lactation (Breast
function/lactation)
Breast Nipple/areolar Deformity (Breast
nipple/areolar deformity)
Breast Volume/hypoplasia (Breast
volume/hypoplasia)
Bronchospasm, Wheezing
(Bronchospasm, wheezing)
Ecchymosis (Bruising (in absence of
grade 3 or 4 thrombocytopenia))
Burn (Burn)
Hypercalcaemia (Calcium, serum-high
(hypercalcemia))
Hypocalcaemia (Calcium, serum-low
(hypocalcemia))
Pulmonary Function Test Nos Decreased
(Carbon monoxide diffusion capacity
(DL(co)))
Arrhythmia Nos (Cardiac Arrhythmia-
Other (Specify))
Cardiac General Other (Cardiac
General-Other (Specify))
Myocardial Ischaemia (Cardiac
ischemia/infarction)
Cardiac Troponin I Increased (Cardiac
troponin I (cTnI))
Cardiac Troponin T Increased (Cardiac
troponin T (cTnT))
Cardiopulmonary Arrest, Cause
Unknown (non-fatal) (Cardiopulmonary
arrest, cause unknown (non-fatal))
Cataract Nec (Cataract)
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Cd4 Lymphocytes Decreased (CD4
count)
Cervical Spine-range Of Motion (Cervical
spine-range of motion)
Chelitis (Cheilitis)
Cholecystitis (Cholecystitis)
Hypercholesteraemia (Cholesterol,
serum-high (hypercholesteremia))
Chyle Or Lymph Leakage (Chyle or
lymph leakage)
Chylothorax (Chylothorax)
Cerebral Ischaemia (CNS
cerebrovascular ischemia)
Cns Necrosis/cystic Progression (CNS
necrosis/cystic progression)
Coagulation Disorder Nos (Coagulation-
Other (Specify))
Learning Disorder Nos (Cognitive
disturbance)
Colitis Nos (Colitis)
Colitis, Infectious (e.g., Clostridium
Difficile) (Colitis, infectious (e.g.,
Clostridium difficile))
Ventricular Asystole (Conduction
abnormality/Atrioventricular heart block -
Asystole)
Conduction Abnormality/atrioventricular
Heart Block (Conduction
abnormality/Atrioventricular heart block -
AV block-first degree)
Conduction Abnormality/atrioventricular
Heart Block - Av Block-second Degree
Mobitz Type I (wenckebach) (Conduction
abnormality/Atrioventricular heart block -
AV block-Second degree Mobitz Type I
(Wenckebach))
Conduction Abnormality/atrioventricular
Heart Block (Conduction
abnormality/Atrioventricular heart block -
AV block-second degree Mobitz Type II)
Conduction Abnormality/atrioventricular
Heart Block (Conduction
abnormality/Atrioventricular heart block -
AV block-third degree (complete AV
block))
Conduction Abnormality/atrioventricular
Heart Block (Conduction
abnormality/Atrioventricular heart block -
Conduction abnormality NOS)
Conduction Abnormality/atrioventricular
Heart Block (Conduction
abnormality/Atrioventricular heart block -
Sick sinus syndrome)
Conduction Abnormality/atrioventricular
Heart Block (Conduction
abnormality/Atrioventricular heart block -
Stokes-Adams syndrome)
Conduction Abnormality/atrioventricular
Heart Block (Conduction
abnormality/Atrioventricular heart block -
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Wolff-Parkinson-White syndrome)
Confusion (Confusion)
Constipation (Constipation)
Constitutional Symptoms Other
(Constitutional Symptoms-Other
(Specify))
Cough (Cough)
Blood Creatine Phosphokinase
Increased (CPK (creatine
phosphokinase))
Blood Creatinine Increased (Creatinine)
Cushingoid (Cushingoid appearance
(e.g., moon face, buffalo hump,
centripetal obesity, cutaneous striae))
Cystitis (Cystitis)
Cytokine Release Syndrome/acute
Infusion Reaction (Cytokine release
syndrome/acute infusion reaction)
Death Not Associated With Ctcae Term
(Death not associated with CTCAE term
- Death NOS)
Death Not Associated With Ctcae Term
(Death not associated with CTCAE term
- Disease progression NOS)
Death Not Associated With Ctcae Term
(Death not associated with CTCAE term
- Multi-organ failure)
Death Not Associated With Ctcae Term
(Death not associated with CTCAE term
- Sudden death)
Dehydration (Dehydration)
Dental: Dentures Or Prosthesis (Dental:
dentures or prosthesis)
Dental: Periodontal Disease (Dental:
periodontal disease)
Dental: Teeth (Dental: teeth)
Dental: Teeth Development (Dental:
teeth development)
Dermal Change Lymphedema,
Phlebolymphedema (Dermal change
lymphedema, phlebolymphedema)
Dermatology/skin Other
(Dermatology/Skin-Other (Specify))
Diarrhoea Nos (Diarrhea)
Disseminated Intravascular Coagulation
(DIC (disseminated intravascular
coagulation))
Distention/bloating, Abdominal
(Distention/bloating, abdominal)
Dizziness (exc Vertigo) (Dizziness)
Dry Eye Nec (Dry eye syndrome)
Dry Mouth (Dry mouth/salivary gland
(xerostomia))
Dry Skin (Dry skin)
Dysphagia (Dysphagia (difficulty
swallowing))
Dyspnoea Nos (Dyspnea (shortness of
breath))
Edema, Larynx (Edema, larynx)
Edema: Head And Neck (Edema: head
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and neck)
Oedema Nos (Edema: limb)
Edema: Trunk/genital (Edema:
trunk/genital)
Edema: Viscera (Edema: viscera)
Ejaculatory Dysfunction (Ejaculatory
dysfunction)
Encephalopathy (Encephalopathy)
Endocrine Other (Endocrine-Other
(Specify))
Enteritis (inflammation Of The Small
Bowel) (Enteritis (inflammation of the
small bowel))
Impotence (Erectile dysfunction)
Oesophagitis Nos (Esophagitis)
Exostosis (Exostosis)
Extrapyramidal Disorder Nec
(Extrapyramidal/involuntary
movement/restlessness)
Extremity-lower (gait/walking) (Extremity-
lower (gait/walking))
Extremity-upper (function) (Extremity-
upper (function))
Eyelid Dysfunction (Eyelid dysfunction)
Fatigue (Fatigue (asthenia, lethargy,
malaise))
Febrile Neutropenia (fever Of Unknown
Origin Without Clinically Or
Microbiologically Documented Infection)
(anc <1.0 X 10^9/l, Fever > (Febrile
neutropenia)
Feminization (Feminization of male)
Forced Expiratory Volume Decreased
(FEV(1))
Pyrexia (Fever (in the absence of
neutropenia, where neutropenia is
defined as ANC <1.0 x 10^9/L))
Blood Fibrinogen Decreased
(Fibrinogen)
Fibrosis-cosmesis (Fibrosis-cosmesis)
Fibrosis-deep Connective Tissue
(Fibrosis-deep connective tissue)
Fistula, Gi (Fistula, GI - Abdomen NOS)
Anal Fistula (Fistula, GI - Anus)
Fistula, Gi (Fistula, GI - Biliary tree)
Fistula, Gi (Fistula, GI -
Colon/cecum/appendix)
Intestinal Fistula (Fistula, GI -
Duodenum)
Tracheo-oesophageal Fistula Nos
(Fistula, GI - Esophagus)
Fistula, Gi (Fistula, GI - Gallbladder)
Fistula, Gi (Fistula, GI - Ileum)
Fistula, Gi (Fistula, GI - Jejunum)
Fistula, Gi (Fistula, GI - Oral cavity)
Fistula, Gi (Fistula, GI - Pancreas)
Fistula, Gi (Fistula, GI - Pharynx)
Fistula, Gi (Fistula, GI - Rectum)
Fistula, Gi (Fistula, GI - Salivary gland)
Fistula, Gi (Fistula, GI - Small bowel
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NOS)
Fistula, Gi (Fistula, GI - Stomach)
Fistula, Gu (Fistula, GU - Bladder)
Fistula, Gu (Fistula, GU - Genital tract-
female)
Fistula, Gu (Fistula, GU - Kidney)
Fistula, Gu (Fistula, GU - Ureter)
Fistula, Gu (Fistula, GU - Urethra)
Fistula, Gu (Fistula, GU - Uterus)
Urogenital Fistula (Fistula, GU - Vagina)
Fistula, Pulmonary/upper Respiratory
(Fistula, pulmonary/upper respiratory -
Bronchus)
Fistula, Pulmonary/upper Respiratory
(Fistula, pulmonary/upper respiratory -
Larynx)
Fistula, Pulmonary/upper Respiratory
(Fistula, pulmonary/upper respiratory -
Lung)
Fistula, Pulmonary/upper Respiratory
(Fistula, pulmonary/upper respiratory -
Oral cavity)
Fistula, Pulmonary/upper Respiratory
(Fistula, pulmonary/upper respiratory -
Pharynx)
Fistula, Pulmonary/upper Respiratory
(Fistula, pulmonary/upper respiratory -
Pleura)
Fistula, Pulmonary/upper Respiratory
(Fistula, pulmonary/upper respiratory -
Trachea)
Flatulence (Flatulence)
Flu-like Syndrome (Flu-like syndrome)
Flushing (Flushing)
Fracture (Fracture)
Gastritis Nos (Gastritis (including bile
reflux gastritis))
Gastrointestinal Other (Gastrointestinal-
Other (Specify))
Gamma-glutamyltransferase Increased
(GGT (gamma-glutamyl transpeptidase))
Glaucoma Nos (Glaucoma)
Glomerular Filtration Rate (Glomerular
filtration rate)
Hyperglycaemia Nos (Glucose, serum-
high (hyperglycemia))
Hypoglycaemia Nos (Glucose, serum-
low (hypoglycemia))
Growth And Development Other (Growth
and Development-Other (Specify))
Growth Velocity (reduction In Growth
Velocity) (Growth velocity (reduction in
growth velocity))
Gynaecomastia (Gynecomastia)
Alopecia (Hair loss/Alopecia (scalp or
body))
Haptoglobin Decreased (Haptoglobin)
Hearing: Patients With/without Baseline
Audiogram And Enrolled In A Monitoring
Program (Hearing: patients with/without
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baseline audiogram and enrolled in a
monitoring program)
Hearing: Patients Without Baseline
Audiogram And Not Enrolled In A
Monitoring Program (Hearing: patients
without baseline audiogram and not
enrolled in a monitoring program)
Dyspepsia (Heartburn/dyspepsia)
Hematoma (Hematoma)
Haemoglobin Decreased (Hemoglobin)
Haemoglobinuria Present
(Hemoglobinuria)
Hemolysis Nos (Hemolysis (e.g.,
immune hemolytic anemia, drug related
hemolysis))
Haemorrhagic Stroke (Hemorrhage,
CNS)
Melaena (Hemorrhage, GI - Abdomen
NOS)
Hemorrhage, Gi (Hemorrhage, GI -
Anus)
Hemorrhage, Gi (Hemorrhage, GI -
Biliary tree)
Hemorrhage, Gi (Hemorrhage, GI -
Cecum/appendix)
Hemorrhage, Gi (Hemorrhage, GI -
Colon)
Hemorrhage, Gi (Hemorrhage, GI -
Duodenum)
Hemorrhage, Gi (Hemorrhage, GI -
Esophagus)
Hemorrhage, Gi (Hemorrhage, GI -
Ileum)
Hemorrhage, Gi (Hemorrhage, GI -
Jejunum)
Hemorrhage, Gi (Hemorrhage, GI - Liver)
Hemorrhage, Gi (Hemorrhage, GI -
Lower GI NOS)
Hemorrhage, Gi (Hemorrhage, GI - Oral
cavity)
Hemorrhage, Gi (Hemorrhage, GI -
Pancreas)
Hemorrhage, Gi (Hemorrhage, GI -
Peritoneal cavity)
Rectal Bleeding (Hemorrhage, GI -
Rectum)
Hemorrhage, Gi (Hemorrhage, GI -
Stoma)
Haematemesis (Hemorrhage, GI -
Stomach)
Hemorrhage, Gi (Hemorrhage, GI -
Upper GI NOS)
Hemorrhage, Gi (Hemorrhage, GI -
Varices (esophageal))
Hemorrhage, Gi (Hemorrhage, GI -
Varices (rectal))
Hemorrhage, Gu (Hemorrhage, GU -
Bladder)
Hemorrhage, Gu (Hemorrhage, GU -
Fallopian tube)
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Hemorrhage, Gu (Hemorrhage, GU -
Kidney)
Hemorrhage, Gu (Hemorrhage, GU -
Ovary)
Hemorrhage, Gu (Hemorrhage, GU -
Prostate)
Hemorrhage, Gu (Hemorrhage, GU -
Retroperitoneum)
Hemorrhage, Gu (Hemorrhage, GU -
Spermatic cord)
Hemorrhage, Gu (Hemorrhage, GU -
Stoma)
Hemorrhage, Gu (Hemorrhage, GU -
Testes)
Hemorrhage, Gu (Hemorrhage, GU -
Ureter)
Hemorrhage, Gu (Hemorrhage, GU -
Urethra)
Haematuria Present (Hemorrhage, GU -
Urinary NOS)
Hemorrhage, Gu (Hemorrhage, GU -
Uterus)
Vaginal Haemorrhage (Hemorrhage, GU
- Vagina)
Hemorrhage, Gu (Hemorrhage, GU - Vas
deferens)
Hemorrhage, Pulmonary/upper
Respiratory (Hemorrhage,
pulmonary/upper respiratory -
Bronchopulmonary NOS)
Hemorrhage, Pulmonary/upper
Respiratory (Hemorrhage,
pulmonary/upper respiratory - Bronchus)
Hemorrhage, Pulmonary/upper
Respiratory (Hemorrhage,
pulmonary/upper respiratory - Larynx)
Hemorrhage, Pulmonary/upper
Respiratory (Hemorrhage,
pulmonary/upper respiratory - Lung)
Hemorrhage, Pulmonary/upper
Respiratory (Hemorrhage,
pulmonary/upper respiratory -
Mediastinum)
Epistaxis (Hemorrhage, pulmonary/upper
respiratory - Nose)
Hemorrhage, Pulmonary/upper
Respiratory (Hemorrhage,
pulmonary/upper respiratory - Pharynx)
Hemorrhage, Pulmonary/upper
Respiratory (Hemorrhage,
pulmonary/upper respiratory - Pleura)
Haemoptysis (Hemorrhage,
pulmonary/upper respiratory -
Respiratory tract NOS)
Hemorrhage, Pulmonary/upper
Respiratory (Hemorrhage,
pulmonary/upper respiratory - Stoma)
Hemorrhage, Pulmonary/upper
Respiratory (Hemorrhage,
pulmonary/upper respiratory - Trachea)
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Post-operative Haemorrhage
(Hemorrhage/bleeding associated with
surgery, intra-operative or post-operative)
Hemorrhage/bleeding Other
(Hemorrhage/Bleeding-Other (Specify))
Hemorrhoids (Hemorrhoids)
Hepatobiliary/pancreas Other
(Hepatobiliary/Pancreas-Other (Specify))
Hiccups (Hiccoughs (hiccups, singultus))
Menopausal Symptoms (Hot
flashes/flushes)
Hydrocephalus (Hydrocephalus)
Skin Discolouration (Hyperpigmentation)
Hypertension Nos (Hypertension)
Hypopigmentation (Hypopigmentation)
Hypotension Nos (Hypotension)
Hypothermia (Hypothermia)
Hypoxia (Hypoxia)
Ileus (Ileus, GI (functional obstruction of
bowel, i.e., neuroconstipation))
Incontinence, Anal (Incontinence, anal)
Urinary Incontinence (Incontinence,
urinary)
Induration/fibrosis (skin And
Subcutaneous Tissue)
(Induration/fibrosis (skin and
subcutaneous tissue))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologicallly) with Grade 3 or 4
neutrophils - Bone (osteomyelitis))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Abdomen NOS)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Anal/perianal)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Appendix)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Artery)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
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(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Biliary tree)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Bladder (urinary))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Blood)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Brain (encephalitis,
infectious))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Brain + Spinal cord
(encephalomyelitis))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Bronchus)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Catheter-related)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Cecum)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Cervix)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Colon)
Infection (documented Clinically Or
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Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Conjunctiva)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Cornea)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Dental-tooth)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Duodenum)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Esophagus)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - External ear (otitis externa))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Eye NOS)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Fallopian tube)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Foreign body (e.g., graft,
implant, prosthesis, stent))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Gallbladder (cholecystitis))
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Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Heart (endocarditis))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Ileum)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Jejunum)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Joint)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Kidney)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Larynx)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Lens)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Lip/perioral)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Liver)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Lung (pneumonia))
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Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Lymphatic)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Mediastinum NOS)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Meninges (meningitis))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Middle ear (otitis media))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Mucosa)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Muscle (infection myositis))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Neck NOS)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Nerve-cranial)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Nerve-peripheral)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Nose)
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Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Oral cavity-gums
(gingivitis))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Pancreas)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Paranasal)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Pelvis NOS)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Penis)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Peristomal)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Peritoneal cavity)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Pharynx)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Pleura (empyema))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
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neutrophils - Prostate)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Rectum)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Salivary gland)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Scrotum)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Sinus)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Skin (cellulitis))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Small bowel NOS)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Soft tissue NOS)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Spinal cord (myelitis))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Spleen)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
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neutrophils - Stomach)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Trachea)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Ungual (nails))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Upper aerodigestive NOS)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Upper airway NOS)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Ureter)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Urethra)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Urinary tract NOS)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Uterus)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Vagina)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
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neutrophils - Vein)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Vulva)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Wound)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Abdomen
NOS)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils -
Anal/perianal)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Appendix)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Artery)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Biliary tree)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Bladder
(urinary))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Blood)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Bone
(osteomyelitis))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Brain
(encephalitis, infectious))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Brain +
Spinal cord (encephalomyelitis))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Bronchus)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Catheter-
related)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Cecum)
Infection With Normal Anc Or Grade 1 Or
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2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Cervix)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Colon)
Infection With Norrmal Anc Or Grade 1
Or 2 Neutrophils (Infection with normal
ANC or Grade 1 or 2 neutrophils -
Conjunctiva)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Cornea)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Dental-
tooth)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Duodenum)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Esophagus)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - External ear
(otitis externa))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Eye NOS)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Fallopian
tube)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Foreign
body (e.g., graft, implant, prosthesis,
stent))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Gallbladder
(cholecystitis))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Heart
(endocarditis))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Ileum)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Jejunum)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Joint)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Kidney)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
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or Grade 1 or 2 neutrophils - Larynx)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Lens)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Lip/perioral)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Liver)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Lung
(pneumonia))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Lymphatic)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils -
Mediastinum NOS)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Meninges
(meningitis))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Middle ear
(otitis media))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Mucosa)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Muscle
(infection myositis))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Neck NOS)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Nerve-
cranial)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Nerve-
peripheral)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Nose)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Oral cavity-
gums (gingivitis))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Pancreas)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Paranasal)
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Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Pelvis NOS)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Penis)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Peristomal)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Peritoneal
cavity)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Pharynx)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Pleura
(empyema))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Prostate)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Rectum)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Salivary
gland)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Scrotum)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Sinus)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Skin
(cellulitis))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Small bowel
NOS)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Soft tissue
NOS)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Spinal cord
(myelitis))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Spleen)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Stomach)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
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or Grade 1 or 2 neutrophils - Trachea)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Ungual
(nails))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Upper
aerodigestive NOS)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Upper
airway NOS)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Ureter)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Urethra)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Urinary
tract NOS)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Uterus)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Vagina)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Vein)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Vulva)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Wound)
Infection With Unknown Anc (Infection
with unknown ANC - Abdomen NOS)
Infection With Unknown Anc (Infection
with unknown ANC - Anal/perianal)
Infection With Unknown Anc (Infection
with unknown ANC - Appendix)
Infection With Unknown Anc (Infection
with unknown ANC - Artery)
Infection With Unknown Anc (Infection
with unknown ANC - Biliary tree)
Infection With Unknown Anc (Infection
with unknown ANC - Bladder (urinary))
Infection With Unknown Anc (Infection
with unknown ANC - Blood)
Infection With Unknown Anc (Infection
with unknown ANC - Bone
(osteomyelitis))
Infection With Unknown Anc (Infection
with unknown ANC - Brain (encephalitis,
infectious))
Infection With Unknown Anc (Infection
with unknown ANC - Brain + Spinal cord
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(encephalomyelitis))
Infection With Unknown Anc (Infection
with unknown ANC - Bronchus)
Implant Infection (Infection with unknown
ANC - Catheter-related)
Infection With Unknown Anc (Infection
with unknown ANC - Cecum)
Infection With Unknown Anc (Infection
with unknown ANC - Cervix)
Infection With Unknown Anc (Infection
with unknown ANC - Colon)
Infection With Unknown Anc (Infection
with unknown ANC - Conjunctiva)
Infection With Unknown Anc (Infection
with unknown ANC - Cornea)
Infection With Unknown Anc (Infection
with unknown ANC - Dental-tooth)
Infection With Unknown Anc (Infection
with unknown ANC - Duodenum)
Infection With Unknown Anc (Infection
with unknown ANC - Esophagus)
Infection With Unknown Anc (Infection
with unknown ANC - External ear (otitis
externa))
Infection With Unknown Anc (Infection
with unknown ANC - Eye NOS)
Infection With Unknown Anc (Infection
with unknown ANC - Fallopian tube)
Infection With Unknown Anc (Infection
with unknown ANC - Foreign body (e.g.,
graft, implant, prosthesis, stent))
Infection With Unknown Anc (Infection
with unknown ANC - Gallbladder
(cholecystitis))
Infection With Unknown Anc (Infection
with unknown ANC - Heart
(endocarditis))
Infection With Unknown Anc (Infection
with unknown ANC - Ileum)
Infection With Unknown Anc (Infection
with unknown ANC - Jejunum)
Infection With Unknown Anc (Infection
with unknown ANC - Joint)
Infection With Unknown Anc (Infection
with unknown ANC - Kidney)
Infection With Unknown Anc (Infection
with unknown ANC - Larynx)
Infection With Unknown Anc (Infection
with unknown ANC - Lens)
Infection With Unknown Anc (Infection
with unknown ANC - Lip/perioral)
Infection With Unknown Anc (Infection
with unknown ANC - Liver)
Infection With Unknown Anc (Infection
with unknown ANC - Lung (pneumonia))
Infection With Unknown Anc (Infection
with unknown ANC - Lymphatic)
Infection With Unknown Anc (Infection
with unknown ANC - Mediastinum NOS)
Infection With Unknown Anc (Infection
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with unknown ANC - Meninges
(meningitis))
Infection With Unknown Anc (Infection
with unknown ANC - Middle ear (otitis
media))
Infection With Unknown Anc (Infection
with unknown ANC - Mucosa)
Infection With Unknown Anc (Infection
with unknown ANC - Muscle (infection
myositis))
Infection With Unknown Anc (Infection
with unknown ANC - Neck NOS)
Infection With Unknown Anc (Infection
with unknown ANC - Nerve-cranial)
Infection With Unknown Anc (Infection
with unknown ANC - Nerve-peripheral)
Infection With Unknown Anc (Infection
with unknown ANC - Nose)
Infection With Unknown Anc (Infection
with unknown ANC - Oral cavity-gums
(gingivitis))
Infection With Unknown Anc (Infection
with unknown ANC - Pancreas)
Infection With Unknown Anc (Infection
with unknown ANC - Paranasal)
Infection With Unknown Anc (Infection
with unknown ANC - Pelvis NOS)
Infection With Unknown Anc (Infection
with unknown ANC - Penis)
Infection With Unknown Anc (Infection
with unknown ANC - Peristomal)
Infection With Unknown Anc (Infection
with unknown ANC - Peritoneal cavity)
Infection With Unknown Anc (Infection
with unknown ANC - Pharynx)
Infection With Unknown Anc (Infection
with unknown ANC - Pleura (empyema))
Infection With Unknown Anc (Infection
with unknown ANC - Prostate)
Infection With Unknown Anc (Infection
with unknown ANC - Rectum)
Infection With Unknown Anc (Infection
with unknown ANC - Salivary gland)
Infection With Unknown Anc (Infection
with unknown ANC - Scrotum)
Infection With Unknown Anc (Infection
with unknown ANC - Sinus)
Infection With Unknown Anc (Infection
with unknown ANC - Skin (cellulitis))
Infection With Unknown Anc (Infection
with unknown ANC - Small bowel NOS)
Infection With Unknown Anc (Infection
with unknown ANC - Soft tissue NOS)
Infection With Unknown Anc (Infection
with unknown ANC - Spinal cord
(myelitis))
Infection With Unknown Anc (Infection
with unknown ANC - Spleen)
Infection With Unknown Anc (Infection
with unknown ANC - Stomach)
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Infection With Unknown Anc (Infection
with unknown ANC - Trachea)
Infection With Unknown Anc (Infection
with unknown ANC - Ungual (nails))
Infection With Unknown Anc (Infection
with unknown ANC - Upper aerodigestive
NOS)
Infection With Unknown Anc (Infection
with unknown ANC - Upper airway NOS)
Infection With Unknown Anc (Infection
with unknown ANC - Ureter)
Infection With Unknown Anc (Infection
with unknown ANC - Urethra)
Infection With Unknown Anc (Infection
with unknown ANC - Urinary tract NOS)
Infection With Unknown Anc (Infection
with unknown ANC - Uterus)
Infection With Unknown Anc (Infection
with unknown ANC - Vagina)
Infection With Unknown Anc (Infection
with unknown ANC - Vein)
Infection With Unknown Anc (Infection
with unknown ANC - Vulva)
Culture Wound Positive (Infection with
unknown ANC - Wound)
Infection Nos (Infection-Other (Specify))
Infertility/sterility (Infertility/sterility)
Injection Site Reaction Nos (Injection site
reaction/extravasation changes)
Prothrombin Time Prolonged (INR
(International Normalized Ratio of
prothrombin time))
Insomnia Nec (Insomnia)
Intra-operative Injury (Intra-operative
injury - Abdomen NOS)
Intra-operative Injury (Intra-operative
injury - Adrenal gland)
Intra-operative Injury (Intra-operative
injury - Anal sphincter)
Intra-operative Injury (Intra-operative
injury - Anus)
Intra-operative Injury (Intra-operative
injury - Appendix)
Intra-operative Injury (Intra-operative
injury - Artery NOS)
Intra-operative Injury (Intra-operative
injury - Artery-aorta)
Intra-operative Injury (Intra-operative
injury - Artery-carotid)
Intra-operative Injury (Intra-operative
injury - Artery-cerebral)
Intra-operative Injury (Intra-operative
injury - Artery-extremity (lower))
Intra-operative Injury (Intra-operative
injury - Artery-extremity (upper))
Intra-operative Injury (Intra-operative
injury - Artery-hepatic)
Intra-operative Injury (Intra-operative
injury - Artery-major visceral artery)
Intra-operative Injury (Intra-operative
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injury - Artery-pulmonary)
Intra-operative Injury (Intra-operative
injury - Biliary tree NOS)
Intra-operative Injury (Intra-operative
injury - Biliary tree-common bile duct)
Intra-operative Injury (Intra-operative
injury - Biliary tree-common hepatic duct)
Intra-operative Injury (Intra-operative
injury - Biliary tree-left hepatic duct)
Intra-operative Injury (Intra-operative
injury - Biliary tree-right hepatic duct)
Bladder Perforation Postoperative (Intra-
operative injury - Bladder)
Intra-operative Injury (Intra-operative
injury - Bone)
Intra-operative Injury (Intra-operative
injury - Brachial plexus)
Intra-operative Injury (Intra-operative
injury - Brain)
Intra-operative Injury (Intra-operative
injury - Breast)
Intra-operative Injury (Intra-operative
injury - Bronchus)
Intra-operative Injury (Intra-operative
injury - Cartilage)
Intra-operative Injury (Intra-operative
injury - Cecum)
Intra-operative Injury (Intra-operative
injury - Cervix)
Intra-operative Injury (Intra-operative
injury - CN I (olfactory))
Intra-operative Injury (Intra-operative
injury - CN II (optic))
Intra-operative Injury (Intra-operative
injury - CN III (oculomotor))
Intra-operative Injury (Intra-operative
injury - CN IV (trochlear))
Intra-operative Injury (Intra-operative
injury - CN IX (glossopharyngeal) motor
pharynx)
Intra-operative Injury (Intra-operative
injury - CN IX (glossopharyngeal)
sensory ear-pharynx-tongue)
Intra-operative Injury (Intra-operative
injury - CN V (trigeminal) motor)
Intra-operative Injury (Intra-operative
injury - CN V (trigeminal) sensory)
Intra-operative Injury (Intra-operative
injury - CN VI (abducens))
Intra-operative Injury (Intra-operative
injury - CN VII (facial) motor-face)
Intra-operative Injury (Intra-operative
injury - CN VII (facial) sensory-taste)
Intra-operative Injury (Intra-operative
injury - CN VIII (vestibulocochlear))
Intra-operative Injury (Intra-operative
injury - CN X (vagus))
Intra-operative Injury (Intra-operative
injury - CN XI (spinal accessory))
Intra-operative Injury (Intra-operative
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injury - CN XII (hypoglossal))
Intra-operative Injury (Intra-operative
injury - Colon)
Intra-operative Injury (Intra-operative
injury - Conjunctiva)
Intra-operativve Injury (Intra-operative
injury - Cornea)
Intra-operative Injury (Intra-operative
injury - Cranial nerve or branch NOS)
Intra-operative Injury (Intra-operative
injury - Duodenum)
Intra-operative Injury (Intra-operative
injury - Esophagus)
Intra-operative Injury (Intra-operative
injury - Extremity-lower)
Intra-operative Injury (Intra-operative
injury - Extremity-upper)
Intra-operative Injury (Intra-operative
injury - Eye NOS)
Intra-operative Injury (Intra-operative
injury - Face NOS)
Intra-operative Injury (Intra-operative
injury - Fallopian tube)
Intra-operative Injury (Intra-operative
injury - Gallbladder)
Intra-operative Injury (Intra-operative
injury - Gingiva)
Intra-operative Injury (Intra-operative
injury - Heart)
Intra-operative Injury (Intra-operative
injury - Ileum)
Intra-operative Injury (Intra-operative
injury - Inner ear)
Intra-operative Injury (Intra-operative
injury - Jejunum)
Intra-operative Injury (Intra-operative
injury - Joint)
Intra-operative Injury (Intra-operative
injury - Kidney)
Intra-operative Injury (Intra-operative
injury - Larynx)
Intra-operative Injury (Intra-operative
injury - Lens)
Intra-operative Injury (Intra-operative
injury - Ligament)
Intra-operative Injury (Intra-operative
injury - Lingual)
Intra-operative Injury (Intra-operative
injury - Lip/perioral area)
Intra-operative Injury (Intra-operative
injury - Liver)
Intra-operative Injury (Intra-operative
injury - Lung)
Intra-operative Injury (Intra-operative
injury - Lung thoracic)
Intra-operative Injury (Intra-operative
injury - Mediastinum)
Intra-operative Injury (Intra-operative
injury - Meninges)
Intra-operative Injury (Intra-operative
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injury - Middle ear)
Intra-operative Injury (Intra-operative
injury - Muscle)
Intra-operative Injury (Intra-operative
injury - Nails)
Intra-operative Injury (Intra-operative
injury - Nasal cavity)
Intra-operative Injury (Intra-operative
injury - Nasopharynx)
Intra-operative Injury (Intra-operative
injury - Neck NOS)
Intra-operative Injury (Intra-operative
injury - Nose)
Intra-operative Injury (Intra-operative
injury - Oral)
Intra-operative Injury (Intra-operative
injury - Oral cavity NOS)
Intra-operative Injury (Intra-operative
injury - Outer ear NOS)
Intra-operative Injury (Intra-operative
injury - Outer ear-pinna)
Intra-operative Injury (Intra-operative
injury - Ovary)
Intra-operative Injury (Intra-operative
injury - Pancreas)
Intra-operative Injury (Intra-operative
injury - Pancreatic duct)
Intra-operative Injury (Intra-operative
injury - Parathyroid)
Intra-operative Injury (Intra-operative
injury - Parotid gland)
Intra-operative Injury (Intra-operative
injury - Pelvis NOS)
Intra-operative Injury (Intra-operative
injury - Penis)
Intra-operative Injury (Intra-operative
injury - Peripheral motor NOS)
Intra-operative Injury (Intra-operative
injury - Peripheral sensory NOS)
Intra-operative Injury (Intra-operative
injury - Peritoneal cavity)
Intra-operative Injury (Intra-operative
injury - Pharynx)
Intra-operative Injury (Intra-operative
injury - Pituitary)
Intra-operative Injury (Intra-operative
injury - Pleura)
Intra-operative Injury (Intra-operative
injury - Prostate)
Intra-operative Injury (Intra-operative
injury - Rectum)
Intra-operative Injury (Intra-operative
injury - Recurrent laryngeal)
Intra-operative Injury (Intra-operative
injury - Retina)
Intra-operative Injury (Intra-operative
injury - Sacral plexus)
Intra-operative Injury (Intra-operative
injury - Salivary duct)
Intra-operative Injury (Intra-operative
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injury - Salivary gland)
Intra-operative Injury (Intra-operative
injury - Sciatic)
Intra-operative Injury (Intra-operative
injury - Scrotum)
Intra-operative Injury (Intra-operative
injury - Sinus)
Intra-operative Injury (Intra-operative
injury - Skin)
Intra-operative Injury (Intra-operative
injury - Small bowel NOS)
Intra-operative Injury (Intra-operative
injury - Soft tissue NOS)
Intra-operative Injury (Intra-operative
injury - Spinal cord)
Intra-operative Injury (Intra-operative
injury - Spleen)
Intra-operative Injury (Intra-operative
injury - Stoma (GI))
Intra-operative Injury (Intra-operative
injury - Stomach)
Intra-operative Injury (Intra-operative
injury - Teeth)
Intra-operative Injury (Intra-operative
injury - Tendon)
Intra-operative Injury (Intra-operative
injury - Testis)
Intra-operative Injury (Intra-operative
injury - Thoracic duct)
Intra-operative Injury (Intra-operative
injury - Thoracodorsal)
Intra-operative Injury (Intra-operative
injury - Thyroid)
Intra-operative Injury (Intra-operative
injury - Tongue)
Intra-operative Injury (Intra-operative
injury - Trachea)
Intra-operative Injury (Intra-operative
injury - Upper aerodigestive NOS)
Intra-operative Injury (Intra-operative
injury - Upper airway NOS)
Intra-operative Injury (Intra-operative
injury - Ureter)
Intra-operative Injury (Intra-operative
injury - Urethra)
Intra-operative Injury (Intra-operative
injury - Urinary conduit)
Intra-operative Injury (Intra-operative
injury - Urinary tract NOS)
Intra-operative Injury (Intra-operative
injury - Uterus)
Intra-operative Injury (Intra-operative
injury - Vagina)
Intra-operative Injury - Vein (Intra-
operative injury - Vein NOS)
Intra-operative Injury (Intra-operative
injury - Vein-extremity (lower))
Intra-operative Injury (Intra-operative
injury - Vein-extremity (upper))
Intra-operative Injury (Intra-operative
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injury - Vein-hepatic)
Intra-operative Injury (Intra-operative
injury - Vein-inferior vena cava)
Intra-operative Injury (Intra-operative
injury - Vein-jugular)
Intra-operative Injury (Intra-operative
injury - Vein-major visceral vein)
Intra-operative Injury (Intra-operative
injury - Vein-portal vein)
Intra-operative Injury (Intra-operative
injury - Vein-pulmonary)
Intra-operative Injury (Intra-operative
injury - Vein-superior vena cava)
Intra-operative Injury (Intra-operative
injury - Vulva)
Intra-operative Injury Other (Intra-
operative Injury-Other (Specify))
Iron Overload (Iron overload)
Menstruation Irregular (Irregular menses
(change from baseline))
Irritability (Irritability (children <3 years of
age))
Joint-effusion (Joint-effusion)
Joint-effusion (Joint-function)
Keratitis Nec (Keratitis (corneal
inflammation/corneal ulceration))
Laryngeal Nerve Dysfunction (Laryngeal
nerve dysfunction)
Leak (including Anastomotic), Gi (Leak
(including anastomotic), GI - Biliary tree)
Leak (including Anastomotic), Gi (Leak
(including anastomotic), GI - Esophagus)
Leak (including Anastomotic), Gi (Leak
(including anastomotic), GI - Large
bowel)
Leak (including Anastomotic), Gi (Leak
(including anastomotic), GI - Leak NOS)
Leak (including Anastomotic), Gi (Leak
(including anastomotic), GI - Pancreas)
Leak (including Anastomotic), Gi (Leak
(including anastomotic), GI - Pharynx)
Leak (including Anastomotic), Gi (Leak
(including anastomotic), GI - Rectum)
Leak (including Anastomotic), Gi (Leak
(including anastomotic), GI - Small
bowel)
Leak (including Anastomotic), Gi (Leak
(including anastomotic), GI - Stoma)
Leak (including Anastomotic), Gi (Leak
(including anastomotic), GI - Stomach)
Leak (including Anastomotic), Gu (Leak
(including anastomotic), GU - Bladder)
Leak (including Anastomotic), Gu (Leak
(including anastomotic), GU - Fallopian
tube)
Leak (including Anastomotic), Gu (Leak
(including anastomotic), GU - Kidney)
Leak (including Anastomotic), Gu (Leak
(including anastomotic), GU - Spermatic
cord)
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Leak (including Anastomotic), Gu (Leak
(including anastomotic), GU - Stoma)
Leak (including Anastomotic), Gu (Leak
(including anastomotic), GU - Ureter)
Leak (including Anastomotic), Gu (Leak
(including anastomotic), GU - Urethra)
Leak (including Anastomotic), Gu (Leak
(including anastomotic), GU - Uterus)
Leak (including Anastomotic), Gu (Leak
(including anastomotic), GU - Vagina)
Leak (including Anastomotic), Gu (Leak
(including anastomotic), GU - Vas
deferens)
Leak, Cerebrospinal Fluid (csf) (Leak,
cerebrospinal fluid (CSF))
Left Ventricular Diastolic Dysfunction
(Left ventricular diastolic dysfunction)
Left Ventricular Failure (Left ventricular
systolic dysfunction)
Leucopenia Nos (Leukocytes (total
WBC))
Encephalopathy Nos
(Leukoencephalopathy (radiolographic
findings))
Libido Decreased (Libido)
Lipase Increased (Lipase)
Hepatic Failure (Liver dysfunction/failure
(clinical))
Local Complication - Device/prosthesis-
related (Local complication -
device/prosthesis-related)
Lumbar Spine-range Of Motion (Lumbar
spine-range of motion)
Lymphatics Other (Lymphatics-Other
(Specify))
Lymphedema-related Fibrosis
(Lymphedema-related fibrosis)
Lymphocele (Lymphocele)
Lymphopenia (Lymphopenia)
Hypermagnesaemia (Magnesium,
serum-high (hypermagnesemia))
Blood Magnesium Decreased
(Magnesium, serum-low
(hypomagnesemia))
Malabsorption (Malabsorption)
Virilism (Masculinization of female)
Amnesia Nec (Memory impairment)
Mental Status (Mental status)
Metabolic/laboratory Other
(Metabolic/Laboratory-Other (Specify))
Mood Alteration - Agitation (Mood
alteration - agitation)
Anxiety Nec (Mood alteration - anxiety)
Depression Nec (Mood alteration -
depression)
Euphoric Mood (Mood alteration -
euphoria)
Mucositis/stomatitis (clinical Exam)
(Mucositis/stomatitis (clinical exam) -
Anus)
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Mucositis/stomatitis (clinical Exam)
(Mucositis/stomatitis (clinical exam) -
Esophagus)
Mucositis/stomatitis (clinical Exam)
(Mucositis/stomatitis (clinical exam) -
Large bowel)
Mucositis/stomatitis (clinical Exam)
(Mucositis/stomatitis (clinical exam) -
Larynx)
Mucositis/stomatitis (clinical Exam)
(Mucositis/stomatitis (clinical exam) -
Oral cavity)
Stomatitis (Mucositis/stomatitis (clinical
exam) - Pharynx)
Mucositis/stomatitis (clinical Exam)
(Mucositis/stomatitis (clinical exam) -
Rectum)
Mucositis/stomatitis (clinical Exam)
(Mucositis/stomatitis (clinical exam) -
Small bowel)
Mucositis/stomatitis (clinical Exam)
(Mucositis/stomatitis (clinical exam) -
Stomach)
Mucositis/stomatitis (clinical Exam)
(Mucositis/stomatitis (clinical exam) -
Trachea)
Mucositis/stomatitis
(functional/symptomatic)
(Mucositis/stomatitis
(functional/symptomatic) - Anus)
Mucositis/stomatitis
(functional/symptomatic)
(Mucositis/stomatitis
(functional/symptomatic) - Esophagus)
Mucositis/stomatitis
(functional/symptomatic)
(Mucositis/stomatitis
(functional/symptomatic) - Large bowel)
Mucositis/stomatitis
(functional/symptomatic)
(Mucositis/stomatitis
(functional/symptomatic) - Larynx)
Mucositis/stomatitis
(functional/symptomatic)
(Mucositis/stomatitis
(functional/symptomatic) - Oral cavity)
Mucositis/stomatitis
(functional/symptomatic)
(Mucositis/stomatitis
(functional/symptomatic) - Pharynx)
Mucositis/stomatitis
(functional/symptomatic)
(Mucositis/stomatitis
(functional/symptomatic) - Rectum)
Mucositis/stomatitis
(functional/symptomatic)
(Mucositis/stomatitis
(functional/symptomatic) - Small bowel)
Mucositis/stomatitis
(functional/symptomatic)
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(Mucositis/stomatitis
(functional/symptomatic) - Stomach)
Mucositis/stomatitis
(functional/symptomatic)
(Mucositis/stomatitis
(functional/symptomatic) - Trachea)
Muscle Weakness, Generalized Or
Specific Area (not Due To Neuropathy)
(Muscle weakness, generalized or
specific area (not due to neuropathy) -
Extraocular)
Muscle Weakness, Generalized Or
Specific Area (not Due To Neuropathy)
(Muscle weakness, generalized or
specific area (not due to neuropathy) -
Extremity-lower)
Muscle Weakness, Generalized Or
Specific Area (not Due To Neuropathy)
(Muscle weakness, generalized or
specific area (not due to neuropathy) -
Extremity-upper)
Muscle Weakness, Generalized Or
Specific Area (not Due To Neuropathy)
(Muscle weakness, generalized or
specific area (not due to neuropathy) -
Facial)
Muscle Weakness, Generalized Or
Specific Area (not Due To Neuropathy)
(Muscle weakness, generalized or
specific area (not due to neuropathy) -
Left-sided)
Muscle Weakness, Generalized Or
Specific Area (not Due To Neuropathy)
(Muscle weakness, generalized or
specific area (not due to neuropathy) -
Ocular)
Muscle Weakness, Generalized Or
Specific Area (not Due To Neuropathy)
(Muscle weakness, generalized or
specific area (not due to neuropathy) -
Pelvic)
Muscle Weakness, Generalized Or
Specific Area (not Due To Neuropathy)
(Muscle weakness, generalized or
specific area (not due to neuropathy) -
Right-sided)
Muscle Weakness, Generalized Or
Specific Area (not Due To Neuropathy)
(Muscle weakness, generalized or
specific area (not due to neuropathy) -
Trunk)
Muscle Weakness Nos (Muscle
weakness, generalized or specific area
(not due to neuropathy) - Whole
body/generalized)
Muscular/skeletal Hypoplasia
(Muscular/skeletal hypoplasia)
Musculoskeletal/soft Tissue Other
(Musculoskeletal/Soft Tissue-Other
(Specify))
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Myelitis (Myelitis)
Myelodysplasia (Myelodysplasia)
Myocarditis Nos (Myocarditis)
Myositis (Myositis (inflammation/damage
of muscle))
Nail Abnormality Nos (Nail changes)
Nasal Cavity/paranasal Sinus Reactions
(Nasal cavity/paranasal sinus reactions)
Nausea (Nausea)
Necrosis, Gi (Necrosis, GI - Anus)
Necrosis, Gi (Necrosis, GI -
Colon/cecum/appendix)
Necrosis, Gi (Necrosis, GI - Duodenum)
Necrosis, Gi (Necrosis, GI - Esophagus)
Necrosis, Gi (Necrosis, GI - Gallbladder)
Necrosis, Gi (Necrosis, GI - Hepatic)
Necrosis, Gi (Necrosis, GI - Ileum)
Necrosis, Gi (Necrosis, GI - Jejunum)
Necrosis, Gi (Necrosis, GI - Oral)
Necrosis, Gi (Necrosis, GI - Pancreas)
Necrosis, Gi (Necrosis, GI - Peritoneal
cavity)
Necrosis, Gi (Necrosis, GI - Pharynx)
Necrosis, Gi (Necrosis, GI - Rectum)
Necrosis, Gi (Necrosis, GI - Small bowel
NOS)
Necrosis, Gi (Necrosis, GI - Stoma)
Necrosis, Gi (Necrosis, GI - Stomach)
Neuroendocrine: Acth Deficiency
(Neuroendocrine: ACTH deficiency)
Inappropriate Adh Secretion
(Neuroendocrine: ADH secretion
abnormality (e.g., SIADH or low ADH))
Neuroendocrine: Gonadotropin Secretion
Abnormality (Neuroendocrine:
gonadotropin secretion abnormality)
Neuroendocrine: Growth Hormone
Secretion Abnormality (Neuroendocrine:
growth hormone secretion abnormality)
Neuroendocrine: Prolactin Hormone
Secretion Abnormality (Neuroendocrine:
prolactin hormone secretion abnormality)
Neurology Other (Neurology-Other
(Specify))
Parosmia (Neuropathy: cranial - CN I
Smell)
Cranial Nerve Injury Nos (Neuropathy:
cranial - CN II Vision)
Neuropathy: Cranial (Neuropathy: cranial
- CN III Pupil, upper eyelid, extra ocular
movements)
Neuropathy: Cranial (Neuropathy: cranial
- CN IV Downward, inward movement of
eye)
Neuropathy: Cranial (Neuropathy: cranial
- CN IX Motor-pharynx; Sensory-ear,
pharynx, tongue)
Neuropathy: Cranial (Neuropathy: cranial
- CN V Motor-jaw muscles; Sensory-
facial)
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Neuropathy: Cranial (Neuropathy: cranial
- CN VI Lateral deviation of eye)
Neuropathy: Cranial (Neuropathy: cranial
- CN VII Motor-face; Sensory-taste)
Neuropathy: Cranial (Neuropathy: cranial
- CN VIII Hearing and balance)
Neuropathy: Cranial (Neuropathy: cranial
- CN X Motor-palate; pharynx, larynx)
Neuropathy: Cranial (Neuropathy: cranial
- CN XI Motor-sternomastoid and
trapezius)
Neuropathy: Cranial (Neuropathy: cranial
- CN XII Motor-tongue)
Peripheral Motor Neuropathy
(Neuropathy: motor)
Peripheral Sensory Neuropathy
(Neuropathy: sensory)
Neutropenia (Neutrophils/granulocytes
(ANC/AGC))
Blindness Night (Night blindness
(nyctalopia))
Nystagmus Nos (Nystagmus)
Obesity (Obesity)
Obstruction, Gi (Obstruction, GI -
Cecum)
Obstruction, Gi (Obstruction, GI - Colon)
Obstruction, Gi (Obstruction, GI -
Duodenum)
Obstruction, Gi (Obstruction, GI -
Esophagus)
Obstruction, Gi (Obstruction, GI -
Gallbladder)
Obstruction, Gi (Obstruction, GI - Ileum)
Obstruction, Gi (Obstruction, GI -
Jejunum)
Obstruction, Gi (Obstruction, GI -
Rectum)
Obstruction, Gi (Obstruction, GI - Small
bowel NOS)
Obstruction, Gi (Obstruction, GI - Stoma)
Obstruction, Gi (Obstruction, GI -
Stomach)
Obstruction, Gu (Obstruction, GU -
Bladder)
Obstruction, Gu (Obstruction, GU -
Fallopian tube)
Obstruction, Gu (Obstruction, GU -
Prostate)
Obstruction, Gu (Obstruction, GU -
Spermatic cord)
Obstruction, Gu (Obstruction, GU -
Stoma)
Obstruction, Gu (Obstruction, GU -
Testes)
Ureteric Obstruction (Obstruction, GU -
Ureter)
Obstruction, Gu (Obstruction, GU -
Urethra)
Obstruction, Gu (Obstruction, GU -
Uterus)
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Obstruction, Gu (Obstruction, GU -
Vagina)
Obstruction, Gu (Obstruction, GU - Vas
deferens)
Obstruction/stenosis Of Airway
(Obstruction/stenosis of airway -
Bronchus)
Obstruction/stenosis Of Airway
(Obstruction/stenosis of airway - Larynx)
Obstruction/stenosis Of Airway
(Obstruction/stenosis of airway -
Pharynx)
Obstruction/stenosis Of Airway
(Obstruction/stenosis of airway -
Trachea)
Conjunctivitis Nec (Ocular surface
disease)
Ocular/visual Other (Ocular/Visual-Other
(Specify))
Odor (patient Odor) (Odor (patient odor))
Diplopia (Ophthalmoplegia/diplopia
(double visioon))
Grade 2 lymphopenia (Opportunistic
infection associated with >)
Optic Disc Edema (Optic disc edema)
Orgasmic Dysfunction (Orgasmic
dysfunction)
Osteonecrosis (Osteonecrosis (avascular
necrosis))
Osteoporosis (Osteoporosis)
Otitis Externa (exc Boil Of Meatus) Nos
(Otitis, external ear (non-infectious))
Otitis Media Serous Nos (Otitis, middle
ear (non-infectious))
Abdominal Pain Nos (Pain - Abdomen
NOS)
Pain (Pain - Anus)
Pain (Pain - Back)
Pain (Pain - Bladder)
Bone Pain (Pain - Bone)
Pain (Pain - Breast)
Pain (Pain - Buttock)
Pain (Pain - Cardiac/heart)
Pain (Pain - Chest wall)
Chest Pain (Pain - Chest/thorax NOS)
Pain (Pain - Dental/teeth/peridontal)
Pain (Pain - Esophagus)
Earache (Pain - External ear)
Pain (Pain - Extremity-limb)
Pain (Pain - Eye)
Pain (Pain - Face)
Pain (Pain - Gallbladder)
Headache Nos (Pain - Head/headache)
Pain (Pain - Intestine)
Arthralgia (Pain - Joint)
Pain (Pain - Kidney)
Pain (Pain - Larynx)
Pain (Pain - Lip)
Hepatic Pain (Pain - Liver)
Pain (Pain - Lymph node)
35 / 47
NCI Standard Adverse Event/Serious Adverse Event CTCAE v3
Template - 2748814v1.0
Pain (Pain - Middle ear)
Myalgia (Pain - Muscle)
Pain (Pain - Neck)
Neuralgia Nos (Pain -
Neuralgia/peripheral nerve)
Pain (Pain - Oral cavity)
Pain (Pain - Oral-gums)
Pain (Pain - Ovulatory)
Pain (Pain - Pain NOS)
Pelvic Pain Nos (Pain - Pelvis)
Pain (Pain - Penis)
Pain (Pain - Pericardium)
Pain (Pain - Perineum)
Pain (Pain - Peritoneum)
Pain (Pain - Phantom (pain associated
with missing limb))
Pleuritic Pain (Pain - Pleura)
Pain (Pain - Prostate)
Proctalgia (Pain - Rectum)
Pain (Pain - Scalp)
Pain (Pain - Scrotum)
Pain (Pain - Sinus)
Pain (Pain - Skin)
Pain (Pain - Stomach)
Pain (Pain - Testicle)
Pain (Pain - Throat/pharynx/larynx)
Tumour Pain (Pain - Tumor pain)
Dysuria (Pain - Urethra)
Dysmenorrhoea (Pain - Uterus)
Pain (Pain - Vagina)
Pain Other (Pain-Other (Specify))
Palpitations (Palpitations)
Pancreas, Exocrine Enzyme Deficiency
(Pancreas, exocrine enzyme deficiency)
Pancreatic Endocrine: Glucose
Intolerance (Pancreatic endocrine:
glucose intolerance)
Pancreatitis Nos (Pancreatitis)
Parathyroid Function, Low
(hypoparathyroidism) (Parathyroid
function, low (hypoparathyroidism))
Perforation, Gi (Perforation, GI -
Appendix)
Perforation, Gi (Perforation, GI - Biliary
tree)
Perforation, Gi (Perforation, GI - Cecum)
Perforation, Gi (Perforation, GI - Colon)
Perforation, Gi (Perforation, GI -
Duodenum)
Perforation, Gi (Perforation, GI -
Esophagus)
Perforation, Gi (Perforation, GI -
Gallbladder)
Perforation, Gi (Perforation, GI - Ileum)
Perforation, Gi (Perforation, GI -
Jejunum)
Perforation, Gi (Perforation, GI - Rectum)
Perforation, Gi (Perforation, GI - Small
bowel NOS)
Perforation, Gi (Perforation, GI -
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Stomach)
Perforation, Gu (Perforation, GU -
Bladder)
Perforation, Gu (Perforation, GU -
Fallopian tube)
Perforation, Gu (Perforation, GU -
Kidney)
Perforation, Gu (Perforation, GU - Ovary)
Perforation, Gu (Perforation, GU -
Prostate)
Perforation, Gu (Perforation, GU -
Spermatic cord)
Perforation, Gu (Perforation, GU -
Stoma)
Perforation, Gu (Perforation, GU -
Testes)
Perforation, Gu (Perforation, GU - Ureter)
Perforation, Gu (Perforation, GU -
Urethra)
Perforation, Gu (Perforation, GU -
Uterus)
Perforation, Gu (Perforation, GU -
Vagina)
Perforation, Gu (Perforation, GU - Vas
deferens)
Pericardial Effusion (Pericardial effusion
(non-malignant))
Pericarditis (Pericarditis)
Peripheral Ischaemia Nos (Peripheral
arterial ischemia)
Personality Change
(Personality/behavioral)
Petechiae (Petechiae/purpura
(hemorrhage/bleeding into skin or
mucosa))
Phlebitis Superficial (Phlebitis (including
superficial thrombosis))
Phlebolymphatic Cording
(Phlebolymphatic cording)
Hypophosphataemia (Phosphate, serum-
low (hypophosphatemia))
Photosensitivity Reaction Nos
(Photosensitivity)
Phrenic Nerve Dysfunction (Phrenic
nerve dysfunction)
Platelet Count Decreased (Platelets)
Pleural Effusion (Pleural effusion (non-
malignant))
Pneumonitis Nos
(Pneumonitis/pulmonary infiltrates)
Pneumothorax Nos (Pneumothorax)
Portal Hypertension (Portal vein flow)
Hyperkalaemia (Potassium, serum-high
(hyperkalemia))
Hypokalaemia (Potassium, serum-low
(hypokalemia))
Proctitis Nos (Proctitis)
Prolapse Of Stoma, Gi (Prolapse of
stoma, GI)
Prolapse Of Stoma, Gu (Prolapse of
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stoma, GU)
Prolonged Chest Tube Drainage Or Air
Leak After Pulmonary Resection
(Prolonged chest tube drainage or air
leak after pulmonary resection)
Prolonged Intubation After Pulmonary
Resection (>24 Hrs After Surgery)
(Prolonged intubation after pulmonary
resection (>24 hrs after surgery))
Electrocardiogram Qt Prolonged
(Prolonged QTc interval)
Proptosis/enophthalmos
(Proptosis/enophthalmos)
Proteinuria Present (Proteinuria)
Pruritus Nos (Pruritus/itching)
Delusion Nos (Psychosis
(hallucinations/delusions))
Activated Partial Thromboplastin Time
Prolonged (PTT (Partial thromboplastin
time))
Puberty (delayed) (Puberty (delayed))
Puberty (precocious) (Puberty
(precocious))
Pulmonary Fibrosis (Pulmonary fibrosis
(radiographic changes))
Pulmonary Hypertension (Pulmonary
hypertension)
Pulmonary/upper Respiratory Other
(Pulmonary/Upper Respiratory-Other
(Specify))
Upper Motor Neurone Lesion (Pyramidal
tract dysfunction (e.g., increased tone,
hyperreflexia, positive Babinski,
decreased fine motor coordination))
Rash: Acne/acneiform (Rash:
acne/acneiform)
Radiation Recall Syndrome (Rash:
dermatitis associated with radiation -
Chemoradiation)
Dermatitis Radiation Nos (Rash:
dermatitis associated with radiation -
Radiation)
Erythema Multiforme (Rash: erythema
multiforme (e.g., Stevens-Johnson
syndrome, toxic epidermal necrolysis))
Localised Exfoliation (Rash: hand-foot
skin reaction)
Dermatitis Exfoliative Nos
(Rash/desquamation)
Renal Failure Nos (Renal failure)
Renal/genitourinary Other
(Renal/Genitourinary-Other (Specify))
Restrictive Cardiomyopathy (Restrictive
cardiomyopathy)
Retinal Detachment (Retinal
detachment)
Retinoic Acid Syndrome (Retinoic acid
syndrome)
Retinopathy (Retinopathy)
Right Ventricular Dysfunction (cor
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Pulmonale) (Right ventricular dysfunction
(cor pulmonale))
Rigors (Rigors/chills)
Salivary Gland Disorder Nos (Salivary
gland changes/saliva)
Scleral Necrosis/melt (Scleral
necrosis/melt)
Secondary Malignancy Possibly Related
To Cancer Treatment (Secondary
Malignancy-possibly related to cancer
treatment (Specify))
Convulsions Nos (Seizure)
Seroma (Seroma)
Serum Sickness (Serum sickness)
Sexual/reproductive Function Other
(Sexual/Reproductive Function-Other
(Specify))
Short Stature (Short stature)
Skin Breakdown/decubitus Ulcer (Skin
breakdown/decubitus ulcer)
Hypernatraemia (Sodium, serum-high
(hypernatremia))
Hyponatraemia (Sodium, serum-low
(hyponatremia))
Soft Tissue Necrosis (Soft tissue
necrosis - Abdomen)
Soft Tissue Necrosis (Soft tissue
necrosis - Extremity-lower)
Soft Tissue Necrosis (Soft tissue
necrosis - Extremity-upper)
Soft Tissue Necrosis (Soft tissue
necrosis - Head)
Soft Tissue Necrosis (Soft tissue
necrosis - Neck)
Soft Tissue Necrosis (Soft tissue
necrosis - Pelvic)
Soft Tissue Necrosis (Soft tissue
necrosis - Thorax)
Depressed Level Of Consciousness
(Somnolence/depressed level of
consciousness)
Speech Disorder Nec (Speech
impairment (e.g., dysphasia or aphasia))
Splenic Function (Splenic function)
Striae (Striae)
Stricture/stenosis (including
Anastomotic), Gi (Stricture/stenosis
(including anastomotic), GI - Anus)
Stricture/stenosis (including
Anastomotic), Gi (Stricture/stenosis
(including anastomotic), GI - Biliary tree)
Stricture/stenosis (including
Anastomotic), Gi (Stricture/stenosis
(including anastomotic), GI - Cecum)
Stricture/stenosis (including
Anastomotic), Gi (Stricture/stenosis
(including anastomotic), GI - Colon)
Stricture/stenosis (including
Anastomotic), Gi (Stricture/stenosis
(including anastomotic), GI - Duodenum)
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Stricture/stenosis (including
Anastomotic), Gi (Stricture/stenosis
(including anastomotic), GI - Esophagus)
Stricture/stenosis (including
Anastomotic), Gi (Stricture/stenosis
(including anastomotic), GI - Ileum)
Stricture/stenosis (including
Anastomotic), Gi (Stricture/stenosis
(including anastomotic), GI - Jejunum)
Stricture/stenosis (including
Anastomotic), Gi (Stricture/stenosis
(including anastomotic), GI -
Pancreas/pancreatic duct)
Stricture/stenosis (including
Anastomotic), Gi (Stricture/stenosis
(including anastomotic), GI - Pharynx)
Stricture/stenosis (including
Anastomotic), Gi (Stricture/stenosis
(including anastomotic), GI - Rectum)
Stricture/stenosis (including
Anastomotic), Gi (Stricture/stenosis
(including anastomotic), GI - Small bowel
NOS)
Stricture/stenosis (including
Anastomotic), Gi (Stricture/stenosis
(including anastomotic), GI - Stoma)
Stricture/stenosis (including
Anastomotic), Gi (Stricture/stenosis
(including anastomotic), GI - Stomach)
Stricture/stenosis (including
Anastomotic), Gu (Stricture/stenosis
(including anastomotic), GU - Bladder)
Stricture/stenosis (including
Anastomotic), Gu (Stricture/stenosis
(including anastomotic), GU - Fallopian
tube)
Stricture/stenosis (including
Anastomotic), Gu (Stricture/stenosis
(including anastomotic), GU - Prostate)
Stricture/stenosis (including
Anastomotic), Gu (Stricture/stenosis
(including anastomotic), GU - Spermatic
cord)
Stricture/stenosis (including
Anastomotic), Gu (Stricture/stenosis
(including anastomotic), GU - Stoma)
Stricture/stenosis (including
Anastomotic), Gu (Stricture/stenosis
(including anastomotic), GU - Testes)
Stricture/stenosis (including
Anastomotic), Gu (Stricture/stenosis
(including anastomotic), GU - Ureter)
Stricture/stenosis (including
Anastomotic), Gu (Stricture/stenosis
(including anastomotic), GU - Urethra)
Stricture/stenosis (including
Anastomotic), Gu (Stricture/stenosis
(including anastomotic), GU - Uterus)
Stricture/stenosis (including
Anastomotic), Gu (Stricture/stenosis
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(including anastomotic), GU - Vagina)
Stricture/stenosis (including
Anastomotic), Gu (Stricture/stenosis
(including anastomotic), GU - Vas
deferens)
Supraventricular And Nodal Arrhythmia
(Supraventricular and nodal arrhythmia -
Atrial fibrillation)
Supraventricular And Nodal Arrhythmia
(Supraventricular and nodal arrhythmia -
Atrial flutter)
Supraventricular And Nodal Arrhythmia
(Supraventricular and nodal arrhythmia -
Atrial tachycardia/paroxysmal atrial
tachycardia)
Supraventricular And Nodal Arrhythmia
(Supraventricular and nodal arrhythmia -
Nodal/junctional)
Supraventricular And Nodal Arrhythmia
(Supraventricular and nodal arrhythmia -
Sinus arrhythmia)
Sinus Bradycardia (Supraventricular and
nodal arrhythmia - Sinus bradycardia)
Sinus Tachycardia (Supraventricular and
nodal arrhythmia - Sinus tachycardia)
Supraventricular Arrhythmia Nos
(Supraventricular and nodal arrhythmia -
Supraventricular arrhythmia NOS)
Supraventricular And Nodal Arrhythmia -
Supraventricular Extrasystoles
(premature Atrial Contractions;
Premature Nodal/junctional
Contractions) (Supraventricular and
nodal arrhythmia - Supraventricular
extrasystoles (premature atrial
contractions; premature nodal/junctional
contractions))
Supraventricular And Nodal Arrhythmia
(Supraventricular and nodal arrhythmia -
Supraventricular tachycardia)
Sweating Increased (Sweating
(diaphoresis))
Syncope (Syncope (fainting))
Syndromes Other (Syndromes-Other
(Specify))
Taste Disturbance (Taste alteration
(dysgeusia))
Telangiectasia (Telangiectasia)
Thrombosis/embolism (vascular Access-
related) (Thrombosis/embolism (vascular
access-related))
Thrombosis Nos
(Thrombosis/thrombus/embolism)
Thrombotic Microangiopathy (e.g.,
Thrombotic Thrombocytopenic
Purpura[ttp] Or Hemolytic Uremic
Syndrome[hus]) (Thrombotic
microangiopathy (e.g., thrombotic
thrombocytopenic purpura or hemolytic
uremic syndrome))
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Thyroid Function, High (hyperthyroidism,
Thyrotoxicosis) (Thyroid function, high
(hyperthyroidism, thyrotoxicosis))
Hypothyroidism (Thyroid function, low
(hypothyroidism))
Tinnitus (Tinnitus)
Tremor Nec (Tremor)
Hypertriglyceridaemia (Triglyceride,
serum-high (hypertriglyceridemia))
Trismus (difficulty, Restriction Or Pain
When Opening Mouth) (Trismus
(difficulty, restriction or pain when
opening mouth))
Tumour Flare (Tumor flare)
Tumour Lysis Syndrome (Tumor lysis
syndrome)
Caecitis (Typhlitis (cecal inflammation))
Ulcer, Gi (Ulcer, GI - Anus)
Ulcer, Gi (Ulcer, GI - Cecum)
Ulcer, Gi (Ulcer, GI - Colon)
Duodenal Ulcer (Ulcer, GI - Duodenum)
Ulcer, Gi (Ulcer, GI - Esophagus)
Ulcer, Gi (Ulcer, GI - Ileum)
Ulcer, Gi (Ulcer, GI - Jejunum)
Ulcer, Gi (Ulcer, GI - Rectum)
Ulcer, Gi (Ulcer, GI - Small bowel NOS)
Ulcer, Gi (Ulcer, GI - Stoma)
Gastric Ulcer (Ulcer, GI - Stomach)
Ulceration (Ulceration)
Hyperuricaemia (Uric acid, serum-high
(hyperuricemia))
Fanconi Syndrome (Urinary electrolyte
wasting (e.g., Fanconi's syndrome, renal
tubular acidosis))
Urinary Frequency (Urinary
frequency/urgency)
Urinary Retention (Urinary retention
(including neurogenic bladder))
Urine Discolouration (Urine color
change)
Urticaria Nos (Urticaria (hives, welts,
wheals))
Uveitis (Uveitis)
Vaginal Discharge (non-infectious)
(Vaginal discharge (non-infectious))
Vulvovaginal Dryness (Vaginal dryness)
Vaginal Mucositis (Vaginal mucositis)
Vaginal Stenosis/length (Vaginal
stenosis/length)
Vaginitis (Vaginitis (not due to infection))
Valvular Heart Disease (Valvular heart
disease)
Vascular Other (Vascular-Other
(Specify))
Vasculitis Nos (Vasculitis)
Vasovagal Attack (Vasovagal episode)
Ventricular Arrhythmia (Ventricular
arrhythmia - Bigeminy)
Ventricular Arrhythmia (Ventricular
arrhythmia - Idioventricular rhythm)
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Ventricular Arrhythmia (Ventricular
arrhythmia - PVCs)
Ventricular Arrhythmia (Ventricular
arrhythmia - Torsade de pointes)
Ventricular Arrhythmia (Ventricular
arrhythmia - Trigeminy)
Ventricular Arrhythmia Nos (Ventricular
arrhythmia - Ventricular arrhythmia NOS)
Ventricular Arrhythmia (Ventricular
arrhythmia - Ventricular fibrillation)
Ventricular Arrhythmia (Ventricular
arrhythmia - Ventricular flutter)
Ventricular Arrhythmia (Ventricular
arrhythmia - Ventricular tachycardia)
Vessel Injury-artery (Vessel injury-artery
- Aorta)
Vessel Injury-artery (Vessel injury-artery
- Carotid)
Vessel Injury-artery (Vessel injury-artery
- Extremity-lower)
Vessel Injury-artery (Vessel injury-artery
- Extremity-upper)
Vessel Injury-artery (Vessel injury-artery
- Other NOS)
Vessel Injury-artery (Vessel injury-artery
- Visceral)
Vessel Injury-vein (Vessel injury-vein -
Extremity-lower)
Vessel Injury-vein (Vessel injury-vein -
Extremity-upper)
Vessel Injury-vein (Vessel injury-vein -
IVC)
Vessel Injury-vein (Vessel injury-vein -
Jugular)
Vessel Injury-vein (Vessel injury-vein -
Other NOS)
Vessel Injury-vein (Vessel injury-vein -
SVC)
Vessel Injury-vein (Vessel injury-vein -
Viscera)
Viral Hepatitis (Viral hepatitis)
Visceral Arterial Ischaemia (Visceral
arterial ischemia (non-myocardial))
Vision Blurred (Vision-blurred vision)
Photopsia (Vision-flashing lights/floaters)
Photophobia (Vision-photophobia)
Vital Capacity (Vital capacity)
Vitreous Hemorrhage (Vitreous
hemorrhage)
Dysphonia (Voice changes/dysarthria
(e.g., hoarseness, loss or alteration in
voice, laryngitis))
Vomiting Nos (Vomiting)
Lacrimation Increased (Watery eye
(epiphora, tearing))
Weight Increased (Weight gain)
Weight Decreased (Weight loss)
Culture Wound Negative (Wound
complication, non-infectious)
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Describe 'Other' Adverse Event (Verbatim AE
Description used to 'reinforce' selected AE Type -
Code.)
Adverse Event Grade (A coded value to identify
the severity of the AE.)
Mild Adverse Event (1)
Moderate Adverse Event (2)
Severe Adverse Event (3)
Life-threatening Or Disabling Adverse
Event (4)
Death Related To Adverse Event (5)
Conditional Adverse Event Data Elements
AE Start Date (Date on which the AE was first
evident.)
Was patient hospitalized for toxicity? (Normally
required only if AE is deemed 'serious'.)
Yes
No
Cycle # (A repeating period of activity involving
treatment and rest.  Several cycles can make up
a course.)
Optional Adverse Event Data Elements
To what is the AE attributed? (List of other
therapies surgery, radiation, etc, disease,
concomitant meds, other. Select MOST likely.)
Biological Therapy (1)
Investigational Agent (10)
Radiation Therapy (11)
Surgery (12)
Chemotherapy (2)
Combined Modality (3)
Concomitant Agent (5)
Medical_device (6)
Disease (7)
Endocrine Therapy (8)
Immunotherapy (9)
Other (99)
Other Attribution, Specify (If 'other' selected in
data element above, must provide a - description
of the presumed cause.)
AE Stop Date (Date on which the AE resolved.)
Unknown Date (0)
Event/occurrence Is Ongoing (1)
MedDRA System Organ Class (SOC)
Hematopoietic And Lymphoid System
Disorder (1)
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Immune System Disorder (10)
Infection And Infestation (11)
Injury, Poisoning And Procedural
Complication Class (12)
Investigation (13)
Metabolism And Nutrition Disorder Class
(14)
Connective And Soft Tissue Disorder
(15)
Neoplasm (16)
Nervous System Disorder (17)
Pregnancy, Puerperium And Perinatal
Condition Class (18)
Psychiatric Disorder (19)
Cardiac Disorders (2)
Urinary Tract Disorder (20)
Reproductive System And Breast
Disorder Class (21)
Respiratory And Thoracic Disorder (22)
Skin Disorder (23)
Social Circumstances (24)
Intervention Or Procedure (25)
Vascular Disorder (26)
Congenital, Familial And Genetic
Disorder Class (3)
Ear And Labyrinth Disorder Class (4)
Endocrine Disorder (5)
Eye Disorder (6)
Gastrointestinal Disorder (7)
General Disorders And Administration
Site Conditions Class (8)
Liver And Biliary Tract Disorder (9)
MedDRA AE Code (CTCAE v3.0) (Code used to
identify the adverse event using a standard
mechanism that facilitates analysis. CTEP¿s
code list and associated Category/Term is
currently a standard.)
AE Attribution (This question is not asked for
baseline assessments. Question should be asked
mandatory for all studies that involve drug
therapy.)
Definite (1)
Possible (2)
Probable (3)
Unlikely (4)
Unrelated (5)
Reporting Period End Date (End of the
assessment period.)
Were adverse events assessed during most
recent period (Indicator to clarify whether any
AEs were identified during the - reporting period.
This is confirmation that the remainder of the
form was intentionally left blank.)
Yes
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No
AE Expected?
Yes
No
Serious? (If a 'yes' response is entered, complete
the SAE section for - this AE.)
Yes
No
Event Onset Time (Enter the time of day when
AE was first evident.  Used when Date of Onset
is insufficient.)
Course (May be used during protocol therapy
period to automatically - set the evaluation
start/end dates to the period of the course of
treatment e.g. user supplies course# and
evaluation period derived.)
AE Evaluation Period Start Date (Date of the
beginning start of the assessment period.)
Pre-existing AE? (Should be derivable if you
capture AEs for specified periods; not needed if
you track an AE until it resolves including
worseningrather than for a defined assessment
period.)
Yes
No
AE Resolved Time (Enter the time of day when
AE was resolved.)
AE Ongoing? (Flag to indicate whether AE has
resolved or not. This ensures that leaving 'Stop
Date' blank was not done inadvertently.)
Yes
No
Participant Status/Outcome
Death (1)
Not Recovered Or Not Resolved (2)
Recovered Or Resolved (3)
Recovered Or Resolved With Sequelae
(4)
Recovering Or Resolving (5)
Unknown (6)
Adverse Event Condition Pattern (This should be
derivable from a review of AEs over time.)
Single Episode (1)
Intermittent (2)
Continuous (3)
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Did event reappear after study agent was
reintroduced? (Enter response from choice list.)
Yes
No
Comments (A general comment that should not
be specific to a single AE.)
Optional Serious Adverse Event
Questions
Why serious? (Select the appropriate response.)
Results In Death (1)
Is Life-threatening (2)
Requires Inpatient Hospitalization Or
Prolongation Of Existing Hospitalization
(3)
Results In Persistent Or Significant
Disability/incapacity (4)
Is A Congenital Anomaly/birth Defect (5)
In The Medical Judgment Of The
Treating Physician And/or Investigator, It
May Jeopardize The Participant Or
Require Intervention To Prevent One Of
These Outcomes (6)
Other, Specify (7)
Meets Criteria Per Protocol But Does Not
Meet Other Criterion (above) (8)
Dose-Limiting Toxicity? (Select the appropriate
response.)
Yes
No
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Pathology Procurement Form AIDS and Cancer Specimen
Resource (ACSR F37 AMC-058 NCT00695422)
Form imported via medical-data-models.org API-version 1
All rights reserved. Please visit https://medical-data-
models.org/forms/9842
Pathology Procurement Form AIDS
and Cancer Specimen Resource
(ACSR F37 AMC-058
NCT00695422)
Header Module
Visit number
Study Coordinator's name
E-mail
Phone Number
Comments
Specimen Procurement
Date Specimen Obtained
Specimen(s) obtained for donation to ACSR
Yes
No
Specimen Type
Peripheral Blood (Blood)
Other (Other)
PBMC (peripheral Blood Mononuclear
Cells) (PBMC)
Plasma (Plasma)
Serum (Serum)
Tissue (Tissue)
Other specify
ACSR site the specimen(s) shipped to
Gwu (GWU)
Jhu (JHU)
Osu (OSU)
Other (Other)
Suny/hscb (SUNY/HSCB)
Ucla (UCLA)
Ucsf (UCSF)
Other, specify
If specimens were not obtained for ACSR, please
indicate reason
Patient Had Previously Donated
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Specimen To Acsr (1)
Patient Refused To Give Informed
Consent For Acsr Specimen Donation
(2)
Patient Was Not Asked To Consider Acsr
Specimen Donation (3)
Other (4)
Other, specify
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Meldebogen Schwangerschaft - TEIL 1
(REGIMS)
siehe http://epi.uni-muenster.de
All rights reserved. Please visit https://medical-data-
models.org/forms/9846
Meldebogen für Schwangerschaft -
TEIL 1
Berichterstatters
Name des Berichterstatters*
Datum der Meldung*
Ausbildung*
anderes Praxispersonal (0)
Neurologe (1)
wenn andere, welche Ausbildung?
Patientendaten
Alter in Jahren
GrößŸe
Gewicht
Schwangerschaft
Datum der letzten Regelblutung*
Errechneter Geburtstermin*
Anzahl früherer Schwangerschaften*
Wenn ja, Datum der letzten Entbindung angeben
Ausgang
k.A. (-1)
Lebendgeburt ohne Abnormalitat (1)
Ektopische Schwangerschaft (2)
Spontanabort (3)
Schwangerschaftsabbruch (4)
Lebendgeburt mit Abnormalitat (5)
Frühgeburt (6)
Totgeburt (7)
Relevante Anamnese (Grunderkrankung,
Begleiterkrankungen, Allergien,
Risikofaktoren, ...)
Relevant in der Anamnese 1
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seit Datum
relevante Anamnese 2
Relevant in der Anamnese 2
seit Datum
Medizinische Angaben
Medikament 1
Mitoxantron (10)
Natalizumab (Tysabri) (11)
Rituximab (14)
Andere ... (16)
Fingolimod (Gilenya) (18)
Interferon Ÿ1A IM (Avonex) (19)
Azathioprin (2)
Interferon Ÿ1A SC (Rebif 22 Âµg, Rebif
44 Âµg) (20)
Interferon Ÿ1B SC (Betaferon, Extavia)
(21)
Alemtuzumab (Lemtrada) (22)
Teriflunomide (Aubagio) (23)
Fumarat (BG-12; Tecfidera) (24)
Cyclophosphamid (4)
Glatirameracetat (Copaxone) (6)
Immunglobuline (7)
* Medikation aus einer MS-Studie (8)
Methotrexat (9)
Dosis
Einheit
mg (Milligramm) (2)
µg (Mikrogramm) (4)
Therapiebeginn
fortgesetzt
Ja
Nein
Therapie beendet am
MS-Medikdation 2: Medikation / Dosis /
Einheit
Medikament 2
Mitoxantron (10)
Natalizumab (Tysabri) (11)
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Rituximab (14)
Andere ... (16)
Fingolimod (Gilenya) (18)
Interferon Ÿ1A IM (Avonex) (19)
Azathioprin (2)
Interferon Ÿ1A SC (Rebif 22 Âµg, Rebif
44 Âµg) (20)
Interferon Ÿ1B SC (Betaferon, Extavia)
(21)
Alemtuzumab (Lemtrada) (22)
Teriflunomide (Aubagio) (23)
Fumarat (BG-12; Tecfidera) (24)
Cyclophosphamid (4)
Glatirameracetat (Copaxone) (6)
Immunglobuline (7)
* Medikation aus einer MS-Studie (8)
Methotrexat (9)
Dosis
Einheit
mg (Milligramm) (2)
µg (Mikrogramm) (4)
Therapiebeginn
fortgesetzt
Ja
Nein
Therapie beendet am
Andere Medikation vor / wahrend der
Schwangerschaft
Begleitmedikation 1 (Handelsname)
Dosis
Einheit
mg (Milligramm) (2)
µg (Mikrogramm) (4)
Therapiebeginn
Therapieende
Indikation
Begleitmedikation 2: Handelsname / Dosis
/ Einheit
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Begleitmedikation 2 (Handelsname)
Dosis
Einheit
mg (Milligramm) (2)
µg (Mikrogramm) (4)
Therapiebeginn
Therapieende
Indikation
Begleitmedikation 3: Handelsname / Dosis
/ Einheit
Begleitmedikation 3 (Handelsname)
Dosis
Einheit
mg (Milligramm) (2)
µg (Mikrogramm) (4)
Therapiebeginn
Therapieende
Indikation
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Erhebungsbogen Nachuntersuchung
Neurologie SHT-Register
Erhebungsbogen Nachuntersuchung Neurologie SHT-
Register
All rights reserved. Please visit https://medical-data-
models.org/forms/9847
Erhebungsbogen Nachuntersuchung
Neurologie SHT-Register
Erhebungsdatum
Datum der Erhebung*
Unfalldatum*
Schule
Schule*
Kindergarten (1)
Grundschule (2)
Förderschule für Kinder mit geistiger
Behinderung (3)
Förderschule für Kinder mit körperlicher
Behinderung (4)
Volksschule / Hauptschule (5)
Realschule (6)
Gymnasium (7)
Gesamtschule (8)
Berufsschule (9)
Aktuelle Schulklasse*
Schulbesuch in Stunden / Tag*
Schulwechsel*
Ja
Nein
Leistungsabfall*
Ja
Nein
Psychopathologischer Befund
Orientierung zur Person*
Ja
Nein
Orientierung zur Zeit*
Ja
Nein
Orientierung zum ort*
Ja
Nein
Orientierung zur Situation*
Ja
Nein
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Konzentrationsschwäche*
Ja
Nein
Gedächtnisschwäche*
Ja
Nein
Wesensveränderungen*
Ja
Nein
Störung des Sozialverhaltens*
Ja
Nein
Störung der Emotionalität*
Ja
Nein
Antriebsstörung*
Ja
Nein
Autoaggressionen*
Ja
Nein
Fremdagressionen*
Ja
Nein
Posttraumatische Belastungsstörung*
Ja (1)
Nein (2)
Nicht bekannt (3)
Depressive Verstimmung/Depression*
Ja (1)
Nein (2)
Nicht bekannt (3)
Psychologische Anbindung*
Ja
Nein
Stimmung*
Positiv (1)
Negativ (2)
Unauffällig (3)
Diagnostik
EEG-Auffälligkeiten*
Ja
Nein
EEG-Auffälligkeit: Verlangsamung*
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Ja
Nein
EEG-Auffälligkeit: Epilepsie typisches Potenzial*
Ja
Nein
EEG-Auffälligkeit: Amplitudenminderung*
Ja
Nein
Anamnese
Erbrechen*
Ja
Nein
Übelkeit*
Ja
Nein
Schwindel*
Ja
Nein
Kopfschmerzen*
Ja
Nein
Parästhesien*
Ja
Nein
Sehstörungen*
Ja
Nein
Sprachstörungen*
Ja
Nein
Geräuschempfindlichkeit*
Ja
Nein
Tinitus*
Ja
Nein
Lichtempfindlichkeit*
Ja
Nein
Schlafanamnese
Nächtlicher Schlaf in Stunden*
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Einschlafstörungen*
Ja
Nein
Durchschlafstörungen*
Ja
Nein
Alpträume*
Ja
Nein
Tagesmüdigkeit*
Ja
Nein
Neurologische Untersuchung
Pupillen isocor*
Ja
Nein
Lichtreaktion links*
positiv (1)
negativ (2)
zweifelhaft (3)
nicht beurteilbar (4)
Lichtreaktion rechts*
positiv (1)
negativ (2)
zweifelhaft (3)
nicht beurteilbar (4)
Nystagmus*
Ja
Nein
Hirnnerven
Hirnnerv I auffällig*
Ja
Nein
Hirnnerv II auffällig*
Ja
Nein
Hirnnerv III auffällig*
Ja
Nein
Hirnnerv IV auffällig*
Ja
Nein
Hirnnerv V auffällig*
Ja
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Nein
Hirnnerv VI auffällig*
Ja
Nein
Hirnnerv VII auffällig*
Ja
Nein
Hirnnerv VIII auffällig*
Ja
Nein
Hirnnerv IX auffällig*
Ja
Nein
Hirnnerv X auffällig*
Ja
Nein
Hirnnerv XI auffällig*
Ja
Nein
Hirnnerv XII auffällig*
Ja
Nein
Reflexstatus
Bizepssehnenreflex, links*
positiv (1)
gesteigert (2)
nicht auslösbar (3)
Bizepssehnenreflex, rechts*
positiv (1)
gesteigert (2)
nicht auslösbar (3)
Trizepssehnenreflex, links*
positiv (1)
gesteigert (2)
nicht auslösbar (3)
Trizepssehnenreflex, rechts*
positiv (1)
gesteigert (2)
nicht auslösbar (3)
Radius-Periost-Reflex, links*
positiv (1)
gesteigert (2)
nicht auslösbar (3)
Radius-Periost-Reflex, rechts*
positiv (1)
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gesteigert (2)
nicht auslösbar (3)
Patellarsehnenreflex, links*
positiv (1)
gesteigert (2)
nicht auslösbar (3)
Patellarsehnenreflex, rechts*
positiv (1)
gesteigert (2)
nicht auslösbar (3)
Achillessehnenreflex, links*
positiv (1)
gesteigert (2)
nicht auslösbar (3)
Achillessehnenreflex, rechts*
positiv (1)
gesteigert (2)
nicht auslösbar (3)
Kloni der Füße*
Nein (1)
Links (2)
Rechts (3)
Beidseits (4)
Babinski positiv*
Ja
Nein
Meningismus*
Ja
Nein
Motorik
Gangbild*
Sicher (1)
Unsicher (2)
Breitbasig (3)
Fersengang auffällig*
Nein (1)
Links (2)
Rechts (3)
Beidseits (4)
Zehengang auffällig*
Nein (1)
Links (2)
Rechts (3)
Beidseits (4)
Seiltänzergang auffällig*
Nein (1)
Links (2)
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Rechts (3)
Beidseits (4)
Monopedalerstand unsicher*
Nein (1)
Links (2)
Rechts (3)
Beidseits (4)
Hüpfen unsicher*
Nein (1)
Links (2)
Rechts (3)
Beidseits (4)
Ataxie*
Nein (1)
Links (2)
Rechts (3)
Beidseits (4)
Romberg auffällig*
Ja
Nein
Unterberger auffällig*
Ja
Nein
Armvorhalteversuch links auffällig*
Ja
Nein
Armvorhalteversuch rechts auffällig*
Ja
Nein
Beinvorhalteversuch links auffällig*
Ja
Nein
Beinvorhalteversuch rechts auffällig*
Ja
Nein
Parese*
Ja
Nein
Spastik*
Ja
Nein
Feinmotorik
Fingerlaufen links auffällig*
Ja
Nein
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Fingerlaufen rechts auffällig*
Ja
Nein
Dysdiadochokinese*
Nein (1)
Links (2)
Rechts (3)
Beidseits (4)
Tremor*
Nein (1)
Links (2)
Rechts (3)
Beidseits (4)
Sensibilität
Sensibilität rechte obere Extremität*
Normal (1)
Vermindert (2)
Sensibilität linke obere Extremität*
Normal (1)
Vermindert (2)
Sensibilität rechte untere Extremität*
Normal (1)
Vermindert (2)
Sensibilität linke untere Extremität*
Normal (1)
Vermindert (2)
Sensibilität Stamm*
Normal (1)
Vermindert (2)
Sensibilität Gesicht*
Normal (1)
Vermindert (2)
Kraftgrad
Kraft rechte obere Extremität*
Normal (1)
Vermindert (2)
Kraft linke obere Extremität*
Normal (1)
Vermindert (2)
Kraft rechte untere Extremität*
Normal (1)
Vermindert (2)
Kraft linke untere Extremität*
Normal (1)
Vermindert (2)
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Vibrationsempfinden
Vibration rechte obere Extremität*
Normal (1)
Vermindert (2)
Vibration linke obere Extremität*
Normal (1)
Vermindert (2)
Vibration rechte untere Extremität*
Normal (1)
Vermindert (2)
Vibration linke untere Extremität*
Normal (1)
Vermindert (2)
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Quality assurance Gynacological Surgery -
Basic  (AQUA)
Form imported via medical-data-models.org API-version 1
All rights reserved. Please visit https://medical-data-
models.org/forms/9850
Quality assurance Gynacological
Surgery - Basic  (AQUA)
Basic documentation
Healthcare Facility Identifier*
Zip Code of Discharge*
Facility's Section Identifier
Medical specialty*
internal medicine (0100)
internal medicine: geriatrics (0102)
internal medicine: cardiology (0103)
internal medicine: nephrology (0104)
internal medicine: hematology and
internal oncology  (0105)
internal medicine: endocrinology (0106)
internal medicine: gastroenterology
(0107)
internal medicine: pneumonology (0108)
internal medicine: rheumatology (0109)
internal medicine: pulmonology (0114)
internal medicine: tumor research (0150)
internal medicine: coloproctology (0151)
internal medicine: infectiology (0152)
internal medicine: diabetes (0153)
internal medicine: naturopathy (0154)
internal medicine: stroke unit (0156)
internal medicine (0190)
geriatry (0200)
geriatry: gynecology  (0224)
geriatry: day unit (for semi-residential
care)   (0260)
geriaty: night unit (for semi-residential
care) (0261)
geriatry (0290)
cardiology (0300)
nephrology (0400)
nephrology: pediatrics (0410)
nephrology: intensive care (0436)
nephrology (0490)
hematology and internal oncology
(0500)
hematology and internal oncology:
pediatrics (0510)
hematology and internal oncology:
gynacology (0524)
hematology and internal oncology:
radiation therapy (0533)
hematology and internal oncology
(0590)
endocrinology (0600)
endicrinology: gastroenterology (0607)
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endocrinology: pediatrics (0610)
endocrinology (0690)
gastroenterology (0700)
gastroenterology: endocrinology (0706)
gastroenterology: pediatrics (0710)
gastroenterology (0790)
pneumology (0800)
rheumatology (0900)
rheumatology: pediatrics (0910)
rheumatology (0990)
pediatrics (1000)
pediatrics: nephrology (1004)
pediatrics: hematology and internal
oncology  (1005)
pediatrics: endocrinology (1006)
pediatrics: gastroenterology (1007)
pediatrics: rheumatology (1009)
pediatrics: pediatric cardiology (1011)
pediatrics: nephrology (1012)
pediatrics: pulmonology (1014)
pediatrics: pediatric neurology (1028)
pediatrics: perinatal medicine (1050)
continuing care for children (1051)
pediatrics (1090)
pediatric cardiology (1100)
pediatric cardiology: intensive care
(1136)
pediatric cardiology (1190)
neonatology (1200)
pediatric surgery (1300)
pulmonology (1400)
pulmonology: pediatrics (1410)
pulmonology (1490)
general surgery (1500)
general surgery: pediatric surgery (1513)
general surgery: trauma surgery (1516)
general surgery: vascular surgery (1518)
general surgery: plastic surgery (1519)
general surgery: thoracic surgery (1520)
general surgery: orthopedics (1523)
general surgery: intensive care (1536)
general surgery: abdominal- and
vascular surgery (1550)
Allgemeine Chirurgie: hand surgery
(1551)
general surgery (1590)
trauma surgery (1600)
neurosurgery (1700)
vascular surgery (1800)
plastic surgery (1900)
thoracic surgery (2000)
thoracic surgery: cardiac surgery (2021)
thoracic surgery: intensive care (2036)
thoracic surgery: cardiac surgery
intensive care (2050)
thoracic surgery (2090)
cardiac surgery (2100)
cardiac surgery: vascular surgery (2118)
cardiac surgery: thoracic surgery (2120)
cardiac surgery: intensive care (2136)
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cardiac surgery: thoracic surgery and
intensive care (2150)
cardiac surgery (2190)
urology (2200)
orthopedics (2300)
orthopedics: rheumatology (2309)
orthopedics: surgery (2315)
orthopedics and trauma surgery (2316)
orthopedics (2390)
gynecology and obstetrics (2400)
gynecology: geriatry (2402)
gynecology: hematology and internal
oncology  (2405)
gynecology: endocrinology (2406)
gynecology (2425)
gynecology and obstetrics (2490)
obstetrics (2500)
otolaryngology (2600)
ophthalmology (2700)
neurology: (2800)
neurology: pediatrics (2810)
neurology: stroke units (2856)
neurology (2890)
general psychiatry: (2900)
general psychiatry: neurology (2928)
general psychiatry: child and adolescent
psychiatry (2930)
general psychiatry: psychosomatics and
psychotherapy (2931)
general psychiatry: addiction treatment
(2950)
general psychiatry: geropsychiatry
(2951)
general psychiatry: forensic treatment
(2952)
general psychiatry: addiction treatment
(day unit) (2953)
general psychiatry: addiction treatment
(night unit) (2954)
general psychiatry: geropsychiatry (day
unit) (2955)
general psychiatry: geropsychiatry (night
unit) (2956)
general psychiatry: day unit (for semi-
residential care) (2960)
general psychiatry: night unit (for semi-
residential care) (2961)
general psychiatry (2990)
child and adolescent psychiatry (3000)
child and adolescent psychiatry: day unit
(for semi-residential care) (3060)
child and adolescent psychiatry: night
unit (for semi-residential care) (3061)
child and adolescent psychiatry (3090)
psychosomatic/psychotherapy (3100)
psychosomatic/psychotherapy: child and
adolescent psychiatry (3110)
psychosomatic/psychotherapy: day unit
(for semi-residential care) (3160)
psychosomatic/psychotherapy: night unit
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(for semi-residential care) (3161)
psychosomatic/psychotherapy (3190)
nuclear medicine (3200)
nuclear medicine: radiation therapy
(3233)
nuclear medicine (3290)
radiation therapy (3300)
radiation therapy: hematology and
internal oncology  (3305)
radiation therapy: radiology (3350)
radiation therapy (3390)
dermatology (3400)
dermatology: day unit (for semi-
residential care) (3460)
dermatology (3490)
dentistry, orthodontics, maxillofacial
surgery (3500)
intensive-care medicine (3600)
intensive-care medicine: internal
medicine (3601)
intensive-care medicine: cardiology
(3603)
intensive-care medicine: pediatrics
(3610)
intensive-care medicine: neurosurgery
(3617)
intensive-care medicine: surgery (3618)
intensive-care medicine: cardiac surgery
(3621)
intensive-care medicine: urology (3622)
intensive-care medicine: gynecology and
obstetrics (3624)
intensive-care medicine: otolaryngology
(3626)
intensive-care medicine: neurology
(3628)
operative intensive-care medicine:
surgery (3650)
intensive-care medicine: thorax-heart
surgery (3651)
intensive-care medicine: heart-thorax
surgery (3652)
intensive-care medicine (3690)
other medical specialty (3700)
angiology (3750)
radiology (3751)
palliative care (3752)
pain therapy (3753)
section for alternative health practice
(3754)
spinal surgery (3755)
addiction medicine (3756)
visceral surgery (3757)
other medical specialty (3790)
Patient identification number*
Date of Birth*
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Hospital admission date (DD.MM.YYYY)*
Diagnosis at admission*
Discharge
Hostpital discharge date  (DD.MM.YYYY)*
Discharge diagnoses*
Reason for Discharge*
treatment finished as planned (1)
transferral to nursing facility (10)
discharge to hospice (11)
external transferral to psychiatric
treatment (13)
treatment finished because of other
reasons, postdischarge treatment is
planned (14)
treatment aborted against medical
advice, postdischarge treatment is
planned (15)
internal transferral with change of DRG
payment areas (17)
treatment finished as planned,
postdischarge treatment is planned (2)
case termination (internal transferral)
with change between full- and partial
stationary care (22)
discharge at the end of the year with
admission in previous year (25)
treatment finished because of other
reasons (3)
treatment aborted against medical
advice (4)
change of jurisdiction of insurer or other
payer (5)
transferral to another hospital (6)
death (7)
transferral to another hospital within
cooperative and governmental policies
(8)
transferral to rehabilitation facility (9)
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Quality assurance Gynacological Surgery -
Procedure  (AQUA)
Form imported via medical-data-models.org API-version 1
All rights reserved. Please visit https://medical-data-
models.org/forms/9851
Quality assurance Gynacological
Surgery - Procedure  (AQUA)
Case history/Clinical Examination
Number of gynecological intervention at this
stay?*
Intervened in the context of the Census
(information must be in Hessen)
yes (1)
ASA classification*
A normal healthy patient (1)
A patient with mild systemic disease (2)
A patient with severe systemic disease
(3)
A patient with severe systemic disease
that is a constant threat to life (4)
A moribund patient who is not expected
to survive without the operation (5)
prior radiation therapy of surgical site*
Yes
No
Previous surgery in the operating area*
Yes
No
emergency*
Yes
No
Prophylaxis
antibiotic prophylaxis perioperative*
Yes
No
Operation
Surgical operation date*
Operative Surgical Procedures*
Procedure Duration (in minutes)*
Complications
Intraoperative Complications*
1 / 5
Yes
No
Type of complication
bladder (1)
ureter (2)
urethra (3)
intestine (4)
uterus (5)
vascular / nerve lesion (6)
Bearing damage (7)
other organ injuries (8)
other intraoperative complications (9)
Postoperative Complications*
Yes
No
Kind of complication
pneumonia (1)
fever> 38 ° C (from 3rd day postop.> 48
h) (10)
sepsis (11)
ileus (12)
cardiovascular complications (2)
deep leg/pelvic vein thrombosis (3)
pulmonary embolism (4)
infection of the urinary tract (5)
seroma/hematoma (6)
OP-paid rebleeding (7)
vascular and/or nerve damage (8)
decubitus (9)
other postoperative complications (99)
Histology
postoperative histology*
Yes
No
Leading diagnosis
adnexa: Cystoma serosum (10)
adnexa: Cystoma mucinosum (11)
adnexa: dermoid cyst (12)
adnexa: endometriosis (13)
adnexa: Inflammation (14)
adnexa: follicular or corpus luteum cyst
(15)
adnexa: Ectopic pregnancy (16)
adnexa: primary malignant neoplasms
including their recurrence (17)
adnexa: histologically normal findings
(18)
adnexa: Modifications to the adnexa, the
key values in the 10 - 17 are not covered
(19)
cervix uteri: ectopia (20)
cervix dysplasia (21)
cervix uteri: carcinoma in situ (22)
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cervix uteri: invasive carcinoma la (23)
cervix uteri: invasive cancer> la (24)
cervix uteri: histologically normal findings
(28)
cervix uteri: changes in the cervix, the
key values in the 20 - 24 are not covered
(29)
corpus uteri: fibroid (30)
corpus uteri: primary malignant
neoplasms including their recurrence
(31)
corpus uteri: histologically normal
findings (38)
corpus uteri: changes in the body of the
uterus, which are not included in the key
values of 30 and 31 (39)
vagina/vulva: inflammatory changes (70)
vagina/vulva: benign neoplasms (71)
vagina/vulva: malignant neoplasms (72)
vagina/vulva: histologically normal
findings (78)
vagina/vulva: changes in the
vagina/vulva, the key values in the 70 -
72 are not covered (79)
endometriosis at other sites (80)
Other histological findings at other sites
(81)
TNM category pT
0 (0)
1 (1)
1a (1a)
1a1 (1a1)
1a2 (1a2)
1b (1b)
1b1 (1b1)
1b2 (1b2)
1c (1c)
2 (2)
2a (2a)
2b (2b)
2c (2c)
3 (3)
3a (3a)
3b (3b)
3c (3c)
4 (4)
is (is)
X (X)
TNM category pN
0 (0)
1 (1)
X (X)
TNM category M
no distant metastases (0)
distant metastases (1)
Staging was not performed (9)
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Tumor grading category
1 (1)
2 (2)
3 (3)
4 (4)
B (B)
X (X)
Other diagnosis
adnexa: Cystoma serosum (10)
adnexa: Cystoma mucinosum (11)
adnexa: dermoid cyst (12)
adnexa: endometriosis (13)
adnexa: Inflammation (14)
adnexa: follicular or corpus luteum cyst
(15)
adnexa: Ectopic pregnancy (16)
adnexa: primary malignant neoplasms
including their recurrence (17)
adnexa: histologically normal findings
(18)
adnexa: Modifications to the adnexa, the
key values in the 10 - 17 are not covered
(19)
cervix uteri: ectopia (20)
cervix dysplasia (21)
cervix uteri: carcinoma in situ (22)
cervix uteri: invasive carcinoma la (23)
cervix uteri: invasive cancer> la (24)
cervix uteri: histologically normal findings
(28)
cervix uteri: changes in the cervix, the
key values in the 20 - 24 are not covered
(29)
corpus uteri: fibroid (30)
corpus uteri: primary malignant
neoplasms including their recurrence
(31)
corpus uteri: histologically normal
findings (38)
corpus uteri: changes in the body of the
uterus, which are not included in the key
values of 30 and 31 (39)
vagina/vulva: inflammatory changes (70)
vagina/vulva: benign neoplasms (71)
vagina/vulva: malignant neoplasms (72)
vagina/vulva: histologically normal
findings (78)
vagina/vulva: changes in the
vagina/vulva, the key values in the 70 -
72 are not covered (79)
endometriosis at other sites (80)
Other histological findings at other sites
(81)
Micturition
assisted bladder emptying more than 24 hours*
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Yes
No
Repeated urinary catheterization
yes (1)
Transurethral indwelling catheter
yes (1)
suprapubic indwelling catheter
yes (1)
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Quality assurance Obstetrics - Mother
(AQUA)
Form imported via medical-data-models.org API-version 1
All rights reserved. Please visit https://medical-data-
models.org/forms/9863
Quality assurance Obstetrics -
Mother (AQUA)
Basic documentation
Healthcare Facility Identifier (mother)*
Zip Code of Discharge*
Facility's Section Identifier (mother)
Medical specialty (mother)*
internal medicine (0100)
internal medicine: geriatrics (0102)
internal medicine: cardiology (0103)
internal medicine: nephrology (0104)
internal medicine: hematology and
internal oncology  (0105)
internal medicine: endocrinology (0106)
internal medicine: gastroenterology
(0107)
internal medicine: pneumonology (0108)
internal medicine: rheumatology (0109)
internal medicine: pulmonology (0114)
internal medicine: tumor research (0150)
internal medicine: coloproctology (0151)
internal medicine: infectiology (0152)
internal medicine: diabetes (0153)
internal medicine: naturopathy (0154)
internal medicine: stroke unit (0156)
internal medicine (0190)
geriatry (0200)
geriatry: gynecology  (0224)
geriatry: day unit (for semi-residential
care)   (0260)
geriaty: night unit (for semi-residential
care) (0261)
geriatry (0290)
cardiology (0300)
nephrology (0400)
nephrology: pediatrics (0410)
nephrology: intensive care (0436)
nephrology (0490)
hematology and internal oncology
(0500)
hematology and internal oncology:
pediatrics (0510)
hematology and internal oncology:
gynacology (0524)
hematology and internal oncology:
radiation therapy (0533)
hematology and internal oncology
(0590)
endocrinology (0600)
endicrinology: gastroenterology (0607)
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endocrinology: pediatrics (0610)
endocrinology (0690)
gastroenterology (0700)
gastroenterology: endocrinology (0706)
gastroenterology: pediatrics (0710)
gastroenterology (0790)
pneumology (0800)
rheumatology (0900)
rheumatology: pediatrics (0910)
rheumatology (0990)
pediatrics (1000)
pediatrics: nephrology (1004)
pediatrics: hematology and internal
oncology  (1005)
pediatrics: endocrinology (1006)
pediatrics: gastroenterology (1007)
pediatrics: rheumatology (1009)
pediatrics: pediatric cardiology (1011)
pediatrics: nephrology (1012)
pediatrics: pulmonology (1014)
pediatrics: pediatric neurology (1028)
pediatrics: perinatal medicine (1050)
continuing care for children (1051)
pediatrics (1090)
pediatric cardiology (1100)
pediatric cardiology: intensive care
(1136)
pediatric cardiology (1190)
neonatology (1200)
pediatric surgery (1300)
pulmonology (1400)
pulmonology: pediatrics (1410)
pulmonology (1490)
general surgery (1500)
general surgery: pediatric surgery (1513)
general surgery: trauma surgery (1516)
general surgery: vascular surgery (1518)
general surgery: plastic surgery (1519)
general surgery: thoracic surgery (1520)
general surgery: orthopedics (1523)
general surgery: intensive care (1536)
general surgery: abdominal- and
vascular surgery (1550)
Allgemeine Chirurgie: hand surgery
(1551)
general surgery (1590)
trauma surgery (1600)
neurosurgery (1700)
vascular surgery (1800)
plastic surgery (1900)
thoracic surgery (2000)
thoracic surgery: cardiac surgery (2021)
thoracic surgery: intensive care (2036)
thoracic surgery: cardiac surgery
intensive care (2050)
thoracic surgery (2090)
cardiac surgery (2100)
cardiac surgery: vascular surgery (2118)
cardiac surgery: thoracic surgery (2120)
cardiac surgery: intensive care (2136)
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cardiac surgery: thoracic surgery and
intensive care (2150)
cardiac surgery (2190)
urology (2200)
orthopedics (2300)
orthopedics: rheumatology (2309)
orthopedics: surgery (2315)
orthopedics and trauma surgery (2316)
orthopedics (2390)
gynecology and obstetrics (2400)
gynecology: geriatry (2402)
gynecology: hematology and internal
oncology  (2405)
gynecology: endocrinology (2406)
gynecology (2425)
gynecology and obstetrics (2490)
obstetrics (2500)
otolaryngology (2600)
ophthalmology (2700)
neurology: (2800)
neurology: pediatrics (2810)
neurology: stroke units (2856)
neurology (2890)
general psychiatry: (2900)
general psychiatry: neurology (2928)
general psychiatry: child and adolescent
psychiatry (2930)
general psychiatry: psychosomatics and
psychotherapy (2931)
general psychiatry: addiction treatment
(2950)
general psychiatry: geropsychiatry
(2951)
general psychiatry: forensic treatment
(2952)
general psychiatry: addiction treatment
(day unit) (2953)
general psychiatry: addiction treatment
(night unit) (2954)
general psychiatry: geropsychiatry (day
unit) (2955)
general psychiatry: geropsychiatry (night
unit) (2956)
general psychiatry: day unit (for semi-
residential care) (2960)
general psychiatry: night unit (for semi-
residential care) (2961)
general psychiatry (2990)
child and adolescent psychiatry (3000)
child and adolescent psychiatry: day unit
(for semi-residential care) (3060)
child and adolescent psychiatry: night
unit (for semi-residential care) (3061)
child and adolescent psychiatry (3090)
psychosomatic/psychotherapy (3100)
psychosomatic/psychotherapy: child and
adolescent psychiatry (3110)
psychosomatic/psychotherapy: day unit
(for semi-residential care) (3160)
psychosomatic/psychotherapy: night unit
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(for semi-residential care) (3161)
psychosomatic/psychotherapy (3190)
nuclear medicine (3200)
nuclear medicine: radiation therapy
(3233)
nuclear medicine (3290)
radiation therapy (3300)
radiation therapy: hematology and
internal oncology  (3305)
radiation therapy: radiology (3350)
radiation therapy (3390)
dermatology (3400)
dermatology: day unit (for semi-
residential care) (3460)
dermatology (3490)
dentistry, orthodontics, maxillofacial
surgery (3500)
intensive-care medicine (3600)
intensive-care medicine: internal
medicine (3601)
intensive-care medicine: cardiology
(3603)
intensive-care medicine: pediatrics
(3610)
intensive-care medicine: neurosurgery
(3617)
intensive-care medicine: surgery (3618)
intensive-care medicine: cardiac surgery
(3621)
intensive-care medicine: urology (3622)
intensive-care medicine: gynecology and
obstetrics (3624)
intensive-care medicine: otolaryngology
(3626)
intensive-care medicine: neurology
(3628)
operative intensive-care medicine:
surgery (3650)
intensive-care medicine: thorax-heart
surgery (3651)
intensive-care medicine: heart-thorax
surgery (3652)
intensive-care medicine (3690)
other medical specialty (3700)
angiology (3750)
radiology (3751)
palliative care (3752)
pain therapy (3753)
section for alternative health practice
(3754)
spinal surgery (3755)
addiction medicine (3756)
visceral surgery (3757)
other medical specialty (3790)
Patient identification number (mother)*
Clinic number mother*
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Birth registry number*
Multiple birth (finding)*
Basic documentation - mother
Date of birth (of the pregnant woman)*
Single mother without a solid partner
Yes
No
Employment during the current pregnancy
Yes
No
Occupation of mother
Housewife (1)
in training, study (2)
unskilled / semi-skilled worker, semi-
skilled assistant (e.g. cleaner) (4)
skilled workers (e.g. baker), simple
officials (e.g. a letter carrier), executive
employees (e.g. typist), small business
(e.g. kiosk lessee) (5)
middle to senior civil servants and
employees, self-employed with medium
and larger operation, the professions
(e.g. lawyer, doctor), Master (6)
unknown (9)
Number of previous pregnancies*
Number of live births
number of stillbirths
number of abortions
number of pregnancy terminations
Other country
Central and Northern Europe, North
America: A, CH, F, B, NL, L, GB, DK, S,
N, FIN, USA (1)
Mediterranean countries: former YU, GR,
I, E, P, Israel, Malta, Cyprus (2)
Eastern Europe: former SU, PL, Czech
Republic, Slovakia, RO, BG, H (3)
Middle East (incl. TR, Afghanistan and
Pakistan) and North Africa (Arab.
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Countries) (4)
Asia (exkl. 4) (5)
other countries (9)
Country of origin: Germany*
Yes
No
Hospital admission date (DD.MM.YYYY)*
Admission time (hh:mm)*
Mother was  transferred add?
Diagnosis at Admission (mother)
Diagnosis at Admission (mother) in combination
with
Stationary pretreatment (in days)
Treatment (in days) after stationary
Zip code of residence
number of EU
Current pregnancy
Number of cigarettes per day after becoming
aware of the pregnancy
Doppler sonography performed
Yes
No
Indication for Doppler sonography
suspected intrauterine growth retardation
(1)
Pregnancy-induced hypertension/pre-
eclampsia (2)
state after shortcomings in
birth/intrauterine fetal death (3)
state after pre-eclampsia/eclampsia (4)
abnormalities of the fetal heart rate
registration (5)
reasonable suspicion of
malformation/fetal disease (6)
multiple pregnancy in unconformably
growth (7)
investigation for suspected heart
failure/heart disease (8)
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Pathological Doppler findings
Yes
No
pathological findings at risk
premature rupture of membranes (60)
exceedance of birth termin (61)
malformation (62)
premature birth (63)
multiple pregnancy (64)
placental insufficiency (suspected) (65)
hypertensive disease of pregnancy (66)
Rh incompatibility (67)
diabetes mellitus (68)
state after cesarean section or other
uterine surgery (69)
placenta previa (70)
placental abruption (71)
other uterine bleeding (72)
chorioamnionitis (suspected) (73)
fever during birth (74)
maternal disease (75)
lack of cooperation of the mother (76)
pathological CTG or auscultation poor
child's heart sounds (77)
green amniotic fluid (78)
acidosis at birth (determined by fetal
blood analysis) (79)
prolapsed cord (80)
suspected other umbilical cord
complications (81)
protracted birth/birth standstill in the
opening period (82)
protracted birth/birth standstill in the
expulsion (83)
absolute or relative disproportion
between childlike head and maternal
pelvis (84)
imminent/uterine rupture occurred (85)
transverse position/angle (86)
breech (87)
occipitoposterior (88)
front main bearing (89)
face position / end position (90)
Low cross position (91)
high straight position (92)
other irregular cephalic presentations
(93)
other (94)
HELLP syndrome (95)
intrauterine (96)
pathological Doppler findings (97)
shoulder dystocia (98)
State after conization
Yes
No
Cervical closure operation
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Yes
No
Tocolysis intravenous
Yes
No
Duration of i.v. tocolysis (in days)
Tokolyse oral
Yes
No
Calculated, if necessary, corrected date of birth
(dd.mm.yyyy)
Duration of gestation on clinical judgment
prenatally secured / suspected abnormalities
Yes
No
Prenatal diagnosis of secured / suspected
malformation
prenatally secured / suspected malformation
secured / suspected on
secured (1)
on suspicion (2)
Contraction stress test
Yes
No
prenatal genetic diagnosis*
not done (0)
invasive (1)
non-invasive (2)
invasive and non-invasive (3)
Pregnant while pregnancy presented to a doctor /
in-patient doctor of the obstetrical clinic*
Yes
No
Pregnancy documented in the maternity log as
risk pregnancy*
no (0)
yes (1)
Pregnant appears without maternity log
(2)
Pregnancy risks*
Yes
No
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pregnancy risk
Family history (diabetes, hypertension,
malformations, genetic diseases, mental
illness) (1)
obesity (10)
dwarfism (11)
skeletal abnormalities (12)
pregnant women under 18 years old (13)
Pregnant over 35 years (14)
grand multiparas (more than 4 children)
(15)
state after Treatment of infertility (16)
s.a. prematurity (gestational age: Under
37 completed weeks). (17)
s.a. birth of a hypotrophic child (less than
2500 g) (18)
s.a. 2 or more miscarriages / abortions
(19)
former own serious diseases (e.g., heart,
lung, liver, kidney, central nervous
system, psyche) (2)
dead / damaged child in history (20)
complications of previous births (21)
postpartum complications (22)
s.a. cesarean section (23)
s.a. other uterine surgery (24)
rapid succession pregnancy (less than 1
year) (25)
other medical history and general
findings (26)
General disorders requiring treatment
(27)
chronic medication (28)
abuse (29)
bleeding / thrombosis (3)
special psychological distress (30)
special social burden (31)
bleeding, pregnancy age: under 28
completed weeks (32)
bleeding, pregnancy Age: 28 completed
weeks or more (33)
placenta previa (34)
multiple pregnancy (35)
hydramnios (36)
oligohydramnios (37)
Date uncertainty (38)
placental insufficiency (39)
allergy (4)
Isthmozervikale insufficiency (40)
preterm labor (41)
anemia (42)
urinary tract infection (43)
Indirect Coombs test positive (44)
risk of other serological findings (45)
hypertension (blood pressure over
140/90) (46)
excretion of 1000 mg of protein per liter
of urine and more (47)
Moderate - Severe edema (48)
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hypotension (49)
previous blood transfusions (5)
gestational (50)
malposition (51)
other specific findings in the course of
pregnancy (52)
hyperemesis (53)
s.a. HELLP syndrome (54)
s.a. eclampsia (55)
s.a. hypertension (56)
specific psychological distress (eg,
familial or professional) (6)
special social burden (integration
problems, economic problems) (7)
Rh incompatibility (at previous
pregnancy) (8)
diabetes mellitus (9)
Total inpatient hospitalization during pregnancy
without leading to the birth of stay in days (in
days)
Gestational week of the first residence, not lead
to birth
Indications for hospitalization
Family history (diabetes, hypertension,
malformations, genetic diseases, mental
illness) (1)
obesity (10)
dwarfism (11)
skeletal abnormalities (12)
pregnant women under 18 years old (13)
Pregnant over 35 years (14)
grand multiparas (more than 4 children)
(15)
state after Treatment of infertility (16)
s.a. prematurity (gestational age: Under
37 completed weeks). (17)
s.a. birth of a hypotrophic child (less than
2500 g) (18)
s.a. 2 or more miscarriages / abortions
(19)
former own serious diseases (e.g., heart,
lung, liver, kidney, central nervous
system, psyche) (2)
dead / damaged child in history (20)
complications of previous births (21)
postpartum complications (22)
s.a. cesarean section (23)
s.a. other uterine surgery (24)
rapid succession pregnancy (less than 1
year) (25)
other medical history and general
findings (26)
General disorders requiring treatment
(27)
chronic medication (28)
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abuse (29)
bleeding / thrombosis (3)
special psychological distress (30)
special social burden (31)
bleeding, pregnancy age: under 28
completed weeks (32)
bleeding, pregnancy Age: 28 completed
weeks or more (33)
placenta previa (34)
multiple pregnancy (35)
hydramnios (36)
oligohydramnios (37)
Date uncertainty (38)
placental insufficiency (39)
allergy (4)
Isthmozervikale insufficiency (40)
preterm labor (41)
anemia (42)
urinary tract infection (43)
Indirect Coombs test positive (44)
risk of other serological findings (45)
hypertension (blood pressure over
140/90) (46)
excretion of 1000 mg of protein per liter
of urine and more (47)
Moderate - Severe edema (48)
hypotension (49)
previous blood transfusions (5)
gestational (50)
malposition (51)
other specific findings in the course of
pregnancy (52)
hyperemesis (53)
s.a. HELLP syndrome (54)
s.a. eclampsia (55)
s.a. hypertension (56)
specific psychological distress (eg,
familial or professional) (6)
special social burden (integration
problems, economic problems) (7)
Rh incompatibility (at previous
pregnancy) (8)
diabetes mellitus (9)
Gestational week of the first check-up
Total number of screening examination
Gestational week of the first ultrasound scan
Total number of ultrasound scans
Body weight at first examination (in kg)
Last weight before birth (in kg)
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Body Height (in cm)*
Gestational week prenatal secured / suspected
malformation
Information about childbirth
Admission Type*
childbirth in the hospital for planned
hospital births (1)
childbirth in the hospital for forwarded
house/practice/birthing center birth, not
originally planned as a inpatient hospital
childbirth (2)
childbirth of the child before hospital
admission (3)
Indication for induction of labor
premature rupture of membranes (60)
exceedance of birth termin (61)
malformation (62)
premature birth (63)
multiple pregnancy (64)
placental insufficiency (suspected) (65)
hypertensive disease of pregnancy (66)
Rh incompatibility (67)
diabetes mellitus (68)
state after cesarean section or other
uterine surgery (69)
placenta previa (70)
placental abruption (71)
other uterine bleeding (72)
chorioamnionitis (suspected) (73)
fever during birth (74)
maternal disease (75)
lack of cooperation of the mother (76)
pathological CTG or auscultation poor
child's heart sounds (77)
green amniotic fluid (78)
acidosis at birth (determined by fetal
blood analysis) (79)
prolapsed cord (80)
suspected other umbilical cord
complications (81)
protracted birth/birth standstill in the
opening period (82)
protracted birth/birth standstill in the
expulsion (83)
absolute or relative disproportion
between childlike head and maternal
pelvis (84)
imminent/uterine rupture occurred (85)
transverse position/angle (86)
breech (87)
occipitoposterior (88)
front main bearing (89)
face position / end position (90)
12 / 17
Quality assurance Obstetrics - Mother (AQUA)
Low cross position (91)
high straight position (92)
other irregular cephalic presentations
(93)
other (94)
HELLP syndrome (95)
intrauterine (96)
pathological Doppler findings (97)
shoulder dystocia (98)
Drug Induced Induction of Labor
Yes
No
Induction of labor with amniotomy
Yes
No
Labor pains drug s. p.*
Yes
No
tocolysis s. p.*
Yes
No
Analgesics*
Yes
No
Acupuncture*
Yes
No
alternative Analgesien*
Yes
No
Episiotomy*
no (0)
median (1)
mediolateral (2)
other (3)
Induction of labor*
Yes
No
Cervical ripening with drug*
Yes
No
Cervical dilatation at admission (in cm)
Lung maturation treatment*
no (0)
yes, the beginning of the lung maturation
treatment was carried out in own clinic
(1)
13 / 17
Quality assurance Obstetrics - Mother (AQUA)
yes, the beginning of the treatment lung
maturity was achieved externally (2)
Lung maturation treatment: at last (dd.mm.yyyy)
Admission-CTG
Yes
No
Doppler ultrasound performed in obstetric
department*
Yes
No
Indications for Doppler sonography in obstetric
department
suspected intrauterine growth retardation
(1)
Pregnancy-induced hypertension/pre-
eclampsia (2)
state after shortcomings in
birth/intrauterine fetal death (3)
state after pre-eclampsia/eclampsia (4)
abnormalities of the fetal heart rate
registration (5)
reasonable suspicion of
malformation/fetal disease (6)
multiple pregnancy in unconformably
growth (7)
investigation for suspected heart
failure/heart disease (8)
Pathological Doppler findings
Yes
No
birth risks*
Yes
No
birth risk
premature rupture of membranes (60)
exceedance of birth termin (61)
malformation (62)
premature birth (63)
multiple pregnancy (64)
placental insufficiency (suspected) (65)
hypertensive disease of pregnancy (66)
Rh incompatibility (67)
diabetes mellitus (68)
state after cesarean section or other
uterine surgery (69)
placenta previa (70)
placental abruption (71)
other uterine bleeding (72)
chorioamnionitis (suspected) (73)
fever during birth (74)
maternal disease (75)
lack of cooperation of the mother (76)
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pathological CTG or auscultation poor
child's heart sounds (77)
green amniotic fluid (78)
acidosis at birth (determined by fetal
blood analysis) (79)
prolapsed cord (80)
suspected other umbilical cord
complications (81)
protracted birth/birth standstill in the
opening period (82)
protracted birth/birth standstill in the
expulsion (83)
absolute or relative disproportion
between childlike head and maternal
pelvis (84)
imminent/uterine rupture occurred (85)
transverse position/angle (86)
breech (87)
occipitoposterior (88)
front main bearing (89)
face position / end position (90)
Low cross position (91)
high straight position (92)
other irregular cephalic presentations
(93)
other (94)
HELLP syndrome (95)
intrauterine (96)
pathological Doppler findings (97)
shoulder dystocia (98)
Abruptio Placentae*
Yes
No
Maternal complications
Laceration of perineum*
no (0)
grade I (1)
grade II (2)
grade III (3)
grade IV (4)
cardiovascular complication (s)
yes (1)
deep leg/pelvic vein thrombosis
yes (1)
pulmonary embolism
yes (1)
Urinary tract infection
yes (1)
Wound infection / abscess
yes (1)
Wound hematoma / rebleedinghemorrhage
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yes (1)
sonstige Komplikation
yes (1)
Discharge diagnosis mother*
More combined discharge diagnosis mother
Reason for Discharge*
treatment finished as planned (1)
transferral to nursing facility (10)
discharge to hospice (11)
external transferral to psychiatric
treatment (13)
treatment finished because of other
reasons, postdischarge treatment is
planned (14)
treatment aborted against medical
advice, postdischarge treatment is
planned (15)
internal transferral with change of DRG
payment areas (17)
treatment finished as planned,
postdischarge treatment is planned (2)
case termination (internal transferral)
with change between full- and partial
stationary  care (22)
discharge at the end of the year with
admission in previous year (25)
treatment finished because of other
reasons (3)
treatment aborted against medical
advice (4)
change of jurisdiction of insurer or other
payer (5)
transferral to another hospital (6)
death (7)
transferral to another hospital within
cooperative and governmental policies
(8)
transferral to rehabilitation facility (9)
Hospital discharge date  (DD.MM.YYYY)*
Pneumonia
yes (1)
general postpartum complications requiring
treatment*
Yes
No
Anemia Hb < 10 g/dl*
Yes
No
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Other soft tissue injuries*
Yes
No
Cervical laceration as soft tissue injury
yes (1)
Laceration of vagina as a soft tissue injury
yes (1)
Labien- / clitoris plan as a soft tissue injury
yes (1)
Vulval and perineal hematoma as a soft tissue
injury
yes (1)
Hemorrhage > 1000 ml*
Yes
No
require revision impaired wound healing of birth
canal because of opening and/or secondary
suture*
Yes
No
Laparoscopic hysterectomy*
Yes
No
Eclampsia*
Yes
No
Sepsis*
Yes
No
Puerperal pyrexia> 38 ° C> 2 days*
Yes
No
Death of mother in connection with the birth
Yes
No
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Quality assurance Obstetrics - Child
(AQUA)
Form imported via medical-data-models.org API-version 1
All rights reserved. Please visit https://medical-data-
models.org/forms/9866
Quality assurance Obstetrics - Child
(AQUA)
Obstetrics - Child
Identification code of pediatrician
Main indication for emergency caesarean section
premature rupture of membranes (60)
exceedance of birth termin (61)
malformation (62)
premature birth (63)
multiple pregnancy (64)
placental insufficiency (suspected) (65)
hypertensive disease of pregnancy (66)
Rh incompatibility (67)
diabetes mellitus (68)
state after cesarean section or other
uterine surgery (69)
placenta previa (70)
placental abruption (71)
other uterine bleeding (72)
chorioamnionitis (suspected) (73)
fever during birth (74)
maternal disease (75)
lack of cooperation of the mother (76)
pathological CTG or auscultation poor
child's heart sounds (77)
green amniotic fluid (78)
acidosis at birth (determined by fetal
blood analysis) (79)
prolapsed cord (80)
suspected other umbilical cord
complications (81)
protracted birth/birth standstill in the
opening period (82)
protracted birth/birth standstill in the
expulsion (83)
absolute or relative disproportion
between childlike head and maternal
pelvis (84)
imminent/uterine rupture occurred (85)
transverse position/angle (86)
breech (87)
occipitoposterior (88)
front main bearing (89)
face position / end position (90)
Low cross position (91)
high straight position (92)
other irregular cephalic presentations
(93)
other (94)
HELLP syndrome (95)
intrauterine (96)
pathological Doppler findings (97)
shoulder dystocia (98)
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Emergency caesarean section
Yes
No
Surgical nurse at caesarean section
no surgical nurse (0)
surgical nurse with nursing exam (1)
surgical nurse without nursing exam (2)
Cesarean section with antibiotics (mother)
no (0)
yes, prophylactic (1)
yes, ongoing antibiotic therapy (2)
Duration of the intervention cut-seam time at
caesarean section (in minutes)
Indications for operative childbirth
premature rupture of membranes (60)
exceedance of birth termin (61)
malformation (62)
premature birth (63)
multiple pregnancy (64)
placental insufficiency (suspected) (65)
hypertensive disease of pregnancy (66)
Rh incompatibility (67)
diabetes mellitus (68)
state after cesarean section or other
uterine surgery (69)
placenta previa (70)
placental abruption (71)
other uterine bleeding (72)
chorioamnionitis (suspected) (73)
fever during birth (74)
maternal disease (75)
lack of cooperation of the mother (76)
pathological CTG or auscultation poor
child's heart sounds (77)
green amniotic fluid (78)
acidosis at birth (determined by fetal
blood analysis) (79)
prolapsed cord (80)
suspected other umbilical cord
complications (81)
protracted birth/birth standstill in the
opening period (82)
protracted birth/birth standstill in the
expulsion (83)
absolute or relative disproportion
between childlike head and maternal
pelvis (84)
imminent/uterine rupture occurred (85)
transverse position/angle (86)
breech (87)
occipitoposterior (88)
front main bearing (89)
face position / end position (90)
Low cross position (91)
high straight position (92)
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other irregular cephalic presentations
(93)
other (94)
HELLP syndrome (95)
intrauterine (96)
pathological Doppler findings (97)
shoulder dystocia (98)
childbirth mode*
Spinal anesthesia
by obstetricians (1)
by anesthesiologists (2)
E-E time at emergency caesarean section (in
minutes)
midwife*
no midwife (0)
hospital midwife (1)
external midwife (2)
Pediatrician arrived after child birth*
Yes
No
Identification code of pediatrician
Pediatricians present at childbirth*
Yes
No
Identification-code of assistant
Assistant in consultant-further education*
Yes
No
Identifikations-Kodierung des Facharztes
Consultant gynecology and obstetrics*
Yes
No
Identification code of the midwife
Epi- / peridural anesthesia
by obstetricians (1)
by anesthesiologists (2)
Other anesthesia
yes (1)
pudendal block
yes (1)
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external CTG
no (0)
intermittent (1)
continuously until birth (2)
continuous until disinfection (3)
CTG control*
Yes
No
Beginning of antibiotics
start of antibiotic treatment was carried
out in own clinic (1)
start of antibiotic treatment was achieved
externally (2)
Date of the first administration of antibiotics after
premature rupture of membranes
no antibiotics (0)
within 24 hours after premature rupture
of membranes (1)
less than 24 hours after premature
rupture of membranes (2)
span of premature rupture to
administration of antibiotics can not be
determined (3)
Time of premature rupture of the membranes
unbekannt
yes (1)
Time of premature rupture of the membranes
(hh:mm)
Date of premature rupture of the membranes
(dd.mm.yy)
Rupture of membranes before labor*
Yes
No
internal CTG
no (0)
intermittent (1)
continuously until birth (2)
continuous until disinfection (3)
Blood gas analysis fetal blood*
Yes
No
General anesthesia
yes (1)
Anesthesia*
Yes
No
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Active press period (in minutes)
Duration of birth from the beginning of regular
contractions (in hours)
Delivery position at the time of birth
birthing bed / horizontal position (1)
Stools / vertical position (2)
underwater birth (3)
other (9)
Position*
veritable vertex presentation (1)
irregular vertex presentation (2)
breech (3)
transverse position (4)
not determined (9)
Fetal blood analysis pH
Base excess of the fetal blood analysis (in
mmol/l)
Ser. no. of multiple birth*
Basic documentation - child
Date of birth of the child (dd.mm.yyyy)*
pH of blood gas analysis umbilical artery
pulse oximetry*
Yes
No
Intubation
Yes
No
substitution volume
Yes
No
buffering
Yes
No
mask ventilation
Yes
No
O2 enrichment
Yes
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No
U2 performed at children's medical examination*
Yes
No
Congenital Abnormality present*
Yes
No
Malformation diagnosed prenatally
no (0)
yes (1)
not determined (2)
Base excess blood gas analysis umbilical artery
(in mmol / l)
Umbilical artery blood gas analysis*
Yes
No
Time of Birth (hh:mm)*
Birth diagnosis child
further combined birth diagnosis child
Gender of the child*
male (1)
female (2)
not determined (3)
APGAR
0 (0)
1 (1)
10 (10)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
7 (7)
8 (8)
9 (9)
APGAR
CodelistItem 594453 (0)
CodelistItem 594454 (1)
CodelistItem 594455 (10)
CodelistItem 594456 (2)
CodelistItem 594457 (3)
CodelistItem 594458 (4)
CodelistItem 594459 (5)
CodelistItem 594460 (6)
CodelistItem 594461 (7)
CodelistItem 594462 (8)
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CodelistItem 594463 (9)
APGAR
CodelistItem 594464 (0)
CodelistItem 594465 (1)
CodelistItem 594466 (10)
CodelistItem 594467 (2)
CodelistItem 594468 (3)
CodelistItem 594469 (4)
CodelistItem 594470 (5)
CodelistItem 594471 (6)
CodelistItem 594472 (7)
CodelistItem 594473 (8)
CodelistItem 594474 (9)
Child's body weight (in g)*
Length of the child (in cm)
Head circumference of the child (in cm)
Morbidity diagnosis of the child
In stillbirth
Stillbirth*
Yes
No
Death before hospital admission in stillbirth
Yes
No
Time of death in stillborn
antepartum death (1 )
death sub partu (2 )
time of death unknown (3 )
Discharge / Transfer
Child transferred to Children's Hospital*
Yes
No
Date of death - live born child (dd.mm.yyyy)
Cause of Death of live-born child
Death of live-born child within the first 7 days
Yes
No
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Reason for Discharge  from the maternity
hospital child*
treatment finished as planned (1)
transferral to nursing facility (10)
discharge to hospice (11)
external transferral to psychiatric
treatment (13)
treatment finished because of other
reasons, postdischarge treatment is
planned (14)
treatment aborted against medical
advice, postdischarge treatment is
planned (15)
internal transferral with change of DRG
payment areas (17)
treatment finished as planned,
postdischarge treatment is planned (2)
case termination (internal transferral)
with change between full- and partial
stationary care (22)
discharge at the end of the year with
admission in previous year (25)
treatment finished because of other
reasons (3)
treatment aborted against medical
advice (4)
change of jurisdiction of insurer or other
payer (5)
transferral to another hospital (6)
death (7)
transferral to another hospital within
cooperative and governmental policies
(8)
transferral to rehabilitation facility (9)
Discharge/transfer diagnosis from the maternity
hospital child
Final discharge from / death / stationary in
maternity hospital (1)
children's Hospital (2)
Discharge / transfer time from the children´s
hospital (hh: mm)
Children's Hospital discharge/transfer date
(DD.MM.YYYY)
Medical specialty Children's Hospital at transfer
the child
internal medicine (0100)
internal medicine: geriatrics (0102)
internal medicine: cardiology (0103)
internal medicine: nephrology (0104)
internal medicine: hematology and
internal oncology  (0105)
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internal medicine: endocrinology (0106)
internal medicine: gastroenterology
(0107)
internal medicine: pneumonology (0108)
internal medicine: rheumatology (0109)
internal medicine: pulmonology (0114)
internal medicine: tumor research (0150)
internal medicine: coloproctology (0151)
internal medicine: infectiology (0152)
internal medicine: diabetes (0153)
internal medicine: naturopathy (0154)
internal medicine: stroke unit (0156)
internal medicine (0190)
geriatry (0200)
geriatry: gynecology  (0224)
geriatry: day unit (for semi-residential
care)   (0260)
geriaty: night unit (for semi-residential
care) (0261)
geriatry (0290)
cardiology (0300)
nephrology (0400)
nephrology: pediatrics (0410)
nephrology: intensive care (0436)
nephrology (0490)
hematology and internal oncology
(0500)
hematology and internal oncology:
pediatrics (0510)
hematology and internal oncology:
gynacology (0524)
hematology and internal oncology:
radiation therapy (0533)
hematology and internal oncology
(0590)
endocrinology (0600)
endicrinology: gastroenterology (0607)
endocrinology: pediatrics (0610)
endocrinology (0690)
gastroenterology (0700)
gastroenterology: endocrinology (0706)
gastroenterology: pediatrics (0710)
gastroenterology (0790)
pneumology (0800)
rheumatology (0900)
rheumatology: pediatrics (0910)
rheumatology (0990)
pediatrics (1000)
pediatrics: nephrology (1004)
pediatrics: hematology and internal
oncology  (1005)
pediatrics: endocrinology (1006)
pediatrics: gastroenterology (1007)
pediatrics: rheumatology (1009)
pediatrics: pediatric cardiology (1011)
pediatrics: nephrology (1012)
pediatrics: pulmonology (1014)
pediatrics: pediatric neurology (1028)
pediatrics: perinatal medicine (1050)
continuing care for children (1051)
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pediatrics (1090)
pediatric cardiology (1100)
pediatric cardiology: intensive care
(1136)
pediatric cardiology (1190)
neonatology (1200)
pediatric surgery (1300)
pulmonology (1400)
pulmonology: pediatrics (1410)
pulmonology (1490)
general surgery (1500)
general surgery: pediatric surgery (1513)
general surgery: trauma surgery (1516)
general surgery: vascular surgery (1518)
general surgery: plastic surgery (1519)
general surgery: thoracic surgery (1520)
general surgery: orthopedics (1523)
general surgery: intensive care (1536)
general surgery: abdominal- and
vascular surgery (1550)
Allgemeine Chirurgie: hand surgery
(1551)
general surgery (1590)
trauma surgery (1600)
neurosurgery (1700)
vascular surgery (1800)
plastic surgery (1900)
thoracic surgery (2000)
thoracic surgery: cardiac surgery (2021)
thoracic surgery: intensive care (2036)
thoracic surgery: cardiac surgery
intensive care (2050)
thoracic surgery (2090)
cardiac surgery (2100)
cardiac surgery: vascular surgery (2118)
cardiac surgery: thoracic surgery (2120)
cardiac surgery: intensive care (2136)
cardiac surgery: thoracic surgery and
intensive care (2150)
cardiac surgery (2190)
urology (2200)
orthopedics (2300)
orthopedics: rheumatology (2309)
orthopedics: surgery (2315)
orthopedics and trauma surgery (2316)
orthopedics (2390)
gynecology and obstetrics (2400)
gynecology: geriatry (2402)
gynecology: hematology and internal
oncology  (2405)
gynecology: endocrinology (2406)
gynecology (2425)
gynecology and obstetrics (2490)
obstetrics (2500)
otolaryngology (2600)
ophthalmology (2700)
neurology: (2800)
neurology: pediatrics (2810)
neurology: stroke units (2856)
neurology (2890)
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general psychiatry: (2900)
general psychiatry: neurology (2928)
general psychiatry: child and adolescent
psychiatry (2930)
general psychiatry: psychosomatics and
psychotherapy (2931)
general psychiatry: addiction treatment
(2950)
general psychiatry: geropsychiatry
(2951)
general psychiatry: forensic treatment
(2952)
general psychiatry: addiction treatment
(day unit) (2953)
general psychiatry: addiction treatment
(night unit) (2954)
general psychiatry: geropsychiatry (day
unit) (2955)
general psychiatry: geropsychiatry (night
unit) (2956)
general psychiatry: day unit (for semi-
residential care) (2960)
general psychiatry: night unit (for semi-
residential care) (2961)
general psychiatry (2990)
child and adolescent psychiatry (3000)
child and adolescent psychiatry: day unit
(for semi-residential care) (3060)
child and adolescent psychiatry: night
unit (for semi-residential care) (3061)
child and adolescent psychiatry (3090)
psychosomatic/psychotherapy (3100)
psychosomatic/psychotherapy: child and
adolescent psychiatry (3110)
psychosomatic/psychotherapy: day unit
(for semi-residential care) (3160)
psychosomatic/psychotherapy: night unit
(for semi-residential care) (3161)
psychosomatic/psychotherapy (3190)
nuclear medicine (3200)
nuclear medicine: radiation therapy
(3233)
nuclear medicine (3290)
radiation therapy (3300)
radiation therapy: hematology and
internal oncology  (3305)
radiation therapy: radiology (3350)
radiation therapy (3390)
dermatology (3400)
dermatology: day unit (for semi-
residential care) (3460)
dermatology (3490)
dentistry, orthodontics, maxillofacial
surgery (3500)
intensive-care medicine (3600)
intensive-care medicine: internal
medicine (3601)
intensive-care medicine: cardiology
(3603)
intensive-care medicine: pediatrics
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(3610)
intensive-care medicine: neurosurgery
(3617)
intensive-care medicine: surgery (3618)
intensive-care medicine: cardiac surgery
(3621)
intensive-care medicine: urology (3622)
intensive-care medicine: gynecology and
obstetrics (3624)
intensive-care medicine: otolaryngology
(3626)
intensive-care medicine: neurology
(3628)
operative intensive-care medicine:
surgery (3650)
intensive-care medicine: thorax-heart
surgery (3651)
intensive-care medicine: heart-thorax
surgery (3652)
intensive-care medicine (3690)
other medical specialty (3700)
angiology (3750)
radiology (3751)
palliative care (3752)
pain therapy (3753)
section for alternative health practice
(3754)
spinal surgery (3755)
addiction medicine (3756)
visceral surgery (3757)
other medical specialty (3790)
Children's Hospital number at Transfer of the
child
Time of death - live born child (hh: mm)
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Mamma Surgery - Surgery
Number of mamma surgery during this stay?*
preoperative wire-marking controlled by imaging
methods*
no (0)
yes, by mammography (1)
yes, by sonography (2)
yes, by MRI (3)
intraoperative sample radiography or
-sonographie
no (0)
yes, intraoperative sample radiography
(1)
yes, intraoperative ultrasonography
preparations (2)
Operation date (DD.MM.YY)*
Operation*
Conducted sentinel node biopsy in this procedure
Yes
No
perioperative antibiotic prophylaxis*
Yes
No
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MSBase Patient profile -
Identification
Identifizierung
Nachname*
Vorname*
Name als Ledige
Geburtsdatum*
Geburtsort
Geburtsland
Geschlecht*
Weiblich (F)
Männlich (M)
Verstorben
Ja
Nein
Todesursache
Patientencode*
Verantwortlicher Arzt
Addresse*
Stadt*
Postleitzahl*
Bundesland
Land
Telefon privat
Telefon Geschäft
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Andere Nummer
E-Mail
Krankenversicherung*
Versicherungsreferenz
Schlüsselwort
Studiencode
Zivilstand
keine Angabe (0)
Verheiratet (1)
Konkubinat (2)
Getrennt (3)
Geschieden (4)
Witwe(r) (5)
Ledig (6)
Ausbildung
Keine Angabe (0)
Primarschule (1)
Weiterführende Schule (2)
Hochschule (3)
Universität (4)
Erwerbstätigkeit
Angestellt/Selbständig (1)
in Rente (2)
Student (3)
Arbeitslos (4)
Hausfrau (5)
2 / 2
MSBase Patient profile - Identification
MSBase Patient profile - Medical History
Form imported via medical-data-models.org API-version 1
All rights reserved. Please visit https://medical-data-
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MSBase Patient profile - Medical
History
Anamnese
Aufnahmedatum im Krankenhaus
Überwiesen durch
Neurologe (1)
Hausarzt (2)
Augenarzt (3)
Spontan (4)
Andere (5)
Name (überwiesen durch)
Häufigkeit der Visiten geplant
1 Monat (1)
1 Jahr (12)
1.5 Jahre (18)
3 Monate (3)
3 Jahre (36)
4 Jahre (48)
6 Monate (6)
9 Monate (9)
# Vorherige Schübe
Ethnische Herkunft
Keine (0)
Afrikaner (1)
Asiate (2)
Kaukasier (3)
Hispanic (4)
Inuit (5)
Semit (6)
HLA Typing durchgeführt
Ja
Nein
Dominante Hand
? (0)
Rechts (1)
Links (2)
Tumor
Diagnosedatum
Ort des Primärkarzinoms
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Histologische Diagnose
Stadium bei Diagnose
I (I)
II (II)
III (III)
IV (IV)
Keine Behandlung
Ja
Nein
Chemotherapie
Ja
Nein
Radiotherapie
Ja
Nein
Operation
Ja
Nein
Sonstiges
Ergebnis
Unbekannt (0)
Anhaltend (1)
Remission (2)
Tod (3)
Datum
Bemerkungen
Krankheiten und Leiden
Erkrankung
Herpes zoster (1)
Allergie auf Sulphurs (10)
Anaphylaxie (11)
Anämie (12)
Angina pectoris (13)
Anorexie (14)
Angst (15)
Arthralgie (16)
Asthenie (17)
Autoimmune Schilddrüsenerkrankung
(18)
Blindheit (19)
Immunosuppression-assoziierte oder
schwere Infektion (2)
Blut und lymphatische Erkrankung (20)
Sehstörung (21)
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Bronchopulmonale Erkrankungen (22)
Kardiovaskuläre Erkrankungen (23)
Brustschmerz (24)
Schüttelfrost (25)
Verstopfung (26)
M. Crohn (27)
Depression (28)
Hauterkrankung (29)
Bauchschmerzen (3)
Diarrhoe (30)
Schwindel (31)
Dyspnoe (32)
Stoffwechselerkrankungen (33)
Epilepsie (34)
Fieber (35)
Grippale Symptome (36)
Gastrointestinale Erkrankungen (37)
Urogenitale Erkrankungen (38)
Kopfschmerz (39)
Allergie auf Aspirin (4)
Lebererkrankung (40)
Hypersensitivität (41)
Hochdruck (42)
Hypertonie (43)
Entzündliche Darmerkrankung (44)
Nekrose an Injektionsstelle (45)
Reaktion an Injektionsstelle (46)
Schlaflosigkeit (47)
auffälliger Lebertest (48)
Lymphopenie (49)
Allergie auf Codein (5)
Migräne (50)
Muskelschmerz (51)
Muskuloskeletale Erkrankungen (52)
Myasthenia gravis (53)
Myelodysplastisches Syndrom (54)
Perniziöse Anämie (58)
Pruritus (59)
Allergie auf Methylprednisolon (6)
Psoriasis (60)
Psychiatrische Erkrankungen (61)
Exanthem (62)
Nierenerkrankungen (63)
auffällige Nierenfunktion (64)
Netzhauterkrankungen (65)
Rheumatoide Arthritis (66)
Rhinitis (67)
Krampfanfälle (68)
Sinusitis (69)
Allergie auf Morphin (7)
Systemischer Lupus Erythematodes
(SLE) (70)
Operation (71)
Schwitzen (72)
Tachykardie (73)
Thromboembolische Ereignisse (74)
Tinnitus (75)
Diabetes mellitus Type I  (76)
Ulcerative Colitis (77)
Vasodilatation (78)
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Vertigo (79)
Allergie auf Penicillin (8)
Vitiligo (80)
Erbrechen (81)
Allergie auf Stemetil (9)
Datum der Diagnose
Schweregrad
mild (1)
mässig (2)
schwer (3)
lebensbedrohend (4)
Behandlungsmodalität
Ergebnis
Unbekannt (0)
Anhaltend (1)
Erholung (2)
Tod (3)
Datum
SAE Schweregrad
Kein SAE (0)
endet tödlich (1)
ist lebensbedrohend (2)
Bleibende/schwere Behinderung (3)
Benötigt/verlängert Hospitalisation (4)
Angeborene Anomalie (5)
Andere wichtige medizinische Leiden (6)
Zusammenhang mit Arzneimittel
Kein Zusammenhang (0)
Zusammenhang (1)
Bemerkungen
Familienanamnese
Verwandtschaft
Vater (1)
Mutter (2)
Bruder (3)
Schwester (4)
Sohn (5)
Tochter (6)
Eineiiger Zwilling (7)
Zweieiiger Zwilling (8)
Sonstig (9)
Nachname
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Vorname
Geburtsdatum Familienmitglied
MS bei Familienmitglied
Ja
Nein
Erkrankung
Herpes zoster (1)
Allergie auf Sulphurs (10)
Anaphylaxie (11)
Anämie (12)
Angina pectoris (13)
Anorexie (14)
Angst (15)
Arthralgie (16)
Asthenie (17)
Autoimmune Schilddrüsenerkrankung
(18)
Blindheit (19)
Immunosuppression-assoziierte oder
schwere Infektion (2)
Blut und lymphatische Erkrankung (20)
Sehstörung (21)
Bronchopulmonale Erkrankungen (22)
Kardiovaskuläre Erkrankungen (23)
Brustschmerz (24)
Schüttelfrost (25)
Verstopfung (26)
M. Crohn (27)
Depression (28)
Hauterkrankung (29)
Bauchschmerzen (3)
Diarrhoe (30)
Schwindel (31)
Dyspnoe (32)
Stoffwechselerkrankungen (33)
Epilepsie (34)
Fieber (35)
Grippale Symptome (36)
Gastrointestinale Erkrankungen (37)
Urogenitale Erkrankungen (38)
Kopfschmerz (39)
Allergie auf Aspirin (4)
Lebererkrankung (40)
Hypersensitivität (41)
Hochdruck (42)
Hypertonie (43)
Entzündliche Darmerkrankung (44)
Nekrose an Injektionsstelle (45)
Reaktion an Injektionsstelle (46)
Schlaflosigkeit (47)
auffälliger Lebertest (48)
Lymphopenie (49)
Allergie auf Codein (5)
Migräne (50)
Muskelschmerz (51)
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Muskuloskeletale Erkrankungen (52)
Myasthenia gravis (53)
Myelodysplastisches Syndrom (54)
Perniziöse Anämie (58)
Pruritus (59)
Allergie auf Methylprednisolon (6)
Psoriasis (60)
Psychiatrische Erkrankungen (61)
Exanthem (62)
Nierenerkrankungen (63)
auffällige Nierenfunktion (64)
Netzhauterkrankungen (65)
Rheumatoide Arthritis (66)
Rhinitis (67)
Krampfanfälle (68)
Sinusitis (69)
Allergie auf Morphin (7)
Systemischer Lupus Erythematodes
(SLE) (70)
Operation (71)
Schwitzen (72)
Tachykardie (73)
Thromboembolische Ereignisse (74)
Tinnitus (75)
Diabetes mellitus Type I  (76)
Ulcerative Colitis (77)
Vasodilatation (78)
Vertigo (79)
Allergie auf Penicillin (8)
Vitiligo (80)
Erbrechen (81)
Allergie auf Stemetil (9)
Start Datum
Ende Datum
Bemerkungen
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MSBase Patient profile - Diagnosis
Form imported via medical-data-models.org API-version 1
All rights reserved. Please visit https://medical-data-
models.org/forms/9904
MSBase Patient profile - Diagnosis
Beginn der Krankheit
Startdatum
Erste Symptome Supratentorial
Ja
Nein
Erste Symptome Sehbahnen
Ja
Nein
Erste Symptome Hirnstamm-Kleinhirn
Ja
Nein
Erste Symptome Rückenmark
Ja
Nein
Erste Symptome Andere
Progression seit Anfang
Ja
Nein
Beginn der Progression
MS Diagnose
Datum MS Diagnose bestätigt
Bestätigt durch Klinische Befunde
Ja
Nein
Bestätigt durch ZSF
Ja
Nein
Bestätigt durch MRT
Ja
Nein
Bestätigt durch Evozierte Potentiale
Ja
Nein
Bestätigt durch Andere
1 / 2
McDonald Kriterien
Nicht MS (0)
Mögliche MS (1)
MS (2)
Poser Kriterien
Klinisch gesichert A1 (A1)
Klinisch gesichert A2 (A2)
Laborgestützt gesichert B1 (B1)
Laborgestützt gesichert B2 (B2)
Laborgestützt gesichert B3 (B3)
Klinisch wahrscheinlich C1 (C1)
Klinisch wahrscheinlich C2 (C2)
Klinisch wahrscheinlich C3 (C3)
Laborgestützt wahrscheinlich D1 (D1)
NMO Kriterien
Nicht NMO (0)
Bestätigte NMO (1)
Krankheitsverlauf
MS Verlauf
Startdatum
Anmerkungen
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MSBase Visits - Symptoms
Form imported via medical-data-models.org API-version 1
All rights reserved. Please visit https://medical-data-
models.org/forms/9906
MSBase Visits - Symptoms
Symptome
Symptome MS
Verschwommenes Sehen (1)
Trigeminus (10)
Trigeminus: Neuralgie (11)
Trigeminus: Atypischer Schmerz (12)
Trigeminus: Paraesthesien (13)
Trigeminus: Hypoaesthesie (14)
Fazialislähmung (15)
Hemispastik (16)
Myokymie (17)
Motorische Schwäche: Obere
Extremitäten (18)
Motorische Schwäche: Untere
Extremitäten (19)
Gesichtsfelddefekt/Skotom (2)
Hemiplegie (20)
Ataxie: Obere Extremitäten (21)
Ataxie: Untere Extremitäten (22)
Gangstörung: Parese (23)
Gangstörung: Ataxie (24)
Gangstörung: Spastizität (25)
Tremor (26)
Parästhesien (27)
Dysaesthesien (28)
Schmerz, Kopfschmerzen (29)
Oszillopsie (3)
Lhermitte's Symptom (30)
Harndrang (31)
Probleme mit Darmentleerung (32)
Sexualstörungen (33)
Stimmungsstörungen (34)
kognitive Probleme (35)
Müdigkeit (36)
Extrapyramidale Symptome (37)
Epileptische Anfälle (38)
Diplopie / Ophthalmoplegie (4)
Dysphagie (5)
Dysarthrie (6)
Vertigo (7)
Nystagmus (8)
Verlust Hörfunktion (9)
Bemerkungen
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Based upon https://www.msbase.org/
All rights reserved. Please visit https://medical-data-
models.org/forms/9907
MSBase Visits - EDSS
EDSS
Pyramidal
Normal (0)
Abnorme Befunde ohne Behinderung (1)
Minimale Behinderung (2)
Leichte oder mittelschwere Paraparese
oder Hemiparese; schwere Monoparese
(3)
Ausgeprägte Paraparese oder
Hemiparese; mittelschwere Tetraparese
(4)
Paraplegie, Hemiplegie oder
ausgeprägte Tetraparese (5)
Tetraplegie (6)
Kleinhirn
Normal (0)
Abnorme Befunde ohne Behinderung (1)
Leichte Ataxie (2)
Mässige Rumpf- oder Extremitätenataxie
(3)
Schwere Extremitätenataxie (4)
Unfähigkeit zu koordinierten
Bewegungen infolge Ataxie (5)
Hirnstamm
Normal (0)
Abnorme Untersuchungsbefunde (1)
Mässiger Nystagmus oder anderweitig
leichte Behinderung (2)
Ausgeprägter Nystagmus, deutliche
Paresen von äusseren Augenmuskeln
oder mässige Funktionsstörungen
anderer Hirnnerven (3)
Deutliche Dysarthrie oder andere
ausgeprägte Funktionsstörungen (4)
Unfähigkeit zu schlucken oder zu
sprechen (5)
Sensorium
Normal (0)
Abschwächung von Vibrationssinn oder
Zahlen-Schreiben, an einer oder zwei
Extremitäten (1)
Leichte Verminderung von Berührungs-,
Schmerz-, oder Lageempfindung;
und/oder mässige Abschwächung des
Vibrationssinnes an einer oder zwei
Extremitaten; oder Abschwächung des
Vibrationssinnes alleine an drei oder vier
Extremitaten (2)
Mässige Verminderung von Berührungs-,
Schmerz-, oder Lageempfindung
und/oder weitgehender Verlust des
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Vibrationssinnes an einer oder zwei
Extremitäten; oder leichte Verminderung
von Berührungs- oder
Schmerzempfindung und/oder massige
Verminderung in allen propriozeptiven
Tests in drei oder vier Extremitäten (3)
Deutliche Verminderung von
Berührungs- oder Schmerzempfindung
oder Verlust der Propriozeption, alleine
oder kombiniert, an einer oder zwei
Extremitäten; oder mässige
Verminderung von Berührungs- oder
Schmerzempfindung und/oder schwere
Einschränkung der Propriozeption in
mehr als zwei Extremitäten (4)
Sensibilitätsverlust in einer oder zwei
Extremitäten; oder Verlust der
Propriozeption am grössten Teil des
Körpers unterhalb des Kopfes (5)
Weitgehender Sensibilitätsverlust
unterhalb des Kopfes (6)
Mastdarm/Blase
Normal (0)
Leichtes Harnverhalten, leichter
Harndrang (1)
Mässig ausgeprägtes Harn- oder
Stuhlverhalten, mässig ausgeprägter
imperativer Harn- bzw. Stuhldrang,
seltene Harninkontinenz (2)
Häufige Urininkontinenz (3)
Benötigt regelmässige intermittierende
Katheterisierung (4)
Verweilkatheter (5)
Verlust der Blasen- und Darmfunktion (6)
Sehfunktionen
Normal (0)
Skotom, Visus (korrigiert) grösser als 6/9
(1)
Schwächeres Auge mit maximalem
Visus (korrigiert) 6/9 - 6/12 (2)
Schwächeres Auge mit maximalem
Visus (korrigiert) 6/18 - 6/24 (3)
Schwächeres Auge mit maximalem
Visus (korrigiert) 6/36 - 6/60 oder Grad 3
plus maximaler Visus des besseren
Auges 6/18 oder weniger (4)
Schwächeres Auge mit maximalem
Visus (korrigiert) 6/60 oder Grad 4 plus
maximaler Visus des besseren Auges
6/18 oder weniger (5)
Grad 5 plus maximaler Visus des
besseren Auges schlechter als 6/18 (6)
Zerebrale Funktionen
Normal (0)
Nur Stimmungsschwankungen,
Müdigkeit beeinträchtigt Aktivität nicht (1)
Leichte organische Wesensveränderung,
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Müdigkeit beeinträchtigt tägliche Aktivität
(2)
Mässiggradige organische
Wesensveränderung (3)
Ausgeprägte organische
Wesensveränderung (4)
Demenz oder chron. Hirnsyndrom -
schwer oder inkompetent (5)
Gehfähigkeit
Voll gehfähig (0)
etwa 500 m ohne Hilfe oder Rast (1)
Ans Bett gebunden, auch während des
Tages (10)
Patient im Bett, kann kommunizieren und
essen (11)
Hilfloser Patient im Bett, unfähig zu
kommunizieren, essen oder schlucken
(12)
etwa 300 m ohne Hilfe oder Rast (2)
etwa 200 m ohne Hilfe oder Rast (3)
etwa 100 m ohne Hilfe oder Rast (4)
etwa 100 m mit einseitiger Unterstützung
(5)
etwa 20 m mit beidseitiger Unterstützung
(6)
Weitgehend an Rollstuhl gebunden
(bewegt Rollstuhl selbst) (7)
An den Rollstuhl gebunden (benötigt
Hilfe für Transfer) (8)
Weitgehend ans Bett oder Stuhl
gebunden (9)
EDSS score
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Based upon
https://www.msbase.org/
All rights reserved. Please visit https://medical-data-
models.org/forms/9923
MSBase Visits - Scripps
Neurokognition
Neurokognition
ND (0)
Normal (1)
Leichte Behinderung (2)
Mittlere Behinderung (3)
Schwere Behinderung (4)
Hirnnerven
Visus
ND (0)
Normal (1)
Leichte Behinderung (2)
Mittlere Behinderung (3)
Schwere Behinderung (4)
Fields Disc Pupils
ND (0)
Normal (1)
Leichte Behinderung (2)
Mittlere Behinderung (3)
Schwere Behinderung (4)
Augenbewegungen
ND (0)
Normal (1)
Leichte Behinderung (2)
Mittlere Behinderung (3)
Schwere Behinderung (4)
Nystagmus
ND (0)
Normal (1)
Leichte Behinderung (2)
Mittlere Behinderung (3)
Schwere Behinderung (4)
Untere Hirnnerven
ND (0)
Normal (1)
Leichte Behinderung (2)
Mittlere Behinderung (3)
Schwere Behinderung (4)
Motorisch
ROben
ND (0)
Normal (1)
Leichte Behinderung (2)
Mittlere Behinderung (3)
Schwere Behinderung (4)
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LOben
ND (0)
Normal (1)
Leichte Behinderung (2)
Mittlere Behinderung (3)
Schwere Behinderung (4)
RUnten
ND (0)
Normal (1)
Leichte Behinderung (2)
Mittlere Behinderung (3)
Schwere Behinderung (4)
LUnten
ND (0)
Normal (1)
Leichte Behinderung (2)
Mittlere Behinderung (3)
Schwere Behinderung (4)
Muskeleigenreflexe
OE
ND (0)
Normal (1)
Leichte Behinderung (2)
Mittlere Behinderung (3)
Schwere Behinderung (4)
UE
ND (0)
Normal (1)
Leichte Behinderung (2)
Mittlere Behinderung (3)
Schwere Behinderung (4)
Babinski
R
ND (0)
Normal (1)
Leichte Behinderung (2)
Mittlere Behinderung (3)
Schwere Behinderung (4)
L
ND (0)
Normal (1)
Leichte Behinderung (2)
Mittlere Behinderung (3)
Schwere Behinderung (4)
Sensorium
ROben
ND (0)
Normal (1)
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Leichte Behinderung (2)
Mittlere Behinderung (3)
Schwere Behinderung (4)
LOben
ND (0)
Normal (1)
Leichte Behinderung (2)
Mittlere Behinderung (3)
Schwere Behinderung (4)
RUnten
ND (0)
Normal (1)
Leichte Behinderung (2)
Mittlere Behinderung (3)
Schwere Behinderung (4)
LUnten
ND (0)
Normal (1)
Leichte Behinderung (2)
Mittlere Behinderung (3)
Schwere Behinderung (4)
Zerebellär
Obere
ND (0)
Normal (1)
Leichte Behinderung (2)
Mittlere Behinderung (3)
Schwere Behinderung (4)
Untere
ND (0)
Normal (1)
Leichte Behinderung (2)
Mittlere Behinderung (3)
Schwere Behinderung (4)
Gang, Rumpf, Gleichgewicht
Gang, Rumpf, Gleichgewicht
ND (0)
Normal (1)
Leichte Behinderung (2)
Mittlere Behinderung (3)
Schwere Behinderung (4)
Mastdarm/Blase/Sexualstörungen
Mastdarm/Blase/Sexualstörungen
ND (0)
Normal (1)
Leichte Behinderung (2)
Mittlere Behinderung (3)
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Schwere Behinderung (4)
Scripps
Scripps, Total
Bemerkungen
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MSBase Visits - MusiQOL
Form imported via medical-data-models.org API-version 1
All rights reserved. Please visit https://medical-data-
models.org/forms/9925
MSBase Visits - MusiQOL
Haben Sie sich aufgrund Ihrer MS in den
letzten 4 Wochen ...
01 Schwierigkeiten gehabt, außer Haus
herumzugehen?
Niemals / Keineswegs (1)
Selten / Kaum (2)
Manchmal / Ein wenig (3)
Oft / Häufig (4)
Immer / Sehr viel (5)
Nicht zutreffend (6)
02 Schwierigkeiten bei Aktivitäten außer Haus
gehabt, d.h. Einkaufen, Kinobesuch... ?
Niemals / Keineswegs (1)
Selten / Kaum (2)
Manchmal / Ein wenig (3)
Oft / Häufig (4)
Immer / Sehr viel (5)
Nicht zutreffend (6)
03 Schwierigkeiten gehabt, daheim
herumzugehen?
Niemals / Keineswegs (1)
Selten / Kaum (2)
Manchmal / Ein wenig (3)
Oft / Häufig (4)
Immer / Sehr viel (5)
Nicht zutreffend (6)
04 Gleichgewichts- oder Gehprobleme geplagt?
Niemals / Keineswegs (1)
Selten / Kaum (2)
Manchmal / Ein wenig (3)
Oft / Häufig (4)
Immer / Sehr viel (5)
Nicht zutreffend (6)
05 Schwierigkeiten bei Freizeitaktivitäten daheim
gehabt, d.h. Heimwerken, Gartenarbeit...?
Niemals / Keineswegs (1)
Selten / Kaum (2)
Manchmal / Ein wenig (3)
Oft / Häufig (4)
Immer / Sehr viel (5)
Nicht zutreffend (6)
06 Schwierigkeiten bei Tätigkeiten am
Arbeitsplatz gehabt, d.h. Integration,
Unterbrechungen, Einschränkungen... ?
Niemals / Keineswegs (1)
Selten / Kaum (2)
Manchmal / Ein wenig (3)
Oft / Häufig (4)
Immer / Sehr viel (5)
Nicht zutreffend (6)
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07 schnell Ermüdungserscheinungen verspürt?
Niemals / Keineswegs (1)
Selten / Kaum (2)
Manchmal / Ein wenig (3)
Oft / Häufig (4)
Immer / Sehr viel (5)
Nicht zutreffend (6)
08 das Gefühl gehabt, keine Energie zu haben?
Niemals / Keineswegs (1)
Selten / Kaum (2)
Manchmal / Ein wenig (3)
Oft / Häufig (4)
Immer / Sehr viel (5)
Nicht zutreffend (6)
09 ängstlich gewesen?
Niemals / Keineswegs (1)
Selten / Kaum (2)
Manchmal / Ein wenig (3)
Oft / Häufig (4)
Immer / Sehr viel (5)
Nicht zutreffend (6)
10 deprimiert oder bedrückt gewesen?
Niemals / Keineswegs (1)
Selten / Kaum (2)
Manchmal / Ein wenig (3)
Oft / Häufig (4)
Immer / Sehr viel (5)
Nicht zutreffend (6)
11 den Tränen nahe gewesen?
Niemals / Keineswegs (1)
Selten / Kaum (2)
Manchmal / Ein wenig (3)
Oft / Häufig (4)
Immer / Sehr viel (5)
Nicht zutreffend (6)
12 wegen einzelner Angelegenheiten oder
Situationen nervös oder verärgert gewesen?
Niemals / Keineswegs (1)
Selten / Kaum (2)
Manchmal / Ein wenig (3)
Oft / Häufig (4)
Immer / Sehr viel (5)
Nicht zutreffend (6)
13 durch ein Nachlassen Ihrer
Gedächtnisleistung belastet worden?
Niemals / Keineswegs (1)
Selten / Kaum (2)
Manchmal / Ein wenig (3)
Oft / Häufig (4)
Immer / Sehr viel (5)
Nicht zutreffend (6)
14 unkonzentriert gewesen bzw. hatten Sie
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Schwierigkeiten sich zu konzentrieren, z.B. beim
Lesen, Ansehen eines Films oder wenn Sie eine
Diskussion verfolgt haben?
Niemals / Keineswegs (1)
Selten / Kaum (2)
Manchmal / Ein wenig (3)
Oft / Häufig (4)
Immer / Sehr viel (5)
Nicht zutreffend (6)
15 Sehprobleme geplagt: sehen Sie schlechter
oder ist Ihr Sehvermögen irgendwie gestört?
Niemals / Keineswegs (1)
Selten / Kaum (2)
Manchmal / Ein wenig (3)
Oft / Häufig (4)
Immer / Sehr viel (5)
Nicht zutreffend (6)
16 unangenehme Empfindungen verspürt, d.h.
Hitze- oder Kältegefühl ...?
Niemals / Keineswegs (1)
Selten / Kaum (2)
Manchmal / Ein wenig (3)
Oft / Häufig (4)
Immer / Sehr viel (5)
Nicht zutreffend (6)
17 mit Ihren Freunden ausgesprochen?
Niemals / Keineswegs (1)
Selten / Kaum (2)
Manchmal / Ein wenig (3)
Oft / Häufig (4)
Immer / Sehr viel (5)
Nicht zutreffend (6)
18 von Ihren Freunden verstanden gefühlt?
Niemals / Keineswegs (1)
Selten / Kaum (2)
Manchmal / Ein wenig (3)
Oft / Häufig (4)
Immer / Sehr viel (5)
Nicht zutreffend (6)
19 von Ihren Freunden ermutigt gefühlt?
Niemals / Keineswegs (1)
Selten / Kaum (2)
Manchmal / Ein wenig (3)
Oft / Häufig (4)
Immer / Sehr viel (5)
Nicht zutreffend (6)
20 mit Ihrem (Ehe-)Partner oder Ihrer Familie
ausgesprochen?
Niemals / Keineswegs (1)
Selten / Kaum (2)
Manchmal / Ein wenig (3)
Oft / Häufig (4)
Immer / Sehr viel (5)
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Nicht zutreffend (6)
21 von Ihrem (Ehe-)Partner oder Ihrer Familie
verstanden gefühlt?
Niemals / Keineswegs (1)
Selten / Kaum (2)
Manchmal / Ein wenig (3)
Oft / Häufig (4)
Immer / Sehr viel (5)
Nicht zutreffend (6)
22 von Ihrem (Ehe-)Partner oder Ihrer Familie
ermutigt gefühlt?
Niemals / Keineswegs (1)
Selten / Kaum (2)
Manchmal / Ein wenig (3)
Oft / Häufig (4)
Immer / Sehr viel (5)
Nicht zutreffend (6)
23 ein harmonisches Liebesleben gehabt?
Niemals / Keineswegs (1)
Selten / Kaum (2)
Manchmal / Ein wenig (3)
Oft / Häufig (4)
Immer / Sehr viel (5)
Nicht zutreffend (6)
24 ein harmonisches Sexualleben gehabt?
Niemals / Keineswegs (1)
Selten / Kaum (2)
Manchmal / Ein wenig (3)
Oft / Häufig (4)
Immer / Sehr viel (5)
Nicht zutreffend (6)
25 Ihre Situation als ungerecht empfunden?
Niemals / Keineswegs (1)
Selten / Kaum (2)
Manchmal / Ein wenig (3)
Oft / Häufig (4)
Immer / Sehr viel (5)
Nicht zutreffend (6)
26 Verbitterung verspürt?
Niemals / Keineswegs (1)
Selten / Kaum (2)
Manchmal / Ein wenig (3)
Oft / Häufig (4)
Immer / Sehr viel (5)
Nicht zutreffend (6)
27 durch die Blicke anderer Leute gekränkt
gefühlt?
Niemals / Keineswegs (1)
Selten / Kaum (2)
Manchmal / Ein wenig (3)
Oft / Häufig (4)
Immer / Sehr viel (5)
Nicht zutreffend (6)
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28 in der Öffentlichkeit unsicher gefühlt?
Niemals / Keineswegs (1)
Selten / Kaum (2)
Manchmal / Ein wenig (3)
Oft / Häufig (4)
Immer / Sehr viel (5)
Nicht zutreffend (6)
29 mit den von den Ärzten, Krankenschwestern,
Psychologen, etc., die mit der Behandlung Ihrer
MS befaßt sind, erteilten Informationen betreffend
Ihrer MS zufrieden gefühlt?
Niemals / Keineswegs (1)
Selten / Kaum (2)
Manchmal / Ein wenig (3)
Oft / Häufig (4)
Immer / Sehr viel (5)
Nicht zutreffend (6)
30 von den Ärzten, Krankenschwestern,
Psychologen, etc., die mit der Behandlung Ihrer
MS befaßt sind, verstanden gefühlt?
Niemals / Keineswegs (1)
Selten / Kaum (2)
Manchmal / Ein wenig (3)
Oft / Häufig (4)
Immer / Sehr viel (5)
Nicht zutreffend (6)
31 mit Ihren Behandlungen zufrieden gewesen?
Niemals / Keineswegs (1)
Selten / Kaum (2)
Manchmal / Ein wenig (3)
Oft / Häufig (4)
Immer / Sehr viel (5)
Nicht zutreffend (6)
Genaue Zeit zu Anfang
Genaue Zeit zu Ende
Scores
Alltägliche Aktivitäten
Seelisches Wohlbefinden
Freundschaften
Symptome
Verhältnis zur Familie
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Zugang zu Gesundheitssystem / Pflege
Gefühls- und Sexualleben
Bewältigung
Ablehnung
MusiQOL Score
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MSBase Visits - Safety
Überblick
Hat der Patient seit seinem letzten Termin ein
Malignom (außer Nicht-Melanom-Hautkrebs)
entwickelt?
Ja
Nein
Hat der Patient seit seinem letzten Termin einen
Nicht-Melanom-Hautkrebs entwickelt?
Ja
Nein
Hat der Patient seit seinem letzten Termin
Herpes Zoster (Gürtelrose) entwickelt?
Ja
Nein
Hat der Patient seit seinem letzten Termin eine
Infektion entwickelt, die durch Immunsuppression
bedingt ist oder schwerwiegend ist?
Hat der Patient seit seinem letzten Termin
irgendeine andere Krankheit entwickelt?
Ja
Nein
Krankheiten und Leiden
Erkrankung
Herpes zoster (1)
Allergie auf Sulphurs (10)
Anaphylaxie (11)
Anämie (12)
Angina pectoris (13)
Anorexie (14)
Angst (15)
Arthralgie (16)
Asthenie (17)
Autoimmune Schilddrüsenerkrankung
(18)
Blindheit (19)
Immunosuppression-assoziierte oder
schwere Infektion (2)
Blut und lymphatische Erkrankung (20)
Sehstörung (21)
Bronchopulmonale Erkrankungen (22)
Kardiovaskuläre Erkrankungen (23)
Brustschmerz (24)
Schüttelfrost (25)
Verstopfung (26)
M. Crohn (27)
Depression (28)
Hauterkrankung (29)
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Bauchschmerzen (3)
Diarrhoe (30)
Schwindel (31)
Dyspnoe (32)
Stoffwechselerkrankungen (33)
Epilepsie (34)
Fieber (35)
Grippale Symptome (36)
Gastrointestinale Erkrankungen (37)
Urogenitale Erkrankungen (38)
Kopfschmerz (39)
Allergie auf Aspirin (4)
Lebererkrankung (40)
Hypersensitivität (41)
Hochdruck (42)
Hypertonie (43)
Entzündliche Darmerkrankung (44)
Nekrose an Injektionsstelle (45)
Reaktion an Injektionsstelle (46)
Schlaflosigkeit (47)
auffälliger Lebertest (48)
Lymphopenie (49)
Allergie auf Codein (5)
Migräne (50)
Muskelschmerz (51)
Muskuloskeletale Erkrankungen (52)
Myasthenia gravis (53)
Myelodysplastisches Syndrom (54)
Perniziöse Anämie (58)
Pruritus (59)
Allergie auf Methylprednisolon (6)
Psoriasis (60)
Psychiatrische Erkrankungen (61)
Exanthem (62)
Nierenerkrankungen (63)
auffällige Nierenfunktion (64)
Netzhauterkrankungen (65)
Rheumatoide Arthritis (66)
Rhinitis (67)
Krampfanfälle (68)
Sinusitis (69)
Allergie auf Morphin (7)
Systemischer Lupus Erythematodes
(SLE) (70)
Operation (71)
Schwitzen (72)
Tachykardie (73)
Thromboembolische Ereignisse (74)
Tinnitus (75)
Diabetes mellitus Type I  (76)
Ulcerative Colitis (77)
Vasodilatation (78)
Vertigo (79)
Allergie auf Penicillin (8)
Vitiligo (80)
Erbrechen (81)
Allergie auf Stemetil (9)
Datum der Diagnose
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Schweregrad
mild (1)
mässig (2)
schwer (3)
lebensbedrohend (4)
Behandlungsmodalität
Ergebnis
Unbekannt (0)
Anhaltend (1)
Erholung (2)
Tod (3)
Datum
SAE Schweregrad
Kein SAE (0)
endet tödlich (1)
ist lebensbedrohend (2)
Bleibende/schwere Behinderung (3)
Benötigt/verlängert Hospitalisation (4)
Angeborene Anomalie (5)
Andere wichtige medizinische Leiden (6)
Zusammenhang mit Arzneimittel
Kein Zusammenhang (0)
Zusammenhang (1)
Bemerkungen
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Schübe
Startdatum
Dauer
Auswirkungen auf ADL-Funktionen
Ja
Nein
Erholung
Complete (1)
Partial (2)
None (3)
Schweregrad
Mild (1)
Moderate (2)
Severe (3)
Behandlungsort
Not Treated (1)
Ambulatory (2)
Hospital (3)
Bemerkungen
Kortikosteroide
Kortikosteroide
ACTH (1)
Cortisone acetate (2)
Dexamethasone (3)
Hydrocortisone (4)
Methylprednisolone (5)
Prednisolone (6)
Prednisone (7)
Startet am
Endet am
Betroffene funktionelle Systeme
Pyramidenbahn
Ja
Nein
Kleinhirn
Ja
1 / 2
Nein
Hirnstamm
Ja
Nein
Sensorium
Ja
Nein
Mastdarm Blase
Ja
Nein
Sehfunktionen
Ja
Nein
Neuropsychologische Funktionen
Ja
Nein
Sonstige
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Krankheiten und Leiden
Erkrankung
Herpes zoster (1)
Allergie auf Sulphurs (10)
Anaphylaxie (11)
Anämie (12)
Angina pectoris (13)
Anorexie (14)
Angst (15)
Arthralgie (16)
Asthenie (17)
Autoimmune Schilddrüsenerkrankung
(18)
Blindheit (19)
Immunosuppression-assoziierte oder
schwere Infektion (2)
Blut und lymphatische Erkrankung (20)
Sehstörung (21)
Bronchopulmonale Erkrankungen (22)
Kardiovaskuläre Erkrankungen (23)
Brustschmerz (24)
Schüttelfrost (25)
Verstopfung (26)
M. Crohn (27)
Depression (28)
Hauterkrankung (29)
Bauchschmerzen (3)
Diarrhoe (30)
Schwindel (31)
Dyspnoe (32)
Stoffwechselerkrankungen (33)
Epilepsie (34)
Fieber (35)
Grippale Symptome (36)
Gastrointestinale Erkrankungen (37)
Urogenitale Erkrankungen (38)
Kopfschmerz (39)
Allergie auf Aspirin (4)
Lebererkrankung (40)
Hypersensitivität (41)
Hochdruck (42)
Hypertonie (43)
Entzündliche Darmerkrankung (44)
Nekrose an Injektionsstelle (45)
Reaktion an Injektionsstelle (46)
Schlaflosigkeit (47)
auffälliger Lebertest (48)
Lymphopenie (49)
Allergie auf Codein (5)
Migräne (50)
Muskelschmerz (51)
Muskuloskeletale Erkrankungen (52)
Myasthenia gravis (53)
Myelodysplastisches Syndrom (54)
Perniziöse Anämie (58)
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Pruritus (59)
Allergie auf Methylprednisolon (6)
Psoriasis (60)
Psychiatrische Erkrankungen (61)
Exanthem (62)
Nierenerkrankungen (63)
auffällige Nierenfunktion (64)
Netzhauterkrankungen (65)
Rheumatoide Arthritis (66)
Rhinitis (67)
Krampfanfälle (68)
Sinusitis (69)
Allergie auf Morphin (7)
Systemischer Lupus Erythematodes
(SLE) (70)
Operation (71)
Schwitzen (72)
Tachykardie (73)
Thromboembolische Ereignisse (74)
Tinnitus (75)
Diabetes mellitus Type I  (76)
Ulcerative Colitis (77)
Vasodilatation (78)
Vertigo (79)
Allergie auf Penicillin (8)
Vitiligo (80)
Erbrechen (81)
Allergie auf Stemetil (9)
Andere Erkrankung
Datum der Diagnose
Schweregrad
mild (1)
mässig (2)
schwer (3)
lebensbedrohend (4)
Behandlungsmodalität
Ergebnis
Unbekannt (0)
Anhaltend (1)
Erholung (2)
Tod (3)
Datum
SAE Schweregrad
Kein SAE (0)
endet tödlich (1)
ist lebensbedrohend (2)
Bleibende/schwere Behinderung (3)
Benötigt/verlängert Hospitalisation (4)
Angeborene Anomalie (5)
Andere wichtige medizinische Leiden (6)
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Zusammenhang mit Arzneimittel
Kein Zusammenhang (0)
Zusammenhang (1)
Bemerkungen
Tumor
Diagnosedatum
Ort des Primärkarzinoms
Histologische Diagnose
Stadium bei Diagnose
I (I)
II (II)
III (III)
IV (IV)
Keine Behandlung
Ja
Nein
Chemotherapie
Ja
Nein
Radiotherapie
Ja
Nein
Operation
Ja
Nein
Sonstiges
Ergebnis
Unbekannt (0)
Anhaltend (1)
Remission (2)
Tod (3)
Datum
Bemerkungen
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Hämatologie
Untersuchungsdatum
Labortest
Leukozyten (1)
Neutrophile (10)
Monozyten (11)
Eosinophile (12)
Basophile (13)
Blutplättchen (14)
Hämoglobin (15)
Erythrozyten (2)
Lymphozyten (3)
Lymphozyten, unterer Grenzwert (4)
Anzahl der T-Zellen (5)
Anzahl der CD4-T-Zellen (6)
Anzahl der CD8-T-Zellen (7)
Anzahl der CD19-B-Zellen (8)
Anzahl der NK-Zellen (9)
Einheit
% (1)
pmol/L (10)
umol/L (11)
10e12/L (2)
10e9/L (3)
L/L (4)
U/L (5)
g/L (6)
g/dL (7)
mmol/L (8)
nmol/L (9)
Abnormal
Ja
Nein
Kommentare
Biochem. Blutuntersuchung
Untersuchungsdatum
Labortest
Gesamtprotein (1)
Bilirubin (10)
Alkalische Phosphatase (11)
Amylase (12)
Lipasen (13)
Albumin (2)
Kalcium (3)
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Harnstoff (4)
Harnsäure (5)
Kreatinin (6)
SGOT / AST (7)
SGPT / ALT (8)
Gamma-GT (9)
Unit
% (1)
pmol/L (10)
umol/L (11)
10e12/L (2)
10e9/L (3)
L/L (4)
U/L (5)
g/L (6)
g/dL (7)
mmol/L (8)
nmol/L (9)
Abnormal
Ja
Nein
Kommentare
Schilddrüsen Funktionen
Untersuchungsdatum
Lab test
Anti-microsomale Antikörper (1)
Anti-thyroglobulin Antikörper (2)
T3 (3)
T4 (4)
TSH (5)
Einheit
% (1)
pmol/L (10)
umol/L (11)
10e12/L (2)
10e9/L (3)
L/L (4)
U/L (5)
g/L (6)
g/dL (7)
mmol/L (8)
nmol/L (9)
Abnormal
Ja
Nein
Kommentare
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Serologische Tests
Untersuchungsdatum
Labortest
Hepatitis-B-Oberflächenantigen (1)
Schwangerschaftstest (10)
Quantiferon-Gold-Test (11)
Mendel-Mantoux-Test (12)
Anti-HCV-Antikörper (2)
Anti-HIV-Antikörper (3)
Anti-Varicella-Antikörper (4)
Anti-JC-Virus-Antikörper im Plasma (5)
JC-Virus-DNA im Urin (6)
Neutralisierender Anti-Interferon-
Antikörper (7)
Neutralisierender Anti-VLA-4-Antikörper
(8)
NMO-IgG (9)
Durchführendes Labor
Testergebnis
negativ (0)
positiv (1)
Kommentare
Test auf Auto-Antikörper
Untersuchungsdatum
Labortest
ANA (1)
Jo1 (10)
Anti-DNA (11)
ANCA (12)
Anti-LKM (13)
Anti-cardiolipin (14)
LAC (15)
Anti-Transglutaminase (16)
Anti-mitochondrial (2)
Anti parietale Zell Antikörper (3)
ASMA (4)
Anti-Ro (5)
La (6)
Sm (7)
RNP (8)
Scl-70 (9)
Einheit
% (1)
pmol/L (10)
umol/L (11)
10e12/L (2)
10e9/L (3)
L/L (4)
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U/L (5)
g/L (6)
g/dL (7)
mmol/L (8)
nmol/L (9)
Abnormal
Ja
Nein
Kommentare
Nächster Labortest
Bezeichnung
Von
Bis
Bemerkungen
Pflegeperson beteiligt
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MSBase Treatments
Krankheiten und Leiden
MS spezifische Behandlung
Avonex (1)
Novantrone (10)
Rebif [22] (11)
Rebif [44] (12)
Tysabri (13)
Azathioprine (2)
Betaferon (3)
Copaxone (4)
Cyclophosphamide (5)
Extavia (6)
Gilenya (7)
IVIG (8)
Methotrexate (9)
Startet am
Endet am
Dosis
Einheit
mcg (1)
MU (2)
mg (3)
g (4)
ml (5)
MIU (6)
Other (7)
Intervall
2 / Woche (1)
/ Std (10)
/ Tag (11)
/ 4 Std (12)
4 / Tag (13)
/ Monat (14)
/ 3 Monat (15)
/ 4 Wochen (16)
Sonstiges (17)
/Woche (2)
2 / Tag (3)
3 / Woche (4)
/ 3 Std (5)
/ 2 Std (6)
3 / Tag (7)
/ 3 Tage (8)
/ 2 Tage (9)
Route
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SC (1)
IM (2)
IV (3)
Oral (4)
Sonstig (5)
Grund für Abbruch
Unerwünschtes Ereignis (1)
Schwangerschaft geplant (10)
Fortschreiten der Krankheit (11)
EDSS-Progression (12)
Geplanter Abbruch (13)
Allergische Reaktion (2)
Mangelnde Besserung (3)
Mangelnde Verträglichkeit (4)
Non-Adhärenz (5)
Handhabung/Bequemlichkeit (6)
Persistierende Schübe (7)
Persistierende MRT-Aktivität (8)
Bestätigte Schwangerschaft (9)
Bemerkungen
Krankheiten und Leiden
MS Medikation
4-aminopyridine (1)
Carbamazepine (10)
Clonazepam (11)
Clozapine (12)
Cortisone acetate (13)
Dantrolene (14)
Desmopressin (15)
Dexamethasone (16)
Diazepam (17)
Hydrocortisone (18)
Methylprednisolone (19)
ACTH (2)
Ondansetron (20)
Oxybutynin (21)
Papaverine (22)
Pemoline (23)
Plasmapheresis (24)
Prednisolone (25)
Prednisone (26)
Primidone (27)
Propranolol (28)
Prostaglandine E (29)
Amantadine (3)
Sativex (30)
Sildenafil (31)
Tizanidine (32)
Amitryptiline (4)
Ampyra (5)
Baclofen (6)
Benzodiazepine (7)
Bethanechol (8)
Botulinum (9)
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Startet am
Endet am
Dosis
Einheit
mcg (1)
MU (2)
mg (3)
g (4)
ml (5)
MIU (6)
Other (7)
Intervall
2 / Week (1)
/ Hour (10)
/ Day (11)
/ 4 Hour (12)
4 / Day (13)
/ Month (14)
/ 3 Month (15)
/ 4 Week (16)
Other (17)
/Week (2)
2 / Day (3)
3 / Week (4)
/ 3 Hour (5)
/ 2 Hour (6)
3 / Day (7)
/ 3 Days (8)
/ 2 Days (9)
Route
SC (1)
IM (2)
IV (3)
Oral (4)
Andere (5)
Grund für Abbruch
Adverse Event (1)
Pregnancy planned (10)
Progression of disease (11)
Progression of EDSS (12)
Scheduled Stop (13)
Allergic reaction (2)
Lack of efficacy (3)
Lack of tolerance (4)
Non adherence (5)
Patient choice/Convenience (6)
Persistence of relapses (7)
Persisting MRI activity (8)
Pregnancy confirmed (9)
Bemerkungen
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Nicht medikamentöse Behandlung
Nicht medikamentöse Behandlung
Neuropsych. Training (1)
Physiotherapie (2)
Psychotherapie (3)
Startet am
Endet am
Bemerkungen
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Childhood Trauma Questionnaire (CTQ)
The German Version of the Childhood Trauma
Questionnaire (CTQ): psychometric characteristics in a
representative sample of the general population
Klinitzke G, Romppel M, Häuser W, Brähler E, Glaesmer H.
Psychother Psychosom Med Psychol. 2012 Feb;62(2):47-
51
All rights reserved. Please visit https://medical-data-
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Childhood Trauma Questionnaire
(CTQ)
Als ich aufwuchs...
1.	...hatte ich nicht genug zu essen.
trifft auf mich überhaupt nicht zu (1)
trifft auf mich sehr selten zu (2)
trifft auf mich einige Male zu (3)
trifft auf mich häufig zu (4)
trifft auf mich sehr häufig zu (5)
2. ...wußte ich, daß sich jemand um mich sorgte
und mich beschützte.
trifft auf mich überhaupt nicht zu (1)
trifft auf mich sehr selten zu (2)
trifft auf mich einige Male zu (3)
trifft auf mich häufig zu (4)
trifft auf mich sehr häufig zu (5)
3. ..bezeichneten mich Personen aus meiner
Familie als ´dumm´, ´faul´ oder ´häßlich´.
trifft auf mich überhaupt nicht zu (1)
trifft auf mich sehr selten zu (2)
trifft auf mich einige Male zu (3)
trifft auf mich häufig zu (4)
trifft auf mich sehr häufig zu (5)
4. ...waren meine Eltern zu betrunken oder von
anderen Drogen ´high´, um für die Familie zu
sorgen.
trifft auf mich überhaupt nicht zu (1)
trifft auf mich sehr selten zu (2)
trifft auf mich einige Male zu (3)
trifft auf mich häufig zu (4)
trifft auf mich sehr häufig zu (5)
5. ...gab es jemand in der Familie, der mir das
Gefühl gab, wichtig und jemand Besonderes zu
sein.
trifft auf mich überhaupt nicht zu (1)
trifft auf mich sehr selten zu (2)
trifft auf mich einige Male zu (3)
trifft auf mich häufig zu (4)
trifft auf mich sehr häufig zu (5)
6. ...mußte ich dreckige Kleidung tragen.
trifft auf mich überhaupt nicht zu (1)
trifft auf mich sehr selten zu (2)
trifft auf mich einige Male zu (3)
trifft auf mich häufig zu (4)
trifft auf mich sehr häufig zu (5)
7. ...hatte ich das Gefühl, geliebt zu werden.
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trifft auf mich überhaupt nicht zu (1)
trifft auf mich sehr selten zu (2)
trifft auf mich einige Male zu (3)
trifft auf mich häufig zu (4)
trifft auf mich sehr häufig zu (5)
8. ...glaubte ich, daß meine Eltern wünschten, ich
wäre nie geboren.
trifft auf mich überhaupt nicht zu (1)
trifft auf mich sehr selten zu (2)
trifft auf mich einige Male zu (3)
trifft auf mich häufig zu (4)
trifft auf mich sehr häufig zu (5)
9. ...wurde ich von jemandem aus meiner Familie
so stark geschlagen, daß ich zum Arzt oder ins
Krankenhaus mußte.
trifft auf mich überhaupt nicht zu (1)
trifft auf mich sehr selten zu (2)
trifft auf mich einige Male zu (3)
trifft auf mich häufig zu (4)
trifft auf mich sehr häufig zu (5)
10. ...gab es nichts, was ich an meiner Familie
ändern wollte.
trifft auf mich überhaupt nicht zu (1)
trifft auf mich sehr selten zu (2)
trifft auf mich einige Male zu (3)
trifft auf mich häufig zu (4)
trifft auf mich sehr häufig zu (5)
11. ...schlugen mich Personen aus meiner
Familie so stark, daß ich blaue Flecken oder
Schrammen davontrug.
trifft auf mich überhaupt nicht zu (1)
trifft auf mich sehr selten zu (2)
trifft auf mich einige Male zu (3)
trifft auf mich häufig zu (4)
trifft auf mich sehr häufig zu (5)
12. ...wurde ich mit einem Gürtel, einem Stock,
einem Riemen oder mit einem harten
Gegenstand bestraft.
trifft auf mich überhaupt nicht zu (1)
trifft auf mich sehr selten zu (2)
trifft auf mich einige Male zu (3)
trifft auf mich häufig zu (4)
trifft auf mich sehr häufig zu (5)
13. ...gaben meine Familienangehörigen
aufeinander acht.
trifft auf mich überhaupt nicht zu (1)
trifft auf mich sehr selten zu (2)
trifft auf mich einige Male zu (3)
trifft auf mich häufig zu (4)
trifft auf mich sehr häufig zu (5)
14. ...sagten Personen aus meiner Familie
verletzende oder beleidigende Dinge zu mir.
trifft auf mich überhaupt nicht zu (1)
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trifft auf mich sehr selten zu (2)
trifft auf mich einige Male zu (3)
trifft auf mich häufig zu (4)
trifft auf mich sehr häufig zu (5)
15. Ich glaube, ich bin körperlich mißhandelt
worden, als ich aufwuchs.
trifft auf mich überhaupt nicht zu (1)
trifft auf mich sehr selten zu (2)
trifft auf mich einige Male zu (3)
trifft auf mich häufig zu (4)
trifft auf mich sehr häufig zu (5)
16. ...hatte ich eine perfekte Kindheit.
trifft auf mich überhaupt nicht zu (1)
trifft auf mich sehr selten zu (2)
trifft auf mich einige Male zu (3)
trifft auf mich häufig zu (4)
trifft auf mich sehr häufig zu (5)
17. ...wurde ich so stark geschlagen oder
verprügelt, daß es jemandem (z.B. Lehrer,
Nachbar oder Arzt) auffiel.
trifft auf mich überhaupt nicht zu (1)
trifft auf mich sehr selten zu (2)
trifft auf mich einige Male zu (3)
trifft auf mich häufig zu (4)
trifft auf mich sehr häufig zu (5)
18. ...hatte ich das Gefühl, es haßte mich jemand
in meiner Familie.
trifft auf mich überhaupt nicht zu (1)
trifft auf mich sehr selten zu (2)
trifft auf mich einige Male zu (3)
trifft auf mich häufig zu (4)
trifft auf mich sehr häufig zu (5)
19. ...fühlten sich meine Familienangehörigen
einander nah.
trifft auf mich überhaupt nicht zu (1)
trifft auf mich sehr selten zu (2)
trifft auf mich einige Male zu (3)
trifft auf mich häufig zu (4)
trifft auf mich sehr häufig zu (5)
20. ...versuchte jemand, mich sexuell zu
berühren oder mich dazu zu bringen, sie oder ihn
sexuell zu berühren.
trifft auf mich überhaupt nicht zu (1)
trifft auf mich sehr selten zu (2)
trifft auf mich einige Male zu (3)
trifft auf mich häufig zu (4)
trifft auf mich sehr häufig zu (5)
21.	...drohte mir jemand, mir weh zu tun oder
Lügen über mich zu erzählen, wenn ich keine
sexuellen Handlungen mit ihm oder ihr ausführen
würde.
trifft auf mich überhaupt nicht zu (1)
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trifft auf mich sehr selten zu (2)
trifft auf mich einige Male zu (3)
trifft auf mich häufig zu (4)
trifft auf mich sehr häufig zu (5)
22.	...hatte ich die beste Familie der Welt.
trifft auf mich überhaupt nicht zu (1)
trifft auf mich sehr selten zu (2)
trifft auf mich einige Male zu (3)
trifft auf mich häufig zu (4)
trifft auf mich sehr häufig zu (5)
23.	...versuchte jemand, mich dazu zu bringen,
sexuelle Dinge zu tun oder bei sexuellen Dingen
zuzusehen.
trifft auf mich überhaupt nicht zu (1)
trifft auf mich sehr selten zu (2)
trifft auf mich einige Male zu (3)
trifft auf mich häufig zu (4)
trifft auf mich sehr häufig zu (5)
24.	...belästigte mich jemand sexuell.
trifft auf mich überhaupt nicht zu (1)
trifft auf mich sehr selten zu (2)
trifft auf mich einige Male zu (3)
trifft auf mich häufig zu (4)
trifft auf mich sehr häufig zu (5)
25.	Ich glaube, ich bin emotional (gefühlsmäßig)
mißbraucht worden, als ich aufwuchs.
trifft auf mich überhaupt nicht zu (1)
trifft auf mich sehr selten zu (2)
trifft auf mich einige Male zu (3)
trifft auf mich häufig zu (4)
trifft auf mich sehr häufig zu (5)
26.	...gab es jemanden, der mich zum Arzt
brachte, wenn ich es brauchte.
trifft auf mich überhaupt nicht zu (1)
trifft auf mich sehr selten zu (2)
trifft auf mich einige Male zu (3)
trifft auf mich häufig zu (4)
trifft auf mich sehr häufig zu (5)
27.	Ich glaube, ich bin sexuell mißbraucht worden,
als ich aufwuchs.
trifft auf mich überhaupt nicht zu (1)
trifft auf mich sehr selten zu (2)
trifft auf mich einige Male zu (3)
trifft auf mich häufig zu (4)
trifft auf mich sehr häufig zu (5)
28. 	...war meine Familie mir eine Quelle der
Unterstützung.
trifft auf mich überhaupt nicht zu (1)
trifft auf mich sehr selten zu (2)
trifft auf mich einige Male zu (3)
trifft auf mich häufig zu (4)
trifft auf mich sehr häufig zu (5)
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NRS pain
Numerical Rating Scale Pain
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NRS pain
NRS_Schmerz
Leiden Sie unter Schmerzen?
Ja
Nein
Wenn ja, wie ausgeprägt sind Ihre Schmerzen
meistens / im Durchschnitt?
Kein Schmerz (0)
1 (1)
Maximal vorstellbarer Schmerz (10)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
7 (7)
8 (8)
9 (9)
Wenn ja, wie ausgeprägt sind Ihre schlimmsten
Schmerzen?
Kein Schmerz (0)
1 (1)
maximal vorstellbarer Schmerz (10)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
7 (7)
8 (8)
9 (9)
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Schauenburg H. [The OPD Structure Questionnaire (OPD-
SQ): first results on
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Welche Antwort trifft im Allgemeinen auf
Sie am besten zu?
1 Ich erlebe mich manchmal wie eine fremde
Person.
trifft gar nicht zu (0)
trifft eher nicht zu (1)
teils/teils (2)
trifft eher zu (3)
trifft völlig zu (4)
2 Wenn ich viel über mich nachdenke, gerate ich
eher in Verwirrung.
trifft gar nicht zu (0)
trifft eher nicht zu (1)
teils/teils (2)
trifft eher zu (3)
trifft völlig zu (4)
3 Wenn man andere zu nahe an sich heran lässt,
kann das gefährlich werden.
trifft gar nicht zu (0)
trifft eher nicht zu (1)
teils/teils (2)
trifft eher zu (3)
trifft völlig zu (4)
4 Ich kann mich anderen oft schwer verständlich
machen.
trifft gar nicht zu (0)
trifft eher nicht zu (1)
teils/teils (2)
trifft eher zu (3)
trifft völlig zu (4)
5 In mir herrscht oft ein solches Gefühlschaos,
dass ich es gar nicht beschreiben könnte.
trifft gar nicht zu (0)
trifft eher nicht zu (1)
teils/teils (2)
trifft eher zu (3)
trifft völlig zu (4)
6 Ich schätze manchmal falsch ein, wie mein
Verhalten auf andere wirkt.
trifft gar nicht zu (0)
trifft eher nicht zu (1)
teils/teils (2)
trifft eher zu (3)
trifft völlig zu (4)
7 Wenn andere viel über mich wissen, fühle ich
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mich oft irgendwie kontrolliert oder beobachtet.
trifft gar nicht zu (0)
trifft eher nicht zu (1)
teils/teils (2)
trifft eher zu (3)
trifft völlig zu (4)
8 Meine Gefühle sind manchmal so intensiv, dass
ich Angst bekomme.
trifft gar nicht zu (0)
trifft eher nicht zu (1)
teils/teils (2)
trifft eher zu (3)
trifft völlig zu (4)
9 Ich bin schon sehr verletzt worden, weil ich
mich in einem Menschen getäuscht hatte.
trifft gar nicht zu (0)
trifft eher nicht zu (1)
teils/teils (2)
trifft eher zu (3)
trifft völlig zu (4)
10 Es fällt mir schwer, zu anderen Kontakt
aufzunehmen.
trifft gar nicht zu (0)
trifft eher nicht zu (1)
teils/teils (2)
trifft eher zu (3)
trifft völlig zu (4)
11 Ich habe kein gutes Selbstbewusstsein.
trifft gar nicht zu (0)
trifft eher nicht zu (1)
teils/teils (2)
trifft eher zu (3)
trifft völlig zu (4)
12 Meine Erfahrung ist: Wenn man Menschen zu
sehr vertraut, kann man böse Überraschungen
erleben.
trifft gar nicht zu (0)
trifft eher nicht zu (1)
teils/teils (2)
trifft eher zu (3)
trifft völlig zu (4)
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Ressourcenrealisierung (RES)
Fragebogen zur Erfassung der aktuellen
Ressourcenrealisierung (RES)
Ausschnitt aus Trösken, A. & Grawe,K. (2004).
Inkongruenzerleben aufgrund brachliegender und fehlender
Ressourcen: Die Rolle von Ressourcenpotentialen und
Ressourcenrealisierung für die Psychologische Therapie.
Verhaltenstherapie & psychosoziale Praxis, 36, 51-62
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Ressourcenrealisierung (RES)
Während der letzten 4 Wochen habe ich
mich wohl gefühlt, weil ...
1 ... ich bei jemandem Geborgenheit und
Sicherheit gefunden habe.
nie (0)
1 (1)
2 (2)
zeitweise (3)
4 (4)
5 (5)
sehr häufig (6)
2 ... ich mit Freunden oder Bekannten zusammen
gewesen bin.
nie (0)
1 (1)
2 (2)
zeitweise (3)
4 (4)
5 (5)
sehr häufig (6)
3 ... ich mit meiner/m PartnerIn oder meiner
Familie zusammen gewesen bin.
nie (0)
1 (1)
2 (2)
zeitweise (3)
4 (4)
5 (5)
sehr häufig (6)
4 ... ich meinem Hobby nachgegangen bin.
nie (0)
1 (1)
2 (2)
zeitweise (3)
4 (4)
5 (5)
sehr häufig (6)
5 ... ich anregende und interessante Erlebnisse
gehabt habe.
nie (0)
1 (1)
2 (2)
zeitweise (3)
4 (4)
5 (5)
sehr häufig (6)
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6 ... ich etwas für meine Gesundheit und Fitneß
getan habe.
nie (0)
1 (1)
2 (2)
zeitweise (3)
4 (4)
5 (5)
sehr häufig (6)
7 ... ich mir Zeit genommen habe, mich auf mich
selbst zu besinnen.
nie (0)
1 (1)
2 (2)
zeitweise (3)
4 (4)
5 (5)
sehr häufig (6)
8 ... ich religiöse oder spirituelle Erlebnisse
gehabt habe.
nie (0)
1 (1)
2 (2)
zeitweise (3)
4 (4)
5 (5)
sehr häufig (6)
9 ... ich mich bewusst entspannt habe.
nie (0)
1 (1)
2 (2)
zeitweise (3)
4 (4)
5 (5)
sehr häufig (6)
10 ... ich etwas erledigt habe, was schon seit
einiger Zeit angestanden hat.
nie (0)
1 (1)
2 (2)
zeitweise (3)
4 (4)
5 (5)
sehr häufig (6)
11 ... ich etwas geleistet habe, auf das ich stolz
sein kann.
nie (0)
1 (1)
2 (2)
zeitweise (3)
4 (4)
5 (5)
sehr häufig (6)
12 ... ich etwas besonders Schönes
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unternommen habe.
nie (0)
1 (1)
2 (2)
zeitweise (3)
4 (4)
5 (5)
sehr häufig (6)
Wenn ich während der letzten 4 Wochen
Stress im Alltag erlebt habe, dann hat es
mir geholfen, ...
1 ... mir einen Überblick über die Situation zu
verschaffen.
nie (0)
1 (1)
2 (2)
zeitweise (3)
4 (4)
5 (5)
sehr häufig (6)
2 ... mich zu motivieren, indem ich mir meine
Ziele oder Fortschritte vor Augen geführt habe.
nie (0)
1 (1)
2 (2)
zeitweise (3)
4 (4)
5 (5)
sehr häufig (6)
3 ... Gespräche zu suchen.
nie (0)
1 (1)
2 (2)
zeitweise (3)
4 (4)
5 (5)
sehr häufig (6)
4 ... von anderen akzeptiert zu werden.
nie (0)
1 (1)
2 (2)
zeitweise (3)
4 (4)
5 (5)
sehr häufig (6)
5 ... mich zu entspannen.
nie (0)
1 (1)
2 (2)
zeitweise (3)
4 (4)
5 (5)
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sehr häufig (6)
6 ... Dampf abzulassen.
nie (0)
1 (1)
2 (2)
zeitweise (3)
4 (4)
5 (5)
sehr häufig (6)
7 ... meinem Hobby oder meinen Interessen
nachzugehen.
nie (0)
1 (1)
2 (2)
zeitweise (3)
4 (4)
5 (5)
sehr häufig (6)
8 ... meine Vorstellungen einzubringen.
nie (0)
1 (1)
2 (2)
zeitweise (3)
4 (4)
5 (5)
sehr häufig (6)
9 ... mich abzugrenzen.
nie (0)
1 (1)
2 (2)
zeitweise (3)
4 (4)
5 (5)
sehr häufig (6)
10 ... mir etwas zu gönnen.
nie (0)
1 (1)
2 (2)
zeitweise (3)
4 (4)
5 (5)
sehr häufig (6)
11 ... zu wissen, daß ich die Situation meistern
kann.
nie (0)
1 (1)
2 (2)
zeitweise (3)
4 (4)
5 (5)
sehr häufig (6)
12 ... mich zurückzuziehen.
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nie (0)
1 (1)
2 (2)
zeitweise (3)
4 (4)
5 (5)
sehr häufig (6)
13 ... zu wissen, daß die Belastung nur
vorübergehend ist.
nie (0)
1 (1)
2 (2)
zeitweise (3)
4 (4)
5 (5)
sehr häufig (6)
14 ... mich mit der Situation abzufinden.
nie (0)
1 (1)
2 (2)
zeitweise (3)
4 (4)
5 (5)
sehr häufig (6)
Während der letzten 4 Wochen habe ich
im Alltag Unterstützung erfahren, indem ...
1 ... jemand etwas mit mir zusammen
unternommen hat.
nie (0)
1 (1)
2 (2)
zeitweise (3)
4 (4)
5 (5)
sehr häufig (6)
2 ... mir jemand hilfreiche Kritik gegeben hat.
nie (0)
1 (1)
2 (2)
zeitweise (3)
4 (4)
5 (5)
sehr häufig (6)
3 ... mir jemand konkrete Perspektiven aufgezeigt
hat.
nie (0)
1 (1)
2 (2)
zeitweise (3)
4 (4)
5 (5)
sehr häufig (6)
4 ... mir jemand konkrete Hilfe angeboten hat.
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nie (0)
1 (1)
2 (2)
zeitweise (3)
4 (4)
5 (5)
sehr häufig (6)
5 ... mir jemand Vertrauen entgegen gebracht
hat.
nie (0)
1 (1)
2 (2)
zeitweise (3)
4 (4)
5 (5)
sehr häufig (6)
6 ... jemand Rücksicht auf mich genommen hat.
nie (0)
1 (1)
2 (2)
zeitweise (3)
4 (4)
5 (5)
sehr häufig (6)
7 ... Personen um mich herum gut miteinander
ausgekommen sind.
nie (0)
1 (1)
2 (2)
zeitweise (3)
4 (4)
5 (5)
sehr häufig (6)
8 ... mir jemand mitfühlend zugehört hat.
nie (0)
1 (1)
2 (2)
zeitweise (3)
4 (4)
5 (5)
sehr häufig (6)
9 ... mir jemand eine kleine Aufmerksamkeit
erwiesen hat.
nie (0)
1 (1)
2 (2)
zeitweise (3)
4 (4)
5 (5)
sehr häufig (6)
10 ... mich jemand ermutigt hat.
nie (0)
1 (1)
2 (2)
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zeitweise (3)
4 (4)
5 (5)
sehr häufig (6)
11 ... ich bei jemandem Dampf ablassen konnte.
nie (0)
1 (1)
2 (2)
zeitweise (3)
4 (4)
5 (5)
sehr häufig (6)
In einer früheren Krise hat es mir
geholfen, ...
1 ... meinen Alltag zu strukturieren.
nie (0)
1 (1)
2 (2)
zeitweise (3)
4 (4)
5 (5)
sehr häufig (6)
2 ... mir über meine Ziele klar zu werden.
nie (0)
1 (1)
2 (2)
zeitweise (3)
4 (4)
5 (5)
sehr häufig (6)
3 ... mir etwas zu gönnen.
nie (0)
1 (1)
2 (2)
zeitweise (3)
4 (4)
5 (5)
sehr häufig (6)
4 ... mir Zeit für mich zu nehmen.
nie (0)
1 (1)
2 (2)
zeitweise (3)
4 (4)
5 (5)
sehr häufig (6)
5 ... so sehr unter Druck zu kommen, daß ich
etwas unternehmen musste.
nie (0)
1 (1)
2 (2)
zeitweise (3)
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4 (4)
5 (5)
sehr häufig (6)
6 ... die Situation zu akzeptieren.
nie (0)
1 (1)
2 (2)
zeitweise (3)
4 (4)
5 (5)
sehr häufig (6)
7 ... meine Schwierigkeiten als Chance zu sehen.
nie (0)
1 (1)
2 (2)
zeitweise (3)
4 (4)
5 (5)
sehr häufig (6)
8 ... der Situation mit Humor zu begegnen.
nie (0)
1 (1)
2 (2)
zeitweise (3)
4 (4)
5 (5)
sehr häufig (6)
9 ... Geduld zu haben.
nie (0)
1 (1)
2 (2)
zeitweise (3)
4 (4)
5 (5)
sehr häufig (6)
10 ... Kraft aus meinem Glauben oder meiner
Spiritualität zu schöpfen.
nie (0)
1 (1)
2 (2)
zeitweise (3)
4 (4)
5 (5)
sehr häufig (6)
11 ... zeitweise bewusst an etwas anderes zu
denken.
12 ... mich mit Aktivitäten abzulenken.
nie (0)
1 (1)
2 (2)
zeitweise (3)
4 (4)
5 (5)
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sehr häufig (6)
13 ... professionelle Hilfe in Anspruch zu nehmen.
nie (0)
1 (1)
2 (2)
zeitweise (3)
4 (4)
5 (5)
sehr häufig (6)
14 ...zu erleben, wie jemand anderes mit einer
ähnlichen Situation umgegangen ist.
nie (0)
1 (1)
2 (2)
zeitweise (3)
4 (4)
5 (5)
sehr häufig (6)
15 ... meine Einstellung zu überdenken.
nie (0)
1 (1)
2 (2)
zeitweise (3)
4 (4)
5 (5)
sehr häufig (6)
16 ... zu denken, daß es mir im Vergleich zu
anderen Menschen immer noch gut geht.
nie (0)
1 (1)
2 (2)
zeitweise (3)
4 (4)
5 (5)
sehr häufig (6)
17 ... zu weinen.
nie (0)
1 (1)
2 (2)
zeitweise (3)
4 (4)
5 (5)
sehr häufig (6)
18 ... von anderen Menschen unterstützt zu
werden.
nie (0)
1 (1)
2 (2)
zeitweise (3)
4 (4)
5 (5)
sehr häufig (6)
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Während der letzten 4 Wochen bin ich
stolz auf mich gewesen, weil ....
1 ... ich für andere da gewesen bin, wenn sie
mich brauchten.
nie (0)
1 (1)
2 (2)
zeitweise (3)
4 (4)
5 (5)
sehr häufig (6)
2 ... ich von anderen Anerkennung bekommen
habe.
nie (0)
1 (1)
2 (2)
zeitweise (3)
4 (4)
5 (5)
sehr häufig (6)
3 ... ich eine gute Leistung erbracht habe.
nie (0)
1 (1)
2 (2)
zeitweise (3)
4 (4)
5 (5)
sehr häufig (6)
4 ... ich eigene Ängste überwinden konnte.
nie (0)
1 (1)
2 (2)
zeitweise (3)
4 (4)
5 (5)
sehr häufig (6)
5 ... ich mir etwas gönnen konnte.
nie (0)
1 (1)
2 (2)
zeitweise (3)
4 (4)
5 (5)
sehr häufig (6)
6 ... ich etwas für mein Wohlbefinden getan habe
(Hobby, Sport...).
nie (0)
1 (1)
2 (2)
zeitweise (3)
4 (4)
5 (5)
sehr häufig (6)
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7 ... ich mutig gewesen bin.
nie (0)
1 (1)
2 (2)
zeitweise (3)
4 (4)
5 (5)
sehr häufig (6)
8 ... ich alles ruhiger und gelassener als sonst
genommen habe.
nie (0)
1 (1)
2 (2)
zeitweise (3)
4 (4)
5 (5)
sehr häufig (6)
9 ... ich mich auf eine wichtige Situation gut
vorbereitet habe.
nie (0)
1 (1)
2 (2)
zeitweise (3)
4 (4)
5 (5)
sehr häufig (6)
10 ... ich meine Meinung gut vertreten konnte.
nie (0)
1 (1)
2 (2)
zeitweise (3)
4 (4)
5 (5)
sehr häufig (6)
11 ... ich etwas Unangenehmes oder
Aufgeschobenes erledigt habe.
nie (0)
1 (1)
2 (2)
zeitweise (3)
4 (4)
5 (5)
sehr häufig (6)
12 ... ich kreativ gewesen bin.
nie (0)
1 (1)
2 (2)
zeitweise (3)
4 (4)
5 (5)
sehr häufig (6)
13 ... ich mich gut konzentrieren konnte.
nie (0)
1 (1)
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2 (2)
zeitweise (3)
4 (4)
5 (5)
sehr häufig (6)
Es ist eine Stärke von mir, daß...
1 ... ich ein Hobby oder besondere Interessen
habe.
nie (0)
1 (1)
2 (2)
zeitweise (3)
4 (4)
5 (5)
sehr häufig (6)
2 ... ich geradlinig bin.
nie (0)
1 (1)
2 (2)
zeitweise (3)
4 (4)
5 (5)
sehr häufig (6)
3 ... ich offen für neue Erfahrungen bin.
nie (0)
1 (1)
2 (2)
zeitweise (3)
4 (4)
5 (5)
sehr häufig (6)
4 ... ich anderen Menschen Mitgefühl
entgegenbringe.
nie (0)
1 (1)
2 (2)
zeitweise (3)
4 (4)
5 (5)
sehr häufig (6)
5 ... ich zuversichtlich in die Zukunft schaue.
nie (0)
1 (1)
2 (2)
zeitweise (3)
4 (4)
5 (5)
sehr häufig (6)
6 ... ich viele schöne Sachen erleben kann.
nie (0)
1 (1)
2 (2)
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zeitweise (3)
4 (4)
5 (5)
sehr häufig (6)
7 ... ich geduldig bin.
nie (0)
1 (1)
2 (2)
zeitweise (3)
4 (4)
5 (5)
sehr häufig (6)
8 ... ich temperamentvoll bin.
nie (0)
1 (1)
2 (2)
zeitweise (3)
4 (4)
5 (5)
sehr häufig (6)
9 ... ich Phantasie habe.
nie (0)
1 (1)
2 (2)
zeitweise (3)
4 (4)
5 (5)
sehr häufig (6)
10 ... ich gut mit Menschen umgehen kann.
nie (0)
1 (1)
2 (2)
zeitweise (3)
4 (4)
5 (5)
sehr häufig (6)
11 ... ich gut Probleme lösen kann.
nie (0)
1 (1)
2 (2)
zeitweise (3)
4 (4)
5 (5)
sehr häufig (6)
12 ... ich selbstbewusst auftrete.
nie (0)
1 (1)
2 (2)
zeitweise (3)
4 (4)
5 (5)
sehr häufig (6)
13 ... ich den Dingen kritisch auf den Grund
13 / 22
Ressourcenrealisierung (RES)
gehe.
nie (0)
1 (1)
2 (2)
zeitweise (3)
4 (4)
5 (5)
sehr häufig (6)
14 ... ich eine rasche Auffassungsgabe habe.
nie (0)
1 (1)
2 (2)
zeitweise (3)
4 (4)
5 (5)
sehr häufig (6)
15 ... ich körperlich fit bin.
nie (0)
1 (1)
2 (2)
zeitweise (3)
4 (4)
5 (5)
sehr häufig (6)
16 ... ich mich attraktiv kleide.
nie (0)
1 (1)
2 (2)
zeitweise (3)
4 (4)
5 (5)
sehr häufig (6)
17 ... ich selbstständig für mich sorgen kann.
nie (0)
1 (1)
2 (2)
zeitweise (3)
4 (4)
5 (5)
sehr häufig (6)
18 ... ich einen guten Geschmack habe.
nie (0)
1 (1)
2 (2)
zeitweise (3)
4 (4)
5 (5)
sehr häufig (6)
19 ... ich zu meinen Schwächen stehen kann.
nie (0)
1 (1)
2 (2)
zeitweise (3)
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4 (4)
5 (5)
sehr häufig (6)
20 ... ich Humor habe.
nie (0)
1 (1)
2 (2)
zeitweise (3)
4 (4)
5 (5)
sehr häufig (6)
21 ... ich zielstrebig handle.
nie (0)
1 (1)
2 (2)
zeitweise (3)
4 (4)
5 (5)
sehr häufig (6)
Gegenwärtige Beziehungen
Welche Person steht Ihnen zur Zeit am
nächsten?
PartnerIn (1)
FreundIn (2)
Mutter (3)
Vater (4)
Schwester (5)
Bruder (6)
eigenes Kind (7)
andere (8)
andere
Meine Beziehungen zu dieser Person ist
zur Zeit dadurch gekennzeichnet, daß...
1 ... wir Verständnis für einander haben.
nie (0)
1 (1)
2 (2)
zeitweise (3)
4 (4)
5 (5)
sehr häufig (6)
2 ... wir uns vertrauen.
nie (0)
1 (1)
2 (2)
zeitweise (3)
4 (4)
5 (5)
sehr häufig (6)
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3 ... wir gerne miteinander Gespräche führen.
nie (0)
1 (1)
2 (2)
zeitweise (3)
4 (4)
5 (5)
sehr häufig (6)
4 ... wir den Kontakt zueinander aufrecht
erhalten.
nie (0)
1 (1)
2 (2)
zeitweise (3)
4 (4)
5 (5)
sehr häufig (6)
5 ... wir uns durch unsere Unterschiede
gegenseitig anregen.
nie (0)
1 (1)
2 (2)
zeitweise (3)
4 (4)
5 (5)
sehr häufig (6)
6 ... wir einen ähnlichen Humor haben.
nie (0)
1 (1)
2 (2)
zeitweise (3)
4 (4)
5 (5)
sehr häufig (6)
7 ... wir ähnliche Ansichten oder Interessen
haben.
nie (0)
1 (1)
2 (2)
zeitweise (3)
4 (4)
5 (5)
sehr häufig (6)
8 ... wir ähnliche Erfahrungen in der
Vergangenheit gemacht haben.
nie (0)
1 (1)
2 (2)
zeitweise (3)
4 (4)
5 (5)
sehr häufig (6)
9 ... sie/ er ein Vorbild für mich ist.
nie (0)
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1 (1)
2 (2)
zeitweise (3)
4 (4)
5 (5)
sehr häufig (6)
10 ... ich ihr/ ihm gegenüber offen und ehrlich
sein kann.
nie (0)
1 (1)
2 (2)
zeitweise (3)
4 (4)
5 (5)
sehr häufig (6)
11 ... ich für sie/ ihn Zärtlichkeit empfinde.
nie (0)
1 (1)
2 (2)
zeitweise (3)
4 (4)
5 (5)
sehr häufig (6)
12 ... wir Erotik und Sexualität teilen.
nie (0)
1 (1)
2 (2)
zeitweise (3)
4 (4)
5 (5)
sehr häufig (6)
13 ... wir für einander da sind, wenn wir einander
brauchen.
nie (0)
1 (1)
2 (2)
zeitweise (3)
4 (4)
5 (5)
sehr häufig (6)
14 ... wir viel Zeit miteinander verbringen.
nie (0)
1 (1)
2 (2)
zeitweise (3)
4 (4)
5 (5)
sehr häufig (6)
15 ... ich mich ihr/ ihm sehr vertraut fühle.
nie (0)
1 (1)
2 (2)
zeitweise (3)
4 (4)
17 / 22
Ressourcenrealisierung (RES)
5 (5)
sehr häufig (6)
16 ... wir Schwierigkeiten gemeinsam überwinden
können.
nie (0)
1 (1)
2 (2)
zeitweise (3)
4 (4)
5 (5)
sehr häufig (6)
Eigenschaften von belastbaren
Angehörigen aus der Herkunftsfamilie
Bitte geben Sie zunächst an, welche
Angehörigen aus Ihrer Herkunftsfamilie Sie als
besonders belastbar oder stabil erlebt haben:
Mutter (1)
Tante(Vater) (10)
Onkel(Mutter) (11)
Onkel(Vater) (12)
andere Person (13)
niemand (14)
Vater (2)
Großmutter(Mutter) (3)
Großmutter(Vater) (4)
Großvater(Mutter) (5)
Großvater(Vater) (6)
Schwester (7)
Bruder (8)
Tante(Mutter) (9)
Eigenschaften von belastbaren
Angehörigen aus der Herkunftsfamilie:
Mein/e ...
1 ... konnte ihre/ seine Fähigkeiten verwirklichen.
nie (0)
1 (1)
2 (2)
zeitweise (3)
4 (4)
5 (5)
sehr häufig (6)
2 ... konnte vieles ertragen.
nie (0)
1 (1)
2 (2)
zeitweise (3)
4 (4)
5 (5)
sehr häufig (6)
... hat hart gearbeitet.
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nie (0)
1 (1)
2 (2)
zeitweise (3)
4 (4)
5 (5)
sehr häufig (6)
4 ... war offen und vertrauenerweckend.
nie (0)
1 (1)
2 (2)
zeitweise (3)
4 (4)
5 (5)
sehr häufig (6)
5 ... war körperlich gesund.
nie (0)
1 (1)
2 (2)
zeitweise (3)
4 (4)
5 (5)
sehr häufig (6)
6 ... konnte ihre/ seine Gefühle ausdrücken.
nie (0)
1 (1)
2 (2)
zeitweise (3)
4 (4)
5 (5)
sehr häufig (6)
7 ... hat ihre/ seine Prinzipien selbstbewusst
vertreten.
nie (0)
1 (1)
2 (2)
zeitweise (3)
4 (4)
5 (5)
sehr häufig (6)
8 ... war für uns Kinder - bzw. für mich als Kind -
da.
nie (0)
1 (1)
2 (2)
zeitweise (3)
4 (4)
5 (5)
sehr häufig (6)
9 ... hat die Verantwortung für die Familie
getragen.
nie (0)
1 (1)
2 (2)
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zeitweise (3)
4 (4)
5 (5)
sehr häufig (6)
10 ... war verlässlich.
nie (0)
1 (1)
2 (2)
zeitweise (3)
4 (4)
5 (5)
sehr häufig (6)
11 ... war diszipliniert.
nie (0)
1 (1)
2 (2)
zeitweise (3)
4 (4)
5 (5)
sehr häufig (6)
12 ... hat Verständnis für mich gehabt.
nie (0)
1 (1)
2 (2)
zeitweise (3)
4 (4)
5 (5)
sehr häufig (6)
13 ... hat an mich geglaubt.
nie (0)
1 (1)
2 (2)
zeitweise (3)
4 (4)
5 (5)
sehr häufig (6)
14 ... konnte aus schwierigen Situationen das
Beste machen.
nie (0)
1 (1)
2 (2)
zeitweise (3)
4 (4)
5 (5)
sehr häufig (6)
15 ... war fröhlich und herzlich.
nie (0)
1 (1)
2 (2)
zeitweise (3)
4 (4)
5 (5)
sehr häufig (6)
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Zur Zeit finde ich Sinn in meinem Leben,
indem ...
1 ...ich Einfluss - z.B. auf wichtige
Entscheidungen - nehme.
nie (0)
1 (1)
2 (2)
zeitweise (3)
4 (4)
5 (5)
sehr häufig (6)
2 ... ich gute Leistungen erbringe.
nie (0)
1 (1)
2 (2)
zeitweise (3)
4 (4)
5 (5)
sehr häufig (6)
3 ... ich mich bemühe, mit anderen Menschen gut
auszukommen.
nie (0)
1 (1)
2 (2)
zeitweise (3)
4 (4)
5 (5)
sehr häufig (6)
4 ... ich für andere da bin, wenn sie mich
brauchen.
nie (0)
1 (1)
2 (2)
zeitweise (3)
4 (4)
5 (5)
sehr häufig (6)
5 ... ich auf meine Gesundheit achte.
nie (0)
1 (1)
2 (2)
zeitweise (3)
4 (4)
5 (5)
sehr häufig (6)
6 ... ich mich mit meinem Glauben oder
Spiritualität auseinandersetze.
nie (0)
1 (1)
2 (2)
zeitweise (3)
4 (4)
5 (5)
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sehr häufig (6)
7 ... ich selbstständig mein Leben meistere.
nie (0)
1 (1)
2 (2)
zeitweise (3)
4 (4)
5 (5)
sehr häufig (6)
8 ... ich mir konkrete Ziele setze, die ich erreichen
möchte.
nie (0)
1 (1)
2 (2)
zeitweise (3)
4 (4)
5 (5)
sehr häufig (6)
9 ... ich mir für nahestehende Personen
(PartnerIn, Familie, Freunde) viel Zeit nehme.
nie (0)
1 (1)
2 (2)
zeitweise (3)
4 (4)
5 (5)
sehr häufig (6)
10 ... ich mein Hobby ausübe.
nie (0)
1 (1)
2 (2)
zeitweise (3)
4 (4)
5 (5)
sehr häufig (6)
11 ... ich mich vielfältig interessiere.
nie (0)
1 (1)
2 (2)
zeitweise (3)
4 (4)
5 (5)
sehr häufig (6)
12 ... ich mich für die Entwicklung meiner
Persönlichkeit engagiere.
nie (0)
1 (1)
2 (2)
zeitweise (3)
4 (4)
5 (5)
sehr häufig (6)
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Quality assurance Pressure Ulcers (Decubitus)
Prophylaxis - Pressure Ulcer (AQUA)
Form imported via medical-data-models.org API-version 1
All rights reserved. Please visit https://medical-data-
models.org/forms/9983
Quality assurance Pressure Ulcers
(Decubitus) Prophylaxis - Pressure
Ulcer (AQUA)
Pressure Ulcer
Number of Pressure Ulcer? (1 ... 99)*
Scale and location of pressure ulcers*
side of lokalisation*
both sides (B)
not specified side location (K)
left side (L)
right side (R)
Was the pressure ulcer present on admission?*
No: No diagnosis at the admission to
hospital (0)
Yes: diagnosis existed at admission to
hospital (1)
Unknown, the result of incomplete
documentation (9)
Was the pressure ulcer present on discharge?*
No: diagnosis was not present on
discharge (0)
Yes: diagnosis was present on
discharged (1)
Unknown, the result of incomplete
documentation (9)
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Quality assurance Hip Replacement - Hip
Fracture (AQUA)
Form imported via medical-data-models.org API-version 1
All rights reserved. Please visit https://medical-data-
models.org/forms/9984
Quality assurance Hip Replacement
- Hip Fracture (AQUA)
Number of interventions femoral fracture
near hip joint
What number endoprosthetic treatment of
femoral fracture near the hip joint incl.
periprosthetic fracture during this stay?*
Anamnesis
Previous surgery of the hip or near hip joint*
Yes
No
pre-existing coxarthrosis*
Yes
No
fracture event*
was reason for the acute hospitalization
(1)
only occurred during the acute inpatient
stay (2)
Date of fracture (only in fractures during the
acute inpatient stay) (dd.mm.yyyy)
time of fracture (hh:mm)
fracture localization*
medial (1)
lateral (2)
pertrochantär (3)
other (9)
femoral fracture near hip - classification by
garden
abduction fracture (1)
unshifted (2)
shifted (3)
completely shifted (4)
Patient was admitted with antithrombotic
Extended therapy*
Yes
No
Type of medication
vitamin K antagonists (eg
phenprocoumon, warfarin) (1)
acetylsalicylic acid (2)
other antiplatelet agents (eg clopidogrel,
1 / 2
prasugrel, ticagrelor, cilostazol) (3)
direct thrombin inhibitors (eg argatroban,
dabigatran) (4)
other (eg rivaroxaban, fondaparinux) (9)
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Anal Cancer NCT00324415 Response - AMC-045
Response Assessment Forms (RA1; RA2) - 2514651v1.0
Cisplatin, Fluorouracil, Cetuximab, and Radiation Therapy
in Treating Patients With HIV and Stage I, Stage II, or
Stage III Anal Cancer
NCT00324415
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=1BB34737-
57FC-61F2-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/9991
Response Assessment Forms (RA1;
RA2 AMC-045)
Header
Visit number
Target Lesions (RA1)
Date of Evaluation
Are there any target lesions
Yes
No
Target Lesion Site
Method of Evaluation
CT Scan (1)
Gallium scan (10)
Bone scan (11)
other (12)
Physical exam (2)
Palpation (3)
Biopsy (4)
MRI scan (5)
PET scan (6)
PET/CT scan (7)
X-ray (8)
Ultrasound (9)
Other Specify (Method of Evaluation)
Longest Diameter of Lesion
Sum of longest diameters of all target lesions
Nontarget Lesions
Are there any non-target lesions?
Yes
No
Nontarget Lesion Site
1 / 2
Follow-up status of nontarget lesion
Complete response (1)
Stable Disease (2)
Progressive disease (3)
Response Assessment Form (ra2)
Evaluable for response
Yes
No
Objective Status at This Evaluation
Complete Response (complete
response)
Partial Response (partial response)
Progressive Disease (progressive
disease)
Stable Disease (stable disease)
Unevaluable (unevaluable)
Is complete response first observed
Yes
No
Complete Response (CR) First Observed Date
Is partial response first observed
Yes
No
Partial Response (PR) First Observed Date
Has the patient been diagnosed with a new
progression?
Yes
No
Progressive Disease First Observed Date
Sites of Progression
Comments
Comments
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Breast Cancer NCT00016276 Treatment - CALGB: 49808 TREATMENT
SUMMARY FORM HERCEPTIN VS OBSERVATION - 2032660v3.0
Combination Chemotherapy, Surgery, and Radiation
Therapy With or Without Dexrazoxane and Trastuzumab in
Treating Women With Stage III or Stage IV Breast Cancer
NCT00016276 
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=9E35395C-
8C3D-227A-E034-080020C9C0E0
All rights reserved. Please visit https://medical-data-
models.org/forms/9994
TREATMENT SUMMARY FORM
HERCEPTIN VS OBSERVATION
Header
CALGB Form
CALGB Study No
CALGB Patient ID
Amended data?
Yes
No
Patient's Name
Participating Group
Patient Hospital Number
Participating Group Protocol No.
Main Member Institution/Adjunct
Participating Group Patient No.
Comments
Treatment Plan
Is patient taking Herceptin?
Yes
No
Initial dose this reporting period (Total dose in mg
Herceptin if randomized)
Last date protocol therapy was given
Number of completed weeks during this reporting
period
1 / 3
Reason Treatment Ended (mark one with an X)
Alternative therapy (Alternative therapy)
Death on study (Death on study)
Disease progression/relapse during
active treatment (Disease
progression/relapse during active
treatment)
Not applicable (Not applicable)
Other complicating disease (Other
complicating disease)
Other, specify (Other, specify)
Patient withdrawal or refusal after
beginning protocol therapy (Patient
withdrawal or refusal after beginning
protocol therapy)
Patient withdrawal or refusal prior to
beginning protocol therapy (Patient
withdrawal or refusal prior to beginning
protocol therapy)
Toxicity/side effects/complications
(Toxicity/side effects/complications)
Treatment completed per protocol criteria
(Treatment completed per protocol
criteria)
Reason Treatment Ended Other, specify
Treatment Schedule - Systemic Therapy
Were there any dose modifications or additions/
omissions to protocol treatment? (mark one with
an X)
No (0)
Yes, planned (1)
Yes, Unplanned (2)
Were any optional protocol therapies given?
Yes
No
Optional Protocol Therapy Name
Were any non-protocol therapies given during
protocol treatment?
Yes
No
Concurrent Non-Protocol Chemotherapy?
Yes
No
Concurrent Non-Protocol Hormonal Therapy?
Yes
No
Concurrent Non-Protocol Biologic Response
Modifier Therapy?
Yes
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No
Concurrent Non-Protocol Radiation Therapy?
Yes
No
Concurrent Non-Protocol High Dose
Chemotherapy/Autologous Stem Cell Transplant?
Yes
No
Did this patient receive any tamoxifen?
Yes
No
Did patient begin taking tamoxifen during this
reporting period? (If Yes)
Yes
No
If Yes, date tamoxifen started
Is the patient still receiving tamoxifen?
Yes
No
If patient discontinued tamoxifen since last follow-
up, give date.
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Brain and Central Nervous System Tumors NCT00053963 Treatment -
ADVL0212: Reporting Period Worksheet (Leukemia) - 2172521v3.0
ADVL0212: Reporting Period Worksheet (Leukemia)
FR901228 in Treating Children With Refractory or
Recurrent Solid Tumors or Leukemia
NCT00053963
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=C0F387DC-
C9D3-5664-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/9995
Reporting Period Worksheet
(Leukemia ADVL0212)
Header
COG Study Number
Institution Name
COG Patient ID
Patient's Initials
Reporting Period Number
Reporting Period start date
Reporting Period End date
Comments
Patient characteristics
Height
Weight
Was patient's bone marrow status evaluated
during this reporting interval?
Yes
No
what was the date of exam?
does patient have bone marrow involvement?
Yes
No
Was patients shortening fraction determined by
echocardiogram?
Yes
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No
what is the percentage?
Is patient off protocol therapy at the end of this
reporting period?
Yes
No
date of last dose for this reporting period
reason treatment ended
Progressive disease (1)
Disease Progression Before Active
Treatment (10)
Other (11)
Patient Off-treatment For Other
Complicating Disease (12)
Patient Withdrawal Or Refusal After
Beginning Protocol Therapy (13)
Patient Withdrawal Or Refusal Before
Beginning Protocol Therapy (14)
Treatment Completed Per Protocol
Criteria (15)
Irreversible dose-limiting toxicity (2)
Patient withdrawal from protocol (3)
Off Study (4)
Alternative Therapy (5)
Lost To Follow-up (6)
Death On Study (7)
Cytogenetic Resistance (8)
Disease Progression, Relapse During
Active Treatment (9)
Did resting heart rate increase by 35%?
Yes
No
Did patient experience any of the following: SVT,
atrial fibrillation, or atrial flutter?
check all that apply
Atrial fibrillation (Atrial fibrillation)
Atrial flutter (Atrial flutter)
SVT (SVT)
Did patient experience prolonged QTc compared
to baseline?
check all that apply
To greater than or equal to 480 msec (1)
Increase of greater than or equal to 50
msec (2)
Increase by 15 % (3)
Was there a T wave inversion in leads II, III, AVF
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(inferior leads) or V4, V5, and V6 (lateral leads)?
Yes
No
Was ST segment at the J-point greater than or
equal to 2 mm below baseline in leads II, II AVF
(inferior leads), V4, V5, V6 (lateral leads)?
Yes
No
Did patient experience ventricular arrhythmia?
Was there a change in Troponin I?
Was there a change to LVEF?
No (0)
Yes, decrease by greater than or equal to
25%, but not below 40% (1)
Yes, decrease to less than or equal to
40% (2)
What was the patient's bone marrow status at the
end of this reporting period?
Treatment
Agent name
Total mg dose of Depsipeptide received during
this reporting period
Were any of the infusions of Depsipeptide
interrupted for any reason?
Yes
No
please state the time point of the interruption
Was there a deviation from protocol therapy?
Unknown (-1)
No (0)
Yes, protocol specified modification for
toxicity (1)
Yes non-protocol specified modification
for toxicity (2)
Yes, other reason for deviation (3)
Yes, Planned (i.e., The Treatment Was
Changed According To Protocol
Guidelines) (4)
Yes, Unplanned (i.e., The Treatment
Change Was Not Part Of Protocol
Guidelines) (5)
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Did the patient receive radiation therapy during
this reporting period?
Yes
No
Specify sites
Was tumor tissue surgically obtained for biology
studies (e.g. biopsy, resection, fine needle
aspiration)?
Yes
No
please describe.
Concomitant Medication
Did patient receive concomitant medications
while on protocol therapy?
Yes
No
Type
Anti-convulsant (Anti-Convulsant)
Anti-fungal (Anti-Fungal)
Corticosteroid (Corticosteroid)
Growth Factor (Growth factor)
Other Specify (Other, specify)
please list type
Start Date
End Date
Description
Reason for Administration
New Cancer
Has a new primary cancer of MDS been
diagnosed that has not been previously reported?
Yes
No
New Cancer Diagnosis Date
Follow-Up
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Vital Status
Alive (Alive)
Dead (Dead)
Was the patient unable to be contacted for
current scheduled follow-up?
Yes
No
Was patient enrolled on another COG therapeutic
study at the end of this reporting period?
Yes
No
Was patient's consent withdrawn?
Yes
No
Did patient relapse or experience disease
progression during this reporting period?
Yes
No
date of relapse or progression
Adverse event
Category
Blood/bone Marrow (Blood/Bone
Marrow)
Cardiovascular (arrhythmia)
(Cardiovascular (Arrhythmia))
Constitutional Symptoms (Constitutional
Symptoms)
Gastrointestinal (Gastrointestinal)
Hepatic (Hepatic)
Infection Febrile Neutropenia
(Infection/Febrile Neutropenia)
Metabolic/laboratory
(Metabolic/Laboratory)
Other, specify [unnamed category]
(Other)
Renal/genitourinary
(Renal/Genitourinary)
Other, specify [unnamed category]
Type
Nausea (0)
Vomiting Nos (1)
Blood Creatine Phosphokinase
Increased (10)
Other, specify [unnamed type] (11)
Febrile Neutropenia (2)
Neutropenia (3)
Aspartate Aminotransferase Increased
(4)
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Alanine Aminotransferase Increased (5)
Blood Creatinine Increased (6)
Platelet Count Decreased (7)
Ventricular Arrhythmia Nos (8)
Fatigue (9)
Other, specify [unnamed type]
Code
Neutrophils/granulocytes (anc/agc) (146)
Platelets (148)
Ventricular Arrhythmia Nos (181)
Fatigue (262)
Nausea (408)
Vomiting (426)
Sgot (ast) (481)
Sgpt (alt) (482)
Febrile Neutropenia (494)
Creatinine Phosphokinase (cpk) (532)
Creatinine (784)
Other, Specify (Other)
Other, specify [unnamed code]
Grade
Attribution
Unrelated (1)
Unlikely (2)
Possible (3)
Probable (4)
Definite (5)
Adverse Drug Experience?
Yes
No
Dose Limiting Toxicity?
Yes
No
Date Onset
Date of test or evaluation showing toxicity
resolved to eligibility requirements or baseline
check box if not resolved [toxicity]
No (No)
Not Applicable (Not applicable)
Yes (Yes)
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Der Notfalldatensatz der eGK nfdm
nfdm of eGK
All rights reserved. Please visit https://medical-data-
models.org/forms/9998
Der Notfalldatensatz der eGK
Notfalldatensatz
Letzte_Aktualisierung*
Versionskennung*
Zusätzliche_Information
Freitext*
Diagnose_1
Diagnose_Code*
Diagnosesicherheit*
Seitenlokalisation*
Text_Diagnose*
Zeitpunkt_Diagnosestellung*
Fremdbefund*
Ja
Nein
Identifier_Codiersystem_Diagnose_1
Versionskennung*
Diagnose_2
Diagnose_Code*
Diagnosesicherheit*
Seitenlokalisation*
Text_Diagnose*
Zeitpunkt_Diagnosestellung*
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Fremdbefund*
Ja
Nein
Identifier_Codiersystem_Diagnose_2
Versionskennung*
Diagnose_3
Diagnose_Code*
Diagnosesicherheit*
Seitenlokalisation*
Text_Diagnose*
Zeitpunkt_Diagnosestellung*
Fremdbefund*
Ja
Nein
Identifier_Codiersystem_Diagnose_3
Versionskennung*
Diagnose_4
Diagnose_Code*
Diagnosesicherheit*
Seitenlokalisation*
Text_Diagnose*
Zeitpunkt_Diagnosestellung*
Fremdbefund*
Ja
Nein
Identifier_Codiersystem_Diagnose_4
Versionskennung*
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Diagnose_5
Diagnose_Code*
Diagnosesicherheit*
Seitenlokalisation*
Text_Diagnose*
Zeitpunkt_Diagnosestellung*
Fremdbefund*
Ja
Nein
Identifier_Codiersystem_Diagnose_5
Versionskennung*
Diagnose_6
Diagnose_Code*
Diagnosesicherheit*
Seitenlokalisation*
Text_Diagnose*
Zeitpunkt_Diagnosestellung*
Fremdbefund*
Ja
Nein
Identifier_Codiersystem_Diagnose_6
Versionskennung*
Diagnose_7
Diagnose_Code*
Diagnosesicherheit*
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Seitenlokalisation*
Text_Diagnose*
Zeitpunkt_Diagnosestellung*
Fremdbefund*
Ja
Nein
Identifier_Codiersystem_Diagnose_7
Versionskennung*
Diagnose_8
Diagnose_Code*
Diagnosesicherheit*
Seitenlokalisation*
Text_Diagnose*
Zeitpunkt_Diagnosestellung*
Fremdbefund*
Ja
Nein
Identifier_Codiersystem_Diagnose_8
Versionskennung*
Diagnose_9
Diagnose_Code*
Diagnosesicherheit*
Seitenlokalisation*
Text_Diagnose*
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Zeitpunkt_Diagnosestellung*
Fremdbefund*
Ja
Nein
Identifier_Codiersystem_Diagnose_9
Versionskennung*
Diagnose_10
Diagnose_Code*
Diagnosesicherheit*
Seitenlokalisation*
Text_Diagnose*
Zeitpunkt_Diagnosestellung*
Fremdbefund*
Ja
Nein
Identifier_Codiersystem_Diagnose_10
Versionskennung*
Diagnose_11
Diagnose_Code*
Diagnosesicherheit*
Seitenlokalisation*
Text_Diagnose*
Zeitpunkt_Diagnosestellung*
Fremdbefund*
Ja
Nein
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Identifier_Codiersystem_Diagnose_11
Versionskennung*
Diagnose_12
Diagnose_Code*
Diagnosesicherheit*
Seitenlokalisation*
Text_Diagnose*
Zeitpunkt_Diagnosestellung*
Fremdbefund*
Ja
Nein
Identifier_Codiersystem_Diagnose_12
Versionskennung*
Diagnose_13
Diagnose_Code*
Diagnosesicherheit*
Seitenlokalisation*
Text_Diagnose*
Zeitpunkt_Diagnosestellung*
Fremdbefund*
Ja
Nein
Identifier_Codiersystem_Diagnose_13
Versionskennung*
Diagnose_14
Diagnose_Code*
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Diagnosesicherheit*
Seitenlokalisation*
Text_Diagnose*
Zeitpunkt_Diagnosestellung*
Fremdbefund*
Ja
Nein
Identifier_Codiersystem_Diagnose_14
Versionskennung*
Diagnose_15
Diagnose_Code*
Diagnosesicherheit*
Seitenlokalisation*
Text_Diagnose*
Zeitpunkt_Diagnosestellung*
Fremdbefund*
Ja
Nein
Identifier_Codiersystem_Diagnose_15
Versionskennung*
Diagnose_16
Diagnose_Code*
Diagnosesicherheit*
Seitenlokalisation*
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Text_Diagnose*
Zeitpunkt_Diagnosestellung*
Fremdbefund*
Ja
Nein
Identifier_Codiersystem_Diagnose_16
Versionskennung*
Diagnose_17
Diagnose_Code*
Diagnosesicherheit*
Seitenlokalisation*
Text_Diagnose*
Zeitpunkt_Diagnosestellung*
Fremdbefund*
Ja
Nein
Identifier_Codiersystem_Diagnose_17
Versionskennung*
Diagnose_18
Diagnose_Code*
Diagnosesicherheit*
Seitenlokalisation*
Text_Diagnose*
Zeitpunkt_Diagnosestellung*
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Fremdbefund*
Ja
Nein
Identifier_Codiersystem_Diagnose_18
Versionskennung*
Diagnose_19
Diagnose_Code*
Diagnosesicherheit*
Seitenlokalisation*
Text_Diagnose*
Zeitpunkt_Diagnosestellung*
Fremdbefund*
Ja
Nein
Identifier_Codiersystem_Diagnose_19
Versionskennung*
Diagnose_20
Diagnose_Code*
Diagnosesicherheit*
Seitenlokalisation*
Text_Diagnose*
Zeitpunkt_Diagnosestellung*
Fremdbefund*
Ja
Nein
Identifier_Codiersystem_Diagnose_20
Versionskennung*
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Allergie_Unverträglichkeiten_1
Text_Allergie_Unverträglichkeit*
Arzneimittel*
Reaktion*
Fremdbefund*
Ja
Nein
Allergie_Unverträglichkeiten_2
Text_Allergie_Unverträglichkeit*
Arzneimittel*
Reaktion*
Fremdbefund*
Ja
Nein
Allergie_Unverträglichkeiten_3
Text_Allergie_Unverträglichkeit*
Arzneimittel*
Reaktion*
Fremdbefund*
Ja
Nein
Allergie_Unverträglichkeiten_4
Text_Allergie_Unverträglichkeit*
Arzneimittel*
Reaktion*
Fremdbefund*
Ja
Nein
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Allergie_Unverträglichkeiten_5
Text_Allergie_Unverträglichkeit*
Arzneimittel*
Reaktion*
Fremdbefund*
Ja
Nein
Allergie_Unverträglichkeiten_6
Text_Allergie_Unverträglichkeit*
Arzneimittel*
Reaktion*
Fremdbefund*
Ja
Nein
Allergie_Unverträglichkeiten_7
Text_Allergie_Unverträglichkeit*
Arzneimittel*
Reaktion*
Fremdbefund*
Ja
Nein
Allergie_Unverträglichkeiten_8
Text_Allergie_Unverträglichkeit*
Arzneimittel*
Reaktion*
Fremdbefund*
Ja
Nein
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Allergie_Unverträglichkeiten_9
Text_Allergie_Unverträglichkeit*
Arzneimittel*
Reaktion*
Fremdbefund*
Ja
Nein
Allergie_Unverträglichkeiten_10
Text_Allergie_Unverträglichkeit*
Arzneimittel*
Reaktion*
Fremdbefund*
Ja
Nein
Behandelnder_Arzt_Institution_1
Vorname_Arzt*
Name_Arzt*
Institutionsbezeichnung*
Telefonnummer*
Behandelnder_Arzt_Institution_2
Vorname_Arzt*
Name_Arzt*
Institutionsbezeichnung*
Telefonnummer*
Behandelnder_Arzt_Institution_3
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Vorname_Arzt*
Name_Arzt*
Institutionsbezeichnung*
Telefonnummer*
Einverständniserklärung_Arzt
Vorname*
Name*
Adresse*
Zu_benachrichtigende_Person_Institution
_1
Vorname*
Name*
Telefonnummer*
Zu_benachrichtigende_Person_Institution
_2
Vorname*
Name*
Telefonnummer*
Zu_benachrichtigende_Person_Institution
_3
Vorname*
Name*
Telefonnummer*
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Versicherter
Versicherter_ID*
Vorname*
Name*
Vorsatzwort*
Namenzusatz*
Titel*
Geburtsdatum*
Besondere_Hinweise
Schwangerschaft*
Ja
Nein
Kommunikationsstörungen_1*
Kommunikationsstörungen_2*
Kommunikationsstörungen_3*
Kommunikationsstörungen_4*
Kommunikationsstörungen_5*
Weglaufgefährdung*
Sonstige_Hinweise*
Schwangerschaft
Errechneter_Entbindungstermin*
Implantate_1
Implantate*
Typenbezeichnung*
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Fremdbefund*
Ja
Nein
Datum_Implantation*
Implantate_2
Implantate*
Typenbezeichnung*
Fremdbefund*
Ja
Nein
Datum_Implantation*
Implantate_3
Implantate*
Typenbezeichnung*
Fremdbefund*
Ja
Nein
Datum_Implantation*
Implantate_4
Implantate*
Typenbezeichnung*
Fremdbefund*
Ja
Nein
Datum_Implantation*
Implantate_5
Implantate*
Typenbezeichnung*
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Fremdbefund*
Ja
Nein
Datum_Implantation*
Implantate_6
Implantate*
Typenbezeichnung*
Fremdbefund*
Ja
Nein
Datum_Implantation*
Implantate_7
Implantate*
Typenbezeichnung*
Fremdbefund*
Ja
Nein
Datum_Implantation*
Implantate_8
Implantate*
Typenbezeichnung*
Fremdbefund*
Ja
Nein
Datum_Implantation*
Implantate_9
Implantate*
Typenbezeichnung*
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Fremdbefund*
Ja
Nein
Datum_Implantation*
Implantate_10
Implantate*
Typenbezeichnung*
Fremdbefund*
Ja
Nein
Datum_Implantation*
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Aids-related Malignancies NCT00695422 On-Study
- AMC-058 Missed Visit Form (F35) - 3063630v1.0
AMC-058 Missed Visit Form (F35)
Detecting Anal and Genital Human Papillomavirus Infection
and Squamous Intraepithelial Lesions in HIV-Positive
Patients Enrolled in AIDS Cancer Clinical Trials
NCT00695422 
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=84985F78-
ADFC-9672-E040-BB89AD43767C
All rights reserved. Please visit https://medical-data-
models.org/forms/9999
Missed Visit Form (NCT00695422
F35 AMC-058 )
Header Module
Visit number
Comments
Missed Visit Information
Missed Visit Date
Reason patient missed visit
Patient Forgot (1)
Other (10)
Health Reasons (2)
Patient Could Not Get Off Work (3)
Patient Unable To Obtain Dependent
Care (4)
Patient Had Transportation Problems (5)
Patient Unhappy With Frequency Of
Visits (6)
Scheduling Difficulties (7)
Patient Decided To Discontinue Study (8)
Patient Experienced An Adverse Event
(9)
Other, specify
Next visit scheduled (Items missed will be made
up at the new visit.)
Yes
No
1 / 1
Leukemia NCT00843882 On-Study - E2905 Baseline
Step 2 Disease Evaluation Form - 2774237v1.0
Lenalidomide With or Without Epoetin Alfa in Treating
Patients With Myelodysplastic Syndrome and Anemia
NCT00843882 
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=54590A88-
E5FE-3BDA-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/10001
Baseline Step 2 Disease Evaluation
Form (E2905 NCT00843882)
Header
ECOG Protocol Number
ECOG Patient ID
DCI Name
Registration Step
Report period
Patient Initials (Last, First)
Participating Group Protocol Number
Participating Group Patient ID
Institution/Affiliate
Please mark an 'X' if data have been amended.
(Please circle amended items in red)
Date data amended (MM/DD/YYYY)
Investigator Signature
Investigator Signature Date
Pre-registration Hematology/chemistry
Hemoglobin (Hgb), LLN
Hemoglobin (Hgb)
Date
1 / 3
Peripheral platelet count, LLN
Peripheral Platelet Count
Date (MM/DD/YYYY)
Peripheral Granulocytes Count LLN
Peripheral Granulocytes Count (AGC/ANC/mm^3
- Do not report % granulocytes: report absolute
count without decimal.)
Date
Peripheral WBC Count
Peripheral WBC count, LLN
Date
Creatinine
Creatinine ULN
Date
Mean pre-transfusion hemoglobin
Bone marrow biopsy
Date of Bone Marrow Biopsy (Aspirate)
Marrow Blasts (%) (Highest)
Marrow Cellularity (%) (If Marrow Cellularity %
has been left blank please code the following to
indicate the reason for leaving it blank.)
Reason bone marrow cellularity was not recorded
Cellularity Status Of Bone Marrow
Unknown, Procedure Resulted In No
Material To Analyze (Dry Tap or
inaspirable)
Local Pathologist Did Not Quantify
Cellularity (Local pathologist did not
quantify cellularity)
2 / 3
Leukemia NCT00843882 On-Study - E2905 Baseline Step 2 Disease
Evaluation Form - 2774237v1.0
Dysplasia
No (No)
Unknown (Unknown)
Yes (Yes)
Specify type
Erythroid (1)
Megakaryocyte (2)
Myeloid (3)
Is cytogenetic abnormality present now
Inevaluable (-1)
No (0)
Yes (1)
International Prognostic Score
Date (Highest - Record earliest date of the
values)
Karyotype (Highest)
Good (1)
Intermediate (2)
Poor (3)
Number of Cytopenias (Highest - Red blood cells-
Hemoglobin <10 g/dl - White blood cells-
Absolute neutrophil count <1800/microliter -
Platelets- Platelet count <100,000/ microliter)
International Prognostic Score (IPSS) (Highest)
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Leukemia NCT00843882 On-Study - E2905 Baseline Step 2 Disease
Evaluation Form - 2774237v1.0
AIDS-Related Lymphoma NCT00310128 Treatment - Lymphoma
Disease Activity and Measurement: L01, L02, L03 - 2402629v3.0
Combination Chemotherapy Followed by Rituximab and
Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients
With Relapsed or Refractory AIDS-Related Non-Hodgkin's
Lymphoma
NCT00310128
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=001EB1B6-
5458-308C-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/10002
Lymphoma Disease Activity and
Measurement (L01, L02, L03
NCT00310128)
Header
Visit Number
Reporting Period
Baseline (Baseline)
Follow-up (Follow-up)
On Treatment (On treatment)
Is there lymph node involvement
Yes
No
Nodal involvement evaluation--Lymphoma
Disease Activity and Measurement (L01)
Lymph Node Type
Celiac Axis/retrocrural/upper Para-aortic
(Celiac Axis/Retrocrular/Upper Para-
Aortic)
Cervical (Cervical)
Epitrochlear/brachial
(Epitrochlear/Brachial)
Hilar (Hilar)
Inguinal/femoral/iliac
(Iliac/Inguinal/Femoral)
Infraclavicular/axillary/pectoral
(Infraclavicular/Axiliary/Pectoral)
Lower Para-aortic (Lower Para-Aortic)
Mediastinal (Mediastinal)
Mesenteric (Mesenteric)
Other (Other Nodal)
Porta Hepatis (Porta Hepatis)
Pre-auricular (Pre-Auricular)
Spleen (Spleen)
Splenic Hilar (Splenic Hilar)
Supraclavicular (Supraclavicular)
Waldeyer's Ring (Waldeyer's Ring)
Other specify (If)
Dimension 1
Dimension 2
1 / 4
Method of Evaluation
Gallium Scan (Gallium scan)
Other (Other)
Pet Scan (PET scan)
Other, specify (If)
Complete response
Yes
No
Is measurable disease present?
Yes
No
Has the patient been diagnosed with a new
progression?
Yes
No
Evaluation documented
Yes
No
Lesion Assessment
Improvement (improvement)
No Change (no change)
Not Evaluated (Not evaluated)
Progression - Increase (progression -
increase)
Extra nodal involvement evaluation--
Lymphoma Disease Activity and
Measurement (L02)
Extranodal extension
Yes
No
Site of Involvement
Ascites (Ascites)
Bone (Bone)
Bone Marrow (Bone Marrow)
Brain (Brain)
Epidural (Epidural)
Gastrointestinal Tract (GI Tract)
Kidney (Kidney)
Liver (Liver)
Lung (Lung)
Meninges (Meninges)
Other Specify (Other)
Pleura (Pleura)
Skin (Skin)
Thyroid (Thyroid)
Other, specify (If)
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AIDS-Related Lymphoma NCT00310128 Treatment - Lymphoma Disease
Activity and Measurement: L01, L02, L03 - 2402629v3.0
Extra Nodal Involvement Evaluation
Objective Status at This Evaluation
Complete Response (Complete
response)
Complete Response Uncertain
(complete response uncertain)
Partial Response (Partial response)
Progressive Disease (progressive
disease)
Stable Disease (stable disease)
Unevaluable (unevaluable)
Date of Evaluation (response)
What is the present status of the best response
No Relapse Observed, But Patent Died
(No relapse observed, but patent died)
Not Applicable (Not applicable)
Relapse Occurred After A Response
Was Achieved (Relapse occurred after a
response was achieved)
Response Continuing Or First Time At
This Response (Response continuing or
first time at this response)
Extra Nodal Involvement Evaluation
Is complete response first observed
Yes
No
Complete Response (CR) First Observed Date (If
yes)
Is complete response confirmed (CR)
Yes
No
Complete Response Confirmed Date
Extra Nodal Involvement Evaluation
Is complete response uncertain first observed
Yes
No
Complete Response uncertain (CRu) First
Observed Date
Is complete response, uncertain, confirmed
(CRU)
Yes
No
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AIDS-Related Lymphoma NCT00310128 Treatment - Lymphoma Disease
Activity and Measurement: L01, L02, L03 - 2402629v3.0
Complete Response Uncertain (CRu) Confirmed
Date
Extra Nodal Involvement Evaluation
Is partial response first observed
Yes
No
Partial Response (PR) First Observed Date
Is partial response confirmed
Yes
No
Partial Response Confirmed Date
Extra Nodal Involvement Evaluation
Was a gallium scan, PET scan, or other
functional imaging study done
Yes
No
Other, specify (If)
Date of scan
Imaging Result
Equivocal (Equivocal)
Involved (involved)
Negative (Negative)
Date of relapse or progression (if applicable)
Please indicate the site of progression
New Site Only (New site only)
New Site Plus Original Site (New site
plus original site)
Original Site Only (Original site only)
Central Nervous System Progression
Yes
No
CNS - leptomeninges
Yes
No
Brain - parenchymal
Yes
No
Comments
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AIDS-Related Lymphoma NCT00310128 Treatment - Lymphoma Disease
Activity and Measurement: L01, L02, L03 - 2402629v3.0
Quality assurance Hip Replacement
-Elective First Implantation (AQUA)
Form imported via medical-data-models.org API-version 1
All rights reserved. Please visit https://medical-data-
models.org/forms/10003
Quality assurance Hip Replacement
-Elective First Implantation (AQUA)
Number of interventions Elective first hip
endoprostheses implantation
What number elective hip endoprosthesis primary
implantation during this stay*
Anamnesis
Previous surgery of hip joint or near hip*
Yes
No
Pain*
no (0)
yes, stress pain (1)
yes, rest pain (2)
Modified Kellgren & Lawrence Score
osteophytes*
no or questionable (0)
clearly (1)
large (2)
Articular space*
not or questionable narrowed (0)
clearly narrowed (1)
advanced narrowed (2)
repealed (3)
sclerosis*
no sclerosis (0)
slight sclerosis (1)
slight sclerosis with cyst formation (2)
sclerosis with cysts (3)
deformation*
no deformation (0)
slight deformation (1)
significant deformation (2)
Severity of joint destruction in rheumatic
diseases
If there is a disease of the rheumatic diseases
localized on the affected side?*
Yes
No
erosive joint destruction (severity according to
Larsen-Dale-Eek)
1 / 2
grade 0 normal (0)
grade 1 slight change (1)
grade 2 definite change (2)
grade 3 distinct change (3)
grade 4 severe change (4)
grade 5 multilierende change (5)
2 / 2
Quality assurance Hip Replacement -Elective First Implantation (AQUA)
Quality assurance Knee Replacement - (partial
)Endoprosthesis Replacement (AQUA)
Form imported via medical-data-models.org API-version 1
All rights reserved. Please visit https://medical-data-
models.org/forms/10007
Quality assurance Knee
Replacement - (partial
)Endoprosthesis Replacement
(AQUA)
Changing or replacing components -
number of interventions
What number change-operation during this stay?*
two-stage exchange*
Yes
No
Preoperative pain history
Pain*
no (0)
yes, stress pain (1)
yes, rest pain (2)
Pathogen- / detection of infection
positive signs of inflammation in the laboratory
before prosthesis explantation (ESR, CRP,
leukocytes)*
Yes
No
microbiological examination before prosthesis
explantation*
not done (0)
performed negatively (1)
performed positively (2)
histopathological examination / diagnosis
(according to consensus classification of
Neosynovialis / periprosthetic membrane) before
Prothesenexplantation preoperatively*
not done (0)
no pathological findings (1)
abrasion-induced type (type I) (2)
infectious type (type II) (3)
mixed type (type III) (4)
indifference type (type IV) (5)
Radiologic diagnostic / clinical findings
Existing of specific radiological / clinical
findings?*
Yes
No
patella pain
1 / 2
yes (1)
patella luxation
yes (1)
patella necrosis
yes (1)
with sliding prosthesis or part replacement
prosthesis: increase in osteoarthritis
yes (1)
Instability of the posterior cruciate ligament
yes (1)
Instability of the collateral ligament
yes (1)
Implants (sub) luxation
yes (1)
periprosthetic fracture
yes (1)
Loss of substance tibia
yes (1)
Loss of substance femur
yes (1)
Relaxation of the patella component
septic (1)
aseptically (2)
Loosening of the tibial component
septic (1)
aseptically (2)
Loosening of the femoral component
septic (1)
aseptically (2)
implant migration
ja (1)
Implant malposition / malrotation
yes (1)
Implant abrasion / Defect of the PE inlay
yes (1)
Implant breakage
yes (1)
Other
yes (1)
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Quality assurance Knee Replacement - (partial )Endoprosthesis
Replacement (AQUA)
Quality assurance Hip Replacement -
Replacement of Endoprosthesis (AQUA)
Form imported via medical-data-models.org API-version 1
All rights reserved. Please visit https://medical-data-
models.org/forms/10008
Quality assurance Hip Replacement
- Replacement of Endoprosthesis
(AQUA)
Number of interventions/change
What number change-operation during this stay?*
two-stage exchange*
Yes
No
Anamnesis / diagnosis
Pain*
no (0)
yes, stress pain (1)
yes, rest pain (2)
Signs of inflammation / pathogen- /
detection of infection
positive signs of inflammation in the laboratory
before prosthesis explantation (ESR, CRP,
leukocytes)*
Yes
No
microbiological examination before prosthesis
explantation*
not done (0)
performed negatively (1)
performed positively (2)
histopathological examination / diagnosis
(according to consensus classification of
Neosynovialis / periprosthetic membrane) before
Prothesenexplantation preoperatively*
not done (0)
no pathological findings (1)
abrasion-induced type (type I) (2)
infectious type (type II) (3)
mixed type (type III) (4)
indifference type (type IV) (5)
Radiologic diagnostic / clinical findings
Existing of specific radiological / clinical
findings?*
Yes
No
Inflammation of the cartilage defect (Cotyloiditis)
acetabulum, eg after duohead-prostheses -
1 / 2
implantation
yes (1)
large bone defect of the femur (from distal to the
trochanter minors)
yes (1)
large bone defect acetabulum
yes (1)
(recurrent) Implants (sub) luxation
yes (1)
periprosthetic fracture
yes (1)
Osteolysis of femur
yes (1)
Osteolysis of acetabulum
yes (1)
Loosening the stem component
yes (1)
Loosening of the acetabular component
yes (1)
Implant malposition of the shaft
yes (1)
Implant malposition of acetabulum
yes (1)
Implant abrasion / wear and tear
yes (1)
Implant breakage
yes (1)
periarticular ossification
yes (1)
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Quality assurance Hip Replacement - Replacement of Endoprosthesis
(AQUA)
Anal Cancer NCT00324415 On-Study - AMC-045 History
of AIDS Defining Disease Form (F03) - 2937261v1.0
Cisplatin, Fluorouracil, Cetuximab, and Radiation Therapy
in Treating Patients With HIV and Stage I, Stage II, or
Stage III Anal Cancer
NCT00324415 
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=72873427-
47DC-3052-E040-BB89AD43686C
All rights reserved. Please visit https://medical-data-
models.org/forms/10009
History of AIDS Defining Disease
Form (F03, AMC-045 NCT00324415
)
Header Module
Visit number
History of AIDS Defining Disease
Date of Evaluation
History of opportunistic diseases and
predisposing disease
Yes
No
Disease Type
Candidiasis Of Bronchi, Trachea Or
Lungs (Candidiasis of bronchi, trachea or
lungs)
Candidiasis, Esophageal (Candidiasis,
esophageal)
Cervical Cancer (Cervical cancer,
invasive)
Cmv Other Than Liver, Spleen Or Nodes,
Onset At Age >1month (CMV other than
liver, spleen or nodes, onset at age
>1month)
Cmv Retinitis (CMV retinitis)
Coccidioidomycosis, Disseminated Or
Extrapulmonary (Coccidioidomycosis,
disseminated or extrapulmonary)
Cryptococcosis (Cryptococcosis,
extrapulmonary)
Cryptosporidiosis, Chronic Intestinal
(Cryptosporidiosis, chronic intestinal)
Encephalopathy (Encephalopathy, HIV-
related)
Herpes Simplex: Chronic Ulcers (> 1
Month's Duration) Or Bronchitis,
Pneumonitis Or Esophagitis (onset At
Age > 1 Month) (Herpes simplex: chronic
ulcers (> 1 month's duration) or
bronchitis, pneumonitis or esophagitis
(onset at age > 1 month))
Histoplasmosis, Disseminated Or
Extrapulmonary (Histoplasmosis,
disseminated or extrapulmonary)
1 / 2
Isosporiasis, Chronic Intestinal (> 1 Mon)
(Isosporiasis, chronic intestinal (> 1
mon))
Kaposi's Sarcoma Aids Related
(Kaposi's sarcoma)
Lymphoma, Primary, Of Brain
(Lymphoma, primary, of brain)
Non-hodgkin's Lymphoma (Lymphoma,
systemic non-Hodgkin's)
Mycobacterium Avium Complex Or
Mycobacterium Kansasii Disseminated
Or Extrapulmonary (Mycobacterium
avium complex or Mycobacterium
kansasii disseminated or
extrapulmonary)
Mycobacterium Tuberculosis Of Any Site,
Pulmonary, Disseminated Or
Extrapulmonary (Mycobacterium
tuberculosis of any site, pulmonary,
disseminated or extrapulmonary)
Mycobacterium, Other Species Or
Unidentified Species, Disseminated Or
Extrapulmonary (Mycobacterium, other
species or unidentified species,
disseminated or extrapulmonary)
Pneumocystis Jirovecii Pneumonia
(Pneumocystis jirovecii pneumonia)
Pneumonia (Pneumonia, recurrent)
Progressive Multifocal
Leukoencephalopathy (pml) (Progressive
multifocal leukoencephalopathy)
Salmonella Septicemia, Recurrent
(Salmonella septicemia, recurrent)
Toxoplasmosis Of The Brain, Onset At
Age >1month (Toxoplasmosis of the
brain, onset at age >1month)
Wasting Syndrome, Due To Hiv (Wasting
syndrome, due to HIV)
Disease status (Please select the disease status
of the diseases listed)
Active (Currently active)
Present (Ever present)
Never Present (Never present)
Comments
2 / 2
Anal Cancer NCT00324415 On-Study - AMC-045 History of AIDS
Defining Disease Form (F03) - 2937261v1.0
Anal Cancer NCT00550589 Lab - AMC-046
HIV Viral Load Form (F40) - 2933354v1.0
AMC-046 HIV Viral Load Form (F40)
Cidofovir in Treating HIV-Infected Patients With High-Grade
Squamous Intraepithelial Lesions of the Skin Near the Anus
NCT00550589
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=715886E9-
A905-36FE-E040-BB89AD430F6F
All rights reserved. Please visit https://medical-data-
models.org/forms/10010
HIV Viral Load Form (F40 AMC-046
NCT00550589)
Header Module
Visit number
HIV Viral Load
Results of HIV viral load assay  (Enter results
from right to left.)
) (Equal to ()
Greater Than (>) (Greater than (>))
Less Than (Less than (<))
Undetectable (Undetectable)
HIV viral load value
Method of detection
Abbott Realtime Hiv-1 Assay (Abbott
RealTime HIV-1 assay)
Cobas Ampliprep/taqman Hiv-1 Assay
(COBAS AmpliPrep/TAQMAN HIV-1
assay)
Other (Other)
Roche Amplicor Monitor Assay (Roche
Amplicor Monitor Assay)
Versant Hiv-1 Rna Assay By Branched
Dna (Versant HIV-1 RNA assay by
branched DNA)
Other, specify
HIV viral load assay type
Standard (Standard)
Ultra (Ultra)
Limits of detection
Lab Facility Name (Testing Laboratory
information)
Comments
1 / 1
Anal Cancer NCT00550589 Registration - AMC-046
Enrollment Form (ENR) Segment A - 2685912v1.0
Cidofovir in Treating HIV-Infected Patients With High-Grade
Squamous Intraepithelial Lesions of the Skin Near the Anus
NCT00550589 
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=3BC16E2A-
1509-2256-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/10011
Enrollment Form (ENR) Segment A
(AMC-046  NCT00550589)
Header Module
Principal Investigator
Age
Date Informed Consent Signed
Comments
Inclusion Criteria
Inclusion Criteria
Date Of Informed Consent (Date of
informed consent)
Does The Investigator Believe That The
Participant Is Capable Of Complying
With The Protocol (Does the investigator
believe that the participant is capable of
complying with the protocol)
3 months (Does the participant have a
life expectancy >)
Does The Participant Have
Documentation Of Hiv-1 Infection By Any
Licensed Elisa Test Kit And Confirmed
By Western Blot At Any Time Prior To
Study Entry (Does the participant have
documentation of HIV-1 infection by any
licensed ELISA test kit and confirmed by
Western blot at any time prior to study
entry)
Does The Participant Have The Ability
And Willingness To Give Informed
Consent (Does the participant have the
ability and willingness to give informed
consent)
If Female, And Of Childbearing Potential,
Has The Participant Had A Negative
Urine Pregnancy Test Within The Past 7
Days (If female, and of childbearing
potential, has the participant had a
negative urine pregnancy test within the
past 7 days)
Participant's Age (in Years) (Participant's
age (in years))
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Exclusion Criteria
Exclusion Criteria
Does The Participant Have Concurrent
Neoplasia Requiring Cytotoxic Therapy
(Does the participant have concurrent
neoplasia requiring cytotoxic therapy)
Does The Participant Have Untreated
Invasive Cancer Of The Lower Genital
Tract (Does the participant have
untreated invasive cancer of the lower
genital tract)
Is The Participant Pregnant Or Breast-
feeding (Is the participant pregnant or
breast-feeding)
Is The Participant Receiving
Corticosteroid Treatment, Other Than
Replacement Doses (Is the participant
receiving corticosteroid treatment, other
than replacement doses)
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Anal Cancer NCT00550589 Registration - AMC-046 Enrollment Form
(ENR) Segment A - 2685912v1.0
Quality assurance Knee Replacement -
First Implantation (AQUA)
Form imported via medical-data-models.org API-version 1
All rights reserved. Please visit https://medical-data-
models.org/forms/10013
Quality assurance Knee
Replacement - First Implantation
(AQUA)
Knee endoprostheses first implantation -
number of interventions
What number of knee endoprosthesis primary
implantation during this stay?*
Preoperation
Previous surgery knee joint or near knee joint*
Yes
No
Preoperative pain history
Pain*
no (0)
yes, stress pain (1)
yes, rest pain (2)
Modified Kellgren & Lawrence Score
osteophytes*
no or incipient eminence or joint-side
patella pole (0)
clearly (1)
Articular space*
no or moderately narrowed (0)
narrowed in half (1)
pronounced narrowed or eliminated (2)
sclerosis*
no sclerosis (0)
moderate subchondral sclerosis (1)
pronounced subchondral sclerosis (2)
sclerosis with cysts femur, tibia, patella
(3)
deformation*
no deformation (0)
unrounding of the femoral condyles (1)
pronounced destruction, deformity (2)
Implantation of a knee sled prostheses
Is the implantation of a knee sled prostheses
intended?*
Yes
No
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Other joint compartments intact
Yes
No
Severity of joint destruction in rheumatic
diseases
If there is a disease of the rheumatic diseases
with manifestation of the affected joint?*
Yes
No
Erosive joint destruction (severity according to
Larsen-Dale-Eek)
grade 0 normal (0)
grade 1 slight change (1)
grade 2 definite change (2)
grade 3 distinct change (3)
grade 4 severe change (4)
grade 5 multilierende change (5)
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Quality assurance Knee Replacement - First Implantation (AQUA)
Anal Cancer NCT00550589 On-Study - AMC-
046 HPV On-Study Form (ONS) - 2989612v1.0
Cidofovir in Treating HIV-Infected Patients With High-Grade
Squamous Intraepithelial Lesions of the Skin Near the Anus
NCT00550589
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=7D8985E5-
2FE1-08A5-E040-BB89AD434A3B
All rights reserved. Please visit https://medical-data-
models.org/forms/10015
On-Study Form (ONS) AMC-046
HPV
Header Module
Visit number
Comments
HIV History
Date of HIV+ diagnosis
CDC HIV Risk Group
Hemophilia (Hemophiliac)
Heterosexual Contact (Heterosexual
contact)
Homosexual Or Bisexual Contact
(Homosexual or bisexual contact)
Iv Drug User (IV drug user)
Other (Other)
Transfusion Recipient (Transfusion
recipient)
Other, specify
Perianal high-grade squamous intraepithelial
lesions (HSIL) biopsy confirmed date
Prior systemic chemotherapy or radiation therapy
Yes
No
Does the participant have a history of high
grade dysplasia
Anal canal
Yes
No
Perianal
Yes
No
Penile
Not Available (N/A)
No (NO)
1 / 3
Yes (YES)
Scrotal
Not Available (N/A)
No (NO)
Yes (YES)
Vulvar
Not Available (N/A)
No (NO)
Yes (YES)
Cervical
Not Available (N/A)
No (NO)
Yes (YES)
Vaginal
Not Available (N/A)
No (NO)
Yes (YES)
Prior Therapy
Prior Treatment? (If "Yes", Check below)
Yes
No
Prior Cautery
Yes
No
Prior trichloroacetic acid (TCA)
Yes
No
Treatment Date
Specify (If "Yes")
Prior Surgery
Yes
No
Prior cryotherapy
Yes
No
Prior topical/intralesional therapy
Yes
No
Other Prior Therapy (e.g. Hyperthermia, etc.)
Yes
No
Specify (If "Yes")
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Name of other prior therapies (If "Yes")
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Breast Cancer NCT00053898 Registration - NSABP
PROTOCOL B-35: REGISTRATION FORM - 2033723v3.0
NSABP PROTOCOL B-35: REGISTRATION FORM
Anastrozole or Tamoxifen in Treating Postmenopausal
Women With Ductal Carcinoma in Situ Who Are
Undergoing Lumpectomy and Radiation Therapy
NCT00053898
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=A053033F-
8CE7-05B1-E034-080020C9C0E0
All rights reserved. Please visit https://medical-data-
models.org/forms/10019
REGISTRATION FORM NSABP
(PROTOCOL B-35 NCT00053898)
Header
Patient Study ID
Patient Medical Record Number
Institution Name
Institution Number
Affiliate Name
Physician of Record (physician to whom study
drug will be sent; must have a valid FDA Number)
Date Informed Consent Signed
Projected Start Date of Treatment (Study Drug
Month Day Year)
Person Completing Form Last Name
Person Completing Form First Name
Person Completing Form Phone
Person Completing Form Fax
Patient Name (Last, First, MI Last First MI)
Patient's Date of Birth  (Month Day Year)
Patient's Social Security Number (USA only)
Race Categories
American Indian Or Alaska Native
(American Indian or Alaska Native)
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Asian (Asian)
Black (Black)
Black or African American (Black or
African American)
Native Hawaiian Or Other Pacific
Islander (Native Hawaiian or Other
Pacific Islander)
Unknown (Unknown)
White (White)
Ethnic Categories
Hispanic (Hispanic)
Hispanic Or Latino (Hispanic or Latino)
Non-hispanic (Non-Hispanic)
Unknown (Unknown)
Method of Payment
Medicaid (Medicaid)
Medicaid & Medicare (Medicaid &
Medicare)
Medicare (Medicare)
Medicare & Private (Medicare & Private)
Military or Veterans Sponsored NOS
(Military or Veterans Sponsored NOS)
Military Sponsored (incl. CHAMPUS &
TRICARE) (Military Sponsored (incl.
CHAMPUS & TRICARE))
No means of payment (no insurance)
(No means of payment (no insurance))
Other (Other)
Private Insurance (Private Insurance)
Self pay (no insurance) (Self pay (no
insurance))
Unknown (Unknown)
Veterans Sponsored (Veterans
Sponsored)
Country of Residence (if not USA)
Canada (Canada)
Mexico (Mexico)
Other (Other)
Puerto Rico (Puerto Rico)
Other
Patient's zip code (USA)
Patient data
Performance Status
Fully active, able to carry on all pre-
disease performance without restriction
(Karnofsky 90-100) (0)
Restricted in physically strenous activity
but ambulatory (K 70-80) (1)
Ambulatory and capable of all selfcare
but unable to carry out any work
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activities (K 50-60) (2)
Capable of only limited selfcare, confined
to bed or chair more than 50% of waking
hours (K 30-40) (3)
Completely disabled (K 10-20) (4)
Age at Registration
Patient Height (cm)
Patient Weight
WBC
SGOT (AST)
Total bilirubin
Alkaline phosphatase
Serum creatinine
Eligibility Checklist
In the opinion of the investigator, is the patient
eligible?
Yes
No
Verification of Postmenopausal Status (Select the
item that best describes the patient.)
Bilateral Oophorectomy (1)
No Bilateral Oophorectomy And No
Hysterectomy: And > 12 Months Since
LMP (2)
Hysterectomy But No Bilateral
Oophorectomy: And Age at least 55 At
Randomization (3)
Hysterectomy But No Bilateral
Oophorectomy: And Age below 55 At
Randomization And FSH Within The
Postmenopausal Range As Determined
By The Investigator (4)
None Of The Above (ineligible) (5)
Date of Last Surgery for Breast Cancer Treatment
(Must be within 84 days of randomization)
Surgical Treatment And Pathology
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Did the patient undergo lumpectomy?
Yes
No
Was the patient diagnosed with invasive or
microinvasive breast cancer?
Yes
No
Did the patient have ductal carcinoma in situ
(DCIS) on histologic examination?
Yes
No
Are the final margins of the resected specimen
histologically free of DCIS?
Yes
No
Were there any clinically or mammographically
suspicious masses or clusters of calcification?
Yes
No
If item 5 is yes, were these suspicious masses or
clusters of calcification biopsied?
Yes
No
If item 5a is yes, are the margins histologically
free of DCIS?
Yes
No
Are there suspicious palpable nodes in the
ipsilateral or contralateral axilla? ([If item 6 is yes,
attach pathologic documentation that these are
not involved with tumor])
Yes
No
Are there palpable supraclavicular or
infraclavicular nodes? ([If item 7 is yes, attach
pathologic documentation that these are not
involved with tumor])
Yes
No
Is there a bilateral malignancy or a mass or
mammographic abnormality in the opposite
breast that is suspicious for malignancy? ([If item
8 is yes, attach pathologic documentation that
this is not malignant])
Yes
No
Did the patient have one or more ipsilateral
axillary nodes or intramammary nodes that were
positive for tumor on histologic examination?
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Yes
No
Did the patient undergo mastectomy?
Yes
No
Other Treatment
Has systemic or radiation therapy been given for
the current DCIS?
Yes
No
Has the patient previously taken, or is the patient
currently taking, aromatase inhibitors or
tamoxifen for treatment or prevention of any
disease?
Yes
No
Is the patient currently taking raloxifene (Evista
[R])or other selective estrogen receptor
modulators (SERMs)? ([Circle "no" if this therapy
is discontinued prior to randomization.])
Yes
No
Has the patient been taking any sex hormonal
therapy, e.g. estrogen or progesterone
replacement therapy, oral contraceptives,
androgens, etc.? ([See Protocol, Section 5.2.11])
Yes
No
If item 14 is yes, was this therapy discontinued
prior to randomization?
Yes
No
Contraindications
Has the patient ever been diagnosed with a non-
breast malignancy?
Yes
No
If item 16 is yes, has the patient been disease-
free for at least 5 years?
Yes
No
If item 16a is no, was the diagnosis squamous or
basal cell carcinoma of the skin which was
effectively treated, carcinoma in situ of the cervix
that has been treated by surgery alone, or lobular
carcinoma in situ (LCIS) of the ipsilateral or
contralateral breast
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Yes
No
Does the patient have a prior history of
documented cerebral vascular accident or
documented transient ischemic attack?
Yes
No
Does the patient have a nonmalignant systemic
disease (cardiovascular, renal, hepatic, etc.) that
would preclude her being subjected to protocol
therapy or would prevent prolonged follow-up?
Yes
No
Does the patient have a psychiatric or addictive
disorder which would preclude obtaining informed
consent?
Yes
No
Does the patient have a prior history of invasive
breast cancer or DCIS?
Yes
No
Does the patient have uncontrolled hypertension?
Yes
No
Does the patient have uncontrolled diabetes?
Yes
No
Does the patient have atrial fibrillation, not
controlled by medication?
Yes
No
Pre-entry Studies
Has the patient had a history and physical in the
last 6 months?
Yes
No
Has the patient had a bilateral mammogram
within the past 12 months?
Yes
No
Has the patient had a hysterectomy?
Yes
No
If item 26 is no, has the patient had a pelvic exam
within the past 12 months?
Yes
No
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Breast Cancer combination chemotherapies
(NCT00024102)
Comparison of Combination Chemotherapy Regimens in
Treating Older Women Who Have Undergone Surgery for
Breast Cancer
NCT00024102
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=A50D6435-
FF10-3254-E034-080020C9C0E0
All rights reserved. Please visit https://medical-data-
models.org/forms/10024
ORIENTATION-MEMORY-
CONCENTRATION TEST FORM
(CALGB, NCT00024102)
Header
CALGBForm
CALGBStudyNo
CALGBPatientID
DateCompleted
Amended data
Yes
No
Patient'sName
ParticipatingGroup
PatientHospitalNumber
ParticipatingGroupProtocolNo.
MainMemberInstitution/Adjunct
ParticipatingGroupPatientNo.
CompletedBy
AssessmentNumber
Orientation-memory-concentration Test
Current year
PerQuestionScore
WeightedScore
1 / 2
Current month
Current time
TOTALSCORE
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Breast Cancer combination chemotherapies
(NCT00024102)
Comparison of Combination Chemotherapy Regimens in
Treating Older Women Who Have Undergone Surgery for
Breast Cancer
NCT00024102
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=A50CFEAE-
D13B-3952-E034-080020C9C0E0
All rights reserved. Please visit https://medical-data-
models.org/forms/10025
CYCLOPHOSPHAMIDE
MEDICATION CALENDAR (CALGB
49907, NCT00024102)
Header
CALGBForm
CALGBStudyNo
CALGBPatientID
Amended data
Yes
No
Patient'sName
CycleNumber
Day1ofcycle
CompletedBy
DateCompleted
Medication calendar
DAYOFWEEK
Dayofcycle
1 (1)
10 (10)
11 (11)
12 (12)
13 (13)
14 (14)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
1 / 2
7 (7)
8 (8)
9 (9)
TOOKPILLS
Tookpillstime
AMorPM
Am (AM)
Pm (PM)
total number of pills
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Prostate cancer (FS RTOG) Phase III Randomized
Study of Adjuvant Therapy for High Risk pT3NO
FS Radiation Therapy Oncology Group Phase III
Randomized Study of Adjuvant Therapy for High Risk
pT3NO Prostate Cancer Initial Follow-up Form
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=11CE883A-
971B-476A-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/10026
Initial Follow-up Form Prostate
Cancer (RTOG)
Header
RTOGStudy
Case#
InstitutionName
InstitutionNo.
PatientName,Last
PatientName,First
AmendedData
DATEfrom
Comments
Signature
Date
Patient data
Patient'sVitalStatus
Alive (Alive)
Dead (Dead)
Unknown or not applicable (Unknown or
not applicable)
DeathDate/LastContactDate
Causeofdeath
Due to other cause, specify (Due to other
cause, specify)
Due To Protocol Treatment (Due to
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protocol treatment)
Due To This Disease (Due to this
disease)
Unknown (Unknown)
Cause of death, specify
Documented clinical assessment for prostate
cancer
Yes
No
CancerFollow-upStatusDate
PERFORMANCESTATUS
-1 (-1)
0 (0)
1 (1)
2 (2)
3 (3)
4 (4)
Follow-upPSAValue(s)
DateofPSAAssessment(s)
Prostate biopsy since last follow-up
Yes
No
BiopsyDate
First progression
Yes
No
Biochemical recurrence
Yes
No
Progression date, biochemical
ProgressionPSAValue
First local-regional recurrence
Yes
No
ProgressionDate,FirstLocal-Regional
SITE(S)OFLOCAL/REGIONALPROGRESSION
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Prostate cancer (FS RTOG) Phase III Randomized Study of Adjuvant
Therapy for High Risk pT3NO
Method to determine progression
Nuclear Scan (Nuclear scan)
Other, Specify (Other, specify)
Pathologic (Pathologic)
Physical Exam (Physical exam)
Radiographic (Radiographic)
Method to determine progression, specify
Distant metastasis
Yes
No
ProgressionDate,FirstDistant
Site(s)ofFirstDistantProgression
Method to determine distant progression
Nuclear Scan (Nuclear scan)
Other, Specify (Other, specify)
Pathologic (Pathologic)
Physical Exam (Physical exam)
Radiographic (Radiographic)
Other,specify(methodusedtodeterminedistantprog
ression)
Radiation therapy
Total dose prostate
Total dose pelvis
RTBeginDate
RTEndDate
Unscheduled interruptions in radiation therapy
No (No)
Yes, due to other reason (Yes, due to
other reason)
Yes, Due To Toxicity (Yes, due to toxicity)
RT interruption reason
Reason end of radiation therapy
Alternative Therapy (Alternative therapy,
specify)
Death On Study (Death on study)
Disease Progression/relapse During
Active Treatment (Disease progression,
relapse during active treatment)
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Other Complicating Disease (Other
complicating disease, specify)
Other, Specify: (Other, specify)
Patient Withdrawal Or Refusal After
Beginning Protocol Therapy (Patient
withdrawal or refusal after beginning
protocol therapy)
Patient Withdrawal Or Refusal Prior To
Beginning Protocol Therapy (Patient
withdrawal or refusal prior to beginning
protocol therapy)
Toxicity/side Effects/complications
(Toxicity/side effects/complications)
Treatment Completed Per Protocol
Criteria (Treatment completed per
protocol criteria)
Alternativetherapy,specify(reasonradiationtherap
yended)
Othercomplicatingdisease,specify(reasonradiatio
ntherapyended)
Other,specify(reasonradiationtherapyended)
Protocol Hormones continued
N/a - Arm 2 - No Hormones (N/A - Arm 2
- No hormones)
No, Previously Reported (No, previously
reported)
No, terminated since last report period
(No, terminated since last report period)
Other, Explain (Other (explain in
comments))
Yes, Per Protocol (Yes, per protocol)
Non-protocol Therapy
Yes
No
Non-ProtocolTherapyAdministeredType
Chemotherapy (Chemotherapy)
Complementary Alternative Medicine,
Specify (Complementary Alternative
Medicine, specify)
Hormones (Hormones)
None (None)
Other Specify (Other, specify)
Radiation To Other Sites, Specify
(Radiation to other sites, specify)
Radiation To Pelvis (Radiation to pelvis)
Surgery (Surgery)
Surgical Procedure Related To Previous
Rt, Specify (Surgical procedure related
to previous RT, specify)
Unknown (Unknown)
4 / 8
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Non-ProtocolTherapyDate,First
Specify(non-protocolprostatecancertherapy)
Renal or genitourinary toxicity
Yes
No
URINARYINCONTINENCE,SeverityGrade
0 (0)
1 (1)
2 (2)
3 (3)
URINARYINCONTINENCE,Attribution
Combined Modality (hormone, Rt)
(Combined modality (Hormone, RT))
Hormones (Hormones)
Other Cause, Specify (Other cause,
specify)
Radiotherapy only (Radiotherapy only)
Tumor And Rx (Tumor and Rx)
Unknown (Unknown)
Specifyifothercause(urinaryincontinence,attributio
n)
URINARYINCONTINENCE,AERBeginDate
URINARYFREQUENCY/URGENCY,SeverityGra
de
0 (0)
1 (1)
2 (2)
3 (3)
URINARYFREQUENCY/URGENCY,Attribution
Combined Modality (hormone, Rt)
(Combined modality (Hormone, RT))
Hormones (Hormones)
Other Cause, Specify (Other cause,
specify)
Radiotherapy only (Radiotherapy only)
Tumor And Rx (Tumor and Rx)
Unknown (Unknown)
Specifyifothercause(urinaryfrequency/urgency,att
ribution)
URINARYFREQUENCY/URGENCY,AERBeginD
ate
ERECTILEIMPOTENCE,SeverityGrade
0 (0)
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1 (1)
2 (2)
3 (3)
ERECTILEIMPOTENCE,Attribution
Combined Modality (hormone, Rt)
(Combined modality (Hormone, RT))
Hormones (Hormones)
Other Cause, Specify (Other cause,
specify)
Radiotherapy only (Radiotherapy only)
Tumor And Rx (Tumor and Rx)
Unknown (Unknown)
Specifyifothercause(erectileimpotence,attribution)
ERECTILEIMPOTENCE,AERBeginDate
Adverse event
Toxicity grade 3 or more
Yes
No
IMT code adverse event
CTCAdverseEventTerm
CTC category
Allergy / Immunology (Allergy /
Immunology)
Auditory/hearing (Auditory/Hearing)
Blood/bone Marrow (Blood/Bone
marrow)
Cardiovascular (arrhythmia)
(Cardiovascular (Arrhythmia))
Cardiovascular (general) (Cardiovascular
(General))
Coagulation (Coagulation)
Constitutional Symptoms (Constitutional
Symptoms)
Dermatology/skin (Dermatology/Skin)
Endocrine (Endocrine)
Gastrointestinal (Gastrointestinal)
Hemorrhage (Hemorrhage)
Hepatic (Hepatic)
Infection Febrile Neutropenia (Infection
Febrile Neutropenia)
Lymphatics (Lymphatics)
Metabolic/laboratory
(Metabolic/Laboratory)
Musculoskeletal (Musculoskeletal)
Neurology (Neurology)
Ocular/visual (Ocular/Visual)
Pain (Pain)
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Pulmonary (Pulmonary)
Renal/genitourinary
(Renal/Genitourinary)
Second Malignancy (Second
Malignancy)
Sexual/reproductive Functions
(Sexual/Reproductive Functions)
Syndromes (Syndromes)
CTC AE grade
3 (3)
4 (4)
5 (5)
9 (9)
CTCADVERSEEVENTONSETDATE
CTCADVERSEEVENTATTRIBUTIONCODE
Combined Modality (hormone, Rt)
(Combined modality (Hormone, RT))
Hormones (Hormones)
Other Cause, Specify (Other cause,
specify)
Radiotherapy only (Radiotherapy only)
Tumor And Rx (Tumor and Rx)
Unknown (Unknown)
Othercause,specify(adverseeventattribution)
Specify(adverseevent)
HQUse
New cancer
NewCancerDiagnosisAnatomicSite
Aml/mds (AML/MDS)
Bcc (BCC)
Bladder (Bladder)
Brain (Brain)
Colorectal (Colorectal)
Esophageal (Esophageal)
Gastric (Gastric)
Liver (Liver)
Lung (Lung)
Melanoma (Melanoma)
Nhl (NHL)
None (None)
Other Hematologic, Specify (Other
Hematologic, specify)
Other Solid, Specify (Other solid,
specify)
Pancreatic (Pancreatic)
Renal (Renal)
Squamous-skin (Squamous-Skin)
Unknown Primary (Unknown primary)
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NewPrimaryCancerDate
Specify(newprimarysite)
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Prostate cancer (FS RTOG) Phase III Randomized Study of Adjuvant
Therapy for High Risk pT3NO
Breast Cancer adjuvant therapy (CALGB
40101 NCT00041119)
CALGB: 40101 FOLLOW-UP FORM
Four Versus Six Cycles of Cyclophosphamide/Doxorubicin
or Paclitaxel in Adjuvant Breast Cancer
NCT00041119
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=A46CA742-
FE60-27F9-E034-080020C9C0E0
All rights reserved. Please visit https://medical-data-
models.org/forms/10027
FOLLOW-UP FORM (CALGB 40101
NCT00041119)
Header
CALGBForm
CALGBStudyNo
CALGBPatientID
From
To
Amended data
Yes
No
Patient'sName
ParticipatingGroup
PatientHospitalNumber
ParticipatingGroupProtocolNo.
MainMemberInstitution/Adjunct
ParticipatingGroupPatientNo.
CompletedBy
DateCompleted
Comments
Patient status
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Vital Status
Alive (Alive)
Dead (Dead)
Lost to Follow-Up (Lost)
Causeofdeath
Due To Other Cause (Due to other
cause)
Due To Protocol Treatment (Due to
protocol treatment)
Due To This Disease (Due to this
disease)
Unknown (Unknown)
DeathReason,Specify
CurrentMenopausalStatus
Regular Menses Continue/resume
(Regular menses continue/resume)
Regular Menses Have Stopped (Regular
menses have stopped)
Resumptiondate
Cessationdate
Clinical assessment since previous follow-up
Yes
No
CancerFollow-upStatusDate
First local-regional recurrence
Yes
No
ProgressionDate,FirstLocal-Regional
ProgressionSite(s),FirstLocal-Regional
Axilla (Axilla)
Axillary nodes (Axillary nodes)
Chest wall (Chest wall)
Infraclavicular nodes (Infraclavicular
nodes)
Internal mammary nodes (Internal
mammary nodes)
Ipsilateral breast (Ipsilateral breast)
Supraclavicular nodes (Supraclavicular
nodes)
ProgressionAssessmentSource
Documented clinical assessment
(Documented clinical assessment)
Patient Self Report Only (Patient self
report only)
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Distant metastasis
Yes
No
ProgressionDate,FirstDistant
ProgressionSite,FirstDistant
New primary cancer or MDS
Yes
No
New Primary Cancer Date
NewPrimarySite
Adverse event
Toxicity grade 3 or more
Yes
No
IMTCode
CTCAdverseEventTerm
Grade
DateofOnset
Therapy
PastTamoxifenInd
Yes
No
Tamoxifen
Yes
No
Datetamoxifenstarted
TamoxifenDiscontinuedDate
Didthepatientreceiveanyaromataseinhibitors?
Yes
No
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Whicharomataseinhibitor?
Anastrozole (Anastrozole)
Letrozole (Letrozole)
Other, Specify (Other, specify)
Other,specify(aromataseinhibitor)
Isthepatientstillreceivingaromataseinhibitor?
Yes
No
Datearomataseinhibitorstarted
Aromatase inhibitor end date
Non-protocol Therapy
Yes
No
Non-ProtocolTherapy
Non-protocol Biologic Response Modifier
Therapy, Specify (Non-protocol biologic
response modifier therapy, specify)
Non-protocol Chemotherapy, Specify
(Non-protocol chemotherapy, specify)
Non-protocol High Dose
Chemotherapy/autologous Cell
Transplant (Non-protocol high dose
chemotherapy/autologous cell transplant)
Non-protocol Hormonal Therapy, Specify
(Non-protocol hormonal therapy, specify)
Non-protocol Radiation Therapy, Specify
(Non-protocol radiation therapy, specify)
Non-ProtocolChemotherapyAdministeredSpecify
Non-
ProtocolHormoneTherapyAdministeredSpecify
Non-
protocolbiologicresponsemodifiertherapy,specify
Non-
ProtocolRadiationTherapyAdministeredSpecify
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Cidofovir HIV (NCT00550589)
AMC-046 Enrollment Form (ENR) Segment B
Cidofovir in Treating HIV-Infected Patients With High-Grade
Squamous Intraepithelial Lesions of the Skin Near the Anus
NCT00550589 
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=3BC16E2A-
1483-2256-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/10028
Enrollment Form (ENR) Segment B
(AMC-046 NCT00550589)
Header Module
PrincipalInvestigatorName
Treatment Begin Date
ResearchCommentsText
Inclusion Criteria
Inclusion Criteria
Date Of Biopsy (Date of biopsy)
Does (do) The Perianal Lesion(s) Have A
Surface Area Of At Least 3 Square
Centimeters (Does (Do) the perianal
lesion(s) have a surface area of at least
3 square centimeters)
Does The Participant Have A Biopsy-
proven Perianal Hsil Within 12 Weeks Of
Study Entry (Does the participant have a
biopsy-proven perianal HSIL within 12
weeks of study entry)
Does The Participant Have A Cd4 Count
Of >200 (Does the participant have a
CD4 count of >200)
Does The Participant Want To Initiate
Haart In The Next 12 Weeks (Does the
participant want to initiate HAART in the
next 12 weeks)
Has The Participant Been On Stable
Haart Therapy For At Least 12 Weeks
Prior To Enrollment (Has the participant
been on stable HAART therapy for at
least 12 weeks prior to enrollment)
Has The Participant Completely Healed
From Treatment (Has the participant
completely healed from treatment)
Has The Participant Undergone
Ablative/surgical Treatment Of Perianal
Dysplasia (Has the participant
undergone ablative/surgical treatment of
perianal dysplasia)
Has The Skin At The Site Of The
Pretreatment Biopsy Re-epithelialized
(Has the skin at the site of the
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pretreatment biopsy re-epithelialized)
Is The Elevated Bilirubin Felt To Be
Secondary To Indinavir Therapy (Is the
elevated bilirubin felt to be secondary to
Indinavir therapy)
Is The Participant Currently Receiving
Haart Therapy (Is the participant
currently receiving HAART therapy)
Is The Participant Receiving No
Antiretroviral Therapy Or A Non-haart
Antiretroviral Regimen (Is the participant
receiving no antiretroviral therapy or a
non-HAART antiretroviral regimen)
1.5 x ULN (Is the total bilirubin <)
3.5 mg/dl and is direct bilirubin normal
(Is total bilirubin <)
Karnofsky Performance Status
(Karnofsky performance status)
8 g/dl); ANC (> (Were the following
laboratory parameters met and
performed within 28 days prior to study
entry: Hemoglobin (>)
Will The Participant Practice Adequate
Birth Control To Prevent Pregnancy
While Receiving Treatment And For
Three Months After Treatment Is
Discontinued (Will the participant
practice adequate birth control to prevent
pregnancy while receiving treatment and
for three months after treatment is
discontinued)
KarnofskyPerformanceStatusScore
BiopsyDate
Exclusion Criteria
Exclusion Criteria
Does The Participant Have Acute, Active
Opportunistic Infection (other Than Oral
Thrush, Yeast Vaginitis, Or Genital
Herpes) Within The Last 14 Days (Does
the participant have acute, active
opportunistic infection (other than oral
thrush, yeast vaginitis, or genital herpes)
within the last 14 days)
Has The Subject Received Topical
Treatment For Perianal Dysplasia Within
4 Weeks Of Study Entry (Has the subject
received topical treatment for perianal
dysplasia within 4 weeks of study entry)
Is The Participant Receiving Acute
Treatment For An Infection (other Than
Oral Thrush, Yeast Vaginitis Or Genital
Herpes) Or Other Serious Medical
Illness Within 14 Days Of Study Entry (Is
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the participant receiving acute treatment
for an infection (other than oral thrush,
yeast vaginitis or genital herpes) or other
serious medical illness within 14 days of
study entry)
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Prostate Cancer Brachytherapy (FS RTOG
Phase III Randomized Study NCT00063882)
FS Radiation Therapy Oncology Group Phase III
Randomized Study of Intermediate Risk Prostate Cancer
Initial Follow-up Form for Acute RT
Interstitial Brachytherapy With or Without External-Beam
Radiation Therapy in Treating Patients With Prostate
Cancer
NCT00063882
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=AA892EFD-
56AF-589E-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/10029
Initial Follow-up Form for Acute RT
(NCT00063882)
Header
RTOGStudy
Case#
InstitutionName
NCIInstitutionNumber
PatientName,Last
PatientName,First
AmendedDataInd
IntervalReportFromDate
Patient data
VitalStatus
Alive (Alive)
Dead (Dead)
DeathDate/LastContactDate
DeathReason
Due To Other Cause (Due to other
cause, specify)
Due To Protocol Treatment (Due to
protocol treatment)
Due To This Disease (Due to this
disease)
N/A (N/A)
Unknown (Unknown)
PrimaryCauseDeathOtherReasonSpecify
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CancerFollow-upStatusInd
No (No)
Unknown (Unknown)
Yes (Yes)
CancerFollow-upStatusDate
PerformanceStatus
Follow-upPSAValue(s)
AssessmentDate
Prostate biopsy since last follow-up
Yes
No
BiopsyDate
Progression
Yes
No
ProgressionInd,Biochemical
No (No)
Unknown (Unknown)
Yes (Yes)
ProgressionDate,FirstBiochemical
ProgressionPSAValue
ProgressionInd,FirstLocal-Regional
No (No)
Unknown (Unknown)
Yes (Yes)
ProgressionDate,FirstLocal-Regional
ProgressionSite(s),FirstLocal-Regional
AssessmentType
Nuclear scan (Nuclear scan)
Other (Other, specify)
Pathologic (Pathologic)
Clinical Examination (Physical exam)
Radiographic (Radiographic)
AssessmentType,Specify
ProgressionInd,FirstDistant
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No (No)
Unknown (Unknown)
Yes (Yes)
ProgressionDate,FirstDistant
ProgressionSite,FirstDistant
NewPrimarySite
NewPrimaryCancerDate
Specify(newprimarysite)
Non-Protocol Therapy
Non-ProtocolTherapyInd
No (No)
Unknown (Unknown)
Yes (Yes)
Non-ProtocolTherapyAdministeredType
Chemotherapy (Chemotherapy)
Complementary Alternative Medicine,
Specify (Complementary Alternative
Medicine, specify)
Hormones (Hormones)
None (None)
Other Specify (Other, specify)
Radiation To Other Sites, Specify
(Radiation to other sites, specify)
Radiation To Pelvis (Radiation to pelvis)
Surgery (Surgery)
Surgical Procedure Related To Previous
Rt, Specify (Surgical procedure related
to previous RT, specify)
Unknown (Unknown)
Radiationtoothersites,specify(non-
protocoltherapytype)
Non-ProtocolTherapyType
SurgicalprocedurerelatedtopreviousRT,specify(no
n-protocoltherapytype)
ComplementaryAlternativeMedicine,specify(non-
protocoltherapytype)
Non-ProtocolTherapyDate,First
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NCT00063882)
Specify(non-protocolprostatecancertherapy)
Adverse event
Toxicity grade 3 or more
Yes
No
IMT code adverse event
CTCAdverseEventTerm
CTCAdverseEventCategory
Allergy/Immunology
(Allergy/Immunology)
Auditory/Hearing (Auditory/Hearing)
Blood/Bone marrow (Blood/Bone
marrow)
Cardiovascular (Arrhythmia)
(Cardiovascular (Arrhythmia))
Cardiovascular (General)
(Cardiovascular (General))
Coagulation (Coagulation)
Constitutional Symptoms (Constitutional
Symptoms)
Dermatology/Skin (Dermatology/Skin)
Endocrine (Endocrine)
Gastrointestinal (Gastrointestinal)
Hemorrhage (Hemorrhage)
Hepatic (Hepatic)
Infection Febrile Neutropenia (Infection
Febrile Neutropenia)
Lymphatics (Lymphatics)
Metabolic/Laboratory
(Metabolic/Laboratory)
Musculoskeletal (Musculoskeletal)
Neurology (Neurology)
Ocular/Visual (Ocular/Visual)
Pain (Pain)
Pulmonary (Pulmonary)
Renal/Genitourinary
(Renal/Genitourinary)
Second Malignancy (Second
Malignancy)
Sexual/Reproductive Function
(Sexual/Reproductive Function)
Syndromes (Syndromes)
CTCAdverseEventGrade
CTCAdverseEventReportBeginDate
CTCAdverseEventAttributionCode
Chemotherapy only (Chemotherapy only)
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NCT00063882)
Combined modality (Combined modality)
Hormones (Hormones)
Other cause, specify (Other cause,
specify)
Radiotherapy only (Radiotherapy only)
Tumor and Rx (Tumor and Rx)
Unknown (Unknown)
CTCAdverseEventTerm,Other
Specify
Comments
SignatureofPersonCompletingThisForm
FormCompletionDate,Original
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Prostate Cancer Brachytherapy (FS RTOG Phase III Randomized Study
NCT00063882)
Neuroblastoma (NCT00053326)
ANBL0321: End of Course Worksheet
Fenretinide in Treating Children With Recurrent or
Resistant Neuroblastoma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=C42A83E1-
AFEA-713E-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/10030
End of Course Worksheet
(ANBL0321 NCT00053326)
Header
Protocol ID COG
Institution Name
PatientCOGIdentifierNumber
Patient Name
Form Completion Date
DataEnteredDate
Research Comments
Tumor therapy
TreatmentCurrentCourseNumber
Chemotherapy Cycle Start Date
Chemotherapy Cycle End Date
AST/ALT Skin toxicity triglycerides calcium or
creatinine abnormal
Yes
No
Agent
Units
Agent Total Dose
Chemotherapy delayed
Yes
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No
TreatmentDelayedReasonText
PatientOff-treatmentInd-3
Yes
No
Date Last Dose
Off Treatment Reason
Alternative Therapy (Alternative therapy)
Completion of planned therapy or 30
courses (Completion of planned therapy
or 30 courses)
Cytogenetic Resistance (Cytogenetic
Resistance)
Death On Study (Death on study)
Disease Progression Before Active
Treatment (Disease Progression before
Active Treatment)
Disease Progression, Relapse During
Active Treatment (Disease progression,
relapse during active treatment)
Failure to respond (Failure to respond)
If the sole measurable tumor lesion must
be irradiated in order to provide symptom
relief (If the sole measurable tumor
lesion must be irradiated in order to
provide symptom relief)
Lost To Follow-up (Lost to follow-up)
Occurrence of pseudotumor cerebri
(Occurrence of pseudotumor cerebri)
Other (Other)
Patient Off-treatment For Other
Complicating Disease (Patient off-
treatment for other complicating disease)
Patient Withdrawal Or Refusal After
Beginning Protocol Therapy (Patient
withdrawal or refusal after beginning
protocol therapy)
Patient Withdrawal Or Refusal Before
Beginning Protocol Therapy (Patient
withdrawal or refusal prior to beginning
protocol therapy)
Patient/parent withdrawal from therapy
(Patient/parent withdrawal from therapy)
Progressive disease (Progressive
disease)
Adverse Event/side Effects/complications
(Same Grade 3 or 4 toxicities recur after
two dose reductions)
Treatment Completed Per Protocol
Criteria (Treatment completed per
protocol criteria)
NeuroblastomaResponseAssessmentType
Bone Marrow Immunocytology (Bone
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marrow immunocytology)
Bone Marrow Morphology (Bone marrow
morphology)
Ct Scan (CT)
Mibg (MIBG scan)
Mri (MRI)
Other, Specify (Other, specify)
Urine Hva/vma (Urine catechols)
TumorResponseInd-3
No (No)
Unknown (Not evaluated this course)
Yes (Yes)
whattypeofresponsewasachieved?
Complete Response (Complete
Response)
Incomplete response/SD (Incomplete
response/SD)
Insufficient evaluation to determine
response status (Insufficient evaluation
to determine response status)
Partial Response (Partial Response)
SD (SD)
Very Good Partial Response (Very Good
Partial Response)
TumorResponseType
Complete MIBG Response (Complete
MIBG Response)
Complete Response (CR)
Death Prior To Completion Of Protocol
Criteria (Early death)
Incomplete Response Or Stable
Disesase (Incomplete response/SD)
Insufficient Evaluation (Insufficient
evaluation to determine response status)
Partial MIBG Response (Partial MIBG
Response)
Progressive Disease (PD)
Partial Response (PR)
Stable Disease (SD)
ResponseConfirmedDate
OverallTumorResponseType
Complete Response (Complete
Response)
Death Prior To Completion Of Protocol
Criteria (Early death)
Incomplete Response Or Stable
Disesase (Incomplete response/SD)
Insufficient Evaluation (Insufficient
evaluation to determine response status)
Partial Response (Partial Response)
Progressive Disease (Progressive
Disease)
Stable Disease (Stable Disease)
Very Good Partial Response (Very Good
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Partial Response)
RTTreatmentInd-3
Yes
No
Radiation Therapy Body Site
Dose Modification
No (No)
Unknown (Unknown)
Yes, Unplanned (i.e., The Treatment
Change Was Not Part Of Protocol
Guidelines) (Yes, non-protocol specified
modification for toxicity)
Yes, other reason for deviation (Yes,
other reason for deviation)
Yes, Planned (i.e., The Treatment Was
Changed According To Protocol
Guidelines) (Yes, protocol specified
modification for toxicity)
DoseModificationText
Patient status
Patient Status
Alive (Alive)
Dead (Dead)
PatientLostFollow-upInd-2
Yes
No
PatientOtherEnrollmentInd-2
Yes
No
Consent Withdrawn
Yes
No
TreatmentReducedCourseInd-2
Yes
No
TreatmentReducedCourseReason
Second malignant neoplasm
Yes
No
SMN date
4 / 6
Neuroblastoma (NCT00053326)
Adverse event
CTCAdverseEventCategory
Dermatology/skin (Dermatology/Skin)
Gastrointestinal (Gastrointestinal)
Hemorrhage/bleeding (Hemorrhage)
Hepatobiliary/pancreas (Hepatic)
Metabolic/laboratory
(Metabolic/Laboratory)
Ocular/visual (Ocular/Visual)
Pain (Pain)
Unnamed Value [specify Category]
(Unnamed Value [specify Category])
CTC Adverse Event Reported Term
CTC Adverse Event Term
Abdominal Pain Nos (Abdominal
pain/Cramping)
Blood Alkaline Phosphatase Nos
Increased (Alkaline Phosphatase)
Alanine Aminotransferase Increased
(ALT (SGPT))
Aspartate Aminotransferase Increased
(AST (SGOT))
Blood Bilirubin Increased (Bilirubin)
Constipation (Constipation)
Diarrhoea Nos (Diarrhea without
colostomy)
Dry Eye Nec (Dry eyes)
Dry Skin (Dry Skin)
Headache Nos (Headache)
Hemorrhage, Gu (Hematuria (in the
absence of vaginal bleeding))
Hypertriglyceridaemia (Hyper-
triglyceridemia)
Hyperglycaemia Nos (Hyperglycemia)
Nausea (Nausea)
Dermatitis Exfoliative Nos
(Rash/Desquamation)
Unnamed Value [specify Type]
(Unnamed Value [specify Type])
Blindness Night (Vision- Night Blindness
(nyctalopia))
Vomiting Nos (Vomiting)
CTC Adverse Event Term
CommonTerminologyCriteriaAdverseEventTerm
COGCode
298 (298)
324 (324)
371 (371)
374 (374)
Nausea (408)
Vomiting (426)
442 (442)
462 (462)
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464 (464)
Sgot (ast) (481)
Sgpt (alt) (482)
538 (538)
548 (548)
666 (666)
686 (686)
702 (702)
716 (716)
specify Code (specify Code)
CTCAdverseEventCOGCodeSpecify
CTCAdverseEventGrade2
CTC Adverse Event Attribution Category
Definite (Definite)
Possible (Possible)
Probable (Probably)
Unlikely (Unlikely)
Unrelated (Unrelated)
Adverse Drug Experience
Yes
No
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Comorbidity score Sorror Score before
Transplant HCT AML
Definitions of comorbidities included in the HCT-CI
Original Paper can be found here:
http://redbook.streamliners.co.nz/Sorror%20Comorbidity%2
0index%20in%20HCT.pdf
All rights reserved. Please visit https://medical-data-
models.org/forms/10034
Comorbidity Score Sorror Score
before Transplant HCT AML
Comorbidity
Arrhythmia
0 (no)
1 (yes)
Cardiac
0 (no)
1 (yes)
Inflammatory bowel disease
0 (no)
1 (yes)
Diabetes
0 (no)
1 (yes)
Cerebrovascular disease
0 (no)
1 (yes)
Psychiatric disturbance
0 (no)
1 (yes)
Hepatic, mild
0 (no)
1 (yes)
Obesity
0 (no)
1 (yes)
Infection
0 (no)
1 (yes)
Infection
0 (no)
1 (yes)
Rheumatologic
0 (no)
2 (yes)
Peptic ulcer
0 (no)
2 (yes)
Moderate/severe renal
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0 (no)
2 (yes)
Moderate pulmonary
0 (no)
2 (yes)
Prior solid tumor
0 (no)
3 (yes)
Heart valve disease
0 (no)
3 (yes)
Severe pulmonary
0 (no)
3 (yes)
Moderate/severe hepatic
0 (no)
3 (yes)
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Comorbidity score Sorror Score before Transplant HCT AML
Breast Cancer (NCT00024102)
Comparison of Combination Chemotherapy Regimens in
Treating Older Women Who Have Undergone Surgery for
Breast Cancer
NCT00024102
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=A55B50C6-
E69C-4D72-E034-080020C9C0E0
All rights reserved. Please visit https://medical-data-
models.org/forms/10037
HEALTH Questionnaire Breast
Cancer (CALGB 49907 FORM C
NCT00024102)
Header
CALGBForm
CALGBStudyNo
CALGBPatientID
DateCompleted
Amendeddata
Yes
No
Patient'sName
ParticipatingGroup
PatientHospitalNumber
ParticipatingGroupProtocolNo.
MainMemberInstitution/Adjunct
ParticipatingGroupPatientNo.
ResponsibleCRA
AssessmentNumber
Patient characteristics
Other cancers or leukemia
Yes
No
Limited by other cancers or leukemia
Not At All (0)
Somewhat (1)
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A Great Deal (2)
Arthritis or rheumatism
Yes
No
Limited by arthritis or rheumatism
Not At All (0)
Somewhat (1)
A Great Deal (2)
Glaucoma
Yes
No
Limited by glaucoma
Not At All (0)
Somewhat (1)
A Great Deal (2)
Emphysema or ChronicBronchitis
Yes
No
Limited by emphysema or chronic bronchitis
Not At All (0)
Somewhat (1)
A Great Deal (2)
High Blood Pressure
Yes
No
Limited by high blood pressure
Not At All (0)
Somewhat (1)
A Great Deal (2)
Heartdisease
Yes
No
Limited by heart disease
Not At All (0)
Somewhat (1)
A Great Deal (2)
Circulation disorder
Yes
No
Limited by circulation disorder
Not At All (0)
Somewhat (1)
A Great Deal (2)
Diabetes
Yes
No
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Limited by diabetes
Not At All (0)
Somewhat (1)
A Great Deal (2)
Stomach or intestinal disorders
Yes
No
Limited by stomach or intestinal disorders
Not At All (0)
Somewhat (1)
A Great Deal (2)
Osteoporosis
Yes
No
Limited by osteoporosis
Not At All (0)
Somewhat (1)
A Great Deal (2)
Chronic Liver or Kidney Disease
Yes
No
Limited by chronic liver or kidney disease
Not At All (0)
Somewhat (1)
A Great Deal (2)
Stroke
Yes
No
Limited by stroke
Not At All (0)
Somewhat (1)
A Great Deal (2)
Depression
Yes
No
Limited by depression
Not At All (0)
Somewhat (1)
A Great Deal (2)
Eyesight
Excellent (Excellent)
Fair (Fair)
Good (Good)
Poor (Poor)
Totally Blind (Totally blind)
Limited by eyesight
Not At All (0)
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Somewhat (1)
A Great Deal (2)
Hearing
Excellent (Excellent)
Fair (Fair)
Good (Good)
Poor (Poor)
Totally Deaf (Totally deaf)
Limited by impaired hearing
Not At All (0)
Somewhat (1)
A Great Deal (2)
Other illnesses
No (No)
Yes, Specify (Yes, specify)
Other physical problems or illnesses
Limited by these illnesses
Not At All (0)
Somewhat (1)
A Great Deal (2)
Doctor visits past 3 months
1 To 2 (1 to 2)
10 To 14 (10 to 14)
15 Or More (15 or more)
3 To 5 (3 to 5)
6 To 9 (6 to 9)
Don't Know (Don't know)
None (None)
Unable to carry out usual activities past 3 months
A Week Or Less (A week or less)
More Than A Week, But Less Than A
Month (More than a week, but less than
a month)
None (None)
One To Two Months (One to two months)
Three Months (Three months)
Days in hospital past 3 months
1 To 2 (1 to 2)
10 To 14 (10 to 14)
15 Or More (15 or more)
3 To 5 (3 to 5)
6 To 9 (6 to 9)
Don't Know (Don't know)
None (None)
Counseling
problem related counselling
Yes
No
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Counseling category
Group Psychotherapy (Group
Psychotherapy)
Individual Psychotherapy (Individual
Psychotherapy)
Other, Specify (Other, specify)
Pastoral Counseling (Pastoral
Counseling)
Relaxation Training Or Hypnosis
(Relaxation Training or Hypnosis)
Social Worker At Hospital (Social Worker
at Hospital)
Support Group For Cancer Patients
(Support Group for Cancer Patients)
Other, specify
Checkanyoftheseservicesthatyouarestillreceiving
Group Psychotherapy (Group
Psychotherapy)
Individual Psychotherapy (Individual
Psychotherapy)
Other, Specify (Other, specify)
Pastoral Counseling (Pastoral
Counseling)
Relaxation Training Or Hypnosis
(Relaxation Training or Hypnosis)
Social Worker At Hospital (Social Worker
at Hospital)
Support Group For Cancer Patients
(Support Group for Cancer Patients)
Other,specify(servicesthatyouarestillreceiving)
problem related counselling
Yes
No
Whattypeofcounselingortreatmentdidyoureceive?
(follow-up)
Group Psychotherapy (Group
Psychotherapy)
Individual Psychotherapy (Individual
Psychotherapy)
Other, Specify (Other, specify)
Pastoral Counseling (Pastoral
Counseling)
Relaxation Training Or Hypnosis
(Relaxation Training or Hypnosis)
Social Worker At Hospital (Social Worker
at Hospital)
Support Group For Cancer Patients
(Support Group for Cancer Patients)
Other services
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Medication
Medicine to treat nausea and/or vomiting
Yes
No
Medicine to treat diarrhea
Yes
No
Medicinetoreducefeelingverytired[fatigue]
Yes
No
Medicinetoreduceswellinginhandsorfeet
Yes
No
Medicineorcreamtotreatmouthsores
Yes
No
Painmedicineforhandsorfeet
Yes
No
Medication regarding skin changes
Yes
No
Other,specify
Yes
No
Other medication
Arthritismedicine
Yes
No
Arthritis medicine
More Than Once A Day (More than
Once a Day)
Once A Day (Once a Day)
Take As Needed (Take As Needed)
Prescriptionpainkiller
Yes
No
Pain killer frequency
More Than Once A Day (More than
Once a Day)
Once A Day (Once a Day)
Take As Needed (Take As Needed)
Over-thecounterpainkillers
Yes
No
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Over the counter painkillers frequency
More Than Once A Day (More than
Once a Day)
Once A Day (Once a Day)
Take As Needed (Take As Needed)
Highbloodpressuremedicine
Yes
No
High blood pressure medicine frequency
More Than Once A Day (More than
Once a Day)
Once A Day (Once a Day)
Take As Needed (Take As Needed)
Pillstomakeyoulosewaterorsalt
Yes
No
Pills to make you lose water or salt frequency
More Than Once A Day (More than
Once a Day)
Once A Day (Once a Day)
Take As Needed (Take As Needed)
Digoxinpillsfortheheart
Yes
No
Digoxin pills for the heart frequency
More Than Once A Day (More than
Once a Day)
Once A Day (Once a Day)
Take As Needed (Take As Needed)
Nitroglycerinforchestpain
Yes
No
Nitroglycerin for chest pain frequency
More Than Once A Day (More than
Once a Day)
Once A Day (Once a Day)
Take As Needed (Take As Needed)
Bloodthinnermedicine
Yes
No
Blood thinner medicine frequency
More Than Once A Day (More than
Once a Day)
Once A Day (Once a Day)
Take As Needed (Take As Needed)
Medicinetoimprovecirculation
Yes
No
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Medicine to improve circulation frequency
More Than Once A Day (More than
Once a Day)
Once A Day (Once a Day)
Take As Needed (Take As Needed)
Insulin injections for diabetes
Yes
No
Insulin injections for diabetes frequency
More Than Once A Day (More than
Once a Day)
Once A Day (Once a Day)
Take As Needed (Take As Needed)
Pillsfordiabetes
Yes
No
Pills for diabetes frequency
More Than Once A Day (More than
Once a Day)
Once A Day (Once a Day)
Take As Needed (Take As Needed)
Ulcermedicine
Yes
No
Ulcer medicine frequency
More Than Once A Day (More than
Once a Day)
Once A Day (Once a Day)
Take As Needed (Take As Needed)
Asthma medicines
Yes
No
Asthma medicines frequency
More Than Once A Day (More than
Once a Day)
Once A Day (Once a Day)
Take As Needed (Take As Needed)
Seizuremedicines
Yes
No
Seizure medicines frequency
More Than Once A Day (More than
Once a Day)
Once A Day (Once a Day)
Take As Needed (Take As Needed)
Thyroidpills
Yes
No
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IfTaken,HowOften:Thyroidpills
More Than Once A Day (More than
Once a Day)
Once A Day (Once a Day)
Take As Needed (Take As Needed)
Cortisone
Yes
No
Cortisone pills or injections frequency
More Than Once A Day (More than
Once a Day)
Once A Day (Once a Day)
Take As Needed (Take As Needed)
Antibiotics
Yes
No
Antibiotics frequency
More Than Once A Day (More than
Once a Day)
Once A Day (Once a Day)
Take As Needed (Take As Needed)
Tranquilizer
Yes
No
Tranquilizers or medicine for your nerves
frequency
More Than Once A Day (More than
Once a Day)
Once A Day (Once a Day)
Take As Needed (Take As Needed)
Sleeping pills
Yes
No
Prescription sleeping pills frequency
More Than Once A Day (More than
Once a Day)
Once A Day (Once a Day)
Take As Needed (Take As Needed)
Over-the-counterpillstohelpyousleep
Yes
No
Over-the-counter pills to help you sleep
frequency
More Than Once A Day (More than
Once a Day)
Once A Day (Once a Day)
Take As Needed (Take As Needed)
Hormones
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Yes
No
Hormones frequency
More Than Once A Day (More than
Once a Day)
Once A Day (Once a Day)
Take As Needed (Take As Needed)
Allergy medicines
Yes
No
Allergy medicines frequency
More Than Once A Day (More than
Once a Day)
Once A Day (Once a Day)
Take As Needed (Take As Needed)
Laxatives
Yes
No
Laxatives frequency
More Than Once A Day (More than
Once a Day)
Once A Day (Once a Day)
Take As Needed (Take As Needed)
Eyedropsforglaucoma
Yes
No
Eye drops for glaucoma frequency
More Than Once A Day (More than
Once a Day)
Once A Day (Once a Day)
Take As Needed (Take As Needed)
Calciumtablets
Yes
No
Calcium tablets frequency
More Than Once A Day (More than
Once a Day)
Once A Day (Once a Day)
Take As Needed (Take As Needed)
Vitaminsand/orminerals
Yes
No
Vitamins and/or minerals frequency
More Than Once A Day (More than
Once a Day)
Once A Day (Once a Day)
Take As Needed (Take As Needed)
Herbal medicine
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Yes
No
Herbal medicines frequency
More Than Once A Day (More than
Once a Day)
Once A Day (Once a Day)
Take As Needed (Take As Needed)
other medication past month
Yes
No
NameofMedicine
Medication frequency
More Than Once A Day (More than
Once a Day)
Once A Day (Once a Day)
Take As Needed (Take As Needed)
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Breast Cancer Chemotherapy
(NCT00087178)
NSABP Protocol B-36 Quality of Life Questionnaire
(English Version)
Comparison of Two Combination Chemotherapy Regimens
in Treating Women With Breast Cancer
NCT00087178
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=C907A026-
1DAB-1D7C-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/10040
Quality of Life Questionnaire
(NSABP Protocol B-36
NCT00087178)
Header
Patient Initials
Patient ID NSABP
Institution Name
Affiliate Name
PersonFormAdministrationLastName
PersonFormAdministrationFirstName
PersonFormAdministrationPhoneNumber
Today'sDate
AssessmentPeriodType
12 Months (12 months)
18 Months (18 months)
24 Months (24 months)
30 Months (30 months)
36 Months (36 months)
6 Months (6 months)
Baseline (baseline)
Day 1 Of Cycle 4 (Day 1 of Cycle 4)
CaseReportFormPersonCompleteType
1 By Clinical Staff On Phone With Patient
(By clinical staff on phone with patient)
0 By Patient In Office (By patient in
doctor's office)
By patient not in doctor's office (By
patient not in doctor's office)
Other (Other)
Questionnaire date
Quality of life
1 / 11
Fatigue
Not at all (1)
A little bit (2)
Somewhat (3)
Quite a bit (4)
Very much (5)
Nausea
Not at all (1)
A little bit (2)
Somewhat (3)
Quite a bit (4)
Very much (5)
Family Need
Not at all (1)
A little bit (2)
Somewhat (3)
Quite a bit (4)
Very much (5)
Pain
Not at all (1)
A little bit (2)
Somewhat (3)
Quite a bit (4)
Very much (5)
Adverse Event
Not at all (1)
A little bit (2)
Somewhat (3)
Quite a bit (4)
Very much (5)
Feel ill
Not at all (1)
A little bit (2)
Somewhat (3)
Quite a bit (4)
Very much (5)
Bed rest
Not at all (1)
A little bit (2)
Somewhat (3)
Quite a bit (4)
Very much (5)
Feel Close to Friends
Not at all (1)
A little bit (2)
Somewhat (3)
Quite a bit (4)
Very much (5)
Emotional Support from Family
Not at all (1)
A little bit (2)
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Somewhat (3)
Quite a bit (4)
Very much (5)
Receive Support from Friends
Not at all (1)
A little bit (2)
Somewhat (3)
Quite a bit (4)
Very much (5)
Family Accepts Illness
Not at all (1)
A little bit (2)
Somewhat (3)
Quite a bit (4)
Very much (5)
Satisfied with Family Communication
Not at all (1)
A little bit (2)
Somewhat (3)
Quite a bit (4)
Very much (5)
Feel Close to Partner
Not at all (1)
A little bit (2)
Somewhat (3)
Quite a bit (4)
Very much (5)
Question no response
Yes
No
sexual satisfaction
Not at all (1)
A little bit (2)
Somewhat (3)
Quite a bit (4)
Very much (5)
Depression
Not at all (1)
A little bit (2)
Somewhat (3)
Quite a bit (4)
Very much (5)
Coping
Not at all (1)
A little bit (2)
Somewhat (3)
Quite a bit (4)
Very much (5)
Losing Hope Against Illness
Not at all (1)
A little bit (2)
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Somewhat (3)
Quite a bit (4)
Very much (5)
Nervousness
Not at all (1)
A little bit (2)
Somewhat (3)
Quite a bit (4)
Very much (5)
Worry About Dying
Not at all (1)
A little bit (2)
Somewhat (3)
Quite a bit (4)
Very much (5)
Worry About Worsening Condition
Not at all (1)
A little bit (2)
Somewhat (3)
Quite a bit (4)
Very much (5)
Able to Work
Not at all (1)
A little bit (2)
Somewhat (3)
Quite a bit (4)
Very much (5)
Work is Fulfilling
Not at all (1)
A little bit (2)
Somewhat (3)
Quite a bit (4)
Very much (5)
Able to Enjoy Life
Not at all (1)
A little bit (2)
Somewhat (3)
Quite a bit (4)
Very much (5)
Accepted Illness
Not at all (1)
A little bit (2)
Somewhat (3)
Quite a bit (4)
Very much (5)
Sleeping Well
Not at all (1)
A little bit (2)
Somewhat (3)
Quite a bit (4)
Very much (5)
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Enjoy Things for Fun
Not at all (1)
A little bit (2)
Somewhat (3)
Quite a bit (4)
Very much (5)
Content with Quality of Life
Not at all (1)
A little bit (2)
Somewhat (3)
Quite a bit (4)
Very much (5)
Dyspnea
Not at all (1)
A little bit (2)
Somewhat (3)
Quite a bit (4)
Very much (5)
Self-conscious about the way I dress
Not at all (1)
A little bit (2)
Somewhat (3)
Quite a bit (4)
Very much (5)
Swollen arm
Not at all (1)
A little bit (2)
Somewhat (3)
Quite a bit (4)
Very much (5)
Feel Sexually Attractive
Not at all (1)
A little bit (2)
Somewhat (3)
Quite a bit (4)
Very much (5)
Bothered by Hair Loss
Not at all (1)
A little bit (2)
Somewhat (3)
Quite a bit (4)
Very much (5)
Worry that other family members get same illness
Not at all (1)
A little bit (2)
Somewhat (3)
Quite a bit (4)
Very much (5)
Worry About Effect of Stress on Illness
Not at all (1)
A little bit (2)
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Somewhat (3)
Quite a bit (4)
Very much (5)
Bothered by Change in Weight
Not at all (1)
A little bit (2)
Somewhat (3)
Quite a bit (4)
Very much (5)
Able to feel like a woman
Not at all (1)
A little bit (2)
Somewhat (3)
Quite a bit (4)
Very much (5)
Headaches
Not at all (1)
A little bit (2)
Somewhat (3)
Quite a bit (4)
Very much (5)
Dyspepsia
Not at all (1)
A little bit (2)
Somewhat (3)
Quite a bit (4)
Very much (5)
Nausea
Not at all (1)
A little bit (2)
Somewhat (3)
Quite a bit (4)
Very much (5)
heartburn
Not at all (1)
A little bit (2)
Somewhat (3)
Quite a bit (4)
Very much (5)
Vomiting
Not at all (1)
A little bit (2)
Somewhat (3)
Quite a bit (4)
Very much (5)
Flatulence
Not at all (1)
A little bit (2)
Somewhat (3)
Quite a bit (4)
Very much (5)
6 / 11
Breast Cancer Chemotherapy (NCT00087178)
mouth sores
Not at all (1)
A little bit (2)
Somewhat (3)
Quite a bit (4)
Very much (5)
Diarrhea
Not at all (1)
A little bit (2)
Somewhat (3)
Quite a bit (4)
Very much (5)
skin problems
Not at all (1)
A little bit (2)
Somewhat (3)
Quite a bit (4)
Very much (5)
numbness or tingling in hands or feet
Not at all (1)
A little bit (2)
Somewhat (3)
Quite a bit (4)
Very much (5)
Fever
Not at all (1)
A little bit (2)
Somewhat (3)
Quite a bit (4)
Very much (5)
Bladder Control Difficulty
Not at all (1)
A little bit (2)
Somewhat (3)
Quite a bit (4)
Very much (5)
constipation
Not at all (1)
A little bit (2)
Somewhat (3)
Quite a bit (4)
Very much (5)
Hot Flashes
Not at all (1)
A little bit (2)
Somewhat (3)
Quite a bit (4)
Very much (5)
Pruritus of genital organs
Not at all (1)
A little bit (2)
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Somewhat (3)
Quite a bit (4)
Very much (5)
Mood swings
Not at all (1)
A little bit (2)
Somewhat (3)
Quite a bit (4)
Very much (5)
vaginal discharge
Not at all (1)
A little bit (2)
Somewhat (3)
Quite a bit (4)
Very much (5)
vaginal bleeding or spotting
Not at all (1)
A little bit (2)
Somewhat (3)
Quite a bit (4)
Very much (5)
vaginal dryness
Not at all (1)
A little bit (2)
Somewhat (3)
Quite a bit (4)
Very much (5)
Painful intercourse female
Not at all (1)
A little bit (2)
Somewhat (3)
Quite a bit (4)
Very much (5)
cramps
Not at all (1)
A little bit (2)
Somewhat (3)
Quite a bit (4)
Very much (5)
Generalized aches and pains
Not at all (1)
A little bit (2)
Somewhat (3)
Quite a bit (4)
Very much (5)
Arthralgia
Not at all (1)
A little bit (2)
Somewhat (3)
Quite a bit (4)
Very much (5)
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swelling of hands
Not at all (1)
A little bit (2)
Somewhat (3)
Quite a bit (4)
Very much (5)
Muscular stiffness
Not at all (1)
A little bit (2)
Somewhat (3)
Quite a bit (4)
Very much (5)
Weight gain
Not at all (1)
A little bit (2)
Somewhat (3)
Quite a bit (4)
Very much (5)
weight loss
Not at all (1)
A little bit (2)
Somewhat (3)
Quite a bit (4)
Very much (5)
Unhappy With Appearance
Not at all (1)
A little bit (2)
Somewhat (3)
Quite a bit (4)
Very much (5)
Forgetfulness
Not at all (1)
A little bit (2)
Somewhat (3)
Quite a bit (4)
Very much (5)
Night sweats
Not at all (1)
A little bit (2)
Somewhat (3)
Quite a bit (4)
Very much (5)
Cold sweats
Not at all (1)
A little bit (2)
Somewhat (3)
Quite a bit (4)
Very much (5)
Difficulty concentrating
Not at all (1)
A little bit (2)
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Somewhat (3)
Quite a bit (4)
Very much (5)
Limitations regarding vigorous activities
No, not limited at all (1)
Yes, limited a little (2)
Yes, limited a lot (4)
Moderate activities
No, not limited at all (1)
Yes, limited a little (2)
Yes, limited a lot (4)
Lifting or Carrying Groceries
No, not limited at all (1)
Yes, limited a little (2)
Yes, limited a lot (4)
Climbing Several Flights of Stairs
No, not limited at all (1)
Yes, limited a little (2)
Yes, limited a lot (4)
Bending, Kneeling or Stooping
No, not limited at all (1)
Yes, limited a little (2)
Yes, limited a lot (4)
Walking More Than a Mile
No, not limited at all (1)
Yes, limited a little (2)
Yes, limited a lot (4)
Walking several hundred yards
No, not limited at all (1)
Yes, limited a little (2)
Yes, limited a lot (4)
Walking one hundred yards
No, not limited at all (1)
Yes, limited a little (2)
Yes, limited a lot (4)
Bathing or dressing yourself
No, not limited at all (1)
Yes, limited a little (2)
Yes, limited a lot (4)
Feel full of life
None of the time (1)
A little of the time (2)
Some of the time (3)
Most of the time (4)
All of the time (5)
A lot of energy
None of the time (1)
A little of the time (2)
Some of the time (3)
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Most of the time (4)
All of the time (5)
feel worn out
None of the time (1)
A little of the time (2)
Some of the time (3)
Most of the time (4)
All of the time (5)
feel tired
None of the time (1)
A little of the time (2)
Some of the time (3)
Most of the time (4)
All of the time (5)
Overall quality of life
0 (0)
1 (1)
10 (10)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
7 (7)
8 (8)
9 (9)
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Refractory tumors in children
(NCT00053963)
ADVL0212: Eligibility Worksheet
FR901228 in Treating Children With Refractory or
Recurrent Solid Tumors or Leukemia
NCT00053963 
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=B1EC07E8-
6588-30D1-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/10041
Eligibility Worksheet (ADVL0212
NCT00053963)
Header
Protocol ID COG
Institution Name
PatientCOGIdentifierNumber
Patient Initials
DataEnteredDate
Research Comments
Eligibility criteria
TreatmentRequiredBeginDateInd-2
Yes
No
PatientRequiredAgeInd-2
Yes
No
DiseaseHistologicDiagnosisInd
No (No)
Patient Has Either A Brain Stem Or Optic
Pathway Tumor (Patient has either a
brain stem or optic pathway tumor)
Yes (Yes)
DiseaseTreatmentRefractoryInd-2
Yes
No
CNSTumorNeurologicalDeficitStableInd
N/a, Patient Does Not Have A Cns Tumor
(N/A, patient does not have a CNS
tumor)
No (No)
Yes (Yes)
Karnofsky Performance Score
1 / 4
Dead (0)
Moribund, fatal processes progressing
rapidly (10)
Normal, no complaints, no evidence of
disease (100)
Hospitalization necessary, very sick,
active supportive treatment necessary
(20)
Severely disabled, hospitalization is
indicated although death is not imminent
(30)
Disabled, requires special care and
assistance (40)
Requires considerable assistance and
frequent medical care (50)
Requires occasional assistance, but is
able to care for most of own needs (60)
Cares for self.  Unable to carry on
normal activity or to do active work (70)
Normal activity with effort, some signs or
symptoms of disease (80)
Able to carry on normal activity, minor
signs or symptoms of disease (90)
LanskyPerformanceStatusScale
0 (0 - Unresponsive)
10 (10 - No play; does not get out of bed)
100 (100 - Fully active, normal)
20 (20 - Often sleeping; play entirely
limited to very passive activities)
30 (30 - In bed; needs assistance even
for quiet play)
40 (40 - Mostly in bed; participates in
quiet activities)
50 (50 - Gets dressed but lies around
much of the day, no active play, able to
participate in all quiet play and activities)
60 (60 - Up and around, but minimal
active play; keeps busy with quieter
activities)
70 (70 - Both greater restriction of and
less time spent in play activity)
80 (80 - Active, but tires more quickly)
90 (90 - Minor restrictions in physically
strenuous activity)
life expectancy 8 weeks
Yes
No
PatientRecoveryEligibilityInd-2
Yes
No
PriorGrowthFactorReceivedInd-2
Yes
No
DexamethasoneAgentDoseStableInd
N/a, Patient Does Not Have A Cns Tumor
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(N/A, patient does not have a CNS
tumor)
N/a, Patient Has Cns Tumor, But Is Not
Receiving Dexamethasone (N/A, patient
has a CNS tumor, but it not receiving
dexamethasone)
No (No)
Yes (Yes)
AnticonvulsantMedicationReceivedInd-2
Yes
No
PatientBoneMarrowFunctionRequiredInd-2
Yes
No
PatientRenalFunctionRequiredInd-2
Yes
No
PatientLiverFunctionRequiredInd-2
Yes
No
PatientCardiacFunctionRequiredInd-2
Yes
No
PatientPulmonaryFunctionRequiredInd-2
Yes
No
PatientCNSFunctionRequiredInd-2
Yes
No
Pregnancy Test
N/a, Patient Is Female, But Not Post-
menarchal (N/A, patient is female, but
not post-menarchal)
N/a, Patient Is Male (N/A, patient is
male)
No (No)
Yes (Yes)
ContraceptionAgreementInd-3
N/A, patient is not of reproductive
potential (N/A, patient is not of
reproductive potential)
No (No)
Unknown (Unknown)
Yes (Yes)
PatientInfectionInd-2
Yes
No
AgentReceivedInd-2
Yes
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No
PatientRequiredCharacteristicsCOGInd-2
Yes
No
Informed Consent
Yes
No
StudyCompleteRequirementsInd-2
Yes
No
TreatmentAssignmentText
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Prostate Cancer adjuvant therapy (FS
RTOG Phase III Study NCT00023829)
FS Radiation Therapy Oncology Group Phase III
Randomized Study of Adjuvant Therapy for High Risk
pT3NO Prostate Cancer Initial Follow-up Form
Adjuvant Radiation Therapy Plus Hormone Therapy
Compared With Radiation Therapy Alone in Treating
Patients With Stage II or Stage III Prostate Cancer
NCT00023829
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=A56DC7B3-
8145-10C4-E034-080020C9C0E0
All rights reserved. Please visit https://medical-data-
models.org/forms/10042
Initial Follow-up Form Prostate
Cancer (NCT00023829)
Header
RTOGStudy
Case#
InstitutionName
InstitutionNo.
PatientName,Last
PatientName,First
AmendedData
DATEfrom
Comments
Signature
Date
Patient characteristics
Patient'sVitalStatus
Alive (Alive)
Dead (Dead)
Unknown or not applicable (Unknown or
not applicable)
DeathDate/LastContactDate
Causeofdeath
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Due to other cause, specify (Due to other
cause, specify)
Due To Protocol Treatment (Due to
protocol treatment)
Due To This Disease (Due to this
disease)
Unknown (Unknown)
PrimaryCauseDeathOtherReasonSpecify
Assessment for prostate cancer since previous
follow-up
Yes
No
CancerFollow-upStatusDate
PERFORMANCESTATUS
-1 (-1)
0 (0)
1 (1)
2 (2)
3 (3)
4 (4)
Follow-upPSAValue(s)
DateofPSAAssessment(s)
Prostate biopsy
Yes
No
BiopsyDate
First progression
Yes
No
ProgressionInd,Biochemical
No (No)
Unknown (Unknown)
Yes (Yes)
ProgressionDate,FirstBiochemical
ProgressionPSAValue
First local-regional recurrence
Yes
No
DATE OF FIRST LOCAL-REGIONAL
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PROGRESSION
SITE(S)OFLOCAL/REGIONALPROGRESSION
Method to determine local/regional progression
Nuclear Scan (Nuclear scan)
Other, Specify (Other, specify)
Pathologic (Pathologic)
Physical Exam (Physical exam)
Radiographic (Radiographic)
Other method, specify
First distant recurrence
Yes
No
ProgressionDate,FirstDistant
Site(s)ofFirstDistantProgression
Method to determine distant progression
Nuclear Scan (Nuclear scan)
Other, Specify (Other, specify)
Pathologic (Pathologic)
Physical Exam (Physical exam)
Radiographic (Radiographic)
Other,specify(methodusedtodeterminedistantprog
ression)
NewCancerDiagnosisAnatomicSite
Aml/mds (AML/MDS)
Bcc (BCC)
Bladder (Bladder)
Brain (Brain)
Colorectal (Colorectal)
Esophageal (Esophageal)
Gastric (Gastric)
Liver (Liver)
Lung (Lung)
Melanoma (Melanoma)
Nhl (NHL)
None (None)
Other Hematologic, Specify (Other
Hematologic, specify)
Other Solid, Specify (Other solid,
specify)
Pancreatic (Pancreatic)
Renal (Renal)
Squamous-skin (Squamous-Skin)
Unknown Primary (Unknown primary)
NewPrimaryCancerDate
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Specify(newprimarysite)
HQUse
PROTOCOLHORMONESCONTINUING
N/a - Arm 2 - No Hormones (N/A - Arm 2
- No hormones)
No, Previously Reported (No, previously
reported)
No, terminated since last report period
(No, terminated since last report period)
Other, Explain (Other (explain in
comments))
Yes, Per Protocol (Yes, per protocol)
Non-protocol Therapy
Yes
No
Non-protocol Therapy Type
Chemotherapy (Chemotherapy)
Complementary Alternative Medicine,
Specify (Complementary Alternative
Medicine, specify)
Hormones (Hormones)
None (None)
Other Specify (Other, specify)
Radiation To Other Sites, Specify
(Radiation to other sites, specify)
Radiation To Pelvis (Radiation to pelvis)
Surgery (Surgery)
Surgical Procedure Related To Previous
Rt, Specify (Surgical procedure related
to previous RT, specify)
Unknown (Unknown)
Non-ProtocolTherapyDate,First
Specify(non-protocolprostatecancertherapy)
Radiation therapy
Total dose prostate
Total dose pelvis
RTBeginDate
RTEndDate
RTInterruptionsInd
No (No)
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Yes, due to other reason (Yes, due to
other reason)
Yes, Due To Toxicity (Yes, due to toxicity)
RT interruption reason
REASON RADIATION THERAPY TREATMENT
ENDED
Alternative Therapy (Alternative therapy,
specify)
Death On Study (Death on study)
Disease Progression/relapse During
Active Treatment (Disease progression,
relapse during active treatment)
Other Complicating Disease (Other
complicating disease, specify)
Other, Specify: (Other, specify)
Patient Withdrawal Or Refusal After
Beginning Protocol Therapy (Patient
withdrawal or refusal after beginning
protocol therapy)
Patient Withdrawal Or Refusal Prior To
Beginning Protocol Therapy (Patient
withdrawal or refusal prior to beginning
protocol therapy)
Toxicity/side Effects/complications
(Toxicity/side effects/complications)
Treatment Completed Per Protocol
Criteria (Treatment completed per
protocol criteria)
Alternativetherapy,specify(reasonradiationtherap
yended)
Othercomplicatingdisease,specify(reasonradiatio
ntherapyended)
Other,specify(reasonradiationtherapyended)
Adverse event
Toxicity grade 3 or more
Yes
No
IMT code adverse event
CTCAdverseEventTerm
COMMON TOXICITY GENERAL CATEGORY
Allergy / Immunology (Allergy /
Immunology)
Auditory/hearing (Auditory/Hearing)
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Blood/bone Marrow (Blood/Bone
marrow)
Cardiovascular (arrhythmia)
(Cardiovascular (Arrhythmia))
Cardiovascular (general) (Cardiovascular
(General))
Coagulation (Coagulation)
Constitutional Symptoms (Constitutional
Symptoms)
Dermatology/skin (Dermatology/Skin)
Endocrine (Endocrine)
Gastrointestinal (Gastrointestinal)
Hemorrhage (Hemorrhage)
Hepatic (Hepatic)
Infection Febrile Neutropenia (Infection
Febrile Neutropenia)
Lymphatics (Lymphatics)
Metabolic/laboratory
(Metabolic/Laboratory)
Musculoskeletal (Musculoskeletal)
Neurology (Neurology)
Ocular/visual (Ocular/Visual)
Pain (Pain)
Pulmonary (Pulmonary)
Renal/genitourinary
(Renal/Genitourinary)
Second Malignancy (Second
Malignancy)
Sexual/reproductive Functions
(Sexual/Reproductive Functions)
Syndromes (Syndromes)
CTCADVERSEEVENTGRADE
1 (1)
2 (2)
3 (3)
4 (4)
CTCADVERSEEVENTONSETDATE
CTCADVERSEEVENTATTRIBUTIONCODE
Combined Modality (hormone, Rt)
(Combined modality (Hormone, RT))
Hormones (Hormones)
Other Cause, Specify (Other cause,
specify)
Radiotherapy only (Radiotherapy only)
Tumor And Rx (Tumor and Rx)
Unknown (Unknown)
Othercause,specify(adverseeventattribution)
Specify(adverseevent)
Renal or genitourinary toxicity
Yes
No
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Urinary Incontinence Severity
0 (0)
1 (1)
2 (2)
3 (3)
URINARYINCONTINENCE,Attribution
Combined Modality (hormone, Rt)
(Combined modality (Hormone, RT))
Hormones (Hormones)
Other Cause, Specify (Other cause,
specify)
Radiotherapy only (Radiotherapy only)
Tumor And Rx (Tumor and Rx)
Unknown (Unknown)
Specifyifothercause(urinaryincontinence,attributio
n)
URINARYINCONTINENCE,AERBeginDate
URINARYFREQUENCY/URGENCY,SeverityGra
de
0 (0)
1 (1)
2 (2)
3 (3)
URINARYFREQUENCY/URGENCY,Attribution
Combined Modality (hormone, Rt)
(Combined modality (Hormone, RT))
Hormones (Hormones)
Other Cause, Specify (Other cause,
specify)
Radiotherapy only (Radiotherapy only)
Tumor And Rx (Tumor and Rx)
Unknown (Unknown)
Specifyifothercause(urinaryfrequency/urgency,att
ribution)
URINARYFREQUENCY/URGENCY,AERBeginD
ate
ERECTILEIMPOTENCE,SeverityGrade
0 (0)
1 (1)
2 (2)
3 (3)
ERECTILEIMPOTENCE,Attribution
Combined Modality (hormone, Rt)
(Combined modality (Hormone, RT))
Hormones (Hormones)
Other Cause, Specify (Other cause,
specify)
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Radiotherapy only (Radiotherapy only)
Tumor And Rx (Tumor and Rx)
Unknown (Unknown)
Specifyifothercause(erectileimpotence,attribution)
ERECTILEIMPOTENCE,AERBeginDate
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Prostate Cancer RTOG (NCT00033631)
F1 Radiation Therapy Oncology Group Phase III Prostate
3D / IMRT Follow-up Form
Radiation Therapy in Treating Patients With Stage II
Prostate Cancer
NCT00033631 
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=11CEC00B-
902D-4DD5-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/10043
Follow-up Form Prostate 3D / IMRT
(NCT00033631)
Header
AmendedData
RTOGStudy
Case#
InstitutionName
InstitutionNo.
Patient Initials
Trial subject ID RTOG
CaseReportFormModifiedInd-2
Comments
Signature
Date
Patient characteristics
Patient'sVitalStatus
Alive (Alive)
Dead (Dead)
DeathDate/LastContactDate
Causeofdeath
Due To Other Cause (Due to other
cause, specify)
Due To Protocol Treatment (Due to
protocol treatment)
Due To This Disease (Due to this
1 / 6
disease)
Unknown (Unknown)
Primary Cause of Death, specify
Assessment since previous follow-up
Yes
No
CancerFollow-upStatusDate
PERFORMANCESTATUS
-1 (-1)
0 (0)
1 (1)
2 (2)
3 (3)
4 (4)
PSA
DateofPSAAssessment(s)
Prostate biopsy
Yes
No
BiopsyDate
First Progression
Yes
No
Biochemical recurrence
Yes
No
ProgressionPSAValue
First local-regional recurrence
Yes
No
ProgressionDate,FirstLocal-Regional
Method to determine progression, local
Not Applicable (0)
Physical Exam (1)
Pathologic (2)
First distant recurrence
Yes
No
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ProgressionDate,FirstDistant
Site(s)ofFirstDistantProgression
Method to determine progression, distant
Not Applicable (NOT APPLICABLE)
Nuclear Scan (Nuclear scan)
Other, Specify (Other, specify)
Pathologic (Pathologic)
Physical Exam (Physical exam)
Radiographic (Radiographic)
Other,specify(methodusedtodeterminedistantprog
ression)
Non-protocol Therapy
DIDTHEPATIENTRECEIVEANYNON-
PROTOCOLPROSTATECANCERTHERAPYSIN
CETHELASTFOLLOW-UP
No (No)
Unknown (Unknown)
Yes (Yes)
Non-ProtocolTherapyAdministeredType
Chemotherapy (Chemotherapy)
Complementary Alternative Medicine,
Specify (Complementary Alternative
Medicine, specify)
Hormones (Hormones)
None (None)
Other Specify (Other, specify)
Radiation To Other Sites, Specify
(Radiation to other sites, specify)
Radiation To Pelvis (Radiation to pelvis)
Surgery (Surgery)
Surgical Procedure Related To Previous
Rt, Specify (Surgical procedure related
to previous RT, specify)
Unknown (Unknown)
Non-ProtocolTherapyDate,First
Specify(non-protocolprostatecancertherapy)
NewCancerDiagnosisAnatomicSite
Aml/mds (AML/MDS)
Bcc (BCC)
Bladder (Bladder)
Brain (Brain)
Colorectal (Colorectal)
Esophageal (Esophageal)
Gastric (Gastric)
Liver (Liver)
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Lung (Lung)
Melanoma (Melanoma)
Nhl (NHL)
None (None)
Other Hematologic, Specify (Other
Hematologic, specify)
Other Solid, Specify (Other solid,
specify)
Pancreatic (Pancreatic)
Renal (Renal)
Squamous-skin (Squamous-Skin)
Unknown Primary (Unknown primary)
NewPrimaryCancerDate
Specify(newprimarysite)
Adverse event
LATERADIATIONTHERAPYADVERSEEVENTS
No (No)
Unknown (Unknown)
Yes (Yes)
LateRTAdverseEventGrade
-1 (-1)
2 (2)
3 (3)
4 (4)
5 (5)
8 (8)
9 (9)
LateRTAdverseEventTerm
Bladder/other Gu Specify
(BLADDER/OTHER GU Specify)
Other Gi, Specify (OTHER GI, specify)
Other, Specify (OTHER, specify)
Skin (SKIN)
Small/large Intestine, Specify
(SMALL/LARGE INTESTINE, specify)
BLADDER/OTHERGUSpecify(lateadverseevent)
SMALL/LARGEINTESTINE,specify(lateadversee
vent)
OTHERGI,specify(lateadverseevent)
OTHER,specify(lateadverseevent)
LateRTAdverseEventOnsetDate
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URINARYINCONTINENCE,SeverityGrade
0 (0)
1 (1)
2 (2)
3 (3)
URINARYINCONTINENCE,Attribution
Not Applicable (Not applicable)
Other cause, specify (Other cause,
specify)
Radiotherapy only (Radiotherapy only)
Tumor and Rx (Tumor and Rx)
Unknown (Unknown)
Specifyifothercause(urinaryincontinence,attributio
n)
URINARYINCONTINENCE,AERBeginDate
URINARYFREQUENCY/URGENCY,SeverityGra
de
0 (0)
1 (1)
2 (2)
3 (3)
URINARYFREQUENCY/URGENCY,Attribution
Not Applicable (Not applicable)
Other cause, specify (Other cause,
specify)
Radiotherapy only (Radiotherapy only)
Tumor and Rx (Tumor and Rx)
Unknown (Unknown)
Specifyifothercause(urinaryfrequency/urgency,att
ribution)
URINARYFREQUENCY/URGENCY,AERBeginD
ate
ERECTILEIMPOTENCE,SeverityGrade
0 (0)
1 (1)
2 (2)
3 (3)
ERECTILEIMPOTENCE,Attribution
Not Applicable (Not applicable)
Other cause, specify (Other cause,
specify)
Radiotherapy only (Radiotherapy only)
Tumor and Rx (Tumor and Rx)
Unknown (Unknown)
Specifyifothercause(erectileimpotence,attribution)
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Quality assurance Pressure Ulcers
(Decubitus) Prophylaxis - Basic (AQUA)
Documentation form for quality assurance in German
Health Care by the institute forapplied quality Improvement
and Research in Health Care (Aqua), https://www.aqua-
institut.de/en/home. Internal Aqua form version: DEK-B
Specification 2015 V02
All rights reserved. Please visit https://medical-data-
models.org/forms/10044
Quality assurance Pressure Ulcers
(Decubitus) Prophylaxis - Basic
(AQUA)
Basic documentation
Institutionskennzeichen*
Entlassungsdatum Krankenhaus (TT.MM.JJJJ)*
Aufnahmegrund*
hospitalization, inpatient (1)
hospitalization, inpatient with prior
preadmission treatment (2)
hospitalization, day-patient (3)
pre-admission treatment without
subsequent inpatient treatment (4)
maternity hospital (5)
birth (6)
recovery due to complications (flat rate)
to KFPV 2003 (7)
inpatient admission to organ removal (8)
Aufnahmedatum Krankenhaus (TT.MM.JJJJ)*
Geschlecht*
male (1)
female (2)
unknown (3)
Geburtsdatum (TT.MM.JJJJ)*
Identifikationsnummer des Patienten*
Fachabteilung ( 301-Vereinbarung)*
internal medicine (0100)
internal medicine: geriatrics (0102)
internal medicine: cardiology (0103)
internal medicine: nephrology (0104)
internal medicine: hematology and
internal oncology  (0105)
internal medicine: endocrinology (0106)
internal medicine: gastroenterology
(0107)
internal medicine: pneumonology (0108)
internal medicine: rheumatology (0109)
internal medicine: pulmonology (0114)
internal medicine: tumor research (0150)
internal medicine: coloproctology (0151)
internal medicine: infectiology (0152)
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internal medicine: diabetes (0153)
internal medicine: naturopathy (0154)
internal medicine: stroke unit (0156)
internal medicine (0190)
geriatry (0200)
geriatry: gynecology  (0224)
geriatry: day unit (for semi-residential
care)   (0260)
geriaty: night unit (for semi-residential
care) (0261)
geriatry (0290)
cardiology (0300)
nephrology (0400)
nephrology: pediatrics (0410)
nephrology: intensive care (0436)
nephrology (0490)
hematology and internal oncology
(0500)
hematology and internal oncology:
pediatrics (0510)
hematology and internal oncology:
gynacology (0524)
hematology and internal oncology:
radiation therapy (0533)
hematology and internal oncology
(0590)
endocrinology (0600)
endicrinology: gastroenterology (0607)
endocrinology: pediatrics (0610)
endocrinology (0690)
gastroenterology (0700)
gastroenterology: endocrinology (0706)
gastroenterology: pediatrics (0710)
gastroenterology (0790)
pneumology (0800)
rheumatology (0900)
rheumatology: pediatrics (0910)
rheumatology (0990)
pediatrics (1000)
pediatrics: nephrology (1004)
pediatrics: hematology and internal
oncology  (1005)
pediatrics: endocrinology (1006)
pediatrics: gastroenterology (1007)
pediatrics: rheumatology (1009)
pediatrics: pediatric cardiology (1011)
pediatrics: nephrology (1012)
pediatrics: pulmonology (1014)
pediatrics: pediatric neurology (1028)
pediatrics: perinatal medicine (1050)
continuing care for children (1051)
pediatrics (1090)
pediatric cardiology (1100)
pediatric cardiology: intensive care
(1136)
pediatric cardiology (1190)
neonatology (1200)
pediatric surgery (1300)
pulmonology (1400)
pulmonology: pediatrics (1410)
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pulmonology (1490)
general surgery (1500)
general surgery: pediatric surgery (1513)
general surgery: trauma surgery (1516)
general surgery: vascular surgery (1518)
general surgery: plastic surgery (1519)
general surgery: thoracic surgery (1520)
general surgery: orthopedics (1523)
general surgery: intensive care (1536)
general surgery: abdominal- and
vascular surgery (1550)
Allgemeine Chirurgie: hand surgery
(1551)
general surgery (1590)
trauma surgery (1600)
neurosurgery (1700)
vascular surgery (1800)
plastic surgery (1900)
thoracic surgery (2000)
thoracic surgery: cardiac surgery (2021)
thoracic surgery: intensive care (2036)
thoracic surgery: cardiac surgery
intensive care (2050)
thoracic surgery (2090)
cardiac surgery (2100)
cardiac surgery: vascular surgery (2118)
cardiac surgery: thoracic surgery (2120)
cardiac surgery: intensive care (2136)
cardiac surgery: thoracic surgery and
intensive care (2150)
cardiac surgery (2190)
urology (2200)
orthopedics (2300)
orthopedics: rheumatology (2309)
orthopedics: surgery (2315)
orthopedics and trauma surgery (2316)
orthopedics (2390)
gynecology and obstetrics (2400)
gynecology: geriatry (2402)
gynecology: hematology and internal
oncology  (2405)
gynecology: endocrinology (2406)
gynecology (2425)
gynecology and obstetrics (2490)
obstetrics (2500)
otolaryngology (2600)
ophthalmology (2700)
neurology: (2800)
neurology: pediatrics (2810)
neurology: stroke units (2856)
neurology (2890)
general psychiatry: (2900)
general psychiatry: neurology (2928)
general psychiatry: child and adolescent
psychiatry (2930)
general psychiatry: psychosomatics and
psychotherapy (2931)
general psychiatry: addiction treatment
(2950)
general psychiatry: geropsychiatry
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(2951)
general psychiatry: forensic treatment
(2952)
general psychiatry: addiction treatment
(day unit) (2953)
general psychiatry: addiction treatment
(night unit) (2954)
general psychiatry: geropsychiatry (day
unit) (2955)
general psychiatry: geropsychiatry (night
unit) (2956)
general psychiatry: day unit (for semi-
residential care) (2960)
general psychiatry: night unit (for semi-
residential care) (2961)
general psychiatry (2990)
child and adolescent psychiatry (3000)
child and adolescent psychiatry: day unit
(for semi-residential care) (3060)
child and adolescent psychiatry: night
unit (for semi-residential care) (3061)
child and adolescent psychiatry (3090)
psychosomatic/psychotherapy (3100)
psychosomatic/psychotherapy: child and
adolescent psychiatry (3110)
psychosomatic/psychotherapy: day unit
(for semi-residential care) (3160)
psychosomatic/psychotherapy: night unit
(for semi-residential care) (3161)
psychosomatic/psychotherapy (3190)
nuclear medicine (3200)
nuclear medicine: radiation therapy
(3233)
nuclear medicine (3290)
radiation therapy (3300)
radiation therapy: hematology and
internal oncology  (3305)
radiation therapy: radiology (3350)
radiation therapy (3390)
dermatology (3400)
dermatology: day unit (for semi-
residential care) (3460)
dermatology (3490)
dentistry, orthodontics, maxillofacial
surgery (3500)
intensive-care medicine (3600)
intensive-care medicine: internal
medicine (3601)
intensive-care medicine: cardiology
(3603)
intensive-care medicine: pediatrics
(3610)
intensive-care medicine: neurosurgery
(3617)
intensive-care medicine: surgery (3618)
intensive-care medicine: cardiac surgery
(3621)
intensive-care medicine: urology (3622)
intensive-care medicine: gynecology and
obstetrics (3624)
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intensive-care medicine: otolaryngology
(3626)
intensive-care medicine: neurology
(3628)
operative intensive-care medicine:
surgery (3650)
intensive-care medicine: thorax-heart
surgery (3651)
intensive-care medicine: heart-thorax
surgery (3652)
intensive-care medicine (3690)
other medical specialty (3700)
angiology (3750)
radiology (3751)
palliative care (3752)
pain therapy (3753)
section for alternative health practice
(3754)
spinal surgery (3755)
addiction medicine (3756)
visceral surgery (3757)
other medical specialty (3790)
Betriebsstätten-Nummer
Entlassender Standort ([0-9]{2})*
Entlassungsgrund ( 301-Vereinbarung)*
treatment finished as planned (1)
transferral to nursing facility (10)
discharge to hospice (11)
external transferral to psychiatric
treatment (13)
treatment finished because of other
reasons, postdischarge treatment is
planned (14)
treatment aborted against medical
advice, postdischarge treatment is
planned (15)
internal transferral with change of DRG
payment areas (17)
treatment finished as planned,
postdischarge treatment is planned (2)
case termination (internal transferral)
with change between full- and partial
stationary care (22)
discharge at the end of the year with
admission in previous year (25)
treatment finished because of other
reasons (3)
treatment aborted against medical
advice (4)
change of jurisdiction of insurer or other
payer (5)
transferral to another hospital (6)
death (7)
transferral to another hospital within
cooperative and governmental policies
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(8)
transferral to rehabilitation facility (9)
Risk factors
Diabetes Mellitus Typ 1 oder 2
(diabetestyp1u2(DIAG))*
Yes
No
Nicht näher bezeichneter Diabetes Mellitus
(diabetesnnb(DIAG))*
Yes
No
Paraparese und Paraplegie, Tetraparese und
Tetraplegie (paraparese(DIAG))*
Yes
No
Hochaufwendige Pflege von Erwachsenen
(hochaufwpflege(PROZ))*
Yes
No
Beatmungsstunden >= 1 Stunde
(beatmungueber1h(DAUBEAT))*
Yes
No
Dauer der Beatmung (in Stunden)
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Breast Cancer (NCT00053898)
Quality of Life Questionnaire
Anastrozole or Tamoxifen in Treating Postmenopausal
Women With Ductal Carcinoma in Situ Who Are
Undergoing Lumpectomy and Radiation Therapy
NCT00053898
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=A0E240A0-
FD2A-46A0-E034-080020C9C0E0
All rights reserved. Please visit https://medical-data-
models.org/forms/10045
Quality of Life Questionnaire Breast
Cancer (NCT00053898)
Header
First 3 Letters Last Name
PatientStudyID
InstitutionName
AffiliateName
Person Form Administration Name
Phone
AmendedDataInd
Yes
No
TimePointforthisQuestionnaire
12 Month Follow-up (12 month follow-up)
18 Month Follow-up (18 month follow-up)
2 Year Follow-up (2 year follow-up)
3 Year Follow-up (3 year follow-up)
30 Month Follow-up (30 month follow-up)
4 Year Follow-up (4 year follow-up)
42 Month Follow-up (42 month follow-up)
5 Year Follow-up (5 year follow-up)
54 Month Follow-up (54 month follow-up)
6 Month Follow-up (6 month follow-up)
6 Year Follow-up (6 year follow-up)
66 Month Follow-up (66 month follow-up)
Baseline (Baseline)
CaseReportFormPersonCompleteType
0 By Patient In Office (0 By patient in
office)
1 By Clinical Staff On Phone With Patient
(1 By clinical staff on phone with patient)
2 By Patient, Mailed To Office (2 By
patient, mailed to office)
Symptom frequency
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Bothered by things
Rarely Or None Of The Time (less Than
1 Day) (1)
Some  Of The Time (1-2 Days) (2)
Occasion (3-4 Days) (3)
Most Of The Time (5-7 Days) (4)
Concentration difficulty
Rarely Or None Of The Time (less Than
1 Day) (1)
Some  Of The Time (1-2 Days) (2)
Occasion (3-4 Days) (3)
Most Of The Time (5-7 Days) (4)
Depression
Rarely Or None Of The Time (less Than
1 Day) (1)
Some  Of The Time (1-2 Days) (2)
Occasion (3-4 Days) (3)
Most Of The Time (5-7 Days) (4)
Everything seems too much of an effort
Rarely Or None Of The Time (less Than
1 Day) (1)
Some  Of The Time (1-2 Days) (2)
Occasion (3-4 Days) (3)
Most Of The Time (5-7 Days) (4)
Hopeful About Future
Rarely Or None Of The Time (less Than
1 Day) (1)
Some  Of The Time (1-2 Days) (2)
Occasion (3-4 Days) (3)
Most Of The Time (5-7 Days) (4)
Fearful mood
Rarely Or None Of The Time (less Than
1 Day) (1)
Some  Of The Time (1-2 Days) (2)
Occasion (3-4 Days) (3)
Most Of The Time (5-7 Days) (4)
Restless sleep
Rarely Or None Of The Time (less Than
1 Day) (1)
Some  Of The Time (1-2 Days) (2)
Occasion (3-4 Days) (3)
Most Of The Time (5-7 Days) (4)
Happy
Rarely Or None Of The Time (less Than
1 Day) (1)
Some  Of The Time (1-2 Days) (2)
Occasion (3-4 Days) (3)
Most Of The Time (5-7 Days) (4)
Lonely
Rarely Or None Of The Time (less Than
1 Day) (1)
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Some  Of The Time (1-2 Days) (2)
Occasion (3-4 Days) (3)
Most Of The Time (5-7 Days) (4)
I could not get going
Rarely Or None Of The Time (less Than
1 Day) (1)
Some  Of The Time (1-2 Days) (2)
Occasion (3-4 Days) (3)
Most Of The Time (5-7 Days) (4)
Everyday Problems During The Past Four
Weeks
HotFlashes
Yes
No
Headaches
Yes
No
Difficuly bladder control
Yes
No
Vaginaldischarge
Yes
No
vaginal bleeding or spotting
Yes
No
Genital itching/irritation
Yes
No
Vaginaldryness
Yes
No
Painwithintercourse
Yes
No
Breastpain
Yes
No
Difficultywithbreastskin
Yes
No
Breast tenderness
Yes
No
Generalachesandpains
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Yes
No
Jointpains
Yes
No
Muscle stiffness
Yes
No
Weightgain
Yes
No
WeightLoss
Yes
No
Unhappywithappearanceofmybody
Yes
No
Decrease in appetite
Yes
No
Forgetfulness
Yes
No
Excitability
Yes
No
Temper problem
Yes
No
Drowsiness
Yes
No
Night sweats
Yes
No
Cold sweats
Yes
No
Difficulty concentrating
Yes
No
Easily distracted
Yes
No
Trouble sleeping
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Yes
No
Early awakening
Yes
No
Unspecified problem
Yes
No
Severity
Extremely (Extremely)
Moderately (Moderately)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Slightly (Slightly)
other problems
Overall health
Health Status
Excellent (Excellent)
Fair (Fair)
Good (Good)
Poor (Poor)
Very Good (Very good)
Limitations regarding moderate activities
No, Not Limited At All (0)
Yes, Limited A Little (1)
Yes, Limited A Lot (2)
Limitation regarding climbing several flight of
stairs
No, Not Limited At All (0)
Yes, Limited A Little (1)
Yes, Limited A Lot (2)
Accomplish less than you would like
Yes
No
Limitation regarding work
Yes
No
Did Not Do Work as Carefully
Yes
No
Pain Interfere With Normal Work
A Little Bit (A little bit)
Extremely (Extremely)
Moderately (Moderately)
Not At All (Not at all)
Quite A Bit (Quite a bit)
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Mood
Felt calm
None Of The Time (0)
A Little Of The Time (1)
Some Of The Time (2)
A Good Bit Of The Time (3)
Most Of The Time (4)
All Of The Time (5)
Feel Full of Pep
None Of The Time (0)
A Little Of The Time (1)
Some Of The Time (2)
A Good Bit Of The Time (3)
Most Of The Time (4)
All Of The Time (5)
Have a Lot of Energy
None Of The Time (0)
A Little Of The Time (1)
Some Of The Time (2)
A Good Bit Of The Time (3)
Most Of The Time (4)
All Of The Time (5)
feel worn out
None Of The Time (0)
A Little Of The Time (1)
Some Of The Time (2)
A Good Bit Of The Time (3)
Most Of The Time (4)
All Of The Time (5)
feel tired
None Of The Time (0)
A Little Of The Time (1)
Some Of The Time (2)
A Good Bit Of The Time (3)
Most Of The Time (4)
All Of The Time (5)
Felt Downhearted and Blue
None Of The Time (0)
A Little Of The Time (1)
Some Of The Time (2)
A Good Bit Of The Time (3)
Most Of The Time (4)
All Of The Time (5)
physical health or emotional problems interfered
with social activities
None Of The Time (0)
A Little Of The Time (1)
Some Of The Time (2)
A Good Bit Of The Time (3)
Most Of The Time (4)
All Of The Time (5)
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Overall quality of life
0 (0)
1 (1)
10 (10)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
7 (7)
8 (8)
9 (9)
Sexual activity
Sexually active past 6 months
Yes
No
Lack of Sexual Interest
Not A Problem (0)
A Little Problem (1)
A Definite Problem (2)
A Serious Problem (3)
Aroused sexually
Not A Problem (0)
A Little Problem (1)
A Definite Problem (2)
A Serious Problem (3)
Enjoy sex
Not A Problem (0)
A Little Problem (1)
A Definite Problem (2)
A Serious Problem (3)
Orgasmic Disorder
Not A Problem (0)
A Little Problem (1)
A Definite Problem (2)
A Serious Problem (3)
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Quality assurance Hip Fracture with
Osteosynthesis (AQUA)
Documentation form for quality assurance in German
Health Care by the institute forapplied quality Improvement
and Research in Health Care (Aqua), https://www.aqua-
institut.de/en/home. Internal Aqua form version: 17-1
Specification 2015 V02
All rights reserved. Please visit https://medical-data-
models.org/forms/10046
Quality assurance Hip Fracture with
Osteosynthesis (AQUA)
Basic documentation
Institutionskennzeichen*
Datum der Fraktur (nur bei Frakturen während
des akut-stationären Aufenthaltes) (TT.MM.JJJJ)
Frakturereignis*
was reason for the acute hospitalization
(1)
only occurred during the acute inpatient
stay (2)
Aufnahmezeitpunkt Krankenhaus*
Aufnahmedatum Krankenhaus*
Geschlecht*
male (1)
female (2)
Geburtsdatum*
Identifikationsnummer des Patienten*
Fachabteilung*
internal medicine (0100)
internal medicine: geriatrics (0102)
internal medicine: cardiology (0103)
internal medicine: nephrology (0104)
internal medicine: hematology and
internal oncology  (0105)
internal medicine: endocrinology (0106)
internal medicine: gastroenterology
(0107)
internal medicine: pneumonology (0108)
internal medicine: rheumatology (0109)
internal medicine: pulmonology (0114)
internal medicine: tumor research (0150)
internal medicine: coloproctology (0151)
internal medicine: infectiology (0152)
internal medicine: diabetes (0153)
internal medicine: naturopathy (0154)
internal medicine: stroke unit (0156)
internal medicine (0190)
geriatry (0200)
geriatry: gynecology  (0224)
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geriatry: day unit (for semi-residential
care)   (0260)
geriaty: night unit (for semi-residential
care) (0261)
geriatry (0290)
cardiology (0300)
nephrology (0400)
nephrology: pediatrics (0410)
nephrology: intensive care (0436)
nephrology (0490)
hematology and internal oncology
(0500)
hematology and internal oncology:
pediatrics (0510)
hematology and internal oncology:
gynacology (0524)
hematology and internal oncology:
radiation therapy (0533)
hematology and internal oncology
(0590)
endocrinology (0600)
endicrinology: gastroenterology (0607)
endocrinology: pediatrics (0610)
endocrinology (0690)
gastroenterology (0700)
gastroenterology: endocrinology (0706)
gastroenterology: pediatrics (0710)
gastroenterology (0790)
pneumology (0800)
rheumatology (0900)
rheumatology: pediatrics (0910)
rheumatology (0990)
pediatrics (1000)
pediatrics: nephrology (1004)
pediatrics: hematology and internal
oncology  (1005)
pediatrics: endocrinology (1006)
pediatrics: gastroenterology (1007)
pediatrics: rheumatology (1009)
pediatrics: pediatric cardiology (1011)
pediatrics: nephrology (1012)
pediatrics: pulmonology (1014)
pediatrics: pediatric neurology (1028)
pediatrics: perinatal medicine (1050)
continuing care for children (1051)
pediatrics (1090)
pediatric cardiology (1100)
pediatric cardiology: intensive care
(1136)
pediatric cardiology (1190)
neonatology (1200)
pediatric surgery (1300)
pulmonology (1400)
pulmonology: pediatrics (1410)
pulmonology (1490)
general surgery (1500)
general surgery: pediatric surgery (1513)
general surgery: trauma surgery (1516)
general surgery: vascular surgery (1518)
general surgery: plastic surgery (1519)
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general surgery: thoracic surgery (1520)
general surgery: orthopedics (1523)
general surgery: intensive care (1536)
general surgery: abdominal- and
vascular surgery (1550)
Allgemeine Chirurgie: hand surgery
(1551)
general surgery (1590)
trauma surgery (1600)
neurosurgery (1700)
vascular surgery (1800)
plastic surgery (1900)
thoracic surgery (2000)
thoracic surgery: cardiac surgery (2021)
thoracic surgery: intensive care (2036)
thoracic surgery: cardiac surgery
intensive care (2050)
thoracic surgery (2090)
cardiac surgery (2100)
cardiac surgery: vascular surgery (2118)
cardiac surgery: thoracic surgery (2120)
cardiac surgery: intensive care (2136)
cardiac surgery: thoracic surgery and
intensive care (2150)
cardiac surgery (2190)
urology (2200)
orthopedics (2300)
orthopedics: rheumatology (2309)
orthopedics: surgery (2315)
orthopedics and trauma surgery (2316)
orthopedics (2390)
gynecology and obstetrics (2400)
gynecology: geriatry (2402)
gynecology: hematology and internal
oncology  (2405)
gynecology: endocrinology (2406)
gynecology (2425)
gynecology and obstetrics (2490)
obstetrics (2500)
otolaryngology (2600)
ophthalmology (2700)
neurology: (2800)
neurology: pediatrics (2810)
neurology: stroke units (2856)
neurology (2890)
general psychiatry: (2900)
general psychiatry: neurology (2928)
general psychiatry: child and adolescent
psychiatry (2930)
general psychiatry: psychosomatics and
psychotherapy (2931)
general psychiatry: addiction treatment
(2950)
general psychiatry: geropsychiatry
(2951)
general psychiatry: forensic treatment
(2952)
general psychiatry: addiction treatment
(day unit) (2953)
general psychiatry: addiction treatment
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(night unit) (2954)
general psychiatry: geropsychiatry (day
unit) (2955)
general psychiatry: geropsychiatry (night
unit) (2956)
general psychiatry: day unit (for semi-
residential care) (2960)
general psychiatry: night unit (for semi-
residential care) (2961)
general psychiatry (2990)
child and adolescent psychiatry (3000)
child and adolescent psychiatry: day unit
(for semi-residential care) (3060)
child and adolescent psychiatry: night
unit (for semi-residential care) (3061)
child and adolescent psychiatry (3090)
psychosomatic/psychotherapy (3100)
psychosomatic/psychotherapy: child and
adolescent psychiatry (3110)
psychosomatic/psychotherapy: day unit
(for semi-residential care) (3160)
psychosomatic/psychotherapy: night unit
(for semi-residential care) (3161)
psychosomatic/psychotherapy (3190)
nuclear medicine (3200)
nuclear medicine: radiation therapy
(3233)
nuclear medicine (3290)
radiation therapy (3300)
radiation therapy: hematology and
internal oncology  (3305)
radiation therapy: radiology (3350)
radiation therapy (3390)
dermatology (3400)
dermatology: day unit (for semi-
residential care) (3460)
dermatology (3490)
dentistry, orthodontics, maxillofacial
surgery (3500)
intensive-care medicine (3600)
intensive-care medicine: internal
medicine (3601)
intensive-care medicine: cardiology
(3603)
intensive-care medicine: pediatrics
(3610)
intensive-care medicine: neurosurgery
(3617)
intensive-care medicine: surgery (3618)
intensive-care medicine: cardiac surgery
(3621)
intensive-care medicine: urology (3622)
intensive-care medicine: gynecology and
obstetrics (3624)
intensive-care medicine: otolaryngology
(3626)
intensive-care medicine: neurology
(3628)
operative intensive-care medicine:
surgery (3650)
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intensive-care medicine: thorax-heart
surgery (3651)
intensive-care medicine: heart-thorax
surgery (3652)
intensive-care medicine (3690)
other medical specialty (3700)
angiology (3750)
radiology (3751)
palliative care (3752)
pain therapy (3753)
section for alternative health practice
(3754)
spinal surgery (3755)
addiction medicine (3756)
visceral surgery (3757)
other medical specialty (3790)
Betriebsstätten-Nummer
Entlassender Standort*
Zeitpunkt der Fraktur
Anamnesis / diagnosis
Einstufung nach ASA-Klassifikation*
normal healthy patient (1)
patient with mild systemic disease (2)
patient with severe systemic disease (3)
patient with severe systemic disease that
is a constant threat to life (4)
moribund patient who is not expected to
survive without the operation (5)
Wundkontaminationsklassifikation*
aseptic procedure (1)
partially aseptic procedure (2)
procedure with contamination (3)
septic procedure (4)
Frakturlokalisation*
medial (1)
lateral (2)
pertrochantär (3)
other (9)
hüftgelenknahe Femurfraktur - Einteilung nach
Garden
abduction fracture (1)
unshifted (2)
shifted (3)
completely shifted (4)
vorbestehende Koxarthrose*
Yes
No
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Patient wurde mit antithrombotischer
Dauertherapie aufgenommen*
Yes
No
Art der Medikation
vitamin K antagonists (eg
phenprocoumon, warfarin) (1)
acetylsalicylic acid (2)
other antiplatelet agents (eg clopidogrel,
prasugrel, ticagrelor, cilostazol) (3)
direct thrombin inhibitors (eg argatroban,
dabigatran) (4)
other (eg rivaroxaban, fondaparinux) (9)
Operation
OP-Datum (TT.MM.JJJJ)*
Uhrzeit OP-Beginn*
Operation*
Dauer des Eingriffs*
perioperative Antibiotikaprophylaxe*
no (0)
single shot (1)
second dose (2)
more often (3)
Operationsverfahren*
DHS, angle plate (1)
intramedullary stabilization (eg, PFN,
gamma nail) (2)
Tightening (3)
other (9)
Intra- and postoperative course
postoperatives Röntgenbild a/p*
Yes
No
Lungenembolie
yes (1)
tiefe Bein-/Beckenvenenthrombose
yes (1)
kardiovaskuläre Komplikation(en)
yes (1)
Pneumonie
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yes (1)
allgemeine behandlungsbedürftige postoperative
Komplikation(en)*
Yes
No
Reoperation wegen Komplikation(en) erforderlich
Yes
No
CDC-Klassifikation
A1 (superficial infection) (1)
A2 (deep infection) (2)
A3 (cavitas/organ) (3)
postoperative Wundinfektion*
Yes
No
sonstige
yes (1)
Fraktur
yes (1)
Nervenschaden
yes (1)
Gefäßläsion
yes (1)
Wundhämatom/Nachblutung
yes (1)
Implantatdislokation
yes (1)
Implantatfehllage
yes (1)
behandlungsbedürftige intra-/postoperative
chirurgische Komplikation(en)*
Yes
No
postoperatives Röntgenbild axial oder
Lauenstein*
Yes
No
sonstige
yes (1)
Discharge
selbstständiges Gehen bei Entlassung möglich
Yes
No
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War der Patient vor der Fraktur selbstständig
gehfähig?
Yes
No
selbstständige Versorgung in der täglichen
Hygiene bei Entlassung möglich
Yes
No
War der Patient vor der Fraktur selbstständig in
der täglichen Hygiene?
Yes
No
Entlassungsdatum Krankenhaus*
Entlassungsdiagnose(n)*
Entlassungsgrund*
treatment finished as planned (1)
transferral to nursing facility (10)
discharge to hospice (11)
external transferral to psychiatric
treatment (13)
treatment finished because of other
reasons, postdischarge treatment is
planned (14)
treatment aborted against medical
advice, postdischarge treatment is
planned (15)
internal transferral with change of DRG
payment areas (17)
treatment finished as planned,
postdischarge treatment is planned (2)
case termination (internal transferral)
with change between full- and partial
stationary care (22)
discharge at the end of the year with
admission in previous year (25)
treatment finished because of other
reasons (3)
treatment aborted against medical
advice (4)
change of jurisdiction of insurer or other
payer (5)
transferral to another hospital (6)
death (7)
transferral to another hospital within
cooperative and governmental policies
(8)
transferral to rehabilitation facility (9)
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Advanced B-Cell Leukemia or Lymphoma
(NCT00057811)
ANHL01P1: Reporting Period
Rituximab, Rasburicase, and Combination Chemotherapy
in Treating Young Patients With Newly Diagnosed
Advanced B-Cell Leukemia or Lymphoma
NCT00057811 
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=BA568824-
31F6-08D7-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/10047
Reporting Period (ANHL01P1
NCT00057811)
Header
Institution Name
Protocol ID COG
PatientCOGIdentifierNumber
Patient Name
Form Completion Date
DataEnteredDate
TreatmentReportingPeriodNumber
Consolidation, 1st course (CYM-RM1)
(Consolidation, 1st course (CYM-RM1))
Consolidation, other than CYM-RM1
(Consolidation, other than CYM-RM1)
Induction, 1st Cycle (Induction, 1st
Cycle)
Induction, 2nd cycle (Induction, 2nd
cycle)
Maintenance, Course 1 (Maintenance,
Course 1)
Maintenance, Course 2 (Maintenance,
Course 2)
Maintenance, Course 3 (Maintenance,
Course 3)
Maintenance, Course 4 (Maintenance,
Course 4)
Reduction Phase (Reduction Phase)
TreatmentCurrentCourseNumber
day number
Reporting Period Start Date
Reporting Period End Date
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Patient characteristics
Patient Height
Patient Weight
assessment
Yes
No
Response
<20% tumor reduction (<20% tumor
reduction)
20% tumor reduction (>)
Complete Response (CR)
Equivocal (Equivocal)
Incomplete Response Or Stable
Disesase (Incomplete response/SD)
Insufficient Evaluation (Insufficient
evaluation to determine response status)
Not done (Not done)
Progression; At Least A 20% Increase In
The Sum Of Ld Of Target Lesions Taking
As References The Smallest Sum Ld
Recorded Since The Treatment Started
Or The Appearance Of One Or More
New Lesions (PD)
Partial Response (PR)
Stable Disease (SD)
Sub-Pilot B or Pilot B <20% reduction
(Sub-Pilot B or Pilot B <20% reduction)
Bone marrow
Yes
No
Reason no bone marrow
Bone marrow date
Bone Marrow Involvement
Yes
No
Blasts, Bone Marrow*
CNS involvement
CNSEvaluationReportingInd-2
Yes
No
CNSInvolvedInd-3
Yes
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No
CSFCellCountInd-3
Yes
No
CSFCellCountDate
Leukocytes (WBC)
Erythrocyte
Blasts
Total number of cells
Diagnostics and treatment
Echocardiogram
Yes
No
Imaging studies
Chest X-ray (1)
Abdominal Ultrasound (2)
Abdominal CT or MRI (3)
Bone Scan (4)
PET Scan (5)
Gallium Scan (6)
Head or spine CT or MRI (7)
Testicular ultrasound (8)
Imaging finding
Evidence of disease (1)
No evidence of disease (2)
Equivocal (3)
Not done (4)
PatientOff-treatmentInd-3
Yes
No
Date Last Dose
Off Treatment Reason
Alternative Therapy (Alternative therapy)
Cytogenetic Resistance (Cytogenetic
resistance)
Death On Study (Death)
Disease Progression Before Active
Treatment (Disease progression before
active treatment)
Disease Progression Before Active
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Treatment (Disease progression/relapse
during active treatment)
Disease Progression, Relapse During
Active Treatment (Group C patients who
have biopsy proven residual disease
after induction (COPADM2))
Lost To Follow-up (Lost to follow-up)
Other (Other)
Patient Withdrawal Or Refusal After
Beginning Protocol Therapy (Patient
declared ineligible)
Patient Off-treatment For Other
Complicating Disease (Patient off-
treatment for other complicating disease)
Patient Withdrawal Or Refusal After
Beginning Protocol Therapy (Patient
withdrawal or refusal after beginning
protocol therapy)
Patient Withdrawal Or Refusal Before
Beginning Protocol Therapy (Patient
withdrawal or refusal prior to beginning a
protocol therapy)
Adverse Event/side Effects/complications
(Toxicity/Side Effects/Complications)
Treatment Completed Per Protocol
Criteria (Treatment completed per
protocol criteria)
Treatment Modification
Yes
No
Treatment Assignment
CYM-RM1 (CYM-RM1)
CYM-RM2 (CYM-RM2)
Residual Tumor
Yes (1)
No (2)
Gross Disease (3)
Microscopic Disease (4)
Unknown/not Documented (5)
TumorBiopsyInd-3
Yes
No
Biopsy Result
Evidence of disease (1)
No evidence of disease (2)
Equivocal (3)
Not done (4)
CTCAdverseEventLysisGrade
RenalAbnormalityInd-3
Yes
No
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CTCAdverseEventRenalFailureGrade
RenalSupportAdministeredInd-2
Yes
No
Dialysis
Hemodialysis (1)
Peritoneal dialysis (2)
CVVH (3)
CVAH (4)
Other, Specify (5)
RenalSupportAdministeredSpecify
Agent
AgentPriorAdministeredReportingInd-2
Yes
No
AgentAdministeredDayDuration
AgentCourseCount
Agent administered during reporting period
Yes
No
CTCAdverseEventStevens-
JohnsonSyndromePresentInd-2
Yes
No
NewCancerDiagnosisInd-3
Yes
No
NewCancerDiagnosisDate
Patient Status
Alive (Alive)
Dead (Dead)
PatientLostFollow-upInd-2
Yes
No
PatientOtherEnrollmentInd-2
Yes
No
PatientWithdrawFollow-upConsentInd-2
Yes
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No
DiseaseProgressionInd-3
Yes
No
DiseaseProgressionDate
Lab values
uric acid
Potassium
Phosphate
Calcium
Blood Urea Nitrogen
Creatinine
LDH
LDH ULN
LDH elevated
ANC
Platelets
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Basic documentation type of insurance
Institutionskennzeichen der Krankenkasse der
Versichertenkarte
Patient identifying data
eGK-Versichertennummer
Providers identifying data
Institutionskennzeichen*
entlassender Standort ([0-9]{2})*
Betriebsstätten-Nummer
Fachabteilung*
internal medicine (0100)
internal medicine: geriatrics (0102)
internal medicine: cardiology (0103)
internal medicine: nephrology (0104)
internal medicine: hematology and
internal oncology  (0105)
internal medicine: endocrinology (0106)
internal medicine: gastroenterology
(0107)
internal medicine: pneumonology (0108)
internal medicine: rheumatology (0109)
internal medicine: pulmonology (0114)
internal medicine: tumor research (0150)
internal medicine: coloproctology (0151)
internal medicine: infectiology (0152)
internal medicine: diabetes (0153)
internal medicine: naturopathy (0154)
internal medicine: stroke unit (0156)
internal medicine (0190)
geriatry (0200)
geriatry: gynecology  (0224)
geriatry: day unit (for semi-residential
care)   (0260)
geriaty: night unit (for semi-residential
care) (0261)
geriatry (0290)
cardiology (0300)
nephrology (0400)
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nephrology: pediatrics (0410)
nephrology: intensive care (0436)
nephrology (0490)
hematology and internal oncology
(0500)
hematology and internal oncology:
pediatrics (0510)
hematology and internal oncology:
gynacology (0524)
hematology and internal oncology:
radiation therapy (0533)
hematology and internal oncology
(0590)
endocrinology (0600)
endicrinology: gastroenterology (0607)
endocrinology: pediatrics (0610)
endocrinology (0690)
gastroenterology (0700)
gastroenterology: endocrinology (0706)
gastroenterology: pediatrics (0710)
gastroenterology (0790)
pneumology (0800)
rheumatology (0900)
rheumatology: pediatrics (0910)
rheumatology (0990)
pediatrics (1000)
pediatrics: nephrology (1004)
pediatrics: hematology and internal
oncology  (1005)
pediatrics: endocrinology (1006)
pediatrics: gastroenterology (1007)
pediatrics: rheumatology (1009)
pediatrics: pediatric cardiology (1011)
pediatrics: nephrology (1012)
pediatrics: pulmonology (1014)
pediatrics: pediatric neurology (1028)
pediatrics: perinatal medicine (1050)
continuing care for children (1051)
pediatrics (1090)
pediatric cardiology (1100)
pediatric cardiology: intensive care
(1136)
pediatric cardiology (1190)
neonatology (1200)
pediatric surgery (1300)
pulmonology (1400)
pulmonology: pediatrics (1410)
pulmonology (1490)
general surgery (1500)
general surgery: pediatric surgery (1513)
general surgery: trauma surgery (1516)
general surgery: vascular surgery (1518)
general surgery: plastic surgery (1519)
general surgery: thoracic surgery (1520)
general surgery: orthopedics (1523)
general surgery: intensive care (1536)
general surgery: abdominal- and
vascular surgery (1550)
Allgemeine Chirurgie: hand surgery
(1551)
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general surgery (1590)
trauma surgery (1600)
neurosurgery (1700)
vascular surgery (1800)
plastic surgery (1900)
thoracic surgery (2000)
thoracic surgery: cardiac surgery (2021)
thoracic surgery: intensive care (2036)
thoracic surgery: cardiac surgery
intensive care (2050)
thoracic surgery (2090)
cardiac surgery (2100)
cardiac surgery: vascular surgery (2118)
cardiac surgery: thoracic surgery (2120)
cardiac surgery: intensive care (2136)
cardiac surgery: thoracic surgery and
intensive care (2150)
cardiac surgery (2190)
urology (2200)
orthopedics (2300)
orthopedics: rheumatology (2309)
orthopedics: surgery (2315)
orthopedics and trauma surgery (2316)
orthopedics (2390)
gynecology and obstetrics (2400)
gynecology: geriatry (2402)
gynecology: hematology and internal
oncology  (2405)
gynecology: endocrinology (2406)
gynecology (2425)
gynecology and obstetrics (2490)
obstetrics (2500)
otolaryngology (2600)
ophthalmology (2700)
neurology: (2800)
neurology: pediatrics (2810)
neurology: stroke units (2856)
neurology (2890)
general psychiatry: (2900)
general psychiatry: neurology (2928)
general psychiatry: child and adolescent
psychiatry (2930)
general psychiatry: psychosomatics and
psychotherapy (2931)
general psychiatry: addiction treatment
(2950)
general psychiatry: geropsychiatry
(2951)
general psychiatry: forensic treatment
(2952)
general psychiatry: addiction treatment
(day unit) (2953)
general psychiatry: addiction treatment
(night unit) (2954)
general psychiatry: geropsychiatry (day
unit) (2955)
general psychiatry: geropsychiatry (night
unit) (2956)
general psychiatry: day unit (for semi-
residential care) (2960)
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general psychiatry: night unit (for semi-
residential care) (2961)
general psychiatry (2990)
child and adolescent psychiatry (3000)
child and adolescent psychiatry: day unit
(for semi-residential care) (3060)
child and adolescent psychiatry: night
unit (for semi-residential care) (3061)
child and adolescent psychiatry (3090)
psychosomatic/psychotherapy (3100)
psychosomatic/psychotherapy: child and
adolescent psychiatry (3110)
psychosomatic/psychotherapy: day unit
(for semi-residential care) (3160)
psychosomatic/psychotherapy: night unit
(for semi-residential care) (3161)
psychosomatic/psychotherapy (3190)
nuclear medicine (3200)
nuclear medicine: radiation therapy
(3233)
nuclear medicine (3290)
radiation therapy (3300)
radiation therapy: hematology and
internal oncology  (3305)
radiation therapy: radiology (3350)
radiation therapy (3390)
dermatology (3400)
dermatology: day unit (for semi-
residential care) (3460)
dermatology (3490)
dentistry, orthodontics, maxillofacial
surgery (3500)
intensive-care medicine (3600)
intensive-care medicine: internal
medicine (3601)
intensive-care medicine: cardiology
(3603)
intensive-care medicine: pediatrics
(3610)
intensive-care medicine: neurosurgery
(3617)
intensive-care medicine: surgery (3618)
intensive-care medicine: cardiac surgery
(3621)
intensive-care medicine: urology (3622)
intensive-care medicine: gynecology and
obstetrics (3624)
intensive-care medicine: otolaryngology
(3626)
intensive-care medicine: neurology
(3628)
operative intensive-care medicine:
surgery (3650)
intensive-care medicine: thorax-heart
surgery (3651)
intensive-care medicine: heart-thorax
surgery (3652)
intensive-care medicine (3690)
other medical specialty (3700)
angiology (3750)
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radiology (3751)
palliative care (3752)
pain therapy (3753)
section for alternative health practice
(3754)
spinal surgery (3755)
addiction medicine (3756)
visceral surgery (3757)
other medical specialty (3790)
Patient
einrichtungsinterne Identifikationsnummer des
Patienten*
Aufnahmedatum (TT.MM.JJJJ)*
Aufnahmeuhrzeit*
Aufnahmegrund*
hospitalization, inpatient, normally (0101
)
hospitalization, inpatient, accidents at
work / occupational disease (11, para. 5
SGB V) (0102 )
hospitalization, inpatient, traffic accident /
sports accident / other accidents (eg 116
SGB X) (0103 )
hospitalization, inpatient, reference to the
action of external force (0104 )
hospitalization, inpatient, free (0105 )
hospitalization, inpatient, war-Cripples
-suffering / BVG-suffering (0106 )
hospitalization, inpatient, emergency
(0107 )
hospitalization, inpatient, normally,
payers exchange (0121 )
hospitalization, inpatient, accidents at
work / occupational disease (11, para. 5
SGB V) cost carrier exchange (0122 )
hospitalization, inpatient, traffic accident /
sports accident / other accidents (eg 116
SGB X) Cost volume change (0123 )
hospitalization, inpatient, reference to the
action of external force, payers exchange
(0124 )
hospitalization, inpatient, free, payers
exchange (0125 )
hospitalization, inpatient, war wounded
Cripples / BVG-suffering, payers
exchange (0126 )
hospitalization, inpatient, emergency,
payers exchange (0127 )
hospitalization, inpatient, normally, IV
(0141 )
hospitalization, inpatient, accidents at
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work / occupational disease (11, para. 5
SGB V), IV (0142 )
hospitalization, inpatient, traffic accident /
sports accident / other accidents (eg 116
SGB X), IV (0143 )
hospitalization, inpatient, reference to the
action of external force, by IV (0144 )
hospitalization, inpatient, free, IV (0145 )
hospitalization, inpatient, war wounded
Cripples / BVG-suffering, IV (0146 )
hospitalization, inpatient, emergency, IV
(0147 )
hospitalization, inpatient with prior pre-
admission treatment, usually (0201 )
hospitalization, inpatient with prior pre-
admission treatment, industrial injury /
occupational disease (11, para. 5 SGB
V) (0202 )
hospitalization, inpatient with prior pre-
admission treatment, traffic accident /
sports accident / other accidents (eg 116
SGB X) (0203 )
hospitalization, inpatient with prior pre-
admission treatment, reference to the
action of external force (0204 )
hospitalization, inpatient with prior
treatment pre-admission free (0205 )
hospitalization, inpatient with prior
treatment pre-admission, war wounded
Cripples / BVG-suffering (0206 )
hospitalization, inpatient with prior pre-
admission care, emergency (0207 )
hospitalization, inpatient with prior pre-
admission treatment, normally, payers
exchange (0221 )
hospitalization, inpatient with prior pre-
admission treatment, industrial injury /
occupational disease (11, para. 5 SGB
V), payers exchange (0222 )
hospitalization, inpatient with prior pre-
admission treatment, traffic accident /
sports accident / other accidents (eg 116
SGB X), cost volume change (0223 )
hospitalization, inpatient with prior pre-
admission treatment, reference to the
action of external force, payers exchange
(0224 )
hospitalization, inpatient with prior
treatment pre-admission, free, payers
exchange (0225 )
hospitalization, inpatient with prior
treatment pre-admission, war wounded
Cripples / BVG-suffering, payers
exchange (0226 )
hospitalization, inpatient with prior pre-
admission care, emergency, payers
exchange (0227 )
hospitalization, inpatient with prior pre-
admission treatment, normally, IV (0241 )
hospitalization, inpatient with prior pre-
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admission treatment, industrial injury /
occupational disease (11, para. 5 SGB
V), IV (0242 )
hospitalization, inpatient with prior pre-
admission treatment, traffic accident /
sports accident / other accidents (eg 116
SGB X), IV (0243 )
hospitalization, inpatient with prior pre-
admission treatment, indication of the
effect of external violence, IV (0244 )
hospitalization, inpatient with prior
treatment pre-admission, free, IV (0245 )
hospitalization, inpatient with prior
treatment pre-admission, war wounded
Cripples / BVG-suffering, IV (0246 )
hospitalization, inpatient with prior pre-
admission care, emergency, IV (0247 )
hospitalization, day patient, usually
(0301 )
hospitalization, day patient, accidents at
work / occupational disease (11, para. 5
SGB V) (0302 )
hospitalization, day patient, traffic
accident / sports accident / other
accidents (eg 116 SGB X) (0303 )
hospitalization, day patient, regard to the
action of external force (0304 )
hospitalization, day patient, free (0305 )
hospitalization, day patient, war wounded
Cripples / BVG-suffering (0306 )
hospital treatment, partial inpatient,
emergency (0307 )
hospitalization, day patient, normally,
payers exchange (0321 )
hospitalization, day patient, accidents at
work / occupational disease (11, para. 5
SGB V), payers exchange (0322 )
hospitalization, day patient, traffic
accident / sports accident / other
accidents (eg 116 SGB X), cost volume
change (0323 )
hospitalization, day patient, regard to the
action of external force, payers exchange
(0324 )
hospitalization, day patient, free, payers
exchange (0325 )
hospitalization, day patient, war wounded
Cripples / BVG-suffering, payers
exchange (0326 )
hospital treatment, partial inpatient,
emergency, payers exchange (0327 )
hospitalization, day patient, normally, IV
(0341 )
hospitalization, day patient, accidents at
work / occupational disease (11, para. 5
SGB V), IV (0342 )
hospitalization, day patient, traffic
accident / sports accident / other
accidents (eg 116 SGB X), IV (0343 )
hospitalization, day patient, regard to the
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action of external force, by IV (0344 )
hospitalization, day patient, free, IV
(0345 )
hospitalization, day patient, war wounded
Cripples / BVG-suffering, IV (0346 )
hospital treatment, partial inpatient,
emergency, IV (0347 )
pre-admission treatment without
subsequent inpatient treatment, usually
(0401 )
pre-admission treatment without
subsequent inpatient treatment,
industrial injury / occupational disease
(11, para. 5 SGB V) (0402 )
pre-admission treatment without
subsequent inpatient treatment, traffic
accident / sports accident / other
accidents (eg 116 SGB X) (0403 )
pre-admission treatment without
subsequent inpatient treatment,
reference to the action of external force
(0404 )
pre-admission treatment without
subsequent inpatient treatment, free
(0405 )
pre-admission treatment without
subsequent inpatient treatment, War
Cripples suffering / BVG-suffering (0406
)
pre-admission treatment without
subsequent inpatient care, emergency
(0407 )
pre-admission treatment without
subsequent inpatient treatment,
normally, payers exchange (0421 )
pre-admission treatment without
subsequent inpatient treatment,
industrial injury / occupational disease
(11, para. 5 SGB V), payers exchange
(0422 )
pre-admission treatment without
subsequent inpatient treatment, traffic
accident / sports accident / other
accidents (eg 116 SGB X), cost volume
change (0423 )
pre-admission treatment without
subsequent inpatient treatment,
reference to the action of external force,
payers exchange (0424 )
pre-admission treatment without
subsequent inpatient treatment, free,
payers exchange (0425 )
pre-admission treatment without
subsequent inpatient treatment, War
Cripples suffering / BVG-suffering,
payers exchange (0426 )
pre-admission treatment without
subsequent inpatient care, emergency,
payers exchange (0427 )
pre-admission treatment without
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subsequent inpatient treatment,
normally, IV (0441 )
pre-admission treatment without
subsequent inpatient treatment,
industrial injury / occupational disease
(11, para. 5 SGB V), IV (0442 )
pre-admission treatment without
subsequent inpatient treatment, traffic
accident / sports accident / other
accidents (eg 116 SGB X), IV (0443 )
pre-admission treatment without
subsequent inpatient treatment,
indication of the effect of external
violence, IV (0444 )
pre-admission treatment without
subsequent inpatient treatment, free, IV
(0445 )
pre-admission treatment without
subsequent inpatient treatment, War
Cripples suffering / BVG-suffering, IV
(0446 )
pre-admission treatment without
subsequent inpatient care, emergency,
IV (0447 )
Stationary delivery, normally (0501 )
Inpatient maternity, employment injury /
occupational disease (11, para. 5 SGB
V) (0502 )
Inpatient maternity, accident / sports
accident / other accidents (eg 116 SGB
X) (0503 )
Inpatient confinement regard to the
action of external force (0504 )
Stationary delivery, free (0505 )
Stationary childbirth, war wounded
suffering / BVG-suffering (0506 )
Inpatient maternity, emergency (0507 )
Stationary delivery, normally, payers
exchange (0521 )
Inpatient maternity, employment injury /
occupational disease (11, para. 5 SGB
V), payers exchange (0522 )
Inpatient maternity, accident / sports
accident / other accidents (eg 116 SGB
X), cost volume change (0523 )
Inpatient confinement regard to the
action of external force, payers exchange
(0524 )
Inpatient confinement, free, payers
exchange (0525 )
Stationary childbirth, war wounded
Cripples / BVG-suffering, payers
exchange (0526 )
Inpatient maternity, emergency, payers
exchange (0527 )
Stationary delivery, normally, IV (0541 )
Inpatient maternity, employment injury /
occupational disease (11, para. 5 SGB
V), IV (0542 )
Inpatient maternity, accident / sports
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accident / other accidents (eg 116 SGB
X), IV (0543 )
Inpatient confinement regard to the
action of external force, by IV (0544 )
Inpatient confinement, free, IV (0545 )
Stationary childbirth, war wounded
Cripples / BVG-suffering, IV (0546 )
Inpatient maternity, emergency, IV (0547
)
born, normally (0601 )
birth, accidents at work / occupational
disease (11, para. 5 SGB V) (0602 )
born, traffic accident / sports accident /
other accidents (eg 116 SGB X) (0603 )
born, reference to the action of external
force (0604 )
born, free (0605 )
born, war wounded suffering / BVG-
suffering (0606 )
born, emergency (0607 )
born, normally, payers exchange (0621 )
birth, accidents at work / occupational
disease (11, para. 5 SGB V), payers
exchange (0622 )
born, traffic accident / sports accident /
other accidents (eg 116 SGB X), cost
volume change (0623 )
born, reference to the action of external
force, payers exchange (0624 )
born, free, payers exchange (0625 )
born, war wounded Cripples / BVG-
suffering, payers exchange (0626 )
born, emergency, payers exchange
(0627 )
born, normally, IV (0641 )
birth, accidents at work / occupational
disease (11, para. 5 SGB V), IV (0642 )
born, traffic accident / sports accident /
other accidents (eg 116 SGB X), IV
(0643 )
born, reference to the action of external
force, by IV (0644 )
born, free, IV (0645 )
born, war wounded Cripples / BVG-
suffering, IV (0646 )
born, emergency, IV (0647 )
recovery due to complications (flat rate)
to KFPV 2003 normally (0701 )
recovery due to complications (flat rate)
to KFPV 2003 work injury / occupational
disease (11, para. 5 SGB V) (0702 )
recovery due to complications (flat rate)
to KFPV 2003 traffic accident / sports
accident / other accidents (eg 116 SGB
X) (0703 )
recovery due to complications (flat rate)
to KFPV 2003 Note on the action of
external force (0704 )
recovery due to complications (flat rate)
to KFPV 2003 free (0705 )
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recovery due to complications (flat rate)
to KFPV 2003 War Cripples suffering /
BVG-suffering (0706 )
recovery due to complications (flat rate)
to KFPV 2003 Emergency (0707 )
recovery due to complications (flat rate)
to KFPV 2003 Normally, payers
exchange (0721 )
recovery due to complications (flat rate)
to KFPV 2003 work injury / occupational
disease (11, para. 5 SGB V), payers
exchange (0722 )
recovery due to complications (flat rate)
to KFPV 2003 traffic accident / sports
accident / other accidents (eg 116 SGB
X), cost volume change (0723 )
recovery due to complications (flat rate)
to KFPV 2003 Note on the action of
external force, payers exchange (0724 )
recovery due to complications (flat rate)
to KFPV 2003 free, cost volume change
(0725 )
recovery due to complications (flat rate)
to KFPV 2003 War Cripples suffering /
BVG-suffering, payers exchange (0726 )
recovery due to complications (flat rate)
to KFPV 2003 emergency, payers
exchange (0727 )
recovery due to complications (flat rate)
to KFPV 2003 Normally, IV (0741 )
recovery due to complications (flat rate)
to KFPV 2003 work injury / occupational
disease (11, para. 5 SGB V), IV (0742 )
recovery due to complications (flat rate)
to KFPV 2003 traffic accident / sports
accident / other accidents (eg 116 SGB
X), IV (0743 )
recovery due to complications (flat rate)
to KFPV 2003 Note on the action of
external force, by IV (0744 )
recovery due to complications (flat rate)
to KFPV 2003 free, IV (0745 )
recovery due to complications (flat rate)
to KFPV 2003 War Cripples suffering /
BVG-suffering, IV (0746 )
recovery due to complications (flat rate)
to KFPV 2003 emergency, IV (0747 )
Hospitalisation for organ removal,
normally (0801 )
Hospitalisation for organ removal,
accidents at work / occupational disease
(11, para. 5 SGB V) (0802 )
Hospitalisation for organ removal, traffic
accident / sports accident / other
accidents (eg 116 SGB X) (0803 )
Hospitalisation for organ removal,
reference to the action of external force
(0804 )
Hospitalisation for organ removal, free
(0805 )
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Hospitalisation for organ removal, war
wounded suffering / BVG-suffering (0806
)
Hospitalisation for organ removal,
emergency (0807 )
Hospitalisation for organ removal,
normally, payers exchange (0821 )
Hospitalisation for organ removal,
accidents at work / occupational disease
(11, para. 5 SGB V), payers exchange
(0822 )
Hospitalisation for organ removal, traffic
accident / sports accident / other
accidents (eg 116 SGB X), cost volume
change (0823 )
Hospitalisation for organ removal,
reference to the action of external force,
payers exchange (0824 )
Hospitalisation for organ removal, free,
payers exchange (0825 )
Hospitalisation for organ removal, war
wounded suffering / BVG-suffering,
payers exchange (0826 )
Hospitalisation for organ removal,
emergency, payers exchange (0827 )
Hospitalisation for organ removal,
normally, IV (0841 )
Hospitalisation for organ removal,
accidents at work / occupational disease
(11, para. 5 SGB V), IV (0842 )
Hospitalisation for organ removal, traffic
accident / sports accident / other
accidents (eg 116 SGB X), IV (0843 )
Hospitalisation for organ removal,
reference to the action of external force,
by IV (0844 )
Hospitalisation for organ removal, free,
IV (0845 )
Hospitalisation for organ removal, war
wounded suffering / BVG-suffering, IV
(0846 )
Hospitalisation for organ removal,
emergency, IV (0847 )
Geburtsdatum (TT.MM.JJJJ)*
Geschlecht*
male (1)
female (2)
Preoperative anamnesis
Gehhilfen (bei Aufnahme oder vor der Fraktur)*
no (0)
Crutches (1)
rollator / walker (2)
wheelchair (3)
bedridden (4)
12 / 15
Quality assurance Hip Replacement - Basic (AQUA)
Gehstrecke (bei Aufnahme oder vor der Fraktur)*
unlimited (1)
go straight possible to 500m (2)
at the station level mobile (walking
distance: 50m) (3)
in-room mobile (4)
immobile (5)
Basic documentation intra- and
postoperative course
Gab es allgemeine behandlungsbedürftige
Komplikationen?*
Yes
No
neu aufgetretener Dekubitus
yes (1)
akute Niereninsuffizienz
yes (1)
akute gastrointestinale Blutung
yes (1)
Apoplex
yes (1)
postoperative katheterassoziierte
Harnwegsinfektion
yes (1)
Lungenembolie
yes (1)
tiefe Bein- /Beckenthrombose
yes (1)
behandlungsbedürftige kardiovaskuläre
Komplikation(en)
yes (1)
Pneumonie
yes (1)
sonstige allgemeine behandlungsbedürftige
Komplikationen
yes (1)
Prevention measures
Ist eine systematische Erfassung der
individuellen Sturzrisikofaktoren des Patienten
erfolgt?*
Yes
No
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Wurden Präventionsmaßnahmen ergriffen? (s.
auch Pflegedokumentation)*
Yes
No
Patient hat Gehtraining erhalten
yes (1)
Patient hat Hilfsmittel erhalten (z.B. Gehhilfen)
und deren Anwendung wurde trainiert
yes (1)
Medikation des Patienten wurde überprüft und
ggf. angepasst
yes (1)
Patient und/oder Angehörige wurden über das
individuelle Sturzrisiko des Patienten, über
potentielle Gefahrenquellen im häuslichen
Umfeld und über mögliche Maßnahmen zur
Sturzprophylaxe aufgeklärt
yes (1)
Postoperative range of motion
Bewegungsausmaß passiv mit Neutral-Null-
Methode bestimmt (betroffene Seite)*
Yes
No
Extension/Flexion 1 bei Entlassung (in Grad)
Extension/Flexion 2 bei Entlassung
Extension/Flexion 3 bei Entlassung
Discharge
Gehstrecke bei Entlassung
unlimited (1)
go straight possible to 500m (2)
at the station level mobile (walking
distance: 50m) (3)
in-room mobile (4)
immobile (5)
Gehhilfen bei Entlassung
no (0)
Crutches (1)
rollator / walker (2)
wheelchair (3)
bedridden (4)
Entlassungsdatum (TT.MM.JJJJ)*
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Entlassungsgrund*
treatment finished as planned (1)
transferral to nursing facility (10)
discharge to hospice (11)
external transferral to psychiatric
treatment (13)
treatment finished because of other
reasons, postdischarge treatment is
planned (14)
treatment aborted against medical
advice, postdischarge treatment is
planned (15)
internal transferral with change of DRG
payment areas (17)
treatment finished as planned,
postdischarge treatment is planned (2)
case termination (internal transferral)
with change between full- and partial
stationary care (22)
discharge at the end of the year with
admission in previous year (25)
treatment finished because of other
reasons (3)
treatment aborted against medical
advice (4)
change of jurisdiction of insurer or other
payer (5)
transferral to another hospital (6)
death (7)
transferral to another hospital within
cooperative and governmental policies
(8)
transferral to rehabilitation facility (9)
Entlassungsdiagnosen (ICD-10-GM)*
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Colorectal cancer metastases
(NCT00268463)
NSABP Protocol C-09: Quality of Life Form
Oxaliplatin and Capecitabine With or Without an Hepatic
Arterial Infusion With Floxuridine in Treating Patients Who
Are Undergoing Surgery and/or Ablation for Liver
Metastases Due to Colorectal Cancer
NCT00268463 
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=FC7E0FCB-
064A-58CD-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/10050
Quality of Life Form Colorectal
Cancer (NSABP C-09
NCT00268463)
Header
Patient Initials
Patient ID NSABP
Institution Name
Affiliate Name
PersonFormAdministrationLastName
PersonFormAdministrationFirstName
PersonFormAdministrationPhoneNumber
Data amended
Yes
No
Thisformisbeingfilledout
By clinical staff, on phone with
participant (By clinical staff, on phone
with participant)
By participant in doctor's office/clinic (By
participant in doctor's office/clinic)
By participant not in doctor's office/clinic
(By participant not in doctor's
office/clinic)
Other (Other)
AssessmentPeriodType
18 Weeks (18 weeks)
4-6 Weeks After Surgery (4-6 weeks
after surgery)
Baseline (Baseline)
Post-chemotherapy (Post chemotherapy)
Hepatic pump
Yes
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No
indicatelocationofhepaticpump
Abdomen (Abdomen)
Lower chest (Lower chest)
QualityofLifeCompleteAssessmentDate
Treatment satisfaction
Treatment convenient
Not at all (1)
A little bit (2)
Somewhat (3)
Quite a bit (4)
Very much (5)
I have not received treatment in the past
month (6)
Treatment satisfaction
Not at all (1)
A little bit (2)
Somewhat (3)
Quite a bit (4)
Very much (5)
I have not received treatment in the past
month (6)
Physical Well-being
Lack of energy
Not at all (1)
A little bit (2)
Somewhat (3)
Quite a bit (4)
Very much (5)
Nausea
Not at all (1)
A little bit (2)
Somewhat (3)
Quite a bit (4)
Very much (5)
Trouble Meeting Family Needs
Not at all (1)
A little bit (2)
Somewhat (3)
Quite a bit (4)
Very much (5)
Pain
Not at all (1)
A little bit (2)
Somewhat (3)
Quite a bit (4)
Very much (5)
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Bothered By Side Effects of Treatment
Not at all (1)
A little bit (2)
Somewhat (3)
Quite a bit (4)
Very much (5)
Feel ill
Not at all (1)
A little bit (2)
Somewhat (3)
Quite a bit (4)
Very much (5)
Forced to be in Bed
Not at all (1)
A little bit (2)
Somewhat (3)
Quite a bit (4)
Very much (5)
Social/family Well-being
feel close to friends
Not at all (1)
A little bit (2)
Somewhat (3)
Quite a bit (4)
Very much (5)
Emotional Support from Family
Not at all (1)
A little bit (2)
Somewhat (3)
Quite a bit (4)
Very much (5)
emotional support from friend
Not at all (1)
A little bit (2)
Somewhat (3)
Quite a bit (4)
Very much (5)
Family accepted illness
Not at all (1)
A little bit (2)
Somewhat (3)
Quite a bit (4)
Very much (5)
Satisfied with Family Communication
Not at all (1)
A little bit (2)
Somewhat (3)
Quite a bit (4)
Very much (5)
Feel close to partner
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Not at all (1)
A little bit (2)
Somewhat (3)
Quite a bit (4)
Very much (5)
Satisfied with sex life
Not at all (1)
A little bit (2)
Somewhat (3)
Quite a bit (4)
Very much (5)
Emotional Well-being
Feel sad
Not at all (1)
A little bit (2)
Somewhat (3)
Quite a bit (4)
Very much (5)
Satisfied with Coping with Illness
Not at all (1)
A little bit (2)
Somewhat (3)
Quite a bit (4)
Very much (5)
Losing Hope Against Illness
Not at all (1)
A little bit (2)
Somewhat (3)
Quite a bit (4)
Very much (5)
Feel Nervous
Not at all (1)
A little bit (2)
Somewhat (3)
Quite a bit (4)
Very much (5)
Worry About Dying
Not at all (1)
A little bit (2)
Somewhat (3)
Quite a bit (4)
Very much (5)
Worry About Worsening Condition
Not at all (1)
A little bit (2)
Somewhat (3)
Quite a bit (4)
Very much (5)
Functional Well-being
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able to work
Not at all (1)
A little bit (2)
Somewhat (3)
Quite a bit (4)
Very much (5)
Work is Fulfilling
Not at all (1)
A little bit (2)
Somewhat (3)
Quite a bit (4)
Very much (5)
Able to Enjoy Life
Not at all (1)
A little bit (2)
Somewhat (3)
Quite a bit (4)
Very much (5)
Accepted Illness
Not at all (1)
A little bit (2)
Somewhat (3)
Quite a bit (4)
Very much (5)
Sleeping Well
Not at all (1)
A little bit (2)
Somewhat (3)
Quite a bit (4)
Very much (5)
Enjoy Things for Fun
Not at all (1)
A little bit (2)
Somewhat (3)
Quite a bit (4)
Very much (5)
Content with Quality of Life
Not at all (1)
A little bit (2)
Somewhat (3)
Quite a bit (4)
Very much (5)
Additional Concerns
Have Swelling or Cramps in Stomach
Not at all (1)
A little bit (2)
Somewhat (3)
Quite a bit (4)
Very much (5)
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weight loss
Not at all (1)
A little bit (2)
Somewhat (3)
Quite a bit (4)
Very much (5)
Have Control of Bowels
Not at all (1)
A little bit (2)
Somewhat (3)
Quite a bit (4)
Very much (5)
Digests Food Well
Not at all (1)
A little bit (2)
Somewhat (3)
Quite a bit (4)
Very much (5)
Diarrhea
Not at all (1)
A little bit (2)
Somewhat (3)
Quite a bit (4)
Very much (5)
Good Appetite
Not at all (1)
A little bit (2)
Somewhat (3)
Quite a bit (4)
Very much (5)
Like My Body Appearance
Not at all (1)
A little bit (2)
Somewhat (3)
Quite a bit (4)
Very much (5)
Ostomy appliance
Yes
No
Embarrassed by ostomy appliance
Not at all (1)
A little bit (2)
Somewhat (3)
Quite a bit (4)
Very much (5)
Difficulty with ostomy appliance
Not at all (1)
A little bit (2)
Somewhat (3)
Quite a bit (4)
Very much (5)
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Numbness or Tingling in Hands
Not at all (1)
A little bit (2)
Somewhat (3)
Quite a bit (4)
Very much (5)
Numbness or Tingling in Feet
Not at all (1)
A little bit (2)
Somewhat (3)
Quite a bit (4)
Very much (5)
Discomfort in Hands
Not at all (1)
A little bit (2)
Somewhat (3)
Quite a bit (4)
Very much (5)
Discomfort in Feet
Not at all (1)
A little bit (2)
Somewhat (3)
Quite a bit (4)
Very much (5)
Joint Pain or Muscle Cramps
Not at all (1)
A little bit (2)
Somewhat (3)
Quite a bit (4)
Very much (5)
Feel Weak All Over
Not at all (1)
A little bit (2)
Somewhat (3)
Quite a bit (4)
Very much (5)
Hearing Trouble
Not at all (1)
A little bit (2)
Somewhat (3)
Quite a bit (4)
Very much (5)
Ringing or Buzzing in Ears
Not at all (1)
A little bit (2)
Somewhat (3)
Quite a bit (4)
Very much (5)
Trouble Buttoning Buttons
Not at all (1)
A little bit (2)
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Somewhat (3)
Quite a bit (4)
Very much (5)
Trouble Feeling Shape of Small Objects
Not at all (1)
A little bit (2)
Somewhat (3)
Quite a bit (4)
Very much (5)
Trouble with Walking
Not at all (1)
A little bit (2)
Somewhat (3)
Quite a bit (4)
Very much (5)
pain in hands or feet by cold temperatures
Not at all (1)
A little bit (2)
Somewhat (3)
Quite a bit (4)
Very much (5)
Difficulty breathing by cold temperatures
Not at all (1)
A little bit (2)
Somewhat (3)
Quite a bit (4)
Very much (5)
Abdominal Pain
Not bothered at all (1)
Bothered a little (2)
Bothered somewhat (3)
Quite bothered (4)
Very bothered (5)
Abdominal wind pain
Not bothered at all (1)
Bothered a little (2)
Bothered somewhat (3)
Quite bothered (4)
Very bothered (5)
Mouthsores
Not at all (1)
A little bit (2)
Somewhat (3)
Quite a bit (4)
Very much (5)
Vomiting
Not at all (1)
A little bit (2)
Somewhat (3)
Quite a bit (4)
Very much (5)
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skin problems
Not bothered at all (1)
Bothered a little (2)
Bothered somewhat (3)
Quite bothered (4)
Very bothered (5)
Erythema
Not bothered at all (1)
Bothered a little (2)
Bothered somewhat (3)
Quite bothered (4)
Very bothered (5)
HairLoss
Not bothered at all (1)
Bothered a little (2)
Bothered somewhat (3)
Quite bothered (4)
Very bothered (5)
Pain at intravenous site
Not bothered at all (1)
Bothered a little (2)
Bothered somewhat (3)
Quite bothered (4)
Very bothered (5)
Eye problems
Not at all (1)
A little bit (2)
Somewhat (3)
Quite a bit (4)
Very much (5)
Other problems
Not at all (1)
A little bit (2)
Somewhat (3)
Quite a bit (4)
Very much (5)
Please specify other problems
Feel Self-Conscious About Appearance
0 (0)
1 (1)
10 (10)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
7 (7)
8 (8)
9 (9)
Satisfied with chemotherapy
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0 (0)
1 (1)
10 (10)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
7 (7)
8 (8)
9 (9)
Fear about dislodged pump
0 (0)
1 (1)
10 (10)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
7 (7)
8 (8)
9 (9)
Discomfort by pump
0 (0)
1 (1)
10 (10)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
7 (7)
8 (8)
9 (9)
Protected body at pump location
0 (0)
1 (1)
10 (10)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
7 (7)
8 (8)
9 (9)
Activity
feel full of life
All of the time (1)
Most of the time (2)
Some of the time (3)
A little of the time (4)
None of the time (5)
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A Lot of Energy
All of the time (1)
Most of the time (2)
Some of the time (3)
A little of the time (4)
None of the time (5)
Feel Worn out
All of the time (1)
Most of the time (2)
Some of the time (3)
A little of the time (4)
None of the time (5)
feel tired
All of the time (1)
Most of the time (2)
Some of the time (3)
A little of the time (4)
None of the time (5)
vigorous activities
0 (0)
1 (1)
10 (10)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
7 (7)
8 (8)
9 (9)
sleep position
0 (0)
1 (1)
10 (10)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
7 (7)
8 (8)
9 (9)
Ability to eat
0 (0)
1 (1)
10 (10)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
7 (7)
8 (8)
9 (9)
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Your ability to lift things
0 (0)
1 (1)
10 (10)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
7 (7)
8 (8)
9 (9)
Hugging family or friends
0 (0)
1 (1)
10 (10)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
7 (7)
8 (8)
9 (9)
Bending over or twisting
0 (0)
1 (1)
10 (10)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
7 (7)
8 (8)
9 (9)
Your ability to travel
0 (0)
1 (1)
10 (10)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
7 (7)
8 (8)
9 (9)
Clothing
0 (0)
1 (1)
10 (10)
2 (2)
3 (3)
4 (4)
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5 (5)
6 (6)
7 (7)
8 (8)
9 (9)
Normal enjoyment of sex
0 (0)
1 (1)
10 (10)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
7 (7)
8 (8)
9 (9)
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Recurring cancer children (ADVL0212
NCT00053963)
ADVL0212: Reporting Period Worksheet
FR901228 in Treating Children With Refractory or
Recurrent Solid Tumors or Leukemia
NCT00053963
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=B1EC15B1-
1989-311F-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/10052
Reporting Period Worksheet cancer
(NCT00053963)
Header
TreatmentReportingPeriodNumber
Reporting Period Start Date
Reporting Period End Date
Protocol ID COG
Institution Name
Patient ID COG
Patient Initials
DataEnteredDate
Research Comments
Patient characteristics
Patient Height
Patient Weight
BoneMarrowEvaluationInd-3
Yes
No
BoneMarrowEvaluationDate
BoneMarrowInvolvementInd-3
Yes
No
EF by echocardiogram
Yes
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No
Shortening fraction
EF by MUGA
Yes
No
EF*
PatientOff-treatmentInd-3
Yes
No
Date Last Dose
Off Treatment Reason
Alternative Therapy (Alternative therapy)
Cytogenetic Resistance (Cytogenetic
Resistance)
Death On Study (Death on study)
Disease Progression Before Active
Treatment (Disease Progression before
Active Treatment)
Disease Progression, Relapse During
Active Treatment (Disease progression,
relapse during active treatment)
Adverse Event/side Effects/complications
(Irreversible dose-limiting toxicity)
Lost To Follow-up (Lost to follow-up)
Off Study (Off Study)
Other (Other)
Patient Off-treatment For Other
Complicating Disease (Patient off-
treatment for other complicating disease)
Patient withdrawal from protocol (Patient
withdrawal from protocol)
Patient Withdrawal Or Refusal After
Beginning Protocol Therapy (Patient
withdrawal or refusal after beginning
protocol therapy)
Patient Withdrawal Or Refusal Before
Beginning Protocol Therapy (Patient
withdrawal or refusal before beginning
protocol therapy)
Relapse/Progressive disease
(Relapse/Progressive disease)
Treatment Completed Per Protocol
Criteria (Treatment completed per
protocol criteria)
assessment
Yes
No
Tumor response
Complete Response (1)
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Partial Response (2)
Stable disease (3)
Progressive Disease (4)
Not evaluable (5)
Agent Total Dose
Drug therapy discontinued
Yes
No
DoseModificationText
Dose Modification
No (No)
Yes, Unplanned (i.e., The Treatment
Change Was Not Part Of Protocol
Guidelines) (Yes non-protocol specified
modification for toxicity)
Yes, other reason for deviation (Yes,
other reason for deviation)
Yes, Planned (i.e., The Treatment Was
Changed According To Protocol
Guidelines) (Yes, protocol specified
modification for toxicity)
RTTreatmentInd-3
Yes
No
Radiation Therapy Body Site
TissueBiologicalSourceSurgicalInd-2
Yes
No
Second malignant neoplasm
Yes
No
NewCancerDiagnosisDate
Concomitant Medication
ConcomitantMedicationReceivedInd-2
Yes
No
ConcomitantMedicationReceivedType
Anti-convulsant (Anti-Convulsant)
Anti-fungal (Anti-Fungal)
Corticosteroid (Corticosteroid)
Growth Factor (Growth factor)
Other Specify (Other, specify)
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ConcomitantMedicationUseSpecify
Treatment Begin Date
Treatment End Date
ConcomitantMedicationReceivedText
Concomitant Medication Use Indication
Patient status
Patient Status
Alive (Alive)
Dead (Dead)
PatientLostFollow-upInd-2
Yes
No
PatientOtherEnrollmentInd-2
Yes
No
PatientWithdrawFollow-upConsentInd-2
Yes
No
DiseaseProgressionInd-3
Yes
No
DiseaseProgressionDate
Adverse event
CTCAdverseEventCategory
Blood/bone Marrow (Blood/Bone
Marrow)
Cardiovascular (arrhythmia)
(Cardiovascular (Arrhythmia))
Constitutional Symptoms (Constitutional
Symptoms)
Gastrointestinal (Gastrointestinal)
Hepatic (Hepatic)
Infection Febrile Neutropenia
(Infection/Febrile Neutropenia)
Metabolic/laboratory
(Metabolic/Laboratory)
Other, specify [unnamed category]
(Other, specify [unnamed category])
Renal/genitourinary
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(Renal/Genitourinary)
CTC Adverse Event Reported Term
CTC Adverse Event Term
Blood Creatine Phosphokinase
Increased (CPK)
Blood Creatinine Increased (Creatinine)
Fatigue (Fatigue)
Not Available (Febrile Neutropenia)
Nausea (Nausea)
Neutropenia (Neutrophils/Granulocytes
(ANC/AGC))
Other, specify [unnamed type] (Other,
specify [unnamed type])
Platelet Count Decreased (Platelets)
Aspartate Aminotransferase Increased
(SGOT (AST))
Alanine Aminotransferase Increased
(SGPT (ALT))
Arrhythmia Nos (Ventricular Arrhythmia)
Vomiting Nos (Vomiting)
CTC Adverse Event Term
CTC AE term code
Neutrophils/granulocytes (anc/agc) (146)
Platelets (148)
Ventricular Arrhythmia Nos (181)
Fatigue (262)
Nausea (408)
Vomiting (426)
Sgot (ast) (481)
Sgpt (alt) (482)
Febrile Neutropenia (494)
Creatinine Phosphokinase (cpk) (532)
Creatinine (784)
Other, Specify (Other, specify [unnamed
code])
CTCAdverseEventCOGCodeSpecify
CTCAdverseEventGrade2
CTC Adverse Event Attribution Category
Definite (Definite)
Possible (Possible)
Probable (Probable)
Unlikely (Unlikely)
Unrelated (Unrelated)
ADRFiledInd-3
Yes
No
ToxicityReportInd-2
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Yes
No
CTCAdverseEventOnsetDate
Adverse Event Resolution Date
CTCAdverseEventResolutionInd
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Colon cancer (NSABP C-08 NCT00096278)
NSABP PROTOCOL C-08: REGISTRATION FORM
Fluorouracil, Leucovorin, and Oxaliplatin With or Without
Bevacizumab in Treating Patients Who Have Undergone
Surgery for Stage II or Stage III Colon Cancer
NCT00096278 
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=D7F6865F-
B506-428D-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/10053
REGISTRATION FORM Colon
cancer (NCT00096278)
Header
Patient ID NSABP
Medical Record Number
Institution Name
Institution Number
Affiliate Name
Investigator Name
InformedConsentFormSignedDate
Person Completing Form Last Name
Person Completing Form First Name
Person Completing Form Phone
ResponsiblePersonFaxNumber
Patient Initials
PatientSocialSecurityNumber
Racial Group
A Person Having Origins In Any Of The
Original Peoples Of North And South
America (including Central America),
And Who Maintains Tribal Affiliation Or
Community Attachment (American Indian
or Alaska Native)
A Person Having Origins In Any Of The
Original Peoples Of The Far East,
Southeast Asia, Or The Indian
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Subcontinent Including, For Example,
Cambodia, China, India, Japan, Korea,
Malaysia, Pakistan, The Philippine
Islands, Thailand, And Vietnam. (Asian)
A Person Having Origins In Any Of The
Black Racial Groups Of Africa. Terms
Such As "haitian" Or "negro" Can Be
Used In Addition To "black Or African
American." (Black or African American)
A Person Having Origins In Any Of The
Original Peoples Of Hawaii, Guam,
Samoa, Or Other Pacific Islands (Native
Hawaiian or Other Pacific Islander)
Patient Is Unsure Of Their Race
(Unknown)
A Person Having Origins In Any Of The
Original Peoples Of Europe, The Middle
East, Or North Africa. (White)
PatientPaymentType
Medicaid (Medicaid)
Medicaid And Medicare (Medicaid &
Medicare)
Medicare (Medicare)
Medicare And Private Insurance
(Medicare & Private)
Military Or Veterans Sponsored Nos
(Military or Veterans Sponsored NOS)
Military Sponsored (including Champus
& Tricare) (Military Sponsored (incl.
CHAMPUS & TRICARE))
No Means Of Payment (no Insurance)
(No means of payment (no insurance))
Other (Other)
Private Insurance (Private Insurance)
Self Pay (no Insurance) (Self pay (no
insurance))
Unknown (Unknown)
Veterans Sponsored (Veterans
Sponsored)
PatientEthnicityCategory
A Person Of Mexican, Puerto Rican,
Cuban, Central Or South American Or
Other Spanish Culture Or Origin,
Regardless Of Race (Hispanic or Latino)
A Person Not Meeting The Definition For
Hispanic Or Latino. (Non-Hispanic)
Patient Is Unsure Of Their Ethnicity
(Unknown)
PatientAddressCountryCode
Australia (Australia)
Canada (Canada)
Mexico (Mexico)
Other (Other)
Puerto Rico (Puerto Rico)
PatientAddressPostalCode
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PerformanceStatusScale
Fully Active, Able To Carry On All Pre-
disease Performance Without Restriction
(karnofsky 90 - 100) (ecog - 0
Asymptomatic) (0)
Restricted In Physically Strenuous
Activity But Ambulatory (k70 - 80) (ecog -
1 Symptomatic - Fully Ambulatory) (1)
Ambulatory And Capable Of All Selfcare
But Unable To Carry Out Any Work
Activities (k 50 - 60) (ecog - 2
Symptomatic; In Bed , 50% Of The Day)
(2)
Capable Of Limited Selfcare, Confined
To Bed Or Chair More Than 50% Of
Waking Hours. (k 30 - 40) (ecog - 3
Symptomatic; In Bed > 50% Of The Day
But Not Bedridden) (3)
Completely Disabled (k10 - 20) (ecog - 4
Bedridden) (4)
2 (Ambulatory and capable of all selfcare
but unable to carry out any work
activities (K 50-60))
3 (Capable of only limited selfcare,
confined to bed or chair more than 50%
of waking hours (K 30-40))
4 (Completely disabled (K 10-20))
0 (Fully active, able to carry on all pre-
disease performance without restriction
(Karnofsky 90-100))
1 (Restricted in physically strenuous
activity but ambulatory (K 70-80))
Patient characteristics
Patient Height
Patient Weight
Gender
Female (Female)
Male (Male)
Birth Date
Surgery Date
TreatmentPlannedDate
LymphNodeExaminedCount
LymphNodePositiveCount
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BloodPressure,Systolic
Bloodpressure,Diastolic
Menopausal status
Postmenopausal (1)
Premenopausal (2)
Creatinine
Creatinine, serum ULN
UrinaryCreatinineProteinAssessmentValue
Laboratory Procedure Date
UrinaryProteinCollectionValue
Tissue donor for cancer research
Yes
No
Tissue donor for research
Yes
No
Consent to contact patient
Yes
No
Consent to collect blood
Yes
No
C-08 Eligibility Checklist
PatientStudyRequirementInd-2
Yes
No
PatientPHIConsentIndicator
Yes
No
Informed Consent
Yes
No
OtherPatientColonTumorInd-2
Yes
No
Abdominal metastases
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Yes
No
EnBlocResectionTumorCompleteInd-2
Yes
No
SystemicTherapyColorectalCarcinomaPerformed
Ind-2
Yes
No
ColonTumorDistanceAnalVergeInd-2
Yes
No
TumorHistologicallyConfirmedInd-2
Yes
No
Liver function
Yes
No
LaboratoryProcedurePost-
OperativePlateletNormalResultInd-2
Yes
No
PatientCoagulationBloodInd-2
Yes
No
NeuropathyAdverseEventToxicityInd-2
Yes
No
Major surgery
Yes
No
Uncontrolled hypertension
Yes
No
Prior neoplasm
Yes
No
heart failure
Yes
No
history of Coronary artery disease
Yes
No
history of TIA
Yes
No
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HistoryofPeripheralVascularDiseasePresentInd-3
Yes
No
History of arterial thrombotic event
Yes
No
PatientWoundHistoryInd-2
Yes
No
PatientGastrointestinalHistoryUlcerationInd-2
Yes
No
PatientAdditionalClinicalTrialEligibilityCriteriaInd-2
Yes
No
Eligibility for trial
Yes
No
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NSCLC (NCT00049543)
Form 1 - Eligibility Checklist and Initial Evaluation
Gefitinib in Treating Patients With Non-Small Cell Lung
Cancer That Has Been Surgically Removed
NCT00049543
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=A7422C05-
78BD-5678-E034-0003BA0B1A09
All rights reserved. Please visit https://medical-data-
models.org/forms/10054
Eligibility Checklist and Initial
Evaluation NSCLC (NCT00049543)
Patient Information
PatientStudyID,CoordinatingGroup
Patient Initials
PatientMedicalRecordNumber
InstitutionName
RegisteredInvestigator
Birth Date
PatientGender
Female (Female)
Male (Male)
PatientRace
Native_american_cdus (American Indian
or Alaska Native)
Asian_cdus (Asian)
Black_cdus (Black or African American)
Pacific_islander_cdus (Native Hawaiian
or other Pacific Islander)
Unknown (Unknown)
White_cdus (White)
PatientEthnicity
Hispanic_or_latino (Hispanic or Latino)
Non_hispanic (Non-Hispanic)
Unknown (Unknown)
PaymentMethod
Medicaid (Medicaid)
Medicaid And Medicare (Medicaid &
Medicare)
Medicare (Medicare)
Medicare And Private Insurance
(Medicare/Private Insurance)
Military Or Veterans Sponsored Nos
(Military or Veterans Sponsored NOS)
Military Sponsored (including Champus
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& Tricare) (Military Sponsored (including
CHAMPUS and TRICARE))
No Means Of Payment (no Insurance)
(No means of payment (no insurance))
Other (Other)
Private Insurance (Private Insurance)
Self Pay (no Insurance) (Self pay (no
insurance))
Unknown (Unknown)
Veterans Sponsored (Veterans
Sponsored)
IRBApprovalDate
ProjectedTreatmentBeginDate
LoggedEntryInitials
LoggedEntryDate
RegulatoryAffairsReviewInitials
RegulatoryAffairsReviewDate
CoordinatorReviewInitials
CoordinatorReviewDate
PhysicianReviewInitials
DataEntryInitials
DataVerificationInitials
Eligibility Checklist
Lung neoplasm
Yes
No
HistologicType
Squamous cell carcinoma (1)
Adenocarcinoma (2)
Adenosquamous carcinoma (3)
Large cell undifferentiated (4)
Other, Specify (5)
PathologicStagePostoperativeInd
StageGrouping
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Refer To Figo Staging For Specific
Gynecologic Cancer (IB)
Refer To Figo Staging For Specific
Gynecologic Cancer (II)
Refer To Figo Staging For Specific
Gynecologic Cancer (IIIA)
LymphNodeAdequateSamplingInd
LymphNodeSamplingExtent
Complete Mediastinal Resection
(Complete mediastinal resection)
No Enlarged Lymph Nodes On Ct Chest,
No Mediastinal Sampling Done (No
enlarged lymph nodes on CT chest, no
mediastinal sampling done)
Nodes >= 1.5 Cm Were Sampled (Nodes
>= 1.5 cm were sampled)
Other (Other)
Partial Mediastinal Resection (Partial
mediastinal resection)
LymphNodeSamplingExtentLargeSite
LymphNodeSamplingOtherExtent
LungCarcinomaSurgicalProcedureTherapyInd-3
GrossDiseaseRemovedInd
SurgicalResectionNegativeMarginIndicator
MaximumTimePostSurgeryIndicator
SurgeryDate
TumorBlocksSentIndicator
MinimumPerformanceStatusIndicator
RequiredHematology14DaysIndicator
Lab,Hematology,SampleCollectionDate
WBC
Lab,Hematology,NeutrophilCount
Lab,Hematology,Platelets
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Units
X10^9/l (10 9/L)
G/dl (g/dL)
G/l (g/L)
Meq/l (mEq/L)
Mg/dl (mg/dl)
Mmol/l (mmol/L)
U/l (U/L)
Ul (uL)
Umol/l (umol/L)
RequiredBiochemistry14DaysIndicator
SpecimenCollectionDate
Bilirubin
Lab,Hepatic,AlkalinePhosphatase
SGOT (AST)
SGPT
Creatinine
HepaticBilirubinLabUpperLimitNormalValue
Alkaline Phosphatase ULN
SGOTLabUpperLimitNormalValue
SGPTLabUpperLimitNormalValue
Creatinine, serum ULN
Adult
Yes
No
PrestudyChestX-RayIndicator
ChestX-RayAssessmentDate
PrestudyChestCTIndicator
Date CT or MR chest
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PrestudyEKGIndicator
DiagnosticElectrocardiogramPerformedDate
EligibilityContraceptionIndicator
PrestudyPostoperativeRadiationTherapyIndicator
Yes
No
PrestudyRadiationTherapyCompleteIndicator
RadiationTherapyToxicityRecoveryIndicator
AdjuvantRTEndDate
PatientConsentSignedIndicator
InformedConsentDateSigned
Patient accessible for treatment and follow-up
Yes
No
TreatmentRequirementBeginIndicator
NoOtherMalignancyIndicator
NoCombinationLungCancerIndicator
OneDiscretePrimaryCancerIndicator
NoOphthalmologicGastrointestinalDiseaseIndicat
or
NoPathologicRiskConditionIndicator
NoPsychiatricImpairmentHistoryIndicator
FemalePatientNotPregnantIndicator
Na (NA)
NoPriorLungChemotherapyIndicator
NoAgentAllergyHistoryIndicator
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NoCYP3A4EnzymeMedicationsIndicator
AdequateSurgicalHealingIndicator
PostoperativeRadiotherapyStatus
Given (Given)
Not Given (Not given)
Randomization
RandomizationDate
InvestigatorSignature
InvestigatorSignatureDate
PersonCompletingForm,LastName
PersonCompletingForm,FirstName
FormCompletionDate,Original
History And Physical Exam
AssessmentDate
PatientCurrentSmokerIndicator
No (No)
Unknown (Unknown)
Yes (Yes)
PatientPreviousSmokerIndicator
No (No)
Unknown (Unknown)
Yes (Yes)
PerformanceStatus
0 (0 = Fully active, able to carry on all
pre-disease performance without
restriction (Karnofsky 90-100))
1 (1 = Restricted in physically strenuous
activity but ambulatory (K 70-80))
2 (2 = Ambulatory and capable of all self-
care but unable to carry out any work
activities (K 50-60))
3 (3 = Capable of only limited self-care,
confined to bed or chair more than 50%
of waking hours (K 30-40))
4 (4 = Completely disabled, cannot carry
on any self-care. Totally confined to bed
or chair (K 10-20))
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PatientHeight
PatientWeight
Investigations
DiagnosticImagingAnatomicSite
Abdomen (Abdomen)
Bone (Bone)
Brain (Brain)
Cardiac (Cardiac)
Chest (Chest)
AssessmentType
Bone Scan (Bone scan)
Chest X-ray (Chest x-ray)
Ct Scan (CT Scan)
Ekg (EKG)
Mri (MRI (NMR))
Not Evaluated (Not evaluated)
Ultrasound (Ultrasound)
PregnancyTestResult
Negative (Negative)
Not Evaluated (Not evaluated)
Positive (Positive)
Baseline Hematology/biochemistry Values
Lab,Hematology,Hemoglobin
Lab,Hematology,Neutrophils,CellPercentage
Lab,Chemistry,LactateDehydrogenase
Lab,Chemistry,LactateDehydrogenase,ULN
Lab,Renal,BUN
BUN ULN
Lab,Electrolytes,Potassium
Potassium LLN
Potassium ULN
Lab,Electrolytes,Sodium
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Sodium LLN
Sodium ULN
Chloride
Chloride LLN
Chloride ULN
Lab,Electrolytes,Calcium
Calcium LLN
Calcium ULN
Chemistry,BloodAlbumin
Albumin LLN
Albumin ULN
Disease History/prior Treatment
PrimarySurgeryDate
NStage,Pathologic
N0, According To Ajcc Criteria (N0)
N1, According To Ajcc Criteria (N1)
N2, According To Ajcc Criteria (N2)
N3, According To Ajcc Criteria (N3)
Nx, According To Ajcc Criteria (Nx)
TStage,Pathologic
Tumor 2 Cm Or Less In Greatest
Dimension (T1)
Tumor More Than 2 Cm But Not More
Than 5 Cm In Greatest Dimension (T2)
Tumor More Than 5 Cm In Greatest
Dimension (T3)
Tumor Of Any Size With Direct (T4)
StageGrouping,Pathologic
Ib, According To Current Ajcc Guidelines
(IB)
Iia, According To Current Ajcc Guidelines
(IIA)
Iib, According To Current Ajcc Guidelines
(IIB)
Iiia, According To Current Ajcc
Guidelines (IIIA)
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HistologicType,OtherName
HistologicGrade
Well Differentiated (Grade I)
Moderate (Grade II)
Poor (Grade III)
VascularInvasionInd
No (No)
Unknown (Unknown)
Yes (Yes)
ParietalPleuralMarginInvolvedInd
No (No)
Unknown (Unknown)
Yes (Yes)
LymphNodeSamplingInd
No (No)
Unknown (Unknown)
Yes (Yes)
LymphNode(s)ExaminedNumber
LymphNode(s)PositiveNumber
LymphNodesType
Highest Mediastinal Node (Highest
mediastinal (1))
Interlobar Node (Interlobar (11))
Left Hilar Node (Left hilar (10L))
Left Lobar Node (Left lobar (12L))
Left Lower Paratracheal Node (Left lower
paratracheal (4L))
Left Segmental Node (Left segmental
(13L))
Left Subsegmental Node (Left
subsegmental (14L))
Left Upper Paratracheal Node (Left
upper paratracheal (2L))
Para-aortic Node (Para-aortic (6))
Paraesophageal (Paraesophageal (8))
Pre- And Retro Paratracheal Node (Pre-
and retro paratracheal (3))
Pulmonary Ligament (Pulmonary
ligament (9))
Right Hilar Node (Right hilar (10R))
Right Lobar Node (Right lobar (12R))
Right Lower Paratracheal Node (Right
lower paratracheal (4R))
Right Segmental Node (Right segmental
(13R))
Right Subsegmental Node (Right
subsegmental (14R))
Right Upper Paratracheal Node (Right
upper paratracheal (2R))
Subaortic Node (Subaortic (5))
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Subcarinal Node (Subcarinal (7))
LymphNodeInvolvement
Equivocal (equivocal)
Not Evaluated (not evaluated)
The Node Is Considered To Be Negative
Based Upon Histological Evaluation.
(pathologically negative)
The Node Is Considered To Be Positive
Based Upon Histological Evaluation.
(pathologically positive)
Unknown (unknown)
SurgicalProcedureType
Bilobectomy (Bilobectomy)
Bronchial Sleeve Resection (Bronchial
sleeve resection)
Lobectomy (Lobectomy)
Pneumonectomy (Pneumonectomy)
TumorSize,MaximumDiameter
TumorLocation,Side
Left (Left)
Right (Right)
TumorLocation,Area
Carina (Carina)
Lower Lobe (Lower lobe)
Mainstem Bronchus (Mainstem
bronchus)
Middle Lobe (Middle lobe)
Other, Specify (Other, specify)
Upper Lobe (Upper lobe)
TumorLocation,AreaOther
TumorLocation,Zone
Indeterminate (Indeterminate)
Predominantly Central (Predominantly
central)
Predominantly Peripheral (Predominantly
peripheral)
Unknown (Unknown)
PleuraInvolvedInd
No (No)
Unknown (Unknown)
Yes (Yes)
TumorMarginInd
No (No)
Unknown (Unknown)
Yes (Yes)
TumorExtension
Chest Wall (Chest Wall)
Diaphragm (Diaphragm)
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Esophagus (Esophagus)
Mediastinum (Mediastinum)
Other, Specify (Other, specify)
Pericardium (Pericardium)
TumorExtension,OtherStructures
PriorAdjuvantRTInd
No (No)
Unknown (Unknown)
Yes (Yes)
AdjuvantRTBeginDate
RTTotalDose
PriorAdjuvantChemotherapyInd
No (No)
Unknown (Unknown)
Yes (Yes)
Adverse event
CTCAdverseEventTerm
Anorexia (anorexia)
Chest Pain (chest pain (non-cardiac and
non-pleuritic))
Constipation (constipation)
Diarrhea For Patients Without Colostomy
(diarrhea (patients without colostomy))
Dry Skin (dry skin)
Dyspnea (dyspnea (shortness of breath))
Fatigue (fatigue (lethargy, malaise,
asthenia))
Infection Without Neutropenia (infection
(without neutropenia))
Nausea (nausea)
Pruritus (pruritus)
Rash/desquamation (rash /
desquamation)
Vomiting (vomiting)
CTCAdverseEventTerm,Other
CTCAdverseEventCategory
Constitutional Symptoms (Constitutional
Symptoms)
Dermatology/skin (Dermatology/Skin)
Gastrointestinal (Gastrointestinal)
Infection (Infection)
Pain (Pain)
Pulmonary (Pulmonary)
CTCAdverseEventGrade
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Comments
Concomitant Medications
AgentName
Other Major Medical Problems
Medical condition date
Medical condition
Patient History Text
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Breast cancer NCT00053898
NSABP PROTOCOL B-35 PATHOLOGIST'S REPORT
FORM
Anastrozole or Tamoxifen in Treating Postmenopausal
Women With Ductal Carcinoma in Situ Who Are
Undergoing Lumpectomy and Radiation Therapy
NCT00053898 
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=A01C3BB9-
FE93-4CD3-E034-080020C9C0E0
All rights reserved. Please visit https://medical-data-
models.org/forms/10055
PATHOLOGIST'S REPORT FORM
(NSABP B-35 NCT00053898)
Header
FirstThreeLettersofPatient'sLastName
PatientStudyID
InstitutionName
AffiliateName
AmendedDataInd
Yes
No
AccessionNumber
Pathology report
Tumor size
Measurement gross or microscopic
Gross (Gross)
Microscopic (Microscopic)
Not Directly Measurable (Not directly
measurable)
EstimatedSize
Number of slides with DCIS
Total slides examined for DCIS
DCIS type
Comedo (Comedo)
Non-comedo (Non-comedo)
HistologicType
Cribriform (Cribriform)
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Micropapillary (Micropapillary)
Other, specify (Other, specify)
Papillary (Papillary)
Solid (Solid)
HistologicType,OtherName
HistologicType,Dominant
Cribriform (Cribriform)
Micropapillary (Micropapillary)
Other, specify (Other, specify)
Papillary (Papillary)
Solid (Solid)
HistologicType,Dominant,Other
Percent Central Necrosis
NuclearGrade
Grade 1 (Grade 1)
Grade 2 (Grade 2)
Grade 3 (Grade 3)
Microcalcifications
None (None)
Present, Involving Benign Ducts
(Present, involving benign tissue
elements)
Present, Involving Both Benign Ducts
And Dcis (Present, involving both benign
tissue elements and DCIS)
Present, Involving Dcis (Present,
involving DCIS)
DCIS,MarginResult
Indefinite (Indefinite)
Negative (Negative)
Positive (Positive)
Unable to evaluate margins (Unable to
evaluate margins)
SurgicalMarginDistance
Pathologist
Pathologist Telephone Number
FormCompletionDate,Original
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Prostate Cancer RTOG NCT00023829
A5 Radiation Therapy Oncology Group Demographic Data
Form - Version 2
Adjuvant Radiation Therapy Plus Hormone Therapy
Compared With Radiation Therapy Alone in Treating
Patients With Stage II or Stage III Prostate Cancer
NCT00023829
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=A46CB05D-
071D-28BA-E034-080020C9C0E0
All rights reserved. Please visit https://medical-data-
models.org/forms/10057
Demographic Data Form Prostate
Cancer RTOG NCT00023829
Header
DateCompleted
RTOGStudy
Case#
Institution
Institution#
PatientName
PatientID#
revised form
Yes
No
Whocompletedthisform?
Not Applicable, No Items Completed (Not
applicable, no items completed)
Other Person (Other person)
Self (Self)
Staff (Staff)
Patient characteristics
PatientRace
Asian (Asian)
Black, Not Hispanic Origin (Black, not
Hispanic origin)
Hispanic (Hispanic)
Native American / Alaskan Nation
(Native American / Alaskan Nation)
Native Hawaiian Or Other Pacific
Islander (Native Hawaiian or other Pacific
Islander)
Other, specify (Other, specify)
Unknown / I Prefer Not To Answer
(Unknown / I prefer not to answer)
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White, Not Hispanic Origin (White, not
Hispanic origin)
Other,specify(race)
AdditionalRace/Ethnicity
Asian (Asian)
Black, Not Hispanic Origin (Black, not
Hispanic origin)
Hispanic (Hispanic)
Native American / Alaskan Nation
(Native American / Alaskan Nation)
Native Hawaiian Or Other Pacific
Islander (Native Hawaiian or other Pacific
Islander)
Unknown / I Prefer Not To Answer
(Unknown / I prefer not to answer)
White, Not Hispanic Origin (White, not
Hispanic origin)
Highestschoolgradecompleted
8th Or Less (8th or less)
9 - 11th Grade (9 - 11th Grade)
Advanced Degree (Advanced degree)
Associate Degree / Some College
(Associate degree / some college)
Bachelor's Degree (Bachelor's degree)
High School Graduate / Ged (High
school graduate / GED)
I Prefer Not To Answer (I prefer not to
answer)
Other, Specify (Other, specify)
Vocational / Technical School (Vocational
/ technical school)
Other,specify(highestschoolgradecompleted)
PersonPediatricReligionName
Catholic (Catholic)
I Prefer Not To Answer (I prefer not to
answer)
Jewish (Jewish)
Morman/latter Day Saints
(Morman/Latter Day Saints)
Muslim / Islam (Muslim / Islam)
None (None)
Other, Specify (Other, specify)
Protestant (Protestant)
Other,specify(religionduringchildhood)
Maritalstatus
Divorced/separated
(Divorced/Separated)
I Prefer Not To Answer (I prefer not to
answer)
Living As Married (Living as married)
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Married (Married)
Single (Single)
Widowed (Widowed)
Wherewereyouborn?
Other Country, Specify (Other country,
specify)
Usa, Specify The 2 Letter State Code,
Eg Ny (USA, specify the 2 letter State
code, eg NY)
USA,specifythe2letterStatecode,egNY
Othercountry,specify(whereyouwereborn)
Wheredidyoulivethelongest
Other Country, Specify (Other country,
specify)
Usa, Specify The 2 Letter State Code,
Eg Ny (USA, specify the 2 letter State
code, eg NY)
Othercountry,specify(whereyoulivedthelongest)
Smoking history
No (No)
Yes, But Quit (Yes, but quit)
Yes, Currently Smoke (Yes, currently
smoke)
Age at starting smoking
Smoking years
number of cigarettes per day
Smoking cessation age
Disease history
Bleeding Problems (Bleeding problems)
Circulation Problems (Circulation
problems)
Diabetes Or Sugar In Urine (Diabetes or
sugar in urine)
Frequent Infections (Frequent infections)
Heart Problems (Heart problems)
High Blood Pressure (High blood
pressure)
Hiv/aids (HIV/AIDS)
Kidney/urine Problems (Kidney/urine
problems)
Liver Problems (Liver problems)
Lung Problems (Lung problems)
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Other (Other)
Psychological Problems (Psychological
problems)
Seizure (Seizure)
Stroke (Stroke)
Thyroid Problems (Thyroid problems)
Specifyother(illness)
Family history
Brothers
Sisters
Sons
Daughters
Adopted
Yes
No
Blood relative with cancer
Brother #1 (Brother #1)
Brother #2 (Brother #2)
Brother #3 (Brother #3)
Brother #4 (Brother #4)
Child #1 (Child #1)
Child #2 (Child #2)
Child #3 (Child #3)
Child #4 (Child #4)
Father (Father)
Mother (Mother)
Sister #1 (Sister #1)
Sister #2 (Sister #2)
Sister #3 (Sister #3)
Sister #4 (Sister #4)
Age at first cancer diagnosis
Cancer type
Breast (Breast)
Colon (Colon)
Head & Neck (Head & Neck)
Lung (Lung)
Non Melanoma Skin (Non Melanoma
Skin)
Other (Other)
Prostate (Prostate)
specify(othercancers)
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Cancer prevention trial
Cancer Prevention Trial
Yes
No
Volunteer for cancer prevention trial
1 (1)
10 (10)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
7 (7)
8 (8)
9 (9)
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Breast Cancer SWOG NCT00070564
SOUTHWEST ONCOLOGY GROUP SPECIMEN
SUBMISSION FORM
Adjuvant Doxorubicin, Cyclophosphamide, and Paclitaxel in
Treating Patients With Breast Cancer
Breast Cancer NCT00070564 
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=A678B75B-
66D7-50A2-E034-0003BA0B1A09
All rights reserved. Please visit https://medical-data-
models.org/forms/10058
SPECIMEN SUBMISSION FORM
Breast Cancer SWOG
NCT00070564
Header
SWOGPatientID
SWOGStudyNo.
RegType
Patient Initials
Disease
MainMemberInstitution/Affiliate
RegisteredInvestigator
ContactPersonatInstitution
PhoneNumber
ParticipatingGroupName
Particip.GroupProtocolNumber
PatientStudyID,ParticipatingGroup
PersonCompletingForm,LastName
FormCompletionDate,Original
Comments
Laboratory ID
SpecimenReceivedDate
1 / 3
SpecimenReceivedTime
SpecimenCondition
Damaged Or Unusable (Damaged or
unusable)
No Specimen Received (No specimen
received)
not usable as received; adequate
submission (not usable as received;
adequate submission)
not usable as received; inadequate
submission (not usable as received;
inadequate submission)
Useable (usable as received)
Specimen
TypeofSpecimen
Karyotype(s), Number (Karyotype(s),
number)
Other, Specify (Other, specify)
Slides, Type And Number (Slides, type
and number)
Tissue, Specify Site(s) (Tissue, specify
site(s))
Tubes Of Blood (Tubes of blood)
Tubes Of Bone Marrow (Tubes of bone
marrow)
Tubes Of Serum (Tubes of serum)
SpecimenSite
Specimen State
Fresh (fresh)
Frozen (frozen)
Fixed (paraffin embedded)
Slides,typeandnumber
KaryotypeCount
SpecimenCellSource,Other
SpecimenCollectionDate
SpecimenCollectionTime
STATUS
Complete Remission/response
Specimen (Complete
remission/response specimen)
Other Specimen, Specify (Other
specimen, specify)
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Prestudy Specimen (Prestudy specimen)
Relapse/recurrence Specimen
(Relapse/recurrence specimen)
Otherspecimen,specify
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Colorectal Cancer (NSABP NCT00096278)
NSABP PROTOCOL C-08 ADVERSE EVENT FORM
Fluorouracil, Leucovorin, and Oxaliplatin With or Without
Bevacizumab in Treating Patients Who Have Undergone
Surgery for Stage II or Stage III Colon Cancer
NCT00096278
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=EF511EA4-
0C5D-199B-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/10059
ADVERSE EVENT FORM Colorectal
Cancer (NSABP C-08
NCT00096278)
Header
Patient Initials
Patient ID NSABP
Institution Name
Affiliate Name
Person Completing Form Last Name
Person Completing Form First Name
Person Completing Form Phone
Data amended
Yes
No
Reporting Period Start Date
Reporting Period End Date
Research Comments
Adverse event
Typeofreport
Bevacizumab Following Completion Or
Discontinuation Of Chemotherapy
(Bevacizumab following completion or
discontinuation of chemotherapy)
Chemotherapy With Or Without
Bevacizumab (Chemotherapy with or
without bevacizumab)
Post Treatment (Post treatment)
BevacizumabAgentAdministeredCount
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PatientHospitalizationInd-2
Yes
No
AdverseEventGradeInd-2
Yes
No
CTC Adverse Event
CTC Adverse Event Term
CTC Adverse Event Grade
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Breast Cancer CALGB NCT00024102
CALGB: NEUROBEHAVOIRAL SCALES FORM
Comparison of Combination Chemotherapy Regimens in
Treating Older Women Who Have Undergone Surgery for
Breast Cancer
Breast Cancer NCT00024102
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=A50CD25E-
BDE1-371E-E034-080020C9C0E0
All rights reserved. Please visit https://medical-data-
models.org/forms/10060
NEUROBEHAVOIRAL SCALES
FORM Breast Cancer CALGB
NCT00024102
Header
CALGBForm
CALGBStudyNo
CALGBPatientID
DateCompleted
Amended data
Yes
No
Patient'sName
ParticipatingGroup
PatientHospitalNumber
ParticipatingGroupProtocolNo.
MainMemberInstitution/Adjunct
ParticipatingGroupPatientNo.
ResponsibleCRA
AssessmentNumber
neurobehavioral problems
distractibility
Above Average (1)
Normal Ability (2)
Mild Problem (3)
1 / 5
Mild to Moderate Problem (4)
Moderate Problem (5)
Moderate to Severe Problem (6)
Severe Problem (7)
Ability to focus on goals
Above Average (1)
Normal Ability (2)
Mild Problem (3)
Mild to Moderate Problem (4)
Moderate Problem (5)
Moderate to Severe Problem (6)
Severe Problem (7)
Remembering events from long ago
Above Average (1)
Normal Ability (2)
Mild Problem (3)
Mild to Moderate Problem (4)
Moderate Problem (5)
Moderate to Severe Problem (6)
Severe Problem (7)
Remembering new information
Above Average (1)
Normal Ability (2)
Mild Problem (3)
Mild to Moderate Problem (4)
Moderate Problem (5)
Moderate to Severe Problem (6)
Severe Problem (7)
Attention and concentration
Above Average (1)
Normal Ability (2)
Mild Problem (3)
Mild to Moderate Problem (4)
Moderate Problem (5)
Moderate to Severe Problem (6)
Severe Problem (7)
Abilitytoreasonthroughacomplicatedproblem
Above Average (Above Average)
Mild Problem (Mild Problem)
Mild To Moderate Problem (Mild to
Moderate Problem)
Moderate Problem (Moderate Problem)
Moderate To Severe Problem (Moderate
to Severe Problem)
Normal Ability (Normal Ability)
Severe Problem (Severe Problem)
Selfawarenessofproblems
Above Average (Above Average)
Mild Problem (Mild Problem)
Mild To Moderate Problem (Mild to
Moderate Problem)
Moderate Problem (Moderate Problem)
Moderate To Severe Problem (Moderate
to Severe Problem)
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Normal Ability (Normal Ability)
Severe Problem (Severe Problem)
Rememberingwhatyouintendedtodo
Above Average (Above Average)
Mild Problem (Mild Problem)
Mild To Moderate Problem (Mild to
Moderate Problem)
Moderate Problem (Moderate Problem)
Moderate To Severe Problem (Moderate
to Severe Problem)
Normal Ability (Normal Ability)
Severe Problem (Severe Problem)
Abilitytoshifteasilyfromoneactivitytothenext
Above Average (Above Average)
Mild Problem (Mild Problem)
Mild To Moderate Problem (Mild to
Moderate Problem)
Moderate Problem (Moderate Problem)
Moderate To Severe Problem (Moderate
to Severe Problem)
Normal Ability (Normal Ability)
Severe Problem (Severe Problem)
Rememberingappointmentsormeetings
Above Average (Above Average)
Mild Problem (Mild Problem)
Mild To Moderate Problem (Mild to
Moderate Problem)
Moderate Problem (Moderate Problem)
Moderate To Severe Problem (Moderate
to Severe Problem)
Normal Ability (Normal Ability)
Severe Problem (Severe Problem)
Generalalertness
Above Average (Above Average)
Mild Problem (Mild Problem)
Mild To Moderate Problem (Mild to
Moderate Problem)
Moderate Problem (Moderate Problem)
Moderate To Severe Problem (Moderate
to Severe Problem)
Normal Ability (Normal Ability)
Severe Problem (Severe Problem)
Abilitytothinkclearly
Above Average (Above Average)
Mild Problem (Mild Problem)
Mild To Moderate Problem (Mild to
Moderate Problem)
Moderate Problem (Moderate Problem)
Moderate To Severe Problem (Moderate
to Severe Problem)
Normal Ability (Normal Ability)
Severe Problem (Severe Problem)
Rememberingnewinformationyouhaveread
Above Average (Above Average)
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Mild Problem (Mild Problem)
Mild To Moderate Problem (Mild to
Moderate Problem)
Moderate Problem (Moderate Problem)
Moderate To Severe Problem (Moderate
to Severe Problem)
Normal Ability (Normal Ability)
Severe Problem (Severe Problem)
Rememberingwhereyouputthings
Above Average (Above Average)
Mild Problem (Mild Problem)
Mild To Moderate Problem (Mild to
Moderate Problem)
Moderate Problem (Moderate Problem)
Moderate To Severe Problem (Moderate
to Severe Problem)
Normal Ability (Normal Ability)
Severe Problem (Severe Problem)
Easeininitiatingorstartingactivitiesbyoneself
Above Average (Above Average)
Mild Problem (Mild Problem)
Mild To Moderate Problem (Mild to
Moderate Problem)
Moderate Problem (Moderate Problem)
Moderate To Severe Problem (Moderate
to Severe Problem)
Normal Ability (Normal Ability)
Severe Problem (Severe Problem)
Abilitytomakedecisions
Above Average (Above Average)
Mild Problem (Mild Problem)
Mild To Moderate Problem (Mild to
Moderate Problem)
Moderate Problem (Moderate Problem)
Moderate To Severe Problem (Moderate
to Severe Problem)
Normal Ability (Normal Ability)
Severe Problem (Severe Problem)
Rememberinginformationlearnedlongago
Above Average (Above Average)
Mild Problem (Mild Problem)
Mild To Moderate Problem (Mild to
Moderate Problem)
Moderate Problem (Moderate Problem)
Moderate To Severe Problem (Moderate
to Severe Problem)
Normal Ability (Normal Ability)
Severe Problem (Severe Problem)
Abilitytobeflexible,ratherthanrigidorhaveanoverlys
etmanner
Above Average (Above Average)
Mild Problem (Mild Problem)
Mild To Moderate Problem (Mild to
Moderate Problem)
Moderate Problem (Moderate Problem)
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Moderate To Severe Problem (Moderate
to Severe Problem)
Normal Ability (Normal Ability)
Severe Problem (Severe Problem)
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Breast Cancer DCIS NCT00053898
NSABP B-35 ADVERSE EVENT FORM (AE)
Anastrozole or Tamoxifen in Treating Postmenopausal
Women With Ductal Carcinoma in Situ Who Are
Undergoing Lumpectomy and Radiation Therapy
NCT00053898
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=A056A959-
00D2-32FA-E034-080020C9C0E0
All rights reserved. Please visit https://medical-data-
models.org/forms/10062
ADVERSE EVENT FORM Breast
Cancer NCT00053898 NSABP B-35
Header
FirstThreeLettersofPatient'sLastName
PatientStudyID
InstitutionName
AffiliateName
PersonCompletingForm,LastName
PersonCompletingForm,FirstName
PersonCompletingForm,Phone
AmendedDataInd
Yes
No
IntervalReportFromDate
IntervalReportToDate
Any grade 2,3,4 or 5 Adverse Event
Yes
No
Patient hospitalization
Yes
No
Adverse event
CTC Adverse Event Term
Abdominal Distension (Abdominal
distension)
Abdominal Infection (Abdominal
infection)
Abdominal Pain (Abdominal pain)
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Abdominal Soft Tissue Necrosis
(Abdominal soft tissue necrosis)
Abducens Nerve Disorder (Abducens
nerve disorder)
Accessory Nerve Disorder (Accessory
nerve disorder)
Acidosis (Acidosis)
Acoustic Nerve Disorder Nos (Acoustic
nerve disorder NOS)
Activated Partial Thromboplastin Time
Prolonged (Activated partial
thromboplastin time prolonged)
Acute Coronary Syndrome (Acute
coronary syndrome)
Acute Kidney Injury (Acute kidney injury)
Adrenal Insufficiency (Adrenal
insufficiency)
Adult Respiratory Distress Syndrome
(Adult respiratory distress syndrome)
Agitation (Agitation)
Akathisia (Akathisia)
Alanine Aminotransferase Increased
(Alanine aminotransferase increased)
Alcohol Intolerance (Alcohol intolerance)
Alkaline Phosphatase Increased
(Alkaline phosphatase increased)
Alkalosis (Alkalosis)
Allergic Reaction (Allergic reaction)
Allergic Rhinitis (Allergic rhinitis)
Alopecia (Alopecia)
Amnesia (Amnesia)
Anal Fistula (Anal fistula)
Anal Hemorrhage (Anal hemorrhage)
Anal Mucositis (Anal mucositis)
Anal Necrosis (Anal necrosis)
Anal Pain (Anal pain)
Anal Stenosis (Anal stenosis)
Anal Ulcer (Anal ulcer)
Anaphylaxis (Anaphylaxis)
Anemia (Anemia)
Ankle Fracture (Ankle fracture)
Anorectal Infection (Anorectal infection)
Anorexia (Anorexia)
Anorgasmia (Anorgasmia)
Anxiety (Anxiety)
Aortic Injury (Aortic injury)
Aortic Valve Disease (Aortic valve
disease)
Aphonia (Aphonia)
Apnea (Apnea)
Appendicitis (Appendicitis)
Appendicitis Perforated (Appendicitis
perforated)
Arachnoiditis (Arachnoiditis)
Arterial Injury (Arterial injury)
Arteritis Infective (Arteritis infective)
Arthralgia (Arthralgia)
Arthritis (Arthritis)
Ascites (Ascites)
Aspartate Aminotransferase Increased
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(Aspartate aminotransferase increased)
Aspiration (Aspiration)
Asystole (Asystole)
Ataxia (Ataxia)
Atelectasis (Atelectasis)
Atrial Fibrillation (Atrial fibrillation)
Atrial Flutter (Atrial flutter)
Atrioventricular Block Complete
(Atrioventricular block complete)
Atrioventricular Block First Degree
(Atrioventricular block first degree)
Autoimmune Disorder (Autoimmune
disorder)
Avascular Necrosis (Avascular necrosis)
Azoospermia (Azoospermia)
Back Pain (Back pain)
Bile Duct Stenosis (Bile duct stenosis)
Biliary Anastomotic Leak (Biliary
anastomotic leak)
Biliary Fistula (Biliary fistula)
Biliary Tract Infection (Biliary tract
infection)
Bladder Anastomotic Leak (Bladder
anastomotic leak)
Bladder Infection (Bladder infection)
Bladder Perforation (Bladder perforation)
Bladder Spasm (Bladder spasm)
Bloating (Bloating)
Blood And Lymphatic System Disorders -
Other, Specify (Blood and lymphatic
system disorders - Other, Specify)
Blood Antidiuretic Hormone Abnormal
(Blood antidiuretic hormone abnormal)
Blood Bilirubin Increased (Blood bilirubin
increased)
Blood Corticotrophin Decreased (Blood
corticotrophin decreased)
Blood Gonadotrophin Abnormal (Blood
gonadotrophin abnormal)
Blood Prolactin Abnormal (Blood
prolactin abnormal)
Blurred Vision (Blurred vision)
Body Odor (Body odor)
Bone Infection (Bone infection)
Bone Marrow Hypocellular (Bone
marrow hypocellular)
Bone Pain (Bone pain)
Brachial Plexopathy (Brachial
plexopathy)
Breast Atrophy (Breast atrophy)
Breast Infection (Breast infection)
Breast Pain (Breast pain)
Bronchial Fistula (Bronchial fistula)
Bronchial Infection (Bronchial infection)
Bronchial Obstruction (Bronchial
obstruction)
Bronchial Stricture (Bronchial stricture)
Bronchopleural Fistula (Bronchopleural
fistula)
Bronchopulmonary Hemorrhage
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(Bronchopulmonary hemorrhage)
Bronchospasm (Bronchospasm)
Bruising (Bruising)
Bullous Dermatitis (Bullous dermatitis)
Burn (Burn)
Buttock Pain (Buttock pain)
Capillary Leak Syndrome (Capillary leak
syndrome)
Carbon Monoxide Diffusing Capacity
Decreased (Carbon monoxide diffusing
capacity decreased)
Cardiac Arrest (Cardiac arrest)
Cardiac Disorders - Other, Specify
(Cardiac disorders - Other, Specify)
Cardiac Troponin I Increased (Cardiac
troponin I increased)
Cardiac Troponin T Increased (Cardiac
troponin T increased)
Cataract (Cataract)
Catheter Related Infection (Catheter
related infection)
Cd4 Lymphocytes Decreased (CD4
lymphocytes decreased)
Cecal Hemorrhage (Cecal hemorrhage)
Cecal Infection (Cecal infection)
Central Nervous System Necrosis
(Central nervous system necrosis)
Cerebrospinal Fluid Leakage
(Cerebrospinal fluid leakage)
Cervicitis Infection (Cervicitis infection)
Cheilitis (Cheilitis)
Chest Pain - Cardiac (Chest pain -
cardiac)
Chest Wall Pain (Chest wall pain)
Chills (Chills)
Cholecystitis (Cholecystitis)
Cholesterol High (Cholesterol high)
Chronic Kidney Disease (Chronic kidney
disease)
Chylothorax (Chylothorax)
Cognitive Disturbance (Cognitive
disturbance)
Colitis (Colitis)
Colonic Fistula (Colonic fistula)
Colonic Hemorrhage (Colonic
hemorrhage)
Colonic Obstruction (Colonic obstruction)
Colonic Perforation (Colonic perforation)
Colonic Stenosis (Colonic stenosis)
Colonic Ulcer (Colonic ulcer)
Concentration Impairment
(Concentration impairment)
Conduction Disorder (Conduction
disorder)
Confusion (Confusion)
Congenital, Familial And Genetic
Disorders - Other, Specify (Congenital,
familial and genetic disorders - Other,
Specify)
Conjunctivitis (Conjunctivitis)
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Conjunctivitis Infective (Conjunctivitis
infective)
Constipation (Constipation)
Constrictive Pericarditis (Constrictive
pericarditis)
Corneal Infection (Corneal infection)
Corneal Ulcer (Corneal ulcer)
Cough (Cough)
Cpk Increased (CPK increased)
Cranial Nerve Infection (Cranial nerve
infection)
Creatinine Increased (Creatinine
increased)
Cushingoid (Cushingoid)
Cystitis Noninfective (Cystitis
noninfective)
Cytokine Release Syndrome (Cytokine
release syndrome)
Death Neonatal (Death neonatal)
Death Nos (Death NOS)
Dehydration (Dehydration)
Delayed Orgasm (Delayed orgasm)
Delayed Puberty (Delayed puberty)
Delirium (Delirium)
Delusions (Delusions)
Dental Caries (Dental caries)
Depressed Level Of Consciousness
(Depressed level of consciousness)
Depression (Depression)
Dermatitis Radiation (Dermatitis
radiation)
Device Related Infection (Device related
infection)
Diarrhea (Diarrhea)
Disseminated Intravascular Coagulation
(Disseminated intravascular coagulation)
Dizziness (Dizziness)
Dry Eye (Dry eye)
Dry Mouth (Dry mouth)
Dry Skin (Dry skin)
Duodenal Fistula (Duodenal fistula)
Duodenal Hemorrhage (Duodenal
hemorrhage)
Duodenal Infection (Duodenal infection)
Duodenal Obstruction (Duodenal
obstruction)
Duodenal Perforation (Duodenal
perforation)
Duodenal Stenosis (Duodenal stenosis)
Duodenal Ulcer (Duodenal ulcer)
Dysarthria (Dysarthria)
Dysesthesia (Dysesthesia)
Dysgeusia (Dysgeusia)
Dysmenorrhea (Dysmenorrhea)
Dyspareunia (Dyspareunia)
Dyspepsia (Dyspepsia)
Dysphagia (Dysphagia)
Dysphasia (Dysphasia)
Dyspnea (Dyspnea)
Ear And Labyrinth Disorders - Other,
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Specify (Ear and labyrinth disorders -
Other, Specify)
Ear Pain (Ear pain)
Edema Cerebral (Edema cerebral)
Edema Face (Edema face)
Edema Limbs (Edema limbs)
Edema Trunk (Edema trunk)
Ejaculation Disorder (Ejaculation
disorder)
Ejection Fraction Decreased (Ejection
fraction decreased)
Electrocardiogram Qt Corrected Interval
Prolonged (Electrocardiogram QT
corrected interval prolonged)
Encephalitis Infection (Encephalitis
infection)
Encephalomyelitis Infection
(Encephalomyelitis infection)
Encephalopathy (Encephalopathy)
Endocarditis Infective (Endocarditis
infective)
Endocrine Disorders - Other, Specify
(Endocrine disorders - Other, Specify)
Endophthalmitis (Endophthalmitis)
Enterocolitis (Enterocolitis)
Enterocolitis Infectious (Enterocolitis
infectious)
Enterovesical Fistula (Enterovesical
fistula)
Epistaxis (Epistaxis)
Erectile Dysfunction (Erectile
dysfunction)
Erythema Multiforme (Erythema
multiforme)
Erythroderma (Erythroderma)
Esophageal Anastomotic Leak
(Esophageal anastomotic leak)
Esophageal Fistula (Esophageal fistula)
Esophageal Hemorrhage (Esophageal
hemorrhage)
Esophageal Infection (Esophageal
infection)
Esophageal Necrosis (Esophageal
necrosis)
Esophageal Obstruction (Esophageal
obstruction)
Esophageal Pain (Esophageal pain)
Esophageal Perforation (Esophageal
perforation)
Esophageal Stenosis (Esophageal
stenosis)
Esophageal Ulcer (Esophageal ulcer)
Esophageal Varices Hemorrhage
(Esophageal varices hemorrhage)
Esophagitis (Esophagitis)
Euphoria (Euphoria)
Exostosis (Exostosis)
External Ear Inflammation (External ear
inflammation)
External Ear Pain (External ear pain)
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Extraocular Muscle Paresis (Extraocular
muscle paresis)
Extrapyramidal Disorder (Extrapyramidal
disorder)
Eye Disorders - Other, Specify (Eye
disorders - Other, Specify)
Eye Infection (Eye infection)
Eye Pain (Eye pain)
Eyelid Function Disorder (Eyelid function
disorder)
Facial Muscle Weakness (Facial muscle
weakness)
Facial Nerve Disorder (Facial nerve
disorder)
Facial Pain (Facial pain)
Fall (Fall)
Fallopian Tube Anastomotic Leak
(Fallopian tube anastomotic leak)
Fallopian Tube Obstruction (Fallopian
tube obstruction)
Fallopian Tube Perforation (Fallopian
tube perforation)
Fallopian Tube Stenosis (Fallopian tube
stenosis)
Fat Atrophy (Fat atrophy)
Fatigue (Fatigue)
Febrile Neutropenia (Febrile
neutropenia)
Fecal Incontinence (Fecal incontinence)
Female Genital Tract Fistula (Female
genital tract fistula)
Feminization Acquired (Feminization
acquired)
Fetal Death (Fetal death)
Fetal Growth Retardation (Fetal growth
retardation)
Fever (Fever)
Fibrinogen Decreased (Fibrinogen
decreased)
Fibrosis Deep Connective Tissue
(Fibrosis deep connective tissue)
Flank Pain (Flank pain)
Flashing Lights (Flashing lights)
Flatulence (Flatulence)
Floaters (Floaters)
Flu Like Symptoms (Flu like symptoms)
Flushing (Flushing)
Forced Expiratory Volume Decreased
(Forced expiratory volume decreased)
Fracture (Fracture)
Gait Disturbance (Gait disturbance)
Gallbladder Fistula (Gallbladder fistula)
Gallbladder Infection (Gallbladder
infection)
Gallbladder Necrosis (Gallbladder
necrosis)
Gallbladder Obstruction (Gallbladder
obstruction)
Gallbladder Pain (Gallbladder pain)
Gallbladder Perforation (Gallbladder
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perforation)
Gastric Anastomotic Leak (Gastric
anastomotic leak)
Gastric Fistula (Gastric fistula)
Gastric Hemorrhage (Gastric
hemorrhage)
Gastric Necrosis (Gastric necrosis)
Gastric Perforation (Gastric perforation)
Gastric Stenosis (Gastric stenosis)
Gastric Ulcer (Gastric ulcer)
Gastritis (Gastritis)
Gastroesophageal Reflux Disease
(Gastroesophageal reflux disease)
Gastrointestinal Anastomotic Leak
(Gastrointestinal anastomotic leak)
Gastrointestinal Disorders - Other,
Specify (Gastrointestinal disorders -
Other, Specify)
Gastrointestinal Fistula (Gastrointestinal
fistula)
Gastrointestinal Pain (Gastrointestinal
pain)
Gastrointestinal Stoma Necrosis
(Gastrointestinal stoma necrosis)
Gastroparesis (Gastroparesis)
General Disorders And Administration
Site Conditions - Other, Specify (General
disorders and administration site
conditions - Other, Specify)
Generalized Muscle Weakness
(Generalized muscle weakness)
Genital Edema (Genital edema)
Ggt Increased (GGT increased)
Gingival Pain (Gingival pain)
Glaucoma (Glaucoma)
Glossopharyngeal Nerve Disorder
(Glossopharyngeal nerve disorder)
Glucose Intolerance (Glucose
intolerance)
Growth Accelerated (Growth
accelerated)
Growth Hormone Abnormal (Growth
hormone abnormal)
Growth Suppression (Growth
suppression)
Gum Infection (Gum infection)
Gynecomastia (Gynecomastia)
Hallucinations (Hallucinations)
Haptoglobin Decreased (Haptoglobin
decreased)
Head Soft Tissue Necrosis (Head soft
tissue necrosis)
Headache (Headache)
Hearing Impaired (Hearing impaired)
Heart Failure (Heart failure)
Hematoma (Hematoma)
Hematosalpinx (Hematosalpinx)
Hematuria (Hematuria)
Hemoglobin Increased (Hemoglobin
increased)
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Hemoglobinuria (Hemoglobinuria)
Hemolysis (Hemolysis)
Hemolytic Uremic Syndrome (Hemolytic
uremic syndrome)
Hemorrhoidal Hemorrhage
(Hemorrhoidal hemorrhage)
Hemorrhoids (Hemorrhoids)
Hepatic Failure (Hepatic failure)
Hepatic Hemorrhage (Hepatic
hemorrhage)
Hepatic Infection (Hepatic infection)
Hepatic Necrosis (Hepatic necrosis)
Hepatic Pain (Hepatic pain)
Hepatitis Viral (Hepatitis viral)
Hepatobiliary Disorders - Other, Specify
(Hepatobiliary disorders - Other, Specify)
Hiccups (Hiccups)
Hip Fracture (Hip fracture)
Hirsutism (Hirsutism)
Hoarseness (Hoarseness)
Hot Flashes (Hot flashes)
Hydrocephalus (Hydrocephalus)
Hypercalcemia (Hypercalcemia)
Hyperglycemia (Hyperglycemia)
Hyperhidrosis (Hyperhidrosis)
Hyperkalemia (Hyperkalemia)
Hypermagnesemia (Hypermagnesemia)
Hypernatremia (Hypernatremia)
Hyperparathyroidism
(Hyperparathyroidism)
Hypersomnia (Hypersomnia)
Hypertension (Hypertension)
Hyperthyroidism (Hyperthyroidism)
Hypertrichosis (Hypertrichosis)
Hypertriglyceridemia
(Hypertriglyceridemia)
Hyperuricemia (Hyperuricemia)
Hypoalbuminemia (Hypoalbuminemia)
Hypocalcemia (Hypocalcemia)
Hypoglossal Nerve Disorder
(Hypoglossal nerve disorder)
Hypoglycemia (Hypoglycemia)
Hypohidrosis (Hypohidrosis)
Hypokalemia (Hypokalemia)
Hypomagnesemia (Hypomagnesemia)
Hyponatremia (Hyponatremia)
Hypoparathyroidism
(Hypoparathyroidism)
Hypophosphatemia (Hypophosphatemia)
Hypotension (Hypotension)
Hypothermia (Hypothermia)
Hypothyroidism (Hypothyroidism)
Hypoxia (Hypoxia)
Ileal Fistula (Ileal fistula)
Ileal Hemorrhage (Ileal hemorrhage)
Ileal Obstruction (Ileal obstruction)
Ileal Perforation (Ileal perforation)
Ileal Stenosis (Ileal stenosis)
Ileal Ulcer (Ileal ulcer)
Ileus (Ileus)
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Immune System Disorders - Other,
Specify (Immune system disorders -
Other, Specify)
Infections And Infestations - Other,
Specify (Infections and infestations -
Other, Specify)
Infective Myositis (Infective myositis)
Infusion Related Reaction (Infusion
related reaction)
Infusion Site Extravasation (Infusion site
extravasation)
Injection Site Reaction (Injection site
reaction)
Injury To Carotid Artery (Injury to carotid
artery)
Injury To Inferior Vena Cava (Injury to
inferior vena cava)
Injury To Jugular Vein (Injury to jugular
vein)
Injury To Superior Vena Cava (Injury to
superior vena cava)
Injury, Poisoning And Procedural
Complications - Other, Specify (Injury,
poisoning and procedural complications -
Other, Specify)
Inr Increased (INR increased)
Insomnia (Insomnia)
Intestinal Stoma Leak (Intestinal stoma
leak)
Intestinal Stoma Obstruction (Intestinal
stoma obstruction)
Intestinal Stoma Site Bleeding (Intestinal
stoma site bleeding)
Intra-abdominal Hemorrhage (Intra-
abdominal hemorrhage)
Intracranial Hemorrhage (Intracranial
hemorrhage)
Intraoperative Arterial Injury
(Intraoperative arterial injury)
Intraoperative Breast Injury
(Intraoperative breast injury)
Intraoperative Cardiac Injury
(Intraoperative cardiac injury)
Intraoperative Ear Injury (Intraoperative
ear injury)
Intraoperative Endocrine Injury
(Intraoperative endocrine injury)
Intraoperative Gastrointestinal Injury
(Intraoperative gastrointestinal injury)
Intraoperative Head And Neck Injury
(Intraoperative head and neck injury)
Intraoperative Hemorrhage
(Intraoperative hemorrhage)
Intraoperative hepatobiliary injury
(Intraoperative hepatobiliary injury)
Intraoperative Musculoskeletal Injury
(Intraoperative musculoskeletal injury)
Intraoperative Neurological Injury
(Intraoperative neurological injury)
Intraoperative Ocular Injury
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(Intraoperative ocular injury)
Intraoperative Renal Injury
(Intraoperative renal injury)
Intraoperative Reproductive Tract Injury
(Intraoperative reproductive tract injury)
Intraoperative Respiratory Injury
(Intraoperative respiratory injury)
Intraoperative Skin Injury (Intraoperative
skin injury)
Intraoperative Splenic Injury
(Intraoperative splenic injury)
Intraoperative Urinary Injury
(Intraoperative urinary injury)
Intraoperative Venous Injury
(Intraoperative venous injury)
Investigations - Other, Specify
(Investigations - Other, Specify)
Iron Overload (Iron overload)
Irregular Menstruation (Irregular
menstruation)
Irritability (Irritability)
Ischemia Cerebrovascular (Ischemia
cerebrovascular)
Ivth Nerve Disorder (IVth nerve disorder)
Jejunal Fistula (Jejunal fistula)
Jejunal Hemorrhage (Jejunal
hemorrhage)
Jejunal Obstruction (Jejunal obstruction)
Jejunal Perforation (Jejunal perforation)
Jejunal Stenosis (Jejunal stenosis)
Jejunal Ulcer (Jejunal ulcer)
Joint Effusion (Joint effusion)
Joint Infection (Joint infection)
Joint Range Of Motion Decreased (Joint
range of motion decreased)
Joint Range Of Motion Decreased
Cervical Spine (Joint range of motion
decreased cervical spine)
Joint Range Of Motion Decreased
Lumbar Spine (Joint range of motion
decreased lumbar spine)
Keratitis (Keratitis)
Kidney Anastomotic Leak (Kidney
anastomotic leak)
Kidney Infection (Kidney infection)
Kyphosis (Kyphosis)
Lactation Disorder (Lactation disorder)
Large Intestinal Anastomotic Leak (Large
intestinal anastomotic leak)
Laryngeal Edema (Laryngeal edema)
Laryngeal Fistula (Laryngeal fistula)
Laryngeal Hemorrhage (Laryngeal
hemorrhage)
Laryngeal Inflammation (Laryngeal
inflammation)
Laryngeal Mucositis (Laryngeal
mucositis)
Laryngeal Obstruction (Laryngeal
obstruction)
Laryngeal Stenosis (Laryngeal stenosis)
11 / 21
Breast Cancer DCIS NCT00053898
Laryngitis (Laryngitis)
Laryngopharyngeal Dysesthesia
(Laryngopharyngeal dysesthesia)
Laryngospasm (Laryngospasm)
Left Ventricular Systolic Dysfunction (Left
ventricular systolic dysfunction)
Lethargy (Lethargy)
Leukemia Secondary To Oncology
Chemotherapy (Leukemia secondary to
oncology chemotherapy)
Leukocytosis (Leukocytosis)
Leukoencephalopathy
(Leukoencephalopathy)
Libido Decreased (Libido decreased)
Libido Increased (Libido increased)
Lip Infection (Lip infection)
Lip Pain (Lip pain)
Lipase Increased (Lipase increased)
Lipohypertrophy (Lipohypertrophy)
Localized Edema (Localized edema)
Lordosis (Lordosis)
Lower Gastrointestinal Hemorrhage
(Lower gastrointestinal hemorrhage)
Lung Infection (Lung infection)
Lymph Gland Infection (Lymph gland
infection)
Lymph Leakage (Lymph leakage)
Lymph Node Pain (Lymph node pain)
Lymphedema (Lymphedema)
Lymphocele (Lymphocele)
Lymphocyte Count Decreased
(Lymphocyte count decreased)
Lymphocyte Count Increased
(Lymphocyte count increased)
Malabsorption (Malabsorption)
Malaise (Malaise)
Mania (Mania)
Mediastinal Hemorrhage (Mediastinal
hemorrhage)
Mediastinal Infection (Mediastinal
infection)
Memory Impairment (Memory
impairment)
Meningismus (Meningismus)
Meningitis (Meningitis)
Menopause (Menopause)
Menorrhagia (Menorrhagia)
Metabolism And Nutrition Disorders -
Other, Specify (Metabolism and nutrition
disorders - Other, Specify)
Middle Ear Inflammation (Middle ear
inflammation)
Mitral Valve Disease (Mitral valve
disease)
Mobitz (type) Ii Atrioventricular Block
(Mobitz (type) II atrioventricular block)
Mobitz Type I (Mobitz type I)
Movements Involuntary (Movements
involuntary)
Mucosal Infection (Mucosal infection)
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Mucositis Oral (Mucositis oral)
Multi-organ Failure (Multi-organ failure)
Muscle Weakness Left-sided (Muscle
weakness left-sided)
Muscle Weakness Lower Limb (Muscle
weakness lower limb)
Muscle Weakness Right-sided (Muscle
weakness right-sided)
Muscle Weakness Trunk (Muscle
weakness trunk)
Muscle Weakness Upper Limb (Muscle
weakness upper limb)
Musculoskeletal And Connective Tissue
Disorder - Other, Specify
(Musculoskeletal and connective tissue
disorders - Other, Specify)
Musculoskeletal Deformity
(Musculoskeletal deformity)
Myalgia (Myalgia)
Myelitis (Myelitis)
Myelodysplastic Syndrome
(Myelodysplastic syndrome)
Myocardial Infarction (Myocardial
infarction)
Myocarditis (Myocarditis)
Myositis (Myositis)
Nail Discoloration (Nail discoloration)
Nail Infection (Nail infection)
Nail Loss (Nail loss)
Nail Ridging (Nail ridging)
Nasal Congestion (Nasal congestion)
Nausea (Nausea)
Neck Edema (Neck edema)
Neck Pain (Neck pain)
Neck Soft Tissue Necrosis (Neck soft
tissue necrosis)
Neoplasms Benign, Malignant And
Unspecified (incl Cysts And Polyps) -
Other, Specify (Neoplasms benign,
malignant and unspecified (incl cysts and
polyps) - Other, Specify)
Nervous System Disorders - Other,
Specify (Nervous system disorders -
Other, Specify)
Neuralgia (Neuralgia)
Neutrophil Count Decreased (Neutrophil
count decreased)
Night Blindness (Night blindness)
Nipple Deformity (Nipple deformity)
Non-cardiac Chest Pain (Non-cardiac
chest pain)
Nystagmus (Nystagmus)
Obesity (Obesity)
Obstruction Gastric (Obstruction gastric)
Oculomotor Nerve Disorder (Oculomotor
nerve disorder)
Olfactory Nerve Disorder (Olfactory
nerve disorder)
Oligospermia (Oligospermia)
Optic Nerve Disorder (Optic nerve
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disorder)
Oral Cavity Fistula (Oral cavity fistula)
Oral Dysesthesia (Oral dysesthesia)
Oral Hemorrhage (Oral hemorrhage)
Oral Pain (Oral pain)
Osteonecrosis Of Jaw (Osteonecrosis of
jaw)
Osteoporosis (Osteoporosis)
Otitis Externa (Otitis externa)
Otitis Media (Otitis media)
Ovarian Hemorrhage (Ovarian
hemorrhage)
Ovarian Infection (Ovarian infection)
Ovarian Rupture (Ovarian rupture)
Ovulation Pain (Ovulation pain)
Pain (Pain)
Pain In Extremity (Pain in extremity)
Pain Of Skin (Pain of skin)
Palmar-plantar Erythrodysesthesia
Syndrome (Palmar-plantar
erythrodysesthesia syndrome)
Palpitations (Palpitations)
Pancreas Infection (Pancreas infection)
Pancreatic Anastomotic Leak (Pancreatic
anastomotic leak)
Pancreatic Duct Stenosis (Pancreatic
duct stenosis)
Pancreatic Enzymes Decreased
(Pancreatic enzymes decreased)
Pancreatic Fistula (Pancreatic fistula)
Pancreatic Hemorrhage (Pancreatic
hemorrhage)
Pancreatic Necrosis (Pancreatic
necrosis)
Pancreatitis (Pancreatitis)
Papilledema (Papilledema)
Papulopustular Rash (Papulopustular
rash)
Paresthesia (Paresthesia)
Paronychia (Paronychia)
Paroxysmal Atrial Tachycardia
(Paroxysmal atrial tachycardia)
Pelvic Floor Muscle Weakness (Pelvic
floor muscle weakness)
Pelvic Infection (Pelvic infection)
Pelvic Pain (Pelvic pain)
Pelvic Soft Tissue Necrosis (Pelvic soft
tissue necrosis)
Penile Infection (Penile infection)
Penile Pain (Penile pain)
Perforation Bile Duct (Perforation bile
duct)
Pericardial Effusion (Pericardial effusion)
Pericardial Tamponade (Pericardial
tamponade)
Pericarditis (Pericarditis)
Perineal Pain (Perineal pain)
Periodontal Disease (Periodontal
disease)
Periorbital Edema (Periorbital edema)
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Periorbital Infection (Periorbital infection)
Peripheral Ischemia (Peripheral
ischemia)
Peripheral Motor Neuropathy (Peripheral
motor neuropathy)
Peripheral Nerve Infection (Peripheral
nerve infection)
Peripheral Sensory Neuropathy
(Peripheral sensory neuropathy)
Peritoneal Infection (Peritoneal infection)
Peritoneal Necrosis (Peritoneal necrosis)
Personality Change (Personality change)
Phantom Pain (Phantom pain)
Pharyngeal Anastomotic Leak
(Pharyngeal anastomotic leak)
Pharyngeal Fistula (Pharyngeal fistula)
Pharyngeal Hemorrhage (Pharyngeal
hemorrhage)
Pharyngeal Mucositis (Pharyngeal
mucositis)
Pharyngeal Necrosis (Pharyngeal
necrosis)
Pharyngeal Stenosis (Pharyngeal
stenosis)
Pharyngitis (Pharyngitis)
Pharyngolaryngeal Pain
(Pharyngolaryngeal pain)
Phlebitis (Phlebitis)
Phlebitis Infective (Phlebitis infective)
Photophobia (Photophobia)
Photosensitivity (Photosensitivity)
Platelet Count Decreased (Platelet count
decreased)
Pleural Effusion (Pleural effusion)
Pleural Hemorrhage (Pleural
hemorrhage)
Pleural Infection (Pleural infection)
Pleuritic Pain (Pleuritic pain)
Pneumonitis (Pneumonitis)
Pneumothorax (Pneumothorax)
Portal Hypertension (Portal
hypertension)
Portal Vein Thrombosis (Portal vein
thrombosis)
Postnasal Drip (Postnasal drip)
Postoperative Hemorrhage
(Postoperative hemorrhage)
Postoperative Thoracic Procedure
Complication (Postoperative thoracic
procedure complication)
Precocious Puberty (Precocious
puberty)
Pregnancy, Puerperium And Perinatal
Conditions - Other, Specify (Pregnancy,
puerperium and perinatal conditions -
Other, Specify)
Premature Delivery (Premature delivery)
Premature Menopause (Premature
menopause)
Presyncope (Presyncope)
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Proctitis (Proctitis)
Productive Cough (Productive cough)
Prolapse Of Intestinal Stoma (Prolapse
of intestinal stoma)
Prolapse Of Urostomy (Prolapse of
urostomy)
Prostate Infection (Prostate infection)
Prostatic Hemorrhage (Prostatic
hemorrhage)
Prostatic Obstruction (Prostatic
obstruction)
Prostatic Pain (Prostatic pain)
Proteinuria (Proteinuria)
Pruritus (Pruritus)
Psychiatric Disorders - Other, Specify
(Psychiatric disorders - Other, Specify)
Psychosis (Psychosis)
Pulmonary Edema (Pulmonary edema)
Pulmonary Fibrosis (Pulmonary fibrosis)
Pulmonary Fistula (Pulmonary fistula)
Pulmonary Hypertension (Pulmonary
hypertension)
Pulmonary Valve Disease (Pulmonary
valve disease)
Purpura (Purpura)
Pyramidal Tract Syndrome (Pyramidal
tract syndrome)
Radiation Recall Reaction (dermatologic)
(Radiation recall reaction (dermatologic))
Radiculitis (Radiculitis)
Rash Acneiform (Rash acneiform)
Rash Maculo-papular (Rash maculo-
papular)
Rash Pustular (Rash pustular)
Rectal Anastomotic Leak (Rectal
anastomotic leak)
Rectal Fistula (Rectal fistula)
Rectal Hemorrhage (Rectal hemorrhage)
Rectal Mucositis (Rectal mucositis)
Rectal Necrosis (Rectal necrosis)
Rectal Obstruction (Rectal obstruction)
Rectal Pain (Rectal pain)
Rectal Perforation (Rectal perforation)
Rectal Stenosis (Rectal stenosis)
Rectal Ulcer (Rectal ulcer)
Recurrent Laryngeal Nerve Palsy
(Recurrent laryngeal nerve palsy)
Renal And Urinary Disorders - Other,
Specify (Renal and urinary disorders -
Other, Specify)
Renal Calculi (Renal calculi)
Renal Colic (Renal colic)
Renal Hemorrhage (Renal hemorrhage)
Reproductive System And Breast
Disorders - Other, Specify (Reproductive
system and breast disorders - Other,
Specify)
Respiratory Failure (Respiratory failure)
Respiratory, Thoracic And Mediastinal
Disorders - Other, Specify (Respiratory,
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thoracic and mediastinal disorders -
Other, Specify)
Restlessness (Restlessness)
Restrictive Cardiomyopathy (Restrictive
cardiomyopathy)
Retinal Detachment (Retinal
detachment)
Retinal Tear (Retinal tear)
Retinal Vascular Disorder (Retinal
vascular disorder)
Retinoic Acid Syndrome (Retinoic acid
syndrome)
Retinopathy (Retinopathy)
Retroperitoneal Hemorrhage
(Retroperitoneal hemorrhage)
Reversible Posterior
Leukoencephalopathy Syndrome
(Reversible posterior
leukoencephalopathy syndrome)
Rhinitis Infective (Rhinitis infective)
Right Ventricular Dysfunction (Right
ventricular dysfunction)
Salivary Duct Inflammation (Salivary duct
inflammation)
Salivary Gland Fistula (Salivary gland
fistula)
Salivary Gland Infection (Salivary gland
infection)
Scalp Pain (Scalp pain)
Scleral Disorder (Scleral disorder)
Scoliosis (Scoliosis)
Scrotal Infection (Scrotal infection)
Scrotal Pain (Scrotal pain)
Seizure (Seizure)
Sepsis (Sepsis)
Seroma (Seroma)
Serum Amylase Increased (Serum
amylase increased)
Serum Sickness (Serum sickness)
Sick Sinus Syndrome (Sick sinus
syndrome)
Sinus Bradycardia (Sinus bradycardia)
Sinus Disorder (Sinus disorder)
Sinus Pain (Sinus pain)
Sinus Tachycardia (Sinus tachycardia)
Sinusitis (Sinusitis)
Skin And Subcutaneous Tissue
Disorders - Other, Specify (Skin and
subcutaneous tissue disorders - Other,
Specify)
Skin Atrophy (Skin atrophy)
Skin Hyperpigmentation (Skin
hyperpigmentation)
Skin Hypopigmentation (Skin
hypopigmentation)
Skin Induration (Skin induration)
Skin Infection (Skin infection)
Skin Ulceration (Skin ulceration)
Sleep Apnea (Sleep apnea)
Small Intestinal Anastomotic Leak (Small
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intestinal anastomotic leak)
Small Intestinal Mucositis (Small
intestinal mucositis)
Small Intestinal Obstruction (Small
intestinal obstruction)
Small Intestinal Perforation (Small
intestinal perforation)
Small Intestinal Stenosis (Small intestinal
stenosis)
Small Intestine Infection (Small intestine
infection)
Small Intestine Ulcer (Small intestine
ulcer)
Sneezing (Sneezing)
Social Circumstances - Other, Specify
(Social circumstances - Other, Specify)
Soft Tissue Infection (Soft tissue
infection)
Soft Tissue Necrosis Lower Limb (Soft
tissue necrosis lower limb)
Soft Tissue Necrosis Upper Limb (Soft
tissue necrosis upper limb)
Somnolence (Somnolence)
Sore Throat (Sore throat)
Spasticity (Spasticity)
Spermatic Cord Anastomotic Leak
(Spermatic cord anastomotic leak)
Spermatic Cord Hemorrhage (Spermatic
cord hemorrhage)
Spermatic Cord Obstruction (Spermatic
cord obstruction)
Spinal Fracture (Spinal fracture)
Spleen Disorder (Spleen disorder)
Splenic Infection (Splenic infection)
Stenosis Of Gastrointestinal Stoma
(Stenosis of gastrointestinal stoma)
Stevens-johnson Syndrome (Stevens-
Johnson syndrome)
Stoma Site Infection (Stoma site
infection)
Stomach Pain (Stomach pain)
Stomal Ulcer (Stomal ulcer)
Stridor (Stridor)
Stroke (Stroke)
Sudden Death Nos (Sudden death NOS)
Suicidal Ideation (Suicidal ideation)
Suicide Attempt (Suicide attempt)
Superficial Soft Tissue Fibrosis
(Superficial soft tissue fibrosis)
Superficial Thrombophlebitis (Superficial
thrombophlebitis)
Superior Vena Cava Syndrome (Superior
vena cava syndrome)
Supraventricular Tachycardia
(Supraventricular tachycardia)
Surgical And Medical Procedures -
Other, Specify (Surgical and medical
procedures - Other, Specify)
Syncope (Syncope)
Telangiectasia (Telangiectasia)
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Testicular Disorder (Testicular disorder)
Testicular Hemorrhage (Testicular
hemorrhage)
Testicular Pain (Testicular pain)
Thromboembolic Event
(Thromboembolic event)
Thrombotic Thrombocytopenic Purpura
(Thrombotic thrombocytopenic purpura)
Tinnitus (Tinnitus)
Tooth Development Disorder (Tooth
development disorder)
Tooth Discoloration (Tooth discoloration)
Tooth Infection (Tooth infection)
Toothache (Toothache)
Toxic Epidermal Necrolysis (Toxic
epidermal necrolysis)
Tracheal Fistula (Tracheal fistula)
Tracheal Hemorrhage (Tracheal
hemorrhage)
Tracheal Mucositis (Tracheal mucositis)
Tracheal Obstruction (Tracheal
obstruction)
Tracheal Stenosis (Tracheal stenosis)
Tracheitis (Tracheitis)
Tracheostomy Site Bleeding
(Tracheostomy site bleeding)
Transient Ischemic Attacks (Transient
ischemic attacks)
Treatment Related Secondary
Malignancy (Treatment related
secondary malignancy)
Tremor (Tremor)
Tricuspid Valve Disease (Tricuspid valve
disease)
Trigeminal Nerve Disorder (Trigeminal
nerve disorder)
Trismus (Trismus)
Tumor Lysis Syndrome (Tumor lysis
syndrome)
Tumor Pain (Tumor pain)
Typhlitis (Typhlitis)
Unequal Limb Length (Unequal limb
length)
Unintended Pregnancy (Unintended
pregnancy)
Upper Gastrointestinal Hemorrhage
(Upper gastrointestinal hemorrhage)
Upper Respiratory Infection (Upper
respiratory infection)
Ureteric Anastomotic Leak (Ureteric
anastomotic leak)
Urethral Anastomotic Leak (Urethral
anastomotic leak)
Urethral Infection (Urethral infection)
Urinary Fistula (Urinary fistula)
Urinary Frequency (Urinary frequency)
Urinary Incontinence (Urinary
incontinence)
Urinary Retention (Urinary retention)
Urinary Tract Infection (Urinary tract
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infection)
Urinary Tract Obstruction (Urinary tract
obstruction)
Urinary Tract Pain (Urinary tract pain)
Urinary Urgency (Urinary urgency)
Urine Discoloration (Urine discoloration)
Urine Output Decreased (Urine output
decreased)
Urostomy Leak (Urostomy leak)
Urostomy Obstruction (Urostomy
obstruction)
Urostomy Site Bleeding (Urostomy site
bleeding)
Urostomy Stenosis (Urostomy stenosis)
Urticaria (Urticaria)
Uterine Anastomotic Leak (Uterine
anastomotic leak)
Uterine Fistula (Uterine fistula)
Uterine Hemorrhage (Uterine
hemorrhage)
Uterine Infection (Uterine infection)
Uterine Obstruction (Uterine obstruction)
Uterine Pain (Uterine pain)
Uterine Perforation (Uterine perforation)
Uveitis (Uveitis)
Vaginismus (Vagginismus)
Vagus Nerve Disorder (Vaggus nerve
disorder)
Vaginal Anastomotic Leak (Vaginal
anastomotic leak)
Vaginal Discharge (Vaginal discharge)
Vaginal Dryness (Vaginal dryness)
Vaginal Fistula (Vaginal fistula)
Vaginal Hemorrhage (Vaginal
hemorrhage)
Vaginal Infection (Vaginal infection)
Vaginal Inflammation (Vaginal
inflammation)
Vaginal Obstruction (Vaginal obstruction)
Vaginal Pain (Vaginal pain)
Vaginal Perforation (Vaginal perforation)
Vaginal Stricture (Vaginal stricture)
Vascular Access Complication (Vascular
access complication)
Vascular Disorders - Other, Specify
(Vascular disorders - Other, Specify)
Vasculitis (Vasculitis)
Vasovagal Reaction (Vasovagal reaction)
Vas Deeeeeferens Anastomotic Leak
(Vass deferens anastomotic leak)
Venous Injury (Venous injury)
Ventricular Arrhythmia (Ventricular
arrhythmia)
Ventricular Fibrillation (Ventricular
fibrillation)
Ventricular Tachycardia (Ventricular
tachycardia)
Vertigo (Vertigo)
Vestibular Disorder (Vestibular disorder)
Virilization (Virilization)
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Visceral Arterial Ischemia (Visceral
arterial ischemia)
Vital Capacity Abnormal (Vital capacity
abnormal)
Vitreous Hemorrhage (Vitreous
hemorrhage)
Voice Alteration (Voice alteration)
Vomiting (Vomiting)
Vulval Infection (Vulval infection)
Watering Eyes (Watering eyes)
Weight Gain (Weight gain)
Weight Loss (Weight loss)
Wheezing (Wheezing)
White Blood Cell Decreased (White
blood cell decreased)
Wolff-parkinson-white Syndrome (Wolff-
Parkinson-White syndrome)
Wound Complication (Wound
complication)
Wound Dehiscence (Wound dehiscence)
Wound Infection (Wound infection)
Wrist Fracture (Wrist fracture)
Adverse Event Severity Grade
Absent Adverse Event (0)
Mild Adverse Event (1)
Moderate Adverse Event (2)
Severe Adverse Event (3)
Life Threatening Adverse Event (4)
Death Related To Adverse Event (5)
CTC Adverse Event Term, Other
NSABP Code
Comments
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NSABP PROTOCOL B-35: FOLLOW-UP FORM
Anastrozole or Tamoxifen in Treating Postmenopausal
Women With Ductal Carcinoma in Situ Who Are
Undergoing Lumpectomy and Radiation Therapy
Breast Cancer NCT00053898
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=A057E605-
C97E-3E81-E034-080020C9C0E0
All rights reserved. Please visit https://medical-data-
models.org/forms/10066
FOLLOW-UP FORM Breast Cancer
NCT00053898 NSABP B-35
Header
FirstThreeLettersofPatient'sLastName
PatientStudyID
InstitutionName
AffiliateName
PersonCompletingForm,LastName
PersonCompletingForm,FirstName
PersonCompletingForm,Phone
AmendedDataInd
Yes
No
Cancer Follow-up Status
Patient'sVitalStatus
Alive (Alive)
Dead (Dead)
DeathDate/LastContactDate
PersonSurvivalInformationSource
Documentation Of Hospital Or Clinic Visit
(Documentation of hospital or clinic visit)
Other (Other)
Phone Contact To Patient (Phone
contact to patient)
OtherInd-3
DeathReason
Due To This Disease (Due to breast
cancer)
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Due To Other Cause (Due to other
cause)
Due To Protocol Treatment (Due to
protocol treatment)
Unknown (Unknown)
DeathReason,Specify
Evidence of recurrence at time of death
No (No)
Unknown (Unknown)
Yes, Autopsy (Yes, autopsy)
Yes, Clinical (Yes, clinical)
CancerFollow-upStatusInd
Yes
No
CancerFollow-upStatusDate
Total mastectomy
Bilateral (Bilateral)
Left (Left)
None (None)
Right (Right)
DateofThisMastectomy
Bone fracture
Hip (Hip)
None (None)
Other (Other)
Wrist (Wrist)
Ifother,(specify)
BoneFractureDate
Sincethelastreportedfollow-
up,hasthepatienthadanyvaginalhormonaltherapy?
Yes
No
Bisphosphonates
Yes
No
Calcitonin
Yes
No
Tamoxifen or Anastrozole
Yes
No
Drug therapy compliance
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About Half (approximately 50%) (About
half (approximately 50%))
About One-fourth (approximately 25%)
(About one-fourth (approximately 25%))
About Three-fourths (approximately
75%) (About three-fourths
(approximately 75%))
All (100%) (All (100%))
Almost All (approximately 90%) (Almost
all (approximately 90%))
Only A Few (less Than 25%) (Only a few
(less than 25%))
PillsEstimateRemainingQuantityTechniqueSource
Both (Both)
Patient Estimate (Patient Estimate)
Pill Count (Pill Count)
Ipsilateral Breast Tumor Recurrence
Recurrence ipsilateral
Yes
No
Date of IBTR
First Local-regional Recurrence
ProgressionInd,FirstLocal-Regional
Yes
No
Disease Site
Axilla (Axilla)
Axillary nodes (Axillary nodes)
Chest wall (Chest wall)
Infraclavicular nodes (Infraclavicular
nodes)
Internal mammary nodes (Internal
mammary nodes)
Supraclavicular nodes (Supraclavicular
nodes)
ProgressionDate,FirstLocal-Regional
First Distant Recurrence
ProgressionInd,FirstDistant
Yes
No
RecurrentDiseaseFirstDistantDiagnosisDate
RecurrentDiseaseFirstDistantDiagnosisText
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New Primary Cancer Or Mds
NewPrimaryCancerInd
Yes
No
NewPrimaryCancerDate
NewPrimarySite
Adverse Events
CTC Adverse Event Term
Abdominal Distension (Abdominal
distension)
Abdominal Infection (Abdominal
infection)
Abdominal Pain (Abdominal pain)
Abdominal Soft Tissue Necrosis
(Abdominal soft tissue necrosis)
Abducens Nerve Disorder (Abducens
nerve disorder)
Accessory Nerve Disorder (Accessory
nerve disorder)
Acidosis (Acidosis)
Acoustic Nerve Disorder Nos (Acoustic
nerve disorder NOS)
Activated Partial Thromboplastin Time
Prolonged (Activated partial
thromboplastin time prolonged)
Acute Coronary Syndrome (Acute
coronary syndrome)
Acute Kidney Injury (Acute kidney injury)
Adrenal Insufficiency (Adrenal
insufficiency)
Adult Respiratory Distress Syndrome
(Adult respiratory distress syndrome)
Agitation (Agitation)
Akathisia (Akathisia)
Alanine Aminotransferase Increased
(Alanine aminotransferase increased)
Alcohol Intolerance (Alcohol intolerance)
Alkaline Phosphatase Increased
(Alkaline phosphatase increased)
Alkalosis (Alkalosis)
Allergic Reaction (Allergic reaction)
Allergic Rhinitis (Allergic rhinitis)
Alopecia (Alopecia)
Amnesia (Amnesia)
Anal Fistula (Anal fistula)
Anal Hemorrhage (Anal hemorrhage)
Anal Mucositis (Anal mucositis)
Anal Necrosis (Anal necrosis)
Anal Pain (Anal pain)
Anal Stenosis (Anal stenosis)
Anal Ulcer (Anal ulcer)
Anaphylaxis (Anaphylaxis)
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Anemia (Anemia)
Ankle Fracture (Ankle fracture)
Anorectal Infection (Anorectal infection)
Anorexia (Anorexia)
Anorgasmia (Anorgasmia)
Anxiety (Anxiety)
Aortic Injury (Aortic injury)
Aortic Valve Disease (Aortic valve
disease)
Aphonia (Aphonia)
Apnea (Apnea)
Appendicitis (Appendicitis)
Appendicitis Perforated (Appendicitis
perforated)
Arachnoiditis (Arachnoiditis)
Arterial Injury (Arterial injury)
Arteritis Infective (Arteritis infective)
Arthralgia (Arthralgia)
Arthritis (Arthritis)
Ascites (Ascites)
Aspartate Aminotransferase Increased
(Aspartate aminotransferase increased)
Aspiration (Aspiration)
Asystole (Asystole)
Ataxia (Ataxia)
Atelectasis (Atelectasis)
Atrial Fibrillation (Atrial fibrillation)
Atrial Flutter (Atrial flutter)
Atrioventricular Block Complete
(Atrioventricular block complete)
Atrioventricular Block First Degree
(Atrioventricular block first degree)
Autoimmune Disorder (Autoimmune
disorder)
Avascular Necrosis (Avascular necrosis)
Azoospermia (Azoospermia)
Back Pain (Back pain)
Bile Duct Stenosis (Bile duct stenosis)
Biliary Anastomotic Leak (Biliary
anastomotic leak)
Biliary Fistula (Biliary fistula)
Biliary Tract Infection (Biliary tract
infection)
Bladder Anastomotic Leak (Bladder
anastomotic leak)
Bladder Infection (Bladder infection)
Bladder Perforation (Bladder perforation)
Bladder Spasm (Bladder spasm)
Bloating (Bloating)
Blood And Lymphatic System Disorders -
Other, Specify (Blood and lymphatic
system disorders - Other, Specify)
Blood Antidiuretic Hormone Abnormal
(Blood antidiuretic hormone abnormal)
Blood Bilirubin Increased (Blood bilirubin
increased)
Blood Corticotrophin Decreased (Blood
corticotrophin decreased)
Blood Gonadotrophin Abnormal (Blood
gonadotrophin abnormal)
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Blood Prolactin Abnormal (Blood
prolactin abnormal)
Blurred Vision (Blurred vision)
Body Odor (Body odor)
Bone Infection (Bone infection)
Bone Marrow Hypocellular (Bone
marrow hypocellular)
Bone Pain (Bone pain)
Brachial Plexopathy (Brachial
plexopathy)
Breast Atrophy (Breast atrophy)
Breast Infection (Breast infection)
Breast Pain (Breast pain)
Bronchial Fistula (Bronchial fistula)
Bronchial Infection (Bronchial infection)
Bronchial Obstruction (Bronchial
obstruction)
Bronchial Stricture (Bronchial stricture)
Bronchopleural Fistula (Bronchopleural
fistula)
Bronchopulmonary Hemorrhage
(Bronchopulmonary hemorrhage)
Bronchospasm (Bronchospasm)
Bruising (Bruising)
Bullous Dermatitis (Bullous dermatitis)
Burn (Burn)
Buttock Pain (Buttock pain)
Capillary Leak Syndrome (Capillary leak
syndrome)
Carbon Monoxide Diffusing Capacity
Decreased (Carbon monoxide diffusing
capacity decreased)
Cardiac Arrest (Cardiac arrest)
Cardiac Disorders - Other, Specify
(Cardiac disorders - Other, Specify)
Cardiac Troponin I Increased (Cardiac
troponin I increased)
Cardiac Troponin T Increased (Cardiac
troponin T increased)
Cataract (Cataract)
Catheter Related Infection (Catheter
related infection)
Cd4 Lymphocytes Decreased (CD4
lymphocytes decreased)
Cecal Hemorrhage (Cecal hemorrhage)
Cecal Infection (Cecal infection)
Central Nervous System Necrosis
(Central nervous system necrosis)
Cerebrospinal Fluid Leakage
(Cerebrospinal fluid leakage)
Cervicitis Infection (Cervicitis infection)
Cheilitis (Cheilitis)
Chest Pain - Cardiac (Chest pain -
cardiac)
Chest Wall Pain (Chest wall pain)
Chills (Chills)
Cholecystitis (Cholecystitis)
Cholesterol High (Cholesterol high)
Chronic Kidney Disease (Chronic kidney
disease)
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Chylothorax (Chylothorax)
Cognitive Disturbance (Cognitive
disturbance)
Colitis (Colitis)
Colonic Fistula (Colonic fistula)
Colonic Hemorrhage (Colonic
hemorrhage)
Colonic Obstruction (Colonic obstruction)
Colonic Perforation (Colonic perforation)
Colonic Stenosis (Colonic stenosis)
Colonic Ulcer (Colonic ulcer)
Concentration Impairment
(Concentration impairment)
Conduction Disorder (Conduction
disorder)
Confusion (Confusion)
Congenital, Familial And Genetic
Disorders - Other, Specify (Congenital,
familial and genetic disorders - Other,
Specify)
Conjunctivitis (Conjunctivitis)
Conjunctivitis Infective (Conjunctivitis
infective)
Constipation (Constipation)
Constrictive Pericarditis (Constrictive
pericarditis)
Corneal Infection (Corneal infection)
Corneal Ulcer (Corneal ulcer)
Cough (Cough)
Cpk Increased (CPK increased)
Cranial Nerve Infection (Cranial nerve
infection)
Creatinine Increased (Creatinine
increased)
Cushingoid (Cushingoid)
Cystitis Noninfective (Cystitis
noninfective)
Cytokine Release Syndrome (Cytokine
release syndrome)
Death Neonatal (Death neonatal)
Death Nos (Death NOS)
Dehydration (Dehydration)
Delayed Orgasm (Delayed orgasm)
Delayed Puberty (Delayed puberty)
Delirium (Delirium)
Delusions (Delusions)
Dental Caries (Dental caries)
Depressed Level Of Consciousness
(Depressed level of consciousness)
Depression (Depression)
Dermatitis Radiation (Dermatitis
radiation)
Device Related Infection (Device related
infection)
Diarrhea (Diarrhea)
Disseminated Intravascular Coagulation
(Disseminated intravascular coagulation)
Dizziness (Dizziness)
Dry Eye (Dry eye)
Dry Mouth (Dry mouth)
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Dry Skin (Dry skin)
Duodenal Fistula (Duodenal fistula)
Duodenal Hemorrhage (Duodenal
hemorrhage)
Duodenal Infection (Duodenal infection)
Duodenal Obstruction (Duodenal
obstruction)
Duodenal Perforation (Duodenal
perforation)
Duodenal Stenosis (Duodenal stenosis)
Duodenal Ulcer (Duodenal ulcer)
Dysarthria (Dysarthria)
Dysesthesia (Dysesthesia)
Dysgeusia (Dysgeusia)
Dysmenorrhea (Dysmenorrhea)
Dyspareunia (Dyspareunia)
Dyspepsia (Dyspepsia)
Dysphagia (Dysphagia)
Dysphasia (Dysphasia)
Dyspnea (Dyspnea)
Ear And Labyrinth Disorders - Other,
Specify (Ear and labyrinth disorders -
Other, Specify)
Ear Pain (Ear pain)
Edema Cerebral (Edema cerebral)
Edema Face (Edema face)
Edema Limbs (Edema limbs)
Edema Trunk (Edema trunk)
Ejaculation Disorder (Ejaculation
disorder)
Ejection Fraction Decreased (Ejection
fraction decreased)
Electrocardiogram Qt Corrected Interval
Prolonged (Electrocardiogram QT
corrected interval prolonged)
Encephalitis Infection (Encephalitis
infection)
Encephalomyelitis Infection
(Encephalomyelitis infection)
Encephalopathy (Encephalopathy)
Endocarditis Infective (Endocarditis
infective)
Endocrine Disorders - Other, Specify
(Endocrine disorders - Other, Specify)
Endophthalmitis (Endophthalmitis)
Enterocolitis (Enterocolitis)
Enterocolitis Infectious (Enterocolitis
infectious)
Enterovesical Fistula (Enterovesical
fistula)
Epistaxis (Epistaxis)
Erectile Dysfunction (Erectile
dysfunction)
Erythema Multiforme (Erythema
multiforme)
Erythroderma (Erythroderma)
Esophageal Anastomotic Leak
(Esophageal anastomotic leak)
Esophageal Fistula (Esophageal fistula)
Esophageal Hemorrhage (Esophageal
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hemorrhage)
Esophageal Infection (Esophageal
infection)
Esophageal Necrosis (Esophageal
necrosis)
Esophageal Obstruction (Esophageal
obstruction)
Esophageal Pain (Esophageal pain)
Esophageal Perforation (Esophageal
perforation)
Esophageal Stenosis (Esophageal
stenosis)
Esophageal Ulcer (Esophageal ulcer)
Esophageal Varices Hemorrhage
(Esophageal varices hemorrhage)
Esophagitis (Esophagitis)
Euphoria (Euphoria)
Exostosis (Exostosis)
External Ear Inflammation (External ear
inflammation)
External Ear Pain (External ear pain)
Extraocular Muscle Paresis (Extraocular
muscle paresis)
Extrapyramidal Disorder (Extrapyramidal
disorder)
Eye Disorders - Other, Specify (Eye
disorders - Other, Specify)
Eye Infection (Eye infection)
Eye Pain (Eye pain)
Eyelid Function Disorder (Eyelid function
disorder)
Facial Muscle Weakness (Facial muscle
weakness)
Facial Nerve Disorder (Facial nerve
disorder)
Facial Pain (Facial pain)
Fall (Fall)
Fallopian Tube Anastomotic Leak
(Fallopian tube anastomotic leak)
Fallopian Tube Obstruction (Fallopian
tube obstruction)
Fallopian Tube Perforation (Fallopian
tube perforation)
Fallopian Tube Stenosis (Fallopian tube
stenosis)
Fat Atrophy (Fat atrophy)
Fatigue (Fatigue)
Febrile Neutropenia (Febrile
neutropenia)
Fecal Incontinence (Fecal incontinence)
Female Genital Tract Fistula (Female
genital tract fistula)
Feminization Acquired (Feminization
acquired)
Fetal Death (Fetal death)
Fetal Growth Retardation (Fetal growth
retardation)
Fever (Fever)
Fibrinogen Decreased (Fibrinogen
decreased)
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Fibrosis Deep Connective Tissue
(Fibrosis deep connective tissue)
Flank Pain (Flank pain)
Flashing Lights (Flashing lights)
Flatulence (Flatulence)
Floaters (Floaters)
Flu Like Symptoms (Flu like symptoms)
Flushing (Flushing)
Forced Expiratory Volume Decreased
(Forced expiratory volume decreased)
Fracture (Fracture)
Gait Disturbance (Gait disturbance)
Gallbladder Fistula (Gallbladder fistula)
Gallbladder Infection (Gallbladder
infection)
Gallbladder Necrosis (Gallbladder
necrosis)
Gallbladder Obstruction (Gallbladder
obstruction)
Gallbladder Pain (Gallbladder pain)
Gallbladder Perforation (Gallbladder
perforation)
Gastric Anastomotic Leak (Gastric
anastomotic leak)
Gastric Fistula (Gastric fistula)
Gastric Hemorrhage (Gastric
hemorrhage)
Gastric Necrosis (Gastric necrosis)
Gastric Perforation (Gastric perforation)
Gastric Stenosis (Gastric stenosis)
Gastric Ulcer (Gastric ulcer)
Gastritis (Gastritis)
Gastroesophageal Reflux Disease
(Gastroesophageal reflux disease)
Gastrointestinal Anastomotic Leak
(Gastrointestinal anastomotic leak)
Gastrointestinal Disorders - Other,
Specify (Gastrointestinal disorders -
Other, Specify)
Gastrointestinal Fistula (Gastrointestinal
fistula)
Gastrointestinal Pain (Gastrointestinal
pain)
Gastrointestinal Stoma Necrosis
(Gastrointestinal stoma necrosis)
Gastroparesis (Gastroparesis)
General Disorders And Administration
Site Conditions - Other, Specify (General
disorders and administration site
conditions - Other, Specify)
Generalized Muscle Weakness
(Generalized muscle weakness)
Genital Edema (Genital edema)
Ggt Increased (GGT increased)
Gingival Pain (Gingival pain)
Glaucoma (Glaucoma)
Glossopharyngeal Nerve Disorder
(Glossopharyngeal nerve disorder)
Glucose Intolerance (Glucose
intolerance)
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Growth Accelerated (Growth
accelerated)
Growth Hormone Abnormal (Growth
hormone abnormal)
Growth Suppression (Growth
suppression)
Gum Infection (Gum infection)
Gynecomastia (Gynecomastia)
Hallucinations (Hallucinations)
Haptoglobin Decreased (Haptoglobin
decreased)
Head Soft Tissue Necrosis (Head soft
tissue necrosis)
Headache (Headache)
Hearing Impaired (Hearing impaired)
Heart Failure (Heart failure)
Hematoma (Hematoma)
Hematosalpinx (Hematosalpinx)
Hematuria (Hematuria)
Hemoglobin Increased (Hemoglobin
increased)
Hemoglobinuria (Hemoglobinuria)
Hemolysis (Hemolysis)
Hemolytic Uremic Syndrome (Hemolytic
uremic syndrome)
Hemorrhoidal Hemorrhage
(Hemorrhoidal hemorrhage)
Hemorrhoids (Hemorrhoids)
Hepatic Failure (Hepatic failure)
Hepatic Hemorrhage (Hepatic
hemorrhage)
Hepatic Infection (Hepatic infection)
Hepatic Necrosis (Hepatic necrosis)
Hepatic Pain (Hepatic pain)
Hepatitis Viral (Hepatitis viral)
Hepatobiliary Disorders - Other, Specify
(Hepatobiliary disorders - Other, Specify)
Hiccups (Hiccups)
Hip Fracture (Hip fracture)
Hirsutism (Hirsutism)
Hoarseness (Hoarseness)
Hot Flashes (Hot flashes)
Hydrocephalus (Hydrocephalus)
Hypercalcemia (Hypercalcemia)
Hyperglycemia (Hyperglycemia)
Hyperhidrosis (Hyperhidrosis)
Hyperkalemia (Hyperkalemia)
Hypermagnesemia (Hypermagnesemia)
Hypernatremia (Hypernatremia)
Hyperparathyroidism
(Hyperparathyroidism)
Hypersomnia (Hypersomnia)
Hypertension (Hypertension)
Hyperthyroidism (Hyperthyroidism)
Hypertrichosis (Hypertrichosis)
Hypertriglyceridemia
(Hypertriglyceridemia)
Hyperuricemia (Hyperuricemia)
Hypoalbuminemia (Hypoalbuminemia)
Hypocalcemia (Hypocalcemia)
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Hypoglossal Nerve Disorder
(Hypoglossal nerve disorder)
Hypoglycemia (Hypoglycemia)
Hypohidrosis (Hypohidrosis)
Hypokalemia (Hypokalemia)
Hypomagnesemia (Hypomagnesemia)
Hyponatremia (Hyponatremia)
Hypoparathyroidism
(Hypoparathyroidism)
Hypophosphatemia (Hypophosphatemia)
Hypotension (Hypotension)
Hypothermia (Hypothermia)
Hypothyroidism (Hypothyroidism)
Hypoxia (Hypoxia)
Ileal Fistula (Ileal fistula)
Ileal Hemorrhage (Ileal hemorrhage)
Ileal Obstruction (Ileal obstruction)
Ileal Perforation (Ileal perforation)
Ileal Stenosis (Ileal stenosis)
Ileal Ulcer (Ileal ulcer)
Ileus (Ileus)
Immune System Disorders - Other,
Specify (Immune system disorders -
Other, Specify)
Infections And Infestations - Other,
Specify (Infections and infestations -
Other, Specify)
Infective Myositis (Infective myositis)
Infusion Related Reaction (Infusion
related reaction)
Infusion Site Extravasation (Infusion site
extravasation)
Injection Site Reaction (Injection site
reaction)
Injury To Carotid Artery (Injury to carotid
artery)
Injury To Inferior Vena Cava (Injury to
inferior vena cava)
Injury To Jugular Vein (Injury to jugular
vein)
Injury To Superior Vena Cava (Injury to
superior vena cava)
Injury, Poisoning And Procedural
Complications - Other, Specify (Injury,
poisoning and procedural complications -
Other, Specify)
Inr Increased (INR increased)
Insomnia (Insomnia)
Intestinal Stoma Leak (Intestinal stoma
leak)
Intestinal Stoma Obstruction (Intestinal
stoma obstruction)
Intestinal Stoma Site Bleeding (Intestinal
stoma site bleeding)
Intra-abdominal Hemorrhage (Intra-
abdominal hemorrhage)
Intracranial Hemorrhage (Intracranial
hemorrhage)
Intraoperative Arterial Injury
(Intraoperative arterial injury)
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Intraoperative Breast Injury
(Intraoperative breast injury)
Intraoperative Cardiac Injury
(Intraoperative cardiac injury)
Intraoperative Ear Injury (Intraoperative
ear injury)
Intraoperative Endocrine Injury
(Intraoperative endocrine injury)
Intraoperative Gastrointestinal Injury
(Intraoperative gastrointestinal injury)
Intraoperative Head And Neck Injury
(Intraoperative head and neck injury)
Intraoperative Hemorrhage
(Intraoperative hemorrhage)
Intraoperative Hepatobiliary Injury
(Intraoperative hepatobiliary injury)
Intraoperative Musculoskeletal Injury
(Intraoperative musculoskeletall injury)
Intraoperative Neurological Injury
(Intraoperative neurological injury)
Intraoperative Ocular Injury
(Intraoperative ocular injury)
Intraoperative Renal Injury
(Intraoperative renal injury)
Intraoperative Reproductive Tract Injury
(Intraoperative reproductive tract injury)
Intraoperative Respiratory Injury
(Intraoperative respiratory injury)
Intraoperative Skin Injury (Intraoperative
skin injury)
Intraoperative Splenic Injury
(Intraoperative splenic injury)
Intraoperative Urinary Injury
(Intraoperative urinary injury)
Intraoperative Venous Injury
(Intraoperative venous injury)
Investigations - Other, Specify
(Investigations - Other, Specify)
Iron Overload (Iron overload)
Irregular Menstruation (Irregular
menstruation)
Irritability (Irritability)
Ischemia Cerebrovascular (Ischemia
cerebrovascular)
Ivth Nerve Disorder (IVth nerve disorder)
Jejunal Fistula (Jejunal fistula)
Jejunal Hemorrhage (Jejunal
hemorrhage)
Jejunal Obstruction (Jejunal obstruction)
Jejunal Perforation (Jejunal perforation)
Jejunal Stenosis (Jejunal stenosis)
Jejunal Ulcer (Jejunal ulcer)
Joint Effusion (Joint effusion)
Joint Infection (Joint infection)
Joint Range Of Motion Decreased (Joint
range of motion decreased)
Joint Range Of Motion Decreased
Cervical Spine (Joint range of motion
decreased cervical spine)
Joint Range Of Motion Decreased
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Lumbar Spine (Joint range of motion
decreased lumbar spine)
Keratitis (Keratitis)
Kidney Anastomotic Leak (Kidney
anastomotic leak)
Kidney Infection (Kidney infection)
Kyphosis (Kyphosis)
Lactation Disorder (Lactation disorder)
Large Intestinal Anastomotic Leak (Large
intestinal anastomotic leak)
Laryngeal Edema (Laryngeal edema)
Laryngeal Fistula (Laryngeal fistula)
Laryngeal Hemorrhage (Laryngeal
hemorrhage)
Laryngeal Inflammation (Laryngeal
inflammation)
Laryngeal Mucositis (Laryngeal
mucositis)
Laryngeal Obstruction (Laryngeal
obstruction)
Laryngeal Stenosis (Laryngeal stenosis)
Laryngitis (Laryngitis)
Laryngopharyngeal Dysesthesia
(Laryngopharyngeal dysesthesia)
Laryngospasm (Laryngospasm)
Left Ventricular Systolic Dysfunction (Left
ventricular systolic dysfunction)
Lethargy (Lethargy)
Leukemia Secondary To Oncology
Chemotherapy (Leukemia secondary to
oncology chemotherapy)
Leukocytosis (Leukocytosis)
Leukoencephalopathy
(Leukoencephalopathy)
Libido Decreased (Libido decreased)
Libido Increased (Libido increased)
Lip Infection (Lip infection)
Lip Pain (Lip pain)
Lipase Increased (Lipase increased)
Lipohypertrophy (Lipohypertrophy)
Localized Edema (Localized edema)
Lordosis (Lordosis)
Lower Gastrointestinal Hemorrhage
(Lower gastrointestinal hemorrhage)
Lung Infection (Lung infection)
Lymph Gland Infection (Lymph gland
infection)
Lymph Leakage (Lymph leakage)
Lymph Node Pain (Lymph node pain)
Lymphedema (Lymphedema)
Lymphocele (Lymphocele)
Lymphocyte Count Decreased
(Lymphocyte count decreased)
Lymphocyte Count Increased
(Lymphocyte count increased)
Malabsorption (Malabsorption)
Malaise (Malaise)
Mania (Mania)
Mediastinal Hemorrhage (Mediastinal
hemorrhage)
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Mediastinal Infection (Mediastinal
infection)
Memory Impairment (Memory
impairment)
Meningismus (Meningismus)
Meningitis (Meningitis)
Menopause (Menopause)
Menorrhagia (Menorrhagia)
Metabolism And Nutrition Disorders -
Other, Specify (Metabolism and nutrition
disorders - Other, Specify)
Middle Ear Inflammation (Middle ear
inflammation)
Mitral Valve Disease (Mitral valve
disease)
Mobitz (type) Ii Atrioventricular Block
(Mobitz (type) II atrioventricular block)
Mobitz Type I (Mobitz type I)
Movements Involuntary (Movements
involuntary)
Mucosal Infection (Mucosal infection)
Mucositis Oral (Mucositis oral)
Multi-organ Failure (Multi-organ failure)
Muscle Weakness Left-sided (Muscle
weakness left-sided)
Muscle Weakness Lower Limb (Muscle
weakness lower limb)
Muscle Weakness Right-sided (Muscle
weakness right-sided)
Muscle Weakness Trunk (Muscle
weakness trunk)
Muscle Weakness Upper Limb (Muscle
weakness upper limb)
Musculoskeletal And Connective Tissue
Disorder - Other, Specify
(Musculoskeletal and connective tissue
disorders - Other, Specify)
Musculoskeletal Deformity
(Musculoskeletal deformity)
Myalgia (Myalgia)
Myelitis (Myelitis)
Myelodysplastic Syndrome
(Myelodysplastic syndrome)
Myocardial Infarction (Myocardial
infarction)
Myocarditis (Myocarditis)
Myositis (Myositis)
Nail Discoloration (Nail discoloration)
Nail Infection (Nail infection)
Nail Loss (Nail loss)
Nail Ridging (Nail ridging)
Nasal Congestion (Nasal congestion)
Nausea (Nausea)
Neck Edema (Neck edema)
Neck Pain (Neck pain)
Neck Soft Tissue Necrosis (Neck soft
tissue necrosis)
Neoplasms Benign, Malignant And
Unspecified (incl Cysts And Polyps) -
Other, Specify (Neoplasms benign,
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malignant and unspecified (incl cysts and
polyps) - Other, Specify)
Nervous System Disorders - Other,
Specify (Nervous system disorders -
Other, Specify)
Neuralgia (Neuralgia)
Neutrophil Count Decreased (Neutrophil
count decreased)
Night Blindness (Night blindness)
Nipple Deformity (Nipple deformity)
Non-cardiac Chest Pain (Non-cardiac
chest pain)
Nystagmus (Nystagmus)
Obesity (Obesity)
Obstruction Gastric (Obstruction gastric)
Oculomotor Nerve Disorder (Oculomotor
nerve disorder)
Olfactory Nerve Disorder (Olfactory
nerve disorder)
Oligospermia (Oligospermia)
Optic Nerve Disorder (Optic nerve
disorder)
Oral Cavity Fistula (Oral cavity fistula)
Oral Dysesthesia (Oral dysesthesia)
Oral Hemorrhage (Oral hemorrhage)
Oral Pain (Oral pain)
Osteonecrosis Of Jaw (Osteonecrosis of
jaw)
Osteoporosis (Osteoporosis)
Otitis Externa (Otitis externa)
Otitis Media (Otitis media)
Ovarian Hemorrhage (Ovarian
hemorrhage)
Ovarian Infection (Ovarian infection)
Ovarian Rupture (Ovarian rupture)
Ovulation Pain (Ovulation pain)
Pain (Pain)
Pain In Extremity (Pain in extremity)
Pain Of Skin (Pain of skin)
Palmar-plantar Erythrodysesthesia
Syndrome (Palmar-plantar
erythrodysesthesia syndrome)
Palpitations (Palpitations)
Pancreas Infection (Pancreas infection)
Pancreatic Anastomotic Leak (Pancreatic
anastomotic leak)
Pancreatic Duct Stenosis (Pancreatic
duct stenosis)
Pancreatic Enzymes Decreased
(Pancreatic enzymes decreased)
Pancreatic Fistula (Pancreatic fistula)
Pancreatic Hemorrhage (Pancreatic
hemorrhage)
Pancreatic Necrosis (Pancreatic
necrosis)
Pancreatitis (Pancreatitis)
Papilledema (Papilledema)
Papulopustular Rash (Papulopustular
rash)
Paresthesia (Paresthesia)
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Paronychia (Paronychia)
Paroxysmal Atrial Tachycardia
(Paroxysmal atrial tachycardia)
Pelvic Floor Muscle Weakness (Pelvic
floor muscle weakness)
Pelvic Infection (Pelvic infection)
Pelvic Pain (Pelvic pain)
Pelvic Soft Tissue Necrosis (Pelvic soft
tissue necrosis)
Penile Infection (Penile infection)
Penile Pain (Penile pain)
Perforation Bile Duct (Perforation bile
duct)
Pericardial Effusion (Pericardial effusion)
Pericardial Tamponade (Pericardial
tamponade)
Pericarditis (Pericarditis)
Perineal Pain (Perineal pain)
Periodontal Disease (Periodontal
disease)
Periorbital Edema (Periorbital edema)
Periorbital Infection (Periorbital infection)
Peripheral Ischemia (Peripheral
ischemia)
Peripheral Motor Neuropathy (Peripheral
motor neuropathy)
Peripheral Nerve Infection (Peripheral
nerve infection)
Peripheral Sensory Neuropathy
(Peripheral sensory neuropathy)
Peritoneal Infection (Peritoneal infection)
Peritoneal Necrosis (Peritoneal necrosis)
Personality Change (Personality change)
Phantom Pain (Phantom pain)
Pharyngeal Anastomotic Leak
(Pharyngeal anastomotic leak)
Pharyngeal Fistula (Pharyngeal fistula)
Pharyngeal Hemorrhage (Pharyngeal
hemorrhage)
Pharyngeal Mucositis (Pharyngeal
mucositis)
Pharyngeal Necrosis (Pharyngeal
necrosis)
Pharyngeal Stenosis (Pharyngeal
stenosis)
Pharyngitis (Pharyngitis)
Pharyngolaryngeal Pain
(Pharyngolaryngeal pain)
Phlebitis (Phlebitis)
Phlebitis Infective (Phlebitis infective)
Photophobia (Photophobia)
Photosensitivity (Photosensitivity)
Platelet Count Decreased (Platelet count
decreased)
Pleural Effusion (Pleural effusion)
Pleural Hemorrhage (Pleural
hemorrhage)
Pleural Infection (Pleural infection)
Pleuritic Pain (Pleuritic pain)
Pneumonitis (Pneumonitis)
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Pneumothorax (Pneumothorax)
Portal Hypertension (Portal
hypertension)
Portal Vein Thrombosis (Portal vein
thrombosis)
Postnasal Drip (Postnasal drip)
Postoperative Hemorrhage
(Postoperative hemorrhage)
Postoperative Thoracic Procedure
Complication (Postoperative thoracic
procedure complication)
Precocious Puberty (Precocious
puberty)
Pregnancy, Puerperium And Perinatal
Conditions - Other, Specify (Pregnancy,
puerperium and perinatal conditions -
Other, Specify)
Premature Delivery (Premature delivery)
Premature Menopause (Premature
menopause)
Presyncope (Presyncope)
Proctitis (Proctitis)
Productive Cough (Productive cough)
Prolapse Of Intestinal Stoma (Prolapse
of intestinal stoma)
Prolapse Of Urostomy (Prolapse of
urostomy)
Prostate Infection (Prostate infection)
Prostatic Hemorrhage (Prostatic
hemorrhage)
Prostatic Obstruction (Prostatic
obstruction)
Prostatic Pain (Prostatic pain)
Proteinuria (Proteinuria)
Pruritus (Pruritus)
Psychiatric Disorders - Other, Specify
(Psychiatric disorders - Other, Specify)
Psychosis (Psychosis)
Pulmonary Edema (Pulmonary edema)
Pulmonary Fibrosis (Pulmonary fibrosis)
Pulmonary Fistula (Pulmonary fistula)
Pulmonary Hypertension (Pulmonary
hypertension)
Pulmonary Valve Disease (Pulmonary
valve disease)
Purpura (Purpura)
Pyramidal Tract Syndrome (Pyramidal
tract syndrome)
Radiation Recall Reaction (dermatologic)
(Radiation recall reaction (dermatologic))
Radiculitis (Radiculitis)
Rash Acneiform (Rash acneiform)
Rash Maculo-papular (Rash maculo-
papular)
Rash Pustular (Rash pustular)
Rectal Anastomotic Leak (Rectal
anastomotic leak)
Rectal Fistula (Rectal fistula)
Rectal Hemorrhage (Rectal hemorrhage)
Rectal Mucositis (Rectal mucositis)
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Rectal Necrosis (Rectal necrosis)
Rectal Obstruction (Rectal obstruction)
Rectal Pain (Rectal pain)
Rectal Perforation (Rectal perforation)
Rectal Stenosis (Rectal stenosis)
Rectal Ulcer (Rectal ulcer)
Recurrent Laryngeal Nerve Palsy
(Recurrent laryngeal nerve palsy)
Renal And Urinary Disorders - Other,
Specify (Renal and urinary disorders -
Other, Specify)
Renal Calculi (Renal calculi)
Renal Colic (Renal colic)
Renal Hemorrhage (Renal hemorrhage)
Reproductive System And Breast
Disorders - Other, Specify (Reproductive
system and breast disorders - Other,
Specify)
Respiratory Failure (Respiratory failure)
Respiratory, Thoracic And Mediastinal
Disorders - Other, Specify (Respiratory,
thoracic and mediastinal disorders -
Other, Specify)
Restlessness (Restlessness)
Restrictive Cardiomyopathy (Restrictive
cardiomyopathy)
Retinal Detachment (Retinal
detachment)
Retinal Tear (Retinal tear)
Retinal Vascular Disorder (Retinal
vascular disorder)
Retinoic Acid Syndrome (Retinoic acid
syndrome)
Retinopathy (Retinopathy)
Retroperitoneal Hemorrhage
(Retroperitoneal hemorrhage)
Reversible Posterior
Leukoencephalopathy Syndrome
(Reversible posterior
leukoencephalopathy syndrome)
Rhinitis Infective (Rhinitis infective)
Right Ventricular Dysfunction (Right
ventricular dysfunction)
Salivary Duct Inflammation (Salivary duct
inflammation)
Salivary Gland Fistula (Salivary gland
fistula)
Salivary Gland Infection (Salivary gland
infection)
Scalp Pain (Scalp pain)
Scleral Disorder (Scleral disorder)
Scoliosis (Scoliosis)
Scrotal Infection (Scrotal infection)
Scrotal Pain (Scrotal pain)
Seizure (Seizure)
Sepsis (Sepsis)
Seroma (Seroma)
Serum Amylase Increased (Serum
amylase increased)
Serum Sickness (Serum sickness)
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Sick Sinus Syndrome (Sick sinus
syndrome)
Sinus Bradycardia (Sinus bradycardia)
Sinus Disorder (Sinus disorder)
Sinus Pain (Sinus pain)
Sinus Tachycardia (Sinus tachycardia)
Sinusitis (Sinusitis)
Skin And Subcutaneous Tissue
Disorders - Other, Specify (Skin and
subcutaneous tissue disorders - Other,
Specify)
Skin Atrophy (Skin atrophy)
Skin Hyperpigmentation (Skin
hyperpigmentation)
Skin Hypopigmentation (Skin
hypopigmentation)
Skin Induration (Skin induration)
Skin Infection (Skin infection)
Skin Ulceration (Skin ulceration)
Sleep Apnea (Sleep apnea)
Small Intestinal Anastomotic Leak (Small
intestinal anastomotic leak)
Small Intestinal Mucositis (Small
intestinal mucositis)
Small Intestinal Obstruction (Small
intestinal obstruction)
Small Intestinal Perforation (Small
intestinal perforation)
Small Intestinal Stenosis (Small intestinal
stenosis)
Small Intestine Infection (Small intestine
infection)
Small Intestine Ulcer (Small intestine
ulcer)
Sneezing (Sneezing)
Social Circumstances - Other, Specify
(Social circumstances - Other, Specify)
Soft Tissue Infection (Soft tissue
infection)
Soft Tissue Necrosis Lower Limb (Soft
tissue necrosis lower limb)
Soft Tissue Necrosis Upper Limb (Soft
tissue necrosis upper limb)
Somnolence (Somnolence)
Sore Throat (Sore throat)
Spasticity (Spasticity)
Spermatic Cord Anastomotic Leak
(Spermatic cord anastomotic leak)
Spermatic Cord Hemorrhage (Spermatic
cord hemorrhage)
Spermatic Cord Obstruction (Spermatic
cord obstruction)
Spinal Fracture (Spinal fracture)
Spleen Disorder (Spleen disorder)
Splenic Infection (Splenic infection)
Stenosis Of Gastrointestinal Stoma
(Stenosis of gastrointestinal stoma)
Stevens-johnson Syndrome (Stevens-
Johnson syndrome)
Stoma Site Infection (Stoma site
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infection)
Stomach Pain (Stomach pain)
Stomal Ulcer (Stomal ulcer)
Stridor (Stridor)
Stroke (Stroke)
Sudden Death Nos (Sudden death NOS)
Suicidal Ideation (Suicidal ideation)
Suicide Attempt (Suicide attempt)
Superficial Soft Tissue Fibrosis
(Superficial soft tissue fibrosis)
Superficial Thrombophlebitis (Superficial
thrombophlebitis)
Superior Vena Cava Syndrome (Superior
vena cava syndrome)
Supraventricular Tachycardia
(Supraventricular tachycardia)
Surgical And Medical Procedures -
Other, Specify (Surgical and medical
procedures - Other, Specify)
Syncope (Syncope)
Telangiectasia (Telangiectasia)
Testicular Disorder (Testicular disorder)
Testicular Hemorrhage (Testicular
hemorrhage)
Testicular Pain (Testicular pain)
Thromboembolic Event
(Thromboembolic event)
Thrombotic Thrombocytopenic Purpura
(Thrombotic thrombocytopenic purpura)
Tinnitus (Tinnitus)
Tooth Development Disorder (Tooth
development disorder)
Tooth Discoloration (Tooth discoloration)
Tooth Infection (Tooth infection)
Toothache (Toothache)
Toxic Epidermal Necrolysis (Toxic
epidermal necrolysis)
Tracheal Fistula (Tracheal fistula)
Tracheal Hemorrhage (Tracheal
hemorrhage)
Tracheal Mucositis (Tracheal mucositis)
Tracheal Obstruction (Tracheal
obstruction)
Tracheal Stenosis (Tracheal stenosis)
Tracheitis (Tracheitis)
Tracheostomy Site Bleeding
(Tracheostomy site bleeding)
Transient Ischemic Attacks (Transient
ischemic attacks)
Treatment Related Secondary
Malignancy (Treatment related
secondary malignancy)
Tremor (Tremor)
Tricuspid Valve Disease (Tricuspid valve
disease)
Trigeminal Nerve Disorder (Trigeminal
nerve disorder)
Trismus (Trismus)
Tumor Lysis Syndrome (Tumor lysis
syndrome)
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Tumor Pain (Tumor pain)
Typhlitis (Typhlitis)
Unequal Limb Length (Unequal limb
length)
Unintended Pregnancy (Unintended
pregnancy)
Upper Gastrointestinal Hemorrhage
(Upper gastrointestinal hemorrhage)
Upper Respiratory Infection (Upper
respiratory infection)
Ureteric Anastomotic Leak (Ureteric
anastomotic leak)
Urethral Anastomotic Leak (Urethral
anastomotic leak)
Urethral Infection (Urethral infection)
Urinary Fistula (Urinary fistula)
Urinary Frequency (Urinary frequency)
Urinary Incontinence (Urinary
incontinence)
Urinary Retention (Urinary retention)
Urinary Tract Infection (Urinary tract
infection)
Urinary Tract Obstruction (Urinary tract
obstruction)
Urinary Tract Pain (Urinary tract pain)
Urinary Urgency (Urinary urgency)
Urine Discoloration (Urine discoloration)
Urine Output Decreased (Urine output
decreased)
Urostomy Leak (Urostomy leak)
Urostomy Obstruction (Urostomy
obstruction)
Urostomy Site Bleeding (Urostomy site
bleeding)
Urostomy Stenosis (Urostomy stenosis)
Urticaria (Urticaria)
Uterine Anastomotic Leak (Uterine
anastomotic leak)
Uterine Fistula (Uterine fistula)
Uterine Hemorrhage (Uterine
hemorrhage)
Uterine Infection (Uterine infection)
Uterine Obstruction (Uterine obstruction)
Uterine Pain (Uterine pain)
Uterine Perforation (Uterine perforation)
Uveitis (Uveitis)
Vaginal Anastomotic Leak (Vaginal
anastomotic leak)
Vaginal Discharge (Vaginal discharge)
Vaginal Dryness (Vaginal dryness)
Vaginal Fistula (Vaginal fistula)
Vaginal Hemorrhage (Vaginal
hemorrhage)
Vaginal Infection (Vaginal infection)
Vaginal Inflammation (Vaginal
inflammation)
Vaginal Obstruction (Vaginal obstruction)
Vaginal Pain (Vaginal pain)
Vaginal Perforation (Vaginal perforation)
Vaginal Stricture (Vaginal stricture)
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Vaginismus (Vaginismus)
Vagus Nerve Disorder (Vagus nerve
disorder)
Vas Deferens Anastomotic Leak (Vas
deferens anastomotic leak)
Vascular Access Complication (Vascular
access complication)
Vascular Disorders - Other, Specify
(Vascular disorders - Other, Specify)
Vasculitis (Vasculitis)
Vasovagal Reaction (Vasovagal reaction)
Venous Injury (Venous injury)
Ventricular Arrhythmia (Ventricular
arrhythmia)
Ventricular Fibrillation (Ventricular
fibrillation)
Ventricular Tachycardia (Ventricular
tachycardia)
Vertigo (Vertigo)
Vestibular Disorder (Vestibular disorder)
Virilization (Virilization)
Visceral Arterial Ischemia (Visceral
arterial ischemia)
Vital Capacity Abnormal (Vital capacity
abnormal)
Vitreous Hemorrhage (Vitreous
hemorrhage)
Voice Alteration (Voice alteration)
Vomiting (Vomiting)
Vulval Infection (Vulval infection)
Watering Eyes (Watering eyes)
Weight Gain (Weight gain)
Weight Loss (Weight loss)
Wheezing (Wheezing)
White Blood Cell Decreased (White
blood cell decreased)
Wolff-parkinson-white Syndrome (Wolff-
Parkinson-White syndrome)
Wound Complication (Wound
complication)
Wound Dehiscence (Wound dehiscence)
Wound Infection (Wound infection)
Wrist Fracture (Wrist fracture)
Adverse Event Severity Grade
Absent Adverse Event (0)
Mild Adverse Event (1)
Moderate Adverse Event (2)
Severe Adverse Event (3)
Life Threatening Adverse Event (4)
Death Related To Adverse Event (5)
Late adverse event
Yes
No
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ELIGIBILITY CHECK
Adjuvant Radiation Therapy Plus Hormone Therapy
Compared With Radiation Therapy Alone in Treating
Patients With Stage II or Stage III Prostate Cancer
Prostate Cancer NCT00023829 
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=A570754B-
7D62-2952-E034-080020C9C0E0
All rights reserved. Please visit https://medical-data-
models.org/forms/10070
ELIGIBILITY CHECK Prostate
Cancer NCT00023829
Header
RTOG Institution #
RTOG Case # (17.)
Completed by
Date
Eligibility Checklist
Does the patient have pathological stage T2-
3N0M0 prostate cancer? (2. If the patient is T2)
Yes (Y)
does the patient have Gleason score >= 7, pre-op
PSA > 10, and positive surgical margins? (3. If
the patient is T3)
Yes (Y)
is the Gleason score >= 7? (If yes)
No (N)
Yes (Y)
does patient have ONE or more of the following:
a) Pre-op PSA > 10? b) Positive surgical
margins? c) Seminal vesicle invasion? (If no)
Not Applicable (NA)
Yes (Y)
does patient have TWO or more of the following:
a) Pre-op PSA > 10? b) Positive surgical
margins? c) Seminal vesicle invasion? (4.)
Not Applicable (NA)
Yes (Y)
Was the pre-op PS   40.0? (5.)
Yes (Y)
Is post-op PSA <= 0.2? (6.)
Yes
No
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Is Zubrod status 0-1? (7.)
Yes (Y)
Are lymph nodes negative by lymph node
sampling or lymph node dissection? (8.)
Yes
No
What is the WBC? (x 1000)
What is the platelet count? (x 1000)
What is the hgb? (>= 11.4)
What is creatinine? (   2.5)
What is ALT? (within 3 x normal)
Will treatment begin within 6 weeks of
randomization? (14.)
Yes
No
If patient was receiving finasteride, has it been
administered 60 days prior to this randomization?
(15.)
Yes
No
If patient was receiving testosterone, has it been
administered 90 days prior to this randomization?
(16.)
Yes
No
Has any prior pharmacologic androgen ablation
for prostate cancer been initiated greater than 10
months before randomization? (17.)
Yes
No
Any prior pelvic radiation therapy or orchiectomy?
(18.)
No (N)
Any previous chemotherapy within the last 5
years?
Yes
No
Have all mandatory lab studies been done? (20.)
Yes
No
Any prior or concurrent malignancy other than
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non-melanoma skin cancer? (If yes)
No (N)
Yes (Y)
disease free for 5 years? (1.)
Yes (Y)
Name of institutional person registering this
case? (2.)
Has the Eligibility Checklist (above) been
completed? (3.)
Yes (Y)
Is the patient eligible for this study? (4.)
Yes (Y)
Date the study-specific Consent Form was
signed? (must be prior to study entry)
Patient's Name (6.)
Verifying Physician (7.)
Patient's ID Number (8.)
Date of Birth (9.)
Race (10.)
Social Security Number (11.)
Patient's Country of Residence (12.)
Zip Code (13.)
Patient's Insurance Status (14.)
Will any component of the patient's care be given
at a military or VA facility? (15.)
Yes
No
Does the patient have seminal vesicle invasion?
(16.)
No (N)
Yes (Y)
Specify pre-operative PSA
below 10 (1)
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above 10 (2)
Specify Gleason score (18.)
Are there positive surgical (inked) margins? (19.)
No (N)
Yes (Y)
Did patient receive neoadjuvant hormonal
therapy? (20.)
No (N)
Yes (Y)
Is the patient going to receive IMRT? (20.)
No (N)
Yes (Y)
Treatment Start Date (21.)
Treatment Assignment
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Prostate Cancer NCT00063882
F1 Radiation Therapy Oncology Group Phase III
Randomized Study of Intermediate Risk Prostate Cancer
Follow-up Form Late RT
Interstitial Brachytherapy With or Without External-Beam
Radiation Therapy in Treating Patients With Prostate
Cancer
NCT00063882
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=AA8904F6-
5E04-5881-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/10071
Follow-up Form Late RT Prostate
Cancer RTOG NCT00063882
Header
RTOG Study
Case #
Institution Name
Institution No.
Patient Name, Last
Patient Name, First
AMENDED DATA
DATE FROM (Q2)
COMMENTS
SIGNATURE
DATE
Cancer Follow-up Status
PATIENT'S VITAL STATUS
Alive (Alive)
Dead (Dead)
DATE OF LAST CONTACT OR DEATH
CAUSE OF DEATH
Due To Other Cause (Due to other
cause, specify)
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Due To Protocol Treatment (Due to
protocol treatment)
Due To This Disease (Due to this
disease)
N/A (N/A)
Unknown (Unknown)
Due to other cause, specify (cause of death)
HAS THE PATIENT HAD A DOCUMENTED
CLINICAL ASSESSMENT FOR PROSTATE
CANCER SINCE SUBMISSION OF THE
PREVIOUS FOLLOWUP FORM?
No (No)
Unknown (Unknown)
Yes (Yes)
DATE OF LAST CLINICAL ASSESSMENT
PERFORMANCE STATUS (ZUBROD)
Follow-up PSA Value(s)
Date of PSA Assessment(s)
HAS THE PATIENT HAD A PROSTATE BIOPSY
SINCE SUBMISSION OF THE LAST
FOLLOWUP FORM?
Yes
No
Biopsy Date
HAS THE PATIENT DEVELOPED A FIRST
PROGRESSION THAT HAS NOT BEEN
PREVIOUSLY REPORTED?
No (No)
Unknown (Unknown)
Yes (Yes)
HAS THE PATIENT BEEN DIAGNOSED WITH
BIOCHEMICAL RECURRENCE SINCE
SUBMISSION OF LAST FOLLOW-UP FORM?
(See Protocol Section 11)
No (No)
Unknown (Unknown)
Yes (Yes)
Date of first biochemical progression
PSA Value at progression
HAS THE PATIENT BEEN DIAGNOSED WITH
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FIRST LOCAL-REGIONAL RECURRENCE
SINCE SUBMISSION OF LAST FOLLOW-UP
FORM? (See Protocol Section 11)
No (No)
Unknown (Unknown)
Yes (Yes)
Date of First Local-Regional Progression
Site(s) of Local/Regional Progression
WHAT WAS THE METHOD USED TO
DETERMINE distant PROGRESSION
Nuclear scan (Nuclear scan)
Other (Other, specify)
Pathologic (Pathologic)
Clinical Examination (Physical exam)
Radiographic (Radiographic)
Other, specify (method used to determine distant
progression)
HAS THE PATIENT BEEN DIAGNOSED WITH
FIRST DISTANT RECURRENCE SINCE
SUBMISSION OF THE LAST FOLLOW-UP
FORM?
No (No)
Unknown (Unknown)
Yes (Yes)
Date of First Distant Progression
Site(s) of First Distant Progression
DID THE PATIENT RECEIVE ANY NON-
PROTOCOL PROSTATE CANCER THERAPY
SINCE THE LAST FOLLOW-UP (If yes, enter
therapy type and date for each therapy delivered
during the follow-up period.)
Yes
No
Non-Protocol Therapy Type
Chemotherapy (Chemotherapy)
Hormones (Hormones)
None (None)
Other Specify (Other, specify)
Radiation To Other Sites, Specify
(Radiation to other sites, specify)
Radiation To Pelvis (Radiation to pelvis)
Surgery (Surgery)
Surgical Procedure Related To Previous
Rt, Specify (Surgical procedure related
to previous RT, specify)
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Radiation to other sites, specify
Other, specify
Surgical procedure related to previous RT, specify
Date of first non-protocol therapy
Specify (non-protocol prostate cancer therapy)
(HAS A NEW PRIMARY CANCER OR MDS
MYELODYSPLASTIC SYNDROME BEEN
DIAGNOSED THAT HAS NOT BEEN
PREVIOUSLY REPORTED?)
New Primary Site
AML/MDS (AML/MDS)
BCC (BCC)
Bladder (Bladder)
Brain (Brain)
Colorectal (Colorectal)
Esophageal (Esophageal)
Gastric (Gastric)
Liver (Liver)
Lung (Lung)
Melanoma (Melanoma)
NHL (NHL)
None (None)
Other Hematologic, specify (Other
Hematologic, specify)
Other solid, specify (Other solid, specify)
Pancreatic (Pancreatic)
Renal (Renal)
Squamous-Skin (Squamous-Skin)
Unknown primary (Unknown primary)
New Primary Site
New Primary Cancer Date
Specify (new primary site)
LATE RADIATION THERAPY ADVERSE
EVENTS
Yes
No
Late RT Adverse Event Grade
Late RT Adverse Event Term
BLADDER/OTHER GU Specify
(BLADDER/OTHER GU Specify)
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OTHER GI, specify (OTHER GI, specify)
OTHER, specify (OTHER, specify)
SKIN (SKIN)
SMALL/LARGE INTESTINE, specify
(SMALL/LARGE INTESTINE, specify)
BLADDER/OTHER GU Specify (late adverse
event)
SMALL/LARGE INTESTINE, specify (late
adverse event)
OTHER GI, specify (late adverse event)
OTHER, specify (late adverse event)
Late RT Adverse Event Onset Date
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Prostate Cancer RTOG NCT00063882
I1 Radiation Therapy Oncology Group Phase III
Randomized Study of Intermediate Risk Prostate Cancer
Initial Evaluation Form
Interstitial Brachytherapy With or Without External-Beam
Radiation Therapy in Treating Patients With Prostate
Cancer
NCT00063882
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=AA891CBF-
EF6D-5893-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/10072
Initial Evaluation Prostate Cancer
RTOG Form NCT00063882
Header
RTOG Study
Case #
Institution Name
Institution No.
Patient Name, Last
Patient Name, First
Amended Data
COMMENTS
Signature
Date
Patient characteristics
PATIENT BIRTH DATE
PERFORMANCE STATUS (ZUBROD)
HAS PATIENT HAD ANOTHER MALIGNANCY
(other than study site)
Yes
No
Specify Site (malignancy other than study site)
1 / 6
DATE ERADICATED (mm/yyyy If not NED from
second malignancy, leave date blank.)
DATE OF INITIAL DIAGNOSIS OF PRIMARY
TUMOR (HISTOPATHOLOGIC TYPE)
HISTOLOGIC TYPE
Adenocarcinoma (Adenocarcinoma)
Other (Other, specify)
Other, specify (histologic type)
GLEASON SCORE, PRIMARY PATTERN ([most
frequently seen] 1-5, 9=unknown)
GLEASON SCORE, SECONDARY PATTERN
([second most frequently seen] 1-5, 9=unknown)
GLEASON SCORE, WORST PATTERN ([worst
pathological grade seen in any specimen] 1-5,
9=unknown)
GLEASON SCORE, COMBINED ([sum of the
primary and secondary, unless unknown]
99=Unknown)
PALPABLE TUMOR (at study entry)
No (No)
Unknown (Unknown)
Yes, Both Lobes (Yes, both lobes)
Yes, Nos (Yes, NOS)
Yes, One Lobe (Yes, one lobe)
LARGEST DIMENSION (cm)
PERPENDICULAR DIMENION (cm)
DIMENSIONS REPORTED ARE
N/a (N/A)
Prostate Dimensions (Prostate
dimensions)
Tumor Dimensions (Tumor dimensions)
Unknown (Unknown)
TUMOR BEYOND CAPSULE AS DETERMINED
BY CLINICAL EXAMINATION
No (No)
Unknown (Unknown)
Yes (Yes)
VOLUME OF GLAND BY TRUS (Grams)
Baseline PSA Date
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Bseline PSA Value
TIME POINT
Diagnostic (Diagnostic)
Pre-hormone (Pre-hormone)
Study Entry (Study entry)
ALKALINE PHOSPHATASE
Abnormal, < normal (Abnormal, <
normal)
Abnormal, elevated (Abnormal, elevated)
Normal (Normal)
Not done (Not done)
Alk Phos Value
SPECIFY (unit of measure)
U/l (u/l)
U/ml (u/ml)
Lab normal range (alkaline phosphatase) (B)
ALT (SGPT)
Abnormal, < Normal (Abnormal, <
normal)
Abnormal, Elevated (Abnormal, elevated)
Normal (Normal)
Not Done (Not done)
ALT Value
Lab normal range (ALT) (C)
TOTAL BILIRUBIN
Abnormal, < normal (Abnormal, <
normal)
Abnormal, elevated (Abnormal, elevated)
Normal (Normal)
Not done (Not done)
Total Bilirubin Value
Lab normal range (total bilirubin) (11 BASELINE
PSA VALUE)
Baseline PSA Date
Baseline PSA Value
TIME POINT
Post-surgery (Post-surgery)
Pre-hormone (Pre-hormone)
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Pre-surgery (Pre-surgery)
Study entry (Study entry)
T STAGE, PATHOLOGIC
T1a, Clinically Inapparent Tumor Not
Palpable Or Visible By Imaging (see Ajcc
Definition) (T1a)
T1b, Clinically Inapparent Tumor Not
Palpable Or Visible By Imaging (see Ajcc
Definition) (T1b)
T1c, Clinically Inapparent Tumor Not
Palpable Or Visible By Imaging (see Ajcc
Definition) (T1c)
T2, Tumor Confined Within The Prostate
(see Ajcc Definition) (T2, NOS)
T2a, Tumor Confined Within The
Prostate (see Ajcc Definition) (T2a)
T2b, Tumor Confined Within The
Prostate (see Ajcc Definition) (T2b)
T3, Tumor Extends Through The
Prostatic Capsule (see Ajcc Definition)
(T3, NOS)
T3a, Tumor Extends Through The
Prostatic Capsule (see Ajcc Definition)
(T3a)
T3b, Tumor Extends Through The
Prostatic Capsule (see Ajcc Definition)
(T3b)
T4, Tumor Is Fixed Or Invades Adjacent
Structures (see Ajcc Definition) (T4)
Primary Tumor Cannot Be Assessed
(TX)
N STAGE, PATHOLOGIC (SURGICAL)
No Regional Lymph Node Metastasis
(N0)
Metastatis In Regional Lymph Node Or
Nodes (see Ajcc Definition) (N1)
No node sampling (No node sampling)
N STAGE, CLINICAL (RADIOGRAPHIC)
N0 (N0)
N1 (N1)
NX (NX)
M STAGE, CLINICAL
No Distant Metastasis (M0)
Distant Metastasis (M1)
Nonregional Lymph Node(s) (M1a)
Bone(s) (M1b)
Other Site(s) (M1c)
Distant Metastsis Cannot Be Assessed
(MX)
Prostate: Prior Treatment
PRIOR PROSTATECTOMY
Yes
No
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Prior prostatectomy date
PRIOR RADIATION THERAPY
Yes
No
Specify (prior radiation therapy)
PRIOR CHEMOTHERAPY (for any reason)
Yes
No
Prior chemotherapy end date
Specify (prior chemotherapy)
PRIOR HORMONAL THERAPY
Yes
No
PRIOR HORMONAL THERAPY TYPE
Yes
No
Prior hormonal therapy start date
Prior hormonal therapy end date (C)
Specify (Prior Hormonal Therapy Type)
ORCHIECTOMY
Yes
No
Orchiectomy date
PRIOR SURGERY (TURP)
Yes
No
Prior surgery (TURP) date
PRIOR OR CURRENT COMPLEMENTARY
ALTERNATIVE MEDICINE (CAM) THERAPY
Yes
No
Specify (prior or current CAM)
Date prior or current CAM therapy started
5 / 6
Prostate Cancer RTOG NCT00063882
Prior CAM therapy end date (if continuing leave
blank)
PRIOR HORMONAL THERAPY TYPE
TESTOSTERONE
Yes
No
PRIOR OTHER HORMONAL THERAPY
Yes
No
Specify (prior other hormonal therapy)
Date prior other hormonal therapy started (D)
Specify (prior or current complementary
alternative medicine therapy)
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PHQ-D
Deutsche Übersetzung des „Patient Health Questionnaire
(PHQ)“
durch B. Löwe, S. Zipfel und W. Herzog, Medizinische
Universitätsklinik Heidelberg
(Englische Originalversion: Spitzer, Kroenke & Williams,
1999).
All rights reserved. Please visit https://medical-data-
models.org/forms/10073
Gesundheitsfragebogen für
Patienten (PHQ-D)
1. Wie stark fühlten Sie sich im Verlauf der
letzten 4 Wochen durch die folgenden
Beschwerden beeinträchtigt?
Wie stark fühlten Sie sich im Verlauf der letzten 4
Wochen durch Bauchschmerzen beeinträchtigt?
Nicht beeinträchtigt (0)
Wenig beeinträchtigt (1)
Stark beeinträchtigt (2)
Wie stark fühlten Sie sich im Verlauf der letzten 4
Wochen durch Rückenschmerzen beeinträchtigt?
Nicht beeinträchtigt (0)
Wenig beeinträchtigt (1)
Stark beeinträchtigt (2)
Wie stark fühlten Sie sich im Verlauf der letzten 4
Wochen durch Schmerzen in Armen, Beinen oder
Gelenken (Knie, Hüften, etc.) beeinträchtigt?
Nicht beeinträchtigt (0)
Wenig beeinträchtigt (1)
Stark beeinträchtigt (2)
Wie stark fühlten Sie sich im Verlauf der letzten 4
Wochen durch Menstruationsschmerzen oder
andere Probleme mit der Menstruation
beeinträchtigt?
Nicht beeinträchtigt (0)
Wenig beeinträchtigt (1)
Stark beeinträchtigt (2)
Wie stark fühlten Sie sich im Verlauf der letzten 4
Wochen durch Schmerzen oder Probleme beim
Geschlechtsverkehr beeinträchtigt?
Nicht beeinträchtigt (0)
Wenig beeinträchtigt (1)
Stark beeinträchtigt (2)
Wie stark fühlten Sie sich im Verlauf der letzten 4
Wochen durch Kopfschmerzen beeinträchtigt?
Nicht beeinträchtigt (0)
Wenig beeinträchtigt (1)
Stark beeinträchtigt (2)
Wie stark fühlten Sie sich im Verlauf der letzten 4
Wochen durch Schmerzen im Brustbereich
beeinträchtigt?
Nicht beeinträchtigt (0)
Wenig beeinträchtigt (1)
Stark beeinträchtigt (2)
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Wie stark fühlten Sie sich im Verlauf der letzten 4
Wochen durch Schwindel beeinträchtigt?
Nicht beeinträchtigt (0)
Wenig beeinträchtigt (1)
Stark beeinträchtigt (2)
Wie stark fühlten Sie sich im Verlauf der letzten 4
Wochen durch Ohnmachtsanfälle beeinträchtigt?
Nicht beeinträchtigt (0)
Wenig beeinträchtigt (1)
Stark beeinträchtigt (2)
Wie stark fühlten Sie sich im Verlauf der letzten 4
Wochen durch Herzklopfen oder Herzrasen
beeinträchtigt?
Nicht beeinträchtigt (0)
Wenig beeinträchtigt (1)
Stark beeinträchtigt (2)
Wie stark fühlten Sie sich im Verlauf der letzten 4
Wochen durch Kurzatmigkeit beeinträchtigt?
Nicht beeinträchtigt (0)
Wenig beeinträchtigt (1)
Stark beeinträchtigt (2)
Wie stark fühlten Sie sich im Verlauf der letzten 4
Wochen durch Verstopfung, einen nervösen
Darm oder Durchfall beeinträchtigt?
Nicht beeinträchtigt (0)
Wenig beeinträchtigt (1)
Stark beeinträchtigt (2)
Wie stark fühlten Sie sich im Verlauf der letzten 4
Wochen durch Übelkeit, Blähungen oder
Verdauungsbeschwerden beeinträchtigt?
Nicht beeinträchtigt (0)
Wenig beeinträchtigt (1)
Stark beeinträchtigt (2)
2. Wie oft fühlten Sie sich im Verlauf der
letzten 2 Wochen durch die folgenden
Beschwerden beeinträchtigt?
Wie oft fühlten Sie sich im Verlauf der letzten 2
Wochen durch wenig Interesse oder Freude an
Ihren Tätigkeiten beeinträchtigt?
Überhaupt nicht (0)
An einzelnen Tagen (1)
An mehr als der Hälfte der Tage (2)
Beinahe jeden Tag (3)
Wie oft fühlten Sie sich im Verlauf der letzten 2
Wochen durch Niedergeschlagenheit, Schwermut
oder Hoffnungslosigkeit beeinträchtigt?
Überhaupt nicht (0)
An einzelnen Tagen (1)
An mehr als der Hälfte der Tage (2)
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Beinahe jeden Tag (3)
Wie oft fühlten Sie sich im Verlauf der letzten 2
Wochen durch Schwierigkeiten ein- oder
durchzuschlafen oder vermehrtem Schlaf
beeinträchtigt?
Überhaupt nicht (0)
An einzelnen Tagen (1)
An mehr als der Hälfte der Tage (2)
Beinahe jeden Tag (3)
Wie oft fühlten Sie sich im Verlauf der letzten 2
Wochen durch Müdigkeit oder das Gefühl, keine
Energie zu haben beeinträchtigt?
Überhaupt nicht (0)
An einzelnen Tagen (1)
An mehr als der Hälfte der Tage (2)
Beinahe jeden Tag (3)
Wie oft fühlten Sie sich im Verlauf der letzten 2
Wochen durch verminderter Appetit oder ein
übermäßiges Bedürfnis zu essen beeinträchtigt?
Überhaupt nicht (0)
An einzelnen Tagen (1)
An mehr als der Hälfte der Tage (2)
Beinahe jeden Tag (3)
Wie oft fühlten Sie sich im Verlauf der letzten 2
Wochen durch eine schlechte Meinung von sich
selbst, das Gefühl, ein Versager zu sein oder die
Familie enttäuscht zu haben beeinträchtigt?
Überhaupt nicht (0)
An einzelnen Tagen (1)
An mehr als der Hälfte der Tage (2)
Beinahe jeden Tag (3)
Wie oft fühlten Sie sich im Verlauf der letzten 2
Wochen durch Schwierigkeiten, sich auf etwas zu
konzentrieren, z.B. beim Zeitunglesen oder
Fernsehen, beeinträchtigt?
Überhaupt nicht (0)
An einzelnen Tagen (1)
An mehr als der Hälfte der Tage (2)
Beinahe jeden Tag (3)
Waren Ihre Bewegungen oder Ihre Sprache so
verlangsamt, dass es auch anderen auffallen
würde? Oder waren Sie im Gegenteil ´zappelig´
oder ruhelos und hatten dadurch einen stärkeren
Bewegungsdrang als sonst?
Überhaupt nicht (0)
An einzelnen Tagen (1)
An mehr als der Hälfte der Tage (2)
Beinahe jeden Tag (3)
Wie oft fühlten Sie sich im Verlauf der letzten 2
Wochen durch Gedanken, dass Sie lieber tot
wären oder sich Leid zufügen möchten,
beeinträchtigt?
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Überhaupt nicht (0)
An einzelnen Tagen (1)
An mehr als der Hälfte der Tage (2)
Beinahe jeden Tag (3)
3. Fragen zum Thema ´Angst´
Hatten Sie in den letzten 4 Wochen eine
Angstattacke (plötzliches Gefühl der Furcht oder
Panik?)
Ja
Nein
Ist dies bereits früher einmal vorgekommen?
Ja
Nein
Treten manche dieser Anfälle völlig unerwartet
auf - d.h. in Situationen, in denen Sie nicht damit
rechnen, dass Sie angespannt oder beunruhigt
reagieren?
Ja
Nein
Empfinden Sie diese Anfälle als stark
beeinträchtigend, und/oder haben Sie Angst vor
erneuten Anfällen?
Ja
Nein
4.  Denken Sie bitte an Ihren letzten
schlimmen Angstanfall
Denken Sie bitte an Ihren letzten schlimmen
Angstanfall. Bekamen Sie schlecht Luft?
Ja
Nein
Denken Sie bitte an Ihren letzten schlimmen
Angstanfall. Hatten Sie Herzrasen, Herzklopfen
oder unregelmäßigen Herzschlag?
Ja
Nein
Denken Sie bitte an Ihren letzten schlimmen
Angstanfall. Hatten Sie Schmerzen oder ein
Druckgefühl in der Brust?
Ja
Nein
Denken Sie bitte an Ihren letzten schlimmen
Angstanfall. Haben Sie geschwitzt?
Ja
Nein
Denken Sie bitte an Ihren letzten schlimmen
Angstanfall. Hatten Sie das Gefühl zu ersticken?
Ja
Nein
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Denken Sie bitte an Ihren letzten schlimmen
Angstanfall. Hatten Sie Hitzewallungen oder
Kälteschauer?
Ja
Nein
Denken Sie bitte an Ihren letzten schlimmen
Angstanfall. Wurde Ihnen übel, hatten Sie
Magenbeschwerden oder das Gefühl, Sie würden
Durchfall bekommen?
Ja
Nein
Denken Sie bitte an Ihren letzten schlimmen
Angstanfall. Fühlten Sie sich schwindelig,
unsicher, benommen oder einer Ohnmacht
nahe?
Ja
Nein
Denken Sie bitte an Ihren letzten schlimmen
Angstanfall. Spürten Sie ein Kribbeln, oder hatten
Sie ein Taubheitsgefühl in Teilen Ihres Körpers?
Ja
Nein
Denken Sie bitte an Ihren letzten schlimmen
Angstanfall. Zitterten oder bebten Sie?
Ja
Nein
Denken Sie bitte an Ihren letzten schlimmen
Angstanfall. Hatten Sie Angst, Sie würden
sterben?
Ja
Nein
5. Wie oft fühlten Sie sich im Verlauf der
letzten 2  Wochen durch die folgenden
Beschwerden beeinträchtigt?
Wie oft fühlten Sie sich im Verlauf der letzten 2
Wochen durch Nervosität, Ängstlichkeit oder
Anspannung beeinträchtigt?
Überhaupt nicht (0)
An einzelnen Tagen (1)
An mehr als der Hälfte der Tage (2)
Beinahe jeden Tag (3)
Wie oft fühlten Sie sich im Verlauf der letzten 2
Wochen durch ein nicht in der Lage sein, Sorgen
zu stoppen oder zu kontrollieren beeinträchtigt?
Überhaupt nicht (0)
An einzelnen Tagen (1)
An mehr als der Hälfte der Tage (2)
Beinahe jeden Tag (3)
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Wie oft fühlten Sie sich im Verlauf der letzten 2
Wochen durch übermäßige Sorgen bezüglich
verschiedener Angelegenheiten beeinträchtigt?
Überhaupt nicht (0)
An einzelnen Tagen (1)
An mehr als der Hälfte der Tage (2)
Beinahe jeden Tag (3)
Wie oft fühlten Sie sich im Verlauf der letzten 2
Wochen durch Schwierigkeiten zu entspannen
beeinträchtigt?
Überhaupt nicht (0)
An einzelnen Tagen (1)
An mehr als der Hälfte der Tage (2)
Beinahe jeden Tag (3)
Wie oft fühlten Sie sich im Verlauf der letzten 2
Wochen durch Rastlosigkeit, so dass Stillsitzen
schwer fällt, beeinträchtigt?
Überhaupt nicht (0)
An einzelnen Tagen (1)
An mehr als der Hälfte der Tage (2)
Beinahe jeden Tag (3)
Wie oft fühlten Sie sich im Verlauf der letzten 2
Wochen durch schnelle Verärgerung oder
Gereiztheit beeinträchtigt?
Überhaupt nicht (0)
An einzelnen Tagen (1)
An mehr als der Hälfte der Tage (2)
Beinahe jeden Tag (3)
Wie oft fühlten Sie sich im Verlauf der letzten 2
Wochen durch einGefühl der Angst, als würde
etwas Schlimmes passieren, beeinträchtigt?
Überhaupt nicht (0)
An einzelnen Tagen (1)
An mehr als der Hälfte der Tage (2)
Beinahe jeden Tag (3)
6.  Fragen zum Thema ´Essen´
Haben Sie öfter das Gefühl, Sie könnten nicht
kontrollieren, wieviel und was Sie essen?
Ja
Nein
Essen Sie öfter - in einem Zeitraum von 2
Stunden - Mengen, die andere Leute als
ungewöhnlich groß bezeichnen würden?
Ja
Nein
Ist dies während der letzten 3 Monate im
Durchschnitt mindestens zweimal in der Woche
vorgekommen?
Ja
Nein
6 / 10
PHQ-D
7.  Haben Sie während der letzten 3
Monate öfters eine oder mehrere der
folgenden Maßnahmen unternommen, um
eine Gewichtszunahme zu vermeiden?
Haben Sie während der letzten 3 Monate sich
selbst öfters zum Erbrechen gebracht?
Ja
Nein
Haben Sie während der letzten 3 Monate öfters
mehr als die doppelte empfohlene Dosis eines
Abführmittels eingenommen?
Ja
Nein
Haben Sie während der letzten 3 Monate öfters
gefastet, d.h. mindestens 24 Stunden lang nichts
gegessen?
Ja
Nein
Haben Sie während der letzten 3 Monate öfters
mehr als eine Stunde Sport getrieben mit dem
ausschließlichen Ziel, nicht zuzunehmen, wenn
Sie wie oben beschrieben gegessen haben?
Ja
Nein
Wenn Sie bei einer oder mehrerer dieser
Maßnahmen, die eine Gewichtszunahme
vermeiden sollen, ´JA´ angekreuzt haben, kam
eine davon im Durchschnitt mindestens zweimal
in der Woche vor?
Ja
Nein
Alkohol
Trinken Sie manchmal Alkohol (einschließlich
Bier oder Wein)?
Ja
Nein
10. Ist bei Ihnen im Laufe der letzten 6
Monate mehr als einmal eine der
folgenden Situationen eingetreten?
Ist bei Ihnen im Laufe der letzten 6 Monate mehr
als einmal die Situation eingetreten, dass Sie
Alkohol getrunken haben, obwohl Ihnen ein Arzt
angeraten hat, aus gesundheitlichen Gründen mit
dem Trinken aufzuhören?
Ja
Nein
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Ist bei Ihnen im Laufe der letzten 6 Monate mehr
als einmal die Situation eingetreten, dass Sie bei
der Arbeit, in der Schule, bei der Versorgung der
Kinder oder bei der Wahrnehmung anderer
Verpflichtungen Alkohol getrunken haben,
angetrunken oder ´verkatert´ waren?
Ja
Nein
Ist bei Ihnen im Laufe der letzten 6 Monate mehr
als einmal die Situation eingetreten, dass Sie der
Arbeit, der Schule oder anderen Verpflichtungen
fern geblieben oder zu spät gekommen sind, weil
Sie getrunken hatten oder ´verkatert´ waren?
Ja
Nein
Ist bei Ihnen im Laufe der letzten 6 Monate mehr
als einmal die Situation eingetreten, dass Sie
Schwierigkeiten hatten mit anderen
auszukommen, weil Sie getrunken hatten?
Ja
Nein
Ist bei Ihnen im Laufe der letzten 6 Monate mehr
als einmal die Situation eingetreten, dass Sie
Auto gefahren sind, nachdem Sie mehrere Gläser
Alkohol bzw. zuviel getrunken hatten?
Ja
Nein
11. Wenn eines oder mehrere der bisher
in diesem Fragebogen beschriebenen
Probleme bei Ihnen vorliegen, geben Sie
bitte an, wie sehr diese Probleme es
Ihnen erschwert haben, Ihre Arbeit zu tun,
Ihre...
Wenn eines oder mehrere der bisher in diesem
Fragebogen beschriebenen Probleme bei Ihnen
vorliegen, geben Sie bitte an, wie sehr diese
Probleme es Ihnen erschwert haben, Ihre Arbeit
zu tun, Ihren Haushalt zu regeln oder mit
anderen Menschen zurecht zu kommen:
Überhaupt nicht erschwert (0)
Etwas erschwert (1)
Relativ stark erschwert (2)
Sehr stark erschwert (3)
12. Wie stark fühlten Sie sich in den
letzten 4 Wochen durch die folgenden
Probleme beeinträchtigt?
Wie stark fühlten Sie sich in den letzten 4
Wochen durch Sorgen über Ihre Gesundheit
beeinträchtigt?
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Nicht beeinträchtigt (0)
Wenig beeinträchtigt (1)
Stark beeinträchtigt (2)
Wie stark fühlten Sie sich in den letzten 4
Wochen durch Ihr Gewicht oder Ihr Aussehen
beeinträchtigt?
Nicht beeinträchtigt (0)
Wenig beeinträchtigt (1)
Stark beeinträchtigt (2)
Wie stark fühlten Sie sich in den letzten 4
Wochen durch wenig oder kein sexuelles
Verlangen oder Vergnügen beim
Geschlechtsverkehr beeinträchtigt?
Nicht beeinträchtigt (0)
Wenig beeinträchtigt (1)
Stark beeinträchtigt (2)
Wie stark fühlten Sie sich in den letzten 4
Wochen durch Schwierigkeiten mit dem
Ehepartner, Lebensgefährten, Freundin/Freund
beeinträchtigt?
Nicht beeinträchtigt (0)
Wenig beeinträchtigt (1)
Stark beeinträchtigt (2)
Wie stark fühlten Sie sich in den letzten 4
Wochen durch Belastung durch die Versorgung
von Kindern, Eltern oder anderen
Familienangehörigen beeinträchtigt?
Nicht beeinträchtigt (0)
Wenig beeinträchtigt (1)
Stark beeinträchtigt (2)
Wie stark fühlten Sie sich in den letzten 4
Wochen durch Stress bei der Arbeit oder in der
Schule beeinträchtigt?
Nicht beeinträchtigt (0)
Wenig beeinträchtigt (1)
Stark beeinträchtigt (2)
Wie stark fühlten Sie sich in den letzten 4
Wochen durch finanzielle Probleme oder Sorgen
beeinträchtigt?
Nicht beeinträchtigt (0)
Wenig beeinträchtigt (1)
Stark beeinträchtigt (2)
Wie stark fühlten Sie sich in den letzten 4
Wochen durch Niemanden zu haben, mit dem
man Probleme besprechen kann, beeinträchtigt?
Nicht beeinträchtigt (0)
Wenig beeinträchtigt (1)
Stark beeinträchtigt (2)
Wie stark fühlten Sie sich in den letzten 4
Wochen durch etwas Schlimmes, das vor kurzem
passiert ist beeinträchtigt?
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Nicht beeinträchtigt (0)
Wenig beeinträchtigt (1)
Stark beeinträchtigt (2)
Wie stark fühlten Sie sich in den letzten 4
Wochen durch Gedanken an schreckliche
Ereignisse von früher oder Träume darüber – z.B.
die Zerstörung des eigenen Heimes, ein
schwerer Unfall, ein Überfall, körperliche Gewalt
oder eine sexuelle Handlung unter Zwang
beeinträchtigt?
Nicht beeinträchtigt (0)
Wenig beeinträchtigt (1)
Stark beeinträchtigt (2)
Letztes Jahr
Sind Sie im letzten Jahr geschlagen, getreten
oder anderweitig von jemandem körperlich
verletzt worden, oder hat Sie jemand zu einer
ungewünschten sexuellen Handlung gezwungen?
Ja
Nein
Medikation
Nehmen Sie Medikamente gegen Angst,
Depressionen oder Stress?
Ja
Nein
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Initial Evaluation Form Prostate
Cancer RTOG NCT00023829
Header
RTOG Study
Case #
Institution Name
Institution No.
Patient Name, Last
Patient Name, First
AMENDED DATA
COMMENTS
Signature
Date
Patient data
PATIENT BIRTH DATE (2)
PERFORMANCE STATUS (3)
-1 (-1)
0 (0)
1 (1)
2 (2)
3 (3)
4 (4)
HAS PATIENT HAD ANOTHER MALIGNANCY
(other than study site)
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Yes
No
Specify Site (malignancy other than study site)
DATE ERADICATED (mm/yyyy If not NED from
second malignancy, leave date blank.)
DATE OF INITIAL DIAGNOSIS OF PRIMARY
TUMOR (5 HISTOPATHOLOGIC TYPE)
HISTOLOGIC TYPE
Adenocarcinoma_2005009
(Adenocarcinoma)
Other_specify_2005013 (Other, specify)
Unknown or not applicable (Unknown or
not applicable)
Other, specify (histologic type) (B)
GLEASON SCORE, PRIMARY PATTERN ([most
frequently seen] 1-5, 9=unknown)
GLEASON SCORE, SECONDARY PATTERN
([second most frequently seen] 1-5, 9=unknown)
GLEASON SCORE, WORST PATTERN ([worst
pathological grade seen in any specimen] 1-5,
9=unknown)
GLEASON SCORE, COMBINED ([sum of the
primary and secondary, unless unknown]
99=Unknown)
ALKALINE PHOSPHATASE
Abnormal, < Normal (Abnormal, <
normal)
Abnormal, Elevated (Abnormal, elevated)
Normal (Normal)
Not Done (Not done)
Alk Phos Value
SPECIFY (unit of measure)
U/l (u/l)
U/ml (u/ml)
Lab normal range (alkaline phosphatase) (B)
ALT (SGPT)
Abnormal, < Normal (Abnormal, <
normal)
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Abnormal, Elevated (Abnormal, elevated)
Normal (Normal)
Not Done (Not done)
ALT Value
Lab normal range (ALT) (C)
TOTAL BILIRUBIN
Abnormal, < Normal (Abnormal, <
normal)
Abnormal, Elevated (Abnormal, elevated)
Normal (Normal)
Not Done (Not done)
Total Bilirubin Value
Lab normal range (total bilirubin) (11 BASELINE
PSA VALUE)
Baseline PSA Date
Baseline PSA Value
TIME POINT (12 GU DYSFUNCTION AT STUDY
ENTRY Use CTC 2.0 to code severity)
Post-surgery (Post-surgery)
Pre-hormone (Pre-hormone)
Pre-surgery (Pre-surgery)
Study Entry (Study entry)
URINARY INCONTINENCE, Severity Grade (0-3)
0 (0)
1 (1)
2 (2)
3 (3)
URINARY INCONTINENCE, Attribution
Not Applicable (Not applicable)
Other (Other)
Surgical (Surgical)
Other (attribution, urinary incontinence)
URINARY FREQUENCY/URGENCY, Severity
Grade (0-3)
0 (0)
1 (1)
2 (2)
3 (3)
URINARY FREQUENCY/URGENCY, Attribution
Not Applicable (Not applicable)
Other (Other)
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Surgical (Surgical)
Other (attribution, urinary frequency/urgency)
ERECTILE IMPOTENCE, Severity Grade (0-3)
0 (0)
1 (1)
2 (2)
3 (3)
ERECTILE IMPOTENCE, Attribution
Not Applicable (Not applicable)
Other (Other)
Surgical (Surgical)
Other (erectile impotence) (13)
T STAGE, PATHOLOGIC (14A)
T2, Tumor Confined Within The Prostate
(see Ajcc Definition) (T2, NOS)
T2a, Tumor Confined Within The
Prostate (see Ajcc Definition) (T2a)
T2b, Tumor Confined Within The
Prostate (see Ajcc Definition) (T2b)
T3, Tumor Extends Through The
Prostatic Capsule (see Ajcc Definition)
(T3, NOS)
T3a, Tumor Extends Through The
Prostatic Capsule (see Ajcc Definition)
(T3a)
T3b, Tumor Extends Through The
Prostatic Capsule (see Ajcc Definition)
(T3b)
T4, Tumor Is Fixed Or Invades Adjacent
Structures (see Ajcc Definition) (T4)
Primary Tumor Cannot Be Assessed
(TX)
N STAGE, PATHOLOGIC (SURGICAL)
No Regional Lymph Node Metastasis
(N0)
Metastatis In Regional Lymph Node Or
Nodes (see Ajcc Definition) (N1)
No node sampling (No node sampling)
N STAGE, CLINICAL (RADIOGRAPHIC)
No Regional Lymph Node Metastasis
(N0)
Metastasis To Movable Ipsilateral Axillary
Lymph Node(s) (N1)
Regional Lymph Nodes Cannot Be
Assessed (e.g., Previously Removed)
(NX)
ROACH RISK CALCULATION (15)
<15% (<15%)
>=15% (>=15%)
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M STAGE, CLINICAL
No Distant Metastasis (M0)
Distant Metastasis (M1)
Nonregional Lymph Node(s) (M1a)
Bone(s) (M1b)
Other Site(s) (M1c)
Distant Metastsis Cannot Be Assessed
(MX)
Prostate: Prior Treatment
PRIOR PROSTATECTOMY
Yes
No
Prior prostatectomy date
POSITIVE SURGICAL MARGINS
Yes
No
SEMINAL VESICLE INVASION (pathologic)
Yes
No
PRIOR RADIATION THERAPY
Yes
No
Specify (prior radiation therapy) (8)
PRIOR CHEMOTHERAPY (for any reason)
Yes
No
Prior chemotherapy end date (9)
PRIOR HORMONAL THERAPY (A)
Yes
No
PRIOR HORMONAL THERAPY TYPE
FINASTERIDE
Yes
No
Prior hormonal therapy end date (C)
PRIOR HORMONAL THERAPY TYPE
TESTOSTERONE
Yes
No
PRIOR OTHER HORMONAL THERAPY
Yes
No
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Specify (prior other hormonal therapy)
Date prior other hormonal therapy started (D)
ORCHIECTOMY
Yes
No
Orchiectomy date
PRIOR OR CURRENT COMPLEMENTARY
ALTERNATIVE MEDICINE (CAM) THERAPY
Yes
No
Specify (prior or current complementary
alternative medicine therapy)
Date prior or current CAM therapy started
Prior CAM therapy end date (if continuing leave
blank)
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Oxaliplatin, Leucovorin, and Fluorouracil With or Without
Bevacizumab in Treating Patients Who Have Undergone
Surgery for Stage II Colon Cancer
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CB9F-41AD-E040-BB89AD433F0D
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Colon Cancer E5202 NCT00217737
Header
ECOG Protocol Number
ECOG Patient ID
DCI Name
Registration Step
Patient Initials (Last, First)
Participating Group Protocol Number
Institution/Affiliate
Participating Group Patient ID
Please mark an 'X' if data have been amended
Yes
No
Date data amended (s)
Reporting Period (1 cycle = 2 weeks)
Cycle 1 (Cycle 1)
Cycle 10 (Cycle 10)
Cycle 11 (Cycle 11)
Cycle 12 (Cycle 12)
Cycle 2 (Cycle 2)
Cycle 3 (Cycle 3)
Cycle 4 (Cycle 4)
Cycle 5 (Cycle 5)
Cycle 6 (Cycle 6)
Cycle 7 (Cycle 7)
Cycle 8 (Cycle 8)
Cycle 9 (Cycle 9)
Investigator Signature
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Investigator Signature Date
Therapy
Was Leucovorin administered
Yes
No
If (racemic) Leucovorin was not given, please
specify why
Drug Not Available (Drug not available)
Toxicity (Toxicity)
Was Levoleucovorin substituted
Not Available (N/A)
No (No)
Yes (Yes)
dose administered (If yes,)
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E5204 Treatment Summary Form
Combination Chemotherapy With or Without Bevacizumab
in Treating Patients Who Have Had Surgery for Stage II or
Stage III Rectal Cancer
NCT00303628
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n.do?method=getFormDetails&formIdSeq=089A3135-
DAA8-2A7E-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
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Treatment Summary Form Colorectal
Cancer E5204 NCT00303628
Header
ECOG Protocol Number
ECOG Patient ID
DCI Name
Registration Step
Reporting Period
End Of Treatment (End of treatment)
Patient Initials (Last, First)
Participating Group Protocol Number
Institution/Affiliate
Participating Group Patient ID
Please mark an 'X' if data have been amended.
(Please circle amended items in red)
Date data amended (s)
Treatment Start Date (mm/dd/yyyy)
Treatment End Date (mm/dd/yyyy)
Investigator Signature
Investigator Signature Date
Patient data
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Patient Vital Status
Alive (Alive)
Dead (Dead)
Date of last contact or death (mm/dd/yyyy)
Primary Cause of Death (if applicable)
Due To Other Cause (Due to other
cause)
Due To Protocol Treatment (Due to
protocol treatment)
Due To This Disease (Due to this
disease)
Unknown (Unknown)
Describe cause of death
Patient Weight Measurement
Urine Protein Concentration
Urine Creatinine Concentration
Date sample obtained (mm/dd/yyyy)
Therapy Administered
Total Number of Cycles given
Agent Name
Agent Dose (Cycle 1)
Dose modification (First)
Dose Delayed (Dose delayed)
Dose Delayed And Reduced (Dose
delayed and reduced)
Dose Held (Dose held)
Dose Reduced (Dose reduced)
No Dose Modification (No dose
modification)
Dose Modification Reason (First)
Adverse Event (Adverse event)
Change In Bsa (Change in BSA)
Dosing Error (Dosing error)
Patient Refusal/noncompliance (Patient
refusal/noncompliance)
Scheduling (Scheduling)
Cumulative Agent Total Dose
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Cycle of dose modification (First)
Was any non-protocol therapy given during
protocol treatment (not previously reported)
Yes
No
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Pancreatic Cancer NCT00088894
CALGB: EQ-5D FORM
Gemcitabine With or Without Bevacizumab in Treating
Patients With Locally Advanced or Metastatic Pancreatic
Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=D602C703-
1CB1-3D8F-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/10077
EQ-5D FORM Pancreatic Cancer
CALGB NCT00088894
Header
CALGB Study No.
CALGB Patient ID
Assessment date
Are data amended?
Yes
No
Patient Initials
Participating Group
Patient Hospital No.
Participating Group Protocol No.
Institution/Affiliate
Participating Group Patient ID
Interviewer or CRA
Assessment Number
EuroQoL five dimension questionnaire
MOBILITY
I Am Confined To Bed (I am confined to
bed)
I Have No Problems In Walking About (I
have no problems in walking about)
I Have Some Problems In Walking About
(I have some problems in walking about)
SELF-CARE
I Am Unable To Wash Or Dress Myself (I
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am unable to wash or dress myself)
I Have No Problems With Self-care (I
have no problems with self-care)
I Have Some Problems Washing Or
Dressing Myself (I have some problems
washing or dressing myself)
USUAL ACTIVITIES
I Am Unable To Perform My Usual
Activities (I am unable to perform my
usual activities)
I Have No Problems With Performing My
Usual Activities (I have no problems with
performing my usual activities)
I Have Some Problems With Performing
My Usual Activities (I have some
problems with performing my usual
activities)
PAIN/DISCOMFORT
I Have Extreme Pain Or Discomfort (I
have extreme pain or discomfort)
I Have Moderate Pain Or Discomfort (I
have moderate pain or discomfort)
I Have No Pain Or Discomfort (I have no
pain or discomfort)
ANXIETY/DEPRESSION
I Am Extremely Anxious Or Depressed (I
am extremely anxious or depressed)
I Am Moderately Anxious Or Depressed
(I am moderately anxious or depressed)
I Am Not Anxious Or Depressed (I am
not anxious or depressed)
indicate on this scale how good or bad your own
health is today, in your opinion
Score
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RTOG 0521 FS: Radiation Therapy Oncology Group Phase
III Randomized Study of Localized, High-Risk Prostate
Cancer Interim Follow-up Form
Hormone Therapy and Radiation Therapy or Hormone
Therapy and Radiation Therapy Followed by Docetaxel and
Prednisone in Treating Patients With Localized Prostate
Cancer
NCT00288080
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=F6C17FD2-
E3B5-62CA-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/10078
Interim Follow-up Form Prostate
Cancer RTOG 0521 FS
NCT00288080
Header
RTOG Study No.
Case #
Institution Name
Institution No.
Patient Initials
RTOG Patient ID
Amended Data
Yes
No
Comments
Signature of Person Completing This Form
Date Form Originally Completed
Patient data
Patient's Vital Status
Alive (Alive)
Dead (Dead)
Date of Last Contact or Death
Primary Cause of Death
Due To Other Cause (Due to other
cause)
Due To Protocol Treatment (Due to
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protocol treatment)
Due To This Disease (Due to this
disease)
Not Applicable (Not applicable)
Unknown (Unknown)
Due to other cause, specify
Has the patient had a documented clinical
assessment for this cancer
Yes
No
Date
Performance Status
Fully Active, Able To Carry On All Pre-
disease Performance Without
Restriction. (0)
Restricted In Physically Strenuous
Activity But Ambulatory And Able To
Carry Out Work Of A Light Or Sedentary
Nature, E.g., Light Housework, Office
Work. (1)
Ambulatory And Capable Of All Selfcare
But Unable To Carry Out Any Work
Activities. Up And About More Than 50%
Of Waking Hours. (2)
Capable Of Only Limited Selfcare,
Confined To Bed Or Chair More Than
50% Of Waking Hours. (3)
Completely Disabled. Cannot Carry On
Any Selfcare. Totally Confined To Bed Or
Chair. (4)
Dead (5)
Has the patient has a prostate biospy (SINCE
SUBMISSION OF THE LAST FOLLOW-UP
FORM)
No (No)
Unknown (Unknown)
Yes, Negative (Yes, negative)
Yes, Positive (Yes, positive)
Yes, Results Unknown (Yes, results
unknown)
Biopsy Date
Was the tumor palpable
Equivocal (Equivocal)
No (No)
Not Evaluated (Not evaluated)
Unknown (Unknown)
Yes (Yes)
Has the patient been diagnosed with biochemical
recurrence since submission of the last follow-up
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No (NO)
Unknown (Unknown)
Yes (YES)
Has the patient been diagnosed with a first local
recurrence (SINCE SUBMISSION OF LAST
FOLLOW-UP FORM See Protocol Section 11)
No (NO)
Unknown (Unknown)
Yes (YES)
Date
Method of Evaluation (DISTANT
PROGRESSION)
Mri (MRI (NMR))
Not Applicable (Not applicable)
Other (Other)
Pathologic (Pathologic)
Physical Exam (Physical exam)
Radiographic (Radiographic)
Other Specify
Has the patient been diagnosed with first distant
progression (SINCE SUBMISSION OF THE
LAST FOLLOW-UP FORM)
No (No)
Unknown (Unknown)
Yes (Yes)
Date
Sites of Progression (First distant)
Has a new primary cancer or MDS been
diagnosed that has not been previously reported
No (No)
Unknown (Unknown)
Yes (Yes)
Second Primary Tumor Site
Aml/mds (AML/MDS)
Bcc (BCC)
Bladder Is The Site Of Second Primary
Or Recurrent Tumor (bladder)
Brain Is The Site Of Second Primary Or
Recurrent Tumor (brain)
Colorectal (Colorectal)
Esophageal (Esophageal)
Gastric (Gastric)
Liver Is The Site Of Second Primary Or
Recurrent Tumor (liver)
Lung Is The Site Of Second Primary Or
Recurrent Tumor (lung)
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Melanoma (Melanoma)
Nhl (NHL)
Other Hematologic (Other hematologic)
Other Solid (Other solid)
Pancreatic (Pancreatic)
Renal (Renal)
Squamous-skin (Squamous-skin)
Unknown Primary (Unknown primary)
Second Primary Cancer Date
Other specify
New or continuing adverse events (IF PATIENT
EXPERIENCED ANY TREATMENT RELATED
ADVERSE EVENTS DURING THIS REPORT
PERIOD, SUBMIT ADVERSE EVENT FORM AE)
No (No)
Unknown (Unknown)
Yes (Yes)
Unnamed Module 4a
PSA Date
PSA Value
Units of Measure
Nanograms Per Deciliter (ng/dL)
Nanograms Per Milliliter (ng/mL)
Nanomoles Per Liter (nmol/l)
Not Otherwise Specified (NOS)
Testosterone
Testosterone
Abnormal (Abnormal)
Normal (Normal)
Not Done (Not done)
Unknown (Unknown)
Testosterone Lower Limit Normal
Testosterone Upper Limit Normal
Treatment Schedule (lhrh Agonist)
Is patient on protocol hormone (LHRH Agonist)
Yes
No
LHRH agonist
Eligard (Eligard)
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Lupron (Lupron)
Other (Other)
Viadur (Viadur)
Zoladex (Zoladex)
Other, specify
LHRH agonist start date (IF STARTED IN THIS
FOLLOW-UP PERIOD)
LHRH agonist end date (IF TERMINATED IN
THIS FOLLOW-UP PERIOD)
Reason Treatment Ended (LHRH Agonist)
Adverse Event/side Effects/complications
(Adverse Event/Side
Effects/Complications)
Alternative Therapy (Alternative therapy)
Death On Study (Death on study)
Disease Progression, Relapse During
Active Treatment (Disease progression,
relapse during active treatment)
Other (Other)
Patient Off-treatment For Other
Complicating Disease (Patient off-
treatment for other complicating disease)
Patient Withdrawal Or Refusal After
Beginning Protocol Therapy (Patient
withdrawal/refusal after beginning
protocol therapy)
Patient Withdrawal Or Refusal Before
Beginning Protocol Therapy (Patient
withdrawal/refusal prior to beginning
protocol therapy)
Treatment Completed Per Protocol
Criteria (Treatment completed per
protocol criteria)
Alternative Therapy, specify
Patient off-treatment for other complicating
disease, specify
Other specify
Total Dose
Is the patient receiving any non-protocol cancer
therapy not previously reported (PROSTATE If
yes, enter therapy type and date for each therapy
delivered during the follow-up period.)
No (No)
Unknown (Unknown)
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Yes (Yes)
Non-Protocol Therapy Type
Chemotherapy (Chemotherapy)
Hormones (Hormones)
None (None)
Other Specify (Other, specify)
Radiation To Other Sites, Specify
(Radiation to other sites, specify)
Radiation To Pelvis (Radiation to pelvis)
Surgery (Surgery)
Date of First Non-Protocol Therapy
Specify
6 / 6
Prostate Cancer NCT00288080
Breast Cancer NCT00041119
CALGB: 40101 ON-STUDY FORM
Four Versus Six Cycles of Cyclophosphamide/Doxorubicin
or Paclitaxel in Adjuvant Breast Cancer
NCT00041119
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=A4E097B4-
CDDD-18B4-E034-080020C9C0E0
All rights reserved. Please visit https://medical-data-
models.org/forms/10081
ON-STUDY FORM Breast Cancer
CALGB 40101 NCT00041119
Header
CALGB Form
CALGB Study No
CALGB Patient ID (Prior Systemic Therapy)
Amended data?
Yes (Yes)
Patient's Name
Participating Group
Patient Hospital Number
Participating Group Protocol No.
Main Member Institution/Adjunct
Participating Group Patient No.
Completed By (Print or Type Name)
Date Completed (M)
Patient data
Menopausal Status
Above Categories Not Applicable And
Age < 50 (Above categories not
applicable AND Age <50)
50 (Above categories not applicable AND
Age >)
Post (prior Bilateral Ovariectomy Or >12
Mo Since Lmp With No Prior
Hysterectomy) (Post)
Pre (<6 Mo Since Lmp And No Prior
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Bilateral Ovariectomy And Not On
Estrogen Replacement) (Pre)
Tumor Laterality (mark one with an X)
Bilateral (Bilateral)
Left (Left)
Right (Right)
Receptor Status, ER (If measured in fmols/mg
cytosol protein >= 10 is positive.  If other
measures are used apply institutional standards;
borderline results should be reported as positive)
Negative (Negative)
Positive (Positive)
Unknown (Unknown)
Receptor Status, PgR (mark one with an X)
Negative (Negative)
Positive (Positive)
Unknown (Unknown)
Histologic Grade (combined histologic grade is
used according to SBR/ELSTON classification.)
Poorly Differentiated (High)
Moderately Differentiated (Intermediate)
Well Differentiated (Low)
HER-2 neu Status
Dako Herceptest <3+/fish+ (Dako
Herceptest <3+/FISH+)
Dako Herceptest 3+ (Dako Herceptest
3+)
Fish+ (ihc Not Done) (FISH+ (IHC not
done))
Ihc (non-dako Herceptest) Strong
Positive (IHC (non-Dako Herceptest)
strong positive)
Negative (Negative)
Not done (Not done)
Unknown (Unknown)
Pathologic primary tumor size
T (disease stage, pathology report)
N (disease stage, pathology report)
M (disease stage, pathology report) (Disease
stage pathology report)
Prior hormonal therapy? (do not include steroids
given with chemotherapy)
Yes
No
Tamoxifen
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Yes
No
Raloxifene
Yes
No
Other, specify (prior hormonal therapy)
Prior adjuvant chemotherapy for this malignancy?
(include pre-op chemotherapy at diagnosis)
Yes
No
specify (prior adjuvant chemotherapy for this
malignancy)
WBC
ANC
Platelets
Serum Creatinine
Bilirubin
Bilirubin (upper limit of normal)
Date of first positive biopsy (M)
Type of biopsy (mark one with an X)
Core Needle (Core needle)
Excisional (Excisional)
Incisional (Incisional)
Most extensive primary surgery (mark one with
an X)
Mastectomy, Nos (Mastectomy, NOS)
Partial
Mastectomy/lumpectomy/excisional
Biopsy (Partial
mastectomy/lumpectomy/excisional
biopsy)
Date of most extensive primary surgery (if
required, use date of last re-excision)
Sentinel node biopsy
Yes
No
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date (sentinel node biopsy) (M)
If done, sentinel node biopsy results (per
protocol)
Negative (Negative)
Positive (Positive)
Was axillary dissection performed?
Yes
No
date (axillary dissection performed) (M)
Total number of axillary lymph nodes examined
Number of positive axillary lymph nodes
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Breast Cancer NCT00024102
CALGB: SOCIAL SUPPORT FORM
Comparison of Combination Chemotherapy Regimens in
Treating Older Women Who Have Undergone Surgery for
Breast Cancer
NCT00024102
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=A50BF99D-
12AE-2D64-E034-080020C9C0E0
All rights reserved. Please visit https://medical-data-
models.org/forms/10082
SOCIAL SUPPORT FORM Breast
Cancer CALGB NCT00024102
Header
CALGB Form
CALGB Study No
CALGB Patient ID
Date Completed (8.)
Amended data?
Yes (Yes)
Patient's Name
Participating Group
Patient Hospital Number
Participating Group Protocol No.
Main Member Institution/Adjunct
Participating Group Patient No.
Responsible CRA
Assessment Number (1.)
Social support
About how many close friends and close relatives
do you have now (people you feel at ease with
and can talk to about what is on your mind)?
([Number of close friends/relatives])
Someone to help if you were confined to bed (3.)
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A Little Of The Time (A Little of the Time)
All Of The Time (All of the Time)
Most Of The Time (Most of the Time)
None Of The Time (None of the Time)
Some Of The Time (Some of the Time)
Someone you can count on to listen to you when
you need to talk (4.)
A Little Of The Time (A Little of the Time)
All Of The Time (All of the Time)
Most Of The Time (Most of the Time)
None Of The Time (None of the Time)
Some Of The Time (Some of the Time)
Someone to give you good advice about a crisis
(5.)
A Little Of The Time (A Little of the Time)
All Of The Time (All of the Time)
Most Of The Time (Most of the Time)
None Of The Time (None of the Time)
Some Of The Time (Some of the Time)
Someone to take you to the doctor if you needed
it (6.)
A Little Of The Time (A Little of the Time)
All Of The Time (All of the Time)
Most Of The Time (Most of the Time)
None Of The Time (None of the Time)
Some Of The Time (Some of the Time)
Someone who shows you love and affection (7.)
A Little Of The Time (A Little of the Time)
All Of The Time (All of the Time)
Most Of The Time (Most of the Time)
None Of The Time (None of the Time)
Some Of The Time (Some of the Time)
Someone to have a good time with
A Little Of The Time (A Little of the Time)
All Of The Time (All of the Time)
Most Of The Time (Most of the Time)
None Of The Time (None of the Time)
Some Of The Time (Some of the Time)
Someone to give you information to help you
understand a situation (9.)
A Little Of The Time (A Little of the Time)
All Of The Time (All of the Time)
Most Of The Time (Most of the Time)
None Of The Time (None of the Time)
Some Of The Time (Some of the Time)
Someone to confide in or talk to about yourself or
your problems (10.)
A Little Of The Time (A Little of the Time)
All Of The Time (All of the Time)
Most Of The Time (Most of the Time)
None Of The Time (None of the Time)
Some Of The Time (Some of the Time)
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Someone who hugs you (11.)
A Little Of The Time (A Little of the Time)
All Of The Time (All of the Time)
Most Of The Time (Most of the Time)
None Of The Time (None of the Time)
Some Of The Time (Some of the Time)
Someone to get together with for relaxation (12.)
A Little Of The Time (A Little of the Time)
All Of The Time (All of the Time)
Most Of The Time (Most of the Time)
None Of The Time (None of the Time)
Some Of The Time (Some of the Time)
Someone to prepare your meals if you were
unable to do it yourself (13.)
A Little Of The Time (A Little of the Time)
All Of The Time (All of the Time)
Most Of The Time (Most of the Time)
None Of The Time (None of the Time)
Some Of The Time (Some of the Time)
Someone whose advice you really want (14.)
A Little Of The Time (A Little of the Time)
All Of The Time (All of the Time)
Most Of The Time (Most of the Time)
None Of The Time (None of the Time)
Some Of The Time (Some of the Time)
Someone to do things with to help you get your
mind off things (15.)
A Little Of The Time (A Little of the Time)
All Of The Time (All of the Time)
Most Of The Time (Most of the Time)
None Of The Time (None of the Time)
Some Of The Time (Some of the Time)
Someone to help you with daily chores if you
were sick (16.)
A Little Of The Time (A Little of the Time)
All Of The Time (All of the Time)
Most Of The Time (Most of the Time)
None Of The Time (None of the Time)
Some Of The Time (Some of the Time)
Someone to share your most private worries and
fears with (17.)
A Little Of The Time (A Little of the Time)
All Of The Time (All of the Time)
Most Of The Time (Most of the Time)
None Of The Time (None of the Time)
Some Of The Time (Some of the Time)
Someone to turn to for suggestions about how to
deal with a personal problem (18.)
A Little Of The Time (A Little of the Time)
All Of The Time (All of the Time)
Most Of The Time (Most of the Time)
None Of The Time (None of the Time)
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Some Of The Time (Some of the Time)
Someone to do something enjoyable with (19.)
A Little Of The Time (A Little of the Time)
All Of The Time (All of the Time)
Most Of The Time (Most of the Time)
None Of The Time (None of the Time)
Some Of The Time (Some of the Time)
Someone who understands your problems (20.)
A Little Of The Time (A Little of the Time)
All Of The Time (All of the Time)
Most Of The Time (Most of the Time)
None Of The Time (None of the Time)
Some Of The Time (Some of the Time)
Someone to love and make you feel wanted
A Little Of The Time (A Little of the Time)
All Of The Time (All of the Time)
Most Of The Time (Most of the Time)
None Of The Time (None of the Time)
Some Of The Time (Some of the Time)
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Breast Cancer NCT00024102
CALGB: ADHERENCE QUESTIONNAIRE FORM
(FOLLOW-UP)
Comparison of Combination Chemotherapy Regimens in
Treating Older Women Who Have Undergone Surgery for
Breast Cancer
NCT00024102
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=A50CC350-
FC34-364B-E034-080020C9C0E0
All rights reserved. Please visit https://medical-data-
models.org/forms/10083
ADHERENCE QUESTIONNAIRE
FORM (FOLLOW-UP) Breast Cancer
Breast Cancer CALGB
NCT00024102
Header
CALGB Form
CALGB Study No
CALGB Patient ID
Date Completed (6.)
Amended data?
Yes
No
Patient's Name
Participating Group
Patient Hospital Number
Participating Group Protocol No.
Main Member Institution/Adjunct
Participating Group Patient No.
Responsible CRA
Assessment Number (1.)
Compliance behavior
The benefits of my cancer treatment outweigh the
1 / 3
difficulties I have in following it. (2.)
Strongly Disagree (1)
Disagree (2)
Neither Agree Nor Disagree (3)
Agree (4)
Strongly Agree (5)
I believe that taking my cancer medication is too
much trouble for what I will get out of it. (3.)
Strongly Disagree (1)
Disagree (2)
Neither Agree Nor Disagree (3)
Agree (4)
Strongly Agree (5)
Because the schedule for taking my cancer
medication is too difficult, it is not be worth
following it. (4.)
Strongly Disagree (1)
Disagree (2)
Neither Agree Nor Disagree (3)
Agree (4)
Strongly Agree (5)
Taking my cancer medication is better for me
than not taking it. (5.)
Strongly Disagree (1)
Disagree (2)
Neither Agree Nor Disagree (3)
Agree (4)
Strongly Agree (5)
Taking my cancer medication is helping me to be
healthy.
Strongly Disagree (1)
Disagree (2)
Neither Agree Nor Disagree (3)
Agree (4)
Strongly Agree (5)
I will be just as healthy even if I were not taking
my cancer medication. (7.)
Strongly Disagree (1)
Disagree (2)
Neither Agree Nor Disagree (3)
Agree (4)
Strongly Agree (5)
I believe that my cancer treatment is helping to
cure me of cancer. (8.)
Strongly Disagree (1)
Disagree (2)
Neither Agree Nor Disagree (3)
Agree (4)
Strongly Agree (5)
It is hard to believe that my cancer treatment is
helping me. (9.)
Strongly Disagree (1)
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Disagree (2)
Neither Agree Nor Disagree (3)
Agree (4)
Strongly Agree (5)
Lots of things are getting in the way of following
the schedule for taking my cancer medication.
(10.)
Strongly Disagree (1)
Disagree (2)
Neither Agree Nor Disagree (3)
Agree (4)
Strongly Agree (5)
I need more assistance in order to follow the
schedule for taking my cancer medication. (11.)
Strongly Disagree (1)
Disagree (2)
Neither Agree Nor Disagree (3)
Agree (4)
Strongly Agree (5)
I am getting the help I need to follow my cancer
medication schedule. (12.)
Strongly Disagree (1)
Disagree (2)
Neither Agree Nor Disagree (3)
Agree (4)
Strongly Agree (5)
I am able to deal with any problems in taking my
cancer medication. (13.)
Strongly Disagree (1)
Disagree (2)
Neither Agree Nor Disagree (3)
Agree (4)
Strongly Agree (5)
The side effects of my cancer medication disrupt
my normal activities.
Strongly Disagree (1)
Disagree (2)
Neither Agree Nor Disagree (3)
Agree (4)
Strongly Agree (5)
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Bladder Cancer NCT01224665
S1011 Pre-Randomization Off-Study Form (#52060)
Standard or Extended Pelvic Lymphadenectomy in Treating
Patients Undergoing Surgery for Invasive Bladder Cancer
NCT01224665
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=9399F2B7-
7E68-06C0-E040-BB89AD436952
All rights reserved. Please visit https://medical-data-
models.org/forms/10084
Pre-Randomization Off-Study Form
Bladder Cancer #52060 S1011
NCT01224665
Header
SWOG Patient ID
SWOG Study No.
Registration Step
Patient Initials (L, F M)
Institution/Affiliate
Physician
Participating Group Name
Participating Group Study No.
Participating Group Patient ID
Comments
Treatment Information
Did the patient receive any treatment (on this
registration step)
Yes
No
Treatment Start Date (MM DD YYYY)
Treatment End Date (MM DD YYYY)
Regimen or Procedure or Site(s)
Off Treatment Reason
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Off Study Reason (select one)
Ineligible For Randomization To
Extended Vs. Standard Lnd Due To
Extent Of Disease At The Time Of
Surgery (1)
Adverse Event/side Effects/complications
(2)
Patient Withdrawal/refusal (3)
Disease Progression (4)
Death On Study (5)
Other (6)
Adverse event/side effects/complications specify
Patient withdrawal/refusal, specify
Sites
Other specify
Off Study Date (MM DD YYYY Date of
progression, death or decision to discontinue)
Additional Treatment
Will patient receive further treatment?
No (No)
Unknown (Unknown)
Yes (Yes)
Yes, specify
Vital Status
Date of Last Contact or Death (MM DD YYYY)
Vital Status
Alive (Alive)
Dead (Dead)
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Gastrointestinal Stromal Tumor
NCT00324987
S0502 Off Treatment Notice
S0502 Imatinib Mesylate With or Without Bevacizumab in
Treating Patients With Metastatic or Unresectable
Gastrointestinal Stromal Tumor
NCT00324987
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=FCCFD537-
4859-4344-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/10085
Off Treatment Notice Gastrointestinal
Stromal Tumor S0502 NCT00324987
Header
SWOG Patient ID
SWOG Study No.
Registration Step
Patient Initials (L, F M)
Institution/Affiliate
Physician
Participating Group Name
Participating Group Study No.
Participating Group Patient ID
Comments
Off Treatment
Treatment Start Date
Treatment End Date
Regimen or Procedure or Site (s)
Off Treatment Reason (select one:)
Treatment Completed Per Protocol
Criteria (1)
Adverse Event/side Effects/complications
(2)
Patient Withdrawal Or Refusal After
Beginning Protocol Therapy (3)
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Patient Withdrawal Or Refusal Before
Beginning Protocol Therapy (4)
Disease Progression, Relapse During
Active Treatment (5)
Death On Study (6)
Other (7)
Specify
Patient withdrawal/refusal after beginning
protocol therapy specify
Patient withdrawal/refusal prior to beginning
protocol therapy specify
Sites
Other specify
Was treatment termination medically required
(For any adverse event,)
Yes
No
Yes specify
Was reason due to adverse event/side
effects/complications (For any patient refusal,)
Yes
No
Specify other reason for refusal
Off Treatment Date (Date of completion,
progression, death or decision to discontinue
therapy:)
Will patient receive further treatment?
No (No)
Unknown (Unknown)
Yes (Yes)
Yes, specify
Date of Last Contact or Death
Vital Status
Alive (Alive)
Dead (Dead)
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SOUTHWEST ONCOLOGY GROUP OFF
TREATMENT NOTICE
SOUTHWEST ONCOLOGY GROUP OFF TREATMENT
NOTICE
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=10265924-
7D4E-50D0-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/10086
SOUTHWEST ONCOLOGY GROUP
OFF TREATMENT NOTICE
Header
SWOG Patient ID
SWOG Study No.
Registration Step
Patient Initials (L, F M)
Institution/Affiliate
Physician
Participating Group Name
Participating Group Study No.
Participating Group Patient ID
Comments
Off Treatment
Off Treatment Reason (select one:)
Treatment Completed Per Protocol
Criteria (1)
Adverse Event/side Effects/complications
(2)
Patient Withdrawal Or Refusal After
Beginning Protocol Therapy (3)
Patient Withdrawal Or Refusal Before
Beginning Protocol Therapy (4)
Disease Progression, Relapse During
Active Treatment (5)
Death On Study (6)
Other (7)
Adverse event/side effects/complications specify
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Patient withdrawal/refusal prior to beginning
protocol therapy, specify
Patient withdrawal/refusal after beginning
protocol therapy, specify
Sites
Other specify
Was treatment termination medically required
(For any adverse event,)
Yes
No
Yes specify
Was reason due to adverse event/side
effects/complications (For any patient refusal,)
Yes
No
Yes specify
Specify other reason for refusal
Off Treatment Date (Date of completion,
progression, death or decision to discontinue
therapy:)
Treatment Start Date
Treatment End Date
Regimen or Procedure or Site (s)
Will patient receive further treatment?
Yes
No
Yes, specify
Date of Last Contact or Death
Vital Status
Alive (Alive)
Dead (Dead)
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Breast Cancer NCT00408408 Toxicity
NSABP Protocol B-40 - Adverse Event Form
A Randomized Phase III Trial of Neoadjuvant Therapy in
Patients With Palpable and Operable Breast Cancer
Evaluating the Effect on Pathologic Complete Response
(pCR) of Adding Capecitabine or Gemcitabine to Docetaxel
When Administered Before AC With or Without
Bevacizumab and Correlative Science Studies Attempting
to Identify Predictors of High Likelihood for pCR With Each
of the Regimens
NCT00408408
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=1ABDA8E9-
5BF6-6122-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/10087
Adverse Event Form Breast Cancer
NSABP B-40 NCT00408408
Header
Patient Initials (Last First Middle)
NSABP Patient ID
Institution/Affiliate
Person Completing Form, Last Name
Person Completing Form, First Name
Person Completing Form, Phone
Are data amended
Yes
No
Comments
Person Completing Form
Date Form Completed
Reporting Period
Treatment group
Docetaxel Followed By Doxorubicin And
Cyclophosphamide (Docetaxel - AC)
Docetaxel And Bevacizumab Followed
By Doxorubicin, Cyclophosphamide And
Bevacizumab (Docetaxel + Bevacizumab
- AC + Bevacizumab)
Docetaxel And Capecitabine Followed
By Doxorubicin And Cyclophosphamide
(Docetaxel/Capecitabine - AC)
Docetaxel, Capecitabine And
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Bevacizumab Followed By Doxorubicin,
Cyclophosphamide And Bevacizumab
(Docetaxel/Capecitabine +
Bevacizumab- AC + Bevacizumab)
Docetaxel And Gemcitabine Followed By
Doxorubicin And Cyclophosphamide
(Docetaxel/Gemcitabine - AC)
Docetaxel, Gemcitabine And
Bevacizumab Followed By Doxorubicin,
Cyclophosphamide And Bevacizumab
(Docetaxel/Gemcitabine + Bevacizumab
- AC + Bevacizumab)
Preoperative Chemotherapy Cycles
Postoperative Bevacizumab Doses
Reporting Period Start Date
Reporting Period End Date
No. of bevacizumab doses given this report
period (If non given doses = 0)
Did the patient require red blood cell (RBC)
tranfusion
Yes
No
Did the patient require platelet transfusion
Yes
No
Was the patient hospitalized for 24 hours or
more?
Yes
No
Adverse Event
Adverse Event
Grade
Severe Adverse Event (3)
Life Threatening Adverse Event (4)
Death Related To Adverse Event (5)
2 / 2
Breast Cancer NCT00408408 Toxicity
Melanoma (Skin) NCT01274338 On-Study
Form
E1609 Hematology/Chemistry Form
Ipilimumab or High-Dose Interferon Alfa-2b in Treating
Patients With High-Risk Stage III or Stage IV Melanoma
That Has Been Removed by Surgery
NCT01274338
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=97E7C12F-
E851-FFC2-E040-BB89AD43160A
All rights reserved. Please visit https://medical-data-
models.org/forms/10088
Hematology/Chemistry On-Study
Form Melanoma E1609
NCT01274338
Header
ECOG Protocol Number
ECOG Patient ID
DCI Name
Registration Step
Patient Initials (Last, First)
Participating Group Protocol Number
Participating Group Patient ID
Institution/Affiliate
Please mark an 'X' if data have been amended.
(Please circle amended items in red)
Date data amended (MM/DD/YYYY)
Investigator Signature
Investigator Signature Date
On Treatment
On Treatment Report Period (Choose one x)
Baseline (baseline)
Relapse (Relapse)
Week 12 (Week 12)
Week 24 (Week 24)
Week 36 (Week 36)
Week 48 (Week 48)
Off Treatment Report Period (since registration -
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Choose one x)
24 Months (24 months post registration)
Relapse (Relapse)
Were hematology/chemistry results obtained this
report period (cycle)?
Yes
No
Date Hematology (Blood) Sample Obtained
Test not done
C-reactive protein ULN
C-reactive Protein
Lactate Dehydrogenase ULN
Lactate Dehydrogenase (LDH)
Peripheral Lymphocyte Count
Peripheral Lymphocyte Count LLN
Anticardiolipin
Equivocal (Equivocal)
Negative (negative)
Not Done (Not Done)
Positive (positive)
Antimicrosomal antibody
Equivocal (Equivocal)
Negative (negative)
Not Done (Not Done)
Positive (positive)
Antinuclear antibody screen
Equivocal (Equivocal)
Negative (negative)
Not Done (Not Done)
Positive (positive)
Antithyroglobulin antibody
Equivocal (Equivocal)
Negative (negative)
Not Done (Not Done)
Positive (positive)
Antithyroperoxidase antibody
Equivocal (Equivocal)
Negative (negative)
Not Done (Not Done)
Positive (positive)
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Thyroid stimulating immunoglobulin
Equivocal (Equivocal)
Negative (negative)
Not Done (Not Done)
Positive (positive)
Assessment date
Explain equivocal results
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Breast Cancer NCT00520975 Quality of
Life
E1105 Quality of Life Assessment Form
First-Line Chemotherapy and Trastuzumab With or Without
Bevacizumab in Treating Patients With Metastatic Breast
Cancer That Overexpresses HER-2/NEU
NCT00520975
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=1736308A-
3F51-3856-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/10089
Quality of Life Assessment Form
Breast Cancer E1105 NCT00520975
Header
ECOG Protocol Number
ECOG Patient ID
DCI Name
Registration Step
Patient Initials (Last, First)
Participating Group Protocol Number
Institution/Affiliate
Participating Group Patient ID
Please mark an 'X' if data have been amended
(Please circle amended items in red)
Date data amended (M D Y)
On Treatment Report Period (Maintenance 1
cycle = 3 weeks)
Cycle 24 (Cycle 24)
Cycle 40 (Cycle 40)
Cycle 5 (Cycle 5)
Cycle 56 (Cycle 56)
Cycle 72 (Cycle 72)
Cycle 8 (cycle 8)
End Of Treatment (End of Treatment)
Quality of life
I have a lack of energy.
Not at all (1)
A little bit (2)
Somewhat (3)
1 / 3
Quite a bit (4)
Very much (5)
I have pain.
Not at all (1)
A little bit (2)
Somewhat (3)
Quite a bit (4)
Very much (5)
I have nausea.
Not at all (1)
A little bit (2)
Somewhat (3)
Quite a bit (4)
Very much (5)
I have certain areas of my body where I
experience significant pain
Not at all (1)
A little bit (2)
Somewhat (3)
Quite a bit (4)
Very much (5)
I have been short of breath.
Not at all (1)
A little bit (2)
Somewhat (3)
Quite a bit (4)
Very much (5)
I worry that my condition will get worse
Not at all (1)
A little bit (2)
Somewhat (3)
Quite a bit (4)
Very much (5)
I am content with the quality of my life right now
Not at all (1)
A little bit (2)
Somewhat (3)
Quite a bit (4)
Very much (5)
Because of my physical condition, I have trouble
meeting the needs of my family.
Not at all (1)
A little bit (2)
Somewhat (3)
Quite a bit (4)
Very much (5)
I am bothered by side effects of treatment.
Not at all (1)
A little bit (2)
Somewhat (3)
Quite a bit (4)
Very much (5)
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Breast Cancer NCT00520975 Quality of Life
I have numbness or tingling in my hands
Not at all (1)
A little bit (2)
Somewhat (3)
Quite a bit (4)
Very much (5)
I have numbness or tingling in my feet
Not at all (1)
A little bit (2)
Somewhat (3)
Quite a bit (4)
Very much (5)
I feel discomfort in my hands
Not at all (1)
A little bit (2)
Somewhat (3)
Quite a bit (4)
Very much (5)
I feel discomfort in my feet
Not at all (1)
A little bit (2)
Somewhat (3)
Quite a bit (4)
Very much (5)
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Breast Cancer NCT00520975 Quality of Life
Breast Cancer SWOG baseline tumor
assessment NCT00075764
SOUTHWEST ONCOLOGY GROUP BASELINE TUMOR
ASSESSMENT FORM (S0226)
S0226 Anastrozole With or Without Fulvestrant as First-
Line Therapy in Postmenopausal Women With Metastatic
Breast Cancer
NCT00075764
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=C322202A-
32BF-25B7-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/10090
BASELINE TUMOR ASSESSMENT
Breast cancer SWOG S0226
NCT00075764
Header
SWOG Patient ID
SWOG Study No.
Registration Step
Patient Initials (L, F M)
Institution/Affiliate
Physician (Groups Other than SWOG)
Group Name
Study No.
Pt. ID (Instructions: Record the requested
information for all target lesions and all sites of
other disease. Please refer to section 10.0 of the
protocol for definitions. Choose all measurable
lesions up to a maximum of 5 lesions per organ
and 10 lesions in total to follow as target lesions.
Record any remaining measurable lesions and all
non-measurable lesions as non-terget lesions.)
Comments
Target Lesions
Lesion Number
Target Lesion Site
1 / 2
Longest Diameter
Assessment Type
Colposcopy (Colposcopy)
CT Scan (CT scan)
Cystoscopy (Cystoscopy)
Cytology (Cytologic confirmation)
Endoscopy (Endoscopy)
Histology (Histologic confirmation)
MRI (MRI scan)
Other (Other)
Palpation (Palpation)
PET scan (PET scan)
Plain film/X-ray with contrast (Plain
film/X-ray with contrast)
Plain film/X-ray without contrast (Plain
film/X-ray without contrast)
Radioisotope scan (Radioisotope scan)
Spiral CT Scan (Spiral CT scan)
Ultrasound (Ultrasound)
Visualization (Visualization)
Assessment Date
Non-target Disease
Lesion Number
Lesion site
Extent
Assessment Type
Colposcopy (Colposcopy)
CT Scan (CT scan)
Cystoscopy (Cystoscopy)
Cytology (Cytologic confirmation)
Endoscopy (Endoscopy)
Histology (Histologic confirmation)
MRI (MRI scan)
Other (Other)
Palpation (Palpation)
PET scan (PET scan)
Plain film/X-ray with contrast (Plain
film/X-ray with contrast)
Plain film/X-ray without contrast (Plain
film/X-ray without contrast)
Radioisotope scan (Radioisotope scan)
Spiral CT Scan (Spiral CT scan)
Ultrasound (Ultrasound)
Visualization (Visualization)
Other tests
Tests/studies
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Colorectal Cancer Non-Protocol Therapy
NCT00303628
E5204 Non-Protocol Therapy Form
Combination Chemotherapy With or Without Bevacizumab
in Treating Patients Who Have Had Surgery for Stage II or
Stage III Rectal Cancer
NCT00303628 
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=089B4967-
A7D1-3905-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/10091
Non-Protocol Therapy Colorectal
Cancer NCT00303628 E5204
Header
ECOG Protocol Number
ECOG Patient ID
DCI Name
Registration Step
Reporting Period
Non-protocol Therapy (Non-Protocol
Therapy)
Patient Initials (Last, First)
Participating Group Protocol Number
Institution/Affiliate
Participating Group Patient ID
Please mark an 'X' if data have been amended.
(Please circle amended items in red)
Date data amended (s - mm/dd/yyyy)
Investigator Signature
Investigator Signature Date
Non-protocol Therapy
Date of First Non-Protocol Therapy
Non-protocol Chemotherapy
Yes
No
1 / 2
Non-protocol Hormonal Therapy
Yes
No
Non-protocol Immunotherapy (Biological
Response Modifiers)
Yes
No
Non-protocol High Dose Chemotherapy/Stem
Cell Transplant (Autologous or Allogeneic)
Yes
No
Non-protocol Surgery
Yes
No
Non-protocol surgery type
Non-protocol Radiation Therapy
Yes
No
Non-protocol RT type
Other Non-protocol Therapy
Yes
No
Name of other non-protocol therapy
Was the non-protocol therapy given for the
disease of this protocol
Yes
No
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Lung Cancer Smoking Survey
NCT00324805
ECOG-E1505 Follow Up Smoking Survey
Chemotherapy With or Without Bevacizumab in Treating
Patients With Stage IB, Stage II, or Stage IIIA Non-Small
Lung Cancer That Was Removed By Surgery
NCT00324805
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=0745B0C2-
1A2A-5046-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/10092
Follow Up Smoking Survey Lung
Cancer NCT00324805 ECOG-E1505
Header
ECOG Protocol Number
ECOG Patient ID
DCI Name
Registration Step
Patient Initials (Last, First)
Participating Group Protocol Number
Institution/Affiliate
Participating Group Patient ID
Please mark an 'X' if data have been amended
(Please circle amended data in red.)
Date data amended (M D Y)
Investigator Signature
Investigator Signature Date
Smoking status
Reporting Period (since registration Both Arms)
12 Months Post Registration (12 Months
Post Registration)
3 Months Post Registration (3 Months
Post Registration)
6 Months Post Registration (6 Months
Post Registration)
9 Months Post Registration (9 Months
Post Registration)
1 / 3
Date data obtained
Does the patient currently smoke cigarettes
No (No)
Patient Refused To Answer (Patient
Refused to Answer)
Unknown (Unknown)
Yes (Yes)
Which of the following applies to the patient's
smoking habit after diagnosis of his/her lung
cancer
No Change In Smoking Habits. Patient
Smokes The Same Amount Now In
Comparison To Before Diagnosis (No
change in smoking habits. Patient
smokes the same amount now in
comparison to before diagnosis)
No Change In Smoking Habits. Patient
Still Does Not Smoke (No change in
smoking habits. Patient still does not
smoke)
Patient Smokes Fewer Cigarettes Now
(Patient smokes fewer cigarettes now)
Patient Smokes More Cigarettes Now
(Patient smokes more cigarettes now)
Patient Stopped Smoking (Patient
stopped smoking)
Date Patient Stopped Smoking (If patient stopped
smoking:)
On average how many cigarettes per day does
the patient smoke
10 To 20 Cigarettes (10 to 20 cigarettes)
Fewer Than 10 Cigarettes (Fewer than
10 cigarettes)
More Than 20 Cigarettes (more than 20
cigarettes)
No Cigarettes (No cigarettes)
Unknown (Unknown)
Nic Alert Test Result
NicAlert Test Performed
Yes
No
Cotinine Concentration Level
Level 0 (Level 0)
Level 1 (Level 1)
Level 2 (Level 2)
Level 3 (Level 3)
Level 4 (Level 4)
Level 5 (Level 5)
Level 6 (Level 6)
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Lung Cancer Smoking Survey NCT00324805
Date of Nic Alert Test
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Lung Cancer Smoking Survey NCT00324805
Melanoma Concomitant Medication
NCT00110019
E2603 Concomitant Medication Form Form No. 2169
Carboplatin and Paclitaxel With or Without Sorafenib in
Treating Patients With Unresectable Stage III or Stage IV
Melanoma
NCT00110019 
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=E7D649ED-
D8C9-54BD-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/10093
Concomitant Medication Melanoma
NCT00110019 E2603 No. 2169
Header
ECOG Protocol Number
ECOG Patient ID
DCI Name
Registration Step
Patient Initials
Participating Group Protocol Number
Institution/Affiliate
Participating Group Patient ID
Please mark an 'X' if data have been amended.
Date data amended
Reporting period Start Date
Reporting period End Date
Comments
Investigator Signature
Investigator Signature Date
Concomitant Medication
On Treatment Report Period (since start of
1 / 3
treatment If treatment was delayed, choose the
intended time period without delays.)
> Cycle 10 (> Cycle 10)
Baseline (Baseline)
Cycle 1 (Cycle 1)
Cycle 10 (Cycle 10)
Cycle 2 (Cycle 2)
Cycle 3 (Cycle 3)
Cycle 4 (Cycle 4)
Cycle 5 (Cycle 5)
Cycle 6 (Cycle 6)
Cycle 7 (Cycle 7)
Cycle 8 (Cycle 8)
Cycle 9 (Cycle 9)
Were concomitant medications used during this
reporting period?
Yes
No
Cycle (specify)
Agent Name (Generic Name)
Dose
Units
Capsules (capsules)
Drops (drops)
Gram (gram)
Inch (inch)
Kilograms (kilogram)
Liter (liter)
Microgram (microgram)
Milliequivalent (milliequivalent)
Milligram (milligram)
Milliliter (milliliter)
Other (other)
Ounce (ounce)
Tablespoon (tablespoon)
Tablets (tablets)
Teaspoon (teaspoon)
Unit (unit)
other unit, specify
Frequency
After Meals (p.c.) (after meals)
As Needed (p.r.n) (as needed)
At Bedtime Or Hour Of Sleep (h.s.) (at
bedtime or hour of sleep)
Before Meals (a.c.) (before meals)
Every 12 Hours (q12hr) (every 12 hours)
Every 4 Hours (q4hr) (every 4 hours)
Every 6 Hours (q6hr) (every 6 hours)
Every 8 Hours (q8hr) (every 8 hours)
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Every Day (q.d.) (every day)
Every Other Day (q.o.d.) (every other
day)
Four Times A Day (q.i.d) (four times a
day)
Immediately (stat) (immediately)
Other (other)
Three Times A Day (t.i.d) (three times a
day)
Three Times A Week (t.i.w) (three times
a week)
Twice A Day (b.i.d) (twice a day)
Twice A Week (b.i.w) (twice a week)
other, specify
Route
Intramuscular (IM)
Inhaled (inhaled)
Intradermal (intradermal)
Intravenous (IV)
Nasal (nasal)
Other (other)
Oral (PO)
Rectal (rectal)
Subcutaneous (SC)
Sublingual (sublingual)
Topical (topical)
Transdermal (transdermal)
other route, specify
Agent Start Date
Is this medication continuing?
Yes
No
Agent End Date
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Melanoma Concomitant Medication NCT00110019
MDS Hematology Form NCT00843882
E2905 Hematology Form
Lenalidomide With or Without Epoetin Alfa in Treating
Patients With Myelodysplastic Syndrome and Anemia
NCT00843882
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=11427DB4-
3795-240D-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/10095
Hematology Form MDS
NCT00843882  E2905
Header
ECOG Protocol Number
ECOG Patient ID
DCI Name
Registration Step
Patient Initials (Last, First)
Participating Group Protocol Number
Participating Group Patient ID
Institution/Affiliate
Are data amended
Yes
No
Investigator Signature
Investigator Signature Date
ON/Off TREATMENT
On Treatment Report Period (Step 2 - Choose
one x)
>cycle 13-step 2 (>Cycle 13-Step 2)
Cycle 1 Step 2 (Cycle 1 Step 2)
Cycle 10 Step 2 (Cycle 10 Step 2)
Cycle 11 Step 2 (Cycle 11 Step 2)
Cycle 12 Step 2 (Cycle 12 Step 2)
Cycle 13-step 2 (Cycle 13-Step 2)
Cycle 2 Step 2 (Cycle 2 Step 2)
Cycle 3 Step 2 (Cycle 3 Step 2)
Cycle 4 Step 2 (Cycle 4 Step 2)
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Cycle 5 Step 2 (Cycle 5 Step 2)
Cycle 6 Step 2 (Cycle 6 Step 2)
Cycle 7 Step 2 (Cycle 7 Step 2)
Cycle 8 Step 2 (Cycle 8 Step 2)
Cycle 9 Step 2 (Cycle 9 Step 2)
Specify Cycle
Off Treatment Report Period (since registration -
Choose one x)
3 Months Post End Of Treatment (3
months post end of treatment)
6 Months Post End Of Treatment (6
months post end of treatment)
Pre-registration Hematology/chemistry
Date Hematology (Blood) Sample Obtained
Test not done (Please mark "X" in Box only if test
not done)
Yes
No
Peripheral Granulocytes Count LLN
Peripheral Granulocytes Count
Peripheral platelet count, LLN (/mm^3x1000)
Peripheral Platelet Count
Peripheral Blasts
Peripheral WBC count, LLN
Peripheral WBC Count
Creatinine ULN
Creatinine
Hemoglobin (Hgb), LLN
Hemoglobin (Hgbg/dl)
CTC Adverse Event Attribution Code (Note: Use
2 / 3
MDS Hematology Form NCT00843882
the standard CTC criteria, not the BMT-specific
CTC criteria.)
Definite (Definite)
Possible (Possible)
Probable (Probable)
Unlikely (Unlikely)
Unrelated (Unrelated)
AE Expedited report filed? (Check box if yes)
Yes
No
CTC Adverse Event Term
CTC Adverse Event Grade
Absent Adverse Event (0)
Mild Adverse Event (1)
Moderate Adverse Event (2)
Severe Adverse Event (3)
Life Threatening Adverse Event (4)
Death Related To Adverse Event (5)
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MDS Hematology Form NCT00843882
Lung Cancer Hematology/Chemistry
NCT00324805
E1505 Hematology/Chemistry Form
Chemotherapy With or Without Bevacizumab in Treating
Patients With Stage IB, Stage II, or Stage IIIA Non-Small
Lung Cancer That Was Removed By Surgery
NCT00324805
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=26A1ECBB-
6572-4421-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/10096
Hematology/Chemistry Form Lung
Cancer NCT00324805  E1505
Header
ECOG Protocol Number
ECOG Patient ID
DCI Name
Registration Step
Patient Initials (Last, First)
Participating Group Protocol Number
Participating Group Patient ID
Institution/Affiliate
Please mark an 'X' if data have been amended.
(Please circle amended items in red)
Date data amended (MM/DD/YYYY)
Investigator Signature
Investigator Signature Date
ON/Off TREATMENT
On Treatment Report Period (Arm B Only -
Choose one x)
Cycle 10 (Cycle 10)
Cycle 11 (Cycle 11)
Cycle 12 (Cycle 12)
Cycle 13 (Cycle 13)
Cycle 14 (Cycle 14)
Cycle 15 (Cycle 15)
Cycle 16 (Cycle 16)
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Cycle 17 (Cycle 17)
Cycle 5 (Cycle 5)
Cycle 6 (Cycle 6)
Cycle 7 (Cycle 7)
Cycle 8 (cycle 8)
Cycle 9 (Cycle 9)
Off Treatment Report Period (since End of
Treatment - Choose one x)
3 Months Post-treatment (3 Months Post-
Treatment)
Pre-registration Hematology/chemistry
Were hematology/chemistry results obtained this
report period (cycle)?
Yes
No
Date Hematology (Blood) Sample Obtained
Peripheral Granulocytes Count
Peripheral Platelet Count
Hemoglobin (g/dl or g/L - If abnormal lab value,
CTC AE Attribution Code must be provided)
Units
Milligrams Per Liter (mg/L)
Millimole Per Liter (mmol/L)
CTC Adverse Event Term (v4)
Hypernatremia (Hypernatremia)
Hyponatremia (Hyponatremia)
CTC AE Grade (Provide CTCAEv4 Grade only if
extenuating circumstance per the CTCAEv4
grading criteria would trigger a higher grade
Hypernatremia/ Hyponatremia than the Sodium
lab value would indicate.)
Mild Adverse Event (1)
Moderate Adverse Event (2)
Severe Adverse Event (3)
Life Threatening Adverse Event (4)
Death Related To Adverse Event (5)
Creatinine ULN (mg/dl or mmol/L)
Creatinine (mg/dl or mmol/L - If abnormal lab
value, CTC AE Attribution Code must be
provided)
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Sodium
Test not done (Please mark "X" in Box only if test
not done)
CTC AE Attribution Code (Leave attribution box
blank if no adverse event.)
Definite (Definite)
Possible (Possible)
Probable (Probable)
Unlikely (Unlikely)
Unrelated (Unrelated)
Action taken for this AE for Chemotherapy
Dose Delayed (Dose delayed)
Dose Held (Dose held)
Dose Held and Reduced (Dose held and
reduced)
Dose Reduced (Dose reduced)
Drug Discontinued (Drug discontinued)
Action taken for this AE for Bevacizumab
Dose Delayed (Dose delayed)
Dose Held (Dose held)
Drug Discontinued (Drug discontinued)
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Lung Cancer Hematology/Chemistry NCT00324805
Breast Cancer Hematology/Chemistry
NCT00433511
E5103 Hematology/Chemistry Form
Doxorubicin, Cyclophosphamide, and Paclitaxel With or
Without Bevacizumab in Treating Patients With Lymph
Node-Positive or High-Risk, Lymph Node-Negative Breast
Cancer
NCT00433511
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=3AE26832-
8814-18AE-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/10097
Hematology/Chemistry On-Study
form Breast Cancer NCT00433511
E5103
Header
ECOG Protocol Number
ECOG Patient ID
DCI Name
Registration Step
Patient Initials (Last, First)
Participating Group Protocol Number
Participating Group Patient ID
Institution/Affiliate
Please mark an 'X' if data have been amended.
(Please circle amended items in red)
Date data amended (MM/DD/YYYY)
Investigator Signature
Investigator Signature Date
Pre-registration Hematology/chemistry
On Treatment Report Period
Baseline (Baseline)
Cycle 1 (Cycle 1)
Cycle 10 (Cycle 10)
Cycle 11 (Cycle 11)
Cycle 12 (Cycle 12)
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Cycle 13 (Cycle 13)
Cycle 14 (Cycle 14)
Cycle 15 (Cycle 15)
Cycle 16 (Cycle 16)
Cycle 17 (Cycle 17)
Cycle 18 (Cycle 18)
Cycle 2 (Cycle 2)
Cycle 3 (Cycle 3)
Cycle 4 (cycle 4)
Cycle 5 (Cycle 5)
Cycle 6 (Cycle 6)
Cycle 7 (Cycle 7)
Cycle 8 (cycle 8)
Cycle 9 (Cycle 9)
Date Hematology (Blood) Sample Obtained
Were hematology/chemistry results obtained this
report period (cycle)?
Yes
No
Peripheral Granulocytes Count (AGC/ANC/mm^3
- Do not report % granulocytes: report absolute
count without decimal.)
Peripheral Platelet Count (/mm^3x1000)
Hemoglobin
Creatinine
Creatinine ULN
Sodium
Test not done (Please mark "X" in Box only if test
not done)
Units
Grams Per Deciliter (g/dL)
Grams Per Liter (g/L)
Milliequivalent Per Liter (mEq/L)
Milligrams Per Deciliter (mg/dL)
Milligrams Per Liter (mg/L)
Millimole Per Liter (mmol/L)
CTC AE Attribution Code (Leave attribution box
blank if no adverse event.)
Definite (Definite)
Possible (Possible)
Probable (Probable)
Unlikely (Unlikely)
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Unrelated (Unrelated)
Action taken for this AE for Chemotherapy
Dose Delayed (Dose delayed)
Dose Held (Dose held)
Dose Held and Reduced (Dose held and
reduced)
Dose Reduced (Dose reduced)
Drug Discontinued (Drug discontinued)
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Breast Cancer NCT00433589 Toxicity
Adverse Events - CTCAE v3.0
Genetic Testing or Clinical Assessment in Determining the
Need for Chemotherapy in Women With Breast Cancer
That Involves No More Than 3 Lymph Nodes
NCT00433589
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=1903495E-
EB08-0BEB-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/10098
Adverse Events Breast Cancer
NCT00433589 CTCAE v3.0
Header
Patient Birth Date
Patient Hospital Number
Institution Name
Institution No.
Physician of Record
Date
Investigator Signature
Clinical Tolerance: CTCAE (version 3.0)
Time
Cycle 2 (Cycle 2)
Cycle 3 (Cycle 3)
Cycle 4 (Cycle 4)
Cycle 5 (Cycle 5)
Cycle 6 (Cycle 6)
Cycle 7 (Cycle 7)
Cycle 8 (Cycle 8)
Date of Assessment
Were adverse events assessed during most
recent period
Yes
No
CTC Adverse Event Term
Allergy/immunology Other
(Allergy/Immunology-Other (Specify))
Cardiac General Other (Cardiac
General-Other (Specify))
Myocardial Ischaemia (Cardiac
ischemia/infarction)
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Hypercholesteraemia (Cholesterol,
serum-high (hypercholesteremia))
Cerebral Ischaemia (CNS
cerebrovascular ischemia)
Constipation (Constipation)
Constitutional Symptoms Other
(Constitutional Symptoms-Other
(Specify))
Cough (Cough)
Dermatology/skin Other
(Dermatology/Skin-Other (Specify))
Diarrhoea Nos (Diarrhea)
Dizziness (exc Vertigo) (Dizziness)
Dyspnoea Nos (Dyspnea (shortness of
breath))
Oedema Nos (Edema: limb)
Endocrine Other (Endocrine-Other
(Specify))
Fatigue (Fatigue (asthenia, lethargy,
malaise))
Febrile Neutropenia (fever Of Unknown
Origin Without Clinically Or
Microbiologically Documented Infection)
(anc <1.0 X 10^9/l, Fever >=38.5
Degrees C) (Febrile neutropenia)
Pyrexia (Fever (in the absence of
neutropenia, where neutropenia is
defined as ANC <1.0 x 10^9/L))
Fracture (Fracture)
Gastrointestinal Other (Gastrointestinal-
Other (Specify))
Alopecia (Hair loss/Alopecia (scalp or
body))
Haemoglobin Decreased (Hemoglobin)
Vaginal Haemorrhage (Hemorrhage, GU
- Vagina)
Hemorrhage/bleeding Other
(Hemorrhage/Bleeding-Other (Specify))
Menopausal Symptoms (Hot
flashes/flushes)
Hypertension Nos (Hypertension)
Hypotension Nos (Hypotension)
Infection Nos (Infection-Other (Specify))
Menstruation Irregular (Irregular menses
(change from baseline))
Left Ventricular Failure (Left ventricular
systolic dysfunction)
Leucopenia Nos (Leukocytes (total
WBC))
Metabolic/laboratory Other
(Metabolic/Laboratory-Other (Specify))
Mood Alteration - Agitation (Mood
alteration - agitation)
Anxiety Nec (Mood alteration - anxiety)
Depression Nec (Mood alteration -
depression)
Musculoskeletal/soft Tissue Other
(Musculoskeletal/Soft Tissue-Other
(Specify))
Nausea (Nausea)
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Neurology Other (Neurology-Other
(Specify))
Peripheral Sensory Neuropathy
(Neuropathy: sensory)
Neutropenia (Neutrophils/granulocytes
(ANC/AGC))
Osteoporosis (Osteoporosis)
Bone Pain (Pain - Bone)
Arthralgia (Pain - Joint)
Myalgia (Pain - Muscle)
Pain Other (Pain-Other (Specify))
Platelet Count Decreased (Platelets)
Pleural Effusion (Pleural effusion (non-
malignant))
Pruritus Nos (Pruritus/itching)
Localised Exfoliation (Rash: hand-foot
skin reaction)
Dermatitis Exfoliative Nos
(Rash/desquamation)
Renal/genitourinary Other
(Renal/Genitourinary-Other (Specify))
Sexual/reproductive Function Other
(Sexual/Reproductive Function-Other
(Specify))
Sweating Increased (Sweating
(diaphoresis))
Thrombosis/embolism (vascular Access-
related) (Thrombosis/embolism (vascular
access-related))
Vomiting Nos (Vomiting)
CTC AE Grade
CTCAE v3.0 Short Name
CTC Adverse Event Allergy/Immunology-Other
(Specify)
CTC Adverse Event Cardiac General-Other
CTC Adverse Event Constitutional Symptoms-
Other (Specify)
CTC Adverse Event Dermatology/Skin-Other
(Specify)
CTC Adverse Event Endocrine-Other (Specify)
CTC Adverse Event Gastrointestinal-Other
(Specify)
CTC Adverse Event Hemorrhage/Bleeding-Other
(Specify)
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CTC Adverse Event Infection-Other (Specify)
CTC Adverse Event Metabolic/Laboratory-Other
(Specify)
CTC Adverse Event Musculoskeletal/Soft Tissue-
Other (Specify)
CTC Adverse Event Neurology-Other (Specify)
CTC Adverse Event Pain-Other (Specify)
CTC Adverse Event Pulmonary/Upper
Respiratory-Other (Specify)
CTC Adverse Event Renal/Genitourinary-Other
(Specify)
CTC Adverse Event Sexual/Reproductive
Function-Other (Specify)
CTC Adverse Event Vascular-Other (Specify)
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Quality assurance Neonatology (AQUA)
Documentation form for quality assurance in German
Health Care by the institute forapplied quality Improvement
and Research in Health Care (Aqua), https://www.aqua-
institut.de/en/home. Internal Aqua form version: NEO
Specification 2015 V02
All rights reserved. Please visit https://medical-data-
models.org/forms/10100
Quality assurance Neonatology
(AQUA)
Basic documentation
Healthcare Facility Identifier*
Zip Code of Discharge*
Facility's Section Identifier
Medical specialty*
internal medicine (0100)
internal medicine: geriatrics (0102)
internal medicine: cardiology (0103)
internal medicine: nephrology (0104)
internal medicine: hematology and
internal oncology  (0105)
internal medicine: endocrinology (0106)
internal medicine: gastroenterology
(0107)
internal medicine: pneumonology (0108)
internal medicine: rheumatology (0109)
internal medicine: pulmonology (0114)
internal medicine: tumor research (0150)
internal medicine: coloproctology (0151)
internal medicine: infectiology (0152)
internal medicine: diabetes (0153)
internal medicine: naturopathy (0154)
internal medicine: stroke unit (0156)
internal medicine (0190)
geriatry (0200)
geriatry: gynecology  (0224)
geriatry: day unit (for semi-residential
care)   (0260)
geriaty: night unit (for semi-residential
care) (0261)
geriatry (0290)
cardiology (0300)
nephrology (0400)
nephrology: pediatrics (0410)
nephrology: intensive care (0436)
nephrology (0490)
hematology and internal oncology
(0500)
hematology and internal oncology:
pediatrics (0510)
hematology and internal oncology:
gynacology (0524)
hematology and internal oncology:
radiation therapy (0533)
hematology and internal oncology
(0590)
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endocrinology (0600)
endicrinology: gastroenterology (0607)
endocrinology: pediatrics (0610)
endocrinology (0690)
gastroenterology (0700)
gastroenterology: endocrinology (0706)
gastroenterology: pediatrics (0710)
gastroenterology (0790)
pneumology (0800)
rheumatology (0900)
rheumatology: pediatrics (0910)
rheumatology (0990)
pediatrics (1000)
pediatrics: nephrology (1004)
pediatrics: hematology and internal
oncology  (1005)
pediatrics: endocrinology (1006)
pediatrics: gastroenterology (1007)
pediatrics: rheumatology (1009)
pediatrics: pediatric cardiology (1011)
pediatrics: nephrology (1012)
pediatrics: pulmonology (1014)
pediatrics: pediatric neurology (1028)
pediatrics: perinatal medicine (1050)
continuing care for children (1051)
pediatrics (1090)
pediatric cardiology (1100)
pediatric cardiology: intensive care
(1136)
pediatric cardiology (1190)
neonatology (1200)
pediatric surgery (1300)
pulmonology (1400)
pulmonology: pediatrics (1410)
pulmonology (1490)
general surgery (1500)
general surgery: pediatric surgery (1513)
general surgery: trauma surgery (1516)
general surgery: vascular surgery (1518)
general surgery: plastic surgery (1519)
general surgery: thoracic surgery (1520)
general surgery: orthopedics (1523)
general surgery: intensive care (1536)
general surgery: abdominal- and
vascular surgery (1550)
Allgemeine Chirurgie: hand surgery
(1551)
general surgery (1590)
trauma surgery (1600)
neurosurgery (1700)
vascular surgery (1800)
plastic surgery (1900)
thoracic surgery (2000)
thoracic surgery: cardiac surgery (2021)
thoracic surgery: intensive care (2036)
thoracic surgery: cardiac surgery
intensive care (2050)
thoracic surgery (2090)
cardiac surgery (2100)
cardiac surgery: vascular surgery (2118)
2 / 14
Quality assurance Neonatology (AQUA)
cardiac surgery: thoracic surgery (2120)
cardiac surgery: intensive care (2136)
cardiac surgery: thoracic surgery and
intensive care (2150)
cardiac surgery (2190)
urology (2200)
orthopedics (2300)
orthopedics: rheumatology (2309)
orthopedics: surgery (2315)
orthopedics and trauma surgery (2316)
orthopedics (2390)
gynecology and obstetrics (2400)
gynecology: geriatry (2402)
gynecology: hematology and internal
oncology  (2405)
gynecology: endocrinology (2406)
gynecology (2425)
gynecology and obstetrics (2490)
obstetrics (2500)
otolaryngology (2600)
ophthalmology (2700)
neurology: (2800)
neurology: pediatrics (2810)
neurology: stroke units (2856)
neurology (2890)
general psychiatry: (2900)
general psychiatry: neurology (2928)
general psychiatry: child and adolescent
psychiatry (2930)
general psychiatry: psychosomatics and
psychotherapy (2931)
general psychiatry: addiction treatment
(2950)
general psychiatry: geropsychiatry
(2951)
general psychiatry: forensic treatment
(2952)
general psychiatry: addiction treatment
(day unit) (2953)
general psychiatry: addiction treatment
(night unit) (2954)
general psychiatry: geropsychiatry (day
unit) (2955)
general psychiatry: geropsychiatry (night
unit) (2956)
general psychiatry: day unit (for semi-
residential care) (2960)
general psychiatry: night unit (for semi-
residential care) (2961)
general psychiatry (2990)
child and adolescent psychiatry (3000)
child and adolescent psychiatry: day unit
(for semi-residential care) (3060)
child and adolescent psychiatry: night
unit (for semi-residential care) (3061)
child and adolescent psychiatry (3090)
psychosomatic/psychotherapy (3100)
psychosomatic/psychotherapy: child and
adolescent psychiatry (3110)
psychosomatic/psychotherapy: day unit
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(for semi-residential care) (3160)
psychosomatic/psychotherapy: night unit
(for semi-residential care) (3161)
psychosomatic/psychotherapy (3190)
nuclear medicine (3200)
nuclear medicine: radiation therapy
(3233)
nuclear medicine (3290)
radiation therapy (3300)
radiation therapy: hematology and
internal oncology  (3305)
radiation therapy: radiology (3350)
radiation therapy (3390)
dermatology (3400)
dermatology: day unit (for semi-
residential care) (3460)
dermatology (3490)
dentistry, orthodontics, maxillofacial
surgery (3500)
intensive-care medicine (3600)
intensive-care medicine: internal
medicine (3601)
intensive-care medicine: cardiology
(3603)
intensive-care medicine: pediatrics
(3610)
intensive-care medicine: neurosurgery
(3617)
intensive-care medicine: surgery (3618)
intensive-care medicine: cardiac surgery
(3621)
intensive-care medicine: urology (3622)
intensive-care medicine: gynecology and
obstetrics (3624)
intensive-care medicine: otolaryngology
(3626)
intensive-care medicine: neurology
(3628)
operative intensive-care medicine:
surgery (3650)
intensive-care medicine: thorax-heart
surgery (3651)
intensive-care medicine: heart-thorax
surgery (3652)
intensive-care medicine (3690)
other medical specialty (3700)
angiology (3750)
radiology (3751)
palliative care (3752)
pain therapy (3753)
section for alternative health practice
(3754)
spinal surgery (3755)
addiction medicine (3756)
visceral surgery (3757)
other medical specialty (3790)
level of care of the receiving department*
perinatal center level 1 (1)
perinatal center level 2 (2)
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perinatal focus (3)
independent children's hospital (4)
other (5)
Child identification number*
Gender*
male (1)
female (2)
not determined (3)
Information on birth
Multiple birth*
Yes
No
primary waiver of curative therapy for deceased
children with a gestational age of 22 + 0 weeks
Yes
No
Level of maternity hospital
perinatal center level 1 (1)
perinatal center level 2 (2)
perinatal focus (3)
independent children's hospital (4)
other (5)
unknown (6)
Transport to neonatology
no transport to neonatology (0)
transport without car (Inborn) (1)
transport vehicle (Outborn) (2)
Where was the child born?*
in maternity hospital (1)
in non-clinical birthing facility (2)
at home (3)
other, eg. as during transport (9)
Child's body weight (in g)*
Time of Birth (hh:mm)
Date of birth of the child (dd.mm.yyyy)*
final (post-natal) given gestational age (plus
additional days)*
final (post-natal) given gestational age (complete
weeks) (in weeks)*
calculated, if necessary, corrected date of birth
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(dd.mm.yyyy)
Ser. no. of multiple birth*
Number Multiple birth childs
Reason for palliative care
Aufnahme
Hospital admission date (DD.MM.YYYY)*
Body temperature at admission (in C)
Head circumference unknown at admission
yes (1)
Head circumference at admission (in cm)
Weight at admission (in g)*
foreign Healthcare Facility Identifier
yes (1)
Medical specialty of the external hospital
internal medicine (0100)
internal medicine: geriatrics (0102)
internal medicine: cardiology (0103)
internal medicine: nephrology (0104)
internal medicine: hematology and
internal oncology  (0105)
internal medicine: endocrinology (0106)
internal medicine: gastroenterology
(0107)
internal medicine: pneumonology (0108)
internal medicine: rheumatology (0109)
internal medicine: pulmonology (0114)
internal medicine: tumor research (0150)
internal medicine: coloproctology (0151)
internal medicine: infectiology (0152)
internal medicine: diabetes (0153)
internal medicine: naturopathy (0154)
internal medicine: stroke unit (0156)
internal medicine (0190)
geriatry (0200)
geriatry: gynecology  (0224)
geriatry: day unit (for semi-residential
care)   (0260)
geriaty: night unit (for semi-residential
care) (0261)
geriatry (0290)
cardiology (0300)
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nephrology (0400)
nephrology: pediatrics (0410)
nephrology: intensive care (0436)
nephrology (0490)
hematology and internal oncology
(0500)
hematology and internal oncology:
pediatrics (0510)
hematology and internal oncology:
gynacology (0524)
hematology and internal oncology:
radiation therapy (0533)
hematology and internal oncology
(0590)
endocrinology (0600)
endicrinology: gastroenterology (0607)
endocrinology: pediatrics (0610)
endocrinology (0690)
gastroenterology (0700)
gastroenterology: endocrinology (0706)
gastroenterology: pediatrics (0710)
gastroenterology (0790)
pneumology (0800)
rheumatology (0900)
rheumatology: pediatrics (0910)
rheumatology (0990)
pediatrics (1000)
pediatrics: nephrology (1004)
pediatrics: hematology and internal
oncology  (1005)
pediatrics: endocrinology (1006)
pediatrics: gastroenterology (1007)
pediatrics: rheumatology (1009)
pediatrics: pediatric cardiology (1011)
pediatrics: nephrology (1012)
pediatrics: pulmonology (1014)
pediatrics: pediatric neurology (1028)
pediatrics: perinatal medicine (1050)
continuing care for children (1051)
pediatrics (1090)
pediatric cardiology (1100)
pediatric cardiology: intensive care
(1136)
pediatric cardiology (1190)
neonatology (1200)
pediatric surgery (1300)
pulmonology (1400)
pulmonology: pediatrics (1410)
pulmonology (1490)
general surgery (1500)
general surgery: pediatric surgery (1513)
general surgery: trauma surgery (1516)
general surgery: vascular surgery (1518)
general surgery: plastic surgery (1519)
general surgery: thoracic surgery (1520)
general surgery: orthopedics (1523)
general surgery: intensive care (1536)
general surgery: abdominal- and
vascular surgery (1550)
Allgemeine Chirurgie: hand surgery
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(1551)
general surgery (1590)
trauma surgery (1600)
neurosurgery (1700)
vascular surgery (1800)
plastic surgery (1900)
thoracic surgery (2000)
thoracic surgery: cardiac surgery (2021)
thoracic surgery: intensive care (2036)
thoracic surgery: cardiac surgery
intensive care (2050)
thoracic surgery (2090)
cardiac surgery (2100)
cardiac surgery: vascular surgery (2118)
cardiac surgery: thoracic surgery (2120)
cardiac surgery: intensive care (2136)
cardiac surgery: thoracic surgery and
intensive care (2150)
cardiac surgery (2190)
urology (2200)
orthopedics (2300)
orthopedics: rheumatology (2309)
orthopedics: surgery (2315)
orthopedics and trauma surgery (2316)
orthopedics (2390)
gynecology and obstetrics (2400)
gynecology: geriatry (2402)
gynecology: hematology and internal
oncology  (2405)
gynecology: endocrinology (2406)
gynecology (2425)
gynecology and obstetrics (2490)
obstetrics (2500)
otolaryngology (2600)
ophthalmology (2700)
neurology: (2800)
neurology: pediatrics (2810)
neurology: stroke units (2856)
neurology (2890)
general psychiatry: (2900)
general psychiatry: neurology (2928)
general psychiatry: child and adolescent
psychiatry (2930)
general psychiatry: psychosomatics and
psychotherapy (2931)
general psychiatry: addiction treatment
(2950)
general psychiatry: geropsychiatry
(2951)
general psychiatry: forensic treatment
(2952)
general psychiatry: addiction treatment
(day unit) (2953)
general psychiatry: addiction treatment
(night unit) (2954)
general psychiatry: geropsychiatry (day
unit) (2955)
general psychiatry: geropsychiatry (night
unit) (2956)
general psychiatry: day unit (for semi-
8 / 14
Quality assurance Neonatology (AQUA)
residential care) (2960)
general psychiatry: night unit (for semi-
residential care) (2961)
general psychiatry (2990)
child and adolescent psychiatry (3000)
child and adolescent psychiatry: day unit
(for semi-residential care) (3060)
child and adolescent psychiatry: night
unit (for semi-residential care) (3061)
child and adolescent psychiatry (3090)
psychosomatic/psychotherapy (3100)
psychosomatic/psychotherapy: child and
adolescent psychiatry (3110)
psychosomatic/psychotherapy: day unit
(for semi-residential care) (3160)
psychosomatic/psychotherapy: night unit
(for semi-residential care) (3161)
psychosomatic/psychotherapy (3190)
nuclear medicine (3200)
nuclear medicine: radiation therapy
(3233)
nuclear medicine (3290)
radiation therapy (3300)
radiation therapy: hematology and
internal oncology  (3305)
radiation therapy: radiology (3350)
radiation therapy (3390)
dermatology (3400)
dermatology: day unit (for semi-
residential care) (3460)
dermatology (3490)
dentistry, orthodontics, maxillofacial
surgery (3500)
intensive-care medicine (3600)
intensive-care medicine: internal
medicine (3601)
intensive-care medicine: cardiology
(3603)
intensive-care medicine: pediatrics
(3610)
intensive-care medicine: neurosurgery
(3617)
intensive-care medicine: surgery (3618)
intensive-care medicine: cardiac surgery
(3621)
intensive-care medicine: urology (3622)
intensive-care medicine: gynecology and
obstetrics (3624)
intensive-care medicine: otolaryngology
(3626)
intensive-care medicine: neurology
(3628)
operative intensive-care medicine:
surgery (3650)
intensive-care medicine: thorax-heart
surgery (3651)
intensive-care medicine: heart-thorax
surgery (3652)
intensive-care medicine (3690)
other medical specialty (3700)
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angiology (3750)
radiology (3751)
palliative care (3752)
pain therapy (3753)
section for alternative health practice
(3754)
spinal surgery (3755)
addiction medicine (3756)
visceral surgery (3757)
other medical specialty (3790)
Facility's Section Identifier of the external hospital
Institution identifier of the external hospital
Admission to Hospital from
External maternity hospital (1)
external Children's Hospital (2)
external clinic as relocation (3)
other than clinical birthing facility (4)
at home (5)
birth in their own maternity hospital (6)
Time (Admission to pediatric departments) (hh:
mm)
Admission to pediatric department (dd.mm.yyyy)
Admission time (hh:mm)*
Body temperature unknown at admission
yes (1)
Diagnostics/therapy
Congenital Abnormality*
no (0)
slight (1)
severe (3)
lethal (4)
final termination of any respiratory support
(dd.mm.yyyy)
Pneumothorax*
no (0)
yes, occurred during spontaneous (1)
yes, occurred under nasal / pharyngeal
ventilation (2)
yes, occurred under intratrachlealer
ventilation (3)
Status at admission
Pneumothorax occurred for the first time
during the inpatient stay (1)
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Pneumothorax was present before
admission (2)
Bronchopulmonary dysplasia (BPD)*
no (0)
yes, moderate BPD (1)
yes, severe BPD (2)
perinatal hypoxia/ischemia (asphyxia)*
no (0)
yes, no therapeutic hypothermia (1)
yes, with therapeutic hypothermia (2)
HIE (Hypoxic ischemic encephalopathy)
Yes
No
Sepsis/SIRS*
Yes
No
Sepsis / SIRS within 72 hours after birth
Yes
No
Sepsis / SIRS later than 72 hours after birth
Yes
No
Number sepsis / SIRS later than 72 hours after
birth
1 (1)
2 (2)
3 (3)
more than 3 (4)
pneumonia*
Yes
No
Pneumonia within 72 hours after birth
Yes
No
Pneumonia later than 72 hours after birth
Yes
No
Antibiotic therapy, systemic*
Yes
No
Necrotizing enterocolitis (NEC) (stage II or III)*
Yes
No
Status at admission
NEC has occurred for the first time
during the inpatient stay (1)
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NEC before admission (2)
final completion of intratracheal ventilation
(dd.mm.yyyy)
Beginning (dd.mm.yyyy)
Type of Congenital Abnormality
largest base deficit (in mmol/l)
Max. FiO2
Min. FiO2
Cranial sonogram done/available*
Yes
No
Intraventricular (IVH) or periventricular (PVH)
hemorrhage
no (0)
IVH grade I (1)
IVH grade II (2)
IVH grade III (3)
periventricular hemorrhage (PVH) (4)
Status at admission
IVH / PVH has occurred for the first time
during the inpatient stay (1)
IVH / PVH was before when admission
(2)
Cystic periventricular leukomalacia (PVL)
Yes
No
Status at admission
PVL has occurred for the first time during
the inpatient stay (1)
PVL present bevore admission (2)
ophthalmologic examination performed /
provided*
Yes
No
Retinopathy of prematurity (ROP)
no (0)
stage 1 (demarcation) (1)
Stage 2 (Celebrities bar) (2)
Stage 3 (extra-retinal fibrovascular
proliferations and Celebrities bar) (3)
stage 4 (partial retinal detachment) (4)
stage 5 (total retinal detachment) (5)
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ROP status at admission
ROP occurred for the first time during the
inpatient stay (1)
ROP present before admission (2)
Oxygen of any kind after Admission (of more than
30 minutes)*
Yes
No
Beginning (dd.mm.yyyy)
final completion (dd.mm.yyyy)
Ventilation is performed (of more than 30
minutes)*
no respiratory support (0)
only nasal / pharyngeal ventilation (1)
intratracheal ventilation (2)
nasal / pharyngeal and intratracheal
ventilation (3)
Newborn Auditory Function Screening*
Yes
No
Operation(s) and procedures
Operation(s) and procedures during this stay*
Yes
No
OP or therapy of a ROP (retinopathy of
prematurity)
no (0)
yes, laser therapy or cryotherapy (1)
yes, intravitreal anti-VEGF therapy (2)
yes, other (3)
OP on NEC (necrotizing enterocolitis)
Yes
No
Indication(s) to further operation(s)
Discharge / transfer
Hospital discharge date / death (DD.MM.YYYY)*
cause of death
Obduktion
Yes
No
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Healthcare Facility Identifier (Hospital)
Reason for Discharge*
treatment finished as planned (1)
transferral to nursing facility (10)
discharge to hospice (11)
external transferral to psychiatric
treatment (13)
treatment finished because of other
reasons, postdischarge treatment is
planned (14)
treatment aborted against medical
advice, postdischarge treatment is
planned (15)
internal transferral with change of DRG
payment areas (17)
treatment finished as planned,
postdischarge treatment is planned (2)
case termination (internal transferral)
with change between full- and partial
stationary  care (22)
discharge at the end of the year with
admission in previous year (25)
treatment finished because of other
reasons (3)
treatment aborted against medical
advice (4)
change of jurisdiction of insurer or other
payer (5)
transferral to another hospital (6)
death (7)
transferral to another hospital within
cooperative and governmental policies
(8)
transferral to rehabilitation facility (9)
Discharge / transfer with additional oxygen
demand*
Yes
No
Head circumference unknown at discharge
yes (1)
Head circumference at discharge (in cm)
Body weight at discharge (in g)*
Hospital discharge time/ death (hh:mm)*
more diagnosis (discharge)*
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Quality assurance Community-Acquired
Pneumonia (AQUA)
Documentation form for quality assurance in German
Health Care by the institute forapplied quality Improvement
and Research in Health Care (Aqua), https://www.aqua-
institut.de/en/home. Internal Aqua form version: PNEU
Specification 2015 V02
All rights reserved. Please visit https://medical-data-
models.org/forms/10101
Quality assurance Community-
Acquired Pneumonia (AQUA)
Basic documentation
Healthcare Facility Identifier*
Zip Code of Discharge*
Facility's Section Identifier
Medical specialty*
internal medicine (0100)
internal medicine: geriatrics (0102)
internal medicine: cardiology (0103)
internal medicine: nephrology (0104)
internal medicine: hematology and
internal oncology  (0105)
internal medicine: endocrinology (0106)
internal medicine: gastroenterology
(0107)
internal medicine: pneumonology (0108)
internal medicine: rheumatology (0109)
internal medicine: pulmonology (0114)
internal medicine: tumor research (0150)
internal medicine: coloproctology (0151)
internal medicine: infectiology (0152)
internal medicine: diabetes (0153)
internal medicine: naturopathy (0154)
internal medicine: stroke unit (0156)
internal medicine (0190)
geriatry (0200)
geriatry: gynecology  (0224)
geriatry: day unit (for semi-residential
care)   (0260)
geriaty: night unit (for semi-residential
care) (0261)
geriatry (0290)
cardiology (0300)
nephrology (0400)
nephrology: pediatrics (0410)
nephrology: intensive care (0436)
nephrology (0490)
hematology and internal oncology
(0500)
hematology and internal oncology:
pediatrics (0510)
hematology and internal oncology:
gynacology (0524)
hematology and internal oncology:
radiation therapy (0533)
hematology and internal oncology
(0590)
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endocrinology (0600)
endicrinology: gastroenterology (0607)
endocrinology: pediatrics (0610)
endocrinology (0690)
gastroenterology (0700)
gastroenterology: endocrinology (0706)
gastroenterology: pediatrics (0710)
gastroenterology (0790)
pneumology (0800)
rheumatology (0900)
rheumatology: pediatrics (0910)
rheumatology (0990)
pediatrics (1000)
pediatrics: nephrology (1004)
pediatrics: hematology and internal
oncology  (1005)
pediatrics: endocrinology (1006)
pediatrics: gastroenterology (1007)
pediatrics: rheumatology (1009)
pediatrics: pediatric cardiology (1011)
pediatrics: nephrology (1012)
pediatrics: pulmonology (1014)
pediatrics: pediatric neurology (1028)
pediatrics: perinatal medicine (1050)
continuing care for children (1051)
pediatrics (1090)
pediatric cardiology (1100)
pediatric cardiology: intensive care
(1136)
pediatric cardiology (1190)
neonatology (1200)
pediatric surgery (1300)
pulmonology (1400)
pulmonology: pediatrics (1410)
pulmonology (1490)
general surgery (1500)
general surgery: pediatric surgery (1513)
general surgery: trauma surgery (1516)
general surgery: vascular surgery (1518)
general surgery: plastic surgery (1519)
general surgery: thoracic surgery (1520)
general surgery: orthopedics (1523)
general surgery: intensive care (1536)
general surgery: abdominal- and
vascular surgery (1550)
Allgemeine Chirurgie: hand surgery
(1551)
general surgery (1590)
trauma surgery (1600)
neurosurgery (1700)
vascular surgery (1800)
plastic surgery (1900)
thoracic surgery (2000)
thoracic surgery: cardiac surgery (2021)
thoracic surgery: intensive care (2036)
thoracic surgery: cardiac surgery
intensive care (2050)
thoracic surgery (2090)
cardiac surgery (2100)
cardiac surgery: vascular surgery (2118)
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cardiac surgery: thoracic surgery (2120)
cardiac surgery: intensive care (2136)
cardiac surgery: thoracic surgery and
intensive care (2150)
cardiac surgery (2190)
urology (2200)
orthopedics (2300)
orthopedics: rheumatology (2309)
orthopedics: surgery (2315)
orthopedics and trauma surgery (2316)
orthopedics (2390)
gynecology and obstetrics (2400)
gynecology: geriatry (2402)
gynecology: hematology and internal
oncology  (2405)
gynecology: endocrinology (2406)
gynecology (2425)
gynecology and obstetrics (2490)
obstetrics (2500)
otolaryngology (2600)
ophthalmology (2700)
neurology: (2800)
neurology: pediatrics (2810)
neurology: stroke units (2856)
neurology (2890)
general psychiatry: (2900)
general psychiatry: neurology (2928)
general psychiatry: child and adolescent
psychiatry (2930)
general psychiatry: psychosomatics and
psychotherapy (2931)
general psychiatry: addiction treatment
(2950)
general psychiatry: geropsychiatry
(2951)
general psychiatry: forensic treatment
(2952)
general psychiatry: addiction treatment
(day unit) (2953)
general psychiatry: addiction treatment
(night unit) (2954)
general psychiatry: geropsychiatry (day
unit) (2955)
general psychiatry: geropsychiatry (night
unit) (2956)
general psychiatry: day unit (for semi-
residential care) (2960)
general psychiatry: night unit (for semi-
residential care) (2961)
general psychiatry (2990)
child and adolescent psychiatry (3000)
child and adolescent psychiatry: day unit
(for semi-residential care) (3060)
child and adolescent psychiatry: night
unit (for semi-residential care) (3061)
child and adolescent psychiatry (3090)
psychosomatic/psychotherapy (3100)
psychosomatic/psychotherapy: child and
adolescent psychiatry (3110)
psychosomatic/psychotherapy: day unit
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(for semi-residential care) (3160)
psychosomatic/psychotherapy: night unit
(for semi-residential care) (3161)
psychosomatic/psychotherapy (3190)
nuclear medicine (3200)
nuclear medicine: radiation therapy
(3233)
nuclear medicine (3290)
radiation therapy (3300)
radiation therapy: hematology and
internal oncology  (3305)
radiation therapy: radiology (3350)
radiation therapy (3390)
dermatology (3400)
dermatology: day unit (for semi-
residential care) (3460)
dermatology (3490)
dentistry, orthodontics, maxillofacial
surgery (3500)
intensive-care medicine (3600)
intensive-care medicine: internal
medicine (3601)
intensive-care medicine: cardiology
(3603)
intensive-care medicine: pediatrics
(3610)
intensive-care medicine: neurosurgery
(3617)
intensive-care medicine: surgery (3618)
intensive-care medicine: cardiac surgery
(3621)
intensive-care medicine: urology (3622)
intensive-care medicine: gynecology and
obstetrics (3624)
intensive-care medicine: otolaryngology
(3626)
intensive-care medicine: neurology
(3628)
operative intensive-care medicine:
surgery (3650)
intensive-care medicine: thorax-heart
surgery (3651)
intensive-care medicine: heart-thorax
surgery (3652)
intensive-care medicine (3690)
other medical specialty (3700)
angiology (3750)
radiology (3751)
palliative care (3752)
pain therapy (3753)
section for alternative health practice
(3754)
spinal surgery (3755)
addiction medicine (3756)
visceral surgery (3757)
other medical specialty (3790)
Patient identification number*
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Quality assurance Community-Acquired Pneumonia (AQUA)
Date of birth (dd.mm.yyyy)*
Gender*
male (1)
female (2)
Hospital admission date (DD.MM.YYYY)*
Admission
Admission from inpatient care facility*
Yes
No
Date of the first blood gas analysis or pulse
oximetry*
no blood gas analysis or pulse oximetry
(0)
within the first 4 hours after admission
(1)
4 to less than 8 hours (2)
8 hours and later (3)
last hospital stay is more than 28 days ago*
Yes
No
Exclusion of severe immunosuppression*
Yes
No
Fresh infiltrate in chest X-ray*
Yes
No
acute symptoms*
Yes
No
Diastolic blood pressure (in mmHg)
Systolic blood pressure (in mmHg)
not determined spontaneous respiratory rate
yes (1)
spontaneous breathing frequency (1 / min)
disorientation
no (0)
yes, pneumonia caused (1)
yes, no pneumonia caused (2)
at admission invasive mechanical ventilation*
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Yes
No
chronic bed rest*
Yes
No
Admission from other hospital or inpatient
rehabilitation facility*
Yes
No
initial antimicrobial therapy*
no antimicrobial therapy (0)
within the first 4 hours after admission
(1)
4 to less than 8 hours (2)
8 hours and späterinitiale antimicrobial
therapy (3)
Course
Beginning of the mobilization*
no mobilization (0)
within the first 24 hours after admission
(1)
after 24 hours and later (2)
Follow-up of C-reactive protein or procalcitonin
concentration within the first 5 days (= 120 h) of
stay*
Yes
No
Decrease of C-reactive protein or procalcitonin
concentration within the first 5 days of stay
Yes
No
Review of the diagnostic or therapeutic procedure
Yes
No
mechanical ventilation*
no (0)
yes, only non-invasive (1)
yes, only invasive (2)
yes, both non-invasive and invasive (3)
Duration (in hours)
Ventilation with positive end-expiratory pressure
of min. 5 cm water column
Yes
No
Has been documented that (due to the severity of
the underlying disease) assessed the pneumonia
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episode as terminal manifestation of a chronic
disease and thus the control of symptoms was
defined as the primary goal of therapy or during
the course?*
Yes
No
Discharge
Hostpital discharge date  (DD.MM.YYYY)*
Discharge diagnosis*
Reason for Discharge*
treatment finished as planned (1)
transferral to nursing facility (10)
discharge to hospice (11)
external transferral to psychiatric
treatment (13)
treatment finished because of other
reasons, postdischarge treatment is
planned (14)
treatment aborted against medical
advice, postdischarge treatment is
planned (15)
internal transferral with change of DRG
payment areas (17)
treatment finished as planned,
postdischarge treatment is planned (2)
case termination (internal transferral)
with change between full- and partial
stationary  care (22)
discharge at the end of the year with
admission in previous year (25)
treatment finished because of other
reasons (3)
treatment aborted against medical
advice (4)
change of jurisdiction of insurer or other
payer (5)
transferral to another hospital (6)
death (7)
transferral to another hospital within
cooperative and governmental policies
(8)
transferral to rehabilitation facility (9)
Analysis of clinical stability criteria against
dismissal
disorientation
no (0)
yes, pneumonia caused (1)
yes, no pneumonia caused (2)
stable oral and / or enteral intake of food
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Yes
No
spontaneous respiratory rate
up to 24 / min (1)
24 / min (2)
not determined (3)
not determined because of long-term
ventilation (4)
heart rate
up to 100 / min (1)
100 / min (2)
not determined (3)
temperature
maximum 37,2C (1)
about 37,2C (2)
not determined (3)
oxygen saturation
less than 90% (1)
at least 90% (2)
not determined (3)
Systolic blood pressure
less than 90 mmHg (1)
at least 90 mmHg (2)
not determined (3)
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Cervical Cancer Baseline assessment
NCT00057928
SOUTHWEST ONCOLOGY GROUP BASELINE TUMOR
ASSESSMENT FORM
S0227 Comparison of Cisplatin Combined With Either
Paclitaxel or Gemcitabine in Treating Patients With
Recurrent, Persistent, or Metastatic Cervical Cancer
NCT00057928
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=A9C374FF-
72CD-367D-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/10102
Baseline assessment Cervical
Cancer NCT00057928 SWOG
Header
SWOG Patient ID
SWOG Study No.
Registration Step
Patient Initials (L, F M)
Institution / Affiliate
Physician (Groups Other than SWOG)
Group Name
Study No.
Pt. ID
Comments
Target Lesions
Lesion number
Lesion site
Longest Diameter
Assessment Type
Colposcopy (Colposcopy)
CT Scan (CT scan)
Cytology (Cytologic confirmation)
Endoscopy (Endoscopy)
Histology (Histologic confirmation)
MRI (MRI scan)
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Other (Other)
Clinical Examination (Palpation)
PET scan (PET scan)
Plain film/X-ray with contrast (Plain
film/X-ray with contrast)
Plain film/X-ray without contrast (Plain
film/X-ray without contrast)
Radioisotope scan (Radioisotope scan)
Spiral CT Scan (Spiral CT scan)
Ultrasound (Ultrasound)
Visualization (Visualization)
Assessment Date
2 / 2
Cervical Cancer Baseline assessment NCT00057928
Colorectal Cancer Follow-Up
NCT00058474
NSABP PROTOCOL R-04: FOLLOW-UP FORM
Radiation Therapy and Either Capecitabine or Fluorouracil
With or Without Oxaliplatin Before Surgery in Treating
Patients With Resectable Rectal Cancer
NCT00058474
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=B7822451-
67BC-24E6-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/10103
FOLLOW-UP FORM Colorectal
Cancer NSABP R-04 NCT00058474
Header
First Three Letters of Patients Last Name
Patient Study ID
Institution Name / Affiliate Name
Person Completing Form, Last Name
Person Completing Form, First Name
Person Completing Form, Phone
Are Data Amended?
Yes
No
Comments
Follow-Up
Patient's Vital Status
Alive (Alive)
Dead (Dead)
Date of Last Contact or Death
Source of Survival Information
Documentation Of Hospital Or Clinic Visit
(Documentation of hospital or clinic visit)
Other (other)
Phone Contact To Patient (Phone
contact to patient)
Other, specify
Primary cause of death
Due To Other Cause, Specify (due to
other cause)
1 / 3
Due To Protocol Treatment (due to
protocol treatment)
Due To This Disease (due to this
disease)
Unknown (unknown)
describe cause of death
Was there evidence of recurrence at the time of
death?
No (no)
Unknown (unknown)
Yes, Autopsy (yes, autopsy)
Yes, Clinical (yes, clinical)
Has the patient had a documented clinical
assessment for this cancer?
Yes
No
Date of last clinical assessment
Has the patient been diagnosed with first local-
regional recurrence?
Yes
No
Site(s) of disease
Anastomosis (anastomosis)
Intra-pelvic Lymph Nodes (intra-pelvic
lymph nodes)
Other, Specify (Other, specify)
Pelvis (pelvis)
Perineum (perineum)
Rectum (rectum)
Retroperitoneal Nodes (retroperitoneal
nodes)
Other, specify
Recurrence Date
Has the patient been diagnosed with first distanct
recurrence/progression?
Yes
No
Date of first distant recurrence
Site(s) of First Distant Recurrence
Has a new primary or MDS been diagnosed that
has not been previously reported?
Yes
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No
Date of diagnosis
Site(s) of new primary
Late Adverse Events
Adverse Event
Acute Coronary Syndrome (Acute
coronary syndrome)
Anorexia (Anorexia)
Arthralgia (Arthralgia)
Back Pain (Back pain)
Cholesterol High (Cholesterol high)
Constipation (Constipation)
Depression (Depression)
Diarrhea (Diarrhea)
Dizziness (Dizziness)
Dyspnea (Dyspnea)
Edema Limbs (Edema limbs)
Fatigue (Fatigue)
Headache (Headache)
Hot Flashes (Hot flashes)
Hypertriglyceridemia
(Hypertriglyceridemia)
Insomnia (Insomnia)
Ischemia Cerebrovascular (Ischemia
cerebrovascular)
Myalgia (Myalgia)
Myocardial Infarction (Myocardial
infarction)
Nausea (Nausea)
Peripheral Ischemia (Peripheral
ischemia)
Somnolence (Somnolence)
Stroke (Stroke)
Thromboembolic Event
(Thromboembolic event)
Transient Ischemic Attacks (Transient
ischemic attacks)
Vaginal Hemorrhage (Vaginal
hemorrhage)
Visceral Arterial Ischemia (Visceral
arterial ischemia)
Grade
Mild Adverse Event (1)
Moderate Adverse Event (2)
Severe Adverse Event (3)
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Imaging Form CALGB
CALGB: Imaging Form
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=46848A6F-
07AE-238A-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/10105
Imaging Form CALGB
Header
CALGB Form
CALGB Study No
CALGB Patient ID
Date of CT Scan
Are data amended
Yes
No
Patient Initials (Last, First Middle)
Patient Hospital No.
Institution/Affiliate
Participating Group
Participating Group Study No.
Participating Group Patient ID
Hospital Name (or imaging center performing
chest CT)
Completed by (Last name, First name)
Date Form Originally Completed
Technique Factors
KVp
Pitch
1 / 4
mA
Scan Length (craniocaudal extent)
Rotation Time
Tumor Features
Tumor Location Area (Mark one)
Lingula (Lingula)
Lower Lobe (left) (Lower Lobe (left))
Lower Lobe (right) (Lower Lobe (right))
Middle Lobe (right) (Middle Lobe (right))
Upper Lobe (left) (Upper Lobe (left))
Upper Lobe (right) (Upper Lobe (right))
Table position of the most superior section in
which aerated lung is visible (For the lung that
contains the tumor provide:)
Table position of the most superior section that
shows the dome of the hemidiaphragm
Table position of the section that best
demonstrated the center of the tumor
Distance from midline to center of tumor
Maximum anteroposterior extent of aerated lung
(same side as tumor)
Distance from the most posterior extent of
aerated lung to center of tumor
Maximum diameter of tumor using lung window
settings
Maximum diameter of tumor, using soft tissue
(chest/abdomen) window settings
Is a previous CT scan available for comparison
Yes
No
Has the tumor changed
New Finding (New finding)
Tumor Size Decreased (Tumor size
decreased)
Tumor Size Increased (Tumor size
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increased)
Indicate previous maximum diameter (on lung
window images - cm)
Date of previous scan
Tumor Appearance
Margin and shape based on lung window settings
(Mark all that apply with an X.)
Ill-defined (Ill-defined)
Lobulated (Lobulated)
Round (Round)
Spiculated (Spiculated)
Well Defined (Well-defined)
Tumor appearance on lung window settings
(Mark all that apply with an X.)
Part Solid/mixed (Part-Solid)
Solid: C45300 (Solid)
If the scan includes non-contrast enhanced
images of the tumor, are any of the following
present (Tumor appearance on soft tissue
chest/abdomen window settings)
Gas- Attenuation Foci (Gas- attenuation
foci)
High- Attenuation Foci (e.g.,
Calcification) (High- attenuation foci
(e.g., calcification))
Water- Attenuation Foci (e.g., Necrosis)
(Water- attenuation foci (e.g., necrosis))
If the scan includes contrast-enhanced images of
the tumor, are any of the following present within
the tumor (Tumor appearance on soft tissue
chest/abdomen window settings)
Gas- Attenuation Foci (Gas- attenuation
foci)
High- Attenuation Foci (e.g.,
Calcification) (High- attenuation foci
(e.g., calcification))
Water- Attenuation Foci (e.g., Necrosis)
(Water- attenuation foci (e.g., necrosis))
Lymph Nodes
Indicate stations of all enlarged lymph nodes
Left Hilar Node (Left hilar (10L))
Left Lower Paratracheal Node (Left lower
paratracheal (4L))
Left Pulmonary Ligament (9l) (Left
pulmonary ligament (9L))
Left Upper Paratracheal Node (Left
upper paratracheal (2L))
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Para-aortic Node (Para-aortic (6))
Paraesophageal (Paraesophageal (8))
Pre-vascular (3a) (Pre-vascular (3A))
Retrotracheal (3p) (Retrotracheal (3P))
Right Hilar Node (Right hilar (10R))
Right Lower Paratracheal Node (Right
lower paratracheal (4R))
Right Pulmonary Ligament (9r) (Right
pulmonary ligament (9R))
Right Upper Paratracheal Node (Right
upper paratracheal (2R))
Subaortic Node (Subaortic (5))
Subcarinal Node (Subcarinal (7))
Was a pre-operative PET scan performed
Yes
No
Date of PET scan (If yes,)
Pet Scan Results
Site of lesion
Lymph Node (Nodal lesion)
Other (Other lesion)
Lung (Primary Lung)
Nodal lesion, specify
SUV Max
SUV Mean
What tests were performed to rule out possible
distant metastases present on PET scan?
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Head and Neck Cancer Staging Diagrams
Oral Cavity NCT00113399 RTOG-0421 I6
RTOG-0421 I6: Radiation Therapy Oncology Group Phase
III Recurrent Head and Neck Study Staging Diagrams /
Oral Cavity
Combination Chemotherapy With or Without Radiation
Therapy in Treating Patients With Recurrent Head and
Neck Cancer That Cannot Be Removed By Surgery
NCT00113399 
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=EB499DEC-
47D0-3F31-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/10106
Staging Diagrams Oral Cavity Head
and Neck Cancer NCT00113399
Header
RTOG Study
Case #
Institution Name
Institution No.
Patient Initials
Patient Study No.
If this is a revised or corrected form, indicate by
checking box.
Signature
Date
Head and Neck cancer characteristics
Indicate side of lesion (R or L)
left (L)
right (R)
CHARACTERISTICS OF TUMOR
Deeply Infiltrating (Deeply infiltrating)
Fixed Tongue (Fixed tongue)
Gross Erosion Of Bone (Gross erosion of
bone)
Impaired Mobility Of Tongue (Impaired
mobility of tongue)
Normal Mobility Of Tongue (Normal
mobility of tongue)
Radiographic Bone Destruction
1 / 2
(Radiographic bone destruction)
LOCATION OF TUMOR (  all that apply)
Buccal Mucosa (Buccal mucosa)
Commissure (Commissure)
Floor Of Mouth (Floor of mouth)
Hard Palate (Hard palate)
Lower Gingiva (Lower gingiva)
Lower Lip (Lower lip)
Oral Tongue (Oral tongue)
Retromolar Trigone (Retromolar Trigone)
Upper gingiva (Upper gingiva)
Upper gingiva (Upper gingiva)
Upper Lip (Upper lip)
SITE OF ORIGIN
Left (LT)
Right (RT)
SITE(S) ALSO INVOLVED
Left (LT)
Right (RT)
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RTOG-0421 I6
Colorectal Cancer Toxicity NCT00303628
E5204
E5204 Adverse Event Form (CTCAE v3.0)
Combination Chemotherapy With or Without Bevacizumab
in Treating Patients Who Have Had Surgery for Stage II or
Stage III Rectal Cancer
NCT00303628
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=089B4062-
6B32-38B1-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/10107
Adverse Event Form (CTCAE v3.0)
Colorectal Cancer NCT00303628
Header
ECOG Protocol Number
ECOG Patient ID
DCI Name
Registration Step
Patient Initials (Last, First)
Participating Group Protocol Number
Institution/Affiliate
Participating Group Patient ID
Please mark an 'X' if data have been amended.
(Please circle amended items in red)
Date data amended (s - mm/dd/yyyy)
Investigator Signature
Investigator Signature Date
Adverse event
On Treatment Report Period (Arms A and B)
Cycle 1 (Cycle 1)
Cycle 10 (Cycle 10)
Cycle 11 (Cycle 11)
Cycle 12 (Cycle 12)
Cycle 2 (Cycle 2)
Cycle 3 (Cycle 3)
Cycle 4 (cycle 4)
Cycle 5 (Cycle 5)
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Cycle 6 (Cycle 6)
Cycle 7 (Cycle 7)
Cycle 8 (cycle 8)
Cycle 9 (Cycle 9)
Off Treatment Report Period (since initial
registration)
9 Years (108 Months Post-Registration)
12 Months (12 Months Post Registration)
10 Years (120 Months Post-Registration)
15 Months (15 Months Post Registration)
18 Months (18 Months Post Registration)
21 Months Post Registration (21 Months
Post Registration)
2 Years (24 Months Post Registration)
3 Months (3 Months Post Registration)
30 Months (30 Months Post Registration)
3 Years (36 Months Post Registration)
42 Months (42 Months Post Registration)
4 Years (48 Months Post Registration)
54 Months (54 Months Post Registration)
6 Months (6 Months Post Registration)
5 Years (60 Months Post Registration)
6 Years (72 Months Post-Registration)
84 Months Post Registration (84 Months
Post-Registration)
9 Months (9 Months Post Registration)
8 Years (96 Months Post-Registration)
Were adverse events assessed during this report
period (cycle)
No (0)
Yes, But No Reportable Adverse Events
Occurred (1)
Yes, And Reportable Adverse Events
Occurred (2)
CTC Adverse Event Report Begin Date (For the
dates below, record the start and end dates of the
time period within current report period in which
patient was assessed for adverse events. -
mm/dd/yyyy)
CTC Adverse Event Report End Date (For the
dates below, record the start and end dates of the
time period within current report period in which
patient was assessed for adverse events. -
mm/dd/yyyy)
Adverse event blood, bone marrow lab
CTC Adverse Event Term (Type)
Hypersensitivity Nos (Allergic
reaction/hypersensitivity (including drug
fever))
Anorexia (Anorexia)
Myocardial Ischaemia (Cardiac
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ischemia/infarction)
Cerebral Ischaemia (CNS
cerebrovascular ischemia)
Constipation (Constipation)
Cough (Cough)
Cytokine Release Syndrome/acute
Infusion Reaction (Cytokine release
syndrome/acute infusion reaction)
Dehydration (Dehydration)
Diarrhoea Nos (Diarrhea)
Dysphagia (Dysphagia (difficulty
swallowing))
Dyspnoea Nos (Dyspnea (shortness of
breath))
Fatigue (Fatigue (asthenia, lethargy,
malaise))
Febrile Neutropenia (fever Of Unknown
Origin Without Clinically Or
Microbiologically Documented Infection)
(anc <1.0 X 10^9/l, Fever >=38.5
Degrees C) (Febrile neutropenia)
Pyrexia (Fever (in the absence of
neutropenia, where neutropenia is
defined as ANC <1.0 x 10^9/L))
Alopecia (Hair loss/Alopecia (scalp or
body))
Haemorrhagic Stroke (Hemorrhage,
CNS)
Hemorrhage, Gi (Hemorrhage, GI -
Lower GI NOS)
Hemorrhage, Gi (Hemorrhage, GI -
Upper GI NOS)
Hemorrhage, Pulmonary/upper
Respiratory (Hemorrhage,
pulmonary/upper respiratory - Lung)
Epistaxis (Hemorrhage, pulmonary/upper
respiratory - Nose)
Hypertension Nos (Hypertension)
Injection Site Reaction Nos (Injection site
reaction/extravasation changes)
Insomnia Nec (Insomnia)
Mucositis/stomatitis (clinical Exam)
(Mucositis/stomatitis (clinical exam) -
Oral cavity)
Stomatitis (Mucositis/stomatitis (clinical
exam) - Pharynx)
Mucositis/stomatitis
(functional/symptomatic)
(Mucositis/stomatitis
(functional/symptomatic) - Oral cavity)
Mucositis/stomatitis
(functional/symptomatic)
(Mucositis/stomatitis
(functional/symptomatic) - Pharynx)
Nail Abnormality Nos (Nail changes)
Nausea (Nausea)
Peripheral Sensory Neuropathy
(Neuropathy: sensory)
Abdominal Pain Nos (Pain - Abdomen
NOS)
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Chest Pain (Pain - Chest/thorax NOS)
Headache Nos (Pain - Head/headache)
Arthralgia (Pain - Joint)
Photosensitivity Reaction Nos
(Photosensitivity)
Proteinuria Present (Proteinuria)
Pulmonary Fibrosis (Pulmonary fibrosis
(radiographic changes))
Localised Exfoliation (Rash: hand-foot
skin reaction)
Dermatitis Exfoliative Nos
(Rash/desquamation)
Rigors (Rigors/chills)
Thrombosis Nos
(Thrombosis/thrombus/embolism)
Urticaria Nos (Urticaria (hives, welts,
wheals))
Dysphonia (Voice changes/dysarthria
(e.g., hoarseness, loss or alteration in
voice, laryngitis))
Vomiting Nos (Vomiting)
CTC Adverse Event Grade (this report period)
CTC Adverse Event Attribution Scale
Definite (definite)
Possible (possible)
Probable (probable)
Unlikely (unlikely)
Unrelated (unrelated)
Adverse event infections
CTC Adverse Event Short Name (use CTCAE v3
terminology)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically) - Select)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
- Select)
Infection With Unknown Anc (Infection
with unknown ANC - Select)
CTC Select AE
Other Adverse Events
Other CTC Adverse Event Term not listed (Use
CTCAE v3.0 terminology AE Term:)
Other, specify (site or subterm)
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Breast Cancer Adverse Event
NCT00382070
NSABP Protocol B-42 - Grade 2 and 3 Adverse Event (AE)
Report Form Worksheet
Letrozole in Treating Postmenopausal Women Who Have
Received Hormone Therapy for Hormone Receptor-Positive
Breast Cancer
NCT00382070
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=17ADF05F-
DB75-341D-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/10116
rade 2 and 3 Adverse Event Report
Breast Cancer NCT00382070
NSABP B-42
Header
NSABP Patient ID
Patient Initials (Last First Middle)
Reporting Period Start Date
Reporting Period End Date
Completed by
Date
Adverse event
Has the patient experienced any of the following?
Any of the listed Grade 2 AEs OR  Any Grade 3
AEs not involving hospitalization OR Any Grade 3
AEs involving hospitalization that are unrelated or
unlikely to be related to letrozole (Since the
previous AE report)
Yes
No
Adverse Event
Abdominal Distension (Abdominal
distension)
Abdominal Infection (Abdominal
infection)
Abdominal Pain (Abdominal pain)
Abdominal Soft Tissue Necrosis
(Abdominal soft tissue necrosis)
Abducens Nerve Disorder (Abducens
nerve disorder)
Accessory Nerve Disorder (Accessory
nerve disorder)
Acidosis (Acidosis)
Acoustic Nerve Disorder Nos (Acoustic
nerve disorder NOS)
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Activated Partial Thromboplastin Time
Prolonged (Activated partial
thromboplastin time prolonged)
Acute Coronary Syndrome (Acute
coronary syndrome)
Acute Kidney Injury (Acute kidney injury)
Adrenal Insufficiency (Adrenal
insufficiency)
Adult Respiratory Distress Syndrome
(Adult respiratory distress syndrome)
Agitation (Agitation)
Akathisia (Akathisia)
Alanine Aminotransferase Increased
(Alanine aminotransferase increased)
Alcohol Intolerance (Alcohol intolerance)
Alkaline Phosphatase Increased
(Alkaline phosphatase increased)
Alkalosis (Alkalosis)
Allergic Reaction (Allergic reaction)
Allergic Rhinitis (Allergic rhinitis)
Alopecia (Alopecia)
Amnesia (Amnesia)
Anal Fistula (Anal fistula)
Anal Hemorrhage (Anal hemorrhage)
Anal Mucositis (Anal mucositis)
Anal Necrosis (Anal necrosis)
Anal Pain (Anal pain)
Anal Stenosis (Anal stenosis)
Anal Ulcer (Anal ulcer)
Anaphylaxis (Anaphylaxis)
Anemia (Anemia)
Ankle Fracture (Ankle fracture)
Anorectal Infection (Anorectal infection)
Anorexia (Anorexia)
Anorgasmia (Anorgasmia)
Anxiety (Anxiety)
Aortic Injury (Aortic injury)
Aortic Valve Disease (Aortic valve
disease)
Aphonia (Aphonia)
Apnea (Apnea)
Appendicitis (Appendicitis)
Appendicitis Perforated (Appendicitis
perforated)
Arachnoiditis (Arachnoiditis)
Arterial Injury (Arterial injury)
Arteritis Infective (Arteritis infective)
Arthralgia (Arthralgia)
Arthritis (Arthritis)
Ascites (Ascites)
Aspartate Aminotransferase Increased
(Aspartate aminotransferase increased)
Aspiration (Aspiration)
Asystole (Asystole)
Ataxia (Ataxia)
Atelectasis (Atelectasis)
Atrial Fibrillation (Atrial fibrillation)
Atrial Flutter (Atrial flutter)
Atrioventricular Block Complete
(Atrioventricular block complete)
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Atrioventricular Block First Degree
(Atrioventricular block first degree)
Autoimmune Disorder (Autoimmune
disorder)
Avascular Necrosis (Avascular necrosis)
Azoospermia (Azoospermia)
Back Pain (Back pain)
Bile Duct Stenosis (Bile duct stenosis)
Biliary Anastomotic Leak (Biliary
anastomotic leak)
Biliary Fistula (Biliary fistula)
Biliary Tract Infection (Biliary tract
infection)
Bladder Anastomotic Leak (Bladder
anastomotic leak)
Bladder Infection (Bladder infection)
Bladder Perforation (Bladder perforation)
Bladder Spasm (Bladder spasm)
Bloating (Bloating)
Blood And Lymphatic System Disorders -
Other, Specify (Blood and lymphatic
system disorders - Other, Specify)
Blood Antidiuretic Hormone Abnormal
(Blood antidiuretic hormone abnormal)
Blood Bilirubin Increased (Blood bilirubin
increased)
Blood Corticotrophin Decreased (Blood
corticotrophin decreased)
Blood Gonadotrophin Abnormal (Blood
gonadotrophin abnormal)
Blood Prolactin Abnormal (Blood
prolactin abnormal)
Blurred Vision (Blurred vision)
Body Odor (Body odor)
Bone Infection (Bone infection)
Bone Marrow Hypocellular (Bone
marrow hypocellular)
Bone Pain (Bone pain)
Brachial Plexopathy (Brachial
plexopathy)
Breast Atrophy (Breast atrophy)
Breast Infection (Breast infection)
Breast Pain (Breast pain)
Bronchial Fistula (Bronchial fistula)
Bronchial Infection (Bronchial infection)
Bronchial Obstruction (Bronchial
obstruction)
Bronchial Stricture (Bronchial stricture)
Bronchopleural Fistula (Bronchopleural
fistula)
Bronchopulmonary Hemorrhage
(Bronchopulmonary hemorrhage)
Bronchospasm (Bronchospasm)
Bruising (Bruising)
Bullous Dermatitis (Bullous dermatitis)
Burn (Burn)
Buttock Pain (Buttock pain)
Capillary Leak Syndrome (Capillary leak
syndrome)
Carbon Monoxide Diffusing Capacity
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Decreased (Carbon monoxide diffusing
capacity decreased)
Cardiac Arrest (Cardiac arrest)
Cardiac Disorders - Other, Specify
(Cardiac disorders - Other, Specify)
Cardiac Troponin I Increased (Cardiac
troponin I increased)
Cardiac Troponin T Increased (Cardiac
troponin T increased)
Cataract (Cataract)
Catheter Related Infection (Catheter
related infection)
CD4 Lymphocytes Decreased (CD4
lymphocytes decreased)
Cecal Hemorrhage (Cecal hemorrhage)
Cecal Infection (Cecal infection)
Central Nervous System Necrosis
(Central nervous system necrosis)
Cerebrospinal Fluid Leakage
(Cerebrospinal fluid leakage)
Cervicitis Infection (Cervicitis infection)
Cheilitis (Cheilitis)
Chest Pain - Cardiac (Chest pain -
cardiac)
Chest Wall Pain (Chest wall pain)
Chills (Chills)
Cholecystitis (Cholecystitis)
Cholesterol High (Cholesterol high)
Chronic Kidney Disease (Chronic kidney
disease)
Chylothorax (Chylothorax)
Cognitive Disturbance (Cognitive
disturbance)
Colitis (Colitis)
Colonic Fistula (Colonic fistula)
Colonic Hemorrhage (Colonic
hemorrhage)
Colonic Obstruction (Colonic obstruction)
Colonic Perforation (Colonic perforation)
Colonic Stenosis (Colonic stenosis)
Colonic Ulcer (Colonic ulcer)
Concentration Impairment
(Concentration impairment)
Conduction Disorder (Conduction
disorder)
Confusion (Confusion)
Congenital, Familial And Genetic
Disorders - Other, Specify (Congenital,
familial and genetic disorders - Other,
Specify)
Conjunctivitis (Conjunctivitis)
Conjunctivitis Infective (Conjunctivitis
infective)
Constipation (Constipation)
Constrictive Pericarditis (Constrictive
pericarditis)
Corneal Infection (Corneal infection)
Corneal Ulcer (Corneal ulcer)
Cough (Cough)
CPK Increased (CPK increased)
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Cranial Nerve Infection (Cranial nerve
infection)
Creatinine Increased (Creatinine
increased)
Cushingoid (Cushingoid)
Cystitis Noninfective (Cystitis
noninfective)
Cytokine Release Syndrome (Cytokine
release syndrome)
Death Neonatal (Death neonatal)
Death NOS (Death NOS)
Dehydration (Dehydration)
Delayed Orgasm (Delayed orgasm)
Delayed Puberty (Delayed puberty)
Delirium (Delirium)
Delusions (Delusions)
Dental Caries (Dental caries)
Depressed Level Of Consciousness
(Depressed level of consciousness)
Depression (Depression)
Dermatitis Radiation (Dermatitis
radiation)
Device Related Infection (Device related
infection)
Diarrhea (Diarrhea)
Disseminated Intravascular Coagulation
(Disseminated intravascular coagulation)
Dizziness (Dizziness)
Dry Eye (Dry eye)
Dry Mouth (Dry mouth)
Dry Skin (Dry skin)
Duodenal Fistula (Duodenal fistula)
Duodenal Hemorrhage (Duodenal
hemorrhage)
Duodenal Infection (Duodenal infection)
Duodenal Obstruction (Duodenal
obstruction)
Duodenal Perforation (Duodenal
perforation)
Duodenal Stenosis (Duodenal stenosis)
Duodenal Ulcer (Duodenal ulcer)
Dysarthria (Dysarthria)
Dysesthesia (Dysesthesia)
Dysgeusia (Dysgeusia)
Dysmenorrhea (Dysmenorrhea)
Dyspareunia (Dyspareunia)
Dyspepsia (Dyspepsia)
Dysphagia (Dysphagia)
Dysphasia (Dysphasia)
Dyspnea (Dyspnea)
Ear And Labyrinth Disorders - Other,
Specify (Ear and labyrinth disorders -
Other, Specify)
Ear Pain (Ear pain)
Edema Cerebral (Edema cerebral)
Edema Face (Edema face)
Edema Limbs (Edema limbs)
Edema Trunk (Edema trunk)
Ejaculation Disorder (Ejaculation
disorder)
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Ejection Fraction Decreased (Ejection
fraction decreased)
Electrocardiogram QT Corrected Interval
Prolonged (Electrocardiogram QT
corrected interval prolonged)
Encephalitis Infection (Encephalitis
infection)
Encephalomyelitis Infection
(Encephalomyelitis infection)
Encephalopathy (Encephalopathy)
Endocarditis Infective (Endocarditis
infective)
Endocrine Disorders - Other, Specify
(Endocrine disorders - Other, Specify)
Endophthalmitis (Endophthalmitis)
Enterocolitis (Enterocolitis)
Enterocolitis Infectious (Enterocolitis
infectious)
Enterovesical Fistula (Enterovesical
fistula)
Epistaxis (Epistaxis)
Erectile Dysfunction (Erectile
dysfunction)
Erythema Multiforme (Erythema
multiforme)
Erythroderma (Erythroderma)
Esophageal Anastomotic Leak
(Esophageal anastomotic leak)
Esophageal Fistula (Esophageal fistula)
Esophageal Hemorrhage (Esophageal
hemorrhage)
Esophageal Infection (Esophageal
infection)
Esophageal Necrosis (Esophageal
necrosis)
Esophageal Obstruction (Esophageal
obstruction)
Esophageal Pain (Esophageal pain)
Esophageal Perforation (Esophageal
perforation)
Esophageal Stenosis (Esophageal
stenosis)
Esophageal Ulcer (Esophageal ulcer)
Esophageal Varices Hemorrhage
(Esophageal varices hemorrhage)
Esophagitis (Esophagitis)
Euphoria (Euphoria)
Exostosis (Exostosis)
External Ear Inflammation (External ear
inflammation)
External Ear Pain (External ear pain)
Extraocular Muscle Paresis (Extraocular
muscle paresis)
Extrapyramidal Disorder (Extrapyramidal
disorder)
Eye Disorders - Other, Specify (Eye
disorders - Other, Specify)
Eye Infection (Eye infection)
Eye Pain (Eye pain)
Eyelid Function Disorder (Eyelid function
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disorder)
Facial Muscle Weakness (Facial muscle
weakness)
Facial Nerve Disorder (Facial nerve
disorder)
Facial Pain (Facial pain)
Fall (Fall)
Fallopian Tube Anastomotic Leak
(Fallopian tube anastomotic leak)
Fallopian Tube Obstruction (Fallopian
tube obstruction)
Fallopian Tube Perforation (Fallopian
tube perforation)
Fallopian Tube Stenosis (Fallopian tube
stenosis)
Fat Atrophy (Fat atrophy)
Fatigue (Fatigue)
Febrile Neutropenia (Febrile
neutropenia)
Fecal Incontinence (Fecal incontinence)
Female Genital Tract Fistula (Female
genital tract fistula)
Feminization Acquired (Feminization
acquired)
Fetal Death (Fetal death)
Fetal Growth Retardation (Fetal growth
retardation)
Fever (Fever)
Fibrinogen Decreased (Fibrinogen
decreased)
Fibrosis Deep Connective Tissue
(Fibrosis deep connective tissue)
Flank Pain (Flank pain)
Flashing Lights (Flashing lights)
Flatulence (Flatulence)
Floaters (Floaters)
Flu Like Symptoms (Flu like symptoms)
Flushing (Flushing)
Forced Expiratory Volume Decreased
(Forced expiratory volume decreased)
Fracture (Fracture)
Gait Disturbance (Gait disturbance)
Gallbladder Fistula (Gallbladder fistula)
Gallbladder Infection (Gallbladder
infection)
Gallbladder Necrosis (Gallbladder
necrosis)
Gallbladder Obstruction (Gallbladder
obstruction)
Gallbladder Pain (Gallbladder pain)
Gallbladder Perforation (Gallbladder
perforation)
Gastric Anastomotic Leak (Gastric
anastomotic leak)
Gastric Fistula (Gastric fistula)
Gastric Hemorrhage (Gastric
hemorrhage)
Gastric Necrosis (Gastric necrosis)
Gastric Perforation (Gastric perforation)
Gastric Stenosis (Gastric stenosis)
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Gastric Ulcer (Gastric ulcer)
Gastritis (Gastritis)
Gastroesophageal Reflux Disease
(Gastroesophageal reflux disease)
Gastrointestinal Anastomotic Leak
(Gastrointestinal anastomotic leak)
Gastrointestinal Disorders - Other,
Specify (Gastrointestinal disorders -
Other, Specify)
Gastrointestinal Fistula (Gastrointestinal
fistula)
Gastrointestinal Pain (Gastrointestinal
pain)
Gastrointestinal Stoma Necrosis
(Gastrointestinal stoma necrosis)
Gastroparesis (Gastroparesis)
General Disorders And Administration
Site Conditions - Other, Specify (General
disorders and administration site
conditions - Other, Specify)
Generalized Muscle Weakness
(Generalized muscle weakness)
Genital Edema (Genital edema)
GGT Increased (GGT increased)
Gingival Pain (Gingival pain)
Glaucoma (Glaucoma)
Glossopharyngeal Nerve Disorder
(Glossopharyngeal nerve disorder)
Glucose Intolerance (Glucose
intolerance)
Growth Accelerated (Growth
accelerated)
Growth Hormone Abnormal (Growth
hormone abnormal)
Growth Suppression (Growth
suppression)
Gum Infection (Gum infection)
Gynecomastia (Gynecomastia)
Hallucinations (Hallucinations)
Haptoglobin Decreased (Haptoglobin
decreased)
Head Soft Tissue Necrosis (Head soft
tissue necrosis)
Headache (Headache)
Hearing Impaired (Hearing impaired)
Heart Failure (Heart failure)
Hematoma (Hematoma)
Hematosalpinx (Hematosalpinx)
Hematuria (Hematuria)
Hemoglobin Increased (Hemoglobin
increased)
Hemoglobinuria (Hemoglobinuria)
Hemolysis (Hemolysis)
Hemolytic Uremic Syndrome (Hemolytic
uremic syndrome)
Hemorrhoidal Hemorrhage
(Hemorrhoidal hemorrhage)
Hemorrhoids (Hemorrhoids)
Hepatic Failure (Hepatic failure)
Hepatic Hemorrhage (Hepatic
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hemorrhage)
Hepatic Infection (Hepatic infection)
Hepatic Necrosis (Hepatic necrosis)
Hepatic Pain (Hepatic pain)
Hepatitis Viral (Hepatitis viral)
Hepatobiliary Disorders - Other, Specify
(Hepatobiliary disorders - Other, Specify)
Hiccups (Hiccups)
Hip Fracture (Hip fracture)
Hirsutism (Hirsutism)
Hoarseness (Hoarseness)
Hot Flashes (Hot flashes)
Hydrocephalus (Hydrocephalus)
Hypercalcemia (Hypercalcemia)
Hyperglycemia (Hyperglycemia)
Hyperhidrosis (Hyperhidrosis)
Hyperkalemia (Hyperkalemia)
Hypermagnesemia (Hypermagnesemia)
Hypernatremia (Hypernatremia)
Hyperparathyroidism
(Hyperparathyroidism)
Hypersomnia (Hypersomnia)
Hypertension (Hypertension)
Hyperthyroidism (Hyperthyroidism)
Hypertrichosis (Hypertrichosis)
Hypertriglyceridemia
(Hypertriglyceridemia)
Hyperuricemia (Hyperuricemia)
Hypoalbuminemia (Hypoalbuminemia)
Hypocalcemia (Hypocalcemia)
Hypoglossal Nerve Disorder
(Hypoglossal nerve disorder)
Hypoglycemia (Hypoglycemia)
Hypohidrosis (Hypohidrosis)
Hypokalemia (Hypokalemia)
Hypomagnesemia (Hypomagnesemia)
Hyponatremia (Hyponatremia)
Hypoparathyroidism
(Hypoparathyroidism)
Hypophosphatemia (Hypophosphatemia)
Hypotension (Hypotension)
Hypothermia (Hypothermia)
Hypothyroidism (Hypothyroidism)
Hypoxia (Hypoxia)
Ileal Fistula (Ileal fistula)
Ileal Hemorrhage (Ileal hemorrhage)
Ileal Obstruction (Ileal obstruction)
Ileal Perforation (Ileal perforation)
Ileal Stenosis (Ileal stenosis)
Ileal Ulcer (Ileal ulcer)
Ileus (Ileus)
Immune System Disorders - Other,
Specify (Immune system disorders -
Other, Specify)
Infections And Infestations - Other,
Specify (Infections and infestations -
Other, Specify)
Infective Myositis (Infective myositis)
Infusion Related Reaction (Infusion
related reaction)
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Infusion Site Extravasation (Infusion site
extravasation)
Injection Site Reaction (Injection site
reaction)
Injury To Carotid Artery (Injury to carotid
artery)
Injury To Inferior Vena Cava (Injury to
inferior vena cava)
Injury To Jugular Vein (Injury to jugular
vein)
Injury To Superior Vena Cava (Injury to
superior vena cava)
Injury, Poisoning And Procedural
Complications - Other, Specify (Injury,
poisoning and procedural complications -
Other, Specify)
INR Increased (INR increased)
Insomnia (Insomnia)
Intestinal Stoma Leak (Intestinal stoma
leak)
Intestinal Stoma Obstruction (Intestinal
stoma obstruction)
Intestinal Stoma Site Bleeding (Intestinal
stoma site bleeding)
Intra-abdominal Hemorrhage (Intra-
abdominal hemorrhage)
Intracranial Hemorrhage (Intracranial
hemorrhage)
Intraoperative Arterial Injury
(Intraoperative arterial injury)
Intraoperative Breast Injury
(Intraoperative breast injury)
Intraoperative Cardiac Injury
(Intraoperative cardiac injury)
Intraoperative Ear Injury (Intraoperative
ear injury)
Intraoperative Endocrine Injury
(Intraoperative endocrine injury)
Intraoperative Gastrointestinal Injury
(Intraoperative gastrointestinal injury)
Intraoperative Head And Neck Injury
(Intraoperative head and neck injury)
Intraoperative Hemorrhage
(Intraoperative hemorrhage)
Intraoperative hepatttttobiliary injury
(Intraoperative hepatobiliary injury)
Intraoperative Musculoskeletal Injury
(Intraoperative musculoskeletal injury)
Intraoperative Neurological Injury
(Intraoperative neurological injury)
Intraoperative Ocular Injury
(Intraoperative ocular injury)
Intraoperative Renal Injury
(Intraoperative renal injury)
Intraoperative Reproductive Tract Injury
(Intraoperative reproductive tract injury)
Intraoperative Respiratory Injury
(Intraoperative respiratory injury)
Intraoperative Skin Injury (Intraoperative
skin injury)
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Intraoperative Splenic Injury
(Intraoperative splenic injury)
Intraoperative Urinary Injury
(Intraoperative urinary injury)
Intraoperative Venous Injury
(Intraoperative venous injury)
Investigations - Other, Specify
(Investigations - Other, Specify)
Iron Overload (Iron overload)
Irregular Menstruation (Irregular
menstruation)
Irritability (Irritability)
Ischemia Cerebrovascular (Ischemia
cerebrovascular)
IVth Nerve Disorder (IVth nerve disorder)
Jejunal Fistula (Jejunal fistula)
Jejunal Hemorrhage (Jejunal
hemorrhage)
Jejunal Obstruction (Jejunal obstruction)
Jejunal Perforation (Jejunal perforation)
Jejunal Stenosis (Jejunal stenosis)
Jejunal Ulcer (Jejunal ulcer)
Joint Effusion (Joint effusion)
Joint Infection (Joint infection)
Joint Range Of Motion Decreased (Joint
range of motion decreased)
Joint Range Of Motion Decreased
Cervical Spine (Joint range of motion
decreased cervical spine)
Joint Range Of Motion Decreased
Lumbar Spine (Joint range of motion
decreased lumbar spine)
Keratitis (Keratitis)
Kidney Anastomotic Leak (Kidney
anastomotic leak)
Kidney Infection (Kidney infection)
Kyphosis (Kyphosis)
Lactation Disorder (Lactation disorder)
Large Intestinal Anastomotic Leak (Large
intestinal anastomotic leak)
Laryngeal Edema (Laryngeal edema)
Laryngeal Fistula (Laryngeal fistula)
Laryngeal Hemorrhage (Laryngeal
hemorrhage)
Laryngeal Inflammation (Laryngeal
inflammation)
Laryngeal Mucositis (Laryngeal
mucositis)
Laryngeal Obstruction (Laryngeal
obstruction)
Laryngeal Stenosis (Laryngeal stenosis)
Laryngitis (Laryngitis)
Laryngopharyngeal Dysesthesia
(Laryngopharyngeal dysesthesia)
Laryngospasm (Laryngospasm)
Left Ventricular Systolic Dysfunction (Left
ventricular systolic dysfunction)
Lethargy (Lethargy)
Leukemia Secondary To Oncology
Chemotherapy (Leukemia secondary to
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oncology chemotherapy)
Leukocytosis (Leukocytosis)
Leukoencephalopathy
(Leukoencephalopathy)
Libido Decreased (Libido decreased)
Libido Increased (Libido increased)
Lip Infection (Lip infection)
Lip Pain (Lip pain)
Lipase Increased (Lipase increased)
Lipohypertrophy (Lipohypertrophy)
Localized Edema (Localized edema)
Lordosis (Lordosis)
Lower Gastrointestinal Hemorrhage
(Lower gastrointestinal hemorrhage)
Lung Infection (Lung infection)
Lymph Gland Infection (Lymph gland
infection)
Lymph Leakage (Lymph leakage)
Lymph Node Pain (Lymph node pain)
Lymphedema (Lymphedema)
Lymphocele (Lymphocele)
Lymphocyte Count Decreased
(Lymphocyte count decreased)
Lymphocyte Count Increased
(Lymphocyte count increased)
Malabsorption (Malabsorption)
Malaise (Malaise)
Mania (Mania)
Mediastinal Hemorrhage (Mediastinal
hemorrhage)
Mediastinal Infection (Mediastinal
infection)
Memory Impairment (Memory
impairment)
Meningismus (Meningismus)
Meningitis (Meningitis)
Menopause (Menopause)
Menorrhagia (Menorrhagia)
Metabolism And Nutrition Disorders -
Other, Specify (Metabolism and nutrition
disorders - Other, Specify)
Middle Ear Inflammation (Middle ear
inflammation)
Mitral Valve Disease (Mitral valve
disease)
Mobitz (type) II Atrioventricular Block
(Mobitz (type) II atrioventricular block)
Mobitz Type I (Mobitz type I)
Movements Involuntary (Movements
involuntary)
Mucosal Infection (Mucosal infection)
Mucositis Oral (Mucositis oral)
Multi-organ Failure (Multi-organ failure)
Muscle Weakness Left-sided (Muscle
weakness left-sided)
Muscle Weakness Lower Limb (Muscle
weakness lower limb)
Muscle Weakness Right-sided (Muscle
weakness right-sided)
Muscle Weakness Trunk (Muscle
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weakness trunk)
Muscle Weakness Upper Limb (Muscle
weakness upper limb)
Musculoskeletal And Connective Tissue
Disorder - Other, Specify
(Musculoskeletal and connective tissue
disorders - Other, Specify)
Musculoskeletal Deformity
(Musculoskeletal deformity)
Myalgia (Myalgia)
Myelitis (Myelitis)
Myelodysplastic Syndrome
(Myelodysplastic syndrome)
Myocardial Infarction (Myocardial
infarction)
Myocarditis (Myocarditis)
Myositis (Myositis)
Nail Discoloration (Nail discoloration)
Nail Infection (Nail infection)
Nail Loss (Nail loss)
Nail Ridging (Nail ridging)
Nasal Congestion (Nasal congestion)
Nausea (Nausea)
Neck Edema (Neck edema)
Neck Pain (Neck pain)
Neck Soft Tissue Necrosis (Neck soft
tissue necrosis)
Neoplasms Benign, Malignant And
Unspecified (incl Cysts And Polyps) -
Other, Specify (Neoplasms benign,
malignant and unspecified (incl cysts and
polyps) - Other, Specify)
Nervous System Disorders - Other,
Specify (Nervous system disorders -
Other, Specify)
Neuralgia (Neuralgia)
Neutrophil Count Decreased (Neutrophil
count decreased)
Night Blindness (Night blindness)
Nipple Deformity (Nipple deformity)
Non-cardiac Chest Pain (Non-cardiac
chest pain)
Nystagmus (Nystagmus)
Obesity (Obesity)
Obstruction Gastric (Obstruction gastric)
Oculomotor Nerve Disorder (Oculomotor
nerve disorder)
Olfactory Nerve Disorder (Olfactory
nerve disorder)
Oligospermia (Oligospermia)
Optic Nerve Disorder (Optic nerve
disorder)
Oral Cavity Fistula (Oral cavity fistula)
Oral Dysesthesia (Oral dysesthesia)
Oral Hemorrhage (Oral hemorrhage)
Oral Pain (Oral pain)
Osteonecrosis Of Jaw (Osteonecrosis of
jaw)
Osteoporosis (Osteoporosis)
Otitis Externa (Otitis externa)
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Otitis Media (Otitis media)
Ovarian Hemorrhage (Ovarian
hemorrhage)
Ovarian Infection (Ovarian infection)
Ovarian Rupture (Ovarian rupture)
Ovulation Pain (Ovulation pain)
Pain (Pain)
Pain In Extremity (Pain in extremity)
Pain Of Skin (Pain of skin)
Palmar-plantar Erythrodysesthesia
Syndrome (Palmar-plantar
erythrodysesthesia syndrome)
Palpitations (Palpitations)
Pancreas Infection (Pancreas infection)
Pancreatic Anastomotic Leak (Pancreatic
anastomotic leak)
Pancreatic Duct Stenosis (Pancreatic
duct stenosis)
Pancreatic Enzymes Decreased
(Pancreatic enzymes decreased)
Pancreatic Fistula (Pancreatic fistula)
Pancreatic Hemorrhage (Pancreatic
hemorrhage)
Pancreatic Necrosis (Pancreatic
necrosis)
Pancreatitis (Pancreatitis)
Papilledema (Papilledema)
Papulopustular Rash (Papulopustular
rash)
Paresthesia (Paresthesia)
Paronychia (Paronychia)
Paroxysmal Atrial Tachycardia
(Paroxysmal atrial tachycardia)
Pelvic Floor Muscle Weakness (Pelvic
floor muscle weakness)
Pelvic Infection (Pelvic infection)
Pelvic Pain (Pelvic pain)
Pelvic Soft Tissue Necrosis (Pelvic soft
tissue necrosis)
Penile Infection (Penile infection)
Penile Pain (Penile pain)
Perforation Bile Duct (Perforation bile
duct)
Pericardial Effusion (Pericardial effusion)
Pericardial Tamponade (Pericardial
tamponade)
Pericarditis (Pericarditis)
Perineal Pain (Perineal pain)
Periodontal Disease (Periodontal
disease)
Periorbital Edema (Periorbital edema)
Periorbital Infection (Periorbital infection)
Peripheral Ischemia (Peripheral
ischemia)
Peripheral Motor Neuropathy (Peripheral
motor neuropathy)
Peripheral Nerve Infection (Peripheral
nerve infection)
Peripheral Sensory Neuropathy
(Peripheral sensory neuropathy)
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Peritoneal Infection (Peritoneal infection)
Peritoneal Necrosis (Peritoneal necrosis)
Personality Change (Personality change)
Phantom Pain (Phantom pain)
Pharyngeal Anastomotic Leak
(Pharyngeal anastomotic leak)
Pharyngeal Fistula (Pharyngeal fistula)
Pharyngeal Hemorrhage (Pharyngeal
hemorrhage)
Pharyngeal Mucositis (Pharyngeal
mucositis)
Pharyngeal Necrosis (Pharyngeal
necrosis)
Pharyngeal Stenosis (Pharyngeal
stenosis)
Pharyngitis (Pharyngitis)
Pharyngolaryngeal Pain
(Pharyngolaryngeal pain)
Phlebitis (Phlebitis)
Phlebitis Infective (Phlebitis infective)
Photophobia (Photophobia)
Photosensitivity (Photosensitivity)
Platelet Count Decreased (Platelet count
decreased)
Pleural Effusion (Pleural effusion)
Pleural Hemorrhage (Pleural
hemorrhage)
Pleural Infection (Pleural infection)
Pleuritic Pain (Pleuritic pain)
Pneumonitis (Pneumonitis)
Pneumothorax (Pneumothorax)
Portal Hypertension (Portal
hypertension)
Portal Vein Thrombosis (Portal vein
thrombosis)
Postnasal Drip (Postnasal drip)
Postoperative Hemorrhage
(Postoperative hemorrhage)
Postoperative Thoracic Procedure
Complication (Postoperative thoracic
procedure complication)
Precocious Puberty (Precocious
puberty)
Pregnancy, Puerperium And Perinatal
Conditions - Other, Specify (Pregnancy,
puerperium and perinatal conditions -
Other, Specify)
Premature Delivery (Premature delivery)
Premature Menopause (Premature
menopause)
Presyncope (Presyncope)
Proctitis (Proctitis)
Productive Cough (Productive cough)
Prolapse Of Intestinal Stoma (Prolapse
of intestinal stoma)
Prolapse Of Urostomy (Prolapse of
urostomy)
Prostate Infection (Prostate infection)
Prostatic Hemorrhage (Prostatic
hemorrhage)
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Prostatic Obstruction (Prostatic
obstruction)
Prostatic Pain (Prostatic pain)
Proteinuria (Proteinuria)
Pruritus (Pruritus)
Psychiatric Disorders - Other, Specify
(Psychiatric disorders - Other, Specify)
Psychosis (Psychosis)
Pulmonary Edema (Pulmonary edema)
Pulmonary Fibrosis (Pulmonary fibrosis)
Pulmonary Fistula (Pulmonary fistula)
Pulmonary Hypertension (Pulmonary
hypertension)
Pulmonary Valve Disease (Pulmonary
valve disease)
Purpura (Purpura)
Pyramidal Tract Syndrome (Pyramidal
tract syndrome)
Radiation Recall Reaction (dermatologic)
(Radiation recall reaction (dermatologic))
Radiculitis (Radiculitis)
Rash Acneiform (Rash acneiform)
Rash Maculo-papular (Rash maculo-
papular)
Rash Pustular (Rash pustular)
Rectal Anastomotic Leak (Rectal
anastomotic leak)
Rectal Fistula (Rectal fistula)
Rectal Hemorrhage (Rectal hemorrhage)
Rectal Mucositis (Rectal mucositis)
Rectal Necrosis (Rectal necrosis)
Rectal Obstruction (Rectal obstruction)
Rectal Pain (Rectal pain)
Rectal Perforation (Rectal perforation)
Rectal Stenosis (Rectal stenosis)
Rectal Ulcer (Rectal ulcer)
Recurrent Laryngeal Nerve Palsy
(Recurrent laryngeal nerve palsy)
Renal And Urinary Disorders - Other,
Specify (Renal and urinary disorders -
Other, Specify)
Renal Calculi (Renal calculi)
Renal Colic (Renal colic)
Renal Hemorrhage (Renal hemorrhage)
Reproductive System And Breast
Disorders - Other, Specify (Reproductive
system and breast disorders - Other,
Specify)
Respiratory Failure (Respiratory failure)
Respiratory, Thoracic And Mediastinal
Disorders - Other, Specify (Respiratory,
thoracic and mediastinal disorders -
Other, Specify)
Restlessness (Restlessness)
Restrictive Cardiomyopathy (Restrictive
cardiomyopathy)
Retinal Detachment (Retinal
detachment)
Retinal Tear (Retinal tear)
Retinal Vascular Disorder (Retinal
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vascular disorder)
Retinoic Acid Syndrome (Retinoic acid
syndrome)
Retinopathy (Retinopathy)
Retroperitoneal Hemorrhage
(Retroperitoneal hemorrhage)
Reversible Posterior
Leukoencephalopathy Syndrome
(Reversible posterior
leukoencephalopathy syndrome)
Rhinitis Infective (Rhinitis infective)
Right Ventricular Dysfunction (Right
ventricular dysfunction)
Salivary Duct Inflammation (Salivary duct
inflammation)
Salivary Gland Fistula (Salivary gland
fistula)
Salivary Gland Infection (Salivary gland
infection)
Scalp Pain (Scalp pain)
Scleral Disorder (Scleral disorder)
Scoliosis (Scoliosis)
Scrotal Infection (Scrotal infection)
Scrotal Pain (Scrotal pain)
Seizure (Seizure)
Sepsis (Sepsis)
Seroma (Seroma)
Serum Amylase Increased (Serum
amylase increased)
Serum Sickness (Serum sickness)
Sick Sinus Syndrome (Sick sinus
syndrome)
Sinus Bradycardia (Sinus bradycardia)
Sinus Disorder (Sinus disorder)
Sinus Pain (Sinus pain)
Sinus Tachycardia (Sinus tachycardia)
Sinusitis (Sinusitis)
Skin And Subcutaneous Tissue
Disorders - Other, Specify (Skin and
subcutaneous tissue disorders - Other,
Specify)
Skin Atrophy (Skin atrophy)
Skin Hyperpigmentation (Skin
hyperpigmentation)
Skin Hypopigmentation (Skin
hypopigmentation)
Skin Induration (Skin induration)
Skin Infection (Skin infection)
Skin Ulceration (Skin ulceration)
Sleep Apnea (Sleep apnea)
Small Intestinal Anastomotic Leak (Small
intestinal anastomotic leak)
Small Intestinal Mucositis (Small
intestinal mucositis)
Small Intestinal Obstruction (Small
intestinal obstruction)
Small Intestinal Perforation (Small
intestinal perforation)
Small Intestinal Stenosis (Small intestinal
stenosis)
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Small Intestine Infection (Small intestine
infection)
Small Intestine Ulcer (Small intestine
ulcer)
Sneezing (Sneezing)
Social Circumstances - Other, Specify
(Social circumstances - Other, Specify)
Soft Tissue Infection (Soft tissue
infection)
Soft Tissue Necrosis Lower Limb (Soft
tissue necrosis lower limb)
Soft Tissue Necrosis Upper Limb (Soft
tissue necrosis upper limb)
Somnolence (Somnolence)
Sore Throat (Sore throat)
Spasticity (Spasticity)
Spermatic Cord Anastomotic Leak
(Spermatic cord anastomotic leak)
Spermatic Cord Hemorrhage (Spermatic
cord hemorrhage)
Spermatic Cord Obstruction (Spermatic
cord obstruction)
Spinal Fracture (Spinal fracture)
Spleen Disorder (Spleen disorder)
Splenic Infection (Splenic infection)
Stenosis Of Gastrointestinal Stoma
(Stenosis of gastrointestinal stoma)
Stevens-Johnson Syndrome (Stevens-
Johnson syndrome)
Stoma Site Infection (Stoma site
infection)
Stomach Pain (Stomach pain)
Stomal Ulcer (Stomal ulcer)
Stridor (Stridor)
Stroke (Stroke)
Sudden Death NOS (Sudden death
NOS)
Suicidal Ideation (Suicidal ideation)
Suicide Attempt (Suicide attempt)
Superficial Soft Tissue Fibrosis
(Superficial soft tissue fibrosis)
Superficial Thrombophlebitis (Superficial
thrombophlebitis)
Superior Vena Cava Syndrome (Superior
vena cava syndrome)
Supraventricular Tachycardia
(Supraventricular tachycardia)
Surgical And Medical Procedures -
Other, Specify (Surgical and medical
procedures - Other, Specify)
Syncope (Syncope)
Telangiectasia (Telangiectasia)
Testicular Disorder (Testicular disorder)
Testicular Hemorrhage (Testicular
hemorrhage)
Testicular Pain (Testicular pain)
Thromboembolic Event
(Thromboembolic event)
Thrombotic Thrombocytopenic Purpura
(Thrombotic thrombocytopenic purpura)
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Tinnitus (Tinnitus)
Tooth Development Disorder (Tooth
development disorder)
Tooth Discoloration (Tooth discoloration)
Tooth Infection (Tooth infection)
Toothache (Toothache)
Toxic Epidermal Necrolysis (Toxic
epidermal necrolysis)
Tracheal Fistula (Tracheal fistula)
Tracheal Hemorrhage (Tracheal
hemorrhage)
Tracheal Mucositis (Tracheal mucositis)
Tracheal Obstruction (Tracheal
obstruction)
Tracheal Stenosis (Tracheal stenosis)
Tracheitis (Tracheitis)
Tracheostomy Site Bleeding
(Tracheostomy site bleeding)
Transient Ischemic Attacks (Transient
ischemic attacks)
Treatment Related Secondary
Malignancy (Treatment related
secondary malignancy)
Tremor (Tremor)
Tricuspid Valve Disease (Tricuspid valve
disease)
Trigeminal Nerve Disorder (Trigeminal
nerve disorder)
Trismus (Trismus)
Tumor Lysis Syndrome (Tumor lysis
syndrome)
Tumor Pain (Tumor pain)
Typhlitis (Typhlitis)
Unequal Limb Length (Unequal limb
length)
Unintended Pregnancy (Unintended
pregnancy)
Upper Gastrointestinal Hemorrhage
(Upper gastrointestinal hemorrhage)
Upper Respiratory Infection (Upper
respiratory infection)
Ureteric Anastomotic Leak (Ureteric
anastomotic leak)
Urethral Anastomotic Leak (Urethral
anastomotic leak)
Urethral Infection (Urethral infection)
Urinary Fistula (Urinary fistula)
Urinary Frequency (Urinary frequency)
Urinary Incontinence (Urinary
incontinence)
Urinary Retention (Urinary retention)
Urinary Tract Infection (Urinary tract
infection)
Urinary Tract Obstruction (Urinary tract
obstruction)
Urinary Tract Pain (Urinary tract pain)
Urinary Urgency (Urinary urgency)
Urine Discoloration (Urine discoloration)
Urine Output Decreased (Urine output
decreased)
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Urostomy Leak (Urostomy leak)
Urostomy Obstruction (Urostomy
obstruction)
Urostomy Site Bleeding (Urostomy site
bleeding)
Urostomy Stenosis (Urostomy stenosis)
Urticaria (Urticaria)
Uterine Anastomotic Leak (Uterine
anastomotic leak)
Uterine Fistula (Uterine fistula)
Uterine Hemorrhage (Uterine
hemorrhage)
Uterine Infection (Uterine infection)
Uterine Obstruction (Uterine obstruction)
Uterine Pain (Uterine pain)
Uterine Perforation (Uterine perforation)
Uveitis (Uveitis)
Vaginal Anastomotic Leak (Vaginal
anastomotic leak)
Vaginal Discharge (Vaginal discharge)
Vaginal Dryness (Vaginal dryness)
Vaginal Fistula (Vaginal fistula)
Vaginal Hemorrhage (Vaginal
hemorrhage)
Vaginal Infection (Vaginal infection)
Vaginal Inflammation (Vaginal
inflammation)
Vaginal Obstruction (Vaginal obstruction)
Vaginal Pain (Vaginal pain)
Vaginal Perforation (Vaginal perforation)
Vaginal Stricture (Vaginal stricture)
Vaginismus (Vaginismus)
Vagus nerve disorder (Vagus nerve
disorder)
Vas Deferens Anastomotic Leak (Vas
deferens anastomotic leak)
Vascular Access Complication (Vascular
access complication)
Vascular Disorders - Other, Specify
(Vascular disorderrs - Other, Specify)
Vascuulittiiss (Vasculitis)
Vasovagal Reaction (Vasovagal reaction)
Venous Injury (Venous injury)
Ventricular Arrhythmia (Ventricular
arrhythmia)
Ventricular Fibrillation (Ventricular
fibrillation)
Ventricular Tachycardia (Ventricular
tachycardia)
Vertigo (Vertigo)
Vestibular Disorder (Vestibular disorder)
Virilization (Virilization)
Visceral Arterial Ischemia (Visceral
arterial ischemia)
Vital Capacity Abnormal (Vital capacity
abnormal)
Vitreous Hemorrhage (Vitreous
hemorrhage)
Voice Alteration (Voice alteration)
Vomiting (Vomiting)
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Vulval Infection (Vulval infection)
Watering Eyes (Watering eyes)
Weight Gain (Weight gain)
Weight Loss (Weight loss)
Wheezing (Wheezing)
White Blood Cell Decreased (White
blood cell decreased)
Wolff-parkinson-white Syndrome (Wolff-
Parkinson-White syndrome)
Wound Complication (Wound
complication)
Wound Dehiscence (Wound dehiscence)
Wound Infection (Wound infection)
Wrist Fracture (Wrist fracture)
Grade
Absent Adverse Event (0)
Mild Adverse Event (1)
Moderate Adverse Event (2)
Severe Adverse Event (3)
Life Threatening Adverse Event (4)
Death Related To Adverse Event (5)
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Breast Cancer On-Study NCT00408408
NSABP B-40
NSABP Protocol B-40 - On-Study Form
A Randomized Phase III Trial of Neoadjuvant Therapy in
Patients With Palpable and Operable Breast Cancer
Evaluating the Effect on Pathologic Complete Response
(pCR) of Adding Capecitabine or Gemcitabine to Docetaxel
When Administered Before AC With or Without
Bevacizumab and Correlative Science Studies Attempting
to Identify Predictors of High Likelihood for pCR With Each
of the Regimens
NCT00408408
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=1B3E2A3A-
F3C8-3045-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/10117
On-Study Form Breast Cancer
NCT00408408
Header
Patient Initials (Last First Middle)
NSABP Patient ID
Institution/Affiliate
Person Completing Form, Last Name
Person Completing Form, First Name
Person Completing Form, Phone
Date Form Completed
Are data amended
Yes
No
Patient characteristics
Tumor Laterality
Left (Left)
Right (Right)
Histologic Type (from diagnostic core needle
biopsy - Mark predominant tumor type if more
than one applies.)
Ductal (Ductal)
Lobular (90% or more) (Lobular)
Other Specify (Other)
Other specify
Receptor Status, ER (from diagnostic core needle
biopsy)
Negative (Negative)
1 / 2
Positive (Positive)
Unknown (Unknown)
Receptor Status, PgR
Negative (Negative)
Positive (Positive)
Unknown (Unknown)
Histologic Grade (from diagnostic core needle
biopsy  Use combined histologic grade
SBR/Elston classification.)
Well Differentiated (Grade I (low))
Moderately Differentiated (Grade II
(intermediate))
Poorly Differentiated (Grade III (high))
HER-2/neu status (if yes  from core needle
biopsy - )
Negative (Negative)
Positive (Positive)
unknown (Unknown)
Does the patient have any first degree relatives
who died from heart disease before the age of 55
("First degree relatives" include parents, children,
brothers and sisters.)
Yes
No
Did the patient take medications for any of the
following medical conditions in the 12 months
prior to study entry
Yes
No
Medical Condition
Hypertension (1)
Angina pectoris (2)
Myocardial Infarction (3)
Congestive Heart Failure (4)
Atrial Fibrillation (5)
Ventricular Arrhythmia (6)
Diabetes (7)
Elevated Fasting Lipid Profile (8)
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Prostate Cancer Toxicity - E1805
E1805 Adverse Event Form (CTCAE v3.0)
Prostate Cancer Toxicity - E1805 
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=0F33944C-
5CE4-6FA2-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/10118
Adverse Event Prostated Cancer
E1805
Header
ECOG Protocol Number
ECOG Patient ID
DCI Name
Registration Step
Patient Initials (Last, First)
Participating Group Protocol Number
Participating Group Patient ID
Institution/Affiliate
Please mark an 'X' if data have been amended.
(Please circle amended items in red)
Date data amended
Investigator Signature
Investigator Signature Date
ON TREATMENT
On Treatment Report Period (Choose one x -
NOTE: If the duration of the final treatment period
is less than the report period intervals listed
below, choose the next highest report period.)
> Cycle 22 Step 2 (> Cycle 22 Step 2)
Cycle 15 Step 2 (Cycle 15 Step 2)
Cycle 16-step 2 (Cycle 16-Step 2)
Cycle 17 Step 2 (Cycle 17 Step 2)
Cycle 18-step 2 (Cycle 18-Step 2)
Cycle 19 Step 2 (Cycle 19 Step 2)
Cycle 20-step 2 (Cycle 20-Step 2)
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Cycle 21 Step 2 (Cycle 21 Step 2)
Cycle 22-step 2 (Cycle 22-Step 2)
Specify Cycle
Off Treatment Report Period (since initial
registration)
9 Years (108 Months Post-Registration)
12 Months (12 Months Post Registration)
10 Years (120 Months Post-Registration)
11 Years Post Registration (132 Months
Post Registration)
12 Years Post Registration (144 Months
Post Registration)
15 Months (15 Months Post Registration)
13 Years Post Registration (156 Months
Post Registration)
14 Years Post Registration (168 Months
Post Registration)
18 Months (18 Months Post Registration)
15 Years Post Registration (180 Months
Post Registration)
21 Months Post Registration (21 Months
Post Registration)
2 Years (24 Months Post Registration)
3 Months (3 Months Post Registration)
30 Months (30 Months Post Registration)
3 Years (36 Months Post Registration)
42 Months (42 Months Post Registration)
4 Years (48 Months Post Registration)
54 Months (54 Months Post Registration)
6 Months (6 Months Post Registration)
5 Years (60 Months Post Registration)
6 Years (72 Months Post-Registration)
84 Months Post Registration (84 Months
Post-Registration)
9 Months (9 Months Post Registration)
8 Years (96 Months Post-Registration)
Adverse Event
Were adverse events assessed during this report
period
Not assessed (0)
Yes, But No Reportable Adverse Events
Occurred (1)
Yes, And Reportable Adverse Events
Occurred (2)
CTC Adverse Event Report Begin Date (For the
dates below, record the start and end dates of the
time period within current report period in which
patient was assessed for adverse events. -
mm/dd/yyyy)
CTC Adverse Event Report End Date (For the
dates below, record the start and end dates of the
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time period within current report period in which
patient was assessed for adverse events. -
mm/dd/yyyy)
Adverse Event BLOOD/BONE MARROW -
LABS
CTC Adverse Event Term
Diarrhoea NOS (Diarrhea)
Fatigue (Fatigue (asthenia, lethargy,
malaise))
Febrile Neutropenia  (fever Of Unknown
Origin Without Clinically Or
Microbiologically Documented Infection,
ANC below 1E9/l, Fever above 38.5C)
(Febrile neutropenia)
Hypertension NOS (Hypertension)
Injection Site Reaction NOS (Injection
site reaction/extravasation changes)
Nausea (Nausea)
Abdominal Pain NOS (Pain - Abdomen
NOS)
Bone Pain (Pain - Bone)
Headache NOS (Pain - Head/headache)
Myalgia (Pain - Muscle)
Dermatitis Exfoliative NOS
(Rash/desquamation)
Rigors and chills (Rigors/chills)
CTC Adverse Event Grade (v3.0)
CTC Adverse Event Attribution Scale
Definite (definite)
Possible (possible)
Probable (probable)
Unlikely (unlikely)
Unrelated (unrelated)
Adverse event associated with infection
CTC Adverse Event Short Name (use CTCAE v3
terminology)
Infection documented clinically or
microbiologically With Grade 3 Or 4
Neutrophils (ANC below 1E9/l) (Infection
(documented clinically) - Select)
Infection With Normal ANC Or Grade 1
or 2 Neutrophils (Infection with normal
ANC - Select)
Infection With Unknown ANC (Infection
with unknown ANC - Select)
CTC Select AE
Other Adverse Events
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Other CTC Adverse Event Term not listed (Use
CTCAE v3.0 terminology AE Term:)
Other, specify (site or subterm)
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Infectiological Surveillance after HSCT -  Department of Internal
Medicine Knappschaftskrankenhaus Bochum-Langendreer
Data derived from paper-based form of the Department of
Internal Medicine. With friendly permission of Prof. Dr. med.
Schmiegel http://www.medunikkh.de/
All rights reserved. Please visit https://medical-data-
models.org/forms/10123
Infectiological Report 2 KKH Bochum
SCT AML
Patient data
Patient name
Date of birth
Request
Specimen
Serologic test for Aspergillus (Galactomannan)
positive
Yes
No
Signature
Signature
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Quality assurance Hip Replacement -
Procedure (AQUA)
Documentation form for quality assurance in German
Health Care by the institute forapplied quality Improvement
and Research in Health Care (Aqua), https://www.aqua-
institut.de/en/home. Internal Aqua form version: HEP-
PROZ Specification 2015 V02
All rights reserved. Please visit https://medical-data-
models.org/forms/10127
Quality assurance Hip Replacement
- Procedure (AQUA)
Intervention procedure
Number of surgical procedure during this stay?*
Operation side*
right (1)
left (2)
Preoperative findings
ASA classification*
normal healthy patient (1)
patient with mild systemic disease (2)
patient with severe systemic disease (3)
patient with severe systemic disease that
is a constant threat to life (4)
moribund patient who is not expected to
survive without the operation (5)
Wound contamination classifcation of procedure*
aseptic procedure (1)
partially aseptic procedure (2)
procedure with contamination (3)
septic procedure (4)
Operation
Type of procedure*
endoprosthetic treatment of femoral
fracture near the hip joint (1)
elective total hip endoprosthesis primary
implantation (2)
reimplantation in the context of a one-
stage exchange (3)
reimplantation in the context of a two-
stage exchange (4)
Date of procedure (dd.mm.yyyy)*
Time starting surgery (hh:mm)*
Procedure(s)*
Perioperative management
1 / 3
perioperative antibiotic prophylaxis*
no (0)
single shot (1)
second dose (2)
more often (3)
Procedure intra- and postoperative course
Requiring treatment intra-/postoperative surgical
complication(s)*
Yes
No
Other specific complications requiring treatment
yes (1)
Secondary necrosis of the wound edges requiring
reoperation
yes (1)
Reoperationspflichtige wound dehiscence
yes (1)
postoperative wound infection (CDC definition)
CDC A1 (superficial infection) (1)
CDC A2 (postoperative deep infection)
(2)
CDC A3 (Organs/body cavity in the OP
area) (3)
periprosthetic fracture
yes (1)
motor nerve injury persistent at discharge
yes (1)
vascular lesion require surgical or interventional
yes (1)
wound hematoma/hemorrhage requiring OP or
intervention
yes (1)
open and closed repositioned endoprostheses
(sub) luxation
yes (1)
Secondary implant dislocation
yes (1)
Primary implant malposition
yes (1)
unplanned followed OP due to complications
yes (1)
Other procedures
Were more endoprosthetic operative procedures
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performed during this stay?*
Yes
No
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Quality assurance Hip Replacement - Procedure (AQUA)
Quality assurance Knee Replacement -
Procedure (AQUA)
Documentation form for quality assurance in German
Health Care by the institute forapplied quality Improvement
and Research in Health Care (Aqua), https://www.aqua-
institut.de/en/home. Internal Aqua form version: KEP-PROZ
Specification 2015 V02
All rights reserved. Please visit https://medical-data-
models.org/forms/10128
Quality assurance Knee
Replacement - Procedure (AQUA)
ProzedurEingriff
Number of endoprothetic procedure during this
stay?*
side of surgery*
right (1)
left (2)
Preoperative state
Gonarthrosis*
no (0)
primary gonarthrosis (1)
secondary osteoarthritis of the knee (2)
Deformity of knee joint*
no (0)
severe valgus knee (1)
severe varus knee (2)
ASA classification*
normal healthy patient (1)
patient with mild systemic disease (2)
patient with severe systemic disease (3)
patient with severe systemic disease that
is a constant threat to life (4)
moribund patient who is not expected to
survive without the operation (5)
Wound contamination classifcation*
aseptic procedure (1)
partially aseptic procedure (2)
procedure with contamination (3)
septic procedure (4)
Surgery
Type of procedure*
elective knee endoprosthesis primary
implantation (1)
one-stage exchange or replacing
components (2)
rhyme plantations as part of a two-stage
change or change components (3)
perioperative antibiotic prophylaxis*
no (0)
single shot (1)
second shot (2)
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often (3)
Date of procedure (dd.mm.yyyy)*
Prozedur(en)*
Intra- and postoperative course of
procedure
Were there specific needs treatment intra- and /
or postoperative complications?*
Yes
No
Other specific complications requiring treatment
yes (1)
Fracture of the patella
yes (1)
Rupture of the quadriceps tendon/patellar
ligament
yes (1)
postoperative mechanical complication of the
artificial joint
yes (1)
Operational require secondary necrosis of the
wound edges
yes (1)
Wound dehiscence requiring reoperations
yes (1)
postoperative wound infection (according to CDC
definition)
CDC A1 (superficial infection) (1)
CDC A2 (postoperative deep infection)
(2)
CDC A3 (Organs/body cavity in the
surgical area) (3)
Periprosthetic Fractures
yes (1)
persistent at discharge, motor nerve damage
Yes, no pain catheter-related (1)
Yes, pain catheter-related (2)
Surgical or interventional needed vascular lesion
Yes, no pain catheter-related (1)
Yes, pain catheter-related (2)
wound hematoma/hemorrhage requiring OP or
intervention
yes (1)
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Deformity of patella
yes (1)
postoperative dislocation of the artificial joint
yes (1)
Secondary implant dislocation
yes (1)
primary implant malposition
femoral component (1)
tibial component (2)
unplanned sequence-OP due to complications
yes (1)
Other procedures
Were more endoprosthetic operative procedures
performed at this stay?*
Yes
No
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Breast Cancer FOLLOW-UP NSABP B-36
NCT00087178
NSABP PROTOCOL B-36: FOLLOW-UP FORM
Comparison of Two Combination Chemotherapy Regimens
in Treating Women With Breast Cancer
NCT00087178
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=C89314D7-
1DBA-74BA-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/10132
FOLLOW-UP Breast Cancer
NCT00087178
Header
Patient Initials (Last, First Middle)
NSABP Patient ID
Institution Name
Affiliate Name
Person Completing Form (Phone)
Are data amended (check box if yes, and circle
amended items)
Yes
No
Vital Status
Patient's Vital Status
Alive (Alive)
Dead (Dead)
Date of Last Contact or Death (month day year)
Source of Survival Information (if alive)
Documentation Of Hospital Or Clinic Visit
(1)
Phone Contact To Patient (2)
Other (3)
Other
Primary cause of Death (if dead)
Due To This Disease (1)
Due To Protocol Treatment (2)
Due To Other Cause, Specify (3)
Unknown (4)
Describe Cause of Death (provide
documentation)
1 / 5
Was there evidence of recurrence at the time of
death?
No (No)
Unknown (Unknown)
Yes, Autopsy (Yes, autopsy)
Yes, Clinical (Yes, clinical)
Cancer Follow-up Status
Has the patient had a documented clinical
assessment for this cancer (since submission of
the last follow-up form)?
Yes
No
Date of Last Clinical Assessment (if applicable)
First Local-regional Recurrence
Has the patient been diagnosed with first local-
regional recurrence (since submission of the last
follow-up form)?
Yes
No
Date of First Local-Regional Recurrence (if
applicable)
Site(s) of First Local-Regional Recurrence (mark
all ipsilateral sites that apply)
Axilla (Axilla)
Axillary Nodes (Axillary nodes)
Chest Wall (Chest wall)
Infraclavicular Nodes (Infraclavicular
nodes)
Internal Mammary (Internal mammary
nodes)
Ipsilateral Breast (Ipsilateral breast)
Supraclavicular Nodes (Supraclavicular
nodes)
First Distant Recurrence
Has the patient been diagnosed with first distant
recurrence/progression (since submission of the
last follow-up form)?
Yes
No
Date of First Distant Recurrence (if applicable)
Site(s) of First Distant Recurrence
New Primary Cancer Or Mds
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Has a new primary cancer or MDS been
diagnosed that has not been previously reported?
Yes
No
Date of Diagnosis (if applicable)
Site(s) of New Primary
Patient data
Has the patient had a menstrual period or vaginal
bleeding in the last 12 months?
Yes
No
Has the patient had a hysterectomy?
Yes
No
Has the patient had a bilateral oophorectomy?
Yes
No
Was patient randomized to receive Celecoxib or
Placebo?
Yes
No
Did the patient experience any of the following
adverse events that have not been previously
reported?
Yes
No
Adverse Events
Adverse Event
Acute Coronary Syndrome (Acute
coronary syndrome)
Anorexia (Anorexia)
Arthralgia (Arthralgia)
Back Pain (Back pain)
Cholesterol High (Cholesterol high)
Constipation (Constipation)
Depression (Depression)
Diarrhea (Diarrhea)
Dizziness (Dizziness)
Dyspnea (Dyspnea)
Edema Limbs (Edema limbs)
Fatigue (Fatigue)
Headache (Headache)
Hot Flashes (Hot flashes)
Hypertriglyceridemia
(Hypertriglyceridemia)
Insomnia (Insomnia)
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Ischemia Cerebrovascular (Ischemia
cerebrovascular)
Myalgia (Myalgia)
Myocardial Infarction (Myocardial
infarction)
Nausea (Nausea)
Peripheral Ischemia (Peripheral
ischemia)
Somnolence (Somnolence)
Stroke (Stroke)
Thromboembolic Event
(Thromboembolic event)
Transient Ischemic Attacks (Transient
ischemic attacks)
Vaginal Hemorrhage (Vaginal
hemorrhage)
Visceral Arterial Ischemia (Visceral
arterial ischemia)
Grade
Mild Adverse Event (1)
Moderate Adverse Event (2)
Severe Adverse Event (3)
Late Adverse Events
Has the patient experienced any severe (Grade
>= 3) adverse event, possibly related to the
chemotherapy, that has not been previously
reported?
Yes
No
Therapy
Did the patient receive any Herceptin treatment
(since randomization since last follow-up)
Yes
No
Herceptin Treatment Start Date
Did the patient receive any systemic hormonal
treatment (since randomization since last follow-
up)
Yes
No
Tamoxifen
Yes
No
Anastrozole
Yes
No
Exemestane
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Yes
No
Letrozole
Yes
No
LHRH agonist
Yes
No
Other, specify
Yes
No
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Framingham Risk Score
The Framingham Risk Score is a sex-specific algorithm
used to estimate the 10-year cardiovascular risk of an
individual. The Framingham Risk Score was first developed
based on data obtained from the Framingham Heart Study,
to estimate the 10-year risk of developing coronary heart
disease. In order to assess the 10-year cardiovascular
disease risk, cerebrovascular events, peripheral artery
disease and heart failure were subsequently added as
disease outcomes for the 2008 Framingham Risk Score, on
top of coronary heart disease.
(http://en.wikipedia.org/wiki/Framingham_Risk_Score)
All rights reserved. Please visit https://medical-data-
models.org/forms/10136
Framingham Risk Score
Score items
Age
Gender
Male (1)
Female (2)
Total Cholesterol
HDL Cholesterol
Smoker
Yes
No
Systolic blood pressure
Are you currently on any medication to treat high
blood pressure?
Yes
No
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Head and Neck Cancer NCT00265941
Follow-Up
RTOG-0522 F1: Follow-up Form
Radiation Therapy and Cisplatin With or Without Cetuximab
in Treating Patients With Stage III or Stage IV Head and
Neck Cancer
NCT00265941
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=F65D686D-
87BE-6280-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/10161
Follow-up Head and Neck Cancer
RTOG-0522 F1 NCT00265941
Header
RTOG Study No.
Case #
Institution Name
Institution No.
Patient Initials
RTOG Patient ID
Amended data
Yes
No
COMMENTS
Person completing form
Form completion date, original
Current Disease Status And Method Of
Determination
PATIENT'S VITAL STATUS
Alive (Alive)
Dead (Dead)
DATE OF LAST CONTACT OR DEATH
PRIMARY CAUSE OF DEATH
Due To Other Cause (Due to other
cause)
Due To Protocol Treatment (Due to
protocol treatment)
Due To Second Primary Or Other
1 / 50
Malignancy (Due to second primary or
other malignancy)
Due To This Disease (Due to this
disease)
Unknown (Unknown)
Due to protocol treatment, specify
HAS THE PATIENT HAD A DOCUMENTED
CLINICAL ASSESSMENT FOR THIS CANCER
(SINCE SUBMISSION OF THE PREVIOUS
FOLLOW-UP FORM)
No (No)
Unknown (Unknown)
Yes (Yes)
DATE OF LAST CLINICAL ASSESSMENT
(Current Status)
Primary tumor (Original study site)
Disease Absent (Disease absent)
Disease Present (Disease present)
Unknown (Unknown)
Nodal Disease Right
Disease Absent (Disease absent)
Disease Present (Disease present)
Unknown (Unknown)
Nodal Disease Left
Disease Absent (Disease absent)
Disease Present (Disease present)
Unknown (Unknown)
Method of Evaluation (see Q5 codetable)
Autopsy (Autopsy)
Clinical (Clinical examination)
Ct Scan (CT scan)
Mri Scan (MRI scan)
Other, Specify (Other, specify)
Pathologic (Pathologic)
Unknown (Unknown)
Other, specify
Disease Events
Event (Event Codes: Primary Tumor site under
study 11,12; Regional Disease including Lymph
Nodes from site under study 21,22,23,24)
Disease Cleared (Disease cleared)
Nodal Clearance-left (Nodal clearance-
left)
Nodal Clearance-right (Nodal clearance-
right)
Nodal Relapse Or Progression-left
(Nodal relapse or progression-left)
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Nodal Relapse Or Progression-right
(Nodal relapse or progression-right)
Relapse (Relapse)
Date First Noted (mm-dd-yyyy)
Has the patient been diagnosed with first distant
recurrence/progression? (SINCE SUBMISSION
OF THE PREVIOUS FOLLOW-UP FORM)
No (No)
Unknown (Unknown)
Yes (Yes)
Date of First Distant Progression
Site(s) of distant progression (S use codetable
below)
AML/MDS (AML/MDS)
BCC (BCC)
Bladder (Bladder)
Brain (Brain)
Colorectal (Colorectal)
Esophageal (Esophageal)
Gastric (Gastric)
Hypopharynx (Hypopharynx)
Larynx (Larynx)
Liver (Liver)
Lung (Lung)
Melanoma (Melanoma)
Nasopharynx (Nasopharynx)
NHL (NHL)
None (None)
Oral Cavity (Oral cavity)
Oropharynx (Oropharynx)
Other H + N (Other H + N)
Other Hematologic (Other Hematologic)
Other Solid (Other solid)
Pancreatic (Pancreatic)
Prostate (Prostate)
Renal (Renal)
Squamous-skin (Squamous-Skin)
Unknown Primary (Unknown primary)
Other hematologic
Other solid, specify
New primary cancer
Has a new primary cancer or MDS been
diagnosed that has not been previously reported?
(MYELODYSPLASTIC SYNDROME SINCE
SUBMISSION OF THE PREVIOUS FOLLOW-UP
FORM)
No (No)
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Unknown (Unknown)
Yes (Yes)
Date of diagnosis
Site(s) of new primary (S USE CODETABLE
FROM Q7)
Aml/mds (AML/MDS)
Bcc (BCC)
Bladder (Bladder)
Brain (Brain)
Colorectal (Colorectal)
Esophageal (Esophageal)
Gastric (Gastric)
Hypopharynx (Hypopharynx)
Larynx (Larynx)
Liver (Liver)
Lung (Lung)
Melanoma (Melanoma)
Nasopharynx (Nasopharynx)
Nhl (NHL)
None (None)
Oral Cavity (Oral cavity)
Oropharynx (Oropharynx)
Other H + N (Other H + N)
Other Hematologic (Other Hematologic)
Other Solid (Other solid)
Pancreatic (Pancreatic)
Prostate (Prostate)
Renal (Renal)
Squamous-skin (Squamous-Skin)
Unknown Primary (Unknown primary)
Other Hematologic, specify
Other solid, specify
Non-Protocol Therapy
Was any non-protocol therapy given (RELATED
TO CANCER UNDER STUDY SINCE
SUBMISSION OF THE PREVIOUS FOLLOW-UP
FORM)
No (No)
Unknown (Unknown)
Yes (Yes)
Non-Protocol Surgery
No (No)
Unknown (Unknown)
Yes (Yes)
Non-protocol Therapy Start Date
Details
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Non-Protocol Chemotherapy
No (No)
Unknown (Unknown)
Yes (Yes)
Non-Protocol Biologic Response Modifier
No (No)
Unknown (Unknown)
Yes (Yes)
Non-protocol radiation therapy to primary
No (No)
Unknown (Unknown)
Yes (Yes)
Non-protocol radiation therapy to nodes (right)
No (No)
Unknown (Unknown)
Yes (Yes)
Non-protocol radiation therapy to nodes (left)
No (No)
Unknown (Unknown)
Yes (Yes)
Non-protocol radiation therapy to other sites
No (No)
Unknown (Unknown)
Yes (Yes)
Other Non-Protocol Therapy
No (No)
Unknown (Unknown)
Yes (Yes)
Was any non-protocol supportive therapy given
(Was any non-protocol supportive therapy given
since submission of the previous follow-up form)
No (No)
Unknown (Unknown)
Yes (Yes)
Type of Supportive Care Given
Other (Other)
Pilocarpine (Pilocarpine)
Swallowing and Tube Feeding
Does the patient currently have swallowing
problems
No (No)
Unknown (Unknown)
Yes (Yes)
How long have swallowing problems been
present (IF YES,)
1 To <7 Months (1 to <7 months)
13 To <19 Months (13 to <19 months)
19 To <24 Months (19 to <24 months)
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2 Years Or Longer (2 years or longer)
7 To <13 Months (7 to <13 months)
Less Than 1 Month (Less than 1 month)
Unknown (Unknown)
Does the patient currently require tube feeding
(12)
No (No)
Unknown (Unknown)
Yes (Yes)
Is patient dependent on tube feeding for >50% of
nutritional support (If yes,)
No (No)
Unknown (Unknown)
Yes (Yes)
Was a feeding tube inserted during this reporting
period (13)
No (No)
Unknown (Unknown)
Yes (Yes)
Date feeding tube placed (13a)
Was a feeding tube discontinued during this
reporting period (14)
No (No)
Unknown (Unknown)
Yes (Yes)
Date Feeding Tube Discontinued (IF YES,)
Was a tracheostomy performed during this
reporting period (15)
No (No)
Unknown (Unknown)
Yes (Yes)
Date trach placed (IF YES,)
Was use of a tracheostomy discontinued during
this reporting period
No (No)
Unknown (Unknown)
Yes (Yes)
Date Tracheostomy was Closed  (IF YES,)
Protocol Specific Adverse Event
Evaluation
CTC Adverse Event Term
Acidosis Nos (Acidosis (metabolic or
respiratory))
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Capillary Leak Syndrome (Acute
vascular leak syndrome)
Adrenal Insufficiency (Adrenal
insufficiency)
Adult Respiratory Distress Syndrome
(Adult respiratory distress syndrome
(ARDS))
Blood Albumin Decreased (Albumin,
serum-low (hypoalbuminemia))
Alcohol Intolerance Syndrome
(antabuse-like Syndrome) (Alcohol
intolerance syndrome (antabuse-like
syndrome))
Blood Alkaline Phosphatase Nos
Increased (Alkaline phosphatase)
Alkalosis Nos (Alkalosis (metabolic or
respiratory))
Hypersensitivity Nos (Allergic
reaction/hypersensitivity (including drug
fever))
Rhinitis Allergic Nos (Allergic rhinitis
(including sneezing, nasal stuffiness,
postnasal drip))
Allergy/immunology Other
(Allergy/Immunology-Other (Specify))
Alanine Aminotransferase Increased
(ALT, SGPT (serum glutamic pyruvic
transaminase))
Blood Amylase Increased (Amylase)
Anorexia (Anorexia)
Apnoea (Apnea)
Arachnoiditis
(Arachnoiditis/meningismus/radiculitis)
Arthritis Nos (Arthritis (non-septic))
Ascites (Ascites (non-malignant))
Aspiration (Aspiration)
Aspartate Aminotransferase Increased
(AST, SGOT (serum glutamic oxaloacetic
transaminase))
Ataxia Nec (Ataxia (incoordination))
Atelectasis (Atelectasis)
Atrophy, Skin (Atrophy, skin)
Atrophy, Subcutaneous Fat (Atrophy,
subcutaneous fat)
Auditory/ear Other (Auditory/Ear-Other
(Specify))
Autoimmune Disorder Nos (Autoimmune
reaction)
Blood Bicarbonate Decreased
(Bicarbonate, serum-low)
Blood Bilirubin Increased (Bilirubin
(hyperbilirubinemia))
Bladder Disorder Nos (Bladder spasms)
Blood/bone Marrow Other (Blood/Bone
Marrow-Other (Specify))
Bone Age (alteration In Bone Age) (Bone
age (alteration in bone age))
Bone Growth: Femoral Head; Slipped
Capital Femoral Epiphysis (Bone growth:
femoral head; slipped capital femoral
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epiphysis)
Bone Growth: Limb Length Discrepancy
(Bone growth: limb length discrepancy)
Bone Growth: Spine Kyphosis/lordosis
(Bone growth: spine kyphosis/lordosis)
Bone Marrow Depression Nos (Bone
marrow cellularity)
Bone: Spine-scoliosis (Bone: spine-
scoliosis)
Brachial Plexopathy (Brachial
plexopathy)
Breast Function/lactation (Breast
function/lactation)
Breast Nipple/areolar Deformity (Breast
nipple/areolar deformity)
Breast Volume/hypoplasia (Breast
volume/hypoplasia)
Bronchospasm, Wheezing
(Bronchospasm, wheezing)
Ecchymosis (Bruising (in absence of
grade 3 or 4 thrombocytopenia))
Burn (Burn)
Hypercalcaemia (Calcium, serum-high
(hypercalcemia))
Hypocalcaemia (Calcium, serum-low
(hypocalcemia))
Pulmonary Function Test Nos Decreased
(Carbon monoxide diffusion capacity
(DL(co)))
Arrhythmia Nos (Cardiac Arrhythmia-
Other (Specify))
Cardiac General Other (Cardiac
General-Other (Specify))
Myocardial Ischaemia (Cardiac
ischemia/infarction)
Cardiac Troponin I Increased (Cardiac
troponin I (cTnI))
Cardiac Troponin T Increased (Cardiac
troponin T (cTnT))
Cardiopulmonary Arrest, Cause
Unknown (non-fatal) (Cardiopulmonary
arrest, cause unknown (non-fatal))
Cataract Nec (Cataract)
Cd4 Lymphocytes Decreased (CD4
count)
Cervical Spine-range Of Motion (Cervical
spine-range of motion)
Chelitis (Cheilitis)
Cholecystitis (Cholecystitis)
Hypercholesteraemia (Cholesterol,
serum-high (hypercholesteremia))
Chyle Or Lymph Leakage (Chyle or
lymph leakage)
Chylothorax (Chylothorax)
Cerebral Ischaemia (CNS
cerebrovascular ischemia)
Cns Necrosis/cystic Progression (CNS
necrosis/cystic progression)
Coagulation Disorder Nos (Coagulation-
Other (Specify))
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Learning Disorder Nos (Cognitive
disturbance)
Colitis Nos (Colitis)
Colitis, Infectious (e.g., Clostridium
Difficile) (Colitis, infectious (e.g.,
Clostridium difficile))
Ventricular Asystole (Conduction
abnormality/Atrioventricular heart block -
Asystole)
Conduction Abnormality/atrioventricular
Heart Block (Conduction
abnormality/Atrioventricular heart block -
AV block-first degree)
Conduction Abnormality/atrioventricular
Heart Block - Av Block-second Degree
Mobitz Type I (wenckebach) (Conduction
abnormality/Atrioventricular heart block -
AV block-Second degree Mobitz Type I
(Wenckebach))
Conduction Abnormality/atrioventricular
Heart Block (Conduction
abnormality/Atrioventricular heart block -
AV block-second degree Mobitz Type II)
Conduction Abnormality/atrioventricular
Heart Block (Conduction
abnormality/Atrioventricular heart block -
AV block-third degree (complete AV
block))
Conduction Abnormality/atrioventricular
Heart Block (Conduction
abnormality/Atrioventricular heart block -
Conduction abnormality NOS)
Conduction Abnormality/atrioventricular
Heart Block (Conduction
abnormality/Atrioventricular heart block -
Sick sinus syndrome)
Conduction Abnormality/atrioventricular
Heart Block (Conduction
abnormality/Atrioventricular heart block -
Stokes-Adams syndrome)
Conduction Abnormality/atrioventricular
Heart Block (Conduction
abnormality/Atrioventricular heart block -
Wolff-Parkinson-White syndrome)
Confusion (Confusion)
Constipation (Constipation)
Constitutional Symptoms Other
(Constitutional Symptoms-Other
(Specify))
Cough (Cough)
Blood Creatine Phosphokinase
Increased (CPK (creatine
phosphokinase))
Blood Creatinine Increased (Creatinine)
Cushingoid (Cushingoid appearance
(e.g., moon face, buffalo hump,
centripetal obesity, cutaneous striae))
Cystitis (Cystitis)
Cytokine Release Syndrome/acute
Infusion Reaction (Cytokine release
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syndrome/acute infusion reaction)
Death Not Associated With Ctcae Term
(Death not associated with CTCAE term
- Death NOS)
Death Not Associated With Ctcae Term
(Death not associated with CTCAE term
- Disease progression NOS)
Death Not Associated With Ctcae Term
(Death not associated with CTCAE term
- Multi-organ failure)
Death Not Associated With Ctcae Term
(Death not associated with CTCAE term
- Sudden death)
Dehydration (Dehydration)
Dental: Dentures Or Prosthesis (Dental:
dentures or prosthesis)
Dental: Periodontal Disease (Dental:
periodontal disease)
Dental: Teeth (Dental: teeth)
Dental: Teeth Development (Dental:
teeth development)
Dermal Change Lymphedema,
Phlebolymphedema (Dermal change
lymphedema, phlebolymphedema)
Dermatology/skin Other
(Dermatology/Skin-Other (Specify))
Diarrhoea Nos (Diarrhea)
Disseminated Intravascular Coagulation
(DIC (disseminated intravascular
coagulation))
Distention/bloating, Abdominal
(Distention/bloating, abdominal)
Dizziness (exc Vertigo) (Dizziness)
Dry Eye Nec (Dry eye syndrome)
Dry Mouth (Dry mouth/salivary gland
(xerostomia))
Dry Skin (Dry skin)
Dysphagia (Dysphagia (difficulty
swallowing))
Dyspnoea Nos (Dyspnea (shortness of
breath))
Edema, Larynx (Edema, larynx)
Edema: Head And Neck (Edema: head
and neck)
Oedema Nos (Edema: limb)
Edema: Trunk/genital (Edema:
trunk/genital)
Edema: Viscera (Edema: viscera)
Ejaculatory Dysfunction (Ejaculatory
dysfunction)
Encephalopathy (Encephalopathy)
Endocrine Other (Endocrine-Other
(Specify))
Enteritis (inflammation Of The Small
Bowel) (Enteritis (inflammation of the
small bowel))
Impotence (Erectile dysfunction)
Oesophagitis Nos (Esophagitis)
Exostosis (Exostosis)
Extrapyramidal Disorder Nec
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(Extrapyramidal/involuntary
movement/restlessness)
Extremity-lower (gait/walking) (Extremity-
lower (gait/walking))
Extremity-upper (function) (Extremity-
upper (function))
Eyelid Dysfunction (Eyelid dysfunction)
Fatigue (Fatigue (asthenia, lethargy,
malaise))
Febrile Neutropenia (fever Of Unknown
Origin Without Clinically Or
Microbiologically Documented Infection)
(anc <1.0 X 10^9/l, Fever >=38.5
Degrees C) (Febrile neutropenia)
Feminization (Feminization of male)
Forced Expiratory Volume Decreased
(FEV(1))
Pyrexia (Fever (in the absence of
neutropenia, where neutropenia is
defined as ANC <1.0 x 10^9/L))
Blood Fibrinogen Decreased
(Fibrinogen)
Fibrosis-cosmesis (Fibrosis-cosmesis)
Fibrosis-deep Connective Tissue
(Fibrosis-deep connective tissue)
Fistula, Gi (Fistula, GI - Abdomen NOS)
Anal Fistula (Fistula, GI - Anus)
Fistula, Gi (Fistula, GI - Biliary tree)
Fistula, Gi (Fistula, GI -
Colon/cecum/appendix)
Intestinal Fistula (Fistula, GI -
Duodenum)
Tracheo-oesophageal Fistula Nos
(Fistula, GI - Esophagus)
Fistula, Gi (Fistula, GI - Gallbladder)
Fistula, Gi (Fistula, GI - Ileum)
Fistula, Gi (Fistula, GI - Jejunum)
Fistula, Gi (Fistula, GI - Oral cavity)
Fistula, Gi (Fistula, GI - Pancreas)
Fistula, Gi (Fistula, GI - Pharynx)
Fistula, Gi (Fistula, GI - Rectum)
Fistula, Gi (Fistula, GI - Salivary gland)
Fistula, Gi (Fistula, GI - Small bowel
NOS)
Fistula, Gi (Fistula, GI - Stomach)
Fistula, Gu (Fistula, GU - Bladder)
Fistula, Gu (Fistula, GU - Genital tract-
female)
Fistula, Gu (Fistula, GU - Kidney)
Fistula, Gu (Fistula, GU - Ureter)
Fistula, Gu (Fistula, GU - Urethra)
Fistula, Gu (Fistula, GU - Uterus)
Urogenital Fistula (Fistula, GU - Vagina)
Fistula, Pulmonary/upper Respiratory
(Fistula, pulmonary/upper respiratory -
Bronchus)
Fistula, Pulmonary/upper Respiratory
(Fistula, pulmonary/upper respiratory -
Larynx)
Fistula, Pulmonary/upper Respiratory
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(Fistula, pulmonary/upper respiratory -
Lung)
Fistula, Pulmonary/upper Respiratory
(Fistula, pulmonary/upper respiratory -
Oral cavity)
Fistula, Pulmonary/upper Respiratory
(Fistula, pulmonary/upper respiratory -
Pharynx)
Fistula, Pulmonary/upper Respiratory
(Fistula, pulmonary/upper respiratory -
Pleura)
Fistula, Pulmonary/upper Respiratory
(Fistula, pulmonary/upper respiratory -
Trachea)
Flatulence (Flatulence)
Flu-like Syndrome (Flu-like syndrome)
Flushing (Flushing)
Fracture (Fracture)
Gastritis Nos (Gastritis (including bile
reflux gastritis))
Gastrointestinal Other (Gastrointestinal-
Other (Specify))
Gamma-glutamyltransferase Increased
(GGT (gamma-glutamyl transpeptidase))
Glaucoma Nos (Glaucoma)
Glomerular Filtration Rate (Glomerular
filtration rate)
Hyperglycaemia Nos (Glucose, serum-
high (hyperglycemia))
Hypoglycaemia Nos (Glucose, serum-
low (hypoglycemia))
Growth And Development Other (Growth
and Development-Other (Specify))
Growth Velocity (reduction In Growth
Velocity) (Growth velocity (reduction in
growth velocity))
Gynaecomastia (Gynecomastia)
Alopecia (Hair loss/Alopecia (scalp or
body))
Haptoglobin Decreased (Haptoglobin)
Hearing: Patients With/without Baseline
Audiogram And Enrolled In A Monitoring
Program (Hearing: patients with/without
baseline audiogram and enrolled in a
monitoring program)
Hearing: Patients Without Baseline
Audiogram And Not Enrolled In A
Monitoring Program (Hearing: patients
without baseline audiogram and not
enrolled in a monitoring program)
Dyspepsia (Heartburn/dyspepsia)
Hematoma (Hematoma)
Haemoglobin Decreased (Hemoglobin)
Haemoglobinuria Present
(Hemoglobinuria)
Hemolysis Nos (Hemolysis (e.g.,
immune hemolytic anemia, drug related
hemolysis))
Haemorrhagic Stroke (Hemorrhage,
CNS)
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Melaena (Hemorrhage, GI - Abdomen
NOS)
Hemorrhage, Gi (Hemorrhage, GI -
Anus)
Hemorrhage, Gi (Hemorrhage, GI -
Biliary tree)
Hemorrhage, Gi (Hemorrhage, GI -
Cecum/appendix)
Hemorrhage, Gi (Hemorrhage, GI -
Colon)
Hemorrhage, Gi (Hemorrhage, GI -
Duodenum)
Hemorrhage, Gi (Hemorrhage, GI -
Esophagus)
Hemorrhage, Gi (Hemorrhage, GI -
Ileum)
Hemorrhage, Gi (Hemorrhage, GI -
Jejunum)
Hemorrhage, Gi (Hemorrhage, GI - Liver)
Hemorrhage, Gi (Hemorrhage, GI -
Lower GI NOS)
Hemorrhage, Gi (Hemorrhage, GI - Oral
cavity)
Hemorrhage, Gi (Hemorrhage, GI -
Pancreas)
Hemorrhage, Gi (Hemorrhage, GI -
Peritoneal cavity)
Rectal Bleeding (Hemorrhage, GI -
Rectum)
Hemorrhage, Gi (Hemorrhage, GI -
Stoma)
Haematemesis (Hemorrhage, GI -
Stomach)
Hemorrhage, Gi (Hemorrhage, GI -
Upper GI NOS)
Hemorrhage, Gi (Hemorrhage, GI -
Varices (esophageal))
Hemorrhage, Gi (Hemorrhage, GI -
Varices (rectal))
Hemorrhage, Gu (Hemorrhage, GU -
Bladder)
Hemorrhage, Gu (Hemorrhage, GU -
Fallopian tube)
Hemorrhage, Gu (Hemorrhage, GU -
Kidney)
Hemorrhage, Gu (Hemorrhage, GU -
Ovary)
Hemorrhage, Gu (Hemorrhage, GU -
Prostate)
Hemorrhage, Gu (Hemorrhage, GU -
Retroperitoneum)
Hemorrhage, Gu (Hemorrhage, GU -
Spermatic cord)
Hemorrhage, Gu (Hemorrhage, GU -
Stoma)
Hemorrhage, Gu (Hemorrhage, GU -
Testes)
Hemorrhage, Gu (Hemorrhage, GU -
Ureter)
Hemorrhage, Gu (Hemorrhage, GU -
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Urethra)
Haematuria Present (Hemorrhage, GU -
Urinary NOS)
Hemorrhage, Gu (Hemorrhage, GU -
Uterus)
Vaginal Haemorrhage (Hemorrhage, GU
- Vagina)
Hemorrhage, Gu (Hemorrhage, GU - Vas
deferens)
Hemorrhage, Pulmonary/upper
Respiratory (Hemorrhage,
pulmonary/upper respiratory -
Bronchopulmonary NOS)
Hemorrhage, Pulmonary/upper
Respiratory (Hemorrhage,
pulmonary/upper respiratory - Bronchus)
Hemorrhage, Pulmonary/upper
Respiratory (Hemorrhage,
pulmonary/upper respiratory - Larynx)
Hemorrhage, Pulmonary/upper
Respiratory (Hemorrhage,
pulmonary/upper respiratory - Lung)
Hemorrhage, Pulmonary/upper
Respiratory (Hemorrhage,
pulmonary/upper respiratory -
Mediastinum)
Epistaxis (Hemorrhage, pulmonary/upper
respiratory - Nose)
Hemorrhage, Pulmonary/upper
Respiratory (Hemorrhage,
pulmonary/upper respiratory - Pharynx)
Hemorrhage, Pulmonary/upper
Respiratory (Hemorrhage,
pulmonary/upper respiratory - Pleura)
Haemoptysis (Hemorrhage,
pulmonary/upper respiratory -
Respiratory tract NOS)
Hemorrhage, Pulmonary/upper
Respiratory (Hemorrhage,
pulmonary/upper respiratory - Stoma)
Hemorrhage, Pulmonary/upper
Respiratory (Hemorrhage,
pulmonary/upper respiratory - Trachea)
Post-operative Haemorrhage
(Hemorrhage/bleeding associated with
surgery, intra-operative or post-operative)
Hemorrhage/bleeding Other
(Hemorrhage/Bleeding-Other (Specify))
Hemorrhoids (Hemorrhoids)
Hepatobiliary/pancreas Other
(Hepatobiliary/Pancreas-Other (Specify))
Hiccups (Hiccoughs (hiccups, singultus))
Menopausal Symptoms (Hot
flashes/flushes)
Hydrocephalus (Hydrocephalus)
Skin Discolouration (Hyperpigmentation)
Hypertension Nos (Hypertension)
Hypopigmentation (Hypopigmentation)
Hypotension Nos (Hypotension)
Hypothermia (Hypothermia)
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Hypoxia (Hypoxia)
Ileus (Ileus, GI (functional obstruction of
bowel, i.e., neuroconstipation))
Incontinence, Anal (Incontinence, anal)
Urinary Incontinence (Incontinence,
urinary)
Induration/fibrosis (skin And
Subcutaneous Tissue)
(Induration/fibrosis (skin and
subcutaneous tissue))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Abdomen NOS)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Anal/perianal)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Appendix)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Artery)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Biliary tree)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Bladder (urinary))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Blood)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Bone (osteomyelitis))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
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Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Brain (encephalitis,
infectious))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Brain + Spinal cord
(encephalomyelitis))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Bronchus)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Catheter-related)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Cecum)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Cervix)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Colon)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Conjunctiva)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Cornea)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Dental-tooth)
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Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Duodenum)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Esophagus)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - External ear (otitis externa))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Eye NOS)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Fallopian tube)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Foreign body (e.g., graft,
implant, prosthesis, stent))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Gallbladder (cholecystitis))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Heart (endocarditis))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Ileum)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
17 / 50
Head and Neck Cancer NCT00265941 Follow-Up
neutrophils - Jejunum)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Joint)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Kidney)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Larynx)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Lens)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Lip/perioral)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Liver)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Lung (pneumonia))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Lymphatic)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Mediastinum NOS)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
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neutrophils - Meninges (meningitis))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Middle ear (otitis media))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Mucosa)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Muscle (infection myositis))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Neck NOS)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Nerve-cranial)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Nerve-peripheral)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Nose)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Oral cavity-gums
(gingivitis))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Pancreas)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
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microbiologically) with Grade 3 or 4
neutrophils - Paranasal)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Pelvis NOS)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Penis)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Peristomal)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Peritoneal cavity)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Pharynx)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Pleura (empyema))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Prostate)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Rectum)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Salivary gland)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
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microbiologically) with Grade 3 or 4
neutrophils - Scrotum)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Sinus)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Skin (cellulitis))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Small bowel NOS)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Soft tissue NOS)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Spinal cord (myelitis))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Spleen)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Stomach)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Trachea)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Ungual (nails))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
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microbiologically) with Grade 3 or 4
neutrophils - Upper aerodigestive NOS)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Upper airway NOS)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Ureter)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Urethra)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Urinary tract NOS)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Uterus)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Vagina)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Vein)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Vulva)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Wound)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Abdomen
NOS)
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Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils -
Anal/perianal)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Appendix)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Artery)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Biliary tree)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Bladder
(urinary))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Blood)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Bone
(osteomyelitis))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Brain
(encephalitis, infectious))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Brain +
Spinal cord (encephalomyelitis))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Bronchus)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Catheter-
related)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Cecum)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Cervix)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Colon)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils -
Conjunctiva)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Cornea)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Dental-
tooth)
Infection With Normal Anc Or Grade 1 Or
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2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Duodenum)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Esophagus)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - External ear
(otitis externa))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Eye NOS)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Fallopian
tube)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Foreign
body (e.g., graft, implant, prosthesis,
stent))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Gallbladder
(cholecystitis))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Heart
(endocarditis))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Ileum)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Jejunum)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Joint)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Kidney)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Larynx)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Lens)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Lip/perioral)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Liver)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Lung
(pneumonia))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Lymphatic)
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Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils -
Mediastinum NOS)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Meninges
(meningitis))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Middle ear
(otitis media))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Mucosa)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Muscle
(infection myositis))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Neck NOS)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Nerve-
cranial)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Nerve-
peripheral)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Nose)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Oral cavity-
gums (gingivitis))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Pancreas)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Paranasal)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Pelvis NOS)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Penis)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Peristomal)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Peritoneal
cavity)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Pharynx)
Infection With Normal Anc Or Grade 1 Or
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2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Pleura
(empyema))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Prostate)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Rectum)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Salivary
gland)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Scrotum)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Sinus)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Skin
(cellulitis))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Small bowel
NOS)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Soft tissue
NOS)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Spinal cord
(myelitis))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Spleen)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Stomach)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Trachea)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Ungual
(nails))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Upper
aerodigestive NOS)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Upper
airway NOS)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Ureter)
Infection With Normal Anc Or Grade 1 Or
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2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Urethra)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Urinary
tract NOS)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Uterus)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Vagina)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Vein)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Vulva)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Wound)
Infection With Unknown Anc (Infection
with unknown ANC - Abdomen NOS)
Infection With Unknown Anc (Infection
with unknown ANC - Anal/perianal)
Infection With Unknown Anc (Infection
with unknown ANC - Appendix)
Infection With Unknown Anc (Infection
with unknown ANC - Artery)
Infection With Unknown Anc (Infection
with unknown ANC - Biliary tree)
Infection With Unknown Anc (Infection
with unknown ANC - Bladder (urinary))
Infection With Unknown Anc (Infection
with unknown ANC - Blood)
Infection With Unknown Anc (Infection
with unknown ANC - Bone
(osteomyelitis))
Infection With Unknown Anc (Infection
with unknown ANC - Brain (encephalitis,
infectious))
Infection With Unknown Anc (Infection
with unknown ANC - Brain + Spinal cord
(encephalomyelitis))
Infection With Unknown Anc (Infection
with unknown ANC - Bronchus)
Implant Infection (Infection with unknown
ANC - Catheter-related)
Infection With Unknown Anc (Infection
with unknown ANC - Cecum)
Infection With Unknown Anc (Infection
with unknown ANC - Cervix)
Infection With Unknown Anc (Infection
with unknown ANC - Colon)
Infection With Unknown Anc (Infection
with unknown ANC - Conjunctiva)
Infection With Unknown Anc (Infection
with unknown ANC - Cornea)
Infection With Unknown Anc (Infection
with unknown ANC - Dental-tooth)
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Infection With Unknown Anc (Infection
with unknown ANC - Duodenum)
Infection With Unknown Anc (Infection
with unknown ANC - Esophagus)
Infection With Unknown Anc (Infection
with unknown ANC - External ear (otitis
externa))
Infection With Unknown Anc (Infection
with unknown ANC - Eye NOS)
Infection With Unknown Anc (Infection
with unknown ANC - Fallopian tube)
Infection With Unknown Anc (Infection
with unknown ANC - Foreign body (e.g.,
graft, implant, prosthesis, stent))
Infection With Unknown Anc (Infection
with unknown ANC - Gallbladder
(cholecystitis))
Infection With Unknown Anc (Infection
with unknown ANC - Heart
(endocarditis))
Infection With Unknown Anc (Infection
with unknown ANC - Ileum)
Infection With Unknown Anc (Infection
with unknown ANC - Jejunum)
Infection With Unknown Anc (Infection
with unknown ANC - Joint)
Infection With Unknown Anc (Infection
with unknown ANC - Kidney)
Infection With Unknown Anc (Infection
with unknown ANC - Larynx)
Infection With Unknown Anc (Infection
with unknown ANC - Lens)
Infection With Unknown Anc (Infection
with unknown ANC - Lip/perioral)
Infection With Unknown Anc (Infection
with unknown ANC - Liver)
Infection With Unknown Anc (Infection
with unknown ANC - Lung (pneumonia))
Infection With Unknown Anc (Infection
with unknown ANC - Lymphatic)
Infection With Unknown Anc (Infection
with unknown ANC - Mediastinum NOS)
Infection With Unknown Anc (Infection
with unknown ANC - Meninges
(meningitis))
Infection With Unknown Anc (Infection
with unknown ANC - Middle ear (otitis
media))
Infection With Unknown Anc (Infection
with unknown ANC - Mucosa)
Infection With Unknown Anc (Infection
with unknown ANC - Muscle (infection
myositis))
Infection With Unknown Anc (Infection
with unknown ANC - Neck NOS)
Infection With Unknown Anc (Infection
with unknown ANC - Nerve-cranial)
Infection With Unknown Anc (Infection
with unknown ANC - Nerve-peripheral)
Infection With Unknown Anc (Infection
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with unknown ANC - Nose)
Infection With Unknown Anc (Infection
with unknown ANC - Oral cavity-gums
(gingivitis))
Infection With Unknown Anc (Infection
with unknown ANC - Pancreas)
Infection With Unknown Anc (Infection
with unknown ANC - Paranasal)
Infection With Unknown Anc (Infection
with unknown ANC - Pelvis NOS)
Infection With Unknown Anc (Infection
with unknown ANC - Penis)
Infection With Unknown Anc (Infection
with unknown ANC - Peristomal)
Infection With Unknown Anc (Infection
with unknown ANC - Peritoneal cavity)
Infection With Unknown Anc (Infection
with unknown ANC - Pharynx)
Infection With Unknown Anc (Infection
with unknown ANC - Pleura (empyema))
Infection With Unknown Anc (Infection
with unknown ANC - Prostate)
Infection With Unknown Anc (Infection
with unknown ANC - Rectum)
Infection With Unknown Anc (Infection
with unknown ANC - Salivary gland)
Infection With Unknown Anc (Infection
with unknown ANC - Scrotum)
Infection With Unknown Anc (Infection
with unknown ANC - Sinus)
Infection With Unknown Anc (Infection
with unknown ANC - Skin (cellulitis))
Infection With Unknown Anc (Infection
with unknown ANC - Small bowel NOS)
Infection With Unknown Anc (Infection
with unknown ANC - Soft tissue NOS)
Infection With Unknown Anc (Infection
with unknown ANC - Spinal cord
(myelitis))
Infection With Unknown Anc (Infection
with unknown ANC - Spleen)
Infection With Unknown Anc (Infection
with unknown ANC - Stomach)
Infection With Unknown Anc (Infection
with unknown ANC - Trachea)
Infection With Unknown Anc (Infection
with unknown ANC - Ungual (nails))
Infection With Unknown Anc (Infection
with unknown ANC - Upper aerodigestive
NOS)
Infection With Unknown Anc (Infection
with unknown ANC - Upper airway NOS)
Infection With Unknown Anc (Infection
with unknown ANC - Ureter)
Infection With Unknown Anc (Infection
with unknown ANC - Urethra)
Infection With Unknown Anc (Infection
with unknown ANC - Urinary tract NOS)
Infection With Unknown Anc (Infection
with unknown ANC - Uterus)
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Infection With Unknown Anc (Infection
with unknown ANC - Vagina)
Infection With Unknown Anc (Infection
with unknown ANC - Vein)
Infection With Unknown Anc (Infection
with unknown ANC - Vulva)
Culture Wound Positive (Infection with
unknown ANC - Wound)
Infection Nos (Infection-Other (Specify))
Infertility/sterility (Infertility/sterility)
Injection Site Reaction Nos (Injection site
reaction/extravasation changes)
Prothrombin Time Prolonged (INR
(International Normalized Ratio of
prothrombin time))
Insomnia Nec (Insomnia)
Intra-operative Injury (Intra-operative
injury - Abdomen NOS)
Intra-operative Injury (Intra-operative
injury - Adrenal gland)
Intra-operative Injury (Intra-operative
injury - Anal sphincter)
Intra-operative Injury (Intra-operative
injury - Anus)
Intra-operative Injury (Intra-operative
injury - Appendix)
Intra-operative Injury (Intra-operative
injury - Artery NOS)
Intra-operative Injury (Intra-operative
injury - Artery-aorta)
Intra-operative Injury (Intra-operative
injury - Artery-carotid)
Intra-operative Injury (Intra-operative
injury - Artery-cerebral)
Intra-operative Injury (Intra-operative
injury - Artery-extremity (lower))
Intra-operative Injury (Intra-operative
injury - Artery-extremity (upper))
Intra-operative Injury (Intra-operative
injury - Artery-hepatic)
Intra-operative Injury (Intra-operative
injury - Artery-major visceral artery)
Intra-operative Injury (Intra-operative
injury - Artery-pulmonary)
Intra-operative Injury (Intra-operative
injury - Biliary tree NOS)
Intra-operative Injury (Intra-operative
injury - Biliary tree-common bile duct)
Intra-operative Injury (Intra-operative
injury - Biliary tree-common hepatic duct)
Intra-operative Injury (Intra-operative
injury - Biliary tree-left hepatic duct)
Intra-operative Injury (Intra-operative
injury - Biliary tree-right hepatic duct)
Bladder Perforation Postoperative (Intra-
operative injury - Bladder)
Intra-operative Injury (Intra-operative
injury - Bone)
Intra-operative Injury (Intra-operative
injury - Brachial plexus)
30 / 50
Head and Neck Cancer NCT00265941 Follow-Up
Intra-operative Injury (Intra-operative
injury - Brain)
Intra-operative Injury (Intra-operative
injury - Breast)
Intra-operative Injury (Intra-operative
injury - Bronchus)
Intra-operative Injury (Intra-operative
injury - Cartilage)
Intra-operative Injury (Intra-operative
injury - Cecum)
Intra-operative Injury (Intra-operative
injury - Cervix)
Intra-operative Injury (Intra-operative
injury - CN I (olfactory))
Intra-operative Injury (Intra-operative
injury - CN II (optic))
Intra-operative Injury (Intra-operative
injury - CN III (oculomotor))
Intra-operative Injury (Intra-operative
injury - CN IV (trochlear))
Intra-operative Injury (Intra-operative
injury - CN IX (glossopharyngeal) motor
pharynx)
Intra-operative Injury (Intra-operative
injury - CN IX (glossopharyngeal)
sensory ear-pharynx-tongue)
Intra-operative Injury (Intra-operative
injury - CN V (trigeminal) motor)
Intra-operative Injury (Intra-operative
injury - CN V (trigeminal) sensory)
Intra-operative Injury (Intra-operative
injury - CN VI (abducens))
Intra-operative Injury (Intra-operative
injury - CN VII (facial) motor-face)
Intra-operative Injury (Intra-operative
injury - CN VII (facial) sensory-taste)
Intra-operative Injury (Intra-operative
injury - CN VIII (vestibulocochlear))
Intra-operative Injury (Intra-operative
injury - CN X (vagus))
Intra-operative Injury (Intra-operative
injury - CN XI (spinal accessory))
Intra-operative Injury (Intra-operative
injury - CN XII (hypoglossal))
Intra-operative Injury (Intra-operative
injury - Colon)
Intra-operative Injury (Intra-operative
injury - Conjunctiva)
Intra-operative Injury (Intra-operative
injury - Cornea)
Intra-operative Injury (Intra-operative
injury - Cranial nerve or branch NOS)
Intra-operative Injury (Intra-operative
injury - Duodenum)
Intra-operative Injury (Intra-operative
injury - Esophagus)
Intra-operative Injury (Intra-operative
injury - Extremity-lower)
Intra-operative Injury (Intra-operative
injury - Extremity-upper)
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Intra-operative Injury (Intra-operative
injury - Eye NOS)
Intra-operative Injury (Intra-operative
injury - Face NOS)
Intra-operative Injury (Intra-operative
injury - Fallopian tube)
Intra-operative Injury (Intra-operative
injury - Gallbladder)
Intra-operative Injury (Intra-operative
injury - Gingiva)
Intra-operative Injury (Intra-operative
injury - Heart)
Intra-operative Injury (Intra-operative
injury - Ileum)
Intra-operative Injury (Intra-operative
injury - Inner ear)
Intra-operative Injury (Intra-operative
injury - Jejunum)
Intra-operative Injury (Intra-operative
injury - Joint)
Intra-operative Injury (Intra-operative
injury - Kidney)
Intra-operative Injury (Intra-operative
injury - Larynx)
Intra-operative Injury (Intra-operative
injury - Lens)
Intra-operative Injury (Intra-operative
injury - Ligament)
Intra-operative Injury (Intra-operative
injury - Lingual)
Intra-operative Injury (Intra-operative
injury - Lip/perioral area)
Intra-operative Injury (Intra-operative
injury - Liver)
Intra-operative Injury (Intra-operative
injury - Lung)
Intra-operative Injury (Intra-operative
injury - Lung thoracic)
Intra-operative Injury (Intra-operative
injury - Mediastinum)
Intra-operative Injury (Intra-operative
injury - Meninges)
Intra-operative Injury (Intra-operative
injury - Middle ear)
Intra-operative Injury (Intra-operative
injury - Muscle)
Intra-operative Injury (Intra-operative
injury - Nails)
Intra-operative Injury (Intra-operative
injury - Nasal cavity)
Intra-operative Injury (Intra-operative
injury - Nasopharynx)
Intra-operative Injury (Intra-operative
injury - Neck NOS)
Intra-operative Injury (Intra-operative
injury - Nose)
Intra-operative Injury (Intra-operative
injury - Oral)
Intra-operative Injury (Intra-operative
injury - Oral cavity NOS)
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Intra-operative Injury (Intra-operative
injury - Outer ear NOS)
Intra-operative Injury (Intra-operative
injury - Outer ear-pinna)
Intra-operative Injury (Intra-operative
injury - Ovary)
Intra-operative Injury (Intra-operative
injury - Pancreas)
Intra-operative Injury (Intra-operative
injury - Pancreatic duct)
Intra-operative Injury (Intra-operative
injury - Parathyroid)
Intra-operative Injury (Intra-operative
injury - Parotid gland)
Intra-operative Injury (Intra-operative
injury - Pelvis NOS)
Intra-operative Injury (Intra-operative
injury - Penis)
Intra-operative Injury (Intra-operative
injury - Peripheral motor NOS)
Intra-operative Injury (Intra-operative
injury - Peripheral sensory NOS)
Intra-operative Injury (Intra-operative
injury - Peritoneal cavity)
Intra-operative Injury (Intra-operative
injury - Pharynx)
Intra-operative Injury (Intra-operative
injury - Pituitary)
Intra-operative Injury (Intra-operative
injury - Pleura)
Intra-operative Injury (Intra-operative
injury - Prostate)
Intra-operative Injury (Intra-operative
injury - Rectum)
Intra-operative Injury (Intra-operative
injury - Recurrent laryngeal)
Intra-operative Injury (Intra-operative
injury - Retina)
Intra-operative Injury (Intra-operative
injury - Sacral plexus)
Intra-operative Injury (Intra-operative
injury - Salivary duct)
Intra-operative Injury (Intra-operative
injury - Salivary gland)
Intra-operative Injury (Intra-operative
injury - Sciatic)
Intra-operative Injury (Intra-operative
injury - Scrotum)
Intra-operative Injury (Intra-operative
injury - Sinus)
Intra-operative Injury (Intra-operative
injury - Skin)
Intra-operative Injury (Intra-operative
injury - Small bowel NOS)
Intra-operative Injury (Intra-operative
injury - Soft tissue NOS)
Intra-operative Injury (Intra-operative
injury - Spinal cord)
Intra-operative Injury (Intra-operative
injury - Spleen)
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Intra-operative Injury (Intra-operative
injury - Stoma (GI))
Intra-operative Injury (Intra-operative
injury - Stomach)
Intra-operative Injury (Intra-operative
injury - Teeth)
Intra-operative Injury (Intra-operative
injury - Tendon)
Intra-operative Injury (Intra-operative
injury - Testis)
Intra-operative Injury (Intra-operative
injury - Thoracic duct)
Intra-operative Injury (Intra-operative
injury - Thoracodorsal)
Intra-operative Injury (Intra-operative
injury - Thyroid)
Intra-operative Injury (Intra-operative
injury - Tongue)
Intra-operative Injury (Intra-operative
injury - Trachea)
Intra-operative Injury (Intra-operative
injury - Upper aerodigestive NOS)
Intra-operative Injury (Intra-operative
injury - Upper airway NOS)
Intra-operative Injury (Intra-operative
injury - Ureter)
Intra-operative Injury (Intra-operative
injury - Urethra)
Intra-operative Injury (Intra-operative
injury - Urinary conduit)
Intra-operative Injury (Intra-operative
injury - Urinary tract NOS)
Intra-operative Injury (Intra-operative
injury - Uterus)
Intra-operative Injury (Intra-operative
injury - Vagina)
Intra-operative Injury - Vein (Intra-
operative injury - Vein NOS)
Intra-operative Injury (Intra-operative
injury - Vein-extremity (lower))
Intra-operative Injury (Intra-operative
injury - Vein-extremity (upper))
Intra-operative Injury (Intra-operative
injury - Vein-hepatic)
Intra-operative Injury (Intra-operative
injury - Vein-inferior vena cava)
Intra-operative Injury (Intra-operative
injury - Vein-jugular)
Intra-operative Injury (Intra-operative
injury - Vein-major visceral vein)
Intra-operative Injury (Intra-operative
injury - Vein-portal vein)
Intra-operative Injury (Intra-operative
injury - Vein-pulmonary)
Intra-operative Injury (Intra-operative
injury - Vein-superior vena cava)
Intra-operative Injury (Intra-operative
injury - Vulva)
Intra-operative Injury Other (Intra-
operative Injury-Other (Specify))
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Iron Overload (Iron overload)
Menstruation Irregular (Irregular menses
(change from baseline))
Irritability (Irritability (children <3 years of
age))
Joint-effusion (Joint-effusion)
Joint-effusion (Joint-function)
Keratitis Nec (Keratitis (corneal
inflammation/corneal ulceration))
Laryngeal Nerve Dysfunction (Laryngeal
nerve dysfunction)
Leak (including Anastomotic), Gi (Leak
(including anastomotic), GI - Biliary tree)
Leak (including Anastomotic), Gi (Leak
(including anastomotic), GI - Esophagus)
Leak (including Anastomotic), Gi (Leak
(including anastomotic), GI - Large
bowel)
Leak (including Anastomotic), Gi (Leak
(including anastomotic), GI - Leak NOS)
Leak (including Anastomotic), Gi (Leak
(including anastomotic), GI - Pancreas)
Leak (including Anastomotic), Gi (Leak
(including anastomotic), GI - Pharynx)
Leak (including Anastomotic), Gi (Leak
(including anastomotic), GI - Rectum)
Leak (including Anastomotic), Gi (Leak
(including anastomotic), GI - Small
bowel)
Leak (including Anastomotic), Gi (Leak
(including anastomotic), GI - Stoma)
Leak (including Anastomotic), Gi (Leak
(including anastomotic), GI - Stomach)
Leak (including Anastomotic), Gu (Leak
(including anastomotic), GU - Bladder)
Leak (including Anastomotic), Gu (Leak
(including anastomotic), GU - Fallopian
tube)
Leak (including Anastomotic), Gu (Leak
(including anastomotic), GU - Kidney)
Leak (including Anastomotic), Gu (Leak
(including anastomotic), GU - Spermatic
cord)
Leak (including Anastomotic), Gu (Leak
(including anastomotic), GU - Stoma)
Leak (including Anastomotic), Gu (Leak
(including anastomotic), GU - Ureter)
Leak (including Anastomotic), Gu (Leak
(including anastomotic), GU - Urethra)
Leak (including Anastomotic), Gu (Leak
(including anastomotic), GU - Uterus)
Leak (including Anastomotic), Gu (Leak
(including anastomotic), GU - Vagina)
Leak (including Anastomotic), Gu (Leak
(including anastomotic), GU - Vas
deferens)
Leak, Cerebrospinal Fluid (csf) (Leak,
cerebrospinal fluid (CSF))
Left Ventricular Diastolic Dysfunction
(Left ventricular diastolic dysfunction)
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Left Ventricular Failure (Left ventricular
systolic dysfunction)
Leucopenia Nos (Leukocytes (total
WBC))
Encephalopathy Nos
(Leukoencephalopathy (radiolographic
findings))
Libido Decreased (Libido)
Lipase Increased (Lipase)
Hepatic Failure (Liver dysfunction/failure
(clinical))
Local Complication - Device/prosthesis-
related (Local complication -
device/prosthesis-related)
Lumbar Spine-range Of Motion (Lumbar
spine-range of motion)
Lymphatics Other (Lymphatics-Other
(Specify))
Lymphedema-related Fibrosis
(Lymphedema-related fibrosis)
Lymphocele (Lymphocele)
Lymphopenia (Lymphopenia)
Hypermagnesaemia (Magnesium,
serum-high (hypermagnesemia))
Blood Magnesium Decreased
(Magnesium, serum-low
(hypomagnesemia))
Malabsorption (Malabsorption)
Virilism (Masculinization of female)
Amnesia Nec (Memory impairment)
Mental Status (Mental status)
Metabolic/laboratory Other
(Metabolic/Laboratory-Other (Specify))
Mood Alteration - Agitation (Mood
alteration - agitation)
Anxiety Nec (Mood alteration - anxiety)
Depression Nec (Mood alteration -
depression)
Euphoric Mood (Mood alteration -
euphoria)
Mucositis/stomatitis (clinical Exam)
(Mucositis/stomatitis (clinical exam) -
Anus)
Mucositis/stomatitis (clinical Exam)
(Mucositis/stomatitis (clinical exam) -
Esophagus)
Mucositis/stomatitis (clinical Exam)
(Mucositis/stomatitis (clinical exam) -
Large bowel)
Mucositis/stomatitis (clinical Exam)
(Mucositis/stomatitis (clinical exam) -
Larynx)
Mucositis/stomatitis (clinical Exam)
(Mucositis/stomatitis (clinical exam) -
Oral cavity)
Stomatitis (Mucositis/stomatitis (clinical
exam) - Pharynx)
Mucositis/stomatitis (clinical Exam)
(Mucositis/stomatitis (clinical exam) -
Rectum)
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Mucositis/stomatitis (clinical Exam)
(Mucositis/stomatitis (clinical exam) -
Small bowel)
Mucositis/stomatitis (clinical Exam)
(Mucositis/stomatitis (clinical exam) -
Stomach)
Mucositis/stomatitis (clinical Exam)
(Mucositis/stomatitis (clinical exam) -
Trachea)
Mucositis/stomatitis
(functional/symptomatic)
(Mucositis/stomatitis
(functional/symptomatic) - Anus)
Mucositis/stomatitis
(functional/symptomatic)
(Mucositis/stomatitis
(functional/symptomatic) - Esophagus)
Mucositis/stomatitis
(functional/symptomatic)
(Mucositis/stomatitis
(functional/symptomatic) - Large bowel)
Mucositis/stomatitis
(functional/symptomatic)
(Mucositis/stomatitis
(functional/symptomatic) - Larynx)
Mucositis/stomatitis
(functional/symptomatic)
(Mucositis/stomatitis
(functional/symptomatic) - Oral cavity)
Mucositis/stomatitis
(functional/symptomatic)
(Mucositis/stomatitis
(functional/symptomatic) - Pharynx)
Mucositis/stomatitis
(functional/symptomatic)
(Mucositis/stomatitis
(functional/symptomatic) - Rectum)
Mucositis/stomatitis
(functional/symptomatic)
(Mucositis/stomatitis
(functional/symptomatic) - Small bowel)
Mucositis/stomatitis
(functional/symptomatic)
(Mucositis/stomatitis
(functional/symptomatic) - Stomach)
Mucositis/stomatitis
(functional/symptomatic)
(Mucositis/stomatitis
(functional/symptomatic) - Trachea)
Muscle Weakness, Generalized Or
Specific Area (not Due To Neuropathy)
(Muscle weakness, generalized or
specific area (not due to neuropathy) -
Extraocular)
Muscle Weakness, Generalized Or
Specific Area (not Due To Neuropathy)
(Muscle weakness, generalized or
specific area (not due to neuropathy) -
Extremity-lower)
Muscle Weakness, Generalized Or
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Specific Area (not Due To Neuropathy)
(Muscle weakness, generalized or
specific area (not due to neuropathy) -
Extremity-upper)
Muscle Weakness, Generalized Or
Specific Area (not Due To Neuropathy)
(Muscle weakness, generalized or
specific area (not due to neuropathy) -
Facial)
Muscle Weakness, Generalized Or
Specific Area (not Due To Neuropathy)
(Muscle weakness, generalized or
specific area (not due to neuropathy) -
Left-sided)
Muscle Weakness, Generalized Or
Specific Area (not Due To Neuropathy)
(Muscle weakness, generalized or
specific area (not due to neuropathy) -
Ocular)
Muscle Weakness, Generalized Or
Specific Area (not Due To Neuropathy)
(Muscle weakness, generalized or
specific area (not due to neuropathy) -
Pelvic)
Muscle Weakness, Generalized Or
Specific Area (not Due To Neuropathy)
(Muscle weakness, generalized or
specific area (not due to neuropathy) -
Right-sided)
Muscle Weakness, Generalized Or
Specific Area (not Due To Neuropathy)
(Muscle weakness, generalized or
specific area (not due to neuropathy) -
Trunk)
Muscle Weakness Nos (Muscle
weakness, generalized or specific area
(not due to neuropathy) - Whole
body/generalized)
Muscular/skeletal Hypoplasia
(Muscular/skeletal hypoplasia)
Musculoskeletal/soft Tissue Other
(Musculoskeletal/Soft Tissue-Other
(Specify))
Myelitis (Myelitis)
Myelodysplasia (Myelodysplasia)
Myocarditis Nos (Myocarditis)
Myositis (Myositis (inflammation/damage
of muscle))
Nail Abnormality Nos (Nail changes)
Nasal Cavity/paranasal Sinus Reactions
(Nasal cavity/paranasal sinus reactions)
Nausea (Nausea)
Necrosis, Gi (Necrosis, GI - Anus)
Necrosis, Gi (Necrosis, GI -
Colon/cecum/appendix)
Necrosis, Gi (Necrosis, GI - Duodenum)
Necrosis, Gi (Necrosis, GI - Esophagus)
Necrosis, Gi (Necrosis, GI - Gallbladder)
Necrosis, Gi (Necrosis, GI - Hepatic)
Necrosis, Gi (Necrosis, GI - Ileum)
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Necrosis, Gi (Necrosis, GI - Jejunum)
Necrosis, Gi (Necrosis, GI - Oral)
Necrosis, Gi (Necrosis, GI - Pancreas)
Necrosis, Gi (Necrosis, GI - Peritoneal
cavity)
Necrosis, Gi (Necrosis, GI - Pharynx)
Necrosis, Gi (Necrosis, GI - Rectum)
Necrosis, Gi (Necrosis, GI - Small bowel
NOS)
Necrosis, Gi (Necrosis, GI - Stoma)
Necrosis, Gi (Necrosis, GI - Stomach)
Neuroendocrine: Acth Deficiency
(Neuroendocrine: ACTH deficiency)
Inappropriate Adh Secretion
(Neuroendocrine: ADH secretion
abnormality (e.g., SIADH or low ADH))
Neuroendocrine: Gonadotropin Secretion
Abnormality (Neuroendocrine:
gonadotropin secretion abnormality)
Neuroendocrine: Growth Hormone
Secretion Abnormality (Neuroendocrine:
growth hormone secretion abnormality)
Neuroendocrine: Prolactin Hormone
Secretion Abnormality (Neuroendocrine:
prolactin hormone secretion abnormality)
Neurology Other (Neurology-Other
(Specify))
Parosmia (Neuropathy: cranial - CN I
Smell)
Cranial Nerve Injury Nos (Neuropathy:
cranial - CN II Vision)
Neuropathy: Cranial (Neuropathy: cranial
- CN III Pupil, upper eyelid, extra ocular
movements)
Neuropathy: Cranial (Neuropathy: cranial
- CN IV Downward, inward movement of
eye)
Neuropathy: Cranial (Neuropathy: cranial
- CN IX Motor-pharynx; Sensory-ear,
pharynx, tongue)
Neuropathy: Cranial (Neuropathy: cranial
- CN V Motor-jaw muscles; Sensory-
facial)
Neuropathy: Cranial (Neuropathy: cranial
- CN VI Lateral deviation of eye)
Neuropathy: Cranial (Neuropathy: cranial
- CN VII Motor-face; Sensory-taste)
Neuropathy: Cranial (Neuropathy: cranial
- CN VIII Hearing and balance)
Neuropathy: Cranial (Neuropathy: cranial
- CN X Motor-palate; pharynx, larynx)
Neuropathy: Cranial (Neuropathy: cranial
- CN XI Motor-sternomastoid and
trapezius)
Neuropathy: Cranial (Neuropathy: cranial
- CN XII Motor-tongue)
Peripheral Motor Neuropathy
(Neuropathy: motor)
Peripheral Sensory Neuropathy
(Neuropathy: sensory)
39 / 50
Head and Neck Cancer NCT00265941 Follow-Up
Neutropenia (Neutrophils/granulocytes
(ANC/AGC))
Blindness Night (Night blindness
(nyctalopia))
Nystagmus Nos (Nystagmus)
Obesity (Obesity)
Obstruction, Gi (Obstruction, GI -
Cecum)
Obstruction, Gi (Obstruction, GI - Colon)
Obstruction, Gi (Obstruction, GI -
Duodenum)
Obstruction, Gi (Obstruction, GI -
Esophagus)
Obstruction, Gi (Obstruction, GI -
Gallbladder)
Obstruction, Gi (Obstruction, GI - Ileum)
Obstruction, Gi (Obstruction, GI -
Jejunum)
Obstruction, Gi (Obstruction, GI -
Rectum)
Obstruction, Gi (Obstruction, GI - Small
bowel NOS)
Obstruction, Gi (Obstruction, GI - Stoma)
Obstruction, Gi (Obstruction, GI -
Stomach)
Obstruction, Gu (Obstruction, GU -
Bladder)
Obstruction, Gu (Obstruction, GU -
Fallopian tube)
Obstruction, Gu (Obstruction, GU -
Prostate)
Obstruction, Gu (Obstruction, GU -
Spermatic cord)
Obstruction, Gu (Obstruction, GU -
Stoma)
Obstruction, Gu (Obstruction, GU -
Testes)
Ureteric Obstruction (Obstruction, GU -
Ureter)
Obstruction, Gu (Obstruction, GU -
Urethra)
Obstruction, Gu (Obstruction, GU -
Uterus)
Obstruction, Gu (Obstruction, GU -
Vagina)
Obstruction, Gu (Obstruction, GU - Vas
deferens)
Obstruction/stenosis Of Airway
(Obstruction/stenosis of airway -
Bronchus)
Obstruction/stenosis Of Airway
(Obstruction/stenosis of airway - Larynx)
Obstruction/stenosis Of Airway
(Obstruction/stenosis of airway -
Pharynx)
Obstruction/stenosis Of Airway
(Obstruction/stenosis of airway -
Trachea)
Conjunctivitis Nec (Ocular surface
disease)
40 / 50
Head and Neck Cancer NCT00265941 Follow-Up
Ocular/visual Other (Ocular/Visual-Other
(Specify))
Odor (patient Odor) (Odor (patient odor))
Diplopia (Ophthalmoplegia/diplopia
(double vision))
Opportunistic Infection Associated With
>=grade 2 Lymphopenia (Opportunistic
infection associated with >=Grade 2
lymphopenia)
Optic Disc Edema (Optic disc edema)
Orgasmic Dysfunction (Orgasmic
dysfunction)
Osteonecrosis (Osteonecrosis (avascular
necrosis))
Osteoporosis (Osteoporosis)
Otitis Externa (exc Boil Of Meatus) Nos
(Otitis, external ear (non-infectious))
Otitis Media Serous Nos (Otitis, middle
ear (non-infectious))
Abdominal Pain Nos (Pain - Abdomen
NOS)
Pain (Pain - Anus)
Pain (Pain - Back)
Pain (Pain - Bladder)
Bone Pain (Pain - Bone)
Pain (Pain - Breast)
Pain (Pain - Buttock)
Pain (Pain - Cardiac/heart)
Pain (Pain - Chest wall)
Chest Pain (Pain - Chest/thorax NOS)
Pain (Pain - Dental/teeth/peridontal)
Pain (Pain - Esophagus)
Earache (Pain - External ear)
Pain (Pain - Extremity-limb)
Pain (Pain - Eye)
Pain (Pain - Face)
Pain (Pain - Gallbladder)
Headache Nos (Pain - Head/headache)
Pain (Pain - Intestine)
Arthralgia (Pain - Joint)
Pain (Pain - Kidney)
Pain (Pain - Larynx)
Pain (Pain - Lip)
Hepatic Pain (Pain - Liver)
Pain (Pain - Lymph node)
Pain (Pain - Middle ear)
Myalgia (Pain - Muscle)
Pain (Pain - Neck)
Neuralgia Nos (Pain -
Neuralgia/peripheral nerve)
Pain (Pain - Oral cavity)
Pain (Pain - Oral-gums)
Pain (Pain - Ovulatory)
Pain (Pain - Pain NOS)
Pelvic Pain Nos (Pain - Pelvis)
Pain (Pain - Penis)
Pain (Pain - Pericardium)
Pain (Pain - Perineum)
Pain (Pain - Peritoneum)
Pain (Pain - Phantom (pain associated
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with missing limb))
Pleuritic Pain (Pain - Pleura)
Pain (Pain - Prostate)
Proctalgia (Pain - Rectum)
Pain (Pain - Scalp)
Pain (Pain - Scrotum)
Pain (Pain - Sinus)
Pain (Pain - Skin)
Pain (Pain - Stomach)
Pain (Pain - Testicle)
Pain (Pain - Throat/pharynx/larynx)
Tumour Pain (Pain - Tumor pain)
Dysuria (Pain - Urethra)
Dysmenorrhoea (Pain - Uterus)
Pain (Pain - Vagina)
Pain Other (Pain-Other (Specify))
Palpitations (Palpitations)
Pancreas, Exocrine Enzyme Deficiency
(Pancreas, exocrine enzyme deficiency)
Pancreatic Endocrine: Glucose
Intolerance (Pancreatic endocrine:
glucose intolerance)
Pancreatitis Nos (Pancreatitis)
Parathyroid Function, Low
(hypoparathyroidism) (Parathyroid
function, low (hypoparathyroidism))
Perforation, Gi (Perforation, GI -
Appendix)
Perforation, Gi (Perforation, GI - Biliary
tree)
Perforation, Gi (Perforation, GI - Cecum)
Perforation, Gi (Perforation, GI - Colon)
Perforation, Gi (Perforation, GI -
Duodenum)
Perforation, Gi (Perforation, GI -
Esophagus)
Perforation, Gi (Perforation, GI -
Gallbladder)
Perforation, Gi (Perforation, GI - Ileum)
Perforation, Gi (Perforation, GI -
Jejunum)
Perforation, Gi (Perforation, GI - Rectum)
Perforation, Gi (Perforation, GI - Small
bowel NOS)
Perforation, Gi (Perforation, GI -
Stomach)
Perforation, Gu (Perforation, GU -
Bladder)
Perforation, Gu (Perforation, GU -
Fallopian tube)
Perforation, Gu (Perforation, GU -
Kidney)
Perforation, Gu (Perforation, GU - Ovary)
Perforation, Gu (Perforation, GU -
Prostate)
Perforation, Gu (Perforation, GU -
Spermatic cord)
Perforation, Gu (Perforation, GU -
Stoma)
Perforation, Gu (Perforation, GU -
42 / 50
Head and Neck Cancer NCT00265941 Follow-Up
Testes)
Perforation, Gu (Perforation, GU - Ureter)
Perforation, Gu (Perforation, GU -
Urethra)
Perforation, Gu (Perforation, GU -
Uterus)
Perforation, Gu (Perforation, GU -
Vagina)
Perforation, Gu (Perforation, GU - Vas
deferens)
Pericardial Effusion (Pericardial effusion
(non-malignant))
Pericarditis (Pericarditis)
Peripheral Ischaemia Nos (Peripheral
arterial ischemia)
Personality Change
(Personality/behavioral)
Petechiae (Petechiae/purpura
(hemorrhage/bleeding into skin or
mucosa))
Phlebitis Superficial (Phlebitis (including
superficial thrombosis))
Phlebolymphatic Cording
(Phlebolymphatic cording)
Hypophosphataemia (Phosphate, serum-
low (hypophosphatemia))
Photosensitivity Reaction Nos
(Photosensitivity)
Phrenic Nerve Dysfunction (Phrenic
nerve dysfunction)
Platelet Count Decreased (Platelets)
Pleural Effusion (Pleural effusion (non-
malignant))
Pneumonitis Nos
(Pneumonitis/pulmonary infiltrates)
Pneumothorax Nos (Pneumothorax)
Portal Hypertension (Portal vein flow)
Hyperkalaemia (Potassium, serum-high
(hyperkalemia))
Hypokalaemia (Potassium, serum-low
(hypokalemia))
Proctitis Nos (Proctitis)
Prolapse Of Stoma, Gi (Prolapse of
stoma, GI)
Prolapse Of Stoma, Gu (Prolapse of
stoma, GU)
Prolonged Chest Tube Drainage Or Air
Leak After Pulmonary Resection
(Prolonged chest tube drainage or air
leak after pulmonary resection)
Prolonged Intubation After Pulmonary
Resection (>24 Hrs After Surgery)
(Prolonged intubation after pulmonary
resection (>24 hrs after surgery))
Electrocardiogram Qt Prolonged
(Prolonged QTc interval)
Proptosis/enophthalmos
(Proptosis/enophthalmos)
Proteinuria Present (Proteinuria)
Pruritus Nos (Pruritus/itching)
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Delusion Nos (Psychosis
(hallucinations/delusions))
Activated Partial Thromboplastin Time
Prolonged (PTT (Partial thromboplastin
time))
Puberty (delayed) (Puberty (delayed))
Puberty (precocious) (Puberty
(precocious))
Pulmonary Fibrosis (Pulmonary fibrosis
(radiographic changes))
Pulmonary Hypertension (Pulmonary
hypertension)
Pulmonary/upper Respiratory Other
(Pulmonary/Upper Respiratory-Other
(Specify))
Upper Motor Neurone Lesion (Pyramidal
tract dysfunction (e.g., increased tone,
hyperreflexia, positive Babinski,
decreased fine motor coordination))
Rash: Acne/acneiform (Rash:
acne/acneiform)
Radiation Recall Syndrome (Rash:
dermatitis associated with radiation -
Chemoradiation)
Dermatitis Radiation Nos (Rash:
dermatitis associated with radiation -
Radiation)
Erythema Multiforme (Rash: erythema
multiforme (e.g., Stevens-Johnson
syndrome, toxic epidermal necrolysis))
Localised Exfoliation (Rash: hand-foot
skin reaction)
Dermatitis Exfoliative Nos
(Rash/desquamation)
Renal Failure Nos (Renal failure)
Renal/genitourinary Other
(Renal/Genitourinary-Other (Specify))
Restrictive Cardiomyopathy (Restrictive
cardiomyopathy)
Retinal Detachment (Retinal
detachment)
Retinoic Acid Syndrome (Retinoic acid
syndrome")
Retinopathy (Retinopathy)
Right Ventricular Dysfunction (cor
Pulmonale) (Right ventricular dysfunction
(cor pulmonale))
Rigors (Rigors/chills)
Salivary Gland Disorder Nos (Salivary
gland changes/saliva)
Scleral Necrosis/melt (Scleral
necrosis/melt)
Secondary Malignancy Possibly Related
To Cancer Treatment (Secondary
Malignancy-possibly related to cancer
treatment (Specify))
Convulsions Nos (Seizure)
Seroma (Seroma)
Serum Sickness (Serum sickness)
Sexual/reproductive Function Other
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(Sexual/Reproductive Function-Other
(Specify))
Short Stature (Short stature)
Skin Breakdown/decubitus Ulcer (Skin
breakdown/decubitus ulcer)
Hypernatraemia (Sodium, serum-high
(hypernatremia))
Hyponatraemia (Sodium, serum-low
(hyponatremia))
Soft Tissue Necrosis (Soft tissue
necrosis - Abdomen)
Soft Tissue Necrosis (Soft tissue
necrosis - Extremity-lower)
Soft Tissue Necrosis (Soft tissue
necrosis - Extremity-upper)
Soft Tissue Necrosis (Soft tissue
necrosis - Head)
Soft Tissue Necrosis (Soft tissue
necrosis - Neck)
Soft Tissue Necrosis (Soft tissue
necrosis - Pelvic)
Soft Tissue Necrosis (Soft tissue
necrosis - Thorax)
Depressed Level Of Consciousness
(Somnolence/depressed level of
consciousness)
Speech Disorder Nec (Speech
impairment (e.g., dysphasia or aphasia))
Splenic Function (Splenic function)
Striae (Striae)
Stricture/stenosis (including
Anastomotic), Gi (Stricture/stenosis
(including anastomotic), GI - Anus)
Stricture/stenosis (including
Anastomotic), Gi (Stricture/stenosis
(including anastomotic), GI - Biliary tree)
Stricture/stenosis (including
Anastomotic), Gi (Stricture/stenosis
(including anastomotic), GI - Cecum)
Stricture/stenosis (including
Anastomotic), Gi (Stricture/stenosis
(including anastomotic), GI - Colon)
Stricture/stenosis (including
Anastomotic), Gi (Stricture/stenosis
(including anastomotic), GI - Duodenum)
Stricture/stenosis (including
Anastomotic), Gi (Stricture/stenosis
(including anastomotic), GI - Esophagus)
Stricture/stenosis (including
Anastomotic), Gi (Stricture/stenosis
(including anastomotic), GI - Ileum)
Stricture/stenosis (including
Anastomotic), Gi (Stricture/stenosis
(including anastomotic), GI - Jejunum)
Stricture/stenosis (including
Anastomotic), Gi (Stricture/stenosis
(including anastomotic), GI -
Pancreas/pancreatic duct)
Stricture/stenosis (including
Anastomotic), Gi (Stricture/stenosis
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(including anastomotic), GI - Pharynx)
Stricture/stenosis (including
Anastomotic), Gi (Stricture/stenosis
(including anastomotic), GI - Rectum)
Stricture/stenosis (including
Anastomotic), Gi (Stricture/stenosis
(including anastomotic), GI - Small bowel
NOS)
Stricture/stenosis (including
Anastomotic), Gi (Stricture/stenosis
(including anastomotic), GI - Stoma)
Stricture/stenosis (including
Anastomotic), Gi (Stricture/stenosis
(including anastomotic), GI - Stomach)
Stricture/stenosis (including
Anastomotic), Gu (Stricture/stenosis
(including anastomotic), GU - Bladder)
Stricture/stenosis (including
Anastomotic), Gu (Stricture/stenosis
(including anastomotic), GU - Fallopian
tube)
Stricture/stenosis (including
Anastomotic), Gu (Stricture/stenosis
(including anastomotic), GU - Prostate)
Stricture/stenosis (including
Anastomotic), Gu (Stricture/stenosis
(including anastomotic), GU - Spermatic
cord)
Stricture/stenosis (including
Anastomotic), Gu (Stricture/stenosis
(including anastomotic), GU - Stoma)
Stricture/stenosis (including
Anastomotic), Gu (Stricture/stenosis
(including anastomotic), GU - Testes)
Stricture/stenosis (including
Anastomotic), Gu (Stricture/stenosis
(including anastomotic), GU - Ureter)
Stricture/stenosis (including
Anastomotic), Gu (Stricture/stenosis
(including anastomotic), GU - Urethra)
Stricture/stenosis (including
Anastomotic), Gu (Stricture/stenosis
(including anastomotic), GU - Uterus)
Stricture/stenosis (including
Anastomotic), Gu (Stricture/stenosis
(including anastomotic), GU - Vagina)
Stricture/stenosis (including
Anastomotic), Gu (Stricture/stenosis
(including anastomotic), GU - Vas
deferens)
Supraventricular And Nodal Arrhythmia
(Supraventricular and nodal arrhythmia -
Atrial fibrillation)
Supraventricular And Nodal Arrhythmia
(Supraventricular and nodal arrhythmia -
Atrial flutter)
Supraventricular And Nodal Arrhythmia
(Supraventricular and nodal arrhythmia -
Atrial tachycardia/paroxysmal atrial
tachycardia)
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Supraventricular And Nodal Arrhythmia
(Supraventricular and nodal arrhythmia -
Nodal/junctional)
Supraventricular And Nodal Arrhythmia
(Supraventricular and nodal arrhythmia -
Sinus arrhythmia)
Sinus Bradycardia (Supraventricular and
nodal arrhythmia - Sinus bradycardia)
Sinus Tachycardia (Supraventricular and
nodal arrhythmia - Sinus tachycardia)
Supraventricular Arrhythmia Nos
(Supraventricular and nodal arrhythmia -
Supraventricular arrhythmia NOS)
Supraventricular And Nodal Arrhythmia -
Supraventricular Extrasystoles
(premature Atrial Contractions;
Premature Nodal/junctional
Contractions) (Supraventricular and
nodal arrhythmia - Supraventricular
extrasystoles (premature atrial
contractions; premature nodal/junctional
contractions))
Supraventricular And Nodal Arrhythmia
(Supraventricular and nodal arrhythmia -
Supraventricular tachycardia)
Sweating Increased (Sweating
(diaphoresis))
Syncope (Syncope (fainting))
Syndromes Other (Syndromes-Other
(Specify))
Taste Disturbance (Taste alteration
(dysgeusia))
Telangiectasia (Telangiectasia)
Thrombosis/embolism (vascular Access-
related) (Thrombosis/embolism (vascular
access-related))
Thrombosis Nos
(Thrombosis/thrombus/embolism)
Thrombotic Microangiopathy (e.g.,
Thrombotic Thrombocytopenic
Purpura[ttp] Or Hemolytic Uremic
Syndrome[hus]) (Thrombotic
microangiopathy (e.g., thrombotic
thrombocytopenic purpura or hemolytic
uremic syndrome))
Thyroid Function, High (hyperthyroidism,
Thyrotoxicosis) (Thyroid function, high
(hyperthyroidism, thyrotoxicosis))
Hypothyroidism (Thyroid function, low
(hypothyroidism))
Tinnitus (Tinnitus)
Tremor Nec (Tremor)
Hypertriglyceridaemia (Triglyceride,
serum-high (hypertriglyceridemia))
Trismus (difficulty, Restriction Or Pain
When Opening Mouth) (Trismus
(difficulty, restriction or pain when
opening mouth))
Tumour Flare (Tumor flare)
Tumour Lysis Syndrome (Tumor lysis
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syndrome)
Caecitis (Typhlitis (cecal inflammation))
Ulcer, Gi (Ulcer, GI - Anus)
Ulcer, Gi (Ulcer, GI - Cecum)
Ulcer, Gi (Ulcer, GI - Colon)
Duodenal Ulcer (Ulcer, GI - Duodenum)
Ulcer, Gi (Ulcer, GI - Esophagus)
Ulcer, Gi (Ulcer, GI - Ileum)
Ulcer, Gi (Ulcer, GI - Jejunum)
Ulcer, Gi (Ulcer, GI - Rectum)
Ulcer, Gi (Ulcer, GI - Small bowel NOS)
Ulcer, Gi (Ulcer, GI - Stoma)
Gastric Ulcer (Ulcer, GI - Stomach)
Ulceration (Ulceration)
Hyperuricaemia (Uric acid, serum-high
(hyperuricemia))
Fanconi Syndrome (Urinary electrolyte
wasting (e.g., Fanconi's syndrome, renal
tubular acidosis))
Urinary Frequency (Urinary
frequency/urgency)
Urinary Retention (Urinary retention
(including neurogenic bladder))
Urine Discolouration (Urine color
change)
Urticaria Nos (Urticaria (hives, welts,
wheals))
Uveitis (Uveitis)
Vaginal Discharge (non-infectious)
(Vaginal discharge (non-infectious))
Vulvovaginal Dryness (Vaginal dryness)
Vaginal Mucositis (Vaginal mucositis)
Vaginal Stenosis/length (Vaginal
stenosis/length)
Vaginitis (Vaginitis (not due to infection))
Valvular Heart Disease (Valvular heart
disease)
Vascular Other (Vascular-Other
(Specify))
Vasculitis Nos (Vasculitis)
Vasovagal Attack (Vasovagal episode)
Ventricular Arrhythmia (Ventricular
arrhythmia - Bigeminy)
Ventricular Arrhythmia (Ventricular
arrhythmia - Idioventricular rhythm)
Ventricular Arrhythmia (Ventricular
arrhythmia - PVCs)
Ventricular Arrhythmia (Ventricular
arrhythmia - Torsade de pointes)
Ventricular Arrhythmia (Ventricular
arrhythmia - Trigeminy)
Ventricular Arrhythmia Nos (Ventricular
arrhythmia - Ventricular arrhythmia NOS)
Ventricular Arrhythmia (Ventricular
arrhythmia - Ventricular fibrillation)
Ventricular Arrhythmia (Ventricular
arrhythmia - Ventricular flutter)
Ventricular Arrhythmia (Ventricular
arrhythmia - Ventricular tachycardia)
Vessel Injury-artery (Vessel injury-artery
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- Aorta)
Vessel Injury-artery (Vessel injury-artery
- Carotid)
Vessel Injury-artery (Vessel injury-artery
- Extremity-lower)
Vessel Injury-artery (Vessel injury-artery
- Extremity-upper)
Vessel Injury-artery (Vessel injury-artery
- Other NOS)
Vessel Injury-artery (Vessel injury-artery
- Visceral)
Vessel Injury-vein (Vessel injury-vein -
Extremity-lower)
Vessel Injury-vein (Vessel injury-vein -
Extremity-upper)
Vessel Injury-vein (Vessel injury-vein -
IVC)
Vessel Injury-vein (Vessel injury-vein -
Jugular)
Vessel Injury-vein (Vessel injury-vein -
Other NOS)
Vessel Injury-vein (Vessel injury-vein -
SVC)
Vessel Injury-vein (Vessel injury-vein -
Viscera)
Viral Hepatitis (Viral hepatitis)
Visceral Arterial Ischaemia (Visceral
arterial ischemia (non-myocardial))
Vision Blurred (Vision-blurred vision)
Photopsia (Vision-flashing lights/floaters)
Photophobia (Vision-photophobia)
Vital Capacity (Vital capacity)
Vitreous Hemorrhage (Vitreous
hemorrhage)
Dysphonia (Voice changes/dysarthria
(e.g., hoarseness, loss or alteration in
voice, laryngitis))
Vomiting Nos (Vomiting)
Lacrimation Increased (Watery eye
(epiphora, tearing))
Weight Increased (Weight gain)
Weight Decreased (Weight loss)
Culture Wound Negative (Wound
complication, non-infectious)
MedDRA Code
CTC AE Grade
CTCAE Begin Date
CTC AE Attribution Code (A. Attribution to
Protocol Treatment: See protocol sections 6&7 for
definition of "protocol treatment" 1=unrelated;
2=unlikely; 3=possible; 4=probable; 5=definite)
Definite (Definite)
Possible (Possible)
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Probable (Probable)
Unlikely (Unlikely)
Unrelated (Unrelated)
Serious adverse event report submitted (B.
Adverse Event report submitted: 1=No; 2=Yes;
9=Unknown)
No (No)
Unknown (Unknown)
Yes (Yes)
Comments
Protocol Specific Adverse Event
Evaluation
New or continuing adverse events (Not reported
in Q6)
No (No)
Unknown (Unknown)
Yes (Yes)
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AML - AZA (5-Azacytidin plus
Standardtherapie bei älteren AML-Patienten)
A randomized, multi-center phase II trial to assess the
efficacy of 5-azacytidine added to standard primary therapy
in elderly patients with newly diagnosed AML
Principal Investigator Prof. Dr. Müller-Tidow
All rights reserved. Please visit https://medical-data-
models.org/forms/10162
Knochenmark-Diagnostik Tag 15
Patientendaten
Pat.-Nr.:*
Knochenmarkuntersuchung
Datum - Knochenmarkuntersuchung*
Obligater Materialversand (Knochenmark + Blut)
zur Bestimmung des Methylierungsstatus nach:*
Münster (1)
Dresden (2)
Frankfurt (3)
kein Versand weil (kein Versand weil)
kein Versand weil*
Versand einer Beckenkammbiopsie nach:*
Münster (1)
Dresden (2)
Frankfurt (3)
kein Versand weil (kein Versand weil)
kein Versand weil*
Zytologie
Blastenanteil*
<5% (1)
> (2)
nicht beurteilbar (3)
wenn >=5%, dann bitte angeben
2. Induktionstherapie geplant? [ja
(Dokumentation weiter auf Seite 13), nein
(Dokumentation weiter auf Seite 17)] *
Ja
Nein
Unterschrift
Datum:*
Name/Unterschrift Prüfarzt*
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Distress Thermometer
Copyright National Comprehensive Cancer Network
German Version:
Anja Mehnert, Diana Müller, Claudia Lehmann und Uwe
Koch. Die deutsche Version des NCCN Distress-
Thermometers. Empirische Prüfung eines Screening-
Instruments zur Erfassung psychosozialer Belastung bei
Krebspatienten. Zeitschrift für Psychiatrie, Psychologie und
Psychotherapie, 54 (3), 2006, 213–223
All rights reserved. Please visit https://medical-data-
models.org/forms/10167
NCCN Distress Thermometer
Distress Thermometer
Anleitung: ERSTENS: Bitte kreisen Sie die Zahl
ein (0-10), die am besten beschreibt, wie belastet
Sie sich in der letzten Woche einschließlich heute
gefühlt haben.
Gar nicht belastet (0)
1 (1)
Extrem belastet (10)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
7 (7)
8 (8)
9 (9)
Praktische Probleme
Wohnsituation
Ja
Nein
Versicherung
Ja
Nein
Arbeit/Schule
Ja
Nein
Beförderung (Transport)
Ja
Nein
Kinderbetreuung
Ja
Nein
Familiäre Probleme
Im Umgang mit dem Partner
Ja
Nein
Im Umgang mit den Kindern
Ja
Nein
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Emotionale Probleme
Sorgen
Ja
Nein
Ängste
Ja
Nein
Traurigkeit
Ja
Nein
Depression
Ja
Nein
Nervosität
Ja
Nein
Spirituelle/religiöse Belange
In Bezug auf Gott
Ja
Nein
Verlust des Glaubens
Ja
Nein
Körperliche Probleme
Schmerzen
Ja
Nein
Übelkeit
Ja
Nein
Erschöpfung
Ja
Nein
Schlaf
Ja
Nein
Bewegung/Mobilität
Ja
Nein
Waschen, Ankleiden
Ja
Nein
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Äußeres Erscheinungsbild
Ja
Nein
Atmung
Ja
Nein
Entzündungen im Mundbereich
Ja
Nein
Essen/Ernährung
Ja
Nein
Verdauungsstörungen
Ja
Nein
Verstopfung
Ja
Nein
Durchfall
Ja
Nein
Veränderungen beim Wasser lassen
Ja
Nein
Fieber
Ja
Nein
Trockene/juckende Haut
Ja
Nein
Trockene/verstopfte Nase
Ja
Nein
Kribbeln in Händen/Füßen
Ja
Nein
Angeschwollen/aufgedunsen fühlen
Ja
Nein
Sexuelle Probleme
Ja
Nein
Sonstige Probleme
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Head and Neck Cancer Follow-Up RTOG
0920 NCT00956007
RTOG 0920 Phase III Head and Neck Cancer Follow-Up
Form (F1)
Radiation Therapy With or Without Cetuximab in Treating
Patients Who Have Undergone Surgery for Locally
Advanced Head and Neck Cancer
NCT00956007
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=5D3AF115-
95FB-1246-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/10168
Follow-Up Head and Neck Cancer
NCT00956007
Header
RTOG Study No.
Case #
Institution Name
Institution No.
Patient Initials
RTOG Patient ID
Amended data
Yes
No
COMMENTS
Person Completing Form
Form completion date, original (MM DD YYYY)
Follow-Up
Date of Last Contact or Death (MM/DD/YYYY)
Patient's Vital Status
Alive (Alive)
Dead (Dead)
Primary Cause of Death
Due To Other Cause (Due to other
cause)
Due To Protocol Treatment (Due to
protocol treatment)
Due To Second Primary Or Other
Malignancy (Due to second primary or
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other malignancy)
Due To This Disease (Due to this
disease)
Unknown (Unknown)
Due to protocol treatment, specify
Due to other cause specify
Swallowing and Tube Feeding
Does the patient currently have swallowing
problems
No (No)
Unknown (Unknown)
Yes (Yes)
How long have swallowing problems been
present (IF YES,)
1 To <7 Months (1 to <7 months)
13 To <19 Months (13 to <19 months)
19 To <24 Months (19 to <24 months)
2 Years Or Longer (2 years or longer)
7 To <13 Months (7 to <13 months)
Less Than 1 Month (Less than 1 month)
Unknown (Unknown)
Does the patient currently require tube feeding
No (No)
Unknown (Unknown)
Yes (Yes)
Is patient dependent on tube feeding for >50% of
nutritional support (If yes,)
No (No)
Unknown (Unknown)
Yes (Yes)
Was a feeding tube inserted during this reporting
period
No (No)
Unknown (Unknown)
Yes (Yes)
Date feeding tube placed (MM/DD/YYYY)
Was a feeding tube discontinued during this
reporting period
No (No)
Unknown (Unknown)
Yes (Yes)
Date Feeding Tube Discontinued (IF YES,
MM/DD/YYYY)
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Was a tracheostomy performed during this
reporting period
No (No)
Unknown (Unknown)
Yes (Yes)
Date trach placed (IF YES, MM/DD/YYYY)
Was use of a tracheostomy discontinued during
this reporting period
No (No)
Unknown (Unknown)
Yes (Yes)
Date Tracheostomy was Closed  (IF YES,
MM/DD/YYYY)
Has the patient had a documented clinical
assessment for this cancer? (SINCE
SUBMISSION OF THE PREVIOUS FOLLOW-UP
FORM)
No (No)
Unknown (Unknown)
Yes (Yes)
Date of Last Clinical Assessment (MM/DD/YYYY)
Disease Events
Has the patient been diagnosed with first local
recurrence or progression (since submission of
the previous follow-up form)
No (No)
Not Applicable, Patient Has Not Been
Assessed (Not applicable, patient has
not been assessed)
Unknown (Unknown)
Yes (Yes)
Date of First Local Progression (MM DD YYYY)
Has the patient been diagnosed with first regional
recurrence or progression (since submission of
the previous follow-up form)
No (No)
Not Applicable, Patient Has Not Been
Assessed (Not applicable, patient has
not been assessed)
Unknown (Unknown)
Yes (Yes)
Date of first regional progression (MM DD YYYY)
Has the patient been diagnosed with first distant
recurrence/progression? (since submission of the
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previous follow-up form)
No (No)
Not Applicable, Patient Has Not Been
Assessed (Not applicable, patient has
not been assessed)
Unknown (Unknown)
Yes (Yes)
Date of First Distant Progression (MM DD YYYY)
Site(s) of distant progression
Bladder (Bladder)
Brain (Brain)
Colorectal (Colorectal)
Esophageal (Esophageal)
Gastric (Gastric)
Hypopharynx (Hypopharynx)
Larynx (Larynx)
Liver (Liver)
Lung (Lung)
Nasopharynx (Nasopharynx)
None (None)
Oral Cavity (Oral cavity)
Oropharynx (Oropharynx)
Other H + N (Other H + N)
Other Solid (Other solid)
Pancreatic (Pancreatic)
Renal (Renal)
Squamous-skin (Squamous-Skin)
Other solid, specify
Has a new primary cancer or MDS been
diagnosed that has not been previously reported?
(MYELODYSPLASTIC SYNDROME SINCE
SUBMISSION OF THE PREVIOUS FOLLOW-UP
FORM)
No (No)
Unknown (Unknown)
Yes (Yes)
Site(s) of new primary
Aml/mds (AML/MDS)
Bcc (BCC)
Bladder (Bladder)
Brain (Brain)
Colorectal (Colorectal)
Esophageal (Esophageal)
Gastric (Gastric)
Hypopharynx (Hypopharynx)
Larynx (Larynx)
Liver (Liver)
Lung (Lung)
Melanoma (Melanoma)
Nasopharynx (Nasopharynx)
Nhl (NHL)
None (None)
Oral Cavity (Oral cavity)
Oropharynx (Oropharynx)
4 / 6
Head and Neck Cancer Follow-Up RTOG 0920 NCT00956007
Other H + N (Other H + N)
Other Hematologic (Other Hematologic)
Other Solid (Other solid)
Pancreatic (Pancreatic)
Prostate (Prostate)
Renal (Renal)
Squamous-skin (Squamous-Skin)
Unknown Primary (Unknown primary)
Other Hematologic, specify
Other solid, specify
Date of diagnosis  (MM/DD/YYYY)
ADDITIONAL NON-PROTOCOL
TREATMENT FOR CANCER
Non-Protocol Therapy Type (begun since
submission of previous follow-up form)
Biologic/targeted Therapy
(Biologic/targeted therapy)
None (None)
Other Specify (Other)
Radiation To Node(s) (Radiation to
node(s))
Radiation To Other Sites, Specify
(Radiation to other sites)
Radiation To Primary (Radiation to
primary)
Surgery For Other Cancer (Surgery for
other cancer)
Surgery For Study Cancer (Surgery for
study cancer)
Systemic Therapy (Systemic therapy)
Unknown (Unknown)
Non-protocol Therapy Start Date
Details
Protocol Specific Adverse Event
Evaluation
CTC Adverse Event Term
CTC AE Grade
CTCAE Begin Date (MM DD YYYY)
5 / 6
Head and Neck Cancer Follow-Up RTOG 0920 NCT00956007
CTC AE Attribution Code
Definite (Definite)
Possible (Possible)
Probable (Probable)
Unlikely (Unlikely)
Unrelated (Unrelated)
SAE report submitted
No (No)
Unknown (Unknown)
Yes (Yes)
New or continuing adverse events (not reported
in Q15-16)
No (No)
Unknown (Unknown)
Yes (Yes)
MedDRA Code
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Multiple Myeloma NCT00602641
E1A06 Adverse Event Form (CTCAE v3)
Melphalan, Prednisone, and Thalidomide or Lenalidomide
in Treating Patients With Newly Diagnosed Multiple
Myeloma
NCT00602641
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=406515E8-
0840-569A-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/10169
Adverse Event Multiple Myeloma
(CTCAE v3) E1A06 NCT00602641
Header
ECOG Protocol Number
ECOG Patient ID
DCI Name
Registration Step (Place ID Label Here)
Patient Initials (Last, First)
Participating Group Protocol Number
Participating Group Patient ID
Institution/Affiliate
Please mark an 'X' if data have been amended.
Date data amended
Investigator Signature
Investigator Signature Date
On Treatment
On Treatment Report Period (Maintenance
Therapy: Begins with Cycle 13)
> Cycle 34 (> Cycle 34)
Cycle 14 (Cycle 14)
Cycle 16 (Cycle 16)
Cycle 18 (Cycle 18)
Cycle 20 (Cycle 20)
Cycle 22 (Cycle 22)
Cycle 24 (Cycle 24)
Cycle 26 (Cycle 26)
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Cycle 28 (Cycle 28)
Cycle 30 (Cycle 30)
Cycle 32 (Cycle 32)
Cycle 34 (Cycle 34)
Specify Cycle
Off Treatment Report Period (Choose one)
9 Years (108 months post registration)
12 Months (12 Months Post Registration)
10 Years (120 months post registration)
15 Months (15 Months Post Registration)
18 Months (18 Months Post Registration)
21 Months Post Registration (21 Months
Post Registration)
2 Years (24 Months Post Registration)
3 Months (3 Months Post Registration)
30 Months (30 Months Post Registration)
3 Years (36 Months Post Registration)
42 Months (42 Months Post Registration)
4 Years (48 Months Post Registration)
54 Months (54 Months Post Registration)
6 Months (6 Months Post Registration)
5 Years (60 Months Post Registration)
6 Years (72 Months Post Registration)
84 Months Post Registration (84 Months
Post Registration)
9 Months (9 Months Post Registration)
8 Years (96 months post registration)
Adverse Event
Were adverse events assessed during this report
period (cycle)
No (0)
Yes, But No Reportable Adverse Events
Occurred (1)
Yes, And Reportable Adverse Events
Occurred (2)
CTC Adverse Event Report Begin Date (For the
dates below, record the start and end dates of the
time period within current report period in which
patient was assessed for adverse events. -
mm/dd/yyyy)
CTC Adverse Event Report End Date (For the
dates below, record the start and end dates of the
time period within current report period in which
patient was assessed for adverse events. -
mm/dd/yyyy)
Blood/Bone Marrow - Labs
CTC Adverse Event Term (Type)
Confusion (Confusion)
Constipation (Constipation)
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Dizziness (exc Vertigo) (Dizziness)
Dyspnoea Nos (Dyspnea (shortness of
breath))
Oedema Nos (Edema: limb)
Fatigue (Fatigue (asthenia, lethargy,
malaise))
Pyrexia (Fever (in the absence of
neutropenia, where neutropenia is
defined as ANC <1.0 x 10^9/L))
Nausea (Nausea)
Peripheral Sensory Neuropathy
(Neuropathy: sensory)
Pruritus Nos (Pruritus/itching)
Dermatitis Exfoliative Nos
(Rash/desquamation)
Thrombosis Nos
(Thrombosis/thrombus/embolism)
Vomiting Nos (Vomiting)
Weight Decreased (Weight loss)
CTC Adverse Event Grade (this report period)
CTC Adverse Event Attribution Scale
Definite (definite)
Possible (possible)
Probable (probable)
Unlikely (unlikely)
Unrelated (unrelated)
Adverse event infection
CTC Adverse Event Short Name
Acidosis NOS (Acidosis)
Rash: Acne/acneiform (Acne)
Neuroendocrine: ACTH Deficiency
(ACTH)
Capillary Leak Syndrome (Acute
vascular leak syndrome)
Inappropriate ADH Secretion (ADH)
Adrenal Insufficiency (Adrenal
insufficiency)
Obstruction/stenosis Of Airway (Airway
obstruction - Select)
Alcohol Intolerance Syndrome
(antabuse-like Syndrome) (Alcohol
intolerance syndrome)
Blood Alkaline Phosphatase NOS
Increased (Alkaline phosphatase)
Alkalosis  NOS (Alkalosis)
Hypersensitivity NOS (Allergic reaction)
Allergy/immunology Other (Allergy-Other
(Specify))
Alopecia (Alopecia)
Alanine Aminotransferase Increased
(ALT)
Blood Amylase Increased (Amylase)
Anorexia (Anorexia)
Apnoea (Apnea)
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Arachnoiditis (Arachnoiditis)
Adult Respiratory Distress Syndrome
(ARDS)
Vessel Injury-artery (Artery injury -
Select)
Arthritis Nos (Arthritis)
Ascites (Ascites)
Aspiration (Aspiration)
Aspartate Aminotransferase Increased
(AST)
Ataxia NEC (Ataxia)
Atelectasis (Atelectasis)
Atrophy, Skin (Atrophy, skin)
Atrophy, Subcutaneous Fat (Atrophy,
subcutaneous fat)
Auditory/ear Other (Auditory/Ear-Other
(Specify))
Autoimmune Disorder NOS
(Autoimmune reaction)
Blood Bicarbonate Decreased
(Bicarbonate, serum-low)
Blood Bilirubin Increased (Bilirubin)
Bladder Disorder Nos (Bladder spasms)
Blood/bone Marrow Other (Blood-Other
(Specify))
Vision Blurred (Blurred vision)
Bone Age (alteration In Bone Age) (Bone
age)
Bone Marrow Depression Nos (Bone
marrow cellularity)
Brachial Plexopathy (Brachial
plexopathy)
Breast Volume/hypoplasia (Breast)
Breast Function/lactation (Breast
function)
Bronchospasm, Wheezing
(Bronchospasm)
Ecchymosis (Bruising)
Burn (Burn)
Arrhythmia Nos (Cardiac Arrhythmia-
Other (Specify))
Cardiac General Other (Cardiac
General-Other (Specify))
Myocardial Ischaemia (Cardiac
ischemia/infarction)
Cardiopulmonary Arrest, Cause
Unknown (non-fatal) (Cardiopulmonary
arrest)
Cataract Nec (Cataract)
Cd4 Lymphocytes Decreased (CD4
count)
Cervical Spine-range Of Motion (Cervical
spine ROM)
Cheilitis (Cheilitis)
Prolonged Chest Tube Drainage Or Air
Leak After Pulmonary Resection (Chest
tube drainage or leak)
Cholecystitis (Cholecystitis)
Hypercholesterolaemia (Cholesterol)
Chyle Or Lymph Leakage (Chyle or
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lymph leakage)
Chylothorax (Chylothorax)
Haemorrhagic Stroke (CNS
Hemorrhage)
Cerebral Ischaemia (CNS ischemia)
Cns Necrosis/cystic Progression (CNS
necrosis)
Coagulation Disorder Nos (Coagulation-
Other (Specify))
Learning Disorder Nos (Cognitive
disturbance)
Colitis Nos (Colitis)
Colitis, Infectious (e.g., Clostridium
Difficile) (Colitis, infectious)
Conduction Abnormality/atrioventricular
Heart Block (Conduction abnormality -
Select)
Confusion (Confusion)
Constipation (Constipation)
Constitutional Symptoms Other
(Constitutional Symptoms-Other
(Specify))
Cough (Cough)
Blood Creatine Phosphokinase
Increased (CPK)
Blood Creatinine Increased (Creatinine)
Leak, Cerebrospinal Fluid (csf) (CSF
leak)
Cardiac Troponin I Increased (cTnI)
Cardiac Troponin T Increased (cTnT)
Cushingoid (Cushingoid)
Cystitis (Cystitis)
Cytokine Release Syndrome/acute
Infusion Reaction (Cytokine release
syndrome)
Death Not Associated With Ctcae Term
(Death not associated with CTCAE term
- Select)
Skin Breakdown/decubitus Ulcer
(Decubitus)
Dehydration (Dehydration)
Puberty (delayed) (Delayed puberty)
Dental: Dentures Or Prosthesis
(Dentures)
Dermal Change Lymphedema,
Phlebolymphedema (Dermal change)
Dermatitis (Dermatitis - Select)
Dermatology/skin Other (Dermatology-
Other (Specify))
Local Complication - Device/prosthesis-
related (Device/prosthesis)
Pancreatic Endocrine: Glucose
Intolerance (Diabetes)
Diarrhoea Nos (Diarrhea)
Disseminated Intravascular Coagulation
(DIC)
Diplopia (Diplopia)
Distention/bloating, Abdominal
(Distention)
Dizziness (exc Vertigo) (Dizziness)
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Pulmonary Function Test Nos Decreased
(DL(co))
Dry Eye Nec (Dry eye)
Dry Mouth (Dry mouth)
Dry Skin (Dry skin)
Dysphagia (Dysphagia)
Dyspnoea Nos (Dyspnea)
Edema, Larynx (Edema, larynx)
Edema: Head And Neck (Edema: head
and neck)
Oedema Nos (Edema: limb)
Edema: Trunk/genital (Edema:
trunk/genital)
Edema: Viscera (Edema: viscera)
Ejaculatory Dysfunction (Ejaculatory
dysfunction)
Encephalopathy (Encephalopathy)
Endocrine Other (Endocrine-Other
(Specify))
Enteritis (inflammation Of The Small
Bowel) (Enteritis)
Impotence (Erectile dysfunction)
Erythema Multiforme (Erythema
multiforme)
Oesophagitis Nos (Esophagitis)
Exostosis (Exostosis)
Extremity-upper (function) (Extremity-
upper (function))
Eyelid Dysfunction (Eyelid dysfunction)
Fatigue (Fatigue)
Febrile Neutropenia (fever Of Unknown
Origin Without Clinically Or
Microbiologically Documented Infection)
(anc <1.0 X 10^9/l, Fever > (Febrile
neutropenia)
Feminization (Feminization of male)
Bone Growth: Femoral Head; Slipped
Capital Femoral Epiphysis (Femoral
head growth)
Forced Expiratory Volume Decreased
(FEV(1))
Pyrexia (Fever)
Blood Fibrinogen Decreased
(Fibrinogen)
Fibrosis-cosmesis (Fibrosis-cosmesis)
Fibrosis-deep Connective Tissue
(Fibrosis-deep connective tissue)
Fistula, Gi (Fistula, GI - Select)
Fistula, Gu (Fistula, GU - Select)
Fistula, Pulmonary/upper Respiratory
(Fistula, pulmonary - Select)
Photopsia (Flashing lights)
Flatulence (Flatulence)
Flu-like Syndrome (Flu-like syndrome)
Flushing (Flushing)
Fracture (Fracture)
Extremity-lower (gait/walking)
(Gait/walking)
Gastritis Nos (Gastritis)
Glomerular Filtration Rate (GFR)
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Gamma-glutamyltransferase Increased
(GGT)
Gastrointestinal Other (GI-Other
(Specify))
Glaucoma Nos (Glaucoma)
Neuroendocrine: Gonadotropin Secretion
Abnormality (Gonadotropin)
Growth And Development Other (Growth
and Development-Other (Specify))
Neuroendocrine: Growth Hormone
Secretion Abnormality (Growth hormone)
Gynaecomastia (Gynecomastia)
Localised Exfoliation (Hand-foot)
Haptoglobin Decreased (Haptoglobin)
Hearing: Patients With/without Baseline
Audiogram And Enrolled In A Monitoring
Program (Hearing (monitoring program))
Hearing: Patients Without Baseline
Audiogram And Not Enrolled In A
Monitoring Program (Hearing (without
monitoring program))
Dyspepsia (Heartburn)
Hematoma (Hematoma)
Haemoglobin Decreased (Hemoglobin)
Haemoglobinuria Present
(Hemoglobinuria)
Hemolysis Nos (Hemolysis)
Hemorrhage, Pulmonary/upper
Respiratory (Hemorrhage pulmonary -
Select)
Post-operative Haemorrhage
(Hemorrhage with surgery)
Hemorrhage/bleeding Other
(Hemorrhage-Other (Specify))
Hemorrhage, Gi (Hemorrhage, GI -
Select)
Hemorrhage, Gu (Hemorrhage, GU -
Select)
Hemorrhoids (Hemorrhoids)
Hepatobiliary/pancreas Other
(Hepatobiliary-Other (Specify))
Hiccups (Hiccoughs)
Menopausal Symptoms (Hot flashes)
Hydrocephalus (Hydrocephalus)
Hypercalcaemia (Hypercalcemia)
Hyperglycaemia Nos (Hyperglycemia)
Hyperkalaemia (Hyperkalemia)
Hypermagnesaemia
(Hypermagnesemia)
Hypernatraemia (Hypernatremia)
Skin Discolouration (Hyperpigmentation)
Hypertension Nos (Hypertension)
Thyroid Function, High (hyperthyroidism,
Thyrotoxicosis) (Hyperthyroidism)
Hypertriglyceridaemia
(Hypertriglyceridemia)
Hyperuricaemia (Hyperuricemia)
Blood Albumin Decreased
(Hypoalbuminemia)
Hypocalcaemia (Hypocalcemia)
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Hypoglycaemia Nos (Hypoglycemia)
Hypokalaemia (Hypokalemia)
Blood Magnesium Decreased
(Hypomagnesemia)
Hyponatraemia (Hyponatremia)
Parathyroid Function, Low
(hypoparathyroidism)
(Hypoparathyroidism)
Hypophosphataemia
(Hypophosphatemia)
Hypopigmentation (Hypopigmentation)
Hypotension Nos (Hypotension)
Hypothermia (Hypothermia)
Hypothyroidism (Hypothyroidism)
Hypoxia (Hypoxia)
Ileus (Ileus)
Urinary Incontinence (Incontinence)
Incontinence, Anal (Incontinence, anal)
Induration/fibrosis (skin And
Subcutaneous Tissue) (Induration)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically) - Select)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
- Select)
Infection With Unknown Anc (Infection
with unknown ANC - Select)
Infection Nos (Infection-Other (Specify))
Infertility/sterility (Infertility/sterility)
Injection Site Reaction Nos (Injection site
reaction)
Prothrombin Time Prolonged (INR)
Insomnia Nec (Insomnia)
Intra-operative Injury (Intraop injury -
Select)
Intra-operative Injury Other (Intraop
Injury-Other (Specify))
Extrapyramidal Disorder Nec (Involuntary
movement)
Iron Overload (Iron overload)
Menstruation Irregular (Irregular menses)
Irritability (Irritability)
Joint-effusion (Joint-effusion)
Joint-function (Joint-function)
Keratitis Nec (Keratitis)
Bone Growth: Spine Kyphosis/lordosis
(Kyphosis/lordosis)
Laryngeal Nerve Dysfunction (Laryngeal
nerve)
Leak (including Anastomotic), Gi (Leak,
GI - Select)
Leak (including Anastomotic), Gu (Leak,
GU - Select)
Left Ventricular Diastolic Dysfunction
(Left ventricular diastolic dysfunction)
Left Ventricular Failure (Left ventricular
systolic dysfunction)
Leucopenia Nos (Leukocytes)
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Encephalopathy Nos
(Leukoencephalopathy)
Libido Decreased (Libido)
Bone Growth: Limb Length Discrepancy
(Limb length)
Lipase Increased (Lipase)
Hepatic Failure (Liver dysfunction)
Lumbar Spine-range Of Motion (Lumbar
spine ROM)
Lymphatics Other (Lymphatics-Other
(Specify))
Lymphedema-related Fibrosis
(Lymphedema-related fibrosis)
Lymphocele (Lymphocele)
Lymphopenia (Lymphopenia)
Malabsorption (Malabsorption)
Virilism (Masculinization of female)
Amnesia Nec (Memory impairment)
Mental Status (Mental status)
Metabolic/laboratory Other (Metabolic-
Other (Specify))
Mood Alteration (Mood alteration -
Select)
Mucositis/stomatitis (clinical Exam)
(Mucositis (clinical exam) - Select)
Mucositis/stomatitis
(functional/symptomatic) (Mucositis
(functional/symptomatic) - Select)
Muscle Weakness, Generalized Or
Specific Area (not Due To Neuropathy)
(Muscle weakness - Select)
Muscular/skeletal Hypoplasia
(Muscular/skeletal hypoplasia)
Musculoskeletal/soft Tissue Other
(Musculoskeletal-Other (Specify))
Myelitis (Myelitis)
Myelodysplasia (Myelodysplasia)
Myocarditis Nos (Myocarditis)
Myositis (Myositis)
Nail Abnormality Nos (Nail changes)
Nasal Cavity/paranasal Sinus Reactions
(Nasal/paranasal reactions)
Nausea (Nausea)
Necrosis, Gi (Necrosis, GI - Select)
Neurology Other (Neurology-Other
(Specify))
Peripheral Motor Neuropathy
(Neuropathy-motor)
Peripheral Sensory Neuropathy
(Neuropathy-sensory)
Neuropathy: Cranial (Neuropathy: cranial
- Select)
Neutropenia (Neutrophils)
Breast Nipple/areolar Deformity
(Nipple/areolar)
Blindness Night (Nyctalopia)
Nystagmus Nos (Nystagmus)
Obesity (Obesity)
Obstruction, Gi (Obstruction, GI - Select)
Obstruction, Gu (Obstruction, GU -
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Select)
Conjunctivitis Nec (Ocular surface
disease)
Ocular/visual Other (Ocular-Other
(Specify))
Opportunistic Infection Associated With
> (Opportunistic infection)
Optic Disc Edema (Optic disc edema)
Orgasmic Dysfunction (Orgasmic
dysfunction)
Osteonecrosis (Osteonecrosis)
Osteoporosis (Osteoporosis)
Otitis Externa (exc Boil Of Meatus) Nos
(Otitis, external)
Otitis Media Serous Nos (Otitis, middle)
Pain (Pain - Select)
Pain Other (Pain-Other (Specify))
Palpitations (Palpitations)
Pancreas, Exocrine Enzyme Deficiency
(Pancreas, exocrine enzyme deficiency)
Pancreatitis Nos (Pancreatitis)
Odor (patient Odor) (Patient odor)
Perforation, Gi (Perforation, GI - Select)
Perforation, Gu (Perforation, GU - Select)
Pericardial Effusion (Pericardial effusion)
Pericarditis (Pericarditis)
Dental: Periodontal Disease
(Periodontal)
Peripheral Ischaemia Nos (Peripheral
arterial ischemia)
Personality Change (Personality)
Petechiae (Petechiae)
Phlebitis Superficial (Phlebitis)
Phlebolymphatic Cording
(Phlebolymphatic cording)
Photophobia (Photophobia)
Photosensitivity Reaction Nos
(Photosensitivity)
Phrenic Nerve Dysfunction (Phrenic
nerve)
Platelet Count Decreased (Platelets)
Pleural Effusion (Pleural effusion)
Pneumonitis Nos (Pneumonitis)
Pneumothorax Nos (Pneumothorax)
Portal Hypertension (Portal flow)
Puberty (precocious) (Precocious
puberty)
Proctitis Nos (Proctitis)
Neuroendocrine: Prolactin Hormone
Secretion Abnormality (Prolactin)
Prolapse Of Stoma, Gi (Prolapse of
stoma, GI)
Prolapse Of Stoma, Gu (Prolapse of
stoma, GU)
Prolonged Intubation After Pulmonary
Resection (>24 Hrs After Surgery)
(Prolonged intubation)
Electrocardiogram Qt Prolonged
(Prolonged QTc)
Proptosis/enophthalmos
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(Proptosis/enophthalmos)
Proteinuria Present (Proteinuria)
Pruritus Nos (Pruritus)
Delusion Nos (Psychosis)
Activated Partial Thromboplastin Time
Prolonged (PTT)
Pulmonary Fibrosis (Pulmonary fibrosis)
Pulmonary Hypertension (Pulmonary
hypertension)
Pulmonary/upper Respiratory Other
(Pulmonary-Other (Specify))
Upper Motor Neurone Lesion (Pyramidal
tract dysfunction)
Dermatitis Exfoliative Nos (Rash)
Growth Velocity (reduction In Growth
Velocity) (Reduction in growth velocity)
Renal Failure Nos (Renal failure)
Renal/genitourinary Other (Renal-Other
(Specify))
Restrictive Cardiomyopathy (Restrictive
cardiomyopathy)
Retinal Detachment (Retinal
detachment)
Retinoic Acid Syndrome (Retinoic acid
syndrome)
Retinopathy (Retinopathy)
Rhinitis Allergic Nos (Rhinitis)
Right Ventricular Dysfunction (cor
Pulmonale) (Right ventricular
dysfunction)
Rigors (Rigors/chills)
Salivary Gland Disorder Nos (Salivary
gland changes)
Scleral Necrosis/melt (Scleral necrosis)
Bone: Spine-scoliosis (Scoliosis)
Secondary Malignancy Possibly Related
To Cancer Treatment (Secondary
Malignancy (possibly related to cancer
treatment))
Convulsions Nos (Seizure)
Seroma (Seroma)
Serum Sickness (Serum sickness)
Sexual/reproductive Function Other
(Sexual-Other (Specify))
Short Stature (Short stature)
Soft Tissue Necrosis (Soft tissue
necrosis - Select)
Depressed Level Of Consciousness
(Somnolence)
Speech Disorder Nec (Speech
impairment)
Splenic Function (Splenic function)
Striae (Striae)
Stricture/stenosis (including
Anastomotic), Gu (Stricture,
anastomotic, GU - Select)
Stricture/stenosis (including
Anastomotic), Gi (Stricture, GI - Select)
Supraventricular And Nodal Arrhythmia
(Supraventricular arrhythmia - Select)
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Sweating Increased (Sweating)
Syncope (Syncope (fainting))
Syndromes Other (Syndromes-Other
(Specify))
Taste Disturbance (Taste alteration)
Dental: Teeth (Teeth)
Dental: Teeth Development (Teeth
development)
Telangiectasia (Telangiectasia)
Thrombosis/embolism (vascular Access-
related) (Thrombosis/embolism (vascular
access))
Thrombosis Nos
(Thrombosis/thrombus/embolism)
Thrombotic Microangiopathy (e.g.,
Thrombotic Thrombocytopenic
Purpura[ttp] Or Hemolytic Uremic
Syndrome[hus]) (Thrombotic
microangiopathy)
Tinnitus (Tinnitus)
Tremor Nec (Tremor)
Trismus (difficulty, Restriction Or Pain
When Opening Mouth) (Trismus)
Tumour Flare (Tumor flare)
Tumour Lysis Syndrome (Tumor lysis
syndrome)
Caecitis (Typhlitis)
Ulcer, Gi (Ulcer, GI - Select)
Ulceration (Ulceration)
Fanconi Syndrome (Urinary electrolyte
wasting)
Urinary Frequency (Urinary frequency)
Urinary Retention (Urinary retention)
Urine Discolouration (Urine color
change)
Urticaria Nos (Urticaria)
Uveitis (Uveitis)
Vaginal Discharge (non-infectious)
(Vaginal discharge)
Vulvovaginal DDryness (Vaginal dryness)
Vaginal Mucositis (Vaginal mucositis)
Vaginal Stenosis/leength (Vaginal
stenosis)
Vaginitis (Vaginitis)
Valvular Heart Disease (Valvular heart
disease)
Vascular Other (Vascular-Other
(Specify))
Vasculitis NOS (Vasculitis)
Vasovagal Attack (Vasovagal episode)
Ventricular Arrhythmia (Ventricular
arrhythmia - Select)
Vessel Injury-vein (Vessel injury - Select)
Viral Hepatitis (Viral hepatitis)
Visceral Arterial Ischaemia (Visceral
arterial ischemia)
Vital Capacity (Vital capacity)
Vitreous Hemorrhage (Vitreous
hemorrhage)
Dysphonia (Voice changes)
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Vomiting NOS (Vomiting)
Lacrimation Increased (Watery eye)
Weight Increased (Weight gain)
Weight Decreased (Weight loss)
Culture Wound Negative (Wound
complication, non-infectious)
CTC Select AE
Abdomen (Abdomen)
Abdomen (Abdomen NOS)
Adrenal Gland (Adrenal gland)
Agitation (Agitation)
Anal Sphincter (Anal sphincter)
Anal/perianal (Anal/perianal)
Anus (Anus)
Anxiety (Anxiety)
Aorta (Aorta)
Appendix (Appendix)
Artery (Artery)
Artery (Artery NOS)
Artery-aorta (Artery-aorta)
Artery-carotid (Artery-carotid)
Artery-cerebral (Artery-cerebral)
Artery-extremity (lower) (Artery-extremity
(lower))
Artery-extremity (upper) (Artery-
extremity (upper))
Artery-hepatic (Artery-hepatic)
Artery-major Visceral Artery (Artery-
major visceral artery)
Artery-pulmonary (Artery-pulmonary)
Asystole (Asystole)
Atrial Fibrillation (Atrial fibrillation)
Atrial Flutter (Atrial flutter)
Atrial Tachycardia/paroxysmal Atrial
Tachycardia (Atrial
tachycardia/Paroxysmal Atrial
Tachycardia)
Av Block-first Degree (AV Block-First
degree)
Av Block-second Degree Mobitz Type I
(wenckebach) (AV Block-Second degree
Mobitz Type I (Wenckebach))
Av Block-second Degree Mobitz Type Ii
(AV Block-Second degree Mobitz Type II)
Av Block-third Degree (complete Av
Block) (AV Block-Third degree (Complete
AV block))
Back (Back)
Bigeminy (Bigeminy)
Biliary Tree (Biliary tree)
Biliary Tree (Biliary tree NOS)
Biliary Tree-common Bile Duct (Biliary
tree-common bile duct)
Biliary Tree-common Hepatic Duct
(Biliary tree-common hepatic duct)
Biliary Tree-left Hepatic Duct (Biliary
tree-left hepatic duct)
Biliary Tree-right Hepatic Duct (Biliary
tree-right hepatic duct)
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Bladder (Bladder)
Bladder (Bladder (urinary))
Blood (Blood)
Bone (Bone)
Bone (osteomyelitis) (Bone
(osteomyelitis))
Brachial Plexus (Brachial plexus)
Brain (Brain)
Brain (encephalitis, Infectious) (Brain
(encephalitis, infectious))
Brain And Spinal Cord
(encephalomyelitis) (Brain + Spinal cord
(encephalomyelitis))
Breast (Breast)
Bronchopulmonary Nos
(Bronchopulmonary NOS)
Bronchus (Bronchus)
Buttock (Buttock)
Cardiac/heart (Cardiac/heart)
Carotid (Carotid)
Cartilage (Cartilage)
Catheter-related (Catheter-related)
Cecum (Cecum)
Cecum/appendix (Cecum/appendix)
Cervix (Cervix)
Chemoradiation (Chemoradiation)
Chest Wall (Chest wall)
Chest/thorax Nos (Chest/thorax NOS)
Cn I (olfactory) (CN I (olfactory))
Cn I Smell (CN I Smell)
Cn Ii (optic) (CN II (optic))
Cn Ii Vision (CN II Vision)
Cn Iii (oculomotor) (CN III (oculomotor))
Cn Iii Pupil, Upper Eyelid, Extra Ocular
Movements (CN III Pupil, upper eyelid,
extra ocular movements)
Cn Iv (trochlear) (CN IV (trochlear))
Cn Iv Downward, Inward Movement Of
Eye (CN IV Downward, inward
movement of eye)
Cn Ix (glossopharyngeal) Motor Pharynx
(CN IX (glossopharyngeal) motor
pharynx)
Cn Ix (glossopharyngeal) Sensory Ear-
pharynx-tongue (CN IX
(glossopharyngeal) sensory ear-
pharynx-tongue)
Cn Ix Motor-pharynx; Sensory-ear,
Pharynx, Tongue (CN IX Motor-pharynx;
Sensory-ear, pharynx, tongue)
Cn V (trigeminal) Motor (CN V
(trigeminal) motor)
Cn V (trigeminal) Sensory (CN V
(trigeminal) sensory)
Cn V Motor-jaw Muscles; Sensory-facial
(CN V Motor-jaw muscles; Sensory-
facial)
Cn Vi (abducens) (CN VI (abducens))
Cn Vi Lateral Deviation Of Eye (CN VI
Lateral deviation of eye)
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Cn Vii (facial) Motor-face (CN VII (facial)
motor-face)
Cn Vii (facial) Sensory-taste (CN VII
(facial) sensory-taste)
Cn Vii Motor-face; Sensory-taste (CN VII
Motor-face; Sensory-taste)
Cn Viii (vestibulocochlear) (CN VIII
(vestibulocochlear))
Cn Viii Hearing And Balance (CN VIII
Hearing and balance)
Cn X (vagus) (CN X (vagus))
Cn X Motor-palate; Pharynx, Larynx (CN
X Motor-palate; pharynx, larynx)
Cn Xi (spinal Accessory) (CN XI (spinal
accessory))
Cn Xi Motor-sternomastoid And
Trapezius (CN XI Motor-sternomastoid
and trapezius)
Cn Xii (hypoglossal) (CN XII
(hypoglossal))
Cn Xii Motor-tongue (CN XII Motor-
tongue)
Colon (Colon)
Colon/cecum/appendix
(Colon/cecum/appendix)
Conduction Abnormality Nos
(Conduction abnormality NOS)
Conjunctiva (Conjunctiva)
Cornea (Cornea)
Cranial Nerve Or Branch Nos (Cranial
nerve or branch NOS)
Death (Death NOS)
Dental-tooth (Dental-tooth)
Dental/teeth/peridontal
(Dental/teeth/peridontal)
Depression (Depression)
Disease Progression (Disease
progression NOS)
Duodenum (Duodenum)
Esophagus (Esophagus)
Euphoria (Euphoria)
External Ear (External ear)
External Ear (otitis Externa) (External
ear (otitis externa))
Extraocular (Extraocular)
Extremity-limb (Extremity-limb)
Extremity-lower (Extremity-lower)
Extremity-upper (Extremity-upper)
Eye (Eye)
Eye (Eye NOS)
Face (Face)
Face (Face NOS)
Facial (Facial)
Fallopian Tube (Fallopian tube)
Foreign Body (e. G., Graft, Implant,
Prosthesis, Stent) (Foreign body (e. g.,
graft, implant, prosthesis, stent))
Gallbladder (Gallbladder)
Gallbladder (cholecystitis) (Gallbladder
(cholecystitis))
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Genital Tract-female (Genital tract-
female)
Gingiva (Gingiva)
Head (Head)
Head/headache (Head/headache)
Heart (Heart)
Heart (endocarditis) (Heart
(endocarditis))
Hepatic (Hepatic)
Idioventricular Rhythm (Idioventricular
rhythm)
Ileum (Ileum)
Inner Ear (Inner ear)
Intestine (Intestine)
Ivc (IVC)
Jejunum (Jejunum)
Joint (Joint)
Jugular (Jugular)
Kidney (Kidney)
Large Bowel (Large bowel)
Larynx (Larynx)
Leak Nos (Leak NOS)
Left-sided (Left-sided)
Lens (Lens)
Ligament (Ligament)
Lingual (Lingual)
Lip (Lip)
Lip/perioral (Lip/perioral)
Lip/perioral Area (Lip/perioral area)
Liver (Liver)
Lower Gi Nos (Lower GI NOS)
Lung (Lung)
Lung (pneumonia) (Lung (pneumonia))
Lung Thoracic (Lung thoracic)
Lymph Node (Lymph node)
Lymphatic (Lymphatic)
Mediastinum (Mediastinum)
Mediastinum (Mediastinum NOS)
Meninges (Meninges)
Meninges (meningitis) (Meninges
(meningitis))
Middle Ear (Middle ear)
Middle Ear (otitis Media) (Middle ear
(otitis media))
Mucosa (Mucosa)
Multi-organ Failure (Multi-organ failure)
Muscle (Muscle)
Muscle (infection Myositis) (Muscle
(infection myositis))
Nails (Nails)
Nasal Cavity (Nasal cavity)
Nasopharynx Nos (Nasopharynx)
Neck (Neck)
Neck (Neck NOS)
Nerve-cranial (Nerve-cranial)
Nerve-peripheral (Nerve-peripheral)
Neuralgia/peripheral Nerve
(Neuralgia/peripheral nerve)
Nodal/junctional (Nodal/Junctional)
Nose Nos (Nose)
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Ocular (Ocular)
Oral (Oral)
Oral Cavity Nos (Oral cavity)
Oral Cavity Nos (Oral cavity NOS)
Oral Cavity-gums (gingivitis) (Oral cavity-
gums (gingivitis))
Oral-gums (Oral-gums)
Other (Other NOS)
Outer Ear Nos (Outer ear NOS)
Outer Ear-pinna (Outer ear-Pinna)
Ovary (Ovary)
Ovulatory (Ovulatory)
Pain (Pain NOS)
Pancreas (Pancreas)
Pancreas/pancreatic Duct
(Pancreas/pancreatic duct)
Pancreatic Duct (Pancreatic duct)
Paranasal (Paranasal)
Parathyroid (Parathyroid)
Parotid Gland (Parotid gland)
Pelvic (Pelvic)
Pelvic (Pelvic NOS)
Penis (Penis)
Pericardium (Pericardium)
Perineum (Perineum)
Peripheral Motor Nos (Peripheral motor
NOS)
Peripheral Sensory Nos (Peripheral
sensory NOS)
Peristomal (Peristomal)
Peritoneal Cavity (Peritoneal cavity)
Peritoneum (Peritoneum)
Phantom (pain Associated With Missing
Limb) (Phantom (pain associated with
missing limb))
Pharynx (Pharynx)
Pituitary (Pituitary)
Pleura (Pleura)
Pleura (empyema) (Pleura (empyema))
Prostate (Prostate)
Pvcs (PVCs)
Radiation (Radiation)
Rectum (Rectum)
Recurrent Laryngeal (Recurrent
laryngeal)
Respiratory Tract Nos (Respiratory tract
NOS)
Retina (Retina)
Retroperitoneum (Retroperitoneum)
Right-sided (Right-sided)
Sacral Plexus (Sacral plexus)
Salivary Duct (Salivary duct)
Salivary Gland (Salivary gland)
Scalp (Scalp)
Sciatic (Sciatic)
Scrotum (Scrotum)
Sick Sinus Syndrome (Sick Sinus
Syndrome)
Sinus (Sinus)
Sinus Arrhythmia (Sinus arrhythmia)
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Sinus Bradycardia (Sinus bradycardia)
Sinus Tachycardia (Sinus tachycardia)
Skin (Skin)
Skin (cellulitis) (Skin (cellulitis))
Small Bowel (Small bowel)
Small Bowel (Small bowel NOS)
Soft Tissue Nos (Soft tissue NOS)
Spermatic Cord (Spermatic cord)
Spinal Cord (Spinal cord)
Spinal Cord (myelitis) (Spinal cord
(myelitis))
Spleen (Spleen)
Stokes-adams Syndrome (Stokes-
Adams Syndrome)
Stoma (Stoma)
Stoma (Stoma (GI))
Stomach (Stomach)
Sudden Death (Sudden death)
Supraventricular Arrhythmia Nos
(Supraventricular arrhythmia NOS)
Supraventricular Extrasystoles
(premature Atrial Contractions;
Premature Nodal/junctional
Contractions) (Supraventricular
extrasystoles (Premature Atrial
Contractions; Premature
Nodal/Junctional Contractions))
Supraventricular Tachycardia
(Supraventricular tachycardia)
Svc (SVC)
Teeth (Teeth)
Tendon (Tendon)
Testes (Testes)
Testicle (Testicle)
Testis (Testis)
Thoracic Duct (Thoracic duct)
Thoracodorsal (Thoracodorsal)
Thorax (Thorax)
Throat/pharynx/larynx
(Throat/pharynx/larynx)
Thyroid (Thyroid)
Tongue (Tongue)
Torsade De Pointes (Torsade de pointes)
Trachea (Trachea)
Trigeminy (Trigeminy)
Trunk (Trunk)
Tumor Pain (Tumor pain)
Ungual (nails) (Ungual (nails))
Upper Aerodigestive Nos (Upper
aerodigestive NOS)
Upper Airway Nos (Upper airway NOS)
Upper Gi (Upper GI NOS)
Ureter (Ureter)
Urethra (Urethra)
Urinary Conduit (Urinary conduit)
Urinary (Urinary NOS)
Urinary Tract Nos (Urinary tract NOS)
Uterus (Uterus)
Vagina (Vagina)
Varices (esophageal) (Varices
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(esophageal))
Varices (rectal) (Varices (rectal))
Vas Deferens (Vas deferens)
Vein (Vein)
Vein (Vein NOS)
Vein-extremity (lower) (Vein-extremity
(lower))
Vein-extremity (upper) (Vein-extremity
(upper))
Vein-hepatic (Vein-hepatic)
Vein-inferior Vena Cava (Vein-inferior
vena cava)
Vein-jugular (Vein-jugular)
Vein-major Visceral Vein (Vein-major
visceral vein)
Vein-portal Vein (Vein-portal vein)
Vein-pulmonary (Vein-pulmonary)
Vein-superior Vena Cava (Vein-superior
vena cava)
Ventricular Arrhythmia Nos (Ventricular
arrhythmia NOS)
Ventricular Fibrillation (Ventricular
fibrillation)
Ventricular Flutter (Ventricular flutter)
Ventricular Tachycardia (Ventricular
tachycardia)
Viscera (Viscera)
Visceral (Visceral)
Vulva (Vulva)
Whole Body/generalized (Whole
body/generalized)
Wolff-parkinson-white Syndrome (Wolff-
Parkinson-White Syndrome)
Wound (Wound)
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Melanoma Adverse Event E1609
NCT01274338
E1609 Adverse Event Form (CTCAE v4) - Arm A
Ipilimumab or High-Dose Interferon Alfa-2b in Treating
Patients With High-Risk Stage III or Stage IV Melanoma
That Has Been Removed by Surgery
NCT01274338
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=97ED76E3-
6554-CD9F-E040-BB89AD430E2E
All rights reserved. Please visit https://medical-data-
models.org/forms/10171
Adverse Event Melanoma (CTCAE
v4) - Arm A NCT01274338
Header
ECOG Protocol Number
ECOG Patient ID
DCI Name
Registration Step (Place ID Label Here)
Patient Initials (Last, First)
Participating Group Protocol Number
Participating Group Patient ID
Institution/Affiliate
Please mark an 'X' if data have been amended.
Date data amended (s M D Y)
Investigator Signature
Investigator Signature Date (M D Y)
On Treatment
On Treatment Report Period
Week 1 (Week 1)
Week 10 (Week 10)
Week 12 (Week 12)
Week 18 (Week 18)
Week 24 (Week 24)
Week 30 (Week 30)
Week 36 (Week 36)
Week 4 (Week 4)
Week 42 (Week 42)
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Week 48 (Week 48)
Week 54 (Week 54)
Week 60 (Week 60)
Week 7 (Week 7)
Off Treatment Report Period (Choose one)
9 Years (108 months post registration)
12 Months (12 Months Post Registration)
10 Years (120 months post registration)
11 Years Post Registration (132 Months
Post Registration)
12 Years Post Registration (144 Months
Post Registration)
15 Months (15 Months Post Registration)
13 Years Post Registration (156 Months
Post Registration)
14 Years Post Registration (168 Months
Post Registration)
18 Months (18 Months Post Registration)
15 Years Post Registration (180 Months
Post Registration)
16 Years Post Registration (192 Months
Post Registration)
17 Years Post Registration (204 Months
Post Registration)
21 Months Post Registration (21 Months
Post Registration)
18 Years Post Registration (216 Months
Post Registration)
19 Years Post Registration (228 Months
Post Registration)
2 Years (24 Months Post Registration)
20 Years Post Registration (240 Months
Post Registration)
3 Months (3 Months Post Registration)
30 Months (30 Months Post Registration)
3 Years (36 Months Post Registration)
42 Months (42 Months Post Registration)
4 Years (48 Months Post Registration)
54 Months (54 Months Post Registration)
6 Months (6 Months Post Registration)
5 Years (60 Months Post Registration)
6 Years (72 Months Post Registration)
84 Months Post Registration (84 Months
Post Registration)
9 Months (9 Months Post Registration)
8 Years (96 months post registration)
Adverse Event
Were adverse events assessed during this report
period (cycle)
No (0)
Yes, But No Reportable Adverse Events
Occurred (1)
Yes, And Reportable Adverse Events
Occurred (2)
CTC Adverse Event Report Begin Date (For the
2 / 3
Melanoma Adverse Event E1609 NCT01274338
dates below, record the start and end dates of the
time period within current report period in which
patient was assessed for adverse events. M D Y)
CTC Adverse Event Report End Date (For the
dates below, record the start and end dates of the
time period within current report period in which
patient was assessed for adverse events. M D Y -
mm/dd/yyyy)
Adverse event hematologic or metabolic
CTC Adverse Event Term
CTC Adverse Event Grade (v4.0 - this
cycle/report period)
Mild Adverse Event (1)
Moderate Adverse Event (2)
Severe Adverse Event (3)
Life Threatening Adverse Event (4)
Death Related To Adverse Event (5)
CTC AE Attribution Code (v4.0)
Definite (definite)
Possible (possible)
Probable (probable)
Unlikely (unlikely)
Unrelated (unrelated)
Was this attributed to investigational protocol
treatment
Yes
No
AE Expedited report filed?
Mark 'X' if likely to be immune-related
Yes
No
III. Other Adverse Events (INCLUDING
INFECTIONS)
Other, specify (specific infection or AE CTC
Adverse Event Term not listed)
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Multiple Myeloma Adverse Event
NCT00522392
E1A05 Adverse Event Form (CTCAE v3) - Form 2861
Bortezomib and Dexamethasone With or Without
Lenalidomide in Treating Patients With Multiple Myeloma
Previously Treated With Dexamethasone
NCT00522392
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=32B7FEFD-
31B1-3074-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/10172
Adverse Event Multiple Myeloma
(CTCAE v3) E1A05 Form 2861
NCT00522392
Header
ECOG Protocol Number
ECOG Patient ID
DCI Name
Registration Step (Place ID Label Here)
Patient Initials (Last, First)
Participating Group Protocol Number
Participating Group Patient ID
Institution/Affiliate
Please mark an 'X' if data have been amended.
Date data amended
Investigator Signature
Investigator Signature Date
On Treatment
On Treatment Report Period (Choose one)
Cycle 1 (Cycle 1)
Cycle 2 (Cycle 2)
Cycle 3 (Cycle 3)
Cycle 4 (cycle 4)
Cycle 5 (Cycle 5)
Cycle 6 (Cycle 6)
Cycle 7 (Cycle 7)
Cycle 8 (cycle 8)
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Off Treatment Report Period (Choose one)
9 Years (108 months post registration)
12 Months (12 Months Post Registration)
10 Years (120 months post registration)
15 Months (15 Months Post Registration)
18 Months (18 Months Post Registration)
21 Months Post Registration (21 Months
Post Registration)
2 Years (24 Months Post Registration)
3 Months (3 Months Post Registration)
30 Months (30 Months Post Registration)
3 Years (36 Months Post Registration)
42 Months (42 Months Post Registration)
4 Years (48 Months Post Registration)
54 Months (54 Months Post Registration)
6 Months (6 Months Post Registration)
5 Years (60 Months Post Registration)
6 Years (72 Months Post Registration)
84 Months Post Registration (84 Months
Post Registration)
9 Months (9 Months Post Registration)
8 Years (96 months post registration)
Adverse Event
Were adverse events assessed during this report
period (cycle)
No (0)
Yes, But No Reportable Adverse Events
Occurred (1)
Yes, And Reportable Adverse Events
Occurred (2)
CTC Adverse Event Report Begin Date (For the
dates below, record the start and end dates of the
time period within current report period in which
patient was assessed for adverse events. -
mm/dd/yyyy)
CTC Adverse Event Report End Date (For the
dates below, record the start and end dates of the
time period within current report period in which
patient was assessed for adverse events. -
mm/dd/yyyy)
AE  Blood/Bone Marrow - Labs
CTC Adverse Event Term (Type)
Anorexia (Anorexia)
Constipation (Constipation)
Diarrhoea NOS (Diarrhea)
Dyspnoea NOS (Dyspnea (shortness of
breath))
Fatigue (Fatigue (asthenia, lethargy,
malaise))
Hypotension NOS (Hypotension)
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Insomnia NEC (Insomnia)
Nausea (Nausea)
Peripheral Motor Neuropathy
(Neuropathy: motor)
Peripheral Sensory Neuropathy
(Neuropathy: sensory)
Abdominal Pain NOS (Pain - Abdomen
NOS)
Headache NOS (Pain - Head/headache)
Pleural Effusion (Pleural effusion (non-
malignant))
Fever (in the absence of neutropenia,
where neutropenia is defined as ANC
below 1.0 x 10^9/L) (Pyrexia)
Dermatitis Exfoliative NOS
(Rash/desquamation)
Thrombosis NOS
(Thrombosis/thrombus/embolism)
Tremor NEC (Tremor)
Vomiting NOS (Vomiting)
CTC Adverse Event Grade (this report period)
CTC Adverse Event Attribution Scale
Definite (definite)
Possible (possible)
Probable (probable)
Unlikely (unlikely)
Unrelated (unrelated)
AE infection
CTC Adverse Event Short Name (use CTCAE v3
terminology)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically) - Select)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
- Select)
Infection With Unknown Anc (Infection
with unknown ANC - Select)
CTC Select AE
Other Adverse Events
Other CTC Adverse Event Term not listed (Use
CTCAE v3.0 terminology AE Term:)
Other, specify (site or subterm)
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Melanoma Adverse Event E1609
NCT01274338
E1609 Adverse Event Form (CTCAE v4) - Arm B
Ipilimumab or High-Dose Interferon Alfa-2b in Treating
Patients With High-Risk Stage III or Stage IV Melanoma
That Has Been Removed by Surgery
NCT01274338 
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=97EE0CB8-
33DE-A52C-E040-BB89AD436A24
All rights reserved. Please visit https://medical-data-
models.org/forms/10173
Adverse Event Melanoma (CTCAE
v4) Arm B NCT01274338
Header
ECOG Protocol Number
ECOG Patient ID
DCI Name
Registration Step (Place ID Label Here)
Patient Initials (Last, First)
Participating Group Protocol Number
Participating Group Patient ID
Institution/Affiliate
Please mark an 'X' if data have been amended.
Date data amended (s M D Y)
Investigator Signature
Investigator Signature Date (M D Y)
On Treatment
On Treatment Report Period
Week 1 (Week 1)
Week 10 (Week 10)
Week 12 (Week 12)
Week 18 (Week 18)
Week 24 (Week 24)
Week 30 (Week 30)
Week 36 (Week 36)
Week 4 (Week 4)
Week 42 (Week 42)
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Week 48 (Week 48)
Week 54 (Week 54)
Week 60 (Week 60)
Week 7 (Week 7)
Off Treatment Report Period (Choose one)
9 Years (108 months post registration)
12 Months (12 Months Post Registration)
10 Years (120 months post registration)
11 Years Post Registration (132 Months
Post Registration)
12 Years Post Registration (144 Months
Post Registration)
15 Months (15 Months Post Registration)
13 Years Post Registration (156 Months
Post Registration)
14 Years Post Registration (168 Months
Post Registration)
18 Months (18 Months Post Registration)
15 Years Post Registration (180 Months
Post Registration)
16 Years Post Registration (192 Months
Post Registration)
17 Years Post Registration (204 Months
Post Registration)
21 Months Post Registration (21 Months
Post Registration)
18 Years Post Registration (216 Months
Post Registration)
19 Years Post Registration (228 Months
Post Registration)
2 Years (24 Months Post Registration)
20 Years Post Registration (240 Months
Post Registration)
3 Months (3 Months Post Registration)
30 Months (30 Months Post Registration)
3 Years (36 Months Post Registration)
42 Months (42 Months Post Registration)
4 Years (48 Months Post Registration)
54 Months (54 Months Post Registration)
6 Months (6 Months Post Registration)
5 Years (60 Months Post Registration)
6 Years (72 Months Post Registration)
84 Months Post Registration (84 Months
Post Registration)
9 Months (9 Months Post Registration)
8 Years (96 months post registration)
Adverse Event
Were adverse events assessed during this report
period (cycle)
No (No)
Yes, And Reportable Adverse Events
Occurred (Yes, and reportable adverse
events occurred)
Yes, But No Reportable Adverse Events
Occurred (Yes, but no reportable adverse
events occurred)
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CTC Adverse Event Report Begin Date (For the
dates below, record the start and end dates of the
time period within current report period in which
patient was assessed for adverse events. M D Y)
CTC Adverse Event Report End Date (For the
dates below, record the start and end dates of the
time period within current report period in which
patient was assessed for adverse events. M D Y -
mm/dd/yyyy)
Adverse event hematologic or metabolic
CTC Adverse Event Term
CTC Adverse Event Grade (v4.0 - this
cycle/report period)
Mild Adverse Event (1)
Moderate Adverse Event (2)
Severe Adverse Event (3)
Life Threatening Adverse Event (4)
Death Related To Adverse Event (5)
CTC AE Attribution Code (v4.0)
Definite (definite)
Possible (possible)
Probable (probable)
Unlikely (unlikely)
Unrelated (unrelated)
Was this attributed to investigational protocol
treatment
Yes
No
AE Expedited report filed?
Mark 'X' if likely to be immune-related
Yes
No
III. Other Adverse Events (INCLUDING
INFECTIONS)
Other, specify (specific infection or AE CTC
Adverse Event Term not listed)
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Leukemia Registration SWOG S0805
NCT00792948
Southwest Oncology Group S0805 Registration Worksheet
Form (Step 2)
Combination Chemotherapy With or Without Donor Stem
Cell Transplant in Treating Patients With Acute
Lymphoblastic Leukemia
NCT00792948
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=8FBEF46D-
B665-4571-E040-BB89AD4363A1
All rights reserved. Please visit https://medical-data-
models.org/forms/10174
Registration Worksheet Leukemia
NCT00792948
Header
Activation Date (MM DD YYYY)
Last Amended Date (MM DD YYYY)
Registration Step
Registrar's SWOG Roster ID Number
SWOG Investigator Number
SWOG Treating Institution Number
Patient Information
SWOG Patient ID
Projected Start Date of Treatment (MM DD
YYYY)
Patient Eligibility
Has the Southwest Oncology Group Registration
Worksheet been completed entirely and is the
patient eligible according to the current version of
protocol section 5.0
Yes
No
1 / 1
Breast Cancer Registration SWOG
NCT00070564
SOUTHWEST ONCOLOGY GROUP REGISTRATION
FORM
Adjuvant Doxorubicin, Cyclophosphamide, and Paclitaxel in
Treating Patients With Breast Cancer
NCT00070564
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=A678842F-
926F-5086-E034-0003BA0B1A09
All rights reserved. Please visit https://medical-data-
models.org/forms/10175
REGISTRATION Breast Cancer
NCT00070564
Header
SWOG Study No.
Registration Step
Assigned Treatment Arm
Activation Date
Last Amended Date
Patient's Name
SWOG Patient ID
Comments
Caller's SWOG Roster ID
SWOG Treating Institution Number
SWOG Investigator Number
IRB Approval Date
Projected Start Date of Treatment
Patient characteristics
Patient's Date of Birth
Patient's Sex
Female (Female)
Male (Male)
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Method of Payment (Method of Payment codes)
Medicaid (Medicaid)
Medicaid And Medicare (Medicaid and
Medicare)
Medicare (Medicare)
Medicare And Private Insurance
(Medicare and Private)
Military (Military)
No Means Of Payment (No insurance
(no means))
Self Pay (No insurance (self-pay))
Other (Other)
Private Insurance (Private)
Unknown (Unknown)
Millitary Or Veterans Administration
(Veterans Admin)
Patient's Ethnicity (Ethnicity Spanish/Hispanic
Origin codes)
No (not Spanish) (No (not Spanish))
Unknown (Unknown)
Central American (Yes, Central
American)
Cuban (Yes, Cuban)
Mexican (Yes, Mexican)
NOS (Yes, NOS)
Other (Yes, Other)
Puerto Rican (Yes, Puerto Rican)
South American (Yes, South American)
Patient's Race (select all that apply)
White or Caucasian (1)
Black or African American (2)
Native Hawaiian or Other Pacific Islander
(3)
Asian (4)
American Indian or Alaska Native (5)
Unknown (6)
Patient's Social Security Number
Patient's ZIP Code
Country of Residence (if not USA)
Postal Code
Patient Consent For Specimen Use
Date Informed Consent Signed
Patient's initial consent given for specimen use
for research on the patient's cancer?
Yes
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No
Patient's initial consent given for specimen use
for research unrelated to the patient's cancer?
Yes
No
Patient's initial consent given for further contact
regarding specimen?
Yes
No
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Breast Cancer ADJUVANT TREATMENT
CALGB 49907 NCT00024102
CALGB: 49907 ADJUVANT TREATMENT SUMMARY
FORM; All Patients
Comparison of Combination Chemotherapy Regimens in
Treating Older Women Who Have Undergone Surgery for
Breast Cancer
NCT00024102
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=A50D76F4-
2138-330D-E034-080020C9C0E0
All rights reserved. Please visit https://medical-data-
models.org/forms/10181
ADJUVANT TREATMENT
SUMMARY Breast Cancer
NCT00024102
Header
CALGB Form
CALGB Study No
CALGB Patient ID
First date protocol therapy was given
Last date protocol therapy was given (M)
Amended data?
Yes (Yes)
Completed By (Print or Type Name)
Date Completed
Patient's Name
Participating Group
Patient Hospital Number
Participating Group Protocol No.
Main Member Institution/Adjunct
Participating Group Patient No.
First Date (Treatment Schedule - Systemic
Therapy)
1 / 3
Comments
Treatment Cycle Information
Total Dose of Drugs for Cycle 1
Agent Name
Adriamycin (Adriamycin)
Capecitabine (Capecitabine)
Cyclophosphamide (Cyclophosphamide)
Fluorouracil (Fluorouracil)
Methotrexate (Methotrexate)
Reason Treatment Ended (mark one with an X)
Alternative Therapy (Alternative therapy)
Death On Study (Death on study)
Disease Progression/relapse During
Active Treatment (Disease progression,
relapse during active treatment)
Other Complicating Disease (Other
complicating disease)
Other, Specify: (Other, specify)
Patient Withdrawal Or Refusal After
Beginning Protocol Therapy (Patient
withdrawal or refusal after beginning
protocol therapy)
Patient Withdrawal Or Refusal Prior To
Beginning Protocol Therapy (Patient
withdrawal or refusal prior to beginning
protocol therapy)
Toxicity/side Effects/complications
(Toxicity/side effects/complications)
Treatment Completed Per Protocol
Criteria (Treatment completed per
protocol criteria)
Other, specify (reason treatment ended)
Were there any dose modifications or additions/
omissions to protocol treatment? (Treatment
Schedule - Other Therapy)
No (No)
Unknown (Unknown)
Yes, Planned (Yes, planned)
Yes, Unplanned (Yes, unplanned)
Were any optional protocol therapies given?
Yes
No
optional protocol therapy name(s)
Was any concurrent non-protocol therapy given
during protocol treatment?
Yes
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No
indicate below (concurrent non-protocol therapy
given during protocol treatment) (mark all that
apply with an X)
Concurrent Non-protocol Biologic
Response Modifier Therapy (Concurrent
non-protocol biologic response modifier
therapy)
Concurrent Non-protocol Chemotherapy
(Concurrent non-protocol chemotherapy)
Concurrent Non-protocol High Dose
Chemotherapy/autologous Stem Cell
Transplant (Concurrent non-protocol high
dose chemotherapy/ autologous stem
cell transplant)
Concurrent Non-protocol Hormonal
Therapy (Concurrent non-protocol
hormonal therapy)
Concurrent Non-protocol Radiation
Therapy (Concurrent non-protocol
radiation therapy)
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Breast Cancer Treatment CALGB 40101
NCT00041119
CALGB: 40101 TREATMENT SUMMARY SUBSET FORM
Four Versus Six Cycles of Cyclophosphamide/Doxorubicin
or Paclitaxel in Adjuvant Breast Cancer
NCT00041119
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=A46C8094-
22BA-26B0-E034-080020C9C0E0
All rights reserved. Please visit https://medical-data-
models.org/forms/10186
TREATMENT SUMMARY Breast
Cancer NCT00041119
Header
CALGB Form
CALGB Study No
CALGB Patient ID
Cycle start date
Cycle end date (M)
Amended data?
Yes
No
Patient's Name
Participating Group
Patient Hospital Number
Participating Group Protocol No.
Main Member Institution/Adjunct
Participating Group Patient No.
Completed By (Print or Type Name)
Date Completed (M)
Breast cancer treatment
Current cycle number
1 / 2
BSA
Total dosage for this cycle, Doxorubicin
Total dosage for this cycle, Cyclophosphamide
Total dosage for this cycle, Paclitaxel
Dose adjustments (mark one with an X)
Reduced (1)
Delayed (2)
Reduced And Delayed (3)
Reason for adjustment (Reasons for dose
adjustment)
Not Satisfactorily Recovered From
Hematologic Toxicity (1)
Holiday/vacation (10)
Other (11)
Grade 3 Or 4 Fatigue (2)
Grade 2 Or 3
Anaphylaxis/hypersensitivity (3)
Grade 3 Or 4 Diarrhea/nausea (4)
Grade 3 Or 4 Mucositis (5)
Grade 2 Or Higher Neuropathy (6)
Grade 3 Or Higher Cardiac Toxicity (7)
Grade 3 Or Higher Infection (8)
Grade 3 Or 4 Other Non-hematologic
Toxicity (9)
Specify (reason for adjustment) (if applicable)
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Breast Cancer Registration SWOG S0226
NCT00075764
Southwest Oncology Group Registration Form (S0226)
S0226 Anastrozole With or Without Fulvestrant as First-
Line Therapy in Postmenopausal Women With Metastatic
Breast Cancer
NCT00075764
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=C3225DE6-
8BA0-26CF-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/10189
Registration Breast Cancer
NCT00075764
Header
SWOG Study No.
Registration Step
Assigned Treatment Arm
Activation Date
Last Amended Date
Patient's Name
SWOG Patient ID
Other Group Patient Number
Participating Group Protocol Number
Caller's SWOG Roster ID
IRB Approval Date
SWOG Investigator Number
Other Group Investigator Number (OR)
Other Group Investigator Name
Other Group Institution Number
Other Group Institution Name
SWOG Treating Institution Number
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Date HIPAA Authorization signed
Method of Payment
Medicaid (Medicaid)
Medicaid and Medicare (Medicaid and
Medicare)
Medicare (Medicare)
Medicare and Private (Medicare and
Private)
Military (Military)
No insurance (no means) (No insurance
(no means))
No insurance (self-pay) (No insurance
(self-pay))
Other, specify at registration (Other,
specify at registration)
Private (Private)
unknown (unknown)
Veterans Admin (Veterans Admin)
Patient Social Security Number
Patient's ZIP Code
Country of Residence
Social Insurance Number
Postal Code
Patient data
Patient's Date of Birth
Projected Start Date of Treatment
Patient Gender
Female (Female)
Male (Male)
Patient's Ethnicity
No (not Spanish) (No (not Spanish))
Unknown (Unknown)
Yes, Central American (Yes, Central
American)
Yes, Cuban (Yes, Cuban)
Yes, Mexican (Yes, Mexican)
Yes, NOS (Yes, NOS)
Yes, Other (Yes, Other)
Yes, Puerto Rican (Yes, Puerto Rican)
Yes, South American (Yes, South
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American)
Patient's Race
American Indian or Alaska Native
(American Indian or Alaska Native)
Asian (Asian)
Black or African American (Black or
African American)
Native Hawaiian or Other Pacific Islander
(Native Hawaiian or Other Pacific
Islander)
White or Caucasian (White or
Caucasian)
Prior adjuvant tamoxifen therapy
Yes
No
Consent
Date Informed Consent Signed
My tissue may be kept for use in research to
learn about, prevent, treat, or cure cancer.
Yes
No
My tissue may be kept for research about other
health problems
Yes
No
Someone from Southwest Oncology Group may
contact me in the future to ask me to take part in
more research
Yes
No
I agree to allow my study doctor, or someone
approved by my study doctor, to contact me
regard future research involving my participation
in this study
Yes
No
I agree to submit blood samples for the purpose
of determining how my body metabolizes the
drugs, fulvestrant and anastrozole
Yes
No
I agree to submit blood samples for the analysis
of human epidermal growth factor receptor 2
(HER-2) protein to see if high levels will predict if
I am less likely to respond to hormone therapy
Yes
No
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I agree to submit a blood specimen for genetic
expression studies to study what role the protocol
treatment is having on my disease
Yes
No
I agree to submit a tissue specimen for the
analysis of estrogen receptor (ER) and human
epidermal growth factor receptor 2 (HER-2) to
see if certain levels will predict if I am likely to
respond to hormone therapy
Yes
No
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Breast Cancer Registration SWOG S0226 NCT00075764
Breast Cancer Cardiac Function NSABP B-
36 NCT00087178
NSABP PROTOCOL B-36 Cardiac Function Form
Comparison of Two Combination Chemotherapy Regimens
in Treating Women With Breast Cancer
NCT00087178 
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=C87A9E46-
9ADC-5B40-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/10190
Cardiac Function Breast Cancer
NCT00087178
Header
Patient Initials (Last, First Middle)
NSABP Patient ID
Institution Name
Affiliate Name
Person Completing Form (Phone)
Are data amended?
Yes
No
Comments
Cardiac function
Time Point
Baseline (0)
At 12 Months (12m)
Date of LVEF ()
Method of Assessment (Every effort should be
made to schedule the follow-up MUGA or
echocardiogram at the same facility that
performed the baseline exam, and the same
method of assessment should be used at both
time points.)
MUGA (1)
ECHO (2)
LVEF
1 / 1
Leukemia Registration SWOG-9007
NCT00996047
Southwest Oncology Group SWOG-9007 Registration
Worksheet Form
Study of Bone Marrow and Blood Samples From Patients
With Leukemia or Other Hematopoietic Cancers
NCT00996047
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=8FB8D1FF-
3D88-5871-E040-BB89AD432FD5
All rights reserved. Please visit https://medical-data-
models.org/forms/10191
Registration Worksheet Leukemia
NCT00996047
Header
Activation Date
Last Amended Date (MM DD YYYY)
Registration Step
SWOG Patient ID
Registrar's SWOG Roster ID Number
SWOG Investigator Number
SWOG Treating Institution Number
Date HIPAA Authorization signed (Not required if
Country of Residence is not USA)
Patient Information
Date Informed Consent Signed
Has the Southwest Oncology Group Registration
Worksheet been completed entirely and is the
patient eligible according to the current version of
protocol section 3.0?
Yes
No
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Prostate Cancer Registration SWOG S0925
NCT01120236
Southwest Oncology Group S0925 Registration Worksheet
Form (Step 1)
Bicalutamide and Goserelin or Leuprolide Acetate With or
Without Cixutumumab in Treating Patients With Newly
Diagnosed Metastatic Prostate Cancer
NCT01120236 
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=94470DE4-
29D5-D339-E040-BB89AD4306AB
All rights reserved. Please visit https://medical-data-
models.org/forms/10192
Registration Worksheet Prostate
Cancer NCT01120236
Header
Activation Date
Last Amended Date (MM DD YYYY)
Registration Step
Swog Patient Id
SWOG Patient ID Status
New Patient (1)
Previous patient (2)
SWOG Patient ID
Demography
Patient First Name
Patient Middle Name
Patient Last Name
FOR SWOG INSTITUTIONS
Registrar's SWOG Roster ID Number
SWOG Investigator Number
SWOG Treating Institution Number
PATIENT INFORMATION
Date Informed Consent Signed (MM DD YYYY)
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Date HIPAA Authorization signed (Not required if
Country of Residence is not USA MM DD YYYY)
Projected Start Date of Treatment (MM DD
YYYY)
Auxiliary Question
Late Induction Registration (i.e. patient has
already initiated LHRH agonist therapy and/or
anti-androgen therapy prior to registration)
Yes
No
Stratification Question
Most recent PSA (use measurements pre-LHRH
agonist therapy in the event patient is a late
induction registration)
<20 ng/ml (1)
>20 ng/ml (2)
Performance status
Indicate how the patient answered the
following questions on the consent form
My specimens may be used for the special
testing described as part of this study.
Yes (1)
No (2)
Not Asked (3)
I agree to allow my study doctor, or someone
approved by my study doctor, to contact me
regarding future research involving my
participation in this study.
Yes (1)
No (2)
Not Asked (3)
Patient Eligibility
Has the Southwest Oncology Group Registration
Worksheet been completed entirely and is the
patient eligible according to the current version of
protocol section 5.0?
Yes
No
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Prostate Cancer Registration SWOG S0925 NCT01120236
Leukemia Registration SWOG S0805
NCT00792948
Southwest Oncology Group S0805 Registration Worksheet
Form (Step 3)
Combination Chemotherapy With or Without Donor Stem
Cell Transplant in Treating Patients With Acute
Lymphoblastic Leukemia
NCT00792948
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=8FBEF46D-
B6C8-4571-E040-BB89AD4363A1
All rights reserved. Please visit https://medical-data-
models.org/forms/10193
Registration Worksheet Leukemia
NCT00792948
Header
Activation Date
Last Amended Date
Registration Step
SWOG Patient ID
Registrar's SWOG Roster ID Number
SWOG Investigator Number
SWOG Treating Institution Number
Projected Start Date of Treatment
Which approved Transplant Center will be used
Approved Rt Facility
RT Start Date
RT Facility Name
RT Facility Number (SWOG institutions only)
RT Physician
Patient Eligibility
Has the Southwest Oncology Group Registration
Worksheet been completed entirely and is the
patient eligible according to the current version of
protocol section 5.0
1 / 2
Yes
No
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Leukemia Registration SWOG S0805 NCT00792948
Cervical Cancer Registration SWOG S0227
NCT00057928
Southwest Oncology Group Registration Form (S0227)
S0227 Comparison of Cisplatin Combined With Either
Paclitaxel or Gemcitabine in Treating Patients With
Recurrent, Persistent, or Metastatic Cervical Cancer
NCT00057928
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=A9C4563A-
B1F7-3ACF-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/10194
Registration Form Cervical Cancer
NCT00057928
Header
SWOG Study No.
Registration Step
Assigned Treatment Arm
Activation Date
Last Amended Date
Patient's Name
SWOG Patient ID
Other Group Patient Number
Other Group Name/Protocol Number
Comments
Caller's SWOG Roster ID
IRB Approval Date
Date Informed Consent Signed
Projected Start Date of Treatment
SWOG Investigator Number
Other Group Investigator Name
Other Group Investigator Number
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SWOG Institution Number
Other Group Institution Name
Other Group Institution Number
Patient data
Patient's Date of Birth
Patient's Sex
Female (Female)
Male (Male)
Method of Payment
Patient's Ethnicity
Patient's Race (select all that apply)
Native_american_cdus (American Indian
or Alaska Native)
Asian_cdus (Asian)
Black_cdus (Black or African American)
Pacific_islander_cdus (Native Hawaiian
or Other Pacific Islander)
Unknown (Unknown)
White_cdus (White or Caucasian)
Patient's Social Security Number
Postal Code
Country of Residence (If a resident of Canada)
Social Insurance Number
2 / 2
Cervical Cancer Registration SWOG S0227 NCT00057928
Lung cancer OFF TREATMENT
NCT00020709
OFF TREATMENT NOTICE
S0023: Combination Chemo Plus RT With or Without
Gefitinib in Treating Patients With Unresectable Stage III
NSCLC
NCT00020709 
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=9CA62D43-
4EE1-361C-E034-080020C9C0E0
All rights reserved. Please visit https://medical-data-
models.org/forms/10196
OFF TREATMENT NOTICE Lung
Cancer NCT00020709
Header
SWOG Patient ID
SWOG Study No.
Registration Step
Patient Initials (L, F,M)
Institution / Affiliate
Physician
Group Name (Groups other than SWOG )
Study No. (Groups other than SWOG )
Pt. ID (Groups other than SWOG )
Patient data
Treatment Start Date
Treatment End Date
Regimen or Procedure or Site(s)
Date of Last Contact (or death)
Vital Status
Alive (Alive)
Dead (Dead)
Notes
1 / 2
Off treatment
Off Treatment Reason (select one:)
Medically required, due to toxicity,
specify (Medically required, due to
toxicity, specify)
Treatment completed per protocol criteria
(Treatment completed per protocol
criteria)
Medically required, due to toxicity, specify
Pt_refused_due_to_toxic2006857
(Patient refused, due to toxicity, specify)
Patient refused, due to toxicity, specify
Pt_refused_oth_than_tox2006859
(Patient refused, other than toxicity,
specify)
Prog_or_relapse_sites_2006860
(Progression or relapse. Sites)
Progression or relapse. Sites
Death_attach_notice_of_2006862
(Death (attach Notice of Death form))
Other_specify_2006863 (Other, specify)
Other, specify
Date of completion, progression, death or
decision to discontinue therapy (Off Treatment
Date)
Will patient receive further treatment?
No (No)
Unknown (Unknown)
Yes, specify (Yes, specify)
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Lung cancer OFF TREATMENT NCT00020709
EADV PruNet
Phan NQ, Blome C, Fritz F, Gerss J, Reich A, Ebata T,
Augustin M, Szepietowski
JC, Ständer S. Assessment of pruritus intensity:
prospective study on validity
and reliability of the visual analogue scale, numerical rating
scale and verbal
rating scale in 471 patients with chronic pruritus. Acta Derm
Venereol. 2012
Sep;92(5):502-7
http://www.ncbi.nlm.nih.gov/pubmed/22170091
VAS, NRS, VRS
All rights reserved. Please visit https://medical-data-
models.org/forms/10209
Pruritus Intensity Scales (VAS, NRS,
VRS)
Pruritus Intensitätsskalen
Auf einer Skala von "kein Jucken" (links) bis
"schlimmstes vorstellbares  Jucken" (rechts), wie
war der Juckreiz durchschnittlich in den letzten
24 Stunden?
Auf einer Skala von "kein Jucken" (links) bis
"schlimmstes vorstellbares Jucken" (rechts), wie
war der Juckreiz am stärksten in den letzten 24
Stunden?
Auf einer Skala von 0 (kein Jucken) bis 10
(schlimmstes vorstellbares Jucken), wie war der
Juckreiz durchschnittlich in den letzten 24
Stunden?
Kein Juckreiz (0)
1 (1)
Schlimmster vorstellbarer Juckreiz (10)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
7 (7)
8 (8)
9 (9)
Auf einer Skala von 0 (kein Jucken) bis 10
(schlimmstes vorstellbares Jucken), wie war der
Juckreiz am stärksten in den letzten 24 Stunden?
Kein Juckreiz (0)
1 (1)
Schlimmster vorstellbarer Juckreiz (10)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
7 (7)
8 (8)
9 (9)
Wie war Ihr Jucken durchschnittlich in den letzten
24 Stunden?
Kein Juckreiz (0)
1 / 2
gering (1)
mittelschwer (2)
schwer (3)
sehr schwer (4)
Wie war Ihr Jucken am stärksten in den letzten
24 Stunden?
Kein Juckreiz (0)
gering (1)
mittelschwer (2)
schwer (3)
sehr schwer (4)
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EADV PruNet
Lung Cancer RADIATION THERAPY
NCT00020709
LUNG CARCINOMA RADIATION THERAPY FORM
S0023: Combination Chemo Plus RT With or Without
Gefitinib in Treating Patients With Unresectable Stage III
NSCLC
NCT00020709 
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=9E343E83-
5FEB-119F-E034-080020C9C0E0
All rights reserved. Please visit https://medical-data-
models.org/forms/10212
RADIATION THERAPY FORM
LUNG CARCINOMA NCT00020709
Header
SWOG Patient ID
SWOG Study No.
Registration Step
Patient Initials (L, F,M)
Social Security No.
Institution / Affiliate
Physician
Hosp. No.
Group Name (Groups other than SWOG )
Study No. (Groups other than SWOG )
Pt. ID (Groups other than SWOG )
Treating Radiation Oncologist
RT Facility
RT Facility Code
Form completed by
Facility
Telephone Number
1 / 3
Date
Radiation Oncologist's Signature
Notes
Treatment Information
Radiation Therapy Start Date
RT End Date
Were there any unscheduled interruptions in
radiation therapy?
Yes
No
If Yes, Specify RT Interruptions Reason
Total Dose to Isocenter (cGy)
Total Fractions
Number of Days
Radiation Source
Co 60 (1)
Megavoltage (2)
Electron (3)
Combination (4)
Other, specify (5)
Other, specify
Specify
Dose
Fractions
Radiation Energy
Maximum Dose to Critical Structures
Spinal Cord
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Lung Cancer RADIATION THERAPY NCT00020709
Heart
Esophagus
Other structures
%Of Total Lung Receiving>=2000 cGy
%Of Left Lung Receiving>=2000 cGy
%Of Right Lung Receiving>=2000 cGy
Primary Tumor location
Left lung (1)
Right lung (2)
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Lung Cancer RADIATION THERAPY NCT00020709
Lymphoma REGISTRATION SWOG S1108
NCT01466881
SWOG S1108 REGISTRATION WORKSHEET
Alisertib in Treating Patients With Relapsed or Refractory
Peripheral T-Cell Non-Hodgkin Lymphoma
NCT01466881
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=AA4F8583-
EC8E-07C8-E040-BB89AD430929
All rights reserved. Please visit https://medical-data-
models.org/forms/10218
REGISTRATION WORKSHEET
Lymphoma NCT01466881
Protocol Information
Trial Activation Date
Last Amended Date
Registration Step
Swog Patient Id
SWOG Patient ID Status
New Patient (New patient)
Previous Patient (Previous patient)
SWOG Patient ID
Registrar's SWOG Roster ID Number
SWOG Investigator Number
SWOG Treating Institution Number
Demography
Patient First Name
Patient Middle Name
Patient Last Name
Patient Information
Date Informed Consent Signed
Date HIPAA Authorization signed (Not required if
Country of Residence is not USA MM DD YYYY)
1 / 2
Projected Start Date of Treatment
Has the SWOG Registration Worksheet been
completed entirely and is the patient eligible
according to the current version of protocol
section 5.0?
Yes
No
Indicate how the patient answered the
following questions on the consent form
My specimens may be kept for use in research to
learn about, prevent, treat, or cure cancer.
Yes
No
My specimens may be kept for use in research
about other health problems (for example:
diabetes, Alzheimer's disease, or heart disease).
Yes
No
Someone may contact me in the future to ask me
to allow other uses of my specimens.
Yes
No
I agree to allow my study doctor, or someone
approved by my study doctor, to contact me
regarding future research involving my
participation in this study
Yes
No
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Lymphoma REGISTRATION SWOG S1108 NCT01466881
Respiratory Therapy
Form from HIS OpenVistA
All rights reserved. Please visit https://medical-data-
models.org/forms/10219
O2 PROTOCOL DOCUMENTATION
Respiratory Therapy
RESPIRATORY THERAPY O2
PROTOCOL DOCUMENTATION
Cardiac rate
OXYGEN MODALITY*
Oxygen Flow*
OXYGEN percentage*
Patient activity checklist*
Oxygen saturation measurement (Oximetry)*
CURRENT Oxygen FLOW [L]*
OXYGENATION*
Comment*
1 / 1
EHR general order entry form
General order entry form from University Hospital of
Münster, Germany
All rights reserved. Please visit https://medical-data-
models.org/forms/10220
General order entry form (MS)
Allgemeine Anforderung
Art der Anforderung*
Auftragsnummer*
Auftragsdatum und -uhrzeit*
Status der Anforderung*
Erläuterung gewünschte Untersuchung*
Multi-Anforderung*
Ja
Nein
Wunschdatum*
Wunschzeit*
Ärztliche Anforderung*
Ja
Nein
Pflegerische Anforderung*
Ja
Nein
Konsil*
Ja
Nein
Anfordernder extern*
Dringlichkeit*
Privatpatient*
Ja
Nein
Chefarztwahl*
Ja
Nein
Einrichtung*
Anfordernder Benutzer*
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Anfordernde Stelle*
Anfordernde Fachabteilung*
Leistende Stelle*
Leistende Fachabteilung*
Empfangende Kostenstelle*
Buchungskreis*
Kostenübernehmer*
Kostenübernehmer Text*
Anfordernde Kostenstelle Nicht aus Fall*
Ja
Nein
Vorbereiten und Kopie*
Ja
Nein
Mit Termin Verknuepfen*
Ja
Nein
Fotodokumentation*
Ja
Nein
Foto erlaubt*
Ja
Nein
Terminverschiebung*
Ja
Nein
Klinische Daten
Gewünschte Untersuchung*
Gewünschte Untersuchungen Text*
Gewünschte Zusatzuntersuchung*
Modalität*
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EHR general order entry form
Anzahl gewünschter Untersuchungen*
Diagnosen*
Diagnose Freitext*
Indikationen*
Fragestellung*
Zusätzliche Fragestellung*
Vorbefunde*
Cave*
CAVE Details*
Laborwerte*
Laborwerte Zusammenfassung*
Gewicht*
Größe*
Dignität*
Mobilität*
aktBefundtext*
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EHR general order entry form
EHR General findings
EHR General findings from University Hospital of Münster,
Germany
All rights reserved. Please visit https://medical-data-
models.org/forms/10221
General findings
Allgemeiner Befund
Durchgeführte Untersuchung*
Befunder*
Befundungsdatum*
Art des Befundes*
Befund Status*
Befund*
Cave*
Diagnosen Zusammenfassung*
Laborwerte textuell*
Vorbefunde*
Beurteilung*
Empfehlung*
Administrative Angaben
Auftragsnummer*
Dringlichkeit*
Art der Anforderung*
Wunschtermin*
Einrichtung*
Anfordernde Fachabteilung*
Anfordernde Stelle*
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Anfordernder Benutzer*
Externer Anforderer*
Ja
Nein
Gewünschte Untersuchung*
Gewünschte Zusatzuntersuchungen*
Gewuenschte Untersuchung Anzahl*
Wunschdatum*
Wunschzeit*
Rückweiser*
Rueckweisungsgrund
Mobilität*
Termin*
Leistende Fachabteilung*
Leistende Stelle*
Zielbenutzer Arzt*
Zusatzempfänger Stelle*
Zusatzempfänger Fachabteilung*
Buchungskreis*
Empfangende Kostenstelle*
Modalität*
Demoliste*
FOTO erlaubt*
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EHR General findings
Ja
Nein
Erfassungsdatum*
Status signiert*
Ja
Nein
Mittig Unterschreibender*
Links Unterschreibender*
3 / 3
EHR General findings
documentation standard - breast cancer -
talk after biopsy
documentation standard - breast cancer - gynecology, with
friendly permission (Dr. Tio)
- kooperatives Brustzentrum Münster, Bereich Senologie an
der Klinik und Poliklinik für Frauenheilkunde und
Geburtshilfe - Leitung: Dr. med. Joke Tio
All rights reserved. Please visit https://medical-data-
models.org/forms/10222
HIS
Administrative information
Admission date*
Patient Identification Number*
Patient sex*
Patient surname *
Patient forename*
Patient date of birth*
Admission hour*
Physician admission*
Patient information
date*
responsible person*
Histopathology*
Operative Surgical Procedures
Excisional Biopsy*
Yes
No
Breast Conservation Treatment*
Yes
No
reconstructive breast conservation treatment*
Yes
No
mastectomy*
Yes
No
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Operative Surgical Procedures *
Sentinel Lymph Node Biopsy*
Yes
No
Axillary Lymph Node Dissection *
Yes
No
Reconstructive Surgical Procedure*
deep inferior epigastric perforators
(DIEP)
Expander (Implantat/Expander)
Yes (ja)
latissimus dorsi muscle flap (Lat. Dorsi)
No (nein, aber Aufklärung erfolgt)
not required (nicht notwendig)
Transverse Rectus Abdominis
Myocutaneous flap (TRAM)
Date of admission *
primary surgeon*
Patient information II
Intention Chemotherpy
Neo-adjuvant - intent (N)
Clinical Trials *
disease stage*
Postoperative (postoperativ)
Preoperative (präoperativ)
X-Ray of Thorax*
Yes
No
date X-Ray of Thorax*
finding X-Ray of Thorax - free text*
finding X-Ray of Thorax*
Abnormal  (auffällig)
Normal (unauffällig)
Ultrasonography of Abdomen*
Yes
No
date Ultrasonography of Abdomen*
2 / 3
documentation standard - breast cancer - talk after biopsy
finding Ultrasonography of Abdomen - free text*
finding Ultrasonography of Abdomen*
Abnormal  (auffällig)
Normal (unauffällig)
Scintigraphy*
Yes
No
date scintigraphy*
finding scintigraphy - free text*
finding scintigraphy *
Abnormal  (auffällig)
Normal (unauffällig)
X-Ray Computed Tomography *
Yes
No
date X-Ray Computed Tomography *
finding X-Ray Computed Tomography - free text*
finding X-Ray Computed Tomography*
Abnormal  (auffällig)
Normal (unauffällig)
distant metastasis*
second opinion desired*
Yes
No
place second opinion*
Signature*
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documentation standard - breast cancer - talk after biopsy
Urinary Tract Cancer Medical History Form
CALGB 90601 NCT00942331
CALGB 90601: Medical History Form
Gemcitabine Hydrochloride and Cisplatin With or Without
Bevacizumab in Treating Patients With Advanced Urinary
Tract Cancer
NCT00942331
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=657DC836-
E20A-2DC7-E040-BB89AD437499
All rights reserved. Please visit https://medical-data-
models.org/forms/10224
Medical History Form Urinary Tract
Cancer NCT00942331
Header
CALGB Form (C-1761)
CALGB Study No. (90601)
CALGB Patient ID
Are data amended
Yes
No
Patient Initials (Last, First, Middle)
Patient Hospital No
Institution/Affiliate
Participating Group
Participating Group Study No.
Participating Group Patient ID
Significant Medical History, Concomitant
Diseases
Myocardial infarction (1 If multiple events, record
date of most recent here, and the earlier ones in
C-260 Remarks Addenda form.)
Yes
No
Date of myocardial infarction (CRF says "Date of
event" MM DD YYYY)
Coronary artery by-pass graft (CABG)
No (No)
Unknown (Unknown)
Yes (Yes)
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Date of CABG (CRF says "Date of event" MM DD
YYYY)
Cardiac stent/angioplasty
No (No)
Unknown (Unknown)
Yes (Yes)
Date of cardiac stent/ angioplasty (CRF says
"Date of event" MM DD YYYY)
Angina pectoris
No (No)
Unknown (Unknown)
Yes (Yes)
Coronary Artery Disease (heart disease)
No (No)
Unknown (Unknown)
Yes (Yes)
Congestive heart failure
No (No)
Unknown (Unknown)
Yes (Yes)
Hypertension
No (No)
Unknown (Unknown)
Yes (Yes)
Peripheral Vascular Disease
No (No)
Unknown (Unknown)
Yes (Yes)
Arterial thrombosis
No (No)
Unknown (Unknown)
Yes (Yes)
Venous thrombosis
No (No)
Unknown (Unknown)
Yes (Yes)
Transient ischemic disease
No (No)
Unknown (Unknown)
Yes (Yes)
Cerebrovascular accident (including stroke)
No (No)
Unknown (Unknown)
Yes (Yes)
Subarachnoid hemorrhage
No (No)
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Unknown (Unknown)
Yes (Yes)
Date of event
Dementia
No (No)
Unknown (Unknown)
Yes (Yes)
Chronic pulmonary disease
No (No)
Unknown (Unknown)
Yes (Yes)
Connective tissue disease
No (No)
Unknown (Unknown)
Yes (Yes)
Arthritis
No (No)
Unknown (Unknown)
Yes (Yes)
Peptic ulcer disease
No (No)
Unknown (Unknown)
Yes (Yes)
Mild liver disease
No (No)
Unknown (Unknown)
Yes (Yes)
Diabetes (without complications)
No (No)
Unknown (Unknown)
Yes (Yes)
Diabetes with end organ disease
No (No)
Unknown (Unknown)
Yes (Yes)
Hemiplegia
No (No)
Unknown (Unknown)
Yes (Yes)
Renal Disease
No (NO)
Unknown (UNKNOWN)
Yes (YES)
Diverticulitis
No (No)
Unknown (Unknown)
Yes (Yes)
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Prior Therapy
Prior chemotherapy?
Yes
No
Current bisphosphonate therapy?
Yes
No
specify date started (If Yes,)
Prior surgery for prostate cancer? (Mark all that
apply with an X.)
Pelvic Lymphadenectomy (Pelvic
lymphadenectomy)
Prostate Biopsy (Prostate biopsy)
Prostatectomy (Prostatectomy)
Transurethral Resection Of The Prostate
(Transurethral resection of the prostate)
Radical prostatectomy, specify date completed
(mm dd yyyy)
Pelvic lymphadenectomy, specify date completed
(mm dd yyyy)
Prior radiation therapy? (Mark all that apply with
an X.)
No Prior Radiation Therapy (No prior
radiation therapy)
Palliative Radiotherapy (Palliative
radiotherapy)
Prostate Bed External Beam Radiation
Therapy After Radical Prostatectomy
(Prostate bed external beam radiation
therapy after radical prostatectomy)
Prostate External Beam Radiation
Therapy (Prostate external beam
radiation therapy)
Prostate Implants (Prostate implants)
Radioisotope Therapy (Radioisotope
therapy)
Total dose administered (cGy)
Radiation therapy start date (mm dd yyyy)
Radiation therapy end date (mm dd yyyy)
Neoadjuvant hormonal therapy prior to surgery?
(prostatectomy)
Yes
No
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Neoadjuvant hormonal therapy prior to radiation?
(for prostate cancer)
Yes
No
Neoadjuvant hormonal therapy start date (mm dd
yyyy)
Neoadjuvant hormonal therapy end date (mm dd
yyyy)
Adjuvant hormonal therapy after surgery?
(prostatectomy)
Yes
No
Adjuvant hormonal therapy after radiation? (for
prostate cancer)
Yes
No
Adjuvant hormonal therapy start date (MM DD
YYYY)
Adjuvant hormonal therapy end date (MM DD
YYYY)
Current type of gonadal suppression (Mark all
that apply with an X.)
Lhrh Agonist (LHRH agonist)
Orchiectomy (Orchiectomy)
Date of orchiectomy (specify MM DD YYYY)
LHRH agonist start date (MM DD YYYY)
LHRH agonist end date (MM DD YYYY)
LHRH agonist treatment type (Mark one with an
X.)
Continuous (Continuous)
Intermittent (Intermittent)
Hormonal Agent (For each hormonal agent listed
below, record whether the agent was
administered 0=not taken; 1=initial; 2=second
line; 3=third line; 99=other reason. If
administered, record agent start and end dates.)
Aminoglutethimide (Aminoglutethimide)
Bicalutamide (Bicalutamide)
Finasteride (Finasteride)
Flutamide (Flutamide)
Ketoconazole (Ketoconazole)
Megestrol Acetate (Megestrol acetate)
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Nilutamide (Nilutamide)
Other (Other)
Other specify
Agent administered status (For each hormonal
agent listed below, record whether the agent was
administered 0=not taken; 1=initial; 2=second
line; 3=third line; 99=other reason.)
Initial (initial)
Not Taken (not taken)
Other (Other reason)
Second Line (second line)
Third Line (third line)
Agent start date (mm/dd/yyyy)
Agent end date (mm/dd/yyyy)
Any other prior therapy?
Yes
No
Other Prior Regimen Name
Other prior therapy start date (MM DD YYYY)
Other prior therapy end date (MM DD YYYY)
Background Information
What is the highest grade you finished in school?
(Mark one with an X.)
1-8 Grades (1-8 grades)
9-11 Grades (9-11 grades)
Advanced Degree (Advanced degree)
College Degree (b.a./b.s.) (College
degree)
High School Graduate (High School
graduate)
Junior College Degree (Junior college
degree)
Some College (Some college)
Some Post-college Work (Some post-
college work)
What is your marital status? (Mark one with an
X.)
Divorced (Divorced)
Married (Married)
Separated (Separated)
Single, Never Married (Single, never
married)
Widowed (Widowed)
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What is your current employment status? (Mark
one with an X.)
Disabled (Disabled)
Employed 32 Hours Or More Per Week
(Employed 32 hours or more per week)
Employed Less Than 32 Hours Per
(Employed less than 32 hours per week)
Full-time Student (Full-time student)
Homemaker (Homemaker)
On Medical Leave (On medical leave)
Other (Other)
Part-time Student (Part-time student)
Retired (Retired)
Unemployed (Unemployed)
Other, specify
Completed by (Last name, First name)
Date form completed (mm dd yyyy)
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Urinary Tract Cancer Medical History Form CALGB 90601 NCT00942331
Glioma evaluation NCCTGroup N0577
NCT00887146
North Central Cancer Treatment Group N0577
Evaluation/Observation Form
Radiation Therapy or Radiation Therapy and Temozolomide
or Temozolomide Alone in Treating Patients With Newly
Diagnosed Anaplastic Glioma
NCT00887146
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=4C096CEC-
61BF-47DB-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/10225
Evaluation/Observation Form Glioma
NCT00887146
Header
Protocol Number
Patient ID
Patient Initials (L F M)
Institution Number
Institution
Are data amended (If yes, highlight amended
areas)
Yes
No
Patient data
Current Cycle Number
Weight (used for this cycle, round to the nearest
tenth)
ECOG Performance Status (check one)
Fully Active, Able To Carry On All Pre-
disease Performance Without
Restriction. (0)
Restricted In Physically Strenuous
Activity But Ambulatory And Able To
Carry Out Work Of A Light Or Sedentary
Nature, E.g., Light Housework, Office
Work. (1)
Ambulatory And Capable Of All Selfcare
But Unable To Carry Out Any Work
Activities. Up And About More Than 50%
Of Waking Hours. (2)
Capable Of Only Limited Selfcare,
Confined To Bed Or Chair More Than
50% Of Waking Hours. (3)
1 / 2
Completely Disabled. Cannot Carry On
Any Selfcare. Totally Confined To Bed Or
Chair. (4)
Observation
Day 1 of this observation cycle
End of observation
Yes
No
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Glioma evaluation NCCTGroup N0577 NCT00887146
Connective Tissue Graft Versus Mucograft Collagen Matrix for
Coverage of Multiple Gingival Recession Defects NCT01440426
ODM derived from
http://clinicaltrials.gov/show/NCT01440426
NCT01440426
All rights reserved. Please visit https://medical-data-
models.org/forms/10226
Eligibility Coverage of Multiple
Gingival Recession Defects
NCT01440426
Inclusion Criteria
Age 18 Years to 70 Years*
Yes
No
2-4 adjacent gingival recession (one at least 3
mm deep)*
Yes
No
Exclusion Criteria
Interdental attachment loss greater than 1 mm at
recession sites*
Yes
No
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B-Cell Leukemia or Lymphoma
Relapse/Progression ANHL01P1 NCT00057811
ANHL01P1: Relapse/Progression
Rituximab, Rasburicase, and Combination Chemotherapy
in Treating Young Patients With Newly Diagnosed
Advanced B-Cell Leukemia or Lymphoma
NCT00057811
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=B9F3BA73-
F2E0-23C7-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/10232
Follow-Up Relapse/Progression B-
Cell Leukemia or Lymphoma
Relapse/Progression NCT00057811
Header
Institution
Institution Personnel
COG Number
COG Number
Today's date
Date worksheet entered into RDE
Disease progression
Date of relapse or progression (Required field.)
Relapse / Progression (Required field)
Progression (Progression)
Recurrence/relapse (Relapse)
Was a biopsy performed to document the
relapse/progression? (Required field)
Yes
No
Primary site (Topography) text (Required field)
Primary site (Topography) ICD-O code (To be
coded by RDC)
First metastatic site (Topography) text (Enter
description of first metastatic site Topography.  If
not involved, leave this field blank.)
First metastatic site (Topography) text (Enter
description of first metastatic site Topography.  If
not involved, leave this field blank.)
1 / 2
First metastatic site (Topography) ICD-O code (To
be coded at the RDC)
First metastatic site (Topography) ICD-O code (To
be coded at the RDC)
COMMENTS
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B-Cell Leukemia or Lymphoma Relapse/Progression ANHL01P1
NCT00057811
Anal Cancer Screen Failure AMC-076
NCT01164722
AMC-076 Screen Failure Form (SFF)
Infrared Coagulator Ablation or Observation in Preventing
Anal Cancer in HIV-Positive Patients With Anal Neoplasia
NCT01164722
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=A80D02C4-
02DA-DA36-E040-BB89AD436D9D
All rights reserved. Please visit https://medical-data-
models.org/forms/10234
Screen Failure Form (SFF) Anals
Cancer NCT01164722
Trial Screen Failure
Anal cytology performed
Yes
No
Most Severe Anal Cytology Result (If "Yes",)
Asc-h (ASC-H)
Ascus (ASCUS)
High Grade Sil (High grade SIL)
Low Grade Sil (Low grade SIL)
Normal (Normal)
Unevaluable (Unevaluable)
High-resolution anoscopy performed
Yes
No
Anal biopsy performed (If "Yes",)
Yes
No
Most severe anal biopsy result (If "Yes",)
Colonic Epithelium (Colonic epithelium)
Condyloma (Condyloma)
Flat Condyloma (Flat condyloma)
High-grade Ain (High-grade AIN)
Invasive Cancer (Invasive cancer)
Low-grade Ain (Low-grade AIN)
Normal Squamous Epithelium (Normal
squamous epithelium)
Squamous Metaplasia (Squamous
metaplasia)
Unevaluable (Unevaluable)
Comments
Primary reason for screen failure
Other, specify
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Ovarian Cancer Registration SWOG S0904
NCT00872989
Southwest Oncology Group S0904 Registration Worksheet
for OPEN - Step 2
Docetaxel With or Without Vandetanib in Treating Patients
With Persistent or Recurrent Ovarian Epithelial Cancer,
Fallopian Tube Cancer, or Primary Peritoneal Cancer
NCT00872989
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=7C965708-
98F3-5904-E040-BB89AD432C8B
All rights reserved. Please visit https://medical-data-
models.org/forms/10235
Registration Worksheet Ovarian
Cancer NCT00872989
SWOG Patient ID
SWOG Patient ID
Registrar's SWOG Roster ID Number
SWOG Investigator Number
SWOG Treating Institution Number
Patient Information
Projected Start Date of Treatment
Has the Southwest Oncology Group Registration
Worksheet been completed entirely and is the
patient eligible according to the current version of
protocol section 5.0
Yes
No
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HIV with Cancer Baseline AMC-061
NCT00890747
AMC-061 Baseline Evaluation Form (B61)
Sunitinib Malate in Treating HIV-Positive Patients With
Cancer Undergoing Highly Active Antiretroviral Therapy
NCT00890747
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=715BD918-
9168-2975-E040-BB89AD434610
All rights reserved. Please visit https://medical-data-
models.org/forms/10236
Baseline Evaluation Form HIV with
Cancer NCT00890747
Visit Number
Visit number
Comments
SOLID TUMOR/LYMPHOMA
ASSESSMENT
Initial Diagnosis Date (mm/dd/yyyy)
Disease status
Both Measurable And Non-measurable
(Both Measurable and Non-Measurable)
Measurable (Measurable)
Non-measurable (Non-Measurable)
Hematopoietic Diagnosis
Burkitt Lymphoma/leukemia (Burkitt
lymphoma/leukemia)
Diffuse Large B-cell Lymphoma (Diffuse
large B-cell lymphoma)
Hodgkin's Lymphoma (Hodgkin
lymphoma)
Kshv/hhv-8+ Plasmablastic Lymphoma
(lymph Node) (KSHV/HHV-8+
plasmablastic lymphoma (lymph node))
Other (Other)
Plasma Lymphoma Of Oral Cavity
(Plasma lymphoma of oral cavity)
Polymorphic B Cell Lymphoma-ptld Type
(Polymorphic B cell lymphoma-PTLD
type)
Primary Effusion Lymphoma (Primary
effusion lymphoma)
Other specify (If)
If diffuse large B-cell lymphoma, specify
morphologic type
Centroblastic (Centroblastic)
Immunoblastic (Immunoblastic)
If Burkitt lymphoma/leukemia, specify
1 / 3
morphologic type
B Cell Lymphoma Unclassifiable,
W/features Intermediate Between Dlbcl
And Burkitt's. (atypical) (B cell lymphoma
unclassifiable, w/features intermediate
between DLBCL and Burkitt's. (Atypical))
Classical (Classical)
Plasmacytoid (Plasmacytoid)
Kaposi's Sarcoma Assessment
Does the patient have >=50 cutaneous lesions
Yes
No
Total Number Raised Lesions
Total Number Flat Lesions
Are there any oral cavity lesions present
Yes
No
Is there visceral disease
Yes
No
Hematologic Malignancy Assessment
Hematologic diagnosis
All (Acute Lymphoblastic Leukemia)
Acute Myeloid Leukemia (Acute Myeloid
Leukemia)
Cll (Chronic Lymphoid Leukemia)
Chronic Myeloproliferative Disorder
(Chronic Myeloproliferative Disease)
Leukemia (Leukemia Miscellaneous)
Acute Lymphoblastic Leukemia
Acute Lymphoblastic Leukemia, Nos
(Acute Lymphoblastic Leukemia, NOS)
Precursor B-lymphoblastic Leukemia
(Precursor B-Lymphoblastic Leukemia
(B-precursor ALL))
Precursor T-lymphoblastic Leukemia
(Precursor T-Lymphoblastic Leukemia
(T-Cell ALL))
Acute Myeloid Leukemia
Acute Myeloid Leukemia Nos (Acute
Myeloid Leukemia, NOS)
Acute Promyelocytic Leukemia (Acute
Promyelocytic Leukemia)
Treatment-related Acute Myeloid
Leukemia (Treatment-related Acute
Myeloid Leukemia)
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Chronic Lymphoid Leukemia
Adult T-cell Lymphoma/leukemia (Adult
T-Cell Leukemia/Lymphoma)
Chronic Lymphocytic Leukemia Nos
(Chronic Lymphocytic Leukemia, NOS)
Hairy Cell Leukemia (Hairy Cell
Leukemia)
Prolymphocytic Leukemia
(Prolymphocytic Leukemia (B or T-Cell))
T-cell Large Granular Lymphocyte
Leukemia (T-Cell Large Granular
Lymphocytic Leukemia)
Chronic Myeloproliferative Disease
Chronic Eosinophilic Leukemia Or
Hypereosinophilic Syndrome (Chronic
Eosinophilic Leukemia/Hypereosinophilic
Syndrome)
Chronic Idiopathic Myelofibrosis (Chronic
Idiopathic Myelofibrosis)
Philadelphia Chromosome Positive
Chronic Myelogenous Leukemia
(Chronic Myelogenous Leukemia,
Philadelphia Chromosome Positive)
Essential Thrombocythemia (Essential
Thrombocythemia)
Polycythemia Vera (Polycythemia Vera)
Leukemia Miscellaneous
Leukemia (Leukemia, NOS)
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Breast Cancer DRUG SUPPLY
NCT00024102 CALGB 49907
CALGB: 49907 CAPECITABINE DRUG SUPPLY RECORD
FORM
Comparison of Combination Chemotherapy Regimens in
Treating Older Women Who Have Undergone Surgery for
Breast Cancer
NCT00024102
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=A50CE624-
6F5F-37E3-E034-080020C9C0E0
All rights reserved. Please visit https://medical-data-
models.org/forms/10237
CAPECITABINE DRUG SUPPLY
RECORD FORM NCT00024102
Header
CALGB Form
CALGB Study No
CALGB Patient ID
Last date of reporting cycle (M)
Amended data?
Yes
No
Patient's Name
Participating Group
Patient Hospital Number
Participating Group Protocol No.
Main Member Institution/Adjunct
Participating Group Patient No.
Drug Supply
Daily capecitabine dose (mg)
Number of 500 mg tablets prescribed to be taken
each day
Number of 500 mg tablets issued
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Date and time the electronic device was placed
on the vial (Use a military-24 hour clock)
Name of the person who filled the vial (Use a
military-24 hour clock)
Date and Time pill count was done
How many 500 mg tablets returned (Exact pill
count)
Date and time the electronic device was removed
from the vial (Use a military-24 hour clock)
Name of the person who performed the return pill
count
Completed By (Print or Type Name)
Date Completed (M)
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Breast Cancer DRUG SUPPLY NCT00024102 CALGB 49907
Upper Back Myofascial Pain Syndrome
NCT00134810
NCT00134810
The main purpose of this study is to determine which is the
best dose of a drug known as
Dysport to give when treating one's type of upper back
pain. The study will also examine the
side effects of this treatment and its overall effect on one's
disorder.
All rights reserved. Please visit https://medical-data-
models.org/forms/10238
Eligibility Upper Back Myofascial
Pain Syndrome NCT00134810
Inclusion criteria
18 Years and older*
Yes
No
No Healthy Volunteers*
Yes
No
Moderate-severe pain in upper back*
Yes
No
Myofascial pain syndrome for more than 6
months*
Yes
No
Active trigger points in upper back*
Yes
No
Exclusion criteria
Fibromyalgia and other non-myofascial pain
conditions of upper back*
Yes
No
Duration of myofascial pain syndrome no longer
than 24 months*
Yes
No
Steroid injections during previous 3 months*
Yes
No
Anaesthetic injection at trigger points during
previous 1 month*
Yes
No
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Prostate Cancer Radiation Therapy
Calculation Form RTOG NCT00023829
T4 Radiation Therapy Oncology Group Protocol Calculation
Form
Adjuvant Radiation Therapy Plus Hormone Therapy
Compared With Radiation Therapy Alone in Treating
Patients With Stage II or Stage III Prostate Cancer
NCT00023829 
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=A4E27DE7-
685D-26F8-E034-080020C9C0E0
All rights reserved. Please visit https://medical-data-
models.org/forms/10240
Radiation Therapy Calculation Form
Prostate Cancer NCT00023829
Header
RTOG Study
Case #
Institution
Institution No.
Patient's Name
Patient's I.D. No.
Form completed by
Date
Radiotherapy
Anatomical Treatment Area (DAILY DOSE
CALCULATIONS)
Field projection (ant, lat, oblique, etc.)
FIELD
Rt Field (I)
Rt Field (II)
Rt Field (III)
Rt Field (IV)
Rt Field (V)
Rt Field (VI)
Manufacturer name and unit energy
Monitor units/minutes
1 / 2
Tumor dose per field for each field @ point of
protocol prescription
SSD/SAD (circle one)
SAD (SAD)
SSD (SSD)
Treatment depth (cm)
Collimator setting (Field size in cm at isocenter)
Equivalent square at SSD/SAD
% DD, TAR, TMR, TPR, TOR
% DD, TAR, TMR, TPR, TOR
% DD (% DD)
TAR (TAR)
TMR (TMR)
TOR (TOR)
TPR (TPR)
CGY/MU (Linac)
CGY/MIN (cobalt)
Wedge
Tray
Comp
Other, specify (transmission factors)
Other, specify (transmission factors)
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Prostate Cancer Radiation Therapy Calculation Form RTOG
NCT00023829
Breast Cancer Radiation Therapy Report
NSABP B-36 NCT00087178
NSABP Protocol B-36 Radiation Therapy Report
Comparison of Two Combination Chemotherapy Regimens
in Treating Women With Breast Cancer
NCT00087178 
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=C87B5190-
AA07-59CE-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/10241
Radiation Therapy Report Breast
Cancer NCT00087178
Header
Patient Initials (Last, First Middle)
NSABP Patient ID
Institution Name
Affiliate Name
Person Completing Form (First Name)
Person Completing Form (Phone)
Are data amended?
Yes
No
Radiation therapy
Was the patient enrolled in NSABP Protocol B-
39/RTOG 0413?
Yes
No
Has the patient received adjuvant RT? (prior to
treatment failure or second primary cancer)
Yes
No
Adjuvant RT Begin Date (month day year)
Adjuvant RT End Date (month day year)
Whole Breast Irradiation
Breast Irradiated
Left (Left)
Right (Right)
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RT Total Dose (cGY)
Total Number of Fractions
Operative Area Boost
Yes
No
Was RT interrupted for more than one week?
Yes
No
Chest Wall Irradiation
Side Irradiated
1 (Left)
2 (Right)
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Breast Cancer Radiation Therapy Report NSABP B-36 NCT00087178
AML AZA NCT00915252
A randomized, multi-center phase II trial to assess the
efficacy of 5-azacytidine added to standard primary therapy
in elderly patients with newly diagnosed AML
NCT00915252
Principal Investigator Prof. Dr. Müller-Tidow
All rights reserved. Please visit https://medical-data-
models.org/forms/10242
Remissionsstatus vor 1.
Konsolidierung AML NCT00915252
Patientendaten
Pat.-Nr.:    -*
Differentialblutbild
Datum:*
Haemoglobin*
Haemoglobin*
[g/dl] ([g/dl])
[mmol/l] ([mmol/l])
Leukozyten *
Leukozyten*
[/nl] ( [/nl])
[/µl] ( [/µl])
[10E3/µl] ([10E3/µl])
[GPt/l] ([GPt/l])
Prozentanteil Neutrophile *
Prozentanteil Stabkernige *
[oder] Prozentanteil Segmentkernige *
Prozentanteil Lymphozyten *
Prozentanteil Monozyten*
Prozentanteil Eosinophile *
Prozentanteil Basophile *
Prozentanteil Blasten*
Prozentanteil Promyelozyten*
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Prozentanteil Myelozyten*
Prozentanteil Metamyelozyten*
Prozentanteil sonstige Zellen*
Thrombozyten*
Thrombozyten*
[/nl] ([/nl])
[/µl] ([/µl])
[10E3/µl] ([10E3/µl])
[GPt/l] ([GPt/l])
Knochenmarkuntersuchung
Datum - Knochenmarkuntersuchung*
Obligater Materialversand (Knochenmark + Blut)
zur Bestimmung des Methylierungsstatus nach:*
Münster (1)
Dresden (2)
Frankfurt (3)
kein Versand weil (kein Versand weil)
kein Versand weil*
Zytologie
Blastenanteil*
<5% (1)
>=5% (2)
nicht beurteilbar (3)
wenn >=5%, dann bitte angeben [%]*
Zytogenetik
Zytogenetik:*
durchgeführt (Befundkopie bitte
mitschicken!) (1)
nicht durchgeführt (2)
Zytogenetische Aberration nachweisbar:*
nein (no)
ja, in      % Interphasen-FISH (yes, in
interphase FISH)
ja, in      /     Metaphasen (yes, in
metaphases)
Anzahl Metaphasen*
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Gesamtzahl Metaphasen*
% Interphasen-FISH*
Neue Aberration nachweisbar:*
Ja
Nein
Molekulargenetik
Molekulargenetik*
durchgeführt (Befundkopie bitte
mitschicken!) (1)
nicht durchgeführt (2)
AML1/ETO:*
ja (1)
nein (2)
nicht untersucht (3)
PML/RARa:*
ja (1)
nein (2)
nicht untersucht (3)
CBFbeta/MYH11:*
ja (1)
nein (2)
nicht untersucht (3)
C/EBPalpha:*
ja (1)
nein (2)
nicht untersucht (3)
NPM1-Mut:*
ja (1)
nicht untersucht (1)
nein (2)
nicht untersucht (3)
IDH-Mutation:*
ja (1)
nein (2)
nicht untersucht (3)
Flt3-Punktmutation:*
ja (1)
nein (2)
nicht untersucht (3)
Flt3-ITD:*
ja (1)
nein (2)
nicht untersucht (3)
Sonstige:*
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Remissionsstatus
Remissionsstatus*
Morphologisch Leukämie-freier Status
(ohne Erreichen peripherer CR-Kriterien)
(1)
Morphologisch komplette Remission
(CR) (2)
Zytogenetisch komplette Remission
(CRc) (3)
Molekulargenetisch komplette Remission
(CRm) (4)
Therapieversagen (partielle Remission
(PR), kein Ansprechen) (Bitte Bogen
"Studienende/Studien-abbruch" Seite 82
ausfüllen!) (5)
Unterschrift
Datum:*
Name/Unterschrift Prüfarzt*
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Anal Cancer NCT01164722 AMC-076
AMC-076 HPV On-Study Form (ONS)
Infrared Coagulator Ablation or Observation in Preventing
Anal Cancer in HIV-Positive Patients With Anal Neoplasia
NCT01164722
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=A80C062E-
17BA-F42E-E040-BB89AD432F38
All rights reserved. Please visit https://medical-data-
models.org/forms/10243
On-Study Form (ONS) Anal Cancer
NCT01164722
Header Module
Visit number
Comments
HIV
Date of HIV+ diagnosis (mm/dd/yyyy)
Date of AIDS diagnosis (mm/dd/yyyy)
CDC HIV Risk Group
Hemophilia (Hemophiliac)
Heterosexual Contact (Heterosexual
contact)
Homosexual Or Bisexual Contact
(Homosexual or bisexual contact)
Iv Drug User (IV drug user)
Other (Other)
Transfusion Recipient (Transfusion
recipient)
Other, specify
Condyloma
History of anal, perianal, or genital condyloma (If
"Yes", answer the following)
Yes
No
History of penile or genital condyloma
Active Genital Condyloma (Active genital
condyloma)
Active Penile Condyloma (Active penile
condyloma)
No History (No history)
Yes, Resolved With History Of Treatment
(Yes, resolved with history of treatment)
Yes, Resolved Without Treatment (Yes,
resolved without treatment)
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History of perianal condyloma
Active Perianal Condyloma (Active
perianal condyloma)
No History (No history)
Yes, Resolved With History Of Treatment
(Yes, resolved with history of treatment)
Yes, Resolved Without Treatment (Yes,
resolved without treatment)
History of intraanal condlyoma
Active Intraanal Condyloma (Active
intraanal condyloma)
No History (No history)
Yes, Resolved With History Of Treatment
(Yes, resolved with history of treatment)
Yes, Resolved Without Treatment (Yes,
resolved without treatment)
Lowest CD4+ Count
Lowest CD4+ count ever reported
Document type
Lab Report (Lab Report)
Physician/provider Report Or Clinical
Note (Physician/provider report or clinical
note)
Subject Recall (Subject recall)
2 / 2
Anal Cancer NCT01164722 AMC-076
EHR4CR data inventory for patient
identification and recruitment
EHR4CR data inventory for patient identification and
recruitment
All rights reserved. Please visit https://medical-data-
models.org/forms/10245
EHR4CR data inventory for patient
identification and recruitment
Demographics
Date of Birth*
Gender*
Admission Date*
Discharge Date*
Case Status*
Medical History
Currently pregnant*
Yes
No
Gravidity (no pregnancies)*
Menauposal Status*
Allergies oder Hypersensitivity reactions*
Diet*
Smoking Status*
Alcohol Abuse*
Substance Abuse*
Currently breast feeding*
Currently pregnant*
Libido*
Medical device
Type*
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Diagnosis
Diagnosis Text*
Diagnosis Date*
Diagnosis Code*
Histologically confirmed diagnosis*
COPD exacerbation*
Procedure
Procedure Text*
Procedure Code*
Procedure Date*
Findings
Date / Time of Finding*
Body Weight*
Body Height*
Temperature*
Pulse*
Blood pressure systolic*
Blood pressure diastolic*
Body Mass Index (BMI)*
Cardiac function*
CT*
ECG*
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Focal lesion*
Forced expiratory volume in 1 second /  forced
vital capacity (FEV1/FVC) ratio*
Gallium scan*
Heart rate*
hypertension*
Infection*
Intraocular pressure*
Lytic bone lesion*
MRI*
Oxigen therapy*
Percent predicted forced expiratory volume in 1
second (FEV1)*
Percentage lesion area*
PET scan*
Spirometry*
Laboratory Findings
Albumin*
Albumin-adjusted serum calcium*
Alkaline Phosphatase*
Amylase*
ANA titer*
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antibodies*
anti-cyclic citrullinated peptide antibodies (anti-
PP)*
Beta HCG in serum *
biPTH*
Blood Urea Nitrogen [BUN] in serum*
BNP*
Ca x P*
Calcitonin*
Calcium in serum *
calculated creatinine clearance*
Cardiac troponin T *
C-Reactive protein (hs-CRP)*
Creatinine clearance*
Creatinine in serum *
CRP in serum*
CRP*
Direct Bilirubin in serum*
Eosinophils*
Erythrocytes *
Fasting C-peptide*
Fasting hypertriglyceridemia*
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EHR4CR data inventory for patient identification and recruitment
Fasting plasma glucose (in serum)*
Ferritin*
Folate*
Gamma GT*
Glomerular Filtration Rate*
Glucose in serum *
Haematocrit *
HbA1c*
HDL in serum *
hepatitis C virus (HCV)*
HER2 status*
Yes
No
KRAS mutation*
Yes
No
LDL in serum *
Leukocytes*
Lipase*
Lymphocytes*
Mantoux Test*
Measles Antibody*
Monoclonal light chain in the urine protein
electrophoresis*
Monoclonal plasma cells in the bone marrow*
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EHR4CR data inventory for patient identification and recruitment
Monoclonal protein in Serum*
Monoclonal protein in Urine*
Neutrophils*
NRAS mutation*
Yes
No
NTproBNP*
Platelets  *
Potassium in serum *
Prolactin*
PSA*
PT*
PT (INR)*
PTT  *
Rheumatoid Factor*
sampling Date / Time of Laboratory Finding*
Serum immunoglobulin free light chain*
serum immunoglobulin kappa lambda free light
chain ratio*
Serum monoclonal paraprotein (M Protein)*
serum pregnancy test*
SGOT (AST)*
SGPT (ALT)*
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EHR4CR data inventory for patient identification and recruitment
Sodium in Serum *
Total bilirubin*
Total Bilirubin in serum*
Total Cholesterol in serum *
Total Protein in serum*
Total testosterone level*
Transferrin saturation*
Triglycerides*
TSH  *
Urine monoclonal light chain protein*
Urine monoclonal paraprotein (M Protein)*
Urine protein to creatine ratio*
Varicella Antibody*
Vitamin B12*
white blood cell count*
Medication
Verbatim Drug name*
Medication Code*
Dosage*
Route*
Medication start date*
Medication end date*
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EHR4CR data inventory for patient identification and recruitment
Drug class*
Drug Group*
Active substance*
Scores&Classifications
AJCC*
Best-corrected visual acuity (BCVA) Score*
CTCAE
Expanded Disability Status Scale (EDSS) score
IPI
modified Rankin Scores&Classification
SELENA-SLEDAI Scores&Classification
SLE
WHO
Patient Characteristics
Day-night cycles
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EHR4CR data inventory for patient identification and recruitment
Leukemia AML-AZA in elderly patients
NCT00915252
A randomized, multi-center phase II trial to assess the
efficacy of 5-azacytidine added to standard primary therapy
in elderly patients with newly diagnosed AML
NCT00915252
5-Azacytidin plus Standardtherapie bei älteren AML-
Patienten
Principal Investigator Prof. Dr. Müller-Tidow
All rights reserved. Please visit https://medical-data-
models.org/forms/10246
Remissionsstatus vor 2.
Konsolidierung Leukämie AML AZA
NCT00915252
Patient data
Pat. No.:    -*
Differential blood count
Date:*
Hemoglobin*
Hemoglobin *
[g/dl] ([g/dl])
[mmol/l] ([mmol/l])
Leukocytes*
Leukocytes*
[/nl] ( [/nl])
[/µl] ( [/µl])
[10E3/µl] ([10E3/µl])
[GPt/l] ([GPt/l])
Neutrophil percentage*
Band neutrophil percentage*
[or] Segmented neutrophil percentage*
Lymphocyte percentage*
Monocyte percentage*
Eosinophil percentage*
Basophil percentage*
Blast cell percentage*
Promyelocyte percentage*
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Myelocyte percentage*
Metamyelocyte percentage*
Percentage of other cells*
Platelets*
Platelets*
[/nl] ([/nl])
[/µl] ([/µl])
[10E3/µl] ([10E3/µl])
[GPt/l] ([GPt/l])
Bone marrow examination
Date - Bone marrow examination*
Obligatory materials shipping (bone marrow +
blood) for determination of methylation status to:*
Münster (1)
Dresden (2)
Frankfurt (3)
no shipping because (kein Versand weil)
no shipping because*
Cytology
Blast percentage*
<5% (1)
>=5% (2)
cannot be assessed (3)
If >=5%, please specify [%]*
Cytogenetics
Cytogenetics:*
performed (Please attach copy of
findings!) (1)
not performed (2)
Cytogenetic aberration detectable:*
no (no)
yes, in      % Interphase FISH (yes, in
interphase FISH)
yes, in      /     metaphases (yes, in
metaphases)
count of metaphases*
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total count of metaphases*
% Interphase FISH*
New aberration detectable:*
Yes
No
Molecular Genetic Analysis
Molecular Genetic Analysis*
performed (Please attach copy of
findings!) (1)
not performed (2)
AML1/ETO:*
yes (1)
no (2)
Not examined for (3)
PML/RARa:*
yes (1)
no (2)
Not examined for (3)
CBFbeta/MYH11:*
yes (1)
no (2)
Not examined for (3)
C/EBPalpha:*
yes (1)
no (2)
Not examined for (3)
NPM1(mut):*
yes (1)
Not examined for (1)
no (2)
Not examined for (3)
IDH mutation:*
yes (1)
no (2)
Not examined for (3)
FLT3 point mutation:*
yes (1)
no (2)
Not examined for (3)
FLT3-ITD:*
yes (1)
no (2)
Not examined for (3)
Other:*
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Remission status
Remission status*
Morphologic leukemia-free status
(without achievement of peripheral CR
criteria) (1)
Morphologic complete remission (CR)
(2)
Relapse (Please fill out form "Reizidiv"
page 83+84 and form
"Studienende/Studien-abbruch" page
82!) (3)
Signature
Date:*
Name/Signature study physician*
4 / 4
Leukemia AML-AZA in elderly patients NCT00915252
A Double-Blind, Placebo-Controlled, Parallel-Group Study
to Assess the Efficacy, Safety, and Tolerability of CAT-354
ODM derived from
http://clinicaltrials.gov/show/NCT00640016
All rights reserved. Please visit https://medical-data-
models.org/forms/10248
Eligibility
Inclusion Criteria
age 18 Years to 80 Years*
Yes
No
Informed consent*
Yes
No
Female infertility or Contraceptive methods*
Yes
No
partner using condom and subject using
spermicide, diaphragm, intra-uterine device or
contraceptive sponge) for 1 month prior to Visit 1
(screening visit) or longer if requested by the
investigator. Women of childbearing potential
must continue to practice birth control during the
study and for at least 2 months after completing
the study. Women of childbearing potential must
have a negative pregnancy test at screening and
Visit 2, 5, 7 and 9.*
Yes
No
Uncontrolled (refractory) asthma despite optimal
treatment*
Yes
No
subjects will have Global Initiative for Asthma
(GINA 2006) clinical features of uncontrolled
asthma despite treatment with a minimum dose
of 800 g beclomethasone dipropionate or
equivalent inhaled corticosteroid per day plus one
or more additional controller i.e. long-acting b-
agonist, leukotriene antagonist or theophylline.
Oral corticosteroids (not parenteral) as additional
treatment at any dose are acceptable. The dose
of inhaled and oral corticosteroids must have
been stable within 4 weeks preceding Visit 1
(screening visit) and will be expected to remain
stable for the duration of the study. If subjects are
on single inhaler combination products at Visit 1
(e.g. fluticasone/salmeterol - Advair/Seretide or
Symbicort (budesonide/formoterol) SMART) they
must receive the two components as two
separate inhaler medications for the purpose of
the trial. This will facilitate withholding the long-
acting b-agonist component before lung function
and challenge testing (see Section 9.5.7). The
GINA 2006 [14] levels of asthma control and
treatment are described in Appendix 3.*
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Yes
No
A forced expiratory volume in 1 second (FEV1)
acceptable for AHR challenge tests (>= 60% of
predicted normal) on the challenge days.*
Yes
No
A provocative concentration of methacholine
causing a 20% fall in FEV1 (PC20) <= 4 mg/mL.*
Yes
No
Aged 18-80 years and are ambulatory and able to
travel to the clinic.7. A 12-lead electrocardiogram
(ECG) with no-clinically significant abnormalities.*
Yes
No
Clinical chemistry, haematology and urinalysis
results within the laboratory reference ranges or
deemed not clinically significant by the
Investigator.*
Yes
No
Body weight (observable entity)*
Yes
No
No other clinically significant abnormality on
history and clinical examination (see also
Exclusion Criteria).*
Yes
No
Able to comply with the requirements of the
protocol. *
Yes
No
Exclusion Criteria
Experienced a severe exacerbation within 28
days preceding Visit 1.*
Yes
No
Onset of uncontrolled seasonal allergy symptoms
within 28 days preceding Visit 1. Subjects with a
history of allergic rhinitis, seasonal allergy or
oesophagitis must be optimally controlled and
remain on a stable treatment regimen during the
study.*
Yes
No
Participation in another study within five half lives
or three months of the start of this study,
2 / 4
A Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the
Efficacy, Safety, and Tolerability of CAT-354
whichever is the longer. This does not apply to
methodological or observational studies in which
no investigational medicinal product (IMP) was
given.*
Yes
No
Lower respiratory tract infection within six weeks
of Visit 1.5.*
Yes
No
Current smokers or ex-smokers with > 10 pack-
years (number of pack years = (number of
cigarettes per day/20) x number of years smoked,
e.g., 20 cigarettes per day for 10 years, or 10
cigarettes per day for 20 years).*
Yes
No
Blood donation (> 550 mL) in the previous two
months.*
Yes
No
Excessive intake of alcohol (as judged by the
Investigator) or evidence of drug or solvent
abuse.*
Yes
No
Subjects with a physician-diagnosis of any other
significant lung disease, including a primary
diagnosis of chronic obstructive pulmonary
disease or bronchiectasis, or lung cancer,
sarcoidosis, tuberculosis, pulmonary fibrosis and
cystic fibrosis.*
Yes
No
Concurrent medication from Visit 1 (screening
visit) and for the duration of the study with any of
the prohibited medications.*
Yes
No
Significant, uncontrolled disease including
serious psychological disorders, chronic renal
failure, uncontrolled hypertension*
Yes
No
hypertension heart disease, psoriasis or stroke*
Yes
No
Any factor which, in the opinion of the
Investigator, would jeopardise the evaluation or
safety or be associated with poor adherence to
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the protocol (i.e. inability to complete study diary,
perform PEF measurements).*
Yes
No
The subject's primary care physician
recommends the subject should not take part in
the study.*
Yes
No
Known hypersensitivity to CAT-354 or its
components, to the challenge agents used in the
study or to related drugs.*
Yes
No
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HIV Eligibility NCT00531206
ODM derived from
http://clinicaltrials.gov/show/NCT00531206
Observational Non-interventional Study About Antiretroviral
Combination Treatment With Aptivus in Combination With
Low-dose Ritonavir in HIV Type 1 Infected Patients
NCT00531206
All rights reserved. Please visit https://medical-data-
models.org/forms/10249
Eligibility HIV NCT00531206
Inclusion Criteria
age at least 18 Years*
Yes
No
Highly pre-treated male and female adult patients
with virus resistant to multiple protease inhibitors.
Aptivus (tipranavir), co-administered with low
dose Norvir (ritonavir), is indicated for
combination antiretroviral treatment of HIV-1
infection in highly pre-treated adult patients with
virus resistant to multiple protease inhibitors.*
Yes
No
Exclusion Criteria
Age < 18 years*
Yes
No
pregnant female patients*
Yes
No
Hypersensitivity to the active substance or to any
of the excipients.*
Yes
No
Patients with moderate or severe (Child-Pugh B
or C) hepatic impairment.*
Yes
No
Rifampicin should not be used with Aptivus
(tipranavir) because co-administration may cause
large decreases in tipranavir concentrations
which may in turn significantly decrease the
tipranavir therapeutic effect.*
Yes
No
Herbal preparations containing St John's wort
must not be used while taking Aptivus (tipranavir)
due to the risk of decreased plasma
concentrations and reduced clinical effects of
tipranavir.*
Yes
No
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Co-administration of Aptivus (tipranavir) with low
dose Norvir (ritonavir), with active substances
that are highly dependent on CYP3A for
clearance and for which elevated plasma
concentrations are associated with serious and/or
life-threatening events is contraindicated. These
active substances include antiarrhythmics
(amiodarone, bepridil, quinidine), antihistamines
(astemizole, terfenadine), ergot derivatives
(dihydroergotamine, ergonovine, ergotamine,
methylergonovine), gastrointestinal motility
agents (cisapride), neuroleptics (pimozide,
sertindole), sedatives/hypnotics (triazolam) and
HMG-CoA reductase inhibitors (simvastatin and
lovastatin). In addition, co-administration of
Aptivus (tipranavir) with low dose Norvir
(ritonavir), with drugs that are highly dependent
on CYP2D6 for clearance, such as the
antiarrhythmics flecainide and propafenone, is
contraindicated.*
Yes
No
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German Quality Management  KVWL
quality management
dataset
German Quality Management 
Onkologische Qualitätssicherung der Kassenärztlichen
Vereinigung Westfalen-Lippe" (OQSWL)
All rights reserved. Please visit https://medical-data-
models.org/forms/10275
dataset KVWL
Patient data
Titel*
Patientennummer*
Nachname*
Vorname*
geb.*
Geschlecht*
Weiblich (F)
Männlich (M)
Street Address*
Patient postal code*
City of residence *
Patient telephone number*
Diagnose
Attending physician *
Registration office/authority*
Diagnosis*
Nachuntersuchung
Date last contact*
Source of information *
Cancer Center  (Cancer Center )
Cancer Registry  (Cancer Registry )
Central Office (Central Office)
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Hospitals (Hospitals)
Newspapers  (Newspapers )
not_coded (not_coded)
Other (Other)
Primary Care Physician (Primary Care
Physician)
Unknown (Unknown)
Collection Date *
reason for termination*
Aftercare completed (Aftercare
completed)
aftercare in other hospital (aftercare in
other hospital)
aftercare not designated (aftercare not
designated)
Aftercare not wanted (Aftercare not
wanted)
Age of Patient (Age of Patient)
no information (no information)
Patient absent (Patient absent)
Patient died (Patient died)
Patient moribund (Patient moribund)
patient moved elsewhere (patient moved
elsewhere)
Primary Care Physician unknowm
(Primary Care Physician unknowm)
uncooperative physician (uncooperative
physician)
Place of Aftercare*
Date of death*
Cause of death*
Death by neoplasm (Death by neoplasm)
Death by neoplasm uncertain (Death by
neoplasm uncertain)
no information (no information)
other cause of death (other cause of
death)
unknown (unknown)
Autopsy*
no information (no information)
not executed (not executed)
Yes (Yes)
Collection*
complete (complete)
incomplete (incomplete)
Autopsie
place of autopsy*
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autopsy identifier*
Date of Receipt*
Date of report*
Tumor Expansion
Primary Neoplasm *
No evidence of neoplasm  (No evidence
of neoplasm )
questionable Result (questionable
Result)
Recurrent Disease (Recurrent Disease)
Residual Disease  (Residual Disease )
Metastatic Malignant Neoplasm to the regional
Lymph Nodes*
No evidence of neoplasm  (No evidence
of neoplasm )
questionable Result (questionable
Result)
Recurrent Disease (Recurrent Disease)
Residual Disease  (Residual Disease )
Distant metastasis (other organs)*
No evidence of neoplasm  (No evidence
of neoplasm )
questionable Result (questionable
Result)
Recurrent Disease (Recurrent Disease)
Residual Disease  (Residual Disease )
Tumor Status*
- (-)
Assessment not possble (Assessment
not possble)
clinical improvement (clinical
improvement)
In complete remission  (In complete
remission )
no information (no information)
No neoplasm (qualifier value)  (No
neoplasm (qualifier value) )
not clarified (not clarified)
not_coded (not_coded)
partial response  (partial response )
Stable Disease (Stable Disease)
Tumor marker increase (Tumor marker
increase)
Tumor Progression (Tumor Progression)
Histopathologyie
Histology ICD-O-3*
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histologic diagnosis text*
Tumor site*
Site of primary tumor (Site of primary
tumor)
Subsite (Subsite)
Histologic Grade*
G1 grade  (G1 grade )
G2 grade (G2 grade)
G3 grade (G3 grade)
G4 Grade (G4 Grade)
Grade cannot be determined  (Grade
cannot be determined )
Grade not designated (Grade not
designated)
High grade (High grade)
Low grade (Low grade)
Neoplasm, Uncertain Whether Benign or
Malignant  (Neoplasm, Uncertain
Whether Benign or Malignant )
no information (no information)
cell type *
B-Cell Lymphomas  (B-Cell Lymphomas
)
Grade cannot be determined  (Grade
cannot be determined )
no information (no information)
Primary Cutaneous Anaplastic Large
Cell Lymphoma  (Primary Cutaneous
Anaplastic Large Cell Lymphoma )
T-Cell Lymphoma  (T-Cell Lymphoma )
Score *
Gleason-Score (Gleason-Score)
no information (no information)
not_coded (not_coded)
Sarcoma by FNCLCC Grade  (Sarcoma
by FNCLCC Grade )
Primary Gleason Pattern *
Secondary Gleason Pattern *
Total Gleason Score for Prostate Cancer *
Staging
Staging*
Ja
Nein
Generic tumor staging descriptor *
Tumor staging descriptor r (Tumor
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staging descriptor r)
Tumor staging descriptor y (Tumor
staging descriptor y)
TNM Classification before any treatment*
Ja
Nein
TNM Classification after operation*
Ja
Nein
TNM Stage descriptor*
T Stage*
Degree of certainty of TNM classification
(observable entity) *
TNM Stage descriptor*
N Stage*
Degree of certainty of TNM classification
(observable entity) *
TNM Stage descriptor*
M Stage*
Degree of certainty of TNM classification
(observable entity) *
Number of sentinel lymph nodes involved*
Number of sentinel lymph nodes examined*
Number of lymph nodes involved by malignant
neoplasm *
Number of lymph nodes examined*
Lymph vessel invasion*
L0 Stage Finding (L0 Stage Finding)
L1 Stage Finding (L1 Stage Finding)
LX Stage Finding (LX Stage Finding)
Venous Invasion*
V0 Stage Finding (V0 Stage Finding)
V1 Stage Finding  (V1 Stage Finding )
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V2 Stage Finding (V2 Stage Finding)
VX Stage Finding (VX Stage Finding)
organ capsule infiltration*
No (No)
no information (no information)
Yes, breakthrough (Yes, breakthrough)
Yes, Infiltration (Yes, Infiltration)
Perineural Invasion*
No (No)
no information (no information)
Status of perineural invasion cannot be
assessed (Status of perineural invasion
cannot be assessed)
Yes (Yes)
Residual tumor stage*
no information (no information)
Not Applicable  (Not Applicable )
not_coded (not_coded)
Residual tumor stage R0 (Residual
tumor stage R0)
Residual tumor stage R1  (Residual
tumor stage R1 )
Residual tumor stage R2 (Residual
tumor stage R2)
Residual tumor stage RX (Residual
tumor stage RX)
UICC-Classification*
available  (available )
no information (no information)
Ann Arbor Lymphoma Staging System *
Ja
Nein
other Staging System *
Ja
Nein
Description Staging System*
Stage*
Microsatellite Instability *
not_coded*
Fernmetastasen
Metastatic Malignant Neoplasm to the Lung*
Ja
Nein
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C-factor status*
C1 certainty  (C1 certainty )
C2 certainty  (C2 certainty )
C3 certainty  (C3 certainty )
C4 certainty  (C4 certainty )
C5 certainty  (C5 certainty )
Metastatic Malignant Neoplasm to the Pleura*
Ja
Nein
C-factor status*
C1 certainty  (C1 certainty )
C2 certainty  (C2 certainty )
C3 certainty  (C3 certainty )
C4 certainty  (C4 certainty )
C5 certainty  (C5 certainty )
Metastatic Malignant Neoplasm to the Liver*
Ja
Nein
C-factor status*
C1 certainty  (C1 certainty )
C2 certainty  (C2 certainty )
C3 certainty  (C3 certainty )
C4 certainty  (C4 certainty )
C5 certainty  (C5 certainty )
Metastatic Malignant Neoplasm to the Spleen *
Ja
Nein
C-factor status*
C1 certainty  (C1 certainty )
C2 certainty  (C2 certainty )
C3 certainty  (C3 certainty )
C4 certainty  (C4 certainty )
C5 certainty  (C5 certainty )
Metastatic Malignant Neoplasm to the Ovary *
Ja
Nein
C-factor status*
C1 certainty  (C1 certainty )
C2 certainty  (C2 certainty )
C3 certainty  (C3 certainty )
C4 certainty  (C4 certainty )
C5 certainty  (C5 certainty )
Metastatic Malignant Neoplasm to the
Peritoneum *
Ja
Nein
C-factor status*
C1 certainty  (C1 certainty )
C2 certainty  (C2 certainty )
C3 certainty  (C3 certainty )
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C4 certainty  (C4 certainty )
C5 certainty  (C5 certainty )
Metastatic Malignat Neoplasm to the adrenal
gland*
Ja
Nein
C-factor status*
C1 certainty  (C1 certainty )
C2 certainty  (C2 certainty )
C3 certainty  (C3 certainty )
C4 certainty  (C4 certainty )
C5 certainty  (C5 certainty )
Metastatic Malignant Neoplasm to the Bone
Marrow*
Ja
Nein
C-factor status*
C1 certainty  (C1 certainty )
C2 certainty  (C2 certainty )
C3 certainty  (C3 certainty )
C4 certainty  (C4 certainty )
C5 certainty  (C5 certainty )
Metastatic Malignant Neoplasm to the Bone *
Ja
Nein
C-factor status*
C1 certainty  (C1 certainty )
C2 certainty  (C2 certainty )
C3 certainty  (C3 certainty )
C4 certainty  (C4 certainty )
C5 certainty  (C5 certainty )
Metastatic Malignant Neoplasm to the Lymph
Node *
Ja
Nein
C-factor status*
C1 certainty  (C1 certainty )
C2 certainty  (C2 certainty )
C3 certainty  (C3 certainty )
C4 certainty  (C4 certainty )
C5 certainty  (C5 certainty )
Secondary malignant neoplasm of skin *
Ja
Nein
C-factor status*
C1 certainty  (C1 certainty )
C2 certainty  (C2 certainty )
C3 certainty  (C3 certainty )
C4 certainty  (C4 certainty )
C5 certainty  (C5 certainty )
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Metastatic malignant neoplasm to brain*
Ja
Nein
C-factor status*
C1 certainty  (C1 certainty )
C2 certainty  (C2 certainty )
C3 certainty  (C3 certainty )
C4 certainty  (C4 certainty )
C5 certainty  (C5 certainty )
Metastatic Malignant Neoplasm to the Kidney *
Ja
Nein
C-factor status*
C1 certainty  (C1 certainty )
C2 certainty  (C2 certainty )
C3 certainty  (C3 certainty )
C4 certainty  (C4 certainty )
C5 certainty  (C5 certainty )
Distant metastasis (other organs)*
Ja
Nein
C-factor status*
C1 certainty  (C1 certainty )
C2 certainty  (C2 certainty )
C3 certainty  (C3 certainty )
C4 certainty  (C4 certainty )
C5 certainty (C5 certainty )
Generalized cancer*
Ja
Nein
C-factor status*
C1 certainty  (C1 certainty )
C2 certainty  (C2 certainty )
C3 certainty  (C3 certainty )
C4 certainty  (C4 certainty )
C5 certainty  (C5 certainty )
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ECOG PATHOLOGY MATERIAL
SUBMISSION FORM (E2100)
ECOG PATHOLOGY MATERIAL SUBMISSION FORM
(E2100)
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=AC84B74E-
4F5E-6306-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/10283
ECOG PATHOLOGY MATERIAL
SUBMISSION FORM (E2100)
Part A
Date Sample Sent to ECOG (M,D,Y)
Data Manager
Telephone No.
FAX No.
ECOG Parent Prot. No.
Seq. No.
Patient's Name
ECOG Prot. No.
ECOG Patient Seq. No.
Participating Group Prot. No.
Participating Group Patient ID No.
Group
Institution
Step No.
Affiliate (COMPLETE FOR SLIDES)
Part B
STATUS (See Below)
Original Diagnostic Material (Original
Diagnostic Material)
Other, Specify (Other, Specify)
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Post-protocol Treatment Biopsy (Post-
Protocol Treatment Biopsy)
Post-surgery Biopsy (Post-Surgery
Biopsy)
Pre-protocol Treatment Biopsy (Pre-
Protocol Treatment Biopsy)
Relapse/recurrence
(Relapse/Recurrence)
Remission/response
(Remission/Response)
STATUS (See Below)
Original Diagnostic Material (Original
Diagnostic Material)
Other, Specify (Other, Specify)
Post-protocol Treatment Biopsy (Post-
Protocol Treatment Biopsy)
Post-surgery Biopsy (Post-Surgery
Biopsy)
Pre-protocol Treatment Biopsy (Pre-
Protocol Treatment Biopsy)
Relapse/recurrence
(Relapse/Recurrence)
Remission/response
(Remission/Response)
Other, Specify (specimen status)
Other, Specify (specimen status)
DATE SPECIMEN COLLECTED (M,D,Y)
DATE SPECIMEN COLLECTED (M,D,Y)
Telephone No.
DISEASE SITE
DISEASE SITE
NUMBER OF SLIDES
TYPE OF STAIN
SPECIMEN ID NUMBERS (COMPLETE FOR
BLOCKS)
SPECIMEN ID NUMBERS (COMPLETE FOR
BLOCKS)
NUMBER OF BLOCKS
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TYPE OF FIXATIVE
Submitting Pathologist
Address
INSTITUTION COMMENTS
Can this sample be retained by the ECOG
Central Tissue Repository? (NOTE: Samples
submitted for protocols requiring submission for
tissue banking will not be returned except for
purposes of individual patient management. For
this reason, the submitting pathologist should
retain at least one paraffin block at their
institution.  )
No (No)
Yes (Yes)
A block has been retained at the submitting
institution
No (No)
Yes (Yes)
Please CIRCLE THE REASON for non-
submission (and INCLUDE a formal letter of
explanation)
Institutional Policy (Institutional Policy)
Insufficient Tissue (Insufficient Tissue)
Other (Other)
Patient Refusal (Patient Refusal)
State Regulations (State Regulations)
specify other (reason for non-submission)
Pathologist or Investigator's Signature
Part C
Date Sample Received by ECOG (M D Y )
Date Sent to Central Lab (M D Y )
Date Sample Sent to Reviewer (M D Y )
Items Received (if different from above)
Name of Reviewer
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NOTES
Ccrr Module For Ecog Pathology Material
Submission Form (e2100)
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E2100 On-Study Form (E2100)
E2100 On-Study Form (E2100)
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=AC34564B-
C2DB-255C-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/10285
E2100 On-Study Form (E2100)
ECOG Clinical trial administrative data
ECOG Protocol No.
ECOG Patient ID
Registration Step
Patient's Name
Participating Group Protocol No.
Participating Group Patient ID
Institution/Affiliate
Are data amended?
Yes
No
Patient Characteristics
Menopausal Status (Choose one:)
Above Categories Not Applicable And
Age <50 (Above categories not
applicable AND Age <50)
Above Categories Not Applicable And
Age >= 50 (Above categories not
applicable AND Age >= 50)
Post (Post)
Pre (Pre)
Advanced Disease Description
ER Status (most recent)
Negative (Negative)
Positive (Positive)
Unknown (Unknown)
Receptor Status Timing (most recent)
At Recurrence (At Recurrence)
Initial Diagnosis (Initial Diagnosis)
Other (Other)
ER Timing, Other, Specify
1 / 5
PgR Status (most recent)
Negative (Negative)
Positive (Positive)
Unknown (Unknown)
PgR Timing, Other, Specify
Her2/Neu expression status by
immunohistochemistry (Choose one:)
0 (0)
1+ (1+)
2+ (2+)
3+ (3+)
Not Done (Not done)
Her2/Neu expression status by FISH (Choose
one:)
8 (8)
Amplified (Amplified)
Non-amplified (Non-amplified)
Not Done (Not done)
Date of Initial Diagnosis of Primary Tumor (M D
Y)
Date Recurrent, Progressive, or Metastatic
Disease First Diagnosed (M D Y)
Site(s) Of Involvement
Local-regional (sites of involvement) (Circle the
involved local-regional sites listed in   below:)
axillary, internal mammary and
infraclavicular nodes (axillary, internal
mammary and infraclavicular nodes)
chest wall (chest wall)
ipsilateraly breast (ipsilateraly breast)
local regional skin and subcutaneous
tissue (local regional skin and
subcutaneous tissue)
Ipsilateral supraclavicular nodes (sites of
involvement)
Yes
No
Opposite breast (sites of involvement)
Yes
No
Distant nodes (sites of involvement)
Yes
No
Distant skin/subcutaneous tissue (sites of
involvement)
Yes
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No
Bone (sites of involvement)
Yes
No
Bone marrow (sites of involvement)
Yes
No
Lung (sites of involvement)
Yes
No
Liver (sites of involvement)
Yes
No
Pleura (sites of involvement)
Yes
No
Brain (sites of involvement)
Yes
No
Other CNS (sites of involvement)
Yes
No
First Other, specify (sites of involvement)
Yes
No
Second Other, specify (sites of involvement)
Yes
No
First Other, specify
Second Other, specify
Prior Systemic Therapy
Prior Adjuvant Hormonal Therapy? (do not
include steroids given with chemotherapy)
Yes
No
Prior Metastatic/Recurrent Hormonal Therapy?
(do not include steroids given with chemotherapy)
Yes
No
Prior Adjuvant Chemotherapy? (include pre-op
chemotherapy at diagnosis)
Yes
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No
Prior Chemotherapy for Metastasis or
Recurrence?
Yes
No
Prior Adjuvant High Dose
Chemotherapy/Autologous Stem Cell Transplant?
Yes
No
Prior High Dose Chemotherapy/Autologous Stem
Cell Transplant for Metastasis or Recurrence?
Yes
No
Prior Adjuvant Immunotherapy?
Yes
No
Prior Immunotherapy for Metastasis or
Recurrence?
Yes
No
Prior Adjuvant Other Therapy?
Yes
No
Prior Metastatic/Recurrent Other Therapy?
Yes
No
Prior Systemic Regimens
Prior Treatment Regimen Name(s)
Prior Treatment Regimen Start Date (M/D/Y)
Prior Treatment Regimen End Date (M/D/Y)
Prior Treatment Regimen Type
Adjuvant (adjuvant)
Advanced (advanced)
Neoadjuvant (neoadjuvant)
Other (other)
Comments
Comments
Investigator Signature
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Date
Ccrr Module For E2100 On-study Form
(e2100)
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E2100 Toxicity Form (E2100)
E2100 Toxicity Form (E2100)
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=AC352024-
CFAE-2651-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/10286
E2100 Toxicity Form (E2100)
ECOG Clinical trial administrative data
ECOG Protocol No.
ECOG Patient ID
Registration Step
Adverse Event Reporting From Date (M D Y)
Adverse Event Reporting To Date (M D Y)
Patient's Name
Participating Group Protocol No.
Participating Group Patient ID
Institution/Affiliate
Are data amended? (CTC Adverse Event -
Hematologic)
Yes
No
Adverse event assessment
CTC Code
Al01 (AL01)
Cg07 (CG07)
Cg08 (CG08)
Cg14 (CG14)
Cn02 (CN02)
Gi27 (GI27)
He01 (HE01)
He02 (HE02)
He04 (HE04)
Hp08 (HP08)
In02 (IN02)
In03 (IN03)
In03 (IN03)
In05 (IN05)
Mu02 (MU02)
Ne20 (NE20)
Pa02 (PA02)
Pa10 (PA10)
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Re08 (RE08)
CTC Adverse Event Term
Allergic Reaction (Allergic reaction)
Arthralgia (Arthralgia)
Epistaxis (Epistaxis)
Febrile Neutropenia W/o Infection
(Febrile neutropenia w/o infection)
Fever W/o Gr 3/4 Neutropenia (Fever w/o
Gr 3/4 neutropenia)
Hemorrhage W/ Grade 3 Or 4 Platelets
(Hemorrhage w/ grade 3 or 4 platelets)
Hemorrhage W/o Grade 3 Or 4 Platelets
(Hemorrhage w/o grade 3 or 4 platelets)
Hypertension (Hypertension)
Hypotension (Hypotension)
Infection W/ Unknown Anc (Infection w/
unknown ANC)
Infection W/grade 3 Or 4 Neutropenia
(Infection w/grade 3 or 4 neutropenia)
Infection W/o Neutropenia (Infection w/o
neutropenia)
Muscle Weakness (Muscle weakness)
Myalgia (Myalgia)
Neuropathy-sensory (Neuropathy-
sensory)
Proteinuria (Proteinuria)
Sgot (ast) (SGOT (AST))
Stomatitis (Stomatitis)
Thrombosis/embolism (including Dvt And
Pe) (Thrombosis/embolism (including
DVT and PE))
CTC Adverse Event Grade (this period)
3 (3)
4 (4)
5 (5)
CTC ADVERSE Event Attribution Code
Possible (possible)
Probable (probable)
Unlikely (unlikely)
Unrelated (unrelated)
Other CTC Adverse Event Term(s) not listed
(Use CTC terminology)
Comments
Comments
Investigator Signature
Date
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E2100 Toxicity Form (E2100)
Ccrr Module For E2100 Toxicity Form
(e2100)
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E2100 Toxicity Form (E2100)
ECOG Baseline Disease Evaluation Form
(RECIST), E2100
ECOG Baseline Disease Evaluation Form (RECIST),
E2100
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=AC353A38-
9217-267B-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/10288
ECOG Baseline Disease Evaluation
Form (RECIST), E2100
ECOG Clinical trial administrative data
ECOG Protocol No.
ECOG Patient ID
Registration Step
Patient's Name
Participating Group Protocol No.
Participating Group Patient ID
Institution/Affiliate
Are data amended?
Yes
No
Target Lesions
Are there any target lesions?
Yes
No
Lesion Number
Site of Lesion (Multiple nontarget lesions within
an organ may be combined as a single site;
report in a consistent manner on subsequent
forms.)
Site Code (Site codes)
Bone (Bone)
Brain (Brain)
Breast (Breast)
Effusion/ascites (Effusion/Ascites)
Gi (GI)
Gu (GU)
Head & Neck (Head & Neck)
Liver (Liver)
Lung (Lung)
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Nodes (Nodes)
Other (specify Site) (Other (specify site))
Skin (Skin)
Method of Evaluation (Method of Evaluation
codes)
Bone Scan (Bone Scan)
Chest X-ray (Chest X-Ray)
Clinical Exam (Clinical Exam)
Ct Scan (CT Scan)
Mri (MRI)
Other (specify In Comments) (Other
(specify in Comments))
Spiral Ct (Spiral CT)
Ultrasound (Ultrasound)
Date of Evaluation (M D Y)
Longest Diameter of Lesion(s) (cm)
Sum of longest diameters of all target lesions
(cm)
Nontarget Lesions
Cytology Result
Negative (Negative)
Not Done (Not done)
Positive (Positive)
Comments
Comments
Investigator Signature
Date
Ccrr Module For Ecog Baseline Disease
Evaluation Form (recist), E2100
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ECOG Baseline Disease Evaluation Form (RECIST), E2100
ECOG Follow-Up Disease Evaluation Form
(RECIST), E2100
ECOG Follow-Up Disease Evaluation Form (RECIST),
E2100
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=AC81CEBA-
3795-431A-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/10289
ECOG Follow-Up Disease Evaluation
Form (RECIST), E2100
ECOG clinical trial administrative data
ECOG Protocol No.
ECOG Patient ID
Registration Step
Cycle Number
Patient's Name
Participating Group Protocol No.
Participating Group Patient ID
Institution/Affiliate
Are data amended?
Yes
No
Target Lesions
Lesion Number
Site of Lesion (Multiple new lesions within an
organ may be combined as a single site.)
Site Code (Site codes)
Bone (Bone)
Brain (Brain)
Breast (Breast)
Effusion/ascites (Effusion/Ascites)
Gi (GI)
Gu (GU)
Head & Neck (Head & Neck)
Liver (Liver)
Lung (Lung)
Nodes (Nodes)
Other (Other)
Skin (Skin)
1 / 4
Method of Evaluation (Method of Evaluation
codes)
Bone Scan (Bone Scan)
Chest X-ray (Chest X-Ray)
Clinical Exam (Clinical Exam)
Ct Scan (CT Scan)
Mri (MRI)
Other (specify In Comments) (Other
(specify in Comments))
Spiral Ct (Spiral CT)
Ultrasound (Ultrasound)
Date of Evaluation (M D Y)
Longest Diameter of Lesion(s) (cm)
BASELINE Longest Diameter of Lesion (cm)
Sum of longest diameters of all target lesions
(cm)
Nontarget Lesions
Follow-up Status of Lesions
Cr (CR)
Incompl. Resp./sd (Incompl. resp./SD)
Pd (PD)
Unequivocal progressive disease in nontarget
lesions is based on: (please describe) (For Site
Code 04 effusion/ascites ONLY:)
Cytology Result
Negative (Negative)
Not Done (Not done)
Positive (Positive)
New Lesions
Was the appearance of any new lesions
documented?
Yes
No
Response Of Target Lesions This
Reporting Period
Has the response of the target lesions changed,
OR has an unconfirmed response changed to a
confirmed response, since last report?
Yes
No
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ECOG Follow-Up Disease Evaluation Form (RECIST), E2100
Response status at this assessment (target
lesions)
Complete Response (CR)
Insufficient Evaluation (Insufficient
evaluation to determine response status)
Progressive Disease Or Progression
(PD)
Stable Disease (SD)
PR/CR first observed date (target lesions) (M D
Y)
Progressive disease observed date (target
lesions) (M D Y)
Overall Response Per Recist Criteria -
Target, Nontarget And New Lesions
Has the overall response changed, OR has an
unconfirmed response changed to a confirmed
response, since last report?
Yes
No
Overall response status at this assessment (For
PD:)
Complete Response (CR)
Null (Insufficient evaluation to determine
response status)
Progressive Disease (PD)
Partial Response (PR)
Stable Disease (SD)
Progressive disease observed date (M D Y)
Has response been confirmed by second
assessment? (Confirmation of response: For
CR/PR, all assessments repeated >= 4 wks after
onset of CR/PR.)
Yes
No
PR/CR first observed date (M D Y)
Symptomatic Deterioration
Is there symptomatic deterioration of the patient's
health status requiring discontinuation of
treatment (this reporting period)?
No (no)
Yes, Specify (yes, specify)
yes, specify (symptomatic deterioration requiring
discontinuation of treatment)
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ECOG Follow-Up Disease Evaluation Form (RECIST), E2100
Symptomatic Deterioration Date (M D Y)
Comments
Comments
Investigator Signature
Date
Ccrr Module For Ecog Follow-up Disease
Evaluation Form (recist), E2100
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ECOG Follow-Up Disease Evaluation Form (RECIST), E2100
FACT-B (Version 4), E2100
FACT-B (Version 4), E2100
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=AC2FF0E4-
063C-2184-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/10293
FACT-B (Version 4), E2100
ECOG clinical trial administrative data
ECOG Protocol No.
ECOG Patient ID (B1)
Registration Step
Date of assessment
Patient's Name
Participating Group Protocol No.
Participating Group Patient ID
Institution/Affiliate (GP1)
Physical Well-being
I have a lack of energy (GP2)
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have nausea (GP3)
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
Because of my physical condition, I have trouble
meeting the needs of my family (GP4)
A Little (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have pain (GP5)
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
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Very Much (Very much)
I am bothered by side effects of treatment (GP6)
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I feel ill (GP7)
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am forced to spend time in bed (GS1)
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
Social/family Well-being
I feel close to my friends (GS2)
A Little (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I get emotional support from my family (GS3)
A Little (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I get support from my friends (GS4)
A Little (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
My family has accepted my illness (GS5)
A Little (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am satisfied with communication about my
illness (GS6)
A Little (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
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Very Much (Very much)
I feel close to my partner (or the person who is
my main support)
A Little (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
(Prefer not to answer next question) (Regardless
of your current level of sexual activity, please
answer the following question.  If you prefer not to
answer it, please check this box and go to the
next section.)
I am satisfied with my sex life.
A Little (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
Emotional Well-being
I feel sad (GE2)
A Little (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am satisfied with how I am coping with my
illness (GE3)
A Little (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am losing hope in the fight against my illness
(GE4)
A Little (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I feel nervous (GE5)
A Little (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I worry about dying (GE6)
A Little (A little bit)
Not At All (Not at all)
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Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I worry that my condition will get worse (GF1)
A Little (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
Functional Well-being
I am able to work (include work at home) (GF2)
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
My work (include work at home) is fulfilling (GF3)
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am able to enjoy life (GF4)
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have accepted my illness (GF5)
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am sleeping well (GF6)
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am enjoying things I usually do for fun (GF7)
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am content with the quality of my life right now
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
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Somewhat (Somewhat)
Very Much (Very much)
Additional Concerns
I have been short of breath (B2)
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am self-concious about the way I dress (B3)
A Little (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
One or both of my arms are swollen and tender
(B4)
A Little (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I feel sexually attractive (B5)
A Little (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am bothered by my hair loss (B6)
A Little (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I worry that other members of my family might
someday get the same illness I have (B7)
A Little (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I worry about the effects of stress on my illness
(B8)
A Little (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am bothered by a change in weight (B9)
A Little (A little bit)
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Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am able to feel like a woman
A Little (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
Ccrr Module For Fact-b (version 4), E2100
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ECOG Non-Protocol Therapy Form (E2100)
ECOG Non-Protocol Therapy Form (E2100)
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=AC221E8E-
B0F2-153B-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/10297
ECOG Non-Protocol Therapy Form
(E2100)
ECOG clinical trial administrative data
ECOG Protocol No.
ECOG Patient ID
Registration Step
Patient's Name
Participating Group Protocol No.
Participating Group Patient ID
Institution/Affiliate
Are data amended?
Yes
No
Non-protocol therapy assessment
Date of FIRST non-protocol therapy (if given prior
to progression/relapse from protocol therapy:)
Type(s) of first non-protocol therapy (which
includes any cancer therapy that is not part of the
planned regimen)
Non-protocol Chemotherapy (Non-
protocol Chemotherapy)
Non-protocol High Dose
Chemotherapy/stem Cell Transplant
(autologous Or Allogeneic) (Non-protocol
High Dose Chemotherapy/Stem Cell
Transplant (Autologous or Allogeneic))
Non-protocol Hormonal Therapy (Non-
protocol Hormonal Therapy)
Non-protocol Immunotherapy/biological
Response Modifiers (Non-protocol
Immunotherapy/Biological Response
Modifiers)
Non-protocol Radiation Therapy (Non-
protocol Radiation Therapy)
Non-protocol Surgery (Non-protocol
1 / 2
Surgery)
Other Non-protocol Therapy (Other Non-
protocol Therapy)
Name of other non-protocol therapy
Was the non-protocol therapy given for the
disease of this protocol? (NOTE: Treatment for a
second primary in the same organ site would not
be considered therapy for disease of this
protocol.)
No (No)
Unknown (Unknown)
Yes (Yes)
Comments
Comments
Investigator Signature
Date
Ccrr Module For Ecog Non-protocol
Therapy Form (e2100)
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E2100 Treatment Form (E2100)
E2100 Treatment Form (E2100)
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=AC347692-
7E8B-258D-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/10300
E2100 Treatment Form (E2100)
ECOG clinical trial administrative data
ECOG Protocol No.
ECOG Patient ID
Registration Step
Patient's Name
Participating Group Protocol No.
Participating Group Patient ID
Institution/Affiliate
Are data amended?
Yes
No
Vital Status
Patient's Vital Status
Alive (Alive)
Dead (Dead)
Date of Last Contact or Death (M D Y)
Cause of Death (if applicable)
Due To Other Cause (Due to other
cause)
Due To Protocol Treatment (Due to
protocol treatment)
Due To This Disease (Due to this
disease)
Unknown (Unknown)
Describe cause of death
Treatment Cycle Information
Cycle Start Date (M D Y)
1 / 3
Cycle Number (Paclitaxel Dose mg)
Dose 1 (Paclitaxel)
Dose 2 (Paclitaxel)
Dose 3 (Paclitaxel) (If applicable)
Dose 1 (Bevacizumab)
Dose 2 (Bevacizumab)
Were there any dose modifications or
additions/omissions to protocol treatment this
report period ? (Choose one:)
No (No)
Yes, Planned (Yes, planned)
Yes, Unplanned (Yes, unplanned)
Was any non-protocol therapy given during
protocol treatment (not previously reported)?
Yes
No
End of treatment evaluation
Last date protocol therapy was given (M D Y)
Reason treatment ended (Choose one:)
7 (7)
Alternative Therapy (Alternative therapy)
Death After Beginning Protocol Therapy
(Death after beginning protocol therapy)
Disease Progression, Relapse During
Active Treatment (Disease progression,
relapse during active treatment)
Other (Other)
Other Complicating Disease (Other
complicating disease)
Patient Withdrawal Or Refusal After
Beginning Protocol Therapy (Patient
withdrawal or refusal after beginning
protocol therapy)
Toxicity/side Effects/complications
(Toxicity/side effects/complications)
Treatment Completed Per Protocol
Criteria (Treatment completed per
protocol criteria)
specify Complicating Disease
specify Other Reasons (reason treatment ended)
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Comments
Comments
Investigator Signature
Date
Ccrr Module For E2100 Treatment Form
(e2100)
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E2100 Treatment Form (E2100)
E2100 Assessment Compliance Form
E2100 Assessment Compliance Form
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=AC30257A-
06A3-20B2-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/10303
E2100 Assessment Compliance
Form
ECOG Clinical trial administrative data
ECOG Protocol No.
ECOG Patient ID
Registration Step
Patient's Name
Participating Group Protocol No.
Participating Group Patient ID
Institution/Affiliate
Are data amended?
Yes
No
Assessment Form information
Assessment Form No.
Date Assessment Scheduled (M D Y)
Was the Assessment Form completed?
Yes
No
Time point
Baseline (baseline)
Day 1 Of Week 17 (day 1 of week 17)
Day 1 Of Week 33 (day 1 of week 33)
Other, Specify (other, specify)
other, specify (time point)
If Assessment Was Completed
Date Assessment Form completed (M D Y)
1 / 3
Was Assessment self-administered?
No (no)
Unknown (unknown)
Yes (yes)
If NO (assessment was not self-administered),
how was patient assisted?
Completed Independently By Another
Person (completed independently by
another person)
Patient Required Clarification Of
Questions Or Instructions (patient
required clarification of questions or
instructions)
Patient Required Other Assistance
(patient required other assistance)
Questions Were Read Aloud To Patient
(questions were read aloud to patient)
If NO (assessment was not self-administered),
what was the reason?
Disability, Please Specify (disability,
please specify)
Language Difficulty (questions Needed
To Be Translated), Specify Language
(language difficulty (questions needed to
be translated), specify language)
Literacy Difficulty (patient Could Not
Read Well Enough) (literacy difficulty
(patient could not read well enough))
Other, Please Specify (other, please
specify)
Telephone Interview (telephone
interview)
language difficulty (questions needed to be
translated), specify language
disability, please specify
other, please specify (reason assessment was
not self-administered)
If NO (assessment was not self-administered),
who assisted or completed assessment?
Family (family)
Friend (friend)
Other, Please Specify (other, please
specify)
Staff (staff)
other, please specify (who assisted or completed
assessment)
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If Assessment Was Not Completed
Indicate primary reason why form was not
completed
Assessment Not Required Per Protocol
Please Specify (assessment not required
per protocol please specify)
Other, Please Specify (other, please
specify)
Patient Did Not Show Up In Clinic/office
Please Specify (patient did not show up
in clinic/office please specify)
Patient Expired (patient expired)
Patient Not Given Form By Staff (patient
not given form by staff)
Patient Refusal (patient refusal)
Patient Too Ill (patient too ill)
Staff Thought Patient Too Ill (staff
thought patient too ill)
Staff Unavailable (staff unavailable)
unable to accommodate disability or language
needs please specify
patient did not show up in clinic/office please
specify
assessment not required per protocol please
specify
other, please specify (primary reason why form
was not completed)
Comments
Comments
Investigator Signature
Date
Ccrr Module For E2100 Assessment
Compliance Form
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E2100 Assessment Compliance Form
S0100 OFF TREATMENT NOTICE
S0100 OFF TREATMENT NOTICE
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=AEB544B0-
C752-4414-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/10324
S0100 OFF TREATMENT NOTICE
SWOG clinical trial administrative data
SWOG Patient ID
SWOG Study No.
Registration Step
Patient Initials (L, F M)
Institution/Affiliate
Physician (Groups other than SWOG)
Group Name
Study No.
Pt. ID
Treatment information
Treatment Start Date
Treatment End Date
Regimen or Procedure or Site(s) (If more room is
needed, please continue on a separate page.)
Off Treatment Reason (select one)
Alternative Therapy (Alternative therapy)
Death (Death)
Death Of Patient Occurred After The
Patient Began Protocol Therapy (Death
after beginning protocol therapy)
Death On Study (Death on study)
Death Prior To Beginning Protocol
Therapy (Death prior to beginning
protocol therapy)
Disease Progression, Relapse During
Active Treatment (Disease progression,
relapse during active treatment)
Progression Of Disease Occurred Prior
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To The Patient Beginning Protocol
Therapy (Disease progression, relapse
prior to beginning protocol therapy)
Medically required, due to toxicity,
specify (Medically required, due to
toxicity, specify)
Other, Specify (Other, specify)
Patient Off-treatment For Other
Complicating Disease (Patient off-
treatment for other complicating disease)
Patient refused, due to toxicity, specify
(Patient refused, due to toxicity, specify)
Patient refused, other than toxicity,
specify (Patient refused, other than
toxicity, specify)
Patient Withdrawal Or Refusal After
Beginning Protocol Therapy (Patient
withdrawal or refusal after beginning
protocol therapy)
Patient Withdrawal Or Refusal Prior To
Beginning Protocol Therapy (Patient
withdrawal or refusal prior to beginning
protocol therapy)
Progression or relapse (Progression or
relapse)
Toxicity/side Effects/complications
(Toxicity/Side effects/Complications)
Treatment Completed Per Protocol
Criteria (Treatment completed per
protocol criteria)
Medically required, due to toxicity, specify
Medically required, due to toxicity, specify
Sites (progression or relapse)
Patient refused, other than toxicity, specify
Patient refused, other than toxicity, specify
Date of completion, progression, death or
decision to discontinue therapy
Will patient receive further treatment?
No (No)
Unknown (Unknown)
Yes (Yes, specify)
Yes, specify (further treatment)
Date of Last Contact (or death)
Vital Status
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Alive (Alive)
Dead (Dead)
Comments
Comments
Ccrr Module For S0100 Off Treatment
Notice
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S0100 OFF TREATMENT NOTICE
HEM
HEM
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=FF1B0A30-
0B37-31B9-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/10326
HEM
Header Module
Segment
Visit number
Record Neutrophil Count And Specimen
Collection Dates
Did the patient achieve ANC recovery
=>500/mm3 on three consecutive
No (No)
Previously reported (Previously reported)
Yes (Yes)
Day 3
Date specimen collected
Record Chimerism Assay Data For
Marrow And/or Blood
Marrow
Was a chimerism performed on a marrow sample
Yes
No
Method of evaluation
Fluorescent in situ hyrbidization (FISH)
(Fluorescent in situ hyrbidization (FISH))
HLA serotyping (HLA serotyping)
Other (Other)
Polymerase chain reaction (Polymerase
chain reaction)
Restriction fragment-length
polymorphisms (RFLP) (Restriction
fragment-length polymorphisms (RFLP))
Standard cytogenetics (Standard
cytogenetics)
Specify other
Cell type
Granulocytes (Granulocytes)
Unmanipulated (Unmanipulated)
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Marrow assay results
All donor cells (All donor cells)
All host cells (All host cells)
Host and donor (Host and donor)
% donor
T Cell Chimerism
Was a chimerism performed on a T cell sample
Yes
No
Type of sample
Blood (Blood)
Marrow (Marrow)
T cell assay results
All donor cells (All donor cells)
All host cells (All host cells)
Host and donor (Host and donor)
% donor
Did the patient achieve a stem cell re-infusion
due to inadequate hematopoietic function
Yes
No
Record date of infusion
Comments
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Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=AEB5527E-
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S0100 NOTICE OF DEATH
SWOG clinical trial administrative data
SWOG Patient ID
Most Recent SWOG Study No.
Patient Initials (L, F M)
Institution/Affiliate
Physician (Groups other than SWOG)
Group Name
Study No.
Pt. ID
Causes Of Death
Date of Death (month/day/year)
Any cancer (select one)
Contributory2005688 (Contributory)
No2005686 (No)
Possible2005689 (Possible)
Primary_cause2005687 (Primary Cause)
Unknown2005690 (Unknown)
If cancer was the primary cause or if cancer
possibly or definitely contributed to death, and the
patient had had multiple tumor types, specify
those which were causes of death
Cancer_of_most_recent_s2005692
(Cancer of most recent SWOG study,
specify cancer)
Cancer_of_oth_swog_stdy2005693
(Cancer of other SWOG study, specify
cancer)
Other_cancer_specify2005694 (Other
cancer, specify)
Cancer of most recent SWOG study, specify
cancer
Cancer of other SWOG study, specify cancer
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Other cancer, specify
Toxicity from disease related treatment (select
one)
Contributory2005699 (Contributory)
No2005697 (No)
Possible2005700 (Possible)
Primary_cause2005698 (Primary Cause)
Unknown2005701 (Unknown)
If Primary Cause, Contributory or Possible,
specify treatment and toxicity
Non-cancer and non-treatment related causes
(select one)
Contributory2005707 (Contributory)
No2005705 (No)
Possible2005708 (Possible)
Primary_cause2005706 (Primary Cause)
Unknown2005709 (Unknown)
If Primary Cause, Contributory or Possible,
specify
Autopsy done?
No (No)
Unknown (Unknown)
Yes (Yes)
Death information obtained from (select all that
apply)
Autopsy Was The Source Of Information
On The Patient's Death (Autopsy report)
Medical record / Death certificate
(Medical record / Death certificate)
Other, specify (Other, specify)
Physician (Physician)
Relative or friend (Relative or friend)
Other, specify (death information obtained)
Comments
Comments
Ccrr Module For S0100 Notice Of Death
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Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=FF1B2D88-
AFFF-3372-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
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Patient infection medical history
Segment
Infection site
Blood/buffy coat (Blood/buffy coat)
Bone cortex (osteomyelitis) (Bone cortex
(osteomyelitis))
Bone marrow (Bone marrow)
Brain (Brain)
Cardiac (endocardium, myocardium,
pericardium) (Cardiac (endocardium,
myocardium, pericardium))
Catheter tip (Catheter tip)
Central nervous system unspecified
(Central nervous system unspecified)
Disseminated - generalized, isolated at 3
or more distinct sites (Disseminated -
generalized, isolated at 3 or more distinct
sites)
Ears (Ears)
Esophagus (Esophagus)
Eyes (Eyes)
Fallopian tubes, uterus, cervix (Fallopian
tubes, uterus, cervix)
Feces/stool (Feces/stool)
Gallbadder and biliary tree (not
hepatitis), pancreas (Gallbadder and
biliary tree (not hepatitis), pancreas)
Gastrointestinal tact unspecified
(Gastrointestinal tact unspecified)
Genital area (Genital area)
Genito-urinary tract uspecified (Genito-
urinary tract uspecified)
Joints (Joints)
Kidneys, renal pelvis, ureters, and
bladder (Kidneys, renal pelvis, ureters,
and bladder)
Large intestine (Large intestine)
Larynx (Larynx)
Lips (Lips)
Liver (Liver)
Lower respiratory tract (lung) (Lower
respiratory tract (lung))
Lymph nodes (Lymph nodes)
Meninges and CSF (Meninges and CSF)
Muscle (excluding cardiac) (Muscle
(excluding cardiac))
Other unspecified (Other unspecified)
Peritoneum (Peritoneum)
Pleural cavity, pleural fluid (Pleural cavity,
pleural fluid)
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Prostate (Prostate)
Rash, pustules, or abcessed not typical
of any of the above (Rash, pustules, or
abcessed not typical of any of the above)
Respiratory tract unspecified
(Respiratory tract unspecified)
Sinuses (Sinuses)
Skin unspecified (Skin unspecified)
Small intestine (Small intestine)
Spinal cord (Spinal cord)
Spleen (Spleen)
Stomach (Stomach)
Testes (Testes)
Tongue, oral cavity, and oro-pharynx
(Tongue, oral cavity, and oro-pharynx)
Upper airway and nasophyarynx (Upper
airway and nasophyarynx)
Vagina (Vagina)
Woundsite (Woundsite)
Infection start date
Infection I
Record the level of certainty of the fungal
infection diagnosis
Possible fungal infection (Possible fungal
infection)
Probable fungal infection (Probable
fungal infection)
Proven fungal infection (Proven fungal
infection)
Type of infection
Bacterial (Bacteria)
Fungal (Fingal)
Other (Other)
Protocoal (Protocoal)
Viral (Viral)
Organism I
Acinetobacter (Acinetobacter (baumanii,
calcoaceticus, lwoffi, other species))
Adenovirus (Adenovirus)
Agrobacterium (Agrobacterium
radiobacter)
Alcaligenes (Alcaligenes xylosoxidans)
Amebiasis (Amebiasis)
Anaerobic bacteria (NOS, except for
bacteroides, clostridium) (Anaerobic
bacteria (NOS, except for bacteroides,
clostridium))
Apserguillus (NOS) (Apserguillus (NOS))
Aspergillus Flavus (Apserguillus flavus)
Aspergillus Fumigatus (Apserguillus
fumigatus)
Aspergillus Niger (Apserguillus Niger)
Bacillus (Bacillus (cereau, other
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species))
Bacteroides (Bacteroides (gracillis,
uniformis, vulgaris, other species))
Borrelia (Borrelia (Lyme disease))
Branhamelia or Moraxella catarrhalis
(other species) (Branhamelia or
Moraxella catarrhalis (other species))
Campylobacter (Campylobacter (all
species))
Candida (NOS) (Candida (NOS))
Candida Albicans (Candida Albicans)
Candida Krusei (Candida Krusei)
Candida Parasilosis (Candida
Parasilosis)
Candida Tropicalis (Candida Tropicalis)
Chlamydia (Chlamydia)
Citrobacter (Citrobacter (freundii, other
species))
Clostridium (all species except difficile)
(Clostridium (all species except difficile))
Clostridium Difficile (Clostridium difficile)
Corynebacterium (Corynebacterium (all
non-diptheria species))
Coxiella (Coxiella)
Cryptococcosis (Cryptococcus species)
Cryptosporidium (Crytosporidium)
Cytomegalovirus (Cytomagalovirus
(CMV))
Echinocoocalyst (Echinocoocalyst)
Enterobacter (Enterobacter)
Enterococcus (Enterococcus (all
species))
Enterovirus (Enterovirus (coxsackie,
echo, polio))
Epstein-barr Virus (Epstein-Barr virus
(EBV))
Escherichia Coli (Escherichia (also E.
coli))
Flavimonas Flavimonas Flavimonas
(Flavimonas oryzihabitans)
Flavobacterium (Flavobacterium)
Fusarium (Fusarium species)
Fusobacteria (Fusobacterium nucleatum)
Giardia (Giardia)
Gram Negative Diplococci (Gram
negative diplococci (NOS))
Gram Negative Rod (Gram negative rod
(NOS))
Gram Positive Cocci (Gram positive
cocci (NOS))
Gram positive rod (NOS) (Gram positive
rod (NOS))
Haemophilus (all species including
influenzae) (Haemophilus (all species
including influenzae))
Helicobacter Pylori (Helicobacter pylori)
Hepatitis A (Hepatitis A (HAV))
Hepatitis B Virus (Hepatitis B (HBV,
Australian anitgen))
Hepatitis C (Hepatitis C (includes non-A
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and non-B, HCV))
Herpes Simplex (Herpes simplex (HSV1,
HSV2))
Herpes Zoster (Herpes zoster (chicken
pox, varicella))
HHV-6 (human herpes virus) (HHV-6
(human herpes virus))
Human Immunodeficiency Virus (HIV-1,
HITLV-III)
Influenza (Influenza (flu))
Klebsiella (Klebsiella)
Lactobacillus (Lactobacillus (bulgaricus,
acidophilus, other species))
Legionella (Legionella)
Leptospira (Leptospira)
Leptotrichia (Leptotrichia buccalis)
Leuconostoc (Leuconostoc (all species))
Listeria (Listeria)
Measles (rubeola) (Measles (rubeola))
Methylobacterium (Methylobacterium)
Micrococcus (Micrococcus (NOS))
Mumps (Mumps)
Musormycosis (zygomycete, rhizopus)
(Musormycosis (zygomycete, rhizopus))
Mycobacteria (avium, bovium,
haemophilum, intercellulare)
(Mycobacteria (avium, bovium,
haemophilum, intercellulare))
Mycobacterium Infection (Mycobacterium
tuberculosis)
Mycoplasma (Mycoplasma)
Mycoplasma (Mycoplasma)
Neisseria (gonorrhea, meningitidis, other
species) (Neisseria (gonorrhea,
meningitidis, other species))
Nocardia (Nocardia)
Other Microorganism, Specify (Other
bacteria (NOS))
Other fungus (Other fungus)
Other Mycobacterium (Other
Mycobacterium)
Other organism (Other organism)
Protozoa, Not Otherwise Specified
(Other protozoal (parasite))
Other viral (Other viral)
Papovavirus (Papovavirus)
Parainfluenza (Parainfluenza)
Pharyngeal/respiratory flora
(Pharyngeal/respiratory flora)
Pneumoncystic (PCP_ (Pneumoncystic
(PCP_)
Polyomavirus (Polyomavirus)
Propionbacterium (acnes, avidium,
granulosum, other species)
(Propionbacterium (acnes, avidium,
granulosum, other species))
Pseudomonas (Pseudomonas or
Burkholderia cepacia)
Pseudomonas or Stenotrophomonas or
Xanthomonas maltophilia (Pseudomonas
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or Stenotrophomonas or Xanthomonas
maltophilia)
Respiratory Syncytial Virus (Respiratory
syncytial virus (RSV))
Rhinovirus (common cold) (Rhinovirus
(common cold))
Rhodococcus (Rhodococcus)
Rickettsia (Rickettsia)
Rotavirus (Rotavirus)
Rubella (German measles) (Rubella
(German measles))
Salmonella (Salmonella (all species))
Serratia (Serratia marcescens)
Shigella (Shigella)
Staphylococcus (Staphylococcus (coag
-))
Staphylococcus (coag +)
(Staphylococcus (coag +))
Staphylococcus (NOS) (Staphylococcus
(NOS))
Stomatococcus Mucilaginosis
(Stomatococcus mucilaginosis)
Streptococcus (Streptococcus (all
species except enterococcus))
Torulopsis Galbrata (a subspecies of
Candida) (Torulopsis Galbrata (a
subspecies of Candida))
Toxoplasma (Toxoplasma)
Treponema (Treponema (syphilis))
Trichomonas (Trichomonas (either
vaginal or gingivitis))
Tuberculosis (NOS, AFB, acid fast
bacillus, Koch bacillus) (Tuberculosis
(NOS, AFB, acid fast bacillus, Koch
bacillus))
Typical tuberculosis (TB, tuberculosis)
(Typical tuberculosis (TB, tuberculosis))
Vibrio (Vibrio (all species))
Yeast (Yeast (NOS))
If other specify
Severity of infection
Life-threatening (Life-threatening/fatal)
Moderate (Moderate)
Severe (Severe)
Infection Ii
Record the level of certainty of the fungal
infection diagnosis
Possible fungal infection (Possible fungal
infection)
Probable fungal infection (Probable
fungal infection)
Proven fungal infection (Proven fungal
infection)
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Type of infection
Bacterial (Bacteria)
Fungal (Fingal)
Other (Other)
Protocoal (Protocoal)
Viral (Viral)
Organism I
Acinetobacter (Acinetobacter (baumanii,
calcoaceticus, lwoffi, other species))
Adenovirus (Adenovirus)
Agrobacterium (Agrobacterium
radiobacter)
Alcaligenes (Alcaligenes xylosoxidans)
Amebiasis (Amebiasis)
Anaerobic bacteria (NOS, except for
bacteroides, clostridium) (Anaerobic
bacteria (NOS, except for bacteroides,
clostridium))
Apserguillus (NOS) (Apserguillus (NOS))
Aspergillus Flavus (Apserguillus flavus)
Aspergillus Fumigatus (Apserguillus
fumigatus)
Aspergillus Niger (Apserguillus Niger)
Bacillus (Bacillus (cereau, other
species))
Bacteroides (Bacteroides (gracillis,
uniformis, vulgaris, other species))
Borrelia (Borrelia (Lyme disease))
Branhamelia or Moraxella catarrhalis
(other species) (Branhamelia or
Moraxella catarrhalis (other species))
Campylobacter (Campylobacter (all
species))
Candida (NOS) (Candida (NOS))
Candida Albicans (Candida Albicans)
Candida Krusei (Candida Krusei)
Candida Parasilosis (Candida
Parasilosis)
Candida Tropicalis (Candida Tropicalis)
Chlamydia (Chlamydia)
Citrobacter (Citrobacter (freundii, other
species))
Clostridium (all species except difficile)
(Clostridium (all species except difficile))
Clostridium Difficile (Clostridium difficile)
Corynebacterium (Corynebacterium (all
non-diptheria species))
Coxiella (Coxiella)
Cryptococcosis (Cryptococcus species)
Cryptosporidium (Crytosporidium)
Cytomegalovirus (Cytomagalovirus
(CMV))
Echinocoocalyst (Echinocoocalyst)
Enterobacter (Enterobacter)
Enterococcus (Enterococcus (all
species))
Enterovirus (Enterovirus (coxsackie,
echo, polio))
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Epstein-barr Virus (Epstein-Barr virus
(EBV))
Escherichia Coli (Escherichia (also E.
coli))
Flavimonas Flavimonas Flavimonas
(Flavimonas oryzihabitans)
Flavobacterium (Flavobacterium)
Fusarium (Fusarium species)
Fusobacteria (Fusobacterium nucleatum)
Giardia (Giardia)
Gram Negative Diplococci (Gram
negative diplococci (NOS))
Gram Negative Rod (Gram negative rod
(NOS))
Gram Positive Cocci (Gram positive
cocci (NOS))
Gram positive rod (NOS) (Gram positive
rod (NOS))
Haemophilus (all species including
influenzae) (Haemophilus (all species
including influenzae))
Helicobacter Pylori (Helicobacter pylori)
Hepatitis A (Hepatitis A (HAV))
Hepatitis B Virus (Hepatitis B (HBV,
Australian anitgen))
Hepatitis C (Hepatitis C (includes non-A
and non-B, HCV))
Herpes Simplex (Herpes simplex (HSV1,
HSV2))
Herpes Zoster (Herpes zoster (chicken
pox, varicella))
HHV-6 (human herpes virus) (HHV-6
(human herpes virus))
Human Immunodeficiency Virus (HIV-1,
HITLV-III)
Influenza (Influenza (flu))
Klebsiella (Klebsiella)
Lactobacillus (Lactobacillus (bulgaricus,
acidophilus, other species))
Legionella (Legionella)
Leptospira (Leptospira)
Leptotrichia (Leptotrichia buccalis)
Leuconostoc (Leuconostoc (all species))
Listeria (Listeria)
Measles (rubeola) (Measles (rubeola))
Methylobacterium (Methylobacterium)
Micrococcus (Micrococcus (NOS))
Mumps (Mumps)
Musormycosis (zygomycete, rhizopus)
(Musormycosis (zygomycete, rhizopus))
Mycobacteria (avium, bovium,
haemophilum, intercellulare)
(Mycobacteria (avium, bovium,
haemophilum, intercellulare))
Mycobacterium Infection (Mycobacterium
tuberculosis)
Mycoplasma (Mycoplasma)
Mycoplasma (Mycoplasma)
Neisseria (gonorrhea, meningitidis, other
species) (Neisseria (gonorrhea,
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meningitidis, other species))
Nocardia (Nocardia)
Other Microorganism, Specify (Other
bacteria (NOS))
Other fungus (Other fungus)
Other Mycobacterium (Other
Mycobacterium)
Other organism (Other organism)
Protozoa, Not Otherwise Specified
(Other protozoal (parasite))
Other viral (Other viral)
Papovavirus (Papovavirus)
Parainfluenza (Parainfluenza)
Pharyngeal/respiratory flora
(Pharyngeal/respiratory flora)
Pneumoncystic (PCP_ (Pneumoncystic
(PCP_)
Polyomavirus (Polyomavirus)
Propionbacterium (acnes, avidium,
granulosum, other species)
(Propionbacterium (acnes, avidium,
granulosum, other species))
Pseudomonas (Pseudomonas or
Burkholderia cepacia)
Pseudomonas or Stenotrophomonas or
Xanthomonas maltophilia (Pseudomonas
or Stenotrophomonas or Xanthomonas
maltophilia)
Respiratory Syncytial Virus (Respiratory
syncytial virus (RSV))
Rhinovirus (common cold) (Rhinovirus
(common cold))
Rhodococcus (Rhodococcus)
Rickettsia (Rickettsia)
Rotavirus (Rotavirus)
Rubella (German measles) (Rubella
(German measles))
Salmonella (Salmonella (all species))
Serratia (Serratia marcescens)
Shigella (Shigella)
Staphylococcus (Staphylococcus (coag
-))
Staphylococcus (coag +)
(Staphylococcus (coag +))
Staphylococcus (NOS) (Staphylococcus
(NOS))
Stomatococcus Mucilaginosis
(Stomatococcus mucilaginosis)
Streptococcus (Streptococcus (all
species except enterococcus))
Torulopsis Galbrata (a subspecies of
Candida) (Torulopsis Galbrata (a
subspecies of Candida))
Toxoplasma (Toxoplasma)
Treponema (Treponema (syphilis))
Trichomonas (Trichomonas (either
vaginal or gingivitis))
Tuberculosis (NOS, AFB, acid fast
bacillus, Koch bacillus) (Tuberculosis
(NOS, AFB, acid fast bacillus, Koch
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bacillus))
Typical tuberculosis (TB, tuberculosis)
(Typical tuberculosis (TB, tuberculosis))
Vibrio (Vibrio (all species))
Yeast (Yeast (NOS))
If other specify
Severity of infection
Life-threatening (Life-threatening/fatal)
Moderate (Moderate)
Severe (Severe)
Infection Iii
Record the level of certainty of the fungal
infection diagnosis
Possible fungal infection (Possible fungal
infection)
Probable fungal infection (Probable
fungal infection)
Proven fungal infection (Proven fungal
infection)
Was an agent(s) administered to treat the
infection(s)
No (No)
Yes (Yes)
Type of infection
Bacterial (Bacteria)
Fungal (Fingal)
Other (Other)
Protocoal (Protocoal)
Viral (Viral)
Organism I
Acinetobacter (Acinetobacter (baumanii,
calcoaceticus, lwoffi, other species))
Adenovirus (Adenovirus)
Agrobacterium (Agrobacterium
radiobacter)
Alcaligenes (Alcaligenes xylosoxidans)
Amebiasis (Amebiasis)
Anaerobic bacteria (NOS, except for
bacteroides, clostridium) (Anaerobic
bacteria (NOS, except for bacteroides,
clostridium))
Apserguillus (NOS) (Apserguillus (NOS))
Aspergillus Flavus (Apserguillus flavus)
Aspergillus Fumigatus (Apserguillus
fumigatus)
Aspergillus Niger (Apserguillus Niger)
Bacillus (Bacillus (cereau, other
species))
Bacteroides (Bacteroides (gracillis,
uniformis, vulgaris, other species))
Borrelia (Borrelia (Lyme disease))
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Branhamelia or Moraxella catarrhalis
(other species) (Branhamelia or
Moraxella catarrhalis (other species))
Campylobacter (Campylobacter (all
species))
Candida (NOS) (Candida (NOS))
Candida Albicans (Candida Albicans)
Candida Krusei (Candida Krusei)
Candida Parasilosis (Candida
Parasilosis)
Candida Tropicalis (Candida Tropicalis)
Chlamydia (Chlamydia)
Citrobacter (Citrobacter (freundii, other
species))
Clostridium (all species except difficile)
(Clostridium (all species except difficile))
Clostridium Difficile (Clostridium difficile)
Corynebacterium (Corynebacterium (all
non-diptheria species))
Coxiella (Coxiella)
Cryptococcosis (Cryptococcus species)
Cryptosporidium (Crytosporidium)
Cytomegalovirus (Cytomagalovirus
(CMV))
Echinocoocalyst (Echinocoocalyst)
Enterobacter (Enterobacter)
Enterococcus (Enterococcus (all
species))
Enterovirus (Enterovirus (coxsackie,
echo, polio))
Epstein-barr Virus (Epstein-Barr virus
(EBV))
Escherichia Coli (Escherichia (also E.
coli))
Flavimonas Flavimonas Flavimonas
(Flavimonas oryzihabitans)
Flavobacterium (Flavobacterium)
Fusarium (Fusarium species)
Fusobacteria (Fusobacterium nucleatum)
Giardia (Giardia)
Gram Negative Diplococci (Gram
negative diplococci (NOS))
Gram Negative Rod (Gram negative rod
(NOS))
Gram Positive Cocci (Gram positive
cocci (NOS))
Gram positive rod (NOS) (Gram positive
rod (NOS))
Haemophilus (all species including
influenzae) (Haemophilus (all species
including influenzae))
Helicobacter Pylori (Helicobacter pylori)
Hepatitis A (Hepatitis A (HAV))
Hepatitis B Virus (Hepatitis B (HBV,
Australian anitgen))
Hepatitis C (Hepatitis C (includes non-A
and non-B, HCV))
Herpes Simplex (Herpes simplex (HSV1,
HSV2))
Herpes Zoster (Herpes zoster (chicken
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pox, varicella))
HHV-6 (human herpes virus) (HHV-6
(human herpes virus))
Human Immunodeficiency Virus (HIV-1,
HITLV-III)
Influenza (Influenza (flu))
Klebsiella (Klebsiella)
Lactobacillus (Lactobacillus (bulgaricus,
acidophilus, other species))
Legionella (Legionella)
Leptospira (Leptospira)
Leptotrichia (Leptotrichia buccalis)
Leuconostoc (Leuconostoc (all species))
Listeria (Listeria)
Measles (rubeola) (Measles (rubeola))
Methylobacterium (Methylobacterium)
Micrococcus (Micrococcus (NOS))
Mumps (Mumps)
Musormycosis (zygomycete, rhizopus)
(Musormycosis (zygomycete, rhizopus))
Mycobacteria (avium, bovium,
haemophilum, intercellulare)
(Mycobacteria (avium, bovium,
haemophilum, intercellulare))
Mycobacterium Infection (Mycobacterium
tuberculosis)
Mycoplasma (Mycoplasma)
Mycoplasma (Mycoplasma)
Neisseria (gonorrhea, meningitidis, other
species) (Neisseria (gonorrhea,
meningitidis, other species))
Nocardia (Nocardia)
Other Microorganism, Specify (Other
bacteria (NOS))
Other fungus (Other fungus)
Other Mycobacterium (Other
Mycobacterium)
Other organism (Other organism)
Protozoa, Not Otherwise Specified
(Other protozoal (parasite))
Other viral (Other viral)
Papovavirus (Papovavirus)
Parainfluenza (Parainfluenza)
Pharyngeal/respiratory flora
(Pharyngeal/respiratory flora)
Pneumoncystic (PCP_ (Pneumoncystic
(PCP_)
Polyomavirus (Polyomavirus)
Propionbacterium (acnes, avidium,
granulosum, other species)
(Propionbacterium (acnes, avidium,
granulosum, other species))
Pseudomonas (Pseudomonas or
Burkholderia cepacia)
Pseudomonas or Stenotrophomonas or
Xanthomonas maltophilia (Pseudomonas
or Stenotrophomonas or Xanthomonas
maltophilia)
Respiratory Syncytial Virus (Respiratory
syncytial virus (RSV))
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Rhinovirus (common cold) (Rhinovirus
(common cold))
Rhodococcus (Rhodococcus)
Rickettsia (Rickettsia)
Rotavirus (Rotavirus)
Rubella (German measles) (Rubella
(German measles))
Salmonella (Salmonella (all species))
Serratia (Serratia marcescens)
Shigella (Shigella)
Staphylococcus (Staphylococcus (coag
-))
Staphylococcus (coag +)
(Staphylococcus (coag +))
Staphylococcus (NOS) (Staphylococcus
(NOS))
Stomatococcus Mucilaginosis
(Stomatococcus mucilaginosis)
Streptococcus (Streptococcus (all
species except enterococcus))
Torulopsis Galbrata (a subspecies of
Candida) (Torulopsis Galbrata (a
subspecies of Candida))
Toxoplasma (Toxoplasma)
Treponema (Treponema (syphilis))
Trichomonas (Trichomonas (either
vaginal or gingivitis))
Tuberculosis (NOS, AFB, acid fast
bacillus, Koch bacillus) (Tuberculosis
(NOS, AFB, acid fast bacillus, Koch
bacillus))
Typical tuberculosis (TB, tuberculosis)
(Typical tuberculosis (TB, tuberculosis))
Vibrio (Vibrio (all species))
Yeast (Yeast (NOS))
If other specify
Severity of infection
Life-threatening (Life-threatening/fatal)
Moderate (Moderate)
Severe (Severe)
Provide Agent(s) Administered For This
Infectious Period
Were additional agents administered for this
infectious period
No (No)
Yes (Yes)
1st agent
Abacavir (abacavir (Ziagen))
Acyclovir (acyclovir (Zovirax))
albendazole (Albenza) (albendazole
(Albenza))
amantadine (Symmetrel, Symadine)
(amantadine (Symmetrel, Symadine))
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Amikacin (amikacin (Amikin))
Amoxicillin (amoxicillin/clavulanate
(Augmentin))
Amphotericin B (amphotericin b (Abelcet,
Amphotec, Fungizone))
Ampicillin (ampicillin (Omnipen,
Polycillin))
ampicillin/sulbactam (Unasyn)
(ampicillin/sulbactam (Unasyn))
Amprenavir (amprenavir (Agenerase))
atovaquone (Meprone) (atovaquone
(Meprone))
Azithromycin (azithromycin (Zithromax,
Z-pak))
Cefaclor (cefaclor (Ceclor))
Cefadroxil (cefadroxil (Duricef, Ultrcef))
Cefazolin (cefazolin (Ancef, Kefzol))
Cefdinir (cefdinir (Omnicef))
cefepime (Maxipime) (cefepime
(Maxipime))
cefixime (Suprax) (cefixime (Suprax))
cefotaxime (Claforan) (cefotaxime
(Claforan))
cefotetan (Cefotan) (cefotetan (Cefotan))
cefoxitin (Mefoxin) (cefoxitin (Mefoxin))
Cefpodoxime (cefpodoxime (Vantin))
Cefprozil (cefprozil (Cefzil))
Ceftazidime (ceftazidime (Fortaz,
Tazicef))
Ceftriaxone (ceftriaxone (Rocephin))
cefuroxime (Ceftin, Kefurox, Zinacef)
(cefuroxime (Ceftin, Kefurox, Zinacef))
Cephalexin (cephalexin (Keflet, Felex,
Leftab))
chloramphenicol (Chloromycetin)
(chloramphenicol (Chloromycetin))
Cidofovir (cidofovir (Vistide))
Ciprofloxacin (ciprofloxacin (Cipro))
clarithomycin (Biaxin) (clarithomycin
(Biaxin))
Clindamycin (clindamycin (Cleocin))
Clotrimazole (clotrimazole (Mycelex,
Lotrimin))
clotrimoxazole/betamethasone
(Lotrisone)
(clotrimoxazole/betamethasone
(Lotrisone))
co-trimoxazole (Bactrium, Septra,
Sulfamethoprim) (co-trimoxazole
(Bactrium, Septra, Sulfamethoprim))
Dapsone (dapsone (DDS))
Dicloxacillin (dicloxacillin (Dycill,
Dynapen, Pathocil))
didanosine (Videx, ddI) (didanosine
(Videx, ddI))
doxycycline (Vibramycin) (doxycycline
(Vibramycin))
Efavirenz (efavirenz (Sustiva))
Erythromycin (erythromycin (Ery-Tab,
Ilosone, Pediamycin))
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erythromycin ethyl/sulfisoxazole
(Pediazole) (erythromycin
ethyl/sulfisoxazole (Pediazole))
erythromycin topical (Akne-mycin,
Eryderm) (erythromycin topical (Akne-
mycin, Eryderm))
ethambutol (Myambutol) (ethambutol
(Myambutol))
Famciclovir (famciclovir (Famvir))
Fluconazole (fluconazole (Diflucan))
flucytosine (Ancobon) (flucytosine
(Ancobon))
foscarnet (Foscavir) (foscarnet
(Foscavir))
Ganciclovir (ganciclovir (Cytovene))
Gatifloxacin (gatifloxacin (Tequin))
Gentamicin (gentamicin (Garamycin,
Gentacidin))
grepafloxacin (Raxar) (grepafloxacin
(Raxar))
hepatitis a vaccine (Havrix, Vaqta)
(hepatitis a vaccine (Havrix, Vaqta))
hepatitis b vaccine (Recombivax HB,
Engerix-B) (hepatitis b vaccine
(Recombivax HB, Engerix-B))
hepatitis c vaccine (hepatitis c vaccine)
Imipenem (imipenem/cilaststin
(Primaxin))
imiquimod (Aldara) (imiquimod (Aldara))
Indinavir (indinavir (Crixivan))
inteferon alfacon-1 (Infergen) (inteferon
alfacon-1 (Infergen))
inteferon beta-1a (Avonex) (inteferon
beta-1a (Avonex))
inteferon beta-1b (Betaseron) (inteferon
beta-1b (Betaseron))
Isoniazid (isoniazid (INH, Lanizid,
Nydrazid))
Itraconazole (itraconazole (Sporonox))
ivermextin (Stromectol) (ivermextin
(Stromectol))
kanamycin (Kantrex) (kanamycin
(Kantrex))
Ketoconazole (ketoconazole (Nizoral))
lamivudine (Epivir, 3TC) (lamivudine
(Epivir, 3TC))
Levofloxacin (levofloxacin (Levaquin))
linezolid (Zyvox) (linezolid (Zyvox))
Lopinavir/ritonavir (kaletra)
(lopinavir/ritonavir (Kaletra))
mefloquine (Larium) (mefloquine
(Larium))
Meropenem (meropenem (Merrem I.V.))
Metronidazole (metronidazole (Flagyl,
Protostat))
minocycline (Arestin) (minocycline
(Arestin))
moxifloxacin hydrochloride (Avelox)
(moxifloxacin hydrochloride (Avelox))
Mupirocin (mupirocin (Bactroban))
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Nafcillin (nafcillin (Nallpen, Unipen))
Nelfinavir (nelfinavir (Viracept))
neomycin (Mycifradin, Myciguent)
(neomycin (Mycifradin, Myciguent))
neomycin/polymxin/hydrocortisone
(Cortisporin)
(neomycin/polymxin/hydrocortisone
(Cortisporin))
Nevirapine (nevirapine (Viramune))
Nitrofurantoin (nitrofurantoin (Macrobid))
Nystatin (nystatin (Mycostatin))
Oseltamivir (oseltamivir (Tamiflu))
other (other)
oxacilllin (Bactocil) (oxacilllin (Bactocil))
palivizumab (Synagis) (palivizumab
(Synagis))
penicillin g (Bicillin) (penicillin g (Bicillin))
Penicillin V (penicillin vk (V-Villin K,
Veetids))
pentamidine (Pentam 300) (pentamidine
(Pentam 300))
pipercillin (Pipracil) (pipercillin (Pipracil))
pipercillin/tazobactam (Zosyn)
(pipercillin/tazobactam (Zosyn))
podofilox (Condylox) (podofilox
(Condylox))
polymyxin (Ak-Spore H.C., Cortisporin
ophthalmic suspension) (polymyxin (Ak-
Spore H.C., Cortisporin ophthalmic
suspension))
PPD skin tests (Mantoux test, Tine test)
(PPD skin tests (Mantoux test, Tine test))
pyrazinamide (Rifadin) (pyrazinamide
(Rifadin))
Pyrimethamine (pyrimethamine
(Daraprim))
quinidine gluconate (Duraquin,
Cardioqiuin) (quinidine gluconate
(Duraquin, Cardioqiuin))
quinupristin/dalfopristin (Synercid)
(quinupristin/dalfopristin (Synercid))
respiratory syncytial immuno globulin
(Respigam) (respiratory syncytial
immuno globulin (Respigam))
Ribavirin (ribavirin (Virazole))
Rifampin (rifampin (Rifadin, Rimactane))
rifampin/isoniazid (rifamate,
Rimactane/INH) (rifampin/isoniazid
(rifamate, Rimactane/INH))
rifampin/isoniazid/pyrazinamide (Rifater)
(rifampin/isoniazid/pyrazinamide
(Rifater))
rimantadine (Flumadine) (rimantadine
(Flumadine))
Ritonavir (ritonavir (Norvir))
Saquinavir (saquinavir mesylate
(Fortovase, Invirase))
stavudine (d4T, Zerit) (stavudine (d4T,
Zerit))
streptomycin (Streptomycin sulfate)
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(streptomycin (Streptomycin sulfate))
Sulfamethoxazole/trimethoprim (bactrim)
(sulfamethoxazole/trimethoprim
(Bactrium))
terbinafine (Lamisil) (terbinafine
(Lamisil))
terconazole (Terazol) (terconazole
(Terazol))
tetracycline (Achromycin) (tetracycline
(Achromycin))
ticarcillin/clavulanate (Ticar, Timentin)
(ticarcillin/clavulanate (Ticar, Timentin))
Tobramycin (tobramycin (Nebcin, Tobrex,
TobraDex))
trimethoprim/sulfamethoxazole
(Bacterium, Septra, Co-trimoxazole)
(trimethoprim/sulfamethoxazole
(Bacterium, Septra, Co-trimoxazole))
valacyclovir (Valtrex) (valacyclovir
(Valtrex))
valganciclovic (Valcyte) (valganciclovic
(Valcyte))
Vancomycin (vancomycin (Vancocin))
zidovudine (AZT, Retrovir) (zidovudine
(AZT, Retrovir))
1st agent
Abacavir (abacavir (Ziagen))
Acyclovir (acyclovir (Zovirax))
albendazole (Albenza) (albendazole
(Albenza))
amantadine (Symmetrel, Symadine)
(amantadine (Symmetrel, Symadine))
Amikacin (amikacin (Amikin))
Amoxicillin (amoxicillin/clavulanate
(Augmentin))
Amphotericin B (amphotericin b (Abelcet,
Amphotec, Fungizone))
Ampicillin (ampicillin (Omnipen,
Polycillin))
ampicillin/sulbactam (Unasyn)
(ampicillin/sulbactam (Unasyn))
Amprenavir (amprenavir (Agenerase))
atovaquone (Meprone) (atovaquone
(Meprone))
Azithromycin (azithromycin (Zithromax,
Z-pak))
Cefaclor (cefaclor (Ceclor))
Cefadroxil (cefadroxil (Duricef, Ultrcef))
Cefazolin (cefazolin (Ancef, Kefzol))
Cefdinir (cefdinir (Omnicef))
cefepime (Maxipime) (cefepime
(Maxipime))
cefixime (Suprax) (cefixime (Suprax))
cefotaxime (Claforan) (cefotaxime
(Claforan))
cefotetan (Cefotan) (cefotetan (Cefotan))
cefoxitin (Mefoxin) (cefoxitin (Mefoxin))
Cefpodoxime (cefpodoxime (Vantin))
Cefprozil (cefprozil (Cefzil))
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Ceftazidime (ceftazidime (Fortaz,
Tazicef))
Ceftriaxone (ceftriaxone (Rocephin))
cefuroxime (Ceftin, Kefurox, Zinacef)
(cefuroxime (Ceftin, Kefurox, Zinacef))
Cephalexin (cephalexin (Keflet, Felex,
Leftab))
chloramphenicol (Chloromycetin)
(chloramphenicol (Chloromycetin))
Cidofovir (cidofovir (Vistide))
Ciprofloxacin (ciprofloxacin (Cipro))
clarithomycin (Biaxin) (clarithomycin
(Biaxin))
Clindamycin (clindamycin (Cleocin))
Clotrimazole (clotrimazole (Mycelex,
Lotrimin))
clotrimoxazole/betamethasone
(Lotrisone)
(clotrimoxazole/betamethasone
(Lotrisone))
co-trimoxazole (Bactrium, Septra,
Sulfamethoprim) (co-trimoxazole
(Bactrium, Septra, Sulfamethoprim))
Dapsone (dapsone (DDS))
Dicloxacillin (dicloxacillin (Dycill,
Dynapen, Pathocil))
didanosine (Videx, ddI) (didanosine
(Videx, ddI))
doxycycline (Vibramycin) (doxycycline
(Vibramycin))
Efavirenz (efavirenz (Sustiva))
Erythromycin (erythromycin (Ery-Tab,
Ilosone, Pediamycin))
erythromycin ethyl/sulfisoxazole
(Pediazole) (erythromycin
ethyl/sulfisoxazole (Pediazole))
erythromycin topical (Akne-mycin,
Eryderm) (erythromycin topical (Akne-
mycin, Eryderm))
ethambutol (Myambutol) (ethambutol
(Myambutol))
Famciclovir (famciclovir (Famvir))
Fluconazole (fluconazole (Diflucan))
flucytosine (Ancobon) (flucytosine
(Ancobon))
foscarnet (Foscavir) (foscarnet
(Foscavir))
Ganciclovir (ganciclovir (Cytovene))
Gatifloxacin (gatifloxacin (Tequin))
Gentamicin (gentamicin (Garamycin,
Gentacidin))
grepafloxacin (Raxar) (grepafloxacin
(Raxar))
hepatitis a vaccine (Havrix, Vaqta)
(hepatitis a vaccine (Havrix, Vaqta))
hepatitis b vaccine (Recombivax HB,
Engerix-B) (hepatitis b vaccine
(Recombivax HB, Engerix-B))
hepatitis c vaccine (hepatitis c vaccine)
Imipenem (imipenem/cilaststin
17 / 23
INF
(Primaxin))
imiquimod (Aldara) (imiquimod (Aldara))
Indinavir (indinavir (Crixivan))
inteferon alfacon-1 (Infergen) (inteferon
alfacon-1 (Infergen))
inteferon beta-1a (Avonex) (inteferon
beta-1a (Avonex))
inteferon beta-1b (Betaseron) (inteferon
beta-1b (Betaseron))
Isoniazid (isoniazid (INH, Lanizid,
Nydrazid))
Itraconazole (itraconazole (Sporonox))
ivermextin (Stromectol) (ivermextin
(Stromectol))
kanamycin (Kantrex) (kanamycin
(Kantrex))
Ketoconazole (ketoconazole (Nizoral))
lamivudine (Epivir, 3TC) (lamivudine
(Epivir, 3TC))
Levofloxacin (levofloxacin (Levaquin))
linezolid (Zyvox) (linezolid (Zyvox))
Lopinavir/ritonavir (kaletra)
(lopinavir/ritonavir (Kaletra))
mefloquine (Larium) (mefloquine
(Larium))
Meropenem (meropenem (Merrem I.V.))
Metronidazole (metronidazole (Flagyl,
Protostat))
minocycline (Arestin) (minocycline
(Arestin))
moxifloxacin hydrochloride (Avelox)
(moxifloxacin hydrochloride (Avelox))
Mupirocin (mupirocin (Bactroban))
Nafcillin (nafcillin (Nallpen, Unipen))
Nelfinavir (nelfinavir (Viracept))
neomycin (Mycifradin, Myciguent)
(neomycin (Mycifradin, Myciguent))
neomycin/polymxin/hydrocortisone
(Cortisporin)
(neomycin/polymxin/hydrocortisone
(Cortisporin))
Nevirapine (nevirapine (Viramune))
Nitrofurantoin (nitrofurantoin (Macrobid))
Nystatin (nystatin (Mycostatin))
Oseltamivir (oseltamivir (Tamiflu))
other (other)
oxacilllin (Bactocil) (oxacilllin (Bactocil))
palivizumab (Synagis) (palivizumab
(Synagis))
penicillin g (Bicillin) (penicillin g (Bicillin))
Penicillin V (penicillin vk (V-Villin K,
Veetids))
pentamidine (Pentam 300) (pentamidine
(Pentam 300))
pipercillin (Pipracil) (pipercillin (Pipracil))
pipercillin/tazobactam (Zosyn)
(pipercillin/tazobactam (Zosyn))
podofilox (Condylox) (podofilox
(Condylox))
polymyxin (Ak-Spore H.C., Cortisporin
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ophthalmic suspension) (polymyxin (Ak-
Spore H.C., Cortisporin ophthalmic
suspension))
PPD skin tests (Mantoux test, Tine test)
(PPD skin tests (Mantoux test, Tine test))
pyrazinamide (Rifadin) (pyrazinamide
(Rifadin))
Pyrimethamine (pyrimethamine
(Daraprim))
quinidine gluconate (Duraquin,
Cardioqiuin) (quinidine gluconate
(Duraquin, Cardioqiuin))
quinupristin/dalfopristin (Synercid)
(quinupristin/dalfopristin (Synercid))
respiratory syncytial immuno globulin
(Respigam) (respiratory syncytial
immuno globulin (Respigam))
Ribavirin (ribavirin (Virazole))
Rifampin (rifampin (Rifadin, Rimactane))
rifampin/isoniazid (rifamate,
Rimactane/INH) (rifampin/isoniazid
(rifamate, Rimactane/INH))
rifampin/isoniazid/pyrazinamide (Rifater)
(rifampin/isoniazid/pyrazinamide
(Rifater))
rimantadine (Flumadine) (rimantadine
(Flumadine))
Ritonavir (ritonavir (Norvir))
Saquinavir (saquinavir mesylate
(Fortovase, Invirase))
stavudine (d4T, Zerit) (stavudine (d4T,
Zerit))
streptomycin (Streptomycin sulfate)
(streptomycin (Streptomycin sulfate))
Sulfamethoxazole/trimethoprim (bactrim)
(sulfamethoxazole/trimethoprim
(Bactrium))
terbinafine (Lamisil) (terbinafine
(Lamisil))
terconazole (Terazol) (terconazole
(Terazol))
tetracycline (Achromycin) (tetracycline
(Achromycin))
ticarcillin/clavulanate (Ticar, Timentin)
(ticarcillin/clavulanate (Ticar, Timentin))
Tobramycin (tobramycin (Nebcin, Tobrex,
TobraDex))
trimethoprim/sulfamethoxazole
(Bacterium, Septra, Co-trimoxazole)
(trimethoprim/sulfamethoxazole
(Bacterium, Septra, Co-trimoxazole))
valacyclovir (Valtrex) (valacyclovir
(Valtrex))
valganciclovic (Valcyte) (valganciclovic
(Valcyte))
Vancomycin (vancomycin (Vancocin))
zidovudine (AZT, Retrovir) (zidovudine
(AZT, Retrovir))
1st agent
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Abacavir (abacavir (Ziagen))
Acyclovir (acyclovir (Zovirax))
albendazole (Albenza) (albendazole
(Albenza))
amantadine (Symmetrel, Symadine)
(amantadine (Symmetrel, Symadine))
Amikacin (amikacin (Amikin))
Amoxicillin (amoxicillin/clavulanate
(Augmentin))
Amphotericin B (amphotericin b (Abelcet,
Amphotec, Fungizone))
Ampicillin (ampicillin (Omnipen,
Polycillin))
ampicillin/sulbactam (Unasyn)
(ampicillin/sulbactam (Unasyn))
Amprenavir (amprenavir (Agenerase))
atovaquone (Meprone) (atovaquone
(Meprone))
Azithromycin (azithromycin (Zithromax,
Z-pak))
Cefaclor (cefaclor (Ceclor))
Cefadroxil (cefadroxil (Duricef, Ultrcef))
Cefazolin (cefazolin (Ancef, Kefzol))
Cefdinir (cefdinir (Omnicef))
cefepime (Maxipime) (cefepime
(Maxipime))
cefixime (Suprax) (cefixime (Suprax))
cefotaxime (Claforan) (cefotaxime
(Claforan))
cefotetan (Cefotan) (cefotetan (Cefotan))
cefoxitin (Mefoxin) (cefoxitin (Mefoxin))
Cefpodoxime (cefpodoxime (Vantin))
Cefprozil (cefprozil (Cefzil))
Ceftazidime (ceftazidime (Fortaz,
Tazicef))
Ceftriaxone (ceftriaxone (Rocephin))
cefuroxime (Ceftin, Kefurox, Zinacef)
(cefuroxime (Ceftin, Kefurox, Zinacef))
Cephalexin (cephalexin (Keflet, Felex,
Leftab))
chloramphenicol (Chloromycetin)
(chloramphenicol (Chloromycetin))
Cidofovir (cidofovir (Vistide))
Ciprofloxacin (ciprofloxacin (Cipro))
clarithomycin (Biaxin) (clarithomycin
(Biaxin))
Clindamycin (clindamycin (Cleocin))
Clotrimazole (clotrimazole (Mycelex,
Lotrimin))
clotrimoxazole/betamethasone
(Lotrisone)
(clotrimoxazole/betamethasone
(Lotrisone))
co-trimoxazole (Bactrium, Septra,
Sulfamethoprim) (co-trimoxazole
(Bactrium, Septra, Sulfamethoprim))
Dapsone (dapsone (DDS))
Dicloxacillin (dicloxacillin (Dycill,
Dynapen, Pathocil))
didanosine (Videx, ddI) (didanosine
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(Videx, ddI))
doxycycline (Vibramycin) (doxycycline
(Vibramycin))
Efavirenz (efavirenz (Sustiva))
Erythromycin (erythromycin (Ery-Tab,
Ilosone, Pediamycin))
erythromycin ethyl/sulfisoxazole
(Pediazole) (erythromycin
ethyl/sulfisoxazole (Pediazole))
erythromycin topical (Akne-mycin,
Eryderm) (erythromycin topical (Akne-
mycin, Eryderm))
ethambutol (Myambutol) (ethambutol
(Myambutol))
Famciclovir (famciclovir (Famvir))
Fluconazole (fluconazole (Diflucan))
flucytosine (Ancobon) (flucytosine
(Ancobon))
foscarnet (Foscavir) (foscarnet
(Foscavir))
Ganciclovir (ganciclovir (Cytovene))
Gatifloxacin (gatifloxacin (Tequin))
Gentamicin (gentamicin (Garamycin,
Gentacidin))
grepafloxacin (Raxar) (grepafloxacin
(Raxar))
hepatitis a vaccine (Havrix, Vaqta)
(hepatitis a vaccine (Havrix, Vaqta))
hepatitis b vaccine (Recombivax HB,
Engerix-B) (hepatitis b vaccine
(Recombivax HB, Engerix-B))
hepatitis c vaccine (hepatitis c vaccine)
Imipenem (imipenem/cilaststin
(Primaxin))
imiquimod (Aldara) (imiquimod (Aldara))
Indinavir (indinavir (Crixivan))
inteferon alfacon-1 (Infergen) (inteferon
alfacon-1 (Infergen))
inteferon beta-1a (Avonex) (inteferon
beta-1a (Avonex))
inteferon beta-1b (Betaseron) (inteferon
beta-1b (Betaseron))
Isoniazid (isoniazid (INH, Lanizid,
Nydrazid))
Itraconazole (itraconazole (Sporonox))
ivermextin (Stromectol) (ivermextin
(Stromectol))
kanamycin (Kantrex) (kanamycin
(Kantrex))
Ketoconazole (ketoconazole (Nizoral))
lamivudine (Epivir, 3TC) (lamivudine
(Epivir, 3TC))
Levofloxacin (levofloxacin (Levaquin))
linezolid (Zyvox) (linezolid (Zyvox))
Lopinavir/ritonavir (kaletra)
(lopinavir/ritonavir (Kaletra))
mefloquine (Larium) (mefloquine
(Larium))
Meropenem (meropenem (Merrem I.V.))
Metronidazole (metronidazole (Flagyl,
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Protostat))
minocycline (Arestin) (minocycline
(Arestin))
moxifloxacin hydrochloride (Avelox)
(moxifloxacin hydrochloride (Avelox))
Mupirocin (mupirocin (Bactroban))
Nafcillin (nafcillin (Nallpen, Unipen))
Nelfinavir (nelfinavir (Viracept))
neomycin (Mycifradin, Myciguent)
(neomycin (Mycifradin, Myciguent))
neomycin/polymxin/hydrocortisone
(Cortisporin)
(neomycin/polymxin/hydrocortisone
(Cortisporin))
Nevirapine (nevirapine (Viramune))
Nitrofurantoin (nitrofurantoin (Macrobid))
Nystatin (nystatin (Mycostatin))
Oseltamivir (oseltamivir (Tamiflu))
other (other)
oxacilllin (Bactocil) (oxacilllin (Bactocil))
palivizumab (Synagis) (palivizumab
(Synagis))
penicillin g (Bicillin) (penicillin g (Bicillin))
Penicillin V (penicillin vk (V-Villin K,
Veetids))
pentamidine (Pentam 300) (pentamidine
(Pentam 300))
pipercillin (Pipracil) (pipercillin (Pipracil))
pipercillin/tazobactam (Zosyn)
(pipercillin/tazobactam (Zosyn))
podofilox (Condylox) (podofilox
(Condylox))
polymyxin (Ak-Spore H.C., Cortisporin
ophthalmic suspension) (polymyxin (Ak-
Spore H.C., Cortisporin ophthalmic
suspension))
PPD skin tests (Mantoux test, Tine test)
(PPD skin tests (Mantoux test, Tine test))
pyrazinamide (Rifadin) (pyrazinamide
(Rifadin))
Pyrimethamine (pyrimethamine
(Daraprim))
quinidine gluconate (Duraquin,
Cardioqiuin) (quinidine gluconate
(Duraquin, Cardioqiuin))
quinupristin/dalfopristin (Synercid)
(quinupristin/dalfopristin (Synercid))
respiratory syncytial immuno globulin
(Respigam) (respiratory syncytial
immuno globulin (Respigam))
Ribavirin (ribavirin (Virazole))
Rifampin (rifampin (Rifadin, Rimactane))
rifampin/isoniazid (rifamate,
Rimactane/INH) (rifampin/isoniazid
(rifamate, Rimactane/INH))
rifampin/isoniazid/pyrazinamide (Rifater)
(rifampin/isoniazid/pyrazinamide
(Rifater))
rimantadine (Flumadine) (rimantadine
(Flumadine))
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Ritonavir (ritonavir (Norvir))
Saquinavir (saquinavir mesylate
(Fortovase, Invirase))
stavudine (d4T, Zerit) (stavudine (d4T,
Zerit))
streptomycin (Streptomycin sulfate)
(streptomycin (Streptomycin sulfate))
Sulfamethoxazole/trimethoprim (bactrim)
(sulfamethoxazole/trimethoprim
(Bactrium))
terbinafine (Lamisil) (terbinafine
(Lamisil))
terconazole (Terazol) (terconazole
(Terazol))
tetracycline (Achromycin) (tetracycline
(Achromycin))
ticarcillin/clavulanate (Ticar, Timentin)
(ticarcillin/clavulanate (Ticar, Timentin))
Tobramycin (tobramycin (Nebcin, Tobrex,
TobraDex))
trimethoprim/sulfamethoxazole
(Bacterium, Septra, Co-trimoxazole)
(trimethoprim/sulfamethoxazole
(Bacterium, Septra, Co-trimoxazole))
valacyclovir (Valtrex) (valacyclovir
(Valtrex))
valganciclovic (Valcyte) (valganciclovic
(Valcyte))
Vancomycin (vancomycin (Vancocin))
zidovudine (AZT, Retrovir) (zidovudine
(AZT, Retrovir))
If yes, specify additional agents administered
Comments
23 / 23
INF
GVH
GVH
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=FF19F489-
B086-2FD8-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/10338
GVH
Header Module
Segment
Start of GVHD assessment period
End of GVHD assessment period
Visit number
Date of staging
Immunosuppressant (prophylaxis) received
Cyclosporine (Cyclosporine)
Not given during assessment period (Not
given during assessment period)
Prednisone (Prednisone)
Tacrolimus (Tacrolimus)
Record most recent blood level of
immunosuppressant (prophylaxis)
Record date blood sample obtained
Record The Highest Level Of Organ
Abnormalities, The Etiologies Contributing
To The Abnormalities And Any Biopsy
Results Pertaining To Gvhd During The
Assessment Period
Skin abnormalities
Generalized erythroderma (Generalized
erythroderma)
Generalized erythroderma with bullus
formation and desquamation
(Generalized erythroderma with bullus
formation and desquamation)
Macular Or Papular Eruption Or
Erythema Without Associated Symptoms
(Maculopapular rash, <25% of body
surface)
Maculopapular rash, 25-50% of body
surface (Maculopapular rash, 25-50% of
body surface)
None (No rash)
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Skin Etiologies
Drug reaction
No (No)
Yes (Yes)
Conditioning regimen toxicity
No (No)
Yes (Yes)
Other
No (No)
Yes (Yes)
GVHD
No (No)
Yes (Yes)
Infection
No (No)
Yes (Yes)
Specify other skin etiologies
Skin biopsy for GVHD
Equivocal (Equivocal)
Negative (Negative)
Unknown (Not done)
Positive (Positive)
Upper GI abnormalities
None (No protracted nausea or vomiting)
Symptomatic; Medical Intervention
Indicated (Persistent nausea, vomiting,
anorexia)
Upper Intestinal Tract Etiologies
Drug reaction
No (No)
Yes (Yes)
Conditioning regimen toxicity
No (No)
Yes (Yes)
GVHD
No (No)
Yes (Yes)
TPN
No (No)
Yes (Yes)
Infection
No (No)
Yes (Yes)
Other
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GVH
No (No)
Yes (Yes)
Specify other skin etiologies
Skin biopsy for GVHD
Equivocal (Equivocal)
Negative (Negative)
Unknown (Not done)
Positive (Positive)
Lower GI abnormalities
Increase Of 4-6 Stools Per Day Over
Baseline; Iv Fluids Indicated <24 Hrs;
Moderate Increase In Ostomy Output
Compared To Baseline; Not Interfering
With Adl (Diarrhea >1000 but less than
or equal to 1500 mL/day or 556-833
mL/m^2)
Increase Of >=7 Stools Per Day Over
Baseline; Incontinence; Iv Fluids >=24
Hrs; Hospitalization; Severe Increase In
Ostomy Output Compared To Baseline;
Interfering With Adl (Diarrhea >1500 or >
833 mL/m^2)
Increase Of <4 Stools Per Day Over
Baseline; Mild Increase In Ostomy
Output Compared To Baseline (Diarrhea
>500 but less than or equal to 1000
mL/day or 280-555 mL/m^2)
Diarrhea less than or equal to 500
mL/day or <280 mL/m^2 (Diarrhea less
than or equal to 500 mL/day or <280
mL/m^2)
None (No diarrhea)
Life-threatening Consequences (e.g.,
Hemodynamic Collapse) (Severe
abdominal pain with or without ileus, or
stool with frank blood or melena)
Lower Intestinal Tract Etiologies
Drug reaction
No (No)
Yes (Yes)
Conditioning regimen toxicity
No (No)
Yes (Yes)
GVHD
No (No)
Yes (Yes)
TPN
No (No)
Yes (Yes)
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Infection
No (No)
Yes (Yes)
Other
No (No)
Yes (Yes)
Specify other skin etiologies
Skin biopsy for GVHD
Equivocal (Equivocal)
Negative (Negative)
Unknown (Not done)
Positive (Positive)
Liver abnormalities
Bilirubin <2.0 mg/dL (Bilirubin <2.0
mg/dL)
Bilirubin >15.0 mg/dL (Bilirubin >15.0
mg/dL)
Bilirubin 2.0-3.0 mg/dL (Bilirubin 2.0-3.0
mg/dL)
Bilirubin 3.1-6.0 mg/dL (Bilirubin 3.1-6.0
mg/dL)
Bilirubin 6.1-15.0 mg/dL (Bilirubin 6.1-
15.0 mg/dL)
Liver Etiologies
If yes, specify agent name
ATG (ATG)
CSA (CSA)
Daclizumab (Daclizumab)
FK506 (FK506)
Methylprednisolone (Methylprednisolone)
MMF (MMF)
Other (Other)
Prednisone (Prednisone)
Topical steriods (Topical steriods)
Specify other agent
Indicate treatment modification
Increased (Increased)
Started (Started)
Stopped (Stopped)
Tapered (Tapered)
Other
No (No)
Yes (Yes)
VOD
No (No)
Yes (Yes)
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Conditioning regimen toxicity
No (No)
Yes (Yes)
Drug reaction
No (No)
Yes (Yes)
GVHD
No (No)
Yes (Yes)
Infection
No (No)
Yes (Yes)
TPN
No (No)
Yes (Yes)
Specify other skin etiologies
Skin biopsy for GVHD
Equivocal (Equivocal)
Negative (Negative)
Unknown (Not done)
Positive (Positive)
Was treatment of GVHD modified during this
assessment period
No (No)
Yes (Yes)
Comments
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CSL
CSL
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=FF1A00BE-
B650-1746-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/10339
CSL
Header Module
Segment
Record number of aphereses performed
One apheresis (One apheresis)
Three apheresis (Three apheresis)
Two apheresis (Two apheresis)
Visit Number
Record Date Each Apheresis Was
Performed
Apheresis #1
Apheresis #1
Apheresis #1
For Each Selection Procedure Performed,
Record The Following Information
Starting Hpc-a Product #1
Viability as determined by 7-AAD flow cytometry
CD3+ T cell count
CD34+ cell count
Total nucleated cell count
Starting Hpc-a Product #2
Viability as determined by 7-AAD flow cytometry
CD3+ T cell count
1 / 3
CD34+ cell count
Total nucleated cell count
Starting Hpc-a Product #3
Viability as determined by 7-AAD flow cytometry
CD3+ T cell count
CD34+ cell count
Record number of columns used for the selection
procedures
One column (One column)
Three columns (Three columns)
Two columns (Two columns)
Total nucleated cell count
For Each Column Used, Record The
Following Information
Pre-selection/post Platelet & Antibody
Wash Product #1
Viability as determined by 7-AAD flow cytometry
CD34+ cell count
Total nucleated cell count
Pre-selection/post Platelet & Antibody
Wash Product #2
Viability as determined by 7-AAD flow cytometry
CD34+ cell count
Total nucleated cell count
Pre-selection/post Platelet & Antibody
Wash Product #3
Viability as determined by 7-AAD flow cytometry
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CSL
CD34+ cell count
Total nucleated cell count
Comments
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Re-Admission/Hospitalization Form (ADM)
Re-Admission/Hospitalization Form (ADM)
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=FF1A99BE-
38AD-3F09-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/10342
Re-Admission/Hospitalization Form
(ADM)
Header Module
Segment
Date of Admission
Date of discharge
Patient discharge status
Alive (Alive)
Dead (Dead)
Record Secondary Discharge Diagnoses
Record PRIMARY discharge diagnosis
Bleeding/Hemorrhage
(Bleeding/Hemorrhage)
Diarrhea (Diarrhea)
Fever (Fever)
Fungal Infection (Fungal Infection)
Graft Failure (Graft Failure)
GVHD (GVHD)
Infection (Infection)
Nausea/Vomiting (Nausea/Vomiting)
Non-Fungal Infection (Non-Fungal
Infection)
Organ Failure (specify organ) (Organ
Failure (specify organ))
Other (specify) (Other (specify))
Pyschiatric (Pyschiatric)
Relapse (Relapse)
Secondary Malignancy (Secondary
Malignancy)
Seizure (Seizure)
Transplant (Transplant)
Trauma (Trauma)
Specify organ
Specify other
GVHD
Contributory (Contributory)
Noncontributory (Noncontributory)
Relapse
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Contributory (Contributory)
Noncontributory (Noncontributory)
Graft Failure
Contributory (Contributory)
Noncontributory (Noncontributory)
Infection
Contributory (Contributory)
Noncontributory (Noncontributory)
Fever
Contributory (Contributory)
Noncontributory (Noncontributory)
Seizure
Contributory (Contributory)
Noncontributory (Noncontributory)
Bleeding/Hemorrhage
Contributory (Contributory)
Noncontributory (Noncontributory)
Diarrhea
Contributory (Contributory)
Noncontributory (Noncontributory)
Nausea/Vomiting
Contributory (Contributory)
Noncontributory (Noncontributory)
Organ Failure
Contributory (Contributory)
Noncontributory (Noncontributory)
Specify organ
Trauma
Contributory (Contributory)
Noncontributory (Noncontributory)
Pyschiatric
Contributory (Contributory)
Noncontributory (Noncontributory)
Secondary Malignancy
Contributory (Contributory)
Noncontributory (Noncontributory)
Other
Contributory (Contributory)
Noncontributory (Noncontributory)
Specify other
Record re-admission institution
Original Transplant Center (Original
Transplant Center)
Other Hospital (Other Hospital)
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Re-Admission/Hospitalization Form (ADM)
Other Transplant Center (Other
Transplant Center)
Comment
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DTH
DTH
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=FF1A2AFC-
A449-1B00-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/10343
DTH
Patient death
Record date of death
Was an autopsy performed
Enter Appropriate Cause Of Death Code
Below. List In Order Of Decreasing
Severity
Seconday cause of death
Accidental death (Accidental death)
Acute GVHD (Acute GVHD)
Adult respiratory distress syndrome
(Adult respiratory distress syndrome)
Autology recovery (Autology recovery)
Bacterial infection (Bacterial infection)
Cardiac (cardiomyopathy)  failure (not
due to GVHD or infection) (Cardiac
(cardiomyopathy)  failure (not due to
GVHD or infection))
Chronic GVHD (Chronic GVHD)
CNS failure (not due to GVHD or
infection) (CNS failure (not due to GVHD
or infection))
Disseminated intravascular coagulation
(Disseminated intravascular coagulation)
EBV (EBV)
Fungal infection (Fungal infection)
Gastrointestinal (Gastrointestinal)
Gastrointestinal hemorrhage
(Gastrointestinal hemorrhage)
Graft rejection or failure (Graft rejection
or failure)
Hemorrhage, not specified (Hemorrhage,
not specified)
Idiopathic (interstitial pneumonia)
(Idiopathic (interstitial pneumonia))
Intracranial hemorrhage (Intracranial
hemorrhage)
Liver failure (not due to GVHD or
infection) (Liver failure (not due to GVHD
or infection))
Multiple organ failure, specify below
(Multiple organ failure, specify below)
Organism not identified (Organism not
identified)
Other failure (not due to GVHD or
infection), specify below (Other failure
(not due to GVHD or infection), specify
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below)
Other hemorrhage, specify below (Other
hemorrhage, specify below)
Other vascular, specify below (Other
vascular, specify below)
Other, specify below (Other, specify
below)
Other, specify below (Other, specify
below)
Other, specify below (Other, specify
below)
Persistent disease (Persistent disease)
Pneumocystic (interstitial pneumonia)
(Pneumocystic (interstitial pneumonia))
Protozoal infection (Protozoal infection)
Pulmonary failure (not due to GVHD or
infection) (Pulmonary failure (not due to
GVHD or infection))
Pulmonary hemorrhage (Pulmonary
hemorrhage)
Recurrence or persistence of
leukemia/malignancy/MDS (Recurrence
or persistence of
leukemia/malignancy/MDS)
Rejection (Rejection)
Renal failure (not due to GVHD or
infection) (Renal failure (not due to
GVHD or infection))
Secondary graft failure (Secondary graft
failure)
Secondary malignancy (Secondary
malignancy)
Thromboembolic (Thromboembolic)
Thrombotic thrombocytopenic purpura
(Thrombotic thrombocytopenic purpura)
Vascular not specified (Vascular not
specified)
Viral infection (Viral infection)
Viral, CMV (interstitial pneumonia) (Viral,
CMV (interstitial pneumonia))
Viral, Other  (interstitial pneumonia)
(Viral, Other  (interstitial pneumonia))
Seconday cause of death
Accidental death (Accidental death)
Acute GVHD (Acute GVHD)
Adult respiratory distress syndrome
(Adult respiratory distress syndrome)
Autology recovery (Autology recovery)
Bacterial infection (Bacterial infection)
Cardiac (cardiomyopathy)  failure (not
due to GVHD or infection) (Cardiac
(cardiomyopathy)  failure (not due to
GVHD or infection))
Chronic GVHD (Chronic GVHD)
CNS failure (not due to GVHD or
infection) (CNS failure (not due to GVHD
or infection))
Disseminated intravascular coagulation
(Disseminated intravascular coagulation)
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EBV (EBV)
Fungal infection (Fungal infection)
Gastrointestinal (Gastrointestinal)
Gastrointestinal hemorrhage
(Gastrointestinal hemorrhage)
Graft rejection or failure (Graft rejection
or failure)
Hemorrhage, not specified (Hemorrhage,
not specified)
Idiopathic (interstitial pneumonia)
(Idiopathic (interstitial pneumonia))
Intracranial hemorrhage (Intracranial
hemorrhage)
Liver failure (not due to GVHD or
infection) (Liver failure (not due to GVHD
or infection))
Multiple organ failure, specify below
(Multiple organ failure, specify below)
Organism not identified (Organism not
identified)
Other failure (not due to GVHD or
infection), specify below (Other failure
(not due to GVHD or infection), specify
below)
Other hemorrhage, specify below (Other
hemorrhage, specify below)
Other vascular, specify below (Other
vascular, specify below)
Other, specify below (Other, specify
below)
Other, specify below (Other, specify
below)
Other, specify below (Other, specify
below)
Persistent disease (Persistent disease)
Pneumocystic (interstitial pneumonia)
(Pneumocystic (interstitial pneumonia))
Protozoal infection (Protozoal infection)
Pulmonary failure (not due to GVHD or
infection) (Pulmonary failure (not due to
GVHD or infection))
Pulmonary hemorrhage (Pulmonary
hemorrhage)
Recurrence or persistence of
leukemia/malignancy/MDS (Recurrence
or persistence of
leukemia/malignancy/MDS)
Rejection (Rejection)
Renal failure (not due to GVHD or
infection) (Renal failure (not due to
GVHD or infection))
Secondary graft failure (Secondary graft
failure)
Secondary malignancy (Secondary
malignancy)
Thromboembolic (Thromboembolic)
Thrombotic thrombocytopenic purpura
(Thrombotic thrombocytopenic purpura)
Vascular not specified (Vascular not
specified)
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Viral infection (Viral infection)
Viral, CMV (interstitial pneumonia) (Viral,
CMV (interstitial pneumonia))
Viral, Other  (interstitial pneumonia)
(Viral, Other  (interstitial pneumonia))
Seconday cause of death
Accidental death (Accidental death)
Acute GVHD (Acute GVHD)
Adult respiratory distress syndrome
(Adult respiratory distress syndrome)
Autology recovery (Autology recovery)
Bacterial infection (Bacterial infection)
Cardiac (cardiomyopathy)  failure (not
due to GVHD or infection) (Cardiac
(cardiomyopathy)  failure (not due to
GVHD or infection))
Chronic GVHD (Chronic GVHD)
CNS failure (not due to GVHD or
infection) (CNS failure (not due to GVHD
or infection))
Disseminated intravascular coagulation
(Disseminated intravascular coagulation)
EBV (EBV)
Fungal infection (Fungal infection)
Gastrointestinal (Gastrointestinal)
Gastrointestinal hemorrhage
(Gastrointestinal hemorrhage)
Graft rejection or failure (Graft rejection
or failure)
Hemorrhage, not specified (Hemorrhage,
not specified)
Idiopathic (interstitial pneumonia)
(Idiopathic (interstitial pneumonia))
Intracranial hemorrhage (Intracranial
hemorrhage)
Liver failure (not due to GVHD or
infection) (Liver failure (not due to GVHD
or infection))
Multiple organ failure, specify below
(Multiple organ failure, specify below)
Organism not identified (Organism not
identified)
Other failure (not due to GVHD or
infection), specify below (Other failure
(not due to GVHD or infection), specify
below)
Other hemorrhage, specify below (Other
hemorrhage, specify below)
Other vascular, specify below (Other
vascular, specify below)
Other, specify below (Other, specify
below)
Other, specify below (Other, specify
below)
Other, specify below (Other, specify
below)
Persistent disease (Persistent disease)
Pneumocystic (interstitial pneumonia)
(Pneumocystic (interstitial pneumonia))
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Protozoal infection (Protozoal infection)
Pulmonary failure (not due to GVHD or
infection) (Pulmonary failure (not due to
GVHD or infection))
Pulmonary hemorrhage (Pulmonary
hemorrhage)
Recurrence or persistence of
leukemia/malignancy/MDS (Recurrence
or persistence of
leukemia/malignancy/MDS)
Rejection (Rejection)
Renal failure (not due to GVHD or
infection) (Renal failure (not due to
GVHD or infection))
Secondary graft failure (Secondary graft
failure)
Secondary malignancy (Secondary
malignancy)
Thromboembolic (Thromboembolic)
Thrombotic thrombocytopenic purpura
(Thrombotic thrombocytopenic purpura)
Vascular not specified (Vascular not
specified)
Viral infection (Viral infection)
Viral, CMV (interstitial pneumonia) (Viral,
CMV (interstitial pneumonia))
Viral, Other  (interstitial pneumonia)
(Viral, Other  (interstitial pneumonia))
Seconday cause of death
Accidental death (Accidental death)
Acute GVHD (Acute GVHD)
Adult respiratory distress syndrome
(Adult respiratory distress syndrome)
Autology recovery (Autology recovery)
Bacterial infection (Bacterial infection)
Cardiac (cardiomyopathy)  failure (not
due to GVHD or infection) (Cardiac
(cardiomyopathy)  failure (not due to
GVHD or infection))
Chronic GVHD (Chronic GVHD)
CNS failure (not due to GVHD or
infection) (CNS failure (not due to GVHD
or infection))
Disseminated intravascular coagulation
(Disseminated intravascular coagulation)
EBV (EBV)
Fungal infection (Fungal infection)
Gastrointestinal (Gastrointestinal)
Gastrointestinal hemorrhage
(Gastrointestinal hemorrhage)
Graft rejection or failure (Graft rejection
or failure)
Hemorrhage, not specified (Hemorrhage,
not specified)
Idiopathic (interstitial pneumonia)
(Idiopathic (interstitial pneumonia))
Intracranial hemorrhage (Intracranial
hemorrhage)
Liver failure (not due to GVHD or
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infection) (Liver failure (not due to GVHD
or infection))
Multiple organ failure, specify below
(Multiple organ failure, specify below)
Organism not identified (Organism not
identified)
Other failure (not due to GVHD or
infection), specify below (Other failure
(not due to GVHD or infection), specify
below)
Other hemorrhage, specify below (Other
hemorrhage, specify below)
Other vascular, specify below (Other
vascular, specify below)
Other, specify below (Other, specify
below)
Other, specify below (Other, specify
below)
Other, specify below (Other, specify
below)
Persistent disease (Persistent disease)
Pneumocystic (interstitial pneumonia)
(Pneumocystic (interstitial pneumonia))
Protozoal infection (Protozoal infection)
Pulmonary failure (not due to GVHD or
infection) (Pulmonary failure (not due to
GVHD or infection))
Pulmonary hemorrhage (Pulmonary
hemorrhage)
Recurrence or persistence of
leukemia/malignancy/MDS (Recurrence
or persistence of
leukemia/malignancy/MDS)
Rejection (Rejection)
Renal failure (not due to GVHD or
infection) (Renal failure (not due to
GVHD or infection))
Secondary graft failure (Secondary graft
failure)
Secondary malignancy (Secondary
malignancy)
Thromboembolic (Thromboembolic)
Thrombotic thrombocytopenic purpura
(Thrombotic thrombocytopenic purpura)
Vascular not specified (Vascular not
specified)
Viral infection (Viral infection)
Viral, CMV (interstitial pneumonia) (Viral,
CMV (interstitial pneumonia))
Viral, Other  (interstitial pneumonia)
(Viral, Other  (interstitial pneumonia))
Primary cause of death
Accidental death (Accidental death)
Acute GVHD (Acute GVHD)
Adult respiratory distress syndrome
(Adult respiratory distress syndrome)
Autology recovery (Autology recovery)
Bacterial infection (Bacterial infection)
Cardiac (cardiomyopathy)  failure (not
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due to GVHD or infection) (Cardiac
(cardiomyopathy)  failure (not due to
GVHD or infection))
Chronic GVHD (Chronic GVHD)
CNS failure (not due to GVHD or
infection) (CNS failure (not due to GVHD
or infection))
Disseminated intravascular coagulation
(Disseminated intravascular coagulation)
EBV (EBV)
Fungal infection (Fungal infection)
Gastrointestinal (Gastrointestinal)
Gastrointestinal hemorrhage
(Gastrointestinal hemorrhage)
Graft rejection or failure (Graft rejection
or failure)
Hemorrhage, not specified (Hemorrhage,
not specified)
Idiopathic (interstitial pneumonia)
(Idiopathic (interstitial pneumonia))
Intracranial hemorrhage (Intracranial
hemorrhage)
Liver failure (not due to GVHD or
infection) (Liver failure (not due to GVHD
or infection))
Multiple organ failure, specify below
(Multiple organ failure, specify below)
Organism not identified (Organism not
identified)
Other failure (not due to GVHD or
infection), specify below (Other failure
(not due to GVHD or infection), specify
below)
Other hemorrhage, specify below (Other
hemorrhage, specify below)
Other vascular, specify below (Other
vascular, specify below)
Other, specify below (Other, specify
below)
Other, specify below (Other, specify
below)
Other, specify below (Other, specify
below)
Due To This Disease (Persistent
disease)
Pneumocystic (interstitial pneumonia)
(Pneumocystic (interstitial pneumonia))
Protozoal infection (Protozoal infection)
Pulmonary failure (not due to GVHD or
infection) (Pulmonary failure (not due to
GVHD or infection))
Pulmonary hemorrhage (Pulmonary
hemorrhage)
Recurrence or persistence of
leukemia/malignancy/MDS (Recurrence
or persistence of
leukemia/malignancy/MDS)
Rejection (Rejection)
Renal failure (not due to GVHD or
infection) (Renal failure (not due to
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GVHD or infection))
Secondary graft failure (Secondary graft
failure)
Due To Second Primary Or Other
Malignancy (Secondary malignancy)
Thromboembolic (Thromboembolic)
Thrombotic thrombocytopenic purpura
(Thrombotic thrombocytopenic purpura)
Vascular not specified (Vascular not
specified)
Viral infection (Viral infection)
Viral, CMV (interstitial pneumonia) (Viral,
CMV (interstitial pneumonia))
Viral, Other  (interstitial pneumonia)
(Viral, Other  (interstitial pneumonia))
Other, specify below
Other, specify below
Other, specify below
Other, specify below
Other, specify below
Comments
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Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=FF1B1538-
4C42-32AF-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/10344
IMM
Header Module
Segment
Visit number
Flow Cytometry
CD14+
CD5+/CD19+ immature B cells
CD19+ B cells
CD5+
CD56+/CD16+/CD3-
CD8
CD4
Percent lymphocyte of CD45+ cells
Date flow cytometry was performed
White blood cell count
Quantitative Immunoglobulins
Date quantitative immunoglobulins assay was
performed
Iga
Value
Lower limit of normal
1 / 2
Upper limit of normal
Igg
Value
Lower limit of normal
Upper limit of normal
Igm
Value
Lower limit of normal
Upper limit of normal
Comments
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IMM
ECOG4599 Baseline Disease Evaluation
Form (RECIST)
ECOG4599 Baseline Disease Evaluation Form (RECIST)
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=A1317E8C-
0271-4779-E034-080020C9C0E0
All rights reserved. Please visit https://medical-data-
models.org/forms/10346
ECOG4599 Baseline Disease
Evaluation Form (RECIST)
Baseline Disease Evaluation Data
Date of data transfer
Transfer Method
Specify other transfer method
Step No.
Patient Name
Particip. Group Protocol Number
Patient Study ID, Participating Group
Institution Name
Affiliate Name
Amended Data Ind
Amended Data Ind
Target Lesion Ind
Lesion, Reference Number, Target
Lesion, Anatomic Site, Target
Site Code, Target
Assessment Type, Target
Assessment Date, Target
Lesion, Tumor Diameter
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Lesion, Diameter, Longest Sum
Lesion, Reference Number, Nontarget
Lesion, Anatomic Site, Nontarget
Site Code, Nontarget
Assessment Type, Nontarget
Assessment Date, Nontarget
Cytology Result
Comments
Comments2
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ECOG 4599 Toxicity Form
ECOG 4599 Toxicity Form
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=A16E9046-
8508-5FB4-E034-080020C9C0E0
All rights reserved. Please visit https://medical-data-
models.org/forms/10369
ECOG 4599 Toxicity Form
ECOG clinical trial administrative data
Date of data transfer
Transfer Method
Specify other transfer method
Patient Name
Particip. Group Protocol Number
Patient Study ID, Participating Group
Institution Name
Affiliate Name
Adverse Event Report Begin Date
Adverse Event Report End Date
Amended Data Ind
Amended Data Ind
CTC Adverse Event Term
CTC Adverse Event Term
CTC Adverse Event Term
CTC Adverse Event Term
CTC Adverse Event Grade
CTC Adverse Event Grade
CTC Adverse Event Grade
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CTC Adverse Event Grade
Treatment Relation
Treatment Relation
Treatment Relation
Treatment Relation
Comments1
Comments2
CTC Code
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ECOG 4599 Treatment Form
ECOG 4599 Toxicity Form
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=A16E9DCC-
CE6C-6087-E034-080020C9C0E0
All rights reserved. Please visit https://medical-data-
models.org/forms/10370
ECOG 4599 Treatment Form
ECOG treatment data
Date of data transfer
Transfer Method
Specify other transfer method
Amended Data Ind
Patient Name
Particip. Group Protocol Number
Patient Study ID, Participating Group
Step Number
Institution Name
Affiliate Name
Patient's Vital Status
Death Date/Last Contact Date
Death Reason
Death Reason, Specify
Course Identification
Treatment Begin Date
Treatment Last Dose End Date
Blood Pressure, Systolic
Blood pressure, Diastolic
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Patient Weight(kg)
Urine dipstick result
Date of urine dipstick
Date Bevacizumab given
Bevacizumab dose (mg)
Dose Modification (Change)
Treatment End Date
Off Treatment Reason
Off Treatment Reason, Complicating Disease
Comments
Comments2
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Southwest Oncology Group Registration
Form
Southwest Oncology Group Registration Form
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=A4CF746B-
17EF-3705-E034-080020C9C0E0
All rights reserved. Please visit https://medical-data-
models.org/forms/10372
Southwest Oncology Group
Registration Form
SWOG clinical trial administrative data
SWOG Study No.
Registration Step
Assigned Treatment Arm
Activation Date
Last Amended Date
Caller's SWOG Roster ID
SWOG Treating Institution Number
Date Informed Consent Signed
SWOG Investigator Number
IRB Approval Date
Projected Start Date of Treatment (Patient
Consent for Specimen Use)
patient demographics
Patient's Name
SWOG Patient ID
Patient's tissue may be kept for use in research to
learn about, prevent, treat, or cure cancer.
Yes
No
Patient's tissue may be kept for use in research
about other health problems (for example: causes
of diabetes, Alzheimer's, and heart disease)
Yes
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No
Someone from the Southwest Oncology Group
may contact the patient in the future to ask him or
her to tak part in more research
Yes
No
Patient's Date of Birth
Patient's Sex
Female (Female)
Male (Male)
Method of Payment
Medicaid (Medicaid)
Medicaid and Medicare (Medicaid and
Medicare)
Medicare (Medicare)
Medicare and Private (Medicare and
Private)
Military (Military)
No insurance (no means) (No insurance
(no means))
No insurance (self-pay) (No insurance
(self-pay))
Other, specify at registration (Other,
specify at registration)
Private (Private)
Unknown (Unknown)
Veterans Admin (Veterans Admin)
Patient's Ethnicity
No_not_spanish2006636 (No (not
Spanish))
Unknown2006635 (Unknown)
Yes_central_american2006640 (Yes,
Central American)
Yes_cuban2006639 (Yes, Cuban)
Yes_mexican2006637 (Yes, Mexican)
Yes_nos2006643 (Yes, NOS)
Yes_other2006642 (Yes, Other)
Yes_puerto_rican2006638 (Yes, Puerto
Rican)
Yes_south_american2006641 (Yes,
South American)
Patient's Race (select all that apply)
Native_american_cdus (American Indian
or Alaska Native)
Asian_cdus (Asian)
Black_cdus (Black or African American)
Pacific_islander_cdus (Native Hawaiian
or Other Pacific Islander)
Other, Specify (Other, Specify)
Unknown (Unknown)
White_cdus (White or Caucasian)
Other, specify (patient's race) (If a U.S. resident)
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Southwest Oncology Group Registration Form
Patient's Social Security Number
Patient's Zip Code
Country of Residence, if not USA (If a resident of
Canada)
Social Insurance Number
Postal Code (Statification Factors)
Stage
Iiib (not Recurrent) (IIIB)
Iv (not Recurrent) (IV)
LDH
</= Uln (</= ULN)
> Uln (> ULN)
Notes
Notes
Ccrr Module For Southwest Oncology
Group Registration Form
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Southwest Oncology Group Registration Form
ECOG 4599 Report Tracking
ECOG 4599 Report Tracking
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=A16E8538-
78E2-5FA3-E034-080020C9C0E0
All rights reserved. Please visit https://medical-data-
models.org/forms/10376
ECOG 4599 Report Tracking
Report Tracking
Report Type
Event
Report Date
Date Received
Date Sent
Comments1
Comments2
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ECOG 4599 Registration Form (RECIST)
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=A16F5E81-
8438-5E56-E034-080020C9C0E0
All rights reserved. Please visit https://medical-data-
models.org/forms/10378
ECOG 4599 Registration Form
ECOG clinical trial administrative data
Cooperative Group Name
Coordinating Group Protocol Number
Person Completing Form, First Name
Person Completing Form, Last Name
Person Completing Form, Phone
Person Completing Form, Fax
Institution Name
Institution City
Institution State
Institution NCI Code
Investigator Name
Affiliate Name
IRB Approval Date
Informed Consent Date Signed
Patient  enrolled on any other CG trial
Other Cooperative Group Trial-Group Name
Other Cooperative Group Trial-Protocol #
Other Cooperative Group Trial-Specify
Patient Identifier
1 / 2
NCI Investigator Number
Investigator Status
Patient Study ID, Coordinating Group
Treatment Arm Number
Registration Date
CTSU Patient Registrar
Is Treating Institution a CCOP of a Coop
U10
Patient Gender
Patient Race/Ethnicity
Comments1
Comments2
Investigator Code
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ECOG 4599 Registration Form
ADEERS
ADEERS
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=A12FFCCA-
ABD0-42E9-E034-080020C9C0E0
All rights reserved. Please visit https://medical-data-
models.org/forms/10389
ADEERS
Administrative data
Date of data transfer
Transfer Method
Specify other transfer method
Amended Data Ind
Report Type
Ticket Number
Amendment Number
Treatment Arm Number
Adverse Event Onset Date
Adverse Event End Date
Recovery or death date
Adverse Event Category
CTC Adverse Event Term
CTC Adverse Event Grade
Hospitalization?
Discharge Summary
CTC Code
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SPECIAL LITERAL LABS
SPECIAL LITERAL LABS
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=A5EB1483-
D974-2E5A-E034-0003BA0B1A09
All rights reserved. Please visit https://medical-data-
models.org/forms/10395
SPECIAL LITERAL LABS
Header Module
Date Completed
TIME
DATE
ASSIGNED TEST NAME
PANEL #
Patient ID
Sheet #
Institution
Protocol #
RESULT
Ccrr Module For Special Literal Labs
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EUMDS registry eligibility NCT00600860
http://www.eumds.org/
All rights reserved. Please visit https://medical-data-
models.org/forms/10399
Eligibility EUMDS registry
NCT00600860
Eligibility
Therapy Related (excluded if secondary/therapy
related MDS)
Yes
No
Written consent
Yes
No
Age > 18 years
Yes
No
IPSS Score: low or intermediate - 1 OR
percentage of marrow blasts < 5% & number of
cytopenias = 0 if cytogenetic profile is
unavailable.
Yes
No
Newly diagnosed
Yes
No
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EUMDS registry patient registration
NCT00600860
http://www.eumds.org/
All rights reserved. Please visit https://medical-data-
models.org/forms/10400
Patient registration EUMDS registry
NCT00600860
Patient registration
EUMDS ID
Local ID
Date of Inclusion
Sex
F (F)
M (M)
Date of diagnosis
D.O.B.
Ethnicity
Caucasian (1)
Filipino (10)
Roma (11)
Other (12)
Not Known (13)
South Asian (2)
North African (3)
Sub-Saharan African (4)
Afro-Carribean (5)
Turk (6)
Kurd (7)
Latin American (8)
Chinese (9)
MDS Diagnosis
5q syndrome (1)
RA (2)
RARA (3)
RCMD (4)
RCMD-RS (5)
RAEB-1 (6)
RAEB-2 (7)
MDS-U (8)
Bone Marrow Blasts
<5% (1)
5% - 10% (2)
11% - 20% (3)
21% - 30% (4)
Cytopenia
0 (0)
1 (1)
2 (2)
1 / 2
3 (3)
Cytogenetics
Good (1)
Intermediate (2)
Poor (3)
Not Available (4)
IPSS Score
0 (0)
0.5 (0.5)
1 (1)
1.5 (1.5)
2 (2)
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EUMDS registry patient registration NCT00600860
EUMDS registry visit details NCT00600860
http://www.eumds.org/
All rights reserved. Please visit https://medical-data-
models.org/forms/10402
Visit details EUMDS registry
NCT00600860
Details at visit
Visit date
Height
Weight
Karnofsky Status
Dead. (0)
Moribund; fatal processes progressing
rapidly. (10)
Normal - no complaints; no evidence of
disease. (100)
Very sick; hospital admission is
necessary; active supportive treament
necessary. (20)
Severely disabled; hospital admission is
indicated although death not imminent.
(30)
Disabled; requires special care and
assistance. (40)
Requires considerable assistance and
frequent medical care. (50)
Requires occasional assistance, but is
able to care for most personal needs.
(60)
Care for self; unable to carry on normal
activity or to do active work. (70)
Normal activity; minor sign of symptoms
of disease. (80)
Able to carry on normal activity; minor
sign or symptoms of disease. (90)
History of MDS Treatment
No previous treatment
Yes
No
Clinical trial
Yes
No
Clinical trial start date
Clinical trial stop date
1 / 3
History of MDS Treatment
Medication
Hydroxyurea (1)
Erythropoietin (2)
Demethylating (3)
Immunosuppressive agent (4)
G-CSF (5)
Prednisolone (6)
Other Agent (7)
Medication start date
Medication ongoing
Yes
No
Medication stop date
Medication comment
Treatment with Iron Chelators
Never treated with iron chelator
Yes
No
Treatment with Iron Chelators
Medication
Deferoxamine (1)
Deferiprone (2)
Deferasirox (3)
Ferritin (4)
Daily dose
Schedule
Start Date
Stop Date/Ongoing
Number of courses
Route of administrion
IV (1)
SC (2)
Red cell transfusion
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EUMDS registry visit details NCT00600860
No transfusions
Yes
No
Date of first transfusion
Number of RBC units transfused
Date of last transfusion
Number of units transfused
Date of blood sample for Hb
Pre-transfusion Hb
Pre-transfusion Hb unit
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EUMDS registry visit details NCT00600860
EHR Blood Cell Count Analysis
Hematology
EHR Blutbild MedA SpHaem02 converted to ODM format.
Routine documentation of University Hospital Muenster
All rights reserved. Please visit https://medical-data-
models.org/forms/10406
Blutbild MedA SpHaem02
Blutbild MedA SpHaem02
Auftragsnummer:*
Auftragsdatum*
Auftragszeit*
retikulo*
AufAbtg*
bemerkbb*
hlpDirektor*
LaborbefundIm*
Unterschriftrechts*
Differential blood count
diffstab
diffmbl
diffsegment
diffpromy
diffeos
diffmyeloc
diffbaso
diffmetam
diffmono
diffleukblasten
1 / 3
diffly
bemerkdiff
Leukocyte Morphology
leugran
leuvakuolen
leudoehle
leuhyperseg
leulymphreizform
leugumprecht
leurote
leumegakaryo
leuapl
leukorrleuko
Erythrocyte Morphology
eryaniso
erypikilo
eryhowell
erypolychromas
eryhypochromas
eryellipto
erybasotup
eryfrag
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EHR Blood Cell Count Analysis Hematology
eryspäro
erytarget
bemerkerys
Platelets
Thromo
Ja
Nein
bemerkung
vermindert
Ja
Nein
vermehrt
Ja
Nein
traniso
Ja
Nein
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EHR Blood Cell Count Analysis Hematology
SPECIAL NUMERIC LABS
SPECIAL NUMERIC LABS
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=A5EB1250-
FB6E-2E58-E034-0003BA0B1A09
All rights reserved. Please visit https://medical-data-
models.org/forms/10412
SPECIAL NUMERIC LABS
Header module
Date Completed
Protocol #
Institution
Sheet #
Patient ID
PANEL #
DATE
ASSIGNED TEST
TIME
Ccrr Module For Special Numeric Labs
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UNANTICIPATED LAB DATA
UNANTICIPATED LAB DATA
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=A5EB171F-
7888-2E5C-E034-0003BA0B1A09
All rights reserved. Please visit https://medical-data-
models.org/forms/10430
UNANTICIPATED LAB DATA
UNANTICIPATED LAB DATA
Date Completed (dy/mth/yr)
Protocol #
Institution
Sheet #
Patient ID
Date (dy/mth/yr)
Time (hr:min)
Lab Test
Body Site
Normal/Abnormal
Abnormal (A)
Normal (N)
Result Type
Literal (L)
Numeric (N)
Result
Ccrr Module For Unanticipated Lab Data
1 / 1
Skin Histopathological Results UKM
MS HAUT Histologie converted to ODM format. Routine
documentation of University Hospital Muenster
All rights reserved. Please visit https://medical-data-
models.org/forms/10436
ODM-Form
Default Itemgroup
Patient ID Data
Purpose
Diagnosis
Histology Number
Date of receipt
Requesting Department/Unit
(operating) Surgeon
Location of Excesion
Prior histologic examinations
Anesthesia
Local (1)
Conductive anesthesia (2)
Total, Narcosis (3)
Preliminary report
Excision technique
Punch biopsy (1)
Partial Biopsy (2)
Total excision (3)
Shave (4)
Specimen procedure
Frozen section (1)
Microbiology (2)
Electron Microscopy (3)
Requested Specimen Cut
across (1)
along (2)
Comments
Macroscopic results
Microscopic results
1 / 2
Immunohistology
Yes
No
Critical Report
Date of results
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Skin Histopathological Results UKM
EUMDS registry general medical history
and concomitant disease NCT00600860
http://www.eumds.org/
All rights reserved. Please visit https://medical-data-
models.org/forms/10437
General medical history and
concomitant disease EUMDS
registry NCT00600860
Medical history
Concomitant Disease
Previous myocardial infarction (1)
Lens opacities (10)
Macular degeneration (11)
Other Ophthalmic Disease (specify) (12)
Hearing Impairment (13)
Diabetes mellitus (14)
Thyroid disease (15)
Pituitary dysfunction (16)
Gonadal dysfunction (17)
Adrenal dysfunction (18)
Renal Disease (19)
Angina (2)
Hepatic Disease (20)
Malignant Disease (21)
Inflammatory Bowel Disease (22)
Cerebro-vascular Disease (23)
Rheumatological Disease (24)
Peptic Ulcer (25)
Auto-immune Disease (26)
Organ Transplant (27)
Alcohol Abuse (28)
Positive HIV Status (29)
Arrhythmia (3)
Enlargement of Lymph Nodes (30)
Splenomegaly (31)
Other (specify) (32)
Heart failure requiring drug treatment (4)
Dyspnoea on moderate activity (5)
Dyspnoea on slight activity (6)
Dyspnoea at rest/ requires oxygen (7)
Psychiatric Disturbance (8)
Infection at Presentation (9)
Start Date
Stop Date
Ongoing
Yes
No
Other
1 / 1
EUMDS registry concomitant treatment
NCT00600860
http://www.eumds.org/
All rights reserved. Please visit https://medical-data-
models.org/forms/10438
concomitant treatment for
concomitant disease EUMDS
registry NCT00600860
Medical history
Medication
Anti-platelet (1)
Anti-infective (10)
Eye drops (11)
Anti-diabetic (12)
Thyroid drugs (13)
Other (please specify) (14)
Corticosteroids (15)
Oestrogen replacement (16)
Other hormonal therapy (17)
Proton pump inhibitors (18)
Anti-epileptic (19)
Anti-coagulant (2)
Vitamin B-12 (20)
Folic acid (21)
Iron replacement (22)
Anti-inflammatory (23)
Opiate analgesia (24)
Bisphosphonates (25)
Chemotherapy (26)
Radiotherapy (27)
Immunosupressive (28)
Cholesterol lowering (3)
Diuretics (4)
Anti-hypertensive (5)
Anti-arrhythmic (6)
Inhalers (7)
Home oxygen (8)
Anti-depressant (9)
Start Date
Stop Date
Ongoing
Yes
No
Other
1 / 1
Oral Health Inventory Profile
Oral Health Inventory Profile
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=853C838C-
C4ED-C9D6-E040-BB89AD4361D8
All rights reserved. Please visit https://medical-data-
models.org/forms/10443
Oral Health Inventory Profile
Oral Health assessment
Have you had trouble pronouncing any words
because of problems with your implant placement
Fairly Often (Fairly often)
Hardly Ever (Hardly ever)
Not At All (Not at all)
Occasionally (Occasionally)
Very Often (Very often)
Have you felt that your sense of taste has
worsened because of problems with the implant
placement
Fairly Often (Fairly often)
Hardly Ever (Hardly ever)
Not At All (Not at all)
Occasionally (Occasionally)
Very Often (Very often)
Have you had painful aching in your mouth due to
the implant placement
Fairly Often (Fairly often)
Hardly Ever (Hardly ever)
Not At All (Not at all)
Occasionally (Occasionally)
Very Often (Very often)
Have you found it uncomfortable to eat any foods
because of problems with your implant placement
Fairly Often (Fairly often)
Hardly Ever (Hardly ever)
Not At All (Not at all)
Occasionally (Occasionally)
Very Often (Very often)
Have you been self-conscious because of
problems with your implant placement
Fairly Often (Fairly often)
Hardly Ever (Hardly ever)
Not At All (Not at all)
Occasionally (Occasionally)
Very Often (Very often)
Have you felt tense because of problems with
your implant placement
Fairly Often (Fairly often)
Hardly Ever (Hardly ever)
Not At All (Not at all)
Occasionally (Occasionally)
Very Often (Very often)
Has your diet been unsatisfactory because of
problems with your implant placement
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Fairly Often (Fairly often)
Hardly Ever (Hardly ever)
Not At All (Not at all)
Occasionally (Occasionally)
Very Often (Very often)
Have you had to interrupt meals because of
problems with your implant placement
Fairly Often (Fairly often)
Hardly Ever (Hardly ever)
Not At All (Not at all)
Occasionally (Occasionally)
Very Often (Very often)
Have you found it difficult to relax because of
problems with your implant placement
Fairly Often (Fairly often)
Hardly Ever (Hardly ever)
Not At All (Not at all)
Occasionally (Occasionally)
Very Often (Very often)
Have you been a bit embarrassed because of
problems with your implant placement
Fairly Often (Fairly often)
Hardly Ever (Hardly ever)
Not At All (Not at all)
Occasionally (Occasionally)
Very Often (Very often)
Have you been a bit irritable with other people
because of problems with your implant placement
Fairly Often (Fairly often)
Hardly Ever (Hardly ever)
Not At All (Not at all)
Occasionally (Occasionally)
Very Often (Very often)
Have you had difficulty doing your usual jobs
because of problems with your implant placement
Fairly Often (Fairly often)
Hardly Ever (Hardly ever)
Not At All (Not at all)
Occasionally (Occasionally)
Very Often (Very often)
Have you felt that life in general was less
satisfying because of problems with your implant
placement
Fairly Often (Fairly often)
Hardly Ever (Hardly ever)
Not At All (Not at all)
Occasionally (Occasionally)
Very Often (Very often)
Have you been totally unable to function because
of problems with your implant placement
Fairly Often (Fairly often)
Hardly Ever (Hardly ever)
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Oral Health Inventory Profile
Not At All (Not at all)
Occasionally (Occasionally)
Very Often (Very often)
Footer Module
Date Questionnaire Completed
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Oral Health Inventory Profile
Supplemental Form
Supplemental Form
A Phase III, Randomized Study of Gemcitabine (Fixed-
Dose Rate Infusion) and Oxaliplatin (NSC 266046) Versus
Gemcitabine (Fixed-Dose Rate Infusion) Versus
Gemcitabine (30-Minute Infusion) in Pancreatic Carcinoma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=A65C81E5-
2ACA-42A6-E034-0003BA0B1A09
All rights reserved. Please visit https://medical-data-
models.org/forms/10450
Supplemental Form
ECOG clinical trial administrative data
Registration Step
Patient?s Name
ECOG Protocol No.
ECOG Protocol No.
ECOG Patient ID
ECOG Patient ID
Participating Group Protocol No.
Participating Group Patient ID
Institution/Affiliate
Data amendment
Are data amended? (If yes, please circle
amended items in red)
No (No)
Yes (Yes)
Reporting Period Start Date (M D Y)
Reporting Period End Date (M D Y)
Cea
Date CEA obtained (M D Y)
CEA Patient Value (ng/ml)
1 / 2
CEA ULN
Ca19-19
Date CA19-19 obtained (M D Y)
CA19-19 Patient Value (U/ml)
Thrombosis / Embolism
Did the patient have a deep vein thrombosis
(DVT) this report period?
No (No)
Yes (Yes)
Did the patient have a pulmonary embolism this
report period?
No (No)
Yes (Yes)
Comments
Comments
Investigator Signature
Date
Ccrr Module For Supplemental Form
2 / 2
Supplemental Form
ACNS1123 Eligibility
ACNS1123 Eligibility
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=
All rights reserved. Please visit https://medical-data-
models.org/forms/10452
FP.0000
Stratification
ACNS1123 Stratum
Stratum 1 - Nggct (Stratum 1 - NGGCT)
Stratum 2 - Germinoma (Stratum 2 -
Germinoma)
Study Treatment
Treatment 1: A,b,a,b,a,b (Treatment 1  A
B A B A B)
Treatment 2: A,a,a,a (Treatment 2 A A A
A)
Treatment Begin Date (Projected date must be no
later than 5 calendar days after the date of study
enrollment.  Enter as MM/DD/YYYY.)
TUMOR LOCATION Elig - Block 1
Is the patient enrolled on the ALTE07C1 study?
No (No)
Yes (Yes)
Is the patient greater than or equal to 3 years and
less than or equal to 21 years at the time of
enrollment?
No (No)
Yes (Yes)
Was definitive diagnostic surgery performed?
No (No)
Yes (Yes)
Date of definitive diagnostic surgery or clinical
diagnosis:
Was lumbar CSF cytology obtained?
No (No)
Yes (Yes)
Was it medically contraindicated? (If no,)
No (No)
Yes (Yes)
Was lumbar CSF cytology negative?
No (No)
Yes (Yes)
TUMOR LOCATION Elig - Block 2
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Does patient have germ cell tumor(s) located in
the suprasellar, pineal, bifocal (pineal +
suprasellar) or  ventricles? (Tumors present in the
above mentioned locations and with unifocal
parenchymal extension)
No (No)
Yes (Yes)
Elig - Block 3
Does patient have newly diagnosed localized
primary CNS NGGCT?
No (No)
Yes (Yes)
Does patient have any of the following elements
on biopsy/resection? (endodermal sinus tumor
yolk sacor embryonal carcinoma or
choriocarcinoma or malignant/immature teratoma
or mixed GCT with malignant GCT elements)
No (NO)
Yes (YES)
Does patient meet any of the following criteria:
(Serum and/or CSF hCGB > 100mIU/mL or Any
elevation of serum and CSF AFP > 10ng/mL or
greater than the institutional normal)
No (No)
Yes (Yes)
Elig - Block 4
Does patient have newly diagnosed localized
primary CNS germinoma?
No (No)
Yes (Yes)
Does patient meet any of the following criteria:
(Serum and/or CSF hCGB > 100mIU/mL or Any
elevation of serum and CSF AFP > 10ng/mL or
greater than the institutional normal)
No (No)
Yes (Yes)
Elig - Block 5
Peripheral absolute neutrophil count (ANC)
(number/uL)
Platelet count (number/uL): (Transfusion
Independent)
Hemoglobin(g/dL) (May receive RBC transfusion)
Elig - Block 5
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ACNS1123 Eligibility
Creatinine clearance (mL/min/1.73m²):
Radioisotope GFR(mL/min/1.73 m²)
Serum creatinine (mg/dL) (At study entry and
based on age/gender per protocol section
3.2.5.2)
Elig - Block 7
Total bilirubin (mg/dl), ULN
Total bilirubin Value (mg/dl):
SGPT (ALT) or SGOT (AST) U/L, ULN:
SGPT (ALT) or SGOT (AST), U/L
Elig - Block 8
Does patient have seizure disorder?
No (No)
Yes (Yes)
Is patient's seizure disorder well controlled?
(Adequate central nervous system function as
defined in protocol section 3.2.5.4)
No (No)
Yes (Yes)
Is patient in status, coma or assisted ventilation
at study entry?
No (No)
Yes (Yes)
Elig - Block 9
Does patient have mature teratoma with normal
tumor markers?
No (No)
Yes (Yes)
Has patient agreed to stop breastfeeding? (If yes
above,)
No (No)
Yes (Yes)
Is patient nursing?
No (No)
Yes (Yes)
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ACNS1123 Eligibility
Is patient pregnant? (If yes above,)
No (No)
Yes (Yes)
Was a pregnancy test performed?
No (No)
Yes (Yes)
Is patient post menarcheal?
No (no)
Yes (yes)
Prior to study enrollment, has patient been
treated with therapy other than surgical
intervention and corticosteroids?
No (No)
Yes (Yes)
Does patient have metastatic disease by either
MRI evaluation or lumbar CSF cytology?
No (No)
Yes (Yes)
Does patient have tumors located outside the
ventricles? (basal ganglia, thalamus)
No (No)
Yes (Yes)
Has patient agreed to use an effective
contraceptive method for the duration of the study
participation?
N/a, Patient Is Not Of Reproductive
Potential (NA patient is not of
reproductive potential)
No (No)
Yes (Yes)
Elig - Block 10
Date Informed Consent Signed
Have all institutional, FDA, and NCI requirements
for human studies been met?
No (No)
Yes (Yes)
Comments
4 / 4
ACNS1123 Eligibility
TX5
TX5
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=FF1AAC43-
4B80-4030-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/10453
TX5
Header module
Segment
Visit number
Record date of evaluation
Record The Highest Grade Of Toxicity
Diagnosed Since The Previous
Evaluation. If This Is The First Evaluation,
Record The Highest Toxicity Diagnosed
Since Day 0. The Toxicity Grades Are
Based On The...
Allergy/immunologic Toxicity
Allergic reaction/hypersensitivity (including drug
fever)
Anaphylaxis (Anaphylaxis)
Death (Death)
Grades 0-2 (Grades 0-2)
Symptomatic Bronchospasm, With Or
Without Urticaria Parenteral
Medication(s) Indicated; Allergy-related
Edema/angioedema; Hypotension
(Symptomatic bronchospasm;
parenteral; medication(s) indicated;
hypotension)
Autoimmune reaction
Autoimmune Reaction With Life-
threatening Consequences
(Anaphylaxis)
Death (Death)
Grades 0-2 (Grades 0-2)
Symptomatic bronchospasm; parenteral;
medication(s) indicated; hypotension
(Symptomatic bronchospasm;
parenteral; medication(s) indicated;
hypotension)
Gi Toxicity
Mucositis/stomatitis (clinical exam)
Confluent Ulcerations Or
Pseudomembranes; Bleeding With Minor
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Trauma (Confluent ulcerlation,
pseudomembranes; bleeding with minor
trauma)
Death (Death)
Grades 0-2 (Grades 0-2)
Tissue Necrosis; Significant
Spontaneous Bleeding; Life-threatening
Consequences (Tissue necrosis;
significant spontaneous bleeding; LT
consequences)
Renal Toxicity
Did the patient experience renal failure severe
enough to warrant dialysis
No (No)
Yes (Yes)
Did the patient receive dialysis
No (No)
Yes (Yes)
Hemorrhagic cystitis
Life-threatening Consequences; Major
Urgent Intervention Indicated
(Catastrophic bleeding; major non-
elective intervention indicated)
Death (Death)
Grades 0-2 (Grades 0-2)
Transfusion, Interventional Radiology,
Endoscopic, Or Operative Intervention
Indicated; Radiation Therapy (i.e.,
Hemostasis Of Bleeding Site)
(Transfusion; IV pain medications;
bladder irrigation indicated)
Hemorrhagic Toxicity
Hemorrhage
Life-threatening Consequences; Major
Urgent Intervention Indicated
(Catastrophic bleeding; requiring major
non-elective intervention)
Death (Death)
Grades 0-3 (Grades 0-3)
Cardiovascular Toxicity
Hypotension
Death (Death)
Grades 0-2 (Grades 0-2)
Shock (e.g., Acidemia; Impairment Of
Vital Organ Function) (Shock (e.g.,
acidemia; impairment of vital organ
function))
Sustained (>=24 Hrs) Therapy, Resolves
Without Persisting Physiologic
2 / 6
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Consequences (Sustained (> or = 24
hours) therapy, resolves without
persisting physiologic consequences)
Cardiac arrhythmia
Death (Death)
Grades 0-2 (Grades 0-2)
Severe (Incompletely controlled
medically, or controlled with device (e.g,
pacemaker))
Life-threatening; Disabling (Life-
threatening; disabling (e.g., arrhythmia
associated with CHF, syncope, shock))
Left ventricular systolic dysfunction
Death (Death)
Grades 0-2 (Grades 0-2)
Refractory Chf Or Poorly Controlled; Ef
<20%; Intervention Such As Ventricular
Assist Device, Ventricular Reduction
Surgery, Or Heart Transplant Indicated
(Refractory CHF or poorly controlled;
intervention with ventricular assist
device)
Symptomatic Chf Responsive To
Intervention; Ef <40 - 20% Sf <15%
(Symtomatic CHF responsive to
intervention)
Neurologic Toxicity
Did the patient experience any seizures during
this assessment period
No (No)
Yes (Yes)
Somnolence
Coma (Coma)
Death (Death)
Grades 0-2 (Grades 0-2)
Obtundation Or Stupor; Difficult To
Arouse; Interfering With Adl
(Obtundation or stupor; difficult to arose;
interfering with ADL)
Record seizure toxicity
Death (Death)
One brief generalized seizure; seizure(s)
well controlled by anticonvulsants (One
brief generalized seizure; seizure(s) well
controlled by anticonvulsants)
Seizures Of Any Kind Which Are
Prolonged, Repetitive, Or Difficult To
Control (e.g., Status Epilepticus,
Intractable Epilepsy) (Seizures of any
kind which are prolonged, repetitive or
difficult to control)
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Coagulation Toxicity
HUS/TTP/thrombotic
Death (Death)
Grades 0-3 (Grades 0-3)
Laboratory Findings And Life-threatening
Or Disabling Consequences (e.g., Cns
Hemorrhage/bleeding Or
Thrombosis/embolism Or Renal Failure)
(Laboratory findings, life-threatening or
disabling consequences)
Vascular Toxicity
Vascular leak syndrome
Death (Death)
Grades 0-3 (Grades 0-3)
Life-threatening, Disabling (Life-
threatening; pressor support or
ventilatory support indicated)
Pulmonary Toxicity
During this assessment period, was an FEV1
performed
No (No)
Yes (Yes)
During this assessment period, was an FVC
performed
N (N)
Yes (Yes)
Record FVC value
Hypoxia (for more and 24 hours)
Death (Death)
Decreased O\2 Saturation At Rest;
Continuous Oxygen Indicated
(Decreased oxygen saturation at rest;
continuous oxygen indicated)
Grades 0-2 (Grades 0-2)
Life-threatening; Intubation Or Ventilation
Indicated (Life-threatening; intubation or
ventilator indicated)
Dyspnea
Death (Death)
Dyspnea At Rest; Intubation/ventilator
Indicated (Dyspnea as rest; intubation or
ventilator indicated)
Dyspnea With Adl (Dyspnea with ADL)
Grades 0-2 (Grades 0-2)
Record FEV1 value obtained
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Hepatic Toxicity
Did the patient develop abnormal liver function
during this assessment period
Did The Patient Develop Any Of The
Following Clinical Sugns/symptoms Of
Abnormal Liver Function During This
Assessment Period
Jaundice
No (No)
Yes (Yes)
Right upper quadrant pain
No (No)
Yes (Yes)
Other clinical signs/symptoms
No (No)
Yes (Yes)
Hepatomegaly
No (No)
Yes (Yes)
Weight gain (>5%) from baseline
No (No)
Yes (Yes)
Specifiy other clinical signs/symptoms
Indicated The Etiology Of The Abnormal
Liver Function
Vod
Etiology
No (No)
Yes (Yes)
Biopsy results
Negative (Negative)
Not Done (Not Done)
Positive (Positive)
Doppler ultrasound results
Confirmed (Confirmed)
Not confirmed (Not confirmed)
Not done (Not done)
Gvhd
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TX5
Etiology
No (No)
Yes (Yes)
Biopsy results
Negative (Negative)
Not Done (Not Done)
Positive (Positive)
Doppler ultrasound results
Confirmed (Confirmed)
Not confirmed (Not confirmed)
Not done (Not done)
Infection
Biopsy results
Negative (Negative)
Not Done (Not Done)
Positive (Positive)
Doppler ultrasound results
Confirmed (Confirmed)
Not confirmed (Not confirmed)
Not done (Not done)
Etiology
No (No)
Yes (Yes)
Other
Etiology
No (No)
Yes (Yes)
Biopsy results
Negative (Negative)
Not Done (Not Done)
Positive (Positive)
Doppler ultrasound results
Confirmed (Confirmed)
Not confirmed (Not confirmed)
Not done (Not done)
Unknown
Etiology
No (No)
Yes (Yes)
Specify other etiology
Comments
6 / 6
TX5
Electroconvulsive Therapy (ECT)
Documentation UKM
EKT PSYCH MS (Version 95) converted to ODM format.
Routine documentation of University Hospital Muenster
All rights reserved. Please visit https://medical-data-
models.org/forms/10472
EKT PSYCH MS (Version 95)
ECT
ECT identification number:
Remainding stimulation
Yes
No
Applied by (Physician Name)
Stimulation type
Right Unilateral (1)
Bilateral (2)
Bifrontal (3)
Energy [%]
Applied Narcotic agent
Etomidat (Etomidat)
Methohexital (Methohexital)
Propofol (Propofol)
Thiopental (Thiopental)
Frequency
Impedance
EEG duration
EMG duration
Post-ictal suppression index [%]
Initial Seizure generalization index [%]
Average ictal EEG amplitude
Maximum generated Coherence [%]
pre-ictal heart rate
Maximum heart rate during convulsion
Comments
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Billing and Coding of Current Therapy
Units
Procedure
Therapy conducted by Physcians +/
Psychologists (1)
Specialists Therapy +/ Nursing Care (2)
Specialists Single Therapy (3)
Date of Procedure
Time of procedure
Duration
Number of
Of which are apprentices or interns
Total number of participants
Further Procedures
Procedure Code
Date and Time
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Electroconvulsive Therapy (ECT) Documentation UKM
AMC-046 Screen Failure Form
NCT00550589
AMC-046 Screen Failure Form
Cidofovir in Treating HIV-Infected Patients With High-Grade
Squamous Intraepithelial Lesions of the Skin Near the Anus
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=3BEAAEF0-
A692-3FA8-E044-0003BA3F9857
NCT00550589
All rights reserved. Please visit https://medical-data-
models.org/forms/10475
AMC-046 Screen Failure Form
NCT00550589
Biopsy/Cytology Status
Anal cytology performed
No (No)
Yes (Yes)
Most Severe Anal Cytology Result (If yes Please
record the result from the cytology form)
Asc-h (ASC-H)
Ascus (ASCUS)
High Grade Sil (High grade SIL)
Low Grade Sil (Low grade SIL)
Normal (Normal)
Unevaluable (Unevaluable)
High-resolution anoscopy performed
No (No)
Yes (Yes)
Perianal biopsy performed
No (No)
Yes (Yes)
Perianal biopsy result (If yes)
Condyloma (Condyloma)
Flat Condyloma (Flat condyloma)
High-grade Pain (perianal Intraepithelial
Neoplasia; Pain 2 Or 3) (High-grade
PAIN (perianal intraepithelial neoplasia;
PAIN 2 or 3))
Invasive Cancer (Invasive cancer)
Low-grade Pain (perianal Intraepithelial
Neoplasia; Pain 1) (Low-grade PAIN
(perianal intraepithelial neoplasia; PAIN
1))
Normal Squamous Epithelium (Normal
squamous epithelium)
Squamous Metaplasia (Squamous
metaplasia)
Unevaluable (Unevaluable)
Screen Failure
Primary reason for screen failure
Cd4 Cell Count (CD4 cell count)
Change In Antiretroviral Therapy Within
12 Weeks Of Enrollment (Change in
antiretroviral therapy within 12 weeks of
1 / 2
enrollment)
Laboratory Parameters Not Met
(Laboratory parameters not met)
Not Biopsy Proven Hsil (Not biopsy
proven HSIL)
Other (Other)
Participant Pregnant (Participant
Pregnant)
Participant Withdrew Consent
(Participant withdrew consent)
Plans To Start Antiretroviral Therapy
Prior To Week 12 (Plans to start
antiretroviral therapy prior to week 12)
Serious Illness Within 45 Days Prior To
Entry (Serious illness within 45 days
prior to entry)
Other, specify
Comments
Comments
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AMC-046 Screen Failure Form NCT00550589
ADVL0212- Review Form (Dr. Chin)
NCT00053963
ADVL0212- Review Form (Dr. Chin)
FR901228 in Treating Children With Refractory or
Recurrent Solid Tumors or Leukemia
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=C0F2E959-
BAAB-54D8-E034-0003BA12F5E7
NCT00053963
All rights reserved. Please visit https://medical-data-
models.org/forms/10476
ADVL0212- Review Form (Dr. Chin)
NCT00053963
ECG Assessment
Date of ECG
Did patient experience any of the following: SVT,
atrial fibrillation, or atrial flutter?
No (No)
Yes (Yes)
check all that apply
Atrial fibrillation (Atrial fibrillation)
Atrial flutter (Atrial flutter)
SVT (SVT)
Did patient experience prolonged QTc compared
to baseline?
No (No)
Yes (Yes)
check all that apply
Increase by 15 % (Increase by 15 %)
Increase of greater than or equal to 50
msec (Increase of greater than or equal
to 50 msec)
To greater than or equal to 480 msec (To
greater than or equal to 480 msec)
Was there a T wave inversion in leads II, III, AVF
(inferior leads) or V4, V5, and V6 (lateral leads)?
No (No)
Yes (Yes)
Was ST segment at the J-point greater than or
equal to 2 mm below baseline in leads II, II AVF
(inferior leads), V4, V5, V6 (lateral leads)?
No (No)
Yes (Yes)
Did patient experience ventricular arrhythmia?
No (No)
Yes, change in both VT and VF (Yes,
change in both VT and VF)
Yes, change in VF (Yes, change in VF)
Yes, change in VT (Yes, change in VT)
Ccrr Module For Advl0212- Review Form
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(dr. Chin)
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ADVL0212- Review Form (Dr. Chin) NCT00053963
NSABP PROTOCOL B-35 ON-STUDY
FORM NCT00053898
NSABP PROTOCOL B-35 ON-STUDY FORM
Anastrozole or Tamoxifen in Treating Postmenopausal
Women With Ductal Carcinoma in Situ Who Are
Undergoing Lumpectomy and Radiation Therapy
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=A051F12F-
A237-0456-E034-080020C9C0E0
NCT00053898
All rights reserved. Please visit https://medical-data-
models.org/forms/10478
NSABP PROTOCOL B-35 ON-
STUDY FORM NCT00053898
NSABP administration data
First Three Letters of Patient's Last Name
Patient Study ID
Institution Name
Affiliate Name
Person Completing Form Last Name
Person Completing Form First Name
Person Completing Form Phone
Are data amended? (If Yes, circle the amended
items in red.)
Yes
No
Biopsy results
Fine Needle Aspiration Cytology (Circle Y or N for
Yes, No)
N (N)
Y (Y)
Core (or Tru Cut) Needle Biopsy (Circle Y or N for
Yes, No)
N (N)
Y (Y)
Incisional Biopsy  (Circle Y or N for Yes, No)
N (N)
Y (Y)
Excisional Biopsy or Lumpectomy (Circle Y or N
for Yes, No)
N (N)
Y (Y)
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Resection of Lumpectomy Margins (Circle Y or N
for Yes, No)
N (N)
Y (Y)
Sentinel Node Biopsy (Circle Y or N for Yes, No)
No (N)
Yes (Y)
Axillary Dissection (Circle Y or N for Yes, No)
No (N)
Yes (Y)
DATE OF PROCEDURE (Month, Day, Year)
ACCESSION NUMBER (Pathology Specimen
Number)
Disease Description
Tumor Laterality
Left Breast (Left Breast)
Right Breast (Right Breast)
Was the tumor or microcalcification evident on
mammogram?
Yes
No
Was the tumor evident by ultrasound?
No (No)
Not Done (Not done)
Yes (Yes)
Was the tumor palpable?
Yes
No
Were there any breast symptoms? (e.g., pain,
nipple discharge or retraction, skin dimpling)
Yes
No
Receptor Status (by Ihc)
ER Status
Negative (Negative by IHC)
Positive (Positive by IHC)
Unknown (Unknown)
PgR
Negative (Negative by IHC)
Positive (Positive by IHC)
Unknown (Unknown)
If unknown, please explain:
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NSABP PROTOCOL B-35 ON-STUDY FORM NCT00053898
Quality Of Life
Did the patient complete the Quality of Life
baseline form?
Yes
No
If the baseline QOL form was not completed,
indicate the reason below. (Protocol Approved
Reasons)
Other Reason (Other reason)
Patient Does Not Speak English, French,
Or Spanish (Patient does not speak
English, French, or Spanish)
Patient Refused (Patient refused)
Other Reason (if applicable)
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NSABP PROTOCOL B-35 ON-STUDY FORM NCT00053898
TL Radiation Therapy Oncology Group
Protocol Calculation Form NCT00063882
TL Radiation Therapy Oncology Group Protocol Calculation
Form
Interstitial Brachytherapy With or Without External-Beam
Radiation Therapy in Treating Patients With Prostate
Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=AA894E4A-
1A32-58C1-E034-0003BA12F5E7
NCT00063882
All rights reserved. Please visit https://medical-data-
models.org/forms/10479
TL Radiation Therapy Oncology
Group Protocol Calculation Form
NCT00063882
RTOG clinical trial administrative data
RTOG Study
Case #
Institution Name
Institution No.
Patient's Name
Patient's I.D. No.
Site of treatment
Anatomical Treatment Area
Radiation Therapy calculation
Field Number
Rt Field (FIELD I)
Rt Field (FIELD II)
Rt Field (FIELD III)
Rt Field (FIELD V)
Rt Field (FIELD VI)
Rt Field (FIIELD IV)
Field projection (ant, lat, oblique, etc.)
Manufacturer name and unit energy
Monitor units/minutes
Tumor dose per field for each field at point of
protocol prescription
1 / 2
SSD/SAD (cm)
Treatment depth (cm)
Collimator setting (Field size in cm at isocenter)
Equivalent square at SSD/SAD
% DD, TAR, TMR, TPR, TOR (indicate as
applicable)
Beam output factor for treatment field size
(include calibration distance factor if applicable)
Cgy/min (CGY/MIN)
Cgy/mu (CGY/MU)
CGY/MU (beam output factor) (Linac)
CGY/MIN (beam output factor) (cobalt)
Transmission Factors
Comp (Comp)
Other, Specify (Other, specify)
Tray (Tray)
Wedge (Wedge)
Wedge (transmission factors)
Tray (transmission factors)
Comp (transmission factors)
Other, specify (transmission factors)
Form completed by
Date
Ccrr Module For Tl Radiation Therapy
Oncology Group Protocol Calculation
Form
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TL Radiation Therapy Oncology Group Protocol Calculation Form
NCT00063882
S0201 Southwest Oncology Group
Registration Form 2055861v3.0
S0201 Southwest Oncology Group Registration Form
2055861v3.0
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=A8B98C1F-
D2E5-127C-E034-0003BA12F5E7 2055861v3.0
All rights reserved. Please visit https://medical-data-
models.org/forms/10480
S0201 Southwest Oncology Group
Registration Form 2055861v3.0
SWOG clinical trial administrative data
SWOG Study No.
Registration Step
Assigned Treatment Arm
Activation Date
Last Amended Date
Patient's Name
SWOG Patient ID
Other Group Patient Number
Other Group Name/Protocol Number
Registration data
Caller's SWOG Roster ID
IRB Approval Date
Projected Start Date of Treatment
Date Informed Consent Signed
SWOG Investigator Number
Other Group Investigator Name
Other Group Investigator Number
SWOG Treating Institution Number
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Other Group Institution Name
Other Group Institution Number (Patient Consent
for Specimen Use)
Patient's inital consent given for specimen use for
research on the patient's cancer
Yes
No
Patient's initial consent given for specimen use
for research unrelated to the patient's cancer
Yes
No
Patient's inital consent given for further contact
regarding specimen
Yes
No
Patient demographics
Patient's Date of Birth
Gender
Female (Female)
Male (Male)
Method of Payment
Medicaid (Medicaid)
Medicaid And Medicare (Medicaid and
Medicare)
Medicare (Medicare)
Medicare And Private Insurance
(Medicare and Private)
Military Sponsored (including Champus
& Tricare) (Military)
No Means Of Payment (no Insurance)
(No insurance (no means))
Self Pay (no Insurance) (No insurance
(self-pay))
Other (Other, specify at registration)
Private Insurance (Private)
Unknown (Unknown)
Veterans Sponsored (Veterans Admin)
Patient's Ethnicity
No_not_spanish2006636 (No (not
Spanish))
Unknown2006635 (Unknown)
Yes_central_american2006640 (Yes,
Central American)
Yes_cuban2006639 (Yes, Cuban)
Yes_mexican2006637 (Yes, Mexican)
Yes_nos2006643 (Yes, NOS)
Yes_other2006642 (Yes, Other)
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S0201 Southwest Oncology Group Registration Form 2055861v3.0
Yes_puerto_rican2006638 (Yes, Puerto
Rican)
Yes_south_american2006641 (Yes,
South American)
Patient's Race (select all that apply)
Native_american_cdus (American Indian
or Alaska Native)
Asian_cdus (Asian)
Black_cdus (Black or African American)
Pacific_islander_cdus (Native Hawaiian
or Other Pacific Islander)
Other, Specify (Other, Specify)
Unknown (Unknown)
White_cdus (White or Caucasian)
Other, specify (patient's race) (If a U.S. resident)
Patient's Social Security Number
Patient's Zip Code
Country of Residence, if not USA (If a resident of
Canada)
Social Insurance Number
Postal Code (Statification Factors)
SLN biopsy
Yes
No
HLA expression
A2+ Only (A2+ only)
Both A2+ And C3+ (both A2+ and C3+)
C3+ Only (C3+ only)
Stage of disease
Iia (IIA)
Iib (IIB)
Iic/iiia (IIC/IIIA)
Ccrr Module For S0201 Southwest
Oncology Group Registration Form
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S0201 Southwest Oncology Group Registration Form 2055861v3.0
ECOG Leukemia Cytogenetics Report
Form 2053765v3.0
ECOG Leukemia Cytogenetics Report Form 2053765v3.0
Combination Chemotherapy With or Without Monoclonal
Antibody Therapy Followed by Stem Cell Transplant in
Treating Patients With Acute Myeloid Leukemia
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=A727E3BC-
7882-2F82-E034-0003BA0B1A09
All rights reserved. Please visit https://medical-data-
models.org/forms/10481
ECOG Leukemia Cytogenetics
Report Form 2053765v3.0
ECOG clinical trial administrative data
Cytogeneticist
Phone No.
Patient's Name
Trtmnt Prot. No.
Trtmnt Prot. No.
Pt. Seq. No.
Pt. Seq. No.
Participating Group Prot. No.
Participating Group Patient ID no.
Group
Institution
Step No.
Affiliate
Cytogenetics samples
Date sample obtained
Is Extra material stored?
No (no)
Yes (yes)
1 / 3
If yes, specify type (extra material)
Number Of Metaphases
Bone Marrow, unsimulated short-term culture
(metaphases)
Bone Marrow, direct preparation (metaphases)
Bone Marrow, Stimulated Culture (metaphases)
Bone Marrow, Stimulated Culture, Specify
mitogen (metaphases)
Bone Marrow, Other Specify (metaphases)
Bone Marrow, Other Specify (metaphases)
Peripheral Blood, unsimulated short-term culture
(metaphases)
Peripheral Bood, direct preparation (metaphases)
Peripheral Bood, Stimulated Culture
(metaphases)
Peripheral Bood, Stimulated Culture, Specify
mitogen (metaphases)
Peripheral Bood, Other Specify (metaphases)
Peripheral Bood, Other Specify (metaphases)
Total Metaphases Analyzed
Number of Abnormal Metaphases
Number of Karotype Preparations
Are results adequate for banded analysis?
No (no)
Yes (yes)
Were FISH studies done?
No (no)
Yes (yes)
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ECOG Leukemia Cytogenetics Report Form 2053765v3.0
If yes, specify probes (FISH)
Total Interphase nuclei
Total abnormal interphases
Total metaphases
Total abnormal metaphases
Complete karyotype description.
Investigator
Date
Ccrr Module For Ecog Leukemia
Cytogenetics Report Form
Date specimens collected
Institution/Affiliate
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ECOG Leukemia Cytogenetics Report Form 2053765v3.0
AMC-052 Histology Result Form
2676563v1.0
AMC-052 Histology Result Form 2676563v1.0
Human Papillomavirus Vaccine Therapy in Treating Men
With HIV-1 Infection
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=3950D614-
2D53-3AAB-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/10482
AMC-052 Histology Result Form
2676563v1.0
Header module
Date anal biopsy obtained
Study week
Anal histology results
Anal Biopsy Location
Anterior (Anterior)
Left Anterior (Left anterior)
Left Lateral (Left lateral)
Left Posterior (Left posterior)
Posterior (Posterior)
Right Anterior (Right anterior)
Right Lateral (Right lateral)
Right Posterior (Right posterior)
Proximity to squamocolumnar junction
At Or Near Squamocolumnar Junction
(At or near squamocolumnar junction)
Distal Or Midcanal (Distal or midcanal)
Perianal (Perianal)
Most severe anal biopsy result
Colonic Epithelium (Colonic epithelium)
Condyloma (Condyloma)
Flat Condyloma (Flat condyloma)
High-grade Ain (High-grade AIN)
Invasive Cancer (Invasive cancer)
Low-grade Ain (Low-grade AIN)
Normal Squamous Epithelium (Normal
squamous epithelium)
Squamous Metaplasia (Squamous
metaplasia)
Unevaluable (Unevaluable)
Modifying diagnosis
Acanthosis (Acanthosis)
Inflammation (Acute inflammation)
Evidence Of Hsv Infection (Evidence of
HSV infection)
Hyperkeratosis (Hyperkeratosis)
Other (Other)
Papillomatosis (Papillomatosis)
Parakeratosis (Parakeratosis)
Subacute Or Chronic Inflammation
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(Subacute or chronic inflammation)
Other, specify
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AMC-052 Histology Result Form 2676563v1.0
CALGB: 80101 BLOOD SAMPLE
TRACKING FORM NCT00052910
CALGB: 80101 BLOOD SAMPLE TRACKING FORM
Chemotherapy and Radiation Therapy After Surgery in
Treating Patients With Stomach or Esophageal Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=9DA6CD3D-
FA7B-5976-E034-080020C9C0E0
NCT00052910
All rights reserved. Please visit https://medical-data-
models.org/forms/10483
CALGB: 80101 BLOOD SAMPLE
TRACKING FORM NCT00052910
CALGB clinical trial administrative data
CALGB Form
CALGB Study No
CALGB Patient ID
Patient's Name
Participating Group
Patient Hospital Number
Participating Group Protocol No.
Main Member Institution/Adjunct
Participating Group Patient No.
Date form submitted
Amended data?
Yes (Yes)
To Be Completed By Submitting Institution
Does specimen accompany this form?
No, Specify Reason (No, specify reason)
Yes, Complete The Remainder Of Form
(Yes, complete the remainder of form)
Specify reason
Date sample collected
Number of tubes of whole blood submitted with
this form
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Sample time Point
1-pre-study (1-pre-study)
Submitted by
Phone #
To Be Completed By Receiving
Institution/laboratory
Date sample received
Sample condition
Clotted (Clotted)
Damaged (Damaged)
Insufficient Amount (Insufficient amount)
Missing (Missing)
Okay (Okay)
Thawed (Thawed)
Sample ID no.
Received by
Is sample evaluable for analysis?
No, Procedural Deviations Definitely
Affect Analysis (No, procedural
deviations definitely affect analysis)
Unsure, Procedural Deviations May
Affect Analysis (Unsure, procedural
deviations may affect analysis)
Yes, Sample Is Evaluable (Yes, sample is
evaluable)
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CALGB: 80101 TREATMENT FORM
NCT00052910
CALGB: 80101 TREATMENT FORM
Chemotherapy and Radiation Therapy After Surgery in
Treating Patients With Stomach or Esophageal Cancer
NCT00052910 
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=9DA6CD3D-
F968-5976-E034-080020C9C0E0
All rights reserved. Please visit https://medical-data-
models.org/forms/10484
CALGB: 80101 TREATMENT FORM
NCT00052910
CALGB clinical trial administrative data
CALGB Form
CALGB Study No
CALGB Patient ID
Amended data?
Patient's Name
Participating Group
Patient Hospital Number
Participating Group Protocol No.
Main Member Institution/Adjunct
Participating Group Patient No.
Treatment Summary
Cycle Number
Start date of first treatment
Date of last treatment
Were there any dose modifications or
additions/omissions to protocol treatment?
No (No)
Yes, planned per protocol (Yes, planned
per protocol)
(i.e., The Treatment Change Was Not
Part Of Protocol Guidelines) (Yes,
1 / 3
unplanned)
Reason for therapy modification
Adverse Event Or Toxicity (Adverse
event or toxicity (including death))
Dosing Error (Dosing error)
Parient Refusal/noncompliance (Patient
refusal/noncompliance)
Scheduling (Scheduling (e.g., physician
schedule, patient schedule, holiday,
vacation, etc.))
Were there any unscheduled interruptions in
radiation therapy?
No (No)
Yes, planned per protocol (Yes, planned
per protocol)
Yes, unplanned (Yes, unplanned)
RT interruptions reason
Adverse event or toxicity (including
death) (Adverse event or toxicity
(including death))
Dosing error (Dosing error)
Patient refusal/noncompliance (Patient
refusal/noncompliance)
Scheduling (e.g., physician schedule,
patient schedule, holiday, vacation, etc.)
(Scheduling (e.g., physician schedule,
patient schedule, holiday, vacation, etc.))
Reason treatment ended
Alternative therapy (Alternative therapy)
Death on study (Death on study)
Death prior to beginning protocol therapy
(Death prior to beginning protocol
therapy)
Disease progression, relapse during
active treatment (Disease progression,
relapse during active treatment)
Disease progression, relapse prior to
beginning protocol therapy (Disease
progression, relapse prior to beginning
protocol therapy)
Other, specify (Other, specify)
Patient off-treatment for other
complicating disease (Patient off-
treatment for other complicating disease)
Patient withdrawal or refusal after
beginning protocol treatment (Patient
withdrawal or refusal after beginning
protocol treatment)
Patient withdrawal or refusal prior to
beginning protocol treatment (Patient
withdrawal or refusal prior to beginning
protocol treatment)
Toxicity/side effects/complications
(Toxicity/side effects/complications)
Treatment completed per protocol criteria
(Treatment completed per protocol
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CALGB: 80101 TREATMENT FORM NCT00052910
criteria)
Other, specify
Completed by
Date completed
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E3200 Treatment Summary Form
NCT00025337
E3200 Treatment Summary Form NCT00025337
Combination Chemotherapy With or Without Bevacizumab
Compared With Bevacizumab Alone in Treating Patients
With Advanced or Metastatic Colorectal Cancer That Has
Been Previously Treated
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=A16FACD4-
477B-6CEF-E034-080020C9C0E0
All rights reserved. Please visit https://medical-data-
models.org/forms/10486
E3200 Treatment Summary Form
NCT00025337
Treatment Summary
Date of data transfer
Transfer Method
Specify other transfer method
Step No.
Patient Name
Particip. Group Protocol Number
Patient Study ID, Participating Group
Institution Name
Affiliate Name
Amended Data Ind
Amended Data Ind
Treatment Arm Number
Treatment Begin Date
Treatment End Date
Off Treatment Reason
Off Treatment Reason, Complicating Disease
Off Treatment Reason, Other
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Total Course Number
Dose Modification (Change)
Dose Modification (Change)
Therapy Modification Name
Therapy Modification Type
Therapy Modification Reason
Comments
Comments2
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E3200 Treatment Summary Form NCT00025337
CALGB: CHANGES IN FUNCTION FORM
NCT00024102
CALGB: CHANGES IN FUNCTION FORM NCT00024102 
Comparison of Combination Chemotherapy Regimens in
Treating Older Women Who Have Undergone Surgery for
Breast Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=A50D6975-
F5AD-3262-E034-080020C9C0E0
NCT00024102
All rights reserved. Please visit https://medical-data-
models.org/forms/10487
CALGB: CHANGES IN FUNCTION
FORM NCT00024102
CALGB clinical trial administrative data
CALGB Form
CALGB Study No
CALGB Patient ID
Date Completed (M)
Patient's Name
Participating Group
Patient Hospital Number
Participating Group Protocol No.
Main Member Institution/Adjunct
Participating Group Patient No.
Amended data?
Yes (Yes)
Assessment data
Responsible CRA
Assessment Number (1.)
Patient status assessment
Has your physical condition gotten (2.)
A Little Better (a little better)
A Little Worse (a little worse)
About The Same (about the same)
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Moderately Better (moderately better)
Moderately Worse (moderately worse)
Very Much Better (very much better)
Very Much Worse (very much worse)
Has your emotional state gotten (3.)
A Little Better (a little better)
A Little Worse (a little worse)
About The Same (about the same)
Moderately Better (moderately better)
Moderately Worse (moderately worse)
Very Much Better (very much better)
Very Much Worse (very much worse)
Has your ability to enjoy your social life gotten (4.)
A Little Better (a little better)
A Little Worse (a little worse)
About The Same (about the same)
Moderately Better (moderately better)
Moderately Worse (moderately worse)
Very Much Better (very much better)
Very Much Worse (very much worse)
Has your overall quality of life gotten
A Little Better (a little better)
A Little Worse (a little worse)
About The Same (about the same)
Moderately Better (moderately better)
Moderately Worse (moderately worse)
Very Much Better (very much better)
Very Much Worse (very much worse)
Ccrr Module For Calgb: Changes In
Function Form
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CALGB: CHANGES IN FUNCTION FORM NCT00024102
AMC-052 HPV On-Study Form
NCT00513526
AMC-052 HPV On-Study Form NCT00513526
Human Papillomavirus Vaccine Therapy in Treating Men
With HIV-1 Infection
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=3950D614-
2D59-3AAB-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/10488
AMC-052 HPV On-Study Form
NCT00513526
HIV status
Date of HIV+ diagnosis
CDC HIV Risk Group
Hemophilia (Hemophiliac)
Heterosexual Contact (Heterosexual
contact)
Homosexual Or Bisexual Contact
(Homosexual or bisexual contact)
Iv Drug User (IV drug user)
Other (Other)
Transfusion Recipient (Transfusion
recipient)
Other, specify
Lowest CD4+ count ever reported
Prior Systemic Chemotherapy
Yes
No
Has the patient received radiation therapy?
Yes
No
Condyloma
History of anal, perianal, or genital condyloma (If
yes check all that apply)
Yes
No
History of penile or genital condyloma
Active Genital Condyloma (Active genital
condyloma)
Active Penile Condyloma (Active penile
condyloma)
No History (No history)
Yes, Resolved With History Of Treatment
(Yes, resolved with history of treatment)
Yes, Resolved Without Treatment (Yes,
resolved without treatment)
History of perianal condyloma
Active Perianal Condyloma (Active
perianal condyloma)
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No History (No history)
Yes, Resolved With History Of Treatment
(Yes, resolved with history of treatment)
Yes, Resolved Without Treatment (Yes,
resolved without treatment)
History of intraanal condlyoma
Active Intraanal Condyloma (Active
intraanal condyloma)
No History (No history)
Yes, Resolved With History Of Treatment
(Yes, resolved with history of treatment)
Yes, Resolved Without Treatment (Yes,
resolved without treatment)
Anal cytology/biopsy
Anal cytology performed (prior to screening to
AMC052)
No (No)
Participant Does Not Recall (Participant
does not recall)
Unknown (Unknown)
Yes (Yes)
Anal cytology result (if yes)
Asc-h (ASC-H)
Ascus (ASCUS)
High Grade Sil (High grade SIL)
Low Grade Sil (Low grade SIL)
Normal (Normal)
No Information Available (Results not
available)
Unknown (Unknown)
Anal or perianal biopsy performed (prior to
screening to AMC052)
No (No)
Participant Does Not Recall (Participant
does not recall)
Unknown (Unknown)
Yes (Yes)
Most severe anal biopsy result
Condyloma (Condyloma)
High-grade Ain (High-grade AIN)
Invasive Cancer (Invasive cancer)
Low-grade Ain (Low-grade AIN)
Normal (Normal)
Squamous Metaplasia (Squamous
metaplasia)
Unknown (Unknown)
Footer module
Smoked at least 100 cigarettes (5 packs) during
lifetime
Yes
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No
Document type
Lab Report (Lab Report)
Physician/provider Report Or Clinical
Note (Physician/provider report or clinical
note)
Subject Recall (Subject recall)
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Radiation Therapy Oncology Group Demographic
Data Form - Version 2 NCT00048997
Radiation Therapy Oncology Group Demographic Data
Form - Version 2 NCT00048997
Radiation Therapy in Preventing CNS Metastases in
Patients With Non-Small Cell Lung Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=9EC372A6-
6D13-05D5-E034-080020C9C0E0
All rights reserved. Please visit https://medical-data-
models.org/forms/10492
Radiation Therapy Oncology Group
Demographic Data Form - Version 2
NCT00048997
Header module
Date Completed
If this is a revised or corrected form, indicate by
checking box.
Patient administration
Case #
Institution
Institution #
Patient Name
Patient ID #
Patient demographics
Who completed this form? (Check one box)
Not Applicable, No Items Completed (Not
applicable, no items completed)
Other Person (Other person)
Self (Self)
Staff (Staff)
Race (Check one box only)
Asian_cdus (Asian)
Black, not Hispanic origin (Black, not
Hispanic origin)
A Person Of Mexican, Puerto Rican,
Cuban, Central Or South American Or
Other Spanish Culture Or Origin,
Regardless Of Race (Hispanic)
Native American / Alaskan Nation
(Native American / Alaskan Nation)
Pacific_islander_cdus (Native Hawaiian
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or other Pacific Islander)
Other, specify (Other, specify)
Unknown / I prefer not to answer
(Unknown / I prefer not to answer)
White, not Hispanic origin (White, not
Hispanic origin)
Race Other, specify
Additional Race/Ethnicity (If you consider yourself
multiracial, check all additional categories that
apply in this question Do not include what you
reported in 2A.)
Asian (Asian)
Black, Not Hispanic Origin (Black, not
Hispanic origin)
Hispanic (Hispanic)
Native American / Alaskan Nation
(Native American / Alaskan Nation)
Native Hawaiian Or Other Pacific
Islander (Native Hawaiian or other Pacific
Islander)
Unknown / I Prefer Not To Answer
(Unknown / I prefer not to answer)
White, Not Hispanic Origin (White, not
Hispanic origin)
Highest school grade completed (Check one box)
8th Or Less (8th or less)
9 - 11th Grade (9 - 11th Grade)
Advanced Degree (Advanced degree)
Associate Degree / Some College
(Associate degree / some college)
Bachelor's Degree (Bachelor's degree)
High School Graduate / Ged (High
school graduate / GED)
I Prefer Not To Answer (I prefer not to
answer)
Other, Specify (Other, specify)
Vocational / Technical School (Vocational
/ technical school)
Highest school grade completed Other, specify
Religion during childhood (Check one box)
Catholic (Catholic)
I Prefer Not To Answer (I prefer not to
answer)
Jewish (Jewish)
Morman/latter Day Saints
(Morman/Latter Day Saints)
Muslim / Islam (Muslim / Islam)
None (None)
Other, Specify (Other, specify)
Protestant (Protestant)
Religion during childhood Other, specify
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NCT00048997
Marital status (Check one box)
Divorced/separated
(Divorced/Separated)
I Prefer Not To Answer (I prefer not to
answer)
Living As Married (Living as married)
Married (Married)
Single (Single)
Widowed (Widowed)
Where were you born? (Check the box of the
country where you were born.)
Other Country, Specify (Other country,
specify)
Usa, Specify The 2 Letter State Code,
Eg Ny (USA, specify the 2 letter State
code, eg NY)
USA, specify the 2 letter State code, eg NY
Where were you born, other country, specify
Where did you live the longest (Check one box)
Other Country, Specify (Other country,
specify)
Usa, Specify The 2 Letter State Code,
Eg Ny (USA, specify the 2 letter State
code, eg NY)
USA, specify the 2 letter State code, eg NY
Where did you live the longest, other country,
specify
Smoked at least 100 cigarette (5 packs) during
lifetime
No (No)
Yes, But Quit (Yes, but quit)
Yes, Currently Smoke (Yes, currently
smoke)
Age began smoking cigarettes
Number of years smoked cigarettes
Average number of cigarettes smoked per day
If quit, age stopped smoking completely
If you have had any of the illness listed below,
please check yes for those that apply.
Bleeding Problems (Bleeding problems)
Circulation Problems (Circulation
problems)
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NCT00048997
Diabetes Or Sugar In Urine (Diabetes or
sugar in urine)
Frequent Infections (Frequent infections)
Heart Problems (Heart problems)
High Blood Pressure (High blood
pressure)
Hiv/aids (HIV/AIDS)
Illness, Specify Other (Illness, specify
other)
Kidney/urine Problems (Kidney/urine
problems)
Liver Problems (Liver problems)
Lung Problems (Lung problems)
Other (Other)
Psychological Problems (Psychological
problems)
Seizure (Seizure)
Stroke (Stroke)
Thyroid Problems (Thyroid problems)
Illness, specify other
How many of the following family members (living
and dead) do you have? (Include only those who
are blood-related.)
Brothers (Brothers)
Daughters (Daughters)
Sisters (Sisters)
Sons (Sons)
Brothers
Sisters
Sons
Daughters
Are you adopted? (Check one)
Yes
No
Blood relative with cancer
Brother #1 (Brother #1)
Brother #2 (Brother #2)
Brother #3 (Brother #3)
Brother #4 (Brother #4)
Child #1 (Child #1)
Child #2 (Child #2)
Child #3 (Child #3)
Child #4 (Child #4)
Father (Father)
Mother (Mother)
Sister #1 (Sister #1)
Sister #2 (Sister #2)
Sister #3 (Sister #3)
4 / 5
Radiation Therapy Oncology Group Demographic Data Form - Version 2
NCT00048997
Sister #4 (Sister #4)
Age when first cancer diagnosed
Type of Cancer
Breast (Breast)
Colon (Colon)
Head & Neck (Head & Neck)
Lung (Lung)
Non Melanoma Skin (Non Melanoma
Skin)
Other (Other)
Prostate (Prostate)
Have you ever heard of Cancer Prevention Trials?
(Check one box)
Yes
No
How likely would you be to volunteer to
participate in Cancer Prevention Trials? (The
numbers below allow you to rate your answer
between 1 - never and 10 - extremely likely. Circle
the number below that best describes your
choice.)
1 (1)
10 (10)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
7 (7)
8 (8)
9 (9)
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Radiation Therapy Oncology Group
Pathology Submission Form NCT00023829
Radiation Therapy Oncology Group Pathology Submission
Form NCT00023829
Adjuvant Radiation Therapy Plus Hormone Therapy
Compared With Radiation Therapy Alone in Treating
Patients With Stage II or Stage III Prostate Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=A46CFF7E-
9D16-2C2B-E034-080020C9C0E0
All rights reserved. Please visit https://medical-data-
models.org/forms/10494
Radiation Therapy NCT00023829
Oncology Group Pathology
Submission Form
RTOG clinical trial administrative data
RTOG Study
Case #
Institution
Institution No.
Patient's Name
Patient's I.D. No.
Pathology submission
TYPE (pathology submission)
Autopsy (Autopsy)
Post-treatment Bx (Post-treatment Bx)
Pre-treatment Bx (Pre-treatment Bx)
Surgical Treatment (Surgical treatment)
Unknown (Unknown)
PROCEDURE DATE
SITE OF MATERIAL (NUMBER OF
SPECIMENS)
H&E Stained Slides
Unstained Slides
Blocks
PATHOLOGY ACCESSION #
RTOG Calendar due date ("P1, P2")
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REQUIRED ENCLOSURES (Check all that apply
and submit with patient study consent form.)
Blocks/slides (Blocks/Slides)
Pathology Report(s) (Pathology
Report(s))
Patient Consent (Patient consent)
This Submission Form (This Submission
Form)
Patient consents to:
Being Contacted About Future Research
(Being contacted about future research)
Current Research As Specified In The
Protocol (Current research as specified
in the protocol)
Future Research Using Tissue Bank
Samples (Future research using Tissue
Bank samples)
SUBMITTED BY
TELEPHONE NO
Ccrr Module For Radiation Therapy
Oncology Group Pathology Submission
Form
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Radiation Therapy Oncology Group Pathology Submission Form
NCT00023829
Radiation Therapy Oncology Group Phase III Prostate
3D / IMRT Pathology Submission Form NCT00033631
Radiation Therapy Oncology Group Phase III Prostate 3D /
IMRT Pathology Submission Form NCT00033631
Radiation Therapy in Treating Patients With Stage II
Prostate Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=11CF5748-
0C1F-4085-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/10495
Radiation Therapy Oncology Group
Phase III Prostate 3D / IMRT
Pathology Submission Form
NCT00033631
RTOG clinical trial administrative data
RTOG Study
Case #
Institution
Institution No.
Patient's Name
Patient's I.D. No.
Instructions
Pathology submission
TYPE (pathology submission)
Autopsy (Autopsy)
Post-treatment Bx (Post-treatment Bx)
Pre-treatment Bx (Pre-treatment Bx)
Surgical Treatment (Surgical treatment)
Unknown (Unknown)
PROCEDURE DATE
SITE OF MATERIAL
H&E Stained Slides (NUMBER OF SPECIMENS)
Unstained Slides (NUMBER OF SPECIMENS)
Blocks (NUMBER OF SPECIMENS)
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PATHOLOGY ACCESSION #
RTOG Calendar due date ("P1, P2")
REQUIRED ENCLOSURES
Blocks/slides (Blocks/Slides)
Pathology Report(s) (Pathology
Report(s))
Patient Consent (Patient consent)
This Submission Form (This Submission
Form)
Patient consents to: (Check all that apply and
submit with patient study consent form.)
Being Contacted About Future Research
(Being contacted about future research)
Current Research As Specified In The
Protocol (Current research as specified
in the protocol)
Future Research Using Tissue Bank
Samples (Future research using Tissue
Bank samples)
SUBMITTED BY
TELEPHONE NO
Ccrr Module For Radiation Therapy
Oncology Group Pathology Submission
Form
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Radiation Therapy Oncology Group Phase III Prostate 3D / IMRT
Pathology Submission Form NCT00033631
Baseline Disease Evaluation Form
(RECIST) NCT00058149
Baseline Disease Evaluation Form (RECIST)
NCT00058149
A Phase III, Randomized Study of Gemcitabine (Fixed-
Dose Rate Infusion) and Oxaliplatin (NSC 266046) Versus
Gemcitabine (Fixed-Dose Rate Infusion) Versus
Gemcitabine (30-Minute Infusion) in Pancreatic Carcinoma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=A6277560-
71F5-3D77-E034-0003BA0B1A09
All rights reserved. Please visit https://medical-data-
models.org/forms/10496
Baseline Disease Evaluation Form
(RECIST) NCT00058149
ECOG clinical trial administrative data
ECOG Protocol No.
ECOG Patient ID
Registration Step
Patient?s Name
Participating Group Protocol No.
Participating Group Patient ID
Institution/Affiliate
Are data amended? (If yes, please circle
amended items in red)
Yes
No
Target Lesions:
Are there any target lesions?
Yes
No
Lesion Number
Site of Lesion (Multiple nontarget lesions within
an organ may be combined as a single site;
report in a consistent manner on subsequent
forms.)
Site Code
Bone (Bone)
Brain (Brain)
Breast (Breast)
Effusion/ascites (Effusion/Ascites)
Gi (GI)
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Gu (GU)
Head & Neck (Head & Neck)
Liver (Liver)
Lung (Lung)
Nodes (Nodes)
Other (specify Site) (Other (specify site))
Skin (Skin)
Other (specify site)
Method of Evaluation
Bone Scan (Bone scan)
Chest X-ray (Chest X-Ray)
Clinical Examination (Clinical Exam)
Ct Scan (CT Scan (non-spiral))
Mri (MRI)
Other (Other (specify in Comments))
Spiral Ct Scan (Spiral CT)
Ultrasound (Ultrasound)
Date of Evaluation (M D Y)
Longest Diameter of Lesion(s) (cm)
Sum of longest diameters of all target lesions
(cm)
Nontarget Lesions:
Cytology Result (For Site Code 04
effusion/ascites ONLY)
Negative (Negative)
Not Done (Not done)
Positive (Positive)
Comments
Comments
Investigator Signature
Date
Ccrr Module For Baseline Disease
Evaluation Form (recist)
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Nontarget Lesions Supplemental Form
NCT00057876
Nontarget Lesions Supplemental Form NCT00057876
Gemcitabine With or Without Radiation Therapy in Treating
Patients With Pancreatic Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=A6238F51-
F0B5-3C1D-E034-0003BA0B1A09
All rights reserved. Please visit https://medical-data-
models.org/forms/10497
Nontarget Lesions Supplemental
Form NCT00057876
ECOG clinical trial administrative data
ECOG Protocol No.
ECOG Patient ID
Registration Step
Cycle Number (Use '00' for baseline; leave blank
if off-treatment or N/A)
Patient?s Name
Participating Group Protocol No.
Participating Group Patient ID
Institution/Affiliate
Are data amended? (If yes, please circle
amended items in red)
Yes
No
Nontarget Lesions:
Lesion Number
Site of Lesion (Multiple nontarget lesions within
an organ may be combined as a single site, but
must be reported in same manner as at
baseline.)
Site Code
Bone (Bone)
Brain (Brain)
Breast (Breast)
Effusion/ascites (Effusion/Ascites)
Gi (GI)
Gu (GU)
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Head & Neck (Head & Neck)
Liver (Liver)
Lung (Lung)
Nodes (Nodes)
Other (Other)
Skin (Skin)
Method of Evaluation
Bone Scan (Bone scan)
Chest X-ray (Chest X-Ray)
Clinical Examination (Clinical Exam)
Ct Scan (CT Scan (non-spiral))
Mri (MRI)
Not Evaluated (Not evaluated)
Other (Other (specify in Comments))
Spiral Ct Scan (Spiral CT)
Ultrasound (Ultrasound)
Date of Evaluation (M D Y)
Follow-up Status of Lesions (Choose one for
each lesion. Leave blank if baseline.)
Cr (CR)
Incompl. Resp./sd (Incompl. resp./SD)
Pd (PD)
Cytology Result (For Site Code 04
effusion/ascites ONLY)
Negative (Negative)
Not Done (Not done)
Positive (Positive)
Unequivocal progressive disease in nontarget
lesions is based on: (please decribe)
Comments
Comments
Investigator Signature
Date
Ccrr Module For Nontarget Lesions
Supplemental Form
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Second Primary Form NCT00057876
Second Primary Form NCT00057876
Gemcitabine With or Without Radiation Therapy in Treating
Patients With Pancreatic Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=A6239C87-
FB3E-3C1F-E034-0003BA0B1A09
All rights reserved. Please visit https://medical-data-
models.org/forms/10499
Second Primary Form
NCT00057876
ECOG clinical trial administrative data
ECOG Protocol No. (If patient has been on other
therapeutic ECOG protocols, please list protocols
and patient ID numbers.)
ECOG Patient ID (If patient has been on other
therapeutic ECOG protocols, please list protocols
and patient ID numbers.)
Registration Step
Patient?s Name
Participating Group Protocol No.
Participating Group Patient ID
Institution/Affiliate
Are data amended? (If yes, please circle
amended items in red)
Yes
No
Second primary cancer assessment
Date of Diagnosis of Second Primary Cancer
Site of Second Primary Cancer
Include information on histologic subtype(s).
Briefly describe cancer therapy the patient has
received prior to the diagnosis of the second
primary and other than that given on ECOG
protocols
Briefly describe treatment planned or given for
the diagnosis of this second primary:
1 / 2
Comments
Comments
Investigator Signature
Date
Ccrr Module For Second Primary Form
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Treatment Form NCT00058149
Treatment Form NCT00058149
A Phase III, Randomized Study of Gemcitabine (Fixed-
Dose Rate Infusion) and Oxaliplatin (NSC 266046) Versus
Gemcitabine (Fixed-Dose Rate Infusion) Versus
Gemcitabine (30-Minute Infusion) in Pancreatic Carcinoma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=A65C8791-
5AF1-42A8-E034-0003BA0B1A09
All rights reserved. Please visit https://medical-data-
models.org/forms/10501
Treatment Form NCT00058149
ECOG clinical trial administrative data
ECOG Protocol No.
ECOG Patient ID
Registration Step
Patient?s Name
Participating Group Protocol No.
Participating Group Patient ID
Institution/Affiliate
Are data amended? (If yes, please circle
amended items in red)
Yes
No
Vital Status
Patient?s Vital Status
Alive (Alive)
Dead (Dead)
Date of Last Contact or Death (M D Y)
Cause of Death (if applicable)
Due To Other Cause (Due to other
cause)
Due To Protocol Treatment (Due to
protocol treatment)
Due To This Disease (Due to this
disease)
Unknown (Unknown)
Describe cause of death
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Arm A
Cycle Number
Oxaliplatin Dose (mg)
Oxaliplatin begin date (M D Y)
Arm B
Arm C
If yes, choose one:
Both planned and unplanned, specify
unplanned changes above (Both planned
and unplanned, specify unplanned
changes above)
(i.e., The Treatment Was Changed
According To Protocol Guidelines)
(Planned (i.e., the treatment was
changed according to protocol
guidelines))
(i.e., The Treatment Change Was Not
Part Of Protocol Guidelines) (Unplanned
(i.e., the treatment change was not part
of protocol guidelines))
Name of therapy
Type of therapy modification
Reason for therapy modification
Non-protocol Therapy
Was any non-protocol therapy given during
protocol treatment (not previously reported)?
Yes
No
Comments
Comments
Investigator Signature
Date
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Ccrr Module For Treatment Form
Patient Weight
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AMC-051 Off Study Summary Form (F50)
NCT00450320
AMC-051 Off Study Summary Form (F50)NCT00450320 
Sirolimus in Treating Patients With HIV-Related Kaposi's
Sarcoma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=2FDFA89A-
08A0-6018-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/10502
AMC-051 Off Study Summary Form
(F50) NCT00450320
Ccrr Module For Off Study Summary -
Rf50
Off Study Date
Off Study Reason (select the primary reason)
Adverse Event/side Effects/complications
(Adverse Event/Side
Effects/Complications)
Death (Death)
Other (Other)
Lost To Follow-up (Patient lost to follow-
up)
Patient Refused Follow-up (Patient
refused follow-up)
Protocol-defined Follow-up Completed
(Protocol-defined follow-up completed)
Other, specify
Comments
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ECOG Follow-Up Disease Evaluation Form
(RECIST) NCT00057876
ECOG Follow-Up Disease Evaluation Form
(RECIST)NCT00057876
Gemcitabine With or Without Radiation Therapy in Treating
Patients With Pancreatic Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=A622D776-
13BD-3BC1-E034-0003BA0B1A09
All rights reserved. Please visit https://medical-data-
models.org/forms/10503
ECOG Follow-Up Disease Evaluation
Form (RECIST) NCT00057876
ECOG clinical trial administrative data
ECOG Protocol No.
ECOG Patient ID
Registration Step
Cycle Number (leave blank if off-treatment or
N/A)
Patient?s Name
Participating Group Protocol No.
Participating Group Patient ID
Institution/Affiliate
Are data amended? (If yes, please circle
amended items in red)
Yes
No
Target Lesions:
Lesion Number
Site of Lesion (Multiple new lesions within an
organ may be combined as a single site.)
Site Code
Bone (Bone)
Brain (Brain)
Breast (Breast)
Effusion/ascites (Effusion/Ascites)
Gi (GI)
Gu (GU)
Head & Neck (Head & Neck)
Liver (Liver)
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Lung (Lung)
Nodes (Nodes)
Other (specify Site) (Other (specify site))
Skin (Skin)
Method of Evaluation
Bone Scan (Bone scan)
Chest X-ray (Chest X-Ray)
Clinical Examination (Clinical Exam)
Ct Scan (CT Scan (non-spiral))
Mri (MRI)
Not Evaluated (Not evaluated)
Other (Other (specify in Comments))
Spiral Ct Scan (Spiral CT)
Ultrasound (Ultrasound)
Date of Evaluation (M D Y)
Longest Diameter of Lesion(s) (cm)
Baseline Longest Diameter of Lesion (cm)
Sum of longest diameters of all target lesions
(cm)
Nontarget Lesions:
Follow-Up Status of Lesions
Cr (CR)
Incompl. Resp./sd (incompl. resp./SD)
Pd (PD)
Cytology Result (For Site Code 04
effusion/ascites ONLY)
Negative (Negative)
Not Done (Not done)
Positive (Positive)
Unequivocal progressive disease in nontarget
lesions is based on: (please describe)
New Lesions
Was the appearance of any new lesions
documented?
Yes
No
Response Of Target Lesions This
Reporting Period
Has the response of the target lesions changed,
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OR has an unconfirmed response changed to a
confirmed response, since last report?
Yes
No
Response status at this assessment
Complete Response (CR)
Insufficient Evaluation (Insufficient
evaluation to determine response status
(unknown))
Progression; At Least A 20% Increase In
The Sum Of Ld Of Target Lesions Taking
As References The Smallest Sum Ld
Recorded Since The Treatment Started
Or The Appearance Of One Or More
New Lesions (PD)
Partial Response (PR)
Stable Disease (SD)
PR/CR first observed date (M D Y)
Progressive disease observed date (For PD:)
Overall Response Per Recist Criteria -
Target, Nontarget And New Lesions
Has the overall response changed, OR has an
unconfirmed response changed to a confirmed
response, since last report?
Yes
No
Overall response status at this assessment
Complete Response (CR)
Null (Insufficient evaluation to determine
response status)
Progressive Disease (PD)
Partial Response (PR)
Stable Disease (SD)
Has response been confirmed by second
assessment? (Confirmation of response: For
CR/PR, all assessments repeated >= 4 wks after
onset of CR/PR.)
no
yes
Symptomatic Deterioration
Is there symptomatic deterioration of the patient's
health status requiring discontinuation of
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ECOG Follow-Up Disease Evaluation Form (RECIST) NCT00057876
treatment (this reporting period)?
no
yes
yes, specify (symptomatic deterioration)
Symptomatic Deterioration Date (M D Y)
Comments
Comments
Investigator Signature
Date
Ccrr Module For Ecog Follow-up Disease
Evaluation Form (recist)
Follow-up Status of Lesion(s)
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Tooth Sensitivity Questionnaire (PO1)
NCT00867997
Tooth Sensitivity Questionnaire (PO1) NCT00867997 
Noncarious Cervical Lesion Treatment Outcomes
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=23E09830-
4E68-45B0-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/10505
Tooth Sensitivity Questionnaire
(PO1) NCT00867997
Tooth Sensitivity Assessment
When I eat cold food or drink cold liquids, I feel
1 (1)
10 (10)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
7 (7)
8 (8)
9 (9)
When I eat hot food or drink hot liquids, I feel
1 (1)
10 (10)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
7 (7)
8 (8)
9 (9)
When I eat sweet food or drink sweet liquids, I
feel
1 (1)
10 (10)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
7 (7)
8 (8)
9 (9)
When I chew food in general, I feel
1 (1)
10 (10)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
7 (7)
8 (8)
9 (9)
1 / 2
When I clench my teeth together, I feel
1 (1)
10 (10)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
7 (7)
8 (8)
9 (9)
I experience sensitivity not related to any of the
above in this tooth
Fairly Often (Fairly often)
Hardly Ever (Hardly ever)
Not At All (Not at all)
Occasionally (Occasionally)
Very Often (Very often)
Date Form Completed
Date Form Completed
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AMC-051 KS Biopsy Form (F32)
NCT00450320
AMC-051 KS Biopsy Form (F32) NCT00450320 
Sirolimus in Treating Patients With HIV-Related Kaposi's
Sarcoma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=2FF95103-
FCAB-6437-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/10507
AMC-051 KS Biopsy Form (F32)
NCT00450320
Header Module
Visit number
Date of Biopsy
Site and size of biopsy
Biopsy site
Abdomen (Abdomen)
Back (Back)
Chest (Chest)
Genital Area (Genital)
Head (Head)
Left Arm (Left arm)
Left Foot (Left foot)
Left Hand (Left hand)
Left Leg (Left leg)
Neck (Neck)
Right Arm (Right arm)
Right Foot (Right foot)
Right Hand (Right hand)
Right Leg (Right leg)
Dimension 1
Dimension 2
Specify the biopsy site
Site and size of biopsy 2
Biopsy  Fixative Type
Specimen Fixative (Please complete the following
if available select one)
Formalin (Formalin)
Glutaraldehyde (Glutaraldehyde)
Oct Media (OCT media)
Saline (Saline)
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Footer Module
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Gemcitabine With or Without Radiation Therapy in Treating
Patients With Pancreatic Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=A65F5E36-
2E67-453E-E034-0003BA0B1A09
All rights reserved. Please visit https://medical-data-
models.org/forms/10508
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ECOG clinical trial administrative data
Registration Step
Date of assessment
Patient?s Name
ECOG Protocol No.
ECOG Protocol No.
ECOG Patient ID
ECOG Patient ID
Participating Group Protocol No.
Participating Group Patient ID
Institution/Affiliate (Physical Well-Being)
Assessment of Quality of Life
I have a lack of energy
A Little (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have nausea
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
Because of my physical condition, I have trouble
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meeting the needs of my family
A Little (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have pain
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am bothered by side effects of treatment
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I feel ill
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am forced to spend time in bed (Social/Family
Well-Being)
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I feel close to my friends
A Little (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I get emotional support from my family
A Little (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I get support from my friends
A Little (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
My family has accepted my illness
A Little (A little bit)
Not At All (Not at all)
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Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am satisfied with family communication about
my illness
A Little (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I feel close to my partner (or the person who is
my main support)
A Little (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am satisfied with my sex life (Emotional Well-
Being)
A Little (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I feel sad
A Little (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am satisfied with how I am coping with my
illness
A Little (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am losing hope in the fight against my illness
A Little (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I feel nervous
A Little (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I worry about dying
A Little (A little bit)
Not At All (Not at all)
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Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I worry that my condition will get worse
(Functional Well-Being)
A Little (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am able to work (include work at home)
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
My work (include work at home) is fulfilling
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am able to enjoy life
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have accepted my illness
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am sleeping well
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am enjoying the things I usually do for fun
A Little (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am content with the quality of my life right now
(Additional Concerns)
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
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Very Much (Very much)
I have swelling or cramps in my stomach area
A Little (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am losing weight
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have control of my bowels
A Little (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I can digest my food well
A Little (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have diarrhea
A Little (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have a good appetite
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am unhappy about a change in my appearance
A Little (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have pain in my back
A Little (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am bothered by constipation
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A Little (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I feel fatigued
A Little (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am able to do my usual activities
A Little (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am bothered by jaundice or yellow color to my
skin
A Little (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have had fevers
A Little (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have had itching
A Little (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have had a change in the way food tastes
A Little (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have had chills
A Little (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
My mouth is dry
A Little (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
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Somewhat (Somewhat)
Very Much (Very much)
I have discomfort or pain in my stomach area
A Little (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
Ccrr Module For Fact-hep (version 4)
Assessment Date
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S0205 Registration Form NCT00075686
S0205 Gemcitabine With or Without Cetuximab as First-
Line Therapy in Treating Patients With Locally Advanced
Unresectable or Metastatic Adenocarcinoma of the
Pancreas
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=A11C9703-
C8D4-1BF2-E034-080020C9C0E0
All rights reserved. Please visit https://medical-data-
models.org/forms/10509
S0205 Registration Form
NCT00075686
SWOG clinical trial administrative data
SWOG Study No.
Registration Step
Assigned Treatment Arm
Activation Date
Last Amended Date
Patient's Name
SWOG Patient ID
SWOG Treating Institution Number
Date Informed Consent Signed
SWOG Investigator Number
IRB Approval Date
Projected Start Date of Treatment
Patient demographics
Patient's Date of Birth
Patient's Sex
Female (Female)
Male (Male)
Method of Payment
Medicaid (Medicaid)
Medicaid and Medicare (Medicaid and
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Medicare)
Medicare (Medicare)
Medicare and Private (Medicare and
Private)
Military (Military)
No insurance (no means) (No insurance
(no means))
No insurance (self-pay) (No insurance
(self-pay))
Other, speicfy at registration (Other,
speicfy at registration)
Private (Private)
Unknown (Unknown)
Veterans Admin (Veterans Admin)
Patient's Ethnicity
No (not Spanish) (No (not Spanish))
Unknown (Unknown)
Yes, Central American (Yes, Central
American)
Yes, Cuban (Yes, Cuban)
Yes, Mexican (Yes, Mexican)
Yes, Nos (Yes, NOS)
Yes, Other (Yes, Other)
Yes, Puerto Rican (Yes, Puerto Rican)
Yes, South American (Yes, South
American)
Patient's Race (select all that apply)
Native_american_cdus (American Indian
or Alaska Native)
Asian_cdus (Asian)
Black_cdus (Black or African American)
Pacific_islander_cdus (Native Hawaiian
or Other Pacific Islander)
Other, specify (Other, specify)
Unknown (Unknown)
White_cdus (White or Caucasian)
Other, specify (If a U.S. resident)
Social Insurance Number
Patient's ZIP Code
Country of Residence, if not USA (If a resident of
Canada)
Postal Code
Stratification Factors
Disease status
Locally Advanced Unresectable (Locally
advanced unresectable)
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Metastatic (Metastatic)
Zubrod Performance Status
0 (0 to 1)
2 (2)
1 (Restricted in physically strenuous
activity but ambulatory (K 70 -     80))
Patient's tissue may be kept for use in research to
learn about, prevent, treat, or cure cancer
Yes
No
Patient's tissue may be kept for research about
other health problems (for example: causes of
diabetes, Alzheimer's disease, and heart
disease)
Yes
No
Someone from the Southwest Oncology Group
may contact the patient in the future to ask him or
her to take part in more research.
Yes
No
Comments
Comments
Ccrr Module For S0205 Registration Form
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The Hamilton  Rating Scale for Depression
UKM
DAST Scores PSYCH MS - Part Hamilton converted to
ODM format. Used as Routine documentation of University
Hospital Muenster
All rights reserved. Please visit https://medical-data-
models.org/forms/10510
The Hamilton  Rating Scale for
Depression UKM
Default Itemgroup
Patient's Name
Date of Assessment
For each item, write the correct number on
the line next to the item. (Only one
response per item)
DEPRESSED MOOD
Absent (0)
These feeling states indicated only on
questioning (1 )
These feeling states spontaneously
reported verbally (2)
Communicates feeling states non-
verbally-i. e. , through facial expression,
posture, (3)
Patient reports VIRTUALLY O N LY these
feeling states in his spontaneous verbal
and nonverbal (4)
voice, and tendency to weep (5)
communication (7)
FEELINGS OF GUILT
Absent (0)
Self reproach, feels he has let people
down (1 )
Ideas of guilt or rumination over past
errors or sinful deeds (2)
Present illness is a punishment.
Delusions of guilt (3)
Hears accusatory or denunciatory voices
and/or experiences threatening visual (4)
h allucinations (h allucinations)
SUICIDE
Absent (0)
Feels life is not worth living (1 )
Wishes he were dead or any thoughts of
possible death to self (2)
Suicidal ideas or gesture (3)
Attempts at suicide (any serious attempt
rates 4) (4)
INSOMNIA EARLY
No difficulty falling asleep (0)
Complains of occasional difficulty falling
asleep-i.e., more th an 1/2 h our (1 )
Complains of nightly difficulty falling
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asleep (2)
INSOMNIA MIDDLE
No difficulty (0)
Patient complains of being restless and
disturbed during the night (1 )
Waking during th e night-any getting out
of bed rates 2 (except for purposes of
voiding) (2)
INSOMNIA LATE
No difficulty (0)
Waking in early h ours of the morning but
goes back to sleep (1 )
Unable to fall asleep again if he gets out
of bed (2)
WORK AND ACTIVITIES
No difficulty (0)
Thoughts and feelings of incapacity,
fatigue or weakness related to activities;
work or hobbies (1)
Loss of interest in activity; h obbies or
work-either directly reported by patient,
or indirect in listlessness, indecision and
vacillation (feels he has to push self to
work or activities) (2)
Decrease in actual time spent in
activities or decrease in productivity (3)
Stopped working because of present
illness (4)
RETARDATION: PSYCHOMOTOR (Slowness of
thought and speech; impaired ability to
concentrate; decreased motor activity)
Normal speech and th ought (0)
Slight retardation at interview (1 )
Obvious retardation at interview (2)
Interview difficult (3)
Complete stupor (4)
AGITATION
None (0)
Fidgetiness (1 )
Playing with hands, h air, etc. (2)
Moving about, can't sit still (3)
Hand wringing, nail biting, h air-pulling,
biting of lips (4)
ANXIETY (PSYCHOLOGICAL)
No difficulty (0)
Subjective tension and irritability (1 )
Worrying about minor matters (2)
Apprehensive attitude apparent in face or
speech (3)
Fears expressed without questioning (4)
Physiological concomitants of anxiety, (i. e. ,
effects of autonomic
overactivity, "butterflies, " indigestion, stomach
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cramps, belching, diarrhea, palpitations,
h yperventilation, paresthesia, sweating, flushing,
tremor, headache, urinary frequency).
Avoid asking about possible medication side
effects (i. e. , dry mouth, constipation)
Absent (0)
Mild (1)
Moderate (2)
Severe (3)
Incapacitating (4)
SOMATIC SYMPTOMS (GASTROINTESTINAL)
None (0)
Loss of appetite but eating without
encouragement from others. Food intake
about normal (1 )
Difficulty eating without urging from
others. Marked reduction of appetite and
food intake (2)
SOMATIC SYMPTOMS GENERAL
None (0)
Heaviness in limbs, back or head.
Backaches, headache, muscle aches.
Loss of energy (1 )
Any clear-cut symptom rates 2 (2)
and fatigability (3)
GENITAL SYMPTOMS (Symptoms such as: loss
of libido; impaired sexual performance; menstrual
disturbances)
Absent (0)
Mild (1)
Severe (2)
HYPOCHONDRIASIS
Not present (0)
Self-absorption (bodily) (1 )
Preoccupation with health (2)
Frequent complaints, requests for help,
etc. (3)
Hypochondriacal delusions (4)
16. LOSS OF WEIGHT (6)
A. When (7)
LOSS OF WEIGHT -A:  According to history
No weight loss (0)
Probably weight loss associated with
present illness (1 )
Definite (according to patient) weight
loss (2)
Not assessed (3)
LOSS OF WEIGHT -B: According to
measurement
Less than 0,5 kg / week (0)
More than 0,5 kg / week (1)
More than 1 kg / week (2)
INSIGHT
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Acknowledges being depressed and ill
(0)
Acknowledges illness but attributes
cause to bad food, climate, overwork,
virus, need for rest, etc. (1 )
Denies being ill at all (2)
DIURNAL VARIATION - A Note whether
symptoms are worse in morning or evening. If NO
diurnal variation, mark none
No variation (0)
Worse in A.M. (1 )
Worse in P.M. (2)
DIURNAL VARIATION - B : When present, mark
the severity of th e variation. Mark
None (0)
Mild (1)
Severe (2)
DEPERSONALIZATION AND DEREALIZATION
(Such as: Feelings of unreality; Nihilistic ideas)
Absent (0)
Mild (1)
Moderate (2)
Severe (3)
Incapacitating (4)
PARANOID SYMPTOMS
None (0)
Suspicious (1 )
Ideas of reference (2)
Delusions of reference and persecution
(3)
OBSESSIONAL AND COMPULSIVE
SYMPTOMS
Absent (0)
Mild (1)
Severe (2)
Total Score
Total Score Hamilton
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T2 Radiation Therapy Oncology Group Initial
Protocol Treatment Form NCT00023829
T2 Radiation Therapy Oncology Group Initial Protocol
Treatment Form NCT00023829
Adjuvant Radiation Therapy Plus Hormone Therapy
Compared With Radiation Therapy Alone in Treating
Patients With Stage II or Stage III Prostate Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=A4E2767E-
4BDF-2632-E034-080020C9C0E0
All rights reserved. Please visit https://medical-data-
models.org/forms/10511
T2 Radiation Therapy Oncology
Group Initial Protocol Treatment
Form NCT00023829
Header module
RTOG Study
Case #
Radiation therapy
# OF INSERTIONS
Institution
Institution No.
Patient's Name
Patient's I.D. No.
Option #
Description
Date RT starts
Surgical Stage: T
Surgical Stage: N
Surgical Stage: M (or)
system
Primary Site
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ENERGY (Check all that apply)
> 10 Mv (> 10 Mv)
2-4 Mv (2-4 Mv)
6-8 Mv (6-8 Mv)
Particle (Particle)
BRACHYTHERAPY
IMPLANT/INSERTION/APPLICATION
No (No)
Yes (Yes)
specify source (brachytherapy)
PLANNED IMPLANT DOSE
FIELDS (Check all that apply)
The Angle Or Type Of Radiation Used
Was 360 Rotation (360 degree rotation)
The Angle Or Type Of Radiation Used
Was Ap (AP)
The Angle Or Type Of Radiation Used
Was Left Arc (Left arc)
The Angle Or Type Of Radiation Used
Was Left Lateral (Left lateral)
The Angle Or Type Of Radiation Used
Was Left Oblique (Left oblique)
Specify Other Angle Or Type Of
Radiation Used (Other, specify)
The Angle Or Type Of Radiation Used
Was Pa (PA)
The Angle Or Type Of Radiation Used
Was Right Arc (Right arc)
The Angle Or Type Of Radiation Used
Was Right Lateral (Right lateral)
The Angle Or Type Of Radiation Used
Was Right Oblique (Right oblique)
Other, specify (fields)
ELECTRONS
No (No)
Yes (Yes)
SITE OF ELECTRON RT
ALL FIELDS TREATED EACH SESSION
No (No)
Yes (Yes)
FRACTIONATION (CHECK ALL THAT APPLY)
10 Fx/week; Twice Per Day (10
FX/Week; twice per day)
5 Fx/week; Once Per Day (5 FX/Week;
once per day)
Other, Specify (Other, specify)
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Other, specify (fractionation) (FOR
FRACTIONATION SCHEDULES OTHER THAN
ONCE PER DAY)
SPECIFY TIME INTERVAL BETWEEN
FRACTIONS
POINT OF PRIMARY TREATMENT
PRESCRIPTION
Intersection Of Multiple Fields
(Intersection of multiple fields)
Isocenter/center Of Rotation
(Isocenter/center of rotation)
Midplane Depth (Midplane depth)
Other, Specify (Other, specify)
Other, specify (points of primary treatment
prescription)
Site of treatment
SITE OF PROTOCOL TREATMENT
Additional Site (ADDITIONAL SITE)
Boost Field #1 (BOOST FIELD #1)
Boost Field #2 (BOOST FIELD #2)
Initial Field (INITIAL FIELD)
Nodes (NODES)
NODES
Abdomen, Mesenteric (ABDOMEN,
Mesenteric)
Breast, Axillary (BREAST, Axillary)
Breast, Int Mammary (BREAST, Int
mammary)
Breast, S'clav (BREAST, S'clav)
Esophagus, Mediastinal (ESOPHAGUS,
Mediastinal)
Esophagus, S'clav (ESOPHAGUS,
S'clav)
Head & Neck, Ant To Cord (HEAD &
NECK, Ant to cord)
Head & Neck, Post To Cord (HEAD &
NECK, Post to cord)
Head & Neck, S'clav (HEAD & NECK,
S'clav)
Lung (lower Lobes), Contra Hilar (LUNG
(LOWER LOBES), Contra hilar)
Lung (lower Lobes), Inf Mediastinal
(LUNG (LOWER LOBES), Inf
mediastinal)
Lung (lower Lobes), Ipsil Hilar/subcar
(LUNG (LOWER LOBES), Ipsil
hilar/subcar)
Lung (upper/mid Lobes), Contra Hilar
(LUNG (UPPER/MID LOBES), Contra
hilar)
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Lung (upper/mid Lobes), Ipsil
Hilar/subcar (LUNG (UPPER/MID
LOBES), Ipsil hilar/subcar)
Lung (upper/mid Lobes), S'clav (LUNG
(UPPER/MID LOBES), S'clav)
Pelvic Primaries, Common Iliac (PELVIC
PRIMARIES, Common iliac)
Pelvic Primaries, Int/ext Iliac (PELVIC
PRIMARIES, Int/ext iliac)
Pelvic Primaries, Para-aortic (PELVIC
PRIMARIES, Para-aortic)
DAILY DOSE
TOTAL FX
TOTAL DOSE
PLANNED TOTAL DOSE, TOTAL FX
PLANNED TOTAL DOSE, TOTAL DOSE
Critical structures
CRITICAL STRUCTURES
ABDOMEN, Kidney (ABDOMEN, Kidney)
ABDOMEN, Liver (ABDOMEN, Liver)
ABDOMEN, Small intestine (ABDOMEN,
Small intestine)
ABDOMEN, Spinal cord (ABDOMEN,
Spinal cord)
BRAIN, Lens (left) (BRAIN, Lens (left))
BRAIN, Lens (right) (BRAIN, Lens
(right))
BRAIN, Spinal cord (BRAIN, Spinal cord)
ESOPHAGUS, Heart (ESOPHAGUS,
Heart)
ESOPHAGUS, Lung (ESOPHAGUS,
Lung)
ESOPHAGUS, Spinal cord
(ESOPHAGUS, Spinal cord)
HEAD & NECK, Spinal cord (HEAD &
NECK, Spinal cord)
LUNG (LOWER LOBES), Contra lung
(LUNG (LOWER LOBES), Contra lung)
LUNG (LOWER LOBES), Heart (LUNG
(LOWER LOBES), Heart)
LUNG (LOWER LOBES), Spinal cord
(LUNG (LOWER LOBES), Spinal cord)
LUNG (UPPER / MID LOBES), Contra
lung (LUNG (UPPER / MID LOBES),
Contra lung)
LUNG (UPPER / MID LOBES), Heart
(LUNG (UPPER / MID LOBES), Heart)
LUNG (UPPER / MID LOBES), Spinal
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cord (LUNG (UPPER / MID LOBES),
Spinal cord)
PELVIC PRIMARIES, Bladder (PELVIC
PRIMARIES, Bladder)
PELVIC PRIMARIES, Rectum (PELVIC
PRIMARIES, Rectum)
PELVIC PRIMARIES, Small bowel
(PELVIC PRIMARIES, Small bowel)
MAXIMUM DOSE (GY)
SPECIFY METHOD USED TO RESTRICT DOSE
Ccrr Module For T2 Radiation Therapy
Oncology Group Initial Protocol Treatment
Form
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Nontarget Lesions Supplemental Form
NCT00058149
Nontarget Lesions Supplemental Form NCT00058149
A Phase III, Randomized Study of Gemcitabine (Fixed-
Dose Rate Infusion) and Oxaliplatin (NSC 266046) Versus
Gemcitabine (Fixed-Dose Rate Infusion) Versus
Gemcitabine (30-Minute Infusion) in Pancreatic Carcinoma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=A65D5AC6-
6244-4284-E034-0003BA0B1A09
All rights reserved. Please visit https://medical-data-
models.org/forms/10512
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Form NCT00058149
ECOG clinical trial administrative data
ECOG Protocol No.
ECOG Patient ID
Registration Step
Cycle Number (Use 00 for baseline; leave blank if
off-treatment or N/A)
Patient?s Name
Participating Group Protocol No.
Participating Group Patient ID
Institution/Affiliate
Are data amended? (If yes, please circle
amended items in red)
Yes
No
Nontarget Lesions:
Lesion Number
Site of Lesion (Multiple nontarget lesions within
an organ may be combined as a single site, but
must be reported in same manner as at
baseline.)
Site Code
Bone (Bone)
Brain (Brain)
Breast (Breast)
Effusion/ascites (Effusion/Ascites)
Gi (GI)
Gu (GU)
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Head & Neck (Head & Neck)
Liver (Liver)
Lung (Lung)
Nodes (Nodes)
Other (Other)
Skin (Skin)
Method of Evaluation
Bone Scan (Bone scan)
Chest X-ray (Chest X-Ray)
Clinical Examination (Clinical Exam)
Ct Scan (CT Scan (non-spiral))
Mri (MRI)
Not Evaluated (Not evaluated)
Other (Other (specify in Comments))
Spiral Ct Scan (Spiral CT)
Ultrasound (Ultrasound)
Date of Evaluation (M D Y)
Follow-up Status of Lesions (Choose one for
each lesion. Leave blank if baseline.)
Cr (CR)
Incompl. Resp./sd (Incompl. resp./SD)
Pd (PD)
Cytology Result (For Site Code 04
effusion/ascites ONLY)
Negative (Negative)
Not Done (Not done)
Positive (Positive)
Unequivocal progressive disease in nontarget
lesions is based on: (please decribe)
Comments
Comments
Investigator Signature
Date
Ccrr Module For Nontarget Lesions
Supplemental Form
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Non-Protocol Therapy Form NCT00058149
A Phase III, Randomized Study of Gemcitabine (Fixed-
Dose Rate Infusion) and Oxaliplatin (NSC 266046) Versus
Gemcitabine (Fixed-Dose Rate Infusion) Versus
Gemcitabine (30-Minute Infusion) in Pancreatic Carcinoma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=A65D54AA-
6F5F-4282-E034-0003BA0B1A09
All rights reserved. Please visit https://medical-data-
models.org/forms/10513
Non-Protocol Therapy Form
NCT00058149
ECOG clinical trial administrative data
ECOG Protocol No.
ECOG Patient ID
Registration Step
Patient?s Name
Participating Group Protocol No.
Participating Group Patient ID
Institution/Affiliate
Are data amended? (If yes, please circle
amended items in red)
Yes
No
Non-Protocol Therapy
Date of FIRST non-protocol therapy ( if given
prior to progression/relapse from protocol
therapy:)
Type(s) of first non-protocol therapy (which
includes any cancer therapy that is not part of the
planned regimen.)
Non-protocol Chemotherapy (Non-
protocol Chemotherapy)
Non-protocol High Dose
Chemotherapy/stem Cell Transplant
(autologous Or Allogeneic) (Non-protocol
High Dose Chemotherapy/Stem Cell
Transplant (Autologous or Allogeneic))
Non-protocol Hormonal Therapy (Non-
protocol Hormonal Therapy)
Non-protocol Immunotherapy/biological
Response Modifiers (Non-protocol
1 / 2
Immunotherapy/Biological Response
Modifiers)
Non-protocol Radiation Therapy (Non-
protocol Radiation Therapy)
Non-protocol Surgery (Non-protocol
Surgery)
Other Non-protocol Therapy (Other Non-
protocol Therapy)
Name of other non-protocol therapy:
Was the non-protocol therapy given for the
disease of this protocol? (NOTE: Treatment for a
second primary in the same organ site would not
be considered therapy for disease of this
protocol.)
No (No)
Unknown (Unknown)
Yes (Yes)
Comments
Comments
Investigator Signature
Date
Ccrr Module For Non-protocol Therapy
Form
Non-protocol RT type
Non-protocol surgery type
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Non-Protocol Therapy Form NCT00058149
ECOG Baseline Disease Evaluation Form
(RECIST) NCT00057876
ECOG Baseline Disease Evaluation Form (RECIST)
NCT00057876
Gemcitabine With or Without Radiation Therapy in Treating
Patients With Pancreatic Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=A62322A5-
CF54-3B58-E034-0003BA0B1A09
All rights reserved. Please visit https://medical-data-
models.org/forms/10514
ECOG Baseline Disease Evaluation
Form (RECIST) NCT00057876
ECOG clinical trial administrative data
ECOG Protocol No.
ECOG Patient ID
Registration Step
Patient?s Name
Participating Group Protocol No.
Participating Group Patient ID
Institution/Affiliate
Are data amended? (If yes, please circle
amended items in red)
Yes
No
Target Lesions
Are there any target lesions?
Yes
No
Lesion Number
Site of Lesion
Site Code
Bone (Bone)
Brain (Brain)
Breast (Breast)
Effusion/ascites (Effusion/Ascites)
Gi (GI)
Gu (GU)
Head & Neck (Head & Neck)
Liver (Liver)
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Lung (Lung)
Nodes (Nodes)
Other (specify Site) (Other (specify site))
Skin (Skin)
Method of Evaluation
Bone Scan (Bone scan)
Chest X-ray (Chest X-Ray)
Clinical Examination (Clinical Exam)
Ct Scan (CT Scan (non-spiral))
Mri (MRI)
Other (Other (specify in Comments))
Spiral Ct Scan (Spiral CT)
Ultrasound (Ultrasound)
Date of Evaluation (M D Y)
Longest Diameter of Lesion(s) (cm)
Sum of longest diameters of all target lesions
(cm)
Nontarget Lesions
Site of Lesion
Cytology Result (For Site Code 04
effusion/ascites ONLY)
Negative (Negative)
Not Done (Not done)
Positive (Positive)
Comments
Comments
Investigator Signature
Date
Ccrr Module For Ecog Baseline Disease
Evaluation Form (recist)
ECOG Protocol Number
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ECOG Baseline Disease Evaluation Form (RECIST) NCT00057876
Adverse Event Form NCT00058149
Adverse Event Form NCT00058149
A Phase III, Randomized Study of Gemcitabine (Fixed-
Dose Rate Infusion) and Oxaliplatin (NSC 266046) Versus
Gemcitabine (Fixed-Dose Rate Infusion) Versus
Gemcitabine (30-Minute Infusion) in Pancreatic Carcinoma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=A6276505-
5438-3D62-E034-0003BA0B1A09
All rights reserved. Please visit https://medical-data-
models.org/forms/10515
Adverse Event Form NCT00058149
ECOG clinical trial administrative data
ECOG Protocol No.
ECOG Patient ID
Registration Step
Adverse Event Reporting From Date (M D Y)
Adverse Event Reporting To Date (M D Y)
Cycle Number (For Arm A, first cycle is 8 weeks,
subsequent cycles are 4 weeks. For Arm B, 1
cycle=4 weeks. For Arm C, 1 cycle=2 weeks.)
Patient?s Name
Participating Group Protocol No.
Participating Group Patient ID
Institution/Affiliate
Are data amended? (If yes, please circle
amended items in red)
Yes
No
Adverse event
CTC Adverse Event Term
CTC Adverse Event Grade (this period)
CTC Adverse Event Attribution Code
Other CTC Adverse Event Term(s) not listed (Use
CTC terminology)
1 / 2
Comments
Comments
Investigator Signature
Date
Ccrr Module For Adverse Event Form
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Adverse Event Form NCT00058149
AMC-051 Complete Physical Exam Form
(F21) NCT00450320
AMC-051 Complete Physical Exam Form
(F21)NCT00450320 
Sirolimus in Treating Patients With HIV-Related Kaposi's
Sarcoma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=2FF95103-
FC9E-6437-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/10516
AMC-051 Complete Physical Exam
Form (F21) NCT00450320
Header Module
Visit number
Date of evaluation
Physical examination
Primary site
Abdomen (Abdomen)
Chest (Chest)
Ear (Ears)
Extremities (Extremities)
Eye (Eyes)
Genitalia (Genital)
Head (Head)
Heart (Heart)
Liver (Liver)
Lung (Lungs)
Lymph Node (Lymph Nodes)
Mouth (Mouth)
Neck (Neck)
Neurologic (Neurological)
Other (Other)
Rectal (Rectal)
Skin (Skin)
Spleen (Spleen)
Other, specify
Assessment
Abnormal (Abnormal)
Normal (Normal)
Not Evaluated (Not Evaluated)
Describe abnormal findings
Footer Module
Comments
1 / 1
T2 Radiation Therapy Oncology Group Phase III Prostate
3D / IMRT Initial Protocol Treatment Form NCT00033631
T2 Radiation Therapy Oncology Group Phase III Prostate
3D / IMRT Initial Protocol Treatment Form NCT00033631
Radiation Therapy in Treating Patients With Stage II
Prostate Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=11CF703E-
9964-4398-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/10517
T2 Radiation Therapy Oncology
Group Phase III Prostate 3D / IMRT
Initial Protocol Treatment Form
NCT00033631
Header module
RTOG Study
Case #
Radiation therapy
# OF INSERTIONS
Institution
Institution No.
Patient's Name
Patient's I.D. No.
Option #
Description
Date RT starts
Surgical Stage: T
Surgical Stage: N
Surgical Stage: M (or)
system
Primary Site
1 / 5
ENERGY (Check all that apply)
> 10 Mv (> 10 Mv)
2-4 Mv (2-4 Mv)
6-8 Mv (6-8 Mv)
Particle (Particle)
BRACHYTHERAPY
IMPLANT/INSERTION/APPLICATION
No (No)
Yes (Yes)
specify source (brachytherapy)
PLANNED IMPLANT DOSE
FIELDS (Check all that apply)
The Angle Or Type Of Radiation Used
Was 360 Rotation (360 degree rotation)
The Angle Or Type Of Radiation Used
Was Ap (AP)
The Angle Or Type Of Radiation Used
Was Left Arc (Left arc)
The Angle Or Type Of Radiation Used
Was Left Lateral (Left lateral)
The Angle Or Type Of Radiation Used
Was Left Oblique (Left oblique)
Specify Other Angle Or Type Of
Radiation Used (Other, specify)
The Angle Or Type Of Radiation Used
Was Pa (PA)
The Angle Or Type Of Radiation Used
Was Right Arc (Right arc)
The Angle Or Type Of Radiation Used
Was Right Lateral (Right lateral)
The Angle Or Type Of Radiation Used
Was Right Oblique (Right oblique)
Other, specify (fields)
ELECTRONS
No (No)
Yes (Yes)
SITE OF ELECTRON RT
ALL FIELDS TREATED EACH SESSION
No (No)
Yes (Yes)
FRACTIONATION (CHECK ALL THAT APPLY)
10 Fx/week; Twice Per Day (10
FX/Week; twice per day)
5 Fx/week; Once Per Day (5 FX/Week;
once per day)
Other, Specify (Other, specify)
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T2 Radiation Therapy Oncology Group Phase III Prostate 3D / IMRT
Initial Protocol Treatment Form NCT00033631
Other, specify (fractionation)
SPECIFY TIME INTERVAL BETWEEN
FRACTIONS (FOR FRACTIONATION
SCHEDULES OTHER THAN ONCE PER DAY)
POINT OF PRIMARY TREATMENT
PRESCRIPTION
Intersection Of Multiple Fields
(Intersection of multiple fields)
Isocenter/center Of Rotation
(Isocenter/center of rotation)
Midplane Depth (Midplane depth)
Other, Specify (Other, specify)
Other, specify (points of primary treatment
prescription)
Site of treatment
SITE OF PROTOCOL TREATMENT
Additional Site (ADDITIONAL SITE)
Boost Field #1 (BOOST FIELD #1)
Boost Field #2 (BOOST FIELD #2)
Initial Field (INITIAL FIELD)
Nodes (NODES)
NODES
Abdomen, Mesenteric (ABDOMEN,
Mesenteric)
Breast, Axillary (BREAST, Axillary)
Breast, Int Mammary (BREAST, Int
mammary)
Breast, S'clav (BREAST, S'clav)
Esophagus, Mediastinal (ESOPHAGUS,
Mediastinal)
Esophagus, S'clav (ESOPHAGUS,
S'clav)
Head & Neck, Ant To Cord (HEAD &
NECK, Ant to cord)
Head & Neck, Post To Cord (HEAD &
NECK, Post to cord)
Head & Neck, S'clav (HEAD & NECK,
S'clav)
Lung (lower Lobes), Contra Hilar (LUNG
(LOWER LOBES), Contra hilar)
Lung (lower Lobes), Inf Mediastinal
(LUNG (LOWER LOBES), Inf
mediastinal)
Lung (lower Lobes), Ipsil Hilar/subcar
(LUNG (LOWER LOBES), Ipsil
hilar/subcar)
Lung (upper/mid Lobes), Contra Hilar
(LUNG (UPPER/MID LOBES), Contra
hilar)
Lung (upper/mid Lobes), Ipsil
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Hilar/subcar (LUNG (UPPER/MID
LOBES), Ipsil hilar/subcar)
Lung (upper/mid Lobes), S'clav (LUNG
(UPPER/MID LOBES), S'clav)
Pelvic Primaries, Common Iliac (PELVIC
PRIMARIES, Common iliac)
Pelvic Primaries, Int/ext Iliac (PELVIC
PRIMARIES, Int/ext iliac)
Pelvic Primaries, Para-aortic (PELVIC
PRIMARIES, Para-aortic)
DAILY DOSE
TOTAL FX
TOTAL DOSE
PLANNED TOTAL DOSE, TOTAL FX
PLANNED TOTAL DOSE, TOTAL DOSE
Critical structures
CRITICAL STRUCTURES
ABDOMEN, Kidney (ABDOMEN, Kidney)
ABDOMEN, Liver (ABDOMEN, Liver)
ABDOMEN, Small intestine (ABDOMEN,
Small intestine)
ABDOMEN, Spinal cord (ABDOMEN,
Spinal cord)
BRAIN, Lens (left) (BRAIN, Lens (left))
BRAIN, Lens (right) (BRAIN, Lens
(right))
BRAIN, Spinal cord (BRAIN, Spinal cord)
ESOPHAGUS, Heart (ESOPHAGUS,
Heart)
ESOPHAGUS, Lung (ESOPHAGUS,
Lung)
ESOPHAGUS, Spinal cord
(ESOPHAGUS, Spinal cord)
HEAD & NECK, Spinal cord (HEAD &
NECK, Spinal cord)
LUNG (LOWER LOBES), Contra lung
(LUNG (LOWER LOBES), Contra lung)
LUNG (LOWER LOBES), Heart (LUNG
(LOWER LOBES), Heart)
LUNG (LOWER LOBES), Spinal cord
(LUNG (LOWER LOBES), Spinal cord)
LUNG (UPPER / MID LOBES), Contra
lung (LUNG (UPPER / MID LOBES),
Contra lung)
LUNG (UPPER / MID LOBES), Heart
(LUNG (UPPER / MID LOBES), Heart)
LUNG (UPPER / MID LOBES), Spinal
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cord (LUNG (UPPER / MID LOBES),
Spinal cord)
PELVIC PRIMARIES, Bladder (PELVIC
PRIMARIES, Bladder)
PELVIC PRIMARIES, Rectum (PELVIC
PRIMARIES, Rectum)
PELVIC PRIMARIES, Small bowel
(PELVIC PRIMARIES, Small bowel)
MAXIMUM DOSE (GY)
SPECIFY METHOD USED TO RESTRICT DOSE
Ccrr Module For T2 Radiation Therapy
Oncology Group Initial Protocol Treatment
Form
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T2 Radiation Therapy Oncology Group Phase III Prostate 3D / IMRT
Initial Protocol Treatment Form NCT00033631
Long-Term Follow-up Form NCT00058149
Long-Term Follow-up Form NCT00058149
A Phase III, Randomized Study of Gemcitabine (Fixed-
Dose Rate Infusion) and Oxaliplatin (NSC 266046) Versus
Gemcitabine (Fixed-Dose Rate Infusion) Versus
Gemcitabine (30-Minute Infusion) in Pancreatic Carcinoma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=A65D4EB3-
58E5-427C-E034-0003BA0B1A09
All rights reserved. Please visit https://medical-data-
models.org/forms/10518
Long-Term Follow-up Form
NCT00058149
ECOG clinical trial administrative data
Registration Step
Patient?s Name
ECOG Protocol No.
ECOG Protocol No.
ECOG Patient ID
ECOG Patient ID
Participating Group Protocol No.
Participating Group Patient ID
Institution/Affiliate
Data amendment
Are data amended? (If yes, please circle
amended items in red)
No (No)
Yes (Yes)
Reporting Period Start Date: (M D Y)
Reporting Period End Date: (M D Y)
Vital Status
Patient's Vital Status
Alive (Alive)
Dead (Dead)
Date of Last Contact or Death (M D Y)
1 / 3
Primary Cause of Death (if applicable)
Due To Other Cause, Specify (Due to
other diease)
Due To Protocol Treatment (Due to
protocol treatment)
Due To This Disease (Due to this
disease)
Unknown (Unknown)
Describe cause of death
Disease Follow-up Status
Has the patient had a documented clinical
assessment for this cancer (since submission of
the previous follow-up form)?
No (No)
Unknown (Unknown, explain in
Comments)
Yes (Yes)
Date of last clinical assessment: (Submit
appropriate ECOG Disease Evaluation Form)
Notice Of Progression
Has the patient developed a first progression that
has not been previously reported?
No (No)
Unknown (Unknown, explain in
Comments)
Yes (Yes)
Date of progression (If yes)
Site(s) of progression (If yes)
Did a physician make a formal diagnosis of
progressive disease? (If no or unknown, specify
basis of PD in Comments)
No (No)
Unknown (Unknown)
Yes (Yes)
Notice Of New Primary
Has a new primary cancer or MDS been
diagnosed that has not been previously reported?
No (No)
Yes (Yes)
Site(s) of new primary:
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Toxicity
Has the patient experienced (prior to diagnosis of
recurrence or second primary) any severe (Grade
>= 3) long term toxicity that has not been
previously reported? (NOTE: Do not report
toxicities occurring after start of non-protocol
therapy.)
No (No)
Yes (Yes)
Non-protocol Therapy
Has the patient received any non-protocol cancer
therapy prior to first progression (not previously
reported)?
No (No)
Yes (Yes)
Comments
Comments
Investigator Signature
Date
Ccrr Module For Long-term Follow-up
Form
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Toxicity Form NCT00057876
Toxicity Form NCT00057876
Gemcitabine With or Without Radiation Therapy in Treating
Patients With Pancreatic Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=A6250BD8-
CD4D-3C31-E034-0003BA0B1A09
All rights reserved. Please visit https://medical-data-
models.org/forms/10519
Toxicity Form NCT00057876
ECOG clinical trial administrative data
ECOG Protocol No.
ECOG Patient ID
Registration Step
Adverse Event Reporting From Date (M D Y)
Adverse Event Reporting To Date (M D Y)
Patient?s Name
Participating Group Protocol No.
Participating Group Patient ID
Institution/Affiliate
Are data amended? (If yes, please circle
amended items in red)
Yes
No
Adverse event
CTC Adverse Event Term
CTC Adverse Event Grade
CTC Adverse Event Attribution Code
Other CTC Adverse Event Term(s) not listed (Use
CTC terminology)
Comments
Comments
1 / 2
Investigator Signature
Date
Ccrr Module For Toxicity Form
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Toxicity Form NCT00057876
AMC-051 Interventions Form (RK5)
NCT00450320
AMC-051 Interventions Form (RK5) NCT00450320 
Sirolimus in Treating Patients With HIV-Related Kaposi's
Sarcoma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=2FF95103-
FD02-6437-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/10520
AMC-051 Interventions Form (RK5)
NCT00450320
Header Module
Visit number
Intervention assessment
Interventions for Oral Cavity Lesions
Local Anesthetic/analgesic (Local
anesthetic/analgesic)
Local Intervention To Ks Lesions (Local
intervention to KS lesions)
Other (Other)
Other, specify
Interventions for gastrointestinal (GI) lesions
Antiemetics (Antiemetics)
Blood Transfusion (Blood transfusions)
Other (Other)
Other, specify
Interventions for Pulmonary Lesions
Bronchodilators (Bronchodilators)
Cough Suppressant (Cough
suppressant)
Other (Other)
Oxygen (Oxygen)
Steroids (Steroids)
Other, specify
Interventions for Extremity Edema
Diuretic (Diuretics)
Other (Other)
Other, specify
Interventions for Periorbital Edema
Analgesics (Analgesics)
Local Therapy (Local therapy)
Other (Other)
Other, specify
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Interventions for Scrotal/Genital Edema
Analgesics (Analgesics)
Other (Other)
Other, specify
Interventions for Foot Kaposi's Sarcoma (KS)
Analgesics (Analgesics)
Other (Other)
Uses Cane, Wheelchair (Uses cane,
wheelchair)
Other, specify
Footer Module
Comments
2 / 2
AMC-051 Interventions Form (RK5) NCT00450320
Off-Treatment Form NCT00058149
Off-Treatment Form
NCT00058149 
A Phase III, Randomized Study of Gemcitabine (Fixed-
Dose Rate Infusion) and Oxaliplatin (NSC 266046) Versus
Gemcitabine (Fixed-Dose Rate Infusion) Versus
Gemcitabine (30-Minute Infusion) in Pancreatic Carcinoma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=A65D62C3-
9044-4286-E034-0003BA0B1A09
All rights reserved. Please visit https://medical-data-
models.org/forms/10521
Off-Treatment Form NCT00058149
ECOG clinical trial administrative data
ECOG Protocol No.
ECOG Patient ID
Registration Step
Patient?s Name
Participating Group Protocol No.
Participating Group Patient ID
Institution/Affiliate
Are data amended? (If yes, please circle
amended items in red)
Yes
No
Vital Status
Patient's Vital Status
Alive (Alive)
Dead (Dead)
Date of Last Contact or Death (M D Y)
Primary Cause of Death (if applicable)
Due To Other Cause, Specify (Due to
other diease)
Due To Protocol Treatment (Due to
protocol treatment)
Due To This Disease (Due to this
disease)
Unknown (Unknown)
Describe cause of death
1 / 2
Reason for treatment termination
Alternative Therapy (alternative therapy,
complete the ECOG Non-Protocol
Therapy Form)
death of patient on study (without
progressive disease) (death of patient on
study (without progressive disease))
Disease Progression, Relapse During
Active Treatment (disease progression,
relapse during active treatment)
error, specify (error, specify)
Other (other complicating disease,
specify)
Other, Specify (other, specify)
patient withdrawal or refusal (patient
withdrawal or refusal)
Toxicity/side Effects/complications
(toxicity/side effects/complications (either
physician directed or patient choice),
specify in Comments)
Treatment Completed Per Protocol
Criteria (treatment completed per
protocol criteria)
specify date of progression/relapse:
other complicating disease, specify
error, specify
other, specify
Date of last dose of protocol treatment (M D Y)
Comments
Comments
Investigator Signature
Date
Ccrr Module For Off-treatment Form
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Follow-Up Disease Evaluation Form
(RECIST) NCT00058149
Follow-Up Disease Evaluation Form (RECIST)
NCT00058149
A Phase III, Randomized Study of Gemcitabine (Fixed-
Dose Rate Infusion) and Oxaliplatin (NSC 266046) Versus
Gemcitabine (Fixed-Dose Rate Infusion) Versus
Gemcitabine (30-Minute Infusion) in Pancreatic Carcinoma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=A6868BEA-
ECA3-53E6-E034-0003BA0B1A09
All rights reserved. Please visit https://medical-data-
models.org/forms/10522
Follow-Up Disease Evaluation Form
(RECIST) NCT00058149
ECOG clinical trial administrative data
ECOG Protocol No.
ECOG Patient ID
Registration Step
Cycle Number (leave blank if off-treatment or
N/A)
Patient?s Name
Participating Group Protocol No.
Participating Group Patient ID
Institution/Affiliate
Are data amended? (If yes, please circle
amended items in red)
Yes
No
Target Lesions:
Lesion Number
Site of Lesion (Multiple new lesions within an
organ may be combined as a single site.)
Site Code
Bone (Bone)
Brain (Brain)
Breast (Breast)
Effusion/ascites (Effusion/Ascites)
Gi (GI)
1 / 4
Gu (GU)
Head & Neck (Head & Neck)
Liver (Liver)
Lung (Lung)
Nodes (Nodes)
Other (specify Site) (Other (specify site))
Skin (Skin)
Method of Evaluation
Bone Scan (Bone scan)
Chest X-ray (Chest X-Ray)
Clinical Examination (Clinical Exam)
Ct Scan (CT Scan (non-spiral))
Mri (MRI)
Not Evaluated (Not evaluated)
Other (Other (specify in Comments))
Spiral Ct Scan (Spiral CT)
Ultrasound (Ultrasound)
Date of Evaluation (M D Y)
Longest Diameter of Lesion(s) (cm)
For Identification: Document BASELINE Longest
Diameter of Lesion (cm)
Sum of longest diameters of all target lesions
(cm)
Nontarget Lesions:
Follow-Up Status of Lesions
Cr (CR)
Incompl. Resp./sd (incompl. resp./SD)
Pd (PD)
Cytology Result (For Site Code 04
effusion/ascites ONLY)
Negative (Negative)
Not Done (Not done)
Positive (Positive)
Unequivocal progressive disease in nontarget
lesions is based on: (please describe)
New Lesions
Was the appearance of any new lesions
documented?
No (no)
Yes (yes, record below)
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Response Of Target Lesions This
Reporting Period
Has the response of the target lesions changed,
OR has an unconfirmed response changed to a
confirmed response, since last report?
No (no, skip to Overall Response)
Yes (yes)
Response status at this assessment (target
lesions)
Complete Response (CR (confirmed or
unconfirmed))
Insufficient Evaluation (Insufficient
evaluation to determine response status
(unknown))
Progressive Disease Or Progression
(PD)
Partial Response (PR (confirmed or
unconfirmed))
Stable Disease (SD)
PR/CR first observed date (M D Y)
Progressive disease observed date (For PD:)
Overall Response Per Recist Criteria -
Target, Nontarget And New Lesions
Has the overall response changed, OR has an
unconfirmed response changed to a confirmed
response, since last report?
No (no, skip this section)
Yes (yes)
Overall response status at this assessment
Complete Response (CR (confirmed or
unconfirmed))
Null (Insufficient evaluation to determine
response status (unknown))
Progressive Disease (PD)
Partial Response (PR (confirmed or
unconfirmed))
Stable Disease (SD)
Has response been confirmed by second
assessment? (Confirmation of response: For
CR/PR, all assessments repeated >= 4 wks after
onset of CR/PR.)
Yes
No
Symptomatic Deterioration
Is there symptomatic deterioration of the patient's
health status requiring discontinuation of
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treatment (this reporting period)?
No (no)
Yes (yes, specify)
yes, specify
Symptomatic Deterioration Date (M D Y)
Comments
Comments
Investigator Signature
Date
Ccrr Module For Follow-up Disease
Evaluation Form (recist)
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On-Study Form NCT00057876
On-Study Form NCT00057876
Gemcitabine With or Without Radiation Therapy in Treating
Patients With Pancreatic Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=A670D091-
E97C-4BF1-E034-0003BA0B1A09
All rights reserved. Please visit https://medical-data-
models.org/forms/10523
On-Study Form NCT00057876
ECOG clinical trial administrative data
ECOG Protocol No.
ECOG Patient ID
Registration Step
Patient?s Name
Participating Group Protocol No.
Participating Group Patient ID
Institution/Affiliate
Are data amended?
Yes
No
Vital status
Performance status
2 (Ambulatory and capable of all selfcare
but unable to carry out any work
activities (K 50-60))
3 (Capable of only limited selfcare,
confined to bed or chair more than 50%
of waking hours (K 30-40))
4 (completely disabled (K 10-20))
0 (Fully active, able to carry on all pre-
disease performance without restriction
(Karnofsky 90-100))
1 (Restricted in physically strenuous
activity but ambulatory (K 70-80))
Weight loss in previous 6 months (choose one)
10 To <20% Of Body Weight (10 - <20%
of body weight)
5 To <10% Of Body Weight (5 - <10% of
body weight)
> Or = 20% Of Body Weight (greater
than or equal to 20% of body weight)
<5% Of Body Weight (less than 5% of
body weight)
1 / 4
Anatomic Description Of Disease
Date of initial diagnosis of primary tumor (first
positive biopsy date)
Primary site (choose one)
Body Of Pancreas (Body of pancreas)
Diffuse (Diffuse)
Head Of Pancreas (Head of pancreas)
Other, Specify (Other, specify)
Pancreas, Not Otherwise Specified
(Pancreas, NOS)
Tail Of Pancreas (Tail of pancreas)
Uncinate Process (Uncinate process)
Unknown (Unknown)
Other specify (primary site)
Histologic Type (choose one)
Acinar Cell Carcinoma (Acinar cell
carcinoma)
Adenosquamous Carcinoma
(Adenosquamous carcinoma)
Ductal Adenocarcinoma (Ductal
adenocarcinoma)
Mixed-type (ductal-endocrine Or Acinar-
endocrine) (Mixed type (ductal-endocrine
or acinar-endocrine)
Mucinous Adenocarcinoma (Mucinous
adenocarcinoma)
Mucinous Noncystic Carcinoma
(Mucinous noncystic carcinoma)
Neuroendocrine Carcinoma
(Neuroendocrine carcinoma)
Other, Specify (Other, specify)
Signet Ring Cell Carcinoma (Signet ring
cell carcinoma)
Small Cell Carcinoma (Small cell
carcinoma)
Undifferentiated (anaplastic) Carcinoma
(Undifferentiated (anaplastic) carcinoma)
Other, specify (histologic type)
Histologic grade (choose one)
Tumor Is Moderately Differentiated
According To Who Grading System
(Moderately differentiated)
Tumor Is Poorly Differentiated According
To Who Grading System (Poorly
differentiated)
Tumor Is Undifferentiated According To
Who Grading System (Undifferentiated)
Unknown (Unknown)
Tumor Is Well Differentiated According
To Who Grading System (Well
differentiated)
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Staging
Clinical T Stage
T0, According To Ajcc Criteria (0)
T1, According To Ajcc Criteria (1)
T2, According To Ajcc Criteria (2)
T3, According To Ajcc Criteria (3)
T4, According To Ajcc Criteria (4)
Tx, According To Ajcc Criteria (X)
Clinical N Stage
No Lymph Node Involvement According
To Ajcc Guidelines (0)
N1, According To Ajcc Criteria (1)
Lymph Node Involvement Cannot Be
Assessed According To Ajcc Guidelines
(use For Esophageal, Gastric, And
Pancreatic) (X)
Clinical M Stage
No Distant Metastases According To
Ajcc Guidelines (0)
Distant Metastases Present According
To Ajcc Guidelines (1)
Distant Metastases Presence Or
Absence Cannot Be Assessed According
To Ajcc Guidelines (X)
Site(s) Of Involvement
Primary tumor/Pancreas
No (No)
Unknown (Unknown)
Yes (Yes)
Regional lymph nodes
No (No)
Unknown (Unknown)
Yes (Yes)
Distant lymph nodes
No (No)
Unknown (Unknown)
Yes (Yes)
Adjacent viscera/vessels
No (No)
Unknown (Unknown)
Yes (Yes)
Liver
No (No)
Unknown (Unknown)
Yes (Yes)
Peritoneum
No (No)
Unknown (Unknown)
Yes (Yes)
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Lung
No (No)
Unknown (Unknown)
Yes (Yes)
Bone
No (No)
Unknown (Unknown)
Yes (Yes)
Other
Yes
No
Specify other disease involvement
Comments
Investigator Signature
Date
Ccrr Module For On-study Form
Other, specify
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Second Primary Form NCT00058149
Second Primary Form NCT00058149
A Phase III, Randomized Study of Gemcitabine (Fixed-
Dose Rate Infusion) and Oxaliplatin (NSC 266046) Versus
Gemcitabine (Fixed-Dose Rate Infusion) Versus
Gemcitabine (30-Minute Infusion) in Pancreatic Carcinoma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=A65D7C21-
CE65-42A1-E034-0003BA0B1A09
All rights reserved. Please visit https://medical-data-
models.org/forms/10524
Second Primary Form
NCT00058149
ECOG clinical trial administrative data
ECOG Protocol No. (If patient has been on other
therapeutic ECOG protocols, please list protocols
and patient ID numbers.)
ECOG Patient ID (If patient has been on other
therapeutic ECOG protocols, please list protocols
and patient ID numbers.)
Registration Step
Patient?s Name
Participating Group Protocol No.
Participating Group Patient ID
Institution/Affiliate
Are data amended? (If yes, please circle
amended items in red)
Yes
No
Secondary primary cancer
Date of Diagnosis of Second Primary Cancer
Site of Second Primary Cancer:
Include information on histologic subtype(s).
Please attach copies of any corroborating
pathology reports.
Briefly describe treatment planned or given for
the diagnosis of this second primary:
Comments
1 / 2
Comments
Investigator Signature
Date
Ccrr Module For Second Primary Form
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AMC-051 Missed Visit Form (F35)
NCT00450320
AMC-051 Missed Visit Form (F35) NCT00450320 
Sirolimus in Treating Patients With HIV-Related Kaposi's
Sarcoma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=2FDFA89A-
0842-6018-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/10525
AMC-051 Missed Visit Form (F35)
NCT00450320
Visit analysis
Visit number
Missed Visit Date
Reason patient missed visit
Health Reasons (Health reasons)
Other (Other)
Patient Could Not Get Off Work (Patient
could not get off work)
Patient Decided To Discontinue Study
(Patient decided to discontinue study)
Patient Experienced An Adverse Event
(Patient experienced an Adverse Event)
Patient Forgot (Patient forgot)
Patient Had Transportation Problems
(Patient had transportation problems)
Patient Unable To Obtain Dependent
Care (Patient unable to obtain dependent
care)
Patient Unhappy With Frequency Of
Visits (Patient unhappy with frequency of
visits)
Scheduling Difficulties (Scheduling
difficulties)
Other, specify
Next visit scheduled
Yes
No
Comments
Comments
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NCT00058149
Assessment Compliance Form NCT00058149
A Phase III, Randomized Study of Gemcitabine (Fixed-
Dose Rate Infusion) and Oxaliplatin (NSC 266046) Versus
Gemcitabine (Fixed-Dose Rate Infusion) Versus
Gemcitabine (30-Minute Infusion) in Pancreatic Carcinoma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=A6276EB5-
A819-3D71-E034-0003BA0B1A09
All rights reserved. Please visit https://medical-data-
models.org/forms/10526
Assessment Compliance Form
NCT00058149
ECOG clinical trial administrative data
Registration Step
Patient?s Name
ECOG Protocol No.
ECOG Protocol No.
ECOG Patient ID
ECOG Patient ID
Participating Group Protocol No.
Participating Group Patient ID
Institution/Affiliate
data amendment
Are data amended? (If yes, please circle
amended items in red)
No (No)
Yes (Yes)
Assessment Form No.
Date Assessment Scheduled (M D Y)
Was Assessment Form completed? (Choose
one:)
No (no)
Yes (yes)
Time point (Choose one:)
16 weeks (16 weeks)
1 / 4
8 weeks (8 weeks)
Baseline (baseline)
Other, Specify (other, specify)
other, specify
If Assessment Was Completed
Date Assessment Form completed (M D Y)
If Assessment Is Intended To Be Self-
administered
Was Assessment self-administered? (Choose
one:)
No (no)
Unknown (unknown)
Yes (yes)
If NO, how was patient assisted? (Choose one:)
Completed Independently By Another
Person (completed independently by
another person)
Patient Required Clarification Of
Questions Or Instructions (patient
required clarification of questions or
instructions)
Patient Required Other Assistance
(patient required other assistance)
Questions Were Read Aloud To Patient
(questions were read aloud to patient)
If NO, what was the reason? (Choose one:)
Disability, Please Specify (disability,
please specify)
Language Difficulty (questions Needed
To Be Translated), Specify Language
(language difficulty (questions needed to
be translated), specify language)
Literacy Difficulty (patient Could Not
Read Well Enough) (literacy difficulty
(patient could not read well enough))
Other, Please Specify (other, please
specify)
Telephone Interview (telephone
interview)
specify language
please specify
other, please specify
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If NO, who assisted or completed assessment?
(Choose one:)
Family (family)
Friend (friend)
Other, Please Specify (other, please
specify)
Staff (staff)
other, please specify
If Assessment Was Not Completed
Indicate primary reason why form was not
completed (Choose one:)
Assessment Not Required Per Protocol
Please Specify (assessment not required
per protocol please specify)
Other, Please Specify (other, please
specify)
Patient Did Not Show Up In Clinic/office
Please Specify (patient did not show up
in clinic/office please specify)
Patient Expired (patient expired)
Patient Not Given Form By Staff (patient
not given form by staff)
Patient Refusal (patient refusal)
Patient Too Ill (patient too ill)
Staff Thought Patient Too Ill (staff
thought patient too ill)
Staff Unavailable (staff unavailable)
Unable To Accommodate Disability Or
Language Needs Please Specify (unable
to accommodate disability or language
needs please specify)
unable to accommodate disability or language
needs please specify
patient did not show up in clinic/office please
specify
assessment not required per protocol please
specify
other, please specify
Comment
Comments
Investigator Signature
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Date
Ccrr Module For Assessment Compliance
Form
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Assessment Compliance Form
NCT00057876
Assessment Compliance Form NCT00057876
Gemcitabine With or Without Radiation Therapy in Treating
Patients With Pancreatic Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=A624C73B-
3251-3CE8-E034-0003BA0B1A09
All rights reserved. Please visit https://medical-data-
models.org/forms/10527
Assessment Compliance Form
NCT00057876
ECOG clinical trial administrative data
Registration Step
Patient?s Name
ECOG Protocol No.
ECOG Protocol No.
ECOG Patient ID
ECOG Patient ID
Participating Group Protocol No.
Participating Group Patient ID
Institution/Affiliate
data amendment
Are data amended? (If yes, please circle
amended items in red)
No (No)
Yes (Yes)
Assessment Form No.
Date Assessment Scheduled (M D Y)
Was Assessment Form completed? (Choose
one:)
No (no)
Yes (yes)
Time point (Choose one:)
9 Months From Baseline (9 months from
1 / 4
baseline)
Baseline (baseline)
Other, Specify (other, specify)
Week 16 (arm A), Week 15 (arm B)
(week 16 (arm A), week 15 (arm B))
Week 6 (week 6)
Time point, other specify
If Assessment Was Completed
Date Assessment Form completed (M D Y)
If Assessment Is Intended To Be Self-
administered
Was Assessment self-administered?
No (no)
Unknown (unknown)
Yes (yes)
If NO, how was patient assisted?
Completed Independently By Another
Person (completed independently by
another person)
Patient Required Clarification Of
Questions Or Instructions (patient
required clarification of questions or
instructions)
Patient Required Other Assistance
(patient required other assistance)
Questions Were Read Aloud To Patient
(questions were read aloud to patient)
If NO, what was the reason?
Disability, Please Specify (disability,
please specify)
Language Difficulty (questions Needed
To Be Translated), Specify Language
(language difficulty (questions needed to
be translated), specify language)
Literacy Difficulty (patient Could Not
Read Well Enough) (literacy difficulty
(patient could not read well enough))
Other, Please Specify (other, please
specify)
Telephone Interview (telephone
interview)
Language difficulty, specify language
disability, please specify
other, please specify (reason)
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If NO, who assisted or completed assessment?
Family (family)
Friend (friend)
Other, Please Specify (other, please
specify)
Staff (staff)
other, please specify (who assisted or completed
assessment)
If Assessment Was Not Completed
Indicate primary reason why form was not
completed
Assessment Not Required Per Protocol
Please Specify (assessment not required
per protocol please specify)
Other, Please Specify (other, please
specify)
Patient Did Not Show Up In Clinic/office
Please Specify (patient did not show up
in clinic/office please specify)
Patient Expired (patient expired)
Patient Not Given Form By Staff (patient
not given form by staff)
Patient Refusal (patient refusal)
Patient Too Ill (patient too ill)
Staff Thought Patient Too Ill (staff
thought patient too ill)
Staff Unavailable (staff unavailable)
Unable To Accommodate Disability Or
Language Needs Please Specify (unable
to accommodate disability or language
needs please specify)
unable to accommodate disability or language
needs please specify
patient did not show up in clinic/office please
specify
assessment not required per protocol please
specify
other, specify (primary reason form was not
completed)
Comment
Comments
Investigator Signature
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Date
Ccrr Module For Assessment Compliance
Form
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Pancreatic Symptom Index NCT00058149
Pancreatic Symptom Index NCT00058149
A Phase III, Randomized Study of Gemcitabine (Fixed-
Dose Rate Infusion) and Oxaliplatin (NSC 266046) Versus
Gemcitabine (Fixed-Dose Rate Infusion) Versus
Gemcitabine (30-Minute Infusion) in Pancreatic Carcinoma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=A65D73CD-
6E86-428A-E034-0003BA0B1A09
All rights reserved. Please visit https://medical-data-
models.org/forms/10529
Pancreatic Symptom Index
NCT00058149
ECOG clinical trial administrative data
Registration Step
Patient?s Name
ECOG Protocol No.
ECOG Protocol No.
ECOG Patient ID
ECOG Patient ID
Participating Group Protocol No.
Participating Group Patient ID
Institution/Affiliate
Date of assessment
Symptom assessment
I have a lack of energy
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have nausea
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have pain
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A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am losing weight
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have pain in my back
A Little (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I feel fatigued
A Little (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have discomfort or pain in my stomach area
A Little (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am bothered by jaundice or yellow color to my
skin
A Little (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am bothered by side effects of treatment
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have a good appetite
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I feel ill
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
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Somewhat (Somewhat)
Very Much (Very much)
I am able to do my usual activities
A Little (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
Ccrr Module For Pancreatic Symptom
Index
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Treatment Form NCT00057876
Treatment Form NCT00057876
Gemcitabine With or Without Radiation Therapy in Treating
Patients With Pancreatic Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=A626A4B2-
8496-3D7F-E034-0003BA0B1A09
All rights reserved. Please visit https://medical-data-
models.org/forms/10530
Treatment Form NCT00057876
ECOG clinical trial administrative data
ECOG Protocol No.
ECOG Patient ID
Registration Step
Patient?s Name
Participating Group Protocol No.
Participating Group Patient ID
Institution/Affiliate
Are data amended? (If yes, please circle
amended items in red)
Yes
No
Vital Status
Patient?s Vital Status
Alive (Alive)
Dead (Dead)
Date of Last Contact or Death (M D Y)
Cause of Death (if applicable)
Due To Other Cause (Due to other
cause)
Due To Protocol Treatment (Due to
protocol treatment)
Due To This Disease (Due to this
disease)
Unknown (Unknown)
Describe cause of death
Assigned Treatment Arm
1 / 3
Induction
Gemcitabine start date
Last date (any modality of) protocol therapy was
given
Total agent dose
RT Begin Date
RT End Date
RT Total Dose (cGy)
Were there any dose modifications or
additions/omissions to protocol treatment?
(Choose one:)
No (No)
Yes, both planned and unplanned (Yes,
both planned and unplanned)
(i.e., The Treatment Was Changed
According To Protocol Guidelines) (Yes,
planned)
(i.e., The Treatment Change Was Not
Part Of Protocol Guidelines) (Yes,
unplanned)
Were there any unscheduled interruptions in
radiation therapy?
No (No)
Yes, Due To Toxicity (Yes, due to toxicity)
Yes, For Other Reasons, Specify (Yes,
for other reasons, specify)
Yes, for other reasons, specify (RT Interruptions)
Consolidation
Total number of cycles given (consolidation only)
Was any non-protocol therapy given during
protocol treatment? (not previously reported)
Yes
No
Reason Treatment Ended (Choose one)
Alternative Therapy (Alternative therapy)
Death After Beginning Protocol Therapy
(Death after beginning protocol therapy)
Disease Progression, Relapse During
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Active Treatment (Disease progression,
relapse during active treatment)
Other (Other)
Patient Off-treatment For Other
Complicating Disease (Other
complicating disease)
Patient Withdrawal Or Refusal After
Beginning Protocol Therapy (Patient
withdrawal or refusal after beginning
protocol therapy)
Toxicity/side Effects/complications
(Toxicity/side effects/complications)
Treatment Completed Per Protocol
Criteria (Treatment completed per
protocol criteria)
Specify complicating disease (reason treatment
ended)
Specify other Reasons (reason treatment ended)
Comments
Comments
Investigator Signature
Date
Ccrr Module For Treatment Form
Agent start date
Agent end date
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AMC-063 Enrollment Form (ENR)
NCT01016730
AMC-063 Enrollment Form (ENR) NCT01016730 
Bortezomib in Treating Patients With Relapsed or
Refractory AIDS-Related Kaposi Sarcoma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=8163A333-
B756-35E0-E040-BB89AD435080
All rights reserved. Please visit https://medical-data-
models.org/forms/10531
AMC-063 Enrollment Form (ENR)
NCT01016730
Header module
Projected Start Date of Treatment (mm/dd/yyyy)
Inclusion/exclusion Criteria
Inclusion Criteria
Participant's Age (in Years) (Participant's
age (in years))
Exclusion Criteria
Exclusion Criteria
If The Participant Is Female, Is She
Pregnant Or Breast-feeding (If the
participant is female, is she pregnant or
breast-feeding)
Age (in years)
Date Informed Consent Signed (mm/dd/yyyy)
Consent For The Use Of Future
Specimens
Does the participant agree to have excess
specimens from this study stored for future AIDS-
related research (or leftover)
Yes
No
Comments
Comments
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On-Study Form NCT00058149
A Phase III, Randomized Study of Gemcitabine (Fixed-
Dose Rate Infusion) and Oxaliplatin (NSC 266046) Versus
Gemcitabine (Fixed-Dose Rate Infusion) Versus
Gemcitabine (30-Minute Infusion) in Pancreatic Carcinoma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=A65D6B91-
79C6-4288-E034-0003BA0B1A09
All rights reserved. Please visit https://medical-data-
models.org/forms/10532
On-Study Form NCT00058149
ECOG clinical trial administrative data
ECOG Protocol No.
ECOG Patient ID
Registration Step
Patient?s Name
Participating Group Protocol No.
Participating Group Patient ID
Institution/Affiliate
Are data amended?
Yes
No
Form No.
Patient vital status
Performance status
2 (Ambulatory and capable of all selfcare
but unable to carry out any work
activities (K 50-60))
3 (Capable of only limited selfcare,
confined to bed or chair more than 50%
of waking hours (K 30-40))
4 (completely disabled (K 10-20))
0 (Fully active, able to carry on all pre-
disease performance without restriction
(Karnofsky 90-100))
1 (Restricted in physically strenuous
activity but ambulatory (K 70-80))
Weight loss in previous 6 months (choose one)
10 To <20% Of Body Weight (10 - <20%
of body weight)
1 / 6
5 To <10% Of Body Weight (5 - <10% of
body weight)
> Or = 20% Of Body Weight (greater
than or equal to 20% of body weight)
<5% Of Body Weight (less than 5% of
body weight)
Disease Description
Date of initial diagnosis of primary tumor (first
positive biopsy date)
Date of most recent prior recurrence (if patient
has responded to prior treatment)
Primary site (choose one)
Body Of Pancreas (Body of pancreas)
Diffuse (Diffuse)
Head Of Pancreas (Head of pancreas)
Other, Specify (Other)
Tail Of Pancreas (Tail of pancreas)
Uncinate Process (Uncinate process)
Unknown (Unknown)
Primary Site, other specify
Histologic grade (choose one)
Tumor Is Moderately Differentiated
According To Who Grading System
(Moderately differentiated)
Tumor Is Poorly Differentiated According
To Who Grading System (Poorly
differentiated)
Tumor Is Undifferentiated According To
Who Grading System (Undifferentiated)
Unknown (Unknown)
Tumor Is Well Differentiated According
To Who Grading System (Well
differentiated)
Histologic Type (choose one)
Ductal Adenocarcinoma (Ductal
adenocarcinoma)
Mixed-type (ductal-endocrine Or Acinar-
endocrine) (Mixed ductal - endocrine
carcinoma)
Neuroendocrine Carcinoma
(Neuroendocrine carcinoma)
Other, Specify (Other)
Undifferentiated (anaplastic) Carcinoma
(Undifferentiated (anaplastic) carcinoma)
Other specify
Is there histologic proof of residual or metastatic
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malignant disease?
No (No)
Unknown (Unknown)
Yes (Yes)
Site(s) Of Involvement
Pancreas
Yes
No
Regional lymph nodes
Yes
No
Distant lymph nodes
Yes
No
Adjacent viscera/vessels
Yes
No
Liver
Yes
No
Peritoneum
Yes
No
Lung
Yes
No
Bone
Yes
No
Other
Yes
No
Other specify
Advanced Disease Status at Registration
Initial Diagnosis (Initial diagnosis)
Recurrence (Recurrence)
CEA (ng/dl)
CEA ULN
Date CEA obtained (M D Y)
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CA19-9 (U/ml)
Date CA19-9 obtained (M D Y)
Baseline Hematology/chemistry
WBC count (x1000), LLN
WBC count (x1000), Value
Date Obtained (M D Y)
Granulocyte count (AGC/ANC), Value
Platelets count (x1000), LLN
Platelets count (x1000), Value
Hemoglobin (g/dl), LLN
Hemoglobin (g/dl), Value
Albumin (g/dl), LLN
Albumin (g/dl), Value
Creatinine (mg/dl), ULN
Creatinine (mg/dl), Value
SGOT (AST) (U/L), ULN
SGOT (AST) (U/L), Value
Bilirubin (mg/dl), ULN
Bilirubin (mg/dl), Value
Prior Therapy
Prior radiation therapy? (Choose one:)
Yes
No
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Prior RT begin date (M D Y)
Prior RT end date (M D Y)
RT site:
Ccrr Module For On-study Form
Site(s) of Involvement, Other specify
Specify agents
Prior surgery
Yes
No
Specify prior thrombotic event
Both Thrombosis And Embolus (both
thrombosis and embolus)
Embolus (embolus)
Thrombosis (thrombosis)
Does the patient have a prior history of deep vein
thrombosis or pulmonary embolus?
Yes
No
Prior thrombosis?
Yes
No
Time frame of thrombosis
> 1 Year Prior To Diagnosis Of Primary
Cancer (> 1 year prior to diagnosis of
primary cancer)
Within 1 Year Of Diagnosis Of Primary
Cancer (within 1 year of diagnosis of
primary cancer)
Prior embolus?
Yes
No
Time frame of embolus
> 1 Year Prior To Diagnosis Of Primary
Cancer (> 1 year prior to diagnosis of
primary cancer)
Within 1 Year Of Diagnosis Of Primary
Cancer (within 1 year of diagnosis of
primary cancer)
date of prior surgery
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Date of initial diagnosis of unresectable locally
advanced disease
Date of initial diagnosis of metastatic disease
Is measurable disease present?
Yes
No
Is non-measurable disease present?
Yes
No
Prior adjuvant chemotherapy end date
Prior adjuvant chemotherapy begin date
Footer module
Comments
Investigator Signature
Date
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AMC-070 Enrollment Form (ENR)
NCT01057121
AMC-070 Enrollment Form (ENR) NCT01057121 
Lenalidomide in Treating Patients With AIDS-Related
Kaposi Sarcoma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=91E4BBD6-
6B89-9CA4-E040-BB89AD437D79
All rights reserved. Please visit https://medical-data-
models.org/forms/10533
AMC-070 Enrollment Form (ENR)
NCT01057121
Header Module
Projected Start Date of Treatment (mm/dd/yyyy)
Inclusion/exclusion Criteria
Inclusion Criteria
Participant's Age (in Years) (Participant's
age (in years))
Exclusion Criteria
Exclusion Criteria
Has There Been Any Evidence Of
Improvement In Ks In The 3 Months
Prior To Study Entry (Has there been
any evidence of improvement in KS in
the 3 months prior to study entry)
Age (in years)
Date Informed Consent Signed (mm/dd/yyyy)
Specimen Consent
Does the participant agree to have excess
specimens from this study stored for future AIDS-
related research (or leftover)
Yes
No
Comments
Comments
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Non-Protocol Therapy Form NCT00057876
Non-Protocol Therapy Form NCT00057876
Gemcitabine With or Without Radiation Therapy in Treating
Patients With Pancreatic Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=A6247E9A-
A888-3C19-E034-0003BA0B1A09
All rights reserved. Please visit https://medical-data-
models.org/forms/10534
Non-Protocol Therapy Form
NCT00057876
ECOG clinical trial administrative data
ECOG Protocol No.
ECOG Patient ID
Registration Step
Patient?s Name
Participating Group Protocol No.
Participating Group Patient ID
Institution/Affiliate
Are data amended? (If yes, please circle
amended items in red)
Yes
No
Non-protocol therapy
Date of FIRST non-protocol therapy (if given prior
to progression/relapse from protocol therapy:)
Type(s) of first non-protocol therapy (which
includes any cancer therapy that is not part of the
planned regimen.)
Non-protocol Chemotherapy (Non-
protocol Chemotherapy)
Non-protocol High Dose
Chemotherapy/stem Cell Transplant
(autologous Or Allogeneic) (Non-protocol
High Dose Chemotherapy/Stem Cell
Transplant (Autologous or Allogeneic))
Non-protocol Hormonal Therapy (Non-
protocol Hormonal Therapy)
Non-protocol Immunotherapy/biological
Response Modifiers (Non-protocol
Immunotherapy/Biological Response
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Modifiers)
Non-protocol Radiation Therapy (Non-
protocol Radiation Therapy)
Non-protocol Surgery (Non-protocol
Surgery)
Other Non-protocol Therapy (Other Non-
protocol Therapy)
Name of other non-protocol therapy:
Was the non-protocol therapy given for the
disease of this protocol? (NOTE: Treatment for a
second primary in the same organ site would not
be considered therapy for disease of this
protocol.)
No (No)
Unknown (Unknown)
Yes (Yes)
Comments
Comments
Investigator Signature
Date
Ccrr Module For Non-protocol Therapy
Form
Non-protocol chemotherapy
no (no)
unknown (unknown)
yes (yes)
Non-protocol hormonal therapy
no (no)
unknown (unknown)
yes (yes)
Non-protocol immunotherapy/biologic response
modifiers
no (no)
unknown (unknown)
yes (yes)
Other non-protocol therapy
no (no)
unknown (unknown)
yes (yes)
Non-protocol surgery
no (no)
unknown (unknown)
yes (yes)
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Non-protocol radiation therapy
no (no)
unknown (unknown)
yes (yes)
Non-protocol high dose chemotherapy/stem cell
transplant
no (no)
unknown (unknown)
yes (yes)
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AMC-048 Missed Visit Form (F35)
NCT00392834
AMC-048 Missed Visit Form (F35)
NCT00392834 
Rituximab and Combination Chemotherapy in Treating
Patients With Newly Diagnosed, HIV-Associated Burkitt's
Lymphoma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=32E1BD21-
3EC8-538C-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/10536
AMC-048 Missed Visit Form (F35)
NCT00392834
Header Module
Visit number
Missed Visit information
Missed Visit Date
Reason patient missed visit
Health Reasons (Health reasons)
Other (Other)
Patient Could Not Get Off Work (Patient
could not get off work)
Patient Decided To Discontinue Study
(Patient decided to discontinue study)
Patient Experienced An Adverse Event
(Patient experienced an Adverse Event)
Patient Forgot (Patient forgot)
Patient Had Transportation Problems
(Patient had transportation problems)
Patient Unable To Obtain Dependent
Care (Patient unable to obtain dependent
care)
Patient Unhappy With Frequency Of
Visits (Patient unhappy with frequency of
visits)
Scheduling Difficulties (Scheduling
difficulties)
Other, specify
Next visit scheduled
No (No)
Yes (Yes)
Comments
Comments
1 / 1
NCT00023829  TF Radiation Therapy Oncology Group Phase III Randomized
Study of Adjuvant Therapy for High Risk pT3NO Prostate Cancer Hormone Protocol
Treatment Summary Form
TF Radiation Therapy Oncology Group Phase III
Randomized Study of Adjuvant Therapy for High Risk
pT3NO Prostate Cancer Hormone Protocol Treatment
Summary Form
Adjuvant Radiation Therapy Plus Hormone Therapy
Compared With Radiation Therapy Alone in Treating
Patients With Stage II or Stage III Prostate Cancer
NCT00023829 
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=A46E13D3-
E2C2-2CC3-E034-080020C9C0E0
All rights reserved. Please visit https://medical-data-
models.org/forms/10537
NCT00023829  TF Radiation
Therapy Oncology Group Phase III
Randomized Study of Adjuvant
Therapy for High Risk pT3NO
Prostate Cancer Hormone Protocol
Treatment Summary Form
RTOG clinical trial administrative data
RTOG Study
Case #
Institution Name
Institution No.
Patient Name, Last
Patient Name, First
Amended Data
Chemotherapy status
Agent (AGENT NAME)
Casodex (Casodex)
Flutamide (Flutamide)
Lupron (Lupron)
Other (Other)
Suprafact (Suprafact)
Unknown Or Not Applicable (Unknown or
not applicable)
Zoladex (Zoladex)
(if other, specify) (agent)
Agent total cumulative dose
1 / 2
First Date above agent protocol therapy was
given
Last Date above agent protocol therapy was
given
Reason treatment ended (REASON
TREATMENT ENDED)
Alternative Therapy (Alternative therapy,
specify below)
Death On Study (Death on study)
Disease Progression, Relapse During
Active Treatment (Disease progression,
relapse during active treatment)
Other complicating disease, specify
below (Other complicating disease,
specify below)
Other, Specify (Other, specify below)
Patient Withdrawal Or Refusal After
Beginning Protocol Therapy (Patient
withdrawal or refusal after beginning
protocol therapy)
Patient Withdrawal Or Refusal Prior To
Beginning Protocol Therapy (Patient
withdrawal or refusal prior to beginning
protocol therapy)
Toxicity/side Effects/complications
(Toxicity/side effects/complications)
Treatment Completed Per Protocol
Criteria (Treatment completed per
protocol criteria)
Unknown or not applicable (Unknown or
not applicable)
(specify) (reason treatment ended)
Comment
Comments
Signature
Date
Ccrr Module For Tf Radiation Therapy
Oncology Group Phase Iii Randomized
Study Of Adjuvant Therapy For High Risk
Pt3no Prostate Cancer Hormone Protocol
Treatment Summary Form
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NCT00023829  TF Radiation Therapy Oncology Group Phase III Randomized
Study of Adjuvant Therapy for High Risk pT3NO Prostate Cancer Hormone Protocol
Treatment Summary Form
AMC-048 Lymphoma Disease Activity and
Measurement: L01, L02 NCT00392834
AMC-048 Lymphoma Disease Activity and Measurement:
L01, L02 NCT00392834 
Rituximab and Combination Chemotherapy in Treating
Patients With Newly Diagnosed, HIV-Associated Burkitt's
Lymphoma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=32E1BD21-
3D6C-538C-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/10538
AMC-048 Lymphoma Disease
Activity and Measurement: L01, L02
NCT00392834
Header Module
Visit number
Reporting Period
Baseline (Baseline)
Follow-up (Follow-up)
On Treatment (On treatment)
Nodal Involvement Evaluation
Is there lymph node involvement
Yes
No
Lymph Node Type
Celiac Axis/retrocrural/upper Para-aortic
(Celiac Axis/Retrocrular/Upper Para-
Aortic)
Cervical (Cervical)
Epitrochlear/brachial
(Epitrochlear/Brachial)
Hilar (Hilar)
Infraclavicular/axillary/pectoral
(Infraclavicular/Axiliary/Pectoral)
Inguinal/femoral/iliac
(inguinal/femoral/iliac)
Lower Para-aortic (Lower Para-Aortic)
Mediastinal (Mediastinal)
Mesenteric (Mesenteric)
Other (Other Nodal)
Porta Hepatis (Porta Hepatis)
Pre-auricular (Pre-Auricular)
Spleen (Spleen)
Splenic Hilar (Splenic Hilar)
Supraclavicular (Supraclavicular)
Waldeyer's Ring (Waldeyer's Ring)
Other specify (If)
Dimension 1
Dimension 2
1 / 3
Method of Evaluation
Biopsy (Biopsy)
Bone Scan (Bone Scan)
Ct Scan (CT scan)
Gallium Scan (Gallium scan)
IVP (IVP)
Lymphangiogram (Lymphangiogram)
Mri Scan (MRI scan)
Other (Other)
Palpation (Palpation)
Ultrasound (Ultrasound)
X-ray (X-Ray)
Other, specify (If)
Complete response
Yes
No
Is measurable disease present?
Yes
No
Has the patient been diagnosed with a new
progression?
Yes
No
Evaluation documented
Yes
No
Lesion Assessment
Improvement (improvement)
No Change (no change)
Not Evaluated (Not evaluated)
Progression - Increase (progression -
increase)
Extra Nodal Involvement Evaluation
Extranodal extension
Yes
No
Site of Involvement
Ascites (Ascites)
Bone (Bone)
Bone Marrow (Bone Marrow)
Brain (Brain)
Epidural (Epidural)
Gastrointestinal Tract (GI Tract)
Kidney (Kidney)
Liver (Liver)
Lung (Lung)
Meninges (Meninges)
Other Specify (Other)
Pleura (Pleura)
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AMC-048 Lymphoma Disease Activity and Measurement: L01, L02
NCT00392834
Skin (Skin)
Thyroid (Thyroid)
Other, specify (If)
3 / 3
AMC-048 Lymphoma Disease Activity and Measurement: L01, L02
NCT00392834
AMC-047 Lymphoma Disease Activity and
Measurement Form (L02) NCT00389818
AMC-047 Lymphoma Disease Activity and Measurement
Form (L02) NCT00389818 
Combination Chemotherapy and Rituximab in Treating
Patients With Newly Diagnosed AIDS-Related B-Cell Non-
Hodgkin's Lymphoma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=7EC8C28B-
31A2-BDAA-E040-BB89AD43228F
All rights reserved. Please visit https://medical-data-
models.org/forms/10539
AMC-047 Lymphoma Disease
Activity and Measurement Form
(L02) NCT00389818
Header Module
Visit Number
Extra Nodal Involvement Evaluation
Extranodal extension (If Yes, continue. Otherwise,
stop)
No (NO)
Yes (YES)
Site of Involvement
Ascites (Ascites)
Bone (Bone)
Bone Marrow (Bone Marrow)
Brain (Brain)
Epidural (Epidural)
Gastrointestinal Tract (GI Tract)
Kidney (Kidney)
Liver (Liver)
Lung (Lung)
Meninges (Meninges)
Other Specify (Other)
Pleura (Pleura)
Skin (Skin)
Thyroid (Thyroid)
Other, specify
Dimension 1 (cm)
Dimension 2 (cm)
Method of Evaluation
Biopsy (Biopsy)
Bone Scan (Bone Scan)
Ct Scan (CT scan)
Gallium Scan (Gallium scan)
IVP (IVP)
Lymphangiogram (Lymphangiogram)
Mri Scan (MRI scan)
Other (Other)
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Palpation (Palpation)
Pet Scan (PET scan)
Pet/ct Scan (PET/CT scan)
Ultrasound (Ultrasound)
X-ray (X-Ray)
Other, specify
Complete response (For "On treatment" and
"Follow up" cycles only)
No (No)
Yes (Yes)
Is measurable disease present? (For "On
treatment" and "Follow up" cycles only)
No (No)
Yes (Yes)
Has the patient been diagnosed with a new
progression? (For "On treatment" and "Follow up"
cycles only)
No (No)
Yes (Yes)
Evaluation documented (For "On treatment" and
"Follow up" cycles only)
No (No)
Yes (Yes)
Lesion Assessment (For "On treatment" and
"Follow up" cycles only)
Improvement (improvement)
No Change (no change)
Not Evaluated (Not evaluated)
Progression - Increase (progression -
increase)
Comments
Comments
2 / 2
AMC-047 Lymphoma Disease Activity and Measurement Form (L02)
NCT00389818
AMC-075B Enrollment Form (ENR)
NCT01193842
AMC-075B Enrollment Form (ENR)NCT01193842
Vorinostat and Combination Chemotherapy With Rituximab
in Treating Patients With Previously Untreated HIV-Related
Diffuse Large B-Cell Non-Hodgkin Lymphoma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=9B26D8A0-
BAA8-E8FB-E040-BB89AD4335F8
All rights reserved. Please visit https://medical-data-
models.org/forms/10541
AMC-075B Enrollment Form (ENR)
NCT01193842
Header Module
Projected Start Date of Treatment (mm/dd/yyyy)
Treating Investigator (The protocol chair may
contact the investigator with questions regarding
the participant enrollment and follow up)
Institution contact phone number (This is the
phone number where the investigator can be
reached directly)
Inclusion/exclusion Criteria
Inclusion Criteria
Participant's Age (in Years) (Participant's
age (in years))
Exclusion Criteria
Exclusion Criteria
Is The Participant Hepatitis B Core
Antibody Positive (Is the participant
Hepatitis B core antibody positive)
Age (in years)
Date Informed Consent Signed (mm/dd/yyyy)
Enrollment Stratification Data
Modified Ann Arbor Stage
I (I)
Ii (II)
Iii (III)
Iv (IV)
Is the serum LDH elevated
Yes
No
1 / 2
Ki-67 Staining Index Score
< 80% (< 80%)
>= 80% (>= 80%)
Inconclusive (Inconclusive)
Hematopoietic Diagnosis
Activated B-cell-like Diffuse Large B-cell
Lymphoma (ABC)
Germinal Center B-cell-like Diffuse Large
B-cell Lymphoma (GCB)
IPI Stratification Score (Participant)
An International Prognostic Index Score
Of 0 Or 1 (0 or 1)
An International Prognostic Index Score
Of 2 Or 3 (2 or 3)
Specimen Consent
Does the participant agree to have excess
specimens from this study stored for future AIDS-
related research (or leftover)
Yes
No
Comments
Comments
2 / 2
AMC-075B Enrollment Form (ENR) NCT01193842
AMC-064 Enrollment Form (ENR)
NCT00981097
AMC-064 Enrollment Form (ENR) NCT00981097
Study of Blood and Tissue Samples From Patients With
Aggressive Non-Hodgkin B-Cell Lymphoma or Hodgkin
Lymphoma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=743022C4-
7EF4-DCE7-E040-BB89AD430CD9
All rights reserved. Please visit https://medical-data-
models.org/forms/10542
AMC-064 Enrollment Form (ENR)
NCT00981097
Header Module
Projected Start Date of Treatment (mm/dd/yyyy)
Inclusion/exclusion Criteria
Inclusion Criteria
Date Informed Consent Obtained (Date
informed consent obtained)
Does The Participant Have A Diagnosis
Of Untreated Aggressive B-cell
Lymphoma, Including Diffuse Large B
Cell/immunoblastic, Burkitt's, Or
Hodgkin's Lymphoma (Does the
participant have a diagnosis of untreated
aggressive B-cell lymphoma, including
diffuse large B cell/immunoblastic,
Burkitt's, or Hodgkin's lymphoma)
Does The Participant Have Diagnostic
Material From Fresh Frozen Tissue Or
Formalin-fixed Paraffin Embedded
Tissue Available (Does the participant
have diagnostic material from fresh
frozen tissue or formalin-fixed paraffin
embedded tissue available)
Does The Participant Have Serologic
Documentation Of Hiv Infection At Any
Time Prior To Study Entry, As Evidenced
By Any Federally Approved Hiv Test
(Does the participant have serologic
documentation of HIV infection at any
time prior to study entry, as evidenced by
any federally approved HIV test)
Does The Participant Have The Ability
And Willingness To Give Written
Informed Consent (Does the participant
have the ability and willingness to give
written informed consent)
Indicate Lymphoma Type: Diffuse Large
B-cell/immunoblastic Lymphoma,
Burkitt's Lymphoma, Or Hodgkin's
Lymphoma (Indicate lymphoma type:
Diffuse large B-cell/immunoblastic
lymphoma, Burkitt's lymphoma, or
Hodgkin's lymphoma)
Is The Participant Willing To Undergo A
Repeat Biopsy (Is the participant willing
1 / 2
to undergo a repeat biopsy)
Is The Participant, In The Opinion Of The
Investigator, Capable Of Complying With
This Protocol (Is the participant, in the
opinion of the Investigator, capable of
complying with this protocol)
Participant's Age (in Years) (Participant's
age (in years))
Exclusion Criteria
Age (in years)
Date Informed Consent Signed (mm/dd/yyyy)
Consent For The Use Of Future
Specimens
Does the participant agree to have excess
specimens from this study stored for future AIDS-
related research (or leftover)
No (No)
Yes (Yes)
Comments
Comments
2 / 2
AMC-064 Enrollment Form (ENR) NCT00981097
NCT00389818  AMC-047 Lymphoma Disease
Activity and Measurement Forms: L01, L02, LYR
AMC-047 Lymphoma Disease Activity and Measurement
Forms: L01, L02, LYR
Combination Chemotherapy and Rituximab in Treating
Patients With Newly Diagnosed AIDS-Related B-Cell Non-
Hodgkin's Lymphoma NCT00389818 
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=1F798C79-
4557-16B7-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/10543
NCT00389818  AMC-047 Lymphoma
Disease Activity and Measurement
Forms: L01, L02, LYR
Header Module
Visit number
Reporting Period
Baseline (Baseline)
Follow-up (Follow-up)
On Treatment (On treatment)
Nodal Involvement Evaluation
Is there lymph node involvement
Yes
No
Lymph Node Type
Celiac Axis/retrocrural/upper Para-aortic
(Celiac Axis/Retrocrular/Upper Para-
Aortic)
Cervical (Cervical)
Epitrochlear/brachial
(Epitrochlear/Brachial)
Hilar (Hilar)
Infraclavicular/axillary/pectoral
(Infraclavicular/Axiliary/Pectoral)
Inguinal/femoral/iliac
(inguinal/femoral/iliac)
Lower Para-aortic (Lower Para-Aortic)
Mediastinal (Mediastinal)
Mesenteric (Mesenteric)
Other (Other Nodal)
Porta Hepatis (Porta Hepatis)
Pre-auricular (Pre-Auricular)
Spleen (Spleen)
Splenic Hilar (Splenic Hilar)
Supraclavicular (Supraclavicular)
Waldeyer's Ring (Waldeyer's Ring)
Other specify (If)
Dimension 1
Dimension 2
1 / 4
Method of Evaluation
Biopsy (Biopsy)
Bone Scan (Bone Scan)
Ct Scan (CT scan)
Gallium Scan (Gallium scan)
IVP (IVP)
Lymphangiogram (Lymphangiogram)
Mri Scan (MRI scan)
Other (Other)
Palpation (Palpation)
Ultrasound (Ultrasound)
X-ray (X-Ray)
Other, specify (If)
Complete response
Yes
No
Is measurable disease present?
Yes
No
Has the patient been diagnosed with a new
progression?
Yes
No
Evaluation documented
Yes
No
Lesion Assessment
Improvement (improvement)
No Change (no change)
Not Evaluated (Not evaluated)
Progression - Increase (progression -
increase)
Extra Nodal Involvement Evaluation
Extranodal extension
Yes
No
Site of Involvement
Ascites (Ascites)
Bone (Bone)
Bone Marrow (Bone Marrow)
Brain (Brain)
Epidural (Epidural)
Gastrointestinal Tract (GI Tract)
Kidney (Kidney)
Liver (Liver)
Lung (Lung)
Meninges (Meninges)
Other Specify (Other)
Pleura (Pleura)
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NCT00389818  AMC-047 Lymphoma Disease Activity and Measurement
Forms: L01, L02, LYR
Skin (Skin)
Thyroid (Thyroid)
Other, specify (If)
Extra Nodal Involvement Evaluation
Date of Last Clinical Assessment
Extra Nodal Involvement Evaluation
Is complete response first observed
Yes
No
Complete Response (CR) First Observed Date (If
yes)
Is complete response confirmed (CR)
Yes
No
Complete Response Confirmed Date
Extra Nodal Involvement Evaluation
Is complete response uncertain first observed
Yes
No
Complete Response uncertain (CRu) First
Observed Date
Is complete response, uncertain, confirmed
(CRU)
Yes
No
Complete Response Uncertain (CRu) Confirmed
Date
Extra Nodal Involvement Evaluation
Is partial response first observed
Yes
No
Partial Response (PR) First Observed Date
Is partial response confirmed
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NCT00389818  AMC-047 Lymphoma Disease Activity and Measurement
Forms: L01, L02, LYR
Yes
No
Partial Response Confirmed Date
Extra Nodal Involvement Evaluation
Progressive Disease First Observed Date
Please indicate the site of progression
New Site Only (New site only)
New Site Plus Original Site (New site
plus original site)
Original Site Only (Original site only)
Central Nervous System Progression
Yes
No
CNS - leptomeninges
Yes
No
Brain - parenchymal
Yes
No
Comments
4 / 4
NCT00389818  AMC-047 Lymphoma Disease Activity and Measurement
Forms: L01, L02, LYR
AMC-047 Baseline Lymphoma Disease Activity
and Assessment Form (LAA) NCT00389818
AMC-047 Baseline Lymphoma Disease Activity and
Assessment Form (LAA) NCT00389818 
Combination Chemotherapy and Rituximab in Treating
Patients With Newly Diagnosed AIDS-Related B-Cell Non-
Hodgkin's Lymphoma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=1F7A7C0A-
E97E-13FB-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/10544
AMC-047 Baseline Lymphoma
Disease Activity and Assessment
Form (LAA) NCT00389818
Header Module
Visit Number
Lymphoma Disease Activity and
Assessment
Modified Ann Arbor Stage
I (I)
Ie (IE)
Ii (II)
Iie (IIE)
Iii (III)
Iiie (IIIE)
Iiie+s (IIIE+S)
Iiis (IIIS)
Iv (IV)
Recurring, drenching night sweats during the
previous month
No (No)
Yes (Yes)
Unexplained, persistent fever >38 degrees C (or
>100 degrees F) in the previous month
No (No)
Yes (Yes)
Unexplained weight loss >10% of body weight in
the previous 6 months
No (No)
Yes (Yes)
Hematopoietic Diagnosis
Burkitt Lymphoma/leukemia (Burkitt
lymphoma/leukemia)
Diffuse Large B-cell Lymphoma (Diffuse
large B-cell lymphoma)
Kshv+ Plasmablastic Lymphoma-lymph
Node (KSHV+ plasmablastic lymphoma-
lymph node)
Other (Other)
Plasma Lymphoma Of Oral Cavity
(Plasma lymphoma of oral cavity)
Polymorphic B Cell Lymphoma-ptld Type
1 / 3
(Polymorphic B cell lymphoma-PTLD
type)
Primary Effusion Lymphoma (Primary
effusion lymphoma)
Other specify
If diffuse large B-cell lymphoma, specify
morphologic type
Centroblastic (Centroblastic)
Immunoblastic (Immunoblastic)
If Burkitt lymphoma/leukemia, specify
morphologic type
Atypical (Atypical)
Classical (Classical)
Plasmacytoid Differentiation
(Plasmacytoid differentiation)
Date of Initial Pathologic Diagnosis
Method of Evaluation
Biopsy (Biopsy)
Cytology (Cytology)
Other (Other)
Other Specify
Is the participant >60 years of age
No (No)
Yes (Yes)
Does the participant have Stage III or IV disease
No (No)
Yes (Yes)
Is the serum LDH elevated
No (No)
Yes (Yes)
Is the ECOG Performance Status 2, 3, or 4
No (No)
Yes (Yes)
Does the participant have two or more extranodal
disease sites
No (No)
Yes (Yes)
International Prognostic Index
0 (0)
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
IPI Risk Category
2 / 3
AMC-047 Baseline Lymphoma Disease Activity and Assessment Form
(LAA) NCT00389818
High Risk (High risk)
High-intermediate Risk (High-
intermediate risk)
Low Risk (Low risk)
Low-intermediate Risk (Low-intermediate
risk)
Comments
3 / 3
AMC-047 Baseline Lymphoma Disease Activity and Assessment Form
(LAA) NCT00389818
AMC-047 Off-Study Summary Form (F50)
NCT00389818
AMC-047 Off-Study Summary Form (F50) NCT00389818 
Combination Chemotherapy and Rituximab in Treating
Patients With Newly Diagnosed AIDS-Related B-Cell Non-
Hodgkin's Lymphoma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=1E9A6C98-
9FDE-6832-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/10545
AMC-047 Off-Study Summary Form
(F50) NCT00389818
Ccrr Module For Off Study Summary -
Rf50
Off Study Date (mm/dd/yyyy)
Off Study Reason (select the primary reason)
Adverse Event/side Effects/complications
(Adverse Event/Side
Effects/Complications)
Death (Death)
Other (Other)
Lost To Follow-up (Patient lost to follow-
up)
Patient Refused Follow-up (Patient
refused follow-up)
Protocol-defined Follow-up Completed
(Protocol-defined follow-up completed)
Other, specify
Comments
1 / 1
AMC-075Z Enrollment Form (ENR)
NCT01193842
AMC-075Z Enrollment Form (ENR) NCT01193842
Vorinostat and Combination Chemotherapy With Rituximab
in Treating Patients With Previously Untreated HIV-Related
Diffuse Large B-Cell Non-Hodgkin Lymphoma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=9B26D8A0-
BB1E-E8FB-E040-BB89AD4335F8
All rights reserved. Please visit https://medical-data-
models.org/forms/10546
AMC-075Z Enrollment Form (ENR)
NCT01193842
Header Module
Projected Start Date of Treatment (mm/dd/yyyy)
Treating Investigator (The protocol chair may
contact the investigator with questions regarding
the participant enrollment and follow up)
Institution contact phone number (This is the
phone number where the investigator can be
reached directly)
Inclusion/exclusion Criteria
Inclusion Criteria
Participant's Age (in Years) (Participant's
age (in years))
Exclusion Criteria
Exclusion Criteria
Is The Participant Hepatitis B Core
Antibody Positive (Is the participant
Hepatitis B core antibody positive)
Age (in years)
Date Informed Consent Signed (mm/dd/yyyy)
Enrollment Stratification Data
Modified Ann Arbor Stage
I (I)
Ii (II)
Iii (III)
Iv (IV)
Is the serum LDH elevated
Yes
No
1 / 2
Ki-67 Staining Index Score
< 80% (< 80%)
>= 80% (>= 80%)
Inconclusive (Inconclusive)
Hematopoietic Diagnosis
Activated B-cell-like Diffuse Large B-cell
Lymphoma (ABC)
Germinal Center B-cell-like Diffuse Large
B-cell Lymphoma (GCB)
IPI Stratification Score (Participant)
An International Prognostic Index Score
Of 0 Or 1 (0 or 1)
An International Prognostic Index Score
Of 2 Or 3 (2 or 3)
Specimen Consent
Does the participant agree to have excess
specimens from this study stored for future AIDS-
related research (or leftover)
Yes
No
Comments
Comments
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AMC-075Z Enrollment Form (ENR) NCT01193842
AMC-048 Off Study Summary (F50)
NCT00392834
AMC-048 Off Study Summary (F50) NCT00392834 
Rituximab and Combination Chemotherapy in Treating
Patients With Newly Diagnosed, HIV-Associated Burkitt's
Lymphoma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=32E1BD21-
3F26-538C-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/10547
AMC-048 Off Study Summary (F50)
NCT00392834
Ccrr Module For Off Study Summary -
Rf50
Off Study Date
Off Study Reason (select the primary reason)
Adverse Event/side Effects/complications
(Adverse Event/Side
Effects/Complications)
Death (Death)
Other (Other)
Lost To Follow-up (Patient lost to follow-
up)
Patient Refused Follow-up (Patient
refused follow-up)
Protocol-defined Follow-up Completed
(Protocol-defined follow-up completed)
Other, specify
Comments
1 / 1
NCT00392834  AMC-048 Baseline Lymphoma
Disease Activity and Assessment Form (LAA)
NCT00392834  AMC-048 Baseline Lymphoma Disease
Activity and Assessment Form (LAA)
Rituximab and Combination Chemotherapy in Treating
Patients With Newly Diagnosed, HIV-Associated Burkitt's
Lymphoma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=32E18FA2-
327E-4AF2-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/10548
NCT00392834  AMC-048 Baseline
Lymphoma Disease Activity and
Assessment Form (LAA)
Header Module
Visit Number
Lymphoma Disease Activity and
Assessment
Modified Ann Arbor Stage
I (I)
Ie (IE)
Ii (II)
Iie (IIE)
Iii (III)
Iiie (IIIE)
Iiie+s (IIIE+S)
Iiis (IIIS)
Iv (IV)
Recurring, drenching night sweats during the
previous month
No (No)
Yes (Yes)
Unexplained, persistent fever >38 degrees C (or
>100 degrees F) in the previous month
No (No)
Yes (Yes)
Unexplained weight loss >10% of body weight in
the previous 6 months
No (No)
Yes (Yes)
Hematopoietic Diagnosis
Burkitt Lymphoma/leukemia (Burkitt
lymphoma/leukemia)
Diffuse Large B-cell Lymphoma (Diffuse
large B-cell lymphoma)
Kshv+ Plasmablastic Lymphoma-lymph
Node (KSHV+ plasmablastic lymphoma-
lymph node)
Other (Other)
Plasma Lymphoma Of Oral Cavity
(Plasma lymphoma of oral cavity)
Polymorphic B Cell Lymphoma-ptld Type
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(Polymorphic B cell lymphoma-PTLD
type)
Primary Effusion Lymphoma (Primary
effusion lymphoma)
Other specify
If diffuse large B-cell lymphoma, specify
morphologic type
Centroblastic (Centroblastic)
Immunoblastic (Immunoblastic)
If Burkitt lymphoma/leukemia, specify
morphologic type
Atypical (Atypical)
Classical (Classical)
Plasmacytoid Differentiation
(Plasmacytoid differentiation)
Date of Initial Pathologic Diagnosis
Method of Evaluation
Biopsy (Biopsy)
Cytology (Cytology)
Other (Other)
Other Specify
Comments
Comments
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NCT00392834  AMC-048 Baseline Lymphoma Disease Activity and
Assessment Form (LAA)
AMC-048 Quantitative Immunoglobulins
Form (QIM) NCT00392834
AMC-048 Quantitative Immunoglobulins Form (QIM)
NCT00392834 
Rituximab and Combination Chemotherapy in Treating
Patients With Newly Diagnosed, HIV-Associated Burkitt's
Lymphoma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=32E1BD21-
4052-538C-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/10549
AMC-048 Quantitative
Immunoglobulins Form (QIM)
NCT00392834
Header Module
Visit number
Sequence number
Quantitative Immunoglobulins
IgG
IgM
IgA
Comments
Comments
1 / 1
AMC-053 Enrollment Form (ENR)
NCT00598169
AMC-053 Enrollment Form (ENR) NCT00598169
Bortezomib, Ifosfamide, Carboplatin, and Etoposide, With
or Without Rituximab, in Treating Patients With Relapsed or
Refractory AIDS-Related Non-Hodgkin Lymphoma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=8B73192C-
C22B-46D4-E040-BB89AD433800
All rights reserved. Please visit https://medical-data-
models.org/forms/10550
AMC-053 Enrollment Form (ENR)
NCT00598169
Header Module
Principal Investigator
Projected Start Date of Treatment (mm/dd/yyyy)
Inclusion/exclusion Criteria
Inclusion Criteria
Participant's Age (in Years) (Participant's
age (in years))
Exclusion Criteria
Exclusion Criteria
Does The Participant Have An Active
Hepatitis B Infection (Does the
participant have an active hepatitis B
infection)
Age (in years)
Karnofsky Performance Status
Date Informed Consent Signed (mm/dd/yyyy)
Comments
Comments
1 / 1
AMC-047 Lymphoma Disease Activity and
Measurement Form (L01) NCT00389818
AMC-047 Lymphoma Disease Activity and Measurement
Form (L01)NCT00389818 
Combination Chemotherapy and Rituximab in Treating
Patients With Newly Diagnosed AIDS-Related B-Cell Non-
Hodgkin's Lymphoma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=7EC8C28B-
3044-BDAA-E040-BB89AD43228F
All rights reserved. Please visit https://medical-data-
models.org/forms/10551
AMC-047 Lymphoma Disease
Activity and Measurement Form
(L01) NCT00389818
Header Module
Visit Number
Reporting Period
Baseline (Baseline)
Follow-up (Follow-up)
On Treatment (On treatment)
Nodal Involvement Evaluation
Is there lymph node involvement
Yes
No
Lymph Node Type
Celiac Axis/retrocrural/upper Para-aortic
(Celiac Axis/Retrocrular/Upper Para-
Aortic)
Cervical (Cervical)
Epitrochlear/brachial
(Epitrochlear/Brachial)
Hilar (Hilar)
Infraclavicular/axillary/pectoral
(Infraclavicular/Axiliary/Pectoral)
Inguinal/femoral/iliac
(inguinal/femoral/iliac)
Lower Para-aortic (Lower Para-Aortic)
Mediastinal (Mediastinal)
Mesenteric (Mesenteric)
Other (Other Nodal)
Porta Hepatis (Porta Hepatis)
Pre-auricular (Pre-Auricular)
Spleen (Spleen)
Splenic Hilar (Splenic Hilar)
Supraclavicular (Supraclavicular)
Waldeyer's Ring (Waldeyer's Ring)
Other specify
Dimension 1 (cm)
Dimension 2 (cm)
1 / 2
Method of Evaluation
Biopsy (Biopsy)
Bone Scan (Bone Scan)
Ct Scan (CT scan)
Gallium Scan (Gallium scan)
IVP (IVP)
Lymphangiogram (Lymphangiogram)
Mri Scan (MRI scan)
Other (Other)
Palpation (Palpation)
Pet Scan (PET scan)
Pet/ct Scan (PET/CT scan)
Ultrasound (Ultrasound)
X-ray (X-Ray)
Other, specify
Complete response (For "On treatment" and
"Follow up" cycles only)
Yes
No
Is measurable disease present? (For "On
treatment" and "Follow up" cycles only)
Yes
No
Has the patient been diagnosed with a new
progression? (For "On treatment" and "Follow up"
cycles only)
Yes
No
Evaluation documented (For "On treatment" and
"Follow up" cycles only)
Yes
No
Lesion Assessment (For "On treatment" and
"Follow up" cycles only)
Improvement (improvement)
No Change (no change)
Not Evaluated (Not evaluated)
Progression - Increase (progression -
increase)
Comments
Comments
2 / 2
AMC-047 Lymphoma Disease Activity and Measurement Form (L01)
NCT00389818
NCT00023829  FF Radiation Therapy Oncology Group Phase III Randomized
Study of Adjuvant Therapy for High Risk pT3NO Prostate Cancer Long Term
Follow-up Form
NCT00023829 FF  Radiation Therapy Oncology Group
Phase III Randomized Study of Adjuvant Therapy for High
Risk pT3NO Prostate Cancer Long Term Follow-up Form
Adjuvant Radiation Therapy Plus Hormone Therapy
Compared With Radiation Therapy Alone in Treating
Patients With Stage II or Stage III Prostate Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=A56DBAD2-
8C43-0FEF-E034-080020C9C0E0
All rights reserved. Please visit https://medical-data-
models.org/forms/10552
NCT00023829  FF Radiation
Therapy Oncology Group Phase III
Randomized Study of Adjuvant
Therapy for High Risk pT3NO
Prostate Cancer Long Term Follow-
up Form
RTOG clinical trial administrative data
RTOG Study
Case #
Institution
Institution No.
Patient Name, Last
Patient Name, First (1)
Amended Data
Medical history
PATIENT'S VITAL STATUS (2)
Alive (Alive)
Dead (Dead)
Unknown or not applicable (Unknown or
not applicable)
DATE OF LAST CONTACT OR DEATH (3)
CAUSE OF DEATH (IF DEAD)
Due to other cause, specify (Due to other
cause, specify)
Due To Protocol Treatment (Due to
protocol treatment)
Due To This Disease (Due to this
disease)
Unknown (Unknown)
1 / 4
Due to other cause, specify (cause of death) (4)
HAS THE PATIENT HAD A DOCUMENTED
CLINICAL ASSESSMENT FOR PROSTATE
CANCER SINCE SUBMISSION OF THE
PREVIOUS FOLLOWUP FORM?
No (No)
Unknown (Unknown)
Yes (Yes)
DATE OF LAST CLINICAL ASSESSMENT (5
PROSTATE: PSA MEASUREMENTS)
Follow-up PSA Value(s)
Date of PSA Assessment(s) (6)
HAS CLINICAL DISEASE STATUS local,
regional, distant CHANGED SINCE THE LAST
REPORT? (7 HAS A NEW PRIMARY CANCER
OR MDS MYELODYSPLASTIC SYNDROME
BEEN DIAGNOSED THAT HAS NOT BEEN
PREVIOUSLY REPORTED?)
No (No)
Unknown (Unknown)
Yes (Yes)
New Primary Site
Aml/mds (AML/MDS)
Bcc (BCC)
Bladder (Bladder)
Brain (Brain)
Colorectal (Colorectal)
Esophageal (Esophageal)
Gastric (Gastric)
Liver (Liver)
Lung (Lung)
Melanoma (Melanoma)
Nhl (NHL)
None (None)
Other Hematologic, Specify (Other
Hematologic, specify)
Other Solid, Specify (Other solid,
specify)
Pancreatic (Pancreatic)
Renal (Renal)
Squamous-skin (Squamous-Skin)
Unknown Primary (Unknown primary)
New Primary Cancer Date (Specify in comments
new primary site)
RENAL/GENITOURINARY TOXICITY ADVERSE
EVENT REPORTS (AER) (Use CTC 2.0 to code
severity)
No (No)
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NCT00023829  FF Radiation Therapy Oncology Group Phase III Randomized
Study of Adjuvant Therapy for High Risk pT3NO Prostate Cancer Long Term
Follow-up Form
Unknown (Unknown)
Yes (Yes)
URINARY INCONTINENCE, Severity Grade (0-3)
0 (0)
1 (1)
2 (2)
3 (3)
URINARY INCONTINENCE, Attribution (see
table below)
Combined modality (Hormone, RT)
(Combined modality (Hormone, RT))
Hormones (Hormones)
Other cause, specify (Other cause,
specify)
Radiotherapy only (Radiotherapy only)
Tumor and Rx (Tumor and Rx)
Unknown (Unknown)
Specify if other cause (urinary incontinence,
attribution)
URINARY INCONTINENCE, AER Begin Date
URINARY FREQUENCY/URGENCY, Severity
Grade (0-3)
0 (0)
1 (1)
2 (2)
3 (3)
URINARY FREQUENCY/URGENCY, Attribution
(see table below)
Combined modality (Hormone, RT)
(Combined modality (Hormone, RT))
Hormones (Hormones)
Other cause, specify (Other cause,
specify)
Radiotherapy only (Radiotherapy only)
Tumor and Rx (Tumor and Rx)
Unknown (Unknown)
Specify if other cause (urinary frequency/urgency,
attribution)
URINARY FREQUENCY/URGENCY, AER Begin
Date
ERECTILE IMPOTENCE, Severity Grade (0-3)
0 (0)
1 (1)
2 (2)
3 (3)
ERECTILE IMPOTENCE, Attribution (see table
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Study of Adjuvant Therapy for High Risk pT3NO Prostate Cancer Long Term
Follow-up Form
below)
Combined modality (Hormone, RT)
(Combined modality (Hormone, RT))
Hormones (Hormones)
Other cause, specify (Other cause,
specify)
Radiotherapy only (Radiotherapy only)
Tumor and Rx (Tumor and Rx)
Unknown (Unknown)
Specify if other cause (erectile impotence,
attribution)
ERECTILE IMPOTENCE, AER Begin Date (9)
NEW OR CONTINUING TOXICITY (>= Severity
Grade 3) SINCE THE LAST REPORT? (10)
No (No)
Unknown (Unknown)
Yes (Yes)
DID THE PATIENT RECEIVE ANY NON-
PROTOCOL PROSTATE CANCER THERAPY
SINCE THE LAST FOLLOW-UP?
No (No)
Unknown (Unknown)
Yes (Yes)
COMMENTS
SIGNATURE
DATE
Ccrr Module For Ff Radiation Therapy
Oncology Group Phase Iii Randomized
Study Of Adjuvant Therapy For High Risk
Pt3no Prostate Cancer Long Term Follow-
up Form
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NCT00023829  FF Radiation Therapy Oncology Group Phase III Randomized
Study of Adjuvant Therapy for High Risk pT3NO Prostate Cancer Long Term
Follow-up Form
Acute Leukemia Disease Assessment Form
NCT00049517
Acute Leukemia Disease Assessment Form NCT00049517
Combination Chemotherapy With or Without Monoclonal
Antibody Therapy Followed by Stem Cell Transplant in
Treating Patients With Acute Myeloid Leukemia
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=A727ECDC-
BAED-2F88-E034-0003BA0B1A09
All rights reserved. Please visit https://medical-data-
models.org/forms/10553
Acute Leukemia Disease
Assessment Form NCT00049517
ECOG clinical trial administrative data
Registration Step
Cycle Number
Patient?s Name
ECOG Protocol No.
ECOG Protocol No.
ECOG Patient ID
ECOG Patient ID
Participating Group Protocol No.
Participating Group Patient ID
Institution/Affiliate
Acute Leukemia Disease assessment
Are data amended? (If yes, please circle
amended items in red)
No (No)
Yes (Yes)
Date of bone marrow biopsy
Marrow blasts (%)
Marrow cellularity (%)
Are all cell lines maturing?
No (no)
1 / 2
Yes (yes)
Are auer rods present?
Auer Rods Absent From Bone Marrow
(absent)
Auer Rods Present In Bone Marrow
(present)
Is there extramedullary disease
No (no)
Yes (yes)
yes, specify sites (extramedullary disease)
Did the patient achieve a complete response
according to clinical/hematologic criteria during
this reporting period?
Null (no)
Null (unknown)
Null (yes)
Date of complete response
Comments
Investigator Signature
Date
Ccrr Module For Acute Leukemia Disease
Assessment Form
specify sites of extramedullary disease
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AMC-047 Missed Visit Form (F35)
NCT00389818
AMC-047 Missed Visit Form (F35) NCT00389818 
Combination Chemotherapy and Rituximab in Treating
Patients With Newly Diagnosed AIDS-Related B-Cell Non-
Hodgkin's Lymphoma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=21D86192-
7394-22F4-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/10554
AMC-047 Missed Visit Form (F35)
NCT00389818
Missed Visit information
Visit number
Missed Visit Date (mm/dd/yyyy)
Reason patient missed visit
Health Reasons (Health reasons)
Other (Other)
Patient Could Not Get Off Work (Patient
could not get off work)
Patient Decided To Discontinue Study
(Patient decided to discontinue study)
Patient Experienced An Adverse Event
(Patient experienced an Adverse Event)
Patient Forgot (Patient forgot)
Patient Had Transportation Problems
(Patient had transportation problems)
Patient Unable To Obtain Dependent
Care (Patient unable to obtain dependent
care)
Patient Unhappy With Frequency Of
Visits (Patient unhappy with frequency of
visits)
Scheduling Difficulties (Scheduling
difficulties)
Other, specify
Next visit scheduled
Yes
No
Comments
Comments
1 / 1
AMC-075A Enrollment Form (ENR)
NCT01193842
AMC-075A Enrollment Form (ENR)NCT01193842
Vorinostat and Combination Chemotherapy With Rituximab
in Treating Patients With Previously Untreated HIV-Related
Diffuse Large B-Cell Non-Hodgkin Lymphoma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=9A5E5C94-
089E-8CEB-E040-BB89AD430BF6
All rights reserved. Please visit https://medical-data-
models.org/forms/10555
AMC-075A Enrollment Form (ENR)
NCT01193842
Header Module
Projected Start Date of Treatment (mm/dd/yyyy)
Treating Investigator (The protocol chair may
contact the investigator with questions regarding
the participant enrollment and follow up)
Institution contact phone number (This is the
phone number where the investigator can be
reached directly)
Inclusion/exclusion Criteria
Inclusion Criteria
Participant's Age (in Years) (Participant's
age (in years))
Exclusion Criteria
Exclusion Criteria
Is The Participant Hepatitis B Core
Antibody Positive (Is the participant
Hepatitis B core antibody positive)
Age (in years)
Date Informed Consent Signed (mm/dd/yyyy)
Enrollment Stratification Data
Modified Ann Arbor Stage
I (I)
Ii (II)
Iii (III)
Iv (IV)
Is the serum LDH elevated
Yes
No
1 / 2
Ki-67 Staining Index Score
< 80% (< 80%)
>= 80% (>= 80%)
Inconclusive (Inconclusive)
Hematopoietic Diagnosis
Activated B-cell-like Diffuse Large B-cell
Lymphoma (ABC)
Germinal Center B-cell-like Diffuse Large
B-cell Lymphoma (GCB)
IPI Stratification Score (Participant)
An International Prognostic Index Score
Of 0 Or 1 (0 or 1)
An International Prognostic Index Score
Of 2 Or 3 (2 or 3)
Specimen Consent
Does the participant agree to have excess
specimens from this study stored for future AIDS-
related research (or leftover)
Yes
No
Comments
Comments
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AMC-075A Enrollment Form (ENR) NCT01193842
T1 Radiation Therapy Oncology Group Phase III Randomized Study of
Intermediate Risk Prostate Cancer Radiotherapy Form NCT00063882
T1 Radiation Therapy Oncology Group Phase III
Randomized Study of Intermediate Risk Prostate Cancer
Radiotherapy Form NCT00063882 
Interstitial Brachytherapy With or Without External-Beam
Radiation Therapy in Treating Patients With Prostate
Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=AA89543F-
5C0D-58C5-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/10557
T1 Radiation Therapy Oncology
Group Phase III Randomized Study
of Intermediate Risk Prostate Cancer
Radiotherapy Form NCT00063882
Header Module
If this is a revised or corrected form, indicate by
checking box
RTOG clinical trial administrative data
RTOG Study
Case #
Institution Name
Institution No.
Patient's Name
Patient's I.D. No.
RADIOTHERAPY documentation
RADIATION THERAPY START DATE (External
Beam)
RADIATION THERAPY END DATE (External
Beam)
TOTAL DOSE (Gy)
WERE THERE ANY UNSCHEDULED
INTERRUPTIONS IN RADIATION THERAPY
(External Beam)
No (No)
Yes, For Other Reasons, Specify (Yes,
1 / 4
due to other reason)
Yes, Due To Toxicity (Yes, due to toxicity)
Specify RT interruption reason
REASON EXTERNAL RADIATION THERAPY
TREATMENT ENDED
Alternative Therapy (Alternative therapy,
specify)
Death On Study (Death on study)
Disease Progression, Relapse During
Active Treatment (Disease progression,
relapse during active treatment)
Other (Other complicating disease,
specify)
Other, Specify (Other, specify)
Patient Withdrawal Or Refusal After
Beginning Protocol Therapy (Patient
withdrawal or refusal after beginning
protocol therapy)
Patient Withdrawal Or Refusal Prior To
Beginning Protocol Therapy (Patient
withdrawal or refusal prior to beginning
protocol therapy)
Toxicity/side Effects/complications
(Toxicity/side effects/complications)
Treatment Completed Per Protocol
Criteria (Treatment completed per
protocol criteria)
Alternative therapy, specify
Other complicating disease, specify
Other, specify
DID TREATMENT INCLUDE IMRT
Yes
No
IF BRACHYTHERAPY NOT UTILIZED,
PROVIDE REASON
Alternative Rx Given, Specify Rx
(Alternative Rx given, specify Rx)
Death (Death)
Inadequate To Treat Extent Of Disease
(Inadequate to treat extent of disease)
Md Preference (MD preference)
Na Dose Administered Within Protocol
Specifications (NA Dose administered
within protocol specifications)
Not Technically Feasible (Not technically
feasible)
Other Reason, Specify (Other reason,
specify)
Patient Refused (Patient refused)
Progression Or Relapse (Progression or
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T1 Radiation Therapy Oncology Group Phase III Randomized Study of
Intermediate Risk Prostate Cancer Radiotherapy Form NCT00063882
relapse)
Toxicity Or Treatment Reaction (Toxicity
or treatment reaction)
specify Rx (alternative Rx given)
Other reason, specify
ISOTOPE TYPE
I-125 (I-125)
Other, Specify (Other, specify)
Pd-103 (Pd-103)
DATE OF PRE-IMPLANT TRUS STUDY
DATE OF IMPLANT
DATE OF POST-IMPLANT CT (BASIC
DOSIMETRY INFORMATION)
AVERAGE ACTIVITY PER SEED AS
MEASURED BY INSTITUTION (Activity)
Date
MIDPOINT APPARENT ACTIVITY STATED BY
THE VENDOR (Activity)
NUMBER OF SEEDS USED
NUMBER OF NEEDLES USED
SEED LOSS (were seeds expelled within the 3
weeks of implant? If yes, report details in
Comments section)
No (No)
Unknown (Unknown)
Yes (Yes)
WERE DOSE VOLUME HISTOGRAMS DONE
No (No)
Unknown (Unknown)
Yes (Yes)
WAS AN INDWELLING URINARY CATHETER
INSERTED SINCE IMPLANT
No (No)
Unknown (Unknown)
Yes (Yes)
DATE INSERTED (Provide estimate if exact date
unknown)
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T1 Radiation Therapy Oncology Group Phase III Randomized Study of
Intermediate Risk Prostate Cancer Radiotherapy Form NCT00063882
DATE REMOVED (Provide estimate if exact date
unknown)
Footer module
COMMENTS
Signature
Date
Ccrr Module For T1 Radiation Therapy
Oncology Group Phase Iii Randomized
Study Of Intermediate Risk Prostate
Cancer Radiotherapy Form
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T1 Radiation Therapy Oncology Group Phase III Randomized Study of
Intermediate Risk Prostate Cancer Radiotherapy Form NCT00063882
AMC-047 Quantitative Immunoglobulins
Form (QIM) NCT00389818
AMC-047 Quantitative Immunoglobulins Form (QIM)
NCT00389818 
Combination Chemotherapy and Rituximab in Treating
Patients With Newly Diagnosed AIDS-Related B-Cell Non-
Hodgkin's Lymphoma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=1E998A2F-
A921-6C68-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/10558
AMC-047 Quantitative
Immunoglobulins Form (QIM)
NCT00389818
Header Module
Visit number
Sequence number
Quantitative Immunoglobulins
IgG
IgM
IgA
Comments
Comments
1 / 1
Radiation Therapy Oncology Group Phase III Lung
Prophylactic Cranial RT MMSE NCT00048997
Radiation Therapy Oncology Group Phase III Lung
Prophylactic Cranial RT MMSE NCT00048997 
Radiation Therapy in Preventing CNS Metastases in
Patients With Non-Small Cell Lung Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=A5D1AB4A-
E01B-3595-E034-080020C9C0E0
All rights reserved. Please visit https://medical-data-
models.org/forms/10560
Radiation Therapy Oncology Group
Phase III Lung Prophylactic Cranial
RT MMSE NCT00048997
Header Module
Case #
Institution
Institution No.
Patient's Name
Patient's I.D. No.
If this is a revised or corrected form, indicate by
checking box.
Neurocognitive Evaluation
Calender Due Date
Date of examination
Date of 1st protocol Rx
What is the year
What is the season
What is the date
What is the day
What is the month
What is the, Score
1 / 3
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
Where are we, state
Where are we, country
Where are we, town
Where are we, hospital
Where are we, floor
Where are we, Score
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
Registration Score
1 (1)
2 (2)
3 (3)
Attention and Calculation Score
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
Recall Score (Language)
1 (1)
2 (2)
3 (3)
Point to the following objects and have patient
name each: a pencil and a watch
1 (1)
2 (2)
Have the patient repeat the following: "No ifs,
ands or buts"
1 (1)
Have the patient follow a 3 step command: "Take
a paper in your right hand, fold it in half, and put it
on the floor."
1 (1)
2 (2)
3 (3)
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Radiation Therapy Oncology Group Phase III Lung Prophylactic Cranial
RT MMSE NCT00048997
Show the patient the statement "Close your eyes
and him read and obey what it says.
1 (1)
Have the patient write a sentence with a subject
and a verb
1 (1)
Have the patient copy the figure
1 (1)
MMSE Total Score
Assess level of consciousness along a continuum
Alert (alert)
Coma (coma)
Drowsy (drowsy)
Stupor (stupor)
If an evaluation is not done, provide the time point
missed and the reason.  If none of the tests are
done, provide the reason.
Name/signature of person performing exam
Date
Ccrr Module For Radiation Therapy
Oncology Group Phase Iii Lung
Prophylactic Cranial Rt Mmse
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RT MMSE NCT00048997
Radiation Therapy Oncology Group Follow-up Form Phase
III Lung Prophylactic Cranial RT 10363 NCT00048997
Radiation Therapy Oncology Group Follow-up Form Phase
III Lung Prophylactic Cranial RT 10363
Radiation Therapy in Preventing CNS Metastases in
Patients With Non-Small Cell Lung Cancer NCT00048997 
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=9EC372A6-
6F06-05D5-E034-080020C9C0E0
All rights reserved. Please visit https://medical-data-
models.org/forms/10561
Radiation Therapy Oncology Group
Follow-up Form Phase III Lung
Prophylactic Cranial RT 10363
NCT00048997
Header Module
Case #
Institution
Institution #
Patient Name
Patient ID #
Patient medical history
If this is a revised or corrected form, indicate by
checking box
DATE OF LAST CLINICAL ASSESSMENT
PATIENT'S VITAL STATUS
Alive (Alive)
Dead (Dead)
Lost (Lost)
Unknown (Unknown)
LAST CONTACT DATE / DEATH DATE
CAUSE OF DEATH
(explain in COMMENTS, requires a
grade 5 toxicity code) ((explain in
COMMENTS, requires a grade 5 toxicity
code))
(whether local, regional, or distant)
((whether local, regional, or distant))
Other cause, specify (Other cause,
specify)
Related to or probably related to a
second primary tumor (Related to or
probably related to a second primary
1 / 4
tumor)
Related to or probably related to
complications of other treatment
(Related to or probably related to
complications of other treatment)
Related to or probably related to
complications of protocol treatment
(Related to or probably related to
complications of protocol treatment)
Related to or probably related to the
cancer under study (Related to or
probably related to the cancer under
study)
Unknown (Unknown)
Cause of death, other specify
PERFORMANCE STATUS (ZUBROD)
HAS THE PATIENT DEVELOPED A FIRST
PROGRESSION NOT PREVIOUSLY
REPORTED? (Complete Q6 A and B)
Yes
No
Sites of progression, lung
No (No)
Unknown/not Evaluated (Unknown/not
evaluated)
Yes (Yes)
Sites of progression, Lymph nodes (distant)
No (No)
Unknown/not Evaluated (Unknown/not
evaluated)
Yes (Yes)
Sites of progression, pleural
No (No)
Unknown/not Evaluated (Unknown/not
evaluated)
Yes (Yes)
Sites of progression, adrenals
No (No)
Unknown/not Evaluated (Unknown/not
evaluated)
Yes (Yes)
Sites of progression, liver
No (No)
Unknown/not Evaluated (Unknown/not
evaluated)
Yes (Yes)
Sites of progression, bone
No (No)
Unknown/not Evaluated (Unknown/not
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Prophylactic Cranial RT 10363 NCT00048997
evaluated)
Yes (Yes)
Sites of progression, CNS (Brain)
No (No)
Unknown/not Evaluated (Unknown/not
evaluated)
Yes (Yes)
CNS (Brain) Date
Sites of progression, Other Specify
No (No)
Unknown/not Evaluated (Unknown/not
evaluated)
Yes (Yes)
Site of progression, other specify
PROGRESSION ASSESSMENT
HAS A NEW PRIMARY OR MDS BEEN
DIAGNOSED THAT HAS NOT BEEN
PREVIOUSLY REPORTED?
No (No)
Unknown (Unknown)
Yes (Yes)
NEW PRIMARY SITE
NEW PRIMARY HISTOLOGIC TYPE
DATE OF DIAGNOSIS
IS THE PATIENT RECEIVING ANY NON-
PROTOCOL CANCER THERAPY NOT
PREVIOUSLY REPORTED?
No (No)
Unknown (Unknown)
Yes (Yes)
Non-Protocol RT
No (No)
Unknown (Unknown)
Yes (Yes)
Date of first non-protocol therapy
Non-Protocol Surgery
No (No)
Unknown (Unknown)
Yes (Yes)
Non-Protocol Chemotherapy
3 / 4
Radiation Therapy Oncology Group Follow-up Form Phase III Lung
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No (No)
Unknown (Unknown)
Yes (Yes)
Other Non-Protocol therapy
No (No)
Unknown (Unknown)
Yes (Yes)
Specify other
ANY CONTINUING OR NEW TREATMENT
TOXICITIES RELATED TO PCI ONLY?
No (No)
Unknown (Unknown)
Yes (Yes)
LATE TREATMENT TOXICITY (occurred >90
days from start of XRT)
SEVERITY GRADE
TOXICITY
#1 Toxicity Other, specify (#1 Toxicity
Other, specify)
#2 Toxicity Other, specify (#2 Toxicity
Other, specify)
Brain (Brain)
Eye (Eye)
Skin (within the irradiated field) (Skin
(within the irradiated field))
Subcutaneous tissue (Subcutaneous
tissue)
#2 Toxicity Other, specify
DATE OF 1ST  OCCURRENCE OF GRADE=>3
Comments
Signature of Person Completing This Form
Date
Comments
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Radiation Therapy Oncology Group Follow-up Form Phase III Lung
Prophylactic Cranial RT 10363 NCT00048997
FOLLOW-UP TUMOR ASSESSMENT
FORM NCT00020709
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NSCLC
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=9CB6D1D2-
A82E-34E4-E034-080020C9C0E0
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FOLLOW-UP TUMOR
ASSESSMENT FORM
NCT00020709
SWOG clinical trial administrative data
SWOG Patient ID
SWOG Study No.
Registration Step
Patient Initials (L, F,M)
Institution / Affiliate
Physician
Group Name (Groups other than SWOG )
Study No. (Groups other than SWOG )
Pt. ID (Groups other than SWOG )
Target lesion status
Target Lesion Site Number
L1 (L1)
L10 (L10)
L2 (L2)
L3 (L3)
L4 (L4)
L5 (L5)
L6 (L6)
L7 (L7)
L8 (L8)
L9 (L9)
Target Lesion Site
RT No Prog.
1 / 3
Longest Diameter (cm )
Target Lesion Assessment Type
CA-125 assay (CA-125 assay)
Colposcopy (Colposcopy)
CT scan (CT scan)
Cytologic confirmation (Cytologic
confirmation)
Endoscopy (Endoscopy)
Histologic confirmation (Histologic
confirmation)
MRI scan (MRI scan)
Other (Other)
Palpation (Palpation)
PET scan (PET scan)
Plain film/X-ray with contrast (Plain
film/X-ray with contrast)
Plain film/X-ray without contrast (Plain
film/X-ray without contrast)
PSA (PSA)
Radioisotope scan (Radioisotope scan)
Ultrasound (Ultrasound)
Visualization (Visualization)
Target Lesion Assessment Date
Non-Target Lesion Site Number
S1 (S1)
S2 (S2)
S3 (S3)
S4 (S4)
S5 (S5)
Non-Target Lesion Site
Extent
Non-Target Lesion Assessment Type
CA-125 assay (CA-125 assay)
Colposcopy (Colposcopy)
CT scan (CT scan)
Cytologic confirmation (Cytologic
confirmation)
Endoscopy (Endoscopy)
Histologic confirmation (Histologic
confirmation)
MRI scan (MRI scan)
Other (Other)
Palpation (Palpation)
PET scan (PET scan)
Plain film/X-ray with contrast (Plain
film/X-ray with contrast)
Plain film/X-ray without contrast (Plain
film/X-ray without contrast)
PSA (PSA)
Radioisotope scan (Radioisotope scan)
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Ultrasound (Ultrasound)
Visualization (Visualization)
Non-Target Lesion Assessment Date
New Lesion Site Number
S1 (S1)
S2 (S2)
New Lesion Site (Specify Site)
New Lesion Site Assessment Type
CA-125 assay (CA-125 assay)
Colposcopy (Colposcopy)
CT scan (CT scan)
Cytologic confirmation (Cytologic
confirmation)
Endoscopy (Endoscopy)
Histologic confirmation (Histologic
confirmation)
MRI scan (MRI scan)
Other (Other)
Palpation (Palpation)
PET scan (PET scan)
Plain film/X-ray with contrast (Plain
film/X-ray with contrast)
Plain film/X-ray without contrast (Plain
film/X-ray without contrast)
PSA (PSA)
Radioisotope scan (Radioisotope scan)
Ultrasound (Ultrasound)
Visualization (Visualization)
New Lesion Site Assessment Date
Notes
Notes
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Radiation Therapy Oncology Group Phase III Lung Prophylactic
Cranial RT Neurocognitive Evaluation Summary Form NCT00048997
Radiation Therapy Oncology Group Phase III Lung
Prophylactic Cranial RT Neurocognitive Evaluation
Summary Form NCT00048997 
Radiation Therapy in Preventing CNS Metastases in
Patients With Non-Small Cell Lung Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=A5472EED-
0175-07F2-E034-080020C9C0E0
All rights reserved. Please visit https://medical-data-
models.org/forms/10564
Radiation Therapy Oncology Group
Phase III Lung Prophylactic Cranial
RT Neurocognitive Evaluation
Summary Form NCT00048997
Header Module
Case #
Institution
Institution No.
Patient's Name
Patient's I.D. No.
If this is a revised or corrected form, indicate by
checking box. (Time Point of Assessment)
Neurocognitive Evaluation
Baseline/Prert
Month During Follow-up (HVLT Administration)
1 (1)
12 (12)
18 (18)
24 (24)
3 (3)
30 (30)
36 (36)
48 (48)
6 (6)
Code reason test not done
Other Reason Test Omitted Specify
(Other reason test omitted specify)
Reason Unknown (Reason unknown)
Test Omitted Due To
Institution/investigator Error (Test omitted
due to institution/investigator error)
Test Omitted, Patient Refused (Test
omitted, patient refused)
1 / 2
Test Omitted, Patient Unable To
Comprehend Instructions (Test omitted,
patient unable to comprehend
instructions)
Other reason test omitted specify (HVLT Results)
Trial #1, #2, #3 Recall, Total Score
Trial #4 Recognition, Total Score
Time test completed
Trial #5 Delayed Recall, Start Time
Trial #5 Delayed Recall, Total Score
Comments
Signature
Date
Ccrr Module For Radiation Therapy
Oncology Group Phase Iii Lung
Prophylactic Cranial Rt Neurocognitive
Evaluation Summary Form
2 / 2
Radiation Therapy Oncology Group Phase III Lung Prophylactic Cranial
RT Neurocognitive Evaluation Summary Form NCT00048997
Radiation Therapy Oncology Group Initial Follow-up Form
Phase III Lung Prophylactic Cranial RT NCT00048997
Radiation Therapy Oncology Group Initial Follow-up Form
Phase III Lung Prophylactic Cranial RT
Radiation Therapy in Preventing CNS Metastases in
Patients With Non-Small Cell Lung Cancer NCT00048997 
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=9EC372A6-
7094-05D5-E034-080020C9C0E0
All rights reserved. Please visit https://medical-data-
models.org/forms/10565
Radiation Therapy Oncology Group
Initial Follow-up Form Phase III Lung
Prophylactic Cranial RT
NCT00048997
Header Module
Case #
Institution
Institution #
Patient Name
Patient ID #
Medical history
DATE OF LAST CLINICAL ASSESSMENT
PATIENT'S VITAL STATUS
Alive (Alive)
Dead (Dead)
Lost (Lost)
Unknown (Unknown)
LAST CONTACT DATE / DEATH DATE
CAUSE OF DEATH
(explain in COMMENTS, requires a
grade 5 toxicity code) ((explain in
COMMENTS, requires a grade 5 toxicity
code))
(whether local, regional, or distant)
((whether local, regional, or distant))
Other cause, specify (Other cause,
specify)
Related to or probably related to a
second primary tumor (Related to or
probably related to a second primary
tumor)
Related to or probably related to
complications of other treatment
(Related to or probably related to
1 / 5
complications of other treatment)
Related to or probably related to
complications of protocol treatment
(Related to or probably related to
complications of protocol treatment)
Related to or probably related to the
cancer under study (Related to or
probably related to the cancer under
study)
Unknown (Unknown)
Cause of death, other specify
PERFORMANCE STATUS (ZUBROD)
HAS THE PATIENT DEVELOPED A FIRST
PROGRESSION NOT PREVIOUSLY
REPORTED? (Complete Q6 A and B)
Yes
No
Sites of progression, lung
No (No)
Unknown/not Evaluated (Unknown/not
evaluated)
Yes (Yes)
Sites of progression, Lymph nodes (distant)
No (No)
Unknown/not Evaluated (Unknown/not
evaluated)
Yes (Yes)
Sites of progression, pleural
No (No)
Unknown/not Evaluated (Unknown/not
evaluated)
Yes (Yes)
Sites of progression, adrenals
No (No)
Unknown/not Evaluated (Unknown/not
evaluated)
Yes (Yes)
Sites of progression, liver
No (No)
Unknown/not Evaluated (Unknown/not
evaluated)
Yes (Yes)
Sites of progression, bone
No (No)
Unknown/not Evaluated (Unknown/not
evaluated)
Yes (Yes)
Sites of progression, CNS (Brain)
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No (No)
Unknown/not Evaluated (Unknown/not
evaluated)
Yes (Yes)
CNS (Brain) Date
Sites of progression, Other Specify
No (No)
Unknown/not Evaluated (Unknown/not
evaluated)
Yes (Yes)
Site of progression, other specify
PROGRESSION ASSESSMENT
HAS A NEW PRIMARY OR MDS BEEN
DIAGNOSED THAT HAS NOT BEEN
PREVIOUSLY REPORTED?
No (No)
Unknown (Unknown)
Yes (Yes)
NEW PRIMARY SITE
NEW PRIMARY HISTOLOGIC TYPE
DATE OF DIAGNOSIS
IS THE PATIENT RECEIVING ANY NON-
PROTOCOL CANCER THERAPY NOT
PREVIOUSLY REPORTED?
No (No)
Unknown (Unknown)
Yes (Yes)
Non-Protocol RT
No (No)
Unknown (Unknown)
Yes (Yes)
Date of first non-protocol therapy
Non-Protocol Surgery
No (No)
Unknown (Unknown)
Yes (Yes)
Non-Protocol Chemotherapy
No (No)
Unknown (Unknown)
Yes (Yes)
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Other Non-Protocol therapy
No (No)
Unknown (Unknown)
Yes (Yes)
Specify other
Revised
IMT CODE TOXICITY CODE BASED ON CTEP
TOXICITY TERM
TERM
GENERAL TOXICITY CATEGORY
Allergy / Immunology (Allergy /
Immunology)
Auditory/Hearing (Auditory/Hearing)
Blood/Bone marrow (Blood/Bone
marrow)
Cardiovascular (Arrhythmia)
(Cardiovascular (Arrhythmia))
Cardiovascular (General)
(Cardiovascular (General))
Coagulation (Coagulation)
Constitutional Symptoms (Constitutional
Symptoms)
Dermatology/Skin (Dermatology/Skin)
Endocrine (Endocrine)
Gastrointestinal (Gastrointestinal)
Hemorrhage (Hemorrhage)
Hepatic (Hepatic)
Infection/Febrile Neutropenia
(Infection/Febrile Neutropenia)
Lymphatics (Lymphatics)
Metabolic/Laboratory
(Metabolic/Laboratory)
Musculoskeletal (Musculoskeletal)
Neurology (Neurology)
Ocular/Visual (Ocular/Visual)
Pain (Pain)
Pulmonary (Pulmonary)
Renal/Genitourinary
(Renal/Genitourinary)
Second Malignancy (Second
Malignancy)
Sexual/Reproductive Function
(Sexual/Reproductive Function)
Syndromes (Syndromes)
SEVERITY GRADE
DATE OF 1ST OCCURRENCE OF GRADE=>3
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ATTRIBUTION
Other cause, specify in "Description"
(Other cause, specify in "Description")
Radiotherapy only (Brain) (Radiotherapy
only (Brain))
Unknown (Unknown)
DESCRIPTION
HQ Use
Comments
Comments
Signature of Person Completing This Form
Date
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Southwest Oncology Group Registration
Form (25757) NCT00020709
Southwest Oncology Group Registration Form (25757)
NCT00020709
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Source Form: NCI FormBuilder:
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Southwest Oncology Group
Registration Form (25757)
NCT00020709
SWOG clinical trial administrative data
SWOG Study No.
Registration Step
Activation Date
Last Amended Date
Patient's Name
SWOG Patient ID
Other Group Patient ID
9977 - ACOSOG (9977 - ACOSOG)
9981 - NCIC (9981 - NCIC)
9982 - CALGB (9982 - CALGB)
9984 - GOG (9984 - GOG)
9987 - MDACC (9987 - MDACC)
9995 - ECOG (9995 - ECOG)
9996 - NCCTG (9996 - NCCTG)
9997 - RTOG (9997 - RTOG)
Other Group Name/Protocol Number
Caller's SWOG Roster ID
Projected Start Date of Treatment
SWOG Investigator Number
Other Group Investigator Name
Other Group Investigator Number
SWOG Treating Institution Number
1 / 2
Other Group Treating Institution Name
Other Group Treating Institution Number
Treating Institution CTEP Code
Stratification Factors
Clinical Stage
IIIA (IIIA)
IIIB (IIIB)
Disease
Measurable (Measurable)
Non-measurable (Non-measurable)
Histologic Subtype
Nonsquamous (Nonsquamous)
Squamous (Squamous)
Notes
Notes
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Radiation Therapy Oncology Group On Study Form
Phase III Lung - Prophylactic Cranial RT NCT00048997
Radiation Therapy Oncology Group On Study Form Phase
III Lung - Prophylactic Cranial RT NCT00048997 
Radiation Therapy in Preventing CNS Metastases in
Patients With Non-Small Cell Lung Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=9EC372A6-
724E-05D5-E034-080020C9C0E0
All rights reserved. Please visit https://medical-data-
models.org/forms/10568
Radiation Therapy Oncology Group
On Study Form Phase III Lung -
Prophylactic Cranial RT
NCT00048997
Header Module
Case #
Institution
Institution #
Patient Name
Patient ID #
Patient Characteristics
PATIENT'S DATE OF BIRTH
PERFORMANCE STATUS (ZUBROD)
PRIOR TREATMENT TYPE (Administered for
current lung cancer)
No (No)
Unknown (Unknown)
Yes (Yes)
PRIOR CHEMOTHERAPY
No (No)
Unknown (Unknown)
Yes (Yes)
Agent Name
Total Agent Cumulative dose
Agent End dose
PRIOR RADIATION
No (No)
1 / 4
Unknown (Unknown)
Yes (Yes)
Prior RT End Date
PRIOR SURGERY
No (No)
Unknown (Unknown)
Yes (Yes)
MOST EXTENSIVE SURGERY
Bilobectomy (Bilobectomy)
Exploratory Thoractomy (Exploratory
Thoractomy)
Lobectomy (Lobectomy)
Other, specify (Other, specify)
Pneumonectomy (Pneumonectomy)
Sleeve Resection (Sleeve Resection)
Most Extensive Surgery Other, Specify
Date of most extensive surgery
DATE OF INITIAL DIAGNOSIS OF PRIMARY
TUMOR
HISTOLOGIC TYPE
Adenocarcinoma (Adenocarcinoma)
Combined squamous & adenocarcinoma
(Combined squamous &
adenocarcinoma)
Large cell (Large cell)
Non-lobar and non-diffuse
bronchoalveolar carcinoma (Non-lobar
and non-diffuse bronchoalveolar
carcinoma)
Non-small Cell Carcinoma, NOS (Non-
small Cell Carcinoma, NOS)
Other, Specify (Other, specify)
Small cell/oat cell (Small cell/oat cell)
Squamous Cell Carcinoma (Squamous
cell carcinoma)
Histologic Type Other, specify
STAGE GROUPING (Prior to planned definitive
therapy)
I (I)
II (II)
IIIa (IIIa)
IIIb (IIIb)
IV (IV)
OVERALL TUMOR RESPONSE (Primary tumor,
after all planned treatment)
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Complete response (Complete
response)
Less than Partial Response (Less than
Partial Response)
Not assessed (Not assessed)
Other (Other)
Partial Response (Partial Response)
Progression (Progression)
Stable (Stable)
Response Duration begin date
HAS THE PATIENT DEVELOPED A FIRST
PROGRESSION NOT PREVIOUSLY
REPORTED? (DISTANT)
Yes
No
PROGRESSION ASSESSMENT
Sites of progression, lung
No (No)
Unknown/not Evaluated (Unknown/not
evaluated)
Yes (Yes)
Sites of progression, Lymph nodes (distant)
No (No)
Unknown/not Evaluated (Unknown/not
evaluated)
Yes (Yes)
Sites of progression, pleural
No (No)
Unknown/not Evaluated (Unknown/not
evaluated)
Yes (Yes)
Sites of progression, adrenals
No (No)
Unknown/not Evaluated (Unknown/not
evaluated)
Yes (Yes)
Sites of progression, liver
No (No)
Unknown/not Evaluated (Unknown/not
evaluated)
Yes (Yes)
Sites of progression, bone
No (No)
Unknown/not Evaluated (Unknown/not
evaluated)
Yes (Yes)
Sites of progression, Other Specify
No (No)
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Unknown/not Evaluated (Unknown/not
evaluated)
Yes (Yes)
Site of progression, other specify
Comments
Comments
Signature of Person Completing This Form
Date
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BASELINE TUMOR ASSESSMENT FORM
NCT00020709
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Source Form: NCI FormBuilder:
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BASELINE TUMOR ASSESSMENT
FORM NCT00020709
SWOG clinical trial administrative data
SWOG Patient ID
SWOG Study No.
Registration Step
Patient Initials (L, F,M)
Institution / Affiliate
Physician
Group Name (Groups other than SWOG )
Study No. (Groups other than SWOG )
Pt. ID (Groups other than SWOG )
Target lesion status
Target Lesion Site Number
L1 (L1)
L10 (L10)
L2 (L2)
L3 (L3)
L4 (L4)
L5 (L5)
L6 (L6)
L7 (L7)
L8 (L8)
L9 (L9)
Target Lesion Site
RT No Prog.
1 / 3
Longest Diameter (cm )
Target Lesion Assessment Type
CA-125 assay (CA-125 assay)
Colposcopy (Colposcopy)
CT scan (CT scan)
Cytologic confirmation (Cytologic
confirmation)
Endoscopy (Endoscopy)
Histologic confirmation (Histologic
confirmation)
MRI scan (MRI scan)
Other (Other)
Palpation (Palpation)
PET scan (PET scan)
Plain film/X-ray with contrast (Plain
film/X-ray with contrast)
Plain film/X-ray without contrast (Plain
film/X-ray without contrast)
PSA (PSA)
Radioisotope scan (Radioisotope scan)
Ultrasound (Ultrasound)
Visualization (Visualization)
Target Lesion Assessment Date
Non-Target Lesion Site Number
S1 (S1)
S2 (S2)
S3 (S3)
S4 (S4)
S5 (S5)
Non-Target Lesion Site
Extent
Non-Target Lesion Assessment Type
CA-125 assay (CA-125 assay)
Colposcopy (Colposcopy)
CT scan (CT scan)
Cytologic confirmation (Cytologic
confirmation)
Endoscopy (Endoscopy)
Histologic confirmation (Histologic
confirmation)
MRI scan (MRI scan)
Other (Other)
Palpation (Palpation)
PET scan (PET scan)
Plain film/X-ray with contrast (Plain
film/X-ray with contrast)
Plain film/X-ray without contrast (Plain
film/X-ray without contrast)
PSA (PSA)
Radioisotope scan (Radioisotope scan)
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Ultrasound (Ultrasound)
Visualization (Visualization)
Non-Target Lesion Assessment Date
Tests
Tests/studies
Assessment Date
Notes
Notes
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FIRST SITE(S) OF PROGRESSION OR
RELAPSE FORM NCT00020709
FIRST SITE(S) OF PROGRESSION OR RELAPSE FORM
NCT00020709 
S0023: Combination Chemo Plus RT With or Without
Gefitinib in Treating Patients With Unresectable Stage III
NSCLC
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=9E343E83-
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All rights reserved. Please visit https://medical-data-
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FIRST SITE(S) OF PROGRESSION
OR RELAPSE FORM NCT00020709
SWOG clinical trial administrative data
SWOG Patient ID
SWOG Study No.
Registration Step
Patient Initials (L, F,M)
Institution / Affiliate
Physician
Group Name (Groups other than SWOG )
Study No. (Groups other than SWOG )
Pt. ID (Groups other than SWOG )
Patient status
Date of last contact or death
Status
Alive2005416 (Alive)
Dead2005417 (Dead)
Progression/ relapse status
Date of progression or relapse
Local Site(s) of Progression or Relapse at the
time progression/relapse was detected (select all
that apply)
Lung parenchyma adjacent to primary tumor
1 / 3
Bronchial stump
Regional/Nodal Site(s) of Progression or Relapse
at the time progression/relapse was detected
Ipsilateral hilar mediastinum (nodal)
Contralateral hilar mediastinum (nodal)
Ipsilateral pleural effusion
Contralateral pleural effusion
Ipsilateral supraclavicular lymph nodes
Contralateral supraclavicular lymph nodes
Distant Site(s) of Progression or Relapse at the
time progression/relapse was detected
Separate lobe of the ipsilateral lung
Opposite lung
Pericardial effusion
Brain
Leptomeninges
Liver
Bone
Adrenal glands
Kidney
Skin or subcutaneous
Other site, specify
For Local Progression or Relapse
2 / 3
FIRST SITE(S) OF PROGRESSION OR RELAPSE FORM
NCT00020709
Progression/Relapse site within previous RT
field?  (select one )
No (No)
Not Applicable (Not Applicable)
Yes (Yes)
For Regional Progression or Relapse
Progression/Relapse site within previous RT
field?  (select one)
No (No)
Not Applicable (Not Applicable)
Yes (Yes)
Notes
Notes
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REPORTING FORM NCT00020709
S0023 ZD1839 DOSE AND TOXICITY REPORTING
FORM NCT00020709 
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Gefitinib in Treating Patients With Unresectable Stage III
NSCLC
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https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
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All rights reserved. Please visit https://medical-data-
models.org/forms/10571
S0023 ZD1839 DOSE AND
TOXICITY REPORTING FORM
NCT00020709
SWOG clinical trial administrative data
SWOG Patient ID
SWOG Study No.
Registration Step
Submission Time
4 week (First) Submission (4 week (First)
Submission)
8 week (Second) Submission (8 week
(Second) Submission)
Other (Other)
Patient Initials (L, F,M)
Institution / Affiliate
Physician
Group Name (Groups other than SWOG )
Study No. (Groups other than SWOG )
Pt. ID (Groups other than SWOG )
Treatment
Reporting Begin Date (4 week period)
Reporting End Date
Were there any dose modifications or
additions/deletions to protocol treatment?
No (No)
Yes, planned (per protocol guidelines)
1 / 3
(Yes, planned (per protocol guidelines))
Yes, unplanned (not per protocol
guidelines) (Yes, unplanned (not per
protocol guidelines))
Delay
No (No)
Yes (Yes)
Dose reduction
No (No)
Yes (Yes)
Total dose for this reporting period (mg ZD1839 1
Tablet = 250 mg)
Toxicity
Were toxicities assessed during this time period?
No (No)
Yes (Yes)
Date of most recent toxicity assessment
CTC 2.0 Code
EY01 (EY01)
EY02 (EY02)
EY30 (EY30)
EY40 (EY40)
EY99 (EY99)
FL40 (FL40)
GI00 (GI00)
GI01 (GI01)
GI10 (GI10)
GI20 (GI20)
GU50 (GU50)
HE00 (HE00)
HE10 (HE10)
HE20 (HE20)
HE30 (HE30)
IM00 (IM00)
IN00 (IN00)
IN05 (IN05)
IN30 (IN30)
LI00 (LI00)
LI12 (LI12)
SK11 (SK11)
Toxicity
Allergy/hypersensitivity
(Allergy/hypersensitivity)
Anemia (Anemia)
Anorexia (Anorexia)
Bilirubin increase (Bilirubin increase)
Conjunctivitis (Conjunctivitis)
Creatinine increase (Creatinine increase)
Diarrhea (Diarrhea)
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Eye, Other (Eye, Other)
Fatigue (Fatigue)
Febrile neutropenia (Febrile neutropenia)
Infection w/o 3-4 neutropenia (Infection
w/o 3-4 neutropenia)
Infection with 3-4 neutropenia (Infection
with 3-4 neutropenia)
Keratitis (Keratitis)
Leukopenia (Leukopenia)
Nausea (Nausea)
Neutropenia/granulocytopenia
(Neutropenia/granulocytopenia)
Rash/Desquamation
(Rash/Desquamation)
SGPT increase (SGPT increase)
Tearing (Tearing)
Thrombocytopenia (Thrombocytopenia)
Vision, NOS (Vision, NOS)
Vomiting (Vomiting)
Grade (1 - 5)
Treatment Relation
definite (definite)
possible (possible)
probable (probable)
unlikely (unlikely)
unrelated (unrelated)
Other Toxicities (specify:)
Notes
Notes
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S0023 LUNG CARCINOMA
FOLLOW UP FORM NCT00020709
SWOG clinical trial administrative data
SWOG Patient ID
SWOG Study No.
Registration Step
Patient Initials (L, F,M)
Institution / Affiliate
Physician
Group Name (Groups other than SWOG )
Study No. (Groups other than SWOG )
Pt. ID (Groups other than SWOG )
Vital Status
Vital Status
Alive (Alive)
Dead (Dead)
Date of last contact or death (If vital status is
Dead, complete and submit Notice of Death
form.)
Disease Follow Up Status
Has the patient had a documented clinical
assessment for this cancer since submission of
the previous follow-up form?
No (No)
Yes (Yes)
1 / 3
If Yes, Date of Last Clinical Assessment
Has the patient developed a first relapse or
progression that has not been previously
reported?
No2007229 (No)
Yes2007230 (Yes)
If Yes, Date of Relapse or Progression
If yes, please submit the Lung Carcinoma First
Site(s) of Progression or Relapse Form.
Notice Of New Primary
Has a new primary cancer or myelodysplastic
syndrome (MDS) been diagnosed that has not
been previously reported?
No2007235 (No)
Yes2007236 (Yes)
If Yes, Date of Diagnosis
New Primary Site
Non-protocol Treatment
Has the patient received any non-protocol cancer
therapy (prior to progression/relapse) not
previously reported?
No2007241 (No)
Yes2007242 (Yes)
If Yes, Date of First Non-Protocol Therapy
Agents
Long Term Toxicity
Has the patient experienced (prior to treatment
for progression or relapse or a second primary,
and prior to non-protocol treatment) any severe
(grade =>3) long term toxicity that has not been
previously reported?
No2007247 (No)
Yes2007248 (Yes)
If Yes, Toxicities and Grades
Notes
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Cranial RT Radiotherapy Summary Form NCT00048997
Radiation Therapy Oncology Group Phase III Lung
Prophylactic Cranial RT Radiotherapy Summary Form
NCT00048997 
Radiation Therapy in Preventing CNS Metastases in
Patients With Non-Small Cell Lung Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=9EC372A6-
73DB-05D5-E034-080020C9C0E0
All rights reserved. Please visit https://medical-data-
models.org/forms/10573
Radiation Therapy Oncology Group
Phase III Lung Prophylactic Cranial
RT Radiotherapy Summary Form
NCT00048997
Header Module
Case #
Patient ID #
Institution
Institution #
Patient Name
RADIOTHERAPY documentation
Total # of treatment days RT interrupted for
toxicity.
Total # of treatment days RT interrupted for other
reasons, specify
Total # of treatment days RT interrupted for other
reasons, specify
If this is a revised or corrected form, indicate by
checking box.
FIRST DATE PROTOCOL THERAPY WAS
GIVEN
LAST DATE PROTOCOL THERAPY WAS GIVEN
Primary Tumor Site, DOSE SUMMARY
(Complete for all treatment fields or as specified
within the protocol. Specify fractions and dose for
each volume a-d, record totals in e. Fractions
Dose Gy)
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Dose (Gy)
Total to Primary Site
Regional Nodes, Dose Summary
Fractions
Fractions
Dose (Gy)
Nodal Sites
Breast: Axillary (Breast: Axillary)
Breast: Internal mammary (Breast:
Internal mammary)
Breast: Other site (Breast: Other site)
Breast: Supraclavicular (Breast:
Supraclavicular)
Esophagus: Mediastinal (Esophagus:
Mediastinal)
Esophagus: Supraclavicular
(Esophagus: Supraclavicular)
Head & Neck: Ant to cord (Head & Neck:
Ant to cord)
Head & Neck: Post to cord (Head &
Neck: Post to cord)
Head & Neck: Supraclavicular (Head &
Neck: Supraclavicular)
Lung (Lower Lobes): Contralateral hilar
(Lung (Lower Lobes): Contralateral hilar)
Lung (Lower Lobes): Inferior mediastinal
(Lung (Lower Lobes): Inferior
mediastinal)
Lung (Lower Lobes): Ipsilateral
hilar/subcarinal (Lung (Lower Lobes):
Ipsilateral hilar/subcarinal)
Lung (Upper/Mid Lobes): Contralateral
hilar (Lung (Upper/Mid Lobes):
Contralateral hilar)
Lung (Upper/Mid Lobes): Ipsilateral
hilar/subcarinal (Lung (Upper/Mid
Lobes): Ipsilateral hilar/subcarinal)
Lung (Upper/Mid Lobes): Supraclavicular
(Lung (Upper/Mid Lobes):
Supraclavicular)
Pelvic/Abdomen Primaries: Common
Iliac (Pelvic/Abdomen Primaries:
Common Iliac)
Pelvic/Abdomen Primaries: Int/Ext. Iliac
(Pelvic/Abdomen Primaries: Int/Ext. Iliac)
Pelvic/Abdomen Primaries: Mesenteric
(Pelvic/Abdomen Primaries: Mesenteric)
Pelvic/Abdomen Primaries: Para-aortic
(Pelvic/Abdomen Primaries: Para-aortic)
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Other volume, specify
Critical Structures
Bladder >50% (Bladder >50%)
Contralateral Ni Lung (Contralateral NI
lung)
Esophagus (Esophagus)
Heart (Heart)
Kidney (Kidney)
Large Bowel (excludes Rectum) (Large
bowel (excludes rectum))
Lens (lt) (Lens (LT))
Lens (rt) (Lens (RT))
Liver (Liver)
Other, Specify (Other, specify)
Other, specify (Other, specify)
Rectum (Rectum)
Small Bowel (Small bowel)
Spinal Cord (Spinal cord)
Maximum Dose (Gy)
WERE THERE ANY DOSE MODIFICATIONS OR
ADDITIONS/OMISSIONS TO PROTOCOL
TREATMENT? (Must be completed for all
patients assigned radiotherapy.)
Alternative RX given, specify RX
(Alternative RX given, specify RX)
Death (Death)
NA - XRT dose administered within
protocol specifications (NA - XRT dose
administered within protocol
specifications)
Other reason, specify (Other reason,
specify)
Patient refused (Patient refused)
Progression or relapse (Progression or
relapse)
Toxicity or treatment reaction (Toxicity or
treatment reaction)
Were there any dose modifications or
additions/omissions to protocol treatment other
reason, specify (TREATMENT MODIFIED)
Split Course Interruption (Complete only if
assigned split course. Total number of days
interrupted for split between first and second
course.)
Signature of Person Completing This Form
Date
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RADIOTHERAPY SUBMISSION FORM -
LUNG NCT00020709
RADIOTHERAPY SUBMISSION FORM - LUNG
NCT00020709 
S0023: Combination Chemo Plus RT With or Without
Gefitinib in Treating Patients With Unresectable Stage III
NSCLC
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=9CA62D43-
501A-361C-E034-080020C9C0E0
All rights reserved. Please visit https://medical-data-
models.org/forms/10574
RADIOTHERAPY SUBMISSION
FORM - LUNG NCT00020709
SWOG clinical trial administrative data
SWOG Study No.
Registration Step
SWOG Patient ID
Patient Initials (L, F M)
Institution / Affiliate
Investigator
RADIOTHERAPY documentation
RT Facility
RT Physician
Radiation Therapy End Date (month, day, year )
Required Materials (if not enclosed, explain in
Notes)
CT Scan (CT Scan)
Lung Carcinoma Radiation Therapy
Form (Lung Carcinoma Radiation
Therapy Form)
Polaroid of Treatment Set-Up (Polaroid of
Treatment Set-Up)
Simulator Films or digital reconstruction
rendering (Simulator Films or digital
reconstruction rendering)
Treatment Prescription Sheet (Treatment
Prescription Sheet)
Dose Volume Histogram
Left Lung (Left Lung)
Right + Left Lung (Right + Left Lung)
Right Lung (Right Lung)
Tumor (Tumor)
1 / 2
Enclosed
Yes
No
Notes
Notes
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NOTICE OF DEATH NCT00020709
NOTICE OF DEATH NCT00020709 
S0023: Combination Chemo Plus RT With or Without
Gefitinib in Treating Patients With Unresectable Stage III
NSCLC
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=9CA62D43-
492B-361C-E034-080020C9C0E0
All rights reserved. Please visit https://medical-data-
models.org/forms/10575
NOTICE OF DEATH NCT00020709
SWOG clinical trial administrative data
SWOG Patient ID
Most Recent SWOG Study No.
Registration Step
Patient Initials (L, F,M)
Institution / Affiliate
Physician
Group Name (Groups other than SWOG )
Study No. (Groups other than SWOG )
Pt. ID (Groups other than SWOG )
Death documentation
Date of Death (month / day / year)
Any cancer (select one)
Contributory (Contributory)
No (No)
Possible (Possible)
Primary Cause (Primary Cause)
Unknown (Unknown)
If cancer was the primary cause or if cancer
possibly or definitely contributed to death, and the
patient had had multiple tumor types, specify
those which were causes of death
Cancer of most recent SWOG study,
specify cancer (Cancer of most recent
SWOG study, specify cancer)
Cancer of other SWOG study, specify
cancer (Cancer of other SWOG study,
specify cancer)
Other cancer, specify (Other cancer,
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specify)
Cancer of most recent SWOG study, specify
cancer
Cancer of other SWOG study, specify cancer
Other cancer, specify
Toxicity from disease related treatment (select
one)
Contributory (Contributory)
No (No)
Possible (Possible)
Primary Cause (Primary Cause)
Unknown (Unknown)
If Primary Cause, Contributory or Possible,
specify treatment and toxicity
Non-cancer and non-treatment related causes
(select one)
Contributory (Contributory)
No (No)
Possible (Possible)
Primary Cause (Primary Cause)
Unknown (Unknown)
If Primary Cause, Contributory or Possible,
specify
Autopsy done?
No (No)
Unknown (Unknown)
Yes (Yes)
Death information obtained from (select all that
apply)
Autopsy report (Autopsy report)
Medical record / Death certificate
(Medical record / Death certificate)
Other, specify (Other, specify)
Physician (Physician)
Relative or friend (Relative or friend)
Other, specify
Notes
Notes
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Relapse/Progression [ABTR01B1]
NCT00898079
Relapse/Progression [ABTR01B1]
Collecting and Storing Malignant, Borderline Malignant
Neoplasms, and Related Samples From Young Patients
With Cancer NCT00898079 
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=BCEF65B1-
5B3C-3739-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/10576
Relapse/Progression [ABTR01B1]
NCT00898079
Header Module
Institution
Institution Personnel
COG Number
COG Number
Today's date
Date worksheet entered into RDE
Relapse/progression status
Date of relapse/progression
Relapse/Progression
Progression (Progression)
Relapse (Relapse)
Sites [relapse/progression]
Bone (Bone)
Bone Marrow (Bone Marrow)
Liver (Liver)
Lung (Lung (parenchymal))
Lymph Nodes, Specify (Lymph Nodes)
Other (Other (specify in text field))
Primary Tumor (Primary Site)
specify [other site of relapse/progression]
COMMENTS
Ccrr Module For Relapse/progression
[abtr01b1]
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E1900 On-Study Form NCT00049517
E1900 On-Study Form
NCT00049517 
Combination Chemotherapy With or Without Monoclonal
Antibody Therapy Followed by Stem Cell Transplant in
Treating Patients With Acute Myeloid Leukemia
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=A7294479-
6D5C-2FC8-E034-0003BA0B1A09
All rights reserved. Please visit https://medical-data-
models.org/forms/10577
E1900 On-Study Form
NCT00049517
ECOG clinical trial administrative data
ECOG Protocol No.
ECOG Patient ID
Registration Step
Patient?s Name
Participating Group Protocol No.
Participating Group Patient ID
Institution/Affiliate
Are data amended?
Yes
No
Disease Description
Date of initial pathologic diagnosis
Leukemia Classification (Choose one)
Disease Classified As Acute
Erythroblastic Leukemia (fab M6) (Acute
erythroblastic leukemia (FAB M6))
Disease Classified As Acute
Megakaryoblastic Leukemia (fab M7)
(Acute megakaryoblastic leukemia (FAB
M7))
Disease Classified As Acute Monocytic
Leukemia (fab M5) (Acute monocytic
leukemia (FAB M5))
Disease Classified As Acute Myeloid
Leukemia W/ Maturation (fab M2) (Acute
myeloid leukemia w/ maturation (FAB
M2))
Disease Classified As Acute Myeloid
Leukemia W/o Maturation (fab M1)
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(Acute myeloid leukemia w/o maturation
(FAB M1))
Disease Classified As Acute
Myelomonocytic Leukemia (fab M4)
(Acute myelomonocytic leukemia (FAB
M4))
Disease Classified As Acute
Promyelocytic Leukemia (fab M3) (Acute
promyelocytic leukemia (FAB M3))
Disease Classified As Acute
Undifferentiated Leukemia (aul) (Acute
undifferentiated leukemia (AUL))
Disease Classified As Aml, Not
Otherwise Specified (nos) (AML, not
otherwise specified (NOS))
Disease Is A Mixed Lineage Acute
Leukemia (Mixed lineage acute
leukemia)
Disease Classified As Specified Other
Leukemia (Other, specify)
Disease Is An Unclassifiable Acute
Leukemia (Unclassifiable acute
leukemia)
Disease Classified As Undifferentiated
Acute Myeloid Leukemia (fab M0)
(Undifferentiated acute myeloid leukemia
(FAB M0))
Other, specify (leukemia classification)
Clinical Onset of AML (Choose one)
Aml Without Prior Clinical History Of Mds
Or Potentially Leukemogenic Treatment
(de novo)
Aml Related To/associated With Prior
Clinical History Of Mds (MDS-related)
Aml Related To/associated With Prior
Clinical History Of Potentially
Leukemogenic Treatment (treatment
related)
Central Nervous System
Yes
No
Peripheral Nervous System
Yes
No
Gingival Hypertrophy
Yes
No
Mediastinal Mass
Yes
No
Skin
Yes
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No
Other
Yes
No
Other, specify (extramedullary disease
involvement)
Baseline Evaluation Data
Patient Height (cm)
Date Hematology Sample Obtained (Bone
marrow biopsy/aspirate)
Date of bone Marrow Biopsy
Peripheral WBC count (/mm 3 ) (x1000)
Peripheral platelet count (/mm 3 ) (x1000)
Peripheral Blasts (%)
Peripheral Neutrophils (%)
Hemoglobin (g/dl)
Marrow Cellularity (%)
CD33 % by flow cytometry
CD33 % by flow cytometry (if dry tap or
inaspirable)
Marrow Cellularity Status (Choose one)
Cellularity Status Of Bone Marrow Is
Aplasitc (severely Hypocellular) (aplastic
(severly hypocellular))
Cellularity Status Of Bone Marrow
Unknown, Procedure Resulted In No
Material To Analyze (dry tap or
inaspirable)
Cellularity Status Of Bone Marrow Is
Hypercellular (hypercellular)
Cellularity Status Of Bone Marrow Is
Hypocellular (hypocellular)
Cellularity Status Of Bone Marrow Is
Normocellular (normocellular)
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Cellularity Status Of Bone Marrow Is
Packed (intensely Hypercellular) (packed
(intensely hypercellular))
Performance status
2 (Ambulatory and capable of all selfcare
but unable to carry out any work
activities (K 50-60))
3 (Capable of only limited selfcare,
confined to bed or chair more than 50%
of waking hours (K 30-40))
4 (completely disabled (K 10-20))
0 (Fully active, able to carry on all pre-
disease performance without restriction
(Karnofsky 90-100))
1 (Restricted in physically strenuous
activity but ambulatory (K 70-80))
Comments
Investigator Signature
Date
Ccrr Module For E1900 On-study Form
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E1900 Second Primary Form
NCT00049517
E1900 Second Primary Form NCT00049517 
Combination Chemotherapy With or Without Monoclonal
Antibody Therapy Followed by Stem Cell Transplant in
Treating Patients With Acute Myeloid Leukemia
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=A72941B2-
95F8-2FC4-E034-0003BA0B1A09
All rights reserved. Please visit https://medical-data-
models.org/forms/10578
E1900 Second Primary Form
NCT00049517
ECOG clinical trial administrative data
ECOG Protocol No. (If patient has been on other
therapeutic ECOG protocols, please list protocols
and patient ID numbers.)
ECOG Patient ID (If patient has been on other
therapeutic ECOG protocols, please list protocols
and patient ID numbers.)
Registration Step
Patient?s Name
Participating Group Protocol No.
Participating Group Patient ID
Institution/Affiliate
Are data amended? (If yes, please circle
amended items in red)
Yes
No
Diagnosis Second Primary Cancer
Date of Diagnosis of Second Primary Cancer
Site of Second Primary Cancer
Include information on histologic subtype(s).
Briefly describe cancer therapy the patient has
received prior to the diagnosis of the second
primary and other than that given on ECOG
protocols
Briefly describe treatment planned or given for
the diagnosis of this second primary:
1 / 2
Comments
Comments
Investigator Signature
Date
Ccrr Module For E1900 Second Primary
Form
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Treatment Form - Allogeneic Transplant
NCT00049517
Treatment Form - Allogeneic Transplant NCT00049517 
Combination Chemotherapy With or Without Monoclonal
Antibody Therapy Followed by Stem Cell Transplant in
Treating Patients With Acute Myeloid Leukemia
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=A727E9EC-
B147-2F86-E034-0003BA0B1A09
All rights reserved. Please visit https://medical-data-
models.org/forms/10579
Treatment Form - Allogeneic
Transplant NCT00049517
ECOG clinical trial administrative data
ECOG Protocol No.
ECOG Patient ID
Registration Step
Patient?s Name
Participating Group Protocol No.
Participating Group Patient ID
Institution/Affiliate
Are data amended? (If yes, please circle
amended items in red)
Yes
No
Vital Status
Patient?s Vital Status
Alive (Alive)
Dead (Dead)
Date of Last Contact or Death (M D Y)
Cause of Death (if applicable)
Due To Other Cause (Due to other
cause)
Due To Protocol Treatment (Due to
protocol treatment)
Due To This Disease (Due to this
disease)
Unknown (Unknown)
Transplant Conditioning Regimen
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Treatment Start Date
Treatment End Date
Agent Name
Agent Total Dose
Donor Information
Relationship to recipient
Other Family Member (other family
member)
Sibling (sibling)
Unrelated (unrelated)
Donor gender
Female (female)
Male (male)
CMV status
Negative (negative)
Positive (positive)
Unknown (unknown)
EBV status
Negative (negative)
Positive (positive)
Unknown (unknown)
Donor birth date
Allogeneic Transplant
Did patient receive protocol transplant?
Yes
No
Date of last peripheral blood stem cell infusion
Total no. of CD34+ cells infused
Transfusions
Number of post-transplant platelet transfusions
Date of most recent platelet transfusion
Number of post-transplant RBC transfusions
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Date of most recent RBC transfusion
Reason Treatment Ended (Choose one)
Alternative Therapy (Alternative therapy)
Death After Beginning Protocol Therapy
(Death after beginning protocol therapy)
Disease Progression, Relapse During
Active Treatment (Disease progression,
relapse during active treatment)
Other (Other)
Patient Off-treatment For Other
Complicating Disease (Other
complicating disease)
Patient Withdrawal Or Refusal After
Beginning Protocol Therapy (Patient
withdrawal or refusal after beginning
protocol therapy)
Toxicity/side Effects/complications
(Toxicity/side effects/complications)
Treatment Completed Per Protocol
Criteria (Treatment completed per
protocol criteria)
Specify complicating disease (reason treatment
ended)
Specify other Reasons (reason treatment ended)
Comments
Comments
Investigator Signature
Date
Ccrr Module For Treatment Form -
Allogeneic Transplant
3 / 3
Treatment Form - Allogeneic Transplant NCT00049517
E1900 Induction Treatment Form
NCT00049517
E1900 Induction Treatment Form NCT00049517 
Combination Chemotherapy With or Without Monoclonal
Antibody Therapy Followed by Stem Cell Transplant in
Treating Patients With Acute Myeloid Leukemia
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=A7294EC6-
E15C-2FD0-E034-0003BA0B1A09
All rights reserved. Please visit https://medical-data-
models.org/forms/10580
E1900 Induction Treatment Form
NCT00049517
ECOG clinical trial administrative data
ECOG Protocol No.
ECOG Patient ID
Registration Step
Patient?s Name
Participating Group Protocol No.
Participating Group Patient ID
Institution/Affiliate
Are data amended? (If yes, please circle
amended items in red)
Yes
No
Vital Status
Patient?s Vital Status
Alive (Alive)
Dead (Dead)
Date of Last Contact or Death (M D Y)
Cause of Death (if applicable)
Due To Other Cause (Due to other
cause)
Due To Protocol Treatment (Due to
protocol treatment)
Due To This Disease (Due to this
disease)
Unknown (Unknown)
Describe cause of death
1 / 3
Treatment Cycle Information
Assigned Treatment Arm (Choose one)
Arm A - Daunorubicin 45 mg/m2 (Arm A
- Daunorubicin 45 mg/m2)
Arm B - Daunorubicin 90 mg/m2 (Arm B
- Daunorubicin 90 mg/m2)
Cycle
Cycle 1 (Cycle 1)
Cycle 2 (Cycle 2)
Weight for this cycle (kg)
Treatment Begin Date
Cytarabine Initial Dose
Number of days GM-CSF was given
GM-CSF Total Cumulative Dose
Was intrathecal methotrexate or cytarabine
administered? (choose one)
Yes
No
Were there any dose modifications or
additions/omissions to protocol treatment?
(Choose one:)
No (No)
(i.e., The Treatment Was Changed
According To Protocol Guidelines) (Yes,
planned)
(i.e., The Treatment Change Was Not
Part Of Protocol Guidelines) (Yes,
unplanned)
Was any non-protocol therapy given during
protocol treatment? (not previously reported)
Yes
No
Last date (any modality of) protocol therapy was
given
Reason Treatment Ended (Choose one)
Alternative Therapy (Alternative therapy)
Death After Beginning Protocol Therapy
(Death after beginning protocol therapy)
Disease Progression, Relapse During
Active Treatment (Disease progression,
relapse during active treatment)
Other (Other)
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Patient Off-treatment For Other
Complicating Disease (Other
complicating disease)
Patient Withdrawal Or Refusal After
Beginning Protocol Therapy (Patient
withdrawal or refusal after beginning
protocol therapy)
Toxicity/side Effects/complications
(Toxicity/side effects/complications)
Treatment Completed Per Protocol
Criteria (Treatment completed per
protocol criteria)
Specify complicating disease (reason treatment
ended)
Specify other Reasons (reason treatment ended)
Comments
Comments
Investigator Signature
Date
Ccrr Module For E1900 Induction
Treatment Form
Agent Name
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Treatment Form - Autologous Transplant
NCT00049517
Treatment Form - Autologous Transplant NCT00049517
Combination Chemotherapy With or Without Monoclonal
Antibody Therapy Followed by Stem Cell Transplant in
Treating Patients With Acute Myeloid Leukemia
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=A727E609-
20CC-2F84-E034-0003BA0B1A09
All rights reserved. Please visit https://medical-data-
models.org/forms/10581
Treatment Form - Autologous
Transplant NCT00049517
ECOG clinical trial administrative data
ECOG Protocol No.
ECOG Patient ID
Registration Step
Patient?s Name
Participating Group Protocol No.
Participating Group Patient ID
Institution/Affiliate
Are data amended? (If yes, please circle
amended items in red)
Yes
No
Vital Status
Patient?s Vital Status
Alive (Alive)
Dead (Dead)
Date of Last Contact or Death (M D Y)
Cause of Death (if applicable)
Due To Other Cause (Due to other
cause)
Due To Protocol Treatment (Due to
protocol treatment)
Due To This Disease (Due to this
disease)
Unknown (Unknown)
High Dose Cytarabine Consolidation
Therapy
1 / 3
Cycle Number
Cycle 1 (Cycle 1)
Cycle 2 (Cycle 2)
Patient weight
Treatment Start Date
GM-CSF Initial Dose
Treatment End Date
Peripheral Bood Stem Cell Harvest
Date of initial PBSC harvest
Total no. of CD34+ cells harvested
Gemtuzumab-ozogamicin Consolidation
Therapy
Cyclophosphamide Total Dose
Transplant Conditioning Regimen
Pbsc Reinfusion
Date of last peripheral blood stem cell infusion
Total number of CD34+ cells infused
Transfusions
Number of post-transplant platelet transfusions
Date of most recent platelet transfusion
Number of post-transplant RBC transfusions
Date of most recent RBC transfusion
Reason Treatment Ended (Choose one)
Alternative Therapy (Alternative therapy)
Death After Beginning Protocol Therapy
(Death after beginning protocol therapy)
Disease Progression, Relapse During
2 / 3
Treatment Form - Autologous Transplant NCT00049517
Active Treatment (Disease progression,
relapse during active treatment)
Other (Other)
Patient Off-treatment For Other
Complicating Disease (Other
complicating disease)
Patient Withdrawal Or Refusal After
Beginning Protocol Therapy (Patient
withdrawal or refusal after beginning
protocol therapy)
Toxicity/side Effects/complications
(Toxicity/side effects/complications)
Treatment Completed Per Protocol
Criteria (Treatment completed per
protocol criteria)
Specify complicating disease (reason treatment
ended)
Specify other Reasons (reason treatment ended)
Comments
Comments
Investigator Signature
Date
Ccrr Module For Treatment Form -
Autologous Transplant
Agent Name
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E1900 Toxicity Form NCT00049517
E1900 Toxicity Form NCT00049517 
Combination Chemotherapy With or Without Monoclonal
Antibody Therapy Followed by Stem Cell Transplant in
Treating Patients With Acute Myeloid Leukemia
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=A7294BEF-
41E2-2FCE-E034-0003BA0B1A09
All rights reserved. Please visit https://medical-data-
models.org/forms/10582
E1900 Toxicity Form NCT00049517
ECOG clinical trial administrative data
ECOG Protocol No.
ECOG Patient ID
Registration Step
Adverse Event Reporting From Date (M D Y)
Adverse Event Reporting To Date (M D Y)
Reporting Period
Current Phase Of Leukemia Treatment
For Patient Is Consolidation
(consolidation)
Current Phase Of Leukemia Treatment
For Patient Is Induction (induction)
post transplant (post transplant)
Patient?s Name
Participating Group Protocol No.
Participating Group Patient ID
Institution/Affiliate
Are data amended? (If yes, please circle
amended items in red)
Yes
No
Adverse event assessment
CTC Adverse Event Term
CTC Adverse Event Grade
CTC Adverse Event Attribution Code
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Definitely (definite)
Possibly (possible)
Probably (probable)
Unlikely (unlikely)
Unrelated (unrelated)
Other CTC Adverse Event Term(s) not listed (Use
CTC terminology)
Comments
Comments
Investigator Signature
Date
Ccrr Module For E1900 Toxicity Form
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E1900 Non-Protocol Therapy Form
NCT00049517
E1900 Non-Protocol Therapy Form NCT00049517 
Combination Chemotherapy With or Without Monoclonal
Antibody Therapy Followed by Stem Cell Transplant in
Treating Patients With Acute Myeloid Leukemia
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=A7293E99-
DB96-2FBE-E034-0003BA0B1A09
All rights reserved. Please visit https://medical-data-
models.org/forms/10583
E1900 Non-Protocol Therapy Form
NCT00049517
ECOG clinical trial administrative data
ECOG Protocol No.
ECOG Patient ID
Registration Step
Patient?s Name
Participating Group Protocol No.
Participating Group Patient ID
Institution/Affiliate
Are data amended? (If yes, please circle
amended items in red)
Yes
No
Non-protocol therapy
Date of FIRST non-protocol therapy (if given prior
to progression/relapse from protocol therapy:)
Type(s) of first non-protocol therapy (which
includes any cancer therapy that is not part of the
planned regimen.)
Non-protocol Chemotherapy (Non-
protocol Chemotherapy)
Non-protocol High Dose
Chemotherapy/stem Cell Transplant
(autologous Or Allogeneic) (Non-protocol
High Dose Chemotherapy/Stem Cell
Transplant (Autologous or Allogeneic))
Non-protocol Hormonal Therapy (Non-
protocol Hormonal Therapy)
Non-protocol Immunotherapy/biological
Response Modifiers (Non-protocol
Immunotherapy/Biological Response
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Modifiers)
Non-protocol Radiation Therapy (Non-
protocol Radiation Therapy)
Non-protocol Surgery (Non-protocol
Surgery)
Other Non-protocol Therapy (Other Non-
protocol Therapy)
Name of other non-protocol therapy:
Was the non-protocol therapy given for the
disease of this protocol? (NOTE: Treatment for a
second primary in the same organ site would not
be considered therapy for disease of this
protocol.)
No (No)
Unknown (Unknown)
Yes (Yes)
Comments
Comments
Investigator Signature
Date
Ccrr Module For E1900 Non-protocol
Therapy Form
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AMC-052 Eligibility Checklist Segment B
NCT00513526
AMC-052 Eligibility Checklist Segment B NCT00513526 
Human Papillomavirus Vaccine Therapy in Treating Men
With HIV-1 Infection
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=3BAEF387-
E2CE-2E35-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/10584
AMC-052 Eligibility Checklist
Segment B NCT00513526
Inclusion Criteria
Inclusion Criteria
Anal Hpv Dna Pcr Result: Type 16;
Positive, Negative Type 18; Positive,
Negative (Anal HPV DNA PCR result:
Type 16; positive, negative Type 18;
positive, negative)
Did The Participant Have A Normal Anal
Cytological Results, Or Ascus/lsil Result,
Within 45 Days Prior To Entry (Did the
participant have a normal anal
cytological results, or ASCUS/LSIL
result, within 45 days prior to entry)
Has The Participant Received
Antiretroviral Therapy Continuously (i.e.
No Interruptions Of Antiretroviral Therapy
Lasting Longer Then 7 Days) For At
Least 6 Months Prior To Entry (Has the
participant received antiretroviral therapy
continuously (i.e. no interruptions of
antiretroviral therapy lasting longer then
7 days) for at least 6 months prior to
entry)
Has The Participant's Antiretroviral
Therapy Remained Unchanged In The
30 Days Prior To Entry (Has the
participant's antiretroviral therapy
remained unchanged in the 30 days prior
to entry)
Is The Participant Planning To Remain
Off Antiretroviral Therapy Within 28
Weeks After Entry (Is the participant
planning to remain off antiretroviral
therapy within 28 weeks after entry)
Is The Participant Receiving
Antiretroviral Therapy (Is the participant
receiving antiretroviral therapy)
Is The Participant's Screening Cd4+ Cell
Count >=350 Cells/mm^3 (within 90
Days Prior To Entry) (Is the participant's
screening CD4+ cell count >=350
cells/mm^3 (within 90 days prior to
entry))
Is The Participant's Screening Cd4+ Cell
Count >200 Cells/mm^3 (Is the
participant's screening CD4+ cell count
>200 cells/mm^3)
Is The Participant's Screening Plasma
1 / 3
Hiv-1 Rna Result (i.e. Viral Load) Below
The Limit Of Detection (with The Lower
Limit Of Detection 200 Copies Or Less)
Or Detectable But < 200 Copies/ml (Is
the participant's screening plasma HIV-1
RNA result (i.e. viral load) below the limit
of detection (with the lower limit of
detection 200 copies or less) or
detectable but < 200 copies/ml)
Karnofsky Performance Status (must Be
>=70 And Assessed Within 45 Or Fewer
Days Prior To Entry) (Karnofsky
performance status (must be >=70 and
assessed within 45 or fewer days prior to
entry))
Were The Following Hematologic
Parameters Met And Performed Within
45 Days Prior To Study Entry: Absolute
Neutrophil Count (>750 Cells/mm^3);
Hemoglobin (>=9.0 G/dl); Platelet Count
(>=100,000/ Mm^3) (Were the following
hematologic parameters met and
performed within 45 days prior to study
entry: Absolute neutrophil count (>750
cells/mm^3); Hemoglobin (>=9.0 g/dL);
Platelet count (>=100,000/ mm^3))
Were The Following Laboratory
Parameters Met And Performed Within
45 Days Prior To Study Entry: Creatinine
(<=3 X Uln); Ast (<=3 X Uln); Alt (<=3 X
Uln); Bilirubin (total Or Direct) (<=2.5 X
Uln) (Were the following laboratory
parameters met and performed within 45
days prior to study entry: Creatinine (<=3
x ULN); AST (<=3 x ULN); ALT (<=3 x
ULN); Bilirubin (total or direct) (<=2.5 x
ULN))
Exclusion Criteria
Exclusion Criteria
Did The Participant Have Serious Illness
Requiring Systemic Treatment And/or
Hospitalization Within 45 Days Prior To
Entry (Did the participant have serious
illness requiring systemic treatment
and/or hospitalization within 45 days
prior to entry)
Does The Participant Have A History Of
Anal Cytological Result With Hsil,
Atypical Squamous Cells Suggestive Of
Hsil, Or Suggestive Of Carcinoma (Does
the participant have a history of anal
cytological result with HSIL, atypical
squamous cells suggestive of HSIL, or
suggestive of carcinoma)
Does The Participant Have A History Of
Anal Or Perianal Carcinoma (Does the
participant have a history of anal or
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perianal carcinoma)
Does The Participant Have A History Of
High Grade Ain (i.e. Ain 2 Or 3) Or High
Grade Perianal Intraepithelial Neoplasia
(Does the participant have a history of
high grade AIN (i.e. AIN 2 or 3) or high
grade perianal intraepithelial neoplasia)
Does The Participant Have Active Drug
Or Alcohol Use Or Dependence That, In
The Opinion Of The Site Investigator,
Would Interfere With Adherence To
Study Requirements (Does the
participant have active drug or alcohol
use or dependence that, in the opinion of
the site investigator, would interfere with
adherence to study requirements)
Has The Participant Received Any
Systemic Antineoplastic Or
Immunomodulatory Treatment, Systemic
Corticosteroids, Investigational Vaccines,
Interleukins, Interferons, Growth Factors,
Or Ivig, <=45 Days Prior To Entry (Has
the participant received any systemic
antineoplastic or immunomodulatory
treatment, systemic corticosteroids,
investigational vaccines, interleukins,
interferons, growth factors, or IVIG, <=45
days prior to entry)
Is The Participant Receiving
Anticoagulation Therapy Other Than
Acetylsalicylic Acid At The Time Of Entry
(Is the participant receiving
anticoagulation therapy other than
acetylsalicylic acid at the time of entry)
Karnofsky Performance Status
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AMC-052 Missed Visit Form (F35)
NCT00513526
AMC-052 Missed Visit Form (F35) NCT00513526 
Human Papillomavirus Vaccine Therapy in Treating Men
With HIV-1 Infection
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=395422A0-
6061-42B3-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/10585
AMC-052 Missed Visit Form (F35)
NCT00513526
Missed Visit data
Visit number
Missed Visit Date
Reason patient missed visit
Health Reasons (Health reasons)
Other (Other)
Patient Could Not Get Off Work (Patient
could not get off work)
Patient Decided To Discontinue Study
(Patient decided to discontinue study)
Patient Experienced An Adverse Event
(Patient experienced an Adverse Event)
Patient Forgot (Patient forgot)
Patient Had Transportation Problems
(Patient had transportation problems)
Patient Unable To Obtain Dependent
Care (Patient unable to obtain dependent
care)
Patient Unhappy With Frequency Of
Visits (Patient unhappy with frequency of
visits)
Scheduling Difficulties (Scheduling
difficulties)
Other, specify
Next visit scheduled
Yes
No
Comments
Comments
1 / 1
AMC-052 Oral Mucosal Tissue Examination
For Oral Warts Form (OHA) NCT00513526
AMC-052 Oral Mucosal Tissue Examination For Oral Warts
Form (OHA)NCT00513526 
Human Papillomavirus Vaccine Therapy in Treating Men
With HIV-1 Infection
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=395233F2-
905B-4E17-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/10588
AMC-052 Oral Mucosal Tissue
Examination For Oral Warts Form
(OHA) NCT00513526
Header Module
Visit number
Sequence number
ORAL WARTS LOCATION AND EXTENT
OF ORAL WART DISEASE
Oral exam performed (at this visit)
No (No)
Yes (Yes)
Specify (If no)
Oral warts present (at this visit)
No (No)
Yes (Yes)
Oral warts location
Dorsum Of Tongue (Dorsum of tongue)
Floor Of Mouth (Floor of mouth)
Hard Palate (Hard palate)
Left Buccal Mucosa (Left buccal
mucosa)
Lower Labial Mucosa (Lower labial
mucosa)
Lower Left Gingiva (Lower left gingiva)
Lower Lip (Lower lip)
Lower Right Gingiva (Lower right
gingiva)
Right Buccal Mucosa (Right buccal
mucosa)
Soft Palate (Soft palate)
Upper Labial Mucosa (Upper labial
mucosa)
Upper Left Gingiva (Upper left gingiva)
Upper Lip (Upper lip)
Upper Right Gingiva (Upper right
gingiva)
Ventral And Lateral Tongue (Ventral and
lateral tongue)
Extent of oral wart disease
1 / 2
No Wart Seen (No wart seen)
Not Evaluated (Not evaluated)
Wart(s) Covering Less Than 25% Of
Area (Wart(s) covering less than 25% of
area)
Warts Covering 25% To 50% Of Area
(Warts covering 25% to 50% of area)
Warts Covering More Than 50% Of Area
(Warts covering more than 50% of area)
Oral wart color
Pink (mucosa Color) (Pink (mucosa
color))
White (White)
Oral wart characteristics
Any Combination (Any combination)
Cauliflower-like (Cauliflower-like)
Smooth (Smooth)
Spiky (Spiky)
Prior History And Treatment
Oral warts previously detected (at the last oral
examination visit for this study)
No (No)
Yes (Yes)
Prior Biopsy for Oral Warts (since the last oral
examination visit for this study)
No (No)
Yes (Yes)
Prior Treatment for Oral Warts (since the last oral
examination visit for this study)
No (No)
Yes (Yes)
Oral Warts Treatment Result (per participant
report)
No Resolution (No resolution)
Partial Resolution (Partial resolution)
Total Resolution (Total resolution)
Unknown (Unknown)
Further information concerning oral warts (If
"Yes" specify in comments)
No (No)
Yes (Yes)
Comments Module
Comments
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NCT00513526
AMC-052 Screen Failure Form
NCT00513526
AMC-052 Screen Failure Form NCT00513526 
Human Papillomavirus Vaccine Therapy in Treating Men
With HIV-1 Infection
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=3A53B09A-
E5AB-7491-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/10589
AMC-052 Screen Failure Form
NCT00513526
Patient infection medical history
HIV risk factor present
No (No)
Yes (Yes)
History of intravenous drug use
No (No)
Yes (Yes)
Anal cytology performed
No (No)
Yes (Yes)
Anal cytology result
Asc-h (ASC-H)
Ascus (ASCUS)
High Grade Sil (High grade SIL)
Low Grade Sil (Low grade SIL)
Normal (Normal)
Unevaluable (Unevaluable)
High-resolution anoscopy performed
No (No)
Yes (Yes)
Anal biopsy performed
No (No)
Yes (Yes)
Most severe anal biopsy result
Colonic Epithelium (Colonic epithelium)
Condyloma (Condyloma)
Flat Condyloma (Flat condyloma)
High-grade Ain (High-grade AIN)
Invasive Cancer (Invasive cancer)
Low-grade Ain (Low-grade AIN)
Normal Squamous Epithelium (Normal
squamous epithelium)
Squamous Metaplasia (Squamous
metaplasia)
Unevaluable (Unevaluable)
Anal HPV DNA PCR obtained
No (no)
Yes (yes)
HPV Type 16 Results
Negative (Negative)
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Not Done (Not done)
Positive (Positive)
Results Not Available (Results not
available)
HPV Type 18 Results
Negative (Negative)
Not Done (Not done)
Positive (Positive)
Results Not Available (Results not
available)
Screen Failure
Primary reason for screen failure
Active Drug Or Alcohol Use Or
Dependence That, In The Opinion Of
The Site Investigator, Would Interfere
With Adherence To Study Requirements
(Active drug or alcohol use or
dependence that, in the opinion of the
site Investigator, would interfere with
adherence to study requirements)
Anal Cytology With Hsil, Asc-h, Or
Suggestive Of Carcinoma (Anal cytology
with HSIL, ASC-H, or suggestive of
carcinoma)
Antiretroviral Therapy Not Continuous
For At Least 6 Months Prior To Entry
(Antiretroviral therapy not continuous for
at least 6 months prior to entry)
Cd4 Cell Count (CD4 cell count)
Change In Antiretroviral Therapy
(Change in antiretroviral therapy)
Current Or History Of Anal Or Perianal
Carcinoma (Current or history of anal or
perianal carcinoma)
Hematologic Parameters Not Met
(Hematologic parameters not met)
Hiv-1 Rna (HIV-1 RNA)
Laboratory Parameters Not Met
(Laboratory parameters not met)
Other (Other)
Participant Is Currently Receiving
Anticoagulation Therapy Other Than
Acetylsalicylic Acid (Participant is
currently receiving anticoagulation
therapy other than acetylsalicylic acid)
Participant Withdrew Consent
(Participant withdrew consent)
Plans To Start Antiretroviral Therapy
Prior To Week 28 (Plans to start
antiretroviral therapy prior to Week 28)
Positive For Both Hpv Type 16 And Hpv
Type 18 (Positive for both HPV type 16
and HPV type 18)
Serious Illness Requiring Systemic
Treatment And/or Hospitalization Within
45 Days Prior To Entry (Serious illness
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requiring systemic treatment and/or
hospitalization within 45 days prior to
entry)
The Maximum Number Of Participants
On Antiretroviral Therapy Are Already
Enrolled (The maximum number of
participants on antiretroviral therapy are
already enrolled)
The Maximum Number Of Participants
With Hpv Type 16 Are Already Enrolled
(The maximum number of participants
with HPV type 16 are already enrolled)
The Maximum Number Of Participants
With Hpv Type 18 Are Already Enrolled
(The maximum number of participants
with HPV type 18 are already enrolled)
Use Of Any Systemic Antineoplastic Or
Immunomodulatory Treatment, Systemic
Corticosteroids, Investigational Vaccines,
Interleukins, Interferons, Growth Factors,
Or Ivig Within 45 Days Prior To Study
Entry (Use of any systemic
antineoplastic or immunomodulatory
treatment, systemic corticosteroids,
investigational vaccines, interleukins,
interferons, growth factors, or IVIG within
45 days prior to study entry)
Other, specify
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CALGB: 80101 Follow-up/Relapse Form
NCT00052910
CALGB: 80101 Follow-up/Relapse Form NCT00052910
Chemotherapy and Radiation Therapy After Surgery in
Treating Patients With Stomach or Esophageal Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=A3614107-
525D-15BB-E034-080020C9C0E0
All rights reserved. Please visit https://medical-data-
models.org/forms/10590
CALGB: 80101 Follow-up/Relapse
Form NCT00052910
CALGB clinical trial administrative data
CALGB Form
CALGB Study No
CALGB Patient ID
Reporting period start date
To: (Date of Last contact or death)
Are data amended?
Yes (Yes)
patient demographics
Patient's Name
Participating Group
Patient Hospital No
Participating Group Protocol No
Institution/Affiliate
Participating Group Patient ID
Patient's vital status (mark one with an X)
Alive (Alive)
Dead (Dead)
Lost (Lost)
Primary cause of death (mark one with an X)
Due To Other Cause, Specify (Due to
other cause, specify)
Due To Protocol Treatment (Due to
protocol treatment)
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Due To This Disease (Due to this
disease)
Due to other cause, specify
Notice Of Progression/relapse
Has the patient developed a progression (or
relapse) during this time period that has not been
previously reported?
No (No)
Yes (Yes)
Date progressive or recurrent disease diagnosed
Site(s) of progression/relapse (mark all that apply
with an X)
Anastomosis (Anastomosis)
Bone (Bone)
Cns/brain (CNS/Brain)
Liver (Liver)
Lung (Lung)
Lymph Nodes (Lymph nodes)
Mesentery/peritoneum
(Mesentery/peritoneum)
Other, Specify (Other, specify)
Residual Stomach (Residual stomach)
Tumor Bed/regional Organs (Tumor
bed/regional organs)
Other, specify (sites of progression)
Lymph nodes, specify site
Stat Use Only
Location of relapse
Distant (Distant)
Local-regional (Local-regional)
Notice Of New Primary
Has a new primary cancer or AML/MDS been
diagnosed that has not been previously reported?
No (No)
Yes (Yes)
Date of diagnosis
Site(s) of new primary
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Completed by (First Name, Last Name)
Date completed
Ccrr Module For Calgb: 80101 Follow-
up/relapse Form
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CALGB: 80101 Follow-up and Relapse
Form NCT00052910
CALGB: 80101 Follow-up and Relapse Form
NCT00052910
Chemotherapy and Radiation Therapy After Surgery in
Treating Patients With Stomach or Esophageal Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=A35FE240-
0E00-10FB-E034-080020C9C0E0
All rights reserved. Please visit https://medical-data-
models.org/forms/10591
CALGB: 80101 Follow-up and
Relapse Form NCT00052910
CALGB clinical trial administrative data
CALGB Form
CALGB Study No
CALGB Patient ID
Reporting period start date
To: (Date of Last contact or death)
Are data amended?
Yes (Yes)
Ccrr Module For Calgb: 80101 Follow-up
And Relapse Form
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CALGB: 80101 Adverse Event Form
NCT00052910
CALGB: 80101 Adverse Event Form NCT00052910
Chemotherapy and Radiation Therapy After Surgery in
Treating Patients With Stomach or Esophageal Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=A35FEF5E-
9EE9-11AA-E034-080020C9C0E0
All rights reserved. Please visit https://medical-data-
models.org/forms/10593
CALGB: 80101 Adverse Event Form
NCT00052910
CALGB clinical trial administrative data
CALGB Form
CALGB Study No
CALGB Patient ID
Reporting period start date
Reporting period end date
Are data amended?
Yes (Yes)
Patient's Name
Participating Group
Patient Hospital No
Participating Group Protocol No
Institution/Affiliate
Participating Group Patient ID
Was an AER/ADRE filed with Central Office
based on an event reported below?
Yes
No
Expected Adverse Events
IMT Code
10407 (10407)
11625 (11625)
127 (127)
1377 (1377)
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1423 (1423)
17477 (17477)
17580 (17580)
18172 (18172)
20042 (20042)
21162 (21162)
21197 (21197)
21521 (21521)
22047 (22047)
2395 (2395)
5765 (5765)
Name
Abdominal pain/cramping (Abdominal
pain/cramping)
ANC (ANC)
Anorexia (Anorexia)
Bilirubin (Bilirubin)
Creatinine (Creatinine)
Diarrhea (Diarrhea)
Fatigue (Fatigue)
Hand-foot skin reaction (Hand-foot skin
reaction)
Nausea (Nausea)
Neuropathy-sensory (Neuropathy-
sensory)
Platelets (Platelets)
Radiation dermatitis (Radiation
dermatitis)
Stomatitis/Mucositis
(Stomatitis/Mucositis)
Vomiting (Vomiting)
WBC (WBC)
Grade
-1 (-1)
0 (0)
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
Treatment Related
Definitely (Definitely related to treatment)
Possibly (Possibly related to treatment)
Probably (Probably related to treatment)
Unlikely (Unlikely to be related to
treatment)
Unrelated (Unrelated to treatment)
IMT Code (other)
Name (other)
Completed By (First Name, Last Name)
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Date Form Completed
Ccrr Module For Calgb: 80101 Adverse
Event Form
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CALGB: 80101 ON-STUDY FORM
NCT00052910
CALGB: 80101 ON-STUDY FORM NCT00052910
Chemotherapy and Radiation Therapy After Surgery in
Treating Patients With Stomach or Esophageal Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=9DA712C5-
6067-535F-E034-080020C9C0E0
All rights reserved. Please visit https://medical-data-
models.org/forms/10594
CALGB: 80101 ON-STUDY FORM
NCT00052910
CALGB clinical trial administrative data
CALGB Form
CALGB Study No
CALGB Patient ID
Amended data?
Yes (Yes)
Patient's Name
Participating Group
Patient Hospital Number
Participating Group Protocol No.
Main Member Institution/Adjunct
Participating Group Patient No.
Tumor  Diagnosis
History of primary cancer other than gastric?
No (No)
Yes, specify type of cancer (Yes, specify
type of cancer)
Yes, specify type of cancer
Year of diagnosis
Caloric intake >/= 1500 Kcal/day
Yes
No
1 / 3
Lab Data At Protocol Entry
ANC (x10 3)
Platelets (x10 3)
Serum Creatinine (mg/dl)
SGOT (U/ml)
Bilirubin (mg/dl)
Patient examined by RT oncologist?
Bilateral renal function as determined by scan?
Prior systemic chemotherapy?
Prior immunotherapy?
Prior radiotherapy?
Gastric Resection Data
Date of gastric resection
Site of gastric primary
Antrum (Antrum)
Cardia (Cardia)
Fundus (Fundus)
GE junction (GE junction)
Pylorus (Pylorus)
Stomach, Not Otherwise Specified
(Stomach, NOS)
Name of institution where resection was done
Medicare ID number of institution
Histology & Staging Data
Differentiation
Moderately well differentiated (grade II)
(Moderately well differentiated (grade II))
Tumor Is Poorly Differentiated According
To Who Grading System (Poorly
differentiated (grade III))
Tumor Is Undifferentiated According To
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Who Grading System (Undifferentiated
(grade IV))
Tumor Is Well Differentiated According
To Who Grading System (Well
differentiated (grade I))
AJCC/UICC TNM Staging: T
AJCC/UICC TNM Staging: N
AJCC/UICC TNM Staging: M
If patient has T2N0M0, does tumor extend
beyond muscularis propria?
Yes
No
Completed by
Date completed
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ANHL01P1: On Study NCT00057811
ANHL01P1: On Study NCT00057811 
Rituximab, Rasburicase, and Combination Chemotherapy
in Treating Young Patients With Newly Diagnosed
Advanced B-Cell Leukemia or Lymphoma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=BA4755F9-
8909-46E4-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/10595
ANHL01P1: On Study
NCT00057811
Header Module
Institution
Institution Personnel
COG Number
COG Number
Today's date
Date worksheet entered into RDE
Treatment administrative data
Accession Number (Pre-populated by the
registration system)
Stratum (Pre-populated by the registration
system)
Treatment Number (Pre-populated by the
registration system)
Treating Institution (Pre-populated by the
registration system)
Treating Physician (Pre-populated by the
registration system)
Date of Randomization (Pre-populated by the
registration system)
Date of Callback (Pre-populated by the
registration system)
Date of Registration (Pre-populated by the
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registration system)
Treatment Start Date (Pre-populated by the
registration system)
Method of Payment (Required field)
Medicaid (Medicaid)
Medicaid And Medicare (Medicaid and
Medicare)
Medicare (Medicare)
Medicare And Private Insurance
(Medicare and Private Insurance)
Military Or Veterans Sponsored Nos
(Military or Veterans Sponsored NOS)
Military Sponsored (including Champus
& Tricare) (Military Sponsored (including
CHAMPUS and TRICARE))
No Means Of Payment (no Insurance)
(No means of payment (no insurance))
Other (Other)
Private Insurance (Private Insurance)
Self Pay (no Insurance) (Self pay (no
insurance))
Unknown (Unknown)
Veterans Sponsored (Veterans
Sponsored)
Does patient have any baseline abnormalities
noted during the initial history and physical
examination? (Required field)
No (No)
Unknown (Unknown)
Yes (Yes)
Diagnosis related information
Imaging Studies prior to start of therapy
(Required field)
Abdominal Ct Or Mri (Abdominal CT or
MRI)
Abdominal Ultrasound (Abdominal
Ultrasound)
Bone Scan (Bone Scan)
Chest X-ray, Pa And Lateral (Chest x-
ray)
Gallium Scan (Gallium Scan)
Head Or Spine Ct Or Mri (Head or spine
CT or MRI)
Pet Scan (PET Scan)
Testicular Ultrasound (Testicular
ultrasound)
Unnamed question [results of imaging studies]
Equivocal (Equivocal)
Evidence Of Disease (Evidence of
disease)
No Evidence Of Disease (No evidence of
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disease)
Not Done (Not done)
Was echocardiogram obtained prior to beginning
therapy? (Required field)
N/A not possible due to patient's clinical
condition (N/A not possible due to
patient's clinical condition)
No (No)
Yes (Yes)
Shortening fraction result percentage value
(Required if above question is yes)
Was a bone marrow evaluation done prior to
study entry? (Required field.)
No (No)
Yes (Yes)
what was the date of the exam (If yes,)
percent (%) malignant blasts in bone marrow
(Required if BM evaluation question is yes.)
does the patient have bone marrow involvement?
(If yes,)
No (No)
Unknown (Unknown)
Yes (Yes)
does the patient have bone marrow involvement?
(If yes,)
No (No)
Unknown (Unknown)
Yes (Yes)
Does patient have malignant blasts in peripheral
blood? (Can be yes or no)
No (No)
Yes (Yes)
Does patient have CNS involvement? (Can be
yes or no.)
No (No)
Yes (Yes)
please check all sites of CNS involvement (If
patient has CNS involvement,)
Any L3 Blasts In Csf (Any L3 blasts in
CSF)
Clinical Spinal Cord Compression
(Clinical spinal cord compression)
Cranial Nerve Palsy (Cranial nerve
palsy)
Isolated Intracerebral Mass (Isolated
intracerebral mass)
Parameningeal Extension: Cranial
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And/or Spinal (Parameningeal extension)
Was cerebrospinal fluid cell count done?
(Required if CNS involvement yes)
No (No)
Yes (Yes)
date CSF fluid cell count was done (Required if
CNS involvement yes)
Number of white cells counted (Required if CNS
involvement yes)
Number of red cells counted (Required if CNS
involvement yes)
Peripheral blast count (Required if above
question is yes.)
Peripheral blast count (Required if above
question is yes.)
Were total number of cells counted in the
cytocentrifuge? (Required if CNS involvement
yes)
No (No)
Yes (Yes)
total number of cells counted (Required if above
question is answered as yes)
Ccrr Module For Anhl01p1: On Study
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USMCI 8214/Z6091:  Pre-Treatment
Measurement Form NCT01167725
USMCI 8214/Z6091:  Pre-Treatment Measurement Form
NCT01167725
Standard Therapy With or Without Surgery and Mitomycin
C in Treating Patients With Advanced Limited Peritoneal
Dissemination of Colon Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=8682D50F-
4AD8-16A5-E040-BB89AD434CFC
All rights reserved. Please visit https://medical-data-
models.org/forms/10596
USMCI 8214/Z6091:  Pre-Treatment
Measurement Form NCT01167725
Header
Visit
Baseline (Baseline)
Patient ID
Institution Number
Institution
Assessment Date
Tumor marker
CEA
CA 19-9
Did the patient have measurable disease at
baseline
Yes
No
Measurable Disease
Number of Non-Nodal Target Lesions
Non-nodal target lesion site(s)
Method of Evaluation
Ct Scan (CT scan)
Pet/ct Scan (PET/CT scan)
Physical Exam (Physical exam)
Non-Nodal Longest Diameter of Lesion(s)
Sum of Longest Diameters of All Non-Nodal
Target Lesions
1 / 2
Nontarget lesion present
Yes
No
Non-measurable Disease
Number of non-measurable peritoneal surface
disease lesions
Non-measurable peritoneal surface disease
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USMCI 8214/Z6091:  Active Monitoring
Measurement Form NCT01167725
USMCI 8214/Z6091:  Active Monitoring Measurement Form
NCT01167725
Standard Therapy With or Without Surgery and Mitomycin
C in Treating Patients With Advanced Limited Peritoneal
Dissemination of Colon Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=865EFDDD-
7136-0774-E040-BB89AD43619B
All rights reserved. Please visit https://medical-data-
models.org/forms/10597
USMCI 8214/Z6091:  Active
Monitoring Measurement Form
NCT01167725
Header
Visit
Systemic Therapy (Systemic Therapy)
Patient ID
Institution Number
Institution
Current Cycle Number
Assessment Date
Tumor assessment
Overall Response Status at This Assessment
Complete Response (CR)
Non-cr/non-pd (Non-CR/Non-PD)
Progressive Disease (PD)
Partial Response (PR)
Stable Disease (SD)
Was progression determined by Symptomatic
Deterioration
Yes
No
Weight loss > 10% of body weight
Yes
No
Worsening of tumor-related symptoms
Yes
No
Decline in performance status of >1 level on
ECOG Zubrod scale
Yes
No
1 / 3
Was symptomatic or new ascites with peritoneal
cytology positive for malignancy found
Yes
No
Was any small bowel obstruction requiring
operation with histologically confirmed malignant
obstruction found
Yes
No
Serum CEA
CA 19-9
Did the patient have measurable disease at
baseline
Yes
No
Measurable Disease
Number of Non-Nodal Target Lesions
Non-Nodal Target Lesion Site(s) Longest
Diameter of Lesion(s)
Sum of Longest Diameters of All Non-Nodal
Target Lesions
Nontarget lesion present
Yes
No
Nontarget Lesion Site
Non-Target Lesion Response Status
Complete Remission (CR)
Not Applicable (N/A)
Non-cr/non-pd (Non-CR/Non-PD)
Not Evaluated (Not evaluated)
Pd (PD)
Non-measurable Disease
Number of non-measurable peritoneal surface
disease lesions
Non-measurable peritoneal surface disease
Method of Evaluation
Ct Scan (CT scan)
2 / 3
USMCI 8214/Z6091:  Active Monitoring Measurement Form
NCT01167725
Pet/ct Scan (PET/CT scan)
Physical Exam (Physical exam)
3 / 3
USMCI 8214/Z6091:  Active Monitoring Measurement Form
NCT01167725
ANHL01P1: Secondary Malignancy Report
NCT00057811
ANHL01P1: Secondary Malignancy Report NCT00057811 
Rituximab, Rasburicase, and Combination Chemotherapy
in Treating Young Patients With Newly Diagnosed
Advanced B-Cell Leukemia or Lymphoma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=B9F3995A-
0FE4-23AE-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/10598
ANHL01P1: Secondary Malignancy
Report NCT00057811
Header Module
Institution
Institution Personnel
COG Number
COG Number
Today's date
Date worksheet entered into RDE
Diagnosis
Date of diagnosis of secondary malignancy
(Required field)
Diagnosis (Morphology) (Required field)
Diagnosis (Morphology) ICD-O code (Coded by
central office personnel)
Primary site (Topography) (Required field)
Primary site (Topography) ICD-O code (Coded by
central office personnel)
COMMENTS
Ccrr Module For Anhl01p1: Secondary
Malignancy Report
1 / 1
Southwest Oncology Group Registration
Form Step 2 (S0303) NCT00070122
Southwest Oncology Group Registration Form Step 2
(S0303)
Combination Chemotherapy and Bevacizumab in Treating
Patients With Locally Advanced, Metastatic, or Recurrent
Colorectal Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=ECDF9D42-
18FA-2B72-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/10600
Southwest Oncology Group
Registration Form Step 2 (S0303)
NCT00070122
SWOG clinical trial data
SWOG Study No.
Registration Step
Activation Date
Last Amended Date
Patient's Name
SWOG Patient ID
Other Group Patient Number
Participating Group/Protocol Number
Further registration details
Caller's SWOG Roster ID
SWOG Investigator Number
Other Group Investigator Name
Other Group Investigator Number
SWOG Treating Institution Number
Other Group Institution Name
Other Group Institution Number
NCI Investigator Number
1 / 2
Projected Start Date of Treatment
Date that the patient was reconsented to the
open-label bevacizumab phase of the study
Original TXPREPID from Step 1
2 / 2
Southwest Oncology Group Registration Form Step 2 (S0303)
NCT00070122
ECOG 3200 Registration Form
NCT00025337
ECOG 3200 Registration Form NCT00025337
Combination Chemotherapy With or Without Bevacizumab
Compared With Bevacizumab Alone in Treating Patients
With Advanced or Metastatic Colorectal Cancer That Has
Been Previously Treated
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=A16F911A-
0D80-6BED-E034-080020C9C0E0
All rights reserved. Please visit https://medical-data-
models.org/forms/10601
ECOG 3200 Registration Form
NCT00025337
ECOG Registration Data
Cooperative Group Name
Coordinating Group Protocol Number
Person Completing Form, First Name
Person Completing Form, Last Name
Person Completing Form, Phone
Person Completing Form, Fax
Institution Name
Institution City
Institution State
Institution NCI Code
Investigator Name
Affiliate Name
IRB Approval Date
Informed Consent Date Signed
Patient  enrolled on any other CG trial
Other Cooperative Group Trial-Group Name
Other Cooperative Group Trial-Protocol #
1 / 2
Other Cooperative Group Trial-Specify
Patient Identifier
NCI Investigator Number
Investigator Status
Patient Study ID, Coordinating Group
Treatment Arm Number
Registration Date
CTSU Patient Registrar
Is Treating Institution a CCOP of a Coop
U10
Patient Gender
Patient Race/Ethnicity
Comments1
Comments2
Investigator Code
2 / 2
ECOG 3200 Registration Form NCT00025337
ECOG 3200 Baseline Disease Evaluation
Form (RECIST) NCT00025337
ECOG 3200 Baseline Disease Evaluation Form (RECIST)
NCT00025337
Combination Chemotherapy With or Without Bevacizumab
Compared With Bevacizumab Alone in Treating Patients
With Advanced or Metastatic Colorectal Cancer That Has
Been Previously Treated
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=A16ECDEF-
5203-62F8-E034-080020C9C0E0
All rights reserved. Please visit https://medical-data-
models.org/forms/10602
ECOG 3200 Baseline Disease
Evaluation Form (RECIST)
NCT00025337
Baseline Disease Evaluation
Date of data transfer
Transfer Method
Specify other transfer method
Step No.
Patient Name
Particip. Group Protocol Number
Patient Study ID, Participating Group
Institution Name
Affiliate Name
Amended Data Ind
Amended Data Ind
Target Lesion Ind
Lesion, Reference Number, Target
Lesion, Anatomic Site, Target
Site Code, Target
Assessment Type, Target
1 / 2
Assessment Date, Target
Lesion, Tumor Diameter
Lesion, Diameter, Longest Sum
Lesion, Reference Number, Nontarget
Lesion, Anatomic Site, Nontarget
Site Code, Nontarget
Assessment Type, Nontarget
Assessment Date, Nontarget
Cytology Result
Comments
Comments2
2 / 2
ECOG 3200 Baseline Disease Evaluation Form (RECIST) NCT00025337
ECOG 3200 Non-Protocol Therapy Form
NCT00025337
ECOG 3200 Non-Protocol Therapy Form NCT00025337
Combination Chemotherapy With or Without Bevacizumab
Compared With Bevacizumab Alone in Treating Patients
With Advanced or Metastatic Colorectal Cancer That Has
Been Previously Treated
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=A170529B-
26A1-6913-E034-080020C9C0E0
All rights reserved. Please visit https://medical-data-
models.org/forms/10603
ECOG 3200 Non-Protocol Therapy
Form NCT00025337
ECOG Non-Protocol Therapy Form
Date of data transfer
Transfer Method
Specify other transfer method
Step No.
Patient Name
Particip. Group Protocol Number
Patient Study ID, Participating Group
Institution Name
Affiliate Name
Amended Data Ind
Amended Data Ind
Non-Protocol Therapy Date, First
Non-Protocol Chemotherapy Ind
Non-Protocol Hormonal Therapy Ind
Non-Protocol Immunotherapy Ind
Non-Protocol HDC/ASCT Ind
Non-Protocol Surgery Ind
1 / 2
Non-Protocol RT Ind
Other Non-Protocol Therapy Ind
Other Non-Protocol Therapy Name
Non-Protocol Therapy given for disease
Comments
Comments2
Non-Protocol Therapy not previously rpt
2 / 2
ECOG 3200 Non-Protocol Therapy Form NCT00025337
ECOG 3200 On-Study Form NCT00025337
ECOG 3200 On-Study Form NCT00025337
Combination Chemotherapy With or Without Bevacizumab
Compared With Bevacizumab Alone in Treating Patients
With Advanced or Metastatic Colorectal Cancer That Has
Been Previously Treated
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=A1706D40-
4AAF-6AB7-E034-080020C9C0E0
All rights reserved. Please visit https://medical-data-
models.org/forms/10604
ECOG 3200 On-Study Form
NCT00025337
COG On-Study Form
Date of data transfer
Transfer Method
Specify other transfer method
Step No.
Patient Name
Particip. Group Protocol Number
Patient Study ID, Participating Group
Institution Name
Affiliate Name
Amended Data Ind
Amended Data Ind
Primary Site Ind
Regional Lymph Node(s) Ind
Distant Lymph Node(s) Ind
Lung Site Ind
Liver Site Ind
Other Abdominal Ind
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Bone Site Ind
Brain Site Ind
Distant Skin/Subcutaneous Tissue Ind
Other Site Ind
Other Site Name
Advanced Disease Registration Status
Prior Surgery Ind
Prior Adjuvant Chemotherapy Ind
Prior Adjuvant Immunotherapy Ind
Prior RT Ind
Sites of prior RT
Prior RT End Date
Performance Status
Date CEA obtained
CEA
CEA ULN
CTC Code
CTC Adverse Event Term
CTC Adverse Event Grade
Comments
Comments2
2 / 2
ECOG 3200 On-Study Form NCT00025337
E3200 Toxicity Form NCT00025337
E3200 Toxicity Form NCT00025337
Combination Chemotherapy With or Without Bevacizumab
Compared With Bevacizumab Alone in Treating Patients
With Advanced or Metastatic Colorectal Cancer That Has
Been Previously Treated
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=A16F9E6C-
1B8C-6C02-E034-080020C9C0E0
All rights reserved. Please visit https://medical-data-
models.org/forms/10605
E3200 Toxicity Form NCT00025337
Toxicity Form
Date of data transfer
Transfer Method
Specify other transfer method
Patient Name
Particip. Group Protocol Number
Patient Study ID, Participating Group
Institution Name
Affiliate Name
CTC Adverse Event Report Begin Date
CTC Adverse Event Report End Date
Amended Data Ind
Amended Data Ind
Specify Adverse Event Term
CTC Adverse Event Term
CTC Adverse Event Term
CTC Adverse Event Term
CTC Adverse Event Term
1 / 2
CTC Adverse Event Grade
CTC Adverse Event Grade
CTC Adverse Event Grade
CTC Adverse Event Grade
Comments
Comments2
CTC Code
2 / 2
E3200 Toxicity Form NCT00025337
ECOG 3200 Nontarget Lesions
Supplemental Form NCT00025337
ECOG 3200 Nontarget Lesions Supplemental Form
NCT00025337
Combination Chemotherapy With or Without Bevacizumab
Compared With Bevacizumab Alone in Treating Patients
With Advanced or Metastatic Colorectal Cancer That Has
Been Previously Treated
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=A1705F91-
E41E-69D5-E034-080020C9C0E0
All rights reserved. Please visit https://medical-data-
models.org/forms/10606
ECOG 3200 Nontarget Lesions
Supplemental Form NCT00025337
ECOG Nontarget Lesions Form
Date of data transfer
Transfer Method
Specify other transfer method
Step Number
Cycle
Patient Name
Particip. Group Protocol Number
Patient Study ID, Participating Group
Institution Name
Affiliate Name
Amended Data Ind
Amended Data Ind
Lesion Number
Lesion Site
Lesion Site Code
Lesion Evaluation Method
Lesion Evaluation Date
1 / 2
Follow Up Status of Lesions
Cytology Result
Other Specify
Comments1
Comments2
2 / 2
ECOG 3200 Nontarget Lesions Supplemental Form NCT00025337
ECOG 3200 Long-Term Follow-up Form
NCT00025337
ECOG 3200 Long-Term Follow-up Form NCT00025337
Combination Chemotherapy With or Without Bevacizumab
Compared With Bevacizumab Alone in Treating Patients
With Advanced or Metastatic Colorectal Cancer That Has
Been Previously Treated
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=A1703F76-
0F9C-684E-E034-080020C9C0E0
All rights reserved. Please visit https://medical-data-
models.org/forms/10607
ECOG 3200 Long-Term Follow-up
Form NCT00025337
ECOG Long-Term Follow-up
Date of data transfer
Transfer Method
Specify other transfer method
Step No.
Patient Name
Particip. Group Protocol Number
Patient Study ID, Participating Group
Institution Name
Affiliate Name
Amended Data Ind
Amended Data Ind
Interval Report From Date
Interval Report To Date
Patient's Vital Status
Death Reason
Death Reason, Specify
Death Date/Last Contact Date
1 / 2
Cancer Follow-up Status Ind
Cancer Follow-up Status Date
Progression Ind
Progression Date
Formal Progressive Disease Diagnosis
Progression Site
New Primary Cancer Ind
New Primary Site
Late Adverse Event Ind
Non protocol therapy prior to first progression
Comments
Comments2
Non-Protocol Therapy Date, First
New Primary Cancer Date
2 / 2
ECOG 3200 Long-Term Follow-up Form NCT00025337
ECOG 3200 Follow-Up Disease Evaluation
Form (RECIST) NCT00025337
ECOG 3200 Follow-Up Disease Evaluation Form (RECIST)
NCT00025337
Combination Chemotherapy With or Without Bevacizumab
Compared With Bevacizumab Alone in Treating Patients
With Advanced or Metastatic Colorectal Cancer That Has
Been Previously Treated
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=A1701C6A-
B902-6656-E034-080020C9C0E0
All rights reserved. Please visit https://medical-data-
models.org/forms/10608
ECOG 3200 Follow-Up Disease
Evaluation Form (RECIST)
NCT00025337
Follow-up disease evaluation
Date of data transfer
Transfer Method
Specify other transfer method
Step No.
Course Identification
Patient Name
Particip. Group Protocol Number
Patient Study ID, Participating Group
Institution Name
Affiliate Name
Amended Data Ind
Amended Data Ind
Lesion, Reference Number, Target
Lesion, Anatomic Site, Target
Site Code, Target
Assessment Type, Target
1 / 3
Assessment Date, Target
Lesion, Tumor Diameter
Lesion, Baseline Tumor Diameter
Lesion, Diameter, Longest Sum
Lesion, Reference Number, Nontarget
Lesion, Anatomic Site, Nontarget
Site Code, Nontarget
Assessment Type, Nontarget
Assessment Date, Nontarget
Lesion, Follow-up Status
Cytology Result, Nontarget
Other Specify
New Lesion Ind
Lesion, Reference Number, New
Lesion, Anatomic Site, New
Site Code, New
Assessment Type, New
Assessment Date, New
Cytology Result, New
Has Target Lesion Response Status Change
Target Lesion Response Status
Response Status Change
2 / 3
ECOG 3200 Follow-Up Disease Evaluation Form (RECIST)
NCT00025337
Overall Response
Progressive Disease Observed Date
Progressive Disease Observed Date
Response Confirmed Ind
PR/CR First Observed Date
PR/CR First Observed Date
Symptomatic Deterioration Ind
Symptomatic Deterioration Specify
Symptomatic Deterioration Date
Comments
Comments2
3 / 3
ECOG 3200 Follow-Up Disease Evaluation Form (RECIST)
NCT00025337
ECOG 3200 Nontarget Lesions
Supplemental Form NCT00025337
ECOG 3200 Nontarget Lesions Supplemental Form
NCT00025337
Combination Chemotherapy With or Without Bevacizumab
Compared With Bevacizumab Alone in Treating Patients
With Advanced or Metastatic Colorectal Cancer That Has
Been Previously Treated
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=A16EE644-
C98A-63E2-E034-080020C9C0E0
All rights reserved. Please visit https://medical-data-
models.org/forms/10609
ECOG 3200 Nontarget Lesions
Supplemental Form NCT00025337
ECOG clinical trial administrative data
Date of data transfer
Transfer Method
Specify other transfer method
Step No.
Patient Name
Particip. Group Protocol Number
Patient Study ID, Participating Group
Institution Name
Affiliate Name
Amended Data Ind
Amended Data Ind
Interval Report From Date
Interval Report To Date
Date CEA obtained
CEA
CEA ULN
Comments
1 / 2
Comments2
2 / 2
ECOG 3200 Nontarget Lesions Supplemental Form NCT00025337
ECOG 3200 Adeers NCT00025337
ECOG 3200 Adeers NCT00025337
Combination Chemotherapy With or Without Bevacizumab
Compared With Bevacizumab Alone in Treating Patients
With Advanced or Metastatic Colorectal Cancer That Has
Been Previously Treated
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=A16EBF94-
4868-61DA-E034-080020C9C0E0
All rights reserved. Please visit https://medical-data-
models.org/forms/10610
ECOG 3200 Adeers NCT00025337
Clinical trial administrative data
Date of data transfer
Transfer Method
Specify other transfer method
Amended Data Ind
Report Type
Ticket Number
Amendment Number
Treatment Arm Number
Adverse Event Onset Date
Adverse Event End Date
Recovery or death date
Adverse Event Category
CTC Adverse Event Term
CTC Adverse Event Grade
Hospitalization?
Discharge Summary
CTC Code
1 / 1
NSABP PROTOCOL B-36 Follow-Up Menstrual
History Questionnaire NCT00087178
NSABP PROTOCOL B-36 Follow-Up Menstrual History
Questionnaire NCT00087178
Comparison of Two Combination Chemotherapy Regimens
in Treating Women With Breast Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=C891F490-
0A7E-745C-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/10611
NSABP PROTOCOL B-36 Follow-Up
Menstrual History Questionnaire
NCT00087178
Header Module
Institution Name
Affiliated Institution Name
Person Form Administration Last Name
Person Form Administration First Name
Staff Member Administering Form, Phone
Data Amended Ind-3
Yes (yes)
NSABP Patient ID
Time Point for this Questionnaire (Evaluations
should be carried out according to schedule,
even if the patient discontinues protocol therapy.
Patients who have experienced breast cancer
recurrence or second primary cancer do not need
to fill out this form.)
12-Month Follow-up (12-Month Follow-
up)
18-Month Follow-up (18-Month Follow-
up)
24-Month Follow-up (24-Month Follow-
up)
30-Month Follow-up (30-Month Follow-
up)
36-Month Follow-up (36-Month Follow-
up)
42-Month Follow-up (42-Month Follow-
up)
6-Month Follow-up (6-Month Follow-up)
Day 1 of Cycle #4 (Day 1 of Cycle #4)
Date Questionnaire Completed (Month Day Year)
1 / 2
Menstrual history
Have you had your uterus removed?
No (No)
Unsure (Unsure)
Yes (Yes)
Have you had both your ovaries removed?
No (No)
Unsure (Unsure)
Yes (Yes)
Have you had a menstrual period or vaginal
bleeding in the last 12 months?
No (No)
Unsure (Unsure)
Yes (Yes)
did you period stop or become less frequent
during the last 12 months? (If yes,)
No (No)
Unsure (Unsure)
Yes (Yes)
When was your last menstrual period (or vaginal
bleeding)? (Month Year)
Ccrr Module For Nsabp Protocol B-36
Follow-up Menstrual History
Questionnaire
2 / 2
NSABP PROTOCOL B-36 Follow-Up Menstrual History Questionnaire
NCT00087178
NSABP PROTOCOL B-35 Treatment Form
for Tamoxifen/Anastrozole NCT00053898
NSABP PROTOCOL B-35 Treatment Form for
Tamoxifen/Anastrozole NCT00053898
Anastrozole or Tamoxifen in Treating Postmenopausal
Women With Ductal Carcinoma in Situ Who Are
Undergoing Lumpectomy and Radiation Therapy
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=A051E957-
2260-0392-E034-080020C9C0E0
All rights reserved. Please visit https://medical-data-
models.org/forms/10612
NSABP PROTOCOL B-35 Treatment
Form for Tamoxifen/Anastrozole
NCT00053898
Header Module
First Three Letters of Patient's Last Name
Patient Study ID
Institution Name
Affiliate Name
Person Completing Form Last Name
Person Completing Form First Name
Person Completing Form Phone
Are data amended? (If Yes, circle the amended
items in red.)
No (No)
Yes (Yes)
Summary Of Tamoxifen/anastrozole
Administration
Treatment Begin Date (0=not begun Month Day
Year)
Treatment End Date (0=not begun Month Day
Year )
Reason for end of treatment
Reason Treatment Ended  (Select the reason that
best explains why treatment has ended, or why
the patient did not begin treatment.)
Alternative Therapy (Alternative therapy)
Death After Beginning Protocol Therapy
(Death after beginning protocol therapy)
Death Prior To Beginning Protocol
1 / 2
Therapy (Death prior to beginning
protocol therapy)
Disease Progression, Relapse During
Active Treatment (Disease progression,
relapse during active treatment)
Disease Progression, Relapse Prior To
Beginning Protocol Therapy (Disease
progression, relapse prior to beginning
protocol therapy)
Other (Other)
Patient Off-treatment For Other
Complicating Disease (Patient off-
treatment for other complicating disease)
Patient Withdrawal Or Refusal After
Beginning Protocol Therapy (Patient
withdrawal or refusal after beginning
protocol therapy)
Patient Withdrawal Or Refusal Prior To
Beginning Protocol Therapy (Patient
withdrawal or refusal prior to beginning
protocol therapy)
Toxicity/side Effects/complications
(Toxicity/Side effects/Complications)
Treatment Completed Per Protocol
Criteria (Treatment completed per
protocol criteria)
Other
2 / 2
NSABP PROTOCOL B-35 Treatment Form for Tamoxifen/Anastrozole
NCT00053898
CALGB: ADJUVANT RADIOTHERAPY
REPORT FORM NCT00024102
CALGB: ADJUVANT RADIOTHERAPY REPORT FORM
NCT00024102 
Comparison of Combination Chemotherapy Regimens in
Treating Older Women Who Have Undergone Surgery for
Breast Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=A50C8257-
093C-33B9-E034-080020C9C0E0
All rights reserved. Please visit https://medical-data-
models.org/forms/10613
CALGB: ADJUVANT
RADIOTHERAPY REPORT FORM
NCT00024102
CALGB Information
CALGB Form
CALGB Study No
CALGB Patient ID
Amended data?
Yes (Yes)
Patient clinical trial data
Patient's Name
Participating Group
Patient Hospital Number
Participating Group Protocol No.
Main Member Institution/Adjunct
Participating Group Patient No.
Radiation Treatment
Has the patient received adjuvant therapy? (prior
to diagnosis of recurrence or second primary
cancer)
No (No)
Yes (Yes)
Date adjuvant radiation therapy started (M)
Date adjuvant radiation therapy ended (M)
1 / 2
Nature of radiotherapy (mark one box with an X)
Any Post-mastectomy Radiotherapy (Any
post-mastectomy radiotherapy)
In-breast And Regional Radiotherapy
Following Breast-conserving Surgery (In-
breast and regional radiotherapy
following breast-conserving surgery)
In-breast Radiotherapy Following Breast-
conserving Surgery (In-breast
radiotherapy following breast-conserving
surgery)
Completed By (Print or Type Name)
Date Completed
Ccrr Module For Calgb: Adjuvant
Radiotherapy Report Form
2 / 2
CALGB: ADJUVANT RADIOTHERAPY REPORT FORM NCT00024102
CALGB: Baseline Solid Tumor Evaluation
Form NCT00053339
CALGB: Baseline Solid Tumor Evaluation Form
NCT00053339
Trastuzumab With or Without Tamoxifen in Treating Women
With Progressive Stage IV Breast Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=A73D1562-
3BF3-473F-E034-0003BA0B1A09
All rights reserved. Please visit https://medical-data-
models.org/forms/10614
CALGB: Baseline Solid Tumor
Evaluation Form NCT00053339
CALGB Information
CALGB Form
CALGB Study No
CALGB Patient ID
Amended data?
Yes (Yes)
Patient clinical trial data
Patient's Name
Participating Group
Patient Hospital Number
Participating Group Protocol No.
Main Member Institution/Adjunct
Participating Group Patient No.
Target Lesion(s) Baseline Evaluation
Lesion Number (unnamed)
Site
Date of Evaluation
Method of Evaluation
Bone Scan (Bone scan)
Chest X-ray (chest x-ray)
Clinical Examination (clinical
1 / 2
examination)
Ct Scan (CT scan)
Mri (MRI (NMR))
Not Evaluated (not evaluated)
Other (other)
Spiral Ct Scan (Spiral CT scan)
Ultrasound (Ultrasound)
If other, specify (method of evaluation)
Longest Diameter (cm)
Sum of Longest Diameteres of All Target lesions
(cm)
Non-target Lesion(s) Baseline Evaluation
Are there any non-target lesions?
No (no)
Yes (yes)
Lesion Number (unnamed)
Site
Date of Evaluation
Method of Evaluation
Bone Scan (Bone scan)
Chest X-ray (chest x-ray)
Clinical Examination (clinical
examination)
Ct Scan (CT scan)
Mri (MRI (NMR))
Not Evaluated (not evaluated)
Other (other)
Spiral Ct Scan (Spiral CT scan)
Ultrasound (Ultrasound)
If other, specify (method of evaluation)
Completed by
Date completed
Ccrr Module For Calgb: Baseline Solid
Tumor Evaluation Form
2 / 2
CALGB: Baseline Solid Tumor Evaluation Form NCT00053339
CALGB: 49903 Advanced Disease On-
study Form NCT00053339
CALGB: 49903 Advanced Disease On-study Form
NCT00053339
Trastuzumab With or Without Tamoxifen in Treating Women
With Progressive Stage IV Breast Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=A73D2625-
44FB-4784-E034-0003BA0B1A09
All rights reserved. Please visit https://medical-data-
models.org/forms/10615
CALGB: 49903 Advanced Disease
On-study Form NCT00053339
CALGB Information
CALGB Form
CALGB Study No
CALGB Patient ID
Amended data?
Yes (Yes)
Patient clinical trial data
Patient's Name
Participating Group
Patient Hospital Number
Participating Group Protocol No.
Main Member Institution/Adjunct
Participating Group Patient No.
Menopausal status (mark one with an X)
Above Categories Not Applicable And
Age < 50 (Above categories not
applicable AND age < 50)
Above Categories Not Applicable And
Age => 50 (Above categories not
applicable AND age >= 50)
Post (prior Bilateral Ovariectomy Or >12
Mo Since Lmp With No Prior
Hysterectomy) (Post)
Pre (<6 Mo Since Lmp And No Prior
Bilateral Ovariectomy And Not On
Estrogen Replacement) (Pre)
1 / 4
Advanced Disease Description
ER status (mark one with an X)
Negative (negative)
Positive (positive)
Unknown (unknown)
other, specify (timing of ER assay)
PgR status (mark one with an X)
Negative (negative)
Positive (positive)
Unknown (unknown)
Timing of ER assay (mark one with an X)
At Recurrence (at recurrence)
Initial Diagnosis (initial diagnosis)
Other (other, specify)
Timing of ER assay (mark one with an X)
At Recurrence (at recurrence)
Initial Diagnosis (initial diagnosis)
Other (other, specify)
other, specify (timing of ER assay)
date of initial diagnosis of primary tumor
date progressive or metastatic disease first
diagnosed
Sites Of Progression
Progression site(s) (mark all that apply with an X)
Bone (bone)
Bone Marrow (bone marrow)
Central Nervous System/brain (brain)
Distant Nodes (distant nodes)
Distant Skin/subcutaneous Tissue
(distant skin/subcutaneous tissue)
Ipsilateral Supraclavicular Nodes
(ipsilateral supraclavicular nodes)
Liver (liver)
Local-regional (including Ipsilateral
Breast; Chest Wall; Axillary, Internal
Mammary, And Infraclavicular Nodes;
Local-regional Skin And Subcutaneous
Tissue) (local-regional)
Lung (lung)
Opposite Breast (opposite breast)
Other Cns (other CNS)
First Other, Specify (other, specify)
Pleura (pleura)
other, specify (progression site)
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CALGB: 49903 Advanced Disease On-study Form NCT00053339
Prior systemic therapy
Prior Adjuvant Chemotherapy (prior
adjuvant chemotherapy)
Prior Adjuvant High Dose
Chemotherapy/autologous Stem Cell
Transplant (prior adjuvant high dose
chemotherapy/autologous stem cell
transplant)
Prior Adjuvant Hormonal Therapy (prior
adjuvant hormonal therapy)
Prior Adjuvant Immunotherapy (prior
adjuvant immunotherapy)
Prior Adjuvant Other Therapy (prior
adjuvant other therapy)
Prior Chemotherapy For Metastatis Or
Recurrence (prior chemotherapy for
metastatis or recurrence)
Prior Hdc/assct For Metastasis Or
Recurrence (prior HDC/ASSCT for
metastasis or recurrence)
Prior Hormonal Therapy For Metastatis
Or Recurrence (prior hormonal therapy
for metastatis or recurrence)
Prior Immunotherapy For Metastasis Or
Recurrence (prior immunotherapy for
metastasis or recurrence)
Prior Other Therapy For Metastasis Or
Recurrence (prior other therapy for
metastasis or recurrence)
Prior Treatment Regimen Name(s)
Prior Treatment Regimen Start Date
Prior Treatment Regimen End Date
Prior Treatment Regimen Type
(adjuvant/advanced)
Laboratory
% Lower limit of institutional normal LVEF
Granulocytes
Total bilirubin (mg/dl)
Creatinine (mg/dl)
Platelet count
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Bilirubin upper limit of institutional laboratory
normal (mg/dl)
% LVEF
Alkaline phosphatase (U/mL)
SGOT (U/mL)
SGPT (U/mL)
Completed by
Date Completed
Ccrr Module For Calgb: 49903 Advanced
Disease On-study Form
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CALGB: 49903 Advanced Disease On-study Form NCT00053339
CALGB: 49903 ADVANCED FOLLOW-UP
FORM NCT00053339
CALGB: 49903 ADVANCED FOLLOW-UP FORM
NCT00053339
Trastuzumab With or Without Tamoxifen in Treating Women
With Progressive Stage IV Breast Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=A73D2007-
5070-476F-E034-0003BA0B1A09
All rights reserved. Please visit https://medical-data-
models.org/forms/10616
CALGB: 49903 ADVANCED
FOLLOW-UP FORM NCT00053339
CALGB Information
CALGB Form
CALGB Study No
CALGB Patient ID
From
To (M)
Amended data?
Yes (Yes)
Patient clinical trial data
Patient's Name
Participating Group
Patient Hospital Number
Participating Group Protocol No.
Main Member Institution/Adjunct
Participating Group Patient No.
Cancer follow up
Vital Status (mark one with an X)
Alive (Alive)
Dead (If dead)
Lost (Lost)
cause of death (mark one with an X)
Due To Other Cause, Specify (Due to
other cause)
1 / 3
Due To This Disease (Due to this
disease)
Due To Protocol Treatment (Due to this
protocol treatment)
Unknown (Unknown)
Date of last contact or death (M)
Has patient had a documented clinical
assessment for this cancer since submission of
the previous follow-up form?
No (No)
Yes (Yes)
Date of last clinical assessment (only provide
date if assessment since submission of previous
follow-up form)
Has the patient achieved a response? (mark one
with an X)
Complete Response (complete response
(CR))
Insufficient Evaluation (insufficient
evaluation to determine response status)
Partial Response (partial response (PR))
Partial Response (progressive disease
(PD))
Stable Disease (stable disease (SD))
date response first documented (Notice of
Progression)
Did the patient develop a first progression (or
relapse) that has not been previously reported?
No (No)
Unknown (Unknown)
Yes (Yes)
Date of progression (M)
Non-protocol Therapy
Is the patient receiving any non-protocol cancer
therapy not previously reported?
No (no)
Yes (yes)
Non-protocol therapy
non-protocol hormonal therapy (non-
protocol hormonal therapy)
non-protocol radiation therapy (non-
protocol radiation therapy)
non-protocol surgery (non-protocol
surgery)
other non-protocol therapy (other non-
protocol therapy)
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other non-protocol therapy, specify name
Date of first non-protocol therapy
Date tamoxifen discontinued
Comments
Completed by
Date completed
Ccrr Module For Calgb: 49903 Advanced
Follow-up Form
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SOUTHWEST ONCOLOGY GROUP FOLLOW-UP
TUMOR ASSESSMENT FORM (S0226) NCT00075764
SOUTHWEST ONCOLOGY GROUP FOLLOW-UP
TUMOR ASSESSMENT FORM (S0226) NCT00075764
S0226 Anastrozole With or Without Fulvestrant as First-
Line Therapy in Postmenopausal Women With Metastatic
Breast Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=C3223C5F-
32FD-268C-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/10617
SOUTHWEST ONCOLOGY GROUP
FOLLOW-UP TUMOR
ASSESSMENT FORM (S0226)
NCT00075764
SWOG clinical trial data
SWOG Patient ID
Study No.
Group Name
Physician
Pt. ID
Date form completed
Patient Initials
Registration Step
SWOG Study No.
Institution/Affiliate
Target Lesions
Lesion number
Target Lesion Site
Longest Diameter (cm)
Assessment Type
Colposcopy (Colposcopy)
CT scan (CT scan)
Cystoscopy (Cystoscopy)
1 / 3
Cytologic confirmation (Cytologic
confirmation)
Endoscopy (Endoscopy)
Histologic confirmation (Histologic
confirmation)
MRI scan (MRI scan)
Other (Other)
Palpation (Palpation)
PET scan (PET scan)
Plain film/X-ray with contrast (Plain
film/X-ray with contrast)
Plain film/X-ray without contrast (Plain
film/X-ray without contrast)
Radioisotope scan (Radioisotope scan)
Spiral CT scan (Spiral CT scan)
Ultrasound (Ultrasound)
Visualization (Visualization)
Assessment Date
Non-target Disease
Lesion site
Extent
Clear increase (Clear increase)
Complete disappearance (Complete
disappearance)
Not assessed (Not assessed)
Present (Present)
Lesion Number
Assessment Type
Colposcopy (Colposcopy)
CT scan (CT scan)
Cystoscopy (Cystoscopy)
Cytologic confirmation (Cytologic
confirmation)
Endoscopy (Endoscopy)
Histologic confirmation (Histologic
confirmation)
MRI scan (MRI scan)
Other (Other)
Palpation (Palpation)
PET scan (PET scan)
Plain film/X-ray with contrast (Plain
film/X-ray with contrast)
Plain film/X-ray without contrast (Plain
film/X-ray without contrast)
Radioisotope scan (Radioisotope scan)
Spiral CT scan (Spiral CT scan)
Ultrasound (Ultrasound)
Visualization (Visualization)
Assessment Date
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SOUTHWEST ONCOLOGY GROUP FOLLOW-UP TUMOR
ASSESSMENT FORM (S0226) NCT00075764
New Lesions
Lesion number
Target Lesion Site
Assessment Type
Colposcopy (Colposcopy)
CT scan (CT scan)
Cystoscopy (Cystoscopy)
Cytologic confirmation (Cytologic
confirmation)
Endoscopy (Endoscopy)
Histologic confirmation (Histologic
confirmation)
MRI scan (MRI scan)
Other (Other)
Palpation (Palpation)
PET scan (PET scan)
Plain film/X-ray with contrast (Plain
film/X-ray with contrast)
Plain film/X-ray without contrast (Plain
film/X-ray without contrast)
Radioisotope scan (Radioisotope scan)
Spiral CT scan (Spiral CT scan)
Ultrasound (Ultrasound)
Visualization (Visualization)
Assessment Date
Assessment Date
Symptomatic deterioration
No (No)
Yes (Yes)
Comments
Comments
Ccrr Module For Southwest Oncology
Group Follow-up Tumor Assessment Form
(s0226)
3 / 3
SOUTHWEST ONCOLOGY GROUP FOLLOW-UP TUMOR
ASSESSMENT FORM (S0226) NCT00075764
NSABP Protocol B-35 Radiation Therapy
Report NCT00053898
NSABP Protocol B-35 Radiation Therapy Report
NCT00053898
Anastrozole or Tamoxifen in Treating Postmenopausal
Women With Ductal Carcinoma in Situ Who Are
Undergoing Lumpectomy and Radiation Therapy
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=A01A1AE7-
8AF7-36F3-E034-080020C9C0E0
All rights reserved. Please visit https://medical-data-
models.org/forms/10618
NSABP Protocol B-35 Radiation
Therapy Report NCT00053898
Header Module
First Three Letters of Patient's Last Name
Patient Study ID
Institution Name
Affiliate Name
Person Completing Form Last Name
Person Completing Form First Name
Person Completing Form Phone
Are data amended? (If Yes, circle the amended
items in red.)
Yes
No
adjuvante radiatio status
Has the patient received adjuvant RT? (prior to
treatment failure or second primary cancer)
Yes
No
Adjuvant RT Begin Date (month day year)
Adjuvant RT End Date (month day year)
Was the patient enrolled in NSABP Protocol B-
39/RTOG 0413?
Yes
No
NSABP Patient ID
1 / 2
Breast
Breast Irradiated
Left (Left)
Right (Right)
RT Total Dose (cGY)
No. of Fractions (if applicable)
Beam Energy (Kev if applicable)
Energy Type (if applicable)
Electron (Electron)
X-ray Or Photon (X-ray or Photon)
Operative Area Boost
Operative Area Boost
By Brachytherapy (By brachytherapy)
By Other Method (By other method)
Not Done (Not done)
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CALGB: HER-2/NEU Status Form
NCT00053339
CALGB: HER-2/NEU Status Form NCT00053339
Trastuzumab With or Without Tamoxifen in Treating Women
With Progressive Stage IV Breast Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=A73D12AD-
990B-4739-E034-0003BA0B1A09
All rights reserved. Please visit https://medical-data-
models.org/forms/10619
CALGB: HER-2/NEU Status Form
NCT00053339
CALGB Information
CALGB Form
CALGB Study No
CALGB Patient ID
Amended data?
Yes (Yes)
Patient clinical trial data
Patient's Name
Participating Group
Patient Hospital Number
Participating Group Protocol No.
Main Member Institution/Adjunct
Participating Group Patient No.
Sample Data
Could the tissue sample be evaluated?
Damaged Or Unusable (no)
Useable (yes)
If no, specify reason (sample could not be
evaluated)
Testing Data
Tumor site tested
Metastatic (metastatic)
1 / 2
Primary (primary)
Staining antibody used for IHC
Cb-11/ventana Kit (CB11)
Dako Herceptest [tm] (DAKO A0485
[Herceptest])
Other, Specify (Other, specify)
Other, specify (staining antibody)
Serum ECD test
Other, Specify (Other, specify)
Other, specify (serum ECD test)
Method of testing
Fluorescence In Situ Hybridization (fish)
(Fluorescent in-situ hybridization (FISH))
Immunohistochemistry (ihc)
(Immunohistochemistry (IHC))
Kit used for FISH
Other, Specify (Other, specify)
Ventana/oncorprobe[tm] (Ventana)
Vysis/path Vysion[tm] (Vysis)
Other, specify (FISH Kit)
Testing Results
Her-2/neu Status
Negative (negative)
Positive (positive)
IHC Lab value
0 (0 or 0% cells staining)
1+ (1 or 1-10% cells staining)
2+ (2 or 11-49% cells staining)
3+ (3 or 50-100% cells staining)
Completed by
Date completed
Ccrr Module For Calgb: Her-2/neu Status
Form
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CALGB: HER-2/NEU Status Form NCT00053339
CALGB COOPERATIVE GROUP ADJUVANT
BREAST CANCER RANDOMIZATION NCT00016276
CALGB COOPERATIVE GROUP ADJUVANT BREAST
CANCER RANDOMIZATION NCT00016276
Combination Chemotherapy, Surgery, and Radiation
Therapy With or Without Dexrazoxane and Trastuzumab in
Treating Women With Stage III or Stage IV Breast Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=9E35395C-
8542-227A-E034-080020C9C0E0
All rights reserved. Please visit https://medical-data-
models.org/forms/10621
CALGB COOPERATIVE GROUP
ADJUVANT BREAST CANCER
RANDOMIZATION NCT00016276
CALGB Information
CALGB Patient Number
Participating Group Code Patient No.
Patient Medical Record No.
Participating Group Code
Main Member Institution/Affiliate
Physician of Record
FAX
Phone
Protocol Administration
IRB/REB Approval Date
Person Completing Form, Last Name
Consent Form Date
Person Completing Form, first Name
Projected Start Date
Person Phone
Person Fax
Date of Registration
1 / 4
Registrar
Patient Demographics / Pre U Treatment
Characteristics
Patient Name (l,f,m.i.)
Social Security Number (USA Only)
Patient Race/ Ethnicity
Black (Black)
Filipino (Filipino)
Hispanic (Hispanic)
Indian (Indian)
Institution Refusal (Institution refusal)
Native American (Native American)
Native Hawaiian (Native Hawaiian)
Oriental (Oriental)
Other (Other)
Patient Refusal (Patient refusal)
Unknown (Unknown)
White (White)
Sex
Female (F)
Male (M)
Birthdate
Method of Payment
Medicaid (Medicaid)
Medicaid And Medicare (Medicaid and
Medicare)
Medicare And Private Insurance
(Medicare and Private Insurance)
Millitary Or Veterans Administration
(Millitary or Veterans Administration)
No Means Of Payment (No means of
payment)
Private Insurance (Private Insurance)
Self Pay (Self Pay)
Unknown (Unknown)
Zip Code
(usa Only) ((USA Only))
Performance Status
Ambulatory And Capable Of All Selfcare
But Unable To Carry Out Any Work
Activities, (Ambulatory and capable of all
selfcare but unable to carry out any work
activities,)
Capable Of Limited Selfcare, Confined
To Bed Or Chair More Than 50% Of
Waking Hours, (Capable of limited
selfcare, confined to bed or chair more
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CALGB COOPERATIVE GROUP ADJUVANT BREAST CANCER
RANDOMIZATION NCT00016276
than 50% of waking hours,)
Completely Disabled (Completely
disabled)
Fully Active, Able To Carry On All Pre-
disease Performance Without
Restriction, (Fully active, able to carry on
all pre-disease performance without
restriction,)
Restricted In Physically Strenuous
Activity But Ambulatory, (Restricted in
physically strenuous activity but
ambulatory,)
Pt Height (cm)
Pt Weight (kg)
BSA (m2)
Patient Eligible?
No (No)
Yes, All Requirements Confirmed (Yes,
all requirements confirmed)
Name of medical oncologist
Name of RT oncologist
RN Coordinator
Surgeon
Stratification Factors
Disease  Type
Inflammatory (Inflammatory)
Noninflammatory, Inoperable Stage
Iii/regional Stage Iv (Noninflammatory,
inoperable Stage III/regional Stage IV)
Operable Stage Iii (Operable Stage III)
ASSIGNED TREATMENT ARM
Patient?s initial consent given for specimen use
for research on the patient?s cancer?
No (No)
Yes (Yes)
Patient?s initial consent given for specimen use
for research unrelated to the patient?s cancer?
No (No)
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RANDOMIZATION NCT00016276
Yes (Yes)
Patient?s initial consent given for further contact
regarding specimen?
No (No)
Yes (Yes)
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CALGB COOPERATIVE GROUP ADJUVANT BREAST CANCER
RANDOMIZATION NCT00016276
CALGB: PHYSICAL PROBLEMS DUE TO
CANCER TREATMENT FORM NCT00024102
CALGB: PHYSICAL PROBLEMS DUE TO CANCER
TREATMENT FORM NCT00024102 
Comparison of Combination Chemotherapy Regimens in
Treating Older Women Who Have Undergone Surgery for
Breast Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=A50CCBC1-
A49F-3714-E034-080020C9C0E0
All rights reserved. Please visit https://medical-data-
models.org/forms/10622
CALGB: PHYSICAL PROBLEMS
DUE TO CANCER TREATMENT
FORM NCT00024102
CALGB clinical trial administrative data
CALGB Form
CALGB Study No
CALGB Patient ID
Date Completed (M)
Amended data?
Yes (Yes)
Patient's Name
Responsible CRA
Assessment Number (ADDITIONAL PHYSICAL
PROBLEMS DUE TO CANCER TREATMENT
[SIDE EFFECTS])
Participating Group
Patient Hospital Number
Participating Group Protocol No.
Main Member Institution/Adjunct
Participating Group Patient No.
Physical examination
Mouth sores
A Little (A Little)
1 / 2
Not At All (Not at All)
Quite A Bit (Quite a Bit)
Very Much (Very Much)
Skin changes (such as redness or peeling) on
hands or feet
A Little (A Little)
Not At All (Not at All)
Quite A Bit (Quite a Bit)
Very Much (Very Much)
Swelling in hands or feet
A Little (A Little)
Not At All (Not at All)
Quite A Bit (Quite a Bit)
Very Much (Very Much)
Pain in hands or feet (OVERALL QUALITY OF
LIFE)
A Little (A Little)
Not At All (Not at All)
Quite A Bit (Quite a Bit)
Very Much (Very Much)
what number would you say best describes your
current stat of health over just the past two
weeks? (3. Imagine that a friend of yours is
expected to live for 15 years with the same
quality of live as you have now.  Suppose
treatment could restore your friend to full health,
but would shorten his/her life.)
At most, how much time would you advise your
friend to give up out of 15 years in order to return
to full health? (months)
Ccrr Module For Calgb: Physical Problems
Due To Cancer Treatment Form
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CALGB: PHYSICAL PROBLEMS DUE TO CANCER TREATMENT
FORM NCT00024102
CALGB: 49808 RADIOTHERAPY REPORT
FORM NCT00016276
CALGB: 49808 RADIOTHERAPY REPORT FORM
NCT00016276
Combination Chemotherapy, Surgery, and Radiation
Therapy With or Without Dexrazoxane and Trastuzumab in
Treating Women With Stage III or Stage IV Breast Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=9E35395C-
8724-227A-E034-080020C9C0E0
All rights reserved. Please visit https://medical-data-
models.org/forms/10623
CALGB: 49808 RADIOTHERAPY
REPORT FORM NCT00016276
CALGB clinical trial administrative data
CALGB Form
CALGB Study No
CALGB Patient ID
From
To (Date of last contact or death)
Amended data?
Yes (Yes)
Patient clinical trial data
Patient's Name
Participating Group
Patient Hospital Number
Participating Group Protocol No.
Main Member Institution/Adjunct
Participating Group Patient No.
Radiation Treatment
Has the patient received radiation therapy?
No (No)
Yes (Yes)
If No, reason
Date radiation therapy ended
1 / 2
What was the total number of days the patient
was treated with radiation?
Was there a break in radiation treatment due to
toxicity?
No (No)
Yes (Yes)
If Yes, reason
Date of last radiation therapy prior to break
Date of first radiation therapy after break
Fields of radiation therapy (mark all that apply
with an X)
Axillary Fields (Axillary fields)
Internal Mammary Fields (Internal
mammary fields)
Ipsilateral Breast (Ipsilateral breast)
Ipsilateral Chest Wall (Ipsilateral chest
wall)
Other, Specify: (Other, specify)
Supraclavicular Field (Supraclavicular
field)
Fields of radiation therapy Other, specify
Did patient begin taking tamoxifen during this
reporting period?
No (No)
Yes (Yes)
If Yes, date tamoxifen started
Comments
Comments
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CALGB: 49808 ADVERSE EVENT FORM DOXORUBICIN +
CYCLOPHOSPHAMIDE + ZINECARD (AC+Z) NCT00016276
CALGB: 49808 ADVERSE EVENT FORM DOXORUBICIN
+ CYCLOPHOSPHAMIDE + ZINECARD (AC+Z)
NCT00016276 
Combination Chemotherapy, Surgery, and Radiation
Therapy With or Without Dexrazoxane and Trastuzumab in
Treating Women With Stage III or Stage IV Breast Cancer 
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=9E35395C-
8D28-227A-E034-080020C9C0E0
All rights reserved. Please visit https://medical-data-
models.org/forms/10626
CALGB: 49808 ADVERSE EVENT
FORM DOXORUBICIN +
CYCLOPHOSPHAMIDE +
ZINECARD (AC+Z) NCT00016276
CALGB clinical trial administrative data
CALGB Form
CALGB Study No
CALGB Patient ID
From
To
Amended data?
Yes (Yes)
Patient clinical trial data
Patient's Name
Participating Group
Patient Hospital Number
Participating Group Protocol No.
Main Member Institution/Adjunct
Participating Group Patient No.
Was an AER/ADR filed with Central Office based
on an event reported below? (see section 16.0 of
the protocol)
No (No)
Yes (Yes)
1 / 2
Expected Adverse Events
IMT Code
CTC Adverse Event Term
CTC Grade
Attribution
Definitely Related To Treatment
(definitely related to treatment)
Possibly Related To Treatment (possibly
related to treatment)
Probably Related To Treatment (probably
related to treatment)
Unlikely To Be Related To Treatment
(unlikely to be related to treatment)
Unrelated To Treatment (unrelated to
treatment)
CTC Adverse Event Term, Specify
Were any other events (Hematologic grade 4-5
only or Non-Hematologic grade 3-5 only) noted
during this time period?
No (No)
Yes, Document Below (Yes, document
below)
Completed By
Date Completed
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CYCLOPHOSPHAMIDE + ZINECARD (AC+Z) NCT00016276
CALGB: 49808 TREATMENT SUMMARY FORM
PACLITAXEL + HERCEPTIN (T+H) NCT00016276
CALGB: 49808 TREATMENT SUMMARY FORM
PACLITAXEL + HERCEPTIN (T+H) NCT00016276
Combination Chemotherapy, Surgery, and Radiation
Therapy With or Without Dexrazoxane and Trastuzumab in
Treating Women With Stage III or Stage IV Breast Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=9E35395C-
8B6D-227A-E034-080020C9C0E0
All rights reserved. Please visit https://medical-data-
models.org/forms/10628
CALGB: 49808 TREATMENT
SUMMARY FORM PACLITAXEL +
HERCEPTIN (T+H) NCT00016276
CALGB clinical trial administrative data
CALGB Form
CALGB Study No
CALGB Patient ID
From
To
Amended data?
Yes (Yes)
Patient clinical trial data
Patient's Name
Participating Group
Patient Hospital Number
Participating Group Protocol No.
Main Member Institution/Adjunct
Participating Group Patient No.
Treatment Plan
Initial dose of week 1 or week 7 (Total dose in
mg)
Herceptin (Herceptin)
Paclitaxel (Paclitaxel)
1 / 3
Last date protocol therapy was given
Number of completed weeks of Paclitaxel during
this reporting period
Reason Treatment Ended (mark one with an X)
Alternative therapy (Alternative therapy)
Death on study (Death on study)
Disease progression/relapse during
active treatment (Disease
progression/relapse during active
treatment)
Not applicable (Not applicable)
Other complicating disease (Other
complicating disease)
Other, specify (Other, specify)
Patient withdrawal or refusal after
beginning protocol therapy (Patient
withdrawal or refusal after beginning
protocol therapy)
Patient withdrawal or refusal prior to
beginning protocol therapy (Patient
withdrawal or refusal prior to beginning
protocol therapy)
Toxicity/side effects/complications
(Toxicity/side effects/complications)
Treatment completed per protocol criteria
(Treatment completed per protocol
criteria)
Reason Treatment Ended Other, specify
Treatment Schedule - Systemic Therapy
Were there any dose modifications or additions/
omissions to protocol treatment?  (mark one with
an X)
No (No)
Yes, Planned (Yes, planned)
Yes, Unplanned (Yes, unplanned)
Treatment Schedule - Other Therapy
Were any optional protocol therapies given?
No (No)
Yes (Yes)
Optional Protocol Therapy Name
Were any non-protocol therapies given during
protocol treatment?
No (No)
Yes (Yes)
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HERCEPTIN (T+H) NCT00016276
Concurrent Non-Protocol Chemotherapy?
No (No)
Yes (Yes)
Concurrent Non-Protocol Hormonal Therapy?
No (No)
Yes (Yes)
Concurrent Non-Protocol Biologic Response
Modifier Therapy?
No (No)
Yes (Yes)
Concurrent Non-Protocol Radiation Therapy?
No (No)
Yes (Yes)
Concurrent Non-Protocol High Dose
Chemotherapy/Autologous Stem Cell Transplant?
No (No)
Yes (Yes)
Comments
Comments
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HERCEPTIN (T+H) NCT00016276
CALGB: SPECIMEN ROUTING FORM
PLASMA NCT00016276
CALGB: SPECIMEN ROUTING FORM PLASMA
NCT00016276
Combination Chemotherapy, Surgery, and Radiation
Therapy With or Without Dexrazoxane and Trastuzumab in
Treating Women With Stage III or Stage IV Breast Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=9E35395C-
82EA-227A-E034-080020C9C0E0
All rights reserved. Please visit https://medical-data-
models.org/forms/10630
CALGB: SPECIMEN ROUTING
FORM PLASMA NCT00016276
CALGB clinical trial administrative data
CALGB Form
CALGB Study No
CALGB Patient ID
Amended data?
Yes (Yes)
Patient clinical trial data
Participating Group
Patient's Name
Patient Hospital Number
Participating Group Protocol No.
Main Member Institution/Adjunct
Participating Group Patient No.
To Be Completed By Submitting Institution
Date Completed
Completed By
If no, specify reason
Blood Sample (plasma)
Date plasma specimen collected
1 / 2
CALGB Treatment Study
Does specimen accompany this form? (If yes,
complete the remainder of this form.)
No (No)
Yes (Yes)
Number of tubes submitted
Date sample sent
Time Period Specimen Collected (mark one with
an X)
At Relapse/progression (At
Relapse/Progression)
During Follow-up, No. Therapy (During
Follow-Up, No. Therapy)
During Initial Treatment (During Initial
Treatment)
Pre-treatment (Pre-treatment)
Responsible treating physician
Phone Number to be used in event of sample
problems
To Be Completed By Receiving
Institution/laboratory
Sample received by
Date sample received
Sample Condition (mark one with an X)
Damaged (Damaged)
Damaged But Stored (Damaged but
stored)
Improperly Stored (Improperly stored)
Insufficient Amount (Insufficient amount)
Missing (Missing)
Okay (Okay)
Thawed But Stored (Thawed but stored)
Sample ID no.
Number of Aliquots
Average aliquot volume (cc)
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CALGB: 49808 RESPONSE/PROGRESSION
FORM NCT00016276
CALGB: 49808 RESPONSE/PROGRESSION FORM
NCT00016276
Combination Chemotherapy, Surgery, and Radiation
Therapy With or Without Dexrazoxane and Trastuzumab in
Treating Women With Stage III or Stage IV Breast Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=9E35395C-
867B-227A-E034-080020C9C0E0
All rights reserved. Please visit https://medical-data-
models.org/forms/10632
CALGB: 49808
RESPONSE/PROGRESSION FORM
NCT00016276
CALGB clinical trial administrative data
CALGB Form
CALGB Study No
CALGB Patient ID
From
To (Date of last contact or death)
Amended data?
Yes (Yes)
Patient clinical trial data
Patient's Name
Participating Group
Patient Hospital Number
Participating Group Protocol No.
Main Member Institution/Adjunct
Participating Group Patient No.
Response Assessment
(clinical/radiographic)
Has the patient achieved a response (not
previously reported)?
No (No)
Yes (Yes)
1 / 3
Date overall partial response first documented
Date overall complete response first documented
Has the patient been diagnosed with a new
progression during this reporting period (not
previously reported)?
No (No)
Yes (Yes)
Date response/stable disease last documented
(IF NO:)
Has the patient been diagnosed with a new local-
regional recurrence since submission of the last
follow-up form? (IF YES:)
No (No)
Yes (Yes)
Date of new Local-Regional Recurrence
Site(s) of First Local-Regional Recurrence (mark
all that apply with an X)
Axilla (Axilla)
Axillary Nodes (Axillary nodes)
Chest Wall (Chest wall)
Infraclavicular Nodes (Infraclavicular
nodes)
Internal Mammary (Internal mammary)
Ipsilateral Breast (Ipsilateral breast)
Supraclavicular Nodes (Supraclavicular
nodes)
How was this recurrence information obtained?
Documented Clinical Assessment
(Documented clinical assessment)
Patient Self Report Only (Patient self
report only)
Has the patient been diagnosed with a first
distant progression since submission of the last
follow-up form? (IF YES, continued)
No (No)
Yes (Yes)
Date of First Distant Progression
Site(s) of First Distant Progression
How was this progression information obtained?
Documented Clinical Assessment
(Documented clinical assessment)
Patient Self Report Only (Patient self
report only)
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Comments
Comments
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CALGB: 49808 RESPONSE/PROGRESSION FORM NCT00016276
CALGB: 49808 TREATMENT SUMMARY FORM DOXORUBICIN
+ CYCLOPHOSPHAMIDE + ZINECARD (AC+Z) NCT00016276
CALGB: 49808 TREATMENT SUMMARY FORM
DOXORUBICIN + CYCLOPHOSPHAMIDE + ZINECARD
(AC+Z)
Combination Chemotherapy, Surgery, and Radiation
Therapy With or Without Dexrazoxane and Trastuzumab in
Treating Women With Stage III or Stage IV Breast Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=9E35395C-
89CA-227A-E034-080020C9C0E0
NCT00016276
All rights reserved. Please visit https://medical-data-
models.org/forms/10633
CALGB: 49808 TREATMENT
SUMMARY FORM DOXORUBICIN +
CYCLOPHOSPHAMIDE +
ZINECARD (AC+Z) NCT00016276
CALGB clinical trial administrative data
CALGB Form
CALGB Study No
CALGB Patient ID
From
To
Amended data?
Yes (Yes)
Patient demographics
Patient's Name
Participating Group
Patient Hospital Number
Participating Group Protocol No.
Main Member Institution/Adjunct
Participating Group Patient No.
Treatment Plan
Initial dose of Cycle 1 or Cycle 3
1 / 3
Cyclophosphamide (Cyclophosphamide)
Doxorubicin (Doxorubicin)
Zinecard (Zinecard)
Last date protocol therapy was given
Number of cycles completed this reporting period
Reason Treatment Ended
Alternative Therapy (Alternative therapy)
Death On Study (Death on study)
Disease Progression/relapse During
Active Treatment (Disease
progression/relapse during active
treatment)
Not Applicable (Not applicable)
Other Complicating Disease (Other
complicating disease)
Other, Specify: (Other, specify)
Patient Withdrawal Or Refusal After
Beginning Protocol Therapy (Patient
withdrawal or refusal after beginning
protocol therapy)
Patient Withdrawal Or Refusal Prior To
Beginning Protocol Therapy (Patient
withdrawal or refusal prior to beginning
protocol therapy)
Toxicity/side Effects/complications
(Toxicity/side effects/complications)
Treatment Completed Per Protocol
Criteria (Treatment completed per
protocol criteria)
Reason Treatment Ended Other, specify
Treatment Schedule - Systemic Therapy
Were there any dose modifications or additions/
omissions to protocol treatment?
No (No)
Yes, Planned (Yes, planned)
Yes, Unplanned (Yes, unplanned)
Treatment Schedule - Other Therapy
Were any optional protocol therapies given?
No (No)
Yes (Yes)
Optional Protocol Therapy Name
Were any non-protocol therapies given during
protocol treatment?
No (No)
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CYCLOPHOSPHAMIDE + ZINECARD (AC+Z) NCT00016276
Yes (Yes)
Concurrent Non-Protocol Chemotherapy?
No (No)
Yes (Yes)
Concurrent Non-Protocol Hormonal Therapy?
No (No)
Yes (Yes)
Concurrent Non-Protocol Biologic Response
Modifier Therapy?
No (No)
Yes (Yes)
Concurrent Non-Protocol Radiation Therapy?
No (No)
Yes (Yes)
Concurrent Non-Protocol High Dose
Chemotherapy/Autologous Stem Cell Transplant?
No (No)
Yes (Yes)
Disease Assessment
Disease Assessment
Mammogram (Mammogram)
Physical Exam (Physical Exam)
Ultrasound (Ultrasound)
Primary Tumor Size
Comments
Comments
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CALGB: 49808 TREATMENT SUMMARY FORM DOXORUBICIN +
CYCLOPHOSPHAMIDE + ZINECARD (AC+Z) NCT00016276
CALGB: SPECIMEN ROUTING FORM
WHOLE BLOOD NCT00016276
CALGB: SPECIMEN ROUTING FORM WHOLE BLOOD
NCT00016276
Combination Chemotherapy, Surgery, and Radiation
Therapy With or Without Dexrazoxane and Trastuzumab in
Treating Women With Stage III or Stage IV Breast Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=9E35395C-
824D-227A-E034-080020C9C0E0
All rights reserved. Please visit https://medical-data-
models.org/forms/10634
CALGB: SPECIMEN ROUTING
FORM WHOLE BLOOD
NCT00016276
CALGB clinical trial administrative data
CALGB Form
CALGB Study No
CALGB Patient ID
Amended data?
Yes (Yes)
Patient demographics
Participating Group
Patient's Name
Patient Hospital Number
Participating Group Protocol No.
Main Member Institution/Adjunct
Participating Group Patient No.
To Be Completed By Submitting Institution
Date Completed
Completed By
If no, specify reason
Blood Sample (plasma)
1 / 2
Date plasma specimen collected
CALGB Treatment Study
Does specimen accompany this form? (If yes,
complete the remainder of this form.)
No (No)
Yes (Yes)
Number of tubes submitted
Date sample sent
Specimen Collected (mark one with an X)
At Relapse/progression (At
Relapse/Progression)
During Follow-up, No. Therapy (During
Follow-Up, No. Therapy)
During Initial Treatment (During Initial
Treatment)
Pre-treatment (Pre-treatment)
Responsible treating physician
Phone Number to be used in event of sample
problems
To Be Completed By Receiving
Institution/laboratory
Sample received by
Date sample received
Sample Condition (mark one with an X)
Damaged (Damaged)
Damaged But Stored (Damaged but
stored)
Improperly Stored (Improperly stored)
Insufficient Amount (Insufficient amount)
Missing (Missing)
Okay (Okay)
Thawed But Stored (Thawed but stored)
Sample ID no.
Number of Aliquots
Average aliquot volume (cc)
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CALGB: TRACKING FORM (TISSUE
BLOCKS) NCT00024102
CALGB: TRACKING FORM (TISSUE BLOCKS)
NCT00024102
Comparison of Combination Chemotherapy Regimens in
Treating Older Women Who Have Undergone Surgery for
Breast Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=A50D4607-
D11F-30F7-E034-080020C9C0E0
All rights reserved. Please visit https://medical-data-
models.org/forms/10635
CALGB: TRACKING FORM
(TISSUE BLOCKS) NCT00024102
CALGB clinical trial administrative data
CALGB Form
CALGB Study No
CALGB Patient ID
Amended data?
Yes (Yes)
Patient demographics
Patient's Name
Participating Group
Patient Hospital Number
Participating Group Protocol No.
Main Member Institution/Adjunct
Participating Group Patient No.
pathology/biopsy  status
Do tissue block/slides accompany this form? (If
No,)
No (No)
Yes (Yes)
specify reason (specimen will not be submitted)
Is patient enrolled in a correlative science study?
(If Yes, give the)
No (No)
Yes (Yes)
1 / 2
correlative study number(s)
Surgical Procedure Date (M)
Date blocks and pathology reports submitted (M)
Tissue pathology (mark one with an X)
Lymph Node Metastasis (Lymph node
metastasis)
Metastasis (Metastasis)
Non-malignant Tissue (Non-malignant
tissue)
Primary Tumor (Primary tumor)
Recurrent Tumor (Recurrent tumor)
Uninvolved Node (Uninvolved node)
Method of extraction (mark one with an X)
Axillary Dissection (Axillary dissection)
Biopsy (Biopsy)
General Surgery, Nos (General surgery,
NOS)
Lumpectomy (Lumpectomy)
Mastectomy (Mastectomy)
Re-excision (Re-excision)
Sentinel Node Dissection (Sentinel node
dissection)
Pathology/accession number
Submitted By (Last Name)
Phone No.
Ccrr Module For Calgb: Tracking Form
(tissue Blocks)
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CALGB: TRACKING FORM (TISSUE BLOCKS) NCT00024102
CALGB: STRESSFUL LIFE EVENTS
FORM NCT00024102
CALGB: STRESSFUL LIFE EVENTS FORM
NCT00024102 
Comparison of Combination Chemotherapy Regimens in
Treating Older Women Who Have Undergone Surgery for
Breast Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=A50D4A4E-
900D-3187-E034-080020C9C0E0
All rights reserved. Please visit https://medical-data-
models.org/forms/10636
CALGB: STRESSFUL LIFE
EVENTS FORM NCT00024102
CALGB clinical trial administrative data
CALGB Form
CALGB Study No
CALGB Patient ID
Date Completed (M)
Amended data?
Yes (Yes)
Patient demographics
Patient's Name
Participating Group
Patient Hospital Number
Participating Group Protocol No.
Main Member Institution/Adjunct
Participating Group Patient No.
Responsible CRA
Assessment Number (Event)
Stressful events
Death of spouse (Occurred in Past Year?)
Yes
No
1 / 3
Death of close family member (3.)
Yes
No
Major personal injury or illness (4.)
Yes
No
Being fired from work (5.)
Yes
No
Divorce (6.)
Yes
No
Major change in financial state (7.)
Yes
No
Retirement (8.)
Yes
No
Marital separation from mate (9.)
Yes
No
Marriage (10.)
Yes
No
Death of close friend (11.)
Yes
No
Major illness of family member (12.)
Yes
No
Major change in leisure or other enjoyable
activities (13.)
Yes
No
Change in responsibilities at work (14.)
Yes
No
Moved (15.)
Yes
No
Changed to a different line of work (16.)
Yes
No
Spouse stopped working outside the home
Yes
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No
Ccrr Module For Calgb: Stressful Life
Events Form
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CALGB: STRESSFUL LIFE EVENTS FORM NCT00024102
CALGB: 49907 ADJUVANT TREATMENT SUMMARY
FORM; Subset of Patients NCT00024102
CALGB: 49907 ADJUVANT TREATMENT SUMMARY
FORM; Subset of Patients NCT00024102
Comparison of Combination Chemotherapy Regimens in
Treating Older Women Who Have Undergone Surgery for
Breast Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=A50CEAE3-
8E50-387D-E034-080020C9C0E0
All rights reserved. Please visit https://medical-data-
models.org/forms/10637
CALGB: 49907 ADJUVANT
TREATMENT SUMMARY FORM;
Subset of Patients NCT00024102
CALGB Information
CALGB Form
CALGB Study No
CALGB Patient ID
Cycle start date
Cycle end date (M)
Amended data?
Yes (Yes)
Patient demographics
Patient's Name
Participating Group
Patient Hospital Number
Participating Group Protocol No.
Main Member Institution/Adjunct
Participating Group Patient No.
Treatment Cycle Information
Current Cycle Number
BSA
1 / 2
Total Dose of Drugs for This Cycle (mg)
Agent Name
Adriamycin (Adriamycin)
Capecitabine (Capecitabine)
Cyclophosphamide (Cyclophosphamide)
Fluorouracil (Fluorouracil)
Methotrexate (Methotrexate)
Comments
Comments
Completed By (Print or Type Name)
Date Completed
Ccrr Module For Calgb: 49907 Adjuvant
Treatment Summary Form; Subset Of
Patients
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CALGB: 49907 ADJUVANT TREATMENT SUMMARY FORM; Subset of
Patients NCT00024102
CALGB:  49808 FOLLOW-UP FORM
NCT00016276
CALGB:  49808 FOLLOW-UP FORM NCT00016276
Combination Chemotherapy, Surgery, and Radiation
Therapy With or Without Dexrazoxane and Trastuzumab in
Treating Women With Stage III or Stage IV Breast Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=9E35395C-
87AF-227A-E034-080020C9C0E0
All rights reserved. Please visit https://medical-data-
models.org/forms/10638
CALGB:  49808 FOLLOW-UP FORM
NCT00016276
CALGB clinical trial administrative data
CALGB Form
CALGB Study No
CALGB Patient ID
From
To (Date of last contact or death)
Amended data?
Yes (Yes)
Patient demographics
Patient's Name
Participating Group
Patient Hospital Number
Participating Group Protocol No.
Main Member Institution/Adjunct
Participating Group Patient No.
Patient vital status
Patient's Vital Status (mark one with an X)
Alive (Alive)
Dead (Dead)
Lost (Lost)
Cause of death (if dead) (mark one with an X)
Due To Other Cause (Due to other
cause)
1 / 4
Due To Protocol Treatment (Due to
protocol treatment)
Due To This Disease (Due to this
disease)
Unknown (Unknown)
Describe cause of death
Disease Assessment
Has patient had a documented clinical
assessment for this cancer since submission of
the previous follow-up form?
No (No)
Yes (Yes)
Date of last clinical assessment (only provide
date if assessment was done since submission of
previous follow-up form)
Notice Of Progression
Has the patient been diagnosed with a new local-
regional recurrence since submission of the last
follow-up form?
No (No)
Yes (Yes)
Date of new local-regional recurrence
Site(s) of first local-regional recurrence (mark all
that apply with an X)
Axilla (Axilla)
Axillary Nodes (Axillary nodes)
Chest Wall (Chest wall)
Infraclavicular Nodes (Infraclavicular
nodes)
Internal mammary nodes (Internal
mammary nodes)
Ipsilateral Breast (Ipsilateral breast)
Supraclavicular Nodes (Supraclavicular
nodes)
How was this recurrence information obtained?
(mark one with an X)
Documented Clinical Assessment
(Documented clinical assessment)
Patient Self Report Only (Patient self
report only)
Has the patient been diagnosed with a first
distant progression since submission of the last
follow-up form?
No (No)
Yes (Yes)
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Date of first distant progression
Site(s) of first distant progression
How was this progression information obtained?
Documented clinical assessment
(Documented clinical assessment)
Patient self report only (Patient self
report only)
Notice Of New Primary
Has a new primary cancer or myelodysplastic
syndrome (MDS) been diagnosed that has not
been previously reported?
No (No)
Yes (Yes)
Date of diagnosis
Site(s) of New Primary (If new primary site is
AML/MDS, please submit NCI AML/MDS form.
All other new primaries must be reported using
the MEDWATCH form.  Submit to CALGB Central
Office)
Long-term Toxicity
Has the patient experienced (prior to diagnosis of
recurrence or second primary) any severe (Grade
>=3), long term toxicity related to protocol
treatment that has not been previously reported?
No (No)
Yes, specify below (Yes, specify below)
IMT Code
CTC Adverse Event Term
CTC Grade (only 3, 4, 5)
Date of Onset
Long-term Therapy
Did this patient receive any tamoxifen?
No (No)
Yes (Yes)
Is the patient still receiving tamoxifen? (If Yes:     )
No (No)
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Yes (Yes)
If patient discontinued tamoxifen since last follow-
up, give date.
Completed By
Date Completed
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CALGB:  49808 FOLLOW-UP FORM NCT00016276
CALGB: 49903 ADVERSE EVENT FORM
NCT00053339
CALGB: 49903 ADVERSE EVENT FORM NCT00053339 
Trastuzumab With or Without Tamoxifen in Treating Women
With Progressive Stage IV Breast Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=A73D2363-
5625-477E-E034-0003BA0B1A09
All rights reserved. Please visit https://medical-data-
models.org/forms/10639
CALGB: 49903 ADVERSE EVENT
FORM NCT00053339
CALGB clinical trial administrative data
CALGB Form
CALGB Study No
CALGB Patient ID
From
To (M)
Amended data?
Yes (Yes)
Patient demographics
Patient's Name
Participating Group
Patient Hospital Number
Participating Group Protocol No.
Main Member Institution/Adjunct
Participating Group Patient No.
ADR Report
Was an ADR Report filed based on an event
reported below?
No (No)
Yes (Yes)
Expected Adverse Events
1 / 2
IMT Code
CTC Adverse Event Term
CTC Grade (Coding Instructions: Use the most
current version of the NCI Common Toxicity
Criteria CTC to determine the grade for each
event with the exception of Hand-foot syndrome
see protocol section 12.8.  If no adverse event is
reported for a specific category, code grade = 0.
DO NOT USE THE CALGB EXPANDED
COMMON TOXICITY CRITERIA.)
Attribution (Attribution Codes)
Definitely (definitely related to treatment)
Possibly (possible related to treatment)
Probably (probably related to treatment)
Unlikely (unlikely to be related to
treatment)
Unrelated (unrelated to treatment)
Person Completing Form
Completed By (Print or Type Name)
Date Completed
Ccrr Module For Calgb: 49903 Adverse
Event Form
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NCI Cooperative Group Not for Arm G Patients Colorectal Ca -
Adjuvant Disease Treatment Summary Form NCT00079274
NCI Cooperative Group Not for Arm G Patients Colorectal
Ca - Adjuvant Disease Treatment Summary Form
NCT00079274
Comparison of Combination Chemotherapy Regimens With
or Without Cetuximab in Treating Patients Who Have
Undergone Surgery For Stage III Colon Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=DFAA3B47-
A18B-66D4-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/10640
NCI Cooperative Group Not for Arm
G Patients Colorectal Ca - Adjuvant
Disease Treatment Summary Form
NCT00079274
Header module
Coordinating Group Protocol Number
Coordinating Group Code
Protocol Title
Patient Study ID
Patient Medical Record Number
Patient Initials (L, FM)
Participating Group Code (Cooperative Group
where credit will be applied)
Institution Name (treating location/performance
site)
Are data amended? (If data are amended, please
circle in red when using paper form)
Yes
No
Colorectal: Treatment Summary Interval -
End Of Treatment
First Date Protocol Therapy was Given (MM DD
YYYY)
Last Date Protocol Therapy was Given (MM DD
YYYY)
Reason Treatment Ended (check one)
Adverse Event/side Effects/complications
1 / 4
(Adverse Event/Side
Effects/Complications)
Alternative Therapy (Alternative therapy)
Cytogenetic Resistance (Cytogenetic
Resistance)
Death On Study (Death on study)
Disease Progression Before Active
Treatment (Disease Progression before
active treatment)
Disease Progression, Relapse During
Active Treatment (Disease progression,
relapse during active treatment)
Other (Other)
Patient Off-treatment For Other
Complicating Disease (Patient off
treatment for other complicating disease)
Patient Withdrawal Or Refusal After
Beginning Protocol Therapy (Patient
withdrawal/refusal after beginning
protocol therapy)
Patient Withdrawal Or Refusal Before
Beginning Protocol Therapy (Patient
withdrawal/refusal prior to beginning
protocol therapy)
Treatment Completed Per Protocol
Criteria (Treatment completed per
protocol criteria)
Colorectal: Treatment Schedule -
Systemic Therapy
Total Number of Cycles Given
Were there any dose modifications or
additions/omissions to protocol treatment?
(decreases/increases)
No (No)
Yes, Planned (i.e., The Treatment Was
Changed According To Protocol
Guidelines) (Yes, planned (i.e., the
treatment was changed according to
protocol guidelines))
Yes, Unplanned (i.e., The Treatment
Change Was Not Part Of Protocol
Guidelines) (Yes, unplanned (i.e., the
treatment change was not part of
protocol guidelines))
Agent Name (Pre-filled with response: C225
[cetuximab])
Agent Name (Pre-filled with response: C225
[cetuximab])
Agent Name (Pre-filled with response: C225
[cetuximab])
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Disease Treatment Summary Form NCT00079274
Was agent modified (decreased/increased) or
omitted?
Yes
No
Was agent modified (decreased/increased) or
omitted?
Yes
No
Was agent modified (decreased/increased) or
omitted?
Yes
No
Reason(s) Modified (If yes, [C225]
decreased/increased/omitted [Reasons modified
are based on Dose Modification Table in protocol
section 8.0])
Allergic Reaction (Allergic reaction)
Gi (specific To Patients >= 70 Years) (GI
(specific to patients >= 70 years))
Nail Changes (Nail changes)
Other (Other)
Other, Non-hematologic, Specify (Other
non-hematologic)
Rash/desquamation
(Rash/desquamation)
Reason(s) Modified (If yes, [C225]
decreased/increased/omitted [Reasons modified
are based on Dose Modification Table in protocol
section 8.0])
Allergic Reaction (Allergic reaction)
Gi (specific To Patients >= 70 Years) (GI
(specific to patients >= 70 years))
Nail Changes (Nail changes)
Other (Other)
Other, Non-hematologic, Specify (Other
non-hematologic)
Rash/desquamation
(Rash/desquamation)
Reason(s) Modified (If yes, [C225]
decreased/increased/omitted [Reasons modified
are based on Dose Modification Table in protocol
section 8.0])
Allergic Reaction (Allergic reaction)
Gi (specific To Patients >= 70 Years) (GI
(specific to patients >= 70 years))
Nail Changes (Nail changes)
Other (Other)
Other, Non-hematologic, Specify (Other
non-hematologic)
Rash/desquamation
(Rash/desquamation)
Other non-hematologic resaon agent modified
([C225] - decreased/increased/omitted)
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Other non-hematologic resaon agent modified
([C225] - decreased/increased/omitted)
Other Reason Agent Modified ([C225]
decreased/increased/omitted)
Other Reason Agent Modified ([C225]
decreased/increased/omitted)
Other Reason Agent Modified ([C225]
decreased/increased/omitted)
Disease Evaluation
Response Status at This Assessment
Ned (NED)
Not Evaluated (Not evaluated)
Recurrence (Recurrence)
Assessment Date (mm dd yyyy)
Comments
Comments
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Disease Treatment Summary Form NCT00079274
SOUTHWEST ONCOLOGY GROUP S0221
AC+G TREATMENT FORM NCT00070564
SOUTHWEST ONCOLOGY GROUP S0221 AC+G
TREATMENT FORM NCT00070564
Adjuvant Doxorubicin, Cyclophosphamide, and Paclitaxel in
Treating Patients With Breast Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=E92C74F6-
D5F3-6BB7-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/10641
SOUTHWEST ONCOLOGY GROUP
S0221 AC+G TREATMENT FORM
NCT00070564
Header
SWOG Patient ID
SWOG Study No.
Registration Step
Patient Initials (L, F M)
Institution / Affiliate
Physician
Participating Group Name
Participating Group Study No.
Participating Group Patient ID
Disease Status
Date of Last Clinical Assessment (submit Follow
Up form if patient has relapsed)
Date of Last Contact or Death
Vital Status
Alive (Alive)
Dead (Dead)
Treatment Status
Assigned treatment arm
Arm 2 (Arm 2)
Arm 4 (Arm 4)
Did the patient start treatment on the assigned
1 / 3
arm?
Yes
No
Treatment Begin Date
Treatment End Date
Weight (first day of treatment)
BSA (first day of treatment)
Agent Name
CTX (CTX)
DOX (DOX)
G-CSF (G-CSF)
Agent Initial Dose
Agent Total Cummulative Dose
Were there any dose modifications or
additions/omissions to protocol treatment?
No (No)
Yes, Planned (i.e., The Treatment Was
Changed According To Protocol
Guidelines) (Yes, planned)
Yes, Unplanned (i.e., The Treatment
Change Was Not Part Of Protocol
Guidelines) (Yes, unplanned)
Adverse event assessment
Did the patient experience one or more episodes
of Grade 3 or 4 neutropenia?
Yes
No
If yes, in which cycle(s) did it/they occur?
Did the patient experience one or more episodes
of Grade 3 or 4 febrile neutropenia?
Yes
No
If yes, in which cycle(s) did it/they occur?
Did the patient experience one or more episodes
of Grade 3 or 4 anemia?
Yes
No
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If yes, in which cycle(s) did it/they occur?
Comments
Comments
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SOUTHWEST ONCOLOGY GROUP S0221
AC TREATMENT FORM NCT00070564
SOUTHWEST ONCOLOGY GROUP S0221 AC
TREATMENT FORM NCT00070564
Adjuvant Doxorubicin, Cyclophosphamide, and Paclitaxel in
Treating Patients With Breast Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=E92C6D7A-
4422-6B28-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/10642
SOUTHWEST ONCOLOGY GROUP
S0221 AC TREATMENT FORM
NCT00070564
Header
SWOG Patient ID
SWOG Study No.
Registration Step
Patient Initials (L, F M)
Institution / Affiliate
Physician
Participating Group Name
Participating Group Study No.
Participating Group Patient ID
Disease Status
Date of Last Clinical Assessment (submit Follow
Up form if patient has relapsed)
Date of Last Contact or Death
Vital Status
Alive (Alive)
Dead (Dead)
Treatment Status
Assigned treatment arm
Arm 1 (Arm 1)
Arm 3 (Arm 3)
Arm 5 (Arm 5)
1 / 3
Arm 6 (Arm 6)
Did the patient start treatment on the assigned
arm?
Yes
No
Treatment Begin Date
Treatment End Date
Weight (first day of treatment)
BSA (first day of treatment)
Agent Name
CTX (CTX)
DOX (DOX)
Pegfilgrastim (Pegfilgrastim)
Agent Initial Dose
Agent Total Cummulative Dose
Were there any dose modifications or
additions/omissions to protocol treatment?
No (No)
Yes, Planned (i.e., The Treatment Was
Changed According To Protocol
Guidelines) (Yes, planned)
Yes, Unplanned (i.e., The Treatment
Change Was Not Part Of Protocol
Guidelines) (Yes, unplanned)
Adverse event assessment
Did the patient experience one or more episodes
of Grade 3 or 4 neutropenia?
Yes
No
If yes, in which cycle(s) did it/they occur?
Did the patient experience one or more episodes
of Grade 3 or 4 febrile neutropenia?
Yes
No
If yes, in which cycle(s) did it/they occur?
Did the patient experience one or more episodes
of Grade 3 or 4 anemia?
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Yes
No
If yes, in which cycle(s) did it/they occur?
Comments
Comments
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SOUTHWEST ONCOLOGY GROUP S0221 AC TREATMENT FORM
NCT00070564
SOUTHWEST ONCOLOGY GROUP S0221
PACLITAXEL TREATMENT FORM NCT00070564
SOUTHWEST ONCOLOGY GROUP S0221 PACLITAXEL
TREATMENT FORM NCT00070564
Adjuvant Doxorubicin, Cyclophosphamide, and Paclitaxel in
Treating Patients With Breast Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=03583163-
D58B-189D-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/10643
SOUTHWEST ONCOLOGY GROUP
S0221 PACLITAXEL TREATMENT
FORM NCT00070564
Header
SWOG Patient ID
SWOG Study No.
Registration Step
Patient Initials (L, F M)
Institution / Affiliate
Physician
Participating Group Name
Participating Group Study No.
Participating Group Patient ID
Disease Status
Date of Last Clinical Assessment (submit Follow
Up form if patient has relapsed)
Date of Last Contact or Death
Vital Status
Alive (Alive)
Dead (Dead)
Treatment Status
Assigned treatment arm
Arm 1 (Arm 1)
Arm 2 (Arm 2)
Arm 3 (Arm 3)
1 / 3
Arm 4 (Arm 4)
Arm 5 (Arm 5)
Arm 6 (Arm 6)
Did the patient start treatment on the assigned
arm?
Yes
No
Treatment Begin Date
Treatment End Date
Weight (first day of treatment)
BSA (first day of treatment)
Agent Name
Agent Initial Dose
Agent Total Cummulative Dose
Were there any dose modifications or
additions/omissions to protocol treatment?
No (No)
Yes, Planned (i.e., The Treatment Was
Changed According To Protocol
Guidelines) (Yes, planned)
Yes, Unplanned (i.e., The Treatment
Change Was Not Part Of Protocol
Guidelines) (Yes, unplanned)
Did the patient receive trastuzumab during this
treatment period
Yes
No
Adverse event assessment
Did the patient experience one or more episodes
of Grade 3 or 4 neutropenia?
Yes
No
If yes, in which cycle(s) did it/they occur?
Did the patient experience one or more episodes
of Grade 3 or 4 febrile neutropenia?
Yes
No
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FORM NCT00070564
If yes, in which cycle(s) did it/they occur?
Did the patient experience one or more episodes
of Grade 3 or 4 anemia?
Yes
No
If yes, in which cycle(s) did it/they occur?
Comments
Comments
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SOUTHWEST ONCOLOGY GROUP S0221 PACLITAXEL TREATMENT
FORM NCT00070564
CALGB: 40301 TREATMENT SUMMARY
FORM (ALL PATIENTS)
CALGB: 40301 TREATMENT SUMMARY FORM (ALL
PATIENTS)
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=E59E81A1-
14EB-4A4A-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/10644
CALGB: 40301 TREATMENT
SUMMARY FORM (ALL PATIENTS)
Header
CALGB Form
CALGB Study No
CALGB Patient ID
Reporting period start date
Reporting period end date
Are data amended
Yes
No
Patient demographics
Patient Initials
Patient Hospital No
Institution/Affiliate
Participating Group
Participating Group Protocol No
Participating Group Patient ID
Treatment Plan
Date of first dose for this reporting period
Date of last dose for this reporting period
Last date of protocol treatment
1 / 3
Reason treatment ended (Mark one with an X.)
Alternative Therapy (Alternative therapy)
Death On Study (Death on study)
Disease Progression, Relapse During
Active Treatment (Disease progression,
relapse during active treatment)
Other (Other)
Patient Off-treatment For Other
Complicating Disease (Patient off-
treatment for other complicating disease)
Patient Withdrawal Or Refusal (Patient
withdrawal or refusal after beginning
protocol therapy)
Patient Withdrawal Or Refusal Before
Beginning Protocol Therapy (Patient
withdrawal or refusal prior to beginning
protocol therapy)
Adverse Event/side Effects/complications
(Toxicity/side effects/complications)
Treatment Completed Per Protocol
Criteria (Treatment completed per
protocol criteria)
Other, specify
Were any optional therapies given
Yes
No
specify optional protocol therapy name (If Yes)
Was any non-protocol therapy given during
protocol treatment
Yes
No
specify (If Yes)
Concurrent Non-protocol Biologic
Response Modifier Therapy (Concurrent
non-protocol biologic response modifier
therapy)
Concurrent Non-protocol Chemotherapy
(Concurrent non-protocol chemotherapy)
Concurrent Non-protocol High Dose
Chemotherapy/autologous Stem Cell
Transplant (Concurrent non-protocol high
dose chemotherapy/autologous stem cell
transplant)
Concurrent Non-protocol Hormonal
Therapy (Concurrent non-protocol
hormonal therapy)
Concurrent Non-protocol Radiation
Therapy (Concurrent non-protocol
radiation therapy)
Comments
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CALGB: 40301 TREATMENT SUMMARY FORM (ALL PATIENTS)
COMMENTS
Completed by
Date form completed
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CALGB: 40301 TREATMENT SUMMARY FORM (ALL PATIENTS)
E5202 Off-Treatment Form NCT00217737
E5202 Off-Treatment Form NCT00217737 
Oxaliplatin, Leucovorin, and Fluorouracil With or Without
Bevacizumab in Treating Patients Who Have Undergone
Surgery for Stage II Colon Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=EF124202-
AE33-032B-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/10645
E5202 Off-Treatment Form
NCT00217737
Header
ECOG Protocol Number
ECOG Patient ID
DCI Name
Registration Step
Time period
End Treatment Step 1 (End treatment
Step 1)
End Treatment Step 2 (End treatment
step 2)
Are data amended
Yes
No
Patient demographics
Patient Initials
Participating Group Protocol Number
Institution/Affiliate
Participating Group Patient ID
Vital Status
Patient?s Vital Status
Alive (Alive)
Dead (Dead)
Date of Last Contact or Death
Primary Cause of Death (if applicable)
1 / 2
Due To Other Cause (Due to other
cause)
Due To Protocol Treatment (Due to
protocol treatment)
Due To This Disease (Due to this
disease)
Unknown (Unknown)
Describe cause of death
Reason treatment ended
Other Adverse Event/side
Effects/complications (Adverse
events/side effects/complications)
Alternative Therapy (Alternative therapy)
Other Complicating Disease
(Complicating Disease)
Death On Study (Death on study)
Disease Progression, Relapse During
Active Treatment (Disease progression,
relapse during active treatment)
Other (Other)
Patient Off-treatment For Other
Complicating Disease (Patient off
treatment for other complicating disease)
Patient Withdrawal Or Refusal After
Beginning Protocol Therapy (Patient
withdrawal or refusal after beginning
protocol therapy)
Treatment Completed Per Protocol
Criteria (Treatment completed per
protocol criteria)
Complicating Disease (specify)
Other (specify)
Last date protocol therapy was given
Comments
Comments
Investigator Signature
Investigator Signature Date
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E5202 Off-Treatment Form NCT00217737
NSABP PROTOCOL C-09: Treatment Form
for Group 1 Patients NCT00268463
NSABP PROTOCOL C-09: Treatment Form for Group 1
Patients NCT00268463
Oxaliplatin and Capecitabine With or Without an Hepatic
Arterial Infusion With Floxuridine in Treating Patients Who
Are Undergoing Surgery and/or Ablation for Liver
Metastases Due to Colorectal Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=FCBE2AD1-
8223-57D3-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/10646
NSABP PROTOCOL C-09:
Treatment Form for Group 1 Patients
NCT00268463
Header module
Patient Initials (Last First Middle)
NSABP Patient ID
Institution Name
Affiliate Name
Person Completing Form Last Name
Person Completing Form First Name
Person Completing Form Phone
Total Number of Cycles Given (0, 1, 2, 3, 4, 5, 6,
7, 8)
Treatment End Date (last dose of last cycle Leave
blank if treatment was not begun)
Are data amended (Check box if yes, and circle
amended items)
Yes
No
Patient Height (cm)
Assessment of Chemotherapy
Cycle Number
Cycle Start Date (*)
1 / 2
Patient Weight (If unknown, leave boxes blank)
Agent Name (total mg)
Agent Total Dose (on each cycle)
Was less than full dose administered because of
toxicity?
Yes
No
Why did treatment end or not begin
(CAPECITABINE Select primary reason)
Adverse Event/side Effects/complications
(Adverse event/side
effects/complications)
Alternative Therapy (Alternative therapy)
Death, Recurrence, Or Second Primary
Cancer (Death, recurrence, or second
primary cancer)
Other (Other)
Patient Withdrawal Or Refusal (Patient
withdrawal or refusal)
Treatment Completed Per Protocol
Criteria (Treatment completed per
protocol criteria)
Why did treatment end or not begin
(CAPECITABINE Select primary reason)
Adverse Event/side Effects/complications
(Adverse event/side
effects/complications)
Alternative Therapy (Alternative therapy)
Death, Recurrence, Or Second Primary
Cancer (Death, recurrence, or second
primary cancer)
Other (Other)
Patient Withdrawal Or Refusal (Patient
withdrawal or refusal)
Treatment Completed Per Protocol
Criteria (Treatment completed per
protocol criteria)
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NSABP PROTOCOL C-09: Treatment Form for Group 1 Patients
NCT00268463
NSABP PROTOCOL C-09: Treatment Form
for Group 2 Patients NCT00268463
NSABP PROTOCOL C-09: Treatment Form for Group 2
Patients NCT00268463
Oxaliplatin and Capecitabine With or Without an Hepatic
Arterial Infusion With Floxuridine in Treating Patients Who
Are Undergoing Surgery and/or Ablation for Liver
Metastases Due to Colorectal Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=FCBE35C9-
1452-58D9-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/10647
NSABP PROTOCOL C-09:
Treatment Form for Group 2 Patients
NCT00268463
Header module
Patient Initials (Last First Middle)
NSABP Patient ID
Institution Name
Affiliate Name
Person Completing Form Last Name
Person Completing Form First Name
Person Completing Form Phone
Total Number of Cycles Given (0, 1, 2, 3, 4, 5, 6,
7, 8)
Treatment End Date (last dose of last cycle Leave
blank if treatment was not begun)
Are data amended (Check box if yes, and circle
amended items)
Yes
No
Patient Height (cm)
Assessment of Chemotherapy
Cycle Number
Cycle Start Date (*)
1 / 3
Patient Weight (If unknown, leave boxes blank)
Agent Name (total mg)
Agent Total Dose (on each cycle)
Was less than full dose administered because of
toxicity?
Yes
No
Why did treatment end or not begin
(CAPECITABINE Select primary reason)
Adverse Event/side Effects/complications
(Adverse event/side
effects/complications)
Alternative Therapy (Alternative therapy)
Death, Recurrence, Or Second Primary
Cancer (Death, recurrence, or second
primary cancer)
Other (Other)
Patient Withdrawal Or Refusal (Patient
withdrawal or refusal)
Treatment Completed Per Protocol
Criteria (Treatment completed per
protocol criteria)
Why did treatment end or not begin
(CAPECITABINE Select primary reason)
Adverse Event/side Effects/complications
(Adverse event/side
effects/complications)
Alternative Therapy (Alternative therapy)
Death, Recurrence, Or Second Primary
Cancer (Death, recurrence, or second
primary cancer)
Other (Other)
Patient Withdrawal Or Refusal (Patient
withdrawal or refusal)
Treatment Completed Per Protocol
Criteria (Treatment completed per
protocol criteria)
Why did treatment end or not begin
(CAPECITABINE Select primary reason)
Adverse Event/side Effects/complications
(Adverse event/side
effects/complications)
Alternative Therapy (Alternative therapy)
Death, Recurrence, Or Second Primary
Cancer (Death, recurrence, or second
primary cancer)
Other (Other)
Patient Withdrawal Or Refusal (Patient
withdrawal or refusal)
Treatment Completed Per Protocol
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NSABP PROTOCOL C-09: Treatment Form for Group 2 Patients
NCT00268463
Criteria (Treatment completed per
protocol criteria)
Treatment Group 2. Complications
Related To Hai Catheter Or Pump
Were there any complications related to the HAI
catheter or pump (complete table per
specifications)
Yes
No
Pump Malfunction (if yes, complete this row)
Yes
No
Catheter Occlusion (if yes, complete this row)
Yes
No
Misperfusion (if yes, complete this row)
Yes
No
Bleeding (if yes, complete this row)
Yes
No
Infection (if yes, complete this row)
Yes
No
Other (if yes, complete this row)
Yes
No
Other, specify
Cycle Number (Mark all that apply)
1 (1)
2 (2)
3 (3)
4 (4)
5-8 (5-8)
Management of Complication (Mark all that
apply)
Other (Other)
Removal Of Catheter/pump (Removal of
catheter/pump)
Other, specify
3 / 3
NSABP PROTOCOL C-09: Treatment Form for Group 2 Patients
NCT00268463
Southwest Oncology Group Off Treatment
Notice NCT00499369
Southwest Oncology Group Off Treatment Notice
NCT00499369 
Irinotecan and Cetuximab With or Without Bevacizumab in
Treating Patients With Metastatic Colorectal Cancer That
Progressed During First-Line Therapy
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=1540B168-
F57F-6FA2-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/10648
Southwest Oncology Group Off
Treatment Notice NCT00499369
SWOG clinical trial administrative data
SWOG Patient ID
SWOG Study No.
Registration Step
Patient Initials (L, F M)
Institution/Affiliate
Physician
Participating Group Name
Participating Group Study No.
Participating Group Patient ID
Date of Last Contact or Death
Vital Status
Alive (Alive)
Dead (Dead)
Protocol treatment
Did the patient receive any protocol treatment (on
this registration step)
Yes
No
Treatment Start Date
Treatment End Date
Regimen or Procedure or Site(s)
1 / 3
Off protocol treatment
Off Treatment Reason (select one:)
Adverse Event/side Effects/complications
(Adverse Event/Side
Effects/Complications)
Death On Study (Death on study)
Disease Progression, Relapse During
Active Treatment (Disease progression,
relapse during active treatment)
Other (Other)
Patient Withdrawal Or Refusal After
Beginning Protocol Therapy (Patient
withdrawal/refusal after beginning
protocol therapy)
Patient Withdrawal Or Refusal Before
Beginning Protocol Therapy (Patient
withdrawal/refusal prior to beginning
protocol therapy)
Treatment Completed Per Protocol
Criteria (Treatment completed per
protocol criteria)
Adverse event/side effects/complications specify
Patient withdrawal/refusal after beginning
protocol therapy specify
Patient withdrawal/refusal prior to beginning
protocol therapy specify
Sites
Other specify
Was treatment termination medically required
(For any adverse event,)
Yes
No
Yes specify
Was reason due to adverse event/side
effects/complications (For any patient refusal,)
Yes
No
Yes specify
Specify other reason for refusal
Off Treatment Date (Date of completion,
progression, death or decision to discontinue
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therapy:)
Further treatment
Will patient receive further treatment?
No (No)
Unknown (Unknown)
Yes (Yes)
Yes, specify
Comments
Comments
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GYNECOLOGIC ONCOLOGY GROUP Treatment
Completion Form - FORM Q0 NCT00565851
GYNECOLOGIC ONCOLOGY GROUP Treatment
Completion Form - FORM Q0 NCT00565851
Carboplatin and Paclitaxel With or Without Bevacizumab
After Surgery in Treating Patients With Recurrent Ovarian
Epithelial Cancer, Primary Peritoneal Cavity Cancer, or
Fallopian Tube Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=DA632D3C-
41EC-2430-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/10649
GYNECOLOGIC ONCOLOGY
GROUP Treatment Completion Form
- FORM Q0 NCT00565851
Header module
Date form originally completed
Date form amended
Person amending form last name
Patient Initials (First, Middle, Last)
Patient Study ID
Person completing form, last name
Treatment Schedule
Total number of cycles given
Last date (any modality of) protocol therapy was
given
Off-treatment Reason
Reason treatment ended (check only one)
Death Of Patient Occurred After The
Patient Began Protocol Therapy (Death
after beginning protocol therapy)
Disease Progression, Relapse During
Active Treatment (Disease progression,
relapse during active treatment)
Other (Other, specify)
Patient Off-treatment For Other
Complicating Disease (Patient off-
treatment for other complicating disease)
Patient Withdrawal Or Refusal For
Reason Other Than Toxicity (Patient
withdrawal or refusal for reason other
1 / 2
than toxicity)
Routine Completion Of Planned Protocol
Treatment (Routine completion of
planned protocol treatment)
Adverse Event/side Effects/complications
(Toxicity/side effects/complications)
Toxicity/side effects/complications, specify
Patient withdrawal or refusal for reason other
than toxicity, specify
Patient off-treatment for other complicating
disease, specify
Other, specify
Will patient receive further treatment?
Yes
No
Yes, specify (below)
Comments
Comments
Participating Group Code
Participating Group Protocol Number
Participating Group Patient ID
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GYNECOLOGIC ONCOLOGY GROUP Treatment Completion Form -
FORM Q0 NCT00565851
CALGB: OFF TREATMENT NOTICE
[80303] NCT00088894
CALGB: OFF TREATMENT NOTICE [80303]
NCT00088894 
Gemcitabine With or Without Bevacizumab in Treating
Patients With Locally Advanced or Metastatic Pancreatic
Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=D5FECAA1-
76F0-6E26-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/10650
CALGB: OFF TREATMENT NOTICE
[80303] NCT00088894
Header
CALGB Study No
Date Completed
Date Completed
Are data amended?
Yes
No
Patient demographics
Patient Initials
Participating Group
Patient Hospital No.
Participating Group Protocol No.
Institution/Affiliate
Participating Group Patient ID
Off protocol treatment
REASON OFF TREATMENT
Adverse Event/side Effects/complications
(Adverse event)
Cytogenetic Resistance (Cytogenetic
Resistance)
Disease Progression Before Active
Treatment (Disease Progression before
Active Treatment)
Lost To Follow-up (Lost to follow-up)
Other (Other, specify)
1 / 2
Patient Off-treatment For Other
Complicating Disease (Patient developed
other disease. Specify)
Patient did not respond to therapy
(Patient did not respond to therapy)
Death On Study (Patient died during
treatment)
Disease Progression, Relapse During
Active Treatment (Patient had disease
progression or relapse during active
treatment)
Patient Withdrawal Or Refusal After
Beginning Protocol Therapy (Patient
refused further protocol treatment, but
consented to be followed)
Patient Withdrawal Or Refusal After
Beginning Protocol Therapy (Patient
refused further protocol treatment,
withdrew consent to be followed)
Alternative Therapy (Patient taken off of
protocol treatment to receive non-
protocol therapy during active protocol
treatment)
Patient Withdrawal Or Refusal Before
Beginning Protocol Therapy (Patient
withdrawal or refusal prior to beginning
protocol therapy)
Treatment Completed Per Protocol
Criteria (Treatment completed per
protocol)
No Treatment, Per Protocol Criteria
(Treatment never started)
Patient developed other disease. Specify
Reason why treatment was not started
Specify type of non-protocol treatment
Other, specify
Last date of protocol treatment
Comments
COMMENTS
Completed by
Date form originally completed
2 / 2
CALGB: OFF TREATMENT NOTICE [80303] NCT00088894
SOUTHWEST ONCOLOGY GROUP S0205
CONCOMITANT MEDICATION FORM NCT00075686
SOUTHWEST ONCOLOGY GROUP S0205
CONCOMITANT MEDICATION FORM NCT00075686
S0205 Gemcitabine With or Without Cetuximab as First-
Line Therapy in Treating Patients With Locally Advanced
Unresectable or Metastatic Adenocarcinoma of the
Pancreas
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=F2EB32AE-
2CB9-236C-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/10651
SOUTHWEST ONCOLOGY GROUP
S0205 CONCOMITANT
MEDICATION FORM NCT00075686
Header
SWOG Patient ID
SWOG Study No.
Registration Step
Patient Initials (L, F M)
Date form completed
Institution/Affiliate
Physician
Participating Group Name
Participating Study No.
Participating Patient ID
Assessment of Chemotherapy
Agent Name (or procedure)
Treatment begin date
Treatment end date
Comments
Comments
1 / 1
NSABP PROTOCOL B-36 Treatment Form
for Celecoxib/Placebo NCT00087178
NSABP PROTOCOL B-36 Treatment Form for
Celecoxib/Placebo NCT00087178
Comparison of Two Combination Chemotherapy Regimens
in Treating Women With Breast Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=C87B7926-
0F4F-5A9C-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/10652
NSABP PROTOCOL B-36 Treatment
Form for Celecoxib/Placebo
NCT00087178
Header
Patient Initials (Last, First Middle)
NSABP Patient ID
Institution Name
Affiliate Name
Person Completing Form (Phone)
Are data amended?
Yes
No
Summary Of Celecoxib/placebo
Treatment Begin Date (0=not begun)
Treatment End Date (0=not begun)
Reason Treatment Ended (Select the reason that
best explains why celecoxib/placebo has ended,
or why the patient did not begin
celecoxib/placebo.)
Alternative Therapy (Alternative therapy)
Death On Study (Death)
Disease Progression, Relapse During
Active Treatment (Disease progression,
relapse during active treatment)
Other (Other (specify))
Patient Off-treatment For Other
Complicating Disease (Patient off-
treatment for other complicating disease)
Patient Withdrawal Or Refusal After
Beginning Protocol Therapy (Patient
withdrawal or refusal)
Patient Withdrawal Or Refusal Before
Beginning Protocol Therapy (Patient
1 / 2
withdrawal or refusal prior to beginning
protocol therapy)
Adverse Event/side Effects/complications
(Toxicity/Side effects/Complications)
Treatment Completed Per Protocol
Criteria (Treatment completed per
protocol criteria)
Other (specify)
Ccrr Module For Nsabp Protocol B-36
Treatment Form For Celecoxib/placebo
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NSABP PROTOCOL B-36 Treatment Form for Celecoxib/Placebo
NCT00087178
CALGB_40302_TX_SUM_FRM
NCT00390455
CALGB: 40302 TREATMENT SUMMARY FORM (ALL
PATIENTS) NCT00390455
Fulvestrant With or Without Lapatinib in Treating
Postmenopausal Women With Stage III or Stage IV Breast
Cancer That is Hormone Receptor-Positive
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=F5A8CF0A-
4F6A-3C78-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/10653
CALGB_40302_TX_SUM_FRM
NCT00390455
Header
CALGB Form
CALGB Study No
CALGB Patient ID
Reporting period start date
Reporting period end date
Are data amended
Yes
No
Patient demographics
Patient Initials
Patient Hospital No
Institution/Affiliate
Participating Group
Participating Group Protocol No
Participating Group Patient ID
Treatment Plan
Date of first dose for this reporting period
Date of last dose for this reporting period
1 / 3
Total Number of Cycles given
Date of Last Clinical Assessment
Last date of protocol treatment
Reason Treatment Ended (mark one with an X)
Adverse Event/side Effects/complications
(Adverse Event/Side
Effects/Complications)
Alternative Therapy (Alternative therapy)
Death On Study (Death on study)
Disease Progression, Relapse During
Active Treatment (Disease progression,
relapse during active treatment)
Other (Other)
Patient Withdrawal Or Refusal After
Beginning Protocol Therapy (Patient
withdrawal/refusal after beginning
protocol therapy)
Patient Withdrawal Or Refusal Before
Beginning Protocol Therapy (Patient
withdrawal/refusal prior to beginning
protocol therapy)
Treatment Completed Per Protocol
Criteria (Treatment completed per
protocol criteria)
Other, specify
Were any optional therapies given
Yes
No
specify optional protocol therapy name (If Yes)
Was any non-protocol therapy given during
protocol treatment
Yes
No
specify (If Yes)
Concurrent Non-protocol Biologic
Response Modifier Therapy (Concurrent
non-protocol biologic response modifier
therapy)
Concurrent Non-protocol Chemotherapy
(Concurrent non-protocol chemotherapy)
Concurrent Non-protocol High Dose
Chemotherapy/autologous Stem Cell
Transplant (Concurrent non-protocol high
dose chemotherapy/autologous stem cell
transplant)
Concurrent Non-protocol Hormonal
Therapy (Concurrent non-protocol
hormonal therapy)
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CALGB_40302_TX_SUM_FRM NCT00390455
Concurrent Non-protocol Radiation
Therapy (Concurrent non-protocol
radiation therapy)
Were supporting agents given during this cycle?
Antibiotic (Antibiotics)
Antidiarrheal (Antidiarrheal)
Antiemetics (Antiemetics)
Erythropoetin (Erythropoetin)
Gcsf (GCSF)
Other (Other)
Comments
COMMENTS
Completed by
Date form completed
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CALGB 90601: Supplemental Adverse Event
Form (Thromboembolic Events) NCT00942331
CALGB 90601: Supplemental Adverse Event Form
(Thromboembolic Events) NCT00942331 
Gemcitabine Hydrochloride and Cisplatin With or Without
Bevacizumab in Treating Patients With Advanced Urinary
Tract Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=65940F04-
CD97-54E2-E040-BB89AD435A8C
All rights reserved. Please visit https://medical-data-
models.org/forms/10654
CALGB 90601: Supplemental
Adverse Event Form
(Thromboembolic Events)
NCT00942331
Header
CALGB Form (C-1766)
CALGB Study No.
CALGB Patient ID
Reporting period start date
Reporting period end date
Are data amended
Yes
No
Patient demographics
Patient Initials (Last, First Middle)
Patient Hospital No.
Institution/Affiliate
Participating Group
Participating Group Study No.
Participating Group Patient ID
Assessment of medication
Cycle number
1 / 3
Medications received during this reporting period
(Mark one with an X)
Anti-platelet (Anti-platelet)
Anticoagulant (Anticoagulant)
Aspirin (Aspirin)
Bp Or Cardiac Medication (BP or cardiac
medication)
None (None)
Nsaid (NSAID)
Statin (Statin)
NSAID, specify
Anti-platelet, specify
Statin, specify
BP or cardiac medication, specify
Anticoagulant, specify
Which of the following arterial thrombotic events
(ATEs) occurred during this reporting period?
(Mark one with an X)
Angina (Angina)
Cva - Hemorrhagic (CVA - hemorrhagic)
Cva - Thrombotic (CVA - thrombotic)
Myocardial Infarction (Myocardial
infarction)
None (None)
Other Arterial Event (Other arterial
event)
Transient Ischemic Attack (Transient
ischemic attack)
Other arterial event, specify
Treatment for ATE (Mark one with an X)
Emergency Room (Emergency room)
Hospitalization (Hospitalization)
Outpatient Management Only
(Outpatient management only)
Outcome of ATE (Mark one with an X)
Not Resolved (Not resolved)
Resolved (Resolved)
Resulted In Death (Resulted in death)
Which of the following venous thrombotic events
(VTEs) occurred during this reporting period?
(Mark one with an X)
Catheter Related (Catheter related)
Dvt (DVT)
None (None)
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CALGB 90601: Supplemental Adverse Event Form (Thromboembolic
Events) NCT00942331
Other Venous Thrombotic Event (Other
venous thrombotic event)
Pulmonary Embolism (Pulmonary
embolism)
Other venous thrombotic event, specify
Specify status
Asymptomatic (asymptomatic)
Symptomatic (symptomatic)
Treatment for VTE (Mark one with an X)
Emergency Room (Emergency room)
Hospitalization (Hospitalization)
Outpatient Management Only
(Outpatient management only)
Outcome of VTE (Mark one with an X)
Not Resolved (Not resolved)
Resolved (Resolved)
Resulted In Death (Resulted in death)
Completed by
Date form completed
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CALGB 90601: Supplemental Adverse Event Form (Thromboembolic
Events) NCT00942331
E5103 Treatment Form - Step 1
NCT00433511
E5103 Treatment Form - Step 1 NCT00433511
Doxorubicin, Cyclophosphamide, and Paclitaxel With or
Without Bevacizumab in Treating Patients With Lymph
Node-Positive or High-Risk, Lymph Node-Negative Breast
Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=22B13531-
DF02-6120-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/10655
E5103 Treatment Form - Step 1
NCT00433511
ECOG clinical trial administrative data
ECOG Protocol Number
ECOG Patient ID
DCI Name
Registration Step
Reporting Period (x)
End Of Treatment (End of treatment)
Patient Initials (Last, First)
Participating Group Protocol Number
Participating Group Patient ID
Institution/Affiliate
Please mark an 'X' if data have been amended.
(Please circle amended items in red)
Date data amended (s)
Reporting Period
On Treatment Report Period
Cycle 1 Step 1 (Cycle 1 Step 1)
Cycle 2 Step 1 (Cycle 2 Step 1)
Cycle 3 Step 1 (Cycle 3 Step 1)
Cycle 4 Step 1 (Cycle 4 Step 1)
Cycle 5 Step 1 (Cycle 5 Step 1)
Cycle 6 Step 1 (Cycle 6 Step 1)
Cycle 7 Step 1 (Cycle 7 Step 1)
Cycle 8 Step 1 (Cycle 8 Step 1)
1 / 3
Therapy Administered
Treatment Regimen
Classical (Classical)
Dose Dense (Dose dense)
Reporting Period Start Date (Day 1 of treatment
m/d/y)
Reporting Period End Date
BSA (Day 1 of this report period)
Weight (kg Note: Code weight loss/gain on the
E5103 Adverse Event form)
Agent Name
Agent Total Dose (mg)
Dose modification
Dose Held (Dose held)
Dose Reduced (Dose held and reduced)
Dose Reduced (Dose reduced)
Agent Stopped (Dose stopped)
No Dose Modification (No dose
modification)
Dose Modification Reason
Adverse Event (Adverse event)
Alternative Therapy For Other Reason
(Alternative therapy for other reason)
Dosing Error (Dosing error)
Other (Other)
Patient Refusal/noncompliance (Patient
refusal/noncompliance)
Scheduling (Scheduling)
Second Primary Cancer (Second
primary)
Other, specify
Adverse Event
Cardiac Toxicity (Cardiac Toxicity)
Gi Toxicity (GI Toxicity)
Hematologic Toxicity (Hematologic
Toxicity)
Hepatic Toxicity (Hepatic Toxicity)
Other (Other)
Renal Toxicity (Renal Toxicity)
Thrombosis (Thrombosis/Embolism)
Other, specify
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Adverse Event
Arterial Thrombotic Event (Arterial
Thrombotic Event)
Cardiac Toxicity (Cardiac Toxicity)
Gi Toxicity (GI Toxicity)
Hemorrhage (Hemorrhage)
Hepatic Toxicity (Hepatic Toxicity)
Neurotoxicity (Neurotoxicity)
Other (Other)
Proteinuria (Proteinuria)
Venous Thrombosis/embolism (Venous
Thrombosis/Embolism)
Wound Dehiscence (Wound Dehiscence)
Non-protocol Therapy
Was any non-protocol cancer therapy given
during protocol treatment (not previously
reported)
Yes
No
Comments
Investigator Signature
Investigator Signature Date
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CALGB 40503 FOLLOW-UP SOLID TUMOR
EVALUATION FORM NCT00601900
CALGB 40503 FOLLOW-UP SOLID TUMOR EVALUATION
FORM NCT00601900
Tamoxifen or Letrozole With or Without Bevacizumab in
Treating Women With Stage III or Stage IV Breast Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=2403CF57-
F8CB-54C8-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/10656
CALGB 40503 FOLLOW-UP SOLID
TUMOR EVALUATION FORM
NCT00601900
Header
CALGB Form
CALGB Study No
CALGB Patient ID
Reporting Period Start Date
Reporting Period End Date
Are data amended
Yes
No
Patient Initials
Patient Hospital No.
Institution/Affiliate
Participating Group
Participating Group Study No
Participating Group Patient ID
Reporting Period
Target Lesion Site
Ascites (Ascites)
Bone (Bone)
Bone Marrow (Bone marrow)
Brain (Brain)
Chest Wall (Chest wall)
Gastrointestinal Tract (Gastrointestinal
1 / 4
tract)
Gynecologic Other (Gynecologic other)
Liver (Liver)
Lung (Lung)
Distant Nodes (Nodes distant)
Nodes Local (Nodes local)
Other (Other)
Ovary (Ovary)
Peritoneum (Peritoneum)
Pleura (Pleura)
Primary Tumor (Primary tumor)
Skin / Subcutaneous Tissue Involvement
(Skin subcutaneous)
Other specify
Date of evaluation (MM DD YYYY)
Method of Evaluation (**)
Bone Scan (Bone Scan)
Chest X-ray (Chest X-ray)
Clinical (Clinical Examination)
Ct Scan (CT Scan)
Mri (MRI)
Other (Other)
Spiral Ct Scan (Spiral CT Scan)
Ultrasound (Ultrasound)
If Other, specify
Longest Diameter of Lesion(s) (s)
Sum of Longest Diameters of All Target Lesions
Response Status at This Assessment, Target
Lesion (s)
Complete Response (Complete
Response)
Insufficient Evaluation To Determine
Response Status (Insufficient evaluation
to determine response status)
Partial Response (Partial Response)
Progressive Disease (Progressive
Disease)
Stable Disease (Stable Disease)
Non-target Lesion(s) Follow-up Evaluation
Nontarget Lesion
Yes
No
Nontarget Lesion Site
Ascites (Ascites)
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NCT00601900
Bone (Bone)
Bone Marrow (Bone marrow)
Brain (Brain)
Chest Wall (Chest wall)
Gastrointestinal Tract (Gastrointestinal
tract)
Gynecologic Other (Gynecologic other)
Liver (Liver)
Lung (Lung)
Distant Nodes (Nodes distant)
Nodes Local (Nodes local)
Other (Other)
Ovary (Ovary)
Peritoneum (Peritoneum)
Pleura (Pleura)
Primary Tumor (Primary tumor)
Skin / Subcutaneous Tissue Involvement
(Skin subcutaneous)
F/U Response Status (Use response status
codes below.)
Complete Response (Complete
Response)
Incomplete Response/sd (Incomplete
Response/SD)
Insufficient Evaluation To Determine
Response Status (Insufficient evaluation
to determine response status)
Progressive Disease (Progressive
Disease)
Response Status at This Assessment, Non-
Target Lesion (s)
Complete Response (Complete
Response)
Incomplete Response/sd (Incomplete
Response/SD)
Insufficient Evaluation To Determine
Response Status (Insufficient evaluation
to determine response status)
Progressive Disease (Progressive
Disease)
New Lesion(s) At Follow-up Evaluation
Was the appearance of any new lesions
documented
Yes
No
Were any of the new lesion(s) in a previously
reported anatomic site
Yes
No
Was the lesion in a new anatomic site
Yes
No
Lesion in previously reported site
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NCT00601900
Ascites (Ascites)
Bone (Bone)
Bone Marrow (Bone marrow)
Brain (Brain)
Chest Wall (Chest wall)
Gastrointestinal Tract (Gastrointestinal
tract)
Gynecologic Other (Gynecologic other)
Liver (Liver)
Lung (Lung)
Distant Nodes (Nodes distant)
Nodes Local (Nodes local)
Other (Other)
Ovary (Ovary)
Peritoneum (Peritoneum)
Pleura (Pleura)
Primary Tumor (Primary tumor)
Skin / Subcutaneous Tissue Involvement
(Skin subcutaneous)
New Lesion Site
Ascites (Ascites)
Bone (Bone)
Bone Marrow (Bone marrow)
Brain (Brain)
Chest Wall (Chest wall)
Gastrointestinal Tract (Gastrointestinal
tract)
Gynecologic Other (Gynecologic other)
Liver (Liver)
Lung (Lung)
Distant Nodes (Nodes distant)
Nodes Local (Nodes local)
Other (Other)
Ovary (Ovary)
Peritoneum (Peritoneum)
Pleura (Pleura)
Primary Tumor (Primary tumor)
Skin / Subcutaneous Tissue Involvement
(Skin subcutaneous)
Target Lesion
Yes
No
Overall Response
Completed by (print or type name)
Date Form Completed (MM DD YYYY)
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CALGB 40503 FOLLOW-UP SOLID TUMOR EVALUATION FORM
NCT00601900
E1105 Treatment Form NCT00520975
E1105 Treatment Form NCT00520975
First-Line Chemotherapy and Trastuzumab With or Without
Bevacizumab in Treating Patients With Metastatic Breast
Cancer That Overexpresses HER-2/NEU
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=17256C2D-
9F93-4AD8-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/10657
E1105 Treatment Form
NCT00520975
Header
ECOG Protocol Number
ECOG Patient ID
DCI Name
Registration Step
Patient Initials
Participating Group Protocol Number
Participating Group Patient ID
Institution/Affiliate
Please mark an 'X' if data have been amended.
(Please circle amended items in red)
Date data amended (s)
On Treatment
On Treatment Report Period (since start of
treatment)
> Cycle 11 (> Cycle 11)
Cycle 1 (Cycle 1)
Cycle 10 (Cycle 10)
Cycle 11 (Cycle 11)
Cycle 2 (Cycle 2)
Cycle 3 (Cycle 3)
Cycle 4 (Cycle 4)
Cycle 5 (Cycle 5)
Cycle 6 (Cycle 6)
Cycle 7 (Cycle 7)
Cycle 8 (Cycle 8)
Cycle 9 (Cycle 9)
1 / 4
Specify Cycle (specify)
Section I - Vital Status
Vital Status
Alive (Alive)
Dead (Dead)
Date of Last Contact or Death
Primary Cause of Death (if applicable)
Due To Other Cause (Due to other
cause)
Due To Protocol Treatment (Due to
protocol treatment)
Due To This Disease (Due to this
disease)
Unknown (Unknown)
Describe cause of death (other)
Patient Charastics
Weight (Day 1 of this report period)
Therapy Administered
Reporting Period Start Date
Reporting Period End Date
Agent Name (Sunitinib/Placebo)
Agent Total Cumulative Dose (mg)
Dose modification
Dose Delayed (Dose delayed)
Dose Delayed And Reduced (Dose
delayed and reduced)
Dose Held (Dose held)
Dose Reduced (Dose reduced)
Drug Discontinued (Drug discontinued)
No Dose Modification (No dose
modification)
Dose Modification Reason
Adverse Event (Adverse event)
Alternative Therapy For Other Reason
(Alternative therapy for other reason)
Dosing Error (Dosing error)
Other (Other)
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Patient Refusal/noncompliance (Patient
refusal/noncompliance)
Scheduling (Scheduling)
Second Primary Cancer (Second
primary)
Other, specify
Serum creatinine (Value used to calculate
Creatinine Clearance)
Date Hematology (Blood) Sample Obtained
Creatinine Clearance (Calculated - Record value
used to determine Carboplatin dose)
Adverse Event (If chemotherapy was modified for
adverse event, mark all that apply)
Cardiac Toxicity (Cardiac Toxicity)
Gi Toxicity (GI Toxicity)
Hematologic Toxicity (Hematologic
Toxicity)
Hepatic Toxicity (Hepatic Toxicity)
Other (Other)
Thrombosis (Thrombosis/Embolism)
Other, specify
Adverse Event (If trastuzumab was modified for
adverse event, mark all that apply)
Allergic Reaction/hypersensitivity
(Allergic reaction/hypersensitivity)
Cardiac Toxicity (Cardiac Toxicity)
Gi Toxicity (GI toxicity)
Hematologic Toxicity (Hematologic
toxicity)
Hepatic Toxicity (Hepatic Toxicity)
Neurotoxicity (Neurotoxicity)
Other (Other)
Thrombosis/embolism
(Thrombosis/Embolism)
Adverse Event (If bevacizumab/placebo was
modified for adverse event, mark all that apply)
Arterial Thrombotic Event (Arterial
Thrombotic Event)
Cardiac Toxicity (Cardiac Toxicity)
Gi Toxicity (GI Toxicity)
Hemorrhage (Hemorrhage)
Hepatic Toxicity (Hepatic Toxicity)
Neurotoxicity (Neurotoxicity)
Other (Other)
Proteinuria (Proteinuria)
Venous Thrombosis/embolism (Venous
Thrombosis/Embolism)
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Wound Dehiscence (Wound Dehiscence)
Section Vi - Non-protocol Therapy
Was any non-protocol therapy given during
protocol treatment (not previously reported)
Yes
No
Investigator Signature
Investigator Signature Date
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E5103 Treatment Form - Step 2 (Arm D
ONLY) NCT00433511
E5103 Treatment Form - Step 2 (Arm D ONLY)
NCT00433511
Doxorubicin, Cyclophosphamide, and Paclitaxel With or
Without Bevacizumab in Treating Patients With Lymph
Node-Positive or High-Risk, Lymph Node-Negative Breast
Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=3C897B97-
5BB5-5817-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/10658
E5103 Treatment Form - Step 2 (Arm
D ONLY) NCT00433511
Header module
ECOG Protocol Number
ECOG Patient ID
DCI Name
Registration Step
Patient Initials (Last, First)
Participating Group Protocol Number
Participating Group Patient ID
Institution/Affiliate
Please mark an 'X' if data have been amended.
(Please circle amended items in red)
Date data amended (s)
Reporting Period
On Treatment Report Period (ARM D ONLY)
Cycle 10 Step 2 (Cycle 10 Step 2)
Cycle 11 Step 2 (Cycle 11 Step 2)
Cycle 12 Step 2 (Cycle 12 Step 2)
Cycle 13-step 2 (Cycle 13-Step 2)
Cycle 14-step 2 (Cycle 14-Step 2)
Cycle 15 Step 2 (Cycle 15 Step 2)
Cycle 16-step 2 (Cycle 16-Step 2)
Cycle 17 Step 2 (Cycle 17 Step 2)
Cycle 18-step 2 (Cycle 18-Step 2)
Cycle 9 Step 2 (Cycle 9 Step 2)
Therapy Administered
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Reporting Period Start Date (Day 1 of treatment
m/d/y)
Reporting Period End Date
Weight (kg Note: Code weight loss/gain on the
E5103 Adverse Event Form)
Agent Name
Agent Total Dose (this cycle - mg)
Dose modification
Dose Delayed (Dose delayed)
Dose Delayed And Reduced (Dose
delayed and reduced)
Dose Held (Dose held)
Dose Reduced (Dose reduced)
Drug Discontinued (Drug discontinued)
No Dose Modification (No dose
modification)
Dose Modification Reason (* If a dose
modification reason represents a qualifying
Grade CTCAE, report the event on the E5103
Adverse Event Form.)
Adverse Event (Adverse event)
Alternative Therapy For Other Reason
(Alternative therapy for other reason)
Dosing Error (Dosing error)
Other (Other)
Patient Refusal/noncompliance (Patient
refusal/noncompliance)
Scheduling (Scheduling)
Second Primary Cancer (Second
primary)
Other, specify
Adverse Event (Instruction: If Bevacizumab dose
was modified for adverse event, mark an 'X' for all
that apply:)
Arterial Thrombotic Event (Arterial
Thrombotic Event)
Cardiac Toxicity (Cardiac Toxicity)
Gi Toxicity (GI Toxicity)
Hemorrhage (Hemorrhage)
Hepatic Toxicity (Hepatic Toxicity)
Neurotoxicity (Neurotoxicity)
Other (Other)
Proteinuria (Proteinuria)
Venous Thrombosis/embolism (Venous
Thrombosis/Embolism)
Wound Dehiscence (Wound Dehiscence)
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Other, specify
Non-protocol Therapy
Was any non-protocol cancer therapy given
during protocol treatment (not previously reported
- * Bisphosphonate Therapy will NOT be
considered non-protocol therapy.)
Yes
No
Comments
Investigator Signature
Investigator Signature Date
3 / 3
E5103 Treatment Form - Step 2 (Arm D ONLY) NCT00433511
CALGB 40601 FOLLOW-UP SOLID TUMOR
EVALUATION FORM NCT00770809
CALGB 40601 FOLLOW-UP SOLID TUMOR EVALUATION
FORM NCT00770809
Paclitaxel and Trastuzumab With or Without Lapatinib in
Treating Patients With Stage II or Stage III Breast Cancer
That Can Be Removed by Surgery
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=3CB30144-
0173-5B57-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/10659
CALGB 40601 FOLLOW-UP SOLID
TUMOR EVALUATION FORM
NCT00770809
CALGB clinical trial administrative data
CALGB Form
CALGB Study No
CALGB Patient ID
Reporting Period Start Date
Reporting Period End Date
Are data amended
Yes
No
Patient Initials
Patient Hospital No.
Institution/Affiliate
Participating Group
Participating Group Study No
Participating Group Patient ID
Reporting Period
Target Lesion Site
Ascites (Ascites)
Bone (Bone)
Bone Marrow (Bone marrow)
Brain (Brain)
Chest Wall (Chest wall)
Gastrointestinal Tract (Gastrointestinal
1 / 4
tract)
Gynecologic Other (Gynecologic other)
Liver (Liver)
Lung (Lung)
Distant Nodes (Nodes distant)
Nodes Local (Nodes local)
Other (Other)
Ovary (Ovary)
Peritoneum (Peritoneum)
Pleura (Pleura)
Primary Tumor (Primary tumor)
Skin / Subcutaneous Tissue Involvement
(Skin subcutaneous)
Other specify
Date of evaluation (MM DD YYYY)
Method of Evaluation (**)
Bone Scan (Bone Scan)
Chest X-ray (Chest X-ray)
Clinical (Clinical Examination)
Ct Scan (CT Scan)
Mri (MRI)
Other (Other)
Spiral Ct Scan (Spiral CT Scan)
Ultrasound (Ultrasound)
If Other, specify
Longest Diameter of Lesion(s) (s)
Sum of Longest Diameters of All Target Lesions
Response Status at This Assessment, Target
Lesion (s)
Complete Response (Complete
Response)
Insufficient Evaluation To Determine
Response Status (Insufficient evaluation
to determine response status)
Partial Response (Partial Response)
Progressive Disease (Progressive
Disease)
Stable Disease (Stable Disease)
Non-target Lesion(s) Follow-up Evaluation
Nontarget Lesion
Yes
No
Nontarget Lesion Site
Ascites (Ascites)
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Bone (Bone)
Bone Marrow (Bone marrow)
Brain (Brain)
Chest Wall (Chest wall)
Gastrointestinal Tract (Gastrointestinal
tract)
Gynecologic Other (Gynecologic other)
Liver (Liver)
Lung (Lung)
Distant Nodes (Nodes distant)
Nodes Local (Nodes local)
Other (Other)
Ovary (Ovary)
Peritoneum (Peritoneum)
Pleura (Pleura)
Primary Tumor (Primary tumor)
Skin / Subcutaneous Tissue Involvement
(Skin subcutaneous)
F/U Response Status (Use response status
codes below.)
Complete Response (Complete
Response)
Incomplete Response/sd (Incomplete
Response/SD)
Insufficient Evaluation To Determine
Response Status (Insufficient evaluation
to determine response status)
Progressive Disease (Progressive
Disease)
Response Status at This Assessment, Non-
Target Lesion (s)
Complete Response (Complete
Response)
Incomplete Response/sd (Incomplete
Response/SD)
Insufficient Evaluation To Determine
Response Status (Insufficient evaluation
to determine response status)
Progressive Disease (Progressive
Disease)
New Lesion(s) At Follow-up Evaluation
Was the appearance of any new lesions
documented
Yes
No
Were any of the new lesion(s) in a previously
reported anatomic site
Yes
No
Was the lesion in a new anatomic site
Yes
No
Lesion in previously reported site
3 / 4
CALGB 40601 FOLLOW-UP SOLID TUMOR EVALUATION FORM
NCT00770809
Ascites (Ascites)
Bone (Bone)
Bone Marrow (Bone marrow)
Brain (Brain)
Chest Wall (Chest wall)
Gastrointestinal Tract (Gastrointestinal
tract)
Gynecologic Other (Gynecologic other)
Liver (Liver)
Lung (Lung)
Distant Nodes (Nodes distant)
Nodes Local (Nodes local)
Other (Other)
Ovary (Ovary)
Peritoneum (Peritoneum)
Pleura (Pleura)
Primary Tumor (Primary tumor)
Skin / Subcutaneous Tissue Involvement
(Skin subcutaneous)
New Lesion Site
Ascites (Ascites)
Bone (Bone)
Bone Marrow (Bone marrow)
Brain (Brain)
Chest Wall (Chest wall)
Gastrointestinal Tract (Gastrointestinal
tract)
Gynecologic Other (Gynecologic other)
Liver (Liver)
Lung (Lung)
Distant Nodes (Nodes distant)
Nodes Local (Nodes local)
Other (Other)
Ovary (Ovary)
Peritoneum (Peritoneum)
Pleura (Pleura)
Primary Tumor (Primary tumor)
Skin / Subcutaneous Tissue Involvement
(Skin subcutaneous)
Target Lesion
Yes
No
Overall Response
Completed by (print or type name)
Date Form Completed (MM DD YYYY)
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E2108 Step 2 Treatment Form
NCT01242800
E2108 Step 2 Treatment Form NCT01242800
Early Surgery or Standard Palliative Therapy in Treating
Patients With Stage IV Breast Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=8E317E27-
15FB-BDB6-E040-BB89AD4354FA
All rights reserved. Please visit https://medical-data-
models.org/forms/10660
E2108 Step 2 Treatment Form
NCT01242800
Header module
ECOG Protocol Number
ECOG Patient ID
DCI Name
Registration Step
Patient Initials (Last, First)
Participating Group Protocol Number
Institution/Affiliate
Participating Group Patient ID
Please mark an 'X' if data have been amended.
(Please circle amended items in red)
Date data amended (M D Y)
On Treatment Report Period
Reporting Period (Choose one)
12 Months Post Randomization (12
Months Post Randomization)
15 Months Post Randomization (15
Months Post Randomization)
21 Months Post Randomization (21
Months Post Randomization)
24 Months Post Randomization (24
Months Post Randomization)
3 Months Post Randomization (3 Months
Post Randomization)
30 Months Post Randomization (30
Months Post Randomization)
36 Months Post Randomization (36
1 / 3
Months Post Randomization)
42 Months Post Randomization (42
Months Post Randomization)
48 Months Post Randomization (48
Months Post Randomization)
54 Months Post Randomization (54
Months Post Randomization)
6 Months Post Randomization (6 Months
Post Randomization)
60 Months Post Randomization (60
Months Post Randomization)
9 Months Post Randomization (9 Months
Post Randomization)
Arm A And Arm B
Reporting Period Start Date
Reporting Period End Date
Therapies Recieved
Has the patient received any therapy during this
reporting period
Yes
No
Has the patient received any chemotherapy
during this reporting period?
No (No)
Not Applicable (Not Applicable)
Yes, Chemotherapy Completed (Yes,
completed)
Yes, Chemotherapy Continuing (Yes,
continuing)
Has the patient received any hormone therapy
during this reporting period?
Yes
No
Was surgery completed as planned this reporting
period
Yes
No
Reason surgery not completed (If no)
Disease Progression (Disease
progression)
Not Required Per Protocol (Not Required
per Protocol)
Other (Other)
Patient Refusal (Patient refusal)
Physician Decision (Physician decision)
Surgery Previously Performed (Surgery
previously performed)
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Unresectable Disease - Axilla
(Unresectable disease - axilla)
Unresectable Disease - Chest Wall
(Unresectable disease - chest wall)
Reason surgery not performed/completed (If
Other Specify other)
Did patient receive radiation therapy this
reporting period
No (No)
Yes, Completed (Yes, completed)
Yes, Continuing (Yes, continuing)
Radiation Therapy Start Date (If yes M D Y)
Radiation Therapy type
Both Local-regional And Metastatic (Both
Local-Regional AND Metastatic)
Local-regional (Local-Regional)
Metastatic (Metastatic)
Facility where Radiation Therapy was
administered
Radiation therapy not administered reason (If no)
Mastectomy - Radiation Therapy Not
Indicated (Mastectomy - radiation
therapy not indicated)
Not Required Per Protocol (Not Required
per Protocol)
Other (Other)
Radiation Therapy Previously Completed
(Radiation therapy previously completed)
Reason radiation therapy not administered (If
Other Specify other)
Comments
Investigator Signature
Investigator Signature Date
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EUMDS registry bone marrow
NCT00600860
http://www.eumds.org/
All rights reserved. Please visit https://medical-data-
models.org/forms/10662
Bone marrow assessment EUMDS
registry NCT00600860
Bone Marrow Aspirate
Date
BM blasts
Ringed sideroblasts
Karyotype
Good (1)
Intermediate (2)
Poor (3)
Not Available (4)
Karyotype string
No. dysplasias
0 (0)
1 (1)
2 (2)
3 (3)
Bone Marrow Biopsy
Date
WBC
BM blasts
Platelets
Revised IPSS
Metaphases normal
Metaphases abnormal
IPSS-R cytogenetics
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Phonak EduLink Speech-in-Noise
Intelligibility Eligibility NCT00167128
ODM derived from
http://clinicaltrials.gov/show/NCT00167128?term=NCT0016
7128&rank=1
The Phonak EduLink-System in Students With Specific
Performance Deficits in Speech-in-Noise Intelligibility
Eligibility NCT00167128 speech-in-noise intelligib
All rights reserved. Please visit https://medical-data-
models.org/forms/10665
Eligibility Speech-in-Noise
Intelligibility NCT00167128
Inclusion Criteria
Students in the 1st to 4th class of primary school*
Yes
No
Diagnosis of specific performance deficits in
speech-in-noise intelligibility based on two or
more standardized tests of auditory processing in
noise including retests*
Yes
No
Exclusion Criteria
Hearing loss, defined as: Air conduction pure
tone thresholds (250-8000 Hz) exceeding 20
dBHL. Air-bone gaps, even in the presence of
normal sensitivity, exceeding 10 dBHL. Abnormal
tympanogram*
Yes
No
History or diagnosis of behavioral and/or
emotional disorders meeting ICD-GM-criteria
(including attention deficit/hyperactivity disorders
(AD-/HD)*
Yes
No
Non-German speaking*
Yes
No
Cognitively impaired children (IQ < 85)*
Yes
No
Children currently using psychoactive
medication*
Yes
No
Students with special education*
Yes
No
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Safety and Efficacy of SH T00660AA in Treatment
of Endometriosis Eligibility NCT00225186
Eligibility NCT00225186 Endometriosis
ODM derived from
http://clinicaltrials.gov/show/NCT00225186
All rights reserved. Please visit https://medical-data-
models.org/forms/10666
Eligibility Endometriosis
NCT00225186
Inclusion Criteria
18 to 45 years*
Yes
No
Female patients with endometriosis-associated
pelvic pain*
Yes
No
Exclusion Criteria
Pregnant or lactating women*
Yes
No
History or suspicion of hormone dependent
tumor*
Yes
No
Therapy resistant endometriosis or need for
primary surgical treatment*
Yes
No
Any other conditions which forbid the
participation*
Yes
No
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EUMDS registry withdrawal NCT00600860
http://www.eumds.org/
All rights reserved. Please visit https://medical-data-
models.org/forms/10667
Withdrawal EUMDS registry
NCT00600860
Withdrawal
Withdrawn
Yes
No
Reason
Progression to leukaemia (1)
Patient treated with intensive
chemotherapy (2)
Drug that changes disease history (3)
Withdrawn consent (4)
Date of exclusion
Treatment after withdrawal
Hypomethylating agents start date
Intensive chemotherapy start date
Allogeneic SCT date
Supportive therapy date
1 / 1
EUMDS registry outcome NCT00600860
http://www.eumds.org/
All rights reserved. Please visit https://medical-data-
models.org/forms/10668
Patient outcome EUMDS registry
NCT00600860
Patient outcome
MDS progression
Yes
No
Progressed to
Date of exclusion
Progression date
Loss to follow up
Yes
No
Date
Patient died
Yes
No
Date of death
MDS related
Yes
No
Unrelated
Yes
No
Cause of death
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Ewing 2008 Study KOF/Status
NCT00824083
EWING 2008, EudraCT 2008-003658-13,
http://clinicaltrials.gov/ct2/show/NCT00824083
All rights reserved. Please visit https://medical-data-
models.org/forms/10669
KOF/Status Ewing NCT00824083
KOF
Körpergröße*
Körpergewicht*
Körperoberfläche*
Körperoberfläche berechnet*
Karnofsky/Lansky
Pubertätsstatus*
Präpubertär (1)
Intrapubertär (2)
Postpubertär (3)
Karnofsky/Lansky-Score*
10% (10)
100% (100)
20% (20)
30% (30)
40% (40)
50% (50)
60% (60)
70% (70)
80% (80)
90% (90)
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Ewing Study primary tumor NCT00824083
EWING 2008, EudraCT 2008-003658-13,
http://clinicaltrials.gov/ct2/show/NCT00824083
All rights reserved. Please visit https://medical-data-
models.org/forms/10670
Primary tumor Ewing Study
NCT00824083
Tumor location
Involvement*
Osseous lesion with or without soft
tissue component (1)
Extra-osseus lesion (no bone
involvement) (2)
Side*
Right (1)
Left (2)
Midline (3)
Bilateral (4)
Supposed origin*
Pevis: other (10)
Pelvis-osseous: os ilium (11)
Pelvis-osseous: ischiopubis (12)
Pelvis-osseous: acetabulum (13)
Pelvis-osseous: os sacrum (14)
Pelvis-extra osseous: pelvic soft tissue
(15)
Pelvis-extra osseous: buttock (16)
Pelvis-extra osseous: hip/ inguinal region
(17)
Pelvis-extra osseous: perineum (18)
Admomen-extra osseous: other (20)
Admomen-extra osseous: intra-
abdominal (21)
Admomen-extra osseous: retroperitoneal
(22)
Admomen-extra osseous: abdominal wall
(23)
Admomen-extra osseous: kidney (24)
Spine-osseous: cervical vertebra(e) (31)
Spine-osseous: dorsal vertebra(e) (32)
Spine-osseous: lumbar vertebra(e) (33)
Spine-extra osseous: cervical intraspinal
(34)
Spine-extra osseous: dorsal intraspinal
(35)
Spine-extra osseous: lumbar intraspinal
(36)
Chest: other (40)
Chest-osseous: scapula (41)
Chest-osseous: clavicula (42)
Chest-osseous: rib (43)
Chest-osseous: sternum (44)
Chest-extra osseous: shoulder (45)
Chest-extra osseous: axilla (46)
Chest-extra osseous: chest wall (47)
Head and Neck: other (50)
Head and Neck-osseous: skull (51)
Head and Neck-osseous: madibula (52)
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Head and Neck-osseous: maxilla (53)
Head and Neck-extra osseous: scalp
(54)
Head and Neck-extra osseous: neck (55)
Head and Neck-extra osseous: face (56)
Upper extremity: other (60)
Upper extremity-osseous: humerus (61)
Upper extremity-osseous: ulna (cubitus)
(62)
Upper extremity-osseous: radius (63)
Upper extremity-osseous: carpus (64)
Upper extremity-osseous: metacarpus
(65)
Upper extremity-osseous: finger (66)
Upper extremity-extra osseous: upper
arm (67)
Upper extremity-extra osseous: elbow
(68)
Upper extremity-extra osseous: forearm
(69)
Upper extremity-extra osseous: wrist (70)
Upper extremity-extra osseous: hand
(71)
Lower extremity: other (80)
Lower extremity-osseous: femur (81)
Lower extremity-osseous: tibia (82)
Lower extremity-osseous: fibula (83)
Lower extremity-osseous: calcanaeum
(84)
Lower extremity-osseous: talus (85)
Lower extremity-osseous: metatarsus
(86)
Lower extremity-osseous: toe (87)
Lower extremity-extra osseous: thigh
(88)
Lower extremity-extra osseous: knee
(89)
Lower extremity-extra osseous: leg (90)
Lower extremity-extra osseous: ankle
(91)
Lower extremity-extra osseous: foot (92)
If local tumor extension please enter site (I)
Pevis: other (10)
Pelvis-osseous: os ilium (11)
Pelvis-osseous: ischiopubis (12)
Pelvis-osseous: acetabulum (13)
Pelvis-osseous: os sacrum (14)
Pelvis-extra osseous: pelvic soft tissue
(15)
Pelvis-extra osseous: buttock (16)
Pelvis-extra osseous: hip/ inguinal region
(17)
Pelvis-extra osseous: perineum (18)
Admomen-extra osseous: other (20)
Admomen-extra osseous: intra-
abdominal (21)
Admomen-extra osseous: retroperitoneal
(22)
Admomen-extra osseous: abdominal wall
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(23)
Admomen-extra osseous: kidney (24)
Spine-osseous: cervical vertebra(e) (31)
Spine-osseous: dorsal vertebra(e) (32)
Spine-osseous: lumbar vertebra(e) (33)
Spine-extra osseous: cervical intraspinal
(34)
Spine-extra osseous: dorsal intraspinal
(35)
Spine-extra osseous: lumbar intraspinal
(36)
Chest: other (40)
Chest-osseous: scapula (41)
Chest-osseous: clavicula (42)
Chest-osseous: rib (43)
Chest-osseous: sternum (44)
Chest-extra osseous: shoulder (45)
Chest-extra osseous: axilla (46)
Chest-extra osseous: chest wall (47)
Head and Neck: other (50)
Head and Neck-osseous: skull (51)
Head and Neck-osseous: madibula (52)
Head and Neck-osseous: maxilla (53)
Head and Neck-extra osseous: scalp
(54)
Head and Neck-extra osseous: neck (55)
Head and Neck-extra osseous: face (56)
Upper extremity: other (60)
Upper extremity-osseous: humerus (61)
Upper extremity-osseous: ulna (cubitus)
(62)
Upper extremity-osseous: radius (63)
Upper extremity-osseous: carpus (64)
Upper extremity-osseous: metacarpus
(65)
Upper extremity-osseous: finger (66)
Upper extremity-extra osseous: upper
arm (67)
Upper extremity-extra osseous: elbow
(68)
Upper extremity-extra osseous: forearm
(69)
Upper extremity-extra osseous: wrist (70)
Upper extremity-extra osseous: hand
(71)
Lower extremity: other (80)
Lower extremity-osseous: femur (81)
Lower extremity-osseous: tibia (82)
Lower extremity-osseous: fibula (83)
Lower extremity-osseous: calcanaeum
(84)
Lower extremity-osseous: talus (85)
Lower extremity-osseous: metatarsus
(86)
Lower extremity-osseous: toe (87)
Lower extremity-extra osseous: thigh
(88)
Lower extremity-extra osseous: knee
(89)
Lower extremity-extra osseous: leg (90)
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Lower extremity-extra osseous: ankle
(91)
Lower extremity-extra osseous: foot (92)
If local tumor extension please enter site (II)
Pevis: other (10)
Pelvis-osseous: os ilium (11)
Pelvis-osseous: ischiopubis (12)
Pelvis-osseous: acetabulum (13)
Pelvis-osseous: os sacrum (14)
Pelvis-extra osseous: pelvic soft tissue
(15)
Pelvis-extra osseous: buttock (16)
Pelvis-extra osseous: hip/ inguinal region
(17)
Pelvis-extra osseous: perineum (18)
Admomen-extra osseous: other (20)
Admomen-extra osseous: intra-
abdominal (21)
Admomen-extra osseous: retroperitoneal
(22)
Admomen-extra osseous: abdominal wall
(23)
Admomen-extra osseous: kidney (24)
Spine-osseous: cervical vertebra(e) (31)
Spine-osseous: dorsal vertebra(e) (32)
Spine-osseous: lumbar vertebra(e) (33)
Spine-extra osseous: cervical intraspinal
(34)
Spine-extra osseous: dorsal intraspinal
(35)
Spine-extra osseous: lumbar intraspinal
(36)
Chest: other (40)
Chest-osseous: scapula (41)
Chest-osseous: clavicula (42)
Chest-osseous: rib (43)
Chest-osseous: sternum (44)
Chest-extra osseous: shoulder (45)
Chest-extra osseous: axilla (46)
Chest-extra osseous: chest wall (47)
Head and Neck: other (50)
Head and Neck-osseous: skull (51)
Head and Neck-osseous: madibula (52)
Head and Neck-osseous: maxilla (53)
Head and Neck-extra osseous: scalp
(54)
Head and Neck-extra osseous: neck (55)
Head and Neck-extra osseous: face (56)
Upper extremity: other (60)
Upper extremity-osseous: humerus (61)
Upper extremity-osseous: ulna (cubitus)
(62)
Upper extremity-osseous: radius (63)
Upper extremity-osseous: carpus (64)
Upper extremity-osseous: metacarpus
(65)
Upper extremity-osseous: finger (66)
Upper extremity-extra osseous: upper
arm (67)
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Upper extremity-extra osseous: elbow
(68)
Upper extremity-extra osseous: forearm
(69)
Upper extremity-extra osseous: wrist (70)
Upper extremity-extra osseous: hand
(71)
Lower extremity: other (80)
Lower extremity-osseous: femur (81)
Lower extremity-osseous: tibia (82)
Lower extremity-osseous: fibula (83)
Lower extremity-osseous: calcanaeum
(84)
Lower extremity-osseous: talus (85)
Lower extremity-osseous: metatarsus
(86)
Lower extremity-osseous: toe (87)
Lower extremity-extra osseous: thigh
(88)
Lower extremity-extra osseous: knee
(89)
Lower extremity-extra osseous: leg (90)
Lower extremity-extra osseous: ankle
(91)
Lower extremity-extra osseous: foot (92)
If local tumor extension please enter site (III)
Pevis: other (10)
Pelvis-osseous: os ilium (11)
Pelvis-osseous: ischiopubis (12)
Pelvis-osseous: acetabulum (13)
Pelvis-osseous: os sacrum (14)
Pelvis-extra osseous: pelvic soft tissue
(15)
Pelvis-extra osseous: buttock (16)
Pelvis-extra osseous: hip/ inguinal region
(17)
Pelvis-extra osseous: perineum (18)
Admomen-extra osseous: other (20)
Admomen-extra osseous: intra-
abdominal (21)
Admomen-extra osseous: retroperitoneal
(22)
Admomen-extra osseous: abdominal wall
(23)
Admomen-extra osseous: kidney (24)
Spine-osseous: cervical vertebra(e) (31)
Spine-osseous: dorsal vertebra(e) (32)
Spine-osseous: lumbar vertebra(e) (33)
Spine-extra osseous: cervical intraspinal
(34)
Spine-extra osseous: dorsal intraspinal
(35)
Spine-extra osseous: lumbar intraspinal
(36)
Chest: other (40)
Chest-osseous: scapula (41)
Chest-osseous: clavicula (42)
Chest-osseous: rib (43)
Chest-osseous: sternum (44)
5 / 7
Ewing Study primary tumor NCT00824083
Chest-extra osseous: shoulder (45)
Chest-extra osseous: axilla (46)
Chest-extra osseous: chest wall (47)
Head and Neck: other (50)
Head and Neck-osseous: skull (51)
Head and Neck-osseous: madibula (52)
Head and Neck-osseous: maxilla (53)
Head and Neck-extra osseous: scalp
(54)
Head and Neck-extra osseous: neck (55)
Head and Neck-extra osseous: face (56)
Upper extremity: other (60)
Upper extremity-osseous: humerus (61)
Upper extremity-osseous: ulna (cubitus)
(62)
Upper extremity-osseous: radius (63)
Upper extremity-osseous: carpus (64)
Upper extremity-osseous: metacarpus
(65)
Upper extremity-osseous: finger (66)
Upper extremity-extra osseous: upper
arm (67)
Upper extremity-extra osseous: elbow
(68)
Upper extremity-extra osseous: forearm
(69)
Upper extremity-extra osseous: wrist (70)
Upper extremity-extra osseous: hand
(71)
Lower extremity: other (80)
Lower extremity-osseous: femur (81)
Lower extremity-osseous: tibia (82)
Lower extremity-osseous: fibula (83)
Lower extremity-osseous: calcanaeum
(84)
Lower extremity-osseous: talus (85)
Lower extremity-osseous: metatarsus
(86)
Lower extremity-osseous: toe (87)
Lower extremity-extra osseous: thigh
(88)
Lower extremity-extra osseous: knee
(89)
Lower extremity-extra osseous: leg (90)
Lower extremity-extra osseous: ankle
(91)
Lower extremity-extra osseous: foot (92)
If tumor of long bones
proximal (1)
Midshaft (2)
Distal (3)
Whole bone (4)
Volumetry of primary tumor
Tumorvolume CT/MR*
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a. Dimensions (length)*
b. Dimensions (width)*
c. Dimensions (height)*
d. Shape*
(almost) spherical (1)
(almost) cylindrical (2)
Tumorvolume calculated (a*b*c*d)*
Categorisation*
<200ml (1)
>=200ml (2)
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Ewing Study disease response VIDE
NCT00824083
EWING 2008, EudraCT 2008-003658-13,
http://clinicaltrials.gov/ct2/show/NCT00824083
All rights reserved. Please visit https://medical-data-
models.org/forms/10671
Disease response VIDE Ewing Study
NCT00824083
Videresp
Date of evaluation*
VIDE course no.*
Evaluation of tumor-related symptoms*
Absence of tumor-related symptoms at
diagnosis (0)
Complete disappearence of symptoms
(1)
Incomplete disappearance of symptoms
(2)
Stable symptoms (3)
Undulating response (4)
Progression of symptoms (5)
Primary tumor
Method of evaluation*
Clinical examination (0)
MRI (1)
CT (2)
Ultrasound (3)
Technetium bone scan (4)
PET CT (5)
other (6)
PET Scan (7)
SUV (max.) primary tumor*
SUV (mean) liver*
Status (RECIST guidlines)*
Complete remission (CR) (1)
Partial remission (PR) (2)
Stable disease (SD) (3)
Progressive disease (PD) (4)
Tumorvolume CT/MR*
a. Dimensions (lenght)*
b. Dimensions (width)*
c. Dimensions (height)*
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d. Shape*
(almost) spherical (1)
(almost) cylindrical (2)
Tumorvolume calculated (a*b*c*d)*
Categorisation
<200ml (1)
>=200ml (2)
Metastasis
Status pulmonary metastase(s) (RECIST
guidlines)*
Complete remission (CR) (1)
Partial remission (PR) (2)
Stable disease (SD) (3)
Progressive disease (PD) (4)
Status extrapulmonary metastase(s) (RECIST
guidlines)*
Complete remission (CR) (1)
Partial remission (PR) (2)
Stable disease (SD) (3)
Progressive disease (PD) (4)
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Rheumatoid Arthritis Photoimmune Therapy
With UVADEX Eligibility NCT00221000
Eligibility NCT00221000 Rheumatoid Arthritis
Safety and Efficacy of Extracorporeal Photoimmune
Therapy With UVADEX for the Treatment of Rheumatoid
Arthritis (RA-1)
ODM derived from
http://clinicaltrials.gov/show/NCT00221000
All rights reserved. Please visit https://medical-data-
models.org/forms/10672
Eligibility Rheumatoid Arthritis
NCT00221000
Inclusion Criteria
18 Years and older*
Yes
No
Patients must have a history of RA per the ACR
criteria for the classification of RA*
Yes
No
Patients must have moderately to severely active
RA*
Yes
No
Patients who are not on oral corticosteroids OR
Patients who have been on a stable dose of oral
corticosteroids at a prednisone equivalent
dosage greater than or equal to 15 mg/day for at
least 4 weeks prior to screening.*
Yes
No
Patients must have a platelet count greater than
or equal to 100,000/cmm.*
Yes
No
Female patients must be one of the following:
postmenopausal, surgically incapable of bearing
children, practicing an acceptable method of birth
control (acceptable methods may include
hormonal contraceptives, intrauterine device, and
spermicide and barrier). Abstinence or
partner/spouse sterility may also qualify at the
Investigator's discretion. If a female patient is of
childbearing potential, she must have a negative
urine pregnancy test at screening.*
Yes
No
Patients must be able and willing to comply with
all study procedures*
Yes
No
Patients must be willing to sign an ICF*
Yes
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No
Patients must have a body weight greater than or
equal to 40 kg (88 lb).*
Yes
No
Exclusion Criteria
Patients who have a form of arthritis or
arthropathy, other than RA, or any current
inflammatory condition that might confound the
assessments (e.g., other connective tissue
diseases or Lyme disease).*
Yes
No
Patients who have been enrolled in any
investigational therapy study for the treatment of
RA within 4 weeks prior to the start of the
Treatment Period, or patients who are scheduled
to receive investigational therapies or a plasma
based apheresis procedure (e.g., a protein A
column) for the treatment of RA during the course
of the study.*
Yes
No
Patients unable to tolerate the extracorporeal
volume shifts associated with ECP treatment due
to the presence of any of the following conditions:
uncompensated congestive heart failure,
pulmonary edema, severe chronic obstructive
pulmonary disease, severe asthma, renal failure,
or hepatic failure.*
Yes
No
Patients with a poor tolerability of venipuncture or
a lack of adequate venous access for required
treatments and blood sampling.*
Yes
No
Patients who have a known hypersensitivity or
allergy to psoralen (methoxsalen)*
Yes
No
Patients who have a known hypersensitivity or
allergy to both heparin and citrate products*
Yes
No
Patients who are taking any of the following
permitted DMARDs and biological agents and
have not been on a stable dose for the specific
indicated periods of time prior to screening: MTX
for at least 8 weeks; leflunomide for at least 8
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weeks; infliximab for at least 14 weeks;
etanercept for at least 12 weeks; adalimumab for
at least 12 weeks*
Yes
No
Patients who are taking any of the following
permitted medications and have not been on a
stable dose for at least 4 weeks prior to
screening: NSAIDs; anakinra;
hydroxychloroquine; chloroquine; sulfasalazine;
D-penicillamine; gold salts; azathioprine; oral
corticosteroids (greater than or equal to 15
mg/day, prednisone equivalent dose).*
Yes
No
Patients whom the Investigator believes cannot
be maintained on stable doses of permitted
concomitant RA medications throughout the
Treatment Period*
Yes
No
Patients who are taking any of the following
prohibited medications: cyclophosphamide;
chlorambucil; intramuscular (IM) or intravenous
(IV) corticosteroid injection(s), within 4 weeks of
screening; intra-articular corticosteroid
injection(s) > 60 mg prednisone equivalent total
dose, within 4 weeks of screening*
Yes
No
Patients who have any known malignant disease
(other than basal cell carcinoma) currently or
within the last 5 years*
Yes
No
Patients who have a pre-existing blood dyscrasia
such as bone marrow hypoplasia, leukopenia,
thrombocytopenia, significant anemia, or a
coagulation disorder*
Yes
No
Patients with a persistent or severe infection
within 12 weeks of screening.*
Yes
No
Patients with a history of drug or alcohol abuse
within 12 weeks of screening.*
Yes
No
Patients with impaired hepatic function at
screening as shown by abnormal liver function
tests (LFT; i.e., aspartate transaminase [AST] or
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alanine transaminase [ALT] levels > 2 x the upper
limit of normal [ULN])*
Yes
No
Women who are pregnant or lactating*
Yes
No
Medical Concepts
Age*
Diagnosis*
Rheumatoid Arthritis*
Moderately*
C-Reactive Protein Measurement*
Medication*
Methotrexate*
Therapeutic Corticosteroid*
Platelet count - finding*
Contraception*
Arthritis*
Inflammation *
Enrollment*
Chronic congestive heart failure*
Lung diseases*
Renal Insufficiency*
Hepatic Insufficiency*
Hypersensitivity*
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Nonsteroidal Antiinflammatory Drug*
Malignant Neoplasms*
White Blood Cell Count procedure (WBC)*
Hemoglobin*
Blood Coagulation Disorders*
Infection*
Alcohol abuse*
Drug abuse*
GOT (Serum)*
GPT (Serum)*
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EWOG MDS 2006 haematological data
NCT00662090
Prospective nonrandomized multicenter study for
epidemiology and characterization of Myelodysplastic
Syndromes(MDS) and Juvenile Myelomonocytic Leukemia
(JMML) in childhood. PI: Prof. Dr. Charlotte Niemeyer
http://clinicaltrials.gov/ct2/show/NCT00662090
http://www.ewog-mds.org/
All rights reserved. Please visit https://medical-data-
models.org/forms/10674
Haematological data on PB/BM
EWOG MDS NCT00662090
Basic data
Datum der KM Aspiration*
Befund Referenzmorphologie*
Prof. Niemeyer (Freiburg) (1)
Schmugge (Zürich) (10)
Dworzak (Wien) (2)
Philippe (Ghent) (3)
Stary (Prag) (4)
Smith (Dublin) (5)
Fenu (Rom) (6)
De Haas (Den Haag) (7)
Kerndrup (Vejle) (8)
Camos (Barcelona) (9)
Anderes (99)
Anderes Labor*
Diagnosis
Klassifikation entsprechend der Morphologie*
Remission (10)
MDR-AML (40)
RC (41)
RARS (42)
RAEB (43)
RAEB-T (44)
JMML (45)
CMML (46)
Noonan Sy. + JMML ähnliches Bild (47)
Hypereosinophiles Syndrom (50)
Myelofibrotisches MDS (60)
MDS, nicht klassifiziert (99)
PB basic data
Regelmäßige Erythrozytentransfusionen
notwendig*
Nein (1)
Ja (2)
Regelmäßige Thrombozytentransfusionen
notwendig*
Nein (1)
Ja (2)
Hb Wert*
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MCV*
Thrombozyten*
Leukozyten*
Retikulozyten*
Erythrozyten*
Differential count
Blasten*
Promyelozyten*
Myelozyten*
Metamyelozyten*
Stabkernige*
Segmentkernige*
Eosinophile*
Basophile*
Lymphozyten*
Monozyten*
Erythroblasten*
BM basic data
Zellgehalt*
Aplastisch (1)
Hypozellulär (2)
Normozellulär (3)
Hyperzellular (4)
Nicht beurteilbar (5)
Megakaryozyten*
Keine (1)
Vermindert (2)
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Normal (3)
Erhöht (4)
Auerstäbchen*
Nein (1)
Ja (2)
Differential count
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Melanoma Eligibility Interferon Alpha
NCT00226408
Standard High-Dose Alpha Interferon Versus Intermittent
High-Dose Alpha Interferon
ODM derived from
http://clinicaltrials.gov/show/NCT00226408
All rights reserved. Please visit https://medical-data-
models.org/forms/10676
Eligibility Melanoma NCT00226408
Inclusion Criteria
18 Years to 70 Years*
Yes
No
Histological documented cutaneous malignant
melanoma Stage IIIa, IIIb, IIIc (AJCC 2002)*
Yes
No
R0 resection dating back no longer than 56 days*
Yes
No
Performance status (ECOG 0-1)*
Yes
No
Bone marrow funktion: White cell count > 3000
cells/ul, platelets > 100000 cells/ul, hemoglobin >
10 g/dl*
Yes
No
Liver and kidney funktion: Serum creatinin < 1.5
times upper limit of normal, AST and ALT < 2.5
times upper limit of normal, Serum bilirubin < 2
times upper limit of normal*
Yes
No
Written inform consent*
Yes
No
Exclusion Criteria
Confirmed distant metastasis*
Yes
No
Choroid or mucosal melanoma*
Yes
No
Pregnant or lactating women and women of
childbearing potential not using a reliable form of
contraception*
Yes
No
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Active autoimmun disease*
Yes
No
patients with history of neuropsychiatric disease
requiring hospitalization*
Yes
No
Severe medical condition such us: Florid
hepatitis, Severe acute infection, Myocardial
infarction within the past year, symptomatic
angina pectoris, Grade III to IV congestive heart
failure, serious pulmonary disease, HIV-positive
patients with an AIDS - defining condition*
Yes
No
treatment in another clinical drug trial within the
last 30 days*
Yes
No
A history of hypersensitivity to interferon alfa*
Yes
No
History of maignant disease during the past 5
years (except for curatively treated skin
carcinoma or in situ carcinoma)*
Yes
No
Prior high dose interferon alfa therapy.Prior
adjuvant low dose or intermediate-dose interferon
alfa therapy is allowed*
Yes
No
Medical concepts
Diagnosis*
Malignant melanoma*
Diagnostic Neoplasm Staging*
Therapeutic procedure*
ECOG performance status finding*
White Blood Cell Count procedure (WBC)*
Platelet count - finding*
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Creatinine*
GOT (Serum)*
GPT (Serum)*
Bilirubin*
Informed Consent*
Metastasis*
pregnant*
Breast feeding, Nursing*
Contraception*
Autoimmune Disease*
Psychosis (Psychotic disorder)*
Hepatitis*
Systemic infection*
Heart infarction*
Chronic congestive heart failure*
Lung diseases*
Acquired Immunodeficiency Syndrome*
Enrollment*
Hypersensitivity*
Malignant Neoplasms*
Medication*
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Rhabdomyosarcoma Treatment CWS-2007-
HR NCT00876031
CWS-2007-HR: A randomised phase-III trial of the
Cooperative Soft-Tissue-Study-Group for localised high-risk
rhabdomyosarcoma and localised Rhabdomyosarcoma-like
Soft Tissue Sarcoma in children, adolescents, and young
adults   http://clinicaltrials.gov/show/NCT00876031
http://www.cws.olgahospital-stuttgart.de
All rights reserved. Please visit https://medical-data-
models.org/forms/10679
Treatment  B4 - Block 2 O-TE
Rhabdomyosarcoma NCT00876031
Block O-TE
Datum Beginn*
Trofosfamid kumulativ/Block*
Etoposid kumulativ/Block*
Sollwert Trofosfamid nach KOF*
Sollwert Etoposid nach KOF*
Abstand vorheriger Block in Tagen
Toxicity common
Karnofsky/Lansky Index*
Tod (0)
10% (10)
100% (100)
20% (20)
30% (30)
40% (40)
50% (50)
60% (60)
70% (70)
80% (80)
90% (90)
Toxicity hematology
Hämoglobin Toxizität*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Grad 5 (5)
Leukozyten (10E9/l)*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
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Grad 5 (5)
Neutrophile Granulozyten*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Grad 5 (5)
Thrombozyten (G/l)*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Grad 5 (5)
Toxicity infection
Infektion*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Grad 5 (5)
Fieber ( Grad C)*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Grad 5 (5)
Toxicity gastrointestinal
Ãœbelkeit*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Grad 5 (5)
Erbrechen [Episoden/24 Std]*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Grad 5 (5)
Mucositis (klinisch)*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
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Grad 3 (3)
Grad 4 (4)
Grad 5 (5)
Diarrhoe*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Grad 5 (5)
Toxicity kidney
Kreatinin*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Grad 5 (5)
Proteinurie (g/24 Std.)*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Grad 5 (5)
HÃ¤maturie/HÃ¤moglobinurie*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Grad 5 (5)
Toxicity neurology
Verwirrtheit*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Grad 5 (5)
Neuropathie sensorisch*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Grad 5 (5)
Neuropathie motorisch*
Grad 0 (0)
Grad 1 (1)
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Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Grad 5 (5)
Toxicity liver
Bilirubin*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Grad 5 (5)
S-GOT/S-GPT*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Grad 5 (5)
Toxicity Herz
Arrhytmie*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Grad 5 (5)
LinksventrikulÃ¤re Herzfunktion*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Grad 5 (5)
Toxicity other
Bezeichnung andere ToxizitÃ¤t*
ToxizitÃ¤t Grad*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Grad 5 (5)
Toxicity comment
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Bemerkungen zur ToxizitÃ¤t
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Rhabdomyosarcoma Treatment CWS-2007-HR NCT00876031
SIOP CNS GCT II NCT01424839
SIOP CNS GCT II: Prospective Trial for the Diagnosis and
Treatment of Children, Adolescents and Young Adults With
Intracranial Germ Cell Tumors. Principal Investigator
Gabriele Calaminus, MD.
http://clinicaltrials.gov/show/NCT01424839
All rights reserved. Please visit https://medical-data-
models.org/forms/10680
Toxicity during chemotherapy course
NCT01424839
Toxicity hematology
HÃ¤moglobin*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Leukozyten*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Neutrophile*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Thrombozyten*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Blutung*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Toxicity neurological
Kopfschmerzen*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
KrampfanfÃ¤lle*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
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Zentrale NeurotoxizitÃ¤t*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Periphere NeurotoxizitÃ¤t*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Toxicity infection
Infektion*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Fieber*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Toxicity gastrointestinal
Übelkeit*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Erbrechen*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Stomatitis*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
DiarrhÃ¶e*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
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Toxicity skin
Alopezie*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
HautverÃ¤nderungen*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Erythema multiforme*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Toxicity renal
Kreatinin*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Proteinurie*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Hämaturie*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
GlomerulÃ¤re Filtrationsrate (GFR)*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
TubulÃ¤re Phosphatreabsorption*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
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Toxicity Hearing
Hörvermögen*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Audiometrie*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Toxicity cardiac
Herzfunktion*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Toxicity metabolic/laboratory
Acidose*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
HypokalzÃ¤mie*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
HyperkalzÃ¤mie*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Hypomagnesemie*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Hypermagnesemie*
Grad 0 (0)
Grad 1 (1)
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Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Hypophosphatemie*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
HypokalÃ¤mie*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
HyperkalÃ¤mie*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Hyponatremia*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Hypernatremie*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Toxicity other
Andere ToxizitÃ¤t aufgetreten*
Nein (1)
Ja (2)
Grad andere ToxizitÃ¤t*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Beschreibung andere ToxizitÃ¤t*
5 / 5
SIOP CNS GCT II NCT01424839
Rhabdomyosarcoma Treatment CWS-2007-
HR NCT00876031
CWS-2007-HR: A randomised phase-III trial of the
Cooperative Soft-Tissue-Study-Group for localised high-risk
rhabdomyosarcoma and localised Rhabdomyosarcoma-like
Soft Tissue Sarcoma in children, adolescents, and young
adults   http://clinicaltrials.gov/show/NCT00876031
http://www.cws.olgahospital-stuttgart.de
CWS-2007-HR B4 - Block 3 O-TI
All rights reserved. Please visit https://medical-data-
models.org/forms/10681
Treatment B4 - Block 3 O-TI
Rhabdomyosarcoma NCT00876031
Block O-TI
Datum Beginn*
Trofosfamid kumulativ/Block*
Idarubicin kumulativ/Block*
Sollwert Trofosfamid nach KOF*
Sollwert Idarubicin nach KOF
Abstand vorheriger Block in Tagen
Toxicity common
Karnofsky/Lansky Index*
Tod (0)
10% (10)
100% (100)
20% (20)
30% (30)
40% (40)
50% (50)
60% (60)
70% (70)
80% (80)
90% (90)
Toxicity hematology
Hämoglobin*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Grad 5 (5)
Leukozyten*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
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Grad 3 (3)
Grad 4 (4)
Grad 5 (5)
Neutrophile Granulozyten*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Grad 5 (5)
Thrombozyten (G/l)*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Grad 5 (5)
Toxicity infection
Infektion*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Grad 5 (5)
Fieber ( Grad C)*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Grad 5 (5)
Toxicity gastrointestinal
Ãœbelkeit*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Grad 5 (5)
Erbrechen [Episoden/24 Std]*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Grad 5 (5)
Mucositis (klinisch)*
Grad 0 (0)
Grad 1 (1)
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Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Grad 5 (5)
Diarrhoe*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Grad 5 (5)
Toxicity kidney
Kreatinin*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Grad 5 (5)
Proteinurie (g/24 Std.)*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Grad 5 (5)
Hämaturie/Hämoglobinurie*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Grad 5 (5)
Toxicity neurology
Verwirrtheit*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Grad 5 (5)
Neuropathie sensorisch*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Grad 5 (5)
Neuropathie motorisch*
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Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Grad 5 (5)
Toxicity liver
Bilirubin*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Grad 5 (5)
S-GOT/S-GPT*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Grad 5 (5)
Toxicity Herz
Arrhytmie*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Grad 5 (5)
Linksventrikuläre Herzfunktion*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Grad 5 (5)
Toxicity other
Bezeichnung andere Toxizität*
Toxizität Grad*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Grad 5 (5)
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Toxicity comment
Bemerkungen zur Toxizität
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Order form pediatric intensive care unit
UKM
Routine documentation of university hospital muenster.
This form serves the purpose of documenting and ordering
medications and syringe pumps in a specific pediatric ICU.
All rights reserved. Please visit https://medical-data-
models.org/forms/10682
Order form pediatric intensive care
unit UKM- Physician's order
Patient Information
Name of the Patient:*
Date of birth:*
Please enter the weight of the patient:
Please enter the height of the patient:
Please enter the body surface area of the patient:
Date of entry:
Parameters to be monitored, please
include the measuring intervals and
threshholds for the respective parameters
Blood pressure (RR)/ Mean arterial pressure
(MAP):
Central venous pressure (CVP):
Pulmonary arterial pressure (PAP)/ Left atrial
pressure (LAP):
Transcutaneous carbon dioxide (TcPCO2):
Oxygen saturation (SaO2):
Weight
Electrolyte Balance
Neurological monitoring:
Special positioning of the patient:
Physiotherapy:
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Aspiration:
Special needs or comments::
Record of liquid and nutrition of the
patient:
Patient's total body liquid volume (ml/ 24h):
Please input the patient's liquid record from the
previous day as follow-
Intake, Excretion, Perspiration, balance and
diuresis (all in ml/ kg/ h):
Enteral nutrition (kcal/ 100 ml):
Please mention the nutrition record as follow
when applicable- Total amount, Enteral,
Parenteral (all in kcal/ kg)
Please enter the liquid measurement as follow
when applicable- Total, Enteral, Parenteral (all in
ml/ kg):
Medication
Name of the medication:
Dose:
Drug administration route:
Time of drug administration:
Drug administration accomplished?
Yes (1)
No (2)
Name of the physician:
Syringe pumps
Name of the drug:
Dose:
Dilution:
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Other related informations:
Therapy instructions
Type of therapy:
Time:
Name of the physician:
Name of the nurse:
Diagnosis order
Diagnosis
Time:
Name of the physician:
Name of the nurse:
Laboratory tests and examination
Laboratory tests:
Examination:
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CLL Lab NCT00090051 BO17072
An open-label, multicenter, randomized, comparative,
phase III study to evaluate the efficacy and safety of
rituximab plus fludarabine and cyclophosphamide (FCR)
versus fludarabine and cyclophosphamide alone (FC) in
previously treated patients with CD20 positive B-cell
chronic lymphocytic leukemia (CLL). FCR Versus FC Alone
in the Treatment of Chronic Lymphocytic Leukemia (CLL) in
Relapsed Patients NCT00090051 Roche BO17072
All rights reserved. Please visit https://medical-data-
models.org/forms/10684
Laboratories of Chronic lymphocytic
leukemia NCT0090051
Laboratory analysis
Sample collection date
Lab ID number
Hematology
Hemoglobin
Hematocrit
Red Blood Cells
Leukocytes (total)
Neutrophils
Basophils
Eosinophils
Lymphocytes
Monocytes
Other cells
Platelets
Prothrombin time
Please comment on any abnormal other cells and
specify white cell morphology
indirect/direct
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Sample collection date
Indirect
negative (1)
positive (2)
Direct
negative (1)
positive (2)
Blood chemistry
Aspartate transaminase (Serum glutamic
oxaloacetic transaminase)
Alanine transaminase (Serum glutamate-pyruvate
transaminase)
Alk. phosphatase
Bilirubin total
Urea (BUN)
Serum creatinine
Estimated creatinine clearance
Lactate dehydrogenase
Total protein
Albumin
Blood glucose (random)
beta-2-microglobulin
Electrocytes
Sodium
Calcium
Potassium
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Phosphate
Lymphocyte immunophenotyping (local
lab)
Sample collection date
Lymphocytes
Monocytes
Neutrophils
Lymphocyte immunophenotyping (local
lab)
Immunophenotyping
CD3+ (1)
kappa (10)
lambda (11)
CD5+/CD19 (2)
CD19+ (3)
CD5+/CD20 (4)
CD20+ (5)
CD79b (6)
CD23 (7)
CD38 (8)
FMC7/lgG1 (SMIG) weak (9)
Lab parameter
gated (1)
total (2)
Comments
Blood sampling for molecular analyses
Sample number 101
Sample collection date (1)
Remarks (2)
Sample Collection Date
Comments
Blood sampling for VH mutation status
and chromosome abnormalities
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Sample number 401
Sample collection date (1)
Remarks (2)
Sample Collection Date
Bone marrow examination
Date of examination
Result of Bone marrow examination
normal result
Yes
No
abnormal result
normocellular (1)
hypocellular (2)
hypercellular (3)
Is bone marrow involved with CLL?
Percentage of bone marrow involvement
Percentage of bone marrow involved with
CLL (1)
diffude pattern of involvement (2)
nodular pattern of involvement (3)
no involvement
Yes
No
Lymphoid nodules in bone marrow?
Yes
No
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CALGB: 40301 FOLLOW-UP FORM
CALGB: 40301 FOLLOW-UP FORM
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=E529E600-
4C6C-184D-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/10689
CALGB: 40301 FOLLOW-UP FORM
Header
CALGB Form
CALGB Study No
CALGB Patient ID
From
To
Are data amended
Yes
No
Patient demographics
Patient Initials
Patient Hospital No
Institution/Affiliate
Participating Group
Participating Group Protocol No
Participating Group Patient ID
Vital Status
Patient's vital status (Mark one with an X.)
Alive (Alive)
Dead (Dead)
Lost To Follow-up (Lost)
Primary cause of death (Mark one with an X.)
Due To Other Cause (Due to other
cause)
Due To Protocol Treatment (Due to
protocol treatment)
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Due To This Disease (Due to this
disease)
Unknown (Unknown)
Describe cause of death
Date of last contact or death
Has the patient had a documented clinical
assessment for this cancer (since submission of
the previous follow-up form?)
Yes
No
Was patient restaged during this time period
Yes
No
Tumor response?
Complete Response (CR)
Partial Response (PR)
Date CR first observed
Was CR confirmed
Yes
No
Date PR first observed
Was PR confirmed
Yes
No
Notice Of Progression
Has the patient developed a first progression that
has not been previously reported (or relapse)
No (No)
Unknown (Unknown)
Yes (Yes)
Date of progression
Is the patient receiving any non-protocol cancer
therapy not previously reported
Yes
No
Non-protocol endocrine therapy (includes medical
and surgical)
Yes
No
Non-protocol surgery
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Yes
No
Non-protocol radiation therapy
Yes
No
Other non-protocol therapy
Yes
No
Other non-protocol therapy, specify
Date of first non-protocol therapy
Has a new primary cancer or MDS been
diagnosed that has not been previously reported
(myelodysplastic syndrome)
Yes
No
Date of diagnosis
Site of new primary (s)
New primary, histologic type
Comments
COMMENTS
Completed by
Date form completed
3 / 3
CALGB: 40301 FOLLOW-UP FORM
CALGB_40301_FOLLOW-UP
SOLID_TUMOR_EVALUATION_FORM
CALGB_40301_FOLLOW-UP
SOLID_TUMOR_EVALUATION_FORM
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=E59F6D70-
277D-48F1-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/10690
CALGB_40301_FOLLOW-UP
SOLID_TUMOR_EVALUATION_FO
RM
Header
CALGB Form
CALGB Study No
CALGB Patient ID
Are data amended
Yes
No
Patient demographics
Patient Initials
Patient Hospital Number
Main Member Institution/Affiliate
Participating Group
Participating Group Study No
Participating Group Patient ID
Reporting Period
Start Date
End Date
Lesion, Anatomic Site, Target
Date of evaluation
Method of Evaluation (**)
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Bone Scan (Bone Scan)
Chest X-ray (Chest X-ray)
Clinical (Clinical Examination)
Ct Scan (CT Scan)
Mri (MRI)
Other (Other)
Spiral Ct Scan (Spiral CT Scan)
Ultrasound (Ultrasound)
If Other, specify
Longest Diameter of Lesion (s)
Sum of Longest Diameters of All Target Lesions
Response Status at This Assessment, Target
Lesion (s)
Complete Response (Complete
Response)
Insufficient Evaluation To Determine
Response Status (Insufficient evaluation
to determine response status)
Partial Response (Partial Response)
Progressive Disease (Progressive
Disease)
Stable Disease (Stable Disease)
Non-target Lesion(s) Follow-up Evaluation
Are there any non-target lesions
Yes
No
Lesion, Anatomic Site, Non-Target
Date of evaluation
Method of Evaluation (**)
Bone Scan (Bone Scan)
Chest X-ray (Chest X-ray)
Clinical (Clinical Examination)
Ct Scan (CT Scan)
Mri (MRI)
Other (Other)
Spiral Ct Scan (Spiral CT Scan)
Ultrasound (Ultrasound)
F/U Response Status (Use response status
codes below.)
Complete Response (Complete
Response)
Incomplete Response/sd (Incomplete
Response/SD)
Insufficient Evaluation To Determine
Response Status (Insufficient evaluation
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to determine response status)
Progressive Disease (Progressive
Disease)
If Other, specify
Response Status at This Assessment, Non-
Target Lesion (s)
Complete Response (Complete
Response)
Incomplete Response/sd (Incomplete
Response/SD)
Insufficient Evaluation To Determine
Response Status (Insufficient evaluation
to determine response status)
Progressive Disease (Progressive
Disease)
New Lesion(s) At Follow-up Evaluation
Was the appearance of any new lesions
documented since the baseline evaluation
Yes
No
Lesion, Anatomic Site, New
Date of evaluation
Method of Evaluation (**)
Bone Scan (Bone Scan)
Chest X-ray (Chest X-ray)
Clinical (Clinical Examination)
Ct Scan (CT Scan)
Mri (MRI)
Other (Other)
Spiral Ct Scan (Spiral CT Scan)
Ultrasound (Ultrasound)
If Other, specify
Overall Response
Overall response (Combine Target, Non-Target,
and New Lesions.)
Complete Response (Complete
Response)
Incomplete Response (Incomplete
Response)
Insufficient Evaluation To Determine
Response Status (Insufficient evaluation
to determine response status)
Partial Response (Partial Response)
Progressive Disease (Progressive
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Disease)
Completed by
Date  form completed
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NSABP PROTOCOL B-39: ADVERSE EVENT
FORM FOR RADIATION THERAPY NCT00103181
NSABP PROTOCOL B-39: ADVERSE EVENT FORM FOR
RADIATION THERAPY NCT00103181 
Radiation Therapy in Treating Women Who Have
Undergone Surgery For Ductal Carcinoma In Situ or Stage
I or Stage II Breast Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=E6F7DDC5-
C879-6CDA-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/10691
NSABP PROTOCOL B-39:
ADVERSE EVENT FORM FOR
RADIATION THERAPY
NCT00103181
Header
Patient Initials
NSABP Patient ID
Institution Name
Affiliated Institution Name
Person Completing Form
Are data amended? (check box if yes, and circle
amended items)
Yes
No
Reporting Period
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
Reporting period
Reporting Period Start Date (as defined in above
table)
Reporting Period End Date (as defined in above
table)
Was patient hospitalized for 24 hours or more?
Yes
No
Adverse Event
1 / 2
Grade
Mild Adverse Event (1)
Moderate Adverse Event (2)
Severe Adverse Event (3)
Life Threatening Adverse Event (4)
Death Related To Adverse Event (5)
Ii. Infections
Comments
Comments
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THERAPY NCT00103181
NSABP Protocol B-40 - Assessment of Selected
Surgical Complications NCT00408408
NSABP Protocol B-40 - Assessment of Selected Surgical
Complications NCT00408408
A Randomized Phase III Trial of Neoadjuvant Therapy in
Patients With Palpable and Operable Breast Cancer
Evaluating the Effect on Pathologic Complete Response
(pCR) of Adding Capecitabine or Gemcitabine to Docetaxel
When Administered Before AC With or Without
Bevacizumab and Correlative Science Studies Attempting
to Identify Predictors of High Likelihood for pCR With Each
of the Regimens
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=1B382093-
6F15-732F-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/10692
NSABP Protocol B-40 - Assessment
of Selected Surgical Complications
NCT00408408
Header
Patient Initials (Last First Middle)
NSABP Patient ID
Institution/Affiliate
Person Completing Form, Last Name
Person Completing Form, First Name
Person Completing Form, Phone
Are data amended
Yes
No
clinical assessment
Time Interval for this Assessment
Date Of Surgery To 3-5 Weeks Following
Surgery (Date of surgery to 3-5 weeks
following surgery)
Day After Previous Time Interval To 12
Months Following Study Entry (Day after
previous time interval to 12 months
following study entry)
Day After Previous Time Interval To 24
Months Following Study Entry (Day after
previous time interval to 24 months
following study entry)
Day After Previous Time Interval To 9
Months Following Study Entry (Day after
previous time interval to 9 months
following study entry)
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Reporting Period Start Date
Reporting Period End Date
Were surgical complications assessed (at this
time interval?)
Yes
No
Surgical Complications
Yes
No
Selected Surgical Complications
Ii. Infections
Adverse Event
Hematoma (Hematoma)
Seroma (Seroma)
Skin Infection (Skin infection)
Soft Tissue Infection (Soft tissue
infection)
Wound Complication (Wound
complication)
Wound Dehiscence (Wound dehiscence)
Wound Infection (Wound infection)
Grade
Mild Adverse Event (1)
Moderate Adverse Event (2)
Severe Adverse Event (3)
Life Threatening Adverse Event (4)
Death Related To Adverse Event (5)
Footer
Comments
Person Completing Form
Date Form Completed
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CALGB_40302_REMARKS_AGENDA
NCT00390455
CALGB: 40302 REMARKS AGENDA NCT00390455
Fulvestrant With or Without Lapatinib in Treating
Postmenopausal Women With Stage III or Stage IV Breast
Cancer That is Hormone Receptor-Positive
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=F5AC8F60-
F4B4-0DB4-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/10693
CALGB_40302_REMARKS_AGEND
A NCT00390455
CALGB clinical trial administrative data
CALGB Form
CALGB Study No
CALGB Patient ID
Are data amended
Yes
No
Patient Initials
Patient Medical Record Number
Institution/Affiliate
Participating Group
Participating Group Protocol Number
Participating Group Patient ID
Reporting period
Reporting Period Start Date
Reporting Period End Date
Page
Comments
COMMENTS
Completed by
1 / 2
Date form completed
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CALGB_40302_FU_FRM NCT00390455
CALGB: 40302 FOLLOW-UP FORM NCT00390455
Fulvestrant With or Without Lapatinib in Treating
Postmenopausal Women With Stage III or Stage IV Breast
Cancer That is Hormone Receptor-Positive
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=F5A8CF0A-
51C1-3C78-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/10694
CALGB_40302_FU_FRM
NCT00390455
CALGB clinical trial administrative data
CALGB Form
CALGB Study No
CALGB Patient ID
Reporting Period Start Date
Reporting Period End Date
Are data amended
Yes
No
Patient Initials
Patient Hospital No
Institution/Affiliate
Participating Group
Participating Group Protocol No
Participating Group Patient ID
Vital Status
Patient's vital status (Mark one with an X.)
Alive (Alive)
Dead (Dead)
Lost To Follow-up (Lost)
Primary cause of death (Mark one with an X.)
Due To Other Cause (Due to other
cause)
1 / 3
Due To Protocol Treatment (Due to
protocol treatment)
Due To This Disease (Due to this
disease)
Unknown (Unknown)
Describe cause of death
Date of last contact or death (MM DD YYYY)
Has the patient had a documented clinical
assessment for this cancer
Yes
No
Was patient restaged during this time period
Yes
No
Overall Response Status at This Assessment (If
yes, complete the following questions and submit
C-817 Follow-up Solid Tumor Measurement
Form.)
Complete Response (CR)
Partial Response (PR)
Complete Response (CR) First Observed Date
(MM DD YYYY)
Is complete response confirmed
Yes
No
Partial Response (PR) First Observed Date (MM
DD YYYY)
Is partial response confirmed
Yes
No
Notice Of Progression
Has the patient developed a first progression that
has not been previously reported (or relapse)
No (No)
Unknown (Unknown)
Yes (Yes)
Date of progression
Sites of Progression
Is the patient receiving any non-protocol cancer
therapy not previously reported
Yes
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No
Non-protocol endocrine therapy (includes medical
and surgical)
Yes
No
Non-protocol surgery
Yes
No
Non-protocol radiation therapy
Yes
No
Other non-protocol therapy
Yes
No
Other non-protocol therapy, specify
Date of first non-protocol therapy
Has a new primary cancer or MDS been
diagnosed that has not been previously reported
(myelodysplastic syndrome)
Yes
No
Date of diagnosis (MM DD YYYY)
Site of new primary (s)
Comments
COMMENTS
Completed by
Date form completed
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E2108 Vital Status Form NCT01242800
E2108 Vital Status Form NCT01242800
Early Surgery or Standard Palliative Therapy in Treating
Patients With Stage IV Breast Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=918F7A63-
0F65-C218-E040-BB89AD43477E
All rights reserved. Please visit https://medical-data-
models.org/forms/10695
E2108 Vital Status Form
NCT01242800
ECOG clinical trial administrative data
ECOG Protocol Number
ECOG Patient ID
DCI Name
Registration Step
Patient Initials (Last, First)
Participating Group Protocol Number
Institution/Affiliate
Participating Group Patient ID
Data amendment
Please mark an 'X' if data have been amended.
(Please circle amended items in red)
Date data amended (M D Y)
Report Period
Reporting Period
Vital Status 12 Months Post Registration
(Vital Status 12 Months Post
Registration)
Vital Status 15 Months Post Registration
(Vital Status 15 Months Post
Registration)
Vital Status 18 Months Post Registration
(Vital Status 18 Months Post
Registration)
Vital Status 21 Months Post Registration
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(Vital Status 21 Months Post
Registration)
Vital Status 24 Months Post Registration
(Vital Status 24 Months Post
Registration)
Vital Status 3 Months Post Registration
(Vital Status 3 Months Post Registration)
Vital Status 30 Months Post Registration
(Vital Status 30 Months Post
Registration)
Vital Status 36 Months Post Registration
(Vital Status 36 Months Post
Registration)
Vital Status 42 Months Post Registration
(Vital Status 42 Months Post
Registration)
Vital Status 48 Months Post Registration
(Vital Status 48 Months Post
Registration)
Vital Status 54 Months Post Registration
(Vital Status 54 Months Post
Registration)
Vital Status 6 Months Post Registration
(Vital Status 6 Months Post Registration)
Vital Status 60 Months Post Registration
(Vital Status 60 Months Post
Registration)
Vital Status 9 Months Post Registration
(Vital Status 9 Months Post Registration)
Arm A And Arm B
Reporting Period Start Date
Reporting Period End Date
Vital Status
Patient's Vital Status
Alive (Alive)
Dead (Dead)
Date of Last Contact or Death
Primary Cause of Death (if applicable)
Due To Other Cause (Due to other
cause)
Due To Protocol Treatment (Due to
protocol treatment)
Due To This Disease (Due to this
disease)
Unknown (Unknown)
Describe cause of death
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Reason Treatment Ended (If this is the first
submission of this form, indicate below reason
why patient was not Randomized to Step 2 of the
study.)
Adverse Event/side Effects/complications
(Adverse Event/Side
Effects/Complications)
Alternative Therapy (Alternative therapy)
Death On Study (Death on study)
Disease Progression, Relapse During
Active Treatment (Disease progression,
relapse during active treatment)
Other (Other)
Patient Off-treatment For Other
Complicating Disease (Patient off-
treatment for other complicating disease)
Patient Withdrawal Or Refusal After
Beginning Protocol Therapy (Patient
withdrawal/refusal after beginning
protocol therapy)
Other Complicating Disease specify
Other specify
Comments
Investigator Signature
Investigator Signature Date
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E2108 Optimal Systemic Therapy Summary
Form NCT01242800
E2108 Optimal Systemic Therapy Summary Form
NCT01242800
Early Surgery or Standard Palliative Therapy in Treating
Patients With Stage IV Breast Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=9192F0DC-
00AE-56AC-E040-BB89AD431CAF
All rights reserved. Please visit https://medical-data-
models.org/forms/10696
E2108 Optimal Systemic Therapy
Summary Form NCT01242800
ECOG clinical trial administrative data
ECOG Protocol Number
ECOG Patient ID
DCI Name
Registration Step
Patient Initials (Last, First)
Participating Group Protocol Number
Institution/Affiliate
Participating Group Patient ID
Data amendment
Please mark an 'X' if data have been amended.
(Please circle amended items in red)
Date data amended (M D Y)
Arm A And Arm B
Reporting Period Start Date
Reporting Period End Date
Vital Status
Patient's Vital Status
Alive (Alive)
Dead (Dead)
1 / 2
Date of Last Contact or Death
Primary Cause of Death (if applicable)
Due To Other Cause (Due to other
cause)
Due To Protocol Treatment (Due to
protocol treatment)
Due To This Disease (Due to this
disease)
Unknown (Unknown)
Describe cause of death
Comments
Investigator Signature
Investigator Signature Date
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E3201 Long-Term Follow-up Form
NCT00068692
E3201 Long-Term Follow-up Form NCT00068692
Comparison of Adjuvant Chemotherapy Regimens in
Treating Patients With Stage II or Stage III Rectal Cancer
Who Are Receiving Radiation Therapy and Fluorouracil
Before or After Surgery
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=B552330D-
76C0-6DB8-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/10697
E3201 Long-Term Follow-up Form
NCT00068692
ECOG clinical trial administrative data
DCI Name
Registration Step
Patient Initials
ECOG Protocol Number
ECOG Protocol Number
ECOG Patient ID
ECOG Patient ID
Participating Group Protocol No.
Participating Group Patient ID
Institution/Affiliate
Off protocol treatment
Off Treatment Time Period
108 months (9 years) (108 months (9
years))
12 Months (12 months)
120 months (10 years) (120 months (10
years))
15 Months (15 months)
18 Months (18 months)
24 Months (24 months)
3 Months (3 months)
30 Months (30 months)
36 Months (36 months)
42 Months (42 months)
48 Months (48 months)
54 Months (54 months)
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6 Months (6 months)
60 Months (60 months)
72 months (6 years) (72 months (6
years))
84 months (7 years) (84 months (7
years))
9 Months (9 months)
96 months (8 years) (96 months (8
years))
Are data amended? (If yes, please circle
amended items in red)
Yes
No
Reporting Period Start Date (M D Y)
Reporting Period End Date (M D Y)
Vital Status
Patient's Vital Status
Alive (Alive)
Dead (Dead)
Date of Last Contact or Death (M D Y)
Primary Cause of Death (if applicable)
Due To Other Cause, Specify (Due to
other diease)
Due To Protocol Treatment (Due to
protocol treatment)
Due To This Disease (Due to this
disease)
Unknown (Unknown)
Describe cause of death
Disease Follow-up Status
Has the patient had a documented clinical
assessment for this cancer (since submission of
the previous follow-up form)?
No (No)
Unknown (Unknown)
Yes (Yes)
Date of last clinical assessment (If yes)
Notice Of Progression
Site(s) of progression
both local/regional and distant (both
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local/regional and distant)
distant (distant)
local/regional (local/regional)
unknown (unknown)
Explain unknown
specify basis for PD
Has the patient developed a first progression that
has not been previously reported?
No (No)
Unknown (Unknown)
Yes (Yes)
Date of progression (If yes)
Did a physician make a formal diagnosis of
progressive disease?
No (No)
Unknown (Unknown)
Yes (Yes)
Notice Of New Primary
Has a new primary cancer or MDS been
diagnosed that has not been previously reported?
Yes
No
Site(s) of new primary
Toxicity
Has the patient experienced (prior to diagnosis of
recurrence or second primary) any severe (Grade
>= 3) long term toxicity that has not been
previously reported?
Yes
No
Non-protocol Therapy
Has the patient received any non-protocol cancer
therapy prior to first progression (not previously
reported)?
Yes
No
Comments
Comments
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Investigator Signature
Investigator Signature Date
Ccrr Module For E3201 Long-term Follow-
up Form
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E5202 Long-Term Follow-up Form
NCT00217737
E5202 Long-Term Follow-up Form NCT00217737
Oxaliplatin, Leucovorin, and Fluorouracil With or Without
Bevacizumab in Treating Patients Who Have Undergone
Surgery for Stage II Colon Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=EF243F73-
4DAD-3443-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/10698
E5202 Long-Term Follow-up Form
NCT00217737
ECOG clinical trial administrative data
ECOG Protocol Number
ECOG Patient ID
DCI Name
Registration Step
Patient demographics
ECOG Protocol Number
Patient Initials
ECOG Patient ID
Participating Group Protocol Number
Institution/Affiliate
Participating Group Patient ID
Off protocol treatment period
Off Treatment Report Period (since initial
registration)
9 Years (108 Months Post-Registration)
12 Months (12 Months Post Registration)
10 Years (120 Months Post-Registration)
15 Months (15 Months Post Registration)
18 Months (18 Months Post Registration)
21 Months Post Registration (21 Months
Post Registration)
2 Years (24 Months Post Registration)
3 Months (3 Months Post Registration)
30 Months (30 Months Post Registration)
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3 Years (36 Months Post Registration)
42 Months (42 Months Post Registration)
4 Years (48 Months Post Registration)
54 Months (54 Months Post Registration)
6 Months (6 Months Post Registration)
5 Years (60 Months Post Registration)
6 Years (72 Months Post-Registration)
84 Months Post Registration (84 Months
Post-Registration)
9 Months (9 Months Post Registration)
8 Years (96 Months Post-Registration)
Data amendment
Please mark an 'X' if data have been amended.
Date data amended
Reporting period
Reporting Period Start Date
Reporting Period End Date
Vital Status
Patient's Vital Status
Alive (Alive)
Dead (Dead)
Date of last contact or death
Primary Cause of Death (if applicable)
Due To Other Cause (Due to other
cause)
Due To Protocol Treatment (Due to
protocol treatment)
Due To This Disease (Due to this
disease)
Unknown (Unknown)
Describe cause of death
Disease Follow-up Status
Has the patient had a documented clinical
assessment for this cancer (since submission of
the previous follow-up form)
No (No)
Unknown (Unknown)
Yes (Yes)
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If unknown, explain
Date of last clinical assessment (If yes)
Date CEA obtained
Mark an 'X' if not done
CEA value
CEA ULN
Notice Of Recurrence
Has the patient been diagnosed with a first
recurrence since the last Follow-Up Form? (Long-
Term)
No (No)
Unknown (Unknown)
Yes (Yes)
If unknown, explain
Date of First Recurrence (If yes)
Site of recurrence (s)
Abdominal Wall, Perineum And Scar
(Abdominal wall, perineum and scar)
Abdominal, Pelvic And Retro-peritoneal
Nodes (Abdominal, pelvic and retro-
peritoneal nodes)
Anastomotic (Anastomotic)
Ascites (Ascites)
Bone Marrow (Bone marrow)
Central Nervous System (Central
nervous system)
Colon, Other Than Site Of Anastomotic
(Colon, other than site of anastomotic)
Liver (Liver)
Lung (Lung)
Multiple (Multiple)
Other (Other)
Pelvic Mass Not Otherwise Specified
(Pelvic mass not otherwise specific)
Peritoneum (Peritoneum)
Skeletal (Skeletal)
Unknown (Unknown)
Explain other, multiple, or unknown
Did a physician make a formal diagnosis of
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recurrence
No (No)
Unknown (Unknown)
Yes (Yes)
Specify basis of recurrence (If no or unknown)
Was the recurrence treated by surgery
No (No)
Unknown (Unknown)
Yes (Yes)
Notice Of New Primary (including Second
Colon Primary)
Has a new primary cancer or myelodysplastic
syndrome been diagnosed that has not been
previously reported (MDS)
Yes
No
Site of New Primary (s)
Adverse Events
Has the patient experienced any severe long
term toxicity that has not been previously
reported (prior to diagnosis of
progression/relapse)
Yes
No
Non-protocol Therapy
Has the patient received any non-protocol cancer
therapy prior to first recurrence (not previously
reported)
Yes
No
Comments
Comments
Investigator Signature
Investigator Signature Date
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PACCT-1 TAILORx Follow-up Form
NCT00310180
PACCT-1 TAILORx Follow-up Form NCT00310180
Hormone Therapy With or Without Combination
Chemotherapy in Treating Women Who Have Undergone
Surgery for Node-Negative Breast Cancer (The TAILORx
Trial)
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=05DF4324-
6BB2-192D-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/10700
PACCT-1 TAILORx Follow-up Form
NCT00310180
Header
ECOG Protocol Number
ECOG Patient ID
DCI Name
Registration Step
Follow-up Report Period
Follow-up Report Period (since registration -
Choose one x)
9 Years (108 months post registration)
12 Months (12 months post registration)
10 Years (120 months post registration)
11 Years Post Registration (132 Months
Post Registration)
12 Years Post Registration (144 Months
Post Registration)
13 Years Post Registration (156 Months
Post Registration)
14 Years Post Registration (168 Months
Post Registration)
18 Months (18 months post registration)
15 Years Post Registration (180 Months
Post Registration)
16 Years Post Registration (192 Months
Post Registration)
17 Years Post Registration (204 Months
Post Registration)
18 Years Post Registration (216 Months
Post Registration)
19 Years Post Registration (228 Months
Post Registration)
2 Years (24 Months post registration)
20 Years Post Registration (240 Months
Post Registration)
30 Months (30 months post registration)
3 Years (36 months post registration)
42 Months Post Registration (42 Months
Post Registration)
4 Years (48 months post registration)
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54 Months Post Registration (54 Months
Post Registration)
6 Months (6 months post registration)
5 Years (60 months post registration)
6 Years (72 months post registration)
84 Months Post Registration (84 months
post registration)
8 Years (96 months post registration)
Reporting period
Reporting Period Start Date (mm/dd/yyy)
Reporting Period End Date (mm/dd/yyy)
Breast: Vital Status
Patient Vital Status
Alive (Alive)
Dead (Dead)
Date of Last Contact or Death (mm/dd/yyy)
Primary Cause of Death (if applicable)
Due To Cardiovascular Disease (Due to
cardiovascular disease)
Due To Other Cause (Due to other
cause)
Due To Other Chronic Disease (Due to
other chronic disease)
Due To Protocol Treatment (Due to
protocol treatment)
Due To Second Primary Or Other
Malignancy (Due to second primary or
other malignancy)
Due To This Disease (Due to this
disease)
Unknown (Unknown)
Describe cause of death
Breast: Disease Follow-up Status
Date of Last Clinical Assessment (only provide
date if assessment since submission of previous
follow-up form)
Not done (Check here and skip the rest of
Section II if a more recent clinical assessment
was not done.)
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Breast: Notice Of Progression - Advanced
Disease
Has the patient been diagnosed with first
ipsilateral breast tumor recurrence (since
submission of the last follow-up form)
Yes
No
Date of first ipsilateral breast tumor recurrence (If
yes:)
Method of Diagnosis (For contralateral breast
primaries:)
Histology (Histologic)
Other (Other)
Radiologic (Radiologic)
Radiologic And Histologic (Radiologic
and Histologic)
Specify
IBTR histology (NOTE: See TAILORx Forms
Completion Guidelines for IBTR definitions)
Both Invasive Carcinoma And Ductal
Carcinoma In Situ (Both invasive
carcinoma and DCIS)
Ductal Carcinoma In Situ (Ductal
carcinoma in situ)
Invasive Carcinoma (Invasive
Carcinoma)
Iib - Local-regional Recurrence
Has the patient been diagnosed with first local-
regional recurrence or progression (since
submission of the last follow-up form)
Yes
No
Date of First Local-Regional Recurrence (If yes: -
mm/dd/yyyy)
Site of first local-regional recurrence (s check all
that apply; all sites refer to the same side as the
original primary)
Ipsilateral Axillary Lymph Nodes And/or
Soft Tissue (Ipsilateral axillary lymph
nodes and/or soft tissue)
Ipsilateral Chest Wall (Ipsilateral chest
wall)
Ipsilateral Infraclavicular Nodes
(Ipsilateral infraclavicular nodes)
Ipsilateral Internal Mammary Nodes
(Ipsilateral internal mammary nodes)
Ipsilateral Supraclavicular Nodes
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(Ipsilateral supraclavicular nodes)
Method of Diagnosis (For contralateral breast
primaries:)
Histology (Histologic)
Other (Other)
Radiologic (Radiologic)
Radiologic And Histologic (Radiologic
and Histologic)
Specify
Iic - Distance Recurrence
Has the patient been diagnosed with first distant
recurrence/progression? (since submission of the
last follow-up form)
Yes
No
Date of First Distant Recurrence (mm/dd/yyyy)
Site(s) of First Distant Recurrence (Indicate -
check all that apply at the completion of the
metastatic workup)
Bone (Bone(s))
Central Nervous System (Central
Nervous System (e.g., brain, meninges))
Liver (Liver)
Lung (Lung(s))
Positive Lymph Node (Non-regional
lymph node(s))
Other (Other)
Pleura (Pleura (pleural effusion))
Skin (Skin (excluding ipsilateral chest
wall))
Other specify
Method of Diagnosis (For contralateral breast
primaries:)
Histology (Histologic)
Other (Other)
Radiologic (Radiologic)
Radiologic And Histologic (Radiologic
and Histologic)
Specify
Section Iii - New Primary Cancers
Has a new primary cancer or MDS been
diagnosed that has not been previously reported?
No (No)
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Yes, All Other Sites (Yes, all other sites)
Yes, Ductal Carcinoma In Situ Of
Ipsilateral Breast (Yes, DCIS of ipsilateral
breast)
Yes, Ductal Carcinoma In Situ Of
Contralateral Breast (Yes, ductal
carcinoma in situ of contralateral breast)
Yes, Invasive Disease In Contralateral
Breast (Yes, invasive disease in
contralateral breast)
Site of New Primary (Recommended term - CRF
shows "specify sites")
Date of diagnosis (If yes: - )
Method of Diagnosis (For contralateral breast
primaries:)
Histology (Histologic)
Other (Other)
Radiologic (Radiologic)
Radiologic And Histologic (Radiologic
and Histologic)
Specify
Section Iv - Treatment
Has the patient received any chemotherapy
during this reporting period?
No (No)
Not Applicable (Not Applicable)
Yes, Chemotherapy Completed (Yes,
chemotherapy completed)
Yes, Chemotherapy Continuing (Yes,
chemotherapy continuing)
Has the patient received any hormone therapy
during this reporting period?
Yes
No
Did patient switch type of hormonal therapy
during this report period
Yes
No
Specify reason for switch in endocrine therapy (If
yes,)
Adverse Events From Prior Hormonal
Therapy (Adverse events from prior
hormonal therapy)
Both Planned Switch For Therapeutic
Reason And For Adverse Events From
Prior Hormonal Therapy (Both)
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Other (Other)
Planned Switch For Therapeutic Reason
(Planned switch for therapeutic reason)
Other, specify
Start date of new hormonal therapy
Specify new type of hormonal therapy given
Aromatase Inhibitor (Aromatase
Inhibitor)
Other (Other)
Tamoxifen (Tamoxifen)
Other, specify
Specify which Aromatase Inhibitor was given (If
aromatase inhibitor:)
Anastrozole (ANASTROZOLE)
Exemestane (EXEMESTANE)
Letrozole (LETROZOLE)
Other (Other)
Other, specify
Tamoxifen (Answer Yes or No for each of the
following therapies the patient consistently took
during this reporting period:)
Yes
No
Aromatase Inhibitor
Yes
No
Specify which Aromatase Inhibitor was given
Anastrozole (ANASTROZOLE)
Exemestane (EXEMESTANE)
Letrozole (LETROZOLE)
Other (Other)
Specify
Other
Yes
No
Specify (If yes, specify)
Did patient receive Ovarian Function Suppression
(OFS) during this follow-up period?
No (No)
Unknown (Unknown)
Yes (Yes)
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Ovarian Function Suppression Type
Medical Suppression Of Ovarian
Function (Medical suppression)
Bilateral Surgical Oophorectomy
(Oophorectomy)
Other (Other)
Radiation Therapy (Ovarian radiation)
Other, specify
Was all hormonal therapy discontinued this report
period
Yes
No
Date any hormonal therapy last given (If yes, -
mm/dd/yyyy)
Footer Module
Investigator Signature
Investigator Signature Date
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CALGB: 80405 FOLLOW-UP AND
RESPONSE FORM NCT00265850
CALGB: 80405 FOLLOW-UP AND RESPONSE FORM
NCT00265850
Cetuximab and/or Bevacizumab Combined With
Combination Chemotherapy in Treating Patients With
Metastatic Colorectal Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=F39BEECE-
F2C5-5BE1-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/10701
CALGB: 80405 FOLLOW-UP AND
RESPONSE FORM NCT00265850
Header
CALGB Form
CALGB Study No
CALGB Patient ID
Reporting period start date
Date of last contact or death (To:)
Are data amended
Yes
No
Patient demographics
Patient Initials
Patient Hospital No
Institution/Affiliate
Participating Group
Participating Group Study No.
Participating Group Patient ID
Patient status assessment
Vital status (Mark one with an X.)
Alive (Alive)
Dead (Dead)
Lost To Follow-up (Lost to follow-up)
1 / 3
Primary cause of death (Mark one with an X.)
Due To Other Cause (Due to other
cause)
Due To Protocol Treatment (Due to
protocol treatment)
Due To This Disease (Due to this
disease)
Due to other cause, specify
Response Data
Date of evaluation (most recent)
Has the patient developed a progression or
relapse during this reporting period?
Yes
No
date progressive disease observed (If Yes,
specify or recurrent)
Sites of progression (for pre-surgical or surgical
response Mark all that apply with an X.)
Bone (Bone)
Central Nervous System/brain
(CNS/brain)
Intra-abdominal (Intra-abdominal)
Liver (Liver)
Local-regional (including Ipsilateral
Breast; Chest Wall; Axillary, Internal
Mammary, And Infraclavicular Nodes;
Local-regional Skin And Subcutaneous
Tissue) (Local/regional)
Lung, Nos (Lung)
Other (Other)
Is the patient receiving any non-protocol cancer
therapy not previously reported?
Yes
No
If Yes, specify any other non-protocol therapy
received during this time period. (Mark all that
apply with an X.)
5fu/leucovorin (5FU/Leucovorin)
Bevacizumab (Bevacizumab)
Cetuximab (Cetuximab)
Cpt-11 (CPT-11)
Other (Other)
Oxaliplatin (Oxaliplatin)
Specify
Non-protocol therapy start date (if during this
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reporting period)
Non-protocol therapy end date (if during this
reporting period)
New Primary Data
Has a new primary cancer or AML/MDS been
diagnosed that has not been previously reported?
Yes
No
New cancer diagnosis date
Site of new primary (Mark all that apply with an
X.)
Breast (Breast)
Lung (Lung)
Other (Other)
Prostate (Prostate)
Skin (Skin)
Completed by
Date form originally completed
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CALGB_40302_FU_SOL_TUM_EVAL_FR
M NCT00390455
CALGB 40302 FOLLOW-UP SOLID TUMOR EVALUATION
FORM NCT00390455
Fulvestrant With or Without Lapatinib in Treating
Postmenopausal Women With Stage III or Stage IV Breast
Cancer That is Hormone Receptor-Positive
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=F593450E-
79E6-42E1-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/10702
CALGB_40302_FU_SOL_TUM_EVA
L_FRM NCT00390455
Header
CALGB Form
CALGB Study No
CALGB Patient ID
Are data amended
Yes
No
Patient demographics
Patient Initials
Patient Hospital Number
Main Member Institution/Affiliate
Participating Group
Participating Group Study No
Participating Group Patient ID
Reporting Period
Start Date (MM DD YYYY)
End Date (MM DD YYYY)
Date of evaluation (MM DD YYYY)
Lesion, Anatomic Site, Target
1 / 4
Method of Evaluation (**)
Bone Scan (Bone Scan)
Chest X-ray (Chest X-ray)
Clinical (Clinical Examination)
Ct Scan (CT Scan)
Mri (MRI)
Other (Other)
Spiral Ct Scan (Spiral CT Scan)
Ultrasound (Ultrasound)
If Other, specify
Longest Diameter of Lesion (s)
Sum of Longest Diameters of All Target Lesions
Response Status at This Assessment, Target
Lesion (s)
Complete Response (Complete
Response)
Insufficient Evaluation To Determine
Response Status (Insufficient evaluation
to determine response status)
Partial Response (Partial Response)
Progressive Disease (Progressive
Disease)
Stable Disease (Stable Disease)
Non-target Lesion(s) Follow-up Evaluation
Are there any non-target lesions
Yes
No
Lesion, Anatomic Site, Non-Target
Date of evaluation (MM DD YYYY)
Method of Evaluation (**)
Bone Scan (Bone Scan)
Chest X-ray (Chest X-ray)
Clinical (Clinical Examination)
Ct Scan (CT Scan)
Mri (MRI)
Other (Other)
Spiral Ct Scan (Spiral CT Scan)
Ultrasound (Ultrasound)
If Other, specify
F/U Response Status (Use response status
codes below.)
Complete Response (Complete
Response)
Incomplete Response/sd (Incomplete
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Response/SD)
Insufficient Evaluation To Determine
Response Status (Insufficient evaluation
to determine response status)
Progressive Disease (Progressive
Disease)
Response Status at This Assessment, Non-
Target Lesion (s)
Complete Response (Complete
Response)
Incomplete Response/sd (Incomplete
Response/SD)
Insufficient Evaluation To Determine
Response Status (Insufficient evaluation
to determine response status)
Progressive Disease (Progressive
Disease)
New Lesion(s) At Follow-up Evaluation
Was the appearance of any new lesions
documented since the baseline evaluation
Yes
No
Lesion, Anatomic Site, New
Date of evaluation (MM DD YYYY)
Method of Evaluation (**)
Bone Scan (Bone Scan)
Chest X-ray (Chest X-ray)
Clinical (Clinical Examination)
Ct Scan (CT Scan)
Mri (MRI)
Other (Other)
Spiral Ct Scan (Spiral CT Scan)
Ultrasound (Ultrasound)
If Other, specify
Overall Response
Overall response (Combine Target, Non-Target,
and New Lesions.)
Complete Response (Complete
Response)
Incomplete Response (Incomplete
Response)
Insufficient Evaluation To Determine
Response Status (Insufficient evaluation
to determine response status)
Partial Response (Partial Response)
Progressive Disease (Progressive
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Disease)
Completed by (print or type name)
Date Form Completed (MM DD YYYY)
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NCI Coop Group Colorectal Ca Tx Form -
Subset of Pts NCT00079274
NCI Cooperative Group Colorectal Cancer - Treatment
Form - Subset of Patients (New) NCT00079274
Comparison of Combination Chemotherapy Regimens With
or Without Cetuximab in Treating Patients Who Have
Undergone Surgery For Stage III Colon Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=DFAA352D-
BA63-664C-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/10703
NCI Coop Group Colorectal Ca Tx
Form - Subset of Pts NCT00079274
Header module
Coordinating Group Protocol Number
Coordinating Group Code
Protocol Title
Patient Study ID
Patient Medical Record Number
Patient Initials (L, FM)
Participating Group Code (Cooperative Group
where credit will be applied)
Institution Name (treating location/performance
site)
Are data amended (If data are amended, please
circle in red when using paper form)
Yes
No
Colorectal: Treatment Reporting Interval -
Monthly During Treatment On The First
400 Patients
Reporting Period (Please indicate which cycles
this CRF includes from time of registration Circle
one:)
Cycles 1 & 2 (Cycles 1 & 2)
Cycles 11 & 12 (Cycles 11 & 12)
Cycles 3 & 4 (Cycles 3 & 4)
Cycles 5 & 6 (Cycles 5 & 6)
Cycles 7 & 8 (Cycles 7 & 8)
Cycles 9 & 10 (Cycles 9 & 10)
Colorectal: Treatment Dosing Information
1 / 2
Reporting Period Start Date (mm dd yyyy)
Reporting Period End Date (mm dd yyyy)
Cycle Number
Current Treatment Arm
Body Surface Area (m2 for this cycle)
Agent Name (Oxal, 5-FU Push, 5-FU Infusion,
C225)
Agent Total Cumulative Dose (units)
Units ()
Milligram (mg)
Colorectal: Treatment Dosing Information
Reporting Period Start Date (mm dd yyyy)
Reporting Period End Date (mm dd yyyy)
Cycle Number
Current Treatment Arm
Body Surface Area (m2 for this cycle)
Agent Name (Oxal, 5-FU Push, 5-FU Infusion,
C225)
Agent Total Cumulative Dose (units)
Units ()
Milligram (mg)
Comments
Comments
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E5204 Long-Term Follow-up Form
NCT00303628
E5204 Long-Term Follow-up Form NCT00303628
Combination Chemotherapy With or Without Bevacizumab
in Treating Patients Who Have Had Surgery for Stage II or
Stage III Rectal Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=089B477B-
71CC-38F7-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/10704
E5204 Long-Term Follow-up Form
NCT00303628
Header
ECOG Protocol Number
ECOG Patient ID
DCI Name
Off Treatment Report Period (since initial
registration - Choose one x)
9 Years (108 months post registration)
12 Months (12 months post registration)
10 Years (120 months post registration)
15 Months (15 months post registration)
18 Months (18 months post registration)
21 Months Post Registration (21 months
post registration)
24 Months (24 months post registration)
3 Months (3 months post registration)
30 Months (30 months post registration)
36 Months (36 months post registration)
42 Months Post Registration (42 Months
Post Registration)
4 Years (48 months post registration)
54 Months Post Registration (54 Months
Post Registration)
6 Months (6 months post registration)
5 Years (60 months post registration)
6 Years (72 months post registration)
84 Months Post Registration (84 months
post registration)
9 Months (9 months post registration)
8 Years (96 months post registration)
Patient Initials (Last, First)
Participating Group Protocol Number
Institution/Affiliate
Participating Group Patient ID
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Data amendment
Please mark an 'X' if data have been amended.
(Please circle amended items in red)
Date data amended (s - mm/dd/yyyy)
Vital Status
Patient's Vital Status
Alive (Alive)
Dead (Dead)
Date of last contact or death (mm/dd/yyyy)
Primary Cause of Death (if applicable)
Due To Other Cause (Due to other
cause)
Due To Protocol Treatment (Due to
protocol treatment)
Due To This Disease (Due to this
disease)
Unknown (Unknown)
Describe cause of death
Section II - Reporting Period
Reporting Period Start Date (mm/dd/yyyy)
Reporting Period End Date (mm/dd/yyyy)
Notice Of New Primary (including Second
Colon Primary)
Has a new primary cancer or myelodysplastic
syndrome been diagnosed that has not been
previously reported (MDS)
Yes
No
Site of New Primary (s)
Disease Follow-up Status
Has the patient had a documented clinical
assessment for this cancer (since submission of
the previous follow-up form)
No (No)
Unknown (Unknown)
Yes (Yes)
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If unknown, please explain
Date of last clinical assessment (If yes)
Cea
Date CEA obtained (mm/dd/yyyy)
CEA Value (ng/ml)
CEA ULN
Notice Of Recurrence
Has the patient been diagnosed with first
recurrence since submission of the last follow-up
form?
No (No)
Unknown (Unknown)
Yes (Yes)
Disease Recurrence Date (If yes)
Site of recurrence (s)
Abdominal Wall, Perineum And Scar
(Abdominal wall, perineum and scar)
Abdominal, Pelvic And Retro-peritoneal
Nodes (Abdominal, pelvic and retro-
peritoneal nodes)
Anastomotic (Anastomotic)
Ascites (Ascites)
Bone Marrow (Bone marrow)
Central Nervous System (Central
nervous system)
Colon (Colon)
Liver (Liver)
Lung (Lung)
Multiple (Multiple)
Other (Other)
Pelvic Mass Not Otherwise Specified
(Pelvic mass not otherwise specific)
Peritoneum (Peritoneum)
Rectum, Other Than Site Of Anastomotic
(Rectum, other than site of anastomotic)
Skeletal (Skeletal)
Unknown (Unknown)
Explain unknown
Did a physician make a formal diagnosis of
recurrence
No (No)
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Unknown (Unknown)
Yes (Yes)
Specify basis of recurrence (If no or unknown)
Was the recurrence treated by surgery
No (No)
Unknown (Unknown)
Yes (Yes)
Adverse Events
Has the patient experienced any severe long
term toxicity that has not been previously
reported (prior to diagnosis of
progression/relapse)
No (No)
Unknown (Unknown)
Yes (Yes)
Non-protocol Therapy
Has the patient received any non-protocol cancer
therapy prior to first recurrence (not previously
reported)
Yes
No
Comments
Investigator Signature
Investigator Signature Date
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E5103 Disease and Vital Status Form
NCT00433511
E5103 Disease and Vital Status Form NCT00433511
Doxorubicin, Cyclophosphamide, and Paclitaxel With or
Without Bevacizumab in Treating Patients With Lymph
Node-Positive or High-Risk, Lymph Node-Negative Breast
Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=22AFE3B9-
AE28-56F9-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/10705
E5103 Disease and Vital Status
Form NCT00433511
ECOG clinical trial administrative data
ECOG Protocol Number
ECOG Patient ID
DCI Name
Registration Step
Patient Initials (Last, First)
Participating Group Protocol Number
Participating Group Patient ID
Institution/Affiliate
Off Treatment
Off Treatment Report Period (since registration)
9 Years (108 months post registration)
12 Months (12 months post registration)
10 Years (120 months post registration)
11 Years Post Registration (132 Months
Post Registration)
12 Years Post Registration (144 Months
Post Registration)
15 Months (15 months post registration)
13 Years Post Registration (156 Months
Post Registration)
14 Years Post Registration (168 Months
Post Registration)
18 Months (18 months post registration)
15 Years Post Registration (180 Months
Post Registration)
21 Months Post Registration (21 months
post registration)
24 Months (24 months post registration)
3 Months (3 months post registration)
30 Months (30 months post registration)
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36 Months (36 months post registration)
42 Months Post Registration (42 Months
Post Registration)
4 Years (48 months post registration)
54 Months Post Registration (54 Months
Post Registration)
6 Months (6 months post registration)
5 Years (60 months post registration)
6 Years (72 months post registration)
84 Months Post Registration (84 months
post registration)
9 Months (9 months post registration)
8 Years (96 months post registration)
Data amendment
Please mark an 'X' if data have been amended.
Date data amended (s m/d/y)
Breast: Vital Status
Patient's Vital Status (*IMPORTANT: As soon as
a grade 5 adverse event is reported, it is
necessary to submit ALL outstanding data in
addition to the adverse event form and AdEERS
report.)
Alive (Alive)
Dead (Dead)
Date of Last Contact or Death (mm/dd/yyy)
Primary Cause of Death (if applicable)
Due To Other Cause (Due to other
cause)
Due To Protocol Treatment (Due to
protocol treatment)
Due To This Disease (Due to this
disease)
Unknown (Unknown)
Describe cause of death
Section II - Reporting Period
Reporting Period Start Date (mm/dd/yyy)
Reporting Period End Date (mm/dd/yyy)
Section Iii - New Primary Cancers
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Has a new primary cancer or MDS been
diagnosed that has not been previously reported?
No (No)
Unknown (Unknown)
Yes (Yes)
Site of New Primary (If new primary site is
AML/MDS/ALL, submit NCI AML/MDS/ALL form -
If new primary site is other than AML/MDS/ALL,
submit ECOG Second Primary Form)
Notice Of First Distance Recurrence
Was first distant recurrence previously reported
Yes
No
Section V - Disease Follow-up Status
Has the patient had a documented clinical
assessment for this cancer?
No (No)
Unknown (Unknown)
Yes (Yes)
If unknown, please explain
Date of last physical exam (this report period)
Mark an 'X' if not done
Date of Chest X-Ray or CT scan
Method of Evaluation
Mammogram (Mammogram)
Result
Negative (negative)
Positive (Positive)
Date of mammogram
Iib - Local-regional Recurrence
Date of Last Clinical Assessment (for this cancer
- since submission of the previous follow-up form
m/d/y)
Mark an 'X' if not done (and skip the rest of this
section if a recent clinical assessment was not
done.)
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Has the patient been diagnosed with first local-
regional recurrence (since submission of the last
follow-up form)
No (NO)
Unknown (Unknown)
Yes (YES)
Date of First Local-Regional Recurrence (If yes: -
mm/dd/yyyy)
Axilla (Sites of local recurrence code all; all sites
refer to the same side as the original primary
1=no, 2=yes)
Yes
No
Axillary Node(s)
Yes
No
Infraclavicular Node(s)
Yes
No
Internal mammary node
Yes
No
Ipsilateral Breast
Yes
No
Supraclavicular Node(s)
Yes
No
Basis of Diagnosis
Clinical (Clinical)
Histology (Histology)
Imaging Only (Imaging only)
Other (Other)
Radiologic (Radiologic)
Radiologic And Histologic (Radiologic
and Histologic)
Other Specify
Iic - Distance Recurrence
Has the patient been diagnosed with first distant
recurrence/progression? (since submission of the
last follow-up form)
No (No)
Unknown (Unknown)
Yes (Yes)
Date of First Distant Recurrence (mm/dd/yyyy)
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Site(s) of First Distant Recurrence
Specify
Section Iv - Treatment
Hormonal therapy  (given this reporting period)
Yes
No
Did patient switch type of hormonal therapy
during this report period (If yes:)
Yes
No
Specify new type of adjuvant hormonal therapy
administered (If yes:)
Anastrozole (Anastrozole)
Exemestane (Exemestane)
Letrozole (Letrozole)
Other (Other)
Tamoxifen (Tamoxifen)
New Adjuvant Hormonal Therapy Start Date
(m/d/y)
Adjuvant Hormonal Therapy Administered Type
(If no: - Initial)
Anastrozole (Anastrozole)
Exemestane (Exemestane)
Letrozole (Letrozole)
Other (Other)
Tamoxifen (Tamoxifen)
Adjuvant hormonal therapy start date (Initial
m/d/y)
Is hormonal therapy continuing
Yes
No
Date any hormonal therapy last given (If yes, -
mm/dd/yyyy)
Did patient receive Ovarian Function Suppression
(OFS) during this follow-up period?
Yes
No
Specify type (If yes:)
Lhrh Agonist (LHRH Agonist)
Bilateral Surgical Oophorectomy
(Oophorectomy)
Radiation Therapy (Ovarian radiation)
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Is LHRH agonist continuing from a previous
reporting period (If LHRH agonist:)
Yes
No
Section Viii - Non-protocol Therapy Prior
To Recurrence
Has the patient received any non-protocol cancer
therapy prior to first recurrence (not previously
reported)
No (No)
Unknown (Unknown)
Yes (Yes)
Footer Module
Investigator Signature
Investigator Signature Date
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CALGB: 80405 SUPPLEMENTAL
ADVERSE EVENT FORM NCT00265850
CALGB: 80405 SUPPLEMENTAL ADVERSE EVENT
FORM NCT00265850
Cetuximab and/or Bevacizumab Combined With
Combination Chemotherapy in Treating Patients With
Metastatic Colorectal Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=F39D4556-
5D0B-6221-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/10706
CALGB: 80405 SUPPLEMENTAL
ADVERSE EVENT FORM
NCT00265850
Header
CALGB Form
CALGB Study No
CALGB Patient ID
Reporting period start date
Reporting period end date
Are data amended
Yes
No
Patient demographics
Patient Initials
Patient Hospital No
Institution/Affiliate
Participating Group
Participating Group Study No.
Participating Group Patient ID
Assessment of medication
Cycle number
Medications received during this reporting period
1 / 4
(Mark one with an X)
Anti-platelet (Anti-platelet)
Anticoagulant (Anticoagulant)
Aspirin (Aspirin)
Bp Or Cardiac Medication (BP or cardiac
medication)
None (None)
Nsaid (NSAID)
Statin (Statin)
NSAID, specify
Anti-platelet, specify
Statin, specify
BP or cardiac medication, specify
Anticoagulant, specify
Which of the following arterial thrombotic events
(ATEs) occurred during this reporting period?
(Mark one with an X)
Angina (Angina)
Cva - Hemorrhagic (CVA - hemorrhagic)
Cva - Thrombotic (CVA - thrombotic)
Myocardial Infarction (Myocardial
infarction)
None (None)
Other Arterial Event (Other arterial
event)
Transient Ischemic Attack (Transient
ischemic attack)
Other arterial event, specify
Treatment for ATE (Mark one with an X)
Emergency Room (Emergency room)
Hospitalization (Hospitalization)
Outpatient Management Only
(Outpatient management only)
Outcome of ATE (Mark one with an X)
Not Resolved (Not resolved)
Resolved (Resolved)
Resulted In Death (Resulted in death)
Which of the following venous thrombotic events
(VTEs) occurred during this reporting period?
(Mark one with an X)
Catheter Related (Catheter related)
Dvt (DVT)
None (None)
Other Venous Thrombotic Event (Other
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venous thrombotic event)
Pulmonary Embolism (Pulmonary
embolism)
Other venous thrombotic event, specify
Was the patient receiving anticoagulants prior to
the VTEt?
Yes
No
Yes, specify
Were anticoagulants used to treate the VTE?
Yes
No
Yes, specify
Treatment for VTE (Mark one with an X)
Emergency Room (Emergency room)
Hospitalization (Hospitalization)
Outpatient Management Only
(Outpatient management only)
Outcome of VTE (Mark one with an X)
Not Resolved (Not resolved)
Resolved (Resolved)
Resulted In Death (Resulted in death)
Did the patient experience an infusion reaction to
cetuximab during the reporting period? (refer to
CTCAE v. 3 Cytokine release syndrome/acute
infusion reaction)
No (No)
Patient Did Not Receive Cetuximab
(Patient did not receive cetuximab)
Yes (Yes)
Yes, specify grade (Report even on C-1399
Adverse Event Form.)
Were steroids given pre-infusion (including as an
antiemetic?)
Yes
No
Was blood drawn for infusion reaction
biomarkers?
Yes
No
Treatment (Mark one with an X)
Emergency Room (Emergency room)
Hospitalization (Hospitalization)
Outpatient Management Only
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(Outpatient management only)
Outcome (Mark one with an X)
Not Resolved (Not resolved)
Resolved (Resolved)
Resulted In Death (Resulted in death)
Was the patient retreated with cetuximab after
the reaction?
Yes
No
If Yes, did the patient experience an acute
infusion reaction upon retreatment?
Yes
No
Completed by
Date form completed
4 / 4
CALGB: 80405 SUPPLEMENTAL ADVERSE EVENT FORM
NCT00265850
E1105 Long-Term Follow-up Form
NCT00520975
E1105 Long-Term Follow-up Form NCT00520975
First-Line Chemotherapy and Trastuzumab With or Without
Bevacizumab in Treating Patients With Metastatic Breast
Cancer That Overexpresses HER-2/NEU
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=17254B43-
1887-46EC-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/10707
E1105 Long-Term Follow-up Form
NCT00520975
Header
ECOG Protocol Number
ECOG Patient ID
DCI Name
Registration Step
Patient demographics
ECOG Protocol Number
Patient Initials (Last, First)
ECOG Patient ID
Participating Group Protocol Number
Institution/Affiliate
Participating Group Patient ID
Off Treatment
Off Treatment Report Period (since registration)
9 Years (108 months post registration)
12 Months Post Randomization (12
Months Post Randomization)
10 Years (120 months post registration)
18 Months Post Randomization (18
Months Post Randomization)
21 Months Post Randomization (21
Months Post Randomization)
24 Months Post Randomization (24
Months Post Randomization)
3 Months Post Randomization (3 Months
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Post Randomization)
30 Months Post Randomization (30
Months Post Randomization)
36 Months Post Randomization (36
Months Post Randomization)
42 Months Post Randomization (42
Months Post Randomization)
48 Months Post Randomization (48
Months Post Randomization)
54 Months Post Randomization (54
Months Post Randomization)
6 Months Post Randomization (6 Months
Post Randomization)
60 Months Post Randomization (60
Months Post Randomization)
6 Years (72 months post registration)
84 Months Post Registration (84 months
post registration)
9 Months Post Randomization (9 Months
Post Randomization)
8 Years (96 months post registration)
Data amendment
Please mark an 'X' if data have been amended
(Please circle amended items in red)
Date data amended (M D Y)
Vital Status
Patient Vital Status
Alive (Alive)
Dead (Dead)
Date of last contact or death (M D Y)
Primary Cause of Death (if applicable)
Due To Other Cause (Due to other
cause)
Due To Protocol Treatment (Due to
protocol treatment)
Due To This Disease (Due to this
disease)
Unknown (Unknown)
Describe cause of death (other)
Section II - Reporting Period
Reporting Period Start Date (M D Y)
Reporting Period End Date (M D Y)
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Notice Of New Primary (including Second
Colon Primary)
Has a new primary cancer or MDS been
diagnosed that has not been previously reported
No (No)
Unknown (Unknown)
Yes (Yes)
Site of New Primary (s)
Disease Follow-up Status
Has the patient had a documented clinical
assessment for this cancer (since submission of
the previous follow-up form)
No (No)
Unknown (Unknown)
Yes (Yes)
If unknown, please explain
Date of last clinical assessment (If yes)
Has the patient developed a first progression (or
relapse) that has not been previously reported?
(Notice of Progression)
No (No)
Unknown (Unknown)
Yes (Yes)
If unknown, please explain
Date of Progression (If yes, - relapse - Submit
E1105 Follow-Up Disease Evaluation Form)
Sites of Progression
Did a physician make a formal diagnosis of
progressive disease?
No (No)
Unknown (Unknown)
Yes (Yes)
Specify basis of progression (If no or unknown:)
Adverse Events
Has the patient experienced any severe long
term toxicity that has not been previously
reported (prior to diagnosis of
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progression/relapse)
No (No)
Unknown (Unknown)
Yes (Yes)
Non-protocol Therapy
Has the patient received any non-protocol cancer
therapy prior to first progression (not previously
reported NOTE: Only the first occurrence of non-
protocol therapy should be reported)
No (No)
Unknown (Unknown)
Yes (Yes)
Comments
Investigator Signature
Investigator Signature Date
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NSABP C-11 Worksheet for Protocol Treatment
and Adverse Event Form NCT01189227
NSABP C-11 Worksheet for Protocol Treatment and
Adverse Event Form NCT01189227
Combination Chemotherapy Before or After Surgery in
Treating Patients With Colorectal Cancer With Liver
Metastases That Could Be Removed By Surgery
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=88F74CE3-
33CF-F61F-E040-BB89AD431381
All rights reserved. Please visit https://medical-data-
models.org/forms/10708
NSABP C-11 Worksheet for Protocol
Treatment and Adverse Event Form
NCT01189227
Header
Patient Initials (Last First Middle)
NSABP Patient ID
Arm 1
Reporting Period
Postoperative Therapy Cycles 11-12
(Postoperative therapy cycles 11-12)
Postoperative Therapy Cycles 7-8
(Postoperative therapy cycles 7-8)
Postoperative Therapy Cycles 9-10
(Postoperative therapy cycles 9-10)
Preoperative Therapy Cycles 1-2
(Preoperative therapy cycles 1-2)
Preoperative Therapy Cycles 3-4
(Preoperative therapy cycles 3-4)
Preoperative Therapy Cycles 5-6
(Preoperative therapy cycles 5-6)
Surgical Complications (Surgical
complications)
Arm 2
Reporting Period
Postoperative Therapy Cycles 11-12
(Postoperative therapy cycles 11-12)
Postoperative Therapy Cycles 7-8
(Postoperative therapy cycles 7-8)
Postoperative Therapy Cycles 9-10
(Postoperative therapy cycles 9-10)
Preoperative Therapy Cycles 1-2
(Preoperative therapy cycles 1-2)
Preoperative Therapy Cycles 3-4
(Preoperative therapy cycles 3-4)
Preoperative Therapy Cycles 5-6
(Preoperative therapy cycles 5-6)
Surgical Complications (Surgical
complications)
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Reporting period
Reporting Period Start Date
Reporting Period End Date
Section 1
Did patient receive protocol therapy during this
reporting period
Yes
No
Agent Name
Dose (Second cycle of reporting period)
120 Mg/m^2 (120 mg/m^2)
1500 Mg/m^2 (1500 mg/m^2)
150mg/m^2 (150mg/m^2)
180 Mg/m^2 (180 mg/m^2)
1900 Mg/m^2 (1900 mg/m^2)
2400 Mg/m^2 (2400 mg/m^2)
260 Mg/m^2 (260 mg/m^2)
320 Mg/m^2 (320 mg/m^2)
400 Mg/m^2 (400 mg/m^2)
5 Mg/kg (5 mg/kg)
50 Mg/m^2 (50 mg/m^2)
65 Mg/m^2 (65 mg/m^2)
85 Mg/m^2 (85 mg/m^2)
Not Given (Not given)
Section 1
Did patient receive protocol therapy during this
reporting period
Yes
No
Agent Name
Dose (Second cycle of reporting period)
120 Mg/m^2 (120 mg/m^2)
1500 Mg/m^2 (1500 mg/m^2)
150mg/m^2 (150mg/m^2)
180 Mg/m^2 (180 mg/m^2)
1900 Mg/m^2 (1900 mg/m^2)
2400 Mg/m^2 (2400 mg/m^2)
260 Mg/m^2 (260 mg/m^2)
320 Mg/m^2 (320 mg/m^2)
400 Mg/m^2 (400 mg/m^2)
5 Mg/kg (5 mg/kg)
50 Mg/m^2 (50 mg/m^2)
65 Mg/m^2 (65 mg/m^2)
85 Mg/m^2 (85 mg/m^2)
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Not Given (Not given)
Header
Was the patient hospitalized with an adverse
event
Yes
No
Adverse Event
Grade
Moderate Adverse Event (2)
Severe Adverse Event (3)
Life Threatening Adverse Event (4)
Selected Surgical Complications
Adverse Event
Grade
Moderate Adverse Event (2)
Severe Adverse Event (3)
Life Threatening Adverse Event (4)
Footer Module
Comments
Last name
First Name
Phone
E-mail
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Leukemia - E2905 Vital Status Form
E2905 Vital Status Form
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=5E1DBBB8-
FEF8-BA97-E040-BB89A6433EF6
All rights reserved. Please visit https://medical-data-
models.org/forms/10709
Leukemia - E2905 Vital Status Form
ECOG clinical trial administrative data
ECOG Protocol Number
ECOG Patient ID
DCI Name
Registration Step
Patient Initials (Last, First)
Participating Group Protocol Number
Participating Group Patient ID
Institution/Affiliate
Data amendment
Please mark an 'X' if data have been amended.
(Please circle amended items in red)
Date data amended (MM/DD/YYYY)
Off protocol treatment period
Off Treatment Report Period (since initial
registration)
9 Years (108 Months Post-Registration)
12 Months (12 Months Post Registration)
10 Years (120 Months Post-Registration)
15 Months (15 Months Post Registration)
18 Months (18 Months Post Registration)
21 Months Post Registration (21 Months
Post Registration)
2 Years (24 Months Post Registration)
3 Months (3 Months Post Registration)
30 Months (30 Months Post Registration)
3 Years (36 Months Post Registration)
42 Months (42 Months Post Registration)
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4 Years (48 Months Post Registration)
54 Months (54 Months Post Registration)
6 Months (6 Months Post Registration)
5 Years (60 Months Post Registration)
6 Years (72 Months Post-Registration)
84 Months Post Registration (84 Months
Post-Registration)
9 Months (9 Months Post Registration)
8 Years (96 Months Post-Registration)
Vital Status
Patient's Vital Status
Alive (Alive)
Dead (Dead)
Date of last contact or death (MM/DD/YYYY)
Primary Cause of Death (if applicable)
Due To Other Cause (Due to other
cause)
Due To Protocol Treatment (Due to
protocol treatment)
Due To This Disease (Due to this
disease)
Unknown (Unknown)
Describe cause of death
Section II - Reporting Period
Reporting Period Start Date (MM/DD/YYYY)
Reporting Period End Date (MM/DD/YYYY)
Notice Of New Primary (including Second
Colon Primary)
Has a new primary cancer or myelodysplastic
syndrome been diagnosed that has not been
previously reported (MDS)
No (No)
Unknown (Unknown)
Yes (Yes)
Site of New Primary (s)
Disease Follow-up Status
Has the patient had a documented clinical
assessment for this cancer (since submission of
the previous follow-up form)
No (No)
Unknown (Unknown)
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Yes (Yes)
If unknown, please explain
Date of last clinical assessment (If yes)
Has the patient developed a first progression (or
relapse) that has not been previously reported?
(Notice of Progression)
No (No)
Unknown (Unknown)
Yes (Yes)
If unknown, please explain
Disease Progression Date (relapse)
Sites of Progression
Did a physician make a formal diagnosis of
progressive disease?
No (No)
Unknown (Unknown)
Yes (Yes)
Specify basis of progression (If no or unknown:)
Adverse Events
Has the patient experienced any severe long
term toxicity that has not been previously
reported (prior to diagnosis of
progression/relapse)
No (No)
Unknown (Unknown)
Yes (Yes)
Non-protocol Therapy
Has the patient received any non-protocol cancer
therapy prior to first progression (not previously
reported)
No (No)
Unknown (Unknown)
Yes (Yes)
Comments
Investigator Signature
Investigator Signature Date
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E1305 Chemotherapy Treatment Form NCT00588770
Chemotherapy With or Without Bevacizumab in Treating
Patients With Recurrent or Metastatic Head and Neck
Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=3ED4DA74-
CDF5-35B6-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/10710
E1305 Chemotherapy Treatment
Form NCT00588770
Header
ECOG Protocol Number
ECOG Patient ID
DCI Name
Registration Step
Patient demographics
ECOG Protocol Number
Patient Initials (Last, First)
ECOG Patient ID
Participating Group Protocol Number
Institution/Affiliate
Participating Group Patient ID
Data amendment
Please mark an 'X' if data have been amended.
(Please circle amended items in red)
Date data amended (M D Y)
Arm A And Arm B
On Treatment Report Period
> Cycle 17 (> Cycle 17)
Cycle 1 (Cycle 1)
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Cycle 10 (Cycle 10)
Cycle 11 (Cycle 11)
Cycle 12 (Cycle 12)
Cycle 13 (Cycle 13)
Cycle 14 (Cycle 14)
Cycle 15 (Cycle 15)
Cycle 16 (Cycle 16)
Cycle 17 (Cycle 17)
Cycle 2 (Cycle 2)
Cycle 3 (Cycle 3)
Cycle 4 (cycle 4)
Cycle 5 (Cycle 5)
Cycle 6 (Cycle 6)
Cycle 7 (Cycle 7)
Cycle 8 (cycle 8)
Cycle 9 (Cycle 9)
Reporting Period Start Date
Reporting Period End Date
On Treatment
Patient Vital Status
Alive (Alive)
Dead (Dead)
Date of Last Contact or Death (M D Y)
Primary Cause of Death (if applicable)
Due To Other Cause (Due to other
cause)
Due To Protocol Treatment (Due to
protocol treatment)
Due To This Disease (Due to this
disease)
Unknown (Unknown)
Describe cause of death
Patient status assessment
ECOG Performance Status (Day 1 of this cycle)
Fully Active, Able To Carry On All Pre-
disease Performance Without
Restriction. (0)
Restricted In Physically Strenuous
Activity But Ambulatory And Able To
Carry Out Work Of A Light Or Sedentary
Nature, E.g., Light Housework, Office
Work. (1)
Ambulatory And Capable Of All Selfcare
But Unable To Carry Out Any Work
Activities. Up And About More Than 50%
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Of Waking Hours. (2)
Capable Of Only Limited Selfcare,
Confined To Bed Or Chair More Than
50% Of Waking Hours. (3)
Completely Disabled. Cannot Carry On
Any Selfcare. Totally Confined To Bed Or
Chair. (4)
Dead (5)
Weight (kg Day 1)
BSA (Patient Body Surface Area Measurement -
m^2 Day 1 of this cycle)
Therapy Administered - Cisplatin
Agent Name
Date Agent Administered (If yes M D Y)
Agent Total Dose (this cycle)
Dose modification
Dose Delayed (Dose delayed)
Dose Delayed And Reduced (Dose
delayed and reduced)
Dose Held (Dose held)
Dose Reduced (Dose reduced)
Drug Discontinued (Drug discontinued)
No Dose Modification (No dose
modification)
Dose Modification Reason
Adverse Event (Adverse event)
Alternative Therapy For Other Reason
(Alternative therapy for other reason)
Dosing Error (Dosing error)
Other (Other)
Patient Refusal/noncompliance (Patient
refusal/noncompliance)
Scheduling (Scheduling)
Second Primary Cancer (Second
primary)
Other, specify
Mark 'X' if agent not given
Therapy Administered - Carboplatin
Agent Name
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Date Agent Administered (If yes M D Y)
Agent Total Dose (this cycle)
Dose modification
Dose Delayed (Dose delayed)
Dose Delayed And Reduced (Dose
delayed and reduced)
Dose Held (Dose held)
Dose Reduced (Dose reduced)
Drug Discontinued (Drug discontinued)
No Dose Modification (No dose
modification)
Dose Modification Reason
Adverse Event (Adverse event)
Alternative Therapy For Other Reason
(Alternative therapy for other reason)
Dosing Error (Dosing error)
Other (Other)
Patient Refusal/noncompliance (Patient
refusal/noncompliance)
Scheduling (Scheduling)
Second Primary Cancer (Second
primary)
Other, specify
Mark 'X' if agent not given
Therapy Administered - Docetaxel
Agent Name
Date Agent Administered (If yes M D Y)
Agent Total Dose (this cycle)
Dose modification
Dose Delayed (Dose delayed)
Dose Delayed And Reduced (Dose
delayed and reduced)
Dose Held (Dose held)
Dose Reduced (Dose reduced)
Drug Discontinued (Drug discontinued)
No Dose Modification (No dose
modification)
Dose Modification Reason
Adverse Event (Adverse event)
Alternative Therapy For Other Reason
(Alternative therapy for other reason)
Dosing Error (Dosing error)
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Other (Other)
Patient Refusal/noncompliance (Patient
refusal/noncompliance)
Scheduling (Scheduling)
Second Primary Cancer (Second
primary)
Other, specify
Mark 'X' if agent not given
Therapy Administered - 5FU
Agent Name
Date of First dose for this reporting period
Date of Last dose for this reporting period
Agent Total Dose (this cycle)
Dose modification
Dose Delayed (Dose delayed)
Dose Delayed And Reduced (Dose
delayed and reduced)
Dose Held (Dose held)
Dose Reduced (Dose reduced)
Drug Discontinued (Drug discontinued)
No Dose Modification (No dose
modification)
Dose Modification Reason
Adverse Event (Adverse event)
Alternative Therapy For Other Reason
(Alternative therapy for other reason)
Dosing Error (Dosing error)
Other (Other)
Patient Refusal/noncompliance (Patient
refusal/noncompliance)
Scheduling (Scheduling)
Second Primary Cancer (Second
primary)
Other, specify
Mark 'X' if agent not given
Chemotherapy Dose Modifications
Serum creatinine
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Date Hematology (Blood) Sample Obtained
Creatinine Clearance (calculated)
Carboplatin was administered
As Part Of Original Chemotherapy
Selected Prior To Registration (As part of
original chemotherapy selected prior to
registration)
In Place Of Cisplatin, Due To
Development Of Specific Intolerable
Cisplatin-associated Toxicities (In place
of Cisplatin, due to development of
specific intolerable Cisplatin-associated
toxicities)
Is this first administration of carboplatin in place
of cisplatin for this patient (Carboplatin
Substitution Section only to be completed if
patient was on Cisplatin regimen and Carboplatin
was administered as a substitution for Cisplatin)
Yes
No
Toxicities that led to the substitution (If yes, -
mark all that apply - )
Grade >=2 Sensory Or Motor
Neuropathy For >1 Week (Grade >=2
sensory or motor neuropathy for >1
week)
Grade 2 Persistent Ototoxicity (Grade 2
persistent ototoxicity)
Grade 4 Nausea And Vomiting Attributed
To Cisplatin Despite Antiemetics (Grade
4 nausea and vomiting attributed to
cisplatin despite antiemetics)
Nephrotoxicity (Nephrotoxicity - see
sections 5.5.1.5. and 5.5.3.4. of the
protocol for details)
Adverse Event (Instructions:  If any agent dose
was modified for adverse event, mark an 'X' for all
that apply:)
Arterial Thrombotic Event (Arterial
Thrombotic Event)
Gi Toxicity (GI toxicity)
Hemorrhage (Hemorrhage)
Hepatic Toxicity (Hepatic Toxicity)
Neurotoxicity (Neurotoxicity)
Other (Other)
Proteinuria (Proteinuria)
Venous Thrombosis/embolism (Venous
Thrombosis/Embolism)
Wound Dehiscence (Wound Dehiscence)
Other, specify
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Non-protocol Therapy
Was any non-protocol therapy given during
protocol treatment?
Yes
No
Comments
Investigator Signature
Investigator Signature Date
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NCT00588770
E1305 Long-Term Follow-up Form NCT00588770
Chemotherapy With or Without Bevacizumab in Treating
Patients With Recurrent or Metastatic Head and Neck
Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=1A097748-
4562-2BCB-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/10711
E1305 Long-Term Follow-up Form
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Header
ECOG Protocol Number
ECOG Patient ID
DCI Name
Registration Step
Patient demographics
Patient Initials (Last, First)
ECOG Protocol Number
ECOG Patient ID
Participating Group Protocol Number
Participating Group Patient ID
Institution/Affiliate
Off protocol treatment period
Off Treatment Report Period (since initial
registration)
12 Months (12 Months Post Registration)
15 Months (15 Months Post Registration)
18 Months (18 Months Post Registration)
21 Months Post Registration (21 Months
Post Registration)
2 Years (24 Months Post Registration)
3 Months (3 Months Post Registration)
30 Months (30 Months Post Registration)
3 Years (36 Months Post Registration)
42 Months (42 Months Post Registration)
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4 Years (48 Months Post Registration)
54 Months (54 Months Post Registration)
6 Months (6 Months Post Registration)
5 Years (60 Months Post Registration)
9 Months (9 Months Post Registration)
Data amendment
Please mark an 'X' if data have been amended
(Please circle amended items in red)
Date data amended (M D Y)
Vital Status
Patient Vital Status
Alive (Alive)
Dead (Dead)
Date of last contact or death (M D Y)
Primary Cause of Death (if applicable)
Due To Other Cause (Due to other
cause)
Due To Protocol Treatment (Due to
protocol treatment)
Due To This Disease (Due to this
disease)
Unknown (Unknown)
Describe cause of death
Section II - Reporting Period
Reporting Period Start Date (M D Y)
Reporting Period End Date (M D Y)
Notice Of New Primary (including Second
Colon Primary)
Has a new primary cancer or MDS been
diagnosed that has not been previously reported
No (No)
Unknown (Unknown)
Yes (Yes)
Site of New Primary (s)
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Disease Follow-up Status
Has the patient had a documented clinical
assessment for this cancer (since submission of
the previous follow-up form)
No (No)
Unknown (Unknown)
Yes (Yes)
If unknown, please explain
Date of last clinical assessment (If yes)
Has the patient developed a first progression (or
relapse) that has not been previously reported?
No (No)
Unknown (Unknown)
Yes (Yes)
If unknown, please explain
Date of Progression (relapse - M D Y - Submit
E1305 Follow-up Disease Evaluation Form
RECIST)
Sites of Progression
Did a physician make a formal diagnosis of
progressive disease?
No (No)
Unknown (Unknown)
Yes (Yes)
Specify basis of progression (If no or unknown)
Adverse Events
Has the patient experienced any severe long
term toxicity that has not been previously
reported (prior to diagnosis of
progression/relapse)
No (No)
Unknown (Unknown)
Yes (Yes)
Non-protocol Therapy
Has the patient received any non-protocol cancer
therapy prior to first progression (not previsouly
reported - NOTE: Only the first occurrence of
non-protocol therapy should be reported)
No (No)
Unknown (Unknown)
Yes (Yes)
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Comments
Investigator Signature
Investigator Signature Date
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E1305 Bevacizumab Treatment Form - Arm
B Only NCT00588770
E1305 Bevacizumab Treatment Form - Arm B Only
NCT00588770
Chemotherapy With or Without Bevacizumab in Treating
Patients With Recurrent or Metastatic Head and Neck
Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=3ED85559-
E1CF-432F-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/10712
E1305 Bevacizumab Treatment Form
- Arm B Only NCT00588770
Header
ECOG Protocol Number
DCI Name
Registration Step
ECOG Patient ID
Patient demographics
Patient Initials (Last, First)
ECOG Protocol Number
Participating Group Protocol Number
Institution/Affiliate
ECOG Patient ID
Participating Group Patient ID
Data amendment
Please mark an 'X' if data have been amended.
(Please circle amended items in red)
Date data amended (M D Y)
Arm A And Arm B
On Treatment Report Period
> Cycle 17 (> Cycle 17)
Cycle 1 (Cycle 1)
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Cycle 10 (Cycle 10)
Cycle 11 (Cycle 11)
Cycle 12 (Cycle 12)
Cycle 13 (Cycle 13)
Cycle 14 (Cycle 14)
Cycle 15 (Cycle 15)
Cycle 16 (Cycle 16)
Cycle 17 (Cycle 17)
Cycle 2 (Cycle 2)
Cycle 3 (Cycle 3)
Cycle 4 (cycle 4)
Cycle 5 (Cycle 5)
Cycle 6 (Cycle 6)
Cycle 7 (Cycle 7)
Cycle 8 (cycle 8)
Cycle 9 (Cycle 9)
Reporting Period Start Date
Reporting Period End Date
On Treatment
Patient Vital Status
Alive (Alive)
Dead (Dead)
Date of Last Contact or Death (M D Y)
Primary Cause of Death (if applicable)
Due To Other Cause (Due to other
cause)
Due To Protocol Treatment (Due to
protocol treatment)
Due To This Disease (Due to this
disease)
Unknown (Unknown)
Describe cause of death
Patient status assessment
ECOG Performance Status (Day 1 of this cycle)
Fully Active, Able To Carry On All Pre-
disease Performance Without
Restriction. (0)
Restricted In Physically Strenuous
Activity But Ambulatory And Able To
Carry Out Work Of A Light Or Sedentary
Nature, E.g., Light Housework, Office
Work. (1)
Ambulatory And Capable Of All Selfcare
But Unable To Carry Out Any Work
Activities. Up And About More Than 50%
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Of Waking Hours. (2)
Capable Of Only Limited Selfcare,
Confined To Bed Or Chair More Than
50% Of Waking Hours. (3)
Completely Disabled. Cannot Carry On
Any Selfcare. Totally Confined To Bed Or
Chair. (4)
Dead (5)
Weight (kg Day 1)
Therapy Administered - Bevacizumab
Agent Name
Was the agent Bevacizumab administered during
this reporting period
Yes
No
Date Agent Administered (If yes M D Y)
Agent Total Dose (this cycle)
Dose modification
Dose Delayed (Dose delayed)
Dose Held (Dose held)
Drug Discontinued (Drug discontinued)
No Dose Modification (No dose
modification)
Dose Modification Reason (If applicable)
Adverse Event (Adverse event)
Alternative Therapy For Other Reason
(Alternative therapy for other reason)
Dosing Error (Dosing error)
Other (Other)
Patient Refusal/noncompliance (Patient
refusal/noncompliance)
Scheduling (Scheduling)
Second Primary Cancer (Second
primary)
Other, specify
Adverse Event (If Bevacizumab dose was
modified for adverse event, mark all that apply)
Arterial Thrombotic Event (Arterial
Thrombotic Event)
Gi Toxicity (GI Toxicity)
Hemorrhage (Hemorrhage)
Hepatic Toxicity (Hepatic Toxicity)
Neurotoxicity (Neurotoxicity)
Other (Other)
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Proteinuria (Proteinuria)
Venous Thrombosis/embolism (Venous
Thrombosis/Embolism)
Wound Dehiscence (Wound Dehiscence)
Other, specify
Non-protocol Therapy
Was any non-protocol therapy given during
protocol treatment?
Yes
No
Anti-coagulant Therapy
Were any low-dose anticoagulant drugs
administered during this reporting period
Yes
No
Anti-Coagulant Drugs
Aspirin > 325mg (Aspirin > 325mg)
Aspirin >81mg And <325mg (Aspirin
>81mg and <325mg)
Aspirin 325mg (Aspirin 325mg)
Aspirin 81mg (Aspirin 81mg)
Aspirin, Other (Aspirin, other)
Coumadin (Coumadin)
Coumadin (prophylactic Dose)
(Coumadin (prophylactic dose))
Coumadin (therapeutic Dose) (Coumadin
(therapeutic dose))
Low Molecular Weight Heparin (Low
Molecular Weight Heparin)
Low Molecular Weight Heparin
(prophylactic Dose) (Low Molecular
Weight Heparin (prophylactic dose))
Low Molecular Weight Heparin
(therapeutic Dose) (Low Molecular
Weight Heparin (therapeutic dose))
Other (Other)
Other, specify
Anti-hypertensive Therapy
Were any antihypertensive drugs administered
during this reporting period
Yes
No
Anti-Hypertensive Drugs
Ace Inhibitor (ACE inhibitors)
Angiotensin Ii Receptor Blocker
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(Angiotensin II inhibitors)
Beta Blocker (Beta blockers)
Calcium Channel Blocker (Calcium
channel blockers)
Diuretic (Diuretics)
Other (Other)
Other, specify
Comments
Investigator Signature
Investigator Signature Date
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NCT00326898
E2805 Long-Term Follow-up Form NCT00326898
Sunitinib or Sorafenib in Treating Patients With Kidney
Cancer That Was Removed By Surgery
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=058702CD-
40BF-2F26-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/10713
E2805 Long-Term Follow-up Form
NCT00326898
Header
ECOG Protocol Number
ECOG Patient ID
DCI Name
Registration Step
Patient demographics
ECOG Protocol Number
Patient Initials
ECOG Patient ID
Participating Group Protocol Number
Institution/Affiliate
Participating Group Patient ID
Off protocol treatment period
Off Treatment Report Period (since initial
registration)
9 Years (108 Months Post-Registration)
12 Months (12 Months Post Registration)
10 Years (120 Months Post-Registration)
15 Months (15 Months Post Registration)
18 Months (18 Months Post Registration)
21 Months Post Registration (21 Months
Post Registration)
2 Years (24 Months Post Registration)
3 Months (3 Months Post Registration)
30 Months (30 Months Post Registration)
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3 Years (36 Months Post Registration)
42 Months (42 Months Post Registration)
4 Years (48 Months Post Registration)
54 Months (54 Months Post Registration)
6 Months (6 Months Post Registration)
5 Years (60 Months Post Registration)
6 Years (72 Months Post-Registration)
84 Months Post Registration (84 Months
Post-Registration)
9 Months (9 Months Post Registration)
8 Years (96 Months Post-Registration)
Data amendment
Please mark an 'X' if data have been amended
Date data amended
Vital Status
Patient Vital Status
Alive (Alive)
Dead (Dead)
Date of last contact or death
Primary Cause of Death (if applicable)
Due To Other Cause (Due to other
cause)
Due To Protocol Treatment (Due to
protocol treatment)
Due To This Disease (Due to this
disease)
Unknown (Unknown)
Describe cause of death
Section II - Reporting Period
Reporting Period Start Date
Reporting Period End Date
Notice Of New Primary (including Second
Colon Primary)
Has a new primary cancer or MDS been
diagnosed that has not been previously reported
(MDS)
No (No)
Unknown (Unknown)
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Yes (Yes)
Site of New Primary (s)
Section V - Last Cycle Of Protocol
Therapy
Was a MUGA performed (this reporting period?)
Yes
No
Date of assessment
Was an Echocardiogram (ECHO) performed (this
reporting period?)
Yes
No
Date of assessment
Left Ventricular Ejection Fraction at Rest
Left Ventricular Ejection Fraction at Rest
LVEF Institutional Lower Limit of Normal
LVEF Institutional Lower Limit of Normal
Disease Follow-up Status
Has the patient had a documented clinical
assessment for this cancer (this reporting period)
No (No)
Unknown (Unknown)
Yes (Yes)
If unknown, please explain
Date of last clinical assessment (If yes)
Adverse Events
Has the patient experienced any severe long
term toxicity that has not been previously
reported (prior to diagnosis of recurrence Grade
>4 hematologic, Grade >3 non-hematologic
NOTE: Do not report adverse events occurring
after start of non-protocol therapy.)
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No (No)
Unknown (Unknown)
Yes (Yes)
Non-protocol Therapy
Has the patient received any non-protocol cancer
therapy prior to first recurrence (not previously
reported)
No (No)
Unknown (Unknown)
Yes (Yes)
Comments
Investigator Signature
Investigator Signature Date
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LA1
LA1
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=FF1A902D-
29B1-3DEE-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/10714
LA1
Header module
Segment
Visit number
Laboratory Assessments
Start of assessment period
End of assessment period
Cbc
Hematocrit
Most recent value
Date of sample
Hemoglobin
Most recent value
Date of sample
Wbc
Most recent value
Date of sample
Neutrophils
Most recent value
Date of sample
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Lymphocytes
Most recent value
Date of sample
Chemistry And Lft's
Creatinine
Assessment period peak value
Date of sample
Bilirubin
Assessment period peak value
Date of sample
Ast
Assessment period peak value
Date of sample
Alt
Assessment period peak value
Date of sample
What is the patient's Karnofsky performance
score
Moribund, Fatal Processes Progressing
Rapidly (10 (Moribund; completely
disabled))
Normal, No Complaints, No Evidence Of
Disease (100 (Normal; no
complaints/fully active_)
Very Sick, Hospitalization Indicated.
Death Not Imminent (20 (Very
sick/limited to very passive activity))
Severely Disabled, Hospitalization
Indicated. Death Not Imminent (30
(severely disabled/needs assistance for
quiet play))
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Disabled, Requires Special Care And
Assistance (40 (Disabled/needs
assistance for quiet play))
Requires Considerable Assistance And
Frequent Medical Care (50 (Requires
considerable assistance/no active play))
Requires Occasional Assistance, But Is
Able To Care For Most Of His/her Needs
(60 (Requires occasional
assistance/minimal active play))
Cares For Self, Unable To Carry On
Normal Activity Or To Do Active Work
(70 (Unable to carry on normal
activity/less time spent at play))
Normal Activity With Effort; Some Signs
Or Symptoms Of Disease (80 (Normal
activity with effort/restricted to strenuous
play))
Able To Carry On Normal Activity; Minor
Signs Or Symptoms Of Disease (90
(Normal activity/minor restrictions in
strenuous play))
Comments
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CALGB: 10603 Supplemental Adverse
Event (AE) Form NCT00651261
CALGB: 10603 Supplemental Adverse Event (AE) Form
NCT00651261 
Daunorubicin, Cytarabine, and Midostaurin in Treating
Patients With Newly Diagnosed Acute Myeloid Leukemia
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=43B71921-
D03B-54F5-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/10715
CALGB: 10603 Supplemental
Adverse Event (AE) Form
NCT00651261
Header
CALGB Form
CALGB Study No
CALGB Patient ID
Reporting Period Start Date
Reporting Period End Date
Are data amended
Yes
No
Patient demographics
Patient Initials
Patient Hospital No.
Institution/Affiliate
Participating Group
Participating Group Study No.
Participating Group Patient ID
Expected Adverse Events
MedDRA Code
MedDRA Code
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CTC adverse event term
CTC adverse event term
Duration
Attributable to which medication
Cytosine Arabinoside (Cytarabine)
Daunorubicin (Daunorubicin)
Midostaurin/placebo
(Midostaurin/Placebo)
Footer Module
Completed by
Date Form Completed
2 / 2
CALGB: 10603 Supplemental Adverse Event (AE) Form NCT00651261
CALGB: 10603 Treatment Form
NCT00651261
CALGB: 10603 Treatment Form NCT00651261 
Daunorubicin, Cytarabine, and Midostaurin in Treating
Patients With Newly Diagnosed Acute Myeloid Leukemia
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=443E6AF2-
2DD2-3E6F-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/10716
CALGB: 10603 Treatment Form
NCT00651261
Header
CALGB Form
CALGB Study No.
CALGB Patient ID
Reporting Period Start Date (MM DD YYYY)
Reporting Period End Date (MM DD YYYY)
Are data amended
Yes
No
Patient demographics
Patient Initials (Last, First Middle)
Patient Hospital No.
Institution/Affiliate
Participating Group
Participating Group Study No.
Participating Group Patient ID
Treatment Phase
Treatment Phase
Consolidation #1 (Consolidation #1)
Consolidation #2 (Consolidation #2)
Consolidation #3 (Consolidation #3)
Consolidation #4 (Consolidation #4)
Continuation (Continuation)
Induction #1 (Induction #1)
Induction #2 (Induction #2)
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Patient status assessment
Patient Weight (kg)
Body Surface Area (m^2)
Did the patient receive any protocol treatment?
Yes
No
First Treatment (cycles 1 ¿ 6)
Medication calendar completed by
Other (Other)
Patient (Patient)
Specify
Number of capsules taken according to
medication calendar
Number of capsules dispensed
Number of capsules returned
Reason for missed/reduced Midostaurin/Placebo
dose
Cardiac Toxicity (Cardiac toxicity)
Heme Toxicity (Heme toxicity)
No Missed Doses (No missed doses)
Other (Other)
Other Non-heme Toxicity (Other non-
heme toxicity)
Pulmonary Toxicity (Pulmonary Toxicity)
Specify
Midostaurin/Placebo Dosing
Time point
Day 1, Dose 1 (Day 1, Dose 1)
Day 1, Dose 2 (Day 1, Dose 2)
Day 3, Dose 1 (Day 3, Dose 1)
Day 3, Dose 2 (Day 3, Dose 2)
Day 5, Dose 1 (Day 5, Dose 1)
Day 5, Dose 2 (Day 5, Dose 2)
QT interval
QTc Interval
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Heart Rate
PR interval
Date of EKG
Daunorubicin Dosing
Time point
Day 1, Dose 1 (Day 1, Dose 1)
Day 1, Dose 2 (Day 1, Dose 2)
Day 3, Dose 1 (Day 3, Dose 1)
Day 3, Dose 2 (Day 3, Dose 2)
Day 5, Dose 1 (Day 5, Dose 1)
Day 5, Dose 2 (Day 5, Dose 2)
Daunorubicin dose received
Total Bilirubin
CTC Adverse Event Grade
Cytarabine Dosing
Time point
Day 1, Dose 1 (Day 1, Dose 1)
Day 1, Dose 2 (Day 1, Dose 2)
Day 3, Dose 1 (Day 3, Dose 1)
Day 3, Dose 2 (Day 3, Dose 2)
Day 5, Dose 1 (Day 5, Dose 1)
Day 5, Dose 2 (Day 5, Dose 2)
Cytarabine Dose Received
Cytarabine Dosing
Time point
Day 1, Dose 1 (Day 1, Dose 1)
Day 1, Dose 2 (Day 1, Dose 2)
Day 3, Dose 1 (Day 3, Dose 1)
Day 3, Dose 2 (Day 3, Dose 2)
Day 5, Dose 1 (Day 5, Dose 1)
Day 5, Dose 2 (Day 5, Dose 2)
Cytarabine Dose Received
CTC Adverse Event Grade
Reason Treatment Ended
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Reason Treatment Ended (Mark one with an X.)
Adverse Event/side Effects/complications
(Adverse Event/Side
Effects/Complications)
Alternative Therapy (Alternative therapy)
Death On Study (Death on study)
Disease Progression Before Active
Treatment (Disease Progression before
active treatment)
Disease Progression, Relapse During
Active Treatment (Disease progression,
relapse during active treatment)
Other (Other)
Patient Off-treatment For Other
Complicating Disease (Patient off-
treatment for other complicating disease)
Patient Withdrawal Or Refusal After
Beginning Protocol Therapy (Patient
withdrawal/refusal after beginning
protocol therapy)
Patient Withdrawal Or Refusal Before
Beginning Protocol Therapy (Patient
withdrawal/refusal prior to beginning
protocol therapy)
Treatment Completed Per Protocol
Criteria (Treatment completed per
protocol criteria)
Adverse event/side effects/complications specify
(s)
Other specify
Overall Response
Completed by (print or type name)
Date Form Completed (MM DD YYYY)
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CALGB-10501 Status And NCI 96 Criteria
Form NCT00513747
CALGB-10501 Status And NCI 96 Criteria Form
NCT00513747 
Early or Delayed Fludarabine and Rituximab in Treating
Patients With Previously Untreated Chronic Lymphocytic
Leukemia
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=34102C37-
B379-2769-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/10717
CALGB-10501 Status And NCI 96
Criteria Form NCT00513747
Header
CALGB Form
CALGB Study No
CALGB Patient ID
Reporting Period Start Date
Reporting Period End Date
Are data amended
Yes
No
Patient demographics
Patient Initials (Last, First Middle)
Patient Hospital No.
Institution/Affiliate
Participating Group
Participating Group Study No
Participating Group Patient ID
Patient Data
Has the patient had a documented clinical
assessment for this cancer? (Mark one with an
X.)
No (No)
Unknown (Unknown)
1 / 4
Yes (Yes)
Date of Last Clinical Assessment (MM DD YYYY
Only provide date if assessment occurred during
this reporting period)
Weight (kg)
BSA (m^2)
Performance Status (Mark one with an X.)
Fully Active, Able To Carry On All Pre-
disease Performance Without
Restriction. (0)
Restricted In Physically Strenuous
Activity But Ambulatory And Able To
Carry Out Work Of A Light Or Sedentary
Nature, E.g., Light Housework, Office
Work. (1)
Ambulatory And Capable Of All Selfcare
But Unable To Carry Out Any Work
Activities. Up And About More Than 50%
Of Waking Hours. (2)
Capable Of Only Limited Selfcare,
Confined To Bed Or Chair More Than
50% Of Waking Hours. (3)
Completely Disabled. Cannot Carry On
Any Selfcare. Totally Confined To Bed Or
Chair. (4)
Notice Of Progression
Has the patient developed a first progression (or
relapse) that has not been previously reported?
(Mark one with an X.)
No (No)
Unknown (Unknown)
Yes (Yes)
Did the patient receive additional therapy?
Yes
No
Does the patient meet treatment initiation (If no)
Yes
No
Specify reason treatment not initiated
Criteria For Treatment
A minimum of any one of the following disease-
related symptoms must be present
Drenching Night Sweats More Than 3
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Times Per Week Without Evidence Of
Infection That Require The Patient To
Change Clothes (Drenching night sweats
more than 3 times per week without
evidence of infection that require the
patient to change clothes)
Evidence Of Progressive Marrow Failure
As Manifested By Autoimmune Anemia
Or Thrombocytopenia Poorly Responsive
To Corticosteroid Therapy (Evidence of
progressive marrow failure as manifested
by autoimmune anemia or
thrombocytopenia poorly responsive to
corticosteroid therapy)
Evidence Of Progressive Marrow Failure
As Manifested By Hemoglobin <11 G/dl
In The Absence Of Autoimmune
Hemolytic Anemia (Evidence of
progressive marrow failure as manifested
by hemoglobin <11 g/dL in the absence
of autoimmune hemolytic anemia)
Evidence Of Progressive Marrow Failure
As Manifested By Lymphocyte Count >
300 X 10^9 /l (Evidence of progressive
marrow failure as manifested by
lymphocyte count > 300 x 10^9 /L)
Evidence Of Progressive Marrow Failure
As Manifested By Massive (i.e., >6 Cm
Below The Left Costal Margin) Or
Progressive Splenomegaly That Is
Causing Pain Or Significantly Early
Satiety (Evidence of progressive marrow
failure as manifested by massive (i.e., >6
cm below the left costal margin) or
progressive splenomegaly that is
causing pain or significantly early satiety)
Evidence Of Progressive Marrow Failure
As Manifested By Massive Nodes Or
Clusters (i.e., >10 Cm In Longest
Diameter) Or Progressive
Lymphadenopathy That Is Causing Pain
Or Significant Disfigurement (Evidence
of progressive marrow failure as
manifested by massive nodes or clusters
(i.e., >10 cm in longest diameter) or
progressive lymphadenopathy that is
causing pain or significant disfigurement)
Evidence Of Progressive Marrow Failure
As Manifested By Thrombocytopenia
<100 X 10^12 /l In The Absence Of
Idiopathic Thrombocytopenia Purpura
(Evidence of progressive marrow failure
as manifested by thrombocytopenia
<100 x 10^12 /L in the absence of
idiopathic thrombocytopenia purpura)
Extreme Fatigue (Extreme fatigue)
Fevers Of Greater Than 100.5 Degrees F
For 2 Weeks Without Evidence Of
Infection (Fevers of greater than 100.5
degrees F for 2 weeks without evidence
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of infection)
Other Disease Related Symptoms (skin
Infitration, Vasculitis, Pemphigus) (Other
disease related symptoms (skin
infitration, vasculitis, pemphigus))
Weight Loss Of 10% Or More Within The
Previous 6 Months (Weight loss of 10%
or more within the previous 6 months)
Date of Symptom/Event Assessment (MM DD
YYYY)
Overall Response
Completed by (print or type name)
Date Form Completed (MM DD YYYY)
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E1208 Maintenance Sorafenib/Placebo
Treatment Form NCT01004978
E1208 Maintenance Sorafenib/Placebo Treatment Form
NCT01004978 
Chemoembolization With or Without Sorafenib Tosylate in
Treating Patients With Liver Cancer That Cannot Be
Removed By Surgery
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=6FF38FDB-
A4BA-3C8D-E040-BB89AD432B43
All rights reserved. Please visit https://medical-data-
models.org/forms/10718
E1208 Maintenance
Sorafenib/Placebo Treatment  Form
NCT01004978
Header
ECOG Protocol Number
DCI Name
Registration Step
ECOG Patient ID
Patient demographics
Patient Initials (Last, First)
ECOG Protocol Number
Participating Group Protocol Number
Institution/Affiliate
ECOG Patient ID
Participating Group Patient ID
On Treatment
On Treatment Report Period
> Cycle 18 (> Cycle 18)
Cycle 10 (Cycle 10)
Cycle 11 (Cycle 11)
Cycle 12 (Cycle 12)
Cycle 13 (Cycle 13)
Cycle 14 (Cycle 14)
Cycle 15 (Cycle 15)
Cycle 16 (Cycle 16)
Cycle 17 (Cycle 17)
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Cycle 18 (Cycle 18)
Cycle 5 (Cycle 5)
Cycle 6 (Cycle 6)
Cycle 7 (Cycle 7)
Cycle 8 (cycle 8)
Cycle 9 (Cycle 9)
Specify Cycle
Data amendment
Please mark an 'X' if data have been amended.
(Please circle amended items in red)
Date data amended (s - mm/dd/yyyy)
Vital Status
Patient's Vital Status
Alive (Alive)
Dead (Dead)
Date of last contact or death (mm/dd/yyyy)
Primary Cause of Death (if applicable)
Due To Other Cause (Due to other
cause)
Due To Protocol Treatment (Due to
protocol treatment)
Due To This Disease (Due to this
disease)
Unknown (Unknown)
Describe cause of death
Reporting Period
Reporting Period Start Date (mm/dd/yyyy)
Reporting Period End Date (mm/dd/yyyy)
Patient Characteristics
Performance Status
Fully Active, Able To Carry On All Pre-
disease Performance Without
Restriction. (0)
Restricted In Physically Strenuous
Activity But Ambulatory And Able To
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Carry Out Work Of A Light Or Sedentary
Nature, E.g., Light Housework, Office
Work. (1)
Ambulatory And Capable Of All Selfcare
But Unable To Carry Out Any Work
Activities. Up And About More Than 50%
Of Waking Hours. (2)
Capable Of Only Limited Selfcare,
Confined To Bed Or Chair More Than
50% Of Waking Hours. (3)
Completely Disabled. Cannot Carry On
Any Selfcare. Totally Confined To Bed Or
Chair. (4)
Weight (Day 1 of this reporting period cycle)
Body Surface Area (BSA Day 1 of this reporting
period cycle)
Therapy Administered
Agent Start Date (Sorafenib/Placebo)
Agent End Date (Sorafenib/Placebo)
Did the patient complete and return the Patient
Pill Diary this cycle
Yes
No
Daily dose prescribed (on Day 1 of this reporting
period mg)
Date of dose modifications
New total dose per day
200 Mg (200 mg)
400 Mg (400 mg)
800 Mg (800 mg)
Dose Held (Dose held)
Dose Modification Reason
Other (Other)
Per Protocol (per protocol)
Specify
Section E: Non-protocol Therapy
Was any non-protocol therapy given during
protocol treatment (not previously reported)?
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Yes
No
Comments
Investigator Signature
Investigator Signature Date
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CALGB-10501 Remarks Agenda Form
NCT00513747
CALGB-10501 Remarks Agenda Form NCT00513747 
Early or Delayed Fludarabine and Rituximab in Treating
Patients With Previously Untreated Chronic Lymphocytic
Leukemia
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=33FA7DED-
1EF1-0F71-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/10719
CALGB-10501 Remarks Agenda
Form NCT00513747
Header
CALGB Form
CALGB Study No
CALGB Patient ID
Are data amended
Yes
No
Patient demographics
Patient Initials
Patient Hospital No.
Institution/Affiliate
Participating Group
Participating Group Study No.
Participating Group Patient ID
Reporting period
Reporting Period Start Date
Reporting Period End Date
Page
Comments
COMMENTS
1 / 2
Completed by
Date form completed
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E2905 Vital Status Form NCT00843882
E2905 Vital Status Form NCT00843882 
Lenalidomide With or Without Epoetin Alfa in Treating
Patients With Myelodysplastic Syndrome and Anemia
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=0EAABFF6-
287B-7357-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/10720
E2905 Vital Status Form
NCT00843882
Header
ECOG Protocol Number
ECOG Patient ID
DCI Name
Registration Step
Patient demographics
Patient Initials (Last, First)
ECOG Protocol Number
ECOG Patient ID
Participating Group Protocol Number
Participating Group Patient ID
Institution/Affiliate
Data amendment
Please mark an 'X' if data have been amended.
(Please circle amended items in red)
Date data amended (MM/DD/YYYY)
Off protocol treatment period
Off Treatment Report Period (since registration)
3 Months Post End Of Treatment (3
months post end of treatment)
1 / 3
6 Months Post End Of Treatment (6
months post end of treatment)
Vital Status
Patient's Vital Status
Alive (Alive)
Dead (Dead)
Date of last contact or death (MM/DD/YYYY)
Primary Cause of Death (if applicable)
Due To Other Cause (Due to other
cause)
Due To Protocol Treatment (Due to
protocol treatment)
Due To This Disease (Due to this
disease)
Unknown (Unknown)
Describe cause of death
Section II - Reporting Period
Reporting Period Start Date (MM/DD/YYYY)
Reporting Period End Date (MM/DD/YYYY)
Notice Of New Primary (including Second
Colon Primary)
Has a new primary cancer or myelodysplastic
syndrome been diagnosed that has not been
previously reported (MDS)
No (No)
Unknown (Unknown)
Yes (Yes)
Site of New Primary (s)
Disease Follow-up Status
Has the patient had a documented clinical
assessment for this cancer (since submission of
the previous follow-up form)
No (No)
Unknown (Unknown)
Yes (Yes)
If unknown, please explain
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Date of last clinical assessment (If yes - Submit
E2905 Follow-up Disease Evaluation Form - and
E2905 Hematology Form)
Has the patient developed a first progression (or
relapse) that has not been previously reported?
(Notice of Progression)
No (No)
Unknown (Unknown)
Yes (Yes)
If unknown, please explain
Disease Progression Date (relapse - Submit
E2905 Follow-up Disease Evaluation Form - and
E2905 Hematology Form)
Sites of Progression
Did a physician make a formal diagnosis of
progressive disease?
No (No)
Unknown (Unknown)
Yes (Yes)
Specify basis of progression (If no or unknown:)
Adverse Events
Has the patient experienced any severe long
term toxicity that has not been previously
reported (prior to diagnosis of
progression/relapse)
No (No)
Unknown (Unknown)
Yes (Yes)
Non-protocol Therapy
Has the patient received any non-protocol cancer
therapy prior to first progression (not previously
reported)
No (No)
Unknown (Unknown)
Yes (Yes)
Comments
Investigator Signature
Investigator Signature Date
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CALGB: 10603 Follow-Up Form
NCT00651261
CALGB: 10603 Follow-Up Form NCT00651261 
Daunorubicin, Cytarabine, and Midostaurin in Treating
Patients With Newly Diagnosed Acute Myeloid Leukemia
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=43C5D677-
EB7A-6D45-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/10721
CALGB: 10603 Follow-Up Form
NCT00651261
Header
CALGB Form (C-1623)
CALGB Study No.
CALGB Patient ID
Reporting Period Start Date
Reporting Period End Date
Are data amended
Yes
No
Patient demographics
Patient Initials (Last, First Middle)
Patient Hospital No.
Institution/Affiliate
Participating Group
Participating Group Study No.
Participating Group Patient ID
Treatment Phase Information
Treatment Phase
Consolidation #1 (Consolidation #1)
Consolidation #2 (Consolidation #2)
Consolidation #3 (Consolidation #3)
Consolidation #4 (Consolidation #4)
Continuation (Continuation)
Induction #1 (Induction #1)
Induction #2 (Induction #2)
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Post-therapy (Post-therapy follow-up)
Aml/all/apl: Vital Status
Patient's Vital Status (Mark one with an X)
Alive (Alive)
Dead (Dead)
Date of Last Contact or Death (mm dd yyyy)
Primary Cause of Death (Mark one with an X)
Due To Other Cause (Due to other
cause)
Due To Protocol Treatment (Due to
protocol treatment)
Due To This Disease (Due to this
disease)
Unknown (Unknown)
Describe cause of death
Aml/all/apl: Disease Follow-up Status
Has the patient had a documented clinical
assessment for this cancer? (during this reporting
period)
No (No)
Unknown (Unknown)
Yes (Yes)
Date of Last Clinical Assessment (mm dd yyyy
only provide date if assessment during this
reporting period)
Did the patient achieve a complete response
according to clinical/ hematologic criteria (during
this reporting period)
No (NO)
Unknown (Unknown)
Yes (YES)
Complete Response (CR) First Observed Date
Did the patient achieve a partial response
according to clinical/ hematologic criteria
No (NO)
Unknown (Unknown)
Yes (YES)
Partial Response (PR) First Observed Date
Cll: Notice Of Progression
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Has the patient developed a first progression (or
relapse) that has not been previously reported?
(Mark one with an X.)
No (No)
Unknown (Unknown)
Yes (Yes)
Date of bone marrow relapse
Date of non-marrow relapse
Type of non-marrow relapse
Cns (CNS)
Gonadal (Gonadal)
Other, Specify (Other, specify)
Peripheral Blood (Peripheral blood)
Skin (Skin)
Other, specify (Type of non-marrow relapse)
Recovery
Did the patient require hospitalization (other than
for chemotherapy administration)
Yes
No
Number of extra days hospitalized
Did the patient require IV antibiotics or
antifungals
Yes
No
Number of days on IV antibiotics/antifungals
Did the patient require platelet transfusion
Yes
No
Number of days platelet transfusion(s) given (If
yes,)
Type of platelet transfusion
Other (Other)
Random Donor (Random donor)
Single Donor (Single donor)
Other specify
Did the patient require red blood cell (RBC)
transfusions?
Yes
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No
Number of units of RBC transfusions (If yes, )
First date ANC (Absolute Neutrophil Count)
dropped below 500/ul
First date of ANC (Absolute Neutrophil Count)
recovery over 500/ul
First date platelets dropped below 20,000/ul
First date platelets recovered over 20,000/ul
(non-transfused)
Notice Of Progression2
Date of First Bone Marrow or Peripheral Blood
Stem Cell (PBSC) Infusion
Type of Bone Marrow or Peripheral Blood Stem
Cell (PBSC) Transplant
Bone Marrow Stem Cells Used For
Transplant Obtained From Recipient
Him/herself (Autologous bone marrow)
Peripheral Blood Stem Cells Used For
Transplant Obtained From Recipient
Him/herself (Autologous PBSC)
Bone Marrow Stem Cells Used For
Transplant Obtained From Antigen-
matched Sibling Or Family Member Of
Recipient (Bone marrow from matched
sibling or family member)
Bone Marrow Stem Cells Used For
Transplant Obtained From Antigen-
matched Individual Unrelated To
Recipient (Bone marrow from matched
unrelated donor)
Cord Blood (Cord blood)
Other Specify (Other)
Peripheral Blood Stem Cells Used For
Transplant Obtained From Antigen-
matched Sibling Or Family Member Of
Recipient (PBSC from matched sibling or
family member)
Peripheral Blood Stem Cells Used For
Transplant Obtained From Antigen-
matched Individual Unrelated To
Recipient (PBSC from matched
unrelated donor)
Other specify
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Notice Of New Primary
Has a new primary cancer or MDS been
diagnosed that has not been previously reported?
Yes
No
New Primary Diagnosis
Date of diagnosis
Site of New Primary (s)
Comments
Completed by (Last name, First name)
Date Form Completed
5 / 5
CALGB: 10603 Follow-Up Form NCT00651261
CALGB: 30607 Follow-Up and Response
Form NCT00693992
CALGB: 30607 Follow-Up and Response Form
NCT00693992 
Sunitinib as Maintenance Therapy in Treating Patients With
Stage III or Stage IV Non-Small Cell Lung Cancer
Previously Treated With Combination Chemotherapy
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=35A0F1D4-
FCF7-1AF2-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/10722
CALGB: 30607 Follow-Up and
Response Form NCT00693992
Header
CALGB Form
CALGB Study No
CALGB Patient ID
Reporting period start date
Reporting Period End Date
Are data amended
Yes
No
Patient demographics
Patient Initials
Patient Hospital No.
Institution/Affiliate
Participating Group
Participating Group Study No.
Participating Group Patient ID
Patient status assessment
Vital status (Mark one with an X.)
Alive (Alive)
Dead (Dead)
Lost To Follow-up (Lost to follow-up)
1 / 3
Primary Cause of Death (Mark one with an X.)
Due To Other Cause (Due to other
cause)
Due To Protocol Treatment (Due to
protocol treatment)
Due To This Disease (Due to this
disease)
Due to other cause, specify
Response Data
Has the patient developed a progression or
relapse that has not been previously reported?
Yes
No
Progressive Disease Observed Date (If Yes,
specify or recurrent)
Sites of progression (for pre-surgical or surgical
response Mark all that apply with an X.)
Bone (Bone)
Central Nervous System (Central
Nervous System)
Distant Lymph Nodes (Distant lymph
nodes)
Liver (Liver)
Lung, Nos (Lung)
Contralateral Lung (Opposite lung)
Other (Other)
Pleura (Pleura)
Regional Lymph Nodes (Regional lymph
nodes)
Other specify
Non-protocol Treatment
Is the patient receiving any non-protocol cancer
therapy not previously reported?
Yes
No
Specify
Date of First Non-Protocol Therapy
New Primary Data
Has a new primary cancer or MDS been
diagnosed that has not been previously reported?
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Yes
No
Site of new primary (Mark all that apply with an
X.)
Breast (Breast)
Lung (Lung)
Other (Other)
Prostate (Prostate)
Skin (Skin)
Other specify
Completed by
Date form originally completed
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E1505 Disease and Vital Status Form
NCT00324805
E1505 Disease and Vital Status Form NCT00324805 
Chemotherapy With or Without Bevacizumab in Treating
Patients With Stage IB, Stage II, or Stage IIIA Non-Small
Lung Cancer That Was Removed By Surgery
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=07D0C4EF-
5573-55B4-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/10723
E1505 Disease and Vital Status
Form NCT00324805
Header
ECOG Protocol Number
ECOG Patient ID
DCI Name
Registration Step
Patient demographics
Patient Initials (Last, First)
ECOG Protocol Number
ECOG Patient ID
Participating Group Protocol Number
Institution/Affiliate
Participating Group Patient ID
Data amendment
Please mark an 'X' if data have been amended.
(Please circle amended items in red)
Date data amended (M D Y)
ON TREATMENT
Reporting Period (since registration)
108 Months Post Registration (108
Months Post Registration)
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12 Months Post Registration (12 Months
Post Registration)
120 Months Post Registration (120
Months Post Registration)
15 Months Post Registration (15 Months
Post Registration)
18 Months Post Registration (18 Months
Post Registration)
21 Months Post Registration (21 Months
Post Registration)
24 Months Post Registration (24 Months
Post Registration)
3 Months Post Registration (3 Months
Post Registration)
30 Months Post Registration (30 Months
Post Registration)
36 Months Post Registration (36 Months
Post Registration)
42 Months Post Registration (42 Months
Post Registration)
48 Months Post Registration (48 Months
Post Registration)
54 Months Post Registration (54 Months
Post Registration)
6 Months Post Registration (6 Months
Post Registration)
60 Months Post Registration (60 Months
Post Registration)
72 Months Post Registration (72 Months
Post Registration)
84 Months Post Registration (84 Months
Post Registration)
9 Months Post Registration (9 Months
Post Registration)
96 Months Post Registration (96 Months
Post Registration)
On Treatment
Patient Vital Status
Alive (Alive)
Dead (Dead)
Date of Last Contact or Death (M D Y)
Primary Cause of Death (if applicable)
Due To Other Cause (Due to other
cause)
Due To Protocol Treatment (Due to
protocol treatment)
Due To This Disease (Due to this
disease)
Unknown (Unknown)
Describe cause of death
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Arm A And Arm B
Reporting Period Start Date
Reporting Period End Date
Section Iii - Notice Of New Primary
Has a new primary cancer or MDS been
diagnosed that has not been previously reported?
No (No)
Unknown (Unknown)
Yes (Yes)
Site of New Primary (s - If new primary site is
AML/MDS/ALL, submit NCI AML/MDS/ALL form -
If new primary site is other than AML/MDS/ALL,
submit ECOG Second Primary Form)
Notice Of Recurrence
Date of most recent physical exam (this reporting
period)
Has the patient had a documented clinical
assessment for this cancer?
No (No)
Unknown (Unknown)
Yes (Yes)
If unknown, please explain
Method of Evaluation (If yes,)
Chest X-ray (Chest x-ray)
Ct Scan (CT scan)
Date of Chest X-Ray or CT scan
Has the patient developed a recurrence that has
not been previously reported
No (No)
Unknown (Unknown)
Yes (Yes)
If unknown, please explain
Date of definitive recurrence diagnosis
Site of recurrence (s Mark with an 'X' all that
apply)
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Central Nervous System (Central
nervous system)
Liver (Liver)
Lung (Lung)
Other (Other)
Skeletal (Skeletal)
Subcutaneous And Lymph Node
Recurrence (Subcutaneous and lymph
node recurrence)
Unknown (Unknown)
Explain other or unknown
What was the first indication of recurrence
Clinical Evaluation (Clinical evaluation)
Development Of Symptoms
(Development of symptoms)
Other (Other)
Routine Radiologic Evaluation (Routine
radiologic evaluation)
Other, specify
If Patient Has Recurrent Disease
Biopsy done
Yes
No
Date of Biopsy (If yes)
Biopsy Result
Atypical/indeterminate
(Atypical/indeterminate)
Benign (Benign)
Malignant (Malignant)
Other (Other)
Other, specify
Section Vi - Non-protocol Therapy Prior To
Recurrence
Has the patient received any non-protocol cancer
therapy prior to first recurrence
No (No)
Unknown (Unknown)
Yes (Yes)
Section Vii - Treatment For First
Recurrence
Treatment given for first recurrence (Please mark
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an ¿X¿ for all treatment given for first recurrence)
Bevacizumab (Bevacizumab)
Angiogenesis Inhibitor (Other anti-
angiogenesis therapy)
Biologic/targeted Therapy (Other
Biologic/targeted therapy)
Chemotherapy (Other Chemotherapy
Regimens)
Other Therapy (Other Therapy)
Platinum-based Chemotherapy
(Platinum-based Chemotherapy)
Radiation Therapy (RT)
Surgical Procedure (Surgical Procedure)
Specify drugs
Specify drugs
Specify drugs
Specify
Comments
Investigator Signature
Investigator Signature Date
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ECOG-E1505 Long-Term Follow-up Form
NCT00324805
ECOG-E1505 Long-Term Follow-up Form NCT00324805 
Chemotherapy With or Without Bevacizumab in Treating
Patients With Stage IB, Stage II, or Stage IIIA Non-Small
Lung Cancer That Was Removed By Surgery
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=076D113B-
20F5-4CB7-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/10724
ECOG-E1505 Long-Term Follow-up
Form NCT00324805
Header
ECOG Protocol Number
ECOG Patient ID
DCI Name
Registration Step
Patient demographics
ECOG Protocol Number
Patient Initials (Last, First)
ECOG Patient ID
Participating Group Protocol Number
Institution/Affiliate
Participating Group Patient ID
Data amendment
Please mark an 'X' if data have been amended
(Please circle amended items in red)
Date data amended (M D Y)
Off protocol treatment period
Off Treatment Report Period (since initial
registration)
9 Years (108 Months Post-Registration)
1 / 5
12 Months (12 Months Post Registration)
10 Years (120 Months Post-Registration)
15 Months (15 Months Post Registration)
18 Months (18 Months Post Registration)
21 Months Post Registration (21 Months
Post Registration)
2 Years (24 Months Post Registration)
3 Months (3 Months Post Registration)
30 Months (30 Months Post Registration)
3 Years (36 Months Post Registration)
42 Months (42 Months Post Registration)
4 Years (48 Months Post Registration)
54 Months (54 Months Post Registration)
6 Months (6 Months Post Registration)
5 Years (60 Months Post Registration)
6 Years (72 Months Post-Registration)
84 Months Post Registration (84 Months
Post-Registration)
9 Months (9 Months Post Registration)
8 Years (96 Months Post-Registration)
Vital Status
Patient Vital Status
Alive (Alive)
Dead (Dead)
Date of last contact or death (M D Y)
Primary Cause of Death (if applicable)
Due To Other Cause (Due to other
cause)
Due To Protocol Treatment (Due to
protocol treatment)
Due To This Disease (Due to this
disease)
Unknown (Unknown)
Describe cause of death
Section II - Reporting Period
Reporting Period Start Date (M D Y)
Reporting Period End Date (M D Y)
Notice Of New Primary (including Second
Colon Primary)
Has a new primary cancer or MDS been
diagnosed that has not been previously reported
No (No)
Unknown (Unknown)
Yes (Yes)
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Site of New Primary (s)
Disease Follow-up Status
Has the patient had a documented clinical
assessment for this cancer (since submission of
the previous follow-up form)
No (No)
Unknown (Unknown)
Yes (Yes)
If unknown, please explain
Date of most recent physical exam
Date of most recent physical exam
Has the patient developed a recurrence that has
not been previously reported
No (No)
Unknown (Unknown)
Yes (Yes)
If unknown, please explain
Date of definitive recurrence diagnosis
Disease Recurrence Date (If yes)
What was the first indication of recurrence
Clinical Evaluation (Clinical evaluation)
Development Of Symptoms
(Development of symptoms)
Other (Other)
Routine Radiologic Evaluation (Routine
radiologic evaluation)
Other, specify
Site of recurrence
Central Nervous System (Central
nervous system)
Liver (Liver)
Lung (Lung)
Other (Other)
Skeletal (Skeletal)
Subcutaneous And Lymph Node
Recurrence (Subcutaneous and lymph
node recurrence)
Unknown (Unknown)
Explain other or unknown
3 / 5
ECOG-E1505 Long-Term Follow-up Form NCT00324805
Biopsy done
Yes
No
Date of Biopsy (If yes submit copy of pathology
report with source documentation cover sheet
attached)
Biopsy Result
Atypical/indeterminate
(Atypical/indeterminate)
Benign (Benign)
Malignant (Malignant)
Other (Other)
Other, specify
Adverse Events
Has the patient experienced any severe long
term toxicity that has not been previously
reported (prior to diagnosis of
progression/relapse)
No (No)
Unknown (Unknown)
Yes (Yes)
Non-protocol Therapy
Has the patient received any non-protocol cancer
therapy prior to first recurrence (not previously
reported)
No (No)
Unknown (Unknown)
Yes (Yes)
Treatment For First Recurrence
Treatment given for first recurrence
Bevacizumab (Bevacizumab)
Angiogenesis Inhibitor (Other anti-
angiogenesis therapy)
Biologic/targeted Therapy (Other
Biologic/targeted therapy)
Chemotherapy (Other Chemotherapy
Regimens)
Other Therapy (Other Therapy)
Platinum-based Chemotherapy
(Platinum-based Chemotherapy)
Radiation Therapy (RT)
Surgical Procedure (Surgical Procedure)
Specify
Specify drugs (Other Chemotherapy Regimens)
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Specify drugs (Other anti-angiogenesis therapy)
Specify drugs (Other Biologic/targeted therapy)
Comments
Investigator Signature
Investigator Signature Date
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E2603 Long-Term Follow-up Form
NCT00110019
E2603 Long-Term Follow-up Form NCT00110019
Carboplatin and Paclitaxel With or Without Sorafenib in
Treating Patients With Unresectable Stage III or Stage IV
Melanoma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=E759E488-
07DC-0DC2-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/10725
E2603 Long-Term Follow-up Form
NCT00110019
Header
ECOG Protocol Number
ECOG Patient ID
DCI Name
Registration Step
Patient demographics
Patient Initials
ECOG Protocol Number
ECOG Patient ID
Participating Group Protocol Number
Institution/Affiliate
Participating Group Patient ID
Off Treatment Report Period (since registration)
12 Months (12 Months Post Registration)
15 Months (15 Months Post Registration)
18 Months (18 Months Post Registration)
21 Months Post Registration (21 Months
Post Registration)
2 Years (24 Months Post Registration)
3 Months (3 Months Post Registration)
30 Months (30 Months Post Registration)
3 Years (36 Months Post Registration)
42 Months (42 Months Post Registration)
4 Years (48 Months Post Registration)
54 Months (54 Months Post Registration)
6 Months (6 Months Post Registration)
5 Years (60 Months Post Registration)
1 / 4
9 Months (9 Months Post Registration)
Data amendment
Please mark an 'X' if data have been amended.
Date data amended
Section I - Vital Status
Patient Vital Status
Alive (Alive)
Dead (Dead)
Date of last contact or death
Primary Cause of Death (if applicable)
Due To Other Cause (Due to other
cause)
Due To Protocol Treatment (Due to
protocol treatment)
Due To This Disease (Due to this
disease)
Unknown (Unknown)
Describe cause of death
Section Ii - Reporting Period
Reporting Period Start Date
Reporting Period End Date
Section Iii - Disease Follow-up Status
Has the patient had a documented clinical
assessment for this cancer (since submission of
the previous follow-up form)
No (No)
Unknown (Unknown)
Yes (Yes)
Explain (If unknown, please)
Date of last clinical assessment (If yes)
Has the patient developed a first progression that
has not been previously reported (or relapse)
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No (No)
Unknown (Unknown)
Yes (Yes)
Explain (If unknown, please)
Date of progression (If yes,)
Site of progression (s)
Did a physician make a formal diagnosis of
progressive disease
No (No)
Unknown (Unknown)
Yes (Yes)
Specify basis of progression (If no or unknown)
Section Iv - Notice Of New Primary
Has a new primary cancer or MDS been
diagnosed that has not been previously reported
No (No)
Unknown (Unknown)
Yes (Yes)
Site of new primary (s)
Section V - Adverse Events
Has the patient experienced any severe long
term toxicity that has not been previously
reported (prior to diagnosis of
progression/relapse)
No (No)
Unknown (Unknown)
Yes (Yes)
Section Vi - Non-protocol Therapy Prior To
Progression
Has the patient received any non-protocol cancer
therapy prior to first progression (not previously
reported)
No (No)
Unknown (Unknown)
Yes (Yes)
Comments
Comments
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Investigator Signature
Investigator Signature Date
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E1A05 Long-Term Follow-up Form - Form
2864v2 NCT00522392
E1A05 Long-Term Follow-up Form - Form 2864v2
NCT00522392 
Bortezomib and Dexamethasone With or Without
Lenalidomide in Treating Patients With Multiple Myeloma
Previously Treated With Dexamethasone
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=32CCB0B7-
FFCD-3284-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/10726
E1A05 Long-Term Follow-up Form -
Form 2864v2 NCT00522392
Header
DCI Name
Registration Step (Place ID Label Here)
Patient Initials (Last, First)
ECOG Protocol Number
ECOG Protocol Number
ECOG Patient ID
ECOG Patient ID
Participating Group Protocol Number
Participating Group Patient ID
Institution/Affiliate
Off Treatment Report Period (since registration)
9 Years (108 months post registration)
12 Months (12 Months Post Registration)
10 Years (120 months post registration)
15 Months (15 Months Post Registration)
18 Months (18 Months Post Registration)
21 Months Post Registration (21 Months
Post Registration)
2 Years (24 Months Post Registration)
3 Months (3 Months Post Registration)
30 Months (30 Months Post Registration)
3 Years (36 Months Post Registration)
42 Months (42 Months Post Registration)
4 Years (48 Months Post Registration)
54 Months (54 Months Post Registration)
6 Months (6 Months Post Registration)
5 Years (60 Months Post Registration)
6 Years (72 Months Post Registration)
1 / 4
84 Months Post Registration (84 Months
Post Registration)
9 Months (9 Months Post Registration)
8 Years (96 months post registration)
Data amendment
Please mark an 'X' if data have been amended.
(Please circle amended items in red)
Date data amended (s M D Y)
Vital Status
Patient Vital Status
Alive (Alive)
Dead (Dead)
Date of Last Contact or Death (mm/dd/yyyy)
Primary Cause of Death (if applicable)
Due To Other Cause (Due to other
cause)
Due To Protocol Treatment (Due to
protocol treatment)
Due To This Disease (Due to this
disease)
Unknown (Unknown)
Describe cause of death
Section Ii - Reporting Period
Report Period Start Date
Report Period End Date
Section Iv - Notice Of New Primary
Has a new primary cancer or MDS been
diagnosed that has not been previously reported?
No (No)
Unknown (Unknown)
Yes (Yes)
Site of new primary (s - If diagnosis of new
primary cancer including AML/MDS, submit
ECOG Second Primary Form.)
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Section Iii - Disease Follow-up Status
Has the patient had a documented clinical
assessment for this cancer (this reporting period)
No (No)
Unknown (Unknown)
Yes (Yes)
If unknown, please explain
Date of last clinical assessment (If yes: - Submit
E1A05 Follow-up Disease Assessment Form)
Has the patient developed a first progression that
has not been previously reported?
No (No)
Unknown (Unknown)
Yes (Yes)
If unknown, please explain
Date of progression (If yes, - relapse)
Site(s) of progression (relapse)
Did a physician make a formal diagnosis of
progression?
No (No)
Unknown (Unknown)
Yes (Yes)
Specify basis of progression (If no or unknown)
Section V - Adverse Events
Has the patient experienced any severe (Grade =
3) long term toxicity that has not been previously
reported? (prior to diagnosis of
progression/relapse - NOTE: See section 5.2 of
the protocol for expedited reporting requirements
for events occurring greater than 30 days past the
last dose of protocol treatment - If yes, submit
E1A05 Adverse Event Form.)
No (No)
Unknown (Unknown)
Yes (Yes)
Section Vi - Non-protocol Therapy Prior To
Progression
Has the patient received any non-protocol cancer
therapy prior to first recurrence (not previously
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reported - NOTE: Only the first occurrence of
non-protocol therapy should be reported)
No (No)
Unknown (Unknown)
Yes (Yes)
Comments
Investigator Signature
Investigator Signature Date
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E1A06 Long-Term Follow-up Form
NCT00602641
E1A06 Long-Term Follow-up Form NCT00602641 
Melphalan, Prednisone, and Thalidomide or Lenalidomide
in Treating Patients With Newly Diagnosed Multiple
Myeloma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=40A52AA0-
223E-3572-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/10727
E1A06 Long-Term Follow-up Form
NCT00602641
Header
ECOG Protocol Number
ECOG Protocol Number
ECOG Patient ID
ECOG Patient ID
DCI Name
Registration Step (Place ID Label Here)
Patient Initials (Last, First)
Participating Group Protocol Number
Participating Group Patient ID
Institution/Affiliate
Off Treatment Report Period (since registration to
step 1)
9 Years (108 months post registration)
12 Months (12 Months Post Registration)
10 Years (120 months post registration)
15 Months (15 Months Post Registration)
18 Months (18 Months Post Registration)
21 Months Post Registration (21 Months
Post Registration)
2 Years (24 Months Post Registration)
3 Months (3 Months Post Registration)
30 Months (30 Months Post Registration)
3 Years (36 Months Post Registration)
42 Months (42 Months Post Registration)
4 Years (48 Months Post Registration)
54 Months (54 Months Post Registration)
6 Months (6 Months Post Registration)
5 Years (60 Months Post Registration)
1 / 4
6 Years (72 Months Post Registration)
84 Months Post Registration (84 Months
Post Registration)
9 Months (9 Months Post Registration)
8 Years (96 months post registration)
Data amendment
Please mark an 'X' if data have been amended.
Date data amended
Vital Status
Patient Vital Status
Alive (Alive)
Dead (Dead)
Date of Last Contact or Death (mm/dd/yyyy)
Primary Cause of Death (if applicable)
Due To Other Cause (Due to other
cause)
Due To Protocol Treatment (Due to
protocol treatment)
Due To This Disease (Due to this
disease)
Unknown (Unknown)
Describe cause of death
Section Ii - Reporting Period
Report Period Start Date
Report Period End Date
Section Iv - Notice Of New Primary
Has a new primary cancer or MDS been
diagnosed that has not been previously reported?
No (No)
Unknown (Unknown)
Yes (Yes)
Site of new primary (s)
Section Iii - Disease Follow-up Status
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Has the patient had a documented clinical
assessment for this cancer (since submission of
the previous follow-up form?)
No (No)
Unknown (Unknown)
Yes (Yes)
If unknown, please explain
Date of last clinical assessment (If yes:)
Has the patient developed a first progression that
has not been previously reported? (or relapse)
No (No)
Unknown (Unknown)
Yes (Yes)
If unknown, please explain
Date of progression (If yes,)
Site(s) of progression
Did a physician make a formal diagnosis of
progression?
No (No)
Unknown (Unknown)
Yes (Yes)
Specify basis of progression (If no or unknown)
Section V - Adverse Events
Has the patient experienced any severe (Grade =
3) long term toxicity that has not been previously
reported? (prior to diagnosis of
progression/relapse)
No (No)
Unknown (Unknown)
Yes (Yes)
Section Vi - Non-protocol Therapy Prior To
Progression
Has the patient received any non-protocol cancer
therapy prior to first recurrence (not previously
reported)
No (No)
Unknown (Unknown)
Yes (Yes)
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Comments
Comments
Investigator Signature
Investigator Signature Date
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E4A08 Long-Term Follow-up Form
NCT01078454
E4A08 Long-Term Follow-up Form NCT01078454 
Melphalan and Dexamethasone With or Without
Bortezomib in Treating Patients With Previously Untreated
Systemic Light-Chain Amyloidosis
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=7BCCF644-
B466-7CED-E040-BB89AD433815
All rights reserved. Please visit https://medical-data-
models.org/forms/10728
E4A08 Long-Term Follow-up Form
NCT01078454
Header
ECOG Protocol Number
ECOG Protocol Number
ECOG Patient ID
ECOG Patient ID
DCI Name
Registration Step (Place ID Label Here)
Patient Initials (Last, First)
Participating Group Protocol Number
Participating Group Patient ID
Institution/Affiliate
Off Treatment Report Period (since registration to
step 1)
12 Months (12 Months Post Registration)
15 Months (15 Months Post Registration)
18 Months (18 Months Post Registration)
21 Months Post Registration (21 Months
Post Registration)
2 Years (24 Months Post Registration)
3 Months (3 Months Post Registration)
30 Months (30 Months Post Registration)
3 Years (36 Months Post Registration)
42 Months (42 Months Post Registration)
4 Years (48 Months Post Registration)
54 Months (54 Months Post Registration)
6 Months (6 Months Post Registration)
5 Years (60 Months Post Registration)
9 Months (9 Months Post Registration)
1 / 3
Data amendment
Please mark an 'X' if data have been amended.
Date data amended
Vital Status
Patient's Vital Status
Alive (Alive)
Dead (Dead)
Date of Last Contact or Death (mm/dd/yyyy)
Primary Cause of Death (if applicable)
Due To Other Cause (Due to other
cause)
Due To Protocol Treatment (Due to
protocol treatment)
Due To This Disease (Due to this
disease)
Unknown (Unknown)
Describe cause of death
Section Ii - Reporting Period
Report Period Start Date
Report Period End Date
Section Iv - Notice Of New Primary
Has a new primary cancer or MDS been
diagnosed that has not been previously reported?
No (No)
Unknown (Unknown)
Yes (Yes)
Site of new primary (s)
Section Iii - Disease Follow-up Status
Has the patient had a documented clinical
assessment for this cancer (since submission of
the previous follow-up form?)
No (No)
Unknown (Unknown)
Yes (Yes)
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If unknown, please explain
Date of last clinical assessment (If yes:)
Has the patient developed a first progression that
has not been previously reported? (or relapse)
No (No)
Unknown (Unknown)
Yes (Yes)
If unknown, please explain
Date of progression (If yes,)
Site(s) of progression
Did a physician make a formal diagnosis of
progression?
No (No)
Unknown (Unknown)
Yes (Yes)
Specify basis of progression (If no or unknown)
Section V - Adverse Events
Has the patient experienced (prior to diagnosis of
progression/relapse) any reportable long term
toxicity that has not been previously reported?
(prior to diagnosis of progression/relapse)
No (No)
Unknown (Unknown)
Yes (Yes)
Section Vi - Non-protocol Therapy Prior To
Progression
Has the patient received any non-protocol cancer
therapy prior to first progression (not previously
reported)
No (No)
Unknown (Unknown)
Yes (Yes)
Comments
Investigator Signature
Investigator Signature Date
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CALGB: 30801 Treatment Form
NCT01041781
CALGB: 30801 Treatment Form NCT01041781 
Gemcitabine Hydrochloride or Pemetrexed Disodium and
Carboplatin With or Without Celecoxib in Treating Patients
With Advanced Non-Small Cell Lung Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=6AF26CA3-
DE27-EEE0-E040-BB89AD436D54
All rights reserved. Please visit https://medical-data-
models.org/forms/10729
CALGB: 30801 Treatment Form
NCT01041781
Header
CALGB Form
CALGB Study No.
CALGB Patient ID
Reporting Period Start Date (MM DD YYYY)
Reporting Period End Date (MM DD YYYY)
Are data amended
Yes
No
Patient demographics
Patient Initials (Last, First Middle)
Patient Hospital No.
Institution/Affiliate
Participating Group
Participating Group Study No.
Participating Group Patient ID
Patient Data
Cycle Number
Patient Weight (kg on Day 1 of cycle)
1 / 3
Serum creatinine (mg/dL)
First Treatment (cycles 1 ¿ 6)
Agent
Agent Total Dose (mg)
Dose Modifications
Were there any dose modifications or
additions/omissions to protocol treatment?
No (No)
Yes, Planned (i.e., The Treatment Was
Changed According To Protocol
Guidelines) (Yes, planned)
Yes, Unplanned (i.e., The Treatment
Change Was Not Part Of Protocol
Guidelines) (Yes, unplanned)
Reason Treatment Ended
Date of Last dose for this reporting period (MM
DD YYYY)
Off Treatment Reason (only applicable if protocol
therapy has been discontinued permanently Mark
one with an X.)
Adverse Event/side Effects/complications
(Adverse Event/Side
Effects/Complications)
Alternative Therapy (Alternative therapy)
Death On Study (Death on study)
Disease Progression, Relapse During
Active Treatment (Disease progression,
relapse during active treatment)
Other (Other)
Patient Off-treatment For Other
Complicating Disease (Patient off-
treatment for other complicating disease)
Patient Withdrawal Or Refusal After
Beginning Protocol Therapy (Patient
withdrawal/refusal after beginning
protocol therapy)
Patient Withdrawal Or Refusal Before
Beginning Protocol Therapy (Patient
withdrawal/refusal prior to beginning
protocol therapy)
Alternative therapy, specify
Other specify
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Overall Response
Completed by (Last name, First name)
Date Form Originally Completed (MM DD YYYY)
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E3A06 Long-Term Follow-up Form
NCT01169337
E3A06 Long-Term Follow-up Form NCT01169337 
Lenalidomide or Observation in Treating Patients With
Asymptomatic High-Risk Smoldering Multiple Myeloma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=870A090F-
65D8-A152-E040-BB89AD430551
All rights reserved. Please visit https://medical-data-
models.org/forms/10730
E3A06 Long-Term Follow-up Form
NCT01169337
Header
ECOG Protocol Number
ECOG Protocol Number
ECOG Patient ID
ECOG Patient ID
DCI Name
Registration Step (Place ID Label Here)
Patient Initials (Last, First)
Participating Group Protocol Number
Participating Group Patient ID
Institution/Affiliate
Off Treatment or Off Observation Report Period
(since registration - Please refer to Off-Treatment
Report Period Assignment Tool located at
http://www.ecog.com/ecoginst/LTFU.html for
coding.)
9 Years (108 months post registration)
12 Months (12 Months Post Registration)
10 Years (120 months post registration)
15 Months (15 Months Post Registration)
18 Months (18 Months Post Registration)
21 Months Post Registration (21 Months
Post Registration)
2 Years (24 Months Post Registration)
3 Months (3 Months Post Registration)
30 Months (30 Months Post Registration)
3 Years (36 Months Post Registration)
42 Months (42 Months Post Registration)
4 Years (48 Months Post Registration)
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54 Months (54 Months Post Registration)
6 Months (6 Months Post Registration)
5 Years (60 Months Post Registration)
6 Years (72 months post registration)
84 Months Post Registration (84 months
post registration)
9 Months (9 Months Post Registration)
8 Years (96 months post registration)
Data amendment
Please mark an 'X' if data have been amended.
Date data amended
Vital Status
Patient's Vital Status
Alive (Alive)
Dead (Dead)
Date of Last Contact or Death (mm/dd/yyyy)
Primary Cause of Death (if applicable)
Due To Other Cause (Due to other
cause)
Due To Protocol Treatment (Due to
protocol treatment)
Due To This Disease (Due to this
disease)
Unknown (Unknown)
Describe cause of death
Section Ii - Reporting Period
Reporting Period Start Date (M D Y)
Reporting Period End Date (M D Y)
Section Iv - Notice Of New Primary
Has a new primary cancer or MDS been
diagnosed that has not been previously reported?
No (No)
Unknown (Unknown)
Yes (Yes)
Site of new primary (s - If new primary site is
AML/MDS/ALL, submit NCI AML/MDS/ALL form -
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If new primary site is other than AML/MDS/ALL,
submit ECOG Second Primary Form)
Section Iii - Disease Follow-up Status
Has the patient had a documented clinical
assessment for this cancer (this reporting period)
No (No)
Unknown (Unknown)
Yes (Yes)
If unknown, please explain
Date of last clinical assessment (If yes: - Submit
E3A06 Follow-Up Disease Assessment Form and
E3A06 Source Document Tracking Coversheet)
Has the patient developed a first progression that
has not been previously reported? (or relapse -
Notice of Progression)
No (No)
Unknown (Unknown)
Yes (Yes)
If unknown, please explain
Date of progression (If yes, - relapse - Submit
E3A06 Follow-Up Disease Assessment Form and
E3A06 Source Document Tracking Coversheet)
Site(s) of progression
Did a physician make a formal diagnosis of
progression?
No (No)
Unknown (Unknown)
Yes (Yes)
Specify basis of progression (If no or unknown)
Section V - Adverse Events
Has the patient experienced (prior to diagnosis of
progression) any reportable long term toxicity that
has not been previously reported (NOTE: See
section 5.2 of the protocol for expedited reporting
requirements for events occurring greater than 30
days past the last dose of protocol treatment.)
No (No)
Unknown (Unknown)
Yes (Yes)
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Section Vi - Non-protocol Therapy Prior To
Progression
Has the patient received any non-protocol cancer
therapy prior to first progression (not previously
reported - NOTE: Only the first occurrence of
non-protocol therapy should be reported)
No (No)
Unknown (Unknown)
Yes (Yes)
Section Vii - Stem Cell Transplant
Was stem cell transplant done
No (No)
Unknown (Unknown)
Yes (Yes)
Comments
Investigator Signature
Investigator Signature Date
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E1609 Treatment Form - Arm B
NCT01274338
E1609 Treatment Form - Arm B NCT01274338
Ipilimumab or High-Dose Interferon Alfa-2b in Treating
Patients With High-Risk Stage III or Stage IV Melanoma
That Has Been Removed by Surgery
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=97E81F9F-
46E0-261A-E040-BB89AD434355
All rights reserved. Please visit https://medical-data-
models.org/forms/10732
E1609 Treatment Form - Arm B
NCT01274338
Header module
ECOG Protocol Number
Patient Initials (Last, First)
ECOG Patient ID
Participating Group Protocol Number
Institution/Affiliate
Participating Group Patient ID
Patient demographics
ECOG Protocol Number
ECOG Patient ID
DCI Name
Registration Step (1)
Data amendment
Please mark an 'X' if data have been amended.
(Please circle amended items in red)
Date data amended (s - mm/dd/yyyy)
On Treatment Reporting Period
On Treatment Reporting Period
Week 1 (Week 1)
Week 13 (Week 13)
Week 19 (Week 19)
1 / 4
Week 25 (Week 25)
Week 31 (Week 31)
Week 37 (Week 37)
Week 43 (Week 43)
Week 49 (Week 49)
Week 5 (Week 5)
Week 9 (Week 9)
Reporting Period
Reporting Period Start Date (mm/dd/yyyy)
Reporting Period End Date (mm/dd/yyyy)
Vital Status
Patient's Vital Status
Alive (Alive)
Dead (Dead)
Date of last contact or death (mm/dd/yyyy)
Primary Cause of Death
Due To Other Cause (Due to other
cause)
Due To Protocol Treatment (Due to
protocol treatment)
Due To This Disease (Due to this
disease)
Unknown (Unknown)
Describe cause of death
Patient Characteristics
Weight (Day 1 of this reporting period)
Body Surface Area (BSA Day 1 of this reporting
period)
Therapy Administered - Section I
Agent Name
Was the agent administered during this reporting
period? (Interferon Alfa)
Yes
No
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Date Agent Administered (If yes:)
Agent Total Dose (MU)
Were there any dose modifications or
additions/omissions to protocol treatment? (this
reporting period)
No (No)
Yes, Both Planned And Unplanned (Yes,
both planned and unplanned)
Yes, Planned (i.e., The Treatment Was
Changed According To Protocol
Guidelines) (Yes, planned)
Yes, Unplanned (i.e., The Treatment
Change Was Not Part Of Protocol
Guidelines) (Yes, unplanned)
Therapy Administered - Section I
Agent Name
Was the agent administered during this reporting
period? (Interferon Alfa)
Yes
No
Date of First dose for this reporting period
Date of Last dose for this reporting period
Agent Total Dose (MU)
Were there any dose modifications or
additions/omissions to protocol treatment? (this
reporting period)
No (No)
Yes, Both Planned And Unplanned (Yes,
both planned and unplanned)
Yes, Planned (i.e., The Treatment Was
Changed According To Protocol
Guidelines) (Yes, planned)
Yes, Unplanned (i.e., The Treatment
Change Was Not Part Of Protocol
Guidelines) (Yes, unplanned)
Did the patient complete Patient Interferon Diary
Yes
No
How much of the agent remained at the end of
the reporting period (Interferon Alfa - MU)
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Section E: Non-protocol Therapy
Was any non-protocol therapy given during
protocol treatment (not previously reported)?
Yes
No
Comments
Investigator Signature
Investigator Signature Date
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CALGB: 80303 MEDICAL RESOURCE UTILIZATION FORM
FOR REGISTERING INSTITUTIONS NCT00088894
CALGB: 80303 MEDICAL RESOURCE UTILIZATION
FORM FOR REGISTERING INSTITUTIONS
NCT00088894
Gemcitabine With or Without Bevacizumab in Treating
Patients With Locally Advanced or Metastatic Pancreatic
Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=D793AA94-
9FDA-0B24-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/10733
CALGB: 80303 MEDICAL
RESOURCE UTILIZATION FORM
FOR REGISTERING
INSTITUTIONS NCT00088894
Header
CALGB Study No
CALGB Patient ID
From
To
Are data amended?
Yes
No
To study week number
Patient demographics
Patient Initials
Participating Group
Patient Hospital No.
Participating Group Protocol No.
Institution/Affiliate
Participating Group Patient ID
Hospitalization And Emergency Room
Data
1 / 3
Was the patient hospitalized or seen in an
Emergency Room during this time period?
Yes
No
Name of hospital/ER
Number of days in ICU
Date of evaluation/admission
Date of discharge
Outpatient Data
Was the patient seen as an outpatient during this
reporting period?
Yes
No
specify number of visits
Evaluation method
Ct Scan (CT Scan)
Mri (MRI)
Other, Specify (Other, specify)
Pet Scan (PET)
Ultrasound (Ultrasound)
Other, specify
Number of tests
Operating Room Data
Procedure Performed Type
Colonoscopy (Colonoscopy)
Endoscopic Retrograde
Cholangiopancreatography (Endoscopic
Retrograde Cholangiopancreatography)
Removal Of Long-lasting Internal Iv
Catheter To Deliver Medicine (Indwelling
IV catheter - placement)
Indwelling IV catheter - removal
(Indwelling IV catheter - removal)
Initiation Of Intravenous Nutrition
(Initiation of intravenous nutrition)
Nerve Block Or Placement Of Internal
Catheter To Treat Pain (Pain alleviation -
nerve block or placement of indwelling
catheter)
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REGISTERING INSTITUTIONS NCT00088894
Placement Of Biliary Drainage Tube Or
Stent In Bile Ducts (Placement of biliary
drainage tube or stent in biliary tree)
Surgery For Intestinal
Obstruction/bypass (Surgery - intestinal
obstruction/bypass)
Other Major Surgery, Specify (Surgery -
other specify)
Placement Of Feeding Tube Or Tube To
Drain Intestines (Tube placement -
feeding or intestinal drainage)
Upper Gastrointestinal Endoscopy Or
Placement Of Stent In The Upper
Intestines (Upper gastrointestinal
endoscopy)
Surgery - other specify
Number of tests
Non-protocol Chemotherapy Data
Did the patient receive any off-protocol
chemotherapy during this time period?
Yes
No
Specify name
No. of sessions
Completed by
Date form completed
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E3805 Long-Term Follow-up Form
NCT00309985
E3805 Long-Term Follow-up Form NCT00309985
Androgen Ablation Therapy With or Without Chemotherapy
in Treating Patients With Metastatic Prostate Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=F96E0588-
18D2-4903-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/10734
E3805 Long-Term Follow-up Form
NCT00309985
Header
ECOG Protocol Number
ECOG Patient ID
DCI Name
Registration Step
Patient demographics
Patient Initials
ECOG Protocol Number
ECOG Patient ID
Participating Group Protocol Number
Institution/Affiliate
Participating Group Patient ID
Off protocol treatment period
Off Treatment Report Period (since initial
registration)
9 Years (108 Months Post-Registration)
12 Months (12 Months Post Registration)
10 Years (120 Months Post-Registration)
15 Months (15 Months Post Registration)
18 Months (18 Months Post Registration)
21 Months Post Registration (21 Months
Post Registration)
2 Years (24 Months Post Registration)
3 Months (3 Months Post Registration)
30 Months (30 Months Post Registration)
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3 Years (36 Months Post Registration)
42 Months (42 Months Post Registration)
4 Years (48 Months Post Registration)
54 Months (54 Months Post Registration)
6 Months (6 Months Post Registration)
5 Years (60 Months Post Registration)
6 Years (72 Months Post-Registration)
84 Months Post Registration (84 Months
Post-Registration)
9 Months (9 Months Post Registration)
8 Years (96 Months Post-Registration)
Data amendment
Please mark an 'X' if data have been amended.
Date data amended
Vital Status
Patient's Vital Status
Alive (Alive)
Dead (Dead)
Date of last contact or death
Primary Cause of Death (if applicable)
Due To Other Cause (Due to other
cause)
Due To Protocol Treatment (Due to
protocol treatment)
Due To This Disease (Due to this
disease)
Unknown (Unknown)
Describe cause of death
Section II - Reporting Period
Reporting Period Start Date
Reporting Period End Date
Notice Of New Primary (including Second
Colon Primary)
Has a new primary cancer or MDS been
diagnosed that has not been previously reported?
(If new primary site is AML/MDS, submit NCI
AML/MDS form If new primary site is other than
AML/MDS, submit ECOG Second Primary Form)
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No (No)
Unknown (Unknown)
Yes (Yes)
Site of New Primary (s)
Section Ii-therapy Administered Androgen
Deprivation
Did the patient receive androgen suppression
Yes
No
Mark an 'X' if continuing
Start date of Androgen Deprivation (If yes M D Y)
Did patient have medical castration
Yes
No
Did patient have surgical castration
Yes
No
Did patient have combined androgen blockade for
longer than 30 days
Yes
No
Treatment For Hormone Refractory
Disease
Date of first therapy for Hormone Refractory
Prostate Cancer (HRPC)
Was therapy given for Hormone Refractory
Prostate Cancer this reporting period
No (No)
Unknown (Unknown)
Yes (Yes)
Date of first therapy for hormone refractory
prostate cancer this reporting period (M D Y
HRPC)
Chemotherapy-Docetaxel
No (No)
Unknown (Unknown)
Yes (Yes)
Chemotherapy-Other
No (No)
3 / 5
E3805 Long-Term Follow-up Form NCT00309985
Unknown (Unknown)
Yes (Yes)
Other, specify
Hormonal therapy
No (No)
Unknown (Unknown)
Yes (Yes)
Other, specify
Immunotherapy/BRM
Yes
No
Immunotherapy/BRM-Specify
Radiotherapy
No (No)
Unknown (Unknown)
Yes (Yes)
Other therapy (including investigational agents or
herbal /complementary therapies given by
physician with therapeutic intent)
No (No)
Unknown (Unknown)
Yes (Yes)
Specify (including investigational agents or herbal
/complementary therapies given by physician with
therapeutic intent)
Disease Follow-up Status
Has the patient had a documented assessment
for this cancer (serological this reporting period)
No (No)
Unknown (Unknown)
Yes (Yes)
If unknown, explain (please)
Date of last assessment (serological)
Has the patient developed a first progression (or
relapse) that has not been previously reported?
(clinical or serological)
No (No)
Unknown (Unknown)
Yes (Yes)
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If unknown, please explain
Date of Progression (relapse)
Sites of Progression
Did a physician make a formal diagnosis of
progressive disease? (HRPC)
No (No)
Unknown (Unknown)
Yes (Yes)
Specify basis of progression (If no or unknown)
Post Hormone Refractory Disease
Did the patient experience clinical progression?
(not previously reported)
No (NO)
Unknown (Unknown)
Yes (YES)
Date of Last Clinical Assessment (M D Y)
Adverse Events
Has the patient experienced any severe long
term toxicity that has not been previously
reported (prior to diagnosis of
progression/relapse)
No (No)
Unknown (Unknown)
Yes (Yes)
Non-protocol Therapy
Has the patient received any non-protocol cancer
therapy prior to first progression (not previously
reported)
No (No)
Unknown (Unknown)
Yes (Yes)
Comments
Investigator Signature
Investigator Signature Date
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E1805 Treatment Form
E1805 Treatment Form
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=0F6F044E-
DE71-412E-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/10735
E1805 Treatment Form
Patient demographics
Patient Initials
ECOG Protocol Number
ECOG Patient ID
Participating Group Protocol Number
Participating Group Patient ID
Institution/Affiliate
Assessment of Chemotherapy
DCI Name
Registration Step
On Treatment Report Period (Choose one x -
NOTE: If the duration of the final treatment period
is less than the report period intervals listed
below, choose the next highest report period.)
> Cycle 22 Step 2 (> Cycle 22 Step 2)
Cycle 15 Step 2 (Cycle 15 Step 2)
Cycle 16-step 2 (Cycle 16-Step 2)
Cycle 17 Step 2 (Cycle 17 Step 2)
Cycle 18-step 2 (Cycle 18-Step 2)
Cycle 19 Step 2 (Cycle 19 Step 2)
Cycle 20-step 2 (Cycle 20-Step 2)
Cycle 21 Step 2 (Cycle 21 Step 2)
Cycle 22-step 2 (Cycle 22-Step 2)
Specify Cycle
Data amendment
Please mark an 'X' if data have been amended.
(Please circle amended items in red)
Date data amended (s - MM/DD/YYYY)
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Reporting period
Reporting Period Start Date (MM/DD/YYYY)
Reporting Period End Date (MM/DD/YYYY)
On Treatment
Vital Status (Provide the most recent survival
status and date.)
Alive (Alive)
Dead (Dead)
Date of Last Contact or Death (MM/DD/YYYY)
Primary Cause of Death (if applicable)
Due To Other Cause (Due to other
cause)
Due To Protocol Treatment (Due to
protocol treatment)
Due To This Disease (Due to this
disease)
Unknown (Unknown)
Describe cause of death
Therapy Administered
Was the agent administered during this reporting
period?
Yes
No
Date of first vaccination (If yes: - this report
period - MM/DD/YYYY)
Specify reason (agent not administered in full
amount)
Therapy Administered
Agent Name (GM-CSF)
Agent Start Date (If yes: - MM/DD/YYYY)
Agent End Date (MM/DD/YYYY)
Non-protocol Therapy
Was any non-protocol therapy given during
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protocol treatment? (not previously reported)
Yes
No
Comments
Investigator Signature
Investigator Signature Date
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CALGB: 80303 MEDICAL RESOURCE UTILIZATION FORM
FOR NON-REGISTERING INSTITUTIONS NCT00088894
CALGB: 80303 MEDICAL RESOURCE UTILIZATION
FORM FOR NON-REGISTERING INSTITUTIONS
NCT00088894
Gemcitabine With or Without Bevacizumab in Treating
Patients With Locally Advanced or Metastatic Pancreatic
Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=D793975A-
CEA2-0A8E-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/10736
CALGB: 80303 MEDICAL
RESOURCE UTILIZATION FORM
FOR NON-REGISTERING
INSTITUTIONS NCT00088894
Header
CALGB Study No
CALGB Patient ID
From
To
Are data amended?
Yes
No
To study week number
Patient demographics
Patient Initials
Participating Group
Patient Hospital No.
Participating Group Protocol No.
Institution/Affiliate
Participating Group Patient ID
Hospitalization And Emergency Room
Data
1 / 3
Was the patient hospitalized or seen in an
Emergency Room during this time period?
Yes
No
Name of hospital/ER
Number of days in ICU
Date of evaluation/admission
Date of discharge
Outpatient Data And Home Visit Data
Was the patient seen as an outpatient during this
reporting period?
Yes
No
specify number of visits
Outpatient Data And Home Visit Data
(continued From Previous Page)
Did a healthcare professional visit the patient's
home during this reporting period?
Yes
No
specify number of visits
Evaluation method
Ct Scan (CT Scan)
Mri (MRI)
Other, Specify (Other, specify)
Pet Scan (PET)
Ultrasound (Ultrasound)
Other, specify
Number of tests
Operating Room Data
Procedure Performed Type
Colonoscopy (Colonoscopy)
Endoscopic Retrograde
Cholangiopancreatography (Endoscopic
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Retrograde Cholangiopancreatography)
Placement Of Long-lasting Internal Iv
Catheter To Deliver Medicine (Indwelling
IV catheter - placement)
Removal Of Long-lasting Internal Iv
Catheter To Deliver Medicine (Indwelling
IV catheter - removal)
Initiation Of Intravenous Nutrition
(Initiation of intravenous nutrition)
Nerve Block Or Placement Of Internal
Catheter To Treat Pain (Pain alleviation -
nerve block or placement of indwelling
catheter)
Placement Of Biliary Drainage Tube Or
Stent In Bile Ducts (Placement of biliary
drainage tube or stent in biliary tree)
Surgery For Intestinal
Obstruction/bypass (Surgery - intestinal
obstruction/bypass)
Other Major Surgery, Specify (Surgery -
other specify)
Placement Of Feeding Tube Or Tube To
Drain Intestines (Tube placement -
feeding or intestinal drainage)
Upper Gastrointestinal Endoscopy Or
Placement Of Stent In The Upper
Intestines (Upper gastrointestinal
endoscopy)
Surgery - other specify
Number of tests
Non-protocol Chemotherapy Data
Did the patient receive any off-protocol
chemotherapy during this time period?
Yes
No
Specify name
No. of sessions
Completed by
Date form completed
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PATIENT DIARY [CALGB 80303]
NCT00088894
PATIENT DIARY [CALGB 80303] NCT00088894
Gemcitabine With or Without Bevacizumab in Treating
Patients With Locally Advanced or Metastatic Pancreatic
Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=D602AE44-
4EF3-3C9E-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/10737
PATIENT DIARY [CALGB 80303]
NCT00088894
Reporting period
From
To
to
to
Overnight Hospital Stays And Emergency
Room Visits
Were you admitted to a hospital or did you visit
and emergency room during this time period at
an institution other than where you registered?
Yes
No
Visit Number
Date of Evaluation/Admission
Date of Discharge
Days in ICU
Hospital Name
Comments
Reporting period
From
To
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to
to
Outpatient And Home Visits
Total number of outpatient visits during this time
period to an institution other than where you
registered
Total number of home visits during this time
period
Comments
Reporting period
From
To
to
to
Examination Data
Did you have any radiologic examinations done
during this time period at an institution other than
where you registered?
Yes
No
Radiologic Examination
Ct Scan (CT Scan)
Mri (MRI)
Other, Specify (Other exam, specify)
Pet Scan (PET or combination PET/CT)
Ultrasound (Ultrasound, including
Doppler)
Other exam, specify
Total Number of Examinations
Comments
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Reporting period
From
To
to
to
Operating Room Data
Did you have any medical procedures done
during this time period at an institution other than
where you registered?
Yes
No
Procedure / Operation
Colonoscopy (Colonoscopy)
Endoscopic Retrograde
Cholangiopancreatography (Endoscopic
Retrograde Cholangiopancreatography)
Initiation Of Intravenous Nutrition
(Initiation of intravenous nutrition)
Nerve Block Or Placement Of Internal
Catheter To Treat Pain (Nerve block of
placement of internal catheter to treat
pain)
Other Major Surgery, Specify (Other
major surgery, specify)
Placement Of Biliary Drainage Tube Or
Stent In Bile Ducts (Placement of biliary
drainage tube or stent in bile ducts)
Placement Of Feeding Tube Or Tube To
Drain Intestines (Placement of feeding
tube or tube to drain intestines)
Placement Of Long-lasting Internal Iv
Catheter To Deliver Medicine (Placement
of long-lasting internal IV catheter to
deliver medicine)
Removal Of Long-lasting Internal Iv
Catheter To Deliver Medicine (Removal
of long-lasting internal IV catheter to
deliver medicine)
Surgery For Intestinal
Obstruction/bypass (Surgery for
intestinal obstruction/bypass)
Upper Gastrointestinal Endoscopy Or
Placement Of Stent In The Upper
Intestines (Upper gastrointestinal
endoscopy or placement of stent in the
upper intestines)
Other major surgery, specify
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Total Number of Procedures
Comments
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CALGB: 90202 Follow-up Solid Tumor
Evaluation Form NCT00079001
CALGB: 90202 Follow-up Solid Tumor Evaluation Form
NCT00079001
Zoledronate in Preventing Skeletal (Bone)-Related Events
in Patients Who Are Receiving Androgen Deprivation
Therapy For Prostate Cancer and Bone Metastases
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=B460627D-
9F78-051C-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/10738
CALGB: 90202 Follow-up Solid
Tumor Evaluation Form
NCT00079001
Header
CALGB Form
CALGB Study No
CALGB Patient ID
Amended data?
Yes (Yes)
Patient demographics
Patient Initials
Participating Group
Patient Hospital Number
Participating Group Protocol No.
Main Member Institution/Adjunct
Participating Group Patient ID
Reporting Period
Start Date
End Date
Target Lesion(s) Follow-up Evaluation
Lesion, Anatomic Site, Target
1 / 3
Date of Evaluation
Method of Evaluation
Bone Scan (Bone scan)
Chest X-ray (chest x-ray)
Clinical Examination (pe) (clinical
examination)
Ct Scan (CT scan)
Mri (MRI (NMR))
Other (other)
Spiral Ct Scan (Spiral CT scan)
Ultrasound (Ultrasound)
If other, specify (method of evaluation)
Longest Diameter of Lesion(s) (cm)
Sum of Longest Diameteres of All Target lesions
(cm)
Non-target Lesion(s) Follow-up Evaluation
Are there any non-target lesions?
Yes
No
Lesion, Anatomic Site, Non-Target
Date of Evaluation
Date of Evaluation
Method of Evaluation
Bone Scan (Bone scan)
Chest X-ray (chest x-ray)
Clinical Examination (pe) (clinical
examination)
Ct Scan (CT scan)
Mri (MRI (NMR))
Other (other)
Spiral Ct Scan (Spiral CT scan)
Ultrasound (Ultrasound)
Method of Evaluation
Bone Scan (Bone scan)
Chest X-ray (chest x-ray)
Clinical Examination (pe) (clinical
examination)
Ct Scan (CT scan)
Mri (MRI (NMR))
Other (other)
Spiral Ct Scan (Spiral CT scan)
Ultrasound (Ultrasound)
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If other, specify (method of evaluation)
If other, specify (method of evaluation)
F/U Response Status
Complete Response (Complete
Response)
Stable Disease Or Unchanged
(Incomplete Response)
Insufficient evaluation to determine
response status (Insufficient evaluation
to determine response status)
Progressive Disease (Progressive
Disease)
Was the appearance of any new lesions
documented since the baseline evaluation?
Yes
No
Lesion, Anatomic Site, New
Overall Response
Complete Response (Complete
Response)
Incomplete Response Or Stable
Disesase (Incomplete Response)
Insufficient Evaluation (Insufficient
evaluation to determine response status)
Partial Response (Partial Response)
Progressive Disease (Progressive
Disease)
Overall Response
Complete Response (Complete
Response)
Incomplete Response Or Stable
Disesase (Incomplete Response)
Insufficient Evaluation (Insufficient
evaluation to determine response status)
Partial Response (Partial Response)
Progressive Disease (Progressive
Disease)
Completed by
Date form completed
Ccrr Module For Calgb: 90202 Follow-up
Solid Tumor Evaluation Form
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E2805 Treatment Form NCT00326898
E2805 Treatment Form NCT00326898
Sunitinib or Sorafenib in Treating Patients With Kidney
Cancer That Was Removed By Surgery
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=054B80EC-
08C8-3374-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/10740
E2805 Treatment Form
NCT00326898
Header
ECOG Protocol Number
ECOG Patient ID
DCI Name
Registration Step
On Treatment Report Period (1 cycle = 6 weeks
Choose one X)
Cycle 1 (Cycle 1)
Cycle 2 (Cycle 2)
Cycle 3 (Cycle 3)
Cycle 4 (cycle 4)
Cycle 5 (Cycle 5)
Cycle 6 (Cycle 6)
Cycle 7 (Cycle 7)
Cycle 8 (cycle 8)
Cycle 9 (Cycle 9)
Patient demographics
ECOG Protocol Number
ECOG Patient ID
Patient Initials (Last, First)
Participating Group Protocol Number
Institution/Affiliate
Participating Group Patient ID
Data amendment
Please mark an 'X' if data have been amended.
1 / 5
Date data amended (s)
Section I - Vital Status
Vital Status
Alive (Alive)
Dead (Dead)
Date of Last Contact or Death (M D Y)
Primary Cause of Death (if applicable)
Due To Other Cause (Due to other
cause)
Due To Protocol Treatment (Due to
protocol treatment)
Due To This Disease (Due to this
disease)
Unknown (Unknown)
Describe cause of death
Section Ii - Patient Characteristics
Reporting Period Start Date (M D Y)
Reporting Period End Date (M D Y)
ECOG Performance Status (Day 1 of this cycle)
Fully Active, Able To Carry On All Pre-
disease Performance Without
Restriction. (0)
Restricted In Physically Strenuous
Activity But Ambulatory And Able To
Carry Out Work Of A Light Or Sedentary
Nature, E.g., Light Housework, Office
Work. (1)
Ambulatory And Capable Of All Selfcare
But Unable To Carry Out Any Work
Activities. Up And About More Than 50%
Of Waking Hours. (2)
Capable Of Only Limited Selfcare,
Confined To Bed Or Chair More Than
50% Of Waking Hours. (3)
Completely Disabled. Cannot Carry On
Any Selfcare. Totally Confined To Bed Or
Chair. (4)
Agent Name: Sorafenib/placebo
Did the patient complete and return the Patient
Pill Calendar this cycle
Yes
No
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Agent Name (Sorafenib/Placebo)
Did the patient return their BAYER bottle this
cycle
Yes
No
Total number of tablets remaining ([hand count
required])
Prescribed dose (number of capsules per day -
on Day 1 of this cycle)
Expected number of tablets taken ([Prescribed
dosenumber of tablets per day *42])
Actual number of capsules taken (by hand count,
if available, otherwise by pill diary)
What was the source of the pill count
Hand Count (Hand count)
Patient Pill Diary (Patient pill diary)
Pill Count Not Done (Pill count not done)
If pill count was not done, please explain
Dose Modifications
Agent Name (Sorafenib/Placebo)
Were there any dose modifications or
additions/omissions to protocol treatment (this
report period)
No (No)
Yes, Both Planned And Unplanned (Yes,
both planned and unplanned)
Yes, Planned (Yes, planned)
Yes, Unplanned (Yes, unplanned)
Start Date of Dose Modification (M D Y)
End Date of Dose Modification (M D Y)
Modified Dose (mg)
Reason for therapy modification
Adverse Event (Adverse event)
Agent Discontinued (Agent discontinued)
Other (Other)
Other, specify
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Assessment of medication
Agent Name (Sorafenib/Placebo)
Did the patient return their Pfizer bottle this cycle
Yes
No
Total number capsules remaining (if yes by hand
count)
Prescribed dose (number of capsules per day -
on Day 1 of this cycle)
Expected number of capsules taken ([Prescribed
dose number of capsules per day *28])
Actual number of capsules taken (by hand count,
if available, otherwise by pill diary)
What was the source of the pill count
Hand Count (Hand count)
Patient Pill Diary (Patient pill diary)
Pill Count Not Done (Pill count not done)
If pill count was not done, please explain
Dose Modifications
Agent Name (Sorafenib/Placebo)
Were there any dose modifications or
additions/omissions to protocol treatment (this
report period)
No (No)
Yes, Both Planned And Unplanned (Yes,
both planned and unplanned)
Yes, Planned (Yes, planned)
Yes, Unplanned (Yes, unplanned)
Start Date of Dose Modification (M D Y)
End Date of Dose Modification (M D Y)
Modified Dose (mg)
Reason for therapy modification
Adverse Event (Adverse event)
Agent Discontinued (Agent discontinued)
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Other (Other)
Other, specify
Section Iv - Blood Pressure
Systolic (mm/Hg)
Diastolic (mm/Hg)
Mark an 'X' if not done
Section V - Last Cycle Of Protocol
Therapy
Date of MUGA
Mark an 'X' if not done
Date of assessment (Note: If patient was
originally registered to the protocol using an
ECHO scan at baseline, an ECHO must be used
in lieu of the - MUGA scan for the entirety of the
study. In this case, fill in the section below.)
Mark an 'X' if not done
Left Ventricular Ejection Fraction at Rest
Left Ventricular Ejection Fraction at Rest
LVEF Institutional Lower Limit of Normal
LVEF Institutional Lower Limit of Normal
Section Vi - Non-protocol Therapy
Was any non-protocol cancer therapy given
during protocol treatment (not previously
reported)
Yes
No
Investigator Signature
Investigator Signature Date
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Southwest Oncology Group S0518
Hypertension Status Form NCT00569127
Southwest Oncology Group S0518 Hypertension Status
Form NCT00569127 
Octreotide and Interferon Alfa-2b or Bevacizumab in
Treating Patients With Metastatic or Locally Advanced,
High-Risk Neuroendocrine Tumor
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=38429791-
B8E2-1FFB-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/10741
Southwest Oncology Group S0518
Hypertension Status  Form
NCT00569127
Header
SWOG Patient ID
SWOG Study No.
Registration Step
Reporting Period Start Date
Patient Initials (L, F M)
Institution/Affiliate
Physician
Participating Group Name
Participating Study No.
Participating Patient ID (Instructions: Please
complete this form after each cycle 1 cycle = 4
weeks. All dates are MONTH, DAY, YEAR.
Explain any blank dates or fields in a Comments
section. Place an X in appropriate boxes. Circle
AMENDED items in red and write AMENDED
across top of form.)
Blood pressure
Date of most recent blood pressure assessment
Blood Pressure, Systolic
Blood pressure, Diastolic
Does the patient have hypertension requiring
1 / 2
medication?
Yes
No
Agent Name
Total Daily Dose of Agent (or Drug)
Comments
Comments
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NCT00569127
E4A08 Treatment Form - Arm A
NCT01078454
E4A08 Treatment Form - Arm A NCT01078454 
Melphalan and Dexamethasone With or Without
Bortezomib in Treating Patients With Previously Untreated
Systemic Light-Chain Amyloidosis
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=7BCCA614-
5432-15BB-E040-BB89AD4326D3
All rights reserved. Please visit https://medical-data-
models.org/forms/10742
E4A08 Treatment Form - Arm A
NCT01078454
Patient demographics
Patient Initials (Last, First)
ECOG Protocol Number
Participating Group Protocol Number
Institution/Affiliate
ECOG Patient ID
Participating Group Patient ID
ECOG clinical trial administrative data
ECOG Protocol Number
DCI Name
Registration Step (1)
ECOG Patient ID
Data amendment
Please mark an 'X' if data have been amended.
(Please circle amended items in red)
Date data amended (s - mm/dd/yyyy)
On Treatment Reporting Period
On Treatment Reporting Period
Cycle 1 (Cycle 1)
Cycle 2 (Cycle 2)
Cycle 3 (Cycle 3)
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Cycle 4 (cycle 4)
Cycle 5 (Cycle 5)
Cycle 6 (Cycle 6)
Cycle 7 (Cycle 7)
Cycle 8 (cycle 8)
Cycle 9 (Cycle 9)
Reporting Period
Reporting Period Start Date (mm/dd/yyyy)
Reporting Period End Date (mm/dd/yyyy)
Vital Status
Patient's Vital Status
Alive (Alive)
Dead (Dead)
Date of last contact or death (mm/dd/yyyy)
Primary Cause of Death
Due To Other Cause (Due to other
cause)
Due To Protocol Treatment (Due to
protocol treatment)
Due To This Disease (Due to this
disease)
Unknown (Unknown)
Describe cause of death
Performance Status
Fully Active, Able To Carry On All Pre-
disease Performance Without
Restriction. (0)
Restricted In Physically Strenuous
Activity But Ambulatory And Able To
Carry Out Work Of A Light Or Sedentary
Nature, E.g., Light Housework, Office
Work. (1)
Ambulatory And Capable Of All Selfcare
But Unable To Carry Out Any Work
Activities. Up And About More Than 50%
Of Waking Hours. (2)
Capable Of Only Limited Selfcare,
Confined To Bed Or Chair More Than
50% Of Waking Hours. (3)
Completely Disabled. Cannot Carry On
Any Selfcare. Totally Confined To Bed Or
Chair. (4)
Patient Characteristics
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Weight (Day 1 of this cycle)
Body Surface Area (BSA Day 1 of this cycle -
m^2)
Blood Pressure, Supine, Systolic
Blood pressure, Supine, Diastolic
Supine, Pulse
Blood Pressure, Standing at 1 minute, Systolic
Blood pressure, Standing at 1 minute, Diastolic
Standing at 1 minute, Pulse
Mark an 'X' if not done
Mark an 'X' if not done
Therapy Administered - Section I
Agent Name
Was the agent administered during this reporting
period? (Dexamethasone)
Yes
No
Date Agent Administered (If yes:)
Agent Total Dose (mg)
Prescribed pill dose
Did the patient complete Patient Pill Diary
Yes
No
How many pills remained at the end of this cycle
Were there any dose modifications or
additions/omissions to protocol treatment
Yes
No
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Therapy Administered - Section I
Agent Name
Was the agent administered during this reporting
period? (Dexamethasone)
Yes
No
Date Agent Administered (If yes:)
Agent Total Dose (mg)
Prescribed pill dose
Did the patient complete Patient Pill Diary
Yes
No
How many pills remained at the end of this cycle
Were there any dose modifications or
additions/omissions to protocol treatment
Yes
No
Section E: Non-protocol Therapy
Was any non-protocol therapy given during
protocol treatment (not previously reported)?
Yes
No
Comments
Investigator Signature
Investigator Signature Date
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CALGB: 90401 FOLLOW-UP FORM
NCT00110214
CALGB: 90401 FOLLOW-UP FORM NCT00110214
Docetaxel and Prednisone With or Without Bevacizumab in
Treating Patients With Prostate Cancer That Did Not
Respond to Hormone Therapy
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=EFB2FF09-
853B-4EB3-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/10743
CALGB: 90401 FOLLOW-UP FORM
NCT00110214
Header
CALGB Form
CALGB Study No
CALGB Patient ID
Reporting period start date
Reporting period end date
Are data amended
Yes
No
Patient demographics
Patient Initials
Patient Hospital No
Institution/Affiliate
Participating Group
Participating Group Study No
Participating Group Patient ID
Vital Status
Patient's vital status (Mark one with an X.)
Alive (Alive)
Dead (Dead)
Lost To Follow-up (Lost to follow-up)
1 / 6
Primary cause of death (Mark one with an X.)
Due To Other Cause (Due to other
cause)
Due To Protocol Treatment (Due to
protocol treatment)
Due To This Disease (Due to this
disease)
Describe cause of death
ECOG Performance Status
Fully Active, Able To Carry On All Pre-
disease Performance Without
Restriction. (0)
Restricted In Physically Strenuous
Activity But Ambulatory And Able To
Carry Out Work Of A Light Or Sedentary
Nature, E.g., Light Housework, Office
Work. (1)
Ambulatory And Capable Of All Selfcare
But Unable To Carry Out Any Work
Activities. Up And About More Than 50%
Of Waking Hours. (2)
Capable Of Only Limited Selfcare,
Confined To Bed Or Chair More Than
50% Of Waking Hours. (3)
Completely Disabled. Cannot Carry On
Any Selfcare. Totally Confined To Bed Or
Chair. (4)
Dead (5)
Patient Weight (current)
TREATMENT STATUS (Mark one with an X.)
Follow-up, Off Protocol Therapy (Follow-
up, off protocol therapy)
Other (Other)
Protocol Therapy (Protocol therapy)
Other, specify
Disease Assessment
Has the patient had a documented clinical
assessment for this cancer?
Yes
No
Date of most recent physical exam
Date of most recent biopsy or surgery
Most recent CT/MRI scan date
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Most recent bone scan date
Number of new bone lesions documented since
baseline
None (0)
1 Bone Lesion (1)
2 Bone Lesions (2)
3 Or More Bone Lesions (3 or more)
Bone Scan Not Done (Bone scan not
done)
Disease Response
Response Status at This Assessment
Complete Response (CR)
Insufficient Evaluation (Insufficient
evaluation to determine response status)
Progressive Disease (PD)
Partial Response (PR)
Stable Disease (SD)
Complete Response (CR) First Observed Date
Partial Response (PR) First Observed Date
Progressive Disease First Observed Date (per
CT/MRI)
Sites of response (Mark all that apply with an X.)
Cns/brain (CNS/Brain)
Liver (Liver)
Lung (Lung)
Lymph Nodes (Lymph nodes)
Other (Other)
Pleura (Pleura)
Other, specify
Complete response
Yes
No
Disease Progression
Has patient developed a first progression that has
not been previously reported? (or relapse)
Yes
No
Sites of progression during this reporting period
(Mark one with an X.)
Biochemical Progression (Biochemical
progression)
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Bone (Bone)
Cns/brain (CNS/Brain)
Liver (Liver)
Lung (Lung)
Lymph Nodes (Lymph nodes)
Other (Other)
Pleura (Pleura)
Biochemical progression first date (PSA)
Biochemical progression confirmed date (PSA)
Other, specify
Date of bone progression
Is there symptomatic deterioration of the patient's
health status requiring discontinuation of
treatment?
Yes
No
Symptomatic deterioration date
Lhrh Agonist
Is patient receiving on-going LH-RH agonist
therapy
Yes
No
Select reason (If no,)
Other (Other)
Prior Orchiectomy (Prior orchiectomy)
Other, specify
LHRH agonist end date
Notice Of New Primary
Has a new primary cancer or MDS been
diagnosed that has not been previously reported?
Yes
No
New Primary Cancer Date
Site of new primary (s)
New Primary, Histologic type
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Long-term Toxicity
Has the patient experienced (prior to diagnosis of
recurrence or second primary) any severe (Grade
> 3), long-term toxicity that has not been
previously reported?
Yes
No
If non-AML/MDS secondary malignancy occurs,
specify type and/or site
Non-protocol Therapy
Has the patient received any non-protocol cancer
therapy (not previously reported?)
Yes
No
NON-PROTOCOL THERAPY
Non-protocol Chemotherapy (Non-
protocol chemotherapy)
Non-protocol Hormonal Therapy (Non-
protocol hormonal therapy)
Non-protocol Radiation Therapy (Non-
protocol radiation therapy)
Non-protocol Surgery (Non-protocol
surgery)
Other Non-protocol Therapy (Other non-
protocol therapy)
Non-protocol hormonal therapy, specify
Non-protocol radiation therapy, specify
Non-protocol chemotherapy, specify
Non-protocol surgery, specify
Other non-protocol therapy, specify
Non-protocol therapy start date (or date
performed)
Non-protocol therapy end date
Complete Section Below Until Progression
Agent code
Codeine (Codeine)
Dihydrocode (synalgos) (Dihydrocode)
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Fentanyl (duragesic, Sublimaze, Actiq)
(Fentanyl)
Hydrocodone (Hydrocodone)
Hydromorphone (dilaudid)
(Hydromorphone)
Levorphanol (levodromoran)
(Levorphanol)
Methadone (Methadone)
Morphine (Morphine)
Other (Other)
Oxymorphone (numorphone)
(Oxymorphone)
Propoxyphene (Propoxyphene)
Other, specify
Agent Total Dose (per day)
Units
Gram (g)
International Unit (IU)
Liter (L)
Microgram (mcg)
Milligram (mg)
Milliliter (mL)
Unit (unit)
Route
Intravenous (IV)
Other (Other)
Oral (PO)
Subcutaneous (SC)
Topical (TOP)
Agent Start Date
Agent End Date
Frequency
Intermittent (Intermittent or as needed)
Indication for use
Curative Treatment (Curative)
Prevention (Prophylaxis)
Footer
Completed by
Date Form Completed
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CALGB: 10603 Lab Results - Coagulation
Test NCT00651261
CALGB: 10603 Lab Results - Coagulation Test
NCT00651261 
Daunorubicin, Cytarabine, and Midostaurin in Treating
Patients With Newly Diagnosed Acute Myeloid Leukemia
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=622FC216-
9994-90D0-E040-BB89AD430CCE
All rights reserved. Please visit https://medical-data-
models.org/forms/10744
CALGB: 10603 Lab Results -
Coagulation Test NCT00651261
Header module
CALGB Form
CALGB Study No.
CALGB Patient ID
Reporting Period Start Date (MM DD YYYY)
Reporting Period End Date (MM DD YYYY)
Are data amended
Yes
No
Patient demographics
Patient Initials (Last, First Middle)
Patient Hospital No.
Institution/Affiliate
Participating Group
Participating Group Study No.
Participating Group Patient ID
Lab data
Name of Laboratory
Laboratory ID (provided by CALGB)
1 / 2
Treatment Phase
Baseline (Baseline)
Consolidation #1 (Consolidation #1)
Consolidation #2 (Consolidation #2)
Consolidation #3 (Consolidation #3)
Consolidation #4 (Consolidation #4)
Continuation (Continuation)
Induction #1 (Induction #1)
Induction #2 (Induction #2)
Post-therapy (Post-therapy follow-up)
Lab collection time point (Mark one with an X)
A Regularly Scheduled Time Point (A
regularly scheduled time point)
An Additional Time Point (An additional
time point)
Lab results
Prothrombin time
INR (International Normalization Ratio)
PTT (Partial Thromboplastin Time )
Fibrinogen
CTC Adverse Event Grade
Overall Response
Completed by (print or type name)
Date Form Completed (MM DD YYYY)
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CALGB: 10603 Lab Results - Thyroid
Function Tests NCT00651261
CALGB: 10603 Lab Results - Thyroid Function Tests
NCT00651261 
Daunorubicin, Cytarabine, and Midostaurin in Treating
Patients With Newly Diagnosed Acute Myeloid Leukemia
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=623366AE-
B316-EBAB-E040-BB89AD43128A
All rights reserved. Please visit https://medical-data-
models.org/forms/10746
CALGB: 10603 Lab Results - Thyroid
Function Tests NCT00651261
Header
CALGB Form
CALGB Study No.
CALGB Patient ID
Reporting Period Start Date (MM DD YYYY)
Reporting Period End Date (MM DD YYYY)
Are data amended
Yes
No
Patient demographics
Patient Initials (Last, First Middle)
Patient Hospital No.
Institution/Affiliate
Participating Group
Participating Group Study No.
Participating Group Patient ID
Lab
Name of Laboratory
Laboratory ID (provided by CALGB)
1 / 2
Treatment Phase
Baseline (Baseline)
Consolidation #1 (Consolidation #1)
Consolidation #2 (Consolidation #2)
Consolidation #3 (Consolidation #3)
Consolidation #4 (Consolidation #4)
Continuation (Continuation)
Induction #1 (Induction #1)
Induction #2 (Induction #2)
Post-therapy (Post-therapy follow-up)
Lab collection time point (Mark one with an X)
A Regularly Scheduled Time Point (A
regularly scheduled time point)
An Additional Time Point (An additional
time point)
T4 (Thyroxine)
TSH (Thyroid Stimulating Hormone/Thyrotropin)
Overall Response
Completed by (print or type name)
Date Form Completed (MM DD YYYY)
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CALGB: 10603 Lab Results - Hematology
Test NCT00651261
CALGB: 10603 Lab Results - Hematology Test
NCT00651261 
Daunorubicin, Cytarabine, and Midostaurin in Treating
Patients With Newly Diagnosed Acute Myeloid Leukemia
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=62302100-2333-
35C1-E040-BB89AD431366
All rights reserved. Please visit https://medical-data-
models.org/forms/10747
CALGB: 10603 Lab Results -
Hematology Test NCT00651261
Header
CALGB Form
CALGB Study No.
CALGB Patient ID
Reporting Period Start Date (MM DD YYYY)
Reporting Period End Date (MM DD YYYY)
Are data amended
Yes
No
Patient demographics
Patient Initials (Last, First Middle)
Patient Hospital No.
Institution/Affiliate
Participating Group
Participating Group Study No.
Participating Group Patient ID
Lab
Name of Laboratory
Laboratory ID (provided by CALGB)
1 / 3
Treatment Phase
Baseline (Baseline)
Consolidation #1 (Consolidation #1)
Consolidation #2 (Consolidation #2)
Consolidation #3 (Consolidation #3)
Consolidation #4 (Consolidation #4)
Continuation (Continuation)
Induction #1 (Induction #1)
Induction #2 (Induction #2)
Post-therapy (Post-therapy follow-up)
Lab collection time point (Mark one with an X)
A Regularly Scheduled Time Point (A
regularly scheduled time point)
An Additional Time Point (An additional
time point)
Lab
WBC
ANC
Absolute Lymphocyte Count
Hemoglobin
Platelet count
CTC Adverse Event Grade (Mark one with a X)
Peripheral Blood
Peripheral Neutrophils (%) (segs + bands)
Peripheral metamyelocytes (%)
Peripheral myelocytes (%)
Peripheral Promyelocytes (%)
Peripheral Blasts (%)
Peripheral Monocytes (%)
Peripheral monoblasts (%)
Peripheral Lymphocytes (%)
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Peripheral Eosinophils (%)
Peripheral Basophils (%)
Overall Response
Completed by (print or type name)
Date Form Completed (MM DD YYYY)
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E2905 Treatment Form NCT00843882
E2905 Treatment Form NCT00843882 
Lenalidomide With or Without Epoetin Alfa in Treating
Patients With Myelodysplastic Syndrome and Anemia
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=0EAAA60E-
08F3-6970-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/10748
E2905 Treatment Form
NCT00843882
Header
ECOG Protocol Number
ECOG Patient ID
DCI Name
Registration Step
Patient demographics
Patient Initials (Last, First)
ECOG Protocol Number
ECOG Patient ID
Participating Group Protocol Number
Participating Group Patient ID
Institution/Affiliate
Data amendment
Please mark an 'X' if data have been amended.
(Please circle amended items in red)
Date data amended (MM/DD/YYYY)
On Treatment
On Treatment Report Period (Step 2 - Choose
one x)
>cycle 13-step 2 (>Cycle 13-Step 2)
1 / 5
Cycle 1 Step 2 (Cycle 1 Step 2)
Cycle 10 Step 2 (Cycle 10 Step 2)
Cycle 11 Step 2 (Cycle 11 Step 2)
Cycle 12 Step 2 (Cycle 12 Step 2)
Cycle 13-step 2 (Cycle 13-Step 2)
Cycle 2 Step 2 (Cycle 2 Step 2)
Cycle 3 Step 2 (Cycle 3 Step 2)
Cycle 4 Step 2 (Cycle 4 Step 2)
Cycle 5 Step 2 (Cycle 5 Step 2)
Cycle 6 Step 2 (Cycle 6 Step 2)
Cycle 7 Step 2 (Cycle 7 Step 2)
Cycle 8 Step 2 (Cycle 8 Step 2)
Cycle 9 Step 2 (Cycle 9 Step 2)
On Treatment Report Period (Step 2 - Choose
one x)
>cycle 13-step 2 (>Cycle 13-Step 2)
Cycle 1 Step 2 (Cycle 1 Step 2)
Cycle 10 Step 2 (Cycle 10 Step 2)
Cycle 11 Step 2 (Cycle 11 Step 2)
Cycle 12 Step 2 (Cycle 12 Step 2)
Cycle 13-step 2 (Cycle 13-Step 2)
Cycle 2 Step 2 (Cycle 2 Step 2)
Cycle 3 Step 2 (Cycle 3 Step 2)
Cycle 4 Step 2 (Cycle 4 Step 2)
Cycle 5 Step 2 (Cycle 5 Step 2)
Cycle 6 Step 2 (Cycle 6 Step 2)
Cycle 7 Step 2 (Cycle 7 Step 2)
Cycle 8 Step 2 (Cycle 8 Step 2)
Cycle 9 Step 2 (Cycle 9 Step 2)
Specify Cycle
Specify Cycle
Reporting period
Reporting Period Start Date (MM/DD/YYYY)
Reporting Period End Date (MM/DD/YYYY)
Vital Status
Patient Vital Status
Alive (Alive)
Dead (Dead)
Date of last contact or death (MM/DD/YYYY)
Primary Cause of Death (if applicable)
Due To Other Cause (Due to other
cause)
Due To Protocol Treatment (Due to
protocol treatment)
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Due To This Disease (Due to this
disease)
Unknown (Unknown)
Describe cause of death
Therapy Administered
Agent Name (Arm B Only)
Was the agent administered during this reporting
period? (Darbepoetin-alpha)
Yes
No
Agent Start Date
Agent End Date
Daily dose prescribed
Date pills initially dispensed (If yes: -
MM/DD/YYYY)
Total number of pills patient took home on initial
dispensing date
Date of pill count (MM/DD/YYYY)
Pill count - Number of pills remaining in the vial(s)
before dispensing new pills
Number of pills lost but not taken
Agent Total Dose (this report period)
Were there any dose modifications or
additions/omissions to protocol treatment
(Paxlitaxel)
No (no)
Yes, Both Planned And Unplanned (Yes,
both planned and unplanned)
Yes, Planned (i.e., The Treatment Was
Changed According To Protocol
Guidelines) (yes, planned)
Yes, Unplanned (i.e., The Treatment
Change Was Not Part Of Protocol
Guidelines) (yes, unplanned)
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Dose modification (If yes:)
Dose Delayed (Dose delayed)
Dose Delayed And Reduced (Dose
delayed and reduced)
Dose Held (Dose held)
Dose Reduced (Dose reduced)
Drug Discontinued (Drug discontinued)
Agent Name: Paclitaxel
Agent Name (Arm B Only)
Was the agent administered during this reporting
period? (Darbepoetin-alpha)
Yes
No
Date of First dose for this reporting period
(MM/DD/YYYY)
Date of Last dose for this reporting period
(MM/DD/YYYY)
Agent Total Dose (this report period)
Were there any dose modifications or
additions/omissions to protocol treatment
(Paxlitaxel)
No (no)
Yes, Both Planned And Unplanned (Yes,
both planned and unplanned)
Yes, Planned (i.e., The Treatment Was
Changed According To Protocol
Guidelines) (yes, planned)
Yes, Unplanned (i.e., The Treatment
Change Was Not Part Of Protocol
Guidelines) (yes, unplanned)
Dose modification (If yes:)
Dose Delayed (Dose delayed)
Dose Delayed And Reduced (Dose
delayed and reduced)
Dose Held (Dose held)
Dose Reduced (Dose reduced)
Drug Discontinued (Drug discontinued)
Steroid Use
Were steroids given (this report period)
No (No)
Yes, Steroids Given, But Not Continuing
Use (Yes, steroids given, but not
continuing use)
Yes, Steroids Given, Continuing Use
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(Yes, steroids given, continuing use)
Reason steroids given
Other (Other)
Prophylaxis For Transfusion Reactions
(Prophylaxis for transfusion reactions)
Other,specify
Myeloid Growth Factor Use
Were myeloid growth factors given (this report
period)
No (No)
Yes, Myeloid Growth Factors Given, But
Not Continuing Use (Yes, myeloid growth
factors given, but not continuing use)
Yes, Myeloid Growth Factors Given,
Continuing Use (Yes, myeloid growth
factors given, continuing use)
Thrombopoietic Agent Use
Did the patient have a deep vein thrombosis
(DVT) this report period? (Report grade and
attribution under thrombosis/embolism on E2905
Adverse Event Form.)
Yes
No
Did the patient have a pulmonary embolism this
report period? (Report grade and attribution
under thrombosis/embolism on E2905 Adverse
Event Form.)
Yes
No
Non-protocol Therapy
Was any non-protocol therapy given during
protocol treatment (not previously reported)
Yes
No
Comments
Investigator Signature
Investigator Signature Date
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CALGB: 10603 Laboratory Normals and
Units Form NCT00651261
CALGB: 10603 Laboratory Normals and Units Form
NCT00651261 
Daunorubicin, Cytarabine, and Midostaurin in Treating
Patients With Newly Diagnosed Acute Myeloid Leukemia
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=621DF241-
3FFA-FE24-E040-BB89AD432D16
All rights reserved. Please visit https://medical-data-
models.org/forms/10749
CALGB: 10603 Laboratory Normals
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Header
CALGB Form
CALGB Study No.
CALGB Patient ID
Reporting Period Start Date (MM DD YYYY)
Reporting Period End Date (MM DD YYYY)
Are data amended
Yes
No
Patient demographics
Patient Initials (Last, First Middle)
Patient Hospital No.
Institution/Affiliate
Participating Group
Participating Group Study No.
Participating Group Patient ID
Lab
Name of Laboratory
Lab
Albumin Measurement (Albumin)
1 / 4
Alkaline Phosphatase Measurement
(Alkaline Phosphatase)
Alanine Aminotransferase Measurement
(ALT (SGPT))
Absolute Neutrophil Count (ANC
(Absolute Neutrophil Count))
Aspartate Aminotransferase
Measurement (AST (SGOT))
Blood Urea Nitrogen Measurement (BUN
(Blood Urea Nitrogen))
Calcium Measurement (Calcium)
Chloride Measurement (Chloride)
Fibrinogen Measurement (Fibrinogen)
Plasma Glucose Measurement
(Glucose)
Hematocrit (Hematocrit)
Hemoglobin Measurement (Hemoglobin)
International Normalized Ratio (INR
(International Normalized Ratio))
Echocardiogram Ejection Fraction (Left
Ventricular Ejection Fraction by
echocardiogram)
Radionuclide Ventriculogram Scan
Ejection Fraction (Left Ventricular
Ejection Fraction by MUGA)
Magnesium Measurement (Magnesium)
Platelet Count (Platelet Count)
Potassium Measurement (Potassium)
Prothrombin Time (PT (Prothrombin
Time))
Partial Thromboplastin Time (PTT
(Partial Thromboplastin Time))
Serum Creatinine Measurement (Serum
Creatinine)
Serum Hcg Measurement (Serum HCG
(Human Chorionic Gonadotropin))
Sodium (Sodium)
Thyroxine (Thyroxine)
Total Bilirubin Measurement (Total
Bilirubin)
Total Protein Measurement (Total
Protein)
Thyroid Stimulating Hormone Thyrotropin
Measurement (TSH (Thyroid Stimulating
Hormone/Thyrotropin))
Uric Acid Crystal Measurement (Uric
Acid)
Urine Human Chorionic Gonadotropin
(Urine HCG (Human Chorionic
Gonadotropin))
Leukocyte Count (WBC Count)
Units
Microliter (/mcL)
/ml (/mL)
/nl (/nL)
/mcl (/uL)
Percent (%)
10^9 Per Liter (10^9/L)
1000 Per Microliter (1000/mcL)
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1000 Per Cubic Millimiter (1000/mm^3)
Cubic Centimeters Per Minute (cc/min)
Cells Per Liter (cells/L)
Grams/24 Hours (g/24 hrs)
Grams Per Deciliter (g/dL)
Grams Per Liter (g/L)
Grams (gm)
Grams Per Deciliter (gm/dL)
Ie/l (IE/L)
International Units Per Liter (iU/L)
International Units Per Liter (IU/L)
K/mm^3 (k/mm^3)
Kilopascal (kPa)
Micrograms/deciliter (mcg/dl)
Micrograms Per Liter (mcg/L)
Micrograms Per Milliliter (mcg/mL)
Mciu/ml (mcIU/mL)
Mckat Per Liter (mcKat/L)
Microliter (mcL)
Micromoles Per Liter (mcmol/L)
Mcmol/l (mcmol/L)
Milliequivalent Per Liter (mEq/L)
Milligrams/24 Hours (mg/24 hrs)
Milligrams Per Deciliter (mg/dL)
Milligrams Per Liter (mg/L)
Minutes (min)
Milliliters Per Minute (ml/min)
Ml/min/1.73m^2 (mL/Min/1.73m^2)
Cubic Millimeters (mm^3)
Millimeters Of Mercury (mmHg)
Millimole Per Liter (mmol/L)
Mu/ml (mU/mL)
Not Applicable (N/A)
N/milligram (n/mg)
Nanograms Per Deciliter (ng/dL)
Nanograms Per Milliliter (ng/mL)
Nanomoles Per Liter (nmol/l)
Not Otherwise Specified (NOS)
Number (number)
Other (Other)
Ratio (Ratio)
Seconds (seconds)
Units Per Liter (U/L)
Vol Frac (Vol Frac)
10^3 Per Microliter (x10^3/mcL)
X10^6 Cells/kg (x10^6 cells/kg)
10^9 Per Liter (x10^9/L)
X1000 (x1000)
Other, specify
ULN
LLN
Overall Response
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Completed by (print or type name)
Date Form Completed (MM DD YYYY)
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CALGB: 10603 Concomitant Medications
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CALGB: 10603 Concomitant Medications Form
NCT00651261 
Daunorubicin, Cytarabine, and Midostaurin in Treating
Patients With Newly Diagnosed Acute Myeloid Leukemia
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=742F65D1-
34F2-9883-E040-BB89AD437120
All rights reserved. Please visit https://medical-data-
models.org/forms/10750
CALGB: 10603 Concomitant
Medications Form NCT00651261
Header
CALGB Form*
CALGB Study No*
CALGB Patient ID*
Reporting Period Start Date*
Reporting Period End Date*
Are data amended*
Yes
No
Patient demographics
Patient Initials (Last, First Middle)*
Patient Hospital No.*
Institution/Affiliate*
Participating Group*
Participating Group Study No*
Participating Group Patient ID*
Medication
Page (___ of ___)*
Concomitant Medication*
1 / 2
Medication Category*
Antibiotic/antiviral/antifungal
(Antibiotic/antiviral/antifungal)
Antiemetic (Antiemetic)
Antihistamine (Antihistamine)
Corticosteroid (Corticosteroid)
Diuretic/antihypertensive
(Diuretic/antihypertensive)
Growth Factor (Growth Factor)
Nsaid/opioid (NSAID/opioid)
Other (Other)
Proton Pump Inhibitor/h2 Antagonist
(Proton pump inhibitor/H2 antagonist)
CYP3A4 inhibitor/inducer*
Yes
No
Agent Total Dose (per day)*
Units*
Start date*
Stop date (or)*
Ongoing*
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E5103 Epirubicin Supplemental Form
NCT00433511
E5103 Epirubicin Supplemental Form NCT00433511
Doxorubicin, Cyclophosphamide, and Paclitaxel With or
Without Bevacizumab in Treating Patients With Lymph
Node-Positive or High-Risk, Lymph Node-Negative Breast
Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=9531CDB7-
EDAC-013E-E040-BB89AD437CC8
All rights reserved. Please visit https://medical-data-
models.org/forms/10751
E5103 Epirubicin Supplemental
Form NCT00433511
Header
ECOG Protocol Number
ECOG Patient ID
DCI Name
Registration Step
Patient demographics
Patient Initials (Last, First)
ECOG Protocol Number
ECOG Patient ID
Participating Group Protocol Number
Institution/Affiliate
Participating Group Patient ID
Data amendment
Please mark an 'X' if data have been amended.
(Please circle amended items in red)
Date data amended (s)
Treatment period
On Treatment Report Period (Choose one X)
Cycle 1 (Cycle 1)
Cycle 2 (Cycle 2)
1 / 2
Cycle 3 (Cycle 3)
Cycle 4 (cycle 4)
Medication
Agent Total Dose (Epirubicin this report period -
mg)
Dose modification
Dose Delayed (Dose delayed)
Dose Delayed And Reduced (Dose
delayed and reduced)
Dose Held (Dose held)
Dose Reduced (Dose reduced)
Drug Discontinued (Drug discontinued)
No Dose Modification (No dose
modification)
Dose Modification Reason (If a dose modification
reason was due to an Adverse Event, please
record all AE grades both reportable and non-
reportable in the appropriate section on E5103
Adverse Event form.)
Adverse Event (Adverse event)
Alternative Therapy For Other Reason
(Alternative therapy for other reason)
Dosing Error (Dosing error)
Other (Other)
Patient Refusal/noncompliance (Patient
refusal/noncompliance)
Scheduling (Scheduling)
Second Primary Cancer (Second
primary)
Other, specify
Comments
Investigator Signature
Investigator Signature Date
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E1105 Follow-Up Disease Evaluation Form
(RECIST) NCT00520975
E1105 Follow-Up Disease Evaluation Form (RECIST)
NCT00520975
First-Line Chemotherapy and Trastuzumab With or Without
Bevacizumab in Treating Patients With Metastatic Breast
Cancer That Overexpresses HER-2/NEU
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=18CBCC2B-
91FD-6306-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/10752
E1105 Follow-Up Disease Evaluation
Form (RECIST) NCT00520975
Header
ECOG Protocol Number
ECOG Patient ID
DCI Name
Registration Step
Patient demographics
Patient Initials
ECOG Protocol Number
Participating Group Protocol Number
ECOG Patient ID
Participating Group Patient ID
Institution/Affiliate
Data amendment
Please mark an 'X' if data have been amended.
(Please circle amended items in red)
Date data amended (s)
Reporting Period
On Treatment Report Period (Maintenance 1
cycle = 3 weeks)
> Cycle 20 (> Cycle 20)
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Cycle 12 (Cycle 12)
Cycle 16 (Cycle 16)
Cycle 20 (Cycle 20)
Cycle 4 (cycle 4)
Cycle 8 (cycle 8)
On Treatment Report Period (Maintenance 1
cycle = 3 weeks)
> Cycle 20 (> Cycle 20)
Cycle 12 (Cycle 12)
Cycle 16 (Cycle 16)
Cycle 20 (Cycle 20)
Cycle 4 (cycle 4)
Cycle 8 (cycle 8)
Specify Cycle
Off Treatment
Off Treatment Report Period (since registration)
9 Years (108 months post registration)
12 Months Post Randomization (12
Months Post Randomization)
10 Years (120 months post registration)
18 Months Post Randomization (18
Months Post Randomization)
21 Months Post Randomization (21
Months Post Randomization)
24 Months Post Randomization (24
Months Post Randomization)
3 Months Post Randomization (3 Months
Post Randomization)
30 Months Post Randomization (30
Months Post Randomization)
36 Months Post Randomization (36
Months Post Randomization)
42 Months Post Randomization (42
Months Post Randomization)
48 Months Post Randomization (48
Months Post Randomization)
54 Months Post Randomization (54
Months Post Randomization)
6 Months Post Randomization (6 Months
Post Randomization)
60 Months Post Randomization (60
Months Post Randomization)
6 Years (72 months post registration)
84 Months Post Registration (84 months
post registration)
9 Months Post Randomization (9 Months
Post Randomization)
8 Years (96 months post registration)
Target Lesions
Lesion Number
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Site of Lesion
Site Code
Bone (Bone)
Brain (Brain)
Breast (Breast)
Effusion/ascites (Effusion/Ascites)
Gi (GI)
Gu (GU)
Head & Neck (Head & Neck)
Liver (Liver)
Lung (Lung)
Nodes (Nodes)
Other (Other)
Skin (Skin)
Method of Evaluation
Bone Scan (Bone scan)
Chest X-ray (Chest X-Ray)
Clinical (Clinical Examination)
Ct Scan (CT Scan)
Mri (MRI)
Not Evaluated (Not evaluated)
Other (Other)
Spiral Ct Scan (Spiral CT scan)
Ultrasound (Ultrasound)
Date of Evaluation
Longest Diameter of Lesion (s)
Baseline Longest Diameter of Lesion (For
Identification: Document - cm)
Sum of longest diameters of all target lesions
(cm)
Nontarget Lesions
Lesion Number
Site of Lesion
Site Code
Bone (Bone)
Brain (Brain)
Breast (Breast)
Effusion/ascites (Effusion/Ascites)
Gi (GI)
Gu (GU)
Head & Neck (Head & Neck)
Liver (Liver)
Lung (Lung)
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Nodes (Nodes)
Other (Other)
Skin (Skin)
Method of Evaluation
Bone Scan (Bone scan)
Chest X-ray (Chest X-Ray)
Clinical (Clinical Examination)
Ct Scan (CT Scan)
Mri (MRI)
Not Evaluated (Not evaluated)
Other (Other)
Spiral Ct Scan (Spiral CT scan)
Ultrasound (Ultrasound)
Date of Evaluation
Follow-up Status of Lesion (s)
Complete Response (CR)
Stable Disease (incompl.resp./SD)
Progressive Disease (PD)
Cytology Result (For Site Code 04 ONLY)
Negative (Negative)
Not Done (Not done)
Positive (Positive)
New Lesions
Lesion Number
Was the appearance of any new lesions
documented
Yes
No
Site of Lesion
Site Code
Bone (Bone)
Brain (Brain)
Breast (Breast)
Effusion/ascites (Effusion/Ascites)
Gi (GI)
Gu (GU)
Head & Neck (Head & Neck)
Liver (Liver)
Lung (Lung)
Nodes (Nodes)
Other (Other)
Skin (Skin)
Method of Evaluation
Bone Scan (Bone scan)
Chest X-ray (Chest X-Ray)
Clinical (Clinical Examination)
Ct Scan (CT Scan)
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Mri (MRI)
Not Evaluated (Not evaluated)
Other (Other)
Spiral Ct Scan (Spiral CT scan)
Ultrasound (Ultrasound)
Date of Evaluation
Cytology Result (For Site Code 04 ONLY)
Negative (Negative)
Not Done (Not done)
Positive (Positive)
Response Of Target Lesions This
Reporting Period
Has the response of the target lesions changed,
OR has an unconfirmed response changed to a
confirmed response, since last report ([NOTE:
Code 'yes' if this is the FIRST documentation of
stable disease.])
Yes
No
Response status at this assessment (target
lesions)
Complete Response (CR)
Insufficient Evaluation (Insufficient
evaluation to determine response status)
Progressive Disease (PD)
Partial Response (PR)
Stable Disease (SD)
PR/CR first observed date (If yes)
Progressive disease observed date (For PD)
Overall Response Per Recist Criteria -
Target, Nontarget And New Lesions
Has the overall response changed, OR has an
unconfirmed response changed to a confirmed
response, since last report ([NOTE: Code ?yes?
if this is the FIRST documentation of stable
disease.])
Yes
No
PR/CR first observed date (If yes)
Overall response status at this assessment
Complete Response (CR)
Insufficient Evaluation (Insufficient
evaluation to determine response status)
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Progressive Disease (PD)
Partial Response (PR)
Stable Disease (SD)
Progressive disease observed date (For PD)
Has response been confirmed by second
assessment (For CR or PR)
Yes
No
Symptomatic Deterioration
Is there symptomatic deterioration of the patient's
health status requiring discontinuation of
treatment (this reporting period)
Yes
No
Specify symptomatic deterioration (If yes)
Symptomatic Deterioration Date
Comments
Comments
Investigator Signature
Investigator Signature Date
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E1105 Nontarget Lesions Supplemental
Form (RECIST) NCT00520975
E1105 Nontarget Lesions Supplemental Form (RECIST)
NCT00520975
First-Line Chemotherapy and Trastuzumab With or Without
Bevacizumab in Treating Patients With Metastatic Breast
Cancer That Overexpresses HER-2/NEU
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=1722483C-
33D9-65D3-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/10753
E1105 Nontarget Lesions
Supplemental Form (RECIST)
NCT00520975
ECOG clinical trial administrative data
Patient Initials
ECOG Protocol Number
ECOG Patient ID
Participating Group Protocol Number
Participating Group Patient ID
Institution/Affiliate
Reporting Period
Baseline (Baseline)
Follow-up (Follow-up)
DCI Name
Registration Step
Data amendment
Please mark an 'X' if data have been amended.
(Please circle amended items in red)
Date data amended (s)
On Treatment
On Treatment Report Period (since start of
treatment)
> Cycle 20 (> Cycle 20)
Cycle 12 (Cycle 12)
Cycle 16 (Cycle 16)
Cycle 20 (Cycle 20)
Cycle 4 (Cycle 4)
1 / 3
Cycle 8 (Cycle 8)
Specify Cycle (specify)
Off Treatment
Off Treatment Report Period (since registration)
9 Years (108 months post registration)
12 Months Post Randomization (12
Months Post Randomization)
18 Months Post Randomization (18
Months Post Randomization)
21 Months Post Randomization (21
Months Post Randomization)
24 Months Post Randomization (24
Months Post Randomization)
3 Months Post Randomization (3 Months
Post Randomization)
30 Months Post Randomization (30
Months Post Randomization)
36 Months Post Randomization (36
Months Post Randomization)
42 Months Post Randomization (42
Months Post Randomization)
48 Months Post Randomization (48
Months Post Randomization)
54 Months Post Randomization (54
Months Post Randomization)
6 Months Post Randomization (6 Months
Post Randomization)
60 Months Post Randomization (60
Months Post Randomization)
6 Years (72 months post registration)
84 Months Post Registration (84 months
post registration)
9 Months Post Randomization (9 Months
Post Randomization)
8 Years (96 months post registration)
Nontarget Lesions
Lesion Number
Site of Lesion (*)
Site Code
Bone (bone)
Brain (Brain)
Breast (Breast)
Effusion/ascites (Effusion/Ascites)
Gi (GI)
Gu (GU)
Head & Neck (Head & Neck)
Liver (Liver)
Lung (Lung)
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Nodes (Nodes)
Other (other)
Skin (Skin)
Method of Evaluation
Bone Scan (Bone scan)
Chest X-ray (Chest X-Ray)
Clinical (Clinical Examination)
Ct Scan (CT Scan)
Mri (MRI)
Not Evaluated (Not evaluated)
Other (other)
Spiral Ct Scan (Spiral CT scan)
Ultrasound (Ultrasound)
Date of Evaluation (Follow-up Status of Lesions)
Follow-Up Status of Lesion (Choose one for each
lesion.  Leave blank if baseline.)
Complete Response (CR)
Incompl. Resp./sd (Incompl. resp./SD)
Progressive Disease (PD)
Cytology Result (For Site Code 04
effusion/ascites ONLY:)
Negative (Negative)
Not Done (Not done)
Positive (Positive)
Comments
Comments
Investigator Signature
Investigator Signature Date
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E2108 Step 2 Disease Evaluation Form
(RECIST 1.1) NCT01242800
E2108 Step 2 Disease Evaluation Form (RECIST 1.1)
NCT01242800
Early Surgery or Standard Palliative Therapy in Treating
Patients With Stage IV Breast Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=8E091CE3-
4B63-4A3C-E040-BB89AD4304A1
All rights reserved. Please visit https://medical-data-
models.org/forms/10754
E2108 Step 2 Disease Evaluation
Form (RECIST 1.1) NCT01242800
ECOG clinical trial administrative data
Patient Initials (Last, First)
ECOG Protocol Number
ECOG Patient ID
Participating Group Protocol Number
Participating Group Patient ID
Institution/Affiliate
DCI Name
Registration Step
Data amendment
Please mark an 'X' if data have been amended.
(Please circle amended items in red)
Date data amended (s M D Y)
On Treatment
On Treatment Report Period (Choose one)
18 Months Post Randomization (18
Months Post Randomization)
30 Months Post Randomization (30
Months Post Randomization)
6 Months Post Randomization (6 Months
Post Randomization)
At Decision For Local Therapy (At
Decision for Local Therapy)
1 / 4
Disease Assessment
Were disease assessment results obtained this
report period? (cycle)
Yes
No
TARGET LESIONS - NON-NODAL
Lesion Number
Site of Lesion (Multiple new lesions within an
organ may be combined as a single site)
Site Code
Bone (Bone)
Brain (Brain)
Breast (Breast)
Effusion/ascites (Effusion/Ascites)
Gi (GI)
Gu (GU)
Head & Neck (Head & Neck)
Liver (Liver)
Lung (Lung)
Nodes (Nodes)
Other (Other)
Skin (Skin)
Method of Evaluation
Bone Scan (Bone scan)
Chest X-ray (Chest x-ray)
Clinical Examination (pe) (Clinical
examination)
Ct Scan (CT scan)
Positron Emission Tomography (FDG-
PET)
Mri (MRI (NMR))
Not Evaluated (Not evaluated)
Other (Other)
Pet/ct Scan (PET/CT scan)
Date of Evaluation (M D Y)
Longest Diameter of Lesion(s) (cm)
Sum of Longest Diameters of All Non-Nodal
Target Lesions
TARGET LESIONS - NODAL
Shortest Axis of Lesions (mm)
Check this box if node reaches sub-clinical level
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(<10 mm)
Sum of Shortest Axes of All Nodal Lesions (mm)
Sum of Longest (Non-Nodal) and Shortest
(Nodal) Axes of All Target Lesions (mm)
Nontarget Lesions
Follow-Up Status of Lesion (s)
Complete Response (CR)
Incompl. Resp./sd (Incompl. resp./SD)
Progressive Disease (PD)
Cytology Result (For Site Code 04
effusion/ascites ONLY)
Negative (Negative)
Not Done (Not done)
Positive (Positive)
Unequivocal progressive disease in nontarget
lesions is based on: (please describe)
New Lesions
Was the appearance of any new lesions
documented
Yes
No
Overall Response Per Recist Criteria -
Target, Nontarget And New Lesions
Best Overall Response to date (response status
of all target, non-target, and new lesions)
Complete Response (CR)
Insufficient Evaluation (Insufficient
evaluation to determine response status)
Progressive Disease (PD)
Partial Response (PR)
Stable Disease (SD)
Has the patient progressed or relapsed
No (No)
Unknown (Unknown)
Yes (Yes)
Progressive disease/Relapse observed date (M D
Y)
Were circulating tumor cells (CTCs) assessed
(during this reporting period)
Yes
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No
CTC Count (If yes,)
Symptomatic Deterioration
Is there symptomatic deterioration of the patient's
health status
Yes
No
Specify symptomatic deterioration (If yes:)
Symptomatic Deterioration Date (M D Y)
Comments
Comments
Investigator Signature
Investigator Signature Date (M D Y)
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E5204 Disease Assessment Form
NCT00303628
E5204 Disease Assessment Form NCT00303628
Combination Chemotherapy With or Without Bevacizumab
in Treating Patients Who Have Had Surgery for Stage II or
Stage III Rectal Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=089B0CA5-
B778-3631-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/10755
E5204 Disease Assessment Form
NCT00303628
ECOG clinical trial administrative data
ECOG Protocol Number
ECOG Patient ID
DCI Name
Registration Step
Patient Initials (Last, First)
Participating Group Protocol Number
Institution/Affiliate
Participating Group Patient ID
Data amendment
Please mark an 'X' if data have been amended.
(Please circle amended items in red)
Date data amended (s - mm/dd/yyyy)
Cycle number
On Treatment Report Period (Choose one x)
Cycle 12 (Cycle 12)
Cycle 6 (Cycle 6)
Vital Status
Patient's Vital Status
Alive (Alive)
Dead (Dead)
1 / 3
Date of last contact or death (mm/dd/yyyy)
Primary Cause of Death (if applicable)
Due To Other Cause (Due to other
cause)
Due To Protocol Treatment (Due to
protocol treatment)
Due To This Disease (Due to this
disease)
Unknown (Unknown)
Describe cause of death
Disease Follow-up Status
Has the patient had a documented clinical
assessment for this cancer (since submission of
the previous follow-up form)
No (No)
Unknown (Unknown)
Yes (Yes)
If unknown, please explain
Date of last clinical assessment (If yes)
Date CEA obtained
CEA value (ng/ml)
CEA ULN
Notice Of Recurrence
Has the patient been diagnosed with a first
recurrence since the last Follow-Up Form? (Long-
Term)
No (No)
Unknown (Unknown)
Yes (Yes)
Date of First Recurrence (If yes)
Site of recurrence (s)
Abdominal Wall, Perineum And Scar
(Abdominal wall, perineum and scar)
Abdominal, Pelvic And Retro-peritoneal
Nodes (Abdominal, pelvic and retro-
peritoneal nodes)
Anastomotic (Anastomotic)
Ascites (Ascites)
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Bone Marrow (Bone marrow)
Central Nervous System (Central
nervous system)
Colon (Colon)
Liver (Liver)
Lung (Lung)
Multiple (Multiple)
Other (Other)
Pelvic Mass Not Otherwise Specified
(Pelvic mass not otherwise specific)
Peritoneum (Peritoneum)
Rectum, Other Than Site Of Anastomotic
(Rectum, other than site of anastomotic)
Skeletal (Skeletal)
Unknown (Unknown)
Explain other, multiple, or unknown
Did a physician make a formal diagnosis of
recurrence
No (No)
Unknown (Unknown)
Yes (Yes)
Specify basis of recurrence (If no or unknown)
Was the recurrence treated by surgery
No (No)
Unknown (Unknown)
Yes (Yes)
Comments
Investigator Signature
Investigator Signature Date
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E5202 Disease Assessment Form
NCT00217737
E5202 Disease Assessment Form NCT00217737
Oxaliplatin, Leucovorin, and Fluorouracil With or Without
Bevacizumab in Treating Patients Who Have Undergone
Surgery for Stage II Colon Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=F64D15FD-
EE93-52E3-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/10756
E5202 Disease Assessment Form
NCT00217737
ECOG clinical trial administrative data
ECOG Protocol Number
ECOG Patient ID
DCI Name
Registration Step
Patient Initials
Participating Group Protocol Number
Institution/Affiliate
Participating Group Patient ID
Data amendment
Please mark an 'X' if data have been amended.
Date data amended
Cycle number
On Treatment Report Period
Cycle 12 (Cycle 12)
Cycle 18 (Cycle 18)
Cycle 24 (Cycle 24)
Cycle 3 (Cycle 3)
Cycle 6 (Cycle 6)
Vital Status
Patient's Vital Status
Alive (Alive)
1 / 3
Dead (Dead)
Date of last contact or death
Primary Cause of Death (if applicable)
Due To Other Cause (Due to other
cause)
Due To Protocol Treatment (Due to
protocol treatment)
Due To This Disease (Due to this
disease)
Unknown (Unknown)
Describe cause of death
Disease Follow-up Status
Has the patient had a documented clinical
assessment for this cancer (since submission of
the previous follow-up form)
No (No)
Unknown (Unknown)
Yes (Yes)
If unknown, explain
Date of last clinical assessment (If yes)
Date CEA obtained
CEA value
CEA ULN
Notice Of Recurrence
Has the patient been diagnosed with a first
recurrence since the last Follow-Up Form? (Long-
Term)
No (No)
Unknown (Unknown)
Yes (Yes)
Date of First Recurrence (If yes)
Site of recurrence (s)
Abdominal Wall, Perineum And Scar
(Abdominal wall, perineum and scar)
Abdominal, Pelvic And Retro-peritoneal
Nodes (Abdominal, pelvic and retro-
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peritoneal nodes)
Anastomotic (Anastomotic)
Ascites (Ascites)
Bone Marrow (Bone marrow)
Central Nervous System (Central
nervous system)
Colon, Other Than Site Of Anastomotic
(Colon, other than site of anastomotic)
Liver (Liver)
Lung (Lung)
Multiple (Multiple)
Other (Other)
Pelvic Mass Not Otherwise Specified
(Pelvic mass not otherwise specific)
Peritoneum (Peritoneum)
Skeletal (Skeletal)
Unknown (Unknown)
Explain other, multiple, or unknown
Did a physician make a formal diagnosis of
recurrence
No (No)
Unknown (Unknown)
Yes (Yes)
Specify basis of recurrence (If no or unknown)
Was the recurrence treated by surgery
No (No)
Unknown (Unknown)
Yes (Yes)
Comments
Comments
Investigator Signature
Investigator Signature Date
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E1305 Nontarget Lesions Supplemental
Form (RECIST) NCT00588770
E1305 Nontarget Lesions Supplemental Form (RECIST)
NCT00588770
Chemotherapy With or Without Bevacizumab in Treating
Patients With Recurrent or Metastatic Head and Neck
Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=19F717BA-
DF10-2BA5-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/10757
E1305 Nontarget Lesions
Supplemental Form (RECIST)
NCT00588770
ECOG clinical trial administrative data
ECOG Protocol Number
ECOG Patient ID
Reporting Period
Baseline (Baseline)
Follow-up (Follow-up)
DCI Name
Registration Step
Patient Initials (Last, First)
Participating Group Protocol Number
Participating Group Patient ID
Institution/Affiliate
Data amendment
Please mark an 'X' if data have been amended.
(Please circle amended items in red)
Date data amended (s)
On Treatment
On Treatment Report Period (since start of
treatment)
> Cycle 38 (> Cycle 38)
Baseline (Baseline)
Cycle 10 (Cycle 10)
Cycle 12 (Cycle 12)
1 / 3
Cycle 14 (Cycle 14)
Cycle 16 (Cycle 16)
Cycle 18 (Cycle 18)
Cycle 2 (Cycle 2)
Cycle 20 (Cycle 20)
Cycle 22 (Cycle 22)
Cycle 24 (Cycle 24)
Cycle 26 (Cycle 26)
Cycle 28 (Cycle 28)
Cycle 30 (Cycle 30)
Cycle 32 (Cycle 32)
Cycle 34 (Cycle 34)
Cycle 36 (Cycle 36)
Cycle 38 (Cycle 38)
Cycle 4 (Cycle 4)
Cycle 6 (Cycle 6)
Cycle 8 (Cycle 8)
Specify Cycle (specify)
Off Treatment
Off Treatment Report Period (since registration)
12 Months (12 months post registration)
15 Months (15 months post registration)
18 Months (18 months post registration)
21 Months Post Registration (21 months
post registration)
24 Months (24 months post registration)
3 Months (3 months post registration)
36 Months (36 months post registration)
42 Months Post Registration (42 Months
Post Registration)
4 Years (48 months post registration)
54 Months Post Randomization (54
Months Post Randomization)
6 Months (6 months post registration)
60 Months Post Randomization (60
Months Post Randomization)
9 Months (9 months post registration)
Nontarget Lesions
Lesion Number
Site of Lesion (*)
Site Code
Bone (bone)
Brain (Brain)
Breast (Breast)
Effusion/ascites (Effusion/Ascites)
Gi (GI)
Gu (GU)
Head & Neck (Head & Neck)
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Liver (Liver)
Lung (Lung)
Nodes (Nodes)
Other (other)
Skin (Skin)
Method of Evaluation
Bone Scan (Bone scan)
Chest X-ray (Chest X-Ray)
Clinical (Clinical Examination)
Ct Scan (CT Scan)
Mri (MRI)
Not Evaluated (Not evaluated)
Other (other)
Spiral Ct Scan (Spiral CT scan)
Ultrasound (Ultrasound)
Date of Evaluation (Follow-up Status of Lesions)
Follow-Up Status of Lesion (Choose one for each
lesion.  Leave blank if baseline.)
Complete Response (CR)
Incompl. Resp./sd (Incompl. resp./SD)
Progressive Disease (PD)
Cytology Result (For Site Code 04
effusion/ascites ONLY:)
Negative (Negative)
Not Done (Not done)
Positive (Positive)
Comments
Comments
Investigator Signature
Investigator Signature Date
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E1305 Follow-Up Disease Evaluation Form
(RECIST) NCT00588770
E1305 Follow-Up Disease Evaluation Form  (RECIST)
NCT00588770
Chemotherapy With or Without Bevacizumab in Treating
Patients With Recurrent or Metastatic Head and Neck
Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=19FAD740-
2B45-48C6-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/10758
E1305 Follow-Up Disease Evaluation
Form  (RECIST) NCT00588770
ECOG clinical trial administrative data
ECOG Protocol Number
ECOG Patient ID
DCI Name
Registration Step
Patient Initials (Last, First)
Participating Group Protocol Number
Participating Group Patient ID
Institution/Affiliate
Data amendment
Please mark an 'X' if data have been amended.
(Please circle amended items in red)
Date data amended
On Treatment
On Treatment Report Period (since start of
treatment)
> Cycle 38 (> Cycle 38)
Baseline (Baseline)
Cycle 10 (Cycle 10)
Cycle 12 (Cycle 12)
Cycle 14 (Cycle 14)
Cycle 16 (Cycle 16)
Cycle 18 (Cycle 18)
Cycle 2 (Cycle 2)
Cycle 20 (Cycle 20)
1 / 4
Cycle 22 (Cycle 22)
Cycle 24 (Cycle 24)
Cycle 26 (Cycle 26)
Cycle 28 (Cycle 28)
Cycle 30 (Cycle 30)
Cycle 32 (Cycle 32)
Cycle 34 (Cycle 34)
Cycle 36 (Cycle 36)
Cycle 38 (Cycle 38)
Cycle 4 (Cycle 4)
Cycle 6 (Cycle 6)
Cycle 8 (Cycle 8)
Specify Cycle (specify)
Off Treatment
Off Treatment Report Period (since registration)
12 Months (12 months post registration)
15 Months (15 months post registration)
18 Months (18 months post registration)
21 Months Post Registration (21 months
post registration)
24 Months (24 months post registration)
3 Months (3 months post registration)
36 Months (36 months post registration)
42 Months Post Registration (42 Months
Post Registration)
4 Years (48 months post registration)
54 Months Post Randomization (54
Months Post Randomization)
6 Months (6 months post registration)
60 Months Post Randomization (60
Months Post Randomization)
9 Months (9 months post registration)
Disease assessment
Were disease assessment results obtained this
report period?
Yes
No
TARGET LESIONS
Lesion Number
Site of Lesion
Site Code
Bone (Bone)
Brain (Brain)
Breast (Breast)
Effusion/ascites (Effusion/Ascites)
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Gi (GI)
Gu (GU)
Head & Neck (Head & Neck)
Liver (Liver)
Lung (Lung)
Nodes (Nodes)
Other (Other)
Skin (Skin)
Method of Evaluation
Bone Scan (Bone scan)
Chest X-ray (Chest x-ray)
Clinical Examination (pe) (Clinical
examination)
Ct Scan (CT scan)
Mri (MRI (NMR))
Not Evaluated (Not evaluated)
Other (Other)
Spiral Ct Scan (Spiral CT scan)
Ultrasound (Ultrasound)
Date of Evaluation
Longest Diameter of Lesion(s) (cm)
Sum of longest diameters of all target lesions
(cm)
Nontarget Lesions
Follow-Up Status of Lesion
Complete Response (CR)
Incompl. Resp./sd (Incompl. resp./SD)
Progressive Disease (PD)
Cytology Result (For Site Code 04
effusion/ascites ONLY)
Negative (Negative)
Not Done (Not done)
Positive (Positive)
New Lesions
Was the appearance of any new lesions
documented
Yes
No
Overall Response Per Recist Criteria -
Target, Nontarget And New Lesions
Best Overall Response to date
Complete Response (CR)
Insufficient Evaluation (Insufficient
evaluation to determine response status)
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Progressive Disease (PD)
Partial Response (PR)
Stable Disease (SD)
Progressive disease/Relapse observed date
Symptomatic Deterioration
Is there symptomatic deterioration of the patient's
health status
Yes
No
Specify symptomatic deterioration (If yes:)
Symptomatic Deterioration Date
Comments
Comments
Investigator Signature
Investigator Signature Date
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E2805 Follow-up Disease Evaluation Form
NCT00326898
E2805 Follow-up Disease Evaluation Form NCT00326898
Sunitinib or Sorafenib in Treating Patients With Kidney
Cancer That Was Removed By Surgery
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=054D0EB8-
8174-3DEA-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/10759
E2805 Follow-up Disease Evaluation
Form NCT00326898
ECOG clinical trial administrative data
ECOG Protocol Number
ECOG Patient ID
DCI Name
Registration Step
Patient Initials
Participating Group Protocol Number
Institution/Affiliate
Participating Group Patient ID
Data amendment
Please mark an 'X' if data have been amended
Date data amended
Cycle number
On Treatment Report Period
End Of Cycle 2 (End of Cycle 2)
End Of Cycle 4 (End of Cycle 4)
End Of Cycle 6 (End of Cycle 6)
End Of Cycle 8 (End of Cycle 8)
Recurrence (Recurrence)
Off Treatment Report Period
9 Years (108 months post registration)
12 Months (12 months post registration)
10 Years (120 months post registration)
15 Months (15 months post registration)
1 / 3
18 Months (18 months post registration)
21 Months Post Registration (21 months
post registration)
24 Months (24 months post registration)
3 Months (3 months post registration)
30 Months (30 months post registration)
36 Months (36 months post registration)
42 Months Post Registration (42 Months
Post Registration)
4 Years (48 months post registration)
54 Months Post Registration (54 Months
Post Registration)
6 Months (6 months post registration)
5 Years (60 months post registration)
6 Years (72 months post registration)
84 Months Post Registration (84 months
post registration)
9 Months (9 months post registration)
8 Years (96 months post registration)
Disease Follow-up Status
Has the patient had a documented clinical
assessment for this cancer (since submission of
the previous follow-up form)
No (No)
Unknown (Unknown)
Yes (Yes)
If unknown, please explain
Date of last clinical assessment (If yes)
Notice Of Recurrence
Recurrent disease
Yes
No
Date of First Recurrence (If yes)
How was recurrence discovered
Clinical Evaluation (Clinical evaluation)
Development Of Symptoms
(Development of symptoms)
Other (Other)
Routine Radiologic Evaluation (Routine
radiologic evaluation)
Other, specify
Site of recurrence
Central Nervous System (Central
nervous system)
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Liver (Liver)
Lung (Lung)
Other (Other)
Other Organs (Other organs)
Renal Bed (Renal bed)
Skeletal (Skeletal)
Subcutaneous And Lymph Node
Recurrence (Subcutaneous and lymph
node recurrence)
Unknown (Unknown)
Explain other or unknown
Biopsy done
No (No)
Unknown (Unknown)
Yes (Yes)
Date of Biopsy
Biopsy Result
Atypical/indeterminate
(Atypical/indeterminate)
Benign (Benign)
Malignant (Malignant)
Other (Other)
Other, specify
Did a physician make a formal diagnosis of
recurrence
No (No)
Unknown (Unknown)
Yes (Yes)
Specify basis of recurrence (If no or unknown)
Was the recurrence treated by surgery
No (No)
Unknown (Unknown)
Yes (Yes)
Comments
Investigator Signature
Investigator Signature Date
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E2906 Donor/Transplant Form
NCT01041703
E2906 Donor/Transplant Form NCT01041703 
Clofarabine or Daunorubicin Hydrochloride and Cytarabine
Followed By Decitabine or Observation in Treating Older
Patients With Newly Diagnosed Acute Myeloid Leukemia
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=842DEB36-
F390-AD41-E040-BB89AD4373C4
All rights reserved. Please visit https://medical-data-
models.org/forms/10760
E2906 Donor/Transplant Form
NCT01041703
ECOG clinical trial administrative data
DCI Name
Registration Step (Place ID Label Here)
Patient Initials (Last, First)
ECOG Protocol Number
ECOG Protocol Number
ECOG Patient ID
ECOG Patient ID
Participating Group Protocol Number
Participating Group Patient ID
Institution/Affiliate
On Treatment
On Treatment Reporting Period
At Transplant (At Transplant)
Data amendment
Please mark an 'X' if data have been amended.
(Please circle amended items in red)
Date data amended (s M D Y)
Vital Status
1 / 3
Patient's Vital Status
Alive (Alive)
Dead (Dead)
Weight (kg Day 1 of this treatment)
Date of Last Contact or Death (M D Y)
Primary Cause of Death (if applicable)
Due To Other Cause (Due to other
cause)
Due To Protocol Treatment (Due to
protocol treatment)
Due To This Disease (Due to this
disease)
Unknown (Unknown)
Describe cause of death
Donor Information
Donor's Relationship to recipient
Not Related (not related)
Other Family Member (Other family
member)
Sibling (sibling)
Allogeneic Transplant
Did the patient receive protocol transplant?
Yes
No
Reason transplant was not done (If no,)
Death (Death)
Failure To Mobilize Stem Cells (Failure to
mobilize stem cells)
Insurance Problems (Insurance
problems)
No Cr Or Morphologic Leukemia-free
State Achieved (No CR or morphologic
leukemia-free state achieved)
Other (Other)
Other Complicating Disease (Other
complicating disease)
Patient Refusal (Patient refusal)
Physician Decision (Physician decision)
Poor Ecog Performance Status (Poor
ECOG performance status)
Relapse (Relapse)
Other specify
Comments
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Investigator Signature
Investigator Signature Date (MM DD YYYY)
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E1208 Nontarget Lesions Supplemental
Form (RECIST) NCT01004978
E1208 Nontarget Lesions Supplemental Form (RECIST)
NCT01004978 
Chemoembolization With or Without Sorafenib Tosylate in
Treating Patients With Liver Cancer That Cannot Be
Removed By Surgery
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=6FCA48E1-
2773-7263-E040-BB89AD434A3E
All rights reserved. Please visit https://medical-data-
models.org/forms/10761
E1208 Nontarget Lesions
Supplemental Form (RECIST)
NCT01004978
Header
ECOG Protocol Number
ECOG Patient ID
Report Period
Baseline (Baseline)
Follow-up (Follow-up)
DCI Name
Registration Step
Patient Initials (Last, First)
Participating Group Protocol Number
Participating Group Patient ID
Institution/Affiliate
Data amendment
Please mark an 'X' if data have been amended.
(Please circle amended items in red)
Date data amended (s M D Y)
On Treatment
On Treatment Report Period (since start of
treatment Choose one)
> 24 Months Post Initial Tace (> 24
months post initial TACE)
10 Months Post Initial Tace (10 months
post initial TACE)
1 / 3
12 Months Post Initial Tace (12 months
post initial TACE)
14 Months Post Initial Tace (14 months
post initial TACE)
16 Months Post Initial Tace (16 months
post initial TACE)
18 Months Post Initial Tace (18 months
post initial TACE)
20 Months Post Initial Tace (20 months
post initial TACE)
22 Months Post Initial Tace (22 months
post initial TACE)
24 Months Post Initial Tace (24 months
post initial TACE)
4 Months Post Initial Tace (4 months post
initial TACE)
8 Months Post Initial Tace (8 months post
initial TACE)
Baseline (baseline)
Specify Cycle
Off Treatment
Off Treatment Report Period (since registration
Choose one)
12 Months (12 months post registration)
15 Months (15 months post registration)
18 Months (18 months post registration)
21 Months Post Registration (21 months
post registration)
24 Months (24 months post registration)
3 Months (3 months post registration)
30 Months (30 months post registration)
36 Months (36 months post registration)
42 Months Post Registration (42 Months
Post Registration)
4 Years (48 months post registration)
6 Months (6 months post registration)
9 Months (9 months post registration)
Nontarget Lesions
Lesion Number
Site of Lesion (Multiple nontarget lesions within
an organ may be combined as a single site, but
must be reported in same manner as at baseline)
Site Code
Bone (bone)
Brain (Brain)
Breast (Breast)
Effusion/ascites (Effusion/Ascites)
Gi (GI)
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Gu (GU)
Head & Neck (Head & Neck)
Liver (Liver)
Lung (Lung)
Nodes (Nodes)
Other (other)
Skin (Skin)
Method of Evaluation
Bone Scan (Bone scan)
Chest X-ray (Chest X-Ray)
Clinical (Clinical Examination)
Ct Scan (CT Scan)
Mri (MRI (NMR))
Not Evaluated (Not evaluated)
Other (other)
Spiral Ct Scan (Spiral CT scan)
Ultrasound (Ultrasound)
Date of Evaluation (M D Y)
Follow-Up Status of Lesion (s Choose one for
each lesion. Leave blank if baseline.)
Complete Response (CR)
Incompl. Resp./sd (Incompl. resp./SD)
Progressive Disease (PD)
Cytology Result (For Site Code 04
effusion/ascites ONLY)
Negative (Negative)
Not Done (Not done)
Positive (Positive)
Comments
Comments
Investigator Signature
Investigator Signature Date (M D Y)
3 / 3
E1208 Nontarget Lesions Supplemental Form (RECIST) NCT01004978
E1208 Source Document Tracking
Coversheet NCT01004978
E1208 Source Document Tracking Coversheet
NCT01004978 
Chemoembolization With or Without Sorafenib Tosylate in
Treating Patients With Liver Cancer That Cannot Be
Removed By Surgery
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=6FDC3F1E-
42D2-1043-E040-BB89AD430FD1
All rights reserved. Please visit https://medical-data-
models.org/forms/10762
E1208 Source Document Tracking
Coversheet NCT01004978
ECOG clinical trial administrative data
ECOG Protocol Number
ECOG Patient ID
DCI Name
Registration Step
Reporting Period
> Cycle 16 (> Cycle 16)
Cycle 1 (Cycle 1)
Cycle 10 (Cycle 10)
Cycle 11 (Cycle 11)
Cycle 12 (Cycle 12)
Cycle 13 (Cycle 13)
Cycle 14 (Cycle 14)
Cycle 15 (Cycle 15)
Cycle 16 (Cycle 16)
Cycle 2 (Cycle 2)
Cycle 3 (Cycle 3)
Cycle 4 (cycle 4)
Cycle 5 (Cycle 5)
Cycle 6 (Cycle 6)
Cycle 7 (Cycle 7)
Cycle 8 (cycle 8)
Cycle 9 (Cycle 9)
Specify Cycle
Patient Initials (Last, First)
Participating Group Protocol Number
Participating Group Patient ID
Institution/Affiliate
Document type
1 / 2
Patient Pill Diary (Patient pill diary)
Report Created Date
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E1208 Follow-Up Disease Evaluation Form
(RECIST) NCT01004978
E1208 Follow-Up Disease Evaluation Form (RECIST)
NCT01004978 
Chemoembolization With or Without Sorafenib Tosylate in
Treating Patients With Liver Cancer That Cannot Be
Removed By Surgery
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=6FDF6DBB-
2BD5-6632-E040-BB89AD434639
All rights reserved. Please visit https://medical-data-
models.org/forms/10764
E1208 Follow-Up Disease Evaluation
Form (RECIST) NCT01004978
ECOG clinical trial administrative data
ECOG Protocol Number
ECOG Patient ID
DCI Name
Registration Step
Patient Initials (Last, First)
Participating Group Protocol Number
Participating Group Patient ID
Institution/Affiliate
Data amendment
Please mark an 'X' if data have been amended.
(Please circle amended items in red)
Date data amended (s M D Y)
On Treatment
On Treatment Report Period (since start of
treatment Choose one)
> 24 Months Post Initial Tace (> 24
months post initial TACE)
10 Months Post Initial Tace (10 months
post initial TACE)
12 Months Post Initial Tace (12 months
post initial TACE)
14 Months Post Initial Tace (14 months
post initial TACE)
16 Months Post Initial Tace (16 months
1 / 4
post initial TACE)
18 Months Post Initial Tace (18 months
post initial TACE)
20 Months Post Initial Tace (20 months
post initial TACE)
22 Months Post Initial Tace (22 months
post initial TACE)
24 Months Post Initial Tace (24 months
post initial TACE)
4 Months Post Initial Tace (4 months post
initial TACE)
8 Months Post Initial Tace (8 months post
initial TACE)
Specify Cycle
Off Treatment
Off Treatment Report Period (since registration
Choose one)
12 Months (12 months post registration)
15 Months (15 months post registration)
18 Months (18 months post registration)
21 Months Post Registration (21 months
post registration)
24 Months (24 months post registration)
3 Months (3 months post registration)
30 Months (30 months post registration)
36 Months (36 months post registration)
42 Months Post Registration (42 Months
Post Registration)
4 Years (48 months post registration)
6 Months (6 months post registration)
9 Months (9 months post registration)
Disease Assessment
Were disease assessment results obtained this
report period? (cycle)
Yes
No
TARGET LESIONS
Lesion Number
Site of Lesion (Multiple new lesions within an
organ may be combined as a single site)
Site Code
Bone (Bone)
Brain (Brain)
Breast (Breast)
Effusion/ascites (Effusion/Ascites)
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Gi (GI)
Gu (GU)
Head & Neck (Head & Neck)
Liver (Liver)
Lung (Lung)
Nodes (Nodes)
Other (Other)
Skin (Skin)
Method of Evaluation
Bone Scan (Bone scan)
Chest X-ray (Chest x-ray)
Clinical Examination (pe) (Clinical
examination)
Ct Scan (CT scan)
Mri (MRI (NMR))
Not Evaluated (Not evaluated)
Other (Other)
Spiral Ct Scan (Spiral CT scan)
Ultrasound (Ultrasound)
Date of Evaluation (M D Y)
Longest Diameter of Lesion(s) (cm)
Sum of longest diameters of all target lesions
(cm)
Nontarget Lesions
Follow-Up Status of Lesion (s)
Complete Response (CR)
Incompl. Resp./sd (Incompl. resp./SD)
Progressive Disease (PD)
Cytology Result (For Site Code 04
effusion/ascites ONLY)
Negative (Negative)
Not Done (Not done)
Positive (Positive)
New Lesions
Was the appearance of any new lesions
documented
Yes
No
Overall Response Per Recist Criteria -
Target, Nontarget And New Lesions
Best Overall Response to date (response status
of all target, non-target, and new lesions)
Complete Response (CR)
Insufficient Evaluation (Insufficient
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evaluation to determine response status)
Progressive Disease (PD)
Partial Response (PR)
Stable Disease (SD)
Has the patient progressed or relapsed
No (No)
Unknown (Unknown)
Yes (Yes)
Progressive disease/Relapse observed date (M D
Y)
Symptomatic Deterioration
Is there symptomatic deterioration of the patient's
health status
Yes
No
Specify symptomatic deterioration (If yes:)
Symptomatic Deterioration Date (M D Y)
Comments
Comments
Investigator Signature
Investigator Signature Date (M D Y)
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E1A06 Assessment Compliance Form
NCT00602641
E1A06 Assessment Compliance Form NCT00602641 
Melphalan, Prednisone, and Thalidomide or Lenalidomide
in Treating Patients With Newly Diagnosed Multiple
Myeloma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=402A1AE1-
F920-56B0-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/10765
E1A06 Assessment Compliance
Form NCT00602641
ECOG clinical trial administrative data
ECOG Protocol Number
ECOG Patient ID
DCI Name
Registration Step
Patient Initials (Last, First)
Participating Group Protocol Number
Institution/Affiliate
Participating Group Patient ID
Reporting Period
On Treatment Report Period (Maintenance:
Begins with Cycle 13)
End Of Cycle 18 (End of Cycle 18)
End Of Cycle 24 (End of Cycle 24)
End Of Cycle 38 (End of Cycle 38)
End Of Treatment (End of Treatment)
Off Treatment Report Period (For Patients who do
not complete 8 cycles of treatment:)
12 Months (12 months post registration)
15 Months (15 months post registration)
18 Months (18 months post registration)
21 Months Post Registration (21 months
post registration)
24 Months (24 months post registration)
3 Months (3 months post registration)
30 Months (30 months post registration)
36 Months (36 months post registration)
6 Months (6 months post registration)
9 Months (9 months post registration)
1 / 4
Date of Assessment
Section Ii - E1a05 Qol Assessment Not
Completed
Was the Assessment Form completed? (E1A05
QOL)
Yes
No
Section Ii - Assessments Not Completed
Patient refusal
Yes
No
Unable to accomodate disability or language
needs
Yes
No
Specify disability or language
Patient did not show up in clinic/office
Yes
No
Specify reason patient did not show up
Staff unavailable
Yes
No
Patient not given form by staff
Yes
No
Patient too ill
Yes
No
Patient expired
Yes
No
Assessment not required per protocol
Yes
No
Specify reason assessment is not required (If no
functioning rectum, please indicate)
Staff thought patient too ill
Yes
No
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Other
Yes
No
Specify other reason
Section Iii Assessment Completed
Was Assessment self-administered?
Yes
No
How Was The Patient Assisted
Were the questions read aloud to patient
Yes
No
Did the patient require clarification of questions or
instructions
Yes
No
Did the patient require other assistance
Yes
No
Were the forms completed independently by
another person
Yes
No
What Was The Reason For Assistance
Did the patient have a language difficulty
(questions needed to tbe translated)
Yes
No
Specify language
Did the patient have a literacy difficulty (patient
could not read well enough)
Yes
No
Was the patient disabled
Yes
No
Specify disability
Were the forms completed via a telephone
interview
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Yes
No
Other
Yes
No
Specify other reason
Patient Bowel Function/uniscale
Questionnaire: Who Assisted Or
Completed Assessment?
Staff
Yes
No
Family
Yes
No
Friend
Yes
No
Other
Yes
No
Specify other person
Comments
Investigator Signature
Investigator Signature Date
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E4A03 Thrombotic Event Form - After
September 14, 2005 NCT00098475
E4A03 Thrombotic Event Form - After September 14, 2005
NCT00098475 
Lenalidomide and Dexamethasone With or Without
Thalidomide in Treating Patients With Multiple Myeloma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=05DBF8A6-
800B-1B35-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/10766
E4A03 Thrombotic Event Form -
After September 14, 2005
NCT00098475
Header
ECOG Protocol Number
ECOG Patient ID
DCI Name
Registration Step
Patient Initials
Participating Group Protocol Number
Institution/Affiliate
Participating Group Patient ID
Data amendment
Please mark an 'X' if data have been amended
Date data amended
On Treatment Report Period
Treatment Evaluation Period Type
Cycle 12 Step 1 (Cycle 12 Step 1)
Cycle 12 Step 2 (Cycle 12 Step 2)
Cycle 4 Step 1 (Cycle 4 Step 1)
Cycle 4 Step 2 (Cycle 4 Step 2)
Cycle 8 Step 1 (Cycle 8 Step 1)
Cycle 8 Step 2 (Cycle 8 Step 2)
Deep Vein Thrombosis
Did patient recieve DVT prophylaxis
1 / 3
Yes
No
Start date of first (prophylactic) treatment
Date of most recent (prophylactic) treatment
Aspirin (81 mg) (Were any of the following given
prior to the first thrombotic event this report
period? answer no 1 or yes 2 for each of the
following)
Yes
No
Aspirin (325 mg)
Yes
No
Aspirin (other dose)
Yes
No
If other dose of Aspirin given, specify dose
Coumadin
Yes
No
If Coumadin given, specify dose
Yes
No
Low molecular weight heparin (enoxaparin;
Lovenox)
Yes
No
Other, specify
Has the patient received erythropoietin-type
agents (e.g., Epogen, Procrit or Aranesp)
Yes
No
Thrombotic Event
Did patient experience a thrombotic event
(NOTE: Event must be reported through AdEERS
and on the E4A03 Adverse Event Form)
Yes
No
Date of thrombotic event (If yes,  - List Date of
thrombotic events this report period. Mark an
¿X¿ in the box on the right if not applicable.)
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Mark an 'X' if N/A
Was the patient on thrombotic prophylaxis
(NOTE: If more then one thrombotic event this
report period, answer question below with
regards to the first thrombotic event this report
period.)
Yes
No
Comments
Investigator Signature
Investigator Signature Date
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NCT00098475
E1609 Assessment Compliance Form
NCT01274338
E1609 Assessment Compliance Form NCT01274338
Ipilimumab or High-Dose Interferon Alfa-2b in Treating
Patients With High-Risk Stage III or Stage IV Melanoma
That Has Been Removed by Surgery
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=97E7C12F-
E701-FFC2-E040-BB89AD43160A
All rights reserved. Please visit https://medical-data-
models.org/forms/10767
E1609 Assessment Compliance
Form NCT01274338
ECOG clinical trial administrative data
ECOG Protocol Number
ECOG Patient ID
DCI Name
Registration Step
Patient Initials (Last, First)
Participating Group Protocol Number
Institution/Affiliate
Participating Group Patient ID
Data amendment
Please mark an 'X' if data have been amended.
Date data amended
On Treatment Report Period
On Treatment Report Period
At Completion Of Treatment (At
Completion of Treatment)
Baseline (baseline)
Week 12 (Week 12)
Week 24 (Week 24)
Week 36 (Week 36)
Week 48 (Week 48)
Week 60 (Week 60)
Off Treatment Report Period
1 / 4
Off Treatment Report Period
Qol 24 Weeks Follow-up (QOL 24 Weeks
Follow-Up)
Qol 48 Weeks Follow-up (QOL 48 Weeks
Follow-Up)
Section I
Assessment date (If not completed, enter date
scheduled per E1609 protocol.)
Section Ii - E1a05 Qol Assessment Not
Completed
Was the Assessment Form completed? (E1609
QOL)
Yes
No
Section Ii - Assessments Not Completed
Patient refusal
Yes
No
Unable to accomodate disability or language
needs
Yes
No
Specify disability or language
Patient did not show up in clinic/office
Yes
No
Specify reason patient did not show up
Staff unavailable
Yes
No
Patient not given form by staff
Yes
No
Patient too ill
Yes
No
Patient expired
Yes
No
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Assessment not required per protocol
Yes
No
Specify reason assessment is not required
Staff thought patient too ill
Yes
No
Other
Yes
No
Specify other reason
Section Iii Assessment Completed
Was Assessment self-administered?
Yes
No
How Was The Patient Assisted
Were the questions read aloud to patient
Yes
No
Did the patient require clarification of questions or
instructions
Yes
No
Did the patient require other assistance
Yes
No
Were the forms completed independently by
another person
Yes
No
What Was The Reason For Assistance
Did the patient have a language difficulty
(questions needed to tbe translated)
Yes
No
Specify language
Did the patient have a literacy difficulty (patient
could not read well enough)
Yes
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No
Was the patient disabled
Yes
No
Specify disability
Were the forms completed via a telephone
interview
Yes
No
Other
Yes
No
Specify other reason
Patient Bowel Function/uniscale
Questionnaire: Who Assisted Or
Completed Assessment?
Staff
Yes
No
Family
Yes
No
Friend
Yes
No
Other
Yes
No
Specify other person
Comments
Investigator Signature
Investigator Signature Date
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E4A08 FACT Neurotoxicity Form
NCT01078454
E4A08 FACT Neurotoxicity Form NCT01078454 
Melphalan and Dexamethasone With or Without
Bortezomib in Treating Patients With Previously Untreated
Systemic Light-Chain Amyloidosis
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=A1D4D782-
1782-0001-E040-BB89AD437022
All rights reserved. Please visit https://medical-data-
models.org/forms/10768
E4A08 FACT Neurotoxicity Form
NCT01078454
ECOG clinical trial administrative data
ECOG Protocol Number
ECOG Patient ID
DCI Name
Registration Step
Patient demographics
ECOG Protocol Number
Patient Initials (Last, First)
ECOG Patient ID
Participating Group Protocol Number
Institution/Affiliate
Participating Group Patient ID
Reporting period
On Treatment Report Period
Baseline (baseline)
End Of Cycle 3 (End of Cycle 3)
End Of Cycle 5 (End of Cycle 5)
End Of Cycle 6 (End of Cycle 6)
End Of Cycle 8 (End of Cycle 8)
End Of Cycle 9 (End of Cycle 9)
End Of Treatment (End of Treatment)
Off Treatment Report Period
12 Months (12 months post registration)
15 Months (15 months post registration)
1 / 3
18 Months (18 months post registration)
3 Months (3 months post registration)
6 Months (6 months post registration)
9 Months (9 months post registration)
Date of Assessment (If not completed, enter date
scheduled per E4A08 protocol.)
Section III - FACT-Neurotoxicty
I have numbness or tingling in my hands
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have numbness or tingling in my feet
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I feel discomfort in my hands
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I feel discomfort in my feet
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have joint pain or muscle cramps
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I feel weak all over
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have trouble hearing
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
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I get a ringing or buzzing in my ears
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have trouble buttoning buttons
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have trouble feeling the shape of small objects
when they are in my hand
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have trouble walking
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
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E4A08 Assessment Compliance Form
NCT01078454
E4A08 Assessment Compliance Form NCT01078454 
Melphalan and Dexamethasone With or Without
Bortezomib in Treating Patients With Previously Untreated
Systemic Light-Chain Amyloidosis
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=9FB6753F-
27C0-044C-E040-BB89AD436EED
All rights reserved. Please visit https://medical-data-
models.org/forms/10769
E4A08 Assessment Compliance
Form NCT01078454
ECOG clinical trial administrative data
ECOG Protocol Number
DCI Name
Registration Step
ECOG Patient ID
Patient demographics
Patient Initials (Last, First)
ECOG Protocol Number
Participating Group Protocol Number
Institution/Affiliate
ECOG Patient ID
Participating Group Patient ID
Reporting period
On Treatment Report Period
Baseline (baseline)
End Of Cycle 3 (End of Cycle 3)
End Of Cycle 5 (End of Cycle 5)
End Of Cycle 6 (End of Cycle 6)
End Of Cycle 8 (End of Cycle 8)
End Of Cycle 9 (End of Cycle 9)
End Of Treatment (End of Treatment)
Off Treatment Report Period
12 Months (12 months post registration)
15 Months (15 months post registration)
1 / 7
18 Months (18 months post registration)
3 Months (3 months post registration)
6 Months (6 months post registration)
9 Months (9 months post registration)
Date of Assessment (If not completed, enter date
scheduled per E4A08 protocol.)
Section Ii - E1a05 Qol Assessment Not
Completed
Were both of the Assessment Forms completed?
(E4A08 Quality of Life)
Yes
No
Section Ii - Assessments Not Completed
Patient refusal
Yes
No
Unable to accomodate disability or language
needs
Yes
No
Specify disability or language
Patient did not show up in clinic/office
Yes
No
Specify reason patient did not show up
Staff unavailable
Yes
No
Patient not given form by staff
Yes
No
Patient too ill
Yes
No
Patient expired
Yes
No
Assessment not required per protocol
Yes
No
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Specify reason assessment is not required (If no
functioning rectum, please indicate)
Staff thought patient too ill
Yes
No
Other
Yes
No
Specify other reason
Section Iii Assessment Completed
Was Assessment self-administered?
Yes
No
How Was The Patient Assisted
Were the questions read aloud to patient
Yes
No
Did the patient require clarification of questions or
instructions
Yes
No
Did the patient require other assistance
Yes
No
Were the forms completed independently by
another person
Yes
No
What Was The Reason For Assistance
Did the patient have a language difficulty
(questions needed to tbe translated)
Yes
No
Specify language
Did the patient have a literacy difficulty (patient
could not read well enough)
Yes
No
Was the patient disabled
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Yes
No
Specify disability
Were the forms completed via a telephone
interview
Yes
No
Other
Yes
No
Specify other reason
Patient Bowel Function/uniscale
Questionnaire: Who Assisted Or
Completed Assessment?
Staff
Yes
No
Family
Yes
No
Friend
Yes
No
Other
Yes
No
Specify other person
Section Ii - Assessments Not Completed
Patient refusal
Yes
No
Unable to accomodate disability or language
needs
Yes
No
Specify disability or language
Patient did not show up in clinic/office
Yes
No
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Specify reason patient did not show up
Staff unavailable
Yes
No
Patient not given form by staff
Yes
No
Patient too ill
Yes
No
Patient expired
Yes
No
Assessment not required per protocol
Yes
No
Specify reason assessment is not required (If no
functioning rectum, please indicate)
Staff thought patient too ill
Yes
No
Other
Yes
No
Specify other reason
Section Iii Assessment Completed
Was Assessment self-administered?
Yes
No
How Was The Patient Assisted
Were the questions read aloud to patient
Yes
No
Did the patient require clarification of questions or
instructions
Yes
No
Did the patient require other assistance
Yes
No
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Were the forms completed independently by
another person
Yes
No
What Was The Reason For Assistance
Did the patient have a language difficulty
(questions needed to tbe translated)
Yes
No
Specify language
Did the patient have a literacy difficulty (patient
could not read well enough)
Yes
No
Was the patient disabled
Yes
No
Specify disability
Were the forms completed via a telephone
interview
Yes
No
Other
Yes
No
Specify other reason
Patient Bowel Function/uniscale
Questionnaire: Who Assisted Or
Completed Assessment?
Staff
Yes
No
Family
Yes
No
Friend
Yes
No
Other
Yes
No
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Specify other person
Comments
Investigator Signature
Investigator Signature Date
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E4A08 Follow-Up Disease Assessment
Form NCT01078454
E4A08 Follow-Up Disease Assessment Form
NCT01078454 
Melphalan and Dexamethasone With or Without
Bortezomib in Treating Patients With Previously Untreated
Systemic Light-Chain Amyloidosis
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=7C874A89-
4467-7914-E040-BB89AD43421F
All rights reserved. Please visit https://medical-data-
models.org/forms/10770
E4A08 Follow-Up Disease
Assessment Form NCT01078454
Header
DCI Name
Registration Step
Patient Initials (Last, First)
ECOG Protocol Number
ECOG Protocol Number
ECOG Patient ID
ECOG Patient ID
Participating Group Protocol Number
Participating Group Patient ID
Institution/Affiliate
On Treatment
On Treatment Report Period (Choose one)
Cycle 1 (Cycle 1)
Cycle 2 (Cycle 2)
Cycle 3 (Cycle 3)
Cycle 4 (cycle 4)
Cycle 5 (Cycle 5)
Cycle 6 (Cycle 6)
Cycle 7 (Cycle 7)
Cycle 8 (cycle 8)
Cycle 9 (Cycle 9)
Off Treatment
Off Treatment Report Period (Choose one)
1 / 10
12 Months (12 Months Post Registration)
15 Months (15 Months Post Registration)
18 Months (18 Months Post Registration)
21 Months Post Registration (21 Months
Post Registration)
2 Years (24 Months Post Registration)
3 Months (3 Months Post Registration)
30 Months (30 Months Post Registration)
3 Years (36 Months Post Registration)
42 Months (42 Months Post Registration)
4 Years (48 Months Post Registration)
54 Months Post Registration (54 Months
Post Registration)
6 Months (6 Months Post Registration)
5 Years (60 months post registration)
9 Months (9 Months Post Registration)
Data amended
Please mark an 'X' if data have been amended.
Date data amended
Protein Measurements
Date of SPEP
Serum total protein (SPEP g/dl)
Serum M-protein spike (g/dl )
If serum M-protein spike was left blank, please
specify
Absent (Not present)
Present But Too Small To Quantify
(Present but too small to quantify)
Date of urine immunofixation (Urine
immunofixation IFE leave blank if not done)
Date of serum FLC assessment
Kappa Free Light Chain (mg/dl)
Lambda Free Light Chain (mg/dl)
Mark an 'X' if not done
Mark an 'X' if not done
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Mark an 'X' if not done
Serum M-protein by immunofixation
Negative (negative)
Positive (positive)
Serum Heavy Chain (If positive:)
A (A)
Biclonal (Biclonal)
D (D)
E (E)
G (G)
M (M)
None (None)
Unknown (Unknown)
Biclonal, specify
Serum Light Chain
Kappa (kappa)
Lambda (lambda)
Unknown (Unknown)
Urine Sample
Date of UPEP (Urine protein electrophoresis
UPEP)
Urine Total protein (UPEP mg/24 hr)
Urine M-protein measurement
If urine M-protein measurement was left blank,
please specify
Absent (Not present)
Present But Too Small To Quantify
(Present but too small to quantify)
Date of urine immunofixation (Urine
immunofixation IFE leave blank if not done)
Urine M-protein by immunofixation
Negative (negative)
Positive (positive)
Urine Light Chain (If positive:)
Kappa (kappa)
Lambda (lambda)
Unknown (unknown)
Mark an 'X' if not done
Mark an 'X' if not done
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Protein Measurements
IgG (mg/dl)
IgG LLN (mg/dl)
IgG ULN (mg/dl)
IgA (mg/dl)
IgA LLN (mg/dl)
IgA ULN (mg/dl)
IgM (mg/dl)
Date Hematology (Blood) Sample Obtained
IgM LLN (mg/dl)
Mark an 'X' if not done
IgM ULN (mg/dl)
Bone Marrow
Was bone marrow biopsy done?
Inadequate Sample (inadequate sample)
No (no)
Yes (yes)
Bone marrow biopsy date
Plasma cells on biopsy (If yes:)
If plasma cells on biopsy was left blank, please
specify (%)
No Percentage Given (No percentage
given)
Absent (Not present)
Present But Too Small To Quantify
(Present but too small to quantify)
Was bone marrow aspirate done?
Inadequate Sample (inadequate sample)
No (no)
Yes (yes)
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Bone marrow aspirate date
Plasma Cells on Aspirate in Interpretation (%) (If
yes:)
If plasma cells on aspirate was left blank, please
specify
No Percentage Given (No percentage
given)
Absent (Not present)
Present But Too Small To Quantify
(Present but too small to quantify)
Was plasma cell clonality done
Yes
No
Plasma cell clonality test date (If Yes,)
Clonality determination method
Flow Cytometry (flow cytometry)
Fluorescent Antibody Technique
(Immunofluorescence)
Immunohistochemistry
(Immunohistochemistry)
Other (other)
Other specify
Result
Kappa (kappa)
Lambda (lambda)
Polyclonal (polyclonal)
Cardiac Assessment
Does patient currently have cardiac involvement
per the protocol criteria
Yes
No
Was an Echocardiogram (ECHO) performed (this
report period)
Yes
No
Date of echocardiogram
Interventricular Septal Wall Thickness (mm)
Left ventricular ejection fraction (%)
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Troponin T ULN
Troponin T
Troponin I ULN
Troponin I
Date Hematology (Blood) Sample Obtained
Mark an 'X' if not done
New York Heart Association Classification
Patients With Cardiac Disease But
Without Resulting Limitation Of Physical
Activity. Ordinary Physical Activity Does
Not Cause Undue Fatigue, Palpitation,
Dyspnea Or Anginal Pain. (Class I)
Patients With Cardiac Disease Resulting
In Slight Limitation Of Physical Activity.
They Are Comfortable At Rest. Ordinary
Physical Activity Results In Fatigue,
Palpitation, Dyspnea Or Anginal Pain.
(Class II)
Patients With Cardiac Disease Resulting
In Marked Limitation Of Physical Activity.
They Are Comfortable At Rest. Less
Than Ordinary Activity Causes Fatigue,
Palpitation, Dyspnea Or Anginal Pain.
(Class III)
Patients With Cardiac Disease Resulting
In Inability To Carry On Any Physical
Activity Without Discomfort. Symptoms
Of Heart Failure Or The Anginal
Syndrome May Be Present Even At
Rest. If Any Physical Activity Is
Undertaken, Discomfort Increases.
(Class IV)
Liver Assessment
Does patient currently have liver involvement per
the protocol criteria
Yes
No
Was a liver measurement done (this report
period)
Yes
No
Date of Liver Evaluation (If Yes:)
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Liver Measurement (cm)
Method of liver evaluation
Medical Examination (Clinical
examination)
Computed Tomography (CT scan)
Radionuclide Imaging (Liver-spleen
scan)
Other (Other)
Ultrasound (Ultrasound)
Specify other method
Alkaline Phosphatase ULN (U/L)
Alkaline Phosphatase (U/L)
Date Hematology (Blood) Sample Obtained
Mark an 'X' if not done
Gi Tract Assessment
Does patient currently have GI tract involvement
per the protocol criteria
Yes
No
Is diarrhea present
Yes
No
Number of stools per day
Was a fecal fat excretion test done (this report
period)
Yes
No
24-hour Fecal Fat Excretion (If Yes, - g)
Date of fecal fat evaluation (start date)
Nerve Assessment
Does patient currently have clinically evident
peripheral nerve involvement per the protocol
criteria
Yes
No
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Date of EMG/NCS
CMAP amplitude
Results of EMG
Abnormal (Abnormal)
Normal (Normal)
Specify EMG result (If abnormal,)
Neuropathy Impairment Score
25% (25%)
50% (50%)
75% Weak (75% weak)
Normal (Normal)
Paralysis (Paralyzed)
Does patient have clinically evident autonomic
nerve involvement per the protocol criteria
Yes
No
Kidney Assessment
Does patient currently have kidney involvement
per the protocol criteria
Yes
No
Creatinine ULN (mg/dl)
Creatinine (mg/dl)
Creatinine Clearance (24 hour ml/min)
eGFR (mL/min per 1.73m^2)
Date Hematology (Blood) Sample Obtained
Mark an 'X' if not done
Objective Response
Has the overall hematologic response changed
(since the previous evaluation)
Yes
No
Objective hematologic status at this evaluation
(confirmed)
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Amyloidogenesis Complete Remission
(Amyloid complete response)
Hematologic Pd (Hematologic
progressive disease)
Minor Response (Minor response)
Stable Disease (No response stable
disease)
Partial Remission (Partial Response)
Stringent Complete Response (scr) Of
Multiple Myeloma Or Plasma Cell
Leukemia (Stringent complete response)
Very Good Partial Response (Very good
partial response)
Stringent complete response first observed date
Amyloid complete response first observed date
Very Good Partial Response First Observed Date
(VGPR)
Partial Response (PR) First Observed Date
Minor Response First Observed Date
Hematologic progressive disease first observed
date (For PD:)
Has the overall organ response changed (since
the previous evaluation)
Yes
No
Objective Organ status at this evaluation
(confirmed)
Organ Pd (Organ improvement)
Organ Better (Organ improvement)
Stable Disease (Stable Disease)
Organ Improvement first observed date (If organ
status is a response IMPR:)
Organ progressive disease first observed date
(For PD:)
Comments
Comments
Investigator Signature Date
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Investigator Signature
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E3A06 Assessment Compliance Form
NCT01169337
E3A06 Assessment Compliance Form NCT01169337 
Lenalidomide or Observation in Treating Patients With
Asymptomatic High-Risk Smoldering Multiple Myeloma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=86D10DC2-
6543-A706-E040-BB89AD434839
All rights reserved. Please visit https://medical-data-
models.org/forms/10771
E3A06 Assessment Compliance
Form NCT01169337
ECOG clinical trial administrative data
ECOG Protocol Number
DCI Name
Registration Step
ECOG Patient ID
Patient demographics
Patient Initials (Last, First)
ECOG Protocol Number
Participating Group Protocol Number
Institution/Affiliate
ECOG Patient ID
Participating Group Patient ID
Data amendment
Please mark an 'X' if data have been amended.
Date data amended
On Treatment or Observation  Report
Period
On Treatment or Observation  Report Period
(Note: Choose "End of Treatment or Observation"
when patient discontinues treatment at any
1 / 5
point.)
Baseline (baseline)
Cycle 12 (Cycle 12)
Cycle 18 (Cycle 18)
Cycle 24 (Cycle 24)
Cycle 30 (Cycle 30)
Cycle 36 (Cycle 36)
Cycle 42 (Cycle 42)
Cycle 48 (Cycle 48)
Cycle 6 (Cycle 6)
End Of Treatment Or Observation (End
of Treatment or Observation)
Off Treatment or Off Observation Report Period
12 Months (12 months post registration)
15 Months (15 months post registration)
18 Months (18 months post registration)
21 Months Post Registration (21 months
post registration)
24 Months (24 months post registration)
3 Months (3 months post registration)
30 Months (30 months post registration)
36 Months (36 months post registration)
42 Months Post Registration (42 Months
Post Registration)
4 Years (48 months post registration)
6 Months (6 months post registration)
9 Months (9 months post registration)
Assessment date
Section Ii - E1a05 Qol Assessment Not
Completed
Was the Assessment Form completed? (E3A06
QOL)
Yes
No
Section Ii - Assessments Not Completed
Patient refusal
Yes
No
Unable to accomodate disability or language
needs
Yes
No
Specify disability or language
Patient did not show up in clinic/office
Yes
No
Specify reason patient did not show up
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Staff unavailable
Yes
No
Patient not given form by staff
Yes
No
Patient too ill
Yes
No
Patient expired
Yes
No
Assessment not required per protocol
Yes
No
Specify reason assessment is not required (If no
functioning rectum, please indicate)
Staff thought patient too ill
Yes
No
Other
Yes
No
Specify other reason
Section Iii Assessment Completed
Was Assessment self-administered?
Yes
No
How Was The Patient Assisted
Were the questions read aloud to patient
Yes
No
Did the patient require clarification of questions or
instructions
Yes
No
Did the patient require other assistance
Yes
No
Were the forms completed independently by
another person
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Yes
No
What Was The Reason For Assistance
Did the patient have a language difficulty
(questions needed to tbe translated)
Yes
No
Specify language
Did the patient have a literacy difficulty (patient
could not read well enough)
Yes
No
Was the patient disabled
Yes
No
Specify disability
Were the forms completed via a telephone
interview
Yes
No
Other
Yes
No
Specify other reason
Patient Bowel Function/uniscale
Questionnaire: Who Assisted Or
Completed Assessment?
Staff
Yes
No
Family
Yes
No
Friend
Yes
No
Other
Yes
No
Specify other person
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Comments
Investigator Signature
Investigator Signature Date
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E4A08 Quality of Life Assessment Form
NCT01078454
E4A08 Quality of Life Assessment Form NCT01078454 
Melphalan and Dexamethasone With or Without
Bortezomib in Treating Patients With Previously Untreated
Systemic Light-Chain Amyloidosis
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=9FB6702E-
208A-1645-E040-BB89AD4344DA
All rights reserved. Please visit https://medical-data-
models.org/forms/10772
E4A08 Quality of Life Assessment
Form NCT01078454
Header
ECOG Protocol Number
ECOG Patient ID
DCI Name
Registration Step
Patient demographics
ECOG Protocol Number
Patient Initials (Last, First)
ECOG Patient ID
Participating Group Protocol Number
Institution/Affiliate
Participating Group Patient ID
Reporting period
On Treatment Report Period
Baseline (baseline)
End Of Cycle 3 (End of Cycle 3)
End Of Cycle 5 (End of Cycle 5)
End Of Cycle 6 (End of Cycle 6)
End Of Cycle 8 (End of Cycle 8)
End Of Cycle 9 (End of Cycle 9)
End Of Treatment (End of Treatment)
Off Treatment Report Period
12 Months (12 months post registration)
15 Months (15 months post registration)
1 / 5
18 Months (18 months post registration)
3 Months (3 months post registration)
6 Months (6 months post registration)
9 Months (9 months post registration)
Date of Assessment (If not completed, enter date
scheduled per E4A08 protocol.)
Physical Well-being
I have a lack of energy (GP2)
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have nausea (GP3)
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
Because of my physical condition, I have trouble
meeting the needs of my family (GP4)
A Little (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have pain (GP5)
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am bothered by side effects of treatment (GP6)
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I feel ill (GP7)
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am forced to spend time in bed (GS1)
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
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Very Much (Very much)
Functional Well-being
I am able to work (include work at home)
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
My work (include work at home) is fulfilling
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am able to enjoy life
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have accepted my illness
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am sleeping well
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am enjoying the things I usually do for fun
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am content with the quality of my life right now
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
Additional Concerns - Mms
I have certain areas of my body where I
experience significant pain
A Little Bit (A little bit)
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Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I feel weak all over
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I feel fatigued
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I feel fatigued
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have trouble concentrating
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I worry about getting infections
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I feel discouraged about my illness
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
Because of my illness, I have difficulty planning
for the future
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I worry that I might get new symptoms of my
illness
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
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Somewhat (Somewhat)
Very Much (Very much)
I have emotional ups and downs
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have bone pain
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I need help doing my usual activities
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have trouble walking because of pain
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have gained weight
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
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E5508 Nontarget Lesions Supplemental
Form (RECIST) NCT01107626
E5508 Nontarget Lesions Supplemental Form (RECIST)
NCT01107626 
Bevacizumab or Pemetrexed Disodium Alone or In
Combination After Induction Therapy in Treating Patients
With Advanced Non-Squamous Non-Small Cell Lung
Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=6D435D37-
5457-AA13-E040-BB89AD43538D
All rights reserved. Please visit https://medical-data-
models.org/forms/10774
E5508 Nontarget Lesions
Supplemental Form (RECIST)
NCT01107626
Header module
ECOG Protocol Number
ECOG Patient ID
Report Period
Baseline (Baseline)
Follow-up (Follow-up)
DCI Name
Registration Step
Patient demographics
Patient Initials (Last, First)
Participating Group Protocol Number
ECOG Protocol Number
Participating Group Patient ID
ECOG Patient ID
Institution/Affiliate
Data amendment
Please mark an 'X' if data have been amended.
(Please circle amended items in red)
Date data amended (s M D Y)
1 / 3
On Treatment
On Treatment Report Period (since start of
treatment Choose one)
> Cycle 30 - Step 2 (> Cycle 30 - Step 2)
Baseline Step 1 (Baseline Step 1)
Cycle 10 Step 2 (Cycle 10 Step 2)
Cycle 12 Step 2 (Cycle 12 Step 2)
Cycle 14-step 2 (Cycle 14-Step 2)
Cycle 16-step 2 (Cycle 16-Step 2)
Cycle 18-step 2 (Cycle 18-Step 2)
Cycle 2 Step 1 (Cycle 2 Step 1)
Cycle 2 Step 2 (Cycle 2 Step 2)
Cycle 20-step 2 (Cycle 20-Step 2)
Cycle 22-step 2 (Cycle 22-Step 2)
Cycle 24-step 2 (Cycle 24-Step 2)
Cycle 26-step 2 (Cycle 26-Step 2)
Cycle 28-step 2 (Cycle 28-Step 2)
Cycle 30 - Step 2 (Cycle 30 - Step 2)
Cycle 4 Step 1 (Cycle 4 Step 1)
Cycle 4 Step 2 (Cycle 4 Step 2)
Cycle 6 Step 2 (Cycle 6 Step 2)
Cycle 8 Step 2 (Cycle 8 Step 2)
Specify Cycle
Off Treatment
Off Treatment Report Period (since registration
Choose one)
12 Months (12 months post registration)
15 Months (15 months post registration)
18 Months (18 months post registration)
21 Months Post Registration (21 months
post registration)
24 Months (24 months post registration)
3 Months (3 months post registration)
30 Months (30 months post registration)
36 Months (36 months post registration)
42 Months Post Registration (42 Months
Post Registration)
4 Years (48 months post registration)
54 Months Post Randomization (54
Months Post Randomization)
6 Months (6 months post registration)
60 Months Post Randomization (60
Months Post Randomization)
9 Months (9 months post registration)
Nontarget Lesions
Lesion Number
Site of Lesion (Multiple nontarget lesions within
an organ may be combined as a single site, but
must be reported in same manner as at baseline)
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Site Code
Bone (bone)
Brain (Brain)
Breast (Breast)
Effusion/ascites (Effusion/Ascites)
Gi (GI)
Gu (GU)
Head & Neck (Head & Neck)
Liver (Liver)
Lung (Lung)
Nodes (Nodes)
Other (other)
Skin (Skin)
Method of Evaluation
Bone Scan (Bone scan)
Chest X-ray (Chest X-Ray)
Clinical (Clinical Examination)
Ct Scan (CT Scan)
Mri (MRI (NMR))
Not Evaluated (Not evaluated)
Other (other)
Spiral Ct Scan (Spiral CT scan)
Ultrasound (Ultrasound)
Date of Evaluation (M D Y)
Follow-Up Status of Lesion (s Choose one for
each lesion. Leave blank if baseline.)
Complete Response (CR)
Incompl. Resp./sd (Incompl. resp./SD)
Progressive Disease (PD)
Cytology Result (For Site Code 04
effusion/ascites ONLY)
Negative (Negative)
Not Done (Not done)
Positive (Positive)
Comments
Investigator Signature
Investigator Signature Date (M D Y)
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E3A06 Quality of Life Assessment Form
NCT01169337
E3A06 Quality of Life Assessment Form NCT01169337 
Lenalidomide or Observation in Treating Patients With
Asymptomatic High-Risk Smoldering Multiple Myeloma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=86D10DC2-
628F-A706-E040-BB89AD434839
All rights reserved. Please visit https://medical-data-
models.org/forms/10775
E3A06 Quality of Life Assessment
Form NCT01169337
Header
ECOG Protocol Number
ECOG Patient ID
DCI Name
Registration Step
Patient demographics
ECOG Protocol Number
Patient Initials (Last, First)
ECOG Patient ID
Participating Group Protocol Number
Institution/Affiliate
Participating Group Patient ID
Reporting period
On Treatment or Observation  Report Period
(Note: Choose "End of Treatment/Observation"
when patient discontinues treatment at any
point.)
Baseline (baseline)
Cycle 12 (Cycle 12)
Cycle 18 (Cycle 18)
Cycle 24 (Cycle 24)
Cycle 30 (Cycle 30)
Cycle 36 (Cycle 36)
Cycle 42 (Cycle 42)
Cycle 48 (Cycle 48)
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Cycle 6 (Cycle 6)
End Of Treatment Or Observation (End
of Treatment or Observation)
Off Treatment or Off Observation Report Period
12 Months (12 months post registration)
15 Months (15 months post registration)
18 Months (18 months post registration)
21 Months Post Registration (21 months
post registration)
24 Months (24 months post registration)
3 Months (3 months post registration)
30 Months (30 months post registration)
36 Months (36 months post registration)
42 Months Post Registration (42 Months
Post Registration)
4 Years (48 months post registration)
6 Months (6 months post registration)
9 Months (9 months post registration)
Date of Assessment
Physical Well-being
I have a lack of energy (GP1)
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have nausea (GP2)
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
Because of my physical condition, I have trouble
meeting the needs of my family (GP3)
A Little (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have pain (GP4)
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am bothered by side effects of treatment (GP5)
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
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Very Much (Very much)
I feel ill (GP6)
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am forced to spend time in bed (GP7)
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
Functional Well-being
I am able to work (include work at home)
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
My work (include work at home) is fulfilling
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am able to enjoy life
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have accepted my illness
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am sleeping well
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am enjoying the things I usually do for fun
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
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I am content with the quality of my life right now
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
Additional Concerns - Mms
I have certain parts of my body where I
experience pain
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I feel weak all over
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I feel fatigued
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I feel fatigued
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have trouble concentrating
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I worry about getting infections
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I feel discouraged about my illness
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
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Because of my illness, I have difficulty planning
for the future
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I worry that I might get new symptoms of my
illness
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have emotional ups and downs
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have bone pain
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I need help doing my usual activities
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have trouble walking because of pain
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have gained weight
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
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E2603 Nontarget Lesions Supplemental Form
(RECIST) Form No. 2170 NCT00110019
E2603 Nontarget Lesions Supplemental Form (RECIST)
Form No. 2170 NCT00110019
Carboplatin and Paclitaxel With or Without Sorafenib in
Treating Patients With Unresectable Stage III or Stage IV
Melanoma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=E7EA6548-
1545-5C84-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/10776
E2603 Nontarget Lesions
Supplemental Form (RECIST) Form
No. 2170 NCT00110019
Header
ECOG Protocol Number
ECOG Patient ID
Select one
Baseline (Baseline)
Follow-up (Follow-up)
DCI Name
Registration Step
Patient demographics
Patient Initials
ECOG Protocol Number
Participating Group Protocol Number
Institution/Affiliate
ECOG Patient ID
Participating Group Patient ID
Data amendment
Please mark an 'X' if data have been amended.
Date data amended
On Treatment
1 / 3
On Treatment Report Period (since start of
treatment)
> Cycle 31 (> Cycle 31)
Baseline (Baseline)
Cycle 10 (Cycle 10)
Cycle 13 (Cycle 13)
Cycle 16 (Cycle 16)
Cycle 19 (Cycle 19)
Cycle 2 (Cycle 2)
Cycle 22 (Cycle 22)
Cycle 25 (Cycle 25)
Cycle 28 (Cycle 28)
Cycle 3 (Cycle 31)
Cycle 4 (Cycle 4)
Cycle 6 (Cycle 6)
Cycle 8 (Cycle 8)
Cycle (specify)
Off Treatment
Off Treatment Report period (since registration)
12 Months (12 Months Post Registration)
15 Months (15 Months Post Registration)
18 Months (18 Months Post Registration)
21 Months Post Registration (21 Months
Post Registration)
2 Years (24 Months Post Registration)
3 Months (3 Months Post Registration)
30 Months (30 Months Post Registration)
3 Years (36 Months Post Registration)
42 Months (42 Months Post Registration)
54 Months (54 Months Post Registration)
6 Months (6 Months Post Registration)
5 Years (60 Months Post Registration)
9 Months (9 Months Post Registration)
Nontarget Lesions
Lesion Number
Site of Lesion (*)
Site Code
Bone (bone)
Brain (Brain)
Breast (Breast)
Effusion/ascites (Effusion/Ascites)
Gi (GI)
Gu (GU)
Head & Neck (Head & Neck)
Liver (Liver)
Lung (Lung)
Nodes (Nodes)
Other (other)
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NCT00110019
Skin (Skin)
Method of Evaluation
Bone Scan (Bone scan)
Chest X-ray (Chest X-Ray)
Clinical (Clinical Examination)
Ct Scan (CT Scan)
Mri (MRI)
Not Evaluated (Not evaluated)
Other (other)
Spiral Ct Scan (Spiral CT scan)
Ultrasound (Ultrasound)
Date of Evaluation (Follow-up Status of Lesions)
Choose one for each lesion. (Leave blank if
baseline.)
Complete Response (CR)
Incompl. Resp./sd (Incompl. resp./SD)
Progressive Disease (PD)
Cytology Result (For Site Code 04
effusion/ascites ONLY:)
Negative (Negative)
Not Done (Not done)
Positive (Positive)
Comments
Comments
Investigator Signature
Investigator Signature Date
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NCT00110019
E1A05 Assessment Compliance Form -
Form 2859 NCT00522392
E1A05 Assessment Compliance Form - Form 2859
NCT00522392 
Bortezomib and Dexamethasone With or Without
Lenalidomide in Treating Patients With Multiple Myeloma
Previously Treated With Dexamethasone
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=32B614B2-
F31F-4860-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/10777
E1A05 Assessment Compliance
Form - Form 2859 NCT00522392
Header
ECOG Protocol Number
DCI Name
Registration Step
ECOG Patient ID
Patient demographics
Patient Initials (Last, First)
ECOG Protocol Number
Participating Group Protocol Number
Institution/Affiliate
ECOG Patient ID
Participating Group Patient ID
Reporting period
On Treatment Report Period (Note: Choose ¿End
of Treatment¿ when patient discontinues
treatment at any point.)
Baseline (baseline)
Cycle 5 (Cycle 5)
End Of Treatment (End of Treatment)
Off Treatment Report Period (For Patients who do
complete 8 cycles of treatment:)
12 Months (12 months post registration)
15 Months (15 months post registration)
18 Months (18 months post registration)
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9 Months (9 months post registration)
Off Treatment Report Period (For Patients who do
complete 8 cycles of treatment:)
12 Months (12 months post registration)
15 Months (15 months post registration)
18 Months (18 months post registration)
9 Months (9 months post registration)
Date of Assessment
Section Ii - E1a05 Qol Assessment Not
Completed
Was the Assessment Form completed? (E1A05
QOL)
Yes
No
Section Ii - Assessments Not Completed
Patient refusal
Yes
No
Unable to accomodate disability or language
needs
Yes
No
Specify disability or language
Patient did not show up in clinic/office
Yes
No
Specify reason patient did not show up
Staff unavailable
Yes
No
Patient not given form by staff
Yes
No
Patient too ill
Yes
No
Patient expired
Yes
No
Assessment not required per protocol
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Yes
No
Specify reason assessment is not required (If no
functioning rectum, please indicate)
Staff thought patient too ill
Yes
No
Other
Yes
No
Specify other reason
Section Iii Assessment Completed
Was Assessment self-administered?
Yes
No
How Was The Patient Assisted
Were the questions read aloud to patient
Yes
No
Did the patient require clarification of questions or
instructions
Yes
No
Did the patient require other assistance
Yes
No
Were the forms completed independently by
another person
Yes
No
What Was The Reason For Assistance
Did the patient have a language difficulty
(questions needed to tbe translated)
Yes
No
Specify language
Did the patient have a literacy difficulty (patient
could not read well enough)
Yes
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No
Was the patient disabled
Yes
No
Specify disability
Were the forms completed via a telephone
interview
Yes
No
Other
Yes
No
Specify other reason
Patient Bowel Function/uniscale
Questionnaire: Who Assisted Or
Completed Assessment?
Staff
Yes
No
Family
Yes
No
Friend
Yes
No
Other
Yes
No
Specify other person
Comments
Investigator Signature
Investigator Signature Date
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E3A06 Follow-Up Disease Assessment
Form NCT01169337
E3A06 Follow-Up Disease Assessment Form
NCT01169337 
Lenalidomide or Observation in Treating Patients With
Asymptomatic High-Risk Smoldering Multiple Myeloma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=86F8EE6F-
85BE-CB7C-E040-BB89AD437687
All rights reserved. Please visit https://medical-data-
models.org/forms/10778
E3A06 Follow-Up Disease
Assessment Form NCT01169337
Header
DCI Name
Registration Step
Patient Initials (Last, First)
ECOG Protocol Number
ECOG Protocol Number
ECOG Patient ID
ECOG Patient ID
Participating Group Protocol Number
Participating Group Patient ID
Institution/Affiliate
Data amendment
Please mark an 'X' if data have been amended.
Date data amended
On Treatment
On Treatment or Observation  Report Period
> Cycle 19 (> Cycle 19)
Cycle 1 (Cycle 1)
Cycle 10 (Cycle 10)
Cycle 11 (Cycle 11)
Cycle 12 (Cycle 12)
Cycle 13 (Cycle 13)
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Cycle 14 (Cycle 14)
Cycle 15 (Cycle 15)
Cycle 16 (Cycle 16)
Cycle 17 (Cycle 17)
Cycle 18 (Cycle 18)
Cycle 19 (Cycle 19)
Cycle 2 (Cycle 2)
Cycle 3 (Cycle 3)
Cycle 4 (cycle 4)
Cycle 5 (Cycle 5)
Cycle 6 (Cycle 6)
Cycle 7 (Cycle 7)
Cycle 8 (cycle 8)
Cycle 9 (Cycle 9)
Specify Cycle
Off Treatment
Off Treatment or Off Observation Report Period
(Choose one)
9 Years (108 months post registration)
12 Months (12 Months Post Registration)
10 Years (120 months post registration)
15 Months (15 Months Post Registration)
18 Months (18 Months Post Registration)
21 Months Post Registration (21 Months
Post Registration)
2 Years (24 Months Post Registration)
3 Months (3 Months Post Registration)
30 Months (30 Months Post Registration)
3 Years (36 Months Post Registration)
42 Months (42 Months Post Registration)
4 Years (48 Months Post Registration)
54 Months (54 Months Post Registration)
6 Months (6 Months Post Registration)
5 Years (60 Months Post Registration)
6 Years (72 Months Post Registration)
84 Months Post Registration (84 Months
Post Registration)
9 Months (9 Months Post Registration)
8 Years (96 months post registration)
Protein Measurements
Mark an 'X' if not done
Mark an 'X' if not done
Mark an 'X' if not done
Date of SPEP
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Serum total protein (SPEP g/dl)
Serum M-protein spike (g/dl NOTE: Leave blank if
serum M-spike was present but too small to
quantify.)
If serum M-protein spike was left blank, please
specify
Absent (Not present)
Present But Too Small To Quantify
(Present but too small to quantify)
Date of serum FLC assessment
Date of Immunofixation
Kappa Free Light Chain
Unit of Measure
Milligrams Per Deciliter (mg/dL)
Milligrams Per Liter (mg/L)
Unit of Measure
Milligrams Per Deciliter (mg/dL)
Milligrams Per Liter (mg/L)
Lambda Free Light Chain
Kappa/Lambda ratio
Serum M-protein by immunofixation
Negative (negative)
Positive (positive)
Urine Sample
Mark an 'X' if not done
Mark an 'X' if not done
Date of UPEP
Urine Total protein (UPEP mg/24 hr)
Urine M-protein measurement
If urine M-protein measurement was left blank,
please specify
Absent (Not present)
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Present But Too Small To Quantify
(Present but too small to quantify)
Date of Immunofixation
Urine M-protein by immunofixation
Negative (negative)
Positive (positive)
Protein Measurements
Mark an 'X' if not done
Date hematology (blood) sample obtained
(Serum Quantitative Immunoglobulins)
IgG (mg/dl)
IgG LLN (mg/dl)
IgG ULN (mg/dl)
IgA (mg/dl)
IgA LLN (mg/dl)
IgA ULN (mg/dl)
IgM (mg/dl)
IgM LLN (mg/dl)
IgM ULN (mg/dl)
Soft Tissue Plasmacytoma
Mark an 'X' if not done
Soft tissue plasmacytoma?
No (no)
Unknown (unknown)
Yes, Both Previously Existing And New
(yes, both previously existing and new)
Yes, New (yes, new)
Yes, Previously Existing (yes, previously
existing)
Lesion Number
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Site of lesion
Date of evaluation (leave blank if not evaluated in
this report period)
Method of evaluation
Clinical (Clinical Examination)
Ct Scan (CT scan (non-spiral))
Mri (MRI (NMR))
Other (Other (specify))
Spiral Ct Scan (Spiral CT scan)
Other Specify
Size of Plasmacytoma (cm)
Size of Plasmacytoma (X cm)
Status of Existing Soft Tissue Plasmacytoma
Decrease (decrease)
Increase (increase)
New (new)
No Change (no change)
Bone Marrow
Was bone marrow biopsy done?
Inadequate Sample (inadequate sample)
No (no)
Yes (yes)
Bone marrow biopsy date
Plasma cells on biopsy (If yes:)
If plasma cells on biopsy was left blank, please
specify (%)
No Percentage Given (No percentage
given)
Absent (Not present)
Present But Too Small To Quantify
(Present but too small to quantify)
Was bone marrow aspirate done?
Inadequate Sample (inadequate sample)
No (no)
Yes (yes)
Bone marrow aspirate date
Plasma cells on aspirate in interpretation (If yes:)
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If plasma cells on aspirate was left blank, please
specify
No Percentage Given (No percentage
given)
Absent (Not present)
Present But Too Small To Quantify
(Present but too small to quantify)
Was plasma cell clonality done
Yes
No
Plasma cell clonality test date
Clonality determination method
Flow Cytometry (flow cytometry)
Fluorescent Antibody Technique
(Immunofluorescence)
Immunohistochemistry
(Immunohistochemistry)
Other (other)
Other specify
Result
Kappa (kappa)
Lambda (lambda)
Polyclonal (polyclonal)
Bone
Was bone assessment done (this reporting
period)
Yes
No
Date of most recent bone assessment
Bone Assessment Method
Bone Scan (Bone scan)
Ct Scan (CT scan)
Mri (nmr) (MRI (NMR))
Other (Other)
Pet Scan (PET scan)
Skeletal Survey (Skeletal survey)
Was the appearance of any new lesions
documented (lytic bone)
No (no)
Unknown (unknown)
Yes (yes)
Other Specify
Peripheral Blood Chemistry
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Beta-2 Microglobulin ULN (ng/ml)
Mark an 'X' if not done
Mark an 'X' if not done
Mark an 'X' if not done
Mark an 'X' if not done
Mark an 'X' if not done
Beta-2 Microglobulin (ng/ml)
Creatinine ULN (mg/dl - Hematology/Chemistry)
Creatinine (mg/dl)
Hemoglobin (Hgb) (g/dl), LLN
Hemoglobin (g/dl)
Calcium LLN (mg/dl)
Calcium ULN (mg/dl)
Calcium (mg/dl)
Date of most recent hematology (blood) sample
obtained
Date of most recent hematology (blood) sample
obtained
Date of most recent hematology (blood) sample
obtained
Date of most recent hematology (blood) sample
obtained
Date of most recent hematology (blood) sample
obtained
Creatinine Clearance
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Objective Response
Has the overall response changed (since
previous evaluation)
Yes
No
Objective status at this evaluation
Complete Remission (Complete
Response)
Stable Disease (No response/stable
disease)
Partial Remission (Partial Response)
Pd (Progressive Disease)
Stringent Complete Response (scr) Of
Multiple Myeloma Or Plasma Cell
Leukemia (Stringent complete response)
Very Good Partial Response (Very good
partial response)
Stringent complete response first observed date
(sCR)
Complete Response (CR) First Observed Date
Very Good Partial Response First Observed Date
(VGPR)
Partial Response (PR) First Observed Date
Progressive Disease First Observed Date (For
PD: - PD)
Comments
Investigator Signature Date
Investigator Signature
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E1A06 Follow-Up Disease Assessment
Form NCT00602641
E1A06 Follow-Up Disease Assessment Form
NCT00602641 
Melphalan, Prednisone, and Thalidomide or Lenalidomide
in Treating Patients With Newly Diagnosed Multiple
Myeloma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=40675C5C-
F939-253D-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/10779
E1A06 Follow-Up Disease
Assessment Form NCT00602641
Header
DCI Name
Registration Step (Place ID Label Here)
Patient Initials (Last, First)
ECOG Protocol Number
ECOG Protocol Number
ECOG Patient ID
ECOG Patient ID
Participating Group Protocol Number
Participating Group Patient ID
Institution/Affiliate
Data amendment
Please mark an 'X' if data have been amended.
Date data amended
On Treatment
On Treatment Report Period (Maintenance
Therapy: Begins with Cycle 13)
> Cycle 34 (> Cycle 34)
Cycle 14 (Cycle 14)
Cycle 16 (Cycle 16)
Cycle 18 (Cycle 18)
Cycle 20 (Cycle 20)
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Cycle 22 (Cycle 22)
Cycle 24 (Cycle 24)
Cycle 26 (Cycle 26)
Cycle 28 (Cycle 28)
Cycle 30 (Cycle 30)
Cycle 32 (Cycle 32)
Cycle 34 (Cycle 34)
On Treatment Report Period (Maintenance
Therapy: Begins with Cycle 13)
> Cycle 34 (> Cycle 34)
Cycle 14 (Cycle 14)
Cycle 16 (Cycle 16)
Cycle 18 (Cycle 18)
Cycle 20 (Cycle 20)
Cycle 22 (Cycle 22)
Cycle 24 (Cycle 24)
Cycle 26 (Cycle 26)
Cycle 28 (Cycle 28)
Cycle 30 (Cycle 30)
Cycle 32 (Cycle 32)
Cycle 34 (Cycle 34)
Specify Cycle
Off Treatment
Off Treatment Report Period
9 Years (108 months post registration)
12 Months (12 Months Post Registration)
10 Years (120 months post registration)
15 Months (15 Months Post Registration)
18 Months (18 Months Post Registration)
21 Months Post Registration (21 Months
Post Registration)
2 Years (24 Months Post Registration)
3 Months (3 Months Post Registration)
30 Months (30 Months Post Registration)
3 Years (36 Months Post Registration)
42 Months (42 Months Post Registration)
4 Years (48 Months Post Registration)
54 Months (54 Months Post Registration)
6 Months (6 Months Post Registration)
5 Years (60 Months Post Registration)
6 Years (72 Months Post Registration)
84 Months Post Registration (84 Months
Post Registration)
9 Months (9 Months Post Registration)
8 Years (96 months post registration)
Protein Measurements
Date of SPEP
Test not done
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Test not done
Test not done
Test not done
Test not done
Test not done
Serum total protein (SPEP g/dl)
Serum M-protein spike (g/dl NOTE: Leave blank if
serum M-spike was present but too small to
quantify.)
If serum M-protein spike was left blank, please
specify (g/dl)
Absent (Not present)
Present But Too Small To Quantify
(Present but too small to quantify)
Date of serum FLC assessment
Kappa Free Light Chain (mg/dl)
Lambda Free Light Chain (mg/dl)
Date of Immunofixation (urine)
Date of Immunofixation (urine)
Date Hematology (Blood) Sample Obtained
Serum M-protein by immunofixation
Negative (negative)
Positive (positive)
Date of UPEP
Urine Total Protein (mg/24hr)
Urine M-Protein Light Chain Excretion (mg/24hr)
If urine M-protein light chain excretion was left
blank, please specify (mg/24 hr)
Absent (Not present)
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Present But Too Small To Quantify
(Present but too small to quantify)
Urine M-Protein by Immunofixation
Negative (negative)
Positive (positive)
IgG (mg/dl)
IgG LLN (mg/dl)
IgG ULN (mg/dl)
IgA (mg/dl)
IgA LLN (mg/dl)
IgA ULN (mg/dl)
IgM (mg/dl)
IgM LLN (mg/dl)
IgM ULN (mg/dl)
Soft Tissue Plasmacytoma
Soft tissue plasmacytoma?
No (no)
Unknown (unknown)
Yes, Both Previously Existing And New
(yes, both previously existing and new)
Yes, New (yes, new)
Yes, Previously Existing (yes, previously
existing)
Test not done
Lesion No.
Site of lesion
Date of evaluation (leave blank if not evaluated in
this report period)
Method of evaluation
Clinical (Clinical Examination)
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Ct Scan (CT scan (non-spiral))
Mri (MRI (NMR))
Not Evaluated (Not evaluated)
Other (Other (specify))
Spiral Ct Scan (Spiral CT scan)
Other Specify
Size of Plasmacytoma (cm)
Size of Plasmacytoma
Status of Existing Soft Tissue Plasmacytoma
Decrease (decrease)
Increase (increase)
New (new)
No Change (no change)
Bone Marrow
Was bone marrow biopsy done?
Inadequate Sample (inadequate sample)
No (no)
Yes (yes)
Bone marrow biopsy date
Plasma cells on biopsy (If yes:)
If plasma cells on biopsy was left blank, please
specify
No Percentage Given (No percentage
given)
Present But Too Small To Quantify
(Present but too small to quantify)
Was bone marrow aspirate done?
Inadequate Sample (inadequate sample)
No (no)
Yes (yes)
Date of Bone Marrow Aspirate
Plasma cells on aspirate in interpretation (If yes:)
If plasma cells on aspirate was left blank, please
specify (%)
No Percentage Given (No percentage
given)
Present But Too Small To Quantify
(Present but too small to quantify)
Bone
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Was bone assessment done (this reporting
period)
Yes
No
Date of most recent bone assessment
Bone Assessment Method
Bone Scan (Bone scan)
Ct Scan (CT scan)
Mri (nmr) (MRI (NMR))
Other (Other)
Pet Scan (PET scan)
Skeletal Survey (Skeletal survey)
Was the appearance of any new lesions
documented (lytic bone)
No (no)
Unknown (unknown)
Yes (yes)
Was there distinct enlargement of existing lesions
(lytic bone - Leave blank if no prior lesions)
No (no)
Unknown (unknown)
Yes (yes)
Other Specify
Explain results (If yes,)
Peripheral Blood Chemistry
Lactate Dehydrogenase ULN
Test not done
Test not done
Test not done
Lactate Dehydrogenase (LDH)
Hemoglobin (g/dL)
Hemoglobin, ULN (g/dL)
Calcium ULN (mg/dl)
Calcium (mg/dl)
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Date Hematology (Blood) Sample Obtained
Date Hematology (Blood) Sample Obtained
Date Hematology (Blood) Sample Obtained
Objective Response
Has the overall response changed (since
previous evaluation)
Yes
No
Objective Status at This Evaluation (confirmed)
Complete Response (complete
response)
No Response/stable Disease (no
response/stable disease)
Partial Response (partial response)
Progressive Disease (progressive
disease)
Unevaluable (unevaluable)
Very Good Partial Response (very good
partial response)
Complete Response (CR) First Observed Date
Very Good Partial Response First Observed Date
(VGPR)
Partial Response (PR) First Observed Date
Progressive Disease First Observed Date (PD)
Comments
Comments
Investigator Signature
Investigator Signature Date
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E1609 Source Document Tracking
Coversheet NCT01274338
E1609 Source Document Tracking Coversheet
NCT01274338 
Ipilimumab or High-Dose Interferon Alfa-2b in Treating
Patients With High-Risk Stage III or Stage IV Melanoma
That Has Been Removed by Surgery
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=9774BC47-
50B5-931D-E040-BB89AD43322B
All rights reserved. Please visit https://medical-data-
models.org/forms/10780
E1609 Source Document Tracking
Coversheet NCT01274338
Header
DCI Name
Registration Step
On Treatment Reporting Period (Arm B only)
Week 13 (Week 13)
Week 19 (Week 19)
Week 25 (Week 25)
Week 31 (Week 31)
Week 37 (Week 37)
Week 43 (Week 43)
Week 49 (Week 49)
Week 5 (Week 5)
Week 9 (Week 9)
Patient demographics
Patient Initials (Last, First)
ECOG Protocol Number
ECOG Patient ID
Participating Group Protocol Number
Participating Group Patient ID
Institution/Affiliate
On Treatment Reporting Period
Off Treatment
Off Treatment Report Period (Choose one)
9 Years (108 months post registration)
12 Months (12 Months Post Registration)
10 Years (120 months post registration)
11 Years Post Registration (132 Months
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Post Registration)
12 Years Post Registration (144 Months
Post Registration)
15 Months (15 Months Post Registration)
13 Years Post Registration (156 Months
Post Registration)
14 Years Post Registration (168 Months
Post Registration)
18 Months (18 Months Post Registration)
15 Years Post Registration (180 Months
Post Registration)
16 Years Post Registration (192 Months
Post Registration)
17 Years Post Registration (204 Months
Post Registration)
21 Months Post Registration (21 Months
Post Registration)
18 Years Post Registration (216 Months
Post Registration)
19 Years Post Registration (228 Months
Post Registration)
2 Years (24 Months Post Registration)
20 Years Post Registration (240 Months
Post Registration)
3 Months (3 Months Post Registration)
30 Months (30 Months Post Registration)
3 Years (36 Months Post Registration)
42 Months (42 Months Post Registration)
4 Years (48 Months Post Registration)
54 Months (54 Months Post Registration)
6 Months (6 Months Post Registration)
5 Years (60 Months Post Registration)
6 Years (72 Months Post Registration)
84 Months Post Registration (84 Months
Post Registration)
9 Months (9 Months Post Registration)
8 Years (96 months post registration)
Document type
Document type
Braf Mutation (BRAF mutation)
Pathology Report (Pathology Report)
Patient Interferon Diary (Patient
Interferon Diary)
Surgical Report (Surgical Report)
Report Created Date
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E1609 Disease Evaluation Form
NCT01274338
E1609 Disease Evaluation Form NCT01274338
Ipilimumab or High-Dose Interferon Alfa-2b in Treating
Patients With High-Risk Stage III or Stage IV Melanoma
That Has Been Removed by Surgery
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=97E81F9F-
47AA-261A-E040-BB89AD434355
All rights reserved. Please visit https://medical-data-
models.org/forms/10781
E1609 Disease Evaluation Form
NCT01274338
Header
ECOG Protocol Number
ECOG Patient ID
DCI Name
Registration Step
Patient demographics
Patient Initials (Last, First)
ECOG Protocol Number
ECOG Patient ID
Participating Group Protocol Number
Participating Group Patient ID
Institution/Affiliate
On Treatment
On Treatment Reporting Period (Arm B)
Week 13 (Week 13)
Week 25 (Week 25)
Week 37 (Week 37)
Week 49 (Week 49)
On Treatment Reporting Period
On Treatment Reporting Period (Arm B)
Week 13 (Week 13)
Week 25 (Week 25)
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Week 37 (Week 37)
Week 49 (Week 49)
Off Treatment
Off Treatment Report Period (Choose one)
9 Years (108 months post registration)
12 Months (12 Months Post Registration)
10 Years (120 months post registration)
11 Years Post Registration (132 Months
Post Registration)
12 Years Post Registration (144 Months
Post Registration)
15 Months (15 Months Post Registration)
13 Years Post Registration (156 Months
Post Registration)
14 Years Post Registration (168 Months
Post Registration)
18 Months (18 Months Post Registration)
15 Years Post Registration (180 Months
Post Registration)
16 Years Post Registration (192 Months
Post Registration)
17 Years Post Registration (204 Months
Post Registration)
21 Months Post Registration (21 Months
Post Registration)
18 Years Post Registration (216 Months
Post Registration)
19 Years Post Registration (228 Months
Post Registration)
2 Years (24 Months Post Registration)
20 Years Post Registration (240 Months
Post Registration)
3 Months (3 Months Post Registration)
30 Months (30 Months Post Registration)
3 Years (36 Months Post Registration)
42 Months (42 Months Post Registration)
4 Years (48 Months Post Registration)
54 Months (54 Months Post Registration)
6 Months (6 Months Post Registration)
5 Years (60 Months Post Registration)
6 Years (72 Months Post Registration)
84 Months Post Registration (84 Months
Post Registration)
9 Months (9 Months Post Registration)
8 Years (96 months post registration)
Data amendment
Please mark an 'X' if data have been amended.
(Please circle amended items in red)
Date data amended (s M D Y)
2 / 7
E1609 Disease Evaluation Form NCT01274338
Section Iii - Disease Follow-up Status
Disease status
Disease Present (Disease present)
No Evidence Of Disease (No evidence of
disease)
Section Iv - New Superficial Disease
Did the patient have evidence of new superficial
disease during this follow-up period
No (No)
Unknown (Unknown)
Yes (Yes)
Single agent chemotherapy (Treatment planned
or given for new superficial disease)
No (No)
Unknown (Unknown)
Yes (Yes)
Drug Combination Chemotherapy
No (No)
Unknown (Unknown)
Yes (Yes)
Radiation Therapy
No (No)
Unknown (Unknown)
Yes (Yes)
Surgery
No (No)
Unknown (Unknown)
Yes (Yes)
Other
No (No)
Unknown (Unknown)
Yes (Yes)
Other, specify
Was the new superficial disease the result of a
recurrence during this follow up period
No (No)
Unknown (Unknown)
Yes (Yes)
Date of Diagnosis of New Superficial Recurrence
Mark an 'X' if N/A
Mark an 'X' if N/A
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Mark an 'X' if N/A
Date of Clinical Confirmation of New Superficial
Recurrence
Date of Pathologic Confirmation of New
Superficial Recurrence
Radiologic (Methods of confirmation )
Yes
No
Radiologic, specify
Pathologic/Cytologic
Yes
No
Other
Yes
No
Other, specify
Regional Skin or Subcutaneous (Sites of new
superficial recurrence this report period - same
extremity if an extremity primary; within 7cm if a
trunk primary)
No (No)
Unknown (Unknown)
Yes (Yes)
Distant Skin or Subcutaneous (site further
removed from the primary than described above
under Regional Skin)
No (No)
Unknown (Unknown)
Yes (Yes)
Regional Lymph Nodes (on or at the base of an
extremity primary; within same quadrant if a trunk
primary)
No (No)
Unknown (Unknown)
Yes (Yes)
Distant Lymph Nodes (nodes further removed
from the primary than described above under
Regional Lymph Nodes)
No (No)
Unknown (Unknown)
Yes (Yes)
Section Iv - New Superficial Disease
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Did the patient have evidence of new visceral
metastatic disease during this follow up period
No (No)
Unknown (Unknown)
Yes (Yes)
Single agent chemotherapy (Treatment planned
or given for new superficial disease)
No (No)
Unknown (Unknown)
Yes (Yes)
Drug Combination Chemotherapy
No (No)
Unknown (Unknown)
Yes (Yes)
Radiation Therapy
No (No)
Unknown (Unknown)
Yes (Yes)
Surgery
No (No)
Unknown (Unknown)
Yes (Yes)
Other
No (No)
Unknown (Unknown)
Yes (Yes)
Other, specify
Did visceral disease initially appear during this
follow up period
No (No)
Unknown (Unknown)
Yes (Yes)
Date of Diagnosis of Visceral Recurrence
Mark an 'X' if N/A
Mark an 'X' if N/A
Mark an 'X' if N/A
Date of Clinical Confirmation of Visceral
Recurrence
Date of Pathologic Confirmation of Visceral
Recurrence
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Radiologic (Methods of confirmation )
Yes
No
Radiologic, specify
Pathologic/Cytologic
Yes
No
Other
Yes
No
Other, specify
Lung, Pleura
No (No)
Unknown (Unknown)
Yes (Yes)
Bone
No (No)
Unknown (Unknown)
Yes (Yes)
Bone specify
Liver
No (No)
Unknown (Unknown)
Yes (Yes)
Non-Liver abdominal organ involvement
No (No)
Unknown (Unknown)
Yes (Yes)
Non-Liver abdominal organ involvement, specify
CNS
No (No)
Unknown (Unknown)
Yes (Yes)
Other
No (No)
Unknown (Unknown)
Yes (Yes)
Other specify
Comments
Investigator Signature
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Investigator Signature Date (M D Y)
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E1A05 Quality of Life Assessment Form -
Form 2858 NCT00522392
E1A05 Quality of Life Assessment Form - Form 2858
NCT00522392 
Bortezomib and Dexamethasone With or Without
Lenalidomide in Treating Patients With Multiple Myeloma
Previously Treated With Dexamethasone
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=32583D04-
8AC6-00D1-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/10782
E1A05 Quality of Life Assessment
Form - Form 2858 NCT00522392
Header
ECOG Protocol Number
DCI Name
Registration Step
ECOG Patient ID
Patient demographics
Patient Initials (Last, First)
ECOG Protocol Number
Participating Group Protocol Number
Institution/Affiliate
ECOG Patient ID
Participating Group Patient ID
Reporting period
On Treatment Report Period (Note: Choose ¿End
of Treatment¿ when patient discontinues
treatment at any point.)
Baseline (baseline)
Cycle 5 (Cycle 5)
End Of Treatment (End of Treatment)
Off Treatment Report Period (For Patients who do
complete 8 cycles of treatment:)
12 Months (12 months post registration)
15 Months (15 months post registration)
18 Months (18 months post registration)
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9 Months (9 months post registration)
Off Treatment Report Period (For Patients who do
complete 8 cycles of treatment:)
12 Months (12 months post registration)
15 Months (15 months post registration)
18 Months (18 months post registration)
9 Months (9 months post registration)
Date of Assessment
Physical Well-being
I have a lack of energy (GP2)
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have nausea (GP3)
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
Because of my physical condition, I have trouble
meeting the needs of my family (GP4)
A Little (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have pain (GP5)
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am bothered by side effects of treatment (GP6)
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I feel ill (GP7)
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am forced to spend time in bed (GS1)
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A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
Functional Well-being
I am able to work (include work at home)
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
My work (include work at home) is fulfilling
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am able to enjoy life
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have accepted my illness
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am sleeping well
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am enjoying the things I usually do for fun
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am content with the quality of my life right now
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
Additional Concerns
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I have numbness or tingling in my hands
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have numbness or tingling in my feet
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I feel discomfort in my hands
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I feel discomfort in my feet
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have joint pain or muscle cramps
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I feel weak all over
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have trouble hearing
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I get a ringing or buzzing in my ears
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have trouble buttoning buttons
A Little Bit (A little bit)
Not At All (Not at all)
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Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have trouble feeling the shape of small objects
when they are in my hand
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have trouble walking
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
Additional Concerns - Mms
I have certain areas of my body where I
experience significant pain
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I feel fatigued
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I feel fatigued
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have trouble concentrating
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I worry about getting infections
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I feel weak all over
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A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I feel discouraged about my illness
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
Because of my illness, I have difficulty planning
for the future
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I worry that I might get new symptoms of my
illness
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have emotional ups and downs
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have bone pain
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I need help doing my usual activities
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have trouble walking because of pain
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have gained weight
A Little Bit (A little bit)
Not At All (Not at all)
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Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
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E1A06 Quality of Life Assessment Form
NCT00602641
E1A06 Quality of Life Assessment Form NCT00602641 
Melphalan, Prednisone, and Thalidomide or Lenalidomide
in Treating Patients With Newly Diagnosed Multiple
Myeloma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=400528BC-
39DF-0A65-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/10783
E1A06 Quality of Life Assessment
Form NCT00602641
Header
ECOG Protocol Number
ECOG Patient ID
DCI Name
Registration Step
Patient demographics
ECOG Protocol Number
Patient Initials (Last, First)
ECOG Patient ID
Participating Group Protocol Number
Institution/Affiliate
Participating Group Patient ID
Reporting period
On Treatment Report Period (Maintenance:
Begins with Cycle 13)
End Of Cycle 18 (End of Cycle 18)
End Of Cycle 24 (End of Cycle 24)
End Of Cycle 38 (End of Cycle 38)
End Of Treatment (End of Treatment)
On Treatment Report Period (Maintenance:
Begins with Cycle 13)
End Of Cycle 18 (End of Cycle 18)
End Of Cycle 24 (End of Cycle 24)
End Of Cycle 38 (End of Cycle 38)
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End Of Treatment (End of Treatment)
Off Treatment Report Period (For Patients who do
not complete 8 cycles of treatment:)
12 Months (12 months post registration)
15 Months (15 months post registration)
18 Months (18 months post registration)
21 Months Post Registration (21 months
post registration)
24 Months (24 months post registration)
3 Months (3 months post registration)
30 Months (30 months post registration)
36 Months (36 months post registration)
6 Months (6 months post registration)
9 Months (9 months post registration)
Date of Assessment
Physical Well-being
I have a lack of energy (GP2)
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have nausea (GP3)
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
Because of my physical condition, I have trouble
meeting the needs of my family (GP4)
A Little (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have pain (GP5)
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am bothered by side effects of treatment (GP6)
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I feel ill (GP7)
A Little Bit (A little bit)
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Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am forced to spend time in bed (GS1)
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
Functional Well-being
I am able to work (include work at home)
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
My work (include work at home) is fulfilling
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am able to enjoy life
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have accepted my illness
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am sleeping well
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am enjoying the things I usually do for fun
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am content with the quality of my life right now
A Little Bit (A little bit)
Not At All (Not at all)
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Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
Additional Concerns
I have numbness or tingling in my hands
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I feel weak all over
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have numbness or tingling in my feet
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I feel discomfort in my hands
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I feel discomfort in my feet
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have joint pain or muscle cramps
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have trouble hearing
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I get a ringing or buzzing in my ears
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
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Somewhat (Somewhat)
Very Much (Very much)
I have trouble buttoning buttons
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have trouble feeling the shape of small objects
when they are in my hand
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have trouble walking
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
Additional Concerns - Mms
I have certain areas of my body where I
experience significant pain
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I feel weak all over
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I feel fatigued
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I feel fatigued
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have trouble concentrating
A Little Bit (A little bit)
Not At All (Not at all)
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Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I worry about getting infections
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I feel discouraged about my illness
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
Because of my illness, I have difficulty planning
for the future
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I worry that I might get new symptoms of my
illness
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have emotional ups and downs
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have bone pain
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I need help doing my usual activities
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have trouble walking because of pain
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
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Very Much (Very much)
I have gained weight
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
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E2603 Follow-Up Disease Evaluation Form
(RECIST) NCT00110019
E2603 Follow-Up Disease Evaluation Form
(RECIST)NCT00110019
Carboplatin and Paclitaxel With or Without Sorafenib in
Treating Patients With Unresectable Stage III or Stage IV
Melanoma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=E80ECD74-
00E9-24F3-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/10784
E2603 Follow-Up Disease Evaluation
Form (RECIST) NCT00110019
Header
ECOG Protocol Number
ECOG Patient ID
DCI Name
Registration Step
Patient demographics
Patient Initials
ECOG Protocol Number
ECOG Patient ID
Participating Group Protocol Number
Institution/Affiliate
Participating Group Patient ID
Data amendment
Please mark an 'X' if data have been amended.
Date data amended
On Treatment
On Treatment Report Period (since start of
treatment)
> Cycle 31 (> Cycle 31)
Cycle 10 (Cycle 10)
1 / 6
Cycle 13 (Cycle 13)
Cycle 16 (Cycle 16)
Cycle 19 (Cycle 19)
Cycle 2 (Cycle 2)
Cycle 22 (Cycle 22)
Cycle 25 (Cycle 25)
Cycle 28 (Cycle 28)
Cycle 3 (Cycle 31)
Cycle 4 (Cycle 4)
Cycle 6 (Cycle 6)
Cycle 8 (Cycle 8)
specify Cycle
Off Treatment
Were disease assessment results obtained this
report period?
Yes
No
Off Treatment Report period (since registration)
12 Months (12 Months Post Registration)
15 Months (15 Months Post Registration)
18 Months (18 Months Post Registration)
21 Months Post Registration (21 Months
Post Registration)
2 Years (24 Months Post Registration)
3 Months (3 Months Post Registration)
30 Months (30 Months Post Registration)
3 Years (36 Months Post Registration)
42 Months (42 Months Post Registration)
4 Years (48 Months Post Registration)
54 Months (54 Months Post Registration)
6 Months (6 Months Post Registration)
5 Years (60 Months Post Registration)
9 Months (9 Months Post Registration)
Target Lesions
Lesion Number
Site of Lesion
Site Code
Bone (Bone)
Brain (Brain)
Breast (Breast)
Effusion/ascites (Effusion/Ascites)
Gi (GI)
Gu (GU)
Head & Neck (Head & Neck)
Liver (Liver)
Lung (Lung)
Nodes (Nodes)
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Other (Other)
Skin (Skin)
Method of Evaluation
Bone Scan (Bone scan)
Chest X-ray (Chest X-Ray)
Clinical (Clinical Examination)
Ct Scan (CT Scan)
Mri (MRI)
Not Evaluated (Not evaluated)
Other (Other)
Spiral Ct Scan (Spiral CT scan)
Ultrasound (Ultrasound)
Date of Evaluation
Longest Diameter of Lesion (s)
Document BASELINE Longest Diameter of
Lesion (For Identification)
Sum of longest diameters of all target lesions
New Lesions
Was the appearance of any new lesions
documented
Yes
No
Lesion Number
Site of Lesion
Site Code
Bone (Bone)
Brain (Brain)
Breast (Breast)
Effusion/ascites (Effusion/Ascites)
Gi (GI)
Gu (GU)
Head & Neck (Head & Neck)
Liver (Liver)
Lung (Lung)
Nodes (Nodes)
Other (Other)
Skin (Skin)
Method of Evaluation
Bone Scan (Bone scan)
Chest X-ray (Chest X-Ray)
Clinical (Clinical Examination)
Ct Scan (CT Scan)
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Mri (MRI)
Not Evaluated (Not evaluated)
Other (Other)
Spiral Ct Scan (Spiral CT scan)
Ultrasound (Ultrasound)
Date of Evaluation
Cytology Result (For Site Code 04 ONLY)
Negative (Negative)
Not Done (Not done)
Positive (Positive)
Nontarget Lesions
Lesion Number
Site of Lesion
Site Code
Bone (Bone)
Brain (Brain)
Breast (Breast)
Effusion/ascites (Effusion/Ascites)
Gi (GI)
Gu (GU)
Head & Neck (Head & Neck)
Liver (Liver)
Lung (Lung)
Nodes (Nodes)
Other (Other)
Skin (Skin)
Date of Evaluation
Method of Evaluation
Bone Scan (Bone scan)
Chest X-ray (Chest X-Ray)
Clinical (Clinical Examination)
Ct Scan (CT Scan)
Mri (MRI)
Not Evaluated (Not evaluated)
Other (Other)
Spiral Ct Scan (Spiral CT scan)
Ultrasound (Ultrasound)
Follow-up Status of Lesion (s)
Complete Response (CR)
Stable Disease (incompl.resp./SD)
Progressive Disease (PD)
Cytology Result (For Site Code 04 ONLY)
Negative (Negative)
Not Done (Not done)
Positive (Positive)
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Unequivocal progressive disease in nontarget
lesions is based on (description required)
Response Of Target Lesions This
Reporting Period
Has the response of the target lesions changed,
OR has an unconfirmed response changed to a
confirmed response, since last report ([NOTE:
Code 'yes' if this is the FIRST documentation of
stable disease.])
Yes
No
Response status at this assessment (target
lesions)
Complete Response (CR)
Insufficient Evaluation (Insufficient
evaluation to determine response status)
Progressive Disease (PD)
Partial Response (PR)
Stable Disease (SD)
PR/CR first observed date (If yes)
Progressive disease observed date (For PD)
Overall Response Per Recist Criteria -
Target, Nontarget And New Lesions
Has the overall response changed, OR has an
unconfirmed response changed to a confirmed
response, since last report ([NOTE: Code ?yes?
if this is the FIRST documentation of stable
disease.])
Yes
No
PR/CR first observed date (If yes)
Overall response status at this assessment
Complete Response (CR)
Insufficient Evaluation (Insufficient
evaluation to determine response status)
Progressive Disease (PD)
Partial Response (PR)
Stable Disease (SD)
Progressive disease observed date (For PD)
Has response been confirmed by second
assessment (For CR or PR)
Yes
No
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Symptomatic Deterioration
Is there symptomatic deterioration of the patient's
health status requiring discontinuation of
treatment (this reporting period)
Yes
No
Specify symptomatic deterioration (If yes)
Symptomatic Deterioration Date
Clinical Progression
Did the patient experience clinical progression?
Yes
No
Clinical progression date
Comments
Comments
Investigator Signature
Investigator Signature Date
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E5508 Follow-Up Disease Evaluation Form
(RECIST) NCT01107626
E5508 Follow-Up Disease Evaluation Form (RECIST)
NCT01107626 
Bevacizumab or Pemetrexed Disodium Alone or In
Combination After Induction Therapy in Treating Patients
With Advanced Non-Squamous Non-Small Cell Lung
Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=6D41D0A3-
B107-13D4-E040-BB89AD430599
All rights reserved. Please visit https://medical-data-
models.org/forms/10785
E5508 Follow-Up Disease Evaluation
Form (RECIST) NCT01107626
Header
ECOG Protocol Number
ECOG Patient ID
DCI Name
Registration Step
Patient demographics
Patient Initials (Last, First)
ECOG Protocol Number
ECOG Patient ID
Participating Group Protocol Number
Participating Group Patient ID
Institution/Affiliate
Data amendment
Please mark an 'X' if data have been amended.
(Please circle amended items in red)
Date data amended (s M D Y)
On Treatment
On Treatment Report Period (since start of
treatment Choose one)
> Cycle 30 - Step 2 (> Cycle 30 - Step 2)
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Cycle 10 Step 2 (Cycle 10 Step 2)
Cycle 12 Step 2 (Cycle 12 Step 2)
Cycle 14-step 2 (Cycle 14-Step 2)
Cycle 16-step 2 (Cycle 16-Step 2)
Cycle 18-step 2 (Cycle 18-Step 2)
Cycle 2 Step 1 (Cycle 2 Step 1)
Cycle 2 Step 2 (Cycle 2 Step 2)
Cycle 20-step 2 (Cycle 20-Step 2)
Cycle 22-step 2 (Cycle 22-Step 2)
Cycle 24-step 2 (Cycle 24-Step 2)
Cycle 26-step 2 (Cycle 26-Step 2)
Cycle 28-step 2 (Cycle 28-Step 2)
Cycle 30 - Step 2 (Cycle 30 - Step 2)
Cycle 4 Step 1 (Cycle 4 Step 1)
Cycle 4 Step 2 (Cycle 4 Step 2)
Cycle 6 Step 2 (Cycle 6 Step 2)
Cycle 8 Step 2 (Cycle 8 Step 2)
Specify Cycle
Off Treatment
Off Treatment Report Period (since registration
Choose one)
12 Months (12 months post registration)
15 Months (15 months post registration)
18 Months (18 months post registration)
21 Months Post Registration (21 months
post registration)
24 Months (24 months post registration)
3 Months (3 months post registration)
30 Months (30 months post registration)
36 Months (36 months post registration)
42 Months Post Registration (42 Months
Post Registration)
4 Years (48 months post registration)
54 Months Post Randomization (54
Months Post Randomization)
6 Months (6 months post registration)
60 Months Post Randomization (60
Months Post Randomization)
9 Months (9 months post registration)
Disease Assessment
Were disease assessment results obtained this
report period? (cycle)
Yes
No
TARGET LESIONS - NON-NODAL
Lesion Number
Site of Lesion (Multiple new lesions within an
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organ may be combined as a single site)
Site Code
Bone (Bone)
Brain (Brain)
Breast (Breast)
Effusion/ascites (Effusion/Ascites)
Gi (GI)
Gu (GU)
Head & Neck (Head & Neck)
Liver (Liver)
Lung (Lung)
Nodes (Nodes)
Other (Other)
Skin (Skin)
Method of Evaluation
Bone Scan (Bone scan)
Chest X-ray (Chest x-ray)
Clinical Examination (pe) (Clinical
examination)
Ct Scan (CT scan)
Mri (MRI (NMR))
Not Evaluated (Not evaluated)
Other (Other)
Spiral Ct Scan (Spiral CT scan)
Ultrasound (Ultrasound)
Date of Evaluation (M D Y)
Longest Diameter of Lesion(s) (cm)
Sum of Longest Diameters of All Non-Nodal
Target Lesions
TARGET LESIONS - NODAL
Lesion Number
Site of Lesion (Multiple new lesions within an
organ may be combined as a single site)
Site Code
Bone (Bone)
Brain (Brain)
Breast (Breast)
Effusion/ascites (Effusion/Ascites)
Gi (GI)
Gu (GU)
Head & Neck (Head & Neck)
Liver (Liver)
Lung (Lung)
Nodes (Nodes)
Other (Other)
Skin (Skin)
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Method of Evaluation
Bone Scan (Bone scan)
Chest X-ray (Chest x-ray)
Clinical Examination (pe) (Clinical
examination)
Ct Scan (CT scan)
Mri (MRI (NMR))
Not Evaluated (Not evaluated)
Other (Other)
Spiral Ct Scan (Spiral CT scan)
Ultrasound (Ultrasound)
Date of Evaluation (M D Y)
Shortest Axis of Lesions (mm)
Check this box if node reaches sub-clinical level
(<10 mm)
Sum of Shortest Axes of All Nodal Lesions (mm)
Sum of Longest (Non-Nodal) and Shortest
(Nodal) Axes of All Target Lesions (mm)
Nontarget Lesions
Lesion Number
Site of Lesion (Multiple new lesions within an
organ may be combined as a single site)
Site Code
Bone (Bone)
Brain (Brain)
Breast (Breast)
Effusion/ascites (Effusion/Ascites)
Gi (GI)
Gu (GU)
Head & Neck (Head & Neck)
Liver (Liver)
Lung (Lung)
Nodes (Nodes)
Other (Other)
Skin (Skin)
Method of Evaluation
Bone Scan (Bone scan)
Chest X-ray (Chest x-ray)
Clinical Examination (pe) (Clinical
examination)
Ct Scan (CT scan)
Mri (MRI (NMR))
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Not Evaluated (Not evaluated)
Other (Other)
Spiral Ct Scan (Spiral CT scan)
Ultrasound (Ultrasound)
Date of Evaluation (M D Y)
Follow-Up Status of Lesion (s)
Complete Response (CR)
Incompl. Resp./sd (Incompl. resp./SD)
Progressive Disease (PD)
Cytology Result (For Site Code 04
effusion/ascites ONLY)
Negative (Negative)
Not Done (Not done)
Positive (Positive)
New Lesions
Was the appearance of any new lesions
documented
Yes
No
Lesion Number
Site of Lesion (Multiple new lesions within an
organ may be combined as a single site)
Site Code
Bone (Bone)
Brain (Brain)
Breast (Breast)
Effusion/ascites (Effusion/Ascites)
Gi (GI)
Gu (GU)
Head & Neck (Head & Neck)
Liver (Liver)
Lung (Lung)
Nodes (Nodes)
Other (Other)
Skin (Skin)
Method of Evaluation
Bone Scan (Bone scan)
Chest X-ray (Chest x-ray)
Clinical Examination (pe) (Clinical
examination)
Ct Scan (CT scan)
Mri (MRI (NMR))
Not Evaluated (Not evaluated)
Other (Other)
Spiral Ct Scan (Spiral CT scan)
Ultrasound (Ultrasound)
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Date of Evaluation (M D Y)
Cytology Result (For Site Code 04
effusion/ascites ONLY)
Negative (Negative)
Not Done (Not done)
Positive (Positive)
Overall Response Per Recist Criteria -
Target, Nontarget And New Lesions
Best Overall Response to date (response status
of all target, non-target, and new lesions)
Complete Response (CR)
Insufficient Evaluation (Insufficient
evaluation to determine response status)
Progressive Disease (PD)
Partial Response (PR)
Stable Disease (SD)
Has the patient progressed or relapsed
No (No)
Unknown (Unknown)
Yes (Yes)
Progressive disease/Relapse observed date (M D
Y)
Symptomatic Deterioration
Is there symptomatic deterioration of the patient's
health status
Yes
No
Specify symptomatic deterioration (If yes:)
Symptomatic Deterioration Date (M D Y)
Comments
Comments
Investigator Signature
Investigator Signature Date (M D Y)
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ECOG Baseline Disease Evaluation Form
(RECIST) NCT00110019
ECOG Baseline Disease Evaluation Form  (RECIST)
NCT00110019
Carboplatin and Paclitaxel With or Without Sorafenib in
Treating Patients With Unresectable Stage III or Stage IV
Melanoma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=E7D4BDF4-
C034-4A08-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/10786
ECOG Baseline Disease Evaluation
Form  (RECIST) NCT00110019
Header
ECOG Protocol Number
ECOG Patient ID
DCI Name
Registration Step
Report period
Baseline (Baseline)
Please mark an 'X' if data have been amended.
Date data amended
Patient demographics
Patient Initials
Participating Group Protocol Number
Institution/Affiliate
Participating Group Patient ID
Target lesion
TARGET LESIONS
Are there any target lesions
Yes
No
Lesion Number
1 / 2
Site of Lesion
Site Code
Bone (bone)
Brain (Brain)
Breast (Breast)
Effusion/ascites (Effusion/Ascites)
Gi (GI)
Gu (GU)
Head & Neck (Head & Neck)
Liver (Liver)
Lung (Lung)
Nodes (Nodes)
Other (other)
Skin (Skin)
Method of Evaluation
Bone Scan (Bone scan)
Chest X-ray (Chest X-Ray)
Clinical (Clinical Examination)
Ct Scan (CT Scan)
Mri (MRI)
Other (other)
Spiral Ct Scan (Spiral CT scan)
Ultrasound (Ultrasound)
Date of Evaluation
Longest Diameter of Lesion
Sum of longest diameters of all target lesions
Nontarget Lesions
Cytology Result (For Site Code 04
effusion/ascites ONLY:)
Negative (Negative)
Not Done (Not done)
Positive (Positive)
Comments
Comments
Investigator Signature
Investigator Signature Date
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North Central Cancer Treatment Group N0723 Active
Monitoring RECIST Measurement Form NCT00738881
North Central Cancer Treatment Group N0723 Active
Monitoring RECIST Measurement Form NCT00738881 
Pemetrexed or Erlotinib as Second-Line Therapy in Treating
Patients With Advanced Non-Small Cell Lung Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=469B812A-
D0E7-3F2C-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/10787
North Central Cancer Treatment
Group N0723 Active Monitoring
RECIST Measurement Form
NCT00738881
Header
Protocol Number
Patient ID
Patient Initials (L F M)
Institution Number
Institution
Are data amended (If yes, highlight amended
areas)
Yes
No
Reporting period
Current Cycle Number
Assessment Date (mm/dd/yyyy)
Overall Response Status at This Assessment (If
PD is selected for overall response status, and
Yes is selected for "Was the appearance of any
new lesions documented" go to Non-Target
Lesions)
Complete Response (CR)
Progressive Disease (PD)
Partial Response (PR)
Stable Disease (SD)
Was the appearance of any new lesions
documented
Yes
No
Symptomatic Deterioration
1 / 2
Yes
No
Target Lesion Site (s)
Longest Diameter of Lesion(s)
Sum of Longest Diameters of All Target Lesions
Nontarget Lesion Site
Follow-Up Status of Lesion (check one)
Complete Response (CR)
Progressive Disease (PD)
Stable Disease (SD)
Mark an 'X' if N/A (Not Applicable)
Mark an 'X' if N/A (Not Applicable)
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North Central Cancer Treatment Group N0723 Active Monitoring RECIST
Measurement Form NCT00738881
North Central Cancer Treatment Group N0723
Pretreatment RECIST Measurement Form NCT00738881
North Central Cancer Treatment Group N0723
Pretreatment RECIST Measurement Form NCT00738881 
Pemetrexed or Erlotinib as Second-Line Therapy in Treating
Patients With Advanced Non-Small Cell Lung Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=46ACBEC0-
5144-1310-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/10788
North Central Cancer Treatment
Group N0723 Pretreatment RECIST
Measurement Form NCT00738881
Header
Protocol Number
Patient ID
Patient Initials (L F M)
Institution Number
Institution
Are data amended (If yes, highlight amended
areas)
Yes
No
Lesion assessment
Assessment Date (mm/dd/yyyy Assessment date
is the date reflecting type of assessment, not the
physician interpretation date.)
Target Lesion Site
Method of Evaluation
Chest X-ray (Chest x-ray)
Ct Scan (CT scan)
Mri (MRI (NMR))
Pet/ct Scan (PET/CT scan)
Physical Exam (Physical exam)
Spiral Ct Scan (Spiral CT scan)
Longest Diameter of Lesion(s) (cm)
Sum of Longest Diameters of All Target Lesions
Nontarget Lesion (check one)
1 / 2
Yes
No
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North Central Cancer Treatment Group N0723 Pretreatment RECIST
Measurement Form NCT00738881
North Central Cancer Treatment Group N0723
Arm A Evaluation/Treatment Form NCT00738881
North Central Cancer Treatment Group N0723 Arm A
Evaluation/Treatment Form NCT00738881 
Pemetrexed or Erlotinib as Second-Line Therapy in Treating
Patients With Advanced Non-Small Cell Lung Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=46ACBEC0-
51A9-1310-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/10789
North Central Cancer Treatment
Group N0723 Arm A
Evaluation/Treatment Form
NCT00738881
Header module
Protocol Number
Patient ID
Patient Initials (L F M)
Institution Number
Institution
Are data amended (If yes, highlight amended
areas)
Yes
No
Treatment assessment
Current Cycle Number
Weight (kg used for this cycle, round to the
nearest tenth)
ECOG Performance Status (check one used for
this cycle)
Fully Active, Able To Carry On All Pre-
disease Performance Without
Restriction. (0)
Restricted In Physically Strenuous
Activity But Ambulatory And Able To
Carry Out Work Of A Light Or Sedentary
Nature, E.g., Light Housework, Office
Work. (1)
Ambulatory And Capable Of All Selfcare
But Unable To Carry Out Any Work
Activities. Up And About More Than 50%
Of Waking Hours. (2)
Capable Of Only Limited Selfcare,
1 / 3
Confined To Bed Or Chair More Than
50% Of Waking Hours. (3)
Completely Disabled. Cannot Carry On
Any Selfcare. Totally Confined To Bed Or
Chair. (4)
Was this cycle of treatment held (check one)
No (no)
Yes, Planned (i.e., The Treatment Was
Changed According To Protocol
Guidelines) (Yes, planned)
Yes, Unplanned (i.e., The Treatment
Change Was Not Part Of Protocol
Guidelines) (Yes, unplanned)
Primary reason treatment held (If yes, planned or
unplanned)
Diarrhea (Diarrhea)
Hematologic (Hematologic)
Metabolic/laboratory
(Metabolic/laboratory)
Mucositis/stomatitis
(Mucositis/stomatitis)
Ocular/visual (Ocular/visual)
Other (Other)
Other Nonhematologic Adverse Events
(Other nonhematologic adverse events)
Pain (Pain)
Other, specify (not per protocol)
Agent Dosing
Agent (Erlotinib)
Agent Start Date (this cycle mm/dd/yyyy)
Initial Dose (day one this cycle If agent was not
given this cycle, enter the dose level received on
last day of treatment.)
Total Dose of Agents/Drugs for this Cycle (If
agent was not given this cycle, enter 0 for dose
level.)
Were there any dose modifications or
additions/omissions to protocol treatment? (Days
1-21 mg)
No (No)
Yes, Planned (i.e., The Treatment Was
Changed According To Protocol
Guidelines) (Yes, planned)
Yes, Unplanned (i.e., The Treatment
Change Was Not Part Of Protocol
Guidelines) (Yes, unplanned)
Reason(s) Modified
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Diarrhea (Diarrhea)
Hematologic (Hematologic)
Increased Per Protocol (Increased per
protocol)
Metabolic/laboratory
(Metabolic/laboratory)
Mucositis/stomatitis
(Mucositis/stomatitis)
Other (Other)
Other Nonhematologic Adverse Events
(Other nonhematologic adverse events)
Pain (Pain)
Other specify (not per protocol)
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Evaluation/Treatment Form NCT00738881
North Central Cancer Treatment Group N0723
Arm B Evaluation/Treatment Form NCT00738881
North Central Cancer Treatment Group N0723 Arm B
Evaluation/Treatment Form NCT00738881 
Pemetrexed or Erlotinib as Second-Line Therapy in Treating
Patients With Advanced Non-Small Cell Lung Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=46ACBEC0-
51D4-1310-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/10790
North Central Cancer Treatment
Group N0723 Arm B
Evaluation/Treatment Form
NCT00738881
Header module
Protocol Number
Patient ID
Patient Initials (L F M)
Institution Number
Institution
Are data amended (If yes, highlight amended
areas)
Yes
No
Assessment of Chemotherapy
Current Cycle Number
Weight (kg used for this cycle, round to the
nearest tenth)
ECOG Performance Status (check one used for
this cycle)
Fully Active, Able To Carry On All Pre-
disease Performance Without
Restriction. (0)
Restricted In Physically Strenuous
Activity But Ambulatory And Able To
Carry Out Work Of A Light Or Sedentary
Nature, E.g., Light Housework, Office
Work. (1)
Ambulatory And Capable Of All Selfcare
But Unable To Carry Out Any Work
Activities. Up And About More Than 50%
Of Waking Hours. (2)
Capable Of Only Limited Selfcare,
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Confined To Bed Or Chair More Than
50% Of Waking Hours. (3)
Completely Disabled. Cannot Carry On
Any Selfcare. Totally Confined To Bed Or
Chair. (4)
BSA
Was this cycle of treatment held (check one)
No (no)
Yes, Planned (i.e., The Treatment Was
Changed According To Protocol
Guidelines) (Yes, planned)
Yes, Unplanned (i.e., The Treatment
Change Was Not Part Of Protocol
Guidelines) (Yes, unplanned)
Primary reason treatment held (If yes, planned or
unplanned)
Diarrhea (Diarrhea)
Hematologic (Hematologic)
Metabolic/laboratory
(Metabolic/laboratory)
Mucositis/stomatitis
(Mucositis/stomatitis)
Other (Other)
Other Nonhematologic Adverse Events
(Other nonhematologic adverse events)
Other, specify (not per protocol)
Agent Dosing
Agent (Erlotinib)
Agent Start Date (this cycle mm/dd/yyyy)
Initial Dose (day one this cycle If agent was not
given this cycle, enter the dose level received on
last day of treatment.)
Total Dose of Agents/Drugs for this Cycle (If
agent was not given this cycle, enter 0 for dose
level.)
Were there any dose modifications or
additions/omissions to protocol treatment? (Days
1-21 mg)
No (No)
Yes, Planned (i.e., The Treatment Was
Changed According To Protocol
Guidelines) (Yes, planned)
Yes, Unplanned (i.e., The Treatment
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Change Was Not Part Of Protocol
Guidelines) (Yes, unplanned)
Reason(s) Modified (If Yes, per Section 8.0. Not
BSA changes)
Diarrhea (Diarrhea)
Hematologic (Hematologic)
Increased Per Protocol (Increased per
protocol)
Mucositis/stomatitis
(Mucositis/stomatitis)
Other (Other)
Other Nonhematologic Adverse Events
(Other nonhematologic adverse events)
Other specify (not per protocol)
Prior Agent Administration
Was folic acid administered (for this cycle check
one)
Yes
No
Was vitamin B12 administered (for this cycle
check one)
Yes
No
Was dexamethasone administered (for this cycle
check one)
Yes
No
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E3805 Assessment Compliance Form
(Form No. 2443) NCT00309985
E3805 Assessment Compliance Form (Form No. 2443)
NCT00309985 
Androgen Ablation Therapy With or Without Chemotherapy
in Treating Patients With Metastatic Prostate Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=04B03C24-
3EEB-4047-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/10791
E3805 Assessment Compliance
Form (Form No. 2443)
NCT00309985
Header
ECOG Protocol Number
ECOG Patient ID
DCI Name
Registration Step
Patient demographics
ECOG Protocol Number
ECOG Patient ID
Patient Initials
Participating Group Protocol Number
Institution/Affiliate
Participating Group Patient ID
Data amendment
Please mark an 'X' if data have been amended.
Date data amended
Baseline
Reporting Period (Choose one x)
Baseline (Baseline)
1 / 4
On Treatment
On Treatment Report Period (Arm A since start of
treatment)
Week 12 (Week 12)
Off Treatment
Off Treatment Report Period (since registration
Choose one x)
12 Months (12 months post registration)
3 Months (3 months post registration)
6 Months (6 months post registration)
9 Months (9 months post registration)
Section I
Assessment Date
Section Ii - Assessments Not Completed
Were all the quality of life forms completed for
this timepoint
Yes
No
Section Ii - Assessments Not Completed
Patient refusal
Yes
No
Unable to accomodate disability or language
needs
Yes
No
Specify disability or language
Patient did not show up in clinic/office
Yes
No
Specify reason patient did not show up
Staff unavailable
Yes
No
Patient not given form by staff
Yes
No
Patient too ill
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Yes
No
Patient expired
Yes
No
Assessment not required per protocol
Yes
No
Specify reason assessment is not required
Staff thought patient too ill
Yes
No
Other
Yes
No
Specify other reason
Section Iii - Assessment Completed
How Was The Patient Assisted
Were the questions read aloud to patient
Yes
No
Did the patient require clarification of questions or
instructions
Yes
No
Did the patient require other assistance
Yes
No
Were the forms completed independently by
another person
Yes
No
What Was The Reason For Assistance
Did the patient have a language difficulty
(questions needed to tbe translated)
Yes
No
Specify language
Did the patient have a literacy difficulty (patient
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could not read well enough)
Yes
No
Was the patient disabled
Yes
No
Specify disability
Were the forms completed via a telephone
interview
Yes
No
Other
Yes
No
Specify other reason
Who Assisted Or Completed Assessment
Staff
Yes
No
Family
Yes
No
Friend
Yes
No
Other
Yes
No
Specify other person
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E3805 Prostate Follow-up PSA Assessment
Form NCT00309985
E3805 Prostate Follow-up PSA Assessment Form
NCT00309985
Androgen Ablation Therapy With or Without Chemotherapy
in Treating Patients With Metastatic Prostate Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=F982C048-
0203-4A00-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/10792
E3805 Prostate Follow-up PSA
Assessment Form NCT00309985
Header
ECOG Protocol Number
ECOG Patient ID
DCI Name
Registration Step
Patient demographics
Patient Initials
ECOG Protocol Number
ECOG Patient ID
Participating Group Protocol Number
Institution/Affiliate
Participating Group Patient ID
Data amendment
Please mark an 'X' if data have been amended.
Date data amended
On Treatment
On Treatment Report Period (Arm A since start of
treatment)
Week 12 (Week 12)
1 / 2
OFF (CHEMOTHERAPY) TREATMENT
Off Treatment Report Period (since initial
registration)
9 Years (108 Months Post-Registration)
12 Months (12 Months Post Registration)
10 Years (120 Months Post-Registration)
15 Months (15 Months Post Registration)
18 Months (18 Months Post Registration)
21 Months Post Registration (21 Months
Post Registration)
2 Years (24 Months Post Registration)
3 Months (3 Months Post Registration)
30 Months (30 Months Post Registration)
3 Years (36 Months Post Registration)
42 Months (42 Months Post Registration)
4 Years (48 Months Post Registration)
54 Months (54 Months Post Registration)
6 Months (6 Months Post Registration)
5 Years (60 Months Post Registration)
6 Years (72 Months Post-Registration)
84 Months Post Registration (84 Months
Post-Registration)
9 Months (9 Months Post Registration)
8 Years (96 Months Post-Registration)
Prostate Specific Antigen (psa)
PSA Value (total)
Date of PSA Assessment
PSA Value, Upper Limit of Normal
Comments
Comments
Investigator Signature
Investigator Signature Date
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North Central Cancer Treatment Group - Neoadjuvant
Surgical Specimen Submission  Form NCT00490139
North Central Cancer Treatment Group - Neoadjuvant
Surgical Specimen Submission Form NCT00490139
ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment
Optimisation) Study; BIG 2-06/N063D
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=666BECA5-
5CC6-3044-E040-BB89AD437F7F
All rights reserved. Please visit https://medical-data-
models.org/forms/10793
North Central Cancer Treatment
Group - Neoadjuvant Surgical
Specimen Submission Form
NCT00490139
Header Module
NCCTG Study No.
Central Pathology ID Number
Patient Initials (L F M)
Institution Number
Institution
Biopsy specimen
Date Specimen collected (DD MM YYYY)
Date Specimen Shipped (DD MM YYYY)
Number of blocks sent
Accession Number including a block number (on
the blocks sent)
Specimen Type (The protocol requests one
normal block and one tumor block. Please
identify.)
Normal Block (Normal block)
Tumor Block (Tumor block)
Comments
Comments
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E1805 Follow-Up Disease Evaluation Form
E1805 Follow-Up Disease Evaluation Form
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=0F37BBF0-
DBF6-3D62-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/10794
E1805 Follow-Up Disease Evaluation
Form
Header
ECOG Protocol Number
ECOG Patient ID
DCI Name
Registration Step
Patient demographics
Patient Initials
ECOG Protocol Number
ECOG Patient ID
Participating Group Protocol Number
Participating Group Patient ID
Institution/Affiliate
Data amendment
Please mark an 'X' if data have been amended.
(Please circle amended items in red)
Date data amended (s - MM/DD/YYYY)
Header
On Treatment Report Period (Choose one x -
NOTE: If the duration of the final treatment period
is less than the report period intervals listed
below, choose the next highest report period.)
> Cycle 22 Step 2 (> Cycle 22 Step 2)
Cycle 15 Step 2 (Cycle 15 Step 2)
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Cycle 16-step 2 (Cycle 16-Step 2)
Cycle 17 Step 2 (Cycle 17 Step 2)
Cycle 18-step 2 (Cycle 18-Step 2)
Cycle 19 Step 2 (Cycle 19 Step 2)
Cycle 20-step 2 (Cycle 20-Step 2)
Cycle 21 Step 2 (Cycle 21 Step 2)
Cycle 22-step 2 (Cycle 22-Step 2)
On Treatment Report Period (Choose one x -
NOTE: If the duration of the final treatment period
is less than the report period intervals listed
below, choose the next highest report period.)
> Cycle 22 Step 2 (> Cycle 22 Step 2)
Cycle 15 Step 2 (Cycle 15 Step 2)
Cycle 16-step 2 (Cycle 16-Step 2)
Cycle 17 Step 2 (Cycle 17 Step 2)
Cycle 18-step 2 (Cycle 18-Step 2)
Cycle 19 Step 2 (Cycle 19 Step 2)
Cycle 20-step 2 (Cycle 20-Step 2)
Cycle 21 Step 2 (Cycle 21 Step 2)
Cycle 22-step 2 (Cycle 22-Step 2)
On Treatment Report Period (Choose one x -
NOTE: If the duration of the final treatment period
is less than the report period intervals listed
below, choose the next highest report period.)
> Cycle 22 Step 2 (> Cycle 22 Step 2)
Cycle 15 Step 2 (Cycle 15 Step 2)
Cycle 16-step 2 (Cycle 16-Step 2)
Cycle 17 Step 2 (Cycle 17 Step 2)
Cycle 18-step 2 (Cycle 18-Step 2)
Cycle 19 Step 2 (Cycle 19 Step 2)
Cycle 20-step 2 (Cycle 20-Step 2)
Cycle 21 Step 2 (Cycle 21 Step 2)
Cycle 22-step 2 (Cycle 22-Step 2)
On Treatment Report Period (Choose one x -
NOTE: If the duration of the final treatment period
is less than the report period intervals listed
below, choose the next highest report period.)
> Cycle 22 Step 2 (> Cycle 22 Step 2)
Cycle 15 Step 2 (Cycle 15 Step 2)
Cycle 16-step 2 (Cycle 16-Step 2)
Cycle 17 Step 2 (Cycle 17 Step 2)
Cycle 18-step 2 (Cycle 18-Step 2)
Cycle 19 Step 2 (Cycle 19 Step 2)
Cycle 20-step 2 (Cycle 20-Step 2)
Cycle 21 Step 2 (Cycle 21 Step 2)
Cycle 22-step 2 (Cycle 22-Step 2)
Specify Cycle
Specify Cycle
Off Treatment
Off Treatment Report Period (since registration -
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Choose one x)
9 Years (108 months post registration)
12 Months (12 months post registration)
10 Years (120 months post registration)
11 Years Post Registration (132 Months
Post Registration)
12 Years Post Registration (144 Months
Post Registration)
15 Months (15 months post registration)
13 Years Post Registration (156 Months
Post Registration)
14 Years Post Registration (168 Months
Post Registration)
18 Months (18 months post registration)
15 Years Post Registration (180 Months
Post Registration)
21 Months Post Registration (21 months
post registration)
24 Months (24 months post registration)
3 Months (3 months post registration)
30 Months (30 months post registration)
3 Years (36 months post registration)
42 Months Post Registration (42 Months
Post Registration)
4 Years (48 months post registration)
54 Months Post Registration (54 Months
Post Registration)
6 Months (6 months post registration)
5 Years (60 months post registration)
6 Years (72 months post registration)
84 Months Post Registration (84 months
post registration)
9 Months (9 months post registration)
8 Years (96 months post registration)
Prostate Specific Antigen (psa)
Was patients PSA assessed (this report period)
Yes
No
PSA Value (total) (ng/ml)
Date of PSA Assessment (MM/DD/YYYY)
Nontarget Lesions
Was patient assessed for clinical progression this
report period
Yes
No
Was the appearance of any new lesions
documented (If yes: - NEW LESIONS)
Yes
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No
Lesion Number
Site of Lesion (Comments - Multiple nontarget
lesions within an organ may be combined as a
single site; report in a consistent manner on
subsequent forms.)
Site Code
Bone (bone)
Brain (Brain)
Breast (Breast)
Effusion/ascites (Effusion/Ascites)
Gi (GI)
Gu (GU)
Head & Neck (Head & Neck)
Liver (Liver)
Lung (Lung)
Nodes (Nodes)
Other (other)
Skin (Skin)
Method of Evaluation
Bone Scan (Bone scan)
Chest X-ray (Chest X-Ray)
Clinical (Clinical Examination)
Ct Scan (CT Scan)
Mri (MRI)
Other (other)
Spiral Ct Scan (Spiral CT scan)
Ultrasound (Ultrasound)
Date of Evaluation (MM/DD/YYYY)
Cytology Result (For site code 04 effusion/ascites
ONLY)
Negative (Negative)
Not Done (Not done)
Positive (Positive)
Confirmatory scan done (If Bone lesions:)
Yes
No
Date of Scans (MM/DD/YYYY)
Symptomatic Deterioration
Is there Symptomatic Deterioration of the
patient's health status requiring discontinuation of
treatment?
Yes
No
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Symptomatic Deterioration Specify
Symptomatic Deterioration Date (MM/DD/YYYY)
Comments
Comments
Investigator Signature
Investigator Signature Date
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E1805 Follow-Up Disease Evaluation Form
Lung Cancer - North Central Cancer
Treatment Group N0723 Notification Form
North Central Cancer Treatment Group N0723 Notification
Form; ***This CRF DELETED FROM STUDY, so no
response to initial CDE-compliance review.***
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=46AC3272-
A577-410A-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/10795
Lung Cancer - North Central Cancer
Treatment Group N0723 Notification
Form
Header
Protocol Number
Patient ID
Patient Initials (L F M)
Institution Number
Institution
Patient status assessment
Date membership CRA aware of event(s)
(mm/dd/yyyy)
Name of person completing form
Phone
Current Cycle Number
Assigned Treatment Arm
Event => Grade 4 (check one)
Yes
No
Date of First Occurrence of Adverse Event
(mm/dd/yyyy)
CTC Adverse Event Term (only one event per
line)
CTC Adverse Event Grade
1 / 2
In your opinion, is this related to the study
medication
No (No)
Unknown (Unknown)
Yes (Yes)
Hospitalization (check one)
Yes
No
Hospital Admission Date (mm/dd/yyyy)
Reason for Hospitalization
Adverse Event (adverse event)
Other Reason (Other reason)
Prophylactic (Prophylactic)
Adverse event, specify type and grade
Prophylactic, specify
Other reason, specify
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Form
E1609 Source Document Tracking
Coversheet NCT01274338
E1609 Source Document Tracking Coversheet
NCT01274338 
Ipilimumab or High-Dose Interferon Alfa-2b in Treating
Patients With High-Risk Stage III or Stage IV Melanoma
That Has Been Removed by Surgery
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=9774BC47-
50B5-931D-E040-BB89AD43322B
All rights reserved. Please visit https://medical-data-
models.org/forms/10796
E1609 Source Document Tracking
Coversheet NCT01274338
Unnamed2
Patienteninitialen (Nachname, Vorname)
ECOG Protokoll-Nummer
ECOG Patienten-ID
Teilnehmende Gruppen Protokoll-Nummer
Teilnehmenden Gruppen Patienten-ID
Institution / Einrichtung
DCI Vorname
Registrierungsschritt
Behandlungs Berichtszeitraum ( Arm A und Arm
B )
Woche 13 (Week 13)
Woche 19 (Week 19)
Woche 25 (Week 25)
Woche 31 (Week 31)
Woche 37 (Week 37)
Woche 43 (Week 43)
Woche 49 (Week 49)
Woche 5 (Week 5)
Woche 9 (Week 9)
Behandlungs Berichtszeitraum
Keine Behandlung
Kein-Behandlungs Berichtszeitraum (Wählen Sie
eine)
9 Jahre (108 months post registration)
12 Monate (12 Months Post Registration)
10 Jahre (120 months post registration)
11 Jahre nach der Registrierunug (132
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Months Post Registration)
12 Jahre nach der Registrierunug (144
Months Post Registration)
15 Monate (15 Months Post Registration)
13 Jahre nach der Registrierunug (156
Months Post Registration)
14 Jahre nach der Registrierunug (168
Months Post Registration)
18 Monate (18 Months Post Registration)
15 Jahre nach der Registrierunug (180
Months Post Registration)
16 Jahre nach der Registrierunug (192
Months Post Registration)
17 Jahre nach der Registrierunug (204
Months Post Registration)
21 Monate nach der Registrierung (21
Months Post Registration)
18 Jahre nach der Registrierunug (216
Months Post Registration)
19 Jahre nach der Registrierunug (228
Months Post Registration)
2 Jahre (24 Months Post Registration)
20 Jahre nach der Registrierunug (240
Months Post Registration)
3 Monate (3 Months Post Registration)
30 Monate (30 Months Post Registration)
3 Jahre (36 Months Post Registration)
42 Monate (42 Months Post Registration)
4 Jahre (48 Months Post Registration)
54 Monate (54 Months Post Registration)
6 Monate (6 Months Post Registration)
5 Jahre (60 Months Post Registration)
6 Jahre (72 Months Post Registration)
84 Monate nach der Registrierunug (84
Months Post Registration)
9 Monate (9 Months Post Registration)
8 Jahre (96 months post registration)
Abschnitt II
Dokumententype
BRAF-Mutation (BRAF mutation)
Pathologie-Bericht (Pathology Report)
Patienten Interferon Tagebuch (Patient
Interferon Diary)
OP-Bericht (Surgical Report)
Datum der Berichtserstellung
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North Central Cancer Treatment Group - Pathology
Specimen Submission Form NCT00490139
North Central Cancer Treatment Group - Pathology
Specimen Submission Form NCT00490139
ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment
Optimisation) Study; BIG 2-06/N063D
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=30AE3367-
6DB2-0D0A-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/10797
North Central Cancer Treatment
Group - Pathology Specimen
Submission Form NCT00490139
Header Module
NCCTG Study No.
Central Pathology ID Number
Patient Initials
Institution Number
Institution
Biopsy specimen / Lab
Date Specimen Shipped
Number of blocks sent
ER Status (Local ER/PrG Result)
Negative (Negative)
Positive (Positive)
ER % cells stained positive
Mark an 'X' if N/A
PgR Status
Negative (Negative)
Not Done (NOT DONE)
Positive (Positive)
PgR % cells stained positive
Is the accession number (including block number)
of the block used to determine the ER/PgR result
available (reported above - check one)
Yes
1 / 3
No
Accession Number including a block number (on
the blocks sent)
Accession Number
Local Her2 Results
IHC Result
Equivocal (Equivocal)
Negative (Negative)
Not Done (Not done / Not available)
Positive (Positive)
Percentage of Invasive Tumor Cells with
Membrane Staining
Staining Antibody
Cb-11/ventana Kit (CB-11/Ventana Kit)
Dako A0485 (DAKO A0485)
Dako Herceptest [tm] (DAKO Herceptest
[TM])
Ihc Not Done (IHC not done)
Ncl-c-erbb2-316 (NCL-c-erbB2-316)
Other Specify (Other)
Tab-250 (TAB-250)
Other specify
Is the accession number (including block number)
of the block used to determine the IHC HER2
result available (reported above - check one)
Yes
No
FISH Result
Amplified (Amplified)
Equivocal (Equivocal)
Not Amplified (Not amplified)
Not Done (Not done)
FISH HER2/neu chromosome 17 Ratio
Chromosome 17 copy number
Monosomy (Monosomy)
Normal (Normal)
Not Done: C49484 (Not done / Not
available)
Polysomy (Polysomy)
FISH Kit or Test Type
Fish Not Done (FISH not done)
Other Specify (Other)
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Ventana Inform (Ventana INFORM)
Ventana/oncorprobe[tm]
(Ventana/Oncorprobe)
Vysis Tricolor Probe (Vysis Tricolor
probe)
Other specify
Is the accession number (including block number)
of the block used to determine the FISH HER2
result available (reported above - check one)
Yes
No
Specimen Type (the protocol requests one
normal block and one tumor block. Please
identify)
Normal Block (Normal block)
Tumor Block (Tumor block)
Comments
Comments
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North Central Cancer Treatment Group - Pathology Specimen
Submission Form NCT00490139
North Central Cancer Treatment Group N0577 Arm
B & C Evaluation/Treatment Form NCT00887146
North Central Cancer Treatment Group N0577 Arm B & C
Evaluation/Treatment Form NCT00887146 
Radiation Therapy or Radiation Therapy and Temozolomide
or Temozolomide Alone in Treating Patients With Newly
Diagnosed Anaplastic Glioma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=4C094A66-
1244-40DD-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/10799
North Central Cancer Treatment
Group N0577 Arm B & C
Evaluation/Treatment Form
NCT00887146
Header
Protocol Number
Patient ID
Patient Initials (L F M)
Institution Number
Institution
Are data amended (If yes, highlight amended
areas)
Yes
No
Assessment of Chemotherapy
Current Cycle Number
Weight (kg used for this cycle, round to the
nearest tenth)
ECOG Performance Status (check one used for
this cycle)
Fully Active, Able To Carry On All Pre-
disease Performance Without
Restriction. (0)
Restricted In Physically Strenuous
Activity But Ambulatory And Able To
Carry Out Work Of A Light Or Sedentary
Nature, E.g., Light Housework, Office
Work. (1)
Ambulatory And Capable Of All Selfcare
But Unable To Carry Out Any Work
Activities. Up And About More Than 50%
Of Waking Hours. (2)
Capable Of Only Limited Selfcare,
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Confined To Bed Or Chair More Than
50% Of Waking Hours. (3)
Completely Disabled. Cannot Carry On
Any Selfcare. Totally Confined To Bed Or
Chair. (4)
Was this cycle of treatment held (check one)
No (no)
Yes, Planned (i.e., The Treatment Was
Changed According To Protocol
Guidelines) (Yes, planned)
Yes, Unplanned (i.e., The Treatment
Change Was Not Part Of Protocol
Guidelines) (Yes, unplanned)
Primary reason treatment held (If yes, planned or
unplanned)
Hematologic (Hematologic)
Other (Other)
Other Nonhematologic Adverse Events
(Other nonhematologic adverse events)
Other, specify (not per protocol)
Agent (Erlotinib)
Agent Start Date (this cycle mm/dd/yyyy)
Initial Dose (day one this cycle If agent was not
given this cycle, enter the dose level received on
last day of treatment.)
Total Dose of Agents/Drugs for this Cycle (If
agent was not given this cycle, enter 0 for dose
level.)
Were there any dose modifications or
additions/omissions to protocol treatment? (Days
1-21 mg)
No (No)
Yes, Planned (i.e., The Treatment Was
Changed According To Protocol
Guidelines) (Yes, planned)
Yes, Unplanned (i.e., The Treatment
Change Was Not Part Of Protocol
Guidelines) (Yes, unplanned)
Reason(s) Modified (If Yes, per Section 8.0. Not
BSA changes)
Hematologic (Hematologic)
Increased Per Protocol (Increased per
protocol)
Other (Other)
Other Nonhematologic Adverse Events
(Other nonhematologic adverse events)
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Other specify (not per protocol)
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North Central Cancer Treatment Group N0577 Arm B & C
Evaluation/Treatment Form NCT00887146
North Central Cancer Treatment Group
N0577 Notification Form NCT00887146
North Central Cancer Treatment Group N0577 Notification
Form NCT00887146 
Radiation Therapy or Radiation Therapy and Temozolomide
or Temozolomide Alone in Treating Patients With Newly
Diagnosed Anaplastic Glioma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=4C07CD25-
652F-2417-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/10800
North Central Cancer Treatment
Group N0577 Notification Form
NCT00887146
Header
Protocol Number
Patient ID
Patient Initials (L F M)
Institution Number
Institution
Patient status assessment
Date membership CRA aware of event(s)
(mm/dd/yyyy)
Name of person completing form
Phone
Current Cycle Number
Assigned Treatment Arm
Event => Grade 4 (check one)
Yes
No
Date of First Occurrence of Adverse Event
(mm/dd/yyyy)
CTC Adverse Event Term (only one event per
line)
CTC Adverse Event Grade
1 / 2
In your opinion, is this related to the study
medication
No (No)
Unknown (Unknown)
Yes (Yes)
Hospitalization (check one)
Yes
No
Hospital Admission Date (mm/dd/yyyy)
Reason for Hospitalization (s)
Adverse Event (adverse event)
Other Reason (Other reason)
Prophylactic (Prophylactic)
Adverse event, specify type and grade
Prophylactic, specify
Other reason, specify
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North Central Cancer Treatment Group N0577 Notification Form
NCT00887146
North Central Cancer Treatment Group N0577 End Of
Active Treatment/Cancel Notification Form NCT00887146
North Central Cancer Treatment Group N0577 End Of
Active Treatment/Cancel Notification Form (Submit Once
Per Patient) NCT00887146 
Radiation Therapy or Radiation Therapy and Temozolomide
or Temozolomide Alone in Treating Patients With Newly
Diagnosed Anaplastic Glioma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=4C090D31-
BAA2-2FAA-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/10801
North Central Cancer Treatment
Group N0577 End Of Active
Treatment/Cancel Notification Form
NCT00887146
Header
Protocol Number
Patient ID
Patient Initials (L F M)
Institution Number
Institution
Are data amended (If yes, highlight amended
areas)
Yes
No
Preregistration Screening Failure
Last Date (any modality of) protocol therapy was
given (mm/dd/yyyy date of last treatment dose on
this study or date decision made not to initiate
protocol treatment)
Off Treatment Date (mm/dd/yyyy date decision
was made to end active treatment or not to
initiate protocol treatment)
This patient will now go to (check one See
Schema and Section 13.0 of the protocol)
Event Monitoring (Event monitoring)
Observation: C15722 (Observation)
Off Study (Off study)
Reason Treatment Ended (check one)
Adverse Event/side Effects/complications
(Adverse Event/Side
Effects/Complications)
Alternative Therapy (Alternative therapy)
1 / 2
Death On Study (Death on study)
Disease Progression Before Active
Treatment (Disease Progression before
active treatment)
Disease Progression, Relapse During
Active Treatment (Disease progression,
relapse during active treatment)
Other (Other)
Patient Off-treatment For Other
Complicating Disease (Patient off-
treatment for other complicating disease)
Patient Withdrawal Or Refusal After
Beginning Protocol Therapy (Patient
withdrawal/refusal after beginning
protocol therapy)
Patient Withdrawal Or Refusal Before
Beginning Protocol Therapy (Patient
withdrawal/refusal prior to beginning
protocol therapy)
Treatment Completed Per Protocol
Criteria (Treatment completed per
protocol criteria)
Patient withdrawal/refusal after beginning
protocol therapy specify
Patient withdrawal/refusal prior to beginning
protocol therapy specify
Adverse event/side effects/complications specify
Alternative Therapy (Specify)
Other Complicating Disease specify
Other specify
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North Central Cancer Treatment Group N0577 End Of Active
Treatment/Cancel Notification Form NCT00887146
North Central Cancer Treatment Group N0723 End Of
Active Treatment/Cancel Notification Form NCT00738881
North Central Cancer Treatment Group N0723 End Of
Active Treatment/Cancel Notification Form NCT00738881 
Pemetrexed or Erlotinib as Second-Line Therapy in Treating
Patients With Advanced Non-Small Cell Lung Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=46AC6BB1-
F9DF-4B4C-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/10802
North Central Cancer Treatment
Group N0723 End Of Active
Treatment/Cancel Notification Form
NCT00738881
Header
Protocol Number
Patient ID
Patient Initials (L F M)
Institution Number
Institution
Are data amended (If yes, highlight amended
areas)
Yes
No
Preregistration Screening Failure
Last Date (any modality of) protocol therapy was
given (mm/dd/yyyy date of last treatment dose on
this study or date decision made not to initiate
protocol treatment)
Off Treatment Date (mm/dd/yyyy date decision
was made to end active treatment or not to
initiate protocol treatment)
The patient will now go to (check one See
Schema and Section 13.0 of the protocol)
Event Monitoring (Event monitoring)
Off Study (Off study)
Reason Treatment Ended (check one)
Adverse Event/side Effects/complications
(Adverse Event/Side
Effects/Complications)
Alternative Therapy (Alternative therapy)
Death On Study (Death on study)
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Disease Progression Before Active
Treatment (Disease Progression before
active treatment)
Disease Progression, Relapse During
Active Treatment (Disease progression,
relapse during active treatment)
Other (Other)
Patient Off-treatment For Other
Complicating Disease (Patient off-
treatment for other complicating disease)
Patient Withdrawal Or Refusal After
Beginning Protocol Therapy (Patient
withdrawal/refusal after beginning
protocol therapy)
Patient Withdrawal Or Refusal Before
Beginning Protocol Therapy (Patient
withdrawal/refusal prior to beginning
protocol therapy)
Treatment Completed Per Protocol
Criteria (Treatment completed per
protocol criteria)
Patient withdrawal/refusal after beginning
protocol therapy specify
Patient withdrawal/refusal prior to beginning
protocol therapy specify
Adverse event/side effects/complications specify
Alternative Therapy
Other Complicating Disease specify
Other specify
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North Central Cancer Treatment Group N0723 End Of Active
Treatment/Cancel Notification Form NCT00738881
North Central Cancer Treatment Group End
of Active Treatment Form NCT00377156
North Central Cancer Treatment Group End of Active
Treatment Form NCT00377156 
Stereotactic Radiation Therapy With or Without Whole-
Brain Radiation Therapy in Treating Patients With Brain
Metastases
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=10B2740B-
6134-4AA3-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/10803
North Central Cancer Treatment
Group End of Active Treatment Form
NCT00377156
Header
NCCTG Protocol Number
NCCTG Patient ID
Patient Initials (L F M)
Institution
Institution Number
Are data amended (If yes, highlight amended
areas)
Yes
No
Preregistration Screening Failure
Off Treatment Date
Last Date (any modality of) protocol therapy was
given
The patient will now go to (check one See
Schema and Section 13.0 of the protocol)
Event Monitoring (Event monitoring)
Observation: C15722 (Observation)
Reason Treatment Ended (check one)
Adverse Event/side Effects/complications
(Adverse Event/Side
Effects/Complications)
Alternative Therapy (Alternative therapy)
Death On Study (Death on study)
Disease Progression Before Active
Treatment (Disease Progression before
active treatment)
Disease Progression, Relapse During
Active Treatment (Disease progression,
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relapse during active treatment)
Other (Other)
Patient Off-treatment For Other
Complicating Disease (Patient off-
treatment for other complicating disease)
Patient Withdrawal Or Refusal After
Beginning Protocol Therapy (Patient
withdrawal/refusal after beginning
protocol therapy)
Patient Withdrawal Or Refusal Before
Beginning Protocol Therapy (Patient
withdrawal/refusal prior to beginning
protocol therapy)
Treatment Completed Per Protocol
Criteria (Treatment completed per
protocol criteria)
Patient withdrawal/refusal after beginning
protocol therapy specify
Alternative Therapy
Adverse event/side effects/complications specify
Other Complicating Disease specify
Other specify
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NCT00377156
E2603 Baseline Data Form NCT00110019
E2603 Baseline Data Form NCT00110019
Carboplatin and Paclitaxel With or Without Sorafenib in
Treating Patients With Unresectable Stage III or Stage IV
Melanoma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=E79B4696-
B7BD-111B-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/10804
E2603 Baseline Data Form
NCT00110019
ECOG clinical trial administrative data
ECOG Protocol Number
ECOG Patient ID
DCI Name
Registration Step
Report period
Baseline (Baseline)
Patient Initials
Participating Group Protocol Number
Institution/Affiliate
Participating Group Patient ID
Data amendment
Please mark an 'X' if data have been amended.
Date data amended
Pre-registration Hematology/chemistry
Lab Facility Name
Test not done
Peripheral WBC Count LLN
Peripheral WBC Count
1 / 5
Peripheral granulocytes count LLN (*)
Peripheral granulocytes count
Peripheral Platelet count LLN
Alkaline phosphatase ULN
Alkaline phosphatase
Hemoglobin LLN (Hgb)
Patient Creatinine Serum ULN
Hemoglobin
Patient Creatine Serum Value
Creatinine clearance (calculated )
Bilirubin ULN
Bilirubin
BUN
SGOT ULN (AST)
SGOT
SGPT ULN (ALT)
SGPT
Albumin LLN
Albumin
Glucose LLN
Glucose ULN
Glucose
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Potassium LLN (K)
Potassium ULN
Potassium
Sodium LLN (Na)
Sodium ULN
Sodium
International Normalization Ratio ULN (INR)
International Normalization Ratio
PTT ULN (partial thromboplastin time)
PTT
Amylase ULN
Amylase
Lactate Dehydrogenase ULN
Lipase ULN
Lipase
Lactate Dehydrogenase (LDH)
Date Hematology Sample Obtained (Blood)
Pre-registration Disease Assessment
Pre-registration Disease Assessment
Bone Scan (Bone scan)
Brain Ct Or Mri (Brain CT or MRI)
Ct Chest (CT chest)
Ct Or Mri Abdomen (CT or MRI
abdomen)
Ct Or Mri Pelvis (CT or MRI pelvis)
Other pre-registration scans/imaging
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Result
Equivocal (equivocal)
Involved (involved)
Negative (negative)
Not Done (not done)
Assessment Date
Explain equivocal results (Continue at bottom of
page if needed)
Comments
Systolic Blood Pressure
Diastolic Blood Pressure
Prior Treatment For This Disease
Prior Investigational Therapies Administered Ind-
2
Yes
No
Prior chemotherapy
Yes
No
Prior immunotherapy
Yes
No
Date of progression on prior treatment regimen
Specify Agent (sor combinations)
List most recent first
Prior Treatment Regimen Start Date
Prior Treatment Regimen End Date
Prior surgery (with therapeutic intent)
Yes
No
Prior surgery type (If yes:)
Prior radiation therapy
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Yes
No
Date prior RT ended (If yes:)
Specify sites of prior RT
Total Dose of RT
Baseline Abnormalities
Investigator Term
CTC Adverse Event Term Type (include subterm
if applicable Use CTCAE v3 terminology)
CTC Adverse Event Grade (Use grade 1-5 per
CTCAE v3)
Comments
Investigator Signature
Investigator Signature Date
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North Central Cancer Treatment Group Neurocognitive
Test Booklet Compliance Form NCT00377156
North Central Cancer Treatment Group Neurocognitive Test
Booklet Compliance Form NCT00377156 
Stereotactic Radiation Therapy With or Without Whole-
Brain Radiation Therapy in Treating Patients With Brain
Metastases
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=10B4EAC2-
97B9-3C65-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/10805
North Central Cancer Treatment
Group Neurocognitive Test Booklet
Compliance Form NCT00377156
Header
NCCTG Protocol Number
NCCTG Patient ID
Patient Initials (L F M)
Institution
Institution Number
Are data amended (If yes, highlight amended
areas)
Yes
No
Reporting period
Cycle Number
Form Completion Date
Was the Neurocognitive Testing Booklet
completed
Yes
No
Reason Neurocognitive Testing Booklet was not
completed (check one)
Other Reason (Other reason)
Patient Not Given Form By Staff (Patient
not given form by staff)
Patient Refused (Patient refused)
Staff Unavailable (Staff unavailable)
Unable To Accomodate Disability Or
Language Needs (Unable to accomodate
disability or language needs)
Other reason, specify
1 / 1
North Central Cancer Treatment Group Active
Monitoring Measurement Form NCT00377156
North Central Cancer Treatment Group Active Monitoring
Measurement Form NCT00377156
Stereotactic Radiation Therapy With or Without Whole-
Brain Radiation Therapy in Treating Patients With Brain
Metastases
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=10B41DF0-
B92C-091E-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/10806
North Central Cancer Treatment
Group Active Monitoring
Measurement Form NCT00377156
Header
NCCTG Protocol Number
NCCTG Patient ID
Patient Initials (L F M)
Institution
Institution Number
Are data amended (If yes, highlight amended
areas)
Yes
No
Reporting period
Current Cycle Number
Assessment Date
Overall Response Status (during this
assessment)
Complete Response (CR)
Progressive Disease (PD)
Partial Response (PR)
Stable Disease (SD)
Was the appearance of any new lesions
documented
Yes
No
Symptomatic Deterioration
Yes
No
Target Lesion Site
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Dimension 1
Dimension 2
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Form NCT00377156
North Central Cancer Treatment Group
Evaluation/Observation Form NCT00377156
North Central Cancer Treatment Group
Evaluation/Observation Form NCT00377156
Stereotactic Radiation Therapy With or Without Whole-
Brain Radiation Therapy in Treating Patients With Brain
Metastases
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=109FB871-
880B-538E-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/10807
North Central Cancer Treatment
Group Evaluation/Observation Form
NCT00377156
Header
NCCTG Protocol Number
NCCTG Patient ID
Patient Initials (L F M)
Institution
Institution Number
Are data amended (If yes, highlight amended
areas)
Yes
No
Patient status assessment
Cycle Number
Weight (used for this cycle, round to the nearest
tenth)
ECOG Performance Status (check one)
Fully Active, Able To Carry On All Pre-
disease Performance Without
Restriction. (0)
Restricted In Physically Strenuous
Activity But Ambulatory And Able To
Carry Out Work Of A Light Or Sedentary
Nature, E.g., Light Housework, Office
Work. (1)
Ambulatory And Capable Of All Selfcare
But Unable To Carry Out Any Work
Activities. Up And About More Than 50%
Of Waking Hours. (2)
Capable Of Only Limited Selfcare,
Confined To Bed Or Chair More Than
50% Of Waking Hours. (3)
1 / 3
Completely Disabled. Cannot Carry On
Any Selfcare. Totally Confined To Bed Or
Chair. (4)
Dead (5)
Neurologic Examination
Cranial nerves (check one)
Abnormal (Abnormal)
Normal (Normal)
Sensation (check one)
Abnormal (Abnormal)
Normal (Normal)
Motor (check one)
Abnormal (Abnormal)
Normal (Normal)
Cerebellar (check one)
Abnormal (Abnormal)
Normal (Normal)
Observation
Day 1 of this observation cycle
End of observation
Yes
No
Observation
Has the patient been assessed for systemic
disease (e.g., disease outside of brain)
Yes
No
Status of systemic disease (If yes,)
Disease Progression (Progression)
Stable/improved Disease
(Stable/Improved)
Unknown (Unknown)
Notice Of First Recurrence
Has the patient been diagnosed with a first local-
regional recurrence of the treated brain lesion(s)
(that has not been previously reported? Note: If
marked "yes" below, submit reports to document
the recurrence.)
Yes
No
Date of first local-regional brain recurrence (If
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yes,)
Site of first local-regional brain recurrence
Has the patient been diagnosed with a first
distant recurrence of the treated brain lesion(s)
(that has not been previously reported? Note: If
marked "yes" below, submit reports to document
the recurrence.)
Yes
No
Date of first distant brain recurrence (If yes,)
Site of first distant brain recurrence
Treatment Of Any Recurrence
Has the patient been treated for any recurrence
of the central nervous system disease (CNS)
Yes
No
Therapy administered (If yes,)
Other (Other)
Palliative Surgery (Palliative Surgery)
Stereotactic Radiosurgery (Stereotactic
Radiosurgery)
Whole-brain Radiotherapy (Whole brain
radiation therapy)
Other, specify
Notice Of New Primary
Has a new primary cancer or MDS been
diagnosed that has not been previously reported?
Yes
No
New Primary Cancer Date
Site of New Primary
3 / 3
North Central Cancer Treatment Group Evaluation/Observation Form
NCT00377156
North Central Cancer Treatment Group
Evaluation/Treatment Form NCT00377156
North Central Cancer Treatment Group
Evaluation/Treatment Form NCT00377156
Stereotactic Radiation Therapy With or Without Whole-
Brain Radiation Therapy in Treating Patients With Brain
Metastases
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=38AF9EF4-
0FAC-2541-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/10808
North Central Cancer Treatment
Group Evaluation/Treatment Form
NCT00377156
Header
NCCTG Protocol Number
NCCTG Patient ID
Patient Initials (L F M)
Institution
Institution Number
Are data amended (If yes, highlight amended
areas)
Yes
No
Reporting period
Current Cycle Number
Was this cycle of treatment held
No (no)
Yes, Unplanned (i.e., The Treatment
Change Was Not Part Of Protocol
Guidelines) (Yes, unplanned)
Primary reason treatment held
Agent
Date first lesion(s) treated
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North Central Cancer Treatment Group
Pretreatment Measurement Form NCT00377156
North Central Cancer Treatment Group Pretreatment
Measurement Form NCT00377156
Stereotactic Radiation Therapy With or Without Whole-
Brain Radiation Therapy in Treating Patients With Brain
Metastases
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=10B2D3B7-
59E0-0044-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/10809
North Central Cancer Treatment
Group Pretreatment Measurement
Form NCT00377156
Header
NCCTG Protocol Number
NCCTG Patient ID
Patient Initials (L F M)
Institution
Institution Number
Are data amended (If yes, highlight amended
areas)
Yes
No
Target lesion
Assessment Date
Target Lesion Site
Method of Evaluation
Mri (MRI (NMR))
Dimension 1
Dimension 2
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E2906 Abbreviated Comprehensive Geriatric
Assessment Battery NCT01041703
E2906 Abbreviated Comprehensive Geriatric Assessment
Battery NCT01041703 
Clofarabine or Daunorubicin Hydrochloride and Cytarabine
Followed By Decitabine or Observation in Treating Older
Patients With Newly Diagnosed Acute Myeloid Leukemia
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=7586A704-
3044-A522-E040-BB89AD4359F8
All rights reserved. Please visit https://medical-data-
models.org/forms/10811
E2906 Abbreviated Comprehensive
Geriatric Assessment Battery
NCT01041703
Header
DCI Name
Registration Step (Place ID Label Here)
Patient Initials (Last, First)
ECOG Protocol Number
ECOG Protocol Number
ECOG Patient ID
ECOG Patient ID
Participating Group Protocol Number
Participating Group Patient ID
Institution/Affiliate
On Treatment
On Treatment Report Period (Choose one)
Baseline Step 1 (Baseline Step 1)
Data amendment
Please mark an 'X' if data have been amended.
(Please circle amended items in red)
Date data amended (s M D Y)
Assessment Date
1 / 8
Date of Assessment
Mini Mental Examination Section
Total Score (ATTENTION AND CALCULATION 1
point for each correct answer Serial 7's: Have
patient begin with 100 and count backward by 7.
Stop after 5 answers. 1 point for each one
correct. Or alternatively: spell 'world' backwards.
Score by number of letters in correct order.
LANGUAGE 1 point for each correct answer
Show the patient the statement "Close your eyes"
and have - him read and obey what it says. Have
the patient write a sentence with a subject and
verb. Have the patient copy the figure)
Gds
Do you feel that your life is empty
Yes
No
Do you feel happy most of the time
Yes
No
Do you often feel helpless
Yes
No
Do you feel pretty worthless the way you are now
Yes
No
Adl
Bathing (sponge bath, tub bath or shower)
I Receive Assistance In Bathing More
Than One Part Of The Body (I receive
assistance in bathing more than one part
of the body)
I Receive Assistance In Bathing Only
One Part Of The Body (I receive
assistance in bathing only one part of the
body)
I Receive No Assistance (I receive no
assistance)
Transfer
I Am Able To Move Into And Out Of Bed
As Well As Into And Out Of Chair
Without Assistance (I am able to move
into and out of bed as well as into and
out of chair without assistance)
I Am Able To Move Into And Out Of Bed
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Or Chair With Assistance (I am able to
move into and out of bed or chair with
assistance)
I Am Not Able To Get Out Of Bed (I am
not able to get out of bed)
Continence
I Am Able To Control Urination And
Bowel Movement Completely By Myself
(I am able to control urination and bowel
movement completely by myself)
I Have Occasional Accidents (I have
occasional accidents)
I Need Someone To Help Me Keep
Control Of Urination Or Bowel Movement
Or A Catheter Is Used Or I Am Unable
To Hold My Urine Or Bowel Movements
(I need someone to help me keep control
of urination or bowel movement OR a
catheter is used OR I am unable to hold
my urine or bowel movements)
Can you go shopping for groceries
I Am Completely Unable To Do Any
Shopping (I am completely unable to do
any shopping)
With Some Help (With some help)
Without Help (Without help)
Can you prepare your own meals
I Am Completely Unable To Prepare Any
Meals (I am completely unable to
prepare any meals)
With Some Help (With some help)
Without Help (Without help)
Can you do your own housework
I Am Completely Unable To Do Any
Housework (I am completely unable to
do any housework)
With Help (With help)
Without Help (Without help)
Can you do your own laundry
I Am Completely Unable To Do Any
Laundry At All (I am completely unable to
do any laundry at all)
With Help (With help)
Without Help (Without help)
Section Ii - Social Support
Someone you can count on to listen to you when
you need to talk
A Little Of The Time (A little of the time)
All Of The Time (All of the time)
Most Of The Time (Most of the time)
None Of The Time (None of the time)
Some Of The Time (Some of the time)
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Someone whose advice you really want
A Little Of The Time (A little of the time)
All Of The Time (All of the time)
Most Of The Time (Most of the time)
None Of The Time (None of the time)
Some Of The Time (Some of the time)
Someone whose advice you really want
A Little Of The Time (A little of the time)
All Of The Time (All of the time)
Most Of The Time (Most of the time)
None Of The Time (None of the time)
Some Of The Time (Some of the time)
Someone to share your most private worries and
fears with
A Little Of The Time (A little of the time)
All Of The Time (All of the time)
Most Of The Time (Most of the time)
None Of The Time (None of the time)
Some Of The Time (Some of the time)
Someone to share your most private worries and
fears with
A Little Of The Time (A little of the time)
All Of The Time (All of the time)
Most Of The Time (Most of the time)
None Of The Time (None of the time)
Some Of The Time (Some of the time)
Someone to turn to for suggestions about how to
deal with a personal problem
A Little Of The Time (A little of the time)
All Of The Time (All of the time)
Most Of The Time (Most of the time)
None Of The Time (None of the time)
Some Of The Time (Some of the time)
Someone to turn to for suggestions about how to
deal with a personal problem
A Little Of The Time (A little of the time)
All Of The Time (All of the time)
Most Of The Time (Most of the time)
None Of The Time (None of the time)
Some Of The Time (Some of the time)
Someone who understands your problems
A Little Of The Time (A little of the time)
All Of The Time (All of the time)
Most Of The Time (Most of the time)
None Of The Time (None of the time)
Some Of The Time (Some of the time)
Section Ii - Social Support
Someone to help you if you were confined to bed
A Little Of The Time (A little of the time)
All Of The Time (All of the time)
Most Of The Time (Most of the time)
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None Of The Time (None of the time)
Some Of The Time (Some of the time)
Someone to take you to the doctor if you needed
it
A Little Of The Time (A little of the time)
All Of The Time (All of the time)
Most Of The Time (Most of the time)
None Of The Time (None of the time)
Some Of The Time (Some of the time)
Someone to prepare your meals if you were
unable to do it yourself
A Little Of The Time (A little of the time)
All Of The Time (All of the time)
Most Of The Time (Most of the time)
None Of The Time (None of the time)
Some Of The Time (Some of the time)
Someone to help with daily chores if you were
sick
A Little Of The Time (A little of the time)
All Of The Time (All of the time)
Most Of The Time (Most of the time)
None Of The Time (None of the time)
Some Of The Time (Some of the time)
Comorbidity Questionnaire
Have you ever had a heart attack
Yes
No
Have you ever been treated for heart failure (You
may have been short of breath and the doctor
may have told you that you had fluid in your lungs
or that your heart was not pumping well.)
Yes
No
Do you have other heart disease
Yes
No
Have you had an operation to unclog or bypass
arteries in your legs
Yes
No
Have you had a stroke, cerebrovascular accident,
blood clot or bleeding in the brain, or transient
ischemic attack (TIA)
Yes
No
Do you have difficulty moving an arm or leg as a
result of the stroke or cerebrovascular accident (If
yes)
5 / 8
E2906 Abbreviated Comprehensive Geriatric Assessment Battery
NCT01041703
Yes
No
Do you have asthma
Yes
No
Do you take medicines for your asthma (If yes
check one box)
No (No)
Yes, I Take Medicines Regularly Even
When I'm Not Having A Flare-up (Yes, I
take medicines regularly even when I'm
not having a flare-up)
Yes, Only With Flare-ups Of My Asthma
(Yes, only with flare-ups of my asthma)
Do you have emphysema, chronic bronchitis, or
chronic obstructive lung disease
Yes
No
Do you take medicines for your lung disease (If
yes check one box)
No (No)
Yes, I Take Medicines Regularly Even
When I'm Not Having A Flare-up (Yes, I
take medicines regularly even when I'm
not having a flare-up)
Yes, Only With Flare-ups Of My Lung
Disease (Yes, only with flare-ups of my
lung disease)
Comorbidity Questionnaire1
Do you have stomach ulcers, or peptic ulcer
disease
Yes
No
Do you have diabetes (high blood sugar)
Yes
No
How is it treated (If yes check one box)
Treated By Insulin Injections (Treated by
insulin injections)
Treated By Medications Taken By Mouth
(Treated by medications taken by mouth)
Treated By Modifying My Diet (Treated by
modifying my diet)
Has the diabetes caused any of the following
problems (If yes)
Problems With Numbness Or Tingling In
Your Feet Or Legs (Problems with
numbness or tingling in your feet or legs)
Problems With Your Eyes, Treated By An
Ophthamologist (Problems with your
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eyes, treated by an ophthamologist)
Problems With Your Kidneys (Problems
with your kidneys)
Have you ever had the following problems with
your kidneys
Have Received Kidney Transplantation
(Have received kidney transplantation)
Have Used Dialysis (Have used dialysis)
Poor Kidney Function (Poor kidney
function)
Do you have arthritis
Yes
No
Do you take medications for it regularly (If yes)
Yes
No
Do you have any of the following conditions
Alzheimer's Disease, Or Another Form
Of Dementia (Alzheimer's Disease, or
another form of dementia)
Anemia (Anemia)
Cancer (Cancer)
Chronic Back Pain (Chronic back pain)
Chronic Sinus Infections (Chronic sinus
infections)
Cirrhosis, Hepatitis, Or Serious Liver
Disease (Cirrhosis, hepatitis, or serious
liver disease)
Dental Problems (Dental Problems)
Depression (Depression)
Osteoporosis (Osteoporosis)
How often do you see your dentist
Every 1-2 Years (Every 1-2 years)
Every 6-12 Months (Every 6-12 months)
I Don't See A Dentist (I don't see a
dentist)
Please list any other health problems you have in
the space below
Medications/sexual Function
On average, how many prescription medicines do
you take each day
1-3 (1-3)
4-6 (4-6)
7-10 (7-10)
More Than 10 (More than 10)
None (None)
On average, how many non-prescription
medicines (over-the-counter) do you take each
day
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1-3 (1-3)
4-6 (4-6)
7-10 (7-10)
More Than 10 (More than 10)
None (None)
During the last 4 weeks, did you have sexual
intercourse
No (No)
Yes, More Than Once (Yes, more than
once)
Yes, Once (Yes, once)
Over the past 4 weeks, how would you rate your
level of sexual desire
High (High)
Low (Low)
Moderation (Moderate)
Very High (Very high)
Very Low/none At All (Very low/none at
all)
Weight
What is your usual weight
How much weight have you lost in the past 6
months
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PACCT-1 TAILORx Medication Form
NCT00310180
PACCT-1 TAILORx Medication Form NCT00310180
Hormone Therapy With or Without Combination
Chemotherapy in Treating Women Who Have Undergone
Surgery for Node-Negative Breast Cancer (The TAILORx
Trial)
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=8401EEDE-
6C53-E54A-E040-BB89AD433901
All rights reserved. Please visit https://medical-data-
models.org/forms/10813
PACCT-1 TAILORx Medication Form
NCT00310180
Header
DCI Name
Patient Initials (Last, First)
ECOG Protocol Number
ECOG Protocol Number
ECOG Patient ID
ECOG Patient ID
Participating Group Protocol Number
Participating Group Patient ID
Institution/Affiliate
Data amendment
Please mark an 'X' if data have been amended.
(Please circle amended items in red)
Date data amended (s M D Y)
On Treatment
Report Period (Choose one)
12 Months (12 months)
3 Months (3 months)
6 Months (6 months)
Baseline (baseline)
Assessment Date
1 / 5
Assessment date
Section I - Patient Characteristics
Height (cm complete at BASELINE only)
Weight (kg)
Month of last mentrual period
Section Ii - Comorbidities (complete
Section At Baseline Only)
Hypertension
Yes
No
Is patient on anti-hypertensive therapy
Yes
No
Hyperlipidemia
Yes
No
Hyperlipidemia
Yes
No
Diabetes
Yes
No
Diabetes (if yes, is patient taking medication for
this condition)
Yes
No
Osteoarthritis
Yes
No
Osteoarthritis
Yes
No
Arthritic conditions other than osteoarthritis
(conditions other than osteoarthritis e.g.,
rheumatoid arthritis)
Yes
No
Arthritic conditions other than osteoarthritis
Yes
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No
Fibromylagia
Yes
No
Fibromyalgia
Yes
No
Depression
Yes
No
Depression
Yes
No
Cardiovascular Disease
Yes
No
Cardiovascular Disease (If yes, is patient taking
medication for this condition)
Yes
No
Cerebrovascular disease (e.g., prior TIA)
Yes
No
Cerebrovascular disease
Yes
No
Pulmonary Disease (e.g., asthma or other
chronic pulmonary conditions)
Yes
No
Pulmonary disease
Yes
No
Liver disease (e.g., hepatitis C or other
conditions)
Yes
No
Liver disease
Yes
No
Neuropathy (e.g., diabetic neuropathy)
No (No)
Unknown (Unknown)
Yes (Yes)
Neuropathy
Yes
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No
Osteopenia/osteoporosis
Yes
No
Osteopenia/osteoporosis
Yes
No
Section Iii - Hormonal Medications
Current hormone therapy
Anastrazole (Anastrazole)
Exemestrane (Exemestrane)
Letrozole (Letrozole)
None (None)
Other (Other)
Tamoxifen (Tamoxifen)
Other specify
Section Iv - Concurrent Medications
Number of prescription medications being taken
within the last 7 days
>7 (>7)
1-3 (1-3)
4-7 (4-7)
None (None)
Did the patient take any of the following within the
last 7 days of visit
Antidepressants - Moderate Cyp2d6
Inhibitors (Antidepressants - Moderate
CYP2D6 inhibitors)
Antidepressants - Strong Cyp2d6
Inhibitors (Antidepressants - Strong
CYP2D6 inhibitors)
Antidepressants - Weak Cyp2d2
Inhibitors Or Non-inhibitors
(Antidepressants - weak CYP2D2
inhibitors or non-inhibitors)
Anxiolytics Or Sedatives (Anxiolytics or
sedatives)
Bisphosophonates For
Treatment/prevention Of Bone Loss
(Bisphosophonates for
treatment/prevention of bone loss)
Cox-2 Inhibitor (COX-2 inhibitor)
Diabetes - Insulin (Diabetes - Insulin)
Diabetes - Metformin Containing Agents
(Diabetes - Metformin containing agents)
Intravaginal Estrogen Preparations
(Intravaginal estrogen preparations)
Non-prescription Supplements For
Memory (Non-prescription supplements
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for memory)
Prescription Medications For Relief Of
Hot Flashes (Non-prescription
supplements for relief of hot flashes)
Non-steriodal Anti-inflammatory Agents
(Non-steriodal anti-inflammatory agents)
Opioids (Opioids)
Prescription Medications For Relief Of
Hot Flashes (Prescription medications
for relief of hot flashes)
Prophylactic Antiplatelet Therapy
(Prophylactic antiplatelet therapy)
Tricyclic Antidepressants (Tricyclic
antidepressants)
Comments
Investigator Signature
Investigator Signature Date (M D Y)
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Symptoms Form NCT00310180
PACCT-1 TAILORx FACT - Endocrine Symptoms Form
NCT00310180 
Hormone Therapy With or Without Combination
Chemotherapy in Treating Women Who Have Undergone
Surgery for Node-Negative Breast Cancer (The TAILORx
Trial)
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=84B85E26-
3D9D-5248-E040-BB89AD43122A
All rights reserved. Please visit https://medical-data-
models.org/forms/10814
PACCT-1 TAILORx FACT -
Endocrine Symptoms Form
NCT00310180
Header
ECOG Protocol Number
ECOG Patient ID
DCI Name
Report Period on Treatment
Report Period (since start of Step 2 Choose one)
12 Months (12 months)
24 Months (24 months)
3 Months (3 months)
36 Months (36 months)
6 Months (6 months)
Baseline (baseline)
Data amendment
Are data amended
Yes
No
Date data amended (s M D Y)
Date data amended (s M D Y)
Assessment Date
Assessment date
Additional Concerns
I have hot flashes
A Little Bit (A little bit)
Not At All (Not at all)
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Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have cold sweats
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have night sweats
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have vaginal discharge
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have vaginal itching/irritation
2 (A little bit)
1 (Not at all)
4 (Quite a bit)
3 (Somewhat)
5 (Very much)
I have vaginal bleeding or spotting
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have vaginal dryness
2 (A little bit)
1 (Not at all)
4 (Quite a bit)
3 (Somewhat)
5 (Very much)
I have pain or discomfort with intercourse
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have lost interest in sex.
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
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I have gained weight
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I feel lightheaded (dizzy).
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have been vomiting
2 (A little bit)
1 (Not at all)
4 (Quite a bit)
3 (Somewhat)
5 (Very much)
I have diarrhea
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I get headaches
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I feel bloated
A Little Bit (A little bit)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
I have breast sensitivity/tenderness
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have mood swings
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am irritable
2 (A little bit)
1 (Not at all)
4 (Quite a bit)
3 (Somewhat)
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5 (Very much)
I have pain in my joints
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
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PACCT-1 TAILORx FACT - Fatique Scale
Form NCT00310180
PACCT-1 TAILORx FACT - Fatique Scale Form
NCT00310180 
Hormone Therapy With or Without Combination
Chemotherapy in Treating Women Who Have Undergone
Surgery for Node-Negative Breast Cancer (The TAILORx
Trial)
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=84B81FA9-
D91A-473F-E040-BB89AD4317EF
All rights reserved. Please visit https://medical-data-
models.org/forms/10815
PACCT-1 TAILORx FACT - Fatique
Scale Form NCT00310180
Header
ECOG Protocol Number
ECOG Patient ID
DCI Name
Report Period on Treatment
Report Period (since start of Step 2 Choose one)
12 Months (12 months)
24 Months (24 months)
3 Months (3 months)
36 Months (36 months)
6 Months (6 months)
Baseline (baseline)
Data amendment
Are data amended
Yes
No
Date data amended (s M D Y)
Date data amended (s M D Y)
Assessment Date
Assessment date
Additional Concerns
I feel fatigued
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
1 / 3
Somewhat (Somewhat)
Very Much (Very much)
I feel weak all over
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I feel listless ("washed out")
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I feel tired
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have trouble starting things because I am tired
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have trouble finishing things because I am tired
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have energy
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am able to do my usual activities
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I need to sleep during the day
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am too tired to eat
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A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I need help doing my usual activities
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am frustrated by being too tired to do the things
I want to do
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have to limit my social activity because I am
tired
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
3 / 3
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E5103 Cardiac Toxicity Form
NCT00433511
E5103 Cardiac Toxicity Form [Form No. 2608v2]
NCT00433511
Doxorubicin, Cyclophosphamide, and Paclitaxel With or
Without Bevacizumab in Treating Patients With Lymph
Node-Positive or High-Risk, Lymph Node-Negative Breast
Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=22AFF315-
4EDF-593F-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/10816
E5103 Cardiac Toxicity Form
NCT00433511
ECOG clinical trial administrative data
ECOG Protocol Number
ECOG Patient ID
DCI Name
Registration Step
Patient demographics
Patient Initials (Last, First)
ECOG Protocol Number
ECOG Patient ID
Participating Group Protocol Number
Participating Group Patient ID
Institution/Affiliate
Data amendment
Please mark an 'X' if data have been amended
(Please circle amended items in red)
Date data amended (M D Y)
On Treatment
On Treatment Report Period (Choose one x)
Baseline Step 1 (Baseline Step 1)
Cycle 15 Step 2 (Cycle 15 Step 2)
1 / 3
Cycle 5 Step 1 (Cycle 5 Step 1)
Cycle 9 Step 2 (Cycle 9 Step 2)
End Of Treatment - Step 1 (End of
Treatment - Step 1)
End Of Treatment - Step 2 (End of
Treatment - Step 2)
Off Treatment
Off Treatment Report Period (since registration)
12 Months (12 months post registration)
Cardiovascular assessment
Has the patient had a documented assessment
of cardiac function (this report period)
Yes
No
Date of Most Recent Cardiac Assessment (m/d/y)
Method of Evaluation (LVEF)
Echocardiogram (Echocardiogram)
Muga Scan (MUGA)
Left Ventricular Ejection Fraction at Rest (%)
LVEF Institutional Lower Limit of Normal (% - per
institutional standard)
Date of LVEF (m/d/y)
Clinical Episode of CHF (requires symptoms
associated with a decrease in LVEF to below the
institutional LLN - Specify whether any of the
following adverse events have occurred during
this report period record an answer for each
event listed below)
No (No)
Unknown (Unknown)
Yes (Yes)
S3 Gallop
No (No)
Unknown (Unknown)
Yes (Yes)
Basilar Rales
No (No)
Unknown (Unknown)
Yes (Yes)
Dyspnea on exertion, orthopnea or paroxysmal
noctural dyspnea
No (No)
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Unknown (Unknown)
Yes (Yes)
Was dyspnea grade 1 (If yes to Dyspnea:)
No (No)
Unknown (Unknown)
Yes (Yes)
Cardiomegaly
No (No)
Unknown (Unknown)
Yes (Yes)
Abnormal ECG (<specify>)
No (No)
Unknown (Unknown)
Yes (Yes)
Specify nature of abnormalities (If yes,)
Comments
Investigator Signature
Investigator Signature Date
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E1105  FACIT-Fatique Subscale (Version 4)
NCT00520975
E1105  FACIT-Fatique Subscale (Version 4) NCT00520975 
First-Line Chemotherapy and Trastuzumab With or Without
Bevacizumab in Treating Patients With Metastatic Breast
Cancer That Overexpresses HER-2/NEU
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=1736471B-
BF38-3BED-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/10817
E1105  FACIT-Fatique Subscale
(Version 4) NCT00520975
Header
ECOG Protocol Number
ECOG Patient ID
DCI Name
Registration Step
Reporting Period
On Treatment Report Period (Maintenance 1
cycle = 3 weeks)
Cycle 24 (Cycle 24)
Cycle 40 (Cycle 40)
Cycle 5 (Cycle 5)
Cycle 56 (Cycle 56)
Cycle 72 (Cycle 72)
Cycle 8 (cycle 8)
End Of Treatment (End of Treatment)
On Treatment Report Period (Maintenance 1
cycle = 3 weeks)
Cycle 24 (Cycle 24)
Cycle 40 (Cycle 40)
Cycle 5 (Cycle 5)
Cycle 56 (Cycle 56)
Cycle 72 (Cycle 72)
Cycle 8 (cycle 8)
End Of Treatment (End of Treatment)
Patient demographics
ECOG Protocol Number
Patient Initials (Last, First)
ECOG Patient ID
1 / 3
Participating Group Protocol Number
Institution/Affiliate
Participating Group Patient ID
Data amendment
Please mark an 'X' if data have been amended
(Please circle amended items in red)
Date data amended (M D Y)
Additional Concerns
I feel fatigued
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I feel weak all over
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I feel listless ("washed out")
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I feel tired
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have trouble starting things because I am tired
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have trouble finishing things because I am tired
A Little Bit (A little bit)
Not At All (Not at all)
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Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have energy
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am able to do my usual activities
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I need to sleep during the day
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am too tired to eat
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I need help doing my usual activities
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am frustrated by being too tired to do the things
I want to do
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have to limit my social activity because I am
tired
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
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E1105 Cardiac Toxicity Form
NCT00520975
E1105 Cardiac Toxicity Form NCT00520975
First-Line Chemotherapy and Trastuzumab With or Without
Bevacizumab in Treating Patients With Metastatic Breast
Cancer That Overexpresses HER-2/NEU
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=171FF705-
FB7F-3F20-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/10818
E1105 Cardiac Toxicity Form
NCT00520975
Header
ECOG Protocol Number
ECOG Patient ID
DCI Name
Registration Step
Patient demographics
Patient Initials (Last, First)
ECOG Protocol Number
ECOG Patient ID
Participating Group Protocol Number
Participating Group Patient ID
Institution/Affiliate
Data amendment
Please mark an 'X' if data have been amended
(Please circle amended items in red)
Date data amended (M D Y)
On Treatment
On Treatment Report Period (Choose one x)
> Cycle 20 (> Cycle 20)
Baseline (baseline)
1 / 3
Cycle 12 (Cycle 12)
Cycle 16 (Cycle 16)
Cycle 20 (Cycle 20)
Cycle 3 (Cycle 3)
Cycle 4 (cycle 4)
Cycle 6 (Cycle 6)
Cycle 8 (cycle 8)
End Of Treatment (End of Treatment)
Specify Cycle
Off Treatment
Off Treatment Report Period (since registration)
9 Years (108 months post registration)
12 Months Post Randomization (12
Months Post Randomization)
10 Years (120 months post registration)
18 Months Post Randomization (18
Months Post Randomization)
21 Months Post Randomization (21
Months Post Randomization)
24 Months Post Randomization (24
Months Post Randomization)
3 Months Post Randomization (3 Months
Post Randomization)
30 Months Post Randomization (30
Months Post Randomization)
36 Months Post Randomization (36
Months Post Randomization)
42 Months Post Randomization (42
Months Post Randomization)
48 Months Post Randomization (48
Months Post Randomization)
54 Months Post Randomization (54
Months Post Randomization)
6 Months Post Randomization (6 Months
Post Randomization)
60 Months Post Randomization (60
Months Post Randomization)
6 Years (72 months post registration)
84 Months Post Registration (84 months
post registration)
9 Months Post Randomization (9 Months
Post Randomization)
8 Years (96 months post registration)
Cardiovascular assessment
Has the patient had a documented assessment
of cardiac function
Yes
No
Date of Most Recent Cardiac Assessment
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Method of Evaluation (LVEF)
Echocardiogram (Echocardiogram)
Muga Scan (MUGA)
Left Ventricular Ejection Fraction at Rest (%)
LVEF Institutional Lower Limit of Normal (% - per
institutional standard)
Date of LVEF
S3 Gallop (Specify whether any of the following
adverse events have occurred during this report
period record an answer for each event listed
below)
No (No)
Unknown (Unknown)
Yes (Yes)
Dyspnea on exertion, orthopnea or paroxysmal
noctural dyspnea
No (No)
Unknown (Unknown)
Yes (Yes)
Basilar Rales
No (No)
Unknown (Unknown)
Yes (Yes)
Cardiomegaly
No (No)
Unknown (Unknown)
Yes (Yes)
Clinical Episode of CHF (defined as having 2 or
more of the above events)
No (No)
Unknown (Unknown)
Yes (Yes)
Abnormal ECG
No (No)
Unknown (Unknown)
Yes (Yes)
Specify nature of abnormalities (If yes,)
Comments
Investigator Signature
Investigator Signature Date
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E1105 Assessment Compliance Form
NCT00520975
E1105 Assessment Compliance Form NCT00520975 
First-Line Chemotherapy and Trastuzumab With or Without
Bevacizumab in Treating Patients With Metastatic Breast
Cancer That Overexpresses HER-2/NEU
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=17223B5E-
5840-64C8-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/10819
E1105 Assessment Compliance
Form NCT00520975
Header
ECOG Protocol Number
ECOG Patient ID
DCI Name
Registration Step
Patient demographics
ECOG Protocol Number
ECOG Patient ID
Patient Initials
Participating Group Protocol Number
Institution/Affiliate
Participating Group Patient ID
Reporting Period
On Treatment Report Period (Maintenance 1
cycle = 3 weeks)
Cycle 24 (Cycle 24)
Cycle 40 (Cycle 40)
Cycle 5 (Cycle 5)
Cycle 56 (Cycle 56)
Cycle 72 (Cycle 72)
Cycle 8 (cycle 8)
End Of Treatment (End of Treatment)
On Treatment Report Period (Maintenance 1
cycle = 3 weeks)
1 / 7
Cycle 24 (Cycle 24)
Cycle 40 (Cycle 40)
Cycle 5 (Cycle 5)
Cycle 56 (Cycle 56)
Cycle 72 (Cycle 72)
Cycle 8 (cycle 8)
End Of Treatment (End of Treatment)
Data amendment
Please mark an 'X' if data have been amended.
Date data amended
Section I
Assessment Date (If assessment not completed,
enter date scheduled per E1105 protocol.)
Section Ii - Assessments Not Completed
Was the Assessment Form completed?
Yes
No
Assessment Form No. (FACIT-F Subscale)
Assessment Form No. (FACIT-F Subscale)
Section Ii - Assessments Not Completed
Patient refusal
Yes
No
Unable to accomodate disability or language
needs
Yes
No
Specify disability or language
Patient did not show up in clinic/office
Yes
No
Specify reason patient did not show up
Staff unavailable
Yes
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No
Patient not given form by staff
Yes
No
Patient too ill
Yes
No
Patient expired
Yes
No
Assessment not required per protocol
Yes
No
Specify reason assessment is not required
Staff thought patient too ill
Yes
No
Other
Yes
No
Specify other reason
Section Ii - Assessments Not Completed
Patient refusal
Yes
No
Unable to accomodate disability or language
needs
Yes
No
Specify disability or language
Patient did not show up in clinic/office
Yes
No
Specify reason patient did not show up
Staff unavailable
Yes
No
Patient not given form by staff
Yes
No
Patient too ill
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Yes
No
Patient expired
Yes
No
Assessment not required per protocol
Yes
No
Specify reason assessment is not required
Staff thought patient too ill
Yes
No
Other
Yes
No
Specify other reason
Section Iii - Assessment Completed
Was Assessment self-administered?
Yes
No
How Was The Patient Assisted
Were the questions read aloud to patient
Yes
No
Did the patient require clarification of questions or
instructions
Yes
No
Did the patient require other assistance
Yes
No
Were the forms completed independently by
another person
Yes
No
How Was The Patient Assisted
Were the questions read aloud to patient
Yes
No
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Did the patient require clarification of questions or
instructions
Yes
No
Did the patient require other assistance
Yes
No
Were the forms completed independently by
another person
Yes
No
What Was The Reason For Assistance
Did the patient have a language difficulty
(questions needed to tbe translated)
Yes
No
Specify language
Did the patient have a literacy difficulty (patient
could not read well enough)
Yes
No
Was the patient disabled
Yes
No
Specify disability
Were the forms completed via a telephone
interview
Yes
No
Other
Yes
No
Specify other reason
What Was The Reason For Assistance
Did the patient have a language difficulty
(questions needed to tbe translated)
Yes
No
Specify language
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Did the patient have a literacy difficulty (patient
could not read well enough)
Yes
No
Was the patient disabled
Yes
No
Specify disability
Were the forms completed via a telephone
interview
Yes
No
Other
Yes
No
Specify other reason
Who Assisted Or Completed Assessment
Staff
Yes
No
Family
Yes
No
Friend
Yes
No
Other
Yes
No
Specify other person
Who Assisted Or Completed Assessment
Staff
Yes
No
Family
Yes
No
Friend
Yes
No
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Other
Yes
No
Specify other person
Comments
Investigator Signature
Investigator Signature Date
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North Central Cancer Treatment Group Arms A  & D Only
Recurrent Research Tissue Submission Form NCT00079274
North Central Cancer Treatment Group Arms A  and D Only
Recurrent Research Tissue Submission Form
NCT00079274
Comparison of Combination Chemotherapy Regimens With
or Without Cetuximab in Treating Patients Who Have
Undergone Surgery For Stage III Colon Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=8BC1F4CF-
E66A-E266-E040-BB89AD436B4E
All rights reserved. Please visit https://medical-data-
models.org/forms/10821
North Central Cancer Treatment
Group Arms A  & D Only Recurrent
Research Tissue Submission Form
NCT00079274
Header module
Coordinating Group Protocol Number
Coordinating Group Code
Protocol Title
Patient Study ID
Patient Medical Record Number
Patient Initials (L, FM)
Participating Group Code (Cooperative Group
where credit will be applied)
Institution Name
Visit
Visit
Other
Instructions
Patient's re-consent given for recurrent tissue
specimen use for research on the patient's
cancer? (per Addendum 12)
Yes
No
Was sample obtained (check one)
Yes
1 / 2
No
Date of collection (If yes, mm/dd/yyyy)
Date Specimen Shipped (mm/dd/yyyy)
Reason (If no check one)
Block Depleted/insufficient Tissue (Block
depleted/insufficient tissue)
Facility Will Not Release Block (Facility
will not release block)
Other (Other)
Specify
Number of slides sent
Institution Name
Number of blocks sent
Accession Number (s on the blocks sent)
Accession Number (s on the blocks sent)
Contact Person at Institution (Institutional Contact
Information: CRA/Nurse)
Street Address
City
State
ZIP Code
Phone Number
Fax Number
Email address
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North Central Cancer Treatment Group Arms A  & D Only Recurrent
Research Tissue Submission Form NCT00079274
NCI Coop Group Colorectal Ca Specimen
Submission Form (Blood) NCT00079274
NCI Cooperative Group Colorectal Cancer - Specimen
Submission Form (Blood) NCT00079274
Comparison of Combination Chemotherapy Regimens With
or Without Cetuximab in Treating Patients Who Have
Undergone Surgery For Stage III Colon Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=DFBE08AC-
264A-081D-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/10822
NCI Coop Group Colorectal Ca
Specimen Submission Form (Blood)
NCT00079274
Header module
Coordinating Group Protocol Number
Coordinating Group Code
Protocol Title
Patient Study ID
Patient Medical Record Number
Patient Initials (L, FM)
Participating Group Code (Cooperative Group
where credit will be applied)
Institution Name (treating location/performance
site)
Are data amended? (If data are amended, please
circle in red when using paper form)
Yes
No
Visit
Visit
Pre-treatment (Pre-Treatment)
Visit (Pre-Treatment prior to randomizationi OR
indicate which follow-up visit number from end of
treatment Arms A & D only)
Other
Research Blood Specimen
1 / 2
Was a research blood specimen collected?
Yes
No
Specimen Collection Date (MM/DD/YYYY)
Reason research blood specimen was not
collected
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NCI Coop Group Colorectal Ca Specimen Submission Form (Blood)
NCT00079274
North Central Tx Group Specimen Submission
Form (Fresh Frozen Tissue) NCT00079274
North Central Treatment Group - Specimen Submission
Form - Fresh Frozen Tissue NCT00079274
Comparison of Combination Chemotherapy Regimens With
or Without Cetuximab in Treating Patients Who Have
Undergone Surgery For Stage III Colon Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=DFBF0C03-
3FAB-1507-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/10823
North Central Tx Group Specimen
Submission Form (Fresh Frozen
Tissue) NCT00079274
Clinical trial administrative data
Coordinating Group Protocol Number
Coordinating Group Code
Protocol Title
Patient Study ID
Patient Medical Record Number
Patient Initials (L, FM)
Participating Group Code (Cooperative Group
where credit will be applied)
Institution Name (treating location/performance
site)
Are data amended? (If data are amended, please
circle in red when using paper form)
Yes
No
INSTRUCTIONS
Was fresh frozen tissue collected?
Yes
No
Date of Collection (mm dd yyyy)
Tissue Source
Reason
Name (Institutional Contact Information)
1 / 2
Address
Phone Number
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North Central Tx Group Specimen Submission Form (Fresh Frozen
Tissue) NCT00079274
North Central Tx Group Pathology
Submission Form NCT00079274
North Central Treatment Group - Pathology Submission
Form NCT00079274
Comparison of Combination Chemotherapy Regimens With
or Without Cetuximab in Treating Patients Who Have
Undergone Surgery For Stage III Colon Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=DFBC7BF9-
4CFD-693B-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/10825
North Central Tx Group Pathology
Submission Form NCT00079274
Clinical trial administrative data
Coordinating Group Protocol Number
Coordinating Group Code
Protocol Title
Patient Study ID
Patient Medical Record Number
Patient Initials (L, FM)
Participating Group Code (Cooperative Group
where credit will be applied)
Institution Name (treating location/performance
site)
Are data amended? (If data are amended, please
circle in red when using paper form)
Yes
No
Instructions
Date materials sent to central laboratory (This
form must accompany pathology materials blocks
and slides listed in Section 17 of the protocol.)
Number of slides sent
Accession Number (s)
Accession Number (s)
Number of blocks sent
1 / 2
Contact Person at Institution (Institutional Contact
Information:)
Street Address
City
State
ZIP Code
Phone Number
Comments
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NCI Coop Group Registration Form
NCT00079274
NCI Cooperative Group Registration Form (New)
NCT00079274
Comparison of Combination Chemotherapy Regimens With
or Without Cetuximab in Treating Patients Who Have
Undergone Surgery For Stage III Colon Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=DFA8E36C-
116F-61ED-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/10826
NCI Coop Group Registration Form
NCT00079274
Clinical trial administrative data
Coordinating Group Protocol Number
Coordinating Group Code
Protocol Title
Patient Study ID
Patient Medical Record Number
Participating Group Code (Cooperative Group
where credit will be applied)
Institution Name (treating locatin/performance
site)
Institution Code (CTEP Assigned number)
Physician of Record
Visit
Reporting Period
Pre-therapy (Pre-treatment)
Protocol Administration
Projected Start Date of Treatment (mm dd yyyy)
Date of Randomization (mm dd yyyy)
Person Completing Form, Last Name
Person Completing Form, First Name
1 / 2
Person Completing Form, Phone
Person Completing Form, Fax
Patient Demographics / Pre-treatment
Characteristics
Patient Initials (L, FM)
Patient Height (cm)
Patient Weight (kg)
Body Surface Area (m^2)
Performance Status (check one)
Fully Active, Able To Carry On All Pre-
disease Performance Without
Restriction. (0)
Restricted In Physically Strenuous
Activity But Ambulatory And Able To
Carry Out Work Of A Light Or Sedentary
Nature, E.g., Light Housework, Office
Work. (1)
Ambulatory And Capable Of All Selfcare
But Unable To Carry Out Any Work
Activities. Up And About More Than 50%
Of Waking Hours. (2)
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NCI Coop Group Registration Form NCT00079274
NCI Coop Group Colorectal Ca Adjuvant
On-Study Form NCT00079274
NCI Cooperative Group Colorectal Cancer - Adjuvant On-
Study Form (New) NCT00079274
Comparison of Combination Chemotherapy Regimens With
or Without Cetuximab in Treating Patients Who Have
Undergone Surgery For Stage III Colon Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=DFAA558D-
FB7F-67DB-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/10827
NCI Coop Group Colorectal Ca
Adjuvant On-Study Form
NCT00079274
Clinical trial administrative data
Coordinating Group Protocol Number
Coordinating Group Code
Protocol Title
Patient Study ID
Patient Medical Record Number
Patient Initials (L, FM)
Participating Group Code (Cooperative Group
where credit will be applied)
Institution Name (treating location/performance
site)
Are data amended (If data are amended, please
circle in red when using paper form)
Yes
No
Colorectal: Disease Characteristics
Primary Site
Ascending Colon (Ascending colon)
Cecum (Cecum)
Descending Colon (Descending colon)
Hepatic Flexure (Hepatic flexure)
Sigmoid Colon (Sigmoid colon)
Splenic Flexure (Splenic flexure)
Transverse Colon (Transverse colon)
Was there bowel obstruction?
Yes
No
Was there bowel perforation?
1 / 2
Yes
No
Disease Extent
Tx (Primary tumor cannot be assessed
(TX))
T4 (Tumor directly invades or is adherent
to other organs or structures and/or
involves the visceral peritoneum (T4))
T2 (Tumor invades muscularis propria
(T2))
T1 (Tumor invades submucosa (Ta))
T3 (Tumor invades through the
muscularis propria into the subserosa, or
into nonperitonealized pericolic or
perirectal tissue (T3))
Number of Lymph Nodes Examined
Number of Positive Lymph Nodes
Surgical Information
Surgery Date (date primary tumor removed; < 56
days prior to randomization)
Type of procedure
Laparoscopic Surgery (Laparoscopic)
Laparoscopic Converted To Open
(Laparoscopic converted to open)
Laparoscopic Hand-assisted
(Laparoscopic hand-assisted)
Open (open)
Comments
Comments
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Colorectal Cancer Follow Up Form NCT00079274
NCI Cooperative Group Not for Arm G Patients Colorectal
Cancer Follow Up Form NCT00079274 
Comparison of Combination Chemotherapy Regimens With
or Without Cetuximab in Treating Patients Who Have
Undergone Surgery For Stage III Colon Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=E022F4E2-
2801-367C-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/10828
NCI Cooperative Group Not for Arm
G Patients Colorectal Cancer Follow
Up Form NCT00079274
Clinical trial administrative data
Coordinating Group Protocol Number
Coordinating Group Code
Protocol Title
Patient Study ID
Patient Medical Record Number
Patient Initials (L, FM)
Participating Group Code (Cooperative Group
where credit will be applied)
Institution Name (treating location/performance
site)
Visit (*Please See Form Instructions* - Please
indicate which follow-up visit number from end of
treatment Circle one)
Other
Were you able to obtain any information about
the patient since the last report
Yes
No
Post-Treatment Follow-Up Visit Date (If yes,
mm/dd/yyyy Continue to next section.)
Date of last attempt to contact patient (If No,
mm/dd/yyyy Stop here, cross off the remainder of
the form, and return form to NCCTG.)
1 / 3
Vital Status
Patient's Vital Status
Alive (Alive)
Dead (Dead)
Death Date/Last Contact Date (MM DD YYYY)
Disease Follow-up Status
Has the patient had a documented clinical
assessment for this cancer? (since submission of
the previous follow-up form)
Yes
No
Date of Last Clinical Assessment (MM DD YYYY)
Has the patient had a colonoscopy assessment
for this cancer since submission of the previous
follow-up form?
Yes
No
Date of last colonoscopy (mm dd yyyy only
provide date if assessment since submission of
previous follow-up form)
Notice Of Recurrence
Has the patient developed a first progression (or
recurrence) that has not been previously
reported?
Yes
No
Date of First Recurrence or Progression (MM DD
YYYY)
Site(s) of Progression
Liver (Liver)
Local (Local)
Lung (Lung)
Other (Other)
Regional (Regional)
Other specify
Notice Of Secondary Resection
If the patient has developed a first progression (or
recurrence), was a secondary resection
performed that has not been previously reported
No (No)
Unknown (Unknown)
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Yes (Yes)
Explain unknown
Notice Of New Primary
Has a new primary cancer or MDS been
diagnosed that has not been previously reported?
(myelodysplastic syndrome)
Yes
No
Date of Diagnosis (MM DD YYYY)
Site of New Primary (If new primary site is
AML/MDS, please submit NCI AML/MDS form.)
Notice Of Long Term Toxicity
Has the patient experienced any grade 3 or
greater, longterm toxicity since the submission of
the last follow-up form? (Note: Use the same
non-MedDRA codes provided on the Toxicity
Form-Summary and Toxicity Form-Subset forms
for the Oxaliplatin induced non-CTCAEs of
Laryngopharyngeal Dysesthesia  and
Paresthesia Dysesthesia )
No (No)
Unknown (Unknown)
Yes (Yes)
CTC Adverse Event Term  (see CTC version 2.0)
MedDRA Code (version 6 for adverse event if a
MedDRA code does not exist leave blank)
Comments
Comments
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NCI Cooperative Group Not For Arm G Patients Colorectal
Cancer - Secondary Resection Follow Up Form NCT00079274
NCI Cooperative Group Not For Arm G Patients Colorectal
Cancer - Secondary Resection Follow Up Form
NCT00079274 
Comparison of Combination Chemotherapy Regimens With
or Without Cetuximab in Treating Patients Who Have
Undergone Surgery For Stage III Colon Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=764CD4CF-
27B8-E740-E040-BB89AD435E74
All rights reserved. Please visit https://medical-data-
models.org/forms/10829
NCI Cooperative Group Not For Arm
G Patients Colorectal Cancer -
Secondary Resection Follow Up
Form NCT00079274
Clinical trial administrative data
Coordinating Group Protocol Number
Coordinating Group Code
Protocol Title
Patient Study ID
Patient Medical Record Number
Patient Initials (L, FM)
Participating Group Code (Cooperative Group
where credit will be applied)
Institution Name (treating location/performance
site)
Resection
Date of secondary resection (submit operative
and pathology reports)
Intent of resection (check one)
Curative Intent And Successful R0
Resection (Curative intent and
successful R0 resection)
Curative Intent But Less Than R0
Resection (Curative intent but less than
R0 resection)
Palliative Intent (Palliative intent)
Sites of resection (secondary)
Liver (Liver)
Local (Local)
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Local (Local)
Lung (Lung)
Other (Other)
Regional (Regional)
Regional (Regional)
Specify
Comments
Comments
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Secondary Resection Follow Up Form NCT00079274
NCI Cooperative Group Arm G Patients Only Colorectal Cancer -
Adjuvant Disease Treatment Summary Form NCT00079274
NCI Cooperative Group Arm G Patients Only Colorectal
Cancer - Adjuvant Disease Treatment Summary Form
NCT00079274 
Comparison of Combination Chemotherapy Regimens With
or Without Cetuximab in Treating Patients Who Have
Undergone Surgery For Stage III Colon Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=53BD5FD0-
1911-70FC-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/10830
NCI Cooperative Group Arm G
Patients Only Colorectal Cancer -
Adjuvant Disease Treatment
Summary Form NCT00079274
Clinical trial administrative data
Coordinating Group Protocol Number
Coordinating Group Code
Protocol Title
Patient Study ID
Patient Medical Record Number
Patient Initials (L, FM)
Participating Group Code (Cooperative Group
where credit will be applied)
Institution Name (treating location/performance
site)
Are data amended? (If data are amended, please
circle in red when using paper form)
Yes
No
Colorectal: Treatment Summary Interval -
End Of Treatment
First date adjuvant therapy was given
Last date adjuvant therapy was given
Colorectal: Treatment Schedule -
Systemic Therapy
1 / 2
Adjuvant chemotherapy for colorectal cancer
(Check one)
5-fu And Leucovorin (5-FU and
Leucovorin)
Oxaliplatin/leucovorin/5-fu (5-FU,
Oxilaplatin, Leucovorin)
Capecitabine (Capecitabine alone)
Capecitabine, Oxaliplatin (Capecitabine,
Oxaliplatin)
Other (Other)
Other, specify
Was bevacizumab used as a component of
adjuvant therapy
Yes
No
Did the patient complete the planned adjuvant
therapy
Yes
No
Comments
Comments
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NCI Cooperative Group Arm G Patients Only
Colorectal Cancer - Follow Up Form NCT00079274
NCI Cooperative Group Arm G Patients Only Colorectal
Cancer - Follow Up Form NCT00079274 
Comparison of Combination Chemotherapy Regimens With
or Without Cetuximab in Treating Patients Who Have
Undergone Surgery For Stage III Colon Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=53BD38C7-
058A-6097-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/10831
NCI Cooperative Group Arm G
Patients Only Colorectal Cancer -
Follow Up Form NCT00079274
Clinical trial administrative data
Coordinating Group Protocol Number
Coordinating Group Code
Protocol Title
Patient Study ID
Patient Medical Record Number
Patient Initials (L, FM)
Participating Group Code (Cooperative Group
where credit will be applied)
Institution Name (treating location/performance
site)
Are data amended? (If data are amended, please
circle in red when using paper form)
Yes
No
Visit (*Please See Form Instructions* - Please
indicate which follow-up visit number from end of
treatment Circle one)
Other
Were you able to obtain any information about
the patient since the last report
Yes
No
Post-Treatment Follow-Up Visit Date (If yes,
mm/dd/yyyy Continue to next section.)
1 / 3
Date of last attempt to contact patient (If No,
mm/dd/yyyy Stop here, cross off the remainder of
the form, and return form to NCCTG.)
Vital Status
Patient's Vital Status
Alive (Alive)
Dead (Dead)
Death Date/Last Contact Date (MM DD YYYY)
Disease Follow-up Status
Has the patient had a documented clinical
assessment for this cancer? (since submission of
the previous follow-up form)
Yes
No
Date of Last Clinical Assessment (MM DD YYYY)
Has the patient had a colonoscopy assessment
for this cancer since submission of the previous
follow-up form?
Yes
No
Date of last colonoscopy (mm dd yyyy only
provide date if assessment since submission of
previous follow-up form)
Notice Of Recurrence
Has the patient developed a first progression (or
recurrence) that has not been previously
reported?
Yes
No
Date of First Recurrence or Progression (MM DD
YYYY)
Site(s) of Progression
Liver (Liver)
Local (Local)
Lung (Lung)
Other (Other)
Regional (Regional)
Other specify
2 / 3
NCI Cooperative Group Arm G Patients Only Colorectal Cancer - Follow
Up Form NCT00079274
Notice Of Secondary Resection
If the patient has developed a first progression (or
recurrence), was a secondary resection
performed that has not been previously reported
No (No)
Unknown (Unknown)
Yes (Yes)
Date of secondary resection (Submit operative
and pathology reports, if completed.)
Intent of resection
Curative Intent And Successful R0
Resection (Curative intent and
successful R0 resection)
Curative Intent But Less Than R0
Resection (Curative intent but less than
R0 resection)
Palliative Intent (Palliative intent)
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Up Form NCT00079274
E4A03 Prophylactic Treatment and
Thrombotic Event Form
E4A03 Prophylactic Treatment and Thrombotic Event Form
Lenalidomide and Dexamethasone With or Without
Thalidomide in Treating Patients With Multiple Myeloma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=2753E114-
BE3E-7461-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/10832
E4A03 Prophylactic Treatment and
Thrombotic Event Form
Header
ECOG Protocol Number
DCI Name
Registration Step
ECOG Patient ID
Patient demographics
Patient Initials
ECOG Protocol Number
Participating Group Protocol Number
Institution/Affiliate
ECOG Patient ID
Participating Group Patient ID
On Treatment Report Period
On Treatment Report Period (Arms S and T : 1
cycle = 28 days - NOTE: When completing this
form for cycle 5 and higher, submit this form
every 4 cycles beginning with cycle 8 ie., the
report period 'Cycle 8' below includes data from
cycles 5-8.)
Cycle 1 Step 1 (Cycle 1 Step 1)
Cycle 12 Step 1 (Cycle 12 Step 1)
Cycle 16-step 1 (Cycle 16-Step 1)
Cycle 2 Step 1 (Cycle 2 Step 1)
Cycle 20-step 1 (Cycle 20-Step 1)
Cycle 3 Step 1 (Cycle 3 Step 1)
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Cycle 4 Step 1 (Cycle 4 Step 1)
Cycle 8 Step 1 (Cycle 8 Step 1)
Data amendment
Please mark an 'X' if data have been amended
Date data amended
Section I - Prophylaxis Treatment
Did patient receive protocol-specified prophylaxis
treatment without
delay/modification/discontinuation this report
period?
Yes
No
International Normalization Ratio (INR)
Type of Therapy Modification
Agent Changed (Agent changed)
Agent Discontinued (Agent discontinued)
Dose Delayed (Dose delay)
Dose Missed (Dose missed)
Dose Or Inr Modfication (Dose or INR
modfication)
Agent
Aspirin 325mg (Aspirin 325mg)
Aspirin, Other (Aspirin, other)
Coumadin (prophylactic Dose)
(Coumadin)
Low Molecular Weight Heparin
(prophylactic Dose) (Low Molecular
Weight Heparin)
Not Applicable (Not applicable)
Agent
Aspirin 325mg (Aspirin 325mg)
Aspirin, Other (Aspirin, other)
Coumadin (prophylactic Dose)
(Coumadin)
Low Molecular Weight Heparin
(prophylactic Dose) (Low Molecular
Weight Heparin)
Not Applicable (Not applicable)
Agent Start Date
Dose Modification Reason
Other (Other)
Other Adverse Event (Other adverse
event)
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Thrombotic Event (Thrombotic event)
Other, specify
Comments
Investigator Signature
Investigator Signature Date
Section Ii - Thrombotic Event(s)
Did patient experience a thrombotic event (this
reporting period)
Yes
No
CTC Adverse Event Term
Acidosis Nos (Acidosis (metabolic or
respiratory))
Capillary Leak Syndrome (Acute
vascular leak syndrome)
Adrenal Insufficiency (Adrenal
insufficiency)
Adult Respiratory Distress Syndrome
(Adult respiratory distress syndrome
(ARDS))
Blood Albumin Decreased (Albumin,
serum-low (hypoalbuminemia))
Alcohol Intolerance Syndrome
(antabuse-like Syndrome) (Alcohol
intolerance syndrome (antabuse-like
syndrome))
Blood Alkaline Phosphatase Nos
Increased (Alkaline phosphatase)
Alkalosis Nos (Alkalosis (metabolic or
respiratory))
Hypersensitivity Nos (Allergic
reaction/hypersensitivity (including drug
fever))
Rhinitis Allergic Nos (Allergic rhinitis
(including sneezing, nasal stuffiness,
postnasal drip))
Allergy/immunology Other
(Allergy/Immunology-Other (Specify))
Alanine Aminotransferase Increased
(ALT, SGPT (serum glutamic pyruvic
transaminase))
Blood Amylase Increased (Amylase)
Anorexia (Anorexia)
Apnoea (Apnea)
Arachnoiditis
(Arachnoiditis/meningismus/radiculitis)
Arthritis Nos (Arthritis (non-septic))
Ascites (Ascites (non-malignant))
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Aspiration (Aspiration)
Aspartate Aminotransferase Increased
(AST, SGOT (serum glutamic oxaloacetic
transaminase))
Ataxia Nec (Ataxia (incoordination))
Atelectasis (Atelectasis)
Atrophy, Skin (Atrophy, skin)
Atrophy, Subcutaneous Fat (Atrophy,
subcutaneous fat)
Auditory/ear Other (Auditory/Ear-Other
(Specify))
Autoimmune Disorder Nos (Autoimmune
reaction)
Blood Bicarbonate Decreased
(Bicarbonate, serum-low)
Blood Bilirubin Increased (Bilirubin
(hyperbilirubinemia))
Bladder Disorder Nos (Bladder spasms)
Blood/bone Marrow Other (Blood/Bone
Marrow-Other (Specify))
Bone Age (alteration In Bone Age) (Bone
age (alteration in bone age))
Bone Growth: Femoral Head; Slipped
Capital Femoral Epiphysis (Bone growth:
femoral head; slipped capital femoral
epiphysis)
Bone Growth: Limb Length Discrepancy
(Bone growth: limb length discrepancy)
Bone Growth: Spine Kyphosis/lordosis
(Bone growth: spine kyphosis/lordosis)
Bone Marrow Depression Nos (Bone
marrow cellularity)
Bone: Spine-scoliosis (Bone: spine-
scoliosis)
Brachial Plexopathy (Brachial
plexopathy)
Breast Function/lactation (Breast
function/lactation)
Breast Nipple/areolar Deformity (Breast
nipple/areolar deformity)
Breast Volume/hypoplasia (Breast
volume/hypoplasia)
Bronchospasm, Wheezing
(Bronchospasm, wheezing)
Ecchymosis (Bruising (in absence of
grade 3 or 4 thrombocytopenia))
Burn (Burn)
Hypercalcaemia (Calcium, serum-high
(hypercalcemia))
Hypocalcaemia (Calcium, serum-low
(hypocalcemia))
Pulmonary Function Test Nos Decreased
(Carbon monoxide diffusion capacity
(DL(co)))
Arrhythmia Nos (Cardiac Arrhythmia-
Other (Specify))
Cardiac General Other (Cardiac
General-Other (Specify))
Myocardial Ischaemia (Cardiac
ischemia/infarction)
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Cardiac Troponin I Increased (Cardiac
troponin I (cTnI))
Cardiac Troponin T Increased (Cardiac
troponin T (cTnT))
Cardiopulmonary Arrest, Cause
Unknown (non-fatal) (Cardiopulmonary
arrest, cause unknown (non-fatal))
Cataract Nec (Cataract)
Cd4 Lymphocytes Decreased (CD4
count)
Cervical Spine-range Of Motion (Cervical
spine-range of motion)
Chelitis (Cheilitis)
Cholecystitis (Cholecystitis)
Hypercholesteraemia (Cholesterol,
serum-high (hypercholesteremia))
Chyle Or Lymph Leakage (Chyle or
lymph leakage)
Chylothorax (Chylothorax)
Cerebral Ischaemia (CNS
cerebrovascular ischemia)
Cns Necrosis/cystic Progression (CNS
necrosis/cystic progression)
Coagulation Disorder Nos (Coagulation-
Other (Specify))
Learning Disorder Nos (Cognitive
disturbance)
Colitis Nos (Colitis)
Colitis, Infectious (e.g., Clostridium
Difficile) (Colitis, infectious (e.g.,
Clostridium difficile))
Ventricular Asystole (Conduction
abnormality/Atrioventricular heart block -
Asystole)
Conduction Abnormality/atrioventricular
Heart Block (Conduction
abnormality/Atrioventricular heart block -
AV block-first degree)
Conduction Abnormality/atrioventricular
Heart Block - Av Block-second Degree
Mobitz Type I (wenckebach) (Conduction
abnormality/Atrioventricular heart block -
AV block-Second degree Mobitz Type I
(Wenckebach))
Conduction Abnormality/atrioventricular
Heart Block (Conduction
abnormality/Atrioventricular heart block -
AV block-second degree Mobitz Type II)
Conduction Abnormality/atrioventricular
Heart Block (Conduction
abnormality/Atrioventricular heart block -
AV block-third degree (complete AV
block))
Conduction Abnormality/atrioventricular
Heart Block (Conduction
abnormality/Atrioventricular heart block -
Conduction abnormality NOS)
Conduction Abnormality/atrioventricular
Heart Block (Conduction
abnormality/Atrioventricular heart block -
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Sick sinus syndrome)
Conduction Abnormality/atrioventricular
Heart Block (Conduction
abnormality/Atrioventricular heart block -
Stokes-Adams syndrome)
Conduction Abnormality/atrioventricular
Heart Block (Conduction
abnormality/Atrioventricular heart block -
Wolff-Parkinson-White syndrome)
Confusion (Confusion)
Constipation (Constipation)
Constitutional Symptoms Other
(Constitutional Symptoms-Other
(Specify))
Cough (Cough)
Blood Creatine Phosphokinase
Increased (CPK (creatine
phosphokinase))
Blood Creatinine Increased (Creatinine)
Cushingoid (Cushingoid appearance
(e.g., moon face, buffalo hump,
centripetal obesity, cutaneous striae))
Cystitis (Cystitis)
Cytokine Release Syndrome/acute
Infusion Reaction (Cytokine release
syndrome/acute infusion reaction)
Death Not Associated With Ctcae Term
(Death not associated with CTCAE term
- Death NOS)
Death Not Associated With Ctcae Term
(Death not associated with CTCAE term
- Disease progression NOS)
Death Not Associated With Ctcae Term
(Death not associated with CTCAE term
- Multi-organ failure)
Death Not Associated With Ctcae Term
(Death not associated with CTCAE term
- Sudden death)
Dehydration (Dehydration)
Dental: Dentures Or Prosthesis (Dental:
dentures or prosthesis)
Dental: Periodontal Disease (Dental:
periodontal disease)
Dental: Teeth (Dental: teeth)
Dental: Teeth Development (Dental:
teeth development)
Dermal Change Lymphedema,
Phlebolymphedema (Dermal change
lymphedema, phlebolymphedema)
Dermatology/skin Other
(Dermatology/Skin-Other (Specify))
Diarrhoea Nos (Diarrhea)
Disseminated Intravascular Coagulation
(DIC (disseminated intravascular
coagulation))
Distention/bloating, Abdominal
(Distention/bloating, abdominal)
Dizziness (exc Vertigo) (Dizziness)
Dry Eye Nec (Dry eye syndrome)
Dry Mouth (Dry mouth/salivary gland
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(xerostomia))
Dry Skin (Dry skin)
Dysphagia (Dysphagia (difficulty
swallowing))
Dyspnoea Nos (Dyspnea (shortness of
breath))
Edema, Larynx (Edema, larynx)
Edema: Head And Neck (Edema: head
and neck)
Oedema Nos (Edema: limb)
Edema: Trunk/genital (Edema:
trunk/genital)
Edema: Viscera (Edema: viscera)
Ejaculatory Dysfunction (Ejaculatory
dysfunction)
Encephalopathy (Encephalopathy)
Endocrine Other (Endocrine-Other
(Specify))
Enteritis (inflammation Of The Small
Bowel) (Enteritis (inflammation of the
small bowel))
Impotence (Erectile dysfunction)
Oesophagitis Nos (Esophagitis)
Exostosis (Exostosis)
Extrapyramidal Disorder Nec
(Extrapyramidal/involuntary
movement/restlessness)
Extremity-lower (gait/walking) (Extremity-
lower (gait/walking))
Extremity-upper (function) (Extremity-
upper (function))
Eyelid Dysfunction (Eyelid dysfunction)
Fatigue (Fatigue (asthenia, lethargy,
malaise))
Febrile Neutropenia (fever Of Unknown
Origin Without Clinically Or
Microbiologically Documented Infection)
(anc <1.0 X 10^9/l, Fever >=38.5
Degrees C) (Febrile neutropenia)
Feminization (Feminization of male)
Forced Expiratory Volume Decreased
(FEV(1))
Pyrexia (Fever (in the absence of
neutropenia, where neutropenia is
defined as ANC <1.0 x 10^9/L))
Blood Fibrinogen Decreased
(Fibrinogen)
Fibrosis-cosmesis (Fibrosis-cosmesis)
Fibrosis-deep Connective Tissue
(Fibrosis-deep connective tissue)
Fistula, Gi (Fistula, GI - Abdomen NOS)
Anal Fistula (Fistula, GI - Anus)
Fistula, Gi (Fistula, GI - Biliary tree)
Fistula, Gi (Fistula, GI -
Colon/cecum/appendix)
Intestinal Fistula (Fistula, GI -
Duodenum)
Tracheo-oesophageal Fistula Nos
(Fistula, GI - Esophagus)
Fistula, Gi (Fistula, GI - Gallbladder)
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Fistula, Gi (Fistula, GI - Ileum)
Fistula, Gi (Fistula, GI - Jejunum)
Fistula, Gi (Fistula, GI - Oral cavity)
Fistula, Gi (Fistula, GI - Pancreas)
Fistula, Gi (Fistula, GI - Pharynx)
Fistula, Gi (Fistula, GI - Rectum)
Fistula, Gi (Fistula, GI - Salivary gland)
Fistula, Gi (Fistula, GI - Small bowel
NOS)
Fistula, Gi (Fistula, GI - Stomach)
Fistula, Gu (Fistula, GU - Bladder)
Fistula, Gu (Fistula, GU - Genital tract-
female)
Fistula, Gu (Fistula, GU - Kidney)
Fistula, Gu (Fistula, GU - Ureter)
Fistula, Gu (Fistula, GU - Urethra)
Fistula, Gu (Fistula, GU - Uterus)
Urogenital Fistula (Fistula, GU - Vagina)
Fistula, Pulmonary/upper Respiratory
(Fistula, pulmonary/upper respiratory -
Bronchus)
Fistula, Pulmonary/upper Respiratory
(Fistula, pulmonary/upper respiratory -
Larynx)
Fistula, Pulmonary/upper Respiratory
(Fistula, pulmonary/upper respiratory -
Lung)
Fistula, Pulmonary/upper Respiratory
(Fistula, pulmonary/upper respiratory -
Oral cavity)
Fistula, Pulmonary/upper Respiratory
(Fistula, pulmonary/upper respiratory -
Pharynx)
Fistula, Pulmonary/upper Respiratory
(Fistula, pulmonary/upper respiratory -
Pleura)
Fistula, Pulmonary/upper Respiratory
(Fistula, pulmonary/upper respiratory -
Trachea)
Flatulence (Flatulence)
Flu-like Syndrome (Flu-like syndrome)
Flushing (Flushing)
Fracture (Fracture)
Gastritis Nos (Gastritis (including bile
reflux gastritis))
Gastrointestinal Other (Gastrointestinal-
Other (Specify))
Gamma-glutamyltransferase Increased
(GGT (gamma-glutamyl transpeptidase))
Glaucoma Nos (Glaucoma)
Glomerular Filtration Rate (Glomerular
filtration rate)
Hyperglycaemia Nos (Glucose, serum-
high (hyperglycemia))
Hypoglycaemia Nos (Glucose, serum-
low (hypoglycemia))
Growth And Development Other (Growth
and Development-Other (Specify))
Growth Velocity (reduction In Growth
Velocity) (Growth velocity (reduction in
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growth velocity))
Gynaecomastia (Gynecomastia)
Alopecia (Hair loss/Alopecia (scalp or
body))
Haptoglobin Decreased (Haptoglobin)
Hearing: Patients With/without Baseline
Audiogram And Enrolled In A Monitoring
Program (Hearing: patients with/without
baseline audiogram and enrolled in a
monitoring program)
Hearing: Patients Without Baseline
Audiogram And Not Enrolled In A
Monitoring Program (Hearing: patients
without baseline audiogram and not
enrolled in a monitoring program)
Dyspepsia (Heartburn/dyspepsia)
Hematoma (Hematoma)
Haemoglobin Decreased (Hemoglobin)
Haemoglobinuria Present
(Hemoglobinuria)
Hemolysis Nos (Hemolysis (e.g.,
immune hemolytic anemia, drug related
hemolysis))
Haemorrhagic Stroke (Hemorrhage,
CNS)
Melaena (Hemorrhage, GI - Abdomen
NOS)
Hemorrhage, Gi (Hemorrhage, GI -
Anus)
Hemorrhage, Gi (Hemorrhage, GI -
Biliary tree)
Hemorrhage, Gi (Hemorrhage, GI -
Cecum/appendix)
Hemorrhage, Gi (Hemorrhage, GI -
Colon)
Hemorrhage, Gi (Hemorrhage, GI -
Duodenum)
Hemorrhage, Gi (Hemorrhage, GI -
Esophagus)
Hemorrhage, Gi (Hemorrhage, GI -
Ileum)
Hemorrhage, Gi (Hemorrhage, GI -
Jejunum)
Hemorrhage, Gi (Hemorrhage, GI - Liver)
Hemorrhage, Gi (Hemorrhage, GI -
Lower GI NOS)
Hemorrhage, Gi (Hemorrhage, GI - Oral
cavity)
Hemorrhage, Gi (Hemorrhage, GI -
Pancreas)
Hemorrhage, Gi (Hemorrhage, GI -
Peritoneal cavity)
Rectal Bleeding (Hemorrhage, GI -
Rectum)
Hemorrhage, Gi (Hemorrhage, GI -
Stoma)
Haematemesis (Hemorrhage, GI -
Stomach)
Hemorrhage, Gi (Hemorrhage, GI -
Upper GI NOS)
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Hemorrhage, Gi (Hemorrhage, GI -
Varices (esophageal))
Hemorrhage, Gi (Hemorrhage, GI -
Varices (rectal))
Hemorrhage, Gu (Hemorrhage, GU -
Bladder)
Hemorrhage, Gu (Hemorrhage, GU -
Fallopian tube)
Hemorrhage, Gu (Hemorrhage, GU -
Kidney)
Hemorrhage, Gu (Hemorrhage, GU -
Ovary)
Hemorrhage, Gu (Hemorrhage, GU -
Prostate)
Hemorrhage, Gu (Hemorrhage, GU -
Retroperitoneum)
Hemorrhage, Gu (Hemorrhage, GU -
Spermatic cord)
Hemorrhage, Gu (Hemorrhage, GU -
Stoma)
Hemorrhage, Gu (Hemorrhage, GU -
Testes)
Hemorrhage, Gu (Hemorrhage, GU -
Ureter)
Hemorrhage, Gu (Hemorrhage, GU -
Urethra)
Haematuria Present (Hemorrhage, GU -
Urinary NOS)
Hemorrhage, Gu (Hemorrhage, GU -
Uterus)
Vaginal Haemorrhage (Hemorrhage, GU
- Vagina)
Hemorrhage, Gu (Hemorrhage, GU - Vas
deferens)
Hemorrhage, Pulmonary/upper
Respiratory (Hemorrhage,
pulmonary/upper respiratory -
Bronchopulmonary NOS)
Hemorrhage, Pulmonary/upper
Respiratory (Hemorrhage,
pulmonary/upper respiratory - Bronchus)
Hemorrhage, Pulmonary/upper
Respiratory (Hemorrhage,
pulmonary/upper respiratory - Larynx)
Hemorrhage, Pulmonary/upper
Respiratory (Hemorrhage,
pulmonary/upper respiratory - Lung)
Hemorrhage, Pulmonary/upper
Respiratory (Hemorrhage,
pulmonary/upper respiratory -
Mediastinum)
Epistaxis (Hemorrhage, pulmonary/upper
respiratory - Nose)
Hemorrhage, Pulmonary/upper
Respiratory (Hemorrhage,
pulmonary/upper respiratory - Pharynx)
Hemorrhage, Pulmonary/upper
Respiratory (Hemorrhage,
pulmonary/upper respiratory - Pleura)
Haemoptysis (Hemorrhage,
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pulmonary/upper respiratory -
Respiratory tract NOS)
Hemorrhage, Pulmonary/upper
Respiratory (Hemorrhage,
pulmonary/upper respiratory - Stoma)
Hemorrhage, Pulmonary/upper
Respiratory (Hemorrhage,
pulmonary/upper respiratory - Trachea)
Post-operative Haemorrhage
(Hemorrhage/bleeding associated with
surgery, intra-operative or post-operative)
Hemorrhage/bleeding Other
(Hemorrhage/Bleeding-Other (Specify))
Hemorrhoids (Hemorrhoids)
Hepatobiliary/pancreas Other
(Hepatobiliary/Pancreas-Other (Specify))
Hiccups (Hiccoughs (hiccups, singultus))
Menopausal Symptoms (Hot
flashes/flushes)
Hydrocephalus (Hydrocephalus)
Skin Discolouration (Hyperpigmentation)
Hypertension Nos (Hypertension)
Hypopigmentation (Hypopigmentation)
Hypotension Nos (Hypotension)
Hypothermia (Hypothermia)
Hypoxia (Hypoxia)
Ileus (Ileus, GI (functional obstruction of
bowel, i.e., neuroconstipation))
Incontinence, Anal (Incontinence, anal)
Urinary Incontinence (Incontinence,
urinary)
Induration/fibrosis (skin And
Subcutaneous Tissue)
(Induration/fibrosis (skin and
subcutaneous tissue))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Abdomen NOS)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Anal/perianal)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Appendix)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Artery)
Infection (documented Clinically Or
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Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Biliary tree)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Bladder (urinary))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Blood)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Bone (osteomyelitis))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Brain (encephalitis,
infectious))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Brain + Spinal cord
(encephalomyelitis))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Bronchus)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Catheter-related)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Cecum)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
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neutrophils - Cervix)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Colon)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Conjunctiva)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Cornea)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Dental-tooth)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Duodenum)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Esophagus)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - External ear (otitis externa))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Eye NOS)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Fallopian tube)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
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neutrophils - Foreign body (e.g., graft,
implant, prosthesis, stent))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Gallbladder (cholecystitis))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Heart (endocarditis))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Ileum)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Jejunum)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Joint)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Kidney)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Larynx)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Lens)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Lip/perioral)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
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microbiologically) with Grade 3 or 4
neutrophils - Liver)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Lung (pneumonia))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Lymphatic)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Mediastinum NOS)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Meninges (meningitis))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Middle ear (otitis media))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Mucosa)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Muscle (infection myositis))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Neck NOS)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Nerve-cranial)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
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microbiologically) with Grade 3 or 4
neutrophils - Nerve-peripheral)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Nose)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Oral cavity-gums
(gingivitis))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Pancreas)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Paranasal)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Pelvis NOS)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Penis)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Peristomal)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Peritoneal cavity)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Pharynx)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
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(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Pleura (empyema))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Prostate)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Rectum)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Salivary gland)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Scrotum)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Sinus)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Skin (cellulitis))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Small bowel NOS)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Soft tissue NOS)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Spinal cord (myelitis))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
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(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Spleen)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Stomach)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Trachea)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Ungual (nails))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Upper aerodigestive NOS)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Upper airway NOS)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Ureter)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Urethra)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Urinary tract NOS)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Uterus)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
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(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Vagina)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Vein)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Vulva)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Wound)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Abdomen
NOS)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils -
Anal/perianal)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Appendix)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Artery)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Biliary tree)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Bladder
(urinary))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Blood)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Bone
(osteomyelitis))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Brain
(encephalitis, infectious))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Brain +
Spinal cord (encephalomyelitis))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Bronchus)
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Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Catheter-
related)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Cecum)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Cervix)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Colon)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils -
Conjunctiva)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Cornea)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Dental-
tooth)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Duodenum)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Esophagus)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - External ear
(otitis externa))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Eye NOS)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Fallopian
tube)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Foreign
body (e.g., graft, implant, prosthesis,
stent))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Gallbladder
(cholecystitis))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Heart
(endocarditis))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Ileum)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Jejunum)
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Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Joint)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Kidney)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Larynx)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Lens)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Lip/perioral)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Liver)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Lung
(pneumonia))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Lymphatic)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils -
Mediastinum NOS)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Meninges
(meningitis))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Middle ear
(otitis media))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Mucosa)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Muscle
(infection myositis))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Neck NOS)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Nerve-
cranial)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Nerve-
peripheral)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Nose)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
21 / 46
E4A03 Prophylactic Treatment and Thrombotic Event Form
or Grade 1 or 2 neutrophils - Oral cavity-
gums (gingivitis))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Pancreas)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Paranasal)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Pelvis NOS)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Penis)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Peristomal)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Peritoneal
cavity)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Pharynx)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Pleura
(empyema))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Prostate)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Rectum)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Salivary
gland)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Scrotum)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Sinus)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Skin
(cellulitis))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Small bowel
NOS)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Soft tissue
NOS)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Spinal cord
(myelitis))
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Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Spleen)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Stomach)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Trachea)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Ungual
(nails))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Upper
aerodigestive NOS)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Upper
airway NOS)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Ureter)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Urethra)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Urinary
tract NOS)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Uterus)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Vagina)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Vein)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Vulva)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Wound)
Infection With Unknown Anc (Infection
with unknown ANC - Abdomen NOS)
Infection With Unknown Anc (Infection
with unknown ANC - Anal/perianal)
Infection With Unknown Anc (Infection
with unknown ANC - Appendix)
Infection With Unknown Anc (Infection
with unknown ANC - Artery)
Infection With Unknown Anc (Infection
with unknown ANC - Biliary tree)
Infection With Unknown Anc (Infection
with unknown ANC - Bladder (urinary))
Infection With Unknown Anc (Infection
with unknown ANC - Blood)
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Infection With Unknown Anc (Infection
with unknown ANC - Bone
(osteomyelitis))
Infection With Unknown Anc (Infection
with unknown ANC - Brain (encephalitis,
infectious))
Infection With Unknown Anc (Infection
with unknown ANC - Brain + Spinal cord
(encephalomyelitis))
Infection With Unknown Anc (Infection
with unknown ANC - Bronchus)
Implant Infection (Infection with unknown
ANC - Catheter-related)
Infection With Unknown Anc (Infection
with unknown ANC - Cecum)
Infection With Unknown Anc (Infection
with unknown ANC - Cervix)
Infection With Unknown Anc (Infection
with unknown ANC - Colon)
Infection With Unknown Anc (Infection
with unknown ANC - Conjunctiva)
Infection With Unknown Anc (Infection
with unknown ANC - Cornea)
Infection With Unknown Anc (Infection
with unknown ANC - Dental-tooth)
Infection With Unknown Anc (Infection
with unknown ANC - Duodenum)
Infection With Unknown Anc (Infection
with unknown ANC - Esophagus)
Infection With Unknown Anc (Infection
with unknown ANC - External ear (otitis
externa))
Infection With Unknown Anc (Infection
with unknown ANC - Eye NOS)
Infection With Unknown Anc (Infection
with unknown ANC - Fallopian tube)
Infection With Unknown Anc (Infection
with unknown ANC - Foreign body (e.g.,
graft, implant, prosthesis, stent))
Infection With Unknown Anc (Infection
with unknown ANC - Gallbladder
(cholecystitis))
Infection With Unknown Anc (Infection
with unknown ANC - Heart
(endocarditis))
Infection With Unknown Anc (Infection
with unknown ANC - Ileum)
Infection With Unknown Anc (Infection
with unknown ANC - Jejunum)
Infection With Unknown Anc (Infection
with unknown ANC - Joint)
Infection With Unknown Anc (Infection
with unknown ANC - Kidney)
Infection With Unknown Anc (Infection
with unknown ANC - Larynx)
Infection With Unknown Anc (Infection
with unknown ANC - Lens)
Infection With Unknown Anc (Infection
with unknown ANC - Lip/perioral)
Infection With Unknown Anc (Infection
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with unknown ANC - Liver)
Infection With Unknown Anc (Infection
with unknown ANC - Lung (pneumonia))
Infection With Unknown Anc (Infection
with unknown ANC - Lymphatic)
Infection With Unknown Anc (Infection
with unknown ANC - Mediastinum NOS)
Infection With Unknown Anc (Infection
with unknown ANC - Meninges
(meningitis))
Infection With Unknown Anc (Infection
with unknown ANC - Middle ear (otitis
media))
Infection With Unknown Anc (Infection
with unknown ANC - Mucosa)
Infection With Unknown Anc (Infection
with unknown ANC - Muscle (infection
myositis))
Infection With Unknown Anc (Infection
with unknown ANC - Neck NOS)
Infection With Unknown Anc (Infection
with unknown ANC - Nerve-cranial)
Infection With Unknown Anc (Infection
with unknown ANC - Nerve-peripheral)
Infection With Unknown Anc (Infection
with unknown ANC - Nose)
Infection With Unknown Anc (Infection
with unknown ANC - Oral cavity-gums
(gingivitis))
Infection With Unknown Anc (Infection
with unknown ANC - Pancreas)
Infection With Unknown Anc (Infection
with unknown ANC - Paranasal)
Infection With Unknown Anc (Infection
with unknown ANC - Pelvis NOS)
Infection With Unknown Anc (Infection
with unknown ANC - Penis)
Infection With Unknown Anc (Infection
with unknown ANC - Peristomal)
Infection With Unknown Anc (Infection
with unknown ANC - Peritoneal cavity)
Infection With Unknown Anc (Infection
with unknown ANC - Pharynx)
Infection With Unknown Anc (Infection
with unknown ANC - Pleura (empyema))
Infection With Unknown Anc (Infection
with unknown ANC - Prostate)
Infection With Unknown Anc (Infection
with unknown ANC - Rectum)
Infection With Unknown Anc (Infection
with unknown ANC - Salivary gland)
Infection With Unknown Anc (Infection
with unknown ANC - Scrotum)
Infection With Unknown Anc (Infection
with unknown ANC - Sinus)
Infection With Unknown Anc (Infection
with unknown ANC - Skin (cellulitis))
Infection With Unknown Anc (Infection
with unknown ANC - Small bowel NOS)
Infection With Unknown Anc (Infection
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with unknown ANC - Soft tissue NOS)
Infection With Unknown Anc (Infection
with unknown ANC - Spinal cord
(myelitis))
Infection With Unknown Anc (Infection
with unknown ANC - Spleen)
Infection With Unknown Anc (Infection
with unknown ANC - Stomach)
Infection With Unknown Anc (Infection
with unknown ANC - Trachea)
Infection With Unknown Anc (Infection
with unknown ANC - Ungual (nails))
Infection With Unknown Anc (Infection
with unknown ANC - Upper aerodigestive
NOS)
Infection With Unknown Anc (Infection
with unknown ANC - Upper airway NOS)
Infection With Unknown Anc (Infection
with unknown ANC - Ureter)
Infection With Unknown Anc (Infection
with unknown ANC - Urethra)
Infection With Unknown Anc (Infection
with unknown ANC - Urinary tract NOS)
Infection With Unknown Anc (Infection
with unknown ANC - Uterus)
Infection With Unknown Anc (Infection
with unknown ANC - Vagina)
Infection With Unknown Anc (Infection
with unknown ANC - Vein)
Infection With Unknown Anc (Infection
with unknown ANC - Vulva)
Culture Wound Positive (Infection with
unknown ANC - Wound)
Infection Nos (Infection-Other (Specify))
Infertility/sterility (Infertility/sterility)
Injection Site Reaction Nos (Injection site
reaction/extravasation changes)
Prothrombin Time Prolonged (INR
(International Normalized Ratio of
prothrombin time))
Insomnia Nec (Insomnia)
Intra-operative Injury (Intra-operative
injury - Abdomen NOS)
Intra-operative Injury (Intra-operative
injury - Adrenal gland)
Intra-operative Injury (Intra-operative
injury - Anal sphincter)
Intra-operative Injury (Intra-operative
injury - Anus)
Intra-operative Injury (Intra-operative
injury - Appendix)
Intra-operative Injury (Intra-operative
injury - Artery NOS)
Intra-operative Injury (Intra-operative
injury - Artery-aorta)
Intra-operative Injury (Intra-operative
injury - Artery-carotid)
Intra-operative Injury (Intra-operative
injury - Artery-cerebral)
Intra-operative Injury (Intra-operative
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injury - Artery-extremity (lower))
Intra-operative Injury (Intra-operative
injury - Artery-extremity (upper))
Intra-operative Injury (Intra-operative
injury - Artery-hepatic)
Intra-operative Injury (Intra-operative
injury - Artery-major visceral artery)
Intra-operative Injury (Intra-operative
injury - Artery-pulmonary)
Intra-operative Injury (Intra-operative
injury - Biliary tree NOS)
Intra-operative Injury (Intra-operative
injury - Biliary tree-common bile duct)
Intra-operative Injury (Intra-operative
injury - Biliary tree-common hepatic duct)
Intra-operative Injury (Intra-operative
injury - Biliary tree-left hepatic duct)
Intra-operative Injury (Intra-operative
injury - Biliary tree-right hepatic duct)
Bladder Perforation Postoperative (Intra-
operative injury - Bladder)
Intra-operative Injury (Intra-operative
injury - Bone)
Intra-operative Injury (Intra-operative
injury - Brachial plexus)
Intra-operative Injury (Intra-operative
injury - Brain)
Intra-operative Injury (Intra-operative
injury - Breast)
Intra-operative Injury (Intra-operative
injury - Bronchus)
Intra-operative Injury (Intra-operative
injury - Cartilage)
Intra-operative Injury (Intra-operative
injury - Cecum)
Intra-operative Injury (Intra-operative
injury - Cervix)
Intra-operative Injury (Intra-operative
injury - CN I (olfactory))
Intra-operative Injury (Intra-operative
injury - CN II (optic))
Intra-operative Injury (Intra-operative
injury - CN III (oculomotor))
Intra-operative Injury (Intra-operative
injury - CN IV (trochlear))
Intra-operative Injury (Intra-operative
injury - CN IX (glossopharyngeal) motor
pharynx)
Intra-operative Injury (Intra-operative
injury - CN IX (glossopharyngeal)
sensory ear-pharynx-tongue)
Intra-operative Injury (Intra-operative
injury - CN V (trigeminal) motor)
Intra-operative Injury (Intra-operative
injury - CN V (trigeminal) sensory)
Intra-operative Injury (Intra-operative
injury - CN VI (abducens))
Intra-operative Injury (Intra-operative
injury - CN VII (facial) motor-face)
Intra-operative Injury (Intra-operative
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injury - CN VII (facial) sensory-taste)
Intra-operative Injury (Intra-operative
injury - CN VIII (vestibulocochlear))
Intra-operative Injury (Intra-operative
injury - CN X (vagus))
Intra-operative Injury (Intra-operative
injury - CN XI (spinal accessory))
Intra-operative Injury (Intra-operative
injury - CN XII (hypoglossal))
Intra-operative Injury (Intra-operative
injury - Colon)
Intra-operative Injury (Intra-operative
injury - Conjunctiva)
Intra-operative Injury (Intra-operative
injury - Cornea)
Intra-operative Injury (Intra-operative
injury - Cranial nerve or branch NOS)
Intra-operative Injury (Intra-operative
injury - Duodenum)
Intra-operative Injury (Intra-operative
injury - Esophagus)
Intra-operative Injury (Intra-operative
injury - Extremity-lower)
Intra-operative Injury (Intra-operative
injury - Extremity-upper)
Intra-operative Injury (Intra-operative
injury - Eye NOS)
Intra-operative Injury (Intra-operative
injury - Face NOS)
Intra-operative Injury (Intra-operative
injury - Fallopian tube)
Intra-operative Injury (Intra-operative
injury - Gallbladder)
Intra-operative Injury (Intra-operative
injury - Gingiva)
Intra-operative Injury (Intra-operative
injury - Heart)
Intra-operative Injury (Intra-operative
injury - Ileum)
Intra-operative Injury (Intra-operative
injury - Inner ear)
Intra-operative Injury (Intra-operative
injury - Jejunum)
Intra-operative Injury (Intra-operative
injury - Joint)
Intra-operative Injury (Intra-operative
injury - Kidney)
Intra-operative Injury (Intra-operative
injury - Larynx)
Intra-operative Injury (Intra-operative
injury - Lens)
Intra-operative Injury (Intra-operative
injury - Ligament)
Intra-operative Injury (Intra-operative
injury - Lingual)
Intra-operative Injury (Intra-operative
injury - Lip/perioral area)
Intra-operative Injury (Intra-operative
injury - Liver)
Intra-operative Injury (Intra-operative
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injury - Lung)
Intra-operative Injury (Intra-operative
injury - Lung thoracic)
Intra-operative Injury (Intra-operative
injury - Mediastinum)
Intra-operative Injury (Intra-operative
injury - Meninges)
Intra-operative Injury (Intra-operative
injury - Middle ear)
Intra-operative Injury (Intra-operative
injury - Muscle)
Intra-operative Injury (Intra-operative
injury - Nails)
Intra-operative Injury (Intra-operative
injury - Nasal cavity)
Intra-operative Injury (Intra-operative
injury - Nasopharynx)
Intra-operative Injury (Intra-operative
injury - Neck NOS)
Intra-operative Injury (Intra-operative
injury - Nose)
Intra-operative Injury (Intra-operative
injury - Oral)
Intra-operative Injury (Intra-operative
injury - Oral cavity NOS)
Intra-operative Injury (Intra-operative
injury - Outer ear NOS)
Intra-operative Injury (Intra-operative
injury - Outer ear-pinna)
Intra-operative Injury (Intra-operative
injury - Ovary)
Intra-operative Injury (Intra-operative
injury - Pancreas)
Intra-operative Injury (Intra-operative
injury - Pancreatic duct)
Intra-operative Injury (Intra-operative
injury - Parathyroid)
Intra-operative Injury (Intra-operative
injury - Parotid gland)
Intra-operative Injury (Intra-operative
injury - Pelvis NOS)
Intra-operative Injury (Intra-operative
injury - Penis)
Intra-operative Injury (Intra-operative
injury - Peripheral motor NOS)
Intra-operative Injury (Intra-operative
injury - Peripheral sensory NOS)
Intra-operative Injury (Intra-operative
injury - Peritoneal cavity)
Intra-operative Injury (Intra-operative
injury - Pharynx)
Intra-operative Injury (Intra-operative
injury - Pituitary)
Intra-operative Injury (Intra-operative
injury - Pleura)
Intra-operative Injury (Intra-operative
injury - Prostate)
Intra-operative Injury (Intra-operative
injury - Rectum)
Intra-operative Injury (Intra-operative
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injury - Recurrent laryngeal)
Intra-operative Injury (Intra-operative
injury - Retina)
Intra-operative Injury (Intra-operative
injury - Sacral plexus)
Intra-operative Injury (Intra-operative
injury - Salivary duct)
Intra-operative Injury (Intra-operative
injury - Salivary gland)
Intra-operative Injury (Intra-operative
injury - Sciatic)
Intra-operative Injury (Intra-operative
injury - Scrotum)
Intra-operative Injury (Intra-operative
injury - Sinus)
Intra-operative Injury (Intra-operative
injury - Skin)
Intra-operative Injury (Intra-operative
injury - Small bowel NOS)
Intra-operative Injury (Intra-operative
injury - Soft tissue NOS)
Intra-operative Injury (Intra-operative
injury - Spinal cord)
Intra-operative Injury (Intra-operative
injury - Spleen)
Intra-operative Injury (Intra-operative
injury - Stoma (GI))
Intra-operative Injury (Intra-operative
injury - Stomach)
Intra-operative Injury (Intra-operative
injury - Teeth)
Intra-operative Injury (Intra-operative
injury - Tendon)
Intra-operative Injury (Intra-operative
injury - Testis)
Intra-operative Injury (Intra-operative
injury - Thoracic duct)
Intra-operative Injury (Intra-operative
injury - Thoracodorsal)
Intra-operative Injury (Intra-operative
injury - Thyroid)
Intra-operative Injury (Intra-operative
injury - Tongue)
Intra-operative Injury (Intra-operative
injury - Trachea)
Intra-operative Injury (Intra-operative
injury - Upper aerodigestive NOS)
Intra-operative Injury (Intra-operative
injury - Upper airway NOS)
Intra-operative Injury (Intra-operative
injury - Ureter)
Intra-operative Injury (Intra-operative
injury - Urethra)
Intra-operative Injury (Intra-operative
injury - Urinary conduit)
Intra-operative Injury (Intra-operative
injury - Urinary tract NOS)
Intra-operative Injury (Intra-operative
injury - Uterus)
Intra-operative Injury (Intra-operative
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injury - Vagina)
Intra-operative Injury - Vein (Intra-
operative injury - Vein NOS)
Intra-operative Injury (Intra-operative
injury - Vein-extremity (lower))
Intra-operative Injury (Intra-operative
injury - Vein-extremity (upper))
Intra-operative Injury (Intra-operative
injury - Vein-hepatic)
Intra-operative Injury (Intra-operative
injury - Vein-inferior vena cava)
Intra-operative Injury (Intra-operative
injury - Vein-jugular)
Intra-operative Injury (Intra-operative
injury - Vein-major visceral vein)
Intra-operative Injury (Intra-operative
injury - Vein-portal vein)
Intra-operative Injury (Intra-operative
injury - Vein-pulmonary)
Intra-operative Injury (Intra-operative
injury - Vein-superior vena cava)
Intra-operative Injury (Intra-operative
injury - Vulva)
Intra-operative Injury Other (Intra-
operative Injury-Other (Specify))
Iron Overload (Iron overload)
Menstruation Irregular (Irregular menses
(change from baseline))
Irritability (Irritability (children <3 years of
age))
Joint-effusion (Joint-effusion)
Joint-effusion (Joint-function)
Keratitis Nec (Keratitis (corneal
inflammation/corneal ulceration))
Laryngeal Nerve Dysfunction (Laryngeal
nerve dysfunction)
Leak (including Anastomotic), Gi (Leak
(including anastomotic), GI - Biliary tree)
Leak (including Anastomotic), Gi (Leak
(including anastomotic), GI - Esophagus)
Leak (including Anastomotic), Gi (Leak
(including anastomotic), GI - Large
bowel)
Leak (including Anastomotic), Gi (Leak
(including anastomotic), GI - Leak NOS)
Leak (including Anastomotic), Gi (Leak
(including anastomotic), GI - Pancreas)
Leak (including Anastomotic), Gi (Leak
(including anastomotic), GI - Pharynx)
Leak (including Anastomotic), Gi (Leak
(including anastomotic), GI - Rectum)
Leak (including Anastomotic), Gi (Leak
(including anastomotic), GI - Small
bowel)
Leak (including Anastomotic), Gi (Leak
(including anastomotic), GI - Stoma)
Leak (including Anastomotic), Gi (Leak
(including anastomotic), GI - Stomach)
Leak (including Anastomotic), Gu (Leak
(including anastomotic), GU - Bladder)
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Leak (including Anastomotic), Gu (Leak
(including anastomotic), GU - Fallopian
tube)
Leak (including Anastomotic), Gu (Leak
(including anastomotic), GU - Kidney)
Leak (including Anastomotic), Gu (Leak
(including anastomotic), GU - Spermatic
cord)
Leak (including Anastomotic), Gu (Leak
(including anastomotic), GU - Stoma)
Leak (including Anastomotic), Gu (Leak
(including anastomotic), GU - Ureter)
Leak (including Anastomotic), Gu (Leak
(including anastomotic), GU - Urethra)
Leak (including Anastomotic), Gu (Leak
(including anastomotic), GU - Uterus)
Leak (including Anastomotic), Gu (Leak
(including anastomotic), GU - Vagina)
Leak (including Anastomotic), Gu (Leak
(including anastomotic), GU - Vas
deferens)
Leak, Cerebrospinal Fluid (csf) (Leak,
cerebrospinal fluid (CSF))
Left Ventricular Diastolic Dysfunction
(Left ventricular diastolic dysfunction)
Left Ventricular Failure (Left ventricular
systolic dysfunction)
Leucopenia Nos (Leukocytes (total
WBC))
Encephalopathy Nos
(Leukoencephalopathy (radiolographic
findings))
Libido Decreased (Libido)
Lipase Increased (Lipase)
Hepatic Failure (Liver dysfunction/failure
(clinical))
Local Complication - Device/prosthesis-
related (Local complication -
device/prosthesis-related)
Lumbar Spine-range Of Motion (Lumbar
spine-range of motion)
Lymphatics Other (Lymphatics-Other
(Specify))
Lymphedema-related Fibrosis
(Lymphedema-related fibrosis)
Lymphocele (Lymphocele)
Lymphopenia (Lymphopenia)
Hypermagnesaemia (Magnesium,
serum-high (hypermagnesemia))
Blood Magnesium Decreased
(Magnesium, serum-low
(hypomagnesemia))
Malabsorption (Malabsorption)
Virilism (Masculinization of female)
Amnesia Nec (Memory impairment)
Mental Status (Mental status)
Metabolic/laboratory Other
(Metabolic/Laboratory-Other (Specify))
Mood Alteration - Agitation (Mood
alteration - agitation)
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Anxiety Nec (Mood alteration - anxiety)
Depression Nec (Mood alteration -
depression)
Euphoric Mood (Mood alteration -
euphoria)
Mucositis/stomatitis (clinical Exam)
(Mucositis/stomatitis (clinical exam) -
Anus)
Mucositis/stomatitis (clinical Exam)
(Mucositis/stomatitis (clinical exam) -
Esophagus)
Mucositis/stomatitis (clinical Exam)
(Mucositis/stomatitis (clinical exam) -
Large bowel)
Mucositis/stomatitis (clinical Exam)
(Mucositis/stomatitis (clinical exam) -
Larynx)
Mucositis/stomatitis (clinical Exam)
(Mucositis/stomatitis (clinical exam) -
Oral cavity)
Stomatitis (Mucositis/stomatitis (clinical
exam) - Pharynx)
Mucositis/stomatitis (clinical Exam)
(Mucositis/stomatitis (clinical exam) -
Rectum)
Mucositis/stomatitis (clinical Exam)
(Mucositis/stomatitis (clinical exam) -
Small bowel)
Mucositis/stomatitis (clinical Exam)
(Mucositis/stomatitis (clinical exam) -
Stomach)
Mucositis/stomatitis (clinical Exam)
(Mucositis/stomatitis (clinical exam) -
Trachea)
Mucositis/stomatitis
(functional/symptomatic)
(Mucositis/stomatitis
(functional/symptomatic) - Anus)
Mucositis/stomatitis
(functional/symptomatic)
(Mucositis/stomatitis
(functional/symptomatic) - Esophagus)
Mucositis/stomatitis
(functional/symptomatic)
(Mucositis/stomatitis
(functional/symptomatic) - Large bowel)
Mucositis/stomatitis
(functional/symptomatic)
(Mucositis/stomatitis
(functional/symptomatic) - Larynx)
Mucositis/stomatitis
(functional/symptomatic)
(Mucositis/stomatitis
(functional/symptomatic) - Oral cavity)
Mucositis/stomatitis
(functional/symptomatic)
(Mucositis/stomatitis
(functional/symptomatic) - Pharynx)
Mucositis/stomatitis
(functional/symptomatic)
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(Mucositis/stomatitis
(functional/symptomatic) - Rectum)
Mucositis/stomatitis
(functional/symptomatic)
(Mucositis/stomatitis
(functional/symptomatic) - Small bowel)
Mucositis/stomatitis
(functional/symptomatic)
(Mucositis/stomatitis
(functional/symptomatic) - Stomach)
Mucositis/stomatitis
(functional/symptomatic)
(Mucositis/stomatitis
(functional/symptomatic) - Trachea)
Muscle Weakness, Generalized Or
Specific Area (not Due To Neuropathy)
(Muscle weakness, generalized or
specific area (not due to neuropathy) -
Extraocular)
Muscle Weakness, Generalized Or
Specific Area (not Due To Neuropathy)
(Muscle weakness, generalized or
specific area (not due to neuropathy) -
Extremity-lower)
Muscle Weakness, Generalized Or
Specific Area (not Due To Neuropathy)
(Muscle weakness, generalized or
specific area (not due to neuropathy) -
Extremity-upper)
Muscle Weakness, Generalized Or
Specific Area (not Due To Neuropathy)
(Muscle weakness, generalized or
specific area (not due to neuropathy) -
Facial)
Muscle Weakness, Generalized Or
Specific Area (not Due To Neuropathy)
(Muscle weakness, generalized or
specific area (not due to neuropathy) -
Left-sided)
Muscle Weakness, Generalized Or
Specific Area (not Due To Neuropathy)
(Muscle weakness, generalized or
specific area (not due to neuropathy) -
Ocular)
Muscle Weakness, Generalized Or
Specific Area (not Due To Neuropathy)
(Muscle weakness, generalized or
specific area (not due to neuropathy) -
Pelvic)
Muscle Weakness, Generalized Or
Specific Area (not Due To Neuropathy)
(Muscle weakness, generalized or
specific area (not due to neuropathy) -
Right-sided)
Muscle Weakness, Generalized Or
Specific Area (not Due To Neuropathy)
(Muscle weakness, generalized or
specific area (not due to neuropathy) -
Trunk)
Muscle Weakness Nos (Muscle
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weakness, generalized or specific area
(not due to neuropathy) - Whole
body/generalized)
Muscular/skeletal Hypoplasia
(Muscular/skeletal hypoplasia)
Musculoskeletal/soft Tissue Other
(Musculoskeletal/Soft Tissue-Other
(Specify))
Myelitis (Myelitis)
Myelodysplasia (Myelodysplasia)
Myocarditis Nos (Myocarditis)
Myositis (Myositis (inflammation/damage
of muscle))
Nail Abnormality Nos (Nail changes)
Nasal Cavity/paranasal Sinus Reactions
(Nasal cavity/paranasal sinus reactions)
Nausea (Nausea)
Necrosis, Gi (Necrosis, GI - Anus)
Necrosis, Gi (Necrosis, GI -
Colon/cecum/appendix)
Necrosis, Gi (Necrosis, GI - Duodenum)
Necrosis, Gi (Necrosis, GI - Esophagus)
Necrosis, Gi (Necrosis, GI - Gallbladder)
Necrosis, Gi (Necrosis, GI - Hepatic)
Necrosis, Gi (Necrosis, GI - Ileum)
Necrosis, Gi (Necrosis, GI - Jejunum)
Necrosis, Gi (Necrosis, GI - Oral)
Necrosis, Gi (Necrosis, GI - Pancreas)
Necrosis, Gi (Necrosis, GI - Peritoneal
cavity)
Necrosis, Gi (Necrosis, GI - Pharynx)
Necrosis, Gi (Necrosis, GI - Rectum)
Necrosis, Gi (Necrosis, GI - Small bowel
NOS)
Necrosis, Gi (Necrosis, GI - Stoma)
Necrosis, Gi (Necrosis, GI - Stomach)
Neuroendocrine: Acth Deficiency
(Neuroendocrine: ACTH deficiency)
Inappropriate Adh Secretion
(Neuroendocrine: ADH secretion
abnormality (e.g., SIADH or low ADH))
Neuroendocrine: Gonadotropin Secretion
Abnormality (Neuroendocrine:
gonadotropin secretion abnormality)
Neuroendocrine: Growth Hormone
Secretion Abnormality (Neuroendocrine:
growth hormone secretion abnormality)
Neuroendocrine: Prolactin Hormone
Secretion Abnormality (Neuroendocrine:
prolactin hormone secretion abnormality)
Neurology Other (Neurology-Other
(Specify))
Parosmia (Neuropathy: cranial - CN I
Smell)
Cranial Nerve Injury Nos (Neuropathy:
cranial - CN II Vision)
Neuropathy: Cranial (Neuropathy: cranial
- CN III Pupil, upper eyelid, extra ocular
movements)
Neuropathy: Cranial (Neuropathy: cranial
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- CN IV Downward, inward movement of
eye)
Neuropathy: Cranial (Neuropathy: cranial
- CN IX Motor-pharynx; Sensory-ear,
pharynx, tongue)
Neuropathy: Cranial (Neuropathy: cranial
- CN V Motor-jaw muscles; Sensory-
facial)
Neuropathy: Cranial (Neuropathy: cranial
- CN VI Lateral deviation of eye)
Neuropathy: Cranial (Neuropathy: cranial
- CN VII Motor-face; Sensory-taste)
Neuropathy: Cranial (Neuropathy: cranial
- CN VIII Hearing and balance)
Neuropathy: Cranial (Neuropathy: cranial
- CN X Motor-palate; pharynx, larynx)
Neuropathy: Cranial (Neuropathy: cranial
- CN XI Motor-sternomastoid and
trapezius)
Neuropathy: Cranial (Neuropathy: cranial
- CN XII Motor-tongue)
Peripheral Motor Neuropathy
(Neuropathy: motor)
Peripheral Sensory Neuropathy
(Neuropathy: sensory)
Neutropenia (Neutrophils/granulocytes
(ANC/AGC))
Blindness Night (Night blindness
(nyctalopia))
Nystagmus Nos (Nystagmus)
Obesity (Obesity)
Obstruction, Gi (Obstruction, GI -
Cecum)
Obstruction, Gi (Obstruction, GI - Colon)
Obstruction, Gi (Obstruction, GI -
Duodenum)
Obstruction, Gi (Obstruction, GI -
Esophagus)
Obstruction, Gi (Obstruction, GI -
Gallbladder)
Obstruction, Gi (Obstruction, GI - Ileum)
Obstruction, Gi (Obstruction, GI -
Jejunum)
Obstruction, Gi (Obstruction, GI -
Rectum)
Obstruction, Gi (Obstruction, GI - Small
bowel NOS)
Obstruction, Gi (Obstruction, GI - Stoma)
Obstruction, Gi (Obstruction, GI -
Stomach)
Obstruction, Gu (Obstruction, GU -
Bladder)
Obstruction, Gu (Obstruction, GU -
Fallopian tube)
Obstruction, Gu (Obstruction, GU -
Prostate)
Obstruction, Gu (Obstruction, GU -
Spermatic cord)
Obstruction, Gu (Obstruction, GU -
Stoma)
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Obstruction, Gu (Obstruction, GU -
Testes)
Ureteric Obstruction (Obstruction, GU -
Ureter)
Obstruction, Gu (Obstruction, GU -
Urethra)
Obstruction, Gu (Obstruction, GU -
Uterus)
Obstruction, Gu (Obstruction, GU -
Vagina)
Obstruction, Gu (Obstruction, GU - Vas
deferens)
Obstruction/stenosis Of Airway
(Obstruction/stenosis of airway -
Bronchus)
Obstruction/stenosis Of Airway
(Obstruction/stenosis of airway - Larynx)
Obstruction/stenosis Of Airway
(Obstruction/stenosis of airway -
Pharynx)
Obstruction/stenosis Of Airway
(Obstruction/stenosis of airway -
Trachea)
Conjunctivitis Nec (Ocular surface
disease)
Ocular/visual Other (Ocular/Visual-Other
(Specify))
Odor (patient Odor) (Odor (patient odor))
Diplopia (Ophthalmoplegia/diplopia
(double vision))
Opportunistic Infection Associated With
>=grade 2 Lymphopenia (Opportunistic
infection associated with >=Grade 2
lymphopenia)
Optic Disc Edema (Optic disc edema)
Orgasmic Dysfunction (Orgasmic
dysfunction)
Osteonecrosis (Osteonecrosis (avascular
necrosis))
Osteoporosis (Osteoporosis)
Otitis Externa (exc Boil Of Meatus) Nos
(Otitis, external ear (non-infectious))
Otitis Media Serous Nos (Otitis, middle
ear (non-infectious))
Abdominal Pain Nos (Pain - Abdomen
NOS)
Pain (Pain - Anus)
Pain (Pain - Back)
Pain (Pain - Bladder)
Bone Pain (Pain - Bone)
Pain (Pain - Breast)
Pain (Pain - Buttock)
Pain (Pain - Cardiac/heart)
Pain (Pain - Chest wall)
Chest Pain (Pain - Chest/thorax NOS)
Pain (Pain - Dental/teeth/peridontal)
Pain (Pain - Esophagus)
Earache (Pain - External ear)
Pain (Pain - Extremity-limb)
Pain (Pain - Eye)
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Pain (Pain - Face)
Pain (Pain - Gallbladder)
Headache Nos (Pain - Head/headache)
Pain (Pain - Intestine)
Arthralgia (Pain - Joint)
Pain (Pain - Kidney)
Pain (Pain - Larynx)
Pain (Pain - Lip)
Hepatic Pain (Pain - Liver)
Pain (Pain - Lymph node)
Pain (Pain - Middle ear)
Myalgia (Pain - Muscle)
Pain (Pain - Neck)
Neuralgia Nos (Pain -
Neuralgia/peripheral nerve)
Pain (Pain - Oral cavity)
Pain (Pain - Oral-gums)
Pain (Pain - Ovulatory)
Pain (Pain - Pain NOS)
Pelvic Pain Nos (Pain - Pelvis)
Pain (Pain - Penis)
Pain (Pain - Pericardium)
Pain (Pain - Perineum)
Pain (Pain - Peritoneum)
Pain (Pain - Phantom (pain associated
with missing limb))
Pleuritic Pain (Pain - Pleura)
Pain (Pain - Prostate)
Proctalgia (Pain - Rectum)
Pain (Pain - Scalp)
Pain (Pain - Scrotum)
Pain (Pain - Sinus)
Pain (Pain - Skin)
Pain (Pain - Stomach)
Pain (Pain - Testicle)
Pain (Pain - Throat/pharynx/larynx)
Tumour Pain (Pain - Tumor pain)
Dysuria (Pain - Urethra)
Dysmenorrhoea (Pain - Uterus)
Pain (Pain - Vagina)
Pain Other (Pain-Other (Specify))
Palpitations (Palpitations)
Pancreas, Exocrine Enzyme Deficiency
(Pancreas, exocrine enzyme deficiency)
Pancreatic Endocrine: Glucose
Intolerance (Pancreatic endocrine:
glucose intolerance)
Pancreatitis Nos (Pancreatitis)
Parathyroid Function, Low
(hypoparathyroidism) (Parathyroid
function, low (hypoparathyroidism))
Perforation, Gi (Perforation, GI -
Appendix)
Perforation, Gi (Perforation, GI - Biliary
tree)
Perforation, Gi (Perforation, GI - Cecum)
Perforation, Gi (Perforation, GI - Colon)
Perforation, Gi (Perforation, GI -
Duodenum)
Perforation, Gi (Perforation, GI -
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Esophagus)
Perforation, Gi (Perforation, GI -
Gallbladder)
Perforation, Gi (Perforation, GI - Ileum)
Perforation, Gi (Perforation, GI -
Jejunum)
Perforation, Gi (Perforation, GI - Rectum)
Perforation, Gi (Perforation, GI - Small
bowel NOS)
Perforation, Gi (Perforation, GI -
Stomach)
Perforation, Gu (Perforation, GU -
Bladder)
Perforation, Gu (Perforation, GU -
Fallopian tube)
Perforation, Gu (Perforation, GU -
Kidney)
Perforation, Gu (Perforation, GU - Ovary)
Perforation, Gu (Perforation, GU -
Prostate)
Perforation, Gu (Perforation, GU -
Spermatic cord)
Perforation, Gu (Perforation, GU -
Stoma)
Perforation, Gu (Perforation, GU -
Testes)
Perforation, Gu (Perforation, GU - Ureter)
Perforation, Gu (Perforation, GU -
Urethra)
Perforation, Gu (Perforation, GU -
Uterus)
Perforation, Gu (Perforation, GU -
Vagina)
Perforation, Gu (Perforation, GU - Vas
deferens)
Pericardial Effusion (Pericardial effusion
(non-malignant))
Pericarditis (Pericarditis)
Peripheral Ischaemia Nos (Peripheral
arterial ischemia)
Personality Change
(Personality/behavioral)
Petechiae (Petechiae/purpura
(hemorrhage/bleeding into skin or
mucosa))
Phlebitis Superficial (Phlebitis (including
superficial thrombosis))
Phlebolymphatic Cording
(Phlebolymphatic cording)
Hypophosphataemia (Phosphate, serum-
low (hypophosphatemia))
Photosensitivity Reaction Nos
(Photosensitivity)
Phrenic Nerve Dysfunction (Phrenic
nerve dysfunction)
Platelet Count Decreased (Platelets)
Pleural Effusion (Pleural effusion (non-
malignant))
Pneumonitis Nos
(Pneumonitis/pulmonary infiltrates)
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Pneumothorax Nos (Pneumothorax)
Portal Hypertension (Portal vein flow)
Hyperkalaemia (Potassium, serum-high
(hyperkalemia))
Hypokalaemia (Potassium, serum-low
(hypokalemia))
Proctitis Nos (Proctitis)
Prolapse Of Stoma, Gi (Prolapse of
stoma, GI)
Prolapse Of Stoma, Gu (Prolapse of
stoma, GU)
Prolonged Chest Tube Drainage Or Air
Leak After Pulmonary Resection
(Prolonged chest tube drainage or air
leak after pulmonary resection)
Prolonged Intubation After Pulmonary
Resection (>24 Hrs After Surgery)
(Prolonged intubation after pulmonary
resection (>24 hrs after surgery))
Electrocardiogram Qt Prolonged
(Prolonged QTc interval)
Proptosis/enophthalmos
(Proptosis/enophthalmos)
Proteinuria Present (Proteinuria)
Pruritus Nos (Pruritus/itching)
Delusion Nos (Psychosis
(hallucinations/delusions))
Activated Partial Thromboplastin Time
Prolonged (PTT (Partial thromboplastin
time))
Puberty (delayed) (Puberty (delayed))
Puberty (precocious) (Puberty
(precocious))
Pulmonary Fibrosis (Pulmonary fibrosis
(radiographic changes))
Pulmonary Hypertension (Pulmonary
hypertension)
Pulmonary/upper Respiratory Other
(Pulmonary/Upper Respiratory-Other
(Specify))
Upper Motor Neurone Lesion (Pyramidal
tract dysfunction (e.g., increased tone,
hyperreflexia, positive Babinski,
decreased fine motor coordination))
Rash: Acne/acneiform (Rash:
acne/acneiform)
Radiation Recall Syndrome (Rash:
dermatitis associated with radiation -
Chemoradiation)
Dermatitis Radiation Nos (Rash:
dermatitis associated with radiation -
Radiation)
Erythema Multiforme (Rash: erythema
multiforme (e.g., Stevens-Johnson
syndrome, toxic epidermal necrolysis))
Localised Exfoliation (Rash: hand-foot
skin reaction)
Dermatitis Exfoliative Nos
(Rash/desquamation)
Renal Failure Nos (Renal failure)
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Renal/genitourinary Other
(Renal/Genitourinary-Other (Specify))
Restrictive Cardiomyopathy (Restrictive
cardiomyopathy)
Retinal Detachment (Retinal
detachment)
Retinoic Acid Syndrome (Retinoic acid
syndrome")
Retinopathy (Retinopathy)
Right Ventricular Dysfunction (cor
Pulmonale) (Right ventricular dysfunction
(cor pulmonale))
Rigors (Rigors/chills)
Salivary Gland Disorder Nos (Salivary
gland changes/saliva)
Scleral Necrosis/melt (Scleral
necrosis/melt)
Secondary Malignancy Possibly Related
To Cancer Treatment (Secondary
Malignancy-possibly related to cancer
treatment (Specify))
Convulsions Nos (Seizure)
Seroma (Seroma)
Serum Sickness (Serum sickness)
Sexual/reproductive Function Other
(Sexual/Reproductive Function-Other
(Specify))
Short Stature (Short stature)
Skin Breakdown/decubitus Ulcer (Skin
breakdown/decubitus ulcer)
Hypernatraemia (Sodium, serum-high
(hypernatremia))
Hyponatraemia (Sodium, serum-low
(hyponatremia))
Soft Tissue Necrosis (Soft tissue
necrosis - Abdomen)
Soft Tissue Necrosis (Soft tissue
necrosis - Extremity-lower)
Soft Tissue Necrosis (Soft tissue
necrosis - Extremity-upper)
Soft Tissue Necrosis (Soft tissue
necrosis - Head)
Soft Tissue Necrosis (Soft tissue
necrosis - Neck)
Soft Tissue Necrosis (Soft tissue
necrosis - Pelvic)
Soft Tissue Necrosis (Soft tissue
necrosis - Thorax)
Depressed Level Of Consciousness
(Somnolence/depressed level of
consciousness)
Speech Disorder Nec (Speech
impairment (e.g., dysphasia or aphasia))
Splenic Function (Splenic function)
Striae (Striae)
Stricture/stenosis (including
Anastomotic), Gi (Stricture/stenosis
(including anastomotic), GI - Anus)
Stricture/stenosis (including
Anastomotic), Gi (Stricture/stenosis
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(including anastomotic), GI - Biliary tree)
Stricture/stenosis (including
Anastomotic), Gi (Stricture/stenosis
(including anastomotic), GI - Cecum)
Stricture/stenosis (including
Anastomotic), Gi (Stricture/stenosis
(including anastomotic), GI - Colon)
Stricture/stenosis (including
Anastomotic), Gi (Stricture/stenosis
(including anastomotic), GI - Duodenum)
Stricture/stenosis (including
Anastomotic), Gi (Stricture/stenosis
(including anastomotic), GI - Esophagus)
Stricture/stenosis (including
Anastomotic), Gi (Stricture/stenosis
(including anastomotic), GI - Ileum)
Stricture/stenosis (including
Anastomotic), Gi (Stricture/stenosis
(including anastomotic), GI - Jejunum)
Stricture/stenosis (including
Anastomotic), Gi (Stricture/stenosis
(including anastomotic), GI -
Pancreas/pancreatic duct)
Stricture/stenosis (including
Anastomotic), Gi (Stricture/stenosis
(including anastomotic), GI - Pharynx)
Stricture/stenosis (including
Anastomotic), Gi (Stricture/stenosis
(including anastomotic), GI - Rectum)
Stricture/stenosis (including
Anastomotic), Gi (Stricture/stenosis
(including anastomotic), GI - Small bowel
NOS)
Stricture/stenosis (including
Anastomotic), Gi (Stricture/stenosis
(including anastomotic), GI - Stoma)
Stricture/stenosis (including
Anastomotic), Gi (Stricture/stenosis
(including anastomotic), GI - Stomach)
Stricture/stenosis (including
Anastomotic), Gu (Stricture/stenosis
(including anastomotic), GU - Bladder)
Stricture/stenosis (including
Anastomotic), Gu (Stricture/stenosis
(including anastomotic), GU - Fallopian
tube)
Stricture/stenosis (including
Anastomotic), Gu (Stricture/stenosis
(including anastomotic), GU - Prostate)
Stricture/stenosis (including
Anastomotic), Gu (Stricture/stenosis
(including anastomotic), GU - Spermatic
cord)
Stricture/stenosis (including
Anastomotic), Gu (Stricture/stenosis
(including anastomotic), GU - Stoma)
Stricture/stenosis (including
Anastomotic), Gu (Stricture/stenosis
(including anastomotic), GU - Testes)
Stricture/stenosis (including
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Anastomotic), Gu (Stricture/stenosis
(including anastomotic), GU - Ureter)
Stricture/stenosis (including
Anastomotic), Gu (Stricture/stenosis
(including anastomotic), GU - Urethra)
Stricture/stenosis (including
Anastomotic), Gu (Stricture/stenosis
(including anastomotic), GU - Uterus)
Stricture/stenosis (including
Anastomotic), Gu (Stricture/stenosis
(including anastomotic), GU - Vagina)
Stricture/stenosis (including
Anastomotic), Gu (Stricture/stenosis
(including anastomotic), GU - Vas
deferens)
Supraventricular And Nodal Arrhythmia
(Supraventricular and nodal arrhythmia -
Atrial fibrillation)
Supraventricular And Nodal Arrhythmia
(Supraventricular and nodal arrhythmia -
Atrial flutter)
Supraventricular And Nodal Arrhythmia
(Supraventricular and nodal arrhythmia -
Atrial tachycardia/paroxysmal atrial
tachycardia)
Supraventricular And Nodal Arrhythmia
(Supraventricular and nodal arrhythmia -
Nodal/junctional)
Supraventricular And Nodal Arrhythmia
(Supraventricular and nodal arrhythmia -
Sinus arrhythmia)
Sinus Bradycardia (Supraventricular and
nodal arrhythmia - Sinus bradycardia)
Sinus Tachycardia (Supraventricular and
nodal arrhythmia - Sinus tachycardia)
Supraventricular Arrhythmia Nos
(Supraventricular and nodal arrhythmia -
Supraventricular arrhythmia NOS)
Supraventricular And Nodal Arrhythmia -
Supraventricular Extrasystoles
(premature Atrial Contractions;
Premature Nodal/junctional
Contractions) (Supraventricular and
nodal arrhythmia - Supraventricular
extrasystoles (premature atrial
contractions; premature nodal/junctional
contractions))
Supraventricular And Nodal Arrhythmia
(Supraventricular and nodal arrhythmia -
Supraventricular tachycardia)
Sweating Increased (Sweating
(diaphoresis))
Syncope (Syncope (fainting))
Syndromes Other (Syndromes-Other
(Specify))
Taste Disturbance (Taste alteration
(dysgeusia))
Telangiectasia (Telangiectasia)
Thrombosis/embolism (vascular Access-
related) (Thrombosis/embolism (vascular
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access-related))
Thrombosis Nos
(Thrombosis/thrombus/embolism)
Thrombotic Microangiopathy (e.g.,
Thrombotic Thrombocytopenic
Purpura[ttp] Or Hemolytic Uremic
Syndrome[hus]) (Thrombotic
microangiopathy (e.g., thrombotic
thrombocytopenic purpura or hemolytic
uremic syndrome))
Thyroid Function, High (hyperthyroidism,
Thyrotoxicosis) (Thyroid function, high
(hyperthyroidism, thyrotoxicosis))
Hypothyroidism (Thyroid function, low
(hypothyroidism))
Tinnitus (Tinnitus)
Tremor Nec (Tremor)
Hypertriglyceridaemia (Triglyceride,
serum-high (hypertriglyceridemia))
Trismus (difficulty, Restriction Or Pain
When Opening Mouth) (Trismus
(difficulty, restriction or pain when
opening mouth))
Tumour Flare (Tumor flare)
Tumour Lysis Syndrome (Tumor lysis
syndrome)
Caecitis (Typhlitis (cecal inflammation))
Ulcer, Gi (Ulcer, GI - Anus)
Ulcer, Gi (Ulcer, GI - Cecum)
Ulcer, Gi (Ulcer, GI - Colon)
Duodenal Ulcer (Ulcer, GI - Duodenum)
Ulcer, Gi (Ulcer, GI - Esophagus)
Ulcer, Gi (Ulcer, GI - Ileum)
Ulcer, Gi (Ulcer, GI - Jejunum)
Ulcer, Gi (Ulcer, GI - Rectum)
Ulcer, Gi (Ulcer, GI - Small bowel NOS)
Ulcer, Gi (Ulcer, GI - Stoma)
Gastric Ulcer (Ulcer, GI - Stomach)
Ulceration (Ulceration)
Hyperuricaemia (Uric acid, serum-high
(hyperuricemia))
Fanconi Syndrome (Urinary electrolyte
wasting (e.g., Fanconi's syndrome, renal
tubular acidosis))
Urinary Frequency (Urinary
frequency/urgency)
Urinary Retention (Urinary retention
(including neurogenic bladder))
Urine Discolouration (Urine color
change)
Urticaria Nos (Urticaria (hives, welts,
wheals))
Uveitis (Uveitis)
Vaginal Discharge (non-infectious)
(Vaginal discharge (non-infectious))
Vulvovaginal Dryness (Vaginal dryness)
Vaginal Mucositis (Vaginal mucositis)
Vaginal Stenosis/length (Vaginal
stenosis/length)
Vaginitis (Vaginitis (not due to infection))
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Valvular Heart Disease (Valvular heart
disease)
Vascular Other (Vascular-Other
(Specify))
Vasculitis Nos (Vasculitis)
Vasovagal Attack (Vasovagal episode)
Ventricular Arrhythmia (Ventricular
arrhythmia - Bigeminy)
Ventricular Arrhythmia (Ventricular
arrhythmia - Idioventricular rhythm)
Ventricular Arrhythmia (Ventricular
arrhythmia - PVCs)
Ventricular Arrhythmia (Ventricular
arrhythmia - Torsade de pointes)
Ventricular Arrhythmia (Ventricular
arrhythmia - Trigeminy)
Ventricular Arrhythmia Nos (Ventricular
arrhythmia - Ventricular arrhythmia NOS)
Ventricular Arrhythmia (Ventricular
arrhythmia - Ventricular fibrillation)
Ventricular Arrhythmia (Ventricular
arrhythmia - Ventricular flutter)
Ventricular Arrhythmia (Ventricular
arrhythmia - Ventricular tachycardia)
Vessel Injury-artery (Vessel injury-artery
- Aorta)
Vessel Injury-artery (Vessel injury-artery
- Carotid)
Vessel Injury-artery (Vessel injury-artery
- Extremity-lower)
Vessel Injury-artery (Vessel injury-artery
- Extremity-upper)
Vessel Injury-artery (Vessel injury-artery
- Other NOS)
Vessel Injury-artery (Vessel injury-artery
- Visceral)
Vessel Injury-vein (Vessel injury-vein -
Extremity-lower)
Vessel Injury-vein (Vessel injury-vein -
Extremity-upper)
Vessel Injury-vein (Vessel injury-vein -
IVC)
Vessel Injury-vein (Vessel injury-vein -
Jugular)
Vessel Injury-vein (Vessel injury-vein -
Other NOS)
Vessel Injury-vein (Vessel injury-vein -
SVC)
Vessel Injury-vein (Vessel injury-vein -
Viscera)
Viral Hepatitis (Viral hepatitis)
Visceral Arterial Ischaemia (Visceral
arterial ischemia (non-myocardial))
Vision Blurred (Vision-blurred vision)
Photopsia (Vision-flashing lights/floaters)
Photophobia (Vision-photophobia)
Vital Capacity (Vital capacity)
Vitreous Hemorrhage (Vitreous
hemorrhage)
Dysphonia (Voice changes/dysarthria
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(e.g., hoarseness, loss or alteration in
voice, laryngitis))
Vomiting Nos (Vomiting)
Lacrimation Increased (Watery eye
(epiphora, tearing))
Weight Increased (Weight gain)
Weight Decreased (Weight loss)
Culture Wound Negative (Wound
complication, non-infectious)
CTC Adverse Event Grade
International Normalization Ratio (INR)
Start date of thrombotic event
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Order Form Pediatric Intensive Care Unit
UKM - Pharmacy Order
"Apothekenanforderung für Infusionslösungen-MS
Anordnungsbogen Päd Int 3" converted to ODM format.
Routine documentation of university hospital muenster.
This form simultaneously also serves the purpose of
creating order forms for the making of mixed infusion bags
for children.
All rights reserved. Please visit https://medical-data-
models.org/forms/10833
Order Form Pediatric Intensive Care
Unit UKM - Pharmacy Order
Patient Information
Name of the patient:*
Date of birth:*
Medication
Partition note:
Name of the Infusion's solution and its
composition:
In ml/24 h:
Dose g/ kg or mmol/ kg:
Dose kcal/ kg:
Infusion Special Arterial or Venous
Administration Routes
Name and dose of Infusion:
Application in/ by:
Artery (1)
Umbilical artery catheter (2)
Left artery pressure  (3)
Pulmonary artery pressure (4)
Central venous pressure (5)
KCL-Bypass (6)
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Coronary Artery Disease Eligibility BX
VELOCITY Stent NCT00235144
The Study of the BX VELOCITY Stent In Patients With De
Novo Coronary Artery Lesions. (E-SIRIUS)
ODM derived from
http://clinicaltrials.gov/show/NCT00235144
All rights reserved. Please visit https://medical-data-
models.org/forms/10834
Eligibility BX VELOCITY Stent
Coronary Artery Disease
NCT00235144
Inclusion Criteria
18 years and older*
Yes
No
Diagnosis of angina pectoris as defined by
Canadian Cardiovascular Society Classification
(CCS I, II, III, IV) OR unstable angina pectoris
(Braunwald Classification B&C, I-II) OR patients
with documented silent ischemia*
Yes
No
Treatment of a single de novo native coronary
artery lesion in a major coronary artery in
patients with single or multi-vessel disease;
patients with multiple lesions can be included
only if the other lesions do not require treatment*
Yes
No
Target vessel diameter at the lesion site is
>=2.50mm and <=3.0mm in diameter (visual
estimate)*
Yes
No
Target lesion is >=15mm and <=32mm in length
(visual estimate)*
Yes
No
Target lesion stenosis is >50% and <100%
(visual estimate)*
Yes
No
Exclusion criteria
Patient has experienced a Q-wave or non-Q-
wave myocardial infarction with documented total
CK >2 times normal within the preceding 24
hours and the CK and CK-MB enzymes remains
above normal at the time of treatment*
Yes
No
Has unstable angina classified as Braunwald III B
or C and A I-II-III, or is having a peri infarction*
Yes
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No
Unprotected left main coronary disease with
>=50% stenosis*
Yes
No
Significant (>50%) stenoses proximal or distal to
the target lesion that might require
revascularization or impede runoff*
Yes
No
Have an ostial target lesion*
Yes
No
Angiographic evidence of thrombus within target
lesion*
Yes
No
Heavily calcified lesion and/or calcified lesion
which cannot be successfully predilated*
Yes
No
Documented left ventricular ejection fraction
<=25%*
Yes
No
Medical concepts
Single vessel disease*
Double vessel disease*
Triple vessel disease*
Coronary artery disease (CAD)*
Vessel lumen diameter*
Stenotic lesion length*
Stenosis*
Acute myocardial infarction*
CK*
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CK-MB*
OPERATIONS / PROCEDURES*
Coronary arteriography*
Thrombus*
Calcification*
3 / 3
Coronary Artery Disease Eligibility BX VELOCITY Stent NCT00235144
Enrollment Checklist NCT00433589
Enrollment Checklist NCT00433589 
Genetic Testing or Clinical Assessment in Determining the
Need for Chemotherapy in Women With Breast Cancer
That Involves No More Than 3 Lymph Nodes
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=188F45BF-
CE4C-20E2-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/10835
Enrollment Checklist NCT00433589
Header
Patient Birth Date
Patient Hospital Number
Institution Name
Institution No.
Physician of Record
Checklist
Date of Initial Diagnosis of Primary Tumor
Primary Surgery Type
Mastectomy, Nos (Mastectomy NOS)
None (None)
Partial Mastectomy, Lumpectomy Or
Excisional Biopsy (Partial
mastectomy/lumpectomy/excisional
biopsy)
Does the tumor involve the surgical margin
No (No)
Unknown (Unknown)
Yes (Yes)
Was axillary dissection performed?
No (No)
Unknown (Unknown)
Yes (Yes)
Pathologic Primary Tumor Size
Histologic Grade
Well Differentiated (Grade I (low))
Moderately Differentiated (Grade II
(intermediate))
Poorly Differentiated (Grade III (high))
Unknown (UNKNOWN)
ER Status
Negative (Negative)
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Not Done (NOT DONE)
Positive (Positive)
Unknown (Unknown)
PgR Status
Negative (Negative)
Not Done (NOT DONE)
Positive (Positive)
Unknown (Unknown)
HER-2/neu status
Equivocal (Equivocal)
Negative (Negative)
Never Done Or Unknown (Never done or
unknown)
Positive (Positive)
Unknown (Unknown)
Performance Status
Fully Active, Able To Carry On All Pre-
disease Performance Without
Restriction. (0)
Restricted In Physically Strenuous
Activity But Ambulatory And Able To
Carry Out Work Of A Light Or Sedentary
Nature, E.g., Light Housework, Office
Work. (1)
Ambulatory And Capable Of All Selfcare
But Unable To Carry Out Any Work
Activities. Up And About More Than 50%
Of Waking Hours. (2)
Capable Of Only Limited Selfcare,
Confined To Bed Or Chair More Than
50% Of Waking Hours. (3)
Completely Disabled. Cannot Carry On
Any Selfcare. Totally Confined To Bed Or
Chair. (4)
Dead (5)
Peripheral Neutrophil Count
Peripheral Neutrophils (%)
Peripheral Platelet Count
Total bilirubin ULN
Total Bilirubin
SGOT (AST) ULN
SGOT
SGPT (ALT) ULN
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SGPT
Alkaline Phosphatase ULN
Alkaline Phosphatase
Serum Creatinine ULN
Serum creatinine
Weight
Other malignancy
Yes
No
Prior Treatment?
Yes
No
Is patient a woman of childbearing potential
Yes
No
Is the patient pregnant or nursing? (If yes:)
No, And Not Nursing (no, and not
nursing)
Yes (Yes)
Date Informed Consent Signed
Consent given for specimen use?
Yes
No
Patient's Initial Consent given for tissue specimen
use for research on the patient's cancer?
Yes
No
Patient's initial consent for sharing specimen(s)
with outside researchers.
Yes
No
Date Form Completed
Investigator Signature
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S0337 Irritative Bladder Symptom Inventory
S0337 Irritative Bladder Symptom Inventory
Gemcitabine After Surgery in Treating Patients With Newly
Diagnosed or Recurrent Bladder Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=FE24FEF5-
9DBA-4A52-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/10836
S0337 Irritative Bladder Symptom
Inventory
Header
SWOG Patient ID
SWOG Study No.
Registration Step
Patient Initials (L, F M)
Date Form Completed
Institution/Affiliate
Physician
Participating Group Name
Participating Group Study No.
Participating Group Patient ID
Planned Assessment
7 Days After Treatment (1 week post-
treatment)
Prestudy (Prestudy)
Bladder Symptoms
Bladder Discomfort
A Little Of The Time (A little of the time)
All Of The Time (All of the time)
Most Of The Time (Most of the time)
None Of The Time (None of the time)
Some Of The Time (Some of the time)
Bladder Pain
A Little Of The Time (A little of the time)
All Of The Time (All of the time)
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Most Of The Time (Most of the time)
None Of The Time (None of the time)
Some Of The Time (Some of the time)
Getting up at night to go to the bathroom
A Little Of The Time (A little of the time)
All Of The Time (All of the time)
Most Of The Time (Most of the time)
None Of The Time (None of the time)
Some Of The Time (Some of the time)
Going to the bathroom frequently during the day
A Little Of The Time (A little of the time)
All Of The Time (All of the time)
Most Of The Time (Most of the time)
None Of The Time (None of the time)
Some Of The Time (Some of the time)
Difficulty sleeping because of bladder problems
A Little Of The Time (A little of the time)
All Of The Time (All of the time)
Most Of The Time (Most of the time)
None Of The Time (None of the time)
Some Of The Time (Some of the time)
Urgency to urinate
A Little Of The Time (A little of the time)
All Of The Time (All of the time)
Most Of The Time (Most of the time)
None Of The Time (None of the time)
Some Of The Time (Some of the time)
Burning sensation in my bladder
A Little Of The Time (A little of the time)
All Of The Time (All of the time)
Most Of The Time (Most of the time)
None Of The Time (None of the time)
Some Of The Time (Some of the time)
Burning and/or discomfort while I go to the
bathroom
A Little Of The Time (A little of the time)
All Of The Time (All of the time)
Most Of The Time (Most of the time)
None Of The Time (None of the time)
Some Of The Time (Some of the time)
Blood in my urine when I went to the bathroom
Yes
No
Indicate the number of days you saw blood
Pain in my penis
A Little Of The Time (A little of the time)
All Of The Time (All of the time)
Most Of The Time (Most of the time)
None Of The Time (None of the time)
Some Of The Time (Some of the time)
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Burning sensation in my penis
A Little Of The Time (A little of the time)
All Of The Time (All of the time)
Most Of The Time (Most of the time)
None Of The Time (None of the time)
Some Of The Time (Some of the time)
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CALGB 40601 ON-STUDY FORM
NCT00770809
CALGB 40601 ON-STUDY FORM NCT00770809
Paclitaxel and Trastuzumab With or Without Lapatinib in
Treating Patients With Stage II or Stage III Breast Cancer
That Can Be Removed by Surgery
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=39F0C5FF-
8DFB-6139-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/10838
CALGB 40601 ON-STUDY FORM
NCT00770809
Header
CALGB Form
CALGB Study No
CALGB Patient ID
Amended Data
Yes
No
Patient demographics
Patient Initials (Last, First Middle)
Patient Hospital No.
Institution/Affiliate
Participating Group
Participating Group Study No.
Participating Group Patient ID
Menopausal Status
Menopausal Status
Above Categories Not Applicable And
Age <50 (Above categories not
applicable AND Age < 50)
Above Categories Not Applicable And
Age >= 50 (Above categories not
applicable AND Age >= 50)
Post (prior Bilateral Ovariectomy Or >12
Mo Since Lmp With No Prior
Hysterectomy) (Post (prior bilateral
ovariectomy OR >12 mo since LMP with
no prior hysterectomy))
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Pre (<6 Mo Since Lmp And No Prior
Bilateral Ovariectomy And Not On
Estrogen Replacement) (Pre (<6 mo
since LMP AND no prior bilateral
ovariectomy AND not on estrogen
replacement))
Disease Description
Tumor Laterality
Bilateral (Bilateral)
Left (Left)
Right (Right)
Receptor Status, ER
Negative (Negative)
Positive (Positive)
Receptor Status, PgR
Negative (Negative)
Positive (Positive)
Histologic Grade
High (High)
Intermediate (Intermediate)
Low (Low)
Histologic Type
Ductal (Ductal)
Lobular (Lobular)
Mixed Ductal And Lobular (Mixed ductal
and lobular)
Other Specify (Other)
Other specify
Type of Biopsy Procedure
Core Biopsy (Core)
Incisional (Incisional)
Clinical Disease Assessment
Method of Evaluation
Mammogram (Mammogram)
Physical Exam (Physical exam)
Ultrasound (Ultrasound)
Primary Tumor Size (cm)
Clinical T Stage
No Evidence Of Primary Tumor (T0)
Tumor 2 Cm Or Less In Greatest
Dimension (T1)
Tumor More Than 0.1 Cm But Not More
Than 0.5 Cm In Greatest Dimension
(T1a)
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Tumor More Than 0.5 Cm But Not More
Than 1 Cm In Greatest Dimension (T1b)
Tumor More Than 1 Cm But Not More
Than 2 Cm In Greatest Dimension (T1c)
Microinvasion 0.1 Cm Or Less In
Greatest Dimension (T1mic)
Tumor More Than 2 Cm But Not More
Than 5 Cm In Greatest Dimension (T2)
Tumor More Than 5 Cm In Greatest
Dimension (T3)
Tumor Of Any Size With Direct (T4)
Extension To Chest Wall (T4a)
Edema (including Peau D'orange) Or
Ulceration Of The Skin Of The Breast Or
Satellite Skin Nodules Confined To The
Same Breast (T4b)
Both T4a And T4b (T4c)
Inflammatory Carcinoma (T4d)
Carcinoma In Situ: Intraductal
Carcinoma, Lobular Carcinoma In Situ,
Or Paget's Disease Of The Nipple With
No Tumor (Tis)
Ductal Carcinoma In Situ (Tis (DCIS))
Lobular Carcinoma In Situ (Tis (LCIS))
Paget's Disease Of The Nipple With No
Tumor. [note: Paget's Disease
Associated With A Tumor Is Classified
According To The Size Of The Tumor.]
(Tis (Paget's))
Primary Tumor Cannot Be Assessed
(TX)
Clinical N Stage
No Regional Lymph Node Metastasis
(N0)
Metastasis To Movable Ipsilateral Axillary
Lymph Node(s) (N1)
Metastasis To Ipsilateral Axillary Lymph
Node(s) Fixed Or Matted, Or In Clinically
Apparent* Ipsilateral Internal Mammary
Nodes In The Absence Of Clinically
Evident Lymph Node Metastasis (N2)
Metastasis In Ipsilateral Axillary Lymph
Nodes Fixed To One Another (matted) Or
To Other Structures (N2a)
Metastasis Only In Clinically Apparent*
Ipsilateral Internal Mammary Nodes And
In The Absence Of Clinically Evident
Axillary Lymph Node Metastasis (N2b)
Metastasis In Ipsilateral Infraclavicular
Lymph Node(s) With Or Without Axillary
Lymph Node Involvement, Or In Clinically
Apparent* Ipsilateral Internal Mammary
Lymph Node(s) And In The Presence Of
Clinically Evident Axillary Lymph Node
Metastasis; Or, Me (N3)
Metastasis In Ipsilateral Infraclavicular
Lymph Node(s) With Or Without Axillary
Lymph Node Involvement, Or In Clinically
Apparent* Ipsilateral Internal Mammary
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Lymph Node(s) And In The Presence Of
Clinically Evident Axillary Lymph Node
Metastasis; Or, Me (N3a)
Metastasis In Ipsilateral Internal
Mammary Lymph Node(s) And Axillary
Lymph Node(s) (N3b)
Metastasis In Ipsilateral Supraclavicular
Lymph Node(s) (N3c)
Regional Lymph Nodes Cannot Be
Assessed (e.g., Previously Removed)
(NX)
Clinical M Stage
No Distant Metastasis (M0)
Distant Metastasis (M1)
Distant Metastasis Cannot Be Assessed
(MX)
Comments
ANC
Peripheral Platelet Count
Left Ventricular Ejection Fraction at Rest (%)
Bilirubin
Bilirubin ULN
SGPT (UL)
SGPT (ALT) ULN (UL)
SGOT (UL)
SGOT (AST) ULN (UL)
Required Laboratory Values
Comments
Footer Module
Completed by (Last name, First name)
Date Form Completed (MM DD YYYY)
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CALGB: 80405 ON-STUDY FORM
NCT00265850
CALGB: 80405 ON-STUDY FORM NCT00265850
Cetuximab and/or Bevacizumab Combined With
Combination Chemotherapy in Treating Patients With
Metastatic Colorectal Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=F39D0458-
B14A-5DB0-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/10839
CALGB: 80405 ON-STUDY FORM
NCT00265850
Header
CALGB Form
CALGB Study No
CALGB Patient ID
Start date of first treatment
Are data amended
Yes
No
Patient demographics
Patient Initials
Patient Hospital No
Institution/Affiliate
Participating Group
Participating Group Study No.
Participating Group Patient ID
Patient Description
Date of original diagnosis of colorectal cancer
(MM DD YYYY)
MedDRA Code (disease)
Has the patient had any prior cancer diagnosed?
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(other than colorectal?)
Yes
No
Type of Prior Cancer (If Yes,)
Prior Cancer Diagnosis Date (year YYYY)
SWOG Patient ID (from SWOG SpecTrak
System)
Lab Data At Protocol Entry
Peripheral WBC Count
Absolute neutrophil count
Peripheral Neutrophils (%)
Hemoglobin
Peripheral platelet count
Bilirubin
Magnesium
SGOT
SGOT (AST) ULN
Creatinine
Creatinine ULN
Albumin
Lactate Dehydrogenase (LDH)
Urinalysis result (Mark one with an X)
0 (0)
1+ (1+)
2+ (2+)
3+ (3+)
4+ (4+)
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Protein from 24 hour urine collection (for patients
who have > 2+ proteinuria)
Disease description (Mark one with an X)
Locally Advanced (Locally advanced)
Metastatic (Metastatic)
Currently involved sites of disease (Mark all that
apply with an X.)
Bone (Bone)
Cns/brain (CNS/Brain)
Intra-abdominal (Intra-abdominal)
Liver (Liver)
Lung (Lung)
Other (Other)
Primary Site Or Tumor Bed (Primary site
or tumor bed)
Intent of treatment (Mark one with an X.)
Neoadjuvant Chemotherapy With The
Potential For Resection Of All Sites Of
Metastatic Disease (Neoadjuvant
chemotherapy with the potential for
resection of all sites of metastatic
disease)
Palliative (Palliative)
For Patients Who Consented To The
Correlative Sciences Companion Study
Specimen collected time (Serum)
Number of hours between last meal and blood
collection
Prior Therapy Data
Date of last surgical resection for colorectal
cancer (If applicable, submit operative and
pathology reports.)
Prior Systemic Chemotherapy
Yes
No
specify agents (If Yes, Mark one with an X.)
5fu Based Therapy (5FU based therapy)
Bevacizumab (Bevacizumab)
Cetuximab (Cetuximab)
Irinotecan (Irinotecan)
Other (Other)
Oxaliplatin (Oxaliplatin)
Other, specify
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Prior Chemotherapy Begin Date
Prior Chemotherapy End Date
Prior chemotherapy for advanced or metastatic
colorectal cancer
Yes
No
Prior radiation therapy (with or without
radiosensitizing chemotherapy)
Yes
No
RT begin date
RT End Date
Patient receiving full-dose anticoagulants
Yes
No
is the patient receiving a stable dose of warfarin
and has an in-range INR or receiving a stable
dose of heparin (If yes,)
Yes
No
Arterial thrombotic event risk factors (Mark all
that apply with an X.)
Diabetes (Diabetes)
History Of Hyperlipidemia (History of
hyperlipidemia)
History Of Hypertension (History of
hypertension)
History Of Smoking (History of smoking)
No Risk Factors (No risk factors)
Peripheral Vascular Disease (Peripheral
vascular disease)
Prior Arterial Thrombotic Event (Prior
arterial thrombotic event)
Prior Coronary Artery Disease (Prior
coronary artery disease)
Prior ATE code
Cardiac Stenting/angioplasty (Cardiac
stenting/angioplasty)
Cva (CVA)
Mi (MI)
Other (Other)
Tia (TIA)
Unstable Angina (Unstable angina)
Other, specify
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Prior ATE onset date (of most recent events)
Does patient have history of significant bleeding
episodes
Yes
No
Specify type
Date (MM DD YYYY)
Does patient have history of GI perforation
Yes
No
Specify date of onset (MM DD YYYY)
Completed by
Date Form Originally Completed (MM DD YYYY)
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SOUTHWEST ONCOLOGY GROUP FOLLOW-UP
TUMOR ASSESSMENT FORM (S0303) NCT00070122
SOUTHWEST ONCOLOGY GROUP FOLLOW-UP
TUMOR ASSESSMENT FORM (S0303) NCT00070122
Combination Chemotherapy and Bevacizumab in Treating
Patients With Locally Advanced, Metastatic, or Recurrent
Colorectal Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=D9879314-
F0D0-1EFA-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/10840
SOUTHWEST ONCOLOGY GROUP
FOLLOW-UP TUMOR
ASSESSMENT FORM (S0303)
NCT00070122
Header
SWOG Patient ID
SWOG Study No.
Registration Step
Patient Initials (L, F M)
Date Form Completed
Institution/Affiliate
Physician (Participating Group)
Group Name
Study No.
Pt. ID
Registration Step
Target lesion
Target Lesions
Longest Diameter (cm)
Assessment Type (*)
Assessment Date
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Non-target disease
Non-Target Disease
Extent
Clear Increase (Clear increase)
Complete Disappearance (Complete
disappearance)
Not Assessed (Not assessed)
Present (Present)
New lesions
New Lesions (Specify Site)
Symptomatic deterioration
No (No)
Yes (Yes, describe in comments)
Comments
Comments
2 / 2
SOUTHWEST ONCOLOGY GROUP FOLLOW-UP TUMOR
ASSESSMENT FORM (S0303) NCT00070122
Southwest Oncology Group FACT-C TOI
S0303 (Version 4) NCT00070122
Southwest Oncology Group FACT-C TOI S0303 (Version 4)
NCT00070122
Combination Chemotherapy and Bevacizumab in Treating
Patients With Locally Advanced, Metastatic, or Recurrent
Colorectal Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=BC722FCC-
6316-417A-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/10841
Southwest Oncology Group FACT-C
TOI S0303 (Version 4)
NCT00070122
SWOG clinical trial administrative data
SWOG Patient ID
SWOG Study No.
Assessment
Prestudy (Prestudy)
Week 13 (Week 13)
Week 7 (Week 7)
Registration Step
Patient Initials (L, F M)
Institution/Affiliate
Physician
Group Name
Study No.
Pt. ID (Physical Well-Being)
I have a lack of energy
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have nausea
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
Because of my phyical condition, I have trouble
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meeting the needs of my family
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have pain
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am bothered by side effects of treatment
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I feel ill
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am forced to spend time in bed (Functional
Well-Being)
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am able to work (include work at home)
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
My work (include work at home) is fulfilling
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am able to enjoy life
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have accepted my illness
A Little Bit (A little bit)
Not At All (Not at all)
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Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am enjoying things I usually do for fun
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am content with the quality of my life right now
(Additional Concerns)
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have swelling or cramps in my stomach area
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am losing weight
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have control of my bowels
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I can digest my food well
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have diarrhea
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have a good appetite
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
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I like the appearance of my body
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
Do you have an ostomy appliance?
No (Not at all)
Yes (yes)
I am embarrassed by my ostomy appliance
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
Caring for my ostomy appliance is difficult
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
Ccrr Module For Southwest Oncology
Group Fact-c Toi S0303 (version 4)
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SOUTHWEST ONCOLOGY GROUP BASELINE
TUMOR ASSESSMENT FORM (S0303) NCT00070122
SOUTHWEST ONCOLOGY GROUP BASELINE TUMOR
ASSESSMENT FORM (S0303) NCT00070122
Combination Chemotherapy and Bevacizumab in Treating
Patients With Locally Advanced, Metastatic, or Recurrent
Colorectal Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=D987428E-
4DF8-08E0-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/10842
SOUTHWEST ONCOLOGY GROUP
BASELINE TUMOR ASSESSMENT
FORM (S0303) NCT00070122
Header
SWOG Patient ID
SWOG Study No.
Registration Step
Patient Initials (L, F M)
Institution/Affiliate
Physician (Participating Group)
Group Name
Study No.
Pt. ID
Evaluation of lesions
Target Lesions
Longest Diameter (cm)
Assessment Type (*)
Assessment Date
Non-Target Disease
Exent
Tests/studies
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Comments
Comments
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Southwest Oncology Group Follow-Up
Tumor Assessment Form NCT00499369
Southwest Oncology Group Follow-Up Tumor Assessment
Form NCT00499369
Irinotecan and Cetuximab With or Without Bevacizumab in
Treating Patients With Metastatic Colorectal Cancer That
Progressed During First-Line Therapy
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=15409265-
EDEB-6C7E-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/10843
Southwest Oncology Group Follow-
Up Tumor Assessment Form
NCT00499369
Header
SWOG Patient ID
SWOG Study No.
Registration Step
Patient Initials (L, F M)
Date form completed
Institution/Affiliate
Physician
Participating Group Name
Participating Group Study No.
Participating Group Patient ID
Target Lesions
Target Lesions
Longest Diameter (cm)
Assessment Type (*)
Colposcopy (Colposcopy)
Ct Scan (CT scan)
Cystoscopy (Cystoscopy)
Cytologic Confirmation (Cytologic
confirmation)
Endoscopy (Endoscopy)
Histologic (Histologic confirmation)
Mri Scan (MRI scan)
Other (Other)
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Palpation (Palpation)
Pet Scan (PET scan)
Plain Film/x-ray With Contrast (Plain
film/X-ray with contrast)
Plain Film/x-ray Without Contrast (Plain
film/X-ray without contrast)
Radioisotope Scan (Radioisotope scan)
Spiral Ct Scan (Spiral CT scan)
Ultrasound (Ultrasound)
Visualization (Visualization)
Assessment Date
Non-target Disease
Non-Target Disease
Extent
Clear Increase (Clear increase)
Complete Disappearance (Complete
disappearance)
Not Assessed (Not assessed)
Present (Present)
New Lesions (specify Site)
New Lesions (Specify Site)
Symptomatic deterioration
Yes
No
Comments
Comments
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Southwest Oncology Group Baseline Tumor
Assessment Form (S0600) NCT00499369
Southwest Oncology Group Baseline Tumor Assessment
Form (S0600) NCT00499369
Irinotecan and Cetuximab With or Without Bevacizumab in
Treating Patients With Metastatic Colorectal Cancer That
Progressed During First-Line Therapy
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=15416480-
960A-679D-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/10844
Southwest Oncology Group Baseline
Tumor Assessment Form (S0600)
NCT00499369
Header
SWOG Patient ID
SWOG Study No.
Registration Step
Patient Initials (L, F M)
Institution/Affiliate
Physician (Participating Group)
Group Name
Study No.
Pt. ID
Evaluation of lesions
Target Lesions
Assessment Date
Assessment Date
Longest Diameter (cm)
Assessment Type (*)
Assessment Type (*)
Non-Target Disease
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Exent
Diagnostic tests
Tests/studies
Assessment Date
Comments
Comments
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Southwest Oncology Group Baseline Tumor Assessment Form (S0600)
NCT00499369
E2902 On-Study Form - Form 2050
NCT00093470
E2902 On-Study Form - Form 2050 NCT00093470 
Tipifarnib in Treating Patients With Acute Myeloid Leukemia
in Remission
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=DBF6D3B9-
09FD-06C3-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/10845
E2902 On-Study Form - Form 2050
NCT00093470
Header
ECOG Protocol Number
ECOG Patient ID
DCI Name
Registration Step
Report Period (Place ID Label Here)
Baseline (Baseline)
Patient Initials
Participating Group Protocol Number
Participating Group Patient ID
Institution/Affiliate
Are data amended
Yes
No
Evaluation of Disease/Cancer
Date of Initial Pathologic Diagnosis
Leukemia Classification
Disease Classified As Acute
Erythroblastic Leukemia (fab M6) (Acute
erythroblastic leukemia (FAB M6))
Disease Classified As Acute
Megakaryoblastic Leukemia (fab M7)
(Acute megakaryoblastic leukemia (FAB
M7))
Disease Classified As Acute Monocytic
Leukemia (fab M5) (Acute monocytic
leukemia (FAB M5))
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Disease Classified As Acute Myeloid
Leukemia W/ Maturation (fab M2) (Acute
myeloid leukemia w/ maturation (FAB
M2))
Disease Classified As Acute Myeloid
Leukemia W/o Maturation (fab M1)
(Acute myeloid leukemia w/o maturation
(FAB M1))
Disease Classified As Acute
Myelomonocytic Leukemia (fab M4)
(Acute myelomonocytic leukemia (FAB
M4))
Disease Classified As Acute
Promyelocytic Leukemia (fab M3) (Acute
promyelocytic leukemia (FAB M3))
Disease Classified As Acute
Undifferentiated Leukemia (aul) (Acute
undifferentiated leukemia (AUL))
Disease Classified As Aml, Not
Otherwise Specified (nos) (AML, not
otherwise specified (NOS))
Disease Is A Mixed Lineage Acute
Leukemia (Mixed lineage acute
leukemia)
Other (Other)
Disease Classified As Refractory Anemia
W/ Excess Blasts In Transformation
(raeb-t) (Refractory anemia with excess
blasts in transformation (RAEB-T))
Disease Is An Unclassifiable Acute
Leukemia (Unclassifiable acute
leukemia)
Disease Classified As Undifferentiated
Acute Myeloid Leukemia (fab M0)
(Undifferentiated acute myeloid leukemia
(FAB M0))
Other, specify
CNS
Yes
No
Peripheral Nervous System
Yes
No
Gingival Hypertrophy
Yes
No
Mediastinal Mass
Yes
No
Skin (cutaneous)
Yes
No
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Other
Yes
No
Total number of complete remissions (including
current)
Current Remission
Complete response (CR) first observed date (for
current CR See section 3.5.1 of the protocol for
definitions.)
Type of post remission therapy
Allogeneic Transplant (allogeneic
transplant)
Autologous Transplant (autologous
transplant)
Chemotherapy (chemotherapy)
None (none)
date chemotherapy ended (If post remission
chemotherapy:)
Current Cr Confirmation
Date Hematology (Blood) Sample Obtained
Peripheral WBC count (/mm3 x1000)
Peripheral Blast Count (%)
Peripheral Neutrophils (%)
Hemoglobin (g/dl)
Peripheral platelet count (/mm3 x1000)
Bone Marrow Biopsy/aspirate
Bone marrow biopsy date (most recent prior to
registration)
Marrow Cellularity (%)
Marrow Blasts (%)
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Marrow Cellularity Status
Cellularity Status Of Bone Marrow Is
Aplasitc (severely Hypocellular) (aplastic
(severely hypocellular))
Cellularity Status Of Bone Marrow
Unknown, Procedure Resulted In No
Material To Analyze (dry tap or
inaspirable)
Cellularity Status Of Bone Marrow Is
Hypercellular (hypercellular)
Cellularity Status Of Bone Marrow Is
Hypocellular (hypocellular)
Cellularity Status Of Bone Marrow Is
Normocellular (normocellular)
Cellularity Status Of Bone Marrow Is
Packed (intensely Hypercellular) (packed
(intensely hypercellular))
At Any Time
Has the patient had a prior autologous
transplant?
Yes
No
date of transplant (If yes:)
Has the patient had a prior allo transplant?
Yes
No
Current Performance Status
Performance status (ECC use only)
Fully Active, Able To Carry On All Pre-
disease Performance Without Restriction
(karnofsky 90 - 100) (ecog - 0
Asymptomatic) (0)
Restricted In Physically Strenuous
Activity But Ambulatory (k70 - 80) (ecog -
1 Symptomatic - Fully Ambulatory) (1)
Ambulatory And Capable Of All Selfcare
But Unable To Carry Out Any Work
Activities (k 50 - 60) (ecog - 2
Symptomatic; In Bed , 50% Of The Day)
(2)
Capable Of Limited Selfcare, Confined
To Bed Or Chair More Than 50% Of
Waking Hours. (k 30 - 40) (ecog - 3
Symptomatic; In Bed > 50% Of The Day
But Not Bedridden) (3)
Completely Disabled (k10 - 20) (ecog - 4
Bedridden) (4)
Baseline Abnormalities
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CTC Adverse Event Term Type (include subterm
if applicable Use CTCAE v3 terminology)
CTC Adverse Event Grade (Use grade 1-4 per
CTCAE v3)
Comments
Comments
Investigator Signature
Investigator Signature Date
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S0502 Baseline Tumor Assessment
Form NCT00324987
Header
SWOG Patient ID
SWOG Study No.
Registration Step
Patient Initials (L, F M)
Institution/Affiliate
Physician (Participating Group)
Participating Group Name
Participating Group Study No.
Participating Group Patient ID
Evaluation of lesions
Target Lesions
Longest Diameter (cm)
Assessment Date
Assessment Date
Assessment Type (*)
Colposcopy (Colposcopy)
Ct Scan (CT scan)
Cystoscopy (Cystoscopy)
Cytologic Confirmation (Cytologic
confirmation)
Endoscopy (Endoscopy)
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Histologic (Histologic confirmation)
Mri Scan (MRI scan)
Other (Other)
Palpation (Palpation)
Pet Scan (PET scan)
Plain Film/x-ray With Contrast (Plain
film/X-ray with contrast)
Plain Film/x-ray Without Contrast (Plain
film/X-ray without contrast)
Radioisotope Scan (Radioisotope scan)
Spiral Ct Scan (Spiral CT scan)
Ultrasound (Ultrasound)
Visualization (Visualization)
Assessment Type (*)
Colposcopy (Colposcopy)
Ct Scan (CT scan)
Cystoscopy (Cystoscopy)
Cytologic Confirmation (Cytologic
confirmation)
Endoscopy (Endoscopy)
Histologic (Histologic confirmation)
Mri Scan (MRI scan)
Other (Other)
Palpation (Palpation)
Pet Scan (PET scan)
Plain Film/x-ray With Contrast (Plain
film/X-ray with contrast)
Plain Film/x-ray Without Contrast (Plain
film/X-ray without contrast)
Radioisotope Scan (Radioisotope scan)
Spiral Ct Scan (Spiral CT scan)
Ultrasound (Ultrasound)
Visualization (Visualization)
Non-target disease
Extent
Diagnostic tests
Tests/studies
Assessment Date
Comments
Comments
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S0502 Imatinib Mesylate With or Without Bevacizumab in
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Gastrointestinal Stromal Tumor
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Header
SWOG Patient ID
SWOG Study No.
Registration Step
Patient Initials (L, F M)
Institution/Affiliate
Physician
Participating Group Name
Participating Group Study No.
Participating Group Patient ID
Off-protocol treatment
Was any off-protocol therapy given after
completion of protocol treatment
No (No)
Unknown (Unknown)
Yes (Yes)
Was treatment given at the same site where
protocol therapy was given?
No (No)
Unknown (Unknown)
Yes (Yes)
Select type (If yes, select all that apply - values
differ from CRF submitted see instructions for
values)
Chemotherapy With Other Agent
(Chemotherapy with other agent)
Chemotherapy With Protocol Agent
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(Chemotherapy with protocol-specified
agent)
Other Therapy (Other procedure)
Radiation Therapy (RT)
Surgery (Surgery)
Specify
Comments
Comments
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CALGB-10501 Two Month Post First
Treatment Restaging Form NCT00513747
CALGB-10501 Two Month Post First Treatment Restaging
Form NCT00513747 
Early or Delayed Fludarabine and Rituximab in Treating
Patients With Previously Untreated Chronic Lymphocytic
Leukemia
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=3410113C-
154F-25BC-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/10848
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Treatment Restaging Form
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Header
CALGB Form
CALGB Study No
CALGB Patient ID
Are data amended
Yes
No
Patient demographics
Patient Initials (Last, First Middle)
Patient Hospital No.
Institution/Affiliate
Participating Group
Participating Group Study No
Participating Group Patient ID
Blood test results
Peripheral WBC Count (x 1000/uL)
Absolute Neutrophil Count (x 1000/uL)
Hemoglobin (g/dL)
IgG (mg/dL)
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IgA (mg/dL)
IgM (mg/dL)
Peripheral Platelet Count (x 1000/uL)
Beta-2 Microglobulin (mcg/ml)
Beta-2 Microglobulin ULN (mcg/ml)
assessment of
splenomegaly/hepatomegaly
Palpable splenomegaly
Yes
No
Palpable hepatomegaly
Yes
No
Coomb's Data
Coomb's Test (Mark one with an X.)
Coomb's Test Performed And Negative
Result (Negative)
Coomb's Test Performed And Positive
Result (Positive)
Coomb's Indirect Test (Mark one with an X.)
Coomb's Test Performed And Negative
Result (Negative)
Coomb's Test Performed And Positive
Result (Positive)
Coomb's Test Date (MM DD YYYY)
Overall Response
Completed by (print or type name)
Date Form Completed (MM DD YYYY)
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Header
SWOG Patient ID
SWOG Study No.
Registration Step
Patient Initials (L, F M)
Date form completed
Institution/Affiliate
Physician
Participating Group Name
Participating Group Study No.
Participating Group Patient ID
Target Lesions
Lesion Number
Target Lesions
Assessment Type (*)
Colposcopy (Colposcopy)
Ct Scan (CT scan)
Cystoscopy (Cystoscopy)
Cytologic Confirmation (Cytologic
confirmation)
Endoscopy (Endoscopy)
Histologic (Histologic confirmation)
Mri Scan (MRI scan)
Other (Other)
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Palpation (Palpation)
Pet Scan (PET scan)
Plain Film/x-ray With Contrast (Plain
film/X-ray with contrast)
Plain Film/x-ray Without Contrast (Plain
film/X-ray without contrast)
Radioisotope Scan (Radioisotope scan)
Spiral Ct Scan (Spiral CT scan)
Ultrasound (Ultrasound)
Visualization (Visualization)
Longest Diameter (cm)
Attenuation code
Lesion Does Demonstrate Uniform
Hypoattenuation In More Than 90% Of
Maximal Section Area (Lesion
demonstrates uniform hypoattenuation in
more than 90% of maximal section area)
Lesion Does Not Demonstrate Uniform
Hypoattenuation In More Than 90% Of
Maximal Section Area (Lesion does not
demonstrate uniform hypoattenuation in
more than 90% of maximal section area)
Other (Other)
Assessment Date
Non-target Disease
Lesion Number
Non-Target Disease
Assessment Type (*)
Colposcopy (Colposcopy)
Ct Scan (CT scan)
Cystoscopy (Cystoscopy)
Cytologic Confirmation (Cytologic
confirmation)
Endoscopy (Endoscopy)
Histologic (Histologic confirmation)
Mri Scan (MRI scan)
Other (Other)
Palpation (Palpation)
Pet Scan (PET scan)
Plain Film/x-ray With Contrast (Plain
film/X-ray with contrast)
Plain Film/x-ray Without Contrast (Plain
film/X-ray without contrast)
Radioisotope Scan (Radioisotope scan)
Spiral Ct Scan (Spiral CT scan)
Ultrasound (Ultrasound)
Visualization (Visualization)
Extent
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Clear Increase (Clear increase)
Complete Disappearance (Complete
disappearance)
Not Assessed (Not assessed)
Present (Present)
Assessment Date
Non-target Disease
Lymph Node Number
Intranodal recurrence
Assessment Type (*)
Colposcopy (Colposcopy)
Ct Scan (CT scan)
Cystoscopy (Cystoscopy)
Cytologic Confirmation (Cytologic
confirmation)
Endoscopy (Endoscopy)
Histologic (Histologic confirmation)
Mri Scan (MRI scan)
Other (Other)
Palpation (Palpation)
Pet Scan (PET scan)
Plain Film/x-ray With Contrast (Plain
film/X-ray with contrast)
Plain Film/x-ray Without Contrast (Plain
film/X-ray without contrast)
Radioisotope Scan (Radioisotope scan)
Spiral Ct Scan (Spiral CT scan)
Ultrasound (Ultrasound)
Visualization (Visualization)
Assessment Date
Recurrence code
Other (Other)
Target Lesion Previously Uniformly
Hypoattenuating And Now Demonstrates
<=1 Cm Hypoattenuating Region Which
Is Round Or Oval And Forms Acute
Margins With Border Of Target Lesion
(Target lesion previously uniformly
hypoattenuating and now demonstrates
<=1 cm hypoattenuating region which is
round or oval and forms acute margins
with border of target lesion)
Target Lesion Previously Uniformly
Hypoattenuating And Now Demonstrates
Hypoattenuating Region Which Is >1 Cm
In Longest Diameter And Is Located
Within Margins Of Target Lesion (Target
lesion previously uniformly
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hypoattenuating and now demonstrates
hypoattenuating region which is >1 cm in
longest diameter and is located within
margins of target lesion)
New Lesions (specify Site)
New Lesions (Specify Site)
Assessment Type (*)
Colposcopy (Colposcopy)
Ct Scan (CT scan)
Cystoscopy (Cystoscopy)
Cytologic Confirmation (Cytologic
confirmation)
Endoscopy (Endoscopy)
Histologic (Histologic confirmation)
Mri Scan (MRI scan)
Other (Other)
Palpation (Palpation)
Pet Scan (PET scan)
Plain Film/x-ray With Contrast (Plain
film/X-ray with contrast)
Plain Film/x-ray Without Contrast (Plain
film/X-ray without contrast)
Radioisotope Scan (Radioisotope scan)
Spiral Ct Scan (Spiral CT scan)
Ultrasound (Ultrasound)
Visualization (Visualization)
Attenuation code
Lesion Does Demonstrate Uniform
Hypoattenuation In More Than 90% Of
Maximal Section Area (Lesion
demonstrates uniform hypoattenuation in
more than 90% of maximal section area)
Lesion Does Not Demonstrate Uniform
Hypoattenuation In More Than 90% Of
Maximal Section Area (Lesion does not
demonstrate uniform hypoattenuation in
more than 90% of maximal section area)
Other (Other)
Assessment Date
Symptomatic deterioration
Symptomatic deterioration
Yes
No
Assessment Date
Comments
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Comments
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CGV
CGV
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
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CGV
Header module
Segment
Start of assessment period
End of assessment period
Visit Number
Answer Questions 3-8 Relating To Acute
Gvhd
Record method used to diagnose acute GVHD
Both (Both)
Clinical Evidence (Clinical Evidence)
Histologic Evidence (Histologic
Evidence)
Was prophylaxis for GVHD given during this
assessment period
Yes
No
Maximum overall grade of acute GVHD during
this assessment period
1 (I)
2 (II)
3 (III)
4 (IV)
0 (No symptoms of acute GVHD)
Did clinical signs and/or symptoms of acute
GVHD develop during this assessment
Yes
No
Date of diagnosis of acute GVHD
If Yes, Specify All Immuno Suppressants
Used For Gvhd Prophylaxis
Tacrolimus
Yes
No
Sirolumis
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Yes
No
MMF
Yes
No
Prednisone
Yes
No
Other
Yes
No
If no, specify the date GVHD prophylaxis was
discontinued
Cyclosporine
Yes
No
Specify other agent used
Answer Questions 9-19 Relating To
Chronic Gvhd
Maximum overall severity of chronic GVHD
during this assessment period
Mild (Mild)
Moderate (Moderate)
No symptoms of chronic GVHD (No
symptoms of chronic GVHD)
Severe (Severe)
Maximum overall grade of chronic GVHD during
this assessment period
Did clinical signs and/or symptoms of
chronic GVHD develop during this
assessment (Did clinical signs and/or
symptoms of chronic GVHD develop
during this assessment)
Extensive (Extensive)
Limited (Limited)
No (No)
Yes (Yes)
Current Karnofsky/Lansky score
Moribund, Fatal Processes Progressing
Rapidly (10 (Moribund; Completely
disabled))
Normal, No Complaints, No Evidence Of
Disease (100 (Normal; No
Complaints/Fully Active))
Very Sick, Hospitalization Indicated.
Death Not Imminent (20 (Very
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sick/limited to very passive activity))
Severely Disabled, Hospitalization
Indicated. Death Not Imminent (30
(Severely disabled/needs assistance for
quiet play))
Disabled, Requires Special Care And
Assistance (40 (Disabled/Able to initiate
quiet activities))
Requires Considerable Assistance And
Frequent Medical Care (50 (Requires
considerable assistance/no active play))
Requires Occasional Assistance, But Is
Able To Care For Most Of His/her Needs
(60 (Requires occasional
assistance/minimal active play))
Cares For Self, Unable To Carry On
Normal Activity Or To Do Active Work
(70 (Unable to carry on normal
activity/less time spent in play))
Normal Activity With Effort; Some Signs
Or Symptoms Of Disease (80 (Normal
acitvity with efforts/restricted in
strenuous play))
Able To Carry On Normal Activity; Minor
Signs Or Symptoms Of Disease (90
(Normal activity/minor restriction in
strenuous play))
Current platelet count
Record method used to diagnose chronic GVHD
Both (Both)
Clinical (Clinical Evidence)
Histology (Histologic Evidence)
Date of diagnosis of chronic GVHD
Current weight
Alkaline phosphatase at time of diagnosis
Total bilirubin at time of diagnosis
Body surface area involved with rash at time of
diagnosis
Indicate The Maximum Severity Of
Involvement For The Following Organ
Systems During This Assessment Period
Extent of skin involvement
<25% of BSA involvement (<25% of BSA
involvement)
>50% of BSA involvement (>50% of BSA
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involvement)
25-50% of BSA involvement (25-50% of
BSA involvement)
Generalized involvement (Generalized
involvement)
No Rash (No Rash)
Esophagus
Dysphagia or odynophagia requiring
dietary changes (Dysphagia or
odynophagia requiring dietary changes)
Need for parenteral nutrition (Need for
parenteral nutrition)
No changes (No changes)
Symptomatic but can ear regular diet
(Symptomatic but can ear regular diet)
Was there other organ involvement
Answer one of the next two questions
Diarrhea (number of stools)
Death (Death)
Increase of <4 stools/day over baseline;
mild increase in ostomy output compared
to baseline (Increase of <4 stools/day
over baseline; mild increase in ostomy
output compared to baseline)
Increase of 4-6 stools;IV fluids indicated
<24 hrs;moderate increase in ostomy
output (Increase of 4-6 stools;IV fluids
indicated <24 hrs;moderate increase in
ostomy output)
Increase of 7 or more stools/day, IV
fluids indicated <24 hrs;moderate
increase in ostomy output (Increase of 7
or more stools/day, IV fluids indicated
<24 hrs;moderate increase in ostomy
output)
Life-threatening consequences (e.g.,
hemodynamic collapse) (Life-threatening
consequences (e.g., hemodynamic
collapse))
Diarrhea (volume of stools)
Diarrhea >1000 but less than or equal to
1500 mL/day or 556-833 mL/m^2
(Diarrhea >1000 but less than or equal to
1500 mL/day or 556-833 mL/m^2)
Diarrhea >1500 mL/day or >833 mL/m^2
(Diarrhea >1500 mL/day or >833
mL/m^2)
Diarrhea >500 but less than or equal to
1000 mL/day or 280-555 mL/m^2
(Diarrhea >500 but less than or equal to
1000 mL/day or 280-555 mL/m^2)
Diarrhea less than or equal to 500
mL/day or <280 mL/m^s (Diarrhea less
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than or equal to 500 mL/day or <280
mL/m^s)
Severe abdominal pain with or without
ileus, stool with frank blood or melena
(Severe abdominal pain with or without
ileus, stool with frank blood or melena)
Fascitis
Yes
No
Serositis
Yes
No
Eosinophilia
Yes
No
Contractures
Mild joint contractures (does not affect
ADL) (Mild joint contractures (does not
affect ADL))
No symptoms (No symptoms)
Severe joint contractures (intereferes
with ADL) (Severe joint contractures
(intereferes with ADL))
Xerophthalmia
Minimal symptoms, normal diet (Minimal
symptoms, normal diet)
No symptoms (No symptoms)
Symptomatic and unable to adequately
aliment or hydrate orally (Symptomatic
and unable to adequately aliment or
hydrate orally)
Symptomatic but can eat and swallow
modified diet (Symptomatic but can eat
and swallow modified diet)
Bronchiolitis obliterans
No (No)
Unknown (Unknown)
Yes, clinical diagnosis (Yes, clinical
diagnosis)
Yes, histologic diagnosis (Yes, histologic
diagnosis)
If there is skin involvement, indicate the type of
rash
Lichenoid
Yes
No
Sclerodermatous
Yes
No
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Maculpapular
Yes
No
Dyspnea
Pulmonary fibrosis
FEV1
Oxygen saturation
Nausea and vomiting
Diarrhea
Malabsorption
Bilirubin level
Vaginitis
Myositis
Yes
No
Specify other organ
Answer Questions 42-48 Related To
Biopsies Performed During This
Assessment Period
Type of biopsy
Liver biopsy (Liver biopsy)
Lower GI biopsy (Lower GI biopsy)
Lung biopse (Lung biopse)
Oral biopsy (Oral biopsy)
Skin biopsy (Skin biopsy)
Upper GI biopsy (Upper GI biopsy)
Were any biopsies performed during this
assessment period for suspected GVHD
Yes
No
Date of biopsy
Result of biopsy
Equivocal (Equivocal)
6 / 10
CGV
Negative (Negative)
Positive (Positive)
Answer Questions 49-52 Relating To Gvhd
Was a specific therapy used to treat GVHD
during this assessment period
No (No)
Yes, continuing from previous
assessment period (Yes, continuing from
previous assessment period)
Yes, initiated this assessment period
(Yes, initiated this assessment period)
If Yes, Indicate Whether Or Not The
Agents Listed Below Were Used To Treat
Gvhd During This Assessment Period
ALS, ALG, ATS, ATG
No, drug not given (No, drug not given)
Yes, no longer taking drug (Yes, no
longer taking drug)
Yes, still taking drug (Yes, still taking
drug)
Etretinate
No, drug not given (No, drug not given)
Yes, no longer taking drug (Yes, no
longer taking drug)
Yes, still taking drug (Yes, still taking
drug)
Lamprene
No, drug not given (No, drug not given)
Yes, no longer taking drug (Yes, no
longer taking drug)
Yes, still taking drug (Yes, still taking
drug)
Etanercept
No, drug not given (No, drug not given)
Yes, no longer taking drug (Yes, no
longer taking drug)
Yes, still taking drug (Yes, still taking
drug)
Zenapax
No, drug not given (No, drug not given)
Yes, no longer taking drug (Yes, no
longer taking drug)
Yes, still taking drug (Yes, still taking
drug)
Chloroquine phosphate
No, drug not given (No, drug not given)
Yes, no longer taking drug (Yes, no
longer taking drug)
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Yes, still taking drug (Yes, still taking
drug)
In vivo anti T-lymphocyte monoclonal antibody
No, drug not given (No, drug not given)
Yes, no longer taking drug (Yes, no
longer taking drug)
Yes, still taking drug (Yes, still taking
drug)
Specify in vivo anti T-lymphocyte monoclonal
antibody used
In vivo immunotoxin (In vivo
immunotoxin)
No, drug not given (No, drug not given)
Yes, no longer taking drug (Yes, no
longer taking drug)
Yes, still taking drug (Yes, still taking
drug)
Specify in vivo immunotoxin
Sirolumis
No, drug not given (No, drug not given)
Yes, no longer taking drug (Yes, no
longer taking drug)
Yes, still taking drug (Yes, still taking
drug)
ECP (Extra-corporeal photopheresis)
No, drug not given (No, drug not given)
Yes, no longer taking drug (Yes, no
longer taking drug)
Yes, still taking drug (Yes, still taking
drug)
Azathioprine
No, drug not given (No, drug not given)
Yes, no longer taking drug (Yes, no
longer taking drug)
Yes, still taking drug (Yes, still taking
drug)
Cyclosporine
No, drug not given (No, drug not given)
Yes, no longer taking drug (Yes, no
longer taking drug)
Yes, still taking drug (Yes, still taking
drug)
Systemic corticosteriods
No, drug not given (No, drug not given)
Yes, no longer taking drug (Yes, no
longer taking drug)
Yes, still taking drug (Yes, still taking
drug)
Topical corticosteroids
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No, drug not given (No, drug not given)
Yes, no longer taking drug (Yes, no
longer taking drug)
Yes, still taking drug (Yes, still taking
drug)
Thalidomide
No, drug not given (No, drug not given)
Yes, no longer taking drug (Yes, no
longer taking drug)
Yes, still taking drug (Yes, still taking
drug)
Tacrolimus
No, drug not given (No, drug not given)
Yes, no longer taking drug (Yes, no
longer taking drug)
Yes, still taking drug (Yes, still taking
drug)
Mycophenolate Mofetil
No, drug not given (No, drug not given)
Yes, no longer taking drug (Yes, no
longer taking drug)
Yes, still taking drug (Yes, still taking
drug)
PUVA (Psoralen and UVA)
No, drug not given (No, drug not given)
Yes, no longer taking drug (Yes, no
longer taking drug)
Yes, still taking drug (Yes, still taking
drug)
Indicate the best response to GVHD therapy
during this assessment period
Other
No (No, drug not given)
Yes, no longer taking drug (Yes, no
longer taking drug)
Yes (Yes, still taking drug)
Specify other agent used
Has treatment been discontinued
Yes
No
If yes, enter date of discontinuation
Answer Questions 53-56 Relating To
Current Patient Status
Are symptoms of GVHD still present
Yes
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No
Current Karnofsky/Lansky score
Moribund, Fatal Processes Progressing
Rapidly (10 (Moribund; Completely
disabled))
Normal, No Complaints, No Evidence Of
Disease (100 (Normal; No
Complaints/Fully Active))
Very Sick, Hospitalization Indicated.
Death Not Imminent (20 (Very
sick/limited to very passive activity))
Severely Disabled, Hospitalization
Indicated. Death Not Imminent (30
(Severely disabled/needs assistance for
quiet play))
Disabled, Requires Special Care And
Assistance (40 (Disabled/Able to initiate
quiet activities))
Requires Considerable Assistance And
Frequent Medical Care (50 (Requires
considerable assistance/no active play))
Requires Occasional Assistance, But Is
Able To Care For Most Of His/her Needs
(60 (Requires occasional
assistance/minimal active play))
Cares For Self, Unable To Carry On
Normal Activity Or To Do Active Work
(70 (Unable to carry on normal
activity/less time spent in play))
Normal Activity With Effort; Some Signs
Or Symptoms Of Disease (80 (Normal
acitvity with efforts/restricted in
strenuous play))
Able To Carry On Normal Activity; Minor
Signs Or Symptoms Of Disease (90
(Normal activity/minor restriction in
strenuous play))
Current platelet count
Current weight
Comments
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Treating Patients With Metastatic or Unresectable
Gastrointestinal Stromal Tumor
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Tomography (PET) Assessment
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Header
SWOG Patient ID
SWOG Study No.
Registration Step
Patient Initials (L, F M)
Institution/Affiliate
Physician
Participating Group Name
Participating Group Study No.
Participating Group Patient ID
Positron Emission Tomography (PET)
Assessment
Timepoint of PET
Prestudy (Prestudy)
Week 4 (Week 4)
Date of PET scan
Serum Glucose
Patient Weight (kg on Day of Scan)
Amount of FDG in Syringe Pre-Injection (mCi)
Amount of FDG in Syringe Post-Injection (mCi)
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Amount of FDG Injected (mCi)
Scan Start Time (HH:MM)
Injection Start Time (HH:MM)
Standard Uptake Value Max (max of index lesion)
Attenuation Type
Computed Tomography (CT)
Rod (Rod)
Length (minutes 3 minute minimum)
Comments
Comments
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CALGB: 10603 Peripheral Blood And Bone
Marrow Report Form NCT00651261
CALGB: 10603 Peripheral Blood And Bone Marrow Report
Form NCT00651261 
Daunorubicin, Cytarabine, and Midostaurin in Treating
Patients With Newly Diagnosed Acute Myeloid Leukemia
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CALGB: 10603 Peripheral Blood And
Bone Marrow Report Form
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Header
CALGB Form (C-1620)
CALGB Study No. (10603)
CALGB Patient ID
Date Hematology (Blood) Sample Obtained
Are data amended
Yes
No
Patient demographics
Patient Initials (Last, First Middle)
Patient Hospital No.
Institution/Affiliate
Participating Group
Participating Group Protocol Number
Participating Group Patient ID
Peripheral Blood
Date of Bone Marrow Aspirate
Hemoglobin (g/dL)
Peripheral Platelet Count (1000/ul)
1 / 3
Peripheral WBC Count (1000/ul)
Peripheral Neutrophils (%) (segs + bands
1000/ul)
Peripheral metamyelocytes
Peripheral myelocytes
Peripheral Promyelocytes (%)
Peripheral Blasts (%)
Peripheral Lymphocytes (%)
Peripheral Monocytes (%)
Peripheral monoblasts (%)
Peripheral Eosinophils (%)
Peripheral Basophils (%)
Bone Marrow
Marrow Cellularity (%)
Bone Marrow Differential
Marrow neutrophils (%)
Marrow metamyelocytes (%)
Marrow myelocytes (%)
Marrow Promyelocytes (%)
Marrow Blasts (%)
Marrow Lymphocytes (%)
Marrow monocytes (%)
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CALGB: 10603 Peripheral Blood And Bone Marrow Report Form
NCT00651261
Marrow monoblasts (%)
Marrow Eosinophils (%)
Marrow Basophils (%)
Marrow erythroid cells (%)
Marrow Plasma Cells (%)
Megakaryocyte status (Mark one with an X.)
Absent (Absent)
Decreased (Decreased)
Increased (Increased)
Normal (Normal)
Unknown (Unknown)
Degree Of Dyspoiesis Present
Myleopoiesis
Absent (Absent)
Marked (Marked)
Minimal (Minimal)
Moderate (Moderate)
Rare (Rare)
Erythropoiesis
Absent (Absent)
Marked (Marked)
Minimal (Minimal)
Moderate (Moderate)
Rare (Rare)
Megakaryopoiesis
Absent (Absent)
Marked (Marked)
Minimal (Minimal)
Moderate (Moderate)
Rare (Rare)
Are auer rods present?
Auer Rods Absent From Bone Marrow
(Absent)
Auer Rods Present In Bone Marrow
(Present)
Not done
Completed by
Date Form Completed
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CALGB: 10603 Peripheral Blood And Bone Marrow Report Form
NCT00651261
SOUTHWEST ONCOLOGY GROUP Post-Consolidation Eligibility
Form: Maintenance Chemotherapy (S0521) NCT00492856
SOUTHWEST ONCOLOGY GROUP Post-Consolidation
Eligibility Form: Maintenance Chemotherapy (S0521)
NCT00492856 
Combination Chemotherapy With or Without Gemtuzumab
Followed By Tretinoin, Mercaptopurine, and Methotrexate
or Observation in Treating Patients With Acute
Promyelocytic Leukemia
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=02DB0EF4-
F2F0-5AA4-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/10853
SOUTHWEST ONCOLOGY GROUP
Post-Consolidation Eligibility Form:
Maintenance Chemotherapy (S0521)
NCT00492856
Header
SWOG Patient ID
SWOG Study No.
Registration Step
Patient Initials (L, F M)
Institution/Affiliate
Physician (Participating Group:)
Participating Group Name
American College Of Surgeons
Oncology Group (ACOSOG)
American College Of Radiology
Oncologic Imaging Network (ACRIN)
Aids-associated Malignancies Clinical
Trials Consortium (AMC)
Cancer And Leukemia Group B (CALGB)
Children's Oncology Group (COG)
Eastern Cooperative Oncology Group
(ECOG)
European Organization For Research
And Treatment Of Cancer (EORTC)
Gynecologic Oncology Group (GOG)
International Breast Cancer Study Group
(IBCSG)
North American Brain Tumor Consortium
(NABTC)
Nabtt Brain Tumor Consortium (NABTT)
North Central Cancer Treatment Group
(NCCTG)
National Cancer Institute Of Canada
Clinical Trials Group (NCIC)
National Surgical Adjuvant Breast And
Bowel Project (NSABP)
Radiation Therapy Oncology Group
(RTOG)
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Southwest Oncology Group (SWOG)
Participating Group Study No.
Participating Group Patient ID
Post-Consolidation Eligibility Assessment
Date of most recent marrow specimen
documenting molecular complete remission
(CRm)
Was an RT-PCR result obtained from the marrow
specimen
Indeterminate (No, Indeterminate)
Yes (Yes)
RT-PCR value from the marrow specimen
(normalized quotient[NQ])
Date of most recent peripheral blood specimen
assessed for molecular complete remission
(CRm)
Was an RT-PCR result obtained from the blood
specimen
Indeterminate (No, Indeterminate)
Yes (Yes)
RT-PCR value from the blood specimen
(normalized quotient[NQ])
Performance Status
Fully Active, Able To Carry On All Pre-
disease Performance Without
Restriction. (0)
Restricted In Physically Strenuous
Activity But Ambulatory And Able To
Carry Out Work Of A Light Or Sedentary
Nature, E.g., Light Housework, Office
Work. (1)
Ambulatory And Capable Of All Selfcare
But Unable To Carry Out Any Work
Activities. Up And About More Than 50%
Of Waking Hours. (2)
Capable Of Only Limited Selfcare,
Confined To Bed Or Chair More Than
50% Of Waking Hours. (3)
Completely Disabled. Cannot Carry On
Any Selfcare. Totally Confined To Bed Or
Chair. (4)
Dead (5)
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SOUTHWEST ONCOLOGY GROUP Post-Consolidation Eligibility Form:
Maintenance Chemotherapy (S0521) NCT00492856
Comments
Comments
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SOUTHWEST ONCOLOGY GROUP Post-Consolidation Eligibility Form:
Maintenance Chemotherapy (S0521) NCT00492856
SOUTHWEST ONCOLOGY GROUP Consolidation
Eligibility Form (S0521) NCT00492856
SOUTHWEST ONCOLOGY GROUP Consolidation
Eligibility Form (S0521) NCT00492856 
Combination Chemotherapy With or Without Gemtuzumab
Followed By Tretinoin, Mercaptopurine, and Methotrexate
or Observation in Treating Patients With Acute
Promyelocytic Leukemia
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=02DF254B-
E5C6-4D39-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/10854
SOUTHWEST ONCOLOGY GROUP
Consolidation Eligibility Form
(S0521) NCT00492856
SWOG clinical trial administrative data
SWOG Patient ID
SWOG Study No.
Registration Step
Patient Initials (L, F M)
Institution/Affiliate
Physician (Participating Group:)
Participating Group Name
American College Of Surgeons
Oncology Group (ACOSOG)
American College Of Radiology
Oncologic Imaging Network (ACRIN)
Aids-associated Malignancies Clinical
Trials Consortium (AMC)
Cancer And Leukemia Group B (CALGB)
Children's Oncology Group (COG)
Eastern Cooperative Oncology Group
(ECOG)
European Organization For Research
And Treatment Of Cancer (EORTC)
Gynecologic Oncology Group (GOG)
International Breast Cancer Study Group
(IBCSG)
North American Brain Tumor Consortium
(NABTC)
Nabtt Brain Tumor Consortium (NABTT)
North Central Cancer Treatment Group
(NCCTG)
National Cancer Institute Of Canada
Clinical Trials Group (NCIC)
National Surgical Adjuvant Breast And
Bowel Project (NSABP)
Radiation Therapy Oncology Group
(RTOG)
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Southwest Oncology Group (SWOG)
Participating Group Study No.
Participating Group Patient ID
Performance status
Performance Status
Fully Active, Able To Carry On All Pre-
disease Performance Without
Restriction. (0)
Restricted In Physically Strenuous
Activity But Ambulatory And Able To
Carry Out Work Of A Light Or Sedentary
Nature, E.g., Light Housework, Office
Work. (1)
Ambulatory And Capable Of All Selfcare
But Unable To Carry Out Any Work
Activities. Up And About More Than 50%
Of Waking Hours. (2)
Capable Of Only Limited Selfcare,
Confined To Bed Or Chair More Than
50% Of Waking Hours. (3)
Completely Disabled. Cannot Carry On
Any Selfcare. Totally Confined To Bed Or
Chair. (4)
Dead (5)
Comments
Comments
2 / 2
SOUTHWEST ONCOLOGY GROUP Consolidation Eligibility Form
(S0521) NCT00492856
SOUTHWEST ONCOLOGY GROUP Post-Consolidation Eligibility
Form: Gemtuzumab Ozogamicin (S0521) NCT00492856
SOUTHWEST ONCOLOGY GROUP Post-Consolidation
Eligibility Form: Gemtuzumab Ozogamicin (S0521)
NCT00492856 
Combination Chemotherapy With or Without Gemtuzumab
Followed By Tretinoin, Mercaptopurine, and Methotrexate
or Observation in Treating Patients With Acute
Promyelocytic Leukemia
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=10156027-
BB31-03EC-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/10855
SOUTHWEST ONCOLOGY GROUP
Post-Consolidation Eligibility Form:
Gemtuzumab Ozogamicin (S0521)
NCT00492856
Header
SWOG Patient ID
SWOG Study No.
Registration Step
Patient Initials (L, F M)
Institution/Affiliate
Physician (Participating Group:)
Participating Group Name
American College Of Surgeons
Oncology Group (ACOSOG)
American College Of Radiology
Oncologic Imaging Network (ACRIN)
Aids-associated Malignancies Clinical
Trials Consortium (AMC)
Cancer And Leukemia Group B (CALGB)
Children's Oncology Group (COG)
Eastern Cooperative Oncology Group
(ECOG)
European Organization For Research
And Treatment Of Cancer (EORTC)
Gynecologic Oncology Group (GOG)
International Breast Cancer Study Group
(IBCSG)
North American Brain Tumor Consortium
(NABTC)
Nabtt Brain Tumor Consortium (NABTT)
North Central Cancer Treatment Group
(NCCTG)
National Cancer Institute Of Canada
Clinical Trials Group (NCIC)
National Surgical Adjuvant Breast And
Bowel Project (NSABP)
Radiation Therapy Oncology Group
(RTOG)
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Southwest Oncology Group (SWOG)
Participating Group Study No.
Participating Group Patient ID
Post-Consolidation Eligibility Assessment
Date of most recent marrow specimen
documenting molecular complete remission
(CRm)
Was an RT-PCR result obtained from the marrow
specimen
Indeterminate (No, Indeterminate)
Yes (Yes)
RT-PCR value from the marrow specimen
(normalized quotient[NQ])
Date of most recent peripheral blood specimen
assessed for molecular complete remission
(CRm)
Was an RT-PCR result obtained from the blood
specimen
Indeterminate (No, Indeterminate)
Yes (Yes)
RT-PCR value from the blood specimen
(normalized quotient[NQ])
Performance Status
Fully Active, Able To Carry On All Pre-
disease Performance Without
Restriction. (0)
Restricted In Physically Strenuous
Activity But Ambulatory And Able To
Carry Out Work Of A Light Or Sedentary
Nature, E.g., Light Housework, Office
Work. (1)
Ambulatory And Capable Of All Selfcare
But Unable To Carry Out Any Work
Activities. Up And About More Than 50%
Of Waking Hours. (2)
Capable Of Only Limited Selfcare,
Confined To Bed Or Chair More Than
50% Of Waking Hours. (3)
Completely Disabled. Cannot Carry On
Any Selfcare. Totally Confined To Bed Or
Chair. (4)
Dead (5)
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SOUTHWEST ONCOLOGY GROUP Post-Consolidation Eligibility Form:
Gemtuzumab Ozogamicin (S0521) NCT00492856
Comments
Comments
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SOUTHWEST ONCOLOGY GROUP Post-Consolidation Eligibility Form:
Gemtuzumab Ozogamicin (S0521) NCT00492856
SOUTHWEST ONCOLOGY GROUP FOLLOW-UP
TUMOR ASSESSMENT FORM NCT00045162
SOUTHWEST ONCOLOGY GROUP FOLLOW-UP
TUMOR ASSESSMENT FORM NCT00045162 
S0124: Cisplatin Combined With Either Irinotecan or
Etoposide in Treating Patients With Extensive-Stage Small
Cell Lung Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=001B724F-
E7F0-4714-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/10856
SOUTHWEST ONCOLOGY GROUP
FOLLOW-UP TUMOR
ASSESSMENT FORM
NCT00045162
Header
SWOG Patient ID
SWOG Study No.
Registration Step
Patient Initials (L, F M)
Date form completed
Institution/Affiliate
Physician
Participating Group Name
Participating Group Study No.
Participating Group Patient ID
Target Lesions
Target Lesions
Longest Diameter (cm)
Assessment Type (*)
Colposcopy (Colposcopy)
Ct Scan (CT scan)
Cystoscopy (Cystoscopy)
Cytologic Confirmation (Cytologic
confirmation)
Endoscopy (Endoscopy)
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Histologic (Histologic confirmation)
Mri Scan (MRI scan)
Other (Other)
Palpation (Palpation)
Pet Scan (PET scan)
Plain Film/x-ray With Contrast (Plain
film/X-ray with contrast)
Plain Film/x-ray Without Contrast (Plain
film/X-ray without contrast)
Radioisotope Scan (Radioisotope scan)
Spiral Ct Scan (Spiral CT scan)
Ultrasound (Ultrasound)
Visualization (Visualization)
Assessment Date
Non-target Disease
Non-Target Disease
Extent
Clear Increase (Clear increase)
Complete Disappearance (Complete
disappearance)
Not Assessed (Not assessed)
Present (Present)
Assessment Type (*)
Colposcopy (Colposcopy)
Ct Scan (CT scan)
Cystoscopy (Cystoscopy)
Cytologic Confirmation (Cytologic
confirmation)
Endoscopy (Endoscopy)
Histologic (Histologic confirmation)
Mri Scan (MRI scan)
Other (Other)
Palpation (Palpation)
Pet Scan (PET scan)
Plain Film/x-ray With Contrast (Plain
film/X-ray with contrast)
Plain Film/x-ray Without Contrast (Plain
film/X-ray without contrast)
Radioisotope Scan (Radioisotope scan)
Spiral Ct Scan (Spiral CT scan)
Ultrasound (Ultrasound)
Visualization (Visualization)
Assessment Date
New Lesions (specify Site)
New Lesions (Specify Site)
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SOUTHWEST ONCOLOGY GROUP FOLLOW-UP TUMOR
ASSESSMENT FORM NCT00045162
Assessment Type (*)
Colposcopy (Colposcopy)
Ct Scan (CT scan)
Cystoscopy (Cystoscopy)
Cytologic Confirmation (Cytologic
confirmation)
Endoscopy (Endoscopy)
Histologic (Histologic confirmation)
Mri Scan (MRI scan)
Other (Other)
Palpation (Palpation)
Pet Scan (PET scan)
Plain Film/x-ray With Contrast (Plain
film/X-ray with contrast)
Plain Film/x-ray Without Contrast (Plain
film/X-ray without contrast)
Radioisotope Scan (Radioisotope scan)
Spiral Ct Scan (Spiral CT scan)
Ultrasound (Ultrasound)
Visualization (Visualization)
Assessment Date
Symptomatic deterioration
Symptomatic deterioration
Yes
No
Assessment Date
Comments
Comments
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SOUTHWEST ONCOLOGY GROUP FOLLOW-UP TUMOR
ASSESSMENT FORM NCT00045162
SOUTHWEST ONCOLOGY GROUP LUNG CARCINOMA FIRST
SITE(S) OF PROGRESSION OR RELAPSE FORM NCT00045162
SOUTHWEST ONCOLOGY GROUP LUNG CARCINOMA
FIRST SITE(S) OF PROGRESSION OR RELAPSE FORM
NCT00045162 
S0124: Cisplatin Combined With Either Irinotecan or
Etoposide in Treating Patients With Extensive-Stage Small
Cell Lung Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=001AFD84-
A62B-538E-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/10857
SOUTHWEST ONCOLOGY GROUP
LUNG CARCINOMA FIRST SITE(S)
OF PROGRESSION OR RELAPSE
FORM NCT00045162
Header
SWOG Patient ID
SWOG Study No.
Registration Step
Patient Initials (L, F M)
Date form completed
Institution/Affiliate
Physician
Participating Group Name
Participating Group Study No.
Participating Group Patient ID
Comments
Comments
1 / 1
S0522 PBSC Collection Summary Form
S0522 PBSC Collection Summary Form
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=0F81963A-
A765-37CC-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/10858
S0522 PBSC Collection Summary
Form
Header
SWOG Patient ID
SWOG Study No.
Registration Step
Patient Initials (L, F, M)
Institution/Affiliate
Physician
Participating Group Name
Participating Group Study No.
Participating Group Patient ID
Disease Status
Date of Last Contact or Death
Vital Status
Alive (Alive)
Dead (Dead)
Urine M-protein
Agent Name (Cyclophosphamide G-CSF GM-
CSF)
Infusion start date
Dose given
Urine M-protein
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Agent Name (Cyclophosphamide G-CSF GM-
CSF)
Agent Start Date
Agent End Date
Total Daily Dose of Agent (or Drug)
Urine M-protein
Agent Name (Cyclophosphamide G-CSF GM-
CSF)
Agent Start Date
Agent End Date
Total Daily Dose of Agent (or Drug)
Dose Modification
Were there any dose modifications or
additions/omissions to protocol treatment?
No (No)
Yes, Planned (i.e., The Treatment Was
Changed According To Protocol
Guidelines) (Yes, planned)
Yes, Unplanned (i.e., The Treatment
Change Was Not Part Of Protocol
Guidelines) (Yes, unplanned)
Bone Marrow Plasmacytosis
Weight
BSA
Performance Status
Fully Active, Able To Carry On All Pre-
disease Performance Without
Restriction. (0)
Restricted In Physically Strenuous
Activity But Ambulatory And Able To
Carry Out Work Of A Light Or Sedentary
Nature, E.g., Light Housework, Office
Work. (1)
Ambulatory And Capable Of All Selfcare
But Unable To Carry Out Any Work
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S0522 PBSC Collection Summary Form
Activities. Up And About More Than 50%
Of Waking Hours. (2)
Capable Of Only Limited Selfcare,
Confined To Bed Or Chair More Than
50% Of Waking Hours. (3)
Completely Disabled. Cannot Carry On
Any Selfcare. Totally Confined To Bed Or
Chair. (4)
Dead (5)
Bone Disease And Anemia
Number of collections
Total CD34+ cells collected
Date of collections
Comments
Comments
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S0522 PBSC Collection Summary Form
Southwest Oncology Group - Osteonecrotic
Jaw Lesion Form (S0777) NCT00644228
Southwest Oncology Group - Osteonecrotic Jaw Lesion
Form (S0777) NCT00644228 
Lenalidomide and Dexamethasone With or Without
Bortezomib in Treating Patients With Previously Untreated
Multiple Myeloma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=33466841-
A648-3522-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/10859
Southwest Oncology Group -
Osteonecrotic Jaw Lesion Form
(S0777) NCT00644228
Header
SWOG Patient ID
SWOG Study No.
Registration Step
Patient Initials (L, F, M)
Institution/Affiliate
Physician
Participating Group Name
Participating Group Study No.
Participating Group Patient ID
osteonecrotic lesions
Number of osteonecrotic lesions
1 (1)
2 (2)
3 (3)
Date of onset
Any signs/symptoms of infection (e.g., mucosal
erythema, swelling, pus, bad taste?)
Yes
No
Lesion 1
Maxilla
Alveolar Ridge (Alveolar ridge)
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Anterior (Anterior)
Buccal (Buccal)
Lingual (Lingual)
Palate (Palate)
Posterior (Posterior)
Mandible
Alveolar Ridge (Alveolar ridge)
Anterior (Anterior)
Buccal (Buccal)
Lingual (Lingual)
Mylohyoid Plate (Mylohyoid plate)
Posterior (Posterior)
Size of lesion (mm)
Associated causative factor(s) (select all that
apply:)
Dental Extraction (Dental extraction)
Denture Trauma (Denture trauma)
No Identified Factor (No identified factor)
Other Dental Surgery (Other dental
surgery)
Periodontal Infection (Periodontal
infection)
Lesion 2
Maxilla
Alveolar Ridge (Alveolar ridge)
Anterior (Anterior)
Buccal (Buccal)
Lingual (Lingual)
Palate (Palate)
Posterior (Posterior)
Mandible
Alveolar Ridge (Alveolar ridge)
Anterior (Anterior)
Buccal (Buccal)
Lingual (Lingual)
Mylohyoid Plate (Mylohyoid plate)
Posterior (Posterior)
Size of lesion (mm)
Associated causative factor(s) (select all that
apply:)
Dental Extraction (Dental extraction)
Denture Trauma (Denture trauma)
No Identified Factor (No identified factor)
Other Dental Surgery (Other dental
surgery)
Periodontal Infection (Periodontal
infection)
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Southwest Oncology Group - Osteonecrotic Jaw Lesion Form (S0777)
NCT00644228
Lesion 3
Maxilla
Alveolar Ridge (Alveolar ridge)
Anterior (Anterior)
Buccal (Buccal)
Lingual (Lingual)
Palate (Palate)
Posterior (Posterior)
Mandible
Alveolar Ridge (Alveolar ridge)
Anterior (Anterior)
Buccal (Buccal)
Lingual (Lingual)
Mylohyoid Plate (Mylohyoid plate)
Posterior (Posterior)
Size of lesion (mm)
Associated causative factor(s) (select all that
apply:)
Dental Extraction (Dental extraction)
Denture Trauma (Denture trauma)
No Identified Factor (No identified factor)
Other Dental Surgery (Other dental
surgery)
Periodontal Infection (Periodontal
infection)
Steroid Use
Did the patient receive steroids within 12 months
of occurrence of the current jaw lesion(s)?
Yes
No
list drug name (If Yes,)
Dates of administration (to:)
Dates of administration
Comments
Comments
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Southwest Oncology Group - Osteonecrotic Jaw Lesion Form (S0777)
NCT00644228
RTOG-0617 I1: Radiation Therapy Oncology Group Phase III High-dose Vs
Standard-dose Conformal XRT with Chemotherapy Initial Evaluation Form
NCT00533949
RTOG-0617 I1: Radiation Therapy Oncology Group Phase
III High-dose Vs Standard-dose Conformal XRT with
Chemotherapy Initial Evaluation Form NCT00533949 
High-Dose or Standard-Dose Radiation Therapy and
Chemotherapy With or Without Cetuximab in Treating
Patients With Newly Diagnosed Stage III Non-Small Cell
Lung Cancer That Cannot Be Removed by Surgery
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=24AC693F-
14F6-1842-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/10860
RTOG-0617 I1: Radiation Therapy
Oncology Group Phase III High-dose
Vs Standard-dose Conformal XRT
with Chemotherapy Initial Evaluation
Form NCT00533949
Clinical trial administrative data
RTOG Study No.
Case #
Institution Name
Institution No.
Patient Initials
RTOG Patient ID
Amended Data (Instructions: Submit this form at
patient's entry on study. Dates are recorded mm-
dd-yyyy  unless otherwise specified.)
Yes
No
Pre-treatment Chacteristics
Patient Birth Date
Performance Status (Zubrod)
Fully Active, Able To Carry On All Pre-
disease Performance Without
Restriction. (0)
Restricted In Physically Strenuous
Activity But Ambulatory And Able To
Carry Out Work Of A Light Or Sedentary
Nature, E.g., Light Housework, Office
Work. (1)
Ambulatory And Capable Of All Selfcare
But Unable To Carry Out Any Work
Activities. Up And About More Than 50%
1 / 8
Of Waking Hours. (2)
Capable Of Only Limited Selfcare,
Confined To Bed Or Chair More Than
50% Of Waking Hours. (3)
Completely Disabled. Cannot Carry On
Any Selfcare. Totally Confined To Bed Or
Chair. (4)
Weight loss within the past month
History of Prior Malignancy (Invasivewithin past 3
years)
Yes
No
Prior malignancy site
Aml/mds (AML/MDS)
Bcc (BCC)
Bladder Is The Site Of Second Primary
Or Recurrent Tumor (Bladder)
Brain Is The Site Of Second Primary Or
Recurrent Tumor (Brain)
Colorectal (Colorectal)
Esophageal (Esophageal)
Gastric (Gastric)
Liver Is The Site Of Second Primary Or
Recurrent Tumor (Liver)
Melanoma (Melanoma)
Nhl (NHL)
Other Hematologic (Other hematologic)
Other Solid (Other solid)
Pancreatic (Pancreatic)
Prostate Is The Site Of Second Primary
Or Recurrent Tumor (Prostate)
Renal (Renal)
Squamous-skin (Squamous-skin)
Unknown Primary (Unknown primary)
Date eradicated
Pulmonary (COPD exacerbation or other
respiratory illness requiring hospitalization or
precluding study therapy within 30 days before
registration)
Yes
No
Infection (acute bacterial or fungal infection
requiring intravenous antibiotics at the time of
registration; Acquired Immune Deficiency
Syndrome)
Yes
No
Hepatic Insufficiency (resulting in clinical jaundice
and/or coagulation defects)
Yes
No
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RTOG-0617 I1: Radiation Therapy Oncology Group Phase III High-dose Vs
Standard-dose Conformal XRT with Chemotherapy Initial Evaluation Form
NCT00533949
Cardiovascular (unstable angina and/or
congestive heart failure and/or transmural
myocardial infarction requiring hospitalization
within the last 6 months)
Yes
No
Other
Yes
No
Other specify
Forced Expiratory Volume 1 (FEV1) (OR, IF
APPLICABLE)
Forced Expiratory Volume 1 (%Predicted FEV1)
Carbon Monoxide Diffusion (DLCO)
Date
Prior treatment for this cancer
Yes
No
Prior Surgery (excludes biospy)
Yes
No
Prior Radiation Therapy (that would result in
overlap of RT fields for this study)
Yes
No
PRIOR CHEMOTHERAPY
Yes
No
T Stage, Clinical
No Evidence Of Primary Tumor (T0)
Tumor 3 Cm Or Less In Greatest
Dimension, Surrounded By Lung Or
Visceral Pleura, Invasion More Proximal
Than The Lobar Bronchus, (i.e., Not In
The Main Bronchus) (T1)
Tumor With Any Of The Following
Features Of Size Or Extent: More Than
3cm In Greatest Dimension; Invades The
Visceral Pleura; Associated With
Atelectasis Or Obstructive Pneumonitis
That Extends To The Hilar Region But
Does Not Involve The Entire Lung (T2)
Tumor Of Any Size That Directly Invades
Any Of The Following: Chest Wall
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RTOG-0617 I1: Radiation Therapy Oncology Group Phase III High-dose Vs
Standard-dose Conformal XRT with Chemotherapy Initial Evaluation Form
NCT00533949
(including Superior Sulcus Tumors),
Diaphragm, Mediastinal Pleura, Parietal
Pericardium; Or Tumor In The Main
Bronchus Less Than 2 Cm Distal To The
Carina, But Without Involvement O* (T3)
Tumor Of Any Size That Directly Invades
Any Of The Following: Chest Wall
(including Superior Sulcus Tumors),
Diaphragm, Mediastinal Pleura, Parietal
Pericardium; Or Tumor In The Main
Bronchus Less Than 2 Cm Distal To The
Carina, But Without Involvement O* (T4)
N Stage, Clinical
No Regional Lymph Node Metastasis
(N0)
Metastasis To Ipsilateral Peribronchial
And/or Ipsilateral Hilar Lymph Nodes,
And Intrapulmonary Nodes Including
Involvement By Direct Extension Of The
Primary Tumor (N1)
Metastasis To Ipsilateral Mediastinal
And/or Subcarinal Lymph Node(s) (N2)
Metastasis To Contralateral Mediastinal,
Contralateral Hilar, Ipsilateral Or
Contralateral Scalene, Or
Supraclavicular Lymph Node(s) (N3)
M Stage, Clinical
No Distant Metastasis (M0)
Distant Metastasis Present (M1)
Histologic Type
Adenocarcinoma (Adenocarcinoma)
Bronchoalveolar (bac) (Bronchoalveolar
carcinoma (BAC))
Large Cell Undifferentiated (Large cell
undifferentiated)
Non-small Cell Lung Cancer (nsclc), Nos
(Non-small cell lung cancer NOS)
Squamous Cell Carcinoma (Squamous
cell carcinoma)
Histologic Confirmation Date
Was thoracotomy performed
Yes
No
Date (If yes,)
Disease Staging
Is measurable disease present? (Based on
RECIST criteria include primary nodes)
No (No)
Unknown (Unknown)
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Yes (Yes)
Baseline sum of the longest diameter (If yes,
what is the - cm)
Is patient unresectable or inoperable
Yes
No
Lymph Node Assessment
Lymph Nodes Type (s)
Highest Mediastinal Node (Highest
mediastinal (1))
Interlobar Node (Interlobar (11))
Left Hilar Node (Left hilar (10L))
Left Lobar Node (Left lobar (12L))
Left Lower Paratracheal Node (Left lower
paratracheal (4L))
Left Segmental Node (Left segmental
(13L))
Left Subsegmental Node (Left
subsegmental (14L))
Left Upper Paratracheal Node (Left
upper paratracheal (2L))
Para-aortic Node (Para-aortic (6))
Paraesophageal (Paraesophageal (8))
Pre- And Retro Paratracheal Node (Pre-
and retro paratracheal (3))
Pulmonary Ligament (Pulmonary
ligament (9))
Right Hilar Node (Right hilar (10R))
Right Lobar Node (Right lobar (12R))
Right Lower Paratracheal Node (Right
lower paratracheal (4R))
Right Segmental Node (Right segmental
(13R))
Right Subsegmental Node (Right
subsegmental (14R))
Right Upper Paratracheal Node (Right
upper paratracheal (2R))
Subaortic Node (Subaortic (5))
Subcarinal Node (Subcarinal (7))
Clinical Lymph Node Assessment
Equivocal (Equivocal)
Negative (Negative)
Not Evaluated (Not evaluated)
Positive (Positive)
Unknown (Unknown)
Pathologic Lymph Node Assessment
Equivocal (Equivocal)
Negative (Negative)
Not Evaluated (Not evaluated)
Positive (Positive)
Unknown (Unknown)
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carcinoma of the lung
Tumor Location Area
Carina (Carina)
Lower Lobe (left) (Lower Lobe (left))
Lower Lobe (right) (Lower Lobe (right))
Mainstem Bronchus (left) (Mainstem
Bronchus (left))
Mainstem Bronchus (right) (Mainstem
Bronchus (right))
Middle Lobe (right) (Middle Lobe (right))
Other, Specify (Other)
Upper Lobe (left) (Upper Lobe (left))
Upper Lobe (right) (Upper Lobe (right))
Other specify
Is Pleural Effusion present?
Yes
No
Is it Malignant?
No (No)
Unknown (Unknown (not tapped))
Yes (Yes)
History and Physical
Yes
No
Date
Presence of peripheral neuropathy > Grade 1
Yes
No
Prior allergic reaction to paclitaxel or other
taxanes or carboplatin
Yes
No
Prior therapy that targeted EGFR pathway
Yes
No
Prior severe infusion reaction to a monocolonal
antibody
Yes
No
Required Pretreatment Studies
Bone Scan or PET Date
Lung MRI or CT Scan Date
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Upper Abdomen CT Scan or MRI Date
Brain MRI or CT Scan Date
Other, specify
Pet Scan
Was PET scan done
Yes
No
Maximum SUV (If yes report)
Pretreatment Labs
Hemoglobin
Peripheral WBC Count
ANC
Peripheral Platelet Count
SGOT
SGOT Upper Limit Normal
SGPT
SGPT Upper Limit Normal
Total Bilirubin
Date
Date
Date
Date
Date
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Date
Date
Date
Total bilirubin ULN (Upper Limit Normal)
Serum creatinine
Serum Creatinine ULN (Upper Limit Normal)
Creatinine Clearance
Date of pregnancy test
Footer
Comments
Person Completing Form
Form Completion Date, Original
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Southwest Oncology Group S0819 Baseline
Tumor Assessment Form NCT00946712
Southwest Oncology Group S0819 Baseline Tumor
Assessment Form NCT00946712 
Carboplatin and Paclitaxel With or Without Bevacizumab
and/or Cetuximab in Treating Patients With Stage IV or
Recurrent Non-Small Cell Lung Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=684CF883-
62F5-1929-E040-BB89AD4373A3
All rights reserved. Please visit https://medical-data-
models.org/forms/10861
Southwest Oncology Group S0819
Baseline Tumor Assessment Form
NCT00946712
Header
SWOG Patient ID
SWOG Study No.
Registration Step
Patient Initials (L, F M)
Institution/Affiliate
Physician (Participating Group)
Participating Group Name
Participating Group Study No.
Participating Group Patient ID
Evaluation of lesions
Target Lesions
Longest Diameter (cm)
Assessment Type (*)
Colposcopy (Colposcopy)
Ct Scan (CT scan)
Cystoscopy (Cystoscopy)
Cytologic Confirmation (Cytologic
confirmation)
Endoscopy (Endoscopy)
Histologic (Histologic confirmation)
Mri Scan (MRI scan)
Other (Other)
Palpation (Palpation)
Pet Scan (PET scan)
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Computed Tomography Positron
Emission Tomography
(PET/Conventional CT)
Spiral Ct Positron Emission Tomography
(PET/Spiral CT)
Plain Film/x-ray With Contrast (Plain
film/X-ray with contrast)
Plain Film/x-ray Without Contrast (Plain
film/X-ray without contrast)
Radioisotope Scan (Radioisotope scan)
Spiral Ct Scan (Spiral CT scan)
Ultrasound (Ultrasound)
Visualization (Visualization)
Assessment Date
Assessment Type (*)
Colposcopy (Colposcopy)
Ct Scan (CT scan)
Cystoscopy (Cystoscopy)
Cytologic Confirmation (Cytologic
confirmation)
Endoscopy (Endoscopy)
Histologic (Histologic confirmation)
Mri Scan (MRI scan)
Other (Other)
Palpation (Palpation)
Pet Scan (PET scan)
Computed Tomography Positron
Emission Tomography
(PET/Conventional CT)
Spiral Ct Positron Emission Tomography
(PET/Spiral CT)
Plain Film/x-ray With Contrast (Plain
film/X-ray with contrast)
Plain Film/x-ray Without Contrast (Plain
film/X-ray without contrast)
Radioisotope Scan (Radioisotope scan)
Spiral Ct Scan (Spiral CT scan)
Ultrasound (Ultrasound)
Visualization (Visualization)
Assessment Date
Non-target disease
Extent
Lesions assessment and/or measurements
provided by
Radiologist (Radiologist)
Treating Physician (Treating Physician)
Diagnostic test
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Tests/studies
Assessment Date
Comments
Comments
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Southwest Oncology Group S0819 Baseline Tumor Assessment Form
NCT00946712
S0522 Follow-Up Tumor Assessment Form
S0522 Follow-Up Tumor Assessment Form
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=0EA7758A-
0910-6EE1-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/10862
S0522 Follow-Up Tumor Assessment
Form
Header
SWOG Patient ID
SWOG Study No.
Registration Step
Patient Initials (L, F M)
Date form completed
Institution/Affiliate
Physician
Participating Group Name
Participating Group Study No.
Participating Group Patient ID
Target Lesions
Target Lesions
Longest Diameter (cm)
Assessment Type (*)
Colposcopy (Colposcopy)
Ct Scan (CT scan)
Cystoscopy (Cystoscopy)
Cytologic Confirmation (Cytologic
confirmation)
Endoscopy (Endoscopy)
Histologic (Histologic confirmation)
Mri Scan (MRI scan)
Other (Other)
Palpation (Palpation)
Pet Scan (PET scan)
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Plain Film/x-ray With Contrast (Plain
film/X-ray with contrast)
Plain Film/x-ray Without Contrast (Plain
film/X-ray without contrast)
Radioisotope Scan (Radioisotope scan)
Spiral Ct Scan (Spiral CT scan)
Ultrasound (Ultrasound)
Visualization (Visualization)
Other Specify
Assessment Date
Non-target Disease
Non-Target Disease
Extent
Clear Increase (Clear increase)
Complete Disappearance (Complete
disappearance)
Not Assessed (Not assessed)
Present (Present)
Assessment Type (*)
Colposcopy (Colposcopy)
Ct Scan (CT scan)
Cystoscopy (Cystoscopy)
Cytologic Confirmation (Cytologic
confirmation)
Endoscopy (Endoscopy)
Histologic (Histologic confirmation)
Mri Scan (MRI scan)
Other (Other)
Palpation (Palpation)
Pet Scan (PET scan)
Plain Film/x-ray With Contrast (Plain
film/X-ray with contrast)
Plain Film/x-ray Without Contrast (Plain
film/X-ray without contrast)
Radioisotope Scan (Radioisotope scan)
Spiral Ct Scan (Spiral CT scan)
Ultrasound (Ultrasound)
Visualization (Visualization)
Other Specify
Assessment Date
New Lesions (specify Site)
New Lesions (Specify Site)
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Assessment Type (*)
Colposcopy (Colposcopy)
Ct Scan (CT scan)
Cystoscopy (Cystoscopy)
Cytologic Confirmation (Cytologic
confirmation)
Endoscopy (Endoscopy)
Histologic (Histologic confirmation)
Mri Scan (MRI scan)
Other (Other)
Palpation (Palpation)
Pet Scan (PET scan)
Plain Film/x-ray With Contrast (Plain
film/X-ray with contrast)
Plain Film/x-ray Without Contrast (Plain
film/X-ray without contrast)
Radioisotope Scan (Radioisotope scan)
Spiral Ct Scan (Spiral CT scan)
Ultrasound (Ultrasound)
Visualization (Visualization)
Other Specify
Assessment Date
Symptomatic deterioration
Symptomatic deterioration
Yes
No
Assessment Date
Comments
Comments
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E4A03 Multiple Myeloma On-Study Form -
Form 2055 NCT00098475
E4A03 Multiple Myeloma On-Study Form - Form 2055
NCT00098475 
Lenalidomide and Dexamethasone With or Without
Thalidomide in Treating Patients With Multiple Myeloma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=DD003264-
3C16-26D3-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/10863
E4A03 Multiple Myeloma On-Study
Form - Form 2055 NCT00098475
Header
ECOG Protocol Number
ECOG Patient ID
DCI Name
Registration Step
Report Period (Place ID Label Here)
Baseline Step 1 (Baseline Step 1)
Patient Initials
Participating Group Protocol Number
Participating Group Patient ID
Institution/Affiliate
Are data amended
Yes
No
Disease Description - Initial Diagnosis
Date of Initial Pathologic Diagnosis
Durie-Salmon Stage (at initial diagnosis - see
attached)
I - All Of The Following Must Be Present
(hemoglobin >10 G/dl; Serum Calcium
<12 Mg/dl; Urine Light Chains <4 G/24
Hrs; Normal Bones On Radiograph Or
Solitary Plasmacytoma; Igg <5 G/dl; Iga
<3 G/dl) (I)
Ii - Fitting Neither Stage I Or Stage Iii (II)
Iii - One Of The Following Must Be
Present (hemoglobin <8.5 G/dl; Serum
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Calcium >12 Mg/dl; Urine Light Chains
>12 G/24 Hrs; Advanced Lytic Bone
Lesions (>3 Lytic Lesions); Igg >7 G/dl;
Iga >5 G/dl) (III)
Unknown (Unknown)
Durie-Salmon Sub-Stage (at initial diagnosis -
see attached)
A (relatively Normal Renal Function -
Serum Creatinine <2.0 Mg/dl) (A)
B (abnormal Renal Function - Serum
Creatinine >= 2.0 Mg/dl) (B)
Unknown (Unknown)
Pre-registration Hematology/chemistry
Peripheral WBC Count LLN (/mm3 x1000)
Peripheral WBC Count
Peripheral Granulocytes Count LLN (AGC.ANC
/mm3)
Peripheral Granulocytes Count
Peripheral platelet count LLN (/mm3 x1000)
Peripheral platelet count
Alkaline Phosphatase ULN (U/L)
Alkaline Phosphatase
Bilirubin ULN (mg/dl)
Bilirubin
Creatinine ULN (mg/dl)
Creatinine
Hemoglobin (Hgb), LLN (g/dl)
Hemoglobin (Hgb)
SGOT (AST) ULN
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SGOT (AST)
SGPT (ALT) ULN
SGPT (ALT)
Albumin LLN (g/dl)
Albumin
Calcium LLN (Ca mg/dl)
Calcium ULN
Calcium
Glucose LLN (mg/dl)
Glucose ULN
Glucose
Potassium LLN (K mmol/L)
Potassium ULN
Potassium
Sodium LLN (Na mmol/L)
Sodium ULN
Sodium
Uric acid LLN (mg/dl)
Uric acid ULN
Uric acid
Date Hematology (Blood) Sample Obtained
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Current Infections (last 6 Months)
CTC Adverse Event Term Type (Specify site for
each event)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
with Grade 3 or 4 neutrophils)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils)
Infection With Unknown Anc (Infection
with unknown ANC)
Specify site
CTC Adverse Event Grade (Use grade 1-4 per
CTCAE v3)
Current Clinical Date
Performance status
Fully Active, Able To Carry On All Pre-
disease Performance Without Restriction
(karnofsky 90 - 100) (ecog - 0
Asymptomatic) (0)
Restricted In Physically Strenuous
Activity But Ambulatory (k70 - 80) (ecog -
1 Symptomatic - Fully Ambulatory) (1)
Ambulatory And Capable Of All Selfcare
But Unable To Carry Out Any Work
Activities (k 50 - 60) (ecog - 2
Symptomatic; In Bed , 50% Of The Day)
(2)
Capable Of Limited Selfcare, Confined
To Bed Or Chair More Than 50% Of
Waking Hours. (k 30 - 40) (ecog - 3
Symptomatic; In Bed > 50% Of The Day
But Not Bedridden) (3)
Completely Disabled (k10 - 20) (ecog - 4
Bedridden) (4)
Serum pregnancy test result
Negative (negative)
Not Applicable, Not Female Of Child-
bearing Potential (not applicable, patient
not female of child-bearing potential)
Unknown (not done)
Positive (positive)
Date of serum pregnancy test
Bone pain on entry to study
Mild Requires Only Non-narcotic
Medication (mild, requires use of non-
narcotic pain relief)
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None (none)
Requires Occasional Narcotics (requires
occasional narcotics)
Requires Per Os Narcotics (requires p.o.
narcotics)
Requires Parenteral Narcotics Or Patch
(requires parenteral narcotics, or patch)
Uncontrollable Pain (uncontrollable pain)
Unknown (unknown)
Is severe osteoporosis present?
No (no)
Unknown (unknown)
Yes (yes)
Number of bones with lytic lesions present
1-3 Bones (1-3 bones)
More Than 3 Bones (more than 3 bones)
None (none)
Unknown (unknown)
Number of lytic lesions > 2 cm in diameter
1-3 Lesions (1-3 bones)
More Than 3 Lesions (more than 3
bones)
None (none)
Unknown (unknown)
Pathologic fracture during previous 1 month
(including compression and rib fractures)
No (no)
Unknown (unknown)
Yes (yes)
Is patient on anti-coagulation therapy?
Yes
No
Prior Therapy
Prior corticosteroids?
Yes
No
Specify (If yes,)
Prior bisphosphanate therapy?
Yes
No
Bisphosphanate type(s) received (If yes,)
Both Pamidronate And Zoledronic Acid
(both pamidronate and zoledronic acid)
Pamidronate (pamidronate)
Zoledronic Acid (zoledronic acid)
Prior radiation therapy?
Yes
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No
Sites of prior RT (If yes,)
Date prior RT ended (Record any symptoms,
complaints or diagnostic test abnormalities that
were present at the time of registration for which
a CTCAE term exists.)
Baseline Abnormalities
CTC Adverse Event Term Type (include subterm
if applicable Use CTCAE v3 terminology)
Peripheral Sensory Neuropathy
(Neuropathy - sensory)
Thrombosis Nos
(Thrombosis/thrombus/embolism)
Comments
Comments
Investigator Signature
Investigator Signature Date
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Southwest Oncology Group S0819 Follow-
Up Tumor Assessment Form NCT00946712
Southwest Oncology Group S0819 Follow-Up Tumor
Assessment Form NCT00946712 
Carboplatin and Paclitaxel With or Without Bevacizumab
and/or Cetuximab in Treating Patients With Stage IV or
Recurrent Non-Small Cell Lung Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=684CF883-
6379-1929-E040-BB89AD4373A3
All rights reserved. Please visit https://medical-data-
models.org/forms/10864
Southwest Oncology Group S0819
Follow-Up Tumor Assessment Form
NCT00946712
Header
SWOG Patient ID
SWOG Study No.
Registration Step
Patient Initials (L, F M)
Date form completed
Institution/Affiliate
Physician
Participating Group Name
Participating Group Study No.
Participating Group Patient ID
Target Lesions
Target Lesions
Longest Diameter (cm)
Assessment Type (*)
Colposcopy (Colposcopy)
Ct Scan (CT scan)
Cystoscopy (Cystoscopy)
Cytologic Confirmation (Cytologic
confirmation)
Endoscopy (Endoscopy)
Histologic (Histologic confirmation)
Mri Scan (MRI scan)
Other (Other)
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Palpation (Palpation)
Pet Scan (PET scan)
Computed Tomography Positron
Emission Tomography
(PET/Conventional CT)
Spiral Ct Positron Emission Tomography
(PET/Spiral CT)
Plain Film/x-ray With Contrast (Plain
film/X-ray with contrast)
Plain Film/x-ray Without Contrast (Plain
film/X-ray without contrast)
Radioisotope Scan (Radioisotope scan)
Spiral Ct Scan (Spiral CT scan)
Ultrasound (Ultrasound)
Visualization (Visualization)
Assessment Date
Lesions assessment and/or measurements
provided by
Radiologist (Radiologist)
Treating Physician (Treating Physician)
Non-target Disease
Non-Target Disease
Extent
Clear Increase (Clear increase)
Complete Disappearance (Complete
disappearance)
Not Assessed (Not assessed)
Present (Present)
Assessment Type (*)
Colposcopy (Colposcopy)
Ct Scan (CT scan)
Cystoscopy (Cystoscopy)
Cytologic Confirmation (Cytologic
confirmation)
Endoscopy (Endoscopy)
Histologic (Histologic confirmation)
Mri Scan (MRI scan)
Other (Other)
Palpation (Palpation)
Pet Scan (PET scan)
Computed Tomography Positron
Emission Tomography
(PET/Conventional CT)
Spiral Ct Positron Emission Tomography
(PET/Spiral CT)
Plain Film/x-ray With Contrast (Plain
film/X-ray with contrast)
Plain Film/x-ray Without Contrast (Plain
film/X-ray without contrast)
Radioisotope Scan (Radioisotope scan)
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Spiral Ct Scan (Spiral CT scan)
Ultrasound (Ultrasound)
Visualization (Visualization)
Assessment Date
New Lesions (specify Site)
New Lesions (Specify Site)
Assessment Type (*)
Colposcopy (Colposcopy)
Ct Scan (CT scan)
Cystoscopy (Cystoscopy)
Cytologic Confirmation (Cytologic
confirmation)
Endoscopy (Endoscopy)
Histologic (Histologic confirmation)
Mri Scan (MRI scan)
Other (Other)
Palpation (Palpation)
Pet Scan (PET scan)
Computed Tomography Positron
Emission Tomography
(PET/Conventional CT)
Spiral Ct Positron Emission Tomography
(PET/Spiral CT)
Plain Film/x-ray With Contrast (Plain
film/X-ray with contrast)
Plain Film/x-ray Without Contrast (Plain
film/X-ray without contrast)
Radioisotope Scan (Radioisotope scan)
Spiral Ct Scan (Spiral CT scan)
Ultrasound (Ultrasound)
Visualization (Visualization)
Assessment Date
Symptomatic deterioration
Symptomatic deterioration
Yes
No
Assessment Date
Comments
Comments
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E5202 Treatment Summary Form - A and B
Only NCT00217737
E5202 Treatment Summary Form - A and B Only
NCT00217737
Oxaliplatin, Leucovorin, and Fluorouracil With or Without
Bevacizumab in Treating Patients Who Have Undergone
Surgery for Stage II Colon Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=EFD59F93-
CAC5-2DAD-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/10865
E5202 Treatment Summary Form - A
and B Only NCT00217737
Header
ECOG Protocol Number
ECOG Patient ID
DCI Name
Registration Step
Report period
End Of First 12 Cycles Of Treatment
(End of First 12 Cycles of Treatment)
End Of Second 12 Cycles Of
Bevacizumab Treatment (End of Second
12 Cycles of Bevacizumab Treatment)
Are data amended (If yes, please circle amended
items in red)
Yes
No
Patient demographics
Patient Initials
Participating Group Protocol Number
Institution/Affiliate
Participating Group Patient ID
Treatment Information For This Time
Period
Assigned Treatment Arm
Oxaliplatin/leucovorin/5-fu
(Oxaliplatin/Leucovorin/5-FU)
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Oxaliplatin/leucovorin/5-fu/bevacizumab
(Oxaliplatin/Leucovorin/5-
FU/Bevacizumab)
Total Number of Cycles Given
Weight (Day 1 of Cycle 1 for this Report Period)
Date Chemotherapy Began
Date Chemotherapy Ended
Dosing
Agent Name
Agent Initial Dose (Dose administered on Day 1
of Cycle 1)
Number of Doses Received
Agent Total Cumulative Dose
Were there any dose modifications or
additions/omissions
Unknown (agent permanently
discontinued)
No (no)
Unknown (yes, both planned and
unplanned)
Yes, Planned (i.e., The Treatment Was
Changed According To Protocol
Guidelines) (yes, planned)
Yes, Unplanned (i.e., The Treatment
Change Was Not Part Of Protocol
Guidelines) (yes, unplanned)
If unplanned, specify change and reason
Investigator Signature
Investigator Signature Date
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NSABP PROTOCOL C-08: BASELINE
HYPERTENSION STATUS FORM NCT00096278
NSABP PROTOCOL C-08: BASELINE HYPERTENSION
STATUS FORM NCT00096278
Fluorouracil, Leucovorin, and Oxaliplatin With or Without
Bevacizumab in Treating Patients Who Have Undergone
Surgery for Stage II or Stage III Colon Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=D7FA2647-
04C2-625B-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/10866
NSABP PROTOCOL C-08:
BASELINE HYPERTENSION
STATUS FORM NCT00096278
Header
Patient Initials (Last, First Middle)
NSABP Patient ID
Institution Name
Affiliate Name
Person Completing Form Last Name
Person Completing Form First Name
Person Completing Form Phone
Are data amended? (check box if yes, and circle
amended items)
Yes
No
Blood pressure assessment
Blood Pressure Systolic (mm Hg)
Blood Pressure Diastolic (mm Hg)
Date of Measurement (Month Day Year)
Does the patient have hypertension requiring
medication?
Yes
No
Generic Name (List the generic names, dose,
and frequency of the medications the patient is
taking for hypertension.)
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Dose
Unit
Gram (g)
Milligram (mg)
Frequency
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NSABP PROTOCOL C-08: BASELINE HYPERTENSION STATUS FORM
NCT00096278
NSABP PROTOCOL C-08: HYPERTENSION
STATUS FORM NCT00096278
NSABP PROTOCOL C-08: HYPERTENSION STATUS
FORM NCT00096278
Fluorouracil, Leucovorin, and Oxaliplatin With or Without
Bevacizumab in Treating Patients Who Have Undergone
Surgery for Stage II or Stage III Colon Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=D7FA15D7-
81B4-61AD-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/10867
NSABP PROTOCOL C-08:
HYPERTENSION STATUS FORM
NCT00096278
Header
Patient Initials (Last, First Middle)
NSABP Patient ID
Institution Name
Affiliate Name
Person Completing Form Last Name
Person Completing Form First Name
Person Completing Form Phone
Are data amended? (check box if yes, and circle
amended items)
Yes
No
Blood pressure assessment
Time point of this assessment
12 (12 months)
12 Months After Protocol Therapy (12
months after protocol therapy)
3 (3 months)
6 (6 months)
6 Months After Protocol Therapy (6
months after protocol therapy)
9 (9 months)
Bevacizumab Alone (Bevacizumab
alone)
Mfolfox6 +/- Bevacizumab (mFOLFOX6
+/- bevacizumab)
Post-therapy (Post-therapy)
Blood Pressure Systolic (mm Hg)
Blood Pressure Diastolic (mm Hg)
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Date of Measurement (Month Day Year)
Does the patient have hypertension requiring
medication?
Yes
No
Has there been an addition of a new anti-
hypertensive agent or a modification of an
existing agent since the last HT form?
Yes
No
Specify the action(s) taken (select all that apply:)
Addition Of New Medication (Addition of
new medication)
Decrease In Dose Of Existing Medication
(Decrease in dose of existing
medication)
Discontinuation Of Existing Medication
(Discontinuation of existing medication)
Increase In Dose Of Existing Medication
(Increase in dose of existing medication)
Reason action(s) taken:
Blood Pressure Poorly Controlled On
Previous Regimen (Blood pressure
poorly controlled on previous regimen)
Previous Dose/medication No Longer
Required (Previous dose/medication no
longer required)
Toxicity/side Effects (Toxicity/side effects)
Generic Name (List the generic names, dose,
unit and frequency of a any new medications the
patient is taking since the last HT form, and b any
medications for which there was a change in
dose or frequency since the last HT form.)
Dose
Unit
Gram (g)
Milligram (mg)
Frequency
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NSABP PROTOCOL C-08: mFOLFOX6
Treatment Form NCT00096278
NSABP PROTOCOL C-08: mFOLFOX6 Treatment Form
NCT00096278
Fluorouracil, Leucovorin, and Oxaliplatin With or Without
Bevacizumab in Treating Patients Who Have Undergone
Surgery for Stage II or Stage III Colon Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=D7F8F3C7-
F4E8-600A-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/10868
NSABP PROTOCOL C-08:
mFOLFOX6 Treatment Form
NCT00096278
Header
Patient Initials (Last, First Middle)
NSABP Patient ID
Institution Name
Affiliate Name
Person Completing Form Last Name
Person Completing Form First Name
Person Completing Form Phone
Are data amended? (check box if yes, and circle
amended items)
Yes
No
Assessment of Chemotherapy
Agent
5-FU Bolus (5-FU Bolus)
5-FU Infusional (5-FU Infusional)
Leucovorin (Leucovorin)
Oxaliplatin (Oxaliplatin)
Begin Date (if patient failed to start, code=00 00
0000)
End Date (if patient failed to start, code=00 00
0000)
Reason Discontinued (enter code no. from below)
Alternative Therapy (Alternative Therapy)
Treatment Completed Per Protocol
Criteria (Completed per protocol)
Death, Recurrence, Or Second Primary
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Cancer (Death, recurrence, or second
primary cancer)
Other (Other reason)
Patient Withdrawal Or Refusal (Patient
withdrawal or refusal)
Physician Withdrawal (Physician
withdrawal)
Adverse Event/side Effects/complications
(Toxicity/Side effects)
Number of Cycles Received
Cumulative Protocol Dose for all Administered
Cycles (mg/m^2)
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CALGB: 80203 TREATMENT FORM
NCT00077233
CALGB: 80203 TREATMENT FORM NCT00077233
Fluorouracil and Leucovorin Plus Either Irinotecan or
Oxaliplatin With or Without Cetuximab in Treating Patients
With Previously Untreated Metastatic Adenocarcinoma of
the Colon or Rectum
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=B4C3AA7D-
9032-06AE-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/10869
CALGB: 80203 TREATMENT FORM
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Header
CALGB Form
CALGB Study No.
CALGB Patient ID
Current cycle number
Are data amended?
Yes
No
Patient demographics
Patient Initials
Participating Group
Patient Hospital No.
Participating Group Protocol No.
Institution/Affiliate
Participating Group Patient ID
Assessment of medication
Date of first dose for this reporting period (cycle)
Date of last dose for this reporting period (cycle)
Agent
1 / 3
Total dose of drug/agent this
Was protocol therapy modified, delayed or
omitted during this time period?
No (no)
Yes, Planned (i.e., The Treatment Was
Changed According To Protocol
Guidelines) (yes, planned per protocol)
Yes, Unplanned (i.e., The Treatment
Change Was Not Part Of Protocol
Guidelines) (yes, unplanned)
If yes, specify reason
adverse event or toxicity (adverse event
or toxicity)
dosing error (dosing error)
patient refusal/noncompliance (patient
refusal/noncompliance)
scheduling (scheduling)
If protocol therapy has been terminated
permanently during this time period, specify
reason treatment ended (mark one with an X)
Alternative Therapy (Alternative therapy)
Death On Study (Death on study)
Death On Study (Death prior to
beginning protocol therapy)
Disease Progression, Relapse During
Active Treatment (Disease progression,
relapse during active treatment)
Disease Progression Before Active
Treatment (Disease progression, relapse
prior to beginning protocol therapy)
Other (Other, specify)
Patient Off-treatment For Other
Complicating Disease (Patient off
treatment for other complicating disease)
Patient Withdrawal Or Refusal After
Beginning Protocol Therapy (Patient
withdrawal or refusal after beginning
protocol therapy)
Patient Withdrawal Or Refusal Before
Beginning Protocol Therapy (Patient
withdrawal or refusal prior to beginning
protocol therapy)
Adverse Event/side Effects/complications
(Toxicity/side effects/complications)
Treatment Completed Per Protocol
Criteria (Treatment completed per
protocol criteria)
Other, specify (reason treatment ended)
Completed By (Print or Type Name)
Date Form Completed (M)
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Ccrr Module For Calgb: 80203 Treatment
Form
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E3201 Group I Treatment Form - Post
Operative Chemotherapy NCT00068692
E3201 Group I Treatment Form - Post Operative
Chemotherapy NCT00068692
Comparison of Adjuvant Chemotherapy Regimens in
Treating Patients With Stage II or Stage III Rectal Cancer
Who Are Receiving Radiation Therapy and Fluorouracil
Before or After Surgery
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=B5521A13-
ADA4-6D2D-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/10870
E3201 Group I Treatment Form -
Post Operative Chemotherapy
NCT00068692
Header
ECOG Protocol Number
ECOG Patient ID
DCI Name
Registration Step
Time period
Off Treatment Step 2 (Off Treatment Step
2)
Patient Initials
Participating Group Protocol No.
Participating Group Patient ID
Institution/Affiliate
Are data amended? (If yes, please circle
amended items in red)
Yes
No
Post Operative Chemotherapy
Assigned Treatment Arm
Total number of cycles given
Chemotherapy begin date
Chemotherapy end date
1 / 2
Patient weight
Agent name
Agent Total Cumulative Dose
Were there any dose modifications or
additions/omissions?
No (no)
yes, both planned and unplanned (yes,
both planned and unplanned)
Yes, Planned (i.e., The Treatment Was
Changed According To Protocol
Guidelines) (yes, planned)
Yes, Unplanned (i.e., The Treatment
Change Was Not Part Of Protocol
Guidelines) (yes, unplanned)
If unplanned, specify change and reason
Comments
Comments
Investigator Signature
Investigator Signature Date
Ccrr Module For E3201 Group I Treatment
Form - Post Operative Chemotherapy
F.1
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E3201 Group I Treatment Form - Post Operative Chemotherapy
NCT00068692
E3201 Group II Treatment Form - Post Op
Chemotherapy and Chemo/RT NCT00068692
E3201 Group II Treatment Form - Post Op Chemotherapy
and Chemo/RT NCT00068692
Comparison of Adjuvant Chemotherapy Regimens in
Treating Patients With Stage II or Stage III Rectal Cancer
Who Are Receiving Radiation Therapy and Fluorouracil
Before or After Surgery
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=B5522EF8-
9DC6-6DB3-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/10871
E3201 Group II Treatment Form -
Post Op Chemotherapy and
Chemo/RT NCT00068692
Header
ECOG Protocol Number
ECOG Patient ID
DCI Name
Registration Step
Time period
Off Treatment Step 2 (Off Treatment Step
2)
Patient Initials
Participating Group Protocol No.
Participating Group Patient ID
Institution/Affiliate
Are data amended? (If yes, please circle
amended items in red)
Yes
No
Post Op Chemotherapy and Chemo/RT
Assigned Treatment Arm
Patient weight
Agent Name
Agent Total Dose
1 / 2
Were there any dose modifications or
additions/omissions?
No (no)
yes, both planned and unplanned (yes,
both planned and unplanned)
Yes, Planned (i.e., The Treatment Was
Changed According To Protocol
Guidelines) (yes, planned)
Yes, Unplanned (i.e., The Treatment
Change Was Not Part Of Protocol
Guidelines) (yes, unplanned)
If unplanned, specify change and reason
Regimen Type Given
Other (Other)
Rt + 5-fu/lu (RT + 5-FU/LU)
Rt + Capecitabine (RT + capecitabine)
Rt + Continuous Infusion 5-fu (RT +
continuous infusion 5-FU)
Specify other regimen
Chemotherapy begin date
Chemotherapy end date
RT begin date
RT end date
RT total dose
Total number of cycles given
Comments
Comments
Investigator Signature
Investigator signature Date
Ccrr Module For E3201 Group Ii
Treatment Form - Post Op Chemotherapy
And Chemo/rt
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NCT00068692
CALGB: 80405 TREATMENT AND
RESPONSE FORM NCT00265850
CALGB: 80405 TREATMENT AND RESPONSE FORM
NCT00265850
Cetuximab and/or Bevacizumab Combined With
Combination Chemotherapy in Treating Patients With
Metastatic Colorectal Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=F39D6C01-
851A-64CF-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/10872
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RESPONSE FORM NCT00265850
Header
CALGB Form
CALGB Study No
CALGB Patient ID
Date of first dose for this reporting period
Reporting Period End Date
Are data amended
Yes
No
Patient demographics
Patient Initials
Patient Hospital No
Institution/Affiliate
Participating Group
Participating Group Study No.
Participating Group Patient ID
Assessment of Chemotherapy
BSA (on date of first dose for this reporting
period)
Cycle number
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Agent name
5-Fluorouracil bolus (5-Fluorouracil
bolus)
5-Fluorouracil infusion (5-Fluorouracil
infusion)
Bevacizumab (Bevacizumab)
Cetuximab (Cetuximab)
Cetuximab (Cetuximab)
Irinotecan (Irinotecan)
Leucovorin (Leucovorin)
Oxaliplatin (Oxaliplatin)
Total Dose of Agents/Drugs for this Cycle
Date of Last dose for this reporting period
Lab results
Magnesium (second 4 weeks of reporting period)
Did the patient receive calcium or magnesium
infusions during this reporting period?
Yes
No
Off-protocol treatment
Off treatment reason (if applicable Mark one with
an X.)
Adverse Event/side Effects/complications
(Adverse event/side
effects/complications)
Alternative Therapy (Alternative therapy)
Death On Study (Death on study)
Disease Progression, Relapse During
Active Treatment (Disease progression,
relapse during active treatment)
Other (Other)
Patient Off-treatment For Other
Complicating Disease (Patient off-
treatment for other complicating disease)
Patient Withdrawal Or Refusal After
Beginning Protocol Therapy (Patient
withdrawal or refusal after beginning
protocol therapy)
Patient Withdrawal Or Refusal Before
Beginning Protocol Therapy (Patient
withdrawal or refusal prior to beginning
protocol therapy)
Alternative therapy, specify
Removed To Receive Non-protocol
Chemotherapy And/or Biologic Therapy
(Removed to receive non-protocol
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chemotherapy and/or biologic therapy)
Removed To Undergo Surgical
Resection (Removed to undergo surgical
resection)
Other, specify
Weeks 1 And 2
Dose level received (^1)
Protocol Defined Dose
Reduction/modification (-1)
Protocol Defined Dose
Reduction/modification (-2)
Protocol Defined Dose
Reduction/modification (-3)
Full Starting Dose (1)
Protocol Agent Not Received. (Not
Received)
Dose modification reason (^2)
Adverse Event (adverse event)
Dosing Error (dosing error)
Hypersensitivity (hypersensitivity)
Patient Refusal/noncompliance (patient
refusal/noncompliance)
Scheduling (scheduling (e.g.,
physician/patient vacation or schedule))
Weeks 3 And 4
Weeks 5 And 6
Weeks 7 And 8
Survival Date
Vital Status
Alive (Alive)
Dead (Dead)
Primary Cause of Death
Due To Other Cause (Due to other
cause)
Due To Protocol Treatment (Due to
protocol treatment)
Due To This Disease (Due to this
disease)
Due to other cause, specify
Date of Last Contact or Death
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Response Data
Date of evaluation (most recent)
Response at this assessment
Complete Response (Complete
response)
Not Assessed (Not assessed
adequately)
Partial Response (Partial response)
Progression (Progression)
Stable Disease (Stable)
Complete response first observed date
Partial response first observed date
Progressive disease first observed date
Sites of progression (for pre-surgical or surgical
response Mark all that apply with an X.)
Bone (Bone)
Central Nervous System/brain
(CNS/brain)
Intra-abdominal (Intra-abdominal)
Liver (Liver)
Local-regional (including Ipsilateral
Breast; Chest Wall; Axillary, Internal
Mammary, And Infraclavicular Nodes;
Local-regional Skin And Subcutaneous
Tissue) (Local/regional)
Lung, Nos (Lung)
Other (Other)
Completed by
Date form originally completed
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Southwest Oncology Group S0421 FACT-P Questionnaire:
Step 1 Randomization Form NCT00134056
Southwest Oncology Group S0421 FACT-P Questionnaire:
Step 1 Randomization Form NCT00134056
Docetaxel and Prednisone With or Without Atrasentan in
Treating Patients With Stage IV Prostate Cancer and Bone
Metastases That Did Not Respond to Previous Hormone
Therapy
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=F159B9D6-
FD84-2C7B-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/10873
Southwest Oncology Group S0421
FACT-P Questionnaire: Step 1
Randomization Form NCT00134056
Header
SWOG Patient ID
SWOG Study No.
Registration Step
Planned Assessment
Prestudy (Prestudy)
Week 10 (Week 10)
Week 19 (Week 19)
Week 28 (Week 28)
Week 37 (Week 37)
Patient Initials (L, F M)
Institution/Affiliate
Physician
Participating Group Name
Participating Study No.
Participating Patient ID
Randomization questions
Below is a list of statements that other people
with your illness have said are important. By
selecting one (1) box per line, please indicate
how true each statement has been for you during
the past 7 days.  Please select a box by marking
an "X" in it.
1 / 7
I have a lack of energy
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have nausea
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
Because of my phyical condition, I have trouble
meeting the needs of my family
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have pain
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am bothered by side effects of treatment
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I feel ill
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am forced to spend time in bed
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I feel close to my friends
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I get emotional support from my family
A Little Bit (A little bit)
Not At All (Not at all)
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Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I get support from my friends
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
My family has accepted my illness
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
Regardless of your current level of sexual activity,
please answer the following question.  If you
prefer not to answer it, please check this box and
go to the next section.
I am satisfied with family communication about
my illness
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I feel close to my partner (or the person who is
my main support)
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am satisfied with my sex life
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I feel sad
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am satisfied with how I am coping with my
illness
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
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Very Much (Very much)
I am losing hope in the fight against my illness
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I feel nervous
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I worry about dying
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I worry that my condition will get worse
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am able to work (include work at home)
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
My work (include work at home) is fulfilling
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am able to enjoy life
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have accepted my illness
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am sleeping well
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A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am enjoying things I usually do for fun
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am content with the quality of my life right now
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am losing weight
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have a good appetite
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have aches and pains that bother me
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have certain areas of my body where I
experience significant pain
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
My pain keeps me from doing things I want to do
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am satisfied with my present comfort level
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
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Somewhat (Somewhat)
Very Much (Very much)
I am able to feel like a man
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have trouble moving my bowels
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have difficulty urinating
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I urinate more frequently than usual
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
My problems with urinating limit my activities
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am able to have and maintain an erection
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
Patient status assessment
How would you rate your overall health during the
past week
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
7 (7)
How would you rate your overall quality of life
during the past week
1 (1)
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2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
7 (7)
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CALGB-10501 Chronic Lymphocytic Leukemia (CLL) Peripheral
Blood And Bone Marrow Report Form NCT00513747
CALGB-10501 Chronic Lymphocytic Leukemia (CLL)
Peripheral Blood And Bone Marrow Report Form
NCT00513747 
Early or Delayed Fludarabine and Rituximab in Treating
Patients With Previously Untreated Chronic Lymphocytic
Leukemia
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=3410488F-
0DB2-2BD3-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/10874
CALGB-10501 Chronic Lymphocytic
Leukemia (CLL) Peripheral Blood
And Bone Marrow Report Form
NCT00513747
Header
CALGB Form
CALGB Study No
CALGB Patient ID
Date of Bone Marrow Biopsy
Are data amended
Yes
No
Patient demographics
Patient Initials (Last, First Middle)
Patient Hospital No.
Institution/Affiliate
Participating Group
Participating Group Study No
Participating Group Patient ID
Bone Marrow
Marrow Cellularity (%)
Marrow Leukemic Cells (%)
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Type of Biopsy Procedure
Aspirate (Aspirate)
Both (Both)
Large Bore Needle (Large bore needle)
Bone Marrow Differential
Marrow neutrophils (%)
Marrow metamyelocytes (%)
Marrow myelocytes (%)
Marrow Promyelocytes (%)
Marrow Blasts (%)
Marrow Lymphocytes (%)
Marrow prolymphocytes (%)
Marrow monocytes (%)
Marrow monoblasts (%)
Marrow Eosinophils (%)
Marrow Basophils (%)
Marrow erythroid cells (%)
Marrow Plasma Cells (%)
Bone Marrow Pattern (of CLL)
Diffuse Pattern (Diffuse pattern)
Interstitial (Interstitial)
Nodular Pattern Evident In Bone Marrow
(Nodular pattern)
Nodular/interstitial (Nodular/Interstitial)
Unknown (Unknown)
Is there bone marrow involvement
Yes
No
Megakaryocyte status (Mark one with an X.)
Absent (Absent)
Decreased (Decreased)
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Increased (Increased)
Normal (Normal)
Unknown (Unknown)
Peripheral Blood
Date Hematology (Blood) Sample Obtained (MM
DD YYYY)
Hemoglobin (g/dL)
Peripheral Platelet Count (1000/ul)
Peripheral WBC Count (1000/ul)
Peripheral Neutrophils (%) (segs + bands
1000/ul)
Peripheral metamyelocytes
Peripheral myelocytes
Peripheral Promyelocytes (%)
Peripheral Blasts (%)
Peripheral Erythroblasts (%)
Peripheral Lymphocytes (%)
Peripheral Prolymphocytes (%)
Peripheral Monocytes (%)
Peripheral monoblasts
Peripheral Eosinophils (%)
Peripheral Basophils (%)
Peripheral reticulocytes
Hematocrit
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Overall Response
Completed by (print or type name)
Date Form Completed (MM DD YYYY)
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Hepatitis C Eligibility NCT00299923
ODM derived from
http://clinicaltrials.gov/show/NCT00299923
Study for Patients With Chronic HCV (GT 1 or 3) Who
Relapsed to Previous (Peg)Interferon/ Ribavirin
Combination Therapy
All rights reserved. Please visit https://medical-data-
models.org/forms/10875
Eligibility Hepatitis C, Chronic
Relapse NCT00299923
Einschlusskriterien
Alter 18 Jahre und älter*
Ja
Nein
Relapsers to combination therapy with negative
HCV-RNA test result at treatment's  end and
positive HCV-RNA test result during follow-up*
Ja
Nein
Termination of (PEG-)IFN alfa-/ribavirin therapy at
least 3 months prior to enrolment*
Ja
Nein
Chronic HCV infection genotype 1 or 3*
Ja
Nein
Serum HCV-RNA quantifiable at >100 IU/mL by
COBAS AmpliPrep or another quantitative HCV-
RNA PCR test (reported in IU)*
Ja
Nein
Compensated liver disease (Child-Pugh A)*
Ja
Nein
Exclusion of HCC in patients with cirrhosis or
transition to cirrhosis. In patients with AFP >50
ng/mL an established assay for exclusion of HCC
has to be done*
Ja
Nein
Negative urine or blood pregnancy test*
Ja
Nein
All fertile males and females must use two
reliable forms of effective contraception
(combined) during treatment with study drugs
and 6 months post treatment*
Ja
Nein
Ausschlusskriterien
1 / 11
Hypersensitiveness to Interferon, PEG-IFN alfa-
2a, Ribavirin and Amantadine or other ingredient
of the drugs*
Ja
Nein
Ongoing pregnancy or breast feeding*
Ja
Nein
Male partners of women who are pregnant or
with women without effective contraception*
Ja
Nein
Signs or symptoms of hepatocellular carcinoma*
Ja
Nein
Chronic HCV infection genotype 2, 4, 5 or 6*
Ja
Nein
Therapy with any systemic anti-viral, anti-
neoplastic or immunomodulatory treatment < 6
months prior to the first dose of study drug and
during study period. Exception: patients who
have had a limited (< 7 days) course of acyclovir
or valacyclovir for herpetic lesions < 1 month
prior to the first administration of test drug are not
excluded.*
Ja
Nein
Any investigational drug < 6 weeks prior to the
first dose of study drug*
Ja
Nein
Positive test for anti-HAV IgM, HBsAg, anti-HBc
IgM, anti-HIV*
Ja
Nein
History or other evidence of a medical condition
associated with chronic liver disease other than
HCV*
Ja
Nein
History or other evidence of decompensated liver
disease or a Child-Pugh score > 6.*
Ja
Nein
Hb <12 g/dL bei Frauen oder <13 g/dL bei
Männern beim Screening*
Ja
Nein
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Any patient with an increased baseline risk for
anemia or for whom anemia would be medically
problematic*
Ja
Nein
Neutrophil count <1,500 cells/mm3 and/or
platelet count <90,000 cells/mm3*
Ja
Nein
Serum creatinin concentration >1.5 mg/dl*
Ja
Nein
History of severe psychiatric disease, especially
depression.*
Ja
Nein
History of a severe seizure disorder that can not
be stabilized by medication*
Ja
Nein
History of immunologically mediated disease*
Ja
Nein
Chronic pulmonary disease associated with
functional limitation*
Ja
Nein
History of severe cardiac disease*
Ja
Nein
History of major organ transplantation except
corneatransplantation*
Ja
Nein
Evidence of severe illness, malignancy, or any
other conditions which would make the patient, in
the opinion of the investigator, unsuitable for the
study*
Ja
Nein
Thyroid dysfunction not adequately controlled*
Ja
Nein
Evidence of severe retinopathy or clinically
relevant ophthalmological disorder due to
diabetes mellitus or hypertension*
Ja
Nein
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Evidence of active drug abuse within one year of
study entry except of a prescribed stable opioid
substitution*
Ja
Nein
Take of Memantine during study period*
Ja
Nein
Cardiomyopathy and myocarditis*
Ja
Nein
AV-Block II and III*
Ja
Nein
Pre-existing bradycardia < 55 counts/min*
Ja
Nein
Known QT-interval (QTc after Bazett > 420 ms)
or recognized U-waves or congenital QT-
syndrome*
Ja
Nein
History of severe ventricular arrhythmia incl.
Torsade de pointes*
Ja
Nein
Simultaneous therapy with Budipin or other
medicine that extend the QT-interval like
(e.g.antiarrhythmic drugs class IA and class III,
antipsychotic drugs, tri- and tetracyclic
antidepressants, antihistaminics, macrolide,
gyrase inhibitors, Azol-antimykotics)*
Ja
Nein
Patients with obstructive glaucoma*
Ja
Nein
Patients with excitableness and confusion*
Ja
Nein
Patients with delirium and exogenic psychosis in
the anamnesis*
Ja
Nein
Prostataadenome*
Ja
Nein
Diuretic medication of the type combination
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Triamterene/ Hydrochlorothiazide*
Ja
Nein
Inability or unwillingness to provide informed
consent or abide by the requirements of the
study*
Ja
Nein
Medizinische Konzepte
Polyethylene Glycols*
Interferon-alpha, IFN-alpha*
Ribavirin*
Hepatitis C virus RNA (substance)*
Test*
negativ*
Therapie*
positiv*
Follow-up*
Period (temporal concept)*
Registrierung*
Hepatitis-C-Virus*
chronisch*
Infektion*
Genotyp*
Serum*
internationale Einheit, IE*
5 / 11
Hepatitis C Eligibility NCT00299923
Polymerase-Kettenreaktion*
quantitativ*
Lebererkrankung*
Child-Pugh Score*
Leberzellkarzinom*
Leberzirrhose*
Alpha-Fetoprotein*
Assay*
Urine pregnancy test negative*
negativer Schwangerschaftstest*
Blut*
fertil*
maskulin, männlich*
feminin, weiblich*
Kontrazeption*
Allergic reaction to substance*
Interferon, IFN*
Peginterferon alpha-2a (substance)*
Amantadin*
Medikation*
Schwangerschaft*
schwanger*
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Stillzeit*
signs*
Symptom*
Systemische Therapie*
Antiviral treatment*
Immunotherapy, antineoplastic*
Immunomodulatory or immunosuppressive
therapy*
Acyclovir*
Valacyclovir*
eczema herpeticum*
Investigational New Drug*
Hepatitis-A-Virus, HAV*
Immunglobulin, IgM*
Hepatitis-B-Oberflächenantigen*
Hepatitis B core IgM level*
HIV-Virus*
End Stage Liver Disease*
Mann*
Frau*
disease risk*
Anämie*
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Baseline*
Neutrophil count (procedure)*
Thrombozyten*
Kreatinin im Serum*
Concentration*
Psychiatric disorder*
Depression*
Epilepsia*
Stabilisierung*
Immunotherapy*
Lungenerkrankung*
Limitation*
Functional Status, Level of function*
Herzkrankheit*
Organtransplantation*
Major (qualifier value)*
Keratoplastik, Hornhauttransplantation*
disorder*
Krebs*
Thyroid dysfunction*
Retinopathy*
Ophthalmological disorder*
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Diabetes mellitus*
Hypertonie*
Drug abuse*
aktiv*
Prescription (procedure)*
Opioid Substitution*
Stability*
Memantine (substance)*
Take- dosing instruction imperative (qualifier
value)*
Kardiomyopathie*
Myokarditis*
AV-Block*
Bradykardie*
QTC interval*
Finding of ECG QT interval (finding)*
U-Welle*
Syndrom*
kongenital*
Ventrikuläre Arrhythmie*
Ventricular tachycardia, polymorphic with Q-T
prolongation*
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simultan*
1-(1,1-Dimethylethyl)-4,4-diphenylpiperidine*
Antiarrhythmic drug*
Antipsychotika*
trizyklisches Antidepressivum*
tetrazyklisches Antidepressivum*
Antihistaminikum*
Makrolid*
Gyraseinhibitor*
Azole antifungal (substance)*
Glaukom*
Engwinkelglaukom*
Excitable*
Konfusion*
Delirium*
Psychose*
exogen*
Anamnese*
Prostatahyperplasie, Prostata-Adenom*
Diuretikum*
Triamteren*
Hydrochlorothiazid*
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Einverständniserklärung*
Erfordernis*
Studie*
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Rhabdomyosarcoma CWS-2007-HR
NCT00876031
CWS-2007-HR: A randomised phase-III trial of the
Cooperative Soft-Tissue-Study-Group for localised high-risk
rhabdomyosarcoma and localised Rhabdomyosarcoma-like
Soft Tissue Sarcoma in children, adolescents, and young
adults   http://clinicaltrials.gov/show/NCT00876031
http://www.cws.olgahospital-stuttgart.de
All rights reserved. Please visit https://medical-data-
models.org/forms/10876
Treatment Rhabdomyosarcoma B4 -
Block 5 O-TI NCT00876031
O-TIE body dimensions
Körpergröße*
Körpergewicht*
Körperoberfläche*
Block O-TI
Datum Beginn*
Trofosfamid kumulativ/Block*
Idarubicin kumulativ/Block*
Sollwert Trofosfamid nach KOF*
Sollwert Idarubicin nach KOF
Abstand vorheriger Block in Tagen
Toxicity common
Karnofsky/Lansky Index*
Tod (0)
10% (10)
100% (100)
20% (20)
30% (30)
40% (40)
50% (50)
60% (60)
70% (70)
80% (80)
90% (90)
Hämatologische Toxizität
Hämoglobin*
Grad 0 (0)
1 / 5
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Grad 5 (5)
Leukozyten (10E9/l)*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Grad 5 (5)
Neutrophile Granulozyten*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Grad 5 (5)
Thrombozyten (G/l)*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Grad 5 (5)
Toxicity infection
Infektion*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Grad 5 (5)
Fieber ( Grad C)*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Grad 5 (5)
Toxicity gastrointestinal
Übelkeit*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Grad 5 (5)
Erbrechen [Episoden/24 Std]*
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Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Grad 5 (5)
Mucositis (klinisch)*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Grad 5 (5)
Diarrhoe*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Grad 5 (5)
Toxicity kidney
Kreatinin*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Grad 5 (5)
Proteinurie (g/24 Std.)*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Grad 5 (5)
Hämaturie/Hämoglobinurie*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Grad 5 (5)
Toxicity neurology
Verwirrtheit*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Grad 5 (5)
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Neuropathie sensorisch*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Grad 5 (5)
Neuropathie motorisch*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Grad 5 (5)
Toxicity liver
Bilirubin*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Grad 5 (5)
S-GOT/S-GPT*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Grad 5 (5)
Toxicity Herz
Arrhythmie*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Grad 5 (5)
Linksventrikuläre Herzfunktion*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Grad 5 (5)
Toxicity other
Bezeichnung andere Toxizität*
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Toxizität Grad*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Grad 5 (5)
Toxicity comment
Bemerkungen zur Toxizität
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Rhabdomyosarcoma CWS-2007-HR
NCT00876031
CWS-2007-HR: A randomised phase-III trial of the
Cooperative Soft-Tissue-Study-Group for localised high-risk
rhabdomyosarcoma and localised Rhabdomyosarcoma-like
Soft Tissue Sarcoma in children, adolescents, and young
adults   http://clinicaltrials.gov/show/NCT00876031
http://www.cws.olgahospital-stuttgart.de
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Treatment B4 -Block 7 O-TI
Rhabdomyosarcoma NCT00876031
Block O-TI
Datum Beginn*
Trofosfamid kumulativ/Block*
Idarubicin kumulativ/Block*
Sollwert Trofosfamid nach KOF*
Sollwert Idarubicin nach KOF
Abstand vorheriger Block in Tagen
Toxicity common
Karnofsky/Lansky Index*
Tod (0)
10% (10)
100% (100)
20% (20)
30% (30)
40% (40)
50% (50)
60% (60)
70% (70)
80% (80)
90% (90)
Toxicity hematology
Hämoglobin*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Grad 5 (5)
Leukozyten (10E9/l)*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
1 / 5
Grad 3 (3)
Grad 4 (4)
Grad 5 (5)
Neutrophile Granulozyten*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Grad 5 (5)
Thrombozyten (G/l)*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Grad 5 (5)
Toxicity infection
Infektion*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Grad 5 (5)
Fieber ( Grad C)*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Grad 5 (5)
Toxicity gastrointestinal
Ãœbelkeit*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Grad 5 (5)
Erbrechen [Episoden/24 Std]*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Grad 5 (5)
Mucositis (klinisch)*
Grad 0 (0)
Grad 1 (1)
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Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Grad 5 (5)
Diarrhoe*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Grad 5 (5)
Toxicity kidney
Kreatinin*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Grad 5 (5)
Proteinurie (g/24 Std.)*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Grad 5 (5)
Hämaturie/Hämoglobinurie*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Grad 5 (5)
Toxicity neurology
Verwirrtheit*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Grad 5 (5)
Neuropathie sensorisch*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Grad 5 (5)
Neuropathie motorisch*
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Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Grad 5 (5)
Toxicity liver
Bilirubin*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Grad 5 (5)
S-GOT/S-GPT*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Grad 5 (5)
Toxicity Herz
Arrhytmie*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Grad 5 (5)
LinksventrikulÃ¤re Herzfunktion*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Grad 5 (5)
Toxicity other
Bezeichnung andere ToxizitÃ¤t*
ToxizitÃ¤t Grad*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Grad 5 (5)
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Toxicity comment
Bemerkungen zur ToxizitÃ¤t
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Rhabdomyosarcoma treatment CWS-2007-
HR NCT00876031
CWS-2007-HR: A randomised phase-III trial of the
Cooperative Soft-Tissue-Study-Group for localised high-risk
rhabdomyosarcoma and localised Rhabdomyosarcoma-like
Soft Tissue Sarcoma in children, adolescents, and young
adults   http://clinicaltrials.gov/show/NCT00876031
http://www.cws.olgahospital-stuttgart.de
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Treatment B4 - Block 4 O-TE
Rhabdomyosarcoma NCT00876031
Block O-TE
Datum Beginn*
Trofosfamid kumulativ/Block*
Etoposid kumulativ/Block*
Sollwert Trofosfamid nach KOF*
Sollwert Etoposid nach KOF*
Abstand vorheriger Block in Tagen
Toxicity common
Karnofsky/Lansky Index*
Tod (0)
10% (10)
100% (100)
20% (20)
30% (30)
40% (40)
50% (50)
60% (60)
70% (70)
80% (80)
90% (90)
Hämatologische Toxizität
Hämoglobin*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Grad 5 (5)
Leukozyten (10E9/l)*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
1 / 5
Grad 5 (5)
Neutrophile Granulozyten*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Grad 5 (5)
Thrombozyten (G/l)*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Grad 5 (5)
Toxicity infection
Infektion*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Grad 5 (5)
Fieber ( Grad C)*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Grad 5 (5)
Toxicity gastrointestinal
Ãœbelkeit*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Grad 5 (5)
Erbrechen [Episoden/24 Std]*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Grad 5 (5)
Mucositis (klinisch)*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
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Grad 3 (3)
Grad 4 (4)
Grad 5 (5)
Diarrhoe*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Grad 5 (5)
Toxicity kidney
Kreatinin*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Grad 5 (5)
Proteinurie (g/24 Std.)*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Grad 5 (5)
Hämaturie/Hämoglobinurie*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Grad 5 (5)
Toxicity neurology
Verwirrtheit*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Grad 5 (5)
Neuropathie sensorisch*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Grad 5 (5)
Neuropathie motorisch*
Grad 0 (0)
Grad 1 (1)
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Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Grad 5 (5)
Toxicity liver
Bilirubin*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Grad 5 (5)
S-GOT/S-GPT*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Grad 5 (5)
Toxicity Herz
Arrhytmie*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Grad 5 (5)
Linksventrikuläre Herzfunktion*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Grad 5 (5)
Toxicity other
Bezeichnung andere Toxizität*
Toxizität Grad*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Grad 5 (5)
Toxicity comment
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Bemerkungen zur Toxizität
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CML TIGER inclusion NCT01657604
Bogen 1 Einschluss Randomisierung TIGER Studie Version
22052012 Condition
NCT01657604
All rights reserved. Please visit https://medical-data-
models.org/forms/10879
Bogen 1 Einschluss Randomisierung
CML NCT01657604
Adiminstrative Daten I
Klinik-Nr.*
Patienten-Nr.*
Geburtsdatum
Geburtsmonat*
Geburtstag*
Adiminstrative Daten II
Beurteilungsdatum*
Diagnosedatum*
Geschlecht*
männlich (männlich)
weiblich (weiblich)
Randomisierung
Medikation*
Nilotinib + PEG-IFN (Nilotinib + PEG-
IFN)
Nilotinib 2*300mg (Nilotinib 2*300mg)
Datum der Randomisierung*
nicht randomisierbar*
Ja
Nein
Grund für nicht mögliche Randomisierung*
Laborwerte
Datum der Laborwerte*
Leukozyten (10^9/l)*
1 / 7
Blasten (%)*
Promyelozyten (%)*
Myelozyten, Metamyelozyten (%)*
Stabkernige (%)*
Segmentkernige (%)*
Eosinophile (%)*
Basophile (%)*
Monozyten (%)*
Lymphozyten (%)*
Normoblasten (%)*
Thrombozyten (10^9/L)*
Hämoglobin
Hämoglobin
Hämatokrit (%)*
Harnstoff (mg/dL)*
Kreatinin (mg/dL)*
Harnsäure (mg/dL)*
Albumin (g/dL)*
Protein (g/dL)*
Bilirubin gesamt (μmol/L)*
Bilirubin gesamt (mg/dL)
Bilirubin direkt (μmol/L)*
2 / 7
CML TIGER inclusion NCT01657604
Bilirubin direkt (mg/dL)*
Bilirubin indirekt (μmol/L)*
Bilirubin indirekt (mg/dL)*
ALAT (SGPT) (U/L)*
ASAT (SGOT) (U/L)*
LDH (U/L)*
Natrium (mmol/L)*
Kalzium (mmol/L)*
Phosphat (mmol/L)*
Lipase (U/L)*
Amylase (U/L)*
Kalium (mmol/L)*
Magnesium (mmol/L)*
TSH (mU/L)*
Glukose (mg/dL)*
Glukose (mmol/L)*
Hämoglobin A1c
Cholesterin (mg/dL)*
Cholesterin (mmol/L)*
Molekularbiologie
nicht durchgeführt*
Ja
Nein
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Datum der Durchführung*
BCR-ABL-Transkripte
b2a2*
Ja
Nein
b3a2*
Ja
Nein
b2a3*
Ja
Nein
b3a3*
Ja
Nein
e1a2*
Ja
Nein
e6a2*
Ja
Nein
e19a2*
Ja
Nein
sonstige*
Ja
Nein
sonstige*
kein BCR-ABL-Transkript*
Ja
Nein
Untersucher/Ort*
Labor-Nr.*
Quality of Life
Fragebogen ausgefüllt*
Ja
Nein
klinischer Befund I
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Datum klinischer Befund*
Körpergröße (cm)*
Gewicht (kg)*
Milzgröße (palpiert unter dem Rippenbogen)*
Milz in US, größter Durchmesser*
Blutdruck
Blutdruck systolisch*
Blutdruck diastolisch*
klinischer Befund II
Herzfrequenz (/min)*
Extramedulläre Manifestationen*
Ja
Nein
welche (z.B. LK, Haut, usw.)*
Vor- und Begleiterkrankungen
Vor- und Begleiterkrankung*
Medikamente
Medikament*
Dosis*
Einheit der Dosis*
Beginn Medikament*
Ende Medikament*
andauernde Medikation*
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Ja
Nein
Knochenmarkanalyse
nich durchgeführt*
Ja
Nein
nicht vorliegend*
Ja
Nein
Datum der Durchführung*
Zellularität*
aplastisch (aplastisch)
hyperzellulär (hyperzellulär)
hypozellulär (hypozellulär)
normozellulär (normozellulär)
stark hyperzellulär (stark hyperzellulär)
Blasten (%)*
Promyelozyten (%)*
Basophile (%)*
Zytogenetik
ausgewertete Mitosen*
Normaler Karyotyp*
Normal, aber mit Zusatzaberrationen*
Philadelphia-Chromosom t(9;22)*
Philadelphia-Chromosom mit
Zusatzaberrationen*
Befunde nach ISCN:*
Nicht auswertbare Mitosen*
Untersucher/Ort*
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Labor-Nr.*
Unterschrift
Kommentar*
Klinik*
Datum*
Unterschrift*
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Rhabdomyosarcoma treatment CWS-2007-
HR NCT00876031
CWS-2007-HR: A randomised phase-III trial of the
Cooperative Soft-Tissue-Study-Group for localised high-risk
rhabdomyosarcoma and localised Rhabdomyosarcoma-like
Soft Tissue Sarcoma in children, adolescents, and young
adults   http://clinicaltrials.gov/show/NCT00876031
http://www.cws.olgahospital-stuttgart.de
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Treatment B4 - Block 6 O-TE
Rhabdomyosarcoma NCT00876031
Block O-TE
Datum Beginn*
Trofosfamid kumulativ/Block*
Etoposid kumulativ/Block*
Sollwert Trofosfamid nach KOF*
Sollwert Etoposid nach KOF*
Abstand vorheriger Block in Tagen
Toxicity common
Karnofsky/Lansky Index*
Tod (0)
10% (10)
100% (100)
20% (20)
30% (30)
40% (40)
50% (50)
60% (60)
70% (70)
80% (80)
90% (90)
Toxicity hematology
Hämoglobin*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Grad 5 (5)
Leukozyten*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
1 / 5
Grad 5 (5)
Neutrophile Granulozyten*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Grad 5 (5)
Thrombozyten (G/l)*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Grad 5 (5)
Toxicity infection
Infektion*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Grad 5 (5)
Fieber ( Grad C)*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Grad 5 (5)
Toxicity gastrointestinal
Übelkeit*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Grad 5 (5)
Erbrechen [Episoden/24 Std]*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Grad 5 (5)
Mucositis (klinisch)*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
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Grad 3 (3)
Grad 4 (4)
Grad 5 (5)
Diarrhoe*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Grad 5 (5)
Toxicity kidney
Kreatinin*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Grad 5 (5)
Proteinurie (g/24 Std.)*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Grad 5 (5)
Hämaturie/Hämoglobinurie*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Grad 5 (5)
Toxicity neurology
Verwirrtheit*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Grad 5 (5)
Neuropathie sensorisch*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Grad 5 (5)
Neuropathie motorisch*
Grad 0 (0)
Grad 1 (1)
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Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Grad 5 (5)
Toxicity liver
Bilirubin*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Grad 5 (5)
S-GOT/S-GPT*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Grad 5 (5)
Toxicity Herz
Arrhytmie*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Grad 5 (5)
Linksventrikuläre Herzfunktion*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Grad 5 (5)
Toxicity other
Bezeichnung andere Toxizität*
Toxizität Grad*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Grad 5 (5)
Toxicity comment
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Cooperative Soft-Tissue-Study-Group for localised high-risk
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Treatment B4 - Block 8 O-TE
Rhabdomyosarcoma NCT00876031
Block O-TE
Datum Beginn*
Trofosfamid kumulativ/Block*
Etoposid kumulativ/Block*
Sollwert Trofosfamid nach KOF*
Sollwert Etoposid nach KOF*
Abstand vorheriger Block in Tagen
Toxicity common
Karnofsky/Lansky Index*
Tod (0)
10% (10)
100% (100)
20% (20)
30% (30)
40% (40)
50% (50)
60% (60)
70% (70)
80% (80)
90% (90)
Toxicity hematology
Hämoglobin*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Grad 5 (5)
Leukozyten (10E9/l)*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
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Grad 3 (3)
Grad 4 (4)
Grad 5 (5)
Neutrophile Granulozyten*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Grad 5 (5)
Thrombozyten (G/l)*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Grad 5 (5)
Toxicity infection
Infektion*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Grad 5 (5)
Fieber ( Grad C)*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Grad 5 (5)
Toxicity gastrointestinal
Übelkeit*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Grad 5 (5)
Erbrechen [Episoden/24 Std]*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Grad 5 (5)
Mucositis (klinisch)*
Grad 0 (0)
Grad 1 (1)
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Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Grad 5 (5)
Diarrhoe*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Grad 5 (5)
Toxicity kidney
Kreatinin*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Grad 5 (5)
Proteinurie (g/24 Std.)*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Grad 5 (5)
Hämaturie/Hämoglobinurie*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Grad 5 (5)
Toxicity neurology
Verwirrtheit*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Grad 5 (5)
Neuropathie sensorisch*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Grad 5 (5)
Neuropathie motorisch*
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Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Grad 5 (5)
Toxicity liver
Bilirubin*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Grad 5 (5)
S-GOT/S-GPT*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Grad 5 (5)
Toxicity Herz
Arrhytmie*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Grad 5 (5)
Linksventrikuläre Herzfunktion*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Grad 5 (5)
Toxicity other
Bezeichnung andere Toxizität*
Toxizität Grad*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Grad 5 (5)
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Toxicity comment
Bemerkungen zur Toxizität
5 / 5
Rhabdomyosarcoma treatment CWS-2007-HR NCT00876031
Rhabdomyosarcoma treatment CWS-2007-
HR NCT00876031
CWS-2007-HR: A randomised phase-III trial of the
Cooperative Soft-Tissue-Study-Group for localised high-risk
rhabdomyosarcoma and localised Rhabdomyosarcoma-like
Soft Tissue Sarcoma in children, adolescents, and young
adults   http://clinicaltrials.gov/show/NCT00876031
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Treatment B4 - Block 1 O-TI
Rhabdomyosarcoma NCT00876031
Datum 1. Block
Datum 1. Block*
O-TIE body dimensions
Körpergröße*
Körpergewicht*
Körperoberfläche*
Block O-TI
Datum Beginn*
Trofosfamid kumulativ/Block*
Idarubicin kumulativ/Block*
Sollwert Trofosfamid nach KOF*
Sollwert Idarubicin nach KOF
Abstand vorheriger Block in Tagen
Toxicity common
Karnofsky/Lansky Index*
Tod (0)
10% (10)
100% (100)
20% (20)
30% (30)
40% (40)
50% (50)
60% (60)
70% (70)
80% (80)
90% (90)
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Toxicity hematology
Hämoglobin*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Grad 5 (5)
Leukozyten (10E9/l)*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Grad 5 (5)
Neutrophile Granulozyten*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Grad 5 (5)
Thrombozyten (G/l)*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Grad 5 (5)
Toxicity infection
Infektion*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Grad 5 (5)
Fieber ( Grad C)*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Grad 5 (5)
Toxicity gastrointestinal
Übelkeit*
Grad 0 (0)
Grad 1 (1)
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Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Grad 5 (5)
Erbrechen [Episoden/24 Std]*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Grad 5 (5)
Mucositis (klinisch)*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Grad 5 (5)
Diarrhoe*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Grad 5 (5)
Toxicity kidney
Kreatinin*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Grad 5 (5)
Proteinurie (g/24 Std.)*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Grad 5 (5)
Hämaturie/Hämoglobinurie*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Grad 5 (5)
Toxicity neurology
Verwirrtheit*
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Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Grad 5 (5)
Neuropathie sensorisch*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Grad 5 (5)
Neuropathie motorisch*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Grad 5 (5)
Toxicity liver
Bilirubin*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Grad 5 (5)
S-GOT/S-GPT*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Grad 5 (5)
Toxicity Herz
Arrhytmie*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Grad 5 (5)
Linksventrikuläre Herzfunktion*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Grad 5 (5)
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Toxicity other
Bezeichnung andere Toxizität*
Toxizität Grad*
Grad 0 (0)
Grad 1 (1)
Grad 2 (2)
Grad 3 (3)
Grad 4 (4)
Grad 5 (5)
Toxicity comment
Bemerkungen zur Toxizität
5 / 5
Rhabdomyosarcoma treatment CWS-2007-HR NCT00876031
Daten der Akutversorgung SHT-Register
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Daten der Akutversorgung SHT-
Register
Daten der Akutversorgung SHT-Register
Schweregrad des SHT
Augen öffnen*
keine Reaktion (1)
auf Schmerzreiz (2)
auf Ansprache (3)
spontan (4)
Sprache*
keine Antwort (1)
unverständlich (2)
inadäquat (3)
desorientiert (4)
orientiert (5)
Motorik*
keine Reaktion (1)
Streckreaktion (2)
Beugereaktion (3)
ungezielte Schmerzabwehr (4)
gezielte Schmerzabwehr (5)
befolgt Aufforderungen (6)
Glasgow Coma Scale*
Art der Verletzung*
gedeckt (1)
offen (2)
penetrierend (3)
Dauer der Bewusstlosigkeit*
Begleitverletzungen
ICD Code*
Polytrauma*
thoraxabdominell (1)
Extremitäten (2)
nein (3)
Spinale Läsion*
Ja
Nein
Höhe der spinalen Läsion*
Katecholaminbedarf*
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Ja
Nein
Länge des Katecholaminbedarfs*
Minim. RRsyst während der 1. 24 Stunden  in
mmHg*
Ja
Nein
Hypoxie (aus Sa=2 < 90%)*
Ja
Nein
Zerebraler Anfall*
Ja
Nein
Zeitliches Auftreten des Zerebralen Anfalls nach
dem Ereignis*
unmittelbar (1)
< 7 Stunden (2)
> 7 Stunden (3)
Häufigkeit Zerebraler Anfälle*
Anisokorie in der Prähospitalphase*
Ja
Nein
Prozeduren
Kraniektomie*
Ja
Nein
Anzahl Kraniektomien*
Dauer Kraniektomie (in Tagen)*
Ventrikel Drainage*
Ja
Nein
Dauer der Ventrikel Drainage (in Tagen)*
Ventrikel Drainage, permanente Ableitung*
Ja
Nein
Hirndruck ICP in cmH2O*
Hirndruck CCP in cmH2O*
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Beatmung*
Ja
Nein
Dauer der Beatmung (in Tagen)*
Hypothermie*
Ja
Nein
Dauer der Hypothermie*
Hochdosisbarbiturattherapie*
Ja
Nein
Dauer der Hochdosisbarbiturattherapie*
Hyperventilation*
Ja
Nein
Hyperosmolare Therapie*
Ja
Nein
Krankenhausaufenthalt
Dauer des Krankenhausaufenthalts (in Tagen)*
Art des Krankenhausaufenthaltes*
Intensivtherapie (1)
Akutversorgung (2)
Kostenträger*
Laborwerte
Neuronenspezifische Enolase (NSE)*
Natrium*
Thrombozyten*
Leukozyten*
Elektrolyte*
Hämoglobin*
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BGA*
pH*
Glukose min*
Glukose max*
LDH*
CK*
S100*
MBP*
GFAP*
Sonstiges
Pubertätsstatus*
präpubertär (1)
postpubertär (2)
EEG-Auffälligkeiten*
Ja
Nein
Dauer der EEG-Auffälligkeiten (in Wochen nach
SHT)*
EEG-Auffälligkeit: Anfallsbereitschaft*
Ja
Nein
EEG-Auffälligkeit: Verlangsamung*
Ja
Nein
EEG-Auffälligkeit*
fokal (1)
generalisiert (2)
Evoziertes Potential AEP/BERA*
Ja
Nein
Evoziertes Potential SEP*
Ja
Nein
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Vasospasmen*
Ja
Nein
Time to Hospital (in Minuten)*
Erstversorgung in NCh-Zentrum*
Ja
Nein
Fieber unter Intensivtherapie*
Ja
Nein
Höhe des Fiebers unter Intensivtherapie*
Kopfschmerzen im Verlauf*
Ja
Nein
Schwere Kopfschmerzen im Verlauf*
Fokales Defizit im Verlauf*
Ja
Nein
Einschätzung des fokalen Defizits im Verlauf*
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Disease Course TIGER Study CML
NCT01657604
Adiminstrative Daten I
Klinik-Nr.*
Patienten-Nr.*
Geburtsdatum
Geburtsmonat*
Geburtstag*
Adiminstrative Daten II
Beurteilungsdatum*
Diagnosedatum*
Geschlecht*
männlich (m)
weiblich (w)
Laborwerte
Datum der Laborwerte*
Leukozyten (10^9/l)*
Blasten (%)*
Promyelozyten (%)*
Myelozyten, Metamyelozyten (%)*
Stabkernige (%)*
Segmentkernige (%)*
Eosinophile (%)*
1 / 6
Basophile (%)*
Monozyten (%)*
Lymphozyten (%)*
Normoblasten (%)*
Thrombozyten (10^9/L)*
Hämoglobin*
Hämoglobin
Hämatokrit (%)*
Harnstoff (mg/dL)*
Kreatinin (mg/dL)*
Harnsäure (mg/dL)*
Albumin (g/dL)*
Protein*
Bilirubin gesamt (μmol/L)*
Bilirubin gesamt (mg/dL)*
Bilirubin direkt (μmol/L)*
Bilirubin direkt (mg/dL)*
Bilirubin indirekt (μmol/L)*
Bilirubin indirekt (mg/dL)*
ALAT (SGPT) (U/L)*
ASAT (SGOT) (U/L)*
LDH (U/L)*
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Natrium (mmol/L)*
Kalzium (mmol/L)*
Phosphat (mmol/L)*
Lipase (U/L)*
Amylase (U/L)*
Kalium (mmol/L)*
Magnesium (mmol/L)*
TSH (mU/L)*
Glukose (mg/dL)*
Glukose (mmol/L)*
Hämoglobin 1Ac (mmol/mol)*
Cholesterin (mg/dL)*
Cholesterin (mmol/L)*
Quality of Life
Fragebogen ausgefüllt*
Ja
Nein
klinischer Befund I
Datum klinischer Befund*
Körpergröße (cm)*
Gewicht (kg)*
Milzgröße (palpiert unter dem Rippenbogen)*
Milz in US, größter Durchmesser*
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Blutdruck
Blutdruck systolisch*
Blutdruck diastolisch*
klinischer Befund II
Herzfrequenz (/min)*
Extramedulläre Manifestationen*
Ja
Nein
welche (z.B. LK, Haut, usw.)*
Molekularbiologie
nicht durchgeführt*
Ja
Nein
Datum der Durchführung*
Nested-RT-PCR*
negativ (neg.)
postitiv (pos.)
BCR-ABL International Scale*
ABL-Transkripte / 5μL*
Material*
Blut (Blut)
Knochenmark (Knochenmark)
Untersucher/Ort*
Labor-Nr.*
Knochenmarkanalyse
nich durchgeführt*
Ja
Nein
nicht vorliegend*
Ja
Nein
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Datum der Durchführung*
Zellularität*
aplastisch (aplastisch)
hyperzellulär (hyperzellulär)
hypozellulär (hypozellulär)
normozellulär (normozellulär)
stark hyperzellulär (stark hyperzellulär)
Blasten (%)*
Promyelozyten (%)*
Basophile (%)*
Zytogenetik
ausgewertete Mitosen*
Normaler Karyotyp*
Normal, aber mit Zusatzaberrationen*
Philadelphia-Chromosom t(9;22)*
Philadelphia-Chromosom mit
Zusatzaberrationen*
Befunde nach ISCN:*
Nicht auswertbare Mitosen*
Untersucher/Ort*
Labor-Nr.*
Unterschrift
Kommentar*
Klinik*
Datum*
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Unterschrift*
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S0522 Osteonecrotic Jaw Lesion
Form
Header
SWOG Patient ID
SWOG Study No.
Registration Step
Patient Initials (L, F, M)
Date Form Completed
Institution/Affiliate
Physician
Participating Group Name
Participating Group Study No.
Participating Group Patient ID
Osteonecrotic lesions
Number of osteonecrotic lesions
1 (1)
2 (2)
3 (3)
Date of onset
Any signs/symptoms of infection (e.g., mucosal
erythema, swelling, pus, bad taste)
Yes
No
Maxilla
Alveolar Ridge (Alveolar ridge)
Anterior (Anterior)
Buccal (Buccal)
Lingual (Lingual)
1 / 2
Palate (Palate)
Posterior (Posterior)
Mandible
Alveolar Ridge (Alveolar ridge)
Anterior (Anterior)
Buccal (Buccal)
Lingual (Lingual)
Mylohyoid Plate (Mylohyoid plate)
Posterior (Posterior)
Size of lesion (mm)
Associated factor(s) (select all that apply:)
Dental Extraction (Dental extraction)
Denture Trauma (Denture trauma)
No Identified Factor (No identified factor)
Other Dental Surgery (Other dental
surgery)
Periodontal Infection (Periodontal
infection)
Steroid Use
Did the patient receive steroids within 12 months
of occurrence of the current jaw lesion(s)
Yes
No
Agent Name (If Yes,)
Agent Begin Date (to:)
Agent End Date
Comments
Comments
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Southwest Oncology Group S0421 Symptom
Questionnaires: Step 1 Randomization Form
NCT00134056 
Docetaxel and Prednisone With or Without Atrasentan in
Treating Patients With Stage IV Prostate Cancer and Bone
Metastases That Did Not Respond to Previous Hormone
Therapy
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=F15B296A-
D2C9-33BF-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
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Southwest Oncology Group S0421
Symptom Questionnaires: Step 1
Randomization Form NCT00134056
SWOG clinical trial symptom
questionnaire
SWOG Patient ID
SWOG Study No.
Registration Step
Patient Initials (L, F M)
Date form completed
Planned Assessment
Prestudy (Prestudy)
Week 10 (Week 10)
Week 13 (Week 13)
Week 16 (Week 16)
Week 19 (Week 19)
Week 22 (Week 22)
Week 25 (Week 25)
Week 28 (Week 28)
Week 31 (Week 31)
Week 34 (Week 34)
Week 37 (Week 37)
Week 4 (Week 4)
Week 7 (Week 7)
Institution/Affiliate
Physician
Participating Group Name
Participating Study No.
Participating Patient ID
1 / 6
Have you had pain than these everyday kinds of
pain today? (Throughout our lives, most of us
have had pain from time to time such as minor
headaches, sprains, and toothaches.)
Yes
No
Please rate your pain by selecting the one
number that best describes your pain at its
WORST in the past 24 hours.
Whole Number (0)
Whole Number (1)
Whole Number (10)
Whole Number (2)
Whole Number (3)
Whole Number (4)
Whole Number (5)
Whole Number (6)
Whole Number (7)
Whole Number (8)
Whole Number (9)
Please rate your pain by selecting the one
number that best describes your pain at its
LEAST in the past 24 hours.
Whole Number (0)
Whole Number (1)
Whole Number (10)
Whole Number (2)
Whole Number (3)
Whole Number (4)
Whole Number (5)
Whole Number (6)
Whole Number (7)
Whole Number (8)
Whole Number (9)
Please rate your pain by selecting the one
number that best describes your pain on the
AVERAGE.
Whole Number (0)
Whole Number (1)
Whole Number (10)
Whole Number (2)
Whole Number (3)
Whole Number (4)
Whole Number (5)
Whole Number (6)
Whole Number (7)
Whole Number (8)
Whole Number (9)
Please rate your pain by selecting the one
number that tells how much pain you have
RIGHT NOW.
Whole Number (0)
Whole Number (1)
Whole Number (10)
Whole Number (2)
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Whole Number (3)
Whole Number (4)
Whole Number (5)
Whole Number (6)
Whole Number (7)
Whole Number (8)
Whole Number (9)
Are you receiving treatments or medications for
your pain?
Yes
No
In the past 24 hours, how much RELIEF have
pain treatments or medications provided? (Please
select the percentage that most shows how
much.)
0% (0)
10% (0.1)
20% (0.2)
30% (0.3)
40% (0.4)
50% (0.5)
60% (0.6)
70% (0.7)
80% (0.8)
90% (0.9)
100% (1)
Select the one number that describes how, during
the past 24 hours, PAIN HAS INTERFERED with
your General Activity
0 (0)
1 (1)
10 (10)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
7 (7)
8 (8)
9 (9)
Select the one number that describes how, during
the past 24 hours, PAIN HAS INTERFERED with
your Mood
0 (0)
1 (1)
10 (10)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
7 (7)
8 (8)
9 (9)
Select the one number that describes how, during
3 / 6
Southwest Oncology Group S0421 Symptom Questionnaires: Step 1
Randomization Form NCT00134056
the past 24 hours, PAIN HAS INTERFERED with
your Walking ability
0 (0)
1 (1)
10 (10)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
7 (7)
8 (8)
9 (9)
Select the one number that describes how, during
the past 24 hours, PAIN HAS INTERFERED with
your Normal work (includes both work outside the
home and housework)
0 (0)
1 (1)
10 (10)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
7 (7)
8 (8)
9 (9)
Select the one number that describes how, during
the past 24 hours, PAIN HAS INTERFERED with
your Relations with other people
0 (0)
1 (1)
10 (10)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
7 (7)
8 (8)
9 (9)
Select the one number that describes how, during
the past 24 hours, PAIN HAS INTERFERED with
your Sleep
0 (0)
1 (1)
10 (10)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
7 (7)
8 (8)
9 (9)
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Select the one number that describes how, during
the past 24 hours, PAIN HAS INTERFERED with
your Enjoyment of life
0 (0)
1 (1)
10 (10)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
7 (7)
8 (8)
9 (9)
Please choose one response to describe your
pain
Discomforting (Discomforting)
Distressing (Distressing)
Excruciating (Excruciating)
Horrible (Horrible)
Mild (Mild)
No Pain (No pain)
How much during the past week did you feel full
of pep?
A Good Bit Of The Time (A good bit of
the time)
A Little Of The Time (A little of the time)
All Of The Time (All of the time)
Most Of The Time (Most of the time)
None Of The Time (None of the time)
Some Of The Time (Some of the time)
How much during the past week did you have a
lot of energy?
A Good Bit Of The Time (A good bit of
the time)
A Little Of The Time (A little of the time)
All Of The Time (All of the time)
Most Of The Time (Most of the time)
None Of The Time (None of the time)
Some Of The Time (Some of the time)
How much during the past week did you feel
worn out?
A Good Bit Of The Time (A good bit of
the time)
A Little Of The Time (A little of the time)
All Of The Time (All of the time)
Most Of The Time (Most of the time)
None Of The Time (None of the time)
Some Of The Time (Some of the time)
How much during the past week did you feel
tired?
A Good Bit Of The Time (A good bit of
the time)
A Little Of The Time (A little of the time)
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All Of The Time (All of the time)
Most Of The Time (Most of the time)
None Of The Time (None of the time)
Some Of The Time (Some of the time)
6 / 6
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Randomization Form NCT00134056
SOUTHWEST ONCOLOGY GROUP FOLLOW-UP
TUMOR ASSESSMENT FORM (S0421) NCT00134056
SOUTHWEST ONCOLOGY GROUP FOLLOW-UP
TUMOR ASSESSMENT FORM (S0421) NCT00134056 
Docetaxel and Prednisone With or Without Atrasentan in
Treating Patients With Stage IV Prostate Cancer and Bone
Metastases That Did Not Respond to Previous Hormone
Therapy
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=F159E224-
5826-3109-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/10887
SOUTHWEST ONCOLOGY GROUP
FOLLOW-UP TUMOR
ASSESSMENT FORM (S0421)
NCT00134056
Header
SWOG Patient ID
SWOG Study No.
Registration Step
Patient Initials (L, F M)
Date form completed
Institution/Affiliate
Physician
Participating Group Name
Participating Group Study No.
Participating Group Patient ID
Target Lesions
Target Lesions
Longest Diameter (cm)
Assessment Type (*)
Colposcopy (Colposcopy)
Ct Scan (CT scan)
Cystoscopy (Cystoscopy)
Cytologic Confirmation (Cytologic
confirmation)
Endoscopy (Endoscopy)
1 / 3
Histologic (Histologic confirmation)
Mri Scan (MRI scan)
Other (Other)
Palpation (Palpation)
Pet Scan (PET scan)
Plain Film/x-ray With Contrast (Plain
film/X-ray with contrast)
Plain Film/x-ray Without Contrast (Plain
film/X-ray without contrast)
Radioisotope Scan (Radioisotope scan)
Spiral Ct Scan (Spiral CT scan)
Ultrasound (Ultrasound)
Visualization (Visualization)
Assessment Date
Non-target Disease
Non-Target Disease
Extent
Clear Increase (Clear increase)
Complete Disappearance (Complete
disappearance)
Not Assessed (Not assessed)
Present (Present)
Assessment Type (*)
Colposcopy (Colposcopy)
Ct Scan (CT scan)
Cystoscopy (Cystoscopy)
Cytologic Confirmation (Cytologic
confirmation)
Endoscopy (Endoscopy)
Histologic (Histologic confirmation)
Mri Scan (MRI scan)
Other (Other)
Palpation (Palpation)
Pet Scan (PET scan)
Plain Film/x-ray With Contrast (Plain
film/X-ray with contrast)
Plain Film/x-ray Without Contrast (Plain
film/X-ray without contrast)
Radioisotope Scan (Radioisotope scan)
Spiral Ct Scan (Spiral CT scan)
Ultrasound (Ultrasound)
Visualization (Visualization)
Assessment Date
New Lesions (specify Site)
New Lesions (Specify Site)
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ASSESSMENT FORM (S0421) NCT00134056
Assessment Type (*)
Colposcopy (Colposcopy)
Ct Scan (CT scan)
Cystoscopy (Cystoscopy)
Cytologic Confirmation (Cytologic
confirmation)
Endoscopy (Endoscopy)
Histologic (Histologic confirmation)
Mri Scan (MRI scan)
Other (Other)
Palpation (Palpation)
Pet Scan (PET scan)
Plain Film/x-ray With Contrast (Plain
film/X-ray with contrast)
Plain Film/x-ray Without Contrast (Plain
film/X-ray without contrast)
Radioisotope Scan (Radioisotope scan)
Spiral Ct Scan (Spiral CT scan)
Ultrasound (Ultrasound)
Visualization (Visualization)
Assessment Date
Symptomatic deterioration
Symptomatic deterioration
Yes
No
Assessment Date
Comments
Comments
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ASSESSMENT FORM (S0421) NCT00134056
NCT00093470 ECOG Acute Leukemia
Disease Assessment Form - Form 1651
NCT00093470  ECOG Acute Leukemia Disease
Assessment Form - Form 1651
Tipifarnib in Treating Patients With Acute Myeloid Leukemia
in Remission
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=DBD30C56-
F431-6847-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/10888
NCT00093470  ECOG Acute
Leukemia Disease Assessment
Form - Form 1651
Header
ECOG Protocol Number
ECOG Patient ID
DCI Name (Place ID Label Here)
Patient Initials (Last, First)
Participating Group Protocol Number
Participating Group Patient ID
Institution/Affiliate
Registration Step
Report Period
Relapsed (Relapse)
Are data amended
Yes
No
ECOG Acute Leukemia Assessment
Date of Bone Marrow Biopsy (or Aspirate
Confirming relapse)
Marrow Blasts (%)
Marrow Cellularity (%)
Date Hematology (Blood) Sample Obtained
Peripheral Leukemic blasts
Yes
1 / 2
No
Peripheral Platelet Count (/mm3 x 1000)
Peripheral Granulocytes Count (AGC/ANC
/mm3*)
Clinical Signs and Symptoms of Relapse
Yes
No
If yes, specify
Date of Relapse
Comments
Comments
Investigator Signature
Investigator Signature Date
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Form 1651
Southwest Oncology Group S0421 Cover Sheet for Patient Completed
Questionnaires: Step 2 Post-Chemo Form NCT00134056
Southwest Oncology Group S0421 Cover Sheet for Patient
Completed Questionnaires: Step 2 Post-Chemo Form
NCT00134056 
Docetaxel and Prednisone With or Without Atrasentan in
Treating Patients With Stage IV Prostate Cancer and Bone
Metastases That Did Not Respond to Previous Hormone
Therapy
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=0F9D56C4-
48DA-2FAB-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/10889
Southwest Oncology Group S0421
Cover Sheet for Patient Completed
Questionnaires: Step 2 Post-Chemo
Form NCT00134056
SWOG clinical trial administrative data
SWOG Patient ID
SWOG Study No.
Registration Step
Patient Initials (L, F M)
Date form completed
Institution/Affiliate
Physician
Participating Group Name
Participating Study No.
Participating Patient ID
Planned Assessment
Week 40 (Week 40)
Week 43 (Week 43)
Week 46 (Week 46)
Week 49 (Week 49)
Week 52 (Week 52)
Was the Pain Medication Log and Pain
Assessment Form completed (required every
cycle and end of treatment [beginning of Week
37])
Yes
No
Did the patient require any assistance in
1 / 2
completing the questionnaire? (If completed,)
Yes
No
Describe (If yes,)
Method of questionnaire administration
By Telephone (by telephone)
In The Clinic (in the clinic)
Other (other)
Other (please specify)
If not completed, please give reason (select one)
Death (death)
Illness/deteriorating Health
(illness/deteriorating health)
Institution Error (institution error)
Not Illness Related (not illness related)
Other (other)
Comments
Comments
Person completing form, last name
Person completing form, phone
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Southwest Oncology Group S0421 Cover Sheet for Patient Completed
Questionnaires: Step 2 Post-Chemo Form NCT00134056
S0522 Baseline Tumor Assessment Form
S0522 Baseline Tumor Assessment Form
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=0EDFE8DB-
E62D-1B98-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/10890
S0522 Baseline Tumor Assessment
Form
Header
SWOG Patient ID
SWOG Study No.
Registration Step
Patient Initials (L, F M)
Institution/Affiliate
Physician
Participating Group Name
Participating Group Study No.
Participating Group Patient ID
Target lesion status
Target Lesions
Longest Diameter (cm)
Assessment Type (*)
Colposcopy (Colposcopy)
Ct Scan (CT scan)
Cystoscopy (Cystoscopy)
Cytologic Confirmation (Cytologic
confirmation)
Endoscopy (Endoscopy)
Histologic (Histologic confirmation)
Mri Scan (MRI scan)
Other (Other)
Palpation (Palpation)
Pet Scan (PET scan)
Plain Film/x-ray With Contrast (Plain
film/X-ray with contrast)
Plain Film/x-ray Without Contrast (Plain
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film/X-ray without contrast)
Radioisotope Scan (Radioisotope scan)
Spiral Ct Scan (Spiral CT scan)
Ultrasound (Ultrasound)
Visualization (Visualization)
Assessment Date
Assessment Date
Assessment Type (*)
Colposcopy (Colposcopy)
Ct Scan (CT scan)
Cystoscopy (Cystoscopy)
Cytologic Confirmation (Cytologic
confirmation)
Endoscopy (Endoscopy)
Histologic (Histologic confirmation)
Mri Scan (MRI scan)
Other (Other)
Palpation (Palpation)
Pet Scan (PET scan)
Plain Film/x-ray With Contrast (Plain
film/X-ray with contrast)
Plain Film/x-ray Without Contrast (Plain
film/X-ray without contrast)
Radioisotope Scan (Radioisotope scan)
Spiral Ct Scan (Spiral CT scan)
Ultrasound (Ultrasound)
Visualization (Visualization)
Non-target disease
Extent
Other Specify
Other Specify
Diagnostic Test
Tests/studies
Assessment Date
Comments
Comments
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S0522 Baseline Tumor Assessment Form
Southwest Oncology Group Follow-Up
Tumor Assessment Form NCT00569127
Southwest Oncology Group Follow-Up Tumor Assessment
Form NCT00569127 
Octreotide and Interferon Alfa-2b or Bevacizumab in
Treating Patients With Metastatic or Locally Advanced,
High-Risk Neuroendocrine Tumor
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=0EFA8F1D-
3BEE-5AD0-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/10891
Southwest Oncology Group Follow-
Up Tumor Assessment Form
NCT00569127
Header
SWOG Patient ID
SWOG Study No.
Registration Step
Patient Initials (L, F M)
Date form completed
Institution/Affiliate
Physician
Participating Group Name
Participating Group Study No.
Participating Group Patient ID
Target Lesions
Target Lesions
Longest Diameter (cm)
Assessment Type (*)
Colposcopy (Colposcopy)
Ct Scan (CT scan)
Cystoscopy (Cystoscopy)
Cytologic Confirmation (Cytologic
confirmation)
Endoscopy (Endoscopy)
Histologic (Histologic confirmation)
Mri Scan (MRI scan)
Other (Other)
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Palpation (Palpation)
Pet Scan (PET scan)
Plain Film/x-ray With Contrast (Plain
film/X-ray with contrast)
Plain Film/x-ray Without Contrast (Plain
film/X-ray without contrast)
Radioisotope Scan (Radioisotope scan)
Spiral Ct Scan (Spiral CT scan)
Ultrasound (Ultrasound)
Visualization (Visualization)
Assessment Date
Non-target Disease
Non-Target Disease
Extent
Clear Increase (Clear increase)
Complete Disappearance (Complete
disappearance)
Not Assessed (Not assessed)
Present (Present)
Assessment Type (*)
Colposcopy (Colposcopy)
Ct Scan (CT scan)
Cystoscopy (Cystoscopy)
Cytologic Confirmation (Cytologic
confirmation)
Endoscopy (Endoscopy)
Histologic (Histologic confirmation)
Mri Scan (MRI scan)
Other (Other)
Palpation (Palpation)
Pet Scan (PET scan)
Plain Film/x-ray With Contrast (Plain
film/X-ray with contrast)
Plain Film/x-ray Without Contrast (Plain
film/X-ray without contrast)
Radioisotope Scan (Radioisotope scan)
Spiral Ct Scan (Spiral CT scan)
Ultrasound (Ultrasound)
Visualization (Visualization)
Assessment Date
New Lesions (specify Site)
New Lesions (Specify Site)
Assessment Type (*)
Colposcopy (Colposcopy)
Ct Scan (CT scan)
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Cystoscopy (Cystoscopy)
Cytologic Confirmation (Cytologic
confirmation)
Endoscopy (Endoscopy)
Histologic (Histologic confirmation)
Mri Scan (MRI scan)
Other (Other)
Palpation (Palpation)
Pet Scan (PET scan)
Plain Film/x-ray With Contrast (Plain
film/X-ray with contrast)
Plain Film/x-ray Without Contrast (Plain
film/X-ray without contrast)
Radioisotope Scan (Radioisotope scan)
Spiral Ct Scan (Spiral CT scan)
Ultrasound (Ultrasound)
Visualization (Visualization)
Assessment Date
Symptomatic deterioration
Symptomatic deterioration
Yes
No
Assessment Date
Comments
Comments
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Southwest Oncology Group Follow-Up Tumor Assessment Form
NCT00569127
SOUTHWEST ONCOLOGY GROUP S0205 BASELINE
PHYSICAL EXAMINATION FORM NCT00075686
SOUTHWEST ONCOLOGY GROUP S0205 BASELINE
PHYSICAL EXAMINATION FORM NCT00075686 
S0205 Gemcitabine With or Without Cetuximab as First-
Line Therapy in Treating Patients With Locally Advanced
Unresectable or Metastatic Adenocarcinoma of the
Pancreas
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=F2FD44E4-
4DFA-66A0-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/10892
SOUTHWEST ONCOLOGY GROUP
S0205 BASELINE PHYSICAL
EXAMINATION FORM
NCT00075686
Header
SWOG Patient ID
SWOG Study No.
Registration Step
Patient Initials
Institution/Affiliate
Physician
Physical examination
Was a physical exam performed?
Yes
No
Date of examination
General appearance
Abnormal (Abnormal)
Normal (Normal)
Not Done (Not done)
Head, eyes, ears, nose, throat
Abnormal (Abnormal)
Normal (Normal)
Not Done (Not done)
Neck
Abnormal (Abnormal)
Normal (Normal)
Not Done (Not done)
Cardiovascular
Abnormal (Abnormal)
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Normal (Normal)
Not Done (Not done)
Lungs
Abnormal (Abnormal)
Normal (Normal)
Not Done (Not done)
Abdomen
Abnormal (Abnormal)
Normal (Normal)
Not Done (Not done)
Lymph nodes
Abnormal (Abnormal)
Normal (Normal)
Not Done (Not done)
Genitourinary
Abnormal (Abnormal)
Normal (Normal)
Not Done (Not done)
Extremities
Abnormal (Abnormal)
Normal (Normal)
Not Done (Not done)
Neurological
Abnormal (Abnormal)
Normal (Normal)
Not Done (Not done)
Skin
Abnormal (Abnormal)
Normal (Normal)
Not Done (Not done)
Other, specify
Musculoskeletal
Abnormal (Abnormal)
Normal (Normal)
Not Done (Not done)
Other, specify
Abnormal (Abnormal)
Normal (Normal)
Not Done (Not done)
If abnormal is marked under exam results, please
specify below
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SOUTHWEST ONCOLOGY GROUP S0205 BASELINE PHYSICAL
EXAMINATION FORM NCT00075686
Southwest Oncology Group Baseline Tumor
Assessment Form NCT00569127
Southwest Oncology Group Baseline Tumor Assessment
Form NCT00569127 
Octreotide and Interferon Alfa-2b or Bevacizumab in
Treating Patients With Metastatic or Locally Advanced,
High-Risk Neuroendocrine Tumor
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=0EFA8A53-
C6B1-5A7F-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/10893
Southwest Oncology Group Baseline
Tumor Assessment Form
NCT00569127
Header
SWOG Patient ID
SWOG Study No.
Registration Step
Patient Initials (L, F M)
Institution/Affiliate
Physician (Participating Group)
Participating Group Name
Participating Group Study No.
Participating Group Patient ID
Target lesion status
Target Lesions
Longest Diameter (cm)
Assessment Date
Assessment Date
Assessment Type (*)
Colposcopy (Colposcopy)
Ct Scan (CT scan)
Cystoscopy (Cystoscopy)
Cytologic Confirmation (Cytologic
confirmation)
Endoscopy (Endoscopy)
1 / 2
Histologic (Histologic confirmation)
Mri Scan (MRI scan)
Other (Other)
Palpation (Palpation)
Pet Scan (PET scan)
Plain Film/x-ray With Contrast (Plain
film/X-ray with contrast)
Plain Film/x-ray Without Contrast (Plain
film/X-ray without contrast)
Radioisotope Scan (Radioisotope scan)
Spiral Ct Scan (Spiral CT scan)
Ultrasound (Ultrasound)
Visualization (Visualization)
Assessment Type (*)
Colposcopy (Colposcopy)
Ct Scan (CT scan)
Cystoscopy (Cystoscopy)
Cytologic Confirmation (Cytologic
confirmation)
Endoscopy (Endoscopy)
Histologic (Histologic confirmation)
Mri Scan (MRI scan)
Other (Other)
Palpation (Palpation)
Pet Scan (PET scan)
Plain Film/x-ray With Contrast (Plain
film/X-ray with contrast)
Plain Film/x-ray Without Contrast (Plain
film/X-ray without contrast)
Radioisotope Scan (Radioisotope scan)
Spiral Ct Scan (Spiral CT scan)
Ultrasound (Ultrasound)
Visualization (Visualization)
Non-target disease
Extent
Diagnostic Test
Tests/studies
Assessment Date
Comments
Comments
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SOUTHWEST ONCOLOGY GROUP FOLLOW-UP
TUMOR ASSESSMENT FORM (S0205) NCT00075686
SOUTHWEST ONCOLOGY GROUP FOLLOW-UP
TUMOR ASSESSMENT FORM (S0205) NCT00075686 
S0205 Gemcitabine With or Without Cetuximab as First-
Line Therapy in Treating Patients With Locally Advanced
Unresectable or Metastatic Adenocarcinoma of the
Pancreas
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=F2EA530F-
C553-139C-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/10894
SOUTHWEST ONCOLOGY GROUP
FOLLOW-UP TUMOR
ASSESSMENT FORM (S0205)
NCT00075686
Header
SWOG Patient ID
SWOG Study No.
Registration Step
Patient Initials (L, F M)
Date form completed
Institution/Affiliate
Physician
Participating Group Name
Participating Group Study No.
Participating Group Patient ID
Target Lesions
Target Lesions
Longest Diameter (cm)
Assessment Type (*)
Colposcopy (Colposcopy)
Ct Scan (CT scan)
Cystoscopy (Cystoscopy)
Cytologic Confirmation (Cytologic
confirmation)
Endoscopy (Endoscopy)
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Histologic (Histologic confirmation)
Mri Scan (MRI scan)
Other (Other)
Palpation (Palpation)
Pet Scan (PET scan)
Plain Film/x-ray With Contrast (Plain
film/X-ray with contrast)
Plain Film/x-ray Without Contrast (Plain
film/X-ray without contrast)
Radioisotope Scan (Radioisotope scan)
Spiral Ct Scan (Spiral CT scan)
Ultrasound (Ultrasound)
Visualization (Visualization)
Assessment Date
Non-target Disease
Non-Target Disease
Extent
Clear Increase (Clear increase)
Complete Disappearance (Complete
disappearance)
Not Assessed (Not assessed)
Present (Present)
Assessment Type (*)
Colposcopy (Colposcopy)
Ct Scan (CT scan)
Cystoscopy (Cystoscopy)
Cytologic Confirmation (Cytologic
confirmation)
Endoscopy (Endoscopy)
Histologic (Histologic confirmation)
Mri Scan (MRI scan)
Other (Other)
Palpation (Palpation)
Pet Scan (PET scan)
Plain Film/x-ray With Contrast (Plain
film/X-ray with contrast)
Plain Film/x-ray Without Contrast (Plain
film/X-ray without contrast)
Radioisotope Scan (Radioisotope scan)
Spiral Ct Scan (Spiral CT scan)
Ultrasound (Ultrasound)
Visualization (Visualization)
Assessment Date
New Lesions (specify Site)
New Lesions (Specify Site)
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ASSESSMENT FORM (S0205) NCT00075686
Assessment Type (*)
Colposcopy (Colposcopy)
Ct Scan (CT scan)
Cystoscopy (Cystoscopy)
Cytologic Confirmation (Cytologic
confirmation)
Endoscopy (Endoscopy)
Histologic (Histologic confirmation)
Mri Scan (MRI scan)
Other (Other)
Palpation (Palpation)
Pet Scan (PET scan)
Plain Film/x-ray With Contrast (Plain
film/X-ray with contrast)
Plain Film/x-ray Without Contrast (Plain
film/X-ray without contrast)
Radioisotope Scan (Radioisotope scan)
Spiral Ct Scan (Spiral CT scan)
Ultrasound (Ultrasound)
Visualization (Visualization)
Assessment Date
Symptomatic deterioration
Symptomatic deterioration
Yes
No
Assessment Date
Comments
Comments
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SOUTHWEST ONCOLOGY GROUP FOLLOW-UP TUMOR
ASSESSMENT FORM (S0205) NCT00075686
SOUTHWEST ONCOLOGY GROUP
BASELINE TUMOR ASSESSMENT FORM
SOUTHWEST ONCOLOGY GROUP BASELINE TUMOR
ASSESSMENT FORM
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=F4422C8B-
0C70-49D1-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/10895
SOUTHWEST ONCOLOGY GROUP
BASELINE TUMOR ASSESSMENT
FORM
Header
SWOG Patient ID
SWOG Study No.
Registration Step
Patient Initials (L, F M)
Institution/Affiliate
Physician (Participating Group)
Participating Group Name
Participating Group Study No.
Participating Group Patient ID
Target lesion status
Target Lesions
Longest Diameter (cm)
Assessment Date
Assessment Date
Assessment Type (*)
Colposcopy (Colposcopy)
Ct Scan (CT scan)
Cystoscopy (Cystoscopy)
Cytologic Confirmation (Cytologic
confirmation)
Endoscopy (Endoscopy)
Histologic (Histologic confirmation)
Mri Scan (MRI scan)
Other (Other)
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Palpation (Palpation)
Pet Scan (PET scan)
Plain Film/x-ray With Contrast (Plain
film/X-ray with contrast)
Plain Film/x-ray Without Contrast (Plain
film/X-ray without contrast)
Radioisotope Scan (Radioisotope scan)
Spiral Ct Scan (Spiral CT scan)
Ultrasound (Ultrasound)
Visualization (Visualization)
Assessment Type (*)
Colposcopy (Colposcopy)
Ct Scan (CT scan)
Cystoscopy (Cystoscopy)
Cytologic Confirmation (Cytologic
confirmation)
Endoscopy (Endoscopy)
Histologic (Histologic confirmation)
Mri Scan (MRI scan)
Other (Other)
Palpation (Palpation)
Pet Scan (PET scan)
Plain Film/x-ray With Contrast (Plain
film/X-ray with contrast)
Plain Film/x-ray Without Contrast (Plain
film/X-ray without contrast)
Radioisotope Scan (Radioisotope scan)
Spiral Ct Scan (Spiral CT scan)
Ultrasound (Ultrasound)
Visualization (Visualization)
Non-target disease
Extent
Diagnostic Test
Tests/studies
Assessment Date
Comments
Comments
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SOUTHWEST ONCOLOGY GROUP BASELINE TUMOR
ASSESSMENT FORM
SOUTHWEST ONCOLOGY GROUP S0205
HOSPITALIZATION FORM NCT00075686
SOUTHWEST ONCOLOGY GROUP S0205
HOSPITALIZATION FORM NCT00075686 
S0205 Gemcitabine With or Without Cetuximab as First-
Line Therapy in Treating Patients With Locally Advanced
Unresectable or Metastatic Adenocarcinoma of the
Pancreas
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=F2EB36D1-
F8D9-23D5-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/10896
SOUTHWEST ONCOLOGY GROUP
S0205 HOSPITALIZATION FORM
NCT00075686
Header
SWOG Patient ID
SWOG Study No.
Registration Step
Patient Initials (L, F M)
Date of completion
Institution/Affiliate
Physician
HOSPITALIZATION Assessment
Hospital admit date
Hospital discharge date
Reason for hospitalization (select all that apply)
Non-study Indication (Non-study
indication)
Other (Other)
Treatment Of Complications Related To
Protocol Therapy (Treatment of
complications related to protocol therapy)
Treatment Of Disease Related
Complications (Treatment of disease
related complications)
Other, specify
Please describe
1 / 2
Treatment administered in hospital (other than
protocol)
Comments
Comments
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SOUTHWEST ONCOLOGY GROUP S0205 HOSPITALIZATION FORM
NCT00075686
SOUTHWEST ONCOLOGY GROUP (S0205)  BASELINE
TUMOR ASSESSMENT FORM NCT00075686
SOUTHWEST ONCOLOGY GROUP (S0205)  BASELINE
TUMOR ASSESSMENT FORM NCT00075686 
S0205 Gemcitabine With or Without Cetuximab as First-
Line Therapy in Treating Patients With Locally Advanced
Unresectable or Metastatic Adenocarcinoma of the
Pancreas
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=F2EA530F-
C48C-139C-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/10897
SOUTHWEST ONCOLOGY GROUP
(S0205)  BASELINE TUMOR
ASSESSMENT FORM
NCT00075686
Header
SWOG Patient ID
SWOG Study No.
Registration Step
Patient Initials (L, F M)
Institution/Affiliate
Physician (Participating Group)
Group Name
Study No.
Patient ID
Target lesion status
Target Lesions
Longest Diameter (cm)
Assessment Type (*)
Colposcopy (Colposcopy)
Ct Scan (CT scan)
Cystoscopy (Cystoscopy)
Cytologic Confirmation (Cytologic
confirmation)
Endoscopy (Endoscopy)
Histologic (Histologic confirmation)
Mri Scan (MRI scan)
Other (Other)
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Palpation (Palpation)
Pet Scan (PET scan)
Plain Film/x-ray With Contrast (Plain
film/X-ray with contrast)
Plain Film/x-ray Without Contrast (Plain
film/X-ray without contrast)
Radioisotope Scan (Radioisotope scan)
Spiral Ct Scan (Spiral CT scan)
Ultrasound (Ultrasound)
Visualization (Visualization)
Assessment Type (*)
Colposcopy (Colposcopy)
Ct Scan (CT scan)
Cystoscopy (Cystoscopy)
Cytologic Confirmation (Cytologic
confirmation)
Endoscopy (Endoscopy)
Histologic (Histologic confirmation)
Mri Scan (MRI scan)
Other (Other)
Palpation (Palpation)
Pet Scan (PET scan)
Plain Film/x-ray With Contrast (Plain
film/X-ray with contrast)
Plain Film/x-ray Without Contrast (Plain
film/X-ray without contrast)
Radioisotope Scan (Radioisotope scan)
Spiral Ct Scan (Spiral CT scan)
Ultrasound (Ultrasound)
Visualization (Visualization)
Non-target disease
Extent
Assessment Date
Assessment Date
Diagnostic Test
Tests/studies
Assessment Date
Comments
Comments
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SOUTHWEST ONCOLOGY GROUP (S0205)  BASELINE TUMOR
ASSESSMENT FORM NCT00075686
SOUTHWEST ONCOLOGY GROUP
FOLLOW-UP TUMOR ASSESSMENT FORM
SOUTHWEST ONCOLOGY GROUP FOLLOW-UP
TUMOR ASSESSMENT FORM
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=F4422C8B-
0D37-49D1-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/10898
SOUTHWEST ONCOLOGY GROUP
FOLLOW-UP TUMOR
ASSESSMENT FORM
Header
SWOG Patient ID
SWOG Study No.
Registration Step
Patient Initials (L, F M)
Date form completed
Institution/Affiliate
Physician
Participating Group Name
Participating Group Study No.
Participating Group Patient ID
Target Lesions
Target Lesions
Longest Diameter (cm)
Assessment Type (*)
Colposcopy (Colposcopy)
Ct Scan (CT scan)
Cystoscopy (Cystoscopy)
Cytologic Confirmation (Cytologic
confirmation)
Endoscopy (Endoscopy)
Histologic (Histologic confirmation)
Mri Scan (MRI scan)
Other (Other)
Palpation (Palpation)
Pet Scan (PET scan)
1 / 3
Plain Film/x-ray With Contrast (Plain
film/X-ray with contrast)
Plain Film/x-ray Without Contrast (Plain
film/X-ray without contrast)
Radioisotope Scan (Radioisotope scan)
Spiral Ct Scan (Spiral CT scan)
Ultrasound (Ultrasound)
Visualization (Visualization)
Assessment Date
Non-target Disease
Non-Target Disease
Extent
Clear Increase (Clear increase)
Complete Disappearance (Complete
disappearance)
Not Assessed (Not assessed)
Present (Present)
Assessment Type (*)
Colposcopy (Colposcopy)
Ct Scan (CT scan)
Cystoscopy (Cystoscopy)
Cytologic Confirmation (Cytologic
confirmation)
Endoscopy (Endoscopy)
Histologic (Histologic confirmation)
Mri Scan (MRI scan)
Other (Other)
Palpation (Palpation)
Pet Scan (PET scan)
Plain Film/x-ray With Contrast (Plain
film/X-ray with contrast)
Plain Film/x-ray Without Contrast (Plain
film/X-ray without contrast)
Radioisotope Scan (Radioisotope scan)
Spiral Ct Scan (Spiral CT scan)
Ultrasound (Ultrasound)
Visualization (Visualization)
Assessment Date
New Lesions (specify Site)
New Lesions (Specify Site)
Assessment Type (*)
Colposcopy (Colposcopy)
Ct Scan (CT scan)
Cystoscopy (Cystoscopy)
Cytologic Confirmation (Cytologic
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ASSESSMENT FORM
confirmation)
Endoscopy (Endoscopy)
Histologic (Histologic confirmation)
Mri Scan (MRI scan)
Other (Other)
Palpation (Palpation)
Pet Scan (PET scan)
Plain Film/x-ray With Contrast (Plain
film/X-ray with contrast)
Plain Film/x-ray Without Contrast (Plain
film/X-ray without contrast)
Radioisotope Scan (Radioisotope scan)
Spiral Ct Scan (Spiral CT scan)
Ultrasound (Ultrasound)
Visualization (Visualization)
Assessment Date
Symptomatic deterioration
Symptomatic deterioration
Yes
No
Assessment Date
Comments
Comments
3 / 3
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S0502 Advanced GIST PreStudy Form
NCT00324987
S0502 Advanced GIST PreStudy Form NCT00324987 
S0502 Imatinib Mesylate With or Without Bevacizumab in
Treating Patients With Metastatic or Unresectable
Gastrointestinal Stromal Tumor
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=FCBF6A0D-
F933-70F8-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/10899
S0502 Advanced GIST PreStudy
Form NCT00324987
Header
SWOG Patient ID
SWOG Study No.
Registration Step
Patient Initials (L, F M)
Institution/Affiliate
Physician
Participating Group Name
Participating Group Study No.
Participating Group Patient ID
Eligibility Verification
Performance Status
Fully Active, Able To Carry On All Pre-
disease Performance Without
Restriction. (0)
Restricted In Physically Strenuous
Activity But Ambulatory And Able To
Carry Out Work Of A Light Or Sedentary
Nature, E.g., Light Housework, Office
Work. (1)
Ambulatory And Capable Of All Selfcare
But Unable To Carry Out Any Work
Activities. Up And About More Than 50%
Of Waking Hours. (2)
Capable Of Only Limited Selfcare,
Confined To Bed Or Chair More Than
50% Of Waking Hours. (3)
Completely Disabled. Cannot Carry On
Any Selfcare. Totally Confined To Bed Or
1 / 6
Chair. (4)
Hemoglobin (g/dl Document values in units listed
Hematologic)
ANC (mcL)
Peripheral Platelet Count (mcL)
Liver metastases (Hepatic)
Yes
No
Collection Date
Collection Date
Total Bilirubin (gm%)
Total bilirubin (mg/dl), ULN (gm%)
SGOT (gm%)
SGOT (AST) ULN (IU)
SGPT (U/L)
SGPT (ALT) ULN (U/L)
PTT (S Coagulation)
PTT ULN (S)
International Normalization Ratio (INR)
Serum Creatinine (mg% Renal)
Serum Creatinine ULN (mg%)
Urine Protein/Creatinine Ratio
Blood Pressure (Cardiovascular)
Blood Pressure
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Cardiovascular/ Gastrointestinal Event
Date of last CVA, TIA, MI or unstable angina (if
applicable)
Date of last abdominal fistula, gastrointestinal
perforation, or intra-abdominal abscess (if
applicable)
Current Disease Status
Site(s) of Disease (recommend to replace SWOG
term "Fill in the box for each involved site" select
all that apply)
Abdominal Organs (Abdominal organs)
Ascites (Ascites)
Bone (Bone)
Lung (Lung)
Lymph Nodes (Lymph nodes)
Mediastinum (Mediastinum)
Mesentery (Mesentery)
Other (Other)
Peritoneum (Peritoneum)
Pleura (Pleura)
Retroperitoneum (Retroperitoneum)
Soft Tissue (Soft Tissue)
Was a complete resection done? (recommend to
replace SWOG term "Was primary completely
resected?")
Yes
No
Recurrent disease?
Yes
No
Tumor Grade
High Grade (High)
Low Grade (Low)
Not Assessed (Ungraded)
Distant metastases present?
Yes
No
Sarcoma Histologic Category
Epithelioid Carcinoma (Epithelioid)
Mixed Spindle Cell And Epithelioid
Carcinoma (Mixed)
Spindle Cell Carcinoma (Spindle cell)
Date of Initial Pathologic Diagnosis (mm/dd/yyyy)
Height (cm)
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Patient History
Does patient have history of adrenal cancer
(Patient History indicative of Carney's triad)
No (No)
Unknown (Unknown)
Yes (Yes)
Prior Treatment Related To This Cancer
Prior Therapy Type (s select ALL that apply)
Agents Administered To Control The
Replication And/or Spread Of Viruses
(Anti-retroviral therapy)
Treatment With An Agent That Prevents
Or Impairs The Translation Of The
Genetic Message For Production Of A
Specific Protein (Antisense)
High Dose Chemotherapy Combined
With Transplantation Of Bone Marrow
Cells (Bone marrow transplant)
Systemic Chemotherapy With A
Regimen Containing Multiple Agents
(Chemotherapy multiple agents
systemic)
Prior Therapy With Agents That Are Not
Known To Cause Damage To Cycling
Cells (Chemotherapy non-cytotoxic)
Non-systemic Chemotherapy Treatment
Or Chemotherapy Not Described By
Chemotherapy Single Agent Systemic Or
Multi-agent Systemic (Chemotherapy
NOS)
Systemic Chemotherapy With A Single
Agent Regimen (Chemotherapy single
agent systemic)
Treatment Of Human Disease By Gene
Transfer (Gene transfer)
Cancer Therapy Which Incorporates
Hormonal Manipulation (Hormonal
therapy)
Biologic Cancer Therapy
(Immunotherapy)
Anticancer Treatment With A Live,
Replication-competent Virus (Oncolytic
virotherapy)
Targeted Ionizing Radiation Therapy
Utilizing Radioactive Implants Or Seeds
(Radiotherapy)
Surgical Procedure, Or Operation, With
Therapeutic Intent (Surgery)
Therapy Nos (Therapy NOS)
Substance Or Group Of Substances
Administered To Induce The Immune
System To Recognize And Destroy
Tumors Or Microorganisms (Vaccine)
Number of prior chemotherapy regimens
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Date Prior Chemotherapy Ended (traditional)
Setting of prior agent targeting VEGF, VEGFR, or
PDGFR
Adjuvant (Adjuvant)
Advanced (Advanced disease)
None (No prior targeting agent)
Date of prior VEGF, VEGFR, PDGF targeted
agent ended
Date of first recurrence following adjuvant therapy
using agents targeting VEGF, VEGFR, PDGFR
Setting of prior imatinib (select all that apply)
Adjuvant (Adjuvant)
Advanced (Advanced disease)
None (No prior targeting agent)
Date of prior KIT targeted agent ended (If
imatinib or other KIT targeted agent used in
Adjuvant Setting, complete the following: )
Date of first recurrence following adjuvant therapy
using agents targeting KIT
Date prior imatinib therapy started (If imatinib
used in Advanced Disease Setting, complete the
following:)
Was patient restaged after initiation of imatinib
therapy
Yes
No
Does patient have clinical evidence of
progressive disease
Yes
No
Prior radiation therapy stop date (if applicable)
Date of Most Recent Surgery (including open
biopsy or significant traumatic injury, if applicable)
Date of last fine needle aspiration or core biopsy
(if applicable)
Therapy specify (other)
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Comments
Comments
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RTOG-0421 TF: Radiation Therapy Oncology Group Phase III Recurrent
Head and Neck Study Treatment Summary Form NCT00113399
RTOG-0421 TF: Radiation Therapy Oncology Group Phase
III Recurrent Head and Neck Study Treatment Summary
Form NCT00113399 
Combination Chemotherapy With or Without Radiation
Therapy in Treating Patients With Recurrent Head and
Neck Cancer That Cannot Be Removed By Surgery
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=EC64FA04-
6994-6A06-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/10900
RTOG-0421 TF: Radiation Therapy
Oncology Group Phase III Recurrent
Head and Neck Study Treatment
Summary Form NCT00113399
RTOG clinical trial administrative data
RTOG Study No.
Case #
Institution Name
Institution No.
Patient Initials
Patient Study No.
AMENDED DATA
Yes
No
Assessment of chemotherapy
PATIENT HEIGHT
PATIENT WEIGHT
BODY SURFACE AREA
CURRENT CYCLE NUMBER
Assigned Treatment Arm
Arm 1, Rt Plus Cisplatin / Paclitaxel (Arm
1, RT plus Cisplatin / Paclitaxel)
Arm 2, Cisplatin / 5-fu (Arm 2, Cisplatin /
5-FU)
Arm 2, Cisplatin / Docetaxel (Arm 2,
Cisplatin / Docetaxel)
Arm 2, Cisplatin / Paclitaxel (Arm 2,
1 / 3
Cisplatin / Paclitaxel)
WAS CARBOPLATIN SUBSTITUTED FOR
CISPLATIN FOR THIS CYCLE?
No (No)
Yes, For Other Reason (Yes, for other
reason)
Yes, For Toxicity (Yes, for toxicity)
CURRENT OBJECTIVE RESPONSE (see
protocol section 11.4)
Complete Response (Complete
response)
Not Assessed (Not assessed)
Partial Response (Partial response)
Progressive Disease (Progressive
disease)
Stable Disease (Stable disease)
Symptomatic Deterioration (Symptomatic
deterioration)
AGENT NAME
CYCLE START DATE
CYCLE END DATE
TOTAL DOSE OF AGENT FOR THIS CYCLE
REASON FOR DOSE MODIFICATION (Use code
table below)
Alternative Therapy (Alternative therapy)
Complete Response To Protocol Therapy
(Complete response to protocol therapy)
Death On Study (Death on study)
Disease Progression, Relapse During
Active Treatment (Disease progression,
relapse during active treatment)
None (None)
Other (Other)
Other Complicating Disease (Other
complicating disease)
Patient Withdrawal Or Refusal After
Beginning Protocol Therapy (Patient
withdrawal or refusal after beginning
protocol therapy)
Patient Withdrawal Or Refusal Prior To
Beginning Protocol Therapy (Patient
withdrawal or refusal prior to beginning
protocol therapy)
Stable Disease (Stable disease)
Adverse Event/side Effects/complications
(Toxicity/side effects/complications)
Treatment Completed Per Protocol
Criteria (Treatment completed per
protocol criteria)
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REASON TREATMENT ENDED (Use code table
below)
Alternative Therapy (Alternative therapy)
Complete Response To Protocol Therapy
(Complete response to protocol therapy)
Death On Study (Death on study)
Disease Progression, Relapse During
Active Treatment (Disease progression,
relapse during active treatment)
None (None)
Other (Other)
Other Complicating Disease (Other
complicating disease)
Patient Withdrawal Or Refusal (Patient
withdrawal or refusal after beginning
protocol therapy)
Patient Withdrawal Or Refusal Prior To
Beginning Protocol Therapy (Patient
withdrawal or refusal prior to beginning
protocol therapy)
Stable Disease (Stable disease)
Toxicity/side Effects/complications
(Toxicity/side effects/complications)
Treatment Completed Per Protocol
Criteria (Treatment completed per
protocol criteria)
Comments
Comments
Name of person completing this form
Form completion date, original
Comments
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CALGB-10501 CLL Medication Sheet Form
NCT00513747
CALGB-10501 CLL Medication Sheet Form NCT00513747 
Early or Delayed Fludarabine and Rituximab in Treating
Patients With Previously Untreated Chronic Lymphocytic
Leukemia
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=3410013A-
D230-2376-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/10901
CALGB-10501 CLL Medication
Sheet Form NCT00513747
Header
CALGB Form
CALGB Study No
CALGB Patient ID
Date of Assessment
Are data amended
Yes
No
Patient demographics
Patient Initials (Last, First Middle)
Patient Hospital No.
Institution/Affiliate
Participating Group
Participating Group Study No
Participating Group Patient ID
Visit number
Patient Medication History
Have you taken any medications for fatigue, sleep
problems, anxiety, or depression in the past two
weeks
Yes
No
1 / 2
Agent Name (If yes)
Was agent administered
Yes
No
Comments
Footer Module
Completed by (print or type name)
Date Form Completed (MM DD YYYY)
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SOUTHWEST ONCOLOGY GROUP S0421 PAIN MEDICATION LOG
AND PAIN ASSESSMENT: Step 2 Post-Chemo Form NCT00134056
SOUTHWEST ONCOLOGY GROUP S0421 PAIN
MEDICATION LOG AND PAIN ASSESSMENT: Step 2
Post-Chemo Form NCT00134056 
Docetaxel and Prednisone With or Without Atrasentan in
Treating Patients With Stage IV Prostate Cancer and Bone
Metastases That Did Not Respond to Previous Hormone
Therapy
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=0F9D64D5-
FB3B-3049-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/10902
SOUTHWEST ONCOLOGY GROUP
S0421 PAIN MEDICATION LOG
AND PAIN ASSESSMENT: Step 2
Post-Chemo Form NCT00134056
Header
SWOG Patient ID
SWOG Study No.
Registration Step
Patient Initials (L, F M)
Institution/Affiliate
Physician
Participating Group Name
Participating Study No.
Participating Patient ID
Planned Assessment
Week 40 (Week 40)
Week 43 (Week 43)
Week 46 (Week 46)
Week 49 (Week 49)
Week 52 (Week 52)
Patient Instructions
Please rate your pain by selecting the one
number that best describes your pain at its
WORST in the past 24 hours.
Whole Number (0)
Whole Number (1)
Whole Number (10)
Whole Number (2)
Whole Number (3)
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Whole Number (4)
Whole Number (5)
Whole Number (6)
Whole Number (7)
Whole Number (8)
Whole Number (9)
Date log started
Patient medical history
Name of Pain Medication
Medication Type (*)
Liquid (Liquid)
Patch (Patch)
Pill (Pill)
Pump (Pump)
Analgesic Code (+)
No Analgesic (No analgesic)
Non-narcotic (Non-narcotic)
Strong Opioid (Strong opioid)
Weak Opioid (Weak opioid)
Dose (Units ^)
Number of pain meds taken at this dose (Tallies /)
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SOUTHWEST ONCOLOGY GROUP S0221
TRASTUZUMAB USE FORM NCT00070564
SOUTHWEST ONCOLOGY GROUP S0221
TRASTUZUMAB USE FORM NCT00070564 
Adjuvant Doxorubicin, Cyclophosphamide, and Paclitaxel in
Treating Patients With Breast Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=0318EAD1-
86F2-752C-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/10903
SOUTHWEST ONCOLOGY GROUP
S0221 TRASTUZUMAB USE FORM
NCT00070564
Header
SWOG Patient ID
SWOG Study No.
Registration Step
Patient Initials (L, F M)
Institution/Affiliate
Physician
Participating Group Name
Participating Group Study No.
Participating Group Patient ID
Trastuzumab Use Assessment
HER-2/neu status
Negative (Negative)
Positive (Positive)
Marker Test Method
Fluorescence In Situ Hybridization (fish)
(Fluorescence in situ hybridization
(FISH))
Immunohistochemistry (ihc)
(Immunohistochemistry (IHC))
When was trastuzumab given?
During Paclitaxel Treatment (During
paclitaxel treatment)
Post-chemotherapy (post-chemotherapy)
Trastuzumab Agent Administration Begin Date
1 / 2
Trastuzumab Agent Administration End Date
Cardiovascular Examination
Left Ventricular Ejection Fraction at Rest
Date of LVEF
Symptomatic CHF
Yes
No
Method of Evaluation
Echocardiogram (Echocardiogram)
Muga Scan (MUGA)
Method of determination
Echocardiogram (Echocardiogram)
Multi-gated Acquisition Scan (MUGA)
Other Specify
Comments
Comments (Comments)
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CALGB: 90202 On-Study NCT00079001
CALGB: 90202 On-Study NCT00079001 
Zoledronate in Preventing Skeletal (Bone)-Related Events
in Patients Who Are Receiving Androgen Deprivation
Therapy For Prostate Cancer and Bone Metastases
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=B4607705-
4BBB-0537-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/10904
CALGB: 90202 On-Study
NCT00079001
Header
CALGB Form
CALGB Study No
CALGB Patient ID
Amended data?
Yes
No
Patient demographics
Patient Initials
Participating Group
American College Of Surgeons
Oncology Group (ACOSOG)
American College Of Radiology
Oncologic Imaging Network (ACRIN)
Aids-associated Malignancies Clinical
Trials Consortium (AMC)
Cancer And Leukemia Group B (CALGB)
Children's Oncology Group (COG)
Eastern Cooperative Oncology Group
(ECOG)
European Organization For Research
And Treatment Of Cancer (EORTC)
Gynecologic Oncology Group (GOG)
International Breast Cancer Study Group
(IBCSG)
North American Brain Tumor Consortium
(NABTC)
Nabtt Brain Tumor Consortium (NABTT)
North Central Cancer Treatment Group
(NCCTG)
National Cancer Institute Of Canada
Clinical Trials Group (NCIC)
National Surgical Adjuvant Breast And
Bowel Project (NSABP)
Radiation Therapy Oncology Group
(RTOG)
Southwest Oncology Group (SWOG)
Patient Medical Record Number
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Participating Group Protocol Number
Institution/Affiliate
Other Patient ID
Initial Diagnosis
Gleason Grade, Primary
Gleason Grade, Secondary
Gleason Score, Combined
Gleason Score Based on Specimen Type
Biopsy (Biopsy (including TURP))
Surgical Specimen (Surgical specimen)
PRIOR TREATMENT
Prior prostatectomy
Yes
No
Prior prostatectomy date
Prior radiation therapy
Yes
No
Prior radiation therapy type
Brachytherapy (implant) (bracytherapy)
External Beam (external beam)
Date prior RT started
Date prior RT ended
Prior neoadjuvant hormone therapy
Yes
No
Prior neoadjuvant hormone therapy type
Lhrh + Antiandrogen (LHRH +
antiandrogen)
Lhrh Alone (LHRH alone)
Date prior neoadjuvant hormone therapy ended
Date prior neoadjuvant hormone therapy started
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Is patient enrolling in CALGB 9594
Yes
No
Registration Date
Current Supplements
Calcium
Yes
No
Vitamin D
Yes
No
Daily Agent Total Dose
Average number of pills per week
Current Treatment
Current hormone therapy
Yes
No
Current hormone therapy type
Lhrh Agonist + Antiandrogen (LHRH
agonist + antiandrogen)
Lhrh Agonist Alone (LHRH agonist
alone)
Orchiectomy + Antiandrogen
(Orchiectomy + antiandrogen)
Orchiectomy Alone (Orchiectomy alone)
Date current hormone therapy started
Metastatic/recurrent Site(s)
Is the primary site or tumor bed involved
Yes
No
Lung
Yes
No
Liver
Yes
No
Pleura
Yes
No
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CNS (excluding Brain)
Yes
No
Bone
Yes
No
Soft Tissue
Yes
No
Other
Yes
No
If sites other than specified, indicate name
Performance Status
Performance Status
Fully Active, Able To Carry On All Pre-
disease Performance Without
Restriction. (0)
Restricted In Physically Strenuous
Activity But Ambulatory And Able To
Carry Out Work Of A Light Or Sedentary
Nature, E.g., Light Housework, Office
Work. (1)
Ambulatory And Capable Of All Selfcare
But Unable To Carry Out Any Work
Activities. Up And About More Than 50%
Of Waking Hours. (2)
Capable Of Only Limited Selfcare,
Confined To Bed Or Chair More Than
50% Of Waking Hours. (3)
Completely Disabled. Cannot Carry On
Any Selfcare. Totally Confined To Bed Or
Chair. (4)
Dead (5)
Laboratory Values
WBC
Peripheral Platelet Count
Peripheral platelet count, LLN
Hemoglobin (mg/dL)
Hemoglobin, LLN
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Hemoglobin, ULN (mg/dL)
Calcium
Calcium LLN
Calcium ULN
Serum Creatinine ULN
Serum Creatinine LLN
Creatinine Clearance (Pre-registration)
Lactate Dehydrogenase (LDH)
Lactate Dehydrogenase LLN
Lactate Dehydrogenase ULN
Alkaline Phosphatase
Alkaline Phosphatase LLN
Alkaline Phosphatase ULN
Baseline PSA Value
Date of Baseline PSA
Serum creatinine (Baseline value used to
calculate zoledronic acid/placebo dose.)
Serum creatinine (Baseline value used to
calculate zoledronic acid/placebo dose.)
Ccrr Module For Calgb: 90202 On-study
Completed by
Date Form Originally Completed
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CALGB: 80303 ON-STUDY FORM
NCT00088894
CALGB: 80303 ON-STUDY FORM NCT00088894 
Gemcitabine With or Without Bevacizumab in Treating
Patients With Locally Advanced or Metastatic Pancreatic
Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=D6006B65-
CAFE-728C-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/10905
CALGB: 80303 ON-STUDY FORM
NCT00088894
Header
CALGB Study No
CALGB Patient ID
Are data amended?
Yes
No
Patient demographics
Patient Initials
Participating Group
Patient Hospital No.
Participating Group Protocol No.
Institution/Affiliate
Participating Group Patient ID
Treatment begin
Treatment start date
Patient Description
Height (cm)
Weight (kg)
BSA (m^2)
Performance Status
1 / 5
Ambulatory And Capable Of All Selfcare
But Unable To Carry Out Any Work
Activities (k 50 - 60) (ecog - 2
Symptomatic; In Bed , 50% Of The Day)
(Ambulatory and capable of selfcare, but
unable to carry out any work activities
(ECOG=2))
Capable Of Limited Selfcare, Confined
To Bed Or Chair More Than 50% Of
Waking Hours. (k 30 - 40) (ecog - 3
Symptomatic; In Bed > 50% Of The Day
But Not Bedridden) (Capable of limited
selfcare, confined to bed or chair more
than 50% of waking hours (ECOG=3))
Completely Disabled (k10 - 20) (ecog - 4
Bedridden) (Completely disabled
(ECOG=4))
Fully Active, Able To Carry On All Pre-
disease Performance Without Restriction
(karnofsky 90 - 100) (ecog - 0
Asymptomatic) (Fully active, able to
carry on all pre-disease performance
without restriction (ECOG=0))
Restricted In Physically Strenuous
Activity But Ambulatory (k70 - 80) (ecog -
1 Symptomatic - Fully Ambulatory)
(Restricted in physically strenuous
activity but ambulatory (ECOG=1))
Has the patient had any prior cancer diagnosed?
Yes
No
specify type of cancer
date of diagnosis
Laboratory Data At Study Entry
Absolute neutrophil count (1000/mcL)
Platelets (1000/mcL)
Total Bilirubin (1000/mcL)
Bilirubin ULN
SGOT (U/L)
SGOT ULN
PT INR
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Serum Creatinine (mg/dL)
CA 19-9
Urine protein
0 (0)
1+ (1+)
2+ (2+)
3+ (3+)
4+ (4+)
24-hour urine collection (grams protein/24 hours)
Examination Data At Study Entry
Evaluation method
Chest X-ray (Chest X-ray)
Ct Scan (CT scan - chest)
Ct Scan (CT scan abdomen/pelvis)
Mri (MRI)
Other, Specify (Other, specify)
Other, specify
Prior Therapy Data
Has the patient had prior chemotherapy or
immunotherapy for the following target areas?
Pancreatic cancer
No (No)
Yes, specify (Yes, specify)
Yes, specify
End date
Has the patient had prior chemotherapy or
immunotherapy for the following target areas?
Resected
No (No)
Yes, specify (Yes, specify)
Has the patient had prior chemotherapy or
immunotherapy for the following target areas?
Metastatic disease - unresected
No (No)
Yes, specify (Yes, specify)
Has the patient had prior chemotherapy or
immunotherapy for the following target areas?
Other cancer, specify
No (No)
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Yes, specify (Yes, specify)
Other cancer, specify
Has the patient had prior radiotherapy for the
following target areas? Pancreatic cancer
No (No)
Yes, specify (Yes, specify)
Has the patient had prior radiotherapy for the
following target areas? Resected
No (No)
Yes, specify (Yes, specify)
Has the patient had prior radiotherapy for the
following target areas? Metastatic disease -
unresected
No (No)
Yes, specify (Yes, specify)
Yes, specify
End date
Has the patient had prior radiotherapy for the
following target areas? Other cancer, specify
No (No)
Yes, specify (Yes, specify)
Yes, specify
Other cancer, specify
End date
Has the patient had any invasive surgical
procedures?
Yes
No
specify date
Is the patient on full-dose anticoagulants?
Yes
No
specify reason
Has the patient taken a thrombolytic agent within
1 month prior to registration?
Yes
No
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Patient Medical History
Does the patient have clinically significant
cardiovascular disease?
Yes
No
Does the patient have a serious or non-healing
wound, ulcer or bone fracture?
Yes
No
Does the patient have an active infection
requiring parental antibiotics?
Yes
No
Completed by
Date form completed
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S0522 Bone Marrow Transplant Treatment
Summary Form
S0522 Bone Marrow Transplant Treatment Summary Form
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=0EE70772-
339E-0657-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/10906
S0522 Bone Marrow Transplant
Treatment Summary Form
Header
SWOG Patient ID
SWOG Study No.
Registration Step
Patient Initials (L, F, M)
Cycle completed
First Transplant (First transplant)
Second Transplant (Second transplant)
Institution/Affiliate
Physician
Participating Group Name
Participating Group Study No.
Participating Group Patient ID
Disease Status
Date of Last Contact or Death
Vital Status
Alive (Alive)
Dead (Dead)
Urine M-protein
Agent Name (Melphalan GM-CSF)
Agent Start Date
Agent End Date
1 / 2
Dose given (mcg)
Urine M-protein
Were there any dose modifications or
additions/omissions to protocol treatment?
No (No)
Yes, Planned (i.e., The Treatment Was
Changed According To Protocol
Guidelines) (Yes, planned)
Yes, Unplanned (i.e., The Treatment
Change Was Not Part Of Protocol
Guidelines) (Yes, unplanned)
Bone Marrow Plasmacytosis
Weight
BSA
Performance Status
Fully Active, Able To Carry On All Pre-
disease Performance Without
Restriction. (0)
Restricted In Physically Strenuous
Activity But Ambulatory And Able To
Carry Out Work Of A Light Or Sedentary
Nature, E.g., Light Housework, Office
Work. (1)
Ambulatory And Capable Of All Selfcare
But Unable To Carry Out Any Work
Activities. Up And About More Than 50%
Of Waking Hours. (2)
Capable Of Only Limited Selfcare,
Confined To Bed Or Chair More Than
50% Of Waking Hours. (3)
Completely Disabled. Cannot Carry On
Any Selfcare. Totally Confined To Bed Or
Chair. (4)
Dead (5)
Bone Disease And Anemia
Date of Bone Marrow or Peripheral Blood Stem
Cell Infusion
Number of CD34-positive cells infused
Comments
Comments
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S0522 Bone Marrow Transplant Treatment Summary Form
S0522 Induction and Consolidation
Treatment Summary Form
S0522 Induction and Consolidation Treatment Summary
Form
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=0F6E2CA3-
0C40-323F-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/10907
S0522 Induction and Consolidation
Treatment Summary Form
Header
SWOG Patient ID
SWOG Study No.
Registration Step
Patient Initials (L, F, M)
Cycle completed
Consolidation (Consolidation)
Induction (Induction)
Institution/Affiliate
Physician
Participating Group Name
Participating Group Study No.
Participating Group Patient ID
Disease Status
Date of Last Contact or Death
Vital Status
Alive (Alive)
Dead (Dead)
Has the patient progressed per the definition of
Section 10.0 of the protocol
Yes
No
Urine M-protein
Agent Name (Dexamethasone Thalidomide
Bortezomib)
1 / 3
Agent Start Date
Agent End Date
Starting daily dose given (mg/m^2)
Ending daily dose given (mg/m^2)
Urine M-protein
Administration of Medication
Were there any dose modifications or
additions/omissions to protocol treatment?
No (No)
Yes, Planned (i.e., The Treatment Was
Changed According To Protocol
Guidelines) (Yes, planned)
Yes, Unplanned (i.e., The Treatment
Change Was Not Part Of Protocol
Guidelines) (Yes, unplanned)
Has the patient received bisphosphonates
(during this treatment segment)
Yes
No
Patient vital status
Weight
BSA
Performance Status
Fully Active, Able To Carry On All Pre-
disease Performance Without
Restriction. (0)
Restricted In Physically Strenuous
Activity But Ambulatory And Able To
Carry Out Work Of A Light Or Sedentary
Nature, E.g., Light Housework, Office
Work. (1)
Ambulatory And Capable Of All Selfcare
But Unable To Carry Out Any Work
Activities. Up And About More Than 50%
Of Waking Hours. (2)
Capable Of Only Limited Selfcare,
Confined To Bed Or Chair More Than
50% Of Waking Hours. (3)
Completely Disabled. Cannot Carry On
Any Selfcare. Totally Confined To Bed Or
2 / 3
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Chair. (4)
Dead (5)
Comments
Comments
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S0522 Induction and Consolidation Treatment Summary Form
SOUTHWEST ONCOLOGY GROUP S0500
TREATMENT SUMMARY FORM NCT00382018
SOUTHWEST ONCOLOGY GROUP S0500 TREATMENT
SUMMARY FORM NCT00382018 
Treatment Decision Making Based on Blood Levels of
Tumor Cells in Women With Metastatic Breast Cancer
Receiving Chemotherapy
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=07CFFD91-
9FFB-3A50-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/10908
SOUTHWEST ONCOLOGY GROUP
S0500 TREATMENT SUMMARY
FORM NCT00382018
Header
SWOG Patient ID
SWOG Study No.
Registration Step
Date Form Completed
Patient Initials (L, F M)
Reason for form submission
Change In Therapy Due To Other
Reason (Change in therapy due to other
reason)
Change In Therapy Due To Progression
(Change in therapy due to progression)
Change In Therapy Due To Toxicity
(Change in therapy due to toxicity)
Discontinuation Of Therapy Due To
Maximal Benefit (Discontinuation of
therapy due to maximal benefit)
End Of Cycle 1 Of First-line
Chemotherapy (End of Cycle 1 of first-
line chemotherapy)
End Of Cycle 1 Of Second-line
Chemotherapy (for Patients Assigned To
Switch Therapy) (End of Cycle 1 of
second-line chemotherapy (for patients
assigned to Switch Therapy))
Initiation Of Mainenance Hormonal
Therapy (Initiation of mainenance
hormonal therapy)
Institution/Affiliate
Physician
Participating Group Name
1 / 3
Participating Study No.
Participating Patient ID (Instructions: Please
complete this form after each cycle 1 cycle = 4
weeks. All dates are MONTH, DAY, YEAR.
Explain any blank dates or fields in a Comments
section. Place an X in appropriate boxes. Circle
AMENDED items in red and write AMENDED
across top of form.)
Status
Vital Status
Alive (Alive)
Dead (Dead)
Date of Last Contact or Death
Has the patient progressed per the definition in
Section 10.0 of the protocol?
Yes
No
Treatment
Which treatment did the patient receive? (select
one)
Combination Therapy (Combination
therapy)
Single Agent (Single agent)
Which treatment did the patient receive?
Capecitabine (Capecitabine)
Cyclophosphamide (Cyclophosphamide)
Docetaxel (Docetaxel)
Doxorubicin (Doxorubicin)
Other (Other)
Paclitaxel (Paclitaxel)
Trastuzumab (Trastuzumab)
Vinorelbine (Vinorelbine)
Other, specify
Cycle Length
2 Weeks (2 weeks)
3 Weeks (3 weeks)
4 Weeks (4 weeks)
Other (Other)
Other, specify
Treatment Begin Date
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SOUTHWEST ONCOLOGY GROUP S0500 TREATMENT SUMMARY
FORM NCT00382018
Date of Last Treatment
Comments
Comments
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SOUTHWEST ONCOLOGY GROUP S0500 TREATMENT SUMMARY
FORM NCT00382018
RTOG-0412 TF: Treatment Summary Form
NCT00113386
RTOG-0412 TF: Treatment Summary Form NCT00113386 
Cisplatin and Docetaxel With or Without Radiation Therapy
in Treating Patients Who Are Undergoing Surgery for Newly
Diagnosed Stage III Non-Small Cell Lung Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=E48A09C8-
DD81-67D1-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/10909
RTOG-0412 TF: Treatment Summary
Form NCT00113386
Treatment Summary
RTOG Study
Case #
Institution
Institution No.
Participant's Initials
Participant's I.D. No.
AMENDED DATA
Yes
No
PATIENT HEIGHT (CM)
PATIENT WEIGHT (KG)
BODY SURFACE AREA (M2)
TREATMENT PHASE
Current Phase Of Leukemia Treatment
For Patient Is Induction (Induction)
Current Phase Of Leukemia Treatment
For Patient Is Maintenance
(Maintenance)
CYCLES
1 And 2 (1 and 2)
3 - 5 (3--5)
ASSIGNED TREATMENT ARM
Induction Chemo / Xrt (Induction chemo /
XRT)
Induction Chemo Alone (Induction
chemo alone)
1 / 3
NEW OR CONTINUING ADVERSE EVENTS
Yes
No
AGENT NAME
AGENT START DATE  (FOR  CYCLES BEING
REPORTED)
AGENT END DATE (FOR  CYCLES BEING
REPORTED)
AGENT TOTAL CUMULATIVE DOSE (FOR
CYCLES BEING REPORTED)
TOTAL  NUMBER  OF CYCLES
DOSE  MODIFICATION (Use code table below)
Alternative Therapy (Alternative therapy)
Death On Study (Death on study)
Disease Progression, Relapse During
Active Treatment (Disease progression,
relapse during active treatment)
None (None)
Other (Other)
Other Complicating Disease (Other
complicating disease)
Patient Withdrawal Or Refusal After
Beginning Protocol Therapy (Patient
withdrawal or refusal after beginning
protocol therapy)
Patient Withdrawal Or Refusal Prior To
Beginning Protocol Therapy (Patient
withdrawal or refusal prior to beginning
protocol therapy)
Adverse Event/side Effects/complications
(Toxicity/side effects/complications)
Treatment Completed Per Protocol
Criteria (Treatment completed per
protocol criteria)
REASON TREATMENT ENDED (Use code table
below)
Alternative Therapy (Alternative therapy)
Death On Study (Death on study)
Disease Progression, Relapse During
Active Treatment (Disease progression,
relapse during active treatment)
None (None)
Other (Other)
Other Complicating Disease (Other
complicating disease)
Patient Withdrawal Or Refusal (Patient
withdrawal or refusal after beginning
protocol therapy)
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RTOG-0412 TF: Treatment Summary Form NCT00113386
Patient withdrawal or refusal prior to
beginningprotocol therapy (Patient
withdrawal or refusal prior to
beginningprotocol therapy)
Toxicity/side Effects/complications
(Toxicity/side effects/complications)
Treatment Completed Per Protocol
Criteria (Treatment completed per
protocol criteria)
Alternative therapy, specify alternative therapy
Other complicating disease, specify complicating
disease
Other, specify
Comments
Name of person completing form
Form completion date, original
3 / 3
RTOG-0412 TF: Treatment Summary Form NCT00113386
SOUTHWEST ONCOLOGY GROUP DENTAL
EXAMINATION FORM (S0307) NCT00127205
SOUTHWEST ONCOLOGY GROUP DENTAL
EXAMINATION FORM (S0307) NCT00127205 
Zoledronate, Clodronate, or Ibandronate in Treating Women
Who Have Undergone Surgery for Stage I, Stage II, or
Stage III Breast
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=DF04A14D-
7376-575B-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/10910
SOUTHWEST ONCOLOGY GROUP
DENTAL EXAMINATION FORM
(S0307) NCT00127205
Header
Time
End Of Protocol Treatment (End of
protocol treatment)
Prestudy (Prestudy)
Institution/Affiliate
Physician
Participating Group Name
Participating Group Study No.
Participating Group Patient ID
SWOG Patient ID
SWOG Study No.
Registration Step
Patient Initials (L, F, M)
Examination Date
Examination Date
Periodontal Examination
Dental plaque levels
Mild (Mild)
Moderate (Moderate)
None (None)
Severe (Severe)
Calculus
1 / 4
Mild (Mild)
Moderate (Moderate)
None (None)
Severe (Severe)
Gingivitis
Generalized (Generalized)
Mild (Mild)
Moderate (Moderate)
None (None)
Patchy (Patchy)
Severe (Severe)
Periodontis
All Pockets 4 Mm Or Less (All pockets 4
mm or less)
Pockets > 6 Mm (Pockets > 6 mm)
Pockets >=4 Mm <=6 Mm (Pockets >=4
mm =<6 mm)
Teeth Numbers
Overall periodontal disease level
Mild (Mild)
Moderate (Moderate)
None (None)
Severe (Severe)
Dentition Examination
Dentition Examination
None (None)
Deep carries (within 3 mm or pulp: List teeth
numbers)
Fractured teeth / restorations (List teeth numbers)
Endodontic Examination
Endodontic Examination
None (None)
Endodontically treated teeth (List teeth numbers)
Failing root canals (List teeth numbers)
Removable Dentures
Removable Dentures
Complete Dentures (Complete dentures)
None (None)
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SOUTHWEST ONCOLOGY GROUP DENTAL EXAMINATION FORM
(S0307) NCT00127205
Removable Partial Dentures (Removable
partial dentures)
Age of dentures
Last reline/adjustment date
Stability
Fair (Fair)
Good (Good)
Poor (Poor)
Stability
Fair (Fair)
Good (Good)
Poor (Poor)
Retention
Fair (Fair)
Good (Good)
Poor (Poor)
Retention
Fair (Fair)
Good (Good)
Poor (Poor)
Evidence of denture sores/denture stomatitis
Mild (Mild)
Moderate (Moderate)
None (None)
Severe (Severe)
SWOG Patient ID
SWOG Study No.
Registration Step
Patient Initials (L, F, M)
Osteonecrotic Jaw Lesions
Site
Size
Date of onset
Associated factor(s)
Dental Extraction (Dental extraction)
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SOUTHWEST ONCOLOGY GROUP DENTAL EXAMINATION FORM
(S0307) NCT00127205
Denture Trauma (Denture trauma)
No Identified Factor (No identified factor)
Other Dental Surgery (Other dental
surgery)
Periodontal Infection (Periodontal
infection)
Signature of examining dentist
date
Comments
Comments
4 / 4
SOUTHWEST ONCOLOGY GROUP DENTAL EXAMINATION FORM
(S0307) NCT00127205
SOUTHWEST ONCOLOGY GROUP S0347 BASELINE
TUMOR ASSESSMENT FORM NCT00103233
SOUTHWEST ONCOLOGY GROUP S0347 BASELINE
TUMOR ASSESSMENT FORM NCT00103233 
Vinorelbine With or Without Trastuzumab in Treating
Women With Progressive Metastatic Breast Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=DDA11E57-
D61E-2277-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/10911
SOUTHWEST ONCOLOGY GROUP
S0347 BASELINE TUMOR
ASSESSMENT FORM
NCT00103233
Header
SWOG Patient ID
SWOG Study No.
Registration Step
Patient Initials (L, F M)
Institution/Affiliate
Physician (Participating Group)
Group Name
Study No.
Patient ID (Instructions: Record the requested
information for all target lesions and all sites of
other disease. Please refer to section 10.0 of the
protocol for definitions. Choose all measurable
lesions up to a maximum of 5 lesions per organ
and 10 lesions in total to follow as target lesions.
Record any remaining measurable lesions and all
non-measurable disease as non-target disease.)
Target lesion status
Target Lesions
Longest Diameter (cm)
Non-target disease
1 / 3
Extent
Assessment Type (*)
Colposcopy (Colposcopy)
Ct Scan (CT scan)
Cystoscopy (Cystoscopy)
Cytologic Confirmation (Cytologic
confirmation)
Endoscopy (Endoscopy)
Histologic Confirmation (Histologic
confirmation)
Mri Scan (MRI scan)
Other (Other)
Palpation (Palpation)
Pet Scan (PET scan)
Plain Film/x-ray With Contrast (Plain
film/X-ray with contrast)
Plain Film/x-ray Without Contrast (Plain
film/X-ray without contrast)
Radioisotope Scan (Radioisotope scan)
Spiral Ct Scan (Spiral CT scan)
Ultrasound (Ultrasound)
Visualization (Visualization)
Assessment Type (*)
Colposcopy (Colposcopy)
Ct Scan (CT scan)
Cystoscopy (Cystoscopy)
Cytologic Confirmation (Cytologic
confirmation)
Endoscopy (Endoscopy)
Histologic Confirmation (Histologic
confirmation)
Mri Scan (MRI scan)
Other (Other)
Palpation (Palpation)
Pet Scan (PET scan)
Plain Film/x-ray With Contrast (Plain
film/X-ray with contrast)
Plain Film/x-ray Without Contrast (Plain
film/X-ray without contrast)
Radioisotope Scan (Radioisotope scan)
Spiral Ct Scan (Spiral CT scan)
Ultrasound (Ultrasound)
Visualization (Visualization)
Assessment Date
Assessment Date
Diagnostic Test
Tests/studies
Assessment Date
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SOUTHWEST ONCOLOGY GROUP S0347 BASELINE TUMOR
ASSESSMENT FORM NCT00103233
Comments
Comments
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SOUTHWEST ONCOLOGY GROUP S0347 BASELINE TUMOR
ASSESSMENT FORM NCT00103233
SOUTHWEST ONCOLOGY GROUP FOLLOW-UP
TUMOR ASSESSMENT FORM (S0347) NCT00103233
SOUTHWEST ONCOLOGY GROUP FOLLOW-UP
TUMOR ASSESSMENT FORM (S0347) NCT00103233 
Vinorelbine With or Without Trastuzumab in Treating
Women With Progressive Metastatic Breast Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=DDF0470A-
283D-06AB-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/10912
SOUTHWEST ONCOLOGY GROUP
FOLLOW-UP TUMOR
ASSESSMENT FORM (S0347)
NCT00103233
Header
SWOG Patient ID
Patient Initials (L, F M)
SWOG Study No.
Institution/Affiliate
Registration Step
Date form completed
Physician
Participating Group Name
Participating Group Study No.
Participating Group Patient ID
Target Lesions
Target Lesions
Longest Diameter (cm)
Assessment Type (*)
Colposcopy (Colposcopy)
Ct Scan (CT scan)
Cystoscopy (Cystoscopy)
Cytologic Confirmation (Cytologic
confirmation)
Endoscopy (Endoscopy)
1 / 3
Histologic Confirmation (Histologic
confirmation)
Mri Scan (MRI scan)
Other (Other)
Palpation (Palpation)
Pet Scan (PET scan)
Plain Film/x-ray With Contrast (Plain
film/X-ray with contrast)
Plain Film/x-ray Without Contrast (Plain
film/X-ray without contrast)
Radioisotope Scan (Radioisotope scan)
Spiral Ct Scan (Spiral CT scan)
Ultrasound (Ultrasound)
Visualization (Visualization)
Assessment Date
Non-target Disease
Non-Target Disease
Extent
Clear Increase (Clear increase)
Complete Disappearance (Complete
disappearance)
Not Assessed (Not assessed)
Present (Present)
Assessment Type (*)
Colposcopy (Colposcopy)
Ct Scan (CT scan)
Cystoscopy (Cystoscopy)
Cytologic Confirmation (Cytologic
confirmation)
Endoscopy (Endoscopy)
Histologic Confirmation (Histologic
confirmation)
Mri Scan (MRI scan)
Other (Other)
Palpation (Palpation)
Pet Scan (PET scan)
Plain Film/x-ray With Contrast (Plain
film/X-ray with contrast)
Plain Film/x-ray Without Contrast (Plain
film/X-ray without contrast)
Radioisotope Scan (Radioisotope scan)
Spiral Ct Scan (Spiral CT scan)
Ultrasound (Ultrasound)
Visualization (Visualization)
Assessment Date
SWOG Patient ID
SWOG Study No.
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SOUTHWEST ONCOLOGY GROUP FOLLOW-UP TUMOR
ASSESSMENT FORM (S0347) NCT00103233
Registration Step
Date form completed
New Lesions
New Lesions (Specify Site)
Assessment Type (*)
Colposcopy (Colposcopy)
Ct Scan (CT scan)
Cystoscopy (Cystoscopy)
Cytologic Confirmation (Cytologic
confirmation)
Endoscopy (Endoscopy)
Histologic Confirmation (Histologic
confirmation)
Mri Scan (MRI scan)
Other (Other)
Palpation (Palpation)
Pet Scan (PET scan)
Plain Film/x-ray With Contrast (Plain
film/X-ray with contrast)
Plain Film/x-ray Without Contrast (Plain
film/X-ray without contrast)
Radioisotope Scan (Radioisotope scan)
Spiral Ct Scan (Spiral CT scan)
Ultrasound (Ultrasound)
Visualization (Visualization)
Assessment Date
Symptomatic deterioration
Symptomatic deterioration
Yes
No
Assessment Date
Comments
Comments
3 / 3
SOUTHWEST ONCOLOGY GROUP FOLLOW-UP TUMOR
ASSESSMENT FORM (S0347) NCT00103233
NCT00288080  RTOG-0521 TF: Radiation Therapy Oncology Group Phase III
Randomized Study of Localized, High-Risk Prostate Cancer Treatment Summary
Form
NCT00288080  RTOG-0521 TF: Radiation Therapy
Oncology Group Phase III Randomized Study of Localized,
High-Risk Prostate Cancer Treatment Summary Form
Hormone Therapy and Radiation Therapy or Hormone
Therapy and Radiation Therapy Followed by Docetaxel and
Prednisone in Treating Patients With Localized Prostate
Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=F6C17FD2-
E75E-62CA-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/10913
NCT00288080  RTOG-0521 TF:
Radiation Therapy Oncology Group
Phase III Randomized Study of
Localized, High-Risk Prostate
Cancer Treatment Summary Form
RTOG clinical trial administrative data
RTOG Study No.
Case #
Amended data
Yes
No
Patient demographics
Institution Name
Institution No.
Patient Initials
RTOG Patient ID
Patient Weight Measurement
Patient Height Measurement
Patient Body Surface Area Measurement
Treatment Schedule - Chemotherapy
Treatment Current Course Number
Agent Name
1 / 3
Cycle Start Date
Cycle end date
Dose per M2
Agent Total Cumulative Dose
Were there any dose modifications or
additions/omissions to protocol treatment?
No (No)
Yes, Planned (i.e., The Treatment Was
Changed According To Protocol
Guidelines) (Yes, planned)
Yes, Unplanned (i.e., The Treatment
Change Was Not Part Of Protocol
Guidelines) (Yes, unplanned)
Reason for Treatment Modification
Adverse Event/side Effects/complications
(Adverse Event/Side
Effects/Complications)
Alternative Therapy (Alternative therapy)
Death On Study (Death on study)
Disease Progression, Relapse During
Active Treatment (Disease progression,
relapse during active treatment)
No Treatment, Per Protocol Criteria (No
treatment, per protocol criteria)
Other (Other)
Patient Off-treatment For Other
Complicating Disease (Patient off-
treatment for other complicating disease)
Patient Withdrawal Or Refusal After
Beginning Protocol Therapy (Patient
withdrawal/refusal after beginning
protocol therapy)
Patient Withdrawal Or Refusal Before
Beginning Protocol Therapy (Patient
withdrawal/refusal prior to beginning
protocol therapy)
Treatment Completed Per Protocol
Criteria (Treatment completed per
protocol criteria)
Reason Treatment Ended
Adverse Event/side Effects/complications
(Adverse Event/Side
Effects/Complications)
Alternative Therapy (Alternative therapy)
Death On Study (Death on study)
Disease Progression, Relapse During
Active Treatment (Disease progression,
relapse during active treatment)
No Treatment, Per Protocol Criteria (No
treatment, per protocol criteria)
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NCT00288080  RTOG-0521 TF: Radiation Therapy Oncology Group Phase III
Randomized Study of Localized, High-Risk Prostate Cancer Treatment Summary
Form
Other (Other)
Patient Off-treatment For Other
Complicating Disease (Patient off-
treatment for other complicating disease)
Patient Withdrawal Or Refusal After
Beginning Protocol Therapy (Patient
withdrawal/refusal after beginning
protocol therapy)
Patient Withdrawal Or Refusal Before
Beginning Protocol Therapy (Patient
withdrawal/refusal prior to beginning
protocol therapy)
Treatment Completed Per Protocol
Criteria (Treatment completed per
protocol criteria)
Alternative Therapy
Patient off-treatment for other complicating
disease, specify
Other
Protocol chemotherapy
Is protocol chemotherapy continuing?
Yes
No
New Adverse Event Occurrence Ind-3
Yes
No
Comments
Comments
Signature of Person Completing This Form
Form Completion Date, Original
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NCT00288080  RTOG-0521 TF: Radiation Therapy Oncology Group Phase III
Randomized Study of Localized, High-Risk Prostate Cancer Treatment Summary
Form
NCT00127205  SOUTHWEST ONCOLOGY GROUP
(S0307) OSTEONECROTIC JAW LESION FORM
NCT00127205  SOUTHWEST ONCOLOGY GROUP
(S0307) OSTEONECROTIC JAW LESION FORM
Zoledronate, Clodronate, or Ibandronate in Treating Women
Who Have Undergone Surgery for Stage I, Stage II, or
Stage III Breast
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=DF063443-
2859-5EC8-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/10914
NCT00127205  SOUTHWEST
ONCOLOGY GROUP (S0307)
OSTEONECROTIC JAW LESION
FORM
Header
SWOG Patient ID
SWOG Study No.
Registration Step
Patient Initials (L, F, M)
Institution/Affiliate
Physician
Participating Group Name
Participating Group Study No.
Participating Group Patient ID
Osteonecrotic lesions
Number of osteonecrotic lesions
1 (1)
2 (2)
3 (3)
Date of onset
Any signs/symptoms of infection (e.g., mucosal
erythema, swelling, pus, bad taste?)
Yes
No
Maxilla
Alveolar Ridge (Alveolar ridge)
1 / 3
Anterior (Anterior)
Buccal (Buccal)
Lingual (Lingual)
Palate (Palate)
Posterior (Posterior)
Maxilla
Alveolar Ridge (Alveolar ridge)
Anterior (Anterior)
Buccal (Buccal)
Lingual (Lingual)
Palate (Palate)
Posterior (Posterior)
Maxilla
Alveolar Ridge (Alveolar ridge)
Anterior (Anterior)
Buccal (Buccal)
Lingual (Lingual)
Palate (Palate)
Posterior (Posterior)
Mandible
Alveolar Ridge (Alveolar ridge)
Anterior (Anterior)
Buccal (Buccal)
Lingual (Lingual)
Mylohyoid Plate (Mylohyoid plate)
Posterior (Posterior)
Mandible
Alveolar Ridge (Alveolar ridge)
Anterior (Anterior)
Buccal (Buccal)
Lingual (Lingual)
Mylohyoid Plate (Mylohyoid plate)
Posterior (Posterior)
Mandible
Alveolar Ridge (Alveolar ridge)
Anterior (Anterior)
Buccal (Buccal)
Lingual (Lingual)
Mylohyoid Plate (Mylohyoid plate)
Posterior (Posterior)
Size of lesion (mm)
Size of lesion (mm)
Size of lesion (mm)
Associated causative factor(s) (select all that
apply:)
Dental Extraction (Dental extraction)
Denture Trauma (Denture trauma)
No Identified Factor (No identified factor)
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NCT00127205  SOUTHWEST ONCOLOGY GROUP (S0307)
OSTEONECROTIC JAW LESION FORM
Other Dental Surgery (Other dental
surgery)
Periodontal Infection (Periodontal
infection)
Associated causative factor(s) (select all that
apply:)
Dental Extraction (Dental extraction)
Denture Trauma (Denture trauma)
No Identified Factor (No identified factor)
Other Dental Surgery (Other dental
surgery)
Periodontal Infection (Periodontal
infection)
Associated causative factor(s) (select all that
apply:)
Dental Extraction (Dental extraction)
Denture Trauma (Denture trauma)
No Identified Factor (No identified factor)
Other Dental Surgery (Other dental
surgery)
Periodontal Infection (Periodontal
infection)
Steroid Use
Did the patient receive steroids within 12 months
of occurrence of the current jaw lesion(s)?
Yes
No
list drug name (If Yes,)
Dates of administration (to:)
Dates of administration
Comments
Comments
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NCT00127205  SOUTHWEST ONCOLOGY GROUP (S0307)
OSTEONECROTIC JAW LESION FORM
SOUTHWEST ONCOLOGY GROUP FOLLOW-UP BONE-
ONLY DISEASE ASSESSMENT FORM NCT00382018
SOUTHWEST ONCOLOGY GROUP FOLLOW-UP BONE-
ONLY DISEASE ASSESSMENT FORM NCT00382018 
Treatment Decision Making Based on Blood Levels of
Tumor Cells in Women With Metastatic Breast Cancer
Receiving Chemotherapy
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=1429A25E-
5A0A-2D94-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/10915
SOUTHWEST ONCOLOGY GROUP
FOLLOW-UP BONE-ONLY
DISEASE ASSESSMENT FORM
NCT00382018
Header
SWOG Patient ID
SWOG Study No.
Registration Step
Patient Initials (L, F M)
Date form completed
Institution/Affiliate
Physician
Participating Group Name
Participating Group Study No.
Participating Group Patient ID
Non-target Disease
Non-Target Disease
Extent
Clear Increase (Clear increase)
Complete Disappearance (Complete
disappearance)
Not Assessed (Not assessed)
Present (Present)
Assessment Type (*)
Colposcopy (Colposcopy)
Ct Scan (CT scan)
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Cystoscopy (Cystoscopy)
Cytologic Confirmation (Cytologic
confirmation)
Endoscopy (Endoscopy)
Histologic (Histologic confirmation)
Mri Scan (MRI scan)
Other (Other)
Palpation (Palpation)
Pet Scan (PET scan)
Plain Film/x-ray With Contrast (Plain
film/X-ray with contrast)
Plain Film/x-ray Without Contrast (Plain
film/X-ray without contrast)
Radioisotope Scan (Radioisotope scan)
Spiral Ct Scan (Spiral CT scan)
Ultrasound (Ultrasound)
Visualization (Visualization)
Assessment Date
New Lesions (specify Site)
New Lesions (Specify Site)
Assessment Type (*)
Colposcopy (Colposcopy)
Ct Scan (CT scan)
Cystoscopy (Cystoscopy)
Cytologic Confirmation (Cytologic
confirmation)
Endoscopy (Endoscopy)
Histologic (Histologic confirmation)
Mri Scan (MRI scan)
Other (Other)
Palpation (Palpation)
Pet Scan (PET scan)
Plain Film/x-ray With Contrast (Plain
film/X-ray with contrast)
Plain Film/x-ray Without Contrast (Plain
film/X-ray without contrast)
Radioisotope Scan (Radioisotope scan)
Spiral Ct Scan (Spiral CT scan)
Ultrasound (Ultrasound)
Visualization (Visualization)
Assessment Date
Symptomatic deterioration
Symptomatic deterioration
Yes
No
Assessment Date
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Comments
Comments
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SOUTHWEST ONCOLOGY GROUP BASELINE
TUMOR ASSESSMENT FORM NCT00382018
SOUTHWEST ONCOLOGY GROUP BASELINE TUMOR
ASSESSMENT FORM NCT00382018 
Treatment Decision Making Based on Blood Levels of
Tumor Cells in Women With Metastatic Breast Cancer
Receiving Chemotherapy
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=07BF0CAC-
47CA-023C-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/10916
SOUTHWEST ONCOLOGY GROUP
BASELINE TUMOR ASSESSMENT
FORM NCT00382018
Header
SWOG Patient ID
SWOG Study No.
Registration Step
Patient Initials (L, F M)
Institution/Affiliate
Physician (Participating Group)
Participating Group Name
Participating Group Study No.
Participating Group Patient ID
Target lesion status
Target Lesions
Longest Diameter (cm)
Assessment Date
Assessment Date
Non-target disease
Extent
Assessment Type (*)
1 / 2
Colposcopy (Colposcopy)
Ct Scan (CT scan)
Cystoscopy (Cystoscopy)
Cytologic Confirmation (Cytologic
confirmation)
Endoscopy (Endoscopy)
Histologic (Histologic confirmation)
Mri Scan (MRI scan)
Other (Other)
Palpation (Palpation)
Pet Scan (PET scan)
Plain Film/x-ray With Contrast (Plain
film/X-ray with contrast)
Plain Film/x-ray Without Contrast (Plain
film/X-ray without contrast)
Radioisotope Scan (Radioisotope scan)
Spiral Ct Scan (Spiral CT scan)
Ultrasound (Ultrasound)
Visualization (Visualization)
Assessment Type (*)
Colposcopy (Colposcopy)
Ct Scan (CT scan)
Cystoscopy (Cystoscopy)
Cytologic Confirmation (Cytologic
confirmation)
Endoscopy (Endoscopy)
Histologic (Histologic confirmation)
Mri Scan (MRI scan)
Other (Other)
Palpation (Palpation)
Pet Scan (PET scan)
Plain Film/x-ray With Contrast (Plain
film/X-ray with contrast)
Plain Film/x-ray Without Contrast (Plain
film/X-ray without contrast)
Radioisotope Scan (Radioisotope scan)
Spiral Ct Scan (Spiral CT scan)
Ultrasound (Ultrasound)
Visualization (Visualization)
Diagnostic Test
Tests/studies
Assessment Date
Comments
Comments
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SOUTHWEST ONCOLOGY GROUP BASELINE TUMOR
ASSESSMENT FORM NCT00382018
NCT00382018  SOUTHWEST ONCOLOGY GROUP
FOLLOW-UP TUMOR ASSESSMENT FORM
NCT00382018 SOUTHWEST ONCOLOGY GROUP
FOLLOW-UP TUMOR ASSESSMENT FORM
Treatment Decision Making Based on Blood Levels of
Tumor Cells in Women With Metastatic Breast Cancer
Receiving Chemotherapy
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=07BF1427-
517D-02CC-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/10917
NCT00382018  SOUTHWEST
ONCOLOGY GROUP FOLLOW-UP
TUMOR ASSESSMENT FORM
Header
SWOG Patient ID
SWOG Study No.
Registration Step
Patient Initials (L, F M)
Date form completed
Institution/Affiliate
Physician
Participating Group Name
Participating Group Study No.
Participating Group Patient ID
Target Lesions
Target Lesions
Longest Diameter (cm)
Assessment Type (*)
Colposcopy (Colposcopy)
Ct Scan (CT scan)
Cystoscopy (Cystoscopy)
Cytologic Confirmation (Cytologic
confirmation)
Endoscopy (Endoscopy)
Histologic (Histologic confirmation)
Mri Scan (MRI scan)
Other (Other)
1 / 3
Palpation (Palpation)
Pet Scan (PET scan)
Plain Film/x-ray With Contrast (Plain
film/X-ray with contrast)
Plain Film/x-ray Without Contrast (Plain
film/X-ray without contrast)
Radioisotope Scan (Radioisotope scan)
Spiral Ct Scan (Spiral CT scan)
Ultrasound (Ultrasound)
Visualization (Visualization)
Assessment Date
Non-target Disease
Non-Target Disease
Extent
Clear Increase (Clear increase)
Complete Disappearance (Complete
disappearance)
Not Assessed (Not assessed)
Present (Present)
Assessment Type (*)
Colposcopy (Colposcopy)
Ct Scan (CT scan)
Cystoscopy (Cystoscopy)
Cytologic Confirmation (Cytologic
confirmation)
Endoscopy (Endoscopy)
Histologic (Histologic confirmation)
Mri Scan (MRI scan)
Other (Other)
Palpation (Palpation)
Pet Scan (PET scan)
Plain Film/x-ray With Contrast (Plain
film/X-ray with contrast)
Plain Film/x-ray Without Contrast (Plain
film/X-ray without contrast)
Radioisotope Scan (Radioisotope scan)
Spiral Ct Scan (Spiral CT scan)
Ultrasound (Ultrasound)
Visualization (Visualization)
Assessment Date
New Lesions (specify Site)
New Lesions (Specify Site)
Assessment Type (*)
Colposcopy (Colposcopy)
Ct Scan (CT scan)
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Cystoscopy (Cystoscopy)
Cytologic Confirmation (Cytologic
confirmation)
Endoscopy (Endoscopy)
Histologic (Histologic confirmation)
Mri Scan (MRI scan)
Other (Other)
Palpation (Palpation)
Pet Scan (PET scan)
Plain Film/x-ray With Contrast (Plain
film/X-ray with contrast)
Plain Film/x-ray Without Contrast (Plain
film/X-ray without contrast)
Radioisotope Scan (Radioisotope scan)
Spiral Ct Scan (Spiral CT scan)
Ultrasound (Ultrasound)
Visualization (Visualization)
Assessment Date
Symptomatic deterioration
Symptomatic deterioration
Yes
No
Assessment Date
Comments
Comments
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TUMOR ASSESSMENT FORM
CALGB 30506 Treatment And Response
Form NCT00863512
CALGB 30506 Treatment And Response Form
NCT00863512 
Chemotherapy or Observation in Treating Patients With
Early Stage Non-Small Cell Lung Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=5E92C67F-
DAF6-CFB0-E040-BB89AD432DA1
All rights reserved. Please visit https://medical-data-
models.org/forms/10918
CALGB 30506 Treatment And
Response Form NCT00863512
Header
CALGB Form
CALGB Study No.
CALGB Patient ID
Date of First dose for this reporting period (MM
DD YYYY)
Reporting Period End Date (MM DD YYYY)
Are data amended
Yes
No
Patient demographics
Patient Initials (Last, First Middle)
Patient Hospital No.
Institution/Affiliate
Participating Group
Participating Group Study No.
Participating Group Patient ID
Patient Data
Cycle Number
Weight (kg)
1 / 3
BSA (m^2)
First Treatment (cycles 1 ¿ 6)
Agent
Total Dose of Agents/Drugs for this Cycle
Dose Modifications
Were there any dose modifications or
additions/omissions to protocol treatment?
No (No)
Yes, Planned (i.e., The Treatment Was
Changed According To Protocol
Guidelines) (Yes, planned)
Yes, Unplanned (i.e., The Treatment
Change Was Not Part Of Protocol
Guidelines) (Yes, unplanned)
Reason Treatment Ended
Off Treatment Reason (only applicable if protocol
therapy has been discontinued permanently Mark
one with an X.)
Adverse Event/side Effects/complications
(Adverse Event/Side
Effects/Complications)
Alternative Therapy (Alternative therapy)
Disease Progression, Relapse During
Active Treatment (Disease progression,
relapse during active treatment)
Other (Other)
Patient Off-treatment For Other
Complicating Disease (Patient off-
treatment for other complicating disease)
Patient Withdrawal Or Refusal After
Beginning Protocol Therapy (Patient
withdrawal/refusal after beginning
protocol therapy)
Patient Withdrawal Or Refusal Before
Beginning Protocol Therapy (Patient
withdrawal/refusal prior to beginning
protocol therapy)
Alternative therapy, specify
Removed To Receive Non-protocol
Chemotherapy And/or Biologic Therapy
(Removed to receive non-protocol
chemotherapy and/or biologic therapy)
Removed To Undergo Surgical
Resection (Removed to undergo surgical
resection)
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Other specify
Was growth factor support employed? (during this
reporting period)
Yes
No
Total No. of Doses (if yes, specify)
Footer Module
Completed by (print or type name)
Date Form Completed (MM DD YYYY)
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SOUTHWEST ONCOLOGY GROUP S0500
CTC SUBMISSION FORM NCT00382018
SOUTHWEST ONCOLOGY GROUP S0500 CTC
SUBMISSION FORM NCT00382018 
Treatment Decision Making Based on Blood Levels of
Tumor Cells in Women With Metastatic Breast Cancer
Receiving Chemotherapy
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=804A6A4D-
69FB-2D51-E040-BB89AD4340B3
All rights reserved. Please visit https://medical-data-
models.org/forms/10919
SOUTHWEST ONCOLOGY GROUP
S0500 CTC SUBMISSION FORM
NCT00382018
Header
SWOG Patient ID
SWOG Study No.
Registration Step
Patient Initials (L, F M)
CTC submission timepoint
Day 169 (Day 169)
Day 22 (Day 22)
Day 253 (Day 253)
Day 50/57 (Day 50/57)
Day 85 (Day 85)
Pretreatment (Pretreatment)
Institution/Affiliate
Physician (Participating Group:)
Group Name
Participating Group Study No.
Participating Group Patient ID (Instructions: All
dates are MONTH, DAY, YEAR. Explain any
blank fields or blank dates in the Comments
section. Place an X in appropriate boxes. Circle
AMENDED items in red and write AMENDED
across the top of the form.)
Blood sample
Was the blood sample drawn and submitted to
Veridex for this timepoint
1 / 2
Yes
No
Date of blood sample collection (IF yes,)
Was this a repeat blood sample collection for this
submission timepoint
Yes
No
Will the patient remain on study for future CTC
blood draws
Yes
No
Off-protocol treatment
Off treatment reason
Day 253 Blood Draw Completed Per
Protocol Criteria (Day 253 blood draw
completed per protocol criteria)
Death (Death)
Other (Other)
Patient Withdrew Consent For All Future
Blood Draws (Patient withdrew consent
for all future blood draws)
Progression Or Relapse (Progression or
relapse)
Other, specify
Off treatment date (Date of completion,
progression, death, or decision to discontinue
CTC blood draws)
Comments
Comments
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E3F05 Non-Protocol Therapy Form
E3F05 Non-Protocol Therapy Form
Radiation Therapy With or Without Temozolomide in
Treating Patients With Low-Grade Glioma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=7004AA2A-
D8EB-35F3-E040-BB89AD435DD6
All rights reserved. Please visit https://medical-data-
models.org/forms/10920
E3F05 Non-Protocol Therapy Form
Header
ECOG Protocol Number
ECOG Patient ID
DCI Name
Registration Step
Reporting Period
Non-protocol Therapy (Non-Protocol
Therapy)
Patient demographics
ECOG Protocol Number
Patient Initials (Last, First)
ECOG Patient ID
Participating Group Protocol Number
Institution/Affiliate
Participating Group Patient ID
Data amendment
Please mark an 'X' if data have been amended.
(Please circle amended items in red)
Date data amended (s M D Y)
Non-Protocol Therapy Date
1 / 3
Date of First Non-Protocol Therapy (if given prior
to progression/relapse from protocol therapy M D
Y)
Type(s) of first non-protocol therapy
Non-protocol Chemotherapy
No (No)
Unknown (Unknown)
Yes (Yes)
Non-protocol Hormonal Therapy
No (No)
Unknown (Unknown)
Yes (Yes)
Non-protocol Immunotherapy (/Biological
Response Modifiers)
No (No)
Unknown (Unknown)
Yes (Yes)
Non-protocol high dose chemotherapy/stem cell
transplant (Autologous or Allogeneic)
No (No)
Unknown (Unknown)
Yes (Yes)
Non-protocol Surgery
No (No)
Unknown (Unknown)
Yes (Yes)
Non-protocol surgery type
Non-protocol Radiation Therapy
No (No)
Unknown (Unknown)
Yes (Yes)
Non-protocol RT type
Other Non-protocol Therapy
No (No)
Unknown (Unknown)
Yes (Yes)
Name of other non-protocol therapy
Was the non-protocol therapy given for the
disease of this protocol (NOTE: Treatment for a
second primary in the same organ site would not
be considered therapy for disease of this
protocol.)
No (No)
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Unknown (Unknown)
Yes (Yes)
Comments
Investigator Signature
Investigator Signature Date (M D Y)
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E3F05 Off-Treatment Form NCT00978458
E3F05 Off-Treatment Form NCT00978458 
Radiation Therapy With or Without Temozolomide in
Treating Patients With Low-Grade Glioma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=6C1889F9-
CF7D-5474-E040-BB89AD431A23
All rights reserved. Please visit https://medical-data-
models.org/forms/10921
E3F05 Off-Treatment Form
NCT00978458
Header
ECOG Protocol Number
ECOG Patient ID
DCI Name
Registration Step
Reporting Period
End Of Treatment (End of treatment)
Patient demographics
Patient Initials (Last, First)
Participating Group Protocol Number
ECOG Protocol Number
Institution/Affiliate
ECOG Patient ID
Participating Group Patient ID
Data amendment
Please mark an 'X' if data have been amended.
(Please circle amended items in red)
Date data amended (s m d y)
Vital Status
1 / 3
Patient's Vital Status
Alive (Alive)
Dead (Dead)
Date of Last Contact or Death (m d y)
Primary Cause of Death (if applicable)
Due To Other Cause (Due to other
cause)
Due To Protocol Treatment (Due to
protocol treatment)
Due To This Disease (Due to this
disease)
Unknown (Unknown)
Describe cause of death
Protocol treatment
Did patient receive protocol therapy
Yes
No
Section I
Reason Treatment Ended
Adverse Event/side Effects/complications
(Adverse Event/Side
Effects/Complications)
Alternative Therapy (Alternative therapy)
Death On Study (Death on study)
Disease Progression, Relapse During
Active Treatment (Disease progression,
relapse during active treatment)
Other (Other)
Patient Off-treatment For Other
Complicating Disease (Patient off-
treatment for other complicating disease)
Patient Withdrawal Or Refusal After
Beginning Protocol Therapy (Patient
withdrawal/refusal after beginning
protocol therapy)
Treatment Completed Per Protocol
Criteria (Treatment completed per
protocol criteria)
Other Complicating Disease specify (specify)
Other specify
Last date protocol therapy was given (m d y)
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Section Ii
Reason treatment never started
Adverse Event/side Effects/complications
(Adverse events/side
effects/complications)
Death Before Beginning Protocol
Therapy (Death before beginning
protocol therapy)
Disease Progression, Relapse Prior To
Beginning Protocol Therapy (Disease
progression, relapse before protocol
treatment)
Medical Decision (Medical decision)
No Treatment, Per Protocol Criteria (No
treatment assigned per protocol)
Other (Other)
Patient_ineligible (Patient ineligible)
Patient Withdrawal/refusal Before
Beginning Protocol Therapy (Patient
withdrawal/refusal before beginning
protocol therapy)
Other specify
Comments
Investigator Signature
Investigator Signature Date (MM DD YYYY)
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Trauma Surgery Medical History UKM
DE MS Dekurs UCH converted to ODM format. Routine
documentation of university hospital muenster.
Form version: 234 (25.08.2014)
All rights reserved. Please visit https://medical-data-
models.org/forms/10922
DE MS Dekurs UCH
Administratives
Patientenaufkleber
Versicherungsstatus
BG (BG)
gesetzlich (gesetzlich)
privat (privat)
Erstbefund erhoben durch
Erstbefunddatum
Dekurs
Diagnosen
Prozeduren
Geplante Prozeduren
Prozedur/Eingriff nach BG-Liste
Ende der Behandlung
Ja
Nein
Wiedervorstellung in 4 Wochen
Ja
Nein
Nachsatz
1 / 1
Quality Assurance Follow-up Liver
Transplant (AQUA)
Documentation form for quality assurance in German
Health Care by the institute forapplied quality Improvement
and Research in Health Care (Aqua), https://www.aqua-
institut.de/en/home. Internal Aqua form version: LTXFU
Specification 2015 V02
All rights reserved. Please visit https://medical-data-
models.org/forms/10924
Quality assurance Follow-up Liver
Transplant (AQUA)
Follow-up(to be filled out after 1, 2 and 3
years)
Health Insurance Identifier*
Zip Code of Discharge*
Facility's Section Identifier
Medical specialty*
internal medicine (0100)
internal medicine: geriatrics (0102)
internal medicine: cardiology (0103)
internal medicine: nephrology (0104)
internal medicine: hematology and
internal oncology  (0105)
internal medicine: endocrinology (0106)
internal medicine: gastroenterology
(0107)
internal medicine: pneumonology (0108)
internal medicine: rheumatology (0109)
internal medicine: pulmonology (0114)
internal medicine: tumor research (0150)
internal medicine: coloproctology (0151)
internal medicine: infectiology (0152)
internal medicine: diabetes (0153)
internal medicine: naturopathy (0154)
internal medicine: stroke unit (0156)
internal medicine (0190)
geriatry (0200)
geriatry: gynecology  (0224)
geriatry: day unit (for semi-residential
care)   (0260)
geriaty: night unit (for semi-residential
care) (0261)
geriatry (0290)
cardiology (0300)
nephrology (0400)
nephrology: pediatrics (0410)
nephrology: intensive care (0436)
nephrology (0490)
hematology and internal oncology
(0500)
hematology and internal oncology:
pediatrics (0510)
hematology and internal oncology:
gynacology (0524)
hematology and internal oncology:
radiation therapy (0533)
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hematology and internal oncology
(0590)
endocrinology (0600)
endicrinology: gastroenterology (0607)
endocrinology: pediatrics (0610)
endocrinology (0690)
gastroenterology (0700)
gastroenterology: endocrinology (0706)
gastroenterology: pediatrics (0710)
gastroenterology (0790)
pneumology (0800)
rheumatology (0900)
rheumatology: pediatrics (0910)
rheumatology (0990)
pediatrics (1000)
pediatrics: nephrology (1004)
pediatrics: hematology and internal
oncology  (1005)
pediatrics: endocrinology (1006)
pediatrics: gastroenterology (1007)
pediatrics: rheumatology (1009)
pediatrics: pediatric cardiology (1011)
pediatrics: nephrology (1012)
pediatrics: pulmonology (1014)
pediatrics: pediatric neurology (1028)
pediatrics: perinatal medicine (1050)
continuing care for children (1051)
pediatrics (1090)
pediatric cardiology (1100)
pediatric cardiology: intensive care
(1136)
pediatric cardiology (1190)
neonatology (1200)
pediatric surgery (1300)
pulmonology (1400)
pulmonology: pediatrics (1410)
pulmonology (1490)
general surgery (1500)
general surgery: pediatric surgery (1513)
general surgery: trauma surgery (1516)
general surgery: vascular surgery (1518)
general surgery: plastic surgery (1519)
general surgery: thoracic surgery (1520)
general surgery: orthopedics (1523)
general surgery: intensive care (1536)
general surgery: abdominal- and
vascular surgery (1550)
Allgemeine Chirurgie: hand surgery
(1551)
general surgery (1590)
trauma surgery (1600)
neurosurgery (1700)
vascular surgery (1800)
plastic surgery (1900)
thoracic surgery (2000)
thoracic surgery: cardiac surgery (2021)
thoracic surgery: intensive care (2036)
thoracic surgery: cardiac surgery
intensive care (2050)
thoracic surgery (2090)
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cardiac surgery (2100)
cardiac surgery: vascular surgery (2118)
cardiac surgery: thoracic surgery (2120)
cardiac surgery: intensive care (2136)
cardiac surgery: thoracic surgery and
intensive care (2150)
cardiac surgery (2190)
urology (2200)
orthopedics (2300)
orthopedics: rheumatology (2309)
orthopedics: surgery (2315)
orthopedics and trauma surgery (2316)
orthopedics (2390)
gynecology and obstetrics (2400)
gynecology: geriatry (2402)
gynecology: hematology and internal
oncology  (2405)
gynecology: endocrinology (2406)
gynecology (2425)
gynecology and obstetrics (2490)
obstetrics (2500)
otolaryngology (2600)
ophthalmology (2700)
neurology: (2800)
neurology: pediatrics (2810)
neurology: stroke units (2856)
neurology (2890)
general psychiatry: (2900)
general psychiatry: neurology (2928)
general psychiatry: child and adolescent
psychiatry (2930)
general psychiatry: psychosomatics and
psychotherapy (2931)
general psychiatry: addiction treatment
(2950)
general psychiatry: geropsychiatry
(2951)
general psychiatry: forensic treatment
(2952)
general psychiatry: addiction treatment
(day unit) (2953)
general psychiatry: addiction treatment
(night unit) (2954)
general psychiatry: geropsychiatry (day
unit) (2955)
general psychiatry: geropsychiatry (night
unit) (2956)
general psychiatry: day unit (for semi-
residential care) (2960)
general psychiatry: night unit (for semi-
residential care) (2961)
general psychiatry (2990)
child and adolescent psychiatry (3000)
child and adolescent psychiatry: day unit
(for semi-residential care) (3060)
child and adolescent psychiatry: night
unit (for semi-residential care) (3061)
child and adolescent psychiatry (3090)
psychosomatic/psychotherapy (3100)
psychosomatic/psychotherapy: child and
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adolescent psychiatry (3110)
psychosomatic/psychotherapy: day unit
(for semi-residential care) (3160)
psychosomatic/psychotherapy: night unit
(for semi-residential care) (3161)
psychosomatic/psychotherapy (3190)
nuclear medicine (3200)
nuclear medicine: radiation therapy
(3233)
nuclear medicine (3290)
radiation therapy (3300)
radiation therapy: hematology and
internal oncology  (3305)
radiation therapy: radiology (3350)
radiation therapy (3390)
dermatology (3400)
dermatology: day unit (for semi-
residential care) (3460)
dermatology (3490)
dentistry, orthodontics, maxillofacial
surgery (3500)
intensive-care medicine (3600)
intensive-care medicine: internal
medicine (3601)
intensive-care medicine: cardiology
(3603)
intensive-care medicine: pediatrics
(3610)
intensive-care medicine: neurosurgery
(3617)
intensive-care medicine: surgery (3618)
intensive-care medicine: cardiac surgery
(3621)
intensive-care medicine: urology (3622)
intensive-care medicine: gynecology and
obstetrics (3624)
intensive-care medicine: otolaryngology
(3626)
intensive-care medicine: neurology
(3628)
operative intensive-care medicine:
surgery (3650)
intensive-care medicine: thorax-heart
surgery (3651)
intensive-care medicine: heart-thorax
surgery (3652)
intensive-care medicine (3690)
other medical specialty (3700)
angiology (3750)
radiology (3751)
palliative care (3752)
pain therapy (3753)
section for alternative health practice
(3754)
spinal surgery (3755)
addiction medicine (3756)
visceral surgery (3757)
other medical specialty (3790)
Recipient ID (ET-Number)*
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Date of Birth (dd.mm.yyyy)*
Gender*
male (1)
female (2)
Date of last transplant (dd.mm.yyyy)*
Date of Follow-up examination (dd.mm.yyyy)*
Type of follow-up inquiry*
patient was personally in hospital (1)
telephone contact with patient  (2)
telephone contact with doctor further
treatment (3)
written information from the doctor
further treatment (4)
information about relatives/carers of
patients  (5)
no contact with patient, doctor further
treatment or relatives/carers of patients
(6)
Follow-up: Years after living donor transplant: ((1,
2, 3))*
Survival status of recipient
Deceased patient*
no (0)
yes (1)
unknown or follow-up not possible (9)
Date of death (dd.mm.yyyy)
Cause of death
Intraoperative death (death on table)
(A1)
Infection-Bacterial infection (B1)
Infection-Viral infection (B2)
Infection-HIV (B3)
Infection-Fungal infection (B4)
Infection-Parasitic infection (B5)
Infection-Other known infect (B6)
Liver complications-Acute rejection (C1)
Liv complic-Recurrence of original dis
(C10)
Liv complic-Recurrence of original dis
(C11)
Liv complic-Recurrence of original dis
(C12)
Liv complic-Recurrence of original dis
(C13)
Liv complic-Recurrence of original dis
(C14)
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Liv complic-Recurrence of original dis
(C15)
Liv complic-Recurrence of original dis
(C16)
Liv complic-Recur of orig dis (C17)
Liver complic-De novo hepatitis B virus
(C18)
Liver complications-De novo hepatitis C
virus (C19)
Liver complications-Chronic rejection
(C2)
Liver complications-De novo hepatitis D
virus (C20)
Liver complic-Massive hemorrhagic
necrosis (C21)
Liver complications-Other viral hepatitis
(C22)
Liver complications-Infection (C23)
Liver complications-Other (C24)
Liver complications-Arterial thrombosis
(C3)
Liver complic-Hepatic vein thrombosis
(C4)
Liver complic-Primary N-function (Retx
or death < (C5)
Liv complic-Primary dysfunction (Retx or
death > 7d) (C6)
Liver complic-Anastomotic biliary complic
(C7)
Liver complic-Non anastomotic biliary
complic (C8)
Liver complic-Recurrence of original dis
(C9)
Gastrointestinal complications-GI
haemorrhage (D1)
Gastrointestinal complications-
Pancreatitis (D2)
Gastrointestinal complic-Visceral
perforation (D3)
Gastrointestinal complications-Other
(D4)
Cardiovascular complications-Myocardial
infarction (E1)
Cardiovascular complications-Other
cause (E2)
Cerebrovascular complications-
Intracranial haemorrhage (F1)
Cerebrovascular complications-Ischemic
stroke (F2)
Cerebrovascular complications-Cerebral
oedema (F3)
Cerebrovascular complications-Cerebral
infection (F4)
Tumor-Recurrence of original tumor (G1)
Tumor-Recurrence of previously
unrelated tumor (G2)
Tumor-De novo solid organ tumor (G3)
Tumor-Donor transmitted tumor (G4)
Tumor-Lympho proliferation disease (G5)
Kidney failure (H1)
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Quality Assurance Follow-up Liver Transplant (AQUA)
Urinary tract infection (H2)
Pulmonary complications-Embolism (I1)
Pulmonary complications-Infection (I2)
Social complic-Non compliance
immunosup therapy (J1)
Social complications-Suicide (J2)
Social complications-Trauma (Motor,
Vehicle,..) (J3)
Bone marrow depression (K1)
Other cause (L1)
Not available (M1)
Hepatocellular carcinoma (HCC) before
transplantation
Yes
No
recurrent HCC
no (0)
yes (1)
unknown (9)
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E6201 Pharmacokinetic Sampling Form
NCT00058149
E6201 Pharmacokinetic Sampling Form NCT00058149
A Phase III, Randomized Study of Gemcitabine (Fixed-
Dose Rate Infusion) and Oxaliplatin (NSC 266046) Versus
Gemcitabine (Fixed-Dose Rate Infusion) Versus
Gemcitabine (30-Minute Infusion) in Pancreatic Carcinoma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=E4B30695-
CCF7-392C-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/10925
E6201 Pharmacokinetic Sampling
Form NCT00058149
ECOG clinical trial administrative data
DCI Name
Registration Step
Report Period
Lab Data (Lab data)
Patient Initials (Last, First)
ECOG Protocol Number
ECOG Protocol Number
ECOG Patient ID
ECOG Patient ID
Participating Group Protocol Number
Participating Group Patient ID
Institution/Affiliate
Pharmacokinetic Sampling
Are data amended (If yes, please circle amended
items in red)
Yes
No
Patient Weight (KG prior to infusion)
Protocol Treatment
Gemcitabine (Gemcitabine)
Infusion start date
1 / 2
Start time (24 hr clock)
Stop time (24 hr clock)
Sample #
Time of sampling
Arm A - 120 min (Arm A - 120 min)
Arm A - 240 min (Arm A - 240 min)
Arm A - 30 min (Arm A - 30 min)
Arm A - 90 min (Arm A - 90 min)
Arm B - 150 min (Arm B - 150 min)
Arm B - 180 min (Arm B - 180 min)
Arm B - 240 min (Arm B - 240 min)
Arm B - 75 min (Arm B - 75 min)
Arm C - 100 min (Arm C - 100 min)
Arm C - 150 min (Arm C - 150 min)
Arm C - 240 min (Arm C - 240 min)
Arm C - 50 min (Arm C - 50 min)
Baseline (Baseline)
Collection date (M/D/Y)
Collection time (24 hr clock)
Cells (CPT = THU)
Plasma (Green top + THU)
Investigator Signature
Investigator Signature Date
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RTOG 0534 I1: Initial Evaluation Form
NCT00567580
RTOG 0534 I1: Initial Evaluation Form NCT00567580
Prostate Radiation Therapy or Short-Term Androgen
Deprivation Therapy and Pelvic Lymph Node Radiation
Therapy With or Without Prostate Radiation Therapy in
Treating Patients With a Rising PSA After Surgery for
Prostate Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=2A2988DD-
5C50-0AA9-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/10926
RTOG 0534 I1: Initial Evaluation
Form NCT00567580
Header module
RTOG Study No.
Case #
Institution Name
Institution No.
Patient Initials
RTOG Patient ID
Amended Data
Yes
No
Patient demographics
Age (years)
Performance Status (ZUBROD 0-5)
Fully Active, Able To Carry On All Pre-
disease Performance Without
Restriction. (0)
Restricted In Physically Strenuous
Activity But Ambulatory And Able To
Carry Out Work Of A Light Or Sedentary
Nature, E.g., Light Housework, Office
Work. (1)
Ambulatory And Capable Of All Selfcare
But Unable To Carry Out Any Work
Activities. Up And About More Than 50%
Of Waking Hours. (2)
Capable Of Only Limited Selfcare,
Confined To Bed Or Chair More Than
50% Of Waking Hours. (3)
Completely Disabled. Cannot Carry On
Any Selfcare. Totally Confined To Bed Or
Chair. (4)
1 / 9
Date Performed (History and Physical
Examination)
Date Performed (Digital Rectal Examination)
Has the patient had any prior cancer diagnosed
(other than study site)
Yes
No
Prior malignancy site
Aml/mds (AML/MDS)
Bcc (BCC)
Bladder Is The Site Of Second Primary
Or Recurrent Tumor (bladder)
Brain Is The Site Of Second Primary Or
Recurrent Tumor (brain)
Colorectal (Colorectal)
Esophageal (Esophageal)
Gastric (Gastric)
Liver Is The Site Of Second Primary Or
Recurrent Tumor (liver)
Lung Is The Site Of Second Primary Or
Recurrent Tumor (lung)
Melanoma (Melanoma)
Nhl (NHL)
Other Hematologic (Other hematologic)
Other Solid (Other solid)
Pancreatic (Pancreatic)
Renal (Renal)
Squamous-skin (Squamous-skin)
Unknown Primary (Unknown primary)
Specify
Date Eradicated (mm-yyyy)
INTERCURRENT DISEASE
History of inflammatory bowel disease
Yes
No
Does patient have a history of hepatitis B or
hepatitis C infection
Yes
No
Heart problems (unstable angina and/or CHF
requiring hospitalization within the last 6 months)
Yes
No
Heart problems (Transmural myocardial infarction
within the last 6 months)
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Yes
No
Infection (acute bacterial or fungal requiring
intravenous antibiotics at the time of registration)
Yes
No
COPD exacerbation or other respiratory illness
requiring hospitalization or precluding study
therapy at registration
Yes
No
Hepatic Insufficiency (resulting in clinical jaundice
and/or coagulation defects)
Yes
No
Does the patient have AIDS (based upon current
CDC definition)
Yes
No
Prostate: Prior Treatment
Prior radiation therapy (pelvic external beam or
brachytherapy)
Yes
No
Prior hormonal therapy (Androgen Deprivation)
Yes
No
Date Prior hormonal therapy Started
Date Prior hormonal therapy Ended
Prior hormonal therapy (ORCHIECTOMY)
No (No)
Yes, Bilateral (Yes, bilateral)
Yes, Unilateral (Yes, unilateral)
Prostate: Initial Diagnosis
Date of Initial Diagnosis of Primary Tumor (PRE-
OPERATIVE)
Histologic Type
Adenocarcinoma/acinar
(Adenocarcinoma/Acinar)
Other Specify (Other)
Other specify
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Gleason Score, Primary Pattern ([most frequently
seen] 1-5, 9=unknown)
Gleason Score, Secondary Pattern ([second
most frequently seen] 1-5, 9=unknown)
Gleason Score, Worst Pattern ([worst
pathological grade seen in any specimen] 1-5,
9=unknown)
Gleason Score, Combined
Prostate: Disease Description Localized
Palpable prostatic fossa mass
Yes
No
Prostatic fossa biopsy (under ultrasound
guidance)
Not Done (Not done)
Unknown (Unknown)
Yes, Negative (Yes, negative)
Yes, Positive (Yes, positive)
Date of prostatic fossa biopsy
Type of Procedure (PROSTATECTOMY)
Other Specify (Other)
Radical Prostatectomy, Laparoscopic
(Radical prostatectomy laparoscopic)
Radical Prostatectomy, Perineal (Radical
prostatectomy perineal)
Radical Prostatectomy, Retropubic
(Radical prostatectomy retropubic)
Radical Prostatectomy Robotic-assisted
(Radical prostatectomy robotic-assisted)
Suprapubic Prostatectomy (Suprapubic
prostatectomy)
Other, specify
Prior Prostatectomy Date
Extraprostatic extension (EPE)
Yes
No
Extraprostatic extension laterality
Both Sides (Both sides)
Left Side (Left side)
Right Side (Right side)
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Side Not Specified (Side not specified)
Invasion of seminal vesicle
Yes
No
Seminal Vesicle Laterality
Both Seminal Vesicles (Both sides)
Structure Of Left Seminal Vesicle (Left
side)
Structure Of Right Seminal Vesicle
(Right side)
Side Not Specified (Side not specified)
Prostatectomy margin
Negative (Negative)
Positive (Positive)
Unknown (Unknown)
Pelvic lymphadenectomy
Yes
No
Pelvic lymphadenectomy Date
Extent of pelvic lymph node dissection
Extended (Extended)
Limited (Limited)
Is the number of lymph nodes examined available
Yes
No
Number of lymph nodes examined right side
Number of lymph nodes examined left side
Number of lymph nodes examined location not
specified
Is there lymph node involvement
Yes
No
Study Entry Psa Measurements
Baseline PSA Value (per protocol definition)
Baseline PSA Date (< 30 days prior to
registration)
Unit of Measure
Nanograms Per Deciliter (ng/dL)
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Nanograms Per Milliliter (ng/mL)
Nanomoles Per Liter (nmol/l)
Not Otherwise Specified (NOS)
Method of Assay
Abbott Labs (Abbott)
Bayer (Bayer)
Dpc (DPC)
Hybritech (Hybritech)
Other (Other)
Additional PSA measurements
Additional PSA measurements (NOT
REPORTED ABOVE)
Yes
No
PSA Date (s)
PSA Value (s)
Unit of Measure
Nanograms Per Deciliter (ng/dL)
Nanograms Per Milliliter (ng/mL)
Nanomoles Per Liter (nmol/l)
Not Otherwise Specified (NOS)
Method of Assay
Abbott Labs (Abbott)
Bayer (Bayer)
Dpc (DPC)
Hybritech (Hybritech)
Other (Other)
Pelvic CT/MRT
CT/MRI pelvis
Yes
No
Date Performed
Bone scan
Yes
No
Date performed
Baseline Lab Values (hematologic)
WBC
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Date
Hemoglobin (g/dL)
Unit of Measure
Nanograms Per Deciliter (ng/dL)
Nanograms Per Milliliter (ng/mL)
Nanomoles Per Liter (nmol/l)
Not Otherwise Specified (NOS)
Date
Peripheral Platelet Count (x 10^3 U/L)
Date
SGPT
SGPT Upper Limit Normal (U/L)
Date
SGOT
SGOT Upper Limit Normal (U/L)
Date
Alkaline Phosphatase
Alkaline Phosphatase Lower Limit Normal (u/L)
Alkaline Phosphatase Upper Limit Normal (u/L)
Date
Testosterone (VALUE)
Testosterone Lower Limit Normal
Testosterone Upper Limit Normal
Date
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Tumor Statging
T Stage, Pathologic
Organ Confined (pT2)
Unilateral (pT2a)
Bilateral (pT2b)
Bilateral (pT2c)
Extraprostatic Extension (pT3)
Extraprostatic Extension (pT3a)
Seminal Vesicle Invasion (pT3b)
Invasion Of Bladder, Rectum (pT4)
N Stage, Pathologic
No Regional Lymph Node Metastasis
(pN0)
Metastatis In Regional Lymph Node Or
Nodes (see Ajcc Definition) (pN1)
Regional Lymph Nodes Cannot Be
Assessed (pNX)
N Stage, Clinical (RADIOGRAPHIC)
No Regional Lymph Node Metastasis
(N0)
Metastatis In Regional Lymph Node Or
Nodes (see Ajcc Definition) (N1)
Regional Lymph Nodes Cannot Be
Assessed (NX)
M Stage, Clinical
No Distant Metastasis (M0)
Distant Metastasis (M1)
Nonregional Lymph Node(s) (M1a)
Bone(s) (M1b)
Other Site(s) (M1c)
Distant Metastasis Cannot Be Assessed
(MX)
Neoadjuvant chemotherapy
Neoadjuvant chemotherapy prior to
prostatectomy
Yes
No
Prior neoadjuvant chemotherapy for any other
disease site if given within 5 years prior to
registration
Yes
No
Prior cryosurgery or brachytherapy of the
prostate
Yes
No
Comments
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Comments
Signature of Person Completing This Form
Date Form Originally Completed
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CALGB 90203: Chemohormonal Treatment
Form NCT00430183
CALGB 90203: Chemohormonal Treatment Form [Form C-
1240 v1 11/08/2006] NCT00430183
Surgery With or Without Docetaxel and Leuprolide or
Goserelin in Treating Patients With High-Risk Localized
Prostate Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=1F187698-
E2E9-7108-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/10927
CALGB 90203: Chemohormonal
Treatment Form NCT00430183
Header
CALGB Form (C-1241)
CALGB Study No.
CALGB Patient ID
Cycle Start Date (mm dd yyyy)
Cycle end date (mm dd yyyy)
Are data amended
Yes
No
Patient demographics
Patient Initials (Last, First Middle)
Patient Hospital No.
Institution/Affiliate
Participating Group
Participating Group Study No.
Participating Group Patient ID
Additional Instructions
Cycle Number
Height (cm)
1 / 5
Weight (kg)
BSA (m^2)
Agent Table Module
Agent Name (Docetaxel #628503)
Agent Dose (mg)
Dose modification (1 Dose Modification codes:
0=No dose modification; 1=Dose held not given;
2=Dose delayed; 3=Dose reduced; 4=Dose
delayed and reduced; 5=Dose discontinued;
6=Dosing error)
Dose Delayed (Dose delayed)
Dose Delayed And Reduced (Dose
delayed and reduced)
Dose Held (Dose held)
Dose Reduced (Dose reduced)
Dosing Error (Dosing error)
Drug Discontinued (Drug discontinued)
No Dose Modification (No dose
modification)
Dose Modification Reason (2 Dose modification
reason codes: 1=Adverse event;
2=Hypersensitiv... 99=Other. Do not report a
dose modification reason for subsequent weeks
or cycles that continue the same dose
modification. Dose changes due to BSA do not
constitute dose modifications.)
Adverse Event (Adverse event)
Hypersensitivity (Hypersensitivity)
Other (Other)
Patient Refusal/noncompliance (Patient
refusal/noncompliance)
Scheduling (Scheduling)
If dose modification reason = 99, specify
Concomitant medications administered during
this cycle (Mark all that apply with an X.)
Darbepoetin Alfa (Darbepoetin alfa)
Dexamethasone (Dexamethasone)
Other (Other)
Other specify
Is protocol chemotherapy continuing? (after this
cycle)
Yes
No
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Date Chemotherapy Ended (mm dd yyyy)
Total number of chemotherapy cycles completed
Reason Treatment Ended (Recommended Term
for CRF text "Reason LHRH Agonist treatment
ended" - 2 Reason treatment ended codes:
18=Treatment completed per protocol criteria;
19=Disease progression, relapse during active
treatment; 20=Adverse event/side effects/...
27=Other.)
Adverse Event/side Effects/complications
(Adverse Event/Side
Effects/Complications)
Alternative Therapy (Alternative therapy)
Death On Study (Death on study)
Disease Progression, Relapse During
Active Treatment (Disease progression,
relapse during active treatment)
Other (Other)
Patient Off-treatment For Other
Complicating Disease (Patient off-
treatment for other complicating disease)
Patient Withdrawal Or Refusal After
Beginning Protocol Therapy (Patient
withdrawal/refusal after beginning
protocol therapy)
Patient Withdrawal Or Refusal Before
Beginning Protocol Therapy (Patient
withdrawal/refusal prior to beginning
protocol therapy)
Treatment Completed Per Protocol
Criteria (Treatment completed per
protocol criteria)
Specify (If reason LHRH agonist treatment ended
= 24-27,)
Hormonal Therapy Module
Is patient receiving on-going LH-RH agonist
therapy (Add NEW CDE for lead question... "Is
patient receiving ongoing LHRH agonist therapy")
Yes
No
LHRH agonist therapy (Mark all that apply with an
X.)
Goserelin (Goserelin (Zoladex))
Leuprolide Acetate (Leuprolide (Eligard))
Leuprolide Acetate (Leuprolide (Lupron))
Other (Other)
Other specify
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LHRH agonist start date (mm dd yyyy)
LHRH agonist last administered date (mm dd
yyyy)
Agent Total Cumulative Dose (Recommended
Term for CRF Text "LHRH Agonist Total Dose to
Date" mg)
Did patient take oral antiandrogen(s)
(Recommended Term for CRF Text "Did patient
take oral antiandrogens during this period"
Allowed, but not recommended by protocol)
Yes
No
Oral antiandrogen therapy (Mark all that apply
with an X.)
Bicalutamide (Bicalutamide (Casodex))
Flutamide (Flutamide (Eulexin))
Nilutamide (Nilutamide (Nilandron))
Other (Other)
Reason Treatment Ended (Recommended Term
for CRF text "Reason LHRH Agonist treatment
ended" - 2 Reason treatment ended codes:
18=Treatment completed per protocol criteria;
19=Disease progression, relapse during active
treatment; 20=Adverse event/side effects/...
27=Other.)
Adverse Event/side Effects/complications
(Adverse Event/Side
Effects/Complications)
Alternative Therapy (Alternative therapy)
Death On Study (Death on study)
Disease Progression, Relapse During
Active Treatment (Disease progression,
relapse during active treatment)
Other (Other)
Patient Off-treatment For Other
Complicating Disease (Patient off-
treatment for other complicating disease)
Patient Withdrawal Or Refusal After
Beginning Protocol Therapy (Patient
withdrawal/refusal after beginning
protocol therapy)
Patient Withdrawal Or Refusal Before
Beginning Protocol Therapy (Patient
withdrawal/refusal prior to beginning
protocol therapy)
Treatment Completed Per Protocol
Criteria (Treatment completed per
protocol criteria)
Other specify
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Specify (If reason LHRH agonist treatment ended
= 24-27,)
Oral Antiandrogen Start Date (Most recent. mm
dd yyyy)
Oral antiandrogen last administered date (mm dd
yyyy)
Has patient refused further protocol therapy or
withdrawn from study
Yes
No
Patient has withdrawn consent for clinical follow-
up (Recommended Term to replace "Clinical
follow-up withdrawn consent date")
Yes
No
Patient has withdrawn consent for survival follow-
up
Yes
No
Withdrawn consent date (mm dd yyyy)
Ccrr Module For Calgb: 90202 Adverse
Event Form
Completed by (Last name, First name)
Date Form Completed (mm dd yyyy)
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E5508 On-Study Form NCT01107626
E5508 On-Study Form NCT01107626 
Bevacizumab or Pemetrexed Disodium Alone or In
Combination After Induction Therapy in Treating Patients
With Advanced Non-Squamous Non-Small Cell Lung
Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=6D435D37-
5591-AA13-E040-BB89AD43538D
All rights reserved. Please visit https://medical-data-
models.org/forms/10929
E5508 On-Study Form
NCT01107626
Header
ECOG Protocol Number
ECOG Patient ID
DCI Name
Registration Step
Report Period
Baseline Step 1 (Baseline step 1)
Patient demographics
Patient Initials (Last, First)
ECOG Protocol Number
ECOG Patient ID
Participating Group Protocol Number
Participating Group Patient ID
Institution/Affiliate
Data amendment
Please mark an 'X' if data have been amended
(Please circle amended items in red)
Date data amended (s M D Y)
Pre-Treatment Characteristics
1 / 7
Patient Weight (kg)
Patient Height (cm)
Performance Status
Fully Active, Able To Carry On All Pre-
disease Performance Without
Restriction. (0)
Restricted In Physically Strenuous
Activity But Ambulatory And Able To
Carry Out Work Of A Light Or Sedentary
Nature, E.g., Light Housework, Office
Work. (1)
Ambulatory And Capable Of All Selfcare
But Unable To Carry Out Any Work
Activities. Up And About More Than 50%
Of Waking Hours. (2)
Capable Of Only Limited Selfcare,
Confined To Bed Or Chair More Than
50% Of Waking Hours. (3)
Completely Disabled. Cannot Carry On
Any Selfcare. Totally Confined To Bed Or
Chair. (4)
Weight Loss in Previous Six Months
<5% Of Body Weight (<5% of body
weight)
> Or = 20% Of Body Weight (> or = 20%
of body weight)
10 To <20% Of Body Weight (10 -<20%
of body weight)
5 To <10% Of Body Weight (5 to < 10%
of body weight)
Menopausal Status
Above Categories Not Applicable And
Age <50 (Above categories not
applicable AND Age < 50)
Above Categories Not Applicable And
Age >= 50 (Above categories not
applicable AND Age >= 50)
Post (prior Bilateral Ovariectomy Or >12
Mo Since Lmp With No Prior
Hysterectomy And Not Currently
Receiving Therapy With Lh-rh Analogs
[e.g., Zoladex]) (Post (prior bilateral
ovariectomy OR >12 mo since LMP with
no prior hysterectomy AND not currently
receiving therapy with LH-RH analogs
(e.g., Zoladex)))
Pre (<6 Mo Since Lmp And No Prior
Bilateral Ovariectomy And Not On
Estrogen Replacement) (Pre (<6 mo
since LMP AND no prior bilateral
ovariectomy AND not on estrogen
replacement))
Smoking History
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Current Smoker (Current smoker)
Former Smoker (Former smoker)
Never Smoker (Never smoker)
Pre-treatment Characteristics1
Test not done (Mark an 'X' if not done)
Urine Dipstick Result
1+ (1+)
2+ (2+)
3+ (3+)
4+ (4+)
Negative (Negative)
Trace (Trace)
Date of urine dipstick (M D Y)
Date lab assessment performed (UPC ratio M D
Y)
Urine Protein/Creatinine Ratio
Description Of Disease At Initial Diagnosis
Stage
Iiib (IIIB)
Iv M1a (IV M1a)
Iv M1b (IV M1b)
Recurrent Disease (Recurrent)
Histologic Type (check one)
Adenocarcinoma (Adenocarcinoma)
Bronchoalveolar (bac) (Bronchoalveolar
carcinoma (BAC))
Large Cell Undifferentiated (Large cell
undifferentiated)
Non-small Cell Lung Cancer (nsclc), Nos
(Non-small cell lung cancer NOS)
Other (Other)
Squamous Cell Carcinoma (Squamous
cell carcinoma)
Specify Other Histologic Type
Metastatic Site
Hilar nodes
No (NO)
Unknown (UNKNOWN)
Yes (YES)
Mediastinal nodes
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No (NO)
Unknown (UNKNOWN)
Yes (YES)
Supraclavicular/scalene nodes
No (NO)
Unknown (UNKNOWN)
Yes (YES)
Ipsilateral Lung
No (No)
Unknown (Unknown)
Yes (Yes)
Contralateral lung
No (No)
Unknown (Unknown)
Yes (Yes)
Pleura
No (NO)
Unknown (UNKNOWN)
Yes (YES)
Liver
No (NO)
Unknown (UNKNOWN)
Yes (YES)
Adrenal (s)
No (No)
Unknown (Unknown)
Yes (Yes)
Bone
No (NO)
Unknown (UNKNOWN)
Yes (YES)
Bone Marrow
No (NO)
Unknown (UNKNOWN)
Yes (YES)
Brain
No (No)
Unknown (Unknown)
Yes (Yes)
Skin
No (No)
Unknown (Unknown)
Yes (Yes)
Other
No (No)
Unknown (Unknown)
Yes (Yes)
Specify other metastatic site
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Medical History
History of Thrombotic Events (must have
occurred greater than 12 months prior to
registration to be eligible Please mark an 'x' for
any/all events that patient has a history of)
Cerebrovascular Accident (Cerebral
Vascular Accident)
Deep Vein Thrombosis (Deep Vein
Thrombosis)
Pulmonary Embolism (Pulmonary
Embolism)
Transient Ischemic Attack (Transient
Ischemic Attack)
Cardiac History (Please mark an 'x' for any/all
events that patient has a history of)
Angina (Angina)
Arrhythmia (Arrhythmias)
Congestive Heart Failure (Congestive
Heart Failure)
Hypertension (Hypertension)
Myocardial Infarction (Myocardial
Infarction)
Is the patient on anticoagulation therapy
Yes
No
Patient Description Pre-registration
Hematology/chemistry
Albumin LLN (g/dl)
Albumin (g/dl)
LDH, ULN (U/L)
LDH (U/L)
Peripheral WBC count, LLN (/mm^3 x1000)
Peripheral WBC Count (/mm^3 x1000)
Peripheral platelet count, LLN (/mm^3 x1000)
Peripheral Platelet Count (/mm^3 x1000)
Creatinine ULN (mg/dl)
Creatinine (mg/dl)
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Hemoglobin (g/dl), LLN (g/dl)
Hemoglobin (g/dl)
Date Hematology (Blood) Sample Obtained (M D
Y)
Prior Treatment
Prior Radiation Therapy
Yes
No
Date Prior RT Ended (If yes M D Y)
Prior chemotherapy
Yes
No
Prior Surgery (for brain metastases)
Yes
No
Prior Adjuvant Chemotherapy
Yes
No
Prior Adjuvant Chemotherapy End Date (M D Y)
Prior other systemic therapy
Yes
No
Specify
Date of last dose (systemic therapy M D Y)
NSCLC Brain Metastases
Does the patient have a history of brain
metastases
Yes
No
Number of brain metastases (If yes prior to any
local treatment to the brain)
1 (1)
2-3 (2-3)
Greater Than 3 (Greater than 3)
Was gamma knife and/or radiosurgery radiation
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administered? (Prior Treatment for brain
metastases)
Yes
No
Was whole brain radiation therapy administered?
(Prior Treatment for brain metastases)
Yes
No
Prior Surgery (for brain metastases)
Yes
No
Baseline Abnormalities
CTC Adverse Event Term
CTC Adverse Event Grade
Mild Adverse Event (1)
Moderate Adverse Event (2)
Severe Adverse Event (3)
Life Threatening Adverse Event (4)
Comments
Investigator Signature
Investigator Signature Date (M D Y)
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CALGB: 90401 Medications Supplement
Form NCT00110214
CALGB: 90401 Medications Supplement Form
NCT00110214
Docetaxel and Prednisone With or Without Bevacizumab in
Treating Patients With Prostate Cancer That Did Not
Respond to Hormone Therapy
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=359FF873-
CDE9-6CE9-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/10930
CALGB: 90401 Medications
Supplement Form NCT00110214
Header
CALGB Form
CALGB Study No.
CALGB Patient ID
Are data amended?
Yes
No
Patient demographics
Patient Initials (Last, First, Middle)
Patient Medical Record Number
Institution/Affiliate
Participating Group
Participating Group Protocol Number
Participating Group Patient ID
Cardiovascular pharmacotherapy
evaluation
In the past 12 months, has the patient taken or
been prescribed any cardiovascular classes of
drug list below?
Yes
No
Cardiovascular drug classes (mark all that apply
below)
1 / 2
Ace Inhibitor (ACE inhibitors)
Beta Blocker (Beta blockers)
Calcium Channel Blocker (Calcium
channel blockers)
Cardiovascular Drugs Nos
(Cardiovascular drugs NOS)
Other Cardiovascular Drugs (Other
cardiovascular drugs)
Agent Name (print in CAPS)
Is patient being treated for diabetes
Yes
No
Diabetes treatment (Mark all that apply)
Diet Modificaiton (Diet modificaiton)
Insulin (Insulin)
Non-insulin (Non-insulin)
Prior history
No (No)
Unknown (Unknown)
Yes (Yes)
Pre-existing condition
Date of most recent event
GI perforation, specify
GU perforation, specify
Other bleeding episodes, specify
Comments
Comments
Completed by
Date Form Originally Completed
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E3805 Chemotherapy Treatment Summary
Form NCT00309985
E3805 Chemotherapy Treatment Summary Form
NCT00309985
Androgen Ablation Therapy With or Without Chemotherapy
in Treating Patients With Metastatic Prostate Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=F9FBC659-
11C3-3E75-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/10931
E3805 Chemotherapy Treatment
Summary Form NCT00309985
Header
ECOG Protocol Number
ECOG Patient ID
DCI Name
Registration Step
Reporting Period
End Of Treatment (End of treatment)
Please mark an 'X' if data have been amended.
Date data amended
Patient demographics
Patient Initials
Participating Group Protocol Number
Institution/Affiliate
Participating Group Patient ID
On Treatment
Vital Status
Alive (Alive)
Dead (Dead)
Date of Last Contact or Death
Primary Cause of Death
Due To Other Cause (Due to other
cause)
1 / 3
Due To Protocol Treatment (Due to
protocol treatment)
Due To This Disease (Due to this
disease)
Unknown (Unknown)
Describe cause of death
Section II - Patient Information
Weight (kg Day 1)
Section III - Therapy Administered
Chemotherapy
Agent Name (Docetaxel)
Was agent administered (Docetaxel)
Yes
No
Date Chemotherapy Began (M D Y)
Date Chemotherapy Ended (Last date
chemotherapy was given prior to hormone
refractory disease)
Agent Total Cumulative Dose
Were there any dose modifications or
additions/omissions to protocol treatment
No (No)
Yes, Both Planned And Unplanned (Yes,
both planned and unplanned)
Yes, Planned (Yes, planned)
Yes, Unplanned (Yes, unplanned)
Type of therapy modification
Reason for Therapy Modification
Section Ii-therapy Administered Androgen
Deprivation
Did the patient receive androgen suppression
(not previously reported)
Yes
No
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Mark an 'X' if continuing from Baseline
Start date of Androgen Deprivation (If yes M D Y)
Did patient have medical castration
Yes
No
Did patient have surgical castration
Yes
No
Did patient have combined androgen blockade for
longer than 30 days
Yes
No
Has the patient developed hormone refractory
prostate cancer? (Section V - Hormone
Refractory Prostate Cancer)
Yes
No
Non-protocol Therapy
Was any non-protocol therapy given during
protocol treatment?
Yes
No
Comments
Investigator Signature
Investigator Signature Date
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CALGB: 90401 ON-STUDY FORM
NCT00110214
CALGB: 90401 ON-STUDY FORM NCT00110214
Docetaxel and Prednisone With or Without Bevacizumab in
Treating Patients With Prostate Cancer That Did Not
Respond to Hormone Therapy
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=EF4A7704-
E232-4EC4-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/10932
CALGB: 90401 ON-STUDY FORM
NCT00110214
Header
CALGB Form
CALGB Study No.
CALGB Patient ID
Are data amended
Yes
No
Patient demographics
Patient Initials
Patient Hospital No.
Institution/Affiliate
Participating Group
Participating Group Study No.
Participating Group Patient ID
Treatment start date
PERFORMANCE STATUS (Mark one with an X.)
Ambulatory And Capable Of All Selfcare
But Unable To Carry Out Any Work
Activities (k 50 - 60) (ecog - 2
Symptomatic; In Bed , 50% Of The Day)
(Ambulatory and capable of selfcare, but
unable to carry out any work activities)
Fully Active, Able To Carry On All Pre-
disease Performance Without Restriction
(karnofsky 90 - 100) (ecog - 0
Asymptomatic) (Fully active, able to
carry on all pre-disease performance
without restriction)
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Restricted In Physically Strenuous
Activity But Ambulatory (k70 - 80) (ecog -
1 Symptomatic - Fully Ambulatory)
(Restricted in physically strenuous
activity but ambulatory)
Height
Weight
Initial Diagnosis
Date of initial pathologic diagnosis
Gleason grade, primary (Enter 1 ? 5.)
Gleason grade, secondary (Enter 1 ? 5.)
Gleason score, combined (Enter 2 ? 10.)
Gleason score based on specimen type (Mark
one with an X.)
Biopsy (Biopsy)
Surgical Specimen (Prostatectomy
specimen)
Disease Assessment
MedDRA disease code
Metastatic disease initial diagnosis date
Disease type (Mark one with an X.)
Measurable Disease (Measurable
disease)
Non-measurable Disease (Non-
measurable disease)
Metastatic disease sites (Mark all that apply with
an X.)
Bone (Bone)
Lymph Node (outside Pelvis) (Lymph
nodes)
Other, Specify (Other)
Visceral (Visceral)
Visceral, specify (Mark all that apply with an X.)
Cns (CNS)
Liver (Liver)
Lung (Lung)
Pleura (Pleura)
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Bone, specify number of sites of involvement
(Mark one with an X.)
< 6 (< 6 bone lesions)
> 20 (> 20 bone lesions)
6 - 20 (6 - 20 bone lesions)
Superscan (Superscan)
Other, specify
Required Lab Data At Study Entry
Peripheral WBC count
Absolute neutrophil count
Peripheral platelet count
Hemoglobin
Bilirubin
Bilirubin ULN
SGOT  (AST)
SGOT ULN
Creatinine
Creatinine ULN
Alkaline phosphatase
Alkaline phosphatase LLN
Alkaline phosphatase ULLN
Lactate dehydrogenase (LDH)
Lactate dehydrogenase LLN
Lactate dehydrogenase ULN
Albumin
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Albumin LLN
C-reactive protein (CRP)
C-reactive protein ULN
Urine protein/creatinine ratio (UPC)
Protein from 24 hour urine collection (Required
only if urine protein/creatinine ratio >= 1.0)
Testosterone
Testosterone ULN
Labs, sample collection date
Psa Assessments
PSA assessments
Pre-treatment Psa 1 (Pre-treatment PSA
1)
Pre-treatment Psa 2 (Pre-treatment PSA
2)
Pre-treatment Psa 3 (Pre-treatment PSA
3)
Pre-treatment Psa 4 (Pre-treatment PSA
4)
PSA date
PSA lab value
PSA assay type (^1)
Abbott Labs (Abbott)
Hybritech (Hybritech)
Other (Other)
Roche (Roche)
Tosoh Nexia (Tosoh Nexia)
Yang Pros-check (Yang)
(Other), specify
medication history
Concomitant medications (Mark all that apply
with an X.)
Anti-coagulant Agents (Anti-coagulant
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agents)
Anti-platelet Agents (Anti-platelet agents)
Aspirin (Aspirin)
Lipid-lowering Drugs (Lipid-lowering
drugs)
Aspirin (Mark one with an X.)
0 Mg/daily (0 mg/daily)
325 Mg/daily (325 mg/daily)
81 Mg/daily (81 mg/daily)
Agent code (*)
Clopidogrel (clopidogrel)
Dipyridamole (dipyridamole)
Other (Other)
Ticlopidine (ticlopidine)
Other, specify generic name
Agent code (**)
Low Molecular Weight Heparin (Low
molecular weight heparin)
Other (Other)
Warfarin (Warfarin)
Other, specify generic name
Dose
Dose
Dose
Frequency (no. of daily doses)
Frequency (no. of daily doses)
Frequency (no. of daily doses)
Agent code (***)
Atorvastatin (atorvastatin)
Cholestyramine (cholestyramine)
Fenofibrate (fenofibrate)
Fluvastatin (fluvastatin)
Gemfibrozil (gemfibrozil)
Lovastatin (lovastatin)
Other (Other)
Pravastatin (pravastatin)
Rosuvastatin (rosuvastatin)
Simvastatin (simvastatin)
Other, specify generic name
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Opiate medication history
Agent code
Codeine (Codeine)
Dihydrocode (synalgos) (Dihydrocode)
Fentanyl (duragesic, Sublimaze, Actiq)
(Fentanyl)
Hydrocodone (Hydrocodone)
Hydromorphone (dilaudid)
(Hydromorphone)
Levorphanol (levodromoran)
(Levorphanol)
Methadone (Methadone)
Morphine (Morphine)
Other (Other)
Oxymorphone (numorphone)
(Oxymorphone)
Propoxyphene (Propoxyphene)
Other, specify
Total Daily Dose of Agent (or Drug)
Units
Gram (g)
International Unit (IU)
Liter (L)
Microgram (mcg)
Milligram (mg)
Milliliter (mL)
Unit (unit)
Route
Intravenous (IV)
Other (Other)
Oral (PO)
Subcutaneous (SC)
Topical (TOP)
Agent Start Date
Agent End Date
Agent Administered Frequency
Intermittent (Intermittent or as needed)
Indication for use
Curative Treatment (Curative)
Prevention (Prophylaxis)
Comments
COMMENTS
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Completed by
Date form completed
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ANBL0321 MIBG Response NCT00053326
ANBL0321 MIBG Response NCT00053326
Fenretinide in Treating Children With Recurrent or
Resistant Neuroblastoma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=B968BED1-
43CF-22DE-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/10933
ANBL0321 MIBG Response
NCT00053326
Header
Study Number
Date of submission into the RDE system (Pre-
populated after data is accepted by the system)
Period Number
Course # (1. Required field)
Tumor Response
MIBG response (See Section 10 of protocol)
Complete Response (CR)
Death Prior To Completion Of Protocol
Criteria (Early death)
Incomplete Response Or Stable
Disesase (Incomplete response/SD)
Not Done (Not Done)
Insufficient Evaluation (Not evaluable)
Progressive Disease (PD)
Partial Response (PR)
QNS info (QNS info)
Stable Disease (SD)
Date of MIBG scan (MM/DD/YYYY)
Comments
Comments (1. Text field)
Ccrr Module For Anbl0321 Mibg
Response
1 / 1
ANBL0321: Bone Marrow Response
NCT00053326
ANBL0321: Bone Marrow Response NCT00053326
Fenretinide in Treating Children With Recurrent or
Resistant Neuroblastoma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=B9B4AFEC-
3E03-1FF8-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/10934
ANBL0321: Bone Marrow Response
NCT00053326
Header
Study Number
Date of submission into the RDE system: Pre-
populated after data is accepted by the system
Bone Marrow Response
Course # (1. Required field)
Date of bone marrow #1 for response (1.
Required field)
Bone marrow #2 morphology result (Submit
report for both aspirates and biopsies to RDC)
Bone Marrow Not Done Or Not Sent To
Reference Laboratory (Bone marrow not
done or not sent to reference laboratory)
Bone Marrow Was Not Evaluable (Bone
marrow was not evaluable)
Neuroblastoma Cells Detected In Bone
Marrow (Neuroblastoma cells detected in
bone marrow)
No Neuroblastoma Cells Detected In
Bone Marrow (No neuroblastoma cells
detected in bone marrow)
Bone marrow #2 morphology result (Submit
report for both aspirates and biopsies to RDC)
Bone Marrow Not Done Or Not Sent To
Reference Laboratory (Bone marrow not
done or not sent to reference laboratory)
Bone Marrow Was Not Evaluable (Bone
marrow was not evaluable)
Neuroblastoma Cells Detected In Bone
Marrow (Neuroblastoma cells detected in
bone marrow)
No Neuroblastoma Cells Detected In
Bone Marrow (No neuroblastoma cells
detected in bone marrow)
Bone marrow #2 immunocytology result: Number
of tumor cells detected (These numbers are
obtained from immunocytology reports from Dr.
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Seeger's lab.  For example, the report may state
2 tumor cells/200,000 mononuclear cells.  This
report would be entered above as Number of
tumor cells = 2; Number of cells counted =
200,000)
Bone marrow #2 immunocytology result: Number
of tumor cells detected (These numbers are
obtained from immunocytology reports from Dr.
Seeger's lab.  For example, the report may state
2 tumor cells/200,000 mononuclear cells.  This
report would be entered above as Number of
tumor cells = 2; Number of cells counted =
200,000)
Bone marrow #2 immunocytology result: Total
number of cells counted (These numbers are
obtained from immunocytology reports from Dr.
Seeger's lab.  For example, the report may state
2 tumor cells/200,000 mononuclear cells.  This
report would be entered above as Number of
tumor cells = 2; Number of cells counted =
200,000)
Bone marrow #2 immunocytology result: Total
number of cells counted (These numbers are
obtained from immunocytology reports from Dr.
Seeger's lab.  For example, the report may state
2 tumor cells/200,000 mononuclear cells.  This
report would be entered above as Number of
tumor cells = 2; Number of cells counted =
200,000)
What is the bone marrow immunocytologic
response at the end of this reporting period?
(See section 10.4 for response definitions)
Complete Response (CR)
Death Prior To Completion Of Protocol
Criteria (Early death)
Incomplete Response Or Stable
Disesase (Incomplete response/SD)
Not Done (Not Done)
Insufficient Evaluation (Not evaluable)
Progressive Disease (PD)
Partial Response (PR)
Stable Disease (SD)
What is the bone marrow immunocytologic
response at the end of this reporting period?
(See section 10.4 for response definitions)
Complete Response (CR)
Death Prior To Completion Of Protocol
Criteria (Early death)
Incomplete Response Or Stable
Disesase (Incomplete response/SD)
Not Done (Not Done)
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Insufficient Evaluation (Not evaluable)
Progressive Disease (PD)
Partial Response (PR)
Stable Disease (SD)
Comments
Ccrr Module For Anbl0321: Bone Marrow
Response
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ACNS0122: Relapse/Progression
Worksheet NCT00047320
ACNS0122: Relapse/Progression Worksheet
NCT00047320 
Neoadjuvant Chemotherapy With or Without Second-Look
Surgery Followed by Radiation Therapy With or Without
Peripheral Stem Cell Transplantation in Treating Patients
With Intracranial Germ Cell Tumors
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=C3107FBD-
6347-26E8-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/10935
ACNS0122: Relapse/Progression
Worksheet NCT00047320
Header
Institution Name
Institution Personnel
Date of Birth
COG Study No
COG Patient ID
Patient Accession Number
Form Original Complete Date
Date From Amended
Date of relapse or progression
Date of relapse or progression
Type Of Recurrence/progression
Recurrence/progression of original involved
sites?
Yes
No
Recurrence/progression in previously uninvolved
neural site?
Yes
No
Extra-neural recurrence/progression?
Yes
No
1 / 4
Sites Of Involvement
Supratentorial [involved?]
Yes
No
Supratentorial [indicate sites involved]
Aqueduct Of Sylvius (Aqueduct of
sylvius)
Basal Ganglia-thalamus (Basal ganglia-
thalamus)
Corpus Callosum (Corpus callosum)
Frontal Lobe (Frontal lobe)
Hypothalamus-optic Chiasm
(Hypothalamus-optic chiasm)
Lateral Ventricle (Lateral ventricle)
Supratentorial Leptomeninges
(Leptomeningeal)
Occipital Lobe (Occipital lobe)
Optic Nerve (Optic nerve)
Other, Specify (Other)
Parietal Lobe (Parietal lobe)
Pineal (Pineal)
Suprasellar (Suprasellar)
Temporal Lobe (Temporal lobe)
Third Ventricle (Third ventricle)
specify [other supratentorial site] (If 1, 2 or 3)
Infratentorial [involved?]
Yes
No
Infratentorial [indicate sites involved]
Cerebellar Hemisphere (Cerebellar
hemisphere)
Cerebellar Peduncle (Cerebellar
penducle)
Cerebellar Vermis (Cerebellar vermis)
Cisterna Magna (Cisterna magna)
Dorsal Exophytic Brainstem (Dorsal
exophytic brainstem)
Fourth Ventricle (Fourth ventricle)
Infratentorial Leptomeninges
(Leptomeningeal)
Medulla (Medulla)
Midbrain (Midbrain)
Other, Specify (Other)
Pons (Pons)
specify [other infratentorial site] (If 1, 2 or 3)
Ttype of involvement?
Existing/non-progressive Tumor
(Existing/Non-progressive tumor)
New Tumor/lesion Site (New tumor site)
Recurrence/progressive Disease
(Recurrence/Progressive disease)
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Uninvolved (uninvolved)
Ttype of involvement?
Existing/non-progressive Tumor
(Existing/Non-progressive tumor)
New Tumor/lesion Site (New tumor site)
Recurrence/progressive Disease
(Recurrence/Progressive disease)
Uninvolved (uninvolved)
Ttype of involvement?
Existing/non-progressive Tumor
(Existing/Non-progressive tumor)
New Tumor/lesion Site (New tumor site)
Recurrence/progressive Disease
(Recurrence/Progressive disease)
Uninvolved (uninvolved)
Ttype of involvement?
Existing/non-progressive Tumor
(Existing/Non-progressive tumor)
New Tumor/lesion Site (New tumor site)
Recurrence/progressive Disease
(Recurrence/Progressive disease)
Uninvolved (uninvolved)
SPINAL CORD [involved?]
Yes
No
SPINAL CORD [indicate sites involved]
Cauda Equina (Cauda equina)
Cervical (Cervical)
Conus (Conus)
Spinal Cord Leptomeninges
(Leptomeningeal)
Other, Specify (Other)
Thoracic Lumbosacral (Thoracic)
specify [other spinal cord site] (If 1, 2 or 3)
DURA [involved?] (Incl. Falx and Tentorium)
Yes
No
DURA [indicate sites involved]
Diffuse (Diffuse)
Nodular (Nodular)
Was CSF positive?
No (No)
Unknown (Not done/Unknown)
Yes (Yes)
Comments
Comments
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Ccrr Module For Acns0122:
Relapse/progression Worksheet
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CALGB-40502 On-Study Form
NCT00785291
CALGB-40502 On-Study Form NCT00785291
Paclitaxel, Paclitaxel Albumin-Stabilized Nanoparticle
Formulation, or Ixabepilone With or Without Bevacizumab
in Treating Patients With Stage IIIC or Stage IV Breast
Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=51FC2EF2-
3D00-0DF1-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/10936
CALGB-40502 On-Study Form
NCT00785291
Header
CALGB Form
CALGB Study No.
CALGB Patient ID
Are data amended
Yes
No
Patient demographics
Patient Initials (Last, First Middle)
Patient Hospital No.
Institution/Affiliate
Participating Group
Participating Group Study No.
Participating Group Patient ID
Patient Characteristics
ECOG Performance Status (Mark one with an X.)
Fully Active, Able To Carry On All Pre-
disease Performance Without
Restriction. (0)
Restricted In Physically Strenuous
Activity But Ambulatory And Able To
Carry Out Work Of A Light Or Sedentary
Nature, E.g., Light Housework, Office
Work. (1)
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MedDRA Disease Code
Stage of disease (T N M)
Disease Description
ER status (Mark one with an X.)
Negative (Negative)
Positive (Positive)
Other, specify
PgR status  (Mark one with an X.)
Negative (Negative)
Positive (Positive)
Timing of assay  (Mark one with an X.)
At Recurrence (At recurrence)
Initial Diagnosis (Initial diagnosis)
Other (Other)
Timing of assay  (Mark one with an X.)
At Recurrence (At recurrence)
Initial Diagnosis (Initial diagnosis)
Other (Other)
Other, specify
Date of Initial Diagnosis of Primary Tumor (MM
DD YYYY)
Date Progressive or Metastatic Disease First
Diagnosed (MM DD YYYY)
Her2/neu Status
IHC Lab Value (Mark one with an X.)
+1 (+1)
+2 (+2)
+3 (+3)
0 (0)
FISH HER2/neu result
Site Of Progression Or Recurrence
Sites of Progression (Mark all that apply with an
X.)
Bone (Bone)
Bone Marrow (Bone marrow)
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Brain (Brain)
Distant Lymph Nodes (Distant nodes)
Distant Skin/subcutaneous Tissue
(Distant skin/subcutaneous tissue)
Ipsilateral Supraclavicular Nodes
(Ipsilateral supraclavicular nodes)
Liver (Liver)
Local-regional (including Ipsilateral
Breast; Chest Wall; Axillary, Internal
Mammary, And Infraclavicular Nodes;
Local-regional Skin And Subcutaneous
Tissue) (Local-regional)
Lung, Nos (Lung)
Contralateral Breast (Opposite breast)
Other (Other)
Other Cns (Other CNS)
Pleura (Pleura)
Other specify
Prior Treatment - Systemic Regimens
Prior Treatment Regimen Name (s)
Prior Treatment Regimen Start Date (MM DD
YYYY)
Prior Treatment Regimen End Date (MM DD
YYYY)
Prior Treatment Regimen Type
Adjuvant (Adjuvant)
Advanced (Advanced)
Neoadjuvant Therapy (Neoadjuvant)
Required Laboratory Values
ANC (u10^3 microL)
Peripheral Platelet Count (u10^3 microL)
Bilirubin (mg/dl)
Bilirubin ULN
SGPT (UL)
SGPT (ALT) ULN (UL)
SGOT (UL)
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SGOT (AST) ULN (UL)
Creatinine (mg/dl)
Serum Beta-HCG (OR)
Negative (Negative)
Not Applicable (Not applicable)
Positive (Positive)
Urine Beta-HCG
Negative (Negative)
Not Applicable (Not applicable)
Positive (Positive)
Urinalysis
Urine Protein (Mark one with an X.)
0 (0)
1+ (1+)
2+ (2+)
3+ (3+)
4+ (4+)
Protein from 24 hour Urine Collection (mg/day)
Urine Protein/Creatinine Ratio (Or if UPC<=1)
Comments
Footer Module
Completed by
Date Form Completed
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E5103 24-months Post-Registration Cardiac
Function Assessment Form NCT00433511
E5103 24-months Post-Registration Cardiac Function
Assessment Form NCT00433511
Doxorubicin, Cyclophosphamide, and Paclitaxel With or
Without Bevacizumab in Treating Patients With Lymph
Node-Positive or High-Risk, Lymph Node-Negative Breast
Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=8C9D1499-
1276-D754-E040-BB89AD43467F
All rights reserved. Please visit https://medical-data-
models.org/forms/10937
E5103 24-months Post-Registration
Cardiac Function Assessment Form
NCT00433511
Header
ECOG Protocol Number
ECOG Patient ID
DCI Name
Registration Step
Report Period
24 Months Post Registration (24 Months
Post Registration)
Please mark an 'X' if data have been amended
(Please circle amended items in red)
Date data amended (s M D Y)
Patient demographics
Patient Initials (Last, First)
Participating Group Protocol Number
Participating Group Patient ID
Institution/Affiliate
Cardiac Function
Has the patient had a documented assessment
of cardiac function
Yes
No
Date of Most Recent Cardiac Assessment (M D
1 / 3
Y)
Clinical Episode of CHF (requires symptoms
associated with a decrease of LVEF to below
LLN)
No (No)
Unknown (Unknown)
Yes (Yes)
S3 Gallop
No (No)
Unknown (Unknown)
Yes (Yes)
Bibasilar Rales
No (No)
Unknown (Unknown)
Yes (Yes)
Cardiomegaly
No (No)
Unknown (Unknown)
Yes (Yes)
Abnormal ECG
No (No)
Unknown (Unknown)
Yes (Yes)
Specify nature of abnormalities (If yes,)
Cardiac Adverse Events
CTC Adverse Event Term
Dyspnoea Nos (Dyspnea (shortness of
breath))
Edema: Head And Neck (Edema: head
and neck)
Oedema Nos (Edema: limb)
Edema: Trunk/genital (Edema:
trunk/genital)
Edema: Viscera (Edema: viscera)
Left Ventricular Diastolic Dysfunction
(Left ventricular diastolic dysfunction)
Left Ventricular Failure (Left ventricular
systolic dysfunction)
Myocarditis Nos (Myocarditis)
Restrictive Cardiomyopathy (Restrictive
cardiomyopathy)
Other, specify
CTC Adverse Event Grade (v3.0 Use grade 1-5
per CTCAE)
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CTC AE Attribution Code
Definite (definite)
Possible (possible)
Probable (probable)
Unlikely (unlikely)
Unrelated (unrelated)
Specify site
LVEF Information
Has the patient had a documented assessment
of LVEF (this report period)
Yes
No
Method of Evaluation
Echocardiogram (Echocardiogram)
Muga Scan (MUGA scan)
Left Ventricular Ejection Fraction at Rest (LVEF
%)
LVEF Institutional Lower Limit of Normal (% per
institutional standard)
Date of LVEF (M D Y)
Comments
Investigator Signature
Investigator Signature Date
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E1105 Quality of Life Assessment Form
NCT00520975
E1105 Quality of Life Assessment Form NCT00520975 
First-Line Chemotherapy and Trastuzumab With or Without
Bevacizumab in Treating Patients With Metastatic Breast
Cancer That Overexpresses HER-2/NEU
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=17363D95-
6129-3B27-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/10938
E1105 Quality of Life Assessment
Form NCT00520975
Header
ECOG Protocol Number
ECOG Patient ID
DCI Name
Registration Step
Patient demographics
ECOG Protocol Number
Patient Initials (Last, First)
ECOG Patient ID
Participating Group Protocol Number
Institution/Affiliate
Participating Group Patient ID
Data amendment
Please mark an 'X' if data have been amended
(Please circle amended items in red)
Date data amended (M D Y)
1 / 1
RTOG 0724 Phase III Cervix Chemo RT (+)/(-) Adjuvant
Chemotherapy: Initial Evaluation Form (I1) NCT00980954
RTOG 0724 Phase III Cervix Chemo RT (+)/(-) Adjuvant
Chemotherapy: Initial Evaluation Form (I1) NCT00980954
Chemotherapy and Pelvic Radiation Therapy With or
Without Additional Chemotherapy in Treating Patients With
High-Risk Early-Stage Cervical Cancer After Radical
Hysterectomy
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=5D016EA3-
A43F-2E2A-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/10939
RTOG 0724 Phase III Cervix Chemo
RT (+)/(-) Adjuvant Chemotherapy:
Initial Evaluation Form (I1)
NCT00980954
Header module
RTOG Study No.
Case #
Institution
Institution No.
Participant Initials
RTOG Patient ID
Amended Data (INSTRUCTIONS: All questions
must be answered per code table and/or
instructions.  Record dates as mm-dd-yyy unless
otherwise specified.)
Yes
No
Assessment
Patient Age
Performance Status (Zubrod)
Normal Activity (0)
Symptoms, But Nearly Fully Ambulatory
(1)
Some Bed Time, But Needs To Be In
Bed <50% Of Normal Daytime (2)
Needs To Be In Bed > 50% Of Normal
Daytime (3)
Unable To Get Out Of Bed (4)
FIGO staging (CLINICAL AJCC 6TH EDITION)
Stage Ia2 Cervical Cancer (IA2)
Stage Ib Cervical Cancer (IB)
Stage Iia Cervical Cancer (IIA)
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Pathologic T Stage
No Evidence Of Primary Tumor (T0)
Cervical Carcinoma Confined To Uterus
(extension To Corpus Should Be
Disregarded) (T1)
Invasive Carcinoma Diagnosed Only By
Microscopy (T1a)
Measured Stromal Invasion 3 Mm Or
Less In Depth And 7 Mm Or Less In
Horizontal Spread (T1a1)
Measured Stromal Invasion More Than 3
Mm And Not More Than 5 Mm With A
Horizontal Spread 7 Mm Or Less (T1a2)
Clinically Visible Lesion Confined To The
Cervix Or Microscopic Lesion Greater
Than T1a2 (T1b)
Clinically Visible Lesion 4 Cm Or Less In
Greatest Dimension (T1b1)
Clinically Visible Lesion More Than 4 Cm
In Greatest Dimension (T1b2)
Cervical Carcinoma Invades Beyond
Uterus But Not To Pelvic Wall Or To The
Lower Third Of The Vagina (T2)
Tumor With Parametrial Involvement
(T2b)
Tumor Extends To The Pelvic Wall
And/or Involves The Lower Third Of The
Vagina, And/or Causes Hydronephrosis
Or Nonfunctioning Kidney (T3)
Tumor Involves Lower Third Of The
Vagina, No Extension To Pelvic Wall
(T3a)
Tumor Extends To Pelvic Wall And/or
Causes Hydronephrosis Or
Nonfunctioning Kidney (T3b)
Tumor Invades Mucosa Of The Bladder
Or Rectum, And/or Extends Beyond True
Pelvis (T4)
Carcinoma In Situ (Tis)
Pathologic N Stage
No Regional Lymph Node Metastasis
(N0)
Regional Lymph Node Metastasis (N1)
Regional Lymph Nodes Cannot Be
Assessed (NX)
Pathologic M Stage
No Distant Metastasis (M0)
Distant Metastasis (M1)
Distant Metastasis Cannot Be Assessed
(MX)
Type of radical hysterectomy
Laparoscopic (Laparoscopic)
Open (Open)
Robotic (Robotic)
Date of radical hysterectomy
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Histologic Category
Histologic Type
Adenocarcinoma, Unspecified
(Adenocarcinoma, unspecified)
Adenosquamous (Adenosquamous
carcinoma)
Squamous Cell Carcinoma (Squamous
cell carcinoma)
Histologic Grade
Well Differentiated (G1-Well
Differentiated)
Moderately Differentiated (G2-
Moderately Differentiated)
Poorly Differentiated (G3-Poorly
Differentiated)
Undifferentiated (G4-Undifferentiated)
Grade Cannot Be Assessed (Gx-Grade
cannot be assessed)
HIGH RISK FEATURES
Positive parametrium
Yes
No
Right parametrium
Not Applicable (N/A)
No (No)
Unknown (Unknown)
Yes (Yes)
Left parametrium
Not Applicable (N/A)
No (No)
Unknown (Unknown)
Yes (Yes)
Positive pelvic nodes
Yes
No
Number of pelvic nodes sampled
Number of pelvic nodes positive
Extracapsular extension
Not Available (N/A)
No (NO)
Yes (YES)
Positive para-aortic nodes (PA)
No (NO)
Not Sampled/dissected (Not
sampled/dissected)
Yes (YES)
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Initial Evaluation Form (I1) NCT00980954
PA nodes completely resected
Not Available (N/A)
No (No)
Yes (Yes)
If positive PA (para-aortic) nodes, PET/CT
negative post-op
Yes
No
Number of PA (para-aortic) nodes sampled
Number of PA (para-aortic) nodes positive
Extracapsular extension
Not Available (N/A)
No (NO)
Yes (YES)
Common Iliac Node Dissection
Negative (negative)
Not Dissected (Not dissected)
Positive (positive)
Examinations
Date of History and Physical Exam
Date of contrast-enhanced CT/MRI of abdomen-
pelvis
Date of Chest X-Ray or CT scan
Date of whole body PET/CT
PET / PET CT of Para-Aortic Nodes
N/a (N/A)
Negative (negative)
Positive (positive)
Baseline Lab Values (hematologic)
WBC (mm^3)
Date
Date
Date
ANC (mm^3)
4 / 7
RTOG 0724 Phase III Cervix Chemo RT (+)/(-) Adjuvant Chemotherapy:
Initial Evaluation Form (I1) NCT00980954
Date (MM DD YYYY)
Platelets (PLT) (BONE MARROW FUNCTION)
Date (MM DD YYYY)
Hemoglobin (g/dL)
Date (MM DD YYYY)
Serum creatinine (mg/dl)
Total Bilirubin (mg/dl)
Date
Bilirubin ULN (mg/dl)
SGOT (AST)
Date (MM DD YYYY)
SGOT (AST) ULN (U/L)
Alkaline Phosphatase
Date
Alkaline Phosphatase ULN
SGPT (ALT)
Date
SGPT (ALT) ULN
Magnesium
Calcium
Date
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RTOG 0724 Phase III Cervix Chemo RT (+)/(-) Adjuvant Chemotherapy:
Initial Evaluation Form (I1) NCT00980954
Severe Active Comorbidity
Residual gross tumor
Yes
No
Neuroendocrine histology
Yes
No
Does the patient have clinical or radiologic
evidence of metastatic disease? (excluding
completely resected PA nodes)
Yes
No
History of Prior Malignancy
Yes
No
Date eradicated (If yes,)
Prior radiation therapy to the pelvis resulting in
overlapping of radiation therapy fields per this
protocol
Yes
No
Hospitalized for unstable angina and/or CHF in
last 6 months
Yes
No
Transmural MI in last 6 months
Yes
No
Acute bacterial or fungal infection requiring
intravenous antibiotics at the time of registration
Yes
No
COPD exacerbation or other respiratory illness
requiring hospitalization or precluding study
therapy at registration
Yes
No
Patient known to be HIV positive
Yes
No
Is CD4 count => 350 cells/mm
Not Available (NA)
No (No)
Yes (Yes)
Date
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RTOG 0724 Phase III Cervix Chemo RT (+)/(-) Adjuvant Chemotherapy:
Initial Evaluation Form (I1) NCT00980954
Prior systemic chemotherapy for current study
cancer
Yes
No
Prior allergic reaction to carboplatin, cisplatin or
paclitaxel
Yes
No
Footer Module
Investigator Signature
Date
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Initial Evaluation Form (I1) NCT00980954
E5103 On-Study Form NCT00433511
E5103 On-Study Form NCT00433511
Doxorubicin, Cyclophosphamide, and Paclitaxel With or
Without Bevacizumab in Treating Patients With Lymph
Node-Positive or High-Risk, Lymph Node-Negative Breast
Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=22AFBF9F-
D69B-53CC-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/10940
E5103 On-Study Form
NCT00433511
ECOG clinical trial administrative data
ECOG Protocol Number
ECOG Patient ID
DCI Name
Registration Step
Reporting Period
Baseline Step 1 (Baseline step 1)
Please mark an 'X' if data have been amended
(Please circle amended items in red)
Date data amended (M D Y)
Patient demographics
Patient Initials (Last,First)
Participating Group Protocol Number
Participating Group Patient ID
Institution/Affiliate
Performance status
ECOG Performance Status (Day 1 of this cycle)
Fully Active, Able To Carry On All Pre-
disease Performance Without
Restriction. (0)
Restricted In Physically Strenuous
Activity But Ambulatory And Able To
Carry Out Work Of A Light Or Sedentary
Nature, E.g., Light Housework, Office
Work. (1)
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Ambulatory And Capable Of All Selfcare
But Unable To Carry Out Any Work
Activities. Up And About More Than 50%
Of Waking Hours. (2)
Capable Of Only Limited Selfcare,
Confined To Bed Or Chair More Than
50% Of Waking Hours. (3)
Completely Disabled. Cannot Carry On
Any Selfcare. Totally Confined To Bed Or
Chair. (4)
Menopausal status (Definitions of Menopausal
Status:  Postmenopausal: Defined as at least one
of the following: 1 age >55 with no spontaneous
menses for at least 12 months; or 2 age </=55
with no spontaneous menses within the past 12
months e.g., spontaneously or...)
Perimenopausal (Perimenopausal)
Postmenopausal (Postmenopausal)
Premenopausal (Premenopausal)
Unknown (Unknown)
Pre-registration Evaluation
Height
Weight (kg)
Prior tamoxifen therapy
No (No)
Unknown (Unknown)
Yes (Yes)
Prior raloxifene therapy? (for chemoprevention)
No (No)
Unknown (Unknown)
Yes (Yes)
Urine Protein/Creatinine Ratio
Date lab assessment performed
Pre-registration Scans/imaging
Method of Evaluation
Bone Scan (Bone scan)
Chest Radiography (Chest CT)
Chest X-ray (Chest x-ray)
Date of Assessment
Result
Negative (negative)
Not Done (not done)
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Positive (Positive)
Disease Description
Tumor Laterality (NOTE: Submit copies of
pathology reports for all diagnostic and
therapeutic surgical procedures with E5103
Source Document Tracking Coversheet)
Bilateral (Bilateral)
Left (Left)
Right (Right)
Breast: Surgical Procedures
Most Extensive Primary Surgery
Mastectomy, Nos (Mastectomy NOS)
Partial Mastectomy, Lumpectomy Or
Excisional Biopsy (Partial
mastectomy/lumpectomy/excisional
biopsy)
Date of Most Extensive Primary Surgery (m/d/y)
Was sentinel node sampling performed
Yes
No
Sentinel Node Biopsy Date (If yes: - m/d/y)
Number of Sentinel Nodes Examined
Number of Positive Sentinel Nodes by H&E (enter
'0' if no positive nodes)
Number of Positive Sentinel Nodes by
Immunohistochemistry (IHC) only (enter '0' if no
positive nodes)
Mark an 'X' if not done
Was axillary dissection performed?
Yes
No
Date of Axillary Dissection (If yes: - m/d/y)
Total number of axillary lymph nodes examined
Number of positive axillary nodes by H&E (enter
'0' if no positive nodes)
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Number of positive axillary nodes by IHC only
(enter '0' if no positive nodes)
Breast: Disease Description
Date of Initial Diagnosis of Primary Tumor (Date
of first positive biopsy)
Pathologic Primary Tumor Size (cm Maximum
diameter of the invasive component; if multiple
lesions, use longest lesion)
Histologic Grade (For breast cancer, a combined
histologic grade is used according to SBR/Elston
classification)
Well Differentiated (Grade I (low))
Moderately Differentiated (Grade II
(intermediate))
Poorly Differentiated (Grade III (high))
Unknown (UNKNOWN)
Nuclear Grade
High (High)
Intermediate (Intermediate)
Low (Low)
Unknown (Unknown)
Receptor Status, ER (as defined by local
laboratory; borderline results should be reported
as positive)
Negative (Negative)
Not Done (NOT DONE)
Positive (Positive)
Unknown (Unknown)
Receptor Status, PgR
Negative (Negative)
Not Done (NOT DONE)
Positive (Positive)
Unknown (Unknown)
Oncotype DX Recurrence Score (If ER+:)
Her2/neu expression status by
immunohistochemistry (DAKO HercepTest)
0 (0)
1+ (1+)
2+ (2+)
3+ (3+)
Not Done: C49484 (not done)
FISH HER2/neu chromosome 17 Ratio
Mark an 'X' if not done
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Breast: Surgical Procedures
Breast: Disease Description
Footer Module
Investigator Signature
Investigator Signature Date
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ECOG Non-Protocol Therapy Form
NCT00520975
ECOG Non-Protocol Therapy Form NCT00520975
First-Line Chemotherapy and Trastuzumab With or Without
Bevacizumab in Treating Patients With Metastatic Breast
Cancer That Overexpresses HER-2/NEU
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=1720CDCE-
4815-5A14-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/10941
ECOG Non-Protocol Therapy Form
NCT00520975
Header
ECOG Protocol Number
ECOG Patient ID
DCI Name
Registration Step
Reporting Period
Non-protocol Therapy (Non-Protocol
Therapy)
Please mark an 'X' if data have been amended
(Please circle amended items in red)
Date data amended (M D Y)
Patient demographics
Patient Initials (Last, First)
Participating Group Protocol Number
Participating Group Patient ID
Institution/Affiliate
Off protocol treatment
Date of FIRST non-protocol therapy (if given prior
to progression/relapse from protocol therapy)
Non-protocol Chemotherapy
No (No)
Unknown (Unknown)
1 / 2
Yes (Yes)
Non-protocol Hormonal Therapy
No (No)
Unknown (Unknown)
Yes (Yes)
Non-protocol Immunotherapy (Biological
Response Modifiers)
No (No)
Unknown (Unknown)
Yes (Yes)
Non-protocol High Dose Chemotherapy/Stem
Cell Transplant (Autologous or Allogeneic)
No (No)
Unknown (Unknown)
Yes (Yes)
Non-protocol Surgery
No (No)
Unknown (Unknown)
Yes (Yes)
Non-protocol surgery type
Non-protocol Radiation Therapy
No (No)
Unknown (Unknown)
Yes (Yes)
Non-protocol RT type
Other Non-protocol Therapy
No (No)
Unknown (Unknown)
Yes (Yes)
Name of other non-protocol therapy
Was the non-protocol therapy given for the
disease of this protocol (NOTE: Treatment for a
second primary in the same organ site would not
be considered therapy for disease of this
protocol.)
No (No)
Unknown (Unknown)
Yes (Yes)
Comments
Investigator Signature
Investigator Signature Date
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E5103 Second Primary Form
NCT00433511
E5103 Second Primary Form [Form No. 1677]
NCT00433511
Doxorubicin, Cyclophosphamide, and Paclitaxel With or
Without Bevacizumab in Treating Patients With Lymph
Node-Positive or High-Risk, Lymph Node-Negative Breast
Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=22AFF315-
4DDD-593F-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/10942
E5103 Second Primary Form
NCT00433511
Header
ECOG Protocol Number (If patient has been on
other therapeutic ECOG protocols, please list
protocols and patient ID numbers)
ECOG Patient ID
DCI Name
Registration Step
Reporting Period
Second Primary Cancer (Second
primary)
Please mark an 'X' if data have been amended
(Please circle amended items in red)
Date data amended (M D Y)
Patient demographics
Patient Initials (Last,First)
Participating Group Protocol Number
Participating Group Patient ID
Institution/Affiliate
Completed By Central Lab
Date of Diagnosis of Second Primary Cancer
(mm/dd/yyyy)
1 / 2
Site of Second Primary Cancer
Include information on histologic subtype (s
Please attach copies of any corroborating
pathology reports.)
Briefly describe cancer therapy the patient has
received prior to the diagnosis of the second
primary and other than that given on ECOG
protocols
Briefly describe treatment planned or given for
the diagnosis of this second primary
Comments
Investigator Signature
Investigator Signature Date
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E1105 Source Document Tracking
Coversheet NCT00520975
E1105 Source Document Tracking Coversheet
NCT00520975 
First-Line Chemotherapy and Trastuzumab With or Without
Bevacizumab in Treating Patients With Metastatic Breast
Cancer That Overexpresses HER-2/NEU
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=3DA6A565-
A759-403A-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/10943
E1105 Source Document Tracking
Coversheet NCT00520975
Header
ECOG Protocol Number
ECOG Patient ID
DCI Name
Registration Step
Reporting Period
Baseline (Baseline)
Patient demographics
Patient Initials (Last, First)
ECOG Protocol Number
Participating Group Protocol Number
ECOG Patient ID
Participating Group Patient ID
Institution/Affiliate
Footer module
Document type (Choose one)
Eligibility Checklist (Eligibility Checklist)
Report Created Date (List the date the source
document was created below.)
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ECOG-E2108 Source Document Tracking
Coversheet NCT01242800
ECOG-E2108 Source Document Tracking Coversheet
NCT01242800 
Early Surgery or Standard Palliative Therapy in Treating
Patients With Stage IV Breast Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=91E2AAB8-
28DA-A87B-E040-BB89AD43631D
All rights reserved. Please visit https://medical-data-
models.org/forms/10944
ECOG-E2108 Source Document
Tracking Coversheet NCT01242800
Header
ECOG Protocol Number
ECOG Patient ID
DCI Name
Registration Step
Reporting Period
Baseline Step 1 (Baseline step 1)
Baseline Step 2 (Baseline step 2)
Surgery (Surgery)
Patient demographics
Patient Initials (Last, First)
Participating Group Protocol Number
ECOG Protocol Number
Institution/Affiliate
ECOG Patient ID
Participating Group Patient ID
Footer module
Document type (Choose all that apply)
Operative Report (Operative Report)
Pathology Report (Pathology Report)
Radiology Report (Radiology Report)
Report Created Date (List the date the source
document was created below.)
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CALGB_40302_ONSTUDY_FRM
NCT00390455
CALGB 40302 ON STUDY FORM NCT00390455
Fulvestrant With or Without Lapatinib in Treating
Postmenopausal Women With Stage III or Stage IV Breast
Cancer That is Hormone Receptor-Positive
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=F593450E-
7E56-42E1-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/10945
CALGB_40302_ONSTUDY_FRM
NCT00390455
Header
CALGB Form
CALGB Study No.
CALGB Patient ID
Are data amended
Yes
No
Patient demographics
Patient Initials
Patient Hospital No
Institution/Affiliate
Participating Group
Participating Group Study No.
Participating Group Patient ID
Patient Characteristics
Post menopausal
Yes
No
MedDRA Disease Code
Is patient on ovarian suppression with GnRH-A
agonist
Yes
No
date started (If yes,)
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Did the patient participate in a first line hormone
Yes
No
Was there a clinical response >= 6 months? (If
yes, )
Yes
No
What was the response? (If yes, )
Complete Response (CR)
Partial Response (PR)
Stable Disease (SD)
Disease Description
ER status (Mark one with an X.)
Negative (Negative)
Positive (Positive)
Unknown (Unknown)
Other, specify
PgR status  (Mark one with an X.)
Negative (Negative)
Positive (Positive)
Unknown (Unknown)
Timing of assay  (Mark one with an X.)
At Recurrence (At recurrence)
Initial Diagnosis (Initial diagnosis)
Other (Other)
Timing of assay  (Mark one with an X.)
At Recurrence (At recurrence)
Initial Diagnosis (Initial diagnosis)
Other (Other)
Other, specify
Date of initial diagnosis of primary tumor
Date progressive or metastatic disease first
diagnosed
Site Of Progression Or Recurrence
Site of progression (s)
Bone (Bone)
Bone Marrow (Bone marrow)
Brain (Brain)
Distant Lymph Nodes (Distant nodes)
Distant Skin/subcutaneous Tissue
(Distant skin/subcutaneous skin)
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Ipsilateral Supraclavicular Nodes
(Ipsilateral supraclavicular nodes)
Liver (Liver)
Local-regional (including Ipsilateral
Breast; Chest Wall; Axillary, Internal
Mammary, And Infraclavicular Nodes;
Local-regional Skin And Subcutaneous
Tissue) (Local-regional)
Lung, Nos (Lung)
Contralateral Breast (Opposite breast)
Other (Other)
Other Cns (Other CNS)
Pleura (Pleura)
Other, specify:
Prior Systemic Therapy
Prior adjuvant hormonal therapy (Do not include
steroids given with chemotherapy.)
Yes
No
Prior endocrine therapy for metastasis or
recurrence (Do not include steroids given with
chemotherapy.)
Yes
No
Prior adjuvant chemotherapy (Include pre-op
chemotherapy at diagnosis.)
Yes
No
Prior chemotherapy for metastasis or recurrence
Yes
No
Prior adjuvant high dose
chemotherapy/Autologous stem cell transplant
(HDC/ASCT )
Yes
No
Prior HDC/ASCT for metastasis or recurrence
Yes
No
Prior Aromatase Inhibitors therapy?
Yes
No
Prior adjuvant trastuzumab?
Yes
No
Prior immunotherapy for metastasis or recurrence
Yes
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No
Prior adjuvant other therapy
Yes
No
Yes, specify (If)
Prior other therapy for metastasis or recurrence
Yes
No
Yes, specify (If)
Prior Systemic Regimens
Prior treatment regimen name (s)
Start date
End date
Prior treatment regimen type
Adjuvant (Adjuvant)
Advanced (Advanced)
Required Laboratory Values
Granulocytes
Platelet count
Creatinine
Bilirubin
Bilirubin ULN
SGPT
SGPT (ALT) ULN
SGOT
SGOT (AST) ULN
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Baseline LVEF
International Normalization Ratio (INR)
HER2/neu Final Diagnosis  (Mark one with an X)
Negative (Negative)
Positive (Positive)
Marker Test Method (Mark one with an X)
Fluorescence In Situ Hybridization (fish)
(Fluorescence in situ hybridization
(FISH))
Immunohistochemistry (ihc)
(Immunohistochemistry (IHC))
Other, Specify (Other)
Serum Extracellular Domain (ecd) Test
(Serum ECD test)
IHC Lab Value
+1 (+1)
+2 (+2)
+3 (+3)
0 (0)
FISH lab value
Negative (Negative)
Positive (Positive)
Serum HER2 ECD results (ng/mL)
Other, specify
Completed by
Date Form Completed
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ACNS0122 Follow-up Worksheet
NCT00047320
ACNS0122 Follow-up Worksheet NCT00047320 
Neoadjuvant Chemotherapy With or Without Second-Look
Surgery Followed by Radiation Therapy With or Without
Peripheral Stem Cell Transplantation in Treating Patients
With Intracranial Germ Cell Tumors
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=BD7AAA29-
31DD-2A8B-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/10946
ACNS0122 Follow-up Worksheet
NCT00047320
Header
COG Study No
Institution Name
COG Patient ID
Patient Initials
Today's date
Date worksheet entered into RDE
Reporting Period Start Date
Reporting Period End Date
Follow-up Studies
Type [imaging studies]
Mri (MRI of Brain with gadolinium)
Mri (MRI of Spine with gadolinium)
Other, Specify (Other, specify)
Specify [other type of imaging study]
Date
Disease Status
Was the patient's disease status evaluated during
this reporting interval?
Yes
No
Type of response
Complete Response (Complete
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Response (CR))
Death Prior To Completion Of Protocol
Criteria (Early death)
Incomplete Response Or Stable
Disesase (Incomplete response/SD)
Less than Partial Response (<PR) (Less
than Partial Response (<PR))
Insufficient Evaluation (Not evaluable)
Partial Response (Partial Response
(PR))
Partial Response (Progressive Disease
(PD))
Recurrent Disease (Recurrent Disease)
Stable Disease (Stable Disease)
Date
Comments
Evaluations
Was a Neurologic assessment done?
No (No)
Not done/not available (Not done/not
available)
Unknown (Unknown)
Yes (Yes)
Was endocrinologic evaluation done?
No (No)
Not done/not available (Not done/not
available)
Unknown (Unknown)
Yes (Yes)
Significant Events During This Reporting
Period
Has a new primary cancer or MDS been
diagnosed that has not been previously reported?
Yes
No
Date SMN diagnosed
Life status at the end of this reporting period
Alive (Alive)
Dead (Dead)
Was the patient confirmed lost to follow-up at the
end of this reporting period?
Yes
No
Was the patient enrolled on another COG
therapeutic study at the end of the reporting
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period?
Yes
No
Did the patient withdraw consent for follow-up at
the end of the reporting period?
Yes
No
Did the patient receive non-protocol anti-cancer
treatment during this reporting period?
Yes
No
Type [non-protocol treatment] (Types of
Treatment)
Bone Marrow Transplant (Bone Marrow
Transplant)
Chemotherapy (Chemotherapy)
Extensive Radiation (Extensive radiation)
Limited Radiation (Limited radiation)
Other Therapy (Other (specify))
Radiation (nos) (Radiation (NOS))
External Beam Radiation (Radiation
Therapy)
Surgery (Surgery)
Specify [other type of non-protocol treatment]
Start Date [non-protocol treatment]
End Date [non-protocol treatment]
Description (drug, dose, etc.)
Ccrr Module For Acns0122 Follow-up
Worksheet
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ADVL0212: Eligibility Worksheet
(Leukemia) NCT00053963
ADVL0212: Eligibility Worksheet (Leukemia) NCT00053963
FR901228 in Treating Children With Refractory or
Recurrent Solid Tumors or Leukemia
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=C0F2D219-
E599-53B9-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/10947
ADVL0212: Eligibility Worksheet
(Leukemia) NCT00053963
Header
Institution Name
COG Study Number
COG Study Number
COG Patient ID
Patient's Initials
Eligibility Assessment
Is the planned start of treatment within five
working days of fulfilling all eligibility criteria?
Yes
No
Is patient less than 22 years of age at the time of
study entry?
Yes
No
Does patient have histologic verification of the
malignancy at original diagnosis
Yes
No
Is patient's disease considered refractory to
conventional therapy, or is there no existing
effective conventional therapy
Yes
No
If patient has a CNS tumor, were neurologic
deficits relatively stable for a minimum of two
weeks prior to study entry?
N/a, Patient Does Not Have A Cns Tumor
(N/A, patient does not have a CNS
tumor)
No (No)
Yes (Yes)
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Karnofsky Performance Score
90 (Able to carry on normal activity,
minor signs or symptoms of disease.)
70 (Cares for self. Unable to carry on
normal activity or to do active work.)
0 (Dead.)
40 (Disabled, requires special care and
assistance.)
20 (Hospitalization necessary, very sick,
active supportive treatment necessary,)
10 (Moribund, fatal processes
progressing rapidly.)
80 (Normal activity with effort, some
signs or symptoms of disease.)
100 (Normal, no complaints, no evidence
of disease.)
50 (Requires considerable assistance
and frequent medical care.)
60 (Requires occasional assistance, but
is able to care for most of own needs.)
30 (Severely disabled, hospitalization is
indicated although death is not
imminent.)
Lansky Play Score
80 (Active, but tires more quickly.)
70 (Both greater restriction of and less
time spent in play activity.)
100 (Fully active, normal.)
50 (Gets dressed but lies around much
of the day, no active play, able to
participate in all quiet play and activities.)
30 (In bed; needs assistance even for
quiet play.)
90 (Minor restrictions in physically
strenuous activity.)
40 (Mostly in bed; participates in quiet
activities.)
10 (No play; does not get out of bed.)
20 (Often sleeping; play entirely limited
to very passive activities.)
0 (Unresponsive.)
60 (Up and around, but minimal active
play; keeps busy with quieter activities.)
Does patient have a life expectancy of greater
than or equal to 8 weeks?
Yes
No
Has patient fully recovered from the acute toxic
effects of all prior chemotherapy, immunotherapy,
or radiotherapy prior to entering this study?
Yes
No
Did patient receive growth factors within 1 week
of entry onto this study?
Yes
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No
If patient has a CNS tumor and is receiving
dexamethasone, is patient on a stable dose for at
least two weeks prior to study entry?
N/a, Patient Does Not Have A Cns Tumor
(N/A, patient does not have a CNS
tumor)
N/a, Patient Has A Cns Tumor, But Is Not
Receiving Dexamethasone (N/A, patient
has CNS tumor, but is not receiving
dexamethasone)
No (No)
Yes (Yes)
Is patient receiving enzyme-inducing
anticonvulsant drugs?
Yes
No
Does patient have adequate bone marrow
function?
Yes
No
Does patient have adequate renal function?
Yes
No
Does patient have adequate liver function?
Yes
No
Does patient have adequate cardiac function?
Yes
No
Does patient have adequate pulmonary function?
Yes
No
Does patient have adequate central nervous
system function?
Yes
No
If female and post-menarchal, was a pregnancy
test obtained?
N/a, Patient Is Female, But Not Post-
menarchal (N/A, patient is female, but
not post-menarchal)
N/a, Patient Is Male (N/A, patient is
male)
No (No)
Yes (Yes)
is the patient pregnant?
No (No)
No, And Not Nursing (no, and not
nursing)
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No, But Nursing (no, but nursing)
Yes (Yes)
has he or she agreed to use an effective
contraceptive method?
N/a, Patient Is Not Of Reproductive
Potential (N/A, patient is not of
reproductive potential)
No (No)
Yes (Yes)
Does patient have an uncontrolled infection?
Yes
No
agent name
Has patient previously received Depsipeptide?
Yes
No
Does patient have the following: Symptoms of
congestive heart failure, Uncontrolled cardiac
rhythm disturbance, or QTC that is greater than
or equal to 480 msec
Yes
No
Date informed consent signed
Comments
Comments
Treatment Assignment
Dose level/duration assignment
Ccrr Module For Advl0212: Eligibility
Worksheet (leukemia)
4 / 4
ADVL0212: Eligibility Worksheet (Leukemia) NCT00053963
E3201 Second Primary Form
NCT00068692
E3201 Second Primary Form NCT00068692
Comparison of Adjuvant Chemotherapy Regimens in
Treating Patients With Stage II or Stage III Rectal Cancer
Who Are Receiving Radiation Therapy and Fluorouracil
Before or After Surgery
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=B5523D6D-
210C-6DCB-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/10948
E3201 Second Primary Form
NCT00068692
Header
ECOG Protocol Number (If patient has been on
other therapeutic ECOG protocols, please list
protocols and patient ID numbers.)
ECOG Patient ID (If patient has been on other
therapeutic ECOG protocols, please list protocols
and patient ID numbers.)
DCI Name
Registration Step
Time period
Second Primary (Second Primary)
Patient Initials
Participating Group Protocol No.
Participating Group Patient ID
Institution/Affiliate
Are data amended? (If yes, please circle
amended items in red)
Yes
No
Second primary cancer assessment
Date of Diagnosis of Second Primary Cancer
Site of Second Primary Cancer
Include information on histologic subtype(s).
1 / 2
Briefly describe cancer therapy the patient has
received prior to the diagnosis of the second
primary and other than that given on ECOG
protocols:
Briefly describe treatment planned or given for
the diagnosis of this second primary:
Comments
Comments
Investigator Signature
Investigator Signature Date
Ccrr Module For E3201 Second Primary
Form
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E3201 Patient Bowel Function/Uniscale
Questionnaire NCT00068692
E3201 Patient Bowel Function/Uniscale Questionnaire
NCT00068692
Comparison of Adjuvant Chemotherapy Regimens in
Treating Patients With Stage II or Stage III Rectal Cancer
Who Are Receiving Radiation Therapy and Fluorouracil
Before or After Surgery
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=B552120F-
3E84-6D21-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/10949
E3201 Patient Bowel
Function/Uniscale Questionnaire
NCT00068692
Header
DCI Name
Registration Step
Time Period (Group 1)
18+/- 2 Months Post Rt (18+/- 2 months
Post RT)
Last Week Of Rt (Last week of RT)
Prior To Surgery (Prior to surgery)
Study Entry (Study Entry)
Time Period (Group 2)
18 +/- 2 Months Post Rt (18 +/- 2 months
post RT)
Last Week Of Rt (Last week of RT)
Prior To Rt (Prior to RT)
Prior To Surgery (Prior to surgery)
Study Entry (Study Entry)
Patient Initials
ECOG Protocol Number
ECOG Protocol Number
ECOG Patient ID
ECOG Patient ID
Participating Group Protocol No.
Participating Group Patient ID
Institution/Affiliate
1 / 3
Patient Bowel Function
Are data amended?
Yes
No
Overall, would you say that you had problems
with your bowel function in the last week?
Yes
No
In the past week, what is the greatest number of
bowel movements you have had in a day?
In the past week, have you had a problem
causing you to get up at night to have a bowel
movement?
Yes
No
In the past week, have you had a problem
causing you to lose control of your bowel
movements?
Yes
No
In the past week, have you had a problem
causing you to have a bowel movement within 30
minutes of a prior bowel movement?
Yes
No
In the past week, have you had to wear protective
clothing or a pad in case you lost control of a
bowel movement?
Yes
No
In the past week, have you had a problem
causing you to be unable to tell the difference
between a stool and gas?
Yes
No
In the past week, have you had a problem
causing you to have stools that are liquid?
Yes
No
In the past week, have you found that once you
feel the urge to have a bowel movement, you
must do so within 15 minutes to avoid an
accident?
Yes
No
In the past week, have you had cramping with a
bowel movement?
Yes
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No
Is your cramping
Mild (mild)
Moderate (moderate)
Severe (severe)
In the past week, have you had blood in your
bowel movement?
Yes
No
Check the description that best describes the
amount of blood in your bowel movement
Enough To Turn Water In Toliet Bowel
Red (enough to turn water in toliet bowel
red)
Mixed With Or Coating Bowel Movement
(mixed with or coating bowel movement)
On Toliet Tissue Only (on toliet tissue
only)
In the past week, how much have problems with
bowel movements affected your normal
activities?
Mild - Not Interfering With Normal Life
Activities (mild - not interfering with
normal life activities)
Moderate - Requires Changes In One's
Life Activities Due To Bowel Function
(Moderate - requires changes in one's
life activities due to bowel function)
No Problems (no problems)
Severe - Unable To Perform Normal Life
Activities Due To Bowel Function (Severe
- unable to perform normal life activities
due to bowel function)
Please circle a number below to indicate how you
would rate your quality of life during the past
week
Ccrr Module For E3201 Patient Bowel
Function/uniscale Questionnaire
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E3201 Assessment Compliance Form
NCT00068692
E3201 Assessment Compliance Form NCT00068692
Comparison of Adjuvant Chemotherapy Regimens in
Treating Patients With Stage II or Stage III Rectal Cancer
Who Are Receiving Radiation Therapy and Fluorouracil
Before or After Surgery
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=B5520E12-
96C0-6D1C-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
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E3201 Assessment Compliance
Form NCT00068692
Header
DCI Name
Registration Step
Time Period (Group 1)
18+/- 2 Months Post Rt (18+/- 2 months
Post RT)
Last Week Of Rt (Last week of RT)
Prior To Surgery (Prior to surgery)
Study Entry (Study Entry)
Time Period (Group 2)
18 +/- 2 Months Post Rt (18 +/- 2 months
post RT)
Last Week Of Rt (Last week of RT)
Prior To Rt (Prior to RT)
Prior To Surgery (Prior to surgery)
Study Entry (Study Entry)
Patient Initials
ECOG Protocol Number
ECOG Protocol Number
ECOG Patient ID
ECOG Patient ID
Participating Group Protocol No.
Participating Group Patient ID
Institution/Affiliate
Assessment Compliance
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Are data amended?
Yes
No
Date assessment completed
Were both of the quality of life forms completed
for this timepoint?
Yes
No
Indicate primary reason why form was not
completed (Choose one:)
Assessment Not Required Per Protocol
Please Specify (assessment not required
per protocol please specify)
Other, Please Specify (other, please
specify)
Patient Did Not Show Up In Clinic/office
Please Specify (patient did not show up
in clinic/office please specify)
Patient Expired (patient expired)
Patient Not Given Form By Staff (patient
not given form by staff)
Patient Refusal (patient refusal)
Patient Too Ill (patient too ill)
Staff Thought Patient Too Ill (staff
thought patient too ill)
Staff Unavailable (staff unavailable)
Unable To Accommodate Disability Or
Language Needs Please Specify (unable
to accommodate disability or language
needs please specify)
unable to accommodate disability or language
needs please specify
patient did not show up in clinic/office please
specify
assessment not required per protocol please
specify
Was Assessment self-administered? (Choose
one:)
No (no)
Unknown (unknown)
Yes (yes)
How was patient assisted? (Choose one:)
Completed Independently By Another
Person (completed independently by
another person)
Patient Required Clarification Of
Questions Or Instructions (patient
required clarification of questions or
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instructions)
Patient Required Other Assistance
(patient required other assistance)
Questions Were Read Aloud To Patient
(questions were read aloud to patient)
what was the reason for assistance? (Choose
one:)
Disability, Please Specify (disability,
please specify)
Language Difficulty (questions Needed
To Be Translated), Specify Language
(language difficulty (questions needed to
be translated), specify language)
Literacy Difficulty (patient Could Not
Read Well Enough) (literacy difficulty
(patient could not read well enough))
Other, Please Specify (other, please
specify)
Telephone Interview (telephone
interview)
specify language
please specify
other, please specify
other, please specify
Who assisted or completed assessment?
(Choose one:)
Family (family)
Friend (friend)
Other, Please Specify (other, please
specify)
Staff (staff)
other, please specify
Comments
Ccrr Module For E3201 Assessment
Compliance Form
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E3201 FACT-D Subscale NCT00068692
E3201 FACT-D Subscale NCT00068692
Comparison of Adjuvant Chemotherapy Regimens in
Treating Patients With Stage II or Stage III Rectal Cancer
Who Are Receiving Radiation Therapy and Fluorouracil
Before or After Surgery
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=B5521641-
4600-6D2A-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/10951
E3201 FACT-D Subscale
NCT00068692
Header
DCI Name
Registration Step
Time Period (Group 1)
18+/- 2 Months Post Rt (18+/- 2 months
Post RT)
Last Week Of Rt (Last week of RT)
Prior To Surgery (Prior to surgery)
Study Entry (Study Entry)
Time Period (Group 2)
18 +/- 2 Months Post Rt (18 +/- 2 months
post RT)
Last Week Of Rt (Last week of RT)
Prior To Rt (Prior to RT)
Prior To Surgery (Prior to surgery)
Study Entry (Study Entry)
Patient Initials
ECOG Protocol Number
ECOG Protocol Number
ECOG Patient ID
ECOG Patient ID
Participating Group Protocol No.
Participating Group Patient ID
Institution/Affiliate
Patient Bowel Function
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Assessment Date
I have control of my bowels
A Little Bit (a little bit)
Not At All (not at all)
Quite A Bit (quite a bit)
Somewhat (somewhat)
Very Much (very much)
I move my bowels more frequently than usual
A Little Bit (a little bit)
Not At All (not at all)
Quite A Bit (quite a bit)
Somewhat (somewhat)
Very Much (very much)
I am afraid to be far from a toliet
A Little Bit (a little bit)
Not At All (not at all)
Quite A Bit (quite a bit)
Somewhat (somewhat)
Very Much (very much)
I have to limit my social activity because of
diarrhea
A Little Bit (a little bit)
Not At All (not at all)
Quite A Bit (quite a bit)
Somewhat (somewhat)
Very Much (very much)
I have to limit my physical activity because of
diarrhea
A Little Bit (a little bit)
Not At All (not at all)
Quite A Bit (quite a bit)
Somewhat (somewhat)
Very Much (very much)
I have to limit my sexual activity because of
diarrhea
A Little Bit (a little bit)
Not At All (not at all)
Quite A Bit (quite a bit)
Somewhat (somewhat)
Very Much (very much)
I am embarrassed by having diarrhea
A Little Bit (a little bit)
Not At All (not at all)
Quite A Bit (quite a bit)
Somewhat (somewhat)
Very Much (very much)
I have abdominal cramps or discomfort due to my
diarrhea
A Little Bit (a little bit)
Not At All (not at all)
Quite A Bit (quite a bit)
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Somewhat (somewhat)
Very Much (very much)
My problem with diarrhea keeps/wakes me up at
night
A Little Bit (a little bit)
Not At All (not at all)
Quite A Bit (quite a bit)
Somewhat (somewhat)
Very Much (very much)
I must move my bowels frequently to avoid
accidents
A Little Bit (a little bit)
Not At All (not at all)
Quite A Bit (quite a bit)
Somewhat (somewhat)
Very Much (very much)
I wear protection for soiling of stool
A Little Bit (a little bit)
Not At All (not at all)
Quite A Bit (quite a bit)
Somewhat (somewhat)
Very Much (very much)
Ccrr Module For E3201 Fact-d Subscale
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E3201 Late Radiation Toxicity Form
NCT00068692
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Comparison of Adjuvant Chemotherapy Regimens in
Treating Patients With Stage II or Stage III Rectal Cancer
Who Are Receiving Radiation Therapy and Fluorouracil
Before or After Surgery
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=B552378A-
6219-6DC3-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/10952
E3201 Late Radiation Toxicity Form
NCT00068692
Header
ECOG Protocol Number
ECOG Patient ID
DCI Name
Registration Step
Patient Initials
Participating Group Protocol No.
Participating Group Patient ID
Institution/Affiliate
Off Treatment Time Period
108 months (9 years) (108 months (9
years))
12 Months (12 months)
120 months (10 years) (120 months (10
years))
15 Months (15 months)
18 Months (18 months)
24 Months (24 months)
3 Months (3 months)
30 Months (30 months)
36 Months (36 months)
42 Months (42 months)
48 Months (48 months)
54 Months (54 months)
6 Months (6 months)
60 Months (60 months)
72 months (6 years) (72 months (6
years))
84 months (7 years) (84 months (7
years))
9 Months (9 months)
96 months (8 years) (96 months (8
years))
1 / 2
Are data amended? (If yes, please circle
amended items in red)
Yes
No
Adverse event assessment
Adverse Event Reporting From Date
Adverse Event Reporting to Date
CTC Adverse Event Term
CTC Adverse Event Grade
CTC Adverse Event Attribution Code
Definite (definitely)
Possible (possibly)
Probable (probably)
Unlikely (unlikely)
Unrelated (unrelated)
Comments
Comments
Investigator Signature
Investigator Signature Date
Ccrr Module For E3201 Late Radiation
Toxicity Form
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E5202 Second Primary Form
NCT00217737
E5202 Second Primary Form NCT00217737
Oxaliplatin, Leucovorin, and Fluorouracil With or Without
Bevacizumab in Treating Patients Who Have Undergone
Surgery for Stage II Colon Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=EF10FE03-
E5AD-7423-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/10953
E5202 Second Primary Form
NCT00217737
Header
ECOG Protocol Number
ECOG Patient ID
DCI Name
Registration Step
Time period
Second Primary Cancer (Second
Primary)
Patient Initials
Patient demographics
Participating Group Protocol Number
Institution/Affiliate
Participating Group Patient ID
Are data amended (If yes, please circle amended
items in red)
Yes
No
Second primary cancer assessment
Date of Diagnosis of Second Primary Cancer
Site of Second Primary Cancer
Include information on histologic subtype (s)
Briefly describe cancer therapy the patient has
received prior to the diagnosis of the second
primary and other than that given on ECOG
1 / 2
protocols
Briefly describe treatment planned or given for
the diagnosis of this second primary
Comments
Comments
Investigator Signature
Investigator Signature Date
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E5202 Source Document Tracking
Coversheet NCT00217737
E5202 Source Document Tracking Coversheet
NCT00217737 
Oxaliplatin, Leucovorin, and Fluorouracil With or Without
Bevacizumab in Treating Patients Who Have Undergone
Surgery for Stage II Colon Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=852743C1-
364D-5F08-E040-BB89AD431700
All rights reserved. Please visit https://medical-data-
models.org/forms/10954
E5202 Source Document Tracking
Coversheet  NCT00217737
Header
ECOG Protocol Number
ECOG Patient ID
DCI Name
Registration Step
Reporting Period
Baseline Step 1 (Baseline step 1)
Recurrence (Recurrence)
Second Primary Cancer (Second
primary)
Patient demographics
Patient Initials (Last, First)
ECOG Protocol Number
ECOG Patient ID
Participating Group Protocol Number
Participating Group Patient ID
Institution/Affiliate
Footer module
Document type
Biopsy (Biopsy)
Colonoscopy (Colonoscopy)
Ct Scan Report (CT scan report)
Mri Scan Report (MRI scan report)
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Other (Other)
Pathology Report (Pathology Report)
Pet Scan Report (PET scan report)
Surgical Report (Surgical Report)
Other, specify
Report Created Date
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CALGB-10501 Chronic Lymphocytic Leukemia
(CLL) First Treatment Form NCT00513747
CALGB-10501 Chronic Lymphocytic Leukemia (CLL) First
Treatment Form NCT00513747 
Early or Delayed Fludarabine and Rituximab in Treating
Patients With Previously Untreated Chronic Lymphocytic
Leukemia
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=3410315B-
B495-28F5-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/10956
CALGB-10501 Chronic Lymphocytic
Leukemia (CLL) First Treatment
Form NCT00513747
Header
CALGB Form
CALGB Study No
CALGB Patient ID
Reporting Period Start Date (MM DD YYYY)
Reporting Period End Date (MM DD YYYY)
Are data amended
Yes
No
Patient demographics
Patient Initials (Last, First Middle)
Patient Hospital No.
Institution/Affiliate
Participating Group
Participating Group Study No
Participating Group Patient ID
Patient Data
Did the patient receive any protocol treatment? (If
no, skip to reason treatment ended.)
Yes
No
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Weight (kg)
BSA
Performance Status (Mark one with an X at end
of cycle)
Fully Active, Able To Carry On All Pre-
disease Performance Without
Restriction. (0)
Restricted In Physically Strenuous
Activity But Ambulatory And Able To
Carry Out Work Of A Light Or Sedentary
Nature, E.g., Light Housework, Office
Work. (1)
Ambulatory And Capable Of All Selfcare
But Unable To Carry Out Any Work
Activities. Up And About More Than 50%
Of Waking Hours. (2)
Capable Of Only Limited Selfcare,
Confined To Bed Or Chair More Than
50% Of Waking Hours. (3)
Completely Disabled. Cannot Carry On
Any Selfcare. Totally Confined To Bed Or
Chair. (4)
First Treatment (cycles 1 ¿ 6)
Cycle Number (Mark one with an X.)
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
Creatinine (mg/dL)
Did creatinine change > 25% during this time
period
Yes
No
Agent Name
Date Agent Administered (MM DD YYYY
Rituximab dose data)
Agent Dose (mg/m^2 Rituximab dose data)
Total Daily Dose of Agent (or Drug) (mg
Rituximab dose data)
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Total Dose of Agents/Drugs for this Cycle (mg
Rituximab dose data)
Were there any adverse events during or
immediately following the Rituximab infusion
during this reporting cycle
Yes
No
Lab Data
Hemoglobin (g/dL)
Peripheral WBC Count (x 1000/uL)
Absolute Neutrophil Count (x 1000/uL)
Peripheral Platelet Count (x 1000/uL)
Lactate Dehydrogenase (LDH) (U/L)
Albumin (mg/dL)
IgG (mg/dL Cycle 1 only)
IgA (mg/dL Cycle 1 only)
IgM (mg/dL Cycle 1 only)
Dose Modifications
Were there any dose modifications or
additions/omissions to protocol treatment? (Mark
one with an X.)
No (No)
Unknown (Unknown)
Yes, Planned (i.e., The Treatment Was
Changed According To Protocol
Guidelines) (Yes, planned)
Yes, Unplanned (i.e., The Treatment
Change Was Not Part Of Protocol
Guidelines) (Yes, unplanned)
Specify reason for modification
Criteria For Treatment
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A minimum of any one of the following disease-
related symptoms must be present
Drenching Night Sweats More Than 3
Times Per Week Without Evidence Of
Infection That Require The Patient To
Change Clothes (Drenching night sweats
more than 3 times per week without
evidence of infection that require the
patient to change clothes)
Evidence Of Progressive Marrow Failure
As Manifested By Autoimmune Anemia
Or Thrombocytopenia Poorly Responsive
To Corticosteroid Therapy (Evidence of
progressive marrow failure as manifested
by autoimmune anemia or
thrombocytopenia poorly responsive to
corticosteroid therapy)
Evidence Of Progressive Marrow Failure
As Manifested By Hemoglobin <11 G/dl
In The Absence Of Autoimmune
Hemolytic Anemia (Evidence of
progressive marrow failure as manifested
by hemoglobin <11 g/dL in the absence
of autoimmune hemolytic anemia)
Evidence Of Progressive Marrow Failure
As Manifested By Lymphocyte Count >
300 X 10^9 /l (Evidence of progressive
marrow failure as manifested by
lymphocyte count > 300 x 10^9 /L)
Evidence Of Progressive Marrow Failure
As Manifested By Massive (i.e., >6 Cm
Below The Left Costal Margin) Or
Progressive Splenomegaly That Is
Causing Pain Or Significantly Early
Satiety (Evidence of progressive marrow
failure as manifested by massive (i.e., >6
cm below the left costal margin) or
progressive splenomegaly that is
causing pain or significantly early satiety)
Evidence Of Progressive Marrow Failure
As Manifested By Massive Nodes Or
Clusters (i.e., >10 Cm In Longest
Diameter) Or Progressive
Lymphadenopathy That Is Causing Pain
Or Significant Disfigurement (Evidence
of progressive marrow failure as
manifested by massive nodes or clusters
(i.e., >10 cm in longest diameter) or
progressive lymphadenopathy that is
causing pain or significant disfigurement)
Evidence Of Progressive Marrow Failure
As Manifested By Thrombocytopenia
<100 X 10^12 /l In The Absence Of
Idiopathic Thrombocytopenia Purpura
(Evidence of progressive marrow failure
as manifested by thrombocytopenia
<100 x 10^12 /L in the absence of
idiopathic thrombocytopenia purpura)
Extreme Fatigue (Extreme fatigue)
4 / 5
CALGB-10501 Chronic Lymphocytic Leukemia (CLL) First Treatment
Form NCT00513747
Fevers Of Greater Than 100.5 Degrees F
For 2 Weeks Without Evidence Of
Infection (Fevers of greater than 100.5
degrees F for 2 weeks without evidence
of infection)
Other Disease Related Symptoms (skin
Infitration, Vasculitis, Pemphigus) (Other
disease related symptoms (skin
infitration, vasculitis, pemphigus))
Weight Loss Of 10% Or More Within The
Previous 6 Months (Weight loss of 10%
or more within the previous 6 months)
Date of Symptom/Event Assessment (MM DD
YYYY)
Reason Treatment Ended
Reason Treatment Ended (Mark one with an X.)
Adverse Event/side Effects/complications
(Adverse Event/Side
Effects/Complications)
Alternative Therapy (Alternative therapy)
Death On Study (Death on study)
Disease Progression Before Active
Treatment (Disease Progression before
active treatment)
Disease Progression, Relapse During
Active Treatment (Disease progression,
relapse during active treatment)
Other (Other)
Patient Off-treatment For Other
Complicating Disease (Patient off-
treatment for other complicating disease)
Patient Withdrawal Or Refusal After
Beginning Protocol Therapy (Patient
withdrawal/refusal after beginning
protocol therapy)
Patient Withdrawal Or Refusal Before
Beginning Protocol Therapy (Patient
withdrawal/refusal prior to beginning
protocol therapy)
Treatment Completed Per Protocol
Criteria (Treatment completed per
protocol criteria)
Other specify
Overall Response
Completed by (print or type name)
Date Form Completed (MM DD YYYY)
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E3201 Surgery Form NCT00068692
E3201 Surgery Form NCT00068692
Comparison of Adjuvant Chemotherapy Regimens in
Treating Patients With Stage II or Stage III Rectal Cancer
Who Are Receiving Radiation Therapy and Fluorouracil
Before or After Surgery
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=B5522261-
773C-6D97-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/10957
E3201 Surgery Form NCT00068692
Header
ECOG Protocol Number
ECOG Patient ID
Registration Step
Time Period
One month post surgery (One month
post surgery)
Study entry (Study entry)
Patient Initials
Participating Group Protocol No.
Participating Group Patient ID
Institution/Affiliate
Are data amended? (If yes, please circle
amended items in red)
Yes
No
Surgery assessment
Patient Group
Group I (Group I)
Group II (Group II)
Planned Surgery Type
Abdominal Perineal Resection
(abdominal perineal resection)
Low Anterior Resection (low anterior
resection)
Low Anterior Resection/coloanal
Anastomosis (low anterior
resection/coloanal anastomosis)
Other, Specify (other, specify)
other, specify (surgery)
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Pre-surgery tumor distance from the anal verge
Rectal tumor status
Fixed (fixed)
Mobile (mobile)
Tethered (tethered)
Did patient undergo surgical resection?
Yes
No
Reason surgery not performed
Surgery date
Do surgery results qualify patient for further
protocol therapy?
Yes
No
Primary surgery type
Abdominal Perineal Resection
(abdominal perineal resection)
Low Anterior Resection (low anterior
resection)
Low Anterior Resection/coloanal
Anastomosis (low anterior
resection/coloanal anastomosis)
Other, Specify (other, specify)
other, specify (surgery)
Was sphincter preserved?
Yes
No
Was there bowel perforation?
Yes
No
Was there bowel obstruction?
Yes
No
Was there tumor spillage?
Yes
No
Were all lymph nodes suggestive of disease
removed?
Yes
No
Was a complete resection done?
Yes
No
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Was completion of an en bloc resection of the
primary tumor documented?
No (no)
Unknown (Unknown)
Yes (yes)
Did the primary tumor adhere to or invade an
adjacent organ?
Yes
No
Specify organs
Number of lymph nodes examined
Number of lymph nodes removed
Distance from the tumor to distal bowel
Distance from the tumor to proximal bowel
Have the radial margins been documented as
grossly free of disease?
Yes
No
Have the radial margins been documented as
histologically free of disease?
Yes
No
Type of anastomosis
End-to-end (end-to-end)
End-to-side (end-to-side)
Was anastomosis stapled?
Yes
No
Was a pouch created?
Yes
No
Length of pouch
Tumor Statging
Pathologic T stage
T1 (T1)
T2 (T2)
T3 (T3)
T4 (T4)
Pathologic N Stage
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No Regional Lymph Node Metastasis
(N0)
Metastasis In 1 To 3 Regional Lymph
Nodes (N1)
Metastasis In 4 Or More Regional Lymph
Nodes (N2)
N3 (N3)
Pathologic M Stage
No Distant Metastasis (M0)
Distant Metastasis (M1)
Comments
Comments
Investigator Signature
Investigator Signature Date
Ccrr Module For E3201 Surgery Form
4 / 4
E3201 Surgery Form NCT00068692
E5204 FACT-D Subscale NCT00303628
E5204 FACT-D Subscale NCT00303628
Combination Chemotherapy With or Without Bevacizumab
in Treating Patients Who Have Had Surgery for Stage II or
Stage III Rectal Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=08EBCA50-
68B9-62C3-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/10958
E5204 FACT-D Subscale
NCT00303628
Header
DCI Name
Registration Step
Reporting Period
12 Months Post-chemotherapy (12
months post-chemotherapy)
3 Months Post-chemotherapy (3 months
post-chemotherapy)
Baseline (Baseline)
Cycle 4, Day 1 (Cycle 4, Day 1)
Patient Initials
ECOG Protocol Number
ECOG Protocol Number
ECOG Patient ID
ECOG Patient ID
Participating Group Protocol No.
Participating Group Patient ID
Institution/Affiliate
Patient Bowel Function
Assessment Date
I have control of my bowels
A Little Bit (a little bit)
Not At All (not at all)
Quite A Bit (quite a bit)
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Somewhat (somewhat)
Very Much (very much)
I move my bowels more frequently than usual
A Little Bit (a little bit)
Not At All (not at all)
Quite A Bit (quite a bit)
Somewhat (somewhat)
Very Much (very much)
I am afraid to be far from a toliet
A Little Bit (a little bit)
Not At All (not at all)
Quite A Bit (quite a bit)
Somewhat (somewhat)
Very Much (very much)
I have to limit my social activity because of
diarrhea
A Little Bit (a little bit)
Not At All (not at all)
Quite A Bit (quite a bit)
Somewhat (somewhat)
Very Much (very much)
I have to limit my physical activity because of
diarrhea
A Little Bit (a little bit)
Not At All (not at all)
Quite A Bit (quite a bit)
Somewhat (somewhat)
Very Much (very much)
I have to limit my sexual activity because of
diarrhea
A Little Bit (a little bit)
Not At All (not at all)
Quite A Bit (quite a bit)
Somewhat (somewhat)
Very Much (very much)
I am embarrassed by having diarrhea
A Little Bit (a little bit)
Not At All (not at all)
Quite A Bit (quite a bit)
Somewhat (somewhat)
Very Much (very much)
I have abdominal cramps or discomfort due to my
diarrhea
A Little Bit (a little bit)
Not At All (not at all)
Quite A Bit (quite a bit)
Somewhat (somewhat)
Very Much (very much)
My problem with diarrhea keeps/wakes me up at
night
A Little Bit (a little bit)
Not At All (not at all)
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Quite A Bit (quite a bit)
Somewhat (somewhat)
Very Much (very much)
I must move my bowels frequently to avoid
accidents
A Little Bit (a little bit)
Not At All (not at all)
Quite A Bit (quite a bit)
Somewhat (somewhat)
Very Much (very much)
I wear protection for soiling of stool
A Little Bit (a little bit)
Not At All (not at all)
Quite A Bit (quite a bit)
Somewhat (somewhat)
Very Much (very much)
Investigator Signature
Investigator Signature
Investigator Signature Date
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E3201 Patient Bowel Function/Uniscale
Questionnaire NCT00068692
E3201 Patient Bowel Function/Uniscale Questionnaire
NCT00068692
Comparison of Adjuvant Chemotherapy Regimens in
Treating Patients With Stage II or Stage III Rectal Cancer
Who Are Receiving Radiation Therapy and Fluorouracil
Before or After Surgery
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=08ED038D-
7845-6501-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/10959
E3201 Patient Bowel
Function/Uniscale Questionnaire
NCT00068692
Header
DCI Name
Registration Step
Time Period (Group 1)
18+/- 2 Months Post Rt (18+/- 2 months
Post RT)
Last Week Of Rt (Last week of RT)
Prior To Surgery (Prior to surgery)
Study Entry (Study Entry)
Time Period (Group 2)
18 +/- 2 Months Post Rt (18 +/- 2 months
post RT)
Last Week Of Rt (Last week of RT)
Prior To Rt (Prior to RT)
Prior To Surgery (Prior to surgery)
Study Entry (Study Entry)
Patient Initials
ECOG Protocol Number
ECOG Protocol Number
ECOG Patient ID
ECOG Patient ID
Participating Group Protocol No.
Participating Group Patient ID
Institution/Affiliate
1 / 3
Patient Bowel Function
Are data amended?
Yes
No
Overall, would you say that you had problems
with your bowel function in the last week?
Yes
No
In the past week, what is the greatest number of
bowel movements you have had in a day?
In the past week, have you had a problem
causing you to get up at night to have a bowel
movement?
Yes
No
In the past week, have you had a problem
causing you to lose control of your bowel
movements?
Yes
No
In the past week, have you had a problem
causing you to have a bowel movement within 30
minutes of a prior bowel movement?
Yes
No
In the past week, have you had to wear protective
clothing or a pad in case you lost control of a
bowel movement?
Yes
No
In the past week, have you had a problem
causing you to be unable to tell the difference
between a stool and gas?
Yes
No
In the past week, have you had a problem
causing you to have stools that are liquid?
Yes
No
In the past week, have you found that once you
feel the urge to have a bowel movement, you
must do so within 15 minutes to avoid an
accident?
Yes
No
In the past week, have you had cramping with a
bowel movement?
Yes
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No
Is your cramping
Mild (mild)
Moderate (moderate)
Severe (severe)
In the past week, have you had blood in your
bowel movement?
Yes
No
Check the description that best describes the
amount of blood in your bowel movement
Enough To Turn Water In Toliet Bowel
Red (enough to turn water in toliet bowel
red)
Mixed With Or Coating Bowel Movement
(mixed with or coating bowel movement)
On Toliet Tissue Only (on toliet tissue
only)
In the past week, how much have problems with
bowel movements affected your normal
activities?
Mild - Not Interfering With Normal Life
Activities (mild - not interfering with
normal life activities)
Moderate - Requires Changes In One's
Life Activities Due To Bowel Function
(Moderate - requires changes in one's
life activities due to bowel function)
No Problems (no problems)
Severe - Unable To Perform Normal Life
Activities Due To Bowel Function (Severe
- unable to perform normal life activities
due to bowel function)
Please circle a number below to indicate how you
would rate your quality of life during the past
week
Ccrr Module For E3201 Patient Bowel
Function/uniscale Questionnaire
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E5204 On-Study Form NCT00303628
E5204 On-Study Form NCT00303628
Combination Chemotherapy With or Without Bevacizumab
in Treating Patients Who Have Had Surgery for Stage II or
Stage III Rectal Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=089B43F4-
F7BD-38D3-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/10960
E5204 On-Study Form
NCT00303628
Header
ECOG Protocol Number
ECOG Patient ID
DCI Name
Registration Step
Report period
Baseline (Baseline)
Please mark an 'X' if data have been amended.
(Please circle amended items in red)
Date data amended (s - mm/dd/yyyy)
Patient demographics
Patient Initials (Last, First)
Participating Group Protocol Number
Institution/Affiliate
Participating Group Patient ID
Baseline Evaluation
ECOG Performance Status (at study entry)
Fully Active, Able To Carry On All Pre-
disease Performance Without
Restriction. (0=)
Restricted In Physically Strenuous
Activity But Ambulatory And Able To
Carry Out Work Of A Light Or Sedentary
Nature, E.g., Light Housework, Office
Work. (1=)
1 / 5
Ambulatory And Capable Of All Selfcare
But Unable To Carry Out Any Work
Activities. Up And About More Than 50%
Of Waking Hours. (2=)
Capable Of Only Limited Selfcare,
Confined To Bed Or Chair More Than
50% Of Waking Hours. (3=)
Completely Disabled. Cannot Carry On
Any Selfcare. Totally Confined To Bed Or
Chair. (4=)
Date CEA obtained (CEA - mm/dd/yyyy)
CEA Value (ng/ml)
CEA ULN
Is patient hypertensive
Yes
No
Is patient on anti-hypertensive therapy
Yes
No
Patient receiving full-dose anticoagulants
Yes
No
Weight (kg)
Weight 1 year ago (patient self-report - kg)
Height (cm)
Diabetes History
Diabetes Mellitus
Yes
No
Approximate year of diagnosis (yyyy)
Is patient insulin dependent
Yes
No
Approximate year insulin started (yyyy)
Does patient manage his/her diabetes with oral
medications
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Yes
No
Pathologic Staging
Histologic Grade (Differentiation) ([From pre-
treatment biopsy specimen])
Moderately Differentiated (Moderately
Differentiated (Grade II))
Poorly Differentiated (Poorly
differentiated (Grade III))
Undifferentiated (Undifferentiated (Grade
IV))
Well Differentiated (Well Differentiated
(Grade I))
Perforation
No (NO)
Unknown (UNKNOWN)
Yes (YES)
Obstruction
No (NO)
Unknown (UNKNOWN)
Yes (YES)
Clinical T Stage (Use the staging definitions in
Appendix V of the protocol)
Tumor Invades Submucosa (T1)
Tumor Invades Muscularis Propria (T2)
Tumor Invades Through The Muscularis
Propria Into The Subserosa, Or Into
Nonperitonealized Pericolic Or Perirectal
Tissues (T3)
Tumor Directly Invades Other Organs Or
Structures, And/or Perforates Visceral
Peritoneum (T4)
Clinical N Stage (Use the staging definitions in
Appendix V of the protocol)
No Regional Lymph Node Metastasis
(N0)
Metastasis In 1 To 3 Regional Lymph
Nodes (N1)
Metastasis In 4 Or More Regional Lymph
Nodes (N2)
Clinical M Stage (Use the staging definitions in
Appendix V of the protocol)
No Distant Metastasis (M0)
Stage Grouping Assessment Method
Ct Scan (CT Scan)
Endoscopic Ultrasound (Endoscopic
ultrasound)
Magnetic Resonance Imaging (MRI)
Physical Exam (Physical Exam)
Pathologic T Stage (Use the staging definitions in
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Appendix V of the protocol)
Tumor Invades Submucosa (T1)
Tumor Invades Muscularis Propria (T2)
Tumor Invades Through The Muscularis
Propria Into The Subserosa, Or Into
Nonperitonealized Pericolic Or Perirectal
Tissues (T3)
Tumor Directly Invades Other Organs Or
Structures, And/or Perforates Visceral
Peritoneum (T4)
Pathologic N Stage (Use the staging definitions in
Appendix V of the protocol)
No Regional Lymph Node Metastasis
(N0)
Metastasis In 1 To 3 Regional Lymph
Nodes (N1)
Metastasis In 4 Or More Regional Lymph
Nodes (N2)
Pathologic M Stage (Use the staging definitions
in Appendix V of the protocol)
No Distant Metastasis (M0)
Distant Metastasis (M1)
Biological Markers
Regimen Type Given
Xrt + 5-fu/lv (leucovorin) (XRT + 5-
FU/LV)
Xrt + Capecitabine (XRT + Capecitabine)
Xrt + Capecitabine + Oxaliplatin (XRT +
Capecitabine + Oxaliplatin)
Xrt + Ci 5-fu + Oxaliplatin (XRT + CI 5-
FU + Oxaliplatin)
Xrt + Ci 5-fu X 5d (XRT + CI 5-FU x 5d)
Xrt + Ci 5-fu X 7d (XRT + CI 5-FU x 7d)
Chemotherapy Begin Date (mm/dd/yyyy)
Chemotherapy End Date (mm/dd/yyyy)
RT Total Dose (Gy)
Total Number of Fractions
RT Begin Date (mm/dd/yyyy)
RT End Date (mm/dd/yyyy)
Prior Surgery For This Disease
Primary Surgery Type
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Abdominal Perineal Resection
(Abdominal perineal resection (APR))
Low Anterior Resection (Low anterior
resection (LAR))
Low Anterior Resection/coloanal
Anastomosis (Low anterior
resection/coloanal anastomosis
(LAR/CAA))
Other (Other)
Other specify
Primary Surgery Date (mm/dd/yyyy)
Was sphincter preserved
Yes
No
Was the tumor fixed to surrounding structures
Yes
No
Was a complete resection done?
Yes
No
Were all lymph nodes suggestive of disease
removed?
Yes
No
Number of Lymph Nodes Examined
Number of Positive Lymph Nodes
Baseline Abnormalities
CTC Adverse Event Term (include subterm if
applicable - Use CTCAE v3 terminology)
CTC Adverse Event Grade (Use grade 1-4 per
CTCAE v3)
Comments
Investigator Signature
Investigator Signature Date
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E5204 Patient Bowel Function/Uniscale
Questionnaire NCT00303628
E5204 Patient Bowel Function/Uniscale Questionnaire
NCT00303628
Combination Chemotherapy With or Without Bevacizumab
in Treating Patients Who Have Had Surgery for Stage II or
Stage III Rectal Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=08ED057C-
100B-64FF-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/10961
E5204 Patient Bowel
Function/Uniscale Questionnaire
NCT00303628
Header
ECOG Protocol Number
ECOG Protocol Number
ECOG Patient ID
ECOG Patient ID
DCI Name
Registration Step
Reporting Period
12 Months Post-chemotherapy (12
months post-chemotherapy)
3 Months Post-chemotherapy (3 months
post-chemotherapy)
Baseline (Baseline)
Cycle 4, Day 1 (Cycle 4, Day 1)
Patient Initials
Participating Group Protocol No.
Participating Group Patient ID
Institution/Affiliate
Assessment Date
Patient Bowel Function
Overall, would you say that you had problems
with your bowel function in the last week?
Yes
No
1 / 3
In the past week, what is the greatest number of
bowel movements you have had in a day?
In the past week, have you had a problem
causing you to get up at night to have a bowel
movement?
Yes
No
In the past week, have you had a problem
causing you to lose control of your bowel
movements?
Yes
No
In the past week, have you had a problem
causing you to have a bowel movement within 30
minutes of a prior bowel movement?
Yes
No
In the past week, have you had to wear protective
clothing or a pad in case you lost control of a
bowel movement?
Yes
No
In the past week, have you had a problem
causing you to be unable to tell the difference
between a stool and gas?
Yes
No
In the past week, have you had a problem
causing you to have stools that are liquid?
Yes
No
In the past week, have you found that once you
feel the urge to have a bowel movement, you
must do so within 15 minutes to avoid an
accident?
Yes
No
In the past week, have you had cramping with a
bowel movement?
Yes
No
Is your cramping
Mild (mild)
Moderate (moderate)
Severe (severe)
In the past week, have you had blood in your
bowel movement?
Yes
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No
Check the description that best describes the
amount of blood in your bowel movement
Enough To Turn Water In Toliet Bowel
Red (enough to turn water in toliet bowel
red)
Mixed With Or Coating Bowel Movement
(mixed with or coating bowel movement)
On Toliet Tissue Only (on toliet tissue
only)
In the past week, how much have problems with
bowel movements affected your normal
activities?
Mild - Not Interfering With Normal Life
Activities (mild - not interfering with
normal life activities)
Moderate - Requires Changes In One's
Life Activities Due To Bowel Function
(Moderate - requires changes in one's
life activities due to bowel function)
No Problems (no problems)
Severe - Unable To Perform Normal Life
Activities Due To Bowel Function (Severe
- unable to perform normal life activities
due to bowel function)
Please circle a number below to indicate how you
would rate your quality of life during the past
week
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E5202 Surgery Form NCT00217737
E5202 Surgery Form NCT00217737
Oxaliplatin, Leucovorin, and Fluorouracil With or Without
Bevacizumab in Treating Patients Who Have Undergone
Surgery for Stage II Colon Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=EFDC60F3-
98DE-1623-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/10962
E5202 Surgery Form NCT00217737
Header
ECOG Protocol Number
ECOG Patient ID
DCI Name
Registration Step
Report period
Baseline Step 1 (Baseline Step 1)
Are data amended (If yes, please circle amended
items in red.)
Yes
No
Patient demographics
Patient Initials
Participating Group Protocol Number
Institution/Affiliate
Participating Group Patient ID
Surgery assessment
Most Extensive Primary Surgery
Left Hemicolectomy (Left
Hemicolectomy)
Not Specified (Not Specified)
Other (Other)
Rectosigmoid Colectomy (Rectosigmoid
Colectomy)
Right Hemicolectomy (Right
Hemicolectomy)
Sigmoidectomy (Sigmoidectomy)
1 / 5
Total Abdominal Colectomy (Total
Abdominal Colectomy)
Transverse Colectomy (Transverse
Colectomy)
Other specify
Date of primary surgery
Proximal margin
Cannot Be Assessed (Cannot be
assessed)
Carcinoma In Situ/adenoma Absent At
Margin (Carcinoma in situ/adenoma
absent at margin)
Carcinoma In Situ/adenoma Present At
Margin (Carcinoma in situ/adenoma
present at margin)
Involved By Invasive Carcinoma
(Involved by invasive carcinoma)
Not Applicable (Not applicable)
Uninvolved By Invasive Carcinoma
(Uninvolved by invasive carcinoma)
Distal margin
Cannot Be Assessed (Cannot be
assessed)
Carcinoma In Situ/adenoma Absent At
Margin (Carcinoma in situ/adenoma
absent at margin)
Carcinoma In Situ/adenoma Present At
Margin (Carcinoma in situ/adenoma
present at margin)
Involved By Invasive Carcinoma
(Involved by invasive carcinoma)
Not Applicable (Not applicable)
Uninvolved By Invasive Carcinoma
(Uninvolved by invasive carcinoma)
Circumferential margin (Radial)
Cannot Be Assessed (Cannot be
assessed)
Carcinoma In Situ/adenoma Absent At
Margin (Carcinoma in situ/adenoma
absent at margin)
Carcinoma In Situ/adenoma Present At
Margin (Carcinoma in situ/adenoma
present at margin)
Involved By Invasive Carcinoma
(Involved by invasive carcinoma)
Not Applicable (Not applicable)
Uninvolved By Invasive Carcinoma
(Uninvolved by invasive carcinoma)
Mesenteric margin
Cannot Be Assessed (Cannot be
assessed)
Carcinoma In Situ/adenoma Absent At
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Margin (Carcinoma in situ/adenoma
absent at margin)
Carcinoma In Situ/adenoma Present At
Margin (Carcinoma in situ/adenoma
present at margin)
Involved By Invasive Carcinoma
(Involved by invasive carcinoma)
Not Applicable (Not applicable)
Uninvolved By Invasive Carcinoma
(Uninvolved by invasive carcinoma)
Distance of invasive carcinoma from nearest
margin (Complete one measurement.)
Other surgery related to tumor
Yes
No
If yes, describe operative procedure
Date of other surgery
Adjacent organs involved and resected
Yes
No
Specify organs
Pneumonia
No (No)
Unknown (Unknown)
Yes (Yes)
Pulmonary embolism
No (No)
Unknown (Unknown)
Yes (Yes)
Myocardial infarction
No (No)
Unknown (Unknown)
Yes (Yes)
Stroke
No (No)
Unknown (Unknown)
Yes (Yes)
DVT
No (No)
Unknown (Unknown)
Yes (Yes)
Bowel obstruction requiring surgery
No (No)
Unknown (Unknown)
Yes (Yes)
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Abscess (intra-abdominal)
No (No)
Unknown (Unknown)
Yes (Yes)
Anastomotic leak
No (No)
Unknown (Unknown)
Yes (Yes)
Fistula
No (No)
Unknown (Unknown)
Yes (Yes)
Wound infection
No (No)
Unknown (Unknown)
Yes (Yes)
Dehiscence
No (No)
Unknown (Unknown)
Yes (Yes)
Evisceration
No (No)
Unknown (Unknown)
Yes (Yes)
Urinary infection
No (No)
Unknown (Unknown)
Yes (Yes)
Regional implants
Yes
No
specify site
Mesentery (Mesentery)
Omentum (Omentum)
Peritoneum (Peritoneum)
Serosa (Serosa)
Tumor Configuration or Features
Polypoid (exophytic) (Exophytic)
Linitis Plastica (diffuse Infiltration)
(Infiltrative)
Other (Other)
Ulcerating (endophytic) (Ulcerating)
Other specify
Lymphatic (small vessel)
Absent (Absent)
Indeterminate (Indeterminate)
Present - Extramural (Present -
Extramural)
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Present - Intramural (Present -
Intramural)
Venous (large vessel)
Absent (Absent)
Indeterminate (Indeterminate)
Present - Extramural (Present -
Extramural)
Present - Intramural (Present -
Intramural)
Perineural
Absent (Absent)
Indeterminate (Indeterminate)
Present - Extramural (Present -
Extramural)
Present - Intramural (Present -
Intramural)
Intratumoral/peritumoral lymphocytic response
Marked (Marked)
Mild To Moderate (Mild to moderate)
None (None)
Description of tumor border configuration
Infiltrating (Infiltrating)
Pushing (Pushing)
None identified
Indeterminate (Indeterminate)
No (No)
Yes (Yes)
Adenoma (s)
Indeterminate (Indeterminate)
No (No)
Yes (Yes)
Chronic ulcerative proctocolitis
Indeterminate (Indeterminate)
No (No)
Yes (Yes)
Crohn's disease
Indeterminate (Indeterminate)
No (No)
Yes (Yes)
Dysplasia
Indeterminate (Indeterminate)
No (No)
Yes (Yes)
Signature
Investigator Signature
Investigator Signature Date
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E3201 Non-Protocol Therapy Form
NCT00068692
E3201 Non-Protocol Therapy Form NCT00068692
Comparison of Adjuvant Chemotherapy Regimens in
Treating Patients With Stage II or Stage III Rectal Cancer
Who Are Receiving Radiation Therapy and Fluorouracil
Before or After Surgery
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=B5523A6B-
BAE4-6DC8-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/10963
E3201 Non-Protocol Therapy Form
NCT00068692
Header
ECOG Protocol Number
ECOG Patient ID
DCI Name
Registration Step
Time period
non-protocol therapy (non-protocol
therapy)
Patient Initials
Participating Group Protocol No.
Participating Group Patient ID
Institution/Affiliate
Are data amended? (If yes, please circle
amended items in red)
Yes
No
Off-protocol treatment
Non-protocol chemotherapy
No (no)
Unknown (unknown)
Yes (yes)
Non-protocol hormonal therapy
No (no)
Unknown (unknown)
Yes (yes)
Non-protocol immunotherapy
No (no)
Unknown (unknown)
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Yes (yes)
Non-protocol high dose chemotherapy/stem cell
transplant
No (no)
unknown (unknown)
Yes (yes)
Non-protocol surgery
No (no)
Unknown (unknown)
Yes (yes)
Non-protocol surgery type
Non-protocol radiation therapy
No (no)
Unknown (unknown)
Yes (yes)
Non-protocol RT type
Other non-protocol therapy
No (no)
Unknown (unknown)
Yes (yes)
Name of other non-protocol therapy
Was the non-protocol therapy given for the
disease of this protocol?
No (no)
Unknown (unknown)
Yes (yes)
Comments
Investigator Signature
Investigator Signature Date
Ccrr Module For E3201 Non-protocol
Therapy Form
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E5204 Second Primary Form
NCT00303628
E5204 Second Primary Form NCT00303628
Combination Chemotherapy With or Without Bevacizumab
in Treating Patients Who Have Had Surgery for Stage II or
Stage III Rectal Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=089B4967-
A89A-3905-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/10964
E5204 Second Primary Form
NCT00303628
Header
ECOG Protocol Number (If patient has been on
other therapeutic ECOG protocols, please list
protocols and patient ID numbers)
ECOG Patient ID (If patient has been on other
therapeutic ECOG protocols, please list protocols
and patient ID numbers)
DCI Name
Registration Step
Reporting Period
Second Primary Cancer (Second
Primary)
Please mark an 'X' if data have been amended.
(Please circle amended items in red)
Date data amended (s - mm/dd/yyyy)
Patient demographics
Patient Initials (Last, First)
Participating Group Protocol Number
Institution/Affiliate
Participating Group Patient ID
Second primary cancer assessment
Date of Diagnosis of Second Primary Cancer
(mm/dd/yyyy)
1 / 2
Site of Second Primary Cancer
Include information on histologic subtype (Please
attach copies of any corroborating pathology
reports)
Briefly describe cancer therapy the patient has
received prior to the diagnosis of the second
primary and other than that given on ECOG
protocols
Briefly describe treatment planned or given for
the diagnosis of this second primary
Comments
Investigator Signature
Investigator Signature Date
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E3201 Group I Treatment Form -
Concurrent Chemo/RT NCT00068692
E3201 Group I Treatment Form - Concurrent Chemo/RT
NCT00068692
Comparison of Adjuvant Chemotherapy Regimens in
Treating Patients With Stage II or Stage III Rectal Cancer
Who Are Receiving Radiation Therapy and Fluorouracil
Before or After Surgery
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=B552598D-
825C-6E3D-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/10965
E3201 Group I Treatment Form -
Concurrent Chemo/RT
NCT00068692
Header
ECOG Protocol Number
ECOG Patient ID
DCI Name
Registration Step
Time Period
Completion of Concurrent Chemo/RT
(Completion of Concurrent Chemo/RT)
Patient Initials
Participating Group Protocol No.
Participating Group Patient ID
Institution/Affiliate
Are data amended?
Yes
No
Assessment of Chemotherapy
Regimen Type Given
Other (Other)
RT + 5-FU/LV (RT + 5-FU/LV)
Rt + Capecitabine (RT + Capecitabine)
Rt + Continuous Infusion 5-fu (RT +
continuous infusion 5-FU)
Specify other regimen
Chemotherapy Begin Date
1 / 2
Chemotherapy End Date
RT Begin Date
RT End Date
RT Total Dose
Comments
Ccrr Module For E3201 Group I Treatment
Form - Concurrent Chemo/rt
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E5204 Source Document Tracking
Coversheet NCT00303628
E5204 Source Document Tracking Coversheet
NCT00303628 
Combination Chemotherapy With or Without Bevacizumab
in Treating Patients Who Have Had Surgery for Stage II or
Stage III Rectal Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=08FD88A5-
89D0-5626-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/10966
E5204 Source Document Tracking
Coversheet NCT00303628
Header
ECOG Protocol Number
ECOG Patient ID
DCI Name
Registration Step
Reporting Period (Choose one)
Baseline (Baseline)
Recurrence (Recurrence)
Second Primary Cancer (Second
primary)
Patient demographics
Patient Initials (Last, First)
ECOG Protocol Number
Participating Group Protocol Number
ECOG Patient ID
Participating Group Patient ID
Institution/Affiliate
Footer module
Document type (Choose one)
Other (Other)
Pathology Report (Pathology Report)
Recurrence Document (Recurrence
Document)
1 / 2
Surgical Report (Surgical Report)
Recurrence Document specify
Other specify
Report Created Date (List the date the source
document was created below.)
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NSABP PROTOCOL B-38Treatment Form for Group 2 - Doxorubicin,
Cyclophosphamide Followed by Paclitaxel (DD AC - P) - Form T2 NCT00093795
NSABP PROTOCOL B-38Treatment Form for Group 2 -
Doxorubicin, Cyclophosphamide Followed by Paclitaxel
(DD AC - P) - Form T2 NCT00093795
Combination Chemotherapy in Treating Women Who Have
Undergone Surgery for Node-Positive Breast Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=DD882133-
10FD-25D3-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/10967
NSABP PROTOCOL B-38Treatment
Form for Group 2 - Doxorubicin,
Cyclophosphamide Followed by
Paclitaxel (DD AC - P) - Form T2
NCT00093795
Assessment of Chemotherapy
Patient Initials
NSABP Patient ID
Institution Name
Affiliate Name
Treating MD, Last Name
Treating MD, First Name
Treating MD, Phone
Person completing Form, Last Name
Person completing Form, First Name
Person completing Form, Phone
Are data amended? (check box if yes, and circle
amended items)
Yes
No
Cycle Number
Cycle Start Date (Leave blank if not given)
Agent Name (Agent Total Dose* mg/m^2)
Cyclophosphamide (Cyclophosphamide)
Doxorubicin (Doxorubicin)
Paclitaxel (Paclitaxel)
1 / 2
Agent Total Dose
Was this cycle delayed due to adverse event(s)?
(Circle Y or N for Yes, No)
Yes
No
Reason Treatment Ended (or Never Started
Select only one)
Adverse Event/side Effects/complications
(Adverse Event/Side
Effects/complications)
Alternative Therapy (Alternative therapy)
Death, Recurrence, Or Second Primary
Cancer (Death, recurrence, or second
primary cancer)
Other (Other)
Patient Withdrawal Or Refusal (Patient
withdrawal or refusal)
Treatment Completed Per Protocol
Criteria (Treatment completed per
protocol criteria)
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NSABP PROTOCOL B-38Treatment Form for Group 2 - Doxorubicin,
Cyclophosphamide Followed by Paclitaxel (DD AC - P) - Form T2 NCT00093795
NSABP PROTOCOL B-38: Treatment Form for Group 1 - Doxorubicin,
Cyclophosphamide, and Docetaxel (TAC) - Form T1 NCT00093795
NSABP PROTOCOL B-38: Treatment Form for Group 1 -
Doxorubicin, Cyclophosphamide, and Docetaxel (TAC) -
Form T1 NCT00093795
Combination Chemotherapy in Treating Women Who Have
Undergone Surgery for Node-Positive Breast Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=DD8782BC-
197F-2A84-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/10968
NSABP PROTOCOL B-38:
Treatment Form for Group 1 -
Doxorubicin, Cyclophosphamide,
and Docetaxel (TAC) - Form T1
NCT00093795
Patient demographics
Patient Initials
NSABP Patient ID
Institution Name
Affiliate Name
Treating MD, Last Name
Treating MD, First Name
Treating MD, Phone
Person completing Form, Last Name
Person completing Form, First Name
Person completing Form, Phone
Are data amended? (check box if yes, and circle
amended items)
Yes
No
Assessment of Chemotherapy
Cycle Number
Cycle Start Date
Agent Name
Cyclophosphamide (Cyclophosphamide)
1 / 2
Docetaxel (Docetaxel)
Doxorubicin (Doxorubicin)
Agent Total Dose (* mg/m^2)
Was this cycle delayed due to adverse event(s)?
(Circle Y or N for Yes, No)
Yes
No
Reason Treatment Ended (or Never Started
Select only one)
Adverse Event/side Effects/complications
(Adverse Event/Side
Effects/complications)
Alternative Therapy (Alternative therapy)
Death, Recurrence, Or Second Primary
Cancer (Death, recurrence, or second
primary cancer)
Other (Other)
Patient Withdrawal Or Refusal (Patient
withdrawal or refusal)
Treatment Completed Per Protocol
Criteria (Treatment completed per
protocol criteria)
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NSABP PROTOCOL B-38: Treatment Form for Group 1 - Doxorubicin,
Cyclophosphamide, and Docetaxel (TAC) - Form T1 NCT00093795
E5204 Assessment Compliance Form
NCT00303628
E5204 Assessment Compliance Form NCT00303628
Combination Chemotherapy With or Without Bevacizumab
in Treating Patients Who Have Had Surgery for Stage II or
Stage III Rectal Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=08F01694-
A022-1380-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/10969
E5204 Assessment Compliance
Form NCT00303628
Header
ECOG Protocol Number
ECOG Patient ID
DCI Name
Registration Step
Patient demographics
Patient Initials
ECOG Protocol Number
ECOG Patient ID
Participating Group Protocol Number
Participating Group Patient ID
Institution/Affiliate
Reporting Period
Reporting Period
12 Months Post-chemotherapy (12
months post-chemotherapy)
3 Months Post-chemotherapy (3 months
post-chemotherapy)
Baseline (Baseline)
Cycle 4, Day 1 (Cycle 4, Day 1)
Data amendment
Please mark an 'X' if data have been amended.
(please circle amended items in red)
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Date data amended (s)
Section I
Assessment Date (If not completed, enter date
scheduled per E5204 protocol)
Section Ii - Assessments Not Completed
Were all the quality of life forms completed for
this timepoint
Yes
No
Section Ii - Assessments Not Completed
Assessment Form No.
Patient refusal
Yes
No
Unable to accomodate disability or language
needs
Yes
No
Specify disability or language
Patient did not show up in clinic/office
Yes
No
Specify reason patient did not show up
Staff unavailable
Yes
No
Patient not given form by staff
Yes
No
Patient too ill
Yes
No
Patient expired
Yes
No
Assessment not required per protocol
2 / 9
E5204 Assessment Compliance Form NCT00303628
Yes
No
Specify reason assessment is not required
Staff thought patient too ill
Yes
No
Other
Yes
No
Specify other reason
Fact-gog/ntx: Indicate Reason(s) Why
Form Was Not Completed
Assessment Form No.
Patient refusal
Yes
No
Unable to accomodate disability or language
needs
Yes
No
Specify disability or language
Patient did not show up in clinic/office
Yes
No
Specify reason patient did not show up
Staff unavailable
Yes
No
Patient not given form by staff
Yes
No
Patient too ill
Yes
No
Patient expired
Yes
No
Assessment not required per protocol
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E5204 Assessment Compliance Form NCT00303628
Yes
No
Specify reason assessment is not required
Staff thought patient too ill
Yes
No
Other
Yes
No
Specify other reason
Patient Bowel Function/uniscale
Questionnaire: Indicate Reason(s) Why
Form Was Not Completed
Assessment Form No.
Patient refusal
Yes
No
Unable to accomodate disability or language
needs
Yes
No
Specify disability or language
Patient did not show up in clinic/office
Yes
No
Specify reason patient did not show up
Staff unavailable
Yes
No
Patient not given form by staff
Yes
No
Patient too ill
Yes
No
Patient expired
Yes
No
4 / 9
E5204 Assessment Compliance Form NCT00303628
Assessment not required per protocol
Yes
No
Specify reason assessment is not required
Staff thought patient too ill
Yes
No
Other
Yes
No
Specify other reason
Section Iii - Assessment Completed
Fact-d Subscale: Was Assessment Self-
administered?
Was Assessment self-administered?
Yes
No
Fact-gog/ntx: Was Assessment Self-
administered?
Was Assessment self-administered?
Yes
No
Patient Bowel Function/uniscale
Questionnaire: Was Assessment Self-
administered?
Was Assessment self-administered?
Yes
No
How Was The Patient Assisted
Were the questions read aloud to patient
Yes
No
Did the patient require clarification of questions or
instructions
Yes
No
Did the patient require other assistance
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E5204 Assessment Compliance Form NCT00303628
Yes
No
Were the forms completed independently by
another person
Yes
No
Fact-gog/ntx: How Was The Patient
Assisted?
Were the questions read aloud to patient
Yes
No
Did the patient require clarification of questions or
instructions
Yes
No
Did the patient require other assistance
Yes
No
Were the forms completed independently by
another person
Yes
No
Patient Bowel Function/uniscale
Questionnaire: How Was The Patient
Assisted?
Were the questions read aloud to patient
Yes
No
Did the patient require clarification of questions or
instructions
Yes
No
Did the patient require other assistance
Yes
No
Were the forms completed independently by
another person
Yes
No
What Was The Reason For Assistance
Did the patient have a language difficulty
(questions needed to be translated)
Yes
No
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E5204 Assessment Compliance Form NCT00303628
Specify language
Did the patient have a literacy difficulty (patient
could not read well enough)
Yes
No
Was the patient disabled
Yes
No
Specify disability
Were the forms completed via a telephone
interview
Yes
No
Other
Yes
No
Specify other reason
Fact-gog/ntx: What Was The Reason For
Assistance?
Did the patient have a language difficulty
(questions needed to be translated)
Yes
No
Specify language
Did the patient have a literacy difficulty (patient
could not read well enough)
Yes
No
Was the patient disabled
Yes
No
Specify disability
Were the forms completed via a telephone
interview
Yes
No
Other
Yes
No
Specify other reason
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E5204 Assessment Compliance Form NCT00303628
Patient Bowel Function/uniscale
Questionnaire: What Was The Reason For
Assistance?
Did the patient have a language difficulty
(questions needed to be translated)
Yes
No
Specify language
Did the patient have a literacy difficulty (patient
could not read well enough)
Yes
No
Was the patient disabled
Yes
No
Specify disability
Were the forms completed via a telephone
interview
Yes
No
Other
Yes
No
Specify other reason
Who Assisted Or Completed Assessment
Staff
Yes
No
Family
Yes
No
Friend
Yes
No
Other
Yes
No
Specify other person
Fact-gog/ntx: Who Assisted Or Completed
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E5204 Assessment Compliance Form NCT00303628
Assessment?
Staff
Yes
No
Family
Yes
No
Friend
Yes
No
Other
Yes
No
Specify other person
Patient Bowel Function/uniscale
Questionnaire: Who Assisted Or
Completed Assessment?
Staff
Yes
No
Family
Yes
No
Friend
Yes
No
Other
Yes
No
Specify other person
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E5204 Assessment Compliance Form NCT00303628
NSABP PROTOCOL B-38Treatment Form for Group 3 - Doxorubicin,
CyclophosphamideFollowed by Paclitaxel and Gemcitabine (DD AC - PG) - Form T3
NCT00093795
NSABP PROTOCOL B-38Treatment Form for Group 3 -
Doxorubicin, CyclophosphamideFollowed by Paclitaxel and
Gemcitabine (DD AC - PG) - Form T3 NCT00093795
Combination Chemotherapy in Treating Women Who Have
Undergone Surgery for Node-Positive Breast Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=DD87CFFD-
F7B4-2E98-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/10970
NSABP PROTOCOL B-38Treatment
Form for Group 3 - Doxorubicin,
CyclophosphamideFollowed by
Paclitaxel and Gemcitabine (DD AC -
PG) - Form T3 NCT00093795
Patient demographics
Patient Initials
NSABP Patient ID
Institution Name
Affiliate Name
Treating MD, Last Name
Treating MD, First Name
Treating MD, Phone
Person completing Form, Last Name
Person completing Form, First Name
Person completing Form, Phone
Are data amended? (check box if yes, and circle
amended items)
Yes
No
Assessment of Chemotherapy
Cycle Number
Cycle Start Date
Agent Name
Cyclophosphamide (Cyclophosphamide)
1 / 2
Doxorubicin (Doxorubicin)
Gemcitabine (Gemcitabine)
Paclitaxel (Paclitaxel)
Agent Total Dose (* mg/m^2)
Was this cycle delayed due to adverse event(s)?
(Circle Y or N for Yes, No)
Yes
No
Reason Treatment Ended (or Never Started
Select only one)
Adverse Event/side Effects/complications
(Adverse Event/Side
Effects/complications)
Alternative Therapy (Alternative therapy)
Death, Recurrence, Or Second Primary
Cancer (Death, recurrence, or second
primary cancer)
Other (Other)
Patient Withdrawal Or Refusal (Patient
withdrawal or refusal)
Treatment Completed Per Protocol
Criteria (Treatment completed per
protocol criteria)
2 / 2
NSABP PROTOCOL B-38Treatment Form for Group 3 - Doxorubicin,
CyclophosphamideFollowed by Paclitaxel and Gemcitabine (DD AC - PG) - Form T3
NCT00093795
NSABP Protocol B-40 - Treatment Form for
Doxorubicin/Cyclophosphamide (All Patients) NCT00408408
NSABP Protocol B-40 - Treatment Form for
Doxorubicin/Cyclophosphamide (All Patients)
NCT00408408
A Randomized Phase III Trial of Neoadjuvant Therapy in
Patients With Palpable and Operable Breast Cancer
Evaluating the Effect on Pathologic Complete Response
(pCR) of Adding Capecitabine or Gemcitabine to Docetaxel
When Administered Before AC With or Without
Bevacizumab and Correlative Science Studies Attempting
to Identify Predictors of High Likelihood for pCR With Each
of the Regimens
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=1B00492A-
70E3-51F1-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/10971
NSABP Protocol B-40 - Treatment
Form for
Doxorubicin/Cyclophosphamide (All
Patients) NCT00408408
Header
Patient Initials (Last First Middle)
NSABP Patient ID
Institution/Affiliate
Treating MD Last Name
Treating MD First Name
Treating MD Phone
Person Completing Form, Last Name
Person Completing Form, First Name
Person Completing Form, Phone
Are data amended
Yes
No
Assessment of Chemotherapy
Total Number of Cycles Given
(Docetaxel/Gemcitabine)
1 (1)
2 (2)
3 (3)
4 (4)
None (None)
1 / 2
Why did treatment end or not begin
(Docetaxel/Gemcitabine)
Adverse Event/side Effects/complications
(Adverse event/side
effects/complications)
Alternative Therapy (Alternative therapy)
Death (Death)
New Lesion (including Second Primary
Cancer) Or Other Sign Of Progression
(New lesion (including second primary
cancer) or other sign of progression)
Other (Other)
Treatment Completed Per Protocol
Criteria (Treatment completed per
protocol criteria)
Other, specify
Cycle Number
Cycle Start Date
Agent Name (Docetaxel, Gemcitabine Day 1,
Gemcitabine Day 8)
Agent Dose (per M^2 - mg/m^2  - Dose used to
calculate the amount of drug to be administered.
In Groups 3A and 3B, full dose of docetaxel is 75
mg/m^2.  Full dose of gemcitabine is 1000
mg/m^2.)
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NSABP Protocol B-40 - Treatment Form for
Doxorubicin/Cyclophosphamide (All Patients) NCT00408408
NSABP Protocol B-40 - Treatment Form for Docetaxel/Gemcitabine
Cycles in Groups 3A and 3B NCT00408408
NSABP Protocol B-40 - Treatment Form for
Docetaxel/Gemcitabine Cycles in Groups 3A and 3B
NCT00408408
A Randomized Phase III Trial of Neoadjuvant Therapy in
Patients With Palpable and Operable Breast Cancer
Evaluating the Effect on Pathologic Complete Response
(pCR) of Adding Capecitabine or Gemcitabine to Docetaxel
When Administered Before AC With or Without
Bevacizumab and Correlative Science Studies Attempting
to Identify Predictors of High Likelihood for pCR With Each
of the Regimens
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=1AF9CE89-
A16C-4210-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/10972
NSABP Protocol B-40 - Treatment
Form for Docetaxel/Gemcitabine
Cycles in Groups 3A and 3B
NCT00408408
Header
Patient Initials (Last First Middle)
NSABP Patient ID
Institution/Affiliate
Treating MD Last Name
Treating MD First Name
Treating MD Phone
Person Completing Form, Last Name
Person Completing Form, First Name
Person Completing Form, Phone
Are data amended
Yes
No
Assessment of Chemotherapy
Total Number of Cycles Given
(Docetaxel/Gemcitabine)
1 (1)
2 (2)
3 (3)
4 (4)
None (None)
1 / 2
Why did treatment end or not begin
(Docetaxel/Gemcitabine)
Adverse Event/side Effects/complications
(Adverse event/side
effects/complications)
Alternative Therapy (Alternative therapy)
Death (Death)
New Lesion (including Second Primary
Cancer) Or Other Sign Of Progression
(New lesion (including second primary
cancer) or other sign of progression)
Other (Other)
Treatment Completed Per Protocol
Criteria (Treatment completed per
protocol criteria)
Other, specify
Cycle Number
Cycle Start Date
Agent Name (Docetaxel, Gemcitabine Day 1,
Gemcitabine Day 8)
Agent Dose (per M^2 - mg/m^2  - Dose used to
calculate the amount of drug to be administered.
In Groups 3A and 3B, full dose of docetaxel is 75
mg/m^2.  Full dose of gemcitabine is 1000
mg/m^2.)
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NSABP Protocol B-40 - Treatment Form for Docetaxel/Gemcitabine
Cycles in Groups 3A and 3B NCT00408408
NSABP Protocol B-40 - Treatment Form for Docetaxel
Cycles in Groups 1A and 1B NCT00408408
NSABP Protocol B-40 - Treatment Form for Docetaxel
Cycles in Groups 1A and 1B NCT00408408
A Randomized Phase III Trial of Neoadjuvant Therapy in
Patients With Palpable and Operable Breast Cancer
Evaluating the Effect on Pathologic Complete Response
(pCR) of Adding Capecitabine or Gemcitabine to Docetaxel
When Administered Before AC With or Without
Bevacizumab and Correlative Science Studies Attempting
to Identify Predictors of High Likelihood for pCR With Each
of the Regimens
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=1B003126-
8EB8-5028-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/10973
NSABP Protocol B-40 - Treatment
Form for Docetaxel Cycles in Groups
1A and 1B NCT00408408
Header
Patient Initials (Last First Middle)
NSABP Patient ID
Institution/Affiliate
Treating MD Last Name
Treating MD First Name
Treating MD Phone
Person Completing Form, Last Name
Person Completing Form, First Name
Person Completing Form, Phone
Are data amended
Yes
No
Assessment of Chemotherapy
Total Number of Cycles Given
(Docetaxel/Gemcitabine)
1 (1)
2 (2)
3 (3)
4 (4)
None (None)
1 / 2
Why did treatment end or not begin
(Docetaxel/Gemcitabine)
Adverse Event/side Effects/complications
(Adverse event/side
effects/complications)
Alternative Therapy (Alternative therapy)
Death (Death)
New Lesion (including Second Primary
Cancer) Or Other Sign Of Progression
(New lesion (including second primary
cancer) or other sign of progression)
Other (Other)
Treatment Completed Per Protocol
Criteria (Treatment completed per
protocol criteria)
Other, specify
Cycle Number
Cycle Start Date
Agent Name (Docetaxel, Gemcitabine Day 1,
Gemcitabine Day 8)
Agent Dose (per M^2 - mg/m^2  - Dose used to
calculate the amount of drug to be administered.
In Groups 3A and 3B, full dose of docetaxel is 75
mg/m^2.  Full dose of gemcitabine is 1000
mg/m^2.)
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NSABP Protocol B-40 - Treatment Form for Docetaxel Cycles in Groups
1A and 1B NCT00408408
E1305 Source Document Tracking
Coversheet NCT00588770
E1305 Source Document Tracking Coversheet
NCT00588770
Chemotherapy With or Without Bevacizumab in Treating
Patients With Recurrent or Metastatic Head and Neck
Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=19F77651-
8901-3675-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/10974
E1305 Source Document Tracking
Coversheet NCT00588770
Header
ECOG Protocol Number
ECOG Patient ID
DCI Name
Registration Step
Reporting Period
Baseline (Baseline)
Patient demographics
Patient Initials (Last, First)
ECOG Protocol Number
Participating Group Protocol Number
ECOG Patient ID
Participating Group Patient ID
Institution/Affiliate
Footer module
Document type (Choose one)
Eligibility Checklist (Eligibility Checklist)
Other (Other)
Pathology Report (Pathology Report)
Surgical Report (Surgical Report)
Other specify
Report Created Date (List the date the source
1 / 2
document was created below.)
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E1305 Source Document Tracking Coversheet NCT00588770
ECOG Second Primary Form
NCT00588770
ECOG Second Primary Form NCT00588770
Chemotherapy With or Without Bevacizumab in Treating
Patients With Recurrent or Metastatic Head and Neck
Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=17220911-5226-
6039-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/10975
ECOG Second Primary Form
NCT00588770
Header
ECOG Protocol Number (If patient has been on
other therapeutic ECOF protocols, please list
protocols and patient ID numbers.)
ECOG Patient ID
DCI Name
Registration Step
Reporting Period
Second Primary Cancer (Second
Primary)
Please mark an 'X' if data have been amended.
Date data amended
Patient demographics
Patient Initials
Participating Group Protocol Number
Participating Group Patient ID
Institution/Affiliate
Second primary cancer assessment
Date of Diagnosis of Second Primary Cancer
Site of Second Primary Cancer
Is it likely that the second primary cancer is
1 / 2
related to any anti-cancer treatment (including
treatment of the protocol) the patient has
received?
Yes
No
Include information on histologic subtype (s)
Briefly describe cancer therapy the patient has
received prior to the diagnosis of the second
primary and other than that given on ECOG
protocols
Briefly describe treatment planned or given for
the diagnosis of this second primary
Comments
Investigator Signature
Investigator Signature Date
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ECOG Second Primary Form NCT00588770
AMC-061 Adverse Events Form (ADV)
NCT00890747
AMC-061 Adverse Events Form (ADV) NCT00890747 
Sunitinib Malate in Treating HIV-Positive Patients With
Cancer Undergoing Highly Active Antiretroviral Therapy
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=71988CF7-
F8CE-68F0-E040-BB89AD4358A1
All rights reserved. Please visit https://medical-data-
models.org/forms/10976
AMC-061 Adverse Events Form
(ADV) NCT00890747
Adverse Event Information
CTC AE Category
CTC Adverse Event Term
CTC Adverse Event Grade
Adverse Event Onset Date (mm/dd/yyyy)
MedDRA Code
If other CTC event selected, please provide
description of event
Was this event expected or anticipated
Yes
No
Agent Name
CTC Adverse Event Attribution Code
Definite (Definite)
Possible (Possible)
Probable (Probable)
Unlikely (Unlikely)
Unrelated (Unrelated)
Alternative etiology
Accident, Trauma, Or External Factors
(Accident, trauma, or external factors)
Concurrent Illness/condition (not Pre-
existing) (Concurrent illness/condition
(not pre-existing))
None Apparent (None apparent)
Other Pre-existing Disease Or Condition
(Other pre-existing disease or condition)
Study Disease (Study disease)
Action Taken at Time of Adverse Event
Hospitalization For Ae (Hospitalization)
Otc/non-rx (OTC/non-Rx)
Other (Other)
Prescription (Prescription)
1 / 2
Protocol Treatment Was Delayed As A
Result Of The Adverse Event (protocol
treatment delayed)
Protocol Treatment Was Discontinued As
A Result Of The Adverse Event (protocol
treatment discontinued)
Study Dose Was Reduced As A Result
Of The Adverse Event (study dose
reduced)
Other, specify
If modification was made to study therapy, who
initiated modification
Patient Initiated (Patient initiated)
Physician Initiated (Physician initiated)
Outcome of Adverse Event
Adverse Event Is Resolved (Resolved)
Adverse Event Is Resolved With
Sequelae (Resolved with sequelae)
Unresolved At Protocol Completion
(Unresolved at protocol completion)
Unresolved, Protocol Ongoing
(Unresolved, protocol ongoing)
AE Resolution Date (If "Resolved" mm/dd/yyyy)
If resolved with sequelae, specify
Was this considered a Serious Adverse Event
Yes
No
Seriousness Attributed to Adverse Event (If "Yes"
check "Yes" for all that apply Please note that
checking "Yes" to any of the events below will
require SAE notification according to protocol
requirements.)
Congenital Anomaly (Congenital
anomaly)
Death (Death)
Disability (Disability/incapacity)
Hospitalized (Hospitalization, initial or
prolonged)
Life Threatening (Life threatening)
Other (Other)
Intervention Required (Required
intervention to prevent permanent
impairment/damage)
Comments
Comments
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AMC-061 Adverse Events Form (ADV) NCT00890747
ECOG Non-Protocol Therapy Form
NCT00588770
ECOG Non-Protocol Therapy Form NCT00588770
Chemotherapy With or Without Bevacizumab in Treating
Patients With Recurrent or Metastatic Head and Neck
Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=1A08BE26-
4EC6-3573-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/10977
ECOG Non-Protocol Therapy Form
NCT00588770
Header
ECOG Protocol Number
ECOG Patient ID
DCI Name
Registration Step
Reporting Period
Non-protocol Therapy (Non-Protocol
Therapy)
Please mark an 'X' if data have been amended
(Please circle amended items in red)
Date data amended (M D Y)
Patient demographics
Patient Initials (Last, First)
Participating Group Protocol Number
Participating Group Patient ID
Institution/Affiliate
Off-protocol treatment
Date of FIRST non-protocol therapy (if given prior
to progression/relapse from protocol therapy)
Non-protocol Chemotherapy
No (No)
Unknown (Unknown)
1 / 2
Yes (Yes)
Non-protocol Hormonal Therapy
No (No)
Unknown (Unknown)
Yes (Yes)
Non-protocol Immunotherapy (Biological
Response Modifiers)
No (No)
Unknown (Unknown)
Yes (Yes)
Non-protocol High Dose Chemotherapy/Stem
Cell Transplant (Autologous or Allogeneic)
No (No)
Unknown (Unknown)
Yes (Yes)
Non-protocol Surgery
No (No)
Unknown (Unknown)
Yes (Yes)
Non-protocol surgery type
Non-protocol Radiation Therapy
No (No)
Unknown (Unknown)
Yes (Yes)
Non-protocol RT type
Other Non-protocol Therapy
No (No)
Unknown (Unknown)
Yes (Yes)
Name of other non-protocol therapy
Was the non-protocol therapy given for the
disease of this protocol (NOTE: Treatment for a
second primary in the same organ site would not
be considered therapy for disease of this
protocol.)
No (No)
Unknown (Unknown)
Yes (Yes)
Comments
Investigator Signature
Investigator Signature Date
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ECOG Non-Protocol Therapy Form NCT00588770
E2805 Second Primary Form
NCT00326898
E2805 Second Primary Form NCT00326898
Sunitinib or Sorafenib in Treating Patients With Kidney
Cancer That Was Removed By Surgery
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=054BADA9-
3263-36C2-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/10978
E2805 Second Primary Form
NCT00326898
Header
ECOG Protocol Number
ECOG Patient ID
DCI Name
Registration Step
Reporting Period
Second Primary Cancer (Second
Primary)
Please mark an 'X' if data have been amended
Date data amended
Patient demographics
Patient Initials
Participating Group Protocol Number
Institution/Affiliate
Participating Group Patient ID
Second primary cancer assessment
Date of Diagnosis of Second Primary Cancer
Site of Second Primary Cancer
Include information on histologic subtype (s)
Briefly describe cancer therapy the patient has
1 / 2
received prior to the diagnosis of the second
primary and other than that given on ECOG
protocols
Briefly describe treatment planned or given for
the diagnosis of this second primary
Comments
Investigator Signature
Investigator Signature Date
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E2805 Second Primary Form NCT00326898
E3F05 Radiation Therapy Form
NCT00978458
E3F05 Radiation Therapy Form NCT00978458 
Radiation Therapy With or Without Temozolomide in
Treating Patients With Low-Grade Glioma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=6C1889F9-
D047-5474-E040-BB89AD431A23
All rights reserved. Please visit https://medical-data-
models.org/forms/10979
E3F05 Radiation Therapy Form
NCT00978458
Header
ECOG Protocol Number
ECOG Patient ID
DCI Name
Registration Step
Reporting Period
End Of Chemoradiation (End of
Chemoradiation)
End Of Radiation (End of Radiation)
Please mark an 'X' if data have been amended.
(Please circle amended items in red)
Date data amended (s m d y)
Patient demographics
Patient Initials (Last,First)
Participating Group Protocol Number
Participating Group Patient ID
Institution/Affiliate
Vital Status
Patient's Vital Status
Alive (Alive)
Dead (Dead)
Date of Last Contact or Death (m d y)
1 / 2
Primary Cause of Death (if applicable)
Due To Other Cause (Due to other
cause)
Due To Protocol Treatment (Due to
protocol treatment)
Due To This Disease (Due to this
disease)
Unknown (Unknown)
Describe cause of death
Therapy Administered
Agent Name (Fractionated RT)
RT begin date (M D Y)
RT End Date (M D Y)
RT Total Dose (cGy)
Was treatment delayed
Yes
No
Treatment was delayed
< 2 Weeks (< 2 weeks)
>= 2 Weeks (>= 2 weeks)
Non-protocol Therapy
Was any non-protocol therapy given during
protocol treatment? (not previously reported )
Yes
No
Comments
Investigator Signature
Investigator Signature Date (MM DD YYYY)
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E3F05 Radiation Therapy Form NCT00978458
NSABP PROTOCOL B-38 Treatment Form for
Hormonal Therapy - Form H NCT00093795
NSABP PROTOCOL B-38 Treatment Form for Hormonal
Therapy - Form H NCT00093795
Combination Chemotherapy in Treating Women Who Have
Undergone Surgery for Node-Positive Breast Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=DADC41AF-
8F18-703B-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/10980
NSABP PROTOCOL B-38 Treatment
Form for Hormonal Therapy - Form
H NCT00093795
Header module
Patient Initials
NSABP Patient ID
Institution Name
Affiliate Name
Person completing Form, Last Name
Person completing Form, First Name
Person completing Form, Phone
Are data amended?
Yes
No
Date Form Completed
Summary Of Hormonal Treatment
Received
Reason form completed
Patient Received 5 Years Of Hormonal
Therapy, And Hormonal Treatment Has
Ended (Patient received 5 years of
hormonal therapy, and hormonal
treatment has ended)
Patient Received 5 Years Of Hormonal
Therapy, And Hormonal Treatment Will
Continue (Patient received 5 years of
hormonal therapy, and hormonal
treatment will continue)
Patient Received Less Than 5 Years Of
Hormonal Therapy, And Hormonal
Treatment Has Ended (Patient received
less than 5 years of hormonal therapy,
and hormonal treatment has ended)
1 / 2
Patient Will Not Begin Hormonal Therapy
(Patient will not begin hormonal therapy)
Agent Name
Was agent administered (If no, skip to next row.)
Yes
No
Agent Begin Date
Agent End Date (Leave date boxes blank if agent
will continue beyond 5 years.)
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NSABP PROTOCOL B-38 Treatment Form for Hormonal Therapy - Form
H NCT00093795
E2805 Non-Protocol Therapy Form
NCT00326898
E2805 Non-Protocol Therapy Form NCT00326898
Sunitinib or Sorafenib in Treating Patients With Kidney
Cancer That Was Removed By Surgery
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=054A9BCE-
D49E-2448-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/10981
E2805 Non-Protocol Therapy Form
NCT00326898
Header
ECOG Protocol Number
ECOG Patient ID
DCI Name
Registration Step
Reporting Period
Non-protocol Therapy (Non-Protocol
Therapy)
Please mark an 'X' if data have been amended
Date data amended
Patient demographics
Patient Initials
Participating Group Protocol Number
Institution/Affiliate
Participating Group Patient ID
Off-protocol treatment
Date of FIRST non-protocol therapy (if given prior
to progression/relapse from protocol therapy)
Non-protocol Chemotherapy
No (No)
Unknown (Unknown)
Yes (Yes)
Non-protocol Hormonal Therapy
1 / 2
No (No)
Unknown (Unknown)
Yes (Yes)
Non-protocol Immunotherapy (Biological
Response Modifiers)
No (No)
Unknown (Unknown)
Yes (Yes)
Non-protocol High Dose Chemotherapy/Stem
Cell Transplant (Autologous or Allogeneic)
No (No)
Unknown (Unknown)
Yes (Yes)
Non-protocol Surgery
No (No)
Unknown (Unknown)
Yes (Yes)
Non-protocol surgery type
Non-protocol Radiation Therapy
No (No)
Unknown (Unknown)
Yes (Yes)
Non-protocol RT type
Other Non-protocol Therapy
No (No)
Unknown (Unknown)
Yes (Yes)
Name of other non-protocol therapy
Was the non-protocol therapy given for the
disease of this protocol (NOTE: Treatment for a
second primary in the same organ site would not
be considered therapy for disease of this
protocol.)
No (No)
Unknown (Unknown)
Yes (Yes)
Comments
Investigator Signature
Investigator Signature Date
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E2805 Non-Protocol Therapy Form NCT00326898
E2603 Baseline Data Form (6/05)
NCT00110019
E2603 Baseline Data Form (6/05) NCT00110019
Carboplatin and Paclitaxel With or Without Sorafenib in
Treating Patients With Unresectable Stage III or Stage IV
Melanoma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=FA0DB0C8-
3665-5AA6-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/10982
E2603 Baseline Data Form (6/05)
NCT00110019
Header
ECOG Protocol Number
DCI Name
Registration Step
Report period
Baseline (Baseline)
ECOG Patient ID
Patient demographics
Patient Initials
ECOG Protocol Number
Participating Group Protocol Number
Institution/Affiliate
ECOG Patient ID
Participating Group Patient ID
Data amendment
Please mark an 'X' if data have been amended.
Date data amended
Pre-registration Hematology/chemistry
Lab Facility Name
1 / 3
Test not done
Peripheral Platelet Count
Peripheral platelet count, LLN
Alkaline Phosphatase
Alkaline Phosphatase ULN
Lactate Dehydrogenase (LDH)
Lactate Dehydrogenase ULN
Date Hematology (Blood) Sample Obtained
Prior Treatment For This Disease
List most recent first
Prior chemotherapy
Yes
No
Prior immunotherapy
Yes
No
Prior investigational therapy?
Yes
No
Specify Agent (sor combinations)
Prior Treatment Regimen Start Date
Date of most recent progression on prior
treatment regimen
Prior Treatment Regimen End Date
Prior surgery (with therapeutic intent)
Yes
No
Prior surgery type (If yes:)
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Prior radiation therapy
Yes
No
Date prior RT ended (If yes:)
Specify sites of prior RT
Total Dose of RT
Comments
Comments
Investigator Signature
Investigator Signature Date
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E2603 Baseline Data Form (6/05) NCT00110019
NSABP PROTOCOL B-36: ON-STUDY
FORM NCT00087178
NSABP PROTOCOL B-36: ON-STUDY FORM
NCT00087178
Comparison of Two Combination Chemotherapy Regimens
in Treating Women With Breast Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=C8932DDB-
5B56-0031-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/10983
NSABP PROTOCOL B-36: ON-
STUDY FORM NCT00087178
Header
Patient Initials (Last, First Middle)
NSABP Patient ID
Institution Name
Affiliate Name
Person Completing Form (Phone)
Are data amended?
Yes
No
Surgery
Most Extensive Primary Surgery
Mastectomy, Nos (Mastectomy, NOS)
Partial
Mastectomy/lumpectomy/excisional
Biopsy (Partial
mastectomy/lumpectomy/excisional
biopsy)
Total Mastectomy (Total Mastectomy)
Were margins histologically free of invasive tumor
and DCIS? (If partial
mastectomy/lumpectomy/excisional biopsy:)
Free (Free)
Not free (Not free)
Surgical Procedures
Core Needle Biopsy (1.)
No (N)
Yes (Y)
Excisional Biopsy or Lumpectomy (2.)
N (N)
Y (Y)
1 / 3
Resection of Lumpectomy Margins (3.)
N (N)
Y (Y)
Total Mastectomy (4.)
N (N)
Y (Y)
Sentinel Node Biopsy (5.)
N (N)
Y (Y)
Axillary Dissection or Axillary Sampling (6.)
N (N)
Y (Y)
DATE OF PROCEDURE (Month, Day, Year)
ACCESSION NUMBER (Pathology Specimen
Number)
Patient status
Menopausal Status (per protocol criteria)
Postmenopausal (Postmenopausal)
Premenopausal (Premenopausal)
Date Baseline QOL Completed by Patient (0=not
applicable)
Date Celecoxib/Placebo Began (0=not begun)
Agent
Disease Description
Tumor Laterality
Left (Left breast)
Right (Right breast)
ER (Receptor Status)
Negative (Negative)
Positive (Positive)
Unknown (Unknown)
PgR (Receptor Status)
Negative (Negative)
Positive (Positive)
Unknown (Unknown)
Pathologic Primary Tumor Size (cm)
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Histologic Grade (Use combined histologic grade
SBR/Elston classification)
High Grade (High)
Intermediate (Intermediate)
Low Grade (Low)
Ccrr Module For Nsabp Protocol B-36:
On-study Form
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NSABP PROTOCOL B-36: ON-STUDY FORM NCT00087178
E2805 Material Submission Form
NCT00326898
E2805 Material Submission Form NCT00326898 
Sunitinib or Sorafenib in Treating Patients With Kidney
Cancer That Was Removed By Surgery
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=05B6F9C4-
7323-1449-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/10984
E2805 Material Submission Form
NCT00326898
Header
ECOG Protocol Number
ECOG Patient ID
Registration Step
DCI Name
Reporting Period
Lab Data (Lab data)
Patient demographics
Patient Initials (Last, First)
ECOG Protocol Number
ECOG Patient ID
Participating Group Protocol Number
Institution/Affiliate
Participating Group Patient ID
Biopsy specimen / Lab
Date material(s) sent to central laboratory
Shipped to
Ecog Pathology Coordinating Office
(ECOG Pathology Coordinating Office)
Other Central Laboratory (Other Central
Laboratory)
Wood Lab (Wood Lab)
1 / 3
Informed consent signed?
Yes
No
Sample No.
Date Specimen collected (MM/DD/YYYY)
Specimen Type
Blue Top Cpt Tube (Blue Top CPT Tube)
Frozen Primary Tumor (Frozen Primary
Tumor)
Other (Other)
Purple Top Edta Tube (Purple Top EDTA
Tube)
Sst Red/gray Top Tube (SST Red/Gray
Top Tube)
Tumor, Fresh In Pbs (Tumor, fresh in
PBS)
Urine (Urine)
Timing of material collection
Cycle 1, Day 1 (Cycle 1, Day 1)
Cycle 1, Day 28 (Cycle 1, Day 28)
Month 3 (Month 3)
Month 6 (Month 6)
Nephrectomy (Nephrectomy)
Other (other)
Prior To Nephrectomy (Prior to
Nephrectomy)
Recurrence (Recurrence)
Number of specimens submitted (tubes, slides,
etc.)
Completed By Central Lab
Date of Receipt of Specimens (M D Y)
Condition of Specimen (s)
Damaged Or Unusable (Damaged or
unusable)
Usable (Useable)
Contacts
Contact Person at Institution
Physician of Record
Institution contact phone number (International)
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Institution contact fax number (International)
Central Laboratory contact name
Central Lab Contact Phone Number
(International)
Central Lab Contact FAX Number (International)
Comments
Comments
Physician of Record
Date
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E2805 Material Submission Form NCT00326898
CALGB 40503 TREATMENT FORM
NCT00601900
CALGB 40503 TREATMENT FORM NCT00601900
Tamoxifen or Letrozole With or Without Bevacizumab in
Treating Women With Stage III or Stage IV Breast Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=2407A0C1-
E943-0D00-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/10985
CALGB 40503 TREATMENT FORM
NCT00601900
Header
CALGB Form
CALGB Study No
CALGB Patient ID
Cycle Start Date (MM DD YYYY)
Cycle end date (MM DD YYYY)
Are data amended
Yes
No
Patient demographics
Patient Initials (Last, First Middle)
Patient Hospital No.
Institution/Affiliate
Participating Group
Participating Group Study No.
Participating Group Patient ID
Cycle number
Current Cycle Number
Bevacizumab/placebo
Agent (Letrozole Tamoxifen)
1 / 2
Weight (this cycle)
Prescribed dose (mg/kg)
Total Actual Dose of Agents/Drugs for this cycle
(mg/kg)
Were there any delays in dose administration
Yes
No
Days Treatment Was Interrupted
Cycle Delayed Reason
Was bevacizumab/placebo treatment
discontinued
Yes
No
Treatment End date
LETROZOLE/TAMOXIFEN
Agent (Letrozole Tamoxifen)
Assigned Treatment Arm
Letrozole (Letrozole)
Tamoxifen (Tamoxifen)
Prescribed dose (mg/kg)
Total Actual Dose of Agents/Drugs for this cycle
(mg/kg)
Were there any delays in dose administration
Yes
No
Days Treatment Was Interrupted
Cycle Delayed Reason
Comments
Completed by (Last name, First name)
Date Form Originally Completed (MM DD YYYY)
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CALGB 40503 TREATMENT FORM NCT00601900
E2902 Material Submission Form - Form
1845 NCT00093470
E2902 Material Submission Form - Form 1845
NCT00093470 
Tipifarnib in Treating Patients With Acute Myeloid Leukemia
in Remission
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=DBE41C5E-
4D6F-6206-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/10986
E2902 Material Submission Form -
Form 1845 NCT00093470
Header
Registration Step
DCI Name
Report Period (Place ID Label Here)
Lab Data (Lab data)
Patient Initials (Last, Middle, First)
ECOG Protocol Number
ECOG Protocol Number
ECOG Patient ID
ECOG Patient ID
Participating Group Protocol Number
Participating Group Patient ID
Institution/Affiliate
Completed By Submitting Institutions
Date Material(s) sent to central laboratory
Shipped to
Ecog Cytogenetics Laboratory (ECOG
Cytogenetics Laboratory)
Ecog Leukemia Translational Studies
Laboratory (ECOG Leukemia
Translational Studies Laboratory)
Other Central Laboratory (Other Central
Laboratory)
Informed consent signed?
1 / 3
Yes
No
Sample No.
#1 (#1)
#2 (#2)
#3 (#3)
#4 (#4)
Date Specimens collected (MM/DD/YYYY)
Tissue/material type
Bone Marrow Aspirate (Bone marrow
aspirate)
Bone Marrow Biopsy (Bone marrow
biopsy)
Bone Marrow Smear (Bone marrow
smear)
Karyotype (Karotypes)
Other (Other)
Peripheral Blood (Peripheral blood)
Type of collection/stain/process
Slide/air Dried Smear (Air-dried smear)
Green Top (heparinized) (green top
(heparinized))
Slide/h&e (H&E slide)
Karyotype (Karotypes)
Other (Other)
Red Top (red top)
Slide/w-g Stain (W-G smear)
Timing of material collection
Initial Diagnosis (Initial Diagnosis)
Other (Other)
Pre-study Value (Pre-study)
Baseline/pretreatment (Pre-Treatment)
Relapse (Upon development of AML
relapse)
Upon Development Of Mds (Upon
development of MDS)
Number of specimens submitted (tubes, slides,
etc.)
Completed By Central Lab
Date of receipt of specimens
Condition of specimen
Damaged Or Unusable (damaged or
unusuable)
Useable (usuable)
Aliquots of sample made
Yes
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No
Contacts
Contact Person at Institution
Institution Contact Phone Number
Physician of Record
Institution Contact FAX Number
Central Laboratory Contact Name
Central Lab Contact Phone Number
Central Lab Contact Fax Number
Comments
Comments
Investigator Signature
Investigator Signature Date
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E2902 Material Submission Form - Form 1845 NCT00093470
E2805  FACIT-Fatique Subscale (Version 4)
NCT00326898
E2805  FACIT-Fatique Subscale (Version 4) NCT00326898 
Sunitinib or Sorafenib in Treating Patients With Kidney
Cancer That Was Removed By Surgery
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=6E9962A5-
327A-5CEE-E040-BB89AD43557D
All rights reserved. Please visit https://medical-data-
models.org/forms/10987
E2805  FACIT-Fatique Subscale
(Version 4) NCT00326898
Patient demographics
Patient Initials (Last, First)
ECOG Protocol Number
Participating Group Protocol Number
Institution/Affiliate
ECOG Patient ID
Participating Group Patient ID
Data amendment
Please mark an 'X' if data have been amended
(Please circle amended items in red)
Date data amended (M D Y)
Additional Concerns
I feel fatigued
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
How often did you feel tired
Always (Always)
Never (Never)
Often (Often)
Rarely (Rarely)
Sometimes (Sometimes)
I feel weak all over
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
1 / 4
Somewhat (Somewhat)
Very Much (Very much)
I feel listless ("washed out")
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have trouble starting things because I am tired
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have trouble finishing things because I am tired
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have energy
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am able to do my usual activities
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I need to sleep during the day
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am too tired to eat
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I need help doing my usual activities
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am frustrated by being too tired to do the things
I want to do
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A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have to limit my social activity because I am
tired
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
Fatigue - Short Form
How often did you feel tired
Always (Always)
Never (Never)
Often (Often)
Rarely (Rarely)
Sometimes (Sometimes)
How often did you experience extreme
exhaustion
Always (Always)
Never (Never)
Often (Often)
Rarely (Rarely)
Sometimes (Sometimes)
How often did you run out of energy
Always (Always)
Never (Never)
Often (Often)
Rarely (Rarely)
Sometimes (Sometimes)
How often did your fatigue limit you at work
(include work at home)
Always (Always)
Never (Never)
Often (Often)
Rarely (Rarely)
Sometimes (Sometimes)
How often were you too tired to think clearly
Always (Always)
Never (Never)
Often (Often)
Rarely (Rarely)
Sometimes (Sometimes)
How often were you too tired to take a bath or
shower
Always (Always)
Never (Never)
Often (Often)
Rarely (Rarely)
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Sometimes (Sometimes)
How often did you have enough energy to
exercise strenuously
Always (Always)
Never (Never)
Often (Often)
Rarely (Rarely)
Sometimes (Sometimes)
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E2905 Baseline Step 1 Disease Evaluation
Form NCT00843882
E2905 Baseline Step 1 Disease Evaluation Form
NCT00843882 
Lenalidomide With or Without Epoetin Alfa in Treating
Patients With Myelodysplastic Syndrome and Anemia
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=0EAB4E64-
72BE-45B3-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/10988
E2905 Baseline Step 1 Disease
Evaluation Form NCT00843882
Header
ECOG Protocol Number
ECOG Patient ID
DCI Name
Registration Step
Report period
Baseline Step 1 (Baseline Step 1)
Patient demographics
Patient Initials (Last, First)
ECOG Protocol Number
ECOG Patient ID
Participating Group Protocol Number
Participating Group Patient ID
Institution/Affiliate
Data amendment
Please mark an 'X' if data have been amended.
(Please circle amended items in red)
Date data amended (MM/DD/YYYY)
Pre-registration Hematology/chemistry
1 / 5
Hemoglobin (Hgb) (g/dl), LLN
Hemoglobin (Hgbg/dl)
Date (MM/DD/YYYY)
Peripheral platelet count, LLN (/mm^3x1000)
Peripheral Platelet Count (/mm^3x1000)
Date (MM/DD/YYYY)
Peripheral Granulocytes Count LLN
(AGC/ANC/mm^3)
Peripheral Granulocytes Count (AGC/ANC/mm^3
- Do not report % granulocytes: report absolute
count without decimal.)
Date
Peripheral WBC Count (/mm^3 x 1000)
Peripheral WBC count, LLN
Date
Creatinine
Creatinine ULN (mg/dl)
Date
Mean pre-transfusion hemoglobin
Leukemia Assessment
MDS classification
Chronic Myelomonocytic Leukemia
(Chronic Myelomonocytic Leukemia)
Myelodysplastic Syndrome Associated
With Isolated Del (5q) Chromosome
Abnormality (MDS associated with
isolated del(5q))
Myelodysplastic Syndrome,
Unclassifiable (Myelodysplastic
Syndrome, unclassified)
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Refractory Anemia (Refractory Anemia)
Raeb-1 (Refractory anemia with excess
blasts-1)
Raeb-2 (Refractory anemia with excess
blasts-2)
Refractory Anemia With Ringed
Sideroblasts (Refractory Anemia with
Ringed Sideroblasts)
Refractory Cytopenia With Multilineage
Dysplasia (Refractory Cytopenia with
Multilineage Dysplasia)
Refractory Cytopenia With Multilineage
Dysplasia And Ringed Sideroblasts
(Refractory Cytopenia with Multilineage
Dysplasia and Ringed Sideroblasts)
Date of Initial Pathologic Diagnosis
Date of Bone Marrow Biopsy (Aspirate)
Marrow Blasts (%) (Highest)
Marrow Cellularity (%)
Reason bone marrow cellularity was not recorded
Cellularity Status Of Bone Marrow
Unknown, Procedure Resulted In No
Material To Analyze (Dry Tap or
inaspirable)
Local Pathologist Did Not Quantify
Cellularity (Local pathologist did not
quantify cellularity)
Dysplasia
No (No)
Unknown (Unknown)
Yes (Yes)
Specify type (mark all that apply)
Erythroid (Erythroid)
Megakaryocyte (Megakaryocyte)
Myeloid (Myeloid)
Is cytogenetic abnormality present now
Inevaluable (Inevaluable)
No (No)
Yes (Yes)
Did the patient require packed red blood cell
(PRBC) transfusions (in the last 8 weeks)
No (No)
Unknown (Unknown)
Yes (Yes)
Total number of units PRBC (transfused in the
last 8 weeks)
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Date of First Transfusion (MM/DD/YYYY)
Date of most recent PRBC transfusion
(MM/DD/YYYY)
International Prognostic Score (ipss)
Marrow Blasts (%) (Highest)
Marrow Blasts (%) (Highest)
Date (Highest - Record earliest date of the values
- MM/DD/YYYY)
Date (Highest - Record earliest date of the values
- MM/DD/YYYY)
Karyotype (Highest)
Good (Good)
Intermediate (Intermediate)
Poor (POOR)
Karyotype (Highest)
Good (Good)
Intermediate (Intermediate)
Poor (POOR)
Number of Cytopenias (Highest - Red blood cells-
Hemoglobin <10 g/dl 100 g/L - White blood cells-
Absolute neutrophil count <1800/microliter -
Platelets- Platelet count <100,000/ microliter)
Number of Cytopenias (Highest - Red blood cells-
Hemoglobin <10 g/dl 100 g/L - White blood cells-
Absolute neutrophil count <1800/microliter -
Platelets- Platelet count <100,000/ microliter)
International Prognostic Score (IPSS) (Highest)
International Prognostic Score (IPSS) (Highest)
Baseline Abnormalities
CTC Adverse Event Term (Use CTCAE v4
terminology)
CTC Adverse Event Grade (Use grade 1-4 per
CTCAE v4)
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Mild Adverse Event (1)
Moderate Adverse Event (2)
Severe Adverse Event (3)
Life Threatening Adverse Event (4)
Comments
Investigator Signature
Investigator Signature Date
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E2902 Treatment Form - Arm A - Form
2051 NCT00093470
E2902 Treatment Form - Arm A - Form 2051
NCT00093470 
Tipifarnib in Treating Patients With Acute Myeloid Leukemia
in Remission
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=DC0913A2-
D106-01B6-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/10989
E2902 Treatment Form - Arm A -
Form 2051 NCT00093470
Header
ECOG Protocol Number
ECOG Patient ID
DCI Name
Registration Step (Place ID Label Here)
Patient Initials (Last, First)
Participating Group Protocol Number
Participating Group Patient ID
Institution/Affiliate
Report Period (Choose one)
> Cycle 33 (> Cycle 33)
Cycle 12 (Cycle 12)
Cycle 15 (Cycle 15)
Cycle 18 (Cycle 18)
Cycle 21 (Cycle 21)
Cycle 24 (Cycle 24)
Cycle 27 (Cycle 27)
Cycle 3 (Cycle 3)
Cycle 30 (Cycle 30)
Cycle 33 (Cycle 33)
Cycle 6 (Cycle 6)
Cycle 9 (Cycle 9)
Cycle (specify)
Are data amended
Yes
No
Vital Status
1 / 3
Patient Vital Status
Alive (Alive)
Dead (Dead)
Primary Cause of Death (if applicable)
Due To Other Cause, Specify (Due to
other cause)
Due To Protocol Treatment (Due to
protocol treatment)
Due To This Disease (Due to this
disease)
Unknown (Unknown)
Describe cause of death
Cycle Information- First Cycle Of Report
Period
Cycle Number
Performance status (Day 1 of this cycle)
Fully Active, Able To Carry On All Pre-
disease Performance Without Restriction
(karnofsky 90 - 100) (ecog - 0
Asymptomatic) (0)
Restricted In Physically Strenuous
Activity But Ambulatory (k70 - 80) (ecog -
1 Symptomatic - Fully Ambulatory) (1)
Ambulatory And Capable Of All Selfcare
But Unable To Carry Out Any Work
Activities (k 50 - 60) (ecog - 2
Symptomatic; In Bed , 50% Of The Day)
(2)
Capable Of Limited Selfcare, Confined
To Bed Or Chair More Than 50% Of
Waking Hours. (k 30 - 40) (ecog - 3
Symptomatic; In Bed > 50% Of The Day
But Not Bedridden) (3)
Completely Disabled (k10 - 20) (ecog - 4
Bedridden) (4)
Cycle Start Date
Cycle End Date (includes 7 days rest)
Prescribed R11577 dose on day 1 of this cycle
Did the patient complete the Patient Medication
Diary this cycle?
Yes
No
Specify reason patient diary was not completed
(If no:)
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total dose of agent for this cycle (If yes:)
Was treatment with the agent held for any part of
this cycle as prescribed by the treating physician?
No (no)
Yes, Planned (i.e., The Treatment Was
Changed According To Protocol
Guidelines) (yes, planned)
Yes, Unplanned (i.e., The Treatment
Change Was Not Part Of Protocol
Guidelines) (yes, unplanned)
Date of last dose (If yes:)
Reason for therapy modification
Cycle Information - Second Cycle Of
Report Period
Cycle Information - Third Cycle Of Report
Period
Non-protocol Therapy
Was any non-protocol therapy given (not
previously reported)
Yes
No
Related Forms
Comments
Comments
Investigator Signature
Investigator Signature Date
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ECOG Second Primary Form - Form 1677
NCT00093470
ECOG Second Primary Form - Form 1677 NCT00093470 
Tipifarnib in Treating Patients With Acute Myeloid Leukemia
in Remission
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=DBF953D3-
6B6E-1AB2-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/10990
ECOG Second Primary Form - Form
1677 NCT00093470
Header
ECOG Protocol Number
ECOG Patient ID
DCI Name (Place ID Label Here)
Patient Initials
Participating Group Protocol Number
Participating Group Patient ID
Institution/Affiliate
Registration Step
Time Period
Second Primary Cancer (Second
Primary)
Are data amended
Yes
No
Second primary cancer assessment
Date of Diagnosis of Second Primary Cancer
Site of Second Primary Cancer
Include information on histologic subtype(s)
(Please attach copies of any corroborating
pathology reports.)
Briefly describe cancer therapy the patient has
received prior to the diagnosis of the second
1 / 2
primary and other than that given on ECOG
protocols
Briefly describe treatment planned or given for
the diagnosis of this second primary
Comments
Comments
Investigator Signature
Investigator Signature Date
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ECOG Non-Protocol Therapy Form - Form
1676 NCT00093470
ECOG Non-Protocol Therapy Form - Form 1676
NCT00093470 
Tipifarnib in Treating Patients With Acute Myeloid Leukemia
in Remission
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=DBE5074B-
BC6B-6EF9-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/10991
ECOG Non-Protocol Therapy Form -
Form 1676 NCT00093470
Header
ECOG Protocol Number
ECOG Patient ID
DCI Name (Place ID Label Here)
Patient Initials
Participating Group Protocol Number
Participating Group Patient ID
Institution/Affiliate
Registration Step
Time Period
Non-protocol Therapy (Non-Protocol
Therapy)
Are data amended
Yes
No
Non-Protocol Therapy
Date of FIRST non-protocol therapy (if given prior
to progression/relapse from protocol therapy)
Non-protocol Chemotherapy
No (no)
Unknown (Unknown)
Yes (yes)
Non-protocol Hormonal Therapy
No (no)
Unknown (Unknown)
Yes (yes)
1 / 2
Non-protocol Immunotherapy (/Biological
Response Modifiers)
No (no)
Unknown (Unknown)
Yes (yes)
Non-protocol High Dose Chemotherapy/Stem
Cell Transplant (Autologous or Allogeneic)
No (no)
Unknown (Unknown)
Yes (yes)
Non-protocol Surgery
No (no)
Unknown (Unknown)
Yes (yes)
Non-protocol surgery type
Non-protocol Radiation Therapy
No (no)
Unknown (Unknown)
Yes (yes)
Non-protocol RT type
Other Non-protocol Therapy
No (no)
Unknown (Unknown)
Yes (yes)
Name of other non-protocol therapy
Was the non-protocol therapy given for the
disease of this protocol? (NOTE: Treatment for a
second primary in the same organ site would not
be considered therapy for disease of this
protocol.)
No (no)
Unknown (Unknown)
Yes (yes)
Comments
Comments (ECC use only)
Investigator Signature
Investigator Signature Date
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E2805 Central Pathology Review Form
NCT00326898
E2805 Central Pathology Review Form NCT00326898
Sunitinib or Sorafenib in Treating Patients With Kidney
Cancer That Was Removed By Surgery
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=05892A45-
3B6E-608C-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/10992
E2805 Central Pathology Review
Form NCT00326898
Header
ECOG Protocol Number
ECOG Patient ID
DCI Name
Registration Step
Reporting Period
Lab (Lab)
Patient demographics
Patient Initials
Participating Group Protocol Number
Institution/Affiliate
Participating Group Patient ID
Data amendment
Please mark an 'X' if data have been amended.
Date data amended
Primary Tumor
Primary Tumor Size
Mark an 'X' if unknown
1 / 3
Pathologic Tumor Stage
Laterality
Bilateral (bilateral)
Cannot Be Determined (Cannot be
determined)
Left (left)
Right (right)
Tumor Invasion
Cannot Be Determined (Cannot be
determined)
Capsule Intact (Capsule intact)
Invading Beyond Gerota's Fascia
(Invading beyond Gerota's fascia)
Invading Other Structures (Invading
other structures)
Invading Perirenal Fat (Invading perirenal
fat)
Invading other structures, specify
Vascular Invasion
Intrarenal (Intrarenal)
Ivc, Subdiaphragmatic (IVC,
subdiaphragmatic)
Ivc, Supradiaphragmatic (IVC,
supradiaphragmatic)
None Seen (None seen)
Renal (Renal)
Lymph Node Status And Metastases
Hilar nodes
Negative (Negative)
Not Sampled (Not sampled)
Positive (Positive)
Periaortic nodes
Negative (Negative)
Not Sampled (Not sampled)
Positive (Positive)
Other nodes
Negative (Negative)
Not Sampled (Not sampled)
Positive (Positive)
Metastases
Absent (Absent)
No Extrarenal Tissues Sampled (No
extrarenal tissues sampled)
Present (Present)
Specify site
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Pathological Features
Histologic Subtype
Chromophobe (Chromophobe)
Clear Cell (Clear cell)
Collecting Duct (Collecting duct)
Other (Other)
Papillary (Papillary)
Rcc, Unclassified (RCC, unclassified)
Other, specify
Type
Mixed (Mixed)
Type 1 (Type 1)
Type 2 (Type 2)
Sarcomatoid Features
Absent (Absent)
Cannot Be Assessed (Cannot be
assessed)
Present (Present)
Percent of tumor that is sarcomatoid (If present,)
Other histopathological findings
Fuhrman Grade
Coagulative necrosis
Absent (Absent)
Cannot Be Assessed (Cannot be
assessed)
Present (Present)
Percent coagulative necrosis (If present,)
Renal Sinus Invasion
Absent (Absent)
Cannot Be Assessed (Cannot be
assessed)
Present (Present)
Type of renal sinus invasion (If present,)
Both (Both)
Pelvic Stroma (Pelvic stroma)
Pelvic Vein (Pelvic vein)
Comments
Investigator Signature
Investigator Signature Date
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E3F05 Brain On-Study Form NCT00978458
E3F05 Brain On-Study Form NCT00978458 
Radiation Therapy With or Without Temozolomide in
Treating Patients With Low-Grade Glioma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=6C76FF0A-
A556-4EDB-E040-BB89AD4325FA
All rights reserved. Please visit https://medical-data-
models.org/forms/10993
E3F05 Brain On-Study Form
NCT00978458
Header
ECOG Protocol Number
ECOG Patient ID
DCI Name
Registration Step
Report Period
Baseline (Baseline)
Patient demographics
Patient Initials (Last, First)
Participating Group Protocol Number
ECOG Protocol Number
Institution/Affiliate
ECOG Patient ID
Participating Group Patient ID
Data amendment
Please mark an 'X' if data have been amended.
(Please circle amended items in red)
Date data amended (s M D Y)
Patient Description Pre-registration
Hematology/chemistry
1 / 4
Height (cm)
Weight (kg)
Peripheral Lymphocyte Count
LLN
Peripheral Granulocytes Count
(AGC/ANC/mm^3)
Peripheral Granulocytes Count LLN
(AGC/ANC/mm^3)
Peripheral Platelet Count (/mm^3 x1000)
Peripheral platelet count, LLN (/mm^3 x1000)
Peripheral Hematocrit Count (%)
Peripheral hematocrit count LLN (%)
SGOT (AST) (U/L)
SGOT (AST) ULN (U/L)
Test not done (Mark an "X" below if test not
done.)
Date Hematology (Blood) Sample Obtained (M D
Y)
Date of Definitive Histologic Diagnosis of Primary
Tumor (M D Y)
Date of Progression (tumor by serial MRI M D Y)
Mark an 'X' if N/A
Histologic Type
Astrocytoma (Astrocytoma)
Oligoastrocytoma (Oligoastrocytoma)
9450-3 Oligodendroglioma, Nos (c71._)
(Oligodendroglioma)
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Prior Brain Surgery
Date of prior surgery (M D Y)
Extent of Resection
Almost Total Resection >90% Removal
(Almost total resection >90% removal)
Biopsy (Biopsy)
Bulk Removal Or 50% To 89% Removal
(Bulk removal or 50% to 89% removal)
Minimal Excision <50% Total Estimated
Volume (Minimal excision <50% total
estimated volume)
Motivation For Study Entry
Medical History (Has patient been diagnosed with
any of the following code response for ALL)
Cognitive Symptoms Or Deficits
(Cognitive symptoms or deficits)
Focal Neurological Symptoms (Focal
neurological symptoms)
Headaches Associated With Mass Effect
(Headaches associated with mass effect)
Tumor Progression By Serial Mris,
Defined As New Enhancement (Tumor
progression by serial MRIs, defined as
New enhancement)
Tumor Progression By Serial Mris,
Defined As New T2 Or Flair Signal
Abnormality (Tumor progression by serial
MRIs, defined as New T2 or FLAIR
signal abnormality)
Uncontrolled Seizures Despite 2
Different Antiepileptic Drug Regimens
(Uncontrolled seizures despite 2 different
antiepileptic drug regimens)
Has the patient progressed radiographically (If
yes answer one of the following questions)
Yes
No
For newly diagnosed patients, or patients
entering at time of progression who have had
surgery for this progression, what was the pre-
operative maximum tumor diameter by T2/FLAIR
(cm)
For patients entering with disease progression
since primary surgery, and are not having new
surgery for this progression, enter maximum
tumor diameter at time of progression (cm)
Is the patient >= 40 years old
Yes
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No
Is the person receiving anti-convulsant
medication?
Yes
No
Adverse Events Present At Time Of
Registration (pre-treatment)
CTC Adverse Event Term (include subterm if
applicable Use Active Version of the NCI CTCAE
v4.0)
Seizure (Seizure)
Thromboembolism (Thromboembolic
event)
Tinnitus (Tinnitus)
CTC Adverse Event Grade (Use grade 1-4 per
CTCAE)
Mild Adverse Event (1)
Moderate Adverse Event (2)
Severe Adverse Event (3)
Life Threatening Adverse Event (4)
Comments
Investigator Signature
Investigator Signature Date (M D Y)
4 / 4
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E1208 Baseline Disease Evaluation Form
(RECIST) NCT01004978
E1208 Baseline Disease Evaluation Form (RECIST)
NCT01004978 
Chemoembolization With or Without Sorafenib Tosylate in
Treating Patients With Liver Cancer That Cannot Be
Removed By Surgery
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=6FC99A84-
9671-F189-E040-BB89AD4377B4
All rights reserved. Please visit https://medical-data-
models.org/forms/10994
E1208 Baseline Disease Evaluation
Form (RECIST) NCT01004978
Header
ECOG Protocol Number
ECOG Patient ID
DCI Name
Registration Step
Report Period
Baseline (Baseline)
Patient demographics
Patient Initials (Last, First)
ECOG Protocol Number
ECOG Patient ID
Participating Group Protocol Number
Participating Group Patient ID
Institution/Affiliate
Data amendment
Please mark an 'X' if data have been amended.
(Please circle amended items in red)
Date data amended (s M D Y)
TARGET LESIONS
1 / 3
Are there any target lesions
Yes
No
Lesion Number
Site of Lesion (Multiple nontarget lesions within
an organ may be combined as a single site;
report in a consistent manner on subsequent
forms)
Site Code
Bone (bone)
Brain (Brain)
Breast (Breast)
Effusion/ascites (Effusion/Ascites)
Gi (GI)
Gu (GU)
Head & Neck (Head & Neck)
Liver (Liver)
Lung (Lung)
Nodes (Nodes)
Other (other)
Skin (Skin)
Method of Evaluation
Bone Scan (Bone scan)
Chest X-ray (Chest X-Ray)
Clinical (Clinical Examination)
Ct Scan (CT Scan)
Mri (MRI (NMR))
Other (other)
Spiral Ct Scan (Spiral CT scan)
Ultrasound (Ultrasound)
Date of Evaluation (M D Y)
Longest Diameter of Lesion(s) (cm)
Sum of longest diameters of all target lesions
(cm)
Nontarget Lesions
Lesion Number
Site of Lesion (Multiple nontarget lesions within
an organ may be combined as a single site;
report in a consistent manner on subsequent
forms)
Site Code
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Bone (bone)
Brain (Brain)
Breast (Breast)
Effusion/ascites (Effusion/Ascites)
Gi (GI)
Gu (GU)
Head & Neck (Head & Neck)
Liver (Liver)
Lung (Lung)
Nodes (Nodes)
Other (other)
Skin (Skin)
Method of Evaluation
Bone Scan (Bone scan)
Chest X-ray (Chest X-Ray)
Clinical (Clinical Examination)
Ct Scan (CT Scan)
Mri (MRI (NMR))
Other (other)
Spiral Ct Scan (Spiral CT scan)
Ultrasound (Ultrasound)
Date of Evaluation (M D Y)
Cytology Result
Negative (Negative)
Not Done (Not done)
Positive (Positive)
Comments
Comments
Investigator Signature
Investigator Signature Date (M D Y)
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E1208 Baseline Disease Evaluation Form (RECIST) NCT01004978
E1208 Second Primary Form
NCT01004978
E1208 Second Primary Form NCT01004978 
Chemoembolization With or Without Sorafenib Tosylate in
Treating Patients With Liver Cancer That Cannot Be
Removed By Surgery
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=6FC65FB7-
39D1-797B-E040-BB89AD4315BB
All rights reserved. Please visit https://medical-data-
models.org/forms/10995
E1208 Second Primary Form
NCT01004978
Header
DCI Name
ECOG Protocol Number (If patient has been on
other therapeutic ECOG protocols, please list
protocols and patient ID numbers)
Registration Step
ECOG Patient ID (If patient has been on other
therapeutic ECOG protocols, please list protocols
and patient ID numbers)
Reporting Period
Second Primary Cancer (Second
Primary)
Patient demographics
Patient Initials (Last, First)
ECOG Protocol Number (If patient has been on
other therapeutic ECOG protocols, please list
protocols and patient ID numbers)
Participating Group Protocol Number
Institution/Affiliate
ECOG Patient ID (If patient has been on other
therapeutic ECOG protocols, please list protocols
and patient ID numbers)
Participating Group Patient ID
Data amendment
1 / 2
Please mark an 'X' if data have been amended.
(Please circle amended items in red)
Date data amended (s M D Y)
Second primary cancer assessment
Date of Diagnosis of Second Primary Cancer (M
D Y)
Site of Second Primary Cancer
Include information on histologic subtype (s
Please attach copies of any corroborating
pathology reports)
ECOG Protocol Number (If patient has been on
other therapeutic ECOG protocols, please list
protocols and patient ID numbers)
ECOG Patient ID (If patient has been on other
therapeutic ECOG protocols, please list protocols
and patient ID numbers)
Briefly describe cancer therapy the patient has
received prior to the diagnosis of the second
primary and other than that given on ECOG
protocols
Briefly describe treatment planned or given for
the diagnosis of this second primary
Comments
Investigator Signature
Investigator Signature Date (M D Y)
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E2905 Non-Protocol Therapy Form
NCT00843882
E2905 Non-Protocol Therapy Form NCT00843882 
Lenalidomide With or Without Epoetin Alfa in Treating
Patients With Myelodysplastic Syndrome and Anemia
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=0EAAC4E1-
8B9B-7470-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/10996
E2905 Non-Protocol Therapy Form
NCT00843882
Header
ECOG Protocol Number
ECOG Patient ID
DCI Name
Registration Step
Reporting Period
Non-protocol Therapy (Non-Protocol
Therapy)
Patient demographics
Patient Initials (Last, First)
ECOG Protocol Number
ECOG Patient ID
Participating Group Protocol Number
Participating Group Patient ID
Institution/Affiliate
Data amendment
Please mark an 'X' if data have been amended.
(Please circle amended items in red)
Date data amended (MM/DD/YYYY)
Non-Protocol Therapy
1 / 3
Date of FIRST non-protocol therapy (if given prior
to progression/relapse from protocol therapy)
Non-protocol Chemotherapy (Types of first non-
protocol therapy - which includes any cancer
therapy that is not part of the planned regimen.)
No (No)
Unknown (Unknown)
Yes (Yes)
Non-protocol Hormonal Therapy
No (No)
Unknown (Unknown)
Yes (Yes)
Non-protocol Immunotherapy (Biological
Response Modifiers)
No (No)
Unknown (Unknown)
Yes (Yes)
Non-protocol High Dose Chemotherapy/Stem
Cell Transplant (Autologous or Allogeneic)
No (No)
Unknown (Unknown)
Yes (Yes)
Non-protocol Surgery
No (No)
Unknown (Unknown)
Yes (Yes)
Non-protocol surgery type
Non-protocol Radiation Therapy
No (No)
Unknown (Unknown)
Yes (Yes)
Non-protocol RT type
Other Non-protocol Therapy
No (No)
Unknown (Unknown)
Yes (Yes)
Name of other non-protocol therapy
Was the non-protocol therapy given for the
disease of this protocol (NOTE: Treatment for a
second primary in the same organ site would not
be considered therapy for disease of this
protocol.)
No (No)
Unknown (Unknown)
Yes (Yes)
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Comments
Investigator Signature
Investigator Signature Date
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E1208 Off-Treatment Form NCT01004978
E1208 Off-Treatment Form NCT01004978 
Chemoembolization With or Without Sorafenib Tosylate in
Treating Patients With Liver Cancer That Cannot Be
Removed By Surgery
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=7041BC2E-
D506-911B-E040-BB89AD432643
All rights reserved. Please visit https://medical-data-
models.org/forms/10997
E1208 Off-Treatment Form
NCT01004978
Header
ECOG Protocol Number
ECOG Patient ID
DCI Name
Registration Step
Reporting Period
End Of Treatment (End of treatment)
Patient demographics
Patient Initials (Last, First)
Participating Group Protocol Number
ECOG Protocol Number
Institution/Affiliate
ECOG Patient ID
Participating Group Patient ID
Data amendment
Please mark an 'X' if data have been amended.
(Please circle amended items in red)
Date data amended (s m d y)
Vital Status
1 / 3
Patient's Vital Status
Alive (Alive)
Dead (Dead)
Date of Last Contact or Death (m d y)
Primary Cause of Death (if applicable)
Due To Other Cause (Due to other
cause)
Due To Protocol Treatment (Due to
protocol treatment)
Due To This Disease (Due to this
disease)
Unknown (Unknown)
Describe cause of death
Protocol therapy
Did patient receive protocol therapy
Yes
No
Off-protocol treatment
Reason Treatment Ended
Adverse Event/side Effects/complications
(Adverse Event/Side
Effects/Complications)
Alternative Therapy (Alternative therapy)
Death On Study (Death on study)
Disease Progression, Relapse During
Active Treatment (Disease progression,
relapse during active treatment)
Other (Other)
Patient Off-treatment For Other
Complicating Disease (Patient off-
treatment for other complicating disease)
Patient Withdrawal Or Refusal After
Beginning Protocol Therapy (Patient
withdrawal/refusal after beginning
protocol therapy)
Treatment Completed Per Protocol
Criteria (Treatment completed per
protocol criteria)
Other Complicating Disease specify (specify)
Other specify
Last date protocol therapy was given (m d y)
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Section Ii
Reason treatment never started
Adverse Event/side Effects/complications
(Adverse events/side
effects/complications)
Death Before Beginning Protocol
Therapy (Death before beginning
protocol therapy)
Disease Progression, Relapse Prior To
Beginning Protocol Therapy (Disease
progression, relapse before protocol
treatment)
Medical Decision (Medical decision)
No Treatment, Per Protocol Criteria (No
treatment assigned per protocol)
Other (Other)
Patient_ineligible (Patient ineligible)
Patient Withdrawal/refusal Before
Beginning Protocol Therapy (Patient
withdrawal/refusal before beginning
protocol therapy)
Other specify
Comments
Investigator Signature
Investigator Signature Date (MM DD YYYY)
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E1208 Hepatic On-Study Form
NCT01004978
E1208 Hepatic On-Study Form NCT01004978 
Chemoembolization With or Without Sorafenib Tosylate in
Treating Patients With Liver Cancer That Cannot Be
Removed By Surgery
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=6FC737FA-
1C8D-FBF0-E040-BB89AD4367A6
All rights reserved. Please visit https://medical-data-
models.org/forms/10998
E1208 Hepatic On-Study Form
NCT01004978
Header
ECOG Protocol Number
ECOG Patient ID
DCI Name
Registration Step
Report Period
Baseline (Baseline)
Patient demographics
Patient Initials (Last, First)
Participating Group Protocol Number
Participating Group Patient ID
Institution/Affiliate
Performance Status
Fully Active, Able To Carry On All Pre-
disease Performance Without
Restriction. (0)
Restricted In Physically Strenuous
Activity But Ambulatory And Able To
Carry Out Work Of A Light Or Sedentary
Nature, E.g., Light Housework, Office
Work. (1)
Ambulatory And Capable Of All Selfcare
But Unable To Carry Out Any Work
Activities. Up And About More Than 50%
Of Waking Hours. (2)
Capable Of Only Limited Selfcare,
Confined To Bed Or Chair More Than
50% Of Waking Hours. (3)
Completely Disabled. Cannot Carry On
Any Selfcare. Totally Confined To Bed Or
1 / 23
Chair. (4)
Height (cm)
Data amendment
Please mark an 'X' if data have been amended
(Please circle amended items in red)
Date data amended (s M D Y)
History Of Disease
Date of Initial Pathologic Diagnosis
Date of First Recurrence or Progression
Mark an 'X' if N/A
Date of Most Recent Prior Recurrence
Description Of Current Disease
Number of lobes involved
Pre-registration Evaluation
Is macrovascular invasion present
Yes
No
Is disease limited to intrahepatic vessels (If Yes:)
Yes
No
Is portal lymphadenopathy present
Yes
No
Has disease been deemed unresectable by a
qualified surgeon
Yes
No
What is the patient's hepatitis B status
Negative Finding (Negative)
Positive Finding (Positive)
Unknown (Unknown)
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What is the patient's hepatitis C status
Negative Finding (Negative)
Positive Finding (Positive)
Unknown (Unknown)
Has the patient received antineoplastic therapy
for non-malignant disease
Yes
No
Specify therapy and indication (If Yes:)
Prior therapy end date (for non-malignant
disease)
Prior RFA treatment
Yes
No
Date last RFA treatment ended
Prior transplant
Yes
No
Date of Transplant
Child Pugh Classification
Encephalopathy status (per CTCA v4.0)
Grade 1-2 (Grade 1-2)
Grade 3-4 (Grade 3-4)
None (None)
Ascites
Moderate (Moderate)
None (None)
Slight (Slight)
Albumin (g/dl)
< 2.8 (< 2.8)
> 3.5 (> 3.5)
2.8-3.5 (2.8-3.5)
Prothrombin time (seconds over control)
< 4 (< 4)
> 6 (> 6)
4-6 (4-6)
Bilirubin (mg/dl)
< 2 (< 2)
> 3 (> 3)
2-3 (2-3)
Child Pugh Score
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Child Pugh Classification (Grade A, B, C Refer to
table above)
Grade A (A)
Grade B (B)
Grade C (C)
Baseline Abnormalities
CTC Adverse Event Term
Abdominal Distension (Abdominal
distension)
Abdominal Infection (Abdominal
infection)
Abdominal Pain (Abdominal pain)
Abdominal Soft Tissue Necrosis
(Abdominal soft tissue necrosis)
Abducens Nerve Disorder (Abducens
nerve disorder)
Accessory Nerve Disorder (Accessory
nerve disorder)
Acidosis (Acidosis)
Acoustic Nerve Disorder Nos (Acoustic
nerve disorder NOS)
Activated Partial Thromboplastin Time
Prolonged (Activated partial
thromboplastin time prolonged)
Acute Coronary Syndrome (Acute
coronary syndrome)
Acute Kidney Injury (Acute kidney injury)
Adrenal Insufficiency (Adrenal
insufficiency)
Adult Respiratory Distress Syndrome
(Adult respiratory distress syndrome)
Agitation (Agitation)
Akathisia (Akathisia)
Alanine Aminotransferase Increased
(Alanine aminotransferase increased)
Alcohol Intolerance (Alcohol intolerance)
Alkaline Phosphatase Increased
(Alkaline phosphatase increased)
Alkalosis (Alkalosis)
Allergic Reaction (Allergic reaction)
Allergic Rhinitis (Allergic rhinitis)
Alopecia (Alopecia)
Amnesia (Amnesia)
Anal Fistula (Anal fistula)
Anal Hemorrhage (Anal hemorrhage)
Anal Mucositis (Anal mucositis)
Anal Necrosis (Anal necrosis)
Anal Pain (Anal pain)
Anal Stenosis (Anal stenosis)
Anal Ulcer (Anal ulcer)
Anaphylaxis (Anaphylaxis)
Anemia (Anemia)
Ankle Fracture (Ankle fracture)
Anorectal Infection (Anorectal infection)
Anorexia (Anorexia)
Anorgasmia (Anorgasmia)
Anxiety (Anxiety)
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Aortic Injury (Aortic injury)
Aortic Valve Disease (Aortic valve
disease)
Aphonia (Aphonia)
Apnea (Apnea)
Appendicitis (Appendicitis)
Appendicitis Perforated (Appendicitis
perforated)
Arachnoiditis (Arachnoiditis)
Arterial Injury (Arterial injury)
Arteritis Infective (Arteritis infective)
Arthralgia (Arthralgia)
Arthritis (Arthritis)
Ascites (Ascites)
Aspartate Aminotransferase Increased
(Aspartate aminotransferase increased)
Aspiration (Aspiration)
Asystole (Asystole)
Ataxia (Ataxia)
Atelectasis (Atelectasis)
Atrial Fibrillation (Atrial fibrillation)
Atrial Flutter (Atrial flutter)
Atrioventricular Block Complete
(Atrioventricular block complete)
Atrioventricular Block First Degree
(Atrioventricular block first degree)
Autoimmune Disorder (Autoimmune
disorder)
Avascular Necrosis (Avascular necrosis)
Azoospermia (Azoospermia)
Back Pain (Back pain)
Bile Duct Stenosis (Bile duct stenosis)
Biliary Anastomotic Leak (Biliary
anastomotic leak)
Biliary Fistula (Biliary fistula)
Biliary Tract Infection (Biliary tract
infection)
Bladder Anastomotic Leak (Bladder
anastomotic leak)
Bladder Infection (Bladder infection)
Bladder Perforation (Bladder perforation)
Bladder Spasm (Bladder spasm)
Bloating (Bloating)
Blood And Lymphatic System Disorders -
Other, Specify (Blood and lymphatic
system disorders - Other, Specify)
Blood Antidiuretic Hormone Abnormal
(Blood antidiuretic hormone abnormal)
Blood Bilirubin Increased (Blood bilirubin
increased)
Blood Corticotrophin Decreased (Blood
corticotrophin decreased)
Blood Gonadotrophin Abnormal (Blood
gonadotrophin abnormal)
Blood Prolactin Abnormal (Blood
prolactin abnormal)
Blurred Vision (Blurred vision)
Body Odor (Body odor)
Bone Infection (Bone infection)
Bone Marrow Hypocellular (Bone
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marrow hypocellular)
Bone Pain (Bone pain)
Brachial Plexopathy (Brachial
plexopathy)
Breast Atrophy (Breast atrophy)
Breast Infection (Breast infection)
Breast Pain (Breast pain)
Bronchial Fistula (Bronchial fistula)
Bronchial Infection (Bronchial infection)
Bronchial Obstruction (Bronchial
obstruction)
Bronchial Stricture (Bronchial stricture)
Bronchopleural Fistula (Bronchopleural
fistula)
Bronchopulmonary Hemorrhage
(Bronchopulmonary hemorrhage)
Bronchospasm (Bronchospasm)
Bruising (Bruising)
Bullous Dermatitis (Bullous dermatitis)
Burn (Burn)
Buttock Pain (Buttock pain)
Capillary Leak Syndrome (Capillary leak
syndrome)
Carbon Monoxide Diffusing Capacity
Decreased (Carbon monoxide diffusing
capacity decreased)
Cardiac Arrest (Cardiac arrest)
Cardiac Disorders - Other, Specify
(Cardiac disorders - Other, Specify)
Cardiac Troponin I Increased (Cardiac
troponin I increased)
Cardiac Troponin T Increased (Cardiac
troponin T increased)
Cataract (Cataract)
Catheter Related Infection (Catheter
related infection)
Cd4 Lymphocytes Decreased (CD4
lymphocytes decreased)
Cecal Hemorrhage (Cecal hemorrhage)
Cecal Infection (Cecal infection)
Central Nervous System Necrosis
(Central nervous system necrosis)
Cerebrospinal Fluid Leakage
(Cerebrospinal fluid leakage)
Cervicitis Infection (Cervicitis infection)
Cheilitis (Cheilitis)
Chest Pain - Cardiac (Chest pain -
cardiac)
Chest Wall Pain (Chest wall pain)
Chills (Chills)
Cholecystitis (Cholecystitis)
Cholesterol High (Cholesterol high)
Chronic Kidney Disease (Chronic kidney
disease)
Chylothorax (Chylothorax)
Cognitive Disturbance (Cognitive
disturbance)
Colitis (Colitis)
Colonic Fistula (Colonic fistula)
Colonic Hemorrhage (Colonic
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hemorrhage)
Colonic Obstruction (Colonic obstruction)
Colonic Perforation (Colonic perforation)
Colonic Stenosis (Colonic stenosis)
Colonic Ulcer (Colonic ulcer)
Concentration Impairment
(Concentration impairment)
Conduction Disorder (Conduction
disorder)
Confusion (Confusion)
Congenital, Familial And Genetic
Disorders - Other, Specify (Congenital,
familial and genetic disorders - Other,
Specify)
Conjunctivitis (Conjunctivitis)
Conjunctivitis Infective (Conjunctivitis
infective)
Constipation (Constipation)
Constrictive Pericarditis (Constrictive
pericarditis)
Corneal Infection (Corneal infection)
Corneal Ulcer (Corneal ulcer)
Cough (Cough)
Cpk Increased (CPK increased)
Cranial Nerve Infection (Cranial nerve
infection)
Creatinine Increased (Creatinine
increased)
Cushingoid (Cushingoid)
Cystitis Noninfective (Cystitis
noninfective)
Cytokine Release Syndrome (Cytokine
release syndrome)
Death Neonatal (Death neonatal)
Death Nos (Death NOS)
Dehydration (Dehydration)
Delayed Orgasm (Delayed orgasm)
Delayed Puberty (Delayed puberty)
Delirium (Delirium)
Delusions (Delusions)
Dental Caries (Dental caries)
Depressed Level Of Consciousness
(Depressed level of consciousness)
Depression (Depression)
Dermatitis Radiation (Dermatitis
radiation)
Device Related Infection (Device related
infection)
Diarrhea (Diarrhea)
Disseminated Intravascular Coagulation
(Disseminated intravascular coagulation)
Dizziness (Dizziness)
Dry Eye (Dry eye)
Dry Mouth (Dry mouth)
Dry Skin (Dry skin)
Duodenal Fistula (Duodenal fistula)
Duodenal Hemorrhage (Duodenal
hemorrhage)
Duodenal Infection (Duodenal infection)
Duodenal Obstruction (Duodenal
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obstruction)
Duodenal Perforation (Duodenal
perforation)
Duodenal Stenosis (Duodenal stenosis)
Duodenal Ulcer (Duodenal ulcer)
Dysarthria (Dysarthria)
Dysesthesia (Dysesthesia)
Dysgeusia (Dysgeusia)
Dysmenorrhea (Dysmenorrhea)
Dyspareunia (Dyspareunia)
Dyspepsia (Dyspepsia)
Dysphagia (Dysphagia)
Dysphasia (Dysphasia)
Dyspnea (Dyspnea)
Ear And Labyrinth Disorders - Other,
Specify (Ear and labyrinth disorders -
Other, Specify)
Ear Pain (Ear pain)
Edema Cerebral (Edema cerebral)
Edema Face (Edema face)
Edema Limbs (Edema limbs)
Edema Trunk (Edema trunk)
Ejaculation Disorder (Ejaculation
disorder)
Ejection Fraction Decreased (Ejection
fraction decreased)
Electrocardiogram Qt Corrected Interval
Prolonged (Electrocardiogram QT
corrected interval prolonged)
Encephalitis Infection (Encephalitis
infection)
Encephalomyelitis Infection
(Encephalomyelitis infection)
Encephalopathy (Encephalopathy)
Endocarditis Infective (Endocarditis
infective)
Endocrine Disorders - Other, Specify
(Endocrine disorders - Other, Specify)
Endophthalmitis (Endophthalmitis)
Enterocolitis (Enterocolitis)
Enterocolitis Infectious (Enterocolitis
infectious)
Enterovesical Fistula (Enterovesical
fistula)
Epistaxis (Epistaxis)
Erectile Dysfunction (Erectile
dysfunction)
Erythema Multiforme (Erythema
multiforme)
Erythroderma (Erythroderma)
Esophageal Anastomotic Leak
(Esophageal anastomotic leak)
Esophageal Fistula (Esophageal fistula)
Esophageal Hemorrhage (Esophageal
hemorrhage)
Esophageal Infection (Esophageal
infection)
Esophageal Necrosis (Esophageal
necrosis)
Esophageal Obstruction (Esophageal
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obstruction)
Esophageal Pain (Esophageal pain)
Esophageal Perforation (Esophageal
perforation)
Esophageal Stenosis (Esophageal
stenosis)
Esophageal Ulcer (Esophageal ulcer)
Esophageal Varices Hemorrhage
(Esophageal varices hemorrhage)
Esophagitis (Esophagitis)
Euphoria (Euphoria)
Exostosis (Exostosis)
External Ear Inflammation (External ear
inflammation)
External Ear Pain (External ear pain)
Extraocular Muscle Paresis (Extraocular
muscle paresis)
Extrapyramidal Disorder (Extrapyramidal
disorder)
Eye Disorders - Other, Specify (Eye
disorders - Other, Specify)
Eye Infection (Eye infection)
Eye Pain (Eye pain)
Eyelid Function Disorder (Eyelid function
disorder)
Facial Muscle Weakness (Facial muscle
weakness)
Facial Nerve Disorder (Facial nerve
disorder)
Facial Pain (Facial pain)
Fall (Fall)
Fallopian Tube Anastomotic Leak
(Fallopian tube anastomotic leak)
Fallopian Tube Obstruction (Fallopian
tube obstruction)
Fallopian Tube Perforation (Fallopian
tube perforation)
Fallopian Tube Stenosis (Fallopian tube
stenosis)
Fat Atrophy (Fat atrophy)
Fatigue (Fatigue)
Febrile Neutropenia (Febrile
neutropenia)
Fecal Incontinence (Fecal incontinence)
Female Genital Tract Fistula (Female
genital tract fistula)
Feminization Acquired (Feminization
acquired)
Fetal Death (Fetal death)
Fetal Growth Retardation (Fetal growth
retardation)
Fever (Fever)
Fibrinogen Decreased (Fibrinogen
decreased)
Fibrosis Deep Connective Tissue
(Fibrosis deep connective tissue)
Flank Pain (Flank pain)
Flashing Lights (Flashing lights)
Flatulence (Flatulence)
Floaters (Floaters)
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Flu Like Symptoms (Flu like symptoms)
Flushing (Flushing)
Forced Expiratory Volume Decreased
(Forced expiratory volume decreased)
Fracture (Fracture)
Gait Disturbance (Gait disturbance)
Gallbladder Fistula (Gallbladder fistula)
Gallbladder Infection (Gallbladder
infection)
Gallbladder Necrosis (Gallbladder
necrosis)
Gallbladder Obstruction (Gallbladder
obstruction)
Gallbladder Pain (Gallbladder pain)
Gallbladder Perforation (Gallbladder
perforation)
Gastric Anastomotic Leak (Gastric
anastomotic leak)
Gastric Fistula (Gastric fistula)
Gastric Hemorrhage (Gastric
hemorrhage)
Gastric Necrosis (Gastric necrosis)
Gastric Perforation (Gastric perforation)
Gastric Stenosis (Gastric stenosis)
Gastric Ulcer (Gastric ulcer)
Gastritis (Gastritis)
Gastroesophageal Reflux Disease
(Gastroesophageal reflux disease)
Gastrointestinal Anastomotic Leak
(Gastrointestinal anastomotic leak)
Gastrointestinal Disorders - Other,
Specify (Gastrointestinal disorders -
Other, Specify)
Gastrointestinal Fistula (Gastrointestinal
fistula)
Gastrointestinal Pain (Gastrointestinal
pain)
Gastrointestinal Stoma Necrosis
(Gastrointestinal stoma necrosis)
Gastroparesis (Gastroparesis)
General Disorders And Administration
Site Conditions - Other, Specify (General
disorders and administration site
conditions - Other, Specify)
Generalized Muscle Weakness
(Generalized muscle weakness)
Genital Edema (Genital edema)
Ggt Increased (GGT increased)
Gingival Pain (Gingival pain)
Glaucoma (Glaucoma)
Glossopharyngeal Nerve Disorder
(Glossopharyngeal nerve disorder)
Glucose Intolerance (Glucose
intolerance)
Growth Accelerated (Growth
accelerated)
Growth Hormone Abnormal (Growth
hormone abnormal)
Growth Suppression (Growth
suppression)
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Gum Infection (Gum infection)
Gynecomastia (Gynecomastia)
Hallucinations (Hallucinations)
Haptoglobin Decreased (Haptoglobin
decreased)
Head Soft Tissue Necrosis (Head soft
tissue necrosis)
Headache (Headache)
Hearing Impaired (Hearing impaired)
Heart Failure (Heart failure)
Hematoma (Hematoma)
Hematosalpinx (Hematosalpinx)
Hematuria (Hematuria)
Hemoglobin Increased (Hemoglobin
increased)
Hemoglobinuria (Hemoglobinuria)
Hemolysis (Hemolysis)
Hemolytic Uremic Syndrome (Hemolytic
uremic syndrome)
Hemorrhoidal Hemorrhage
(Hemorrhoidal hemorrhage)
Hemorrhoids (Hemorrhoids)
Hepatic Failure (Hepatic failure)
Hepatic Hemorrhage (Hepatic
hemorrhage)
Hepatic Infection (Hepatic infection)
Hepatic Necrosis (Hepatic necrosis)
Hepatic Pain (Hepatic pain)
Hepatitis Viral (Hepatitis viral)
Hepatobiliary Disorders - Other, Specify
(Hepatobiliary disorders - Other, Specify)
Hiccups (Hiccups)
Hip Fracture (Hip fracture)
Hirsutism (Hirsutism)
Hoarseness (Hoarseness)
Hot Flashes (Hot flashes)
Hydrocephalus (Hydrocephalus)
Hypercalcemia (Hypercalcemia)
Hyperglycemia (Hyperglycemia)
Hyperhidrosis (Hyperhidrosis)
Hyperkalemia (Hyperkalemia)
Hypermagnesemia (Hypermagnesemia)
Hypernatremia (Hypernatremia)
Hyperparathyroidism
(Hyperparathyroidism)
Hypersomnia (Hypersomnia)
Hypertension (Hypertension)
Hyperthyroidism (Hyperthyroidism)
Hypertrichosis (Hypertrichosis)
Hypertriglyceridemia
(Hypertriglyceridemia)
Hyperuricemia (Hyperuricemia)
Hypoalbuminemia (Hypoalbuminemia)
Hypocalcemia (Hypocalcemia)
Hypoglossal Nerve Disorder
(Hypoglossal nerve disorder)
Hypoglycemia (Hypoglycemia)
Hypohidrosis (Hypohidrosis)
Hypokalemia (Hypokalemia)
Hypomagnesemia (Hypomagnesemia)
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Hyponatremia (Hyponatremia)
Hypoparathyroidism
(Hypoparathyroidism)
Hypophosphatemia (Hypophosphatemia)
Hypotension (Hypotension)
Hypothermia (Hypothermia)
Hypothyroidism (Hypothyroidism)
Hypoxia (Hypoxia)
Ileal Fistula (Ileal fistula)
Ileal Hemorrhage (Ileal hemorrhage)
Ileal Obstruction (Ileal obstruction)
Ileal Perforation (Ileal perforation)
Ileal Stenosis (Ileal stenosis)
Ileal Ulcer (Ileal ulcer)
Ileus (Ileus)
Immune System Disorders - Other,
Specify (Immune system disorders -
Other, Specify)
Infections And Infestations - Other,
Specify (Infections and infestations -
Other, Specify)
Infective Myositis (Infective myositis)
Infusion Related Reaction (Infusion
related reaction)
Infusion Site Extravasation (Infusion site
extravasation)
Injection Site Reaction (Injection site
reaction)
Injury To Carotid Artery (Injury to carotid
artery)
Injury To Inferior Vena Cava (Injury to
inferior vena cava)
Injury To Jugular Vein (Injury to jugular
vein)
Injury To Superior Vena Cava (Injury to
superior vena cava)
Injury, Poisoning And Procedural
Complications - Other, Specify (Injury,
poisoning and procedural complications -
Other, Specify)
Inr Increased (INR increased)
Insomnia (Insomnia)
Intestinal Stoma Leak (Intestinal stoma
leak)
Intestinal Stoma Obstruction (Intestinal
stoma obstruction)
Intestinal Stoma Site Bleeding (Intestinal
stoma site bleeding)
Intra-abdominal Hemorrhage (Intra-
abdominal hemorrhage)
Intracranial Hemorrhage (Intracranial
hemorrhage)
Intraoperative Arterial Injury
(Intraoperative arterial injury)
Intraoperative Breast Injury
(Intraoperative breast injury)
Intraoperative Cardiac Injury
(Intraoperative cardiac injury)
Intraoperative Ear Injury (Intraoperative
ear injury)
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Intraoperative Endocrine Injury
(Intraoperative endocrine injury)
Intraoperative Gastrointestinal Injury
(Intraoperative gastrointestinal injury)
Intraoperative Head And Neck Injury
(Intraoperative head and neck injury)
Intraoperative Hemorrhage
(Intraoperative hemorrhage)
Intraoperative Hepatobiliary Injury
(Intraoperative hepatobiliary injury)
Intraoperative Musculoskeletal Injury
(Intraoperative musculoskeletal injury)
Intraoperative Neurological Injury
(Intraoperative neurological injury)
Intraoperative Ocular Injury
(Intraoperative ocular injury)
Intraoperative Renal Injury
(Intraoperative renal injury)
Intraoperative Reproductive Tract Injury
(Intraoperative reproductive tract injury)
Intraoperative Respiratory Injury
(Intraoperative respiratory injury)
Intraoperative Skin Injury (Intraoperative
skin injury)
Intraoperative Splenic Injury
(Intraoperative splenic injury)
Intraoperative Urinary Injury
(Intraoperative urinary injury)
Intraoperative Venous Injury
(Intraoperative venous injury)
Investigations - Other, Specify
(Investigations - Other, Specify)
Iron Overload (Iron overload)
Irregular Menstruation (Irregular
menstruation)
Irritability (Irritability)
Ischemia Cerebrovascular (Ischemia
cerebrovascular)
Ivth Nerve Disorder (IVth nerve disorder)
Jejunal Fistula (Jejunal fistula)
Jejunal Hemorrhage (Jejunal
hemorrhage)
Jejunal Obstruction (Jejunal obstruction)
Jejunal Perforation (Jejunal perforation)
Jejunal Stenosis (Jejunal stenosis)
Jejunal Ulcer (Jejunal ulcer)
Joint Effusion (Joint effusion)
Joint Infection (Joint infection)
Joint Range Of Motion Decreased (Joint
range of motion decreased)
Joint Range Of Motion Decreased
Cervical Spine (Joint range of motion
decreased cervical spine)
Joint Range Of Motion Decreased
Lumbar Spine (Joint range of motion
decreased lumbar spine)
Keratitis (Keratitis)
Kidney Anastomotic Leak (Kidney
anastomotic leak)
Kidney Infection (Kidney infection)
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Kyphosis (Kyphosis)
Lactation Disorder (Lactation disorder)
Large Intestinal Anastomotic Leak (Large
intestinal anastomotic leak)
Laryngeal Edema (Laryngeal edema)
Laryngeal Fistula (Laryngeal fistula)
Laryngeal Hemorrhage (Laryngeal
hemorrhage)
Laryngeal Inflammation (Laryngeal
inflammation)
Laryngeal Mucositis (Laryngeal
mucositis)
Laryngeal Obstruction (Laryngeal
obstruction)
Laryngeal Stenosis (Laryngeal stenosis)
Laryngitis (Laryngitis)
Laryngopharyngeal Dysesthesia
(Laryngopharyngeal dysesthesia)
Laryngospasm (Laryngospasm)
Left Ventricular Systolic Dysfunction (Left
ventricular systolic dysfunction)
Lethargy (Lethargy)
Leukemia Secondary To Oncology
Chemotherapy (Leukemia secondary to
oncology chemotherapy)
Leukocytosis (Leukocytosis)
Leukoencephalopathy
(Leukoencephalopathy)
Libido Decreased (Libido decreased)
Libido Increased (Libido increased)
Lip Infection (Lip infection)
Lip Pain (Lip pain)
Lipase Increased (Lipase increased)
Lipohypertrophy (Lipohypertrophy)
Localized Edema (Localized edema)
Lordosis (Lordosis)
Lower Gastrointestinal Hemorrhage
(Lower gastrointestinal hemorrhage)
Lung Infection (Lung infection)
Lymph Gland Infection (Lymph gland
infection)
Lymph Leakage (Lymph leakage)
Lymph Node Pain (Lymph node pain)
Lymphedema (Lymphedema)
Lymphocele (Lymphocele)
Lymphocyte Count Decreased
(Lymphocyte count decreased)
Lymphocyte Count Increased
(Lymphocyte count increased)
Malabsorption (Malabsorption)
Malaise (Malaise)
Mania (Mania)
Mediastinal Hemorrhage (Mediastinal
hemorrhage)
Mediastinal Infection (Mediastinal
infection)
Memory Impairment (Memory
impairment)
Meningismus (Meningismus)
Meningitis (Meningitis)
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Menopause (Menopause)
Menorrhagia (Menorrhagia)
Metabolism And Nutrition Disorders -
Other, Specify (Metabolism and nutrition
disorders - Other, Specify)
Middle Ear Inflammation (Middle ear
inflammation)
Mitral Valve Disease (Mitral valve
disease)
Mobitz (type) Ii Atrioventricular Block
(Mobitz (type) II atrioventricular block)
Mobitz Type I (Mobitz type I)
Movements Involuntary (Movements
involuntary)
Mucosal Infection (Mucosal infection)
Mucositis Oral (Mucositis oral)
Multi-organ Failure (Multi-organ failure)
Muscle Weakness Left-sided (Muscle
weakness left-sided)
Muscle Weakness Lower Limb (Muscle
weakness lower limb)
Muscle Weakness Right-sided (Muscle
weakness right-sided)
Muscle Weakness Trunk (Muscle
weakness trunk)
Muscle Weakness Upper Limb (Muscle
weakness upper limb)
Musculoskeletal And Connective Tissue
Disorder - Other, Specify
(Musculoskeletal and connective tissue
disorders - Other, Specify)
Musculoskeletal Deformity
(Musculoskeletal deformity)
Myalgia (Myalgia)
Myelitis (Myelitis)
Myelodysplastic Syndrome
(Myelodysplastic syndrome)
Myocardial Infarction (Myocardial
infarction)
Myocarditis (Myocarditis)
Myositis (Myositis)
Nail Discoloration (Nail discoloration)
Nail Infection (Nail infection)
Nail Loss (Nail loss)
Nail Ridging (Nail ridging)
Nasal Congestion (Nasal congestion)
Nausea (Nausea)
Neck Edema (Neck edema)
Neck Pain (Neck pain)
Neck Soft Tissue Necrosis (Neck soft
tissue necrosis)
Neoplasms Benign, Malignant And
Unspecified (incl Cysts And Polyps) -
Other, Specify (Neoplasms benign,
malignant and unspecified (incl cysts and
polyps) - Other, Specify)
Nervous System Disorders - Other,
Specify (Nervous system disorders -
Other, Specify)
Neuralgia (Neuralgia)
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Neutrophil Count Decreased (Neutrophil
count decreased)
Night Blindness (Night blindness)
Nipple Deformity (Nipple deformity)
Non-cardiac Chest Pain (Non-cardiac
chest pain)
Nystagmus (Nystagmus)
Obesity (Obesity)
Obstruction Gastric (Obstruction gastric)
Oculomotor Nerve Disorder (Oculomotor
nerve disorder)
Olfactory Nerve Disorder (Olfactory
nerve disorder)
Oligospermia (Oligospermia)
Optic Nerve Disorder (Optic nerve
disorder)
Oral Cavity Fistula (Oral cavity fistula)
Oral Dysesthesia (Oral dysesthesia)
Oral Hemorrhage (Oral hemorrhage)
Oral Pain (Oral pain)
Osteonecrosis Of Jaw (Osteonecrosis of
jaw)
Osteoporosis (Osteoporosis)
Otitis Externa (Otitis externa)
Otitis Media (Otitis media)
Ovarian Hemorrhage (Ovarian
hemorrhage)
Ovarian Infection (Ovarian infection)
Ovarian Rupture (Ovarian rupture)
Ovulation Pain (Ovulation pain)
Pain (Pain)
Pain In Extremity (Pain in extremity)
Pain Of Skin (Pain of skin)
Palmar-plantar Erythrodysesthesia
Syndrome (Palmar-plantar
erythrodysesthesia syndrome)
Palpitations (Palpitations)
Pancreas Infection (Pancreas infection)
Pancreatic Anastomotic Leak (Pancreatic
anastomotic leak)
Pancreatic Duct Stenosis (Pancreatic
duct stenosis)
Pancreatic Enzymes Decreased
(Pancreatic enzymes decreased)
Pancreatic Fistula (Pancreatic fistula)
Pancreatic Hemorrhage (Pancreatic
hemorrhage)
Pancreatic Necrosis (Pancreatic
necrosis)
Pancreatitis (Pancreatitis)
Papilledema (Papilledema)
Papulopustular Rash (Papulopustular
rash)
Paresthesia (Paresthesia)
Paronychia (Paronychia)
Paroxysmal Atrial Tachycardia
(Paroxysmal atrial tachycardia)
Pelvic Floor Muscle Weakness (Pelvic
floor muscle weakness)
Pelvic Infection (Pelvic infection)
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Pelvic Pain (Pelvic pain)
Pelvic Soft Tissue Necrosis (Pelvic soft
tissue necrosis)
Penile Infection (Penile infection)
Penile Pain (Penile pain)
Perforation Bile Duct (Perforation bile
duct)
Pericardial Effusion (Pericardial effusion)
Pericardial Tamponade (Pericardial
tamponade)
Pericarditis (Pericarditis)
Perineal Pain (Perineal pain)
Periodontal Disease (Periodontal
disease)
Periorbital Edema (Periorbital edema)
Periorbital Infection (Periorbital infection)
Peripheral Ischemia (Peripheral
ischemia)
Peripheral Motor Neuropathy (Peripheral
motor neuropathy)
Peripheral Nerve Infection (Peripheral
nerve infection)
Peripheral Sensory Neuropathy
(Peripheral sensory neuropathy)
Peritoneal Infection (Peritoneal infection)
Peritoneal Necrosis (Peritoneal necrosis)
Personality Change (Personality change)
Phantom Pain (Phantom pain)
Pharyngeal Anastomotic Leak
(Pharyngeal anastomotic leak)
Pharyngeal Fistula (Pharyngeal fistula)
Pharyngeal Hemorrhage (Pharyngeal
hemorrhage)
Pharyngeal Mucositis (Pharyngeal
mucositis)
Pharyngeal Necrosis (Pharyngeal
necrosis)
Pharyngeal Stenosis (Pharyngeal
stenosis)
Pharyngitis (Pharyngitis)
Pharyngolaryngeal Pain
(Pharyngolaryngeal pain)
Phlebitis (Phlebitis)
Phlebitis Infective (Phlebitis infective)
Photophobia (Photophobia)
Photosensitivity (Photosensitivity)
Platelet Count Decreased (Platelet count
decreased)
Pleural Effusion (Pleural effusion)
Pleural Hemorrhage (Pleural
hemorrhage)
Pleural Infection (Pleural infection)
Pleuritic Pain (Pleuritic pain)
Pneumonitis (Pneumonitis)
Pneumothorax (Pneumothorax)
Portal Hypertension (Portal
hypertension)
Portal Vein Thrombosis (Portal vein
thrombosis)
Postnasal Drip (Postnasal drip)
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Postoperative Hemorrhage
(Postoperative hemorrhage)
Postoperative Thoracic Procedure
Complication (Postoperative thoracic
procedure complication)
Precocious Puberty (Precocious
puberty)
Pregnancy, Puerperium And Perinatal
Conditions - Other, Specify (Pregnancy,
puerperium and perinatal conditions -
Other, Specify)
Premature Delivery (Premature delivery)
Premature Menopause (Premature
menopause)
Presyncope (Presyncope)
Proctitis (Proctitis)
Productive Cough (Productive cough)
Prolapse Of Intestinal Stoma (Prolapse
of intestinal stoma)
Prolapse Of Urostomy (Prolapse of
urostomy)
Prostate Infection (Prostate infection)
Prostatic Hemorrhage (Prostatic
hemorrhage)
Prostatic Obstruction (Prostatic
obstruction)
Prostatic Pain (Prostatic pain)
Proteinuria (Proteinuria)
Pruritus (Pruritus)
Psychiatric Disorders - Other, Specify
(Psychiatric disorders - Other, Specify)
Psychosis (Psychosis)
Pulmonary Edema (Pulmonary edema)
Pulmonary Fibrosis (Pulmonary fibrosis)
Pulmonary Fistula (Pulmonary fistula)
Pulmonary Hypertension (Pulmonary
hypertension)
Pulmonary Valve Disease (Pulmonary
valve disease)
Purpura (Purpura)
Pyramidal Tract Syndrome (Pyramidal
tract syndrome)
Radiation Recall Reaction (dermatologic)
(Radiation recall reaction (dermatologic))
Radiculitis (Radiculitis)
Rash Acneiform (Rash acneiform)
Rash Maculo-papular (Rash maculo-
papular)
Rash Pustular (Rash pustular)
Rectal Anastomotic Leak (Rectal
anastomotic leak)
Rectal Fistula (Rectal fistula)
Rectal Hemorrhage (Rectal hemorrhage)
Rectal Mucositis (Rectal mucositis)
Rectal Necrosis (Rectal necrosis)
Rectal Obstruction (Rectal obstruction)
Rectal Pain (Rectal pain)
Rectal Perforation (Rectal perforation)
Rectal Stenosis (Rectal stenosis)
Rectal Ulcer (Rectal ulcer)
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Recurrent Laryngeal Nerve Palsy
(Recurrent laryngeal nerve palsy)
Renal And Urinary Disorders - Other,
Specify (Renal and urinary disorders -
Other, Specify)
Renal Calculi (Renal calculi)
Renal Colic (Renal colic)
Renal Hemorrhage (Renal hemorrhage)
Reproductive System And Breast
Disorders - Other, Specify (Reproductive
system and breast disorders - Other,
Specify)
Respiratory Failure (Respiratory failure)
Respiratory, Thoracic And Mediastinal
Disorders - Other, Specify (Respiratory,
thoracic and mediastinal disorders -
Other, Specify)
Restlessness (Restlessness)
Restrictive Cardiomyopathy (Restrictive
cardiomyopathy)
Retinal Detachment (Retinal
detachment)
Retinal Tear (Retinal tear)
Retinal Vascular Disorder (Retinal
vascular disorder)
Retinoic Acid Syndrome (Retinoic acid
syndrome)
Retinopathy (Retinopathy)
Retroperitoneal Hemorrhage
(Retroperitoneal hemorrhage)
Reversible Posterior
Leukoencephalopathy Syndrome
(Reversible posterior
leukoencephalopathy syndrome)
Rhinitis Infective (Rhinitis infective)
Right Ventricular Dysfunction (Right
ventricular dysfunction)
Salivary Duct Inflammation (Salivary duct
inflammation)
Salivary Gland Fistula (Salivary gland
fistula)
Salivary Gland Infection (Salivary gland
infection)
Scalp Pain (Scalp pain)
Scleral Disorder (Scleral disorder)
Scoliosis (Scoliosis)
Scrotal Infection (Scrotal infection)
Scrotal Pain (Scrotal pain)
Seizure (Seizure)
Sepsis (Sepsis)
Seroma (Seroma)
Serum Amylase Increased (Serum
amylase increased)
Serum Sickness (Serum sickness)
Sick Sinus Syndrome (Sick sinus
syndrome)
Sinus Bradycardia (Sinus bradycardia)
Sinus Disorder (Sinus disorder)
Sinus Pain (Sinus pain)
Sinus Tachycardia (Sinus tachycardia)
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Sinusitis (Sinusitis)
Skin And Subcutaneous Tissue
Disorders - Other, Specify (Skin and
subcutaneous tissue disorders - Other,
Specify)
Skin Atrophy (Skin atrophy)
Skin Hyperpigmentation (Skin
hyperpigmentation)
Skin Hypopigmentation (Skin
hypopigmentation)
Skin Induration (Skin induration)
Skin Infection (Skin infection)
Skin Ulceration (Skin ulceration)
Sleep Apnea (Sleep apnea)
Small Intestinal Anastomotic Leak (Small
intestinal anastomotic leak)
Small Intestinal Mucositis (Small
intestinal mucositis)
Small Intestinal Obstruction (Small
intestinal obstruction)
Small Intestinal Perforation (Small
intestinal perforation)
Small Intestinal Stenosis (Small intestinal
stenosis)
Small Intestine Infection (Small intestine
infection)
Small Intestine Ulcer (Small intestine
ulcer)
Sneezing (Sneezing)
Social Circumstances - Other, Specify
(Social circumstances - Other, Specify)
Soft Tissue Infection (Soft tissue
infection)
Soft Tissue Necrosis Lower Limb (Soft
tissue necrosis lower limb)
Soft Tissue Necrosis Upper Limb (Soft
tissue necrosis upper limb)
Somnolence (Somnolence)
Sore Throat (Sore throat)
Spasticity (Spasticity)
Spermatic Cord Anastomotic Leak
(Spermatic cord anastomotic leak)
Spermatic Cord Hemorrhage (Spermatic
cord hemorrhage)
Spermatic Cord Obstruction (Spermatic
cord obstruction)
Spinal Fracture (Spinal fracture)
Spleen Disorder (Spleen disorder)
Splenic Infection (Splenic infection)
Stenosis Of Gastrointestinal Stoma
(Stenosis of gastrointestinal stoma)
Stevens-johnson Syndrome (Stevens-
Johnson syndrome)
Stoma Site Infection (Stoma site
infection)
Stomach Pain (Stomach pain)
Stomal Ulcer (Stomal ulcer)
Stridor (Stridor)
Stroke (Stroke)
Sudden Death Nos (Sudden death NOS)
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Suicidal Ideation (Suicidal ideation)
Suicide Attempt (Suicide attempt)
Superficial Soft Tissue Fibrosis
(Superficial soft tissue fibrosis)
Superficial Thrombophlebitis (Superficial
thrombophlebitis)
Superior Vena Cava Syndrome (Superior
vena cava syndrome)
Supraventricular Tachycardia
(Supraventricular tachycardia)
Surgical And Medical Procedures -
Other, Specify (Surgical and medical
procedures - Other, Specify)
Syncope (Syncope)
Telangiectasia (Telangiectasia)
Testicular Disorder (Testicular disorder)
Testicular Hemorrhage (Testicular
hemorrhage)
Testicular Pain (Testicular pain)
Thromboembolic Event
(Thromboembolic event)
Thrombotic Thrombocytopenic Purpura
(Thrombotic thrombocytopenic purpura)
Tinnitus (Tinnitus)
Tooth Development Disorder (Tooth
development disorder)
Tooth Discoloration (Tooth discoloration)
Tooth Infection (Tooth infection)
Toothache (Toothache)
Toxic Epidermal Necrolysis (Toxic
epidermal necrolysis)
Tracheal Fistula (Tracheal fistula)
Tracheal Hemorrhage (Tracheal
hemorrhage)
Tracheal Mucositis (Tracheal mucositis)
Tracheal Obstruction (Tracheal
obstruction)
Tracheal Stenosis (Tracheal stenosis)
Tracheitis (Tracheitis)
Tracheostomy Site Bleeding
(Tracheostomy site bleeding)
Transient Ischemic Attacks (Transient
ischemic attacks)
Treatment Related Secondary
Malignancy (Treatment related
secondary malignancy)
Tremor (Tremor)
Tricuspid Valve Disease (Tricuspid valve
disease)
Trigeminal Nerve Disorder (Trigeminal
nerve disorder)
Trismus (Trismus)
Tumor Lysis Syndrome (Tumor lysis
syndrome)
Tumor Pain (Tumor pain)
Typhlitis (Typhlitis)
Unequal Limb Length (Unequal limb
length)
Unintended Pregnancy (Unintended
pregnancy)
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Upper Gastrointestinal Hemorrhage
(Upper gastrointestinal hemorrhage)
Upper Respiratory Infection (Upper
respiratory infection)
Ureteric Anastomotic Leak (Ureteric
anastomotic leak)
Urethral Anastomotic Leak (Urethral
anastomotic leak)
Urethral Infection (Urethral infection)
Urinary Fistula (Urinary fistula)
Urinary Frequency (Urinary frequency)
Urinary Incontinence (Urinary
incontinence)
Urinary Retention (Urinary retention)
Urinary Tract Infection (Urinary tract
infection)
Urinary Tract Obstruction (Urinary tract
obstruction)
Urinary Tract Pain (Urinary tract pain)
Urinary Urgency (Urinary urgency)
Urine Discoloration (Urine discoloration)
Urine Output Decreased (Urine output
decreased)
Urostomy Leak (Urostomy leak)
Urostomy Obstruction (Urostomy
obstruction)
Urostomy Site Bleeding (Urostomy site
bleeding)
Urostomy Stenosis (Urostomy stenosis)
Urticaria (Urticaria)
Uterine Anastomotic Leak (Uterine
anastomotic leak)
Uterine Fistula (Uterine fistula)
Uterine Hemorrhage (Uterine
hemorrhage)
Uterine Infection (Uterine infection)
Uterine Obstruction (Uterine obstruction)
Uterine Pain (Uterine pain)
Uterine Perforation (Uterine perforation)
Uveitis (Uveitis)
Vaginal Anastomotic Leak (Vaginal
anastomotic leak)
Vaginal Discharge (Vaginal discharge)
Vaginal Dryness (Vaginal dryness)
Vaginal Fistula (Vaginal fistula)
Vaginal Hemorrhage (Vaginal
hemorrhage)
Vaginal Infection (Vaginal infection)
Vaginal Inflammation (Vaginal
inflammation)
Vaginal Obstruction (Vaginal obstruction)
Vaginal Pain (Vaginal pain)
Vaginal Perforation (Vaginal perforation)
Vaginal Stricture (Vaginal stricture)
Vaginismus (Vaginismus)
Vagus Nerve Disorder (Vagus nerve
disorder)
Vas Deferens Anastomotic Leak (Vas
deferens anastomotic leak)
Vascular Access Complication (Vascular
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access complication)
Vascular Disorders - Other, Specify
(Vascular disorders - Other, Specify)
Vasculitis (Vasculitis)
Vasovagal Reaction (Vasovagal reaction)
Venous Injury (Venous injury)
Ventricular Arrhythmia (Ventricular
arrhythmia)
Ventricular Fibrillation (Ventricular
fibrillation)
Ventricular Tachycardia (Ventricular
tachycardia)
Vertigo (Vertigo)
Vestibular Disorder (Vestibular disorder)
Virilization (Virilization)
Visceral Arterial Ischemia (Visceral
arterial ischemia)
Vital Capacity Abnormal (Vital capacity
abnormal)
Vitreous Hemorrhage (Vitreous
hemorrhage)
Voice Alteration (Voice alteration)
Vomiting (Vomiting)
Vulval Infection (Vulval infection)
Watering Eyes (Watering eyes)
Weight Gain (Weight gain)
Weight Loss (Weight loss)
Wheezing (Wheezing)
White Blood Cell Decreased (White
blood cell decreased)
Wolff-parkinson-white Syndrome (Wolff-
Parkinson-White syndrome)
Wound Complication (Wound
complication)
Wound Dehiscence (Wound dehiscence)
Wound Infection (Wound infection)
Wrist Fracture (Wrist fracture)
CTC Adverse Event Grade
Mild Adverse Event (1)
Moderate Adverse Event (2)
Severe Adverse Event (3)
Life Threatening Adverse Event (4)
Comments
Investigator Signature
Investigator Signature Date (M D Y)
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E2905 Second Primary Form
NCT00843882
E2905 Second Primary Form NCT00843882 
Lenalidomide With or Without Epoetin Alfa in Treating
Patients With Myelodysplastic Syndrome and Anemia
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=0EAAC99D-
1E15-00B1-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/10999
E2905 Second Primary Form
NCT00843882
Header
ECOG Protocol Number (If patient has been on
other therapeutic ECOG protocols, please list
protocols and patient ID numbers.)
ECOG Patient ID
DCI Name
Registration Step
Reporting Period
Second Primary Cancer (Second
Primary)
Patient demographics
Patient Initials (Last, First)
ECOG Protocol Number (If patient has been on
other therapeutic ECOG protocols, please list
protocols and patient ID numbers.)
ECOG Patient ID
Participating Group Protocol Number
Participating Group Patient ID
Institution/Affiliate
Data amendment
Please mark an 'X' if data have been amended.
(Please circle amended items in red)
Date data amended (MM/DD/YYYY)
1 / 2
Second primary cancer assessment
Date of Diagnosis of Second Primary Cancer
(MM/DD/YYYY)
ECOG Protocol Number (If patient has been on
other therapeutic ECOG protocols, please list
protocols and patient ID numbers.)
Site of Second Primary Cancer
ECOG Patient ID
Include information on histologic subtype (s)
Briefly describe cancer therapy the patient has
received prior to the diagnosis of the second
primary and other than that given on ECOG
protocols
Briefly describe treatment planned or given for
the diagnosis of this second primary
Comments
Investigator Signature
Investigator Signature Date
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E2905 Material Submission Form
NCT00843882
E2905 Material Submission Form NCT00843882 
Lenalidomide With or Without Epoetin Alfa in Treating
Patients With Myelodysplastic Syndrome and Anemia
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=0EAADB73-
1609-079C-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11000
E2905 Material Submission Form
NCT00843882
Header
ECOG Protocol Number
ECOG Patient ID
Registration Step
DCI Name
Reporting Period
Lab Data (Lab data)
Patient demographics
Patient Initials
ECOG Protocol Number
ECOG Patient ID
Participating Group Protocol Number
Participating Group Patient ID
Institution/Affiliate
Completed By Submitting Institutions
Date Material(s) sent to central laboratory
(MM/DD/YYYY)
Shipped to
Ecog Pathology Coordinating Office
(ECOG Pathology Coordinating Office)
H. Lee Moffitt Cancer Center (H. Lee
Moffitt Cancer Center)
Mayo Central Laboratory For Clinical
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Trials (Mayo Central Laboratory for
Clinical Trials)
Other Central Laboratory (Other Central
Laboratory)
Informed consent signed?
Yes
No
Sample No.
Date Specimens collected (MM/DD/YYYY)
Samples Submission
Bone Marrow Aspirate (Bone marrow
aspirate)
Karyotype (Karotypes)
Other (Other)
Peripheral Blood (Peripheral blood)
Timing of material collection
Initial Diagnosis (Initial Diagnosis)
Other (Other)
Pre-study Value (Pre-study)
Baseline/pretreatment (Pre-Treatment)
Relapse (Upon development of AML
relapse)
Upon Development Of Mds (Upon
development of MDS)
Number of specimens submitted (tubes, slides,
etc.)
Leukemia Classification
Disease Classified As All, Not Otherwise
Specified (nos); (ALL, not otherwise
specified (NOS);)
Disease Classified As Aml, Not
Otherwise Specified (nos) (AML, not
otherwise specified (NOS))
Disease Classified As Chronic
Lymphocytic Leukemia (cll) (Chronic
lymphocytic leukemia (CLL))
Disease Classified As Chronic
Myelogenous Leukemia (cml), Chronic
Phase (Chronic myelogenous leukemia
(CML), chronic phase)
Disease Classified As Chronic
Myelogenous Leukemia, (cml), Blast
Crisis (Chronic myelogenous leukemia,
(CML), blast crisis)
Disease Classified As Myelodysplastic
Syndrome (mds) Nos (Myelodysplastic
syndrome (MDS) NOS)
Other (Other)
Absolute Blast Count
2 / 3
E2905 Material Submission Form NCT00843882
Contact Person at Institution
Physician of Record
Institution contact phone number
Institution Contact Person Fax Number
Completed By Central Lab
Date of Receipt of Specimens (MM/DD/YYYY)
Condition of Specimen
Damaged Or Unusable (Damaged or
unusable)
Usable (Usable)
Sample No.
Central Laboratory contact name
Central Lab Contact Phone Number
Central Lab Contact FAX Number
Comments
Comments
Investigator Signature
Investigator Signature Date
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E2906 Off-Treatment Form NCT01041703
E2906 Off-Treatment Form NCT01041703 
Clofarabine or Daunorubicin Hydrochloride and Cytarabine
Followed By Decitabine or Observation in Treating Older
Patients With Newly Diagnosed Acute Myeloid Leukemia
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=74BCE806-
54DC-4D7A-E040-BB89AD437934
All rights reserved. Please visit https://medical-data-
models.org/forms/11001
E2906 Off-Treatment Form
NCT01041703
Header
ECOG Protocol Number
ECOG Patient ID
DCI Name
Registration Step
Reporting Period
End Of Treatment - Step 1 (End of
Treatment - Step 1)
End Of Treatment - Step 2 (End of
Treatment - Step 2)
End Of Treatment - Step 3 (End of
Treatment - Step 3)
Patient demographics
Patient Initials (Last, First)
Participating Group Protocol Number
Institution/Affiliate
Participating Group Patient ID
Did patient receive protocol therapy
Yes
No
Data amendment
Please mark an 'X' if data have been amended.
(Please circle amended items in red)
Date data amended (s m d y)
1 / 3
Vital Status
Patient's Vital Status
Alive (Alive)
Dead (Dead)
Date of Last Contact or Death (m d y)
Primary Cause of Death (if applicable)
Due To Other Cause (Due to other
cause)
Due To Protocol Treatment (Due to
protocol treatment)
Due To This Disease (Due to this
disease)
Unknown (Unknown)
Describe cause of death
Section I
Reason Treatment Ended
Adverse Event/side Effects/complications
(Adverse Event/Side
Effects/Complications)
Alternative Therapy (Alternative therapy)
Death On Study (Death on study)
Disease Progression, Relapse During
Active Treatment (Disease progression,
relapse during active treatment)
Other (Other)
Patient Off-treatment For Other
Complicating Disease (Patient off-
treatment for other complicating disease)
Patient Withdrawal Or Refusal After
Beginning Protocol Therapy (Patient
withdrawal/refusal after beginning
protocol therapy)
Treatment Completed Per Protocol
Criteria (Treatment completed per
protocol criteria)
Other Complicating Disease specify (specify)
Other specify
Last date protocol therapy was given (m d y)
Section II
Reason treatment never started
Adverse Event/side Effects/complications
(Adverse events/side
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effects/complications)
Death Before Beginning Protocol
Therapy (Death before beginning
protocol therapy)
Disease Progression, Relapse Prior To
Beginning Protocol Therapy (Disease
progression, relapse before protocol
treatment)
Medical Decision (Medical decision)
No Treatment, Per Protocol Criteria (No
treatment assigned per protocol)
Other (Other)
Patient_ineligible (Patient ineligible)
Patient Withdrawal/refusal Before
Beginning Protocol Therapy (Patient
withdrawal/refusal before beginning
protocol therapy)
Comments
Investigator Signature
Investigator Signature Date (MM DD YYYY)
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ECOG-E1505 Cardiac History Form
NCT00324805
ECOG-E1505 Cardiac History Form NCT00324805 
Chemotherapy With or Without Bevacizumab in Treating
Patients With Stage IB, Stage II, or Stage IIIA Non-Small
Lung Cancer That Was Removed By Surgery
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=109F5E08-
51E4-23CB-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11002
ECOG-E1505 Cardiac History Form
NCT00324805
Header
ECOG Protocol Number
ECOG Patient ID
DCI Name
Registration Step
Reporting Period
Baseline (Baseline)
Patient demographics
Patient Initials (Last, First)
ECOG Protocol Number
ECOG Patient ID
Participating Group Protocol Number
Participating Group Patient ID
Institution/Affiliate
Data amendment
Please mark an 'X' if data have been amended
(Please circle amended items in red)
Date data amended (M D Y)
Patient History
1 / 3
Does the patient have a history of
thromboembolic events (arterial)
Yes
No
Stroke (If yes:)
No (No)
Unknown (Unknown)
Yes (Yes)
Transient ischemic attack
No (No)
Unknown (Unknown)
Yes (Yes)
Other significant peripheral arterial disease
No (No)
Unknown (Unknown)
Yes (Yes)
Has the patient suffered cardiovascular disease?
Yes
No
Myocardial infarction
No (No)
Unknown (Unknown)
Yes (Yes)
Angina
No (No)
Unknown (Unknown)
Yes (Yes)
Unstable angina
No (No)
Unknown (Unknown)
Yes (Yes)
Recovery or Latest Date (last known date of
disease activity)
Recovery or Latest Date (last known date of
disease activity)
Recovery or Latest Date (last known date of
disease activity)
Recovery or Latest Date (last known date of
disease activity)
Recovery or Latest Date (last known date of
disease activity)
Recovery or Latest Date (last known date of
disease activity)
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Specify (If other:)
Data Unknown Text
Hypertension history
Yes
No
Aspirin (81 mg) (Were any of the following given
for the above events - answer no 1 or yes 2 for
each of the following)
Yes
No
Aspirin (325mg)
Yes
No
Aspirin (Other Dose)
Yes
No
Specify dose (If other dose of Aspirin given, - mg)
Coumadin
Yes
No
Specify dose (If Coumadin given, - mg)
Low molecular weight heparin
Yes
No
Other
Yes
No
Specify
Comments
Investigator Signature
Investigator Signature Date
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ECOG-E1505 Non-Protocol Therapy Form
NCT00324805
ECOG-E1505 Non-Protocol Therapy Form NCT00324805 
Chemotherapy With or Without Bevacizumab in Treating
Patients With Stage IB, Stage II, or Stage IIIA Non-Small
Lung Cancer That Was Removed By Surgery
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=07459985-
9AA6-4ED3-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11003
ECOG-E1505 Non-Protocol Therapy
Form NCT00324805
Header
ECOG Protocol Number
ECOG Patient ID
DCI Name
Registration Step
Reporting Period
Non-protocol Therapy (Non-Protocol
Therapy)
Patient demographics
ECOG Protocol Number
Patient Initials (Last, First)
ECOG Patient ID
Participating Group Protocol Number
Institution/Affiliate
Participating Group Patient ID
Data amendment
Please mark an 'X' if data have been amended
(Please circle amended items in red)
Date data amended (M D Y)
1 / 3
Non-Protocol Therapy
Date of FIRST non-protocol therapy (if given prior
to progression/relapse from protocol therapy)
Non-protocol Chemotherapy
No (No)
Unknown (Unknown)
Yes (Yes)
Specify
Non-protocol Hormonal Therapy
No (No)
Unknown (Unknown)
Yes (Yes)
Non-protocol hormonal therapy, specify
Non-protocol Immunotherapy (Biological
Response Modifiers)
No (No)
Unknown (Unknown)
Yes (Yes)
Non-protocol Immunotherapy/Biological
Response Modifiers, Specify
Non-protocol High Dose Chemotherapy/Stem
Cell Transplant (Autologous or Allogeneic)
No (No)
Unknown (Unknown)
Yes (Yes)
Non-protocol Surgery
No (No)
Unknown (Unknown)
Yes (Yes)
Non-protocol surgery type
Non-protocol Radiation Therapy
No (No)
Unknown (Unknown)
Yes (Yes)
Non-protocol RT type
Other Non-protocol Therapy
No (No)
Unknown (Unknown)
Yes (Yes)
Name of other non-protocol therapy
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Was the non-protocol therapy given for the
disease of this protocol (NOTE: Treatment for a
second primary in the same organ site would not
be considered therapy for disease of this
protocol.)
No (No)
Unknown (Unknown)
Yes (Yes)
Comments
Investigator Signature
Investigator Signature Date
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ECOG-E1505 Second Primary Form
NCT00324805
ECOG-E1505 Second Primary Form NCT00324805 
Chemotherapy With or Without Bevacizumab in Treating
Patients With Stage IB, Stage II, or Stage IIIA Non-Small
Lung Cancer That Was Removed By Surgery
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=0745957A-
3C65-4EBD-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11004
ECOG-E1505 Second Primary Form
NCT00324805
Header
ECOG Protocol Number
ECOG Patient ID
DCI Name
Registration Step
Reporting Period
Second Primary Cancer (Second
Primary)
Patient demographics
ECOG Protocol Number
Patient Initials (Last, First)
ECOG Patient ID
Participating Group Protocol Number
Institution/Affiliate
Participating Group Patient ID
Data amendment
Please mark an 'X' if data have been amended
(Please circle amended items in red)
Date data amended (M D Y)
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Second primary cancer assessment
Date of Diagnosis of Second Primary Cancer
ECOG Protocol Number
Site of Second Primary Cancer
ECOG Patient ID
Include information on histologic subtype (s)
Briefly describe cancer therapy the patient has
received prior to the diagnosis of the second
primary and other than that given on ECOG
protocols
Briefly describe treatment planned or given for
the diagnosis of this second primary
Comments
Investigator Signature
Investigator Signature Date
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ECOG-E1505 Source Document Tracking
Cover Sheet NCT00324805
ECOG-E1505 Source Document Tracking Cover Sheet
NCT00324805 
Chemotherapy With or Without Bevacizumab in Treating
Patients With Stage IB, Stage II, or Stage IIIA Non-Small
Lung Cancer That Was Removed By Surgery
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=080E4673-
1BE3-69B1-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11005
ECOG-E1505 Source Document
Tracking Cover Sheet NCT00324805
Header
ECOG Protocol Number
ECOG Patient ID
DCI Name
Registration Step
Reporting Period (Choose one)
Baseline (Baseline)
Recurrence (Recurrence)
Patient demographics
Patient Initials (Last, First)
Participating Group Protocol Number
ECOG Protocol Number
Institution/Affiliate
ECOG Patient ID
Participating Group Patient ID
Footer module
Document type (Choose one)
Eligibility Checklist (Eligibility Checklist)
Other (Other)
Pathology Report (Pathology Report)
Surgical Report (Surgical Report)
Other, specify
1 / 2
Report Created Date (List the date the source
document was created below.)
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E5508 Off-Treatment Form NCT01107626
E5508 Off-Treatment Form NCT01107626 
Bevacizumab or Pemetrexed Disodium Alone or In
Combination After Induction Therapy in Treating Patients
With Advanced Non-Squamous Non-Small Cell Lung
Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=6D41D0A3-
B031-13D4-E040-BB89AD430599
All rights reserved. Please visit https://medical-data-
models.org/forms/11006
E5508 Off-Treatment Form
NCT01107626
Header
ECOG Protocol Number
ECOG Patient ID
DCI Name
Registration Step
Reporting Period
End Of Treatment (End of treatment)
Patient demographics
Patient Initials (Last, First)
Participating Group Protocol Number
Institution/Affiliate
Participating Group Patient ID
Did patient receive protocol therapy
Yes
No
Data amendment
Please mark an 'X' if data have been amended.
(Please circle amended items in red)
Date data amended (s m d y)
Vital Status
Patient's Vital Status
Alive (Alive)
1 / 3
Dead (Dead)
Date of Last Contact or Death (m d y)
Primary Cause of Death (if applicable)
Due To Other Cause (Due to other
cause)
Due To Protocol Treatment (Due to
protocol treatment)
Due To This Disease (Due to this
disease)
Unknown (Unknown)
Describe cause of death
Section I
Reason Treatment Ended
Adverse Event/side Effects/complications
(Adverse Event/Side
Effects/Complications)
Alternative Therapy (Alternative therapy)
Death On Study (Death on study)
Disease Progression, Relapse During
Active Treatment (Disease progression,
relapse during active treatment)
Other (Other)
Patient Off-treatment For Other
Complicating Disease (Patient off-
treatment for other complicating disease)
Patient Withdrawal Or Refusal After
Beginning Protocol Therapy (Patient
withdrawal/refusal after beginning
protocol therapy)
Treatment Completed Per Protocol
Criteria (Treatment completed per
protocol criteria)
Other Complicating Disease specify (specify)
Other specify
Last date protocol therapy was given (m d y)
Section II
Reason treatment never started
Adverse Event/side Effects/complications
(Adverse events/side
effects/complications)
Death Before Beginning Protocol
Therapy (Death before beginning
protocol therapy)
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Disease Progression, Relapse Prior To
Beginning Protocol Therapy (Disease
progression, relapse before protocol
treatment)
Medical Decision (Medical decision)
No Treatment, Per Protocol Criteria (No
treatment assigned per protocol)
Other (Other)
Patient_ineligible (Patient ineligible)
Patient Withdrawal/refusal Before
Beginning Protocol Therapy (Patient
withdrawal/refusal before beginning
protocol therapy)
Comments
Investigator Signature
Investigator Signature Date (MM DD YYYY)
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E3A06 Off-Observation Form (Arm B)
NCT01169337
E3A06 Off-Observation Form (Arm B) NCT01169337 
Lenalidomide or Observation in Treating Patients With
Asymptomatic High-Risk Smoldering Multiple Myeloma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=87092C3C-
C0F8-AC0D-E040-BB89AD4362E7
All rights reserved. Please visit https://medical-data-
models.org/forms/11007
E3A06 Off-Observation Form (Arm
B) NCT01169337
Header
ECOG Protocol Number
ECOG Patient ID
DCI Name
Registration Step
Reporting Period
End Of Observation (End of
Observation)
Patient demographics
Patient Initials (Last, First)
Participating Group Protocol Number
Institution/Affiliate
Participating Group Patient ID
Was patient observed
Yes
No
Data amendment
Please mark an 'X' if data have been amended.
(Please circle amended items in red)
Date data amended (s - mm/dd/yyyy)
Vital Status
Patient's Vital Status
Alive (Alive)
1 / 3
Dead (Dead)
Date of Last Contact or Death (mm/dd/yyyy)
Primary Cause of Death (if applicable)
Due To Other Cause (Due to other
cause)
Due To This Disease (Due to this
disease)
Unknown (Unknown)
Describe cause of death
Section I
Date of last Observation
Reason Observation Ended
Adverse Events/side
Effects/complications (Adverse
events/side effects/complications)
Alternative Therapy (Alternative therapy)
Death On Study (Death on study)
Disease Progression During Observation
(Disease progression, relapse during
observation)
Other (Other)
Patient Off Observation For Other
Complicating Disease (Patient off
observation for other complicating
disease)
Patient Withdrawal/refusal After
Beginning Observation (Patient
withdrawal/refusal after beginning
observation)
Other complicating disease, specify
Other specify
Section II
Reason observation never started
Adverse Events/side
Effects/complications (Adverse
events/side effects/complications)
Death Before Beginning Observation
(Death before beginning observation)
Disease Progression Before Observation
(Disease progression, relapse before
observation)
Medical Decision (Medical decision)
Other (Other)
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Patient_ineligible (Patient ineligible)
Patient Withdrawal/refusal Before
Beginning Observation (Patient
withdrawal/refusal before beginning
observation)
Other specify
Comments
Investigator Signature
Investigator Signature Date
Comment
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VEGF-AS Administration Form for Protocol
043 NCT00310128
VEGF-AS Administration Form for Protocol 043
NCT00310128 
Combination Chemotherapy Followed by Rituximab and
Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients
With Relapsed or Refractory AIDS-Related Non-Hodgkin's
Lymphoma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=FFA090C4-
D408-6439-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11008
VEGF-AS Administration Form for
Protocol 043 NCT00310128
Administration Form
Dose assigned
100 mg (100 mg)
150 mg (150 mg)
200 mg (200 mg)
50 mg (50 mg)
have all adverse events been reported on the
Adverse Event Form
Yes
No
Course number
Treatment start date for this course
Dose administered
Has the patient received a dose escalation or
dose reduction of this agent during this
administration
No (No)
Unknown (Unknown)
Yes, Planned (i.e., The Treatment Was
Changed According To Protocol
Guidelines) (Yes, planned)
Yes, Unplanned (i.e., The Treatment
Change Was Not Part Of Protocol
Guidelines) (Yes, unplanned)
Did the patient experience any adverse events
Yes
No
1 / 1
E1A06 Baseline Disease Assessment Form
NCT00602641
E1A06 Baseline Disease Assessment Form NCT00602641 
Melphalan, Prednisone, and Thalidomide or Lenalidomide
in Treating Patients With Newly Diagnosed Multiple
Myeloma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=400398E0-
9B0D-6F60-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11009
E1A06 Baseline Disease
Assessment Form NCT00602641
Header
ECOG Protocol Number
ECOG Patient ID
DCI Name
Registration Step
Reporting Period
Baseline (Baseline)
Patient Initials (Last, First)
Participating Group Protocol Number
Participating Group Patient ID
Institution/Affiliate
Please mark an 'X' if data have been amended.
Date data amended
Protein Measurements
Date of SPEP
Serum total protein (SPEP g/dl)
Serum M-protein spike (g/dl NOTE: Leave blank if
serum M-spike was present but too small to
quantify.)
If serum M-protein spike was left blank, please
specify
1 / 6
Absent (Not present)
Present But Too Small To Quantify
(Present but too small to quantify)
Albumin LLN (g/dl)
Albumin (Value)
Date of serum FLC assessment
Kappa Free Light Chain (mg/dl)
Lambda Free Light Chain (mg/dl)
Date of urine immunofixation (Urine
immunofixation IFE leave blank if not done)
Serum M-protein by immunofixation
Negative (negative)
Positive (positive)
Serum Heavy Chain (If positive:)
A (A)
Biclonal (Biclonal)
D (D)
E (E)
G (G)
M (M)
Unknown (Unknown)
Biclonal, specify
Serum Light Chain
Kappa (kappa)
Lambda (lambda)
Unknown (Unknown)
Date hematology (blood) sample obtained
(Serum Quantitative Immunoglobulins)
IgG (mg/dl)
IgG LLN (mg/dl)
IgG ULN (mg/dl)
IgA (mg/dl)
IgA LLN (mg/dl)
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IgA ULN (mg/dl)
IgM (mg/dl)
IgM LLN (mg/dl)
IgM ULN (mg/dl)
Urine Sample
Date of UPEP (Urine protein electrophoresis
UPEP)
Urine Total protein (UPEP mg/24 hr)
Urine M-protein light chain excretion (mg/24 hr
NOTE: Leave blank if urine M-protein light chain
excretion was present but too small to quantify.)
If urine M-protein light chain excretion was left
blank, please specify
Absent (Not present)
Present But Too Small To Quantify
(Present but too small to quantify)
Urine M-protein by immunofixation
Negative (negative)
Positive (positive)
Urine Light Chain (If positive:)
Kappa (kappa)
Lambda (lambda)
Unknown (unknown)
Soft Tissue Plasmacytoma
Soft tissue plasmacytoma?
Yes
No
Lesion No.
Site of lesion
Biopsy proven?
Yes
No
Date of evaluation
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Method of evaluation
Clinical (Clinical Examination)
Ct Scan (CT scan (non-spiral))
Mri (MRI (NMR))
Other (Other (specify))
Spiral Ct Scan (Spiral CT scan)
Other Specify
Size of Plasmacytoma (cm)
Size of Plasmacytoma
Bone Marrow
Was bone marrow biopsy done?
Inadequate Sample (inadequate sample)
No (no)
Yes (yes)
Bone marrow biopsy date
Plasma cells on biopsy (If yes:)
If plasma cells on biopsy was left blank, please
specify (%)
No Percentage Given (No percentage
given)
Present But Too Small To Quantify
(Present but too small to quantify)
Was bone marrow aspirate done?
Inadequate Sample (inadequate sample)
No (no)
Yes (yes)
Date of Bone Marrow Aspirate
Plasma cells on aspirate in interpretation (If yes:)
If plasma cells on aspirate was left blank, please
specify
No Percentage Given (No percentage
given)
Present But Too Small To Quantify
(Present but too small to quantify)
Are sheets of plasma cells present?
Yes
No
4 / 6
E1A06 Baseline Disease Assessment Form NCT00602641
Bone
Date of most recent bone assessment
Were lytic bone lesions present at study entry
(Bone assessment method)
Yes
No
Bone Assessment Method
Bone Scan (Bone scan)
Ct Scan (CT scan)
Mri (nmr) (MRI (NMR))
Other (Other)
Pet Scan (PET scan)
Skeletal Survey (Skeletal survey)
Peripheral Blood Chemistry
C-reactive protein ULN (mg/dl)
C-reactive protein (mg/dl)
Date of most recent hematology (blood) sample
obtained
Lactate dehydrogenase ULN
Lactate dehydrogenase (LDH) (U/L)
Beta-2 Microglobulin ULN (ng/ml)
Beta-2 Microglobulin (ng/ml)
Creatinine ULN (mg/dl)
Creatinine (mg/dl)
Hemoglobin (Hgb) (g/dl), LLN
Hemoglobin (g/dl)
Calcium LLN (mg/dl)
Calcium ULN (mg/dl)
Calcium (mg/dl)
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Comments
Comments
Investigator Signature Date
Investigator Signature
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RTOG-0525 F1: Follow-Up Form
NCT00304031
RTOG-0525 F1: Follow-Up Form NCT00304031 
Radiation Therapy and Temozolomide in Treating Patients
With Newly Diagnosed Glioblastoma or Gliosarcoma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=FD9AAA90-
325E-6D58-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11010
RTOG-0525 F1: Follow-Up Form
NCT00304031
Clinical trial administrative data
RTOG Study No.
Case #
Institution Name
Institution No.
Patient Initials
RTOG Patient ID
AMENDED DATA
Yes
No
Assessment
Date of Assessment
Patient Vital Status
Alive (Alive)
Dead (Dead)
Date of Last Contact or Death
Patient Death Primary Reason
Complications Of Protocol Radiation
Therapy (Complications of protocol
radiation therapy)
Complications Of Protocol Surgery
(Complications of protocol surgery)
Due To Other Cause (Due to other
cause)
Due To This Disease (Due to this
disease)
Unknown (Unknown)
Due to other cause, specify (cause of death)
1 / 5
Karnofsky Performance Status
Dead (0)
Moribund, Fatal Processes Progressing
Rapidly (10)
Normal, No Complaints, No Evidence Of
Disease (100)
Very Sick, Hospitalization Indicated.
Death Not Imminent (20)
Severely Disabled, Hospitalization
Indicated. Death Not Imminent (30)
Disabled, Requires Special Care And
Assistance (40)
Requires Considerable Assistance And
Frequent Medical Care (50)
Requires Occasional Assistance, But Is
Able To Care For Most Of His/her Needs
(60)
Cares For Self, Unable To Carry On
Normal Activity Or To Do Active Work
(70)
Normal Activity With Effort; Some Signs
Or Symptoms Of Disease (80)
Able To Carry On Normal Activity; Minor
Signs Or Symptoms Of Disease (90)
Neurological Function Status
Minor Neurologic Symptoms, Fully Active
At Home/work Without Assistance (Minor
neurologic symptoms, fully active at
home/work without assistance)
Moderate Neurologic Symptoms, Fully
Active At Home/work But Requires
Assistance (Moderate neurologic
symptoms, fully active at home/work but
requires assistance)
Moderate Neurologic Symptoms, Less
Than Fully Active At Home/work And
Requires Assitance (Moderate
neurologic symptoms, less than fully
active at home/work and requires
assistance)
No Neurologic Symptoms, Fully Active At
Home/work Without Assistance (No
neurologic symptoms, fully active at
home/work without assistance)
Severe Neurologic Symptoms, Totally
Inactive Requiring Complete Assistance
At Home Or Institution, Unable To Work
(Severe neurologic symptoms, totally
inactive requiring complete assistance at
home or institution, unable to work)
Disease Progression
Has the patient been diagnosed with first regional
recurrence or progression
No (No)
Not Applicable, Patient Has Not Been
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Assessed (Not applicable, patient has
not been assessed)
Unknown (Unknown)
Yes (Yes)
Disease Recurrence Most Recent Date
Method of Evaluation
Ct Scan (CT scan)
Mri Scan (MRI scan)
Other (Other)
Pet Scan (PET scan)
Other Specify
Non-Protocol Therapy
Is the patient receiving any non-protocol cancer
therapy not previously reported?
Yes
No
Non protocol surgery
None (None)
Other (Other)
Partial Resection (Partial resection)
Stereotactic Biopsy (Stereotactic biopsy)
Total Tumor Resection (Total tumor
resection)
Other, specify
Date of Surgery
Was there gross evidence of tumor?
No (No)
Unknown (Unknown)
Yes (Yes)
Was RT necrosis present
No (No)
Unknown (Unknown)
Yes (Yes)
Non-protocol Therapy To Brain
Non-Protocol Radiation Therapy?
No (No)
Unknown (Unknown)
Yes (Yes)
Non-Protocol Radiosurgery?
No (No)
Unknown (Unknown)
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Yes (Yes)
Non-Protocol brachytherapy
No (No)
Unknown (Unknown)
Yes (Yes)
Non-Protocol Chemotherapy
No (No)
Unknown (Unknown)
Yes (Yes)
Non-Protocol Therapy Administered Date
Dose
Corticosteroids
No (No)
Unknown (Unknown)
Yes (Yes)
Specify
Anticonvulsants
Yes
No
Specify
Chemotherapy
No (No)
Unknown (Unknown)
Yes (Yes)
Date of initial dose
If terminated since last report give date
Specify
Other
No (No)
Unknown (Unknown)
Yes (Yes)
Other, specify
New or continuing adverse events
Yes
No
Was a follow up scan performed
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Yes
No
Footer
Comments
Completed by
Date Form Originally Completed
5 / 5
RTOG-0525 F1: Follow-Up Form NCT00304031
E1A06 Multiple Myeloma On-Study Form
NCT00602641
E1A06 Multiple Myeloma On-Study Form NCT00602641 
Melphalan, Prednisone, and Thalidomide or Lenalidomide
in Treating Patients With Newly Diagnosed Multiple
Myeloma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=4001ACAE-
416E-2CD1-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11011
E1A06 Multiple Myeloma On-Study
Form NCT00602641
Header
ECOG Protocol Number
ECOG Patient ID
DCI Name
Registration Step
Report Period (Place ID Label Here)
Baseline Step 1 (Baseline Step 1)
Patient Initials (Last, First)
Participating Group Protocol Number
Participating Group Patient ID
Institution/Affiliate
Please mark an 'X' if data have been amended.
Date data amended
Disease Description - Initial Diagnosis
Date of Initial Pathologic Diagnosis
Durie-Salmon Stage (at initial diagnosis - see
attached)
I - All Of The Following Must Be Present
(hemoglobin >10 G/dl; Serum Calcium
<12 Mg/dl; Urine Light Chains <4 G/24
Hrs; Normal Bones On Radiograph Or
Solitary Plasmacytoma; Igg <5 G/dl; Iga
<3 G/dl) (I)
Ii - Fitting Neither Stage I Or Stage Iii (II)
Iii - One Of The Following Must Be
1 / 4
Present (hemoglobin <8.5 G/dl; Serum
Calcium >12 Mg/dl; Urine Light Chains
>12 G/24 Hrs; Advanced Lytic Bone
Lesions (>3 Lytic Lesions); Igg >7 G/dl;
Iga >5 G/dl) (III)
Unknown (Unknown)
Durie-Salmon Sub-Stage (at initial diagnosis -
see attached)
A (relatively Normal Renal Function -
Serum Creatinine <2.0 Mg/dl) (A)
B (abnormal Renal Function - Serum
Creatinine >= 2.0 Mg/dl) (B)
Unknown (Unknown)
Current Clinical Date
Performance Status
Fully Active, Able To Carry On All Pre-
disease Performance Without
Restriction. (0)
Restricted In Physically Strenuous
Activity But Ambulatory And Able To
Carry Out Work Of A Light Or Sedentary
Nature, E.g., Light Housework, Office
Work. (1)
Ambulatory And Capable Of All Selfcare
But Unable To Carry Out Any Work
Activities. Up And About More Than 50%
Of Waking Hours. (2)
Capable Of Only Limited Selfcare,
Confined To Bed Or Chair More Than
50% Of Waking Hours. (3)
Completely Disabled. Cannot Carry On
Any Selfcare. Totally Confined To Bed Or
Chair. (4)
Dead (5)
Height
Bone pain on entry to study
Mild Requires Only Non-narcotic
Medication (mild, requires use of non-
narcotic pain relief)
None (none)
Requires Occasional Narcotics (requires
occasional narcotics)
Requires Parenteral Narcotics Or Patch
(requires parenteral narcotics, or patch)
Requires Per Os Narcotics (requires per
os narcotics)
Uncontrollable Pain (uncontrollable pain)
Unknown (unknown)
Is severe osteoporosis present?
No (no)
Unknown (unknown)
Yes (yes)
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Number of bones with lytic lesions present
1-3 Bones (1-3 bones)
More Than 3 Bones (more than 3 bones)
None (none)
Unknown (unknown)
Number of lytic lesions > 2 cm in diameter
1-3 Lesions (1-3 bones)
More Than 3 Lesions (more than 3
bones)
None (none)
Unknown (unknown)
Pathologic fracture during previous 1 month
(including compression and rib fractures)
No (no)
Unknown (unknown)
Yes (yes)
Presence of infection in past six months
No (No)
Unknown (Unknown)
Yes (Yes)
Is the patient on anticoagulant therapy
No (No)
Unknown (Unknown)
Yes (Yes)
Prior Therapy
Has the patient received bisphosphonates
Yes
No
Bisphosphanate type(s) received (If yes,)
Both Pamidronate And Zoledronic Acid
(both pamidronate and zoledronic acid)
Other (Other)
Pamidronate (pamidronate)
Zoledronic Acid (zoledronic acid)
Other, specify
Baseline Abnormalities
CTC Adverse Event Term
Peripheral Sensory Neuropathy
(Neuropathy: sensory)
Thrombosis Nos
(Thrombosis/thrombus/embolism)
CTC Adverse Event Grade (Use grade 1-4 per
CTCAE v3)
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Comments
Comments
Investigator Signature
Investigator Signature Date
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E3A06 Non-Protocol Therapy Form
NCT01169337
E3A06 Non-Protocol Therapy Form NCT01169337 
Lenalidomide or Observation in Treating Patients With
Asymptomatic High-Risk Smoldering Multiple Myeloma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=870ADAF5-
DCBE-EB0C-E040-BB89AD43277D
All rights reserved. Please visit https://medical-data-
models.org/forms/11012
E3A06 Non-Protocol Therapy Form
NCT01169337
Header
ECOG Protocol Number
ECOG Patient ID
DCI Name
Registration Step
Reporting Period
Non-protocol Therapy (Non-Protocol
Therapy)
Please mark an 'X' if data have been amended.
(Please circle amended items in red)
Date data amended (s M D Y)
Patient demographics
Patient Initials (Last, First)
Participating Group Protocol Number
Institution/Affiliate
Participating Group Patient ID
Non-Protocol Therapy Date
Date of First Non-Protocol Therapy (if given prior
to progression from protocol therapy M D Y)
Type(s) of first non-protocol therapy
Non-protocol Chemotherapy
No (No)
Unknown (Unknown)
1 / 3
Yes (Yes)
Non-Protocol Chemotherapy Type
Non-protocol Hormonal Therapy
No (No)
Unknown (Unknown)
Yes (Yes)
Non-protocol Immunotherapy (/Biological
Response Modifiers)
No (No)
Unknown (Unknown)
Yes (Yes)
Non-Protocol Immunotherapy Type
Non-Protocol High Dose Chemotherapy/Stem
Cell Transplant
No (No)
Unknown (Unknown)
Yes (Yes)
Non-Protocol High Dose Chemotherapy/Stem
Cell Transplant Type
Non-protocol Surgery
No (No)
Unknown (Unknown)
Yes (Yes)
Non-protocol surgery type
Non-protocol Radiation Therapy
No (No)
Unknown (Unknown)
Yes (Yes)
Non-protocol RT type
Other Non-protocol Therapy
No (No)
Unknown (Unknown)
Yes (Yes)
Name of other non-protocol therapy
Was the non-protocol therapy given for the
disease of this protocol (NOTE: Treatment for a
second primary in the same organ site would not
be considered therapy for disease of this
protocol. Note:  Submit ECOG Second Primary
Form if applicable.)
No (No)
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Unknown (Unknown)
Yes (Yes)
Comments
Investigator Signature
Investigator Signature Date (M D Y)
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ECOG Second Primary Form
NCT01169337
ECOG Second Primary Form NCT01169337 
Lenalidomide or Observation in Treating Patients With
Asymptomatic High-Risk Smoldering Multiple Myeloma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=8B34F8AB-
6B35-638A-E040-BB89AD4311DF
All rights reserved. Please visit https://medical-data-
models.org/forms/11013
ECOG Second Primary Form
NCT01169337
Header
ECOG Protocol Number (If patient has been on
other therapeutic ECOG protocols, please list
protocols and patient ID numbers)
ECOG Patient ID (If patient has been on other
therapeutic ECOG protocols, please list protocols
and patient ID numbers)
DCI Name
Registration Step
Reporting Period
Second Primary Cancer (Second
Primary)
Please mark an 'X' if data have been amended.
(Please circle amended items in red)
Date data amended (s - mm/dd/yyyy)
Patient demographics
Patient Initials (Last, First)
Participating Group Protocol Number
Institution/Affiliate
Participating Group Patient ID
Second primary cancer assessment
Date of Diagnosis of Second Primary Cancer
(mm/dd/yyyy)
1 / 2
Site of Second Primary Cancer
Include information on histologic subtype (Please
attach copies of any corroborating pathology
reports)
Briefly describe cancer therapy the patient has
received prior to the diagnosis of the second
primary and other than that given on ECOG
protocols
Briefly describe treatment planned or given for
the diagnosis of this second primary
Comments
Investigator Signature
Investigator Signature Date
Comments
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E5508 Second Primary Form
NCT01107626
E5508 Second Primary Form NCT01107626
Bevacizumab or Pemetrexed Disodium Alone or In
Combination After Induction Therapy in Treating Patients
With Advanced Non-Squamous Non-Small Cell Lung
Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=6D41D0A3-
ADCA-13D4-E040-BB89AD430599
All rights reserved. Please visit https://medical-data-
models.org/forms/11014
E5508 Second Primary Form
NCT01107626
Header
ECOG Protocol Number (If patient has been on
other therapeutic ECOG protocols, please list
protocols and patient ID numbers)
ECOG Patient ID (If patient has been on other
therapeutic ECOG protocols, please list protocols
and patient ID numbers)
DCI Name
Registration Step
Reporting Period
Second Primary Cancer (Second
Primary)
Please mark an 'X' if data have been amended.
(Please circle amended items in red)
Date data amended (s M D Y)
Patient demographics
Patient Initials (Last, First)
Participating Group Protocol Number
Institution/Affiliate
Participating Group Patient ID
Second primary cancer assessment
Date of Diagnosis of Second Primary Cancer (M
D Y)
1 / 2
Site of Second Primary Cancer
Include information on histologic subtype (s
Please attach copies of any corroborating
pathology reports)
Briefly describe cancer therapy the patient has
received prior to the diagnosis of the second
primary and other than that given on ECOG
protocols
Briefly describe treatment planned or given for
the diagnosis of this second primary
Comments
Investigator Signature
Investigator Signature Date (M D Y)
Comments
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E1609 Off-Treatment Form NCT01274338
E1609 Off-Treatment Form NCT01274338 
Ipilimumab or High-Dose Interferon Alfa-2b in Treating
Patients With High-Risk Stage III or Stage IV Melanoma
That Has Been Removed by Surgery
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=97EE3297-
340E-F402-E040-BB89AD436AF2
All rights reserved. Please visit https://medical-data-
models.org/forms/11015
E1609 Off-Treatment Form
NCT01274338
Header
ECOG Protocol Number
ECOG Patient ID
DCI Name
Registration Step
Reporting Period
End Of Treatment (End of treatment)
Please mark an 'X' if data have been amended.
(Please circle amended items in red)
Date data amended (s m d y)
Patient demographics
Patient Initials (Last, First)
Participating Group Protocol Number
Institution/Affiliate
Participating Group Patient ID
Did patient receive protocol therapy
Yes
No
Vital Status
Patient's Vital Status
Alive (Alive)
Dead (Dead)
Date of Last Contact or Death (m d y)
1 / 3
Primary Cause of Death (if applicable)
Due To Other Cause (Due to other
cause)
Due To Protocol Treatment (Due to
protocol treatment)
Due To This Disease (Due to this
disease)
Unknown (Unknown)
Describe cause of death
Section I
Reason Treatment Ended
Adverse Event/side Effects/complications
(Adverse Event/Side
Effects/Complications)
Alternative Therapy (Alternative therapy)
Death On Study (Death on study)
Disease Progression, Relapse During
Active Treatment (Disease progression,
relapse during active treatment)
Other (Other)
Patient Off-treatment For Other
Complicating Disease (Patient off-
treatment for other complicating disease)
Patient Withdrawal Or Refusal After
Beginning Protocol Therapy (Patient
withdrawal/refusal after beginning
protocol therapy)
Treatment Completed Per Protocol
Criteria (Treatment completed per
protocol criteria)
Other Complicating Disease specify (specify)
Other specify
Last date protocol therapy was given (m d y)
Section II
Reason treatment never started
Adverse Event/side Effects/complications
(Adverse events/side
effects/complications)
Death Before Beginning Protocol
Therapy (Death before beginning
protocol therapy)
Disease Progression, Relapse Prior To
Beginning Protocol Therapy (Disease
progression, relapse before protocol
treatment)
Medical Decision (Medical decision)
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No Treatment, Per Protocol Criteria (No
treatment assigned per protocol)
Other (Other)
Patient_ineligible (Patient ineligible)
Patient Withdrawal/refusal Before
Beginning Protocol Therapy (Patient
withdrawal/refusal before beginning
protocol therapy)
Comments
Investigator Signature
Investigator Signature Date (MM DD YYYY)
Comments
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NCT00098475  E4A03 Thrombotic Event
Prior September 14, 2005 Summary Form
NCT00098475  E4A03 Thrombotic Event Prior September
14, 2005 Summary Form
Lenalidomide and Dexamethasone With or Without
Thalidomide in Treating Patients With Multiple Myeloma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=0615D022-
651B-5424-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11016
NCT00098475  E4A03 Thrombotic
Event Prior September 14, 2005
Summary Form
Header
ECOG Protocol Number
ECOG Patient ID
DCI Name
Registration Step
Reporting Period
Deep Vein Thrombosis (DVT)
Please mark an 'X' if data have been amended
Date data amended
Patient demographics
Patient Initials
Participating Group Protocol Number
Institution/Affiliate
Participating Group Patient ID
Deep Vein Thrombosis
Did patient recieve DVT prophylaxis (prior to
September 14, 2005)
Yes
No
Start date of first (prophylactic) treatment
Date of most recent (prophylactic) treatment
1 / 3
Aspirin (81 mg) (Were any of the following given
prior to the first thrombotic event this report
period? answer no 1 or yes 2 for each of the
following)
Yes
No
Aspirin (325 mg)
Yes
No
Aspirin (other dose)
Yes
No
If other dose of Aspirin given, specify dose
Coumadin
Yes
No
If Coumadin given, specify dose
Yes
No
Low molecular weight heparin (enoxaparin;
Lovenox)
Yes
No
Other, specify
Has the patient received erythropoietin-type
agents (e.g., Epogen, Procrit or Aranesp) (prior to
the first thrombotic event?)
Yes
No
Thrombotic Event
Did patient experience a thrombotic event
(NOTE: Event must be reported through AdEERS
and on the E4A03 Adverse Event Form)
Yes
No
Date of thrombotic event (If yes,  - List Date of
thrombotic events this report period. Mark an
¿X¿ in the box on the right if not applicable.)
Mark an 'X' if N/A
Was the patient on thrombotic prophylaxis
(NOTE: If more then one thrombotic event this
report period, answer question below with
regards to the first thrombotic event this report
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Summary Form
period.)
Yes
No
Comments
Investigator Signature
Investigator Signature Date
Comments
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Summary Form
E3A06 Off-Treatment Form (Arm A)
NCT01169337
E3A06 Off-Treatment Form (Arm A) NCT01169337 
Lenalidomide or Observation in Treating Patients With
Asymptomatic High-Risk Smoldering Multiple Myeloma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=87090469-
26FC-270C-E040-BB89AD4326B4
All rights reserved. Please visit https://medical-data-
models.org/forms/11017
E3A06 Off-Treatment Form (Arm A)
NCT01169337
Header
ECOG Protocol Number
ECOG Patient ID
DCI Name
Registration Step
Reporting Period
End Of Treatment (End of treatment)
Please mark an 'X' if data have been amended.
(Please circle amended items in red)
Date data amended (s - mm/dd/yyyy)
Patient demographics
Patient Initials (Last, First)
Participating Group Protocol Number
Institution/Affiliate
Participating Group Patient ID
Did patient receive protocol therapy
Yes
No
Vital Status
Patient's Vital Status
Alive (Alive)
Dead (Dead)
Date of Last Contact or Death (mm/dd/yyyy)
1 / 3
Primary Cause of Death (if applicable)
Due To Other Cause (Due to other
cause)
Due To Protocol Treatment (Due to
protocol treatment)
Due To This Disease (Due to this
disease)
Unknown (Unknown)
Describe cause of death
Section I
Reason Treatment Ended
Adverse Event/side Effects/complications
(Adverse Event/Side
Effects/Complications)
Alternative Therapy (Alternative therapy)
Death On Study (Death on study)
Disease Progression, Relapse During
Active Treatment (Disease progression,
relapse during active treatment)
Other (Other)
Patient Off-treatment For Other
Complicating Disease (Patient off-
treatment for other complicating disease)
Patient Withdrawal Or Refusal After
Beginning Protocol Therapy (Patient
withdrawal/refusal after beginning
protocol therapy)
Treatment Completed Per Protocol
Criteria (Treatment completed per
protocol criteria)
Other Complicating Disease specify (specify)
Other specify
Last date protocol therapy was given
(mm/dd/yyyy)
Section II
Reason treatment never started
Adverse Event/side Effects/complications
(Adverse events/side
effects/complications)
Death Before Beginning Protocol
Therapy (Death before beginning
protocol therapy)
Disease Progression, Relapse Prior To
Beginning Protocol Therapy (Disease
progression, relapse before protocol
treatment)
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Medical Decision (Medical decision)
No Treatment, Per Protocol Criteria (No
treatment assigned per protocol)
Other (Other)
Patient_ineligible (Patient ineligible)
Patient Withdrawal/refusal Before
Beginning Protocol Therapy (Patient
withdrawal/refusal before beginning
protocol therapy)
Comments
Investigator Signature
Investigator Signature Date
Comments
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E5508 Non-Protocol Therapy Form
NCT01107626
E5508 Non-Protocol Therapy Form NCT01107626 
Bevacizumab or Pemetrexed Disodium Alone or In
Combination After Induction Therapy in Treating Patients
With Advanced Non-Squamous Non-Small Cell Lung
Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=6D41D0A3-
AE1C-13D4-E040-BB89AD430599
All rights reserved. Please visit https://medical-data-
models.org/forms/11018
E5508 Non-Protocol Therapy Form
NCT01107626
Header
ECOG Protocol Number
ECOG Patient ID
DCI Name
Registration Step
Reporting Period
Non-protocol Therapy (Non-Protocol
Therapy)
Please mark an 'X' if data have been amended.
(Please circle amended items in red)
Date data amended (s M D Y)
Patient demographics
Patient Initials (Last, First)
Participating Group Protocol Number
Institution/Affiliate
Participating Group Patient ID
Non-Protocol Therapy Date
Date of First Non-Protocol Therapy (if given prior
to progression/relapse from protocol therapy M D
Y)
Type(s) of first non-protocol therapy
1 / 3
Non-protocol Chemotherapy
No (No)
Unknown (Unknown)
Yes (Yes)
Non-protocol Hormonal Therapy
No (No)
Unknown (Unknown)
Yes (Yes)
Non-protocol Immunotherapy (/Biological
Response Modifiers)
No (No)
Unknown (Unknown)
Yes (Yes)
Non-protocol high dose chemotherapy/stem cell
transplant (Autologous or Allogeneic)
No (No)
Unknown (Unknown)
Yes (Yes)
Non-protocol Surgery
No (No)
Unknown (Unknown)
Yes (Yes)
Non-protocol surgery type
Non-protocol Radiation Therapy
No (No)
Unknown (Unknown)
Yes (Yes)
Non-protocol RT type
Other Non-protocol Therapy
No (No)
Unknown (Unknown)
Yes (Yes)
Name of other non-protocol therapy
Was the non-protocol therapy given for the
disease of this protocol (NOTE: Treatment for a
second primary in the same organ site would not
be considered therapy for disease of this
protocol.)
No (No)
Unknown (Unknown)
Yes (Yes)
Comments
Investigator Signature
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Investigator Signature Date (M D Y)
Comments
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CALGB: 40301 TREATMENT SUMMARY
FORM (SUBSET OF PATIENTS)
CALGB: 40301 TREATMENT SUMMARY FORM (SUBSET
OF PATIENTS)
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=E5A00141-
D565-5413-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11019
CALGB: 40301 TREATMENT
SUMMARY FORM (SUBSET OF
PATIENTS)
Header
CALGB Form
CALGB Study No
CALGB Patient ID
Last date of reporting period
Are data amended
Yes
No
Patient demographics
Patient Initials
Patient Hospital No
Institution/Affiliate
Participating Group
Participating Group Protocol No
Participating Group Patient ID
Assessment of Chemotherapy
Cycle start date
Current cycle number  (Tipifarnib/Placebo)
Number of tablets issued
Dose
1 / 2
Cycle end date
Number of tablets remaining
Were there any dose modifications or
additions/omissions to protocol treatment
(Tipifarnib or Placebo)
No (No)
Unknown (Unknown)
Yes, Planned (i.e., The Treatment Was
Changed According To Protocol
Guidelines) (Yes, planned)
Yes, Unplanned (i.e., The Treatment
Change Was Not Part Of Protocol
Guidelines) (Yes, unplanned)
specify reason why (If Yes)
specify reason why (If Yes)
Completed by
Date form completed
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CALGB: 40301 TREATMENT SUMMARY FORM (SUBSET OF
PATIENTS)
EBS
EBS
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=FF198F4E-
0236-24CA-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11020
EBS
Header module
Was a peripheral blood sample drawn for EBV
testing during this assessment period
Yes
No
Were the results greater than 1000 copies/mL
No (No)
Results not available (Results not
available)
Yes (Yes)
If yes was rituximab administered
Yes
No
Visit number
If yes, record the date the peripheral blood
sample for EBV testing was shipped
Date rituximab administered
Dose of rituximab administered
Has the patient developed a post-transplant
lymphopropliferative disorder
Comments (Comments)
No (No)
Yes (Yes)
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EBE
EBE
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=FF198939-
7887-2482-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11021
EBE
Header module
Were the results greater than 1000 copies/mL
No (No)
Results not available (Results not
available)
Yes (Yes)
If yes, was rituximab administered
Yes
No
Date EBV sample drawn
Record the date the peripheral blood sample for
EBV testing was shipped
Date rituximab administered
Dose of rituximab administered
Has the patient developed a post-transplant
lymphopropliferative disorder
Yes
No
Comments
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E1305 Treatment Form NCT00588770
Chemotherapy With or Without Bevacizumab in Treating
Patients With Recurrent or Metastatic Head and Neck
Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=19F79B13-
026F-5DCC-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11022
E1305 Treatment Form
NCT00588770
Header
ECOG Protocol Number
ECOG Patient ID
DCI Name
Registration Step
Please mark an 'X' if data have been amended.
(Please circle amended items in red)
Date data amended (M D Y)
Patient demographics
Patient Initials (Last, First)
Participating Group Protocol Number
Participating Group Patient ID
Institution/Affiliate
Arm A And Arm B
On Treatment Report Period
> Cycle 17 (> Cycle 17)
Cycle 1 (Cycle 1)
Cycle 10 (Cycle 10)
Cycle 11 (Cycle 11)
Cycle 12 (Cycle 12)
Cycle 13 (Cycle 13)
Cycle 14 (Cycle 14)
Cycle 15 (Cycle 15)
Cycle 16 (Cycle 16)
Cycle 17 (Cycle 17)
Cycle 2 (Cycle 2)
Cycle 3 (Cycle 3)
1 / 4
Cycle 4 (cycle 4)
Cycle 5 (Cycle 5)
Cycle 6 (Cycle 6)
Cycle 7 (Cycle 7)
Cycle 8 (cycle 8)
Cycle 9 (Cycle 9)
Specify Cycle
Reporting Period Start Date
Reporting Period End Date
On Treatment
Patient Vital Status
Alive (Alive)
Dead (Dead)
Date of Last Contact or Death (M D Y)
Primary Cause of Death (if applicable)
Due To Other Cause (Due to other
cause)
Due To Protocol Treatment (Due to
protocol treatment)
Due To This Disease (Due to this
disease)
Unknown (Unknown)
Describe cause of death
ECOG Performance Status (Day 1 of this cycle)
Fully Active, Able To Carry On All Pre-
disease Performance Without
Restriction. (0)
Restricted In Physically Strenuous
Activity But Ambulatory And Able To
Carry Out Work Of A Light Or Sedentary
Nature, E.g., Light Housework, Office
Work. (1)
Ambulatory And Capable Of All Selfcare
But Unable To Carry Out Any Work
Activities. Up And About More Than 50%
Of Waking Hours. (2)
Capable Of Only Limited Selfcare,
Confined To Bed Or Chair More Than
50% Of Waking Hours. (3)
Completely Disabled. Cannot Carry On
Any Selfcare. Totally Confined To Bed Or
Chair. (4)
Weight (kg Day 1)
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Patient Body Surface Area Measurement (m^2
BSA Day 1 of this cycle)
Agent Name: Cisplatin
Was the agent Cisplatin administered during this
reporting period (cycle)
Yes
No
Date Agent Administered (If yes M D Y)
Agent Dose (mg)
Agent Name: Carboplatin
Was the agent Carboplatin administered during
this reporting period (cycle)
Yes
No
Serum creatinine (Value used to calculate
Creatinine Clearance - mg/dl)
Creatinine Clearance (Record value used to
determine Carboplatin dose - ml/min)
Agent Name: Docetaxel
Was the agent Docetaxel administered during
this reporting period (cycle)
Yes
No
Agent Name: 5-fu
Was the agent 5-FU administered during this
reporting period (cycle)
Yes
No
Date of First dose for this reporting period (If
yes:)
Date of Last dose for this reporting period
Agent Total Dose (this report period)
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Agent Name: Bevacizumab
Was the agent Bevacizumab administered during
this reporting period (cycle)
Yes
No
Dose modification (Bevacizumab)
Dose Delayed (Dose delayed)
Dose Held (Dose held)
Drug Discontinued (Drug discontinued)
No Dose Modification (No dose
modification)
Non-protocol Therapy
Was any non-protocol therapy given during
protocol treatment? (not previously reported)
Yes
No
Comments
Investigator Signature
Investigator Signature Date
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E1208 Treatment Form NCT01004978
E1208 Treatment Form NCT01004978 
Chemoembolization With or Without Sorafenib Tosylate in
Treating Patients With Liver Cancer That Cannot Be
Removed By Surgery
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=6FCB9730-
7048-93EE-E040-BB89AD434904
All rights reserved. Please visit https://medical-data-
models.org/forms/11023
E1208 Treatment Form
NCT01004978
Header
DCI Name
Registration Step
On Treatment Report Period
> Cycle 16 (> Cycle 16)
Cycle 1 (Cycle 1)
Cycle 10 (Cycle 10)
Cycle 11 (Cycle 11)
Cycle 12 (Cycle 12)
Cycle 13 (Cycle 13)
Cycle 14 (Cycle 14)
Cycle 15 (Cycle 15)
Cycle 16 (Cycle 16)
Cycle 2 (Cycle 2)
Cycle 3 (Cycle 3)
Cycle 4 (cycle 4)
Cycle 5 (Cycle 5)
Cycle 6 (Cycle 6)
Cycle 7 (Cycle 7)
Cycle 8 (cycle 8)
Cycle 9 (Cycle 9)
Specify Cycle
Please mark an 'X' if data have been amended.
(Please circle amended items in red)
Date data amended (s - mm/dd/yyyy)
Patient demographics
Patient Initials (Last, First)
ECOG Protocol Number
Participating Group Protocol Number
Institution/Affiliate
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ECOG Patient ID
Participating Group Patient ID
Vital Status
Patient's Vital Status
Alive (Alive)
Dead (Dead)
Date of last contact or death (mm/dd/yyyy)
Primary Cause of Death
Due To Other Cause (Due to other
cause)
Due To Protocol Treatment (Due to
protocol treatment)
Due To This Disease (Due to this
disease)
Unknown (Unknown)
Describe cause of death
Patient Characteristics
Reporting Period Start Date
Reporting Period End Date
Performance Status
Fully Active, Able To Carry On All Pre-
disease Performance Without
Restriction. (0)
Restricted In Physically Strenuous
Activity But Ambulatory And Able To
Carry Out Work Of A Light Or Sedentary
Nature, E.g., Light Housework, Office
Work. (1)
Ambulatory And Capable Of All Selfcare
But Unable To Carry Out Any Work
Activities. Up And About More Than 50%
Of Waking Hours. (2)
Capable Of Only Limited Selfcare,
Confined To Bed Or Chair More Than
50% Of Waking Hours. (3)
Completely Disabled. Cannot Carry On
Any Selfcare. Totally Confined To Bed Or
Chair. (4)
Weight (Day 1 of this reporting period cycle)
Body Surface Area (BSA Day 1 of this reporting
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period cycle)
Bilirubin ULN (mg/dl)
Bilirubin (mg/dl)
Therapy Administered - Section I
Agent Start Date (Sorafenib/Placebo)
Agent End Date (Sorafenib/Placebo)
Did the patient complete and return the Patient
Pill Diary this cycle
Yes
No
Daily dose prescribed (on Day 1 of this reporting
period)
Date of dose modifications (If the prescribed
dose changed during this cycle including
prescribed dose interruptions)
New total dose per day
200 Mg (200 mg)
400 Mg (400 mg)
800 Mg (800 mg)
Dose Held (Dose held)
Dose Modification Reason
Other (Other)
Per Protocol (per protocol)
Specify (on line)
Tace Administration
Was agent administered (TACE this reporting
period)
Yes
No
Date Agent Administered (TACE M D Y)
Agent
Dose (mg)
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Mark 'X' if agent not given (this reporting period)
What method does institution plan to use to
administer TACE?
Conventional Method (Conventional
method)
Dc Beads (DC Beads)
Section E: Non-protocol Therapy
Was any non-protocol therapy given during
protocol treatment (not previously reported)?
Yes
No
Comments
Investigator Signature
Investigator Signature Date
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ECOG-E1505 Bevicizumab Treatment Form
ECOG-E1505 Bevicizumab Treatment Form
Chemotherapy With or Without Bevacizumab in Treating
Patients With Stage IB, Stage II, or Stage IIIA Non-Small
Lung Cancer That Was Removed By Surgery
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=07960353-
2F29-55A4-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11024
ECOG-E1505 Bevicizumab
Treatment Form
Header
ECOG Protocol Number
ECOG Patient ID
DCI Name
Registration Step
Please mark an 'X' if data have been amended.
(Please circle amended items in red)
Date data amended (M D Y)
Patient demographics
Patient Initials (Last, First)
Participating Group Protocol Number
Institution/Affiliate
Participating Group Patient ID
ARM B ONLY
On Treatment Report Period
Cycle 1 (Cycle 1)
Cycle 10 (Cycle 10)
Cycle 11 (Cycle 11)
Cycle 12 (Cycle 12)
Cycle 13 (Cycle 13)
Cycle 14 (Cycle 14)
Cycle 15 (Cycle 15)
Cycle 16 (Cycle 16)
Cycle 17 (Cycle 17)
Cycle 2 (Cycle 2)
Cycle 3 (Cycle 3)
Cycle 4 (cycle 4)
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Cycle 5 (Cycle 5)
Cycle 6 (Cycle 6)
Cycle 7 (Cycle 7)
Cycle 8 (cycle 8)
Cycle 9 (Cycle 9)
Reporting Period Start Date
Reporting Period End Date
On Treatment
Patient Vital Status
Alive (Alive)
Dead (Dead)
Date of Last Contact or Death (M D Y)
Primary Cause of Death (if applicable)
Due To Other Cause (Due to other
cause)
Due To Protocol Treatment (Due to
protocol treatment)
Due To This Disease (Due to this
disease)
Unknown (Unknown)
Describe cause of death
Weight (kg Day 1)
Date physical exam performed (most recent)
Mark an 'X' if not done
Agent Name: Bevicizumab
Was the agent Bevacizumab administered during
this reporting period (cycle)
Yes
No
Date Agent Administered (If yes)
Agent Dose (mg)
Chemotherapy Dose Modifications
Dose modification (this cycle only)
Dose Delayed (Dose delayed)
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Dose Held (Dose held)
Drug Discontinued (Drug discontinued)
No Dose Modification (No dose
modification)
Dose Modification Reason (this cycle only)
Adverse Event (Adverse event)
Alternative Therapy For Other Reason
(Alternative therapy for other reason)
Dosing Error (Dosing error)
Other (Other)
Patient Refusal/noncompliance (Patient
refusal/noncompliance)
Scheduling (Scheduling)
Second Primary Cancer (Second
primary)
Other, specify
Modification due to Adverse Event (mark an ¿X¿
for all that apply:)
Arterial Thrombotic Event (Arterial
Thrombotic Event)
Gi Toxicity (GI toxicity)
Hemorrhage (Hemorrhage)
Hepatic Toxicity (Hepatic Toxicity)
Neurotoxicity (Neurotoxicity)
Other (Other)
Proteinuria (Proteinuria)
Venous Thrombosis/embolism (Venous
Thrombosis/Embolism)
Wound Dehiscence (Wound Dehiscence)
Other, specify
Non-protocol Therapy
Was any non-protocol therapy given during
protocol treatment (not previously reported)
Yes
No
Comments
Investigator Signature
Investigator Signature Date
Comments
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E1A05 Multiple Myeloma On-Study Form -
Form 2855 NCT00522392
E1A05 Multiple Myeloma On-Study Form - Form 2855
NCT00522392 
Bortezomib and Dexamethasone With or Without
Lenalidomide in Treating Patients With Multiple Myeloma
Previously Treated With Dexamethasone
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=3240927B-
84FC-4104-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11025
E1A05 Multiple Myeloma On-Study
Form - Form 2855 NCT00522392
Header
ECOG Protocol Number
ECOG Patient ID
DCI Name
Registration Step
Report Period (Place ID Label Here)
Baseline Step 1 (Baseline Step 1)
Patient Initials (Last, First)
Participating Group Protocol Number
Participating Group Patient ID
Institution/Affiliate
Please mark an 'X' if data have been amended.
Date data amended
Disease Description - Initial Diagnosis
Date of Initial Pathologic Diagnosis
Durie-Salmon Stage (at initial diagnosis - see
attached)
I - All Of The Following Must Be Present
(hemoglobin >10 G/dl; Serum Calcium
<12 Mg/dl; Urine Light Chains <4 G/24
Hrs; Normal Bones On Radiograph Or
Solitary Plasmacytoma; Igg <5 G/dl; Iga
<3 G/dl) (I)
Ii - Fitting Neither Stage I Or Stage Iii (II)
Iii - One Of The Following Must Be
1 / 47
Present (hemoglobin <8.5 G/dl; Serum
Calcium >12 Mg/dl; Urine Light Chains
>12 G/24 Hrs; Advanced Lytic Bone
Lesions (>3 Lytic Lesions); Igg >7 G/dl;
Iga >5 G/dl) (III)
Unknown (Unknown)
Durie-Salmon Sub-Stage (at initial diagnosis -
see attached)
A (relatively Normal Renal Function -
Serum Creatinine <2.0 Mg/dl) (A)
B (abnormal Renal Function - Serum
Creatinine >= 2.0 Mg/dl) (B)
Unknown (Unknown)
Current Clinical Date
Performance Status
Fully Active, Able To Carry On All Pre-
disease Performance Without
Restriction. (0)
Restricted In Physically Strenuous
Activity But Ambulatory And Able To
Carry Out Work Of A Light Or Sedentary
Nature, E.g., Light Housework, Office
Work. (1)
Ambulatory And Capable Of All Selfcare
But Unable To Carry Out Any Work
Activities. Up And About More Than 50%
Of Waking Hours. (2)
Capable Of Only Limited Selfcare,
Confined To Bed Or Chair More Than
50% Of Waking Hours. (3)
Completely Disabled. Cannot Carry On
Any Selfcare. Totally Confined To Bed Or
Chair. (4)
Dead (5)
Bone pain on entry to study
Mild Requires Only Non-narcotic
Medication (mild, requires use of non-
narcotic pain relief)
None (none)
Requires Occasional Narcotics (requires
occasional narcotics)
Requires Parenteral Narcotics Or Patch
(requires parenteral narcotics, or patch)
Requires Per Os Narcotics (requires per
os narcotics)
Uncontrollable Pain (uncontrollable pain)
Unknown (unknown)
Is severe osteoporosis present?
No (no)
Unknown (unknown)
Yes (yes)
Number of bones with lytic lesions present
1-3 Bones (1-3 bones)
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More Than 3 Bones (more than 3 bones)
None (none)
Unknown (unknown)
Number of lytic lesions > 2 cm in diameter
1-3 Lesions (1-3 bones)
More Than 3 Lesions (more than 3
bones)
None (none)
Unknown (unknown)
Pathologic fracture during previous 1 month
(including compression and rib fractures)
No (no)
Unknown (unknown)
Yes (yes)
Presence of infection in past six months
No (No)
Unknown (Unknown)
Yes (Yes)
Is patient on anti-coagulation therapy prior to
randomization?
Yes
No
Prior Therapy
Prior Treatment Regimen
Cyclophosphamide, Lenalidomide And
Dexamethasone (Cyclophosphamide,
lenalidomide and dexamethasone)
Dexamethasone (Dexamethasone)
Lenalidomide And Dexamethasone
(Lenalidomide and dexamethasone)
Liposomal Doxorubicin And
Dexamethasone (Liposomal doxorubicin
and dexamethasone)
Other (Other)
Thalidomide And Dexamethasone
(Thalidomide and dexamethasone)
Vincristine, Doxorubicin And
Dexamethasone (Vincristine, doxorubicin
and dexamethasone)
The combination of dexamethasone plus (If
other,)
Bortezomib (Bortezomib)
Lenalidomide (Lenalidomide)
Liposome-encapsulated Doxorubicin
Citrate (Liposomal Doxorubicin Citrate)
Thalidomide (Thalidomide)
Vincristine (vcr) (Vincristine (VCR))
Agent total dose (Cummulative dose
dexamethasone received during all induction)
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Agent Start Date
Agent End Date
Total number of cycles given
Disease response at registration
Complete Remission (Complete
Response)
Not Complete Response (Not Complete
Response)
Has the patient received bisphosphonates
Yes
No
Bisphosphanate type(s) received (If yes,)
Both Pamidronate And Zoledronic Acid
(both pamidronate and zoledronic acid)
Other (Other)
Pamidronate (pamidronate)
Zoledronic Acid (zoledronic acid)
Bisphosphonates, specify
Prior radiation therapy?
Yes
No
Date Prior RT Ended
Baseline Abnormalities
CTC Adverse Event Term
Acidosis Nos (Acidosis (metabolic or
respiratory))
Capillary Leak Syndrome (Acute
vascular leak syndrome)
Adrenal Insufficiency (Adrenal
insufficiency)
Adult Respiratory Distress Syndrome
(Adult respiratory distress syndrome
(ARDS))
Blood Albumin Decreased (Albumin,
serum-low (hypoalbuminemia))
Alcohol Intolerance Syndrome
(antabuse-like Syndrome) (Alcohol
intolerance syndrome (antabuse-like
syndrome))
Blood Alkaline Phosphatase Nos
Increased (Alkaline phosphatase)
Alkalosis Nos (Alkalosis (metabolic or
respiratory))
Hypersensitivity Nos (Allergic
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reaction/hypersensitivity (including drug
fever))
Rhinitis Allergic Nos (Allergic rhinitis
(including sneezing, nasal stuffiness,
postnasal drip))
Allergy/immunology Other
(Allergy/Immunology-Other (Specify))
Alanine Aminotransferase Increased
(ALT, SGPT (serum glutamic pyruvic
transaminase))
Blood Amylase Increased (Amylase)
Anorexia (Anorexia)
Apnoea (Apnea)
Arachnoiditis
(Arachnoiditis/meningismus/radiculitis)
Arthritis Nos (Arthritis (non-septic))
Ascites (Ascites (non-malignant))
Aspiration (Aspiration)
Aspartate Aminotransferase Increased
(AST, SGOT (serum glutamic oxaloacetic
transaminase))
Ataxia Nec (Ataxia (incoordination))
Atelectasis (Atelectasis)
Atrophy, Skin (Atrophy, skin)
Atrophy, Subcutaneous Fat (Atrophy,
subcutaneous fat)
Auditory/ear Other (Auditory/Ear-Other
(Specify))
Autoimmune Disorder Nos (Autoimmune
reaction)
Blood Bicarbonate Decreased
(Bicarbonate, serum-low)
Blood Bilirubin Increased (Bilirubin
(hyperbilirubinemia))
Bladder Disorder Nos (Bladder spasms)
Blood/bone Marrow Other (Blood/Bone
Marrow-Other (Specify))
Bone Age (alteration In Bone Age) (Bone
age (alteration in bone age))
Bone Growth: Femoral Head; Slipped
Capital Femoral Epiphysis (Bone growth:
femoral head; slipped capital femoral
epiphysis)
Bone Growth: Limb Length Discrepancy
(Bone growth: limb length discrepancy)
Bone Growth: Spine Kyphosis/lordosis
(Bone growth: spine kyphosis/lordosis)
Bone Marrow Depression Nos (Bone
marrow cellularity)
Bone: Spine-scoliosis (Bone: spine-
scoliosis)
Brachial Plexopathy (Brachial
plexopathy)
Breast Function/lactation (Breast
function/lactation)
Breast Nipple/areolar Deformity (Breast
nipple/areolar deformity)
Breast Volume/hypoplasia (Breast
volume/hypoplasia)
Bronchospasm, Wheezing
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(Bronchospasm, wheezing)
Ecchymosis (Bruising (in absence of
grade 3 or 4 thrombocytopenia))
Burn (Burn)
Hypercalcaemia (Calcium, serum-high
(hypercalcemia))
Hypocalcaemia (Calcium, serum-low
(hypocalcemia))
Pulmonary Function Test Nos Decreased
(Carbon monoxide diffusion capacity
(DL(co)))
Arrhythmia Nos (Cardiac Arrhythmia-
Other (Specify))
Cardiac General Other (Cardiac
General-Other (Specify))
Myocardial Ischaemia (Cardiac
ischemia/infarction)
Cardiac Troponin I Increased (Cardiac
troponin I (cTnI))
Cardiac Troponin T Increased (Cardiac
troponin T (cTnT))
Cardiopulmonary Arrest, Cause
Unknown (non-fatal) (Cardiopulmonary
arrest, cause unknown (non-fatal))
Cataract Nec (Cataract)
Cd4 Lymphocytes Decreased (CD4
count)
Cervical Spine-range Of Motion (Cervical
spine-range of motion)
Chelitis (Cheilitis)
Cholecystitis (Cholecystitis)
Hypercholesteraemia (Cholesterol,
serum-high (hypercholesteremia))
Chyle Or Lymph Leakage (Chyle or
lymph leakage)
Chylothorax (Chylothorax)
Cerebral Ischaemia (CNS
cerebrovascular ischemia)
Cns Necrosis/cystic Progression (CNS
necrosis/cystic progression)
Coagulation Disorder Nos (Coagulation-
Other (Specify))
Learning Disorder Nos (Cognitive
disturbance)
Colitis Nos (Colitis)
Colitis, Infectious (e.g., Clostridium
Difficile) (Colitis, infectious (e.g.,
Clostridium difficile))
Ventricular Asystole (Conduction
abnormality/Atrioventricular heart block -
Asystole)
Conduction Abnormality/atrioventricular
Heart Block (Conduction
abnormality/Atrioventricular heart block -
AV block-first degree)
Conduction Abnormality/atrioventricular
Heart Block - Av Block-second Degree
Mobitz Type I (wenckebach) (Conduction
abnormality/Atrioventricular heart block -
AV block-Second degree Mobitz Type I
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(Wenckebach))
Conduction Abnormality/atrioventricular
Heart Block (Conduction
abnormality/Atrioventricular heart block -
AV block-second degree Mobitz Type II)
Conduction Abnormality/atrioventricular
Heart Block (Conduction
abnormality/Atrioventricular heart block -
AV block-third degree (complete AV
block))
Conduction Abnormality/atrioventricular
Heart Block (Conduction
abnormality/Atrioventricular heart block -
Conduction abnormality NOS)
Conduction Abnormality/atrioventricular
Heart Block (Conduction
abnormality/Atrioventricular heart block -
Sick sinus syndrome)
Conduction Abnormality/atrioventricular
Heart Block (Conduction
abnormality/Atrioventricular heart block -
Stokes-Adams syndrome)
Conduction Abnormality/atrioventricular
Heart Block (Conduction
abnormality/Atrioventricular heart block -
Wolff-Parkinson-White syndrome)
Confusion (Confusion)
Constipation (Constipation)
Constitutional Symptoms Other
(Constitutional Symptoms-Other
(Specify))
Cough (Cough)
Blood Creatine Phosphokinase
Increased (CPK (creatine
phosphokinase))
Blood Creatinine Increased (Creatinine)
Cushingoid (Cushingoid appearance
(e.g., moon face, buffalo hump,
centripetal obesity, cutaneous striae))
Cystitis (Cystitis)
Cytokine Release Syndrome/acute
Infusion Reaction (Cytokine release
syndrome/acute infusion reaction)
Death Not Associated With Ctcae Term
(Death not associated with CTCAE term
- Death NOS)
Death Not Associated With Ctcae Term
(Death not associated with CTCAE term
- Disease progression NOS)
Death Not Associated With Ctcae Term
(Death not associated with CTCAE term
- Multi-organ failure)
Death Not Associated With Ctcae Term
(Death not associated with CTCAE term
- Sudden death)
Dehydration (Dehydration)
Dental: Dentures Or Prosthesis (Dental:
dentures or prosthesis)
Dental: Periodontal Disease (Dental:
periodontal disease)
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Dental: Teeth (Dental: teeth)
Dental: Teeth Development (Dental:
teeth development)
Dermal Change Lymphedema,
Phlebolymphedema (Dermal change
lymphedema, phlebolymphedema)
Dermatology/skin Other
(Dermatology/Skin-Other (Specify))
Diarrhoea Nos (Diarrhea)
Disseminated Intravascular Coagulation
(DIC (disseminated intravascular
coagulation))
Distention/bloating, Abdominal
(Distention/bloating, abdominal)
Dizziness (exc Vertigo) (Dizziness)
Dry Eye Nec (Dry eye syndrome)
Dry Mouth (Dry mouth/salivary gland
(xerostomia))
Dry Skin (Dry skin)
Dysphagia (Dysphagia (difficulty
swallowing))
Dyspnoea Nos (Dyspnea (shortness of
breath))
Edema, Larynx (Edema, larynx)
Edema: Head And Neck (Edema: head
and neck)
Oedema Nos (Edema: limb)
Edema: Trunk/genital (Edema:
trunk/genital)
Edema: Viscera (Edema: viscera)
Ejaculatory Dysfunction (Ejaculatory
dysfunction)
Encephalopathy (Encephalopathy)
Endocrine Other (Endocrine-Other
(Specify))
Enteritis (inflammation Of The Small
Bowel) (Enteritis (inflammation of the
small bowel))
Impotence (Erectile dysfunction)
Oesophagitis Nos (Esophagitis)
Exostosis (Exostosis)
Extrapyramidal Disorder Nec
(Extrapyramidal/involuntary
movement/restlessness)
Extremity-lower (gait/walking) (Extremity-
lower (gait/walking))
Extremity-upper (function) (Extremity-
upper (function))
Eyelid Dysfunction (Eyelid dysfunction)
Fatigue (Fatigue (asthenia, lethargy,
malaise))
Febrile Neutropenia (fever Of Unknown
Origin Without Clinically Or
Microbiologically Documented Infection)
(anc <1.0 X 10^9/l, Fever >=38.5
Degrees C) (Febrile neutropenia)
Feminization (Feminization of male)
Forced Expiratory Volume Decreased
(FEV(1))
Pyrexia (Fever (in the absence of
8 / 47
E1A05 Multiple Myeloma On-Study Form - Form 2855 NCT00522392
neutropenia, where neutropenia is
defined as ANC <1.0 x 10^9/L))
Blood Fibrinogen Decreased
(Fibrinogen)
Fibrosis-cosmesis (Fibrosis-cosmesis)
Fibrosis-deep Connective Tissue
(Fibrosis-deep connective tissue)
Fistula, Gi (Fistula, GI - Abdomen NOS)
Anal Fistula (Fistula, GI - Anus)
Fistula, Gi (Fistula, GI - Biliary tree)
Fistula, Gi (Fistula, GI -
Colon/cecum/appendix)
Intestinal Fistula (Fistula, GI -
Duodenum)
Tracheo-oesophageal Fistula Nos
(Fistula, GI - Esophagus)
Fistula, Gi (Fistula, GI - Gallbladder)
Fistula, Gi (Fistula, GI - Ileum)
Fistula, Gi (Fistula, GI - Jejunum)
Fistula, Gi (Fistula, GI - Oral cavity)
Fistula, Gi (Fistula, GI - Pancreas)
Fistula, Gi (Fistula, GI - Pharynx)
Fistula, Gi (Fistula, GI - Rectum)
Fistula, Gi (Fistula, GI - Salivary gland)
Fistula, Gi (Fistula, GI - Small bowel
NOS)
Fistula, Gi (Fistula, GI - Stomach)
Fistula, Gu (Fistula, GU - Bladder)
Fistula, Gu (Fistula, GU - Genital tract-
female)
Fistula, Gu (Fistula, GU - Kidney)
Fistula, Gu (Fistula, GU - Ureter)
Fistula, Gu (Fistula, GU - Urethra)
Fistula, Gu (Fistula, GU - Uterus)
Urogenital Fistula (Fistula, GU - Vagina)
Fistula, Pulmonary/upper Respiratory
(Fistula, pulmonary/upper respiratory -
Bronchus)
Fistula, Pulmonary/upper Respiratory
(Fistula, pulmonary/upper respiratory -
Larynx)
Fistula, Pulmonary/upper Respiratory
(Fistula, pulmonary/upper respiratory -
Lung)
Fistula, Pulmonary/upper Respiratory
(Fistula, pulmonary/upper respiratory -
Oral cavity)
Fistula, Pulmonary/upper Respiratory
(Fistula, pulmonary/upper respiratory -
Pharynx)
Fistula, Pulmonary/upper Respiratory
(Fistula, pulmonary/upper respiratory -
Pleura)
Fistula, Pulmonary/upper Respiratory
(Fistula, pulmonary/upper respiratory -
Trachea)
Flatulence (Flatulence)
Flu-like Syndrome (Flu-like syndrome)
Flushing (Flushing)
Fracture (Fracture)
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Gastritis Nos (Gastritis (including bile
reflux gastritis))
Gastrointestinal Other (Gastrointestinal-
Other (Specify))
Gamma-glutamyltransferase Increased
(GGT (gamma-glutamyl transpeptidase))
Glaucoma Nos (Glaucoma)
Glomerular Filtration Rate (Glomerular
filtration rate)
Hyperglycaemia Nos (Glucose, serum-
high (hyperglycemia))
Hypoglycaemia Nos (Glucose, serum-
low (hypoglycemia))
Growth And Development Other (Growth
and Development-Other (Specify))
Growth Velocity (reduction In Growth
Velocity) (Growth velocity (reduction in
growth velocity))
Gynaecomastia (Gynecomastia)
Alopecia (Hair loss/Alopecia (scalp or
body))
Haptoglobin Decreased (Haptoglobin)
Hearing: Patients With/without Baseline
Audiogram And Enrolled In A Monitoring
Program (Hearing: patients with/without
baseline audiogram and enrolled in a
monitoring program)
Hearing: Patients Without Baseline
Audiogram And Not Enrolled In A
Monitoring Program (Hearing: patients
without baseline audiogram and not
enrolled in a monitoring program)
Dyspepsia (Heartburn/dyspepsia)
Hematoma (Hematoma)
Haemoglobin Decreased (Hemoglobin)
Haemoglobinuria Present
(Hemoglobinuria)
Hemolysis Nos (Hemolysis (e.g.,
immune hemolytic anemia, drug related
hemolysis))
Haemorrhagic Stroke (Hemorrhage,
CNS)
Melaena (Hemorrhage, GI - Abdomen
NOS)
Hemorrhage, Gi (Hemorrhage, GI -
Anus)
Hemorrhage, Gi (Hemorrhage, GI -
Biliary tree)
Hemorrhage, Gi (Hemorrhage, GI -
Cecum/appendix)
Hemorrhage, Gi (Hemorrhage, GI -
Colon)
Hemorrhage, Gi (Hemorrhage, GI -
Duodenum)
Hemorrhage, Gi (Hemorrhage, GI -
Esophagus)
Hemorrhage, Gi (Hemorrhage, GI -
Ileum)
Hemorrhage, Gi (Hemorrhage, GI -
Jejunum)
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Hemorrhage, Gi (Hemorrhage, GI - Liver)
Hemorrhage, Gi (Hemorrhage, GI -
Lower GI NOS)
Hemorrhage, Gi (Hemorrhage, GI - Oral
cavity)
Hemorrhage, Gi (Hemorrhage, GI -
Pancreas)
Hemorrhage, Gi (Hemorrhage, GI -
Peritoneal cavity)
Rectal Bleeding (Hemorrhage, GI -
Rectum)
Hemorrhage, Gi (Hemorrhage, GI -
Stoma)
Haematemesis (Hemorrhage, GI -
Stomach)
Hemorrhage, Gi (Hemorrhage, GI -
Upper GI NOS)
Hemorrhage, Gi (Hemorrhage, GI -
Varices (esophageal))
Hemorrhage, Gi (Hemorrhage, GI -
Varices (rectal))
Hemorrhage, Gu (Hemorrhage, GU -
Bladder)
Hemorrhage, Gu (Hemorrhage, GU -
Fallopian tube)
Hemorrhage, Gu (Hemorrhage, GU -
Kidney)
Hemorrhage, Gu (Hemorrhage, GU -
Ovary)
Hemorrhage, Gu (Hemorrhage, GU -
Prostate)
Hemorrhage, Gu (Hemorrhage, GU -
Retroperitoneum)
Hemorrhage, Gu (Hemorrhage, GU -
Spermatic cord)
Hemorrhage, Gu (Hemorrhage, GU -
Stoma)
Hemorrhage, Gu (Hemorrhage, GU -
Testes)
Hemorrhage, Gu (Hemorrhage, GU -
Ureter)
Hemorrhage, Gu (Hemorrhage, GU -
Urethra)
Haematuria Present (Hemorrhage, GU -
Urinary NOS)
Hemorrhage, Gu (Hemorrhage, GU -
Uterus)
Vaginal Haemorrhage (Hemorrhage, GU
- Vagina)
Hemorrhage, Gu (Hemorrhage, GU - Vas
deferens)
Hemorrhage, Pulmonary/upper
Respiratory (Hemorrhage,
pulmonary/upper respiratory -
Bronchopulmonary NOS)
Hemorrhage, Pulmonary/upper
Respiratory (Hemorrhage,
pulmonary/upper respiratory - Bronchus)
Hemorrhage, Pulmonary/upper
Respiratory (Hemorrhage,
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pulmonary/upper respiratory - Larynx)
Hemorrhage, Pulmonary/upper
Respiratory (Hemorrhage,
pulmonary/upper respiratory - Lung)
Hemorrhage, Pulmonary/upper
Respiratory (Hemorrhage,
pulmonary/upper respiratory -
Mediastinum)
Epistaxis (Hemorrhage, pulmonary/upper
respiratory - Nose)
Hemorrhage, Pulmonary/upper
Respiratory (Hemorrhage,
pulmonary/upper respiratory - Pharynx)
Hemorrhage, Pulmonary/upper
Respiratory (Hemorrhage,
pulmonary/upper respiratory - Pleura)
Haemoptysis (Hemorrhage,
pulmonary/upper respiratory -
Respiratory tract NOS)
Hemorrhage, Pulmonary/upper
Respiratory (Hemorrhage,
pulmonary/upper respiratory - Stoma)
Hemorrhage, Pulmonary/upper
Respiratory (Hemorrhage,
pulmonary/upper respiratory - Trachea)
Post-operative Haemorrhage
(Hemorrhage/bleeding associated with
surgery, intra-operative or post-operative)
Hemorrhage/bleeding Other
(Hemorrhage/Bleeding-Other (Specify))
Hemorrhoids (Hemorrhoids)
Hepatobiliary/pancreas Other
(Hepatobiliary/Pancreas-Other (Specify))
Hiccups (Hiccoughs (hiccups, singultus))
Menopausal Symptoms (Hot
flashes/flushes)
Hydrocephalus (Hydrocephalus)
Skin Discolouration (Hyperpigmentation)
Hypertension Nos (Hypertension)
Hypopigmentation (Hypopigmentation)
Hypotension Nos (Hypotension)
Hypothermia (Hypothermia)
Hypoxia (Hypoxia)
Ileus (Ileus, GI (functional obstruction of
bowel, i.e., neuroconstipation))
Incontinence, Anal (Incontinence, anal)
Urinary Incontinence (Incontinence,
urinary)
Induration/fibrosis (skin And
Subcutaneous Tissue)
(Induration/fibrosis (skin and
subcutaneous tissue))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Abdomen NOS)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
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Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Anal/perianal)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Appendix)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Artery)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Biliary tree)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Bladder (urinary))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Blood)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Bone (osteomyelitis))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Brain (encephalitis,
infectious))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Brain + Spinal cord
(encephalomyelitis))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Bronchus)
13 / 47
E1A05 Multiple Myeloma On-Study Form - Form 2855 NCT00522392
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Catheter-related)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Cecum)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Cervix)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Colon)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Conjunctiva)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Cornea)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Dental-tooth)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Duodenum)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Esophagus)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - External ear (otitis externa))
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Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Eye NOS)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Fallopian tube)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Foreign body (e.g., graft,
implant, prosthesis, stent))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Gallbladder (cholecystitis))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Heart (endocarditis))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Ileum)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Jejunum)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Joint)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Kidney)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
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neutrophils - Larynx)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Lens)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Lip/perioral)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Liver)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Lung (pneumonia))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Lymphatic)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Mediastinum NOS)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Meninges (meningitis))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Middle ear (otitis media))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Mucosa)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
16 / 47
E1A05 Multiple Myeloma On-Study Form - Form 2855 NCT00522392
neutrophils - Muscle (infection myositis))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Neck NOS)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Nerve-cranial)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Nerve-peripheral)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Nose)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Oral cavity-gums
(gingivitis))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Pancreas)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Paranasal)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Pelvis NOS)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Penis)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
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microbiologically) with Grade 3 or 4
neutrophils - Peristomal)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Peritoneal cavity)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Pharynx)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Pleura (empyema))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Prostate)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Rectum)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Salivary gland)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Scrotum)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Sinus)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Skin (cellulitis))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
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microbiologically) with Grade 3 or 4
neutrophils - Small bowel NOS)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Soft tissue NOS)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Spinal cord (myelitis))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Spleen)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Stomach)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Trachea)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Ungual (nails))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Upper aerodigestive NOS)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Upper airway NOS)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Ureter)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
19 / 47
E1A05 Multiple Myeloma On-Study Form - Form 2855 NCT00522392
microbiologically) with Grade 3 or 4
neutrophils - Urethra)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Urinary tract NOS)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Uterus)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Vagina)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Vein)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Vulva)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Wound)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Abdomen
NOS)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils -
Anal/perianal)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Appendix)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Artery)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Biliary tree)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Bladder
(urinary))
Infection With Normal Anc Or Grade 1 Or
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2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Blood)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Bone
(osteomyelitis))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Brain
(encephalitis, infectious))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Brain +
Spinal cord (encephalomyelitis))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Bronchus)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Catheter-
related)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Cecum)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Cervix)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Colon)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils -
Conjunctiva)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Cornea)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Dental-
tooth)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Duodenum)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Esophagus)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - External ear
(otitis externa))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Eye NOS)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Fallopian
tube)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
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or Grade 1 or 2 neutrophils - Foreign
body (e.g., graft, implant, prosthesis,
stent))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Gallbladder
(cholecystitis))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Heart
(endocarditis))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Ileum)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Jejunum)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Joint)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Kidney)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Larynx)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Lens)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Lip/perioral)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Liver)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Lung
(pneumonia))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Lymphatic)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils -
Mediastinum NOS)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Meninges
(meningitis))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Middle ear
(otitis media))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Mucosa)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Muscle
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(infection myositis))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Neck NOS)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Nerve-
cranial)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Nerve-
peripheral)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Nose)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Oral cavity-
gums (gingivitis))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Pancreas)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Paranasal)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Pelvis NOS)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Penis)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Peristomal)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Peritoneal
cavity)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Pharynx)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Pleura
(empyema))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Prostate)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Rectum)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Salivary
gland)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Scrotum)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
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or Grade 1 or 2 neutrophils - Sinus)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Skin
(cellulitis))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Small bowel
NOS)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Soft tissue
NOS)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Spinal cord
(myelitis))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Spleen)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Stomach)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Trachea)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Ungual
(nails))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Upper
aerodigestive NOS)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Upper
airway NOS)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Ureter)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Urethra)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Urinary
tract NOS)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Uterus)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Vagina)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Vein)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Vulva)
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Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Wound)
Infection With Unknown Anc (Infection
with unknown ANC - Abdomen NOS)
Infection With Unknown Anc (Infection
with unknown ANC - Anal/perianal)
Infection With Unknown Anc (Infection
with unknown ANC - Appendix)
Infection With Unknown Anc (Infection
with unknown ANC - Artery)
Infection With Unknown Anc (Infection
with unknown ANC - Biliary tree)
Infection With Unknown Anc (Infection
with unknown ANC - Bladder (urinary))
Infection With Unknown Anc (Infection
with unknown ANC - Blood)
Infection With Unknown Anc (Infection
with unknown ANC - Bone
(osteomyelitis))
Infection With Unknown Anc (Infection
with unknown ANC - Brain (encephalitis,
infectious))
Infection With Unknown Anc (Infection
with unknown ANC - Brain + Spinal cord
(encephalomyelitis))
Infection With Unknown Anc (Infection
with unknown ANC - Bronchus)
Implant Infection (Infection with unknown
ANC - Catheter-related)
Infection With Unknown Anc (Infection
with unknown ANC - Cecum)
Infection With Unknown Anc (Infection
with unknown ANC - Cervix)
Infection With Unknown Anc (Infection
with unknown ANC - Colon)
Infection With Unknown Anc (Infection
with unknown ANC - Conjunctiva)
Infection With Unknown Anc (Infection
with unknown ANC - Cornea)
Infection With Unknown Anc (Infection
with unknown ANC - Dental-tooth)
Infection With Unknown Anc (Infection
with unknown ANC - Duodenum)
Infection With Unknown Anc (Infection
with unknown ANC - Esophagus)
Infection With Unknown Anc (Infection
with unknown ANC - External ear (otitis
externa))
Infection With Unknown Anc (Infection
with unknown ANC - Eye NOS)
Infection With Unknown Anc (Infection
with unknown ANC - Fallopian tube)
Infection With Unknown Anc (Infection
with unknown ANC - Foreign body (e.g.,
graft, implant, prosthesis, stent))
Infection With Unknown Anc (Infection
with unknown ANC - Gallbladder
(cholecystitis))
Infection With Unknown Anc (Infection
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with unknown ANC - Heart
(endocarditis))
Infection With Unknown Anc (Infection
with unknown ANC - Ileum)
Infection With Unknown Anc (Infection
with unknown ANC - Jejunum)
Infection With Unknown Anc (Infection
with unknown ANC - Joint)
Infection With Unknown Anc (Infection
with unknown ANC - Kidney)
Infection With Unknown Anc (Infection
with unknown ANC - Larynx)
Infection With Unknown Anc (Infection
with unknown ANC - Lens)
Infection With Unknown Anc (Infection
with unknown ANC - Lip/perioral)
Infection With Unknown Anc (Infection
with unknown ANC - Liver)
Infection With Unknown Anc (Infection
with unknown ANC - Lung (pneumonia))
Infection With Unknown Anc (Infection
with unknown ANC - Lymphatic)
Infection With Unknown Anc (Infection
with unknown ANC - Mediastinum NOS)
Infection With Unknown Anc (Infection
with unknown ANC - Meninges
(meningitis))
Infection With Unknown Anc (Infection
with unknown ANC - Middle ear (otitis
media))
Infection With Unknown Anc (Infection
with unknown ANC - Mucosa)
Infection With Unknown Anc (Infection
with unknown ANC - Muscle (infection
myositis))
Infection With Unknown Anc (Infection
with unknown ANC - Neck NOS)
Infection With Unknown Anc (Infection
with unknown ANC - Nerve-cranial)
Infection With Unknown Anc (Infection
with unknown ANC - Nerve-peripheral)
Infection With Unknown Anc (Infection
with unknown ANC - Nose)
Infection With Unknown Anc (Infection
with unknown ANC - Oral cavity-gums
(gingivitis))
Infection With Unknown Anc (Infection
with unknown ANC - Pancreas)
Infection With Unknown Anc (Infection
with unknown ANC - Paranasal)
Infection With Unknown Anc (Infection
with unknown ANC - Pelvis NOS)
Infection With Unknown Anc (Infection
with unknown ANC - Penis)
Infection With Unknown Anc (Infection
with unknown ANC - Peristomal)
Infection With Unknown Anc (Infection
with unknown ANC - Peritoneal cavity)
Infection With Unknown Anc (Infection
with unknown ANC - Pharynx)
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Infection With Unknown Anc (Infection
with unknown ANC - Pleura (empyema))
Infection With Unknown Anc (Infection
with unknown ANC - Prostate)
Infection With Unknown Anc (Infection
with unknown ANC - Rectum)
Infection With Unknown Anc (Infection
with unknown ANC - Salivary gland)
Infection With Unknown Anc (Infection
with unknown ANC - Scrotum)
Infection With Unknown Anc (Infection
with unknown ANC - Sinus)
Infection With Unknown Anc (Infection
with unknown ANC - Skin (cellulitis))
Infection With Unknown Anc (Infection
with unknown ANC - Small bowel NOS)
Infection With Unknown Anc (Infection
with unknown ANC - Soft tissue NOS)
Infection With Unknown Anc (Infection
with unknown ANC - Spinal cord
(myelitis))
Infection With Unknown Anc (Infection
with unknown ANC - Spleen)
Infection With Unknown Anc (Infection
with unknown ANC - Stomach)
Infection With Unknown Anc (Infection
with unknown ANC - Trachea)
Infection With Unknown Anc (Infection
with unknown ANC - Ungual (nails))
Infection With Unknown Anc (Infection
with unknown ANC - Upper aerodigestive
NOS)
Infection With Unknown Anc (Infection
with unknown ANC - Upper airway NOS)
Infection With Unknown Anc (Infection
with unknown ANC - Ureter)
Infection With Unknown Anc (Infection
with unknown ANC - Urethra)
Infection With Unknown Anc (Infection
with unknown ANC - Urinary tract NOS)
Infection With Unknown Anc (Infection
with unknown ANC - Uterus)
Infection With Unknown Anc (Infection
with unknown ANC - Vagina)
Infection With Unknown Anc (Infection
with unknown ANC - Vein)
Infection With Unknown Anc (Infection
with unknown ANC - Vulva)
Culture Wound Positive (Infection with
unknown ANC - Wound)
Infection Nos (Infection-Other (Specify))
Infertility/sterility (Infertility/sterility)
Injection Site Reaction Nos (Injection site
reaction/extravasation changes)
Prothrombin Time Prolonged (INR
(International Normalized Ratio of
prothrombin time))
Insomnia Nec (Insomnia)
Intra-operative Injury (Intra-operative
injury - Abdomen NOS)
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Intra-operative Injury (Intra-operative
injury - Adrenal gland)
Intra-operative Injury (Intra-operative
injury - Anal sphincter)
Intra-operative Injury (Intra-operative
injury - Anus)
Intra-operative Injury (Intra-operative
injury - Appendix)
Intra-operative Injury (Intra-operative
injury - Artery NOS)
Intra-operative Injury (Intra-operative
injury - Artery-aorta)
Intra-operative Injury (Intra-operative
injury - Artery-carotid)
Intra-operative Injury (Intra-operative
injury - Artery-cerebral)
Intra-operative Injury (Intra-operative
injury - Artery-extremity (lower))
Intra-operative Injury (Intra-operative
injury - Artery-extremity (upper))
Intra-operative Injury (Intra-operative
injury - Artery-hepatic)
Intra-operative Injury (Intra-operative
injury - Artery-major visceral artery)
Intra-operative Injury (Intra-operative
injury - Artery-pulmonary)
Intra-operative Injury (Intra-operative
injury - Biliary tree NOS)
Intra-operative Injury (Intra-operative
injury - Biliary tree-common bile duct)
Intra-operative Injury (Intra-operative
injury - Biliary tree-common hepatic duct)
Intra-operative Injury (Intra-operative
injury - Biliary tree-left hepatic duct)
Intra-operative Injury (Intra-operative
injury - Biliary tree-right hepatic duct)
Bladder Perforation Postoperative (Intra-
operative injury - Bladder)
Intra-operative Injury (Intra-operative
injury - Bone)
Intra-operative Injury (Intra-operative
injury - Brachial plexus)
Intra-operative Injury (Intra-operative
injury - Brain)
Intra-operative Injury (Intra-operative
injury - Breast)
Intra-operative Injury (Intra-operative
injury - Bronchus)
Intra-operative Injury (Intra-operative
injury - Cartilage)
Intra-operative Injury (Intra-operative
injury - Cecum)
Intra-operative Injury (Intra-operative
injury - Cervix)
Intra-operative Injury (Intra-operative
injury - CN I (olfactory))
Intra-operative Injury (Intra-operative
injury - CN II (optic))
Intra-operative Injury (Intra-operative
injury - CN III (oculomotor))
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Intra-operative Injury (Intra-operative
injury - CN IV (trochlear))
Intra-operative Injury (Intra-operative
injury - CN IX (glossopharyngeal) motor
pharynx)
Intra-operative Injury (Intra-operative
injury - CN IX (glossopharyngeal)
sensory ear-pharynx-tongue)
Intra-operative Injury (Intra-operative
injury - CN V (trigeminal) motor)
Intra-operative Injury (Intra-operative
injury - CN V (trigeminal) sensory)
Intra-operative Injury (Intra-operative
injury - CN VI (abducens))
Intra-operative Injury (Intra-operative
injury - CN VII (facial) motor-face)
Intra-operative Injury (Intra-operative
injury - CN VII (facial) sensory-taste)
Intra-operative Injury (Intra-operative
injury - CN VIII (vestibulocochlear))
Intra-operative Injury (Intra-operative
injury - CN X (vagus))
Intra-operative Injury (Intra-operative
injury - CN XI (spinal accessory))
Intra-operative Injury (Intra-operative
injury - CN XII (hypoglossal))
Intra-operative Injury (Intra-operative
injury - Colon)
Intra-operative Injury (Intra-operative
injury - Conjunctiva)
Intra-operative Injury (Intra-operative
injury - Cornea)
Intra-operative Injury (Intra-operative
injury - Cranial nerve or branch NOS)
Intra-operative Injury (Intra-operative
injury - Duodenum)
Intra-operative Injury (Intra-operative
injury - Esophagus)
Intra-operative Injury (Intra-operative
injury - Extremity-lower)
Intra-operative Injury (Intra-operative
injury - Extremity-upper)
Intra-operative Injury (Intra-operative
injury - Eye NOS)
Intra-operative Injury (Intra-operative
injury - Face NOS)
Intra-operative Injury (Intra-operative
injury - Fallopian tube)
Intra-operative Injury (Intra-operative
injury - Gallbladder)
Intra-operative Injury (Intra-operative
injury - Gingiva)
Intra-operative Injury (Intra-operative
injury - Heart)
Intra-operative Injury (Intra-operative
injury - Ileum)
Intra-operative Injury (Intra-operative
injury - Inner ear)
Intra-operative Injury (Intra-operative
injury - Jejunum)
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Intra-operative Injury (Intra-operative
injury - Joint)
Intra-operative Injury (Intra-operative
injury - Kidney)
Intra-operative Injury (Intra-operative
injury - Larynx)
Intra-operative Injury (Intra-operative
injury - Lens)
Intra-operative Injury (Intra-operative
injury - Ligament)
Intra-operative Injury (Intra-operative
injury - Lingual)
Intra-operative Injury (Intra-operative
injury - Lip/perioral area)
Intra-operative Injury (Intra-operative
injury - Liver)
Intra-operative Injury (Intra-operative
injury - Lung)
Intra-operative Injury (Intra-operative
injury - Lung thoracic)
Intra-operative Injury (Intra-operative
injury - Mediastinum)
Intra-operative Injury (Intra-operative
injury - Meninges)
Intra-operative Injury (Intra-operative
injury - Middle ear)
Intra-operative Injury (Intra-operative
injury - Muscle)
Intra-operative Injury (Intra-operative
injury - Nails)
Intra-operative Injury (Intra-operative
injury - Nasal cavity)
Intra-operative Injury (Intra-operative
injury - Nasopharynx)
Intra-operative Injury (Intra-operative
injury - Neck NOS)
Intra-operative Injury (Intra-operative
injury - Nose)
Intra-operative Injury (Intra-operative
injury - Oral)
Intra-operative Injury (Intra-operative
injury - Oral cavity NOS)
Intra-operative Injury (Intra-operative
injury - Outer ear NOS)
Intra-operative Injury (Intra-operative
injury - Outer ear-pinna)
Intra-operative Injury (Intra-operative
injury - Ovary)
Intra-operative Injury (Intra-operative
injury - Pancreas)
Intra-operative Injury (Intra-operative
injury - Pancreatic duct)
Intra-operative Injury (Intra-operative
injury - Parathyroid)
Intra-operative Injury (Intra-operative
injury - Parotid gland)
Intra-operative Injury (Intra-operative
injury - Pelvis NOS)
Intra-operative Injury (Intra-operative
injury - Penis)
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Intra-operative Injury (Intra-operative
injury - Peripheral motor NOS)
Intra-operative Injury (Intra-operative
injury - Peripheral sensory NOS)
Intra-operative Injury (Intra-operative
injury - Peritoneal cavity)
Intra-operative Injury (Intra-operative
injury - Pharynx)
Intra-operative Injury (Intra-operative
injury - Pituitary)
Intra-operative Injury (Intra-operative
injury - Pleura)
Intra-operative Injury (Intra-operative
injury - Prostate)
Intra-operative Injury (Intra-operative
injury - Rectum)
Intra-operative Injury (Intra-operative
injury - Recurrent laryngeal)
Intra-operative Injury (Intra-operative
injury - Retina)
Intra-operative Injury (Intra-operative
injury - Sacral plexus)
Intra-operative Injury (Intra-operative
injury - Salivary duct)
Intra-operative Injury (Intra-operative
injury - Salivary gland)
Intra-operative Injury (Intra-operative
injury - Sciatic)
Intra-operative Injury (Intra-operative
injury - Scrotum)
Intra-operative Injury (Intra-operative
injury - Sinus)
Intra-operative Injury (Intra-operative
injury - Skin)
Intra-operative Injury (Intra-operative
injury - Small bowel NOS)
Intra-operative Injury (Intra-operative
injury - Soft tissue NOS)
Intra-operative Injury (Intra-operative
injury - Spinal cord)
Intra-operative Injury (Intra-operative
injury - Spleen)
Intra-operative Injury (Intra-operative
injury - Stoma (GI))
Intra-operative Injury (Intra-operative
injury - Stomach)
Intra-operative Injury (Intra-operative
injury - Teeth)
Intra-operative Injury (Intra-operative
injury - Tendon)
Intra-operative Injury (Intra-operative
injury - Testis)
Intra-operative Injury (Intra-operative
injury - Thoracic duct)
Intra-operative Injury (Intra-operative
injury - Thoracodorsal)
Intra-operative Injury (Intra-operative
injury - Thyroid)
Intra-operative Injury (Intra-operative
injury - Tongue)
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Intra-operative Injury (Intra-operative
injury - Trachea)
Intra-operative Injury (Intra-operative
injury - Upper aerodigestive NOS)
Intra-operative Injury (Intra-operative
injury - Upper airway NOS)
Intra-operative Injury (Intra-operative
injury - Ureter)
Intra-operative Injury (Intra-operative
injury - Urethra)
Intra-operative Injury (Intra-operative
injury - Urinary conduit)
Intra-operative Injury (Intra-operative
injury - Urinary tract NOS)
Intra-operative Injury (Intra-operative
injury - Uterus)
Intra-operative Injury (Intra-operative
injury - Vagina)
Intra-operative Injury - Vein (Intra-
operative injury - Vein NOS)
Intra-operative Injury (Intra-operative
injury - Vein-extremity (lower))
Intra-operative Injury (Intra-operative
injury - Vein-extremity (upper))
Intra-operative Injury (Intra-operative
injury - Vein-hepatic)
Intra-operative Injury (Intra-operative
injury - Vein-inferior vena cava)
Intra-operative Injury (Intra-operative
injury - Vein-jugular)
Intra-operative Injury (Intra-operative
injury - Vein-major visceral vein)
Intra-operative Injury (Intra-operative
injury - Vein-portal vein)
Intra-operative Injury (Intra-operative
injury - Vein-pulmonary)
Intra-operative Injury (Intra-operative
injury - Vein-superior vena cava)
Intra-operative Injury (Intra-operative
injury - Vulva)
Intra-operative Injury Other (Intra-
operative Injury-Other (Specify))
Iron Overload (Iron overload)
Menstruation Irregular (Irregular menses
(change from baseline))
Irritability (Irritability (children <3 years of
age))
Joint-effusion (Joint-effusion)
Joint-effusion (Joint-function)
Keratitis Nec (Keratitis (corneal
inflammation/corneal ulceration))
Laryngeal Nerve Dysfunction (Laryngeal
nerve dysfunction)
Leak (including Anastomotic), Gi (Leak
(including anastomotic), GI - Biliary tree)
Leak (including Anastomotic), Gi (Leak
(including anastomotic), GI - Esophagus)
Leak (including Anastomotic), Gi (Leak
(including anastomotic), GI - Large
bowel)
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Leak (including Anastomotic), Gi (Leak
(including anastomotic), GI - Leak NOS)
Leak (including Anastomotic), Gi (Leak
(including anastomotic), GI - Pancreas)
Leak (including Anastomotic), Gi (Leak
(including anastomotic), GI - Pharynx)
Leak (including Anastomotic), Gi (Leak
(including anastomotic), GI - Rectum)
Leak (including Anastomotic), Gi (Leak
(including anastomotic), GI - Small
bowel)
Leak (including Anastomotic), Gi (Leak
(including anastomotic), GI - Stoma)
Leak (including Anastomotic), Gi (Leak
(including anastomotic), GI - Stomach)
Leak (including Anastomotic), Gu (Leak
(including anastomotic), GU - Bladder)
Leak (including Anastomotic), Gu (Leak
(including anastomotic), GU - Fallopian
tube)
Leak (including Anastomotic), Gu (Leak
(including anastomotic), GU - Kidney)
Leak (including Anastomotic), Gu (Leak
(including anastomotic), GU - Spermatic
cord)
Leak (including Anastomotic), Gu (Leak
(including anastomotic), GU - Stoma)
Leak (including Anastomotic), Gu (Leak
(including anastomotic), GU - Ureter)
Leak (including Anastomotic), Gu (Leak
(including anastomotic), GU - Urethra)
Leak (including Anastomotic), Gu (Leak
(including anastomotic), GU - Uterus)
Leak (including Anastomotic), Gu (Leak
(including anastomotic), GU - Vagina)
Leak (including Anastomotic), Gu (Leak
(including anastomotic), GU - Vas
deferens)
Leak, Cerebrospinal Fluid (csf) (Leak,
cerebrospinal fluid (CSF))
Left Ventricular Diastolic Dysfunction
(Left ventricular diastolic dysfunction)
Left Ventricular Failure (Left ventricular
systolic dysfunction)
Leucopenia Nos (Leukocytes (total
WBC))
Encephalopathy Nos
(Leukoencephalopathy (radiolographic
findings))
Libido Decreased (Libido)
Lipase Increased (Lipase)
Hepatic Failure (Liver dysfunction/failure
(clinical))
Local Complication - Device/prosthesis-
related (Local complication -
device/prosthesis-related)
Lumbar Spine-range Of Motion (Lumbar
spine-range of motion)
Lymphatics Other (Lymphatics-Other
(Specify))
33 / 47
E1A05 Multiple Myeloma On-Study Form - Form 2855 NCT00522392
Lymphedema-related Fibrosis
(Lymphedema-related fibrosis)
Lymphocele (Lymphocele)
Lymphopenia (Lymphopenia)
Hypermagnesaemia (Magnesium,
serum-high (hypermagnesemia))
Blood Magnesium Decreased
(Magnesium, serum-low
(hypomagnesemia))
Malabsorption (Malabsorption)
Virilism (Masculinization of female)
Amnesia Nec (Memory impairment)
Mental Status (Mental status)
Metabolic/laboratory Other
(Metabolic/Laboratory-Other (Specify))
Mood Alteration - Agitation (Mood
alteration - agitation)
Anxiety Nec (Mood alteration - anxiety)
Depression Nec (Mood alteration -
depression)
Euphoric Mood (Mood alteration -
euphoria)
Mucositis/stomatitis (clinical Exam)
(Mucositis/stomatitis (clinical exam) -
Anus)
Mucositis/stomatitis (clinical Exam)
(Mucositis/stomatitis (clinical exam) -
Esophagus)
Mucositis/stomatitis (clinical Exam)
(Mucositis/stomatitis (clinical exam) -
Large bowel)
Mucositis/stomatitis (clinical Exam)
(Mucositis/stomatitis (clinical exam) -
Larynx)
Mucositis/stomatitis (clinical Exam)
(Mucositis/stomatitis (clinical exam) -
Oral cavity)
Stomatitis (Mucositis/stomatitis (clinical
exam) - Pharynx)
Mucositis/stomatitis (clinical Exam)
(Mucositis/stomatitis (clinical exam) -
Rectum)
Mucositis/stomatitis (clinical Exam)
(Mucositis/stomatitis (clinical exam) -
Small bowel)
Mucositis/stomatitis (clinical Exam)
(Mucositis/stomatitis (clinical exam) -
Stomach)
Mucositis/stomatitis (clinical Exam)
(Mucositis/stomatitis (clinical exam) -
Trachea)
Mucositis/stomatitis
(functional/symptomatic)
(Mucositis/stomatitis
(functional/symptomatic) - Anus)
Mucositis/stomatitis
(functional/symptomatic)
(Mucositis/stomatitis
(functional/symptomatic) - Esophagus)
Mucositis/stomatitis
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(functional/symptomatic)
(Mucositis/stomatitis
(functional/symptomatic) - Large bowel)
Mucositis/stomatitis
(functional/symptomatic)
(Mucositis/stomatitis
(functional/symptomatic) - Larynx)
Mucositis/stomatitis
(functional/symptomatic)
(Mucositis/stomatitis
(functional/symptomatic) - Oral cavity)
Mucositis/stomatitis
(functional/symptomatic)
(Mucositis/stomatitis
(functional/symptomatic) - Pharynx)
Mucositis/stomatitis
(functional/symptomatic)
(Mucositis/stomatitis
(functional/symptomatic) - Rectum)
Mucositis/stomatitis
(functional/symptomatic)
(Mucositis/stomatitis
(functional/symptomatic) - Small bowel)
Mucositis/stomatitis
(functional/symptomatic)
(Mucositis/stomatitis
(functional/symptomatic) - Stomach)
Mucositis/stomatitis
(functional/symptomatic)
(Mucositis/stomatitis
(functional/symptomatic) - Trachea)
Muscle Weakness, Generalized Or
Specific Area (not Due To Neuropathy)
(Muscle weakness, generalized or
specific area (not due to neuropathy) -
Extraocular)
Muscle Weakness, Generalized Or
Specific Area (not Due To Neuropathy)
(Muscle weakness, generalized or
specific area (not due to neuropathy) -
Extremity-lower)
Muscle Weakness, Generalized Or
Specific Area (not Due To Neuropathy)
(Muscle weakness, generalized or
specific area (not due to neuropathy) -
Extremity-upper)
Muscle Weakness, Generalized Or
Specific Area (not Due To Neuropathy)
(Muscle weakness, generalized or
specific area (not due to neuropathy) -
Facial)
Muscle Weakness, Generalized Or
Specific Area (not Due To Neuropathy)
(Muscle weakness, generalized or
specific area (not due to neuropathy) -
Left-sided)
Muscle Weakness, Generalized Or
Specific Area (not Due To Neuropathy)
(Muscle weakness, generalized or
specific area (not due to neuropathy) -
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Ocular)
Muscle Weakness, Generalized Or
Specific Area (not Due To Neuropathy)
(Muscle weakness, generalized or
specific area (not due to neuropathy) -
Pelvic)
Muscle Weakness, Generalized Or
Specific Area (not Due To Neuropathy)
(Muscle weakness, generalized or
specific area (not due to neuropathy) -
Right-sided)
Muscle Weakness, Generalized Or
Specific Area (not Due To Neuropathy)
(Muscle weakness, generalized or
specific area (not due to neuropathy) -
Trunk)
Muscle Weakness Nos (Muscle
weakness, generalized or specific area
(not due to neuropathy) - Whole
body/generalized)
Muscular/skeletal Hypoplasia
(Muscular/skeletal hypoplasia)
Musculoskeletal/soft Tissue Other
(Musculoskeletal/Soft Tissue-Other
(Specify))
Myelitis (Myelitis)
Myelodysplasia (Myelodysplasia)
Myocarditis Nos (Myocarditis)
Myositis (Myositis (inflammation/damage
of muscle))
Nail Abnormality Nos (Nail changes)
Nasal Cavity/paranasal Sinus Reactions
(Nasal cavity/paranasal sinus reactions)
Nausea (Nausea)
Necrosis, Gi (Necrosis, GI - Anus)
Necrosis, Gi (Necrosis, GI -
Colon/cecum/appendix)
Necrosis, Gi (Necrosis, GI - Duodenum)
Necrosis, Gi (Necrosis, GI - Esophagus)
Necrosis, Gi (Necrosis, GI - Gallbladder)
Necrosis, Gi (Necrosis, GI - Hepatic)
Necrosis, Gi (Necrosis, GI - Ileum)
Necrosis, Gi (Necrosis, GI - Jejunum)
Necrosis, Gi (Necrosis, GI - Oral)
Necrosis, Gi (Necrosis, GI - Pancreas)
Necrosis, Gi (Necrosis, GI - Peritoneal
cavity)
Necrosis, Gi (Necrosis, GI - Pharynx)
Necrosis, Gi (Necrosis, GI - Rectum)
Necrosis, Gi (Necrosis, GI - Small bowel
NOS)
Necrosis, Gi (Necrosis, GI - Stoma)
Necrosis, Gi (Necrosis, GI - Stomach)
Neuroendocrine: Acth Deficiency
(Neuroendocrine: ACTH deficiency)
Inappropriate Adh Secretion
(Neuroendocrine: ADH secretion
abnormality (e.g., SIADH or low ADH))
Neuroendocrine: Gonadotropin Secretion
Abnormality (Neuroendocrine:
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gonadotropin secretion abnormality)
Neuroendocrine: Growth Hormone
Secretion Abnormality (Neuroendocrine:
growth hormone secretion abnormality)
Neuroendocrine: Prolactin Hormone
Secretion Abnormality (Neuroendocrine:
prolactin hormone secretion abnormality)
Neurology Other (Neurology-Other
(Specify))
Parosmia (Neuropathy: cranial - CN I
Smell)
Cranial Nerve Injury Nos (Neuropathy:
cranial - CN II Vision)
Neuropathy: Cranial (Neuropathy: cranial
- CN III Pupil, upper eyelid, extra ocular
movements)
Neuropathy: Cranial (Neuropathy: cranial
- CN IV Downward, inward movement of
eye)
Neuropathy: Cranial (Neuropathy: cranial
- CN IX Motor-pharynx; Sensory-ear,
pharynx, tongue)
Neuropathy: Cranial (Neuropathy: cranial
- CN V Motor-jaw muscles; Sensory-
facial)
Neuropathy: Cranial (Neuropathy: cranial
- CN VI Lateral deviation of eye)
Neuropathy: Cranial (Neuropathy: cranial
- CN VII Motor-face; Sensory-taste)
Neuropathy: Cranial (Neuropathy: cranial
- CN VIII Hearing and balance)
Neuropathy: Cranial (Neuropathy: cranial
- CN X Motor-palate; pharynx, larynx)
Neuropathy: Cranial (Neuropathy: cranial
- CN XI Motor-sternomastoid and
trapezius)
Neuropathy: Cranial (Neuropathy: cranial
- CN XII Motor-tongue)
Peripheral Motor Neuropathy
(Neuropathy: motor)
Peripheral Sensory Neuropathy
(Neuropathy: sensory)
Neutropenia (Neutrophils/granulocytes
(ANC/AGC))
Blindness Night (Night blindness
(nyctalopia))
Nystagmus Nos (Nystagmus)
Obesity (Obesity)
Obstruction, Gi (Obstruction, GI -
Cecum)
Obstruction, Gi (Obstruction, GI - Colon)
Obstruction, Gi (Obstruction, GI -
Duodenum)
Obstruction, Gi (Obstruction, GI -
Esophagus)
Obstruction, Gi (Obstruction, GI -
Gallbladder)
Obstruction, Gi (Obstruction, GI - Ileum)
Obstruction, Gi (Obstruction, GI -
Jejunum)
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Obstruction, Gi (Obstruction, GI -
Rectum)
Obstruction, Gi (Obstruction, GI - Small
bowel NOS)
Obstruction, Gi (Obstruction, GI - Stoma)
Obstruction, Gi (Obstruction, GI -
Stomach)
Obstruction, Gu (Obstruction, GU -
Bladder)
Obstruction, Gu (Obstruction, GU -
Fallopian tube)
Obstruction, Gu (Obstruction, GU -
Prostate)
Obstruction, Gu (Obstruction, GU -
Spermatic cord)
Obstruction, Gu (Obstruction, GU -
Stoma)
Obstruction, Gu (Obstruction, GU -
Testes)
Ureteric Obstruction (Obstruction, GU -
Ureter)
Obstruction, Gu (Obstruction, GU -
Urethra)
Obstruction, Gu (Obstruction, GU -
Uterus)
Obstruction, Gu (Obstruction, GU -
Vagina)
Obstruction, Gu (Obstruction, GU - Vas
deferens)
Obstruction/stenosis Of Airway
(Obstruction/stenosis of airway -
Bronchus)
Obstruction/stenosis Of Airway
(Obstruction/stenosis of airway - Larynx)
Obstruction/stenosis Of Airway
(Obstruction/stenosis of airway -
Pharynx)
Obstruction/stenosis Of Airway
(Obstruction/stenosis of airway -
Trachea)
Conjunctivitis Nec (Ocular surface
disease)
Ocular/visual Other (Ocular/Visual-Other
(Specify))
Odor (patient Odor) (Odor (patient odor))
Diplopia (Ophthalmoplegia/diplopia
(double vision))
Opportunistic Infection Associated With
>=grade 2 Lymphopenia (Opportunistic
infection associated with >=Grade 2
lymphopenia)
Optic Disc Edema (Optic disc edema)
Orgasmic Dysfunction (Orgasmic
dysfunction)
Osteonecrosis (Osteonecrosis (avascular
necrosis))
Osteoporosis (Osteoporosis)
Otitis Externa (exc Boil Of Meatus) Nos
(Otitis, external ear (non-infectious))
Otitis Media Serous Nos (Otitis, middle
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ear (non-infectious))
Abdominal Pain Nos (Pain - Abdomen
NOS)
Pain (Pain - Anus)
Pain (Pain - Back)
Pain (Pain - Bladder)
Bone Pain (Pain - Bone)
Pain (Pain - Breast)
Pain (Pain - Buttock)
Pain (Pain - Cardiac/heart)
Pain (Pain - Chest wall)
Chest Pain (Pain - Chest/thorax NOS)
Pain (Pain - Dental/teeth/peridontal)
Pain (Pain - Esophagus)
Earache (Pain - External ear)
Pain (Pain - Extremity-limb)
Pain (Pain - Eye)
Pain (Pain - Face)
Pain (Pain - Gallbladder)
Headache Nos (Pain - Head/headache)
Pain (Pain - Intestine)
Arthralgia (Pain - Joint)
Pain (Pain - Kidney)
Pain (Pain - Larynx)
Pain (Pain - Lip)
Hepatic Pain (Pain - Liver)
Pain (Pain - Lymph node)
Pain (Pain - Middle ear)
Myalgia (Pain - Muscle)
Pain (Pain - Neck)
Neuralgia Nos (Pain -
Neuralgia/peripheral nerve)
Pain (Pain - Oral cavity)
Pain (Pain - Oral-gums)
Pain (Pain - Ovulatory)
Pain (Pain - Pain NOS)
Pelvic Pain Nos (Pain - Pelvis)
Pain (Pain - Penis)
Pain (Pain - Pericardium)
Pain (Pain - Perineum)
Pain (Pain - Peritoneum)
Pain (Pain - Phantom (pain associated
with missing limb))
Pleuritic Pain (Pain - Pleura)
Pain (Pain - Prostate)
Proctalgia (Pain - Rectum)
Pain (Pain - Scalp)
Pain (Pain - Scrotum)
Pain (Pain - Sinus)
Pain (Pain - Skin)
Pain (Pain - Stomach)
Pain (Pain - Testicle)
Pain (Pain - Throat/pharynx/larynx)
Tumour Pain (Pain - Tumor pain)
Dysuria (Pain - Urethra)
Dysmenorrhoea (Pain - Uterus)
Pain (Pain - Vagina)
Pain Other (Pain-Other (Specify))
Palpitations (Palpitations)
Pancreas, Exocrine Enzyme Deficiency
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(Pancreas, exocrine enzyme deficiency)
Pancreatic Endocrine: Glucose
Intolerance (Pancreatic endocrine:
glucose intolerance)
Pancreatitis Nos (Pancreatitis)
Parathyroid Function, Low
(hypoparathyroidism) (Parathyroid
function, low (hypoparathyroidism))
Perforation, Gi (Perforation, GI -
Appendix)
Perforation, Gi (Perforation, GI - Biliary
tree)
Perforation, Gi (Perforation, GI - Cecum)
Perforation, Gi (Perforation, GI - Colon)
Perforation, Gi (Perforation, GI -
Duodenum)
Perforation, Gi (Perforation, GI -
Esophagus)
Perforation, Gi (Perforation, GI -
Gallbladder)
Perforation, Gi (Perforation, GI - Ileum)
Perforation, Gi (Perforation, GI -
Jejunum)
Perforation, Gi (Perforation, GI - Rectum)
Perforation, Gi (Perforation, GI - Small
bowel NOS)
Perforation, Gi (Perforation, GI -
Stomach)
Perforation, Gu (Perforation, GU -
Bladder)
Perforation, Gu (Perforation, GU -
Fallopian tube)
Perforation, Gu (Perforation, GU -
Kidney)
Perforation, Gu (Perforation, GU - Ovary)
Perforation, Gu (Perforation, GU -
Prostate)
Perforation, Gu (Perforation, GU -
Spermatic cord)
Perforation, Gu (Perforation, GU -
Stoma)
Perforation, Gu (Perforation, GU -
Testes)
Perforation, Gu (Perforation, GU - Ureter)
Perforation, Gu (Perforation, GU -
Urethra)
Perforation, Gu (Perforation, GU -
Uterus)
Perforation, Gu (Perforation, GU -
Vagina)
Perforation, Gu (Perforation, GU - Vas
deferens)
Pericardial Effusion (Pericardial effusion
(non-malignant))
Pericarditis (Pericarditis)
Peripheral Ischaemia Nos (Peripheral
arterial ischemia)
Personality Change
(Personality/behavioral)
Petechiae (Petechiae/purpura
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(hemorrhage/bleeding into skin or
mucosa))
Phlebitis Superficial (Phlebitis (including
superficial thrombosis))
Phlebolymphatic Cording
(Phlebolymphatic cording)
Hypophosphataemia (Phosphate, serum-
low (hypophosphatemia))
Photosensitivity Reaction Nos
(Photosensitivity)
Phrenic Nerve Dysfunction (Phrenic
nerve dysfunction)
Platelet Count Decreased (Platelets)
Pleural Effusion (Pleural effusion (non-
malignant))
Pneumonitis Nos
(Pneumonitis/pulmonary infiltrates)
Pneumothorax Nos (Pneumothorax)
Portal Hypertension (Portal vein flow)
Hyperkalaemia (Potassium, serum-high
(hyperkalemia))
Hypokalaemia (Potassium, serum-low
(hypokalemia))
Proctitis Nos (Proctitis)
Prolapse Of Stoma, Gi (Prolapse of
stoma, GI)
Prolapse Of Stoma, Gu (Prolapse of
stoma, GU)
Prolonged Chest Tube Drainage Or Air
Leak After Pulmonary Resection
(Prolonged chest tube drainage or air
leak after pulmonary resection)
Prolonged Intubation After Pulmonary
Resection (>24 Hrs After Surgery)
(Prolonged intubation after pulmonary
resection (>24 hrs after surgery))
Electrocardiogram Qt Prolonged
(Prolonged QTc interval)
Proptosis/enophthalmos
(Proptosis/enophthalmos)
Proteinuria Present (Proteinuria)
Pruritus Nos (Pruritus/itching)
Delusion Nos (Psychosis
(hallucinations/delusions))
Activated Partial Thromboplastin Time
Prolonged (PTT (Partial thromboplastin
time))
Puberty (delayed) (Puberty (delayed))
Puberty (precocious) (Puberty
(precocious))
Pulmonary Fibrosis (Pulmonary fibrosis
(radiographic changes))
Pulmonary Hypertension (Pulmonary
hypertension)
Pulmonary/upper Respiratory Other
(Pulmonary/Upper Respiratory-Other
(Specify))
Upper Motor Neurone Lesion (Pyramidal
tract dysfunction (e.g., increased tone,
hyperreflexia, positive Babinski,
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decreased fine motor coordination))
Rash: Acne/acneiform (Rash:
acne/acneiform)
Radiation Recall Syndrome (Rash:
dermatitis associated with radiation -
Chemoradiation)
Dermatitis Radiation Nos (Rash:
dermatitis associated with radiation -
Radiation)
Erythema Multiforme (Rash: erythema
multiforme (e.g., Stevens-Johnson
syndrome, toxic epidermal necrolysis))
Localised Exfoliation (Rash: hand-foot
skin reaction)
Dermatitis Exfoliative Nos
(Rash/desquamation)
Renal Failure Nos (Renal failure)
Renal/genitourinary Other
(Renal/Genitourinary-Other (Specify))
Restrictive Cardiomyopathy (Restrictive
cardiomyopathy)
Retinal Detachment (Retinal
detachment)
Retinoic Acid Syndrome (Retinoic acid
syndrome)
Retinopathy (Retinopathy)
Right Ventricular Dysfunction (cor
Pulmonale) (Right ventricular dysfunction
(cor pulmonale))
Rigors (Rigors/chills)
Salivary Gland Disorder Nos (Salivary
gland changes/saliva)
Scleral Necrosis/melt (Scleral
necrosis/melt)
Secondary Malignancy Possibly Related
To Cancer Treatment (Secondary
Malignancy-possibly related to cancer
treatment (Specify))
Convulsions Nos (Seizure)
Seroma (Seroma)
Serum Sickness (Serum sickness)
Sexual/reproductive Function Other
(Sexual/Reproductive Function-Other
(Specify))
Short Stature (Short stature)
Skin Breakdown/decubitus Ulcer (Skin
breakdown/decubitus ulcer)
Hypernatraemia (Sodium, serum-high
(hypernatremia))
Hyponatraemia (Sodium, serum-low
(hyponatremia))
Soft Tissue Necrosis (Soft tissue
necrosis - Abdomen)
Soft Tissue Necrosis (Soft tissue
necrosis - Extremity-lower)
Soft Tissue Necrosis (Soft tissue
necrosis - Extremity-upper)
Soft Tissue Necrosis (Soft tissue
necrosis - Head)
Soft Tissue Necrosis (Soft tissue
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necrosis - Neck)
Soft Tissue Necrosis (Soft tissue
necrosis - Pelvic)
Soft Tissue Necrosis (Soft tissue
necrosis - Thorax)
Depressed Level Of Consciousness
(Somnolence/depressed level of
consciousness)
Speech Disorder Nec (Speech
impairment (e.g., dysphasia or aphasia))
Splenic Function (Splenic function)
Striae (Striae)
Stricture/stenosis (including
Anastomotic), Gi (Stricture/stenosis
(including anastomotic), GI - Anus)
Stricture/stenosis (including
Anastomotic), Gi (Stricture/stenosis
(including anastomotic), GI - Biliary tree)
Stricture/stenosis (including
Anastomotic), Gi (Stricture/stenosis
(including anastomotic), GI - Cecum)
Stricture/stenosis (including
Anastomotic), Gi (Stricture/stenosis
(including anastomotic), GI - Colon)
Stricture/stenosis (including
Anastomotic), Gi (Stricture/stenosis
(including anastomotic), GI - Duodenum)
Stricture/stenosis (including
Anastomotic), Gi (Stricture/stenosis
(including anastomotic), GI - Esophagus)
Stricture/stenosis (including
Anastomotic), Gi (Stricture/stenosis
(including anastomotic), GI - Ileum)
Stricture/stenosis (including
Anastomotic), Gi (Stricture/stenosis
(including anastomotic), GI - Jejunum)
Stricture/stenosis (including
Anastomotic), Gi (Stricture/stenosis
(including anastomotic), GI -
Pancreas/pancreatic duct)
Stricture/stenosis (including
Anastomotic), Gi (Stricture/stenosis
(including anastomotic), GI - Pharynx)
Stricture/stenosis (including
Anastomotic), Gi (Stricture/stenosis
(including anastomotic), GI - Rectum)
Stricture/stenosis (including
Anastomotic), Gi (Stricture/stenosis
(including anastomotic), GI - Small bowel
NOS)
Stricture/stenosis (including
Anastomotic), Gi (Stricture/stenosis
(including anastomotic), GI - Stoma)
Stricture/stenosis (including
Anastomotic), Gi (Stricture/stenosis
(including anastomotic), GI - Stomach)
Stricture/stenosis (including
Anastomotic), Gu (Stricture/stenosis
(including anastomotic), GU - Bladder)
Stricture/stenosis (including
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Anastomotic), Gu (Stricture/stenosis
(including anastomotic), GU - Fallopian
tube)
Stricture/stenosis (including
Anastomotic), Gu (Stricture/stenosis
(including anastomotic), GU - Prostate)
Stricture/stenosis (including
Anastomotic), Gu (Stricture/stenosis
(including anastomotic), GU - Spermatic
cord)
Stricture/stenosis (including
Anastomotic), Gu (Stricture/stenosis
(including anastomotic), GU - Stoma)
Stricture/stenosis (including
Anastomotic), Gu (Stricture/stenosis
(including anastomotic), GU - Testes)
Stricture/stenosis (including
Anastomotic), Gu (Stricture/stenosis
(including anastomotic), GU - Ureter)
Stricture/stenosis (including
Anastomotic), Gu (Stricture/stenosis
(including anastomotic), GU - Urethra)
Stricture/stenosis (including
Anastomotic), Gu (Stricture/stenosis
(including anastomotic), GU - Uterus)
Stricture/stenosis (including
Anastomotic), Gu (Stricture/stenosis
(including anastomotic), GU - Vagina)
Stricture/stenosis (including
Anastomotic), Gu (Stricture/stenosis
(including anastomotic), GU - Vas
deferens)
Supraventricular And Nodal Arrhythmia
(Supraventricular and nodal arrhythmia -
Atrial fibrillation)
Supraventricular And Nodal Arrhythmia
(Supraventricular and nodal arrhythmia -
Atrial flutter)
Supraventricular And Nodal Arrhythmia
(Supraventricular and nodal arrhythmia -
Atrial tachycardia/paroxysmal atrial
tachycardia)
Supraventricular And Nodal Arrhythmia
(Supraventricular and nodal arrhythmia -
Nodal/junctional)
Supraventricular And Nodal Arrhythmia
(Supraventricular and nodal arrhythmia -
Sinus arrhythmia)
Sinus Bradycardia (Supraventricular and
nodal arrhythmia - Sinus bradycardia)
Sinus Tachycardia (Supraventricular and
nodal arrhythmia - Sinus tachycardia)
Supraventricular Arrhythmia Nos
(Supraventricular and nodal arrhythmia -
Supraventricular arrhythmia NOS)
Supraventricular And Nodal Arrhythmia -
Supraventricular Extrasystoles
(premature Atrial Contractions;
Premature Nodal/junctional
Contractions) (Supraventricular and
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nodal arrhythmia - Supraventricular
extrasystoles (premature atrial
contractions; premature nodal/junctional
contractions))
Supraventricular And Nodal Arrhythmia
(Supraventricular and nodal arrhythmia -
Supraventricular tachycardia)
Sweating Increased (Sweating
(diaphoresis))
Syncope (Syncope (fainting))
Syndromes Other (Syndromes-Other
(Specify))
Taste Disturbance (Taste alteration
(dysgeusia))
Telangiectasia (Telangiectasia)
Thrombosis/embolism (vascular Access-
related) (Thrombosis/embolism (vascular
access-related))
Thrombosis Nos
(Thrombosis/thrombus/embolism)
Thrombotic Microangiopathy (e.g.,
Thrombotic Thrombocytopenic
Purpura[ttp] Or Hemolytic Uremic
Syndrome[hus]) (Thrombotic
microangiopathy (e.g., thrombotic
thrombocytopenic purpura or hemolytic
uremic syndrome))
Thyroid Function, High (hyperthyroidism,
Thyrotoxicosis) (Thyroid function, high
(hyperthyroidism, thyrotoxicosis))
Hypothyroidism (Thyroid function, low
(hypothyroidism))
Tinnitus (Tinnitus)
Tremor Nec (Tremor)
Hypertriglyceridaemia (Triglyceride,
serum-high (hypertriglyceridemia))
Trismus (difficulty, Restriction Or Pain
When Opening Mouth) (Trismus
(difficulty, restriction or pain when
opening mouth))
Tumour Flare (Tumor flare)
Tumour Lysis Syndrome (Tumor lysis
syndrome)
Caecitis (Typhlitis (cecal inflammation))
Ulcer, Gi (Ulcer, GI - Anus)
Ulcer, Gi (Ulcer, GI - Cecum)
Ulcer, Gi (Ulcer, GI - Colon)
Duodenal Ulcer (Ulcer, GI - Duodenum)
Ulcer, Gi (Ulcer, GI - Esophagus)
Ulcer, Gi (Ulcer, GI - Ileum)
Ulcer, Gi (Ulcer, GI - Jejunum)
Ulcer, Gi (Ulcer, GI - Rectum)
Ulcer, Gi (Ulcer, GI - Small bowel NOS)
Ulcer, Gi (Ulcer, GI - Stoma)
Gastric Ulcer (Ulcer, GI - Stomach)
Ulceration (Ulceration)
Hyperuricaemia (Uric acid, serum-high
(hyperuricemia))
Fanconi Syndrome (Urinary electrolyte
wasting (e.g., Fanconi's syndrome, renal
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tubular acidosis))
Urinary Frequency (Urinary
frequency/urgency)
Urinary Retention (Urinary retention
(including neurogenic bladder))
Urine Discolouration (Urine color
change)
Urticaria Nos (Urticaria (hives, welts,
wheals))
Uveitis (Uveitis)
Vaginal Discharge (non-infectious)
(Vaginal discharge (non-infectious))
Vulvovaginal Dryness (Vaginal dryness)
Vaginal Mucositis (Vaginal mucositis)
Vaginal Stenosis/length (Vaginal
stenosis/length)
Vaginitis (Vaginitis (not due to infection))
Valvular Heart Disease (Valvular heart
disease)
Vascular Other (Vascular-Other
(Specify))
Vasculitis Nos (Vasculitis)
Vasovagal Attack (Vasovagal episode)
Ventricular Arrhythmia (Ventricular
arrhythmia - Bigeminy)
Ventricular Arrhythmia (Ventricular
arrhythmia - Idioventricular rhythm)
Ventricular Arrhythmia (Ventricular
arrhythmia - PVCs)
Ventricular Arrhythmia (Ventricular
arrhythmia - Torsade de pointes)
Ventricular Arrhythmia (Ventricular
arrhythmia - Trigeminy)
Ventricular Arrhythmia Nos (Ventricular
arrhythmia - Ventricular arrhythmia NOS)
Ventricular Arrhythmia (Ventricular
arrhythmia - Ventricular fibrillation)
Ventricular Arrhythmia (Ventricular
arrhythmia - Ventricular flutter)
Ventricular Arrhythmia (Ventricular
arrhythmia - Ventricular tachycardia)
Vessel Injury-artery (Vessel injury-artery
- Aorta)
Vessel Injury-artery (Vessel injury-artery
- Carotid)
Vessel Injury-artery (Vessel injury-artery
- Extremity-lower)
Vessel Injury-artery (Vessel injury-artery
- Extremity-upper)
Vessel Injury-artery (Vessel injury-artery
- Other NOS)
Vessel Injury-artery (Vessel injury-artery
- Visceral)
Vessel Injury-vein (Vessel injury-vein -
Extremity-lower)
Vessel Injury-vein (Vessel injury-vein -
Extremity-upper)
Vessel Injury-vein (Vessel injury-vein -
IVC)
Vessel Injury-vein (Vessel injury-vein -
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Jugular)
Vessel Injury-vein (Vessel injury-vein -
Other NOS)
Vessel Injury-vein (Vessel injury-vein -
SVC)
Vessel Injury-vein (Vessel injury-vein -
Viscera)
Viral Hepatitis (Viral hepatitis)
Visceral Arterial Ischaemia (Visceral
arterial ischemia (non-myocardial))
Vision Blurred (Vision-blurred vision)
Photopsia (Vision-flashing lights/floaters)
Photophobia (Vision-photophobia)
Vital Capacity (Vital capacity)
Vitreous Hemorrhage (Vitreous
hemorrhage)
Dysphonia (Voice changes/dysarthria
(e.g., hoarseness, loss or alteration in
voice, laryngitis))
Vomiting Nos (Vomiting)
Lacrimation Increased (Watery eye
(epiphora, tearing))
Weight Increased (Weight gain)
Weight Decreased (Weight loss)
Culture Wound Negative (Wound
complication, non-infectious)
CTC Adverse Event Grade (Use grade 1-4 per
CTCAE v3)
Comments
Comments
Investigator Signature
Investigator Signature Date
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ECOG-E1505 Chemotherapy Treatment
Form NCT00324805
ECOG-E1505 Chemotherapy Treatment Form
NCT00324805 
Chemotherapy With or Without Bevacizumab in Treating
Patients With Stage IB, Stage II, or Stage IIIA Non-Small
Lung Cancer That Was Removed By Surgery
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=0792E7F9-
9EC5-424E-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11026
ECOG-E1505 Chemotherapy
Treatment Form NCT00324805
Header
ECOG Protocol Number
ECOG Patient ID
DCI Name
Registration Step
Please mark an 'X' if data have been amended.
(Please circle amended items in red)
Date data amended (M D Y)
Patient demographics
Patient Initials (Last, First)
Participating Group Protocol Number
Institution/Affiliate
Participating Group Patient ID
Arm A And Arm B
On Treatment Report Period
Cycle 1 (Cycle 1)
Cycle 2 (Cycle 2)
Cycle 3 (Cycle 3)
Cycle 4 (cycle 4)
Reporting Period Start Date
Reporting Period End Date
On Treatment
1 / 4
Patient Vital Status
Alive (Alive)
Dead (Dead)
Date of Last Contact or Death (M D Y)
Primary Cause of Death (if applicable)
Due To Other Cause (Due to other
cause)
Due To Protocol Treatment (Due to
protocol treatment)
Due To This Disease (Due to this
disease)
Unknown (Unknown)
Describe cause of death
Weight (kg Day 1)
Patient Body Surface Area Measurement (m^2
BSA Day 1 of this cycle)
Date physical exam performed (most recent)
Mark an 'X' if not done
Agent Name: Cisplatin (Regimen 1, 2,
3,&4)
Was the agent Cisplatin administered during this
reporting period (cycle)
Yes
No
Date Agent Administered (If yes M D Y)
Agent Dose (mg)
Agent Name: Vinorelbine (Regimen 1)
Was the agent Vinorelbine administered during
this reporting period (cycle)
Yes
No
How was the agent administered for Day 8
Intravenous Administration Of Drug (IV)
Oral Administration Of Drug (PO)
Agent Name: Docetaxel (Regimen 2)
Was the agent Docetaxel administered during
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this reporting period (cycle)
Yes
No
Agent Name: Gemcitabine (Regimen 3)
Was the agent Gemcitabine administered during
this reporting period (cycle)
Yes
No
Agent Name: Pemetrexed (Regimen 4)
Was the agent Pemetrexed administered during
this reporting period
Yes
No
Chemotherapy Dose Modifications
Dose modification (this cycle only)
Dose Delayed (Dose delayed)
Dose Delayed And Reduced (Dose
delayed and reduced)
Dose Held (Dose held)
Dose Reduced (Dose reduced)
Drug Discontinued (Drug discontinued)
No Dose Modification (No dose
modification)
Dose Modification Reason (this cycle only)
Adverse Event (Adverse event)
Alternative Therapy For Other Reason
(Alternative therapy for other reason)
Dosing Error (Dosing error)
Other (Other)
Patient Refusal/noncompliance (Patient
refusal/noncompliance)
Scheduling (Scheduling)
Second Primary Cancer (Second
primary)
Other, specify
Modification due to Adverse Event (mark an ¿X¿
for all that apply:)
Gi Toxicity (GI toxicity)
Hematologic Toxicity (Hematologic
toxicity)
Hepatic Toxicity (Hepatic Toxicity)
Other (Other)
Renal Toxicity (Renal toxicity)
Thrombosis/embolism
(Thrombosis/Embolism)
Other, specify
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Non-protocol Therapy
Was any non-protocol therapy given during
protocol treatment?
Yes
No
Comments
Investigator Signature
Investigator Signature Date
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E1609 Treatment/Vital Status Form - Arm A
NCT01274338
E1609 Treatment/Vital Status Form - Arm A NCT01274338
Ipilimumab or High-Dose Interferon Alfa-2b in Treating
Patients With High-Risk Stage III or Stage IV Melanoma
That Has Been Removed by Surgery
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=97E81F9F-
45B5-261A-E040-BB89AD434355
All rights reserved. Please visit https://medical-data-
models.org/forms/11027
E1609 Treatment/Vital Status Form -
Arm A NCT01274338
Clinical trial administrative data
Patient Initials (Last, First)
ECOG Protocol Number
Participating Group Protocol Number
Institution/Affiliate
ECOG Patient ID
Participating Group Patient ID
DCI Name
Registration Step (1)
Please mark an 'X' if data have been amended.
(Please circle amended items in red)
Date data amended (s - mm/dd/yyyy)
On Treatment Reporting Period
On Treatment Reporting Period
Week 1 (Week 1)
Week 10 (Week 10)
Week 24 (Week 24)
Week 36 (Week 36)
Week 4 (Week 4)
Week 48 (Week 48)
Week 60 (Week 60)
Week 7 (Week 7)
Reporting Period Start Date (mm/dd/yyyy)
Reporting Period End Date (mm/dd/yyyy)
1 / 3
Vital Status
Patient's Vital Status
Alive (Alive)
Dead (Dead)
Date of last contact or death (mm/dd/yyyy)
Primary Cause of Death
Due To Other Cause (Due to other
cause)
Due To Protocol Treatment (Due to
protocol treatment)
Due To This Disease (Due to this
disease)
Unknown (Unknown)
Describe cause of death
Weight (Day 1 of this reporting period)
Patient Characteristics
Therapy Administered - Section I
Agent Name
Was the agent administered during this reporting
period? (Ipilimumab)
Yes
No
Date Agent Administered (If yes:)
Agent Dose (mg)
Were there any dose modifications or
additions/omissions to protocol treatment?
No (No)
Yes, Both Planned And Unplanned (Yes,
both planned and unplanned)
Yes, Planned (i.e., The Treatment Was
Changed According To Protocol
Guidelines) (Yes, planned)
Yes, Unplanned (i.e., The Treatment
Change Was Not Part Of Protocol
Guidelines) (Yes, unplanned)
Section E: Non-protocol Therapy
Was any non-protocol therapy given during
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protocol treatment (not previously reported)?
Yes
No
Comments
Investigator Signature
Investigator Signature Date
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E1A05 Baseline Disease Assessment Form
- Form 2856
E1A05 Baseline Disease Assessment Form - Form 2856
Bortezomib and Dexamethasone With or Without
Lenalidomide in Treating Patients With Multiple Myeloma
Previously Treated With Dexamethasone
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=3251CFC1-
99F1-2218-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11028
E1A05 Baseline Disease
Assessment Form - Form 2856
Header
ECOG Protocol Number
ECOG Patient ID
DCI Name
Registration Step
Reporting Period
Baseline (Baseline)
Patient Initials (Last, First)
Participating Group Protocol Number
Participating Group Patient ID
Institution/Affiliate
Please mark an 'X' if data have been amended.
Date data amended
Protein Measurements
Date of SPEP
Serum total protein (SPEP g/dl)
Serum M-protein spike (g/dl NOTE: Leave blank if
serum M-spike was present but too small to
quantify.)
If serum M-protein spike was left blank, please
specify
1 / 6
Absent (Not present)
Present But Too Small To Quantify
(Present but too small to quantify)
Albumin LLN (g/dl)
Albumin (Value)
Date of serum FLC assessment
Kappa Free Light Chain (mg/dl)
Lambda Free Light Chain (mg/dl)
Date of urine immunofixation (Urine
immunofixation IFE leave blank if not done)
Serum M-protein by immunofixation
Negative (negative)
Positive (positive)
Serum Heavy Chain (If positive:)
A (A)
Biclonal (Biclonal)
D (D)
E (E)
G (G)
M (M)
Unknown (Unknown)
Biclonal, specify
Serum Light Chain
Kappa (kappa)
Lambda (lambda)
Unknown (Unknown)
Date hematology (blood) sample obtained
(Serum Quantitative Immunoglobulins)
IgG (mg/dl)
IgG LLN (mg/dl)
IgG ULN (mg/dl)
IgA (mg/dl)
IgA LLN (mg/dl)
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IgA ULN (mg/dl)
IgM (mg/dl)
IgM LLN (mg/dl)
IgM ULN (mg/dl)
Urine Sample
Date of UPEP (Urine protein electrophoresis
UPEP)
Urine Total protein (UPEP mg/24 hr)
Urine M-protein light chain excretion (mg/24 hr
NOTE: Leave blank if urine M-protein light chain
excretion was present but too small to quantify.)
If urine M-protein light chain excretion was left
blank, please specify
Absent (Not present)
Present But Too Small To Quantify
(Present but too small to quantify)
Urine M-protein by immunofixation
Negative (negative)
Positive (positive)
Urine Light Chain (If positive:)
Kappa (kappa)
Lambda (lambda)
Unknown (unknown)
Soft Tissue Plasmacytoma
Soft tissue plasmacytoma?
Yes
No
Lesion No.
Site of lesion
Biopsy proven?
Yes
No
Date of evaluation
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Method of evaluation
Clinical (Clinical Examination)
Ct Scan (CT scan (non-spiral))
Mri (MRI (NMR))
Other (Other (specify))
Spiral Ct Scan (Spiral CT scan)
Other Specify
Size of Plasmacytoma (cm)
Size of Plasmacytoma
Bone Marrow
Was bone marrow biopsy done?
Inadequate Sample (inadequate sample)
No (no)
Yes (yes)
Bone marrow biopsy date
Plasma cells on biopsy (If yes:)
If plasma cells on biopsy was left blank, please
specify (%)
Absent (Not present)
Present But Too Small To Quantify
(Present but too small to quantify)
Was bone marrow aspirate done?
Inadequate Sample (inadequate sample)
No (no)
Yes (yes)
Date of Bone Marrow Aspirate
Plasma cells on aspirate in interpretation (If yes:)
If plasma cells on aspirate was left blank, please
specify
Absent (Not present)
Present But Too Small To Quantify
(Present but too small to quantify)
Are sheets of plasma cells present?
Yes
No
Bone
4 / 6
E1A05 Baseline Disease Assessment Form - Form 2856
Date of most recent bone assessment
Were lytic bone lesions present at study entry
(Bone assessment method)
Yes
No
Bone Assessment Method
Bone Scan (Bone scan)
Ct Scan (CT scan)
Mri (nmr) (MRI (NMR))
Other (Other)
Pet Scan (PET scan)
Skeletal Survey (Skeletal survey)
Peripheral Blood Chemistry
Date of most recent hematology (blood) sample
obtained
C-reactive protein ULN (mg/dl)
C-reactive protein (mg/dl)
Lactate dehydrogenase ULN
Lactate dehydrogenase (LDH) (U/L)
Beta-2 Microglobulin ULN (ng/ml)
Beta-2 Microglobulin (ng/ml)
Glucose LLN (mg/dl)
Glucose ULN (mg/dl)
Glucose (mg/dl)
Creatinine ULN (mg/dl)
Creatinine (mg/dl)
Hemoglobin (Hgb) (g/dl), LLN
Hemoglobin (g/dl)
Calcium LLN (mg/dl)
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Calcium ULN (mg/dl)
Calcium (mg/dl)
Comments
Comments
Investigator Signature Date
Investigator Signature
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E4A08 Treatment Form - Arm B
E4A08 Treatment Form - Arm B
Melphalan and Dexamethasone With or Without
Bortezomib in Treating Patients With Previously Untreated
Systemic Light-Chain Amyloidosis
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=7C86B76A-
95A7-0556-E040-BB89AD4336E4
All rights reserved. Please visit https://medical-data-
models.org/forms/11029
E4A08 Treatment Form - Arm B
ECOG clinical trial administrative data
Patient Initials (Last, First)
ECOG Protocol Number
Participating Group Protocol Number
Institution/Affiliate
ECOG Patient ID
Participating Group Patient ID
DCI Name
Registration Step (1)
Please mark an 'X' if data have been amended.
(Please circle amended items in red)
Date data amended (s - mm/dd/yyyy)
On Treatment Reporting Period
On Treatment Reporting Period
Cycle 1 (Cycle 1)
Cycle 2 (Cycle 2)
Cycle 3 (Cycle 3)
Cycle 4 (cycle 4)
Cycle 5 (Cycle 5)
Cycle 6 (Cycle 6)
Cycle 7 (Cycle 7)
Cycle 8 (cycle 8)
Reporting Period Start Date (mm/dd/yyyy)
Reporting Period End Date (mm/dd/yyyy)
1 / 4
Vital Status
Patient's Vital Status
Alive (Alive)
Dead (Dead)
Date of last contact or death (mm/dd/yyyy)
Primary Cause of Death
Due To Other Cause (Due to other
cause)
Due To Protocol Treatment (Due to
protocol treatment)
Due To This Disease (Due to this
disease)
Unknown (Unknown)
Describe cause of death
Performance Status
Fully Active, Able To Carry On All Pre-
disease Performance Without
Restriction. (0)
Restricted In Physically Strenuous
Activity But Ambulatory And Able To
Carry Out Work Of A Light Or Sedentary
Nature, E.g., Light Housework, Office
Work. (1)
Ambulatory And Capable Of All Selfcare
But Unable To Carry Out Any Work
Activities. Up And About More Than 50%
Of Waking Hours. (2)
Capable Of Only Limited Selfcare,
Confined To Bed Or Chair More Than
50% Of Waking Hours. (3)
Completely Disabled. Cannot Carry On
Any Selfcare. Totally Confined To Bed Or
Chair. (4)
Patient Characteristics
Weight (Day 1 of this cycle)
Body Surface Area (BSA Day 1 of this cycle -
m^2)
Blood Pressure, Supine, Systolic
Blood pressure, Supine, Diastolic
Supine, Pulse
Mark an 'X' if not done
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Blood Pressure, Standing at 1 minute, Systolic
Blood pressure, Standing at 1 minute, Diastolic
Standing at 1 minute, Pulse
Therapy Administered - Section I
Agent Name
Was the agent administered during this reporting
period? (Bortezomib)
Yes
No
Date Agent Administered (If yes:)
Agent Dose
Prescribed pill dose
Did the patient complete Patient Pill Diary
Yes
No
How many pills remained at the end of this cycle
Were there any dose modifications or
additions/omissions to protocol treatment
Yes
No
Therapy Administered - Section I
Were there any dose modifications or
additions/omissions to protocol treatment
Yes
No
Therapy Administered - Section I
Were there any dose modifications or
additions/omissions to protocol treatment? (this
cycle)
No (No)
Yes, Both Planned And Unplanned (Yes,
both planned and unplanned)
Yes, Planned (i.e., The Treatment Was
Changed According To Protocol
Guidelines) (Yes, planned)
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Yes, Unplanned (i.e., The Treatment
Change Was Not Part Of Protocol
Guidelines) (Yes, unplanned)
Section E: Non-protocol Therapy
Was any non-protocol therapy given during
protocol treatment (not previously reported)?
Yes
No
Comments
Investigator Signature
Investigator Signature Date
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E4A08 Non-Protocol Therapy Form (Form
3342) NCT01078454
E4A08 Non-Protocol Therapy Form (Form 3342)
NCT01078454 
Melphalan and Dexamethasone With or Without
Bortezomib in Treating Patients With Previously Untreated
Systemic Light-Chain Amyloidosis
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=7BCCF644-
B58E-7CED-E040-BB89AD433815
All rights reserved. Please visit https://medical-data-
models.org/forms/11030
E4A08 Non-Protocol Therapy Form
(Form 3342) NCT01078454
Header
ECOG Protocol Number
ECOG Patient ID
DCI Name
Registration Step
Reporting Period
Non-protocol Therapy (Non-Protocol
Therapy)
Patient Initials (Last, First)
Participating Group Protocol Number
Institution/Affiliate
Participating Group Patient ID
Please mark an 'X' if data have been amended.
(Please circle amended items in red)
Date data amended (s - mm/dd/yyyy)
Type(s) of first non-protocol therapy
Date of First Non-Protocol Therapy (if given prior
to progression/relapse from protocol therapy -
mm/dd/yyyy)
Non-protocol Chemotherapy
No (No)
Unknown (Unknown)
Yes (Yes)
Non-Protocol Chemotherapy Type
1 / 3
Non-protocol Hormonal Therapy
No (No)
Unknown (Unknown)
Yes (Yes)
Non-protocol Immunotherapy (/Biological
Response Modifiers)
No (No)
Unknown (Unknown)
Yes (Yes)
Non-Protocol Immunotherapy Type
Non-Protocol High Dose Chemotherapy/Stem
Cell Transplant
No (No)
Unknown (Unknown)
Yes (Yes)
Non-Protocol High Dose Chemotherapy/Stem
Cell Transplant Type
Non-protocol Surgery
No (No)
Unknown (Unknown)
Yes (Yes)
Non-protocol surgery type
Non-protocol Radiation Therapy
No (No)
Unknown (Unknown)
Yes (Yes)
Non-protocol RT type
Other Non-protocol Therapy
No (No)
Unknown (Unknown)
Yes (Yes)
Name of other non-protocol therapy
Was the non-protocol therapy given for the
disease of this protocol (NOTE: Treatment for a
second primary in the same organ site would not
be considered therapy for disease of this
protocol. Note:  Submit ECOG Second Primary
Form if applicable.)
No (No)
Unknown (Unknown)
Yes (Yes)
Comments
Investigator Signature
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Investigator Signature Date
Comments
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ECOG Off-Treatment Form NCT00110019
ECOG Off-Treatment Form NCT00110019 
Carboplatin and Paclitaxel With or Without Sorafenib in
Treating Patients With Unresectable Stage III or Stage IV
Melanoma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=E75D701E-
FC7C-3DEF-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11031
ECOG Off-Treatment Form
NCT00110019
ECOG clinical trial administrative data
ECOG Protocol Number
ECOG Patient ID
DCI Name
Registration Step
Time period
End Of Treatment (End of Treatment)
Patient Initials
Participating Group Protocol Number
Institution/Affiliate
Participating Group Patient ID
Please mark an 'X' if data have been amended.
Date data amended
Vital Status
Patient?s Vital Status
Alive (Alive)
Dead (Dead)
Date of Last Contact or Death
Primary Cause of Death (if applicable)
Due To Other Cause (Due to other
cause)
Due To Protocol Treatment (Due to
protocol treatment)
Due To This Disease (Due to this
1 / 2
disease)
Unknown (Unknown)
Describe cause of death
Reason treatment ended
Adverse Event/side Effects/complications
(Adverse events/side
effects/complications)
Alternative Therapy (Alternative therapy)
Complicating Disease (Complicating
Disease)
Death On Study (Death on study)
Disease Progression, Relapse During
Active Treatment (Disease progression,
relapse during active treatment)
Other (Other)
Patient Off-treatment For Other
Complicating Disease (Patient off
treatment for other complicating disease)
Patient Withdrawal Or Refusal After
Beginning Protocol Therapy (Patient
withdrawal or refusal after beginning
protocol therapy)
Treatment Completed Per Protocol
Criteria (Treatment completed per
protocol criteria)
Complicating Disease (specify)
Other (specify)
Last date protocol therapy was given
Comments
Comments
Investigator Signature
Investigator Signature Date
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E4A08 Baseline Disease Assessment Form
NCT01078454
E4A08 Baseline Disease Assessment Form NCT01078454 
Melphalan and Dexamethasone With or Without
Bortezomib in Treating Patients With Previously Untreated
Systemic Light-Chain Amyloidosis
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=7BCCA614-
5186-15BB-E040-BB89AD4326D3
All rights reserved. Please visit https://medical-data-
models.org/forms/11032
E4A08 Baseline Disease
Assessment Form NCT01078454
Header
DCI Name
Registration Step
Reporting Period
Baseline (Baseline)
Patient Initials (Last, First)
ECOG Protocol Number
ECOG Protocol Number
ECOG Patient ID
ECOG Patient ID
Participating Group Protocol Number
Participating Group Patient ID
Institution/Affiliate
Data amendment
Please mark an 'X' if data have been amended.
Date data amended
Protein Measurements
Date of SPEP
Serum total protein (SPEP g/dl)
1 / 8
Serum M-protein spike (g/dl )
If serum M-protein spike was left blank, please
specify
Absent (Not present)
Present But Too Small To Quantify
(Present but too small to quantify)
Albumin LLN (g/dl)
Albumin (Value)
Date of urine immunofixation (Urine
immunofixation IFE leave blank if not done)
Date of serum FLC assessment
Kappa Free Light Chain (mg/dl)
Mark an 'X' if not done
Mark an 'X' if not done
Lambda Free Light Chain (mg/dl)
Mark an 'X' if not done
Serum M-protein by immunofixation
Negative (negative)
Positive (positive)
Serum Heavy Chain (If positive:)
A (A)
Biclonal (Biclonal)
D (D)
E (E)
G (G)
M (M)
None (None)
Unknown (Unknown)
Biclonal, specify
Serum Light Chain
Kappa (kappa)
Lambda (lambda)
Unknown (Unknown)
Urine Sample
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Date of UPEP (Urine protein electrophoresis
UPEP)
Urine Total protein (UPEP mg/24 hr)
Urine M-protein measurement
If urine M-protein measurement was left blank,
please specify
Absent (Not present)
Present But Too Small To Quantify
(Present but too small to quantify)
Date of urine immunofixation (Urine
immunofixation IFE leave blank if not done)
Urine M-protein by immunofixation
Negative (negative)
Positive (positive)
Urine Light Chain (If positive:)
Kappa (kappa)
Lambda (lambda)
Unknown (unknown)
Mark an 'X' if not done
Mark an 'X' if not done
Protein Measurements
IgG (mg/dl)
IgG LLN (mg/dl)
IgG ULN (mg/dl)
IgA (mg/dl)
IgA LLN (mg/dl)
IgA ULN (mg/dl)
IgM (mg/dl)
Date Hematology (Blood) Sample Obtained
IgM LLN (mg/dl)
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Mark an 'X' if not done
IgM ULN (mg/dl)
Other Biopsy
Organ biopsy results
Aspirate Adipocyte (Fat Aspirate)
Fat Biopsy (Fat Biopsy)
Gastrointestinal (Gastrointestinal)
Heart (Heart)
Kidney (Kidney)
Liver (Liver)
Other (Other)
Nerve (Peripheral Nerve)
Specify other site
Biopsy done (Mark 'X' for all that apply)
Positive congo red staining for amyloid
No (No)
Not Done (Not done)
Yes (Yes)
Bone Marrow
Was bone marrow biopsy done?
Inadequate Sample (inadequate sample)
No (no)
Yes (yes)
Bone marrow biopsy date
Plasma cells on biopsy (If yes:)
If plasma cells on biopsy was left blank, please
specify (%)
No Percentage Given (No percentage
given)
Absent (Not present)
Present But Too Small To Quantify
(Present but too small to quantify)
Was bone marrow aspirate done?
Inadequate Sample (inadequate sample)
No (no)
Yes (yes)
Bone marrow aspirate date
Plasma Cells on Aspirate in Interpretation (%) (If
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yes:)
If plasma cells on aspirate was left blank, please
specify
No Percentage Given (No percentage
given)
Absent (Not present)
Present But Too Small To Quantify
(Present but too small to quantify)
Was plasma cell clonality done
Yes
No
Plasma cell clonality test date (If Yes,)
Clonality determination method
Flow Cytometry (flow cytometry)
Fluorescent Antibody Technique
(Immunofluorescence)
Immunohistochemistry
(Immunohistochemistry)
Other (other)
Other specify
Result
Kappa (kappa)
Lambda (lambda)
Polyclonal (polyclonal)
Bone Involvement
Were lytic bone lesions present at study entry
No (no)
Unknown (unknown)
Yes (yes)
Cardiac Assessment
Does patient currently have cardiac involvement
per the protocol criteria
Yes
No
Was an Echocardiogram (ECHO) performed (at
baseline)
Yes
No
Date of echocardiogram
Interventricular Septal Wall Thickness (mm)
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Left ventricular ejection fraction (%)
Troponin T ULN
Troponin T
Troponin I ULN
Troponin I
Date Hematology (Blood) Sample Obtained
Mark an 'X' if not done
New York Heart Association Classification
Patients With Cardiac Disease But
Without Resulting Limitation Of Physical
Activity. Ordinary Physical Activity Does
Not Cause Undue Fatigue, Palpitation,
Dyspnea Or Anginal Pain. (Class I)
Patients With Cardiac Disease Resulting
In Slight Limitation Of Physical Activity.
They Are Comfortable At Rest. Ordinary
Physical Activity Results In Fatigue,
Palpitation, Dyspnea Or Anginal Pain.
(Class II)
Patients With Cardiac Disease Resulting
In Marked Limitation Of Physical Activity.
They Are Comfortable At Rest. Less
Than Ordinary Activity Causes Fatigue,
Palpitation, Dyspnea Or Anginal Pain.
(Class III)
Patients With Cardiac Disease Resulting
In Inability To Carry On Any Physical
Activity Without Discomfort. Symptoms
Of Heart Failure Or The Anginal
Syndrome May Be Present Even At
Rest. If Any Physical Activity Is
Undertaken, Discomfort Increases.
(Class IV)
Liver Assessment
Does patient currently have clinically evident liver
involvement per the protocol criteria
Yes
No
Was a liver measurement done (at baseline)
Yes
No
Date of Liver Evaluation
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Liver Measurement (cm)
Method of liver evaluation
Medical Examination (Clinical
examination)
Computed Tomography (CT scan)
Radionuclide Imaging (Liver-spleen
scan)
Other (Other)
Ultrasound (Ultrasound)
Specify other method
Gi Tract Assessment
Does patient currently have clinically evident GI
tract involvement per the protocol criteria
Yes
No
Is there GI bleeding
Yes
No
Is diarrhea present
Yes
No
Number of stools per day
Was a fecal fat excretion test done
Yes
No
24-hour Fecal Fat Excretion (If Yes, - g)
Date of fecal fat evaluation (start date)
Nerve Assessment
Does patient currently have clinically evident
peripheral nerve involvement per the protocol
criteria
Yes
No
Date of EMG/NCS
CMAP amplitude
Results of EMG
Abnormal (Abnormal)
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Normal (Normal)
Specify EMG result (If abnormal,)
Neuropathy Impairment Score
25% (25%)
50% (50%)
75% Weak (75% weak)
Normal (Normal)
Paralysis (Paralyzed)
Does patient have clinically evident autonomic
nerve involvement per the protocol criteria
Yes
No
Kidney Assessment
Does patient currently have clinically evident
kidney involvement per the protocol criteria
Yes
No
Peripheral Blood Chemistry
Beta-2 Microglobulin (ng/ml)
Beta-2 Microglobulin ULN (ng/ml)
Lactate dehydrogenase (LDH) (U/L)
Lactate dehydrogenase ULN
Date Hematology (Blood) Sample Obtained
Mark an 'X' if not done
Mark an 'X' if not done
Comments
Comments
Investigator Signature Date
Investigator Signature
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E3A06 Baseline Disease Assessment Form
NCT01169337
E3A06 Baseline Disease Assessment Form NCT01169337 
Lenalidomide or Observation in Treating Patients With
Asymptomatic High-Risk Smoldering Multiple Myeloma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=86CCB2A8-
7843-F281-E040-BB89AD432A9E
All rights reserved. Please visit https://medical-data-
models.org/forms/11033
E3A06 Baseline Disease
Assessment Form NCT01169337
Header
DCI Name
Registration Step
Reporting Period
Baseline (Baseline)
Patient Initials (Last, First)
ECOG Protocol Number
ECOG Protocol Number
ECOG Patient ID
ECOG Patient ID
Participating Group Protocol Number
Participating Group Patient ID
Institution/Affiliate
Data amendment
Please mark an 'X' if data have been amended.
Date data amended
Protein Measurements
Date of SPEP
Serum total protein (SPEP g/dl)
1 / 7
Serum M-protein spike (g/dl NOTE: Leave blank if
serum M-spike was present but too small to
quantify.)
If serum M-protein spike was left blank, please
specify
Absent (Not present)
Present But Too Small To Quantify
(Present but too small to quantify)
Date of urine immunofixation (Urine
immunofixation IFE leave blank if not done)
Albumin LLN (g/dl)
Albumin (Value)
Date of serum FLC assessment
Kappa Free Light Chain
Unit of Measure
Milligrams Per Deciliter (mg/dL)
Milligrams Per Liter (mg/L)
Unit of Measure
Milligrams Per Deciliter (mg/dL)
Milligrams Per Liter (mg/L)
Mark an 'X' if not done
Mark an 'X' if not done
Lambda Free Light Chain
Mark an 'X' if not done
Mark an 'X' if not done
Kappa/Lambda ratio
Serum M-protein by immunofixation
Negative (negative)
Positive (positive)
Serum Heavy Chain (If positive:)
A (A)
Biclonal (Biclonal)
D (D)
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E (E)
G (G)
M (M)
Unknown (Unknown)
Biclonal, specify
Serum Light Chain
Kappa (kappa)
Lambda (lambda)
Unknown (Unknown)
Date hematology (blood) sample obtained
(Serum Quantitative Immunoglobulins)
IgG (mg/dl)
IgG LLN (mg/dl)
IgG ULN (mg/dl)
IgA (mg/dl)
IgA LLN (mg/dl)
IgA ULN (mg/dl)
IgM (mg/dl)
IgM LLN (mg/dl)
IgM ULN (mg/dl)
Urine Sample
Date of UPEP (Urine protein electrophoresis
UPEP)
Urine Total protein (UPEP mg/24 hr)
Urine M-protein measurement (mg/24 hr)
If urine M-protein measurement was left blank,
please specify
Absent (Not present)
Present But Too Small To Quantify
(Present but too small to quantify)
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Date of urine immunofixation (Urine
immunofixation IFE leave blank if not done)
Urine M-protein by immunofixation
Negative (negative)
Positive (positive)
Urine Light Chain (If positive:)
Kappa (kappa)
Lambda (lambda)
Unknown (unknown)
Mark an 'X' if not done
Mark an 'X' if not done
Bone Marrow
Was bone marrow biopsy done?
Inadequate Sample (inadequate sample)
No (no)
Yes (yes)
Bone marrow biopsy date
Plasma cells on biopsy (If yes:)
If plasma cells on biopsy was left blank, please
specify (%)
No Percentage Given (No percentage
given)
Absent (Not present)
Present But Too Small To Quantify
(Present but too small to quantify)
Was bone marrow aspirate done?
Inadequate Sample (inadequate sample)
No (no)
Yes (yes)
Bone marrow aspirate date
Plasma cells on aspirate in interpretation (If yes:)
If plasma cells on aspirate was left blank, please
specify
No Percentage Given (No percentage
given)
Absent (Not present)
Present But Too Small To Quantify
(Present but too small to quantify)
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Are sheets of plasma cells present?
Yes
No
Was plasma cell clonality done
Yes
No
Plasma cell clonality test date
Clonality determination method
Flow Cytometry (flow cytometry)
Fluorescent Antibody Technique
(Immunofluorescence)
Immunohistochemistry
(Immunohistochemistry)
Other (other)
Other specify
Result
Kappa (kappa)
Lambda (lambda)
Polyclonal (polyclonal)
Mri: Spine And Pelvis
Date of most recent MRI assessment
MRI Results
Bone Lesion (Bone lesions)
Bone Marrow Signal Abnormalities
(Bone marrow signal abnormalities)
No Abnormality (No abnormality)
Other (Other)
Specify
Peripheral Blood Chemistry
C-reactive protein ULN (mg/dl)
C-reactive protein (mg/dl)
Date of most recent hematology (blood) sample
obtained
Date of most recent hematology (blood) sample
obtained
Date of most recent hematology (blood) sample
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obtained
Date of most recent hematology (blood) sample
obtained
Date of most recent hematology (blood) sample
obtained
Date of most recent hematology (blood) sample
obtained
Date of most recent hematology (blood) sample
obtained
Lactate dehydrogenase ULN
Lactate dehydrogenase (LDH) (U/L)
Beta-2 Microglobulin ULN (ng/ml)
Beta-2 Microglobulin (ng/ml)
Mark an 'X' if not done
Mark an 'X' if not done
Mark an 'X' if not done
Mark an 'X' if not done
Mark an 'X' if not done
Mark an 'X' if not done
Mark an 'X' if not done
Creatinine ULN (mg/dl)
Creatinine (mg/dl)
Hemoglobin (Hgb) (g/dl), LLN
Hemoglobin (g/dl)
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Calcium LLN (mg/dl)
Calcium ULN (mg/dl)
Calcium (mg/dl)
Creatinine Clearance
Comments
Investigator Signature Date
Investigator Signature
Comments
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E5508 Baseline Disease Evaluation Form
(RECIST 1.1) NCT01107626
E5508 Baseline Disease Evaluation Form (RECIST 1.1)
NCT01107626 
Bevacizumab or Pemetrexed Disodium Alone or In
Combination After Induction Therapy in Treating Patients
With Advanced Non-Squamous Non-Small Cell Lung
Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=6D42B202-
CDD6-89E9-E040-BB89AD430258
All rights reserved. Please visit https://medical-data-
models.org/forms/11034
E5508 Baseline Disease Evaluation
Form (RECIST 1.1) NCT01107626
Header
ECOG Protocol Number
ECOG Patient ID
DCI Name
Registration Step
Report Period
Baseline Step 1 (Baseline step 1)
Patient Initials (Last, First)
Participating Group Protocol Number
Participating Group Patient ID
Institution/Affiliate
Data amendment
Please mark an 'X' if data have been amended.
(Please circle amended items in red)
Date data amended (s M D Y)
TARGET LESIONS
Are there any target lesions
Yes
No
TARGET LESIONS - NON NODAL
Lesion Number
1 / 3
Site of Lesion (Multiple nontarget lesions within
an organ may be combined as a single site;
report in a consistent manner on subsequent
forms)
Site Code
Bone (bone)
Brain (Brain)
Breast (Breast)
Effusion/ascites (Effusion/Ascites)
Gi (GI)
Gu (GU)
Head & Neck (Head & Neck)
Liver (Liver)
Lung (Lung)
Nodes (Nodes)
Other (other)
Skin (Skin)
Method of Evaluation
Bone Scan (Bone scan)
Chest X-ray (Chest X-Ray)
Clinical (Clinical Examination)
Ct Scan (CT Scan)
Mri (MRI (NMR))
Other (other)
Spiral Ct Scan (Spiral CT scan)
Ultrasound (Ultrasound)
Date of Evaluation (M D Y)
Longest Diameter of Lesion(s) (mm)
Sum of Longest Diameters of All Non-Nodal
Target Lesions (mm)
TARGET LESIONS - NODAL
Shortest Axis of Lesions (mm)
Sum of Shortest Axes of All Nodal Lesions (mm)
Sum of Longest (Non-Nodal) and Shortest
(Nodal) Axes of All Target Lesions (mm)
Nontarget Lesions
Cytology Result (For Site Code 04
effusion/ascites ONLY:)
Negative (Negative)
Not Done (Not done)
Positive (Positive)
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Comments
Comments
Investigator Signature
Investigator Signature Date (M D Y)
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E4A03 Baseline Disease Assessment Form
- Form 2056 NCT00098475
E4A03 Baseline Disease Assessment Form - Form 2056
NCT00098475 
Lenalidomide and Dexamethasone With or Without
Thalidomide in Treating Patients With Multiple Myeloma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=DD1177E1-
5195-20DB-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/11035
E4A03 Baseline Disease
Assessment Form - Form 2056
NCT00098475
Header
ECOG Protocol Number
ECOG Patient ID
DCI Name
Registration Step
Report Period (Choose one)
Baseline Step 1 (Baseline - Step 1)
Baseline Step 2 (Baseline - Step 2)
Patient Initials
Participating Group Protocol Number
Participating Group Patient ID
Institution/Affiliate
Are data amended (Serum protein
electrophoresis SPEP)
Yes
No
Protein Measurements
Date of SPEP
Serum total protein (SPEP g/dl)
Serum M-protein spike (g/dl NOTE: Leave blank if
serum M-spike was present but too small to
quantify.)
1 / 5
Is serum M-spike present but too small to
quantify? (If serum M-spike was left blank)
Yes
No
Date of serum immunoelectrophoresis (Serum
immunoelectrophoresis leave blank if not done)
Serum M-protein by immunoelectrophoresis
Negative (negative)
Positive (positive)
Date of urine immunofixation (Urine
immunofixation IFE leave blank if not done)
Serum M-protein by immunofixation
Negative (negative)
Positive (positive)
Serum Heavy Chain (If positive:)
A (A)
Biclonal (Biclonal)
D (D)
E (E)
G (G)
M (M)
Unknown (Unknown)
Specify
Serum Light Chain
Kappa (kappa)
Lambda (lambda)
Unknown (Unknown)
Date hematology (blood) sample obtained
IgG
IgG LLN
IgG ULN
IgA
IgA LLN
IgA ULN
IgM
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IgM LLN
IgM ULN
Urine Sample
Date of UPEP (Urine protein electrophoresis
UPEP)
Urine Total protein (UPEP mg/24 hr)
Urine M-protein light chain excretion (mg/24 hr
NOTE: Leave blank if urine M-protein light chain
excretion was present but too small to quantify.)
Is urine M-protein light chain excretion present
but too small to quantify? (If urine M-protein light
chain excretion was left blank:)
Yes
No
Date of urine immunoelectrophoresis (Urine
immunoelectrophoresis leave blank if not done)
Urine M-protein by immunoelectrophoresis
Negative (negative)
Positive (positive)
Urine M-protein by immunofixation
Negative (negative)
Positive (positive)
Urine Light Chain (If positive:)
Kappa (kappa)
Lambda (lambda)
Unknown (unknown)
Bone Marrow
Was bone marrow biopsy done?
Inadequate Sample (inadequate sample)
No (no)
Yes (yes)
Plasma cells on biopsy (If yes:)
Bone marrow biopsy date
Was bone marrow aspirate done?
Inadequate Sample (inadequate sample)
No (no)
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Yes (yes)
Plasma cells on aspirate in interpretation (If yes:)
Are sheets of plasma cells present?
Yes
No
Soft Tissue Plasmacytoma
Soft tissue plasmacytoma?
Yes
No
Lesion No.
Site of lesion
Biopsy proven?
Yes
No
Date of evaluation
Method of evaluation
Clinical (Clinical Examination)
Ct Scan (CT scan (non-spiral))
Mri (MRI (NMR))
Other (Other (specify))
Spiral Ct Scan (Spiral CT scan)
Specify other assessment method
Size of Plasmacytoma (cm)
New Plasmacytoma Longest Dimension
Measurement
Bone
Date of bone assessment
Lytic bone lesions present? (Bone assessment
method)
Yes
No
CT scan
Yes
No
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MRI (NMR)
Yes
No
Bone scan
Yes
No
Pet scan
Yes
No
Skeletal survey
Yes
No
Other
Yes
No
Peripheral Blood Chemistry
C-reactive protein ULN
C-reactive protein (mg/dl)
Lactate dehydrogenase ULN
Lactate dehydrogenase (LDH) (U/L)
Beta-2 Microglobulin ULN
Beta-2 Microglobulin (ng/ml)
Comments
Comments
Investigator Signature Date
Investigator Signature
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E4A03 Follow-up Disease Assessment
Form - Form 2058 NCT00098475
E4A03 Follow-up Disease Assessment Form - Form 2058
NCT00098475 
Lenalidomide and Dexamethasone With or Without
Thalidomide in Treating Patients With Multiple Myeloma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=DCEB2086-
C366-716B-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/11037
E4A03 Follow-up Disease
Assessment Form - Form 2058
NCT00098475
Header
ECOG Protocol Number
ECOG Patient ID
DCI Name
Step
Patient Initials
Participating Group Protocol Number
Participating Group Patient ID
Institution/Affiliate
Are data amended (If this form covers an On
Treatment Report Period:)
Yes
No
On Treatment
On Treatment Time Period  (Step 2: Arms C and
D)
Cycle 1 (Cycle 1 Step 2)
Cycle 10 (Cycle 10 Step 2)
Cycle 11 (Cycle 11 Step 2)
Cycle 12 (Cycle 12 Step 2)
Cycle 2 (Cycle 2 Step 2)
Cycle 3 (Cycle 3 Step 2)
Cycle 4 (Cycle 4 Step 2)
Cycle 5 (Cycle 5 Step 2)
Cycle 6 (Cycle 6 Step 2)
Cycle 7 (Cycle 7 Step 2)
Cycle 8 (Cycle 8 Step 2)
Cycle 9 (Cycle 9 Step 2)
1 / 7
Off Treatment
Off Treatment Report Period (since registration)
12 Months (12 Months Post Registration)
15 Months (15 Months Post Registration)
18 Months (18 Months Post Registration)
21 Months Post Registration (21 Months
Post Registration)
2 Years (24 Months Post Registration)
3 Months (3 Months Post Registration)
30 Months (30 Months Post Registration)
3 Years (36 Months Post Registration)
42 Months (42 Months Post Registration)
4 Years (48 Months Post Registration)
54 Months (54 Months Post Registration)
6 Months (6 Months Post Registration)
5 Years (60 Months Post Registration)
6 Years (72 Months Post Registration)
84 Months Post Registration (84 Months
Post Registration)
9 Months (9 Months Post Registration)
Cycle Number
Protein Measurements
Date of SPEP
Serum total protein (SPEP g/dl)
Is serum M-protein present but too small to
quantify?
Yes
No
Serum M-protein spike (g/dl)
Date of serum immunoelectrophoresis (Serum
immunoelectrophoresis leave blank if not done)
Serum M-protein by immunoelectrophoresis
Negative (negative)
Positive (positive)
Date of urine immunofixation (Urine
immunofixation IFE leave blank if not done)
Serum M-protein by immunofixation
Negative (negative)
Positive (positive)
Date of UPEP (Urine protein electrophoresis
UPEP)
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Urine Total protein (UPEP mg/24 hr)
Is urine M-protein light chain excretion present
but too small to quantify?
Yes
No
Urine M-protein light chain excretion (mg/24 hr)
Date of urine immunoelectrophoresis (Urine
immunoelectrophoresis leave blank if not done)
Urine M-protein by immunoelectrophoresis
Negative (negative)
Positive (positive)
Urine M-protein by immunofixation
Negative (negative)
Positive (positive)
Serum Quantitative Immunoglobulins
Date hematology (blood) sample obtained
IgG
IgG LLN
IgG ULN
IgA
IgA LLN
IgA ULN
IgM
IgM LLN
IgM ULN
Bone Marrow
Was bone marrow biopsy done?
Inadequate Sample (inadequate sample)
No (no)
Yes (yes)
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Plasma cells on biopsy (If yes, %)
Bone marrow biopsy date
Was bone marrow aspirate done?
Inadequate Sample (inadequate sample)
No (no)
Yes (yes)
Plasma cells on aspirate in interpretation (If yes,
%)
Bone marrow aspirate date
Soft Tissue Plasmacytoma
Soft tissue plasmacytoma?
No (no)
Unknown (unknown)
Yes, Both Previously Existing And New
(yes, both previously existing and new)
Yes, New (yes, new)
Yes, Previously Existing (yes, previously
existing)
Lesion No.
Site of lesion
Date of Evaluation (Leave blank if not evaluated
this report period)
Method of evaluation
Clinical (Clinical Examination)
Ct Scan (CT scan (non-spiral))
Mri (MRI (NMR))
Not Evaluated (Not evaluated)
Other (Other (specify))
Spiral Ct Scan (Spiral CT scan)
Specify other assessment method
Size of Plasmacytoma (cm)
New Plasmacytoma Longest Dimension
Measurement
Current status of plasmacytoma (*)
Decrease (decrease)
Increase (increase)
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New (new)
No Change (no change)
Bone
Was bone assessed this report period?
Yes
No
Date of bone assessment (If yes,)
CT scan
Yes
No
MRI (NMR)
Yes
No
Bone scan
Yes
No
Pet scan
Yes
No
Skeletal survey
Yes
No
Other
Yes
No
Was there distinct enlargement of existing
lesions? (* Leave blank if no prior lesions.)
No (no)
Unknown (unknown)
Yes (yes)
Explain results (If yes:)
Was the appearance of any new lesions
documented?
No (no)
Unknown (unknown)
Yes (yes)
Peripheral Blood Chemistry
C-reactive protein ULN
C-reactive protein (mg/dl)
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Lactate dehydrogenase ULN (LDH)
Lactate dehydrogenase (LDH) (U/L)
Beta-2 Microglobulin ULN
Beta-2 Microglobulin (ng/ml)
Objective Response
Since the previous evaluation, has the overall
response changed?
Yes
No
Objective status at this evaluation (confirmed)
Complete Response (complete response
(CR))
Minimal Response (minimal response
(MR))
No Response/stable Disease (no
response/stable disease (NR, SD))
Partial Response (partial response (PR))
Progressive Disease (progressive
disease (PD))
Unevaluable (unevaluable)
Complete response (CR) first observed date
Very good partial response first observed date
(VGPR)
Partial response (PR) first observed date
Minimal response first observed date (MR)
Progressive disease first observed date (For PD:
PD)
Date of disease plateau
Comments
Comments
Investigator Signature Date
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Investigator Signature
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NSABP PROTOCOL C-08: BEVACIZUMAB
TREATMENT FORM NCT00096278
NSABP PROTOCOL C-08: BEVACIZUMAB TREATMENT
FORM NCT00096278
Fluorouracil, Leucovorin, and Oxaliplatin With or Without
Bevacizumab in Treating Patients Who Have Undergone
Surgery for Stage II or Stage III Colon Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=D7F6B84C-
2C3E-4583-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/11038
NSABP PROTOCOL C-08:
BEVACIZUMAB TREATMENT
FORM NCT00096278
Header
Patient Initials (Last, First Middle)
NSABP Patient ID
Institution Name
Affiliate Name
Person Completing Form Last Name
Person Completing Form First Name
Person Completing Form Phone
Are data amended? (check box if yes, and circle
amended items)
Yes
No
BEVACIZUMAB TREATMENT
Begin Date (if patient failed to start, code=00 00
0000)
End Date (if patient failed to start, code=00 00
0000)
Total Number of Doses Received (enter "0" if
never started)
Treatment Discontinued Type (select primary
reason)
Alternative Therapy (Alternative Therapy)
Alternative Therapy (Alternative Therapy)
Completed Per Protocol (Completed per
protocol)
Treatment Completed Per Protocol
1 / 3
Criteria (Completed per protocol)
Death, Recurrence, Or Second Primary
Cancer (Death, recurrence, or second
primary cancer)
Death, Recurrence, Or Second Primary
Cancer (Death, recurrence, or second
primary cancer)
Other Adverse Event/side
Effects/complications (Other Adverse
Event/Side Effects/Complications)
Other (Other reason, specify)
Other, Specify (Other, specify)
Patient Withdrawal Or Refusal (Patient
withdrawal or refusal)
Patient Withdrawal Or Refusal (Patient
withdrawal or refusal)
Physician Withdrawal (Physician
withdrawal)
Physician Withdrawal (Physician
withdrawal)
Protocol Mandated Discontinuation
(Protocol Mandated Discontinuation)
Adverse Event/side Effects/complications
(Toxicity/Side effects)
Other reason, specify
Adverse events which require discontinuation of
bevacizumab
Grade 1, 2, 3, Or 4 Gi Perforation, Gi
Leak, Or Gi Fistula (Grade 1, 2, 3, or 4
GI perforation, GI leak, or GI fistula)
Grade 2, 3, Or 4 Cardiac
Ischemia/infarction (Grade 2, 3, or 4
Cardiac ischemia/infarction)
Grade 2, 3, Or 4 Cns Cerebrovascular
Ischemia (Grade 2, 3, or 4 CNS
cerebrovascular ischemia)
Grade 2, 3, Or 4 Visceral Or Peripheral
Arterial Ischemia (Grade 2, 3, or 4
Visceral or peripheral arterial ischemia)
Grade 2, 3, Or 4 Wound Complication,
Non-infectious (Grade 2, 3, or 4 Wound
complication, non-infectious)
Grade 3 Or 4 Hemorrhage (Grade 3 or 4
Hemorrhage)
Grade 4 Acute Infusion Reaction Or
Allergic Reaction/hypersensitivity (Grade
4 Acute infusion reaction or Allergic
reaction/hypersensitivity)
Grade 4 Hypertension (Grade 4
Hypertension)
Grade 4 Intra-abdominal
Abscess/infection (Grade 4 Intra-
abdominal abscess/Infection)
Grade 4 Proteinuria (Grade 4
Proteinuria)
Grade 4 Thrombosis/thrombus/embolism
(Grade 4
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NCT00096278
Thrombosis/Thrombus/Embolism)
Other Clinically Significant Grade 4 Ae
Related To Bevacizumab (Other clinically
significant Grade 4 AE related to
Bevacizumab)
Comments
Comments
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ECOG Non-Protocol Therapy Form No.
1676 NCT00110019
ECOG Non-Protocol Therapy Form No. 1676
NCT00110019
Carboplatin and Paclitaxel With or Without Sorafenib in
Treating Patients With Unresectable Stage III or Stage IV
Melanoma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=E7EC4891-
0058-0F53-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11039
ECOG Non-Protocol Therapy Form
No. 1676 NCT00110019
ECOG clinical trial administrative data
ECOG Protocol Number
ECOG Patient ID
DCI Name
Registration Step
Time period
Non-protocol Therapy (Non-Protocol
Therapy)
Patient Initials
Participating Group Protocol Number
Institution/Affiliate
Participating Group Patient ID
Data amendment
Please mark an 'X' if data have been amended.
Date data amended
Non-Protocol Therapy
Date of FIRST non-protocol therapy (if given prior
to progression/relapse from protocol therapy)
Non-protocol Chemotherapy
No (No)
Unknown (Unknown)
Yes (Yes)
Non-protocol Hormonal Therapy
1 / 2
No (No)
Unknown (Unknown)
Yes (Yes)
Non-protocol Immunotherapy (Biological
Response Modifiers)
No (No)
Unknown (Unknown)
Yes (Yes)
Non-protocol High Dose Chemotherapy/Stem
Cell Transplant (Autologous or Allogeneic)
No (No)
Unknown (Unknown)
Yes (Yes)
Non-protocol Surgery
No (No)
Unknown (Unknown)
Yes (Yes)
Non-protocol surgery type
Non-protocol Radiation Therapy
No (No)
Unknown (Unknown)
Yes (Yes)
Non-protocol RT type
Other Non-protocol Therapy
No (No)
Unknown (Unknown)
Yes (Yes)
Name of other non-protocol therapy
Was the non-protocol therapy given for the
disease of this protocol (NOTE: Treatment for a
second primary in the same organ site would not
be considered therapy for disease of this
protocol.)
No (No)
Unknown (Unknown)
Yes (Yes)
Comments
Comments
Investigator Signature
Investigator Signature Date
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E4A08 Off-Treatment Form NCT01078454
E4A08 Off-Treatment Form NCT01078454 
Melphalan and Dexamethasone With or Without
Bortezomib in Treating Patients With Previously Untreated
Systemic Light-Chain Amyloidosis
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=7BCCF644-
B39C-7CED-E040-BB89AD433815
All rights reserved. Please visit https://medical-data-
models.org/forms/11040
E4A08 Off-Treatment Form
NCT01078454
Header
ECOG Protocol Number
ECOG Patient ID
DCI Name
Registration Step
Reporting Period
End Of Treatment (End of treatment)
Patient Initials (Last, First)
Participating Group Protocol Number
Institution/Affiliate
Participating Group Patient ID
Data amendment
Please mark an 'X' if data have been amended.
(Please circle amended items in red)
Date data amended (s - mm/dd/yyyy)
Vital Status
Patient Vital Status
Alive (Alive)
Dead (Dead)
Date of Last Contact or Death (mm/dd/yyyy)
Primary Cause of Death (if applicable)
Due To Other Cause (Due to other
1 / 3
cause)
Due To Protocol Treatment (Due to
protocol treatment)
Due To This Disease (Due to this
disease)
Unknown (Unknown)
Describe cause of death
Protocol treatment
Did patient receive protocol therapy (this step)
Yes
No
Section I
Reason Treatment Ended (this step)
Adverse Event/side Effects/complications
(Adverse Event/Side
Effects/Complications)
Alternative Therapy (Alternative therapy)
Death On Study (Death on study)
Disease Progression, Relapse During
Active Treatment (Disease progression,
relapse during active treatment)
Other (Other)
Patient Off-treatment For Other
Complicating Disease (Patient off-
treatment for other complicating disease)
Patient Withdrawal Or Refusal After
Beginning Protocol Therapy (Patient
withdrawal/refusal after beginning
protocol therapy)
Treatment Completed Per Protocol
Criteria (Treatment completed per
protocol criteria)
Other Complicating Disease specify (specify)
Other specify
Last date protocol therapy was given
(mm/dd/yyyy)
Section II
Reason treatment never started
Adverse Event/side Effects/complications
(Adverse events/side
effects/complications)
Death Before Beginning Protocol
Therapy (Death before beginning
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protocol therapy)
Disease Progression, Relapse Prior To
Beginning Protocol Therapy (Disease
progression, relapse before protocol
treatment)
Medical Decision (Medical decision)
No Treatment, Per Protocol Criteria (No
treatment assigned per protocol)
Other (Other)
Patient_ineligible (Patient ineligible)
Patient Withdrawal/refusal Before
Beginning Protocol Therapy (Patient
withdrawal/refusal before beginning
protocol therapy)
Comments
Investigator Signature
Investigator Signature Date
Comments
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E3A06 Multiple Myeloma On-Study Form
NCT01169337
E3A06 Multiple Myeloma On-Study Form NCT01169337 
Lenalidomide or Observation in Treating Patients With
Asymptomatic High-Risk Smoldering Multiple Myeloma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=86CCB2A8-
771D-F281-E040-BB89AD432A9E
All rights reserved. Please visit https://medical-data-
models.org/forms/11041
E3A06 Multiple Myeloma On-Study
Form NCT01169337
Header
DCI Name
Registration Step
Report Period (Place ID Label Here)
Baseline (Baseline)
Patient Initials (Last, First)
ECOG Protocol Number
ECOG Protocol Number
ECOG Patient ID
ECOG Patient ID
Participating Group Protocol Number
Participating Group Patient ID
Institution/Affiliate
Data amendment
Please mark an 'X' if data have been amended.
Date data amended
Disease Description - Initial Diagnosis
Date of Initial Pathologic Diagnosis
1 / 3
Current Clinical Date
Performance Status
Fully Active, Able To Carry On All Pre-
disease Performance Without
Restriction. (0)
Restricted In Physically Strenuous
Activity But Ambulatory And Able To
Carry Out Work Of A Light Or Sedentary
Nature, E.g., Light Housework, Office
Work. (1)
Ambulatory And Capable Of All Selfcare
But Unable To Carry Out Any Work
Activities. Up And About More Than 50%
Of Waking Hours. (2)
Capable Of Only Limited Selfcare,
Confined To Bed Or Chair More Than
50% Of Waking Hours. (3)
Completely Disabled. Cannot Carry On
Any Selfcare. Totally Confined To Bed Or
Chair. (4)
Height (cm)
Bone Pain (on entry of study)
Mild Requires Only Non-narcotic
Medication (mild, requires use of non-
narcotic pain relief)
None (none)
Requires Occasional Narcotics (requires
occasional narcotics)
Requires Parenteral Narcotics Or Patch
(requires parenteral narcotics, or patch)
Requires Per Os Narcotics (requires per
os narcotics)
Uncontrollable Pain (uncontrollable pain)
Unknown (unknown)
Is severe osteoporosis present? (unrelated to
myeloma)
No (no)
Unknown (unknown)
Yes (yes)
Has the patient received bisphosphonates (for
osteoporosis )
Yes
No
Is the patient on anticoagulant therapy (ONLY for
deep vein thrombosis)
Yes
No
Baseline Abnormalities
CTC Adverse Event Term (Use CTCAE v4.0
terminology)
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Fatigue (Fatigue)
CTC Adverse Event Grade (v4.0 Use grade 1-4
per CTCAE)
Mild Adverse Event (1)
Moderate Adverse Event (2)
Severe Adverse Event (3)
Life Threatening Adverse Event (4)
Comments
Investigator Signature
Investigator Signature Date
Comments
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E1805 Second Primary Form
E1805 Second Primary Form
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=0F345290-
C780-6CB1-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11042
E1805 Second Primary Form
ECOG clinical trial administrative data
ECOG Protocol Number (If patient has been on
other therapeutic ECOG protocols, please list
protocols and patient ID numbers.)
ECOG Patient ID
DCI Name
Registration Step
Reporting Period
Second Primary Cancer (Second
Primary)
Patient Initials (Last, First)
Participating Group Protocol Number
Participating Group Patient ID
Institution/Affiliate
Data amendment
Please mark an 'X' if data have been amended.
(Please circle amended items in red)
Date data amended (MM/DD/YYYY)
Second primary cancer assessment
Date of Diagnosis of Second Primary Cancer
(MM/DD/YYYY)
Site of Second Primary Cancer
Include information on histologic subtype (s)
Briefly describe cancer therapy the patient has
received prior to the diagnosis of the second
1 / 2
primary and other than that given on ECOG
protocols
Briefly describe treatment planned or given for
the diagnosis of this second primary
Comments
Investigator Signature
Investigator Signature Date
Comments
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E1805 Second Primary Form
ECOG Baseline Disease Evaluation Form
(RECIST) NCT00309985
ECOG Baseline Disease Evaluation Form  (RECIST)
NCT00309985
Androgen Ablation Therapy With or Without Chemotherapy
in Treating Patients With Metastatic Prostate Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=F97FF9CE-
5363-2533-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11043
ECOG Baseline Disease Evaluation
Form  (RECIST) NCT00309985
Header
ECOG Protocol Number
ECOG Patient ID
DCI Name
Registration Step
Reporting Period
Baseline (Baseline)
Data amendment
Please mark an 'X' if data have been amended.
Date data amended
Patient demographics
ECOG Protocol Number
ECOG Patient ID
Patient Initials
Participating Group Protocol Number
Institution/Affiliate
Participating Group Patient ID
TARGET LESIONS
Are there any target lesions
1 / 3
Yes
No
Lesion Number
Site of Lesion (Comments - Multiple nontarget
lesions within an organ may be combined as a
single site; report in a consistent manner on
subsequent forms.)
Site Code
Bone (bone)
Brain (Brain)
Breast (Breast)
Effusion/ascites (Effusion/Ascites)
Gi (GI)
Gu (GU)
Head & Neck (Head & Neck)
Liver (Liver)
Lung (Lung)
Nodes (Nodes)
Other (other)
Skin (Skin)
Method of Evaluation
Bone Scan (Bone scan)
Chest X-ray (Chest X-Ray)
Clinical (Clinical Examination)
Ct Scan (CT Scan)
Mri (MRI)
Other (other)
Spiral Ct Scan (Spiral CT scan)
Ultrasound (Ultrasound)
Date of Evaluation
Longest Diameter of Lesion
Sum of longest diameters of all target lesions
Nontarget Lesions
Lesion Number
Site of Lesion (Comments - Multiple nontarget
lesions within an organ may be combined as a
single site; report in a consistent manner on
subsequent forms.)
Site Code
Bone (bone)
Brain (Brain)
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Breast (Breast)
Effusion/ascites (Effusion/Ascites)
Gi (GI)
Gu (GU)
Head & Neck (Head & Neck)
Liver (Liver)
Lung (Lung)
Nodes (Nodes)
Other (other)
Skin (Skin)
Method of Evaluation
Bone Scan (Bone scan)
Chest X-ray (Chest X-Ray)
Clinical (Clinical Examination)
Ct Scan (CT Scan)
Mri (MRI)
Other (other)
Spiral Ct Scan (Spiral CT scan)
Ultrasound (Ultrasound)
Date of Evaluation
Cytology Result
Negative (Negative)
Not Done (Not done)
Positive (Positive)
Comments
Comments
Investigator Signature
Investigator Signature Date
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CALGB: 90401 PRE-STUDY FORM
NCT00110214
CALGB: 90401 PRE-STUDY FORM NCT00110214
Docetaxel and Prednisone With or Without Bevacizumab in
Treating Patients With Prostate Cancer That Did Not
Respond to Hormone Therapy
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=EF49FDF3-
32C2-58F5-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11044
CALGB: 90401 PRE-STUDY FORM
NCT00110214
Header
CALGB Form (C-1390)
CALGB Study No. (90401)
CALGB Patient ID
Are data amended
Yes
No
Patient demographics
Patient Initials (Last, First, Middle)
Patient Hospital No
Institution/Affiliate
Participating Group
Participating Group Study No.
Participating Group Patient ID
Significant Medical History, Concomitant
Diseases
Myocardial infarction (1 If multiple events, record
date of most recent here, and the earlier ones in
C-260 Remarks Addenda form.)
No (No)
Unknown (Unknown)
Yes (Yes)
Date of myocardial infarction (CRF says "Date of
event" MM DD YYYY)
Coronary artery by-pass graft (CABG)
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No (No)
Unknown (Unknown)
Yes (Yes)
Date of CABG (CRF says "Date of event" MM DD
YYYY)
Cardiac stent/angioplasty
No (No)
Unknown (Unknown)
Yes (Yes)
Date of cardiac stent/ angioplasty (CRF says
"Date of event" MM DD YYYY)
Angina pectoris
No (No)
Unknown (Unknown)
Yes (Yes)
Coronary Artery Disease (heart disease)
No (No)
Unknown (Unknown)
Yes (Yes)
Congestive heart failure
No (No)
Unknown (Unknown)
Yes (Yes)
Hypertension
No (No)
Unknown (Unknown)
Yes (Yes)
Peripheral Vascular Disease
No (No)
Unknown (Unknown)
Yes (Yes)
Arterial thrombosis
No (No)
Unknown (Unknown)
Yes (Yes)
Venous thrombosis
No (No)
Unknown (Unknown)
Yes (Yes)
Transient ischemic disease
No (No)
Unknown (Unknown)
Yes (Yes)
Cerebrovascular accident (including stroke)
No (No)
Unknown (Unknown)
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Yes (Yes)
Subarachnoid hemorrhage
No (No)
Unknown (Unknown)
Yes (Yes)
Dementia
No (No)
Unknown (Unknown)
Yes (Yes)
Chronic pulmonary disease
No (No)
Unknown (Unknown)
Yes (Yes)
Connective tissue disease
No (No)
Unknown (Unknown)
Yes (Yes)
Arthritis
No (No)
Unknown (Unknown)
Yes (Yes)
Peptic ulcer disease
No (No)
Unknown (Unknown)
Yes (Yes)
Mild liver disease
No (No)
Unknown (Unknown)
Yes (Yes)
Diabetes (without complications)
No (No)
Unknown (Unknown)
Yes (Yes)
Diabetes with end organ disease
No (No)
Unknown (Unknown)
Yes (Yes)
Hemiplegia
No (No)
Unknown (Unknown)
Yes (Yes)
AIDS
No (No)
Unknown (Unknown)
Yes (Yes)
Renal Disease
No (NO)
Unknown (UNKNOWN)
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Yes (YES)
Prior Therapy
Prior chemotherapy?
Yes
No
Current bisphosphonate therapy?
Yes
No
specify date started (If Yes,)
Prior surgery for prostate cancer? (Mark all that
apply with an X.)
Pelvic Lymphadenectomy (Pelvic
lymphadenectomy)
Prostate Biopsy (Prostate biopsy)
Prostatectomy (Prostatectomy)
Transurethral Resection Of The Prostate
(Transurethral resection of the prostate)
Radical prostatectomy, specify date completed
(mm dd yyyy)
Pelvic lymphadenectomy, specify date completed
(mm dd yyyy)
Prior radiation therapy? (Mark all that apply with
an X.)
No Prior Radiation Therapy (No prior
radiation therapy)
Palliative Radiotherapy (Palliative
radiotherapy)
Prostate Bed External Beam Radiation
Therapy After Radical Prostatectomy
(Prostate bed external beam radiation
therapy after radical prostatectomy)
Prostate External Beam Radiation
Therapy (Prostate external beam
radiation therapy)
Prostate Implants (Prostate implants)
Radioisotope Therapy (Radioisotope
therapy)
Total dose administered (cGy)
Radiation therapy start date (mm dd yyyy)
Radiation therapy end date (mm dd yyyy)
Neoadjuvant hormonal therapy prior to surgery?
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(prostatectomy)
Yes
No
Neoadjuvant hormonal therapy prior to radiation?
(for prostate cancer)
Yes
No
Neoadjuvant hormonal therapy start date (mm dd
yyyy)
Neoadjuvant hormonal therapy end date (mm dd
yyyy)
Adjuvant hormonal therapy after surgery?
(prostatectomy)
Yes
No
Adjuvant hormonal therapy after radiation? (for
prostate cancer)
Yes
No
Adjuvant hormonal therapy start date (MM DD
YYYY)
Adjuvant hormonal therapy end date (MM DD
YYYY)
Current type of gonadal suppression (Mark all
that apply with an X.)
Lhrh Agonist (LHRH agonist)
Orchiectomy (Orchiectomy)
Date of orchiectomy (specify MM DD YYYY)
LHRH agonist start date (MM DD YYYY)
LHRH agonist end date (MM DD YYYY)
LHRH agonist treatment type (Mark one with an
X.)
Continuous (Continuous)
Intermittent (Intermittent)
Hormonal Agent (For each hormonal agent listed
below, record whether the agent was
administered 0=not taken; 1=initial; 2=second
line; 3=third line; 99=other reason. If
administered, record agent start and end dates.)
Aminoglutethimide (Aminoglutethimide)
Bicalutamide (Bicalutamide)
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Finasteride (Finasteride)
Flutamide (Flutamide)
Ketoconazole (Ketoconazole)
Megestrol Acetate (Megestrol acetate)
Nilutamide (Nilutamide)
Other (Other)
Other specify
Agent administered status (For each hormonal
agent listed below, record whether the agent was
administered 0=not taken; 1=initial; 2=second
line; 3=third line; 99=other reason.)
Initial (initial)
Not Taken (not taken)
Other (Other reason)
Second Line (second line)
Third Line (third line)
Agent start date (mm/dd/yyyy)
Agent end date (mm/dd/yyyy)
Any other prior therapy?
Yes
No
Other Prior Regimen Name
Other prior therapy start date (MM DD YYYY)
Other prior therapy end date (MM DD YYYY)
Background Information
What is the highest grade you finished in school?
(Mark one with an X.)
1-8 Grades (1-8 grades)
9-11 Grades (9-11 grades)
Advanced Degree (Advanced degree)
College Degree (b.a./b.s.) (College
degree)
High School Graduate (High School
graduate)
Junior College Degree (Junior college
degree)
Some College (Some college)
Some Post-college Work (Some post-
college work)
What is your marital status? (Mark one with an
X.)
Divorced (Divorced)
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Married (Married)
Separated (Separated)
Single, Never Married (Single, never
married)
Widowed (Widowed)
What is your current employment status? (Mark
one with an X.)
Disabled (Disabled)
Employed 32 Hours Or More Per Week
(Employed 32 hours or more per week)
Employed Less Than 32 Hours Per
(Employed less than 32 hours per week)
Full-time Student (Full-time student)
Homemaker (Homemaker)
On Medical Leave (On medical leave)
Other (Other)
Part-time Student (Part-time student)
Retired (Retired)
Unemployed (Unemployed)
Other, specify
Completed by (Last name, First name)
Date form completed (mm dd yyyy)
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ECOG E3805 Non-Protocol Therapy Form
NCT00309985
ECOG E3805 Non-Protocol Therapy Form NCT00309985
Androgen Ablation Therapy With or Without Chemotherapy
in Treating Patients With Metastatic Prostate Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=F96D3B5A-
17EF-3C77-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11045
ECOG E3805 Non-Protocol Therapy
Form NCT00309985
Header
ECOG Protocol Number
ECOG Patient ID
DCI Name
Registration Step
Reporting Period
Non-protocol Therapy (Non-Protocol
Therapy)
Patient demographics
ECOG Protocol Number
Patient Initials
ECOG Patient ID
Participating Group Protocol Number
Institution/Affiliate
Participating Group Patient ID
Data amendment
Please mark an 'X' if data have been amended.
Date data amended
Non-Protocol Therapy
Date of FIRST non-protocol therapy (if given prior
1 / 3
to progression/relapse from protocol therapy)
Non-protocol Chemotherapy
No (No)
Unknown (Unknown)
Yes (Yes)
Non-protocol Hormonal Therapy
No (No)
Unknown (Unknown)
Yes (Yes)
Non-protocol Immunotherapy (Biological
Response Modifiers)
No (No)
Unknown (Unknown)
Yes (Yes)
Non-protocol High Dose Chemotherapy/Stem
Cell Transplant (Autologous or Allogeneic)
No (No)
Unknown (Unknown)
Yes (Yes)
Non-protocol Surgery
No (No)
Unknown (Unknown)
Yes (Yes)
Non-protocol surgery type
Non-protocol Radiation Therapy
No (No)
Unknown (Unknown)
Yes (Yes)
Non-protocol RT type
Other Non-protocol Therapy
No (No)
Unknown (Unknown)
Yes (Yes)
Name of other non-protocol therapy
Was the non-protocol therapy given for the
disease of this protocol (NOTE: Treatment for a
second primary in the same organ site would not
be considered therapy for disease of this
protocol.)
No (No)
Unknown (Unknown)
Yes (Yes)
Comments
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Comments
Investigator Signature
Investigator Signature Date
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ECOG Follow-Up Disease Evaluation Form
(RECIST) NCT00309985
ECOG Follow-Up Disease Evaluation Form  (RECIST)
NCT00309985
Androgen Ablation Therapy With or Without Chemotherapy
in Treating Patients With Metastatic Prostate Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=F9FAC2E9-
6EE0-1CD5-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11046
ECOG Follow-Up Disease Evaluation
Form  (RECIST) NCT00309985
Header
ECOG Protocol Number
ECOG Patient ID
DCI Name
Registration Step
Patient demographics
ECOG Protocol Number
ECOG Patient ID
Patient Initials
Participating Group Protocol Number
Institution/Affiliate
Participating Group Patient ID
Data amendment
Please mark an 'X' if data have been amended.
Date data amended
Report Periods
Reporting Period
At Hormone Refractory (At hormone
refractory)
1 / 5
Were disease assessment results obtained this
report period?
Yes
No
TARGET LESIONS
Lesion Number
Site of Lesion
Site Code
Bone (Bone)
Brain (Brain)
Breast (Breast)
Effusion/ascites (Effusion/Ascites)
Gi (GI)
Gu (GU)
Head & Neck (Head & Neck)
Liver (Liver)
Lung (Lung)
Nodes (Nodes)
Other (Other)
Skin (Skin)
Method of Evaluation
Bone Scan (Bone scan)
Chest X-ray (Chest x-ray)
Clinical Examination (pe) (Clinical
examination)
Ct Scan (CT scan)
Mri (MRI (NMR))
Not Evaluated (Not evaluated)
Other (Other)
Spiral Ct Scan (Spiral CT scan)
Ultrasound (Ultrasound)
Date of Evaluation
Longest Diameter of Lesion
Baseline Lesion Tumor Diameter Measurement
Sum of longest diameters of all target lesions
Nontarget Lesions
Lesion Number
Site of Lesion
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Site Code
Bone (Bone)
Brain (Brain)
Breast (Breast)
Effusion/ascites (Effusion/Ascites)
Gi (GI)
Gu (GU)
Head & Neck (Head & Neck)
Liver (Liver)
Lung (Lung)
Nodes (Nodes)
Other (Other)
Skin (Skin)
Method of Evaluation
Bone Scan (Bone scan)
Chest X-ray (Chest x-ray)
Clinical Examination (pe) (Clinical
examination)
Ct Scan (CT scan)
Mri (MRI (NMR))
Not Evaluated (Not evaluated)
Other (Other)
Spiral Ct Scan (Spiral CT scan)
Ultrasound (Ultrasound)
Date of Evaluation
Cytology Result
Negative (Negative)
Not Done (Not done)
Positive (Positive)
New Lesions
Lesion Number
Site of Lesion
Site Code
Bone (Bone)
Brain (Brain)
Breast (Breast)
Effusion/ascites (Effusion/Ascites)
Gi (GI)
Gu (GU)
Head & Neck (Head & Neck)
Liver (Liver)
Lung (Lung)
Nodes (Nodes)
Other (Other)
Skin (Skin)
Method of Evaluation
Bone Scan (Bone scan)
Chest X-ray (Chest x-ray)
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Clinical Examination (pe) (Clinical
examination)
Ct Scan (CT scan)
Mri (MRI (NMR))
Not Evaluated (Not evaluated)
Other (Other)
Spiral Ct Scan (Spiral CT scan)
Ultrasound (Ultrasound)
Date of Evaluation
Cytology Result
Negative (Negative)
Not Done (Not done)
Positive (Positive)
Response Of Target Lesions This
Reporting Period
Has the response of the target lesions changed,
OR has an unconfirmed response changed to a
confirmed response, since last report
Yes
No
Response Status at This Assessment
Complete Response (CR)
Insufficient Evaluation (Insufficient
evaluation to determine response status)
Progressive Disease (PD)
Partial Response (PR)
Stable Disease (SD)
PR/CR First Observed Date
Progressive Disease (PD) Observed Date
Overall Response Per Recist Criteria -
Target, Nontarget And New Lesions
Has the overall response changed, OR has an
unconfirmed response changed to a confirmed
response, since last report
Yes
No
Overall Response Status at This Assessment
Complete Response (CR)
Insufficient Evaluation (Insufficient
evaluation to determine response status)
Progressive Disease (PD)
Partial Response (PR)
Stable Disease (SD)
PR/CR First Observed Date
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Progressive Disease (PD) Observed Date
Has response been confirmed by second
assessment?
Yes
No
Symptomatic Deterioration
Is there Symptomatic Deterioration of the
patient's health status requiring discontinuation of
treatment?
Yes
No
Symptomatic Deterioration Specify
Symptomatic Deterioration Date
Comments
Comments
Investigator Signature
Investigator Signature Date
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E1805 On-Study Form
E1805 On-Study Form
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=0F2A22D3-
D6F2-3C2D-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11047
E1805 On-Study Form
Header
ECOG Protocol Number
ECOG Patient ID
DCI Name
Registration Step
Reporting Period
Baseline (Baseline)
Patient demographics
Patient Initials (Last, First)
Participating Group Protocol Number
Participating Group Patient ID
Institution/Affiliate
ECOG Performance Status
Fully Active, Able To Carry On All Pre-
disease Performance Without
Restriction. (0)
Restricted In Physically Strenuous
Activity But Ambulatory And Able To
Carry Out Work Of A Light Or Sedentary
Nature, E.g., Light Housework, Office
Work. (1)
Ambulatory And Capable Of All Selfcare
But Unable To Carry Out Any Work
Activities. Up And About More Than 50%
Of Waking Hours. (2)
Capable Of Only Limited Selfcare,
Confined To Bed Or Chair More Than
50% Of Waking Hours. (3)
Completely Disabled. Cannot Carry On
Any Selfcare. Totally Confined To Bed Or
Chair. (4)
Data amendment
Please mark an 'X' if data have been amended.
1 / 5
(Please circle amended items in red)
Date data amended (s - MM/DD/YYYY)
Description Of Primary Disease
Date of Initial Diagnosis of Primary Tumor
(MM/DD/YYYY)
Pathologic T Stage
Organ Confined (pT2)
Unilateral (pT2a)
Bilateral (pT2b)
Extraprostatic Extension (pT3)
Extraprostatic Extension (pT3a)
Seminal Vesicle Invasion (pT3b)
Invasion Of Bladder, Rectum (pT4)
Mark an 'X' if unknown
Pathologic N Stage
No Regional Lymph Node Metastasis
(N0)
Metastatis In Regional Lymph Node Or
Nodes (see Ajcc Definition) (N1)
Regional Lymph Nodes Cannot Be
Assessed (NX)
Pathologic M Stage
No Distant Metastasis (M0)
Distant Metastasis (M1)
Nonregional Lymph Node(s) (M1a)
Bone(s) (M1b)
Other Site(s) With Or Without Bone
Disease (M1c)
Distant Metastasis Cannot Be Assessed
(not Evaluated By Any Modality) (MX)
Clinical T Stage
No Evidence Of Primary Tumor (T0)
Clinically Inapparent Tumor Not Palpable
Nor Visible By Imaging (T1)
Tumor Incidental Histologic Finding In
5% Or Less Of Tissue Resected (T1a)
Tumor Incidental Histologic Finding In
More Than 5% Of Tissue Resected
(T1b)
Tumor Identified By Needle Biopsy (eg,
Because Of Elevated Psa) (T1c)
Tumor Confined Within The Prostate (T2)
Tumor Involves One Lobe (T2a)
Tumor Involves Both Lobes (T2b)
Tumor Extends Through The Prostate
Capule (T3)
Extracapsular Extension (unilateral Or
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Bilateral) (T3a)
Tumor Invades Seminal Vesicle(s) (T3b)
Tumor Is Fixed Or Invades Adjacent
Structures Other Than Seminal Vesicles:
Bladder Neck, External Sphincter, Or
Rectum, Levator Muscles, And/or Pelvic
Wall (T4)
Primary Tumor Cannot Be Assessed
(TX)
Clinical N Stage
No Regional Lymph Node Metastasis
(N0)
Metastatis In Regional Lymph Node Or
Nodes (see Ajcc Definition) (N1)
Regional Lymph Nodes Cannot Be
Assessed (NX)
Clinical M Stage
No Distant Metastasis (M0)
Distant Metastasis (M1)
Nonregional Lymph Node(s) (M1a)
Bone(s) (M1b)
Other Site(s) (M1c)
Distant Metastasis Cannot Be Assessed
(MX)
Gleason Score, Primary Pattern (01-105, -1 =
unknown - The most frequent pattern gleason
grade among all available specimens.)
Gleason Score, Secondary Pattern (01-105, -1 =
unknown - The second most frequent pattern
gleason grade among all available specimens.)
Radiographic Evidence
Radiographic evidence of pathologically enlarged
pelvic nodes
Yes
No
Radiographic evidence of pathologically enlarged
retroperitoneal lymph nodes
Yes
No
Androgen Deprivation
Baseline PSA Value (ng/ml)
Date of PSA Assessment (MM/DD/YYYY)
Prior Treatment
3 / 5
E1805 On-Study Form
Chemotherapy
Yes
No
Specify agent (s)
Date Prior Chemotherapy Ended (MM/DD/YYYY)
Radiation Therapy
Yes
No
Specify Site (If yes:)
Date Prior RT Ended (MM/DD/YYYY)
Prior Immunotherapy
Yes
No
Date Prior Immunotherapy Ended (If yes: -
MM/DD/YYYY)
Hormonal therapy
Yes
No
Date Prior hormonal therapy Ended
(MM/DD/YYYY)
Bisphosphonates
Yes
No
Bisphosphonates continuing
Yes
No
Gene Therapy
Yes
No
Prostatectomy
Yes
No
Other Prior Therapy
Yes
No
Name of other prior therapy (If yes,)
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Comments
Investigator Signature
Investigator Signature Date
Comments
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ECOG E3805 Second Primary Form
NCT00309985
ECOG-E3805 Second Primary Form NCT00309985
Androgen Ablation Therapy With or Without Chemotherapy
in Treating Patients With Metastatic Prostate Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=F96D3B5A-
1922-3C77-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11048
ECOG E3805 Second Primary Form
NCT00309985
Header
ECOG Protocol Number
DCI Name
Registration Step
Reporting Period
Second Primary Cancer (Second
Primary)
Patient demographics
ECOG Protocol Number
Patient Initials
Participating Group Protocol Number
Institution/Affiliate
Participating Group Patient ID
Data amendment
Please mark an 'X' if data have been amended.
Date data amended
Second primary cancer assessment
Date of Diagnosis of Second Primary Cancer
ECOG Protocol Number
Site of Second Primary Cancer
1 / 2
Include information on histologic subtype (s)
Briefly describe cancer therapy the patient has
received prior to the diagnosis of the second
primary and other than that given on ECOG
protocols
Briefly describe treatment planned or given for
the diagnosis of this second primary
Comments
Comments
Investigator Signature
Investigator Signature Date
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E1805 Non-Protocol Therapy Form
E1805 Non-Protocol Therapy Form
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=0F344F0F-
C203-6C20-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11049
E1805 Non-Protocol Therapy Form
Header
ECOG Protocol Number
DCI Name
Registration Step
Reporting Period
Non-protocol Therapy (Non-Protocol
Therapy)
Patient demographics
Patient Initials (Last, First)
ECOG Protocol Number
Participating Group Protocol Number
Participating Group Patient ID
Institution/Affiliate
Data amendment
Please mark an 'X' if data have been amended.
(Please circle amended items in red)
Date data amended (MM/DD/YYYY)
Non-Protocol Therapy
Date of FIRST non-protocol therapy (if given prior
to progression/relapse from protocol therapy)
Non-protocol Chemotherapy (Types of first non-
protocol therapy - which includes any cancer
therapy that is not part of the planned regimen.)
No (No)
Unknown (Unknown)
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Yes (Yes)
Non-protocol Hormonal Therapy
No (No)
Unknown (Unknown)
Yes (Yes)
Non-protocol Immunotherapy (Biological
Response Modifiers)
No (No)
Unknown (Unknown)
Yes (Yes)
Non-protocol High Dose Chemotherapy/Stem
Cell Transplant (Autologous or Allogeneic)
No (No)
Unknown (Unknown)
Yes (Yes)
Non-protocol Surgery
No (No)
Unknown (Unknown)
Yes (Yes)
Non-protocol surgery type
Non-protocol Radiation Therapy
No (No)
Unknown (Unknown)
Yes (Yes)
Non-protocol RT type
Other Non-protocol Therapy
No (No)
Unknown (Unknown)
Yes (Yes)
Name of other non-protocol therapy
Was the non-protocol therapy given for the
disease of this protocol (NOTE: Treatment for a
second primary in the same organ site would not
be considered therapy for disease of this
protocol.)
No (No)
Unknown (Unknown)
Yes (Yes)
Comments
Investigator Signature
Investigator Signature Date
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E3805 Hormone Refractory Disease Form
E3805 Hormone Refractory Disease Form
Androgen Ablation Therapy With or Without Chemotherapy
in Treating Patients With Metastatic Prostate Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=F97FF9CE-
553B-2533-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11050
E3805 Hormone Refractory Disease
Form
Header
ECOG Protocol Number
DCI Name
Registration Step
Reporting Period (Select one)
Hormone Refractory Disease (Hormone
refractory disease)
Patient demographics
ECOG Protocol Number
Patient Initials
Participating Group Protocol Number
Institution/Affiliate
Participating Group Patient ID
Data amendment
Please mark an 'X' if data have been amended.
Date data amended
Diagnosis Of Hormone Refractory
Disease
Increasing PSA level per protocol (Note: Two
consecutive increases must be documented with
each measurement obtained at least 2 weeks
apart)
Yes
No
1 / 2
Date of first PSA progression
Radiographic Progression per RECIST criteria
Yes
No
Date of First Clinical Progression
Testosterone level at progression (ng/dl)
Testosterone level at progression (ng/dl)
Mark an 'X' if not assessed
Mark an 'X' if not assessed
New lesions (If yes, Basis of progression per
RECIST please answer yes or no for each of the
following 1=no, 2=yes)
Yes
No
Progression in existing measurable sites
Yes
No
Progression in existing non-measurable sites
(including bone)
Yes
No
Other
Yes
No
Other, specify
Comments
Comments
Investigator Signature
Investigator Signature Date
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Breast Cancer - PACCT-1 TAILORx Second
Primary Form - Omitted for 1/5/2011 revision
PACCT-1 TAILORx Second Primary Form - Omitted for
1/5/2011 revision
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=0618400D-
589D-7445-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11051
Breast Cancer - PACCT-1 TAILORx
Second Primary Form - Omitted for
1/5/2011 revision
Header
ECOG Protocol Number
ECOG Patient ID
DCI Name
Registration Step
Reporting Period
Second Primary Cancer (Second
primary)
Second primary cancer assessment
Date of Diagnosis of Second Primary Cancer
(mm/dd/yyyy)
Site of Second Primary Cancer
Acute Lymphocytic Leukemia (Acute
Lymphocytic Leukemia (ALL))
Acute Myelogenous Leukemia (Acute
Myelogenous Leukemia (AML))
Adrenal (Adrenal)
Aids-related Lymphoma (AIDS-related
Lymphoma)
Anal Canal (Anal Canal)
Basal Cell Carcinoma (Basal Cell
Carcinoma)
Bladder, Urinary Tract (Bladder, Urinary
Tract)
Brain Tumor (Brain Tumor)
Breast (Breast)
Breast, In Situ (Breast, in situ)
Carcinoid (Carcinoid)
Cervix (Cervix)
Chronic Lymphocytic Leukemia (Chronic
Lymphocytic Leukemia (CLL))
Chronic Myelogenous Leukemia
(Chronic Myelogenous Leukemia (CML))
Colon (Colon)
Endometrium, Uterine Corpus
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(Endometrium, Uterine Corpus)
Esophagus (Esophagus)
Gastric Cancer (Gastric Cancer)
Hairy Cell Leukemia (Hairy Cell
Leukemia)
Head And Neck (Head and Neck)
Hodgkin's Lymphoma (Hodgkin's
Disease)
Islet Cell/carcinoid (Islet Cell/Carcinoid)
Kaposi Sarcoma (Kaposi sarcoma)
Leukemia (Leukemia)
Liver, Gall Bladder, Bile Duct (Liver, Gall
Bladder, Bile Duct)
Lung Cancer (Lung cancer)
Lymphoma (Lymphoma)
Lymphosarcoma (Lymphosarcoma)
Melanoma (Melanoma)
Mesothelioma (Mesothelioma)
Myelodysplastic Syndrome
(Myelodysplastic Syndrome)
Myeloma (Myeloma)
Non-hodgkin's Lymphoma (Non-
Hodgkin's Lymphoma)
Non-small Cell Lung Cancer (Non-Small
Cell Lung Cancer)
Osteosarcoma (Osteosarcoma)
Other (Other)
Other Gyn (Other GYN)
Other Non-melanoma Skin Cancer
(Other non-melanoma skin cancer)
Ovarian (Ovarian)
Pancreas (Pancreas)
Penile (Penile)
Pleural Effusion (Pleural effusion)
Promyelocytic Leukemia (Promyelocytic
Leukemia (APL))
Prostate (Prostate)
Rectum (Rectum)
Renal Cell (Renal Cell)
Sarcoma (Sarcoma)
Small Intestine (Small Intestine)
Small-cell Lung Cancer (Small-Cell Lung
Cancer)
Spinal Cord (Spinal Cord)
Testis, Germ Cell, Seminoma (Testis,
Germ Cell, Seminoma)
Thymoma (Thymoma)
Thyroid (Thyroid)
Waldenstrom's Macroglobulinemia
(Waldenstrom's Macroglobulinemia)
Specify
Include information on histologic subtype (s
Please attach copies of any corroborating
pathology reports.)
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1/5/2011 revision
Comments
Investigator Signature
Investigator Signature Date
Comments
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Breast Cancer - PACCT-1 TAILORx Second Primary Form - Omitted for
1/5/2011 revision
E4A08 Amyloidosis On-Study Form
E4A08 Amyloidosis On-Study Form
Melphalan and Dexamethasone With or Without
Bortezomib in Treating Patients With Previously Untreated
Systemic Light-Chain Amyloidosis
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=7BCC7419-
6688-3B46-E040-BB89AD431B25
All rights reserved. Please visit https://medical-data-
models.org/forms/11052
E4A08 Amyloidosis On-Study Form
Header
DCI Name
Registration Step (1)
Reporting Period
Baseline (Baseline)
Patient Initials (Last, First)
ECOG Protocol Number
ECOG Protocol Number
ECOG Patient ID
ECOG Patient ID
Participating Group Protocol Number
Participating Group Patient ID
Institution/Affiliate
Data amendment
Please mark an 'X' if data have been amended.
(Please circle amended items in red)
Date data amended (s)
Disease Description - Initial Diagnosis
Date of Initial Pathologic Diagnosis
Height (cm)
1 / 3
Blood Pressure, Supine, Systolic
Blood pressure, Supine, Diastolic
Supine, Pulse
Blood Pressure, Standing at 1 minute, Systolic
Blood pressure, Standing at 1 minute, Diastolic
Standing at 1 minute, Pulse
Pre-registration Hematology/chemistry
Creatinine ULN (mg/dl)
Creatinine (mg/dl)
Creatinine Clearance (24 hour ml/min)
eGFR (mL/min per 1.73m^2)
Alkaline Phosphatase ULN (U/L)
Alkaline Phosphatase (U/L)
Date Hematology (Blood) Sample Obtained
Current Clinical Data
Performance Status
Fully Active, Able To Carry On All Pre-
disease Performance Without
Restriction. (0)
Restricted In Physically Strenuous
Activity But Ambulatory And Able To
Carry Out Work Of A Light Or Sedentary
Nature, E.g., Light Housework, Office
Work. (1)
Ambulatory And Capable Of All Selfcare
But Unable To Carry Out Any Work
Activities. Up And About More Than 50%
Of Waking Hours. (2)
Capable Of Only Limited Selfcare,
Confined To Bed Or Chair More Than
50% Of Waking Hours. (3)
Completely Disabled. Cannot Carry On
Any Selfcare. Totally Confined To Bed Or
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Chair. (4)
Leg Swelling
Yes
No
Carpel tunnel
Yes
No
Purpura (skin)
Yes
No
Macroglossia
Yes
No
Weight loss > 10% of body weight
Yes
No
Other
Yes
No
Specify other symptoms
Baseline Abnormalities
CTC Adverse Event Term
Peripheral Motor Neuropathy (Peripheral
motor neuropathy)
Peripheral Sensory Neuropathy
(Peripheral sensory neuropathy)
CTC Adverse Event Grade
Mild Adverse Event (1)
Moderate Adverse Event (2)
Severe Adverse Event (3)
Life Threatening Adverse Event (4)
Comments
Investigator Signature
Investigator Signature Date
Comments
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E1305 On-Study Form NCT00588770
E1305 On-Study Form NCT00588770
Chemotherapy With or Without Bevacizumab in Treating
Patients With Recurrent or Metastatic Head and Neck
Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=1A0A6D56-
A371-47E3-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11053
E1305 On-Study Form
NCT00588770
Header
ECOG Protocol Number
ECOG Patient ID
DCI Name
Registration Step
Reporting Period
Baseline (Baseline)
Patient Initials (Last, First)
Participating Group Protocol Number
Participating Group Patient ID
Institution/Affiliate
Data amendment
Please mark an 'X' if data have been amended
(Please circle amended items in red)
Date data amended (M D Y)
Patient Information
ECOG Performance Status (at study entry)
Fully Active, Able To Carry On All Pre-
disease Performance Without
Restriction. (0)
Restricted In Physically Strenuous
Activity But Ambulatory And Able To
Carry Out Work Of A Light Or Sedentary
Nature, E.g., Light Housework, Office
1 / 8
Work. (1)
Ambulatory And Capable Of All Selfcare
But Unable To Carry Out Any Work
Activities. Up And About More Than 50%
Of Waking Hours. (2)
Capable Of Only Limited Selfcare,
Confined To Bed Or Chair More Than
50% Of Waking Hours. (3)
Completely Disabled. Cannot Carry On
Any Selfcare. Totally Confined To Bed Or
Chair. (4)
Height
Weight Loss in Previous Six Months
<5% Of Body Weight (< 5% of body
weight)
> Or = 20% Of Body Weight (> or = 20%
of body weight)
10 To <20% Of Body Weight (10 -<20%
of body weight)
5 To 10% Of Body Weight (5-10% of
body weight)
Prior Radiation Therapy to head and neck
Yes
No
Date prior RT to head and neck ended (If yes: -
most recent)
Prior Radiation Therapy to other sites
Yes
No
Date prior RT to other sites ended (If yes: - most
recent)
Planned Chemotherapy Regimen
Carboplatin And 5-fluorouracil
(Carboplatin and 5-Fluorouracil)
Carboplatin And Docetaxel (Carboplatin
and Docetaxel)
Cisplatin And 5-fluorouracil (Cisplatin
and 5-Fluorouracil)
Cisplatin And Docetaxel (Cisplatin and
Docetaxel)
Smoking History
Cigarette Smoker <20 Pack-years
(Cigarette smoker, <20 pack-years)
Cigarette Smoker >40 Pack-years
(Cigarette smoker, >40 pack-years)
Cigarette Smoker 20-40 Pack-years
(Cigarette smoker, 20-40 pack-years)
Never Smoked (Never smoked)
Pipe Or Cigar Smoker Only (Pipe or
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cigar smoker only)
Unknown (Unknown)
Does the patient currently smoke
Yes
No
Does the patient currently consume alcohol
Yes
No
Average Alcohol Consumption (NOTE: 1 drink = 1
oz. whiskey = 12 oz. beer)
1 To 10 Drinks Per Week (1 to 10 drinks
per week)
1 To 5 Drinks Per Month (1 to 5 drinks
per month)
11 To 30 Drinks Per Week (11 to 30
drinks per week)
Less Than 1 Drink Per Month (Less than
1 drink per month)
More Than 30 Drinks Per Week (More
than 30 drinks per week)
Unknown (Unknown)
Urine Dipstick Result
1+ (1+)
2+ (2+)
3+ (3+)
4+ (4+)
Negative (Negative)
Trace (Trace)
Mark an 'X' if not done (UPC Ratio)
Date of urine dipstick
Urine Protein/Creatinine Ratio
Date of Urine Protein/Creatinine Ratio
Patient History
Does the patient have a history of
thromboembolic events (arterial)
Yes
No
Specify
Recovery or Latest Date (last known date of
disease activity)
Has the patient suffered cardiovascular disease?
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Yes
No
Myocardial infarction
No (No)
Unknown (Unknown)
Yes (Yes)
Stable Angina
No (No)
Unknown (Unknown)
Yes (Yes)
Unstable angina
No (No)
Unknown (Unknown)
Yes (Yes)
Other
No (No)
Unknown (Unknown)
Yes (Yes)
Specify (If other:)
Hypertension history
Yes
No
Prior Treatment For Disease
Prior Induction or Adjuvant Chemotherapy
Yes
No
Date Chemotherapy Ended (most recent)
Prior systemic therapy (as part of curative
therapy) (Provide an answer for all)
Carboplatin (Carboplatin)
Cetuximab (Cetuximab)
Cisplatin (Cisplatin)
Docetaxel (Docetaxel)
Fluorouracil (Fluorouracil)
Other (Other)
Paclitaxel (Paclitaxel)
Other, specify
Prior Surgery
Yes
No
Date of Most Recent Surgery
4 / 8
E1305 On-Study Form NCT00588770
Head & Neck: Disease Description
Histologic Grade
Cannot Be Assessed (grade X) (Grade
cannot be assessed (Grade X))
Moderately Differentiated (grade Ii)
(Moderately differentiated (Grade II))
Poorly Differentiated (grade Iii) (Poorly
differentiated (Grade III))
Undifferentiated (grade Iv)
(Undifferentiated (Grade IV))
Well Differentiated (grade I) (Well
differentiated (Grade I))
Primary Site (Select region category bolded only
if specific site is unknown or there are > 1 specific
sites)
Antrum (Antrum)
Base Of Tongue (Base of tongue)
Buccal Mucosa (Buccal mucosa)
Ethmoid (Ethmoid)
Faucial Arch (Faucial arch)
Floor Of Mouth (Floor of mouth)
Frontal (Frontal)
Glottic Larynx (Glottic larynx)
Hard Palate (Hard palate)
Hypopharynx Nos (Hypopharynx NOS)
Larynx Nos (Larynx NOS)
Lateral Wall (Lateral wall)
Lip And Oral Cavity (Lip and oral cavity)
Lower Gingiva (Lower gingiva)
Nasal Cavity (Nasal cavity)
Nasopharynx Nos (Nasopharynx NOS)
No Primary Identified (no primary
identified)
Nose Nos (Nose NOS)
Oral Cavity Nos (Oral cavity NOS)
Oral Tongue (Oral Tongue)
Oropharynx Nos (Oropharynx NOS)
Other (Other)
Paranasal Sinuses Nos (Paranasal
sinuses NOS)
Parotid (Parotid)
Postcricoid Area (Postcricoid area)
Posterior Pharyngeal Wall (Posterior
pharyngeal wall)
Posterior Superior Wall (Posterior
superior wall)
Posterior Wall (Posterior wall)
Pyriform Fossa (Pyriform fossa)
Retromolar Trigone (Retromolar trigone)
Salivary Glands Nos (Salivary glands
NOS)
Soft Palate (Soft palate)
Sphenoid (Sphenoid)
Subglottic Larynx (Subglottic larynx)
Submandibular (Submandibular)
Supraglottic Larynx (Supraglottic larynx)
Tonsillar Fossa Tonsil (Tonsillar fossa,
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tonsil)
Upper Gingiva (Upper gingiva)
Other specify
Disease Description
Date of initial diagnosis of metastatic/recurrent
disease
Disease Status
Both (Both)
Metastatic (Metastatic)
Recurrent (Recurrent)
Primary disease status
Eradicated But Recurred Locally
(Eradicated, but recurred locally)
Eradicated No Recurrence (Eradicated,
no recurrence)
Residual Disease After Prior Therapy
(Residual disease after prior therapy)
Unknown (Unknown)
Untreated (Untreated)
Regional Lymph Node Status (Local/)
Involved Nodes Eradicated (involved
nodes eradicated)
Involved Nodes Eradicated, But New
Involvement (involved nodes eradicated,
but new involvement)
Involved Nodes Not Treated (involved
nodes not treated)
Never Involved (never involved)
Never Involved, But Removed
Prophylactically (never involved, but
removed prophylactically)
Other (Other)
Unknown (Unknown)
Lung
Involved (involved)
Not Involved Or No Clinical Evidence Of
Involvement (Not involved or no clinical
evidence of involvement)
Unknown (Unknown)
Brain
Involved (involved)
Not Involved Or No Clinical Evidence Of
Involvement (Not involved or no clinical
evidence of involvement)
Unknown (Unknown)
Liver
Involved (involved)
Not Involved Or No Clinical Evidence Of
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Involvement (Not involved or no clinical
evidence of involvement)
Unknown (Unknown)
Skin
Involved (involved)
Not Involved Or No Clinical Evidence Of
Involvement (Not involved or no clinical
evidence of involvement)
Unknown (Unknown)
Distant lymph nodes
Involved (involved)
Not Involved Or No Clinical Evidence Of
Involvement (Not involved or no clinical
evidence of involvement)
Unknown (Unknown)
Distant nodes specify
Mediatstinal lymph nodes
Involved (involved)
Not Involved Or No Clinical Evidence Of
Involvement (Not involved or no clinical
evidence of involvement)
Unknown (Unknown)
Bone
Involved (involved)
Not Involved Or No Clinical Evidence Of
Involvement (Not involved or no clinical
evidence of involvement)
Unknown (Unknown)
Bone specify
Soft tissue
Involved (involved)
Not Involved Or No Clinical Evidence Of
Involvement (Not involved or no clinical
evidence of involvement)
Unknown (Unknown)
Soft tissue specify
Other visceral
Involved (involved)
Not Involved Or No Clinical Evidence Of
Involvement (Not involved or no clinical
evidence of involvement)
Unknown (Unknown)
Other visceral specify
Other
Involved (involved)
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Not Involved Or No Clinical Evidence Of
Involvement (Not involved or no clinical
evidence of involvement)
Unknown (Unknown)
Other specify
Baseline Abnormalities
CTC Adverse Event Term
CTC Adverse Event Grade
Mild Adverse Event (1)
Moderate Adverse Event (2)
Severe Adverse Event (3)
Life Threatening Adverse Event (4)
Comments
Investigator Signature
Investigator Signature Date
Comments
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E3F05 Baseline Primary Brain Tumor
Disease Evaluation Form NCT00978458
E3F05 Baseline Primary Brain Tumor Disease Evaluation
Form NCT00978458 
Radiation Therapy With or Without Temozolomide in
Treating Patients With Low-Grade Glioma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=6C1947D6-
6AFF-2C82-E040-BB89AD4371C6
All rights reserved. Please visit https://medical-data-
models.org/forms/11054
E3F05 Baseline Primary Brain Tumor
Disease Evaluation Form
NCT00978458
Header
ECOG Protocol Number
ECOG Patient ID
DCI Name
Registration Step
Report Period
Baseline (Baseline)
Patient Initials
Participating Group Protocol Number
Participating Group Patient ID
Institution/Affiliate
Data amendment
Please mark an 'X' if data have been amended.
(Please circle amended items in red)
Date data amended (s M D Y)
Section I Measurable Lesions
Does patient have radiographically visible
disease
Yes
No
Date of Baseline MRI
Is measurable disease present?
1 / 4
Yes
No
Is enhancing measureable disease present (if
yes, complete T2/FLAIR section below and
T1/Contrast section p.2)
Yes
No
Is non-enhancing measureable disease present
(if yes, complete T2/FLAIR section below)
Yes
No
T2/FLAIR
Lesion Number
Site of Lesion
Date of Evaluation (M D Y)
Longest Bidimensional Measurements of Lesions
(cm)
Longest Bidimensional Measurements of Lesions
(cm)
Product of Longest Bidimensional Measurements
(cm^2)
Tumor Laterality
Bilateral (bilateral)
Left (left)
Right (right)
Site
Basal Ganglia (Basal ganglia)
Brainstem (Brainstem)
Frontal Lobe (Frontal)
Multifocal (Multifocal)
Occipital Lobe (Occipital)
Other (Other)
Parietal Lobe (Parietal)
Temporal Lobe (Temporal)
Unknown (Unknown)
Specify
Does tumor cross midline
Yes
No
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Sum of Products of Greatest Diameters (of all
enhancing measurable lesions - cm^2)
T1/Contrast
Section Ii Non-measurable Lesions
Is non-measurable disease present?
Yes
No
Is enhancing non-measureable disease present
(if yes, complete T2/FLAIR section below and
T1/Contrast section p.3)
Yes
No
Is non-enhancing non-measureable disease
present (if yes, complete T2/FLAIR section
below)
Yes
No
Nontarget Lesions
Nontarget Lesions
Section Iii
Is the patient receiving corticosteroids?
Yes
No
Name of Medication (If yes)
Decadron (Decadron)
Other Specify (Other)
Other,specify
Total Daily Dose of Agent (or Drug) (Decadron or
Dexamethasone equivalent mg)
Agent Start Date (Current Dose M D Y)
Comments
Comments
Investigator Signature
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Investigator Signature Date (M D Y)
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NSABP PROTOCOL B-36 Treatment Form
for Hormonal Therapy NCT00087178
NSABP PROTOCOL B-36 Treatment Form for Hormonal
Therapy NCT00087178
Comparison of Two Combination Chemotherapy Regimens
in Treating Women With Breast Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=C87A821C-
DEFE-5AA6-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/11055
NSABP PROTOCOL B-36 Treatment
Form for Hormonal Therapy
NCT00087178
Header
Patient Initials (Last, First Middle)
NSABP Patient ID
Institution Name
Affiliate Name
Person Completing Form, Last Name
Person Completing Form, First Name
Person Completing Form, Phone
Are data amended
Yes (Yes)
Form complete date
Date Form Completed
Reason form completed
Patient Received 5 Years Of Hormonal
Therapy, And Hormonal Treatment Has
Ended (Patient received 5 years of
hormonal therapy, and hormonal
treatment has ended)
Patient Received 5 Years Of Hormonal
Therapy, And Hormonal Treatment Will
Continue (Patient received 5 years of
hormonal therapy, and hormonal
treatment will continue)
Patient Received Less Than 5 Years Of
Hormonal Therapy, And Hormonal
Treatment Has Ended (Patient received
less than 5 years of hormonal therapy,
and hormonal treatment has ended)
Patient Will Not Begin Hormonal Therapy
(Patient will not begin hormonal therapy)
1 / 2
Hormonal Therapy
Tamoxifen
Yes
No
Aromatase Inhibitor
Yes
No
Other, specify
Yes
No
Agent Start Date
Agent End Date
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E2108 Optimal Systemic Therapy Summary
Form NCT01242800
E2108 Optimal Systemic Therapy Summary Form
NCT01242800
Early Surgery or Standard Palliative Therapy in Treating
Patients With Stage IV Breast Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=91E1D8B2-
2FF5-DD0A-E040-BB89AD434391
All rights reserved. Please visit https://medical-data-
models.org/forms/11056
E2108 Optimal Systemic Therapy
Summary Form NCT01242800
ECOG clinical trial administrative data
ECOG Patient ID
DCI Name
Registration Step
Patient Initials (Last, First)
Participating Group Protocol Number
Institution/Affiliate
Participating Group Patient ID
Report Period
Reporting Period
End Of Treatment - Step 1 (End of
Treatment - Step 1)
Data amendment
Please mark an 'X' if data have been amended.
(Please circle amended items in red)
Date data amended (M D Y)
Arm A And Arm B
Date Systemic Therapy Began
Date Systemic Therapy Ended
Vital Status
1 / 5
Patient's Vital Status
Alive (Alive)
Dead (Dead)
Date of Last Contact or Death
Primary Cause of Death (if applicable)
Due To Other Cause (Due to other
cause)
Due To Protocol Treatment (Due to
protocol treatment)
Due To This Disease (Due to this
disease)
Unknown (Unknown)
Describe cause of death
Therapy Administered - Chemotherapy
Has the patient received any chemotherapy
during this reporting period? (as part of optimal
systemic therapy)
No (No)
Not Applicable (Not Applicable)
Yes, Chemotherapy Completed (Yes,
chemotherapy completed)
Yes, Chemotherapy Continuing (Yes,
chemotherapy continuing)
Chemotherapy Course 1
Albumin-bound Paclitaxel (Albumin-
bound paclitaxel)
Bevacizumab (Bevacizumab)
Capecitabine (Capecitabine)
Carboplatin (Carboplatin)
Cisplatin (Cisplatin)
Cyclophosphamide (Cyclophosphamide)
Docetaxel (Docetaxel)
Doxorubicin (Doxorubicin)
Epirubicin (Epirubicin)
Fluorouracil (Fluorouracil Cl)
Gemcitabine (Gemcitabine)
Ixabepilone (Ixabepilone)
Lapatinib (Lapatinib)
Methotrexate (Methotrexate)
Other (Other)
Paclitaxel (Paclitaxel)
Pegylated Liposomal Doxorubicin
(Pegylated liposomal doxorubicin)
Trastuzumab (Trastuzumab)
Vinorelbine (Vinorelbine)
Chemotherapy Course 2
Albumin-bound Paclitaxel (Albumin-
bound paclitaxel)
Bevacizumab (Bevacizumab)
Capecitabine (Capecitabine)
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Carboplatin (Carboplatin)
Cisplatin (Cisplatin)
Cyclophosphamide (Cyclophosphamide)
Docetaxel (Docetaxel)
Doxorubicin (Doxorubicin)
Epirubicin (Epirubicin)
Fluorouracil (Fluorouracil Cl)
Gemcitabine (Gemcitabine)
Ixabepilone (Ixabepilone)
Lapatinib (Lapatinib)
Methotrexate (Methotrexate)
Other (Other)
Paclitaxel (Paclitaxel)
Pegylated Liposomal Doxorubicin
(Pegylated liposomal doxorubicin)
Trastuzumab (Trastuzumab)
Vinorelbine (Vinorelbine)
Chemotherapy Course 3
Albumin-bound Paclitaxel (Albumin-
bound paclitaxel)
Bevacizumab (Bevacizumab)
Capecitabine (Capecitabine)
Carboplatin (Carboplatin)
Cisplatin (Cisplatin)
Cyclophosphamide (Cyclophosphamide)
Docetaxel (Docetaxel)
Doxorubicin (Doxorubicin)
Epirubicin (Epirubicin)
Fluorouracil (Fluorouracil Cl)
Gemcitabine (Gemcitabine)
Ixabepilone (Ixabepilone)
Lapatinib (Lapatinib)
Methotrexate (Methotrexate)
Other (Other)
Paclitaxel (Paclitaxel)
Pegylated Liposomal Doxorubicin
(Pegylated liposomal doxorubicin)
Trastuzumab (Trastuzumab)
Vinorelbine (Vinorelbine)
Specify
Therapy Administered - Hormone Therapy
Has the patient received any hormone therapy
during this reporting period? (as part of optimal
systemic therapy)
Yes
No
Hormone Therapy Course 1
Anastrozole (Anastrozole)
Aromatase Inhibitor - Anastrazole
(arimidex) (Aromatase Inhibitor -
Anastrazole (Arimidex))
Aromatase Inhibitor - Exemestane
(aromasin) (Aromatase Inhibitor -
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Exemestane (Aromasin))
Aromatase Inhibitor - Letrozole (femara)
(Aromatase Inhibitor - Letrozole
(Femara))
Ethinyl Estradiol (Ethinyl Estradiol)
Exemestane (Exemestane)
Fluoxymesterone (Fluoxymesterone)
Fulvestrant (Fulvestrant)
Letrozole (Letrozole)
Megestrol Acetate (Megestrol Acetate)
Other (Other)
Ovarian Function Suppression (ofs) -
Medical Suppression (Ovarian Function
Suppression (OFS) - Medical
suppression)
Ovarian Function Suppression (ofs) -
Oophorectomy (Ovarian Function
Suppression (OFS) - Oophorectomy)
Ovarian Function Suppression (ofs) -
Ovarian Radiation (Ovarian Function
Suppression (OFS) - Ovarian radiation)
Tamoxifen (Tamoxifen)
Toremifene (Toremifene)
Hormone Therapy Course 2
Anastrozole (Anastrozole)
Aromatase Inhibitor - Anastrazole
(arimidex) (Aromatase Inhibitor -
Anastrazole (Arimidex))
Aromatase Inhibitor - Exemestane
(aromasin) (Aromatase Inhibitor -
Exemestane (Aromasin))
Aromatase Inhibitor - Letrozole (femara)
(Aromatase Inhibitor - Letrozole
(Femara))
Ethinyl Estradiol (Ethinyl Estradiol)
Exemestane (Exemestane)
Fluoxymesterone (Fluoxymesterone)
Fulvestrant (Fulvestrant)
Letrozole (Letrozole)
Megestrol Acetate (Megestrol Acetate)
Other (Other)
Ovarian Function Suppression (ofs) -
Medical Suppression (Ovarian Function
Suppression (OFS) - Medical
suppression)
Ovarian Function Suppression (ofs) -
Oophorectomy (Ovarian Function
Suppression (OFS) - Oophorectomy)
Ovarian Function Suppression (ofs) -
Ovarian Radiation (Ovarian Function
Suppression (OFS) - Ovarian radiation)
Tamoxifen (Tamoxifen)
Toremifene (Toremifene)
Hormone Therapy Course 3
Anastrozole (Anastrozole)
Aromatase Inhibitor - Anastrazole
(arimidex) (Aromatase Inhibitor -
Anastrazole (Arimidex))
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Aromatase Inhibitor - Exemestane
(aromasin) (Aromatase Inhibitor -
Exemestane (Aromasin))
Aromatase Inhibitor - Letrozole (femara)
(Aromatase Inhibitor - Letrozole
(Femara))
Ethinyl Estradiol (Ethinyl Estradiol)
Exemestane (Exemestane)
Fluoxymesterone (Fluoxymesterone)
Fulvestrant (Fulvestrant)
Letrozole (Letrozole)
Megestrol Acetate (Megestrol Acetate)
Other (Other)
Ovarian Function Suppression (ofs) -
Medical Suppression (Ovarian Function
Suppression (OFS) - Medical
suppression)
Ovarian Function Suppression (ofs) -
Oophorectomy (Ovarian Function
Suppression (OFS) - Oophorectomy)
Ovarian Function Suppression (ofs) -
Ovarian Radiation (Ovarian Function
Suppression (OFS) - Ovarian radiation)
Tamoxifen (Tamoxifen)
Toremifene (Toremifene)
Specify
Therapy Administered - New Progression
Has the patient been diagnosed with a new
progression? (while receiving systemic therapy)
Yes
No
Basis for Progressive Disease
Enlargement Of Existing Sites By 20%
Or More (Enlargement of existing sites
by 20% or more)
New Sites Of Disease (New sites of
disease)
Symptomatic Deterioration In The
Presence Of Radiographic Evidence Of
Disease (Symptomatic deterioration in
the presence of radiographic evidence of
disease)
Date of Progression
Comments
Investigator Signature
Investigator Signature Date
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NSABP Protocol B-40 - Treatment Form for
Bevacizumab NCT00408408
NSABP Protocol B-40 - Treatment Form for Bevacizumab
NCT00408408
A Randomized Phase III Trial of Neoadjuvant Therapy in
Patients With Palpable and Operable Breast Cancer
Evaluating the Effect on Pathologic Complete Response
(pCR) of Adding Capecitabine or Gemcitabine to Docetaxel
When Administered Before AC With or Without
Bevacizumab and Correlative Science Studies Attempting
to Identify Predictors of High Likelihood for pCR With Each
of the Regimens
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=1B7D839C-
1CA0-14D8-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11057
NSABP Protocol B-40 - Treatment
Form for Bevacizumab
NCT00408408
Header
Patient Initials (Last First Middle)
NSABP Patient ID
Institution/Affiliate
Person Completing Form, Last Name
Person Completing Form, First Name
Person Completing Form, Phone
Are data amended
Yes
No
BEVACIZUMAB TREATMENT
Time point
Postoperative Bevacizumab
(Postoperative Bevacizumab)
Preoperative Bevacizumab (Preoperative
Bevacizumab)
Total No. of Doses
Agent Start Date
Agent End Date
Reason Treatment Ended (Bevacizumabor Never
Started)
1 / 2
Adverse Event/side Effects/complications
(Adverse event/side
effects/complications)
Alternative Therapy (Alternative therapy)
Death (Death)
New Lesion (including Second Primary
Cancer) Or Other Sign Of Progression
(New lesion (including second primary
cancer) or other sign of progression)
Other (Other)
Treatment Completed Per Protocol
Criteria (Treatment completed per
protocol criteria)
Other, specify (if applicable)
Ii. Infections
Adverse Event
Grade
Mild Adverse Event (1)
Moderate Adverse Event (2)
Severe Adverse Event (3)
Life Threatening Adverse Event (4)
Death Related To Adverse Event (5)
Comments
Comments
Person Completing Form
Date Form Completed
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E2805 Renal Cell Carcinoma On-Study
Form NCT00326898
E2805 Renal Cell Carcinoma On-Study Form
NCT00326898
Sunitinib or Sorafenib in Treating Patients With Kidney
Cancer That Was Removed By Surgery
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=053ADDEA-
1681-66BC-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11058
E2805 Renal Cell Carcinoma On-
Study Form NCT00326898
Header
ECOG Protocol Number
DCI Name
Registration Step
Reporting Period
Baseline (Baseline)
Participating Group Protocol Number
Institution/Affiliate
Data amendment
Please mark an 'X' if data have been amended
Date data amended
Patient demographics
ECOG Patient ID
ECOG Performance Status (Prior to Surgery)
Fully Active, Able To Carry On All Pre-
disease Performance Without
Restriction. (0)
Restricted In Physically Strenuous
Activity But Ambulatory And Able To
Carry Out Work Of A Light Or Sedentary
Nature, E.g., Light Housework, Office
Work. (1)
Ambulatory And Capable Of All Selfcare
But Unable To Carry Out Any Work
Activities. Up And About More Than 50%
Of Waking Hours. (2)
Capable Of Only Limited Selfcare,
Confined To Bed Or Chair More Than
50% Of Waking Hours. (3)
1 / 6
Completely Disabled. Cannot Carry On
Any Selfcare. Totally Confined To Bed Or
Chair. (4)
Mark an 'X' if N/A
History Of Disease
Does the patient have a history of
thromboembolic events
Yes
No
Does the patient have a history of cardiovascular
disease
Yes
No
Date of Initial Pathologic Diagnosis
Date of Most Recent Prior Recurrence
Descriptionof Primary Disease
Clinical T Stage
No Evidence Of Primary Tumor (T0)
Tumor 7 Cm Or Less In Greatest
Dimension Limited To The Kidney (T1)
Tumor Less Than 4 Cm Limited To
Kidney (T1a)
Tumor Greater Than 4 Cm But Less
Than 7 Cm Limited To The Kidney (T1b)
Tumor Greater Than 7 Cm In Greatest
Dimension Limited To The Kidney (T2)
Tumor Extends Into Major Veins Or
Invades The Adrenal Gland Or
Perinephric Tissues But Not Beyond
Gerotas Fascia (T3)
Tumor Invades The Adrenal Gland Or
Perinephric Tissues But Not Beyond
Gerotas Fascia (T3a)
Tumor Grossly Extends Into The Renal
Vein(s) Or Vena Cava Below The
Diaphragm (T3b)
Tumor Grossly Extends Into The Renal
Vein(s) Or Vena Cava Above The
Diaphragm (T3c)
Tumor Invades Beyond Gerotas Fascia
(T4)
Primary Tumor Cannot Be Assessed
(TX)
Clinical N Stage
No Regional Lymph Node Metastasis
(N0)
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Metastasis In A Single Regional Lymph
Node (N1)
Metastasis In More Than One Regional
Lymph Node (N2)
Regional Lymph Node Cannot Be
Assessed (NX)
Clinical M Stage
No Distant Metastasis (M0)
Distant Metastasis (M1)
Distant Metastasis Cannot Be Assessed
(MX)
Description Of Current Disease
How was disease discovered
Incidental Renal Cell (Incidental renal
cell)
Symptomatic Renal Cell (Symptomatic
renal cell)
Current Disease Symptoms
Hematuria (Disease symptoms present prior to
surgery)
No (No)
Unknown (Unknown)
Yes (Yes)
Dyspnea (Disease symptoms present prior to
surgery)
No (No)
Unknown (Unknown)
Yes (Yes)
Pain (Disease symptoms present prior to
surgery)
No (No)
Unknown (Unknown)
Yes (Yes)
Chills (Disease symptoms present prior to
surgery)
No (No)
Unknown (Unknown)
Yes (Yes)
Fatigue (Disease symptoms present prior to
surgery)
No (No)
Unknown (Unknown)
Yes (Yes)
Fever >38 degrees C or 100 degrees F (Disease
symptoms present prior to surgery)
No (No)
Unknown (Unknown)
Yes (Yes)
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Night sweats (Disease symptoms present prior to
surgery)
No (No)
Unknown (Unknown)
Yes (Yes)
Weight loss >= 10% (Disease symptoms present
prior to surgery)
No (No)
Unknown (Unknown)
Yes (Yes)
Elevated LDH (Disease symptoms present prior
to surgery)
No (No)
Unknown (Unknown)
Yes (Yes)
Low hemoglobin (Disease symptoms present
prior to surgery)
No (No)
Unknown (Unknown)
Yes (Yes)
Elevated serum calcium (Disease symptoms
present prior to surgery)
No (No)
Unknown (Unknown)
Yes (Yes)
Other symptoms (Disease symptoms present
prior to surgery)
No (No)
Unknown (Unknown)
Yes (Yes)
Hematuria (Disease symptoms present after
surgery)
No (No)
Unknown (Unknown)
Yes (Yes)
Dyspnea (Disease symptoms present after
surgery)
No (No)
Unknown (Unknown)
Yes (Yes)
Pain (Disease symptoms present after surgery)
No (No)
Unknown (Unknown)
Yes (Yes)
Chills (Disease symptoms present after surgery)
No (No)
Unknown (Unknown)
Yes (Yes)
Fatigue (Disease symptoms present after
surgery)
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No (No)
Unknown (Unknown)
Yes (Yes)
Fever >38 degrees C or 100 degrees F (Disease
symptoms present after surgery)
No (No)
Unknown (Unknown)
Yes (Yes)
Night sweats (Disease symptoms present after
surgery)
No (No)
Unknown (Unknown)
Yes (Yes)
Weight loss >= 10% (Disease symptoms present
after surgery)
No (No)
Unknown (Unknown)
Yes (Yes)
Elevated LDH (Disease symptoms present after
surgery)
No (No)
Unknown (Unknown)
Yes (Yes)
Low hemoglobin (Disease symptoms present
after surgery)
No (No)
Unknown (Unknown)
Yes (Yes)
Elevated serum calcium (Disease symptoms
present after surgery)
No (No)
Unknown (Unknown)
Yes (Yes)
Other symptoms (Disease symptoms present
after surgery)
No (No)
Unknown (Unknown)
Yes (Yes)
Specify other symptoms (Disease symptoms
present after surgery)
Muga Scanning
Date of assessment
Left Ventricular Ejection Fraction at Rest
LVEF Institutional Lower Limit of Normal
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Date of assessment (Note: If patient was unable
to obtain MUGA scan due to the shortage of the
isotope Technetium-99, an ECHO may be
substituted - at baseline and all subsequent visits
for new patients. In this case, fill in the section
below.)
Footer Module
Investigator Signature
Investigator Signature Date
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E2805 Surgery Form NCT00326898
E2805 Surgery Form NCT00326898
Sunitinib or Sorafenib in Treating Patients With Kidney
Cancer That Was Removed By Surgery
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=053C633F-
4176-6FE5-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11059
E2805 Surgery Form NCT00326898
Header
ECOG Protocol Number
ECOG Patient ID
DCI Name
Registration Step
Reporting Period
Baseline (Baseline)
Patient demographics
ECOG Protocol Number
ECOG Patient ID
Patient Initials (Last, First)
Participating Group Protocol Number
Institution/Affiliate
Participating Group Patient ID
Data amendment
Please mark an 'X' if data have been amended.
Date data amended (M D Y)
Section I - Surgery And Staging
Person completing this form
Other (Other)
Urologist Performing Surgery (urologist
performing surgery)
1 / 5
Other, specify
When did the patient pre-register for this study
After Surgery (after surgery)
Before Surgery (before surgery)
Type of surgery
Partial Nephrectomy (partial
nephrectomy)
Radical Nephrectomy (radical
nephrectomy)
Surgery Date (M D Y)
Which kidney was affected/operated on
Bilateral (Bilateral)
Left (Left)
Right (Right)
Surgical approach
Laparoscopic Surgery (Laparoscopic)
Open (open)
Type of open nephrectomy (If open, point of
incision)
11th Rib (11th rib)
Chevron (chevron)
Other (OTHER)
Subcostal (subcostal)
Thoraco-abdominal (thoraco-abdominal)
Unknown (Unknown)
if other, specify
Type of laparoscopic nephrectomy
Hand Assisted (hand assisted)
Other (OTHER)
Pure Laparoscopic Retroperitoneal (pure
laparoscopic retroperitoneal)
Pure Laparoscopic Transperitoneal (pure
laparoscopic transperitoneal)
Unknown (Unknown)
if other, specify
Is gross disease unifocal or multifocal?
Multifocal (Multifocal)
Unifocal (Unifocal)
Unknown (Unknown)
Was kidney embolization performed
No (No)
Unknown (Unknown)
Yes (Yes)
What were the radiographic findings of the
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contralateral kidney
Abnormal (ABNORMAL)
Normal (Normal)
Was an adrenalectomy performed
No (No)
Unknown (Unknown)
Yes, Full (yes, full)
Yes, Partial (yes, partial)
Was a lymphadenectomy performed
Yes
No
Number of Lymph Nodes Examined (If yes,)
Number of grossly positive nodes
Number of nodes positive, including
microscopically positive
Number of extracapsular spread nodes
Mark an 'X' if unknown
Surgical Margin Resection Status
All Margins Pathologically Negative (R0)
R0.5 (R0.5)
Microscopically Positive Margins Or
Microscopic Residual Disease (R1)
Macroscopically Positive Margins Or
Gross Residual Disease (R2)
Presence Of Residual Disease Cannot
Be Assessed (RX)
Is renal vein wall invasion identified at the margin
Yes
No
Histologic type (of primary)
Chromophobe (Chromophobe)
Conventional Clear Cell Carcinoma
(conventional clear cell carcinoma)
Mixed Histology < 25% Clear Cell (mixed
histology < 25% clear cell)
Mixed Histology > 25% Clear Cell (mixed
histology > 25% clear cell)
Papillary Carcinoma (Papillary
Carcinoma)
Unclassified (unclassified)
Presence of sarcomatoid features
Yes
No
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Pathologic Tumor Staging
Pathologic T Stage
No Evidence Of Primary Tumor (T0)
Tumor 7 Cm Or Less In Greatest
Dimension Limited To The Kidney (T1)
Tumor Less Than 4 Cm Limited To
Kidney (T1a)
Tumor Greater Than 4 Cm But Less
Than 7 Cm Limited To The Kidney (T1b)
Tumor Greater Than 7 Cm In Greatest
Dimension Limited To The Kidney (T2)
Tumor Extends Into Major Veins Or
Invades The Adrenal Gland Or
Perinephric Tissues But Not Beyond
Gerotas Fascia (T3)
Tumor Invades The Adrenal Gland Or
Perinephric Tissues But Not Beyond
Gerotas Fascia (T3a)
Tumor Grossly Extends Into The Renal
Vein(s) Or Vena Cava Below The
Diaphragm (T3b)
Tumor Grossly Extends Into The Renal
Vein(s) Or Vena Cava Above The
Diaphragm (T3c)
Tumor Invades Beyond Gerotas Fascia
(T4)
Primary Tumor Cannot Be Assessed
(TX)
Pathologic N Stage
No Regional Lymph Node Metastasis
(N0)
Metastasis In A Single Regional Lymph
Node (N1)
Metastasis In More Than One Regional
Lymph Node (N2)
Regional Lymph Node Cannot Be
Assessed (NX)
Pathologic M Stage
No Distant Metastasis (M0)
Distant Metastasis (M1)
Distant Metastasis Cannot Be Assessed
(MX)
Fuhrman Grade
Section Ii - Surgical Complications
Were there any post-operative or early
complications
No (No)
Unknown (Unknown)
Yes (Yes)
Mark all that apply (with an 'X')
Cardiopulmonary Complication
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(Cardiopulmonary complication)
Heart/lung Bypass (heart/lung bypass)
Hemorrhage (HEMORRHAGE)
Other, Specify (Other, Specify)
Pneumonia (PNEUMONIA)
Renal Failure (Renal failure)
Wound Dehiscence/fistula (Wound
dehiscence/fistula)
Wound Infection (Wound infection)
Other, specify
Section Iii - Tumor Location
Type of dissection (with an 'X')
Bilateral (Bilateral)
Great Vessels Left And Right (Great
vessels left and right)
Hilar Left And Right (Hilar left and right)
Left (Left)
Right (Right)
Footer
Investigator Signature
Investigator Signature Date
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E2905 On-Study Form NCT00843882
E2905 On-Study Form NCT00843882 
Lenalidomide With or Without Epoetin Alfa in Treating
Patients With Myelodysplastic Syndrome and Anemia
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=0EA9BECA-
9DE5-1273-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11060
E2905 On-Study Form
NCT00843882
Header
ECOG Protocol Number
ECOG Patient ID
DCI Name
Registration Step
Reporting Period
Baseline Step 1 (Baseline step 1)
Patient Initials (Last, First)
Participating Group Protocol Number
Participating Group Patient ID
Institution/Affiliate
Data amendment
Please mark an 'X' if data have been amended.
(Please circle amended items in red)
Date data amended (s - MM/DD/YYYY)
Current Performance Status
ECOG Performance Status
Fully Active, Able To Carry On All Pre-
disease Performance Without
Restriction. (0)
Restricted In Physically Strenuous
Activity But Ambulatory And Able To
Carry Out Work Of A Light Or Sedentary
Nature, E.g., Light Housework, Office
1 / 4
Work. (1)
Ambulatory And Capable Of All Selfcare
But Unable To Carry Out Any Work
Activities. Up And About More Than 50%
Of Waking Hours. (2)
Capable Of Only Limited Selfcare,
Confined To Bed Or Chair More Than
50% Of Waking Hours. (3)
Completely Disabled. Cannot Carry On
Any Selfcare. Totally Confined To Bed Or
Chair. (4)
Weight
Height
Is bone marrow iron stain available for patient
Yes
No
Transferrin saturation
Serum ferritin
Does the patient have a history of
thromboembolic events
Yes
No
Does the patient have any history of the following
(If yes,)
Blood Clot (Clot)
Coronary Thrombosis (Coronary
thrombosis)
Deep Vein Thrombosis (Deep Vein
Thrombosis)
Pulmonary Embolism (Pulmonary
Embolism)
Did it occur in the last 3 years (If yes,)
Yes
No
Baseline Abnormalities
Radiotherapy
Yes
No
Chemotherapy
Yes
No
Immunotherapy
Yes
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No
Leukocyte Growth Factor
Yes
No
Year last given (If yes,)
Was this disease MDS secondary due to
treatment
Yes
No
Cytarabine
Yes
No
Azacitidine
No (No)
Unknown (Unknown)
Yes (Yes)
Decitabine
Yes
No
Cyclosporin
Yes
No
ATG (anti-thymocyte globulin)
Yes
No
Thalidomide
Yes
No
Year last given (If yes,)
Prior Darpoietin Alpha (DA)
Yes
No
Date (DA first administered)
Date (DA last administered)
Prior Epoetin Alpha
Yes
No
Date (If yes, - EPO last administered)
Did patient have prior EPO failure
Yes
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No
Low EPO response profile (If no,)
Yes
No
Serum EPO Level (at study entry)
Date (EPO level done)
Other prior erythropoietic growth factor (other
than rhu-EPO and Darbepoetin Alfa)
Yes
No
Date agent ended (erythropoietic growth factor)
Comments
Investigator Signature
Investigator Signature Date
Comments
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ECOG-E1505 On-Study Form
NCT00324805
ECOG-E1505 On-Study Form NCT00324805 
Chemotherapy With or Without Bevacizumab in Treating
Patients With Stage IB, Stage II, or Stage IIIA Non-Small
Lung Cancer That Was Removed By Surgery
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=078250FE-
30E9-0714-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11061
ECOG-E1505 On-Study Form
NCT00324805
ECOG clinical trial administrative data
ECOG Protocol Number
ECOG Patient ID
DCI Name
Registration Step
Reporting Period
Baseline (Baseline)
Patient Initials (Last, First)
Participating Group Protocol Number
Participating Group Patient ID
Institution/Affiliate
Data amendment
Please mark an 'X' if data have been amended
(Please circle amended items in red)
Date data amended (M D Y)
Pre-Treatment Characteristics
ECOG Performance Status
Fully Active, Able To Carry On All Pre-
disease Performance Without
Restriction. (0)
Restricted In Physically Strenuous
Activity But Ambulatory And Able To
Carry Out Work Of A Light Or Sedentary
Nature, E.g., Light Housework, Office
1 / 6
Work. (1)
Ambulatory And Capable Of All Selfcare
But Unable To Carry Out Any Work
Activities. Up And About More Than 50%
Of Waking Hours. (2)
Capable Of Only Limited Selfcare,
Confined To Bed Or Chair More Than
50% Of Waking Hours. (3)
Completely Disabled. Cannot Carry On
Any Selfcare. Totally Confined To Bed Or
Chair. (4)
Height (cm)
Weight (kg)
Weight Loss in Previous Six Months
<5% Of Body Weight (<5% of body
weight)
> Or = 20% Of Body Weight (> or = 20%
of body weight)
10 To <20% Of Body Weight (10 -<20%
of body weight)
5 To <10% Of Body Weight (5 to < 10%
of body weight)
Urine Protein/Creatinine Ratio
Protein from 24 hour Urine Collection (g - *Value
is the total amount of protein, in grams, from a
24-hour urine collection. - Required only if Urine
Protein/Creatinine Ration >/= 1.0)
Date lab assessment performed
Patients Registered To Receive Regimen
4 (pemetrexed/cisplatin)
Creatinine Clearance (Calculated - ml/min)
Patient History
Does the patient have a history of
thromboembolic events (arterial)
Yes
No
Specify
Recovery or Latest Date (last known date of
disease activity - M D Y)
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Has the patient suffered cardiovascular disease?
Yes
No
Myocardial infarction
No (No)
Unknown (Unknown)
Yes (Yes)
Stable Angina
No (No)
Unknown (Unknown)
Yes (Yes)
Unstable angina
No (No)
Unknown (Unknown)
Yes (Yes)
Other
No (No)
Unknown (Unknown)
Yes (Yes)
Specify (Other)
Hypertension history
Yes
No
Description Of Disease At Initial Diagnosis
Date of initial pathologic diagnosis (M D Y)
Histologic Type
Adenocarcinoma (Adenocarcinoma)
Bronchoalveolar (bac) (Bronchoalveolar
carcinoma (BAC))
Combined/mixed, Specify Subcategories
(Combined/mixed)
Large Cell Carcinoma (Large cell
carcinoma)
Non-small Cell Lung Cancer (nsclc), Nos
(Non-small cell lung cancer NOS)
Other (Other specify)
Squamous Cell Carcinoma (Squamous
cell carcinoma)
Specify combined/mixed histologic types
Specify Other Histologic Type
Tumor Location Area
Lingula (Lingula)
Lower Lobe (left) (Lower Lobe (left))
Lower Lobe (right) (Lower Lobe (right))
Middle Lobe (right) (Middle Lobe (right))
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Other, Specify (Other)
Upper Lobe (left) (Upper Lobe (left))
Upper Lobe (right) (Upper Lobe (right))
Other specify
Stage (as determined by surgical evaluation)
Ib- T2n0 (IB- T2N0)
Iia- T1n1 (IIA- T1N1)
Iib- T2n1 (IIB- T2N1)
Iib- T3n0 (IIB- T3N0)
Iiia- T1n2 (IIIA- T1N2)
Iiia- T2n2 (IIIA- T2N2)
Iiia- T3n1 (IIIA- T3N1)
Iiia- T3n2 (IIIA- T3N2)
Pathologic Primary Tumor Size
Chemotherapy Regimen
Cisplatin And Docetaxel (Cisplatin and
Docetaxel)
Cisplatin And Gemcitabine (Cisplatin and
Gemcitabine)
Cisplatin And Pemetrexed (Cisplatin and
pemetrexed)
Cisplatin And Vinorelbine (Cisplatin and
Vinorelbine)
History Of Disease
Resection Type (Instruction: Specifying Unknown
is not a valid option.)
Bilobectomy (Bilobectomy)
Intrapericardial Pneumonectomy
(Intrapericardial pneumonectomy)
Lobectomy (Lobectomy)
Lobectomy And Chest Wall Resection
(Lobectomy and chest wall resection)
Other (Other)
Pneumonectomy (Pneumonectomy)
Sleeve Lobectomy (Sleeve lobectomy)
Other, specify
Date of Resection
Type of Mediastinal Lymph Node Dissection
(Instruction: Specifying Unknown is not a valid
option.)
Complete Mediastinal Lymph Node
Dissection (Complete mediastinal lymph
node dissection)
Incomplete Sampling (Incomplete
sampling)
Other (Other)
Systematic Sampling (Systematic
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sampling)
Other, specify
Date of Lymph Node Dissection
Pre-operative mediastinoscopy
Yes
No
Date (If yes)
N Stage, Pathologic
No Lymph Node Metastasis (pN0)
Metastasis To Ipsilateral Peribronchial
And/or Ipsilateral Hilar Lymph Nodes,
And Intrapulmonary Nodes Including
Involvement By Direct Extension Of The
Primary Tumor (pN1)
Metastasis To Ipsilateral Mediastinal
And/or Subcarinal Lymph Node(s) (pN2)
Involvement
Negative (negative)
Not Sampled (Not sampled)
Positive (positive)
Unknown (unknown)
Node Levels
10l (10L)
10r (10R)
11l (11L)
11r (11R)
12-14l (12-14L)
12-14r (12-14R)
1l (1L)
1r (1R)
2l (2L)
2r (2R)
3l (3L)
3r (3R)
4l (4L)
4r (4R)
5 (5)
6 (6)
7l (7L)
7r (7R)
8l (8L)
8r (8R)
9l (9L)
9r (9R)
Does the patient have a history of wound healing
complications (Patients must have recovered
from any wound healing complications prior to
study entry)
Yes
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No
Specify (If yes:)
Baseline Abnormalities
CTC Adverse Event Term
CTC Adverse Event Grade (v.4.0)
Mild Adverse Event (1)
Moderate Adverse Event (2)
Severe Adverse Event (3)
Life Threatening Adverse Event (4)
Comments
Investigator Signature
Investigator Signature Date
Comments
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E1A05 Supplemental Follow-Up Form -
Form 2863 NCT00522392
E1A05 Supplemental Follow-Up Form - Form 2863
NCT00522392 
Bortezomib and Dexamethasone With or Without
Lenalidomide in Treating Patients With Multiple Myeloma
Previously Treated With Dexamethasone
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=32CD04AD-
D3EA-187A-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11062
E1A05 Supplemental Follow-Up
Form - Form 2863 NCT00522392
ECOG clinical trial administrative data
ECOG Protocol Number
ECOG Patient ID
DCI Name
Registration Step (Place ID Label Here)
Patient Initials (Last, First)
Participating Group Protocol Number
Participating Group Patient ID
Institution/Affiliate
Report Period (choose one)
Post Treatment 6 Months (Post treatment
6 months)
Are data amended
Yes
No
In The 6 Months Following The End Of All
Protocol Treatment
Date form completed
Did the patient have a peripheral blood stem cell
harvest? (Answer ?no? if patient is preparing for
allogeneic transplant and donor cells were
harvested.)
Yes
No
Date of initial PBSC harvest (If yes:)
1 / 2
Was stem cell harvest successful?
Yes
No
Did the patient receive high-dose chemotherapy
in preparation for stem cell transplantation
Yes
No
Date high-dose chemotherapy began
Specify agent
Melphalan (Melphalan)
Other (Other)
Other, specify
Did the patient have a stem cell transplant?
Yes
No
Type of transplant (If yes:)
Allogeneic (allogeneic)
Autologous (autologous)
Syngeneic (syngeneic)
Date of stem cell transplant
Did the patient engraft?
No (no)
Unknown (unknown)
Yes (yes)
Comments
Comments
Investigator Signature
Investigator Signature Date
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E1A05 Supplemental Follow-Up Form - Form 2863 NCT00522392
ECOG E3805 On-Study Form
NCT00309985
ECOG E3805 On-Study Form NCT00309985
Androgen Ablation Therapy With or Without Chemotherapy
in Treating Patients With Metastatic Prostate Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=F96DE7A1-
1997-4F8E-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11063
ECOG E3805 On-Study Form
NCT00309985
ECOG clinical trial administrative data
ECOG Protocol Number
ECOG Patient ID
DCI Name
Registration Step
Reporting Period
Baseline (Baseline)
Patient Initials
Participating Group Protocol Number
Institution/Affiliate
Participating Group Patient ID
Data amendment
Please mark an 'X' if data have been amended.
Date data amended
Patient status
Performance Status
Fully Active, Able To Carry On All Pre-
disease Performance Without
Restriction. (0)
Restricted In Physically Strenuous
Activity But Ambulatory And Able To
Carry Out Work Of A Light Or Sedentary
Nature, E.g., Light Housework, Office
Work. (1)
1 / 7
Ambulatory And Capable Of All Selfcare
But Unable To Carry Out Any Work
Activities. Up And About More Than 50%
Of Waking Hours. (2)
Capable Of Only Limited Selfcare,
Confined To Bed Or Chair More Than
50% Of Waking Hours. (3)
Completely Disabled. Cannot Carry On
Any Selfcare. Totally Confined To Bed Or
Chair. (4)
Weight (Day 1 - kg)
Height (cm)
Description Of Primary Disease
Gleason Grade, Primary
Mark an 'X' if unknown
Gleason Grade, Secondary
PSA Value at Diagnosis
Date of diagnosis
Pathologic T Stage
Organ Confined (pT2)
Unilateral (pT2a)
Bilateral (pT2b)
Extraprostatic Extension (pT3)
Extraprostatic Extension (pT3a)
Seminal Vesicle Invasion (pT3b)
Invasion Of Bladder, Rectum (pT4)
Pathologic N Stage
No Regional Lymph Node Metastasis
(N0)
Metastatis In Regional Lymph Node Or
Nodes (see Ajcc Definition) (N1)
Regional Lymph Nodes Cannot Be
Assessed (NX)
Pathologic M Stage
No Distant Metastasis (M0)
Nonregional Lymph Node(s) (M1a)
Bone(s) (M1b)
Other Site(s) With Or Without Bone
Disease (M1c)
Distant Metastasis Cannot Be Assessed
(not Evaluated By Any Modality) (MX)
Clinical T Stage
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No Evidence Of Primary Tumor (T0)
Clinically Inapparent Tumor Not Palpable
Nor Visible By Imaging (T1)
Tumor Incidental Histologic Finding In
5% Or Less Of Tissue Resected (T1a)
Tumor Incidental Histologic Finding In
More Than 5% Of Tissue Resected
(T1b)
Tumor Identified By Needle Biopsy (eg,
Because Of Elevated Psa) (T1c)
Tumor Confined Within The Prostate (T2)
Tumor Involves One Lobe (T2a)
Tumor Involves Both Lobes (T2b)
Tumor Extends Through The Prostate
Capule (T3)
Extracapsular Extension (unilateral Or
Bilateral) (T3a)
Tumor Invades Seminal Vesicle(s) (T3b)
Tumor Is Fixed Or Invades Adjacent
Structures Other Than Seminal Vesicles:
Bladder Neck, External Sphincter, Or
Rectum, Levator Muscles, And/or Pelvic
Wall (T4)
Primary Tumor Cannot Be Assessed
(TX)
Clinical N Stage
No Regional Lymph Node Metastasis
(N0)
Metastatis In Regional Lymph Node Or
Nodes (see Ajcc Definition) (N1)
Regional Lymph Nodes Cannot Be
Assessed (NX)
Clinical M Stage
No Distant Metastasis (M0)
Distant Metastasis (M1)
Nonregional Lymph Node(s) (M1a)
Bone(s) (M1b)
Other Site(s) (M1c)
Distant Metastasis Cannot Be Assessed
(MX)
Extent Of Disease
Did the patient have High or Low Volume Disease
High Volume (High Volume)
Low Volume (Low Volume)
Visceral disease (Nature of High Volume Disease
- Extensive Disease - NOTE: High Volume
Disease Extensive Disease: Metastases involving
at least one lesion in any bony structure beyond
the vertebral column and pelvic bone or any
involvement with viscera. In the absence of
visceral lesions, there must be 4 or more bone
lesions.)
Yes
No
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Lung (Visceral)
Yes
No
Liver (Visceral)
Yes
No
Other (Visceral)
Yes
No
Other visceral specify
4 or more bone lesions
No (No)
Not Evaluable (Not evaluable)
Yes (Yes)
Bone Metastasis (If High Volume Disease
Extensive Disease, answer each of the following)
Yes
No
Number of bone metastases (If yes: - Are any of
the following involved?)
Vertebral column
Yes
No
Pelvic bone
Yes
No
Ribs
Yes
No
Arms
Yes
No
Legs
Yes
No
Skull
Yes
No
Other
Yes
No
Specify
4 / 7
ECOG E3805 On-Study Form NCT00309985
Prior Treatment
Prior Surgery
Yes
No
Prior Prostatectomy
Yes
No
Prior Orchiectomy
Yes
No
Date of prior surgery (most recent)
Prior Radiation Therapy
Yes
No
RT Purpose Type (If yes,)
Definitive (definitive)
Palliative (palliative)
Date Prior RT Ended
Prior RT Site
Prior Hormonal Therapy (NOTE: ADT received
within 120 days prior to randomization should
NOT be coded in this section. Please report
details of prior ADT in the Androgen Deprivation
section on page 3.)
Yes
No
Was prior hormonal therapy adjuvant? (If yes,)
Yes
No
Date Prior hormonal therapy Ended
Prior Hormonal Therapy Type
Any Other Prior Therapy? (excluding
chemotherapy)
Yes
No
Date Other Prior Therapy Ended
Name of other prior therapies
Has or will the patient received bisphosphonates
5 / 7
ECOG E3805 On-Study Form NCT00309985
(or other FDA approved drugs for delaying
skeletal related events) at the start of ADT?
Yes
No
Androgen Deprivation
Baseline PSA Value (ng/ml)
Date of PSA Assessment
Baseline Psa Value
Has patient begun Androgen Deprivation
Yes
No
Start date of Androgen Deprivation
Pre-ADT PSA
Type of Androgen Deprivation
Combined (Combined)
Hormonal (Hormonal)
Surgical (Surgical)
Is androgen blockade planned to be continued?
Yes
No
Highest PSA (since start of ADT)
Lowest PSA (since start of ADT)
Metabolic Syndrome
Fasting AM glucose > 110 mg/dl
No (No)
Unknown (Unknown)
Yes (Yes)
Hypertension (SBP >= 140 and/or DBP <= 90
mmHG)
No (No)
Unknown (Unknown)
Yes (Yes)
Obesity (BMI >= 30 kg/m^2)
No (No)
Unknown (Unknown)
Yes (Yes)
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ECOG E3805 On-Study Form NCT00309985
Hypertriglyceridemia (triglycerides > 150 mg/dl)
No (No)
Unknown (Unknown)
Yes (Yes)
HDL >40 mg/dl
No (No)
Unknown (Unknown)
Yes (Yes)
At the time of study entry was patient receiving
metformin
No (No)
Unknown (Unknown)
Yes (Yes)
Is treatment with metformin planning on being
continued while on study
No (No)
Unknown (Unknown)
Yes (Yes)
Baseline Abnormalities
CTC Adverse Event Term
CTC Adverse Event Grade
Comments
Investigator Signature
Investigator Signature Date
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Unknown ECOG Lung Onstudy
Unknown
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=109F4E7D-
3810-226A-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11064
Unknown ECOG Lung Onstudy
ECOG clinical trial administrative data
ECOG Protocol Number
ECOG Patient ID
DCI Name
Registration Step
Reporting Period
Baseline (Baseline)
Patient Initials (Last, First)
Participating Group Protocol Number
Participating Group Patient ID
Institution/Affiliate
Data amendment
Please mark an 'X' if data have been amended
(Please circle amended items in red)
Date data amended (M D Y)
Pre-Treatment Characteristics
ECOG Performance Status
Fully Active, Able To Carry On All Pre-
disease Performance Without
Restriction. (0)
Restricted In Physically Strenuous
Activity But Ambulatory And Able To
Carry Out Work Of A Light Or Sedentary
Nature, E.g., Light Housework, Office
Work. (1)
Ambulatory And Capable Of All Selfcare
But Unable To Carry Out Any Work
1 / 5
Activities. Up And About More Than 50%
Of Waking Hours. (2)
Capable Of Only Limited Selfcare,
Confined To Bed Or Chair More Than
50% Of Waking Hours. (3)
Completely Disabled. Cannot Carry On
Any Selfcare. Totally Confined To Bed Or
Chair. (4)
Height (cm)
Weight (kg)
Weight Loss in Previous Six Months
<5% Of Body Weight (<5% of body
weight)
> Or = 20% Of Body Weight (> or = 20%
of body weight)
10 To <20% Of Body Weight (10 -<20%
of body weight)
5 To <10% Of Body Weight (5 to < 10%
of body weight)
Description Of Disease At Initial Diagnosis
Date of initial pathologic diagnosis (M D Y)
Histologic Type
Adenocarcinoma (Adenocarcinoma)
Bronchoalveolar (bac) (Bronchoalveolar
carcinoma (BAC))
Combined/mixed, Specify Subcategories
(Combined/mixed)
Large Cell Carcinoma (Large cell
carcinoma)
Non-small Cell Lung Cancer (nsclc), Nos
(Non-small cell lung cancer NOS)
Other (Other specify)
Squamous Cell Carcinoma (Squamous
cell carcinoma)
Specify combined/mixed histologic types
Specify Other Histologic Type
Tumor Location Area
Lingula (Lingula)
Lower Lobe (left) (Lower Lobe (left))
Lower Lobe (right) (Lower Lobe (right))
Middle Lobe (right) (Middle Lobe (right))
Other, Specify (Other)
Upper Lobe (left) (Upper Lobe (left))
Upper Lobe (right) (Upper Lobe (right))
Other specify
2 / 5
Unknown ECOG Lung Onstudy
Data Unknown Text
Stage (as determined by surgical evaluation)
Ib- T2n0 (IB- T2N0)
Iia- T1n1 (IIA- T1N1)
Iib- T2n1 (IIB- T2N1)
Iib- T3n0 (IIB- T3N0)
Iiia- T1n2 (IIIA- T1N2)
Iiia- T2n2 (IIIA- T2N2)
Iiia- T3n1 (IIIA- T3N1)
Iiia- T3n2 (IIIA- T3N2)
Chemotherapy Regimen
Carboplatin And Paclitaxel (Carboplatin
and Paclitaxel)
Cisplatin And Docetaxel (Cisplatin and
Docetaxel)
Cisplatin And Gemcitabine (Cisplatin and
Gemcitabine)
Cisplatin And Vinorelbine (Cisplatin and
Vinorelbine)
History Of Disease
Resection Type
Bilobectomy (Bilobectomy)
Intrapericardial Pneumonectomy
(Intrapericardial pneumonectomy)
Lobectomy (Lobectomy)
Lobectomy And Chest Wall Resection
(Lobectomy and chest wall resection)
Other (Other)
Pneumonectomy (Pneumonectomy)
Sleeve Lobectomy (Sleeve lobectomy)
Unknown (Unknown)
Other, specify
Date of Resection
Type of Mediastinal Lymph Node Dissection
Complete Mediastinal Lymph Node
Dissection (Complete mediastinal lymph
node dissection)
Incomplete Sampling (Incomplete
sampling)
None (None)
Other (Other)
Systematic Sampling (Systematic
sampling)
Unknown (Unknown)
Other, specify
Date of Lymph Node Dissection
3 / 5
Unknown ECOG Lung Onstudy
Pre-operative mediastinoscopy
Yes
No
Date (If yes)
Involvement
Negative (negative)
Positive (positive)
Unknown (unknown)
Node Levels
1 (1)
10l (10L)
10r (10R)
11l (11L)
11r (11R)
12-13l (12-13L)
12-13r (12-13R)
2l (2L)
2r (2R)
3 (3)
4r (4R)
5 (5)
6 (6)
7 (7)
Does the patient have a history of wound healing
complications (Patients must have recovered
from any wound healing complications prior to
study entry)
Yes
No
Specify (If yes:)
Recovery or Latest Date (last known date of
disease activity - M D Y)
Baseline Abnormalities
CTC Adverse Event Term Type (include subterm
if applicable Use CTCAE v3 terminology)
CTC Adverse Event Grade (Use grade 1-4 per
CTCAE v3)
Comments
Investigator Signature
Investigator Signature Date
4 / 5
Unknown ECOG Lung Onstudy
Comments
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Unknown ECOG Lung Onstudy
Concomitant Medication Form, GOG-0212,
Form CMED NCT00108745
Concomitant Medication Form, GOG-0212, Form CMED
NCT00108745
Paclitaxel or Polyglutamate Paclitaxel or Observation in
Treating Patients With Stage III or Stage IV Ovarian
Epithelial or Peritoneal Cancer or Fallopian Tube Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=FD45FED6-
D996-72B6-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11065
Concomitant Medication Form,
GOG-0212, Form CMED
NCT00108745
Header Module
Date form originally completed (m d y)
Date form amended (m d y)
Person amending form, last name
Patient Initials (First, Middle, Last)
Patient Study ID
Person Completing Form, Last Name
Participating Group Protocol Number
Participating Group Patient ID
Page Number (of)
Medication Information
Did patient receive concomitant medications
while on protocol therapy?
Yes
No
Concomitant Medication
Units
Capsules (Capsules)
Drops (Drops)
Gram (Gram)
Microgram (Microgram)
Microliter (Microliter)
Milligram (Milligram)
Milliliter (Milliliter)
Not Specified (Not specified)
Ounce (Ounce)
1 / 3
Puffer (Puffer)
Spray (Spray)
Suppository (Suppository)
Tablespoon (Tablespoon)
Teaspoon (Teaspoon)
Concomitant Medication Administered Dose
Route
Ear (Auricular)
Skin (Dermal)
Inhaled (Inhaled)
Intra-articular (Intra-articular)
Intramuscular (Intramuscular)
Intranasal (Intranasal)
Intravenous (intravenous)
Not Specified (Not specified)
Ocular (Ocular)
Oral (oral)
Rectal (rectal)
Subcutaneous (Subcutaneous)
Sublingual (Sublingual)
Vaginal (vaginal)
Agent Administered Frequency
Am (AM)
Daily (Daily)
Eight Times A Day (Eight times a day)
Four Times A Day (q.i.d) (four times a
day (Q.I.D))
Not Specified (Not specified)
Pm/bedtime (PM/bedtime)
Six Times A Day (Six times a day)
Three Times A Day (t.i.d) (three times a
day (T.I.D))
Twice A Day (b.i.d) (twice a day (B.I.D))
When Needed (When needed)
Start Date
Date last taken
Ongoing?
No (No)
Unknown (Unknown)
Yes (Yes)
Reason
Advertisement (Advertisement)
Doctor Prescription (Doctor prescription)
Holistic Advisement (Holistic
advisement)
New Condition (New condition)
Non Medical Advise (Non medical
advise)
Unspecified (Not specified)
Own Description (Own description)
2 / 3
Concomitant Medication Form, GOG-0212, Form CMED NCT00108745
Pre-existing Condition (Pre-existing
condition)
Comment
COMMENT
3 / 3
Concomitant Medication Form, GOG-0212, Form CMED NCT00108745
Unknown ECOG Lung Onstudy CRF
Unknown Onstudy
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=109F578D-
E5FE-234C-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11066
Unknown ECOG Lung Onstudy CRF
ECOG clinical trial administrative data
ECOG Protocol Number
ECOG Patient ID
DCI Name
Registration Step
Reporting Period
Baseline (Baseline)
Patient Initials (Last, First)
Participating Group Protocol Number
Participating Group Patient ID
Institution/Affiliate
Data amendment
Please mark an 'X' if data have been amended
(Please circle amended items in red)
Date data amended (M D Y)
Pre-Treatment Characteristics
ECOG Performance Status
Fully Active, Able To Carry On All Pre-
disease Performance Without
Restriction. (0)
Restricted In Physically Strenuous
Activity But Ambulatory And Able To
Carry Out Work Of A Light Or Sedentary
Nature, E.g., Light Housework, Office
Work. (1)
Ambulatory And Capable Of All Selfcare
But Unable To Carry Out Any Work
1 / 5
Activities. Up And About More Than 50%
Of Waking Hours. (2)
Capable Of Only Limited Selfcare,
Confined To Bed Or Chair More Than
50% Of Waking Hours. (3)
Completely Disabled. Cannot Carry On
Any Selfcare. Totally Confined To Bed Or
Chair. (4)
Height (cm)
Weight (kg)
Weight Loss in Previous Six Months
<5% Of Body Weight (<5% of body
weight)
> Or = 20% Of Body Weight (> or = 20%
of body weight)
10 To <20% Of Body Weight (10 -<20%
of body weight)
5 To <10% Of Body Weight (5 to < 10%
of body weight)
Description Of Disease At Initial Diagnosis
Date of initial pathologic diagnosis (M D Y)
Histologic Type
Adenocarcinoma (Adenocarcinoma)
Bronchoalveolar (bac) (Bronchoalveolar
carcinoma (BAC))
Combined/mixed, Specify Subcategories
(Combined/mixed)
Large Cell Carcinoma (Large cell
carcinoma)
Non-small Cell Lung Cancer (nsclc), Nos
(Non-small cell lung cancer NOS)
Other (Other specify)
Squamous Cell Carcinoma (Squamous
cell carcinoma)
Specify combined/mixed histologic types
Specify Other Histologic Type
Tumor Location Area
Lingula (Lingula)
Lower Lobe (left) (Lower Lobe (left))
Lower Lobe (right) (Lower Lobe (right))
Middle Lobe (right) (Middle Lobe (right))
Other, Specify (Other)
Upper Lobe (left) (Upper Lobe (left))
Upper Lobe (right) (Upper Lobe (right))
Other specify
2 / 5
Unknown ECOG Lung Onstudy CRF
Data Unknown Text
Stage (as determined by surgical evaluation)
Ib- T2n0 (IB- T2N0)
Iia- T1n1 (IIA- T1N1)
Iib- T2n1 (IIB- T2N1)
Iib- T3n0 (IIB- T3N0)
Iiia- T1n2 (IIIA- T1N2)
Iiia- T2n2 (IIIA- T2N2)
Iiia- T3n1 (IIIA- T3N1)
Iiia- T3n2 (IIIA- T3N2)
Chemotherapy Regimen
Carboplatin And Paclitaxel (Carboplatin
and Paclitaxel)
Cisplatin And Docetaxel (Cisplatin and
Docetaxel)
Cisplatin And Gemcitabine (Cisplatin and
Gemcitabine)
Cisplatin And Vinorelbine (Cisplatin and
Vinorelbine)
History Of Disease
Resection Type
Bilobectomy (Bilobectomy)
Intrapericardial Pneumonectomy
(Intrapericardial pneumonectomy)
Lobectomy (Lobectomy)
Lobectomy And Chest Wall Resection
(Lobectomy and chest wall resection)
Other (Other)
Pneumonectomy (Pneumonectomy)
Sleeve Lobectomy (Sleeve lobectomy)
Unknown (Unknown)
Other, specify
Date of Resection
Type of Mediastinal Lymph Node Dissection
Complete Mediastinal Lymph Node
Dissection (Complete mediastinal lymph
node dissection)
Incomplete Sampling (Incomplete
sampling)
None (None)
Other (Other)
Systematic Sampling (Systematic
sampling)
Unknown (Unknown)
Other, specify
Date of Lymph Node Dissection
3 / 5
Unknown ECOG Lung Onstudy CRF
Pre-operative mediastinoscopy
Yes
No
Date (If yes)
Involvement
Negative (negative)
Positive (positive)
Unknown (unknown)
Node Levels
1 (1)
10l (10L)
10r (10R)
11l (11L)
11r (11R)
12-13l (12-13L)
12-13r (12-13R)
2l (2L)
2r (2R)
3 (3)
4r (4R)
5 (5)
6 (6)
7 (7)
Does the patient have a history of wound healing
complications (Patients must have recovered
from any wound healing complications prior to
study entry)
Yes
No
Specify (If yes:)
Recovery or Latest Date (last known date of
disease activity - M D Y)
Baseline Abnormalities
CTC Adverse Event Term Type (include subterm
if applicable Use CTCAE v3 terminology)
CTC Adverse Event Grade (Use grade 1-4 per
CTCAE v3)
Comments
Investigator Signature
Investigator Signature Date
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Comments
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Unknown ECOG Lung Onstudy CRF
E3F05 Second Primary Form
NCT00978458
E3F05 Second Primary Form NCT00978458 
Radiation Therapy With or Without Temozolomide in
Treating Patients With Low-Grade Glioma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=7004D1D0-
8F94-615D-E040-BB89AD436FDA
All rights reserved. Please visit https://medical-data-
models.org/forms/11067
E3F05 Second Primary Form
NCT00978458
ECOG clinical trial administrative data
ECOG Protocol Number (If patient has been on
other therapeutic ECOG protocols, please list
protocols and patient ID numbers)
ECOG Patient ID (If patient has been on other
therapeutic ECOG protocols, please list protocols
and patient ID numbers)
DCI Name
Registration Step
Reporting Period
Second Primary Cancer (Second
Primary)
Patient Initials (Last, First)
Participating Group Protocol Number
Institution/Affiliate
Participating Group Patient ID
Data amendment
Please mark an 'X' if data have been amended.
(Please circle amended items in red)
Date data amended (s M D Y)
Second primary cancer assessment
Date of Diagnosis of Second Primary Cancer (M
D Y)
1 / 2
Site of Second Primary Cancer
Include information on histologic subtype (s
Please attach copies of any corroborating
pathology reports)
Briefly describe cancer therapy the patient has
received prior to the diagnosis of the second
primary and other than that given on ECOG
protocols
Briefly describe treatment planned or given for
the diagnosis of this second primary
Comments
Investigator Signature
Investigator Signature Date (M D Y)
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E3F05 Source Document Tracking
Coversheet Form NCT00978458
E3F05 Source Document Tracking Coversheet Form
NCT00978458 
Radiation Therapy With or Without Temozolomide in
Treating Patients With Low-Grade Glioma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=6C1889F9-
CDBB-5474-E040-BB89AD431A23
All rights reserved. Please visit https://medical-data-
models.org/forms/11068
E3F05 Source Document Tracking
Coversheet Form NCT00978458
ECOG clinical trial administrative data
ECOG Protocol Number
ECOG Patient ID
DCI Name
Registration Step
Reporting Period (Choose one)
Baseline (Baseline)
Cycle 1 (Cycle 1)
Cycle 2 (Cycle 2)
Cycle 3 (Cycle 3)
Cycles 10 - 12 (Cycles 10 - 12)
Cycles 4 - 6 (Cycles 4 - 6)
Cycles 7 - 9 (Cycles 7 - 9)
End Of Chemoradiation (End of
Chemoradiation)
Patient Initials (Last, First)
Participating Group Protocol Number
Participating Group Patient ID
Institution/Affiliate
Document type
Pathology Report (Pathology Report)
Patient Pill Diary (Patient pill diary)
1 / 1
PACCT-1 TAILORx Chemotherapy Form
NCT00310180
PACCT-1 TAILORx Chemotherapy Form NCT00310180
Hormone Therapy With or Without Combination
Chemotherapy in Treating Women Who Have Undergone
Surgery for Node-Negative Breast Cancer (The TAILORx
Trial)
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=05DD92D7-
B59A-692F-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11074
PACCT-1 TAILORx Chemotherapy
Form NCT00310180
Header
ECOG Protocol Number
ECOG Patient ID
DCI Name
Registration Step Number
Reporting Period
Completion Of Chemotherapy
(Completion of chemotherapy)
Assessment of Chemotherapy
Chemotherapy Regimen (see protocol Appendix
II for schedules; if drugs were substituted or
omitted during treatment because of toxicity,
indicate the initial planned regimen)
Not Given (Chemotherapy not given)
Dose Dense Anthracycline (doxorubicin)
And Cyclophosphamide (ac) Therapy
(dose dense AC)
Dose Dense Anthracycline (doxorubicin)
And Cyclophosphamide (ac) Followed By
A Taxane (dose dense AC followed by a
taxane)
5-fluorouracil, Epirubicin,
Cyclophosphamide (fec) (FEC)
Intravenous Cyclophosphamide,
Methotrexate, And Fluorouracil (cmf) (IV
CMF)
Oral Cyclophosphamide, Methotrexate
And 5-fluorouracil (cmf) (Oral CMF)
Other (Other)
Other Regimen Given As Part Of A Ctsu
Adjuvant Therapy Protocol (other
regimen given as part of a CTSU
adjuvant therapy protocol)
Standard Anthracycline And
Cyclophosphamide (ac) Therapy
(standard AC)
1 / 2
Standard Anthracycline (doxorubicin)
And Cyclophosphamide (ac) Followed By
A Taxane (standard AC followed by a
taxane)
Doxorubicin, Cyclophosphamide, And
Docetaxel (tac) (TAC)
Docetaxel And Cyclophosphamide (tc)
Therapy (TC)
specify study number and treatment arm (given
as part of a CTSU adjuvant therapy protocol)
specify drugs and schedule (other chemotherapy
regimen)
Date Chemotherapy Began (date 1st cycle given
m/d/y)
Date Chemotherapy Ended (date last cycle given
m/d/y)
Taxane Use
Docetaxel (Docetaxel)
None: C41132 (None)
Paclitaxel (Paclitaxel)
Total number of chemotherapy cycles completed
Footer Module
Investigator Signature
Investigator Signature Date
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PACCT-1 TAILORx Chemotherapy Form NCT00310180
PACCT-1 TAILORx Non-Protocol Therapy
Form NCT00310180
PACCT-1 TAILORx Non-Protocol Therapy Form
NCT00310180 
Hormone Therapy With or Without Combination
Chemotherapy in Treating Women Who Have Undergone
Surgery for Node-Negative Breast Cancer (The TAILORx
Trial)
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=06183E11-
630F-7413-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11075
PACCT-1 TAILORx Non-Protocol
Therapy Form NCT00310180
Header
ECOG Protocol Number
ECOG Patient ID
DCI Name
Registration Step
Reporting Period
Non-protocol Therapy (Non-protocol
therapy)
Non-Protocol Therapy
Date of Non-protocol therapy (First - if given prior
to progression/relapse from protocol therapy: -
Types of first non-protocol therapy - which
includes any cancer therapy that is not part of the
planned regimen. - Mark an answer
&#56256;&#56375; for each type of therapy:)
Non-Protocol Chemotherapy
No (No)
Unknown (Unknown)
Yes (Yes)
Non-Protocol Hormonal Therapy? (/Biological
Response Modifiers)
No (No)
Unknown (Unknown)
Yes (Yes)
Non-Protocol Immunotherapy?
No (No)
Unknown (Unknown)
Yes (Yes)
Non-protocol high dose chemotherapy/stem cell
transplant (Autologous or Allogeneic)
No (No)
Unknown (Unknown)
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Yes (Yes)
Non-Protocol Surgery?
No (No)
Unknown (Unknown)
Yes (Yes)
Non-Protocol Surgery Type
Non-protocol radiation therapy to primary
No (No)
Unknown (Unknown)
Yes (Yes)
Non-protocol radiation therapy, specify
Other Non-Protocol Therapy
No (No)
Unknown (Unknown)
Yes (Yes)
Name of Other Non-Protocol Therapy
Was any non-protocol therapy given during
protocol treatment? (NOTE: Treatment for a
second primary in the same organ site would not
be considered therapy for disease of this
protocol. - NOTE: Submit PACCT-1 Second
Primary Form if applicable.)
Yes
No
Comments
Investigator Signature
Investigator Signature Date
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PACCT-1 TAILORx Material Submission
Form NCT00310180
PACCT-1 TAILORx Material Submission Form
NCT00310180 
Hormone Therapy With or Without Combination
Chemotherapy in Treating Women Who Have Undergone
Surgery for Node-Negative Breast Cancer (The TAILORx
Trial)
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=05D8C864-
DEF0-3C5D-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11076
PACCT-1 TAILORx Material
Submission Form NCT00310180
Header
ECOG Protocol Number
ECOG Patient ID
Registration Step
DCI Name
Reporting Period
Lab Data (Lab data)
Patient demographics
Patient Initials (Last,First)
Participating Group Protocol Number
Institution/Affiliate
Participating Group Patient ID
Completed by Submitting Institutions
Date material(s) sent to central laboratory
Shipped to
Ecog Pathology Coordinating Office
(ECOG Pathology Coordinating Office)
Other Central Laboratory (Other Central
Laboratory)
Informed consent signed?
Yes
No
1 / 3
Sample No.
Date Specimen Obtained (MM/DD/YYYY)
Specimen Type (s)
Other (Other)
Peripheral Blood With Acid Citrate
Dextrose Anticoagulant (Peripheral
blood, ACD)
Peripheral Blood, Citrate Cpt (Peripheral
Blood, citrate CPT)
Peripheral Blood, Paxgene Dna
(Peripheral Blood, PAXgene DNA)
Plasma, Edta Purple Top Tube (Plasma,
EDTA)
Serum (Serum)
Serum In Serum Separating Tube
(Serum, SST)
Timing of material collection
Baseline (Baseline)
Other (other)
Number of specimens submitted (tubes, slides,
etc.)
Frozen Tumor Tissue
Specimen Collected And Available Upon
Request; Stored At Local
Institution/facility (Available, retained at
Local Site until requested)
Specimen Collected And Submitted To
Group Central Institution/facility
(Available, will submit to ECOG PCO)
Not Available (None available)
Completed By Central Lab
Date of Receipt of Specimens ( m/d/y)
Condition of Specimen (s)
Damaged Or Unusable (Damaged or
unusable)
Usable (Useable)
Contacts
Contact Person at Institution
Physician of Record
Institution contact phone number
2 / 3
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Institution contact fax number
Central Laboratory contact name
Central Lab Contact Phone Number
Central Lab Contact FAX Number
Comments
Date
Comments
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PACCT-1 TAILORx On-Study Form
NCT00310180
PACCT-1 TAILORx On-Study Form NCT00310180
Hormone Therapy With or Without Combination
Chemotherapy in Treating Women Who Have Undergone
Surgery for Node-Negative Breast Cancer (The TAILORx
Trial)
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=05D9BCF6-
1191-5BFE-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11077
PACCT-1 TAILORx On-Study Form
NCT00310180
Header
ECOG Protocol Number
ECOG Patient ID
DCI Name
Registration Step Number
Reporting Period
Baseline (Baseline)
Menopausal status
Menopausal status (NOTE: See TAILORx Forms
Completion Guidelines for defintions)
Postmenopausal (Postmenopausal)
Premenopausal/perimenopausal
(Premenopausal/Perimenopausal)
Unknown (Unknown)
Breast: Surgical Procedures
Most Extensive Primary Surgery (check one)
Mastectomy, Nos (Mastectomy NOS)
Partial Mastectomy, Lumpectomy Or
Excisional Biopsy (Partial
mastectomy/lumpectomy/excisional
biopsy)
Date of Most Extensive Primary Surgery
Was sentinel node sampling performed
Yes
No
Sentinel Node Biopsy Date
Was axillary dissection performed?
Yes
No
1 / 3
Date of Axillary Dissection
Number of Lymph Nodes Examined (If sentinel
node biopsy and axillary node dissection were
performed, enter the sum of nodes examined.)
Breast: Disease Description
Date of Initial Diagnosis of Primary Tumor (Date
of first positive biopsy)
Mammogram (Breast cancer was detectable by
the following answer yes or no for each of the
following:)
Yes
No
Physical Exam
Yes
No
Other
Yes
No
Specify (If yes,)
Tumor Laterality
Left (Left)
Right (Right)
Pathologic Primary Tumor Size (cm Maximum
diameter of the invasive component; if multiple
lesions, use longest lesion)
Histologic Grade (For breast cancer, a combined
histologic grade is used according to SBR/Elston
classification)
Well Differentiated (Grade I (low))
Moderately Differentiated (Grade II
(intermediate))
Poorly Differentiated (Grade III (high))
Unknown (UNKNOWN)
Nuclear Grade
High (High)
Intermediate (Intermediate)
Low (Low)
Unknown (Unknown)
Receptor Status, ER (as defined by local
laboratory; borderline results should be reported
as positive)
Negative (Negative)
Not Done (NOT DONE)
Positive (Positive)
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Unknown (Unknown)
Receptor Status, PgR
Negative (Negative)
Not Done (NOT DONE)
Positive (Positive)
Unknown (Unknown)
Pathologic N Stage (CRF says "TNM Nodal
Staging" - CDE is Recommended Term)
No Regional Lymph Node Metastasis
Histologically, No Additional Examination
For Isolated Tumor Cells (itc) (pN0)
No Regional Lymph Node Metastasis
Histologically, Negative Ihc (pN0(i-))
No Regional Lymph Node Metastasis
Histologically, Positive Ihc, No Ihc Cluster
>0.2 Mm (pN0(i+))
No Regional Lymph Node Metastasis
Histologically, Negative Molecular
Findings (rt-pcr) (pN0(mol-))
No Regionally Lymph Node Metastasis
Histologically, Positive Molecular
Findings (rt-pcr) (pN0(mol+))
Oncotype DX Recurrence Score
Requisition Number
Date of Oncotype DX Score Report
After receiving the treatment assignment, indicate
which treatment(s) patient has agreed to receive
(Choose all that apply)
Chemotherapy (Chemotherapy)
Hormone Therapy (Hormone Therapy)
Date Chemotherapy Began (or will begin)
Footer Module
Investigator Signature
Investigator Signature Date
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E5103 Non-Protocol Therapy Form
NCT00433511
E5103 Non-Protocol Therapy Form [Form No. 2814v2]
NCT00433511 
Doxorubicin, Cyclophosphamide, and Paclitaxel With or
Without Bevacizumab in Treating Patients With Lymph
Node-Positive or High-Risk, Lymph Node-Negative Breast
Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=22AFF315-
4D41-593F-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11078
E5103 Non-Protocol Therapy Form
NCT00433511
ECOG clinical trial administrative data
ECOG Protocol Number
ECOG Patient ID
DCI Name
Registration Step
Reporting Period
Non-protocol Therapy (Non-protocol
therapy)
Patient demographics
Patient Initials (Last,First)
ECOG Protocol Number
ECOG Patient ID
Participating Group Protocol Number
Participating Group Patient ID
Institution/Affiliate
Data amendment
Please mark an 'X' if data have been amended
(Please circle amended items in red)
Date data amended (M D Y)
1 / 3
Non-Protocol Therapy
Date of Non-protocol therapy (First - if given prior
to progression/relapse from protocol therapy: -
Types of first non-protocol therapy - which
includes any cancer therapy that is not part of the
planned regimen. - Mark an answer X for each
type of therapy: - Note: Protocol chemotherapy
given after the patient is off-treatment will not be
considered non-protocol therapy.)
Non-Protocol Chemotherapy
No (No)
Unknown (Unknown)
Yes (Yes)
Non-Protocol Hormonal Therapy?
No (No)
Unknown (Unknown)
Yes (Yes)
Non-Protocol Immunotherapy? (/Biological
Response Modifiers)
No (No)
Unknown (Unknown)
Yes (Yes)
Non-protocol high dose chemotherapy/stem cell
transplant (Autologous or Allogeneic)
No (No)
Unknown (Unknown)
Yes (Yes)
Non-Protocol Surgery
No (No)
Unknown (Unknown)
Yes (Yes)
Non-Protocol Surgery Type
Non-Protocol Radiation Therapy?
No (No)
Unknown (Unknown)
Yes (Yes)
Non-Protocol RT Type
Other Non-Protocol Therapy
No (No)
Unknown (Unknown)
Yes (Yes)
Name of Other Non-Protocol Therapy
Was the non-protocol therapy given for the
disease of this protocol (NOTE: Treatment for a
2 / 3
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second primary in the same organ site would not
be considered therapy for disease of this
protocol. - NOTE: Submit ECOG Second Primary
Form if applicable.)
No (No)
Unknown (Unknown)
Yes (Yes)
Comments
Investigator Signature
Investigator Signature Date
Comments
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E2603 Treatment Form NCT00110019
E2603 Treatment Form NCT00110019
Carboplatin and Paclitaxel With or Without Sorafenib in
Treating Patients With Unresectable Stage III or Stage IV
Melanoma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=E79ADF68-
8651-1E39-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11079
E2603 Treatment Form
NCT00110019
Header
ECOG Protocol Number
ECOG Patient ID
DCI Name
Registration Step
Patient demographics
Patient Initials
ECOG Protocol Number
ECOG Patient ID
Participating Group Protocol Number
Institution/Affiliate
Participating Group Patient ID
On Treatment Report Period (Choose one)
> Cycle 10 (> Cycle 10)
Cycle 10 (Cycle 10)
Cycle 2 (Cycle 2)
Cycle 3 (Cycle 3)
Cycle 4 (Cycle 4)
Cycle 5 (Cycle 5)
Cycle 6 (Cycle 6)
Cycle 7 (Cycle 7)
Cycle 8 (Cycle 8)
Cycle 9 (Cycle 9)
cycle (specify)
1 / 5
Data amendment
Please mark an 'X' if data have been amended.
Date data amended
Vital Status
Patient Vital Status
Alive (Alive)
Dead (Dead)
Date of last contact or death
Primary Cause of Death (if applicable)
Due To Other Cause (Due to other
cause)
Due To Protocol Treatment (Due to
protocol treatment)
Due To This Disease (Due to this
disease)
Unknown (Unknown)
Describe cause of death
Cycle Information
Cycle Start Date
Cycle End Date
ECOG Performance status (Day 1 of this cycle)
Fully Active, Able To Carry On All Pre-
disease Performance Without Restriction
(karnofsky 90 - 100) (ecog - 0
Asymptomatic) (0)
Restricted In Physically Strenuous
Activity But Ambulatory (k70 - 80) (ecog -
1 Symptomatic - Fully Ambulatory) (1)
Ambulatory And Capable Of All Selfcare
But Unable To Carry Out Any Work
Activities (k 50 - 60) (ecog - 2
Symptomatic; In Bed , 50% Of The Day)
(2)
Capable Of Limited Selfcare, Confined
To Bed Or Chair More Than 50% Of
Waking Hours. (k 30 - 40) (ecog - 3
Symptomatic; In Bed > 50% Of The Day
But Not Bedridden) (3)
Completely Disabled (k10 - 20) (ecog - 4
Bedridden) (4)
Blood Pressure, Systolic
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Blood Pressure, Diastolic (systolic/diastolic)
Mark an 'X' if not done
Therapy Administered
Mark here if carboplatin has previously been
discontinued on a previous cycle
Were there any dose modifications or
additions/omissions to protocol treatment
(Paxlitaxel)
No (no)
Unknown (yes, both planned and
unplanned)
Yes, Planned (i.e., The Treatment Was
Changed According To Protocol
Guidelines) (yes, planned)
Yes, Unplanned (i.e., The Treatment
Change Was Not Part Of Protocol
Guidelines) (yes, unplanned)
other, specify
Date agent administered
Dose Modified Reason
Not Per Protocol (not per protocol)
Per Protocol (per protocol)
Agent Dose
Agent Name: Paclitaxel
Mark here if paclitaxel has previously been
discontinued on a previous cycle
Were there any dose modifications or
additions/omissions to protocol treatment
(Paxlitaxel)
No (no)
Unknown (yes, both planned and
unplanned)
Yes, Planned (i.e., The Treatment Was
Changed According To Protocol
Guidelines) (yes, planned)
Yes, Unplanned (i.e., The Treatment
Change Was Not Part Of Protocol
Guidelines) (yes, unplanned)
other, specify
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E2603 Treatment Form NCT00110019
Date agent administered
Agent Dose
Dose Modified Reason
Not Per Protocol (not per protocol)
Per Protocol (per protocol)
Agent Name: Bay 43-9006 Or Placebo
Number of pills per dose
Date of dose modifications
New dose
Frequency
Dose Held (Dose held)
Once A Day (q.d.) (Once a day (Q.D.))
Twice A Day (b.i.d) (twice a day (B.I.D))
Frequency
Dose Held (Dose held)
Once A Day (q.d.) (Once a day (Q.D.))
Twice A Day (b.i.d) (twice a day (B.I.D))
Dose Modified Reason
Not Per Protocol (not per protocol)
Per Protocol (per protocol)
Did the patient complete the Patient Pill Calendar
this cycle
Yes
No
Total Number of Pills Taken (this cycle, based on
the Patient Pill Calendar)
Non-protocol Therapy
Was any non-protocol therapy given during
protocol treatment (not previously reported)
Yes
No
Related Forms
Comments
Comments
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Investigator Signature
Investigator Signature Date
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E2603 Treatment Form - Cycle 1
NCT00110019
E2603 Treatment Form - Cycle 1 NCT00110019
Carboplatin and Paclitaxel With or Without Sorafenib in
Treating Patients With Unresectable Stage III or Stage IV
Melanoma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=FB6616F9-
842C-441D-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11080
E2603 Treatment Form - Cycle 1
NCT00110019
Header
ECOG Protocol Number
ECOG Patient ID
DCI Name
Registration Step
Patient demographics
Patient Initials
ECOG Protocol Number
Participating Group Protocol Number
ECOG Patient ID
Institution/Affiliate
Participating Group Patient ID
On Treatment Report Period
Cycle 1 (Cycle 1)
Data amendment
Please mark an 'X' if data have been amended.
Date data amended
Vital Status
Patient Vital Status
1 / 5
Alive (Alive)
Dead (Dead)
Date of last contact or death
Primary Cause of Death (if applicable)
Due To Other Cause (Due to other
cause)
Due To Protocol Treatment (Due to
protocol treatment)
Due To This Disease (Due to this
disease)
Unknown (Unknown)
Describe cause of death
Cycle Information
Cycle Start Date
Cycle End Date
ECOG Performance status (Day 1 of this cycle)
Fully Active, Able To Carry On All Pre-
disease Performance Without Restriction
(karnofsky 90 - 100) (ecog - 0
Asymptomatic) (0)
Restricted In Physically Strenuous
Activity But Ambulatory (k70 - 80) (ecog -
1 Symptomatic - Fully Ambulatory) (1)
Ambulatory And Capable Of All Selfcare
But Unable To Carry Out Any Work
Activities (k 50 - 60) (ecog - 2
Symptomatic; In Bed , 50% Of The Day)
(2)
Capable Of Limited Selfcare, Confined
To Bed Or Chair More Than 50% Of
Waking Hours. (k 30 - 40) (ecog - 3
Symptomatic; In Bed > 50% Of The Day
But Not Bedridden) (3)
Completely Disabled (k10 - 20) (ecog - 4
Bedridden) (4)
Blood Pressure, Systolic (Note: Code
hypotension/hypertension on adverse event form)
Blood Pressure, Diastolic (systolic/diastolic)
Mark an 'X' if not done
Weight  (Day 1 of this cycle)
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Therapy Administered
Were there any dose modifications or
additions/omissions to protocol treatment
(Paxlitaxel)
No (no)
Unknown (yes, both planned and
unplanned)
Yes, Planned (i.e., The Treatment Was
Changed According To Protocol
Guidelines) (yes, planned)
Yes, Unplanned (i.e., The Treatment
Change Was Not Part Of Protocol
Guidelines) (yes, unplanned)
other, specify
Date agent administered
Agent Dose
Dose Modification Reason
Not Per Protocol (not per protocol)
Per Protocol (per protocol)
AUC
Creatinine Clearance (Record value used to
determine Carboplatin dose)
Serum Creatinine (Value used to calculate
Creatinine Clearance)
Date obtained
Agent Name: Paclitaxel
Were there any dose modifications or
additions/omissions to protocol treatment
(Paxlitaxel)
No (no)
Unknown (yes, both planned and
unplanned)
Yes, Planned (i.e., The Treatment Was
Changed According To Protocol
Guidelines) (yes, planned)
Yes, Unplanned (i.e., The Treatment
Change Was Not Part Of Protocol
Guidelines) (yes, unplanned)
other, specify
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Date agent administered
Agent Dose
Dose Modification Reason
Not Per Protocol (not per protocol)
Per Protocol (per protocol)
Agent Name: Bay 43-9006 Or Placebo
Number of pills per dose
Date of dose modifications
New dose
Frequency
Dose Held (Dose held)
Once A Day (q.d.) (Once a day (Q.D.))
Twice A Day (b.i.d) (twice a day (B.I.D))
Frequency
Dose Held (Dose held)
Once A Day (q.d.) (Once a day (Q.D.))
Twice A Day (b.i.d) (twice a day (B.I.D))
Dose Modification Reason
Not Per Protocol (not per protocol)
Per Protocol (per protocol)
Did the patient complete the Patient Pill Calendar
this cycle
Yes
No
Total Number of Pills Taken (this cycle, based on
the Patient Pill Calendar)
Non-protocol Therapy
Was any non-protocol therapy given during
protocol treatment (not previously reported)
Yes
No
Related Forms
Comments
Comments
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E2603 Treatment Form - Cycle 1 NCT00110019
Investigator Signature
Investigator Signature Date
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E1105 On-Study Form NCT00520975
E1105 On-Study Form NCT00520975
First-Line Chemotherapy and Trastuzumab With or Without
Bevacizumab in Treating Patients With Metastatic Breast
Cancer That Overexpresses HER-2/NEU
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=171FAB32-
7984-3641-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11081
E1105 On-Study Form
NCT00520975
Header
ECOG Protocol Number
ECOG Patient ID
DCI Name
Registration Step
Reporting Period
Baseline (Baseline)
Patient demographics
Patient Initials
ECOG Performance Status (Day 1 of this cycle)
Fully Active, Able To Carry On All Pre-
disease Performance Without
Restriction. (0)
Restricted In Physically Strenuous
Activity But Ambulatory And Able To
Carry Out Work Of A Light Or Sedentary
Nature, E.g., Light Housework, Office
Work. (1)
Ambulatory And Capable Of All Selfcare
But Unable To Carry Out Any Work
Activities. Up And About More Than 50%
Of Waking Hours. (2)
Capable Of Only Limited Selfcare,
Confined To Bed Or Chair More Than
50% Of Waking Hours. (3)
Completely Disabled. Cannot Carry On
Any Selfcare. Totally Confined To Bed Or
Chair. (4)
Participating Group Protocol Number
Participating Group Patient ID
Institution/Affiliate
1 / 5
Data amendment
Please mark an 'X' if data have been amended.
Date data amended
Pre-registration Evaluation
Height
Weight
Carboplatin planned
Yes
No
Menopausal status
Perimenopausal (Perimenopausal)
Postmenopausal (Postmenopausal)
Premenopausal (Premenopausal)
Unknown (Unknown)
Urine Protein/Creatinine Ratio
Date lab assessment performed
Protein from 24 hour Urine Collection
Prior Treatment
Most Extensive Primary Surgery
Mastectomy, Nos (Mastectomy NOS)
None (None)
Partial Mastectomy, Lumpectomy Or
Excisional Biopsy (Partial
mastectomy/lumpectomy/excisional
biopsy)
Mark an 'X' if not done
Date of Most Extensive Primary Surgery
Prior Hormonal Therapy (in adjuvant or
metastatic setting)
Yes
No
Prior Treatment Regimen Type
Adjuvant (Adjuvant)
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Metastatic (Metastatic)
Prior Therapy Stop Date (most recent Lapatinib)
Prior Radiation Therapy
Yes
No
Prior Taxane Therapy (in the adjuvant or
neoadjuvant setting)
Yes
No
Prior Doxorubicin Therapy (in the adjuvant or
neoadjuvant setting)
Yes
No
Agent Total Cumulative Dose (mg - if yes:)
Prior Epirubicin Therapy (in the adjuvant or
neoadjuvant setting)
Yes
No
Prior Trastuzumab Therapy (in the adjuvant
setting)
Yes
No
Prior Lapatinib Therapy (in the adjuvant or
neoadjuvant setting?)
Yes
No
Prior Other Chemotherapy (in the adjuvant or
metastatic setting)
Yes
No
Prior Chemotherapy End Date (other - if yes:)
Disease Description
Date of Definitive Histologic Diagnosis of Primary
Tumor
Contralateral diagnosis date (if applicable)
Date of First Local-Regional Recurrence
Date of Initial Diagnosis of Metastatic Disease
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ER Status
Negative (Negative)
Not Done (NOT DONE)
Positive (Positive)
Unknown (Unknown)
PgR Status
Negative (Negative)
Not Done (NOT DONE)
Positive (Positive)
Unknown (Unknown)
Her2/neu expression status by
immunohistochemistry (DAKO HercepTest)
0 (0)
1+ (1+)
2+ (2+)
3+ (3+)
Not Done: C49484 (not done)
FISH HER2/neu chromosome 17 Ratio (_._)
Local-regional (Sites of Involvement At Study
Entry - Record an answer for each site including
"Other)
No (NO)
Unknown (UNKNOWN)
Yes (YES)
Ipsilateral supraclavicular nodes
No (NO)
Unknown (UNKNOWN)
Yes (YES)
Opposite Breast
No (NO)
Unknown (UNKNOWN)
Yes (YES)
Distant Lymph Nodes
No (NO)
Unknown (UNKNOWN)
Yes (YES)
Distant Skin/subcutaneous Tissue
No (No)
Unknown (Unknown)
Yes (Yes)
Bone
No (NO)
Unknown (UNKNOWN)
Yes (YES)
Bone Marrow
No (No)
Unknown (Unknown)
Yes (Yes)
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Lung
No (NO)
Unknown (UNKNOWN)
Yes (YES)
Liver
No (NO)
Unknown (UNKNOWN)
Yes (YES)
Pleura
No (NO)
Unknown (UNKNOWN)
Yes (YES)
Brain
No (NO)
Unknown (UNKNOWN)
Yes (YES)
Other CNS
No (NO)
Unknown (UNKNOWN)
Yes (YES)
Other (Second)
No (NO)
Unknown (UNKNOWN)
Yes (YES)
Other specify (Second)
Comments
Investigator Signature
Investigator Signature Date
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ECOG Off-Treatment Form NCT00520975
ECOG Off-Treatment Form NCT00520975 
First-Line Chemotherapy and Trastuzumab With or Without
Bevacizumab in Treating Patients With Metastatic Breast
Cancer That Overexpresses HER-2/NEU
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=1723190D-
DFB9-084E-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11082
ECOG Off-Treatment Form
NCT00520975
Header
ECOG Protocol Number
ECOG Patient ID
DCI Name
Registration Step
Reporting Period
End Of Treatment (End of treatment)
Patient demographics
Patient Initials
ECOG Protocol Number
ECOG Patient ID
Participating Group Protocol Number
Participating Group Patient ID
Institution/Affiliate
Data amendment
Please mark an 'X' if data have been amended.
(Please circle amended items in red)
Date data amended
Vital Status
1 / 3
Vital Status
Alive (Alive)
Dead (Dead)
Date of Last Contact or Death
Primary Cause of Death (if applicable)
Due To Other Cause (Due to other
cause)
Due To Protocol Treatment (Due to
protocol treatment)
Due To This Disease (Due to this
disease)
Unknown (Unknown)
Describe cause of death
Protocol therapy
Did patient receive protocol therapy?
Yes
No
Section I
Reason Treatment Ended
Adverse Event/side Effects/complications
(Adverse Event/Side
Effects/Complications)
Alternative Therapy (Alternative therapy)
Death On Study (Death on study)
Disease Progression, Relapse During
Active Treatment (Disease progression,
relapse during active treatment)
Other (Other)
Patient Off-treatment For Other
Complicating Disease (Patient off-
treatment for other complicating disease)
Patient Withdrawal Or Refusal After
Beginning Protocol Therapy (Patient
withdrawal/refusal after beginning
protocol therapy)
Treatment Completed Per Protocol
Criteria (Treatment completed per
protocol criteria)
Other Complicating Disease specify
Other specify
Last date protocol therapy was given
2 / 3
ECOG Off-Treatment Form NCT00520975
Section II
Reason treatment never started
Adverse Event/side Effects/complications
(Adverse events/side
effects/complications)
Death Before Beginning Protocol
Therapy (Death before beginning
protocol therapy)
Disease Progression, Relapse Prior To
Beginning Protocol Therapy (Disease
progression, relapse before protocol
treatment)
Medical Decision (Medical decision)
No Treatment, Per Protocol Criteria (No
treatment assigned per protocol)
Other (Other)
Patient_ineligible (Patient ineligible)
Patient Withdrawal/refusal Before
Beginning Protocol Therapy (Patient
withdrawal/refusal before beginning
protocol therapy)
Other specify
Comments
Investigator Signature
Investigator Signature Date
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ECOG Baseline Disease Evaluation Form
(RECIST) NCT00520975
ECOG Baseline Disease Evaluation Form  (RECIST)
NCT00520975
First-Line Chemotherapy and Trastuzumab With or Without
Bevacizumab in Treating Patients With Metastatic Breast
Cancer That Overexpresses HER-2/NEU
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=171FC80B-
42C1-397E-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11083
ECOG Baseline Disease Evaluation
Form  (RECIST) NCT00520975
Header
ECOG Protocol Number
ECOG Patient ID
DCI Name
Registration Step
Report Period
Baseline (Baseline)
Patient demographics
Patient Initials
ECOG Protocol Number
ECOG Patient ID
Participating Group Protocol Number
Participating Group Patient ID
Institution/Affiliate
Data amendment
Please mark an 'X' if data have been amended.
(Please circle amended items in red)
Date data amended
TARGET LESIONS
1 / 3
Are there any target lesions
Yes
No
Lesion Number
Site of Lesion (Comments - Multiple nontarget
lesions within an organ may be combined as a
single site; report in a consistent manner on
subsequent forms.)
Site Code
Bone (bone)
Brain (Brain)
Breast (Breast)
Effusion/ascites (Effusion/Ascites)
Gi (GI)
Gu (GU)
Head & Neck (Head & Neck)
Liver (Liver)
Lung (Lung)
Nodes (Nodes)
Other (other)
Skin (Skin)
Method of Evaluation
Bone Scan (Bone scan)
Chest X-ray (Chest X-Ray)
Clinical (Clinical Examination)
Ct Scan (CT Scan)
Mri (MRI)
Other (other)
Spiral Ct Scan (Spiral CT scan)
Ultrasound (Ultrasound)
Date of Evaluation
Longest Diameter of Lesion (s cm)
Sum of longest diameters of all target lesions
Nontarget Lesions
Lesion Number
Site of Lesion (Comments - Multiple nontarget
lesions within an organ may be combined as a
single site; report in a consistent manner on
subsequent forms.)
Site Code
Bone (bone)
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Brain (Brain)
Breast (Breast)
Effusion/ascites (Effusion/Ascites)
Gi (GI)
Gu (GU)
Head & Neck (Head & Neck)
Liver (Liver)
Lung (Lung)
Nodes (Nodes)
Other (other)
Skin (Skin)
Method of Evaluation
Bone Scan (Bone scan)
Chest X-ray (Chest X-Ray)
Clinical (Clinical Examination)
Ct Scan (CT Scan)
Mri (MRI)
Other (other)
Spiral Ct Scan (Spiral CT scan)
Ultrasound (Ultrasound)
Date of Evaluation
Cytology Result
Negative (Negative)
Not Done (Not done)
Positive (Positive)
Comments
Comments
Investigator Signature
Investigator Signature Date
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ECOG Baseline Disease Evaluation Form  (RECIST) NCT00520975
CALGB 40503 ELIGIBILITY CHECKLIST
NCT00601900
CALGB 40503 ELIGIBILITY CHECKLIST NCT00601900 
Tamoxifen or Letrozole With or Without Bevacizumab in
Treating Women With Stage III or Stage IV Breast Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=2DB1C326-
547F-15B1-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11085
CALGB 40503 ELIGIBILITY
CHECKLIST NCT00601900
Header
CALGB Study No
CALGB Patient ID
Patient demographics
Patient Initials (Last, First Middle)
Patient Hospital No.
Institution/Affiliate
Participating Group
Participating Group Study No.
Participating Group Patient ID
Eligibility Criteria
Eligibility criteria
>= 18 Years Of Age (>= 18 years of age)
>= 2 Weeks Since Prior Radiotherapy
And All Toxicities Resolved (>= 2 weeks
since prior radiotherapy and all toxicities
resolved)
Beta-hcg Negative (in Premenopausal
Women) (Beta-Hcg negative (in
premenopausal women))
Bilirubin <= 1.5 X Uln Unless Due To
Gilbert's Syndrome (Bilirubin <= 1.5 x
ULN unless due to Gilbert's Syndrome)
Bisphosphonate Therapy Allowed
(Bisphosphonate therapy allowed)
Creatinine <= 2.0 Mg/dl (Creatinine <=
2.0 mg/dl)
Ecog (zubrod) Ps <= 1; Life Expectancy
>=12 Wk (ECOG (Zubrod) PS <= 1; life
1 / 3
expectancy >=12 wk)
Granulocytes >= 1000/ul (Granulocytes
>= 1000/ul)
Histologic Dx Of Primary, Metastatic
Stage Iv Or Locally Advanced,
Unresectable Stage Iiib Cancer Of The
Female Breast (using Ajcc Criteria, 6th
Edition) Not Amenable To Local Therapy
(Histologic dx of primary, metastatic
Stage IV or locally advanced,
unresectable Stage IIIB cancer of the
female breast (using AJCC criteria, 6th
edition) not amenable to local therapy)
Inr <= 1.6, Unless On Full Dose Warfarin
(INR <= 1.6, unless on full dose warfarin)
Measurable/non-measurable Disease By
Recist Criteria (Measurable/non-
measurable disease by RECIST criteria)
No Arterial Thrombotic Events, Tia, Cva,
Acute Mi Or Unstable Angina Within 6
Months Of Registration (No arterial
thrombotic events, TIA, CVA, acute MI or
unstable angina within 6 months of
registration)
No Clinically Significant Cardiovascular
Disease (No clinically significant
cardiovascular disease)
No Concurrent Active Secondary
Malignancy (No concurrent active
secondary malignancy)
No History Of Abdominal Fistula Or
Intraabdominal Abscess Within 6 Months
Nor Gi Perforation Within 12 Months Of
Registration (No history of abdominal
fistula or intraabdominal abscess within 6
months nor GI perforation within 12
months of registration)
No History Of Significant Bleeding Within
6 Months Of Registration (No history of
significant bleeding within 6 months of
registration)
No Known Allergies To Aromatase
Inhibitors Or Estrogen Receptor
Modulators (No known allergies to
aromatase inhibitors or estrogen
receptor modulators)
No Known Cns Metastases (No known
CNS metastases)
No Major Surgery Within 28 Days Of
Registration (No major surgery within 28
days of registration)
No Prior Bevacizumab Or Anti-vegf
Therapy (No prior bevacizumab or anti-
VEGF therapy)
No Prior Chemotherapy For Metastatic
Disease (No prior chemotherapy for
metastatic disease)
No Serious, Non-healing Wound, Ulcer
Or Bone Fx (No serious, non-healing
wound, ulcer or bone fx)
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Ovarian Suppression Required For
Premenopausal Women (Ovarian
suppression required for premenopausal
women)
Patients On Full Dose Anticoagulant
Must Be On A Stable Dose Of Warfarin
(Patients on full dose anticoagulant must
be on a stable dose of warfarin)
Platelet Count >= 100,000/ul (Platelet
count >= 100,000/ul)
Prior Adjuvant Or Neoadjuvant
Chemotherapy Allowed (Prior adjuvant or
neoadjuvant chemotherapy allowed)
Prior Endocrine Therapy Not Required,
But Is Permitted In Adjuvant Setting; No
Prior Endocrine Therapy For Metastatic
Disease Unless Initiated Within 4 Weeks
Prior To Protocol Registration (Prior
endocrine therapy not required, but is
permitted in adjuvant setting; No prior
endocrine therapy for metastatic disease
unless initiated within 4 weeks prior to
protocol registration)
Transaminases (alt, Ast) <= 2.5 X Uln
(Transaminases (ALT, AST) <= 2.5 x
ULN)
Tumors That Are Er And/or Pgr Positive
(Tumors that are ER and/or PgR
positive)
Urinalysis <= 1+ Protein (Urinalysis <=
1+ protein)
Women Can Be Either Pre- Or
Postmenopausal (Women can be either
pre- or postmenopausal)
Footer Module
Completed by (Last name, First name)
Date Form Completed (MM DD YYYY)
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CALGB 40503 ELIGIBILITY CHECKLIST NCT00601900
CALGB 40503 BASELINE SOLID TUMOR
EVALUATION FORM NCT00601900
CALGB 40503 BASELINE SOLID TUMOR EVALUATION
FORM NCT00601900
Tamoxifen or Letrozole With or Without Bevacizumab in
Treating Women With Stage III or Stage IV Breast Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=240398A9-
9A49-483A-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11086
CALGB 40503 BASELINE SOLID
TUMOR EVALUATION FORM
NCT00601900
Header
CALGB Form
CALGB Study No
CALGB Patient ID
Are data amended
Yes
No
Patient demographics
Patient Initials (Last, First Middle)
Patient Hospital No.
Institution/Affiliate
Participating Group
Participating Group Study No
Participating Group Patient ID
TARGET LESION(S) BASELINE
EVALUATION
Target Lesion Site
Ascites (Ascites)
Bone (Bone)
Bone Marrow (Bone marrow)
Brain (Brain)
Chest Wall (Chest wall)
Gastrointestinal Tract (Gastrointestinal
tract)
1 / 3
Gynecologic Other (Gynecologic other)
Liver (Liver)
Lung (Lung)
Distant Nodes (Nodes distant)
Nodes Local (Nodes local)
Other (Other)
Ovary (Ovary)
Peritoneum (Peritoneum)
Pleura (Pleura)
Primary Tumor (Primary tumor)
Skin / Subcutaneous Tissue Involvement
(Skin subcutaneous)
Other specify
Date of evaluation (* When several tests are
performed, select the date of the most recent test
and most definitive result.)
Method of Evaluation (**)
Bone Scan (Bone Scan)
Chest X-ray (Chest X-ray)
Clinical (Clinical Examination)
Ct Scan (CT Scan)
Mri (MRI)
Other (Other)
Spiral Ct Scan (Spiral CT Scan)
Ultrasound (Ultrasound)
If Other, specify
Longest Diameter of Lesion(s) (s)
Sum of Longest Diameters of All Target Lesions
Non-target Lesion(s) Follow-up Evaluation
Are there any non-target lesions
Yes
No
Nontarget Lesion Site
Ascites (Ascites)
Bone (Bone)
Bone Marrow (Bone marrow)
Brain (Brain)
Chest Wall (Chest wall)
Gastrointestinal Tract (Gastrointestinal
tract)
Gynecologic Other (Gynecologic other)
Liver (Liver)
Lung (Lung)
Distant Nodes (Nodes distant)
Nodes Local (Nodes local)
Other (Other)
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Ovary (Ovary)
Peritoneum (Peritoneum)
Pleura (Pleura)
Primary Tumor (Primary tumor)
Skin / Subcutaneous Tissue Involvement
(Skin subcutaneous)
Other specify
Date of evaluation (* When several tests are
performed, select the date of the most recent test
and most definitive result.)
Method of Evaluation (**)
Bone Scan (Bone Scan)
Chest X-ray (Chest X-ray)
Clinical (Clinical Examination)
Ct Scan (CT Scan)
Mri (MRI)
Other (Other)
Spiral Ct Scan (Spiral CT Scan)
Ultrasound (Ultrasound)
If Other, specify
Footer module
Completed by (print or type name)
Date Form Completed (MM DD YYYY)
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CALGB 40503 BASELINE SOLID TUMOR EVALUATION FORM
NCT00601900
CALGB 40503 TISSUE TRACKING FORM
NCT00601900
CALGB 40503 TISSUE TRACKING FORM NCT00601900 
Tamoxifen or Letrozole With or Without Bevacizumab in
Treating Women With Stage III or Stage IV Breast Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=23F62179-
72EA-407A-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11087
CALGB 40503 TISSUE TRACKING
FORM NCT00601900
Header
CALGB Form
CALGB Study No.
CALGB Patient ID
Are data amended
Yes
No
Patient demographics
Patient Initials
Patient Hospital No.
Institution/Affiliate
Participating Group
Participating Group Study No
Participating Group Patient ID
Pathology/Biopsy
Does institutional pathology report accompany
this form
Yes
No
Does specimen accompany this form
Yes
No
Form without specimen, reason
Date specimen collected
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Date specimen submitted (MM DD YYYY)
Tissue pathology (Mark one with an X.)
Lymph Node Metastasis (Lymph node
metastasis)
Metastasis (Metastasis)
Primary Tumor (Primary tumor)
Recurrent Tumor (Recurrent tumor)
Method of extraction (Mark one with an X.)
Axillary Dissection (Axillary dissection)
Biopsy (Biopsy)
General Surgery, Nos (General surgery,
NOS)
Lumpectomy (Lumpectomy)
Mastectomy (Mastectomy)
Re-excision (Re-excision)
Sentinel Node Dissection (Sentinel node
dissection)
Type of specimen submitted (Mark one with an
X.)
Formalin Fixed Paraffin Embedded
Tissue Block (Formalin fixed paraffin
embedded tissue block)
Punch Biopsies From Ffpe Block (Punch
biopsies from FFPE block)
Unstained Superfrost Plus Slides
(Unstained superfrost plus slides)
Formalin fixed paraffin embedded tissue block,
specify number
Punch biopsies from FFPE block, specify number
Unstained superfrost plus slides, specify number
Institutional surgical pathology number
LabTrak shipment ID
Submitted by (Last name, First name)
Phone number
Email Address
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CALGB HER2/neu Testing Form
NCT00770809
CALGB HER2/neu Testing Form NCT00770809
Paclitaxel and Trastuzumab With or Without Lapatinib in
Treating Patients With Stage II or Stage III Breast Cancer
That Can Be Removed by Surgery
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=3CB1A910-
D444-4DE4-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11088
CALGB HER2/neu Testing Form
NCT00770809
Header
CALGB Form
CALGB Study No
CALGB Patient ID
Amended Data
Yes
No
Patient demographics
Patient Initials (Last, First Middle)
Patient Hospital No.
Institution/Affiliate
Participating Group
Participating Group Study No.
Participating Group Patient ID
Testing Data
Immunohistochemistry Kit or Test Type
Cb-11 Other (CB-11 other)
Cb-11/ventana Kit (CB-11/Ventana Kit)
Dako Herceptest [tm] (DAKO Herceptest
[TM])
Ihc Not Done (IHC not done)
Other Specify (Other)
Other specify
Herceptest Score
0 (0)
1 / 2
1+ (1+)
2+ (2+)
3+ (3+)
Ventana Scoring System (Score)
0 (0)
1+ (1+)
2+ (2+)
3+ (3+)
Scoring system
+1 (+1)
0 (0)
2+ (2+)
3+ (3+)
Results
FISH Kit or Test Type
Fish Not Done (FISH not done)
Other Specify (Other, specify)
Ventana Inform (Ventana INFORM)
Vysis/path Vysion[tm] (Vysis/PathVysion)
FISH HER2/neu chromosome 17 Ratio
Other, specify
Results
Testing Results
HER-2/neu status
Negative (Negative)
Positive (Positive)
Footer Module
Completed by (Last name, First name)
Date Form Completed (MM DD YYYY)
Comments
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CALGB: 40601 POST-NEOADJUVANT CHEMOTHERAPY
SURGICAL EVALUATION FORM NCT00770809
CALGB: 40601 POST-NEOADJUVANT CHEMOTHERAPY
SURGICAL EVALUATION FORM NCT00770809
Paclitaxel and Trastuzumab With or Without Lapatinib in
Treating Patients With Stage II or Stage III Breast Cancer
That Can Be Removed by Surgery
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=3A7CAEA0-
52A1-0226-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11089
CALGB: 40601 POST-
NEOADJUVANT CHEMOTHERAPY
SURGICAL EVALUATION FORM
NCT00770809
Header
CALGB Form
CALGB Study No
CALGB Patient ID
Date of evaluation
Amended Data
Yes
No
Patient demographics
Patient Initials (Last, First Middle)
Patient Hospital No.
Institution/Affiliate
Participating Group
Participating Group Study No.
Participating Group Patient ID
Breast Conserving Therapy
Was the patient (after receiving neoadjuvant
chemotherapy) a candidate for breast conserving
treatment
Yes
No
1 / 3
Reason not a candidate (If no,)
Absolute Contraindication To Radiation
Therapy (Absolute contraindication to
radiation therapy)
Diffuse Suspicious Microcalcifications
(Diffuse suspicious microcalcifications)
Multicentric Breast Cancer (Multicentric
breast cancer)
Other (Other)
Probable Poor Cosmetic Outcome
(Probable poor cosmetic outcome)
Breast Cancer Pt4 Tnm Finding (T4)
Tumor Is Too Large In Relation To Native
Breast Size (Tumor is too large in
relation to native breast size)
Other, specify
Absolute contraindication to radiation therapy
Connective Tissue Disorder (Connective
Tissue Disorder)
Patient Access To Prescribed Radiation
Therapy (Patient access to prescribed
radiation therapy)
Patient Compliance With Prescribed
Radiation Therapy (Patient compliance
with prescribed radiation therapy)
Prior Radiation Therapy (Prior radiation
therapy)
Connective tissue disorder, specify
Was breast conserving treatment attempted?
Yes
No
Reason not attempted?
Other (Other)
Patient Choice (Patient choice)
Other, specify
Patient choice
Avoid Possible Radiation Therapy (Avoid
possible radiation therapy)
Avoid Possible Return Trip To The
Operating Room (Avoid possible return
trip to the operating room)
Was BCT successful?
Yes
No
Reason BCT unsuccessful?
Other (Other)
Positive Surgical Margin (Positive
Margins)
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CALGB: 40601 POST-NEOADJUVANT CHEMOTHERAPY SURGICAL
EVALUATION FORM NCT00770809
Other, specify
Axillary Node
Was the patient's post-neoadjuvent
chemotherapy treatment axillary nodal status
evaluated?
Yes
No
Method of Evaluation
Axillary Dissection (Axillary dissection)
Clinical Examination (pe) (Clinical
examination)
Fine Needle Aspiration Biopsy (Fine
needle aspiration biopsy)
Mri Scan (MRI scan)
Other (Other)
Pet Scan (PET scan)
Sentinel Node Biopsy (Sentinel node
biopsy)
Ultrasound (Ultrasound)
Other Specify
Results
Equivocal (Equivocal)
Not Applicable (N/A)
Negative (Negative)
Positive (Positive)
Unknown (Unknown)
Date of Evaluation
Was blue dye used
Yes
No
Was technetium used
Yes
No
Footer Module
Completed by (Last name, First name)
Date Form Completed (MM DD YYYY)
Comments
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CALGB: 40601 POST-NEOADJUVANT CHEMOTHERAPY SURGICAL
EVALUATION FORM NCT00770809
CALGB-40502 Treatment Summary Form
NCT00785291
CALGB-40502 Treatment Summary Form NCT00785291
Paclitaxel, Paclitaxel Albumin-Stabilized Nanoparticle
Formulation, or Ixabepilone With or Without Bevacizumab
in Treating Patients With Stage IIIC or Stage IV Breast
Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=51FC1981-
9DE6-0C8A-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11090
CALGB-40502 Treatment Summary
Form NCT00785291
Header
CALGB Form
CALGB Study No
CALGB Patient ID
Reporting period end date (MM DD YYYY)
Are data amended
Yes
No
Patient demographics
Patient Initials (Last, First Middle)
Patient Hospital No.
Institution/Affiliate
Participating Group
Participating Group Study No.
Participating Group Patient ID
Treatment Plan
Start Date of First Treatment (MM DD YYYY)
Date of Last Clinical Assessment (MM DD YYYY)
Total number of weeks treatment was given
1 / 3
Last date protocol therapy was given (MM DD
YYYY)
Reason Treatment Ended (mark one with an X)
Adverse Event/side Effects/complications
(Adverse Event/Side
Effects/Complications)
Alternative Therapy (Alternative therapy)
Death On Study (Death on study)
Disease Progression, Relapse During
Active Treatment (Disease progression,
relapse during active treatment)
Other (Other)
Patient Off-treatment For Other
Complicating Disease (Patient off-
treatment for other complicating disease)
Patient Withdrawal Or Refusal After
Beginning Protocol Therapy (Patient
withdrawal/refusal after beginning
protocol therapy)
Patient Withdrawal Or Refusal Before
Beginning Protocol Therapy (Patient
withdrawal/refusal prior to beginning
protocol therapy)
Other specify
MedDRA Code
CTC Adverse Event Term
CTC AE Grade
CTC AE Attribution Code
Definite (Definite)
Possible (Possible)
Probable (Probable)
Unlikely (Unlikely)
Unrelated (Unrelated)
Were any Optional Therapies given?
Yes
No
Optional Therapy Name
Was any non-protocol therapy given during
protocol treatment?
Yes
No
specify (If Yes)
Concurrent Non-protocol Biologic
Response Modifier Therapy (Concurrent
non-protocol biologic response modifier
therapy)
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Concurrent Non-protocol Chemotherapy
(Concurrent non-protocol chemotherapy)
Concurrent Non-protocol High Dose
Chemotherapy/autologous Stem Cell
Transplant (Concurrent non-protocol high
dose chemotherapy/autologous stem cell
transplant)
Concurrent Non-protocol Hormonal
Therapy (Concurrent non-protocol
hormonal therapy)
Concurrent Non-protocol Radiation
Therapy (Concurrent non-protocol
radiation therapy)
Were supporting agents given during this cycle?
Antibiotic (Antibiotics)
Antidiarrheal (Antidiarrheal)
Antiemetics (Antiemetics)
Blood Or Blood Products (Blood or blood
products)
Epoetin Alfa (Epoetin)
Gcsf (GCSF)
Gm-csf (GM-CSF)
Other (Other)
Other, specify
Comments
COMMENTS
Completed by (Last name, First name)
Date form completed (MM DD YYYY)
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CALGB 40601 ELIGIBILITY CHECKLIST
NCT00770809
CALGB 40601 ELIGIBILITY CHECKLIST NCT00770809 
Paclitaxel and Trastuzumab With or Without Lapatinib in
Treating Patients With Stage II or Stage III Breast Cancer
That Can Be Removed by Surgery
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=39E2B924-
90AB-3340-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11091
CALGB 40601 ELIGIBILITY
CHECKLIST NCT00770809
Header
CALGB Study No
CALGB Patient ID
Patient demographics
Patient Initials (Last, First Middle)
Patient Hospital No.
Institution/Affiliate
Participating Group
Participating Group Study No.
Participating Group Patient ID
Eligibility Criteria
Eligibility criteria
Alt <= 2.5 X Uln (ALT <= 2.5 x ULN)
Anc >= 1,000/mcl (ANC >= 1,000/mcl)
Ast <= 2.5 X Uln (AST <= 2.5 x ULN)
Cardiac Ejection Fraction > 50% By
Echocardiogram Or Muga Scan (Cardiac
ejection fraction > 50% by
echocardiogram or MUGA scan)
Clinical Stage Ii-iii Operable Invasive
Breast Cancer With Intent To Perform
Surgical Resection After Neoadjuvant
Therapy (Clinical stage II-III operable
invasive breast cancer with intent to
perform surgical resection after
neoadjuvant therapy)
Ecog (zubrod) Ps <= 1; Life Expectancy
>=12 Wk (ECOG (Zubrod) Performance
Status 0-1)
1 / 2
Er/pgr Status Is Known (ER/PgR status
is known)
Invasive Breast Cancer (Invasive breast
cancer)
Multicentric Or Bilateral Disease Is
Eligible If Target Lesion Meets Eligibility
Criteria (Multicentric or bilateral disease
is eligible if target lesion meets eligibility
criteria)
No Medication With Known Potential For
Interaction With Lapatinib For At Least 7
Days Prior To Study Entry (No
medication with known potential for
interaction with lapatinib for at least 7
days prior to study entry)
No Prior Chemotherapy, Hormone
Therapy, Biologic Or Radiation Therapy
With Therapeutic Intent For This Cancer
(No prior chemotherapy, hormone
therapy, biologic or radiation therapy with
therapeutic intent for this cancer)
Patient Consents To Undergo
Pretreatment Biopsy And To Acquisition
Of Tissue Obtained At The Time Of
Surgery (Patient consents to undergo
pretreatment biopsy and to acquisition of
tissue obtained at the time of surgery)
Patients Not Pregnant Or Nursing
(Patients not pregnant or nursing)
Platelet Count >= 100,000/mm^3
(Platelet count >= 100,000/mm^3)
Beta-hcg Negative (in Premenopausal
Women) (Serum Beta-HCG negative)
Target Lesion In Breast Is > 1 Cm By
Either Clinical Or Radiographic
Measurement. Patients With Axillary
Disease As Only Site Are Not Eligible To
Participate (Target lesion in breast is > 1
cm by either clinical or radiographic
measurement. Patients with axillary
disease as only site are not eligible to
participate)
Bilirubin <= 1.5 X Uln Unless Due To
Gilbert's Syndrome (Total Bilirubin <= 1.5
x ULN unless due to Gilbert's Syndrome)
Tumors Are Her2 Positive As Defined In
Section 4.3 (Tumors are HER2 positive
as defined in section 4.3)
>= 18 Years Of Age (Women or men at
least 18 years of age)
Footer Module
Completed by (Last name, First name)
Date Form Completed (MM DD YYYY)
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CALGB-40502 Blood/Serum Specimen
Submission Form NCT00785291
CALGB-40502 Blood/Serum Specimen Submission Form
NCT00785291 
Paclitaxel, Paclitaxel Albumin-Stabilized Nanoparticle
Formulation, or Ixabepilone With or Without Bevacizumab
in Treating Patients With Stage IIIC or Stage IV Breast
Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=51FC0759-
FD7B-0A76-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11092
CALGB-40502 Blood/Serum
Specimen Submission Form
NCT00785291
Header
CALGB Form
CALGB Study No.
CALGB Patient ID
Are data amended
Yes
No
Patient demographics
Patient Initials (Last, First, Middle)
Patient Hospital No.
Institution/Affiliate
Participating Group
Participating Group Study No.
Participating Group Patient ID
To Be Completed By Submitting Institution
Does specimen accompany this form
Yes
No
Specify reason
Institution Error (Institution error)
Patient Refusal (Patient refusal)
Sample Lost Or Destroyed (Sample lost
1 / 2
or destroyed)
Specimen Type
Whole Blood (Whole blood)
Type of specimen submitted (Mark one with an
X.)
5 Cc Green Top (5 cc Green Top)
5 Ml Edta Purple Top (5 ml EDTA Purple
Top)
7.5 Cc Cell Saver (7.5 cc Cell Saver)
Time Specimen Collected (24-hour clock)
Date specimen collected (MM DD YYYY)
LabTrak shipment ID
Date shipped (MM DD YYYY)
Sample period (^1 For sample period, enter the
cycle number completed prior to specimen
collection or scheduled collection if specimen no
obtained; or enter "0" for pre-study.)
Number of tubes submitted
Approximate volume of sample (ml)
Responsible CRA
CRA phone number
CRA email
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CALGB 40601 TISSUE TRACKING FORM
NCT00770809
CALGB 40601 TISSUE TRACKING FORM NCT00770809 
Paclitaxel and Trastuzumab With or Without Lapatinib in
Treating Patients With Stage II or Stage III Breast Cancer
That Can Be Removed by Surgery
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=39F3A5C5-
5409-0A51-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11093
CALGB 40601 TISSUE TRACKING
FORM NCT00770809
Header
CALGB Form
CALGB Study No.
CALGB Patient ID
Are data amended
Yes
No
Patient demographics
Patient Initials
Patient Hospital No.
Institution/Affiliate
Participating Group
Participating Group Study No
Participating Group Patient ID
TISSUE TRACKING
Does specimen accompany this form
Yes
No
Specify reason
Institution Error (Institution error)
Other (Other)
Patient Refusal (Patient refusal)
Sample Lost Or Destroyed (Sample lost
or destroyed)
Specify
1 / 2
Date specimen collected
Tissue pathology (Mark one with an X.)
Lymph Node Metastasis (Lymph node
metastasis)
Metastasis (Metastasis)
Primary Tumor (Primary tumor)
Recurrent Tumor (Recurrent tumor)
Method of extraction (Mark one with an X.)
Axillary Dissection (Axillary dissection)
Biopsy (Biopsy)
General Surgery, Nos (General surgery,
NOS)
Lumpectomy (Lumpectomy)
Mastectomy (Mastectomy)
Re-excision (Re-excision)
Sentinel Node Dissection (Sentinel node
dissection)
Type of specimen submitted (Mark one with an
X.)
Formalin Fixed Paraffin Embedded
Tissue Block (Formalin fixed paraffin
embedded tissue block)
Frozen Section (Frozen section)
Punch Biopsies From Ffpe Block (Punch
biopsies from FFPE block)
Unstained Superfrost Plus Slides
(Unstained superfrost plus slides)
Formalin fixed paraffin embedded tissue block,
specify number
Punch biopsies from FFPE block, specify number
Unstained superfrost plus slides, specify number
Frozen section, specify number
Institutional surgical pathology number
LabTrak shipment ID
Submitted by (Last name, First name)
Date specimen submitted (MM DD YYYY)
Phone number
Email Address
2 / 2
CALGB 40601 TISSUE TRACKING FORM NCT00770809
CALGB 40601 BLOOD SPECIMEN
SUBMISSION FORM NCT00770809
CALGB 40601 BLOOD SPECIMEN SUBMISSION FORM
NCT00770809 
Paclitaxel and Trastuzumab With or Without Lapatinib in
Treating Patients With Stage II or Stage III Breast Cancer
That Can Be Removed by Surgery
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=39F53CE5-
0ECF-0100-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11094
CALGB 40601 BLOOD SPECIMEN
SUBMISSION FORM NCT00770809
Header
CALGB Form
CALGB Study No.
CALGB Patient ID
Are data amended
Yes
No
Patient demographics
Patient Initials (Last, First, Middle)
Patient Hospital No.
Institution/Affiliate
Participating Group
Participating Group Study No.
Participating Group Patient ID
To Be Completed By Submitting Institution
Does specimen accompany this form
Yes
No
Specify reason
Institution Error (Institution error)
Patient Refusal (Patient refusal)
Sample Lost Or Destroyed (Sample lost
or destroyed)
1 / 2
Specimen Type
Whole Blood (Whole blood)
Type of specimen submitted (Mark one with an
X.)
10 Ml Sst/tiger (10 ml SST/Tiger)
7.5 Cc Cell Saver (7.5 cc Cell Saver)
Pharmacogenomics Edta (purple Top)
(Pharmacogenomics EDTA (Purple Top))
Time Specimen Collected (24-hour clock)
Date specimen collected (MM DD YYYY)
LabTrak shipment ID
Sample period (^1 For sample period, enter the
cycle number completed prior to specimen
collection or scheduled collection if specimen no
obtained; or enter "0" for pre-study.)
Number of tubes submitted
Approximate volume of sample (ml)
Completed by
Date Form Completed
Phone number to be used in event of sample
problems
Email Address
Footer Module
Completed by
Date Form Completed
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CALGB-40502 PHYSICAL ACTIVITY
QUESTIONNAIRE NCT00785291
CALGB-40502 PHYSICAL ACTIVITY QUESTIONNAIRE
NCT00785291
Paclitaxel, Paclitaxel Albumin-Stabilized Nanoparticle
Formulation, or Ixabepilone With or Without Bevacizumab
in Treating Patients With Stage IIIC or Stage IV Breast
Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=7B07C2F1-
242E-5D8F-E040-BB89AD4327F7
All rights reserved. Please visit https://medical-data-
models.org/forms/11095
CALGB-40502 PHYSICAL ACTIVITY
QUESTIONNAIRE NCT00785291
Header
CALGB Form
CALGB Study No
CALGB Patient ID
Date form completed (MM DD YYYY)
Are data amended
Yes
No
Patient demographics
Patient Initials (Last, First Middle)
Patient Hospital No.
Institution/Affiliate
Participating Group
Participating Group Study No.
Participating Group Patient ID
During The Past Month, About How Much
Time Did You Spend Doing These
Recreational Activities Each Week?
Walking for exercise or walking to work
1 Hour (1 hour)
1 To 1.5 Hours (1 to 1.5 hours)
1 To 4 Minutes (1 to 4 min.)
11 Or More Hours (11 or more hours)
1 / 5
2 To 3 Hours (2 to 3 hours)
20 To 59 Minutes (20 to 59 min.)
4 To 6 Hours (4 to 6 hours)
5 To 19 Minutes (5 to 19 min.)
7 To 10 Hours (7 to 10 hours)
Zero (Zero)
Jogging (slower than 10-minute mile)
1 Hour (1 hour)
1 To 1.5 Hours (1 to 1.5 hours)
1 To 4 Minutes (1 to 4 min.)
11 Or More Hours (11 or more hours)
2 To 3 Hours (2 to 3 hours)
20 To 59 Minutes (20 to 59 min.)
4 To 6 Hours (4 to 6 hours)
5 To 19 Minutes (5 to 19 min.)
7 To 10 Hours (7 to 10 hours)
Zero (Zero)
Running (10-minute miles or faster)
1 Hour (1 hour)
1 To 1.5 Hours (1 to 1.5 hours)
1 To 4 Minutes (1 to 4 min.)
11 Or More Hours (11 or more hours)
2 To 3 Hours (2 to 3 hours)
20 To 59 Minutes (20 to 59 min.)
4 To 6 Hours (4 to 6 hours)
5 To 19 Minutes (5 to 19 min.)
7 To 10 Hours (7 to 10 hours)
Zero (Zero)
Bicycling (including stationary bicycle)
1 Hour (1 hour)
1 To 1.5 Hours (1 to 1.5 hours)
1 To 4 Minutes (1 to 4 min.)
11 Or More Hours (11 or more hours)
2 To 3 Hours (2 to 3 hours)
20 To 59 Minutes (20 to 59 min.)
4 To 6 Hours (4 to 6 hours)
5 To 19 Minutes (5 to 19 min.)
7 To 10 Hours (7 to 10 hours)
Zero (Zero)
Tennis, squash, racquetball
1 Hour (1 hour)
1 To 1.5 Hours (1 to 1.5 hours)
1 To 4 Minutes (1 to 4 min.)
11 Or More Hours (11 or more hours)
2 To 3 Hours (2 to 3 hours)
20 To 59 Minutes (20 to 59 min.)
4 To 6 Hours (4 to 6 hours)
5 To 19 Minutes (5 to 19 min.)
7 To 10 Hours (7 to 10 hours)
Zero (Zero)
Lap swimming
1 Hour (1 hour)
1 To 1.5 Hours (1 to 1.5 hours)
1 To 4 Minutes (1 to 4 min.)
11 Or More Hours (11 or more hours)
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2 To 3 Hours (2 to 3 hours)
20 To 59 Minutes (20 to 59 min.)
4 To 6 Hours (4 to 6 hours)
5 To 19 Minutes (5 to 19 min.)
7 To 10 Hours (7 to 10 hours)
Zero (Zero)
Other aerobic exercise (aerobic dancing, ski or
stair machine, etc.)
1 Hour (1 hour)
1 To 1.5 Hours (1 to 1.5 hours)
1 To 4 Minutes (1 to 4 min.)
11 Or More Hours (11 or more hours)
2 To 3 Hours (2 to 3 hours)
20 To 59 Minutes (20 to 59 min.)
4 To 6 Hours (4 to 6 hours)
5 To 19 Minutes (5 to 19 min.)
7 To 10 Hours (7 to 10 hours)
Zero (Zero)
Any other vigorous activities (lawn mowing, etc.)
1 Hour (1 hour)
1 To 1.5 Hours (1 to 1.5 hours)
1 To 4 Minutes (1 to 4 min.)
11 Or More Hours (11 or more hours)
2 To 3 Hours (2 to 3 hours)
20 To 59 Minutes (20 to 59 min.)
4 To 6 Hours (4 to 6 hours)
5 To 19 Minutes (5 to 19 min.)
7 To 10 Hours (7 to 10 hours)
Zero (Zero)
Lower intensity exercise (yoga, stretching,
Pilates, toning)
1 Hour (1 hour)
1 To 1.5 Hours (1 to 1.5 hours)
1 To 4 Minutes (1 to 4 min.)
11 Or More Hours (11 or more hours)
2 To 3 Hours (2 to 3 hours)
20 To 59 Minutes (20 to 59 min.)
4 To 6 Hours (4 to 6 hours)
5 To 19 Minutes (5 to 19 min.)
7 To 10 Hours (7 to 10 hours)
Zero (Zero)
Weight training or resistance exercises (including
free weights or machines such as Nautilus)
1 Hour (1 hour)
1 To 1.5 Hours (1 to 1.5 hours)
1 To 4 Minutes (1 to 4 min.)
11 Or More Hours (11 or more hours)
2 To 3 Hours (2 to 3 hours)
20 To 59 Minutes (20 to 59 min.)
4 To 6 Hours (4 to 6 hours)
5 To 19 Minutes (5 to 19 min.)
7 To 10 Hours (7 to 10 hours)
Zero (Zero)
During The Past Month, About How Much
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Time Did You Spend Doing These
Activities Each Week?
Standing or walking around at work or away from
home
0 Hours (0 hours)
1 Hour (1 hour)
11 To 20 Hours (11 to 20 hours)
2 To 5 Hours (2 to 5 hours)
21 To 40 Hours (21 to 40 hours)
40 To 60 Hours (40 to 60 hours)
6 To 10 Hours (6 to 10 hours)
61 To 90 Hours (61 to 90 hours)
Over 90 Hours (over 90 hours)
Standing or walking around at home
0 Hours (0 hours)
1 Hour (1 hour)
11 To 20 Hours (11 to 20 hours)
2 To 5 Hours (2 to 5 hours)
21 To 40 Hours (21 to 40 hours)
40 To 60 Hours (40 to 60 hours)
6 To 10 Hours (6 to 10 hours)
61 To 90 Hours (61 to 90 hours)
Over 90 Hours (over 90 hours)
Sitting at work or away from home or while
driving
0 Hours (0 hours)
1 Hour (1 hour)
11 To 20 Hours (11 to 20 hours)
2 To 5 Hours (2 to 5 hours)
21 To 40 Hours (21 to 40 hours)
40 To 60 Hours (40 to 60 hours)
6 To 10 Hours (6 to 10 hours)
61 To 90 Hours (61 to 90 hours)
Over 90 Hours (over 90 hours)
Sitting at home while watching TV/videos/DVDs
0 Hours (0 hours)
1 Hour (1 hour)
11 To 20 Hours (11 to 20 hours)
2 To 5 Hours (2 to 5 hours)
21 To 40 Hours (21 to 40 hours)
40 To 60 Hours (40 to 60 hours)
6 To 10 Hours (6 to 10 hours)
61 To 90 Hours (61 to 90 hours)
Over 90 Hours (over 90 hours)
Other sitting at home (that is, not watching
TV/videos/DVDs)
0 Hours (0 hours)
1 Hour (1 hour)
11 To 20 Hours (11 to 20 hours)
2 To 5 Hours (2 to 5 hours)
21 To 40 Hours (21 to 40 hours)
40 To 60 Hours (40 to 60 hours)
6 To 10 Hours (6 to 10 hours)
61 To 90 Hours (61 to 90 hours)
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Over 90 Hours (over 90 hours)
Vital status
What is your usual walking pace outdoors
Brisk Pace (3 To 3.9 Mph) (Brisk pace (3
to 3.9 mph))
Easy, Casual (less Than 2 Mph) (Easy,
casual (less than 2 mph))
Normal, Average (Normal, average)
Unable To Walk (Unable to walk)
Very Brisk/striding (4 Mph Or Faster)
(Very brisk/striding (4 mph or faster))
How many flights of stairs (not individual steps)
do you climb daily
10 To 14 Flights Of Stairs (10 to 14
flights)
15 Or More Flights Of Stairs (15 or more
flights)
2 Flights Of Stairs Or Less (2 flights or
less)
3 To 4 Flights Of Stairs (3 to 4 flights)
5 To 9 Flights Of Stairs (5 to 9 flights)
Comments
Comments
Completed by (Last name, First name)
Date form completed (MM DD YYYY)
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CALGB: Pharmacogenomic Submission and
Quality Assurance Form NCT00770809
The Pharmacogenomic Submission and Quality Assurance
Form, a CDE-compliant CALGB CRF to be used on
CALGB protocols. NCT00770809 
Paclitaxel and Trastuzumab With or Without Lapatinib in
Treating Patients With Stage II or Stage III Breast Cancer
That Can Be Removed by Surgery
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=3CB305DE-
32D4-5C21-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11096
CALGB: Pharmacogenomic
Submission and Quality Assurance
Form NCT00770809
Header
CALGB Form
CALGB Study No.
CALGB Patient ID
Form Submission Date (MM/DD/YYYY)
Are data amended
Yes
No
Patient demographics
Patient Initials (Last, First Middle)
Patient Hospital No
Institution/Affiliate
Participating Group
Participating Group Study No.
Participating Group Patient ID
Biopsy and Cytology Specimens
Does specimen accompany this form
Yes
No
Specify reason (If no,)
Institution Error (Institution error)
Other (Other)
Patient Refusal (Patient refusal)
1 / 2
Sample Lost Or Destroyed (Sample lost
or destroyed)
Biopsy and Cytology Specimens collection
Date Specimen Collected (MM DD YYYY)
Collection Time (24-hour clock)
Was blood sample collected in an EDTA
Vacutainer tube (purple top)
Yes
No
Was blood sample stored either at 4 degrees C or
frozen within 24 hours of collection
Yes
No
Was blood sample shipped to the PCO on a cold
pack
Yes
No
Biopsy and Cytology Specimens shipment
Date Specimen Shipped (specimen)
Time specimen shipped (24-hour clock)
LabTrak sample ID
LabTrak shipment ID
Submitted by
CRA email
CRA phone number
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CALGB BASELINE SOLID TUMOR
EVALUATION FORM NCT00770809
CALGB BASELINE SOLID TUMOR EVALUATION FORM
NCT00770809
Paclitaxel and Trastuzumab With or Without Lapatinib in
Treating Patients With Stage II or Stage III Breast Cancer
That Can Be Removed by Surgery
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=3CB305DE-
3347-5C21-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11097
CALGB BASELINE SOLID TUMOR
EVALUATION FORM NCT00770809
Header
CALGB Form
CALGB Study No
CALGB Patient ID
Are data amended
Yes
No
Patient demographics
Patient Initials (Last, First Middle)
Patient Hospital No.
Institution/Affiliate
Participating Group
Participating Group Study No
Participating Group Patient ID
TARGET LESION(S) BASELINE
EVALUATION
Target Lesion Site
Ascites (Ascites)
Bone (Bone)
Bone Marrow (Bone marrow)
Brain (Brain)
Chest Wall (Chest wall)
Gastrointestinal Tract (Gastrointestinal
tract)
1 / 3
Gynecologic Other (Gynecologic other)
Liver (Liver)
Lung (Lung)
Distant Nodes (Nodes distant)
Nodes Local (Nodes local)
Other (Other)
Ovary (Ovary)
Peritoneum (Peritoneum)
Pleura (Pleura)
Primary Tumor (Primary tumor)
Skin / Subcutaneous Tissue Involvement
(Skin subcutaneous)
Other specify
Date of evaluation (* When several tests are
performed, select the date of the most recent test
and most definitive result.)
Method of Evaluation (**)
Bone Scan (Bone Scan)
Chest X-ray (Chest X-ray)
Clinical (Clinical Examination)
Ct Scan (CT Scan)
Mri (MRI)
Other (Other)
Spiral Ct Scan (Spiral CT Scan)
Ultrasound (Ultrasound)
If Other, specify
Longest Diameter of Lesion(s) (s)
Sum of Longest Diameters of All Target Lesions
Non-target Lesion(s) Follow-up Evaluation
Are there any non-target lesions
Yes
No
Nontarget Lesion Site
Ascites (Ascites)
Bone (Bone)
Bone Marrow (Bone marrow)
Brain (Brain)
Chest Wall (Chest wall)
Gastrointestinal Tract (Gastrointestinal
tract)
Gynecologic Other (Gynecologic other)
Liver (Liver)
Lung (Lung)
Distant Nodes (Nodes distant)
Nodes Local (Nodes local)
Other (Other)
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Ovary (Ovary)
Peritoneum (Peritoneum)
Pleura (Pleura)
Primary Tumor (Primary tumor)
Skin / Subcutaneous Tissue Involvement
(Skin subcutaneous)
Other specify
Date of evaluation (* When several tests are
performed, select the date of the most recent test
and most definitive result.)
Method of Evaluation (**)
Bone Scan (Bone Scan)
Chest X-ray (Chest X-ray)
Clinical (Clinical Examination)
Ct Scan (CT Scan)
Mri (MRI)
Other (Other)
Spiral Ct Scan (Spiral CT Scan)
Ultrasound (Ultrasound)
If Other, specify
Footer module
Completed by (print or type name)
Date Form Completed (MM DD YYYY)
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CALGB: 40601 POST SURGERY
HISTOPATHOLOGY REVIEW FORM NCT00770809
CALGB: 40601 POST SURGERY HISTOPATHOLOGY
REVIEW FORM NCT00770809
Paclitaxel and Trastuzumab With or Without Lapatinib in
Treating Patients With Stage II or Stage III Breast Cancer
That Can Be Removed by Surgery
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=3A58BBD2-
8485-72B0-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11098
CALGB: 40601 POST SURGERY
HISTOPATHOLOGY REVIEW FORM
NCT00770809
Header
CALGB Form
CALGB Study No
CALGB Patient ID
Reporting Period End Date
Are data amended
Yes
No
Patient demographics
Patient Initials
Patient Hospital No.
Institution/Affiliate
Participating Group
Participating Group Study No.
Participating Group Patient ID
Specimen Details
Breast Specimen
Main Specimen With Separately
Submitted Margins (Main specimen with
separately submitted margins)
Single Specimen (Single specimen)
Type
Lumpectomy (Lumpectomy)
1 / 6
Mastectomy (Mastectomy)
Total number of specimen slices
Dimension 1
Dimension 2
Dimension 3
Main specimen entirely submitted for histology?
Yes
No
Gross Findings
Gross pathology present? (Mark all that apply)
Gross Stromal Alterations/fibrosis (Gross
stromal alterations/fibrosis)
Multifocal Discrete Masses (Multifocal
discrete masses)
None Present (None present)
Single Discrete Mass (Single discrete
mass)
Histologic Findings
Invasive cancer
Not Present (Not present)
Present (Present)
Size
Microscopic Foci Of Invasive Carcinoma
(<0.2 Mm) Only (Microscopic foci of
invasive carcinoma (<0.2 mm) only)
Microscopic Foci Of Invasive Carcinoma
(>0.2-2 Mm) Only (Microscopic foci of
invasive carcinoma (>0.2-2 mm) only)
Multifocal (Multifocal)
Single Discrete Mass Present (Single
discrete mass present)
Total number of specimen slices
Dimension 1
Dimension 2
Dimension 3
Cellularity of invasive cancer
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Histologic Type
Ductal (Ductal)
Lobular (Lobular)
Mixed Ductal And Lobular (Mixed ductal
and lobular)
Other Specify (Other)
Other, specify
Nuclear Grade
High (High)
Intermediate (Intermediate)
Low (Low)
Mitotic score
Tubule Formation
Indeterminate (Indeterminate)
Majority Of Tumor, >75% (1 Pt) (Majority
of tumor, >75%)
Minimal, < 10% (3 Pt) (Minimal, <10%)
Moderate, 10% To 75 % (2 Pt)
(Moderate, 10% to 75%)
Histologic Grade
High (High)
Intermediate (Intermediate)
Low (Low)
Lymphovascular Invasion
Yes
No
Margins
Does the tumor involve the surgical margin
No (No)
Unknown (Unknown)
Yes (Yes)
Tumor distance from margin
<= 1mm (<= 1mm)
> 1mm (> 1mm)
Dcis
Is DCIS present?
Yes
No
DCIS % (of overall tumor)
Total histologic span of DCIS (cm)
Number of slides with DCIS
3 / 6
CALGB: 40601 POST SURGERY HISTOPATHOLOGY REVIEW FORM
NCT00770809
Total number of slides
Histologic type of DCIS
Apocrine Dcis (Apocrine)
Calcifications (Calcifications)
Clinging Dcis (Clinging)
Cribiform Dcis (Cribiform)
Intracystic Dcis (Intracystic)
Micropapillary Dcis (Micropapillary)
Necrosis (Necrosis)
Other (Other)
Papillary Carcinoma In Situ (Papillary
carcinoma in situ)
Solid Dcis (Solid)
Other:
Nuclear Grade of DCIS
High (High)
Intermediate (Intermediate)
Low (Low)
Lymph Nodes
Was sentinel node sampling performed
Yes
No
Number of Positive Sentinel Nodes
Number of Sentinel Nodes Examined
Was axillary dissection performed?
Yes
No
Number of axillary nodes examined
Number of positive axillary lymph nodes
Diameter of largest positive LN metastasis (ALN
or SLN) (cm)
Disease Staging
Pathologic T Stage
No Evidence Of Primary Tumor (yT0)
Tumor 2 Cm Or Less In Greatest
Dimension (yT1)
Microinvasion 0.1 Cm Or Less In
Greatest Dimension (yT1mic)
Tumor More Than 2 Cm But Not More
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Than 5 Cm In Greatest Dimension (yT2)
Tumor More Than 5 Cm In Greatest
Dimension (yT3)
Tumor Of Any Size With Direct (yT4)
Carcinoma In Situ: Intraductal
Carcinoma, Lobular Carcinoma In Situ,
Or Paget's Disease Of The Nipple With
No Tumor (yTis)
Primary Tumor Cannot Be Assessed
(yTX)
Pathologic N Stage
No Regional Lymph Node Metastasis
Histologically, No Additional Examination
For Isolated Tumor Cells (itc) (ypN0)
No Regional Lymph Node Metastasis
Histologically, Positive Ihc, No Ihc Cluster
>0.2 Mm (ypN0(i+))
Metastasis In 1 To 3 Axillary Lymph
Nodes, And/or In Internal Mammary
Nodes With Microscopic Disease
Detected By Sln Dissection But Not
Clinically Apparent (ypN1)
Metastasis In 4 To 9 Axillary Lymph
Nodes, Or In Clinically Apparent **
Internal Mammary Lymph Nodes In The
Absence Of Axillary Lymph Node
Metastasis To Ipsilateral Axillary Lymph
Node(s) Fixed To Each Other Or To
Other Structures (ypN2)
Metastasis In Clinically Apparent*
Internal Mammary Lymph Nodes In The
Absence Of Axillary Lymph Node
Metastasis (ypN2b)
Metastasis In >= Axillary Lymph Nodes,
Or In Infraclavicular Lymph Nodes, Or In
Clinically Apparent* Ipsilateral Internal
Mammary Lymph Node(s) In The
Presence Of 1 Or More Positive Axillary
Lymph Node(s); Or, In >3 Axillary Lymph
Nodes With Clinically N (ypN3)
Regional Lymph Nodes Cannot Be
Assessed (e.g., Not Removed For
Pathologic Study Or Previously
Removed) (ypNX)
Pathologic M Stage
No Distant Metastasis (yM0)
Distant Metastasis (yM1)
Distant Metastasis Cannot Be Assessed
(yMX)
Stage
Tis, N0, M0 (0)
T1*, N0, M0 (I)
T0, N1, M0 Or T1*, N1, M0 Or T2, N0,
M0 (IIA)
T2, N1, M0 Or T3, N0, M0 (IIB)
T0, N2, M0 Or T1*, N2, M0 Or T2, N2,
M0 Or T3, N1, M0 Or T3, N2, M0 (IIIA)
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T4, N0, M0 Or T4, N1, M0 Or T4, N2, M0
(IIIB)
Any T, N3, M0 (IIIC)
Any T, Any N, M1 (IV)
Final status of T4 tumor (If patient diagnosed with
T4 at baseline, indicate)
Chest Wall Only (Chest wall only)
Inflammatory Disease (Inflammatory)
Skin And Chest Wall (Skin and chest
wall)
Skin Only (Skin only)
Comments
COMMENTS
Completed by (Last name, First name)
Date form completed (MM DD YYYY)
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CALGB_40301_SOLID_TUMOR_EVALUA
TION_FORM
CALGB_40301_SOLID_TUMOR_EVALUATION_FORM
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=E5681B87-
12C3-56CB-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11099
CALGB_40301_SOLID_TUMOR_EV
ALUATION_FORM
Header
CALGB Form
CALGB Study No
CALGB Patient ID
Are data amended
Yes
No
Patient demographics
Patient Initials
Patient Hospital Number
Main Member Institution/Affiliate
Participating Group
Participating Group Protocol No
Participating Group Patient ID
Target Lesion(s) Baseline Evaluation
Lesion, Anatomic Site, Target
Date of evaluation (*)
Method of Evaluation (**)
Bone Scan (Bone Scan)
Chest X-ray (Chest X-ray)
Clinical (Clinical Examination)
Ct Scan (CT Scan)
Mri (MRI)
Other (Other)
Spiral Ct Scan (Spiral CT Scan)
Ultrasound (Ultrasound)
1 / 2
If Other, specify
Longest Diameter of Lesion (s)
Sum of Longest Diameters of All Target Lesions
Non-target Lesion(s) Baseline Evaluation
Are there any non-target lesions
Yes
No
Lesion, Anatomic Site, Non-Target
Date of evaluation (*)
Method of Evaluation (**)
Bone Scan (Bone Scan)
Chest X-ray (Chest X-ray)
Clinical (Clinical Examination)
Ct Scan (CT Scan)
Mri (MRI)
Other (Other)
Spiral Ct Scan (Spiral CT Scan)
Ultrasound (Ultrasound)
If Other, specify
Completed by
Date form completed
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CALGB: 40601 PRE-NEOADJUVANT CHEMOTHERAPY
SURGICAL EVALUATION FORM NCT00770809
CALGB: 40601 PRE-NEOADJUVANT CHEMOTHERAPY
SURGICAL EVALUATION FORM NCT00770809
Paclitaxel and Trastuzumab With or Without Lapatinib in
Treating Patients With Stage II or Stage III Breast Cancer
That Can Be Removed by Surgery
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=3A963C4E-
69F2-4844-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11100
CALGB: 40601 PRE-
NEOADJUVANT CHEMOTHERAPY
SURGICAL EVALUATION FORM
NCT00770809
Header
CALGB Form
CALGB Study No
CALGB Patient ID
Date of evaluation
Amended Data
Yes
No
Patient demographics
Patient Initials (Last, First Middle)
Patient Hospital No.
Institution/Affiliate
Participating Group
Participating Group Study No.
Participating Group Patient ID
Breast Conserving Therapy
Was the patient's clinical breast exam normal?
No (No)
Unknown (Unknown)
Yes (Yes)
1 / 3
Describe abnormality (If no,)
Is the patient currently(before receiving
neoadjuvant chemotherapy) a candidate for
breast conserving treatment
Yes
No
Reason not a candidate (If no,)
Absolute Contraindication To Radiation
Therapy (Absolute contraindication to
radiation therapy)
Diffuse Suspicious Microcalcifications
(Diffuse suspicious microcalcifications)
Multicentric Breast Cancer (Multicentric
breast cancer)
Other (Other)
Probable Poor Cosmetic Outcome
(Probable poor cosmetic outcome)
Breast Cancer Pt4 Tnm Finding (T4)
Tumor Is Too Large In Relation To Native
Breast Size (Tumor is too large in
relation to native breast size)
Other, specify
Absolute contraindication to radiation therapy
Connective Tissue Disorder (Connective
Tissue Disorder)
Patient Access To Prescribed Radiation
Therapy (Patient access to prescribed
radiation therapy)
Patient Compliance With Prescribed
Radiation Therapy (Patient compliance
with prescribed radiation therapy)
Prior Radiation Therapy (Prior radiation
therapy)
Connective tissue disorder, specify
Axillary Node
Was the patient's pre-neoadjuvent chemotherapy
treatment axillary nodal status evaluated?
Yes
No
Method of Evaluation
Axillary Dissection (Axillary dissection)
Excisional Biopsy Or Lumpectomy
(Excisional biopsy or lumpectomy)
Fine Needle Aspiration Biopsy (Fine
needle aspiration biopsy)
Mri Scan (MRI scan)
Other (Other)
Pet Scan (PET scan)
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Sentinel Node Biopsy (Sentinel node
biopsy)
Clinical N Stage
No Regional Lymph Node Metastasis
(N0)
Metastasis To Movable Ipsilateral Axillary
Lymph Node(s) (N1)
Metastasis To Ipsilateral Axillary Lymph
Node(s) Fixed Or Matted, Or In Clinically
Apparent* Ipsilateral Internal Mammary
Nodes In The Absence Of Clinically
Evident Lymph Node Metastasis (N2)
Results
Equivocal (Equivocal)
Not Applicable (N/A)
Negative (Negative)
Positive (Positive)
Unknown (Unknown)
If positive, specify why ultrasound criteria made it
positive
Date of Evaluation
Other Specify
Sentinel Node Biopsy Date
Was blue dye used
Yes
No
Was technetium used
Yes
No
Date of dissection
Footer Module
Comments
Completed by (Last name, First name)
Date Form Completed (MM DD YYYY)
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CALGB 40601 TREATMENT SUMMARY
FORM (ALL PATIENTS) NCT00770809
CALGB 40601 TREATMENT SUMMARY FORM (ALL
PATIENTS) NCT00770809
Paclitaxel and Trastuzumab With or Without Lapatinib in
Treating Patients With Stage II or Stage III Breast Cancer
That Can Be Removed by Surgery
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=3A0384BB-
F251-120F-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11101
CALGB 40601 TREATMENT
SUMMARY FORM (ALL PATIENTS)
NCT00770809
Header
CALGB Form
CALGB Study No
CALGB Patient ID
Reporting period end date (MM DD YYYY)
Are data amended
Yes
No
Patient demographics
Patient Initials (Last, First Middle)
Patient Hospital No.
Institution/Affiliate
Participating Group
Participating Group Study No.
Participating Group Patient ID
Treatment Plan
Start Date of First Treatment
Date of Last Clinical Assessment
Total number of weeks treatment was given
1 / 3
Last date protocol therapy was given
Reason Treatment Ended (mark one with an X)
Adverse Event/side Effects/complications
(Adverse Event/Side
Effects/Complications)
Alternative Therapy (Alternative therapy)
Death On Study (Death on study)
Disease Progression, Relapse During
Active Treatment (Disease progression,
relapse during active treatment)
Other (Other)
Patient Off-treatment For Other
Complicating Disease (Patient off-
treatment for other complicating disease)
Patient Withdrawal Or Refusal After
Beginning Protocol Therapy (Patient
withdrawal/refusal after beginning
protocol therapy)
Patient Withdrawal Or Refusal Before
Beginning Protocol Therapy (Patient
withdrawal/refusal prior to beginning
protocol therapy)
Treatment Completed Per Protocol
Criteria (Treatment completed per
protocol criteria)
Other specify
Were any Optional Therapies given?
No (No)
Unknown (Unknown)
Yes (Yes)
Optional Therapy Name
Was any non-protocol therapy given during
protocol treatment? (concurrent)
Yes
No
specify (If Yes)
Concurrent Non-protocol Biologic
Response Modifier Therapy (Concurrent
non-protocol biologic response modifier
therapy)
Concurrent Non-protocol Chemotherapy
(Concurrent non-protocol chemotherapy)
Concurrent Non-protocol High Dose
Chemotherapy/autologous Stem Cell
Transplant (Concurrent non-protocol high
dose chemotherapy/autologous stem cell
transplant)
Concurrent Non-protocol Hormonal
Therapy (Concurrent non-protocol
hormonal therapy)
Concurrent Non-protocol Radiation
Therapy (Concurrent non-protocol
2 / 3
CALGB 40601 TREATMENT SUMMARY FORM (ALL PATIENTS)
NCT00770809
radiation therapy)
Non-protocol Therapy Start Date
Were supporting agents given during this cycle?
Antibiotic (Antibiotics)
Antidiarrheal (Antidiarrheal)
Antiemetics (Antiemetics)
Blood Or Blood Products (Blood or blood
products)
Epoetin Alfa (Epoetin)
Gcsf (GCSF)
Gm-csf (GM-CSF)
Other (Other)
Other, specify
Comments
COMMENTS
Completed by (Last name, First name)
Date form completed (MM DD YYYY)
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CALGB 40601 TREATMENT SUMMARY FORM (ALL PATIENTS)
NCT00770809
CALGB-40502 Tissue Tracking Form
NCT00785291
CALGB-40502 Tissue Tracking Form NCT00785291 
Paclitaxel, Paclitaxel Albumin-Stabilized Nanoparticle
Formulation, or Ixabepilone With or Without Bevacizumab
in Treating Patients With Stage IIIC or Stage IV Breast
Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=51FAFFC3-
3D7C-099B-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11102
CALGB-40502 Tissue Tracking Form
NCT00785291
Header
CALGB Form
CALGB Study No.
CALGB Patient ID
Are data amended
Yes
No
Patient demographics
Patient Initials
Patient Hospital No.
Institution/Affiliate
Participating Group
Participating Group Study No
Participating Group Patient ID
Biopsy and Cytology Specimens
Does institutional pathology report accompany
this form
Yes
No
Does specimen accompany this form
Yes
No
Form without specimen, reason
1 / 2
Date specimen collected
Tissue pathology (Mark one with an X.)
Lymph Node Metastasis (Lymph node
metastasis)
Metastasis (Metastasis)
Primary Tumor (Primary tumor)
Recurrent Tumor (Recurrent tumor)
Method of extraction (Mark one with an X.)
Axillary Dissection (Axillary dissection)
Biopsy (Biopsy)
General Surgery, Nos (General surgery,
NOS)
Lumpectomy (Lumpectomy)
Mastectomy (Mastectomy)
Re-excision (Re-excision)
Sentinel Node Dissection (Sentinel node
dissection)
Type of specimen submitted (Mark one with an
X.)
Formalin Fixed Paraffin Embedded
Tissue Block (Formalin fixed paraffin
embedded tissue block)
Punch Biopsies From Ffpe Block (Punch
biopsies from FFPE block)
Unstained Superfrost Plus Slides
(Unstained superfrost plus slides)
Formalin fixed paraffin embedded tissue block,
specify number
Punch biopsies from FFPE block, specify number
Unstained superfrost plus slides, specify number
Institutional surgical pathology number
LabTrak shipment ID
Date shipped
Date shipped
Responsible CRA (Last name, First name)
CRA phone number
CRA email
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CALGB-40502 Tissue Tracking Form NCT00785291
CALGB: 80405 Pharmacogenomic Submission
and Quality Assurance Form NCT00265850
The Pharmacogenomic Submission and Quality Assurance
Form, a CDE-compliant CALGB CRF to be used on
CALGB protocols NCT00265850 .
Cetuximab and/or Bevacizumab Combined With
Combination Chemotherapy in Treating Patients With
Metastatic Colorectal Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=136FE59E-
9938-7353-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11103
CALGB: 80405 Pharmacogenomic
Submission and Quality Assurance
Form NCT00265850
Header
CALGB Form
CALGB Study No.
CALGB Patient ID
Form Submission Date (MM/DD/YYYY)
Are data amended
Yes
No
Patient demographics
Patient Initials (Last, First Middle)
Patient Hospital No
Institution/Affiliate
Participating Group
Participating Group Study No.
Participating Group Patient ID
Pathology/Biopsy
Does specimen accompany this form
Yes
No
Specify reason (If no,)
Institution Error (Institution error)
Other (Other)
Patient Refusal (Patient refusal)
1 / 2
Sample Lost Or Destroyed (Sample lost
or destroyed)
Biopsy and Cytology Specimens collection
Date Specimen Collected (MM DD YYYY)
Collection Time (24-hour clock)
Was blood sample collected in an EDTA
Vacutainer tube (purple top)
Yes
No
Was blood sample stored either at 4 degrees C or
frozen within 24 hours of collection
Yes
No
Was blood sample shipped to the PCO on a cold
pack
Yes
No
Biopsy and Cytology Specimens shipment
Date Specimen Shipped (specimen)
Time specimen shipped (24-hour clock)
LabTrak sample ID
LabTrak shipment ID
Submitted by
CRA email
CRA phone number
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CALGB: 80405 Pharmacogenomic Submission and Quality Assurance
Form NCT00265850
CALGB: 80405 INSTITUTIONAL K-RAS
RESULTS FORM NCT00265850
CALGB: 80405 INSTITUTIONAL K-RAS RESULTS FORM
NCT00265850 
Cetuximab and/or Bevacizumab Combined With
Combination Chemotherapy in Treating Patients With
Metastatic Colorectal Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=89DBD804-
8FC1-077E-E040-BB89AD4341B8
All rights reserved. Please visit https://medical-data-
models.org/forms/11104
CALGB: 80405 INSTITUTIONAL K-
RAS RESULTS FORM
NCT00265850
Header
CALGB Form
CALGB Study No.
CALGB Patient ID
Are data amended?
Yes
No
Patient demographics
Patient Initials
Participating Group
Patient Hospital No.
Participating Group Study No.
Institution/Affiliate
Participating Group Patient ID
K-ras
Date Sample Obtained
Block #
Date of K-ras testing
Name of CLIA certified lab
1 / 2
Intra-tumor K-ras mutation
Absent (Absent)
Present (Present)
Footer module
Comments
Completed by
Date Form Completed
2 / 2
CALGB: 80405 INSTITUTIONAL K-RAS RESULTS FORM
NCT00265850
CALGB: SOLID TUMOR EVALUATION
FORM NCT00265850
CALGB: SOLID TUMOR EVALUATION FORM
NCT00265850
Cetuximab and/or Bevacizumab Combined With
Combination Chemotherapy in Treating Patients With
Metastatic Colorectal Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=F8798A2C-
BB78-089F-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11105
CALGB: SOLID TUMOR
EVALUATION FORM NCT00265850
Header
CALGB Form (C-1700)
CALGB Study No.
CALGB Patient ID
Date of disease evaluation
Are data amended?
Yes
No
Patient demographics
Patient Initials
Participating Group
Patient Hospital No.
Participating Group Study No.
Institution/Affiliate
Participating Group Patient ID
Target Lesion(s)
Lesion Number
Target Lesion Site
Method of Evaluation
Ct Scan (CT scan)
1 / 3
Mri Scan (MRI scan)
Other (Other)
X-ray (X-ray)
Other Specify
Longest diameter of lesion(s) (cm)
Resolved
Yes
No
Sum of Longest Diameters of All Target Lesions
(cm)
Response Status at This Assessment, Target
Lesion
Complete Response (Complete
Response)
Insufficient Evaluation To Determine
Response Status (Insufficient evaluation
to determine response status)
Partial Response (Partial Response)
Progressive Disease (Progressive
Disease)
Stable Disease (Stable Disease)
Response Status at This Assessment, Non-
Target Lesion (Mark one with an X)
Complete Response (Complete
Response)
Incomplete Response/sd (Incomplete
Response/SD)
Insufficient Evaluation To Determine
Response Status (Insufficient evaluation
to determine response status)
Progressive Disease (Progressive
Disease)
Overall Response Status at This Assessment
Complete Response (CR)
Insufficient Evaluation (Insufficient
evaluation to determine response status)
Progressive Disease (PD)
Partial Response (PR)
Stable Disease (SD)
Non-target Lesion(s)
Nontarget Lesion Site
Method of Evaluation
Ct Scan (CT scan)
Mri Scan (MRI scan)
Other (Other)
2 / 3
CALGB: SOLID TUMOR EVALUATION FORM NCT00265850
X-ray (X-ray)
Other Specify
Follow-up status of lesion
Absent (Absent)
Increased To Pd (Increased to PD)
Present (Present)
Footer module
Completed by
Date Form Completed
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CALGB: SOLID TUMOR EVALUATION FORM NCT00265850
CALGB: 80405 SURGICAL RESECTION
FORM NCT00265850
CALGB: 80405 SURGICAL RESECTION FORM
NCT00265850
Cetuximab and/or Bevacizumab Combined With
Combination Chemotherapy in Treating Patients With
Metastatic Colorectal Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=F39D5B9C-
C840-63E9-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11106
CALGB: 80405 SURGICAL
RESECTION FORM NCT00265850
Header
CALGB Form
CALGB Study No
CALGB Patient ID
Date of resection
Are data amended
Yes
No
Patient demographics
Patient Initials
Patient Hospital No
Institution/Affiliate
Participating Group
Participating Group Study No.
Participating Group Patient ID
Sites of resection
Sites of resection (Mark one with an X)
Brain (Brain)
Liver (Liver)
Local/regional (Local/regional)
Lung (Lung)
Other (Other)
Ovary (Ovary)
1 / 3
Other, specify
Disease status after surgery (Mark one with an X)
No Evidence Of Disease (No evidence of
disease)
Surgery Was Unsuccessful (Surgery was
unsuccessful)
Surgical Complications And Morbidities
Estimated blood loss
Did any of the following complications occur intra-
or post-operatively (within 30 days? Mark one
with an X)
Anastomotic Leak (Anastomotic leak)
Colostomy/ileostomy Ischemia
(Colostomy/ileostomy ischemia)
Deep Vein Thrombosis/pulmonary
Embolism (Deep vein
thrombosis/pulmonary embolism)
Dehiscence Of Wound (Dehiscence of
wound)
Intra-abdominal Infection (Intra-
abdominal infection)
Myocardial Infarction (Myocardial
infarction)
Pneumonia Requiring Antibiotics
(Pneumonia requiring antibiotics)
Post-operative Fever > 38.1 C Or 100.6
F (Post-operative fever > 38.1 C or 100.6
F)
Red Cell Transfusion Required Intra-
operatively Or Within 24 Hours Post-
operatively (Red cell transfusion required
intra-operatively or within 24 hours post-
operatively)
Small Bowel Obstruction (Small bowel
obstruction)
Urinary Outlet Obstruction (Urinary outlet
obstruction)
specify number of units (If yes,)
specify duration (If yes,)
Wound infection, specify site
Will patient resume protocol chemotherapy?
Yes
No
specify date of first chemotherapy after surgery (If
yes,)
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CALGB: 80405 SURGICAL RESECTION FORM NCT00265850
Completed by
Date form completed
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CALGB: 80405 SURGICAL RESECTION FORM NCT00265850
CALGB: 80405 SPECIMEN SUBMISSION
FORM NCT00265850
CALGB: 80405 SPECIMEN SUBMISSION FORM
NCT00265850
Cetuximab and/or Bevacizumab Combined With
Combination Chemotherapy in Treating Patients With
Metastatic Colorectal Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=F39D1FAF-
A35A-5FC5-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11107
CALGB: 80405 SPECIMEN
SUBMISSION FORM NCT00265850
Header
CALGB Form
CALGB Study No
CALGB Patient ID
Are data amended
Yes
No
Patient demographics
Patient Initials
Patient Hospital No
Institution/Affiliate
Participating Group
Participating Group Study No
Participating Group Patient ID
Biopsy specimen
Other
Sample period (Mark one with an X)
At Restaging (At restaging)
At Time Of Cetuximab-infusion
Reactions (At time of cetuximab-infusion
reactions)
End Of Protocol Therapy (End of
protocol therapy)
1 / 2
Pre-treatment (Pre-treatment)
Specimen type
Did patient consent to this sample collection?
Yes
No
If the patient consented, was specimen
submitted?
Yes
No
No, specify reason
Other (^1)
Institution Error (Institution error)
Patient Refusal (Patient refusal)
Sample Lost Or Destroyed (Sample lost
or destroyed)
Number of tubes submitted
Time specimen collected
Number of hours between last meal and blood
collection
Completed by
Date form originally completed
2 / 2
CALGB: 80405 SPECIMEN SUBMISSION FORM NCT00265850
CALGB: 80405 HOSPITALIZATION FORM
NCT00265850
CALGB: 80405 HOSPITALIZATION FORM NCT00265850
Cetuximab and/or Bevacizumab Combined With
Combination Chemotherapy in Treating Patients With
Metastatic Colorectal Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=F39BBD2B-
88A8-5844-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11108
CALGB: 80405 HOSPITALIZATION
FORM NCT00265850
Header module
CALGB Form
CALGB Study No.
CALGB Patient ID
Hospital admit date
Are data amended
Yes
No
Patient demographics
Patient Initials
Patient Hospital No.
Institution/Affiliate
Participating Group
Participating Group Study No.
Participating Group Patient ID
Hospitalization
Hospital discharge date
Reason for hospitalization (Mark all that apply
with an X)
Non-study Indication (Non-study
indication)
Other (Other)
1 / 2
Resection Of Disease (Resection of
disease)
Treatment Of Complications Related To
Protocol Therapy (Treatment of
complications related to protocol therapy)
Treatment Of Disease Related
Complications (Treatment of disease
related complications)
Other, specify
Completed by (Last name, First name)
Date from originally completed
2 / 2
CALGB: 80405 HOSPITALIZATION FORM NCT00265850
CALGB: 80405 BLOOD SAMPLE
SUBMISSION FORM NCT00265850
CALGB: 80405 BLOOD SAMPLE SUBMISSION FORM
NCT00265850 
Cetuximab and/or Bevacizumab Combined With
Combination Chemotherapy in Treating Patients With
Metastatic Colorectal Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=D5EBD8BC-
16F4-0822-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/11109
CALGB: 80405 BLOOD SAMPLE
SUBMISSION FORM NCT00265850
Header
CALGB Form
CALGB Study No.
CALGB Patient ID
Date form submitted
Are data amended?
Yes
No
Patient demographics
Patient Initials
Participating Group
Patient Hospital No.
Participating Group Study No.
Institution/Affiliate
Participating Group Patient ID
Biopsy specimen
Does specimen accompany this form?
Yes
No
specify reason
Institution Error (Institution error)
Other (Other)
Patient Refusal (Patient refusal)
1 / 2
Sample Lost Or Destroyed (Sample lost
or destroyed)
Sample Period
Second Malignancy (Diagnosis of
second malignancy)
Other Specify (Other, specify)
Sample Or Specimen Collected After
Patient Received Treatment For Cancer
(Post-treatment)
Sample Or Specimen Collected Before
Patient Was Diagnosed With Cancer
(Pre-diagnosis)
Sample Or Specimen Collected Before
Patient Received Treatment For Cancer
(Pre-treatment)
Progression Or Relapse
(Progression/Relapse)
Unknown (Unknown)
LabTrak shipment ID
Number of tubes of whole blood submitted with
this form
Submitted by
Phone number
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CALGB: 80405 BLOOD SAMPLE SUBMISSION FORM NCT00265850
CALGB-10501 Lymphoma Measurement
Form NCT00513747
CALGB-10501 Lymphoma Measurement Form
NCT00513747 
Early or Delayed Fludarabine and Rituximab in Treating
Patients With Previously Untreated Chronic Lymphocytic
Leukemia
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=3410554E-
9E7A-2D64-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11110
CALGB-10501 Lymphoma
Measurement Form NCT00513747
Header
CALGB Form
CALGB Study No
CALGB Patient ID
Are data amended
Yes
No
Patient demographics
Patient Initials (Last, First Middle)
Patient Hospital No.
Institution/Affiliate
Participating Group
Participating Group Study No
Participating Group Patient ID
Measurable Sites
Is measurable disease present?
Yes
No
Lesion Number
Site of Lesion
1 / 3
Method of Evaluation
Other Specify
Greatest Perpendicular Measurements
Greatest Perpendicular Measurements
Product of Measurements
Date of Evaluation (MM DD YYYY)
Sum of Products of Measurements
Measurable Sites
Is non-measurable disease present?
Yes
No
Lesion Number
Site of Lesion
Method of Evaluation
Other Specify
Lesion Assessment
Disappearance (disappearance)
Improvement (improvement)
No Change (no change)
Not Evaluated (not evaluated)
Progression - Increase (progression -
increase)
Worsening (worsening)
Date of Evaluation (MM DD YYYY)
Bone Marrow Biopsy
Date of Bone Marrow Biopsy (MM DD YYYY)
Type of Biopsy Procedure
Bilateral (Bilateral)
Unilateral (Unilateral)
2 / 3
CALGB-10501 Lymphoma Measurement Form NCT00513747
Bone Marrow Biopsy Result
Indeterminate (indeterminate)
Involved (involved)
Not Involved (not involved)
Marrow Malignant Cells (%)
Bone Marrow Pattern (Mark all that apply)
Chronic Lymphocytic Leukemia (Chronic
Lymphocytic Leukemia)
Diffuse Large Cell Lymphoma (Diffuse
large cell lymphoma)
Other (Other)
Prolymphocyte (Prolymphocyte)
Other, specify
Percent Involved (If yes)
Objective Status at This Evaluation
Complete Response (complete
response)
Complete Response Uncertain
(complete response uncertain)
Partial Response (partial response)
Progressive Disease (progressive
disease)
Stable Disease (stable disease)
Footer Module
Completed by (print or type name)
Date Form Completed (MM DD YYYY)
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CALGB-10501 Lymphoma Measurement Form NCT00513747
CALGB-10501 Diagnostic Blood/Bone
Marrow Evaluation Form NCT00513747
CALGB-10501 Diagnostic Blood/Bone Marrow Evaluation
Form NCT00513747 
Early or Delayed Fludarabine and Rituximab in Treating
Patients With Previously Untreated Chronic Lymphocytic
Leukemia
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=3410554E-
9E96-2D64-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11111
CALGB-10501 Diagnostic
Blood/Bone Marrow Evaluation Form
NCT00513747
Header
CALGB Form
CALGB Study No (Treatment)
CALGB Companion Study No.
CALGB Patient ID
Are data amended
Yes
No
Patient demographics
Patient Initials (Last, First Middle)
Patient Hospital No.
Institution/Affiliate
Participating Group
Participating Group Study No
Participating Group Patient ID
Header
LabTrak sample ID (CALGB only if LabTrak is
being used)
Biopsy specimen
Date Specimen Obtained (MM DD YYYY)
1 / 3
Leukemia Classification (Mark one with an X.)
Disease Classified As All, Not Otherwise
Specified (nos); (ALL, not otherwise
specified (NOS))
Disease Classified As Aml, Not
Otherwise Specified (nos) (AML, not
otherwise specified (NOS))
Disease Classified As Chronic
Lymphocytic Leukemia (cll) (Chronic
lymphocytic leukemia (CLL))
Disease Classified As Cml, Not
Otherwise Specified (nos); (CML, not
otherwise specified (NOS))
Disease Classified As Myelodysplastic
Syndrome (mds) Nos (Myelodysplastic
syndrome (MDS) NOS)
Other (Other)
Other specify
Has the patient developed progression of MDS to
Acute Myelogenous Leukemia (AML)
Yes
No
Clinical Onset of AML (Mark one with an X.)
Aml Without Prior Clinical History Of Mds
Or Potentially Leukemogenic Treatment
(de novo)
Aml Related To/associated With Prior
Clinical History Of Mds (MDS-related)
Aml Related To/associated With Prior
Clinical History Of Potentially
Leukemogenic Treatment (Treatment
related)
WHO Diagnosis
FAB subtype
Source of Cells used for Analysis (Specimens
must be submitted within one week of date
sample obtained. Mark one with an X.)
Bone Marrow (Bone marrow)
Bone Marrow Aspirate (Bone marrow
aspirate)
Other Specify (Other)
Peripheral Blood (Peripheral blood)
Other specify
Sample Period (Mark one with an X.)
Complete Response To Protocol Therapy
(Complete response)
Other Specify (Other)
Sample Or Specimen Collected Before
2 / 3
CALGB-10501 Diagnostic Blood/Bone Marrow Evaluation Form
NCT00513747
Patient Received Treatment For Cancer
(Pre-treatment)
Progression Or Relapse
(Progression/Relapse)
Other specify
Required document types (Mark all that apply
with an X.)
Cbc Report (CBC report)
Cytogenetic Report (Cytogenetic Report)
Flow Cytometry/immunophenotype
Report (Flow
cytometry/immunophenotype report)
Pathology Report (Pathology Report)
Specify reason reports not submitted
Contact information
Investigator Name
Phone
Fax Number
Footer module
Completed by (print or type name)
Date Form Completed (MM DD YYYY)
3 / 3
CALGB-10501 Diagnostic Blood/Bone Marrow Evaluation Form
NCT00513747
CALGB-10501 Background Information
Form NCT00513747
CALGB-10501 Background Information Form
NCT00513747 
Early or Delayed Fludarabine and Rituximab in Treating
Patients With Previously Untreated Chronic Lymphocytic
Leukemia
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=3690E09A-
EDF2-082A-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11112
CALGB-10501 Background
Information Form NCT00513747
Header
CALGB Form
CALGB Study No
CALGB Patient ID
Are data amended
Yes
No
Patient demographics
Patient Initials (Last, First Middle)
Patient Hospital No.
Institution/Affiliate
Participating Group
Participating Group Study No
Participating Group Patient ID
If you do not wish to answer any of the following
questions, please mark with an 'X.'
Background Information
Date Form Completed (MM DD YYYY)
What is the highest grade you finished in school?
(Mark one with an X.)
1-8 Grades (1-8 grades)
1 / 2
9-11 Grades (9-11 grades)
Advanced Degree (Advanced degree)
College Degree (b.a./b.s.) (College
degree (B.A./B.S.))
High School Graduate (High School
graduate)
Junior College Degree (Junior college
degree)
Some College (Some college)
Some Post-college Work (Some post-
college work)
Marital status (Mark one with an X.)
Divorced (Divorced)
Married (Married)
Never Married (Never married)
Separated (Separated)
Widowed (Widowed)
With whom do you live (Mark all that apply with
an X.)
Children Aged 18 Years Or Younger
(Children aged 18 years or younger)
Children Aged 19 Years Or Older
(Children aged 19 years or older)
Live Alone (Live alone)
Other (Other)
Other Relative (Other relative)
Parent(s)/parent(s)-in-law
(Parent(s)/Parent(s)-In-Law)
Spouse/partner (Spouse/Partner)
Other relative, specify
Other, specify
What is your current employment status? (Mark
all that apply with an X.)
Disabled (Disabled)
Employed 32 Hours Or More Per Week
(Employed 32 hours or more per week)
Employed Less Than 32 Hours Per
Week (Employed less than 32 hours per
week)
Full-time Student (Full-time student)
Homemaker (Homemaker)
On Medical Leave (On medical leave)
Other (Other)
Part-time Student (Part-time student)
Retired (Retired)
Unemployed (Unemployed)
Other, specify (Thank You Very Much For Your
Voluntary Participation Please Return To The
Person Who Handed You This Form)
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CALGB-10501 Background Information Form NCT00513747
CALGB: Pharmacogenomic Submission
and Quality Assurance Form
The Pharmacogenomic Submission and Quality Assurance
Form, a CDE-compliant CALGB CRF to be used on most
CALGB protocols.
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=01347EC9-
2FD9-7195-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11113
CALGB: Pharmacogenomic
Submission and Quality Assurance
Form
Header
CALGB Form
CALGB Study No.
CALGB Patient ID
Form Submission Date (MM/DD/YYYY)
Are data amended
Yes
No
Patient demographics
Patient Initials (Last, First Middle)
Patient Hospital No
Institution/Affiliate
Participating Group
Participating Group Study No.
Participating Group Patient ID
Biopsy specimen
Does specimen accompany this form
Yes
No
Specify reason (If no,)
Institution Error (Institution error)
Other (Other)
Patient Refusal (Patient refusal)
1 / 3
Sample Lost Or Destroyed (Sample lost
or destroyed)
Biopsy and Cytology Specimens collection
Date Specimen Collected (MM DD YYYY)
Collection Time (24-hour clock)
Sample type (Mark all that apply with an X.)
Buccal Cells (Buccal cells)
Whole Blood (Whole blood)
Was blood sample collected in an EDTA
Vacutainer tube (purple top)
Yes
No
Was blood sample stored either at 4 degrees C or
frozen within 24 hours of collection
Yes
No
Was buccal cell sample immediately submersed
in 250 microliters of lysis buffer
Yes
No
Was buccal cell sample stored at -20 degrees C
Yes
No
Biopsy and Cytology Specimens shipment
Date shipped (specimen)
Time specimen shipped (24-hour clock)
Shipment type (Mark one with an X.)
Cold Pack (Cold pack)
Dry Ice (Dry ice)
Specify reason (If Dry ice,)
Buccal Sample (Buccal sample)
Other (Other)
Sample Shipped After Being Stored
(Sample shipped after being stored)
Sample Shipped With Other Samples
(Sample shipped with other samples)
Other, specify
LabTrak sample ID
2 / 3
CALGB: Pharmacogenomic Submission and Quality Assurance Form
LabTrak shipment ID
Submitted by
Phone Number
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CALGB: Pharmacogenomic Submission and Quality Assurance Form
CALGB: 10603 FLT3 Sample Submission
Form NCT00651261
CALGB: 10603 FLT3 Sample Submission Form
NCT00651261 
Daunorubicin, Cytarabine, and Midostaurin in Treating
Patients With Newly Diagnosed Acute Myeloid Leukemia
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=43756F18-
4AF2-4FD2-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11114
CALGB: 10603 FLT3 Sample
Submission Form NCT00651261
CALGB clinical trial administrative data
CALGB Form (C-714)
CALGB Study No.
CALGB Patient ID
Shipment date
Are data amended
Yes
No
Patient Initials (Last, First Middle)
Patient Hospital No.
Institution/Affiliate
Participating Group (Country Name for
International site:)
Participating Group Protocol Number
Participating Group Patient ID
Blood test results
Sample period
Pre-treatment (Pre-Treatment)
Relapse (Relapse)
Specimen Cell Source
Bone Marrow Aspirate (Bone marrow
aspirate)
Peripheral Blood (Peripheral blood)
Peripheral WBC Count
1 / 2
Peripheral Blasts (%)
Date of peripheral blood count
Shipping Information
Responsible CRA
Email address
Fax Number
Phone
Courier Tracking Number
Emergency contact number (Please provide a
pager or cell phone number for questions outside
of regular business hours.)
Shipped by
Footer Module
Comments
Completed by
Date Form Completed
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CALGB: 10603 FLT3 Sample Submission Form NCT00651261
CALGB-10501 EQ-5D Form NCT00513747
CALGB-10501 EQ-5D Form NCT00513747 
Early or Delayed Fludarabine and Rituximab in Treating
Patients With Previously Untreated Chronic Lymphocytic
Leukemia
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=340EDF8E-
59DA-1F88-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11115
CALGB-10501 EQ-5D Form
NCT00513747
Header
CALGB Form
CALGB Study No
CALGB Patient ID
Date of Assessment
Are data amended
Yes
No
Patient demographics
Patient Initials (Last, First Middle)
Patient Hospital No.
Institution/Affiliate
Participating Group
Participating Group Study No
Participating Group Patient ID
Patient status assessment
MOBILITY
I Am Confined To Bed (I am confined to
bed)
I Have No Problems In Walking About (I
have no problems in walking about)
I Have Some Problems In Walking About
(I have some problems in walking about)
1 / 2
SELF CARE
I Am Unable To Wash Or Dress Myself (I
am unable to wash or dress myself)
I Have No Problems With Self Care (I
have no problems with self care)
I Have Some Problems Washing Or
Dressing Myself (I have some problems
washing or dressing myself)
USUAL ACTIVITIES (e.g. work, study,
housework, family, or leisure activities)
I Am Unable To Perform My Usual
Activities (I am unable to perform my
usual activities)
I Have No Problems With Performing My
Usual Activities (I have no problems with
performing my usual activities)
I Have Some Problems With Performing
My Usual Activities (I have some
problems with performing my usual
activities)
PAIN/DISCOMFORT
I Have Extreme Pain Or Discomfort (I
have extreme pain or discomfort)
I Have Moderate Pain Or Discomfort (I
have moderate pain or discomfort)
I Have No Pain Or Discomfort (I have no
pain or discomfort)
ANXIETY/DEPRESSION
I Am Extremely Anxious Or Depressed (I
am extremely anxious or depressed)
I Am Moderately Anxious Or Depressed
(I am moderately anxious or depressed)
I Am Not Anxious Or Depressed (I am
not anxious or depressed)
Health score (To help people say how good or
bad a health state is, we - have drawn a scale
rather like a thermometer on which - the best
state you can imagine is marked 100 and the -
worst state you can imagine is marked 0.)
Comments
Completed by
Visit number
Comments
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CALGB-10501 EQ-5D Form NCT00513747
CALGB-10501 Impact Of Event Scale-
Revised Form NCT00513747
CALGB-10501 Impact Of Event Scale- Revised Form
NCT00513747 
Early or Delayed Fludarabine and Rituximab in Treating
Patients With Previously Untreated Chronic Lymphocytic
Leukemia
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=340EF355-
2CAB-21DF-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11116
CALGB-10501 Impact Of Event
Scale- Revised Form NCT00513747
Header
CALGB Form
CALGB Study No
CALGB Patient ID
Are data amended
Yes
No
Patient demographics
Patient Initials (Last, First Middle)
Patient Hospital No.
Institution/Affiliate
Participating Group
Participating Group Study No
Participating Group Patient ID
Visit number
Impact Of Event
Any reminder brought back feelings about it
A Little Bit (A little bit)
Extremely (Extremely)
Moderately (Moderately)
Not At All (Not at all)
Quite A Bit (Quite a bit)
1 / 2
I had trouble staying asleep
A Little Bit (A little bit)
Extremely (Extremely)
Moderately (Moderately)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Other things kept making me think about it
A Little Bit (A little bit)
Extremely (Extremely)
Moderately (Moderately)
Not At All (Not at all)
Quite A Bit (Quite a bit)
I thought about it when I didn't mean to
A Little Bit (A little bit)
Extremely (Extremely)
Moderately (Moderately)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Pictures about it popped into my mind
A Little Bit (A little bit)
Extremely (Extremely)
Moderately (Moderately)
Not At All (Not at all)
Quite A Bit (Quite a bit)
I had waves of strong feelings about it
A Little Bit (A little bit)
Extremely (Extremely)
Moderately (Moderately)
Not At All (Not at all)
Quite A Bit (Quite a bit)
I had dreams about it
A Little Bit (A little bit)
Extremely (Extremely)
Moderately (Moderately)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Overall Response
Completed by (print or type name)
Date Form Completed (MM DD YYYY)
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CALGB-10501 Impact Of Event Scale- Revised Form NCT00513747
CALGB-10501 Infectious Complications
Form NCT00513747
CALGB-10501 Infectious Complications Form
NCT00513747 
Early or Delayed Fludarabine and Rituximab in Treating
Patients With Previously Untreated Chronic Lymphocytic
Leukemia
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=3410554E-
9E86-2D64-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11117
CALGB-10501 Infectious
Complications Form NCT00513747
Header
CALGB Form
CALGB Study No
CALGB Patient ID
Date of Onset of Infection (MM DD YYYY)
Infection form number
Are data amended
Yes
No
Patient demographics
Patient Initials (Last, First Middle)
Patient Hospital No.
Institution/Affiliate
Participating Group
Participating Group Study No
Participating Group Patient ID
Cycle number
Cycle number during which infection was
diagnosed
1 / 3
Causitive Agent
Causative Infectious Agent (Mark one with an X.)
Gram Negative Bacillus (Bacterial -
Gram negative)
Gram Positive Bacillus (Bacterial - Gram
positive)
Bacterial - Other (Bacterial - other)
Fungal - Aspergillus (Fungal -
Aspergillus)
Fungal - Candida (Fungal - Candida)
Fungal - Other (Fungal - other)
Other (Other)
Parasitic Infection (Parasitic)
Pneumocystis Carinii (Pneumocystis
(PCP))
Specific Infectious Causative Agent Not
Determined (Specific infectious
causative agent not determined)
Viral - Cytomegalovirus (cmv) (Viral -
Cytomegalovirus (CMV))
Viral - Herpes Simplex (hsv) (Viral -
Herpes Simplex (HSV))
Viral - Other (Viral - other)
Viral - Varicella Zoster (vzv) (Viral -
Varicella Zoster (VZV))
Other, specify
Other, specify
Other, specify
Other, Specify
Primary Site of Infection (Mark one with an X.)
Blood (Blood)
Bone/joint (Bone/Joint)
Cns (CNS)
Disseminated (multiple Sites)
(Disseminated (multiple sites))
Ear (Ear)
Eye (Eye)
Gastrointestinal Tract (GI)
Liver/spleen (Liver/Spleen)
Lower Respiratory Tract (lrt) (Lower
Respiratory Tract (LRT))
Other (Other)
Reproductive System (Reproductive
system)
Skin And Soft Tissue (Skin/Soft Tissue)
Upper Respiratory Tract (urt) (Upper
Respiratory Tract (URT))
Urinary Tract (Urinary tract)
Other, specify
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CALGB-10501 Infectious Complications Form NCT00513747
Labs At Time Of Infection
Peripheral WBC Count (X 10^3/uL)
Peripheral Neutrophils (%) (segs + bands)
CTC Adverse Event Grade (Mark one with an X.)
Outcome of infection (Mark one with an X.)
Death Due To Infection (Death due to
infection)
Death Due To Other Causes (Death due
to other causes)
Not Resolved (Not resolved)
Other (Other)
Adverse Event Is Resolved (Resolved)
Other, specify
CTC AE Attribution Code
Definite (Definite)
Possible (Possible)
Probable (Probable)
Unlikely (Unlikely)
Unrelated (Unrelated)
Footer Module
Completed by (print or type name)
Date Form Completed (MM DD YYYY)
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CALGB-10501 Infectious Complications Form NCT00513747
CALGB: 10603 FLT3 Results Form
NCT00651261
CALGB: 10603 FLT3 Results Form NCT00651261 
Daunorubicin, Cytarabine, and Midostaurin in Treating
Patients With Newly Diagnosed Acute Myeloid Leukemia
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=437820BA-
09C1-2BB7-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11118
CALGB: 10603 FLT3 Results Form
NCT00651261
CALGB clinical trial administrative data
CALGB Form (C-714)
CALGB Study No.
CALGB Patient ID
Date of Receipt of Specimens
Are data amended
Yes
No
Patient Initials (Last, First Middle)
Patient Hospital No.
Institution/Affiliate
Participating Group (Country Name for
International site:)
Participating Group Protocol Number
Participating Group Patient ID
Pathology submission
Molecular Pathology Laboratory Number
Date of Report
Results (Indicatin of Study:  FLT3 gene Mutation
Analysis)
Flt3 Tyrosine Kinase Domain Point
Mutation (FLT3 TKD)
Internal Tandem Duplication (itd) Allelic
Ratio < 0.7 (ITD Allelic Ratio < 0.7)
1 / 2
Internal Tandem Duplication (itd) Allelic
Ratio => 0.7 (ITD Allelic Ratio => 0.7)
No Flt3 Gene Mutation (No FLT3 gene
mutation)
Allelic Ratio
Footer Module
Completed by
Date Form Completed
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CALGB: 10603 FLT3 Results Form NCT00651261
CALGB-10501 Hospital Anxiety And
Depression Scale Form NCT00513747
CALGB-10501 Hospital Anxiety And Depression Scale
Form NCT00513747 
Early or Delayed Fludarabine and Rituximab in Treating
Patients With Previously Untreated Chronic Lymphocytic
Leukemia
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=340EDF8E-
59E2-1F88-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11119
CALGB-10501 Hospital Anxiety And
Depression Scale Form
NCT00513747
Header
CALGB Form
CALGB Study No
CALGB Patient ID
Date Form Completed
Are data amended
Yes
No
Responsible CRA
Patient demographics
Patient Initials (Last, First Middle)
Patient Hospital No.
Institution/Affiliate
Participating Group
Participating Group Study No
Participating Group Patient ID
Visit number
Hospital Anxiety And Depression
Assessment
1 / 3
I feel tense or wound up (Mark one with an X.)
A Lot Of The Time (A lot of the time)
From Time To Time, Occasionally (From
time to time, occasionally)
Most Of The Time (Most of the time)
Not At All (Not at all)
I still enjoy the things I used to enjoy (Mark one
with an X.)
Definitely As Much (Definitely as much)
Hardly At All (Hardly at all)
Not Quite So Much (Not quite so much)
Only A Little (Only a little)
I get a sort of frightened feeling as if something
awful is about to happen (Mark one with an X.)
A Little, But It Doesn't Worry Me (A little,
but it doesn't worry me)
Not At All (Not at all)
Very Definitely And Quite Badly (Very
definitely and quite badly)
Yes, But Not Too Badly (Yes, but not too
badly)
I can laugh and see the funny side of things
(Mark one with an X.)
As Much As I Always Could (As much as
I always could)
Definitely Not So Much Now (Definitely
not so much now)
Not At All (Not at all)
Not Quite So Much Now (Not quite so
much now)
Worrying thoughts go through my mind (Mark
one with an X.)
A Great Deal Of The Time (A great deal
of the time)
A Lot Of The Time (A lot of the time)
From Time To Time But Not Too Often
(From time to time but not too often)
Only Occasionally (Only occasionally)
I feel cheerful (Mark one with an X.)
Most Of The Time (Most of the time)
Not At All (Not at all)
Not Often (Not often)
Sometimes (Sometimes)
I can sit at ease and feel relaxed (Mark one with
an X.)
Definitely (Definitely)
Not At All (Not at all)
Not Often (Not often)
Usually (Usually)
I feel as if I am slowed down (Mark one with an
X.)
Nearly All The Time (Nearly all the time)
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CALGB-10501 Hospital Anxiety And Depression Scale Form
NCT00513747
Not At All (Not at all)
Sometimes (Sometimes)
Very Often (Very often)
I get a sort of frightened feeling like butterflies in
my stomach (Mark one with an X.)
Not At All (Not at all)
Occasionally (Occasionally)
Quite Often (Quite often)
Very Often (Very often)
I have lost interest in my appearance (Mark one
with an X.)
Definitely (Definitely)
I Don't Take So Much Care As I Should (I
don't take so much care as I should)
I May Not Take Quite As Much Care (I
may not take quite as much care)
I Take Just As Much Care As Ever (I take
just as much care as ever)
I feel restless as if I have to be on the move
(Mark one with an X.)
Not At All (Not at all)
Not Very Much (Not very much)
Very Much Indeed (Very much indeed)
I look forward with enjoyment to things (Mark one
with an X.)
As Much As I Ever Did (As much as I
ever did)
Definitely Less Than I Used To
(Definitely less than I used to)
Hardly At All (Hardly at all)
Rather Less Than I Used To (Rather less
than I used to)
I get sudden feelings of panic (Mark one with an
X.)
Not At All (Not at all)
Not Very Often (Not very often)
Quite Often (Quite often)
Very Often Indeed (Very often indeed)
I can enjoy a good book or radio or TV program
(Mark one with an X.)
Not Often (Not often)
Often (Often)
Sometimes (Sometimes)
Very Seldom (Very seldom)
3 / 3
CALGB-10501 Hospital Anxiety And Depression Scale Form
NCT00513747
CALGB-10501 Concerns About Cancer
Progression Form NCT00513747
CALGB-10501 Concerns About Cancer Progression Form
NCT00513747 
Early or Delayed Fludarabine and Rituximab in Treating
Patients With Previously Untreated Chronic Lymphocytic
Leukemia
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=340EDF8E-
59EA-1F88-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11120
CALGB-10501 Concerns About
Cancer Progression Form
NCT00513747
Header
CALGB Form
CALGB Study No
CALGB Patient ID
Date of Assessment
Are data amended
Yes
No
Patient demographics
Patient Initials (Last, First Middle)
Patient Hospital No.
Institution/Affiliate
Participating Group
Participating Group Study No
Participating Group Patient ID
Visit number
Concerns About Cancer Assessment
How much time do you spend thinking about the
possibility that your leukemia could get worse
1 (1)
2 (2)
3 (3)
1 / 2
4 (4)
5 (5)
6 (6)
How much does the possibility that your leukemia
could get worse upset you
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
How often do you worry about the possibility that
your leukemia could get worse
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
How afraid are you that your leukemia may get
worse
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
Footer Module
Completed by (print or type name)
Date Form Completed (MM DD YYYY)
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CALGB-10501 Concerns About Cancer Progression Form NCT00513747
CALGB: 10603 PK SAMPLE SUBMISSION
FORM NCT00651261
CALGB: 10603 PK SAMPLE SUBMISSION FORM
NCT00651261 
Daunorubicin, Cytarabine, and Midostaurin in Treating
Patients With Newly Diagnosed Acute Myeloid Leukemia
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=4A5E657C-
0395-0FAD-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11121
CALGB: 10603 PK SAMPLE
SUBMISSION FORM NCT00651261
CALGB clinical trial administrative data
CALGB Form (C-714)
CALGB Study No.
CALGB Patient ID
Shipment date
Are data amended
Yes
No
Patient Initials (Last, First Middle)
Patient Hospital No.
Institution/Affiliate
Participating Group (Country Name for
International site:)
Participating Group Protocol Number
Participating Group Patient ID
Sample Submission Data
Sample Period (Continuation Therapy)
Cycle 12 - Day 1 (Cycle 12 - Day 1)
Cycle 8 - Day 1 (Cycle 8 - Day 1)
Date sample collected
If not collected, specify reason
Institution Error (Institutional error)
1 / 2
Other (Other)
Patient Refusal (Patient refusal)
Other, specify
Shipping Information
Responsible CRA
Email address
Fax Number
Phone
Courier Tracking Number
Shipped by
Footer Module
Comments
Completed by
Date Form Completed
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CALGB: 10603 PK SAMPLE SUBMISSION FORM NCT00651261
CALGB: Preoperative Imaging Form
NCT00499330
CALGB: Preoperative Imaging Form NCT00499330 
Comparison of Different Types of Surgery in Treating
Patients With Stage IA Non-Small Cell Lung Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=225E819D-
88A9-6685-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11122
CALGB: Preoperative Imaging Form
NCT00499330
Header
CALGB Form
CALGB Study No
CALGB Patient ID
Date of CT Scan
Are data amended
Yes
No
Hospital Name (or imaging center performing
chest CT)
Patient demographics
Patient Initials (Last, First Middle)
Patient Hospital No.
Institution/Affiliate
Participating Group
Participating Group Study No.
Participating Group Patient ID
Technique Factors
KVp
Pitch
mA
1 / 4
Scan Length (craniocaudal extent)
Rotation Time
Tumor Features
Tumor Location Area (Mark one)
Lingula (Lingula)
Lower Lobe (left) (Lower Lobe (left))
Lower Lobe (right) (Lower Lobe (right))
Middle Lobe (right) (Middle Lobe (right))
Upper Lobe (left) (Upper Lobe (left))
Upper Lobe (right) (Upper Lobe (right))
Table position of the most superior section in
which aerated lung is visible (For the lung that
contains the tumor provide:)
Table position of the most superior section that
shows the dome of the hemidiaphragm
Table position of the section that best
demonstrated the center of the tumor
Distance from midline to center of tumor
Maximum anteroposterior extent of aerated lung
(same side as tumor)
Distance from the most posterior extent of
aerated lung to center of tumor
Maximum diameter of tumor using lung window
settings
Maximum diameter of tumor, using soft tissue
(chest/abdomen) window settings
Tumor Features (cont)
Is a previous CT scan available for comparison
Yes
No
Has the tumor changed
New Finding (New finding)
Tumor Size Decreased (Tumor size
decreased)
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CALGB: Preoperative Imaging Form NCT00499330
Tumor Size Increased (Tumor size
increased)
Indicate previous maximum diameter (on lung
window images - cm)
Date of previous scan
Tumor Appearance
Margin and shape based on lung window settings
(Mark all that apply with an X.)
Ill-defined (Ill-defined)
Lobulated (Lobulated)
Round (Round)
Spiculated (Spiculated)
Well Defined (Well-defined)
Tumor appearance on lung window settings
(Mark all that apply with an X.)
Part Solid/mixed (Part-Solid)
Solid: C45300 (Solid)
If the scan includes non-contrast enhanced
images of the tumor, are any of the following
present (Tumor appearance on soft tissue
chest/abdomen window settings)
Gas- Attenuation Foci (Gas- attenuation
foci)
High- Attenuation Foci (e.g.,
Calcification) (High- attenuation foci
(e.g., calcification))
Water- Attenuation Foci (e.g., Necrosis)
(Water- attenuation foci (e.g., necrosis))
If the scan includes contrast-enhanced images of
the tumor, are any of the following present within
the tumor (Tumor appearance on soft tissue
chest/abdomen window settings)
Gas- Attenuation Foci (Gas- attenuation
foci)
High- Attenuation Foci (e.g.,
Calcification) (High- attenuation foci
(e.g., calcification))
Water- Attenuation Foci (e.g., Necrosis)
(Water- attenuation foci (e.g., necrosis))
Lymph Nodes
Indicate stations of all enlarged lymph nodes
Left Hilar Node (Left hilar (10L))
Left Lower Paratracheal Node (Left lower
paratracheal (4L))
Left Pulmonary Ligament (9l) (Left
pulmonary ligament (9L))
Left Upper Paratracheal Node (Left
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upper paratracheal (2L))
Para-aortic Node (Para-aortic (6))
Paraesophageal (Paraesophageal (8))
Pre-vascular (3a) (Pre-vascular (3A))
Retrotracheal (3p) (Retrotracheal (3P))
Right Hilar Node (Right hilar (10R))
Right Lower Paratracheal Node (Right
lower paratracheal (4R))
Right Pulmonary Ligament (9r) (Right
pulmonary ligament (9R))
Right Upper Paratracheal Node (Right
upper paratracheal (2R))
Subaortic Node (Subaortic (5))
Subcarinal Node (Subcarinal (7))
Was a pre-operative PET scan performed
Yes
No
Date of PET scan (If yes,)
Pet Scan Results
Site of lesion
Lymph Node (Nodal lesion)
Other (Other lesion)
Lung (Primary Lung)
Nodal lesion, specify
SUV Max
SUV Mean
What tests were performed to rule out possible
distant metastases present on PET scan?
Footer module
Completed by (Last name, First name)
Date Form Originally Completed
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CALGB: Thoracic Lymph Node Sampling
Report NCT00499330
CALGB: Thoracic Lymph Node Sampling Report
NCT00499330 
Comparison of Different Types of Surgery in Treating
Patients With Stage IA Non-Small Cell Lung Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=225E819D-
890F-6685-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11123
CALGB: Thoracic Lymph Node
Sampling Report NCT00499330
Header
CALGB Form
CALGB Study No
CALGB Patient ID
Date of Procedure
Are data amended
Yes
No
Patient demographics
Patient Initials (Last, First Middle)
Patient Hospital No.
Institution/Affiliate
Participating Group
Participating Group Study No.
Participating Group Patient ID
Surgical Approach Right Sided Nodes
Surgical Procedure Method (Mark one with an X.
Complete a separate form for each procedure.)
Mediastinoscopy (Mediastinoscopy)
Thoracoscopy / Video-assisted (vats)
(Thoracoscopy / Video-assisted (VATS))
Thoracoscopy / Video-assisted (vats),
With Conversion To Thoracotomy
(Thoracoscopy / Video-assisted (VATS),
1 / 3
with conversion to Thoracotomy)
Thoracotomy (thoracotomy)
Right Sided Nodes
Lymph Nodes Type
Interlobar Node (Interlobar (11))
Intralobar (12-14) (Intralobar (12-14))
Left Hilar Node (Left hilar (10L))
Left Lower Paratracheal Node (Left lower
paratracheal (4L))
Left Upper Paratracheal Node (Left
upper paratracheal (2L))
Paraesophageal (Paraesophageal (8))
Pulmonary Ligament (Pulmonary
ligament (9))
Subaortic Node (Subaortic (5))
Subcarinal Node (Subcarinal (7))
Was biopsy performed
Yes
No
Portion of node biopsied
Part (Part)
Whole (Whole)
Lymph Node Involvement
Negative (negative)
Not Evaluated (not evaluated)
Positive (positive)
Surgical Approach Left Sided Nodes
Surgical Procedure Method (Mark one with an X.
Complete a separate form for each procedure.)
Mediastinoscopy (Mediastinoscopy)
Thoracoscopy / Video-assisted (vats)
(Thoracoscopy / Video-assisted (VATS))
Thoracoscopy / Video-assisted (vats),
With Conversion To Thoracotomy
(Thoracoscopy / Video-assisted (VATS),
with conversion to Thoracotomy)
Thoracotomy (thoracotomy)
Left Sided Nodes
Lymph Nodes Type
Interlobar Node (Interlobar (11))
Intralobar (12-14) (Intralobar (12-14))
Left Hilar Node (Left hilar (10L))
Left Lower Paratracheal Node (Left lower
paratracheal (4L))
Left Upper Paratracheal Node (Left
upper paratracheal (2L))
Paraesophageal (Paraesophageal (8))
Pulmonary Ligament (Pulmonary
2 / 3
CALGB: Thoracic Lymph Node Sampling Report NCT00499330
ligament (9))
Subaortic Node (Subaortic (5))
Subcarinal Node (Subcarinal (7))
Other, specify
Was biopsy performed
Yes
No
Portion of node biopsied
Part (Part)
Whole (Whole)
Lymph Node Involvement
Negative (negative)
Not Evaluated (not evaluated)
Positive (positive)
Footer module
Completed by (Last name, First name)
Date Form Originally Completed
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CALGB: Thoracic Lymph Node Sampling Report NCT00499330
CALGB-10501 Summary Response /
Progression Form for Leukemia NCT00513747
CALGB-10501 Summary Response / Progression Form for
Leukemia NCT00513747 
Early or Delayed Fludarabine and Rituximab in Treating
Patients With Previously Untreated Chronic Lymphocytic
Leukemia
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=33F80721-
319D-3F50-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11124
CALGB-10501 Summary Response /
Progression Form for Leukemia
NCT00513747
Header
CALGB Form
CALGB Study No
CALGB Patient ID
Date of Assessment
Are data amended
Yes
No
Patient demographics
Patient Initials (Last, First Middle)
Patient Hospital No.
Institution/Affiliate
Participating Group
Participating Group Study No.
Participating Group Patient ID
Leukemia Response Assessment
Has the patient achieved a response? (during this
time period)
Yes
No
Complete Response (CR) First Observed Date
(MM DD YYYY)
1 / 2
Nodular partial response (NPR) first observed
date (MM DD YYYY)
Partial Response (PR) First Observed Date (MM
DD YYYY)
Stable Disease First Observed Date (SD)
Has the patient been diagnosed with a new
progression (during this reporting period not
previously reported)
Yes
No
Progressive Disease (PD) Observed Date
(Second MM DD YYYY)
Progressive Disease (PD) Observed Date
(Second MM DD YYYY)
Liver Assessment
No (NO)
Unknown (Unknown)
Yes (YES)
Spleen Assessment
No (NO)
Unknown (Unknown)
Yes (YES)
Lymph Node Assessment
No (NO)
Unknown (Unknown)
Yes (YES)
Lymphocytes (> 50% increase in absolute
number of circulating lymphocyctes to at least
5000/uL)
No (NO)
Unknown (Unknown)
Yes (YES)
Comments
Completed by (Last name, First name)
Date Form Completed (MM DD YYYY)
Comments
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CALGB-10501 Chronic Lymphocytic Leukemia
(CLL) Immunophenotype Form NCT00513747
CALGB-10501 Chronic Lymphocytic Leukemia (CLL)
Immunophenotype Form NCT00513747 
Early or Delayed Fludarabine and Rituximab in Treating
Patients With Previously Untreated Chronic Lymphocytic
Leukemia
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=340EF355-
2CB3-21DF-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11125
CALGB-10501 Chronic Lymphocytic
Leukemia (CLL) Immunophenotype
Form NCT00513747
Header
CALGB Form
CALGB Study No
CALGB Patient ID
Date immunophenotyping performed (MM DD
YYYY)
Are data amended
Yes
No
Patient demographics
Patient Initials (Last, First Middle)
Patient Hospital No.
Institution/Affiliate
Participating Group
Participating Group Study No
Participating Group Patient ID
Immunophenotype
Source of Cells used for Analysis
Bone Marrow (Bone marrow)
Lymph Node (Lymph node)
Other Specify (Other)
Peripheral Blood (Peripheral blood)
1 / 3
Marrow Leukemic Cells (%)
Peripheral Leukemic Cells (%)
Leukemic Cells in Other Tissue (%)
B-cell Lineage
Antigen
Cd10 (CD10)
Cd117 (CD117)
Cd11b (CD11b)
Cd13 (CD13)
Cd14 (CD14)
Cd15 (CD15)
Cd19 (CD19)
Cd1a (CD1a)
Cd2 (CD2)
Cd20 (CD20)
Cd21 (CD21)
Cd22 Surface (CD22 surface)
Cd23 (CD23)
Cd25 (CD25)
Cd3 Intracytoplasmic (CD3
intracytoplasmic)
Cd3 Surface (CD3 surface)
Cd33 (CD33)
Cd34 (CD34)
Cd38 (CD38)
Cd4 (CD4)
Cd4+/cd8+ (CD4+/CD8+)
Cd41 (CD41)
Cd45 (CD45)
Cd5 (CD5)
Cd52 (CD52)
Cd56 (CD56)
Cd61 (CD61)
Cd65 (CD65)
Cd7 (CD7)
Cd79a Intracytoplasmic (CD79a
intracytoplasmic)
Cd8 (CD8)
Fmc-7 (FMC-7)
Hla-dr (HLA-DR)
Ig-kappa Surface (Ig-kappa surface)
Ig-lambda Surface (Ig-lambda surface)
Igd Surface (IgD surface)
Igg Surface (IgG surface)
Igm Surface (IgM surface)
Myeloperoxidase (Myeloperoxidase)
Terminal Transferase (tdt) (Terminal
Transferase (TdT))
Other specify
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Form NCT00513747
Test not done
Antigen percent positivity
Antigen Status
Antigen Intensity Lab Performed, Result
Faintly Positive (faintly positive)
Antigen Intensity Lab Performed, Result
Moderately Positive (moderately positive)
Antigen Intensity Lab Performed, Result
Negative (negative)
Antigen Intensity Lab Performed, Result
Strongly Positive (strongly positive)
Comments
Comments
Completed by (print or type name)
Date Form Completed (MM DD YYYY)
3 / 3
CALGB-10501 Chronic Lymphocytic Leukemia (CLL) Immunophenotype
Form NCT00513747
CALGB-10501 Chronic Lymphocytic Leukemia
(CLL) On-Study Form NCT00513747
CALGB-10501 Chronic Lymphocytic Leukemia (CLL) On-
Study Form NCT00513747 
Early or Delayed Fludarabine and Rituximab in Treating
Patients With Previously Untreated Chronic Lymphocytic
Leukemia
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=3410113C-
1559-25BC-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11126
CALGB-10501 Chronic Lymphocytic
Leukemia (CLL) On-Study Form
NCT00513747
Header
CALGB Form
CALGB Study No
CALGB Patient ID
Are data amended
Yes
No
Patient demographics
Patient Initials (Last, First Middle)
Patient Hospital No.
Institution/Affiliate
Participating Group
Participating Group Study No
Participating Group Patient ID
Patient status assessment
MedDRA Code
Date of Initial Pathologic Diagnosis (MM DD
YYYY)
Height (cm)
1 / 5
Weight (kg)
BSA (m^2)
Was an abdominal CT performed
Yes
No
Size of Largest Lymph Node
> 1 Cm But < 2 Cm (> 1 cm but < 2 cm)
>= 2 Cm But < 5 Cm (>= 2 cm but < 5
cm)
>= 5 Cm (>= 5 cm)
Does the patient have a history of bug bite
hypersensitivity
Yes
No
Military Service Type (Mark all that apply with an
X.)
Iraq War 1990-1991 (IRAQ War 1990-
1991)
Iraq War 2001-present (IRAQ War 2001-
present)
Korean War (Korean War)
No Military Service (No military service)
Vietnam War (Vietnam War)
Has the patient taken antibiotics? (last year)
Yes
No
Did the patient require hospitalization (last year)
Yes
No
Does the patient have a history of varicella zoster
Yes
No
Rai Stage Classification
Rai Stage Classification (Mark one with an X.)
Lymphocytosis In Blood With
Lymphocyte Count > 15,000/mcl And
Bone Marrow Populated With Mature
Lymphocytes Comprising >40% Of
Nucleated Cells (Stage 0)
Same As Stage 0 With
Lymphadenopathy (Stage I)
Blood Or Platelet Transfusions
Total number of units PRBC (given during the
three-month period prior to starting therapy)
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NCT00513747
Total number of units platelets (given during the
three-month period prior to starting therapy)
Organ Involvement
Palpable splenomegaly
Examination Performed And
Splenomegaly Absent (No)
Examination Of Spleen Not Performed
(Not examined)
Spleen Removed Via Prior Surgery
(Surgically absent)
Examination Performed And
Splenomegaly Present (Yes)
Splenomegaly by scan (or X-ray)
Examination Performed And
Splenomegaly Absent (No)
Examination Of Spleen Not Performed
(Not examined)
Spleen Removed Via Prior Surgery
(Surgically absent)
Examination Performed And
Splenomegaly Present (Yes)
Date of Splenectomy (MM DD YYYY)
Palpable hepatomegaly
Examination Performed And
Hepatomegaly Absent (No)
Examination Of Liver Not Performed (Not
examined)
Examination Performed And
Hepatomegaly Present (Yes)
Hepatomegaly by scan (or X-ray)
Examination Performed And
Hepatomegaly Absent (No)
Examination Of Liver Not Performed (Not
examined)
Examination Performed And
Hepatomegaly Present (Yes)
Lymph Node Involvement
Is there lymph node involvement (If Yes, complete
the following)
Yes
No
Number of Positive Lymph Nodes
Any lymph node or aggregate with a diameter
greater than 10 cm (if pediatric, >6 cm)
Yes
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No
Any lymph node or aggregate with a diameter
greater than 5 cm
Yes
No
Any lymph node or aggregate with a diameter >2
cm
Yes
No
Any lymph node or aggregate with a diameter >1
cm but <2 cm
Yes
No
Lab Data/values
Creatinine (mg/dl)
Creatinine ULN (mg/dl)
Lactate Dehydrogenase (LDH) (U/L)
Lactate Dehydrogenase ULN (U/L)
Beta-2 Microglobulin (mg/liter)
Beta-2 Microglobulin ULN (mg/liter)
CMV IgG
Negative (negative)
Positive (positive)
Varicella IgG
Negative (negative)
Positive (positive)
Albumin
IgG (mg)
IgA (mg)
IgM (mg)
Coomb's Test (Mark one with an X.)
Coomb's Test Performed And Negative
Result (Negative)
Coomb's Test Performed And Positive
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Result (Positive)
Coomb's Indirect Test
Coomb's Test Performed And Negative
Result (Negative)
Coomb's Test Performed And Positive
Result (Positive)
Coomb's Test Date (MM DD YYYY)
Peripheral CD56 Positive Cells (%)
Peripheral CD16 positive cells (%)
Peripheral CD4 positive cells (%)
Peripheral CD8 positive cells (%)
Peripheral CD19 positive cells (%)
Chest X-ray Or Thoracic Ct
Chest X-Ray Or Thoracic CT (Mark one with an
X.)
Abnormal Mediastinal Enlargement
(hilar/paratracheal) (Abnormal
mediastinal enlargement
(hilar/paratracheal))
Abnormal, Interstitial Disease In Lung
(Abnormal, interstitial disease in lung)
Abnormal, Nodules In Lung Parenchyma
(Abnormal, nodules in lung parenchyma)
Abnormal, Other (Abnormal, other)
Normal (Normal)
Other, specify
Footer module
Completed by (print or type name)
Date Form Completed (MM DD YYYY)
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NCT00513747
NCT00513747 CALGB-10501 Chronic Lymphocytic
Leukemia (CLL) Second Treatment Form
NCT00513747  CALGB-10501 Chronic Lymphocytic
Leukemia (CLL) Second Treatment Form
Early or Delayed Fludarabine and Rituximab in Treating
Patients With Previously Untreated Chronic Lymphocytic
Leukemia
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=3410315B-
B4A7-28F5-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11127
NCT00513747 CALGB-10501
Chronic Lymphocytic Leukemia
(CLL) Second Treatment Form
Header
CALGB Form
CALGB Study No
CALGB Patient ID
Start Date of Second Treatment
Are data amended
Yes
No
Patient demographics
Patient Initials (Last, First Middle)
Patient Hospital No.
Institution/Affiliate
Participating Group
Participating Group Study No
Participating Group Patient ID
Patient Data
Weight (kg)
BSA (m^2)
Performance Status (Mark one with an X at end
of cycle)
1 / 3
Fully Active, Able To Carry On All Pre-
disease Performance Without
Restriction. (0)
Restricted In Physically Strenuous
Activity But Ambulatory And Able To
Carry Out Work Of A Light Or Sedentary
Nature, E.g., Light Housework, Office
Work. (1)
Ambulatory And Capable Of All Selfcare
But Unable To Carry Out Any Work
Activities. Up And About More Than 50%
Of Waking Hours. (2)
Capable Of Only Limited Selfcare,
Confined To Bed Or Chair More Than
50% Of Waking Hours. (3)
Completely Disabled. Cannot Carry On
Any Selfcare. Totally Confined To Bed Or
Chair. (4)
Does the patient meet treatment initiation (NCI 96
criteria for)
Yes
No
Specify reason treatment not initiated (if no)
Criteria For Treatment
A minimum of any one of the following disease-
related symptoms must be present
Drenching Night Sweats More Than 3
Times Per Week Without Evidence Of
Infection That Require The Patient To
Change Clothes (Drenching night sweats
more than 3 times per week without
evidence of infection that require the
patient to change clothes)
Evidence Of Progressive Marrow Failure
As Manifested By Autoimmune Anemia
Or Thrombocytopenia Poorly Responsive
To Corticosteroid Therapy (Evidence of
progressive marrow failure as manifested
by autoimmune anemia or
thrombocytopenia poorly responsive to
corticosteroid therapy)
Evidence Of Progressive Marrow Failure
As Manifested By Hemoglobin <11 G/dl
In The Absence Of Autoimmune
Hemolytic Anemia (Evidence of
progressive marrow failure as manifested
by hemoglobin <11 g/dL in the absence
of autoimmune hemolytic anemia)
Evidence Of Progressive Marrow Failure
As Manifested By Lymphocyte Count >
300 X 10^9 /l (Evidence of progressive
marrow failure as manifested by
lymphocyte count > 300 x 10^9 /L)
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Second Treatment Form
Evidence Of Progressive Marrow Failure
As Manifested By Massive (i.e., >6 Cm
Below The Left Costal Margin) Or
Progressive Splenomegaly That Is
Causing Pain Or Significantly Early
Satiety (Evidence of progressive marrow
failure as manifested by massive (i.e., >6
cm below the left costal margin) or
progressive splenomegaly that is
causing pain or significantly early satiety)
Evidence Of Progressive Marrow Failure
As Manifested By Massive Nodes Or
Clusters (i.e., >10 Cm In Longest
Diameter) Or Progressive
Lymphadenopathy That Is Causing Pain
Or Significant Disfigurement (Evidence
of progressive marrow failure as
manifested by massive nodes or clusters
(i.e., >10 cm in longest diameter) or
progressive lymphadenopathy that is
causing pain or significant disfigurement)
Evidence Of Progressive Marrow Failure
As Manifested By Thrombocytopenia
<100 X 10^12 /l In The Absence Of
Idiopathic Thrombocytopenia Purpura
(Evidence of progressive marrow failure
as manifested by thrombocytopenia
<100 x 10^12 /L in the absence of
idiopathic thrombocytopenia purpura)
Extreme Fatigue (Extreme fatigue)
Fevers Of Greater Than 100.5 Degrees F
For 2 Weeks Without Evidence Of
Infection (Fevers of greater than 100.5
degrees F for 2 weeks without evidence
of infection)
Other Disease Related Symptoms (skin
Infitration, Vasculitis, Pemphigus) (Other
disease related symptoms (skin
infitration, vasculitis, pemphigus))
Weight Loss Of 10% Or More Within The
Previous 6 Months (Weight loss of 10%
or more within the previous 6 months)
Date of Symptom/Event Assessment (MM DD
YYYY)
Footer Module
Completed by (print or type name)
Date Form Completed (MM DD YYYY)
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Second Treatment Form
CALGB 90203: Late Postoperative
Complications Form NCT00430183
CALGB 90203: Late Postoperative Complications Form
[Form C-1275 v1 11/06/2006] NCT00430183
Surgery With or Without Docetaxel and Leuprolide or
Goserelin in Treating Patients With High-Risk Localized
Prostate Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=1E774671-
33FE-1976-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11128
CALGB 90203: Late Postoperative
Complications Form NCT00430183
Header
CALGB Form (C-1241)
CALGB Study No.
CALGB Patient ID
Assessment Date (mm dd yyyy)
Are data amended
Yes
No
Reporting Period (time since surgery Mark one
with an X.)
12 Months (12 months)
3 Months (3 months)
6 Months (6 months)
9 Months (9 months)
Patient demographics
Patient Initials (Last, First Middle)
Patient Hospital No.
Institution/Affiliate
Participating Group
Participating Group Study No.
Participating Group Patient ID
Postoperative Complications
MedDRA Code
1 / 2
CTC AE Grade (2 AE is defined as Adverse
Event; 1 Use NCI CTCAE v3.x or most current
version with MedDRA codes posted at
http://www.calgb.org to grade each adverse
event. Grade= -1 if category not evaluated.
Grade= 0 if category evaluated by event not
reported.)
CTC Adverse Event Term (Specify below any
other postoperative complications, grade 3 or
higher, that occurred during this reporting period.)
Oedema Nos (Edema: limb)
Edema: Trunk/genital (Edema:
trunk/genital)
Impotence (Erectile dysfunction)
Urinary Incontinence (Incontinence,
urinary)
Leak (including Anastomotic), Gu (Leak
(including anastomotic), GU - Urethra)
Lymphocele (Lymphocele)
Stricture/stenosis (including
Anastomotic), Gu (Stricture/stenosis
(including anastomotic), GU - Bladder)
Thrombosis Nos
(Thrombosis/thrombus/embolism)
Urinary Frequency (Urinary
frequency/urgency)
Urinary Retention (Urinary retention
(including neurogenic bladder))
Specify type of corrective procedure
Total number of corrective procedures (since
surgery)
Footer Module
Completed by (Last name, First name)
Date Form Completed (mm dd yyyy)
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CALGB: 90202 Baseline Solid Tumor
Evaluation Form NCT00079001
CALGB: 90202 Baseline Solid Tumor Evaluation Form
NCT00079001
Zoledronate in Preventing Skeletal (Bone)-Related Events
in Patients Who Are Receiving Androgen Deprivation
Therapy For Prostate Cancer and Bone Metastases
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=B4605F45-
F7E1-0518-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/11129
CALGB: 90202 Baseline Solid Tumor
Evaluation Form NCT00079001
Header
CALGB Form
CALGB Study No
CALGB Patient ID
Amended data?
Yes (Yes)
Patient demographics
Patient Initials
Participating Group
Patient Hospital Number
Participating Group Protocol No.
Main Member Institution/Adjunct
Participating Group Patient ID
Target Lesion(s) Baseline Evaluation
Lesion, Anatomic Site, Target
Date of Evaluation
Method of Evaluation
Bone Scan (Bone scan)
Chest X-ray (chest x-ray)
Clinical Examination (pe) (clinical
examination)
Ct Scan (CT scan)
Mri (MRI (NMR))
1 / 2
Other (other)
Spiral Ct Scan (Spiral CT scan)
Ultrasound (Ultrasound)
If other, specify (method of evaluation)
Longest Diameter of Lesion(s) (cm)
Sum of Longest Diameteres of All Target lesions
(cm)
Non-target Lesion(s) Baseline Evaluation
Are there any non-target lesions?
Yes
No
Lesion, Anatomic Site, Non-Target
Date of Evaluation
Method of Evaluation
Bone Scan (Bone scan)
Chest X-ray (chest x-ray)
Clinical Examination (pe) (clinical
examination)
Ct Scan (CT scan)
Mri (MRI (NMR))
Other (other)
Spiral Ct Scan (Spiral CT scan)
Ultrasound (Ultrasound)
If other, specify (method of evaluation)
Completed by
Date form completed
Ccrr Module For Calgb: 90202 Baseline
Solid Tumor Evaluation Form
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CALGB: ARTERIAL THROMBOEMBOLIC
EVENT REPORT NCT00110214
CALGB: ARTERIAL THROMBOEMBOLIC EVENT
REPORT NCT00110214
Docetaxel and Prednisone With or Without Bevacizumab in
Treating Patients With Prostate Cancer That Did Not
Respond to Hormone Therapy
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=EF4BCCC7-
ECC6-11A8-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11130
CALGB: ARTERIAL
THROMBOEMBOLIC EVENT
REPORT NCT00110214
Header
CALGB Form
CALGB Study No
CALGB Patient ID
Start date of primary AE (^2)
Endt date of primary AE (^2)
Are data amended
Yes
No
Patient demographics
Patient Initials
Patient Hospital No
Institution/Affiliate
Participating Group
Participating Group Study No
Participating Group Patient ID
ARTERIAL THROMBOEMBOLIC EVENT
REPORT
Course number on which event occurred (s)
1 / 3
Total number of courses to date
Description of event (s Record if not submitting
AdEERS report.)
MedDRA code
Adverse event
Myocardial Ischaemia (Cardiac
ischemia/infarction)
Cerebral Ischaemia (CNS
cerebrovascular ischemia)
Peripheral Ischaemia Nos (Peripheral
arterial ischemia)
Cardiac-ischemia/infarction Grade (Mark one with
an X.)
CNS cerebrovascular ischemia Grade
Peripheral arterial ischemia Grade
CTC AE attribution code
Definite (definite)
Possible (possible)
Probable (probable)
Unlikely (unlikely)
Unrelated (unrelated)
Is primary AE (^2)
CTC AE grade
Treatment of event (s Mark all that apply with an
X.)
Hospitalization (Hospitalization)
Surgery (Surgery)
Hospital admission date
Hospital discharge date
Surgery, specify
Present status (Mark all that apply with an X.)
Removed From Protocol Treatment
(Removed from protocol treatment)
Resumed Protocol Treatment (Resumed
protocol treatment)
Removed from protocol treatment, specify date
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CALGB: ARTERIAL THROMBOEMBOLIC EVENT REPORT
NCT00110214
Completed by
Date form completed
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CALGB: ARTERIAL THROMBOEMBOLIC EVENT REPORT
NCT00110214
CALGB: C-1001 NEW PRIMARY CANCER
FORM [80303] NCT00088894
CALGB: C-1001 NEW PRIMARY CANCER FORM [80303]
NCT00088894
Gemcitabine With or Without Bevacizumab in Treating
Patients With Locally Advanced or Metastatic Pancreatic
Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=D5FEE4C9-
F395-6F2C-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/11131
CALGB: C-1001 NEW PRIMARY
CANCER FORM [80303]
NCT00088894
Header
CALGB Study No.
CALGB Patient ID
Are data amended?
Yes
No
Patient demographics
Patient's Initials
Participating Group
Patient Hospital No.
Participating Group Protocol No.
Institution/Affiliate
Participating Group Patient ID
NEW PRIMARY CANCER ASSESSMENT
Site(s) of New Primary
New Primary, Histologic Type
Date of Diagnosis
Comments
Comments
1 / 2
Completed by
Date Form Completed
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CALGB: C-1001 NEW PRIMARY CANCER FORM [80303]
NCT00088894
CALGB: 90401 Solid Tumor Evaluation
Form NCT00110214
CALGB: 90401 Solid Tumor Evaluation Form
NCT00110214
Docetaxel and Prednisone With or Without Bevacizumab in
Treating Patients With Prostate Cancer That Did Not
Respond to Hormone Therapy
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=EF4A5A98-
EEC8-4D5E-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11132
CALGB: 90401 Solid Tumor
Evaluation Form NCT00110214
Header
CALGB Form
CALGB Study No.
CALGB Patient ID
Are data amended?
Yes
No
Patient demographics
Patient Initials
Patient Hospital No.
Institution/Affiliate
Participating Group
Participating Group Study No.
Participating Group Patient ID
List All Target And Non-target Sites To Be
Used For Response:
Treating Physician
Date of evaluation
Target Lesion(s)
1 / 2
Response status at this assessment (CR,
Incomplete Response/SD, PD:)
Complete Response; Disapperance Of
All Target Lesions (CR)
Incomplete Response Or Stable
Disesase (Incomplete Response/SD)
Progressive Disease (PD)
Lesion, anatomic site, target
Method of Evaluation
Longest diameter of lesion (s cm)
Sum of longest diameters of all target lesions
Non-target Lesion(s)
Response status at this assessment (CR,
Incomplete Response/SD, PD:)
Complete Response; Disapperance Of
All Target Lesions (CR)
Incomplete Response Or Stable
Disesase (Incomplete Response/SD)
Progressive Disease (PD)
Lesion, anatomic site, non-target
Method of Evaluation
Follow-up Status of Lesion* (*)
Absent (Absent)
Present (Present)
Completed by (Print or Type Name)
Date form originally completed
2 / 2
CALGB: 90401 Solid Tumor Evaluation Form NCT00110214
CALGB: 90401 Prostate Specific Antigen
Form NCT00110214
CALGB: 90401 Prostate Specific Antigen Form
NCT00110214
Docetaxel and Prednisone With or Without Bevacizumab in
Treating Patients With Prostate Cancer That Did Not
Respond to Hormone Therapy
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=EF4A65EE-
63BC-4DD3-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11133
CALGB: 90401 Prostate Specific
Antigen Form NCT00110214
Header
CALGB Form
CALGB Study No.
CALGB Patient ID
Are data amended?
Yes
No
Patient demographics
Patient Initials (Last, First, Middle)
Patient Medical Record Number
Institution/Affiliate
Participating Group
Participating Group Protocol Number
Participating Group Patient ID
Prostate Specific Antigen
PSA date (MM DD YYYY)
PSA value (total)
Status (STATUS CODES)
Baseline Value (Baseline value)
Follow-up, Off Treatment Value (Follow-
up, off treatment value)
1 / 2
Pre-study Value (Pre-study value)
Protocol Treatment Value (Protocol
treatment value)
Completed by (Last name, First name)
Date form originally completed (MM DD YYYY)
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CALGB: 90401 Prostate Specific Antigen Form NCT00110214
CALGB: SOLID TUMOR EVALUATION
FORM [80303] NCT00088894
CALGB: SOLID TUMOR EVALUATION FORM [80303]
NCT00088894
Gemcitabine With or Without Bevacizumab in Treating
Patients With Locally Advanced or Metastatic Pancreatic
Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=D6012DD9-
1E79-035F-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/11134
CALGB: SOLID TUMOR
EVALUATION FORM [80303]
NCT00088894
Header
CALGB Study No.
CALGB Patient ID
Are data amended?
Yes
No
Patient demographics
Patient's Initials
Participating Group
Patient Hospital No.
Participating Group Study No.
Institution/Affiliate
Participating Group Patient ID
Treating Physician
Date of evaluation
Target Lesion(s)
Follow-up response status
Complete Response (CR)
Stable Disease Or Unchanged
(Incomplete Response/SD)
Progressive Disease (PD)
Lesion Site Number
1 / 2
Lesion, anatomic site, target
Method of Evaluation
Longest diameter of lesion(s) (cm)
Sum of longest diameter of all target lesions
Non-target Lesion(s)
Follow-up Status of Lesion
No (absent)
Yes (present)
Footer module
Complete by
Date completed
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CALGB: 90203 OP REPORT ADDENDUM
FORM NCT00430183
CALGB: 90203 OP REPORT ADDENDUM FORM
NCT00430183
Surgery With or Without Docetaxel and Leuprolide or
Goserelin in Treating Patients With High-Risk Localized
Prostate Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=A40A6739-
F48D-DA39-E040-BB89AD4318C2
All rights reserved. Please visit https://medical-data-
models.org/forms/11135
CALGB: 90203 OP REPORT
ADDENDUM FORM NCT00430183
Header Module
CALGB Form (C-714)
CALGB Study No.
CALGB Patient ID
Are data amended
Yes
No
Patient Initials (Last, First Middle)
Patient Hospital No.
Institution/Affiliate
Participating Group
Participating Group Study No.
Participating Group Patient ID
Pathology: Lymphadenectomy
Number of lymph nodes dissected?
Extent of lymph node dissection?
Extended (Extended)
Limited (Limited)
Which lymph node areas were dissected (Mark
all that apply with an X.)
External Iliac (external iliac)
Hypogastric (hypogastric)
Obturator Lymph Node (obturator)
Were the nodes grossly positive
Yes
1 / 3
No
Was a frozen section of the lymph node(s)
performed
Yes
No
Specify Results
Negative (Negative)
Positive (Positive)
T Stage, Pathologic (CRF must use existing CDE
which matches CAP/AJCC 2006 versions - no
pathologic staging of tumor for T0/T1 in that
system.)
Organ Confined (pT2)
Unilateral (pT2a)
Bilateral (pT2b)
Bilateral (pT2c)
Extraprostatic Extension (pT3)
Extraprostatic Extension (pT3a)
Seminal Vesicle Invasion (pT3b)
Invasion Of Bladder, Rectum (pT4)
Clinically Inapparent Tumor Not Palpable
Nor Visible By Imaging (T1)
Was all gross disease resected?
Yes
No
Difficulty of the surgical procedure
Average (Average)
Moderately Difficult (Moderately difficult)
Very Difficult (Very difficult)
Were there any intraoperative complications?
Yes
No
Pathologic Disease Classification
N Stage, Pathologic
No Regional Lymph Node Metastasis
(pN0)
Metastatis In Regional Lymph Node Or
Nodes (see Ajcc Definition) (pN1)
Regional Lymph Nodes Cannot Be
Assessed (pNX)
T Stage, Pathologic (CRF must use existing CDE
which matches CAP/AJCC 2006 versions - no
pathologic staging of tumor for T0/T1 in that
system.)
Organ Confined (pT2)
Unilateral (pT2a)
Bilateral (pT2b)
Bilateral (pT2c)
Extraprostatic Extension (pT3)
Extraprostatic Extension (pT3a)
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Seminal Vesicle Invasion (pT3b)
Invasion Of Bladder, Rectum (pT4)
Clinically Inapparent Tumor Not Palpable
Nor Visible By Imaging (T1)
Ccrr Module For Calgb: 90202 Adverse
Event Form
Completed by (Last name, First name)
Date Form Completed (mm dd yyyy)
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CALGB: 90401 SPECIMEN SUBMISSION
FORM NCT00110214
CALGB: 90401 SPECIMEN SUBMISSION FORM
NCT00110214
Docetaxel and Prednisone With or Without Bevacizumab in
Treating Patients With Prostate Cancer That Did Not
Respond to Hormone Therapy
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=EF4CB17A-
D97A-295A-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11136
CALGB: 90401 SPECIMEN
SUBMISSION FORM NCT00110214
Header
CALGB Form
CALGB Study No
CALGB Patient ID
Are data amended
Yes
No
Patient demographics
Patient Initials
Patient Hospital No
Institution/Affiliate
Participating Group
Participating Group Study No
Participating Group Patient ID
Biopsy specimen
Sample number
Date specimen collected (s)
Number of tubes submitted (purple-top for
pharmacogenomic study 60404)
1 / 2
Number of tubes submitted (purple-top for
pharmacogenomic study 60404)
Number of tubes submitted (purple-top for
pharmacogenomic study 60404)
If none submitted, specify reason (^1)
Institution Error (Institution error)
Other (Other)
Patient Refusal (Patient refusal)
Sample Lost Or Destroyed (Sample lost
or destroyed)
If none submitted, specify reason (^1)
Institution Error (Institution error)
Other (Other)
Patient Refusal (Patient refusal)
Sample Lost Or Destroyed (Sample lost
or destroyed)
If none submitted, specify reason (^1)
Institution Error (Institution error)
Other (Other)
Patient Refusal (Patient refusal)
Sample Lost Or Destroyed (Sample lost
or destroyed)
Shipment date
Shipped by:
Phone number
LabTrak sample ID (^2)
LabTrak sample ID (^2)
LabTrak sample ID (^2)
LabTrak sample ID (^2)
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CALGB 90601: Eligibility Checklist
NCT00942331
CALGB 90601: Eligibility Checklist NCT00942331
Gemcitabine Hydrochloride and Cisplatin With or Without
Bevacizumab in Treating Patients With Advanced Urinary
Tract Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=657F334E-
CCEE-8AE9-E040-BB89AD43469A
All rights reserved. Please visit https://medical-data-
models.org/forms/11137
CALGB 90601: Eligibility Checklist
NCT00942331
Header
CALGB Study No
CALGB Patient ID
Patient demographics
Patient Initials (Last, First Middle)
Patient Hospital No.
Institution/Affiliate
Participating Group
Participating Group Study No.
Participating Group Patient ID
Eligibility Criteria
Patient eligibility
>= 4 Weeks From Any Intravesical
Therapy (>= 4 weeks from any
intravesical therapy)
>= 4 Weeks Since Any Radiation
Therapy (including Palliative) Or Major
Surgery And Fully Recovered (>= 4
weeks since any radiation therapy
(including palliative) or major surgery
and fully recovered)
Age >= 18 Yrs (Age >= 18 yrs)
Anc >= 1500/mcl (ANC >= 1500/mcl)
Ast <= 2.0 X Uln (AST <= 2.0 x ULN)
Bilirubin <= 1.25 X Uln (Bilirubin <= 1.25
x ULN)
Calculated Creatinine Clearance >= 60
Ml/min (Calculated Creatinine Clearance
>= 60 mL/min)
1 / 3
Ecog Performance Status: 0-1 (ECOG
Performance Status: 0-1)
Histologically Documented Metastatic Or
Unresectable Transitional Cell
Carcinoma Of The Urinary Tract With
Progressive Metastatic Disease Or
Locally Advanced Disease (Histologically
documented metastatic or unresectable
transitional cell carcinoma of the urinary
tract with)
No Arterial Thrombotic Events Within 6
Months (No arterial thrombotic events
within 6 months)
No Clinically Significant Peripheral
Arterial Disease (No clinically significant
peripheral arterial disease)
No Clinically Significant Peripheral
Neuropathy (grade >= 2) (No clinically
significant peripheral neuropathy (grade
>= 2))
No Current Congestive Heart Failure
(nyha Class Ii Or Higher) (No current
congestive heart failure (NYHA Class II
or higher))
No History Of Gastrointestinal
Perforation Within 12 Months Of
Registration (No history of
gastrointestinal perforation within 12
months of registration)
No Known Brain Metastases (brain
Imaging (mri/ct) Is Not Required) (No
known brain metastases (brain imaging
(MRI/CT) is not required))
No Known Hypersensitivity To Chinese
Hamster Ovary Cell Products (No known
hypersensitivity to Chinese hamster
ovary cell products)
No Prior Bevicizumab/ Or Other
Angiogenesis Inhibitors (No prior
bevicizumab/ or other angiogenesis
inhibitors)
No Prior Combination Chemotherapy For
Metastatic Disease (No prior
combination chemotherapy for metastatic
disease)
No Serious Or Non-healing Wound,
Ulcer Or Bone Fracture (No serious or
non-healing wound, ulcer or bone
fracture)
No Significant History Of Bleeding
Events Within 6 Months Of Registration
(No significant history of bleeding events
within 6 months of registration)
Not Pregnant Or Nursing (Not pregnant
or nursing)
Patients On Full-dose Anticoagulants
Must Be On A Stable Dose Of Warfarin
And Have An In-range Inr Or Be On A
Stable Dose Of Lmw Heparin (Patients
on full-dose anticoagulants must be on a
2 / 3
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stable dose of warfarin and have an in-
range INR or be on a stable dose of
LMW heparin)
Patients With History Of Hypertension
Must Be Well Controlled (< 150/90)
(Patients with history of hypertension
must be well controlled (< 150/90))
Platelet Count >= 100,000/mm^3
(Platelet count >= 100,000/mm^3)
Prior Neoadjuvant / Adjuvant
Chemotherapy Is Permissible (Prior
neoadjuvant / adjuvant chemotherapy is
permissible)
Footer Module
Completed by (Last name, First name)
Date Form Completed (MM DD YYYY)
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CALGB 90601: Tissue Tracking Form
NCT00942331
CALGB 90601: Tissue Tracking Form NCT00942331 
Gemcitabine Hydrochloride and Cisplatin With or Without
Bevacizumab in Treating Patients With Advanced Urinary
Tract Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=65402ABE-
C426-902C-E040-BB89AD435D5A
All rights reserved. Please visit https://medical-data-
models.org/forms/11138
CALGB 90601: Tissue Tracking
Form NCT00942331
Header
CALGB Form
CALGB Study No.
CALGB Patient ID
Are data amended
Yes
No
Patient demographics
Patient Initials
Patient Hospital No.
Institution/Affiliate
Participating Group
Participating Group Study No.
Participating Group Patient ID
TISSUE TRACKING
Does institutional pathology report accompany
this form
Yes
No
Does specimen accompany this form
Yes
No
Form without specimen, reason
Date specimen collected
1 / 2
Tissue pathology (Mark one with an X.)
Metastasis (Metastasis)
Primary Tumor (Primary tumor)
Metastatic site specify
Method of extraction (Mark one with an X.)
Biopsy (Biopsy)
General Surgery, Nos (General surgery,
NOS)
Re-excision (Re-excision)
Type of specimen submitted (Mark one with an
X.)
Formalin Fixed Paraffin Embedded
Tissue Block (Formalin fixed paraffin
embedded tissue block)
Other (Other)
Formalin fixed paraffin embedded tissue block,
specify number
Other, specify
Specify number (other )
Institutional surgical pathology number
LabTrak shipment ID
Date shipped
Date shipped
Responsible CRA (Last name, First name)
CRA phone number
CRA email
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CALGB: 90104 SPECIMEN SUBMISSION
FORM NCT00014534
CALGB: 90104 SPECIMEN SUBMISSION FORM
NCT00014534
Combination Chemotherapy in Treating Patients With
Bladder Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=E5F4A97F-
274E-398C-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11139
CALGB: 90104 SPECIMEN
SUBMISSION FORM NCT00014534
Header
CALGB Form
CALGB Study No
CALGB Patient ID
Are data amended?
Yes
No
Patient demographics
Patient Initials
Patient Hospital No
Institution/Affiliate
Participating Group
Participating Group Study No
Participating Group Patient ID
SPECIMEN SUBMISSION
Does specimen accompany this form
Yes
No
Form without specimen, reason
Date specimen collected
Specimen Tissue source (Mark one with an X.)
Lymph Node Metastasis (Lymph node
metastasis)
1 / 2
Primary Tumor (Primary tumor)
Specimen collection method (Mark one with an
X.)
Biopsy (Biopsy)
Cystectomy (Cystectomy)
Pelvic Lymph Node Dissection (Pelvic
lymph node dissection)
Number of blocks submitted
Number of slides submitted
Pathology accession number
LabTrak sample ID (Required of all institutions
with access to LabTrak.)
Shipment date
Shipped by
Phone number
LabTrak shipment ID (Required of all institutions
with access to LabTrak.)
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CALGB: 80802 Imaging Form
NCT01015833
CALGB: 80802 Imaging Form NCT01015833 
Sorafenib Tosylate With or Without Doxorubicin
Hydrochloride in Treating Patients With Locally Advanced
or Metastatic Liver Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=741B4E5D-
7BA2-2FBB-E040-BB89AD432970
All rights reserved. Please visit https://medical-data-
models.org/forms/11140
CALGB: 80802 Imaging Form
NCT01015833
Header
CALGB Form
CALGB Study No
CALGB Patient ID
Date of CT Scan
Are data amended
Yes
No
Patient demographics
Patient Initials (Last, First Middle)
Patient Hospital No.
Institution/Affiliate
Participating Group
Participating Group Study No.
Participating Group Patient ID
Hospital Name (or imaging center performing
chest CT)
Reporting Period
Baseline (Baseline)
Follow-up (Follow-up)
On Treatment (On treatment)
Cycle Number
1 / 2
Evaluation of lesions
Lesion Number
Site of Lesion
Series number
Section number
Maximum diameter of tumor
Present on previous CT scan
No, New Lesion (No, new lesion)
Yes, Same Size As Previous Scan (Yes,
same size as previous scan)
Yes, Size Decreased From Previous
Scan (Yes, size decreased from previous
scan)
Yes, Size Increased From Previous Scan
(Yes, size increased from previous scan)
Footer
Completed by (Last name, First name)
Date Form Originally Completed
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CALGB: 80802 Imaging Form NCT01015833
CALGB: 140503 Surgical Resection Form
NCT00499330
CALGB: 140503 Surgical Resection Form NCT00499330 
Comparison of Different Types of Surgery in Treating
Patients With Stage IA Non-Small Cell Lung Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=218D55B1-
930A-6505-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11141
CALGB: 140503 Surgical Resection
Form NCT00499330
Header
CALGB Form
CALGB Study No
CALGB Patient ID
Are data amended
Yes
No
Patient demographics
Patient Initials (Last, First Middle)
Patient Hospital No.
Institution/Affiliate
Participating Group
Participating Group Study No.
Participating Group Patient ID
Operative Data
Surgical Procedure Type (Post-Operative Data)
Incomplete/failed Resection
(Incomplete/failed resection)
Lobectomy (Lobectomy)
Other (Other)
Segmentectomy (Segmentectomy)
Wedge Resection (Wedge resection)
Other, specify
Specify reason
Other (Other)
1 / 4
Positive Lymph Node (Positive Lymph
Node)
Positive Margins On Permanent Sections
(Positive margins on permanent
sections)
Specify
Surgical Approach
Thoracoscopy / Video-assisted (vats)
(Thoracoscopy / Video-assisted (VATS))
Thoracoscopy / Video-assisted (vats),
With Conversion To Thoracotomy
(Thoracoscopy / Video-assisted (VATS),
with conversion to Thoracotomy)
Thoracotomy (thoracotomy)
Is the surgeon VATS credentialed (If VATS,)
Yes
No
Surgical Margin Distance (as determined by
surgeon)
Is surgical margin not available, mark with an X
If frozen section, does the tumor involve the
surgical margin
Yes
No
If permanent section, does the tumor involve the
surgical margin
Yes
No
Specify treatment
Anatomic Segmentectomy (Anatomic
segmentectomy)
No Treatment (No treatment)
Off-study Lobectomy (Off-study
lobectomy)
Re-wedge (Re-wedge)
Specify treatment
Anatomic Segmentectomy (Anatomic
segmentectomy)
No Treatment (No treatment)
Off-study Lobectomy (Off-study
lobectomy)
Re-wedge (Re-wedge)
Type of Mediastinal Lymph Node Dissection
Complete Mediastinal Lymph Node
Dissection (Complete mediastinal lymph
node dissection)
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None (None)
Simple Sampling (Simple sampling)
Systematic Sampling (Systematic
sampling)
Histology
Adenocarcinoma (Adenocarcinoma)
Benign Mass (Benign mass)
Carcinoid (Carcinoid)
Other (Other specify)
Small Cell Carcinoma (oat Cell) (Small
cell carcinoma (oat cell))
Unknown (Unknown)
Other specify
Histologic Grade (Differentiation)
Well Differentiated (Grade I)
Moderately Differentiated (Grade II)
Poorly Differentiated (Grade III)
Undifferentiated (Grade IV)
Maximum Diameter (cm)
Pathologic T-N-M Staging
Pathologic T Stage
No Evidence Of Primary Tumor (T0)
Tumor 3 Cm Or Less In Greatest
Dimension, Surrounded By Lung Or
Visceral Pleura, Invasion More Proximal
Than The Lobar Bronchus, (i.e., Not In
The Main Bronchus) (T1)
Tumor With Any Of The Following
Features Of Size Or Extent: More Than
3cm In Greatest Dimension; Invades The
Visceral Pleura; Associated With
Atelectasis Or Obstructive Pneumonitis
That Extends To The Hilar Region But
Does Not Involve The Entire Lung (T2)
Tumor Of Any Size That Directly Invades
Any Of The Following: Chest Wall
(including Superior Sulcus Tumors),
Diaphragm, Mediastinal Pleura, Parietal
Pericardium; Or Tumor In The Main
Bronchus Less Than 2 Cm Distal To The
Carina, But Without Involvement O* (T3)
Tumor Of Any Size That Invades Any Of
The Following: Mediastinum, Heart,
Great Vessels, Trachea, Esophagus,
Vertebral Body, Carina; Or Separate
Tumor Nodules In The Same Lobe; Or
Tumor With A Malignant Pleural Effusion
(T4)
Carcinoma In Situ (Tis)
Primary Tumor Cannot Be Assessed, Or
Tumor Proven By The Presence Of
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Malignant Cells In Sputum Or Bronchial
Washings But Not Visualized By Imaging
Or Bronchoscopy (TX)
Pathologic N Stage
No Regional Lymph Node Metastasis
(N0)
Metastasis To Ipsilateral Peribronchial
And/or Ipsilateral Hilar Lymph Nodes,
And Intrapulmonary Nodes Including
Involvement By Direct Extension Of The
Primary Tumor (N1)
Metastasis To Ipsilateral Mediastinal
And/or Subcarinal Lymph Node(s) (N2)
Metastasis To Contralateral Mediastinal,
Contralateral Hilar, Ipsilateral Or
Contralateral Scalene, Or
Supraclavicular Lymph Node(s) (N3)
Regional Lymph Nodes Cannot Be
Assessed (NX)
Clinical M Stage ([M] Mark one with an X.)
No Distant Metastasis (M0)
Distant Metastasis Present (M1)
Distant Metastasis Cannot Be Assessed
(MX)
Surgical Complications And Morbidities
Completed by
Date Form Originally Completed
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CALGB: Post-Operative Chest CT Scan
Form NCT00499330
CALGB: Post-Operative Chest CT Scan Form
NCT00499330 
Comparison of Different Types of Surgery in Treating
Patients With Stage IA Non-Small Cell Lung Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=2221FAA3-
582D-4F78-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11142
CALGB: Post-Operative Chest CT
Scan Form NCT00499330
Header
CALGB Form
CALGB Study No
CALGB Patient ID
Date of CT Scan
Are data amended
Yes
No
Hospital Name (or imaging center performing
chest CT)
Patient demographics
Patient Initials (Last, First Middle)
Patient Hospital No.
Institution/Affiliate
Participating Group
Participating Group Study No.
Participating Group Patient ID
Technique Factors
KVp
Pitch
1 / 3
mA
Scan Length (craniocaudal extent)
Rotation Time
Residual gross tumor
Yes
No
Greatest diameter of largest residual gross tumor
mass (on the lung window settings)
Are any non-calcified lung nodules or masses
present
Yes
No
Evaluation of lesions
Lesion Number
Lesion Anatomic Site
Table position of section that best shows lesion
Maximum diameter of tumor using the lung
window settings
Present on previous CT scan
No, New Lesion (No, new lesion)
Yes, Same Size As Previous Scan (Yes,
same size as previous scan)
Yes, Size Decreased From Previous
Scan (Yes, size decreased from previous
scan)
Yes, Size Increased From Previous Scan
(Yes, size increased from previous scan)
Longest Diameter of Lesion(s)
Lymph Nodes
Indicate stations of all enlarged lymph nodes
Left Hilar Node (Left hilar (10L))
Left Lower Paratracheal Node (Left lower
paratracheal (4L))
Left Pulmonary Ligament (9l) (Left
pulmonary ligament (9L))
Left Upper Paratracheal Node (Left
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upper paratracheal (2L))
Para-aortic Node (Para-aortic (6))
Paraesophageal (Paraesophageal (8))
Pre-vascular (3a) (Pre-vascular (3A))
Retrotracheal (3p) (Retrotracheal (3P))
Right Hilar Node (Right hilar (10R))
Right Lower Paratracheal Node (Right
lower paratracheal (4R))
Right Pulmonary Ligament (9r) (Right
pulmonary ligament (9R))
Right Upper Paratracheal Node (Right
upper paratracheal (2R))
Subaortic Node (Subaortic (5))
Subcarinal Node (Subcarinal (7))
Was a pre-operative PET scan performed
Yes
No
Date of PET scan (If yes,)
Pet Scan Results
Site of lesion
Lymph Node (Nodal lesion)
Other (Other lesion)
Lung (Primary Lung)
Nodal lesion, specify
SUV Max
SUV Mean
What tests were performed to rule out possible
distant metastases present on PET scan?
Footer
Completed by (Last name, First name)
Date Form Originally Completed
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CALGB: 140503 Imaging Form
NCT00499330
CALGB: 140503 Imaging Form NCT00499330 
Comparison of Different Types of Surgery in Treating
Patients With Stage IA Non-Small Cell Lung Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=46856687-
F39F-1DA6-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11143
CALGB: 140503 Imaging Form
NCT00499330
Header
CALGB Form
CALGB Study No
CALGB Patient ID
Date of CT Scan
Hospital Name (or imaging center performing
chest CT)
Reporting Period
Postoperative (Postoperative)
Preoperative (Preoperative)
Are data amended
Yes
No
Patient demographics
Patient Initials (Last, First Middle)
Patient Hospital No.
Institution/Affiliate
Participating Group
Participating Group Study No.
Participating Group Patient ID
Preoperative Imaging Data
Tumor Location Area (Mark one)
1 / 2
Lower Lobe (left) (Lower Lobe (left))
Lower Lobe (right) (Lower Lobe (right))
Middle Lobe (right) (Middle Lobe (right))
Upper Lobe (left) (Upper Lobe (left))
Upper Lobe (right) (Upper Lobe (right))
Series number
Section number
Maximum diameter of tumor using the lung
window settings
Post-Operative Imaging Data
Are any non-calcified lung nodules or masses
present
Yes
No
Lesion Number
Lesion Anatomic Site
Present on previous CT scan
No, New Lesion (No, new lesion)
Yes, Same Size As Previous Scan (Yes,
same size as previous scan)
Yes, Size Decreased From Previous
Scan (Yes, size decreased from previous
scan)
Yes, Size Increased From Previous Scan
(Yes, size increased from previous scan)
Is lesion on a staple line (Arm B Patients only)
Yes
No
Footer
Completed by (Last name, First name)
Date Form Originally Completed
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CALGB: 40301 BLOOD AND SERUM
TRACKING FORM
CALGB: 40301 BLOOD AND SERUM TRACKING FORM
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=E5B77509-
B017-544D-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11144
CALGB: 40301 BLOOD AND
SERUM TRACKING FORM
Header
CALGB Form
CALGB Study No.
CALGB Patient ID
Are data amended
Yes
No
Patient demographics
Patient Initials
Patient Hospital No
Institution/Affiliate
Participating Group
Participating Group Protocol No
Participating Group Patient ID
To Be Completed By Submitting Institution
Sample type (Mark one with an X.)
Serum (Serum)
Whole Blood (Whole blood)
Date plasma specimen collected
Does specimen accompany this form
Yes
No
specify reason (If No)
Number of tubes submitted
1 / 3
Date sample sent
Time period specimen collected (Mark one with
an X.)
At Disease Progression (At disease
progression)
During Chemotherapy (During
chemotherapy)
Pre-treatment (Pre-treatment)
Responsible treating physician
Phone number to be used in event of sample
problems
Completed by
Date form completed
To Be Completed By Receiving
Institution/laboratory
Sample condition (Mark one with an X.)
Damaged (Damaged)
Damaged But Stored (Damaged but
stored)
Improperly Stored (Improperly stored)
Insufficient Amount (Insufficient amount)
Missing (Missing)
Okay (Okay)
Thawed But Stored (Thawed but stored)
Date sample received
Sample ID number
Number of aliquots
Average aliquot volume
Received by
For Statistical Center Use Only
Specimen type
Blood sample
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Method of sample collection
Class of units
Unit of measure
Sample container
Sample storage
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CALGB: 40301 TISSUE TRACKING FORM
CALGB: 40301 TISSUE TRACKING FORM
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=E5B77509-
AF5C-544D-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11145
CALGB: 40301 TISSUE TRACKING
FORM
Header
CALGB Form
CALGB Study No.
CALGB Patient ID
Are data amended
Yes
No
Patient demographics
Patient Initials
Patient Hospital No
Institution/Affiliate
Participating Group
Participating Group Study No
Participating Group Patient ID
TISSUE TRACKING
Does institutional pathology report accompany
this form
Yes
No
Does specimen accompany this form
Yes
No
Form without specimen, reason
Date specimen collected
Tissue pathology (Mark one with an X.)
1 / 2
Lymph Node Metastasis (Lymph node
metastasis)
Metastasis (Metastasis)
Non-malignant Tissue (Non-malignant
tissue)
Primary Tumor (Primary tumor)
Recurrent Tumor (Recurrent tumor)
Uninvolved Node (Uninvolved node)
Method of extraction (Mark one with an X.)
Axillary Dissection (Axillary)
Biopsy (Biopsy)
General Surgery, Nos (General surgery,
NOS)
Lumpectomy (Lumpectomy)
Mastectomy (Mastectomy)
Re-excision (Re-excision)
Sentinel Node Dissection (Sentinel node
dissection)
Type of specimen submitted (Mark one with an
X.)
Formalin Fixed Paraffin Embedded
Tissue Block (Formalin fixed paraffin
embedded tissue block)
Punch Biopsies From Ffpe Block (Punch
biopsies from FFPE block)
Unstained Superfrost Plus Slides
(Unstained superfrost plus slides)
Formalin fixed paraffin embedded tissue block,
specify number
Punch biopsies from FFPE block, specify number
Unstained superfrost plus slides, specify number
Institutional surgical pathology number
Submitted by
Date specimen submitted
Phone number
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CALGB: ADJUVANT RADIOTHERAPY
REPORT FORM 2 NCT00041119
CALGB: ADJUVANT RADIOTHERAPY REPORT FORM 2
NCT00041119 
Four Versus Six Cycles of Cyclophosphamide/Doxorubicin
or Paclitaxel in Adjuvant Breast Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=E03851EE-
EEDC-5498-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/11146
CALGB: ADJUVANT
RADIOTHERAPY REPORT FORM 2
NCT00041119
Header
CALGB Form
CALGB Study No
CALGB Patient ID
Are data amended
Yes
No
Patient demographics
Patient Initials
Participating Group
Patient Hospital No.
Participating Group Study No.
Institution/Affiliate
Participating Group Patient ID
Radiation Treatment
Has the patient received adjuvant radiation
therapy (prior to diagnosis of recurrence or
second primary cancer)
Yes
No
Date adjuvant radiation therapy started
Date adjuvant radiation therapy ended
1 / 2
Nature of radiotherapy (mark one box with an X)
Chest Wall And/or Nodal Radiation After
Mastectomy (Chest wall and/or nodal
radiation after mastectomy)
Intra-operative Brachytherapy Following
Breast Conserving Surgery (Intra-
operative brachytherapy following breast
conserving surgery)
Partial Breast Radiation - Brachytherapy
- Following Breast Conserving Surgery
(Partial breast radiation - brachytherapy -
following breast conserving surgery)
Partial Breast Radiation - External Beam
- Following Breast Conserving Surgery
(Partial breast radiation - external beam -
following breast conserving surgery)
Whole Breast Radiation - External Beam
- Following Breast Conserving Surgery
(Whole breast radiation - external beam -
following breast conserving surgery)
Completed By (Last Name, First Name)
Date form completed
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CALGB: ADJUVANT RADIOTHERAPY REPORT FORM 2
NCT00041119
CALGB: 40101 TRASTUZUMAB
MONITORING FORM NCT00041119
CALGB: 40101 TRASTUZUMAB MONITORING FORM
NCT00041119
Four Versus Six Cycles of Cyclophosphamide/Doxorubicin
or Paclitaxel in Adjuvant Breast Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=FD4BCDD9-
1BFD-6EE8-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11147
CALGB: 40101 TRASTUZUMAB
MONITORING FORM NCT00041119
Header
CALGB Form
CALGB Study No
CALGB Patient ID
Are data amended
Yes
No
Patient demographics
Patient Initials
Patient Hospital No
Institution/Affiliate
Participating Group
Participating Group Study No
Participating Group Patient ID
Testing Results
Did the patient receive trastuzumab?
Yes
No
Trastuzumab Agent Not Administration Specify
Date trastuzumab started
Date trastuzumab discontinued
1 / 2
Reason for ending trastuzumab treatment
Cardiac Adverse Event (Cardiac adverse
event)
Completed Per Protocol Criteria
(Completed per protocol criteria)
Non-cardiac Adverse Event (Non-cardiac
adverse event)
Other (Other)
Other Cardiac Adverse Event (Other
cardiac adverse event)
Other, specify
Footer
Completed by
Date Form Completed
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CALGB: 40101 HER-2/neu TESTING
FORM NCT00041119
CALGB: 40101 HER-2/neu TESTING FORM
NCT00041119
Four Versus Six Cycles of Cyclophosphamide/Doxorubicin
or Paclitaxel in Adjuvant Breast Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=FD4C7CA2-
BB12-68FB-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11148
CALGB: 40101 HER-2/neu
TESTING FORM NCT00041119
Header
CALGB Form
CALGB Study No
CALGB Patient ID
Are data amended
Yes
No
Patient demographics
Patient Initials
Patient Hospital No
Institution/Affiliate
Participating Group
Participating Group Study No
Participating Group Patient ID
Testing Data
Immunohistochemistry Kit or Test Type
Cb-11 Other (CB-11 other)
Cb-11/ventana Kit (CB-11/Ventana Kit)
Dako Herceptest [tm] (DAKO Herceptest
[TM])
Ihc Not Done (IHC not done)
Other, Specify (Other, specify)
Scoring System (Score)
0 (0)
1+ (1+)
2+ (2+)
1 / 2
3+ (3+)
Scoring system
+1 (+1)
0 (0)
2+ (2+)
3+ (3+)
Other, specify
Results
FISH Kit or Test Type
Fish Not Done (FISH not done)
Other Specify (Other, specify)
Ventana Inform (Ventana INFORM)
Vysis/path Vysion[tm] (Vysis/PathVysion)
FISH HER2/neu chromosome 17 Ratio
Ventana Score
0 (0)
1+ (1+)
2+ (2+)
3+ (3+)
Ventana Score
0 (0)
1+ (1+)
2+ (2+)
3+ (3+)
Other, specify
Results
Testing Results
HER-2/neu status
Negative (Negative)
Positive (Positive)
Footer
Completed by
Date Form Completed
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CALGB_40302_TISS_TRCK_FRM
NCT00390455
CALGB: 40302 TISSUE TRACKING FORM NCT00390455
Fulvestrant With or Without Lapatinib in Treating
Postmenopausal Women With Stage III or Stage IV Breast
Cancer That is Hormone Receptor-Positive
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=F5AC8F60-
F3F9-0DB4-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11149
CALGB_40302_TISS_TRCK_FRM
NCT00390455
Header
CALGB Form
CALGB Study No.
CALGB Patient ID
Are data amended
Yes
No
Patient demographics
Patient Initials
Patient Hospital No
Institution/Affiliate
Participating Group
Participating Group Study No
Participating Group Patient ID
TISSUE TRACKING
Does institutional pathology report accompany
this form
Yes
No
Does specimen accompany this form
Yes
No
Form without specimen, reason
Date specimen collected
1 / 2
Tissue pathology (Mark one with an X.)
Lymph Node Metastasis (Lymph node
metastasis)
Metastasis (Metastasis)
Primary Tumor (Primary tumor)
Recurrent Tumor (Recurrent tumor)
Method of extraction (Mark one with an X.)
Axillary Dissection (Axillary dissection)
Biopsy (Biopsy)
General Surgery, Nos (General surgery,
NOS)
Lumpectomy (Lumpectomy)
Mastectomy (Mastectomy)
Re-excision (Re-excision)
Sentinel Node Dissection (Sentinel node
dissection)
Type of specimen submitted (Mark one with an
X.)
Formalin Fixed Paraffin Embedded
Tissue Block (Formalin fixed paraffin
embedded tissue block)
Punch Biopsies From Ffpe Block (Punch
biopsies from FFPE block)
Unstained Superfrost Plus Slides
(Unstained superfrost plus slides)
Formalin fixed paraffin embedded tissue block,
specify number
Punch biopsies from FFPE block, specify number
Unstained superfrost plus slides, specify number
Institutional surgical pathology number
Submitted by (last name, first name)
Date specimen submitted
Phone number
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CALGB Memorial Symptom Assessment
Scale Condensed Form NCT00390455
CALGB Memorial Symptom Assessment Scale Condensed
Form NCT00390455 
Fulvestrant With or Without Lapatinib in Treating
Postmenopausal Women With Stage III or Stage IV Breast
Cancer That is Hormone Receptor-Positive
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=0D7D5091-
6484-2392-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11150
CALGB Memorial Symptom
Assessment Scale Condensed Form
NCT00390455
Header
CALGB Form
CALGB Study No
CALGB Patient ID
Are data amended
Yes
No
Patient demographics
Patient Initials
Patient Medical Record Number
Institution/Affiliate
Participating Group
Participating Group Protocol Number
Participating Group Patient ID
Responsible CRA
Memorial Symptom Assessment
Lack of energy (DURING THE PAST 7 DAYS, did
you have any of the following symptoms?)
Yes
No
Lack of energy (If YES, how much did it
DISTRESS or BOTHER you?)
1 / 4
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
Lack of appetite (DURING THE PAST 7 DAYS,
did you have any of the following symptoms?)
Yes
No
Lack of appetite (If YES, how much did it
DISTRESS or BOTHER you?)
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
Pain (DURING THE PAST 7 DAYS, did you have
any of the following symptoms?)
Yes
No
Pain (If YES, how much did it DISTRESS or
BOTHER you?)
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
Dry Mouth (DURING THE PAST 7 DAYS, did you
have any of the following symptoms?)
Yes
No
Dry Mouth (If YES, how much did it DISTRESS or
BOTHER you?)
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
Weight loss (DURING THE PAST 7 DAYS, did
you have any of the following symptoms?)
Yes
No
Weight loss (If YES, how much did it DISTRESS
or BOTHER you?)
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
Feeling drowsy (DURING THE PAST 7 DAYS, did
you have any of the following symptoms?)
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Yes
No
Feeling drowsy (If YES, how much did it
DISTRESS or BOTHER you?)
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
Difficulty sleeping (DURING THE PAST 7 DAYS,
did you have any of the following symptoms?)
Yes
No
Difficulty sleeping (If YES, how much did it
DISTRESS or BOTHER you?)
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
Shortness of breath (DURING THE PAST 7
DAYS, did you have any of the following
symptoms?)
Yes
No
Shortness of breath (If YES, how much did it
DISTRESS or BOTHER you?)
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
Nausea (DURING THE PAST 7 DAYS, did you
have any of the following symptoms?)
Yes
No
Nausea (If YES, how much did it DISTRESS or
BOTHER you?)
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
Cough (DURING THE PAST 7 DAYS, did you
have any of the following symptoms?)
Yes
No
Cough (If YES, how much did it DISTRESS or
BOTHER you?)
A Little Bit (A little bit)
3 / 4
CALGB Memorial Symptom Assessment Scale Condensed Form
NCT00390455
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
Worrying (During the past 7 days did you have
any of the following symptoms?)
Yes
No
Worrying (If YES, how OFTEN did it occur?)
Almost Constantly (Almost constantly)
Frequently (Frequently)
Occasionally (Occasionally)
Rarely (Rarely)
Feeling sad (During the past 7 days did you have
any of the following symptoms?)
Yes
No
Feeling sad (If YES, how OFTEN did it occur?)
Almost Constantly (Almost constantly)
Frequently (Frequently)
Occasionally (Occasionally)
Rarely (Rarely)
Feeling nervous (During the past 7 days did you
have any of the following symptoms?)
Yes
No
Feeling nervous (If YES, how OFTEN did it
occur?)
Almost Constantly (Almost constantly)
Frequently (Frequently)
Occasionally (Occasionally)
Rarely (Rarely)
Assessment of Quality of Life
How would you rate your overall quality of life
during the past week? (Mark one with an X)
0 (0)
10 (10)
100 (100)
20 (20)
30 (30)
40 (40)
50 (50)
60 (60)
70 (70)
80 (80)
90 (90)
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CALGB 40302 BLOOD SPECIMEN
SUBMISSION FORM NCT00390455
CALGB 40302 BLOOD SPECIMEN SUBMISSION FORM
NCT00390455 
Fulvestrant With or Without Lapatinib in Treating
Postmenopausal Women With Stage III or Stage IV Breast
Cancer That is Hormone Receptor-Positive
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=F5C14987-
3DF4-656C-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11151
CALGB 40302 BLOOD SPECIMEN
SUBMISSION FORM NCT00390455
Header
CALGB Form
CALGB Study No.
CALGB Patient ID
Are data amended
Yes
No
Patient demographics
Patient Initials
Patient Hospital No
Institution/Affiliate
Participating Group
Participating Group Protocol No
Participating Group Patient ID
To Be Completed By Submitting Institution
Other
Does specimen accompany this form
Yes
No
No, specify reason
Institution Error (Institution error)
Other (Other)
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Patient Refusal (Patient refusal)
Sample Lost Or Destroyed (Sample lost
or destroyed)
Specimen type (Mark one with an X.)
Plasma (Plasma)
Serum (Serum)
Whole Blood (Whole blood)
Specimen Collected Time
Date specimen collected
Sample period (^1 For sample period, enter the
cycle number completed prior to specimen
collection or scheduled collection if specimen no
obtained; or enter "0" for pre-study.)
Number of tubes submitted
Approximate volume of sample
Completed by (Last name, First name)
Date form completed
Phone number to be used in event of sample
problems
To Be Completed By Receiving
Institution/laboratory
Sample condition (Mark one with an X.)
Clotted (Clotted)
Damaged (Damaged)
Damaged But Stored (Damaged but
stored)
Frozen But Stored (Frozen but stored)
Improperly Stored (Improperly stored)
Insufficient Amount (Insufficient amount)
Missing (Missing)
Okay (Okay)
Thawed But Stored (Thawed but stored)
Date received
Number of tubes banked
Average volume per tube
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M NCT00390455
CALGB 40302 BASELINE SOLID TUMOR EVALUATION
FORM NCT00390455
Fulvestrant With or Without Lapatinib in Treating
Postmenopausal Women With Stage III or Stage IV Breast
Cancer That is Hormone Receptor-Positive
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=F593450E-
7C24-42E1-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11152
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Header
CALGB Form
CALGB Study No
CALGB Patient ID
Are data amended
Yes
No
Patient demographics
Patient Initials
Patient Hospital Number
Main Member Institution/Affiliate
Participating Group
Participating Group Study No
Participating Group Patient ID
TARGET LESION(S) BASELINE
EVALUATION
Lesion, Anatomic Site, Target
Date of evaluation (* When several tests are
performed, select the date of the most recent test
and most definitive result.)
Method of Evaluation (**)
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Bone Scan (Bone Scan)
Chest X-ray (Chest X-ray)
Clinical (Clinical Examination)
Ct Scan (CT Scan)
Mri (MRI)
Other (Other)
Spiral Ct Scan (Spiral CT Scan)
Ultrasound (Ultrasound)
If Other, specify
Longest Diameter of Lesion (s)
Sum of Longest Diameters of All Target Lesions
Non-target Lesion(s) Follow-up Evaluation
Are there any non-target lesions
Yes
No
Lesion, Anatomic Site, Non-Target
Date of evaluation (* When several tests are
performed, select the date of the most recent test
and most definitive result.)
Method of Evaluation (**)
Bone Scan (Bone Scan)
Chest X-ray (Chest X-ray)
Clinical (Clinical Examination)
Ct Scan (CT Scan)
Mri (MRI)
Other (Other)
Spiral Ct Scan (Spiral CT Scan)
Ultrasound (Ultrasound)
If Other, specify
Footer module
Completed by (print or type name)
Date Form Completed (MM DD YYYY)
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RTOG-0421 T1: Radiation Therapy Oncology Group Phase III
Recurrent Head and Neck Study Radiotherapy Form NCT00113399
RTOG-0421 T1: Radiation Therapy Oncology Group Phase
III Recurrent Head and Neck Study Radiotherapy Form
NCT00113399
Combination Chemotherapy With or Without Radiation
Therapy in Treating Patients With Recurrent Head and
Neck Cancer That Cannot Be Removed By Surgery
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=EC6123B9-
9BBD-1DCD-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11154
RTOG-0421 T1: Radiation Therapy
Oncology Group Phase III Recurrent
Head and Neck Study Radiotherapy
Form NCT00113399
RTOG clinical trial administrative data
RTOG Study
Case #
Institution
Institution No.
Participant's Initials
Participant's ID No.
Amended data
Yes
No
Radiation Therapy
RADIATION THERAPY START DATE
RADIATION THERAPY END DATE
ELAPSED DAYS
TOTAL FRACTIONS
TOTAL DOSE
WERE THERE ANY UNSCHEDULED
INTERRUPTIONS IN RADIATION THERAPY?
No (No)
Yes, Due To Other Reason (Yes, due to
other reason)
Yes, Due To Toxicity (Yes, due to toxicity)
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Specify RT interruption reason
REASON RADIATION THERAPY TREATMENT
ENDED
Alternative Therapy (Alternative therapy)
Death On Study (Death on study)
Disease Progression, Relapse During
Active Treatment (Disease progression,
relapse during active treatment)
Other (Other)
Other Complicating Disease (Other
complicating disease)
Patient Withdrawal Or Refusal After
Beginning Protocol Therapy (Patient
withdrawal or refusal after beginning
protocol therapy)
Patient Withdrawal Or Refusal Prior To
Beginning Protocol Therapy (Patient
withdrawal or refusal prior to beginning
protocol therapy)
Toxicity/side Effects/complications
(Toxicity/side effects/complications)
Treatment Completed Per Protocol
Criteria (Treatment completed per
protocol criteria)
Alternative therapy, specify
Other complicating disease, specify
Other, specify
Comments
Comments
Signature of person completing form
Date form completed, original
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RTOG-0522 QP: Miscellaneous Patient
Assessment Form NCT00265941
RTOG-0522 QP: Radiation Therapy Oncology Group
Miscellaneous Patient Assessment Form NCT00265941
Radiation Therapy and Cisplatin With or Without Cetuximab
in Treating Patients With Stage III or Stage IV Head and
Neck Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=F6217E11-
C5E7-5543-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11155
RTOG-0522 QP: Miscellaneous
Patient Assessment Form
NCT00265941
RTOG clinical trial administrative data
RTOG Study No.
Case #
Institution Name
Institution No.
Patient Initials
RTOG Patient ID
Miscellaneous Patient Assessment
SCHEDULED DATA POINT (CHECK ONE)
At Completion Of Radiotherapy (At
completion of radiotherapy)
Other (Other)
Other Followup (other followup)
Pre Treatment Assessment (Pre
treatment assessment)
other followup
Other, specify
IF NO PATIENT ASSESSMENT, SPECIFY
REASON (CHECK ONE)
Other Reason (Other reason)
Patient Refused, Including Attempts By
Telephone Interview (Patient refused,
including attempts by telephone
interview)
Patient Refused, Telephone Interview
Not Attempted (Patient refused,
telephone interview not attempted)
Patient Unable To Be Contacted (Patient
unable to be contacted)
Patient Was Too Ill (Patient was too ill)
Questionnaire Not Completed Due To
1 / 3
Institutional Error (Questionnaire not
completed due to institutional error)
Patient refused, including attempts by telephone
interview, specify reason for refusal
Patient refused, telephone interview not
attempted, specify reason for refusal
Other reason, specify
WAS INFORMATION OBTAINED BY
TELEPHONE INTERVIEW (CHECK ONE)
Yes
No
DATE OF EVALUATION
RATER'S NAME
Normalcy of Diet Rating
0= Non-oral Feeding (tube Fed) (0)
10= Cold Liquids (10)
100= Full Diet (no Restrictions) (100)
20= Warm Liquids (20)
30= Pureed Foods (in Blender) (30)
40= Soft Foods Requiring No Chewing
(e.g., Mashed Potatoes, Apple Sauce,
Pudding) (40)
50= Soft, Chewable Foods (e.g.,
Macaroni, Canned/soft Fruits, Cooked
Vegetables, Fish, Hamburger, Small
Pieces Of Meat) (50)
60= Dry Bread And Crackers (60)
70= Raw Carrots, Celery (70)
80= All Meat (80)
90= Full Diet (liquid Assist) (90)
Public Eating Rating
0= Always Eats Alone (0)
100= No Restriction Of Place, Food Or
Companion (eats Out At Any
Opportunity) (100)
25= Eats Only At Home In Presence Of
Selected Persons (25)
50= Eats Only In Presence Of Selected
Persons In Selected Places (50)
75= No Restriction Of Place, But
Restricts Diet When In Public (eats
Anywhere, But May Limit Intake To Less
"messy" Foods, E.g., Liquids) (75)
Understandability of Speech Rating
0= Never Understandable; May Use
Written Communication (0)
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100= Always Understandable (100)
25= Difficult To Understand (25)
50= Usually Understandable; Face-to-
face Contact Necessary (50)
75= Understandable Most Of The Time;
Occasional Repetition Necessary (75)
Comments
COMMENTS
Responsible Person Signature Text
Date Form Originally Completed
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RTOG-0421 I7: Radiation Therapy Oncology Group Phase III Recurrent
Head and Neck Study Dosimetry Nodal Planning Diagram NCT00113399
RTOG-0421 I7: Radiation Therapy Oncology Group Phase
III Recurrent Head and Neck Study Dosimetry Nodal
Planning Diagram NCT00113399
Combination Chemotherapy With or Without Radiation
Therapy in Treating Patients With Recurrent Head and
Neck Cancer That Cannot Be Removed By Surgery
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=EC502BE7-
41DA-14BE-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11156
RTOG-0421 I7: Radiation Therapy
Oncology Group Phase III Recurrent
Head and Neck Study Dosimetry
Nodal Planning Diagram
NCT00113399
RTOG clinical trial administrative data
RTOG Study No.
Case #
Institution Name
Institution No.
Patient Initials
Patient Study No.
If this is a revised or corrected form, indicate by
checking box.
Yes (Yes)
Lymph Nodes
NODAL SITES (*)
Buccinator (Buccinator)
Infra-auricular (Infra-auricular)
Jugulodigastric (Jugulodigastric)
Lower (Lower)
Lower Jugular (Lower jugular)
Middle (Middle)
Midjugular (Midjugular)
Occipital (Occipital)
Other (Other)
Postauricular (Postauricular)
Preauricular (Preauricular)
Prelaryngeal (Prelaryngeal)
Pretracheal (Pretracheal)
Submandibular (Submandibular)
Submental (Submental)
Upper (Upper)
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Other
<= 3 CM
Lt (LT)
Rt (RT)
>3-6 CM
Lt (LT)
Rt (RT)
>6CM
Lt (LT)
Rt (RT)
NODES FIXED
Lt (LT)
Rt (RT)
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Head and Neck Study Dosimetry Nodal Planning Diagram NCT00113399
RTOG-0421 I6: Radiation Therapy Oncology Group Phase III Recurrent
Head and Neck Study Staging Diagrams / Oropharynx NCT00113399
RTOG-0421 I6: Radiation Therapy Oncology Group Phase
III Recurrent Head and Neck Study Staging Diagrams /
Oropharynx NCT00113399
Combination Chemotherapy With or Without Radiation
Therapy in Treating Patients With Recurrent Head and
Neck Cancer That Cannot Be Removed By Surgery
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=EB371128-
681B-6F85-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11157
RTOG-0421 I6: Radiation Therapy
Oncology Group Phase III Recurrent
Head and Neck Study Staging
Diagrams / Oropharynx
NCT00113399
RTOG clinical trial administrative data
RTOG Study
Case #
Institution Name
Institution No.
Patient Initials
Patient Study No.
If this is a revised or corrected form, indicate by
checking box.
Yes (Yes)
Head and Neck  Tumor assessment
Indicate side of lesion (R or L)
CHARACTERISTICS OF TUMOR
Deeply Infiltrating (Deeply infiltrating)
Fixed Tongue (Fixed tongue)
Impaired Mobility Of Tongue (Impaired
mobility of tongue)
Invades Adjacent Structures (Invades
adjacent structure)
Normal Mobility Of Tongue (Normal
mobility of tongue)
LOCATION OF TUMOR (  all that apply)
Anterior Tonsillar Pillar (Anterior Tonsillar
Pillar)
Base Of Tongue, Vallecula (Base of
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tongue, Vallecula)
OROPHARYNX (OROPHARYNX)
Oropharynx, Nos (Oropharynx, NOS)
Pharyngeal Wall (Pharyngeal Wall)
Soft Palate, Uvula (Soft Palate, Uvula)
Tonsillar Fossa Tonsil (Tonsillar Fossa)
SITE OF ORIGIN
Left (LT)
Right (RT)
SITE(S) ALSO INVOLVED
Left (LT)
Right (RT)
Signature
Date
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RTOG-0522 IM: Local PET/CT Qualitative and Semi-
Quantitative Assessment Form NCT00265941
RTOG-0522 IM: Local PET/CT Qualitative and Semi-
Quantitative Assessment Form NCT00265941
Radiation Therapy and Cisplatin With or Without Cetuximab
in Treating Patients With Stage III or Stage IV Head and
Neck Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=F7655132-
1754-5B7C-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11158
RTOG-0522 IM: Local PET/CT
Qualitative and Semi-Quantitative
Assessment Form NCT00265941
Header
RTOG Study No.
Case #
Institution Name
Institution No.
Patient Initials
RTOG Patient ID
Qualitative and Semi-Quantitative
Assessment
Amended data
Yes
No
Timepoint of PET/CT Imaging
Post-treatment (Post-treatment)
Pre-treatment (Pre-treatment)
Was PET/CT Imaging completed?
Yes
No
If no, provide reason
Claustrophobia (Claustrophobia)
Equipment Not Available (Do not have
required equipment)
Equipment Failure (Equipment failure)
Injection Site Complications (Injection
site complications)
Insurance (Insurance)
Medical Reason (Medical reason)
Other (Other)
Patient Refusal (Patient refusal)
Scheduling Problem (Scheduling
problem)
Unknown (Unknown)
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Other, specify
Date of PET/CT Exam (mm-dd-yyyy)
Date of PET/CT Interpretation (mm-dd-yyyy)
Image Quality
Adequate (Adequate)
Inadequate (Inadequate)
Suboptimal (Suboptimal)
Reason Image Inadequate
Entire Study Not Complete (Entire study
not complete)
N/a (N/A)
Noisy Images (Noisy images)
Other (Other)
Patient Motion (Patient motion)
Radiotracer Infiltration (Radiotracer
infiltration)
Suvs Cannot Be Calculated (SUVs
cannot be calculated)
SUVs cannot be calculated, specify (reason)
Other, specify
Semi-quantitative Assessment
Primary Tumor Site
Definitely Abnormal (Definitely abnormal)
Definitely Normal (Definitely normal)
Indeterminate (Indeterminate)
Not Imaged, Cannot Evaluate (Not
imaged, cannot evaluate)
Probably Abnormal (Probably abnormal)
Probably Normal (Probably normal)
Level I (Submandibular) Left
Definitely Abnormal (Definitely abnormal)
Definitely Normal (Definitely normal)
Indeterminate (Indeterminate)
Not Imaged, Cannot Evaluate (Not
imaged, cannot evaluate)
Probably Abnormal (Probably abnormal)
Probably Normal (Probably normal)
Level II (Upper 1/3 Internal Jugular) Left
Definitely Abnormal (Definitely abnormal)
Definitely Normal (Definitely normal)
Indeterminate (Indeterminate)
Not Imaged, Cannot Evaluate (Not
imaged, cannot evaluate)
Probably Abnormal (Probably abnormal)
Probably Normal (Probably normal)
Level III (Mid 1/3 Internal Jugular) Left
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Definitely Abnormal (Definitely abnormal)
Definitely Normal (Definitely normal)
Indeterminate (Indeterminate)
Not Imaged, Cannot Evaluate (Not
imaged, cannot evaluate)
Probably Abnormal (Probably abnormal)
Probably Normal (Probably normal)
Level IV (Lower 1/3 Internal Jugular) Left
Definitely Abnormal (Definitely abnormal)
Definitely Normal (Definitely normal)
Indeterminate (Indeterminate)
Not Imaged, Cannot Evaluate (Not
imaged, cannot evaluate)
Probably Abnormal (Probably abnormal)
Probably Normal (Probably normal)
Level V (Posterior Triangle) Left
Definitely Abnormal (Definitely abnormal)
Definitely Normal (Definitely normal)
Indeterminate (Indeterminate)
Not Imaged, Cannot Evaluate (Not
imaged, cannot evaluate)
Probably Abnormal (Probably abnormal)
Probably Normal (Probably normal)
Retropharyngeal Left
Definitely Abnormal (Definitely abnormal)
Definitely Normal (Definitely normal)
Indeterminate (Indeterminate)
Not Imaged, Cannot Evaluate (Not
imaged, cannot evaluate)
Probably Abnormal (Probably abnormal)
Probably Normal (Probably normal)
Other Location Left
Definitely Abnormal (Definitely abnormal)
Definitely Normal (Definitely normal)
Indeterminate (Indeterminate)
Not Imaged, Cannot Evaluate (Not
imaged, cannot evaluate)
Probably Abnormal (Probably abnormal)
Probably Normal (Probably normal)
Level I (Submandibular) Right
Definitely Abnormal (Definitely abnormal)
Definitely Normal (Definitely normal)
Indeterminate (Indeterminate)
Not Imaged, Cannot Evaluate (Not
imaged, cannot evaluate)
Probably Abnormal (Probably abnormal)
Probably Normal (Probably normal)
Level II (Upper 1/3 Internal Jugular) Right
Definitely Abnormal (Definitely abnormal)
Definitely Normal (Definitely normal)
Indeterminate (Indeterminate)
Not Imaged, Cannot Evaluate (Not
imaged, cannot evaluate)
Probably Abnormal (Probably abnormal)
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Probably Normal (Probably normal)
Level III (Mid 1/3 Internal Jugular) Right
Definitely Abnormal (Definitely abnormal)
Definitely Normal (Definitely normal)
Indeterminate (Indeterminate)
Not Imaged, Cannot Evaluate (Not
imaged, cannot evaluate)
Probably Abnormal (Probably abnormal)
Probably Normal (Probably normal)
Level IV (Lower 1/3 Internal Jugular) Right
Definitely Abnormal (Definitely abnormal)
Definitely Normal (Definitely normal)
Indeterminate (Indeterminate)
Not Imaged, Cannot Evaluate (Not
imaged, cannot evaluate)
Probably Abnormal (Probably abnormal)
Probably Normal (Probably normal)
Level V (Posterior Triangle) Right
Definitely Abnormal (Definitely abnormal)
Definitely Normal (Definitely normal)
Indeterminate (Indeterminate)
Not Imaged, Cannot Evaluate (Not
imaged, cannot evaluate)
Probably Abnormal (Probably abnormal)
Probably Normal (Probably normal)
Retropharyngeal Right
Definitely Abnormal (Definitely abnormal)
Definitely Normal (Definitely normal)
Indeterminate (Indeterminate)
Not Imaged, Cannot Evaluate (Not
imaged, cannot evaluate)
Probably Abnormal (Probably abnormal)
Probably Normal (Probably normal)
SUV (peak)
SUV (peak)
SUV (peak)
SUV (peak)
SUV (peak)
SUV (peak)
SUV (peak)
SUV (peak)
4 / 5
RTOG-0522 IM: Local PET/CT Qualitative and Semi-Quantitative
Assessment Form NCT00265941
SUV (peak)
SUV (peak)
SUV (peak)
SUV (peak)
SUV (peak)
SUV (peak)
SUV (peak)
Other location Right
Definitely Abnormal (Definitely abnormal)
Definitely Normal (Definitely normal)
Indeterminate (Indeterminate)
Not Imaged, Cannot Evaluate (Not
imaged, cannot evaluate)
Probably Abnormal (Probably abnormal)
Probably Normal (Probably normal)
Other location, specify (Right)
Other location, specify (Right)
Indicate Any Lymphadenopathy
Were there any distant metastases with PET
findings?
Yes
No
Specify site
Comments
COMMENTS
Signature of Nuclear Medicine M.D.
Person Completing Form
Form Completion Date, Original (mm-dd-yyyy)
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RTOG-0421 I6: Radiation Therapy Oncology Group Phase III Recurrent
Head and Neck Study Staging Diagrams / Paranasal Sinus NCT00113399
RTOG-0421 I6: Radiation Therapy Oncology Group Phase
III Recurrent Head and Neck Study Staging Diagrams /
Paranasal Sinus NCT00113399
Combination Chemotherapy With or Without Radiation
Therapy in Treating Patients With Recurrent Head and
Neck Cancer That Cannot Be Removed By Surgery
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=EB4E1FCE-
11F3-0594-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11159
RTOG-0421 I6: Radiation Therapy
Oncology Group Phase III Recurrent
Head and Neck Study Staging
Diagrams / Paranasal Sinus
NCT00113399
RTOG clinical trial administrative data
RTOG Study
Case #
Institution Name
Institution No.
Patient Initials
Patient Study No.
If this is a revised or corrected form, indicate by
checking box.
Yes (Yes)
Head and Neck Tumor assessment
LOCATION OF TUMOR (  all that apply)
Ethmoid (ETHMOID)
Frontal (FRONTAL)
Maxillary (MAXILLARY)
Nasal Cavity (NASAL CAVITY)
Sphenoid (SPHENOID)
MAXILLARY
Both (Both)
Infrastructure (Infrastructure)
Suprastructure (Suprastructure)
NASAL CAVITY
Floor (Floor)
Lateral Wall (Lateral wall)
Roof (Roof)
Septum (Septum)
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ETHMOID
Anterior (Anterior)
Posterior (Posterior)
CHARACTERISTICS OF TUMOR (  all that
apply)
Base Of Skull Involvement (Base of skull
involvement)
Intra Cranial Extension (Intra Cranial
Extension)
Nasopharynx Involvement (Nasopharynx
involvement)
Orbital Content Involved (Orbital Content
involved)
Palate (Palate)
Periorbita Involved (Periorbita involved)
Periorbita Not Involved (Periorbita not
involved)
Radiographic Destruction Of Bone
(RADIOGRAPHIC DESTRUCTION OF
BONE)
Skin / Subcutaneous Tissue Involvement
(Skin / subcutaneous tissue involvement)
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RTOG-0421 QP: Radiation Therapy Oncology Group Performance
Status Scale Miscellaneous Patient Assessment Form NCT00113399
RTOG-0421 QP: Radiation Therapy Oncology Group
Performance Status Scale Miscellaneous Patient
Assessment Form NCT00113399
Combination Chemotherapy With or Without Radiation
Therapy in Treating Patients With Recurrent Head and
Neck Cancer That Cannot Be Removed By Surgery
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=EB3722D1-
7299-70BB-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11160
RTOG-0421 QP: Radiation Therapy
Oncology Group Performance Status
Scale Miscellaneous Patient
Assessment Form NCT00113399
RTOG clinical trial administrative data
RTOG Study
Case #
Institution Name
Institution No.
Patient Initials
Patient Study No.
Miscellaneous Patient Assessment
SCHEDULED DATA POINT (CHECK ONE)
At Completion Of Radiotherapy (At
completion of radiotherapy)
Four Weeks Followup (Four weeks
followup)
Other (Other)
Other Followup (other followup)
Pre Treatment Assessment (Pre
treatment assessment)
other followup
Other, specify
IF NO PATIENT ASSESSMENT, SPECIFY
REASON (CHECK ONE)
Other Reason (Other reason)
Patient Refused, Including Attempts By
Telephone Interview (Patient refused,
including attempts by telephone
interview)
Patient Refused, Telephone Interview
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Not Attempted (Patient refused,
telephone interview not attempted)
Patient Unable To Be Contacted (Patient
unable to be contacted)
Patient Was Too Ill (Patient was too ill)
Questionnaire Not Completed Due To
Institutional Error (Questionnaire not
completed due to institutional error)
Patient refused, including attempts by telephone
interview, specify reason for refusal
Patient refused, telephone interview not
attempted, specify reason for refusal
Other reason, specify
WAS INFORMATION OBTAINED BY
TELEPHONE INTERVIEW (CHECK ONE)
Yes
No
DATE OF EVALUATION
RATER'S NAME
NORMALCY OF DIET RATING (CHECK ONE)
80= All Meat (All meat)
70= Carrots, Celery (Carrots, celery)
10= Cold Liquids (Cold liquids)
60= Dry Bread And Crackers (Dry bread
and crackers)
100= Full Diet (no Restrictions) (Full diet)
0= Non-oral Feeding (tube Fed) (Non-
oral feeding)
90= Peanuts (Peanuts)
30= Pureed Foods (in Blender) (Pureed
foods)
40= Soft Foods Requiring No Chewing
(e.g., Mashed Potatoes, Apple Sauce,
Pudding) (Soft foods requiring no
chewing)
50= Soft, Chewable Foods (e.g.,
Macaroni, Canned/soft Fruits, Cooked
Vegetables, Fish, Hamburger, Small
Pieces Of Meat) (Soft, chewable foods)
20= Warm Liquids (Warm liquids)
PUBLIC EATING RATING (CHECK ONE)
0= Always Eats Alone (Always eats
alone)
25= Eats Only At Home In Presence Of
Selected Persons (Eats only at home in
presence of selected persons)
50= Eats Only In Presence Of Selected
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Persons In Selected Places (Eats only in
presence of selected persons in selected
places)
75= No Restriction Of Place, But
Restricts Diet When In Public (eats
Anywhere, But May Limit Intake To Less
"messy" Foods, E.g., Liquids) (No
restriction of place, but restricts diet
when in public)
100= No Restriction Of Place, Food Or
Companion (eats Out At Any
Opportunity) (No restriction of place,
food or companion)
UNDERSTANDABILITY OF SPEECH RATING
(CHECK ONE)
100= Always Understandable (Always
understandable)
25= Difficult To Understand (Difficult to
understand)
0= Never Understandable; May Use
Written Communication (Never
understandable; may use written
communication)
75= Understandable Most Of The Time;
Occasional Repetition Necessary
(Understandable most of the time;
occasional repetition necessary)
50= Usually Understandable; Face-to-
face Contact Necessary (Usually
understandable; face-to-face contact
necessary)
Comments
COMMENTS
Signature
Date
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RTOG-0522 FA: FACT (Function
Assessment Cancer Therapy) NCT00265941
RTOG-0522 FA: FACT (Function Assessment Cancer
Therapy) NCT00265941
Radiation Therapy and Cisplatin With or Without Cetuximab
in Treating Patients With Stage III or Stage IV Head and
Neck Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=F60B771F-
164B-2C87-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11161
RTOG-0522 FA: FACT (Function
Assessment Cancer Therapy)
NCT00265941
RTOG clinical trial administrative data
RTOG Study No.
Case #
Institution
Institution No.
Patient Initials
RTOG Patient ID
AMENDED DATA
Yes
No
Physical Well-being
I have a lack of energy
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have nausea
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
Because of my physical condition, I have trouble
meeting the needs of my family
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have pain
1 / 6
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am bothered by side effects of treatment
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I feel ill
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am forced to spend time in bed
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
Social/family Well-being
I feel close to my friends
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I get emotional support from my family
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I get support from my friends
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
My family has accepted my illness
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am satisfied with family communication about
my illness
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A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I feel close to my partner (or the person who is
my main support)
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am satisfied with my sex life
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
Emotional Well-being
I feel sad
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am satisfied with how I am coping with my
illness
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am losing hope in the fight against my illness
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I feel nervous
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I worry about dying
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I worry that my condition will get worse
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A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
Functional Well-being
I am able to work (include work at home)
2 (A little bit)
1 (Not at all)
4 (Quite a bit)
3 (Somewhat)
5 (Very much)
My work is fulfilling (include work at home)
2 (A little bit)
1 (Not at all)
4 (Quite a bit)
3 (Somewhat)
5 (Very much)
I am able to enjoy life
2 (A little bit)
1 (Not at all)
4 (Quite a bit)
3 (Somewhat)
5 (Very much)
I have accepted my illness
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am sleeping well
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am enjoying the things I usually do for fun
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am content with the quality of my life right now
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
Additional Concerns
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I am able to eat the foods that I like
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
My mouth is dry
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have trouble breathing
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
My voice has its usual quality and strength
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am able to eat as much food as I want
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am unhappy with how my face and neck look
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I can swallow naturally and easily
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I smoke cigarettes or other tobacco products
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I drink alcohol (e.g. beer, wine, etc.)
A Little Bit (A little bit)
Not At All (Not at all)
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Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am able to communicate with others
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I can eat solid foods
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have pain in my mouth, throat or neck
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
COMMENTS
Person completing form
Form completion date, original
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RTOG-0421 SS: Radiation Therapy Oncology Group Head & Neck Symptom
Index-10 (FHNSI-10) Miscellaneous Patient Assessment Form NCT00113399
RTOG-0421 SS: Radiation Therapy Oncology Group Head
& Neck Symptom Index-10 (FHNSI-10) Miscellaneous
Patient Assessment Form NCT00113399
Combination Chemotherapy With or Without Radiation
Therapy in Treating Patients With Recurrent Head and
Neck Cancer That Cannot Be Removed By Surgery
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=EB3734B1-
A6F3-725D-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11162
RTOG-0421 SS: Radiation Therapy
Oncology Group Head & Neck
Symptom Index-10 (FHNSI-10)
Miscellaneous Patient Assessment
Form NCT00113399
RTOG clinical trial administrative data
RTOG Study
Case #
Institution Name
Institution No.
Patient Initials
Patient Study No.
Miscellaneous Patient Assessment
I have pain
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have a lack of energy
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I can swallow naturally and easily
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
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I have pain in my mouth, throat, or neck
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have trouble breathing
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am able to communicate with others
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have nausea
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I can eat solid foods
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I worry that my condition will get worse
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am content with the quality of my life right now
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am unhappy with how my face and neck look
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
My appearance keeps me from participating in
activities
A Little Bit (A little bit)
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Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am bothered by an unpleasant odor at the site
of my disease
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am bothered by the built-up of secretions in my
mouth or neck
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have tingling or numbness in my hands or feet
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
Comments
COMMENTS
Signature
Date
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RTOG-0522 I7: Radiation Therapy Oncology Group Phase III Head
and Neck Study Dosimetry Nodal Planning Diagram NCT00265941
RTOG-0522 I7: Radiation Therapy Oncology Group Phase
III Head and Neck Study Dosimetry Nodal Planning
Diagram NCT00265941
Radiation Therapy and Cisplatin With or Without Cetuximab
in Treating Patients With Stage III or Stage IV Head and
Neck Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=F6217E11-
C792-5543-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11163
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Oncology Group Phase III Head and
Neck Study Dosimetry Nodal
Planning Diagram NCT00265941
RTOG clinical trial administrative data
RTOG Study No.
Case #
Institution Name
Institution No.
Patient Initials
RTOG Patient ID
Amended data
Yes
No
Head and Neck Lymph node
NODAL SITES (*)
Buccinator (Buccinator)
Infra-auricular (Infra-auricular)
Jugulodigastric (Jugulodigastric)
Lower (Lower)
Lower Jugular (Lower jugular)
Middle (Middle)
Midjugular (Midjugular)
Occipital (Occipital)
Other (Other)
Postauricular (Postauricular)
Preauricular (Preauricular)
Prelaryngeal (Prelaryngeal)
Pretracheal (Pretracheal)
Submandibular (Submandibular)
Submental (Submental)
Upper (Upper)
Other
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<= 3 CM
Lt (LT)
Rt (RT)
>3-6 CM
Lt (LT)
Rt (RT)
>6CM
Lt (LT)
Rt (RT)
NODES FIXED
Lt (LT)
Rt (RT)
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RTOG-0421 I6: Radiation Therapy Oncology Group Phase III Recurrent
Head and Neck Study Staging Diagrams / Larynx NCT00113399
RTOG-0421 I6: Radiation Therapy Oncology Group Phase
III Recurrent Head and Neck Study Staging Diagrams /
Larynx NCT00113399
Combination Chemotherapy With or Without Radiation
Therapy in Treating Patients With Recurrent Head and
Neck Cancer That Cannot Be Removed By Surgery
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=EB4905D5-
B71C-6C3A-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11164
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Oncology Group Phase III Recurrent
Head and Neck Study Staging
Diagrams / Larynx NCT00113399
RTOG clinical trial administrative data
RTOG Study
Case #
Institution Name
Institution No.
Patient Initials
Patient Study No.
If this is a revised or corrected form, indicate by
checking box.
Yes (Yes)
Larynx Tumor
SITE CHARACTERISTICS (  all that apply)
Glottis (Glottis)
Subglottis (Subglottis)
Supraglottis (Supraglottis)
Supraglottis
Involves >1 Subsite (Involves >1 subsite)
Limited To One Subsite (Limited to one
subsite)
Glottis
Extends To Supraglottis And/or
Subglottis (Extends to Supraglottis
and/or Subglottis)
Subglottis
Extends To Vocal Cord(s) (Extends to
vocal cord(s))
GENERAL CHARACTERISTICS (  all that apply)
1 / 2
Deeply Infiltrating (Deeply infiltrating)
Exophytic Only (Exophytic only)
Fixed Vocal Cord (Fixed vocal cord)
Gross Cartilage Involvement (Gross
cartilage involvement)
Impaired Mobility Of Vocal Cord
(Impaired mobility of vocal cord)
Invasion Beyond Larynx (Invasion
beyond larynx)
No Cartilage Involvement (No cartilage
involvement)
Normal Mobility Of Vocal Cords (Normal
mobility of vocal cords)
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RTOG-0421 I6: Radiation Therapy Oncology Group Phase III Recurrent
Head and Neck Study Staging Diagrams / Hypopharynx NCT00113399
RTOG-0421 I6: Radiation Therapy Oncology Group Phase
III Recurrent Head and Neck Study Staging Diagrams /
Hypopharynx NCT00113399
Combination Chemotherapy With or Without Radiation
Therapy in Treating Patients With Recurrent Head and
Neck Cancer That Cannot Be Removed By Surgery
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
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3B1D-2588-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11165
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Oncology Group Phase III Recurrent
Head and Neck Study Staging
Diagrams / Hypopharynx
NCT00113399
RTOG clinical trial administrative data
RTOG Study
Case #
Institution Name
Institution No.
Participant's Initials
Participant's ID No.
If this is a revised or corrected form, indicate by
checking box.
Yes (Yes)
Head and Neck Tumor
CHARACTERISTICS OF TUMOR (  all that
apply)
Deeply Infiltrating (Deeply infiltrating)
Fixation Of Hemilarynx (Fixation of
hemilarynx)
Invades Adjacent Structures (Invades
adjacent structures)
Invades More Than One Subsite Of
Hypopharynx (Invades more than one
subsite of hypopharynx)
Limited To One Subsite And <= 2cm
(Limited to one subsite and <= 2cm)
Size >2cm <=4cm (Size >2cm <=4cm)
LOCATION OF TUMOR (  all that apply)
Postcricoid Area (Postcricoid Area)
Posterior Wall (Posterior Wall)
1 / 2
Pyriform Fossa (Pyriform Fossa)
SITE OF ORIGIN
Left (LT)
Right (RT)
SITE(S) ALSO INVOLVED
Left (LT)
Right (RT)
Signature
Date
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RTOG 0617 T1: Radiation Therapy Oncology Group Phase III High-dose Vs
Standard-dose Conformal XRT with Chemotherapy Radiotherapy Form
NCT00533949
RTOG 0617 T1: Radiation Therapy Oncology Group Phase
III High-dose Vs Standard-dose Conformal XRT with
Chemotherapy Radiotherapy Form NCT00533949 
High-Dose or Standard-Dose Radiation Therapy and
Chemotherapy With or Without Cetuximab in Treating
Patients With Newly Diagnosed Stage III Non-Small Cell
Lung Cancer That Cannot Be Removed by Surgery
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=24AC4268-
6E7A-0EA0-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11166
RTOG 0617 T1: Radiation Therapy
Oncology Group Phase III High-dose
Vs Standard-dose Conformal XRT
with Chemotherapy Radiotherapy
Form NCT00533949
RTOG clinical trial administrative data
RTOG Study No.
Case #
Institution Name
Institution No.
Patient Initials
RTOG Patient ID
Amended data
Yes
No
Radiation Therapy
RADIATION THERAPY START DATE
RADIATION THERAPY END DATE
ELAPSED DAYS
RT Total Fraction Count
RT Total Dose
Were there any unscheduled interruptions in
radiation therapy?
No (No)
1 / 2
Yes, Due To Other Reason (Yes, due to
other reason)
Yes, Due To Toxicity (Yes, due to toxicity)
Specify RT interruption reason
Reason Treatment Ended
Adverse Event/side Effects/complications
(Adverse Event/Side
Effects/Complications)
Alternative Therapy (Alternative therapy)
Death On Study (Death on study)
Disease Progression, Relapse During
Active Treatment (Disease progression,
relapse during active treatment)
Other (Other)
Patient Off-treatment For Other
Complicating Disease (Patient off-
treatment for other complicating disease)
Patient Withdrawal Or Refusal After
Beginning Protocol Therapy (Patient
withdrawal/refusal after beginning
protocol therapy)
Patient Withdrawal Or Refusal Before
Beginning Protocol Therapy (Patient
withdrawal/refusal prior to beginning
protocol therapy)
Treatment Completed Per Protocol
Criteria (Treatment completed per
protocol criteria)
Alternative therapy, specify
Other complicating disease, specify
Other, specify
Type of Radiation Therapy Administered
3d Conformal (3D conformal)
Imrt (IMRT)
Comments
Comments
Person Completing Form
Date Form Originally Completed
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RTOG-0412 I1 Rev1: Initial Evaluation Form
NCT00113386
RTOG-0412 I1 Rev1: Initial Evaluation Form NCT00113386
Cisplatin and Docetaxel With or Without Radiation Therapy
in Treating Patients Who Are Undergoing Surgery for Newly
Diagnosed Stage III Non-Small Cell Lung Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=ED65A888-
399B-7059-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11167
RTOG-0412 I1 Rev1: Initial
Evaluation Form NCT00113386
Header
RTOG Study No.
Case #
Institution
Institution No.
Patient Initials
Patient Study I.D.
Amended Data (Instructions: Submit this form at
patient's entry on study. Dates are recorded mm-
dd-yyyy  unless otherwise specified.)
Yes
No
Pre-treatment Chacteristics
PATIENT BIRTH DATE
Performance Status (Zubrod)
Fully Active, Able To Carry On All Pre-
disease Performance Without
Restriction. (0)
Restricted In Physically Strenuous
Activity But Ambulatory And Able To
Carry Out Work Of A Light Or Sedentary
Nature, E.g., Light Housework, Office
Work. (1)
Ambulatory And Capable Of All Selfcare
But Unable To Carry Out Any Work
Activities. Up And About More Than 50%
Of Waking Hours. (2)
Capable Of Only Limited Selfcare,
Confined To Bed Or Chair More Than
50% Of Waking Hours. (3)
Completely Disabled. Cannot Carry On
Any Selfcare. Totally Confined To Bed Or
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Chair. (4)
Dead (5)
Weight loss in previous 6 Months
HISTORY OF PRIOR MALIGNANCY (within past
3 years)
Yes
No
Yes, specify site
PULMONARY
Yes
No
INFECTION
Yes
No
HEPATIC INSUFFICIENCY
Yes
No
CARDIOVASCULAR
Yes
No
CORONARY ARTERY DISEASE
Yes
No
OTHER
Yes
No
OTHER, SPECIFY
Forced Expiratory Volume (FEV1)
% DIFFUSION CAPACITY (DLCO)
Predicted Postresection FEV1 based on
Quantitative V/Q Scan
PRIOR RADIATION THERAPY AS TREATMENT
FOR THIS CANCER
Yes
No
PRIOR CHEMOTHERAPY AS TREATMENT
FOR THIS CANCER
Yes
No
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T Stage, Clinical
No Evidence Of Primary Tumor (T0)
Tumor 3 Cm Or Less In Greatest
Dimension, Surrounded By Lung Or
Visceral Pleura, Invasion More Proximal
Than The Lobar Bronchus, (i.e., Not In
The Main Bronchus) (T1)
Tumor With Any Of The Following
Features Of Size Or Extent: More Than
3cm In Greatest Dimension; Invades The
Visceral Pleura; Associated With
Atelectasis Or Obstructive Pneumonitis
That Extends To The Hilar Region But
Does Not Involve The Entire Lung (T2)
Tumor Of Any Size That Directly Invades
Any Of The Following: Chest Wall
(including Superior Sulcus Tumors),
Diaphragm, Mediastinal Pleura, Parietal
Pericardium; Or Tumor In The Main
Bronchus Less Than 2 Cm Distal To The
Carina, But Without Involvement O* (T3)
Tumor Of Any Size That Directly Invades
Any Of The Following: Chest Wall
(including Superior Sulcus Tumors),
Diaphragm, Mediastinal Pleura, Parietal
Pericardium; Or Tumor In The Main
Bronchus Less Than 2 Cm Distal To The
Carina, But Without Involvement O* (T4)
Carcinoma In Situ (Tis)
Primary Tumor Cannot Be Assessed, Or
Tumor Proven By The Presence Of
Malignant Cells In Sputum Or Bronchial
Washings But Not Visualized By Imaging
Or Bronchoscopy (Tx)
N STAGE, CLINICAL (N2)
No Regional Lymph Node Metastasis
(N0)
Metastasis To Ipsilateral Peribronchial
And/or Ipsilateral Hilar Lymph Nodes,
And Intrapulmonary Nodes Including
Involvement By Direct Extension Of The
Primary Tumor (N1)
Metastasis To Ipsilateral Mediastinal
And/or Subcarinal Lymph Node(s) (N2)
Metastasis To Contralateral Mediastinal,
Contralateral Hilar, Ipsilateral Or
Contralateral Scalene, Or
Supraclavicular Lymph Node(s) (N3)
Regional Lymph Nodes Cannot Be
Assessed (NX)
M STAGE, CLINICAL (MO)
No Distant Metastasis (M0)
Distant Metastasis Present (M1)
Distant Metastasis Cannot Be Assessed
(MX)
HISTOLOGIC TYPE
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Adenocarcinoma (Adenocarcinoma)
Bronchoalveolar (bac) (Bronchoalveolar
carcinoma)
Large Cell Undifferentiated (Large cell
undifferentiated)
Non-small Cell Lung Cancer (nsclc), Nos
(Non-small cell lung cancer NOS)
Squamous Cell Carcinoma (Squamous
cell carcinoma)
HOW WAS SPECIMEN OBTAINED
Sample Or Specimen Collected Via
Biopsy (Biopsy)
Sample Or Specimen Collected Via Fine
Needle Aspiration (Fine needle
aspiration)
Sample Or Specimen Collected Via
Induced Sputum (Sputum)
Fine needle aspiration, specify site
Lymph Node Assessment
LYMPH NODE TYPES
Highest Mediastinal (Highest mediastinal
(1))
Interlobar Node (Interlobar (11))
Left Hilar Node (Left hilar (10L))
Left Lobar Node (Left lobar (12L))
Left Lower Paratracheal Node (Left lower
paratracheal (4L))
Left Segmental Node (Left segmental
(13L))
Left Subsegmental Node (Left
subsegmental (14L))
Left Upper Paratracheal Node (Left
upper paratracheal (2L))
Para-aortic Node (Para-aortic (6))
Paraesophageal Node (Paraesophageal
(8))
Pre And Retro Paratracheal Node (Pre
and retro paratracheal (3))
Pulmonary Ligament (Pulmonary
ligament (9))
Right Hilar Node (Right hilar (10R))
Right Lobar Node (Right lobar (12R))
Right Lower Paratracheal Node (Right
lower paratracheal (4R))
Right Segmental Node (Right segmental
(13R))
Right Subsegmental Node (Right
subsegmental (14R))
Right Upper Paratracheal Node (Right
upper paratracheal (2R))
Subaortic Node (Subaortic (5))
Subcarinal Node (Subcarinal (7))
CLINICAL LYMPH NODE ASSESSMENT
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Equivocal (Equivocal)
Negative (Negative)
Not Evaluated (Not evaluated)
Positive (Positive)
Unknown (Unknown)
PATHOLOGIC LYMPH NODE ASSESSMENT
Equivocal (Equivocal)
Negative (Negative)
Not Evaluated (Not evaluated)
Positive (Positive)
Unknown (Unknown)
PARALYZED LEFT TRUE VOCAL CORD ON
BRONCHOSCOPY OR INDIRECT
LARYNGOSCOPY
Yes
No
NODES VISIBLE IN THE AP REGION ON CT
SCAN (LEVEL 5)
Yes
No
DISTINCT PRIMARY TUMOR SEPARATE FROM
NODES VISIBLE ON CT SCAN
Yes
No
SUBCARINAL NODES NOT VISIBLE ON CT
SCAN
Yes
No
TUMOR LOCATION, AREA
Carina (Carina)
Lower Lobe (left) (Lower Lobe (left))
Lower Lobe (right) (Lower Lobe (right))
Mainstem Bronchus (left) (Mainstem
Bronchus (left))
Mainstem Bronchus (right) (Mainstem
Bronchus (right))
Middle Lobe (right) (Middle Lobe (right))
Other, Specify (Other)
Upper Lobe (left) (Upper Lobe (left))
Upper Lobe (right) (Upper Lobe (right))
Other, specify
IS PLEURAL EFFUSION PRESENT (must
complete 14a)
Yes
No
IS IT MALIGNANT (not tapped)
No (No)
Unknown (Unknown)
Yes (Yes)
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Comments
Comments
Person completing form
Form completion date, original
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RTOG-0521 T1: Radiation Therapy Oncology Group Phase III Randomized Study of
Localized, High-Risk Prostate Cancer Radiotherapy Form NCT00288080
RTOG-0521 T1: Radiation Therapy Oncology Group Phase
III Randomized Study of Localized, High-Risk Prostate
Cancer Radiotherapy Form NCT00288080 
Hormone Therapy and Radiation Therapy or Hormone
Therapy and Radiation Therapy Followed by Docetaxel and
Prednisone in Treating Patients With Localized Prostate
Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=F6709418-
1311-5298-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11168
RTOG-0521 T1: Radiation Therapy
Oncology Group Phase III
Randomized Study of Localized,
High-Risk Prostate Cancer
Radiotherapy Form NCT00288080
RTOG clinical trial administrative data
RTOG Study No.
Case #
Institution Name
Institution No.
Patient Initials
RTOG Patient ID
Amended data
Yes
No
Radiation Therapy
RADIATION THERAPY START DATE
RADIATION THERAPY END DATE
ELAPSED DAYS
RT Total Fraction Count
RT Total Dose
Were there any unscheduled interruptions in
radiation therapy?
No (No)
1 / 3
Yes, Due To Other Reason (Yes, due to
other reason)
Yes, Due To Toxicity (Yes, due to toxicity)
Specify RT interruption reason
Reason Treatment Ended
Adverse Event/side Effects/complications
(Adverse Event/Side
Effects/Complications)
Alternative Therapy (Alternative therapy)
Death On Study (Death on study)
Disease Progression, Relapse During
Active Treatment (Disease progression,
relapse during active treatment)
Other (Other)
Patient Off-treatment For Other
Complicating Disease (Patient off-
treatment for other complicating disease)
Patient Withdrawal Or Refusal After
Beginning Protocol Therapy (Patient
withdrawal/refusal after beginning
protocol therapy)
Patient Withdrawal Or Refusal Before
Beginning Protocol Therapy (Patient
withdrawal/refusal prior to beginning
protocol therapy)
Treatment Completed Per Protocol
Criteria (Treatment completed per
protocol criteria)
Alternative therapy, specify
Other complicating disease, specify
Other, specify
New or continuing adverse events (*IF PATIENT
EXPERIENCED ANY TREATMENT RELATED
ADVERSE EVENTS DURING THIS REPORT
PERIOD, SUBMIT ADVERSE EVENT FORM AE)
Yes
No
Type of Radiation Therapy Administered
3d Conformal (3D conformal)
Imrt (IMRT)
Comments
Comments
Signature of Person Completing This Form
2 / 3
RTOG-0521 T1: Radiation Therapy Oncology Group Phase III Randomized Study of
Localized, High-Risk Prostate Cancer Radiotherapy Form NCT00288080
Form Completion Date, Original
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Z6051 Peri-Operative Data Form (POD)
NCT00726622
Z6051 Peri-Operative Data Form (POD) NCT00726622
Laparoscopic-Assisted Resection or Open Resection in
Treating Patients With Stage IIA, Stage IIIA, or Stage IIIB
Rectal Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=42E9B163-
4B1E-2A67-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11170
Z6051 Peri-Operative Data Form
(POD) NCT00726622
Header Module
American College of Surgeons Oncology Group
Visit Period Type
1-2 Weeks Post-surgery (1-2 weeks
post-surgery)
Patient ID (Pt. ID issued during registration
unless pt. previously registered to an ACOSOG
study.)
Patient Initials
Institution Name
Institution No.
Miscellaneous Patient  OP Assessment
Date of Assessment
Number of days requiring parenteral narcotics
Number of days receiving oral analgesics
Number of days postop before first flatus
Number of days postop before first bowel
movement
Length of hospital stay
Days in ICU (including day of surgery)
Ae Module
CTC Adverse Event Term
Not Assessed
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Not present
CTC Adverse Event Grade (1-5)
CTC AE Attribution Code (see above)
Definite (definite)
Possible (possible)
Probable (probable)
Unlikely (unlikely)
Unrelated (unrelated)
Other Ae Module
Were any additional adverse events experienced
by the patient
No (No)
Unknown (Unknown)
Yes (Yes)
CTC Adverse Event Term
CTC Adverse Event Grade (1-5)
CTC AE Attribution Code (see above)
Definite (definite)
Possible (possible)
Probable (probable)
Unlikely (unlikely)
Unrelated (unrelated)
Anesthetic complications, specify
Was a re-operation necessary?
Yes
No
Reason for re-operation
Date of re-operation
Pre-operative Ostomy Education
Did patient receive pre-operative ostomy
education
Yes
No
Choose type of education
By A Wound Ostomy Continence Nurse
(wocn) (By a Wound Ostomy Continence
Nurse)
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Other (Other)
Patient Brochure (Patient brochure)
Physician Teaching (Physician teaching)
Video (Video)
Other, specify
When did the education occur
Administered Following Surgical
Procedure. (Post-surgery)
Administered Prior To A Surgical
Procedure. (Pre-surgery)
Footer Module
Completed by
Date Form Completed
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KS Evaluation and Clinical Benefit Form:
RK1 NCT00310128
KS Evaluation and Clinical Benefit Form: RK1
NCT00310128 
Combination Chemotherapy Followed by Rituximab and
Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients
With Relapsed or Refractory AIDS-Related Non-Hodgkin's
Lymphoma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=0059EF25-
C95F-0C32-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11171
KS Evaluation and Clinical Benefit
Form: RK1 NCT00310128
Patient demographics
Center
Protocol
Participant ID
Visit Number
Assessment date
Time period
Baseline (Entry/Baseline)
On treatment (On treatment)
End Of Treatment (Post therapy
evaluation)
History And Symptoms
Patient symptoms of oral cavity lesions
No symptoms (No symptoms)
Oral cavity symptoms interfering
w/function most/all of the time, or
recurrent bleeding (Oral cavity symptoms
interfering w/function most/all of the time,
or recurrent bleeding)
Oral cavity symptoms not interfering with
function (Oral cavity symptoms not
interfering with function)
Symptoms interfering w/functions
sometimes, or occasional bleeding; can
take adequate nutrition (Symptoms
interfering w/functions sometimes, or
occasional bleeding; can take adequate
nutrition)
Patient symptoms of foot KS
Active but cannot perform more than
normal activities (Active but cannot
perform more than normal activities)
Lesions present but no symptoms. Able
1 / 14
to perform normal activities (Lesions
present but no symptoms. Able to
perform normal activities)
Moderate impairment of activity because
of foot KS (Moderate impairment of
activity because of foot KS)
Normal activities mildly limited because
of foot KS (Normal activities mildly
limited because of foot KS)
Severe impairment of activity due to foot
KS (Severe impairment of activity due to
foot KS)
Patient symptoms of scrotal/genital swelling
No scrotal/genital edema (No
scrotal/genital edema)
Swelling interferes with urination, sexual
function, withdrawing foreskin all the time
(Swelling interferes with urination, sexual
function, withdrawing foreskin all the
time)
Swelling interferes with urination, sexual
function, withdrawing foreskin sometimes
(Swelling interferes with urination, sexual
function, withdrawing foreskin
sometimes)
Swelling of the scrotum noted at all times
but no symptoms (Swelling of the
scrotum noted at all times but no
symptoms)
Swelling of the scrotum noted
occasionally (Swelling of the scrotum
noted occasionally)
Patient symptoms of periorbital edema
No periorbital edema (No periorbital
edema)
Swelling of eyes noted at all times and
interferes with eyesight or function at all
times (Swelling of eyes noted at all times
and interferes with eyesight or function at
all times)
Swelling of eyes noted at all times and
interferes with eyesight or function
sometimes (Swelling of eyes noted at all
times and interferes with eyesight or
function sometimes)
Swelling of the eyes noted at all times
but does not interfere with eyesight or
function (Swelling of the eyes noted at all
times but does not interfere with eyesight
or function)
Swelling of the eyes noted occasionally
or improves over the day (Swelling of the
eyes noted occasionally or improves over
the day)
Patient symptoms of edema
Completely resolves with limb elevation
and rings/shoes fit without difficulty
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(Completely resolves with limb elevation
and rings/shoes fit without difficulty)
Does not completely resolve with limb
elevation or rings/shoes do not fit
normally (Does not completely resolve
with limb elevation or rings/shoes do not
fit normally)
No edema, no symptoms (No edema, no
symptoms)
No improvement with limb elevation or
interferes with normal function (No
improvement with limb elevation or
interferes with normal function)
Significantly reduced function
(Significantly reduced function)
Anatomic Site of Worst Pain
Pain
Absent (Absent)
Present (Present)
What was the average pain experienced by the
patient over the last 24 hours
Discomforting pain (Discomforting pain)
Distressing pain (Distressing pain)
Excruciating pain (Excruciating pain)
Horrible pain (Horrible pain)
Mild pain (Mild pain)
No pain (No pain)
Is the patient on analgesics
No (No)
Unknown (Unknown)
Yes (Yes)
Is the patient experiencing tumor-related pain
Yes
No
Specify
Patient symptoms
No symptoms (No symptoms)
Severely limited activities, +/- hemoptysis
(Severely limited activities, +/-
hemoptysis)
Symptoms at rest, requiring oxygen or
hemoptysis (Symptoms at rest, requiring
oxygen or hemoptysis)
Symptoms on exertion (Symptoms on
exertion)
Symptoms on normal activity (Symptoms
on normal activity)
Specify
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GI Symptoms
Gross bleeding requiring transfusions,
evidence of obstruction, unable to
maintain adequate intake (Gross
bleeding requiring transfusions, evidence
of obstruction, unable to maintain
adequate intake)
Gross bleeding, or frequent GI
symptoms (Gross bleeding, or frequent
GI symptoms)
Minimal GI symptoms (Minimal GI
symptoms)
No symptoms (No symptoms)
Specify
Does the patient have other related oral cavity
symptoms
Yes
No
Comments
Are there any GI lesions present at this
evaluation
No (No)
Unknown (Not evaluated)
Yes (Yes)
Does the patient have other related pulmonary
symptoms
Yes
No
Evaluation Of Cutaneous Lesions
At entry, does the patient have >=50 lesions
Yes
No
Total Number Raised Lesions
Total Number Flat Lesions
Total Number New Lesions
Character of cutaneous Lesions
>=25% increase in the number of raised
lesions since baseline or since best
response (>=25% increase in the
number of raised lesions since baseline
or since best response)
None of the above (None of the above)
Since baseline, >=50% of raised have
become flat (Since baseline, >=50% of
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raised have become flat)
Representative Area
Abdomen (Abdomen)
Back (Back)
Chest (Chest)
Genital (Genital)
Head (Head)
Left arm (Left arm)
Left foot (Left foot)
Left hand (Left hand)
Left leg (Left leg)
Neck (Neck)
Right arm (Right arm)
Right foot (Right foot)
Right hand (Right hand)
Right leg (Right leg)
Total body (Total body)
Specify number of lesions
Evaluation Of Marker Lesions
Site Code
Abdomen (Abdomen)
Back (Back)
Chest (Chest)
Genital (Genital)
Head (Head)
Left arm (Left arm)
Left foot (Left foot)
Left hand (Left hand)
Left leg (Left leg)
Neck (Neck)
Right arm (Right arm)
Right foot (Right foot)
Right hand (Right hand)
Right leg (Right leg)
Total body (Total body)
Specify
Comments
Specify number of lesions
Evaluation Of Foot Ks
Foot KS
Absent (Absent)
Present (Present)
Photos taken
Yes
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No
Physical findings
Yes
No
Specify
Compared to previous evaluation
Improvement (Better)
No Change (Same)
Worsening (Worse)
Date of Evaluation
Evaluation Of Oral Cavity
Are there any oral cavity lesions present at this
evaluation
No (No)
Not evaluated (Not evaluated)
Yes (Yes)
Explain
Number of new lesions
Performed
Yes
No
Are there any pulmonary KS lesions present at
this evaluation
No (No)
Not evaluated (Not evaluated)
Yes (Yes)
Indicate if the lesions are measurable or
evaluable
Both measurable and evaluable (Both
measurable and evaluable)
Evaluable (Evaluable)
Measurable (Measurable)
Are there any pulmonary symptoms related to
Kaposi's Sarcoma
Yes
No
Explain
Performed
Yes
No
Are there any GI symptoms related to Kaposi's
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Sarcoma
Yes
No
Oral lesions
A resolution of all oral lesions since
baseline (A resolution of all oral lesions
since baseline)
A worsening of oral lesions since
baseline or best response (A worsening
of oral lesions since baseline or best
response)
An improvement of oral lesions since
baseline (An improvement of oral lesions
since baseline)
New oral lesions (New oral lesions)
None of the above (None of the above)
Are oral symptoms related to Kaposi's Sarcoma
No (No)
No symptoms (No symptoms)
Yes (Yes)
Explain
Number of raised lesions
Kaposi's Sarcoma Present
Yes
No
Photos taken
Yes
No
Date of Evaluation
Number of flat lesions
Are there lesions which are not countable or
measurable
Yes
No
Comments
Assessment date
Assessment date
Specify number of lesions
Are there any GI lesions present at this
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evaluation
No (No)
Unknown (Not evaluated)
Yes (Yes)
Sites
Buccal Mucosa (Buccal mucosa)
Floor Of Mouth (Floor of mouth)
Upper Gingiva (Gingiva/gums)
Hard Palate (Hard palate)
Posterior Pharyngeal Wall (Posterior
pharynx)
Soft Palate (Soft palate)
Oral Tongue (Tongue)
Tonsils (Tonsils)
Uvula (Uvula)
Evaluation method
Ct Scan (CT scan)
Chest X-ray (CXR)
Evaluation method
Ct Scan (CT scan)
Chest X-ray (CXR)
Pleural effusion
Yes
No
Lesions Measurements
Bronchoscopy Performed
Yes
No
Other tests
Any other tests peformed
Yes
No
Site of Lesion
Dimension 1
Dimension 2
Comments
Comments
Comments
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Bronchoscopy date
Edema Evaluation
Is there any tumor-associated edema at this
evaluation
Yes
No
Edema Site
Genital (Genital)
Left arm (Left arm)
Left foot (Left foot)
Left hand (Left hand)
Left leg (Left leg)
Other (Other)
Periorbital (Periorbital)
Right arm (Right arm)
Right foot (Right foot)
Right hand (Right hand)
Right leg (Right leg)
Other, specify
Edema present
Yes
No
Edema Evaluation
A resolution of all tumor-associated
edema since baseline (A resolution of all
tumor-associated edema since baseline)
A worsening of tumor-associated edema
since baseline or best response (A
worsening of tumor-associated edema
since baseline or best response)
An improvement of tumor-associated
edema since baseline (An improvement
of tumor-associated edema since
baseline)
New tumor-associated edema (New
tumor-associated edema)
No Change (No Change)
Compared to previous evaluation
Improvement (Better)
No Change (Same)
Worsening (Worse)
Evaluation Of Extremity Edema
Status of edema
Absent (Absent)
Present (Present)
Specific location
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Limb Girth
Comments
Evaluation Of Periorbital Edema
Photos taken
Yes
No
Physical findings
Yes
No
Specify
Date of Evaluation
Evaluation Of Scrotal/genital Swelling
Photos taken
Yes
No
Date
Physical findings
Yes
No
Specify
Evaluation Of Visceral Disease
Has an evaluation for visceral disease been done
Yes
No
Site of Lesion
Abdomen (Abdomen)
Back (Back)
Chest (Chest)
Genital (Genital)
Head (Head)
Left arm (Left arm)
Left foot (Left foot)
Left hand (Left hand)
Left leg (Left leg)
Neck (Neck)
Right arm (Right arm)
Right foot (Right foot)
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Right hand (Right hand)
Right leg (Right leg)
Total body (Total body)
KS involvement
Absent (Absent)
Present (Present)
Visceral Evaluation
A complete resolution of visceral disease
since baseline (A complete resolution of
visceral disease since baseline)
A decrease in visceral disease since
baseline (A decrease in visceral disease
since baseline)
A worsening of visceral disease since
baseline, or since the best response (A
worsening of visceral disease since
baseline, or since the best response)
Evidence of a new site of visceral
diseases since baseline, or since the
best response (Evidence of a new site of
visceral diseases since baseline, or
since the best response)
No Change (No Change)
Not applicable, Entry/Baseline evaluation
(Not applicable, Entry/Baseline
evaluation)
Has a visceral disease evaluation been done
since the last KS evaluation
Yes
No
Date of Evaluation
Comments
Procedure
Bronchoscopy (Bronchoscopy)
Chest X-ray (Chest X-ray)
Colonoscopy (Colonoscopy)
Other (Other)
Sigmoidoscopy (Sigmoidoscopy)
Upper endoscopy (Upper endoscopy)
Specify Procedure
Interventions (in Addition To Study Drug
Therapy)
Local anesthetic/analgesic
Yes
No
Diuretics
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Yes
No
Others
Yes
No
Specify
Local Therapy
Yes
No
Others
Yes
No
Specify
Others
Yes
No
Specify
Uses cane, wheelchair
Yes
No
Others
Yes
No
Specify
Specify
Others
Yes
No
Local interventions to KS lesions
Yes
No
Cough suppressant
Yes
No
Bronchodilators
Yes
No
Others
Yes
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No
Oxygen
Yes
No
Specify
Others
Yes
No
Specify
Comments
Antiemetics
Yes
No
Blood transfusions
Yes
No
Steroids
Yes
No
Analgesics
Yes
No
Analgesics
Yes
No
Analgesics
Yes
No
Overall Assessment
What is the present status of the best response
No relapse observed, but patient died
(No relapse observed, but patient died)
Not Applicable (Not Applicable)
Relapse occurred after a response was
achieved (Relapse occurred after a
response was achieved)
Response continuing or first time at this
response (Response continuing or first
time at this response)
During this reporting period, did a clinical
complete response occur
Yes
No
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Specify date of onset
Best overall response attained since
Entry/Baseline
Clinical complete response (Clinical
complete response)
Complete Response (Complete)
Partial Response (Partial response)
Progression (Progression)
Stable Disease (Stable)
Not Assessed (Unevaluable)
Other (Unknown)
Date of Relapse or progression
During this reporting period, did a complete
response occur
Yes
No
Comments
Specify date of onset
During this reporting period, did a partial
response occur
Yes
No
Specify date of onset
During this reporting period, did progression with
no response occur
Yes
No
Specify date of onset
Signature
Date
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Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
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RTOG 0848:   Phase III Pancreas-
Resected + Adjuvant Treatment
Surgery Form (S1) NCT01013649
Header Module
RTOG Study No.
Case #
Institution Name
Institution No.
Patient Initials
RTOG Patient ID
Amended Data
Yes
No
Gastro intestinal Surgical Procedure
Procedure
Whipple Procedure (Classic
Pancreaticoduodenectomy (Whipple))
Other (Other)
Pylorus Preserving
Pancreaticoduodonectomy (Pylorus
preserving pancreaticoduodonectomy)
Other, specify
Date of surgery
Pancreatic Head
Yes
No
Uncinate Process
Yes
No
Pancreatic Body
Yes
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No
Tumor Size, Largest Dimension
Additional dimension
Additional dimension
Other Organs Resected
Spleen
Yes
No
Gallbladder
Yes
No
Distal half stomach
Yes
No
Distal portion common bile duct
Yes
No
Duodenum
Yes
No
Proximal jejunum
Yes
No
Colon
Yes
No
Superior Mesenteric Vein
Yes
No
Portal Vein
Yes
No
Other
Yes
No
Histologic Type
Ductal Adenocarcinoma (Ductal
adenocarcinoma)
Intraductal Papillary Mucinous Neoplasm
(Intraductal papillary mucinous
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neoplasm)
Other Specify (Other)
Undifferentiated (anaplastic) Carcinoma
(Undifferentiated (anaplastic) carcinoma)
Other specify
G1 (WELL DIFFERENTIATED)
Yes
No
GX (CAN NOT BE ASSESSED)
Yes
No
G2 (MODERATELY DIFFERENTIATED)
Yes
No
G3 (POORLY DIFFERENTIATED)
Yes
No
G4 (UNDIFFERENTIATED)
Yes
No
Other
Yes
No
Other, specify
Pathologic T Stage
T1, According To Ajcc Criteria (T1)
T2, According To Ajcc Criteria (T2)
T3, According To Ajcc Criteria (T3)
Pathologic T Stage
T1, According To Ajcc Criteria (T1)
T2, According To Ajcc Criteria (T2)
T3, According To Ajcc Criteria (T3)
Pathologic N Stage
No Lymph Node Involvement According
To Ajcc Guidelines (use For Esophageal,
Gastric, And Pancreatic) (N0)
N1, According To Ajcc Criteria (N1)
N2, According To Ajcc Criteria (N2)
Pathologic N Stage
No Lymph Node Involvement According
To Ajcc Guidelines (use For Esophageal,
Gastric, And Pancreatic) (N0)
N1, According To Ajcc Criteria (N1)
N2, According To Ajcc Criteria (N2)
Pathologic M Stage
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No Distant Metastases According To
Ajcc Guidelines (M0)
Distant Metastases Present According
To Ajcc Guidelines (M1)
Number of Lymph Nodes Examined
Number of Lymph Nodes Positive
Bile duct
Negative (Negative)
Positive (Positive)
Pancreatic parenchyma
Negative (Negative)
Positive (Positive)
Retroperitoneal
Negative (Negative)
Positive (Positive)
Overall Margin Status
All Margins Pathologically Negative (R0)
Microscopically Positive Margins Or
Microscopic Residual Disease (R1)
Macroscopically Positive Margins Or
Gross Residual Disease (R2)
Tumor invasion
Is there the presence of gross disease at the
SMA (superior mesenteric artery)
Yes
No
Venous/lymphatic invasion (Large/small vessel)
Absent (Absent)
Present (Present)
Perineural invasion
Absent (Absent)
Present (Present)
Perineural Involvement
Yes
No
Additional Pathologic Findings
Pancreatic intraepithelial neoplasia
No (No)
Not Identified (Not Identified)
Yes (Yes)
Specify highest grade
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Chronic pancreatitis
No (No)
Not Identified (Not Identified)
Yes (Yes)
Acute pancreatitis
No (No)
Not Identified (Not Identified)
Yes (Yes)
Duodenum
No (No)
Not Identified (Not Identified)
Yes (Yes)
Other
No (No)
Not Identified (Not Identified)
Yes (Yes)
Specify
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Radiation Therapy in Treating Patients With Stage II
Prostate Cancer
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RTOG-0415 T1: Radiotherapy Form
NCT00331773
RTOG clinical trial administrative data
RTOG Study No.
Case #
Institution Name
Institution No.
Patient Initials
RTOG Patient ID
Amended data
Yes
No
Radiation Therapy
Radiation Therapy Start Date
Radiation Therapy End Date
Elapsed days
RT Total Fraction Count
RT Total Dose
Were there any unscheduled interruptions in
radiation therapy
No (No)
Yes, Due To Other Reason (Yes, due to
other reason)
Yes, Due To Toxicity (Yes, due to toxicity)
Specify RT interruption reason
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Reason Treatment Ended
Adverse Event/side Effects/complications
(Adverse Event/Side
Effects/Complications)
Alternative Therapy (Alternative therapy)
Death On Study (Death on study)
Disease Progression, Relapse During
Active Treatment (Disease progression,
relapse during active treatment)
Other (Other)
Patient Off-treatment For Other
Complicating Disease (Patient off-
treatment for other complicating disease)
Patient Withdrawal Or Refusal After
Beginning Protocol Therapy (Patient
withdrawal/refusal after beginning
protocol therapy)
Patient Withdrawal Or Refusal Before
Beginning Protocol Therapy (Patient
withdrawal/refusal prior to beginning
protocol therapy)
Treatment Completed Per Protocol
Criteria (Treatment completed per
protocol criteria)
Alternative therapy, specify
Other specify
Type of Radiation Therapy Administered
3d Conformal (3D conformal)
Imrt (IMRT)
What method of daily prostate localization was
used
Cone Beam (Cone beam)
Fiducial Markers (Fiducial markers)
Other (Other)
Ultra Sound (Ultra sound)
Other, specify
New or continuing adverse events (*IF PATIENT
EXPERIENCED ANY TREATMENT RELATED
ADVERSE EVENTS DURING THIS REPORT
PERIOD, SUBMIT ADVERSE EVENT FORM AE)
Yes
No
Comments
Comments
Signature of Person Completing This Form
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Date Form Originally Completed
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Patient Information
NCIC Patient ID
Patient Initials (first-middle-last)
Patient Medical Record Number (if permitted by
IRB)
Intergroup Patient Serial No
Institution Name
NCI Institution Number (CTEP assigned)
Investigator First Name
Investigator Last Name
Investigator Number (NCI Investigator Number)
Cause Of Death
Date of Death (yyyy mmm dd)
Primary Cause of Death (check one)
Due To Other Cause (Due to other
cause)
Due To Protocol Treatment (Due to
protocol treatment)
Due To This Disease (Due to this
disease)
Unknown (Unknown)
Due to other cause specify
Month Of Report
Autopsy? (If yes, attach copy of final report)
No (No)
Unknown (Unknown)
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Yes (Yes)
Adverse Event Status
Has the patient experienced any new or
continuing symptoms or adverse events since the
last report? (possibly, probably or definitely
related to protocol therapy)
Yes
No
CTC Adverse Event Term (CTCAE Version 4.0)
Abdominal Pain (Abdominal pain)
Alopecia (Alopecia)
Non-infectious Cystitis (Cystitis
noninfective)
Diarrhea (Diarrhea)
Impotence (Erectile dysfunction)
Fatigue (Fatigue)
Proctitis (Proctitis)
Urinary Frequency (Urinary frequency)
Urinary Incontinence (Urinary
incontinence)
Urinary Retention (Urinary retention)
Grade (Worst this time period If event no present,
leave this field blank.)
Absent Adverse Event (0)
Mild Adverse Event (1)
Moderate Adverse Event (2)
Severe Adverse Event (3)
Life Threatening Adverse Event (4)
Death Related To Adverse Event (5)
CTC Adverse Event Attribution Code (*Serious
Adverse Event form required only if malignancy is
thought to be possibly, probably, or definitely
related to protocol therapy. See protocol...)
Definite (Definite)
Possible (Possible)
Probable (Probable)
Unlikely (Unlikely)
Unrelated (Unrelated)
Seriousness Attributed to Adverse Event (Enter
appropriate code as follows: 0=not serious;
1=death; 2=life threatening; 3=hospitalization,
initial or prolonged; 4=disability...)
Congenital Anomaly (Congenital
anomaly)
Death (Death)
Disability (Disability/incapacity)
Hospitalized (Hospitalization, initial or
prolonged)
Life Threatening (Life threatening)
Not Serious (Not serious)
Other (Other)
Intervention Required (Required
intervention to prevent permanent
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impairment/damage)
SAE report submitted (NCIC CTG use only
Default=N enter Y only for adverse events
recorded on SAE report)
Yes
No
Physical Exam
Non-protocol 5 alpha reductase inhibitors
Yes
No
Date of First Non-Protocol Therapy (for Prostate
Cancer yyyy-mmm-dd)
Agent
Reason for use
Non-protocol non-steroidal antiandrogen therapy
Yes
No
Agent
Non-protocol LHRH analogues
Yes
No
Agent
Non-Protocol Surgery? (for prostate cancer)
Yes
No
Date of Non-protocol therapy (If yes, Date of Non-
protocol surgery yyyy-mmm-dd)
Non-Protocol Surgery Type
Non-Protocol Radiation Therapy? (for prostate
cancer)
Yes
No
Non-protocol Radiation Therapy Start Date (If
yes, yyyy-mmm-dd)
Non-Protocol RT Type
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Complementary and alternative medicines (for
lower urinary tract symptoms or prostate cancer?
CRF: Complementary and Alternative Medicines)
Yes
No
Agent (If yes, *e.g. Saw Palmetto, Vitamin B/E,
Selenium, Lycopene  CRF: Agent)
Other Non-Protocol Therapy (for prostate
cancer?)
Yes
No
Name of Other Non-Protocol Therapy (If yes, for
Prostate Cancer)
Other Malignancies Or Marrow Dysplasia
Has a new primary cancer or MDS been
diagnosed that has not been previously reported?
(myelodysplastic syndrome)
Yes
No
Date of Diagnosis (yyyy-mmm-dd)
Malignancy Type (e.g., bladder)
New Primary Diagnosis
(Histology/Cytopathology)
Comments
Comments
Supporting Documentation
Investigator Signature
Person Completing Form, Last Name
Person Completing Form, First Name
Date Form Originally Completed (yyyy - mmm -
dd)
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Miscellaneous Patient Assessment Form NCT00265941
RTOG-00522 HP: Radiation Therapy Oncology Group
Miscellaneous Patient Assessment Form NCT00265941
Radiation Therapy and Cisplatin With or Without Cetuximab
in Treating Patients With Stage III or Stage IV Head and
Neck Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=F5E8260F-
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All rights reserved. Please visit https://medical-data-
models.org/forms/11176
RTOG-0522 HP: Radiation Therapy
Oncology Group Miscellaneous
Patient Assessment Form
NCT00265941
RTOG clinical trial administrative data
RTOG Study No.
Case #
Institution Name
Institution No.
Patient Initials
RTOG Patient ID
Amended data
Yes
No
Miscellaneous Patient Assessment
MOBILITY
I Am Confined To Bed (I am confined to
bed)
I Have No Problems In Walking About (I
have no problems in walking about)
I Have Some Problems In Walking About
(I have some problems in walking about)
SELF CARE
I Am Unable To Wash Or Dress Myself (I
am unable to wash or dress myself)
I Have No Problems With Self Care (I
have no problems with self care)
I Have Some Problems Washing Or
Dressing Myself (I have some problems
washing or dressing myself)
USUAL ACTIVITIES (e.g. work, study,
housework, family, or leisure activities)
I Am Unable To Perform My Usual
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Activities (I am unable to perform my
usual activities)
I Have No Problems With Performing My
Usual Activities (I have no problems with
performing my usual activities)
I Have Some Problems With Performing
My Usual Activities (I have some
problems with performing my usual
activities)
PAIN/DISCOMFORT
I Have Extreme Pain Or Discomfort (I
have extreme pain or discomfort)
I Have Moderate Pain Or Discomfort (I
have moderate pain or discomfort)
I Have No Pain Or Discomfort (I have no
pain or discomfort)
ANXIETY/DEPRESSION
I Am Extremely Anxious Or Depressed (I
am extremely anxious or depressed)
I Am Moderately Anxious Or Depressed
(I am moderately anxious or depressed)
I Am Not Anxious Or Depressed (I am
not anxious or depressed)
Score (Best Imaginable Health State)
HAVE YOU EXPERIENCED SERIOUS ILLNESS
In yourself?
Yes
No
HAVE YOU EXPERIENCED SERIOUS ILLNESS
In your family?
Yes
No
HAVE YOU EXPERIENCED SERIOUS ILLNESS
In caring for others?
Yes
No
WHAT IS YOUR AGE IN YEARS?
Are you
Female (FEMALE)
Male (MALE)
ARE YOU A current smoker
Yes
No
ARE YOU An ex-smoker
Yes
No
ARE YOU A never smoker
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Yes
No
DO YOU NOW, OR DID YOU EVER, WORK IN
HEALTH OR SOCIAL SERVICES?
Yes
No
IF SO, IN WHAT CAPACITY?
WHICH OF THE FOLLOWING BEST
DESCRIBES YOUR MAIN ACTIVITY?
Homemaker (Housework)
Employed (In employment or self
employment)
Other (Other)
Retired (Retired)
Unemployed (Seeking work)
Student (Student)
Other
DID YOUR EDUCATION CONTINUE AFTER
THE MINIMUM SCHOOL LEAVING AGE?
Yes
No
DO YOU HAVE A DEGREE OR EQUIVALENT
PROFESSIONAL QUALIFICATION?
Yes
No
IF YOU KNOW YOUR POSTCODE, WOULD
YOU PLEASE WRITE IT HERE
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Z1041: Tissue Specimen Bank Submission
(TSBS) NCT00513292
Z1041: Tissue Specimen Bank Submission (TSBS)
NCT00513292 
Combination Chemotherapy and Paclitaxel Plus
Trastuzumab in Treating Women With Palpable Breast
Cancer That Can Be Removed by Surgery
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=210001BA-
4B81-38BC-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
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Z1041: Tissue Specimen Bank
Submission (TSBS) NCT00513292
Patient demographics
Visit
Baseline (Baseline)
Surgery (Surgery)
Unscheduled (Unscheduled)
Patient ID
Patient Initials (F M L)
Institution No.
Institution Name
Biopsy and Cytology Specimens
Did patient consent for collection of tissue
samples
Yes
No
Patient's Initial Consent given for tissue specimen
use for research on the patient's cancer?
No (No)
Unknown (Unknown)
Yes (Yes)
Were specimen(s) submitted to the ACOSOG
Central Specimen Bank
Yes
No
Specify reason (If not submitted,)
Specimen obtained at
Baseline (Baseline)
Definitive Surgery (Definitive surgery)
Date Specimen collected
Date Specimen Shipped
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Core biopsy tissue in RNAlater (1 requested)
Core biopsy tissue fixed in 10% buffered formalin
(1 requested)
Core biopsy tissue snap frozen in OCT (2
requested)
Breast tumor area (4 unstained sections each
from 10-15 blocks)
Residual breast tumor (4 unstained sections from
one representative block)
Representative block of residual tumor and
positive nodes (s)
Shipped by
Courier Tracking #
Date of Receipt of Specimens (s)
Specimen Type
Core Biopsy In Rnalater (Core biopsy in
RNAlater)
Tissue Fixed With Formalin (Formalin-
fixed tumor tissue)
Frozen Tissue, Not Fixed, Embedded
With Oct (OCT-embedded tumor tissue)
Representative Block Of Residual Tumor
(Representative block of residual tumor)
Unstained Slides From Breast Tumor
Area (Unstained slides from breast tumor
area)
Unstained Slides From Residual Breast
Tumor (Unstained slides from residual
breast tumor)
No specimen received (check if none)
Specimen Received Count
Condition of specimen (s)
Damaged Or Unusable (Damaged or
unusable)
Usable (Usable)
Site Information
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Contact Person at Institution
Phone
E-mail
Fax
Footer module
Completed by
Date Form Completed
3 / 3
Z1041: Tissue Specimen Bank Submission (TSBS) NCT00513292
CALGB 50901 Adverse Event Form
NCT01190449
CALGB 50901 Adverse Event Form NCT01190449 
Ofatumumab in Treating Patients With Previously Untreated
Stage II, Stage III, or Stage IV Follicular Non-Hodgkin
Lymphoma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=9F2AAC9E-
3AD0-BFF6-E040-BB89AD436B9A
All rights reserved. Please visit https://medical-data-
models.org/forms/11179
CALGB 50901 Adverse Event Form
NCT01190449
Adverse Event Evaluation
Adverse Event Reporting from Date
Adverse Event Reporting to Date
CTCAE Term
Abdominal Distension (Abdominal
distension)
Abdominal Infection (Abdominal
infection)
Abdominal Pain (Abdominal pain)
Abdominal Soft Tissue Necrosis
(Abdominal soft tissue necrosis)
Abducens Nerve Disorder (Abducens
nerve disorder)
Accessory Nerve Disorder (Accessory
nerve disorder)
Acidosis (Acidosis)
Acoustic Nerve Disorder Nos (Acoustic
nerve disorder NOS)
Activated Partial Thromboplastin Time
Prolonged (Activated partial
thromboplastin time prolonged)
Acute Coronary Syndrome (Acute
coronary syndrome)
Acute Kidney Injury (Acute kidney injury)
Adrenal Insufficiency (Adrenal
insufficiency)
Adult Respiratory Distress Syndrome
(Adult respiratory distress syndrome)
Agitation (Agitation)
Akathisia (Akathisia)
Alanine Aminotransferase Increased
(Alanine aminotransferase increased)
Alcohol Intolerance (Alcohol intolerance)
Alkaline Phosphatase Increased
(Alkaline phosphatase increased)
Alkalosis (Alkalosis)
Allergic Reaction (Allergic reaction)
Allergic Rhinitis (Allergic rhinitis)
Alopecia (Alopecia)
Amnesia (Amnesia)
Anal Fistula (Anal fistula)
Anal Hemorrhage (Anal hemorrhage)
Anal Mucositis (Anal mucositis)
Anal Necrosis (Anal necrosis)
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Anal Pain (Anal pain)
Anal Stenosis (Anal stenosis)
Anal Ulcer (Anal ulcer)
Anaphylaxis (Anaphylaxis)
Anemia (Anemia)
Ankle Fracture (Ankle fracture)
Anorectal Infection (Anorectal infection)
Anorexia (Anorexia)
Anorgasmia (Anorgasmia)
Anxiety (Anxiety)
Aortic Injury (Aortic injury)
Aortic Valve Disease (Aortic valve
disease)
Aphonia (Aphonia)
Apnea (Apnea)
Appendicitis (Appendicitis)
Appendicitis Perforated (Appendicitis
perforated)
Arachnoiditis (Arachnoiditis)
Arterial Injury (Arterial injury)
Arteritis Infective (Arteritis infective)
Arthralgia (Arthralgia)
Arthritis (Arthritis)
Ascites (Ascites)
Aspartate Aminotransferase Increased
(Aspartate aminotransferase increased)
Aspiration (Aspiration)
Asystole (Asystole)
Ataxia (Ataxia)
Atelectasis (Atelectasis)
Atrial Fibrillation (Atrial fibrillation)
Atrial Flutter (Atrial flutter)
Atrioventricular Block Complete
(Atrioventricular block complete)
Atrioventricular Block First Degree
(Atrioventricular block first degree)
Autoimmune Disorder (Autoimmune
disorder)
Avascular Necrosis (Avascular necrosis)
Azoospermia (Azoospermia)
Back Pain (Back pain)
Bile Duct Stenosis (Bile duct stenosis)
Biliary Anastomotic Leak (Biliary
anastomotic leak)
Biliary Fistula (Biliary fistula)
Biliary Tract Infection (Biliary tract
infection)
Bladder Anastomotic Leak (Bladder
anastomotic leak)
Bladder Infection (Bladder infection)
Bladder Perforation (Bladder perforation)
Bladder Spasm (Bladder spasm)
Bloating (Bloating)
Blood And Lymphatic System Disorders -
Other, Specify (Blood and lymphatic
system disorders - Other, Specify)
Blood Antidiuretic Hormone Abnormal
(Blood antidiuretic hormone abnormal)
Blood Bilirubin Increased (Blood bilirubin
increased)
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Blood Corticotrophin Decreased (Blood
corticotrophin decreased)
Blood Gonadotrophin Abnormal (Blood
gonadotrophin abnormal)
Blood Prolactin Abnormal (Blood
prolactin abnormal)
Blurred Vision (Blurred vision)
Body Odor (Body odor)
Bone Infection (Bone infection)
Bone Marrow Hypocellular (Bone
marrow hypocellular)
Bone Pain (Bone pain)
Brachial Plexopathy (Brachial
plexopathy)
Breast Atrophy (Breast atrophy)
Breast Infection (Breast infection)
Breast Pain (Breast pain)
Bronchial Fistula (Bronchial fistula)
Bronchial Infection (Bronchial infection)
Bronchial Obstruction (Bronchial
obstruction)
Bronchial Stricture (Bronchial stricture)
Bronchopleural Fistula (Bronchopleural
fistula)
Bronchopulmonary Hemorrhage
(Bronchopulmonary hemorrhage)
Bronchospasm (Bronchospasm)
Bruising (Bruising)
Bullous Dermatitis (Bullous dermatitis)
Burn (Burn)
Buttock Pain (Buttock pain)
Capillary Leak Syndrome (Capillary leak
syndrome)
Carbon Monoxide Diffusing Capacity
Decreased (Carbon monoxide diffusing
capacity decreased)
Cardiac Arrest (Cardiac arrest)
Cardiac Disorders - Other, Specify
(Cardiac disorders - Other, Specify)
Cardiac Troponin I Increased (Cardiac
troponin I increased)
Cardiac Troponin T Increased (Cardiac
troponin T increased)
Cataract (Cataract)
Catheter Related Infection (Catheter
related infection)
Cd4 Lymphocytes Decreased (CD4
lymphocytes decreased)
Cecal Hemorrhage (Cecal hemorrhage)
Cecal Infection (Cecal infection)
Central Nervous System Necrosis
(Central nervous system necrosis)
Cerebrospinal Fluid Leakage
(Cerebrospinal fluid leakage)
Cervicitis Infection (Cervicitis infection)
Cheilitis (Cheilitis)
Chest Pain - Cardiac (Chest pain -
cardiac)
Chest Wall Pain (Chest wall pain)
Chills (Chills)
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Cholecystitis (Cholecystitis)
Cholesterol High (Cholesterol high)
Chronic Kidney Disease (Chronic kidney
disease)
Chylothorax (Chylothorax)
Cognitive Disturbance (Cognitive
disturbance)
Colitis (Colitis)
Colonic Fistula (Colonic fistula)
Colonic Hemorrhage (Colonic
hemorrhage)
Colonic Obstruction (Colonic obstruction)
Colonic Perforation (Colonic perforation)
Colonic Stenosis (Colonic stenosis)
Colonic Ulcer (Colonic ulcer)
Concentration Impairment
(Concentration impairment)
Conduction Disorder (Conduction
disorder)
Confusion (Confusion)
Congenital, Familial And Genetic
Disorders - Other, Specify (Congenital,
familial and genetic disorders - Other,
Specify)
Conjunctivitis (Conjunctivitis)
Conjunctivitis Infective (Conjunctivitis
infective)
Constipation (Constipation)
Constrictive Pericarditis (Constrictive
pericarditis)
Corneal Infection (Corneal infection)
Corneal Ulcer (Corneal ulcer)
Cough (Cough)
Cpk Increased (CPK increased)
Cranial Nerve Infection (Cranial nerve
infection)
Creatinine Increased (Creatinine
increased)
Cushingoid (Cushingoid)
Cystitis Noninfective (Cystitis
noninfective)
Cytokine Release Syndrome (Cytokine
release syndrome)
Death Neonatal (Death neonatal)
Death Nos (Death NOS)
Dehydration (Dehydration)
Delayed Orgasm (Delayed orgasm)
Delayed Puberty (Delayed puberty)
Delirium (Delirium)
Delusions (Delusions)
Dental Caries (Dental caries)
Depressed Level Of Consciousness
(Depressed level of consciousness)
Depression (Depression)
Dermatitis Radiation (Dermatitis
radiation)
Device Related Infection (Device related
infection)
Diarrhea (Diarrhea)
Disseminated Intravascular Coagulation
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(Disseminated intravascular coagulation)
Dizziness (Dizziness)
Dry Eye (Dry eye)
Dry Mouth (Dry mouth)
Dry Skin (Dry skin)
Duodenal Fistula (Duodenal fistula)
Duodenal Hemorrhage (Duodenal
hemorrhage)
Duodenal Infection (Duodenal infection)
Duodenal Obstruction (Duodenal
obstruction)
Duodenal Perforation (Duodenal
perforation)
Duodenal Stenosis (Duodenal stenosis)
Duodenal Ulcer (Duodenal ulcer)
Dysarthria (Dysarthria)
Dysesthesia (Dysesthesia)
Dysgeusia (Dysgeusia)
Dysmenorrhea (Dysmenorrhea)
Dyspareunia (Dyspareunia)
Dyspepsia (Dyspepsia)
Dysphagia (Dysphagia)
Dysphasia (Dysphasia)
Dyspnea (Dyspnea)
Ear And Labyrinth Disorders - Other,
Specify (Ear and labyrinth disorders -
Other, Specify)
Ear Pain (Ear pain)
Edema Cerebral (Edema cerebral)
Edema Face (Edema face)
Edema Limbs (Edema limbs)
Edema Trunk (Edema trunk)
Ejaculation Disorder (Ejaculation
disorder)
Ejection Fraction Decreased (Ejection
fraction decreased)
Electrocardiogram Qt Corrected Interval
Prolonged (Electrocardiogram QT
corrected interval prolonged)
Encephalitis Infection (Encephalitis
infection)
Encephalomyelitis Infection
(Encephalomyelitis infection)
Encephalopathy (Encephalopathy)
Endocarditis Infective (Endocarditis
infective)
Endocrine Disorders - Other, Specify
(Endocrine disorders - Other, Specify)
Endophthalmitis (Endophthalmitis)
Enterocolitis (Enterocolitis)
Enterocolitis Infectious (Enterocolitis
infectious)
Enterovesical Fistula (Enterovesical
fistula)
Epistaxis (Epistaxis)
Erectile Dysfunction (Erectile
dysfunction)
Erythema Multiforme (Erythema
multiforme)
Erythroderma (Erythroderma)
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Esophageal Anastomotic Leak
(Esophageal anastomotic leak)
Esophageal Fistula (Esophageal fistula)
Esophageal Hemorrhage (Esophageal
hemorrhage)
Esophageal Infection (Esophageal
infection)
Esophageal Necrosis (Esophageal
necrosis)
Esophageal Obstruction (Esophageal
obstruction)
Esophageal Pain (Esophageal pain)
Esophageal Perforation (Esophageal
perforation)
Esophageal Stenosis (Esophageal
stenosis)
Esophageal Ulcer (Esophageal ulcer)
Esophageal Varices Hemorrhage
(Esophageal varices hemorrhage)
Esophagitis (Esophagitis)
Euphoria (Euphoria)
Exostosis (Exostosis)
External Ear Inflammation (External ear
inflammation)
External Ear Pain (External ear pain)
Extraocular Muscle Paresis (Extraocular
muscle paresis)
Extrapyramidal Disorder (Extrapyramidal
disorder)
Eye Disorders - Other, Specify (Eye
disorders - Other, Specify)
Eye Infection (Eye infection)
Eye Pain (Eye pain)
Eyelid Function Disorder (Eyelid function
disorder)
Facial Muscle Weakness (Facial muscle
weakness)
Facial Nerve Disorder (Facial nerve
disorder)
Facial Pain (Facial pain)
Fall (Fall)
Fallopian Tube Anastomotic Leak
(Fallopian tube anastomotic leak)
Fallopian Tube Obstruction (Fallopian
tube obstruction)
Fallopian Tube Perforation (Fallopian
tube perforation)
Fallopian Tube Stenosis (Fallopian tube
stenosis)
Fat Atrophy (Fat atrophy)
Fatigue (Fatigue)
Febrile Neutropenia (Febrile
neutropenia)
Fecal Incontinence (Fecal incontinence)
Female Genital Tract Fistula (Female
genital tract fistula)
Feminization Acquired (Feminization
acquired)
Fetal Death (Fetal death)
Fetal Growth Retardation (Fetal growth
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retardation)
Fever (Fever)
Fibrinogen Decreased (Fibrinogen
decreased)
Fibrosis Deep Connective Tissue
(Fibrosis deep connective tissue)
Flank Pain (Flank pain)
Flashing Lights (Flashing lights)
Flatulence (Flatulence)
Floaters (Floaters)
Flu Like Symptoms (Flu like symptoms)
Flushing (Flushing)
Forced Expiratory Volume Decreased
(Forced expiratory volume decreased)
Fracture (Fracture)
Gait Disturbance (Gait disturbance)
Gallbladder Fistula (Gallbladder fistula)
Gallbladder Infection (Gallbladder
infection)
Gallbladder Necrosis (Gallbladder
necrosis)
Gallbladder Obstruction (Gallbladder
obstruction)
Gallbladder Pain (Gallbladder pain)
Gallbladder Perforation (Gallbladder
perforation)
Gastric Anastomotic Leak (Gastric
anastomotic leak)
Gastric Fistula (Gastric fistula)
Gastric Hemorrhage (Gastric
hemorrhage)
Gastric Necrosis (Gastric necrosis)
Gastric Perforation (Gastric perforation)
Gastric Stenosis (Gastric stenosis)
Gastric Ulcer (Gastric ulcer)
Gastritis (Gastritis)
Gastroesophageal Reflux Disease
(Gastroesophageal reflux disease)
Gastrointestinal Anastomotic Leak
(Gastrointestinal anastomotic leak)
Gastrointestinal Disorders - Other,
Specify (Gastrointestinal disorders -
Other, Specify)
Gastrointestinal Fistula (Gastrointestinal
fistula)
Gastrointestinal Pain (Gastrointestinal
pain)
Gastrointestinal Stoma Necrosis
(Gastrointestinal stoma necrosis)
Gastroparesis (Gastroparesis)
General Disorders And Administration
Site Conditions - Other, Specify (General
disorders and administration site
conditions - Other, Specify)
Generalized Muscle Weakness
(Generalized muscle weakness)
Genital Edema (Genital edema)
Ggt Increased (GGT increased)
Gingival Pain (Gingival pain)
Glaucoma (Glaucoma)
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Glossopharyngeal Nerve Disorder
(Glossopharyngeal nerve disorder)
Glucose Intolerance (Glucose
intolerance)
Growth Accelerated (Growth
accelerated)
Growth Hormone Abnormal (Growth
hormone abnormal)
Growth Suppression (Growth
suppression)
Gum Infection (Gum infection)
Gynecomastia (Gynecomastia)
Hallucinations (Hallucinations)
Haptoglobin Decreased (Haptoglobin
decreased)
Head Soft Tissue Necrosis (Head soft
tissue necrosis)
Headache (Headache)
Hearing Impaired (Hearing impaired)
Heart Failure (Heart failure)
Hematoma (Hematoma)
Hematosalpinx (Hematosalpinx)
Hematuria (Hematuria)
Hemoglobin Increased (Hemoglobin
increased)
Hemoglobinuria (Hemoglobinuria)
Hemolysis (Hemolysis)
Hemolytic Uremic Syndrome (Hemolytic
uremic syndrome)
Hemorrhoidal Hemorrhage
(Hemorrhoidal hemorrhage)
Hemorrhoids (Hemorrhoids)
Hepatic Failure (Hepatic failure)
Hepatic Hemorrhage (Hepatic
hemorrhage)
Hepatic Infection (Hepatic infection)
Hepatic Necrosis (Hepatic necrosis)
Hepatic Pain (Hepatic pain)
Hepatitis Viral (Hepatitis viral)
Hepatobiliary Disorders - Other, Specify
(Hepatobiliary disorders - Other, Specify)
Hiccups (Hiccups)
Hip Fracture (Hip fracture)
Hirsutism (Hirsutism)
Hoarseness (Hoarseness)
Hot Flashes (Hot flashes)
Hydrocephalus (Hydrocephalus)
Hypercalcemia (Hypercalcemia)
Hyperglycemia (Hyperglycemia)
Hyperhidrosis (Hyperhidrosis)
Hyperkalemia (Hyperkalemia)
Hypermagnesemia (Hypermagnesemia)
Hypernatremia (Hypernatremia)
Hyperparathyroidism
(Hyperparathyroidism)
Hypersomnia (Hypersomnia)
Hypertension (Hypertension)
Hyperthyroidism (Hyperthyroidism)
Hypertrichosis (Hypertrichosis)
Hypertriglyceridemia
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(Hypertriglyceridemia)
Hyperuricemia (Hyperuricemia)
Hypoalbuminemia (Hypoalbuminemia)
Hypocalcemia (Hypocalcemia)
Hypoglossal Nerve Disorder
(Hypoglossal nerve disorder)
Hypoglycemia (Hypoglycemia)
Hypohidrosis (Hypohidrosis)
Hypokalemia (Hypokalemia)
Hypomagnesemia (Hypomagnesemia)
Hyponatremia (Hyponatremia)
Hypoparathyroidism
(Hypoparathyroidism)
Hypophosphatemia (Hypophosphatemia)
Hypotension (Hypotension)
Hypothermia (Hypothermia)
Hypothyroidism (Hypothyroidism)
Hypoxia (Hypoxia)
Ileal Fistula (Ileal fistula)
Ileal Hemorrhage (Ileal hemorrhage)
Ileal Obstruction (Ileal obstruction)
Ileal Perforation (Ileal perforation)
Ileal Stenosis (Ileal stenosis)
Ileal Ulcer (Ileal ulcer)
Ileus (Ileus)
Immune System Disorders - Other,
Specify (Immune system disorders -
Other, Specify)
Infections And Infestations - Other,
Specify (Infections and infestations -
Other, Specify)
Infective Myositis (Infective myositis)
Infusion Related Reaction (Infusion
related reaction)
Infusion Site Extravasation (Infusion site
extravasation)
Injection Site Reaction (Injection site
reaction)
Injury To Carotid Artery (Injury to carotid
artery)
Injury To Inferior Vena Cava (Injury to
inferior vena cava)
Injury To Jugular Vein (Injury to jugular
vein)
Injury To Superior Vena Cava (Injury to
superior vena cava)
Injury, Poisoning And Procedural
Complications - Other, Specify (Injury,
poisoning and procedural complications -
Other, Specify)
Inr Increased (INR increased)
Insomnia (Insomnia)
Intestinal Stoma Leak (Intestinal stoma
leak)
Intestinal Stoma Obstruction (Intestinal
stoma obstruction)
Intestinal Stoma Site Bleeding (Intestinal
stoma site bleeding)
Intra-abdominal Hemorrhage (Intra-
abdominal hemorrhage)
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Intracranial Hemorrhage (Intracranial
hemorrhage)
Intraoperative Arterial Injury
(Intraoperative arterial injury)
Intraoperative Breast Injury
(Intraoperative breast injury)
Intraoperative Cardiac Injury
(Intraoperative cardiac injury)
Intraoperative Ear Injury (Intraoperative
ear injury)
Intraoperative Endocrine Injury
(Intraoperative endocrine injury)
Intraoperative Gastrointestinal Injury
(Intraoperative gastrointestinal injury)
Intraoperative Head And Neck Injury
(Intraoperative head and neck injury)
Intraoperative Hemorrhage
(Intraoperative hemorrhage)
Intraoperative Hepatobiliary Injury
(Intraoperative hepatobiliary injury)
Intraoperative Musculoskeletal Injury
(Intraoperative musculoskeletal injury)
Intraoperative Neurological Injury
(Intraoperative neurological injury)
Intraoperative Ocular Injury
(Intraoperative ocular injury)
Intraoperative Renal Injury
(Intraoperative renal injury)
Intraoperative Reproductive Tract Injury
(Intraoperative reproductive tract injury)
Intraoperative Respiratory Injury
(Intraoperative respiratory injury)
Intraoperative Skin Injury (Intraoperative
skin injury)
Intraoperative Splenic Injury
(Intraoperative splenic injury)
Intraoperative Urinary Injury
(Intraoperative urinary injury)
Intraoperative Venous Injury
(Intraoperative venous injury)
Investigations - Other, Specify
(Investigations - Other, Specify)
Iron Overload (Iron overload)
Irregular Menstruation (Irregular
menstruation)
Irritability (Irritability)
Ischemia Cerebrovascular (Ischemia
cerebrovascular)
Ivth Nerve Disorder (IVth nerve disorder)
Jejunal Fistula (Jejunal fistula)
Jejunal Hemorrhage (Jejunal
hemorrhage)
Jejunal Obstruction (Jejunal obstruction)
Jejunal Perforation (Jejunal perforation)
Jejunal Stenosis (Jejunal stenosis)
Jejunal Ulcer (Jejunal ulcer)
Joint Effusion (Joint effusion)
Joint Infection (Joint infection)
Joint Range Of Motion Decreased (Joint
range of motion decreased)
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Joint Range Of Motion Decreased
Cervical Spine (Joint range of motion
decreased cervical spine)
Joint Range Of Motion Decreased
Lumbar Spine (Joint range of motion
decreased lumbar spine)
Keratitis (Keratitis)
Kidney Anastomotic Leak (Kidney
anastomotic leak)
Kidney Infection (Kidney infection)
Kyphosis (Kyphosis)
Lactation Disorder (Lactation disorder)
Large Intestinal Anastomotic Leak (Large
intestinal anastomotic leak)
Laryngeal Edema (Laryngeal edema)
Laryngeal Fistula (Laryngeal fistula)
Laryngeal Hemorrhage (Laryngeal
hemorrhage)
Laryngeal Inflammation (Laryngeal
inflammation)
Laryngeal Mucositis (Laryngeal
mucositis)
Laryngeal Obstruction (Laryngeal
obstruction)
Laryngeal Stenosis (Laryngeal stenosis)
Laryngitis (Laryngitis)
Laryngopharyngeal Dysesthesia
(Laryngopharyngeal dysesthesia)
Laryngospasm (Laryngospasm)
Left Ventricular Systolic Dysfunction (Left
ventricular systolic dysfunction)
Lethargy (Lethargy)
Leukemia Secondary To Oncology
Chemotherapy (Leukemia secondary to
oncology chemotherapy)
Leukocytosis (Leukocytosis)
Leukoencephalopathy
(Leukoencephalopathy)
Libido Decreased (Libido decreased)
Libido Increased (Libido increased)
Lip Infection (Lip infection)
Lip Pain (Lip pain)
Lipase Increased (Lipase increased)
Lipohypertrophy (Lipohypertrophy)
Localized Edema (Localized edema)
Lordosis (Lordosis)
Lower Gastrointestinal Hemorrhage
(Lower gastrointestinal hemorrhage)
Lung Infection (Lung infection)
Lymph Gland Infection (Lymph gland
infection)
Lymph Leakage (Lymph leakage)
Lymph Node Pain (Lymph node pain)
Lymphedema (Lymphedema)
Lymphocele (Lymphocele)
Lymphocyte Count Decreased
(Lymphocyte count decreased)
Lymphocyte Count Increased
(Lymphocyte count increased)
Malabsorption (Malabsorption)
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Malaise (Malaise)
Mania (Mania)
Mediastinal Hemorrhage (Mediastinal
hemorrhage)
Mediastinal Infection (Mediastinal
infection)
Memory Impairment (Memory
impairment)
Meningismus (Meningismus)
Meningitis (Meningitis)
Menopause (Menopause)
Menorrhagia (Menorrhagia)
Metabolism And Nutrition Disorders -
Other, Specify (Metabolism and nutrition
disorders - Other, Specify)
Middle Ear Inflammation (Middle ear
inflammation)
Mitral Valve Disease (Mitral valve
disease)
Mobitz (type) Ii Atrioventricular Block
(Mobitz (type) II atrioventricular block)
Mobitz Type I (Mobitz type I)
Movements Involuntary (Movements
involuntary)
Mucosal Infection (Mucosal infection)
Mucositis Oral (Mucositis oral)
Multi-organ Failure (Multi-organ failure)
Muscle Weakness Left-sided (Muscle
weakness left-sided)
Muscle Weakness Lower Limb (Muscle
weakness lower limb)
Muscle Weakness Right-sided (Muscle
weakness right-sided)
Muscle Weakness Trunk (Muscle
weakness trunk)
Muscle Weakness Upper Limb (Muscle
weakness upper limb)
Musculoskeletal And Connective Tissue
Disorder - Other, Specify
(Musculoskeletal and connective tissue
disorders - Other, Specify)
Musculoskeletal Deformity
(Musculoskeletal deformity)
Myalgia (Myalgia)
Myelitis (Myelitis)
Myelodysplastic Syndrome
(Myelodysplastic syndrome)
Myocardial Infarction (Myocardial
infarction)
Myocarditis (Myocarditis)
Myositis (Myositis)
Nail Discoloration (Nail discoloration)
Nail Infection (Nail infection)
Nail Loss (Nail loss)
Nail Ridging (Nail ridging)
Nasal Congestion (Nasal congestion)
Nausea (Nausea)
Neck Edema (Neck edema)
Neck Pain (Neck pain)
Neck Soft Tissue Necrosis (Neck soft
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tissue necrosis)
Neoplasms Benign, Malignant And
Unspecified (incl Cysts And Polyps) -
Other, Specify (Neoplasms benign,
malignant and unspecified (incl cysts and
polyps) - Other, Specify)
Nervous System Disorders - Other,
Specify (Nervous system disorders -
Other, Specify)
Neuralgia (Neuralgia)
Neutrophil Count Decreased (Neutrophil
count decreased)
Night Blindness (Night blindness)
Nipple Deformity (Nipple deformity)
Non-cardiac Chest Pain (Non-cardiac
chest pain)
Nystagmus (Nystagmus)
Obesity (Obesity)
Obstruction Gastric (Obstruction gastric)
Oculomotor Nerve Disorder (Oculomotor
nerve disorder)
Olfactory Nerve Disorder (Olfactory
nerve disorder)
Oligospermia (Oligospermia)
Optic Nerve Disorder (Optic nerve
disorder)
Oral Cavity Fistula (Oral cavity fistula)
Oral Dysesthesia (Oral dysesthesia)
Oral Hemorrhage (Oral hemorrhage)
Oral Pain (Oral pain)
Osteonecrosis Of Jaw (Osteonecrosis of
jaw)
Osteoporosis (Osteoporosis)
Otitis Externa (Otitis externa)
Otitis Media (Otitis media)
Ovarian Hemorrhage (Ovarian
hemorrhage)
Ovarian Infection (Ovarian infection)
Ovarian Rupture (Ovarian rupture)
Ovulation Pain (Ovulation pain)
Pain (Pain)
Pain In Extremity (Pain in extremity)
Pain Of Skin (Pain of skin)
Palmar-plantar Erythrodysesthesia
Syndrome (Palmar-plantar
erythrodysesthesia syndrome)
Palpitations (Palpitations)
Pancreas Infection (Pancreas infection)
Pancreatic Anastomotic Leak (Pancreatic
anastomotic leak)
Pancreatic Duct Stenosis (Pancreatic
duct stenosis)
Pancreatic Enzymes Decreased
(Pancreatic enzymes decreased)
Pancreatic Fistula (Pancreatic fistula)
Pancreatic Hemorrhage (Pancreatic
hemorrhage)
Pancreatic Necrosis (Pancreatic
necrosis)
Pancreatitis (Pancreatitis)
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Papilledema (Papilledema)
Papulopustular Rash (Papulopustular
rash)
Paresthesia (Paresthesia)
Paronychia (Paronychia)
Paroxysmal Atrial Tachycardia
(Paroxysmal atrial tachycardia)
Pelvic Floor Muscle Weakness (Pelvic
floor muscle weakness)
Pelvic Infection (Pelvic infection)
Pelvic Pain (Pelvic pain)
Pelvic Soft Tissue Necrosis (Pelvic soft
tissue necrosis)
Penile Infection (Penile infection)
Penile Pain (Penile pain)
Perforation Bile Duct (Perforation bile
duct)
Pericardial Effusion (Pericardial effusion)
Pericardial Tamponade (Pericardial
tamponade)
Pericarditis (Pericarditis)
Perineal Pain (Perineal pain)
Periodontal Disease (Periodontal
disease)
Periorbital Edema (Periorbital edema)
Periorbital Infection (Periorbital infection)
Peripheral Ischemia (Peripheral
ischemia)
Peripheral Motor Neuropathy (Peripheral
motor neuropathy)
Peripheral Nerve Infection (Peripheral
nerve infection)
Peripheral Sensory Neuropathy
(Peripheral sensory neuropathy)
Peritoneal Infection (Peritoneal infection)
Peritoneal Necrosis (Peritoneal necrosis)
Personality Change (Personality change)
Phantom Pain (Phantom pain)
Pharyngeal Anastomotic Leak
(Pharyngeal anastomotic leak)
Pharyngeal Fistula (Pharyngeal fistula)
Pharyngeal Hemorrhage (Pharyngeal
hemorrhage)
Pharyngeal Mucositis (Pharyngeal
mucositis)
Pharyngeal Necrosis (Pharyngeal
necrosis)
Pharyngeal Stenosis (Pharyngeal
stenosis)
Pharyngitis (Pharyngitis)
Pharyngolaryngeal Pain
(Pharyngolaryngeal pain)
Phlebitis (Phlebitis)
Phlebitis Infective (Phlebitis infective)
Photophobia (Photophobia)
Photosensitivity (Photosensitivity)
Platelet Count Decreased (Platelet count
decreased)
Pleural Effusion (Pleural effusion)
Pleural Hemorrhage (Pleural
14 / 21
CALGB 50901 Adverse Event Form NCT01190449
hemorrhage)
Pleural Infection (Pleural infection)
Pleuritic Pain (Pleuritic pain)
Pneumonitis (Pneumonitis)
Pneumothorax (Pneumothorax)
Portal Hypertension (Portal
hypertension)
Portal Vein Thrombosis (Portal vein
thrombosis)
Postnasal Drip (Postnasal drip)
Postoperative Hemorrhage
(Postoperative hemorrhage)
Postoperative Thoracic Procedure
Complication (Postoperative thoracic
procedure complication)
Precocious Puberty (Precocious
puberty)
Pregnancy, Puerperium And Perinatal
Conditions - Other, Specify (Pregnancy,
puerperium and perinatal conditions -
Other, Specify)
Premature Delivery (Premature delivery)
Premature Menopause (Premature
menopause)
Presyncope (Presyncope)
Proctitis (Proctitis)
Productive Cough (Productive cough)
Prolapse Of Intestinal Stoma (Prolapse
of intestinal stoma)
Prolapse Of Urostomy (Prolapse of
urostomy)
Prostate Infection (Prostate infection)
Prostatic Hemorrhage (Prostatic
hemorrhage)
Prostatic Obstruction (Prostatic
obstruction)
Prostatic Pain (Prostatic pain)
Proteinuria (Proteinuria)
Pruritus (Pruritus)
Psychiatric Disorders - Other, Specify
(Psychiatric disorders - Other, Specify)
Psychosis (Psychosis)
Pulmonary Edema (Pulmonary edema)
Pulmonary Fibrosis (Pulmonary fibrosis)
Pulmonary Fistula (Pulmonary fistula)
Pulmonary Hypertension (Pulmonary
hypertension)
Pulmonary Valve Disease (Pulmonary
valve disease)
Purpura (Purpura)
Pyramidal Tract Syndrome (Pyramidal
tract syndrome)
Radiation Recall Reaction (dermatologic)
(Radiation recall reaction (dermatologic))
Radiculitis (Radiculitis)
Rash Acneiform (Rash acneiform)
Rash Maculo-papular (Rash maculo-
papular)
Rash Pustular (Rash pustular)
Rectal Anastomotic Leak (Rectal
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anastomotic leak)
Rectal Fistula (Rectal fistula)
Rectal Hemorrhage (Rectal hemorrhage)
Rectal Mucositis (Rectal mucositis)
Rectal Necrosis (Rectal necrosis)
Rectal Obstruction (Rectal obstruction)
Rectal Pain (Rectal pain)
Rectal Perforation (Rectal perforation)
Rectal Stenosis (Rectal stenosis)
Rectal Ulcer (Rectal ulcer)
Recurrent Laryngeal Nerve Palsy
(Recurrent laryngeal nerve palsy)
Renal And Urinary Disorders - Other,
Specify (Renal and urinary disorders -
Other, Specify)
Renal Calculi (Renal calculi)
Renal Colic (Renal colic)
Renal Hemorrhage (Renal hemorrhage)
Reproductive System And Breast
Disorders - Other, Specify (Reproductive
system and breast disorders - Other,
Specify)
Respiratory Failure (Respiratory failure)
Respiratory, Thoracic And Mediastinal
Disorders - Other, Specify (Respiratory,
thoracic and mediastinal disorders -
Other, Specify)
Restlessness (Restlessness)
Restrictive Cardiomyopathy (Restrictive
cardiomyopathy)
Retinal Detachment (Retinal
detachment)
Retinal Tear (Retinal tear)
Retinal Vascular Disorder (Retinal
vascular disorder)
Retinoic Acid Syndrome (Retinoic acid
syndrome)
Retinopathy (Retinopathy)
Retroperitoneal Hemorrhage
(Retroperitoneal hemorrhage)
Reversible Posterior
Leukoencephalopathy Syndrome
(Reversible posterior
leukoencephalopathy syndrome)
Rhinitis Infective (Rhinitis infective)
Right Ventricular Dysfunction (Right
ventricular dysfunction)
Salivary Duct Inflammation (Salivary duct
inflammation)
Salivary Gland Fistula (Salivary gland
fistula)
Salivary Gland Infection (Salivary gland
infection)
Scalp Pain (Scalp pain)
Scleral Disorder (Scleral disorder)
Scoliosis (Scoliosis)
Scrotal Infection (Scrotal infection)
Scrotal Pain (Scrotal pain)
Seizure (Seizure)
Sepsis (Sepsis)
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Seroma (Seroma)
Serum Amylase Increased (Serum
amylase increased)
Serum Sickness (Serum sickness)
Sick Sinus Syndrome (Sick sinus
syndrome)
Sinus Bradycardia (Sinus bradycardia)
Sinus Disorder (Sinus disorder)
Sinus Pain (Sinus pain)
Sinus Tachycardia (Sinus tachycardia)
Sinusitis (Sinusitis)
Skin And Subcutaneous Tissue
Disorders - Other, Specify (Skin and
subcutaneous tissue disorders - Other,
Specify)
Skin Atrophy (Skin atrophy)
Skin Hyperpigmentation (Skin
hyperpigmentation)
Skin Hypopigmentation (Skin
hypopigmentation)
Skin Induration (Skin induration)
Skin Infection (Skin infection)
Skin Ulceration (Skin ulceration)
Sleep Apnea (Sleep apnea)
Small Intestinal Anastomotic Leak (Small
intestinal anastomotic leak)
Small Intestinal Mucositis (Small
intestinal mucositis)
Small Intestinal Obstruction (Small
intestinal obstruction)
Small Intestinal Perforation (Small
intestinal perforation)
Small Intestinal Stenosis (Small intestinal
stenosis)
Small Intestine Infection (Small intestine
infection)
Small Intestine Ulcer (Small intestine
ulcer)
Sneezing (Sneezing)
Social Circumstances - Other, Specify
(Social circumstances - Other, Specify)
Soft Tissue Infection (Soft tissue
infection)
Soft Tissue Necrosis Lower Limb (Soft
tissue necrosis lower limb)
Soft Tissue Necrosis Upper Limb (Soft
tissue necrosis upper limb)
Somnolence (Somnolence)
Sore Throat (Sore throat)
Spasticity (Spasticity)
Spermatic Cord Anastomotic Leak
(Spermatic cord anastomotic leak)
Spermatic Cord Hemorrhage (Spermatic
cord hemorrhage)
Spermatic Cord Obstruction (Spermatic
cord obstruction)
Spinal Fracture (Spinal fracture)
Spleen Disorder (Spleen disorder)
Splenic Infection (Splenic infection)
Stenosis Of Gastrointestinal Stoma
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(Stenosis of gastrointestinal stoma)
Stevens-johnson Syndrome (Stevens-
Johnson syndrome)
Stoma Site Infection (Stoma site
infection)
Stomach Pain (Stomach pain)
Stomal Ulcer (Stomal ulcer)
Stridor (Stridor)
Stroke (Stroke)
Sudden Death Nos (Sudden death NOS)
Suicidal Ideation (Suicidal ideation)
Suicide Attempt (Suicide attempt)
Superficial Soft Tissue Fibrosis
(Superficial soft tissue fibrosis)
Superficial Thrombophlebitis (Superficial
thrombophlebitis)
Superior Vena Cava Syndrome (Superior
vena cava syndrome)
Supraventricular Tachycardia
(Supraventricular tachycardia)
Surgical And Medical Procedures -
Other, Specify (Surgical and medical
procedures - Other, Specify)
Syncope (Syncope)
Telangiectasia (Telangiectasia)
Testicular Disorder (Testicular disorder)
Testicular Hemorrhage (Testicular
hemorrhage)
Testicular Pain (Testicular pain)
Thromboembolic Event
(Thromboembolic event)
Thrombotic Thrombocytopenic Purpura
(Thrombotic thrombocytopenic purpura)
Tinnitus (Tinnitus)
Tooth Development Disorder (Tooth
development disorder)
Tooth Discoloration (Tooth discoloration)
Tooth Infection (Tooth infection)
Toothache (Toothache)
Toxic Epidermal Necrolysis (Toxic
epidermal necrolysis)
Tracheal Fistula (Tracheal fistula)
Tracheal Hemorrhage (Tracheal
hemorrhage)
Tracheal Mucositis (Tracheal mucositis)
Tracheal Obstruction (Tracheal
obstruction)
Tracheal Stenosis (Tracheal stenosis)
Tracheitis (Tracheitis)
Tracheostomy Site Bleeding
(Tracheostomy site bleeding)
Transient Ischemic Attacks (Transient
ischemic attacks)
Treatment Related Secondary
Malignancy (Treatment related
secondary malignancy)
Tremor (Tremor)
Tricuspid Valve Disease (Tricuspid valve
disease)
Trigeminal Nerve Disorder (Trigeminal
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nerve disorder)
Trismus (Trismus)
Tumor Lysis Syndrome (Tumor lysis
syndrome)
Tumor Pain (Tumor pain)
Typhlitis (Typhlitis)
Unequal Limb Length (Unequal limb
length)
Unintended Pregnancy (Unintended
pregnancy)
Upper Gastrointestinal Hemorrhage
(Upper gastrointestinal hemorrhage)
Upper Respiratory Infection (Upper
respiratory infection)
Ureteric Anastomotic Leak (Ureteric
anastomotic leak)
Urethral Anastomotic Leak (Urethral
anastomotic leak)
Urethral Infection (Urethral infection)
Urinary Fistula (Urinary fistula)
Urinary Frequency (Urinary frequency)
Urinary Incontinence (Urinary
incontinence)
Urinary Retention (Urinary retention)
Urinary Tract Infection (Urinary tract
infection)
Urinary Tract Obstruction (Urinary tract
obstruction)
Urinary Tract Pain (Urinary tract pain)
Urinary Urgency (Urinary urgency)
Urine Discoloration (Urine discoloration)
Urine Output Decreased (Urine output
decreased)
Urostomy Leak (Urostomy leak)
Urostomy Obstruction (Urostomy
obstruction)
Urostomy Site Bleeding (Urostomy site
bleeding)
Urostomy Stenosis (Urostomy stenosis)
Urticaria (Urticaria)
Uterine Anastomotic Leak (Uterine
anastomotic leak)
Uterine Fistula (Uterine fistula)
Uterine Hemorrhage (Uterine
hemorrhage)
Uterine Infection (Uterine infection)
Uterine Obstruction (Uterine obstruction)
Uterine Pain (Uterine pain)
Uterine Perforation (Uterine perforation)
Uveitis (Uveitis)
Vaginal Anastomotic Leak (Vaginal
anastomotic leak)
Vaginal Discharge (Vaginal discharge)
Vaginal Dryness (Vaginal dryness)
Vaginal Fistula (Vaginal fistula)
Vaginal Hemorrhage (Vaginal
hemorrhage)
Vaginal Infection (Vaginal infection)
Vaginal Inflammation (Vaginal
inflammation)
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Vaginal Obstruction (Vaginal obstruction)
Vaginal Pain (Vaginal pain)
Vaginal Perforation (Vaginal perforation)
Vaginal Stricture (Vaginal stricture)
Vaginismus (Vaginismus)
Vagus Nerve Disorder (Vagus nerve
disorder)
Vas Deferens Anastomotic Leak (Vas
deferens anastomotic leak)
Vascular Access Complication (Vascular
access complication)
Vascular Disorders - Other, Specify
(Vascular disorders - Other, Specify)
Vasculitis (Vasculitis)
Vasovagal Reaction (Vasovagal reaction)
Venous Injury (Venous injury)
Ventricular Arrhythmia (Ventricular
arrhythmia)
Ventricular Fibrillation (Ventricular
fibrillation)
Ventricular Tachycardia (Ventricular
tachycardia)
Vertigo (Vertigo)
Vestibular Disorder (Vestibular disorder)
Virilization (Virilization)
Visceral Arterial Ischemia (Visceral
arterial ischemia)
Vital Capacity Abnormal (Vital capacity
abnormal)
Vitreous Hemorrhage (Vitreous
hemorrhage)
Voice Alteration (Voice alteration)
Vomiting (Vomiting)
Vulval Infection (Vulval infection)
Watering Eyes (Watering eyes)
Weight Gain (Weight gain)
Weight Loss (Weight loss)
Wheezing (Wheezing)
White Blood Cell Decreased (White
blood cell decreased)
Wolff-parkinson-white Syndrome (Wolff-
Parkinson-White syndrome)
Wound Complication (Wound
complication)
Wound Dehiscence (Wound dehiscence)
Wound Infection (Wound infection)
Wrist Fracture (Wrist fracture)
CTC AE Grade
Absent Adverse Event (0)
Mild Adverse Event (1)
Moderate Adverse Event (2)
Severe Adverse Event (3)
Life Threatening Adverse Event (4)
Death Related To Adverse Event (5)
CTC AE Attribution Code
Definite (Definite)
Possible (Possible)
Probable (Probable)
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Unlikely (Unlikely)
Unrelated (Unrelated)
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Z1041: Tumor Measurement Report (TMR)
NCT00513292
Z1041: Tumor Measurement Report (TMR) NCT00513292
Combination Chemotherapy and Paclitaxel Plus
Trastuzumab in Treating Women With Palpable Breast
Cancer That Can Be Removed by Surgery
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=214B3C72-
1BE1-3F2B-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11180
Z1041: Tumor Measurement Report
(TMR) NCT00513292
Header Module
Visit
C1d21 (C1D21)
C2d21 (C2D21)
C3d21 (C3D21)
C4d21 (C4D21)
C5d21 (C5D21)
C6d21 (C6D21)
C7d21 (C7D21)
C8d21 (C8D21)
Unscheduled (Unscheduled)
Date
Patient Study ID
Patient Initials
Institution No.
Institution Name
Header
Was a tumor assessment performed at this visit
(for target lesions?)
Yes
No
Date of Evaluation
Lesion Number
Organ
Axilla (Axilla)
Target Lesion Site (Describe specific location)
Longest Diameter of Lesion(s) (cm)
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Header
TARGET LESIONS
Sum of Longest Diameters of All Target Lesions
(Sum of both breast and axilla target lesions -
cm)
Baseline sum of the longest diameter (cm)
Percent change ([Current - Baseline/Baseline] X
100)
Percent change
% Decrease (% decrease)
% Increase (% increase)
Smallest previous sum of the longest diameter
(cm)
Percent change ([Current - Smallest previous
sum/Smallest previous sum] X 100)
Percent change
% Decrease (% decrease)
% Increase (% increase)
Non-target Lesions
Was an assessment performed for non-target
lesions at this visit?
Yes
No
Are there any nontarget lesions?
Yes
No
Organ
Ascites (Ascites)
Bone (Bone)
Brain (Brain)
Breast (Breast)
Cervix Uteri (Cervix)
Fallopian Tube (Fallopian tube)
Gastrointestinal Tract (GI)
Genitourinary (GU)
Head And Neck (Head and Neck)
Liver (Liver)
Lung (Lung)
Lymph Node (Lymph node)
Other (Other)
Soft Tissue (Other soft tissue)
2 / 4
Z1041: Tumor Measurement Report (TMR) NCT00513292
Ovary (Ovary)
Peritoneum (Peritoneum)
Pleural/pericardial Effusion
(Pleural/pericardial effusion)
Skin (Skin)
Uterus (Uterus)
Nontarget Lesion Site (Describe specific location)
Method of Evaluation
Ct Scan (CT scan)
Mri Scan (MRI scan)
Other (Other)
Physical Exam (Physical exam)
Spiral Ct Scan (Spiral CT scan)
Ultrasound (Ultrasound)
X-ray (X-ray)
Lesion status
Absent (Absent)
New (New)
Present (Present)
Progressive Disease (Progressive)
Was the non-target lesion identified on the
baseline evaluation
Yes
No
Has the patient been diagnosed with a distant
metastatic progression that has not been
previously reported
Yes
No
Follow-up Status Of Target Lesions
Target Lesion Response Status
Not Applicable (NA)
Target Lesion Response Status
Complete Response (Complete
Response)
Partial Response (Partial Response)
Progressive Disease (Progressive
Disease)
Stable Disease (Stable Disease)
Non-Target Lesion Response Status
Not Applicable (NA)
Non-Target Lesion Response Status
Complete Response (Complete
Response)
Incomplete Response/sd (Incomplete
Response/SD)
Progressive Disease (Progressive
Disease)
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Overall Response
Not Applicable (NA)
Overall Response Status at This Assessment
Complete Response (CR)
Insufficient Evaluation (Insufficient
evaluation to determine response status)
Progressive Disease (PD)
Partial Response (PR)
Stable Disease (SD)
Footer
Completed by
Date Form Completed
Comments
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Z1041: Axillary Surgery Report Form
NCT00513292
Z1041: Axillary Surgery Report Form NCT00513292
Combination Chemotherapy and Paclitaxel Plus
Trastuzumab in Treating Women With Palpable Breast
Cancer That Can Be Removed by Surgery
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=20CEC788-
35ED-51B6-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11181
Z1041: Axillary Surgery Report Form
NCT00513292
Patient demographics
Visit
Surgery (Surgery)
Patient ID (Pt. ID issued during registration or
previously issued patient ID)
Patient Initials (F M L)
Institution No.
Institution Name
Axillary Surgical Procedures (slnd/alnd)
Was sentinel node sampling performed
Yes
No
Sentinel Node Biopsy Date
Number of Sentinel Nodes Examined
Number of Positive Sentinel Nodes by H&E
Was axillary dissection performed?
Yes
No
Date of Axillary Dissection
Total number of axillary lymph nodes examined
(Do not include previously counted sentinel
nodes for either the total number excised of for
the number of positive nodes.)
Number of positive axillary nodes by H&E
1 / 2
Axilla Pathologic Response (NOTE: Refer to
Protocol Section 7.6.2)
Not Applicable (Not Applicable)
Not Pathologic Complete Response (Not
Pathologic Complete Response)
Pathologic Complete Response
(Pathologic Complete Response)
Completed by
Date Form Completed
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Z1041: Study Drug Completion - FEC-
75/Paclitaxel (SDCFP) NCT00513292
Z1041: Study Drug Completion - FEC-75/Paclitaxel
(SDCFP) NCT00513292
Combination Chemotherapy and Paclitaxel Plus
Trastuzumab in Treating Women With Palpable Breast
Cancer That Can Be Removed by Surgery
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=20FE4AE7-
E041-0F11-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11182
Z1041: Study Drug Completion -
FEC-75/Paclitaxel (SDCFP)
NCT00513292
Header Module
Visit
C1d21 (C1D21)
C2d21 (C2D21)
C3d21 (C3D21)
C4d21 (C4D21)
C5d21 (C5D21)
C6d21 (C6D21)
C7d21 (C7D21)
C8d21 (C8D21)
Unscheduled (Unscheduled)
Date
Patient ID
Patient Initials
Institution No.
Institution Name
Assessment Date
Assessment of Chemotherapy
Dose administered date
Agent Total Cumulative Dose (since last visit mg)
Agent name (FEC-75 was given, complete:)
Cyclophosphamide (Cyclophosphamide)
Epirubicin (Epirubicin)
Fluorouracil (Fluorouracil)
Agent name (FEC-75 was given, complete:)
Cyclophosphamide (Cyclophosphamide)
Epirubicin (Epirubicin)
Fluorouracil (Fluorouracil)
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Agent Total Dose (mg)
Were there any dose modifications or
additions/omissions to protocol treatment?
No (No)
Yes, Planned (i.e., The Treatment Was
Changed According To Protocol
Guidelines) (Yes, planned)
Yes, Unplanned (i.e., The Treatment
Change Was Not Part Of Protocol
Guidelines) (Yes, unplanned)
Dose Modification Reason (If yes, )
Cardiotoxicity (Cardiotoxicity)
Cns Toxicity (CNS toxicity)
Gi Toxicity (GI toxicity)
Hematologic Toxicity (Hematologic
toxicity)
Hepatic Dysfunction (Hepatic
dysfunction)
Infection/fever (Infection/fever)
Not Available (NA)
Other (Other)
Pulmonary Toxicity (Pulmonary toxicity)
Weight Change >= 4.5 Kg (Weight
Change >= 4.5 kg)
Other, specify
Completed by
Date Form Completed
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RTOG 0815 I1: Radiation Therapy Oncology Group Phase III Randomized Study of
Dose-Escalated Radiotherapy With/Without STAD for Intermediate-Risk Prostate
Cancer Initial Evaluation Form NCT00936390
RTOG 0815 I1: Radiation Therapy Oncology Group Phase
III Randomized Study of Dose-Escalated Radiotherapy
With/Without STAD for Intermediate-Risk Prostate Cancer
Initial Evaluation Form NCT00936390 
Radiation Therapy With or Without Androgen-Deprivation
Therapy in Treating Patients With Prostate Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=656A1892-
7AD2-3044-E040-BB89AD432827
All rights reserved. Please visit https://medical-data-
models.org/forms/11183
RTOG 0815 I1: Radiation Therapy
Oncology Group Phase III
Randomized Study of Dose-
Escalated Radiotherapy
With/Without STAD for Intermediate-
Risk Prostate Cancer Initial
Evaluation Form NCT00936390
RTOG clinical trial administrative data
RTOG Study No.
Case #
Institution Name
Institution No.
Patient Initials
RTOG Patient ID
Amended Data
Yes
No
Miscellaneous Patient Assessment
Performance Status (ZUBROD 0-4)
Fully Active, Able To Carry On All Pre-
disease Performance Without
Restriction. (0)
Restricted In Physically Strenuous
Activity But Ambulatory And Able To
Carry Out Work Of A Light Or Sedentary
Nature, E.g., Light Housework, Office
Work. (1)
Ambulatory And Capable Of All Selfcare
But Unable To Carry Out Any Work
Activities. Up And About More Than 50%
Of Waking Hours. (2)
Capable Of Only Limited Selfcare,
Confined To Bed Or Chair More Than
50% Of Waking Hours. (3)
Completely Disabled. Cannot Carry On
1 / 7
Any Selfcare. Totally Confined To Bed Or
Chair. (4)
History and physical/digital rectal
Yes
No
ACE 27 score
Date Performed
Has the patient had any prior cancer diagnosed
(invasive)
Yes
No
Prior malignancy site
Aml/mds (AML/MDS)
Bcc (BCC)
Bladder Is The Site Of Second Primary
Or Recurrent Tumor (bladder)
Brain Is The Site Of Second Primary Or
Recurrent Tumor (brain)
Colorectal (Colorectal)
Esophageal (Esophageal)
Gastric (Gastric)
Liver Is The Site Of Second Primary Or
Recurrent Tumor (liver)
Lung Is The Site Of Second Primary Or
Recurrent Tumor (lung)
Melanoma (Melanoma)
Nhl (NHL)
Other Hematologic (Other hematologic)
Other Solid (Other solid)
Pancreatic (Pancreatic)
Renal (Renal)
Squamous-skin (Squamous-skin)
Unknown Primary (Unknown primary)
Specify
Date Eradicated (mm-yyyy)
Is patient receiving brachytherapy (LDR/HDR)
Yes
No
CT/MRI abdomen/pelvis
Yes
No
Date Performed
Bone scan
Yes
2 / 7
RTOG 0815 I1: Radiation Therapy Oncology Group Phase III Randomized Study of
Dose-Escalated Radiotherapy With/Without STAD for Intermediate-Risk Prostate
Cancer Initial Evaluation Form NCT00936390
No
Date performed
Transrectal Ultrasound
No (No)
Not Applicable (Not Applicable)
Yes (Yes)
Prostate volume
Date performed
AUA score
Date performed
Does the patient have 2 or 3 risk factors
Yes
No
Other Patient Disease Type
Heart problems (unstable angina and/or CHF
requiring hospitalization within the last 6 months)
Yes
No
Heart problems (Transmural myocardial infarction
within the last 6 months)
Yes
No
Infection (acute bacterial or fungal requiring
intravenous antibiotics at the time of registration)
Yes
No
COPD exacerbation or other respiratory illness
requiring hospitalization or precluding study
therapy at registration
Yes
No
Hepatic Insufficiency (resulting in clinical jaundice
and/or coagulation defects)
Yes
No
Does the patient have AIDS (based upon current
CDC definition)
Yes
No
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Prostate: Prior Treatment
Prior surgery
Yes
No
Prior radiation therapy (pelvic)
Yes
No
Prior chemotherapy
Yes
No
Prior Hormonal Therapy
Yes
No
Prior finasteride therapy
Yes
No
Prior finasteride therapy end date
Prior dutasteride therapy
Yes
No
Prior dutasteride therapy end date
Prostate: Initial Diagnosis
Histologic Type
Adenocarcinoma, Conventional, Not
Otherwise Specified (Adenocarcinoma,
conventional NOS)
Other Specify (Other)
Other specify
Diagnosis Date
Total number of core biopsies taken
Number of positive core biopsies
Total % of core biopsies taken
Total % of positive core biopsies taken
Gleason Score, Primary Pattern ([most frequently
seen] 1-5, 9=unknown)
Gleason Score, Secondary Pattern ([second
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most frequently seen] 1-5, 9=unknown)
Gleason Score, Worst Pattern ([worst
pathological grade seen in any specimen] 1-5,
9=unknown)
Gleason Score, Combined
Study Entry Psa Measurements
Baseline PSA Date
Baseline PSA Value
Unit of Measure
Nanograms Per Deciliter (ng/dL)
Nanograms Per Milliliter (ng/mL)
Nanomoles Per Liter (nmol/l)
Not Otherwise Specified (NOS)
Method of Assay
Abbott Labs (Abbott)
Bayer (Bayer)
Dpc (DPC)
Hybritech (Hybritech)
Other (Other)
Unknown (Unknown)
Addtitional PSA Measurements
Pre-diagnostic PSA measurements
Yes
No
PSA Date (s)
PSA Value (s)
Cancer Staging
Was the tumor palpable? (at study entry)
No (No)
Yes, <= 1/2 Of One Lobe (Yes, <= 1/2 of
one lobe)
Yes, > 1/2 Of One Lobe (Yes, > 1/2 of
one lobe)
Yes, Both Lobes (Yes, both lobes)
Yes, Nos (Yes, NOS)
Extracapsular Extension? (by clinical
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examination)
Yes
No
T Stage, Clinical (AJCC 6th Edition)
Tumor Incidental Histologic Finding In
5% Or Less Of Tissue Resected (T1a)
Tumor Incidental Histologic Finding In
More Than 5% Of Tissue Resected
(T1b)
Tumor Identified By Needle Biopsy (eg,
Because Of Elevated Psa) (T1c)
Tumor Confined Within The Prostate (T2)
Tumor Involves One Lobe (T2a)
Tumor Involves Both Lobes (T2b)
Tumor Involves Both Lobes (T2c)
Tumor Extends Through The Prostate
Capule (T3)
Extracapsular Extension (unilateral Or
Bilateral) (T3a)
Tumor Invades Seminal Vesicle(s) (T3b)
Tumor Is Fixed Or Invades Adjacent
Structures Other Than Seminal Vesicles:
Bladder Neck, External Sphincter, Or
Rectum, Levator Muscles, And/or Pelvic
Wall (T4)
Primary Tumor Cannot Be Assessed
(TX)
N Stage, Pathologic
No Regional Lymph Node Metastasis
(pN0)
Metastatis In Regional Lymph Node Or
Nodes (see Ajcc Definition) (pN1)
Regional Lymph Nodes Cannot Be
Assessed (pNX)
N Stage, Clinical (RADIOGRAPHIC)
No Regional Lymph Node Metastasis
(N0)
Metastatis In Regional Lymph Node Or
Nodes (see Ajcc Definition) (N1)
Regional Lymph Nodes Cannot Be
Assessed (NX)
M Stage, Clinical
No Distant Metastasis (M0)
Distant Metastasis (M1)
Nonregional Lymph Node(s) (M1a)
Bone(s) (M1b)
Other Site(s) (M1c)
Distant Metastasis Cannot Be Assessed
(MX)
Baseline Lab Values (hematologic)
WBC
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Hemoglobin
ANC
Platelet count
Testosterone (VALUE)
Testosterone Lower Limit Normal
Testosterone Upper Limit Normal
SGPT (ALT) or SGOT (AST) (Test)
SGPT (ALT) or SGOT (AST) (Value)
Date performed
Footer
Comments
Signature of Person Completing This Form
Date Form Originally Completed
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Death Worksheet [ABTR01B1]
NCT00898079
Death Worksheet [ABTR01B1] NCT00898079 
Collecting and Storing Malignant, Borderline Malignant
Neoplasms, and Related Samples From Young Patients
With Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=BCEF6DCD-
9661-3744-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/11184
Death Worksheet [ABTR01B1]
NCT00898079
Header
Name
Study Number
Study Number
COG Number
Patient Name
Today's Date
Date worksheet entered into RDE
Death Assessment
Date of Death
Cause of Death
ARDS (ARDS)
GVHD (GVHD)
Hemorrhage (Hemorrhage)
Infection (Infection)
Multi-Organ Failure (Multi-Organ Failure)
Other Drug (Other Drug)
Due To Other Cause, Specify (Other,
Specify)
Due To Protocol Treatment (Study
drug(s))
Due To This Disease (Tumor)
Unknown (Unknown)
Which of the above causes was the main reason
this patient died?
ARDS (ARDS)
GVHD (GVHD)
Hemorrhage (Hemorrhage)
Infection (Infection)
Multi-Organ Failure (Multi-Organ Failure)
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Other Drug (Other Drug)
Due To Other Cause, Specify (Other,
Specify)
Due To Protocol Treatment (Study
drug(s))
Due To This Disease (Tumor)
Unknown (Unknown)
Other, Specify
Other, Specify
Autopsy Done?
Yes
No
COMMENT
Ccrr Module For Death Worksheet
[abtr01b1]
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ANBL0321: Secondary Malignancy
Worksheet NCT00053326
ANBL0321: Secondary Malignancy Worksheet
NCT00053326
Fenretinide in Treating Children With Recurrent or
Resistant Neuroblastoma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=B96858A4-
76C7-1B0B-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/11185
ANBL0321: Secondary Malignancy
Worksheet NCT00053326
Header
Study Number
Study Number
Name
COG Number
Patient Name
Today's date
Date worksheet entered into RDE
Secondary Malignancy
Date of diagnosis of secondary malignancy (1.
Required field)
Diagnosis (Morphology)
Diagnosis ICD-O code (Morphology)
Primary site (Topography)
Primary site ICD-O code (Topography)
Comments
Ccrr Module For Anbl0321: Secondary
Malignancy Worksheet
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Baseline Abnormalities [ANBL0321] NCT00053326
Fenretinide in Treating Children With Recurrent or
Resistant Neuroblastoma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=C3B3D263-
6B48-4DA2-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/11186
Baseline Abnormalities [ANBL0321]
NCT00053326
Header
Patient Identifier
Name
Modifier
Date Last Modified
Baseline Abnormalities
Were there any baseline abnormalities found on
initial history and physical exam?
No (No)
Unknown (Unknown)
Yes (Yes)
CTC Code
Grade
Onset Date
Comment
Ccrr Module For Baseline Abnormalities
[anbl0321]
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Worksheet NCT00723294
ACOSOG-Z1072 OPEN Registration Worksheet
NCT00723294
Cryoablation Therapy in Treating Patients With Invasive
Ductal Breast Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=7FF941F7-
5D5F-47CE-E040-BB89AD432465
All rights reserved. Please visit https://medical-data-
models.org/forms/11187
ACOSOG-Z1072 OPEN Registration
Worksheet NCT00723294
Patient demographics
Date of Birth (month day year)
Gender of a Person
Female Gender (Female Gender)
Male Gender (Male Gender)
Unknown (Unknown)
Ethnicity
A Person Of Mexican, Puerto Rican,
Cuban, Central Or South American Or
Other Spanish Culture Or Origin,
Regardless Of Race. (Hispanic or Latino)
A Person Not Meeting The Definition For
Hispanic Or Latino. (Not Hispanic or
Latino)
Not Provided Or Available (Not reported)
Country of Residence
Zip code
Race
A Person Having Origins In Any Of The
Original Peoples Of North And South
America (including Central America),
And Who Maintains Tribal Affiliation Or
Community Attachment. (American
Indian or Alaska Native)
A Person Having Origins In Any Of The
Original Peoples Of The Far East,
Southeast Asia, Or The Indian
Subcontinent Including, For Example,
Cambodia, China, India, Japan, Korea,
Malaysia, Pakistan, The Philippine
Islands, Thailand, And Vietnam. (Asian)
A Person Having Origins In Any Of The
Black Racial Groups Of Africa. Terms
Such As "haitian" Or "negro" Can Be
Used In Addition To "black Or African
American." (Black or African American)
A Person Having Origins In Any Of The
Original Peoples Of Hawaii, Guam,
Samoa, Or Other Pacific Islands. (Native
Hawaiian or other Pacific Islander)
Not Provided Or Available (Not
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Reported)
Could Not Be Determined Or Unsure
(Unknown)
A Person Having Origins In Any Of The
Original Peoples Of Europe, The Middle
East, Or North Africa. (White)
Method of Payment
Medicaid (Medicaid)
Medicaid And Medicare (Medicaid and
Medicare)
Medicare (Medicare)
Medicare And Private Insurance
(Medicare and Private Insurance)
Military Or Veterans Sponsored Nos
(Military or Veterans Sponsored, Not
Otherwise Specified (NOS))
Military Sponsored (including Champus
& Tricare) (Military Sponsored (including
CHAMPUS & TRICARE))
No Means Of Payment (no Insurance)
(No means of payment (no insurance))
Other (Other)
Private Insurance (Private Insurance)
Self Pay (no Insurance) (Self Pay (No
Insurance))
Unknown (Unknown)
Veterans Sponsored (Veterans
Sponsored)
General Information
Pt ID# (Local Patient Identifier)
Last (initial)
First (initial)
Middle (initial optional)
E-mail (for Registration Confirmation)
Has patient previously been registered to an
ACOSOG study
Yes
No
Coordinating Group Patient ID (if yes previously
issued ACOSOG Patient ID)
Date Informed Consent Signed (month day year)
Was HIPAA Authorization included in Study
Informed Consent
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Yes
No
HIPAA Authorization Date (If no month day year)
Eligibility Criteria
Unifocal primary invasive ductal breast carcinoma
diagnosed by core needle biopsy (NOTE:
Patients with multifocal and/or multicentric
ipsilateral breast cancer, multifocal calcifications,
or DCIS with microinvasion are NOT eligible.
Patients with contralateral disease will remain
eligible.)
Yes
No
No history of en bloc open surgical biopsy and/or
lumpectomy for diagnosis/treatment of the index
breast cancer (Note: Prior rotational and/or
vacuum-assisted core biopsies are permitted if
no significant distortion is seen on imaging that
could obscure visualization and detection of
residual disease on MRI, or visualization of
cancer on ultrasound for cryoablation procedure.)
Yes
No
Tumor size <= 2.0 cm in greatest diameter
(Specifically, the tumor must measure <=2.0 cm
in the axis parallel to the treatment probe and
<=1.5 cm in the axis anti-parallel to the treatment
probe. Largest size measured by required scans
mammogram, ultrasound and MRI will be used to
determine eligibility.)
Yes
No
Tumor enhancement on pre-study MRI
Yes
No
Tumor with < 25% intraductal components in the
aggregate
Yes
No
No prior or planned neoadjuvant chemotherapy
for breast cancer
Yes
No
Non-pregnant and non-lactating (Patients of
childbearing potential must have a negative
serum or urine pregnancy test. Note: Peri-
menopausal women must be mernorrheic for >12
months to be considered not of childbearing
potential. If not a woman of childbearing potential
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or male mark NA)
N/a (N/A)
No (No)
Yes (Yes)
Negative pregnancy test date (If a woman of
childbearing potential serum or urine
mm/dd/yyyy)
Adequate breast size for safe cryoablation (Male
breast cancer patients and female breast cancer
patients with breasts too small to allow safe
cryoablation are not eligible as the minimal
thickness of the breast tissue does not lend itself
to cryoablation. For patients with breast implants,
the treating physician must document that
adequate distance exists between the lesion and
the implant to ensure that the ablated lesion will
not contact or jeopardize the implant.)
Yes
No
Patients with prior in-situ or invasive breast
carcinomas are eligible if the prior carcinomas
occurred in the contralateral breast. Patients with
prior in-situ or invasive carcinomas of the
ipsilateral breast are not eligible
Yes
No
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ACNS0122 Eligibility Worksheet
NCT00047320
ACNS0122 Eligibility Worksheet NCT00047320 
Neoadjuvant Chemotherapy With or Without Second-Look
Surgery Followed by Radiation Therapy With or Without
Peripheral Stem Cell Transplantation in Treating Patients
With Intracranial Germ Cell Tumors
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=BD908887-
2F0D-1578-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/11188
ACNS0122 Eligibility Worksheet
NCT00047320
Header
Name
Study Number
Study Number
COG Number
Patient Name
Today's date
Date worksheet entered into RDE
Eligibility Assessment
Was the patient greater than 3 years of age and
less than 25 years of age at diagnosis?
Yes
No
Did the patient have histologic verification of one
of the following? -Endodermal sinus tumor (yolk
sac tumor); -Embryonal carcinoma;
-Choriocarcinoma; -Immature teratoma;
-Teratoma with malignant transformation; -Mixed
germ cell tumor
Yes
No
Did the patient have any histologically confirmed
germ cell tumor with elevation of serum/CSF beta
HCG >50 IU/dl or any elevation of CSF alpha
fetoprotein >10IU/L
Yes
No
Did the patient have histologically unconfirmed
pineal and/or suprasellar tumors with serum/CSF
tumor markers of beta>50 IU/dl or any elevation
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of alpha fetoprotein >10 IU/L?
Yes
No
Was surgery performed?
Yes
No
was a cranial MRI with gadolinium obtained prior
to induction or pre-operative and post-operative?
(If yes,)
Yes
No
No
No
No
Will the start of treatment begin within 31 days of
initial diagnosis and within 7 days from study
enrollment?
Yes
No
Karnofsky Performance Score
90 (Able to carry on normal activity,
minor signs or symptoms of disease.)
70 (Cares for self.  Unable to carry on
normal activity or to do active work.)
0 (Dead.)
40 (Disabled, requires special care and
assistance.)
20 (Hospitalization necessary, very sick,
active supportive treatment necessary,)
10 (Moribund, fatal processes
progressing rapidly.)
80 (Normal activity with effort, some
signs or symptoms of disease.)
100 (Normal, no complaints, no evidence
of disease.)
50 (Requires considerable assistance
and frequent medical care.)
60 (Requires occasional assistance, but
is able to care for most of own needs.)
30 (Severely disabled, hospitalization is
indicated although death is not
imminent.)
Lansky Play Score
80 (Active, but tires more quickly.)
70 (Both greater restriction of and less
time spent in play activity.)
100 (Fully active, normal)
50 (Gets dressed but lies around much
of the day, no active play, able to
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participate in all quiet play and activities.)
30 (In bed; needs assistance even for
quiet play.)
90 (Minor restrictions in physically
strenuous activity.)
40 (Mostly in bed; participates in quiet
activities.)
10 (No play; does not get out of bed.)
20 (Often sleeping; play entirely limited
to very passive activities.)
0 (Unresponsive.)
60 (Up and around, but minimal active
play; keeps busy with quieter activities.)
Does the patient have a life expectancy of more
than or equal to 2 months?
Yes
No
Does the patient have a life expectancy of more
than or equal to 2 months?
Yes
No
Has patient received prior treatment other than
surgery and corticosteriods?
Yes
No
Did patient receive growth hormone therapy?
Yes
No
Does the patient have adequate bone marrow
function?
Yes
No
Does the patient have adequate renal function?
Yes
No
Does the patient have adequate Central Nervous
System function?
Yes
No
is the patient pregnant and/or breastfeeding? (If
female,)
No (No)
No, And Not Nursing (no, and not
nursing)
No, But Nursing (no, but nursing)
Yes (Yes)
Has the patient and/or their parents or legal
guardians signed a written informed consent?
Yes
No
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Have all institutional, FDA, and NCI requirements
for human studies been met?
Yes
No
Ccrr Module For Acns0122 Eligibility
Worksheet
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ACNS0122: Endocrine Status Worksheet
NCT00047320
ACNS0122: Endocrine Status Worksheet NCT00047320 
Neoadjuvant Chemotherapy With or Without Second-Look
Surgery Followed by Radiation Therapy With or Without
Peripheral Stem Cell Transplantation in Treating Patients
With Intracranial Germ Cell Tumors
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=BD9127F7-
5FAB-1376-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/11189
ACNS0122: Endocrine Status
Worksheet NCT00047320
Header
Name
Study Number
Study Number
COG Number
Patient Name
Today's date
Date worksheet entered into RDE
Patient status assessment
Date of evaluation
When was the evaluation done?
Follow-up (During follow up)
On Study (During therapy)
Off Treatment (End of therapy)
Prior To Study Entry (Prior to study
entry)
Standing height in cm
Weight in kg
BSA
Endocrine Status
Somatomedian C
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IGF-BP3
Cortisol
Sodium (8 AM Electrolytes)
Potassium (8 AM Electrolytes)
Bicarbonate (8 AM Electrolytes)
Chloride (8 AM Electrolytes)
Urine Specific Gravity
Free T4
Free T4
FSH
Testosterone
Estradiol
LH
hCG
Was radiographic evaluation for bone age done?
Yes
No
bone age according to Greulich-Pyle Atlas (If
yes,)
Pubertal Status
Breasts
Menarche
Yes
No
Pubic hair
Pubic hair
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Genitalia
Testicular volume
Comments
Comments
Ccrr Module For Acns0122: Endocrine
Status Worksheet
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Neoadjuvant Chemotherapy With or Without Second-Look
Surgery Followed by Radiation Therapy With or Without
Peripheral Stem Cell Transplantation in Treating Patients
With Intracranial Germ Cell Tumors
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=BD7B6161-
4826-29D3-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/11190
ACNS0122 Surgical Checklist
Worksheet NCT00047320
Header
Name
Study Number
Study Number
COG Number
Patient Name
Today's date
Date worksheet entered into RDE
Primary Surgery
Date of surgery?
When was surgery performed?
After Study Entry (After study entry)
At Recurrence/progression (At
recurrence/progression)
At Second Look (At second-look)
Prior To Study Entry (Prior to study
entry)
Reason For Surgery
Was tumor biopsied or resected during this
surgery?
No (No)
YES (YES)
Yes - tissue sampling only (Yes - tissue
sampling only)
Yes - tumor resection or debulking (Yes -
tumor resection or debulking)
what was the extent of tumor resection? (If yes,)
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Biopsy Only (Biopsy Only)
Extensive Subtotal Resection (Extensive
Subtotal Resection)
Gross Total Resection (Gross Total
Resection)
Partial Resection (Partial Resection)
Subtotal Resection (Subtotal Resection)
Was shunt operation performed?
No (No)
Yes, Shunt Insertion (Yes - Shunt
insertion)
Yes, Shunt Removal (Yes - Shunt
removal)
Yes, Shunt Revision (Yes - Shunt
revision)
Was cyst aspiration performed?
No (No)
Unknown (Unknown)
Yes (Yes)
Was there any other purpose for this surgery?
Interval Debulking (Interval debulking)
No (No)
Other, Specify (Other, specify)
Palliative Therapy (Palliative therapy)
Second Look Procedure (Second look
procedure)
Yes (Yes)
specify [other purpose for this surgery] (If yes,)
Cns Peri-operative Complications
Were there neurological complications of the
surgery?
No (No)
Unknown (Unknown)
Yes (Yes)
specify [neurological complications of surgery] (If
yes,)
Was there CNS infection associated with this
surgery?
No (No)
Unknown (Unknown)
Yes (Yes)
specify [CNS infection associated with surgery] (If
yes,)
Post-op Steroids Used
Were steroids used post-operatively?
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No (No)
Unknown (Unknown)
Yes (Yes)
for how long? (If yes,)
3-6 Days (3-6 days)
7-14 Days (7-14 days)
More Than 14 Days (After 14 days)
Unknown (Unknown)
Comments
Comments
Ccrr Module For Acns0122 Surgical
Checklist Worksheet
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ACNS0122 Institutional Neuropathology
Worksheet NCT00047320
ACNS0122 Institutional Neuropathology Worksheet
NCT00047320 
Neoadjuvant Chemotherapy With or Without Second-Look
Surgery Followed by Radiation Therapy With or Without
Peripheral Stem Cell Transplantation in Treating Patients
With Intracranial Germ Cell Tumors
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=BD40C955-
FB29-0C2A-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/11191
ACNS0122 Institutional
Neuropathology Worksheet
NCT00047320
Header
Study Number
Study Number
Name
COG Number
Patient Name
Today's date
Date worksheet entered into RDE
Neuropathology
Institutional Pathologist
Date of this review
What are the institutional surgical pathology
numbers?
Date of procedure during which sample was
obtained
Specimen obtained
Sample Or Specimen Collected After
Patient Received Treatment For Cancer
(After study entry)
Progression Or Relapse (At
recurrence/progression)
At the time of death (At the time of
death)
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Second Malignancy (Diagnosis of
second malignancy)
Other Specify (Other, specify)
Sample Or Specimen Collected Before
Patient Was Diagnosed With Cancer
(Pre-diagnosis)
Sample Or Specimen Collected Before
Patient Received Treatment For Cancer
(Prior to study entry)
Unknown (Unknown)
What is the diagnosis?
Choriocarcinoma (Choriocarcinoma)
Embryonal Carcinoma (Embryonal
carcinoma)
Yolk Sac Tumor (Endodermal sinus
tumor)
Immature teratoma and teratoma with
malignant transformation (Immature
teratoma and teratoma with malignant
transformation)
Mixed Germ Cell Tumor (Mixed germ cell
tumor)
Other, Specify (Other)
Teratoma (Teratoma)
specify [other diagnosis] (If other,)
Comments
Comments
Ccrr Module For Acns0122 Institutional
Neuropathology Worksheet
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GOG-0219 Surgical Reporting Form
NCT00262821
GOG-0219 Surgical Reporting Form NCT00262821
Cisplatin and Radiation Therapy With or Without
Tirapazamine in Treating Patients With Cervical Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=05D7A2BB-
BA3D-24FB-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11192
GOG-0219 Surgical Reporting Form
NCT00262821
Header Module
Date form originally completed
Date form amended
Person amending form, last name
Patient Initials
Patient Study ID
Person completing form, last name
Participating group code
Participating group protocol number
Participating group patient ID
Gynecologic Surgical Procedure
Gynecologic Surgical Procedure Performed Type
Bilateral Salpingo-oophorectomy
(bilateral salpingo-oophorectomy)
Deep Lymphadenectomy (Deep
lymphadenectomy)
Exenteration (Exenteration)
Hemivolvectomy (Hemi volvectomy)
Interval Debulking (Interval debulking)
Omentectomy (omentectomy)
Other, Specify (other specify)
Para-aortic Node Sampling/dissection
(para-aortic node sampling/dissection)
Pelvic Node Sampling/dissection (pelvic
node sampling/dissection)
Peritoneal Sampling (Peritoneal
sampling)
Primary Debulking (Primary debulking)
Radical Hysterectomy (radical
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hysterectomy)
Radical Trachelectomy (radical
trachelectomy)
Radical Vulvectomy (Radical vulvectomy)
Reassessment Laparotomy
(Reassessment laparotomy)
Superficial Lymphadenectomy
(Superficial lymphadenectomy)
Total Abdominal Hysterectomy (Total
abdominal hysterectomy)
Total Vaginal Hysterectomy (Total vaginal
hysterectomy)
Unilateral Salpingo-oophorectomy
(unilateral salpingo-oophorectomy)
Other, specify
Surgical stage
0 (0)
Refer To Figo Staging For Specific
Gynecologic Cancer (1)
Refer To Figo Staging For Specific
Gynecologic Cancer (1A)
Refer To Figo Staging For Specific
Gynecologic Cancer (1B)
Refer To Figo Staging For Specific
Gynecologic Cancer (1C)
Refer To Figo Staging For Specific
Gynecologic Cancer (2)
Refer To Figo Staging For Specific
Gynecologic Cancer (2A)
Refer To Figo Staging For Specific
Gynecologic Cancer (2B)
Refer To Figo Staging For Specific
Gynecologic Cancer (2C)
Refer To Figo Staging For Specific
Gynecologic Cancer (3)
Refer To Figo Staging For Specific
Gynecologic Cancer (3A)
Refer To Figo Staging For Specific
Gynecologic Cancer (3B)
Refer To Figo Staging For Specific
Gynecologic Cancer (3C)
Refer To Figo Staging For Specific
Gynecologic Cancer (4)
Refer To Figo Staging For Specific
Gynecologic Cancer (4A)
Refer To Figo Staging For Specific
Gynecologic Cancer (4B)
Not Available (Not available)
Persistent (Persistent)
Recurrent (Recurrent)
Date of surgery
Percent of gross tumor removed
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Residual gross tumor
Yes
No
Summary of operative findings (*)
Abdominal Organs (Abdominal organs)
Adb. Ureter - Lt. (Adb. Ureter - lt.)
Adb. Ureter - Rt. (Adb. Ureter - rt.)
Ant. Abdomen (Ant. Abdomen)
Anus (Anus)
Appendix (Appendix)
Ascending Colon (Ascending colon)
Bladder - Mucosa (Bladder - mucosa)
Bladder - Muscularis (Bladder -
muscularis)
Clitoris (Clitoris)
Common Iliac - Lt. (Common iliac - lt.)
Common Iliac - Rt. (Common iliac - rt.)
Deep Groin - Lt. (Deep groin - lt.)
Deep Groin - Rt. (Deep groin - rt.)
Descending Colon (Descending colon)
Duodenum (Duodenum)
External Iliac - Lt. (External iliac - lt.)
External Iliac - Rt. (External iliac - rt.)
Fallopian Tube - Lt. (Fallopian tube - lt.)
Fallopian Tube - Rt. (Fallopian tube - rt.)
Gall Bladder (Gall bladder)
Gutters - Lt. (Gutters - lt.)
Gutters - Rt. (Gutters - rt.)
Ileum (Ileum)
Internal - Lt. (Internal - lt.)
Internal - Rt. (Internal - rt.)
Introitus (Introitus)
Jejunum (Jejunum)
Kidney - Lt. (Kidney - lt.)
Kidney - Rt. (Kidney - rt.)
Labium Major - Lt. (Labium major - lt.)
Labium Major - Rt. (Labium major - rt.)
Labium Minor - Lt. (Labium minor - lt.)
Labium Minor - Rt. (Labium minor - rt.)
Large Bowel (Large bowel)
Left Scalene (Left scalene)
Liver Parenchyma (Liver parenchyma)
Liver Surface (Liver surface)
Obturator - Lt. (Obturator - lt.)
Obturator - Rt. (Obturator - rt.)
Omentum - Gastrocolic (Omentum -
gastrocolic)
Omentum - Infracolic (Omentum -
infracolic)
Ovary - Lt. (Ovary - lt.)
Ovary - Rt. (Ovary - rt.)
Pancreas (Pancreas)
Para-aortic - Lt. (Para-aortic - lt.)
Para-aortic - Rt. (Para-aortic - rt.)
Parametrium - Lt. (Parametrium - lt.)
Parametrium - Rt. (Parametrium - rt.)
Pelvic - Lt. (Pelvic - lt.)
Pelvic - Rt. (Pelvic - rt.)
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Pelvic Bladder (Pelvic bladder)
Pelvic Cul-de-sac (Pelvic cul-de-sac)
Perineal Body (Perineal body)
Sig. Mucosa (Sig. Mucosa)
Sig. Muscularis (Sig. Muscularis)
Small Bowel (Small bowel)
Spleen (Spleen)
Stomach (Stomach)
Subdiaphragm - Lt. (subdiaphragm - lt.)
Subdiaphragm - Rt. (subdiaphragm - rt.)
Superficial Gr. - Lt. (Superficial gr. - lt.)
Superficial Gr. - Rt. (Superficial gr. - rt.)
Transverse Colon (Transverse colon)
Ureter - Lt. (Ureter - lt.)
Ureter - Rt. (Ureter - rt.)
Urethra (Urethra)
Uterus-cervix (Uterus-cervix)
Uterus-corpus (Uterus-corpus)
Vagina (Vagina)
Exam
No Tumor (No tumor)
Not Examined (Not examined)
Organ Absent (Organ absent)
Suspicious (Suspicious)
Tumor Present (Tumor present)
Proc
Biopsy Only (Biopsy only)
Left Intact (Left intact)
Not Applicable (Not applicable)
Removed Completely (Removed
completely)
Removed Partially (Removed partially)
Miscellaneous Patient Assessment
Greatest diameter of largest residual gross tumor
mass
Microscopic disease only
Yes
No
Ascites
Yes
No
Cytology of peritoneal or ascitic fluids
Negative (Negative)
Not Done (Not done)
Positive (Positive)
Suspicious (Suspicious)
Unavailable (Unavailable)
Comments
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RTOG-1005 I1: Radiation Therapy Oncology Group Phase III Whole Breast
Irradiation for Early Stage Breast Cancer - Initial Evaluation Form NCT01349322
RTOG-1005 I1: Radiation Therapy Oncology Group Phase
III Whole Breast Irradiation for Early Stage Breast Cancer -
Initial Evaluation Form NCT01349322 
Higher-Dose Radiation Therapy or Standard Radiation
Therapy in Treating Patients With Early-Stage Breast
Cancer That Was Removed by Surgery
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=9C06B696-
F1B0-F7B4-E040-BB89AD434CCB
All rights reserved. Please visit https://medical-data-
models.org/forms/11193
RTOG-1005 I1: Radiation Therapy
Oncology Group Phase III Whole
Breast Irradiation for Early Stage
Breast Cancer - Initial Evaluation
Form NCT01349322
RTOG clinical trial administrative data
RTOG Study No.
Case #
Institution Name
Institution No.
Patient Initials
RTOG Patient ID
Amended Data
Yes
No
Patient status
Patient Age
Performance Status (Zubrod)
Normal Activity (0)
Symptoms, But Nearly Fully Ambulatory
(1)
Some Bed Time, But Needs To Be In
Bed <50% Of Normal Daytime (2)
Needs To Be In Bed > 50% Of Normal
Daytime (3)
Unable To Get Out Of Bed (4)
Date
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Tumor Involvement
pStage 0 breast cancer with nuclear grade 3
DCIS and patient age < 50 years
Yes
No
ypStage 0, I, II breast cancer resected by
lumpectomy after neoadjuvant systemic therapy
Yes
No
pStage I, II breast cancer AND at leat one of the
following
Yes
No
Pstage I, Ii Breast Cancer And At Leaet
One Of The Following (see Below And
Code All)
Age < 50 years
Yes
No
Positive axillary nodes
Yes
No
Lymphovascular space invasion
Yes
No
More than 2 close resection margins (> 0 mm to
<= 2 mm)
Yes
No
1 Close resection margin and extensive in-situ
component (EIC)
Yes
No
Focally positive resection margins
Yes
No
Non-hormone sensitive breast cancer (ER and
PR-NEGATIVE)
Yes
No
Grade III histology
Yes
No
Oncotype recurrence score > 25
Yes
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No
Tumor Information
Date lumpectomy performed
Date of Most Recent Surgery (excluding
diagnostic lumpectomy reported above)
Date of last dose of chemotherapy
Histologic Grade
G1 Low Combined Histologic Grade
(favorable) (G1)
G2 Intermediate Combined Histologic
Grade (moderately Favorable) (G2)
G3 High Combined Histologic Grade
(unfavorable) (G3)
Is gross disease unifocal or multifocal?
Multifocal (Multifocal)
Unifocal (Unifocal)
If multifocal, is the cancer resectable through a
single lumpectomy incision with negative margins
Yes
No
Which breast was diagnosed with breast cancer
Left Breast (Left breast)
Right Breast (Right breast)
Receptor Status, ER
Negative (Negative)
Positive (Positive)
Receptor Status, PgR
Negative (Negative)
Positive (Positive)
Unknown (Unknown)
Pathologic Primary Tumor Size (cm)
Margin Status
Close Resection Margins; > 0 Mm To <=
2 Mm (Close resection margins; > 0 mm
to <= 2 mm)
Focally Positive Resection Margin
(Focally positive resection margin)
Negative Margins Defined As No Tumor
At The Resected Specimen Edge
(Negative margins defined as no tumor
at the resected specimen edge)
Is there clear delineation on CT scan of the
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extent of the target lumpectomy cavity for boost
Yes
No
Is the patient receiving anti endocrine therapy at
the time of the study entry
Yes
No
Type of anti endocrine therapy (If yes,)
Aromatase Inhibitor (Aromatase inhibitor)
Other (Other)
Tamoxifen (Tamoxifen)
Other, specify
Start date
Study Cancer
Axillary Staging Method
Axillary Lymph Node Dissection Alone
(Axillary lymph node dissection alone)
Sentinel Node Biopsy Alone (Sentinel
node biopsy alone)
Sentinel Node Biopsy Alone Or Followed
By Axillary Node Dissection, For
Clinically Negative Node Patients As
Described Below (Sentinel node biopsy
alone or followed by axillary node
dissection, for clinically negative node
patients as described below)
Sentinel Node Biopsy Followed By
Axillary Dissection Or Sampling With A
Minimum Total Of 6 Axillary Nodes If Any
Of The Following Are Present (Sentinel
node biopsy followed by axillary
dissection or sampling with a minimum
total of 6 axillary nodes if any of the
following are present)
Microscopic sentinel node positive (pN1mic)
Yes
No
One or two sentinel nodes positive (pN1) without
extracapsular extension AND pT1 or pT2 AND no
lymphovascular invasion AND at least one
additional negative SNP
Yes
No
> 2 positive SN
Yes
No
Solitary SN that is positive without other sentinel
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nodes dissected
Yes
No
Clinically (by either imaging or examination) T3
disease
Yes
No
The presence of one or more positive SNs with
extracapsular extension, clinically node positive
disease, or LVI in the primary tumor
Yes
No
Baseline Lab Values (hematologic)
ANC (mm^3)
Date (MM DD YYYY)
Platelet count (mm^3)
Date (MM DD YYYY)
Hemoglobin (g/dL)
Date (MM DD YYYY)
Diagnosis Work-up
History and Physical
Yes
No
Bilateral mammogram
Yes
No
CT scan
Yes
No
Chest X-Ray
Yes
No
Chest CT scan
Yes
No
Bone scan
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Yes
No
Abdomen/Pelvis CT Scan
Yes
No
Chest/Abdomen/Pelvis CT Scan or PET/CT
Yes
No
Patient Weight (kg)
Patient Height (cm)
Examination Date (MM DD YYYY)
Severe Active Comorbidity
AJCC pathologic T4, N2 or N3, or M1 breast
cancer
Yes
No
Does treatment plan include regional node
irradiation
Yes
No
Invasive breast cancer and low risk for 5-year in
breast recurrence after lumpectomy with negative
margins
Yes
No
Is there a plan to administer concurrent
chemotherapy for the current breast cancer
Yes
No
History of Prior Malignancy (invasive)
Yes
No
Date eradicated (If yes MM DD YYYY)
Prior radiotherapy to the breast or prior radiation
to the region of the ipsilateral breast that would
result in overlap of radiation therapy fields
Yes
No
Prior invasive or in-situ carcinoma of the breast
Yes
No
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Are there two or more breast cancers not
resectable through a single lumpectomy incision
Yes
No
DCIS and age >= 50 years
Yes
No
DCIS and age < 50 years and grade 1 or 2
Yes
No
Suspicious unresected microcalcifications,
densities, or palpable abnormalities (in the
ipsilateral or contralateral breast)
Yes
No
Were they biopsied and found to be benign (If
yes, )
Yes
No
Non-epithelial breast malignancies
Yes
No
Does the patient have paget's disease of the
nipple
Yes
No
Hospitalized for unstable angina and/or CHF in
last 6 months
Yes
No
Transmural MI in last 6 months (myocardial
infarction)
Yes
No
Acute bacterial or fungal infection requiring
intravenous antibiotics at the time of registration
Yes
No
Chronic obstructive pulmonary disease
exacerbation or other respiratory illness requiring
hospitalization or precluding study therapy within
30 days before registration
Yes
No
Hepatic insufficiency resulting in clinical jaundice
and/or coagulation defects
Yes
No
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Acquired Immune Deficiency Syndrome based
upon current CDC definition (AIDS)
Yes
No
Active systemic lupus erythematosus, or any
history of scleroderma, dermatomyositis with
active rash
Yes
No
Medical or psychiatric condition that would
prevent the patient from receiving the protocol
therapy or providing informed consent
Yes
No
Is patient a woman of childbearing potential
Yes
No
Is she willing to exercise an effective form of birth
control during radiation therapy (If yes,)
Yes
No
Negative serum pregnancy test
Yes
No
Negative serum pregnancy test date (MM DD
YYYY)
Is the patient pregnant or lactating at time of
study entry?
Yes
No
Footer Module
Comments
Investigator Signature
Date
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USMCI 8214/Z6091: Tissue Sample
Submission Form NCT01167725
USMCI 8214/Z6091: Tissue Sample Submission Form
NCT01167725
Standard Therapy With or Without Surgery and Mitomycin
C in Treating Patients With Advanced Limited Peritoneal
Dissemination of Colon Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=62328DCB-
01DD-B01D-E040-BB89AD435CDE
All rights reserved. Please visit https://medical-data-
models.org/forms/11194
USMCI 8214/Z6091: Tissue Sample
Submission Form NCT01167725
Header Module
Visit
Post Surgery (Post Surgery)
Patient ID
Institution No.
Institution Name
Was sample obtained
Yes
No
Reason (If no,)
Biopsy specimen
Tissue/material type
Peritoneal Surface Tumor (Peritoneal
surface tumor)
Primary Colon Tumor (Primary colon
tumor)
Block/Slides Type
20-30 Unstained Slides (20-30 unstained
slides)
2mm Core Biopsy (2mm core biopsy)
One Representative Block (One
representative block)
Date of collection
Number Blocks/Slides
Accession Number
Amount of Tissue Obtained
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Footern Module
First Name (Submitted by)
Last name
Date Specimen Shipped
Email Address
Phone
Fax
Specimen Received Date
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CALGB 40601 FOLLOW-UP FORM
NCT00770809
CALGB 40601 FOLLOW-UP FORM NCT00770809
Paclitaxel and Trastuzumab With or Without Lapatinib in
Treating Patients With Stage II or Stage III Breast Cancer
That Can Be Removed by Surgery
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=3A098B5D-
E41F-1055-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11195
CALGB 40601 FOLLOW-UP FORM
NCT00770809
Header
CALGB Form
CALGB Study No
CALGB Patient ID
Reporting Period Start Date
Reporting Period End Date (date of last contact
or death)
Are data amended
Yes
No
Patient demographics
Patient Initials
Patient Hospital No.
Institution/Affiliate
Participating Group
Participating Group Study No.
Participating Group Patient ID
Vital Status
Patient's vital status (Mark one with an X.)
Alive (Alive)
Dead (Dead)
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Primary cause of death (Mark one with an X.)
Due To Other Cause (Due to other
cause)
Due To Protocol Treatment (Due to
protocol treatment)
Due To This Disease (Due to this
disease)
Unknown (Unknown)
Describe cause of death
Did the patient continue treatment with AC?
Yes
No
Treatment Regimen
Classical (Classical)
Dose Dense (Dose dense)
Did the patient continue treatment with
trastuzumab?
Yes
No
Treatment start date
Treatment end date
Did the patient continue treatment with endocrine
therapy for ER/PgR positive disease?
Yes
No
Treatment start date
Treatment end date
Has the patient had a documented clinical
assessment for this cancer
Yes
No
Date of Last Clinical Assessment
Was patient restaged during this time period (If
Yes, complete the following questions and submit
C-817 Follow-Up Solid Tumor Measurement
Form)
Yes
No
Overall Tumor Response
Complete Response (CR)
Partial Response (PR)
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CR First Observed Date (MM DD YYYY)
PR First Observed Date (MM DD YYYY)
Notice Of Progression
Has the patient been diagnosed with a first local-
regional progression (since submission of the last
follow-up form?)
Yes
No
Date of First Local-Regional Progression
Site of First Local-Regional Progression
Axilla (Axilla)
Axillary Nodes (Axillary nodes)
Chest Wall (Chest wall)
Infraclavicular Nodes (Infraclavicular
nodes)
Internal Mammary Nodes (Internal
mammary nodes)
Ipsilateral Breast (Ipsilateral breast)
Supraclavicular Nodes (Supraclavicular
nodes)
Has the patient been diagnosed with first distant
progression?
Yes
No
Date of First Distant Progression
Site of First Distant Recurrence
How was this progression information obtained?
Clinical Assessment (Clinical
assessment)
Patient Self Report Only (Patient self-
report only)
How was this progression information obtained?
Clinical Assessment (Clinical
assessment)
Patient Self Report Only (Patient self-
report only)
Expected Adverse Events
Has the patient experienced any grade >= 2
treatment related adverse event? (prior to
diagnosis of recurrence or new malignancy)
Yes
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No
MedDRA Code
CTC adverse event term
Peripheral Motor Neuropathy
(Neuropathy: motor)
Peripheral Sensory Neuropathy
(Neuropathy: sensory)
CTC AE grade (^2)
CTC AE Attribution Code (^2)
Definite (definite)
Possible (possible)
Probable (probable)
Unlikely (unlikely)
Unrelated (unrelated)
Adverse Event Onset Date
Comments
COMMENTS
Completed by (Last name, First name)
Date form completed (MM DD YYYY)
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SOUTHWEST ONCOLOGY GROUP S0226
ADVERSE EVENT FORM NCT00075764
SOUTHWEST ONCOLOGY GROUP S0226 ADVERSE
EVENT FORM NCT00075764 
S0226 Anastrozole With or Without Fulvestrant as First-
Line Therapy in Postmenopausal Women With Metastatic
Breast Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=C3226D1D-
8263-26E7-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/11196
SOUTHWEST ONCOLOGY GROUP
S0226 ADVERSE EVENT FORM
NCT00075764
Header
SWOG Patient ID
SWOG Study No.
Registration Step
Patient Initials (L, F M)
Institution/Affiliate
Physician
Participating Group Name
Participating Study No.
Participating Patient ID (Instructions: Please
complete this form after each cycle one cycle = 3
weeks. Report adverse events occuring up until
the next cycle of treatment begins. Document the
worst Grade seen during the reporting interval.
Do not code a pre-existing condition as an
adverse event unless it worsens due to treatment.
All dates are MONTH, DAY, YEAR.  Explain any
blank dates or fields in the Comments section.
Place an X in appropriate boxes. Circle
AMENDED items in red.)
Toxicity
Reporting period start date
Reporting period end date
Were adverse events assessed during this time
period
1 / 3
No (No)
Yes, And Reportable Adverse Events
Occurred (Yes, and reportable adverse
events occurred)
Yes, But No Reportable Adverse Events
Occurred (Yes, but no reportable adverse
events occurred)
Adverse event assessment
CTC Adverse Event Term
Anorexia (Anorexia)
Confusion (Confusion)
Constipation (Constipation)
Constitutional Symptoms Other
(Constitutional Symptoms-Other
(Specify))
Cough (Cough)
Diarrhoea Nos (Diarrhea)
Dizziness (exc Vertigo) (Dizziness)
Dry Mouth (Dry mouth/salivary gland
(xerostomia))
Dyspnoea Nos (Dyspnea (shortness of
breath))
Oedema Nos (Edema: limb)
Fatigue (Fatigue (asthenia, lethargy,
malaise))
Pyrexia (Fever (in the absence of
neutropenia, where neutropenia is
defined as ANC <1.0 x 10^9/L))
Vaginal Haemorrhage (Hemorrhage, GU
- Vagina)
Menopausal Symptoms (Hot
flashes/flushes)
Hypotension Nos (Hypotension)
Infection With Unknown Anc (Infection
with unknown ANC - Urinary tract NOS)
Infection Nos (Infection-Other (Specify))
Injection Site Reaction Nos (Injection site
reaction/extravasation changes)
Insomnia Nec (Insomnia)
Mood Alteration - Agitation (Mood
alteration - agitation)
Anxiety Nec (Mood alteration - anxiety)
Depression Nec (Mood alteration -
depression)
Mucositis/stomatitis (clinical Exam)
(Mucositis/stomatitis (clinical exam) -
Oral cavity)
Stomatitis (Mucositis/stomatitis (clinical
exam) - Pharynx)
Mucositis/stomatitis
(functional/symptomatic)
(Mucositis/stomatitis
(functional/symptomatic) - Oral cavity)
Mucositis/stomatitis
(functional/symptomatic)
(Mucositis/stomatitis
(functional/symptomatic) - Pharynx)
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Nausea (Nausea)
Peripheral Motor Neuropathy
(Neuropathy: motor)
Peripheral Sensory Neuropathy
(Neuropathy: sensory)
Abdominal Pain Nos (Pain - Abdomen
NOS)
Pain (Pain - Back)
Bone Pain (Pain - Bone)
Chest Pain (Pain - Chest/thorax NOS)
Headache Nos (Pain - Head/headache)
Arthralgia (Pain - Joint)
Myalgia (Pain - Muscle)
Pelvic Pain Nos (Pain - Pelvis)
Pain Other (Pain-Other (Specify))
Pruritus Nos (Pruritus/itching)
Dermatitis Exfoliative Nos
(Rash/desquamation)
Rigors (Rigors/chills)
Thrombosis/embolism (vascular Access-
related) (Thrombosis/embolism (vascular
access-related))
Thrombosis Nos
(Thrombosis/thrombus/embolism)
Tumour Flare (Tumor flare)
Vulvovaginal Dryness (Vaginal dryness)
Vaginitis (Vaginitis (not due to infection))
Vomiting Nos (Vomiting)
Weight Increased (Weight gain)
CTC Adverse Event Grade
Adverse Event Status Code (Status codes)
continues at same or lower grade
(continues at same or lower grade)
increased grade OR improved then
worsened (increased grade OR improved
then worsened)
new (new)
Adverse Event Status Code (Status codes)
continues at same or lower grade
(continues at same or lower grade)
increased grade OR improved then
worsened (increased grade OR improved
then worsened)
new (new)
CTC Adverse Event Term, Other
Comments
Comments
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USMCI 8214/Z6091:  Off Treatment Form
NCT01167725
USMCI 8214/Z6091:  Off Treatment Form NCT01167725 
Standard Therapy With or Without Surgery and Mitomycin
C in Treating Patients With Advanced Limited Peritoneal
Dissemination of Colon Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=6A5AE56E-
244B-4E28-E040-BB89AD4362AC
All rights reserved. Please visit https://medical-data-
models.org/forms/11197
USMCI 8214/Z6091:  Off Treatment
Form NCT01167725
Header Module
Visit
Follow-up (Follow-Up)
Patient ID
Institution No.
Institution Name
Protocol Design
Date of Last Treatment
This patient will now go to
Follow-up (Follow-up)
Off Study (Off study)
Reason Treatment Ended (or Never Initiated)
Adverse Event/side Effects/complications
(Adverse Event/Side
Effects/Complications)
Alternative Therapy (Alternative therapy)
Death On Study (Death on study)
Disease Progression Before Active
Treatment (Disease Progression before
active treatment)
Disease Progression, Relapse During
Active Treatment (Disease progression,
relapse during active treatment)
Other (Other)
Patient Off-treatment For Other
Complicating Disease (Patient off-
treatment for other complicating disease)
Patient Withdrawal Or Refusal After
Beginning Protocol Therapy (Patient
withdrawal/refusal after beginning
protocol therapy)
Patient Withdrawal Or Refusal Before
Beginning Protocol Therapy (Patient
withdrawal/refusal prior to beginning
protocol therapy)
Treatment Completed Per Protocol
1 / 2
Criteria (Treatment completed per
protocol criteria)
Specify
Completed by
Date Form Completed
Phone
Fax
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CALGB-40502 Follow-Up Form
NCT00785291
CALGB-40502 Follow-Up Form NCT00785291
Paclitaxel, Paclitaxel Albumin-Stabilized Nanoparticle
Formulation, or Ixabepilone With or Without Bevacizumab
in Treating Patients With Stage IIIC or Stage IV Breast
Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=51FC17F4-
984D-0C38-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11198
CALGB-40502 Follow-Up Form
NCT00785291
Header
CALGB Form
CALGB Study No
CALGB Patient ID
Reporting Period Start Date
Reporting Period End Date (date of last contact
or death)
Are data amended
Yes
No
Patient demographics
Patient Initials
Patient Hospital No.
Institution/Affiliate
Participating Group
Participating Group Study No.
Participating Group Patient ID
Vital Status
Patient's vital status (Mark one with an X. If the
patient is lost, follow instructions on form C-1742
and in the CALGB Policies and Procedures
chapter 8 to have Data Operations change a
1 / 4
patient's survival status to: "Confirmed lost to
follow-up")
Alive (Alive)
Dead (Dead)
Primary cause of death (Mark one with an X.)
Due To Other Cause (Due to other
cause)
Due To Protocol Treatment (Due to
protocol treatment)
Due To This Disease (Due to this
disease)
Unknown (Unknown)
Describe cause of death
Has the patient had a documented clinical
assessment for this cancer (during this reporting
period?)
Yes
No
Date of Last Clinical Assessment (MM DD YYYY)
Notice Of Progression
Has the patient been diagnosed with first local-
regional recurrence (since submission of the last
follow-up form?)
Yes
No
Date of First Local-Regional Progression (MM DD
YYYY)
Site of First Local-Regional Progression (s)
Axilla (Axilla)
Axillary Nodes (Axillary nodes)
Chest Wall (Chest wall)
Infraclavicular Nodes (Infraclavicular
nodes)
Internal Mammary Nodes (Internal
mammary nodes)
Ipsilateral Breast (Ipsilateral breast)
Supraclavicular Nodes (Supraclavicular
nodes)
Has the patient been diagnosed with first distant
recurrence/progression? (since submission of the
last follow-up form?)
Yes
No
Date of First Distant Progression (MM DD YYYY)
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Site of First Distant Recurrence (s)
How was this progression information obtained?
(Mark one with an X.)
Clinical Assessment (Clinical
assessment)
Patient Self Report Only (Patient self-
report only)
How was this progression information obtained?
(Mark one with an X.)
Clinical Assessment (Clinical
assessment)
Patient Self Report Only (Patient self-
report only)
Non-protocol Therapy
Did the patient receive additional therapy?
(during this reporting period)
Yes
No
Subsequent Treatment Type (Specify subsequent
therapy type as: Chemotherapye.g., adriamycin,
capecitabine, gemcitabine, taxanes, vinorelbine,
vinblastine Hormonal e.g., anastrozole,
exemestane, fulvestrant, letrozole, toremifene,
tamoxifen, raloxifene Biological e.g.,
bevacizumab, lapatinib, sorafenib, sunitinib,
trastuzumab Bisphosphonate e.g., pamidronate,
zoledronic acid Radiation Surgery Other)
Agent
Agent Total Cumulative Dose (During this
reporting period)
Units
Agent Start Date (MM DD YYYY)
Agent End Date (MM DD YYYY)
Long-term Adverse Events
Has the patient experienced (prior to diagnosis of
recurrence or second primary) any severe (Grade
>=3), long term toxicity that has not been
previously reported (If yes complete the section
below)
Yes
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No
MedDRA Code
CTC Adverse Event Term
Peripheral Motor Neuropathy
(Neuropathy: motor)
Peripheral Sensory Neuropathy
(Neuropathy: sensory)
CTC AE Grade
CTC AE Attribution Code
Definite (Definite)
Possible (Possible)
Probable (Probable)
Unlikely (Unlikely)
Unrelated (Unrelated)
AE Onset Date (MM DD YYYY)
Notice Of Progression
Has a new primary cancer or MDS been
diagnosed that has not been previously reported?
(myelodysplastic syndrome)
Yes
No
Date of diagnosis (MM DD YYYY)
Site of new primary (s If new primary site is
AML/MDS, submit NCI AML/MDS form.)
Comments
Comments
Completed by (Last name, First name)
Date form completed (MM DD YYYY)
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CALGB: 80405 ADVERSE EVENT (AE)
FORM NCT00265850
CALGB: 80405 ADVERSE EVENT (AE) FORM
NCT00265850
Cetuximab and/or Bevacizumab Combined With
Combination Chemotherapy in Treating Patients With
Metastatic Colorectal Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=F39BC806-
6212-58D3-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11199
CALGB: 80405 ADVERSE EVENT
(AE) FORM NCT00265850
Header
CALGB Form
CALGB Study No
CALGB Patient ID
Reporting period start date
Reporting period end date
Are data amended
Yes
No
Patient demographics
Patient Initials
Patient Hospital No
Institution/Affiliate
Participating Group
Participating Group Study No.
Participating Group Patient ID
Expected Adverse Events
Has an AdEERS been filed (with Central Office
based on an event reported below?)
Yes
No
1 / 2
Cycle number
MedDRA code (^1)
CTC adverse event term
CTC AE grade
CTC AE Attribution Code
Definite (definite)
Possible (possible)
Probable (probable)
Unlikely (unlikely)
Unrelated (unrelated)
Completed by
Date form originally completed
2 / 2
CALGB: 80405 ADVERSE EVENT (AE) FORM NCT00265850
Z6051 Registration Worksheet (RW)
NCT00726622
Z6051 Registration Worksheet (RW) NCT00726622
Laparoscopic-Assisted Resection or Open Resection in
Treating Patients With Stage IIA, Stage IIIA, or Stage IIIB
Rectal Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=42C2D65A-
ED39-4B6E-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11200
Z6051 Registration Worksheet (RW)
NCT00726622
Header Module
Visit
Prior To Registration (Prior to
Registration)
Patient ID (Pt. ID issued during registration or
previously issued patient ID)
Patient Initials
Institution Name
Institution No.
Has patient previously been registered to an
ACOSOG study
Yes
No
Coordinating Group Protocol Number
Pre-neoadjuvant Therapy Examination
Data
Date of diagnostic endoscopy with biopsy
Tumor distance from anal verge (cm)
Tumor Size, Largest Dimension (cm)
Clinical T Stage
Tumor Invades Submucosa (T1)
Tumor Invades Muscularis Propria (T2)
Tumor Invades Through The Muscularis
Propria Into The Subserosa, Or Into
Nonperitonealized Pericolic Or Perirectal
Tissues (T3)
Tumor Directly Invades Other Organs Or
Structures, And/or Perforates Visceral
1 / 7
Peritoneum (T4)
Clinical N Stage
No Regional Lymph Node Metastasis
(N0)
Metastasis In 1 To 3 Regional Lymph
Nodes (N1)
Metastasis In 4 Or More Regional Lymph
Nodes (N2)
Clinical M Stage
No Distant Metastases (M0)
Distant Metastasis (M1)
ECOG Performance Status (/Zubrod)
Fully Active, Able To Carry On All Pre-
disease Performance Without
Restriction. (0)
Restricted In Physically Strenuous
Activity But Ambulatory And Able To
Carry Out Work Of A Light Or Sedentary
Nature, E.g., Light Housework, Office
Work. (1)
Ambulatory And Capable Of All Selfcare
But Unable To Carry Out Any Work
Activities. Up And About More Than 50%
Of Waking Hours. (2)
Capable Of Only Limited Selfcare,
Confined To Bed Or Chair More Than
50% Of Waking Hours. (3)
Completely Disabled. Cannot Carry On
Any Selfcare. Totally Confined To Bed Or
Chair. (4)
Pregnancy test done
Yes
No
Date of pregnancy test  (If Yes,)
Reason pregnancy test not performed
Other (Other)
Patient Is Female But Is Not Of
Childbearing Potential (Patient is female
but is not of childbearing potential)
Patient Is Male (Patient is male)
Other, specify
No concurrent or previous invasive pelvic
malignancy (cervical, uterine and rectal) within
five years prior to registration.
Yes
No
Specify diagnosis
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Date of Diagnosis of Previous Malignancy
Neoadjuvant Therapy Date
Start date
End date
Therapy received
Bolus Fluorouracil (Bolus 5FU)
Capecitabine (Capecitabine)
Infusional Fluorouracil (Infusional 5FU)
Other (Other)
Radiation Therapy (Radiation Therapy)
Total dose (cGy)
Other specify
Post-treatment exam done
Yes
No
Method of Evaluation (check all that apply)
Ct Scan (CT scan)
Mri Scan (MRI scan)
Other (Other)
Ultrasound (Ultrasound)
Other Specify
Post-treatment maximum dimension of tumor
(cm)
Footer Module
Completed by
Date Form Completed
Patient Information
Registration Date
Patient Initials
Date of Birth
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Gender
Female Gender (FEMALE)
Male Gender (MALE)
Race
A Person Having Origins In Any Of The
Original Peoples Of North And South
America (including Central America),
And Who Maintains Tribal Affiliation Or
Community Attachment. (American
Indian or Alaska Native)
A Person Having Origins In Any Of The
Original Peoples Of The Far East,
Southeast Asia, Or The Indian
Subcontinent Including, For Example,
Cambodia, China, India, Japan, Korea,
Malaysia, Pakistan, The Philippine
Islands, Thailand, And Vietnam. (Asian)
A Person Having Origins In Any Of The
Black Racial Groups Of Africa. Terms
Such As "haitian" Or "negro" Can Be
Used In Addition To "black Or African
American." (Black or African American)
A Person Having Origins In Any Of The
Original Peoples Of Hawaii, Guam,
Samoa, Or Other Pacific Islands. (Native
Hawaiian or other Pacific Islander)
Could Not Be Determined Or Unsure
(Unknown)
A Person Having Origins In Any Of The
Original Peoples Of Europe, The Middle
East, Or North Africa. (White)
Ethnicity
A Person Of Mexican, Puerto Rican,
Cuban, Central Or South American Or
Other Spanish Culture Or Origin,
Regardless Of Race. (Hispanic or Latino)
A Person Not Meeting The Definition For
Hispanic Or Latino. (Not Hispanic or
Latino)
Could Not Be Determined Or Unsure
(Unknown)
Method of Payment
Medicaid (Medicaid)
Medicaid And Medicare (Medicaid and
Medicare)
Medicare (Medicare)
Medicare And Private Insurance
(Medicare and Private Insurance)
Military Or Veterans Sponsored Nos
(Military or Veterans Sponsored, Not
Otherwise Specified (NOS))
Military Sponsored (including Champus
& Tricare) (Military Sponsored (including
CHAMPUS & TRICARE))
No Means Of Payment (no Insurance)
(No means of payment (no insurance))
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Other (Other)
Private Insurance (Private Insurance)
Self Pay (no Insurance) (Self Pay (No
Insurance))
Veterans Sponsored (Veterans
Sponsored)
Other, specify
Weight
Height
Patient Zip Code
Postal code (Canada)
Other Country Postal Code (Other)
Country of Residence
Date Informed Consent Signed
HIPAA Authorization form (OR)
Included In Study Informed Consent
(Included in Study Informed Consent)
HIPAA Authorization Date
Eligibility Criteria
Histologic diagnosis of adenocarcinoma of the
rectum (<= 12cm from the anal verge)
Yes
No
T3N0M0, T1-3N1-2M0 disease as determined by
pre-neoadjuvant therapy CT scans and pelvic
MRI or transrectal ultrasound. Patients with T4
disease are not eligible
Yes
No
Completion of pre-operative 5FU-based
chemotherapy and/or radiation therapy.
Capecitabine may be substituted for 5FU.
Yes
No
Age >= 18 years
Yes
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No
ECOG (Zubrod) Performance Status <= 2
Yes
No
Body Mass Index <= 34 (The same value applies
to both male and female patients)
Yes
No
No evidence of conditions that would preclude
use of a laparoscopic approach (e.g., multiple
previous major laparotomies, severe adhesions).
Yes
No
No systemic disease (cardiovascular, renal,
hepatic, etc.) that would preclude surgery. No
other severe incapacitating disease, i.e., ASA IV
(a patient with severe systemic disease that is a
constant threat to life) or ASA V (a moribund
patient who is not expected to survive without the
operation)
Yes
No
No history of psychiatric or addictive disorders or
other conditions that, in the opinion of the
investigator, would preclude the patient from
meeting the study requirements.
Yes
No
No concurrent or previous invasive pelvic
malignancy (cervical, uterine and rectal) within
five years prior to registration.
Yes
No
Randomization
Randomization
Laparoscopic-assisted Rectal Resection
(Laparoscopic-assisted rectal resection)
Open Laparotomy And Rectal Resection
(Open laparotomy and rectal resection)
Colorectal Surgical Procedure
Planned operative procedure
Z6051-f2-l2 (Abdominal perineal
resection)
Z6051-f2-l1 (Low anterior resection)
Site of primary tumor
Z6051-f1-l1 (High rectum)
Z6051-f1-l3 (Low rectum)
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Z6051-f1-l2 (Middle rectum)
Date of CT/MRI scan
Date of EUS/MRI scan
Consent
My tissue specimens (if available) may be kept for
use in future research to learn about, prevent, or
treat cancer.
Yes
No
My tissue specimens (if available) may be kept for
use in research to learn about, prevent, or treat
other health
problems (for example: diabetes, Alzheimer¿s
disease, or heart disease).
Yes
No
My tissue specimens (if available) may be kept for
use in future genetic research.
Yes
No
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Surgical Reporting Form, GOG-0209, Form
C NCT00063999
Surgical Reporting Form, GOG-0209, Form C
NCT00063999
Combination Chemotherapy in Treating Patients With Stage
III, Stage IV, or Recurrent Endometrial Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=0CC6BA74-
781F-740A-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11201
Surgical Reporting Form, GOG-
0209, Form C NCT00063999
Header Module
Date form originally completed (m d y)
Date form amended (m d y)
Person amending form, last name
Patient Initials (First, Middle, Last)
Patient Study ID
Person completing form, last name
Gynecologic Surgical Procedure
Surgery Date (m d y)
Percent of gross tumor removed (%)
Residual gross tumor
Yes
No
Operative procedure performed (check all that
apply)
Bilateral Salpingo-oophorectomy
(bilateral salpingo-oophorectomy)
Deep Lymphadenectomy (Deep
lymphadenectomy)
Exenteration (Exenteration)
Hemivolvectomy (Hemi volvectomy)
Interval Debulking (Interval debulking)
Omentectomy (omentectomy)
Other, Specify (other specify)
Para-aortic Node Sampling/dissection
(para-aortic node sampling/dissection)
Pelvic Node Sampling/dissection (pelvic
node sampling/dissection)
Primary Debulking (Primary debulking)
Radical Hysterectomy (radical
hysterectomy)
1 / 4
Radical Trachelectomy (radical
trachelectomy)
Radical Vulvectomy (Radical vulvectomy)
Reassessment Laparotomy
(Reassessment laparotomy)
Superficial Lymphadenectomy
(Superficial lymphadenectomy)
Total Abdominal Hysterectomy (Total
abdominal hysterectomy)
Total Vaginal Hysterectomy (Total vaginal
hysterectomy)
Unilateral Salpingo-oophorectomy
(unilateral salpingo-oophorectomy)
Other, specify
Surgical approach
Laparoscopic Surgery (Laparoscopic)
Open (open)
Stage
0 (0)
Refer To Figo Staging For Specific
Gynecologic Cancer (1)
Refer To Figo Staging For Specific
Gynecologic Cancer (1A)
Refer To Figo Staging For Specific
Gynecologic Cancer (1B)
Refer To Figo Staging For Specific
Gynecologic Cancer (1C)
Refer To Figo Staging For Specific
Gynecologic Cancer (2)
Refer To Figo Staging For Specific
Gynecologic Cancer (2A)
Refer To Figo Staging For Specific
Gynecologic Cancer (2B)
Refer To Figo Staging For Specific
Gynecologic Cancer (2C)
Refer To Figo Staging For Specific
Gynecologic Cancer (3)
Refer To Figo Staging For Specific
Gynecologic Cancer (3A)
Refer To Figo Staging For Specific
Gynecologic Cancer (3B)
Refer To Figo Staging For Specific
Gynecologic Cancer (3C)
Refer To Figo Staging For Specific
Gynecologic Cancer (4)
Refer To Figo Staging For Specific
Gynecologic Cancer (4A)
Refer To Figo Staging For Specific
Gynecologic Cancer (4B)
Not Available (Not available)
Persistent (Persistent)
Recurrent (Recurrent)
Miscellaneous Assessment
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Greatest diameter of largest residual gross tumor
mass
Microscopic disease only
Yes
No
Ascites
Yes
No
Cytology of peritoneal or ascitic fluids
Negative (Negative)
Not Done (Not done)
Positive (Positive)
Suspicious (Suspicious)
Unavailable (Unavailable)
Summary of operative findings
Summary of operative findings (*)
Adb. Ureter - Lt. (Adb. Ureter - lt.)
Adb. Ureter - Rt. (Adb. Ureter - rt.)
Ant. Abdomen (Ant. Abdomen)
Anus (Anus)
Appendix (Appendix)
Ascending Colon (Ascending colon)
Bladder - Mucosa (Bladder - mucosa)
Bladder - Muscularis (Bladder -
muscularis)
Clitoris (Clitoris)
Common Iliac - Lt. (Common iliac - lt.)
Common Iliac - Rt. (Common iliac - rt.)
Deep Groin - Lt. (Deep groin - lt.)
Deep Groin - Rt. (Deep groin - rt.)
Descending Colon (Descending colon)
Duodenum (Duodenum)
External Iliac - Lt. (External iliac - lt.)
External Iliac - Rt. (External iliac - rt.)
Fallopian Tube - Lt. (Fallopian tube - lt.)
Fallopian Tube - Rt. (Fallopian tube - rt.)
Gall Bladder (Gall bladder)
Gutters - Lt. (Gutters - lt.)
Gutters - Rt. (Gutters - rt.)
Ileum (Ileum)
Internal - Lt. (Internal - lt.)
Internal - Rt. (Internal - rt.)
Introitus (Introitus)
Jejunum (Jejunum)
Kidney - Lt. (Kidney - lt.)
Kidney - Rt. (Kidney - rt.)
Labium Major - Lt. (Labium major - lt.)
Labium Major - Rt. (Labium major - rt.)
Labium Minor - Lt. (Labium minor - lt.)
Labium Minor - Rt. (Labium minor - rt.)
Large Bowel (Large bowel)
Left Scalene (Left scalene)
Liver Parenchyma (Liver parenchyma)
3 / 4
Surgical Reporting Form, GOG-0209, Form C NCT00063999
Liver Surface (Liver surface)
Obturator - Lt. (Obturator - lt.)
Obturator - Rt. (Obturator - rt.)
Omentum - Gastrocolic (Omentum -
gastrocolic)
Omentum - Infracolic (Omentum -
infracolic)
Ovary - Lt. (Ovary - lt.)
Ovary - Rt. (Ovary - rt.)
Pancreas (Pancreas)
Para-aortic - Lt. (Para-aortic - lt.)
Para-aortic - Rt. (Para-aortic - rt.)
Parametrium - Lt. (Parametrium - lt.)
Parametrium - Rt. (Parametrium - rt.)
Pelvic - Lt. (Pelvic - lt.)
Pelvic - Rt. (Pelvic - rt.)
Pelvic Bladder (Pelvic bladder)
Pelvic Cul-de-sac (Pelvic cul-de-sac)
Perineal Body (Perineal body)
Sig. Mucosa (Sig. Mucosa)
Sig. Muscularis (Sig. Muscularis)
Small Bowel (Small bowel)
Spleen (Spleen)
Stomach (Stomach)
Subdiaphragm - Lt. (subdiaphragm - lt.)
Subdiaphragm - Rt. (subdiaphragm - rt.)
Superficial Gr. - Lt. (Superficial gr. - lt.)
Superficial Gr. - Rt. (Superficial gr. - rt.)
Transverse Colon (Transverse colon)
Ureter - Lt. (Ureter - lt.)
Ureter - Rt. (Ureter - rt.)
Urethra (Urethra)
Uterus-cervix (Uterus-cervix)
Uterus-corpus (Uterus-corpus)
Vagina (Vagina)
Exam (*Examined: 1=tumor present; 2=no tumor;
3=suspicious; 4=organ absent; 5=not examined)
No Tumor (No tumor)
Not Examined (Not examined)
Organ Absent (Organ absent)
Suspicious (Suspicious)
Tumor Present (Tumor present)
Proc (*Procedure: 1=removed partially;
2=removed completely; 3=biopsy only; 4=left
intact; 5=not applicable)
Biopsy Only (Biopsy only)
Left Intact (Left intact)
Not Applicable (Not applicable)
Removed Completely (Removed
completely)
Removed Partially (Removed partially)
Comments
Comments
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Follow Up Status AML UKM
Routine documentation of University Hospital Muenster.  
Unit: Hematology and Internistic Oncology.
Based on items of original form: FollowUp Tumornachsorge
MS
All rights reserved. Please visit https://medical-data-
models.org/forms/11203
Follow Up Status AML UKM
Administrative Data
Patientenaufkleber
Studienpatient?
Letzter Kontakt
Krankheitsstatus
Initial Diagnosis (0)
Complete Remission (CR) (1)
Complete Remission, unconfirmed
(CRu) (2)
Persistent AML (3)
Aplasia (4)
Second Remission/Free of leukemic
blasts (5)
unknown (6)
Death (7)
Complete Remission (8)
Relaps (9)
Datum
Datum ungenau
Ja
Nein
Überlebensstatus
dead (dead)
surviving (surviving)
Diagnosen
Diagnosis
ICD-Code
Therapien
Prozedurname
Prozedurcode (OPS)
Weitere Angaben
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Stammzelltransplantation
Ja
Nein
Infektion
Ja
Nein
FAB
M1 (M1)
M2 (M2)
M3 (M3)
M4 (M4)
M5 (M5)
M6 (M6)
M7 (M7)
MO (MO)
unknown (unknown)
FLT3ITD mutation positiv
Ja
Nein
FLT3TKD mutation positiv
Ja
Nein
CEPBA positive
Ja
Nein
Zytogenetik
11q23 (11q23)
5q- (5q-)
complex (complex)
inv(16) (inv(16))
normal (normal)
other (other)
t(15;17) (t(15;17))
t(8;21) (t(8;21))
trisomy 8 (trisomy 8)
unknown (unknown)
Rezidive
Nummer
Lokalisation
Blood/Bone marrow (Blood/Bone
marrow)
Extramedullary (Extramedullary)
Other (Other)
ZNS (ZNS)
Sonstiges
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Kommentare
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Follow Up Status AML UKM
ASIA score
Items used as routine documentation by the university
hospital muenster.
Derived from original form "Biobank MS". Converted to
ODM format.
All rights reserved. Please visit https://medical-data-
models.org/forms/11206
ASIA score
Patienteninformationen
Name des Patienten:
Geburtsdatum:
Geschlecht:
männlich  (1)
weiblich (2)
Untersucher:
Aufnahmedatum:
SENSIBILITÄT - Sensible Kennzonen
Innervation:
C2 (1)
T3 (10)
T4 (11)
T5 (12)
T6 (13)
T7 (14)
T8 (15)
T9 (16)
T10 (17)
T11 (18)
T12 (19)
C3 (2)
L1 (20)
L2 (21)
L3 (22)
L4 (23)
L5 (24)
S1 (25)
S2 (26)
S3 (27)
S4-5 (28)
C4 (3)
C5	 (4)
C6 (5)
C7 (6)
C8 (7)
T1 (8)
T2 (9)
Berührung rechts:
keine Angabe (1)
fehlend (0) (2)
eingeschränkt (1) (3)
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normal (2) (4)
nicht prüfbar (5)
Berührung links:
keine Angabe (1)
fehlend (0) (2)
eingeschränkt (1) (3)
normal (2) (4)
nicht prüfbar (5)
Nadelstich rechts:
keine Angabe (1)
fehlend (0) (2)
eingeschränkt (1) (3)
normal (2) (4)
nicht prüfbar (5)
Nadelstich links:
keine Angabe (1)
fehlend (0) (2)
eingeschränkt (1) (3)
normal (2) (4)
nicht prüfbar (5)
Sensorische Gesamtpunktzahl
Berührungs-Score:
Nadelstich-Score:
Perianale Empfindung?
Ja
Nein
MOTORIK - Kennmuskeln
Kennmuskeln:
C5 Ellbogenbeuger (1)
S1 Fusssenker (10)
C6 Handgelenkstrecker (2)
C7 Ellbogenstrecker (3)
C8 Fingerbeuger (distale Phalanx des
Mittelfingers) (4)
T1 Fingerabspreizer (5)
L2 Hüftbeuger (6)
L3 Kniestrecker (7)
L4 Fussheber (8)
L5 Grosszehenstrecker (9)
Rechts:
komplette Lähmung (0) (1 )
tastbare oder sichtbare Kontraktion (1) (2
)
aktive Bewegung, Schwerkraft
aufgehoben (2) (3 )
aktive Bewegung, gegen Schwerkraft (3)
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(4 )
aktive Bewegung, gegen geringen
Widerstand (4) (5 )
aktive Bewegung, gegen vollen
Widerstand (5) (6 )
nicht prüfbar (7)
Keine Angabe (8)
Links:
komplette Lähmung (0) (1 )
tastbare oder sichtbare Kontraktion (1) (2
)
aktive Bewegung, Schwerkraft
aufgehoben (2) (3 )
aktive Bewegung, gegen Schwerkraft (3)
(4 )
aktive Bewegung, gegen geringen
Widerstand (4) (5 )
aktive Bewegung, gegen vollen
Widerstand (5) (6 )
nicht prüfbar (7)
Keine Angabe (8)
Motorik Gesamtpunktzahl
Motorik - Score:
Willkürliche Analsphinkterkontraktion?
Ja
Nein
Neurologische Höhen (Das kaudalste
Segment mit normaler Funktion)
Sensibilität rechts:
Sensibilität links:
Motorik rechts:
Motorik links:
Zone mit teilweise erhaltener Funktion
(Kaudale Grenze partiell innervierter
Segmente)
Sensibilität rechts:
Sensibilität links:
Motorik rechts:
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Motorik links:
Klassifikation
Komplett oder inkomplett? (Inkomplett=Vorliegen
irgendwelcher sensibler oder motorischer
Funktion in tiefstem
sakralem Segment)
Komplett (1)
Inkomplett (2)
ASIA Klassifikation:
A komplett; keine sensible oder
motorische Funktion in den sakralen
Segmenten S4 und S5 vorhanden (1)
B inkomplett; motorisch komplett,
sensible Funktion unterhalb des
neurologischen Niveaus und bis in die
sakralen Segmente S4 und S5 erhalten
(2)
C inkomplett; motorische Funktion
unterhalb des neurologischen Niveaus
erhalten; die Mehrzahl der Kennmuskeln
unterhalb des neurologischen Niveaus
besitzen einen Kraftgrad <3 (3)
D inkomplett; motorische Funktion
unterhalb des neurologischen Niveaus
erhalten; die Mehrzahl der Kennmuskeln
unterhalb des neurologischen Niveaus
besitzen einen Kraftgrad von 3 und mehr
(4)
E normal; sensible und motorische
Funktion völlig ungestört (keine
Beeinträchtigung) (5)
Klinische Syndrome:
Central Cord (1)
Brown-Sequard (2)
Anterior Cord (3)
Conus Medullaris (4)
Cauda Equina (5)
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EHR Medical History Cardiac Patients
EHR Medical History Cardiac Patients.
From the University Hospital of Münster, Germany,
Department of Nuclear Medicine.
AN MS MSZ Studie NUK
All rights reserved. Please visit https://medical-data-
models.org/forms/11208
Anamnese Kardiologische Patienten
Anamnese
Erhoben am*
Erhoben um*
Erhoben von*
Erhebungsmodus der Anamnese*
Fremdanamnese*
Jetzige Anamnese*
Luftnot*
Ödeme*
Synkopen*
Nykturie*
Alter*
>= 0
<= 120
years
Größe*
>= 0
<= 250
cm
Gewicht*
>= 0
<= 250
kg
Vorerkrankungen*
Operationen*
Medikamente*
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Allergien*
Alkohol*
Nikotin*
Risikofaktoren*
Diabetes*
Diabetes Typ 1 (1)
Diabetes Typ 2 (2)
Apoplex*
Ja
Nein
Apoplex Datum*
PAVK*
Ja
Nein
Niereninsuffizienz*
Ja
Nein
dialysepflichtig*
Ja
Nein
NTXVorbereitung*
Ja
Nein
Familienkrankheiten*
Radiatio*
Ja
Nein
Praechemotherapie*
Ja
Nein
Kardiomyopathie*
Ja
Nein
Kinderkrankheiten*
Weitere Erkrankungen*
Beruf*
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Familienstand*
Verheiratet (1)
Getrennt (2)
Verwitwet (3)
Ledig (4)
Geschieden (5)
Häusliche Situation (versorgt ja/nein)*
Stuhlgang*
Miktion*
Nachtschweiß*
Fieber*
Husten*
Auswurf*
Appetit*
Durst*
Schlaf*
Regelblutung*
Schwangerschaft*
Ja
Nein
Stillzeit*
Ja
Nein
Geburten*
Anzahl Kinder*
Indikation und klinische Fragestellung
Verdacht auf KHK*
Ja
Nein
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Bekannte KHK*
Ja
Nein
Herzinfarkt*
Ja
Nein
Angina pectoris*
Herzrhythmusstörungen*
ICD*
Ja
Nein
Schockschwelle*
Schrittmacher*
Ja
Nein
Verdacht auf toxische Kardiomyopathie*
Ja
Nein
Herztransplantation*
Ja
Nein
Datum Herztransplantation*
Lyse*
Ja
Nein
Stent*
Ja
Nein
Bypass*
RCA*
LCA*
LAD*
RCX*
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SIOP CNS GCT II
SIOP CNS GCT II: Prospective Trial for the Diagnosis and
Treatment of Children, Adolescents and Young Adults With
Intracranial Germ Cell Tumors. Principal Investigator
Gabriele Calaminus, MD.
http://clinicaltrials.gov/show/NCT01424839
All rights reserved. Please visit https://medical-data-
models.org/forms/11210
Physical development and additional
pretherapeutic measurements
Physical development
Größe*
>= 0
cm
Perzentile Größe*
>= 0
%
Sitzhöhe*
>= 0
cm
Kopfumfang*
cm
Gewicht*
>= 0
kg
Perzentile Gewicht*
%
Sexual development
Tannerstadium
Schambehaarung*
Stadium 1 (1)
Stadium 2 (2)
Stadium 3 (3)
Stadium 4 (4)
Stadium 5 (5)
Tannerstadium der mÃ¤nnlichen Genitalien*
Stadium 1 (1)
Stadium 2 (2)
Stadium 3 (3)
Stadium 4 (4)
Stadium 5 (5)
Kyrokonservierung der Spermien durchgefÃ¼hrt*
Nein (1)
Ja (2)
Tannerstadium der weiblichen Brust*
Stadium 1 (1)
Stadium 2 (2)
Stadium 3 (3)
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Stadium 4 (4)
Stadium 5 (5)
Alter bei Menarche*
YY,MM
Letzte Menstruationsblutung vor Therapie*
Zurzeit schwanger*
Nein (1)
Ja (2)
Kyrokonservierung von Eizellen durchgefÃ¼hrt*
Nein (1)
Ja (2)
Renal toxicity
Renale Funktion*
Normal (0)
Nicht normal, CTC Grad 1 (1)
Nicht normal, CTC Grad 2 (2)
Nicht normal, CTC Grad 3 (3)
Nicht normal, CTC Grad 4 (4)
Toxicity Pure tone audiogram or BAER
Audiogramm oder BAER*
Normal (0)
Nicht normal, CTC Grad 1 (1)
Nicht normal, CTC Grad 2 (2)
Nicht normal, CTC Grad 3 (3)
Nicht normal, CTC Grad 4 (4)
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CDASH Vital Signs (fine 2)
modified from http://www.cdisc.org
All rights reserved. Please visit https://medical-data-
models.org/forms/11211
CDASH Vital Signs (fine 2)
Date of Vital Signs measurement
Date of vital signs*
Height
Height collected?*
NO (N)
YES (Y)
Height*
>= 0
cm
Clinically Significant*
NO (N)
YES (Y)
Weight
Weight collected?*
NO (N)
YES (Y)
Weight*
>= 0
kg
Clinically Significant*
NO (N)
YES (Y)
Blood pressure
BP collected?*
NO (N)
YES (Y)
Time*
Diastolic*
mmHg
Systolic*
mmHg
BP Location*
ANKLE (ANKLE)
BRACHIAL ARTERY (BRACHIAL
ARTERY)
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BP Position*
PRONE (PRONE)
SITTING (SITTING)
STANDING (STANDING)
SUPINE (SUPINE)
BP Clinically Significant*
NO (N)
YES (Y)
Pulse
Pulse collected?*
NO (N)
YES (Y)
Pulse*
BEATS/MIN
Pulse Location*
BRACHIAL ARTERY (BRACHIAL
ARTERY)
CAROTID ARTERY (CAROTID
ARTERY)
RADIAL ARTERY (RADIAL ARTERY)
Pulse Position*
PRONE (PRONE)
SITTING (SITTING)
STANDING (STANDING)
SUPINE (SUPINE)
Clinically Significant*
NO (N)
YES (Y)
Temperature
Temperature collected?*
NO (N)
YES (Y)
Temperature*
°C
Temperature Location*
AXILLA (AXILLA)
EAR (EAR)
Clinically Significant*
NO (N)
YES (Y)
Frame size
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Frame Size collected?*
NO (N)
YES (Y)
Frame Size*
LARGE (LARGE)
MEDIUM (MEDIUM)
SMALL (SMALL)
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SHORT STAY RECORD ID NOTE-ENDO
Form from HIS OpenVista
All rights reserved. Please visit https://medical-data-
models.org/forms/11212
HIS
SHORT STAY RECORD ID NOTE-ENDO
Age*
>= 0
<= 120
years
Sex*
male (1)
female (2)
Racial group
Height
>= 0
cm
Weight
>= 0
kg
Hypersensitivity*
Chief complaint (CC)
Abnormal GI Xray*
Yes
No
Abdominal Pain*
Yes
No
Abnormal weight loss (finding)*
Yes
No
Achalasia*
Yes
No
Anaemia*
Yes
No
Ascites*
Yes
No
Irregular bowel habits*
Yes
No
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Liver Cirrhosis*
Yes
No
Screening for Colorectal Cancer*
Yes
No
Common Bile Duct Leak
Yes
No
Common Bile Duct Stone*
Yes
No
Constipation*
Yes
No
Diarrhea*
Yes
No
Indigestion*
Yes
No
Deglutition Disorders*
Yes
No
Elevated Liver Function Tests*
Yes
No
Oesophageal Varices *
Yes
No
Family History of Colon Cancer*
Yes
No
Family History of Polyps*
Yes
No
Family History of Polyposis*
Yes
No
Foreign Body in Colon*
Yes
No
Foreign Body in Esophagus*
Yes
No
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Foreign Body in Stomach*
Yes
No
Peptic Ulcer*
Yes
No
Gastroesophageal reflux disease (GERD)*
Yes
No
Gastrointestinal Hemorrhage*
Yes
No
Haematemesis*
Yes
No
History of Barrett's*
Yes
No
History of Cholangiocarcinoma*
Yes
No
History of Colon Cancer*
Yes
No
History of Crohn's Disease*
Yes
No
History of Diverticulosis*
Yes
No
History of Esophageal Cancer*
Yes
No
History of Esophageal/ Gastric Varicies*
Yes
No
History of Gastric Cancer*
Yes
No
History of Pancreatic Cancer*
Yes
No
History of Peptic Ulcer Disease*
Yes
No
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History of Polyps*
Yes
No
History of Ulcerative Colitis*
Yes
No
Blood in Stool*
Yes
No
Iron Deficiency Anaemia*
Yes
No
Icterus*
Yes
No
Melaena*
Yes
No
Nausea*
Yes
No
Emesis*
Yes
No
Occult/Guaiac Positive Stool*
Yes
No
Pancreatitis*
Yes
No
Portal Hypertension*
Yes
No
gastric reflux*
Yes
No
Abnormal weight loss*
Yes
No
Other*
History of present illness*
Home Medications*
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Physical examination
Temperature
°C
Pulse Rate
beats/minute
Respiration rate, Breathing rate (BR)
/min
Blood pressure (BP)*
mmHg
General Apperance unremarkable*
Yes
No
general appearance*
HEENT within normal limits*
Yes
No
Head, Ears, Eyes, Nose and Throat*
Neck supple, no jugular vein distention*
Yes
No
Neck, Collum, Cervical*
Chest, Thorax*
Mammary region*
Heart S1 S2 present, Regular rhythm and rate*
Yes
No
Heart*
Abdomen Soft, (+) Bowel sounds, Normal tone*
Yes
No
Abdomen*
Lymph Nodes not palpable*
Yes
No
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lymph nodes*
GENITALIA/RECTAL*
Extremities No clubbing, cyanosis or edema*
Yes
No
Extremities, Limb structure*
Skin: No abnormalities detected*
Yes
No
Integument*
Neurological: No abnormalities detected*
Yes
No
Neurologic system, Nervous system, Nervous
system structure*
ADMITTING DIAGNOSIS (AD)*
PLAN: Endoscopy*
ASA score, Finding of American Society of
Anesthesiologists physical status classification
Teeth*
Normal (1)
Loose Teeth (2)
Dental Prosthesis(es) (3)
Co-Existing Dental Abnormalities (4)
Mallampati score*
The soft palate, uvula, fauces, and pillars
are visible (Class 1)
The soft palate, uvula and fauces are
visible (Class 2)
The soft palate and base of uvula are
visible (Class 3)
The hard palate only is visible (Class 4)
NECK EXTENSION
past medical History, prior medical History
past medical History, prior medical History*
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Prior Surgery, History of (H/O)  surgery, Past
surgical history*
Family history (FH)*
Social and personal history, Social and personal
circumstances*
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NUTRITION SCREENING CONSULT
RESULTS MAIN
Form from HIS OpenVistA
All rights reserved. Please visit https://medical-data-
models.org/forms/11213
HIS
BASIC EVALUATION
Age*
>= 0
<= 120
years
Patient sex*
Female (1)
Male (2)
Unknown (3)
Height
>= 0
cm
Weight*
Weight change (increase|decrease| stable)*
Ideal Body Weight (IBW) +/-10%*
Weight status (underweight| normal| overweight|
obese)*
Diet
PO intake*
COMMENTS
Patient triggered for problem swallowing difficulty*
Yes
No
Patient states no problems with swallowing
difficulty*
Yes
No
Swallow difficulty due to sore throat. Nursing
Notified.*
Yes
No
Patient needs diet consistency change to  diet.*
Yes
No
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Patient needs special foods of appropriate
consistency.*
Yes
No
other*
Patient triggered for poor po intake > 5 days.*
Yes
No
Patient requests oral supplements of *
Patient states no problems with po intake.*
Yes
No
Patient states po intake improved>50% at all
meals.*
Yes
No
Patient states no appetite.*
Yes
No
Patient states unable to eat certain foods:*
Patient started on nutrition support*
Yes
No
other*
Patient triggered for unintentional weight loss of
10 pounds or more in 3 months.*
Yes
No
Patient states no weight loss.*
Yes
No
Patient was on a diet, weight loss was
intentional.*
Yes
No
Patient states weight loss due to increased
activity.*
Yes
No
other*
Patient triggered for food allergies*
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Yes
No
Patient states they have no food
allergies/intolerances.*
Yes
No
Patient has no food intolerances to*
All food allergies/intolerances were identified.*
Yes
No
other*
Patient triggered for being pregnant and less than
16 years old of age.*
Yes
No
Patient is greater than 16 years old of age.*
Yes
No
Patient is not pregnant.*
Yes
No
other*
Patient triggered for being pregnant and on
special diet.*
Yes
No
Patient is not pregnant.*
Yes
No
Patient is not on a special diet.*
Yes
No
Patient is on  diet for*
Patient understands special diet, does not need
additional information.*
Yes
No
Patient does not understand special diet.*
Yes
No
Patient triggered for being below 10th percentile
of Pediatric Growth Charts.*
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Yes
No
Patient is at 50th percentile or greater on growth
charts.*
Yes
No
Patient is between 25th and 50th percentile on
growth charts.*
Yes
No
Patient seen due to extended length of stay in
hospital.*
Yes
No
other*
GOALS
Patient to resume po intake (if currently NPO).*
Yes
No
Patient to transition to solid foods (if on CL or FL
diet).*
Yes
No
Patient to be provided foods of appropriate
consistency to decrease swallowing difficulty.*
Yes
No
Patient to continue po intake>75% at
meals/snacks.*
Yes
No
PO intake to be greater than 50% at all
meals/snacks.*
Yes
No
Weight gain of 1-2 lbs per week.*
Yes
No
Patient will not receive foods that they have
indicated as being allergic or intolerate to.*
Yes
No
Patient to understand diet currently ordered by
physician.*
Yes
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No
Patient to be seen by dietician due to:*
other*
LEVEL OF CARE
Level of care, HCPCS Level II National Modifiers*
PLAN
Continue with diet as currently ordered.*
Yes
No
Advance diet as tolerated.*
Yes
No
Explain menu process. Encourage continued
good intake > 50%.*
Yes
No
Encourage patient to mark menu selections.*
Yes
No
Obtain food preferences. Place in computer and
notify kitchen.*
Yes
No
Discuss adding oral supplement with nursing or
dietician.*
Yes
No
Provide snacks to increase po intake.*
Yes
No
Notify diet office of food allergens or intolerances
via computer.*
Yes
No
Provided educational handout on diet. Give RD
contact information for further questions.*
Yes
No
Inform dietician of need for extensive diet
education on  diet.*
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Yes
No
Follow patient per protocol.*
Yes
No
Refer to dietician
Yes
No
other*
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Ewing Study
EWING 2008, EudraCT 2008-003658-13,
http://clinicaltrials.gov/ct2/show/NCT00824083
All rights reserved. Please visit https://medical-data-
models.org/forms/11215
VAI and/or VAC Courses
Body dimensions
Körpergröße
>= 0
cm
Körpergewicht
>= 0
kg
Körperoberfläche
>= 0
m²
Körperoberfläche berechnet
>= 0
m²
Patient < 1 Jahr oder < 10 kg*
Nein (0)
Ja (1)
VAI/VAC course
Tag 1 dieses Kurses*
Kurs-Nr. (bitte Hinweis lesen!)*
Verzögerung >5 Tage
Nein (0)
Ja, wegen Toxizität des vorhergehenden
Kurses (1)
Ja, aus anderen Gründen (2)
Gleichzeitige Radiotherapie
Ja
Nein
VAI oder VAC
VAI (1)
VAC (2)
Protokollabweichung/-modifizierung in diesem
Kurs
Ja
Nein
Schedule deviation CTC-Code
Grund für Protokollabweichung/-modifizierung*
Problem der Medikation (0)
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Allgemeinzustand (1)
Post-Transplantations-Kurs (102)
Arzt-/Klinische Entscheidung (nur
verwenden, wenn kein anderer Code
zutrifft!) (103)
Post Amputation (104)
Tox. Hämoglobin (11)
Tox. Leukozyten (12)
Tox. Granulozyten (13)
Tox. Thrombozyten (14)
Tox. Infektion (21)
Tox. Fieber (22)
Tox. Stomatitis (31)
Tox. Erbrechen (32)
Tox. Diarrhoe (33)
Tox. Hautveränderungen (40)
Tox. Kreatinin (51)
Tox. Proteinurie (52)
Tox. Hämaturie (53)
Tox. Glomeruläre Filtrationsrate (GFR)
(54)
Tox. Tubuläre Phosphatreabsorption (55)
Tox. Bilirubin (61)
Tox. SGOT/SGPT (62)
Tox. Herzfunktion (71)
Tox. ECHO: LV-SF (72)
Tox. Zentrale Neurotoxizität (81)
Tox. Periphere Neurotoxizität (82)
Tox. Sonstige Toxizität (90)
Technische Probleme (93)
Planungsprobleme (94)
Patienten-/Elternablehnung (95)
Zu geringes Gewicht/zu jung (96)
Fehler (97)
Mobilisationskurs (98)
Radiotherapie (99)
Adminstration of VAI or VAC
chemotherapy
Vincristin (VCR) kumulative Gesamtdosis pro
Kurs*
mg
Vincristin (VCR) kumulative Gesamtdosis pro
Kurs lt. Protokoll*
mg
Actinomycin D (ACT) kumulative Gesamtdosis
pro Kurs*
mg
Actinomycin D (ACT) kumulative Gesamtdosis
pro Kurs lt. Protokoll*
mg
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Ifosfamid (IFO) kumulative Gesamtdosis pro
Kurs*
mg
Ifosfamid (IFO) kumulative Gesamtdosis pro Kurs
lt. Protokoll*
mg
Cyclophosphamid (CYC) kumulative
Gesamtdosis pro Kurs*
mg
Cyclophosphamid (CYC) kumulative
Gesamtdosis pro Kurs lt. Protokoll*
mg
Andere Zytostatika*
Nein (0)
Ja (1)
Other cytotoxic drug
Generischer Wirkstoffname
Aclarubicin (1)
Erwinia-Asparaginase (NSC-106977,
Porton Asparaginase) (10)
PEG-ASP (11)
Azacytidine (12)
Carmustine (BCNU, 1,3-bis(2-
chloroethyl)-l-nitrosourea) (13)
Bleomycin (14)
Antibody 14G2a (14G2a)
Busulfan (Busulphan, Busulfanum,
Myelosan, BSF) (15)
Carboplatin (CBDCA, JM8, NSC
241240) (16)
Lomustine (17)
Cladribine (CdA, 2-CdA, 2-chloro-2'-
deoxyadenosine, NSC-105014-F) (18)
Chlorambucil (Chlorambucilum, NSC-
3088, WR-139013, Chlorbutinum) (19)
Nimustine (2)
Cyclophosphamide (Cyclo, CPA, CPM,
CTX, CYC, CYT) (20)
Ciclosporin (Cyclosporin) (21)
Cisplatin, (Cis-platinum, cis-
diamminedichloroplatinum, CDDP, DDP,
CIS, Platinum) (22)
Dexamethasone (23)
Daunorubicin (daunomycin, DNR,
rubidomycin) (24)
Doxorubicin (Adriamycin, Hydroxyl
daunorubicin, Dox, Adria) (25)
Dacarbazine (DIC, Imidazole
carboxamide, dimethyl-triazeno-
imidazole-carboxamide) (26)
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Epirubicin (4'-epi-doxorubicin, NSC-
256942, IMI28, epi DX) (27)
Fludarabine (2-F-ara-AMP, FAMP, NSC-
312887, Fludarabine phosphate) (28)
Fluorouracil (5-Fluorouracil, 5FU) (29)
Actinomycin D (Dactinomycin) (3)
G-CSF (30)
GM-CSF (31)
Hydroxyurea (32)
Idarubicin (33)
Interferon ALPHA (34)
Interferon GAMMA (35)
Ifosfamide (36)
Folinic Acid (LV, calcium leucovorin,
calcium folinate, citrovorum factor) (37)
Mechlorethamine (38)
Melphalan (39)
Amsacrine (Acridinyl, Anisidide, m-
AMSA, AMSA, Amsidyl) (4)
Mesna (40)
Mitoxantrone (42)
Mercaptopurine (43)
Methotrexate (44)
Prednisone (45)
Procarbazine (46)
Paclitaxel (47)
Thiotepa (48)
Tioguanine (49)
Cytarabine (Cytosine Arabinoside, Ara-
C, Arabinosylcytosine) (5)
Trofosfamide (50)
Vinblastine (51)
Vincristine (52)
Vindesine (53)
Teniposid (54)
Etoposide (VP-16, VP-16-213, EPEG,
EPE, epipodophyllotoxin) (55)
Daunoxome (56)
Rasburicase (57)
Rituximab (58)
Budesonide (59)
Asparaginase (L-asparaginase,
Colaspase, L-ASP, Crasnitin, Elspar) (6)
Immunglobuline (human) (60)
Treosulfan (61)
Alemtuzumab (62)
Coli Asparaginase (9)
Co-trimoxazol (93)
Hydrocortisone (94)
Anderes (999)
Antithymozyten globuline (ATG)
Tretinoin (ATRA) (ATRA)
Beclomethasone (BEC)
Antibody ch14.18 (CH1418)
Epoetin alfa (Erythropoetin) (ERYPOa)
Epoetin beta (Erythropoetin) (ERYPOb)
Etanercept (ETAN)
Tacrolimus (FK506)
Interleukin 1 (IL1)
Interleukin 12 (IL12)
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Interleukin 13 (IL13)
Interleukin 2 (IL2)
Interleukin 3 (IL3)
Interleukin 4 (IL4)
Interleukin 6 (IL6)
Interleukin 7 (IL7)
Interleukin 8 (IL8)
Mitomycin (MIT)
Mycophenolat (MMF)
Monoclonal AB (MonoAB)
Muromonab (OKT3)
Imatinib (STI571)
Topotecan (TOPO)
Falls anderes Generikum, Name*
Kumulative Gesamtdosis pro Kurs*
mg
Supportive drug treatment
G-CSF/GM-CSF*
Nein (0)
Ja (1)
Sonstige Zytokintherapie (z.B. EPO)*
Nein (0)
Ja (1)
Sonstiges Zytokin*
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Administration of high dose
chemotherapy
Body dimensions
Körpergröße
>= 0
cm
Körpergewicht
>= 0
kg
Körperoberfläche
>= 0
m²
Körperoberfläche berechnet
>= 0
m²
Patient < 1 Jahr oder < 10 kg*
Nein (0)
Ja (1)
High dose chemotherapy course
Tag 1 dieses Kurses*
Verzögerung >5 Tage
Ja
Nein
Grund für Verzögerung
Wegen OP-bedingten Komplikationen (1)
Bedingt durch Probleme bei der
Stammzellsammlung (2)
Wegen Beeinträchtigung des
Allgemeinzustandes (3)
Aus anderen Gründen (4)
Anderer Grund*
High dose chemotherapy regimen
Art der Hochdosistherapie*
Bu-Mel (1)
Andere (2)
Treo-Mel (3)
Andere Therapie*
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Deviation of high dose chemotherapy
Protokollabweichung/-modifizierung in diesem
Kurs*
Nein (0)
Ja (1)
Grund*
Wegen kardialer Toxizität (1)
Wegen renaler Toxizität (2)
Wegen pulmonaler Toxizität (3)
Wegen Lebertoxizität (4)
Aus anderen Gründen (5)
Anderer Grund*
Adminstration of high dose chemotherapy
Busulfan (BU) IV kumulative Gesamtdosis pro
Kurs*
mg
Busulfan (BU) IV kumulative Gesamtdosis pro
Kurs lt. Protokoll*
mg
Busulfan (BU) IV verabreicht Ã¼ber*
Tage
Treosulfan (TREO) kumulative Gesamtdosis pro
Kurs*
mg
Treosulfan (TREO) kumulative Gesamtdosis pro
Kurs lt. Protokoll*
mg
Treosulfan (TREO) verabreicht Ã¼ber*
Tage
Melphalan (MEL) kumulative Gesamtdosis pro
Kurs*
mg
Melphalan (MEL) kumulative Gesamtdosis pro
Kurs lt. Protokoll*
mg
Melphalan (MEL) verabreicht Ã¼ber*
Tage
Andere Zytostatika*
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Nein (0)
Ja (1)
Other cytotoxic drug
Generischer Wirkstoffname*
Aclarubicin (1)
Erwinia-Asparaginase (NSC-106977,
Porton Asparaginase) (10)
PEG-ASP (11)
Azacytidine (12)
Carmustine (BCNU, 1,3-bis(2-
chloroethyl)-l-nitrosourea) (13)
Bleomycin (14)
Antibody 14G2a (14G2a)
Busulfan (Busulphan, Busulfanum,
Myelosan, BSF) (15)
Carboplatin (CBDCA, JM8, NSC
241240) (16)
Lomustine (17)
Cladribine (CdA, 2-CdA, 2-chloro-2'-
deoxyadenosine, NSC-105014-F) (18)
Chlorambucil (Chlorambucilum, NSC-
3088, WR-139013, Chlorbutinum) (19)
Nimustine (2)
Cyclophosphamide (Cyclo, CPA, CPM,
CTX, CYC, CYT) (20)
Ciclosporin (Cyclosporin) (21)
Cisplatin, (Cis-platinum, cis-
diamminedichloroplatinum, CDDP, DDP,
CIS, Platinum) (22)
Dexamethasone (23)
Daunorubicin (daunomycin, DNR,
rubidomycin) (24)
Doxorubicin (Adriamycin, Hydroxyl
daunorubicin, Dox, Adria) (25)
Dacarbazine (DIC, Imidazole
carboxamide, dimethyl-triazeno-
imidazole-carboxamide) (26)
Epirubicin (4'-epi-doxorubicin, NSC-
256942, IMI28, epi DX) (27)
Fludarabine (2-F-ara-AMP, FAMP, NSC-
312887, Fludarabine phosphate) (28)
Fluorouracil (5-Fluorouracil, 5FU) (29)
Actinomycin D (Dactinomycin) (3)
G-CSF (30)
GM-CSF (31)
Hydroxyurea (32)
Idarubicin (33)
Interferon ALPHA (34)
Interferon GAMMA (35)
Ifosfamide (36)
Folinic Acid (LV, calcium leucovorin,
calcium folinate, citrovorum factor) (37)
Mechlorethamine (38)
Melphalan (39)
Amsacrine (Acridinyl, Anisidide, m-
AMSA, AMSA, Amsidyl) (4)
Mesna (40)
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Mitoxantrone (42)
Mercaptopurine (43)
Methotrexate (44)
Prednisone (45)
Procarbazine (46)
Paclitaxel (47)
Thiotepa (48)
Tioguanine (49)
Cytarabine (Cytosine Arabinoside, Ara-
C, Arabinosylcytosine) (5)
Trofosfamide (50)
Vinblastine (51)
Vincristine (52)
Vindesine (53)
Teniposid (54)
Etoposide (VP-16, VP-16-213, EPEG,
EPE, epipodophyllotoxin) (55)
Daunoxome (56)
Rasburicase (57)
Rituximab (58)
Budesonide (59)
Asparaginase (L-asparaginase,
Colaspase, L-ASP, Crasnitin, Elspar) (6)
Immunglobuline (human) (60)
Treosulfan (61)
Alemtuzumab (62)
Coli Asparaginase (9)
Co-trimoxazol (93)
Hydrocortisone (94)
Anderes (999)
Antithymozyten globuline (ATG)
Tretinoin (ATRA) (ATRA)
Beclomethasone (BEC)
Antibody ch14.18 (CH1418)
Epoetin alfa (Erythropoetin) (ERYPOa)
Epoetin beta (Erythropoetin) (ERYPOb)
Etanercept (ETAN)
Tacrolimus (FK506)
Interleukin 1 (IL1)
Interleukin 12 (IL12)
Interleukin 13 (IL13)
Interleukin 2 (IL2)
Interleukin 3 (IL3)
Interleukin 4 (IL4)
Interleukin 6 (IL6)
Interleukin 7 (IL7)
Interleukin 8 (IL8)
Mitomycin (MIT)
Mycophenolat (MMF)
Monoclonal AB (MonoAB)
Muromonab (OKT3)
Imatinib (STI571)
Topotecan (TOPO)
Falls anderes Generikum, Name*
Kumulative Gesamtdosis pro Kurs*
mg
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Add-on R1
Body dimensions
Körpergröße
>= 0
cm
Körpergewicht
>= 0
kg
Körperoberfläche
>= 0
m²
Körperoberfläche berechnet
>= 0
m²
Patient < 1 Jahr oder < 10 kg
Ja
Nein
Add-on Kurs
Tag 1 dieses Kurses*
Kurs-Nr. (bitte Hinweis lesen!)*
Verzögerung?
Nein (0)
Ja, wegen Toxizität des vorhergehenden
Kurses (1)
Ja, aus anderen Gründen (2)
Protokollabweichung/-modifizierung in diesem
Kurs*
Nein (0)
Ja (1)
Zoledronsäure*
mg
Dosis Zoledronsäure lt. Protokoll
mg
Gleichzeitige Radiotherapie
Ja
Nein
Schedule deviation CTC-Code
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Grund für Protokollabweichung/-modifizierung
Problem der Medikation (0)
Allgemeinzustand (1)
Post-Transplantations-Kurs (102)
Arzt-/Klinische Entscheidung (nur
verwenden, wenn kein anderer Code
zutrifft!) (103)
Post Amputation (104)
Tox. Hämoglobin (11)
Tox. Leukozyten (12)
Tox. Granulozyten (13)
Tox. Thrombozyten (14)
Tox. Infektion (21)
Tox. Fieber (22)
Tox. Stomatitis (31)
Tox. Erbrechen (32)
Tox. Diarrhoe (33)
Tox. Hautveränderungen (40)
Tox. Kreatinin (51)
Tox. Proteinurie (52)
Tox. Hämaturie (53)
Tox. Glomeruläre Filtrationsrate (GFR)
(54)
Tox. Tubuläre Phosphatreabsorption (55)
Tox. Bilirubin (61)
Tox. SGOT/SGPT (62)
Tox. Herzfunktion (71)
Tox. ECHO: LV-SF (72)
Tox. Zentrale Neurotoxizität (81)
Tox. Periphere Neurotoxizität (82)
Tox. Sonstige Toxizität (90)
Technische Probleme (93)
Planungsprobleme (94)
Patienten-/Elternablehnung (95)
Zu geringes Gewicht/zu jung (96)
Fehler (97)
Mobilisationskurs (98)
Radiotherapie (99)
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REGIMS
Schwerwiegendes unerwünschtes Ereignis (SUE) in der
Therapie SUE
Berichtsformular Bitte ausfüllen und faxen oder senden an:
Westfälische Wilhelms-Universität
Münster, Institut für Epidemiologie und Sozialmedizin,
Albert-Schweitzer-Campus 1, Gebäude
03, 48149 Münster Fax: (0251) 83-55300, E-Mail:
regims@uni-muenster.de
http://epi.uni-muenster.de
All rights reserved. Please visit https://medical-data-
models.org/forms/11218
SUE Report
SUE
Datum der Meldung*
SUE-Nummer*
Typ der Meldung*
Erstmeldung (1)
Folgemeldung (2)
Patientenangaben
Alter*
>= 0
<= 120
Jahre
Geschlecht*
männlich (1)
weiblich (2)
Gewicht
>= 0
kg
Größe
>= 0
cm
Schwangerschaft
Ja
Nein
falls ja, Schwangerschaftswoche
SUE: Beschreibung
Beschreibung SUE (diagnostisch oder
symptomatisch)*
Beginn-Datum*
Enddatum (wenn nicht fortlaufend)
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Intensität*
leicht (1)
mittel (2)
schwer (3)
Kriterien für den Schweregrad*
Nein (0)
Todesfolge (1)
lebensbedrohlich (2)
Krankenhausaufenthalt /
Aufenthaltsverlängerung (3)
kongen. Fehlbildungen (4)
Behinderung / Invalidität (5)
sonstiges med. wichtiges Ereignis (6)
SUE: Behandlung
Behandlung des SUEs*
keine (0)
Behandlung mit Medikamenten (1)
andere (2)
wenn andere Behandlung, welche
SUE: Ausgang
Ausgang*
unbekannt (-1)
anhaltend (1)
wiederhergestellt (2)
wiederhergestellt mit Folgen (3)
Tod (4)
Falls Tod, bitte Datum
Todesursache
Wurde eine Autopsie durchgeführt
unbekannt (-1)
nein (0)
ja (1)
SUE: MS-Medikation
MS-Medikament*
Einnahme seit
bis (wenn nicht fortlaufend)
Tagesdosis
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Einheit
mg (1)
µg (4)
Maßnahme
keine (0)
Dosis reduziert (1)
Dosis erhöht (2)
Unterbrechung der Medikation (3)
Medikament abgesetzt (4)
Kausalität zum Ereignis
nicht erhebbar (-1)
nicht kausal (0)
unwahrscheinlich (1)
möglich (2)
wahrscheinlich (3)
kausal (4)
SUE: Begleitmedikation
Andere Medikation (Handelsname)
Einnahme seit
bis (wenn nicht fortlaufend)
Tagesdosis
Einheit
mg (1)
µg (4)
Indikation
Kausalität zum Ereignis
nicht erhebbar (-1)
nicht kausal (0)
unwahrscheinlich (1)
möglich (2)
wahrscheinlich (3)
kausal (4)
SUE: Relevante Vorerkrankung /
Sypmtome
Relevante Vorerkrankung
von
bis (wenn nicht anhaltend)
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Ergebnisse der relevanten Diagnostischen
Untersuchungen
Resultate der relevanten diagnostischen Tests
(unter Angabe von Referenzwerten, falls
vorhanden)
Kontaktdaten des Berichterstatters
Name des Berichterstatters*
Telefon-Nr*
Faxnr.
Email
Unterschrift
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Key Data Elements
Anamnese und Körperliche Untersuchung
Brustschmerz (Angina) oder Äquivalent*
nicht kardial (1)
atypisch (2)
stabile Angina (3)
Variante (4)
instabile Angina (5)
akuter STEMI (6)
Angina Schweregrad [CCS]*
1 (1)
2 (2)
3 (3)
4 (4)
Herzinsuffizienz-Klasse [NYHA]*
1 (1)
2 (2)
3 (3)
4 (4)
Synkope*
Ja
Nein
Datum der Synkope*
Patientenanamnese
Hoher Blutdruck in der Anamnese*
Ja
Nein
History of Dyslipidemia*
Ja
Nein
History of Diabetes*
[No] ([No])
[null] ([null])
Yes - type 1 (Yes - type 1)
Yes - type 2 (Yes - type 2)
History of Tobacco use*
[null] ([null])
Current everyday smoker (Current
everyday smoker)
Current some day smoker (Current some
day smoker)
Former smoker (Former smoker)
Never smoker (Never smoker)
Smoker, current status (Smoker, current
status)
1 / 11
Unknown (Unknown)
History of Chronic lung disease*
Ja
Nein
History of Chronic kidney disease*
[null] ([null])
0 (0)
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
History of Dialysis*
Ja
Nein
History of Illicit drug use*
Ja
Nein
History of HIV Infection*
Ja
Nein
History of Atrial arrhythmias*
[No] ([No])
[null] ([null])
AF, first detected (AF, first detected)
AF, paroxysmal (AF, paroxysmal)
AF, permanent (AF, permanent)
AF, persistent (AF, persistent)
Atrial flutter (Atrial flutter)
Atrial tachycardia (Atrial tachycardia)
Sick sinus syndrome (Sick sinus
syndrome)
History of Paroxysmal supraventricular
tachycardia*
Ja
Nein
History of Ventricular arrhythmias*
[No] ([No])
[null] ([null])
VF (VF)
VT, nonsustained (VT, nonsustained)
VT, sustained (VT, sustained)
History of Venous thrombembolism*
[No] ([No])
[null] ([null])
Yes - DVT (Yes - DVT)
Yes - Pulmonary embolism (Yes -
Pulmonary embolism)
History of Depression*
Ja
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Nein
History of Coronary artery disease*
Ja
Nein
History of Cerebral artery disease*
Ja
Nein
History of Peripheral artery disease*
Ja
Nein
History of Aorta disease*
Ja
Nein
History of Renal artery disease*
Ja
Nein
History of Myocardial infarction*
Ja
Nein
Date of myocardial infarction*
History of Sudden cardiac arrest*
Ja
Nein
Date of cardiac arrest*
History of Heart failure*
Ja
Nein
Family History
Family History of Coronary artery disease*
Ja
Nein
Familiy History of Sudden cardiac death*
Ja
Nein
Patient Assessment
Systolic blood pressure*
Diastolic blood pressure*
3 / 11
ACCF/AHA 2011 Key Data Elements and Definitions of a Base
Cardiovascular Vocabulary for Electronic Health Records
Weight*
Waist circumference*
Größe*
>= 0
cm
Herzfrequenz*
>= 0
bpm
Laborergebnisse
Gesamtcholesterin*
Unit - Total cholesterol*
Triglyzeride
Unit- Triglycerides*
LDL cholesterol*
Unit - LDL cholesterol*
HDL cholesterol*
Unit - HDL cholesterol*
Fasting blood sugar*
Unit - Fasting blood sugar*
Creatinine*
Unit - Creatinine*
BUN*
Unit - BUN*
Sodium*
Unit - Sodium*
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Hemoglobin*
Unit - Hemoglobin*
Hemoglobin A1c*
Unit - Hemoglobin A1c*
Hematocrit*
Unit - Hematocrit*
Diagnostic and Therapeutic Procedures
Elements
Cardiac diagnostic procedure*
Biopsy of right ventricle (RVBx) (Biopsy
of right ventricle (RVBx))
Cardiac CT angiography (CTA) (Cardiac
CT angiography (CTA))
Cardiac MR angiography (Cardiac MR
angiography)
CT (noncontrast) (CT (noncontrast))
ECG (ECG)
Electrophysiology study (EPS)
(Electrophysiology study (EPS))
Event monitor (Event monitor)
Holter monitor (Holter monitor)
Left-heart catherization (LHC) (Left-heart
catherization (LHC))
MRI (MRI)
Nuclear stress test (Nuclear stress test)
PET (PET)
Right-heart catherization (RHC) (Right-
heart catherization (RHC))
Stress ECG (Stress ECG)
Stress echocardiography (Stress
echocardiography)
Stress MRI (Stress MRI)
Transesophageal echocardiography
(TEE) (Transesophageal
echocardiography (TEE))
Transthoracic echocardiography (TTE)
(Transthoracic echocardiography (TTE))
Date of cardiac diagnostic procedure*
Diagnostic Procedure Results
Ejection fraction (quantitative)*
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Ejection fraction (qualitative)*
Hyperdynamic (Hyperdynamic)
Mild dysfunction (Mild dysfunction)
Moderate dysfunction (Moderate
dysfunction)
Normal (Normal)
Severe dysfunction (Severe dysfunction)
Left ventricle size, end diastole (quantitative)
(cm)*
Left ventricle size, end systole (quantitative) (cm)*
Left atrium size (quantitative) (cm)*
Aortic valve area (cm2)*
Aortic valve regurgitation*
Mild (Mild)
Moderate (Moderate)
None (None)
Severe (Severe)
Mitral valve area (cm2)*
Mitral valve regurgitation*
Mild (Mild)
Moderate (Moderate)
None (None)
Severe (Severe)
Stress test result*
Abnormal (Abnormal)
Indeterminate (Indeterminate)
Normal (Normal)
Myocardium ischemic amount (qualitative)*
Large (Large)
Medium (Medium)
None (None)
Small (Small)
Coronary calcium score*
Coronary artery number of diseased vessels
(excludes left main disease)*
0 (0)
1 (1)
2 (2)
3 (3)
Left main coronary artery stenosis*
[null] ([null])
No (No)
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Yes (Yes)
Proximal LAD coronary artery stenosis*
[null] ([null])
No (No)
Yes (Yes)
Third-degree AV block (complete heart block)*
[null] ([null])
No (No)
Yes (Yes)
Left bundle-branch block*
[null] ([null])
No (No)
Yes (Yes)
Intraventricular conduction delay (nonspecific)*
[null] ([null])
No (No)
Yes (Yes)
Therapeutic Procedures
Cardiac therapeutic procedure*
Ablation, atrial (eg, for AF) (Ablation,
atrial (eg, for AF))
Ablation, other (eg, reciprocating
tachycardia ablation) (Ablation, other (eg,
reciprocating tachycardia ablation))
Ablation, ventricular (eg, for VT)
(Ablation, ventricular (eg, for VT))
Aortic balloon valvotomy (Aortic balloon
valvotomy)
Aortic valve replacement (Aortic valve
replacement)
CABG (CABG)
Chemical cardioversion (Chemical
cardioversion)
Closure device, atrial (Closure device,
atrial)
Closure device, ventricular (Closure
device, ventricular)
CRT (CRT)
Electrical cardioversion (Electrical
cardioversion)
Heart transplant (Heart transplant)
ICD (ICD)
Lead extraction (Lead extraction)
Left atrial appendage occlusion (Left
atrial appendage occlusion)
Left VAD (Left VAD)
Mitral balloon valvotomy (Mitral balloon
valvotomy)
Mitral commissurotomy (Mitral
commissurotomy)
Mitral valve repair (Mitral valve repair)
Mitral valve replacement (Mitral valve
replacement)
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Pacemaker (Pacemaker)
PCI (PCI)
Percutaneous mitral repair
(Percutaneous mitral repair)
Pericardial stripping (Pericardial
stripping)
Pericardial window (Pericardial window)
Pericardiocentesis (Pericardiocentesis)
Pulmonary valve replacement
(Pulmonary valve replacement)
Pulmonic valvuloplasty (Pulmonic
valvuloplasty)
Right VAD (Right VAD)
Septal ablation (Septal ablation)
Surgical maze (Surgical maze)
Transcetheter aortic valve implant
(Transcetheter aortic valve implant)
Tricuspid valve repair (Tricuspid valve
repair)
Tricuspid valve replacement (Tricuspid
valve replacement)
Ventricular aneurysm resection
(Ventricular aneurysm resection)
Date of cardiac therapeutic procedure*
Therapeutic Procedure Device Implants
Implanted device*
Aortic valve, mechanical (Aortic valve,
mechanical)
Aortic valve, tissue (Aortic valve, tissue)
Aortic valve, transcutaneous (Aortic
valve, transcutaneous)
Atrial lead, left (Atrial lead, left)
Atrial lead, right (Atrial lead, right)
Bare-metal stent (Bare-metal stent)
Biventricular pacemaker (Biventricular
pacemaker)
Cardioverter-defibrilator with
resynchronization (Cardioverter-
defibrilator with resynchronization)
Cardioverter-defibrillator (Cardioverter-
defibrillator)
Closure device, atrial (Closure device,
atrial)
Closure device, ventricular (Closure
device, ventricular)
Drug-eluting stent (Drug-eluting stent)
Dual-chamber pacemaker (Dual-
chamber pacemaker)
Left VAD (Left VAD)
Mitral valve, mechanical (Mitral valve,
mechanical)
Mitral valve, tissue (Mitral valve, tissue)
Right VAD (Right VAD)
Single-chamber pacemaker (Single-
8 / 11
ACCF/AHA 2011 Key Data Elements and Definitions of a Base
Cardiovascular Vocabulary for Electronic Health Records
chamber pacemaker)
Total artificial heart (Total artificial heart)
Ventricular lead, left (Ventricular lead,
left)
Ventricular lead, right (Ventricular lead,
right)
Manufacturer*
Model*
Serial number*
Device parameters*
Coronary lesions treated*
Coronary graft anastomoses*
Pharmacological Therapy Data Elements
Aspirin*
No (No)
No - exception (No - exception)
No - exclusion (No - exclusion)
Yes (Yes)
P2Y12 blocker*
No (No)
No - exception (No - exception)
No - exclusion (No - exclusion)
Yes (Yes)
Nonsteroidal anti-inflammatory*
No (No)
No - exception (No - exception)
No - exclusion (No - exclusion)
Yes (Yes)
Steroid, systemic*
No (No)
No - exception (No - exception)
No - exclusion (No - exclusion)
Yes (Yes)
Cyclo-oxygenase 2 inhibitor*
No (No)
No - exception (No - exception)
No - exclusion (No - exclusion)
Yes (Yes)
Anticoagulant*
No (No)
No - exception (No - exception)
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No - exclusion (No - exclusion)
Yes (Yes)
Beta blocker*
No (No)
No - exception (No - exception)
No - exclusion (No - exclusion)
Yes (Yes)
Alpha blocker*
No (No)
No - exception (No - exception)
No - exclusion (No - exclusion)
Yes (Yes)
ACE inhibitor*
No (No)
No - exception (No - exception)
No - exclusion (No - exclusion)
Yes (Yes)
ARB*
No (No)
No - exception (No - exception)
No - exclusion (No - exclusion)
Yes (Yes)
Calcium channel blocker*
No (No)
No - exception (No - exception)
No - exclusion (No - exclusion)
Yes (Yes)
Antiarrhythmics*
No (No)
No - exception (No - exception)
No - exclusion (No - exclusion)
Yes (Yes)
Direct renin inhibitors*
No (No)
No - exception (No - exception)
No - exclusion (No - exclusion)
Yes (Yes)
Nitrate*
No (No)
No - exception (No - exception)
No - exclusion (No - exclusion)
Yes (Yes)
Statin*
No (No)
No - exception (No - exception)
No - exclusion (No - exclusion)
Yes (Yes)
Nonstatin antilipidemic*
No (No)
No - exception (No - exception)
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No - exclusion (No - exclusion)
Yes (Yes)
Insulin*
No (No)
No - exception (No - exception)
No - exclusion (No - exclusion)
Yes (Yes)
Noninsulin hypoglycemic*
No (No)
No - exception (No - exception)
No - exclusion (No - exclusion)
Yes (Yes)
Diuretic*
No (No)
No - exception (No - exception)
No - exclusion (No - exclusion)
Yes (Yes)
Aldosterone receptor antagonist*
No (No)
No - exception (No - exception)
No - exclusion (No - exclusion)
Yes (Yes)
Outcomes Data Elements
Death*
Ja
Nein
Date of death*
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Leukemia, Myelocytic, Acute Treatment -
DTX
DTX
Leukemia, Myelocytic, Acute Treatment - DTX
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=FF1A56B4-
3737-1DDD-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11220
AML treatment DTX
For questions 1-28, record the highest
grade of toxicity present after initiation of
mobilization, but prior to apheresis.
Record the grade of toxicity present at the
time of contact with the donor,...
Segment
Visit number
Flu-like Sumptoms
Fever in absence of infections
Constitutional Symptoms
Fatigue (lethargy, malaise, asthenia)
Ocular/visual
Inflammation of the eyes
Dermatologic
Skin (rash)
Local
Ulceration
Cardiac
Hypotension (low blood pressure)
Pulmonary
Pneumothorax
Gastrointestinal
1 / 9
Nausea
Vomiting
Anorexia
Vascular
Venous thrombosis/embolism
Deep Vein Thrombosis Or Cardiac
Thrombosis; Intervention (e.g.,
Anticoagulation, Lysis, Filter, Invasive
Procedure) Indicated (Deep vein
thrombosis, or cardiac thrombosis;
intervention indicated (Grade 3))
Deep Vein Thrombosis Or Cardiac
Thrombosis; Intervention (e.g.,
Anticoagulation, Lysis, Filter, Invasive
Procedure) Not Indicated (Deep vein
thrombosis, or cardiac thrombosis;
intervention not indicated (Grade 2))
Embolic Event Including Pulmonary
Embolism Or Life-threatening Thrombus
(Embolic event including pumonary
embolism or life-threatening thrombus
(Grade 4))
None (None (Grade 0))
Neurologic
Insomnia
Dizziness, vertigo, lightheadedness
Syncope
Hematological
Low platelet count
Infection Sites
For Each Of The Sites Listed Below,
Indicate The Severity Of Infection Present
Peripheral IV site
IV antibiotic, antifungal, antiviral
intervention indciated (Grade 3) (IV
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antibiotic, antifungal, antiviral
intervention indciated (Grade 3))
Life-threatening consequences (Grade 4)
(Life-threatening consequences (Grade
4))
Localized, local intervention indicated
(Grade 2) (Localized, local intervention
indicated (Grade 2))
None (Grade 0) (None (Grade 0))
Central catheter site
IV antibiotic, antifungal, antiviral
intervention indciated (Grade 3) (IV
antibiotic, antifungal, antiviral
intervention indciated (Grade 3))
Life-threatening consequences (Grade 4)
(Life-threatening consequences (Grade
4))
Localized, local intervention indicated
(Grade 2) (Localized, local intervention
indicated (Grade 2))
None (Grade 0) (None (Grade 0))
Other site
None (Grade 0)
Localized, local intervention indicated
(Grade 2)
IV antibiotic, antifungal, antiviral
intervention indicated (Grade 3)
Life-threatening consequences (Grade 4)
Specify site
Pain Sites
For Each Of The Sites Listed Below,
Indicate The Severity Of Pain Present
Back
Disabling (Grade 4) (Disabling (Grade 4))
Mild pain not interfering with function
(Grade 1) (Mild pain not interfering with
function (Grade 1))
Moderate pain interfering with function
but not ADL (Grade 2) (Moderate pain
interfering with function but not ADL
(Grade 2))
None (Grade 0) (None (Grade 0))
Severe pain severly interfering with ADL
(Grade 3) (Severe pain severly
interfering with ADL (Grade 3))
IV site
Disabling (Grade 4) (Disabling (Grade 4))
Mild pain not interfering with function
(Grade 1) (Mild pain not interfering with
function (Grade 1))
Moderate pain interfering with function
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but not ADL (Grade 2) (Moderate pain
interfering with function but not ADL
(Grade 2))
None (Grade 0) (None (Grade 0))
Severe pain severly interfering with ADL
(Grade 3) (Severe pain severly
interfering with ADL (Grade 3))
Neck
Disabling (Grade 4) (Disabling (Grade 4))
Mild pain not interfering with function
(Grade 1) (Mild pain not interfering with
function (Grade 1))
Moderate pain interfering with function
but not ADL (Grade 2) (Moderate pain
interfering with function but not ADL
(Grade 2))
None (Grade 0) (None (Grade 0))
Severe pain severly interfering with ADL
(Grade 3) (Severe pain severly
interfering with ADL (Grade 3))
Headache
Disabling (Grade 4) (Disabling (Grade 4))
Mild pain not interfering with function
(Grade 1) (Mild pain not interfering with
function (Grade 1))
Moderate pain interfering with function
but not ADL (Grade 2) (Moderate pain
interfering with function but not ADL
(Grade 2))
None (Grade 0) (None (Grade 0))
Severe pain severly interfering with ADL
(Grade 3) (Severe pain severly
interfering with ADL (Grade 3))
Muscle
Disabling (Grade 4) (Disabling (Grade 4))
Mild pain not interfering with function
(Grade 1) (Mild pain not interfering with
function (Grade 1))
Moderate pain interfering with function
but not ADL (Grade 2) (Moderate pain
interfering with function but not ADL
(Grade 2))
None (Grade 0) (None (Grade 0))
Severe pain severly interfering with ADL
(Grade 3) (Severe pain severly
interfering with ADL (Grade 3))
Joint
Disabling (Grade 4) (Disabling (Grade 4))
Mild pain not interfering with function
(Grade 1) (Mild pain not interfering with
function (Grade 1))
Moderate pain interfering with function
but not ADL (Grade 2) (Moderate pain
interfering with function but not ADL
(Grade 2))
None (Grade 0) (None (Grade 0))
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Severe pain severly interfering with ADL
(Grade 3) (Severe pain severly
interfering with ADL (Grade 3))
Limb (leg or arm)
Disabling (Grade 4) (Disabling (Grade 4))
Mild pain not interfering with function
(Grade 1) (Mild pain not interfering with
function (Grade 1))
Moderate pain interfering with function
but not ADL (Grade 2) (Moderate pain
interfering with function but not ADL
(Grade 2))
None (Grade 0) (None (Grade 0))
Severe pain severly interfering with ADL
(Grade 3) (Severe pain severly
interfering with ADL (Grade 3))
Bone
Disabling (Grade 4) (Disabling (Grade 4))
Mild pain not interfering with function
(Grade 1) (Mild pain not interfering with
function (Grade 1))
Moderate pain interfering with function
but not ADL (Grade 2) (Moderate pain
interfering with function but not ADL
(Grade 2))
None (Grade 0) (None (Grade 0))
Severe pain severly interfering with ADL
(Grade 3) (Severe pain severly
interfering with ADL (Grade 3))
Other site
Specify site
Donor Pre-apheresis Vital Signs
Pulse
beats/min
Systolic blood pressure
mmHg
Temperature
°C
Donor Pre-apheresis Hematology
Date of sample collection
WBC Cerebrospinal Fluid
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Platelets
1000/uL
Erythrocytes
Hemoglobin
g/dL
First Apheresis
Procedure time from the blood cell separator
Time procedure started
Time procedure ended
Does your center's blood cell separator calculate
the time to complete the procedure
Yes
No
Volume of whole blood cell processed
Did the donor receive clacium replacement to
treat or prevent symptoms of hypocalcemia
Yes
No
Specify Therapy
Oral calcium for prevention
Yes
No
IV calcium for prevention
Yes
No
Oral calcium for treatment
Yes
No
IV calcium for treatment
Yes
No
Did the donor experience symptoms of
hypocalcemia
Yes
No
Specify symptoms
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Persistent, moderate numbness or
tingling (Persistent, moderate numbness
or tingling)
Severe numbness or tingling (Severe
numbness or tingling)
Tetany (Tetany)
Transient numbness or tingling (Transient
numbness or tingling)
Second Apheresis
Was a second apheresis prodecure performed
Yes
No
Procedure time from the blood cell separator
Time procedure started
Time procedure ended
Does your center's blood cell separator calculate
the time to complete the procedure
Yes
No
Volume of whole blood cell processed
Did the donor receive clacium replacement to
treat or prevent symptoms of hypocalcemia
Yes
No
Specify Therapy
Oral calcium for prevention
Yes
No
IV calcium for prevention
Yes
No
Oral calcium for treatment
Yes
No
IV calcium for treatment
Yes
No
Did the donor experience symptoms of
hypocalcemia
Yes
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No
Specify symptoms
Persistent, moderate numbness or
tingling (Persistent, moderate numbness
or tingling)
Severe numbness or tingling (Severe
numbness or tingling)
Tetany (Tetany)
Transient numbness or tingling (Transient
numbness or tingling)
Third Apheresis
Was a third apheresis prodecure performed
Yes
No
Procedure time from the blood cell separator
Time procedure started
Time procedure ended
Does your center's blood cell separator calculate
the time to complete the procedure
Yes
No
Volume of whole blood cell processed
Did the donor receive clacium replacement to
treat or prevent symptoms of hypocalcemia
Yes
No
Specify Therapy
Oral calcium for prevention
Yes
No
IV calcium for prevention
Yes
No
Oral calcium for treatment
Yes
No
IV calcium for treatment
Yes
No
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Did the donor experience symptoms of
hypocalcemia
Yes
No
Specify symptoms
Persistent, moderate numbness or
tingling (Persistent, moderate numbness
or tingling)
Severe numbness or tingling (Severe
numbness or tingling)
Transient numbness or tingling (Transient
numbness or tingling)
Donor Post-apheresis Hematology
Date of sample collection
WBC Cerebrospinal Fluid
Platelets
1000/uL
Erythrocytes
Hemoglobin
g/dL
Comments
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The Vital Signs form for C3D 3.12 Adopters
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Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=0139EB40-
6292-1375-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
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VITAL SIGNS
Vital Signs
Course Number
Course Day Number
Evaluation Date
Lab Collection Time
Karnofsky Performance Status Score
Dead (0)
Moribund, Fatal Processes Progressing
Rapidly (10)
Normal, No Complaints, No Evidence Of
Disease (100)
Very Sick, Hospitalization Indicated.
Death Not Imminent (20)
Severely Disabled, Hospitalization
Indicated. Death Not Imminent (30)
Disabled, Requires Special Care And
Assistance (40)
Requires Considerable Assistance And
Frequent Medical Care (50)
Requires Occasional Assistance, But Is
Able To Care For Most Of His/her Needs
(60)
Cares For Self, Unable To Carry On
Normal Activity Or To Do Active Work
(70)
Normal Activity With Effort; Some Signs
Or Symptoms Of Disease (80)
Able To Carry On Normal Activity; Minor
Signs Or Symptoms Of Disease (90)
Body weight
>= 0
kg
Body surface area
>= 0
m²
Temperature
°C
Pulse
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beats/min
Alpha DVG Respiration Rate
Not Obtained (Not Obtained)
Systolic Blood Pressure Value
>= 0
mmHg
Diastolic Blood Pressure Value
>= 0
mmHg
Pulse Oximetry Value
%
Research Comments Text
Height
>= 0
cm
Comments
Note Date
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modified from http://www.cdisc.org
All rights reserved. Please visit https://medical-data-
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CDASH Vital Signs
Generelle Information
Wurden Vitalzeichen erhoben?*
Ja
Nein
Vitalzeichen
Datum der Messung der Vitalzeichen*
Körpergröße*
>= 0
cm
Körpergewicht*
>= 0
kg
Diastolischer Blutdruck*
>= 0
mmHg
Systolischer Blutdruck*
>= 0
mmHg
Ort der Blutdruckmessung*
Fußknöchel (ANKLE)
A. brachialis (BRACHIAL ARTERY)
Position der Blutdruckmessung*
in Bauchlage (PRONE)
sitzend (SITTING)
stehend (STANDING)
in Rückenlage (SUPINE)
Puls*
>= 0
BEATS/MIN
Ort der Pulsmessung*
A. brachialis (BRACHIAL ARTERY)
A. carotis (CAROTID ARTERY)
A. radialis (RADIAL ARTERY)
Position bei der Pulsmessung*
in Bauchlage (PRONE)
sitzend (SITTING)
stehend (STANDING)
in Rückenlage (SUPINE)
Körpertemperatur*
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°C
Ort der Temperaturmessung*
Axilla (AXILLA)
Ohr (EAR)
Körperbau*
groß (LARGE)
mittel (MEDIUM)
klein (SMALL)
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RTOG-0525 TF: Treatment Summary Form NCT00304031 
Radiation Therapy and Temozolomide in Treating Patients
With Newly Diagnosed Glioblastoma or Gliosarcoma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=FE10D5B1-
3CDE-10E3-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11224
RTOG-0525 TF: Treatment Summary
Form NCT00304031
RTOG clinical trial administrative data
RTOG Study No.
Case #
Institution Name
Institution No.
Patient Initials
RTOG Patient ID
AMENDED DATA
Yes
No
Assessment
Weight (CM)
Kg
Height (KG)
cm
BSA (M2)
Karnofsky Performance Status
Dead (0)
Moribund, Fatal Processes Progressing
Rapidly (10)
Normal, No Complaints, No Evidence Of
Disease (100)
Very Sick, Hospitalization Indicated.
Death Not Imminent (20)
Severely Disabled, Hospitalization
Indicated. Death Not Imminent (30)
Disabled, Requires Special Care And
Assistance (40)
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Requires Considerable Assistance And
Frequent Medical Care (50)
Requires Occasional Assistance, But Is
Able To Care For Most Of His/her Needs
(60)
Cares For Self, Unable To Carry On
Normal Activity Or To Do Active Work
(70)
Normal Activity With Effort; Some Signs
Or Symptoms Of Disease (80)
Able To Carry On Normal Activity; Minor
Signs Or Symptoms Of Disease (90)
Neurological Function Status
Minor Neurologic Symptoms, Fully Active
At Home/work Without Assistance (Minor
neurologic symptoms, fully active at
home/work without assistance)
Moderate Neurologic Symptoms, Fully
Active At Home/work But Requires
Assistance (Moderate neurologic
symptoms, fully active at home/work but
requires assistance)
Moderate Neurologic Symptoms, Less
Than Fully Active At Home/work And
Requires Assitance (Moderate
neurologic symptoms, less than fully
active at home/work and requires
assistance)
No Neurologic Symptoms, Fully Active At
Home/work Without Assistance (No
neurologic symptoms, fully active at
home/work without assistance)
Severe Neurologic Symptoms, Totally
Inactive Requiring Complete Assistance
At Home Or Institution, Unable To Work
(Severe neurologic symptoms, totally
inactive requiring complete assistance at
home or institution, unable to work)
Disease Progression
Protocol Temozolomide Agent Administered
Course Type
Concurrent Rt And Tmz (42 Days)
(Concurrent RT and TMZ (42 days))
Tmz Days 1-21 Of 28 Day Cycle 12
Cycle Maximum (TMZ days 1-21 of 28
day cycle 12 cycle maximum)
Tmz Days 1-5 Of 28 Day Cycle 12 Cycle
Maximum (TMZ days 1-5 of 28 day cycle
12 cycle maximum)
Is protocol chemotherapy continuing?
Yes
No
New or continuing adverse events
Yes
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No
Assessment of Chemotherapy
Cycle Start Date
Treatment Course End Date
Total Dose of Agents/Drugs for this Cycle
Total No. of Doses
Reason for Treatment Modification
Adverse Event/side Effects/complications
(Adverse event/side
effects/complications)
Alternative Therapy (Alternative therapy)
Death On Study (Death on study)
Disease Progression, Relapse During
Active Treatment (Disease progression,
relapse during active treatment)
None (None)
Other (Other)
Other Complicating Disease (Other
complicating disease)
Patient Withdrawal Or Refusal After
Beginning Protocol Therapy (Patient
withdrawal/refusal after beginning
protocol therapy)
Patient Withdrawal Or Refusal Prior To
Beginning Protocol Therapy (Patient
withdrawal/refusal prior to beginning
protocol therapy)
Treatment Completed Per Protocol
Criteria (Treatment completed per
protocol criteria)
Reason for Treatment Modification
Adverse Event/side Effects/complications
(Adverse event/side
effects/complications)
Alternative Therapy (Alternative therapy)
Death On Study (Death on study)
Disease Progression, Relapse During
Active Treatment (Disease progression,
relapse during active treatment)
None (None)
Other (Other)
Other Complicating Disease (Other
complicating disease)
Patient Withdrawal Or Refusal After
Beginning Protocol Therapy (Patient
withdrawal/refusal after beginning
protocol therapy)
Patient Withdrawal Or Refusal Prior To
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Beginning Protocol Therapy (Patient
withdrawal/refusal prior to beginning
protocol therapy)
Treatment Completed Per Protocol
Criteria (Treatment completed per
protocol criteria)
Alternative Therapy
Alternative Therapy
Other specify
Other specify
Reason Treatment Ended
Adverse Event/side Effects/complications
(Adverse Event/Side
Effects/Complications)
Alternative Therapy (Alternative therapy)
Death On Study (Death on study)
Disease Progression, Relapse During
Active Treatment (Disease progression,
relapse during active treatment)
Other (Other)
Patient Off-treatment For Other
Complicating Disease (Patient off-
treatment for other complicating disease)
Patient Withdrawal Or Refusal After
Beginning Protocol Therapy (Patient
withdrawal/refusal after beginning
protocol therapy)
Patient Withdrawal Or Refusal Before
Beginning Protocol Therapy (Patient
withdrawal/refusal prior to beginning
protocol therapy)
Treatment Completed Per Protocol
Criteria (Treatment completed per
protocol criteria)
Footer
Comments
Signature of Person Completing This Form
Date Form Originally Completed
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Reconsent Form NCT00265759
Exemestane, Letrozole, or Anastrozole in Treating
Postmenopausal Women Who Are Undergoing Surgery for
Stage II or Stage III Breast Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=4851EA3B-
4710-1AC2-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11225
Reconsent Form NCT00265759
Header Module
Visit
Reconsent (Reconsent)
Patient ID
Institution No.
Patient Initials
Institution Name
Reconsent
Amendment #
Date of reconsent
Patient's Initial Consent given for blood specimen
use for research on the patient's cancer?
Yes
No
Patient's Initial Consent given for blood specimen
use for research unrelated to the patient's
cancer?
Yes
No
Patient's Initial Consent given for tissue specimen
use for research on the patient's cancer?
Yes
No
Patient's Initial Consent given for tissue specimen
use for research unrelated to the patient's
cancer?
Yes
No
Patient's initial consent given for further contact
regarding specimen?
Yes
No
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Patient's Initial Consent given for participation in
Cancer Genome Atlas project?
Yes
No
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Z1031: Blood Specimen Submission Form
NCT00265759
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Exemestane, Letrozole, or Anastrozole in Treating
Postmenopausal Women Who Are Undergoing Surgery for
Stage II or Stage III Breast Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=FAB0CCBC-
BF59-4F42-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11226
Z1031: Blood Specimen Submission
Form NCT00265759
Patient demographics
Visit
Surgery (Surgery)
Week 12 (Week 12)
Week 15 (Week 15)
Week 16 (Week 16)
Week 4 (Week 4)
Week 8 (Week 8)
Within 14 Days Prior To Intervention
(Within 14 days prior to intervention)
Patient ID (Pt. ID issued during registration or
previously issued patient ID)
Institution No.
Patient Initials (F M L)
Institution Name
To Be Completed By Acosog Central
Specimen Bank
Were specimen(s) submitted to the ACOSOG
Central Specimen Bank
Yes
No
Date of Receipt of Specimens (s)
Specimen Type (mark all that apply)
Plasma (Plasma)
Serum (Serum)
Whole Blood (Whole Blood)
No specimen received
Specimen Received Number
Specimen Received Number
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Condition of Specimen (s)
Damaged Or Unusable (Damaged or
unusable)
Inadequate (Inadequate)
No Specimen Received (No specimen
received)
Usable (Usable)
Completed by
Date Form Completed
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Exemestane, Letrozole, or Anastrozole in Treating
Postmenopausal Women Who Are Undergoing Surgery for
Stage II or Stage III Breast Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=FA4EA60A-
04CB-56D4-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11227
Z1031: Specimen Banking Consent
Form NCT00265759
Patient demographics
Visit
Prior To Registration (Prior to
Registration)
Patient ID (Pt. ID issued during registration or
previously issued patient ID)
Institution No.
Patient Initials (F M L)
Institution Name
Instructions
Patient's Initial Consent given for blood specimen
use for research on the patient's cancer?
Yes
No
Patient's Initial Consent given for blood specimen
use for research unrelated to the patient's
cancer?
Yes
No
Patient's Initial Consent given for tissue specimen
use for research on the patient's cancer?
Yes
No
Patient's Initial Consent given for tissue specimen
use for research unrelated to the patient's
cancer?
Yes
No
Patient's initial consent given for further contact
regarding specimen?
Yes
No
Patient's Initial Consent given for participation in
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Cancer Genome Atlas project?
Yes
No
Completed by
Date Form Completed
2 / 2
Z1031: Specimen Banking Consent Form NCT00265759
Z6051 Stoma Quality of Life Scale
(SQOLS) NCT00726622
Z6051 Stoma Quality of Life Scale (SQOLS) NCT00726622
Laparoscopic-Assisted Resection or Open Resection in
Treating Patients With Stage IIA, Stage IIIA, or Stage IIIB
Rectal Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=4AD922C0-
C82B-483B-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11228
Z6051 Stoma Quality of Life Scale
(SQOLS) NCT00726622
Patient demographics
Visit
Month 12 (Month 12)
Patient ID (Pt. ID issued during registration
unless pt. previously registered to an ACOSOG
study.)
Patient Initials
Institution Name
Institution No.
Date
Quality of life assessment
I am able to participate in hobbies that I enjoy
Agree (Agree)
Disagree (Disagree)
Neither (Neither)
Strongly Agree (Strongly agree)
Strongly Disagree (Strongly disagree)
I do not enjoy eating out in public because of
concerns regarding my stoma
Agree (Agree)
Disagree (Disagree)
Neither (Neither)
Strongly Agree (Strongly agree)
Strongly Disagree (Strongly disagree)
I am able to go out with friends
Agree (Agree)
Disagree (Disagree)
Neither (Neither)
Strongly Agree (Strongly agree)
Strongly Disagree (Strongly disagree)
I am able to perform the same duties at
work/school
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Always (Always)
Frequently (Frequently)
Never (Never)
Occasionally (Occasionally)
Seldom (Seldom)
I worry about traveling because of my stoma
Agree (Agree)
Disagree (Disagree)
Neither (Neither)
Strongly Agree (Strongly agree)
Strongly Disagree (Strongly disagree)
I enjoy sexual activity less because of my stoma
Agree (Agree)
Disagree (Disagree)
Neither (Neither)
Strongly Agree (Strongly agree)
Strongly Disagree (Strongly disagree)
I feel less attractive because of my stoma
Agree (Agree)
Disagree (Disagree)
Neither (Neither)
Strongly Agree (Strongly agree)
Strongly Disagree (Strongly disagree)
My sexual partner is not bothered by my stoma
Agree (Agree)
Disagree (Disagree)
Neither (Neither)
Strongly Agree (Strongly agree)
Strongly Disagree (Strongly disagree)
I don't mind if others are aware I have a stoma
Agree (Agree)
Disagree (Disagree)
Neither (Neither)
Strongly Agree (Strongly agree)
Strongly Disagree (Strongly disagree)
I feel attractive in my clothing
Always (Always)
Frequently (Frequently)
Never (Never)
Occasionally (Occasionally)
Seldom (Seldom)
I am statisfied with the foods I eat
Always (Always)
Frequently (Frequently)
Never (Never)
Occasionally (Occasionally)
Seldom (Seldom)
I have financial concerns regarding my ostomy
supplies
Always (Always)
Frequently (Frequently)
Never (Never)
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Occasionally (Occasionally)
Seldom (Seldom)
I have problems with odor
Always (Always)
Frequently (Frequently)
Never (Never)
Occasionally (Occasionally)
Seldom (Seldom)
I am embarrassed by gas (noises or rapid filling
of bag)
Always (Always)
Frequently (Frequently)
Never (Never)
Occasionally (Occasionally)
Seldom (Seldom)
I am worried my stoma will leak
Always (Always)
Frequently (Frequently)
Never (Never)
Occasionally (Occasionally)
Seldom (Seldom)
I am bothered by skin irritation around the stoma
Always (Always)
Frequently (Frequently)
Never (Never)
Occasionally (Occasionally)
Seldom (Seldom)
I manage the same responsibilities at home
Always (Always)
Frequently (Frequently)
Never (Never)
Occasionally (Occasionally)
Seldom (Seldom)
Social situations make me feel anxious
Always (Always)
Frequently (Frequently)
Never (Never)
Occasionally (Occasionally)
Seldom (Seldom)
I find an ostomy support group helpful
Always (Always)
Frequently (Frequently)
Never (Never)
Occasionally (Occasionally)
Seldom (Seldom)
Rate your overall satisfaction with your life right
now on a scale of 0 to 100 (With 0 being very
unhappy to 100 totally satisfied.)
What effect has your stoma had on your quality of
life
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Improved My Quality Of Life (Improved
my quality of life)
Made My Quality Of Life Worse (Made
my quality of life worse)
No Effect On My Quality Of Life (No
effect on my quality of life)
When you left the hospital how prepared did you
feel to take care of your new stoma/ostomy (Rate
your level of preparedness on a scale of 0 to 100.
With 0 being totally unprepared to 100 feeling
totally prepared and confident.)
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USMCI 8214/Z6091:  Surgical Data Form
NCT01167725
USMCI 8214/Z6091:  Surgical Data Form NCT01167725
Standard Therapy With or Without Surgery and Mitomycin
C in Treating Patients With Advanced Limited Peritoneal
Dissemination of Colon Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=62067A0E-
23F3-1D8C-E040-BB89AD435F13
All rights reserved. Please visit https://medical-data-
models.org/forms/11229
USMCI 8214/Z6091:  Surgical Data
Form NCT01167725
Patient demographics
Visit
Post Surgery (Post Surgery)
Patient ID
Institution No.
Institution Name
Assessment of surgery
Was surgery performed
Yes
No
Reason surgery not performed
Other (Other)
Patient Refusal And Withdrawal From
Trial (Patient refusal and withdrawal from
trial)
Physician Decision (Physician decision)
Other, specify
Was attempted surgery completed
Yes
No
Surgeon's First Initial
Surgeon's Last Name
Surgery Date
Surgery Duration
Estimated blood loss
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Total number of units PRBC
Ascites drained
Yes
No
Intraperitoneal heated chemotherapy
administered
Yes
No
Mitomycin dose
Target inflow temperature (Degree Celsius)
Perfusate volume (L)
Peritoneal Carcinomatosis Index
Anatomic region
Central (Central)
Epigastric (Epigastrium)
Left Flank (Left flank)
Left Lower (Left Lower)
Left Upper (Left Upper)
Lower Ileum (Lower ileum)
Lower Jejunum (Lower jejunum)
Pelvis (Pelvis)
Right Flank (Right flank)
Right Lower (Right Lower)
Right Upper (Right Upper)
Upper Ileum (Upper ileum)
Upper Jejunum (Upper jejunum)
PCI at exploration
CT/Laparoscopic PCI
PCI at completion
Total PCI Score (CT/Laparoscopic PCI)
Total PCI Score (PCI at Exploration)
Total PCI Score (PCI at Completion)
Reconstructions/diversions
Reconstructions/Diversions
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Colo-colostomy (Colo-colostomy)
Colostomy (Colostomy)
Gastrojejunostomy (Gastrojejunostomy)
Ileostomy (Ileostomy)
Peritoneal Drainage Tube(s) (Peritoneal
drainage tube(s))
Small Bowel-to-colon (Small bowel-to-
colon)
Small Bowel-to-rectum (Small bowel-to-
rectum)
Small Bowel-to-small Bowel (Small
bowel-to-small bowel)
Tube Gastrostomy (Tube gastrostomy)
Tube Jejunostomy (Tube jejunostomy)
Reconstructions/Diversions
Yes
No
Extent Of Resection
Extent of Resection
Bladder (Bladder)
Colon (Colon)
Ovary Fallopian Tube (Fallopian
tubes/Ovaries)
Gallbladder (Gallbladder)
Greater Omentum (Greater Omentum)
Lesser Omentum (Lesser Omentum)
Pancreas (Pancreas)
Rectum (Rectum)
Small Bowel (Small Bowel)
Stomach (Stomach)
Uterus (Uterus)
Extent of Resection
Yes
No
Peritonectomy
Peritonectomy
Left Upper (Left Upper)
Omental Bursa (Omental Bursa)
Parietal (Parietal)
Pelvic (Pelvic)
Right Upper (Right Upper)
Peritonectomy
Yes
No
Residual disease
Residual disease after cytoreduction, CC Score
No Residual Disease (CC0)
Residual Disease < 0.25 Cm (CC1)
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Residual Disease 0.25-2.5 Cm (CC2)
Residual Disease > 2.5 Cm (CC3)
Residual disease after cytoreduction, RR Score
Complete Removal Of All Visible Tumor
With Negative Microscopic Margins Or
Cytology (R0)
Complete Removal Of All Visible Tumor
With Positive Microscopic Margins Or
Cytology (R1)
Minimal Residual Tumor Nodule(s)
Disease =< 0.5 Cm (R2a)
Gross Residual Tumor Nodule(s) > 0.5
Cm, But =< 2.0 Cm (R2b)
Extensive Residual Disease Remaining,
Nodule(s) > 2.0 Cm (R2c)
Footer Module
Completed by
Date Form Completed
Phone
Fax
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(Short Form) NCT01167725
USMCI 8214/Z6091:  Brief Pain Inventory (Short Form)
NCT01167725
Standard Therapy With or Without Surgery and Mitomycin
C in Treating Patients With Advanced Limited Peritoneal
Dissemination of Colon Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=665B3662-
59E6-0174-E040-BB89AD431E1F
All rights reserved. Please visit https://medical-data-
models.org/forms/11230
USMCI 8214/Z6091:  Brief Pain
Inventory (Short Form)
NCT01167725
Header Module
Patient ID
Institution No.
Protocol No.
Brief Pain Assessment
Throughout our lives, most of us have had pain
from time to time (such as minor headaches,
sprains, and toothaches).  Have you had pain
other than these everyday kinds of pain today?
(1.)
Yes
No
Put an X on the area that hurts the most (Front)
Put an X on the area that hurts the most (Back)
Please rate your pain by marking the box beside
the number that best describes your pain at its
WORST in the past 24 hours. (3.)
Whole Number (0)
Whole Number (1)
Whole Number (10)
Whole Number (2)
Whole Number (3)
Whole Number (4)
Whole Number (5)
Whole Number (6)
Whole Number (7)
Whole Number (8)
Whole Number (9)
Please rate your pain by marking the box beside
the number that best describes your pain at its
LEAST in the past 24 hours. (4.)
Whole Number (0)
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Whole Number (1)
Whole Number (10)
Whole Number (2)
Whole Number (3)
Whole Number (4)
Whole Number (5)
Whole Number (6)
Whole Number (7)
Whole Number (8)
Whole Number (9)
Please rate your pain by marking the box beside
the number that best describes your pain on the
AVERAGE. (5.)
Whole Number (0)
Whole Number (1)
Whole Number (10)
Whole Number (2)
Whole Number (3)
Whole Number (4)
Whole Number (5)
Whole Number (6)
Whole Number (7)
Whole Number (8)
Whole Number (9)
Please rate your pain by marking the box beside
the number that tells how much pain you have
RIGHT NOW. (6.)
Whole Number (0)
Whole Number (1)
Whole Number (10)
Whole Number (2)
Whole Number (3)
Whole Number (4)
Whole Number (5)
Whole Number (6)
Whole Number (7)
Whole Number (8)
Whole Number (9)
What treatments or medications are you receiving
for your pain
In the past 24 hours, how much RELIEF have
pain treatments or medications provided? (Please
select the percentage that shows how much.)
0% (0%)
10% (10%)
100% (100%)
20% (20%)
30% (30%)
40% (40%)
50% (50%)
60% (60%)
70% (70%)
80% (80%)
90% (90%)
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Assessment of Patient Activity
General Activity (9.)
Whole Number (0)
Whole Number (1)
Whole Number (10)
Whole Number (2)
Whole Number (3)
Whole Number (4)
Whole Number (5)
Whole Number (6)
Whole Number (7)
Whole Number (8)
Whole Number (9)
Mood (10.)
Whole Number (0)
Whole Number (1)
Whole Number (10)
Whole Number (2)
Whole Number (3)
Whole Number (4)
Whole Number (5)
Whole Number (6)
Whole Number (7)
Whole Number (8)
Whole Number (9)
Walking ability (11.)
Whole Number (0)
Whole Number (1)
Whole Number (10)
Whole Number (2)
Whole Number (3)
Whole Number (4)
Whole Number (5)
Whole Number (6)
Whole Number (7)
Whole Number (8)
Whole Number (9)
Normal work (includes both work outside the
home and housework)
Whole Number (0)
Whole Number (1)
Whole Number (10)
Whole Number (2)
Whole Number (3)
Whole Number (4)
Whole Number (5)
Whole Number (6)
Whole Number (7)
Whole Number (8)
Whole Number (9)
Relations with other people (13.)
Whole Number (0)
Whole Number (1)
Whole Number (10)
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Whole Number (2)
Whole Number (3)
Whole Number (4)
Whole Number (5)
Whole Number (6)
Whole Number (7)
Whole Number (8)
Whole Number (9)
Sleep (14.)
Whole Number (0)
Whole Number (1)
Whole Number (10)
Whole Number (2)
Whole Number (3)
Whole Number (4)
Whole Number (5)
Whole Number (6)
Whole Number (7)
Whole Number (8)
Whole Number (9)
Enjoyment of life
Whole Number (0)
Whole Number (1)
Whole Number (10)
Whole Number (2)
Whole Number (3)
Whole Number (4)
Whole Number (5)
Whole Number (6)
Whole Number (7)
Whole Number (8)
Whole Number (9)
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Z6051 Linear Analogue Self Assessment
(LASA) NCT00726622
Z6051 Linear Analogue Self Assessment (LASA)
NCT00726622
Laparoscopic-Assisted Resection or Open Resection in
Treating Patients With Stage IIA, Stage IIIA, or Stage IIIB
Rectal Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=4ADAA9F4-
0F8E-4B77-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11231
Z6051 Linear Analogue Self
Assessment (LASA) NCT00726622
Header Module
Visit
1-2 Weeks Post-surgery (1-2 weeks
post-surgery)
4-6 Weeks Post-surgery (4-6 weeks
post-surgery)
Day 3 (Day 3)
Month 12 (Month 12)
Month 3 (Month 3)
Pre-operative (Pre-Op)
Patient ID (Pt. ID issued during registration
unless pt. previously registered to an ACOSOG
study.)
Patient Initials
Institution Name
Institution No.
Date
Quality of life self-assessment
Your overall Quality of Life
0 (0)
1 (1)
10 (10)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
7 (7)
8 (8)
9 (9)
your overall mental (intellectual) well being?
Whole Number (0)
Whole Number (1)
Whole Number (10)
Whole Number (2)
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Whole Number (3)
Whole Number (4)
Whole Number (5)
Whole Number (6)
Whole Number (7)
Whole Number (8)
Whole Number (9)
your overall physical well being
Whole Number (0)
Whole Number (1)
Whole Number (10)
Whole Number (2)
Whole Number (3)
Whole Number (4)
Whole Number (5)
Whole Number (6)
Whole Number (7)
Whole Number (8)
Whole Number (9)
your overall emotional well being?
Whole Number (0)
Whole Number (1)
Whole Number (10)
Whole Number (2)
Whole Number (3)
Whole Number (4)
Whole Number (5)
Whole Number (6)
Whole Number (7)
Whole Number (8)
Whole Number (9)
your overall spiritual well being?
Whole Number (0)
Whole Number (1)
Whole Number (10)
Whole Number (2)
Whole Number (3)
Whole Number (4)
Whole Number (5)
Whole Number (6)
Whole Number (7)
Whole Number (8)
Whole Number (9)
your level of anxiety, on the average?
0 (0)
1 (1)
10 (10)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
7 (7)
8 (8)
9 (9)
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Z6051 Final Pathology Form (FP)
NCT00726622
Z6051 Final Pathology Form (FP) NCT00726622
Laparoscopic-Assisted Resection or Open Resection in
Treating Patients With Stage IIA, Stage IIIA, or Stage IIIB
Rectal Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=42E72873-
3BA9-5A49-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11232
Z6051 Final Pathology Form (FP)
NCT00726622
Header Module
American College of Surgeons Oncology Group
Visit Period Type
4-6 Weeks Post-surgery (4-6 weeks
post-surgery)
Patient ID (Pt. ID issued during registration
unless pt. previously registered to an ACOSOG
study.)
Patient Initials
Institution Name
Institution No.
Tumor assessment
Total length of resected sample (Note: if
differentiation is mixed, code lesser degree of
differentiation. Example: "well to moderately
differentiated" would be coded as moderately
differentiated:)
cm
Residual tumor in sample
Yes
No
Tumor size
cm
Lymphovascular Invasion
Yes
No
Histologic Grade (Differentiation)
Moderately Differentiated (Moderately
Differentiated (Grade II))
Poorly Differentiated (Poorly
differentiated (Grade III))
Undifferentiated (Undifferentiated (Grade
IV))
Well Differentiated (Well Differentiated
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(Grade I))
Distance to Nearest Radial Margin
mm
Circumferential margin
Negative Finding (Negative)
Positive Finding (Positive)
Distance from Primary Tumor to Distal Margin of
Resection
cm
Distal margin
Negative Finding (Negative)
Positive Finding (Positive)
Number of Lymph Nodes Examined
Number of Positive Lymph Nodes
Completeness of TME resection
Complete Total Mesorectal Excision
(Complete)
Incomplete Total Mesorectal Excision
(Incomplete)
Nearly Complete Total Mesorectal
Excision (Nearly Complete)
Pathologic T Stage
No Evidence Of Primary Tumor (T0)
Tumor Invades Submucosa (T1)
Tumor Invades Muscularis Propria (T2)
Tumor Invades Through The Muscularis
Propria Into The Subserosa, Or Into
Nonperitonealized Pericolic Or Perirectal
Tissues (T3)
Tumor Directly Invades Other Organs Or
Structures, And/or Perforates Visceral
Peritoneum (T4)
Carcinoma In Situ: Intraepithelial Or
Invasion Of Lamina Propria (Tis)
Primary Tumor Cannot Be Assessed
(TX)
Pathologic N Stage
No Regional Lymph Node Metastasis
(N0)
Metastasis In 1 To 3 Regional Lymph
Nodes (N1)
Metastasis In 4 Or More Regional Lymph
Nodes (N2)
Regional Lymph Node Cannot Be
Assessed (NX)
Pathologic M Stage
No Distant Metastasis (M0)
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Distant Metastasis (M1)
Distant Metastasis Cannot Be Assessed
(MX)
Footer Module
Completed by
Date Form Completed
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USMCI 8214/Z6091:  SF-36 Patient Self
Assessment Questionnaire NCT01167725
USMCI 8214/Z6091:  SF-36 Patient Self Assessment
Questionnaire NCT01167725
Standard Therapy With or Without Surgery and Mitomycin
C in Treating Patients With Advanced Limited Peritoneal
Dissemination of Colon Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=665C50CD-
E1EF-DFF5-E040-BB89AD43117E
All rights reserved. Please visit https://medical-data-
models.org/forms/11233
USMCI 8214/Z6091:  SF-36 Patient
Self Assessment Questionnaire
NCT01167725
Header Module
Patient ID
Institution No.
Protocol No.
Patient Initials
In general, would you say your health is
Excellent (Excellent)
Fair (Fair)
Good (Good)
Poor (Poor)
Very Good (Very good)
Compared to one year ago, how would you rate
your health in general now
About The Same As One Year Ago
(About the same as one year ago)
Much Better Now Than One Year Ago
(Much better now than one year ago)
Much Worse Now Than One Year Ago
(Much worse now than one year ago)
Somewhat Better Now Than One Year
Ago (Somewhat better now than one
year ago)
Somewhat Worse Now Than One Year
Ago (Somewhat worse now than one
year ago)
Physical Activity Assessment
Vigorous activities, such as running, lifting heavy
objects, participating in strenuous sports
No, Not Limited At All (No, not limited at
all)
Yes, Limited A Little (Yes, limited a little)
Yes, Limited A Lot (Yes, limited a lot)
Moderate activities, such as moving a table,
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pushing a vacuum cleaner, bowling, or playing
golf
No, Not Limited At All (No, not limited at
all)
Yes, Limited A Little (Yes, limited a little)
Yes, Limited A Lot (Yes, limited a lot)
Lifting or carrying groceries
No, Not Limited At All (No, not limited at
all)
Yes, Limited A Little (Yes, limited a little)
Yes, Limited A Lot (Yes, limited a lot)
Climbing several flights of stairs
No, Not Limited At All (No, not limited at
all)
Yes, Limited A Little (Yes, limited a little)
Yes, Limited A Lot (Yes, limited a lot)
Climbing one flight of stairs
No, Not Limited At All (No, not limited at
all)
Yes, Limited A Little (Yes, limited a little)
Yes, Limited A Lot (Yes, limited a lot)
Bending, kneeling or stooping
No, Not Limited At All (No, not limited at
all)
Yes, Limited A Little (Yes, limited a little)
Yes, Limited A Lot (Yes, limited a lot)
Walking more than a mile
No, Not Limited At All (No, not limited at
all)
Yes, Limited A Little (Yes, limited a little)
Yes, Limited A Lot (Yes, limited a lot)
Walking several blocks
No, Not Limited At All (No, not limited at
all)
Yes, Limited A Little (Yes, limited a little)
Yes, Limited A Lot (Yes, limited a lot)
Walking one block
No, Not Limited At All (No, not limited at
all)
Yes, Limited A Little (Yes, limited a little)
Yes, Limited A Lot (Yes, limited a lot)
Bathing or dressing yourself
No, Not Limited At All (No, not limited at
all)
Yes, Limited A Little (Yes, limited a little)
Yes, Limited A Lot (Yes, limited a lot)
Reduction in Activity
Cut down on the amount of time you spent on
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work or other activities (During the past week
have you experienced any of the following
problems with your work or other regular daily
activities as a result of any emotional problems)
Yes
No
Accomplished less than you would like
Yes
No
Were limited in the kind of work or other activities
Yes
No
Had difficulty performing the work or other
activities (for example, it took extra effort)
Yes
No
Comments
Disease interference with patient life
During the past 4 weeks, to what extent has your
physical health or emotional problems interfered
with your normal social activities with family,
friends, neighbors, or groups
Extremely (Extremely)
Moderately (Moderately)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Slightly (Slightly)
Didn't do work or other activities as carefully as
usual
Yes
No
How much bodily pain have you had during the
past 4 weeks
Mild (Mild)
Moderate (Moderate)
None (None)
Severe (Severe)
Very Mild (Very mild)
Very Severe (Very severe)
During the past 4 weeks, how much did pain
interfere with your normal work (including both
work outside the home and housework)
A Little Bit (A little bit)
Extremely (Extremely)
Moderately (Moderately)
Not At All (Not at all)
Quite A Bit (Quite a bit)
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Mental Health Assessmen
Did you feel full of pep
A Good Bit Of The Time (A good bit of
the time)
A Little Of The Time (A little of the time)
All Of The Time (All of the time)
Most Of The Time (Most of the time)
None Of The Time (None of the time)
Some Of The Time (Some of the time)
Have you been a nervous person
A Good Bit Of The Time (A good bit of
the time)
A Little Of The Time (A little of the time)
All Of The Time (All of the time)
Most Of The Time (Most of the time)
None Of The Time (None of the time)
Some Of The Time (Some of the time)
Have you felt so down in the dumps nothing could
cheer you up
A Good Bit Of The Time (A good bit of
the time)
A Little Of The Time (A little of the time)
All Of The Time (All of the time)
Most Of The Time (Most of the time)
None Of The Time (None of the time)
Some Of The Time (Some of the time)
Have you felt calm and peaceful
A Good Bit Of The Time (A good bit of
the time)
A Little Of The Time (A little of the time)
All Of The Time (All of the time)
Most Of The Time (Most of the time)
None Of The Time (None of the time)
Some Of The Time (Some of the time)
Did you have a lot of energy
A Good Bit Of The Time (A good bit of
the time)
A Little Of The Time (A little of the time)
All Of The Time (All of the time)
Most Of The Time (Most of the time)
None Of The Time (None of the time)
Some Of The Time (Some of the time)
Have you felt downhearted and blue
A Good Bit Of The Time (A good bit of
the time)
A Little Of The Time (A little of the time)
All Of The Time (All of the time)
Most Of The Time (Most of the time)
None Of The Time (None of the time)
Some Of The Time (Some of the time)
Did you feel worn out
A Good Bit Of The Time (A good bit of
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the time)
A Little Of The Time (A little of the time)
All Of The Time (All of the time)
Most Of The Time (Most of the time)
None Of The Time (None of the time)
Some Of The Time (Some of the time)
Have you been a happy person
A Good Bit Of The Time (A good bit of
the time)
A Little Of The Time (A little of the time)
All Of The Time (All of the time)
Most Of The Time (Most of the time)
None Of The Time (None of the time)
Some Of The Time (Some of the time)
Did you feel tired
A Good Bit Of The Time (A good bit of
the time)
A Little Of The Time (A little of the time)
All Of The Time (All of the time)
Most Of The Time (Most of the time)
None Of The Time (None of the time)
Some Of The Time (Some of the time)
During the past 4 weeks, how much of the time
has your physical health or emotional problems
interfered with your social activities (like visiting
friends, relatives, etc.)
A Little Of The Time (A little of the time)
All Of The Time (All of the time)
Most Of The Time (Most of the time)
None Of The Time (None of the time)
Some Of The Time (Some of the time)
Patient health expectations
I seem to be sick a little easier than other people
Definitely False (Definitely false)
Definitely True (Definitely true)
Mostly False (Mostly false)
Mostly True (Mostly true)
Not Sure (Not sure)
I am as healthy as anybody I know
Definitely False (Definitely false)
Definitely True (Definitely true)
Mostly False (Mostly false)
Mostly True (Mostly true)
Not Sure (Not sure)
I expect my health to get worse
Definitely False (Definitely false)
Definitely True (Definitely true)
Mostly False (Mostly false)
Mostly True (Mostly true)
Not Sure (Not sure)
My health is excellent
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Definitely False (Definitely false)
Definitely True (Definitely true)
Mostly False (Mostly false)
Mostly True (Mostly true)
Not Sure (Not sure)
Assessment of Patient Activity
Ability to do sports
Greatly (Greatly)
Moderately (Moderately)
Not At All (Not at all)
Slightly (Slightly)
Totally (Totally)
Ability to do work
Greatly (Greatly)
Moderately (Moderately)
Not At All (Not at all)
Slightly (Slightly)
Totally (Totally)
Social activities
Greatly (Greatly)
Moderately (Moderately)
Not At All (Not at all)
Slightly (Slightly)
Totally (Totally)
Ability do to household chores
Greatly (Greatly)
Moderately (Moderately)
Not At All (Not at all)
Slightly (Slightly)
Totally (Totally)
Life satisfaction scale
If you had to live with the current symptoms of
your affected extremity for the rest of your life,
how satisfied would you be
Neutral (Neutral)
Somewhat Dissatisfied (Somewhat
dissatisfied)
Somewhat Satisfied (Somewhat
satisfied)
Very Dissatisfied (Very dissatisfied)
Very Satisfied (Very satisfied)
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Z6051 Mayo Bowel Function Questionnaire
(MBFQ) NCT00726622
Z6051 Mayo Bowel Function Questionnaire (MBFQ)
NCT00726622
Laparoscopic-Assisted Resection or Open Resection in
Treating Patients With Stage IIA, Stage IIIA, or Stage IIIB
Rectal Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=4AEB4B3D-
5518-0337-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11234
Z6051 Mayo Bowel Function
Questionnaire (MBFQ)
NCT00726622
Header Module
Visit
1-2 Weeks Post-surgery (1-2 weeks
post-surgery)
3-4 Weeks Post-surgery (3-4 weeks
post-surgery)
4-6 Weeks Post-surgery (4-6 weeks
post-surgery)
Month 12 (Month 12)
Month 3 (Month 3)
Patient ID (Pt. ID issued during registration
unless pt. previously registered to an ACOSOG
study.)
Patient Initials
Institution Name
Institution No.
Date
Patient Bowel Function
Overall, would you say that you had problems
with your bowel function in the past week?
Yes
No
In the past week, what is the greatest number of
bowel movements you have had in a day?
In the past week, have you had a problem
causing you to get up at night to have a bowel
movement?
Yes
No
1 / 3
In the past week, have you had a problem
causing you to have a bowel movement within 30
minutes of a prior bowel movement?
Yes
No
In the past week, have you had a problem
causing you to lose control of your bowel
movements?
Yes
No
In the past week, have you had to wear protective
clothing or a pad in case you lost control of a
bowel movement?
Yes
No
In the past week, have you had a problem
causing you to be unable to tell the difference
between a stool and gas?
Yes
No
In the past week, have you had a problem
causing you to have stools that are liquid?
Yes
No
In the past week, have you found that once you
feel the urge to have a bowel movement, you
must do so within 15 minutes to avoid an
accident?
Yes
No
Do you have any other problems or comments
you would like to make about your bowel function
over the past week
Yes
No
Do you have any other problems or comments
you would like to make about your bowel function
over the past week
Was there any thing that confused or bothered
you about the previous questions?
Yes
No
Was there any thing that confused or bothered
you about the previous questions?
In the past week, have you had cramping with a
bowel movement?
Yes
No
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Is your cramping (If yes,)
Mild (mild)
Moderate (moderate)
Severe (severe)
In the past week, have you had blood in your
bowel movement?
Yes
No
Check the description that best describes the
amount of blood in your bowel movement
Enough To Turn Water In Toliet Bowel
Red (Enough to turn water in toliet bowel
red)
Mixed With Or Coating Bowel Movement
(Mixed with or coating bowel movement)
On Toliet Tissue Only (On toliet tissue
only)
In the past week, how much have problems with
bowel movements affected your normal
activities?
Mild - Not Interfering With Normal Life
Activities (Mild - not interfering with
normal life activities)
Moderate - Requires Changes In One's
Life Activities Due To Bowel Function
(Moderate - requires changes in one's
life activities due to bowel function)
No Problems (No problems)
Severe - Unable To Perform Normal Life
Activities Due To Bowel Function (Severe
- unable to perform normal life activities
due to bowel function)
How would you describe your overall Quality of
Life?
0 (0)
1 (1)
10 (10)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
7 (7)
8 (8)
9 (9)
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Z1031: Mammogram/Ultrasound Report
NCT00265759
Z1031: Mammogram/Ultrasound Report NCT00265759
Exemestane, Letrozole, or Anastrozole in Treating
Postmenopausal Women Who Are Undergoing Surgery for
Stage II or Stage III Breast Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=FA4F2D20-
A115-51B3-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11235
Z1031: Mammogram/Ultrasound
Report NCT00265759
Patient demographics
Visit
Week 12 (Week 12)
Week 15 (Week 15)
Week 16 (Week 16)
Week 4 (Week 4)
Week 8 (Week 8)
Within 14 Days Prior To Intervention
(Within 14 days prior to intervention)
Year 10 (Year 10)
Year 2 (Year 2)
Year 3 (Year 3)
Year 4 (Year 4)
Year 6 (Year 6)
Year 8 (Year 8)
Patient ID (Pt. ID issued during registration or
previously issued patient ID)
Institution No.
Patient Initials (F M L)
Institution Name
Date of Assessment (provide date of patient?s
clinic visit)
Mammography/ultrasound Measurements
Tumor size measured by mammogram
Yes
No
Tumor size measured by ultrasound
Yes
No
Axillary node measured by ultrasound (largest
node only)
Yes
No
Dimension 1 (cm)
1 / 2
cm
Dimension 1 (cm)
cm
Dimension 1 (cm)
cm
Dimension 2 (Longest perpendicular axis)
cm
Unknown (Unknown)
Dimension 2 (Longest perpendicular axis)
cm
Unknown (Unknown)
Dimension 2 (Longest perpendicular axis)
cm
Unknown (Unknown)
Comments (Please note any additional
radiological studies performed)
Completed by
Date Form Completed
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Z1031: Mammogram/Ultrasound Report NCT00265759
Z1031: Tissue Specimen Bank Submission
Form NCT00265759
Z1031: Tissue Specimen Bank Submission Form
NCT00265759
Exemestane, Letrozole, or Anastrozole in Treating
Postmenopausal Women Who Are Undergoing Surgery for
Stage II or Stage III Breast Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=FA4AB6A1-
9BAB-1A10-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11236
Z1031: Tissue Specimen Bank
Submission Form NCT00265759
Patient demographics
Visit
Surgery (Surgery)
Week 12 (Week 12)
Week 15 (Week 15)
Week 16 (Week 16)
Week 2 (Week 2)
Week 4 (Week 4)
Week 8 (Week 8)
Within 14 Days Prior To Intervention
(Within 14 days prior to intervention)
Patient ID (Pt. ID issued during registration or
previously issued patient ID)
Institution No.
Patient Initials (F M L)
Institution Name
Biopsy specimen
Were specimen(s) submitted to the ACOSOG
Central Specimen Bank
Yes
No
Date of Receipt of Specimens (mm dd yyyy)
Specimen Type
Tissue Fixed With Formalin (Formalin-
fixed tumor tissue)
Frozen Tissue, Not Fixed, Embedded
With Oct (OCT-embedded tumor tissue)
Paraffin Embedded Surgical Block
(Paraffin embedded surgical block)
Sections On Superfrost Plus Slides
(Sections on superfrost plus slides)
No specimen received (Check if none)
1 / 2
Specimen Received Count
Condition of specimen (Check the box that best
describes the condition of the specimens)
Adequate (Adequate)
Damaged Or Unusable (Damaged or
unusable)
Inadequate (Inadequate)
Usable (Usable)
Completed by
Date Form Completed (mm dd yyyy)
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Z1031: Breast Surgery Report Form
NCT00265759
Z1031: Breast Surgery Report Form NCT00265759
Exemestane, Letrozole, or Anastrozole in Treating
Postmenopausal Women Who Are Undergoing Surgery for
Stage II or Stage III Breast Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=FAB0D6CB-
D9B7-4FC5-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
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Z1031: Breast Surgery Report Form
NCT00265759
Patient demographics
Visit
Surgery (Surgery)
Patient ID (Pt. ID issued during registration or
previously issued patient ID)
Institution No.
Patient Initials (F M L)
Institution Name
Surgery assessment
Was primary breast surgery performed
Yes
No
Surgery Date (Year Month e.g., JAN  Day)
Type of procedure recommended by surgeon to
patient
Modified Radical Mastectomy (Modified
Radical Mastectomy)
Other (Other)
Partial Mastectomy (Partial Mastectomy)
Radical Mastectomy (Radical
Mastectomy)
Surgery Not Recommended (Surgery not
recommended)
Other, specify
Surgery not recommended, reason
Type of procedure performed
Modified Radical Mastectomy (Modified
Radical Mastectomy)
Modified Radical Mastectomy After
1 / 2
Partial Mastectomy As First Attempt
(Modified Radical Mastectomy after
Partial Mastectomy as first attempt)
Other (Other)
Partial Mastectomy - With Re-excision
(Partial Mastectomy with re-excision)
Partial Mastectomy Without Re-excision
(Partial Mastectomy without re-excision)
Radical Mastectomy (Radical
Mastectomy)
Surgery Not Performed (Surgery not
performed)
Other, specify
Primary reason for type of procedure
Patient Preference (Patient preference)
Surgeon Decision (Surgeon decision)
Amount of disease present at surgery (Tumor
Pathology if resected)
Macroscopic < 2 Cm (Macroscopic < 2
cm)
Macroscopic >= 2 Cm (Macroscopic >= 2
cm)
Microscopic (Microscopic)
None (None)
Tumor Pathology (if Resected)
Dimension 1 (cm)
cm
Dimension 2 (Longest perpendicular axis)
cm
Margin Status (mark one)
Close (Close)
Negative (Negative)
Positive (Positive)
Histologic Grade
Well Differentiated (Grade I (low))
Moderately Differentiated (Grade II
(intermediate))
Poorly Differentiated (Grade III (high))
Completed by
Date Form Completed
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Z1031: Pre-resection Visit Form
NCT00265759
Z1031: Pre-resection Visit Form NCT00265759
Exemestane, Letrozole, or Anastrozole in Treating
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Stage II or Stage III Breast Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=FA5E66B8-
9BAC-016B-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11238
Z1031: Pre-resection Visit Form
NCT00265759
Patient demographics
Visit
Week 12 (Week 12)
Week 16 (Week 16)
Week 4 (Week 4)
Week 8 (Week 8)
Patient ID (Pt. ID issued during registration or
previously issued patient ID)
Institution No.
Patient Initials (F M L)
Institution Name
Pre-resection assessment
Date of Assessment (Year Month e.g., JAN  Day)
Dimension 1 (cm)
cm
Not done (or)
Not done (or)
Dimension 2
cm
Increase of >25% in clinical tumor size relative to
baseline measurement (caliper)
Yes
No
Clinical evidence of increased nodal disease
present
Yes
No
Increase of >25% in tumor size confirmed
Yes
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No
Increase of >25% in tumor size confirmed
Yes
No
Does the patient have clinical or radiologic
evidence of metastatic disease?
Yes
No
Clinical evidence of new breast primary lesion
identified and confirmed
Yes
No
If any disease progression confirmed (mark one)
Other (Other)
Proceed To Chemotherapy (Proceed to
chemotherapy)
Proceed To Or (Proceed to OR)
Study Treatment Continued (Study
treatment continued)
Other, specify
Completed by
Date Form Completed
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Z1031: Adjuvant Therapy Form
NCT00265759
Z1031: Adjuvant Therapy Form NCT00265759
Exemestane, Letrozole, or Anastrozole in Treating
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Z1031: Adjuvant Therapy Form
NCT00265759
Patient demographics
Visit
30 Days Post Surgery (30 Days post
surgery)
Year 2 (Year 2)
Year 4 (Year 4)
Year 5 (Year 5)
Patient ID (Pt. ID issued during registration or
previously issued patient ID)
Institution No.
Patient Initials (F M L)
Institution Name
Assessment Date
Adjuvant Endocrine Therapy
Endocrine therapy provided between current visit
and previous visit
Yes
No
Therapy (mark all that apply)
Anastrozole (Anastrozole)
Other (Other)
Tamoxifen (Tamoxifen)
Other, specify
Adjuvant Chemotherapy Therapy
Chemotherapy provided between current visit
and previous visit
Yes
No
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Adjuvant Radiation Therapy
Has the patient received adjuvant RT (since the
previous visit?)
Yes
No
Region irradiated (mark all that apply)
Axillary (Axillary)
Breast (Breast)
Chest (Chest)
Internal Mammary (Internal mammary)
Other (Other)
Supraclavicular (Supraclavicular)
Other, specify
Completed by
Date Form Completed
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NCT00565851 GYNECOLOGIC ONCOLOGY GROUP
Quality of Life Cover Sheet - FORM QCS-0202
NCT00565851 GYNECOLOGIC ONCOLOGY GROUP
Quality of Life Cover Sheet - FORM QCS-0202
Carboplatin and Paclitaxel With or Without Bevacizumab
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Fallopian Tube Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=DAA11499-
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All rights reserved. Please visit https://medical-data-
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NCT00565851 GYNECOLOGIC
ONCOLOGY GROUP Quality of Life
Cover Sheet - FORM QCS-0202
Header module
Date form originally completed
Date form amended
Person amending form last name
Patient Initials
Patient Study ID
Person completing form, last name
Quality Of Life Tracking Information
Scheduled time to obtain Quality of Life
Questionnaire and cover sheet
Pre-cycle 1 (Pre-cycle 1)
Pre-cycle 3 (Pre-cycle 3)
Pre-cycle 6 (Pre-cycle 6)
Prior To Surgery (Prior to surgery, if
randomized to surgery)
Was QOL Questionnaire completed?
Yes
No
Date quesionaire due (m/d/y)
Date quesionaire completed (m/d/y)
Please indicate reason (If no, check one)
Other (Other)
Patient Died (Patient died)
Patient Kept Appointment For
Examination, But Could Not Complete
Questionnaire Due To Illness (Patient
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kept appointment for examination, but
could not complete questionnaire due to
illness)
Patient Kept Appointment For
Examination, But Refused To Complete
Questionnaire For Reasons Other Than
Illness (Patient kept appointment for
examination, but refused to complete
questionnaire for reasons other than
illness.)
Patient Off Study Treatment And Cannot
Be Contacted For Follow-up (Patient off
study treatment and cannot be contacted
for follow-up)
Test Omitted Due To
Institution/investigator Error
(Questionnaire not administered due to
institutional error)
Specify reason
Other. Please specify
Contact Information
Signature of person completing this form (Data
Manager/Nurse Oncologist)
Phone
Date (m/d/y)
Participating Group Code
Participating Group Protocol Number
Participating Group Patient ID
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NCT00565851 GYNECOLOGIC ONCOLOGY GROUP Quality of Life
Cover Sheet - FORM QCS-0202
GYNECOLOGIC ONCOLOGY GROUP
Pathology Form - FORM F NCT00565851
GYNECOLOGIC ONCOLOGY GROUP Pathology Form -
FORM F NCT00565851
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GYNECOLOGIC ONCOLOGY
GROUP Pathology Form - FORM F
NCT00565851
Patient demographics
Date form originally completed
Date form amended
Person amending form last name
Patient Initials (First, Middle, Last)
Patient Study ID
Person completing form, last name
Primary Disease Assessment
Primary site
Cervix (Cervix)
Endometrium (Endometrium)
Fallopian Tube (Fallopian tube)
Gestational Trophoblastic Disease (GTD)
Other, Specify (Other, specify)
Ovary (Ovary)
Peritoneum (Peritoneum)
Uterine Sarcoma (Uterine sarcoma)
Vagina (Vagina)
Vulva (Vulva)
Method of evaluation
Biopsy (Biopsy)
Cytology (Cytology)
Other, Specify (Other, specify)
Surgery (Surgery)
Histologic type (check one)
Adenocarcinoma With Squamous
Differentiation (Adenocarcinoma with
squamous differentiation)
Adenocarcinoma, Unspecified
(Adenocarcinoma, unspecified)
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Adenosquamous (Adenosquamous
carcinoma)
Benign (Benign NOS)
Carcinosarcoma, MMT
(Carcinosarcoma, MMT)
Clear Cell Carcinoma (Clear cell
carcinoma)
Dysgerminoma (Dysgerminoma)
Endodermal Sinus Tumor (yolk Sac
Tumor) (Endodermal sinus tumor)
Endometrial Stromal Sarcoma
(Endometrial stromal sarcoma)
Endometrioid Adenocarcinoma
(Endometrioid adenocarcinoma)
Fibroma (Fibroma)
Germ Cell Tumor, Mixed (Germ cell
tumor, mixed)
Granulosa Cell Tumor (Granulosa cell
tumor)
Leiomyosarcoma (Leiomyosarcoma)
Mixed Epithelial Carcinoma, Specify
Components (Mixed epithelial
carcinoma)
Mucinous Adenocarcinoma (Mucinous
adenocarcinoma)
Mucinous Cystadenoma (benign)
(Mucinous cystadenoma)
Mucinous Tumor Of Low Malignant
Potential (Mucinous tumor of LMP)
Normal Tissue (Normal tissue)
Other, Specify (Other, specify)
Serous Adenocarcinoma (Serous
adenocarcinoma)
Serous Cystadenoma (benign) (Serous
cystadenoma)
Serous Tumor Of Low Malignant
Potential (Serous tumor of LMP)
Sex-cord/stromal, Unclassified (Sex
cord/stromal, unclassified)
Small Cell Carcinoma (Small cell
carcinoma)
Squamous Cell Carcinoma (Squamous
cell carcinoma, invasive)
Teratoma, Immature, Specify
Components (Teratoma, immature)
Teratoma, Mature (Teratoma, mature)
Transitional Cell Carcinoma, Including
Brenner Tumor (Transitional cell
carcinoma)
Undifferentiated Carcinoma
(Undifferentiated carcinoma)
Villoglandular Carcinoma (Villoglandular
carcinoma)
Other, specify
Date of evaluation
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GYNECOLOGIC ONCOLOGY GROUP Pathology Form - FORM F
NCT00565851
Histological grade (Differentiation)
Grade 1-well Differentiated (1)
Grade 2-moderately Differentiated (2)
Grade 3-poorly Differentiated (3)
Indeterminate (Indeterminate)
Not Applicable (Not applicable)
Grade Unknown (Unknown)
Specimen site
Bladder Peritoneum (Bladder
peritoneum)
Bowel Peritoneum/serosa (Bowel
peritoneum/serosa)
Cervix (Cervix)
Corpus (Corpus)
Cul-de-sac (Cul-de-sac)
Diaphragm (Diaphragm)
Endometrium (Endometrium)
Fallopian Tube (Fallopian tube)
Lymph Node(s) (Lymph node(s), specify)
Metastatic Site (Metastatic site, specify)
Omentum (Omentum)
Other (Other, specify)
Ovary (Ovary)
Paracolic Gutter Left (Paracolic gutter
left)
Paracolic Gutter Right (Paracolic gutter
right)
Pelvic Wall Left (Pelvic wall left)
Pelvic Wall Right (Pelvic wall right)
Peritoneum/uterine Serosa
(Peritoneum/uterine serosa)
Metastatic site, specify
Other, specify
Other, specify
Other, specify
Specimen ID (of the blocks/slides)
Lymph node(s), specify
Secondary Disease Assessment
Method of evaluation
Biopsy (Biopsy)
Cytology (Cytology)
Other, Specify (Other, specify)
Surgery (Surgery)
3 / 4
GYNECOLOGIC ONCOLOGY GROUP Pathology Form - FORM F
NCT00565851
Disease status
Disease Continues To Be Present
Following Initial Treatment (Persistent)
Progression (Progression)
Recurrence/relapse (Recurrence)
Date of evaluation
Specimen site
Bladder Peritoneum (Bladder
peritoneum)
Bowel Peritoneum/serosa (Bowel
peritoneum/serosa)
Cervix (Cervix)
Corpus (Corpus)
Cul-de-sac (Cul-de-sac)
Diaphragm (Diaphragm)
Endometrium (Endometrium)
Fallopian Tube (Fallopian tube)
Lymph Node(s) (Lymph node(s), specify)
Metastatic Site (Metastatic site, specify)
Omentum (Omentum)
Other (Other, specify)
Ovary (Ovary)
Paracolic Gutter Left (Paracolic gutter
left)
Paracolic Gutter Right (Paracolic gutter
right)
Pelvic Wall Left (Pelvic wall left)
Pelvic Wall Right (Pelvic wall right)
Peritoneum/uterine Serosa
(Peritoneum/uterine serosa)
Lymph node(s), specify
Metastatic site, specify
Other, specify
Other, specify
Specimen ID (of the blocks/slides)
Participating group code
Participating group protocol number
Participating group patient ID
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GYNECOLOGIC ONCOLOGY GROUP Pathology Form - FORM F
NCT00565851
NCT00565851 GYNECOLOGIC ONCOLOGY
GROUP Pre-Treatment Summary Form - FORM DR
NCT00565851 GYNECOLOGIC ONCOLOGY GROUP Pre-
Treatment Summary Form - FORM DR
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Source Form: NCI FormBuilder:
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NCT00565851 GYNECOLOGIC
ONCOLOGY GROUP Pre-Treatment
Summary Form - FORM DR
Patient demographics
Date form originally completed
Date form amended
Person amending form last name
Patient Initials (First, Middle, Last)
Patient Study ID
Person completing form, last name
Non-invasive Diagnostic Procedures
Chest X-Ray Result
Abnormal (Abnormal)
Normal (Normal)
Not Done (Not done)
EKG Result
Abnormal (Abnormal)
Normal (Normal)
Not Done (Not done)
MRI Result
Abnormal (Abnormal)
Normal (Normal)
Not Done (Not done)
CT Result
Abnormal (Abnormal)
Normal (Normal)
Not Done (Not done)
Other Result
Abnormal (Abnormal)
Normal (Normal)
Not Done (Not done)
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Abnormal, specify
Abnormal, specify
Abnormal, specify
Abnormal, specify
Abnormal, specify
Tumor Evaluation
Are there any target lesions?
Yes
No
Comments
Comments
Participating Group Code
Participating Group Protocol Number
Participating Group Patient ID
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NCT00565851 GYNECOLOGIC ONCOLOGY GROUP Pre-Treatment
Summary Form - FORM DR
GYNECOLOGIC ONCOLOGY GROUP
Registration Form - FORM R NCT00565851
GYNECOLOGIC ONCOLOGY GROUP Registration Form -
FORM R NCT00565851
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Fallopian Tube Cancer
Source Form: NCI FormBuilder:
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GYNECOLOGIC ONCOLOGY
GROUP Registration Form - FORM
R NCT00565851
Patient demographics
Date form originally completed
Date form amended
Person amending form last name
Patient Name, Last
Patient Name, First
Patient Study ID
Person Completing Form, Last Name
Tracking Information
Institution name (/affiliate)
Treating physician
Patient medical record number
Patient's date of birth
Patient social security number
Patient's zip code (USA)
Country of residence (if not USA)
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Demographic Information
Patient race (mark all that apply)
A Person Having Origins In Any Of The
Original Peoples Of North And South
America (including Central America),
And Who Maintains Tribal Affiliation Or
Community Attachment (American Indian
or Alaska Native)
A Person Having Origins In Any Of The
Original Peoples Of The Far East,
Southeast Asia, Or The Indian
Subcontinent Including, For Example,
Cambodia, China, India, Japan, Korea,
Malaysia, Pakistan, The Philippine
Islands, Thailand, And Vietnam. (Asian)
A Person Having Origins In Any Of The
Black Racial Groups Of Africa. Terms
Such As "haitian" Or "negro" Can Be
Used In Addition To "black Or African
American." (Black or African American)
A Person Having Origins In Any Of The
Original Peoples Of Hawaii, Guam,
Samoa, Or Other Pacific Islands (Native
Hawaiian or other Pacific Islander)
Patient Is Unsure Of Their Race
(Unknown)
A Person Having Origins In Any Of The
Original Peoples Of Europe, The Middle
East, Or North Africa. (White)
Patient ethnicity (check one)
A Person Of Mexican, Puerto Rican,
Cuban, Central Or South American Or
Other Spanish Culture Or Origin,
Regardless Of Race (Hispanic or Latino)
A Person Not Meeting The Definition For
Hispanic Or Latino. (Non-Hispanic)
Patient Is Unsure Of Their Ethnicity
(Unknown)
Method of payment
Medicaid (Medicaid)
Medicaid And Medicare (Medicaid &
Medicare)
Medicare (Medicare)
Medicare And Private Insurance
(Medicare & Private Insurance)
Military Or Veterans Sponsored Nos
(Military or Veterans Sponsored NOS)
Military Sponsored (including Champus
& Tricare) (Military Sponsored (including
CHAMPUS & TRICARE))
No Means Of Payment (no Insurance)
(No means of payment (no insurance))
Other (Other)
Private Insurance (Private Insurance)
Self Pay (no Insurance) (Self pay (no
insurance))
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NCT00565851
Unknown (Unknown)
Veterans Sponsored (Veterans
Sponsored)
Patient height (cm)
cm
Patient weight (kg)
Kg
Performance status (Zubrod)
Fully Active, Able To Carry On All Pre-
disease Performance Without Restriction
(karnofsky 90 - 100) (ecog - 0
Asymptomatic) (0)
Restricted In Physically Strenuous
Activity But Ambulatory (k70 - 80) (ecog -
1 Symptomatic - Fully Ambulatory) (1)
Ambulatory And Capable Of All Selfcare
But Unable To Carry Out Any Work
Activities (k 50 - 60) (ecog - 2
Symptomatic; In Bed , 50% Of The Day)
(2)
Capable Of Limited Selfcare, Confined
To Bed Or Chair More Than 50% Of
Waking Hours. (k 30 - 40) (ecog - 3
Symptomatic; In Bed > 50% Of The Day
But Not Bedridden) (3)
Completely Disabled (k10 - 20) (ecog - 4
Bedridden) (4)
Has the patient had any prior cancer diagnosed?
Yes
No
Prior cancer type
Prior cancer diagnosis date
Comments
Comments
Participating Group Code
Participating Group Protocol Number
Participating Group Patient ID
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NCT00565851 GYNECOLOGIC ONCOLOGY
GROUP Solid Tumor Evaluation Form - FORM D2M
NCT00565851 GYNECOLOGIC ONCOLOGY GROUP
Solid Tumor Evaluation Form - FORM D2M
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NCT00565851 GYNECOLOGIC
ONCOLOGY GROUP Solid Tumor
Evaluation Form - FORM D2M
Patient demographics
Date form originally completed
Date form amended
Person amending form last name
Patient Initials (First, Middle, Last)
Patient Study ID
Person completing form, last name
Target Lesion(s) Evaluation
Site of Lesion
Date of evaluation
Method of evaluation (*)
If other, specify
Longest diameter of lesion (s cm)
cm
Sum of longest diameters of all target lesions
Non-target Lesion(s) Evaluation
Are there any nontarget lesions? (If no, skip to
the New Lesions section below.)
Yes
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No
Site of Lesion
Date of evaluation
Method of evaluation (*)
If other, specify
Follow-up status of lesion (s^)
Complete Response (Complete
response)
Progressive Disease (Progressive
disease)
Stable Disease Or Unchanged (Stable)
New Target Lesion(s) At Follow-up
Evaluation
Was the appearance of any new lesions
documented since the baseline evaluation? (If no,
skip the Overall Response section below.)
Yes
No
Site of Lesion
Date of evaluation
Method of evaluation (*)
If other, specify
Overall Response
Overall response status at this assessment
(check one)
Complete Response (CR)
Insufficient Evaluation (Insufficient
evaluation to determine response status)
Progressive Disease (PD)
Partial Response (PR)
Stable Disease (SD)
Response confirmed date (m/d/y)
Comments
Comments
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Evaluation Form - FORM D2M
Participating group code
Participating group protocol number
Participating group patient ID
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NCT00565851 GYNECOLOGIC ONCOLOGY GROUP Solid Tumor
Evaluation Form - FORM D2M
NCT00565851 GYNECOLOGIC ONCOLOGY GROUP
Recurrent Gynecologic Cancer - On Study Form - FORM OSR
NCT00565851 GYNECOLOGIC ONCOLOGY GROUP
Recurrent Gynecologic Cancer - On Study Form - FORM
OSR
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models.org/forms/11245
NCT00565851 GYNECOLOGIC
ONCOLOGY GROUP Recurrent
Gynecologic Cancer - On Study
Form - FORM OSR
Patient demographics
Date form originally completed
Date form amended
Person amending form last name
Patient Initials (First, Middle, Last)
Patient Study ID
Person completing form, last name
Disease Description - Prior History
Date of definitive histologic diagnosis of primary
Stage (at diagnosis FIGO)
Refer To Figo Staging For Specific
Gynecologic Cancer (I)
Refer To Figo Staging For Specific
Gynecologic Cancer (II)
Refer To Figo Staging For Specific
Gynecologic Cancer (III)
Refer To Figo Staging For Specific
Gynecologic Cancer (IV)
Primary surgery date
Primary surgery type (check all that apply)
Bilateral Salpingo-oophorectomy
(Bilateral salpingo-oophorectomy)
Cervical Conization (Cervical conization)
Omentectomy (Omentectomy)
Other, Specify (Other)
Para-aortic Node Sampling/dissection
(Para-aortic node sampling/dissection)
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Partial Hysterectomy (Partial
hysterectomy)
Pelvic Node Sampling/dissection (Pelvic
node sampling/dissection)
Radical Hysterectomy (Radical
hysterectomy)
Radical Trachelectomy (Radical
trachelectomy)
Total Hysterectomy (Total hysterectomy)
Unilateral Salpingo-oophorectomy
(Unilateral salpingo-oophorectomy)
Other, specify
Disease Description - Current History
Current status of disease
Disease Continues To Be Present
Following Initial Treatment (Persistent)
Primary Tumor (Primary (advanced))
Progression (Progression)
Recurrence/relapse (Recurrence)
Date of first recurrence or progression
What was the method used to determine
progression? (recurrence or)
Clinical Examination (Clinical)
Histology (Histologic)
Radiographic (Radiographic)
Site(s) of disease (at study entry)
Ascites (Ascites)
Bladder (Bladder)
Bone (Bone)
Cervix (Cervix)
Cns/brain (CNS/Brain)
Colon (Colon)
Endometrium (Endometrium)
Liver (Liver)
Lung (Lung)
Lymph Nodes (Lymph nodes)
Other (Other)
Ovary (Ovary)
Parametrial Involvement (Parametrial
involvement)
Peritoneum (Peritoneum)
Pleura (Pleura)
Pleural Effusion (Pleural effusion)
Skin (Skin)
Uterus (Uterus)
Lymph nodes, specify
Other, specify
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NCT00565851 GYNECOLOGIC ONCOLOGY GROUP Recurrent
Gynecologic Cancer - On Study Form - FORM OSR
Prior Treatment For Gynecologic Cancer
Prior systemic chemotherapy?
Yes
No
Date prior chemotherapy started
Date prior chemotherapy ended
Chemotherapy regimen
First Line Agent (First line, specify
agent(s))
Other, Specify (Other, specify agent(s))
Second Line Agent (Second line, specify
agent(s))
First line, specify agent(s)
Second line, specify agent(s)
Other, specify agent(s)
Prior hormonal therapy?
Yes
No
Yes, specify
No. of courses
Non-protocol biologic response modifier?
Yes
No
Prior radiation therapy?
Yes
No
Yes, specify
Yes, specify
Is the site of recurrence within the field previously
treated by radiation therapy?
Yes
No
Comments
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Gynecologic Cancer - On Study Form - FORM OSR
Comments
Participating group code
Participating group protocol number
Participating group patient ID
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NCT00522392 
Bortezomib and Dexamethasone With or Without
Lenalidomide in Treating Patients With Multiple Myeloma
Previously Treated With Dexamethasone
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=32B7FEFD-
3249-3074-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
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E1A05 Follow-Up Disease
Assessment Form - Form 2862
NCT00522392
Header
ECOG Protocol Number
ECOG Patient ID
DCI Name
Registration Step (Place ID Label Here)
Patient Initials (Last, First)
Participating Group Protocol Number
Participating Group Patient ID
Institution/Affiliate
Please mark an 'X' if data have been amended.
Date data amended
On Treatment
On Treatment Report Period (Choose one)
Cycle 1 (Cycle 1)
Cycle 2 (Cycle 2)
Cycle 3 (Cycle 3)
Cycle 4 (cycle 4)
Cycle 5 (Cycle 5)
Cycle 6 (Cycle 6)
Cycle 7 (Cycle 7)
Cycle 8 (cycle 8)
Off Treatment
Off Treatment Report Period (Choose one)
9 Years (108 months post registration)
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12 Months (12 Months Post Registration)
10 Years (120 months post registration)
15 Months (15 Months Post Registration)
18 Months (18 Months Post Registration)
21 Months Post Registration (21 Months
Post Registration)
2 Years (24 Months Post Registration)
3 Months (3 Months Post Registration)
30 Months (30 Months Post Registration)
3 Years (36 Months Post Registration)
42 Months (42 Months Post Registration)
4 Years (48 Months Post Registration)
54 Months (54 Months Post Registration)
6 Months (6 Months Post Registration)
5 Years (60 Months Post Registration)
6 Years (72 Months Post Registration)
84 Months Post Registration (84 Months
Post Registration)
9 Months (9 Months Post Registration)
8 Years (96 months post registration)
Protein Measurements
Date of SPEP
Test not done
Serum total protein (SPEP g/dl)
Serum M-protein spike (g/dl NOTE: Leave blank if
serum M-spike was present but too small to
quantify.)
If serum M-protein spike was left blank, please
specify (g/dl)
Absent (Not present)
Present But Too Small To Quantify
(Present but too small to quantify)
Albumin LLN (g/dl)
Albumin (Value)
Date of serum FLC assessment
Kappa Free Light Chain (mg/dl)
Lambda Free Light Chain (mg/dl)
Date of Immunofixation (urine)
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Serum M-protein by immunofixation
Negative (negative)
Positive (positive)
Date of UPEP
Urine Total Protein (mg/24hr)
Urine M-Protein Light Chain Excretion (mg/24hr)
If urine M-protein light chain excretion was left
blank, please specify (mg/24 hr)
Absent (Not present)
Present But Too Small To Quantify
(Present but too small to quantify)
Urine M-Protein by Immunofixation
Negative (negative)
Positive (positive)
Unknown (unknown)
Date hematology (blood) sample obtained
(Serum Quantitative Immunoglobulins)
IgG (mg/dl)
IgG LLN (mg/dl)
IgG ULN (mg/dl)
IgA (mg/dl)
IgA LLN (mg/dl)
IgA ULN (mg/dl)
IgM (mg/dl)
IgM LLN (mg/dl)
IgM ULN (mg/dl)
Soft Tissue Plasmacytoma
Soft tissue plasmacytoma?
No (no)
Unknown (unknown)
Yes, New (yes, new)
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Yes, Previously Existing (yes, previously
existing)
Lesion No.
Site of lesion
Date of evaluation (leave blank if not evaluated in
this report period)
Method of evaluation
Clinical (Clinical Examination)
Ct Scan (CT scan (non-spiral))
Mri (MRI (NMR))
Other (Other (specify))
Spiral Ct Scan (Spiral CT scan)
Other Specify
Size of Plasmacytoma (cm)
Size of Plasmacytoma
Status of Existing Soft Tissue Plasmacytoma
Decrease (decrease)
Increase (increase)
New (new)
No Change (no change)
Bone Marrow
Was bone marrow biopsy done?
Inadequate Sample (inadequate sample)
No (no)
Yes (yes)
Bone marrow biopsy date
Plasma cells on biopsy (If yes:)
If plasma cells on biopsy was left blank, please
specify
Absent (Not present)
Present But Too Small To Quantify
(Present but too small to quantify)
Was bone marrow aspirate done?
Inadequate Sample (inadequate sample)
No (no)
Yes (yes)
Date of Bone Marrow Aspirate
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Plasma cells on aspirate in interpretation (If yes:)
If plasma cells on aspirate was left blank, please
specify (%)
Absent (Not present)
Present But Too Small To Quantify
(Present but too small to quantify)
Bone
Was bone assessment done (this reporting
period)
Yes
No
Date of most recent bone assessment
CT scan
Yes
No
MRI (NMR)
Yes
No
Bone scan
Yes
No
Pet scan
Yes
No
Skeletal survey
Yes
No
Other
Yes
No
Was the appearance of any new lesions
documented (lytic bone)
No (no)
Unknown (unknown)
Yes (yes)
Was there distinct enlargement of existing lesions
(lytic bone - Leave blank if no prior lesions)
No (no)
Unknown (unknown)
Yes (yes)
Explain results (If yes,)
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Peripheral Blood Chemistry
Glucose LLN (mg/dl)
mg/dL
Glucose ULN (mg/dl)
mg/dL
Glucose (mg/dl)
Date of most recent hematology (blood) sample
obtained
CTC Adverse Event Attribution Code
Definite (Definite)
Possible (Possible)
Probable (Probable)
Unlikely (Unlikely)
Unrelated (Unrelated)
Calcium LLN (mg/dl)
Calcium ULN (mg/dl)
Calcium (mg/dl)
mg/dL
Objective Response
Has the overall response changed
Yes
No
Objective Status at This Evaluation
Complete Response (complete
response)
No Response/stable Disease (no
response/stable disease)
Partial Response (partial response)
Progressive Disease (progressive
disease)
Unevaluable (unevaluable)
Very Good Partial Response (very good
partial response)
Complete Response (CR) First Observed Date
Very Good Partial Response First Observed Date
(VGPR)
Partial Response (PR) First Observed Date
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Progressive Disease First Observed Date (PD)
Comments
Comments
Investigator Signature
Investigator Signature Date
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General Info
Age*
>= 0
<= 120
years
Sex*
Racial group
Body height
>= 0
cm
Body weight
>= 0
kg
Chief complaint (CC)*
History of present illness*
Prior Health History
Past medical history*
Prior Surgery, History of (H/O)  surgery, Past
surgical history*
current medication list, active medication*
Allergies*
Review of systems*
Family history (FH) of*
Social and personal history, Social and personal
circumstances*
Immunisation*
Physical Exam
1 / 6
Temperature
°C
Pulse*
beats/min
Respiration rate, Breathing rate (BR)
/min
Blood pressure (BP)
mmHg
Pain*
general appearance*
Head, Ears, Eyes, Nose and Throat*
Neck, Collum, Cervical*
Chest, Thorax*
Mammary region*
Heart*
Abdomen*
lymph nodes*
Genital Organs/Rectal
Extremities, Limb structure*
Integument*
Neurologic system, Nervous system, Nervous
system structure*
summary, conclusion*
Plan*
Finding of American Society of Anesthesiologists
physical status classification*
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AIRWAY ASSESSMENT FOR PATIENTS
RECEIVING MODERATE SEDATION*
Teeth*
Mallampati score*
Neck Extension (normal/RESTRICTED/NO
MOBILITY)
Treating Physician*
Procedure
Date of procedure*
Preoperative diagnosis*
Post-operative diagnosis*
Primary Surgeon*
first assistant surgeon*
anesthesist*
ANESTHESIA/SEDATION
Medication
ANTIBIOTIC: Ancef*
Yes
No
ANTIBIOTIC: Rocephin*
Yes
No
ANTIBIOTIC: Levaquin*
Yes
No
ANTIBIOTIC: Other*
OTHER MEDS GIVEN*
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TECHNICAL PROCEDURE
Drainage of abscess*
Yes
No
Aortography, Contrast aortogram*
Yes
No
Aortogram and Runoff*
Yes
No
AV Fistulagram*
Yes
No
Biliary Drain*
Yes
No
Angiogram carotid, Carotid angiography*
Yes
No
Cerebral angiogram, Angiogram cerebral,
Fluoroscopic angiography of cerebral artery*
Yes
No
Chest drain, chest tube, thoracic tube*
Yes
No
Chest tube/Empyema
Yes
No
Central venous catheter (CVC), Central venous
line*
Yes
No
CVC/Port
Yes
No
CVC Temporary*
Yes
No
CVC Tunneled*
Yes
No
Dialysis Access Declot*
Yes
No
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Endovenous laser treatment (ELT)*
Yes
No
Extremity Angiogram
Yes
No
Balloon Vertebroplasty*
Yes
No
Percutaneous insertion of nephrostomy tube*
Yes
No
Peripherally-Inserted Central Catheter (PICC),
PICC line*
Yes
No
Pulmonary arteriogram, Pulmonary artery
angiography*
Yes
No
radiofrequency ablation (RFA) procedure
Yes
No
transarterial chemoembolization*
Yes
No
Thrombolysis*
Yes
No
Embolisation of uterine artery*
Yes
No
Other procedure*
FINDINGS
None (1)
Same (2)
N/A (3)
Successful (4)
Unsuccessful (5)
Findings text*
bleeding, blood loss, hemorrhage*
Contrast medium, Contrast agent*
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FLUORO TIME*
SPECIMEN(s)REMOVED (yes|no)*
Yes
No
Specimen*
COMPLICATIONS: No immediate *
Yes
No
Complications*
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H and P or consult specialty
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All rights reserved. Please visit https://medical-data-
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H and P or consult specialty
Reason for visit*
Chief complaint (CC)*
HISTORY OF PRESENT ILLNESS
History of present illness*
SOURCE(S) OF HISTORY (Patient, Family,
Outside records, Unobtainable)*
SOURCE(S) OF HISTORY comment*
REVIEW OF SYSTEMS
REVIEW OF SYSTEMS: see form Review of
systems*
PAST HISTORY
Adult disease*
Childhood Illness*
Prior Surgery, History of (H/O)  surgery, Past
surgical history*
Traumatic injury, trauma*
Female Specific History
Date of last menstrual period (LMP)*
Date of last Papanicolaou test (PAP)*
Pap smear, smear cervix, vaginal smear,
Papanicolaou Test*
Date of last mammogram (MMG)*
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Mammogram*
Age at menarche*
Menstruation, Menses*
Contraception, Birth control*
Pregnancy, Gestation*
Abortion, Pregnancy with abortive outcome*
Number of full term pregnancies*
Number of spontaneous abortions*
Number of therapeutic abortions*
Number of other types Abortions*
Age at first pregnancy*
FAMILY HISTORY
Family history (FH)*
SOCIAL HISTORY
Social and personal history, Social and personal
circumstances*
ALLERGIES
No Known Allergies*
Yes
No
Hypersensitivity*
MEDICATIONS
Inpatient Medications*
current medication list, active medication*
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Home Medications*
PHYSICAL EXAM - General
VITAL signs*
Temperature*
°C
Pulse*
beats/min
Respiration rate, Breathing rate (BR)
/min
Blood pressure (BP)*
mmHg
Pain*
Body weight
>= 0
kg
GENERAL
PHYSICAL EXAM - HEAD
HEAD (Normocephalic, atraumatic)*
Yes
No
Head*
PHYSICAL EXAM - EYES
EYES (Pupils are RRE and react to light and
accomodation, Conjunctivae pink and moist,
Extraocular muscles intact)*
Yes
No
Pupil*
conjunctiva*
Sclera*
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Extraocular muscles (EOM)*
Fundoscopy*
Physical Exam - Ears, Nose, Throat
Ear canals patent. TM's intact. Nares patent and
pink without epistaxis. Mucosa pink. No
pharyngitis. Natural dentition.*
Yes
No
EAR R ext canal*
EAR R tympanic membrane (TM)*
EAR L ext canal*
EAR L tympanic membrane (TM)*
Nasal septum, Septum nasi*
Nasal mucosa, Mucosa of nose*
Nose R Nares*
Nose L Nares*
Mouth mucosa, Oral Mucosa*
Pharynx, Throat*
Tonsils*
Dentition*
Physical Exam - Neck
Neck, Collum, Cervical*
Yes
No
Adenopathy*
Carotid bruit*
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Jugular venous distension (JVD)*
Thyroid gland, Glandula thyroidea, thyroid*
Trachea, windpipe*
Physical Exam - BREAST
symmetric without masses*
Yes
No
inspection: Right breast*
inspection: Right nipple*
inspection: Left breast*
inspection: Left nipple*
palpation: Right breast*
palpation: Right nipple*
palpation: Left breast*
palpation: Left nipple*
Physical Exam - CHEST
normal for inspection, percussion, palpation, and
auscultation of the lungs.*
Yes
No
Chest significant for:*
Location*
Additional lung sounds*
Location*
Physical Exam - HEART
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PMI at 5th intercostal space, mid clavicular line,
normal S1,S2 without murmur or gallop*
Yes
No
Palpation: PMI is*
Rhythm*
Heart Sounds:    S1 is , S2 is, S3 is, S4 is*
PE HEART RUB TEXT*
PE HEART OTHER SOUNDS TEXT*
Murmur:   grade*
Murmur heard best at *
Murmur radiates *
Heart - OTHER1*
Physical Exam - VASCULAR
Pulses present and equal bilat.*
Yes
No
Aorta*
Pulses R/L: carotid*
Pulses R/L: brachial*
Pulses R/L: radial*
Pulses R/L: femoral*
Pulses R/L: popliteal*
Pulses R/L: posterior tibial*
Pulses R/L: dorsalis pedis*
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Physical Exam - ABDOMEN
soft, flat, nontender with normal bowel sounds. no
organomegaly, no ascites, no palpable mass, no
hernia.*
Yes
No
Appearance*
Bowel Sounds (BS), Borborygmi*
Midepigastric bruit*
Abdominal tenderness*
Rebound*
Liver, Hepar*
Spleen*
Hernia*
Physical Exam -
GENITOURINARY/RECTAL: MALE
GU Assessment*
Urine appears*
Urine is adequate*
Urine output (UO), Urinary volume, Micturition
volume*
Foley catheter*
Suprapubic catheter (SPC)*
scrotal contents*
Penis*
rectal: sphincter tone*
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Haemorrhoids, Piles*
Prostate, Prostate Gland*
mass*
Physical Exam -
GENITOURINARY/RECTAL: FEMALE
GU Assessment FEMALE*
Urine appears*
Urine is adequate*
Urine Output [ml]*
Foley catheter*
Suprapubic catheter (SPC)*
External genitalia*
Urethra*
Vagina*
Urinary Bladder*
Cervix uteri*
Uterus*
Uterine adnexa*
rectal: sphincter tone*
Haemorrhoids, Piles*
mass*
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Physical Exam -MUSCULOSKELETAL
Musculoskeletal System, Musculo-skeletal
system*
Gait, Manner of walking*
Station*
Digits*
Nails*
Joints, Bones, Muscles
Head & Neck (inspection & palpation, ROM,
stability, muscle strength, tone)
Spine/Ribs/Pelvis (inspection & palpation, ROM,
stability, muscle strength, tone)*
Right Shoulder (inspection & palpation, ROM,
stability, muscle strength, tone)*
Right Elbow (inspection & palpation, ROM,
stability, muscle strength, tone)*
Right Wrist (inspection & palpation, ROM,
stability, muscle strength, tone)*
Left Shoulder (inspection & palpation, ROM,
stability, muscle strength, tone)*
Left Elbow (inspection & palpation, ROM, stability,
muscle strength, tone)*
Left Wrist (inspection & palpation, ROM, stability,
muscle strength, tone)*
Right Hip (inspection & palpation, ROM, stability,
muscle strength, tone)*
Right Knee (inspection & palpation, ROM,
stability, muscle strength, tone)*
Right Ankle (inspection & palpation, ROM,
stability, muscle strength, tone)*
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Left Hip (inspection & palpation, ROM, stability,
muscle strength, tone)*
Left Knee (inspection & palpation, ROM, stability,
muscle strength, tone)*
Left Ankle (inspection & palpation, ROM, stability,
muscle strength, tone)*
Physical Exam - EXTREMITIES
Significant for:*
Pitting edema*
pretibial: R / L*
ankle: R / L*
foot: R / L*
Posterior tibial pulse R/L*
Pulses R/L: dorsalis pedis*
capillary fill time R/L*
sensation by monofilament test R/L*
toenails*
skin*
Physical Exam - LYMPHATIC
no adenopathy*
Yes
No
adenopathy (generalized, localized)*
Neck, Collum, Cervical*
Axilla, axillary region*
10 / 17
H and P or consult specialty
Inguinal region*
other*
Physical Exam - SKIN
Inspection and palpation of skin and
subcutaneous tissue reveals no acute rashes,
lesions, or induration.*
Yes
No
inspection, visual examination*
Palpation*
Physical Exam - Wound and Incision Care
Wound*
WOUND LOCATION*
WOUND MEASUREMENT (Length, Width, Depth
[cm])*
UNDERMINING Wound*
Yes
No
TUNNELING Wound*
Yes
No
SURROUNDING SKIN:   WOUND BASE*
Sensation, Esthesia, Sensory function, Sensory
perception*
EXUDATE*
COLOR OF DRAINAGE*
ODOR: Before Cleaning *
Yes
No
ODOR: After Cleaning *
11 / 17
H and P or consult specialty
Yes
No
CLEANSED WITH/IRRIGATED WITH*
WOUND MED applied*
FILLED WITH*
COVERED WITH*
SECURED WITH*
PRESSURE RELIEF*
COMMENTS*
PHOTOGRAPH DATE*
NARRATIVE *
Surgical incision*
Location*
CLOSURE TYPE*
DRESSING TYPE*
DRESSING APPEARANCE*
Drains, Drain device*
NARRATIVE *
Physical Exam - NEUROLOGIC
Oriented x 3, cranial nerves 2-12 intact, no gross
sensory or motor deficits, reflexes symmetric, no
cerebellar signs, no involuntary movements*
Yes
No
Consciousness related finding*
Responsive to*
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Orientation as to time, place and people*
Proverb*
Writing*
Reading (activity)*
Memory function*
Registration*
Naming Intact*
Speech, Speaking, using verbal communication*
OTHER*
Score normal*
Yes
No
Concentration normal*
Yes
No
Cranial nerves normal*
Yes
No
Comment*
Muscle Tonus, Muscle tone, Muscle tension*
Muscle Strength R/L*
Grip R/L*
Biceps brachii, Biceps brachii muscle*
Triceps brachii muscle, Triceps brachii*
Quadriceps femoris muscle, Quadriceps femoris*
Hip Extensors R/L*
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Dorsiflexion   R/L*
Plantarflexion  R/L*
Sensation, Esthesia, Sensory function, Sensory
perception*
Pin prick sensation, Discrimination between
sharp and blunt*
Comment*
Light touch*
Vibration*
Comment*
Position Sense, Position sensation, Postural
sense*
Temperature*
Stereognosis, Stereognostic perception, Touch
discrimination*
Biceps reflex R/L*
Triceps reflex R/L*
Deep Tendon Reflexes Brachioradialis R/L*
Patellar reflex, Knee reflex, Quadriceps reflex,
Knee jerk (KJ) R/L*
Deep Tendon Reflexes Achilles R/L*
Abnormal reflexes*
Involuntary Movements*
Cerebellar Signs*
Gait, Manner of walking*
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Comment*
Station*
PSYCHIATRIC
Alert, oriented to person, place, and time,
judgement and insight good, recent and remote
memory intact, normal mood and affect.*
Yes
No
Judgement & Insight
Orientation as to time, place and people*
Recent Memory*
Remote Memory, Palinmnesis*
Mood/Affect
Laboratory Results
Laboratory results reviewed*
Yes
No
Prior 24 hour labs*
Other*
Radiology Results
Radiology results reviewed*
Yes
No
Radiology report*
ASSESSMENT
acceptable for surgery*
Yes
No
progressing well*
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Yes
No
stable medically*
Yes
No
Active Problems*
Other*
PLAN
Continue Home Regimen*
Yes
No
Continue Home Meds*
Yes
No
Continue Chemotherapy*
Yes
No
Continue IV Antibiotics*
Yes
No
Continue PO Antibiotics*
Yes
No
Deep venous thrombosis prophylaxis*
Yes
No
O2 Protocol*
Yes
No
Follow Up X-Rays*
Yes
No
UTI treatment*
Yes
No
Monitor Blood Pressure and Heart Rate*
Yes
No
Monitor Diabetes Mellitus*
Yes
No
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Accuchecks AC & HS*
Yes
No
Accuchecks Q6H*
Yes
No
Sliding Scale Regular Insulin*
Yes
No
Check Follow Up Labs*
Yes
No
Appreciate following patient with you*
Yes
No
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Transfer assessment
ADMITTING DIAGNOSIS (AD)*
Treating Physician, Treating Doctor*
Date of admission*
FAMILY NOTIFIED*
Yes
No
BELONGINGS WITH PATIENT*
Yes
No
MEDICATIONS WITH PATIENT*
Yes
No
IV MEDICATIONS WITH PATIENT*
Yes
No
PENDING LABS*
Temperature*
°C
Pulse*
beats/min
Respiratory Rate (/min)
Blood pressure (BP)
mmHg
Date surgery
CODE STATUS*
DATE CODE STATUS ORDERED*
REASON FOR TRANSFER*
Mode of transfer*
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Functional Status, Level of function*
Mental Status, Mental State*
Patient activity*
Activities of Daily Living (ADL), Activities of
everyday life*
Diet*
Tube Feeding via @ with @ strength of @*
Last residual amount was @ CC'S and it was
checked at @*
IV Therapy
intravenous therapy*
Size of catheter*
Location*
Intravenous fluid, Fluid for intravenous
administration*
LEFT TO COUNT [ml]*
Rate: @ ml/hr*
IV Site APPEARANCE*
Central venous catheter (CVC), Central venous
line*
Intravenous fluid, Fluid for intravenous
administration*
TPN/LIPIDS: TPN @ ml/hr and Lipids @ ml/hr*
IV Site APPEARANCE*
SITE CHANGE DUE*
2 / 4
TRANSFER ASSESSMENT INTERDISCIPLINARY NOTE
IV REASSESSMENT*
IV Site APPEARANCE*
NARRATIVE*
Wound
WOUND CARE*
SITE:  LAST DRESSING CHANGE*
ELIMINATION
Date of last bowel movement*
Is the patient incontinent of stool? *
Is the patient incontinent of urine? *
OTHER CARE
O2, Oxygen*
Drains, Drain device*
Pain Therapy*
Respiratory Therapy (RT), Respiratory care*
LAST TIME PATIENT WAS MEDICATED*
Isolation*
TYPE OF ISOLATION*
DAILY WEIGHTS*
Yes
No
Fall Risk, At risk for falling*
Yes
No
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AT RISK FOR SKIN BREAKDOWN*
Physical restraints, Physical restraint equipment*
Date/Time of Restraints order: *
SPECIAL PRECAUTIONS*
4 / 4
TRANSFER ASSESSMENT INTERDISCIPLINARY NOTE
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Overview
Age*
>= 0
<= 120
years
Height
>= 0
cm
Body weight
>= 0
kg
Temperature*
°C
Pulse*
beats/min
Respiratory Rate (/min)
Blood pressure (BP)
mmHg
PT'S RESIDENCE*
LANGUAGE/COMMUNICATION BARRIER*
PRIMARY LANGUAGE*
Chief complaint (CC)*
General practitioner (GP)
Anesthesia Specific
Hypersensitivities*
Are you allergic to adhesive tape?*
Yes
No
Are you allergic to rubber products?*
Yes
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No
Previous Surgeries?*
Surgery involving an anesthetic?*
General anaesthesia (GA)*
Yes
No
Spinal Anaesthesia*
Yes
No
epidural anesthesia
*
Yes
No
Regional Anesthesia Procedure*
Yes
No
Local anaesthesia (LA)*
Yes
No
anesthetic: Moderate sedation*
Yes
No
anesthetic: Axillary block*
Yes
No
Have you or a family member ever had a problem
with an anesthesic? If Yes, describe:*
Health History - Endocrine
Diabetes mellitus*
Yes
No
If Diabetes, last time med taken*
Hyperthyroidism*
Yes
No
Hypothyroidism*
Yes
No
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Health History - Neurologic
Cerebrovascular accident (CVA)*
Convulsion*
Loss of Sensation*
Migraines and/or Headaches*
Blackout or Fainting Spells*
Health History - Cardiovascular
Heart Attack/MI*
Hypertension*
Rapid heart beat, high heart frequency, heart rate
increased*
Cardiac Arrhythmia*
Disease affecting entire cardiovascular system*
Ischemic chest pain*
Health History - Respiratory
Lung diseases*
Chronic congestive heart failure*
Chronic cough*
Asthma*
Chronic Obstructive Pulmonary Disease,
Bronchial infection, Pulmonary Emphysema
Pneumonitis*
Health History - Genitourinary
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Abnormal Kidney function*
Haemodialysis*
Yes
No
Peritoneal Dialysis (PD)*
Yes
No
Health History - Gastrointestinal
Icterus*
Hepatitis*
gastric reflux*
Peptic Ulcer*
Health History - Other
Bleeding diathesis*
Transfusion*
Malignant Neoplasms*
Bleeding Disorders*
SAS - Sleep apnea syndrome *
HAVE YOU HAD ANY MAJOR ILLNESS*
DO YOU HAVE DENTURES*
Yes
No
DO YOU HAVE BRIDGEWORK*
Yes
No
DO YOU HAVE CAPPED TEETH*
Yes
No
DO YOU HAVE LOOSE TEETH*
Yes
No
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Medication*
Steroids*
Health History - Women's health
DATE OF LAST PERIOD*
pregnant*
Yes
No
Weeks Gestation*
Estimated date of confinement (delivery date)*
Health History - Substance abuse and
Smoking
Substance abuse problem*
Do you currently smoke/use tobacco products?
Yes
No
What type of tobacco products?*
How much?*
Have you ever smoked /used tobacco products?*
Yes
No
When did you quit?(If has used products in the
past 12 months,MUST give smoking cessation
advice/information)*
What type of tobacco products?*
How much?*
Pediatric Smoking: Does anyone in your
household currently use tobacco products?*
Yes
No
What type of tobacco products?*
5 / 7
HEALTH HISTORY I_ANESTHESIA MULTIDISCIPLINARY
How much?*
Has anyone in the house hold quit using tobacco
products in the last 12 months?*
Yes
No
When did the person in your house hold quit?(If
has used products in the past 12 months, MUST
give smoking cessation advice/information)*
What type of tobacco products?*
How much?*
Tobacco/Smoking Cessation information/advice
given to Patient*
Yes
No
Tobacco/Smoking Cessation information/advice
given to Other*
Yes
No
In what format was the smoking cessation given
(Verbal, Handwritten, Pre-printed)?*
How much alcohol?*
How often alcohol? *
RECREATIONAL DRUGS*
Immunizations
Immunisation*
SPECIALTY CLINIC specific
SPECIALTY CLINIC specific*
Nutrition
Current body weight
>= 0
kg
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Have you experienced any unexplained weight
loss or gain in the past 6 months?  *
Yes
No
As compared to normal, would you rate your food
intake during the past month as either:
CHANGED- MORE- LESS*
Assistance / Mobility
Do you live alone?              *
Yes
No
Needs assistance at home*
Yes
No
If yes, Name and phone number of person and/or
facility that assists*
Equipment needed for WOUND(S)*
Wound*
How long have you had the wound(s)?*
How did the wounds start? *
How have you been treating the wound(s)? *
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PHYSICAL THERAPY INITIAL
EVALUATION
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General Info
PHYSICAL THERAPY ORDER
operative procedures*
HISTORY OF PRESENT ILLNESS WITH ONSET
DATE*
SOCIAL/HEALTH HABITS(PAST &
CURRENT)
Alcohol abuse*
Yes
No
Smoker*
Yes
No
Living Situation, Dwelling
Assisted Living, Residential Care*
Yes
No
Home (Lives Alone)*
Yes
No
Home with parent(s)*
Yes
No
Home w/Significant Other*
Yes
No
Home w/Spouse*
Yes
No
Home w/Family (Children)*
Yes
No
Home w/Friend (Caretaker)*
Yes
No
Dependent in ADLs*
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Yes
No
Independent in ADLs*
Yes
No
Nursing Home (NH)*
Yes
No
Assisted Living Facility, Retirement Center*
Yes
No
Requires Assistance with ADLs*
Yes
No
Other*
Yes
No
Stairs to enter*
Yes
No
Stairs indoors*
Yes
No
REMAIN ON FIRST FLOOR*
Yes
No
OTHER OBSTACLES OF CONCERN*
Medical history
PREMORBID FUNCTIONAL STATUS*
Family history (FH)*
Medical/surgical history*
MEDICATIONS REVIEWED*
Yes
No
PERTINENT MEDICATIONS AFFECTING
THERAPY*
CLINICAL TESTS*
I.D. VERIFIED BY*
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I.D. VERIFICATION*
Review of systems
Height
>= 0
cm
Body weight
>= 0
kg
Pulse*
beats/min
Respiration rate, Breathing rate (BR)
/min
Blood pressure (BP)
mmHg
Edema*
Yes
No
Ankle Edema
left (L)
right (R)
Foot Edema
left (L)
right (R)
Hand Edema
left (L)
right (R)
Knee Edema
left (L)
right (R)
Leg oedema, Edema of leg
left (L)
right (R)
INTEGUMENTARY within normal limits
Yes
No
Integument*
MUSCULOSKELETAL WNL
Yes
No
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Musculoskeletal System, Musculo-skeletal
system
ROM/STRENGTH*
NEUROMUSCULAR WNL*
Yes
No
Neuromuscular
Gait, Manner of walking
BALANCE
MOTOR CONTROL
COMMUNICATION WNL*
Yes
No
COMMUNICATION
language ability, verbal ability*
Orientation as to time, place and people*
Oriented (1)
Disoriented (2)
Memory loss, Loss of memory*
no memory loss (1)
Long term memory loss (2)
Recent memory loss (3)
EMOTIONAL/BEHAVIORAL RESPONSES WNL*
Yes
No
Emotional / Behavioral responses*
LEARNING BARRIERS*
Yes
No
Hearing impaired
Yes
No
Language/Needs interpreter*
Yes
No
unable to read
Yes
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No
Vision impaired
Yes
No
EDUCATION NEEDS*
Yes
No
Education ADLs
Yes
No
Education Disease
Yes
No
Education Equipment*
Yes
No
Education Exercise Program*
Yes
No
Education Safety*
Yes
No
Education Transfers*
Yes
No
other Education needs*
KEYS TO TEST AND MEASURES
AEROBIC CAPACITY/ENDURANCE*
AROUSAL, ATTENTION, AND COGNITION*
ASSISTIVE AND ADAPTIVE EQUIPMENT*
CIRCULATION*
GAIT, LOCOMOTION, AND BALANCE*
INTEGUMENTARY INTEGRITY*
MOTOR FUNCTION (MOTOR CONTROL AND
MOTOR LEARNING)*
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MUSCLE PERFORMANCE
(STRENGTH,POWER,AND ENDURANCE)*
NEUROMOTOR DEVELOPMENT AND
SENSORY INTEGRATION*
ORTHOTIC, PROTECTIVE, AND SUPPORTIVE
DEVICES*
Pain*
POSTURE
RANGE OF MOTION (INCLUDING MUSCLE
LENGTH)*
REFLEX INTEGRITY
SENSORY INTEGRITY
SELF CARE AND HOME MANAGEMENT*
WORK REINTEGRATION*
EVALUATION*
Diagnosis
Cardiovascular Pattern(s)*
Yes
No
Integumentary Pattern(s)*
Yes
No
Musculoskeletal Pattern(s)*
Yes
No
Neuromuscular Pattern(s)*
Yes
No
Diagnosis*
PROGNOSIS, Goals, Interventions, Plan
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Prognosis, prediction of outcome*
Goals, Objectives*
Interventions
TODAYS*
Educated - family*
Yes
No
Educated - patient*
Yes
No
Educated - significant other*
Yes
No
Educated - returns Demonstration*
Yes
No
Educated - Verbalizes understanding*
Yes
No
DISCHARGE PLANS
Discharge status*
FREQUENCY OF VISITS/DURATION OF
EPISODE OF CARE*
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SIOP CNS GCT II
SIOP CNS GCT II: Prospective Trial for the Diagnosis and
Treatment of Children, Adolescents and Young Adults With
Intracranial Germ Cell Tumors. Principal Investigator
Gabriele Calaminus, MD.
http://clinicaltrials.gov/show/NCT01424839
All rights reserved. Please visit https://medical-data-
models.org/forms/11253
Follow up
Zustand des Patienten
Datum der letzten Information*
Status des Patienten*
Komplette Remission (CR) (1)
Lebt, keine näheren Angaben (10)
Partielle Remission (PR) (2)
Progress (PD) (3)
Rezidiv (4)
2. Tumor (5)
An Tumorerkrankung verstorben (DOD)
(6)
An Komplikationen verstorben (DOC) (7)
Verstorben, sonstiger Grund (8)
Lost to Follow-up (LFU) (9)
Körperliche Untersuchung
Datum der körperlichen Untersuchung
Größe
>= 0
cm
Gewicht*
>= 0
kg
Sexual development
Pubertätsstatus*
Altersgemäß (1)
Pubertas praecox (2)
Pubertas tarda (3)
Tannerstadium
Schambehaarung
Stadium 1 (1)
Stadium 2 (2)
Stadium 3 (3)
Stadium 4 (4)
Stadium 5 (5)
Tannerstadium der männlichen Genitalien
Stadium 1 (1)
Stadium 2 (2)
Stadium 3 (3)
Stadium 4 (4)
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Stadium 5 (5)
Tannerstadium der weiblichen Brust
Stadium 1 (1)
Stadium 2 (2)
Stadium 3 (3)
Stadium 4 (4)
Stadium 5 (5)
Normale testikuläre Funktion
Ja
Nein
Normale ovarielle Funktion
Ja
Nein
Special examination
Datum der speziellen Untersuchung*
MRT oder CT mit Kontrastmitteln*
Normal (1)
Auffällig (2)
Spinale MRT (bei Metastasen)*
Normal (1)
Auffällig (2)
Ophthalmologische Untersuchung*
Normal (1)
Auffällig (2)
Audiogramm (BAER)
Normal (1)
Auffällig (2)
Neurologische Untersuchung
Normal (1)
Auffällig (2)
Endokrinologische Untersuchung
Normal (1)
Auffällig (2)
Serum-Phosphat
mmol/L
Serum-Kreatinin
>= 0
mg/dl
Wurden Tumormarker gemessen
Ja
Nein
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Persisting side effects of therapy
Langzeitfolgen aufgetreten
Ja
Nein
Welche Langzeitfolgen*
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PHYSICAL THERAPY CONSULT
RESULTS
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Diagnosis
Diagnosis*
Height
>= 0
cm
Body weight
>= 0
kg
VITALS
Referring Physician
Objective
Test and Measures
Sensation
Proprioception
Tone
Manual muscle testing
Activity tolerance
Bed mobility
Transfer
Integumentary status*
Communication
Learning Barriers
Education needs
Motor function
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Orthotic/ Prosthetic Devices
Additional comments
Assessment
Assessment*
Plan
Planned*
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Based upon
https://www.msbase.org/
All rights reserved. Please visit https://medical-data-
models.org/forms/11256
MSBase Visits - Basic
Status
Datum
untersucht von
Erster Termin
Ja
Nein
Administrativ
Ja
Nein
Routine
Ja
Nein
Verdacht auf Schub
Ja
Nein
Telefon
Ja
Nein
Retrospectiv
Ja
Nein
McDonald Kriterien
Poser Kriterien
Krankheitsverlauf
Remarks
Behinderung
EDSS
0.0 (0.0)
0.5 (0.5)
1.0 (1.0)
1.5 (1.5)
10.0 (10.0)
2.0 (2.0)
3.5 (3.5)
4.0 (4.0)
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4.5 (4.5)
5.0 (5.0)
5.5 (5.5)
6.0 (6.0)
6.5 (6.5)
7.0 (7.0)
7.5 (7.5)
8.0 (8.0)
8.5 (8.5)
9.0 (9.0)
9.5 (9.5)
Ambulation index
Zeit um 8 m zu gehen
seconds
Nine hole peg Test (rechts)
seconds
Nine hole peg Test (links)
seconds
Dominante hand
Links (1)
Rechts (2)
PASAT test
/ 60
Seit letzter Visite
Anzahl versäumte Arbeitstage
Anzahl Tage in Rehabilitation
Anzahl Spitaltage
Anzahl ambulante Visiten
Vitalzeichen
Körpergröße
>= 0
cm
Gewicht
>= 0
kg
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Systolischer Blutdruck
mmHg
Diastolischer Blutdruck
mmHg
Puls
bpm
Datum nächster Termin
Startdatum
Startzeit
Enddatum
Ende Zeit
Ganzer Tag
Ja
Nein
Bemerkungen
Pflegeperson beteiligt
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Treatment of Children, Adolescents and Young Adults With
Intracranial Germ Cell Tumors. Principal Investigator
Gabriele Calaminus, MD.
http://clinicaltrials.gov/show/NCT01424839
All rights reserved. Please visit https://medical-data-
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Course
Course
Kurs-Nr.*
Welche Chemotherapie wurde in diesem Kurs
verabreicht*
CarboPE (1)
EI (2)
PEI (3)
HDPEI (4)
Andere Strategie (5)
Etoposid oder Etoposidphosphat in diesem Kurs
gegeben*
Nur Etoposid (1)
Nur Etoposidphosphat (2)
Beides, Etoposid und Etoposidphosphat
(3)
Ifosfamid oder Cyclofosfamid in diesem Kurs
gegeben*
Nur Ifosfamid (1)
Nur Cyclofosfamid (2)
Beides, Ifosfamid und Cyclofosfamid (3)
Welche andere Chemotherapie wurde in diesem
Kurs verabreicht*
Startdatum des Kurses*
Intervall > 21 Tage*
Nein (1)
Ja (2)
Grund für Intervallverlängerung*
Verlängerte Aplasie (1)
Nephropathie (2)
Klinischer Status (3)
Operation (4)
Andere (5)
Body dimensions
Größe
>= 0
cm
Gewicht*
>= 0
1 / 6
kg
Körperoberfläche*
>= 0
m²
KOF berechnet*
>= 0
m²
Alter bei Kursbeginn*
YY,MM
Chemo course medication Cisplatin
Absolute Dosis pro Tag*
>= 0
mg/d
Tag der ersten Gabe*
Tag der letzten Gabe*
Anzahl Applikationstage*
Tage
Relative Dosis pro Tag in mg/m²/d*
>= 0
mg/m²/d
Relative Dosis pro Tag in mg/kg/d*
>= 0
mg/kg/d
Kumulative Dosis in mg/m²*
>= 0
mg/m²
Kumulative Dosis in mg/kg*
>= 0
mg/kg
Chemo course medication Cisplatin
Absolute Dosis pro Tag*
>= 0
mg/d
Tag der ersten Gabe*
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Tag der letzten Gabe*
Anzahl Applikationstage*
Tage
Relative Dosis pro Tag in mg/m²/d*
>= 0
mg/m²/d
Relative Dosis pro Tag in mg/kg/d*
>= 0
mg/kg/d
Kumulative Dosis in mg/m²*
>= 0
mg/m²
Kumulative Dosis in mg/kg*
>= 0
mg/kg
Chemo course medication Etoposide
Absolute Dosis pro Tag*
>= 0
mg/d
Tag der ersten Gabe*
Tag der letzten Gabe*
Anzahl Applikationstage*
Tage
Relative Dosis pro Tag in mg/m²/d*
>= 0
mg/m²/d
Relative Dosis pro Tag in mg/kg/d*
>= 0
mg/kg/d
Kumulative Dosis in mg/m²*
>= 0
mg/m²
Kumulative Dosis in mg/kg*
>= 0
mg/kg
Chemo course medication
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Etoposidphosphat
Absolute Dosis pro Tag*
>= 0
mg/d
Tag der ersten Gabe*
Tag der letzten Gabe*
Anzahl Applikationstage*
Tage
Relative Dosis pro Tag in mg/m²/d*
>= 0
mg/m²/d
Relative Dosis pro Tag in mg/kg/d*
>= 0
mg/kg/d
Kumulative Dosis in mg/m²*
>= 0
mg/m²
Kumulative Dosis in mg/kg*
>= 0
mg/kg
Chemo course medication Ifosfamide
Absolute Dosis pro Tag*
>= 0
mg/d
Tag der ersten Gabe*
Tag der letzten Gabe*
Anzahl Applikationstage*
Tage
Relative Dosis pro Tag in mg/m²/d*
>= 0
mg/m²/d
Relative Dosis pro Tag in mg/kg/d*
>= 0
mg/kg/d
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Kumulative Dosis in mg/m²*
>= 0
mg/m²
Kumulative Dosis in mg/kg*
>= 0
mg/kg
Chemo course medication
cyclophosphamide
Absolute Dosis pro Tag*
>= 0
mg/d
Tag der ersten Gabe*
Tag der letzten Gabe*
Anzahl Applikationstage*
Tage
Relative Dosis pro Tag in mg/m²/d*
>= 0
mg/m²/d
Relative Dosis pro Tag in mg/kg/d*
>= 0
mg/kg/d
Kumulative Dosis in mg/m²*
>= 0
mg/m²
Kumulative Dosis in mg/kg*
>= 0
mg/kg
Applied drug in this course
Medikament*
Absolute Dosis pro Tag*
>= 0
mg/d
Tag der ersten Gabe*
Tag der letzten Gabe*
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Anzahl Applikationstage*
Tage
Relative Dosis pro Tag in mg/m²/d*
>= 0
mg/m²/d
Relative Dosis pro Tag in mg/kg/d*
>= 0
mg/kg/d
Kumulative Dosis in mg/m²*
>= 0
mg/m²
Kumulative Dosis in mg/kg*
>= 0
mg/kg
End of chemotherapy course
Wurde die Chemotherapiedosis in diesem Kurs
reduziert*
Nein (1)
Ja (2)
Warum wurde die Chemotherapiedosis in diesem
Kurs reduziert*
Verlängerte Aplasie (1)
Nephropathie (2)
Klinischer Status (3)
Anderer Grund (5)
CD34 positive Stammzell-Aphaerese*
x 10E6
CD34 positive Stammzell-Support*
x 10E6
Letzter Tag des Kurses*
Letzter Tag des Kurses*
Ist die Chemotherapie mit diesem Kurs
abgeschlossen*
Nein (1)
Ja (2)
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NCT00090987  AMC Clinical Trials - Gleevec Administration
& Compliance Form for Protocol #042 - PR4202
NCT00090987  AMC Clinical Trials - Gleevec
Administration & Compliance Form for Protocol #042 -
PR4202
Imatinib Mesylate in Treating Patients With HIV-Related
Kaposi's Sarcoma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=EA0B255D-
5729-3870-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
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Administration & Compliance
Were tablets dispensed at this visit?
Yes
No
Dose assigned
400 mg per day (400 mg per day)
600 mg per day (600 mg per day)
Were tablets returned at this visit?
Yes
No
Patient Initials
Patient Study ID
Current Cycle Number
Date of Evaluation
Date tablets returned/dispensed
Number of Gleevec tablets returned
Number of Gleevec tablets dispensed
Were there any dose modifications/omissions to
protocol treatment during this cycle?
No (No)
Unknown (Unknown)
Yes, Planned (i.e., The Treatment Was
Changed According To Protocol
Guidelines) (Yes, planned)
Yes, Unplanned (i.e., The Treatment
Change Was Not Part Of Protocol
Guidelines) (Yes, unplanned)
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Evaluation and Clinical Benefits Form - RKS04
NCT00075777  AMC Clinical Trials - Kaposi's Sarcoma
Evaluation and Clinical Benefits Form - RKS04
Valproic Acid in Treating Patients With Kaposi's Sarcoma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=DB5869F0-
3E8A-0820-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/11259
NCT00075777  AMC Clinical Trials -
Kaposi's Sarcoma Evaluation and
Clinical Benefits Form - RKS04
Kaposi's Sarcoma Evaluation and Clinical
Benefits
Documentation
Endoscopy (Endoscopy)
Radiology (Radiology)
Edema Site
Genital (Genital)
Left Arm (Left Arm)
Left Foot (Left Foot)
Left Hand (Left Hand)
Left Leg (Left Leg)
Other (Other)
Periorbital (Periorbital)
Right Arm (Right Arm)
Right Foot (Right Foot)
Right Hand (Right Hand)
Right Leg (Right Leg)
If Other, Specify
Edema Present?
Yes
No
Compared to Previous Evaluation
Better (Better)
Same (Same)
Worse (Worse)
Tumor associated edema
A resolution of all tumor-associated
edema since baseline (A resolution of all
tumor-associated edema since baseline)
A worsening of tumor-associated edema
since baseline or best response (A
worsening of tumor-associated edema
since baseline or best response)
An improvement of tumor-associated
edema since baseline (An improvement
of tumor-associated edema since
baseline)
New tumor-associated edema (New
tumor-associated edema)
No change (No change)
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Edema
Absent (Absent)
Present (Present)
Specific Location
Limb Girth
Other Findings
Photos Taken?
Yes
No
If Photos taken, Date?
Is there any tumor-associated edema at this
evaluation?
Yes
No
Findings
Other Tests
Findings
Are there any pulmonary KS lesions present at
this evaluation?
No (No)
Not Evaluated (Not Evaluated)
Yes (Yes)
If YES, indicate if the lesions are measurable or
evaluable
Evaluable (Evaluable)
Measurable (Measurable)
Are the pulmonary symptoms related to Kaposi's
Sarcoma?
Yes
No
If not, explain
Documentation
CT Scan (CT Scan)
CXR (CXR)
Pleural Effusion?
Yes
No
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Number of new lesions
Measurements
Bronchoscopy Date
Findings
Physical findings
Photos Taken?
Yes
No
Interventions for Extremity Edema
Diuretics (Diuretics)
None (None)
Others (Others)
Others, specify
Interventions for Periorbital Edema:
Analgesics (Analgesics)
Local Therapy (Local Therapy)
None (None)
Others (Others)
Others, specify
Interventions for Scrotal/Genital Swelling
Analgesics (Analgesics)
None (None)
Others (Others)
Others, specify
Interventions for Foot KS
Analgesics (Analgesics)
None (None)
Others (Others)
Uses cane, wheelchair (Uses cane,
wheelchair)
Others, specify
Best overall response attained since
Entry/Baseline
Clinical complete response (Clinical
complete response)
Complete (Complete)
Partial Response (Partial Response)
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Progression (no prior response)
(Progression (no prior response))
Stable (since baseline) (Stable (since
baseline))
Unevaluable (Unevaluable)
Unknown (Unknown)
What is the present status of the best response?
No relapse observed, but patient died
(No relapse observed, but patient died)
Not applicable (Not applicable)
Relapse occurred after a response was
achieved (Relapse occurred after a
response was achieved)
Response continuing or first time at this
response (Response continuing or first
time at this response)
Response
Clinical complete response (Clinical
complete response)
Complete response (Complete
response)
Partial response (Partial response)
Progression with no prior response
(Progression with no prior response)
Others, specify
Interventions for Pulmonary Lesion
Bronchodilators (Bronchodilators)
Cough suppressant (Cough
suppressant)
None (None)
Others (Others)
Oxygen (Oxygen)
Steroids (Steroids)
Others, specify
If Photos taken, Date?
Physical findings
Has a visceral disease evaluation been done
since the last KS evaluation?
Yes
No
Site Code
KS Invol
Absent (Absent)
Present (Present)
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Visc Eval
A complete resolution of visceral disease
since baseline (A complete resolution of
visceral disease since baseline)
A decrease in visceral disease since
baseline (A decrease in visceral disease
since baseline)
A worsening of visceral disease since
baseline, or since the best response (A
worsening of visceral disease since
baseline, or since the best response)
Evidence of a new site of visceral
disease (Evidence of a new site of
visceral disease)
No change (No change)
Not applicable, Entry/Baseline evaluation
(Not applicable, Entry/Baseline
evaluation)
Proced
Bronchoscopy (Bronchoscopy)
Chest X-ray (Chest X-ray)
Colonoscopy (Colonoscopy)
Other (Other)
Sigmoldoscopy (Sigmoldoscopy)
Upper endoscopy (Upper endoscopy)
Specify Procedure
Interventions for Oral Cavity Lesions
Local anesthetic/analgesic (Local
anesthetic/analgesic)
Local intervention to KS lesions (Local
intervention to KS lesions)
None (None)
Others (Others)
Others, specify
Interventions for GI Lesions
Antiemetics (Antiemetics)
Blood transfusions (due to GI bleeding)
(Blood transfusions (due to GI bleeding))
None (None)
Others (Others)
Date of Onset
If not, explain
Character of cutaneous lesions
>= 25% increase in the number of
lesions since baseline or since best
response (>= 25% increase in the
number of lesions since baseline or
since best response)
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None of the above (None of the above)
Since baseline, >= 50% of raised have
become flat (Since baseline, >= 50% of
raised have become flat)
Patient symptoms of foot KS
Active but cannot perform more than
normal activities (Active but cannot
perform more than normal activities)
Lesions present but no symptoms. Able
to perform more than normal activities
(e.g., run, dance, hike.) (Lesions present
but no symptoms. Able to perform more
than normal activities (e.g., run, dance,
hike.))
Moderate impairment of activity because
of foot KS (Moderate impairment of
activity because of foot KS)
Normal activities mildly limited because
of foot KS (Normal activities mildly
limited because of foot KS)
Severe impairment of activity due to foot
KS (Severe impairment of activity due to
foot KS)
At entry, does the patient have >= 50 lesions?
Yes
No
Representative Area
Total Number Raised Lesions
Total Number Flat Lesions
Total Number New Lesions
Evaluation of Cutaneous Lesions
>= 25% increase in the number of
lesions since baseline or since best
response (>= 25% increase in the
number of lesions since baseline or
since best response)
>= 50% decrease in the number of
lesions since baseline (>= 50% decrease
in the number of lesions since baseline)
Complete Resolution (Complete
Resolution)
None of the above (None of the above)
Which Kaposi's Sarcoma evaluation does this
represent?
Entry/Baseline (Entry/Baseline)
On Treatment (On Treatment)
Post Therapy Evaluation (Post Therapy
Evaluation)
Site Code
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Abdomen (Abdomen)
Back (Back)
Chest (Chest)
Genital (Genital)
Head (Head)
Left Arm (Left Arm)
Left Foot (Left Foot)
Left Hand (Left Hand)
Left Leg (Left Leg)
Neck (Neck)
Right Arm (Right Arm)
Right Foot (Right Foot)
Right Hand (Right Hand)
Right Leg (Right Leg)
Total body (<50 lesions) (Total body (<50
lesions))
Specify
Perpendicular Diameters
Patient symptoms of scrotal/genital swelling
No scrotal/genital edema (No
scrotal/genital edema)
Swelling interferes with urination, sexual
function, withdrawing foreskin all the time
(Swelling interferes with urination, sexual
function, withdrawing foreskin all the
time)
Swelling interferes with urination, sexual
function, withdrawing foreskin sometimes
(Swelling interferes with urination, sexual
function, withdrawing foreskin
sometimes)
Swelling of the scrotum noted at all times
but no symptoms (Swelling of the
scrotum noted at all times but no
symptoms)
Swelling of the scrotum noted
occasionally (Swelling of the scrotum
noted occasionally)
Patient Symptoms of Periorbital Edema
No periorbital edema (No periorbital
edema)
Swelling of eyes noted at all times and
interferes with eyesight or function at all
times (Swelling of eyes noted at all times
and interferes with eyesight or function at
all times)
Swelling of eyes noted at all times and
interferes with eyesight or function
sometimes (Swelling of eyes noted at all
times and interferes with eyesight or
function sometimes)
Swelling of the eyes noted at all times
but does not interfere with eyesight or
function (Swelling of the eyes noted at all
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times but does not interfere with eyesight
or function)
Swelling of the eyes noted occasionally
or improves over the day (Swelling of the
eyes noted occasionally or improves over
the day)
Patient Symptoms of Edema
Completely resolves with limb elevation
and rings/shoes fit without difficulty
(Completely resolves with limb elevation
and rings/shoes fit without difficulty)
Does not completely resolve with limb
elevation or rings/shoes do not fit
normally (Does not completely resolve
with limb elevation or rings/shoes do not
fit normally)
No edema, no symptoms (No edema, no
symptoms)
No improvement with limb elevation or
interferes with normal function (No
improvement with limb elevation or
interferes with normal function)
Significantly reduced function
(Significantly reduced function)
Patient Symptoms of Oral Cavity Lesions
No symptoms (No symptoms)
Oral cavity symptoms interfering with
function most/all of the time, or recurrent
bleeding, or requires alteration of food
choices, or restriction of food intake (Oral
cavity symptoms interfering with function
most/all of the time, or recurrent
bleeding, or requires alteration of food
choices, or restriction of food intake)
Oral cavity symptoms interfering with
functions sometimes, or occasional
bleeding. Still able to take adequate
nutrition. (Oral cavity symptoms
interfering with functions sometimes, or
occasional bleeding. Still able to take
adequate nutrition.)
Oral cavity symptoms not interfering with
function (Oral cavity symptoms not
interfering with function)
Other related symptoms (e.g., swallowing, eating,
speaking)
GI symptoms
Gross bleeding requiring transfusions,
evidence of obstruction, or unable to
maintain adequate food intake with
involuntary weight loss of > 5% from
baseline (Gross bleeding requiring
transfusions, evidence of obstruction, or
unable to maintain adequate food intake
with involuntary weight loss of > 5% from
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baseline)
Gross bleeding, or frequent GI
symptoms (Gross bleeding, or frequent
GI symptoms)
Minimal GI symptoms (Minimal GI
symptoms)
No symptoms (No symptoms)
Other related symptoms (e.g., swallowing, eating,
speaking)
Patient symptoms
No symptoms (No symptoms)
Severely limited activities, +/- gross
hemoptysis (Severely limited activities,
+/- gross hemoptysis)
Symptoms at rest, requiring O or
hemoptysis (Symptoms at rest, requiring
O or hemoptysis)
Symptoms on exertion (Symptoms on
exertion)
Symptoms on normal activity (Symptoms
on normal activity)
Other related symptoms (e.g., swallowing, eating,
speaking)
Is the patient experiencing tumor-related pain?
Yes
No
Is the patient on analgesics?
No (No)
Unknown (Unknown)
Yes (Yes)
What was the average pain experienced by the
patient over the last 24 hours?
Discomforting pain (Discomforting pain)
Distressing pain (Distressing pain)
Excruciating pain (Excruciating pain)
Horrible pain (Horrible pain)
Mild pain (Mild pain)
No pain (No pain)
Pain
Absent (Absent)
Present (Present)
Anatomic Site of Worst Pain
Product of Diameters
Photos Taken?
Yes
No
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Are oral symptoms related to Kaposi's Sarcoma?
No (No)
No symptoms (No symptoms)
Yes (Yes)
If not, explain
Are the GI symptoms related to Kaposi's
Sarcoma?
Yes
No
Oral Site
Buccal Mucosa (Buccal Mucosa)
Floor of Mouth (Floor of Mouth)
Gingiva / Gums (Gingiva / Gums)
Hard Palate (Hard Palate)
Posterior Pharnyx (Posterior Pharnyx)
Soft Palate (Soft Palate)
Tongue (Tongue)
Tonsils (Tonsils)
Uvula (Uvula)
Kaposi's Sarcoma Present?
Yes
No
Photos Taken?
Yes
No
If Photos taken, Date?
Oral cavity evaluation
A resolution of all oral lesions since
baseline (A resolution of all oral lesions
since baseline)
A worsening of oral lesions since
baseline or best response (A worsening
of oral lesions since baseline or best
response)
An improvement of oral lesions since
baseline (An improvement of oral lesions
since baseline)
New oral lesions (New oral lesions)
None of the above (None of the above)
Are there any GI lesions present at this
evaluation?
No (No)
Not Evaluated (Not Evaluated)
Yes (Yes)
Are there lesions which are not countable or
measurable?
Yes
No
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Foot KS
Absent (Absent)
Present (Present)
Sum of Products
Evaluation of Marker Lesions
>= 25% increase in the sum of the
products of the diameters of all marker
lesions since baseline, or since best
response (>= 25% increase in the sum of
the products of the diameters of all
marker lesions since baseline, or since
best response)
>= 50% decrease in the sum of the
product of the diameters of all marker
lesions since baseline (>= 50% decrease
in the sum of the product of the
diameters of all marker lesions since
baseline)
Complete Resolution (Complete
Resolution)
None of the above (None of the above)
Compared to previous evaluation
Better (Better)
Same (Same)
Worse (Worse)
Photos Taken?
Yes
No
If Photos taken, Date?
Physical findings
Are there any oral cavity lesions present at this
evaluation?
No (No)
Not Evaluated (Not Evaluated)
Yes (Yes)
Number of flat lesions
Number of raised lesions
Patient Initials
Study #
Site #
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ID #
Cycle #
Comments
Comments
Date of Procedure
Date of Procedure
Date of Procedure
Date of Procedure
Number of lesions
Specify Site
Specify Site
Date of relapse
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Notification Form NCT00377156
North Central Cancer Treatment Group Notification Form
NCT00377156 
Stereotactic Radiation Therapy With or Without Whole-
Brain Radiation Therapy in Treating Patients With Brain
Metastases
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=10DC830B-
A4D7-3095-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11260
North Central Cancer Treatment
Group Notification Form
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Header
NCCTG Protocol Number
NCCTG Patient ID
Patient Initials (L F M)
Institution Number
Institution
Notification Form
Date membership CRA aware of event(s)
(mm/dd/yyyy)
Person Completing Form (Submitting)
Phone (#)
Cycle Number
Event => Grade 4
Yes
No
Assigned Treatment Arm
Date of First Occurrence of Adverse Event
Common Toxicity Criteria Adverse Event Term
Type
CTC AE Grade
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CTC AE Attribution Code
Definite (Definite)
Possible (Possible)
Probable (Probable)
Unlikely (Unlikely)
Unrelated (Unrelated)
Hospitalization
Yes
No
Hospital Admission Date (mm/dd/yyyy)
Reason for Hospitalization (s)
Adverse Event (adverse event)
Other (Other)
Prophylactic (Prophylactic)
Adverse event, specify type and grade
Prophylactic, specify
Other, specify
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AMC Clinical Trials - Eligibility Form for
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AMC Clinical Trials - Eligibility Form for Protocol #042 -
PR4201 NCT00090987 
Imatinib Mesylate in Treating Patients With HIV-Related
Kaposi's Sarcoma
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Eligibility Assessment
Has the patient received granulocyte colony
stimulating factor within 2 weeks of study entry?
Yes
No
Does the patient have the ability and willingness
to give informed
consent ?
Yes
No
In the opinion of the investigator, is the patient
capable of complying with this protocol?
Yes
No
Does the patient have no previous imatinib
therapy?
N/A (N/A)
No (No)
Yes (Yes)
If the patient is a male of child fathering potential,
does he agree to practice adequate birth control?
Yes
No
Does the patient have a concurrent active
opportunistic infection (OI)?
Yes
No
If the patient more than 5 years free of another
primary malignancy? Exception: if the other
primary malignancy is not currently clinically
significant nor requiring active intervention, or if
other primary malignancy is a basal cell cancer or
a cervical
Yes
No
Does the patient have acute treatment for an
infection or other serious medical illness within 14
days prior to study entry?
Yes
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No
Has the patient had anti-neoplastic treatment for
Kaposi's Sarcoma (including chemotherapy,
radiation therapy, local therapy, biological therapy,
or investigational therapy) within 4 weeks (6
weeks for nitrosourea or mitomycin-C) of study
entry?
Yes
No
Has the patient had previous local therapy of any
KS indicator lesion within 60 days (Exception: the
lesion has progressed since treatment)?
Yes
No
Does the patient have another severe and/or life-
threatening medical disease?
Yes
No
Has the patient had a major surgery within 2
weeks prior to study entry?
Yes
No
Is the patient using coumadin and systemic
corticosteroid treatment, other than replacement
doses?
Yes
No
Does the patient have a life expectancy of greater
than or equal to 3 months?
Yes
No
Are the patient's AST (SGOT) and ALT (SGPT)
<= 2.5 x the upper limit of normal within 21 days
of study entry ?
Yes
No
Does the patient have biopsy proven KS involving
the skin, lymph nodes, oral cavity, gastrointestinal
(GI) tract and/or lungs?
Yes
No
Does the patient have at least five measurable,
previously non-radiated, cutaneous lesions,
which can be used as indicator lesions?
Additionally, patient will need three lesions
greater or equal to 5 x 5 m that are accessible for
4 mm punch biopsy.
Yes
No
Does the patient have serologic documentation of
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HIV infection any time prior to study entry, as
evidenced by positive ELISA, positive Western
Blot, or other federally approved licensed HIV
test?
Yes
No
Is the patient's baseline Karnofsky performance
status >= 60%?
Yes
No
If the patient is a female capable of childbearing,
has she had a negative pregnancy test within 72
hours before initiation of study drug dosing?
N/A (N/A)
No (No)
Yes (Yes)
If the patient is reproductive potential, does he or
she agree to employ an effective barrier method
of birth control throughout the study and for up to
3 months following discontinuation of study drug?
Yes
No
Is the patient's hemoglobin >= 8 g/dl within 21
days of study entry?
Yes
No
Is the patient's absolute neutrophil count >= 1000
cells/ mm^3 and platelets >=75,000 cells/mm^3
within 21 days of study entry?
Yes
No
Is the patient's serum creatinine < 1.5 mg/dl or a
measured creatinine clearance of > 60 ml/min
with 21 days prior to study entry?
Yes
No
Is the patient's total bilirubin normal within 21
days of study entry?
Yes
No
Patient Initials
Patient Study ID
Date of Assessment
Is the patient age 18 or older?
Yes
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No
Does the patient have Grade III/IV cardiac
problems as defined by the New York Heart
Association Criteria (e.g. congestive heart failure,
myocardial infarction) within 6 months of study?
Yes
No
If the patient is female, is she pregnant or breast-
feeding?
Yes
No
Does the patient have an acute or known chronic
live disease (e.g. chronic active hepatitis,
cirrhosis)? Exception: Patients with known
Hepatitis C infection but with documentation of no
or minimal fibrosis on liver biopsy may be
enrolled.
Yes
No
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Valproic Acid in Treating Patients With Kaposi's Sarcoma
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Eligibility Assessment
Does the patient have a history of lipoatrophy or
hypercholesterolemia
secondary to retroviral treatment?
Yes
No
If the patient is a male of child fathering potential,
does he agree to practice adequate birth control?
N/A (N/A)
No (No)
Yes (Yes)
Is the patient capable of complying with the
protocol?
Yes
No
If the patient is receiving antiretroviral therapy,
has the patient been on a stable regimen for at
least 4 weeks prior to study entry? Patients may
receive any FDA approved antiretroviral therapy
or agents available through a treatment IND,
except regime
Yes
No
Has the patient had a concurrent, acute, active
opportunistic infection
other than oral thrush or genital herpes within 14
days of enrollment?
Yes
No
Does the patient have visceral Kaposi's
Sarcoma?
Yes
No
Does the patient have oral Kaposi's sarcoma as
the only site of disease?
Yes
No
Does the patient have a concurrent neoplasm
requiring cytotoxic therapy?
Yes
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No
Has the patient had anti-neoplastic treatment for
Kaposi's Sarcoma
(including chemotherapy, radiation therapy, local
therapy, biological
therapy, or investigational therapy) within two
weeks of study entry?
Yes
No
Has the patient had previous local therapy of any
KS-marker lesion
within 60 days (Exception: the lesion has clearly
progressed since
treatment)?
Yes
No
Has the patient used investigational agents other
than antiretroviral
drugs available under expanded access or
compassionate use protocols?
Yes
No
Does the patient have a history of valproic acid or
valproate use in the
previous year?
Yes
No
Does the patient have evidence of a prior MI or
cardiac ischemia?
Yes
No
Is the patient using AZT ?
Yes
No
Does the patient have a history of lactic acidosis
greater than
2 mmoles / liter?
Yes
No
If the patient is a female capable of childbearing ,
does she agree
to practice adequate birth control to prevent
pregnancy while
receiving treatment and for three months after
treatment is
discontinued?
N/A (N/A)
No (No)
Yes (Yes)
If the patient is a female capable of childbearing,
has she had a
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negative serum beta-HCG within 72 hours prior
to study entry?
N/A (N/A)
No (No)
Yes (Yes)
Does the patient have biopsy proven KS involving
the skin and /or lymph nodes, HIV related, not
requiring systemic treatment (radiation or
chemotherapy) less than 2 weeks before
enrollment?
Yes
No
Is the patient's baseline Karnofsky performance
status >= 60%?
Yes
No
Is the patient's hemoglobin >= 8 g/dl within 14
days of study entry?
Yes
No
Is the patient's absolute neutrophil count >= 750
cells/ mm and platelets
>=5,000 cells/mm within 14 days of study entry?
Yes
No
Is the patient's serum creatinine < 1.5 times the
upper limit of normal within 14 days of study
entry?
Yes
No
Is the patient's total bilirubin <=1.5x ULN within
14 days of study entry?
If not, is the patient's total bilirubin <= 3.5 mg/dl
with a normal direct
bilirubin, and is the elevated bilirubin thought to
be secondary to Indinavir therapy?
Yes
No
Are the patient's AST (SGOT) and ALT (SGPT)
<= 3 x the upper limit of normal within 14 days of
study entry ?
Yes
No
Is the patient's albumin > 2.5?
Yes
No
Does the patient have the ability and willingness
to give informed
consent ?
Yes
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No
Patient Initials
Patient Study ID
Date of Assessment
Does the patient have serologic documentation of
HIV infection
any time prior to study entry, as evidenced by
positive ELISA, positive Western Blot, or viral
load determination?
Yes
No
the patient's life expectancy >= 3 months?
Yes
No
Is the patient age 18 or older?
Yes
No
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Header
Coordinating Group Protocol No.
Coordinating Group Code
Protocol Title
Patient Study ID
Institution/Affiliate
Other Patient ID
Participating Group Code
Patient Name (initials acceptable)
Amyloid: Form Administration
Person Completing Form
Are data amended (If data are amended, please
circle in red when using paper form)
Yes
No
Amyloid: Disease Description
Date of Initial Pathologic Diagnosis
Heart (Clinical Involvement?* Y=yes, N=no
*Symptomatic)
Yes
No
Kidney
Yes
No
Liver
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Yes
No
Stomach
Yes
No
Gastrointestinal/small bowel
Yes
No
Colon/rectum
Yes
No
Peripheral Nerve Neuropathy
Yes
No
Soft Tissue
Yes
No
Skin
Yes
No
Macroglossia
Yes
No
Autonomic Nerve Neuropathy (** Note:
Autonomic neuropathy includes any
gastroparesis, pseudo-obstruction, and/or
orthostatic hypotension not attributable to
medications or volume depletion.)
Yes
No
Other
Yes
No
Other Site Name (If yes,)
Biopsy done (Y=yes, N=no)
Yes
No
Biopsy Result (If done,)
Negative (Negative)
Positive (Positive)
Unknown (Unknown)
Dominant Presentation (at Diagnosis check only
one)
Autonomic Nerve Neuropathy
(Autonomic Nerve Neuropathy)
Colon/rectum (Colon/rectum)
Gastrointestinal/small Bowel
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(Gastrointestinal/small bowel)
Heart (Heart)
Kidney (Kidney)
Liver (Liver)
Macroglossia (Macroglossia)
Other (Other)
Peripheral Nerve Neuropathy (Peripheral
Nerve Neuropathy)
Skin (Skin)
Soft Tissue (Soft Tissue)
Stomach (stomach)
Other specify
Disease Symptoms Present (at Diagnosis)
Carpal Tunnel (Carpal tunnel)
Diarrhea (Diarrhea)
Fatigue (Fatigue)
Leg Swelling (Leg swelling)
Light-headedness (Light-headedness)
Macroglossia (Macroglossia)
Other (Other)
Painful/numb Feet (Painful/numb feet)
Purpura (skin) (Purpura (skin))
Syncope (Syncope)
Weight Loss >= 10% Of Body Weight
(Weight loss >= 10% of body weight)
Other specify
Serum Total Protein (SPEP at diagnosis)
Serum M-Protein Spike (SPEP If immunofixation
is positive but M-spike is not quantifiable, enter
.01 or follow protocol guidelines for entering M-
spike.)
Serum M-Protein by Immunofixation (at
diagnosis)
Equivocal (Equivocal)
Negative (Negative)
Positive (Positive)
Unknown (Unknown)
Serum Heavy Chain (If positive or equivocal,
check all that apply)
A (A)
D (D)
E (E)
G (G)
M (M)
Unknown (Unknown)
Serum Light Chain (check all that apply)
Kappa (Kappa)
Lambda (Lambda)
Unknown (Unknown)
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Biclonal
Yes
No
Yes specify
Oligoclonal
Yes
No
Yes specify
Urine Total Protein (UPEP at diagnosis)
Urine M-Protein Light Chain Excretion (If
immunofixation is positive but M-protein is not
quantifiable, enter .01 or follow protocol
guidelines for entering M-protein.)
Unit of Measure
Grams/24 Hours (g/24 hrs)
Milligrams/24 Hours (mg/24 hrs)
Unit of Measure
Grams/24 Hours (g/24 hrs)
Milligrams/24 Hours (mg/24 hrs)
Urine M-Protein by Immunofixation (at diagnosis)
Equivocal (Equivocal)
Negative (Negative)
Positive (Positive)
Unknown (Unknown)
Urine Light Chain (If positive or equivocal,)
Kappa (Kappa)
Lambda (Lambda)
Unknown (Unknown)
Amyloid: Prior Treatment
Prior Treatment? (If yes, respond to treatment-
specific questions below.)
Yes
No
No. of Planned Regimens (If yes, Note: Multiple
drug/staged regimens count as 1; e.g., VAD +
transplant)
Prior Treatment Regimen Name(s) (* Prior
Treatment Regimen Name)
Adriamycin (Adriamycin)
Alpha-interferon (Alpha-interferon)
Carmustine (bcnu) (Carmustine (BCNU))
Colchicine (Colchicine)
4 / 6
Primary Amyloidosis - On-Study Form
Corticosteroids (Corticosteroids)
Cyclophosphamide (Cyclophosphamide)
Dexamethasone (Dexamethasone)
Interferon (Interferon)
Iododeoxyrubicin (Iododeoxyrubicin)
Melphalan (lpam) (Melphalan (LPAM))
Mp (MP)
Other (Other)
Prednisone (Prednisone)
Ps-341 (PS-341)
Revimid (Revimid)
Thalidomide (Thalidomide)
Vad (VAD)
Vincristine (vcr) (Vincristine (VCR))
Other Prior Regimen Name (** If Other specify)
Prior Treatment Regimen Start Date
Prior Treatment Regimen End Date
Reason Stopped (?  Reason Stopped)
Alternative Treatment (Alternative
treatment)
Completed Treatment (Completed
treatment)
Maintenance Only (Maintenance only)
Patient Refusal (Patient refusal)
Progression (Progression)
Response/improvement
(Response/Improvement)
Toxicity (Toxicity)
Unknown (Unknown)
Hematologic Response (?  Hematologic
Response)
Complete Response (Complete
Response)
Inevaluable (Inevaluable)
Partial Response (Partial Response)
Progression (Progression)
Unknown (Unknown)
Organ Response (?  Organ Response)
No (No)
Unknown (Unknown)
Yes (Yes)
Prior Bone Marrow or Peripheral Blood Stem Cell
Transplant?
Yes
No
Prior Transplant Type (If yes,)
Allogeneic (Allogeneic)
Autologous (Autologous)
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Number of autologous transplants
Date of Last Transplant
Number of allogeneic transplants
Allogeneic Transplant Type
Mini (non-myeloablative) (Mini (non-
myeloablative))
Myeloablative (Myeloablative)
Unknown (Unknown)
Date of Transplant
DLI
Yes
No
Date of Last DLI (If yes,)
Total body irradiation
No (No)
Unknown (Unknown)
Yes (Yes)
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Header
Patient Initials
Patient Study ID
Valproic Acid Assessment
Current Cycle Number
Date of Evaluation
Day
Date Agent Administered
Total # of Capsule(s) Taken per Day
Date of Day 5
Date of Day 28
Total # of Capsule(s) Taken per Day
Reduction grade
1st reduction (1st reduction)
2nd reduction (2nd reduction)
3rd reduction (3rd reduction)
4th reduction (4th reduction)
Start Date
Stop Date
Total # of Capsule(s) Taken per Day
Were there any dose modifications or
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additions/omissions to protocol treatment?
No (No)
Unknown (Unknown)
Yes, Planned (i.e., The Treatment Was
Changed According To Protocol
Guidelines) (Yes, planned)
Yes, Unplanned (i.e., The Treatment
Change Was Not Part Of Protocol
Guidelines) (Yes, unplanned)
valproic acid serum level checked at 72-96 hours
(on or about day 8)?
Yes
No
record serum valproic acid concentration
Is valproic acid therapy discontinued early for the
patient?
Yes
No
record serum valproic acid concentration at the
drug discontinuation
Any additional comments about valproic acid
administration?
Yes
No
Comments
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Procurement
Other, specify
If specimens were not obtained for ACSR, please
indicate reason
Other (Other)
Patient had previously donated
specimens to ACSR. (Patient had
previously donated specimens to ACSR.)
Patient refused to give informed consent
for ACSR specimen donation. (Patient
refused to give informed consent for
ACSR specimen donation.)
Patient was not asked to consider ACSR
specimen donation. (Patient was not
asked to consider ACSR specimen
donation.)
Other, specify
ACSR site the specimen(s) shipped to
GWU (GWU)
OSU (OSU)
Other (Other)
SUNY/HSCB (SUNY/HSCB)
UCLA (UCLA)
UCSF (UCSF)
Study Coordinator's Name
Specimen(s) obtained for donation to ACSR?
Yes
No
Patient Initials
Study #
Site #
ID #
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Cycle #
Indicate date
Indicate date
Types of specimens collected
Other (Other)
PBMC (PBMC)
Plasma (Plasma)
Serum (Serum)
Tissue (Tissue)
Peripheral Blood (Whole Blood)
Other, specify
Phone Number
E-mail Address
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Header Module
Visit
4-6 Weeks Post-surgery (4-6 weeks
post-surgery)
Month 12 (Month 12)
Month 3 (Month 3)
Pre-operative (Pre-Op)
Patient ID (Pt. ID issued during registration
unless pt. previously registered to an ACOSOG
study.)
Patient Initials
Institution Name
Institution No.
Date
Female Sexual Function Assessment
Over the past 4 weeks, how often did you feel
sexual desire or interest
A Few Times (A few times)
Almost Always Or Always (Almost always
or always)
Almost Never Or Never (Almost never or
never)
Most Times (Most times)
Sometimes (Sometimes)
Over the past 4 weeks, how would you rate your
level (degree) of sexual desire or interest
High (High)
Low (Low)
Moderation (Moderate)
Very High (Very high)
Very Low Or None At All (Very low or
none at all)
Over the past 4 weeks, how often did you feel
sexually aroused ('turned on') during sexual
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activity or intercourse?
A Few Times (A few times)
Almost Always Or Always (Almost always
or always)
Almost Never Or Never (Almost never or
never)
Most Times (Most times)
No Sexual Activity (No sexual activity)
Sometimes (Sometimes)
Over the past 4 weeks, how would you rate your
level of sexual arousal ('turn on') during sexual
activity or intercourse?
High (High)
Low (Low)
Moderation (Moderate)
No Sexual Activity (No sexual activity)
Very High (Very high)
Very Low Or None At All (Very low or
none at all)
Over the past 4 weeks, how confident were you
about becoming sexually aroused during sexual
activity or intercourse?
High Confidence (High confidence)
Low Confidence (Low confidence)
Moderate Confidence (Moderate
confidence)
No Sexual Activity (No sexual activity)
Very High Confidence (Very high
confidence)
Very Low Or No Confidence (Very low or
no confidence)
Over the past 4 weeks, how often have you been
satisfied with your arousal (excitement) during
sexual activity or intercourse
A Few Times (A few times)
Almost Always Or Always (Almost always
or always)
Almost Never Or Never (Almost never or
never)
Most Times (Most times)
No Sexual Activity (No sexual activity)
Sometimes (Sometimes)
Over the past 4 weeks, how often did you
become lubricated ('wet') during sexual activity or
intercourse
A Few Times (A few times)
Almost Always Or Always (Almost always
or always)
Almost Never Or Never (Almost never or
never)
Most Times (Most times)
No Sexual Activity (No sexual activity)
Sometimes (Sometimes)
Over the past 4 weeks, how difficult was it to
2 / 5
Z6051 Female Sexual Function Index (FSFI) NCT00726622
become lubricated ('wet') during sexual activity or
intercourse
Difficult (Difficult)
Extremely Difficult Or Impossible
(Extremely difficult or impossible)
No Sexual Activity (No sexual activity)
Not Difficult (Not difficult)
Slightly Difficult (Slightly difficult)
Very Difficult (Very difficult)
Over the past 4 weeks, how often did you
maintain your lubrication ('wetness') until
completion of sexual activity or intercourse
A Few Times (A few times)
Almost Always Or Always (Almost always
or always)
Almost Never Or Never (Almost never or
never)
Most Times (Most times)
No Sexual Activity (No sexual activity)
Sometimes (Sometimes)
Over the past 4 weeks, how difficult was it to
maintain your lubrication ('wetness') until
completion of sexual activity or intercourse
Difficult (Difficult)
Extremely Difficult Or Impossible
(Extremely difficult or impossible)
No Sexual Activity (No sexual activity)
Not Difficult (Not difficult)
Slightly Difficult (Slightly difficult)
Very Difficult (Very difficult)
Over the past 4 weeks, when you had sexual
stimulation or intercourse, how often did you
reach orgasm (climax)
A Few Times (A few times)
Almost Never Or Never (Almost never or
never)
Most Times (Most times)
Sometimes (Sometimes)
Over the past 4 weeks, when you had sexual
stimulation or intercourse, how difficult was it for
you to reach orgasm (climax)
Difficult (Difficult)
Extremely Difficult Or Impossible
(Extremely difficult or impossible)
No Sexual Activity (No sexual activity)
Not Difficult (Not difficult)
Slightly Difficult (Slightly difficult)
Very Difficult (Very difficult)
Over the past 4 weeks, how satisfied were you
with your ability to reach orgasm (climax) during
sexual activity or intercourse
About Equally Satisfied And Dissatisfied
(About equally satisfied and dissatisfied)
Moderately Dissatisfied (Moderately
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dissatisfied)
Moderately Satisfied (Moderately
satisfied)
No Sexual Activity (No sexual activity)
Very Dissatisfied (Very dissatisfied)
Very Satisfied (Very satisfied)
Over the past 4 weeks, how satisfied have you
been with the amount of emotional closeness
during sexual activity between you and your
partner
About Equally Satisfied And Dissatisfied
(About equally satisfied and dissatisfied)
Moderately Dissatisfied (Moderately
dissatisfied)
Moderately Satisfied (Moderately
satisfied)
Very Dissatisfied (Very dissatisfied)
Very Satisfied (Very satisfied)
Over the past 4 weeks, how satisfied have you
been with your sexual relationship with your
partner
About Equally Satisfied And Dissatisfied
(About equally satisfied and dissatisfied)
Moderately Dissatisfied (Moderately
dissatisfied)
Moderately Satisfied (Moderately
satisfied)
Very Dissatisfied (Very dissatisfied)
Very Satisfied (Very satisfied)
Over the past 4 weeks, how satisfied have you
been with your overall sexual life
About Equally Satisfied And Dissatisfied
(About equally satisfied and dissatisfied)
Moderately Dissatisfied (Moderately
dissatisfied)
Moderately Satisfied (Moderately
satisfied)
Very Dissatisfied (Very dissatisfied)
Very Satisfied (Very satisfied)
Over the past 4 weeks, how often did you
experience discomfort or pain during vaginal
penetration
A Few Times (A few times)
Almost Always Or Always (Almost always
or always)
Almost Never Or Never (Almost never or
never)
Did Not Attempt Intercourse (Did not
attempt intercourse)
Most Times (Most times)
Sometimes (Sometimes)
Over the past 4 weeks, how often did you
experience discomfort or pain following vaginal
penetration
A Few Times (A few times)
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Almost Always Or Always (Almost always
or always)
Almost Never Or Never (Almost never or
never)
Did Not Attempt Intercourse (Did not
attempt intercourse)
Most Times (Most times)
Sometimes (Sometimes)
Over the past 4 weeks, how would you rate your
level (degree) of discomfort or pain during or
following vaginal penetration
Did Not Attempt Intercourse (Did not
attempt intercourse)
High (High)
Low (Low)
Moderation (Moderate)
Very High (Very high)
Very Low Or None At All (Very low or
none at all)
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GOG-0218 Surgical Reporting Form
NCT00262847
GOG-0218 Surgical Reporting Form NCT00262847
Carboplatin and Paclitaxel With or Without Bevacizumab in
Treating Patients With Stage III or Stage IV Ovarian
Epithelial, Primary Peritoneal Cancer, or Fallopian Tube
Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=F11BB717-
3E92-5D5B-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11268
GOG-0218 Surgical Reporting Form
NCT00262847
Header Module
Date form originally completed
Date form amended
Person amending form, last name
Patient Initials
Patient Study ID
Person completing form, last name
Participating group code
Participating group protocol number
Participating group patient ID
Surgery assessment
Operative procedure performed
Surgical stage
0 (0)
Refer To Figo Staging For Specific
Gynecologic Cancer (1)
Refer To Figo Staging For Specific
Gynecologic Cancer (1A)
Refer To Figo Staging For Specific
Gynecologic Cancer (1B)
Refer To Figo Staging For Specific
Gynecologic Cancer (1C)
Refer To Figo Staging For Specific
Gynecologic Cancer (2)
Refer To Figo Staging For Specific
Gynecologic Cancer (2A)
Refer To Figo Staging For Specific
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Gynecologic Cancer (2B)
Refer To Figo Staging For Specific
Gynecologic Cancer (2C)
Refer To Figo Staging For Specific
Gynecologic Cancer (3)
Refer To Figo Staging For Specific
Gynecologic Cancer (3A)
Refer To Figo Staging For Specific
Gynecologic Cancer (3B)
Refer To Figo Staging For Specific
Gynecologic Cancer (3C)
Refer To Figo Staging For Specific
Gynecologic Cancer (4)
Refer To Figo Staging For Specific
Gynecologic Cancer (4A)
Refer To Figo Staging For Specific
Gynecologic Cancer (4B)
Not Available (Not available)
Persistent (Persistent)
Recurrent (Recurrent)
Date of surgery
Percent of gross tumor removed
%
Residual gross tumor
Yes
No
Greatest diameter of largest residual gross tumor
mass
cm
Microscopic disease only
Yes
No
Ascites
Yes
No
Cytology of peritoneal or ascitic fluids
Negative (Negative)
Not Done (Not done)
Positive (Positive)
Suspicious (Suspicious)
Unavailable (Unavailable)
Gynecologic involvement
Summary of operative findings (*)
Abdominal Organs (Abdominal organs)
Adb. Ureter - Lt. (Adb. Ureter - lt.)
Adb. Ureter - Rt. (Adb. Ureter - rt.)
Ant. Abdomen (Ant. Abdomen)
2 / 4
GOG-0218 Surgical Reporting Form NCT00262847
Anus (Anus)
Appendix (Appendix)
Ascending Colon (Ascending colon)
Bladder - Mucosa (Bladder - mucosa)
Bladder - Muscularis (Bladder -
muscularis)
Clitoris (Clitoris)
Common Iliac - Lt. (Common iliac - lt.)
Common Iliac - Rt. (Common iliac - rt.)
Deep Groin - Lt. (Deep groin - lt.)
Deep Groin - Rt. (Deep groin - rt.)
Descending Colon (Descending colon)
Duodenum (Duodenum)
External Iliac - Lt. (External iliac - lt.)
External Iliac - Rt. (External iliac - rt.)
Fallopian Tube - Lt. (Fallopian tube - lt.)
Fallopian Tube - Rt. (Fallopian tube - rt.)
Gall Bladder (Gall bladder)
Gutters - Lt. (Gutters - lt.)
Gutters - Rt. (Gutters - rt.)
Ileum (Ileum)
Internal - Lt. (Internal - lt.)
Internal - Rt. (Internal - rt.)
Introitus (Introitus)
Jejunum (Jejunum)
Kidney - Lt. (Kidney - lt.)
Kidney - Rt. (Kidney - rt.)
Labium Major - Lt. (Labium major - lt.)
Labium Major - Rt. (Labium major - rt.)
Labium Minor - Lt. (Labium minor - lt.)
Labium Minor - Rt. (Labium minor - rt.)
Large Bowel (Large bowel)
Left Scalene (Left scalene)
Liver Parenchyma (Liver parenchyma)
Liver Surface (Liver surface)
Obturator - Lt. (Obturator - lt.)
Obturator - Rt. (Obturator - rt.)
Omentum - Gastrocolic (Omentum -
gastrocolic)
Omentum - Infracolic (Omentum -
infracolic)
Ovary - Lt. (Ovary - lt.)
Ovary - Rt. (Ovary - rt.)
Pancreas (Pancreas)
Para-aortic - Lt. (Para-aortic - lt.)
Para-aortic - Rt. (Para-aortic - rt.)
Parametrium - Lt. (Parametrium - lt.)
Parametrium - Rt. (Parametrium - rt.)
Pelvic - Lt. (Pelvic - lt.)
Pelvic - Rt. (Pelvic - rt.)
Pelvic Bladder (Pelvic bladder)
Pelvic Cul-de-sac (Pelvic cul-de-sac)
Perineal Body (Perineal body)
Sig. Mucosa (Sig. Mucosa)
Sig. Muscularis (Sig. Muscularis)
Small Bowel (Small bowel)
Spleen (Spleen)
Stomach (Stomach)
Subdiaphragm - Lt. (subdiaphragm - lt.)
Subdiaphragm - Rt. (subdiaphragm - rt.)
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Superficial Gr. - Lt. (Superficial gr. - lt.)
Superficial Gr. - Rt. (Superficial gr. - rt.)
Transverse Colon (Transverse colon)
Ureter - Lt. (Ureter - lt.)
Ureter - Rt. (Ureter - rt.)
Urethra (Urethra)
Uterus-cervix (Uterus-cervix)
Uterus-corpus (Uterus-corpus)
Vagina (Vagina)
Exam
No Tumor (No tumor)
Not Examined (Not examined)
Organ Absent (Organ absent)
Suspicious (Suspicious)
Tumor Present (Tumor present)
Proc
Biopsy Only (Biopsy only)
Left Intact (Left intact)
Not Applicable (Not applicable)
Removed Completely (Removed
completely)
Removed Partially (Removed partially)
Footer Module
Comments
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Southwest Oncology Group Registration
Form (S0303) NCT00070122
Southwest Oncology Group Registration Form (S0303)
NCT00070122
Combination Chemotherapy and Bevacizumab in Treating
Patients With Locally Advanced, Metastatic, or Recurrent
Colorectal Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=BC61CF50-
FD6D-101D-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/11269
Southwest Oncology Group
Registration Form (S0303)
NCT00070122
Header
SWOG Study No.
Registration Step
Assigned Treatment Arm
Activation Date
Last Amended Date
Patient's Name
SWOG Patient ID
Other Group Patient Number
Participating Group/Protocol Number
Patient demographics
Patient's Date of Birth
Patient Gender
Female (Female)
Male (Male)
Method of Payment
Medicaid (Medicaid)
Medicaid And Medicare (Medicaid and
Medicare)
Medicare (Medicare)
Medicare And Private Insurance
(Medicare and Private)
Military Sponsored (including Champus
& Tricare) (Military)
No Means Of Payment (no Insurance)
(No insurance (no means))
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Self Pay (no Insurance) (No insurance
(self-pay))
Other (Other, specify at registration)
Private Insurance (Private)
Unknown (unknown)
Veterans Sponsored (Veterans Admin)
Patient's Ethnicity
A Person Not Meeting The Definition For
Hispanic Or Latino. (No (not Spanish))
Patient Is Unsure Of Their Ethnicity
(Unknown)
A Person Of Mexican, Puerto Rican,
Cuban, Central Or South American Or
Other Spanish Culture Or Origin,
Regardless Of Race (Yes, Central
American)
A Person Of Mexican, Puerto Rican,
Cuban, Central Or South American Or
Other Spanish Culture Or Origin,
Regardless Of Race (Yes, Cuban)
A Person Of Mexican, Puerto Rican,
Cuban, Central Or South American Or
Other Spanish Culture Or Origin,
Regardless Of Race (Yes, Mexican)
A Person Of Mexican, Puerto Rican,
Cuban, Central Or South American Or
Other Spanish Culture Or Origin,
Regardless Of Race (Yes, NOS)
A Person Of Mexican, Puerto Rican,
Cuban, Central Or South American Or
Other Spanish Culture Or Origin,
Regardless Of Race (Yes, Other)
A Person Of Mexican, Puerto Rican,
Cuban, Central Or South American Or
Other Spanish Culture Or Origin,
Regardless Of Race (Yes, Puerto Rican)
A Person Of Mexican, Puerto Rican,
Cuban, Central Or South American Or
Other Spanish Culture Or Origin,
Regardless Of Race (Yes, South
American)
Patient's Race (select all that apply)
A Person Having Origins In Any Of The
Original Peoples Of North And South
America (including Central America),
And Who Maintains Tribal Affiliation Or
Community Attachment (American Indian
or Alaska Native)
A Person Having Origins In Any Of The
Original Peoples Of The Far East,
Southeast Asia, Or The Indian
Subcontinent Including, For Example,
Cambodia, China, India, Japan, Korea,
Malaysia, Pakistan, The Philippine
Islands, Thailand, And Vietnam. (Asian)
A Person Having Origins In Any Of The
Black Racial Groups Of Africa. Terms
Such As "haitian" Or "negro" Can Be
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Used In Addition To "black Or African
American." (Black or African American)
A Person Having Origins In Any Of The
Original Peoples Of Hawaii, Guam,
Samoa, Or Other Pacific Islands (Native
Hawaiian or Other Pacific Islander)
A Person Having Origins In Any Of The
Original Peoples Of Europe, The Middle
East, Or North Africa. (White or
Caucasian)
Patient Social Security Number
Patient's ZIP Code
Country of Residence (if not USA)
Social Insurance Number
Postal Code
Performance Status
0-1 (0-1)
2 (2)
Prior Adjuvant Therapy
Yes
No
Is the patient able to understand and read
English?
Yes
No
Caller's SWOG Roster ID
SWOG Treating Institution Number
IRB Approval Date
Date Informed Consent Signed
Projected Start Date of Treatment
SWOG Investigator Number
Date HIPAA Authorization signed
My tissue may be kept for use in research to
learn about, prevent, treat, or cure cancer.
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Yes
No
My tissue may be kept for research about other
health problems
Yes
No
Someone from Southwest Oncology Group may
contact me in the future to ask me to take part in
more research
Yes
No
Ccrr Module For Southwest Oncology
Group Registration Form (s0303)
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Southwest Oncology Group Registration
Form (S0521) NCT00492856
Southwest Oncology Group Registration Form (S0521)
NCT00492856 
Combination Chemotherapy With or Without Gemtuzumab
Followed By Tretinoin, Mercaptopurine, and Methotrexate
or Observation in Treating Patients With Acute
Promyelocytic Leukemia
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=101036B0-
53B1-5DC9-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11270
Southwest Oncology Group
Registration Form (S0521)
NCT00492856
Header
SWOG Study No.
Registration Step
Assigned Treatment Arm
Activation Date
Caller's SWOG Roster ID
SWOG Patient ID
Other Group Patient Number
Participating Group/Protocol Number
Last Amended Date
Patient demographics
Patient's Name
Patient's Date of Birth
Patient Gender
Female (Female)
Male (Male)
Method of Payment
Medicaid (Medicaid)
Medicaid And Medicare (Medicaid and
Medicare)
Medicare (Medicare)
Medicare and Private (Medicare and
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Private)
Military Sponsored (including Champus
& Tricare) (Military)
No Means Of Payment (no Insurance)
(No insurance (no means))
Self Pay (no Insurance) (No insurance
(self-pay))
Other (Other, specify at registration)
Private Insurance (Private)
Unknown (Unknown)
Veterans Sponsored (Veterans Admin)
Patient's Ethnicity
No (not Spanish) (No (not Spanish))
Unknown (Unknown)
Yes, Central American (Yes, Central
American)
Yes, Cuban (Yes, Cuban)
Yes, Mexican (Yes, Mexican)
Yes, Nos (Yes, NOS)
Yes, Other (Yes, Other)
Yes, Puerto Rican (Yes, Puerto Rican)
Yes, South American (Yes, South
American)
Patient's Race (select all that apply)
A Person Having Origins In Any Of The
Original Peoples Of North And South
America (including Central America),
And Who Maintains Tribal Affiliation Or
Community Attachment (American Indian
or Alaska Native)
A Person Having Origins In Any Of The
Original Peoples Of The Far East,
Southeast Asia, Or The Indian
Subcontinent Including, For Example,
Cambodia, China, India, Japan, Korea,
Malaysia, Pakistan, The Philippine
Islands, Thailand, And Vietnam. (Asian)
A Person Having Origins In Any Of The
Black Racial Groups Of Africa. Terms
Such As "haitian" Or "negro" Can Be
Used In Addition To "black Or African
American." (Black or African American)
A Person Having Origins In Any Of The
Original Peoples Of Hawaii, Guam,
Samoa, Or Other Pacific Islands (Native
Hawaiian or Other Pacific Islander)
Patient Is Unsure Of Their Race
(unknown)
A Person Having Origins In Any Of The
Original Peoples Of Europe, The Middle
East, Or North Africa. (White)
Patient Social Security Number
Patient Zip Code
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Country of Residence (if not USA) (If a resident
of Canada)
Social Insurance Number
Postal code
Miscellaneous Patient Information
IRB Approval Date
Projected Start Date of Treatment
Date Informed Consent Signed
SWOG Investigator Number (OR)
Other Group Investigator Name
Other Group Investigator Number
SWOG Treating Institution Number (OR)
Other Group Institution Name
Other Group Institution Number
Date HIPAA Authorization signed (Not required
for non-American sites)
My specimens may be kept for use in research to
learn about, prevent, treat or cure cancer
Yes
No
My specimens may be kept for use in research
about other health problems (for example:
diabetes, Alzheimer's disease, or heart disease.)
Yes
No
Someone may contact me in the future to ask me
to allow other uses of my specimens
Yes
No
I agree to allow my study doctor, or someone
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approved by my study doctor, to contact me
regard future research involving my participation
in this study
Yes
No
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NCT00565851 GYNECOLOGIC ONCOLOGY
GROUP Surgical Reporting Form - FORM C
NCT00565851 GYNECOLOGIC ONCOLOGY GROUP
Surgical Reporting Form - FORM C
Carboplatin and Paclitaxel With or Without Bevacizumab
After Surgery in Treating Patients With Recurrent Ovarian
Epithelial Cancer, Primary Peritoneal Cavity Cancer, or
Fallopian Tube Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=DA3F6FCF-
2BF6-2D9B-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/11271
NCT00565851 GYNECOLOGIC
ONCOLOGY GROUP Surgical
Reporting Form - FORM C
Patient demographics
Date form originally completed
Date form amended
Person amending form last name
Patient Initials (First, Middle, Last)
Patient Study ID
Person completing form, last name
Surgery assessment
Operative procedure performed
Surgical stage
0 (0)
Refer To Figo Staging For Specific
Gynecologic Cancer (1)
Refer To Figo Staging For Specific
Gynecologic Cancer (1A)
Refer To Figo Staging For Specific
Gynecologic Cancer (1B)
Refer To Figo Staging For Specific
Gynecologic Cancer (1C)
Refer To Figo Staging For Specific
Gynecologic Cancer (2)
Refer To Figo Staging For Specific
Gynecologic Cancer (2A)
Refer To Figo Staging For Specific
Gynecologic Cancer (2B)
Refer To Figo Staging For Specific
Gynecologic Cancer (2C)
Refer To Figo Staging For Specific
Gynecologic Cancer (3)
Refer To Figo Staging For Specific
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Gynecologic Cancer (3A)
Refer To Figo Staging For Specific
Gynecologic Cancer (3B)
Refer To Figo Staging For Specific
Gynecologic Cancer (3C)
Refer To Figo Staging For Specific
Gynecologic Cancer (4)
Refer To Figo Staging For Specific
Gynecologic Cancer (4A)
Refer To Figo Staging For Specific
Gynecologic Cancer (4B)
Not Available (Not available)
Persistent (Persistent)
Recurrent (Recurrent)
Date of surgery
Percent of gross tumor removed
%
Residual gross tumor
Yes
No
Greatest diameter of largest residual gross tumor
mass
cm
Microscopic disease only
Yes
No
Ascites
Yes
No
Cytology of peritoneal or ascitic fluids
Negative (Negative)
Not Done (Not done)
Positive (Positive)
Suspicious (Suspicious)
Unavailable (Unavailable)
Summary of operative findings (*)
Abdominal Organs (Abdominal organs)
Adb. Ureter - Lt. (Adb. Ureter - lt.)
Adb. Ureter - Rt. (Adb. Ureter - rt.)
Ant. Abdomen (Ant. Abdomen)
Anus (Anus)
Appendix (Appendix)
Ascending Colon (Ascending colon)
Bladder - Mucosa (Bladder - mucosa)
Bladder - Muscularis (Bladder -
muscularis)
Clitoris (Clitoris)
Common Iliac - Lt. (Common iliac - lt.)
Common Iliac - Rt. (Common iliac - rt.)
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Reporting Form - FORM C
Deep Groin - Lt. (Deep groin - lt.)
Deep Groin - Rt. (Deep groin - rt.)
Descending Colon (Descending colon)
Duodenum (Duodenum)
External Iliac - Lt. (External iliac - lt.)
External Iliac - Rt. (External iliac - rt.)
Fallopian Tube - Lt. (Fallopian tube - lt.)
Fallopian Tube - Rt. (Fallopian tube - rt.)
Gall Bladder (Gall bladder)
Gutters - Lt. (Gutters - lt.)
Gutters - Rt. (Gutters - rt.)
Ileum (Ileum)
Internal - Lt. (Internal - lt.)
Internal - Rt. (Internal - rt.)
Introitus (Introitus)
Jejunum (Jejunum)
Kidney - Lt. (Kidney - lt.)
Kidney - Rt. (Kidney - rt.)
Labium Major - Lt. (Labium major - lt.)
Labium Major - Rt. (Labium major - rt.)
Labium Minor - Lt. (Labium minor - lt.)
Labium Minor - Rt. (Labium minor - rt.)
Large Bowel (Large bowel)
Left Scalene (Left scalene)
Liver Parenchyma (Liver parenchyma)
Liver Surface (Liver surface)
Obturator - Lt. (Obturator - lt.)
Obturator - Rt. (Obturator - rt.)
Omentum - Gastrocolic (Omentum -
gastrocolic)
Omentum - Infracolic (Omentum -
infracolic)
Pancreas (Pancreas)
Para-aortic - Lt. (Para-aortic - lt.)
Para-aortic - Rt. (Para-aortic - rt.)
Parametrium - Lt. (Parametrium - lt.)
Parametrium - Rt. (Parametrium - rt.)
Pelvic - Lt. (Pelvic - lt.)
Pelvic - Rt. (Pelvic - rt.)
Pelvic Bladder (Pelvic bladder)
Pelvic Cul-de-sac (Pelvic cul-de-sac)
Perineal Body (Perineal body)
Sig. Mucosa (Sig. Mucosa)
Sig. Muscularis (Sig. Muscularis)
Small Bowel (Small bowel)
Spleen (Spleen)
Stomach (Stomach)
Subdiaphragm - Lt. (subdiaphragm - lt.)
Subdiaphragm - Rt. (subdiaphragm - rt.)
Superficial Gr. - Lt. (Superficial gr. - lt.)
Superficial Gr. - Rt. (Superficial gr. - rt.)
Transverse Colon (Transverse colon)
Ureter - Lt. (Ureter - lt.)
Ureter - Rt. (Ureter - rt.)
Urethra (Urethra)
Uterus-cervix (Uterus-cervix)
Uterus-corpus (Uterus-corpus)
Vagina (Vagina)
Exam
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No Tumor (No tumor)
Not Examined (Not examined)
Organ Absent (Organ absent)
Suspicious (Suspicious)
Tumor Present (Tumor present)
Proc
Biopsy Only (Biopsy only)
Left Intact (Left intact)
Not Applicable (Not applicable)
Removed Completely (Removed
completely)
Removed Partially (Removed partially)
Diagrams of operative findings
Diagrams of residual tumors
Comments
Comments
Participating group code
Participating group protocol number
Participating group patient ID
4 / 4
NCT00565851 GYNECOLOGIC ONCOLOGY GROUP Surgical
Reporting Form - FORM C
Southwest Oncology Group Registration
Form (S0421) NCT00134056
Southwest Oncology Group Registration Form (S0421)
NCT00134056
Docetaxel and Prednisone With or Without Atrasentan in
Treating Patients With Stage IV Prostate Cancer and Bone
Metastases That Did Not Respond to Previous Hormone
Therapy
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=F15A11DF-
588A-2157-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11272
Southwest Oncology Group
Registration Form (S0421)
NCT00134056
Header
SWOG Study No.
Registration Step
Assigned Treatment Arm
Activation Date
Caller's SWOG Roster ID
Last Amended Date
Patient demographics
Patient's Name
SWOG Patient ID
Other Group Patient Number
Participating Group/Protocol Number
Patient's Date of Birth
Patient Gender
Female (Female)
Male (Male)
Method of Payment
Medicaid (Medicaid)
Medicaid And Medicare (Medicaid and
Medicare)
Medicare (Medicare)
Medicare And Private Insurance
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(Medicare and Private)
Military Sponsored (including Champus
& Tricare) (Military)
No Means Of Payment (no Insurance)
(No insurance (no means))
No insurance (self-pay) (No insurance
(self-pay))
Other (Other, specify at registration)
Private Insurance (Private)
Unknown (Unknown)
Military Or Veterans Sponsored Nos
(Veterans Admin)
Patient's Ethnicity
No (not Spanish) (No (not Spanish))
Unknown (Unknown)
Yes, Central American (Yes, Central
American)
Yes, Cuban (Yes, Cuban)
Yes, Mexican (Yes, Mexican)
Yes, Nos (Yes, NOS)
Yes, Other (Yes, Other)
Yes, Puerto Rican (Yes, Puerto Rican)
Yes, South American (Yes, South
American)
Patient's Race (select all that apply)
A Person Having Origins In Any Of The
Original Peoples Of North And South
America (including Central America),
And Who Maintains Tribal Affiliation Or
Community Attachment. (American
Indian or Alaska Native)
A Person Having Origins In Any Of The
Original Peoples Of The Far East,
Southeast Asia, Or The Indian
Subcontinent Including, For Example,
Cambodia, China, India, Japan, Korea,
Malaysia, Pakistan, The Philippine
Islands, Thailand, And Vietnam. (Asian)
A Person Having Origins In Any Of The
Black Racial Groups Of Africa. Terms
Such As "haitian" Or "negro" Can Be
Used In Addition To "black Or African
American." (Black or African American)
A Person Having Origins In Any Of The
Original Peoples Of Hawaii, Guam,
Samoa, Or Other Pacific Islands. (Native
Hawaiian or Other Pacific Islander)
Could Not Be Determined Or Unsure
(unknown)
A Person Having Origins In Any Of The
Original Peoples Of Europe, The Middle
East, Or North Africa. (White)
Patient Social Security Number
Patient's ZIP Code
2 / 4
Southwest Oncology Group Registration Form (S0421) NCT00134056
Country of Residence (if not USA) (If a resident
of Canada)
Social Insurance Number
Postal Code
Stratification factors
Progression Of Measurable Or Evaluable
Disease (Progression of measurable or
evaluable disease)
Psa Progression Only (PSA progression
only)
Extraskeletal metastases
Yes
No
Worst pain (by Brief Pain Inventory)
< 4 (< 4)
>= 4 (>= 4)
Is the patient currently receiving
bisphosphonate?
Yes
No
Prior radical prostatectomy
Yes
No
Miscellaneous Patient Information
IRB Approval Date
Projected Start Date of Treatment
Date Informed Consent Signed
SWOG Investigator Number
Other Group Investigator Name
Other Group Investigator Number
SWOG Treating Institution Number (OR)
Other Group Institution Name
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Other Group Institution Number
Date HIPAA Authorization signed (Not required
for non-American sites)
Pharmacy number
My specimens may be kept for use in research to
learn about, prevent, treat, or cure cancer.
Yes
No
My specimens may be kept for research about
other health problems (for example: causes of
diabetes, Alzheimer's disease, and heart
disease.)
Yes
No
Someone may contact me in the future to ask me
to take part in more research.
Yes
No
I agree to allow my study doctor, or someone
approved by my study doctor, to contact me
regard future research involving my participation
in this study
Yes
No
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Southwest Oncology Group Registration
Form (S0518) NCT00569127
Southwest Oncology Group Registration Form (S0518)
NCT00569127 
Octreotide and Interferon Alfa-2b or Bevacizumab in
Treating Patients With Metastatic or Locally Advanced,
High-Risk Neuroendocrine Tumor
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=0F0F2E10-
4CEC-212A-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11273
Southwest Oncology Group
Registration Form (S0518)
NCT00569127
Header
SWOG Study No.
Registration Step
Assigned Treatment Arm
Activation Date
Last Amended Date
Patient demographics
Patient's Name
SWOG Patient ID
Other Group Patient Number
Participating Group/Protocol Number
Patient's Date of Birth
Patient Gender
Female (Female)
Male (Male)
Method of Payment
Medicaid (Medicaid)
Medicaid And Medicare (Medicaid and
Medicare)
Medicare (Medicare)
Medicare and Private (Medicare and
Private)
Military Sponsored (including Champus
& Tricare) (Military)
1 / 4
No Means Of Payment (no Insurance)
(No insurance (no means))
Self Pay (no Insurance) (No insurance
(self-pay))
Other (Other, specify at registration)
Private Insurance (Private)
Unknown (Unknown)
Veterans Sponsored (Veterans Admin)
Patient's Ethnicity
No (not Spanish) (No (not Spanish))
Unknown (Unknown)
Yes, Central American (Yes, Central
American)
Yes, Cuban (Yes, Cuban)
Yes, Mexican (Yes, Mexican)
Yes, Nos (Yes, NOS)
Yes, Other (Yes, Other)
Yes, Puerto Rican (Yes, Puerto Rican)
Yes, South American (Yes, South
American)
Patient's Race (select all that apply)
A Person Having Origins In Any Of The
Original Peoples Of North And South
America (including Central America),
And Who Maintains Tribal Affiliation Or
Community Attachment. (American
Indian or Alaska Native)
A Person Having Origins In Any Of The
Original Peoples Of The Far East,
Southeast Asia, Or The Indian
Subcontinent Including, For Example,
Cambodia, China, India, Japan, Korea,
Malaysia, Pakistan, The Philippine
Islands, Thailand, And Vietnam. (Asian)
A Person Having Origins In Any Of The
Black Racial Groups Of Africa. Terms
Such As "haitian" Or "negro" Can Be
Used In Addition To "black Or African
American." (Black or African American)
A Person Having Origins In Any Of The
Original Peoples Of Hawaii, Guam,
Samoa, Or Other Pacific Islands. (Native
Hawaiian or other Pacific Islander)
Could Not Be Determined Or Unsure
(Unknown)
A Person Having Origins In Any Of The
Original Peoples Of Europe, The Middle
East, Or North Africa. (White)
Patient Social Security Number
Patient Zip Code
Country of Residence (if not USA) (If a resident
of Canada)
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Social Insurance Number
Postal code
Miscellaneous Patient Information
Caller's SWOG Roster ID
IRB Approval Date
Projected Start Date of Treatment
Date Informed Consent Signed
SWOG Investigator Number (OR)
Other Group Investigator Name
Other Group Investigator Number
SWOG Treating Institution Number (OR)
Other Group Institution Name
Other Group Institution Number
Date HIPAA Authorization signed (Not required
for non-American sites)
My specimens may be kept for use in research to
learn about, prevent, treat or cure cancer
Yes
No
My specimens may be kept for use in research
about other health problems (for example:
diabetes, Alzheimer's disease, or heart disease.)
Yes
No
Someone may contact me in the future to ask me
to allow other uses of my specimens
Yes
No
I agree to allow my study doctor, or someone
approved by my study doctor, to contact me
regard future research involving my participation
in this study
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Yes
No
Stratification Factors
Histologic Grade
Intermediate (Intermediate)
Low (Low)
Prior Octreotide within 2 months prior to
registration
Yes
No
Disease progression since initial diagnosis
Yes
No
Site
Other Sites (Other sites)
Small Bowel, Cecum, Appendix (Small
bowel, cecum, appendix)
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Southwest Oncology Group Registration Form (S0518) NCT00569127
Southwest Oncology Group Registration
Form (S0600) NCT00499369
Southwest Oncology Group Registration Form (S0600)
NCT00499369
Irinotecan and Cetuximab With or Without Bevacizumab in
Treating Patients With Metastatic Colorectal Cancer That
Progressed During First-Line Therapy
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=15404476-
282E-46CA-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11274
Southwest Oncology Group
Registration Form (S0600)
NCT00499369
Header
SWOG Study No.
Registration Step
Assigned Treatment Arm
Activation Date
Last Amended Date
Patient demographics
Patient's Name
SWOG Patient ID
Other Group Patient Number
Participating Group/Protocol Number
Patient's Date of Birth
Patient Gender
Female (Female)
Male (Male)
Patient Zip Code
Country of Residence (if not USA)
Social Insurance Number (If a resident of
Canada)
1 / 3
Postal code
Patient's Ethnicity
No (not Spanish) (No (not Spanish))
Unknown (Unknown)
Yes, Central American (Yes, Central
American)
Yes, Cuban (Yes, Cuban)
Yes, Mexican (Yes, Mexican)
Yes, Nos (Yes, NOS)
Yes, Other (Yes, Other)
Yes, Puerto Rican (Yes, Puerto Rican)
Yes, South American (Yes, South
American)
Miscellaneous Patient Information
Caller's SWOG Roster ID
IRB Approval Date
Projected Start Date of Treatment
Date Informed Consent Signed
SWOG Investigator Number (OR)
Other Group Investigator Name
Other Group Investigator Number
SWOG Treating Institution Number (OR)
Other Group Institution Name
Other Group Institution Number
HIPAA Authorization Date (Not required for non-
American sites)
Method of Payment
Medicaid (Medicaid)
Medicaid And Medicare (Medicaid and
Medicare)
Medicare (Medicare)
Medicare And Private Insurance
(Medicare and Private Insurance)
Military Or Veterans Sponsored Nos
(Military or Veterans Sponsored, Not
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Otherwise Specified (NOS))
No Means Of Payment (no Insurance)
(No means of payment (no insurance))
Other (Other)
Private Insurance (Private Insurance)
Self Pay (no Insurance) (Self Pay (No
Insurance))
Unknown (Unknown)
Veterans Sponsored (Veterans
Sponsored)
Performance status (Stratification Factors:)
>=1 (>=1)
0 (0)
Discontinuation of oxaliplatin while on first line
therapy
Yes
No
Planned concurrent chemotherapy
Irinotecan + 5-fluorouracil/leucovorin
Regimen (folfiri) (FOLFIRI)
Irinotecan Hydrochloride (Single agent
irinotecan)
Time from last dose of bevacizumab
14-42 Days (14-42 days)
43 Days Or Higher (43 days or higher)
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Southwest Oncology Group Registration Form (S0600) NCT00499369
Southwest Oncology Group Registration
Form (S0502) NCT00324987
Southwest Oncology Group Registration Form (S0502)
NCT00324987 
S0502 Imatinib Mesylate With or Without Bevacizumab in
Treating Patients With Metastatic or Unresectable
Gastrointestinal Stromal Tumor
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=398EB7EC-
7565-1438-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11275
Southwest Oncology Group
Registration Form (S0502)
NCT00324987
Header
SWOG Study No.
Registration Step
Assigned Treatment Arm
Activation Date
Last Amended Date
Patient demographics
Patient's Name
Patient's Date of Birth
Patient Gender
Female (Female)
Male (Male)
Method of Payment
Medicaid (Medicaid)
Medicaid And Medicare (Medicaid and
Medicare)
Medicare (Medicare)
Medicare And Private Insurance
(Medicare and Private Insurance)
Military Or Veterans Sponsored Nos
(Military or Veterans Sponsored, Not
Otherwise Specified (NOS))
No Means Of Payment (no Insurance)
(No means of payment (no insurance))
Other (Other)
Private Insurance (Private Insurance)
Self Pay (no Insurance) (Self Pay (No
Insurance))
Unknown (Unknown)
Veterans Sponsored (Veterans
1 / 4
Sponsored)
Patient's Ethnicity
No (not Spanish) (No (not Spanish))
Unknown (Unknown)
Yes, Central American (Yes, Central
American)
Yes, Cuban (Yes, Cuban)
Yes, Mexican (Yes, Mexican)
Yes, Nos (Yes, NOS)
Yes, Other (Yes, Other)
Yes, Puerto Rican (Yes, Puerto Rican)
Yes, South American (Yes, South
American)
Patient Race (select all that apply)
A Person Having Origins In Any Of The
Original Peoples Of North And South
America (including Central America),
And Who Maintains Tribal Affiliation Or
Community Attachment. (American
Indian or Alaska Native)
A Person Having Origins In Any Of The
Original Peoples Of The Far East,
Southeast Asia, Or The Indian
Subcontinent Including, For Example,
Cambodia, China, India, Japan, Korea,
Malaysia, Pakistan, The Philippine
Islands, Thailand, And Vietnam. (Asian)
A Person Having Origins In Any Of The
Black Racial Groups Of Africa. Terms
Such As "haitian" Or "negro" Can Be
Used In Addition To "black Or African
American." (Black or African American)
A Person Having Origins In Any Of The
Original Peoples Of Hawaii, Guam,
Samoa, Or Other Pacific Islands. (Native
Hawaiian or other Pacific Islander)
Could Not Be Determined Or Unsure
(Unknown)
A Person Having Origins In Any Of The
Original Peoples Of Europe, The Middle
East, Or North Africa. (White)
Patient Social Security Number (If a U.S.
resident)
Patient Zip Code
Country of Residence (if not USA)
Social Insurance Number (If a resident of
Canada)
Postal code
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SWOG Patient ID
Other Group Patient Number
Participating Group/Protocol Number
Miscellaneous Patient Information
Caller's SWOG Roster ID
IRB Approval Date
Projected Start Date of Treatment
Date Informed Consent Signed
SWOG Investigator Number (OR)
Other Group Investigator Name
Other Group Investigator Number
SWOG Treating Institution Number (OR)
Other Group Institution Name
Other Group Institution Number
HIPAA Authorization Date (Not required for non-
American sites)
My specimens may be kept for use in research to
learn about, prevent, treat or cure cancer
Yes
No
My specimens may be kept for research about
other health problems
Yes
No
Someone may contact me in the future to ask me
to allow other uses of my specimens.
Yes
No
I agree to allow my study doctor, or someone
approved by my study doctor, to contact me
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regard future research involving my participation
in this study
Yes
No
I agree to participate in this study of fresh tissue
Yes
No
I agree to participate in this study of blood
Yes
No
Performance status
>=1 (>=1)
0 (0)
Disease status
Measurable (Measurable)
Non-measurable (Non-Measurable)
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Southwest Oncology Group Registration Form (S0502) NCT00324987
PRL1013 - Week 1 Recall Evaluation Form
NCT01268605
PRL1013 - Week 1 Recall Evaluation Form NCT01268605
Postoperative Hypersensitivity Randomized Comparative
Effectiveness Research Trial (POH RCERT)
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=AA2ADCC9-
4CDC-BB84-E040-BB89AD43774B
All rights reserved. Please visit https://medical-data-
models.org/forms/11276
PRL1013 - Week 1 Recall Evaluation
Form NCT01268605
Header
Site Code
Date of visit
Subject ID
Subject Initials
Treatment arm
Restoration With Dba (RD)
Restoration With Rmgi (RR)
Date of evaluation
Dental status
Tooth quadrant
Lower Left Quadrant (Lower Left)
Lower Right Quadrant (Lower Right)
Upper Left Quadrant (Upper Left)
Upper Right Quadrant (Upper Right)
During chewing of food
Yes
No
During clenching
Yes
No
Did you check the occlusion on the treated tooth
(If "Yes" to either of the above)
Yes
No
Did you adjust the occlusion (If "Yes")
Yes
No
Air velocity
Air stimulation pain level
0 (0)
1 / 3
1 (1)
10 (10)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
7 (7)
8 (8)
9 (9)
Does the pain linger >4 seconds (after removal of
air blast)
Yes
No
Cold stimulation pain level
0 (0)
1 (1)
10 (10)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
7 (7)
8 (8)
9 (9)
Time to cold sensation (length of time from pellet
application until subjet raises hand)
min
Does the pain linger > 4 seconds
Yes
No
Rescue Treatment
Did the patient receive rescue treatment (since
the last visit)
Yes
No
Which rescue treatment was provided
Dental Bonding Agent (DBA alone)
Dental Bonding Agent Dental Liner
(Liner+DBA)
Not Applicable (N/A)
Date  rescue treatment performed
Was the tooth evaluated for pulpitis
Yes
No
Was there evidence of pulpitis (If "Yes")
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PRL1013 - Week 1 Recall Evaluation Form NCT01268605
Yes
No
Was endodontic therapy performed (If "Yes")
Yes
No
Date of endodontic treatment (If "Yes")
Economic Impact
How much time did it take the patient to travel to
the dental office today
min
0-15 Minutes (0-15 minutes)
16-30 Minutes (16-30 minutes)
31-60 Minutes (31-60 minutes)
61-90 Minutes (61-90 minutes)
91-120 Minutes (91-120 minutes)
More Than 120 Minutes (More than 120
minutes)
How much did it cost the patient to travel to the
dental office today (including parking)
$0-10 ($0-10)
$11-20 ($11-20)
$21-30 ($21-30)
More Than $30 (More than $30)
Did the patient have to take time away from work
to come to the dental office to treat the
hypersensitivity
Yes
No
How much time did he/she take off (If "Yes")
0-30 Minutes (0-30 minutes)
1-2 Hours (1-2 hours)
2-3 Hours (2-3 hours)
3-4 Hours (3-4 hours)
31-60 Minutes (31-60 minutes)
More Than 4 Hours (More than 4 hours)
What is the total estimated cost for the rescue
treatment if patient was not participating in the
study
$0-50 ($0-50)
$101-150 ($101-150)
$151-200 ($151-200)
$201-250 ($201-250)
$51-100 ($51-100)
More Than $250 (More than $250)
Footer Module
Comments
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PRL1013 - Week 1 Recall Evaluation Form NCT01268605
Southwest Oncology Group Registration
Form (S0347) NCT00103233
Southwest Oncology Group Registration Form (S0347)
NCT00103233
Vinorelbine With or Without Trastuzumab in Treating
Women With Progressive Metastatic Breast Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=DE0362CF-
1A71-1531-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/11278
Southwest Oncology Group
Registration Form (S0347)
NCT00103233
Header
SWOG Study No.
Registration Step
Assigned Treatment Arm
Activation Date
Last Amended Date
Patient demographics
Patient's Name
Patient's Date of Birth
Patient Gender
Female (Female)
Male (Male)
Method of Payment
Medicaid (Medicaid)
Medicaid And Medicare (Medicaid and
Medicare)
Medicare (Medicare)
Medicare and Private (Medicare and
Private)
Military Sponsored (including Champus
& Tricare) (Military)
No Means Of Payment (no Insurance)
(No insurance (no means))
Self Pay (no Insurance) (No insurance
(self-pay))
Other (Other, specify at registration)
Private Insurance (Private)
Unknown (Unknown)
Veterans Sponsored (Veterans Admin)
1 / 3
Patient's Ethnicity
No (not Spanish) (No (not Spanish))
Unknown (Unknown)
Yes, Central American (Yes, Central
American)
Yes, Cuban (Yes, Cuban)
Yes, Mexican (Yes, Mexican)
Yes, Nos (Yes, NOS)
Yes, Other (Yes, Other)
Yes, Puerto Rican (Yes, Puerto Rican)
Yes, South American (Yes, South
American)
Patient's Race (select all that apply)
A Person Having Origins In Any Of The
Original Peoples Of North And South
America (including Central America),
And Who Maintains Tribal Affiliation Or
Community Attachment (American Indian
or Alaska Native)
A Person Having Origins In Any Of The
Original Peoples Of The Far East,
Southeast Asia, Or The Indian
Subcontinent Including, For Example,
Cambodia, China, India, Japan, Korea,
Malaysia, Pakistan, The Philippine
Islands, Thailand, And Vietnam. (Asian)
A Person Having Origins In Any Of The
Black Racial Groups Of Africa. Terms
Such As "haitian" Or "negro" Can Be
Used In Addition To "black Or African
American." (Black or African American)
A Person Having Origins In Any Of The
Original Peoples Of Hawaii, Guam,
Samoa, Or Other Pacific Islands (Native
Hawaiian or Other Pacific Islander)
Patient Is Unsure Of Their Race
(unknown)
A Person Having Origins In Any Of The
Original Peoples Of Europe, The Middle
East, Or North Africa. (White)
Patient Social Security Number
Patient's ZIP Code
Country of Residence (if not USA) (If a resident
of Canada)
Social Insurance Number
Postal Code
SWOG Patient ID
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Other Group Patient Number
Participating Group/Protocol Number
Miscellaneous Patient Information
Caller's SWOG Roster ID
IRB Approval Date
Projected Start Date of Treatment
Date Informed Consent Signed
SWOG Investigator Number (OR)
Other Group Investigator Name
Other Group Investigator Number
SWOG Treating Institution Number (OR)
Other Group Institution Name
Other Group Institution Number
Date HIPAA Authorization signed (Not required
for non-American sites)
My tissue and blood may be kept for use in
research to learn about, prevent, treat, or cure
cancer.
Yes
No
My tissue and blood may be kept for research
about other health problems (for example: causes
of diabetes, Alzheimer's disease, and heart
disease).
Yes
No
Someone from the Southwest Oncology Group
may contact me in the future to ask me to take
part in more research.
Yes
No
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Southwest Oncology Group Registration Form (S0347) NCT00103233
Southwest Oncology Group Registration
Form (S0307) NCT00127205
Southwest Oncology Group Registration Form (S0307)
NCT00127205
Zoledronate, Clodronate, or Ibandronate in Treating Women
Who Have Undergone Surgery for Stage I, Stage II, or
Stage III Breast
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=DEA4C71E-
40E2-1358-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/11279
Southwest Oncology Group
Registration Form (S0307)
NCT00127205
Header
SWOG Study No.
Registration Step
Assigned Treatment Arm
Activation Date
Last Amended Date
Patient demographics
Patient's Name
Patient's Date of Birth
Patient Gender
Female (Female)
Male (Male)
Method of Payment
Medicaid (Medicaid)
Medicaid And Medicare (Medicaid and
Medicare)
Medicare (Medicare)
Medicare And Private Insurance
(Medicare and Private)
Military Sponsored (including Champus
& Tricare) (Military)
No Means Of Payment (no Insurance)
(No insurance (no means))
Self Pay (no Insurance) (No insurance
(self-pay))
Other (Other, specify at registration)
Private Insurance (Private)
Unknown (Unknown)
Military Or Veterans Sponsored Nos
(Veterans Admin)
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Patient's Ethnicity
No (not Spanish) (No (not Spanish))
Unknown (Unknown)
Yes, Central American (Yes, Central
American)
Yes, Cuban (Yes, Cuban)
Yes, Mexican (Yes, Mexican)
Yes, Nos (Yes, NOS)
Yes, Other (Yes, Other)
Yes, Puerto Rican (Yes, Puerto Rican)
Yes, South American (Yes, South
American)
Patient's Race (select all that apply)
A Person Having Origins In Any Of The
Original Peoples Of North And South
America (including Central America),
And Who Maintains Tribal Affiliation Or
Community Attachment (American Indian
or Alaska Native)
A Person Having Origins In Any Of The
Original Peoples Of The Far East,
Southeast Asia, Or The Indian
Subcontinent Including, For Example,
Cambodia, China, India, Japan, Korea,
Malaysia, Pakistan, The Philippine
Islands, Thailand, And Vietnam. (Asian)
A Person Having Origins In Any Of The
Black Racial Groups Of Africa. Terms
Such As "haitian" Or "negro" Can Be
Used In Addition To "black Or African
American." (Black or African American)
A Person Having Origins In Any Of The
Original Peoples Of Hawaii, Guam,
Samoa, Or Other Pacific Islands (Native
Hawaiian or Other Pacific Islander)
Patient Is Unsure Of Their Race
(unknown)
A Person Having Origins In Any Of The
Original Peoples Of Europe, The Middle
East, Or North Africa. (White)
Patient Social Security Number (If a U.S.
resident)
Patient's ZIP Code
Country of Residence (if not USA)
Social Insurance Number (If a resident of
Canada)
Postal Code
SWOG Patient ID
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Other Group Patient Number
Participating Group/Protocol Number
Miscellaneous Patient Information
Caller's SWOG Roster ID
IRB Approval Date
Projected Start Date of Treatment
Date Informed Consent Signed
SWOG Investigator Number
Other Group Investigator Name
Other Group Investigator Number
SWOG Treating Institution Number (OR)
Other Group Institution Name
Other Group Institution Number
Date HIPAA Authorization signed (Not required
for non-American sites)
My specimens may be kept for use in research to
learn about, prevent, treat, or cure cancer.
Yes
No
My specimens may be kept for research about
other health problems (for example: causes of
diabetes, Alzheimer's disease, and heart
disease).
Yes
No
Someone from the Southwest Oncology Group
may contact me in the future to ask me to take
part in more research.
Yes
No
I agree to allow my study doctor, or someone
approved by my study doctor, to contact me
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regard future research involving my participation
in this study
Yes
No
I agree to submit a tissue specimen for analysis
of the substance parathyroid hormone related
protein (PTHrP) to see if this predicts the risk of
my breast cancer spreading to the bones
Yes
No
I agree to submit a blood specimen for analysis of
the substance n-telopeptide to see if high levels
predict the risk of my breast cancer spreading to
the bones
Yes
No
I agree to submit a whole blood sample for
genetic studies related to the development of
side-effects to the kinds of drugs used in this
study
Yes
No
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Southwest Oncology Group Registration
Form (S0500) NCT00382018
Southwest Oncology Group Registration Form (S0500)
NCT00382018
Treatment Decision Making Based on Blood Levels of
Tumor Cells in Women With Metastatic Breast Cancer
Receiving Chemotherapy
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=07BE67DB-
E4E8-6CBC-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11280
Southwest Oncology Group
Registration Form (S0500)
NCT00382018
Header
SWOG Study No.
Registration Step
Assigned Treatment Arm
Activation Date
Last Amended Date
Patient demographics
Patient's Name
Patient's Date of Birth
Patient Gender
Female (Female)
Male (Male)
Method of Payment
Medicaid (Medicaid)
Medicaid And Medicare (Medicaid and
Medicare)
Medicare (Medicare)
Medicare and Private (Medicare and
Private)
Military Sponsored (including Champus
& Tricare) (Military)
No Means Of Payment (no Insurance)
(No insurance (no means))
Self Pay (no Insurance) (No insurance
(self-pay))
Other (Other, specify at registration)
Private Insurance (Private)
Unknown (Unknown)
Veterans Sponsored (Veterans Admin)
1 / 4
Patient's Ethnicity
No (not Spanish) (No (not Spanish))
Unknown (Unknown)
Yes, Central American (Yes, Central
American)
Yes, Cuban (Yes, Cuban)
Yes, Mexican (Yes, Mexican)
Yes, Nos (Yes, NOS)
Yes, Other (Yes, Other)
Yes, Puerto Rican (Yes, Puerto Rican)
Yes, South American (Yes, South
American)
Patient's Race (select all that apply)
A Person Having Origins In Any Of The
Original Peoples Of North And South
America (including Central America),
And Who Maintains Tribal Affiliation Or
Community Attachment (American Indian
or Alaska Native)
A Person Having Origins In Any Of The
Original Peoples Of The Far East,
Southeast Asia, Or The Indian
Subcontinent Including, For Example,
Cambodia, China, India, Japan, Korea,
Malaysia, Pakistan, The Philippine
Islands, Thailand, And Vietnam. (Asian)
A Person Having Origins In Any Of The
Black Racial Groups Of Africa. Terms
Such As "haitian" Or "negro" Can Be
Used In Addition To "black Or African
American." (Black or African American)
A Person Having Origins In Any Of The
Original Peoples Of Hawaii, Guam,
Samoa, Or Other Pacific Islands (Native
Hawaiian or Other Pacific Islander)
Patient Is Unsure Of Their Race
(unknown)
A Person Having Origins In Any Of The
Original Peoples Of Europe, The Middle
East, Or North Africa. (White)
Patient Social Security Number
Patient Zip Code
Country of Residence (if not USA) (If a resident
of Canada)
Social Insurance Number
Postal code
SWOG Patient ID
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Other Group Patient Number
Participating Group/Protocol Number
Miscellaneous Patient Information
Caller's SWOG Roster ID
IRB Approval Date
Projected Start Date of Treatment
Date Informed Consent Signed
SWOG Investigator Number (OR)
Other Group Investigator Name
Other Group Investigator Number
SWOG Treating Institution Number (OR)
Other Group Institution Name
Other Group Institution Number
Date HIPAA Authorization signed (Not required
for non-American sites)
My specimens may be kept for use in research to
learn about, prevent, treat or cure cancer
Yes
No
My specimens may be kept for use in research
about other health problems (for example:
diabetes, Alzheimer's disease, or heart disease).
Yes
No
Someone may contact me in the future to ask me
to allow other uses of my specimens
Yes
No
I agree to allow my study doctor, or someone
approved by my study doctor, to contact me
regard future research involving my participation
in this study
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Yes
No
Stratification Factors
HER-2 Status
Negative (Negative)
Positive (Positive)
Disease Type
Measurable Disease With Or Without
Non-measurable Disease (Measurable
disease with or without non-measurable
disease)
Non-measurable Disease Only Including
Bone Metastasis (Non-measurable
disease only including bone metastasis)
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NCT00324987  Southwest Oncology Group
Registration Form (S0502 Registration Step 2)
NCT00324987  Southwest Oncology Group Registration
Form (S0502 Registration Step 2)
S0502 Imatinib Mesylate With or Without Bevacizumab in
Treating Patients With Metastatic or Unresectable
Gastrointestinal Stromal Tumor
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=398E9509-
E384-0DBF-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11281
NCT00324987  Southwest Oncology
Group Registration Form (S0502
Registration Step 2)
Header
SWOG Study No.
Registration Step
Assigned Treatment Arm
Activation Date
Last Amended Date
Caller's SWOG Roster ID
SWOG Investigator Number (OR)
Other Group Investigator Name
Other Group Investigator Number
SWOG Treating Institution Number (OR)
Other Group Institution Name
Other Group Institution Number
Projected Start Date of Treatment
Patient demographics
Patient's Name
SWOG Patient ID
Other Group Patient Number
1 / 2
Participating Group/Protocol Number
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NCT00324987  Southwest Oncology Group Registration Form (S0502
Registration Step 2)
Southwest Oncology Group Registration
Form - Step #4 NCT00492856
Southwest Oncology Group Registration Form - Step #4
NCT00492856 
Combination Chemotherapy With or Without Gemtuzumab
Followed By Tretinoin, Mercaptopurine, and Methotrexate
or Observation in Treating Patients With Acute
Promyelocytic Leukemia
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=0FFCFA5D-
3AA8-184B-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11282
Southwest Oncology Group
Registration Form - Step #4
NCT00492856
SWOG clinical trial administrative data
SWOG Study No.
Registration Step
Assigned Treatment Arm
Activation Date
Last Amended Date
Caller's SWOG Roster ID
SWOG Investigator Number (OR)
Other Group Investigator Name
Other Group Investigator Number
SWOG Treating Institution Number (OR)
Other Group Institution Name
Other Group Institution Number
Projected Start Date of Treatment
Patient demographics
Patient's Name
SWOG Patient ID
1 / 2
Other Group Patient Number
Participating Group/Protocol Number
2 / 2
Southwest Oncology Group Registration Form - Step #4 NCT00492856
Southwest Oncology Group Registration
Form - Step #3 NCT00492856
Southwest Oncology Group Registration Form - Step #3
NCT00492856 
Combination Chemotherapy With or Without Gemtuzumab
Followed By Tretinoin, Mercaptopurine, and Methotrexate
or Observation in Treating Patients With Acute
Promyelocytic Leukemia
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=01E95CDA-
068E-07BB-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11283
Southwest Oncology Group
Registration Form - Step #3
NCT00492856
SWOG clinical trial administrative data
SWOG Study No.
Registration Step
Assigned Treatment Arm
Activation Date
Last Amended Date
Caller's SWOG Roster ID
SWOG Investigator Number (OR)
Other Group Investigator Name
Other Group Investigator Number
SWOG Treating Institution Number (OR)
Other Group Institution Name
Other Group Institution Number
Projected Start Date of Treatment
Patient demographics
Patient's Name
SWOG Patient ID
1 / 2
Other Group Patient Number
Participating Group/Protocol Number
Stratification Factors
Age at first registration
> 60 Years (> 60 years)
15-60 Years (15-60 years)
APL risk group
Intermediate Risk (Intermediate)
Low Risk (Low)
Did patient receive consolidation cycle 3 or 4
(ATRA plus Daunorubicin)
Yes
No
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Southwest Oncology Group Registration Form - Step #3 NCT00492856
Southwest Oncology Group Registration
Form - Step #2 NCT00492856
Southwest Oncology Group Registration Form - Step #2
NCT00492856 
Combination Chemotherapy With or Without Gemtuzumab
Followed By Tretinoin, Mercaptopurine, and Methotrexate
or Observation in Treating Patients With Acute
Promyelocytic Leukemia
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=0FFCF3C0-
B4A4-173B-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11284
Southwest Oncology Group
Registration Form - Step #2
NCT00492856
SWOG clinical trial administrative data
SWOG Study No.
Registration Step
Assigned Treatment Arm
Activation Date
Last Amended Date
Caller's SWOG Roster ID
SWOG Investigator Number (OR)
Other Group Investigator Name
Other Group Investigator Number
SWOG Treating Institution Number (OR)
Other Group Institution Name
Other Group Institution Number
Projected Start Date of Treatment
Patient demographics
Patient's Name
SWOG Patient ID
1 / 2
Other Group Patient Number
Participating Group/Protocol Number
2 / 2
Southwest Oncology Group Registration Form - Step #2 NCT00492856
Southwest Oncology Group Registration
Form Step 2 (S0421) NCT00134056
Southwest Oncology Group Registration Form Step 2
(S0421) NCT00134056
Docetaxel and Prednisone With or Without Atrasentan in
Treating Patients With Stage IV Prostate Cancer and Bone
Metastases That Did Not Respond to Previous Hormone
Therapy
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=0F977EF7-
B9B7-51FB-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11285
Southwest Oncology Group
Registration Form Step 2 (S0421)
NCT00134056
SWOG clinical trial administrative data
SWOG Study No.
Registration Step
Assigned Treatment Arm
Activation Date
Last Amended Date
Caller's SWOG Roster ID
SWOG Investigator Number
Other Group Investigator Name
Other Group Investigator Number
SWOG Treating Institution Number (OR)
Other Group Institution Name
Other Group Institution Number
Projected Start Date of Treatment
Pharmacy number
Patient demographics
Patient's Name
1 / 2
SWOG Patient ID
Other Group Patient Number
Participating Group/Protocol Number
2 / 2
Southwest Oncology Group Registration Form Step 2 (S0421)
NCT00134056
Southwest Oncology Group Registration
Form - Step #2
Southwest Oncology Group Registration Form - Step #2
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=0FFCDFB9-
D989-1505-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11286
Southwest Oncology Group
Registration Form - Step #2
SWOG clinical trial administrative data
SWOG Study No.
Registration Step
Assigned Treatment Arm
Activation Date
Last Amended Date
Caller's SWOG Roster ID
SWOG Investigator Number (OR)
Other Group Investigator Name
Other Group Investigator Number
SWOG Treating Institution Number (OR)
Other Group Institution Name
Other Group Institution Number
Projected Start Date of Treatment
Patient demographics
Patient's Name
SWOG Patient ID
Other Group Patient Number
Participating Group/Protocol Number
1 / 1
Southwest Oncology Group Registration Form
(S0518) - Registration Step 2 NCT00569127
Southwest Oncology Group Registration Form (S0518) -
Registration Step 2 NCT00569127 
Octreotide and Interferon Alfa-2b or Bevacizumab in
Treating Patients With Metastatic or Locally Advanced,
High-Risk Neuroendocrine Tumor
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=383979A5-
7234-6E65-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11287
Southwest Oncology Group
Registration Form (S0518) -
Registration Step 2 NCT00569127
Header
SWOG Study No.
Registration Step
Assigned Treatment Arm
Activation Date
Last Amended Date
Caller's SWOG Roster ID
SWOG Investigator Number (OR)
Other Group Investigator Name
Other Group Investigator Number
SWOG Treating Institution Number (OR)
Other Group Institution Name
Other Group Institution Number
Projected Start Date of Treatment
To which treatment arm was the patient assigned
at initial registration
Bevacizumab Octreotide (Octreotide plus
bevacizumab)
Interferon Alpha 2 Octreotide (Octreotide
plus interferon alpha 2-b)
Patient demographics
1 / 2
Patient's Name
SWOG Patient ID
Other Group Patient Number
Participating Group/Protocol Number
2 / 2
Southwest Oncology Group Registration Form (S0518) - Registration
Step 2 NCT00569127
Southwest Oncology Group Registration
Form - Step #2
Southwest Oncology Group Registration Form - Step #2
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=0FFCD621-
CF87-13C0-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11288
Southwest Oncology Group
Registration Form - Step #2
SWOG clinical trial administrative data
SWOG Study No.
Registration Step
Assigned Treatment Arm
Activation Date
Last Amended Date
Caller's SWOG Roster ID
SWOG Investigator Number (OR)
Other Group Investigator Name
Other Group Investigator Number
SWOG Treating Institution Number (OR)
Other Group Institution Name
Other Group Institution Number
Projected Start Date of Treatment
Patient demographics
Patient's Name
SWOG Patient ID
Other Group Patient Number
Participating Group/Protocol Number
1 / 2
Stratification Factors
Age at first registration
> 60 Years (> 60 years)
15-60 Years (15-60 years)
Risk classification at first registration
Intermediate Risk (Intermediate risk)
Low Risk (Low risk)
2 / 2
Southwest Oncology Group Registration Form - Step #2
ANBL0321: Eligibility Worksheet
NCT00053326
ANBL0321: Eligibility Worksheet NCT00053326
Fenretinide in Treating Children With Recurrent or
Resistant Neuroblastoma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=C42A6818-
CD59-6B25-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/11289
ANBL0321: Eligibility Worksheet
NCT00053326
Header
Study Number
Name
COG Number
Patient Name
Today's date
Date worksheet entered into RDE
Eligibility Assessment
Will patient begin treatment within five calendar
days of fulfilling all eligibility criteria?
Yes
No
Was patient no greater than 21 years of age
inclusive when originally diagnosed with
neuroblastoma?
Yes
No
Does patient have high-risk neuroblastoma with
one of the following: 1) Recurrent disease; or 2)
Resistant/refractory disease
Yes
No
Has patient ever had a relapse?
Yes
No
Does patient have one of the following sites of
disease
Bone Marrow With Tumor Cells Seen On
Routine Morphology Of Bilateral Aspirate
And/or Biopsy (Bone marrow with tumor
cells seen on routine morphology of
1 / 4
bilateral aspirate and/or biopsy)
>= 5 Tumor Cells/10^6 Normal
Mononuclear Cells In The Bone Marrow
By Immunocytologic Analysis (Greater
than or equal to 5 tumor cells/10^6
normal mononuclear cells in the bone
marrow by immunocytologic analysis on
two successive bone marrows done at
least three weeks apart)
Measurable Tumor On Mri Or Ct Scan Or
X-ray (Measurable tumor on MRI or CT
scan or X-ray)
Mibg Scan With Positive Uptake At
Minimum Of One Site (MIBG scan with
positive uptake at minimum of one site)
Has the patient had previous histologic
verification of neuroblastoma and/or
demonstration of tumor cells in the bone marrow
with increased urinary catecholamines?
Yes
No
Has patient fully recovered from the acute toxic
effects of all prior chemotherapy, immunotherapy,
or radiotherapy prior to entering this study?
Yes
No
Did patient received growth factors within 2 days
of entry onto this study?
Yes
No
Does patient have hemoglobin greater than 7.5
gm/dl?
g/dL
Yes
No
Does patient have adequate renal function?
Yes
No
Does patient have adequate liver function?
Yes
No
Does patient have adequate central nervous
system function?
Yes
No
Does patient meet the following criteria at time of
study enrollment?
Yes
No
Is the patient pregnant?
N/A, patient is male (N/A, patient is
2 / 4
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male)
No (No)
No, And Not Nursing (no, and not
nursing)
No, But Nursing (no, but nursing)
Yes (Yes)
Agent
Has patient received Fenretinide?
Yes
No
Has patient received an allogeneic stem cell
transplant?
Yes
No
Is the patient able to take the number of capsules
prescribed by protocol in intact form?
Yes
No
Have the patient and/or the parents or legal
guardians signed a written informed consent?
Yes
No
Have all institutional, FDA, and NCI requirements
for human studies been met?
Yes
No
Performance status
Karnofsky Performance Score
90 (Able to carry on normal activity,
minor signs or symptoms of disease)
70 (Cares for self. Unable to carry on
normal activity or to do active work)
0 (Dead)
40 (Disabled, requires special care and
assistance)
20 (Hospitalization necessary, very sick,
active supportive treatment necessary)
10 (Moribund, fatal processes
progressing rapidly)
80 (Normal activity with effort, some
signs or symptoms of disease)
100 (Normal, no complaints, no evidence
of disease)
50 (Requires considerable assistance
and frequent medical care)
60 (Requires occasional assistance, but
is able to care for most of own needs)
30 (Severely disabled, hospitalization is
indicated although death is not imminent)
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ANBL0321: Eligibility Worksheet NCT00053326
Lansky Play Score
80 (Active, but tires more quickly)
70 (Both greater restriction of and less
time spent in play activity)
100 (Fully active, normal)
50 (Gets dressed but lies around much
of the day, no active play, able to
participate in all quiet play and activities)
30 (In bed; needs assistance even for
quiet play)
90 (Minor restrictions in physically
strenuous activity)
40 (Mostly in bed; participates in quiet
activities)
10 (No play; does not get out of bed)
20 (Often sleeping; play entirely limited
to very passive activities)
0 (Unresponsive)
60 (Up and around, but minimal active
play; keeps busy with quieter activities)
Does patient have a life expectancy of greater
than or equal to 2 months?
Yes
No
Comments
Comments
Ccrr Module For Anbl0321: Eligibility
Worksheet
4 / 4
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PRL1013 - Week 4 Recall Evaluation Form
NCT01268605
PRL1013 - Week 4 Recall Evaluation Form NCT01268605
Postoperative Hypersensitivity Randomized Comparative
Effectiveness Research Trial (POH RCERT)
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=AA2C2281-
C10C-C660-E040-BB89AD43194D
All rights reserved. Please visit https://medical-data-
models.org/forms/11290
PRL1013 - Week 4 Recall Evaluation
Form NCT01268605
Header
Site Code
Date of visit
Subject ID
Subject Initials
Treatment arm
Restoration With Dba (RD)
Restoration With Rmgi (RR)
Dental status
Date of evaluation
Tooth quadrant
Lower Left Quadrant (Lower Left)
Lower Right Quadrant (Lower Right)
Upper Left Quadrant (Upper Left)
Upper Right Quadrant (Upper Right)
Air velocity
Air stimulation pain level
0 (0)
1 (1)
10 (10)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
7 (7)
8 (8)
9 (9)
Does the pain linger >4 seconds (after removal of
air blast)
Yes
No
1 / 3
Cold stimulation pain level
0 (0)
1 (1)
10 (10)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
7 (7)
8 (8)
9 (9)
Time to cold sensation (length of time from pellet
application until subjet raises hand)
min
Does the pain linger > 4 seconds
Yes
No
During chewing of food
Yes
No
During clenching
Yes
No
Did you check the occlusion on the treated tooth
(If "Yes" to either of the above)
Yes
No
Did you adjust the occlusion (If "Yes")
Yes
No
Rescue Treatment
Did the patient receive rescue treatment (since
the last visit)
Yes
No
Which rescue treatment was provided
Dental Bonding Agent (DBA alone)
Dental Bonding Agent Dental Liner
(Liner+DBA)
Not Applicable (N/A)
Date  rescue treatment performed
Was the tooth evaluated for pulpitis
Yes
No
2 / 3
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Was there evidence of pulpitis (If "Yes")
Yes
No
Was endodontic therapy performed (If "Yes")
Yes
No
Date of endodontic treatment (If "Yes")
Economic Impact
How much time did it take the patient to travel to
the dental office today
min
0-15 Minutes (0-15 minutes)
16-30 Minutes (16-30 minutes)
31-60 Minutes (31-60 minutes)
61-90 Minutes (61-90 minutes)
91-120 Minutes (91-120 minutes)
More Than 120 Minutes (More than 120
minutes)
How much did it cost the patient to travel to the
dental office today (including parking)
$0-10 ($0-10)
$11-20 ($11-20)
$21-30 ($21-30)
More Than $30 (More than $30)
Did the patient have to take time away from work
to come to the dental office to treat the
hypersensitivity
Yes
No
How much time did he/she take off (If "Yes")
0-30 Minutes (0-30 minutes)
1-2 Hours (1-2 hours)
2-3 Hours (2-3 hours)
3-4 Hours (3-4 hours)
31-60 Minutes (31-60 minutes)
More Than 4 Hours (More than 4 hours)
What is the total estimated cost for the rescue
treatment if patient was not participating in the
study
$0-50 ($0-50)
$101-150 ($101-150)
$151-200 ($151-200)
$201-250 ($201-250)
$51-100 ($51-100)
More Than $250 (More than $250)
Footer Module
Comments
3 / 3
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ANHL01P1: Institutional Pathology Form
[reload] NCT00057811
ANHL01P1: Institutional Pathology Form [reload]
NCT00057811 
Rituximab, Rasburicase, and Combination Chemotherapy
in Treating Young Patients With Newly Diagnosed
Advanced B-Cell Leukemia or Lymphoma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=BA57175F-
244D-0585-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/11291
ANHL01P1: Institutional Pathology
Form [reload] NCT00057811
Header
Name
Study Number
COG Number
Patient Name
Today's date
Date worksheet entered into RDE
Pathology evaluation
Institutional Pathologist (Name)
Institutional surgical pathology number(s) (Must
be able to accept numbers and letters)
Date sample obtained from patient (mm/dd/yyyy)
Time sample obtained (One must be chosen)
Any other time after study entry (Any
other time after study entry)
Death (Death)
Other Specify (Other)
Sample Or Specimen Collected After
Patient Received Treatment For Cancer
(Post-treatment)
Sample Or Specimen Collected Before
Patient Was Diagnosed With Cancer
(Pre-diagnosis)
Sample Or Specimen Collected Before
Patient Received Treatment For Cancer
(Pre-treatment (at study entry))
Unknown (Unknown)
please specify [time sample obtained] (Required
if #4 is chosen for time sample obtained.)
1 / 5
Method for obtaining tissue samples (Required
field)
(pleural effusion or ascites fluid ((pleural
effusion or ascites fluid)
Sample Or Specimen Collected Via
Abdominal Effusion Or Ascites
(Abdominal/ascites effusion)
Sample Or Specimen Collected Via
Pleural Effusion (Body fluid cytology)
Bone marrow aspirate (Bone marrow
aspirate)
Bone marrow biopsy (Bone marrow
biopsy)
Sample Or Specimen Collected Via
Bronchial Alveolar Lavage (Bronchial
alveolar lavage (BAL))
Sample Or Specimen Collected Via
Bronchial Brushing Or Washing
(Bronchial brushing/washing)
Cytology (Cytology)
Sample Or Specimen Collected Via Fine
Needle Aspiration (Fine needle
aspiration)
Sample Or Specimen Collected Via
Mediastinoscopy (Mediastinoscopy)
Sample Or Specimen Collected Via
Biopsy (Needle core biopsy)
Other Specify (Other, specify)
Sample Or Specimen Collected Via
Pericardial Effusion (Pericardial effusion)
Sample Or Specimen Collected Via
Pleural Lavage (Pleural lavage)
Sample Or Specimen Collected Via
Induced Sputum (Sputum, induced)
Sample Or Specimen Collected Via
Spontaneous Sputum (Sputum,
spontaneous)
Sample Or Specimen Collected Via
Biopsy (Surgical biopsy)
Source of tissue samples (Required field)
Bone Biopsy (Bone biopsy)
Bone Marrow (Bone marrow)
Cerebrospinal Fluid (Cerebrospinal fluid)
Lymph Node (Lymph node)
Other Specify (Other site of tumor,
specify below)
Peripheral Blood (Peripheral blood)
Peritoneal Fluid (Peritoneal fluid)
Pleural Fluid (Pleural effusion or ascites)
Primary tumor (Primary tumor)
Soft Tissue Mass (Soft tissue mass)
please specify source [of tissue samples]
and primary tumor site (Text field)
2 / 5
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Pathologic diagnosis (Required field)
Large Cell Lymphoma (Large cell
lymphoma)
Lymphoblastic Lymphoma
(Lymphoblastic Lymphoma)
Other Malignancy, Specify (Other
malignancy, specify ICD-O code below))
Other Non-hodgkin's Lymphoma (Other
non-Hodgkin's lymphoma)
Other Non-hodgkin's Lymphoma
Subtype, Unknown (Other non-Hodgkin's
lymphoma subtype, unknown)
Small, Non-cleaved Cell Lymphoma
(Small, non-cleaved cell lymphoma)
Unknown/not Evaluated (Unknown/Not
evaluated)
please fill in the ICD-O code of the pathologic
diagnosis (If option #4 or #6 was chosen in the
above question,)
Immunophenotype (One must be chosen)
Mixed Cells Immunophenotype (B & T
cell/Bi-phenotype)
B-cell Immunophenotype (B-cell)
Non-t/non-b Cell Immunophenotype
(Non-T/Non-B)
Not Done (Not Done)
Other Specified Immunophenotype
(Other, specify)
T-cell Immunophenotype (T-cell)
Indeterminate Immunophenotype
(Unknown)
Lymphoma Classification Diagnosis (See
Appendix ? for explanation of Diagnosis Code to
be entered - Melissa to assign appendix number)
Results From Fresh Or Frozen Tissue
Antigen Type
ALK-1 (ALK-1)
Cd2 (CD1)
Cd10 (CD10)
Cd15 (CD15)
Cd2 (CD2)
Cd20 (CD20)
CD22 (CD22)
Cd22 Intracytoplasmic (CD22
intracytoplasmic)
Cd22 Surface (CD22 surface)
Cd24 (CD24)
Cd25 (CD25)
CD3 (CD3)
Cd3 Intracytoplasmic (CD3
intracytoplasmic)
Cd3 Surface (CD3 surface)
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Cd30 (CD30)
Cd34 (CD34)
Cd4 (CD4)
Cd43 (CD43)
Cd45 (CD45 (LCA))
Cd45 (CD45RA)
Cd45 (CD45RO)
Cd5 (CD5)
CD68 (CD68)
Cd7 (CD7)
CD79a (CD79a)
Cd79a Intracytoplasmic (CD79a
intracytoplasmic)
Cd79a Surface (CD79a surface)
Cd79b Intracytoplasmic (CD79b
intracytoplasmic)
Cd79b Surface (CD79b surface)
Cd8 (CD8)
CD80 (CD80)
EBER (EBER)
EBV LMP (EBV LMP)
Glycophorin (Glycophorin)
Ig-kappa Intracytoplasmic (Ig-kappa
intracytoplasmic)
Ig-kappa Surface (Ig-kappa surface)
Ig-lambda Intracytoplasmic (Ig-lambda
intracytoplasmic)
Ig-lambda Surface (Ig-lambda surface)
Iga Surface (IgA surface)
Igd Surface (IgD surface)
Igg Surface (IgG surface)
Igm Intracytoplasmic (IgM
intracytoplasmic)
Igm Surface (IgM surface)
Kappa (Kappa)
Ki67 (Ki67)
Lactoferrin (Lactoferrin)
Lambda (Lambda)
Lung-resistance-related Or Major Vault
Protein (lrp/mvp) (Lung-resistance-
related or major vault protein
(LRP/MVP))
Lysozyme (Muramidase) (Lysozyme
(Muramidase))
Multidrug Resistance-associated Protein
(mrp) (Multidrug resistance-associated
protein (MRP))
Myeloperoxidase (Myeloperoxidase)
Other (Other)
P-glycoprotein (pgp/mdr1) (P-
glycoprotein (Pgp/MDR1))
Terminal Transferase (tdt) (TDT)
Results from paraffin embedded tissue (One
must be chosen)
Indeterminate (Equivocal)
No (Negative)
Not Done (Not done/Not evaluable)
Yes (Positive)
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TDT Method (One must be chosen)
Both (Both)
Flow Cytometry, Not Otherwise Specified
(Flow cytometry)
Flow Cytometry, 2 Color (Flow cytometry,
2 color)
Flow Cytometry, 3 Color (Flow cytometry,
3 color)
Flow Cytometry, 4 Or More Color (Flow
cytometry, 4 or more color)
Immunofluorescence
(Immunofluorescence)
Immunohistochemistry
(Immunohistochemistry)
Other Specify (Other, specify)
Unknown (Unknown)
Results From Paraffin Embedded Tissue
SLIDE/TISSUE SUBMISSION: For Central
Review? (One must be chosen)
Yes
No
Is any frozen tissue available? (One must be
chosen)
Yes
No
Fixative used (BIOPSY TISSUE PROCESSING
DETAILS)
B5 (B5)
Formalin (Formalin)
Other (Other)
Unknown (Unknown)
Zinc Formalin (Zinc Formalin)
please specify [biopsy tissue processing details,
fixative used] (Probably should accept numbers
and letters)
Number of hours in fixative before processing
Greater Than 48 Hours (>48 hours)
24 Hours Or Less (24 hours or less)
25-48 Hours (25-48 hours)
Unknown (Unknown)
Is there evidence of clonality by gene
rearrangement? (Required field)
Yes
No
Ccrr Module For Anhl01p1: Institutional
Pathology Form [reload]
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Z1041: Surgery Report (SR) NCT00513292
Z1041: Surgery Report (SR) NCT00513292
Combination Chemotherapy and Paclitaxel Plus
Trastuzumab in Treating Women With Palpable Breast
Cancer That Can Be Removed by Surgery
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=20FE940E-
EC37-2E9D-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11292
Z1041: Surgery Report (SR)
NCT00513292
Header module
Visit
Surgery (Surgery)
Patient ID (Pt. ID issued during registration or
previously issued patient ID)
Patient Initials (F M L)
Institution No.
Institution Name
Surgery assessment
Was primary breast surgery performed
Yes
No
Surgery Date (If yes,)
Reason surgery not performed
Disease Progression (Disease
progression)
Other (Other)
Patient Refusal (Patient refusal)
Other, specify
Type of procedure performed
Modified Radical Mastectomy (Modified
Radical Mastectomy)
Other (Other)
Partial Mastectomy - With Re-excision
(Partial Mastectomy with re-excision)
Partial Mastectomy Without Re-excision
(Partial Mastectomy without re-excision)
Radical Mastectomy (Radical
Mastectomy)
Other, specify
1 / 2
Pathologic Response (NOTE: Refer to Protocol
Section 7.6.2)
Not Pathologic Complete Response (Not
Pathologic Complete Response)
Pathologic Complete Response
(Pathologic Complete Response)
Gross residual tumor resected
Yes
No
Tumor Pathology (if Resected)
Longest diameter (Tumor size - cm)
cm
Margin Status (mark one)
Close (Close)
Negative (Negative)
Positive (Positive)
Histologic Grade
Well Differentiated (Grade I (low))
Moderately Differentiated (Grade II
(intermediate))
Poorly Differentiated (Grade III (high))
Completed by
Date Form Completed
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Z1041: Surgery Report (SR) NCT00513292
Z1041: Study Drug Completion -
Trastuzumab (SDCT) NCT00513292
Z1041: Study Drug Completion - Trastuzumab (SDCT)
NCT00513292
Combination Chemotherapy and Paclitaxel Plus
Trastuzumab in Treating Women With Palpable Breast
Cancer That Can Be Removed by Surgery
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=20FDDD9E-
AEC2-1D91-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11293
Z1041: Study Drug Completion -
Trastuzumab (SDCT) NCT00513292
Header Module
Visit
C8d21 (C8D21)
Mo6fu (Mo6FU)
Mo9fu (Mo9FU)
Unscheduled (Unscheduled)
Date
Patient ID (Pt. ID issued during registration or
previously issued Patient ID)
Patient Initials (F M L)
Institution No.
Institution Name
Assessment Date
Study Drug Assessment
This form was completed based on information
from
Adjuvant Period (Adjuvant period)
Neoadjuvant Period (Neoadjuvant
period)
Date of First dose for this reporting period
Date of Last dose for this reporting period
Number of weeks Trastuzumab given (this period)
Were there any dose modifications or
additions/omissions to protocol treatment?
No (No)
Yes, Planned (i.e., The Treatment Was
1 / 2
Changed According To Protocol
Guidelines) (Yes, planned)
Yes, Unplanned (i.e., The Treatment
Change Was Not Part Of Protocol
Guidelines) (Yes, unplanned)
Dose Modification Reason
Cardiotoxicity (Cardiotoxicity)
Cns Toxicity (CNS toxicity)
Gi Toxicity (GI toxicity)
Hematologic Toxicity (Hematologic
toxicity)
Hepatic Dysfunction (Hepatic
dysfunction)
Infection/fever (Infection/fever)
Other (Other)
Pulmonary Toxicity (Pulmonary toxicity)
Weight Change >= 4.5 Kg (Weight
Change >= 4.5 kg)
Other, specify
Did the patient receive RT during this reporting
period
No (No)
Unknown (Unknown)
Yes (Yes)
Did the patient receive any hormone therapy
during this reporting period?
No (No)
Unknown (Unknown)
Yes (Yes)
Completed by
Date Form Completed
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Z1041: Study Drug Completion - Trastuzumab (SDCT) NCT00513292
Z1041: Cardiac Monitoring Report (CMR)
NCT00513292
Z1041: Cardiac Monitoring Report (CMR) NCT00513292
Combination Chemotherapy and Paclitaxel Plus
Trastuzumab in Treating Women With Palpable Breast
Cancer That Can Be Removed by Surgery
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=210D4AF7-
8079-0B44-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11294
Z1041: Cardiac Monitoring Report
(CMR) NCT00513292
Header module
Visit
C4d21 (C4D21)
C8d21 (C8D21)
Date
Patient ID
Patient Initials (F M L)
Institution No.
Institution Name
Muga
Was a MUGA performed
Yes
No
MUGA date
Left Ventricular Ejection Fraction from MUGA
(LVEF)
%
MUGA LLN (for LVEF)
%
Was an ECHO performed
Yes
No
ECHO date
Left Ventricular Ejection Fraction from ECHO
(LVEF)
%
ECHO LLN (for LVEF)
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%New York Heart Association Classification
Patients With Cardiac Disease But
Without Resulting Limitation Of Physical
Activity. Ordinary Physical Activity Does
Not Cause Undue Fatigue, Palpitation,
Dyspnea Or Anginal Pain. (Class I)
Patients With Cardiac Disease Resulting
In Slight Limitation Of Physical Activity.
They Are Comfortable At Rest. Ordinary
Physical Activity Results In Fatigue,
Palpitation, Dyspnea Or Anginal Pain.
(Class II)
Patients With Cardiac Disease Resulting
In Marked Limitation Of Physical Activity.
They Are Comfortable At Rest. Less
Than Ordinary Activity Causes Fatigue,
Palpitation, Dyspnea Or Anginal Pain.
(Class III)
Patients With Cardiac Disease Resulting
In Inability To Carry On Any Physical
Activity Without Discomfort. Symptoms
Of Heart Failure Or The Anginal
Syndrome May Be Present Even At
Rest. If Any Physical Activity Is
Undertaken, Discomfort Increases.
(Class IV)
Unknown (Unknown)
Has patient taken cardiac medications since the
last reporting period
Yes
No
Was there a cardiac related death
No (No)
Yes, Definite (Yes, definite)
Yes, Probable (Yes, probable)
Completed by
Date Form Completed
Comments
Comments
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Z1041: Specimen Banking Consent Form
NCT00513292
Z1041: Specimen Banking Consent Form NCT00513292 
Combination Chemotherapy and Paclitaxel Plus
Trastuzumab in Treating Women With Palpable Breast
Cancer That Can Be Removed by Surgery
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=211E71CB-
E68F-6FF2-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11295
Z1041: Specimen Banking Consent
Form NCT00513292
Header module
Visit
Baseline (Baseline)
Patient ID (Pt. ID issued during registration or
previously issued patient ID)
Patient Initials (F M L)
Institution No.
Institution Name
Instructions
Patient's Initial Consent given for blood specimen
use for research on the patient's cancer?
Yes
No
Patient's Initial Consent given for blood specimen
use for research unrelated to the patient's
cancer?
Yes
No
Patient's Initial Consent given for tissue specimen
use for research on the patient's cancer?
Yes
No
Patient's Initial Consent given for tissue specimen
use for research unrelated to the patient's
cancer?
Yes
No
Patient's initial consent given for further contact
regarding specimen?
Yes
No
Patient's Initial Consent given for participation in
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Cancer Genome Atlas project?
Yes
No
Completed by
Date Form Completed
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Z1041: Specimen Banking Consent Form NCT00513292
NCT00134056 SOUTHWEST ONCOLOGY GROUP
S0421 TREATMENT FORM: Step 2 Post-Chemo Form
NCT00134056 SOUTHWEST ONCOLOGY GROUP S0421
TREATMENT FORM: Step 2 Post-Chemo Form
Docetaxel and Prednisone With or Without Atrasentan in
Treating Patients With Stage IV Prostate Cancer and Bone
Metastases That Did Not Respond to Previous Hormone
Therapy
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=0F9D489B-
B059-2EB5-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11296
NCT00134056 SOUTHWEST
ONCOLOGY GROUP S0421
TREATMENT FORM: Step 2 Post-
Chemo Form
Header
SWOG Patient ID
SWOG Study No.
Registration Step
Patient Initials (L, F M)
Institution/Affiliate
Physician
Participating Group Name
Participating Study No.
Participating Patient ID (Instructions: Please
complete this form after each cycle 1 cycle = 4
weeks. All dates are MONTH, DAY, YEAR.
Explain any blank dates or fields in a Comments
section. Place an X in appropriate boxes. Circle
AMENDED items in red and write AMENDED
across top of form.)
Status
Vital Status
Alive (Alive)
Dead (Dead)
Date of Last Contact or Death
Has the patient progressed per the definition in
Section 10.0 of the protocol?
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Yes
No
Treatment
Were there any dose modifications or
additions/omissions to protocol treatment?
No (No)
Yes, Planned (i.e., The Treatment Was
Changed According To Protocol
Guidelines) (Yes, planned)
Yes, Unplanned (i.e., The Treatment
Change Was Not Part Of Protocol
Guidelines) (Yes, unplanned)
Assessment of Chemotherapy
Current cycle number
Treatment start date
Date of last treatment
Arm 1 + Arm 2
Was pill taken daily (Prednisone dose)
Yes
No
If no
Comments
Comments
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TREATMENT FORM: Step 2 Post-Chemo Form
DEM
DEM
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=FF1A18C7-
58B3-19A7-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11297
DEM
Patient demographics
Name code
IBMTR IUBMID # (if already known or assigned)
Secondary race
African American (African American)
African Black (both parents born in
Africa) (African Black (both parents born
in Africa))
American Indian (not otherwise
specified) (American Indian (not
otherwise specified))
Asian (not otherwise specified) (Asian
(not otherwise specified))
Black (not otherwise specified) (Black
(not otherwise specified))
Black, other specify (Black, other specify)
Caribbean Black (Caribbean Black)
Caribbean Indian (Caribbean Indian)
Chinese (Chinese)
Eastern European (Eastern European)
European (not otherwise specified)
(European (not otherwise specified))
Filipino (pilipino) (Filipino (pilipino))
Guamanian (Guamanian)
Hawaiian (Hawaiian)
Indian/South Asian (Indian/South Asian)
Japanese (Japanese)
Korean (Korean)
Mediterranean (Mediterranean)
Native Alaskan/Eskimo/Aleut (Native
Alaskan/Eskimo/Aleut)
Native American (not otherwise
specified) (Native American (not
otherwise specified))
Native Pacific Islander (not otherwise
specified) (Native Pacific Islander (not
otherwise specified))
North American Indian (North American
Indian)
North Coast of Africa (North Coast of
Africa)
Northern European (Northern European)
Not answered (Not answered)
Other Southeast Asian (Other Southeast
Asian)
Other, specify (Other, specify)
Samoan (Samoan)
South or Central American Black (South
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or Central American Black)
South or Central American Indian (South
or Central American Indian)
South or Central American White (South
or Central American White)
Unknown (Unknown)
Vietnamese (Vietnamese)
Western European (Western European)
White (not otherwise specified) (White
(not otherwise specified))
White Caribbean (White Caribbean)
White North American (White North
American)
Gender
Female (Female)
Male (Male)
Date of Birth
Ethnicity
A Person Of Mexican, Puerto Rican,
Cuban, Central Or South American Or
Other Spanish Culture Or Origin,
Regardless Of Race. (Hispanic or Latino)
Not Provided Or Available (Not
answered)
A Person Not Meeting The Definition For
Hispanic Or Latino. (Not Hispanic or
Latino)
Could Not Be Determined Or Unsure
(Unknown)
Race
African American (African American)
African Black (both parents born in
Africa) (African Black (both parents born
in Africa))
American Indian (not otherwise
specified) (American Indian (not
otherwise specified))
Asian (not otherwise specified) (Asian
(not otherwise specified))
Black (not otherwise specified) (Black
(not otherwise specified))
Black, other specify (Black, other specify)
Caribbean Black (Caribbean Black)
Caribbean Indian (Caribbean Indian)
Chinese (Chinese)
Eastern European (Eastern European)
European (not otherwise specified)
(European (not otherwise specified))
Filipino (pilipino) (Filipino (pilipino))
Guamanian (Guamanian)
Hawaiian (Hawaiian)
Indian/South Asian (Indian/South Asian)
Japanese (Japanese)
Korean (Korean)
Mediterranean (Mediterranean)
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Native Alaskan/Eskimo/Aleut (Native
Alaskan/Eskimo/Aleut)
Native American (not otherwise
specified) (Native American (not
otherwise specified))
Native Pacific Islander (not otherwise
specified) (Native Pacific Islander (not
otherwise specified))
North American Indian (North American
Indian)
North Coast of Africa (North Coast of
Africa)
Northern European (Northern European)
Not Provided Or Available (Not
answered)
Other Southeast Asian (Other Southeast
Asian)
Other, specify (Other, specify)
Samoan (Samoan)
South or Central American Black (South
or Central American Black)
South or Central American Indian (South
or Central American Indian)
South or Central American White (South
or Central American White)
Could Not Be Determined Or Unsure
(Unknown)
Vietnamese (Vietnamese)
Western European (Western European)
White (not otherwise specified) (White
(not otherwise specified))
White Caribbean (White Caribbean)
White North American (White North
American)
Specify race
Specify race
Comments
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E2905 Leukemia Cytogenetics Report Form
NCT00843882
E2905 Leukemia Cytogenetics Report Form NCT00843882
Lenalidomide With or Without Epoetin Alfa in Treating
Patients With Myelodysplastic Syndrome and Anemia
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=0EAAE2F5-
F92E-0A7F-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11298
E2905 Leukemia Cytogenetics
Report Form NCT00843882
ECOG clinical trial administrative data
Registration Step
Patient's Name (Place ID Label Here)
ECOG Protocol Number
ECOG Protocol Number
ECOG Patient ID
ECOG Patient ID
Participating Group Protocol Number
Participating Group Patient ID
Institution/Affiliate
Leukemia Cytogenetics Evaluation
Name of Cytogeneticist
Phone Number
Date specimens collected (MM/DD/YYYY)
Is extra material stored?
No (no)
Unknown (Unknown)
Yes (yes)
Extra material type
Unstimulated short-term culture (24 - 72 hours)
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Direct preparation (metaphases)
Stimulated Culture (metaphases)
Mitogen type
Other culture method
Other culture method
Culture method and duration
Unstimulated short-term culture (24 - 72 hours)
Stimulated culture
Mitogen type
Culture method and duration
Number of karyotype preparations
Are results adequate for banded analysis?
No (no)
Unknown (Unknown)
Yes (yes)
Were FISH studies performed?
No (no)
Unknown (Unknown)
Yes (yes)
FISH probe(s), specify
Total number of interphase nuclei
Total Number of Abnormal Interphases
Total Number of Metaphases
Total Number of Metaphases
Total Number of Abnormal Metaphases
Total Number of Abnormal Metaphases
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Footer module
Complete ISCN (1995) Karyotype Description
Physician of record
Date form originally completed
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Ewing Study Medical History NCT00824083
EWING 2008, EudraCT 2008-003658-13,
http://clinicaltrials.gov/ct2/show/NCT00824083
All rights reserved. Please visit https://medical-data-
models.org/forms/11299
Anamnese Ewing Studie
NCT00824083
Allgemeine Anamnese
Anlass der Erfassung*
Tumorsymptomatik (1)
U1-U9 (2)
Zufallsbefund (3)
Syndrome/ hereditäre Grunderkrankungen
Ja
Nein
Welche*
Familiäre Krebsbelastung
Ja
Nein
Welche*
Time to diagnosis
Schmerzen*
Ja
Nein
Seit wann*
Schwellung
Ja
Nein
Seit wann*
Pathologische Fraktur*
Ja
Nein
Seit wann*
Vorbehandlung vor Diagnose*
Ja
Nein
Welche Vorbehandlung vor Diagnose
Seit wann*
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Psychoeducation_End
"Psychoedukation_Ende" converted to ODM format. Used
as a routine documentation by the university hospital
muenster.
All rights reserved. Please visit https://medical-data-
models.org/forms/11300
Psychoeducation_End
Ziel (kreuzen Sie dazu bitte zwischen 1=
gar nicht bis 5 =sehr an)
Aufklärung und Information über die Erkrankung
1 Gar nicht (1)
2 (2)
3 (3)
4 (4)
5 Sehr (5)
Auseinandersetzung mit der Krankheit
1 Gar nicht (1)
2 (2)
3 (3)
4 (4)
5 Sehr (5)
Aufklärung und Information über
Behandlungsmöglichkeiten
1 Gar nicht (1)
2 (2)
3 (3)
4 (4)
5 Sehr (5)
Kontakte knüpfen, Bekanntschaften machen
1 Gar nicht (1)
2 (2)
3 (3)
4 (4)
5 Sehr (5)
Verbesserung der Bewältigung der Erkrankung
1 Gar nicht (1)
2 (2)
3 (3)
4 (4)
5 Sehr (5)
Aktiv etwas für die Gesundheit tun
1 Gar nicht (1)
2 (2)
3 (3)
4 (4)
5 Sehr (5)
Steigerung des psychischen Wohlbefindens
1 Gar nicht (1)
2 (2)
3 (3)
4 (4)
5 Sehr (5)
In persönlichen Dingen weiterkommen
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1 Gar nicht (1)
2 (2)
3 (3)
4 (4)
5 Sehr (5)
Unterstützung von ebenfalls Betroffenen
1 Gar nicht (1)
2 (2)
3 (3)
4 (4)
5 Sehr (5)
Hilfen zur Lebensveränderung
1 Gar nicht (1)
2 (2)
3 (3)
4 (4)
5 Sehr (5)
Seelisch stabiler werden
1 Gar nicht (1)
2 (2)
3 (3)
4 (4)
5 Sehr (5)
Wiederherstellung der allgemeinen
Leistungsfähigkeit
1 Gar nicht (1)
2 (2)
3 (3)
4 (4)
5 Sehr (5)
Verbesserung des körperlichen Zustands
1 Gar nicht (1)
2 (2)
3 (3)
4 (4)
5 Sehr (5)
andere (Bitte nennen)
Aussage (kreuzen Sie dazu bitte zwischen
1= sehr unzutreffend bis  6 = sehr
zutreffend an)
Ich habe mich in der Gruppe wohlgefühlt.
Gar nicht (1)
2 (2)
3 (3)
4 (4)
5 (5)
Sehr (6)
Ich habe die Gruppe als hilfreich empfunden.
Gar nicht (1)
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2 (2)
3 (3)
4 (4)
5 (5)
Sehr (6)
Das Gruppenangebot hat mir insgesamt
geholfen.
Gar nicht (1)
2 (2)
3 (3)
4 (4)
5 (5)
Sehr (6)
Ich habe neue Einsichten gewonnen.
Gar nicht (1)
2 (2)
3 (3)
4 (4)
5 (5)
Sehr (6)
Ich bin weitergekommen.
Gar nicht (1)
2 (2)
3 (3)
4 (4)
5 (5)
Sehr (6)
Mein Vertrauen in mich ist gestärkt worden.
Gar nicht (1)
2 (2)
3 (3)
4 (4)
5 (5)
Sehr (6)
Ich kann Probleme bewältigen.
Gar nicht (1)
2 (2)
3 (3)
4 (4)
5 (5)
Sehr (6)
Ich verstehe mich selbst und kann mich
auseinandersetzen.
Gar nicht (1)
2 (2)
3 (3)
4 (4)
5 (5)
Sehr (6)
Ich fühle mich besser.
Gar nicht (1)
2 (2)
3 (3)
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4 (4)
5 (5)
Sehr (6)
Es haben mich einige Gruppenmitglieder gestört.
Gar nicht (1)
2 (2)
3 (3)
4 (4)
5 (5)
Sehr (6)
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Biobank
"Biobank MS"converted to ODM format. Used as a routine
documentation by the university hospital muenster.
All rights reserved. Please visit https://medical-data-
models.org/forms/11301
Biobank
Patienteninformationen
Name des Patienten:
Geburtsdatum:
Geschlecht:
männlich (1)
weiblich (2)
Fall-Nr.:
Aufnahme in Station:
Aufnahmedatum:
Diagnose
Akute myeloische Leukämie (AML)
Ja
Nein
Akute lymphatische Leukämie (ALL)
Ja
Nein
Chronische myeloische Leukämie (CML)
Ja
Nein
Sonstiges
Karyotyp
Gutes zytogenetisches Risiko
Ja
Nein
Hohes Risiko, andere Abberation
Ja
Nein
Hohes Risiko, komplexer Karyotyp
Ja
Nein
Intermediäres Risiko, nicht normal
Ja
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Nein
Normaler Karyotyp
Ja
Nein
Andere
Ja
Nein
Flt3-
Ja
Nein
NPM+
Ja
Nein
Unbekannt
Ja
Nein
Untersuchung
Untersuchungsdatum:
Blastenanteil (in %):
Entnommene Probe
Probennummer:
Stadium:
Beschreibung:
Material:
Lagerort
Zellzahl:
Entnommen:
Ja
Nein
Datum:
Weitere Angaben:
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Human genetics intestinal cancer
"Humangenetik Darmkrebs MS" converted to ODM format.
Used as a routine documentation by the university hospital
muenster.
All rights reserved. Please visit https://medical-data-
models.org/forms/11302
Human genetics intestinal cancer
Patienteninformationen
Name des Patienten:
Geburtsdatum:
Geschlecht:
männlich 2= weiblich (1)
Fall-Nr.:
Aufnahme in Station:
Aufnahmedatum:
Questions
Wurde bei einem erstgradig Verwandten von
Ihnen (Eltern, Geschwister oder Kinder)
Darmkrebs festgestellt?
Ja
Nein
Wurde bei Ihnen oder einem Verwandten vor dem
50. Lebensjahr Darmkrebs festgestellt?
Ja
Nein
Wurden bei Ihnen oder einem Verwandten
gleichzeitig oder nacheinander zwei
Krebserkrankungen in einem der unten
genannten Organe* festgestellt?
* Dickdarm, Dünndarm, Magen, Gebärmutter
(nicht Gebärmutterhals), Eierstöcke,
Bauchspeicheldrüse, Gallenwege,ableitende
Harnwege, Gehirn oder Talgdrüsen
Ja
Nein
Gibt es in Ihrer Familie eine Person, die an
Darmkrebs erkrankt ist und noch mindestens
einen erstgradig Verwandten (Eltern, Geschwister
oder Kinder) hat, bei dem vor dem 50.
Lebensjahr eine Krebserkrankung in einem der
unten genannten Organe* festgestellt wurde?
* Dickdarm, Dünndarm, Magen, Gebärmutter
(nicht Gebärmutterhals), Eierstöcke,
Bauchspeicheldrüse, Gallenwege, ableitende
Harnwege, Gehirn oder Talgdrüsen
Ja
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Nein
Gibt es in Ihrer Familie eine Person, die an
Darmkrebs erkrankt ist und noch mindestens
zwei weitere Verwandte hat, bei denen eine
Krebserkrankung in einem der unten genannten
Organe* festgestellt wurde?
* Dickdarm, Dünndarm, Magen, Gebärmutter
(nicht Gebärmutterhals), Eierstöcke,
Bauchspeicheldrüse, Gallenwege, ableitende
Harnwege, Gehirn oder Talgdrüsen
Ja
Nein
Wurden bei einem Familienangehörigen ein
Polyp (Adenom) im Dickdarm vor den 40.
Lebensjahr gefunden?
Ja
Nein
Wurden bei einem Familienmitglied zahlreiche
Polypen (Adenome) im Dickdarm gefunden oder
die Diagnose eines Polyposis gestellt?
Ja
Nein
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Psychoeducation_Start
"Psychoedukation_Beginn" converted to ODM format. The
form is used for routine documentation by the university
hospital muenster.
All rights reserved. Please visit https://medical-data-
models.org/forms/11303
Psychoeducation_Start
Erwartung (kreuzen Sie dazu bitte
zwischen 1= gar nicht bis 5 =sehr an)
Aufklärung und Information über die Erkrankung
1 Gar nicht (1)
2  (2)
3 (3)
4 (4)
5 Sehr (5)
Auseinandersetzung mit der Krankheit
1 Gar nicht (1)
2 (2)
3 (3)
4 (4)
5 Sehr (5)
Aufklärung und Information über
Behandlungsmöglichkeiten
1 Gar nicht (1)
2 (2)
3 (3)
4 (4)
5 Sehr (5)
Kontakte knüpfen, Bekanntschaften machen
1 Gar nicht (1)
2 (2)
3 (3)
4 (4)
5 Sehr (5)
Verbesserung der Bewältigung der Erkrankung
1 Gar nicht (1)
2 (2)
3 (3)
4 (4)
5 Sehr (5)
Aktiv etwas für die Gesundheit tun
1 Gar nicht (1)
2 (2)
3 (3)
4 (4)
5 Sehr (5)
Steigerung des psychischen Wohlbefindens
1 Gar nicht (1)
2 (2)
3 (3)
4 (4)
5 Sehr (5)
In persönlichen Dingen weiterkommen
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1 Gar nicht (1)
2 (2)
3 (3)
4 (4)
5 Sehr (5)
Unterstützung von ebenfalls Betroffenen
1 Gar nicht (1)
2 (2)
3 (3)
4 (4)
5 Sehr (5)
Hilfen zur Lebensveränderung
1 Gar nicht (1)
2 (2)
3 (3)
4 (4)
5 Sehr (5)
Seelisch stabiler werden
1 Gar nicht (1)
2 (2)
3 (3)
4 (4)
5 Sehr (5)
Wiederherstellung der allgemeinen
Leistungsfähigkeit
1 Gar nicht (1)
2 (2)
3 (3)
4 (4)
5 Sehr (5)
Verbesserung des körperlichen Zustands
1 Gar nicht (1)
2 (2)
3 (3)
4 (4)
5 Sehr (5)
andere (Bitte nennen)
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DAST Basic Documentation_Admission
Items used as routine documentation by the university
hospital muenster.
Derived from original form "DAST Aufnahme PSYCH MS",
converted to ODM format.
All rights reserved. Please visit https://medical-data-
models.org/forms/11306
DAST Basic
Documentation_Admission
Patienteninformationen
Name des Patienten:*
Geburtsdatum:*
Aufnahmedatum:
Erfassungsdatum:
Geschlecht:
Male (1)
Female (2)
Alter in Jahren:
Familienstand:
Verheiratet  (1)
Ledig (2)
Verwitwet (3)
Geschieden/ getrennt  (4)
Feste Partnerschaft (5)
Wie viele Kinder haben Sie?
Wie viele Personen leben in Ihrem Haushalt?
Bitte geben Sie folgendes ein: Anzahl Kinder,
Anzahl Erwachsene und Insgesamt.
In welchem Land sind Sie geboren
(Abstammung)?
Wenn Sie nicht in Deutschland geboren wurden,
seit wie vielen Jahren leben Sie in Deutschland?
In welchem Land sind Ihre Eltern geboren
(Abstammung)?
Höchster erreichter Schulabschluss:
ohne Abschluss (1)
Volks- /Hauptschulabschluss  (2)
Real- /Handels- /Fachoberschulreife
(Mittlere Reife) (3)
Fach- /Hochschulreife (Abitur) (4)
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Hochschul- /Fachhochschulabschluss (5)
Sonstiges (6)
Anzahl der Schuljahre: Wie viele Jahre sind Sie
insgesamt zur Schule gegangen?
Höchste(r) erreichte(r) Berufsabschluss/
Berufsausbildung:
Derzeitige berufliche Situation:
anderweitig ohne berufliche
Beschäftigung (1)
Berufstätig (1. Arbeitsmarkt)  (2)
Selbstständig  (3)
Freier Beruf (4)
Handwerker (5)
Facharbeiter/ -in (6)
Angestellte(r) (7)
Psychiatrische Erkrankungen bei Erstgrad-
Familienangehörigen? Wenn ja, bei WEM und
WELCHE (Vater, Mutter, Schwester, Bruder,
Großvater, Großmutter, Onkel, Tante, andere)
Vorbehandlungen in den letzten 8 Wochen
vor der jetzigen Aufnahme:
Keine?
Ja
Nein
Antidepressive Therapie mit (Generikum, mg/d,
Dauer in Tagen):
Elektrokonvulsionstherapie, EKT. Wenn ja,
Anzahl der Einzelstimulationen:
Schlafentzug?
Ja
Nein
Lichttherapie?
Ja
Nein
Psychotherapie: Einzeltherapiesitzungen?
Ja
Nein
Psychotherapie: Gruppentherapiesitzungen?
Ja
Nein
Sonstige:
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Psychiatrische Aufnahme-Diagnosen
(DSM-IV)
Hauptdiagnose:
Nebendiagnose(n):
Körpergröße (in cm):
Körpergewicht (in kg):
EKG bei Aufnahme, QTC-Zeit (in Sek):
Zeitpunkt der ersten depressiven Episode:
Anzahl der bisherigen depressiven Episoden:
Anzahl der bisherigen stationär- psychiatrischen
Krankenhausaufenthalte:
Clinical Global Impression (Schweregrad der
Krankheit), bitte geben Sie an, wie hoch Sie den
jetzigen Grad der
seelischen Erkrankung des Patienten für den
Zeitraum der letzten Woche einschätzen.
0 Nicht beurteilbar (1)
1 Patient ist überhaupt nicht krank. (2)
2 Patient ist ein Grenzfall psychiatrischer
Erkrankung. (3)
3 Patient ist nur leicht krank. (4)
4 Patient ist mäßig krank. (5)
5 Patient ist deutlich krank. (6)
6 Patient ist schwer krank (7)
Skala zur globalen Erfassung des
Funktionsniveaus (GAF),die Bewertung der GAF-
Skala sollte sich auf den Zeitraum der letzten
Woche vor Aufnahme beziehen.
Unzureichende Informationen. (0)
100-91 Optimale Funktion in allen
Bereichen.  (1)
10-1 Ständige Gefahr oder anhaltende
Unfähigkeit. (10)
90-81 Gute Leistungsfähigkeit auf allen
Gebieten. (2)
80-71 Höchstens leichte
Beeinträchtigungen. (3)
70-61 Leichte Beeinträchtigung. (4)
60-51 Mäßig ausgeprägte Störung. (5)
50-41 Ernsthafte Beeinträchtigung. (6)
40-31 Starke Beeinträchtigung in
mehreren Bereichen (7)
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30-21 Leistungsunfähigkeit in fast allen
Bereichen. (8)
20-11 Selbst- und Fremdgefährlichkeit.
(9)
Punktzahl:
Beurteilungsbogen bei Aufnahme
Beck-Depressions-Inventar, BDI:
Keine Angabe (1)
Liegt vor (2)
Patient/ -in ist zu krank (3)
Verweigert (4)
Sonstiges (5)
Hamilton-Skala, HAM:
Keine Angabe (1)
Liegt vor (2)
Patient/ -in ist zu krank (3)
Verweigert (4)
Sonstiges (5)
Young Mania Rating Scale, YMRS- C:
Keine Angabe (1)
Liegt vor (2)
Patient/ -in ist zu krank (3)
Verweigert (4)
Sonstiges (5)
Sonstiges:
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ECOG Leukemia Cytogenetics Report
Form - Form 365R NCT00093470
ECOG Leukemia Cytogenetics Report Form - Form 365R
NCT00093470 
Tipifarnib in Treating Patients With Acute Myeloid Leukemia
in Remission
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=DBD09A24-
987A-53C7-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/11307
ECOG Leukemia Cytogenetics
Report Form - Form 365R
NCT00093470
ECOG clinical trial administrative data
Registration Step (Place ID Label Here)
Patient Name
ECOG Protocol Number
ECOG Protocol Number
ECOG Patient ID
ECOG Patient ID
Participating Group Protocol Number
Participating Group Patient ID
Institution/Affiliate
Leukemia Cytogenetics Evaluation
Name of Cytogeneticist
Phone Number
Date specimens collected
Is extra material stored?
No (no)
Unknown (Unknown)
Yes (yes)
Extra material type
Unstimulated short-term culture (24 - 72 hours)
1 / 3
Direct preparation
Stimulated culture
Mitogen type
Other culture method
Other culture method
Culture method and duration
Unstimulated short-term culture (24 - 72 hours)
Stimulated culture
Mitogen type
Culture method and duration
Number of karyotype preparations
Are results adequate for banded analysis?
No (no)
Unknown (Unknown)
Yes (yes)
Were FISH studies performed?
No (no)
Unknown (Unknown)
Yes (yes)
FISH probes, specify
Total number of interphase nuclei
Total number of abnormal interphases
Total number of metaphases
Total number of metaphases
Total number of abnormal metaphases
Total number of abnormal metaphases
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Footer Module
Complete ISCN (1995) Karyotype Description
Physician of record
Date form originally completed
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CALGB: 90202 SPECIMEN ROUTING
FORM (SERUM) NCT00079001
CALGB: 90202 SPECIMEN ROUTING FORM (Serum)
NCT00079001
Zoledronate in Preventing Skeletal (Bone)-Related Events
in Patients Who Are Receiving Androgen Deprivation
Therapy For Prostate Cancer and Bone Metastases
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=B4605919-
9C2B-050C-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/11308
CALGB: 90202 SPECIMEN
ROUTING FORM (SERUM)
NCT00079001
CALGB clinical trial administrative data
CALGB Form
CALGB Study No
CALGB Patient ID
Amended data
Yes (Yes)
Patient?s Name
Patient Hospital Number
Main Member Institution/Adjunct
Participating Group
Participating Group Protocol No.
Participating Group Patient No.
To Be Completed By Submitting Institution
Sample No.
Date of Collection of Sample for Analysis
Does specimen accompany this form?
Yes
No
Specimen Period Collected Time
12 Months After Protocol Therapy (12
months)
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6 Months After Protocol Therapy (6
months)
At Disease Progression (At disease
progression)
Baseline (Baseline)
Specify reason
Institution Error (Institution error)
Other (Other)
Patient Refusal (Patient refusal)
Sample Lost Or Destroyed (Sample lost
or destroyed)
No specify
Biopsy and Cytology Specimens shipment
Number of tubes submitted
LabTrak sample ID
Shipment date
Responsible Person Name
Responsible Person Phone Number
LabTrak shipment ID
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CALGB: NOTIFICATION OF DEATH
[80303] NCT00088894
CALGB: NOTIFICATION OF DEATH [80303]
NCT00088894
Gemcitabine With or Without Bevacizumab in Treating
Patients With Locally Advanced or Metastatic Pancreatic
Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=D5F17800-
793F-633B-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/11309
CALGB: NOTIFICATION OF DEATH
[80303] NCT00088894
Header
CALGB Study No
CALGB Patient ID
Amended data?
Yes
No
Patient demographics
Patient's Name
Participating Group
Patient Hospital Number
Participating Group Protocol No.
Main Member Institution/Adjunct
Participating Group Patient No.
Death Assessment
Date of Death
Cause of Death (specify)
Cause of Death
Due To Second Primary Or Other
Malignancy (Due to second primary or
other malignancy)
Due To Other Cause, Specify (Not
related to protocol treatment or protocol
disease)
1 / 2
Due To This Disease (Protocol disease
related)
Due To Protocol Treatment (Protocol
treatment related)
Unknown (Unknown)
Comments
Comments
Completed by
Date Completed
2 / 2
CALGB: NOTIFICATION OF DEATH [80303] NCT00088894
CALGB: QOL ASSESSMENT SUMMARY
FORM [803030] NCT00088894
CALGB: QOL ASSESSMENT SUMMARY FORM [803030]
NCT00088894
Gemcitabine With or Without Bevacizumab in Treating
Patients With Locally Advanced or Metastatic Pancreatic
Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=D5EBCEB3-
8BEC-0795-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/11310
CALGB: QOL ASSESSMENT
SUMMARY FORM [803030]
NCT00088894
Header
CALGB Study No
CALGB Patient ID
Date Completed
Are data amended?
Yes
No
Patient demographics
Patient's Name
Participating Group
Patient Hospital Number
Participating Group Protocol No.
Main Member Institution/Adjunct
Participating Group Patient No.
Method of Evaluation
Method of assessment
Interview In Clinic/hospital (Interview in
clinic/hospital)
Mailed Questionnaire (Mailed
questionnaire)
Self-report Questionnaire Administered
In Clinic/hospital (Self-report
questionnaire administered in
clinic/hospital)
Telephone Interview (Telephone
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interview)
date questionnaire was sent to patient
Number of attempts made to contact patient by
telephone and/or mail
Language in which assessment was conducted
English (English)
French (French)
Other, Specify (Other, specify)
Spanish (Spanish)
Other, specify
Quality of life assessment
Completed (Completed)
Not Done (Not done)
Partially Completed (Partially completed)
number of QOL instrument(s) completed
indicate reasons(s) below (If the assessment was
partially completed or not done,)
Assessments Discontinued Due To
Disease Progression Or Relapse, Per
Protocol (Assessments discontinued due
to disease progression or relapse, per
protocol)
Interviewer Forgot To Call Patient Or Mail
Questionnaire (Interviewer forgot to call
patient or mail questionnaire)
Other, Specify (Other, specify)
Patient Died (Patient died)
Patient Does Not Receive Questionnaire
Or Repeatedly Loses Questionnaire And
Does Not Wish To Be Interviewed By
Telephone (Patient does not receive
questionnaire or repeatedly loses
questionnaire and does not wish to be
interviewed by telephone)
Patient Does Not Speak Language In
Which Instruments Are Available (Patient
does not speak language in which
instruments are available)
Patient Does Not Understand Questions
(Patient does not understand questions)
Patient Refuses (Patient refuses)
Patient Repeatedly Cancels Interview
Due To Non-medical Reasons (Patient
repeatedly cancels interview due to non-
medical reasons)
Patient Too Medically Ill (Patient too
medically ill)
Unable To Locate Patient (Unable to
locate patient)
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Unable To Successfully Reach Patient
(Unable to successfully reach patient)
Other, specify
Footer module
Interviewer OR CRA
Assessment Number
Comments
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NCT00088894
CALGB: CHANGES IN FUNCTION FORM
[80303] NCT00088894
CALGB: CHANGES IN FUNCTION FORM [80303]
NCT00088894
Gemcitabine With or Without Bevacizumab in Treating
Patients With Locally Advanced or Metastatic Pancreatic
Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=D6000337-
794D-6FBE-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/11311
CALGB: CHANGES IN FUNCTION
FORM [80303] NCT00088894
Header
CALGB Study No
CALGB Patient ID
Date Completed
Amended data?
Yes
No
Patient demographics
Patient's Name
Participating Group
Patient Hospital Number
Participating Group Protocol No.
Main Member Institution/Adjunct
Participating Group Patient No.
CHANGES IN FUNCTION
Has your physical condition gotten
A Little Better (a little better)
A Little Worse (a little worse)
About The Same (about the same)
Moderately Better (moderately better)
Moderately Worse (moderately worse)
Very Much Better (very much better)
Very Much Worse (very much worse)
Has your emotional state gotten
1 / 2
A Little Better (a little better)
A Little Worse (a little worse)
About The Same (about the same)
Moderately Better (moderately better)
Moderately Worse (moderately worse)
Very Much Better (very much better)
Very Much Worse (very much worse)
Has your ability to enjoy your social life gotten
A Little Better (a little better)
A Little Worse (a little worse)
About The Same (about the same)
Moderately Better (moderately better)
Moderately Worse (moderately worse)
Very Much Better (very much better)
Very Much Worse (very much worse)
Has your overall quality of life gotten
A Little Better (a little better)
A Little Worse (a little worse)
About The Same (about the same)
Moderately Better (moderately better)
Moderately Worse (moderately worse)
Very Much Better (very much better)
Very Much Worse (very much worse)
Footer module
Interviewer or CRA
Assessment Number
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Southwest Oncology Group Registration
Form (17418) NCT00020709
Southwest Oncology Group Registration Form (17418)
NCT00020709
S0023: Combination Chemo Plus RT With or Without
Gefitinib in Treating Patients With Unresectable Stage III
NSCLC
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=9CA62D43-
4B63-361C-E034-080020C9C0E0
All rights reserved. Please visit https://medical-data-
models.org/forms/11312
Southwest Oncology Group
Registration Form (17418)
NCT00020709
SWOG clinical trial administrative data
SWOG Study No.
Registration Step
Treatment Arm Number
Activation Date
Last Amended Date
Patient's Name
SWOG Patient ID
Other Group Identifier Code
Ctsu (9976)
P9977_acosog2004790 (9977)
9977 - ACOSOG (9977 - ACOSOG)
Epp (9979)
P9981_ncic2004791 (9981)
9981 - NCIC (9981 - NCIC)
P9982_calgb2004792 (9982)
9982 - CALGB (9982 - CALGB)
Nsabp (9983)
P9984_gog2004793 (9984)
9984 - GOG (9984 - GOG)
P9987_mdacc2004794 (9987)
9987 - MDACC (9987 - MDACC)
P9995_ecog2004795 (9995)
9995 - ECOG (9995 - ECOG)
P9996_ncctg2004796 (9996)
9996 - NCCTG (9996 - NCCTG)
P9997_rtog2004797 (9997)
9997 - RTOG (9997 - RTOG)
Protocol Participating Identifier Number
Caller's SWOG Roster ID
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IRB Approval Date
Projected Start Date of Treatment
Date Informed Consent Signed
SWOG Investigator Number
Other Group Investigator Name
Other Group Investigator Number
SWOG Treating Institution Number
Other Group Treating Institution Name
Other Group Treating Institution Number
Protocol Privacy Approved Date
Radiology Lab Identifier Number
RT Physician
Treating Institution CTEP Code
RT Facility
Patient demographics
Patient's Social Security Number (If a U.S.
resident)
Gender
Female (FEMALE)
Male (MALE)
Unknown (UNKNOWN)
Method of Payment
Medicaid (Medicaid)
Medicaid And Medicare (Medicaid and
Medicare)
Medicare (Medicare)
Medicare And Private Insurance
(Medicare and Private Insurance)
Military Or Veterans Sponsored Nos
(Military or Veterans Sponsored NOS)
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Military Sponsored (including Champus
& Tricare) (Military Sponsored (including
CHAMPUS & TRICARE))
No Means Of Payment (no Insurance)
(No means of payment (no insurance))
Other (Other)
Private Insurance (Private Insurance)
Self Pay (no Insurance) (Self Pay (No
Insurance))
Unknown (Unknown)
Veterans Sponsored (Veterans
Sponsored)
Patient's Ethnicity
No (not Spanish) (No (not Spanish))
Unknown (Unknown)
Yes, Central American (Yes, Central
American)
Yes, Cuban (Yes, Cuban)
Yes, Mexican (Yes, Mexican)
Yes, Nos (Yes, NOS)
Yes, Other (Yes, Other)
Yes, Puerto Rican (Yes, Puerto Rican)
Yes, South American (Yes, South
American)
Race
A Person Having Origins In Any Of The
Original Peoples Of North And South
America (including Central America),
And Who Maintains Tribal Affiliation Or
Community Attachment (American Indian
or Alaska Native)
A Person Having Origins In Any Of The
Original Peoples Of The Far East,
Southeast Asia, Or The Indian
Subcontinent Including, For Example,
Cambodia, China, India, Japan, Korea,
Malaysia, Pakistan, The Philippine
Islands, Thailand, And Vietnam. (Asian)
A Person Having Origins In Any Of The
Black Racial Groups Of Africa. Terms
Such As "haitian" Or "negro" Can Be
Used In Addition To "black Or African
American." (Black or African American)
A Person Having Origins In Any Of The
Original Peoples Of Hawaii, Guam,
Samoa, Or Other Pacific Islands (Native
Hawaiian or other Pacific Islander)
Patient Refused Or Data Not Available
(Not Reported)
Patient Is Unsure Of Their Race
(Unknown)
A Person Having Origins In Any Of The
Original Peoples Of Europe, The Middle
East, Or North Africa. (White)
Patient's ZIP Code (If a U.S. resident)
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Country of Residence, if not USA (if not USA)
Social Insurance Number (If a resident of
Canada)
Patient's Date of Birth
Postal Code (If a resident of Canada)
NCI Investigator Number
Patient Consent For Specimen Use
My tissue and blood may be kept for use in
research to learn about, prevent, treat, or cure
cancer
No (No)
No (No)
Yes (Yes)
Yes (Yes)
My tissue and blood may be kept for research
about other health problems (for example: causes
of diabetes, Alzheimer's disease, and heart
disease)
No (No)
No (No)
Yes (Yes)
Yes (Yes)
Someone from the Southwest Oncology Group
may contact me in the future to ask me to take
part in more research
No (No)
No (No)
Yes (Yes)
Yes (Yes)
Notes
Notes
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NSABP PROTOCOL R-04:
REGISTRATION FORM NCT00058474
NSABP PROTOCOL R-04: REGISTRATION FORM
NCT00058474
Radiation Therapy and Either Capecitabine or Fluorouracil
With or Without Oxaliplatin Before Surgery in Treating
Patients With Resectable Rectal Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=B7825AE7-
F18A-259D-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/11313
NSABP PROTOCOL R-04:
REGISTRATION FORM
NCT00058474
Ccrr Module For Nsabp Protocol R-04:
Registration Form
NSABP Patient ID
Patient Medical Record Number
Institution Name
Institution Number
Affiliate Name
Physician of Record (physician to whom
subsequent bottles will be sent must have a valid
FDA Number)
Date Informed Consent Signed (Month Day Year)
Person Completing Form, Last Name
Person Completing Form, Last Name
Person Completing Form, First Name
Person Completing Form, Phone
Person Completing Form, Fax
Last
First
Middle
1 / 9
Patient Birth Date (Month Day Year)
Patient Social Security Number (USA only)
Race Categories (more than one may be marked)
A Person Having Origins In Any Of The
Original Peoples Of North And South
America (including Central America),
And Who Maintains Tribal Affiliation Or
Community Attachment (American Indian
or Alaska Native)
A Person Having Origins In Any Of The
Original Peoples Of The Far East,
Southeast Asia, Or The Indian
Subcontinent Including, For Example,
Cambodia, China, India, Japan, Korea,
Malaysia, Pakistan, The Philippine
Islands, Thailand, And Vietnam. (Asian)
A Person Having Origins In Any Of The
Black Racial Groups Of Africa. Terms
Such As "haitian" Or "negro" Can Be
Used In Addition To "black Or African
American." (Black)
A Person Having Origins In Any Of The
Original Peoples Of Hawaii, Guam,
Samoa, Or Other Pacific Islands (Native
Hawaiian or Other Pacific Islander)
Patient Is Unsure Of Their Race
(Unknown)
A Person Having Origins In Any Of The
Original Peoples Of Europe, The Middle
East, Or North Africa. (White)
Method of Payment (mark primary method only)
Medicaid (Medicaid)
Medicaid And Medicare (Medicaid &
Medicare)
Medicare (Medicare)
Medicare And Private Insurance
(Medicare & Private)
Military Or Veterans Sponsored Nos
(Military or Veterans Sponsored NOS)
Military Sponsored (including Champus
& Tricare) (Military Sponsored)
No Means Of Payment (no Insurance)
(No means of payment)
Other (Other)
Private Insurance (Private Insurance)
Self Pay (no Insurance) (Self pay)
Unknown (Unknown)
Veterans Sponsored (Veterans
Sponsored)
Ethnicity
A Person Of Mexican, Puerto Rican,
Cuban, Central Or South American Or
Other Spanish Culture Or Origin,
Regardless Of Race (Hispanic or Latino)
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A Person Not Meeting The Definition For
Hispanic Or Latino. (Non-Hispanic)
Patient Is Unsure Of Their Ethnicity
(Unknown)
Other
Other
Patient's Zip Code (USA)
Performance Status
Ambulatory and capable of all selfcare
but unable to carry out any work
activities (Ambulatory and capable of all
selfcare but unable to carry out any work
activities)
Capable of only limited selfcare, confined
to bed or chair more than 50% of waking
hours (Capable of only limited selfcare,
confined to bed or chair more than 50%
of waking hours)
Completely disabled (Completely
disabled)
Fully active, able to carry on all pre-
disease performance without restriction
(Fully active, able to carry on all pre-
disease performance without restriction)
Restricted in physically strenous activity
but ambulatory (Restricted in physically
strenous activity but ambulatory)
Patient Height
cm
Patient Weight
Kg
Patient Gender
Female Gender (FEMALE)
Male Gender (MALE)
In the opinion of the investigator, is the patient
eligible?
Yes
No
Certificiation Of Eligibility
Date
Date
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Date
Date
Date
Date
Method of Evaluation (or)
Proctoscopy/sigmoidoscopy
(Proctoscopy/sigmoidoscopy)
Method of Evaluation (or)
Proctoscopy/sigmoidoscopy
(Proctoscopy/sigmoidoscopy)
Method of Evaluation (or)
Proctoscopy/sigmoidoscopy
(Proctoscopy/sigmoidoscopy)
Method of Evaluation (or)
Proctoscopy/sigmoidoscopy
(Proctoscopy/sigmoidoscopy)
Method of Evaluation (or)
Proctoscopy/sigmoidoscopy
(Proctoscopy/sigmoidoscopy)
Method of Evaluation (or)
Proctoscopy/sigmoidoscopy
(Proctoscopy/sigmoidoscopy)
Result
Negative (negative)
Positive (Positive)
Suspicious (Suspicious)
Result
Negative (negative)
Positive (Positive)
Suspicious (Suspicious)
Result
Negative (negative)
Positive (Positive)
Suspicious (Suspicious)
Staging Of Primary Tumor
Procedure Used to Definitively Stage Primary
Tumor
Ct/combined Pet/ct (CT/Combined
PET/CT)
Magnetic Resonance Imaging (MRI)
Ultrasound (Ultrasound)
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Date
Quality Of Life
Did the patient complete the Quality of Life
baseline form?
Yes
No
If the baseline QOL form was not completed,
indicate the reason below.
Other Reason (Other reason)
Patient Does Not Speak English, French,
Or Spanish (Patient does not speak
English, French, or Spanish)
Patient Refused (Patient refused)
Other reason, specify
Hematologies
Date of Hematologies (Year Day Month)
Hemoglobin (g/dL)
g/dL
Platelets (thsnd/mm?)
ANC (AGC/ - thsnd/mm^3)
Chemistries
Date
Total Bilirubin (mg/dL)
Bilirubin ULN
Alkaline Phosphatase
Alkaline Phosphatase ULN
AST (SGOT)
SGOT (AST) ULN
Creatinine
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mg/dL
Creatinine ULN
mg/dL
Creatinine Clearance (Calculated)
Are there multiple rectal tumors?
Yes
No
Is the tumor fixed to surrounding structures?
No (No)
Yes (Yes, Specify)
Yes, specify
Tumor Extension
Clinical T Stage
No Evidence Of Primary Tumor (T0)
Tumor Invades Submucosa (T1)
Tumor Invades Muscularis Propria (T2)
Tumor Invades Through The Muscularis
Propria Into The Subserosa, Or Into
Nonperitonealized Pericolic Or Perirectal
Tissues (T3)
Tumor Directly Invades Other Organs Or
Structures, And/or Perforates Visceral
Peritoneum (T4)
Carcinoma In Situ: Intraepithelial Or
Invasion Of Lamina Propria (Tis)
Primary Tumor Cannot Be Assessed
(TX)
Regional Lymph Nodes (Evidence of positive >=
1.0 cm)
Yes
No
Intended Operative Procedure
Non-sphincter Saving Surgery (NON-
SPHINCTER SAVING SURGERY)
Sphincter Saving Surgery (SPHINCTER
SAVING SURGERY)
Biopsy specimen
Did the patient have a previous biopsy sample
collected in RNAlater
Yes
No
I agree to undergo an additional biopsy so that a
sample of my tumor can be collected in RNAlater
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solution and sent to the NSABP (If no, then how
did the patient answer the following question from
the consent form:)
Yes
No
I agree to let my doctor release the coded link to
my R-04 study identification number so my
biopsy sample that was collected in RNAlater
may be used in the R-04 study (If yes, then how
did the patient answer the following question from
the consent form:)
Yes
No
Code (If yes, provide)
Your blood and tissue samples may be kept by
the NSABP for use in future research to learn
about, prevent, detect, or treat cancer (My)
Yes
No
I agree to allow my study doctor, or someone
approved by my study doctor, to contact me
regard future research involving my participation
in this study (My study doctor or someone he or
she chooses may contact me in the future to ask
me to take part in more research)
Yes
No
Eligibility Checklist (This is not a complete list of
the eligibility criteria. Please see protocol.)
Does The Patient Have A Tumor That Is
Clinically Stage Ii Or Iii And A Diagnosis
Of Adenocarcinoma Of The Rectum
Obtained By A Biopsy Technique Which
Leaves The Major Portion Of The Tumor
Intact (Does the patient have a tumor
that is clinically Stage II or III and a
diagnosis of adenocarcinoma of the
rectum obtained by a biopsy technique
which leaves the major portion of the
tumor intact)
Does The Patient Have Clinically
Significant Peripheral Neuropathy At The
Time Of Randomization (defined In The
Ctcae V3.0 As Grade 2 Or Greater
Neurosensory Or Neuromotor Toxicity)
(Does the patient have clinically
significant peripheral neuropathy at the
time of randomization (defined in the
CTCAE v3.0 as grade 2 or greater
neurosensory or neuromotor toxicity))
Does The Patient Have Ischemic Heart
Disease (class Iii Or Class Iv Myocardial
Disease - New York Heart Association),
Uncontrolled Hypertension, Symptomatic
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Arrhythmia Or A History Of Myocardial
Infarction Within The Past 6 Months
(Does the patient have ischemic heart
disease (class III or class IV myocardial
disease - New York Heart Association),
uncontrolled hypertension, symptomatic
arrhythmia or a history of myocardial
infarction within the past 6 months)
Does The Patient Have Psychiatric Or
Addictive Disorders That Would Preclude
Obtaining Informed Consent (Does the
patient have psychiatric or addictive
disorders that would preclude obtaining
informed consent)
Does The Patient Have Synchronous
Colon Cancer (Does the patient have
synchronous colon cancer)
Does The Patient Meet All Other
Eligibility Criteria (Does the patient meet
all other eligibility criteria)
Does The Surgeon Consider The Tumor
To Be Amenable To Curative Resection
(Does the surgeon consider the tumor to
be amenable to curative resection)
Has The Patient Authorized The Release
Of Protected Health Information To The
Nsabp (Has the patient authorized the
release of Protected Health Information
to the NSABP)
Has The Patient Consented To
Participate In This Study And Signed
And Dated An Approved Consent Form
(Has the patient consented to participate
in this study and signed and dated an
approved consent form)
Has The Patient Had A Prior Invasive
Rectal Malignancy (regardless Of The
Disease-free Interval) (Has the patient
had a prior invasive rectal malignancy
(regardless of the disease-free interval))
Has The Patient Had Any Prior
Malignancies In The Past 5 Years Other
Than Squamous Or Basal Cell
Carcinoma Of The Skin, Melanoma In
Situ, Carcinoma In Situ Of The Cervix ,
Or Carcinoma In Situ Of The Colon Or
Rectum That Have Been Effectively
Treated (Has the patient had any prior
malignancies in the past 5 years other
than squamous or basal cell carcinoma
of the skin, melanoma in situ, carcinoma
in situ of the cervix , or carcinoma in situ
of the colon or rectum that have been
effectively treated)
Has The Patient Received Any Therapy
For This Cancer Prior To Randomization
Or Had Prior Pelvic Radiation For Any
Reason (Has the patient received any
therapy for this cancer prior to
randomization or had prior pelvic
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radiation for any reason)
Is The Distal Border Of The Tumor
Located Less Than 12 Cm From The
Anal Verge (Is the distal border of the
tumor located less than 12 cm from the
anal verge)
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ANHL01P1: Specimen Transmittal Form
NCT00057811
ANHL01P1: Specimen Transmittal Form NCT00057811 
Rituximab, Rasburicase, and Combination Chemotherapy
in Treating Young Patients With Newly Diagnosed
Advanced B-Cell Leukemia or Lymphoma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=B9F4AC9E-
7F52-271D-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/11315
ANHL01P1: Specimen Transmittal
Form NCT00057811
Header
Institution Name (Display Only)
Institution Personnel
Institution Patient Identifier
Today's date
Date worksheet entered into RDE
Specimen Information
COG Accession # (Display Only)
Birth Date (Display Only)
Institution Code (Display Only)
Lead CRA (Display Only)
and phone number [Treating Physician] (Display
Only)
Treating Physician (Display Only)
Tentative Diagnosis (Display Only)
PCHTN Registration # (Call 1-800-347-2486 to
obtain a registration number)
Medical Record # (Text)
Specimen Time Point (1. Required)
Diagnosis (Diagnosis)
1 / 2
Other (Other)
Other Specify (Other, specify)
Sample Or Specimen Collected After
Patient Received Treatment For Cancer
(Post-treatment)
Sample Or Specimen Collected Before
Patient Was Diagnosed With Cancer
(Pre-diagnosis)
Sample Or Specimen Collected Before
Patient Received Treatment For Cancer
(Pre-treatment)
Relapse (Relapse)
Unknown (Unknown)
Date Sent to PCHTN (MM/DD/YYYY)
Courier Name (Default FedEx)
Courier Number (PCHTN: 1290-2562-0)
Courier Tracking Number
Comments (1. Text V2000)
Specimen Type (Pick one.)
Bone Marrow (aspirate Smear) (Bone
marrow (aspirate smear))
Bone Marrow (biopsy Section) (Bone
Marrow (biopsy section))
Cytology Slides (stained) (Cytology
Slides (stained))
Cytology Slides (unstained) (Cytology
Slides (unstained))
Paraffin Blocks (Paraffin Blocks)
Peripheral Blood Smear Slide (Peripheral
blood smear slide)
Stained Slides (Stained Slides)
Unstained Slides (Unstained Slides)
Peripheral Blood Smear Slide (# of Specimens)
Specimen Pathology ID # (SPID)
Date Specimen Obtained (MM/DD/YYYY)
Ccrr Module For Anhl01p1: Specimen
Transmittal Form
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GOG-0240: Fast Fact Sheet for Protocol
0240 (Cervix) NCT00803062
GOG-0240: Fast Fact Sheet for Protocol 0240 (Cervix)
NCT00803062
Paclitaxel and Cisplatin or Topotecan With or Without
Bevacizumab in Treating Patients With Stage IVB,
Recurrent, or Persistent Cervical Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=79B3F748-
B0A4-3597-E040-BB89AD433B56
All rights reserved. Please visit https://medical-data-
models.org/forms/11316
GOG-0240: Fast Fact Sheet for
Protocol 0240 (Cervix)
NCT00803062
Patient demographics
Patient Name, Last
Patient Name, First
Patient Name, Middle
Patient Social Security Number
GOG Institution Code
GOG Affiliate Code
Previous GOG #
Treating physician
Other Physician
Patient Hospital No.
Date of Birth
Patient Zip Code
Country
Race
A Person Having Origins In Any Of The
Original Peoples Of North And South
America (including Central America),
And Who Maintains Tribal Affiliation Or
Community Attachment. (American
Indian or Alaska Native)
A Person Having Origins In Any Of The
Original Peoples Of The Far East,
Southeast Asia, Or The Indian
1 / 9
Subcontinent Including, For Example,
Cambodia, China, India, Japan, Korea,
Malaysia, Pakistan, The Philippine
Islands, Thailand, And Vietnam. (Asian)
A Person Having Origins In Any Of The
Black Racial Groups Of Africa. Terms
Such As "haitian" Or "negro" Can Be
Used In Addition To "black Or African
American." (Black or African American)
A Person Having Origins In Any Of The
Original Peoples Of Hawaii, Guam,
Samoa, Or Other Pacific Islands. (Native
Hawaiian or other Pacific Islander)
Could Not Be Determined Or Unsure
(Unknown)
A Person Having Origins In Any Of The
Original Peoples Of Europe, The Middle
East, Or North Africa. (White)
Ethnicity
A Person Of Mexican, Puerto Rican,
Cuban, Central Or South American Or
Other Spanish Culture Or Origin,
Regardless Of Race. (Hispanic or Latino)
A Person Not Meeting The Definition For
Hispanic Or Latino. (Not Hispanic or
Latino)
Could Not Be Determined Or Unsure
(Unknown)
Method of Payment
Medicaid (Medicaid)
Medicaid And Medicare (Medicaid and
Medicare)
Medicare (Medicare)
Medicare And Private Insurance
(Medicare and Private Insurance)
Military Or Veterans Sponsored Nos
(Military or Veterans Sponsored, Not
Otherwise Specified (NOS))
Military Sponsored (including Champus
& Tricare) (Military Sponsored (including
CHAMPUS & TRICARE))
No Means Of Payment (no Insurance)
(No means of payment (no insurance))
Other (Other)
Private Insurance (Private Insurance)
Self Pay (no Insurance) (Self Pay (No
Insurance))
Unknown (Unknown)
Veterans Sponsored (Veterans
Sponsored)
Miscellaneous Patient Information
Did the patient sign an approved informed
consent
Yes
No
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Has HIPAA authorization been obtained
Yes
No
What is the primary disease site
Cervix (Cervix)
What is the cell type
Adenocarcinoma (Adenocarcinoma)
Adenosquamous (Adenosquamous
carcinoma)
Squamous Cell Carcinoma (Squamous
cell carcinoma)
What was the grade of the primary tumor
Grade 1-well Differentiated (1)
Grade 2-moderately Differentiated (2)
Grade 3-poorly Differentiated (3)
Date primary confirmed
Select statement that most appropriately
describes the status of the disease
Persistent Disease, Post 1st Line
Therapy (Persistent disease, post 1st line
therapy)
Recurrent Disease (Recurrent Disease)
Stage Ivb Cervical Cancer (Stage IVB)
How was the Stage IV disease, recurrence or
persistence confirmed
Biopsy (Biopsy)
Ct Scan (CT scan)
Mri (MRI (NMR))
Palpation (Palpation)
X-ray (Plain X-Ray)
Spiral Ct (Spiral CT)
Date confirmed recurrent or persistent
Performance Status
Fully Active, Able To Carry On All Pre-
disease Performance Without
Restriction. (0)
Restricted In Physically Strenuous
Activity But Ambulatory And Able To
Carry Out Work Of A Light Or Sedentary
Nature, E.g., Light Housework, Office
Work. (1)
Does the patient have measurable disease
defined as at least one lesion that can be
accurately measured in at least one dimension
Yes
No
Is the measurable disease >= 20 mm when
measured by conventional techniques, including
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palpation, plain X-ray, CT and MRI or >=10mm
when measured by spiral CT
Yes
No
What method of evaluation is used to obtain
tumor measurements
Ct Scan (CT scan)
Mri (MRI (NMR))
Palpation (Palpation)
X-ray (Plain X-Ray)
Spiral Ct (Spiral CT)
What additional method of evaluation is used to
obtain tumor measurements (if any)
Computed Tomography (CT Scan)
Magnetic Resonance Imaging (MRI)
No Additional Method (No Additional
Method)
Palpation (Palpation)
X-ray (Plain X-Ray)
Spiral Ct (Spiral CT)
If measurable lesion is less than 30 mm or if
treating physician determines it to be clinically
indicated, has a confirmatory biopsy been done
No (No)
Not Applicable (Not Applicable)
Yes (Yes)
Does the patient have at least one target lesion to
be used to assess response on this protocol as
defined by RECIST
Yes
No
Is the measurable disease in a previously
irradiated field
Yes
No
Does the patient have disease in an irradiated
field as the only site of measurable disease (If
yes,)
No (No)
Not Applicable (Not Applicable)
Yes (Yes)
Has progression been documented or a biopsy
obtained to confirm persistent disease at least 90
days following completion of radiation treatment
(If yes,)
No (No)
Not Applicable (Not Applicable)
Yes (Yes)
Has the patient recovered from the effects of
recent surgery, radiotherapy or chemo-
radiotherapy
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No (No)
No Prior Rx (No prior Rx)
Yes (Yes)
If the patient received radiation therapy alone,
have at least 3 weeks elapsed since the last
treatment day
No Rt Alone (No Rt alone)
Not Applicable (Not Applicable)
Yes (Yes)
If the patient had a major surgical procedure,
have at least 6 weeks elapsed from the time of
the procedure
No Surgery (No surgery)
Not Applicable (Not Applicable)
Yes (Yes)
If the patient received chemo-radiation, have at
least 6 weeks elapsed since the last administered
of chemo-radiotherapy
No Chemo-rt (No chemo-RT)
Not Applicable (Not Applicable)
Yes (Yes)
Did the patient receive prior platinum therapy as
a radiation sensitizer
Yes
No
List chemotherapy drugs used
Date last administered
Has the patient received concurrent paclitaxel
and/or concurrent topotecan with radiation
No (No)
Not Applicable (Not Applicable)
Yes (Yes)
Are any of the target lesions in a previously
irradiated field
Yes
No
Will the patient have the following paramenters
measured within 14 days prior to initiating
protocol therapy (CBC, Differential, Platelets,
Serum Creatinine, Urinanalysis, Bilirubin, DGOT,
Alkaline Phosphatase, Electrolytes, BUN,
Calcium, Magnesium, Phosphate and Albumin)
Yes
No
Will the patient have the following parameters
measured within 28 days prior to initiating
protocol therapy (History and Physical Exam,
Toxicity Assessment, CA-125, Imaging of chest,
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pelvis and abdomen, EKG and Tumor
Measurements radiographic or clinical)
Yes
No
Is the patient free of active infection requiring
antibiotics
Yes
No
Has the patient completed a baseline Quality of
Life assessment and Smoking Questionnaire
Yes
No
Is the patient's cancer amenable to curative
treatment with surgery or radiation therapy
Yes
No
Does the patient have craniospinal metastasis
Yes
No
Does the patient have bilateral hydronephrosis
which cannot be alleviated by stenting or
percutaneous drainage
Yes
No
If the patient has had a prior invasive malignancy
(except non-melanoma skin cancer), has she had
any evidence of disease within the last 5 years or
does the prior malignancy treatment
contraindicate the current protocol therapy
No (No)
No Prior Malignant Neoplasm (No prior
malignancy)
Yes (Yes)
Does patient have a concomitant malignancy
other than non-melanoma skin cancer
Yes
No
Has the patient received a trial of chemotherapy
that was not in combination with radiation therapy
Yes
No
Does the patient have a serious non-healing
wound, ulcer, or bone fracture
Yes
No
Does the patient have active bleeding or
pathologic conditions that carry high risk of
bleeding such as known bleeding disorder,
coagulopathy or tumor involving major vessels
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Yes
No
Does the patient have a history or evidence upon
physical examination of CNS disease, including
primary brain tumor, seizures not controlled with
standard medical therapy, any brain metastases,
or history of cerebrovascular accident (CVA,
stroke), transient ischemic attack (TIA) or
subarachnoid hemorrhage within six months of
the first date of treatment on this study
Yes
No
Does the patient have uncontrolled hypertension
defined as systolic pressure greater than 150mm
Hg or diastolic greater than 90mm Hg
Yes
No
Has the patient had unstable angina or a
myocardial infarction within the past six months
Yes
No
Does the patient have New York Heart
Association Grade II or greater congestive heart
failure
Yes
No
Does the patient have serious cardiac arrhythmia
requiring medication
Yes
No
Does the patient have CTCAE Grade 2 or greater
peripheral vascular disease
Yes
No
Does the patient have pre-existing Grade 2 or
greater peripheral neuropathy
Yes
No
Does the patient have a history of CVA within the
last six months
Yes
No
Does the patient have known hypersensitivity to
Chinese hamster ovary cell products or other
recombinant human or humanized antibodies
Yes
No
Has the patient had a major surgical procedure,
open biopsy or significant traumatic injury within
28 days prior to the first date of Bevacizumab
therapy
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Yes
No
Is a major surgical procedure anticipated for this
patient during the course of this study
Yes
No
Has the patient had a core biopsy within 7 days
prior to randomization
Yes
No
Is the patient pregnant or nursing
Yes
No
If patient is of childbearing potential, has she
agreed to use contraceptive measures during
study therapy and for at least 6 months after
completion of Bevacizumab therapy
No (No)
Not Applicable (Not Applicable)
Yes (Yes)
Has the patient received prior therapy with any
anti-VEGF drug, including Bevacizumab
Yes
No
Does the patient have clinical symptoms or signs
of gastrointestinal obstruction and require
parenteral hydration and/or nutrition
Yes
No
Does the patient have a medical history or
condition not otherwise previously specified
which in the opinion of the investigator should
exclude her from participating in this study
Yes
No
Anticipated date treatment will start
Lab Results
Date of Results (if more than one, enter earliest)
ANC (must be 1,500/mcl or greater)
Platelets (must be 100,000/mcl or greater)
1000/uL
Is the Serum Creatinine less than or equal to
ULN (CTCAE v3.0 Grade 1)
8 / 9
GOG-0240: Fast Fact Sheet for Protocol 0240 (Cervix) NCT00803062
Yes
No
Calculated creatinine clearance
Is the bilirubin less than or equal to 1.5 X ULN
(CTCAE v3.0 Grade 1)
Yes
No
Are SGOT and Alkaline Phosphatase less than or
equal to 2.5 times institutional ULN
Yes
No
Is the PT INR less than or equal to 1.5 (or an in-
range INR, usually between 2 and 3, if a patient
is on a stable dose of therapeutic warfarin) and
the PTT less than 1.2 times the Upper Limit of
Normal
Yes
No
Does the patient have a urine protein-to-
creatinine ratio (UPCR) less than 1.0 mg/dL
Yes
No
Comments
Provide comments about this Fast Fact Sheet
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DAST Basic Documentation_Discharge
Items used as routine documentation by the university
hospital muenster.
Derived from original form "DAST Entlassung PSYCH MS",
converted to ODM format.
All rights reserved. Please visit https://medical-data-
models.org/forms/11319
DAST Basic
Documentation_Discharge
Patienteninformationen
Name des Patienten:*
Geburtsdatum:*
Aufnahmedatum:
Erfassungsdatum:
Somatische Therapien
Medikamentöse Therapie:
Ja
Nein
Elektrokonvulsionstherapie:
Ja
Nein
Schlafentzug:
Ja
Nein
Lichttherapie:
Ja
Nein
Keine:
Ja
Nein
Sonstige:
Ja
Nein
Psychotherapiesitzungen
Keine:
Ja
Nein
Anzahl der Einzeltermine ( <30 min Dauer):
Anzahl der Einzeltermine ( >30 min Dauer):
Gruppentermine:
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Psychotherapeutisches Hauptverfahren
Keine Psychotherapie:
Ja
Nein
Supportive Psychotherapie:
Ja
Nein
Tiefenpsychologische Therapie:
Ja
Nein
Kognitive Verhaltenstherapie:
Ja
Nein
Gesprächstherapie nach Rogers:
Ja
Nein
Interpersonelle Psychotherapie:
Ja
Nein
Psychodynamisch-interaktionelle
Gruppentherapie:
Ja
Nein
Sonstige:
Ja
Nein
Unbekannt/Unklar:
Ja
Nein
Weitere therapeutische Verfahren
Keine:
Ja
Nein
Psychoedukation (Gruppe/Einzel):
Ja
Nein
Kognitives Training (Gruppe/Einzel):
Ja
Nein
Entspannungstraining (Gruppe/Einzel):
Ja
Nein
Soziales Kompetenztraining (Gruppe):
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Ja
Nein
Symptommanagementtraining (Gruppe/Einzel):
Ja
Nein
Verhaltenstherapeutische Angehörigengruppe:
Ja
Nein
Sonstige:
Ja
Nein
Entlassungsmedikation, EKG und
Körpergewicht
Name des Medikamentes (aus somatischer
Indikation):
Dosis des Medikamentes (aus somatischer
Indikation) in mg oder ml:
Name des Medikamentes (aus psychiatrischer
Indikation):
Dosis des Medikamentes (aus psychiatrischer
Indikation) in mg oder ml:
QTC- Zeit in Elektrokardiogramm (in Sekunden):
Körpergewicht (in kg):
Probleme in der Psychotherapie
Keine / Entfällt:
Ja
Nein
Mangelnde Änderungsmotivation:
Ja
Nein
Verschlechterung der Symptomatik:
Ja
Nein
Abbruch (durch Therapeut), bitte nennen Sie die
Gründe:
Sonstige (bitte angeben):
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(Teil-)stationäre Weiterbehandlung durch:
Unbekannt/ Unklar:
Ja
Nein
Eigenständige Tagesklinik:
Ja
Nein
Nachstationäre Behandlung:
Ja
Nein
Andere psychiatrische Klinik:
Ja
Nein
Psychotherapeutische/ Somatische Klinik:
Ja
Nein
Stationäre Einrichtung fur Suchtkranke:
Ja
Nein
Sonstiges:
Ja
Nein
Weiterversorgung und Ambulante
Nachbetreuung durch:
Keine / Unzutreffend:
Ja
Nein
Hausarzt:
Nein (1)
Ja, Kontakt aufgenommen (2)
Ja, Kontakt nicht aufgenommen (3)
Nervenarzt/Psychiater:
Nein (1)
Ja, Kontakt aufgenommen (2)
Ja, Kontakt nicht aufgenommen (3)
Ärztl./Psychol. Psychotherapeut:
Nein (1)
Ja, Kontakt aufgenommen (2)
Ja, Kontakt nicht aufgenommen (3)
Eigene Ambulanz / Poliklinik:
Nein (1)
Ja, Kontakt aufgenommen (2)
Ja, Kontakt nicht aufgenommen (3)
Andere psychiatrische Ambulanz:
Nein (1)
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Ja, Kontakt aufgenommen (2)
Ja, Kontakt nicht aufgenommen (3)
Sozialpsychiatrischer Dienst:
Nein (1)
Ja, Kontakt aufgenommen (2)
Ja, Kontakt nicht aufgenommen (3)
Beratungsstelle:
Nein (1)
Ja, Kontakt aufgenommen (2)
Ja, Kontakt nicht aufgenommen (3)
Selbsthilfegruppen / Laiendienste:
Ja
Nein
Ambulanter Pflegedienst:
Ja
Nein
Berufliche Rehabilitation, amb. Arbeitstraining:
Ja
Nein
Betreute Wohnform (Heim, WG, o.ä.):
Ja
Nein
Forensik:
Ja
Nein
Tagesstätte (z.B. psychiatr., Altentagesstätte):
Ja
Nein
Sonstiges:
Ja
Nein
Unbekannt / Unklar:
Ja
Nein
Entlassungsdiagnosen
Psychatrische Entlassungsdiagnosen nach ICD-
10:
Psychatrische Entlassungsdiagnosen nach DSM-
IV:
Somatische Entlassungsdiagnosen:
Clinical Global Impression (Schweregrad der
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Krankheit), bitte geben Sie an, wie hoch Sie den
jetzigen Grad der seelischen Erkrankung des
Patienten für den Zeitraum der letzten Woche
einschätzen.
0 Nicht beurteilbar (1)
1 Patient ist überhaupt nicht krank. (2)
2 Patient ist Grenzfall psychiatrischer
Erkrankung. (3)
3 Patient ist nur leicht krank. (4)
4 Patient ist mäßig krank. (5)
5 Patient ist deutlich krank. (6)
6 Patient ist schwer krank. (7)
Therapy Beurteilung
Clinical Global Impression Scale of Change (CGI-
C), Gesamtbeurteilung der Zustandsänderung.
Bitte vergleichen Sie den jetzigen Zustand des
Patienten mit dem beim letzten Kontakt mit Ihnen,
und geben Sie an, inwieweit sich das
Krankheitsbild des Patienten geändert hat.
0 Nicht beurteilbar. (1)
1 Zustand ist sehr viel besser. (2)
2 Zustand ist viel besser. (3)
3 Zustand ist nur wenig besser. (4)
4 Zustand ist unverändert. (5)
5 Zustand ist etwas schlechter. (6)
6 Zustand ist viel schlechter. (7)
Therapeutische Wirksamkeit (gewünschte
Arzneiwirkungen):
0 Nicht beurteilbar.  (1)
1 Sehr gut- umfassende Besserung,
vollständige oder fast vollständige
Remission aller Symptome (2)
2 Mäßig- deutliche Besserung,teilweise
Remission der Symptome (3)
3 Gering- leichte Besserung, eine
weitere Behandlung des Patienten ist
dennoch nötig. (4)
4 Zustand unverändert oder
verschlechtert. (5)
Unerwünschte Wirkungen (Therapie-Risiken):
0 Nicht beurteilbar. (1)
1 Keine. (2)
2 Beeinträchtigen den Patienten nicht
wesentlich. (3)
3 Beeinträchtigen den Patienten
wesentlich. (4)
4 Überwiegen die therapeutische
Wirksamkeit. (5)
Skala zur globalen Erfassung des
Funktionsniveaus (GAF)
Skala zur globalen Erfassung des
Funktionsniveaus (GAF). Die Bewertung der
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GAF-Skala sollte sich auf den Zeitraum der
letzten Woche vor Aufnahme beziehen.
100-91 Optimale Funktion in allen
Bereichen. (1)
10-1 Ständige Gefahr oder anhaltende
Unfähigkeit. (10)
0 Unzureichende Informationen (11)
90-81 Gute Leistungsfähigkeit auf allen
Gebieten. (2)
80-71 Höchstens leichte
Beeinträchtigungen. (3)
70-61 Leichte Beeinträchtigung. (4)
60-51 Mäßig ausgeprägte Störung. (5)
50-41 Ernsthafte Beeinträchtigung. (6)
40-31 Starke Beeinträchtigung in
mehreren Bereichen.  (7)
 30-21 Leistungsunfähigkeit in fast allen
Bereichen. (8)
20-11 Selbst- und Fremdgefährlichkeit.
(9)
Punktzahl:
Beurteilungsbogen bei Aufnahme
Beck-Depressions-Inventar:
Keine Angabe (1)
Liegt vor (2)
Patient/ -in ist zu krank (3)
Verweigert (4)
Sonstiges (5)
Hamilton Anxiety Rating Scale:
Keine Angabe (1)
Liegt vor (2)
Patient/ -in ist zu krank (3)
Verweigert (4)
Sonstiges (5)
Young Mania Rating Scale:
Keine Angabe (1)
Liegt vor (2)
Patient/ -in ist zu krank (3)
Verweigert (4)
Sonstiges (5)
Sonstiges:
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Advanced Chronic Myelogenous Leukemia
(CML) NCT00123487 – Screening
Study documentation part: Screening
This is a phase III study of BMS-354825 in subjects with
chronic myelogenous leukemia in accelerated phase, or in
myeloid or lymphoid blast phase or with Philadelphia
chromosome positive (Ph+) acute lymphoblastic leukemia
who are
resistant or intolerant to imatinib mesylate (Gleevec).Trial
Number: NCT00123487. Drug: dasatinib. Phase 3.
All rights reserved. Please visit https://medical-data-
models.org/forms/11320
Advanced Chronic Myelogenous
Leukemia (CML) NCT00123487 –
Screening
Subject details
Subject number:
Subject initial:
Visit date:
Demographics
Date of birth:
Gender at birth:
Male (1)
Female (2)
Race:
White (1)
Black or African American (2)
Asian (3)
American Indian or Alaska Native (4)
Native Hawaiian or Other Pacific Islander
(5)
Other Race (6)
If you chose the option "Other race" above,
please specify:
Ethnicity (For United states only):
Hispanic or Latino (1)
Not Hispanic or Latino (2)
Informed consent
Was informed consent obtained prior to any study
related procedures?
Yes
No
If you chose "Yes" above, please enter the date
subject or legally authorized representative
signed informed consent.
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Eligibility criteria
Did the subject fail any eligibility criteria?
Yes
No
If you chose "Yes" above, record the failed criteria
number(s) as specified in the protocol or on the
Eligibility criteria worksheet as follow: 
Inclusion Number(s),
Exclusion Number(s).
Pre-randomization status
Will the subject be randomized?
Yes
No
If you chose "No" above, please indicate primary
reason for not being randomized?
Adverse event (1)
Subject withdrew consent (2)
Death (3)
Lost to follow-up (4)
Poor/ Non-compliance (5)
Pregnancy (6)
Subject no longer meets study criteria
(7)
Administrative reason by sponsor (8)
Other (9)
Please specify if you chose "Subject withdrew
consent" , "Poor/ Non-Compliance" , "Subject no
longer meets study criteria" or "Other":
Please specify the date of last contact, if you
chose "Lost to follow-up":
Treatment assignment
Please choose the treatment group the subject is
assigned:
70 mg twice daily (1)
140 mg once daily (2)
Name of the investigator:
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NCT01366183 Fast Fact Sheet for Protocol
0273 (Ovary, Fallopian Tube, Peritoneal)
NCT01366183 Fast Fact Sheet for Protocol 0273 (Ovary,
Fallopian Tube, Peritoneal)
Chemotherapy Toxicity On Quality of Life in Older Patients
With Stage I, Stage II, Stage III, or Stage IV Ovarian
Epithelial, Primary Peritoneal Cavity, or Fallopian Tube
Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=A6C752A1-
D805-7EE2-E040-BB89AD43385E
All rights reserved. Please visit https://medical-data-
models.org/forms/11323
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Protocol 0273 (Ovary, Fallopian
Tube, Peritoneal)
Tracking Information
GOG Institution Code
GOG Affiliate Code
Previous GOG #
Treating physician
Other Physician
Patient Hospital No.
Date of Birth
Patient Last Name
Patient First Name
Patient Middle Name
Miscellaneous Patient Information
Did the patient sign an approved informed
consent
Yes
No
Has HIPAA authorization been obtained?
Exempt - Non-usa Participant (Exempt -
non-USA participant)
Yes: C49488 (Yes)
Did the patient agree to provide blood samples
from which plasma will be extracted to be tested
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for research purposes?
Yes
No
Does the patient have histologically or
cytologically confirmed epithelial ovarian,
fallopian tube or primary peritoneal cancer?
Yes
No
What is the primary disease site
Fallopian Tube (Fallopian tube)
Ovary (Ovary)
Peritoneum (Peritoneum)
What is the cell type
Adenocarcinoma With Squamous
Differentiation (Adenocarcinoma with
Squamous Differentiation)
Adenocarcinoma, Unspecified
(Adenocarcinoma, unspecified)
Adenosquamous (Adenosquamous
carcinoma)
Clear Cell Carcinoma (Clear cell
carcinoma)
Endometrioid Adenocarcinoma
(Endometrioid adenocarcinoma)
Malignant Ovarian Brenner Tumor
(Malignant Brenner's tumor)
Mixed Epithelial Carcinoma, Specify
Components (Mixed epithelial
carcinoma)
Mucinous Adenocarcinoma (Mucinous
adenocarcinoma)
Serous Adenocarcinoma (Serous
adenocarcinoma)
Squamous Cell Carcinoma (Squamous
cell carcinoma)
Unclassified Carcinoma (Unclassified
carcinoma)
Undifferentiated Carcinoma
(Undifferentiated carcinoma)
Stage
Stage I (Stage I)
Stage Ii (Stage II)
Stage Iii (Stage III)
Stage Iv (Stage IV)
Was primary staging surgery done?
Yes
No
If done, what was the date of primary staging
surgery?
If primary surgery was not done, what was the
method used to diagnosis disease?
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Biopsy (Biopsy)
Fine-needle Aspiration (FNA)
Not Applicable (Not Applicable)
Paracentesis (Paracentesis)
Surgery (Surgery)
What is the date of patient disease diagnosis by
surgery, biopsy, FNA or paracentesis?
Has the patient had any previous treatment for
this malignancy other than surgery?
Yes
No
Has the patient recovered from the effects of
recent surgery?
Yes
No
Date of Results
ANC greater than or equal to 1,500/mcl?
Yes
No
Platelets greater than or equal to 100,000/mcl?
Yes
No
Is Bilirubin less than or equal to ULN?
Yes
No
Is the Serum Creatinine less than or equal to
ULN
No (No)
No (no)
Yes (Yes)
Yes (yes)
Performance Status
Fully Active, Able To Carry On All Pre-
disease Performance Without
Restriction. (0)
Restricted In Physically Strenuous
Activity But Ambulatory And Able To
Carry Out Work Of A Light Or Sedentary
Nature, E.g., Light Housework, Office
Work. (1)
Ambulatory And Capable Of All Selfcare
But Unable To Carry Out Any Work
Activities. Up And About More Than 50%
Of Waking Hours. (2)
Capable Of Only Limited Selfcare,
Confined To Bed Or Chair More Than
50% Of Waking Hours. (3)
Is the patient age 75 years or older?
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Yes
No
Does the patient and physician agree that they
plan to conduct treatment according to Regimen
1 or Regimen 2, as described in Appendix I or II
respectively?
Yes
No
Which treatment regimen will the patient be
receiving?
Regimen 1 (Regimen 1)
Regimen 2 (Regimen 2)
Is the patient able to understand and read
English?
Yes
No
Is the patient free of active infection requiring
antibiotics
Yes
No
Has the patient had previous cancer treatment
which contraindicates this protocol therapy
Yes
No
Does that patient have any medical history or
conditions not otherwise previously specified
which in the opinion of the investigator should
exclude participation in this study?
Yes
No
Anticipated date treatment will start
Comments
Provide comments about this Fast Fact Sheet
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NCT01275664 Fast Fact Sheet for Protocol 0272
(Ovary, Fallopian Tube, Primary Peritoneal)
NCT01275664 Fast Fact Sheet for Protocol 0272 (Ovary,
Fallopian Tube, Primary Peritoneal)
Granisetron, Aprepitant, and Dexamethasone in Preventing
Nausea and Vomiting in Patients Receiving Chemotherapy
for Stage II, III, or IV Ovarian Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=9B7A8945-
C35E-FFEC-E040-BB89AD43462D
All rights reserved. Please visit https://medical-data-
models.org/forms/11324
NCT01275664 Fast Fact Sheet for
Protocol 0272 (Ovary, Fallopian
Tube, Primary Peritoneal)
Patient demographics
GOG Institution Code
GOG Affiliate Code
Previous GOG #
Treating physician
Other Physician
Patient Hospital No.
Date of Birth
Patient Last Name
Patient First Name
Patient Middle Name
What is the patient's ID number on GOG-0252?
Miscellaneous Patient Information
Did the patient sign an approved informed
consent
Yes
No
Has HIPAA authorization been obtained?
Exempt - Non-usa Participant (Exempt -
non-USA participant)
Yes: C49488 (Yes)
Has the patient enrolled in this study 48 hours or
more in advance of starting treatment on cycle 1
1 / 2
on GOG-0252?
Yes
No
Which arm has the patient been randomized to
on GOG-0252?
Intraperitoneal Carboplatin (IP
carboplatin)
Intraperitoneal Cisplatin (IP cisplatin)
Intravenous Carboplatin (IV carboplatin)
What is the primary disease site
Fallopian Tube (Fallopian tube)
Ovary (Ovary)
Peritoneum (Peritoneum)
Is the patient able to understand and read
English?
Yes
No
Is the patient able to complete assessments?
Yes
No
Is the patient able to comply with anti-emetic
therapy?
Yes
No
Has the patient met the pre-entry requirements
as specified in section 7.0
Yes
No
Is the patient known to be hypersensitive to
aprepitant, granisetron or any kind of the
components of the patch or to dexamethasone?
Yes
No
In the treating physician's opinion, does the
patient have a medical condition, or currently take
medications, which are felt to contraindicate safe
or effective administration of the standard three
drug anti-emetic regimen used in this study?
Yes
No
Anticipated date treatment will start
Comments
Provide comments about this Fast Fact Sheet
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CALGB-40502 Health Survey
NCT00785291
CALGB-40502 Health Survey NCT00785291
Paclitaxel, Paclitaxel Albumin-Stabilized Nanoparticle
Formulation, or Ixabepilone With or Without Bevacizumab
in Treating Patients With Stage IIIC or Stage IV Breast
Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=523BB798-
CD9E-215F-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11325
CALGB-40502 Health Survey
NCT00785291
Header
CALGB Form
CALGB Study No
CALGB Patient ID
Date Form Completed
Are data amended
Yes
No
Patient demographics
Patient Initials (Last, First Middle)
Patient Hospital No.
Institution/Affiliate
Participating Group
Participating Group Study No.
Participating Group Patient ID
Health Before Cancer Diagnosis
Do you have heart disease
Yes
No
Do you have high blood pressure
Yes
No
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Do you have emphysema or bronchitis
Yes
No
Do you have diabetes
Yes
No
Do you have ulcers or stomach disease
Yes
No
Do you have kidney disease
Yes
No
Do you have anemia or other blood disease
Yes
No
Do you have depression
Yes
No
Do you have arthritis
Yes
No
Do you get treatment for it
Yes
No
Does it limit your activities
Yes
No
Section Ii - Social Support
Someone you can count on to listen when you
need to talk
A Little Of The Time (A little of the time)
All Of The Time (All of the time)
Most Of The Time (Most of the time)
None Of The Time (None of the time)
Some Of The Time (Some of the time)
Some whose advice you really want
A Little Of The Time (A little of the time)
All Of The Time (All of the time)
Most Of The Time (Most of the time)
None Of The Time (None of the time)
Sometimes (Sometimes)
Some whose advice you really want
A Little Of The Time (A little of the time)
All Of The Time (All of the time)
Most Of The Time (Most of the time)
None Of The Time (None of the time)
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Sometimes (Sometimes)
Someone to share your most private worries and
fears with
A Little Of The Time (A little of the time)
All Of The Time (All of the time)
Most Of The Time (Most of the time)
None Of The Time (None of the time)
Some Of The Time (Some of the time)
Someone to share your most private worries and
fears with
A Little Of The Time (A little of the time)
All Of The Time (All of the time)
Most Of The Time (Most of the time)
None Of The Time (None of the time)
Some Of The Time (Some of the time)
Someone to turn to for suggestions about how to
deal with a personal problem
A Little Of The Time (A little of the time)
All Of The Time (All of the time)
Most Of The Time (Most of the time)
None Of The Time (None of the time)
Some Of The Time (Some of the time)
Someone to turn to for suggestions about how to
deal with a personal problem
A Little Of The Time (A little of the time)
All Of The Time (All of the time)
Most Of The Time (Most of the time)
None Of The Time (None of the time)
Some Of The Time (Some of the time)
Someone who understands your problems
A Little Of The Time (A little of the time)
All Of The Time (All of the time)
Most Of The Time (Most of the time)
None Of The Time (None of the time)
Some Of The Time (Some of the time)
Section Ii - Social Support
Someone to do something enjoyable with
A Little Of The Time (A little of the time)
All Of The Time (All of the time)
Most Of The Time (Most of the time)
None Of The Time (None of the time)
Some Of The Time (Some of the time)
Someone to do something enjoyable with
A Little Of The Time (A little of the time)
All Of The Time (All of the time)
Most Of The Time (Most of the time)
None Of The Time (None of the time)
Some Of The Time (Some of the time)
Someone to do things with, to help you get your
mind off things
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A Little Of The Time (A little of the time)
All Of The Time (All of the time)
Most Of The Time (Most of the time)
None Of The Time (None of the time)
Some Of The Time (Some of the time)
Someone to do things with, to help you get your
mind off things
A Little Of The Time (A little of the time)
All Of The Time (All of the time)
Most Of The Time (Most of the time)
None Of The Time (None of the time)
Some Of The Time (Some of the time)
Section Ii - Social Support
Someone to help you if you were confined to bed
A Little Of The Time (A little of the time)
All Of The Time (All of the time)
Most Of The Time (Most of the time)
None Of The Time (None of the time)
Some Of The Time (Some of the time)
Someone to take you to the doctor if you needed
it
A Little Of The Time (A little of the time)
All Of The Time (All of the time)
Most Of The Time (Most of the time)
None Of The Time (None of the time)
Some Of The Time (Some of the time)
Someone to prepare meals if you were unable to
do it yourself
A Little Of The Time (A little of the time)
All Of The Time (All of the time)
Most Of The Time (Most of the time)
None Of The Time (None of the time)
Some Of The Time (Some of the time)
Someone to help with daily chores if you were
sick
A Little Of The Time (A little of the time)
All Of The Time (All of the time)
Most Of The Time (Most of the time)
None Of The Time (None of the time)
Some Of The Time (Some of the time)
Someone to turn to for suggestions about how to
deal with a personal problem
A Little Of The Time (A little of the time)
All Of The Time (All of the time)
Most Of The Time (Most of the time)
None Of The Time (None of the time)
Some Of The Time (Some of the time)
Someone to turn to for suggestions about how to
deal with a personal problem
A Little Of The Time (A little of the time)
All Of The Time (All of the time)
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Most Of The Time (Most of the time)
None Of The Time (None of the time)
Some Of The Time (Some of the time)
Section Ii - Social Support
Someone to love and make you feel wanted
A Little Of The Time (A little of the time)
All Of The Time (All of the time)
Most Of The Time (Most of the time)
None Of The Time (None of the time)
Some Of The Time (Some of the time)
Someone to love and make you feel wanted
A Little Of The Time (A little of the time)
All Of The Time (All of the time)
Most Of The Time (Most of the time)
None Of The Time (None of the time)
Some Of The Time (Some of the time)
Someone who hugs you
A Little Of The Time (A little of the time)
All Of The Time (All of the time)
Most Of The Time (Most of the time)
None Of The Time (None of the time)
Some Of The Time (Some of the time)
Section Iii - Demographics
Race
A Person Having Origins In Any Of The
Original Peoples Of North And South
America (including Central America),
And Who Maintains Tribal Affiliation Or
Community Attachment. (American
Indian or Alaska Native)
A Person Having Origins In Any Of The
Original Peoples Of The Far East,
Southeast Asia, Or The Indian
Subcontinent Including, For Example,
Cambodia, China, India, Japan, Korea,
Malaysia, Pakistan, The Philippine
Islands, Thailand, And Vietnam. (Asian)
A Person Having Origins In Any Of The
Black Racial Groups Of Africa. Terms
Such As "haitian" Or "negro" Can Be
Used In Addition To "black Or African
American." (Black or African American)
A Person Having Origins In Any Of The
Original Peoples Of Hawaii, Guam,
Samoa, Or Other Pacific Islands. (Native
Hawaiian or other Pacific Islander)
Not Provided Or Available (Not
Reported)
Could Not Be Determined Or Unsure
(Unknown)
A Person Having Origins In Any Of The
Original Peoples Of Europe, The Middle
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East, Or North Africa. (White)
Other specify
Ethnicity
A Person Of Mexican, Puerto Rican,
Cuban, Central Or South American Or
Other Spanish Culture Or Origin,
Regardless Of Race. (Hispanic or Latino)
A Person Not Meeting The Definition For
Hispanic Or Latino. (Not Hispanic or
Latino)
Not Provided Or Available (Not reported)
Could Not Be Determined Or Unsure
(Unknown)
What is the highest grade you finished in school?
1-8 Grades (1-8 grades)
9-11 Grades (9-11 grades)
Advanced Degree (Advanced degree)
College Degree (b.a./b.s.) (College
degree (B.A./B.S.))
High School Graduate (High School
graduate)
Junior College Degree (Junior college
degree)
Some College (Some college)
Some Post-college Work (Some post-
college work)
Marital status
Divorced (Divorced)
Domestic Partnership (Domestic
Partnership)
I Prefer Not To Answer (I prefer not to
answer)
Married (Married)
Never Married (Never married)
Separated (Separated)
Unknown/not Reported (Unknown/Not
Reported)
Widowed (Widowed)
Is the place where you live
Occupied Without Payment Or Cash
Rent (Occupied without payment or cash
rent)
Other (Other)
Owned Or Being Bought By You Or By
Someone Who Lives With You (Owned
or being bought by you or by someone
who lives with you)
Rented By You Or By Someone Who
Lives With You (Rented by you or by
someone who lives with you)
Other, specify
Method of Payment (The type of health insurance
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do you currently have)
Medicaid (Medicaid)
Medicaid And Medicare (Medicaid and
Medicare)
Medicare (Medicare)
Medicare And Private Insurance
(Medicare and Private Insurance)
Military Or Veterans Sponsored Nos
(Military or Veterans Sponsored, Not
Otherwise Specified (NOS))
Military Sponsored (including Champus
& Tricare) (Military Sponsored (including
CHAMPUS & TRICARE))
No Means Of Payment (no Insurance)
(No means of payment (no insurance))
Other (Other)
Private Insurance (Private Insurance)
Self Pay (no Insurance) (Self Pay (No
Insurance))
Unknown (Unknown)
Veterans Sponsored (Veterans
Sponsored)
Other, specify
When you go to the drug store to get your
medications, do you have trouble coming up with
the money to pay for them
A Little Of The Time (A little of the time)
All Of The Time (All of the time)
Most Of The Time (Most of the time)
None Of The Time (None of the time)
Some Of The Time (Some of the time)
Household Income (your best estimate of your
family income last year, including income from all
sources, before taxes)
$15,001 - $20,000 ($15,001 - $20,000)
$20,001 - $30,000 ($20,001 - $30,000)
$30,001 - $45,000 ($30,001 - $45,000)
$45,001 - $60,000 ($45,001 - $60,000)
$60,001 - $75,000 ($60,001 - $75,000)
Less Than $15,000 (Less than $15,000)
More Than $75,000 (More than $75,000)
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RTOG-0412 A5: Demographic Data Form -
version 2 NCT00113386
RTOG-0412 A5: Demographic Data Form - version 2
NCT00113386
Cisplatin and Docetaxel With or Without Radiation Therapy
in Treating Patients Who Are Undergoing Surgery for Newly
Diagnosed Stage III Non-Small Cell Lung Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=E499E60B-
975C-4FA9-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11326
RTOG-0412 A5: Demographic Data
Form - version 2 NCT00113386
RTOG clinical trial administrative data
Other, specify
RTOG Study
Case #
Institution Name
Institution No.
Participant's Initials
RTOG Patient ID
Date Completed (INSTRUCTIONS: Submit this
form at patient's entry on study. Complete the
information by filling in boxes or blanks as
requested.  See separate page for instructions)
Who completed this form? (Check one box)
Not Applicable, No Items Completed (Not
applicable, no items completed)
Other Person (Other person)
Self (Self)
Staff (Staff)
Race (Check one box only)
A Person Having Origins In Any Of The
Original Peoples Of The Far East,
Southeast Asia, Or The Indian
Subcontinent Including, For Example,
Cambodia, China, India, Japan, Korea,
Malaysia, Pakistan, The Philippine
Islands, Thailand, And Vietnam. (Asian)
A Person Having Origins In Any Of The
Black Racial Groups Of Africa. Terms
Such As "haitian" Or "negro" Can Be
Used In Addition To "black Or African
American." (Black, not Hispanic origin)
Hispanic (Hispanic)
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A Person Having Origins In Any Of The
Original Peoples Of North And South
America (including Central America),
And Who Maintains Tribal Affiliation Or
Community Attachment (Native
American / Alaskan Nation)
A Person Having Origins In Any Of The
Original Peoples Of Hawaii, Guam,
Samoa, Or Other Pacific Islands (Native
Hawaiian or other Pacific Islander)
Other (Other)
Patient Is Unsure Of Their Race
(Unknown / I prefer not to answer)
A Person Having Origins In Any Of The
Original Peoples Of Europe, The Middle
East, Or North Africa. (White, not
Hispanic origin)
Additional Race/Ethnicity (If you consider yourself
multiracial, check all additional categories that
apply in this question Do not include what you
reported in 2A.)
Asian (Asian)
Black, not Hispanic origin (Black, not
Hispanic origin)
Hispanic (Hispanic)
A Person Of Mexican, Puerto Rican,
Cuban, Central Or South American Or
Other Spanish Culture Or Origin,
Regardless Of Race (HISPANIC OR
LATINO)
Native American / Alaskan Nation
(Native American / Alaskan Nation)
Native Hawaiian or other Pacific Islander
(Native Hawaiian or other Pacific
Islander)
A Person Not Meeting The Definition For
Hispanic Or Latino. (NOT HISPANIC OR
LATINO)
Patient Refused Or Data Not Available
(Not reported)
Patient Is Unsure Of Their Ethnicity
(Unknown / I prefer not to answer)
White, not Hispanic origin (White, not
Hispanic origin)
Highest school grade completed (Check one box)
8th Or Less (8th or less)
9 - 11th Grade (9 - 11th Grade)
Advanced Degree (Advanced degree)
Associate Degree / Some College
(Associate degree / some college)
Bachelor's Degree (Bachelor's degree)
High School Graduate / Ged (High
school graduate / GED)
I Prefer Not To Answer (I prefer not to
answer)
Other (Other)
Vocational / Technical School (Vocational
/ technical school)
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Other, specify
Religion during childhood (Check one box)
Catholic (Catholic)
I Prefer Not To Answer (I prefer not to
answer)
Jewish (Jewish)
Morman/latter Day Saints
(Mormon/Latter Day Saints)
Muslim / Islam (Muslim / Islam)
None (None)
Other, Specify (Other)
Protestant (Protestant)
Other, specify
Marital status (Check one box)
Divorced (Divorced/Separated)
I Prefer Not To Answer (I prefer not to
answer)
Living As Married (Living as married)
Married (Married)
Single (Single)
Widowed (Widowed)
Where were you born? (Check one box)
Other Country (Other country)
Usa (USA)
USA, specify the 2 letter State code  (e.g. NY)
Other country, specify
Where did you live the longest (Check one box)
Other Country (Other country)
Usa (USA)
USA, specify the 2 letter State code  (e.g. NY)
Other country, specify (Cigarette History?)
Smoked at least 100 cigarette (5 packs) during
lifetime
No (No)
Yes (Yes)
Yes, Currently Smoke (Yes, currently
smoke)
Age began smoking cigarettes
Number of years smoked cigarettes
Average number of cigarettes smoked per day
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If quit, age stopped smoking completely
If you have had any of the illnesses listed below,
please check yes for those that apply (= Yes 2)
Bleeding Problems (Bleeding problems)
Circulation Problems (Circulation
problems)
Diabetes Or Sugar In Urine (Diabetes or
sugar in urine)
Frequent Infections (Frequent infections)
Heart Problems (Heart problems)
High Blood Pressure (High blood
pressure)
Hiv/aids (HIV/AIDS)
Kidney/urine Problems (Kidney/urine
problems)
Liver Problems (Liver problems)
Lung Problems (Lung problems)
Other (Other)
Psychological Problems (Psychological
problems)
Seizure (Seizure)
Stroke (Stroke)
Thyroid Problems (Thyroid problems)
Specify other
How many of the following family members (living
and dead) do you have (Include only those who
are blood-related.)
Brothers (Brothers)
Daughters (Daughters)
Sisters (Sisters)
Sons (Sons)
Are you adopted (Check one)
Yes
No
Blood relative with cancer (= yes 2)
Brother #1 (Brother #1)
Brother #2 (Brother #2)
Brother #3 (Brother #3)
Brother #4 (Brother #4)
Child #1 (Child #1)
Child #2 (Child #2)
Child #3 (Child #3)
Child #4 (Child #4)
Father (Father)
Mother (Mother)
Sister #1 (Sister #1)
Sister #2 (Sister #2)
Sister #3 (Sister #3)
Sister #4 (Sister #4)
Age when first cancer diagnosed
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Type of cancer (= yes 2)
Breast (Breast)
Colon (Colon)
Head & Neck (Head & Neck)
Lung (Lung)
Non Melanoma Skin (Non Melanoma
Skin)
Other (Other)
Prostate (Prostate)
specify
Have you ever heard of Cancer Prevention Trials
(Check one box)
Yes
No
How likely would you be to volunteer to
participate in Cancer Prevention Trials (The
numbers below allow you to rate your answer
between 1 - never and 10 - extremely likely.
Circle the number below that best describes your
choice.)
1 (1)
10 (10)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
7 (7)
8 (8)
9 (9)
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NCT00053326
ANBL0321: PK Specimen Shipping Form NCT00053326
Fenretinide in Treating Children With Recurrent or
Resistant Neuroblastoma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=C42AE414-
4572-73E3-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/11327
ANBL0321: PK Specimen Shipping
Form NCT00053326
Header
Institution Name
COG Study Number
COG Study Number
COG Number
Date form originally completed
Date worksheet entered into RDE
Patient Initials
Patient Information
Medical Record Number
Course Number
1 (1)
2 (2)
5 (5)
Accession Number
COG Number
Body Surface Area
Units [agent UOM]
Milligram (mg)
Units [agent UOM]
Milligram (mg)
Units [agent UOM]
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Milligram (mg)
PM Dose
PM Dose
PM Dose
Biopsy and Cytology Specimens
Course Number
1 (1)
2 (2)
5 (5)
Date
Date
Time AM Dose Given
Actual Collection Time
Actual Collection Time
Please check each box if sample being sent for
course/timepoint
Yes
No
Sample Amount
Biopsy and Cytology Specimens shipment
Specimen is being shipped to following lab
Ames Lab (Ames Lab)
Reynolds Lab (Reynolds Lab)
Carrier
Account Number
Carrier Tracking Number
Date Shipped
Estimated date and time of arrival
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Specimen Type
Peripheral Blood (Blood in green top
tube)
Ccrr Module For Anbl0321: Pk Specimen
Shipping Form
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RTOG-0525 A5: Demographic Data Form
NCT00304031
RTOG-0525 A5: Demographic Data Form NCT00304031 
Radiation Therapy and Temozolomide in Treating Patients
With Newly Diagnosed Glioblastoma or Gliosarcoma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=FD96C32B-
E9A8-2499-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11328
RTOG-0525 A5: Demographic Data
Form NCT00304031
Header
RTOG Study No.
Case #
Institution Name
Institution No.
Patient Initials
RTOG Patient ID
Date Completed
Amended Data
Yes
No
Who completed this form (Check one box)
Not Applicable, No Items Completed (Not
applicable, no items completed)
Other Person (Other person)
Self (Self)
Staff (Staff)
Patient demographics
Race
A Person Having Origins In Any Of The
Original Peoples Of North And South
America (including Central America),
And Who Maintains Tribal Affiliation Or
Community Attachment. (American
Indian or Alaska Native)
A Person Having Origins In Any Of The
Original Peoples Of The Far East,
Southeast Asia, Or The Indian
Subcontinent Including, For Example,
Cambodia, China, India, Japan, Korea,
Malaysia, Pakistan, The Philippine
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Islands, Thailand, And Vietnam. (Asian)
A Person Having Origins In Any Of The
Black Racial Groups Of Africa. Terms
Such As "haitian" Or "negro" Can Be
Used In Addition To "black Or African
American." (Black or African American)
A Person Having Origins In Any Of The
Original Peoples Of Hawaii, Guam,
Samoa, Or Other Pacific Islands. (Native
Hawaiian or other Pacific Islander)
Not Provided Or Available (Not
Reported)
Could Not Be Determined Or Unsure
(Unknown)
A Person Having Origins In Any Of The
Original Peoples Of Europe, The Middle
East, Or North Africa. (White)
Ethnicity (If you consider yourself multiracial,
check all additional categories that apply in this
question Do not include what you reported in 2A.)
A Person Of Mexican, Puerto Rican,
Cuban, Central Or South American Or
Other Spanish Culture Or Origin,
Regardless Of Race. (HISPANIC OR
LATINO)
A Person Not Meeting The Definition For
Hispanic Or Latino. (NOT HISPANIC OR
LATINO)
Not Provided Or Available (Not reported)
Could Not Be Determined Or Unsure
(UNKNOWN)
Highest school grade completed
8th Or Less (8th or less)
9 - 11th Grade (9 - 11th Grade)
Advanced Degree (Advanced degree)
Associate Degree / Some College
(Associate degree/some college)
Bachelor's Degree (Bachelor's degree)
High School Graduate / Ged (High
school graduate/GED)
I Prefer Not To Answer (I prefer not to
answer)
Other (Other)
Vocational / Technical School
(Vocational/technical school)
Other, specify
Religion during childhood (Check one box)
Catholic (Catholic)
I Prefer Not To Answer (I prefer not to
answer)
Jewish (Jewish)
Morman/latter Day Saints
(Morman/Latter Day Saints)
Muslim / Islam (Muslim/Islam)
None (None)
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Other (Other)
Protestant (Protestant)
Other, specify
Marital status (Check one box)
Divorced/separated
(Divorced/Separated)
I Prefer Not To Answer (I prefer not to
answer)
Living As Married (Living as married)
Married (Married)
Single (Single)
Widowed (Widowed)
Where were you born (Check one box)
Other Country (Other country)
Usa (USA)
specify the 2 letter State code (eg NY)
Other country, specify
Where did you live the longest (Check one box)
Other Country (Other country)
Usa (USA)
specify the 2 letter State code (eg NY)
Other country, specify
Cigarette History
Smoked at least 100 cigarette during lifetime (5
packs)
No (No)
Yes, But Quit (Yes, but quit)
Yes, Currently Smoke (Yes, currently
smoke)
Age began smoking cigarettes
Number of years smoked cigarettes
Average number of cigarettes smoked per day
If quit, age stopped smoking completely
If you have had any of the illnesses listed below,
please check yes for those that apply (check =
Yes)
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Bleeding Problems (Bleeding problems)
Circulation Problems (Circulation
problems)
Diabetes Or Sugar In Urine (Diabetes or
sugar in urine)
Frequent Infections (Frequent infections)
Heart Problems (Heart problems)
High Blood Pressure (High blood
pressure)
Hiv/aids (HIV/AIDS)
Kidney/urine Problems (Kidney/urine
problems)
Liver Problems (Liver problems)
Lung Problems (Lung problems)
Other (Other)
Psychological Problems (Psychological
problems)
Seizure (Seizure)
Stroke (Stroke)
Thyroid Problems (Thyroid problems)
Specify other
Family History
How many brothers do you have (How many of
the following family members do you have living
and dead Include only those who are blood-
related)
How many sisters do you have
How many sons do you have
How many daughters do you have
Are you adopted (Check one)
Yes
No
Blood relative with cancer (check = yes)
Brother #1 (Brother #1)
Brother #2 (Brother #2)
Brother #3 (Brother #3)
Brother #4 (Brother #4)
Child #1 (Child  #1)
Child #2 (Child  #2)
Child #3 (Child  #3)
Child #4 (Child  #4)
Father (Father)
Mother (Mother)
Sister #1 (Sister  #1)
Sister #2 (Sister  #2)
Sister #3 (Sister  #3)
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Sister #4 (Sister  #4)
Age when first cancer diagnosed
Type of Cancer (check = yes)
Breast (Breast)
Colon (Colon)
Head & Neck (Head & Neck)
Lung (Lung)
Non Melanoma Skin (Non Melanoma
Skin)
Other (Other)
Prostate (Prostate)
Specify
Have you ever heard of Cancer Prevention Trials
(Check one box)
Yes
No
How likely would you be to volunteer to
participate in Cancer Prevention Trials (The
numbers below allow you to rate your answer
between 1 - never and 10 - extremely likely. Circle
the number below that best describes your
choice.)
1 (1)
10 (10)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
7 (7)
8 (8)
9 (9)
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NCT00655876 Radiation Therapy Oncology Group Phase
III Esophagus Demographic Data Form - Version 2
NCT00655876 Radiation Therapy Oncology Group Phase
III Esophagus Demographic Data Form - Version 2
Paclitaxel, Cisplatin, and Radiation Therapy With or Without
Cetuximab in Treating Patients With Locally Advanced
Esophageal Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=2A01D294-
A8B2-3C08-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11329
NCT00655876 Radiation Therapy
Oncology Group Phase III
Esophagus Demographic Data Form
- Version 2
Header
RTOG Study No.
Case #
Institution Name
Institution No.
Patient Initials
RTOG Patient ID
Date Completed
Amended Data
Yes
No
Who completed this form (Check one box)
Not Applicable, No Items Completed (Not
applicable, no items completed)
Other Person (Other person)
Self (Self)
Staff (Staff)
Patient demographics
Patient Race Category
A Person Having Origins In Any Of The
Original Peoples Of North And South
America (including Central America),
And Who Maintains Tribal Affiliation Or
Community Attachment. (American
Indian or Alaska Native)
A Person Having Origins In Any Of The
Original Peoples Of The Far East,
Southeast Asia, Or The Indian
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Subcontinent Including, For Example,
Cambodia, China, India, Japan, Korea,
Malaysia, Pakistan, The Philippine
Islands, Thailand, And Vietnam. (Asian)
A Person Having Origins In Any Of The
Black Racial Groups Of Africa. Terms
Such As "haitian" Or "negro" Can Be
Used In Addition To "black Or African
American." (Black or African American)
A Person Having Origins In Any Of The
Original Peoples Of Hawaii, Guam,
Samoa, Or Other Pacific Islands. (Native
Hawaiian or other Pacific Islander)
Not Provided Or Available (Not
Reported)
Could Not Be Determined Or Unsure
(Unknown)
A Person Having Origins In Any Of The
Original Peoples Of Europe, The Middle
East, Or North Africa. (White)
Patient Ethnic Group Cateogy (If you consider
yourself multiracial, check all additional
categories that apply in this question Do not
include what you reported in 2A.)
A Person Of Mexican, Puerto Rican,
Cuban, Central Or South American Or
Other Spanish Culture Or Origin,
Regardless Of Race. (HISPANIC OR
LATINO)
A Person Not Meeting The Definition For
Hispanic Or Latino. (NOT HISPANIC OR
LATINO)
Not Provided Or Available (Not reported)
Could Not Be Determined Or Unsure
(UNKNOWN)
Highest school grade completed
8th Or Less (8th or less)
9 - 11th Grade (9 - 11th Grade)
Advanced Degree (Advanced degree)
Associate Degree / Some College
(Associate degree/some college)
Bachelor's Degree (Bachelor's degree)
High School Graduate / Ged (High
school graduate/GED)
I Prefer Not To Answer (I prefer not to
answer)
Other (Other)
Vocational / Technical School
(Vocational/technical school)
Other, specify
Religion during childhood (Check one box)
Catholic (Catholic)
I Prefer Not To Answer (I prefer not to
answer)
Jewish (Jewish)
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Demographic Data Form - Version 2
Morman/latter Day Saints
(Morman/Latter Day Saints)
Muslim / Islam (Muslim/Islam)
None (None)
Other (Other)
Protestant (Protestant)
Other, specify
Marital status (Check one box)
Divorced/separated
(Divorced/Separated)
I Prefer Not To Answer (I prefer not to
answer)
Living As Married (Living as married)
Married (Married)
Single (Single)
Widowed (Widowed)
Where were you born (Check one box)
Other Country (Other country)
Usa (USA)
specify the 2 letter State code (eg NY)
Other country, specify
Where did you live the longest (Check one box)
Other Country (Other country)
Usa (USA)
specify the 2 letter State code (eg NY)
Other country, specify
Cigarette History
Smoked at least 100 cigarette during lifetime (5
packs)
No (No)
Yes, But Quit (Yes, but quit)
Yes, Currently Smoke (Yes, currently
smoke)
Age began smoking cigarettes
Number of years smoked cigarettes
Average number of cigarettes smoked per day
If quit, age stopped smoking completely
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NCT00655876 Radiation Therapy Oncology Group Phase III Esophagus
Demographic Data Form - Version 2
If you have had any of the illnesses listed below,
please check yes for those that apply (check =
Yes)
Bleeding Problems (Bleeding problems)
Circulation Problems (Circulation
problems)
Diabetes Or Sugar In Urine (Diabetes or
sugar in urine)
Frequent Infections (Frequent infections)
Heart Problems (Heart problems)
High Blood Pressure (High blood
pressure)
Hiv/aids (HIV/AIDS)
Kidney/urine Problems (Kidney/urine
problems)
Liver Problems (Liver problems)
Lung Problems (Lung problems)
Other (Other)
Psychological Problems (Psychological
problems)
Seizure (Seizure)
Stroke (Stroke)
Thyroid Problems (Thyroid problems)
Specify other
Family History
How many brothers do you have (How many of
the following family members do you have living
and dead Include only those who are blood-
related)
How many sisters do you have
How many sons do you have
How many daughters do you have
Are you adopted (Check one)
Yes
No
Blood relative with cancer (check = yes)
Brother #1 (Brother #1)
Brother #2 (Brother #2)
Brother #3 (Brother #3)
Brother #4 (Brother #4)
Child #1 (Child  #1)
Child #2 (Child  #2)
Child #3 (Child  #3)
Child #4 (Child  #4)
Father (Father)
Mother (Mother)
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Sister #1 (Sister  #1)
Sister #2 (Sister  #2)
Sister #3 (Sister  #3)
Sister #4 (Sister  #4)
Age when first cancer diagnosed
Type of Cancer (check = yes)
Breast (Breast)
Colon (Colon)
Head & Neck (Head & Neck)
Lung (Lung)
Non Melanoma Skin (Non Melanoma
Skin)
Other (Other)
Prostate (Prostate)
Specify
Have you ever heard of Cancer Prevention Trials
(Check one box)
Yes
No
How likely would you be to volunteer to
participate in Cancer Prevention Trials (The
numbers below allow you to rate your answer
between 1 - never and 10 - extremely likely. Circle
the number below that best describes your
choice.)
1 (1)
10 (10)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
7 (7)
8 (8)
9 (9)
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Demographic Data Form - Version 2
RTOG-0421 A5: Demographic Data Form
NCT00113399
RTOG-0421 A5: Demographic Data Form NCT00113399
Combination Chemotherapy With or Without Radiation
Therapy in Treating Patients With Recurrent Head and
Neck Cancer That Cannot Be Removed By Surgery
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=F6EB0379-
F984-6A30-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11330
RTOG-0421 A5: Demographic Data
Form NCT00113399
Header
RTOG Study
Case #
Institution
Institution No.
Patient Initials
Patient Study No.
Amended
Yes
No
Who completed this form (Check one box)
Not Applicable, No Items Completed (Not
applicable, no items completed)
Other Person (Other person)
Self (Self)
Staff (Staff)
Patient demographics
Race
A Person Having Origins In Any Of The
Original Peoples Of The Far East,
Southeast Asia, Or The Indian
Subcontinent Including, For Example,
Cambodia, China, India, Japan, Korea,
Malaysia, Pakistan, The Philippine
Islands, Thailand, And Vietnam. (Asian)
A Person Having Origins In Any Of The
Black Racial Groups Of Africa. Terms
Such As "haitian" Or "negro" Can Be
Used In Addition To "black Or African
American." (Black, not Hispanic origin)
Hispanic (Hispanic)
A Person Having Origins In Any Of The
Original Peoples Of North And South
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America (including Central America),
And Who Maintains Tribal Affiliation Or
Community Attachment. (Native
American/Alaskan Nation)
A Person Having Origins In Any Of The
Original Peoples Of Hawaii, Guam,
Samoa, Or Other Pacific Islands. (Native
Hawaiian or other Pacific Islander)
Other (Other)
Could Not Be Determined Or Unsure
(Unknown/I prefer not to answer)
A Person Having Origins In Any Of The
Original Peoples Of Europe, The Middle
East, Or North Africa. (White, not
Hispanic origin)
Other, specify
Additional Race/Ethnicity (If you consider yourself
multiracial, check all additional categories that
apply in this question Do not include what you
reported in 2A.)
Asian (Asian)
Black, not Hispanic origin (Black, not
Hispanic origin)
Hispanic (Hispanic)
A Person Of Mexican, Puerto Rican,
Cuban, Central Or South American Or
Other Spanish Culture Or Origin,
Regardless Of Race. (HISPANIC OR
LATINO)
Native American/Alaskan Nation (Native
American/Alaskan Nation)
Native Hawaiian or other Pacific Islander
(Native Hawaiian or other Pacific
Islander)
A Person Not Meeting The Definition For
Hispanic Or Latino. (NOT HISPANIC OR
LATINO)
Not Provided Or Available (Not reported)
Could Not Be Determined Or Unsure
(Unknown/I prefer not to answer)
White, not Hispanic origin (White, not
Hispanic origin)
(Check one box)
8th Or Less (8th or less)
9 - 11th Grade (9 - 11th Grade)
Advanced Degree (Advanced degree)
Associate Degree / Some College
(Associate degree/some college)
Bachelor's Degree (Bachelor's degree)
High School Graduate / Ged (High
school graduate/GED)
I Prefer Not To Answer (I prefer not to
answer)
Other (Other)
Vocational / Technical School
(Vocational/technical school)
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Other, specify
Religion during childhood (Check one box)
Catholic (Catholic)
I Prefer Not To Answer (I prefer not to
answer)
Jewish (Jewish)
Morman/latter Day Saints
(Morman/Latter Day Saints)
Muslim / Islam (Muslim/Islam)
None (None)
Other, Specify (Other)
Protestant (Protestant)
Other, specify
Marital status (Check one box)
Divorced (Divorced/Separated)
I Prefer Not To Answer (I prefer not to
answer)
Living As Married (Living as married)
Married (Married)
Single (Single)
Widowed (Widowed)
Where were you born (Check one box)
Other Country (Other country)
Usa (USA)
specify the 2 letter State code (eg NY)
Other country, specify
Where did you live the longest (Check one box)
Other Country (Other country)
Usa (USA)
specify the 2 letter State code (eg NY)
Other country, specify
Cigarette History
Smoked at least 100 cigarette during lifetime (5
packs)
No (No)
Yes, But Quit (Yes, but quit)
Yes, Currently Smoke (Yes, currently
smoke)
Age began smoking cigarettes
Number of years smoked cigarettes
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Average number of cigarettes smoked per day
If quit, age stopped smoking completely
If you have had any of the illnesses listed below,
please check yes for those that apply (check =
Yes)
Bleeding Problems (Bleeding problems)
Circulation Problems (Circulation
problems)
Diabetes Or Sugar In Urine (Diabetes or
sugar in urine)
Frequent Infections (Frequent infections)
Heart Problems (Heart problems)
High Blood Pressure (High blood
pressure)
Hiv/aids (HIV/AIDS)
Kidney/urine Problems (Kidney/urine
problems)
Liver Problems (Liver problems)
Lung Problems (Lung problems)
Other (Other)
Psychological Problems (Psychological
problems)
Seizure (Seizure)
Stroke (Stroke)
Thyroid Problems (Thyroid problems)
Specify other
Family History
How many of the following family members do
you have
How many brothers do you have
How many sisters do you have
How many sons do you have
How many daughters do you have
Are you adopted (Check one)
Yes
No
Blood relative with cancer (check = yes)
Brother #1 (Brother #1)
Brother #2 (Brother #2)
Brother #3 (Brother #3)
Brother #4 (Brother #4)
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Child #1 (Child  #1)
Child #2 (Child  #2)
Child #3 (Child  #3)
Child #4 (Child  #4)
Father (Father)
Mother (Mother)
Sister #1 (Sister  #1)
Sister #2 (Sister  #2)
Sister #3 (Sister  #3)
Sister #4 (Sister  #4)
Age when first cancer diagnosed
Type of Cancer (check = yes)
Breast (Breast)
Colon (Colon)
Head & Neck (Head & Neck)
Lung (Lung)
Non Melanoma Skin (Non Melanoma
Skin)
Other (Other)
Prostate (Prostate)
Specify
Have you ever heard of Cancer Prevention Trials
(Check one box)
Yes
No
How likely would you be to volunteer to
participate in Cancer Prevention Trials (The
numbers below allow you to rate your answer
between 1 - never and 10 - extremely likely. Circle
the number below that best describes your
choice.)
1 (1)
10 (10)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
7 (7)
8 (8)
9 (9)
5 / 5
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CALGB: HER-2/neu TESTING FORM
NCT00024102
CALGB: HER-2/neu TESTING FORM NCT00024102
Comparison of Combination Chemotherapy Regimens in
Treating Older Women Who Have Undergone Surgery for
Breast Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=0DF2A238-
0D66-4C86-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11331
CALGB: HER-2/neu TESTING
FORM NCT00024102
Header
CALGB Form
CALGB Study No
CALGB Patient ID
Amended data?
Yes (Yes)
Patient demographics
Patient Initials (Last, First Middle)
Participating Group
Patient Hospital No.
Participating Group Study No.
Institution/Affiliate
Participating Group Patient ID
TESTING DATA
Immunohistochemistry Kit or Test Type (Mark all
that apply with an X)
Cb-11 Other (CB-11 other)
Cb-11/ventana Kit (CB-11/Ventana Kit)
Dako Herceptest [tm] (DAKO Herceptest
[TM])
Ihc Not Done (IHC not done)
Other, Specify (Other, specify)
Scoring System (Score) (Mark one with an X)
0 (0)
1+ (1+)
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2+ (2+)
3+ (3+)
Scoring System (Score) (Mark one with an X)
0 (0)
1+ (1+)
2+ (2+)
3+ (3+)
Other, specify
Results
FISH Assessment Test Type (Mark all that apply
with an X)
Fish Not Done (FISH not done)
Other Specify (Other, specify)
Ventana Inform (Ventana INFORM)
Vysis/path Vysion[tm] (Vysis/PathVysion)
FISH HER2/neu chromosome 17 Ratio
Ventana Scoring System (Score)
0 (0)
1+ (1+)
2+ (2+)
3+ (3+)
Ventana Scoring System (Score)
0 (0)
1+ (1+)
2+ (2+)
3+ (3+)
Other, specify
Results
Testing Results
HER-2/neu status (Mark one with an Xby
institutional standards)
Negative (Negative)
Positive (Positive)
Form completed by
Completed by
Date Form Completed
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CALGB: TRASTUZUMAB MONITORING
FORM NCT00024102
CALGB: TRASTUZUMAB MONITORING FORM
NCT00024102
Comparison of Combination Chemotherapy Regimens in
Treating Older Women Who Have Undergone Surgery for
Breast Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=0DF41E5E-
5CC3-5A4A-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11332
CALGB: TRASTUZUMAB
MONITORING FORM NCT00024102
Header
CALGB Form
CALGB Study No
CALGB Patient ID
Amended data?
Yes (Yes)
Patient demographics
Patient Initials (Last, First Middle)
Participating Group
Patient Hospital No.
Participating Group Study No.
Institution/Affiliate
Participating Group Patient ID
Testing Results
Did the patient receive any Herceptin treatment?
Yes
No
No, specify reason
Date trastuzumab started (mm/dd/yyyy)
Date trastuzumab discontinued (mm/dd/yyyy)
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Reason for ending trastuzumab treatment (Mark
one with an X)
Cardiac Adverse Event (Cardiac adverse
event)
Completed Per Protocol Criteria
(Completed per protocol criteria)
Non-cardiac Adverse Event (Non-cardiac
adverse event)
Other (Other)
Other Cardiac Adverse Event (Other
cardiac adverse event)
Other, specify
Form completed by
Completed by
Date Form Completed
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RTOG-0522 A5: Demographic Data Form
NCT00265941
RTOG-0522 A5: Demographic Data Form NCT00265941
Radiation Therapy and Cisplatin With or Without Cetuximab
in Treating Patients With Stage III or Stage IV Head and
Neck Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=FA3C72BE-
9A73-28F6-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11333
RTOG-0522 A5: Demographic Data
Form NCT00265941
Header
RTOG Study No.
Case #
Institution Name
Institution No.
Patient Initials
RTOG Patient ID
Date Completed
Amended Data
Yes
No
Who completed this form (Check one box)
Not Applicable, No Items Completed (Not
applicable, no items completed)
Other Person (Other person)
Self (Self)
Staff (Staff)
Patient demographics
Patient Race Category
A Person Having Origins In Any Of The
Original Peoples Of North And South
America (including Central America),
And Who Maintains Tribal Affiliation Or
Community Attachment. (American
Indian or Alaska Native)
A Person Having Origins In Any Of The
Original Peoples Of The Far East,
Southeast Asia, Or The Indian
Subcontinent Including, For Example,
Cambodia, China, India, Japan, Korea,
Malaysia, Pakistan, The Philippine
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Islands, Thailand, And Vietnam. (Asian)
A Person Having Origins In Any Of The
Black Racial Groups Of Africa. Terms
Such As "haitian" Or "negro" Can Be
Used In Addition To "black Or African
American." (Black or African American)
A Person Having Origins In Any Of The
Original Peoples Of Hawaii, Guam,
Samoa, Or Other Pacific Islands. (Native
Hawaiian or other Pacific Islander)
Not Provided Or Available (Not
Reported)
Could Not Be Determined Or Unsure
(Unknown)
A Person Having Origins In Any Of The
Original Peoples Of Europe, The Middle
East, Or North Africa. (White)
Patient Ethnic Group Category (If you consider
yourself multiracial, check all additional
categories that apply in this question Do not
include what you reported in 2A.)
A Person Of Mexican, Puerto Rican,
Cuban, Central Or South American Or
Other Spanish Culture Or Origin,
Regardless Of Race. (HISPANIC OR
LATINO)
A Person Not Meeting The Definition For
Hispanic Or Latino. (NOT HISPANIC OR
LATINO)
Not Provided Or Available (Not reported)
Could Not Be Determined Or Unsure
(UNKNOWN)
Highest school grade completed
8th Or Less (8th or less)
9 - 11th Grade (9 - 11th Grade)
Advanced Degree (Advanced degree)
Associate Degree / Some College
(Associate degree/some college)
Bachelor's Degree (Bachelor's degree)
High School Graduate / Ged (High
school graduate/GED)
I Prefer Not To Answer (I prefer not to
answer)
Other (Other)
Vocational / Technical School
(Vocational/technical school)
Other, specify
Religion during childhood (Check one box)
Catholic (Catholic)
I Prefer Not To Answer (I prefer not to
answer)
Jewish (Jewish)
Morman/latter Day Saints
(Morman/Latter Day Saints)
Muslim / Islam (Muslim/Islam)
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None (None)
Other (Other)
Protestant (Protestant)
Other, specify
Marital status (Check one box)
Divorced/separated
(Divorced/Separated)
I Prefer Not To Answer (I prefer not to
answer)
Living As Married (Living as married)
Married (Married)
Single (Single)
Widowed (Widowed)
Where were you born (Check one box)
Other Country (Other country)
Usa (USA)
specify the 2 letter State code (eg NY)
Other country, specify
Where did you live the longest (Check one box)
Other Country (Other country)
Usa (USA)
specify the 2 letter State code (eg NY)
Other country, specify
Cigarette History
Smoked at least 100 cigarette during lifetime (5
packs)
No (No)
Yes, But Quit (Yes, but quit)
Yes, Currently Smoke (Yes, currently
smoke)
Age began smoking cigarettes
Number of years smoked cigarettes
Average number of cigarettes smoked per day
If quit, age stopped smoking completely
If you have had any of the illnesses listed below,
please check yes for those that apply (check =
Yes)
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Bleeding Problems (Bleeding problems)
Circulation Problems (Circulation
problems)
Diabetes Or Sugar In Urine (Diabetes or
sugar in urine)
Frequent Infections (Frequent infections)
Heart Problems (Heart problems)
High Blood Pressure (High blood
pressure)
Hiv/aids (HIV/AIDS)
Kidney/urine Problems (Kidney/urine
problems)
Liver Problems (Liver problems)
Lung Problems (Lung problems)
Other (Other)
Psychological Problems (Psychological
problems)
Seizure (Seizure)
Stroke (Stroke)
Thyroid Problems (Thyroid problems)
Specify other
Family History
How many brothers do you have (How many of
the following family members do you have living
and dead Include only those who are blood-
related)
How many sisters do you have
How many sons do you have
How many daughters do you have
Are you adopted (Check one)
Yes
No
Blood relative with cancer (check = yes)
Brother #1 (Brother #1)
Brother #2 (Brother #2)
Brother #3 (Brother #3)
Brother #4 (Brother #4)
Child #1 (Child  #1)
Child #2 (Child  #2)
Child #3 (Child  #3)
Child #4 (Child  #4)
Father (Father)
Mother (Mother)
Sister #1 (Sister  #1)
Sister #2 (Sister  #2)
Sister #3 (Sister  #3)
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Sister #4 (Sister  #4)
Age when first cancer diagnosed
Type of Cancer (check = yes)
Breast (Breast)
Colon (Colon)
Head & Neck (Head & Neck)
Lung (Lung)
Non Melanoma Skin (Non Melanoma
Skin)
Other (Other)
Prostate (Prostate)
Specify
Have you ever heard of Cancer Prevention Trials
(Check one box)
Yes
No
How likely would you be to volunteer to
participate in Cancer Prevention Trials (The
numbers below allow you to rate your answer
between 1 - never and 10 - extremely likely. Circle
the number below that best describes your
choice.)
1 (1)
10 (10)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
7 (7)
8 (8)
9 (9)
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NSABP PROTOCOL B-38: REGISTRATION
FORM - B-38 Form A NCT00093795
NSABP PROTOCOL B-38: REGISTRATION FORM - B-38
Form A NCT00093795
Combination Chemotherapy in Treating Women Who Have
Undergone Surgery for Node-Positive Breast Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=DAB2AAA8-
0A4D-252C-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/11334
NSABP PROTOCOL B-38:
REGISTRATION FORM - B-38 Form
A NCT00093795
NSABP REGISTRATION FORM
Patient Initials
Patient Medical Record Number
NSABP Patient ID
Institution Number
Institution Name
Affiliate Name
Physician of Record
Date Informed Consent Signed
Person completing Form, Last Name
Person completing Form, First Name
Person completing Form, Phone
Person completing Form, Fax
Patient's Date of Birth
Patient's Social Security Number (USA only)
Race
A Person Having Origins In Any Of The
Original Peoples Of North And South
America (including Central America),
And Who Maintains Tribal Affiliation Or
Community Attachment (American Indian
or Alaska Native)
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A Person Having Origins In Any Of The
Original Peoples Of The Far East,
Southeast Asia, Or The Indian
Subcontinent Including, For Example,
Cambodia, China, India, Japan, Korea,
Malaysia, Pakistan, The Philippine
Islands, Thailand, And Vietnam. (Asian)
A Person Having Origins In Any Of The
Black Racial Groups Of Africa. Terms
Such As "haitian" Or "negro" Can Be
Used In Addition To "black Or African
American." (Black or African American)
A Person Having Origins In Any Of The
Original Peoples Of Hawaii, Guam,
Samoa, Or Other Pacific Islands (Native
Hawaiian or Other Pacific Islander)
Patient Is Unsure Of Their Race
(Unknown)
A Person Having Origins In Any Of The
Original Peoples Of Europe, The Middle
East, Or North Africa. (White)
Method of Payment
Medicaid (Medicaid)
Medicaid And Medicare (Medicaid and
Medicare)
Medicare (Medicare)
Medicare And Private Insurance
(Medicare and Private Insurance)
Military Or Veterans Sponsored Nos
(Military or Veterans Sponsored NOS)
Military Sponsored (including Champus
& Tricare) (Military Sponsored including
(CHAMPUS & TRICARE))
No Means Of Payment (no Insurance)
(No means of payment (no insurance))
Other (Other)
Private Insurance (Private Insurance)
Self Pay (no Insurance) (Self pay (no
insurance))
Unknown (Unknown)
Veterans Sponsored (Veterans
Sponsored)
Ethnicity
A Person Of Mexican, Puerto Rican,
Cuban, Central Or South American Or
Other Spanish Culture Or Origin,
Regardless Of Race (Hispanic or Latino)
A Person Not Meeting The Definition For
Hispanic Or Latino. (Non-Hispanic)
Patient Is Unsure Of Their Ethnicity
(Unknown)
Country of Residence (if not USA)
Canada (Canada)
Mexico (Mexico)
Other (Other)
Puerto Rico (Puerto Rico)
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Other
Participant's Zip Code (USA)
Your blood and tissue samples may be kept by
the NSABP for use in this study and future
research to learn about, prevent, detect, or treat
cancer.
Yes
No
Your blood and tissue samples may be used for
research about other health problems (for
example: causes of heart disease, osteoporosis,
diabetes).
Yes
No
Your study doctor (or someone he or she
chooses) may contact you in the future to ask you
to take part in more research.
Yes
No
Patient Height
cm
Patient Weight
Kg
Number of Positive Nodes
1 - 3 (1-3)
10+ (10+)
4 - 9 (4-9)
Receptor Status
Er And Pgr Negative (ER and PgR
Negative)
Er Or Pgr Positive (ER or PgR Positive)
Type of Surgery and Planned Radiotherapy
Lumpectomy Plus Local Rt With
Regional Rt (Lumpectomy + local RT
with regional RT)
Lumpectomy And Local Rt Without
Regional Rt (Lumpectomy and local RT
without regional RT)
Mastectomy With Either Local Or
Regional Rt (Mastectomy with either
local or regional RT)
Mastectomy Without Rt (Mastectomy
without RT)
In the opinion of the investigator, is the patient
eligible?
Yes
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NCT00533949 A5: Radiation Therapy Oncology Group Phase III High-dose Vs
Standard-dose Conformal XRT with Chemotherapy Demographic Data Form -
Version
NCT00533949 A5: Radiation Therapy Oncology Group
Phase III High-dose Vs Standard-dose Conformal XRT with
Chemotherapy Demographic Data Form - Version
High-Dose or Standard-Dose Radiation Therapy and
Chemotherapy With or Without Cetuximab in Treating
Patients With Newly Diagnosed Stage III Non-Small Cell
Lung Cancer That Cannot Be Removed by Surgery
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=24F9E1D9-
7462-4C05-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11335
NCT00533949 A5: Radiation
Therapy Oncology Group Phase III
High-dose Vs Standard-dose
Conformal XRT with Chemotherapy
Demographic Data Form - Version
Header
RTOG Study No.
Case #
Institution Name
Institution No.
Patient Initials
RTOG Patient ID
Date Completed
Amended Data
Yes
No
Who completed this form (Check one box)
Not Applicable, No Items Completed (Not
applicable, no items completed)
Other Person (Other person)
Self (Self)
Staff (Staff)
Patient demographics
Race
A Person Having Origins In Any Of The
Original Peoples Of North And South
America (including Central America),
And Who Maintains Tribal Affiliation Or
Community Attachment. (American
Indian or Alaska Native)
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A Person Having Origins In Any Of The
Original Peoples Of The Far East,
Southeast Asia, Or The Indian
Subcontinent Including, For Example,
Cambodia, China, India, Japan, Korea,
Malaysia, Pakistan, The Philippine
Islands, Thailand, And Vietnam. (Asian)
A Person Having Origins In Any Of The
Black Racial Groups Of Africa. Terms
Such As "haitian" Or "negro" Can Be
Used In Addition To "black Or African
American." (Black or African American)
A Person Having Origins In Any Of The
Original Peoples Of Hawaii, Guam,
Samoa, Or Other Pacific Islands. (Native
Hawaiian or other Pacific Islander)
Not Provided Or Available (Not
Reported)
Could Not Be Determined Or Unsure
(Unknown)
A Person Having Origins In Any Of The
Original Peoples Of Europe, The Middle
East, Or North Africa. (White)
Ethnicity (If you consider yourself multiracial,
check all additional categories that apply in this
question Do not include what you reported in 2A.)
A Person Of Mexican, Puerto Rican,
Cuban, Central Or South American Or
Other Spanish Culture Or Origin,
Regardless Of Race. (HISPANIC OR
LATINO)
A Person Not Meeting The Definition For
Hispanic Or Latino. (NOT HISPANIC OR
LATINO)
Not Provided Or Available (Not reported)
Could Not Be Determined Or Unsure
(UNKNOWN)
Highest school grade completed
8th Or Less (8th or less)
9 - 11th Grade (9 - 11th Grade)
Advanced Degree (Advanced degree)
Associate Degree / Some College
(Associate degree/some college)
Bachelor's Degree (Bachelor's degree)
High School Graduate / Ged (High
school graduate/GED)
I Prefer Not To Answer (I prefer not to
answer)
Other (Other)
Vocational / Technical School
(Vocational/technical school)
Other, specify
Religion during childhood (Check one box)
Catholic (Catholic)
I Prefer Not To Answer (I prefer not to
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Standard-dose Conformal XRT with Chemotherapy Demographic Data Form -
Version
answer)
Jewish (Jewish)
Morman/latter Day Saints
(Morman/Latter Day Saints)
Muslim / Islam (Muslim/Islam)
None (None)
Other (Other)
Protestant (Protestant)
Other, specify
Marital status (Check one box)
Divorced (Divorced)
Domestic Partnership (Domestic
Partnership)
I Prefer Not To Answer (I prefer not to
answer)
Married (Married)
Never Married (Never married)
Separated (Separated)
Widowed (Widowed)
Where were you born (Check one box)
Other Country (Other country)
Usa (USA)
specify the 2 letter State code (eg NY)
Other country, specify
Where did you live the longest (Check one box)
Other Country (Other country)
Usa (USA)
specify the 2 letter State code (eg NY)
Other country, specify
Cigarette History
Smoked at least 100 cigarette during lifetime (5
packs)
No (No)
Yes, But Quit (Yes, but quit)
Yes, Currently Smoke (Yes, currently
smoke)
Age began smoking cigarettes
Number of years smoked cigarettes
Average number of cigarettes smoked per day
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If quit, age stopped smoking completely
If you have had any of the illnesses listed below,
please check yes for those that apply (check =
Yes)
Bleeding Problems (Bleeding problems)
Circulation Problems (Circulation
problems)
Diabetes Or Sugar In Urine (Diabetes or
sugar in urine)
Frequent Infections (Frequent infections)
Heart Problems (Heart problems)
High Blood Pressure (High blood
pressure)
Hiv/aids (HIV/AIDS)
Kidney/urine Problems (Kidney/urine
problems)
Liver Problems (Liver problems)
Lung Problems (Lung problems)
Other (Other)
Psychological Problems (Psychological
problems)
Seizure (Seizure)
Stroke (Stroke)
Thyroid Problems (Thyroid problems)
Specify other
Family History
Brothers (How many of the following family
members do you have living and dead Include
only those who are blood-related)
Sisters (How many of the following family
members do you have living and dead Include
only those who are blood-related)
Sons (How many of the following family members
do you have living and dead Include only those
who are blood-related)
Daughters (How many of the following family
members do you have living and dead Include
only those who are blood-related)
Are you adopted (Check one)
Yes
No
Blood relative with cancer (check = yes)
Brother #1 (Brother #1)
Brother #2 (Brother #2)
Brother #3 (Brother #3)
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Brother #4 (Brother #4)
Child #1 (Child  #1)
Child #2 (Child  #2)
Child #3 (Child  #3)
Child #4 (Child  #4)
Father (Father)
Mother (Mother)
Sister #1 (Sister  #1)
Sister #2 (Sister  #2)
Sister #3 (Sister  #3)
Sister #4 (Sister  #4)
Age when first cancer diagnosed
Type of Cancer (check = yes)
Breast (Breast)
Colon (Colon)
Head & Neck (Head & Neck)
Lung (Lung)
Non Melanoma Skin (Non Melanoma
Skin)
Other (Other)
Prostate (Prostate)
Specify
Have you ever heard of Cancer Prevention Trials
(Check one box)
Yes
No
How likely would you be to volunteer to
participate in Cancer Prevention Trials (The
numbers below allow you to rate your answer
between 1 - never and 10 - extremely likely. Circle
the number below that best describes your
choice.)
1 (1)
10 (10)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
7 (7)
8 (8)
9 (9)
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NSABP PROTOCOL B-39: REGISTRATION
FORM - B-39 Form A NCT00103181
NSABP PROTOCOL B-39: REGISTRATION FORM - B-39
Form A NCT00103181
Radiation Therapy in Treating Women Who Have
Undergone Surgery For Ductal Carcinoma In Situ or Stage
I or Stage II Breast Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=E6E4EDBC-
FF93-23A2-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11336
NSABP PROTOCOL B-39:
REGISTRATION FORM - B-39 Form
A NCT00103181
NSABP REGISTRATION FORM
Patient Initials
NSABP Patient ID
Institution Name
Affiliate Name
Date Informed Consent Signed (MM DD YYYY)
Person Completing Form Last Name
Person Completing Form First Name
Person Completing Form Phone
Person Completing Form Fax
Patient's Date of Birth (MM DD YYYY)
Patient's Social Security Number (USA only)
Race (more than one may be marked)
A Person Having Origins In Any Of The
Original Peoples Of North And South
America (including Central America),
And Who Maintains Tribal Affiliation Or
Community Attachment (American Indian
or Alaska Native)
A Person Having Origins In Any Of The
Original Peoples Of The Far East,
Southeast Asia, Or The Indian
Subcontinent Including, For Example,
Cambodia, China, India, Japan, Korea,
Malaysia, Pakistan, The Philippine
Islands, Thailand, And Vietnam. (Asian)
A Person Having Origins In Any Of The
1 / 4
Black Racial Groups Of Africa. Terms
Such As "haitian" Or "negro" Can Be
Used In Addition To "black Or African
American." (Black or African American)
A Person Having Origins In Any Of The
Original Peoples Of Hawaii, Guam,
Samoa, Or Other Pacific Islands (Native
Hawaiian or Other Pacific Islander)
Patient Is Unsure Of Their Race
(Unknown)
A Person Having Origins In Any Of The
Original Peoples Of Europe, The Middle
East, Or North Africa. (White)
Method of Payment (mark primary method only)
Medicaid (Medicaid)
Medicaid And Medicare (Medicaid and
Medicare)
Medicare (Medicare)
Medicare And Private Insurance
(Medicare and Private Insurance)
Military Or Veterans Sponsored Nos
(Military or Veterans Sponsored NOS)
Military Sponsored (including Champus
& Tricare) (Military Sponsored (incl.
CHAMPUS & TRICARE))
No Means Of Payment (no Insurance)
(No means of payment (no insurance))
Other (Other)
Private Insurance (Private Insurance)
Self Pay (no Insurance) (Self pay (no
insurance))
Unknown (Unknown)
Veterans Sponsored (Veterans
Sponsored)
Ethnicity
A Person Of Mexican, Puerto Rican,
Cuban, Central Or South American Or
Other Spanish Culture Or Origin,
Regardless Of Race (Hispanic or Latino)
A Person Not Meeting The Definition For
Hispanic Or Latino. (Non-Hispanic)
Patient Is Unsure Of Their Ethnicity
(Unknown)
Country of Residence (if not USA)
Canada (Canada)
Mexico (Mexico)
Other (Other)
Puerto Rico (Puerto Rico)
Other
Participant's Zip Code (USA)
Your blood and tissues samples may be kept by
the NSABP for use in future research to learn
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about, prevent, detect, or treat cancer.
Yes
No
Your blood and tissue samples may be used for
research about other health
problems (for example: causes of heart disease,
osteoporosis, diabetes).
Yes
No
Your study doctor (or someone he or she
chooses) may contact you in the future to ask you
to take part in more research.
Yes
No
Patient Height
cm
Patient Weight
Kg
Disease Stage
Dcis Only (DCIS only)
Invasive And Node Negative (Invasive
and node negative)
Invasive With 1-3 Positive Nodes
(Invasive with 1-3 positive nodes)
Menopausal status
Postmenopausal (Postmenopausal)
Premenopausal (Premenopausal)
Hormonal Status
Er-negative And Pgr-negative (ER-
negative and PgR-negative)
Er-positive And/or Pgr-positive (ER-
positive and/or PgR-positive)
Intention to Receive Chemotherapy
Yes
No
Footer module
RT Facility Code (required)
NCI Investigator Number (Surgeon)
Investigator Name (Surgeon)
PBI Technique
3d Conformal External Beam Radiation
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(3D Conformal External Beam Radiation)
Contura Mlb (Contura MLB)
Mammosite (single Lumen) (MammoSite
(single lumen))
Mammosite Ml (MammoSite ML)
Multi-catheter Brachytherapy (Multi-
Catheter Brachytherapy)
Savi (SAVI)
Certification Of Eligibility:
In the opinion of the investigator, is the patient
eligible?
Yes
No
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RTOG 0534 A5: Demographic Data Form
NCT00567580
RTOG 0534 A5: Demographic Data Form NCT00567580
Prostate Radiation Therapy or Short-Term Androgen
Deprivation Therapy and Pelvic Lymph Node Radiation
Therapy With or Without Prostate Radiation Therapy in
Treating Patients With a Rising PSA After Surgery for
Prostate Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=2A131B2A-
EFC4-56FD-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11338
RTOG 0534 A5: Demographic Data
Form NCT00567580
Header
RTOG Study No.
Case #
Institution Name
Institution No.
Patient Initials
RTOG Patient ID
Date Completed
Amended Data
Yes
No
Who completed this form (Check one box)
Not Applicable, No Items Completed (Not
applicable, no items completed)
Other Person (Other person)
Self (Self)
Staff (Staff)
Patient demographics
Patient Race Category (Check all that apply)
A Person Having Origins In Any Of The
Original Peoples Of North And South
America (including Central America),
And Who Maintains Tribal Affiliation Or
Community Attachment. (American
Indian or Alaska Native)
A Person Having Origins In Any Of The
Original Peoples Of The Far East,
Southeast Asia, Or The Indian
Subcontinent Including, For Example,
Cambodia, China, India, Japan, Korea,
Malaysia, Pakistan, The Philippine
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Islands, Thailand, And Vietnam. (Asian)
A Person Having Origins In Any Of The
Black Racial Groups Of Africa. Terms
Such As "haitian" Or "negro" Can Be
Used In Addition To "black Or African
American." (Black or African American)
A Person Having Origins In Any Of The
Original Peoples Of Hawaii, Guam,
Samoa, Or Other Pacific Islands. (Native
Hawaiian or other Pacific Islander)
Not Provided Or Available (Not
Reported)
Could Not Be Determined Or Unsure
(Unknown)
A Person Having Origins In Any Of The
Original Peoples Of Europe, The Middle
East, Or North Africa. (White)
Patient Ethnic Group Cateogy (If you consider
yourself multiracial, check all additional
categories that apply in this question Do not
include what you reported in 2A.)
A Person Of Mexican, Puerto Rican,
Cuban, Central Or South American Or
Other Spanish Culture Or Origin,
Regardless Of Race. (HISPANIC OR
LATINO)
A Person Not Meeting The Definition For
Hispanic Or Latino. (NOT HISPANIC OR
LATINO)
Not Provided Or Available (Not reported)
Could Not Be Determined Or Unsure
(UNKNOWN)
Highest school grade completed (Check one box)
8th Or Less (8th or less)
9 - 11th Grade (9 - 11th Grade)
Advanced Degree (Advanced degree)
Associate Degree / Some College
(Associate degree/some college)
Bachelor's Degree (Bachelor's degree)
High School Graduate / Ged (High
school graduate/GED)
I Prefer Not To Answer (I prefer not to
answer)
Other (Other)
Vocational / Technical School
(Vocational/technical school)
Other, specify
Religion during childhood (Check one box)
Catholic (Catholic)
I Prefer Not To Answer (I prefer not to
answer)
Jewish (Jewish)
Morman/latter Day Saints
(Morman/Latter Day Saints)
Muslim / Islam (Muslim/Islam)
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None (None)
Other (Other)
Protestant (Protestant)
Other, specify
Marital status
Divorced (Divorced)
Domestic Partnership (Domestic
Partnership)
I Prefer Not To Answer (I prefer not to
answer)
Married (Married)
Never Married (Never married)
Separated (Separated)
Widowed (Widowed)
Where were you born (Check one box)
Other Country (Other country)
Usa (USA)
specify the 2 letter State code (eg NY)
Other country, specify
Where did you live the longest (Check one box)
Other Country (Other country)
Usa (USA)
specify the 2 letter State code (eg NY)
Other country, specify
Cigarette History
Smoked at least 100 cigarette during lifetime (5
packs)
No (No)
Yes, But Quit (Yes, but quit)
Yes, Currently Smoke (Yes, currently
smoke)
Age began smoking cigarettes
Number of years smoked cigarettes
Average number of cigarettes smoked per day
If quit, age stopped smoking completely
If you have had any of the illnesses listed below,
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please check yes for those that apply (check =
Yes)
Bleeding Problems (Bleeding problems)
Circulation Problems (Circulation
problems)
Diabetes Or Sugar In Urine (Diabetes or
sugar in urine)
Frequent Infections (Frequent infections)
Heart Problems (Heart problems)
High Blood Pressure (High blood
pressure)
Hiv/aids (HIV/AIDS)
Kidney/urine Problems (Kidney/urine
problems)
Liver Problems (Liver problems)
Lung Problems (Lung problems)
Other (Other)
Psychological Problems (Psychological
problems)
Seizure (Seizure)
Stroke (Stroke)
Thyroid Problems (Thyroid problems)
Specify other
Family History
How many brothers do you have (How many of
the following family members do you have living
and dead Include only those who are blood-
related)
How many sisters do you have
How many sons do you have
How many daughters do you have
Are you adopted (Check one)
Yes
No
Blood relative with cancer (check = yes)
Brother #1 (Brother #1)
Brother #2 (Brother #2)
Brother #3 (Brother #3)
Brother #4 (Brother #4)
Child #1 (Child  #1)
Child #2 (Child  #2)
Child #3 (Child  #3)
Child #4 (Child  #4)
Father (Father)
Mother (Mother)
Sister #1 (Sister  #1)
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Sister #2 (Sister  #2)
Sister #3 (Sister  #3)
Sister #4 (Sister  #4)
Age when first cancer diagnosed
Type of Cancer (check = yes)
Breast (Breast)
Colon (Colon)
Head & Neck (Head & Neck)
Lung (Lung)
Non Melanoma Skin (Non Melanoma
Skin)
Other (Other)
Prostate (Prostate)
Specify
Have you ever heard of Cancer Prevention Trials
(Check one box)
Yes
No
How likely would you be to volunteer to
participate in Cancer Prevention Trials (The
numbers below allow you to rate your answer
between 1 - never and 10 - extremely likely. Circle
the number below that best describes your
choice.)
1 (1)
10 (10)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
7 (7)
8 (8)
9 (9)
5 / 5
RTOG 0534 A5: Demographic Data Form NCT00567580
NCT00408408 NSABP Protocol B-40 - WORKSHEET FOR
REPORTING BREAST RECONSTRUCTION INFORMATION
NCT00408408 NSABP Protocol B-40 - WORKSHEET FOR
REPORTING BREAST RECONSTRUCTION
INFORMATION
A Randomized Phase III Trial of Neoadjuvant Therapy in
Patients With Palpable and Operable Breast Cancer
Evaluating the Effect on Pathologic Complete Response
(pCR) of Adding Capecitabine or Gemcitabine to Docetaxel
When Administered Before AC With or Without
Bevacizumab and Correlative Science Studies Attempting
to Identify Predictors of High Likelihood for pCR With Each
of the Regimens
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=7D9B7B8C-
E72A-A457-E040-BB89AD4372F6
All rights reserved. Please visit https://medical-data-
models.org/forms/11339
NCT00408408 NSABP Protocol B-
40 - WORKSHEET FOR
REPORTING BREAST
RECONSTRUCTION
INFORMATION
Header
Patient Initials (Last First Middle)
NSABP Patient ID
BREAST RECONSTRUCTION
INFORMATION
Time Interval for this Assessment
Date Of Surgery To 3-5 Weeks Following
Surgery (Date of surgery to 3-5 weeks
following surgery)
Day After Previous Time Interval To 12
Months Following Study Entry (Day after
previous time interval to 12 months
following study entry)
Day After Previous Time Interval To 24
Months Following Study Entry (Day after
previous time interval to 24 months
following study entry)
Day After Previous Time Interval To 9
Months Following Study Entry (Day after
previous time interval to 9 months
following study entry)
Did the patient receive breast reconstruction
Yes
No
Type of breast reconstruction (If yes, mark all that
apply)
Breast Implant (Breast Implant)
Free Flap (Free Flap)
Other (Other)
Rotated Flap (Rotated flap)
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Breast Tissue Expander (Tissue
Expanders)
Other, specify
Footer
Comments
Person Completing Form
Date Form Completed
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NSABP PROTOCOL C-09: ON-STUDY
FORM NCT00268463
NSABP PROTOCOL C-09: ON-STUDY FORM
NCT00268463
Oxaliplatin and Capecitabine With or Without an Hepatic
Arterial Infusion With Floxuridine in Treating Patients Who
Are Undergoing Surgery and/or Ablation for Liver
Metastases Due to Colorectal Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=FC7D974C-
8A71-3E64-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11340
NSABP PROTOCOL C-09: ON-
STUDY FORM NCT00268463
Header
Patient Initials (Last First Middle)
NSABP Patient ID
Institution Name
Affiliate Name
Person Completing Form Last Name
Person Completing Form First Name
Person Completing Form Phone
Patient Gender
Female (Female)
Male (Male)
Date of Pre-Entry CT or MRI Scan of Abdomen
and Pelvis (Submit report with Form ON.)
Are data amended (If yes, check box and circle
amended items)
Yes
No
Primary Colorectal Tumor
Date of Resection (primary colorectal tumor)
Classification of Colorectal Tumor
Colon Cancer (Colon Cancer)
Rectal Cancer (Rectal Cancer)
Did the patient receive adjuvant chemotherapy for
the primary colorectal cancer
Yes
No
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Was oxaliplatin chemotherapy administered
Yes
No
N Stage, Pathologic (primary colorectal tumor)
N0, According To Ajcc Criteria (N0)
N1, According To Ajcc Criteria (N1)
N2, According To Ajcc Criteria (N2)
Nx, According To Ajcc Criteria (NX)
T Stage, Pathologic (If multiple primary colorectal
tumors, report on most advanced.)
T0, According To Ajcc Criteria (T0)
T1, According To Ajcc Criteria (T1)
T2, According To Ajcc Criteria (T2)
T3, According To Ajcc Criteria (T3)
T4, According To Ajcc Criteria (T4)
Tis, According To Ajcc Criteria (Tis)
Tx, According To Ajcc Criteria (TX)
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NCT00057811  CHILDREN'S ONCOLOGY GROUP
CYTOGENETICS REPORTING FORM [ANHL01P1]
NCT00057811  CHILDREN'S ONCOLOGY GROUP
CYTOGENETICS REPORTING FORM [ANHL01P1]
Rituximab, Rasburicase, and Combination Chemotherapy
in Treating Young Patients With Newly Diagnosed
Advanced B-Cell Leukemia or Lymphoma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=BA472941-
6B83-4501-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/11341
NCT00057811  CHILDREN'S
ONCOLOGY GROUP
CYTOGENETICS REPORTING
FORM [ANHL01P1]
Header
Institution
Institution Personnel
Institution Patient Identifier
Institution Patient Identifier
Today's date
Date worksheet entered into RDE
Miscellaneous Patient Information
Sex (Required field)
Female (Female)
Male (Male)
Unknown (UNKNOWN)
If not at study entry, was the primary diagnosis
specimen submitted to a cytogenetics laboratory
(Required field)
No (No)
Not At Study Entry (Not at study entry)
Yes (Yes)
Specimen Time (Choose one)
During therapy (During therapy)
Other Specify (Other, specify below)
Sample Or Specimen Collected After
Patient Received Treatment For Cancer
(Post-treatment)
Sample Or Specimen Collected Before
Patient Was Diagnosed With Cancer
(Pre-diagnosis)
Sample Or Specimen Collected Before
Patient Received Treatment For Cancer
(Pre-treatment)
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Primary diagnosis specimen (Primary
diagnosis specimen)
Relapse (Relapse)
Staging (Staging)
Unknown (Unknown)
please specify [specimen time] (Text)
Cytogenetics Laboratory Specimen Number
(Required field)
Data Specimen Collected (mm/dd/yyyy)
Date Specimen Received in Cytogenetics
Laboratory (mm/dd/yyyy)
Specimen Type (Required field)
Body fluid (Body fluid)
Bone Biopsy (Bone biopsy)
Bone Marrow (Bone marrow aspirate)
Bone Marrow (Bone marrow biopsy)
Cerebrospinal Fluid (Cerebrospinal fluid)
Fine needle aspirate (Fine needle
aspirate)
Other Specify (Other, specify below)
Peripheral Blood (Peripheral blood)
Peritoneal Fluid (Peritoneal fluid)
Pleural Fluid (Pleural fluid)
Soft Tissue Mass (Soft tissue mass)
Lymph Node (Surgical biopsy of lymph
node)
Surgical biopsy of tumor (Surgical biopsy
of tumor)
please specify [specimen type] (Text)
Pathology Specimen Number (corresponding to
cytogenetics specimen)
Pathology specimen involved by malignancy?
Yes
No
Ccrr Module For Children's Oncology
Group Cytogenetics Reporting Form
[anhl01p1]
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NSABP PROTOCOL R-04 Radiation
Therapy Report  NCT00058474
NSABP PROTOCOL R-04 Radiation Therapy Report
NCT00058474
Radiation Therapy and Either Capecitabine or Fluorouracil
With or Without Oxaliplatin Before Surgery in Treating
Patients With Resectable Rectal Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=B782329A-
7D15-2500-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/11342
NSABP PROTOCOL R-04 Radiation
Therapy Report NCT00058474
Header module
Last
First
Middle
NSABP Patient ID
Person Completing Form, Last Name (Person
Completing Form, First Name)
Person Completing Form, First Name
Person Completing Form, Phone
Institution Name / Affiliate
Are data amended
Yes
No
Radiation Therapy Report
Has the patient received pre-operative RT? (prior
to treatment failure or second primary cancer)
Yes
No
Pre-operative RT begin date
Pre-operative RT end date
Was the tumor fixed to surrounding structures?
Yes
No
Were there any unscheduled interruptions in
radiation therapy?
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Yes
No
Reasons (If yes, indicate)
Chemotherapy-related Adverse Event
(Chemotherapy-related AE)
Non-medical Reason (Non-medical
reason)
Other Medical Reason (Other medical
reason)
Radiation Reaction: Gastrointestinal
Adverse Event (Radiation reaction:
gastrointestinal AE)
Radiation Reaction: Other Adverse Event
(Radiation reaction: Other AE)
Radiation Reaction: Skin Adverse Event
(Radiation reaction: skin AE)
Specify
Was a Boost given?
Yes
No
If no Boost, indicate reason(s).
Other,specify (Other,specify)
Patient Refusal (Patient Refusal)
Small Bowel In Field (Small Bowel in
Field)
Toxicity (Toxicity)
Other,specify
RT Total Dose, Whole Pelvis (prior to boost)
RT Total Dose, Boost (cGY)
No. of Fractions, Whole Pelvis (prior to boost)
No. of Fractions, Boost (cGY)
Beam Energy
Energy Type
Boost, Electron (Boost, Electron)
Boost, X-ray or Photon (Boost, X-ray or
Photon)
Whole Pelvis, Electron (Whole Pelvis,
Electron)
Whole Pelvis, X-ray or Photon (Whole
Pelvis, X-ray or Photon)
Field Size (Anterior cm)
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ABTR01B1: Specimen Shipping Form
NCT00898079
ABTR01B1: Specimen Shipping Form NCT00898079 
Collecting and Storing Malignant, Borderline Malignant
Neoplasms, and Related Samples From Young Patients
With Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=BCEE8B04-
749D-37DA-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/11343
ABTR01B1: Specimen Shipping
Form NCT00898079
Header
Patient Identifier
Name
Modifier
Date Last Modified
Disease / Patient Status
Disease/Patient Status at time of sampling
Death (Death)
Diagnosis Of Primary (Diagnosis of
Primary)
Second Malignancy (Diagnosis of
Secondary Malignancy)
Progression Or Relapse (Relapse)
Second-look Surgery (Second Look
Surgery)
Accession Number
Date of Diagnosis
Central Review Diagnosis [ICD-O Morphology]
Institutional assessment of site of disease [ICD-O
Topography]
Tumor stage
I (1)
Ii (2)
Iii (3)
Iv (4)
V (5)
Unknown/not Applicable (Unknown/NA)
Other Disease-Specific Stage
1 / 3
BPC Number
Shipping Information
Carrier
Account Number
Carrier Tracking Number
Date Shipped
Source of Tissue Sample
Distant Metastases (metastasis)
Other, Specify (other)
Primary (primary)
Recurrent Tumor (recurrence)
Unknown (unknown)
Patient Status Information
Chemotherapy Status
Post-treatment (Post-chemotherapy)
Pre-treatment (Pre-chemotherapy)
XRT Status
Post-treatment (Post-XRT)
Pre-treatment (Pre-XRT)
was sample from radiation port? (If Post-XRT,)
Yes
No
Is this a rare tumor?
Yes
No
Central Review Diagnosis [ICD-O Morphology]
Percent Tumor Estimate
Material sent
Peripheral Blood (Blood)
Bone Marrow (Bone Marrow)
Tissue Fixed With Formalin (Formalin
Fixed Tissue)
Frozen Tissue, Not Fixed, Embedded
With Oct (OCT Embedded
Tumor/Tissue)
Paraffin Blocks (Paraffin block(s))
Serum (Serum)
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Frozen Tissue, Not Fixed, Without The
Use Of Oct (Snap Frozen Tumor/Tissue)
Stained Slides (Stained Slides)
Unstained Slides (Unstained Slides)
Sites from which specimen was taken [ICD-O
Topography]
Date Specimen Obtained
Paperwork Sent
Specimen Shipment Form (ABTR01B1
Shipping Form)
Operative Report(s) (Copy of Operative
Report)
Pathology Checklist (Copy of Pathology
Checklist)
Pathology Report(s) (Copy of Pathology
Report)
Has informed consent been given to for the
patient's specimens to be used in research to
learn about, prevent, or treat cancer? (Consent
Instruction 1:)
Yes
No
Has informed consent been given to for the
patient's specimens to be used in research to
learn about other health problems? (Consent
Instruction 2:)
Yes
No
Has informed consent been given for contact
sometime in the future about taking part in more
research? (Consent Instruction 3:)
Yes
No
Ccrr Module For Abtr01b1: Specimen
Shipping Form
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GRF
GRF
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=FF19E559-
5522-2E71-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11344
GRF
Header module
Segment
Record number of columns used for the selection
One column (One column)
Three columns (Three columns)
Two columns (Two columns)
Visit number
Record Date Of Each Cd34 Cell Selection
Procedure
Selection #3
Selection #3
Selection #3
For Each Column Used For Cell Selection,
Record The Following Information
Final Product #1
Was the entire final product infused
Yes
No
Log10 T cell depletion
CD34+ cell yield
CD34+ cell purity
Sterility results - 14 day cultures
Negative (Negative)
Positive (Positive)
Endotoxin concentration
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CD14+ monocytes
CD19+ or CD20+ B cells
CD3-CD56+ CD16+ NK cells
CD3+ CD8+ T cells
CD3+ CD4+ T cells
Sterility results - gram stain
Negative (Negative)
Positive (Positive)
Total nucleated cell count
CD34+ cell count
CD3+ T cell count
Final Product #2
Was the entire final product infused
Yes
No
Log10 T cell depletion
CD34+ cell yield
CD34+ cell purity
Sterility results - 14 day cultures
Negative (Negative)
Positive (Positive)
Endotoxin concentration
CD14+ monocytes
CD19+ or CD20+ B cells
CD3-CD56+ CD16+ NK cells
CD3+ CD8+ T cells
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CD3+ CD4+ T cells
Sterility results - gram stain
Negative (Negative)
Positive (Positive)
Total nucleated cell count
CD34+ cell count
CD3+ T cell count
Final Product #3
CD34+ cell purity
Log10 T cell depletion
CD34+ cell yield
Sterility results - 14 day cultures
Negative (Negative)
Positive (Positive)
Endotoxin concentration
Was the entire final product infused
Yes
No
CD14+ monocytes
CD19+ or CD20+ B cells
CD3-CD56+ CD16+ NK cells
CD3+ CD8+ T cells
CD3+ CD4+ T cells
Sterility results - gram stain
Negative (Negative)
Positive (Positive)
Total nucleated cell count
CD34+ cell count
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CD3+ T cell count
Record patient's weight at time of infusion
Kg
Comments
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ABTR01B1: Eligibility NCT00898079 
Collecting and Storing Malignant, Borderline Malignant
Neoplasms, and Related Samples From Young Patients
With Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=BCEF5AA5-
5C2A-372E-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/11345
ABTR01B1: Eligibility NCT00898079
Header
Patient Identifier
Name
Modifier
Date Last Modified
Eligibility Assessment
Does patient have neuroblastoma or acute
lymphoblastic leukemias?
Yes
No
Is patient eligible for a disease-specific
biology/banking protocol or studies?
Yes
No
Have or will specimens be shipped within ten
days of registration?
Yes
No
Has written informed consent been obtained?
Yes
No
Is the patient currently either at: 1) diagnosis of
primary neoplasm; 2) second-look surgery; or 3)
development of a secondary neoplasm?
Yes
No
Ccrr Module For Abtr01b1: Eligibility
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NCT00769379 NSABP Protocol B-43 Worksheet
for Postoperative Adjuvant Hormonal Therapy
NCT00769379 NSABP Protocol B-43 Worksheet for
Postoperative Adjuvant Hormonal Therapy
Radiation Therapy With or Without Trastuzumab in Treating
Women With Ductal Carcinoma In Situ Who Have
Undergone Lumpectomy
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=3991797E-
2E18-69DD-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11346
NCT00769379 NSABP Protocol B-
43 Worksheet for Postoperative
Adjuvant Hormonal Therapy
Header
NSABP Patient ID
Patient Initials (Last First Middle)
Reporting Period
12 Months (12 months)
24 Months (24 months)
36 Months (36 months)
48 Months (48 months)
60 Months (60 months)
72 Months (72 months)
Since being entered on study, has the patient
received any postoperative adjuvant hormonal
treatment?
Yes
No
New Data
Does this report contain any new data or has any
data been changed from the last report?
Yes (1)
No (2)
Agent
Agent
Aromatase Inhibitor (Aromatase
Inhibitor)
Other (Other)
Tamoxifen (Tamoxifen)
Other, specify
Begin date
End date
1 / 2
Treatment Ended
Has all postoperative adjuvant hormonal
treatment ended?
Yes
No
Reason Treatment Ended (Last Postoperative
Adjuvant HT)
Adverse Event/side Effects/complications
(Adverse Event/Side
Effects/Complications)
Death On Study (Death on study)
Disease Progression, Relapse During
Active Treatment (Disease progression,
relapse during active treatment)
Other (Other)
Patient Withdrawal Or Refusal After
Beginning Protocol Therapy (Patient
withdrawal/refusal after beginning
protocol therapy)
Treatment Completed Per Protocol
Criteria (Treatment completed per
protocol criteria)
Other specify
Comments
Comments
Footer
Person Completing Form
Date Form Completed
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ACNS0122 PBSC Harvest Worksheet
NCT00047320
ACNS0122 PBSC Harvest Worksheet NCT00047320 
Neoadjuvant Chemotherapy With or Without Second-Look
Surgery Followed by Radiation Therapy With or Without
Peripheral Stem Cell Transplantation in Treating Patients
With Intracranial Germ Cell Tumors
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=BD8E5AF7-
9FAF-0089-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/11348
ACNS0122 PBSC Harvest
Worksheet NCT00047320
Header
Institution Name
COG Study No
COG Study No
COG Patient ID
Patient Initials
Today's date
Date worksheet entered into RDE
Height / Weight
Height in
cm
Weight
Kg
Peripheral stem cell transplantation
Did the patient have PBSC harvest during this
reporting period?
Yes
No
Date [PBSC harvest]
Description (number of cells collected)
Was Bone Marrow harvesting performed?
Yes
No
1 / 2
date performed (If yes,)
Organ function
Did the patient have adequate CD34+ cells
collected?
Yes
No
Does the patient have adequate bone marrow
function?
Yes
No
Does the patient have adequate renal function?
Yes
No
Does the patient have adequate liver function?
Yes
No
Does the patient have adequate Central Nervous
System function?
Yes
No
Comments
Comments
Ccrr Module For Acns0122 Pbsc Harvest
Worksheet
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BMTCTN-0702: Enrollment (ENR)
BMTCTN-0702: Enrollment (ENR)
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=7662DD82-
8F7A-AEEF-E040-BB89AD43018E
All rights reserved. Please visit https://medical-data-
models.org/forms/11349
BMTCTN-0702: Enrollment (ENR)
Patient demographics
Patient Initials
IUBMID #
CRID #
Gender
Female (Female)
Male (Male)
Patient's Date of Birth
Patient Weight (Kg)
Kg
Date patient's weight assessed
Total number of CD34+ cells (or CD34+ cells/kg)
in the autograft
Units
X10^6 Cells (x10^6 cells)
X10^6 Cells/kg (x10^6 cells/kg)
Ethnicity and Race
Ethnicity
A Person Of Mexican, Puerto Rican,
Cuban, Central Or South American Or
Other Spanish Culture Or Origin,
Regardless Of Race. (Hispanic or Latino)
A Person Not Meeting The Definition For
Hispanic Or Latino. (Not Hispanic or
Latino)
Not Provided Or Available (Not reported)
Could Not Be Determined Or Unsure
(Unknown)
Race
African American (African American)
African Black (both Parents Born In
Africa) (African Black (Both Parents Born
in Africa))
American Indian (not Otherwise
Specified) (American Indian (Not
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Otherwise Specified))
Asian (not Otherwise Specified) (Asian
(Not Otherwise Specified))
Black (not Otherwise Specified) (Black
(Not Otherwise Specified))
Black, Other Specify (Black, Other
Specify)
Caribbean Black (Caribbean Black)
Caribbean Indian (Caribbean Indian)
Chinese (Chinese)
Eastern European (Eastern European)
European (not Otherwise Specified)
(European (Not Otherwise Specified))
Filipino (pilipino) (Filipino (Pilipino))
Guamanian (Guamanian)
Hawaiian (Hawaiian)
Indian/south Asian (Indian/South Asian)
Japanese (Japanese)
Korean (Korean)
Mediterranean (Mediterranean)
Middle Eastern (Middle Eastern)
Native Alaskan/eskimo/aleut (Native
Alaskan/Eskimo/Aleut)
Native American (not Otherwise
Specified) (Native American (Not
Otherwise Specified))
Native Pacific Islander (not Otherwise
Specified) (Native Pacific Islander (Not
Otherwise Specified))
North American Indian (North American
Indian)
North Coast Of Africa (North Coast of
Africa)
Northern European (Northern European)
Not Answered (Not Answered)
Other Southeast Asian (Other Southeast
Asian)
Other, Specify (Other, Specify)
Samoan (Samoan)
South Or Central American (South or
Central American)
South Or Central American Black (South
or Central American Black)
South Or Central American Indian (South
or Central American Indian)
Unknown (Unknown)
Vietnamese (Vietnamese)
Western European (Western European)
White (not Otherwise Specified) (White
(Not Otherwise Specified))
White Caribbean (White Caribbean)
White North American (White North
American)
Specify race
Secondary Race
African American (African American)
African Black (both Parents Born In
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Africa) (African Black (Both Parents Born
in Africa))
American Indian (not Otherwise
Specified) (American Indian (Not
Otherwise Specified))
Asian (not Otherwise Specified) (Asian
(Not Otherwise Specified))
Black (not Otherwise Specified) (Black
(Not Otherwise Specified))
Black, Other Specify (Black, Other
Specify)
Caribbean Black (Caribbean Black)
Caribbean Indian (Caribbean Indian)
Chinese (Chinese)
Eastern European (Eastern European)
European (not Otherwise Specified)
(European (Not Otherwise Specified))
Filipino (pilipino) (Filipino (Pilipino))
Guamanian (Guamanian)
Hawaiian (Hawaiian)
Indian/south Asian (Indian/South Asian)
Japanese (Japanese)
Korean (Korean)
Mediterranean (Mediterranean)
Middle Eastern (Middle Eastern)
Native Alaskan/eskimo/aleut (Native
Alaskan/Eskimo/Aleut)
Native American (not Otherwise
Specified) (Native American (Not
Otherwise Specified))
Native Pacific Islander (not Otherwise
Specified) (Native Pacific Islander (Not
Otherwise Specified))
North American Indian (North American
Indian)
North Coast Of Africa (North Coast of
Africa)
Northern European (Northern European)
Not Answered (Not Answered)
Other Southeast Asian (Other Southeast
Asian)
Other, Specify (Other, Specify)
Samoan (Samoan)
South Or Central American (South or
Central American)
South Or Central American Black (South
or Central American Black)
South Or Central American Indian (South
or Central American Indian)
Unknown (Unknown)
Vietnamese (Vietnamese)
Western European (Western European)
White (not Otherwise Specified) (White
(Not Otherwise Specified))
White Caribbean (White Caribbean)
White North American (White North
American)
Specify secondary race
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Myeloma Follow-On Enrollment Form -
Segment A
Date Informed Consent Signed (Record)
Patient Zip Code
Patient Method of Payment
Medicaid (Medicaid)
Medicaid And Medicare (Medicaid and
Medicare)
Medicare (Medicare)
Medicare And Private Insurance
(Medicare and Private Insurance)
Military Or Veterans Sponsored Nos
(Military or Veterans Sponsored, Not
Otherwise Specified (NOS))
Military Sponsored (including Champus
& Tricare) (Military Sponsored (including
CHAMPUS & TRICARE))
No Means Of Payment (no Insurance)
(No means of payment (no insurance))
Other (Other)
Private Insurance (Private Insurance)
Self Pay (no Insurance) (Self Pay (No
Insurance))
Unknown (Unknown)
Veterans Sponsored (Veterans
Sponsored)
Does the patient meet the criteria for
symptomatic multiple myeloma (Inclusion
Criteria)
Yes
No
Has the patient received at least two cycles of
initial systemic therapy
Yes
No
Date systemic therapy began
Date systemic therapy ended
Start date of mobilization therapy (Record)
Proposed start date of conditioning (Record)
Left Ventricular Ejection Fraction
Left Ventricular Ejection Fraction at Rest
%
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Date LVEF performed
Bilirubin
Bilirubin (Most Recent Value)
mg/dL
Bilirubin Upper Limit Normal (For Your Institution)
Date Sample Obtained
Alt
SGPT (ALT) (Most Recent Value)
SGPT Upper Limit Normal (For Your Institution)
Ast
SGOT (AST) (Most Recent Value)
U/L
SGOT Upper Limit Normal (For Your Institution)
Serum Creatinine
Creatinine Clearance
Date creatinine clearance sample obtained
Dlco (corrected For Hemoglobin)
DLCO (Most Recent Value)
%
Fev1
FEV1 (Most Recent Value corrected for
hemoglobin )
Fvc
FVC (Most Recent Value corrected for
hemoglobin )
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Patient Exclusion Criteria
Does the patient have non-secretory multiple
myeloma
Yes
No
Does the patient have plasma cell leukemia
Yes
No
What is the patient's Karnofsky/Lansky Score
Dead (0)
Moribund, Fatal Processes Progressing
Rapidly (10)
Normal, No Complaints, No Evidence Of
Disease (100)
Very Sick, Hospitalization Indicated.
Death Not Imminent (20)
Severely Disabled, Hospitalization
Indicated. Death Not Imminent (30)
Disabled, Requires Special Care And
Assistance (40)
Requires Considerable Assistance And
Frequent Medical Care (50)
Requires Occasional Assistance, But Is
Able To Care For Most Of His/her Needs
(60)
Cares For Self, Unable To Carry On
Normal Activity Or To Do Active Work
(70)
Normal Activity With Effort; Some Signs
Or Symptoms Of Disease (80)
Able To Carry On Normal Activity; Minor
Signs Or Symptoms Of Disease (90)
Does the patient have > grade 2 sensory
neuropathy
Yes
No
Does the patient have an uncontrolled viral,
bacterial or fungal infection
Yes
No
Is the patient HIV seropositive
Yes
No
Did the patient experience a myocardial infarction
within the past 6 months, Class III or IV heart
failure, uncontrolled angina, severe uncontrolled
ventricular arrhythmias, or electrocardiographic
evidence of acute ischemia or active conduction
system abnormalities (Did the patient experience
a myocardial infarction within the past 6 months,
Class III or IV heart failure, uncontrolled angina,
severe uncontrolled ventricular arrhythmias, or
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electrocardiographic evidence of acute ischemia
or active conduction system abnormalities)
Yes
No
Does the patient have known hypersensitivity to
bortezomib, boron, or mannitol
Yes
No
Has the patient received other investigational
agents within the past 14 days
Yes
No
Does the patient have a history of any malignant
diseases other than multiple myeloma, basal cell
carcinoma or cervical carcinoma in situ
No (No)
Yes (Yes)
Yes, Approved By Study Chair/mm (Yes,
Approved by Study Chair/MM)
Exclusion Criteria (cont.)
Date confirmed by study chair
Was the malignancy treated with curative intent
>5 year
Yes
No
Is the patient pregnant or breastfeeding
No (No)
Not Applicable (Not Applicable)
Yes (Yes)
Is the patient willing to use contraceptive
techniques during the length of lenalidomide
maintenance therapy
No (No)
Not Applicable (Not Applicable)
Yes (Yes)
Has the patient had a previous autologous or
allogeneic stem cell transplant
Yes
No
Did the patient receive mid-intensity melphalan
as prior systemic therapy
Yes
No
Has the patient received a prior organ transplant
requiring immunosuppressive therapy
Yes
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No
Did the patient experience disease progression
prior to enrollment
Yes
No
Did the patient receive lenalidomide as initial
therapy for multiple myeloma and experience
toxicities resulting in treatment discontinuation
Yes
No
Did the patient experience thromboembolic
events while on full anticoagulation during prior
therapy with lenalidomide or thalidomide
No (No)
Unknown (Unknown)
Yes (Yes)
Is the patient willing to take deep vein thrombosis
prophylaxis
Yes
No
Did the patient get denied for medical cost
coverage by third party payers to undergo an
intervention on any of the treatment arms
Yes
No
Donor Inclusion Criteria
Did the patient give consent to provide blood for
the PRIMeR ancillary study and for future
research purposes
Yes
No
Did the patient give consent to provide bone
marrow for the PRIMeR ancillary study and for
future research purposes
Yes
No
Date the bone marrow aspirate was obtained
Date the serum sample was obtained
Date the plasma sample was obtained
Date the PBMC sample was obtained
Risk Status
Patient risk status
8 / 9
BMTCTN-0702: Enrollment (ENR)
High Risk (High Risk)
Standard Risk (Standard Risk)
Comments
Comments
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GOG-0255: Fast Fact Sheet for Protocol
0255 (Ovary) NCT00857545
GOG-0255: Fast Fact Sheet for Protocol 0255 (Ovary)
NCT00857545
OPT-821 With or Without Vaccine Therapy in Treating
Patients With Ovarian Epithelial Cancer, Fallopian Tube
Cancer, or Peritoneal Cancer in Second or Third Complete
Remission
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=8AD3D0D0-
DD90-47BC-E040-BB89AD43777A
All rights reserved. Please visit https://medical-data-
models.org/forms/11350
GOG-0255: Fast Fact Sheet for
Protocol 0255 (Ovary)
NCT00857545
Patient demographics
GOG Institution Code
GOG Affiliate Code
Previous GOG #
Treating physician
Other Physician
Patient Hospital No.
Date of Birth
Patient Name, Last
Patient Name, First
Patient Name, Middle
Patient Social Security Number
Patient Zip Code
Country
Race
A Person Having Origins In Any Of The
Original Peoples Of North And South
America (including Central America),
And Who Maintains Tribal Affiliation Or
Community Attachment. (American
Indian or Alaska Native)
1 / 6
A Person Having Origins In Any Of The
Original Peoples Of The Far East,
Southeast Asia, Or The Indian
Subcontinent Including, For Example,
Cambodia, China, India, Japan, Korea,
Malaysia, Pakistan, The Philippine
Islands, Thailand, And Vietnam. (Asian)
A Person Having Origins In Any Of The
Black Racial Groups Of Africa. Terms
Such As "haitian" Or "negro" Can Be
Used In Addition To "black Or African
American." (Black or African American)
A Person Having Origins In Any Of The
Original Peoples Of Hawaii, Guam,
Samoa, Or Other Pacific Islands. (Native
Hawaiian or other Pacific Islander)
Not Provided Or Available (Not
Reported)
Could Not Be Determined Or Unsure
(Unknown)
A Person Having Origins In Any Of The
Original Peoples Of Europe, The Middle
East, Or North Africa. (White)
Ethnicity
A Person Of Mexican, Puerto Rican,
Cuban, Central Or South American Or
Other Spanish Culture Or Origin,
Regardless Of Race. (Hispanic or Latino)
A Person Not Meeting The Definition For
Hispanic Or Latino. (Not Hispanic or
Latino)
Not Provided Or Available (Not reported)
Could Not Be Determined Or Unsure
(Unknown)
Method of Payment
Medicaid (Medicaid)
Medicaid And Medicare (Medicaid and
Medicare)
Medicare (Medicare)
Medicare And Private Insurance
(Medicare and Private Insurance)
Military Or Veterans Sponsored Nos
(Military or Veterans Sponsored, Not
Otherwise Specified (NOS))
Military Sponsored (including Champus
& Tricare) (Military Sponsored (including
CHAMPUS & TRICARE))
No Means Of Payment (no Insurance)
(No means of payment (no insurance))
Other (Other)
Private Insurance (Private Insurance)
Self Pay (no Insurance) (Self Pay (No
Insurance))
Unknown (Unknown)
Veterans Sponsored (Veterans
Sponsored)
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Miscellaneous Patient Information
Did the patient sign an approved informed
consent
Yes
No
Has HIPAA authorization been obtained
Yes
No
Is the disease recurrent or persistent
Persistent (Persistent)
Recurrent (Recurrent)
What is the site of the disease
Fallopian Tube (Fallopian tube)
Ovary (Ovary)
Peritoneum (Peritoneum)
Was the primary disease documented
histologically
Yes
No
Date primary confirmed
Has the patient had initial cytoreductive surgery
Yes
No
Has the patient had at least one platinum-based
chemotherapy regimen as part of the primary
treatment
Yes
No
Has the patient had recurrent disease at least
once during or after initial therapy
Yes
No
Is the patient now in clinical remission, including
having normal CA-125 values, a negative
physical exam, and no evidence of definitive
disease by CT of the abdomen and pelvis
Yes
No
Date of CT assessment confirming remission
Is the patient within four months of their last
treatment
Yes
No
What was the grade of the primary tumor
Grade 1-well Differentiated (1)
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Grade 2-moderately Differentiated (2)
Grade 3-poorly Differentiated (3)
What is the cell type
Adenocarcinoma With Squamous
Differentiation (Adenocarcinoma with
Squamous Differentiation)
Adenocarcinoma, Unspecified
(Adenocarcinoma, unspecified)
Adenosquamous (Adenosquamous
carcinoma)
Clear Cell Carcinoma (Clear cell
carcinoma)
Endometrioid Adenocarcinoma
(Endometrioid adenocarcinoma)
Mixed Epithelial Carcinoma, Specify
Components (Mixed epithelial
carcinoma)
Mucinous Adenocarcinoma (Mucinous
adenocarcinoma)
Other Carcinoma (Other carcinoma)
Serous Adenocarcinoma (Serous
adenocarcinoma)
Squamous Cell Carcinoma (Squamous
cell carcinoma)
Transitional Cell Carcinoma, Including
Brenner Tumor (Transitional cell
carcinoma (including Brenner))
Unclassified Carcinoma (Unclassified
carcinoma)
Undifferentiated Carcinoma
(Undifferentiated carcinoma)
Villoglandular Carcinoma (Villoglandular
carcinoma)
Is the patient of childbearing potential
Yes
No
If the patient is of childbearing potential, has she
had a negative serum pregancy test and been
practicing an effective form of contraception
No (No)
Not Applicable (Not Applicable)
Yes (Yes)
Is patient currently breastfeeding
Yes
No
Has the patient met the pre-entry requirements
as specified in section 7.0
Yes
No
Will the patient have a history and physical exam
and radiographic disease assessment within 28
days prior to initiating protocol therapy
Yes
No
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Will the patient have the following paramenters
measured within 14 days prior to initiating
protocol therapy (Toxicity Assessment, CBC,
Differential, Hepatic Profile, Creatinine, Amylase,
Urinalysis, Prothrombin Time, TSH, Serum CA-
125 and ANC)
Yes
No
Does the patient have any invasive malignancies
(other than non-melanoma skin cancer) that have
shown any evidence of the other cancer present
within the last five years
Yes
No
Is the patient at least 18 years of age as of this
date
Yes
No
Has the patient had previous cancer treatment
which contraindicates this protocol therapy
Yes
No
Does the patient have an allergy to shellfish
Yes
No
Are there circumstances that will not permit
completion of study therapy or the required
follow-up
Yes
No
Anticipated date treatment will start
Lab Results
Date of Results (if more than one, enter earliest)
ANC (must be 1,000/mcl or greater)
Platelets (must be 100,000/mcl or greater)
1000/uL
Is the creatinine less than or equal to 1.5 X ULN
Yes
No
Is the bilirubin less than or equal to 2.5 X ULN
Yes
No
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Are the SGOT and SGPT less than or equal to
2.5 x ULN
Yes
No
Is the alkaline phosphatase less than or equal to
2.5 X ULN
Yes
No
CA125 Laboratory upper limit of normal
Performance Status
Fully Active, Able To Carry On All Pre-
disease Performance Without
Restriction. (0)
Restricted In Physically Strenuous
Activity But Ambulatory And Able To
Carry Out Work Of A Light Or Sedentary
Nature, E.g., Light Housework, Office
Work. (1)
Ambulatory And Capable Of All Selfcare
But Unable To Carry Out Any Work
Activities. Up And About More Than 50%
Of Waking Hours. (2)
Comments
Provide comments about this Fast Fact Sheet
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AEWS0331: Eligibility Worksheet
NCT00020566
AEWS0331: Eligibility Worksheet NCT00020566 
Combination Chemotherapy With or Without Peripheral
Stem Cell Transplantation, Radiation Therapy, and/or
Surgery in Treating Patients With Ewing's Sarcoma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=BED15863-
3519-3BB6-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/11351
AEWS0331: Eligibility Worksheet
NCT00020566
Header
Institution Name
Contact Person at Institution
COG Study Number
COG Accession Number
Date Form Originally Completed
Date Form Amended
Method of Payment
Medicaid (Medicaid)
Medicare (Medicare)
Medicare And Private Insurance
(Medicare and Private Insurance)
Military Or Veterans Sponsored Nos
(Military or Veterans sponsored NOS)
Military Sponsored (including Champus
& Tricare) (Military sponsored (including
CHAMPUS and TRICARE))
No Means Of Payment (no Insurance)
(No means of payment (no insurance))
Other (Other)
Private Insurance (Private Insurance)
Self Pay (no Insurance) (Self pay (no
insurance))
Unknown (Unknown)
Veterans Sponsored (Veterans
sponsored)
Patient demographics
Group ID #
Patient meets all eligibility criteria?
Yes
No
1 / 2
Patient or the parent's legally acceptable
representative must provide a signed and dated
written informed consent prior to registration and
any study-related procedures.
Yes
No
Have all institutional, FDA, and NCI requirements
for human studies been met?
Yes
No
Date of Birth
Comments
Comments
Ccrr Module For Aews0331: Eligibility
Worksheet
2 / 2
AEWS0331: Eligibility Worksheet NCT00020566
E1305 Material Submission Form
NCT00588770
E1305 Material Submission Form NCT00588770
Chemotherapy With or Without Bevacizumab in Treating
Patients With Recurrent or Metastatic Head and Neck
Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=1A0A35C2-
22E0-420A-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11352
E1305 Material Submission Form
NCT00588770
Header
Registration Step
DCI Name
Reporting Period
Lab Data (Lab data)
Patient Initials (Last, Middle, First)
ECOG Protocol Number
ECOG Protocol Number
ECOG Patient ID
ECOG Patient ID
Participating Group Protocol Number
Participating Group Patient ID
Institution/Affiliate
Completed By Submitting Institutions
Date Material(s) sent to central laboratory
Shipped to
Ecog Pathology Coordinating Office
(ECOG Pathology Coordinating Office)
Other Central Laboratory (Other Central
Laboratory)
Informed consent signed?
Yes
No
1 / 3
Sample No.
Date Specimen collected (MM/DD/YYYY)
Tissue/material type
Other (Other)
Peripheral Blood, Dna Paxgene Tube
(Peripheral Blood, DNA PAXgene tube)
Peripheral Blood, Edta Purple Top Tube
(Peripheral Blood, EDTA purple top tube)
Peripheral Blood, Rna Paxgene Tube
(Peripheral Blood, RNA PAXgene tube)
Plasma, Edta Purple Top Tube (Plasma,
EDTA purple top tube)
Serum, Red Top Tube (Serum, Red top
tube)
Tumor Tissue, Snap Frozen (Tumor
tissue, snap frozen)
Timing of material collection
Baseline/pretreatment (baseline)
Cycle 3, Day 1 (Cycle 3, Day 1)
Other (Other)
Number of specimens submitted (tubes, slides,
etc.)
Completed By Central Lab
Date of receipt of specimens (MM/DD/YYYY)
Condition of Specimen (s)
Damaged Or Unusable (Damaged or
unusable)
Usable (Usable)
Contacts
Contact Person at Institution
Institution Contact Phone Number
Physician of Record
Institution Contact FAX Number
Central Laboratory Contact Name
Central Lab Contact Phone Number
2 / 3
E1305 Material Submission Form NCT00588770
Central Lab Contact FAX Number
Comments
Comments
Physician of Record
Date
3 / 3
E1305 Material Submission Form NCT00588770
E1505 Material Submission Form
NCT00324805
E1505 Material Submission Form NCT00324805 
Chemotherapy With or Without Bevacizumab in Treating
Patients With Stage IB, Stage II, or Stage IIIA Non-Small
Lung Cancer That Was Removed By Surgery
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=10A10233-
B176-5D06-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11353
E1505 Material Submission Form
NCT00324805
Header
ECOG Protocol Number
ECOG Protocol Number
ECOG Patient ID
ECOG Patient ID
Registration Step
DCI Name
Reporting Period
Lab Data (Lab data)
Patient Initials (Last, Middle, First)
Participating Group Protocol Number
Participating Group Patient ID
Institution/Affiliate
Completed By Submitting Institutions
Date Material(s) sent to central laboratory
Shipped to
Ecog Pathology Coordinating Office
(ECOG Pathology Coordinating Office)
Other Central Laboratory (Other Central
Laboratory)
Informed consent signed?
Yes
No
1 / 3
Sample No.
Date Specimen collected (MM/DD/YYYY)
Samples Submission
Other (Other)
Peripheral Blood, Dna Paxgene Tube
(Peripheral Blood, DNA PAXgene tube)
Peripheral Blood, Edta Purple Top Tube
(Peripheral Blood, EDTA purple top tube)
Peripheral Blood, Rna Paxgene Tube
(Peripheral Blood, RNA PAXgene tube)
Plasma, Edta Purple Top Tube (Plasma,
EDTA purple top tube)
Serum, Red Top Tube (Serum, Red top
tube)
Tumor Tissue, Snap Frozen (Tumor
tissue, snap frozen)
Timing of material collection
Baseline/pretreatment (baseline)
Month 15 (Month 15)
Other (Other)
Week 13 (Week 13)
Week 25 (Week 25)
Number of specimens submitted (tubes, slides,
etc.)
Completed By Central Lab
Date of receipt of specimens (MM/DD/YYYY)
Condition of Specimen (s)
Damaged Or Unusable (Damaged or
unusable)
Usable (Usable)
Contacts
Contact Person at Institution
Institution Contact Phone Number
Physician of Record
Institution Contact FAX Number
Central Laboratory Contact Name
Central Lab Contact Phone Number
2 / 3
E1505 Material Submission Form NCT00324805
Central Lab Contact FAX Number
Comments
Comments
Physician of Record
3 / 3
E1505 Material Submission Form NCT00324805
E4A03 Material Submission Form - Form
1982 NCT00098475
E4A03 Material Submission Form - Form 1982
NCT00098475 
Lenalidomide and Dexamethasone With or Without
Thalidomide in Treating Patients With Multiple Myeloma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=DC5F3896-
F51E-2E80-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/11354
E4A03 Material Submission Form -
Form 1982 NCT00098475
Header
Registration Step
DCI Name
Report Period (Place ID Label Here)
Lab Data (Lab data)
Patient Initials (Last, Middle, First)
ECOG Protocol Number
ECOG Protocol Number
ECOG Patient ID
ECOG Patient ID
Participating Group Protocol Number
Participating Group Patient ID
Institution/Affiliate
Completed By Submitting Institutions
Date Material(s) sent to central laboratory
Shipped to
Myeloma Tumor Biology Laboratory
(Myeloma Tumor Biology Laboratory, Phil
Greipp, M.D.)
Other Central Laboratory (Other Central
Laboratory)
Informed consent signed?
Yes
No
1 / 3
Sample No.
#1 (#1)
#2 (#2)
#3 (#3)
#4 (#4)
Date Specimens collected (MM/DD/YYYY)
Tissue/material type
Bone Marrow Aspirate (Bone marrow
aspirate)
Bone Marrow Core Biopsy (Bone marrow
core biopsy)
Other (Other)
Peripheral Blood (Peripheral blood)
Type of collection/stain/process
Other (Other)
Pcli (PCLI (plasma cell labeling index))
Slide, Unstained, Charged
(slide/unstained/charged)
Yellow Top (acd) (yellow top (ACD))
Timing of material collection
Baseline/pretreatment (baseline)
Discontinuation Of Protocol Treatment
(discontinuation of protocol treatment)
Other (Other)
Number of specimens submitted (tubes, slides,
etc.)
Completed By Central Lab
Date of receipt of specimens
Condition of specimen
Damaged Or Unusable (damaged or
unusuable)
Useable (usuable)
Contacts
Contact Person at Institution
Institution Contact Phone Number
Physician of Record
Institution Contact FAX Number
Central Laboratory Contact Name
2 / 3
E4A03 Material Submission Form - Form 1982 NCT00098475
Central Lab Contact Phone Number
Central Lab Contact Fax Number
Comments
Comments
Investigator Signature
Investigator Signature Date
3 / 3
E4A03 Material Submission Form - Form 1982 NCT00098475
E1805 Material Submission Form
E1805 Material Submission Form
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=0F33B3C2-
E012-716D-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11355
E1805 Material Submission Form
Header
Registration Step
DCI Name
Reporting Period
Lab Data (Lab data)
Patient Initials (Last, Middle, First)
ECOG Protocol Number
ECOG Protocol Number
ECOG Patient ID
ECOG Patient ID
Participating Group Protocol Number
Participating Group Patient ID
Institution/Affiliate
Completed By Submitting Institutions
Date Material(s) sent to central laboratory
Shipped to
Immunologic Monitoring And Cellular
Products Lab (Immunologic Monitoring
and Cellular Products Lab)
Other Central Laboratory (Other Central
Laboratory)
Informed consent signed?
Yes
No
Sample No.
Date Specimen Obtained (MM/DD/YYYY)
1 / 2
Samples Submission
Other (Other)
Peripheral Blood Heparin Green Top
(Periph Bld Heparin Green Top)
Peripheral Blood Red Top (Periph Bld
Red Top)
Timing of material collection
Baseline/pretreatment (baseline)
Other (Other)
Week 12 (Week 12)
Week 24 (Week 24)
Number of specimens submitted (tubes, slides,
etc.)
Completed By Central Lab
Date of receipt of specimens (MM/DD/YYYY)
Condition of Specimen (s)
Damaged Or Unusable (Damaged or
unusable)
Usable (Usable)
Contacts
Contact Person at Institution
Institution Contact Phone Number
Physician of Record
Institution Contact FAX Number
Central Laboratory Contact Name
Central Lab Contact Phone Number
Central Lab Contact FAX Number
Comments
Comments
Investigator Signature
Investigator Signature Date
2 / 2
E1805 Material Submission Form
NSABP Protocol B-43 Worksheet for On-
Study Form NCT00769379
NSABP Protocol B-43 Worksheet for On-Study Form
NCT00769379
Radiation Therapy With or Without Trastuzumab in Treating
Women With Ductal Carcinoma In Situ Who Have
Undergone Lumpectomy
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=3978C2FD-
DE23-3859-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11357
NSABP Protocol B-43 Worksheet for
On-Study Form NCT00769379
Header
NSABP Patient ID
Patient Initials (Last First Middle)
Tumor assessment
Tumor Laterality
Left (Left)
Right (Right)
Date Lumpectomy performed
Margins at time of lumpectomy
Free Surgical Margin (Free)
Involved Surgical Margin (Not Free)
Was lumpectomy margins re-excised? (If not
free,)
Yes
No
Date of final re-excision (If re-excised)
Margins after final re-excision
Free Surgical Margin (Free)
Involved Surgical Margin (Not Free)
DCIS type
Comedocarcinoma (Comedo)
Intraductal Non-comedo Breast
Adenocarcinoma (Non-Comedo)
Unknown (Unknown)
Necrosis
No (NO)
Unknown (UNKNOWN)
Yes (YES)
Is DCIS size documented
Yes
No
1 / 2
Primary tumor size measurement
Unit of Measurement
Centimeters (cm)
Millimeters (mm)
Is measurement gross or microscopic?
Gross (Gross)
Microscopic (Microscopic)
Unknown (Unknown)
Was axillary staging done
Yes
No
Total number of axillary lymph nodes examined
Total number of positive axillary nodes
Patient History (at Entry)
Hyperlipidemia requiring medical therapy
Yes
No
Diabetes requiring medical therapy
Yes
No
Hypertension requiring medical therapy
Yes
No
Comments
Comments
Footer
Person Completing Form
Date Form Completed
2 / 2
NSABP Protocol B-43 Worksheet for On-Study Form NCT00769379
E1105 Material Submission Form
NCT00520975
E1105 Material Submission Form NCT00520975 
First-Line Chemotherapy and Trastuzumab With or Without
Bevacizumab in Treating Patients With Metastatic Breast
Cancer That Overexpresses HER-2/NEU
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=17221122-
2E12-611D-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11358
E1105 Material Submission Form
NCT00520975
Header
Registration Step
DCI Name
Reporting Period
Lab Data (Lab data)
Patient Initials (Last, Middle, First)
ECOG Protocol Number
ECOG Protocol Number
ECOG Patient ID
ECOG Patient ID
Participating Group Protocol Number
Participating Group Patient ID
Institution/Affiliate
Completed By Submitting Institutions
Date Material(s) sent to central laboratory
Shipped to
Ecog Pathology Coordinating Office
(ECOG Pathology Coordinating Office)
Other Central Laboratory (Other Central
Laboratory)
Informed consent signed?
Yes
No
1 / 3
Sample No.
Date Specimen collected (MM/DD/YYYY)
Sample submission
Other (Other)
Peripheral Blood Immunicon (Periph Bld
Immunicon)
Peripheral Blood, Dna Paxgene Tube
(Peripheral Blood, DNA PAXgene tube)
Peripheral Blood, Edta Purple Top Tube
(Peripheral Blood, EDTA purple top tube)
Plasma/serum Citrate Cpt
(Plasma/Serum Citrate CPT)
Serum In Serum Separating Tube
(Serum, SST)
Urine (Urine)
Timing of material collection
Baseline/pretreatment (baseline)
Cycle 2, Day 1 (Cycle 2, day 1)
Cycle 4, Day 1 (Cycle 4, day 1)
Other (Other)
Progression (Progression)
Number of specimens submitted (tubes, slides,
etc.)
Completed By Central Lab
Date of receipt of specimens (MM/DD/YYYY)
Condition of Specimen (s)
Damaged Or Unusable (Damaged or
unusable)
Usable (Usable)
Contacts
Contact Person at Institution
Institution Contact Phone Number
Physician of Record
Institution Contact FAX Number
Central Laboratory Contact Name
Central Lab Contact Phone Number
2 / 3
E1105 Material Submission Form NCT00520975
Central Lab Contact FAX Number
Comments
Comments
Physician of Record
3 / 3
E1105 Material Submission Form NCT00520975
SOUTHWEST ONCOLOGY GROUP
NOTICE OF DEATH (S0227) NCT00057928
SOUTHWEST ONCOLOGY GROUP NOTICE OF DEATH
(S0227) NCT00057928
S0227 Comparison of Cisplatin Combined With Either
Paclitaxel or Gemcitabine in Treating Patients With
Recurrent, Persistent, or Metastatic Cervical Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=A9C42A3E-
20F3-39F5-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/11359
SOUTHWEST ONCOLOGY GROUP
NOTICE OF DEATH (S0227)
NCT00057928
Header
SWOG Patient ID
Most Recent SWOG Study No.
Patient Initials (L, F, M)
Institution / Affiliate
Physician (Groups other than SWOG)
Group Name
Study No.
Pt. ID
Date of death
Date of Death (month / day / year)
Causes Of Death
Any cancer (select one)
Contributory2005688 (Contributory)
No2005686 (No)
Possible2005689 (Possible)
Primary_cause2005687 (Primary Cause)
Unknown2005690 (Unknown)
If cancer was the primary cause or if cancer
possibly or definitely contributed to death, and the
patient had had multiple tumor types, specify
those which were causes of death
Cancer_of_most_recent_s2005692
(Cancer of most recent SWOG study,
specify cancer)
Cancer_of_oth_swog_stdy2005693
1 / 3
(Cancer of other SWOG study, specify
cancer)
Other_cancer_specify2005694 (Other
cancer, specify)
Cancer of most recent SWOG study, specify
cancer
Cancer of other SWOG study, specify cancer
Other cancer, specify
Toxicity from disease related treatment (select
one)
Contributory2005699 (Contributory)
No2005697 (No)
Possible2005700 (Possible)
Primary_cause2005698 (Primary Cause)
Unknown2005701 (Unknown)
If Primary Cause, Contributory or Possible,
specify treatment and toxicity
Non-cancer and non-treatment related causes
(select one)
Contributory2005707 (Contributory)
No2005705 (No)
Possible2005708 (Possible)
Primary_cause2005706 (Primary Cause)
Unknown2005709 (Unknown)
If Primary Cause, Contributory or Possible,
specify
Autopsy done?
No (No)
Unknown (Unknown)
Yes (Yes)
Death information obtained from (select all that
apply)
Autopsy Was The Source Of Information
On The Patient's Death (Autopsy report)
Death Certificate Was The Source Of
Information On The Patient's Death
(Medical record / Death certificate)
The Source Of Information On The
Patient's Death Is Not On This List,
Specify Other (Other, specify)
Clinical Evidence Was The Source Of
Information On The Patient's Death
(Physician)
Relative or friend (Relative or friend)
Other, specify
2 / 3
SOUTHWEST ONCOLOGY GROUP NOTICE OF DEATH (S0227)
NCT00057928
Notes
Notes
Ccrr Module For Southwest Oncology
Group Notice Of Death (s0227)
3 / 3
SOUTHWEST ONCOLOGY GROUP NOTICE OF DEATH (S0227)
NCT00057928
GYNECOLOGIC ONCOLOGY GROUP
Follow-Up Form - FORM Q NCT00565851
GYNECOLOGIC ONCOLOGY GROUP Follow-Up Form -
FORM Q NCT00565851
Carboplatin and Paclitaxel With or Without Bevacizumab
After Surgery in Treating Patients With Recurrent Ovarian
Epithelial Cancer, Primary Peritoneal Cavity Cancer, or
Fallopian Tube Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=DA625200-
CCA6-1B50-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/11360
GYNECOLOGIC ONCOLOGY
GROUP Follow-Up Form - FORM Q
NCT00565851
Header module
Date form originally completed
Date form amended
Person amending form last name
Patient name, last
Patient name, first
Patient Study ID
Person completing form, last name
Vital Status
Patient's vital status
Alive (Alive)
Dead (Dead)
Last contact date/death date
Primary cause of death:
Due To Other Cause, Specify (Due to
other cause)
Due To Protocol Treatment (Due to
protocol treatment)
Due To This Disease (Due to this
disease)
Unknown (Unknown)
Describe cause of death
Is the patient lost to follow-up?
Yes
1 / 3
No
Notice Of Progression
Has the patient been diagnosed with a new
progression?
Yes
No
Date of progression (/recurrence)
Site(s) of progression
What was the method used to determine
progression?
Histology (Histologic)
Physical Exam (Physical exam)
Radiographic (Radiographic)
Tumor Markers (Tumor marker)
Ca125 And Other Biomarkers
Marker name (s)
Marker value (s)
Date(s) of CA125  (or other biomarkers)
Notice Of New Primary
Has a new primary cancer or MDS been
diagnosed that has not been previously reported?
(myelodysplastic syndrome)
Yes
No
Date of diagnosis
Site(s) of new primary
Late Adverse Event
Has the patient experienced (prior to diagnosis of
recurrence or second primary) any severe (Grade
>=3), long term toxicity that has not been
previously reported?
Yes
No
Late adverse event term
2 / 3
GYNECOLOGIC ONCOLOGY GROUP Follow-Up Form - FORM Q
NCT00565851
Late adverse event grade
Late adverse event onset date
CTC adverse event attribution code (*)
Definite (Definitely)
Possible (Possibly)
Probable (Probably)
Unlikely (Unlikely)
Unrelated (Unrelated)
Non-protocol Therapy
Is the patient receiving any non-protocol cancer
therapy not previously reported?
Yes
No
Name of other non-protocol therapy
Date of first non-protocol therapy
Comments
Comments
Participating Group Code
Participating Group Protocol Number
Participating Group Patient ID
3 / 3
GYNECOLOGIC ONCOLOGY GROUP Follow-Up Form - FORM Q
NCT00565851
NCT00057928 SOUTHWEST ONCOLOGY
GROUP S0227 ADVERSE EVENT FORM
NCT00057928 SOUTHWEST ONCOLOGY GROUP S0227
ADVERSE EVENT FORM
S0227 Comparison of Cisplatin Combined With Either
Paclitaxel or Gemcitabine in Treating Patients With
Recurrent, Persistent, or Metastatic Cervical Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=A9C36E5D-
1E71-3661-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/11362
NCT00057928 SOUTHWEST
ONCOLOGY GROUP S0227
ADVERSE EVENT FORM
Header
SWOG Patient ID
SWOG Study No.
Registration Step
Cycle Number
Patient Initials (L, F M)
Institution / Affiliate
Physician (Groups Other than SWOG)
Group Name
Study No.
Pt. ID (Instructions: Please complete this form
after each cycle one cycle = 3 weeks. Report
adverse events occuring up until the next cycle of
treatment begins. Document the worst Grade
seen during the reporting interval. Do not code a
pre-existing condition as an adverse event unless
it worsens due to treatment. All dates are
MONTH, DAY, YEAR.  Explain any blank dates or
fields in the Comments section. Place an X in
appropriate boxes. Circle AMENDED items in
red.)
Toxicity
Reporting period start date
Reporting period end date
1 / 2
Were toxicities assessed during this time period
No (No)
toxicities were assessed but none were
seen (toxicities were assessed but none
were seen)
Yes (Yes)
Date of most recent toxicity assessment
Adverse event assessment
CTC Adverse Event Term
CTC Adverse Event Grade (1 - 5)
CTC Adverse Event Attribution Code (Attribution
codes)
Definitely (definite)
Possibly (possible)
Probably (probable)
Unlikely (unlikely)
Unrelated (unrelated)
Adverse Event Status Code (Status codes)
New Late Adverse Event (new)
persistent (persistent)
resolved and recurred (resolved and
recurred)
CTC Adverse Event Term, Other
Comments
Comments
Ccrr Module For Southwest Oncology
Group S0227 Adverse Event Form
2 / 2
NCT00057928 SOUTHWEST ONCOLOGY GROUP S0227 ADVERSE
EVENT FORM
NCT00057928  SOUTHWEST ONCOLOGY
GROUP OFF TREATMENT NOTICE (S0227)
NCT00057928  SOUTHWEST ONCOLOGY GROUP OFF
TREATMENT NOTICE (S0227)
S0227 Comparison of Cisplatin Combined With Either
Paclitaxel or Gemcitabine in Treating Patients With
Recurrent, Persistent, or Metastatic Cervical Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=A9C44FD3-
7B1D-3AAB-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/11363
NCT00057928  SOUTHWEST
ONCOLOGY GROUP OFF
TREATMENT NOTICE (S0227)
Header
SWOG Patient ID
SWOG Study No.
Registration Step
Patient Initials (L, F M)
Institution / Affiliate
Physician (Groups other than SWOG)
Group Name
Study No.
Pt. ID
Treatment period
Treatment Start Date
Treatment End Date
Regimen or Procedure or Site(s)
Off-protocol treatment
Off Treatment Reason
Death (Death)
Patient Withdrawal, Medically Required
Due To Toxicity (Medically required, due
to toxicity)
Specify Other Reason (Other, specify)
Patient Withdrawal Or Refusal
1 / 2
Subsequent To Toxicity (Patient refused,
due to toxicity)
Patient Withdrawal Or Refusal For
Reason Other Than Toxicity (Patient
refused, other than toxicity, specify)
Progression or relapse, specify site
(Progression or relapse, specify site)
Patient refused, other than toxicity, specify
Progression or relapse, specify site
Other, specify (Off Treatment Date)
Date of completion, progression, death or
decision to discontinue therapy
Further treatment
Will patient receive further treatment?
No (No)
Unknown (Unknown)
Yes (Yes, specify)
Yes, specify
Vital status
Date of Last Contact (or death)
Vital Status
Alive (Alive)
Dead (Dead)
Comments
Comments
Ccrr Module For Southwest Oncology
Group Off Treatment Notice (s0227)
2 / 2
NCT00057928  SOUTHWEST ONCOLOGY GROUP OFF TREATMENT
NOTICE (S0227)
NCT00057928 SOUTHWEST ONCOLOGY
GROUP S0227 FOLLOW UP FORM (S0227)
NCT00057928 SOUTHWEST ONCOLOGY GROUP S0227
FOLLOW UP FORM (S0227)
S0227 Comparison of Cisplatin Combined With Either
Paclitaxel or Gemcitabine in Treating Patients With
Recurrent, Persistent, or Metastatic Cervical Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=A9C447B6-
E4F0-3A7F-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/11364
NCT00057928 SOUTHWEST
ONCOLOGY GROUP S0227
FOLLOW UP FORM (S0227)
Header
SWOG Patient ID
SWOG Study No.
Registration Step
Patient Initials (L, F M)
Reporting Period Start Date (Date off protocol for
the first follow-up form; last report period end
date otherwise)
Institution / Affiliate
Physician (Groups other than SWOG)
Group Name
Study No.
Pt. ID
Reporting Period End Date (Date of completion
of the current form.)
Vital Status
Vital Status
Dead (Dead)
Date of last contact or death
Disease Follow Up Status
1 / 3
Has the patient had a documented clinical
assessment for this cancer since submission of
the previous follow-up form?
Yes
No
Date of Last Clinical Assessment (If Yes)
Notice Of First Relapse Or Progression
Has the patient developed a first protocol defined
relapse or progression that has not been
previously reported
Yes
No
Date of progression/relapse
Site
Notice Of New Primary
Has a new primary cancer or myelodysplastic
syndrome (MDS) been diagnosed that has not
been previously reported?
Yes
No
Date of Diagnosis (If Yes)
New Primary Site
Comments
Comments
Non-protocol Treatment
Has the patient received any (non-protocol)
cancer treatment in this reporting period
Yes
No
Non-Protocol Surgery (If Yes, complete the
following)
No (No)
Yes (Yes, specify)
Non-Protocol Chemotherapy (if yes, Treatment
Start Date)
2 / 3
NCT00057928 SOUTHWEST ONCOLOGY GROUP S0227 FOLLOW UP
FORM (S0227)
No (No)
Yes (Yes, specify)
Non-Protocol Hormonal Therapy (if yes,
Treatment Start Date)
No (No)
Yes (Yes, specify)
Non-Protocol Immunotherapy (if yes, Treatment
Start Date)
No (No)
Yes (Yes, specify)
Non-Protocol Radiation Therapy (if yes,
Treatment Start Date)
No (No)
Yes (Yes, specify)
Other Non-Protocol Therapy (if yes, Treatment
Start Date)
No (No)
Yes (Yes, specify)
Yes, specify
Long Term Toxicity
Has the patient experienced (prior to treatment
for progression or relapse or a second primary,
and prior to non-protocol treatment) any severe
(grade >= 3) long term toxicity that has not been
previously reported?
Yes
No
Neuropathy-motor
Yes
No
Grade
Neuropathy-sensory
Yes
No
Other (specify Toxicities and Grades)
Comments
Ccrr Module For Southwest Oncology
Group S0227 Follow Up Form (s0227)
3 / 3
NCT00057928 SOUTHWEST ONCOLOGY GROUP S0227 FOLLOW UP
FORM (S0227)
NSABP PROTOCOL C-08: MENSTRUAL
STATUS FORM NCT00096278
NSABP PROTOCOL C-08: MENSTRUAL STATUS FORM
NCT00096278
Fluorouracil, Leucovorin, and Oxaliplatin With or Without
Bevacizumab in Treating Patients Who Have Undergone
Surgery for Stage II or Stage III Colon Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=D7F6C655-
DE00-4623-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/11365
NSABP PROTOCOL C-08:
MENSTRUAL STATUS FORM
NCT00096278
Header
Patient Initials (Last, First Middle)
NSABP Patient ID
Institution Name
Affiliate Name
Person Completing Form Last Name
Person Completing Form First Name
Person Completing Form Phone
Are data amended? (check box if yes, and circle
amended items)
Yes
No
MENSTRUAL STATUS
Time Point of this Assessment
12 Months (12 months)
18 Months (18 months)
24 Months (24 months)
6 Months (6 months)
Date of Assessment (month day year)
Date of Last Menstrual Period (month day year)
Yes
No
1 / 1
NCT00268463 NSABP Protocol C-09: Missing
Data Form for Quality of Life Questionnaire
NCT00268463 NSABP Protocol C-09: Missing Data Form
for Quality of Life Questionnaire
Oxaliplatin and Capecitabine With or Without an Hepatic
Arterial Infusion With Floxuridine in Treating Patients Who
Are Undergoing Surgery and/or Ablation for Liver
Metastases Due to Colorectal Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=FC8000EE-
F527-1AEA-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11366
NCT00268463 NSABP Protocol C-
09: Missing Data Form for Quality of
Life Questionnaire
Header
Patient Initials (Last First Middle)
NSABP Patient ID
Institution Name
Affiliate Name
Person Completing Form Last Name
Person Completing Form First Name
Person Completing Form Phone
Today's Date (Month Day Year)
Are Data Amended
Yes
No
Missing Data Form for Quality of Life
Time Point for this Form (mark one)
18 Weeks After The Start Of
Chemotherapy (18 weeks after the start
of chemotherapy)
4-6 Weeks After Surgery (4-6 weeks
after surgery)
Post-chemotherapy (Post chemotherapy)
Reason QOL was Not Assessed During Clinic
Visit (Mark the main reason and add comments
below.)
Patient Refused To Complete
Questionnaire For Reason Other Than
Illness Or Upset (Patient refused to
1 / 2
complete questionnaire for reason other
than illness or upset)
Patient Stated That She Was Too Ill Or
Upset To Complete Questionnaire
(Patient stated that she was too ill or
upset to complete questionnaire)
Patient Was Unavailable (e.g.,
Scheduling Or Transportation Difficulties)
(Patient was unavailable)
Staff Concerned For Patient's Medical Or
Emotional Condition (Staff concerned for
patient's medical or emotional condition)
Staff Oversight Or Understaffing (Staff
oversight or understaffing)
Reason QOL was Not Obtained by Phone or Mail
(Mark all that apply and add comments below.)
Patient Refused To Complete
Questionnaire (Patient refused to
complete questionnaire)
Patient's Medical Or Emotional Condition
(Patient's medical or emotional condition)
Questionnaire Was Mailed To Patient,
But She Did Not Return It (for Unknown
Reasons) (Questionnaire was mailed to
patient but she did not return it)
Staff Oversight Or Understaffing (Staff
oversight or understaffing)
Staff Was Unable To Contact Patient By
Phone (Staff was unable to contact
patient by phone)
Comments
2 / 2
NCT00268463 NSABP Protocol C-09: Missing Data Form for Quality of
Life Questionnaire
SOUTHWEST ONCOLOGY GROUP
NOTICE OF DEATH (S0303) NCT00070122
SOUTHWEST ONCOLOGY GROUP NOTICE OF DEATH
(S0303) NCT00070122
Combination Chemotherapy and Bevacizumab in Treating
Patients With Locally Advanced, Metastatic, or Recurrent
Colorectal Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=BC722876-
4198-4172-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/11367
SOUTHWEST ONCOLOGY GROUP
NOTICE OF DEATH (S0303)
NCT00070122
Header
SWOG Patient ID
Most Recent SWOG Study No.
Patient Initials (L, F, M)
Institution/Affiliate
Physician (Groups other than SWOG)
Group Name
Study No.
Pt. ID
Date of death
Date of Death (month / day / year)
Causes Of Death
Any cancer (select one)
Contributory2005688 (Contributory)
No2005686 (No)
Possible2005689 (Possible)
Primary_cause2005687 (Primary Cause)
Unknown2005690 (Unknown)
If cancer was the primary cause or if cancer
possibly or definitely contributed to death, and the
patient had had multiple tumor types, specify
those which were causes of death
Cancer_of_most_recent_s2005692
(Cancer of most recent SWOG study,
specify cancer)
Cancer_of_oth_swog_stdy2005693
1 / 3
(Cancer of other SWOG study, specify
cancer)
Other_cancer_specify2005694 (Other
cancer, specify)
Cancer of most recent SWOG study, specify
cancer
Cancer of other SWOG study, specify cancer
Other cancer, specify
Toxicity from disease related treatment (select
one)
Contributory2005699 (Contributory)
No2005697 (No)
Possible2005700 (Possible)
Primary_cause2005698 (Primary Cause)
Unknown2005701 (Unknown)
If Primary Cause, Contributory or Possible,
specify treatment and toxicity
Non-cancer and non-treatment related causes
(select one)
Contributory2005707 (Contributory)
No2005705 (No)
Possible2005708 (Possible)
Primary_cause2005706 (Primary Cause)
Unknown2005709 (Unknown)
If Primary Cause, Contributory or Possible,
specify
Autopsy?
No (No)
Unknown (Unknown)
Yes (Yes)
Source of death information (select all that apply)
Autopsy Was The Source Of Information
On The Patient's Death (Autopsy report)
Death Certificate Was The Source Of
Information On The Patient's Death
(Medical record / Death certificate)
The Source Of Information On The
Patient's Death Is Not On This List,
Specify Other (Other, specify)
Clinical Evidence Was The Source Of
Information On The Patient's Death
(Physician)
Relative or friend (Relative or friend)
Other, specify
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SOUTHWEST ONCOLOGY GROUP NOTICE OF DEATH (S0303)
NCT00070122
Comments
Comments
Ccrr Module For Southwest Oncology
Group Notice Of Death (s0303)
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SOUTHWEST ONCOLOGY GROUP NOTICE OF DEATH (S0303)
NCT00070122
CALGB-10501 Family History
Questionnaire Form NCT00513747
CALGB-10501 Family History Questionnaire Form
NCT00513747 
Early or Delayed Fludarabine and Rituximab in Treating
Patients With Previously Untreated Chronic Lymphocytic
Leukemia
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=3410315B-
B48B-28F5-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11368
CALGB-10501 Family History
Questionnaire Form NCT00513747
Header
CALGB Form
CALGB Study No
CALGB Patient ID
Date Form Completed
Are data amended
Yes
No
Patient demographics
Patient Initials (Last, First Middle)
Patient Hospital No.
Institution/Affiliate
Participating Group
Participating Group Study No
Participating Group Patient ID
If you do not wish to answer any of the following
questions, please mark with an 'X.'
Family history
Have any of your blood relatives ever been
diagnosed with cancer
No (No)
Unknown (Unknown)
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Yes (Yes)
Blood relative with cancer
Aunt #1 (Aunt #1)
Aunt #2 (Aunt #2)
Aunt #3 (Aunt #3)
Aunt #4 (Aunt #4)
Brother #1 (Brother #1)
Brother #2 (Brother #2)
Brother #3 (Brother #3)
Brother #4 (Brother #4)
Child #1 (Child #1)
Child #2 (Child #2)
Child #3 (Child #3)
Child #4 (Child #4)
Cousin #1 (Cousin #1)
Cousin #2 (Cousin #2)
Cousin #3 (Cousin #3)
Cousin #4 (Cousin #4)
Father (Father)
Mother (Mother)
Sister #1 (Sister #1)
Sister #2 (Sister #2)
Sister #3 (Sister #3)
Sister #4 (Sister #4)
Uncle #1 (Uncle #1)
Uncle #2 (Uncle #2)
Uncle #3 (Uncle #3)
Uncle #4 (Uncle #4)
Vital Status
Alive (Alive)
Dead (Dead)
Type of Cancer
Breast (Breast)
Cll (CLL)
Colon (Colon)
Head & Neck (Head & Neck)
Hodgkin's Lymphoma (Hodgkin's
lymphoma)
Lung (Lung)
Non Melanoma Skin (Non Melanoma
Skin)
Non-hodgkin's Lymphoma (Non-
Hodgkin's lymphoma)
Other (Other)
Prostate (Prostate)
Specify
Total number of siblings with cancer
Total number of siblings without cancer
Total number of children with cancer
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CALGB-10501 Family History Questionnaire Form NCT00513747
Total number of children without cancer
Overall Response
Can we contact you in the future by mail,
telephone or e-mail
Yes
No
Phone
Email Address
Comments
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CALGB-10501 Family History Questionnaire Form NCT00513747
CALGB: 10603 Leukemia Pathology Form -
Cytogenetics NCT00651261
CALGB: 10603 Leukemia Pathology Form - Cytogenetics
NCT00651261 
Daunorubicin, Cytarabine, and Midostaurin in Treating
Patients With Newly Diagnosed Acute Myeloid Leukemia
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=46C44DBD-
4DDE-66EA-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11369
CALGB: 10603 Leukemia Pathology
Form - Cytogenetics NCT00651261
Header
CALGB Form
CALGB Study No.
CALGB Patient ID
Date of Receipt of Specimens
Are data amended
Yes
No
Patient demographics
Patient Initials (Last, First Middle)
Patient Hospital No.
Institution/Affiliate
Participating Group
Participating Group Study No.
Participating Group Patient ID
Cytogenetics
Gender
Female Gender (FEMALE)
Male Gender (MALE)
Specimen Accession Number
Sample period
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First Complete Remission (First
complete remission)
First Relapse (First relapse)
Other (Other)
Pre-treatment (Pre-Treatment)
Other specify
Specimen Cell Source
Bone Marrow Aspirate (Bone marrow
aspirate)
Other Specify (Other)
Peripheral Blood (Peripheral blood)
Other specify
Collection Hour (If analyzed at an additional
timepoint, specify)
Number of cells analyzed
Number of cells analyzed
Number of cells analyzed
Number of cells analyzed
Number of cells analyzed
Type of stimulation
No Stimulation (No stimulation)
Other Mitogen (Other mitogen)
Phytohemagglutinin (PHA)
Specify
Type of synchronization
Methotrexate (Methotrexate)
No Synchronization (No synchronization)
Other (Other)
Specify
Did this patient's karyotypes receive central
review within your cooperative group
Yes
No
Karyotype Description
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CALGB: 10603 Leukemia Pathology Form - Cytogenetics NCT00651261
Footer Module
Completed by (print or type name)
Date Form Completed (MM DD YYYY)
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CALGB: 10603 Leukemia Pathology Form - Cytogenetics NCT00651261
NCT00113399 RTOG-0421 HP: Radiation Therapy Oncology Group Health
Utility Measurement Euro (EQ-5D) Miscellaneous Patient Assessment Form
NCT00113399 RTOG-0421 HP: Radiation Therapy
Oncology Group Health Utility Measurement Euro (EQ-5D)
Miscellaneous Patient Assessment Form
Combination Chemotherapy With or Without Radiation
Therapy in Treating Patients With Recurrent Head and
Neck Cancer That Cannot Be Removed By Surgery
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=EBAEDD99-
A13F-1374-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11370
NCT00113399 RTOG-0421 HP:
Radiation Therapy Oncology Group
Health Utility Measurement Euro
(EQ-5D) Miscellaneous Patient
Assessment Form
RTOG clinical trial administrative data
RTOG Study
Case #
Institution Name
Institution No.
Participant's Initials
Participant's ID No.
Amended data
Yes
No
Miscellaneous Patient Assessment
MOBILITY
I Am Confined To Bed (I am confined to
bed)
I Have No Problems In Walking About (I
have no problem in walking about)
I Have Some Problems In Walking About
(I have some problem in walking about)
SELF CARE
I Am Unable To Wash Or Dress Myself (I
am able to wash or dress myself)
I Have No Problem With Self Care (I
have no problem with self care)
I Have Some Problem Washing Or
Dressing Myself (I have some problem
washing or dressing myself)
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USUAL ACTIVITIES (e.g. work, study,
housework, family, or leisure activities)
I Am Unable To Perform My Usual
Activities (I am unable to perform my
usual activities)
I Have No Problems With Performing My
Usual Activities (I have no problem with
performing my usual activities)
I Have Some Problems With Performing
My Usual Activities (I have some
problem with performing my usual
activities)
PAIN/DISCOMFORT
I Have Extreme Pain Or Discomfort (I
have extreme pain or discomfort)
I Have Moderate Pain Or Discomfort (I
have moderate pain or discomfort)
I Have No Pain Or Discomfort (I have no
pain or discomfort)
ANXIETY/DEPRESSION (TO THE PATIENT: To
help people say how good or bad a health state
is, we have drawn a scale rather like a
thermometer on which the best state you can
imagine is marked 100 and the worst state you
can imagine is marked 0.)
I Am Extremely Anxious Or Depressed (I
am extremely anxious or depressed)
I Am Moderately Anxious Or Depressed
(I am moderately anxious or depressed)
I Am Not Anxious Or Depressed (I am
not anxious or depressed)
Score
HAVE YOU EXPERIENCED SERIOUS ILLNESS
In yourself?
Yes
No
HAVE YOU EXPERIENCED SERIOUS ILLNESS
In your family?
Yes
No
HAVE YOU EXPERIENCED SERIOUS ILLNESS
In caring for others?
Yes
No
WHAT IS YOUR AGE IN YEARS?
ARE YOU
Female (Female)
Male (Male)
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NCT00113399 RTOG-0421 HP: Radiation Therapy Oncology Group Health
Utility Measurement Euro (EQ-5D) Miscellaneous Patient Assessment Form
ARE YOU A current smoker
Yes
No
ARE YOU An ex-smoker
Yes
No
ARE YOU A never smoker
Yes
No
DO YOU NOW, OR DID YOU EVER, WORK IN
HEALTH OR SOCIAL SERVICES?
Yes
No
IF SO, IN WHAT CAPACITY?
WHICH OF THE FOLLOWING BEST
DESCRIBES YOUR MAIN ACTIVITY?
Homemaker (Housework)
Employed (In employment or self
employment)
Other (Other)
Retired (Retired)
Unemployed (Seeking work)
Student (Student)
DID YOUR EDUCATION CONTINUE AFTER
THE MINIMUM SCHOOL LEAVING AGE?
Yes
No
DO YOU HAVE A DEGREE OR EQUIVALENT
PROFESSIONAL QUALIFICATION?
Yes
No
IF YOU KNOW YOUR POSTCODE, WOULD
YOU PLEASE WRITE IT HERE
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NCT00113399 RTOG-0421 HP: Radiation Therapy Oncology Group Health
Utility Measurement Euro (EQ-5D) Miscellaneous Patient Assessment Form
NSABP PROTOCOL C-08: LIVER
FUNCTION TEST FORM NCT00096278
NSABP PROTOCOL C-08: LIVER FUNCTION TEST
FORM NCT00096278 
Fluorouracil, Leucovorin, and Oxaliplatin With or Without
Bevacizumab in Treating Patients Who Have Undergone
Surgery for Stage II or Stage III Colon Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=EF512FA7-
1C84-1AF2-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11371
NSABP PROTOCOL C-08: LIVER
FUNCTION TEST  FORM
NCT00096278
Header
Patient Initials (Last, First Middle)
NSABP Patient ID
Institution Name
Affiliate Name
Person Completing Form Last Name
Person Completing Form First Name
Person Completing Form Phone
Are data amended? (check box if yes, and circle
amended items)
Yes
No
Liver function
Date Lab Assessment Performed
Bilirubin
mg/dL
Bilirubin ULN
Bilirubin Ratio
CTC AE Bilirubin Grade
AST, SGOT
U/L
1 / 2
SGOT ULN
SGOT Ratio
CTC AE SGOT Grade
Alkaline phosphatase
Alkaline phosphatase ULN
Alkaline phosphatase Ratio
CTC AE Alkaline phosphatase Grade
ALT, SGPT
SGPT ULN
SGPT Ratio
CTC AE SGPT Grade
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NSABP PROTOCOL C-08: LIVER FUNCTION TEST FORM
NCT00096278
NCT00096278  NSABP PROTOCOL C-08:
LIVER FUNCTION TEST FOLLOW-UP FORM
NCT00096278  NSABP PROTOCOL C-08: LIVER
FUNCTION TEST FOLLOW-UP FORM
Fluorouracil, Leucovorin, and Oxaliplatin With or Without
Bevacizumab in Treating Patients Who Have Undergone
Surgery for Stage II or Stage III Colon Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=EF5136E1-
073F-1BFA-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11372
NCT00096278  NSABP PROTOCOL
C-08: LIVER FUNCTION TEST
FOLLOW-UP FORM
Header
Patient Initials (Last, First Middle)
NSABP Patient ID
Institution Name
Affiliate Name
Person Completing Form Last Name
Person Completing Form First Name
Person Completing Form Phone
Are data amended? (check box if yes, and circle
amended items)
Yes
No
Liver function
Date Lab Assessment Performed
Bilirubin
mg/dL
Bilirubin ULN
AST, SGOT
U/L
SGOT ULN
Alkaline phosphatase
1 / 2
Alkaline phosphatase ULN
ALT, SGPT
SGPT ULN
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NCT00096278  NSABP PROTOCOL C-08: LIVER FUNCTION TEST
FOLLOW-UP FORM
NCT00096278 NSABP PROTOCOL C-08:
CALCIUM/MAGNESIUM INFUSION FORM
NCT00096278 NSABP PROTOCOL C-08:
CALCIUM/MAGNESIUM INFUSION FORM
Fluorouracil, Leucovorin, and Oxaliplatin With or Without
Bevacizumab in Treating Patients Who Have Undergone
Surgery for Stage II or Stage III Colon Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=39F147FB-
7A6B-4A1A-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11373
NCT00096278 NSABP PROTOCOL
C-08: CALCIUM/MAGNESIUM
INFUSION FORM
Header
Patient Initials (Last, First Middle)
NSABP Patient ID
Institution Name
Affiliate Name
Person Completing Form Last Name
Person Completing Form First Name
Person Completing Form Phone
Are data amended? (check box if yes, and circle
amended items)
Yes
No
Total number of cycles given
Total number of cycles given (enter "0" if never
started - Instructions: Please report the number
of cycles where calcium/magnesium infusions
were given.  This should not exceed the number
of cycles where oxaliplatin was given reported on
Form FF.)
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NSABP PROTOCOL C-08 PROTEINURIA
FORM NCT00096278
NSABP PROTOCOL C-08 PROTEINURIA FORM
NCT00096278 
Fluorouracil, Leucovorin, and Oxaliplatin With or Without
Bevacizumab in Treating Patients Who Have Undergone
Surgery for Stage II or Stage III Colon Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=D7F8A203-
ECB2-5C86-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/11375
NSABP PROTOCOL C-08
PROTEINURIA FORM
NCT00096278
Header
Patient Initials (Last, First Middle)
NSABP Patient ID
Institution Name
Affiliate Name
Person Completing Form Last Name
Person Completing Form First Name
Person Completing Form Phone
Are data amended? (check box if yes, and circle
amended items)
Yes
No
PROTEINURIA
Phase of Treatment (mark one)
Bevacizumab Alone (Bevacizumab
alone)
Mfolfox6 +/- Bevacizumab (mFOLFOX6
+/- bevacizumab)
Post-therapy (Post-therapy)
Urine Protein/Creatinine Ratio
Protein from 24 hour Urine Collection (g)
g/24 hours
Date of Measurement (month day year)
Date of Measurement (month day year)
1 / 1
NSABP PROTOCOL C-09: Surgery/Pathology
Report Form NCT00268463
NSABP PROTOCOL C-09: Surgery/Pathology Report Form
NCT00268463
Oxaliplatin and Capecitabine With or Without an Hepatic
Arterial Infusion With Floxuridine in Treating Patients Who
Are Undergoing Surgery and/or Ablation for Liver
Metastases Due to Colorectal Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=FC8164B8-
5C86-09B5-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11376
NSABP PROTOCOL C-09:
Surgery/Pathology Report Form
NCT00268463
Header
Patient Initials (Last First Middle)
NSABP Patient ID
Institution Name
Affiliate Name
Person Completing Form Last Name
Person Completing Form First Name
Person Completing Form Phone
Are data amended (check box if yes, and circle
amended items)
Yes
No
Investigator Number
Investigator Name
Hepatic surgery
Was hepatic surgery initiated? (If no, disregard
remaining questions.)
Yes
No
Date of Hepatic Surgery (Month Day Year)
Size of largest ablated lesion (Leave boxes blank
if ablation was not employed.)
1 / 4
cm
Was gross extrahepatic disease identified (non-
contiguous metastases)
Yes
No
Hepatic Lesions
TOTAL (according to intraoperative palpation or
intraoperative ultrasound 0=none)
TOTAL Treated (by resection and/or ablation
0=none)
Hepatic Surgical Resection
Hepatic Cryoablation
Hepatic Radiofrequency Ablation
Was any hepatic margin determined to be grossly
or microscopically positive on intraoperative
evaluation
Yes
No
Is there explicit documentation in the operative
report that a rim of normal liver tissue at the
positive margin was ablated or resected during
the surgical procedure (if yes)
Yes
No
A positive margin was (If yes, mark all that apply)
Ablated (Ablated)
Resected (Resected)
Placement Of Intra-arterial Catheter
Was intra-arterial catheter implanted (If no, mark
primary reason.)
Yes
No
Pump type (IF yes,)
External (External)
Internal (Internal)
Primary Reason
Medical Reasons (Medical reasons)
Other (Other)
Other Technical Difficulty (Other
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NSABP PROTOCOL C-09: Surgery/Pathology Report Form
NCT00268463
technical difficulty)
Patient Refused (Patient refused)
Unable To Cannulate Artery (Unable to
cannulate artery)
Other, specify
Final Pathology Report
Number Examined
Number Positive
Were final histologic margins negative for all
resected metastatic lesions
Yes
No
Number Examined
Number Positive
Post-Surgery Treatment Plan
Group 1 Patient: Capecitabine +
Oxaliplatin (Group 1 Patient:
Capecitabine + Oxaliplatin)
Group 1 Patient: Other Plan (Group 1
Patient: Other plan)
Group 2 Patient: Fudr + Capecitabine +
Oxaliplatin (Group 2 Patient: FUDR +
Capecitabine + Oxaliplatin)
Group 2 Patient: Only Capecitabine +
Oxaliplatin (Group 2 Patient: Only
Capecitabine + Oxaliplatin)
Group 2 Patient: Other Plan (Group 2
Patient: Other Plan)
explain the REASON for the "OTHER PLAN"
(When applicable, and briefly describe the
intended treatment)
Documentation Submitted with Form SP (Mark all
that apply.)
Operative Report (Operative report)
Pathology Report (Pathology report)
Report Of Intraoperative Ultrasound
(Report of intraoperative ultrasound)
Report Of Post-operative Ct Or Mri Scan
Of Abdomen (Report of post-operative
CT or MRI scan of abdomen)
Report Of Postoperative Arterial Flow
Scan With Form Maa (Report of
postoperative arterial flow scan with
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NCT00268463
Form MAA)
Comments (optional)
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NCT00268463
Southwest Oncology Group Notice of Death
NCT00499369
Southwest Oncology Group Notice of Death NCT00499369
Irinotecan and Cetuximab With or Without Bevacizumab in
Treating Patients With Metastatic Colorectal Cancer That
Progressed During First-Line Therapy
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=1540B71E-
561F-704F-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11378
Southwest Oncology Group Notice of
Death NCT00499369
SWOG clinical trial administrative data
SWOG Patient ID
Most Recent SWOG Study No.
Patient Initials (L, F, M)
Institution/Affiliate
Physician
Participating Group Name
Participating Group Study No.
Participating Group Patient ID
Date of death
Date of Death
Causes Of Death
Any cancer (select one)
Contributory (Contributory)
No (No)
Possible (Possible)
Primary Cause (Primary Cause)
Unknown (Unknown)
If cancer was the primary cause or if cancer
possibly or definitely contributed to death, and the
patient had had multiple tumor types, specify
those which were causes of death
Cancer Of Most Recent Swog Study
(Cancer of most recent SWOG study)
Cancer Of Other Swog Study (Cancer of
other SWOG study)
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Other Cancer (Other cancer)
Cancer of most recent SWOG study, specify
Cancer of other SWOG study, specify
Other cancer, specify
Toxicity from disease related treatment (select
one:)
Contributory (Contributory)
No (No)
Possible (Possible)
Primary Cause (Primary Cause)
Unknown (Unknown)
If Primary Cause, Contributory or Possible,
specify treatment and toxicity
Non-cancer and non-treatment related causes
(select one:)
Contributory (Contributory)
No (No)
Possible (Possible)
Primary Cause (Primary Cause)
Unknown (Unknown)
If Primary Cause, Contributory or Possible,
specify
Autopsy?
No (No)
Unknown (Unknown)
Yes (Yes)
Source(s) of death information
Autopsy Report (Autopsy report)
Medical Record / Death Certificate
(Medical record / Death certificate)
Other (Other)
Physician (Physician)
Relative Or Friend (Relative or friend)
Other, specify
Comments
Comments
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PRL1013: Adverse Event Form
NCT01268605
PRL1013: Adverse Event Form NCT01268605 
Postoperative Hypersensitivity Randomized Comparative
Effectiveness Research Trial (POH RCERT)
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=A651C58C-
D9BC-9A03-E040-BB89AD4309CC
All rights reserved. Please visit https://medical-data-
models.org/forms/11379
PRL1013: Adverse Event Form
NCT01268605
Header Module
Site Number
Patient ID
Date of visit
Patient Initials
Adverse event assessment
Adverse Event description
Adverse Event Onset Date
Severity of event
Death Related To Adverse Event (Fatal)
Life Threatening Or Disabling Adverse
Event (Life-threatening)
Mild Adverse Event (Mild)
Moderate Adverse Event (Moderate)
Severe Adverse Event (Severe)
Relation of event to restoration on study
tooth/teeth
Definite (Definite)
Possible (Possible)
Probable (Probable)
Unlikely (Unlikely)
Unrelated (Unrelated)
Was this event expected or anticipated
Yes
No
Restoration replaced
Yes
No
Restoration replaced with temporary or sedative
dressing
Yes
1 / 3
No
Pulpectomy and temporization
Yes
No
Endodontic therapy or referral
Yes
No
Extraction
Yes
No
New medication taken
Yes
No
Hospitalization
Yes
No
Other
Yes
No
Specify
Outcome of event
Resolved (RESOLVED)
Unresolved At Protocol Completion
(Unresolved at protocol completion)
Unresolved, Protocol Ongoing
(Unresolved, protocol ongoing)
Date of resolution (If "Resolved",)
Was this considered a Serious Adverse Event
Yes
No
Death
Yes
No
Life-threatening
Yes
No
Disability/Incapacity
Yes
No
Congenital abnormality
Yes
No
Required intervention to prevent permanent
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impairment/damage
Yes
No
Hospitalization, initial or prolonged
Yes
No
Other
Yes
No
Specify
Comments
Comments
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GOG-0258 Surgical Reporting Form (C)
NCT00942357
GOG-0258 Surgical Reporting Form (C) NCT00942357
Carboplatin and Paclitaxel With or Without Cisplatin and
Radiation Therapy in Treating Patients With Stage I, Stage
II, Stage III, or Stage IVA Endometrial Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=644E86D7-
D919-D7C8-E040-BB89AD4321CC
All rights reserved. Please visit https://medical-data-
models.org/forms/11380
GOG-0258 Surgical Reporting Form
(C) NCT00942357
Header Module
Date form originally completed (m d y)
Date form amended (m d y)
Person amending form, last name
Patient Initials (First, Middle, Last)
Patient Study ID
Person completing form, last name
Surgery assessment
Operative procedure performed (check all that
apply)
Bilateral Salpingo-oophorectomy
(bilateral salpingo-oophorectomy)
Deep Lymphadenectomy (Deep
lymphadenectomy)
Exenteration (Exenteration)
Hemivolvectomy (Hemi volvectomy)
Interval Debulking (Interval debulking)
Omentectomy (omentectomy)
Other, Specify (other specify)
Para-aortic Node Sampling/dissection
(para-aortic node sampling/dissection)
Pelvic Node Sampling/dissection (pelvic
node sampling/dissection)
Primary Debulking (Primary debulking)
Radical Hysterectomy (radical
hysterectomy)
Radical Trachelectomy (radical
trachelectomy)
Radical Vulvectomy (Radical vulvectomy)
Reassessment Laparotomy
(Reassessment laparotomy)
Superficial Lymphadenectomy
(Superficial lymphadenectomy)
Total Abdominal Hysterectomy (Total
abdominal hysterectomy)
1 / 4
Total Vaginal Hysterectomy (Total vaginal
hysterectomy)
Unilateral Salpingo-oophorectomy
(unilateral salpingo-oophorectomy)
Other, specify
Surgical approach
Laparoscopic Surgery (Laparoscopic)
Open (open)
Stage
0 (0)
Refer To Figo Staging For Specific
Gynecologic Cancer (1)
Refer To Figo Staging For Specific
Gynecologic Cancer (1A)
Refer To Figo Staging For Specific
Gynecologic Cancer (1B)
Refer To Figo Staging For Specific
Gynecologic Cancer (1C)
Refer To Figo Staging For Specific
Gynecologic Cancer (2)
Refer To Figo Staging For Specific
Gynecologic Cancer (2A)
Refer To Figo Staging For Specific
Gynecologic Cancer (2B)
Refer To Figo Staging For Specific
Gynecologic Cancer (2C)
Refer To Figo Staging For Specific
Gynecologic Cancer (3)
Refer To Figo Staging For Specific
Gynecologic Cancer (3A)
Refer To Figo Staging For Specific
Gynecologic Cancer (3B)
Refer To Figo Staging For Specific
Gynecologic Cancer (3C)
Refer To Figo Staging For Specific
Gynecologic Cancer (4)
Refer To Figo Staging For Specific
Gynecologic Cancer (4A)
Refer To Figo Staging For Specific
Gynecologic Cancer (4B)
Not Available (Not available)
Persistent (Persistent)
Recurrent (Recurrent)
Surgery Date (m d y)
Percent of gross tumor removed (%)
%
Residual gross tumor
Yes
No
Greatest diameter of largest residual gross tumor
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mass
cm
Microscopic disease only
Yes
No
Ascites
Yes
No
Cytology of peritoneal or ascitic fluids
Negative (Negative)
Not Done (Not done)
Positive (Positive)
Suspicious (Suspicious)
Unavailable (Unavailable)
Summary of operative findings (*)
Adb. Ureter - Lt. (Adb. Ureter - lt.)
Adb. Ureter - Rt. (Adb. Ureter - rt.)
Ant. Abdomen (Ant. Abdomen)
Anus (Anus)
Appendix (Appendix)
Ascending Colon (Ascending colon)
Bladder - Mucosa (Bladder - mucosa)
Bladder - Muscularis (Bladder -
muscularis)
Clitoris (Clitoris)
Common Iliac - Lt. (Common iliac - lt.)
Common Iliac - Rt. (Common iliac - rt.)
Deep Groin - Lt. (Deep groin - lt.)
Deep Groin - Rt. (Deep groin - rt.)
Descending Colon (Descending colon)
Duodenum (Duodenum)
External Iliac - Lt. (External iliac - lt.)
External Iliac - Rt. (External iliac - rt.)
Fallopian Tube - Lt. (Fallopian tube - lt.)
Fallopian Tube - Rt. (Fallopian tube - rt.)
Gall Bladder (Gall bladder)
Gutters - Lt. (Gutters - lt.)
Gutters - Rt. (Gutters - rt.)
Ileum (Ileum)
Internal - Lt. (Internal - lt.)
Internal - Rt. (Internal - rt.)
Introitus (Introitus)
Jejunum (Jejunum)
Kidney - Lt. (Kidney - lt.)
Kidney - Rt. (Kidney - rt.)
Labium Major - Lt. (Labium major - lt.)
Labium Major - Rt. (Labium major - rt.)
Labium Minor - Lt. (Labium minor - lt.)
Labium Minor - Rt. (Labium minor - rt.)
Large Bowel (Large bowel)
Left Scalene (Left scalene)
Liver Parenchyma (Liver parenchyma)
Liver Surface (Liver surface)
Obturator - Lt. (Obturator - lt.)
Obturator - Rt. (Obturator - rt.)
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Omentum - Gastrocolic (Omentum -
gastrocolic)
Omentum - Infracolic (Omentum -
infracolic)
Ovary - Lt. (Ovary - lt.)
Ovary - Rt. (Ovary - rt.)
Pancreas (Pancreas)
Para-aortic - Lt. (Para-aortic - lt.)
Para-aortic - Rt. (Para-aortic - rt.)
Parametrium - Lt. (Parametrium - lt.)
Parametrium - Rt. (Parametrium - rt.)
Pelvic - Lt. (Pelvic - lt.)
Pelvic - Rt. (Pelvic - rt.)
Pelvic Bladder (Pelvic bladder)
Pelvic Cul-de-sac (Pelvic cul-de-sac)
Perineal Body (Perineal body)
Sig. Mucosa (Sig. Mucosa)
Sig. Muscularis (Sig. Muscularis)
Small Bowel (Small bowel)
Spleen (Spleen)
Stomach (Stomach)
Subdiaphragm - Lt. (subdiaphragm - lt.)
Subdiaphragm - Rt. (subdiaphragm - rt.)
Superficial Gr. - Lt. (Superficial gr. - lt.)
Superficial Gr. - Rt. (Superficial gr. - rt.)
Transverse Colon (Transverse colon)
Ureter - Lt. (Ureter - lt.)
Ureter - Rt. (Ureter - rt.)
Urethra (Urethra)
Uterus-cervix (Uterus-cervix)
Uterus-corpus (Uterus-corpus)
Vagina (Vagina)
Exam (*Examined: 1=tumor present; 2=no tumor;
3=suspicious; 4=organ absent; 5=not examined)
No Tumor (No tumor)
Not Examined (Not examined)
Organ Absent (Organ absent)
Suspicious (Suspicious)
Tumor Present (Tumor present)
Proc (*Procedure: 1=removed partially;
2=removed completely; 3=biopsy only; 4=left
intact; 5=not applicable)
Biopsy Only (Biopsy only)
Left Intact (Left intact)
Not Applicable (Not applicable)
Removed Completely (Removed
completely)
Removed Partially (Removed partially)
Comments
Comments
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Gynecologic Oncology Group Surgical
Reporting Form (Form C) NCT00951496
Gynecologic Oncology Group Surgical Reporting Form
(Form C) NCT00951496
Bevacizumab and Intravenous or Intraperitoneal
Chemotherapy in Treating Patients With Stage II, Stage III,
or Stage IV Ovarian Epithelial Cancer, Fallopian Tube
Cancer, or Primary Peritoneal Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=4F53ABD3-
7FB6-64F0-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11381
Gynecologic Oncology Group
Surgical Reporting Form (Form C)
NCT00951496
Header Module
Date form originally completed (m d y)
Date form amended (m d y)
Person amending form, last name
Patient Initials (First, Middle, Last)
Patient Study ID
Person completing form, last name
Header
Operative procedure performed (check all that
apply)
Bilateral Salpingo-oophorectomy
(bilateral salpingo-oophorectomy)
Deep Lymphadenectomy (Deep
lymphadenectomy)
Exenteration (Exenteration)
Hemivolvectomy (Hemi volvectomy)
Interval Debulking (Interval debulking)
Omentectomy (omentectomy)
Other, Specify (other specify)
Para-aortic Node Sampling/dissection
(para-aortic node sampling/dissection)
Pelvic Node Sampling/dissection (pelvic
node sampling/dissection)
Primary Debulking (Primary debulking)
Radical Hysterectomy (radical
hysterectomy)
Radical Trachelectomy (radical
trachelectomy)
Radical Vulvectomy (Radical vulvectomy)
Reassessment Laparotomy
(Reassessment laparotomy)
Superficial Lymphadenectomy
1 / 4
(Superficial lymphadenectomy)
Total Abdominal Hysterectomy (Total
abdominal hysterectomy)
Total Vaginal Hysterectomy (Total vaginal
hysterectomy)
Unilateral Salpingo-oophorectomy
(unilateral salpingo-oophorectomy)
Other, specify
Surgical approach
Laparoscopic Surgery (Laparoscopic)
Open (open)
Stage
0 (0)
Refer To Figo Staging For Specific
Gynecologic Cancer (1)
Refer To Figo Staging For Specific
Gynecologic Cancer (1A)
Refer To Figo Staging For Specific
Gynecologic Cancer (1B)
Refer To Figo Staging For Specific
Gynecologic Cancer (1C)
Refer To Figo Staging For Specific
Gynecologic Cancer (2)
Refer To Figo Staging For Specific
Gynecologic Cancer (2A)
Refer To Figo Staging For Specific
Gynecologic Cancer (2B)
Refer To Figo Staging For Specific
Gynecologic Cancer (2C)
Refer To Figo Staging For Specific
Gynecologic Cancer (3)
Refer To Figo Staging For Specific
Gynecologic Cancer (3A)
Refer To Figo Staging For Specific
Gynecologic Cancer (3B)
Refer To Figo Staging For Specific
Gynecologic Cancer (3C)
Refer To Figo Staging For Specific
Gynecologic Cancer (4)
Refer To Figo Staging For Specific
Gynecologic Cancer (4A)
Refer To Figo Staging For Specific
Gynecologic Cancer (4B)
Not Available (Not available)
Persistent (Persistent)
Recurrent (Recurrent)
Surgery Date (m d y)
Percent of gross tumor removed (%)
%
Residual gross tumor
Yes
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No
Greatest diameter of largest residual gross tumor
mass
cm
Microscopic disease only
Yes
No
Ascites
Yes
No
Cytology of peritoneal or ascitic fluids
Negative (Negative)
Not Done (Not done)
Positive (Positive)
Suspicious (Suspicious)
Unavailable (Unavailable)
Summary of operative findings (*)
Adb. Ureter - Lt. (Adb. Ureter - lt.)
Adb. Ureter - Rt. (Adb. Ureter - rt.)
Ant. Abdomen (Ant. Abdomen)
Anus (Anus)
Appendix (Appendix)
Ascending Colon (Ascending colon)
Bladder - Mucosa (Bladder - mucosa)
Bladder - Muscularis (Bladder -
muscularis)
Clitoris (Clitoris)
Common Iliac - Lt. (Common iliac - lt.)
Common Iliac - Rt. (Common iliac - rt.)
Deep Groin - Lt. (Deep groin - lt.)
Deep Groin - Rt. (Deep groin - rt.)
Descending Colon (Descending colon)
Duodenum (Duodenum)
External Iliac - Lt. (External iliac - lt.)
External Iliac - Rt. (External iliac - rt.)
Fallopian Tube - Lt. (Fallopian tube - lt.)
Fallopian Tube - Rt. (Fallopian tube - rt.)
Gall Bladder (Gall bladder)
Gutters - Lt. (Gutters - lt.)
Gutters - Rt. (Gutters - rt.)
Ileum (Ileum)
Internal - Lt. (Internal - lt.)
Internal - Rt. (Internal - rt.)
Introitus (Introitus)
Jejunum (Jejunum)
Kidney - Lt. (Kidney - lt.)
Kidney - Rt. (Kidney - rt.)
Labium Major - Lt. (Labium major - lt.)
Labium Major - Rt. (Labium major - rt.)
Labium Minor - Lt. (Labium minor - lt.)
Labium Minor - Rt. (Labium minor - rt.)
Large Bowel (Large bowel)
Left Scalene (Left scalene)
Liver Parenchyma (Liver parenchyma)
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Liver Surface (Liver surface)
Obturator - Lt. (Obturator - lt.)
Obturator - Rt. (Obturator - rt.)
Omentum - Gastrocolic (Omentum -
gastrocolic)
Omentum - Infracolic (Omentum -
infracolic)
Ovary - Lt. (Ovary - lt.)
Ovary - Rt. (Ovary - rt.)
Pancreas (Pancreas)
Para-aortic - Lt. (Para-aortic - lt.)
Para-aortic - Rt. (Para-aortic - rt.)
Parametrium - Lt. (Parametrium - lt.)
Parametrium - Rt. (Parametrium - rt.)
Pelvic - Lt. (Pelvic - lt.)
Pelvic - Rt. (Pelvic - rt.)
Pelvic Bladder (Pelvic bladder)
Pelvic Cul-de-sac (Pelvic cul-de-sac)
Perineal Body (Perineal body)
Sig. Mucosa (Sig. Mucosa)
Sig. Muscularis (Sig. Muscularis)
Small Bowel (Small bowel)
Spleen (Spleen)
Stomach (Stomach)
Subdiaphragm - Lt. (subdiaphragm - lt.)
Subdiaphragm - Rt. (subdiaphragm - rt.)
Superficial Gr. - Lt. (Superficial gr. - lt.)
Superficial Gr. - Rt. (Superficial gr. - rt.)
Transverse Colon (Transverse colon)
Ureter - Lt. (Ureter - lt.)
Ureter - Rt. (Ureter - rt.)
Urethra (Urethra)
Uterus-cervix (Uterus-cervix)
Uterus-corpus (Uterus-corpus)
Vagina (Vagina)
Exam (*Examined: 1=tumor present; 2=no tumor;
3=suspicious; 4=organ absent; 5=not examined)
No Tumor (No tumor)
Not Examined (Not examined)
Organ Absent (Organ absent)
Suspicious (Suspicious)
Tumor Present (Tumor present)
Proc (*Procedure: 1=removed partially;
2=removed completely; 3=biopsy only; 4=left
intact; 5=not applicable)
Biopsy Only (Biopsy only)
Left Intact (Left intact)
Not Applicable (Not applicable)
Removed Completely (Removed
completely)
Removed Partially (Removed partially)
Comments
Comments
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GOG-0241 Surgical Reporting Form (C)
NCT01081262
GOG-0241 Surgical Reporting Form (C) NCT01081262
Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine,
With or Without Bevacizumab, as First-Line Therapy in
Treating Patients With Newly Diagnosed Stage II, Stage III,
Stage IV, or Recurrent Stage I Epithelial Ovarian Cancer or
Fallopian Tube Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=8D1826DA-
E8EB-F792-E040-BB89AD433BF7
All rights reserved. Please visit https://medical-data-
models.org/forms/11382
GOG-0241 Surgical Reporting Form
(C) NCT01081262
Header Module
Date form originally completed (m d y)
Date form amended (m d y)
Person amending form, last name
Patient Initials (First, Middle, Last)
Patient Study ID
Person completing form, last name
Surgery assessment
Operative procedure performed (check all that
apply)
Bilateral Salpingo-oophorectomy
(bilateral salpingo-oophorectomy)
Deep Lymphadenectomy (Deep
lymphadenectomy)
Exenteration (Exenteration)
Hemivolvectomy (Hemi vulvectomy)
Interval Debulking (Interval debulking)
Omentectomy (omentectomy)
Other, Specify (other specify)
Para-aortic Node Sampling/dissection
(para-aortic node sampling/dissection)
Pelvic Node Sampling/dissection (pelvic
node sampling/dissection)
Primary Debulking (Primary debulking)
Radical Hysterectomy (radical
hysterectomy)
Radical Trachelectomy (radical
trachelectomy)
Radical Vulvectomy (Radical vulvectomy)
Reassessment Laparotomy
(Reassessment laparotomy)
Superficial Lymphadenectomy
(Superficial lymphadenectomy)
Total Abdominal Hysterectomy (Total
abdominal hysterectomy)
1 / 4
Total Vaginal Hysterectomy (Total vaginal
hysterectomy)
Unilateral Salpingo-oophorectomy
(unilateral salpingo-oophorectomy)
Other, specify
Surgical approach
Laparoscopic Surgery (Laparoscopic)
Open (open)
Stage
0 (0)
Refer To Figo Staging For Specific
Gynecologic Cancer (1)
Refer To Figo Staging For Specific
Gynecologic Cancer (1A)
Refer To Figo Staging For Specific
Gynecologic Cancer (1B)
Refer To Figo Staging For Specific
Gynecologic Cancer (1C)
Refer To Figo Staging For Specific
Gynecologic Cancer (2)
Refer To Figo Staging For Specific
Gynecologic Cancer (2A)
Refer To Figo Staging For Specific
Gynecologic Cancer (2B)
Refer To Figo Staging For Specific
Gynecologic Cancer (2C)
Refer To Figo Staging For Specific
Gynecologic Cancer (3)
Refer To Figo Staging For Specific
Gynecologic Cancer (3A)
Refer To Figo Staging For Specific
Gynecologic Cancer (3B)
Refer To Figo Staging For Specific
Gynecologic Cancer (3C)
Refer To Figo Staging For Specific
Gynecologic Cancer (4)
Refer To Figo Staging For Specific
Gynecologic Cancer (4A)
Refer To Figo Staging For Specific
Gynecologic Cancer (4B)
Not Available (Not available)
Persistent (Persistent)
Recurrent (Recurrent)
Surgery Date (m d y)
Percent of gross tumor removed (%)
%
Residual gross tumor
Yes
No
Greatest diameter of largest residual gross tumor
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mass
cm
Microscopic disease only
Yes
No
Ascites
Yes
No
Cytology of peritoneal or ascitic fluids
Negative (Negative)
Not Done (Not done)
Positive (Positive)
Suspicious (Suspicious)
Unavailable (Unavailable)
Summary of operative findings
Adb. Ureter - Lt. (Adb. Ureter - lt.)
Adb. Ureter - Rt. (Adb. Ureter - rt.)
Ant. Abdomen (Ant. Abdomen)
Anus (Anus)
Appendix (Appendix)
Ascending Colon (Ascending colon)
Bladder - Mucosa (Bladder - mucosa)
Bladder - Muscularis (Bladder -
muscularis)
Clitoris (Clitoris)
Common Iliac - Lt. (Common iliac - lt.)
Common Iliac - Rt. (Common iliac - rt.)
Deep Groin - Lt. (Deep groin - lt.)
Deep Groin - Rt. (Deep groin - rt.)
Descending Colon (Descending colon)
Duodenum (Duodenum)
External Iliac - Lt. (External iliac - lt.)
External Iliac - Rt. (External iliac - rt.)
Fallopian Tube - Lt. (Fallopian tube - lt.)
Fallopian Tube - Rt. (Fallopian tube - rt.)
Gall Bladder (Gall bladder)
Gutters - Lt. (Gutters - lt.)
Gutters - Rt. (Gutters - rt.)
Ileum (Ileum)
Internal - Lt. (Internal - lt.)
Internal - Rt. (Internal - rt.)
Introitus (Introitus)
Jejunum (Jejunum)
Kidney - Lt. (Kidney - lt.)
Kidney - Rt. (Kidney - rt.)
Labium Major - Lt. (Labium major - lt.)
Labium Major - Rt. (Labium major - rt.)
Labium Minor - Lt. (Labium minor - lt.)
Labium Minor - Rt. (Labium minor - rt.)
Large Bowel (Large bowel)
Left Scalene (Left scalene)
Liver Parenchyma (Liver parenchyma)
Liver Surface (Liver surface)
Obturator - Lt. (Obturator - lt.)
Obturator - Rt. (Obturator - rt.)
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Omentum - Gastrocolic (Omentum -
gastrocolic)
Omentum - Infracolic (Omentum -
infracolic)
Ovary - Lt. (Ovary - lt.)
Ovary - Rt. (Ovary - rt.)
Pancreas (Pancreas)
Para-aortic - Lt. (Para-aortic - lt.)
Para-aortic - Rt. (Para-aortic - rt.)
Parametrium - Lt. (Parametrium - lt.)
Parametrium - Rt. (Parametrium - rt.)
Pelvic - Lt. (Pelvic - lt.)
Pelvic - Rt. (Pelvic - rt.)
Pelvic Bladder (Pelvic bladder)
Pelvic Cul-de-sac (Pelvic cul-de-sac)
Perineal Body (Perineal body)
Sig. Mucosa (Sig. Mucosa)
Sig. Muscularis (Sig. Muscularis)
Small Bowel (Small bowel)
Spleen (Spleen)
Stomach (Stomach)
Subdiaphragm - Lt. (subdiaphragm - lt.)
Subdiaphragm - Rt. (subdiaphragm - rt.)
Superficial Gr. - Lt. (Superficial gr. - lt.)
Superficial Gr. - Rt. (Superficial gr. - rt.)
Transverse Colon (Transverse colon)
Ureter - Lt. (Ureter - lt.)
Ureter - Rt. (Ureter - rt.)
Urethra (Urethra)
Uterus-cervix (Uterus-cervix)
Uterus-corpus (Uterus-corpus)
Vagina (Vagina)
Exam
No Tumor (No tumor)
Not Examined (Not examined)
Organ Absent (Organ absent)
Suspicious (Suspicious)
Tumor Present (Tumor present)
Proc
Biopsy Only (Biopsy only)
Left Intact (Left intact)
Not Applicable (Not applicable)
Removed Completely (Removed
completely)
Removed Partially (Removed partially)
Comments
Comments
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SOUTHWEST ONCOLOGY GROUP
NOTICE OF DEATH
SOUTHWEST ONCOLOGY GROUP NOTICE OF DEATH
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=F4422C8B-
0E58-49D1-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11383
SOUTHWEST ONCOLOGY GROUP
NOTICE OF DEATH
Header
SWOG Patient ID
Most Recent SWOG Study No.
Patient Initials (L, F, M)
Institution/Affiliate
Physician
Participating Group Name
Participating Group Study No.
Participating Group Patient ID
Date of death
Date of Death (month / day / year)
Causes Of Death
Any cancer (select one)
Contributory (Contributory)
No (No)
Possible (Possible)
Primary Cause (Primary Cause)
Unknown (Unknown)
If cancer was the primary cause or if cancer
possibly or definitely contributed to death, and the
patient had had multiple tumor types, specify
those which were causes of death
Cancer Of Most Recent Swog Study
(Cancer of most recent SWOG study)
Cancer Of Other Swog Study (Cancer of
other SWOG study)
Other Cancer (Other cancer)
Cancer of most recent SWOG study, specify
1 / 2
cancer
Cancer of other SWOG study, specify cancer
Other cancer, specify
Toxicity from disease related treatment (select
one)
Contributory (Contributory)
No (No)
Possible (Possible)
Primary Cause (Primary Cause)
Unknown (Unknown)
If Primary Cause, Contributory or Possible,
specify treatment and toxicity
Non-cancer and non-treatment related causes
(select one)
Contributory (Contributory)
No (No)
Possible (Possible)
Primary Cause (Primary Cause)
Unknown (Unknown)
If Primary Cause, Contributory or Possible,
specify
Autopsy?
No (No)
Unknown (Unknown)
Yes (Yes)
Source(s) of death information
Autopsy Report (Autopsy report)
Medical Record / Death Certificate
(Medical record / Death certificate)
Other (Other)
Physician (Physician)
Relative Or Friend (Relative or friend)
Other, specify
Comments
Comments
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S0502 Notice of Death NCT00324987
S0502 Notice of Death NCT00324987 
S0502 Imatinib Mesylate With or Without Bevacizumab in
Treating Patients With Metastatic or Unresectable
Gastrointestinal Stromal Tumor
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=FCCFDBA1-
76C9-4428-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11384
S0502 Notice of Death
NCT00324987
Header
SWOG Patient ID
Most Recent SWOG Study No.
Patient Initials (L, F, M)
Institution/Affiliate
Physician
Participating Group Name
Participating Group Study No.
Participating Group Patient ID
Date of death
Date of Death (month / day / year)
Causes Of Death
Any cancer (select one)
Contributory (Contributory)
No (No)
Possible (Possible)
Primary Cause (Primary Cause)
Unknown (Unknown)
If cancer was the primary cause or if cancer
possibly or definitely contributed to death, and the
patient had had multiple tumor types, specify
those which were causes of death
Cancer Of Most Recent Swog Study
(Cancer of most recent SWOG study)
Cancer Of Other Swog Study (Cancer of
other SWOG study)
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Other Cancer (Other cancer)
Cancer of most recent SWOG study, specify
cancer
Cancer of other SWOG study, specify cancer
Other cancer, specify
Toxicity from disease related treatment (select
one)
Contributory (Contributory)
No (No)
Possible (Possible)
Primary Cause (Primary Cause)
Unknown (Unknown)
If Primary Cause, Contributory or Possible,
specify treatment and toxicity
Non-cancer and non-treatment related causes
(select one)
Contributory (Contributory)
No (No)
Possible (Possible)
Primary Cause (Primary Cause)
Unknown (Unknown)
If Primary Cause, Contributory or Possible,
specify
Autopsy?
No (No)
Unknown (Unknown)
Yes (Yes)
Source(s) of death information
Autopsy Report (Autopsy report)
Medical Record / Death Certificate
(Medical record / Death certificate)
Other (Other)
Physician (Physician)
Relative Or Friend (Relative or friend)
Other, specify
Comments
Comments
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NCT01120249 Southwest Oncology Group
S0931 Notice of Death Form (Form #49467)
NCT01120249 Southwest Oncology Group S0931 Notice of
Death Form (Form #49467)
Everolimus in Treating Patients With Kidney Cancer Who
Have Undergone Surgery
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=7DFF9CE4-
74B5-C651-E040-BB89AD435F69
All rights reserved. Please visit https://medical-data-
models.org/forms/11385
NCT01120249 Southwest Oncology
Group S0931 Notice of Death Form
(Form #49467)
Header
SWOG Patient ID
Most Recent SWOG Study No.
Patient Initials (L, F, M)
Institution/Affiliate
Physician
Participating Group Name
Participating Group Study No.
Participating Group Patient ID
Date of death
Date of Death (month / day / year)
Causes Of Death
Any cancer (select one)
Contributory (Contributory)
No (No)
Possible (Possible)
Primary Cause (Primary Cause)
Unknown (Unknown)
If cancer was the primary cause or if cancer
possibly or definitely contributed to death, and the
patient had had multiple tumor types, specify
those which were causes of death
Cancer Of Most Recent Swog Study
(Cancer of most recent SWOG study)
Cancer Of Other Swog Study (Cancer of
other SWOG study)
1 / 2
Other Cancer (Other cancer)
Cancer of most recent SWOG study, specify
cancer
Cancer of other SWOG study, specify cancer
Other cancer, specify
Toxicity from disease related treatment (select
one)
Contributory (Contributory)
No (No)
Possible (Possible)
Primary Cause (Primary Cause)
Unknown (Unknown)
If Primary Cause, Contributory or Possible,
specify treatment and toxicity
Non-cancer and non-treatment related causes
(select one)
Contributory (Contributory)
No (No)
Possible (Possible)
Primary Cause (Primary Cause)
Unknown (Unknown)
If Primary Cause, Contributory or Possible,
specify
Autopsy?
No (No)
Unknown (Unknown)
Yes (Yes)
Source(s) of death information
Autopsy Report (Autopsy report)
Medical Record / Death Certificate
(Medical record / Death certificate)
Other (Other)
Physician (Physician)
Relative Or Friend (Relative or friend)
Other, specify
Comments
Comments
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NCT01120249 Southwest Oncology Group S0931 Notice of Death Form
(Form #49467)
SOUTHWEST ONCOLOGY GROUP
NOTICE OF DEATH NCT00492856
SOUTHWEST ONCOLOGY GROUP NOTICE OF DEATH
NCT00492856 
Combination Chemotherapy With or Without Gemtuzumab
Followed By Tretinoin, Mercaptopurine, and Methotrexate
or Observation in Treating Patients With Acute
Promyelocytic Leukemia
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=02E129DB-
D909-1188-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11386
SOUTHWEST ONCOLOGY GROUP
NOTICE OF DEATH NCT00492856
Header
SWOG Patient ID
Most Recent SWOG Study No.
Patient Initials (L, F, M)
Institution/Affiliate
Physician
Participating Group Name
Participating Group Study No.
Participating Group Patient ID
Date of death
Date of Death (month / day / year)
Causes Of Death
Any cancer (select one)
Contributory (Contributory)
No (No)
Possible (Possible)
Primary Cause (Primary Cause)
Unknown (Unknown)
If cancer was the primary cause or if cancer
possibly or definitely contributed to death, and the
patient had had multiple tumor types, specify
those which were causes of death
Cancer Of Most Recent Swog Study
(Cancer of most recent SWOG study)
Cancer Of Other Swog Study (Cancer of
other SWOG study)
1 / 2
Other Cancer (Other cancer)
Cancer of most recent SWOG study, specify
cancer
Cancer of other SWOG study, specify cancer
Other cancer, specify
Toxicity from disease related treatment (select
one)
Contributory (Contributory)
No (No)
Possible (Possible)
Primary Cause (Primary Cause)
Unknown (Unknown)
If Primary Cause, Contributory or Possible,
specify treatment and toxicity
Non-cancer and non-treatment related causes
(select one)
Contributory (Contributory)
No (No)
Possible (Possible)
Primary Cause (Primary Cause)
Unknown (Unknown)
If Primary Cause, Contributory or Possible,
specify
Autopsy?
No (No)
Unknown (Unknown)
Yes (Yes)
Source(s) of death information
Autopsy Report (Autopsy report)
Medical Record / Death Certificate
(Medical record / Death certificate)
Other (Other)
Physician (Physician)
Relative Or Friend (Relative or friend)
Other, specify
Comments
Comments
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SOUTHWEST ONCOLOGY GROUP NOTICE OF DEATH NCT00492856
Southwest Oncology Group Notice of Death
Southwest Oncology Group Notice of Death
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=A50CB146-
A9FE-3595-E034-080020C9C0E0
All rights reserved. Please visit https://medical-data-
models.org/forms/11387
Southwest Oncology Group Notice of
Death
SWOG clinical trial administrative data
SWOG Patient ID
Most Recent SWOG Study No.
Patient Initials (L, F M)
Institution/Affiliate
Physician (Groups other than SWOG)
Group Name
Study No.
Pt. ID
Date of death
Date of Death (month/day/year)
Causes Of Death
If cancer was the primary cause or if cancer
possibly or definitely contributed to death, and the
patient had had multiple tumor types, specify
those which were causes of death
Cancer_of_most_recent_s2005692
(Cancer of most recent SWOG study,
specify cancer)
Cancer_of_oth_swog_stdy2005693
(Cancer of other SWOG study, specify
cancer)
Other_cancer_specify2005694 (Other
cancer, specify)
Cancer of most recent SWOG study, specify
cancer
Cancer of other SWOG study, specify cancer
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Other cancer, specify
If Primary Cause, Contributory or Possible,
specify treatment and toxicity
Non-cancer and non-treatment related causes
(select one)
Contributory (Contributory)
No (No)
Possible (Possible)
Primary Cause (Primary Cause)
Unknown (Unknown)
Non-cancer and non-treatment related causes
(select one)
Contributory (Contributory)
No (No)
Possible (Possible)
Primary Cause (Primary Cause)
Unknown (Unknown)
Non-cancer and non-treatment related causes
(select one)
Contributory (Contributory)
No (No)
Possible (Possible)
Primary Cause (Primary Cause)
Unknown (Unknown)
If Primary Cause, Contributory or Possible,
specify
Autopsy done?
No (No)
Unknown (Unknown)
Yes (Yes)
Death information obtained from (select all that
apply)
Autopsy Was The Source Of Information
On The Patient's Death (Autopsy report)
Death Certificate Was The Source Of
Information On The Patient's Death
(Medical record / Death certificate)
The Source Of Information On The
Patient's Death Is Not On This List,
Specify Other (Other, specify)
Clinical Evidence Was The Source Of
Information On The Patient's Death
(Physician)
Relative or friend (Relative or friend)
Other, specify (death information obtained)
Notes
2 / 3
Southwest Oncology Group Notice of Death
Notes
Ccrr Module For Southwest Oncology
Group Notice Of Death
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Southwest Oncology Group Notice of Death
ABTR01B1: On Study Worksheet
NCT00898079
ABTR01B1: On Study Worksheet NCT00898079 
Collecting and Storing Malignant, Borderline Malignant
Neoplasms, and Related Samples From Young Patients
With Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=C08BFA5F-
2EAD-673E-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/11388
ABTR01B1: On Study Worksheet
NCT00898079
Header
Institution Name
COG Study Number
COG Study Number
COG Patient ID
Patient Initials
Date form originally completed
Date worksheet entered into RDE
Miscellaneous Patient Information
Patient Accession number
Stratum
Treatment Number
Treating Institution
Treating Physician
Date of Registration
Treatment Start Date
Method of Payment
Medicaid (Medicaid)
Medicaid And Medicare (Medicaid and
Medicare)
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Medicare (Medicare)
Medicare And Private Insurance
(Medicare and Private Insurance)
Military Or Veterans Sponsored Nos
(Military or Veterans sponsored NOS)
Military Sponsored (including Champus
& Tricare) (Military sponsored (including
CHAMPUS and TRICARE))
No Means Of Payment (no Insurance)
(No means of payment (no insurance))
Other (Other)
Private Insurance (Private Insurance)
Self Pay (no Insurance) (Self pay (no
insurance))
Unknown (Unknown)
Veterans Sponsored (Veterans
sponsored)
Date of original diagnosis
Comments
Ccrr Module For Abtr01b1: On Study
Worksheet
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ABTR01B1: On Study Worksheet NCT00898079
Southwest Oncology Group Lung
Carcinoma Follow Up Form
Southwest Oncology Group Lung Carcinoma Follow Up
Form
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=A4CDF62A-
7230-112A-E034-080020C9C0E0
All rights reserved. Please visit https://medical-data-
models.org/forms/11389
Southwest Oncology Group Lung
Carcinoma Follow Up Form
SWOG clinical trial administrative data
SWOG Patient ID
SWOG Study No.
Registration Step
Patient Initials (L, F M)
Institution/Affiliate
Physician (Groups other than SWOG)
Group Name
Study No.
Pt. ID (Vital Status)
Lung Carcinoma Follow Up
Has the patient experienced (prior to treatment
for progression or relapse or a second primary,
and prior to non-protocol treatment) any severe
(grade>/=3) long term toxicity that has not been
previously reported?
Yes
No
Vital Status
Alive (Alive)
Dead (Dead)
Date of last contact or death (If vital status is
Dead, complete and submit Notice of Death
form.)
Has the patient had a documented clinical
assessment for this cancer since submission of
the previous follow-up form?
Yes
1 / 3
No
Date of Last Clinical Assessment (Notice of First
Relapse or Progression)
Has the patient developed a first progression (or
relapse) that has not been previously reported?
Yes
No
Date of Relapse or Progression (If yes, please
submit the Lung Carcinoma First Sites of
Progression or Relapse Form.)
Has a new primary cancer or myelodysplastic
syndrome (MDS) been diagnosed that has not
been previously reported? (If yes,)
Yes
No
Date of Diagnosis
New Primary Site (Further Treatment)
Has the patient received further (non-protocol)
treatment for this cancer? (If yes,)
Yes
No
Date of first non-protocol therapy
Specify regimen (Note: If multiple regimens were
received, please specify only the first regimen
received after going off protocol treatment.)
Did the patient respond to this treatment?
Yes
No
Has the patient received prophylactic cranial
irradiation (PCI)?
Yes
No
PCI Start Date (Long Term Toxicity)
Toxicities and Grades
Comments
Comments
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Southwest Oncology Group Lung Carcinoma Follow Up Form
Ccrr Module For Southwest Oncology
Group Lung Carcinoma Follow Up Form
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Southwest Oncology Group Lung Carcinoma Follow Up Form
Form 5 - On & Off Treatment Follow-Up
Report NCT00049543
Form 5 - On & Off Treatment Follow-Up Report
NCT00049543 
Gefitinib in Treating Patients With Non-Small Cell Lung
Cancer That Has Been Surgically Removed
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=A0E01D72-
7CAF-3016-E034-080020C9C0E0
All rights reserved. Please visit https://medical-data-
models.org/forms/11390
Form 5 - On & Off Treatment Follow-
Up Report NCT00049543
1. Patient Information
Pt. Serial #
Hospital #
Pt. Initials
Intergroup Patient Serial #
Site #
Patient's Social Security # (USA only)
Institution
Investigator
2. Month Of Report
Month of report: (circle one)
1 (1)
12 (12)
15 (15)
18 (18)
21 (21)
24 (24)
27 Months (27)
3 (3)
30 (30)
36 (36)
42 (42)
48 (48)
54 (54)
6 (6)
60 (60)
9 (9)
Other Month (Other)
Header
1 / 8
3. Physical Exam
Date of Attendance
Weight (kg)
Performance status (ECOG circle one see
Appendix II of protocol)
0 (0)
1 (1)
2 (2)
3 (3)
4 (4)
4. Disease Status
4. DISEASE STATUS
No Evidence Of Disease (Absent)
Cancer Present (Present)
5. Systemic Therapy Report
During the timeframe of this report, were full
doses of Iressa/placebo taken daily by the
patient?
No (No)
(i.e., The Treatment Was Changed
According To Protocol Guidelines) (Yes)
(i.e, The Treatment Change Was Not
Part Of Protocol Guidelines) (Yes,
unplanned)
give reason (If no, check _ all that apply)
dose modification due toxicity (dose
modification due toxicity)
other: specify (other: specify)
patient non compliant/forgot (patient non
compliant/forgot)
permanent cessation of protocol therapy
(permanent cessation of protocol
therapy)
temporary interruption for toxicity
(temporary interruption for toxicity)
dose modification due toxicity - please specify
toxicity and grade
temporary interruption for toxicity - please specify
toxicity and grade
other: specify
Will this patient continue to receive protocol
2 / 8
Form 5 - On & Off Treatment Follow-Up Report NCT00049543
therapy?
Yes
No
If this is the first On Treatment Follow-up, give
date study medication was first taken
Ncic Ctg Use Only
Logged
Entry date
Study Coord
Coordinator Review Date
Phy
Data Ent'd
Verified
Header
6. Notice Of New Primary
Have any other malignancies or myelodysplastic
syndrome been diagnosed?
Yes
No
date of diagnosis
Site of new primary
Describe (An Adverse Event Report must be sent
to NCIC CTG within 15 working days that
diagnosis is known to the investigator. See
protocol section 11.0 for details.)
Ncic Ctg Use
Malignancy Type
7. Hematology
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Form 5 - On & Off Treatment Follow-Up Report NCT00049543
Units (Note: please circle one)
X10^9/l (10^9/L)
1000/mm3 (1000/mm3)
G/dl (g/dl)
G/l (g/L)
Meq/l (mEq/L)
Mg/dl (mg/dL)
Mmol/l (mmol/L)
S/i (SI Units)
U/l (U/L)
Ul (ul)
Umol/l (umol/L)
Imperial (US Imperial Units)
Date
Hemoglobin
Platelets
WBC
Neutrophils %
Neutrophils x 109/L
Bands* x 109/L
8. Biochemistry
Date
total bilirubin
U/L
U/l (U/L)
AST (SGOT)
Alkaline Phosphatase
UNL
9. Treatment Given Since Last Report To
Ncic Ctg
Is the patient receiving any non-protocol cancer
therapy not previously reported? (if yes, specify
below)
4 / 8
Form 5 - On & Off Treatment Follow-Up Report NCT00049543
Yes
No
Non-Protocol Hormonal Therapy?  (include
medical and surgical)
Yes
No
Non-Protocol Chemotherapy?
Yes
No
Non-Protocol Immunotherapy?
Yes
No
Non-Protocol Biologic Response Modifier?
Yes
No
Non-Protocol High Dose Chemotherapy/
Autologous Stem Cell Transplant?
Yes
No
Non-Protocol Radiation Therapy?
Yes
No
Non-Protocol Surgery?
Yes
No
Other Non-Protocol Therapy?
Yes
No
(specify)
First ever chemotherapy or EGFR inhibitor given:
(specify)
Date started
Second ever chemotherapy or EGFR inhibitor
given: (specify)
Date started(2nd)
Ncic Ctg Use2
1st line
2nd line
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Form 5 - On & Off Treatment Follow-Up Report NCT00049543
10. On Treatment Long Term Toxicity
NCIC CTG Use only
Acute Toxicity Database (Acute toxicity
database)
Delayed Toxicity Database (Delayed
toxicity database)
Did the patient experience any toxicities during
the timeframe of this report? (if yes, please
complete form below)
Yes
No
Toxicity Term
Anorexia (ANOREXIA)
Chest Pain (CHEST PAIN (NON-
CARDIAC AND NON-PLEURITIC))
Constipation (CONSTIPATION)
diarrhea (diarrhea)
Diarrhea For Patients Without Colostomy
(DIARRHEA (PATIENTS WITHOUT
COLOSTOMY))
Dry Skin (DRY SKIN)
Dyspnea (DYSPNEA (SHORTNESS OF
BREATH))
fatigue (fatigue)
Fatigue (FATIGUE (LETHARGY,
MALAISE, ASTHENIA))
Infection Without Neutropenia
(INFECTION (WITHOUT
NEUTROPENIA))
Nausea (nausea)
Pruritus (PRURITUS)
rash / acne (rash / acne)
Rash/desquamation
(RASH/DESQUAMATION)
Unnamed2 (Unnamed2)
uveitis/keratitis (uveitis/keratitis)
Vomiting (vomiting)
rash / acne (please circle)
Acne (acne)
Rash (rash)
CTC Adverse Event Term, Other
Category Code*
Constitutional Symptoms (Constitutional
Symptoms)
Dermatology/skin (Dermatology/Skin)
FL (FL)
Gastrointestinal (Gastrointestinal)
GI (GI)
Infection (Infection)
OC (OC)
Pain (Pain)
Pulmonary (Pulmonary)
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SK (SK)
NCIC CTG use only Tox Code
Dia (DIA)
Ker (KER)
Let (LET)
Nau (NAU)
Ras (RAS)
Vom (VOM)
Worst Severity/Grade* (0=None NA=Not
Assessed * Code/grade according to Common
Toxicity Criteria, Version 2.0)
Relation to Protocol Therapy
Unrelated (1=unrelated)
Unlikely (2=unlikely)
Possibly (3=possible)
Probably (4=probable)
Definitely (5=definite)
COMMENTS
11. Comments
12. Have You Attached Copies Of
12. HAVE YOU ATTACHED COPIES OF
Supporting documentation (Supporting
documentation)
13. Investigator Signature
Date
Name of Clinical Research Associate
Ccrr Module For Form 5 - On & Off
Treatment Follow-up Report
Other
Person Completing Form, First Name
SGPT
Lactate Dehydrogenase (LDH)
Creatinine
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Form 5 - On & Off Treatment Follow-Up Report NCT00049543
BUN
Potassium (K)
Sodium (Na)
Chloride (Cl)
Calcium (Ca)
Albumin
Imaging Site
Chest (Chest)
Method of Evaluation
Chest X-ray (Chest X-Ray)
Ct Scan (CT Scan)
Mri (MRI (NMR))
Not Evaluated (Not evaluated)
Date of Evaluation
8 / 8
Form 5 - On & Off Treatment Follow-Up Report NCT00049543
NCT00048997  Radiation Therapy Oncology Group Phase III
Lung Prophylactic Cranial RT Activities of Daily Living Scale
NCT00048997  Radiation Therapy Oncology Group Phase
III Lung Prophylactic Cranial RT Activities of Daily Living
Scale
Radiation Therapy in Preventing CNS Metastases in
Patients With Non-Small Cell Lung Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=A5472762-
3A45-07E6-E034-080020C9C0E0
All rights reserved. Please visit https://medical-data-
models.org/forms/11391
NCT00048997  Radiation Therapy
Oncology Group Phase III Lung
Prophylactic Cranial RT Activities of
Daily Living Scale
Header module
Case #
Institution
Institution No.
Patient's Name
Patient's I.D. No.
If this is a revised or corrected form, indicate by
checking box.
Daily Living Scale
If not completed by patient, by whom and why?
(Self Care Activities)
Eating
Don't Know (Don't know)
Independent, But Slow Or Some Spills
(Independent, but slow or some spills)
Must Be Fed Most Foods (Must be fed
most foods)
Need Help To Cut Or Pour; Spills Often
(Need help to cut or pour; spills often)
No Problem (No problem)
Dressing
Don't Know (Don't know)
Independent, But Slow Or Clumsy
(Independent, but slow or clumsy)
Need Help With Dressing (Need help
with dressing)
No Problem (No problem)
Wrong Sequence, Forget Items (Wrong
sequence, forget items)
1 / 2
Bathing
Bathe Self With Assistance (Bathe self
with assistance)
Bathe Self, But Needs To Be Reminded
(Bathe self, but needs to be reminded)
Don't Know (Don't know)
Must Be Bathed By Others (Must be
bathed by others)
No Problem (No problem)
Elimination
Don't Know (Don't know)
Go To The Bathroom Independently (Go
to the bathroom independently)
Got To The Bathroom When Reminded;
Some Accidents (Got to the bathroom
when reminded; some accidents)
Have No Control Over Either Bowel Or
Bladder (Have no control over either
bowel or bladder)
Needs Assistance For Elimination
(Needs assistance for elimination)
Mobility in home
Do Not Get Out Of Bed (Do not get out
of bed)
Don't Know (Don't know)
Move Into And Out Of Bed Or Chair
Independently (may Use A Cane Or
Walker For Support) (Move into and out
of bed or chair independently (may use a
cane or walker for support))
Move Into And Out Of Bed Or Chair With
Assistance (Move into and out of bed or
chair with assistance)
No Problems (No problems)
Comments
Patient Initials
Date completed
Ccrr Module For Radiation Therapy
Oncology Group Phase Iii Lung
Prophylactic Cranial Rt Activities Of Daily
Living Scale
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NCT00048997  Radiation Therapy Oncology Group Phase III Lung
Prophylactic Cranial RT Activities of Daily Living Scale
Form 5S - Post Progression Follow-Up
Report NCT00049543
Form 5S - Post Progression Follow-Up Report
NCT00049543 
Gefitinib in Treating Patients With Non-Small Cell Lung
Cancer That Has Been Surgically Removed
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=A0E053B5-
CFD0-32A7-E034-080020C9C0E0
All rights reserved. Please visit https://medical-data-
models.org/forms/11392
Form 5S - Post Progression Follow-
Up Report NCT00049543
Patient Information
Pt. Serial #
Institution
Hospital #
Investigator
Pt. Initials
Month Of Report
Month of report: (circle one)
12 (12)
15 (15)
18 (18)
21 (21)
24 (24)
3 (3)
30 (30)
36 (36)
42 (42)
48 (48)
54 (54)
6 (6)
60 (60)
9 (9)
Other Month (OTHER)
Other
Date of Attendance
Disease Status
3. DISEASE STATUS
No Evidence Of Disease (Absent)
Cancer Present (Present)
Unknown (Unknown)
1 / 5
Notice Of New Primary
Have any other malignancies or myelodysplastic
syndrome been diagnosed?
Yes
No
date of diagnosis
Site of new primary
Describe (An Adverse Event Report must be sent
to NCIC CTG within 15 working days that
diagnosis is known to the investigator. See
protocol section 11.0 for details.)
Ncic Ctg Use
Malignancy Type
Ncic Ctg Use Only
Logged
Logged Entry Date
Study Coord
Coordinator Review Date
Phy
Data Ent'd
Verified
Header
Treatment Given Since Last Report To
Ncic Ctg
Is the patient receiving any non-protocol cancer
therapy not previously reported? (if yes, specify
below)
Yes
No
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Form 5S - Post Progression Follow-Up Report NCT00049543
Non-Protocol Hormonal Therapy?  (include
medical and surgical)
Yes
No
Non-Protocol Chemotherapy?
Yes
No
Non-Protocol Immunotherapy?
Yes
No
Non-Protocol Biologic Response Modifier?
Yes
No
Non-Protocol High Dose Chemotherapy/
Autologous Stem Cell Transplant?
Yes
No
Non-Protocol Radiation Therapy?
Yes
No
Non-Protocol Surgery?
Yes
No
Other Non-Protocol Therapy?
Yes
No
(specify)
First ever chemotherapy or EGFR inhibitor given:
(specify)
Date started
Second ever chemotherapy or EGFR inhibitor
given: (specify)
Date started2nd
Long Term Toxicity
Did the patient experience any long term
toxicities of protocol treatment that has not yet
been reported? (if yes, please complete form
below)
Yes
No
3 / 5
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Toxicity Term
Anorexia (ANOREXIA)
Chest Pain (CHEST PAIN (NON-
CARDIAC AND NON-PLEURITIC))
Constipation (CONSTIPATION)
Diarrhea For Patients Without Colostomy
(DIARRHEA (PATIENTS WITHOUT
COLOSTOMY))
Dry Skin (DRY SKIN)
Dyspnea (DYSPNEA (SHORTNESS OF
BREATH))
Fatigue (FATIGUE (LETHARGY,
MALAISE, ASTHENIA))
Infection Without Neutropenia
(INFECTION (WITHOUT
NEUTROPENIA))
Nausea (NAUSEA)
Pruritus (PRURITUS)
Rash/desquamation
(RASH/DESQUAMATION)
Vomiting (VOMITING)
Category Code*
Constitutional Symptoms (Constitutional
Symptoms)
Dermatology/skin (Dermatology/Skin)
Gastrointestinal (Gastrointestinal)
Infection (Infection)
Pain (Pain)
Pulmonary (Pulmonary)
Worst Severity/Grade* (0=None NA=Not
Assessed * Code/grade according to Common
Toxicity Criteria, Version 2.0)
Relation to Protocol Therapy
Unrelated (1=unrelated)
Unlikely (2=unlikely)
Possibly (3=possible)
Probably (4=probable)
Definitely (5=definite)
Comments
COMMENTS
Investigator Signature
Signature of Responsible Investigator
Person Completing Form, Last Name
Date
4 / 5
Form 5S - Post Progression Follow-Up Report NCT00049543
Ccrr Module For Form 5s - Post
Progression Follow-up Report
Person Completing Form, First Name
Non-Protocol EGFR Inhibitor Ind
Yes
No
CTC Adverse Event Term, Other
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Form 6 - Final Report NCT00049543
Form 6 - Final Report NCT00049543 
Gefitinib in Treating Patients With Non-Small Cell Lung
Cancer That Has Been Surgically Removed
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=A1AD599A-
E8FC-3686-E034-080020C9C0E0
All rights reserved. Please visit https://medical-data-
models.org/forms/11393
Form 6 - Final Report NCT00049543
1. Patient Information
Pt. Serial #
Hospital #
Pt. Initials
Intergroup Patient Serial #
Site #
Patient's Social Security # (USA only)
Institution
Investigator
2. Cause Of Death
Date of death
Cause of Death
combination NSCLC and non-protocol
treatment complication (combination
NSCLC and non-protocol treatment
complication)
combination NSCLC and protocol
treatment complication (combination
NSCLC and protocol treatment
complication)
non-protocol treatment complication
(non-protocol treatment complication)
Due To This Disease (NSCLC)
Due To Other Cause (other condition or
circumstance)
other primary malignancy (other primary
malignancy)
Due To Protocol Treatment (protocol
treatment complication)
1 / 6
Unknown (UNKNOWN)
other primary malignancy (specify & send report)
NCIC CTG use only code
Describe
Status of NSCLC at Time of Death
Absent (Absent)
Present (Present)
Unknown (Unknown)
3. Autopsy
Autopsy performed
No (No)
Unknown (UNKNOWN)
Yes (Yes)
NCIC CTG Use only: Received
4. Other Malignancies Or Marrow
Dysplasia
Have any other malignancies or myelodysplastic
syndrome (MDS) been diagnosed?
Yes
No
Date of diagnosis
Site of new primary
Describe (An Adverse Event Report must be sent
to NCIC CTG within 15 working days that
diagnosis is known to the investigator. See
protocol section 11.0 for details.)
Ncic Ctg Use
Malignancy Type
Ncic Ctg Use Only
Logged
Header
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Study Coord
Coordinator Review Date
Phy
Data Ent'd
Verified
5. Treatment Given Since Last Report To
Ncic Ctg
Is the patient receiving any non-protocol cancer
therapy not previously reported? (if yes, specify
below)
Yes
No
Non-Protocol Hormonal Therapy?  (include
medical and surgical)
Yes
No
Non-Protocol Chemotherapy?
Yes
No
Non-Protocol Immunotherapy?
Yes
No
Non-Protocol Biologic Response Modifier?
Yes
No
Non-Protocol High Dose Chemotherapy/
Autologous Stem Cell Transplant?
Yes
No
Non-Protocol Radiation Therapy?
Yes
No
Non-Protocol Surgery?
Yes
No
Other Non-Protocol Therapy?
Yes
No
(specify)
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First ever chemotherapy or EGFR inhibitor given:
(specify)
Date started
Second ever chemotherapy or EGFR inhibitor
given: (specify)
Date started(2nd)
Ncic Ctg Use2
1st line
2nd line
6. Delayed Toxicity/adverse
Event/intercurrent Illness
NCIC CTG use only
Acute Toxicity Database (Acute toxicity
database)
Delayed Toxicity Database (Delayed
toxicity database)
Did the patient experience any long term
toxicities of protocol treatment that has not yet
been reported? (if yes, please complete form
below)
Yes
No
Late Toxicity Term
Anorexia (Anorexia)
Chest Pain (Chest Pain (non-cardiac and
non-pleuritic))
Constipation (CONSTIPATION)
Diarrhea For Patients Without Colostomy
(Diarrhea (patients without colostomy))
Dry Skin (Dry skin)
Dyspnea (Dyspnea (shortness of
breath))
Fatigue (Fatigue  (lethargy, malaise,
asthenia))
Infection Without Neutropenia (Infection
(without neutropenia))
Nausea (Nausea)
Pruritus (Pruritus)
Rash/desquamation
(Rash/Desquamation)
Vomiting (Vomiting)
Category Code*
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Constitutional Symptoms (Constitutional
Symptoms)
Dermatology/skin (Dermatology/Skin)
Gastrointestinal (GASTROINTESTINAL)
Infection (Infection)
Pain (Pain)
Pulmonary (PULMONARY)
NCIC CTG use only Tox Code
Worst Severity/Grade* (0=None NA=Not
Assessed * Code/grade according to Common
Toxicity Criteria, Version 2.0)
Relation to Protocol Therapy
Unrelated (1=unrelated)
Unlikely (2=unlikely)
Possibly (3=possible)
Probably (4=probable)
Definitely (5=definite)
COMMENTS
7. Comments
8. Have You Attached Copies Of
8. HAVE YOU ATTACHED COPIES OF (please _)
Autopsy Report (if applicable) (Autopsy
Report (if applicable))
Supporting documentation (if applicable)
(Supporting documentation (if
applicable))
9. Investigator Signature
Signature of Responsible Investigator
Name of Clinical Research Associate
Date
Ccrr Module For Form 6 - Final Report
Person Completing Form, First Name
CTC Adverse Event Term, Other
Non-Protocol EGFR Inhibitor Ind
5 / 6
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Yes
No
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SOUTHWEST ONCOLOGY GROUP
NOTICE OF DEATH NCT00045162
SOUTHWEST ONCOLOGY GROUP NOTICE OF DEATH
NCT00045162 
S0124: Cisplatin Combined With Either Irinotecan or
Etoposide in Treating Patients With Extensive-Stage Small
Cell Lung Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=001AE9A4-
74CD-520B-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11394
SOUTHWEST ONCOLOGY GROUP
NOTICE OF DEATH NCT00045162
SWOG clinical trial administrative data
SWOG Patient ID
Most Recent SWOG Study No.
Patient Initials (L, F, M)
Institution/Affiliate
Physician
Participating Group Name
Participating Group Study No.
Participating Group Patient ID
Date of death
Date of Death (month / day / year)
Causes Of Death
Any cancer (select one)
Contributory (Contributory)
No (No)
Possible (Possible)
Primary Cause (Primary Cause)
Unknown (Unknown)
If cancer was the primary cause or if cancer
possibly or definitely contributed to death, and the
patient had had multiple tumor types, specify
those which were causes of death
Cancer Of Most Recent Swog Study
(Cancer of most recent SWOG study)
Cancer Of Other Swog Study (Cancer of
other SWOG study)
1 / 2
Other Cancer (Other cancer)
Cancer of most recent SWOG study, specify
cancer
Cancer of other SWOG study, specify cancer
Other cancer, specify
Toxicity from disease related treatment (select
one)
Contributory (Contributory)
No (No)
Possible (Possible)
Primary Cause (Primary Cause)
Unknown (Unknown)
If Primary Cause, Contributory or Possible,
specify treatment and toxicity
Non-cancer and non-treatment related causes
(select one)
Contributory (Contributory)
No (No)
Possible (Possible)
Primary Cause (Primary Cause)
Unknown (Unknown)
If Primary Cause, Contributory or Possible,
specify
Autopsy?
No (No)
Unknown (Unknown)
Yes (Yes)
Source(s) of death information
Autopsy Report (Autopsy report)
Medical Record / Death Certificate
(Medical record / Death certificate)
Other (Other)
Physician (Physician)
Relative Or Friend (Relative or friend)
Other, specify
Comments
Comments
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Southwest Oncology Group S0201
Adjuvant Melanoma Follow Up
Southwest Oncology Group S0201 Adjuvant Melanoma
Follow Up
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=A8BA0178-
CF14-0F96-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/11395
Southwest Oncology Group S0201
Adjuvant Melanoma Follow Up
SWOG clinical trial administrative data
SWOG Patient No
SWOG Study No.
Registration Step
Patient Initials (L, F M)
Institution/Member
Physician (Groups other than SWOG)
Group Name
Study No.
Pt. No
Vital Status
Vital Status
Alive (Alive)
Dead (Dead)
Date of last contact or death
Disease Follow-up Status
Has the patient been assessed for this cancer
since submission of the last form?
Yes
No
Date of assessment
Notice Of First Relapse Or Progression
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Has the patient had a first relapse or progression
of this cancer that has not been previously
reported?
Yes
No
Date of Relapse
Site(s) of relapse
Distant Metastasis (distant metastasis)
In-transit Recurrence (in-transit
recurrence)
Local Recurrence (local-recurrence)
Regional Recurrence (regional
recurrence)
Notice Of New Primary
Has a new malignant neoplasm or
myelodysplastic syndrome (MDS) been
diagnosed since the last form?
Yes
No
Date of new primary
Specify new primary site
Non-protocol Treatment
Has the patient received any (non-protocol)
cancer treatment since submission of the last
S0201 Adjuvant Melanoma Follow-up Form?
Yes
No
Surgery?
Yes
No
Date (surgery)
Specify (surgery
Systemic therapy?
Yes
No
Date (systemic therapy)
Specify agents, dose, schedule
Radiation Therapy?
Yes
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No
Date (RT)
Specify (RT)
Other therapy?
Yes
No
Specify (other therapy)
Ccrr Module For Southwest Oncology
Group S0201 Adjuvant Melanoma Follow
Up
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Southwest Oncology Group S0201 Adjuvant Melanoma Follow Up
Southwest Oncology Group S0201
Pathology Submission Form
Southwest Oncology Group S0201 Pathology Submission
Form
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=A8BA7D80-
B069-121E-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/11396
Southwest Oncology Group S0201
Pathology Submission Form
SWOG clinical trial administrative data
SWOG Patient ID
Patient Initials (L, F M)
Disease
Institution/Member
Physician (Groups other than SWOG)
Group Name
Study No.
Pt. No
Pathology submission
No. of slides
No. of blocks
Date sample obtained
One representative H&E stained section from
each block of the primary tumor
Yes
No
Section of sentinel regional lymph node(s) (ind)
Yes
No
Sections of non-sentinel lymph node(s) (Ind)
Yes
No
Operative reports (ind)
Yes
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No
Pathology reports (ind)
Yes
No
Specimen Number
Comments
Ccrr Module For Southwest Oncology
Group S0201 Pathology Submission Form
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S0522 Notice of Death Form
S0522 Notice of Death Form
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=0EA721AF-
3EE8-4BBC-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11397
S0522 Notice of Death Form
SWOG clinical trial administrative data
SWOG Patient ID
Most Recent SWOG Study No.
Patient Initials (L, F, M)
Institution/Affiliate
Physician
Participating Group Name
Participating Group Study No.
Participating Group Patient ID
Date of death
Date of Death (month / day / year)
Causes Of Death
Any cancer (select one)
Contributory (Contributory)
No (No)
Possible (Possible)
Primary Cause (Primary Cause)
Unknown (Unknown)
If cancer was the primary cause or if cancer
possibly or definitely contributed to death, and the
patient had had multiple tumor types, specify
those which were causes of death
Cancer Of Most Recent Swog Study
(Cancer of most recent SWOG study)
Cancer Of Other Swog Study (Cancer of
other SWOG study)
Other Cancer (Other cancer)
Cancer of most recent SWOG study, specify
cancer
Cancer of other SWOG study, specify cancer
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Other cancer, specify
Toxicity from disease related treatment (select
one)
Contributory (Contributory)
No (No)
Possible (Possible)
Primary Cause (Primary Cause)
Unknown (Unknown)
If Primary Cause, Contributory or Possible,
specify treatment and toxicity
Non-cancer and non-treatment related causes
(select one)
Contributory (Contributory)
No (No)
Possible (Possible)
Primary Cause (Primary Cause)
Unknown (Unknown)
If Primary Cause, Contributory or Possible,
specify
Autopsy?
No (No)
Unknown (Unknown)
Yes (Yes)
Source(s) of death information
Autopsy Report (Autopsy report)
Medical Record / Death Certificate
(Medical record / Death certificate)
Other (Other)
Physician (Physician)
Relative Or Friend (Relative or friend)
Other, specify
Comments
Comments
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S0201 Southwest Oncology Group
Adjuvant Melanoma Off Treatment Notice
S0201 Southwest Oncology Group Adjuvant Melanoma Off
Treatment Notice
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=A93556CA-
1C7B-6F30-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/11398
S0201 Southwest Oncology Group
Adjuvant Melanoma Off Treatment
Notice
SWOG clinical trial administrative data
SWOG Patient No.
SWOG Study No.
Registration Step
Patient Initials (L, F M)
Institution/Member
Physician (Groups other than SWOG)
Group Name
Study No.
Pt. No.
Off-protocol treatment
Reason off Treatment (select one)
Death Of Patient Occurred After The
Patient Began Protocol Therapy (Death)
Other, Specify (Other, specify)
Patient Withdrawal Or Refusal After
Beginning Protocol Therapy (Patient
refused, due to toxicity, specify)
Patient Off-treatment For Other
Complicating Disease (Patient refused,
other than toxicity, specify)
Disease Progression, Relapse During
Active Treatment (Progression or
relapse)
Toxicity/side Effects/complications
(Toxicity, medically required, specify)
Treatment Completed Per Protocol
Criteria (Treatment/observation
completed per protocol)
Off Treatment due to the following toxicities
flu-like symptoms (flu-like symptoms)
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granuloma (granuloma)
local injection site reaction/pain (local
injection site reaction/pain)
other, specify in Comments (other,
specify in Comments)
Sites (progression or relapse)
Distant Metastasis (distant metastasis)
In-transit Recurrence (in-transit
recurrence)
Local Recurrence (local recurrence)
Regional Recurrence (regional
recurrence)
Other, specify (off treatment reason) (Date off
treatment date of completion, death, or decision
to discontinue therapy)
Will patient receive further treatment?
No (No)
Unknown (Unknown)
Yes (Yes, specify)
Yes, specify (further treatment)
Date of Last Contact (or death)
Vital Status
Alive (Alive)
Dead (Dead)
Comments
Comments
By
Date
Ccrr Module For S0201 Southwest
Oncology Group Adjuvant Melanoma Off
Treatment Notice
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S0201 Southwest Oncology Group Adjuvant Melanoma Off Treatment
Notice
Southwest Oncology Group Off Treatment
Notice
Southwest Oncology Group Off Treatment Notice
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=A4CF364E-
8E7A-263A-E034-080020C9C0E0
All rights reserved. Please visit https://medical-data-
models.org/forms/11399
Southwest Oncology Group Off
Treatment Notice
SWOG clinical trial administrative data
SWOG Patient ID
SWOG Study No.
Registration Step
Patient Initials (L, F M)
Institution/Affiliate
Physician (Groups other than SWOG)
Group Name
Study No.
Pt. ID
Reporting period
Treatment Start Date
Treatment End Date
Regimen or Procedure or Site(s) (If more room is
needed, please continue on a separate page.)
Off Treatment Reason (select one)
Alternative Therapy (Alternative Therapy)
Death (Death)
Death After Beginning Protocol Therapy
(Death after beginning protocol therapy)
Death On Study (Death on study)
Death Prior To Beginning Protocol
Therapy (Death prior to beginning
protocol therapy)
Disease Progression, Relapse During
Active Treatment (Disease progression,
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relapse during active treatment)
Disease Progression, Relapse Prior To
Beginning Protocol Therapy (Disease
progression, relapse prior to beginning
protocol therapy)
Medically required, due to toxicity,
specify (Medically required, due to
toxicity, specify)
Other, Specify (Other, specify)
Patient Declared Ineligible (Patient
declared ineligible)
Patient Off-treatment For Other
Complicating Disease (Patient off-
treatment for other complicating disease)
Patient refused, due to toxicity, specify
(Patient refused, due to toxicity, specify)
Patient refused, other than toxicity,
specify (Patient refused, other than
toxicity, specify)
Patient Withdrawal Or Refusal After
Beginning Protocol Therapy (Patient
withdrawal or refusal after beginning
protocol therapy)
Patient Withdrawal Or Refusal Prior To
Beginning Protocol Therapy (Patient
withdrawal or refusal prior to beginning
protocol therapy)
Progression or relapse (Progression or
relapse)
Toxicity/side Effects/complications
(Toxicity/Side effects/Complications)
Treatment Completed Per Protocol
Criteria (Treatment completed per
protocol criteria)
Medically required, due to toxicity, specify
Patient refused, due to toxicity, specify
Sites (progression or relapse)
Other, specify (Off Treatment Date)
Other, specify (Off Treatment Date)
Date of completion, progression, death or
decision to discontinue therapy
Will patient receive further treatment?
No (No)
Unknown (Unknown)
Yes (Yes, specify)
Yes, specify (further treatment)
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Date of Last Contact (or death)
Vital Status
Alive (Alive)
Dead (Dead)
Notes
Notes
Ccrr Module For Southwest Oncology
Group Off Treatment Notice
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Southwest Oncology Group S0201
Specimen Submission Form
Southwest Oncology Group S0201 Specimen Submission
Form
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=A8BA795E-
3805-1204-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/11400
Southwest Oncology Group S0201
Specimen Submission Form
SWOG clinical trial administrative data
SWOG Patient No
SWOG Study No.
Reg Type
Patient Initials (L, F M)
Disease
Institution/Member
Physician
Contact Person at Institution
Telephone No. (Groups other than SWOG)
Group Name
Study No.
Pt. No
Specimen
Type of specimen (check only one)
Karyotype(s), Number (karyotype)
Other, Specify (other, specify)
Slides, Type And Number (slides)
Tissue, Specify Site(s) (tissue)
Tubes Of Blood (tubes of blood)
Tubes Of Bone Marrow (tubes of bone
marrow)
Tubes Of Serum (tubes of serum)
Tissue, specify sites
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Tissue, check one
Fresh (fresh)
Frozen (frozen)
parrafin embedded (parrafin embedded)
Slides, type and number
karyotype, number
Date specimen collected
Time specimen collected
Reasons for specimen submission (Check all that
apply)
Complete Remission/response
Specimen (complete remission/response
specimen)
Other Specimen, Specify (other
specimen, specify)
Prestudy Submission (prestudy
submission)
Relapse/recurrence Specimen
(relapse/recurrence specimen)
Other specimen, specify (reason for submission)
Treatment study No.
For Central Laboratory Use Only
Central laboratory identification number
Date
time specimen received
condition of specimen (check only one)
Damaged Or Unusable (not usable as
received; adequate submission)
Damaged Or Unusable (not usable as
received; inadequate submission)
Useable (usable as received)
By
Notes from central laboratory
Date
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Ccrr Module For Southwest Oncology
Group S0201 Specimen Submission Form
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Southwest Oncology Group S0201 Specimen Submission Form
Southwest Oncology Group FACT-L TOI
(Version 4)
Southwest Oncology Group FACT-L TOI (Version 4)
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=A4CF50CD-
3A8F-2ECB-E034-080020C9C0E0
All rights reserved. Please visit https://medical-data-
models.org/forms/11401
Southwest Oncology Group FACT-L
TOI (Version 4)
SWOG clinical trial administrative data
SWOG Patient ID
SWOG Study No.
Assessment
Prestudy (Prestudy)
Week 13 (Week 13)
Week 7 (Week 7)
Registration Step
Patient Initials (L, F M)
Institution/Affiliate
Physician (Physical Well-Being)
Quality of life self-assessment
I have a lack of energy
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have nausea
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
Because of my phyical condition, I have trouble
meeting the needs of my family
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have pain
A Little Bit (A little bit)
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Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am bothered by side effects of treatment
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I feel ill
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am forced to spend time in bed (Functional
Well-Being)
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am able to work (include work at home)
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
My work (include work at home) is fulfilling
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am able to enjoy life
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have accepted my illness
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am sleeping well
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
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Very Much (Very much)
I am enjoying things I usually do for fun
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am content with the quality of my life right now
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
Patient demographics
SWOG Patient ID
SWOG Study No.
Assessment
Prestudy (Prestudy)
Week 13 (Week 13)
Week 7 (Week 7)
Registration Step
Patient Initials (L, F M)
I have been short of breath
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am losing weight
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
My thinking is clear
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have been coughing
A Little Bit (A little bit)
Not At All (Not at all)
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Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have a good appetite
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I feel tightness in my chest
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
Breathing is easy for me
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
Ccrr Module For Southwest Oncology
Group Fact-l Toi (version 4)
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SOUTHWEST ONCOLOGY GROUP
NOTICE OF DEATH (S0421) NCT00134056
SOUTHWEST ONCOLOGY GROUP NOTICE OF DEATH
(S0421) NCT00134056
Docetaxel and Prednisone With or Without Atrasentan in
Treating Patients With Stage IV Prostate Cancer and Bone
Metastases That Did Not Respond to Previous Hormone
Therapy
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=F159FB7F-
5AEC-328A-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11402
SOUTHWEST ONCOLOGY GROUP
NOTICE OF DEATH (S0421)
NCT00134056
SWOG clinical trial administrative data
SWOG Patient ID
Most Recent SWOG Study No.
Patient Initials (L, F, M)
Institution/Affiliate
Physician
Participating Group Name
Participating Group Study No.
Participating Group Patient ID
Date of death
Date of Death (month / day / year)
Causes Of Death
Any cancer (select one)
Contributory (Contributory)
No (No)
Possible (Possible)
Primary Cause (Primary Cause)
Unknown (Unknown)
If cancer was the primary cause or if cancer
possibly or definitely contributed to death, and the
patient had had multiple tumor types, specify
those which were causes of death
Cancer Of Most Recent Swog Study
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(Cancer of most recent SWOG study)
Cancer Of Other Swog Study (Cancer of
other SWOG study)
Other Cancer (Other cancer)
Cancer of most recent SWOG study, specify
cancer
Cancer of other SWOG study, specify cancer
Other cancer, specify
Toxicity from disease related treatment (select
one)
Contributory (Contributory)
No (No)
Possible (Possible)
Primary Cause (Primary Cause)
Unknown (Unknown)
If Primary Cause, Contributory or Possible,
specify treatment and toxicity
Non-cancer and non-treatment related causes
(select one)
Contributory (Contributory)
No (No)
Possible (Possible)
Primary Cause (Primary Cause)
Unknown (Unknown)
If Primary Cause, Contributory or Possible,
specify
Autopsy?
No (No)
Unknown (Unknown)
Yes (Yes)
Source(s) of death information
Autopsy Report (Autopsy report)
Medical Record / Death Certificate
(Medical record / Death certificate)
Other (Other)
Physician (Physician)
Relative Or Friend (Relative or friend)
Other, specify
Comments
Comments
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NCT00134056
Southwest Oncology Group Quality of Life
Cover Sheet
Southwest Oncology Group Quality of Life Cover Sheet
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=A4CF40B1-
65D3-2947-E034-080020C9C0E0
All rights reserved. Please visit https://medical-data-
models.org/forms/11403
Southwest Oncology Group Quality
of Life Cover Sheet
SWOG clinical trial administrative data
SWOG Patient ID
SWOG Study No.
Registration Step
Assessment
Prestudy (Prestudy)
Week 13 (Week 13)
Week 7 (Week 7)
Patient Initials (L, F M)
Institution/Affiliate
Physician
Amended Data
Yes (Yes)
By
Phone
Was the Medical Conditions Questionnaire
completed (Prestudy Only)?
Yes
No
Date
Was the FACT-L TOI completed?
Yes
No
If completed, in general, did the patient require
assistance?
Yes
No
If Yes, describe
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If completed, questionnaire(s) administered
By Telephone (By telephone)
In The Clinic (In the clinic)
Other (please Specify) (Other (please
specify))
Other (please specify)
If Not Completed, please give reason (select one)
Death (Death)
Illness/deteriorating Health
(Illness/deteriorating health)
Institution Error (Institution error)
Not Illness Related (Not illness related)
Other (Other)
Notes
Notes
Ccrr Module For Southwest Oncology
Group Quality Of Life Cover Sheet
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Southwest Oncology Group Medical
Conditions Questionnaire
Southwest Oncology Group Medical Conditions
Questionnaire
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=A4CF6FCD-
888E-36E1-E034-080020C9C0E0
All rights reserved. Please visit https://medical-data-
models.org/forms/11404
Southwest Oncology Group Medical
Conditions Questionnaire
SWOG clinical trial administrative data
SWOG Patient ID
SWOG Study No.
Registration Step
Patient Initials (L, F M)
Date
Institution/Affiliate
Physician
Medical Conditions
Have you ever had a heart attack?
Yes
No
Have you ever been treated for heart failure?
(You may have been short of breath and the
doctor may have told you that you had fluid in
your lungs or that your heart was not pumping
well.)
Yes
No
Have you had an operation to unclog or bypass
the arteries in your legs?
Yes
No
Have you had an operation or procedure to
unclog or bypass the arteries in your heart?
Yes
No
Have you had a stroke, cerebrovascular accident,
blood clot or bleeding in the brain, or transient
ischemic attack (TIA)?
Yes
No
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If you have had any of these problems, do you
have difficulty moving an arm or leg as a result of
the stroke or cerebrovascular accident?
Yes
No
Do you have asthma?
Yes
No
If you have asthma, do you take medicines for
your asthma?
No (No)
Yes, I Take Medicines Regularly, Even
When I'm Not Having A Flare-up (Yes, I
take medicines regularly, even when I'm
not having a flare-up)
Yes, Only With Flare-ups Of My Asthma
(Yes, only with flare-ups of my asthma)
Do you have emphysema, chronic bronchitis, or
chronic obstructive lung disease?
Yes
No
If you have any of these lung diseases, do you
take medicines for your condition?
No (No)
Yes, I Take Medicines Regularly, Even
When I'm Not Having A Flare-up (Yes, I
take medicines regularly, even when I'm
not having a flare-up)
Yes, Only With Flare-ups Of My Asthma
(Yes, only with flare-ups of my asthma)
Do you have stomach ulcers, or peptic ulcer
disease?
Yes
No
If you have any of these conditions, has it been
diagnosed by a doctor looking into your stomach
through a scope, or by asking you to swallow a
chalky dye and then having x-rays taken?
Yes
No
Do you have diabetes (high blood sugar)?
Yes
No
If you have diabetes, are you being treated for it?
No (No)
Yes, Treated By Insuling Injections (Yes,
treated by insuling injections)
Yes, Treated By Medications Taken By
Mouth (Yes, treated by medications
taken by mouth)
Yes, Treated By Modifying My Diet (Yes,
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treated by modifying my diet)
If you have diabetes, has it caused problems with
your kidneys?
Yes
No
If you have diabetes, has it caused problems with
your eyes, treated by an ophthalmologist?
Yes
No
Have you ever had poor kidney function (blood
tests show high creatinine)?
Yes
No
Have you have used hemodialysis or peritoneal
dialysis?
Yes
No
Have you ever received a kidney transplantation?
Yes
No
Do you have rheumatoid arthritis?
Yes
No
If you have rheumatoid arthritis, do you take
medications for it regularly?
Yes
No
Do you have lupus (systemic lupus
erythematosus)?
Yes
No
Do you have polymyalgia rheumatica
(inflammatory disorder causing joint and muscle
pain)?
Yes
No
Do you have Alzheimer's Disease, or another
form of dementia?
Yes
No
Do you have cirrhosis, or serious liver damage?
Yes
No
Have you had any type of cancer (other than
common skin cancer such as basal or squamous
cell skin cancer) that was successfully treated
more than 5 years ago?
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Yes
No
If you were treated for cancer more than 5 years
ago had the cancer spread, or metastasized, to
other parts of your body?
Yes
No
Do you have AIDS (acquired immunodeficiency
syndrome)?
Yes
No
Have you had weight loss that required medical
treatment?
Yes
No
Ccrr Module For Southwest Oncology
Group Medical Conditions Questionnaire
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Southwest Oncology Group Follow-Up
Tumor Assessment Form
Southwest Oncology Group Follow-Up Tumor Assessment
Form
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=A50B6C19-
55BD-164C-E034-080020C9C0E0
All rights reserved. Please visit https://medical-data-
models.org/forms/11405
Southwest Oncology Group Follow-
Up Tumor Assessment Form
SWOG clinical trial administrative data
SWOG Patient ID
SWOG Study No.
Registration Step
Patient Initials (L, F M)
Date form completed
Institution/Affiliate
Physician (Groups other than SWOG)
Group Name
Study No.
Pt. ID
Target Lesions
(L1, etc. question)
L1 (L1)
L10 (L10)
L2 (L2)
L3 (L3)
L4 (L4)
L5 (L5)
L6 (L6)
L7 (L7)
L8 (L8)
L9 (L9)
Site of Lesions
Longest Diameter of Lesions (cm)
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Assessment Type
Colposcopy (Colposcopy)
Ct Scan (CT scan)
Cytology (Cytologic confirmation)
Endoscopy (Endoscopy)
Histology (Histologic confirmation)
Mri (MRI scan)
Other (Other)
Palpation (Palpation)
PET scan (PET scan)
Plain film/X-ray with contrast (Plain
film/X-ray with contrast)
Plain film/X-ray without contrast (Plain
film/X-ray without contrast)
Radioisotope scan (Radioisotope scan)
Spiral Ct Scan (Sprial CT scan)
Ultrasound (Ultrasound)
Visualization (Visualization)
Assessment Date
Non-target Disease
(S1, etc. question)
S1 (S1)
S2 (S2)
S3 (S3)
S4 (S4)
S5 (S5)
Site of Disease
Disease Extent
Clear increase (describe in comments on
page 2) (Clear increase (describe in
comments on page 2))
Complete disapperance (Complete
disapperance)
Not assessed (Not assessed)
Present (Present)
Assessment Type
Colposcopy (Colposcopy)
Ct Scan (CT scan)
Cytology (Cytologic confirmation)
Endoscopy (Endoscopy)
Histology (Histologic confirmation)
Mri (MRI scan)
Other (Other)
Palpation (Palpation)
PET scan (PET scan)
Plain film/X-ray with contrast (Plain
film/X-ray with contrast)
Plain film/X-ray without contrast (Plain
film/X-ray without contrast)
Radioisotope scan (Radioisotope scan)
Spiral Ct Scan (Sprial CT scan)
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Ultrasound (Ultrasound)
Visualization (Visualization)
Assessment Date
New Lesions
(S1, etc. question)
New Lesions, specify site
Assessment Type
Colposcopy (Colposcopy)
Ct Scan (CT scan)
Cytology (Cytologic confirmation)
Endoscopy (Endoscopy)
Histology (Histologic confirmation)
Mri (MRI scan)
Other (Other)
Palpation (Palpation)
PET scan (PET scan)
Plain film/X-ray with contrast (Plain
film/X-ray with contrast)
Plain film/X-ray without contrast (Plain
film/X-ray without contrast)
Radioisotope scan (Radioisotope scan)
Spiral Ct Scan (Sprial CT scan)
Ultrasound (Ultrasound)
Visualization (Visualization)
Assessment Date
Symptomatic deterioration
Symptomatic deterioration
Yes
No
Comments
Comments
Ccrr Module For Southwest Oncology
Group Follow-up Tumor Assessment Form
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Southwest Oncology Group S0819 Notice
Of Death Form NCT00946712
Southwest Oncology Group S0819 Notice Of Death Form
NCT00946712 
Carboplatin and Paclitaxel With or Without Bevacizumab
and/or Cetuximab in Treating Patients With Stage IV or
Recurrent Non-Small Cell Lung Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=684CF883-
6439-1929-E040-BB89AD4373A3
All rights reserved. Please visit https://medical-data-
models.org/forms/11407
Southwest Oncology Group S0819
Notice Of Death Form
NCT00946712
SWOG clinical trial administrative data
SWOG Patient ID
Most Recent SWOG Study No.
Patient Initials (L, F, M)
Institution/Affiliate
Physician
Participating Group Name
Participating Group Study No.
Participating Group Patient ID
Date of death
Date of Death (month / day / year)
Causes Of Death
Any cancer (select one)
Contributory (Contributory)
No (No)
Possible (Possible)
Primary Cause (Primary Cause)
Unknown (Unknown)
If cancer was the primary cause or if cancer
possibly or definitely contributed to death, and the
patient had had multiple tumor types, specify
those which were causes of death
Cancer Of Most Recent Swog Study
(Cancer of most recent SWOG study)
Cancer Of Other Swog Study (Cancer of
other SWOG study)
1 / 2
Other Cancer (Other cancer)
Cancer of most recent SWOG study, specify
cancer
Cancer of other SWOG study, specify cancer
Other cancer, specify
Toxicity from disease related treatment (select
one)
Contributory (Contributory)
No (No)
Possible (Possible)
Primary Cause (Primary Cause)
Unknown (Unknown)
If Primary Cause, Contributory or Possible,
specify treatment and toxicity
Non-cancer and non-treatment related causes
(select one)
Contributory (Contributory)
No (No)
Possible (Possible)
Primary Cause (Primary Cause)
Unknown (Unknown)
If Primary Cause, Contributory or Possible,
specify
Autopsy?
No (No)
Unknown (Unknown)
Yes (Yes)
Source(s) of death information
Autopsy Report (Autopsy report)
Medical Record / Death Certificate
(Medical record / Death certificate)
Other (Other)
Physician (Physician)
Relative Or Friend (Relative or friend)
Other, specify
Comments
Comments
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Southwest Oncology Group Baseline Tumor
Assessment Form
Southwest Oncology Group Baseline Tumor Assessment
Form
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=A50B77BD-
3730-1660-E034-080020C9C0E0
All rights reserved. Please visit https://medical-data-
models.org/forms/11408
Southwest Oncology Group Baseline
Tumor Assessment Form
SWOG clinical trial administrative data
SWOG Patient ID
SWOG Study No.
Registration Step
Patient Initials (L, F M)
Institution/Affiliate
Physician (Groups other than SWOG)
Group Name
Study No.
Pt. ID (Target Lesions)
Tumor assessment
(L1, etc. question)
L1 (L1)
L10 (L10)
L2 (L2)
L3 (L3)
L4 (L4)
L5 (L5)
L6 (L6)
L7 (L7)
L8 (L8)
L9 (L9)
Site of Lesions
Longest Diameter of Lesions (cm)
Assessment Type
Colposcopy (Colposcopy)
Ct Scan (CT scan)
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Cytology (Cytologic confirmation)
Endoscopy (Endoscopy)
Histology (Histologic confirmation)
Mri (MRI scan)
Other (Other)
Palpation (Palpation)
PET scan (PET scan)
Plain film/X-ray with contrast (Plain
film/X-ray with contrast)
Plain film/X-ray without contrast (Plain
film/X-ray without contrast)
Radioisotope scan (Radioisotope scan)
Spiral Ct Scan (Sprial CT scan)
Ultrasound (Ultrasound)
Visualization (Visualization)
Assessment Date
(S1, etc. question)
S1 (S1)
S2 (S2)
S3 (S3)
S4 (S4)
S5 (S5)
Site of Disease
Disease Extent
Tests/studies
Comments
Comments
Ccrr Module For Southwest Oncology
Group Baseline Tumor Assessment Form
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Southwest Oncology Group Advanced Non-
Small Cell Lung Carcinoma Prestudy Form
Southwest Oncology Group Advanced Non-Small Cell Lung
Carcinoma Prestudy Form
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=A508BD48-
3F65-74B8-E034-080020C9C0E0
All rights reserved. Please visit https://medical-data-
models.org/forms/11409
Southwest Oncology Group
Advanced Non-Small Cell Lung
Carcinoma Prestudy Form
SWOG clinical trial administrative data
SWOG Patient ID
SWOG Study No.
Registration Step
Patient Initials (L, F M)
Institution/Affiliate
Physician
Group Name
Study No.
Pt. ID
Patient And Disease Description
Weight Loss Prior Six Months
> Or = 20% Of Body Weight (? 20%)
<5% Of Body Weight (< 5%)
10 To <20% Of Body Weight (10 - <20%)
5 To <10% Of Body Weight (5 - < 10%)
Histologic Type
Adenocarcinoma (Adenocarcinoma)
Bronchoalveolar Carcinoma (bac)
(Bronchioloalveolar carcinoma (BAC))
Combined/mixed, Specify Subcategories
(Combined/mixed,specify)
Large Cell Undifferentiated (Large Cell
undifferentiated)
Non-small Cell Lung Cancer (nsclc), Nos
(Non Small Cell Lung Cancer, NOS)
Squamous Cell Carcinoma (Squamous
cell carcinoma)
Combined/mixed,specify
1 / 2
Type of Disease
Initial Diagnosis (New Diagnosis)
Recurrence (Recurrent)
Metastatic Involvement
Multiple Lesions In Multiple Organs
(Multiple lesions in multiple organs)
Multiple Lesions In Single Site Or Organ
(Multiple lesions in single site or organ)
Single Lesion In Single Site Or Organ
(Single lesion in single site or organ)
Stage
Iiib (not Recurrent) (IIB)
Iv (not Recurrent) (IV)
Pleural Effusion
Yes
No
If Yes, Malignant
Yes
No
Current Laboratory Values
Albumin
LDH
LDH ULN
Prior Treatment Related To This Cancer
Prior Surgery
Yes
No
Prior Radiation Therapy
Yes
No
Comments
Comments
Ccrr Module For Southwest Oncology
Group Advanced Non-small Cell Lung
Carcinoma Prestudy Form
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Southwest Oncology Group Advanced Non-Small Cell Lung Carcinoma
Prestudy Form
SOUTHWEST ONCOLOGY GROUP
NOTICE OF DEATH NCT00644228
SOUTHWEST ONCOLOGY GROUP NOTICE OF DEATH
NCT00644228 
Lenalidomide and Dexamethasone With or Without
Bortezomib in Treating Patients With Previously Untreated
Multiple Myeloma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=33567017-5235-
711E-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11410
SOUTHWEST ONCOLOGY GROUP
NOTICE OF DEATH NCT00644228
SWOG clinical trial administrative data
SWOG Patient ID
Most Recent SWOG Study No.
Patient Initials (L, F, M)
Institution/Affiliate
Physician
Participating Group Name
Participating Group Study No.
Participating Group Patient ID
Date of death
Date of Death (month / day / year)
Causes Of Death
Any cancer (select one)
Contributory (Contributory)
No (No)
Possible (Possible)
Primary Cause (Primary Cause)
Unknown (Unknown)
If cancer was the primary cause or if cancer
possibly or definitely contributed to death, and the
patient had had multiple tumor types, specify
those which were causes of death
Cancer Of Most Recent Swog Study
(Cancer of most recent SWOG study)
Cancer Of Other Swog Study (Cancer of
other SWOG study)
1 / 2
Other Cancer (Other cancer)
Cancer of most recent SWOG study, specify
cancer
Cancer of other SWOG study, specify cancer
Other cancer, specify
Toxicity from disease related treatment (select
one)
Contributory (Contributory)
No (No)
Possible (Possible)
Primary Cause (Primary Cause)
Unknown (Unknown)
If Primary Cause, Contributory or Possible,
specify treatment and toxicity
Non-cancer and non-treatment related causes
(select one)
Contributory (Contributory)
No (No)
Possible (Possible)
Primary Cause (Primary Cause)
Unknown (Unknown)
If Primary Cause, Contributory or Possible,
specify
Autopsy?
No (No)
Unknown (Unknown)
Yes (Yes)
Source(s) of death information
Autopsy Report (Autopsy report)
Medical Record / Death Certificate
(Medical record / Death certificate)
Other (Other)
Physician (Physician)
Relative Or Friend (Relative or friend)
Other, specify
Comments
Comments
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S0201 Southwest Oncology Group Notice
of Death
S0201 Southwest Oncology Group Notice of Death
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=A8BA67DA-
F224-11AC-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/11411
S0201 Southwest Oncology Group
Notice of Death
SWOG clinical trial administrative data
SWOG Patient ID
Most Recent SWOG Study No.
Patient Initials (L, F M)
Institution/Affiliate
Physician (Groups other than SWOG)
Group Name
Study No.
Pt. ID
Date of death
Date of Death (month/day/year)
Causes Of Death
Any cancer (select one)
Contributory2005688 (Contributory)
No2005686 (No)
Possible2005689 (Possible)
Primary_cause2005687 (Primary Cause)
Unknown2005690 (Unknown)
If cancer was the primary cause or if cancer
possibly or definitely contributed to death, and the
patient had had multiple tumor types, specify
those which were causes of death
Cancer_of_most_recent_s2005692
(Cancer of most recent SWOG study,
specify cancer)
Cancer_of_oth_swog_stdy2005693
(Cancer of other SWOG study, specify
cancer)
Other_cancer_specify2005694 (Other
1 / 3
cancer, specify)
Cancer of most recent SWOG study, specify
cancer
Cancer of other SWOG study, specify cancer
Other cancer, specify
Toxicity from disease related treatment (select
one)
Contributory2005699 (Contributory)
No2005697 (No)
Possible2005700 (Possible)
Primary_cause2005698 (Primary Cause)
Unknown2005701 (Unknown)
If Primary Cause, Contributory or Possible,
specify treatment and toxicity
Non-cancer and non-treatment related causes
(select one)
Contributory2005707 (Contributory)
No2005705 (No)
Possible2005708 (Possible)
Primary_cause2005706 (Primary Cause)
Unknown2005709 (Unknown)
If Primary Cause, Contributory or Possible,
specify
Autopsy done?
No (No)
Unknown (Unknown)
Yes (Yes)
Death information obtained from (select all that
apply)
Autopsy Was The Source Of Information
On The Patient's Death (Autopsy report)
Death Certificate Was The Source Of
Information On The Patient's Death
(Medical record / Death certificate)
Other, specify (Other, specify)
Clinical Evidence Was The Source Of
Information On The Patient's Death
(Physician)
Relative or friend (Relative or friend)
Other, specify (death information obtained)
Notes
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Notes
Ccrr Module For S0201 Southwest
Oncology Group Notice Of Death
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S0201 Southwest Oncology Group Notice of Death
S0205 LASA QUALITY OF LIFE
QUESTIONNAIRE NCT00075686
S0205 LASA QUALITY OF LIFE QUESTIONNAIRE
NCT00075686
S0205 Gemcitabine With or Without Cetuximab as First-
Line Therapy in Treating Patients With Locally Advanced
Unresectable or Metastatic Adenocarcinoma of the
Pancreas
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=A66316F3-
7D6E-48C9-E034-0003BA0B1A09
All rights reserved. Please visit https://medical-data-
models.org/forms/11412
S0205 LASA QUALITY OF LIFE
QUESTIONNAIRE NCT00075686
SWOG clinical trial administrative data
SWOG Patient ID
SWOG Study No.
Registration Step
Planned Assessment
Prestudy (Prestudy)
Week 13 (Week 13)
Week 17 (Week 17)
Week 5 (Week 5)
Week 9 (Week 9)
Patient Initials (L, F M)
Institution
Affiliate
Physician (1.)
Quality of life assessment
your overall Quality of Life? (2.)
Whole Number (0)
Whole Number (1)
Whole Number (10)
Whole Number (2)
Whole Number (3)
Whole Number (4)
Whole Number (5)
Whole Number (6)
Whole Number (7)
Whole Number (8)
Whole Number (9)
your overall mental (intellectual) well being? (3.)
Whole Number (0)
1 / 3
Whole Number (1)
Whole Number (10)
Whole Number (2)
Whole Number (3)
Whole Number (4)
Whole Number (5)
Whole Number (6)
Whole Number (7)
Whole Number (8)
Whole Number (9)
your overall physical well being (4.)
Whole Number (0)
Whole Number (1)
Whole Number (10)
Whole Number (2)
Whole Number (3)
Whole Number (4)
Whole Number (5)
Whole Number (6)
Whole Number (7)
Whole Number (8)
Whole Number (9)
your overall emotional well being? (5.)
Whole Number (0)
Whole Number (1)
Whole Number (10)
Whole Number (2)
Whole Number (3)
Whole Number (4)
Whole Number (5)
Whole Number (6)
Whole Number (7)
Whole Number (8)
Whole Number (9)
your level of social activity? (6.)
Whole Number (0)
Whole Number (1)
Whole Number (10)
Whole Number (2)
Whole Number (3)
Whole Number (4)
Whole Number (5)
Whole Number (6)
Whole Number (7)
Whole Number (8)
Whole Number (9)
your overall spiritual well being? (7.)
Whole Number (0)
Whole Number (1)
Whole Number (10)
Whole Number (2)
Whole Number (3)
Whole Number (4)
Whole Number (5)
Whole Number (6)
Whole Number (7)
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Whole Number (8)
Whole Number (9)
your level of fatigue, on the average? (8.)
Whole Number (0)
Whole Number (1)
Whole Number (10)
Whole Number (2)
Whole Number (3)
Whole Number (4)
Whole Number (5)
Whole Number (6)
Whole Number (7)
Whole Number (8)
Whole Number (9)
your level of support from friends and family?
Whole Number (0)
Whole Number (1)
Whole Number (10)
Whole Number (2)
Whole Number (3)
Whole Number (4)
Whole Number (5)
Whole Number (6)
Whole Number (7)
Whole Number (8)
Whole Number (9)
Ccrr Module For S0205 Lasa Quality Of
Life Questionnaire
Ccrr Module For S0205 Lasa Quality Of
Life Questionnaire
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ANBL0321: Relapse/Progression
Worksheet NCT00053326
ANBL0321: Relapse/Progression Worksheet
NCT00053326
Fenretinide in Treating Children With Recurrent or
Resistant Neuroblastoma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=B968B3D2-
B7BF-21FC-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/11413
ANBL0321: Relapse/Progression
Worksheet NCT00053326
Header
Name
Study Number
Study Number
COG Number
Patient Initials
Today's date
Date worksheet entered into RDE
Relapse/Progression
Date of relapse or progression (1. Required field)
Sites of disease progression (Check all that
apply)
Bone (Bone)
Bone Marrow (Bone Marrow)
Other (Other)
Soft Tissue Lesion (Soft Tissue Lesion)
please specify site(s) [sites of disease
progression] (1. Text Field)
Neuroblastoma Progression Assessment Type
(Check all that apply)
Bone Marrow (Bone marrow)
Bone Marrow (Bone marrow)
Bone Scan (Bone scan)
Bone Scan (Bone scan)
Ct Scan (CT)
Ct Scan (CT)
Mibg (MIBG)
Mibg (MIBG)
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Mri (MRI)
Mri (MRI)
Other Specify (Other, specify)
Other Specify (Other, specify)
Urine Catechols (Urine catechols)
Urine Catechols (Urine catechols)
Other, specify [tests done to document
progression]
Comments
Ccrr Module For Anbl0321:
Relapse/progression Worksheet
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S0205 Notice of Death NCT00075686
S0205 Notice of Death NCT00075686
S0205 Gemcitabine With or Without Cetuximab as First-
Line Therapy in Treating Patients With Locally Advanced
Unresectable or Metastatic Adenocarcinoma of the
Pancreas
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=A11CBC94-
4007-1D74-E034-080020C9C0E0
All rights reserved. Please visit https://medical-data-
models.org/forms/11414
S0205 Notice of Death
NCT00075686
Header
SWOG Patient ID
Most Recent SWOG Study No.
Patient Initials (L, F M)
Institution
Affiliate
Physician (Groups other than SWOG)
Group Name
Study No.
Pt. ID
Date of death
Date of Death (month / day / year)
Causes Of Death
Non-cancer and non-treatment related causes
(select one)
Contributory (Contributory)
No (No)
Possible (Possible)
Primary Cause (Primary Cause)
Unknown (Unknown)
Non-cancer and non-treatment related causes
(select one)
Contributory (Contributory)
No (No)
1 / 3
Possible (Possible)
Primary Cause (Primary Cause)
Unknown (Unknown)
Non-cancer and non-treatment related causes
(select one)
Contributory (Contributory)
No (No)
Possible (Possible)
Primary Cause (Primary Cause)
Unknown (Unknown)
If Primary Cause, Contributory or Possible,
specify
If Primary Cause, Contributory or Possible,
specify
If Primary Cause, Contributory or Possible,
specify
If Primary Cause, Contributory or Possible,
specify
If Primary Cause, Contributory or Possible,
specify
If Primary Cause, Contributory or Possible,
specify
Autopsy done?
No (No)
Unknown (Unknown)
Yes (Yes)
Death information obtained from (select all that
apply)
Autopsy Was The Source Of Information
On The Patient's Death (Autopsy report)
Death Certificate Was The Source Of
Information On The Patient's Death
(Medical record / Death certificate)
The Source Of Information On The
Patient's Death Is Not On This List,
Specify Other (Other, specify)
Physician (Physician)
Relative or friend (Relative or friend)
Other, specify
Notes
Notes
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Ccrr Module For S0205 Notice Of Death
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S0205 Off Treatment Notice NCT00075686
S0205 Off Treatment Notice NCT00075686 
S0205 Gemcitabine With or Without Cetuximab as First-
Line Therapy in Treating Patients With Locally Advanced
Unresectable or Metastatic Adenocarcinoma of the
Pancreas
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=A11E1F7E-
5275-2148-E034-080020C9C0E0
All rights reserved. Please visit https://medical-data-
models.org/forms/11415
S0205 Off Treatment Notice
NCT00075686
SWOG clinical trial administrative data
SWOG Patient ID
SWOG Study No.
Registration Step
Patient Initials (L, F M)
Institution
Affiliate
Physician (Groups other than SWOG)
Group Name
Study No.
Pt. ID
Reporting period
Treatment Start Date
Treatment End Date
Regimen or Procedure or Site(s)
Off Treatment Reason (select one)
Death (Death)
Death After Beginning Protocol Therapy
(Death after beginning protocol therapy)
Death On Study (Death on study)
Death Prior To Beginning Protocol
Therapy (Death prior to beginning
1 / 3
protocol therapy)
Disease Progression, Relapse During
Active Treatment (Disease progression,
relapse during active treatment)
Disease Progression, Relapse Prior To
Beginning Protocol Therapy (Disease
progression, relapse prior to beginning
protocol therapy)
Medically required, due to toxicity,
specify (Medically required, due to
toxicity, specify)
Other, Specify (Other, specify)
Patient Off-treatment For Other
Complicating Disease (Patient off-
treatment for other complicating disease)
Patient refused, due to toxicity, specify
(Patient refused, due to toxicity, specify)
Patient refused, other than toxicity,
specify (Patient refused, other than
toxicity, specify)
Patient Withdrawal Or Refusal After
Beginning Protocol Therapy (Patient
withdrawal or refusal after beginning
protocol therapy)
Patient Withdrawal Or Refusal Prior To
Beginning Protocol Therapy (Patient
withdrawal or refusal prior to beginning
protocol therapy)
Progression or relapse (Progression or
relapse)
Toxicity/side Effects/complications
(Toxicity/Side effects/Complications)
Treatment Completed Per Protocol
Criteria (Treatment completed per
protocol criteria)
Patient refused, due to toxicity, specify
Patient refused, due to toxicity, specify
Sites
Other, specify (Off Treatment Date)
Other, specify (Off Treatment Date)
Date of completion, progression, death or
decision to discontinue therapy
Will patient receive further treatment?
No (No)
Unknown (Unknown)
Yes, specify (Yes, specify)
Yes, specify
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Date of Last Contact (or death)
Vital Status
Alive (Alive)
Dead (Dead)
Notes
Notes
Ccrr Module For S0205 Off Treatment
Notice
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NCT00033631 FF Radiation Therapy Oncology Group
Phase III Prostate 3D / IMRT Long Term Follow-up Form
NCT00033631 FF Radiation Therapy Oncology Group
Phase III Prostate 3D / IMRT Long Term Follow-up Form
Radiation Therapy in Treating Patients With Stage II
Prostate Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=11CEB6D6-
9D7B-4CCB-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11416
NCT00033631 FF Radiation Therapy
Oncology Group Phase III Prostate
3D / IMRT Long Term Follow-up
Form
RTOG clinical trial administrative data
RTOG Study
Case #
Institution
Institution No.
Patient Initials
RTOG Patient ID
Prostate 3D / IMRT Long Term Follow-up
PATIENT'S VITAL STATUS
Alive (Alive)
Dead (Dead)
DATE OF LAST CONTACT OR DEATH
CAUSE OF DEATH (IF DEAD)
Due to other cause, specify (Due to other
cause, specify)
Due To Protocol Treatment (Due to
protocol treatment)
Due To This Disease (Due to this
disease)
Unknown (Unknown)
Due to other cause, specify (cause of death)
HAS THE PATIENT HAD A DOCUMENTED
CLINICAL ASSESSMENT FOR PROSTATE
CANCER SINCE SUBMISSION OF THE
PREVIOUS FOLLOWUP FORM?
No (No)
1 / 4
Unknown (Unknown)
Yes (Yes)
DATE OF LAST CLINICAL ASSESSMENT (5
PROSTATE: PSA MEASUREMENTS)
Follow-up PSA Value(s) (Prostate: PSA
Measurements obtained since the last follow-up
visiti and date obtained)
Date of PSA Assessment(s)
HAS CLINICAL DISEASE STATUS local,
regional, distant CHANGED SINCE THE LAST
REPORT? (7 HAS A NEW PRIMARY CANCER
OR MDS MYELODYSPLASTIC SYNDROME
BEEN DIAGNOSED THAT HAS NOT BEEN
PREVIOUSLY REPORTED?)
No (No)
Unknown (Unknown)
Yes (Yes)
New Primary Site (Has a new primary cancer or
MDS Myelodysplastic Syndrome been diagnosed
that has not been previously reported If new
primary is AML/MDS, please submit NCI
AML/MDS Form)
Aml/mds (AML/MDS)
Bcc (BCC)
Bladder (Bladder)
Brain (Brain)
Colorectal (Colorectal)
Esophageal (Esophageal)
Gastric (Gastric)
Liver (Liver)
Lung (Lung)
Melanoma (Melanoma)
Nhl (NHL)
None (None)
Other Hematologic, Specify (Other
Hematologic, specify)
Other Solid, Specify (Other solid,
specify)
Pancreatic (Pancreatic)
Renal (Renal)
Squamous-skin (Squamous-Skin)
Unknown Primary (Unknown primary)
New Primary Cancer Date (Specify in comments
new primary site)
RENAL/GENITOURINARY TOXICITY ADVERSE
EVENT REPORTS (AER) (Use CTC 2.0 to code
severity)
No (No)
Unknown (Unknown)
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3D / IMRT Long Term Follow-up Form
Yes (Yes)
URINARY INCONTINENCE, Severity Grade (0-3)
0 (0)
1 (1)
2 (2)
3 (3)
URINARY INCONTINENCE, Attribution (see
table below)
Not Applicable (Not applicable)
Other cause, specify (Other cause,
specify)
Radiotherapy only (Radiotherapy only)
Tumor and Rx (Tumor and Rx)
Unknown (Unknown)
Specify if other cause (urinary incontinence,
attribution)
URINARY INCONTINENCE, AER Begin Date
URINARY FREQUENCY/URGENCY, Severity
Grade (0-3)
0 (0)
1 (1)
2 (2)
3 (3)
URINARY FREQUENCY/URGENCY, Attribution
(see table below)
Not Applicable (Not applicable)
Other cause, specify (Other cause,
specify)
Radiotherapy only (Radiotherapy only)
Tumor and Rx (Tumor and Rx)
Unknown (Unknown)
Specify if other cause (urinary frequency/urgency,
attribution)
URINARY FREQUENCY/URGENCY, AER Begin
Date
ERECTILE IMPOTENCE, Severity Grade (0-3)
0 (0)
1 (1)
2 (2)
3 (3)
ERECTILE IMPOTENCE, Attribution (see table
below)
Not Applicable (Not applicable)
Other cause, specify (Other cause,
specify)
Radiotherapy only (Radiotherapy only)
Tumor and Rx (Tumor and Rx)
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NCT00033631 FF Radiation Therapy Oncology Group Phase III Prostate
3D / IMRT Long Term Follow-up Form
Unknown (Unknown)
Specify if other cause (erectile impotence,
attribution)
ERECTILE IMPOTENCE, AER Begin Date
NEW OR CONTINUING TOXICITY (>= Severity
Grade 3) SINCE THE LAST REPORT?
No (No)
Unknown (Unknown)
Yes (Yes)
DID THE PATIENT RECEIVE ANY NON-
PROTOCOL PROSTATE CANCER THERAPY
SINCE THE LAST FOLLOW-UP?
No (No)
Unknown (Unknown)
Yes (Yes)
COMMENTS
SIGNATURE
DATE
Ccrr Module For Ff Radiation Therapy
Oncology Group Phase Iii Randomized
Study Of Adjuvant Therapy For High Risk
Pt3no Prostate Cancer Long Term Follow-
up Form
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NCT00033631 FF Radiation Therapy Oncology Group Phase III Prostate
3D / IMRT Long Term Follow-up Form
NCT00075686 COVERSHEET FOR PATIENT-
COMPLETE QUESTIONNAIRES: S0205
NCT00075686 COVERSHEET FOR PATIENT-COMPLETE
QUESTIONNAIRES: S0205
S0205 Gemcitabine With or Without Cetuximab as First-
Line Therapy in Treating Patients With Locally Advanced
Unresectable or Metastatic Adenocarcinoma of the
Pancreas
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=B186CE8D-
98A1-0591-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/11417
NCT00075686 COVERSHEET FOR
PATIENT-COMPLETE
QUESTIONNAIRES: S0205
Header
SWOG Patient ID
SWOG Study No.
Registration Step
Patient Initials (L, F M)
Planned Assessment
Prestudy (Prestudy)
Week 13 (Week 13)
Week 17 (Week 17)
Week 5 (Week 5)
Week 9 (Week 9)
Institution/Affiliate
DATE
Physician
BY
PHONE
Miscellaneous Patient Information
Was the Pain Medication Log completed?
Yes
No
Was the Brief Pain Inventory completed?
Yes
No
Was the LASA Patient Quality of Life
1 / 2
Questionnaire completed?
Yes
No
If Completed, In general did the patient require
assistance?
Yes
No
Describe (If Yes,)
If Completed, Questionnaire administered
By Telephone (By telephone)
In The Clinic (In the clinic)
Other (Other)
Other (please specify)
If Not completed, Please give reason (select one)
Death (Death)
Illness/deteriorating Health
(Illness/deteriorating health)
Institution Error (Institution error)
Not Illness Related (Not illness related)
Other (Other)
Other (specify)
Ccrr Module For Coversheet For Patient-
complete Questionnaires: S0205
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NCT00075686 COVERSHEET FOR PATIENT-COMPLETE
QUESTIONNAIRES: S0205
ANBL0321: On Study Worksheet
NCT00053326
ANBL0321: On Study Worksheet NCT00053326
Fenretinide in Treating Children With Recurrent or
Resistant Neuroblastoma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=B9543982-
264A-44CD-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/11418
ANBL0321: On Study Worksheet
NCT00053326
Header
Name
Study Number
Study Number
COG Number
Patient Initials
Today's date
Date worksheet entered into RDE
Miscellaneous Patient Information
Accession number (Pre-populated by the
registration system.)
Stratum (Pre-populated by the registration
system.)
Treatment Number (Pre-populated by the
registration system.)
Treating Institution (Pre-populated by the
registration system.)
Treating Physician (Pre-populated by the
registration system.)
Date of Randomization (Pre-populated by the
registration system.)
Date of call back (Pre-populated by the
1 / 3
registration system.)
Date of Registration (Pre-populated by the
registration system.)
Treatment Start Date (Pre-populated by the
registration system.)
Method of Payment
Medicaid (Medicaid)
Medicaid And Medicare (Medicaid and
Medicare)
Medicare (Medicare)
Medicare And Private Insurance
(Medicare and Private Insurance)
Military Or Veterans Sponsored Nos
(Military or Veterans sponsored NOS)
Military Sponsored (including Champus
& Tricare) (Military sponsored (including
CHAMPUS and TRICARE))
No Means Of Payment (no Insurance)
(No means of payment (no insurance))
Other (Other)
Private Insurance (Private Insurance)
Self Pay (no Insurance) (Self pay (no
insurance))
Unknown (Unknown)
Veterans Sponsored (Veterans
sponsored)
Date of original diagnosis (1. Required field)
Was biopsy of tumor site done to confirm active
tumor for study eligibility? (1. Required field)
Yes
No
list site(s) [biopsy of tumor site(s)] (and submit
pathology reports from biopsy sites to the RDC)
Bone Lesion (Bone lesion)
Bone Marrow Aspirate (Bone marrow
aspirate)
Bone Marrow Biopsy (Bone marrow
biopsy)
Other, Specify (Other, specify)
Soft Tissue Lesion (Soft tissue lesion)
Other, specify [biopsy of tumor site(s)]
Scans done at study entry (Check on all study
scans and submit reports to the RDC)
Bone Scan (Bone scan)
Ct Scan (CT)
Mibg (MIBG)
Mri (MRI)
2 / 3
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Other, Specify (Other, specify)
Other, specify [scans done at study entry]
Comments
Comments
Ccrr Module For Anbl0321: On Study
Worksheet
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ANBL0321: On Study Worksheet NCT00053326
Southwest Oncology Group Notice of Death
NCT00569127
Southwest Oncology Group Notice of Death NCT00569127
Octreotide and Interferon Alfa-2b or Bevacizumab in
Treating Patients With Metastatic or Locally Advanced,
High-Risk Neuroendocrine Tumor
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=0EFA99AB-
504B-5B4E-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11419
Southwest Oncology Group Notice of
Death NCT00569127
SWOG clinical trial administrative data
SWOG Patient ID
Most Recent SWOG Study No.
Patient Initials (L, F, M)
Institution/Affiliate
Physician
Participating Group Name
Participating Group Study No.
Participating Group Patient ID
Date of death
Date of Death (month / day / year)
Causes Of Death
Any cancer (select one)
Contributory (Contributory)
No (No)
Possible (Possible)
Primary Cause (Primary Cause)
Unknown (Unknown)
If cancer was the primary cause or if cancer
possibly or definitely contributed to death, and the
patient had had multiple tumor types, specify
those which were causes of death
Cancer Of Most Recent Swog Study
(Cancer of most recent SWOG study)
Cancer Of Other Swog Study (Cancer of
other SWOG study)
1 / 2
Other Cancer (Other cancer)
Cancer of most recent SWOG study, specify
cancer
Cancer of other SWOG study, specify cancer
Other cancer, specify
Toxicity from disease related treatment (select
one)
Contributory (Contributory)
No (No)
Possible (Possible)
Primary Cause (Primary Cause)
Unknown (Unknown)
If Primary Cause, Contributory or Possible,
specify treatment and toxicity
Non-cancer and non-treatment related causes
(select one)
Contributory (Contributory)
No (No)
Possible (Possible)
Primary Cause (Primary Cause)
Unknown (Unknown)
If Primary Cause, Contributory or Possible,
specify
Autopsy?
No (No)
Unknown (Unknown)
Yes (Yes)
Source(s) of death information
Autopsy Report (Autopsy report)
Medical Record / Death Certificate
(Medical record / Death certificate)
Other (Other)
Physician (Physician)
Relative Or Friend (Relative or friend)
Other, specify
Comments
Comments
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ANBL0321: Pre-Existing Conditions At
Time of Study Entry NCT00053326
ANBL0321: Pre-Existing Conditions At Time of Study Entry
NCT00053326
Fenretinide in Treating Children With Recurrent or
Resistant Neuroblastoma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=B9B49D1C-
054C-1FC6-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/11420
ANBL0321: Pre-Existing Conditions
At Time of Study Entry
NCT00053326
Header
Institution Name
Study Number
Study Number
COG Number
Patient's Initials
Date worksheet entered into RDE
Adverse event assessment
Name of Pre-existing condition (Use CTC version
2.0)
CTC Code of Pre-existing condition
Start Date (MM/DD/YYYY)
End Date (leave blank if on-going at the time of
study enrollment)
Comment
What is being done to treat the pre-existing
condition? (Choices: No therapy, Supportive
Care, Medication, Other : specify)
Medication (Medication)
No Therapy (No therapy)
Other, Specify (Other : specify)
Supportive Care (Supportive Care)
Other: specify [what is being done to treat pre-
existing condition]
1 / 2
Comments
Comments
Ccrr Module For Anbl0321: Pre-existing
Conditions At Time Of Study Entry
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ANBL0321: Pre-Existing Conditions At Time of Study Entry
NCT00053326
BRIEF PAIN INVENTORY (SHORT FORM)
NCT00075686
BRIEF PAIN INVENTORY (SHORT FORM) NCT00075686
S0205 Gemcitabine With or Without Cetuximab as First-
Line Therapy in Treating Patients With Locally Advanced
Unresectable or Metastatic Adenocarcinoma of the
Pancreas
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=A66323E9-
44F6-48CB-E034-0003BA0B1A09
All rights reserved. Please visit https://medical-data-
models.org/forms/11421
BRIEF PAIN INVENTORY (SHORT
FORM) NCT00075686
SWOG clinical trial administrative data
SWOG Patient ID
SWOG Study No.
Registration Step
Planned Assessment
Prestudy (Prestudy)
Week 13 (Week 13)
Week 17 (Week 17)
Week 5 (Week 5)
Week 9 (Week 9)
Patient Initials (L, F M)
Date of Completion
Institution
Affiliate
Physician (1.)
Quality of life assessment
Throughout our lives, most of us have had pain
from time to time (such as minor headaches,
sprains, and toothaches).  Have you had pain
other than these everyday kinds of pain today?
(2.)
Yes
No
Please rate your pain by selecting the one
number that best describes your pain at its
WORST in the past 24 hours. (3.)
Whole Number (0)
1 / 4
Whole Number (1)
Whole Number (10)
Whole Number (2)
Whole Number (3)
Whole Number (4)
Whole Number (5)
Whole Number (6)
Whole Number (7)
Whole Number (8)
Whole Number (9)
Please rate your pain by selecting the one
number that best describes your pain at its
LEAST in the past 24 hours. (4.)
Whole Number (0)
Whole Number (1)
Whole Number (10)
Whole Number (2)
Whole Number (3)
Whole Number (4)
Whole Number (5)
Whole Number (6)
Whole Number (7)
Whole Number (8)
Whole Number (9)
Please rate your pain by selecting the one
number that best describes your pain on the
AVERAGE. (5.)
Whole Number (0)
Whole Number (1)
Whole Number (10)
Whole Number (2)
Whole Number (3)
Whole Number (4)
Whole Number (5)
Whole Number (6)
Whole Number (7)
Whole Number (8)
Whole Number (9)
Please rate your pain by selecting the one
number that tells how much pain you have
RIGHT NOW. (6.)
Whole Number (0)
Whole Number (1)
Whole Number (10)
Whole Number (2)
Whole Number (3)
Whole Number (4)
Whole Number (5)
Whole Number (6)
Whole Number (7)
Whole Number (8)
Whole Number (9)
Are you receiving treatments or medications for
your pain? (7.)
Yes
No
2 / 4
BRIEF PAIN INVENTORY (SHORT FORM) NCT00075686
In the past 24 hours, how much RELIEF have
pain treatments or medications provided? (Please
select the percentage that shows how much.)
0% (0%)
10% (10%)
100% (100%)
20% (20%)
30% (30%)
40% (40%)
50% (50%)
60% (60%)
70% (70%)
80% (80%)
90% (90%)
General Activity (9.)
Whole Number (0)
Whole Number (1)
Whole Number (10)
Whole Number (2)
Whole Number (3)
Whole Number (4)
Whole Number (5)
Whole Number (6)
Whole Number (7)
Whole Number (8)
Whole Number (9)
Mood (10.)
Whole Number (0)
Whole Number (1)
Whole Number (10)
Whole Number (2)
Whole Number (3)
Whole Number (4)
Whole Number (5)
Whole Number (6)
Whole Number (7)
Whole Number (8)
Whole Number (9)
Walking ability (11.)
Whole Number (0)
Whole Number (1)
Whole Number (10)
Whole Number (2)
Whole Number (3)
Whole Number (4)
Whole Number (5)
Whole Number (6)
Whole Number (7)
Whole Number (8)
Whole Number (9)
Normal work (includes both work outside the
home and housework)
Whole Number (0)
Whole Number (1)
Whole Number (10)
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Whole Number (2)
Whole Number (3)
Whole Number (4)
Whole Number (5)
Whole Number (6)
Whole Number (7)
Whole Number (8)
Whole Number (9)
Relations with other people (13.)
Whole Number (0)
Whole Number (1)
Whole Number (10)
Whole Number (2)
Whole Number (3)
Whole Number (4)
Whole Number (5)
Whole Number (6)
Whole Number (7)
Whole Number (8)
Whole Number (9)
Sleep (14.)
Whole Number (0)
Whole Number (1)
Whole Number (10)
Whole Number (2)
Whole Number (3)
Whole Number (4)
Whole Number (5)
Whole Number (6)
Whole Number (7)
Whole Number (8)
Whole Number (9)
Enjoyment of life
Whole Number (0)
Whole Number (1)
Whole Number (10)
Whole Number (2)
Whole Number (3)
Whole Number (4)
Whole Number (5)
Whole Number (6)
Whole Number (7)
Whole Number (8)
Whole Number (9)
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BRIEF PAIN INVENTORY (SHORT FORM) NCT00075686
S0205 Follow Up Form NCT00075686
S0205 Follow Up Form NCT00075686
S0205 Gemcitabine With or Without Cetuximab as First-
Line Therapy in Treating Patients With Locally Advanced
Unresectable or Metastatic Adenocarcinoma of the
Pancreas
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=A11B693E-
8E8F-02FA-E034-080020C9C0E0
All rights reserved. Please visit https://medical-data-
models.org/forms/11422
S0205 Follow Up Form
NCT00075686
SWOG clinical trial administrative data
SWOG Patient ID
SWOG Study No.
Registration Step
Patient Initials (L, F M)
Institution
Affiliate
Physician (Groups other than SWOG)
Group Name
Study No.
Pt. ID (VITAL STATUS)
Miscellaneous Patient Information
Vital Status
Alive (Alive)
Dead (Dead)
Date of last contact or death (DISEASE FOLLOW
UP STATUS)
Has the patient had a documented clinical
assessment for this cancer since submission of
the previous follow-up form?
Yes
No
If Yes, Date of Last Clinical Assessment (NOTICE
1 / 2
OF FIRST RELAPSE OR PROGRESSION)
Has the patient developed a first relapse or
progression that has not been previously
reported
Yes
No
If Yes, Date of Relapse or Progression
Site(s) of Relapse or Progression (NOTICE OF
NEW PRIMARY)
Has a new primary cancer or myelodysplastic
syndrome (MDS) been diagnosed that has not
been previously reported?
Yes
No
If Yes, Date of Diagnosis
New Primary Site (FURTHER TREATMENT)
Has the patient received further (non-protocol)
treatment for this cancer?
Yes
No
Specify Regimen (Note: If multiple regimens were
received, please specify only the first regiment
received after going off protocol treatment.)
Comments
Comments
Ccrr Module For S0205 Follow Up Form
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S0205 Follow Up Form NCT00075686
ANBL0321: CT/MRI Response Assessment
Form NCT00053326
ANBL0321: CT/MRI Response Assessment Form
NCT00053326
Fenretinide in Treating Children With Recurrent or
Resistant Neuroblastoma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=B968DB9B-
1F21-22F4-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/11423
ANBL0321: CT/MRI Response
Assessment Form NCT00053326
Header
Study Number
Study Number
Name
COG Number
Patient Initials
Today's date
Date worksheet entered into RDE
CT/MRI Response Assessment
Date of response evaluation (The date shown can
be edited.  Please record the actual date of the
radiological assessment that confirms the
response status was made.)
Disease measurement at study entry (Disease
measurement = sum of longest diameter in one
dimension of all CT/MRI lesions)
Disease measurement at study entry (Disease
measurement = sum of longest diameter in one
dimension of all CT/MRI lesions)
Response by CT/MRI lesions (1. Required field)
Complete Response (Complete
response)
Death Prior To Completion Of Protocol
Criteria (Early death)
Incomplete Response Or Stable
Disesase (Incomplete response/SD)
Insufficient Evaluation (Not evaluable)
1 / 2
Partial Response (Partial response)
Progressive Disease (Progressive
disease)
Stable Disease (Stable disease)
Very good partial response (Very good
partial response)
ICD-O Topography Code of Lesion (1a)
Largest Dimension (cm)
cm
Method of measurement (1c)
Ct Scan (Computed Tomography-
Conventional)
Spiral Ct Scan (Computed Tomography-
spiral)
Mri (MRI)
Other, Specify (Other, Specify)
other, Specify (1. If other is selected as method of
measurement, this must be completed.)
New Lesion
Were any new lesions detected (1. Required
field)
Yes
No
If other lesions were detected at study entry, did
any of those demonstrate progression at this
evaluation? (1. Required field)
N/a (N/A, No other lesions)
No (No)
Yes (Yes)
Comments
Ccrr Module For Anbl0321: Ct/mri
Response Assessment Form
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ANBL0321: CT/MRI Response Assessment Form NCT00053326
Concomitant Medication Form
NCT00058149
Concomitant Medication Form NCT00058149
A Phase III, Randomized Study of Gemcitabine (Fixed-
Dose Rate Infusion) and Oxaliplatin (NSC 266046) Versus
Gemcitabine (Fixed-Dose Rate Infusion) Versus
Gemcitabine (30-Minute Infusion) in Pancreatic Carcinoma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=A6277C4D-
6BBD-3D79-E034-0003BA0B1A09
All rights reserved. Please visit https://medical-data-
models.org/forms/11424
Concomitant Medication Form
NCT00058149
ECOG clinical trial administrative data
ECOG Prot. No.
ECOG Patient Seq. No.
Registration Step
Patient?s Name
Participating Group Prot. No.
Participating Group Patient ID No.
Step No.
Group
Institution
Network
Affiliate
Are data amended? (If yes, please circle
amended items in red)
Yes
No
Reporting period Start Date: (M D Y)
Reporting period End Date: (M D Y)
Concomitant Medication
Generic Name (Use brand or trade if generic
name unknown)
1 / 3
Dose
Units
capsules (caps) (capsules (caps))
drops (gtts) (drops (gtts))
gram (gm) (gram (gm))
inch (inch) (inch (inch))
kilogram (kg) (kilogram (kg))
liter (l) (liter (l))
microgram (mcg) (microgram (mcg))
milliequivalent (mEq) (milliequivalent
(mEq))
milligram (mg) (milligram (mg))
milliliter (ml) (milliliter (ml))
other, specify (other, specify)
ounce (oz) (ounce (oz))
tablespoon (tbsp) (tablespoon (tbsp))
tablets (tabs) (tablets (tabs))
teaspoon (tsp) (teaspoon (tsp))
unit (u) (unit (u))
other, specify
Frequency
After Meals (p.c.) (after meals (P.C.))
As Needed (p.r.n) (as needed (P.R.N))
At Bedtime Or Hour Of Sleep (h.s.) (at
bedtime or hour of sleep (H.S.))
Before Meals (a.c.) (before meals (A.C.))
Every 12 Hours (q12hr) (every 12 hours
(Q12hr))
Every 4 Hours (q4hr) (every 4 hours
(Q4hr))
Every 6 Hours (q6hr) (every 6 hours
(Q6hr))
Every 8 Hours (q8hr) (every 8 hours
(Q8hr))
Every Day (q.d.) (every day (Q.D.))
Every Other Day (q.o.d.) (every other day
(Q.O.D.))
Four Times A Day (q.i.d) (four times a
day (Q.I.D))
Immediately (stat) (immediately (Stat))
Other, Specify (other, specify)
Three Times A Day (t.i.d) (three times a
day (T.I.D))
Three Times A Week (t.i.w) (three times
a week (T.I.W))
Twice A Day (b.i.d) (twice a day (B.I.D))
Twice A Week (b.i.w) (twice a week
(B.I.W))
Route
inhaled (inhaled)
intradermal (intradermal)
Intramuscular Administration Of Drug
(intramuscular (i.m.))
Intravenous Administration Of Drug
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(intravenous (i.v.))
nasal (nasal)
Oral Administration Of Drug (oral (p.o.))
other, specify (other, specify)
rectal (rectal)
subcutaneous (s.c.) (subcutaneous
(s.c.))
sublingual (sublingual)
topical (topical)
transdermal (transdermal)
Start Date (Leave blank if continuing from a prior
report period)
Is this medication continuing?
Yes
No
Stop Date (Leave blank if continuing)
Comments
Comments
Investigator Signature
Date
Ccrr Module For Concomitant Medication
Form
Institution/Affiliate
Patient Initials
DCI Name
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Concomitant Medication Form NCT00058149
ANBL0321: Prior Therapy Worksheet
NCT00053326
ANBL0321: Prior Therapy Worksheet NCT00053326
Fenretinide in Treating Children With Recurrent or
Resistant Neuroblastoma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=B92CFA2B-
A3FF-34F4-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/11425
ANBL0321: Prior Therapy Worksheet
NCT00053326
Header
Name
Study Number
Study Number
COG Number
Patient Initials
Today's date
Date worksheet entered into RDE
Cancer Prior Treatment
Did the patient have anti-cancer therapy prior to
enrollment on this study? (1. Required field)
Yes
No
Type Of Prior Therapy
Type
Start Date (MM/DD/YYYY)
End Date (MM/DD/YYYY)
Description (agent, dose, etc.)
Stem cell transplant
Did patient have a stem cell transplant? (1.
Required field)
1 / 2
Yes
No
number of stem cell transplants (1. Numerical
field)
list date of most recent stem cell infusion
(MM/DD/YYYY)
chemotherapy regimen for transplant (1. Text
field)
Did patient have prior retinoids? (1. Required
field)
Yes
No
type of retinoid
13-cis-retinoic Acid (13-cis-retinoic acid)
Fenretinide (Fenretinide)
Other, Specify (Other, specify)
please specify [type of retinoid] (1. Text field)
Stop date of retinoids (MM/DD/YYYY)
Comments
Comments
General Validations/notes
Ccrr Module For Anbl0321: Prior Therapy
Worksheet
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ANBL0321: Prior Therapy Worksheet NCT00053326
NCT00075686 COVER SHEET FOR PATIENT-
COMPLETE QUESTIONNAIRES: S0205
NCT00075686 COVER SHEET FOR PATIENT-COMPLETE
QUESTIONNAIRES: S0205
S0205 Gemcitabine With or Without Cetuximab as First-
Line Therapy in Treating Patients With Locally Advanced
Unresectable or Metastatic Adenocarcinoma of the
Pancreas
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=A6631050-
8DCA-48C7-E034-0003BA0B1A09
All rights reserved. Please visit https://medical-data-
models.org/forms/11426
NCT00075686 COVERSHEET FOR
PATIENT-COMPLETE
QUESTIONNAIRES: S0205
Header
SWOG Patient ID
SWOG Study No.
Registration Step
Patient Initials (L, F M)
Planned Assessment
Prestudy (Prestudy)
Week 13 (Week 13)
Week 17 (Week 17)
Week 5 (Week 5)
Week 9 (Week 9)
Institution
Affiliate
Physician
BY
PHONE
DATE
Miscellaneous Patient Information
Was the Brief Pain Inventory completed?
Yes
No
Date (1.)
1 / 3
Which types of assistance were required? (select
all that apply)
Asked For Help With The Response
Format (Asked for help with the response
format)
Asked To Explain Meaning Of Terms
(Asked to explain meaning of terms)
Needed Questionnaire Read Aloud And
Needed Nurse/cra To Write Patient
Verbal Answers On Form (Needed
questionnaire read aloud and needed
nurse/CRA to write patient verbal
answers on form)
Needed Questionnaire Read Aloud But
Able To Answer Questions On His/her
Own (Needed questionnaire read aloud
but able to answer questions on his/her
own)
No Assistance Required (No assistance
required)
Other (specify) (Other (specify))
Wanted help from family members to
answer questions but you explained that
this questionnaire should involve only
his/her opinions. (Wanted help from
family members to answer questions but
you explained that this questionnaire
should involve only his/her opinions.)
Other (specify)
If the Brief Pain Inventory Not completed, Please
give reason (select one)
Illness/deteriorating Health
(Illness/deteriorating health)
Institution Error (Institution error)
Not Illness Related (Not illness related)
Other (specify) (Other (specify))
Other (specify)
Was the LASA Patient Quality of Life
Questionnaire completed? (If Yes,)
Yes
No
If LASA Patient Quality of Life Questionnaire Not
completed, Please give reason (select one)
Illness/deteriorating Health
(Illness/deteriorating health)
Institution Error (Institution error)
Not Illness Related (Not illness related)
Other (specify) (Other (specify))
Ccrr Module For Cover Sheet For Patient-
complete Questionnaires: S0205
Ccrr Module For Cover Sheet For Patient-
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NCT00075686 COVER SHEET FOR PATIENT-COMPLETE
QUESTIONNAIRES: S0205
complete Questionnaires: S0205
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NCT00075686 COVER SHEET FOR PATIENT-COMPLETE
QUESTIONNAIRES: S0205
ANHL01P1: Death
ANHL01P1: Death
Rituximab, Rasburicase, and Combination Chemotherapy
in Treating Young Patients With Newly Diagnosed
Advanced B-Cell Leukemia or Lymphoma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=B9F3CF39-
DAC9-242F-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/11427
ANHL01P1: Death
Header
Institution
Institution Personnel
Institution Patient Identifier
Institution Patient Identifier
Today's date
Date worksheet entered into RDE
Death Assessment
Date of Death (Required field)
Cause of Death (Required field)
Due To Other Cause, Specify (ARDS)
Due To This Disease (Disease related)
Due To Other Cause, Specify (Infection)
Due To Other Cause, Specify (Multi-
organ failure)
Due To Other Cause, Specify (Other,
specify below)
Due To Protocol Treatment (Toxicity)
Unknown (Unknown)
Which of the above causes was the main reason
this patient died? (Required field)
Due To Other Cause, Specify (ARDS)
Due To This Disease (Disease related)
Due To Other Cause, Specify (Infection)
Due To Other Cause, Specify (Multi-
organ failure)
Due To Other Cause, Specify (Other,
specify below)
Due To Protocol Treatment (Toxicity)
Unknown (Unknown)
please specify [main reason patient died] (If other
chosen above,)
1 / 2
please specify [main reason patient died] (If other
chosen above,)
Autopsy Done? (Required field)
No (No)
Unknown (Unknown)
Yes (Yes)
COMMENTS
Ccrr Module For Anhl01p1: Death
2 / 2
ANHL01P1: Death
AE5
AE5
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=FF18A56F-
0A56-0F3B-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11428
AE5
Miscellaneous Information
Segment
Reviewed
Date of Onset
Event description
Reviewed by
Review date
Comment 2 - All Other Reviewers/Data
Coordinating Center
Comment 2 - All Other Reviewers/Data
Coordinating Center
1 / 1
AE4
AE4
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=FF18A11D-
FD35-0EE3-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11429
AE4
Header module
Segment
Date of Onset
Event description
Laboratory Test Results
Result Pending
Site Name??? (Include??)
No relevant laboratory test results
Test
Collection Data
Result (including units)
Diagnostic Tests (ex: Mr, Ct Scan,
Ultrasound)
No relevant diagnostic tests
Test
Date Performed
Comments
Comments
1 / 1
FUS
FUS
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=FF19DD32-
5E3B-2DCF-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11430
FUS
Header module
Segment
Visit number
Date of last contact
Since The Date Of The Last Visit Indicate
If Any Of The Following Have Occurred
Has the patient died
Yes
No
Has the patient been treated for
progression/relapse
Yes
No
Date of patient death
Has the patient relapsed or experienced disease
progression
Yes
No
Date of relapse or progression
Date treatment administered
Indicate type of treatment
Chemotherapy (Chemotherapy)
DLI (DLI)
Other cellular therapy (Other cellular
therapy)
Other (Other cellular therapy)
PBSCs (PBSCs)
Radiation Therapy (Radiation)
Second transplant (Second transplant)
Specify other treatment
Has the patient experienced any new clinically
significant infections
Yes
1 / 2
No
If Yes, An Infection Form Must Be
Submitted
Date of infection
Has the patient been hospitalized
Yes
No
If Yes, An Re-admission Form Must Be
Submitted
Date of hospitalization
Has the patient received a non-protocol specified
transplant
Yes
No
Date of non-protocol specified transplant
Comments
2 / 2
FUS
AE3
AE3
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=FF190472-
F5B5-019C-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11431
AE3
Header module
Segment
Date of Onset
Event description
Study Product/suspect Medication Data
Study Product Name
Dose of Study Product(s) at SAE onset
Route of Study Product(s) at SAE onset
Schedule of Study Product(s) at SAE onset
Concomitant Medications
Non-concomitant medications
Medications
Start Date
Stop Date
Dose, Route, Schedule
Comment
1 / 1
AE6
AE6
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=FF18A8F9-
ECF8-0F73-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11432
AE6
Miscellaneous Information
Segment
If No, what additional information is required
Is this review complete
Yes
No
Do you recommend the patient be withdrawn
from further protocol therapy
Yes
No
Does this require expedited reporting to the
DSMB
Yes
No
Does this require expedited reporting to the FDA
Yes
No
Has this event been determined to be an
unexpected, grade 3-5 adverse event
Yes
No
Date of Onset
Event description
Comments
1 / 1
CDASH Medical History
modified from http://www.cdisc.org
All rights reserved. Please visit https://medical-data-
models.org/forms/11436
CDASH Medical History
Generelle Information
Anamnese erhoben?*
Nein (N)
Ja (Y)
Datum der Anamnese*
Hoher Blutdruck
Hoher Blutdruck in der Anamnese*
Nein (N)
Ja (Y)
Startdatum laut Anamnese*
Endedatum laut Anamnese*
Fortbestehend*
Nein (N)
Ja (Y)
Appendektomie
Appendektomie in der Anamnese*
Nein (N)
Ja (Y)
Startdatum laut Anamnese*
Weitere Angaben
Medizinischer Zustand oder Ereignis in der
Anamnese*
Erkrankung/Symptome unter Kontrolle zum
Zeitpunkt der Anamnese*
Nein (N)
Ja (Y)
Startdatum des anamnestischen Ereignisses*
Endedatum des anamnestischen Ereignisses*
fortbestehend*
Nein (N)
Ja (Y)
1 / 1
ACNS0122 On Study Worksheet
NCT00047320
ACNS0122 On Study Worksheet NCT00047320 
Neoadjuvant Chemotherapy With or Without Second-Look
Surgery Followed by Radiation Therapy With or Without
Peripheral Stem Cell Transplantation in Treating Patients
With Intracranial Germ Cell Tumors
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=BD40A64A-
F8D7-0B76-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/11437
ACNS0122 On Study Worksheet
NCT00047320
Header
COG Study Number
Institution Name
COG Patient ID
Patient Initials
Today's date
Date worksheet entered into RDE
Miscellaneous Patient Information
Accession number
Stratum
Assigned Treatment Arm
Treating Institution Code
Treating Physician
XRT associated with this study?
Conditional (Conditional)
No (No)
Yes (Yes)
Date of Registration
Treatment Start Date
Method of Payment
Medicaid (Medicaid)
Medicaid And Medicare (Medicaid and
1 / 5
Medicare)
Medicare (Medicare)
Medicare And Private Insurance
(Medicare and Private Insurance)
Military Or Veterans Sponsored Nos
(Military or Veterans Sponsored NOS)
Military Sponsored (including Champus
& Tricare) (Military sponsored (including
CHAMPUS and TRICARE))
No Means Of Payment (no Insurance)
(No means of payment (no insurance))
Other (Other)
Private Insurance (Private Insurance)
Self Pay (no Insurance) (Self pay (no
insurance))
Unknown (Unknown)
Veterans Sponsored (Veterans
sponsored)
Pre-study Neurosurgeries
Was surgery performed prior to study
enrollment?
Yes
No
how many? [pre-study neurosurgeries) (If yes,)
Pre-treatment Imaging Studies
Type [imaging studies]
Mri (MRI of Spine with gadolinium)
Mri (MRI of Spine without gadolinium)
Mri (MRI of the Brain with gadolinium)
Mri (MRI of the Brain without gadolinium)
Other, Specify (Other (specify))
Specify
Date
Tumor Location
Were Supratentorial sites involved?
Yes
No
Were there other Supratentorial sites?
No (No)
Other, Specify (Other, specify)
Yes (Yes)
specify [other supratentorial sites] (If yes,)
2 / 5
ACNS0122 On Study Worksheet NCT00047320
Were Infratentorial sites involved?
Yes
No
check all Infratentorial sites involved on T1 post
gadolinium MRI (If yes,)
Cerebellar Hemisphere (Cerebellar
hemisphere)
Cerebellar Penducle (Cerebellar
penducle)
Cerebellar Vermis (Cerebellar vermis)
Cistema Magna (Cistema magna)
Dorsal Exophytic Brainstem (Dorsal
exophytic brainstem)
Fourth Ventricle (Fourth ventricle)
Infratentorial Leptomeninges
(Infratentorial Leptomeninges)
Medulla (Medulla)
Midbrain (Midbrain)
Other, Specify (Other, specify)
Pons (Pons)
Were there other Infratentorial sites?
No (No)
Other, Specify (Other, specify)
Yes (Yes)
specify [other infratentorial sites] (If yes,)
Was Spinal Cord involved at diagnosis?
Yes
No
Were there other Spinal Chord sites?
No (No)
Other, Specify (Other, specify)
Yes (Yes)
specify [other spinal cord sites] (If yes,)
Was Dura involved?
Yes
No
indicate type of involvement [dura] (If yes,)
Diffuse (Diffuse)
Nodular (Nodular)
Was CSF cytological evaluation of lumbar fluid
positive?
No (No)
Not Evaluated (Not evaluated)
Unknown (Unknown)
Yes (Yes)
Were there other sites involved?
Yes
No
3 / 5
ACNS0122 On Study Worksheet NCT00047320
specify [other sites involved] (If yes,)
Primary Disease
What is the primary disease site?
Aqueduct Of Sylvius (Aquaduct of
sylvius)
Basal Ganglia (Basal ganglia-thalamus)
Brainstem (Brainstem)
Cauda Equina (Cauda equina)
Cavernous Sinus (Cavernous sinus)
Cerebellar Hemisphere (Cerebellar
hemisphere)
Cerebellar Peduncle (Cerebellar
penducle)
Cerebellar Vermis (Cerebellar vermis)
Cerebellum (Cerebellum)
Cervical (Cervical)
Cisterna Magna (Cistema magna)
Conus (Conus)
Corpus Callosum (Corpus callosum)
Diffuse (Diffuse)
Dorsal Exophytic Brainstem (Dorsal
exophytic brainstem)
Fourth Ventricle (Fourth ventricle)
Frontal Lobe (Frontal lobe)
Hypothalamus (Hypothalamus-optic
chiasm)
Infratentorial Leptomeninges
(Infratentorial Leptomeninges)
Lateral Ventricle (Lateral ventricle)
Leptomeningeal (Leptomeningeal)
Lumbar (Lumbar)
Medulla (Medulla)
Midbrain (Midbrain)
Nodular (Nodular)
Occipital Lobe (Occipital lobe)
Optic Chiasm (Optic chiasm)
Optic Nerve (Optic nerve)
Other, Specify (Other, specify)
Parietal Lobe (Parietal lobe)
Pineal (Pineal)
Pons (Pons)
Spinal Cord (c1 And Below) (Spinal Cord
Leptomeninges)
Supratentorial Leptomeninges
(Supratentorial Leptomeninges)
Temporal Lobe (Temporal lobe)
Thalamus (Thalamus)
Third Ventricle (Third ventricle)
Thoracic (Thoracic Lumbosacral)
Comments
Comments
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ACNS0122 On Study Worksheet NCT00047320
Ccrr Module For Acns0122 On Study
Worksheet
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ACNS0122 Death Worksheet
NCT00047320
ACNS0122 Death Worksheet NCT00047320 
Neoadjuvant Chemotherapy With or Without Second-Look
Surgery Followed by Radiation Therapy With or Without
Peripheral Stem Cell Transplantation in Treating Patients
With Intracranial Germ Cell Tumors
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=BD40BB6B-
6EA3-0C19-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/11438
ACNS0122 Death Worksheet
NCT00047320
Header
Institution Name
COG Study No
COG Study No
COG Patient ID
Patient Initials
Today's date
Date worksheet entered into RDE
Death Assessment
Date of Death
Contributing Cause of Death
Due To Protocol Treatment ("Drug")
ARDS (ARDS)
GVHD (GVHD)
Hemorrhage (Hemorrhage)
Infection (Infection)
Multi-Organ Failure (Multi-Organ Failure)
Other Drug (Other Drug)
Due To Other Cause, Specify (Other,
Specify)
Due To This Disease (Tumor)
Unknown (Unknown)
Primary cause of Death
Due To Protocol Treatment ("Drug")
ARDS (ARDS)
GVHD (GVHD)
Hemorrhage (Hemorrhage)
Infection (Infection)
Multi-Organ Failure (Multi-Organ Failure)
Other Drug (Other Drug)
1 / 2
Due To Other Cause, Specify (Other,
Specify)
Due To This Disease (Tumor)
Unknown (Unknown)
please specify [primary cause of death] (If
'Other',)
please specify [primary cause of death] (If
'Other',)
Autopsy?
Yes
No
How were the side effects of protocol therapy
related to the patient's death?
Exclusive Cause Of Death (Exclusive
cause of death)
Major Contribution To Death (Major
contributions to death)
Minor Contribution To Death (Minor
contributions to death)
Not Related (Not related)
Comments
Comments
Ccrr Module For Acns0122 Death
Worksheet
2 / 2
ACNS0122 Death Worksheet NCT00047320
NCT00075764  SOUTHWEST ONCOLOGY
GROUP OFF TREATMENT NOTICE (S0226)
NCT00075764  SOUTHWEST ONCOLOGY GROUP OFF
TREATMENT NOTICE (S0226)
S0226 Anastrozole With or Without Fulvestrant as First-
Line Therapy in Postmenopausal Women With Metastatic
Breast Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=C322362B-
EAC8-25F3-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/11440
NCT00075764  SOUTHWEST
ONCOLOGY GROUP OFF
TREATMENT NOTICE (S0226)
Header
SWOG Patient ID
SWOG Study No.
Registration Step
Patient Initials (L, F M)
Institution/Affiliate
Physician
Participating Group Name
Participating Study No.
Participating Patient ID
Reporting period
Treatment Start Date
Treatment End Date
Regimen or Procedure or Site(s)
Off-protocol treatment
Off Treatment Reason
Death_attach_notice_of_2005652
(Death)
Medly_required_due_to_t2005648
(Medically required, due to toxicity)
Other_specify_2005653 (Other, specify)
Pt_refused_due_to_toxic2005649
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(Patient refused, due to toxicity)
Pt_refused_oth_than_tox2005650
(Patient refused, other than toxicity,
specify)
Prog_or_relapse_sites_2005651
(Progression or relapse, specify site)
Tx_cmpltd_per_prot_crit2005647
(Treatment completed per protocol
criteria)
Patient refused, other than toxicity, specify
Progression or relapse, specify site
Other, specify (Off Treatment Date)
Date of completion, progression, death or
decision to discontinue therapy
Further treatment
Will patient receive further treatment?
No (No)
Unknown (Unknown)
Yes (Yes, specify)
Yes, specify
Vital status
Date of Last Contact (or death)
Vital Status
Alive (Alive)
Dead (Dead)
Comments
Comments
Ccrr Module For Southwest Oncology
Group Off Treatment Notice (s0226)
2 / 2
NCT00075764  SOUTHWEST ONCOLOGY GROUP OFF TREATMENT
NOTICE (S0226)
E3201 Off-Treatment Form NCT00068692
E3201 Off-Treatment Form NCT00068692 
Comparison of Adjuvant Chemotherapy Regimens in
Treating Patients With Stage II or Stage III Rectal Cancer
Who Are Receiving Radiation Therapy and Fluorouracil
Before or After Surgery
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=B55228B2-
AF79-6DA3-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/11441
E3201 Off-Treatment Form
NCT00068692
Header
ECOG Protocol Number
ECOG Patient ID
DCI Name
Registration Step
Time period
Off Treatment (Off Treatment)
Patient Initials
Participating Group Protocol No.
Participating Group Patient ID
Institution/Affiliate
Are data amended? (If yes, please circle
amended items in red)
Yes
No
Vital Status
Patient's Vital Status
Alive (Alive)
Dead (Dead)
Date of Last Contact or Death (M D Y)
Primary Cause of Death (if applicable)
Due To Other Cause, Specify (Due to
other diease)
Due To Protocol Treatment (Due to
protocol treatment)
Due To This Disease (Due to this
1 / 2
disease)
Unknown (Unknown)
Describe cause of death
Reason for treatment ended
Alternative Therapy (Alternative therapy)
Death Of Patient Occurred After The
Patient Began Protocol Therapy (death
after beginning protocol therapy)
Disease Progression, Relapse During
Active Treatment (disease progression,
relapse during active treatment)
Other, Specify (other, specify)
Patient Off-treatment For Other
Complicating Disease (patient off
treatment for other complicating disease)
Patient Withdrawal Or Refusal After
Beginning Protocol Therapy (patient
withdrawal or refusal after beginning
protocol therapy)
Toxicity/side Effects/complications
(toxicity/side effects/complications)
Treatment Completed Per Protocol
Criteria (treatment completed per
protocol criteria)
Complicating disease (specify)
other, specify
Last date protocol therapy was given (M D Y)
Comments
Comments
Investigator Signature
Investigator Signature Date
Ccrr Module For E3201 Off-treatment
Form
2 / 2
E3201 Off-Treatment Form NCT00068692
NCT00070122  SOUTHWEST ONCOLOGY
GROUP OFF TREATMENT NOTICE (S0303)
NCT00070122  SOUTHWEST ONCOLOGY GROUP OFF
TREATMENT NOTICE (S0303)
Combination Chemotherapy and Bevacizumab in Treating
Patients With Locally Advanced, Metastatic, or Recurrent
Colorectal Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=BC630F99-
24B7-10CE-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/11442
NCT00070122  SOUTHWEST
ONCOLOGY GROUP OFF
TREATMENT NOTICE (S0303)
Header
SWOG Patient ID
SWOG Study No.
Registration Step
Patient Initials (L, F M)
Institution/Affiliate
Physician (Groups other than SWOG)
Group Name
Study No.
Pt. ID
Reporting period
Treatment Start Date
Treatment End Date
Regimen or Procedure or Site(s)
Off-protocol treatment
Off Treatment Reason
Death On Study (Death)
Adverse Event/side Effects/complications
(Medically required, due to toxicity)
Other (Other, specify)
Patient Withdrawal Or Refusal After
Beginning Protocol Therapy (Patient
1 / 2
refused, due to toxicity)
Patient Withdrawal Or Refusal Before
Beginning Protocol Therapy (Patient
refused, other than toxicity, specify)
Disease Progression, Relapse During
Active Treatment (Progression or
relapse, specify site)
Treatment Completed Per Protocol
Criteria (Treatment completed per
protocol criteria)
Patient refused, other than toxicity, specify
Progression or relapse, specify site
Other, specify (Off Treatment Date)
Date of completion, progression, death or
decision to discontinue therapy
Further treatment
Will patient receive further treatment?
No (No)
Unknown (Unknown)
Yes (Yes, specify)
Yes, specify
Vital status
Date of Last Contact (or death)
Vital Status
Alive (Alive)
Dead (Dead)
Comments
Comments
Ccrr Module For Southwest Oncology
Group Off Treatment Notice (s0303)
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NCT00070122  SOUTHWEST ONCOLOGY GROUP OFF TREATMENT
NOTICE (S0303)
ADVL0212: Pre-Existing Conditions At Time
of Study Entry NCT00053963
ADVL0212: Pre-Existing Conditions At Time of Study Entry
NCT00053963 
FR901228 in Treating Children With Refractory or
Recurrent Solid Tumors or Leukemia
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=BB5F4F72-
BF42-1043-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/11443
ADVL0212: Pre-Existing Conditions
At Time of Study Entry
NCT00053963
Header
Institution Name
Study Number
Study Number
COG Number
Patient's Initials
Date worksheet entered into RDE
Adverse event assessment
Name of Pre-existing condition (Use CTC version
2.0)
CTC Code of Pre-existing condition
Start Date (MM/DD/YYYY)
End Date (leave blank if on-going at the time of
study enrollment)
Comment
What is being done to treat the pre-existing
condition? (Choices: No therapy, Supportive
Care, Medication, Other : specify)
Medication (Medication)
No Therapy (No therapy)
Other, Specify (Other : specify)
Supportive Care (Supportive Care)
Other: specify [what is being done to treat pre-
existing condition]
1 / 2
Comments
Comments
Ccrr Module For Advl0212: Pre-existing
Conditions At Time Of Study Entry
2 / 2
ADVL0212: Pre-Existing Conditions At Time of Study Entry
NCT00053963
S0522 Off Treatment Notice Duplicate 2?
S0522 Off Treatment Notice
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=1035CDC8-
384B-0643-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11444
S0522 Off Treatment Notice
Duplicate 2?
Header
SWOG Patient ID
SWOG Study No.
Registration Step
Patient Initials (L, F M)
Institution/Affiliate
Physician
Participating Group Name
Participating Group Study No.
Participating Group Patient ID
Treatment period
Treatment Start Date
Treatment End Date
Regimen or Procedure or Site(s)
Off-protocol treatment
Off Treatment Reason (select one:)
Death (Death)
Medically Required, Due To Toxicity
(Medically required, due to toxicity)
Other (Other)
Patient Refused, Due To Toxicity (Patient
refused, due to toxicity)
Patient Refused, Other Than Toxicity
(Patient refused, other than toxicity)
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Progression Or Relapse (Progression or
relapse.)
Treatment Completed Per Protocol
Criteria (Treatment completed per
protocol criteria)
Medically required, due to toxicity, specify
Patient refused, due to toxicity, specify
Patient refused, other than toxicity, specify
Sites
Other, specify
Off Treatment Date (Date of completion,
progression, death or decision to discontinue
therapy:)
Further treatment
Will patient receive further treatment?
No (No)
Unknown (Unknown)
Yes (Yes)
Yes, specify
Vital status
Date of Last Contact (or death)
Vital Status
Alive (Alive)
Dead (Dead)
Comments
Comments
2 / 2
S0522 Off Treatment Notice Duplicate 2?
S0522 Off Treatment Notice Duplicate?
S0522 Off Treatment Notice
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=1035C05F-
4049-044E-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11445
S0522 Off Treatment Notice
Duplicate?
Header
SWOG Patient ID
SWOG Study No.
Registration Step
Patient Initials (L, F M)
Institution/Affiliate
Physician
Participating Group Name
Participating Group Study No.
Participating Group Patient ID
Report Period on Treatment
Treatment Start Date
Treatment End Date
Regimen or Procedure or Site(s)
Off-protocol treatment
Off Treatment Reason (select one:)
Death (Death)
Medically Required, Due To Toxicity
(Medically required, due to toxicity)
Other (Other)
Patient Refused, Due To Toxicity (Patient
refused, due to toxicity)
Patient Refused, Other Than Toxicity
(Patient refused, other than toxicity)
1 / 2
Progression Or Relapse (Progression or
relapse.)
Treatment Completed Per Protocol
Criteria (Treatment completed per
protocol criteria)
Medically required, due to toxicity, specify
Patient refused, due to toxicity, specify
Patient refused, other than toxicity, specify
Sites
Other, specify
Off Treatment Date (Date of completion,
progression, death or decision to discontinue
therapy:)
Further treatment
Will patient receive further treatment?
No (No)
Unknown (Unknown)
Yes (Yes)
Yes, specify
Vital status
Date of Last Contact (or death)
Vital Status
Alive (Alive)
Dead (Dead)
Comments
Comments
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S0522 Off Treatment Notice Duplicate?
CALGB: 80303 FOLLOW-UP FORM
NCT00088894
CALGB: 80303 FOLLOW-UP FORM NCT00088894
Gemcitabine With or Without Bevacizumab in Treating
Patients With Locally Advanced or Metastatic Pancreatic
Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=D5EC9696-
FBE6-0D66-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/11446
CALGB: 80303 FOLLOW-UP FORM
NCT00088894
Header
CALGB Study No
CALGB Patient ID
Reporting period start date
To (Date of last contact)
Are data amended?
Yes
No
Patient demographics
Patient Initials
Participating Group
Patient Hospital No.
Participating Group Protocol No.
Institution/Affiliate
Participating Group Patient ID
Survival status
Alive (Alive)
Dead (Dead)
Lost to follow-up (Lost to follow-up)
Performance status
Ambulatory And Capable Of All Selfcare
But Unable To Carry Out Any Work
Activities (k 50 - 60) (ecog - 2
Symptomatic; In Bed , 50% Of The Day)
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(Ambulatory and capable of selfcare, but
unable to carry out any work activities
(ECOG=2))
Capable Of Limited Selfcare, Confined
To Bed Or Chair More Than 50% Of
Waking Hours. (k 30 - 40) (ecog - 3
Symptomatic; In Bed > 50% Of The Day
But Not Bedridden) (Capable of limited
selfcare, confined to bed or chair more
than 50% of waking hours (ECOG=3))
Completely Disabled (k10 - 20) (ecog - 4
Bedridden) (Completely disabled
(ECOG=4))
Fully Active, Able To Carry On All Pre-
disease Performance Without Restriction
(karnofsky 90 - 100) (ecog - 0
Asymptomatic) (Fully active, able to
carry on all pre-disease performance
without restriction (ECOG=0))
Restricted In Physically Strenuous
Activity But Ambulatory (k70 - 80) (ecog -
1 Symptomatic - Fully Ambulatory)
(Restricted in physically strenuous
activity but ambulatory (ECOG=1))
Treatment Data
Treatment type
No (Patient is in post-treatment follow-
up)
Yes (Patient is receiving protocol
therapy)
Number of cycles given during this time period
Status of assigned treatment
Yes (Therapy has been terminated
permanently)
No (Therapy is being continued)
Date treatment ended or date of last dose given
Was protocol treatment modified or delayed
during this time period?
No (No)
Unknown (Unknown)
Yes (Yes)
Yes, Planned (i.e., The Treatment Was
Changed According To Protocol
Guidelines) (Yes, planned)
Yes, Unplanned (i.e., The Treatment
Change Was Not Part Of Protocol
Guidelines) (Yes, unplanned)
specify
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CALGB: 80303 FOLLOW-UP FORM NCT00088894
Has the patient received non-protocol therapy for
cancer during the follow-up period?
Yes
No
specify
Is the patient on full-dose anticoagulants?
Yes
No
specify reason
Examination Data
Evaluation method
CA 19-9 (CA 19-9)
Chest X-ray (Chest X-ray)
Ct Scan (CT Scan - abdomen/pelvis)
Ct Scan (CT Scan - chest)
Mri (MRI)
Other, Specify (Other, specify)
Other, specify
CA 19-9 Results, Value
CA 19-9 Results, Date collected
Tumor Response Data
Best overall tumor response to date
Complete Response (Complete
response)
Partial Response (Partial response)
Progressive Disease (Progression)
Stable Disease (Stable disease)
Unevaluable (Unevaluable)
CR confirmed
Yes
No
PR confirmed
Yes
No
SD confirmed
Yes
No
Date of CR onset
Date of PR onset
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Date of progression
Completed by
Date form completed
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CALGB: 80303 FOLLOW-UP FORM NCT00088894
CALGB: 90202 TREATMENT SUMMARY
NCT00079001
CALGB: 90202 TREATMENT SUMMARY NCT00079001
Zoledronate in Preventing Skeletal (Bone)-Related Events
in Patients Who Are Receiving Androgen Deprivation
Therapy For Prostate Cancer and Bone Metastases
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=B4606983-
04B2-052B-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/11447
CALGB: 90202 TREATMENT
SUMMARY NCT00079001
Header
CALGB Form
CALGB Study No
CALGB Patient ID
First date (any modality of) protocol therapy was
given
Last date (any modality of) protocol therapy was
given
Amended data?
Yes
No
Patient demographics
Patient Initials
Participating Group
Patient Hospital No.
Participating Group Protocol No.
Institution/Affiliate
Participating Group Patient ID
Treatment Phase
Treatment Phase
Double-blinded (Double-blinded)
Open Label (Open label)
1 / 4
Total number of cycles completed
TREATMENT SUMMARY
Patient's vital status
Alive (alive)
Dead (dead)
Primary cause of death
Due To Other Cause, Specify (due to
other cause)
Due To Protocol Treatment (due to
protocol treatment)
Due To This Disease (due to this
disease)
Unknown (unknown)
Describe cause of death
Date of last contact or death
Has the patient had a documented clinical
assessment for this cancer since submission of
the previous follow-up form?
No (no)
Unknown (unknown)
Yes (yes)
Date of last clinical assessment
treatment step
Reason treatment ended (mark one with an X)
Alternative Therapy (Alternative therapy)
Death On Study (Death on study)
Disease Progression, Relapse During
Active Treatment (Disease
progression/relapse during active
treatment)
Other (Other, specify)
Patient Off-treatment For Other
Complicating Disease (Patient off
treatment for other complicating disease)
Patient Withdrawal Or Refusal After
Beginning Protocol Therapy (Patient
withdrawal or refusal after beginning
protocol therapy)
Patient Withdrawal Or Refusal Before
Beginning Protocol Therapy (Patient
withdrawal or refusal prior to beginning
protocol therapy)
Adverse Event/side Effects/complications
(Toxicity/side effects/complications)
Treatment Completed Per Protocol
2 / 4
CALGB: 90202 TREATMENT SUMMARY NCT00079001
Criteria (Treatment completed per
protocol criteria)
Patient off treatment for other complicating
disease, specify
Alternative therapy, specify
Other, specify (reason treatment ended)
Were there any dose modifications or
additions/omissions to protocol treatment?
No (no)
Unknown (unknown)
Yes, Planned (i.e., The Treatment Was
Changed According To Protocol
Guidelines) (yes, planned)
Yes, Unplanned (i.e., The Treatment
Change Was Not Part Of Protocol
Guidelines) (Yes, unplanned)
specify therapy
Indicate reason for therapy modification
Has the patient developed a first progression (or
relapse) that has not been previously reported?
Yes
No
Date of first biochemical progression
PSA value at progression
Date of first skeletal related event
Site of skeletal related event
Fracture (fracture)
Radiation To Bone (radiation to bone)
Spinal Cord Compression (spinal cord
compression)
Surgery To Bone (surgery to bone)
Date of first distant progression
Site(s) of first distant progression
PSA value (total)
Date of PSA assessment
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CALGB: 90202 TREATMENT SUMMARY NCT00079001
Is the patient receiving any non-protocol therapy
not previously reported?
Yes
No
Non-protocol hormonal therapy
Yes
No
Non-protocol surgery
Yes
No
Non-protocol radiation therapy
Yes
No
Other non-protocol therapy
Yes
No
If yes, specify therapy
Date of first non-protocol therapy
Completed By (Print or Type Name)
Date Completed (M)
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CALGB: 90202 TREATMENT SUMMARY NCT00079001
S0337 Notice of Death NCT00445601
S0337 Notice of Death NCT00445601
Gemcitabine After Surgery in Treating Patients With Newly
Diagnosed or Recurrent Bladder Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=FE24F40B-
3D03-490A-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11448
S0337 Notice of Death
NCT00445601
Header
SWOG Patient ID
Most Recent SWOG Study No.
Patient Initials (L, F, M)
Institution/Affiliate
Physician
Participating Group Name
Participating Group Study No.
Participating Group Patient ID
Date of death
Date of Death (month / day / year)
Causes Of Death
Any cancer (select one)
Contributory (Contributory)
No (No)
Possible (Possible)
Primary Cause (Primary Cause)
Unknown (Unknown)
If cancer was the primary cause or if cancer
possibly or definitely contributed to death, and the
patient had had multiple tumor types, specify
those which were causes of death
Cancer Of Most Recent Swog Study
(Cancer of most recent SWOG study)
Cancer Of Other Swog Study (Cancer of
other SWOG study)
1 / 2
Other Cancer (Other cancer)
Cancer of most recent SWOG study, specify
cancer
Cancer of other SWOG study, specify cancer
Other cancer, specify
Toxicity from disease related treatment (select
one)
Contributory (Contributory)
No (No)
Possible (Possible)
Primary Cause (Primary Cause)
Unknown (Unknown)
If Primary Cause, Contributory or Possible,
specify treatment and toxicity
Non-cancer and non-treatment related causes
(select one)
Contributory (Contributory)
No (No)
Possible (Possible)
Primary Cause (Primary Cause)
Unknown (Unknown)
If Primary Cause, Contributory or Possible,
specify
Autopsy?
No (No)
Unknown (Unknown)
Yes (Yes)
Source(s) of death information
Autopsy Report (Autopsy report)
Medical Record / Death Certificate
(Medical record / Death certificate)
Other (Other)
Physician (Physician)
Relative Or Friend (Relative or friend)
Other, specify
Comments
Comments
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S0337 Notice of Death NCT00445601
NCT00068601  SOUTHWEST ONCOLOGY
GROUP OFF TREATMENT NOTICE (S0230)
NCT00068601  SOUTHWEST ONCOLOGY GROUP OFF
TREATMENT NOTICE (S0230)
Goserelin in Preventing Ovarian Failure in Women
Receiving Chemotherapy for Breast Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=BEA9EB97-
F44C-2E37-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/11449
NCT00068601  SOUTHWEST
ONCOLOGY GROUP OFF
TREATMENT NOTICE (S0230)
Header
SWOG Patient ID
SWOG Study No.
Registration Step
Patient Initials (L, F M)
Institution/Affiliate
Physician (Groups other than SWOG)
Group Name
Study No.
Pt. ID
Treatment period
Treatment Start Date
Treatment End Date
Regimen or Procedure or Site(s)
Off-protocol treatment
Off Treatment Reason
Death On Study (Death)
Adverse Event/side Effects/complications
(Medically required, due to toxicity)
Other (Other, specify)
Patient Withdrawal Or Refusal After
Beginning Protocol Therapy (Patient
1 / 2
refused, due to toxicity)
Patient Withdrawal Or Refusal Before
Beginning Protocol Therapy (Patient
refused, other than toxicity, specify)
Disease Progression, Relapse During
Active Treatment (Progression or
relapse, specify site)
Treatment Completed Per Protocol
Criteria (Treatment completed per
protocol criteria)
Progression or relapse, specify site
Other, specify (Off Treatment Date)
Other, specify (Off Treatment Date)
Date of completion, progression, death or
decision to discontinue therapy
Further treatment
Will patient receive further treatment?
No (No)
Unknown (Unknown)
Yes (Yes, specify)
Yes, specify
Vital status
Date of Last Contact (or death)
Vital Status
Alive (Alive)
Dead (Dead)
Comments
Comments
Ccrr Module For Southwest Oncology
Group Off Treatment Notice (s0230)
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NCT00068601  SOUTHWEST ONCOLOGY GROUP OFF TREATMENT
NOTICE (S0230)
NCT00127205  SOUTHWEST ONCOLOGY
GROUP OFF TREATMENT NOTICE (S0307)
NCT00127205  SOUTHWEST ONCOLOGY GROUP OFF
TREATMENT NOTICE (S0307)
Zoledronate, Clodronate, or Ibandronate in Treating Women
Who Have Undergone Surgery for Stage I, Stage II, or
Stage III Breast
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=DE9FCB2F-
D7B1-4925-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/11450
NCT00127205  SOUTHWEST
ONCOLOGY GROUP OFF
TREATMENT NOTICE (S0307)
Header
SWOG Patient ID
SWOG Study No.
Registration Step
Patient Initials (L, F M)
Institution/Affiliate
Physician
Participating Group Name
Participating Group Study No.
Participating Group Patient ID
Treatment period
Treatment Start Date
Treatment End Date
Regimen or Procedure or Site(s)
Off-protocol treatment
Off Treatment Reason (select one:)
Death (Death)
Medically Required, Due To Toxicity
(Medically required, due to toxicity)
Other (Other)
Patient Refused, Due To Toxicity (Patient
refused, due to toxicity)
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Patient Refused, Other Than Toxicity
(Patient refused, other than toxicity)
Progression Or Relapse (Progression or
relapse.)
Treatment Completed Per Protocol
Criteria (Treatment completed per
protocol criteria)
Medically required, due to toxicity, specify
Patient refused, due to toxicity, specify
Patient refused, other than toxicity, specify
Sites
Other, specify
Off Treatment Date (Date of completion,
progression, death or decision to discontinue
therapy:)
Further treatment
Will patient receive further treatment?
No (No)
Unknown (Unknown)
Yes (Yes)
Yes, specify
Vital status
Date of Last Contact (or death)
Vital Status
Alive (Alive)
Dead (Dead)
Comments
Comments
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NCT00127205  SOUTHWEST ONCOLOGY GROUP OFF TREATMENT
NOTICE (S0307)
NCT00127205 SOUTHWEST ONCOLOGY
GROUP S0307 TREATMENT SUMMARY FORM
NCT00127205 SOUTHWEST ONCOLOGY GROUP S0307
TREATMENT SUMMARY FORM
Zoledronate, Clodronate, or Ibandronate in Treating Women
Who Have Undergone Surgery for Stage I, Stage II, or
Stage III Breast
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=DEC8DDEA-
4CD8-1431-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/11451
NCT00127205 SOUTHWEST
ONCOLOGY GROUP S0307
TREATMENT SUMMARY FORM
Header
SWOG Patient ID
SWOG Study No.
Registration Step
Patient Initials (L, F M)
Interval
0-6 Months (0-6 months)
1 Yr-2 Yr (1 yr-2 yr)
2 Yr-3 Yr (2 yr-3 yr)
6 Mo-1 Yr (6 mo-1 yr)
Institution/Affiliate
Physician
Participating Group Name
Participating Group Study No.
Participating Group Patient ID (Instructions:
Please complete this form at 6 months, 1 year, 2
years, and 3 years. All dates are MONTH, DAY,
YEAR. Explain any blank dates or fields in the
Comments section. Place an X in appropriate
boxes. Circle AMENDED items in red and write
AMENDED across the top of the form.)
Disease Status
Date of Last Clinical Assessment (submit Follow
Up form if patient has relapsed)
1 / 3
Date of Last Contact or Death
Vital Status
Alive (Alive)
Dead (Dead)
Treatment Status
Assigned Treatment Arm
Arm 1 (Arm 1)
Arm 2 (Arm 2)
Arm 3 (Arm 3)
Was the patient treated on the assigned arm
during this interval?
Yes
No
Interval Treatment Start Date
Interval Treatment End Date
Were there any dose modifications or
additions/omissions to protocol treatment during
this interval?
No (No)
Yes, Planned (i.e., The Treatment Was
Changed According To Protocol
Guidelines) (Yes, planned)
Yes, Unplanned (i.e., The Treatment
Change Was Not Part Of Protocol
Guidelines) (Yes, unplanned)
In the past month, how many pills did the patient
miss
Has the patient received any chemotherapy
during this interval?
Yes
No
Has the patient received radiation therapy during
this interval?
Yes
No
Has the patient received any hormone therapy
during this interval?
Yes
No
If yes
Aromatase Inhibitor (Aromatase inhibitor)
Ovarian Suppression (Ovarian
suppression)
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NCT00127205 SOUTHWEST ONCOLOGY GROUP S0307
TREATMENT SUMMARY FORM
Serm (SERM)
Is the patient currently taking a statin
(atorvastatin Lipitor, pravastatin Pravachol,
simvastatin Zocor,
lovastatin Mevacor, fluvastatin Lescol,
rosuvastatin Crestor?)
Yes
No
Fracture status
Has the patient had a fracture since submission
of the last follow-up form?
Yes
No
indicate site
Ankle (Ankle)
Arm (Arm)
Hip (Hip)
Leg (Leg)
Pelvis (Pelvis)
Spine (Spine)
Wrist (Wrist)
Was the fracture traumatic (from greater than
standing height?)
Yes
No
Has the patient had osteonecrosis or
osteomyelitis of the jaw since submission of the
last follow-up form? (If yes, submit S0307
Osteonecrotic Jaw Lesion Form)
Yes
No
Comments
Comments
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NCT00127205 SOUTHWEST ONCOLOGY GROUP S0307
TREATMENT SUMMARY FORM
NSABP PROTOCOL C-08 ON-STUDY
FORM NCT00096278
NSABP PROTOCOL C-08 ON-STUDY FORM
NCT00096278
Fluorouracil, Leucovorin, and Oxaliplatin With or Without
Bevacizumab in Treating Patients Who Have Undergone
Surgery for Stage II or Stage III Colon Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=DE27BCD2-
EB22-2947-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/11452
NSABP PROTOCOL C-08 ON-
STUDY FORM NCT00096278
Header
Patient Initials (Last, First Middle)
NSABP Patient ID
Institution Name
Affiliate Name
Person Completing Form Last Name
Person Completing Form First Name
Person Completing Form Phone
Are data amended? (check box if yes, and circle
amended items)
Yes
No
Tumor assessment
Date of Resection (Month Day Year)
Are there Multiple Primary Tumors?
No (No)
Unknown (Unknown)
Yes (Yes)
Location of Tumor (Select One for Each Primary
Tumor)
Appendix (Appendix)
Ascending Colon (Ascending Colon)
Cecum (Cecum)
Descending Colon (Descending Colon)
Hepatic Flexure (Hepatic Flexure)
Rectum (Rectum)
Sigmoid Colon (Sigmoid colon)
Splenic Flexure (Splenic Flexure)
Transverse Colon (Transverse Colon)
1 / 3
distance from the anal verge on endoscopy to the
distal extent of lowest lying tumor (If location is
sigmoid colon or rectum)
cm
Was there bowel obstruction?
Yes
No
Was there tumor perforation?
Yes
No
type of perforation (If yes,)
Contained (Contained)
Free (Free)
Was tumor resected en bloc? ([Refer to C-08
Nurse/CRA Guidelines.])
Yes
No
Accession Number (Pathology)
Histologic Grade (differentiation)
High Grade (poor Differentiation And/or
Undifferentiated) (High grade)
Low Grade (well And/or Moderate
Differentiation) (Low grade)
All surgical margins of resection are negative for
tumor
Yes
No
Which margin is involved? (mark all that apply)
Circumferential (Circumferential)
Distal (Distal)
Proximal (Proximal)
Number of lymph nodes examined
Number of positive lymph nodes
Tnm Classification
T Stage, Pathological ([If multiple tumors, report
on most advanced.])
T0, According To Ajcc Criteria (T0)
T1, According To Ajcc Criteria (T1)
T2, According To Ajcc Criteria (T2)
T3, According To Ajcc Criteria (T3)
T4, According To Ajcc Criteria (T4)
Tis, According To Ajcc Criteria (Tis)
Tx, According To Ajcc Criteria (TX)
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NSABP PROTOCOL C-08 ON-STUDY FORM NCT00096278
N Stage, Pathological
N0, According To Ajcc Criteria (N0)
N1, According To Ajcc Criteria (N1)
N2, According To Ajcc Criteria (N2)
Nx, According To Ajcc Criteria (NX)
Vascular assessment
Hypertension (1.)
No (no)
Unknown (unknown)
Yes (yes)
Diabetes Mellitus (2.)
No (no)
Unknown (unknown)
Yes (yes)
Previous vascular event (3.)
No (no)
Unknown (unknown)
Yes (yes)
Previous vascular event
Cerebrovascular Event (Cerebrovascular
event)
Myocardial Infarction (Myocardial
infarction)
Other (Other)
Peripheral Arterial Event (Peripheral
arterial event)
Vascular Aneurysm (Vascular aneurysm)
Venous Thromboembolic Event (Venous
thromboembolic event)
Smoking (4.)
Currently Smoking (Currently smoking)
Never Smoked (Never smoked)
Smoked In The Past (Smoked in the
past)
Family history of cardiac disease (5.)
No (no)
Unknown (unknown)
Yes (yes)
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NSABP PROTOCOL C-08 ON-STUDY FORM NCT00096278
CALGB: 80203 Follow-up and Response
Form NCT00077233
CALGB: 80203 Follow-up and Response Form
NCT00077233
Fluorouracil and Leucovorin Plus Either Irinotecan or
Oxaliplatin With or Without Cetuximab in Treating Patients
With Previously Untreated Metastatic Adenocarcinoma of
the Colon or Rectum
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=B4C3AFD5-
EA93-071F-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/11453
CALGB: 80203 Follow-up and
Response Form NCT00077233
Header
CALGB Form
CALGB Study No.
CALGB Patient ID
Reporting period start date
To: (date of last contact or death)
Are data amended?
Yes
No
Patient demographics
Patient Initials
Participating Group
Patient Hospital No.
Participating Group Protocol No.
Institution/Affiliate
Participating Group Patient ID
Miscellaneous Patient Assessment
Patients vital status
Alive (alive)
Dead (dead)
lost (lost)
1 / 3
Cause of death
Due To Other Cause, Specify (due to
other cause)
Due To Protocol Treatment (due to
protocol treatment)
Due To This Disease (due to this
disease)
Due to other cause, specify
Date of evaluation (response)
Site(s) of progression
Intra-abdominal/pelvic (Intra-
abdominal/pelvic)
Liver (Liver)
local/regional (local/regional)
Lung and/or pleura (Lung and/or pleura)
Other (Other)
Other, specify site
Complete response first observed date
Partial response first observed date
Progressive disease first observed date
Is the patient receiving any non-protocol cancer
therapy not previously reported?
Yes
No
specify therapy
Has a new primary cancer or AML/MDS been
diagnosed that has not been previously reported?
Yes
No
Specify date of diagnosis
Site(s) of new primary
Completed by
Date form completed
Ccrr Module For Calgb: 80203 Follow-up
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CALGB: 80203 Follow-up and Response Form NCT00077233
And Response Form
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CALGB: 80203 Follow-up and Response Form NCT00077233
CALGB: 80405 CETUXIMAB SKIN
ADVERSE EVENT FORM NCT00265850
CALGB: 80405 CETUXIMAB SKIN ADVERSE EVENT
FORM NCT00265850
Cetuximab and/or Bevacizumab Combined With
Combination Chemotherapy in Treating Patients With
Metastatic Colorectal Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=F39BDD07-
7359-5A3C-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11454
CALGB: 80405 CETUXIMAB SKIN
ADVERSE EVENT FORM
NCT00265850
CALGB clinical trial administrative data
CALGB Form
CALGB Study No
CALGB Patient ID
Are data amended
Yes
No
Patient demographics
Patient Initials
Patient Hospital No
Institution/Affiliate
Participating Group
Participating Group Study No.
Participating Group Patient ID
Cetuximab Skin Adverse Events
Cycle number
Reporting Period Start Date
Reporting Period End Date
Did any Cetuximab related skin adverse events
1 / 2
occur during this reporting period
Yes
No
MedDRA code
CTC AE Grade (1-5)
Cetuximab Dose Modification (*)
Dose Held (Dose held)
Dose Held And Reduced (Dose held and
reduced)
Dose Reduced (Dose reduced)
Drug Discontinued (Drug discontinued)
No Dose Modification (No dose
modification)
Adverse event onset date
Adverse event end date
If ongoing, mark with an X
CTC Adverse Event Dermatology/Skin-Other
(Specify)
Completed by
Date form originally completed
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CALGB: 80405 CETUXIMAB SKIN ADVERSE EVENT FORM
NCT00265850
E2902 Treatment (Observation) Form - Arm
B - Form 2052 NCT00093470
E2902 Treatment (Observation) Form - Arm B - Form 2052
NCT00093470 
Tipifarnib in Treating Patients With Acute Myeloid Leukemia
in Remission
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=DC08F7A4-
CBE4-0CF3-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/11455
E2902 Treatment (Observation)
Form - Arm B - Form 2052
NCT00093470
Header
ECOG Protocol Number
ECOG Patient ID
DCI Name (Place ID Label Here)
Patient Initials (Last, First)
Participating Group Protocol Number
Participating Group Patient ID
Institution/Affiliate
Registration Step
Observation Report Period (Choose one)
> Cycle 33 (> Cycle 33)
Cycle 12 (Cycle 12)
Cycle 15 (Cycle 15)
Cycle 18 (Cycle 18)
Cycle 21 (Cycle 21)
Cycle 24 (Cycle 24)
Cycle 27 (Cycle 27)
Cycle 3 (Cycle 3)
Cycle 30 (Cycle 30)
Cycle 33 (Cycle 33)
Cycle 6 (Cycle 6)
Cycle 9 (Cycle 9)
Cycle (specify)
Are data amended
Yes
No
Vital Status
1 / 3
Patient Vital Status
Alive (Alive)
Dead (Dead)
Primary Cause of Death (if applicable)
Due To Other Cause, Specify (Due to
other cause)
Due To Protocol Treatment (Due to
protocol treatment)
Due To This Disease (Due to this
disease)
Unknown (Unknown)
Describe cause of death
Date of last contact or death
Report Period Information
Report Period Start Date
Report Period End Date
Performance status (Evaluation closest to start of
Report Period)
Fully Active, Able To Carry On All Pre-
disease Performance Without Restriction
(karnofsky 90 - 100) (ecog - 0
Asymptomatic) (0)
Restricted In Physically Strenuous
Activity But Ambulatory (k70 - 80) (ecog -
1 Symptomatic - Fully Ambulatory) (1)
Ambulatory And Capable Of All Selfcare
But Unable To Carry Out Any Work
Activities (k 50 - 60) (ecog - 2
Symptomatic; In Bed , 50% Of The Day)
(2)
Capable Of Limited Selfcare, Confined
To Bed Or Chair More Than 50% Of
Waking Hours. (k 30 - 40) (ecog - 3
Symptomatic; In Bed > 50% Of The Day
But Not Bedridden) (3)
Completely Disabled (k10 - 20) (ecog - 4
Bedridden) (4)
Non-protocol Therapy
Was any non-protocol therapy given (not
previously reported)
Yes
No
Related Forms
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E2902 Treatment (Observation) Form - Arm B - Form 2052
NCT00093470
Comments
Comments
Investigator Signature
Investigator Signature Date
3 / 3
E2902 Treatment (Observation) Form - Arm B - Form 2052
NCT00093470
E2902 Long-Term Follow-up Form - Form
2049 NCT00093470
E2902 Long-Term Follow-up Form - Form 2049
NCT00093470 
Tipifarnib in Treating Patients With Acute Myeloid Leukemia
in Remission
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=DBE2127B-
9F53-454A-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/11456
E2902 Long-Term Follow-up Form -
Form 2049 NCT00093470
Header
ECOG Protocol Number
ECOG Patient ID
DCI Name (Place ID Label Here)
Patient Initials (Last, First)
Participating Group Protocol Number
Participating Group Patient ID
Institution/Affiliate
Off Treatment Report Period (since registration)
12 Months (12 Months Post Registration)
15 Months (15 Months Post Registration)
18 Months (18 Months Post Registration)
21 Months Post Registration (21 Months
Post Registration)
2 Years (24 Months Post Registration)
3 Months (3 Months Post Registration)
30 Months (30 Months Post Registration)
3 Years (36 Months Post Registration)
42 Months (42 Months Post Registration)
4 Years (48 Months Post Registration)
54 Months (54 Months Post Registration)
6 Months (6 Months Post Registration)
5 Years (60 Months Post Registration)
9 Months (9 Months Post Registration)
Are data amended
Yes
No
Section I - Vital Status
Patient Vital Status
Alive (Alive)
Dead (Dead)
1 / 3
Primary Cause of Death (if applicable)
Due To Other Cause, Specify (Due to
other cause)
Due To Protocol Treatment (Due to
protocol treatment)
Due To This Disease (Due to this
disease)
Unknown (Unknown)
Describe cause of death
Date of last contact or death
Section Ii - Reporting Period
Report Period Start Date
Report Period End Date
Section Iii - Disease Follow-up Status
Has the patient had a documented clinical
assessment for this cancer (since submission of
the previous follow-up form?)
No (No)
Unknown (Unknown)
Yes (Yes)
Explain (If unknown)
Date of last clinical assessment (If yes)
Has the patient developed a first progression
(relapse) that has not been previously reported?
No (No)
Unknown (Unknown)
Yes (Yes)
Date of progression (If yes,)
Site(s) of progression
Did a physician make a formal diagnosis of
progression?
No (No)
Unknown (Unknown)
Yes (Yes)
Specify basis of progression (If no or unknown)
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E2902 Long-Term Follow-up Form - Form 2049 NCT00093470
Section Iv - Notice Of New Primary
Has a new primary cancer or myelodysplastic
syndrome (MDS) been diagnosed that has not
been previously reported?
No (No)
Unknown (Unknown)
Yes (Yes)
Site of new primary (s)
Section V - Adverse Events
Has the patient experienced (prior to diagnosis of
progression/relapse) any severe (Grade >=3)
long term toxicity that has not been previously
reported?
No (No)
Unknown (Unknown)
Yes (Yes)
Section Vi - Non-protocol Therapy Prior To
Progression
Has the patient received any non-protocol cancer
therapy prior to first progression (not previously
reported)?
No (No)
Unknown (Unknown)
Yes (Yes)
Comments
Comments
Investigator Signature
Investigator Signature Date
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E2902 Long-Term Follow-up Form - Form 2049 NCT00093470
E4A03 Long-Term Follow-up Form - Form
2054 NCT00098475
E4A03 Long-Term Follow-up Form - Form 2054
NCT00098475 
Lenalidomide and Dexamethasone With or Without
Thalidomide in Treating Patients With Multiple Myeloma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=DC5EBC73-
A98A-3534-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/11457
E4A03 Long-Term Follow-up Form -
Form 2054 NCT00098475
Header
ECOG Protocol Number
ECOG Patient ID
DCI Name
Registration Step (Place ID Label Here)
Patient Initials (Last, First)
Participating Group Protocol Number
Participating Group Patient ID
Institution/Affiliate
Off Treatment Report Period (since registration to
step 1)
12 Months (12 Months Post Registration)
15 Months (15 Months Post Registration)
18 Months (18 Months Post Registration)
21 Months Post Registration (21 Months
Post Registration)
2 Years (24 Months Post Registration)
3 Months (3 Months Post Registration)
30 Months (30 Months Post Registration)
3 Years (36 Months Post Registration)
42 Months (42 Months Post Registration)
4 Years (48 Months Post Registration)
54 Months (54 Months Post Registration)
6 Months (6 Months Post Registration)
5 Years (60 Months Post Registration)
6 Years (72 Months Post Registration)
84 Months Post Registration (84 Months
Post Registration)
9 Months (9 Months Post Registration)
Are data amended
Yes
No
1 / 3
Section I - Vital Status
Patient Vital Status
Alive (Alive)
Dead (Dead)
Primary Cause of Death (if applicable)
Due To Other Cause, Specify (Due to
other cause)
Due To Protocol Treatment (Due to
protocol treatment)
Due To This Disease (Due to this
disease)
Unknown (Unknown)
Describe cause of death
Date of last contact or death
Section Ii - Reporting Period
Report Period Start Date
Report Period End Date
Section Iii - Disease Follow-up Status
Has the patient had a documented clinical
assessment for this cancer (since submission of
the previous follow-up form?)
No (No)
Unknown (Unknown)
Yes (Yes)
Explain (If unknown)
Date of last clinical assessment (If yes:)
Has the patient developed a first progression (or
relapse) that has not been previously reported?
No (No)
Unknown (Unknown)
Yes (Yes)
Date of progression (relapse - If yes,)
Site(s) of progression
Did a physician make a formal diagnosis of
progressive disease?
No (No)
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Unknown (Unknown)
Yes (Yes)
Specify basis of progression (If no or unknown)
Section Iv - Notice Of New Primary
Has a new primary cancer or MDS been
diagnosed that has not been previously reported?
No (No)
Unknown (Unknown)
Yes (Yes)
Site of new primary (s - If diagnosis of new
primary cancer including AML/MDS, submit
ECOG Second Primary Form)
Section V - Adverse Events
Has the patient experienced (prior to diagnosis of
progression/relapse) any reportable long term
toxicity that has not been previously reported?
(NOTE: See section 5.2 of the protocol for
expedited reporting requirements for events
occurring greater than 30 days past the last dose
of protocol treatment.)
No (No)
Unknown (Unknown)
Yes (Yes)
Section Vi - Non-protocol Therapy Prior To
Progression
Has the patient received any non-protocol cancer
therapy prior to first progression (not previously
reported)
No (No)
Unknown (Unknown)
Yes (Yes)
Comments
Comments
Investigator Signature
Investigator Signature Date
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NCT00377156  North Central Cancer Treatment
Group Patient FACT-Br Booklet Compliance Form
NCT00377156  North Central Cancer Treatment Group
Patient FACT-Br Booklet Compliance Form
Stereotactic Radiation Therapy With or Without Whole-
Brain Radiation Therapy in Treating Patients With Brain
Metastases
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=10B5559C-
8474-2D2B-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11458
NCT00377156  North Central
Cancer Treatment Group Patient
FACT-Br Booklet Compliance Form
Header
NCCTG Protocol Number
NCCTG Patient ID
Patient Initials (L F M)
Institution
Institution Number
Are data amended (If yes, highlight amended
areas)
Yes
No
Miscellaneous Patient Information
Cycle Number
Form Completion Date
Reason Patient Questionnaire was not completed
(check one)
Other Reason (Other reason)
Patient Not Given Form By Staff (Patient
not given form by staff)
Patient Refused (Patient refused)
Staff Unavailable (Staff unavailable)
Unable To Accomodate Disability Or
Language Needs (Unable to accomodate
disability or language needs)
Other reason, specify
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NCT00053963
ADVL0212: On Study Worksheet [reload] NCT00053963 
FR901228 in Treating Children With Refractory or
Recurrent Solid Tumors or Leukemia
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=B304C5F5-
C7EC-0452-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/11459
ADVL0212: On Study Worksheet
[reload] NCT00053963
Header
Study Number
Institution Name
COG Number
Patient's Initials
Date worksheet entered into RDE
Method of Payment
Medicaid (Medicaid)
Medicaid And Medicare (Medicaid and
Medicare)
Medicare (Medicare)
Medicare And Private Insurance
(Medicare and Private Insurance)
Military Or Veterans Sponsored Nos
(Military or Veterans sponsored NOS)
Military Sponsored (including Champus
& Tricare) (Military sponsored (including
CHAMPUS and TRICARE))
No Means Of Payment (no Insurance)
(No means of payment (no insurance))
Other (Other)
Private Insurance (Private Insurance)
Self Pay (no Insurance) (Self pay (no
insurance))
Unknown (Unknown)
Veterans Sponsored (Veterans
sponsored)
Treatment related information
Accession number (Pre-populated by the
registration system.)
Stratum (Pre-populated by the registration
system.)
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Treatment Number (Pre-populated by the
registration system.)
Treating Institution (Pre-populated by the
registration system.)
Treating Physician (Pre-populated by the
registration system.)
Date of Randomization (Pre-populated by the
registration system.)
Date of call back (Pre-populated by the
registration system.)
Date of Registration (Pre-populated by the
registration system.)
Treatment Start Date (Pre-populated by the
registration system.)
Diagnosis
Does patient have measurable disease? (1.
Required field)
Yes
No
Did patient have a bone marrow evaluation just
prior to study entry? (1. Required field)
Yes
No
what was the date of the exam? (MM/DD/YYYY)
does patient have bone marrow involvement?
(Reset)
Yes
No
Has patient had radiation therapy delivered to
20% or more of her or his bone marrow? (1.
Required field <attach help text document
ADVL0212 marrow help.doc>)
Yes
No
Was patient's shortening fraction determined by
echocardiogram? (1. Required field)
Yes
No
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what was the percentage? (1. Must be greater
than or equal to 28%)
Was patient's ejection fraction determined by
MUGA? (1. Required field)
Yes
No
what was the percentage? (1. Must be greater
than or equal to 45%)
Hemogram
Test date (MM/DD/YYYY)
Hgb (g/dL)
g/dL
WBC (1. Accepted range is 0.9-50.  A value of
less than 0.9 or greater than 50 generates a
warning on the institutional data receipt, but does
not prevent data entry)
Assessment Lab (unit of measure)
International Units Per Liter (IU/L)
Mu/ml (mU/mL)
Platelets (1. Accepted range is 30-1500.  A value
of less than 30 or greater than 1500 generates a
warning on the institutional data receipt, but does
not prevent data entry)
Segs (%)
%
Bands (%)
%
Was red cell transfusion given as a result of
CBC? (1. Required field)
No Transfusion (No)
Unknown (Unknown)
Yes (Yes)
Transfusion With Platelets And Red
Blood Cells (Yes, both)
Transfusion With Platelets (Yes,
platelets)
Transfusion With Red Blood Cells (Yes,
red blood cells)
Chemistries
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Test date (MM/DD/YYYY)
ALT (acceptable units: IU/L, or mU/mL)
ALT (institutional upper limit of normal)
AST (acceptable units: IU/L, or mU/mL)
AST (institutional upper limit of normal)
T. Bilirubin (mg/dL)
mg/dL
T. Bilirubin- institutional upper limit or normal
(mg/dL)
mg/dL
Creatinine (mg/dL)
mg/dL
Creatinine- institutional upper limit of normal
(mg/dL)
mg/dL
Comments
Comments
Ccrr Module For Advl0212: On Study
Worksheet [reload]
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CALGB Randomization (CALGB 49903)
NCT00053339
CALGB Randomization (CALGB 49903) NCT00053339
Trastuzumab With or Without Tamoxifen in Treating Women
With Progressive Stage IV Breast Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=A73D2B92-
2BAF-4794-E034-0003BA0B1A09
All rights reserved. Please visit https://medical-data-
models.org/forms/11460
CALGB Randomization (CALGB
49903) NCT00053339
Header
CALGB Patient ID
Affiliate/Treating Institution
Participating Group Patient No.
Patient Hospital Record No.
Participating Group Code
Physician of Record
Fax
Phone
Protocol Administration
IRB Approval Date
Consent Form Date
Projected Start Date
Person Completing Form, Last Name
Person Completing Form, first Name
Person Phone
Fax
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Patient Demographics / Pre-treatment
Characteristics
Patient Name (l,f,m.i.)
Social Security # (USA Only)
Patient Race/Ethnicity
Black_cdus (Black)
Filipino (Filipino)
Hispanic (Hispanic)
Indian (Indian)
Institution refusal (Institution refusal)
Native_american_cdus (Native
American)
Pacific_islander_cdus (Native Hawaiian)
Asian_cdus (Oriental)
Other (Other)
Patient refusal (Patient refusal)
Unknown (Unknown)
White_cdus (White)
Sex
Female (F)
Male (M)
Birthdate (M)
Method of Payment
Medicaid (Medicaid)
Medicaid and Medicare (Medicaid and
Medicare)
Medicare (Medicare)
Medicare and Private Insurance
(Medicare and Private Insurance)
Military or Veterans Administration
Sponsored (Military or Veterans
Administration Sponsored)
No means of payment (No means of
payment)
Private Insurance (Private Insurance)
Self Pay (Self Pay)
Unknown (Unknown)
Zip Code (USA Only)
Country of Residence (if not USA)
Performance Status
2 (Ambulatory and capable of all selfcare
but unable to carry out any work
activities)
3 (Capable of limited selfcare, confined
to bed or chair more than 50% of waking
hours)
4 (Completely disabled)
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0 (Fully active, able to carry on all pre-
disease performance without restriction)
1 (Restricted physically strenuous
activity but ambulatory)
Pt Height (cm)
Pt Weight (kg)
BSA
Certification Of Eligibility
Patient eligible? (STRATIFICATION FACTORS)
Yes
No
Registration data
ASSIGNED TREATMENT ARM
Arm 1 (Arm 1)
Arm 2 (Arm 2)
Date of Registration
Registrar
Ccrr Module For Calgb Randomization
(calgb 49903)
Participating Group Name
CALGB Patient ID
IRB Approval Date
Affiliate/Treating Institution
Patient Initials
Prior Chemotherapy
Main Member Institution
Responsible Contact
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NCI Coop Group Colorectal Ca Toxicity
Form - Subset of Pts NCT00079274
NCI Cooperative Group Colorectal Cancer - Toxicity Form -
Subset of Patients NCT00079274
Comparison of Combination Chemotherapy Regimens With
or Without Cetuximab in Treating Patients Who Have
Undergone Surgery For Stage III Colon Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=DFBB64C6-
A974-5B18-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/11461
NCI Coop Group Colorectal Ca
Toxicity Form - Subset of Pts
NCT00079274
Header
Coordinating Group Protocol Number
Coordinating Group Code
Protocol Title
Patient Study ID
Patient Medical Record Number
Patient Initials (L, FM)
Participating Group Code (Cooperative Group
where credit will be applied)
Institution Name (treating location/performance
site)
Are data amended? (If data are amended, please
circle in red when using paper form)
Yes
No
Treatment Reporting Interval
Reporting Period (Please indicate which cycles
this CRF includes from time of registration:)
Cycles 1 & 2 (Cycles 1 & 2)
Cycles 11 & 12 (Cycles 11 & 12)
Cycles 3 & 4 (Cycles 3 & 4)
Cycles 5 & 6 (Cycles 5 & 6)
Cycles 7 & 8 (Cycles 7 & 8)
Cycles 9 & 10 (Cycles 9 & 10)
Adverse Event (First Cycle of Reporting
Period)
Current Treatment Arm
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Cycle Number
Assessment Date (Date patient evaluated for
adverse events this cycle mm dd yyyy)
Are all adverse event grades less than those
required for reporting as listed below (If so, skip
rest of form.)
Yes
No
CTC Adverse Event Term
Myocardial Ischaemia (Cardiac
ischemia/infarction)
Cough (Cough)
Diarrhoea Nos (Diarrhea)
Dyspnoea Nos (Dyspnea (shortness of
breath))
Febrile Neutropenia (fever Of Unknown
Origin Without Clinically Or
Microbiologically Documented Infection)
(anc <1.0 X 10^9/l, Fever >=38.5
Degrees C) (Febrile neutropenia)
Hypoxia (Hypoxia)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Abdomen NOS)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Biliary tree)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Bladder (urinary))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Catheter-related)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Colon)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
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microbiologically) with Grade 3 or 4
neutrophils - Kidney)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Lung (pneumonia))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Pelvis NOS)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Pleura (empyema))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Skin (cellulitis))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Upper aerodigestive NOS)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Upper airway NOS)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Urinary tract NOS)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Wound)
Blood Magnesium Decreased
(Magnesium, serum-low
(hypomagnesemia))
Mucositis/stomatitis (clinical Exam)
(Mucositis/stomatitis (clinical exam) -
Oral cavity)
Stomatitis (Mucositis/stomatitis (clinical
exam) - Pharynx)
Mucositis/stomatitis
(functional/symptomatic)
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(Mucositis/stomatitis
(functional/symptomatic) - Oral cavity)
Mucositis/stomatitis
(functional/symptomatic)
(Mucositis/stomatitis
(functional/symptomatic) - Pharynx)
Nausea (Nausea)
Neutropenia (Neutrophils/granulocytes
(ANC/AGC))
Platelet Count Decreased (Platelets)
Pneumonitis Nos
(Pneumonitis/pulmonary infiltrates)
Thrombotic Microangiopathy (e.g.,
Thrombotic Thrombocytopenic
Purpura[ttp] Or Hemolytic Uremic
Syndrome[hus]) (Thrombotic
microangiopathy (e.g., thrombotic
thrombocytopenic purpura or hemolytic
uremic syndrome))
Vomiting Nos (Vomiting)
CTC Adverse Event Term (NOTE: Permission
given to maintain these 2 non-CTC valid values
because approval given previously-DO NOT use
for future protocols)
Laryngopharngeal Dysesthesias
(Laryngopharyngeal Dysesthesias)
Paresthesias/dysesthesias
(Paresthesias/dysesthesias)
Other
MedDRA Code (v.6.0)
CTC Adverse Event Grade (Report the Highest
Grade only report Grades listed below)
Adverse Event (Second Cycle of
Reporting Period)
Current Treatment Arm
Cycle Number
Assessment Date (Date patient evaluated for
adverse events this cycle mm dd yyyy)
Are all adverse event grades less than those
required for reporting as listed below (If so, skip
rest of form.)
Yes
No
CTC Adverse Event Term
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Myocardial Ischaemia (Cardiac
ischemia/infarction)
Cough (Cough)
Diarrhoea Nos (Diarrhea)
Dyspnoea Nos (Dyspnea (shortness of
breath))
Febrile Neutropenia (fever Of Unknown
Origin Without Clinically Or
Microbiologically Documented Infection)
(anc <1.0 X 10^9/l, Fever >=38.5
Degrees C) (Febrile neutropenia)
Hypoxia (Hypoxia)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Abdomen NOS)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Biliary tree)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Bladder (urinary))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Catheter-related)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Colon)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Kidney)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Lung (pneumonia))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Pelvis NOS)
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Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Pleura (empyema))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Skin (cellulitis))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Upper aerodigestive NOS)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Upper airway NOS)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Urinary tract NOS)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Wound)
Blood Magnesium Decreased
(Magnesium, serum-low
(hypomagnesemia))
Mucositis/stomatitis (clinical Exam)
(Mucositis/stomatitis (clinical exam) -
Oral cavity)
Stomatitis (Mucositis/stomatitis (clinical
exam) - Pharynx)
Mucositis/stomatitis
(functional/symptomatic)
(Mucositis/stomatitis
(functional/symptomatic) - Oral cavity)
Mucositis/stomatitis
(functional/symptomatic)
(Mucositis/stomatitis
(functional/symptomatic) - Pharynx)
Nausea (Nausea)
Neutropenia (Neutrophils/granulocytes
(ANC/AGC))
Platelet Count Decreased (Platelets)
Pneumonitis Nos
(Pneumonitis/pulmonary infiltrates)
Thrombotic Microangiopathy (e.g.,
Thrombotic Thrombocytopenic
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Purpura[ttp] Or Hemolytic Uremic
Syndrome[hus]) (Thrombotic
microangiopathy (e.g., thrombotic
thrombocytopenic purpura or hemolytic
uremic syndrome))
Vomiting Nos (Vomiting)
CTC Adverse Event Term (NOTE: Permission
given to maintain these 2 non-CTC valid values
because approval given previously-DO NOT use
for future protocols)
Laryngopharngeal Dysesthesias
(Laryngopharyngeal Dysesthesias)
Paresthesias/dysesthesias
(Paresthesias/dysesthesias)
Other
MedDRA Code (v.6.0)
CTC Adverse Event Grade (Report the Highest
Grade only report Grades listed below)
Comments
Comments
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NCI Coop Group Colorectal Ca Toxicity
Form - Summary NCT00079274
NCI Cooperative Group Colorectal Cancer - Toxicity Form -
Summary NCT00079274
Comparison of Combination Chemotherapy Regimens With
or Without Cetuximab in Treating Patients Who Have
Undergone Surgery For Stage III Colon Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=DFCFE73F-
F995-164B-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/11462
NCI Coop Group Colorectal Ca
Toxicity Form - Summary
NCT00079274
Header
Coordinating Group Protocol Number
Coordinating Group Code
Protocol Title
Patient Study ID
Patient Medical Record Number
Patient Initials (L, FM)
Participating Group Code (Cooperative Group
where credit will be applied)
Institution Name (treating location/performance
site)
Are data amended? (If data are amended, please
circle in red when using paper form)
Yes
No
Adverse Events
Date last protocol therapy was given (Date
patient evaluated for adverse events this cycle
mm dd yyyy)
Are all adverse event grades less than those
required for reporting as listed below (If so, skip
rest of form.)
Yes
No
CTC Adverse Event Term
Myocardial Ischaemia (Cardiac
ischemia/infarction)
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Cough (Cough)
Diarrhoea Nos (Diarrhea)
Dyspnoea Nos (Dyspnea (shortness of
breath))
Febrile Neutropenia (fever Of Unknown
Origin Without Clinically Or
Microbiologically Documented Infection)
(anc <1.0 X 10^9/l, Fever >=38.5
Degrees C) (Febrile neutropenia)
Hypoxia (Hypoxia)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Abdomen NOS)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Biliary tree)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Bladder (urinary))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Catheter-related)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Colon)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Kidney)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Lung (pneumonia))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Pelvis NOS)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
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Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Pleura (empyema))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Skin (cellulitis))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Upper aerodigestive NOS)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Upper airway NOS)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Urinary tract NOS)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Wound)
Blood Magnesium Decreased
(Magnesium, serum-low
(hypomagnesemia))
Mucositis/stomatitis (clinical Exam)
(Mucositis/stomatitis (clinical exam) -
Oral cavity)
Stomatitis (Mucositis/stomatitis (clinical
exam) - Pharynx)
Mucositis/stomatitis
(functional/symptomatic)
(Mucositis/stomatitis
(functional/symptomatic) - Oral cavity)
Mucositis/stomatitis
(functional/symptomatic)
(Mucositis/stomatitis
(functional/symptomatic) - Pharynx)
Nausea (Nausea)
Neutropenia (Neutrophils/granulocytes
(ANC/AGC))
Platelet Count Decreased (Platelets)
Pneumonitis Nos
(Pneumonitis/pulmonary infiltrates)
Thrombotic Microangiopathy (e.g.,
Thrombotic Thrombocytopenic
Purpura[ttp] Or Hemolytic Uremic
Syndrome[hus]) (Thrombotic
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microangiopathy (e.g., thrombotic
thrombocytopenic purpura or hemolytic
uremic syndrome))
Vomiting Nos (Vomiting)
CTC Adverse Event Term (NOTE: Permission
given to maintain these 2 non-CTC valid values
because approval given previously-DO NOT use
for future protocols)
Laryngopharngeal Dysesthesias
(Laryngopharyngeal Dysesthesias)
Paresthesias/dysesthesias
(Paresthesias/dysesthesias)
Other
MedDRA Code (v.6.0)
CTC Adverse Event Grade (Report the Highest
Grade only report Grades listed below)
Comments
Comments
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ADVL0212: Secondary Malignancy Report
Worksheet NCT00053963
ADVL0212: Secondary Malignancy Report Worksheet
NCT00053963 
FR901228 in Treating Children With Refractory or
Recurrent Solid Tumors or Leukemia
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=B1EADE06-
A88A-30BB-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/11463
ADVL0212: Secondary Malignancy
Report Worksheet NCT00053963
Header
Institution Name
Study Number
Study Number
COG Number
Patient's Initials
Date worksheet entered into RDE
Secondary Malignancy
Date of diagnosis of secondary malignancy (1.
Required field)
Diagnosis (Morphology)
Diagnosis ICD-O code (Morphology)
Primary site (Topography)
Primary site ICD-O code (Topography)
Comments
Ccrr Module For Advl0212: Secondary
Malignancy Report Worksheet
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SOUTHWEST ONCOLOGY GROUP
S0303 FOLLOW UP FORM NCT00070122
SOUTHWEST ONCOLOGY GROUP S0303 FOLLOW UP
FORM NCT00070122
Combination Chemotherapy and Bevacizumab in Treating
Patients With Locally Advanced, Metastatic, or Recurrent
Colorectal Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=BC72229E-
9073-416E-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/11464
SOUTHWEST ONCOLOGY GROUP
S0303 FOLLOW UP FORM
NCT00070122
Header
SWOG Patient ID
SWOG Study No.
Registration Step
Patient Initials (L, F M)
Institution/Affiliate
Physician (Groups other than SWOG)
Group Name
Study No.
Pt. ID
Vital Status
Vital Status
Alive (Alive)
Dead (Dead)
Date of last contact or death
Disease Follow Up Status
Has the patient had a documented clinical
assessment for this cancer since submission of
the previous follow-up form?
Yes
No
Date of Last Clinical Assessment (If Yes)
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Notice Of First Relapse Or Progression
Has the patient developed a first relapse or
progression that has not been previously
reported
Yes
No
Date of Relapse or Progression
Site(s) of Relapse or Progression
Notice Of New Primary
Has a new primary cancer or myelodysplastic
syndrome (MDS) been diagnosed that has not
been previously reported?
Yes
No
Date of Diagnosis (If Yes)
New Primary Site
Non-protocol Treatment
Has the patient received any non-protocol cancer
therapy not previously reported?
Yes
No
Date of First Non-Protocol Therapy
Agents
Long Term Toxicity
Has the patient experienced (prior to treatment
for progression or relapse or a second primary,
and prior to non-protocol treatment) any severe
(grade >= 3) long term toxicity that has not been
previously reported?
Yes
No
Toxicities and Grades
Comments
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SOUTHWEST ONCOLOGY GROUP S0303 FOLLOW UP FORM
NCT00070122
Notes
Ccrr Module For Southwest Oncology
Group S0303 Follow Up Form
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SOUTHWEST ONCOLOGY GROUP S0303 FOLLOW UP FORM
NCT00070122
ADVL0212: Prior Therapy Worksheet
NCT00053963
ADVL0212: Prior Therapy Worksheet NCT00053963 
FR901228 in Treating Children With Refractory or
Recurrent Solid Tumors or Leukemia
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=B1EADAE4-
318A-307A-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/11465
ADVL0212: Prior Therapy Worksheet
NCT00053963
Header
Institution Name
Study Number
Study Number
COG Number
Patient's Initials
Date worksheet entered into RDE
Anti-cancer therapy
Did the patient have anti-cancer therapy prior to
enrollment on this study? (1. Required field)
Yes
No
Type Of Prior Therapy
Type
Start Date (MM/DD/YYYY)
End Date (MM/DD/YYYY)
Description (agent, dose, etc.)
Comments
Comments
General Validations
1 / 2
Ccrr Module For Advl0212: Prior Therapy
Worksheet
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NCT00070122 Southwest Oncology Group Cover
Sheet for Patient Completed Questionnaires: S0303
NCT00070122 Southwest Oncology Group Cover Sheet for
Patient Completed Questionnaires: S0303
Combination Chemotherapy and Bevacizumab in Treating
Patients With Locally Advanced, Metastatic, or Recurrent
Colorectal Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=BC61FBE6-
1957-10AE-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/11466
NCT00070122 Southwest Oncology
Group Cover Sheet for Patient
Completed Questionnaires: S0303
SWOG clinical trial miscellaneous patient
information
SWOG Patient ID
SWOG Study No.
Planned Assessment
Prestudy (Prestudy)
Week 13 (Week 13)
Week 7 (Week 7)
Registration Step
Patient Initials (L, F M)
Institution/Affiliate
Physician of Record
Date form originally completed
Group Name
Study No.
Pt. ID
Amended Data
Yes (Yes)
Was the FACT-C TOI completed?
Yes
No
Was the chemotherapy convenience and
satisfaction questionnaire completed?
Yes
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No
Date completed
Date completed
In general, did the patient require assistance?
Yes
No
If yes, describe (assistance to patient)
Questionnaire administered
By Telephone (by telephone)
In The Clinic (in the clinic)
Other (other)
Other (please specifyquestionnaire administered)
If not completed, please give reason
Death (death)
Illness/deteriorating Health
(illness/deteriorating health)
Institution Error (institution error)
Not Illness Related (not illness related)
Other (other)
Person completing form, last name
Person completing form, phone
Comments
Ccrr Module For Southwest Oncology
Group Cover Sheet For Patient Completed
Questionnaires: S0303
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NCT00070122 Southwest Oncology Group Cover Sheet for Patient
Completed Questionnaires: S0303
Southwest Oncology Group S0600 Baseline
Abnormalities Form NCT00499369
Southwest Oncology Group S0600 Baseline Abnormalities
Form NCT00499369
Irinotecan and Cetuximab With or Without Bevacizumab in
Treating Patients With Metastatic Colorectal Cancer That
Progressed During First-Line Therapy
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=15416480-
968A-679D-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11467
Southwest Oncology Group S0600
Baseline Abnormalities Form
NCT00499369
Header
SWOG Patient ID
SWOG Study No.
Registration Step
Patient Initials (L, F M)
Institution/Affiliate
Physician (Participating Group)
Participating Group Name
Participating Group Study No.
Participating Group Patient ID
Adverse event assessment
CTC Adverse Event  Term (Pre-treatment)
Blood Alkaline Phosphatase Nos
Increased (Alkaline phosphatase)
Alanine Aminotransferase Increased
(ALT, SGPT (serum glutamic pyruvic
transaminase))
Anorexia (Anorexia)
Aspartate Aminotransferase Increased
(AST, SGOT (serum glutamic oxaloacetic
transaminase))
Ataxia Nec (Ataxia (incoordination))
Blood Bilirubin Increased (Bilirubin
(hyperbilirubinemia))
Bronchospasm, Wheezing
(Bronchospasm, wheezing)
Myocardial Ischaemia (Cardiac
ischemia/infarction)
Cardiac Troponin I Increased (Cardiac
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troponin I (cTnI))
Cerebral Ischaemia (CNS
cerebrovascular ischemia)
Colitis Nos (Colitis)
Constipation (Constipation)
Cough (Cough)
Blood Creatinine Increased (Creatinine)
Cytokine Release Syndrome/acute
Infusion Reaction (Cytokine release
syndrome/acute infusion reaction)
Dehydration (Dehydration)
Diarrhoea Nos (Diarrhea)
Dizziness (exc Vertigo) (Dizziness)
Dyspnoea Nos (Dyspnea)
Fatigue (Fatigue)
Pyrexia (Fever)
Dyspepsia (Heartburn/dyspepsia)
Haemoglobin Decreased (Hemoglobin)
Haemorrhagic Stroke (Hemorrhage,
CNS)
Melaena (Hemorrhage, GI - Abdomen
NOS)
Hemorrhage, Gi (Hemorrhage, GI -
Colon)
Hemorrhage, Gi (Hemorrhage, GI -
Lower GI NOS)
Rectal Bleeding (Hemorrhage, GI -
Rectum)
Hemorrhage, Gi (Hemorrhage, GI -
Upper GI NOS)
Hemorrhage, Pulmonary/upper
Respiratory (Hemorrhage,
pulmonary/upper respiratory - Lung)
Epistaxis (Hemorrhage, pulmonary/upper
respiratory - Nose)
Hypertension Nos (Hypertension)
Hypotension Nos (Hypotension)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Abdomen
NOS)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Colon)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Lung
(pneumonia))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Pleura
(empyema))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Rectum)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Small bowel
NOS)
Leak (including Anastomotic), Gi (Leak
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Southwest Oncology Group S0600 Baseline Abnormalities Form
NCT00499369
(including anastomotic), GI - Large
bowel)
Left Ventricular Diastolic Dysfunction
(Left ventricular diastolic dysfunction)
Left Ventricular Failure (Left ventricular
systolic dysfunction)
Leucopenia Nos (Leukocytes (total
WBC))
Nasal Cavity/paranasal Sinus Reactions
(Nasal cavity/paranasal sinus reactions)
Nausea (Nausea)
Peripheral Sensory Neuropathy
(Neuropathy - sensory)
Neutropenia (Neutrophils/granulocytes)
Abdominal Pain Nos (Pain - Abdomen
NOS)
Pain (Pain - Back)
Chest Pain (Pain - Chest/thorax NOS)
Headache Nos (Pain - Head/headache)
Arthralgia (Pain - Joint)
Myalgia (Pain - Muscle)
Proteinuria Present (Proteinuria)
Renal Failure Nos (Renal failure)
Rigors (Rigors/chills)
Speech Disorder Nec (Speech
impairment (e.g., dysphasia or aphasia))
Supraventricular Arrhythmia Nos
(Supraventricular and nodal arrhythmia -
Supraventricular arrhythmia NOS)
Thrombosis Nos
(Thrombosis/thrombus/embolism)
Ventricular Arrhythmia (Ventricular
arrhythmia - Ventricular fibrillation)
Visceral Arterial Ischaemia (Visceral
arterial ischemia (non-myocardial))
Vision Blurred (Vision-blurred vision)
Dysphonia (Voice changes/dysarthria
(e.g., hoarseness, loss or alteration in
voice, laryngitis))
Vomiting Nos (Vomiting)
Weight Decreased (Weight loss)
CTC AE Grade (3.0 1-4)
CTC Adverse Event Term, Other (pre-treatment
specify using CTCAE 3.0 terminology)
Comments
Comments
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NCT00499369
S0502 Baseline Abnormalities Form
NCT00324987
S0502 Baseline Abnormalities Form NCT00324987 
S0502 Imatinib Mesylate With or Without Bevacizumab in
Treating Patients With Metastatic or Unresectable
Gastrointestinal Stromal Tumor
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=FCBF779E-
AB7C-7258-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11468
S0502 Baseline Abnormalities Form
NCT00324987
Header
SWOG Patient ID
SWOG Study No.
Registration Step
Patient Initials (L, F M)
Institution/Affiliate
Physician
Participating Group Name
Participating Group Study No.
Participating Group Patient ID
Adverse event assessment
CTC Adverse Event Term (Pre-Treatment)
Blood Alkaline Phosphatase Nos
Increased (Alkaline phosphatase)
Alanine Aminotransferase Increased
(ALT, SGPT (serum glutamic pyruvic
transaminase))
Anorexia (Anorexia)
Aspartate Aminotransferase Increased
(AST, SGOT (serum glutamic oxaloacetic
transaminase))
Blood Bilirubin Increased (Bilirubin
(hyperbilirubinemia))
Blood Creatinine Increased (Creatinine)
Diarrhoea Nos (Diarrhea)
Fatigue (Fatigue (asthenia, lethargy,
malaise))
Febrile Neutropenia (fever Of Unknown
Origin Without Clinically Or
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Microbiologically Documented Infection)
(anc <1.0 X 10^9/l, Fever >=38.5
Degrees C) (Febrile neutropenia)
Pyrexia (Fever (in the absence of
neutropenia, where neutropenia is
defined as ANC <1.0 x 10^9/L))
Flatulence (Flatulence)
Dyspepsia (Heartburn/dyspepsia)
Haemoglobin Decreased (Hemoglobin)
Haemorrhagic Stroke (Hemorrhage,
CNS)
Hemorrhage, Gi (Hemorrhage, GI - Liver)
Hemorrhage, Gi (Hemorrhage, GI -
Lower GI NOS)
Haematemesis (Hemorrhage, GI -
Stomach)
Hemorrhage, Gi (Hemorrhage, GI -
Upper GI NOS)
Haemoptysis (Hemorrhage,
pulmonary/upper respiratory -
Respiratory tract NOS)
Hemorrhage, Pulmonary/upper
Respiratory (Hemorrhage,
pulmonary/upper respiratory - Trachea)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Abdomen
NOS)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils -
Anal/perianal)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Bladder
(urinary))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Cecum)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Colon)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Duodenum)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Esophagus)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Ileum)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Jejunum)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Kidney)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Larynx)
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Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Liver)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Lung
(pneumonia))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils -
Mediastinum NOS)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Mucosa)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Oral cavity-
gums (gingivitis))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Peritoneal
cavity)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Small bowel
NOS)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Soft tissue
NOS)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Stomach)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Trachea)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Upper
aerodigestive NOS)
Infection With Unknown Anc (Infection
with unknown ANC - Bladder (urinary))
Infection With Unknown Anc (Infection
with unknown ANC - Bronchus)
Infection With Unknown Anc (Infection
with unknown ANC - Colon)
Infection With Unknown Anc (Infection
with unknown ANC - Esophagus)
Infection With Unknown Anc (Infection
with unknown ANC - Lung (pneumonia))
Infection With Unknown Anc (Infection
with unknown ANC - Oral cavity-gums
(gingivitis))
Infection With Unknown Anc (Infection
with unknown ANC - Sinus)
Leucopenia Nos (Leukocytes (total
WBC))
Lymphopenia (Lymphopenia)
Mucositis/stomatitis (clinical Exam)
(Mucositis/stomatitis (clinical exam) -
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Oral cavity)
Nausea (Nausea)
Neutropenia (Neutrophils/granulocytes
(ANC/AGC))
Headache Nos (Pain - Head/headache)
Myalgia (Pain - Muscle)
Platelet Count Decreased (Platelets)
Proteinuria Present (Proteinuria)
Dermatitis Exfoliative Nos
(Rash/desquamation)
Rigors (Rigors/chills)
Thrombosis Nos
(Thrombosis/thrombus/embolism)
Vomiting Nos (Vomiting)
Weight Increased (Weight gain)
CTC AE Grade (3.0 1-4)
CTC Adverse Event Term Other (pre-treatment
specify using CTCAE 3.0 terminology)
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NCT00087178  NSABP Protocol B-36 Missing
Data Form for Quality of Life Questionnaire
NCT00087178  NSABP Protocol B-36 Missing Data Form
for Quality of Life Questionnaire
Comparison of Two Combination Chemotherapy Regimens
in Treating Women With Breast Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=C8CBE2C5-
1EEF-3461-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/11470
NCT00087178  NSABP Protocol B-
36 Missing Data Form for Quality of
Life Questionnaire
Header
Patient Initials (Last, First Middle)
NSABP Patient ID
Institution Name
Affiliate Name
Person Completing Form (First Name)
Person Completing Form (First Name)
Person Completing Form (Phone)
Today's Date (Month Day Year)
Are data amended?
Yes
No
Missing Data Form for Quality of Life
Questionnaire
Time Point for this Form (mark one)
12 month follow-up (12 month follow-up)
18 month follow-up (18 month follow-up)
24 month follow-up (24 month follow-up)
30 month follow-up (30 month follow-up)
36 month follow-up (36 month follow-up)
42 month follow-up (42 month follow-up)
6 month follow-up (6 month follow-up)
Day 1 of Cycle #4 (Day 1 of Cycle #4)
Form(s) missing (mark one or both)
MH-F (MH-F)
QOL (QOL)
Reason QOL/MH-F was Not Obtained by Phone
or Mail (Mark all that apply and add comments
1 / 2
below.)
Other (specify) (Other (specify))
Patient refused to complete
questionnaire (Patient refused to
complete questionnaire)
Questionnaire was mailed to patient but
she did not return it (Questionnaire was
mailed to patient but she did not return it)
Staff oversight or understaffing (Staff
oversight or understaffing)
Staff was unable to contact patient by
phone (Staff was unable to contact
patient by phone)
Reason QOL/MH-F was Not Obtained by Phone
or Mail (Mark all that apply and add comments
below.)
Other (specify) (Other (specify))
Patient refused to complete
questionnaire (Patient refused to
complete questionnaire)
Questionnaire was mailed to patient but
she did not return it (Questionnaire was
mailed to patient but she did not return it)
Staff oversight or understaffing (Staff
oversight or understaffing)
Staff was unable to contact patient by
phone (Staff was unable to contact
patient by phone)
Other (specify)
Other (specify)
Comments
Comments
Ccrr Module For Nsabp Protocol B-36
Missing Data Form For Quality Of Life
Questionnaire
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NSABP Protocol B-38Radiation Therapy
Report - Form E1 NCT00093795
NSABP Protocol B-38Radiation Therapy Report - Form E1
NCT00093795
Combination Chemotherapy in Treating Women Who Have
Undergone Surgery for Node-Positive Breast Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=DADAB169-
7D18-68F8-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/11471
NSABP Protocol B-38Radiation
Therapy Report - Form E1
NCT00093795
Patient demographics
Was the patient enrolled in NSABP Protocol B-
39/RTOG 0413?
Yes
No
NSABP Patient ID (B-39 if applicable)
Patient Initials
Institution Name
Affiliate Name
Person completing Form, Last Name
Person completing Form, First Name
Person completing Form, Phone
Are data amended?
Yes
No
Has the patient received adjuvant RT?
Yes
No
Adjuvant RT Begin Date
Adjuvant RT End Date
If Post-lumpectomy: Whole Breast
Irradiation
Breast Irradiated
Left (Left)
Right (Right)
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Therapy Received
Chest Wall Rt (Chest Wall RT)
Regional Rt (Regional RT)
RT Total Chest Wall Dose
Was RT interrupted for more than one week?
Yes
No
If Post-lumpectomy: Chest Wall Irradiation
Side Irradiated
1 (Left)
2 (Right)
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NCT00093795
NSABP Protocol B-40 - Postoperative
Adjuvant Treatments NCT00408408
NSABP Protocol B-40 - Postoperative Adjuvant Treatments
NCT00408408
A Randomized Phase III Trial of Neoadjuvant Therapy in
Patients With Palpable and Operable Breast Cancer
Evaluating the Effect on Pathologic Complete Response
(pCR) of Adding Capecitabine or Gemcitabine to Docetaxel
When Administered Before AC With or Without
Bevacizumab and Correlative Science Studies Attempting
to Identify Predictors of High Likelihood for pCR With Each
of the Regimens
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=1B7DA758-
8A3B-186C-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11472
NSABP Protocol B-40 -
Postoperative Adjuvant Treatments
NCT00408408
Header
Patient Initials (Last First Middle)
NSABP Patient ID
Person Completing Form
Institution/Affiliate
Person Completing Form, Last Name
Person Completing Form, First Name
Person Completing Form, Phone
Date Form Completed
Are data amended
Yes
No
Postoperative Radiation Therapy (RT)
Post-lumpectomy breast RT
Yes
No
Post-mastectomy chest wall RT
Yes
No
Regional nodal RT
Yes
No
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Postoperative Systemic Adjuvant Therapy
Postoperative Adjuvant Hormonal Therapy
Yes
No
Postoperative Bevacizumab
Yes
No
Postoperative Trastuzumab
Yes
No
Postoperative Chemotherapy
Yes
No
Other
Yes
No
Specify (If yes)
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NCT00936390  RTOG 0815 F0: Radiation Therapy Oncology Group Phase III
Randomized Study of Dose- Escalated Radiotherapy With/Without STAD for
Intermediate-Risk Prostate Cancer Initial Follow-up Form
NCT00936390  RTOG 0815 F0: Radiation Therapy
Oncology Group Phase III Randomized Study of Dose-
Escalated Radiotherapy With/Without STAD for
Intermediate-Risk Prostate Cancer Initial Follow-up Form
Radiation Therapy With or Without Androgen-Deprivation
Therapy in Treating Patients With Prostate Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=655253E9-
5F19-860D-E040-BB89AD434872
All rights reserved. Please visit https://medical-data-
models.org/forms/11473
NCT00936390  RTOG 0815 F0:
Radiation Therapy Oncology Group
Phase III Randomized Study of
Dose- Escalated Radiotherapy
With/Without STAD for Intermediate-
Risk Prostate Cancer Initial Follow-
up Form
Header
RTOG Study No.
Case #
Institution Name
Institution No.
Patient Initials
RTOG Patient ID
Amended Data
Yes
No
Vital status
Patient's Vital Status
Alive (Alive)
Dead (Dead)
Date of Last Contact or Death
Primary Cause of Death
Due To Other Cause (Due to other
cause)
Due To Protocol Treatment (Due to
protocol treatment)
Due To This Disease (Due to this
disease)
Not Applicable (Not applicable)
Unknown (Unknown)
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Due to other cause, specify
Has the patient had a documented clinical
assessment for this cancer (SINCE
SUBMISSION OF THE PREVIOUS FOLLOW-UP
FORM)
No (No)
Unknown (Unknown)
Yes (Yes)
Date
Performance Status
Fully Active, Able To Carry On All Pre-
disease Performance Without
Restriction. (0)
Restricted In Physically Strenuous
Activity But Ambulatory And Able To
Carry Out Work Of A Light Or Sedentary
Nature, E.g., Light Housework, Office
Work. (1)
Ambulatory And Capable Of All Selfcare
But Unable To Carry Out Any Work
Activities. Up And About More Than 50%
Of Waking Hours. (2)
Capable Of Only Limited Selfcare,
Confined To Bed Or Chair More Than
50% Of Waking Hours. (3)
Completely Disabled. Cannot Carry On
Any Selfcare. Totally Confined To Bed Or
Chair. (4)
Dead (5)
Prostate Biopsy
Has the patient had a prostate biopsy (SINCE
SUBMISSION OF THE LAST FOLLOW-UP
FORM)
No (No)
Unknown (Unknown)
Yes, Negative (Yes, negative)
Yes, Positive (Yes, positive)
Yes, Results Unknown (Yes, results
unknown)
Biopsy Date
Is the tumor palpable
Equivocal (Equivocal)
No (No)
Not Evaluated (Not evaluated)
Unknown (Unknown)
Yes (Yes)
Neoplasm recurrence
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NCT00936390  RTOG 0815 F0: Radiation Therapy Oncology Group Phase III
Randomized Study of Dose- Escalated Radiotherapy With/Without STAD for
Intermediate-Risk Prostate Cancer Initial Follow-up Form
Has the patient been diagnosed with biochemical
recurrence since submission of the last follow-up
form
No (NO)
Unknown (Unknown)
Yes (YES)
Has the patient been diagnosed with a first local
recurrence (SINCE SUBMISSION OF LAST
FOLLOW-UP FORM See Protocol Section 11)
No (NO)
Unknown (Unknown)
Yes (YES)
Date
Method of Evaluation (DISTANT
PROGRESSION)
Mri (MRI (NMR))
Not Applicable (Not applicable)
Other (Other)
Pathologic (Pathologic)
Physical Exam (Physical exam)
Radiographic (Radiographic)
Other Specify
Has the patient been diagnosed with first distant
progression (SINCE SUBMISSION OF THE
LAST FOLLOW-UP FORM)
No (No)
Unknown (Unknown)
Yes (Yes)
Date
Sites of Progression (First distant)
PROSTATE: PSA MEASUREMENTS
PSA Date
PSA Value
ng/ml
Units
Nanograms Per Deciliter (ng/dL)
Nanograms Per Milliliter (ng/mL)
Nanomoles Per Liter (nmol/l)
Not Otherwise Specified (NOS)
Method of Assay
Abbott Labs (Abbott)
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Bayer (Bayer)
Dpc (DPC)
Hybritech (Hybritech)
Other (Other)
Unknown (Unknown)
Treatment Schedule (lhrh Agonist)
Is patient on protocol hormone (ORAL
ANTIANDROGEN)
Yes
No
LHRH agonist
Eligard (Eligard)
Lupron (Lupron)
Other (Other)
Viadur (Viadur)
Zoladex (Zoladex)
Other, specify
LHRH agonist start date (IF STARTED IN THIS
FOLLOW-UP PERIOD)
LHRH agonist end date (IF TERMINATED IN
THIS FOLLOW-UP PERIOD)
Reason Treatment Ended
Adverse Event/side Effects/complications
(Adverse Event/Side
Effects/Complications)
Alternative Therapy (Alternative therapy)
Death On Study (Death on study)
Disease Progression, Relapse During
Active Treatment (Disease progression,
relapse during active treatment)
Other (Other)
Patient Off-treatment For Other
Complicating Disease (Patient off-
treatment for other complicating disease)
Patient Withdrawal Or Refusal After
Beginning Protocol Therapy (Patient
withdrawal/refusal after beginning
protocol therapy)
Patient Withdrawal Or Refusal Before
Beginning Protocol Therapy (Patient
withdrawal/refusal prior to beginning
protocol therapy)
Treatment Completed Per Protocol
Criteria (Treatment completed per
protocol criteria)
Alternative Therapy, Specify
Patient off-treatment for other complicating
disease, specify
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Other specify
Total Dose (TO DATE)
Treatment Schedule (oral Antiandrogen)
Oral antiandrogen taken
Casodex (Casodex)
Eulexin (Eulexin)
Other (Other)
Other, specify
Oral Antiandrogen Start Date (IF STARTED IN
THIS FOLLOW-UP PERIOD)
Oral Antiandrogen End Date (IF TERMINATED IN
THIS FOLLOW-UP PERIOD)
Lab Values
Lab Values (Month 3)
Abnormal (Abnormal)
Normal (Normal)
Not Done (Not done)
Unknown (Unknown)
Testosterone
ng/dl
Date
Testosterone Lower Limit Normal
Testosterone Upper Limit Normal
Lab Values
Baseline Lab Values (hematologic)
WBC (mm^3)
Hemoglobin (g/dL)
g/dL
Peripheral Platelet Count (x 10^3 U/L)
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1000/uL
ANC (mm^3)
Date
Baseline Lab Values (hematologic)
Test (Month 3)
Value
Baseline Lab Values (hematologic)
Non-protocol Therapy
Is the patient receiving any non-protocol cancer
therapy not previously reported (PROSTATE If
yes, enter therapy type and date for each therapy
delivered during the follow-up period.)
No (No)
Unknown (Unknown)
Yes (Yes)
Non-Protocol Therapy Type
Chemotherapy (Chemotherapy)
Hormones (Hormones)
None (None)
Other Specify (Other, specify)
Radiation To Other Sites, Specify
(Radiation to other sites, specify)
Radiation To Pelvis (Radiation to pelvis)
Surgery (Surgery)
Date of First Non-Protocol Therapy
Specify
Primary cancer
Has a new primary cancer or MDS been
diagnosed that has not been previously reported
No (No)
Unknown (Unknown)
Yes (Yes)
Second Primary Tumor Site
Aml/mds (AML/MDS)
Bcc (BCC)
Bladder Is The Site Of Second Primary
Or Recurrent Tumor (bladder)
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Brain Is The Site Of Second Primary Or
Recurrent Tumor (brain)
Colorectal (Colorectal)
Esophageal (Esophageal)
Gastric (Gastric)
Liver Is The Site Of Second Primary Or
Recurrent Tumor (liver)
Lung Is The Site Of Second Primary Or
Recurrent Tumor (lung)
Melanoma (Melanoma)
Nhl (NHL)
Other Hematologic (Other hematologic)
Other Solid (Other solid)
Pancreatic (Pancreatic)
Renal (Renal)
Squamous-skin (Squamous-skin)
Unknown Primary (Unknown primary)
Second Primary Cancer Date
Other specify
Protocol Specific Adverse Event
Evaluation
Any Treatment Related Adverse Events
No (No)
Unknown (Unknown)
Yes (Yes)
MedDRA disease code
CTC Adverse Event Term
Retinoic Acid Syndrome ("Retinoic acid
syndrome")
Acidosis Nos (Acidosis)
Rash: Acne/acneiform (Acne)
Neuroendocrine: Acth Deficiency (ACTH)
Capillary Leak Syndrome (Acute
vascular leak syndrome)
Inappropriate Adh Secretion (ADH)
Adrenal Insufficiency (Adrenal
insufficiency)
Obstruction/stenosis Of Airway (Airway
obstruction - Select)
Alcohol Intolerance Syndrome
(antabuse-like Syndrome) (Alcohol
intolerance syndrome)
Blood Alkaline Phosphatase Nos
Increased (Alkaline phosphatase)
Alkalosis Nos (Alkalosis)
Hypersensitivity Nos (Allergic reaction)
Allergy/immunology Other (Allergy-Other
(Specify))
Alopecia (Alopecia)
Alanine Aminotransferase Increased
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(ALT)
Blood Amylase Increased (Amylase)
Anorexia (Anorexia)
Apnoea (Apnea)
Arachnoiditis (Arachnoiditis)
Adult Respiratory Distress Syndrome
(ARDS)
Vessel Injury-artery (Artery injury -
Select)
Arthritis Nos (Arthritis)
Ascites (Ascites)
Aspiration (Aspiration)
Aspartate Aminotransferase Increased
(AST)
Ataxia Nec (Ataxia)
Atelectasis (Atelectasis)
Atrophy, Skin (Atrophy, skin)
Atrophy, Subcutaneous Fat (Atrophy,
subcutaneous fat)
Auditory/ear Other (Auditory/Ear-Other
(Specify))
Autoimmune Disorder Nos (Autoimmune
reaction)
Blood Bicarbonate Decreased
(Bicarbonate, serum-low)
Blood Bilirubin Increased (Bilirubin)
Bladder Disorder Nos (Bladder spasms)
Blood/bone Marrow Other (Blood-Other
(Specify))
Vision Blurred (Blurred vision)
Bone Age (alteration In Bone Age) (Bone
age)
Bone Marrow Depression Nos (Bone
marrow cellularity)
Brachial Plexopathy (Brachial
plexopathy)
Breast Volume/hypoplasia (Breast)
Breast Function/lactation (Breast
function)
Bronchospasm, Wheezing
(Bronchospasm)
Ecchymosis (Bruising)
Burn (Burn)
Arrhythmia Nos (Cardiac Arrhythmia-
Other (Specify))
Cardiac General Other (Cardiac
General-Other (Specify))
Myocardial Ischaemia (Cardiac
ischemia/infarction)
Cardiopulmonary Arrest, Cause
Unknown (non-fatal) (Cardiopulmonary
arrest)
Cataract Nec (Cataract)
Cd4 Lymphocytes Decreased (CD4
count)
Cervical Spine-range Of Motion (Cervical
spine ROM)
Cheilitis (Cheilitis)
Prolonged Chest Tube Drainage Or Air
Leak After Pulmonary Resection (Chest
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tube drainage or leak)
Cholecystitis (Cholecystitis)
Hypercholesterolaemia (Cholesterol)
Chyle Or Lymph Leakage (Chyle or
lymph leakage)
Chylothorax (Chylothorax)
Haemorrhagic Stroke (CNS
Hemorrhage)
Cerebral Ischaemia (CNS ischemia)
Cns Necrosis/cystic Progression (CNS
necrosis)
Coagulation Disorder Nos (Coagulation-
Other (Specify))
Learning Disorder Nos (Cognitive
disturbance)
Colitis Nos (Colitis)
Colitis, Infectious (e.g., Clostridium
Difficile) (Colitis, infectious)
Conduction Abnormality/atrioventricular
Heart Block (Conduction abnormality -
Select)
Confusion (Confusion)
Constipation (Constipation)
Constitutional Symptoms Other
(Constitutional Symptoms-Other
(Specify))
Cough (Cough)
Blood Creatine Phosphokinase
Increased (CPK)
Blood Creatinine Increased (Creatinine)
Leak, Cerebrospinal Fluid (csf) (CSF
leak)
Cardiac Troponin I Increased (cTnI)
Cardiac Troponin T Increased (cTnT)
Cushingoid (Cushingoid)
Cystitis (Cystitis)
Cytokine Release Syndrome/acute
Infusion Reaction (Cytokine release
syndrome)
Death Not Associated With Ctcae Term
(Death not associated with CTCAE term
- Select)
Skin Breakdown/decubitus Ulcer
(Decubitus)
Dehydration (Dehydration)
Puberty (delayed) (Delayed puberty)
Dental: Dentures Or Prosthesis
(Dentures)
Dermal Change Lymphedema,
Phlebolymphedema (Dermal change)
Dermatitis (Dermatitis - Select)
Dermatology/skin Other (Dermatology-
Other (Specify))
Local Complication - Device/prosthesis-
related (Device/prosthesis)
Pancreatic Endocrine: Glucose
Intolerance (Diabetes)
Diarrhoea Nos (Diarrhea)
Disseminated Intravascular Coagulation
(DIC)
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Diplopia (Diplopia)
Distention/bloating, Abdominal
(Distention)
Dizziness (exc Vertigo) (Dizziness)
Pulmonary Function Test Nos Decreased
(DL(co))
Dry Eye Nec (Dry eye)
Dry Mouth (Dry mouth)
Dry Skin (Dry skin)
Dysphagia (Dysphagia)
Dyspnoea Nos (Dyspnea)
Edema, Larynx (Edema, larynx)
Edema: Head And Neck (Edema: head
and neck)
Oedema Nos (Edema: limb)
Edema: Trunk/genital (Edema:
trunk/genital)
Edema: Viscera (Edema: viscera)
Ejaculatory Dysfunction (Ejaculatory
dysfunction)
Encephalopathy (Encephalopathy)
Endocrine Other (Endocrine-Other
(Specify))
Enteritis (inflammation Of The Small
Bowel) (Enteritis)
Impotence (Erectile dysfunction)
Erythema Multiforme (Erythema
multiforme)
Oesophagitis Nos (Esophagitis)
Exostosis (Exostosis)
Extremity-upper (function) (Extremity-
upper (function))
Eyelid Dysfunction (Eyelid dysfunction)
Fatigue (Fatigue)
Febrile Neutropenia (fever Of Unknown
Origin Without Clinically Or
Microbiologically Documented Infection)
(anc <1.0 X 10^9/l, Fever >=38.5
Degrees C) (Febrile neutropenia)
Feminization (Feminization of male)
Bone Growth: Femoral Head; Slipped
Capital Femoral Epiphysis (Femoral
head growth)
Forced Expiratory Volume Decreased
(FEV(1))
Pyrexia (Fever)
Blood Fibrinogen Decreased
(Fibrinogen)
Fibrosis-cosmesis (Fibrosis-cosmesis)
Fibrosis-deep Connective Tissue
(Fibrosis-deep connective tissue)
Fistula, Gi (Fistula, GI - Select)
Fistula, Gu (Fistula, GU - Select)
Fistula, Pulmonary/upper Respiratory
(Fistula, pulmonary - Select)
Photopsia (Flashing lights)
Flatulence (Flatulence)
Flu-like Syndrome (Flu-like syndrome)
Flushing (Flushing)
Fracture (Fracture)
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Extremity-lower (gait/walking)
(Gait/walking)
Gastritis Nos (Gastritis)
Glomerular Filtration Rate (GFR)
Gamma-glutamyltransferase Increased
(GGT)
Gastrointestinal Other (GI-Other
(Specify))
Glaucoma Nos (Glaucoma)
Neuroendocrine: Gonadotropin Secretion
Abnormality (Gonadotropin)
Growth And Development Other (Growth
and Development-Other (Specify))
Neuroendocrine: Growth Hormone
Secretion Abnormality (Growth hormone)
Gynaecomastia (Gynecomastia)
Localised Exfoliation (Hand-foot)
Haptoglobin Decreased (Haptoglobin)
Hearing: Patients With/without Baseline
Audiogram And Enrolled In A Monitoring
Program (Hearing (monitoring program))
Hearing: Patients Without Baseline
Audiogram And Not Enrolled In A
Monitoring Program (Hearing (without
monitoring program))
Dyspepsia (Heartburn)
Hematoma (Hematoma)
Haemoglobin Decreased (Hemoglobin)
Haemoglobinuria Present
(Hemoglobinuria)
Hemolysis Nos (Hemolysis)
Hemorrhage, Pulmonary/upper
Respiratory (Hemorrhage pulmonary -
Select)
Post-operative Haemorrhage
(Hemorrhage with surgery)
Hemorrhage/bleeding Other
(Hemorrhage-Other (Specify))
Hemorrhage, Gi (Hemorrhage, GI -
Select)
Hemorrhage, Gu (Hemorrhage, GU -
Select)
Hemorrhoids (Hemorrhoids)
Hepatobiliary/pancreas Other
(Hepatobiliary-Other (Specify))
Hiccups (Hiccoughs)
Menopausal Symptoms (Hot flashes)
Hydrocephalus (Hydrocephalus)
Hypercalcaemia (Hypercalcemia)
Hyperglycaemia Nos (Hyperglycemia)
Hyperkalaemia (Hyperkalemia)
Hypermagnesaemia
(Hypermagnesemia)
Hypernatraemia (Hypernatremia)
Skin Discolouration (Hyperpigmentation)
Hypertension Nos (Hypertension)
Thyroid Function, High (hyperthyroidism,
Thyrotoxicosis) (Hyperthyroidism)
Hypertriglyceridaemia
(Hypertriglyceridemia)
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Hyperuricaemia (Hyperuricemia)
Blood Albumin Decreased
(Hypoalbuminemia)
Hypocalcaemia (Hypocalcemia)
Hypoglycaemia Nos (Hypoglycemia)
Hypokalaemia (Hypokalemia)
Blood Magnesium Decreased
(Hypomagnesemia)
Hyponatraemia (Hyponatremia)
Parathyroid Function, Low
(hypoparathyroidism)
(Hypoparathyroidism)
Hypophosphataemia
(Hypophosphatemia)
Hypopigmentation (Hypopigmentation)
Hypotension Nos (Hypotension)
Hypothermia (Hypothermia)
Hypothyroidism (Hypothyroidism)
Hypoxia (Hypoxia)
Ileus (Ileus)
Urinary Incontinence (Incontinence)
Incontinence, Anal (Incontinence, anal)
Induration/fibrosis (skin And
Subcutaneous Tissue) (Induration)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically) - Select)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
- Select)
Infection With Unknown Anc (Infection
with unknown ANC - Select)
Infection Nos (Infection-Other (Specify))
Infertility/sterility (Infertility/sterility)
Injection Site Reaction Nos (Injection site
reaction)
Prothrombin Time Prolonged (INR)
Insomnia Nec (Insomnia)
Intra-operative Injury (Intraop injury -
Select)
Intra-operative Injury Other (Intraop
Injury-Other (Specify))
Extrapyramidal Disorder Nec (Involuntary
movement)
Iron Overload (Iron overload)
Menstruation Irregular (Irregular menses)
Irritability (Irritability)
Joint-effusion (Joint-effusion)
Joint-function (Joint-function)
Keratitis Nec (Keratitis)
Bone Growth: Spine Kyphosis/lordosis
(Kyphosis/lordosis)
Laryngeal Nerve Dysfunction (Laryngeal
nerve)
Leak (including Anastomotic), Gi (Leak,
GI - Select)
Leak (including Anastomotic), Gu (Leak,
GU - Select)
Left Ventricular Diastolic Dysfunction
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(Left ventricular diastolic dysfunction)
Left Ventricular Failure (Left ventricular
systolic dysfunction)
Leucopenia Nos (Leukocytes)
Encephalopathy Nos
(Leukoencephalopathy)
Libido Decreased (Libido)
Bone Growth: Limb Length Discrepancy
(Limb length)
Lipase Increased (Lipase)
Hepatic Failure (Liver dysfunction)
Lumbar Spine-range Of Motion (Lumbar
spine ROM)
Lymphatics Other (Lymphatics-Other
(Specify))
Lymphedema-related Fibrosis
(Lymphedema-related fibrosis)
Lymphocele (Lymphocele)
Lymphopenia (Lymphopenia)
Malabsorption (Malabsorption)
Virilism (Masculinization of female)
Amnesia Nec (Memory impairment)
Mental Status (Mental status)
Metabolic/laboratory Other (Metabolic-
Other (Specify))
Mood Alteration (Mood alteration -
Select)
Mucositis/stomatitis (clinical Exam)
(Mucositis (clinical exam) - Select)
Mucositis/stomatitis
(functional/symptomatic) (Mucositis
(functional/symptomatic) - Select)
Muscle Weakness, Generalized Or
Specific Area (not Due To Neuropathy)
(Muscle weakness - Select)
Muscular/skeletal Hypoplasia
(Muscular/skeletal hypoplasia)
Musculoskeletal/soft Tissue Other
(Musculoskeletal-Other (Specify))
Myelitis (Myelitis)
Myelodysplasia (Myelodysplasia)
Myocarditis Nos (Myocarditis)
Myositis (Myositis)
Nail Abnormality Nos (Nail changes)
Nasal Cavity/paranasal Sinus Reactions
(Nasal/paranasal reactions)
Nausea (Nausea)
Necrosis, Gi (Necrosis, GI - Select)
Neurology Other (Neurology-Other
(Specify))
Peripheral Motor Neuropathy
(Neuropathy-motor)
Peripheral Sensory Neuropathy
(Neuropathy-sensory)
Neuropathy: Cranial (Neuropathy: cranial
- Select)
Neutropenia (Neutrophils)
Breast Nipple/areolar Deformity
(Nipple/areolar)
Blindness Night (Nyctalopia)
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Nystagmus Nos (Nystagmus)
Obesity (Obesity)
Obstruction, Gi (Obstruction, GI - Select)
Obstruction, Gu (Obstruction, GU -
Select)
Conjunctivitis Nec (Ocular surface
disease)
Ocular/visual Other (Ocular-Other
(Specify))
Opportunistic Infection Associated With
>=grade 2 Lymphopenia (Opportunistic
infection)
Optic Disc Edema (Optic disc edema)
Orgasmic Dysfunction (Orgasmic
dysfunction)
Osteonecrosis (Osteonecrosis)
Osteoporosis (Osteoporosis)
Otitis Externa (exc Boil Of Meatus) Nos
(Otitis, external)
Otitis Media Serous Nos (Otitis, middle)
Pain (Pain - Select)
Pain Other (Pain-Other (Specify))
Palpitations (Palpitations)
Pancreas, Exocrine Enzyme Deficiency
(Pancreas, exocrine enzyme deficiency)
Pancreatitis Nos (Pancreatitis)
Odor (patient Odor) (Patient odor)
Perforation, Gi (Perforation, GI - Select)
Perforation, Gu (Perforation, GU - Select)
Pericardial Effusion (Pericardial effusion)
Pericarditis (Pericarditis)
Dental: Periodontal Disease
(Periodontal)
Peripheral Ischaemia Nos (Peripheral
arterial ischemia)
Personality Change (Personality)
Petechiae (Petechiae)
Phlebitis Superficial (Phlebitis)
Phlebolymphatic Cording
(Phlebolymphatic cording)
Photophobia (Photophobia)
Photosensitivity Reaction Nos
(Photosensitivity)
Phrenic Nerve Dysfunction (Phrenic
nerve)
Platelet Count Decreased (Platelets)
Pleural Effusion (Pleural effusion)
Pneumonitis Nos (Pneumonitis)
Pneumothorax Nos (Pneumothorax)
Portal Hypertension (Portal flow)
Puberty (precocious) (Precocious
puberty)
Proctitis Nos (Proctitis)
Neuroendocrine: Prolactin Hormone
Secretion Abnormality (Prolactin)
Prolapse Of Stoma, Gi (Prolapse of
stoma, GI)
Prolapse Of Stoma, Gu (Prolapse of
stoma, GU)
Prolonged Intubation After Pulmonary
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Resection (>24 Hrs After Surgery)
(Prolonged intubation)
Electrocardiogram Qt Prolonged
(Prolonged QTc)
Proptosis/enophthalmos
(Proptosis/enophthalmos)
Proteinuria Present (Proteinuria)
Pruritus Nos (Pruritus)
Delusion Nos (Psychosis)
Activated Partial Thromboplastin Time
Prolonged (PTT)
Pulmonary Fibrosis (Pulmonary fibrosis)
Pulmonary Hypertension (Pulmonary
hypertension)
Pulmonary/upper Respiratory Other
(Pulmonary-Other (Specify))
Upper Motor Neurone Lesion (Pyramidal
tract dysfunction)
Dermatitis Exfoliative Nos (Rash)
Growth Velocity (reduction In Growth
Velocity) (Reduction in growth velocity)
Renal Failure Nos (Renal failure)
Renal/genitourinary Other (Renal-Other
(Specify))
Restrictive Cardiomyopathy (Restrictive
cardiomyopathy)
Retinal Detachment (Retinal
detachment)
Retinopathy (Retinopathy)
Rhinitis Allergic Nos (Rhinitis)
Right Ventricular Dysfunction (cor
Pulmonale) (Right ventricular
dysfunction)
Rigors (Rigors/chills)
Salivary Gland Disorder Nos (Salivary
gland changes)
Scleral Necrosis/melt (Scleral necrosis)
Bone: Spine-scoliosis (Scoliosis)
Secondary Malignancy Possibly Related
To Cancer Treatment (Secondary
Malignancy (possibly related to cancer
treatment))
Convulsions Nos (Seizure)
Seroma (Seroma)
Serum Sickness (Serum sickness)
Sexual/reproductive Function Other
(Sexual-Other (Specify))
Short Stature (Short stature)
Soft Tissue Necrosis (Soft tissue
necrosis - Select)
Depressed Level Of Consciousness
(Somnolence)
Speech Disorder Nec (Speech
impairment)
Splenic Function (Splenic function)
Striae (Striae)
Stricture/stenosis (including
Anastomotic), Gu (Stricture,
anastomotic, GU - Select)
Stricture/stenosis (including
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Anastomotic), Gi (Stricture, GI - Select)
Supraventricular And Nodal Arrhythmia
(Supraventricular arrhythmia - Select)
Sweating Increased (Sweating)
Syncope (Syncope (fainting))
Syndromes Other (Syndromes-Other
(Specify))
Taste Disturbance (Taste alteration)
Dental: Teeth (Teeth)
Dental: Teeth Development (Teeth
development)
Telangiectasia (Telangiectasia)
Thrombosis/embolism (vascular Access-
related) (Thrombosis/embolism (vascular
access))
Thrombosis Nos
(Thrombosis/thrombus/embolism)
Thrombotic Microangiopathy (e.g.,
Thrombotic Thrombocytopenic
Purpura[ttp] Or Hemolytic Uremic
Syndrome[hus]) (Thrombotic
microangiopathy)
Tinnitus (Tinnitus)
Tremor Nec (Tremor)
Trismus (difficulty, Restriction Or Pain
When Opening Mouth) (Trismus)
Tumour Flare (Tumor flare)
Tumour Lysis Syndrome (Tumor lysis
syndrome)
Caecitis (Typhlitis)
Ulcer, Gi (Ulcer, GI - Select)
Ulceration (Ulceration)
Fanconi Syndrome (Urinary electrolyte
wasting)
Urinary Frequency (Urinary frequency)
Urinary Retention (Urinary retention)
Urine Discolouration (Urine color
change)
Urticaria Nos (Urticaria)
Uveitis (Uveitis)
Vaginal Discharge (non-infectious)
(Vaginal discharge)
Vulvovaginal Dryness (Vaginal dryness)
Vaginal Mucositis (Vaginal mucositis)
Vaginal Stenosis/length (Vaginal
stenosis)
Vaginitis (Vaginitis)
Valvular Heart Disease (Valvular heart
disease)
Vascular Other (Vascular-Other
(Specify))
Vasculitis Nos (Vasculitis)
Vasovagal Attack (Vasovagal episode)
Ventricular Arrhythmia (Ventricular
arrhythmia - Select)
Vessel Injury-vein (Vessel injury - Select)
Viral Hepatitis (Viral hepatitis)
Visceral Arterial Ischaemia (Visceral
arterial ischemia)
Vital Capacity (Vital capacity)
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Vitreous Hemorrhage (Vitreous
hemorrhage)
Dysphonia (Voice changes)
Vomiting Nos (Vomiting)
Lacrimation Increased (Watery eye)
Weight Increased (Weight gain)
Weight Decreased (Weight loss)
Culture Wound Negative (Wound
complication, non-infectious)
Other CTC Adverse Event Term not listed
CTC AE Grade
CTCAE Begin Date (MM DD YYYY)
Attribution
Definite (Definite)
Possible (Possible)
Probable (Probable)
Unlikely (Unlikely)
Unrelated (Unrelated)
SAE report submitted
No (No)
Unknown (Unknown)
Yes (Yes)
Footer
Comments
Signature of Person Completing This Form
Date Form Originally Completed
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Patient Completed Questionnaires:
Step 1 Randomization Form
SWOG clinical trial administrative data
SWOG Patient ID
SWOG Study No.
Registration Step
Patient Initials (L, F M)
Institution/Affiliate
Physician
Date form completed
Participating Group Name
Participating Study No.
Participating Patient ID
Planned Assessment
Prestudy (Prestudy)
Week 10 (Week 10)
Week 13 (Week 13)
Week 16 (Week 16)
Week 19 (Week 19)
Week 22 (Week 22)
Week 25 (Week 25)
Week 28 (Week 28)
Week 31 (Week 31)
Week 34 (Week 34)
Week 37 (Week 37)
Week 4 (Week 4)
Week 7 (Week 7)
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Was the symptom questionnaire completed?
(required every cycle and end of treatment
[beginning of Week 37])
Yes
No
Was the Pain Medication Log completed?
(required every cycle and end of treatment
[beginning of Week 37])
Yes
No
Was the FACT-P completed? (required Prestudy,
Cycles 4[week 10], 7[week 19], 10[week 28], and
end of treatment [beginning of Week 37])
Yes
No
Did the patient require any assistance in
completing the questionnaire? (If completed,)
Yes
No
Describe (If yes,)
Method of questionnaire administration
By Telephone (by telephone)
In The Clinic (in the clinic)
Other (other)
Other (please specify)
If not completed, please give reason (select one)
Death (death)
Illness/deteriorating Health
(illness/deteriorating health)
Institution Error (institution error)
Not Illness Related (not illness related)
Other (other)
Form completed by
Person completing form, last name
Person completing form, phone
Comments
Comments
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NCT00134056 Southwest Oncology Group S0421 Cover Sheet for
Patient Completed Questionnaires: Step 1 Randomization Form
ADVL0212: Response Assessment
NCT00053963
ADVL0212: Response Assessment NCT00053963 
FR901228 in Treating Children With Refractory or
Recurrent Solid Tumors or Leukemia
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=B1EAE217-
B511-30BD-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/11475
ADVL0212: Response Assessment
NCT00053963
Header
Study Number
Institution Name
COG Number
Patient's Initials
Date worksheet entered into RDE
Sites Of Measurable Disease At The Time
Of Study Entry
ICD-O Topography Code of Lesion (1a)
Largest Dimension (cm)
cm
Method of measurement (1c)
Ct Scan (Computed Tomography-
Conventional)
Spiral Ct Scan (Computed Tomography-
spiral)
Mri (MRI)
Other, Specify (Other, Specify)
Physical Exam (Physical Exam)
Ultrasound (Ultrasound)
X-ray (X-ray)
other, Specify (1. If other is selected as method of
measurement, this must be completed.)
Were any other lesions detected at study entry?
(1. Required field)
Yes
No
Evaluation of lesions
1 / 2
Date of response evaluation (The date shown can
be edited.  Please record the actual date of the
radiological assessment that confirms the
response status was made.)
Were any new lesions detected (1. Required
field)
Yes
No
If other lesions were detected at study entry, did
any of these demonstrate progression at this
evaluation? (1. Required field)
N/a (N/A, No other lesions)
No (No)
Yes (Yes)
Comments
Comments
Ccrr Module For Advl0212: Response
Assessment
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ADVL0212: Response Assessment NCT00053963
S0337 Cover Sheet for Patient-Completed
Questionnaires NCT00445601
S0337 Cover Sheet for Patient-Completed Questionnaires
NCT00445601
Gemcitabine After Surgery in Treating Patients With Newly
Diagnosed or Recurrent Bladder Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=FE26037B-
446B-4AC6-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11476
S0337 Cover Sheet for Patient-
Completed Questionnaires
NCT00445601
Header
SWOG Patient ID
SWOG Study No.
Registration Step
Patient Initials (L, F M)
Date Form Completed
Institution/Affiliate
Physician
Participating Group Name
Participating Group Study No.
Participating Group Patient ID
Planned Assessment
7 Days After Treatment (1 week post-
treatment)
Prestudy (Prestudy)
Patient response to questionnaire
Was the Irritative Bladder symptom Inventory
completed?
Yes
No
Did the patient require any assistance in
completing the questionnaire? (If completed,)
Yes
No
1 / 2
Describe (If yes,)
If Completed, Questionnaire administered
By Telephone (By telephone)
In The Clinic (In the clinic)
Other (Other)
Other (Please specify)
If Not Completed, please give reason (select one)
Death (Death)
Illness/deteriorating Health
(Illness/deteriorating health)
Institution Error (Institution error)
Not Illness Related (Not illness related)
Other (Other)
Patient Unable To Communicate In
English (Patient is unable to understand
and read English)
Other
Form completed by
Person Completing Form, Last Name
Person Completing Form, Phone
Comments
Comments
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S0337 Cover Sheet for Patient-Completed Questionnaires NCT00445601
NSABP Protocol B-40 - Tumor Response
Form NCT00408408
NSABP Protocol B-40 - Tumor Response Form
NCT00408408
A Randomized Phase III Trial of Neoadjuvant Therapy in
Patients With Palpable and Operable Breast Cancer
Evaluating the Effect on Pathologic Complete Response
(pCR) of Adding Capecitabine or Gemcitabine to Docetaxel
When Administered Before AC With or Without
Bevacizumab and Correlative Science Studies Attempting
to Identify Predictors of High Likelihood for pCR With Each
of the Regimens
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=1B7DC2CF-
E4EE-1B7D-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11477
NSABP Protocol B-40 - Tumor
Response Form NCT00408408
Header
Patient Initials (Last First Middle)
NSABP Patient ID
Reason Form Submitted
Discretionary Assessment Which
Identified Protocol-defined Progressive
Disease (Discretionary assessment
which identified protocol-defined
Progressive Disease)
Required Assessment At The End Of
The Ac Cycles (Required assessment at
the end of the AC cycles)
Required Assessment At The End Of
The Docetaxel Regimen (Required
assessment at the end of the docetaxel
regimen)
Form completed by
Institution/Affiliate
Person Completing Form, Last Name
Person Completing Form, First Name
Person Completing Form, Phone
Are data amended
Yes
No
Target Lesions
Were the target lesions measured on this
1 / 3
evaluation
Yes
No
Date of Evaluation
Response status of Target lesion (s)
Complete Response (Complete
Response)
Incomplete Response Or Stable Disease
(Incomplete Response or Stable
Disease)
Partial Response (Partial Response)
Lesion Number
Target Lesion Site
Axilla (Axilla)
Breast (Breast)
Longest Diameter of Lesion (s)
cm
Sum of longest diameters of all target lesions
(cm)
Smallest Sum of Longest Diameters of all Target
Lesions
cm
Date Smallest Sum Observed
Nontarget Lesions
Were nontarget lesions identified on the baseline
evaluation
Yes
No
Were the nontarget lesions assessed on this
evaluation
Yes
No
Response Status of NONTARGET Lesions
Complete Response (Complete
Response)
Incomplete Response/sd (Incomplete
Response/SD)
Progressive Disease (Progressive
Disease)
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NSABP Protocol B-40 - Tumor Response Form NCT00408408
New Lesions
Was the appearance of any new lesions
documented
Yes
No
New Lesion Site
Axilla (Axilla)
Breast (Breast)
Other (Other)
Specify
Was there any other manifestation of disease
progression (other than progression of target
lesions, progression of nontarget lesions, or the
appearance of a new lesion)
Yes
No
Specify (If yes)
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NSABP Protocol B-40 - Tumor Response Form NCT00408408
NCT00408408 NSABP Protocol B-40 - Left
Ventricular Assessment Form (Form LVA)
NCT00408408 NSABP Protocol B-40 - Left Ventricular
Assessment Form (Form LVA)
A Randomized Phase III Trial of Neoadjuvant Therapy in
Patients With Palpable and Operable Breast Cancer
Evaluating the Effect on Pathologic Complete Response
(pCR) of Adding Capecitabine or Gemcitabine to Docetaxel
When Administered Before AC With or Without
Bevacizumab and Correlative Science Studies Attempting
to Identify Predictors of High Likelihood for pCR With Each
of the Regimens
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=1B73772A-
3FC1-6011-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11478
NCT00408408 NSABP Protocol B-
40 - Left Ventricular Assessment
Form (Form LVA)
Header
Patient Initials (Last First Middle)
NSABP Patient ID
Form completed by
Institution/Affiliate
Person Completing Form, Last Name
Person Completing Form, First Name
Person Completing Form, Phone
Date Form Completed
Are data amended
Yes
No
Left Ventricular Assessment
Patients assigned to Group 1A, 2A, or 3A (Time
point)
18 Months After Study Entry (18 months
after study entry)
3-4 Weeks After Last Chemotherapy
Dose (3-4 weeks after last chemotherapy
dose)
3-5 Weeks After Surgery (3-5 weeks
after surgery)
After 4 Post-operative Doses Of
Bevacizumab (After 4 post-operative
1 / 2
doses of bevacizumab)
Baseline (Baseline)
Other Time Point During First Two Years
Following Study Entry (Other time point
during first two years following study
entry)
Patients assigned to Group 1B, 2B, or 3B (Time
point)
18 Months After Study Entry (18 months
after study entry)
3-4 Weeks After Last Chemotherapy
Dose (3-4 weeks after last chemotherapy
dose)
3-5 Weeks After Surgery (3-5 weeks
after surgery)
After 4 Post-operative Doses Of
Bevacizumab (After 4 post-operative
doses of bevacizumab)
Baseline (Baseline)
Other Time Point During First Two Years
Following Study Entry (Other time point
during first two years following study
entry)
Was LVEF assessment performed at this time
point
Yes
No
Date of Assessment
Method of Evaluation
Echocardiogram (Echocardiogram)
Muga Scan (MUGA)
LVEF Patient Value
%
LVEF Institutional Lower Limit of Normal
%
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NCT00408408 NSABP Protocol B-40 - Left Ventricular Assessment Form
(Form LVA)
NSABP Protocol B-40 - Surgery/Pathology
Report Form NCT00408408
NSABP Protocol B-40 - Surgery/Pathology Report Form
NCT00408408
A Randomized Phase III Trial of Neoadjuvant Therapy in
Patients With Palpable and Operable Breast Cancer
Evaluating the Effect on Pathologic Complete Response
(pCR) of Adding Capecitabine or Gemcitabine to Docetaxel
When Administered Before AC With or Without
Bevacizumab and Correlative Science Studies Attempting
to Identify Predictors of High Likelihood for pCR With Each
of the Regimens
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=1B254729-
F8DC-4048-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11479
NSABP Protocol B-40 -
Surgery/Pathology Report Form
NCT00408408
Header
Patient Initials (Last First Middle)
NSABP Patient ID
Form completed by
Institution/Affiliate
Person Completing Form, Last Name
Person Completing Form, First Name
Person Completing Form, Phone
Date Form Completed
Are data amended
Yes (yes)
Breast
Was primary breast surgery performed
Yes
No
Date of procedure (primary breast surgery)
Type of procedure performed (provide pathology
report)
Lumpectomy (Lumpectomy)
Mastectomy (Mastectomy)
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Was there any histologic evidence of invasive
tumor cells in the surgical breast specimen
Yes
No
Was there any histologic evidence of DCIS in the
surgical breast specimen
Yes
No
Was HER-2/neu status determined (from surgical
breast specimen)
Yes
No
HER-2/neu status (if yes)
Negative (Negative)
Positive (Positive)
Was receptor status determined (ER or PgRfrom
surgical breast specimen?)
Yes
No
Receptor Status, ER (If yes,)
Negative (Negative)
Positive (Positive)
Unknown (Unknown)
Receptor Status, PgR
Negative (Negative)
Positive (Positive)
Unknown (Unknown)
Axilla
Was patient nodal status determined
Yes
No
Was FNA or core biopsy or sentinel node biopsy
of axillary nodes performed before initiation of
therapy
Yes
No
Was the cytology/biopsy positive (If yes,)
Yes
No
Axillary Staging Method (provide applicable
pathology reports)
Sentinel Node Biopsy Alone (Sentinel
node biopsy alone)
Sentinel Node Biopsy Followed By
Surgical Evaluation Of Axilla (Sentinel
node biopsy followed by surgical
evaluation of axilla)
Surgical Evaluation Of The Axilla Without
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NSABP Protocol B-40 - Surgery/Pathology Report Form NCT00408408
Prior Sentinel Node Biopsy (Surgical
evaluation of the axilla without prior
sentinel node biopsy)
Total number examined (Axillary Nodes Both
Sentinel and Non-Sentinel)
Number of positive axillary lymph nodes
Number Examined (Non-Axillary Sentinel Nodes)
Number Positive (Non-Axillary Sentinel Nodes)
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NSABP Protocol B-40 - Surgery/Pathology Report Form NCT00408408
ADVL0212: Relapse/Progression
Worksheet NCT00053963
ADVL0212: Relapse/Progression Worksheet
NCT00053963 
FR901228 in Treating Children With Refractory or
Recurrent Solid Tumors or Leukemia
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=B1EAD72E-
7E69-3077-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/11480
ADVL0212: Relapse/Progression
Worksheet NCT00053963
Header
Institution Name
Study Number
Study Number
COG Number
Patient's Initials
Date worksheet entered into RDE
Relapse/Progression
Date of relapse or progression (1. Required field)
Primary site text (tumor at diagnosis)
Primary site ICD-O code (Topography)
Third metastatic text (Enter description of third
metastatic site Topography.  If not involved, leave
this field blank.)
Third metastatic text (Enter description of third
metastatic site Topography.  If not involved, leave
this field blank.)
Third metastatic text (Enter description of third
metastatic site Topography.  If not involved, leave
this field blank.)
Third metastatic site ICD-O code (Topography)
Third metastatic site ICD-O code (Topography)
1 / 2
Third metastatic site ICD-O code (Topography)
Comments
Ccrr Module For Advl0212:
Relapse/progression Worksheet
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ADVL0212: Relapse/Progression Worksheet NCT00053963
ADVL0212: On Study Worksheet
(Leukemia) NCT00053963
ADVL0212: On Study Worksheet (Leukemia)
NCT00053963 
FR901228 in Treating Children With Refractory or
Recurrent Solid Tumors or Leukemia
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=C10238B2-
42BD-142E-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/11481
ADVL0212: On Study Worksheet
(Leukemia) NCT00053963
Patient demographics
Accession number
Stratum
Treatment Arm Number
Treating Institution Code
Treating Physician
Randomization Date
Date of call back
Date of Registration
Projected Start Date of Treatment
COG Study Number
Institution Name
COG Patient Identifier Number
Patient's Initials Name
Data Entered Date
Method of Payment
Medicaid (Medicaid)
Medicaid And Medicare (Medicaid and
Medicare)
Medicare (Medicare)
Medicare And Private Insurance
(Medicare and Private Insurance)
1 / 4
Military Or Veterans Sponsored Nos
(Military or Veterans sponsored NOS)
Military Sponsored (including Champus
& Tricare) (Military sponsored (including
CHAMPUS and TRICARE))
No Means Of Payment (no Insurance)
(No means of payment (no insurance))
Other (Other)
Private Insurance (Private Insurance)
Self Pay (no Insurance) (Self pay (no
insurance))
Unknown (Unknown)
Veterans Sponsored (Veterans
sponsored)
Bone Marrow
Is measurable disease present?
Yes
No
Did patient have a bone marrow evaluation just
prior to study entry?
Yes
No
what was the date of the exam?
does patient have bone marrow involvement?
Yes
No
Has patient had radiation therapy delivered to
20% or more of her or his bone marrow?
Yes
No
Date CBC done
WBC (x 10^3/mcL)
1000/uL
Blasts in peripheral blood (%)
%
Bone Marrow Differential, Blasts (%)
%
Blasts present in the cytocentrifuge (%)
1000/uL
Was patient's ejection fraction determined by
MUGA?
Yes
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ADVL0212: On Study Worksheet (Leukemia) NCT00053963
No
what was the percentage?
Hemogram
Hematology Lab Collected Date
Hemoglobin
g/dL
WBC (g/dL)
Assessment Lab  (unit of measure)
International Units Per Liter (IU/L)
Mu/ml (mU/mL)
Peripheral Platelet Count
Segs
%
Bands
%
Was red cell transfusion given?
No Transfusion (No)
Yes (Yes)
Transfusion With Platelets And Red
Blood Cells (Yes, both)
Transfusion With Platelets (Yes,
platelets)
Transfusion With Red Blood Cells (Yes,
red blood cells)
Chemistries
Chemistry Lab Collected Date
SGPT ALT
SGPT ALT (institutional upper limit of normal)
SGOT AST
SGOT AST (institutional upper limit of normal)
Total Bilirubin Value
mg/dL
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ADVL0212: On Study Worksheet (Leukemia) NCT00053963
Total Bilirubin - institutional upper limit of normal
mg/dL
Creatinine
mg/dL
Creatinine - institutional upper limit of normal
mg/dL
Comments
Comments
Ccrr Module For Advl0212: On Study
Worksheet (leukemia)
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ADVL0212: On Study Worksheet (Leukemia) NCT00053963
SOUTHWEST ONCOLOGY GROUP
NOTICE OF DEATH (S0230) NCT00068601
SOUTHWEST ONCOLOGY GROUP NOTICE OF DEATH
(S0230)NCT00068601
Goserelin in Preventing Ovarian Failure in Women
Receiving Chemotherapy for Breast Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=BEA922CE-
409A-2413-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/11482
SOUTHWEST ONCOLOGY GROUP
NOTICE OF DEATH (S0230)
NCT00068601
Header
SWOG Patient ID
Most Recent SWOG Study No.
Patient Initials (L, F, M)
Institution/Affiliate
Physician (Groups other than SWOG)
Group Name
Study No.
Pt. ID
Date of death
Date of Death (month / day / year)
Causes Of Death
Any cancer (select one)
Contributory2005688 (Contributory)
No2005686 (No)
Possible2005689 (Possible)
Primary_cause2005687 (Primary Cause)
Unknown2005690 (Unknown)
If cancer was the primary cause or if cancer
possibly or definitely contributed to death, and the
patient had had multiple tumor types, specify
those which were causes of death
Cancer_of_most_recent_s2005692
(Cancer of most recent SWOG study,
specify cancer)
Cancer_of_oth_swog_stdy2005693
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(Cancer of other SWOG study, specify
cancer)
Other_cancer_specify2005694 (Other
cancer, specify)
Cancer of most recent SWOG study, specify
cancer
Cancer of other SWOG study, specify cancer
Other cancer, specify
Toxicity from disease related treatment (select
one)
Contributory2005699 (Contributory)
No2005697 (No)
Possible2005700 (Possible)
Primary_cause2005698 (Primary Cause)
Unknown2005701 (Unknown)
If Primary Cause, Contributory or Possible,
specify treatment and toxicity
Non-cancer and non-treatment related causes
(select one)
Contributory2005707 (Contributory)
No2005705 (No)
Possible2005708 (Possible)
Primary_cause2005706 (Primary Cause)
Unknown2005709 (Unknown)
If Primary Cause, Contributory or Possible,
specify
Autopsy?
No (No)
Unknown (Unknown)
Yes (Yes)
Source of death information (select all that apply)
Autopsy Was The Source Of Information
On The Patient's Death (Autopsy report)
Death Certificate Was The Source Of
Information On The Patient's Death
(Medical record / Death certificate)
The Source Of Information On The
Patient's Death Is Not On This List,
Specify Other (Other, specify)
Clinical Evidence Was The Source Of
Information On The Patient's Death
(Physician)
Relative or friend (Relative or friend)
Other, specify
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SOUTHWEST ONCOLOGY GROUP NOTICE OF DEATH (S0230)
NCT00068601
Comments
Comments
Ccrr Module For Southwest Oncology
Group Notice Of Death (s0230)
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SOUTHWEST ONCOLOGY GROUP NOTICE OF DEATH (S0230)
NCT00068601
SOUTHWEST ONCOLOGY GROUP
NOTICE OF DEATH NCT00070564
SOUTHWEST ONCOLOGY GROUP NOTICE OF DEATH
NCT00070564
Adjuvant Doxorubicin, Cyclophosphamide, and Paclitaxel in
Treating Patients With Breast Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=A678BEDB-
9FFF-50A6-E034-0003BA0B1A09
All rights reserved. Please visit https://medical-data-
models.org/forms/11483
SOUTHWEST ONCOLOGY GROUP
NOTICE OF DEATH NCT00070564
Header
SWOG Patient ID
Most Recent SWOG Study No.
Patient Initials (L, F, M)
Institution / Affiliate
Physician
Group Name (Groups other than SWOG)
Study No. (Groups other than SWOG)
Pt. ID (Groups other than SWOG)
Date of death
Date of Death (month / day / year)
Causes Of Death
If cancer was the primary cause or if cancer
possibly or definitely contributed to death, and the
patient had had multiple tumor types, specify
those which were causes of death
Cancer of most recent SWOG study,
specify cancer (Cancer of most recent
SWOG study, specify cancer)
Cancer of other SWOG study, specify
cancer (Cancer of other SWOG study,
specify cancer)
Other cancer, specify (Other cancer,
specify)
Non-cancer and non-treatment related causes
(select one)
1 / 3
Contributory (Contributory)
No (No)
Possible (Possible)
Primary Cause (Primary Cause)
Unknown (Unknown)
Non-cancer and non-treatment related causes
(select one)
Contributory (Contributory)
No (No)
Possible (Possible)
Primary Cause (Primary Cause)
Unknown (Unknown)
Non-cancer and non-treatment related causes
(select one)
Contributory (Contributory)
No (No)
Possible (Possible)
Primary Cause (Primary Cause)
Unknown (Unknown)
If Primary Cause, Contributory or Possible,
specify
If Primary Cause, Contributory or Possible,
specify
If Primary Cause, Contributory or Possible,
specify
If Primary Cause, Contributory or Possible,
specify
If Primary Cause, Contributory or Possible,
specify
Autopsy done?
No (No)
Unknown (Unknown)
Yes (Yes)
Death information obtained from (select all that
apply)
Autopsy Was The Source Of Information
On The Patient's Death (Autopsy report)
Death Certificate Was The Source Of
Information On The Patient's Death
(Medical record / Death certificate)
The Source Of Information On The
Patient's Death Is Not On This List,
Specify Other (Other, specify)
Clinical Evidence Was The Source Of
Information On The Patient's Death
(Physician)
2 / 3
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Relative or friend (Relative or friend)
Other, specify
COMMENTS
Comments
Ccrr Module For Southwest Oncology
Group Notice Of Death
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SOUTHWEST ONCOLOGY GROUP NOTICE OF DEATH NCT00070564
SOUTHWEST ONCOLOGY GROUP
NOTICE OF DEATH (S0226)  NCT00075764
SOUTHWEST ONCOLOGY GROUP NOTICE OF DEATH
(S0226) NCT00075764
S0226 Anastrozole With or Without Fulvestrant as First-
Line Therapy in Postmenopausal Women With Metastatic
Breast Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=C3223013-
0891-25E5-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/11484
SOUTHWEST ONCOLOGY GROUP
NOTICE OF DEATH (S0226)
NCT00075764
Header
SWOG Patient ID
Most Recent SWOG Study No.
Patient Initials (L, F, M)
Institution/Affiliate
Physician
Participating Group Name
Participating Study No.
Participating Patient ID
Date of death
Date of Death (month / day / year)
Causes Of Death
Any cancer (select one)
Contributory2005688 (Contributory)
No2005686 (No)
Possible2005689 (Possible)
Primary_cause2005687 (Primary Cause)
Unknown2005690 (Unknown)
If cancer was the primary cause or if cancer
possibly or definitely contributed to death, and the
patient had had multiple tumor types, specify
those which were causes of death
Cancer_of_most_recent_s2005692
(Cancer of most recent SWOG study,
specify cancer)
Cancer_of_oth_swog_stdy2005693
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(Cancer of other SWOG study, specify
cancer)
Other_cancer_specify2005694 (Other
cancer, specify)
Cancer of most recent SWOG study, specify
cancer
Cancer of other SWOG study, specify cancer
Other cancer, specify
Toxicity from disease related treatment (select
one)
Contributory2005699 (Contributory)
No2005697 (No)
Possible2005700 (Possible)
Primary_cause2005698 (Primary Cause)
Unknown2005701 (Unknown)
If Primary Cause, Contributory or Possible,
specify treatment and toxicity
Non-cancer and non-treatment related causes
(select one)
Contributory2005707 (Contributory)
No2005705 (No)
Possible2005708 (Possible)
Primary_cause2005706 (Primary Cause)
Unknown2005709 (Unknown)
If Primary Cause, Contributory or Possible,
specify
Autopsy?
No (No)
Unknown (Unknown)
Yes (Yes)
Source of death information (select all that apply)
Autopsy Was The Source Of Information
On The Patient's Death (Autopsy report)
Death Certificate Was The Source Of
Information On The Patient's Death
(Medical record / Death certificate)
The Source Of Information On The
Patient's Death Is Not On This List,
Specify Other (Other, specify)
Clinical Evidence Was The Source Of
Information On The Patient's Death
(Physician)
The Source Of Information On The
Patient's Death Is Not On This List,
Specify Other (Relative or friend)
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SOUTHWEST ONCOLOGY GROUP NOTICE OF DEATH (S0226)
NCT00075764
Other, specify
Comments
Comments
Ccrr Module For Southwest Oncology
Group Notice Of Death (s0226)
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SOUTHWEST ONCOLOGY GROUP NOTICE OF DEATH (S0226)
NCT00075764
SOUTHWEST ONCOLOGY GROUP OFF
TREATMENT NOTICE NCT00070564
SOUTHWEST ONCOLOGY GROUP OFF TREATMENT
NOTICE NCT00070564 
Adjuvant Doxorubicin, Cyclophosphamide, and Paclitaxel in
Treating Patients With Breast Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=A678BAD9-
E0F6-50A4-E034-0003BA0B1A09
All rights reserved. Please visit https://medical-data-
models.org/forms/11485
SOUTHWEST ONCOLOGY GROUP
OFF TREATMENT NOTICE
NCT00070564
Header
SWOG Patient ID
SWOG Study No.
Registration Step
Patient Initials (L, F M)
Institution / Affiliate
Physician (Groups other than SWOG)
Group Name (Groups other than SWOG)
Study No. (Groups other than SWOG)
Pt. ID (Groups other than SWOG)
Treatment period
Treatment Start Date
Treatment End Date
Regimen or Procedure or Site(s)
Off-protocol treatment
Off Treatment Reason (select one)
Death (Death)
Medically required, due to toxicity,
specify (Medically required, due to
toxicity, specify)
Other, Specify (Other, specify)
Patient refused, due to toxicity, specify
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(Patient refused, due to toxicity, specify)
Patient refused, other than toxicity,
specify (Patient refused, other than
toxicity, specify)
Progression or relapse. Sites
(Progression or relapse. Sites)
Treatment Completed Per Protocol
Criteria (Treatment completed per
protocol criteria)
Patient refused, due to toxicity, specify
Patient refused, due to toxicity, specify
Progression or relapse. Sites
Other, specify (Off Treatment Date)
Other, specify (Off Treatment Date)
Date of completion, progression, death or
decision to discontinue therapy
Further treatment
Will patient receive further treatment?
No (No)
Unknown (Unknown)
Yes (Yes, specify)
Yes, specify
Vital status
Date of Last Contact (or death)
Vital Status
Alive (Alive)
Dead (Dead)
COMMENTS
Comments
Ccrr Module For Southwest Oncology
Group Off Treatment Notice
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SOUTHWEST ONCOLOGY GROUP OFF TREATMENT NOTICE
NCT00070564
NCT00103181 NSABP Protocol B-39 Radiation Therapy Report
for Patients Randomized to PBI (Group 2 Patients Only)
NCT00103181 NSABP Protocol B-39 Radiation Therapy
Report for Patients Randomized to PBI (Group 2 Patients
Only)
Radiation Therapy in Treating Women Who Have
Undergone Surgery For Ductal Carcinoma In Situ or Stage
I or Stage II Breast Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=E74A3E53-
F9E9-58E3-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11486
NCT00103181 NSABP Protocol B-
39 Radiation Therapy Report for
Patients Randomized to PBI (Group
2 Patients Only)
Header
Patient Initials
Institution Name
NSABP Patient Study ID
Affiliated Institution Name
Person Completing Form Last Name
Person Completing Form First Name
Person Completing Form Phone
Are data amended (check box if yes, and circle
amended items)
Yes
No
Radiation Therapy Report
Type of Radiation Therapy Received (prior to
treatment failure or second primary cancer)
No Breast Irradiation (No Breast
Irradiation)
Partial Breast Irradiation (Partial Breast
Irradiation)
Whole Breast Irradiation (Whole Breast
Irradiation)
PBI Technique (mark one)
3d Conformal External Beam Radiation
(3D Conformal External Beam Radiation)
Mammosite Balloon Catheter
(MammoSite Balloon Catheter)
Multi-catheter Brachytherapy (Multi-
Catheter Brachytherapy)
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Side Irradiated
1 (Left)
2 (Right)
RT Facility Code
RT Treatment Begin Date
RT Treatment End Date
RT Total Dose (PBI)
Total Number
of Fractions (PBI)
Were there any unscheduled interruptions in
radiation therapy due to toxicity?
Yes
No
Were there any unscheduled interruptions in
radiation therapy for other reasons?
Yes
No
Reason PBI Treatment Ended
Adverse Event/side Effects/complications
(Adverse event/side
effects/complications)
Death, Recurrence, Or Second Primary
Cancer (Death, recurrence, or second
primary cancer)
Other (Other)
Patient Withdrawal Or Refusal (Patient
withdrawal or refusal after beginning
protocol therapy)
Treatment Completed Per Protocol
Criteria (Treatment completed per
protocol criteria)
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NCT00103181 NSABP Protocol B-39 Radiation Therapy Report for
Patients Randomized to PBI (Group 2 Patients Only)
B-38 Adverse Event Supplemental Form
NCT00093795
B-38 Adverse Event Supplemental Form NCT00093795 
Combination Chemotherapy in Treating Women Who Have
Undergone Surgery for Node-Positive Breast Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=DE9273A8-
3CCD-041D-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/11487
B-38 Adverse Event Supplemental
Form NCT00093795
Patient demographics
Patient Initials
NSABP Patient ID
Cycle Number
Cycle Start Date
Cycle Stop Date
Adverse event assessment
CTCAE v3.0 Short Name
CTCAE v3.0 "Select" Term (if applicable)
CTCAE v3.0 Grade
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FORM 6 - FINAL REPORT NCT00090974
Quality Of Life Companion Study For JMA27 (NCIC-
MA.27): A Randomized Phase III Trial Of Exemestane
Versus Anastrozole With Or Without Celecoxib In
Postmenopausal Women With Receptor Positive Primary
Breast Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=ABE51386-
B5AC-5668-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/11488
FORM 6 - FINAL REPORT
NCT00090974
Patient Information
Patient Study ID, Coordinating Group
Patient Initials (first - middle - last)
Patient Medical Record Number
Investigator Name
Institution Name
Registered Investigator (NCI Investigator #)
Cause Of Death
Date of death (yyyy mmm dd)
Primary Cause of Death (check one)
Cardiovascular death (specify)
(Cardiovascular death (specify))
Due To Other Cause, Specify (Due to
other cause, describe primary cause of
death)
Due To Protocol Treatment (Due to
protocol treatment)
Due To This Disease (Due to this
disease)
Unknown (Unknown)
Due to other cause, describe primary cause of
death
Autopsy
Autopsy?
No (No)
Unknown (UNKNOWN)
Yes (Yes)
1 / 6
Disease Status
Status of most recent clinical assessment
Cancer Present (Cancer Present)
No Evidence Of Disease (No evidence of
disease)
Other Malignancies Or Myelodysplastic
Syndrome
Has a new primary cancer or MDS been
diagnosed that has not been previously reported?
Yes
No
Date of diagnosis (yyyy mmm dd)
Malignancy Type
Site(s) of New Primary
Describe (new primary cancer or MDS)
Toxicity Evaluation
Did the patient experience any new or continuing
toxicities since the last report?
Yes
No
CTC Adverse Event Term (Code/grade according
to NCI Common Toxicity Criteria, Version 2.0)
abdominal pain or cramping (abdominal
pain or cramping)
anorexia (anorexia)
arthralgia (joint pain) (arthralgia (joint
pain))
constipation (constipation)
cough (cough)
diarrhea (patients without colostomy)
(diarrhea (patients without colostomy))
dizziness/lightheadedness
(dizziness/lightheadedness)
dyspepsia/heartburn
(dyspepsia/heartburn)
dyspnea (shortness of breath) (dyspnea
(shortness of breath))
edema (edema)
fatigue (lethary/malaise/asthenia)
(fatigue (lethary/malaise/asthenia))
flatulence (flatulence)
headache (headache)
hot flashes/flushes (hot flashes/flushes)
hypercholesterolemia
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(hypercholesterolemia)
infection (without neutropenia) (infection
(without neutropenia))
nausea (nausea)
other (other)
rash/desquamation (rash/desquamation)
sweating (diaphoresis) (sweating
(diaphoresis))
vaginal bleeding (vaginal bleeding)
vomiting (vomiting)
CTC Adverse Event Term, Other (specify)
CTC Adverse Event Category (Code/grade
according to NCI Common Toxicity Criteria,
Version 2.0)
cardiovascular (cardiovascular)
constitutional symptoms (constitutional
symptoms)
dermatology/skin (dermatology/skin)
endocrine (endocrine)
gastrointestinal (gastrointestinal)
hemorrhage (hemorrhage)
infection (infection)
metabolic (metabolic)
neurology (neurology)
pain (pain)
pulmonary (pulmonary)
CTC Adverse Event Grade (Code/grade
according to NCI Common Toxicity Criteria,
Version 2.0)
CTC Adverse Event Attribution Code
Definitely (definite)
possible (possible)
Probably (probable)
Unlikely (unlikely)
Unrelated (unrelated)
COMMENTS
Adverse Events
Has the patient experienced a bone fracture
since submission of last follow-up form?
Yes
No
Bone Fracture Site, Spinal (Check)
No (No)
Unknown (Unknown)
Yes (Yes)
Bone Fracture Site, Wrist (Check)
No (No)
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Unknown (Unknown)
Yes (Yes)
Bone Fracture Site, Pelvis (Check)
No (No)
Unknown (Unknown)
Yes (Yes)
Bone Fracture Site, Hip (Check)
No (No)
Unknown (Unknown)
Yes (Yes)
Bone Fracture Site, Femur (Check)
No (No)
Unknown (Unknown)
Yes (Yes)
Bone Fracture Site, Tibia (Check)
No (No)
Unknown (Unknown)
Yes (Yes)
Bone Fracture Site, Ankle (Check)
No (No)
Unknown (Unknown)
Yes (Yes)
Bone Fracture Site, Other (specify) (Check)
No (No)
Unknown (Unknown)
Yes (Yes)
indicate site (bone fracture site)
Date of Bone Fracture (yyyy-mmm-dd)
Has the patient had a new diagnosis of
osteoporosis since submission of last follow-up
form?
Yes
No
Date of new diagnosis of osteoporosis (yyyy
mmm dd)
Has the patient suffered cardiovascular disease
since submission of last follow-up form?
Cardiovascular Event, Myocardial infarction
(Report only events which have occurred since
last report or conditions which were present at
the time of last report and have worsened since.
Report non-ischemic events in the "other"
category.)
No (No)
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Unknown (Unknown)
Yes (Yes)
Cardiovascular Event, Stroke/transient ischemic
attack (TIA) (Report only events which have
occurred since last report or conditions which
were present at the time of last report and have
worsened since.  Report non-ischemic events in
the "other" category.)
No (No)
Unknown (Unknown)
Yes (Yes)
Cardiovascular Event, On-going angina (no
surgical intervention) (Report only events which
have occurred since last report or conditions
which were present at the time of last report and
have worsened since.  Report non-ischemic
events in the "other" category.)
No (No)
Unknown (Unknown)
Yes (Yes)
Cardiovascular Event, Angina requiring
percutaneous transluminal coronary angioplasty
(PTCA) (Report only events which have occurred
since last report or conditions which were present
at the time of last report and have worsened
since.  Report non-ischemic events in the "other"
category.)
No (No)
Unknown (Unknown)
Yes (Yes)
Cardiovascular Event, Thromboembolic event
(Report only events which have occurred since
last report or conditions which were present at
the time of last report and have worsened since.
Report non-ischemic events in the "other"
category.)
No (No)
Unknown (Unknown)
Yes (Yes)
Cardiovascular Event, Other (specify) (Report
only events which have occurred since last report
or conditions which were present at the time of
last report and have worsened since.  Report
non-ischemic events in the "other" category.)
No (No)
Unknown (Unknown)
Yes (Yes)
please describe event (cardiovascular event)
Date of Most Recent Episode (yyyy-mmm-dd)
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Treatment Given Since Last Report To
Ncic Ctg
Is the patient receiving any non-protocol cancer
therapy not previously reported?
Yes
No
Non-Protocol Raloxifene Therapy?
Yes
No
Non-Protocol Bisphosphonate Therapy?
Yes
No
Non-Protocol Lipid Lowering Therapy?
Yes
No
Other Non-Protocol Therapy?
Yes
No
Other Non-Protocol Therapy Name
Comments
Supporting Documentation
Investigator Signature
Investigator Signature
Person Completing Form, Last Name
Person Completing Form, First Name
Form Completion Date, Original (yyyy mmm dd)
Ccrr Module For Form 6 - Final Report
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NSABP PROTOCOL B-38: ON-STUDY
FORM - Form ON NCT00093795
NSABP PROTOCOL B-38: ON-STUDY FORM - Form ON
NCT00093795
Combination Chemotherapy in Treating Women Who Have
Undergone Surgery for Node-Positive Breast Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=DACC4A44-
B180-0E7B-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/11489
NSABP PROTOCOL B-38: ON-
STUDY FORM - Form ON
NCT00093795
Header module
Patient Initials
NSABP Patient ID
Institution Name
Affiliate Name
Person completing Form, Last Name
Person completing Form, First Name
Person completing Form, Phone
Are data amended?
Yes
No
Surgical Procedures
Core (or Tru Cut) Needle Biopsy
No (N)
Yes (Y)
Excisional Biopsy or Lumpectomy
N (N)
Y (Y)
Patient Initials
NSABP Patient ID
Resection of Lumpectomy Margins
N (N)
Y (Y)
Total Mastectomy
No (N)
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Yes (Y)
Sentinel Lymphadenectomy
No (N)
Yes (Y)
Axillary Lymphadenectomy
No (N)
Yes (Y)
Date of Procedure
Accession Number
Tumor Laterality
Left (Left Breast)
Right (Right Breast)
Most Extensive Primary Surgery
Mastectomy, Nos (Mastectomy)
Partial Mastectomy, Lumpectomy Or
Excisional Biopsy (Partial
mastectomy/lumpectomy/excisional
biopsy)
Are the final margins of the resected specimen
histologically free of invasive tumor and DCIS
Yes
No
Axillary Evaluation
Axillary Lymphadenectomy Without
Sentinel Node Procedure (Axillary
lymphadenectomy without sentinel node
procedure)
Sentinel Lymphadenectomy Alone
(Sentinel lymphadenectomy alone)
Sentinel Lymphadenectomy Followed By
Removal Of Additional Non-sentinel
Nodes (Sentinel lymphadenectomy
followed by removal of additional non-
sentinel nodes)
Total Number of Positive Nodes
ER
Negative (Negative)
Positive (Positive)
Unknown (Unknown)
PgR
Negative (Negative)
Positive (Positive)
Unknown (Unknown)
Pathologic Primary Tumor Size
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Menopausal status
Postmenopausal (Postmenopausal)
Premenopausal (Premenopausal)
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NSABP PROTOCOL B-39: ON-STUDY
FORM NCT00103181
NSABP PROTOCOL B-39: ON-STUDY FORM
NCT00103181
Radiation Therapy in Treating Women Who Have
Undergone Surgery For Ductal Carcinoma In Situ or Stage
I or Stage II Breast Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=E74657B5-
A500-0931-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11490
NSABP PROTOCOL B-39: ON-
STUDY FORM NCT00103181
Header
Patient Initials
NSABP Patient ID
Institution Name
Affiliated Institution Name
Person Completing Form Last Name
Person Completing Form First Name
Person Completing Form Phone
Are data amended (check box if yes, and circle
amended items)
Yes
No
Surgical Procedure
Core (or Tru Cut) Needle Biopsy
Yes
No
Excisional Biopsy or Lumpectomy
Yes
No
Resection of Lumpectomy Margins (If more than
one, list final resection.)
Yes
No
Sentinel Node Biopsy
Yes
No
Axillary Dissection or Axillary Sampling
Yes
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No
DATE OF PROCEDURE
ACCESSION NUMBER (Pathology Specimen
Number)
Tumor assessment
Tumor Laterality
Left (Left breast)
Right (Right breast)
Date of Last Surgery for Breast Cancer Treatment
(last surgery prior to randomization, including
lumpectomy, re-excision of lumpectomy margins,
axillary procedures)
Are the final margins of the resected specimen
histologically free of invasive tumor and DCIS
Yes
No
Disease Stage
Dcis Only (DCIS only)
Invasive And Node Negative (Invasive
and node-negative)
Invasive And Node-positive (Invasive and
node-positive)
Total Number of Axillary Nodes Examined (*)
Total Number of Positive Axillary Nodes (*)
ER
Negative (Negative)
Positive (Positive)
Unknown (Unknown)
PgR
Negative (Negative)
Positive (Positive)
Unknown (Unknown)
Histologic Grade (Use combined histologic grade
SBR/Elston classification.)
Well Differentiated (Grade I (low))
Moderately Differentiated (Grade II
(intermediate))
Poorly Differentiated (Grade III (high))
Is gross disease unifocal or multifocal (Answer
without regard to whether disease is DCIS only,
invasive only, or mixed DCIS/invasive.)
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Multifocal (Multifocal)
Unifocal (Unifocal)
Pathologic Primary Tumor Size (Answer without
regard to whether disease is DCIS only, invasive
only, or mixed DCIS/invasive.)
3 Cm Or Less (3 cm or less)
More Than 3 Cm (More than 3 cm)
The Invasive Tumor
Histologic Type
Ductal (Ductal)
Lobular (Lobular (pure > or =90%))
Other Specify (Other)
Pathologic Primary Tumor Size Measurement
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FORM 5 - SYSTEMIC THERAPY &
FOLLOW-UP REPORT NCT00090974
FORM 5 - SYSTEMIC THERAPY & FOLLOW-UP REPORT
NCT00090974
Quality Of Life Companion Study For JMA27 (NCIC-
MA.27): A Randomized Phase III Trial Of Exemestane
Versus Anastrozole With Or Without Celecoxib In
Postmenopausal Women With Receptor Positive Primary
Breast Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=ABF6F62D-
7F89-673B-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/11491
FORM 5 - SYSTEMIC THERAPY &
FOLLOW-UP REPORT
NCT00090974
Patient Information
Patient Study ID, Coordinating Group
Patient Initials (first - middle - last)
Patient Medical Record Number
Investigator Name
Institution Name
Registered Investigator (NCI Investigator #)
Month Of Report
Month of report (circle one or enter # of months
from randomization)
12 (12)
6 (6)
Other Month (Other)
Other (month of report)
Physical Exam
Date of last clinical assessment (yyyy mmm dd)
Patient Weight (kg)
Status of most recent clinical assessment
Cancer Present (Cancer Present)
No Evidence Of Disease (No evidence of
disease)
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Systemic Therapy Report
Treatment Begin Date (yyyy mmm dd)
Were there any dose modifications or
additions/omissions to protocol treatment?
No (No)
(i.e., The Treatment Was Changed
According To Protocol Guidelines) (Yes
Planned)
(i.e., The Treatment Change Was Not
Part Of Protocol Guidelines) (Yes
Unplanned)
Explanation (Yes, planned modifications to
protocol treatment)
Explanation (Yes, unplanned modifications to
protocol treatment)
Number of Aromatase Inhibitor pills missed or
lost since last follow-up
Number of Celecoxib/Placebo pills missed or lost
since last follow-up
Has Aromatase Inhibitor been permanently
discontinued?
Yes
No
Celecoxib/Placebo End Date (yyyy mmm dd)
Has Celecoxib/Placebo been permanently
discontinued?
Yes
No
Adverse Events
Has the patient experienced a bone fracture
since submission of last follow-up form?
Yes
No
Bone Fracture Site, Spinal (Check)
No (No)
Unknown (Unknown)
Yes (Yes)
Bone Fracture Site, Wrist (Check)
No (No)
Unknown (Unknown)
Yes (Yes)
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Bone Fracture Site, Pelvis (Check)
No (No)
Unknown (Unknown)
Yes (Yes)
Bone Fracture Site, Hip (Check)
No (No)
Unknown (Unknown)
Yes (Yes)
Bone Fracture Site, Femur (Check)
No (No)
Unknown (Unknown)
Yes (Yes)
Bone Fracture Site, Tibia (Check)
No (No)
Unknown (Unknown)
Yes (Yes)
Bone Fracture Site, Ankle (Check)
No (No)
Unknown (Unknown)
Yes (Yes)
Bone Fracture Site, Other (specify) (Check)
No (No)
Unknown (Unknown)
Yes (Yes)
indicate site (bone fracture site)
Date of Bone Fracture (yyyy-mmm-dd)
Has the patient had a new diagnosis of
osteoporosis since submission of last follow-up
form?
Yes
No
Date of new diagnosis of osteoporosis (yyyy
mmm dd)
Has the patient suffered cardiovascular disease
since submission of last follow-up form?
Yes
No
Cardiovascular Event, Myocardial infarction
(Report only events which have occurred since
last report or conditions which were present at
the time of last report and have worsened since.
Report non-ischemic events in the "other"
category.)
No (No)
Unknown (Unknown)
Yes (Yes)
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Cardiovascular Event, Stroke/transient ischemic
attack (TIA) (Report only events which have
occurred since last report or conditions which
were present at the time of last report and have
worsened since.  Report non-ischemic events in
the "other" category.)
No (No)
Unknown (Unknown)
Yes (Yes)
Cardiovascular Event, On-going angina (no
surgical intervention) (Report only events which
have occurred since last report or conditions
which were present at the time of last report and
have worsened since.  Report non-ischemic
events in the "other" category.)
No (No)
Unknown (Unknown)
Yes (Yes)
Cardiovascular Event, Angina requiring
percutaneous transluminal coronary angioplasty
(PTCA) (Report only events which have occurred
since last report or conditions which were present
at the time of last report and have worsened
since.  Report non-ischemic events in the "other"
category.)
No (No)
Unknown (Unknown)
Yes (Yes)
Cardiovascular Event, Thromboembolic event
(Report only events which have occurred since
last report or conditions which were present at
the time of last report and have worsened since.
Report non-ischemic events in the "other"
category.)
No (No)
Unknown (Unknown)
Yes (Yes)
Cardiovascular Event, Other (specify) (Report
only events which have occurred since last report
or conditions which were present at the time of
last report and have worsened since.  Report
non-ischemic events in the "other" category.)
No (No)
Unknown (Unknown)
Yes (Yes)
please describe event (cardiovascular event)
Date of Most Recent Episode (yyyy-mmm-dd)
Other Malignancies Or Myelodysplastic
Syndrome
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Has a new primary cancer or MDS been
diagnosed that has not been previously reported?
Yes
No
Date of diagnosis (yyyy mmm dd)
Malignancy Type
Site(s) of New Primary
Describe (new primary cancer) (See protocol
section 11.0 for details of reporting.)
Hematology
Date Hematology (Blood) Sample Obtained (yyyy
mmm dd)
Peripheral WBC Count (Value)
Lab Unit of Measure (circle unit used)
Mg/dl (mg/dL)
Umol/l (umol/L)
Peripheral Neutrophil Count (granulocytes)
Peripheral Neutrophils % (Value)
Peripheral Platelet Count (Value)
Hemoglobin (Value)
Biochemistry
Specimen Collection Date -- Biochemistry (yyyy
mmm dd)
SGOT (AST) (Value)
SGOT (AST) ULN
SGPT (ALT) (Value)
SGPT (ALT) ULN
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Alkaline Phosphatase (Value)
Alkaline Phosphatase ULN
Creatinine (Value)
Creatinine ULN
Calcium(Ca) (Value)
Calcium LLN
Calcium ULN
Investigations
Imaging site
Chest (CHEST)
Method of Evaluation
Bilateral Mammogram (Bilateral
Mammogram)
Date of Evaluation (yyyy-mmm-dd)
Toxicity Evaluation
Did the patient experience any new or continuing
toxicities of protocol treatment since the last
report?
Yes
No
CTC Adverse Event Term (Code/grade according
to NCI Common Toxicity Criteria, Version 2.0)
abdominal pain or cramping (abdominal
pain or cramping)
anorexia (anorexia)
arthralgia (joint pain) (arthralgia (joint
pain))
constipation (constipation)
cough (cough)
diarrhea (patients without colostomy)
(diarrhea (patients without colostomy))
dizziness/lightheadedness
(dizziness/lightheadedness)
dyspepsia/heartburn
(dyspepsia/heartburn)
dyspnea (shortness of breath) (dyspnea
(shortness of breath))
edema (edema)
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fatigue (lethary/malaise/asthenia)
(fatigue (lethary/malaise/asthenia))
flatulence (flatulence)
headache (headache)
hot flashes/flushes (hot flashes/flushes)
hypercholesterolemia
(hypercholesterolemia)
infection (without neutropenia) (infection
(without neutropenia))
nausea (nausea)
other (other)
rash/desquamation (rash/desquamation)
sweating (diaphoresis) (sweating
(diaphoresis))
vaginal bleeding (vaginal bleeding)
vomiting (vomiting)
CTC Adverse Event Term, Other (specify)
CTC Adverse Event Category (Code/grade
according to NCI Common Toxicity Criteria,
Version 2.0)
cardiovascular (cardiovascular)
constitutional symptoms (constitutional
symptoms)
dermatology/skin (dermatology/skin)
endocrine (endocrine)
gastrointestinal (gastrointestinal)
hemorrhage (hemorrhage)
infection (infection)
metabolic (metabolic)
neurology (neurology)
pain (pain)
pulmonary (pulmonary)
CTC Adverse Event Grade (Code/grade
according to NCI Common Toxicity Criteria,
Version 2.0)
CTC Adverse Event Attribution Code
Definitely (definite)
Possibly (possible)
Probably (probable)
Unlikely (unlikely)
Unrelated (unrelated)
COMMENTS
Treatment Given Since Last Report To
Ncic Ctg
Is the patient receiving any non-protocol cancer
therapy not previously reported?
Yes
No
7 / 8
FORM 5 - SYSTEMIC THERAPY & FOLLOW-UP REPORT
NCT00090974
Non-Protocol Raloxifene Therapy
Yes
No
Non-Protocol Bisphosphonate Therapy
Yes
No
Non-Protocol Lipid Lowering Therapy
Yes
No
Other Non-Protocol Therapy
Yes
No
Other Non-Protocol Therapy Name
Comments
Supporting Documentation
Investigator Signature
Investigator Signature
Person Completing Form, Last Name
Person Completing Form, First Name
Form Completion Date, Original (yyyy mmm dd)
Ccrr Module For Form 5 - Systemic
Therapy & Follow-up Report
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SOUTHWEST ONCOLOGY GROUP
S0230 FOLLOW UP FORM NCT00068601
SOUTHWEST ONCOLOGY GROUP S0230 FOLLOW UP
FORM NCT00068601
Goserelin in Preventing Ovarian Failure in Women
Receiving Chemotherapy for Breast Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=BEA9E0F7-
8786-2E1B-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/11492
SOUTHWEST ONCOLOGY GROUP
S0230 FOLLOW UP FORM
NCT00068601
Header
SWOG Patient ID
SWOG Study No.
Registration Step
Patient Initials (L, F M)
Institution/Affiliate
Physician (Groups other than SWOG)
Group Name
Study No.
Pt. ID
Vital Status
Vital Status
Alive (Alive)
Dead (Dead)
Date of last contact or death
Disease Follow Up Status
Has the patient had a documented clinical
assessment for this cancer since submission of
the previous follow-up form?
Yes
No
Date of Last Clinical Assessment (If Yes)
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Notice Of First Relapse Or Progression
Has the patient developed a first relapse or
progression that has not been previously
reported
Yes
No
Date of Relapse or Progression
Site(s) of Relapse or Progression
Notice Of New Primary
Has a new primary cancer or myelodysplastic
syndrome (MDS) been diagnosed that has not
been previously reported?
Yes
No
Date of Diagnosis (If Yes)
New Primary Site
Non-protocol Treatment
Has the patient received any non-protocol cancer
therapy not previously reported?
Yes
No
Date of First Non-Protocol Therapy
Agents
Long Term Toxicity
Has the patient experienced (prior to treatment
for progression or relapse or a second primary,
and prior to non-protocol treatment) any severe
(grade >= 3) long term toxicity that has not been
previously reported?
Yes
No
Toxicities and Grades
Comments
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Notes
Ccrr Module For Southwest Oncology
Group S0230 Follow Up Form
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SOUTHWEST ONCOLOGY GROUP
NOTICE OF DEATH (S0347) NCT00103233
SOUTHWEST ONCOLOGY GROUP NOTICE OF DEATH
(S0347) NCT00103233
Vinorelbine With or Without Trastuzumab in Treating
Women With Progressive Metastatic Breast Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=DDB47D84-
5BBC-3521-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/11495
SOUTHWEST ONCOLOGY GROUP
NOTICE OF DEATH (S0347)
NCT00103233
Header
SWOG Patient ID
Most Recent SWOG Study No.
Patient Initials (L, F, M)
Institution/Affiliate
Physician
Participating Group Name
Participating Group Study No.
Participating Group Patient ID
Date of death
Date of Death (month / day / year)
Causes Of Death
Any cancer (select one)
Contributory (Contributory)
No (No)
Possible (Possible)
Primary Cause (Primary Cause)
Unknown (Unknown)
If cancer was the primary cause or if cancer
possibly or definitely contributed to death, and the
patient had had multiple tumor types, specify
those which were causes of death
Cancer Of Most Recent Swog Study
(Cancer of most recent SWOG study)
Cancer Of Other Swog Study (Cancer of
other SWOG study)
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Other Cancer (Other cancer)
Cancer of most recent SWOG study, specify
cancer
Cancer of other SWOG study, specify cancer
Other cancer, specify
Toxicity from disease related treatment (select
one)
Contributory (Contributory)
No (No)
Possible (Possible)
Primary Cause (Primary Cause)
Unknown (Unknown)
If Primary Cause, Contributory or Possible,
specify treatment and toxicity
Non-cancer and non-treatment related causes
(select one)
Contributory (Contributory)
No (No)
Possible (Possible)
Primary Cause (Primary Cause)
Unknown (Unknown)
If Primary Cause, Contributory or Possible,
specify
Autopsy?
No (No)
Unknown (Unknown)
Yes (Yes)
Source(s) of death information
Autopsy Report (Autopsy report)
Medical Record / Death Certificate
(Medical record / Death certificate)
Other (Other)
Physician (Physician)
Relative Or Friend (Relative or friend)
Other, specify
Comments
Comments
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NCT00103233  SOUTHWEST ONCOLOGY GROUP
S0347 BASELINE ABNORMALITIES FORM
NCT00103233  SOUTHWEST ONCOLOGY GROUP
S0347 BASELINE ABNORMALITIES FORM
Vinorelbine With or Without Trastuzumab in Treating
Women With Progressive Metastatic Breast Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=E1F033A3-
4D84-26EB-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/11497
NCT00103233  SOUTHWEST
ONCOLOGY GROUP S0347
BASELINE ABNORMALITIES
FORM
Header
SWOG Patient ID
SWOG Study No.
Registration Step
Patient Initials (L, F M)
Institution/Affiliate
Physician (Participating Group)
Group Name
Study No.
Patient ID (Instructions: Using CTCAE 3.0 Grade
definitions, please grade any abnormalities or
conditions present PRIOR to protocol treatment.
Circle AMENDED items in red and write
AMENDED across top of form.)
Adverse event assessment
CTC Adverse Event  Term (Pre-treatment)
Hypersensitivity Nos (Allergic
reaction/hypersensitivity)
Constipation (Constipation)
Cough (Cough)
Diarrhoea Nos (Diarrhea)
Dizziness (exc Vertigo) (Dizziness)
Dyspnoea Nos (Dyspnea)
Fatigue (Fatigue)
Pyrexia (Fever)
Hypotension Nos (Hypotension)
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Injection Site Reaction Nos (Injection site
reaction/extravasation changes)
Insomnia Nec (Insomnia)
Left Ventricular Diastolic Dysfunction
(Left ventricular diastolic dysfunction)
Left Ventricular Failure (Left ventricular
systolic dysfunction)
Leucopenia Nos (Leukocytes)
Muscle Weakness Nos (Muscle
weakness, generalized or specific area -
whole body/generalized)
Nausea (Nausea)
Peripheral Motor Neuropathy
(Neuropathy - motor)
Peripheral Sensory Neuropathy
(Neuropathy - sensory)
Neutropenia (Neutrophils/granulocytes)
Chest Pain (Pain - Chest/thorax NOS)
Headache Nos (Pain - Head/headache)
Tumour Pain (Pain - Tumor pain)
Platelet Count Decreased (Platelets)
Pneumonitis Nos
(Pneumonitis/pulmonary infiltrates)
Dermatitis Exfoliative Nos
(Rash/desquamation)
Rigors (Rigors/chills)
Vomiting Nos (Vomiting)
CTC AE Grade (3.0 1-4)
CTC Adverse Event Term, Other (pre-treatment
specify using CTCAE 3.0 terminology)
Comments
Comments
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ABNORMALITIES FORM
NSABP PROTOCOL B-39: FOLLOW-UP
FORM NCT00103181
NSABP PROTOCOL B-39: FOLLOW-UP FORM
NCT00103181
Radiation Therapy in Treating Women Who Have
Undergone Surgery For Ductal Carcinoma In Situ or Stage
I or Stage II Breast Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=E6FAF17E-
75C9-2EDC-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11498
NSABP PROTOCOL B-39:
FOLLOW-UP FORM NCT00103181
Header
Patient Initials (Last, First, Middle)
Institution Name
NSABP Patient ID (for this "other" protocol, if not
previously reported)
Affiliated Institution Name
Person Completing Form Last Name
Person Completing Form First Name
Person Completing Form Phone
Are data amended? (check box if yes, and circle
amended items)
Yes
No
Vital Status
Patient's Vital Status
Alive (Alive)
Dead (Dead)
Date of Last Contact or Death
Source of Survival Information (if alive)
Documentation Of Hospital Or Clinic Visit
(Documentation of hospital or clinic visit)
Other (Other)
Phone Contact To Patient (Phone
contact to patient)
Other
Primary Cause of Death (if dead)
Due To Other Cause (Due to other
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cause)
Due To Protocol Treatment (Due to
protocol treatment)
Due To This Disease (Due to this
disease)
Unknown (Unknown)
Describe Cause of Death (provide
documentation)
Was there evidence of recurrence at the time of
death?
No (No)
Unknown (Unknown)
Yes (Yes)
Type of Evidence (if yes,)
Autopsy (Autopsy)
Clinical (Clinical)
Cancer Follow-up Status
Has the patient had a documented clinical
assessment for this cancer (since submission of
the last follow-up form?)
Yes
No
Date of Last Clinical Assessment (if applicable)
First Local-regional Recurrence
Has the patient been diagnosed with first local-
regional recurrence (since submission of the last
follow-up form?)
Yes
No
Date of First Local-Regional Recurrence (if
applicable)
Site(s) of First Local-Regional Recurrence (mark
all ipsilateral sites that apply)
Axilla (Axilla)
Axillary Nodes (Axillary nodes)
Chest Wall (Chest wall)
Infraclavicular Nodes (Infraclavicular
nodes)
Internal Mammary (Internal mammary
nodes)
Ipsilateral Breast (Ipsilateral breast)
Supraclavicular Nodes (Supraclavicular
nodes)
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First Distant Recurrence
Has the patient been diagnosed with first distant
recurrence/progression (since submission of the
last follow-up form?)
Yes
No
Date of First Distant Recurrence (if applicable)
Site(s) of First Distant Recurrence
New Primary Cancer Or Mds
Has a new primary cancer or MDS been
diagnosed that has not been previously reported?
Yes
No
Date of Diagnosis (if applicable)
Site(s) of New Primary
Since the last follow-up, has the patient received
any adjuvant hormonal therapy? (prior to cancer
recurrence or second primary cancer)
Aromatase Inhibitor (Aromatase inhibitor)
No (No)
Other (Other)
Serm (SERM)
Yes (Yes)
Has the patient undergone total mastectomy of
the ipsilateral breast that was not previously
reported on Form F?
Yes
No
Total Mastectomy Date (ipsilateral breast only)
In-breast Tumor Recurrence
DATE OF IBTR
LOCATION OF IBTR
At The Site Of The Primary Tumor (At
the site of the primary tumor)
Elsewhere In The Breast (Elsewhere in
the breast)
TREATMENT OF IBTR
Lumpectomy Followed (or To Be
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Followed) By Rt (Lumpectomy followed
(or to be followed) by RT)
Lumpectomy Without Rt (Lumpectomy
without RT)
Mastectomy Followed (or To Be
Followed) By Rt (Mastectomy followed
(or to be followed) by RT)
Mastectomy Without Rt (Mastectomy
without RT)
NSABP breast cancer protocol
Is this patient also enrolled in another NSABP
breast cancer protocol?
Yes
No
Other NSABP Protocol (if not previously
reported)
NSABP Patient ID (for this "other" protocol, if not
previously reported)
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NCT00087178  NSABP PROTOCOL B-36 Form CFMD
Missing Data Form for One-Year Cardiac Function Assessment
NCT00087178  NSABP PROTOCOL B-36 Form CFMD
Missing Data Form for One-Year Cardiac Function
Assessment
Comparison of Two Combination Chemotherapy Regimens
in Treating Women With Breast Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=F4191978-
F435-325C-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11499
NCT00087178  NSABP PROTOCOL
B-36 Form CFMD Missing Data
Form for One-Year Cardiac Function
Assessment
Header module
Patient Initials (Last, First Middle)
Patient ID Number
Institution Name
Affiliate Name
Person Completing Form (Last Name)
Person Completing Form (First Name)
Person Completing Form (Phone)
Today's date (Month Day Year)
Are data amended?
Yes
No
Cardiac Performance Status
Reason Cardiac Function was not Assessed
(Mark the main reason. If necessary, add
comments below.)
Patient Refused Assessment Or Was
Unavailable Because Of Illness Or
Emotional Upset (Patient refused
assessment or was unavailable because
of illness or emotional upset)
Patient Refused Assessment Or Was
Unavailable For A Reason Other Than
Illness Or Upset (Patient refused
assessment or was unavailable for a
reason other than illness or upset)
Staff Concerned For Patient's Medical Or
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Emotional Condition (Staff concerned for
patient's medical or emotional condition)
Staff Oversight Or Understaffing (Staff
oversight or understaffing)
Comments
Comments (optional)
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NCT00087178  NSABP PROTOCOL B-36 Form CFMD Missing Data
Form for One-Year Cardiac Function Assessment
NCT00087178 NSABP PROTOCOL B-36
Baseline Menstrual History Questionnaire
NCT00087178 NSABP PROTOCOL B-36 Baseline
Menstrual History Questionnaire
Comparison of Two Combination Chemotherapy Regimens
in Treating Women With Breast Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=C893003F-
B432-7480-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/11500
NCT00087178 NSABP PROTOCOL
B-36 Baseline Menstrual History
Questionnaire
Header
Patient Initials (Last, First Middle)
NSABP Patient ID
Date Questionnaire Completed
Date Questionnaire Completed (Month Day Year)
Section A
Have you had your uterus removed?
No (No)
Unknown (Unsure)
Yes (Yes)
Have you had both your ovaries removed?
No (No)
Unknown (Unsure)
Yes (Yes)
Have you had a menstrual period or vaginal
bleeding in the last 12 months? (If you have had
bleeding in the last 12 months, continue to
Section B. Otherwise, stop here.)
No (No)
Unknown (Unsure)
Yes (Yes)
Section B
When was your last menstrual period (or vaginal
bleeding)? (Month Year)
Did your periods stop or become less frequent
during the last 12 months?
No (No)
Unknown (Unsure)
Yes (Yes)
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Have you taken hormone replacement therapy
(estrogen and/or progesterone) at any time in the
last 12 months?
No (No)
Unknown (Unsure)
Yes (Yes)
Have you taken hormonal contraceptives (birth
control pills, Norplant, Depo-Provera) at any time
in the last 12 months?
No (No)
Unknown (Unsure)
Yes (Yes)
Ccrr Module For Nsabp Protocol B-36
Baseline Menstrual History Questionnaire
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NCT00087178 NSABP PROTOCOL B-36 Baseline Menstrual History
Questionnaire
E4A03 Treatment Form - Step 2 - Form
2062 NCT00098475
E4A03 Treatment Form - Step 2 - Form 2062
NCT00098475 
Lenalidomide and Dexamethasone With or Without
Thalidomide in Treating Patients With Multiple Myeloma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=DC838DEF-
F7CB-2893-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/11501
E4A03 Treatment Form - Step 2 -
Form 2062 NCT00098475
Header
ECOG Protocol Number
ECOG Patient ID
Registration Step
DCI Name (Place ID Label Here)
Patient Initials
Participating Group Protocol Number
Participating Group Patient ID
Institution/Affiliate
On Treatment Report Period (1 cycle = 28 days)
Cycle 12 Step 2 (Cycle 12 step 2)
Cycle 4 Step 2 (Cycle 4 step 2)
Cycle 8 Step 2 (Cycle 8 step 2)
Are data amended
Yes
No
Section A: Vital Status
Patient Vital Status
Alive (Alive)
Dead (Dead)
Primary Cause of Death (if applicable)
Due To Other Cause, Specify (Due to
other cause)
Due To Protocol Treatment (Due to
protocol treatment)
Due To This Disease (Due to this
disease)
Unknown (Unknown)
1 / 4
Describe cause of death
Date of Last Contact or Death
Day 1 of this Report Period
ECOG Performance status (Day 1 of this report
period)
Fully Active, Able To Carry On All Pre-
disease Performance Without Restriction
(karnofsky 90 - 100) (ecog - 0
Asymptomatic) (0)
Restricted In Physically Strenuous
Activity But Ambulatory (k70 - 80) (ecog -
1 Symptomatic - Fully Ambulatory) (1)
Ambulatory And Capable Of All Selfcare
But Unable To Carry Out Any Work
Activities (k 50 - 60) (ecog - 2
Symptomatic; In Bed , 50% Of The Day)
(2)
Capable Of Limited Selfcare, Confined
To Bed Or Chair More Than 50% Of
Waking Hours. (k 30 - 40) (ecog - 3
Symptomatic; In Bed > 50% Of The Day
But Not Bedridden) (3)
Completely Disabled (k10 - 20) (ecog - 4
Bedridden) (4)
Weight (Day 1 of this report period)
Kg
Cycle Number
Did patient receive pamidronate or zoledronic
acid this report period?
Yes
No
Bisphosphanate type(s) received (If yes:)
Both Pamidronate And Zoledronic Acid
(both pamidronate and zoledronic acid)
Pamidronate (pamidronate)
Zoledronic Acid (zoledronic acid)
Did the patient complete the Patient Diary?
Yes
No
Section B: Therapy Administered During
First Four Cycles Only
Prescribed Dose (mg/day If dose is held, enter
'0')
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Agent Start Date
Agent End Date
Total No. of Days at this Dose Level
Total Dosage at this Dose Level
Were there any dose modifications or
additions/omissions to protocol treatment this
report period?
No (no)
Yes, Planned (i.e., The Treatment Was
Changed According To Protocol
Guidelines) (yes, planned)
Yes, Unplanned (i.e., The Treatment
Change Was Not Part Of Protocol
Guidelines) (yes, unplanned)
Reason for dose modification
Section C: Dexamethasone
Section D: Post Cycle 4 Treatment
Summary
Total number of cycles (this report period)
Agent(s) Modified (If yes:)
Dexamethasone (Dexamethasone)
Cycle of dose modification
Modified dose (mg/day)
Date of dose modifications (Dexamethasone)
Section E: Non-protocol Therapy
Was any non-protocol therapy given during
protocol treatment (not previously reported)?
Yes
No
Section F: Related Forms
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Comments
Comments
Investigator Signature
Investigator Signature Date
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E4A03 Treatment Form - Step 2 - Form 2062 NCT00098475
E4A03 Treatment Form - Step 1 - Form
2059 NCT00098475
E4A03 Treatment Form - Step 1 - Form 2059
NCT00098475 
Lenalidomide and Dexamethasone With or Without
Thalidomide in Treating Patients With Multiple Myeloma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=DC861384-
6E80-3EBD-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/11502
E4A03 Treatment Form - Step 1 -
Form 2059 NCT00098475
Header
ECOG Protocol Number
ECOG Patient ID
Registration Step
DCI Name (Place ID Label Here)
Patient Initials
Participating Group Protocol Number
Participating Group Patient ID
Institution/Affiliate
On Treatment Report Period (1 cycle = 28 days)
Cycle 12 Step 1 (Cycle 12 step 1)
Cycle 4 Step 1 (Cycle 4 step 1)
Cycle 8 Step 1 (Cycle 8 step 1)
Are data amended
Yes
No
Section A: Vital Status
Patient Vital Status
Alive (Alive)
Dead (Dead)
Primary Cause of Death (if applicable)
Due To Other Cause, Specify (Due to
other cause)
Due To Protocol Treatment (Due to
protocol treatment)
Due To This Disease (Due to this
disease)
Unknown (Unknown)
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Describe cause of death
Date of Last Contact or Death
Day 1 of this Report Period
ECOG Performance status (Day 1 of this report
period)
Fully Active, Able To Carry On All Pre-
disease Performance Without Restriction
(karnofsky 90 - 100) (ecog - 0
Asymptomatic) (0)
Restricted In Physically Strenuous
Activity But Ambulatory (k70 - 80) (ecog -
1 Symptomatic - Fully Ambulatory) (1)
Ambulatory And Capable Of All Selfcare
But Unable To Carry Out Any Work
Activities (k 50 - 60) (ecog - 2
Symptomatic; In Bed , 50% Of The Day)
(2)
Capable Of Limited Selfcare, Confined
To Bed Or Chair More Than 50% Of
Waking Hours. (k 30 - 40) (ecog - 3
Symptomatic; In Bed > 50% Of The Day
But Not Bedridden) (3)
Completely Disabled (k10 - 20) (ecog - 4
Bedridden) (4)
Weight (Day 1 of this report period)
Kg
Cycle Number
Did patient receive pamidronate or zoledronic
acid this report period?
Yes
No
Bisphosphanate type(s) received (If yes:)
Both Pamidronate And Zoledronic Acid
(both pamidronate and zoledronic acid)
Pamidronate (pamidronate)
Zoledronic Acid (zoledronic acid)
Did the patient complete the Patient Diary?
Yes
No
Section B: Therapy Administered During
First Four Cycles Only
Prescribed Dose (mg/day If dose is held, enter
'0')
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Agent Start Date
Agent End Date
Total No. of Day at this Dose Level
Total Dosage at this Dose Level
Were there any dose modifications or
additions/omissions to protocol treatment this
report period?
No (no)
Yes, Planned (i.e., The Treatment Was
Changed According To Protocol
Guidelines) (yes, planned)
Yes, Unplanned (i.e., The Treatment
Change Was Not Part Of Protocol
Guidelines) (yes, unplanned)
Reason for dose modification
Section C: Dexamethasone
Section D: Post Cycle 4 Treatment
Summary
Total number of cycles (this report period)
Agent(s) Modified (If yes:)
Dexamethasone (Dexamethasone)
Cycle of dose modification
Modified dose (mg/day)
Date of dose modifications (Dexamethasone)
Section E: Non-protocol Therapy
Was any non-protocol therapy given during
protocol treatment (not previously reported)?
Yes
No
Section F: Related Forms
3 / 4
E4A03 Treatment Form - Step 1 - Form 2059 NCT00098475
Comments
Comments
Investigator Signature
Investigator Signature Date
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FORM 5S - SHORT FOLLOW-UP REPORT
NCT00090974
FORM 5S - SHORT FOLLOW-UP REPORT NCT00090974
Quality Of Life Companion Study For JMA27 (NCIC-
MA.27): A Randomized Phase III Trial Of Exemestane
Versus Anastrozole With Or Without Celecoxib In
Postmenopausal Women With Receptor Positive Primary
Breast Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=ABE490D9-
DEFA-56EC-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/11503
FORM 5S - SHORT FOLLOW-UP
REPORT NCT00090974
Patient Information
Patient Study ID, Coordinating Group
Patient Initials (first - middle - last)
Patient Medical Record Number
Investigator Name
Institution Name
Registered Investigator (NCI Investigator #)
Month Of Report
Month of report (circle one)
12 (12)
24 (24)
36 (36)
48 (48)
60 (60)
Other Month (Other)
Other (month of report)
Date of last clinical assessment (yyyy mmm dd)
Disease Status
Status of most recent clinical assessment
Cancer Present (Cancer Present)
No Evidence Of Disease (No evidence of
disease)
Other Malignancies Or Myelodysplastic
Syndrome
Has a new primary cancer or MDS been
diagnosed that has not been previously reported?
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Yes
No
Date of diagnosis (yyyy mmm dd)
Malignancy Type
Site(s) of New Primary
Describe (new primary cancer or MDS)
Investigations
Imaging site
Chest (Chest)
Method of Evaluation
Bilateral Mammogram (Bilateral
Mammogram)
Date of Evaluation (yyyy-mmm-dd)
Toxicity Evaluation
Did the patient experience any new or continuing
toxicities of protocol treatment since the last
report?
Yes
No
CTC Adverse Event Term (Code/grade according
to NCI Common Toxicity Criteria, Version 2.0)
abdominal pain or cramping (abdominal
pain or cramping)
anorexia (anorexia)
arthralgia (joint pain) (arthralgia (joint
pain))
constipation (constipation)
cough (cough)
diarrhea (patients without colostomy)
(diarrhea (patients without colostomy))
dizziness/lightheadedness
(dizziness/lightheadedness)
dyspepsia/heartburn
(dyspepsia/heartburn)
dyspnea (shortness of breath) (dyspnea
(shortness of breath))
edema (edema)
fatigue (lethary/malaise/asthenia)
(fatigue (lethary/malaise/asthenia))
flatulence (flatulence)
headache (headache)
hot flashes/flushes (hot flashes/flushes)
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hypercholesterolemia
(hypercholesterolemia)
infection (without neutropenia) (infection
(without neutropenia))
nausea (nausea)
other (other)
rash/desquamation (rash/desquamation)
sweating (diaphoresis) (sweating
(diaphoresis))
vaginal bleeding (vaginal bleeding)
vomiting (vomiting)
CTC Adverse Event Term, Other (specify)
CTC Adverse Event Category (Code/grade
according to NCI Common Toxicity Criteria,
Version 2.0)
cardiovascular (cardiovascular)
constitutional symptoms (constitutional
symptoms)
dermatology/skin (dermatology/skin)
endocrine (endocrine)
gastrointestinal (gastrointestinal)
hemorrhage (hemorrhage)
infection (infection)
metabolic (metabolic)
neurology (neurology)
pain (pain)
pulmonary (pulmonary)
CTC Adverse Event Grade (Code/grade
according to NCI Common Toxicity Criteria,
Version 2.0)
CTC Adverse Event Attribution Code
Definitely (definite)
Possibly (possible)
Probably (probable)
Unlikely (unlikely)
Unrelated (unrelated)
COMMENTS
Treatment Given Since Last Report To
Ncic Ctg
Raloxifene Therapy
Yes
No
Bisphosphonate Therapy
Yes
No
Name
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Lipid-lowering Therapy
Yes
No
Name
Is the patient receiving any non-protocol cancer
therapy not previously reported? (Cancer
Therapy)
Yes
No
Name of non-protocol cancer therapy
Adverse Events
Has the patient experienced a bone fracture
since last report?
Yes
No
Bone Fracture Site, Spinal (Check)
No (No)
Unknown (Unknown)
Yes (Yes)
Bone Fracture Site, Wrist (Check)
No (No)
Unknown (Unknown)
Yes (Yes)
Bone Fracture Site, Pelvis (Check)
No (No)
Unknown (Unknown)
Yes (Yes)
Bone Fracture Site, Hip (Check)
No (No)
Unknown (Unknown)
Yes (Yes)
Bone Fracture Site, Femur (Check)
No (No)
Unknown (Unknown)
Yes (Yes)
Bone Fracture Site, Tibia (Check)
No (No)
Unknown (Unknown)
Yes (Yes)
Bone Fracture Site, Ankle (Check)
No (No)
Unknown (Unknown)
Yes (Yes)
Bone Fracture Site, Other (specify) (Check)
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No (No)
Unknown (Unknown)
Yes (Yes)
indicate site (bone fracture site)
Date of Bone Fracture (yyyy-mmm-dd)
Has the patient had a new diagnosis of
osteoporosis since last report?
Yes
No
Date of new diagnosis of osteoporosis (yyyy
mmm dd)
Has the patient suffered cardiovascular disease
since submission of last follow-up form?
Cardiovascular Event, Myocardial infarction
(Report only events which have occurred since
last report or conditions which were present at
the time of last report and have worsened since.
Report non-ischemic events in the "other"
category.)
No (No)
Unknown (Unknown)
Yes (Yes)
Cardiovascular Event, Stroke/transient ischemic
attack (TIA) (Report only events which have
occurred since last report or conditions which
were present at the time of last report and have
worsened since.  Report non-ischemic events in
the "other" category.)
No (No)
Unknown (Unknown)
Yes (Yes)
Cardiovascular Event, On-going angina (no
surgical intervention) (Report only events which
have occurred since last report or conditions
which were present at the time of last report and
have worsened since.  Report non-ischemic
events in the "other" category.)
No (No)
Unknown (Unknown)
Yes (Yes)
Cardiovascular Event, Angina requiring
percutaneous transluminal coronary angioplasty
(PTCA) (Report only events which have occurred
since last report or conditions which were present
at the time of last report and have worsened
since.  Report non-ischemic events in the "other"
category.)
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No (No)
Unknown (Unknown)
Yes (Yes)
Cardiovascular Event, Thromboembolic event
(Report only events which have occurred since
last report or conditions which were present at
the time of last report and have worsened since.
Report non-ischemic events in the "other"
category.)
No (No)
Unknown (Unknown)
Yes (Yes)
Cardiovascular Event, Other (specify) (Report
only events which have occurred since last report
or conditions which were present at the time of
last report and have worsened since.  Report
non-ischemic events in the "other" category.)
No (No)
Unknown (Unknown)
Yes (Yes)
please describe event (cardiovascular event)
Date of Most Recent Episode (yyyy-mmm-dd)
Comments
Supporting Documentation
Investigator Signature
Investigator Signature
Person Completing Form, Last Name
Person Completing Form, First Name
Form Completion Date, Original (yyyy mmm dd)
Ccrr Module For Form 5s - Short Follow-
up Report
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ANBL0321: Death Worksheet
NCT00053326
ANBL0321: Death Worksheet NCT00053326 
Fenretinide in Treating Children With Recurrent or
Resistant Neuroblastoma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=B9B55D16-
FD2B-1EE8-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/11504
ANBL0321: Death Worksheet
NCT00053326
Header
Name
Study Number
Study Number
COG Number
Patient Initials
Today's date
Date worksheet entered into RDE
Death Assessment
Date of Death (1. Required field)
Cause of Death (1. Required field)
Due To This Disease (Due to this
disease)
Due To Protocol Treatment (Fenretinide)
Due To Other Cause, Specify (Other,
Specify)
Unknown (Unknown)
Agent [agent name]
Agent [agent name]
Other, Specify [main reason patient died]
Other, Specify [main reason patient died]
Which of the above causes was the main reason
this patient died? (1. Required field)
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Due To This Disease (Due to this
disease)
Due To Protocol Treatment (Fenretinide)
Due To Other Cause, Specify (Other,
Specify)
Unknown (Unknown)
Autopsy Done? (1. Required field)
Yes
No
How were the side effects of ANBL0321 therapy
related to the patient's death? (1. Required field)
Exclusive Cause Of Death (Exclusive
cause of death)
Major Contribution To Death (Major
contribution to death)
Minor Contribution To Death (Minor
contribution to death)
Not Related (Not related)
Comments
Ccrr Module For Anbl0321: Death
Worksheet
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NSABP PROTOCOL B-38: FOLLOW-UP
FORM - Form F38 NCT00093795
NSABP PROTOCOL B-38: FOLLOW-UP FORM - Form
F38 NCT00093795
Combination Chemotherapy in Treating Women Who Have
Undergone Surgery for Node-Positive Breast Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=DAB4C879-
F3AC-4161-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/11505
NSABP PROTOCOL B-38:
FOLLOW-UP FORM - Form F38
NCT00093795
Header module
Patient Initials
NSABP Patient ID
Institution Name
Affiliate Name
Person completing Form, Last Name
Person completing Form, First Name
Person completing Form, Phone
Are data amended?
Yes
No
Vital Status
Patient's Vital Status
Alive (Alive)
Dead (Dead)
Date of Last Contact or Death
Source of Survival Information (if alive)
Documentation Of Hospital Or Clinic Visit
(Documentation of hospital or clinic visit)
Other (Other)
Phone Contact To Patient (Phone
contact to patient)
Other
Primary Cause of Death
Due To Other Cause, Specify (Due to
other cause)
1 / 5
Due To Protocol Treatment (Due to
protocol treatment)
Due To This Disease (Due to this
disease (breast cancer))
Unknown (Unknown)
Describe Cause of Death
Was there evidence of recurrence at the time of
death?
No (No)
Unknown (Unknown)
Yes, Autopsy (Yes, autopsy)
Yes, Clinical (Yes, clinical)
Cancer Follow-up Status
Has the patient had a documented clinical
assessment for this cancer (since submission of
the last follow-up form)?
Yes
No
Date of Last Clinical Assessment
Hormonal Therapy
Since the last follow-up, has the patient started
any hormonal therapy per protocol (tamoxifen or
aromatase inhibitor)?
Yes
No
First Local-regional Recurrence
Has the patient been diagnosed with first local-
regional recurrence (since submission of the last
follow-up form)?
Yes
No
Date of First Local-Regional Recurrence
Site(s) of First Local-Regional Recurrence
Axilla (Axilla)
Axillary Nodes (Axillary nodes)
Chest Wall (Chest wall)
Infraclavicular Nodes (Infraclavicular
nodes)
Internal Mammary (Internal mammary
nodes)
Ipsilateral Breast (Ipsilateral breast)
Supraclavicular Nodes (Supraclavicular
nodes)
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NCT00093795
First Distant Recurrence
Has the patient been diagnosed with first distant
recurrence/progression (since submission of the
last
follow-up form)?
Yes
No
Date of First Distant Recurrence
Site(s) of First Distant Recurrence
New Primary Cancer Or Mds
Has a new primary cancer or MDS been
diagnosed that has not been previously reported?
Yes
No
Date of Diagnosis
Site(s) of New Primary
Is this the first time Page 2 of Form F38
has been completed for this patient?
Is this the first time Page 2 of Form F38 has been
completed for this patient?
Yes
No
If Yes, Answer The Questions In This
Column.
Did the patient receive any Herceptin treatment?
(since randomization)
Yes
No
Herceptin Treatment Start Date (If yes, if not
previously reported)
Did the patient receive any systemic hormonal
treatment? (If yes, answer for each listed
treatment.)
Yes
No
Tamoxifen
No (No)
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NCT00093795
Unknown (Unknown)
Yes (Yes)
Anastrozole
No (No)
Unknown (Unknown)
Yes (Yes)
Exemestane
No (No)
Unknown (Unknown)
Yes (Yes)
Letrozole
No (No)
Unknown (Unknown)
Yes (Yes)
Raloxifene
No (No)
Unknown (Unknown)
Yes (Yes)
LHRH agonist
No (No)
Unknown (Unknown)
Yes (Yes)
Other
No (No)
Unknown (Unknown)
Yes (Yes)
Other, specify
If No, Answer The Questions In This
Column.
Did the patient receive any Herceptin treatment?
(since randomization)
Yes
No
Herceptin Treatment Start Date (If yes, if not
previously reported)
Did the patient receive any systemic hormonal
treatment? (If yes, answer for each listed
treatment.)
Yes
No
Tamoxifen
No (No)
Unknown (Unknown)
Yes (Yes)
4 / 5
NSABP PROTOCOL B-38: FOLLOW-UP FORM - Form F38
NCT00093795
Anastrozole
No (No)
Unknown (Unknown)
Yes (Yes)
Exemestane
No (No)
Unknown (Unknown)
Yes (Yes)
Letrozole
No (No)
Unknown (Unknown)
Yes (Yes)
Raloxifene
No (No)
Unknown (Unknown)
Yes (Yes)
LHRH agonist
No (No)
Unknown (Unknown)
Yes (Yes)
Other
No (No)
Unknown (Unknown)
Yes (Yes)
Other, specify
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NSABP PROTOCOL B-38: FOLLOW-UP FORM - Form F38
NCT00093795
SOUTHWEST ONCOLOGY GROUP
NOTICE OF DEATH (S0307) NCT00127205
SOUTHWEST ONCOLOGY GROUP NOTICE OF DEATH
(S0307) NCT00127205
Zoledronate, Clodronate, or Ibandronate in Treating Women
Who Have Undergone Surgery for Stage I, Stage II, or
Stage III Breast
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=DE91BEC2-
18BC-080C-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/11506
SOUTHWEST ONCOLOGY GROUP
NOTICE OF DEATH (S0307)
NCT00127205
Header
SWOG Patient ID
Most Recent SWOG Study No.
Patient Initials (L, F, M)
Institution/Affiliate
Physician
Participating Group Name
Participating Group Study No.
Participating Group Patient ID
Date of death
Date of Death
Causes Of Death
Any cancer (select one)
Contributory (Contributory)
No (No)
Possible (Possible)
Primary Cause (Primary Cause)
Unknown (Unknown)
If cancer was the primary cause or if cancer
possibly or definitely contributed to death, and the
patient had had multiple tumor types, specify
those which were causes of death
Cancer Of Most Recent Swog Study
(Cancer of most recent SWOG study)
Cancer Of Other Swog Study (Cancer of
other SWOG study)
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Other Cancer (Other cancer)
Cancer of most recent SWOG study, specify
Cancer of other SWOG study, specify
Other cancer, specify
Toxicity from disease related treatment (select
one:)
Contributory (Contributory)
No (No)
Possible (Possible)
Primary Cause (Primary Cause)
Unknown (Unknown)
If Primary Cause, Contributory or Possible,
specify treatment and toxicity
Non-cancer and non-treatment related causes
(select one:)
Contributory (Contributory)
No (No)
Possible (Possible)
Primary Cause (Primary Cause)
Unknown (Unknown)
If Primary Cause, Contributory or Possible,
specify
Autopsy?
No (No)
Unknown (Unknown)
Yes (Yes)
Source(s) of death information
Autopsy Report (Autopsy report)
Medical Record / Death Certificate
(Medical record / Death certificate)
Other (Other)
Physician (Physician)
Relative Or Friend (Relative or friend)
Other, specify
Comments
Comments
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SOUTHWEST ONCOLOGY GROUP NOTICE OF DEATH (S0307)
NCT00127205
ACNS0122: RADIATION THERAPY
WORKSHEET NCT00047320
ACNS0122: RADIATION THERAPY WORKSHEET
NCT00047320 
Neoadjuvant Chemotherapy With or Without Second-Look
Surgery Followed by Radiation Therapy With or Without
Peripheral Stem Cell Transplantation in Treating Patients
With Intracranial Germ Cell Tumors
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=BD90B467-
C41E-1633-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/11507
ACNS0122: RADIATION THERAPY
WORKSHEET NCT00047320
Header
Institution Name
COG Study No
COG Study No
COG Patient ID
Patient Initials
Today's date
Date worksheet entered into RDE
Treatment period
Reporting Period
Reporting Period start date
Reporting Period end date
Tumor Evaluation
Type [imaging studies] (Type of imaging studies:)
Mri (MRI of Brain with gadolinium)
Mri (MRI of Brain without gadolinium)
Mri (MRI of Spine with gadolinium)
Mri (MRI of Spine without gadolinium)
Other, Specify (Other (specify))
Specify [other type of imaging study]
Date
1 / 6
Disease Status
Was the patient's disease status evaluated during
this reporting interval?
Yes
No
Comments
Type of response
Complete Response (Complete
Response (CR))
Continuing complete response
(Continuing complete response)
Death Prior To Completion Of Protocol
Criteria (Early death)
Incomplete Response Or Stable
Disesase (Incomplete response/SD)
Insufficient Evaluation (Not evaluable)
Partial Response (Partial Response
(PR))
Partial Response (Progressive Disease
(PD))
Recurrent Disease (Recurrent Disease)
Stable Disease (Stable Disease)
Date
Evaluations
Was a Neurologic assessment done?
No (No)
No (No)
Not done/not available (Not done/not
available)
Yes (Yes)
Was endocrinologic evaluation done?
No (No)
Not done/not available (Not done/not
available)
Unknown (Unknown)
Yes (Yes)
Significant Events During This Reporting
Period
Were there any dose modifications or
additions/omissions to protocol treatment?
No (No)
Yes (Yes)
Yes, Planned (i.e., The Treatment Was
Changed According To Protocol
Guidelines) (Yes, planned)
Yes, Unplanned (i.e., The Treatment
Change Was Not Part Of Protocol
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Guidelines) (Yes, unplanned)
please specify [other reason for dose
modifications] (If yes,)
please specify [other reason for dose
modifications] (If yes,)
please specify [other reason for dose
modifications] (If yes,)
Has a new primary cancer or MDS been
diagnosed that has not been previously reported?
Yes
No
Date of diagnosis
Is patient off protocol therapy?
Yes
No
date off [protocol therapy] (If yes,)
Reason off protocol therapy
Adverse Event/side Effects/complications
(Adverse Event/Side
Effects/Complications)
Alternative Therapy (Alternative therapy)
Treatment Completed Per Protocol
Criteria (Completion of protocol therapy.)
Cytogenetic Resistance (Cytogenetic
Resistance)
Death On Study (Death on study)
Decision of the patient?s family to
withdraw the patient from protocol
therapy. (Decision of the patient?s family
to withdraw the patient from protocol
therapy.)
Disease Progression Before Active
Treatment (Disease Progression before
Active Treatment)
Lost To Follow-up (Lost to follow-up)
Disease Progression, Relapse During
Active Treatment (Neuraxis
dissemination during or after
chemotherapy)
Disease Progression, Relapse During
Active Treatment (Neuraxis
dissemination or locally progressive
disease during or after radiation therapy.)
Other (Other)
Patient Off-treatment For Other
Complicating Disease (Patient off-
treatment for other complicating disease)
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Patient refusal or withdrawal from
therapy. (Patient refusal or withdrawal
from therapy.)
Patient Withdrawal Or Refusal After
Beginning Protocol Therapy (Patient
withdrawal or refusal after beginning
protocol therapy)
Patient Withdrawal Or Refusal Before
Beginning Protocol Therapy (Patient
withdrawal or refusal prior to beginning
protocol therapy)
Patient withdrawn from protocol therapy
due to physician?s choice. (Patient
withdrawn from protocol therapy due to
physician?s choice.)
Life status at the end of this reporting period
Alive (Alive)
Dead (Dead)
Was patient confirmed lost to follow up at the end
of this reporting period?
Yes
No
Was patient enrolled on another COG therapeutic
study at the end of this reporting period?
Yes
No
Did the patient withdraw consent for follow-up at
the end of the reporting period?
Yes
No
Did the patient receive non-protocol anti-cancer
treatment during this reporting period?
Yes
No
Type [non-protocol treatment] (Types of
Treatment)
Bone Marrow Transplant (Bone Marrow
Transplant)
Chemotherapy (Chemotherapy)
Extensive Radiation (Extensive radiation)
Limited Radiation (Limited radiation)
Other Therapy (Other (specify))
External Beam Radiation (Radiation)
Radiation (nos) (Radiation (NOS))
Surgery (Surgery)
Specify [other type of non-protocol treatment]
Start Date [non-protocol treatment]
End Date [non-protocol treatment]
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Description (drug, dose, etc.)
Treatment Plan After This Treatment
Period
What is the patient's treatment plan after
chemotherapy?
Conformal Radiation Therapy (Conformal
Radiation Therapy)
No Further Therapy (No further therapy)
Other Specify (Other, specify)
Second-look Surgery (Second surgery)
please specify [other treatment plan after
chemotherapy] (If 'Other',)
Toxicities
Category
Type
Code
Grade
Attribution
Definite (Definite)
Possible (Possible)
Probable (Probable)
Unlikely (Unlikely)
Unrelated (Unrelated)
Adverse Drug Experience?
Yes
No
Date Onset
Date of test or evaluation showing toxicity
resolved to eligibility requirement or baseline
check box if not resolved
Comments
Comments
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Ccrr Module For Acns0122: Radiation
Therapy Worksheet
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NCT00103181 NSABP Protocol B-39 Radiation Therapy Report
for Patients Randomized to PBI (Group 2 Patients Only)
NCT00103181 NSABP Protocol B-39 Radiation Therapy
Report for Patients Randomized to WBI (Group 1 Patients
Only)
Radiation Therapy in Treating Women Who Have
Undergone Surgery For Ductal Carcinoma In Situ or Stage
I or Stage II Breast Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=E74B2A88-
D6F8-68E8-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11509
NCT00103181 NSABP Protocol B-
39 Radiation Therapy Report for
Patients Randomized to PBI (Group
2 Patients Only)
Header
Patient Initials
Institution Name
NSABP Patient ID
Affiliated Institution Name
Person Completing Form Last Name
Person Completing Form First Name
Person Completing Form Phone
Are data amended (check box if yes, and circle
amended items)
Yes
No
Radiation Therapy
Type of Radiation Therapy Received (prior to
treatment failure or second primary cancer)
No Breast Irradiation (No Breast
Irradiation)
Partial Breast Irradiation (Partial Breast
Irradiation)
Whole Breast Irradiation (Whole Breast
Irradiation)
Side Irradiated
1 (Left)
2 (Right)
RT Facility Code
1 / 3
RT Begin Date
RT End Date
Whole Breast Prior To Boost
Total Dose Prior to Boost
Total Number of Fractions Prior to Boost
Was a boost given? (If yes, complete this
section.)
Yes
No
RT Total Dose to Boost Field
Total Number of Fractions to Boost Field
Unscheduled Interruptions
Were there any unscheduled interruptions in
radiation therapy
Yes
No
Was RT interruption possibly, probably, or
definitely due to RT toxicity
Yes
No
Reason Treatment Ended
Adverse Event/side Effects/complications
(Adverse event/side
effects/complications)
Death, Recurrence, Or Second Primary
Cancer (Death, recurrence, or second
primary cancer)
Other (Other)
Patient Withdrawal Or Refusal (Patient
withdrawal or refusal after beginning
protocol therapy)
Treatment Completed Per Protocol
Criteria (Treatment completed per
protocol criteria)
Dosimetry technique used for treatment planning
3d Conformal Radiation Therapy (3D-
conformal)
External Contour Fluoroscopy (External
contour (flouro))
Field In Field (Field in field)
Other (Other)
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NCT00103181 NSABP Protocol B-39 Radiation Therapy Report for
Patients Randomized to PBI (Group 2 Patients Only)
Single Axial Ct Slice (Single axial CT
slice)
Other, specify
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NCT00103181 NSABP Protocol B-39 Radiation Therapy Report for
Patients Randomized to PBI (Group 2 Patients Only)
NCT00382018 SOUTHWEST ONCOLOGY
GROUP NOTICE OF DEATH
NCT00382018 SOUTHWEST ONCOLOGY GROUP
NOTICE OF DEATH
Treatment Decision Making Based on Blood Levels of
Tumor Cells in Women With Metastatic Breast Cancer
Receiving Chemotherapy
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=07BF17A4-
2762-0342-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11510
NCT00382018 SOUTHWEST
ONCOLOGY GROUP NOTICE OF
DEATH
Header
SWOG Patient ID
Most Recent SWOG Study No.
Patient Initials (L, F, M)
Institution/Affiliate
Physician
Participating Group Name
Participating Group Study No.
Participating Group Patient ID
Date of death
Date of Death (month / day / year)
Causes Of Death
Any cancer (select one)
Contributory (Contributory)
No (No)
Possible (Possible)
Primary Cause (Primary Cause)
Unknown (Unknown)
If cancer was the primary cause or if cancer
possibly or definitely contributed to death, and the
patient had had multiple tumor types, specify
those which were causes of death
Cancer Of Most Recent Swog Study
(Cancer of most recent SWOG study)
Cancer Of Other Swog Study (Cancer of
other SWOG study)
1 / 2
Other Cancer (Other cancer)
Cancer of most recent SWOG study, specify
cancer
Cancer of other SWOG study, specify cancer
Other cancer, specify
Toxicity from disease related treatment (select
one)
Contributory (Contributory)
No (No)
Possible (Possible)
Primary Cause (Primary Cause)
Unknown (Unknown)
If Primary Cause, Contributory or Possible,
specify treatment and toxicity
Non-cancer and non-treatment related causes
(select one)
Contributory (Contributory)
No (No)
Possible (Possible)
Primary Cause (Primary Cause)
Unknown (Unknown)
If Primary Cause, Contributory or Possible,
specify
Autopsy?
No (No)
Unknown (Unknown)
Yes (Yes)
Source(s) of death information
Autopsy Report (Autopsy report)
Medical Record / Death Certificate
(Medical record / Death certificate)
Other (Other)
Physician (Physician)
Relative Or Friend (Relative or friend)
Other, specify
Comments
Comments
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ACNS0122 Consolidation Worksheet
NCT00047320
ACNS0122 Consolidation Worksheet NCT00047320 
Neoadjuvant Chemotherapy With or Without Second-Look
Surgery Followed by Radiation Therapy With or Without
Peripheral Stem Cell Transplantation in Treating Patients
With Intracranial Germ Cell Tumors
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=BD4225D7-
47E1-0D12-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/11511
ACNS0122 Consolidation Worksheet
NCT00047320
Reporting period
Reporting Period
Reporting Period start date
Reporting Period end date
Height
cm
Weight
Kg
BSA
Tumor Evaluation
Type [imaging studies]
Mri (Cranial MRI with gadolinium)
Mri (MRI of Spine with gadolinium)
Other, Specify (Other (specify))
Specify [other type of imaging study]
Date
Disease Status
Was the patient's disease status evaluated during
this reporting interval?
Yes
No
Type of response
Complete Response (Complete
Response (CR))
Death Prior To Completion Of Protocol
Criteria (Early death)
1 / 6
Incomplete Response Or Stable
Disesase (Incomplete response/SD)
Less than Partial Response (<PR) (Less
than Partial Response (<PR))
Insufficient Evaluation (Not evaluable)
Partial Response (Partial Response
(PR))
Progressive Disease (Progressive
Disease (PD))
Recurrent Disease (Recurrent Disease)
Stable Disease (Stable Disease)
Date
Comments
Evaluations
Was a Neurologic assessment done?
No (No)
Not done/not available (Not done/not
available)
Unknown (Unknown)
Yes (Yes)
Was endocrinologic evaluation done?
No (No)
Not done/not available (Not done/not
available)
Unknown (Unknown)
Yes (Yes)
Significant Events During This Reporting
Period
Were there any dose modifications or
additions/omissions to protocol treatment?
No (No)
Yes (Yes)
Yes, Planned (i.e., The Treatment Was
Changed According To Protocol
Guidelines) (Yes, planned)
Yes, Unplanned (i.e., The Treatment
Change Was Not Part Of Protocol
Guidelines) (Yes, unplanned)
specify [other reason for dose modifications] (If
due to other reason,)
specify [other reason for dose modifications] (If
due to other reason,)
specify [other reason for dose modifications] (If
due to other reason,)
2 / 6
ACNS0122 Consolidation Worksheet NCT00047320
Has a new primary cancer or MDS been
diagnosed that has not been previously reported?
Yes
No
Date of diagnosis
Is patient off protocol therapy?
Yes
No
date off [protocol therapy] (If yes,)
Reason treatment ended
Adverse Event/side Effects/complications
(Adverse Event/Side
Effects/Complications)
Alternative Therapy (Alternative therapy)
Treatment Completed Per Protocol
Criteria (Completion of protocol therapy.)
Cytogenetic Resistance (Cytogenetic
Resistance)
Death On Study (Death on study)
Decision of the patient?s family to
withdraw the patient from protocol
therapy. (Decision of the patient?s family
to withdraw the patient from protocol
therapy.)
Disease Progression Before Active
Treatment (Disease Progression before
Active Treatment)
Lost To Follow-up (Lost to follow-up)
Disease Progression, Relapse During
Active Treatment (Neuraxis
dissemination during or after
chemotherapy)
Disease Progression, Relapse During
Active Treatment (Neuraxis
dissemination or locally progressive
diseases during or after radiation
therapy.)
Other (Other)
Patient Off-treatment For Other
Complicating Disease (Patient off-
treatment for other complicating disease)
Patient refusal or withdrawal from
therapy. (Patient refusal or withdrawal
from therapy.)
Patient Withdrawal Or Refusal After
Beginning Protocol Therapy (Patient
withdrawal or refusal after beginning
protocol therapy)
Patient Withdrawal Or Refusal Before
Beginning Protocol Therapy (Patient
withdrawal or refusal prior to beginning
protocol therapy)
Patient withdrawn from protocol therapy
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due to physician?s choice. (Patient
withdrawn from protocol therapy due to
physician?s choice.)
Life status at the end of this reporting period
Alive (Alive)
Dead (Dead)
Was patient unable to be contacted for current
scheduled follow-up?
Yes
No
Was the patient enrolled on another COG
therapeutic study at the end of the reporting
period?
Yes
No
Did the patient withdraw consent for follow-up at
the end of the reporting period?
Yes
No
Did the patient receive non-protocol anti-cancer
treatment during this reporting period?
Yes
No
Type [non-protocol treatment] (Types of
Treatment)
Bone Marrow Transplant (Bone Marrow
Transplant)
Chemotherapy (Chemotherapy)
Extensive Radiation (Extensive radiation)
Limited Radiation (Limited radiation)
Other Therapy (Other (specify))
External Beam Radiation (Radiation)
Radiation (nos) (Radiation (NOS))
Surgery (Surgery)
Specify [other type of non-protocol treatment]
Start Date [non-protocol treatment]
End Date [non-protocol treatment]
Description (drug, dose, etc.)
Treatment Plan After This Treatment
Period
What is the patient's treatment plan after
chemotherapy?
Conformal Radiation Therapy (Conformal
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Radiation Therapy)
No Further Therapy (No further therapy)
Other Specify (Other, specify)
Second-look Surgery (Second surgery)
please specify [other treatment plan after
chemotherapy] (If 'Other',)
Toxicities
Category
Type
Code
Grade
Attribution
Definite (Definite)
Possible (Possible)
Probable (Probable)
Unlikely (Unlikely)
Unrelated (Unrelated)
Adverse Drug Experience?
Yes
No
Date Onset
Date of test or evaluation showing toxicity
resolved to eligibility requirement or baseline
check box if not resolved
Comments
Comments
Ccrr Module For Acns0122 Consolidation
Worksheet
Institution Name
COG Study No
COG Study No
5 / 6
ACNS0122 Consolidation Worksheet NCT00047320
COG Patient ID
Patient Initials
Date Form Originally Completed
Date worksheet entered into RDE
6 / 6
ACNS0122 Consolidation Worksheet NCT00047320
E3201 Step 2 Baseline Data Form (Group I)
NCT00068692
E3201 Step 2 Baseline Data Form (Group I) NCT00068692
Comparison of Adjuvant Chemotherapy Regimens in
Treating Patients With Stage II or Stage III Rectal Cancer
Who Are Receiving Radiation Therapy and Fluorouracil
Before or After Surgery
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=B5522BC2-
8C05-6DAC-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/11513
E3201 Step 2 Baseline Data Form
(Group I) NCT00068692
Header
DCI Name
Registration Step
Time period
Baseline Step 2 (Baseline Step 2)
Patient Initials
ECOG Protocol Number
ECOG Protocol Number
ECOG Patient ID
ECOG Patient ID
Participating Group Protocol No.
Participating Group Patient ID
Institution/Affiliate
Data amendment
Are data amended? (If yes, please circle
amended items in red)
Yes
No
Performance status
2 (Ambulatory and capable of all selfcare
but unable to carry out any work
activities (K 50-60))
3 (Capable of only limited selfcare,
confined to bed or chair more than 50%
of waking hours (K 30-40))
1 / 2
4 (completely disabled (K 10-20))
0 (Fully active, able to carry on all pre-
disease performance without restriction
(Karnofsky 90-100))
1 (Restricted in physically strenuous
activity but ambulatory (K 70-80))
Date CEA obtained
CEA patient value
CEA ULN
CTC Adverse Event Term
CTC Adverse Event Grade
CTC Adverse Event Attribution Code
Definite (definitely)
Possible (possibly)
Probable (probably)
Unlikely (unlikely)
Unrelated (unrelated)
Comments
Ccrr Module For E3201 Step 2 Baseline
Data Form (group I)
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E3201 On-Study Form NCT00068692
E3201 On-Study Form NCT00068692
Comparison of Adjuvant Chemotherapy Regimens in
Treating Patients With Stage II or Stage III Rectal Cancer
Who Are Receiving Radiation Therapy and Fluorouracil
Before or After Surgery
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=B5520AD5-
E6B5-6D17-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/11516
E3201 On-Study Form
NCT00068692
Header
ECOG Protocol Number
ECOG Patient ID
DCI Name
Registration Step
Time Period
Study Entry (Study Entry)
Patient Initials
Participating Group Protocol No.
Participating Group Patient ID
Institution/Affiliate
Are data amended?
Yes
No
Tumor Statging
Histologic Grade (Differentiation)
Moderately Differentiated (grade II)
(Moderately Differentiated (grade II))
Poorly Differentiated (Grade III) (Poorly
Differentiated (Grade III))
Undifferentiated (Grade IV)
(Undifferentiated (Grade IV))
Well Differentiated (grade I) (Well
Differentiated (grade I))
Clinical T Stage
T1 (T1)
T2 (T2)
T3 (T3)
1 / 2
T4 (T4)
Clinical N Stage
No Regional Lymph Node Metastasis
(N0)
Metastasis In 1 To 3 Regional Lymph
Nodes (N1)
Metastasis In 4 Or More Regional Lymph
Nodes (N2)
N3 (N3)
Clinical M Stage
No Distant Metastasis (M0)
Distant Metastasis (M1)
Performance status
2 (Ambulatory and capable of all selfcare
but unable to carry out any work
activities (K 50-60))
3 (Capable of only limited selfcare,
confined to bed or chair more than 50%
of waking hours (K 30-40))
4 (completely disabled (K 10-20))
0 (Fully active, able to carry on all pre-
disease performance without restriction
(Karnofsky 90-100))
1 (Restricted in physically strenuous
activity but ambulatory (K 70-80))
Patient height
cm
Date CEA obtained
CEA patient value
CEA ULN
CTC Adverse Event Term
CTC Adverse Event Grade
Comments
Ccrr Module For E3201 On-study Form
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E3201 On-Study Form NCT00068692
E3201 Adverse Event Form NCT00068692
E3201 Adverse Event Form NCT00068692
Comparison of Adjuvant Chemotherapy Regimens in
Treating Patients With Stage II or Stage III Rectal Cancer
Who Are Receiving Radiation Therapy and Fluorouracil
Before or After Surgery
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=B5521EAE-
B379-6D90-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/11517
E3201 Adverse Event Form
NCT00068692
Header
Registration Step
Adverse Event Reporting From Date (M D Y)
Adverse Event Reporting To Date (M D Y)
Patient Initials
ECOG Protocol Number
ECOG Protocol Number
ECOG Patient ID
ECOG Patient ID
Participating Group Protocol No.
Participating Group Patient ID
Institution/Affiliate
Data amendment
Are data amended? (If yes, please circle
amended items in red)
Yes
No
Adverse event assessment
CTC Adverse Event Term
CTC Adverse Event Grade
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CTC Adverse Event Attribution Code
Definite (definitely)
Possible (possibly)
Probable (probably)
Unlikely (unlikely)
Unrelated (unrelated)
Other CTC Adverse Event Term(s) not listed (Use
CTC terminology)
Comments
Comments
Investigator Signature
Date
Ccrr Module For E3201 Adverse Event
Form
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E5202 Colon Cancer On-Study Form
NCT00217737
E5202 Colon Cancer On-Study Form NCT00217737
Oxaliplatin, Leucovorin, and Fluorouracil With or Without
Bevacizumab in Treating Patients Who Have Undergone
Surgery for Stage II Colon Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=EF21AC34-
1C36-1B9F-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11518
E5202 Colon Cancer On-Study Form
NCT00217737
Header
ECOG Protocol Number
ECOG Patient ID
DCI Name
Registration Step
Report period
Baseline (Baseline)
Patient demographics
Patient Initials
ECOG Protocol Number
Participating Group Protocol Number
ECOG Patient ID
Institution/Affiliate
Participating Group Patient ID
Data amendment
Are data amended (If yes, please circle amended
items in red)
Yes
No
Baseline Evaluation
Height
cm
1 / 4
Performance status
Fully Active, Able To Carry On All Pre-
disease Performance Without
Restriction. (0=)
Restricted In Physically Strenuous
Activity But Ambulatory And Able To
Carry Out Work Of A Light Or Sedentary
Nature, E.g., Light Housework, Office
Work. (1=)
Ambulatory And Capable Of All Selfcare
But Unable To Carry Out Any Work
Activities. Up And About More Than 50%
Of Waking Hours. (2=)
Capable Of Only Limited Selfcare,
Confined To Bed Or Chair More Than
50% Of Waking Hours. (3=)
Completely Disabled. Cannot Carry On
Any Selfcare. Totally Confined To Bed Or
Chair. (4=)
Histologic Type
Adenocarcinoma (Adenocarcinoma)
Adenosquamous Carcinoma
(Adenosquamous adenocarcinoma)
Medullary Carcinoma (Medullary
carcinoma)
Mucinous (colloid) Adenocarcinoma
(Mucinous adenocarcinoma)
Other (Other)
Signet-ring Cell Adenocarcinoma (Signet
ring cell adenocarcinoma)
Small Cell Carcinoma (oat Cell) (Small
cell carcinoma)
Squamous Cell Carcinoma (Squamous
cell carcinoma)
Undifferentiated Or Solid Carcinoma
(Undifferentiated or solid carcinoma)
Other Specify
Histologic Grade (Differentiation)
Moderately Differentiated (Moderately
Differentiated)
Poorly Differentiated (Poorly
Differentiated)
Well Differentiated (Well Differentiated)
Pathologic Staging
Pathologic T Stage
T1, According To Ajcc Criteria (T1)
T2, According To Ajcc Criteria (T2)
T3, According To Ajcc Criteria (T3)
T4, According To Ajcc Criteria (T4)
If T3, select one of the following
Tumor Invades Through The Muscularis
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Propria Into The Subserosa Or The
Nonperitonealized Pericolic Or Perirectal
Soft Tissues; Invades 5 Mm Or Less
Beyond The Border Of The Muscularis
Propria (a/b)
Tumor Invades Through The Muscularis
Propria Into The Subserosa Or The
Nonperitonealized Pericolic Or Perirectal
Soft Tissue; Invades Greater Than 5 Mm
Beyond The Border Of The Muscularis
Propria (c/d)
Indeterminate (Indeterminate)
Number of Lymph Nodes Examined
Cea
Date CEA obtained
CEA value
CEA ULN
Disease Description
Primary Site
Ascending Colon (Ascending Colon)
Cecum (Cecum)
Colon Site Not Otherwise Specified
(Colon, not otherwise specified)
Descending Colon (Descending Colon)
Hepatic Flexure (Hepatic Flexure)
Multiple Sites (Multiple sites)
Rectum (Rectal)
Sigmoid Colon (Sigmoid Colon)
Splenic Flexure (Splenic Flexure)
Transverse Colon (Transverse Colon)
Unable To Determine Exact Site (Unable
to determine exact site)
If multiple sites, specify
Primary Tumor Size (Enter the greatest
dimension)
Was there bowel obstruction
No (No)
Unknown (unknown)
Yes (Yes)
Was there bowel perforation
Indeterminate (Indeterminate)
No (No)
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Yes (Yes)
Biological Markers
Microsatellite Instability Status
Microsatellite Instability - High (MSI-H)
Microsatellite Instability - Low (MSI-L)
Microsatellite Instability - Stable (MSS)
18q Loss of Heterozygosity Status (LOH)
With Loh (With LOH)
Without Loh (Without LOH)
Comments
Comments
Investigator Signature
Investigator Signature Date
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NSABP Protocol B-36 Form ALERT
NCT00087178
NSABP Protocol B-36 Form ALERT NCT00087178 
Comparison of Two Combination Chemotherapy Regimens
in Treating Women With Breast Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=C87A9592-
E554-5B27-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/11519
NSABP Protocol B-36 Form ALERT
NCT00087178
Header
Patient Initials (Last, First Middle)
NSABP Patient ID
Institution Name
Affiliate Name
Treating MD (Last Name)
Treating MD (First Name)
Treating MD (Phone)
Person Completing Form (First Name)
Person Completing Form (First Name)
Person Completing Form (Phone)
Are data amended?
Yes
No
Miscellaneous Patient Information
Date of this Report (Month Day Year)
Adverse Event Onset Date (Month Day Year)
Patient's Age at Time of AE
Was patient hospitalized for 24 hours or more?
1 / 2
Specify [aromatase inhibitor]
Specify [aromatase inhibitor]
Date of Most Recent Treatment (0=not begun)
Adverse event assessment
Describe the adverse event.
CTCAE v3.0 Short Name
CTCAE v3.0 "Select" Term (if applicable)
ALERT Category (letter, number)
Ccrr Module For Nsabp Protocol B-36
Form Alert
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E1305 Sensory Neuropathy Form
NCT00588770
E1305 Sensory Neuropathy Form NCT00588770
Chemotherapy With or Without Bevacizumab in Treating
Patients With Recurrent or Metastatic Head and Neck
Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=3EFA1187-
27D1-22F1-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11520
E1305 Sensory Neuropathy Form
NCT00588770
Header
ECOG Protocol Number
ECOG Patient ID
DCI Name
Registration Step
Patient demographics
Patient Initials (Last, First)
ECOG Protocol Number
ECOG Patient ID
Participating Group Protocol Number
Participating Group Patient ID
Institution/Affiliate
Data amendment
Please mark an 'X' if data have been amended
(Please circle amended items in red)
Date data amended (s M D Y)
Off Treatment
Off Treatment Report Period (Choose one)
12 Months Post-treatment (12 Months
Post-Treatment)
1 / 2
6 Months Post-treatment (6 Months Post-
Treatment)
9 Months Post-treatment (9 Months Post-
Treatment)
Adverse Events
Were adverse events assessed during this report
period (Sensory Neuropathy cycle)
No (No)
Yes, And Reportable Adverse Events
Occurred (Yes, and reportable adverse
events occurred)
Yes, But No Reportable Adverse Events
Occurred (Yes, but no reportable adverse
events occurred)
CTC Adverse Event Report Begin Date (M D Y)
CTC Adverse Event Report End Date (M D Y)
Blood/bone Marrow - Labs
CTC Adverse Event Term
Peripheral Sensory Neuropathy
(Peripheral sensory neuropathy)
CTC Adverse Event Grade (v4.0 this cycle)
Moderate Adverse Event (2)
Severe Adverse Event (3)
Life Threatening Adverse Event (4)
Death Related To Adverse Event (5)
CTC AE Attribution Code
Definite (Definite)
Possible (Possible)
Probable (Probable)
Unlikely (Unlikely)
Unrelated (Unrelated)
Outcome of Adverse Event
Adverse Event Was Fatal (fatal)
Adverse Event Has Improved (improved)
Adverse Event Is Resolved (resolved)
Adverse Event Is Unchanged
(unchanged)
Adverse Event Is Worse (worsened)
Comments
Investigator Signature
Investigator Signature Date
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ADVL0212: Death Worksheet
NCT00053963
ADVL0212: Death Worksheet NCT00053963 
FR901228 in Treating Children With Refractory or
Recurrent Solid Tumors or Leukemia
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=B1EAD089-
F0A7-3073-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/11521
ADVL0212: Death Worksheet
NCT00053963
Header
Name of Institution
Study Number
Study Number
COG Number
Patient's Initials
Date worksheet entered into RDE
Death Assessment
Date of Death (MM/DD/YYYY)
Cause of Death (Check all that apply)
ARDS (ARDS)
Due To Protocol Treatment
(Depsipeptide)
GVHD (GVHD)
Hemorrhage (Hemorrhage)
Infection (Infection)
Multi-Organ Failure (Multi-Organ Failure)
Due To Other Cause, Specify (Other)
Other Drug (Other Drug)
Due To This Disease (Tumor)
Unknown (Unknown)
please specify the name of the drug (1. Text field)
please specify the cause of death not listed (1.
Text field)
Which of the above causes was the main reason
this patient died? (Pick One)
ARDS (ARDS)
Due To Protocol Treatment
(Depsipeptide)
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GVHD (GVHD)
Hemorrhage (Hemorrhage)
Infection (Infection)
Multi-Organ Failure (Multi-Organ Failure)
Due To Other Cause, Specify (Other)
Other Drug (Other Drug)
Due To This Disease (Tumor)
Unknown (Unknown)
Autopsy Done? (1. Required field)
Yes
No
How were the side effects of ADVL0212 therapy
related to the patient's death? (1. Required field)
Exclusive Cause Of Death (Exclusive
cause of death)
Major Contribution To Death (Major
contribution to death)
Minor Contribution To Death (Minor
contribution to death)
Not Related (Not related)
Comments
Ccrr Module For Advl0212: Death
Worksheet
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ADVL0212: Death Worksheet NCT00053963
E2902 Adverse Event Form - (CTCAE v3)
NCT00093470
E2902 Adverse Event Form - (CTCAE v3) NCT00093470 
Tipifarnib in Treating Patients With Acute Myeloid Leukemia
in Remission
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=DBCDA63A-
8A39-2CC7-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/11522
E2902 Adverse Event Form -
(CTCAE v3) NCT00093470
Header
DCI Name (Place ID Label Here)
Patient Initials (Last, First)
ECOG Protocol Number
ECOG Protocol Number
ECOG Patient ID
ECOG Patient ID
Participating Group Protocol Number
Participating Group Patient ID
Institution/Affiliate
Registration Step
Data amendment
Are data amended
Yes
No
On Treatment Or Observation
On Treatment Report Period (Choose one)
> Cycle 33 (> Cycle 33)
Cycle 1 (Cycle 12)
Cycle 15 (Cycle 15)
Cycle 18 (Cycle 18)
Cycle 2 (Cycle 21)
Cycle 24 (Cycle 24)
Cycle 27 (Cycle 27)
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Cycle 3 (Cycle 3)
Cycle 30 (Cycle 30)
Cycle 33 (Cycle 33)
Cycle 6 (Cycle 6)
Cycle 9 (Cycle 9)
Cycle (specify)
Off Treatment
Off Treatment Report Period (since registration)
12 Months (12 Months Post Registration)
15 Months (15 Months Post Registration)
18 Months (18 Months Post Registration)
21 Months Post Registration (21 Months
Post Registration)
2 Years (24 Months Post Registration)
3 Months (3 Months Post Registration)
30 Months (30 Months Post Registration)
3 Years (36 Months Post Registration)
42 Months (42 Months Post Registration)
4 Years (48 Months Post Registration)
54 Months (54 Months Post Registration)
6 Months (6 Months Post Registration)
5 Years (60 Months Post Registration)
9 Months (9 Months Post Registration)
Were adverse events assessed during this report
period? (For the dates below, record the start and
end dates of the time period within current report
period in which patient was assessed for adverse
events.)
No (No)
Yes, And Reportable Adverse Events
Occurred (Yes, and reportable adverse
events occurred)
Yes, But No Reportable Adverse Events
Occurred (Yes, but no reportable adverse
events occurred)
CTC Adverse Event Report Begin Date
CTC Adverse Event Report End Date (BL104)
Adverse event assessment
CTC Adverse Event (v3.0) Grade (this
cycle/report period)
CTC Adverse Event (v3.0) Grade (this
cycle/report period)
CTC Adverse Event (v3.0) Grade (this
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cycle/report period)
CTC Adverse Event Attribution Scale
CTC Adverse Event Attribution Scale
CTC Adverse Event Attribution Scale
CTC Adverse Event Term Type
Anorexia (Anorexia)
Ataxia Nec (Ataxia (incoordination))
Confusion (Confusion)
Constipation (Constipation)
Diarrhoea Nos (Diarrhea)
Dyspnoea Nos (Dyspnea (shortness of
breath))
Fatigue (Fatigue (asthenia, lethargy,
malaise))
Febrile Neutropenia (fever Of Unknown
Origin Without Clinically Or
Microbiologically Documented Infection)
(anc <1.0 X 10^9/l, Fever >=38.5
Degrees C) (Febrile neutropenia (fever of
unknown origin without infection))
Mood Alteration - Agitation (Mood
Alteration-agitation)
Anxiety Nec (Mood Alteration-anxiety)
Nausea (Nausea)
Peripheral Sensory Neuropathy
(Neuropathy: sensory)
Abdominal Pain Nos (Pain - Abdomen
NOS)
Arthralgia (Pain - Joint)
Myalgia (Pain - Muscle)
Dermatitis Exfoliative Nos
(Rash/desquamation)
Thrombosis Nos
(Thrombosis/thrombus/embolism)
Vomiting Nos (Vomiting)
CTC Adverse Event Term Type
Anorexia (Anorexia)
Ataxia Nec (Ataxia (incoordination))
Confusion (Confusion)
Constipation (Constipation)
Diarrhoea Nos (Diarrhea)
Dyspnoea Nos (Dyspnea (shortness of
breath))
Fatigue (Fatigue (asthenia, lethargy,
malaise))
Febrile Neutropenia (fever Of Unknown
Origin Without Clinically Or
Microbiologically Documented Infection)
(anc <1.0 X 10^9/l, Fever >=38.5
Degrees C) (Febrile neutropenia (fever of
unknown origin without infection))
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Mood Alteration - Agitation (Mood
Alteration-agitation)
Anxiety Nec (Mood Alteration-anxiety)
Nausea (Nausea)
Peripheral Sensory Neuropathy
(Neuropathy: sensory)
Abdominal Pain Nos (Pain - Abdomen
NOS)
Arthralgia (Pain - Joint)
Myalgia (Pain - Muscle)
Dermatitis Exfoliative Nos
(Rash/desquamation)
Thrombosis Nos
(Thrombosis/thrombus/embolism)
Vomiting Nos (Vomiting)
CTC Adverse Event Term Type
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
with Grade 3 or 4 neutrophils)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils)
Infection With Unknown Anc (Infection
with unknown ANC)
Specify site (Other CTC Adverse Event Terms not
listed)
Other Adverse Events
AE Term
Specify site/sub-term (if applicable)
CTC Adverse Event (v3.0) Grade (this
cycle/report period)
CTC Adverse Event Attribution Scale
Comments
Comments
Investigator Signature
Investigator Signature Date
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E2902 Off-Treatment Form - Form 1783
NCT00093470
E2902 Off-Treatment Form - Form 1783 NCT00093470 
Tipifarnib in Treating Patients With Acute Myeloid Leukemia
in Remission
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=DBE7425E-
10C1-1895-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/11523
E2902 Off-Treatment Form - Form
1783 NCT00093470
Header
DCI Name (Place ID Label Here)
Patient Initials (Last, First)
ECOG Protocol Number
ECOG Protocol Number
ECOG Patient ID
ECOG Patient ID
Participating Group Protocol Number
Participating Group Patient ID
Institution/Affiliate
Registration Step
Time Period
End Of Treatment (End of Treatment)
Data amendment
Are data amended
Yes
No
Vital Status
Patient Vital Status
Alive (Alive)
Dead (Dead)
Primary Cause of Death (if applicable)
1 / 2
Due To Other Cause, Specify (Due to
other cause)
Due To Protocol Treatment (Due to
protocol treatment)
Due To This Disease (Due to this
disease)
Unknown (Unknown)
Describe cause of death
Date of last contact or death
Off-protocol treatment
Reason treatment ended
Adverse Event/side Effects/complications
(Adverse events/side
effects/complications)
Alternative Therapy (Alternative therapy)
Death On Study (Death on study)
Disease Progression, Relapse During
Active Treatment (Disease progression,
relapse during active treatment)
Other (Other)
Patient Off-treatment For Other
Complicating Disease (Patient off
treatment for other complicating disease)
Patient Withdrawal Or Refusal (Patient
withdrawal or refusal after beginning
protocol therapy)
Treatment Completed Per Protocol
Criteria (Treatment completed per
protocol criteria)
Complicating Disease (specify)
Other (specify)
Last date protocol therapy was given
Comments
Comments
Investigator Signature
Investigator Signature Date
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NSABP PROTOCOL B-38ADVERSE
EVENT FORM - Form AE NCT00093795
NSABP PROTOCOL B-38ADVERSE EVENT FORM - Form
AE NCT00093795 
Combination Chemotherapy in Treating Women Who Have
Undergone Surgery for Node-Positive Breast Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=DD8C2A7C-
C75C-5AD7-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/11525
NSABP PROTOCOL B-38ADVERSE
EVENT FORM - Form AE
NCT00093795
Header module
Institution Name
Affiliate Name
Person completing Form, Last Name
Patient Initials
Person completing Form, First Name
Person completing Form, Phone
Current Cycle Number
NSABP Patient ID
Are data amended?
Yes
No
Cycle Start Date
Cycle Stop Date
Any grade 2, 3, 4, or 5 adverse event?
Yes
No
Was patient hospitalized for 24 hours or more?
Yes
No
Treatment Group (Did the patient receive
Cytokine support?)
Doxorubicin, Cyclophosphamide
Followed By Paclitaxel (dd Ac - P) (DD
AC - P)
Doxorubicin, Cyclophosphamide
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Followed By Paclitaxel And Gemcitabine
(dd Ac - Pg) (DD AC - PG)
Doxorubicin, Cyclophosphamide, And
Docetaxel (tac) (TAC)
Filgrastim (Neupogen)
Yes
No
Pegfilgrastim (Neulasta)
Yes
No
Erythropoietin/Darbepoetin (Did the patient
require:)
Yes
No
Red Blood Cell (RBC) Transfusion
Yes
No
Platelet Transfusion
Yes
No
Hematology Lab Values
Was a hematology sample obtained? (around
Day 21 of this cycle for Group 1, or around Day
14 of this cycle for Group 2 or 3)
Yes
No
Date Hematology Sample Obtained
Peripheral WBC Count
1000/uL
Absolute Neutophil Count
Peripheral Platelet Count
1000/uL
Hemoglobin
g/dL
Patient Initials
Current Cycle Number
NSABP Patient ID
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NSABP PROTOCOL B-38ADVERSE EVENT FORM - Form AE
NCT00093795
CTCAE v3.0
SHORT NAME
CTCAE v3.0 Short Name
CTCAE v3.0 "Select" Term
CTCAE v3.0 Grade
CTCAE v3.0 Grade
Adverse Event Report Ind-2
Yes (Yes)
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NSABP PROTOCOL B-38ADVERSE EVENT FORM - Form AE
NCT00093795
E4A03 OffTreatment Form - Form 2061
NCT00098475
E4A03 OffTreatment Form - Form 2061 NCT00098475 
Lenalidomide and Dexamethasone With or Without
Thalidomide in Treating Patients With Multiple Myeloma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=DC6DD8F5-
44B5-1431-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/11526
E4A03 OffTreatment Form - Form
2061 NCT00098475
Header
ECOG Protocol Number
ECOG Patient ID
DCI Name
Registration Step (Place ID Label Here)
Patient Initials (Last, First)
Participating Group Protocol Number
Participating Group Patient ID
Institution/Affiliate
Report Period (choose one)
End Treatment Step 1 (End treatment
step 1)
End Treatment Step 2 (End treatment
step 2)
Are data amended
Yes
No
Vital Status
Patient Vital Status
Alive (Alive)
Dead (Dead)
Primary Cause of Death (if applicable)
Due To Other Cause, Specify (Due to
other cause)
Due To Protocol Treatment (Due to
protocol treatment)
Due To This Disease (Due to this
disease)
1 / 2
Unknown (Unknown)
Describe cause of death
Date of last contact or death
Off-protocol treatment
Reason treatment ended
Adverse Event/side Effects/complications
(Adverse events/side
effects/complications)
Alternative Therapy (Alternative therapy)
Death On Study (Death on study)
Disease Progression, Relapse During
Active Treatment (Disease progression,
relapse during active treatment)
Other (Other)
Patient Off-treatment For Other
Complicating Disease (Patient off
treatment for other complicating disease)
Patient Withdrawal Or Refusal (Patient
withdrawal or refusal after beginning
protocol therapy)
Treatment Completed Per Protocol
Criteria (Treatment completed per
protocol criteria)
Complicating Disease (specify)
Other (specify)
Last date protocol therapy was given
Comments
Comments
Investigator Signature
Investigator Signature Date
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E4A03 Adverse Event Form (CTCAE v3) -
Form 2060 NCT00098475
E4A03 Adverse Event Form (CTCAE v3) - Form 2060
NCT00098475 
Lenalidomide and Dexamethasone With or Without
Thalidomide in Treating Patients With Multiple Myeloma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=DD63253D-
82BC-1466-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/11527
E4A03 Adverse Event Form (CTCAE
v3) - Form 2060 NCT00098475
Header
ECOG Protocol Number
ECOG Patient ID
DCI Name
Step
Patient Initials
Participating Group Protocol Number
Participating Group Patient ID
Institution/Affiliate
Are data amended
Yes
No
On Treatment
On Treatment Report Period (Choose one)
Cycle 12 Step 1 (Cycle 12 Step 1)
Cycle 12 Step 2 (Cycle 12 Step 2)
Cycle 4 Step 1 (Cycle 4 Step 1)
Cycle 4 Step 2 (Cycle 4 Step 2)
Cycle 8 Step 1 (Cycle 8 Step 1)
Cycle 8 Step 2 (Cycle 8 Step 2)
Off Treatment Report Period (since registration)
12 Months (12 Months Post Registration)
15 Months (15 Months Post Registration)
18 Months (18 Months Post Registration)
21 Months Post Registration (21 Months
Post Registration)
2 Years (24 Months Post Registration)
3 Months (3 Months Post Registration)
30 Months (30 Months Post Registration)
1 / 3
3 Years (36 Months Post Registration)
42 Months (42 Months Post Registration)
4 Years (48 Months Post Registration)
54 Months (54 Months Post Registration)
6 Months (6 Months Post Registration)
5 Years (60 Months Post Registration)
6 Years (72 Months Post Registration)
84 Months Post Registration (84 Months
Post Registration)
9 Months (9 Months Post Registration)
Off Treatment
Cycle Number
Adverse event assessment
Were adverse events assessed during this report
period? (For the dates below, record the start and
end dates of the time period within current report
period in which patient was assessed for adverse
events.)
No (No)
Yes, And Reportable Adverse Events
Occurred (Yes, and reportable adverse
events occurred)
Yes, But No Reportable Adverse Events
Occurred (Yes, but no reportable adverse
events occurred)
Adverse Event Report Begin Date
Adverse Event Report End Date
CTC Adverse Event Term Type
CTC Adverse Event Attribution Scale
CTC Adverse Event (v3.0) Grade (worst grade
this report period)
Common Toxicity Criteria Adverse Event
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
with Grade 3 or 4 neutrophils)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils)
Infection With Unknown Anc (Infection
with unknown ANC)
Specify site
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Other Adverse Events
AE Term
Specify site/sub-term (if applicable)
Comments
Comments
Investigator Signature
Investigator Signature Date
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CALGB 40503 ADVERSE EVENT (AE)
FORM NCT00601900
CALGB 40503 ADVERSE EVENT (AE) FORM
NCT00601900 
Tamoxifen or Letrozole With or Without Bevacizumab in
Treating Women With Stage III or Stage IV Breast Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=24060959-
A5E8-3054-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11528
CALGB 40503 ADVERSE EVENT
(AE) FORM NCT00601900
CALGB clinical trial administrative data
CALGB Form
CALGB Study No
CALGB Patient ID
CTC adverse event report begin date
CTC adverse event report end date
Are data amended
Yes
No
Patient demographics
Patient Initials
Patient Hospital No.
Institution/Affiliate
Participating Group
Participating Group Study No.
Participating Group Patient ID
Adverse event report
Has an Adverse Event Expedited Report been
submitted? (with Central Office based on an
event reported below)
Yes
No
1 / 2
Expected Adverse Events
MedDRA Code
MedDRA Code
CTC adverse event term
CTC adverse event term
CTC AE Attribution Code (^2)
Definite (definite)
Possible (possible)
Probable (probable)
Unlikely (unlikely)
Unrelated (unrelated)
CTC AE Attribution Code (^2)
Definite (definite)
Possible (possible)
Probable (probable)
Unlikely (unlikely)
Unrelated (unrelated)
CTC Adverse Event Short Name
Hemorrhage, Pulmonary/upper
Respiratory (Hemorrhage pulmonary -
Select)
Hemorrhage, Gi (Hemorrhage, GI -
Select)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
- Select)
Perforation, Gi (Perforation, GI - Select)
CTC Select AE
CTC AE grade (^2)
CTC AE grade (^2)
Completed by (Last name, First name)
Date form completed (MM DD YYYY)
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CALGB-40502 Adverse Event (AE) Form
NCT00785291
CALGB-40502 Adverse Event (AE) Form NCT00785291 
Paclitaxel, Paclitaxel Albumin-Stabilized Nanoparticle
Formulation, or Ixabepilone With or Without Bevacizumab
in Treating Patients With Stage IIIC or Stage IV Breast
Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=51FAEE67-
09C6-06EB-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11529
CALGB-40502 Adverse Event (AE)
Form NCT00785291
Header
CALGB Form
CALGB Study No
CALGB Patient ID
CTC adverse event report begin date (MM DD
YYYY)
CTC adverse event report end date (MM DD
YYYY)
Are data amended
Yes
No
Patient demographics
Patient Initials (Last First Middle)
Patient Hospital No.
Institution/Affiliate
Participating Group
Participating Group Study No.
Participating Group Patient ID
Adverse event report
Has an AdEERS been filed (with Central Office
based on an event reported below)
Yes
1 / 2
No
Expected Adverse Events
CTC adverse event term
CTC adverse event term
CTC AE Attribution Code (^3)
Definite (definite)
Probable (possible)
Definite (probable)
Possible (unlikely)
Unlikely (unrelated)
CTC AE Attribution Code (^3)
Definite (definite)
Probable (possible)
Definite (probable)
Possible (unlikely)
Unlikely (unrelated)
CTC Adverse Event Term
Perforation, Gi (Hemorrhage, GI - Select)
Supraventricular And Nodal Arrhythmia
(Supraventricular arrhythmia - Select)
CTC Select AE
MedDRA Code (Specify any other events, grade
3 or higher, that occurred during this time period.
Report secondary malignancies other than
AML/MDS here and on Form C-1001)
MedDRA Code (Specify any other events, grade
3 or higher, that occurred during this time period.
Report secondary malignancies other than
AML/MDS here and on Form C-1001)
CTC AE grade (^1)
CTC AE grade (^1)
Completed by (Last name, First name)
Date form completed (MM DD YYYY)
2 / 2
CALGB-40502 Adverse Event (AE) Form NCT00785291
CALGB 40601 RADIATION THERAPY
FORM
CALGB 40601 RADIATION THERAPY FORM
Paclitaxel and Trastuzumab With or Without Lapatinib in
Treating Patients With Stage II or Stage III Breast Cancer
That Can Be Removed by Surgery
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=3A1E51E7-
0B3F-2826-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11530
CALGB 40601 RADIATION
THERAPY FORM
Header
CALGB Form
CALGB Study No
CALGB Patient ID
Reporting Period End Date
Are data amended
Yes
No
Patient demographics
Patient Initials
Patient Hospital No.
Institution/Affiliate
Participating Group
Participating Group Study No.
Participating Group Patient ID
Radiation Therapy
Has the patient received radiation therapy to the
breast?
Yes
No
RT Dose per Fraction (GY)
1 / 3
Total Dose of Radiation Therapy (GY)
Radiation Therapy Start Date
Radiation Therapy End Date
Radiation Therapy
Has the patient received elective postmastectomy
radiation therapy?
Yes
No
RT Dose per Fraction (GY)
Total Dose of Radiation Therapy (GY)
Radiation Therapy Start Date
Radiation Therapy End Date
Radiation Therapy
Has the patient received regional nodal radiation
therapy?
Yes
No
Has the patient received regional nodal radiation
therapy to supraclavicular nodes?
Yes
No
RT Dose per Fraction (GY)
Has the patient received regional nodal radiation
therapy to axillary nodes?
Yes
No
Total Dose of Radiation Therapy (GY)
Has the patient received regional nodal radiation
therapy to internal mammary nodes?
Yes
No
Radiation Therapy Start Date
Radiation Therapy End Date
2 / 3
CALGB 40601 RADIATION THERAPY FORM
Expected Adverse Events
CTC adverse event term
Fibrosis-cosmesis (Fibrosis-cosmesis)
Pulmonary Fibrosis (Pulmonary fibrosis
(radiographic changes))
Adverse Event Onset Date
Adverse Event Onset Date
CTC Adverse Event Term
Cardiac General Other (Cardiac
General-Other (Specify))
MedDRA Code
MedDRA Code
CTC Select AE
CTC AE grade (^2)
CTC AE grade (^2)
CTC AE Attribution Code (^2)
Definite (definite)
Possible (possible)
Probable (probable)
Unlikely (unlikely)
Unrelated (unrelated)
CTC AE Attribution Code (^2)
Definite (definite)
Possible (possible)
Probable (probable)
Unlikely (unlikely)
Unrelated (unrelated)
Comments
COMMENTS
Completed by (Last name, First name)
Date form completed (MM DD YYYY)
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CALGB 40601 RADIATION THERAPY FORM
CALGB 40601 ADVERSE EVENT (AE)
FORM NCT00770809
CALGB 40601 ADVERSE EVENT (AE) FORM
NCT00770809 
Paclitaxel and Trastuzumab With or Without Lapatinib in
Treating Patients With Stage II or Stage III Breast Cancer
That Can Be Removed by Surgery
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=3A08A78F-
7A27-503F-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11531
CALGB 40601 ADVERSE EVENT
(AE) FORM NCT00770809
Header
CALGB Form
CALGB Study No
CALGB Patient ID
CTC adverse event report begin date
CTC adverse event report end date
Are data amended
Yes
No
Patient demographics
Patient Initials
Patient Hospital No.
Institution/Affiliate
Participating Group
Participating Group Study No.
Participating Group Patient ID
Adverse event report
Has an Adverse Event Expedited Report been
submitted? (with Central Office based on an
event reported below)
Yes
No
1 / 2
Expected Adverse Events
MedDRA Code
MedDRA Code
CTC adverse event term
CTC adverse event term
CTC AE Attribution Code (^2)
Definite (definite)
Possible (possible)
Probable (probable)
Unlikely (unlikely)
Unrelated (unrelated)
CTC AE Attribution Code (^2)
Definite (definite)
Possible (possible)
Probable (probable)
Unlikely (unlikely)
Unrelated (unrelated)
CTC AE grade (^2)
CTC AE grade (^2)
Completed by (Last name, First name)
Date form completed (MM DD YYYY)
2 / 2
CALGB 40601 ADVERSE EVENT (AE) FORM NCT00770809
CALGB: 40301 ADVERSE EVENT FORM
CALGB: 40301 ADVERSE EVENT FORM
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=E515D4BC-
7692-43EF-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11532
CALGB: 40301 ADVERSE EVENT
FORM
Header
CALGB Form
CALGB Study No
CALGB Patient ID
CTC adverse event report begin date
CTC adverse event report end date
Are data amended
Yes
No
Patient demographics
Patient Initials
Patient Hospital Number
Institution/Affiliate
Participating Group
Participating Group Protocol No
Participating Group Patient ID
Adverse event report
Has an AdEERS been filed (with Central Office
based on an event reported below)
Yes
No
Expected Adverse Events
1 / 2
CTC AE Attribution Code (^2)
Definite (definite)
Possible (possible)
Probable (probable)
Unlikely (unlikely)
Unrelated (unrelated)
CTC AE Attribution Code (^2)
Definite (definite)
Possible (possible)
Probable (probable)
Unlikely (unlikely)
Unrelated (unrelated)
MedDRA code (^1)
MedDRA code (^1)
CTC adverse event term
CTC adverse event term
CTC AE grade (^2)
CTC AE grade (^2)
Completed by
Date form completed
2 / 2
CALGB: 40301 ADVERSE EVENT FORM
CALGB: 80203 ADVERSE EVENT FORM
NCT00077233
CALGB: 80203 ADVERSE EVENT FORM  NCT00077233
Fluorouracil and Leucovorin Plus Either Irinotecan or
Oxaliplatin With or Without Cetuximab in Treating Patients
With Previously Untreated Metastatic Adenocarcinoma of
the Colon or Rectum
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=B4C3B499-
D669-0736-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/11533
CALGB: 80203 ADVERSE EVENT
FORM NCT00077233
Header
CALGB Form
CALGB Study No.
CALGB Patient ID
From
To
Are data amended?
Yes
No
Patient demographics
Patient Intitials
Participating Group
Patient Hospital Number
Participating Group Protocol No.
Main Member Institution/Adjunct
Participating Group Patient No.
AER/ADR filed?
Was an AER/ADR filed with Central Office based
on an event reported below?
Yes
No
1 / 2
Expected Adverse Events
MedDRA Code
Name
Grade
Treatment Related
Definite (definitely related to treatment)
Possible (possibly related to treatment)
Probable (probably related to treatment)
Unlikely (unlikely to be related to
treatment)
Unrelated (unrelated to treatment)
Completed By (Print or Type Name)
Date form completed (M)
Ccrr Module For Calgb: 80203 Adverse
Event Form
2 / 2
CALGB: 80203 ADVERSE EVENT FORM NCT00077233
CALGB: 80802 Adverse Event (AE) Form
NCT01015833
CALGB: 80802 Adverse Event (AE) Form NCT01015833 
Sorafenib Tosylate With or Without Doxorubicin
Hydrochloride in Treating Patients With Locally Advanced
or Metastatic Liver Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=741A9174-
BBAD-70FC-E040-BB89AD436A0F
All rights reserved. Please visit https://medical-data-
models.org/forms/11534
CALGB: 80802 Adverse Event (AE)
Form NCT01015833
Header
CALGB Form
CALGB Study No
CALGB Patient ID
CTC Adverse Event Report Begin Date (MM DD
YYYY)
CTC Adverse Event Report End Date (MM DD
YYYY)
Are data amended
Yes
No
Patient demographics
Patient Initials (Last, First Middle)
Patient Hospital No.
Institution/Affiliate
Participating Group
Participating Group Study No.
Participating Group Patient ID
Adverse Event Expedited Reporting
System filed?
Has an AdEERS been filed (with Central Office
based on an event reported below)
1 / 2
Yes
No
Cycle Number
Expected Adverse Events
CTC AE Attribution Code (^2)
Definite (definite)
Possible (possible)
Probable (probable)
Unlikely (unlikely)
Unrelated (unrelated)
CTC AE Attribution Code (^2)
Definite (definite)
Possible (possible)
Probable (probable)
Unlikely (unlikely)
Unrelated (unrelated)
MedDRA Code (Specify any other events grade 2
or higher that occurred during this time period.
Report secondary malignancies including
AML/MDS here and on Form C-1001)
MedDRA Code (Specify any other events grade 2
or higher that occurred during this time period.
Report secondary malignancies including
AML/MDS here and on Form C-1001)
CTCAE Term
CTCAE Term
CTC AE grade (^2)
CTC AE grade (^2)
Completed by (Last name, First name)
Date Form Completed
2 / 2
CALGB: 80802 Adverse Event (AE) Form NCT01015833
CALGB-10501 Adverse Event (AE) Form
NCT00513747
CALGB-10501 Adverse Event (AE) Form NCT00513747 
Early or Delayed Fludarabine and Rituximab in Treating
Patients With Previously Untreated Chronic Lymphocytic
Leukemia
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=33F76A98-
AE8B-2E5F-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11535
CALGB-10501 Adverse Event (AE)
Form NCT00513747
Header
CALGB Form (C-1595)
CALGB Study No
CALGB Patient ID
CTC adverse event report begin date (MM DD
YYYY)
CTC adverse event report end date (MM DD
YYYY)
Are data amended
Yes
No
Patient demographics
Patient Initials (Last, First Middle)
Patient Hospital No.
Institution/Affiliate
Participating Group
Participating Group Study No.
Participating Group Patient ID
Adverse event report
Has an Adverse Event Expedited Report been
submitted? (with Central Office based on an
event reported below)
1 / 3
Yes
No
Reporting Period
Cycle 1 First Treatment (Cycle 1 First
Treatment)
Cycle 2 First Treatment (Cycle 2 First
Treatment)
Cycle 3 First Treatment (Cycle 3 First
Treatment)
Cycle 4 First Treatment (Cycle 4 First
Treatment)
Cycle 5 First Treatment (Cycle 5 First
Treatment)
Cycle 6 First Treatment (Cycle 6 First
Treatment)
During Observation (During Observation)
Two Months Post First Treatment Cycles
(Two Months Post First Treatment
Cycles)
Expected Adverse Events
CTC adverse event term
CTC adverse event term
CTC AE Attribution Code (^2)
Definite (definite)
Possible (possible)
Probable (probable)
Unlikely (unlikely)
Unrelated (unrelated)
CTC AE Attribution Code (^2)
Definite (definite)
Possible (possible)
Probable (probable)
Unlikely (unlikely)
Unrelated (unrelated)
CTC Adverse Event Term
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically) - Select)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
- Select)
CTC Select AE
MedDRA Code (Specify any other events grade 2
or higher that occurred during this time period.
Report secondary malignancies including
AML/MDS here and on Form C-1001)
2 / 3
CALGB-10501 Adverse Event (AE) Form NCT00513747
MedDRA Code (Specify any other events grade 2
or higher that occurred during this time period.
Report secondary malignancies including
AML/MDS here and on Form C-1001)
CTC AE grade (^2)
CTC AE grade (^2)
Completed by (Last name, First name)
Date Form Completed
3 / 3
CALGB-10501 Adverse Event (AE) Form NCT00513747
CALGB: 10603 Adverse Event (AE) Form
NCT00651261
CALGB: 10603 Adverse Event (AE) Form NCT00651261 
Daunorubicin, Cytarabine, and Midostaurin in Treating
Patients With Newly Diagnosed Acute Myeloid Leukemia
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=43B71921-
CF4D-54F5-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11536
CALGB: 10603 Adverse Event (AE)
Form NCT00651261
Header
CALGB Form (C-1595)
CALGB Study No.
CALGB Patient ID
CTC Adverse Event Report Begin Date (MM DD
YYYY)
CTC adverse event report end date (MM DD
YYYY)
Are data amended
Yes
No
Patient demographics
Patient Initials (Last, First Middle)
Patient Hospital No.
Institution/Affiliate
Participating Group
Participating Group Protocol Number
Participating Group Patient ID
Adverse Drug Reaction Report
Has an Adverse Drug Reaction Report been
filed? (with Central Office based on an event
reported below)
Yes
1 / 2
No
Treatment Phase
Consolidation #1 (Consolidation #1)
Consolidation #2 (Consolidation #2)
Consolidation #3 (Consolidation #3)
Consolidation #4 (Consolidation #4)
Induction #1 (Induction #1)
Induction #2 (Induction #2)
Maintenance (Maintenance)
Expected Adverse Events
CTC adverse event term
CTC adverse event term
CTC AE Attribution Code (^2)
Definite (definite)
Possible (possible)
Probable (probable)
Unlikely (unlikely)
Unrelated (unrelated)
CTC AE Attribution Code (^2)
Definite (definite)
Possible (possible)
Probable (probable)
Unlikely (unlikely)
Unrelated (unrelated)
MedDRA Code (Specify any other events grade 2
or higher that occurred during this time period.
Report secondary malignancies including
AML/MDS here and on Form C-1001)
MedDRA Code (Specify any other events grade 2
or higher that occurred during this time period.
Report secondary malignancies including
AML/MDS here and on Form C-1001)
CTC AE grade (^2)
CTC AE grade (^2)
Completed by (Last name, First name)
Date Form Completed
2 / 2
CALGB: 10603 Adverse Event (AE) Form NCT00651261
CALGB 30607 ADVERSE EVENT (AE)
FORM NCT00693992
CALGB 30607 ADVERSE EVENT (AE) FORM
NCT00693992 
Sunitinib as Maintenance Therapy in Treating Patients With
Stage III or Stage IV Non-Small Cell Lung Cancer
Previously Treated With Combination Chemotherapy
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=3E7014BB-
6920-2114-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11537
CALGB 30607 ADVERSE EVENT
(AE) FORM NCT00693992
Header
CALGB Form
CALGB Study No
CALGB Patient ID
CTC adverse event report begin date
CTC adverse event report end date
Are data amended
Yes
No
Patient demographics
Patient Initials
Patient Hospital No.
Institution/Affiliate
Participating Group
Participating Group Study No.
Participating Group Patient ID
Adverse event report
Has an Adverse Event Expedited Report been
submitted? (with Central Office based on an
event reported below)
Yes
No
1 / 2
Cycle Number
Expected Adverse Events
CTC AE Attribution Code (^2)
Definite (definite)
Possible (possible)
Probable (probable)
Unlikely (unlikely)
Unrelated (unrelated)
CTC AE Attribution Code (^2)
Definite (definite)
Possible (possible)
Probable (probable)
Unlikely (unlikely)
Unrelated (unrelated)
MedDRA Code
MedDRA Code
CTC adverse event term
CTC adverse event term
CTC AE grade (^2)
CTC AE grade (^2)
Completed by (Last name, First name)
Date form completed (MM DD YYYY)
2 / 2
CALGB 30607 ADVERSE EVENT (AE) FORM NCT00693992
CALGB: Thoracic Surgical Complications
Form NCT00499330
CALGB: Thoracic Surgical Complications Form
NCT00499330 
Comparison of Different Types of Surgery in Treating
Patients With Stage IA Non-Small Cell Lung Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=218BCF6D-
8009-5542-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11538
CALGB: Thoracic Surgical
Complications Form NCT00499330
Header
CALGB Form (C-1241)
CALGB Study No.
CALGB Patient ID
Date of Procedure
Are data amended
Yes
No
Patient demographics
Patient Initials (Last, First Middle)
Patient Hospital No.
Institution/Affiliate
Participating Group
Participating Group Study No.
Participating Group Patient ID
Adverse Drug Reaction Report
Has an Adverse Drug Reaction Report been
filed?
Yes
No
Surgical Approach
Mediastinoscopy (Mediastinoscopy)
Thoracoscopy / Video-assisted (vats)
1 / 2
(Thoracoscopy / Video-assisted (VATS))
Thoracoscopy / Video-assisted (vats),
With Conversion To Thoracotomy
(Thoracoscopy / Video-assisted (VATS),
with conversion to Thoracotomy)
Thoracotomy (thoracotomy)
Expected Adverse Events
MedDRA Code
CTC Adverse Event Term
CTC AE Grade
CTC AE Attribution Code
Definite (Definite)
Possible (Possible)
Probable (Probable)
Unlikely (Unlikely)
Unrelated (Unrelated)
Expected Adverse Events
MedDRA Code
CTC Adverse Event Term
Intra-operative Injury (Intraop injury -
Select)
CTC Select AE
CTC Adverse Event Term
CTC AE Grade
CTC AE Attribution Code
Definite (Definite)
Possible (Possible)
Probable (Probable)
Unlikely (Unlikely)
Unrelated (Unrelated)
Ccrr Module For Calgb: 90202 Adverse
Event Form
Completed by (Last name, First name)
Date Form Completed (mm dd yyyy)
2 / 2
CALGB: Thoracic Surgical Complications Form NCT00499330
CALGB 30610 ADVERSE EVENT (AE)
FORM NCT00632853
CALGB 30610 ADVERSE EVENT (AE) FORM
NCT00632853 
Three Different Radiation Therapy Regimens in Treating
Patients With Limited-Stage Small Cell Lung Cancer
Receiving Cisplatin and Etoposide
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=3C4CD434-
CC4A-4FEC-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11539
CALGB 30610 ADVERSE EVENT
(AE) FORM NCT00632853
Header
CALGB Form
CALGB Study No
CALGB Patient ID
CTC adverse event report begin date
CTC adverse event report end date
Are data amended
Yes
No
Patient demographics
Patient Initials
Patient Hospital No.
Institution/Affiliate
Participating Group
Participating Group Study No.
Participating Group Patient ID
Adverse event report
Has an Adverse Event Expedited Report been
submitted? (with Central Office based on an
event reported below)
Yes
No
1 / 2
Cycle Number
Expected Adverse Events
CTC adverse event term
CTC adverse event term
CTC AE Attribution Code (^2)
Definite (definite)
Possible (possible)
Probable (probable)
Unlikely (unlikely)
Unrelated (unrelated)
CTC AE Attribution Code (^2)
Definite (definite)
Possible (possible)
Probable (probable)
Unlikely (unlikely)
Unrelated (unrelated)
MedDRA Code
MedDRA Code
CTC AE grade (^2)
CTC AE grade (^2)
Completed by (Last name, First name)
Date form completed (MM DD YYYY)
2 / 2
CALGB 30610 ADVERSE EVENT (AE) FORM NCT00632853
CALGB: 30801 Adverse Event (AE) Form
NCT01041781
CALGB: 30801 Adverse Event (AE) Form NCT01041781 
Gemcitabine Hydrochloride or Pemetrexed Disodium and
Carboplatin With or Without Celecoxib in Treating Patients
With Advanced Non-Small Cell Lung Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=6AF26CA3-
DF39-EEE0-E040-BB89AD436D54
All rights reserved. Please visit https://medical-data-
models.org/forms/11540
CALGB: 30801 Adverse Event (AE)
Form NCT01041781
Header
CALGB Form
CALGB Study No
CALGB Patient ID
CTC adverse event report begin date
CTC adverse event report end date
Are data amended
Yes
No
Patient demographics
Patient Initials
Patient Hospital No.
Institution/Affiliate
Participating Group
Participating Group Study No.
Participating Group Patient ID
Adverse Event Expedited Reporting
System filed?
Has an AdEERS been filed (with Central Office
based on an event reported below)
Yes
No
1 / 2
Cycle Number
Expected Adverse Events
CTC Adverse Event Term
Hemorrhage, Gi (Hemorrhage, GI -
Select)
Pain (Pain - Select)
Ulcer, Gi (Ulcer, GI - Select)
CTC Select AE
CTC AE Attribution Code (3^TREATMENT
ATTRIBUTION CODES)
Definite (definite)
Possible (possible)
Probable (probable)
Unlikely (unlikely)
Unrelated (unrelated)
CTC AE Attribution Code (3^TREATMENT
ATTRIBUTION CODES)
Definite (definite)
Possible (possible)
Probable (probable)
Unlikely (unlikely)
Unrelated (unrelated)
MedDRA Code
MedDRA Code
CTC adverse event term
CTC adverse event term
CTC AE grade (1^Use NCI CTCAE v3.x or most
current version with MedDRA codes posted at
http://www.calgb.org to grade each adverse
event.)
CTC AE grade (1^Use NCI CTCAE v3.x or most
current version with MedDRA codes posted at
http://www.calgb.org to grade each adverse
event.)
Completed by (Last name, First name)
Date form completed (MM DD YYYY)
2 / 2
CALGB: 30801 Adverse Event (AE) Form NCT01041781
CALGB: SURVIVAL DATA FORM [80303]
NCT00088894
CALGB: SURVIVAL DATA FORM [80303] NCT00088894
Gemcitabine With or Without Bevacizumab in Treating
Patients With Locally Advanced or Metastatic Pancreatic
Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=D5F16DBD-
40A4-62FE-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/11541
CALGB: SURVIVAL DATA FORM
[80303] NCT00088894
Header
CALGB Study No.
CALGB Patient ID
Are data amended?
Yes
No
Patient demographics
Patient Initials
Participating Group
Patient Hospital No.
Participating Group Protocol No.
Institution/Affiliate
Participating Group Patient ID
Patient status
Date patient last known alive or date of death
Survival Status
Alive (Alive)
Dead (Dead)
Lost to follow-up (Lost to follow-up)
Patient withdrew consent for survival
follow-up (Patient withdrew consent for
survival follow-up)
Footer module
Completed by
1 / 2
Date form completed
2 / 2
CALGB: SURVIVAL DATA FORM [80303] NCT00088894
CALGB: 90202 ADVERSE EVENT FORM
NCT00079001
CALGB: 90202 ADVERSE EVENT FORM NCT00079001
Zoledronate in Preventing Skeletal (Bone)-Related Events
in Patients Who Are Receiving Androgen Deprivation
Therapy For Prostate Cancer and Bone Metastases
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=B4606682-
4CF2-0526-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/11542
CALGB: 90202 ADVERSE EVENT
FORM NCT00079001
Header
CALGB Form
CALGB Study No
CALGB Patient ID
From
To
Amended data?
Yes
No
Patient demographics
Patients Intitials
Participating Group
Patient Hospital No.
Participating Group Protocol No.
Main Member Institution/Adjunct
Participating Group Patient ID
AER/ADR filed?
Was an AER/ADR filed with Central Office based
on an event reported below?
Yes
No
1 / 2
Expected Adverse Events
MedDRA Code
Name
Grade
Treatment Related
Definite (definitely related to treatment)
Possible (possibly related to treatment)
Probable (probably related to treatment)
Unlikely (unlikely to be related to
treatment)
Unrelated (unrelated to treatment)
Completed By (Print or Type Name)
Date form completed (M)
Ccrr Module For Calgb: 90202 Adverse
Event Form
2 / 2
CALGB: 90202 ADVERSE EVENT FORM NCT00079001
NCT00430183 CALGB 90203: Adverse
Event (AE) Form - Chemohormonal Therapy
NCT00430183 CALGB 90203: Adverse Event (AE) Form -
Chemohormonal Therapy [Form C-1241 v1 10/24/2006]
Surgery With or Without Docetaxel and Leuprolide or
Goserelin in Treating Patients With High-Risk Localized
Prostate Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=1E6FF6CD-
5345-2F6A-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11543
NCT00430183 CALGB 90203:
Adverse Event (AE) Form -
Chemohormonal Therapy
Header
CALGB Form (C-1241)
CALGB Study No.
CALGB Patient ID
CTC Adverse Event Report Begin Date (mm dd
yyyy)
CTC Adverse Event Report End Date (mm dd
yyyy)
Are data amended
Yes
No
Patient demographics
Patient Initials (Last, First Middle)
Patient Hospital No.
Institution/Affiliate
Participating Group
Participating Group Study No.
Participating Group Patient ID
Adverse event report
Has an Adverse Event Expedited Report been
submitted?
Yes
1 / 3
No
Expected Adverse Events
MedDRA Code (1 Use NCI CTCAE v3.x or most
current version with MedDRA codes posted at
http://www.calgb.org to grade each adverse
event. Grade= -1 if category not evaluated.
Grade= 0 if category evaluated by event not
reported.)
CTC Adverse Event Term
Hypersensitivity Nos (Allergic
reaction/hypersensitivity (including drug
fever))
Blood Bilirubin Increased (Bilirubin
(hyperbilirubinemia))
Bronchospasm, Wheezing
(Bronchospasm, wheezing)
Diarrhoea Nos (Diarrhea)
Oedema Nos (Edema: limb)
Edema: Trunk/genital (Edema:
trunk/genital)
Fatigue (Fatigue (asthenia, lethargy,
malaise))
Mucositis/stomatitis
(functional/symptomatic)
(Mucositis/stomatitis
(functional/symptomatic) - Oral cavity)
Nausea (Nausea)
Peripheral Sensory Neuropathy
(Neuropathy: sensory)
Neutropenia (Neutrophils/granulocytes
(ANC/AGC))
Arthralgia (Pain - Joint)
Myalgia (Pain - Muscle)
Platelet Count Decreased (Platelets)
Dermatitis Exfoliative Nos
(Rash/desquamation)
Vomiting Nos (Vomiting)
CTC AE Grade (2 AE is defined as Adverse
Event; 1 Use NCI CTCAE v3.x or most current
version with MedDRA codes posted at
http://www.calgb.org to grade each adverse
event. Grade= -1 if category not evaluated.
Grade= 0 if category evaluated by event not
reported.)
CTC AE Attribution Code (2 AE is defined as
Adverse Event; 3 Treatment Attribution Codes: 1=
unrelated, 2= unlikely, 3= possible, 4= probably,
5= definite)
Definite (Definite)
Possible (Possible)
Probable (Probable)
Unlikely (Unlikely)
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NCT00430183 CALGB 90203: Adverse Event (AE) Form -
Chemohormonal Therapy
Unrelated (Unrelated)
Footer Module
Completed by (Last name, First name)
Date Form Completed (mm dd yyyy)
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CALGB: 90401 ADVERSE EVENT FORM
NCT00110214
CALGB: 90401 ADVERSE EVENT FORM NCT00110214
Docetaxel and Prednisone With or Without Bevacizumab in
Treating Patients With Prostate Cancer That Did Not
Respond to Hormone Therapy
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=EF49C164-
F42D-540E-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11544
CALGB: 90401 ADVERSE EVENT
FORM NCT00110214
Header
CALGB Form
CALGB Study No
CALGB Patient ID
CTC adverse event report begin date
CTC adverse event report end date
Are data amended
Yes
No
Patient demographics
Patient Initials
Patient Hospital Number
Institution/Affiliate
Participating Group
Participating Group Study No
Participating Group Patient ID
Adverse Event Expedited Reporting
System filed?
Has an AdEERS been filed (with Central Office
based on an event reported below)
Yes
No
1 / 2
Expected Adverse Events
MedDRA code (^1)
MedDRA code (^1)
CTC adverse event term
CTC adverse event term
CTC AE grade (^2)
CTC AE grade (^2)
CTC AE Attribution Code (^2)
Definite (definite)
Possible (possible)
Probable (probable)
Unlikely (unlikely)
Unrelated (unrelated)
CTC AE Attribution Code (^2)
Definite (definite)
Possible (possible)
Probable (probable)
Unlikely (unlikely)
Unrelated (unrelated)
Completed by
Date form completed
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CALGB: 80303 ADVERSE EVENT (AE)
FORM NCT00088894
CALGB: 80303 ADVERSE EVENT (AE) FORM
NCT00088894
Gemcitabine With or Without Bevacizumab in Treating
Patients With Locally Advanced or Metastatic Pancreatic
Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=D5F0751F-
2386-5B3C-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/11545
CALGB: 80303 ADVERSE EVENT
(AE) FORM NCT00088894
Header
CALGB Study No.
CALGB Patient ID
CTC adverse event report begin date
CTC adverse event report end date
Are data amended?
Yes
No
Patient demographics
Patient Initials
Participating Group
Patient Hospital Number
Participating Group Protocol No.
Institution/Affiliate
Participating Group Patient ID
Adverse Event Expedited Reporting
System filed?
Has an AdEERS been filed (with Central Office
based on an event reported below?)
Yes
No
Expected Adverse Events
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CTC adverse event term
Blood Alkaline Phosphatase Nos
Increased (Alkaline Phosphatase)
Hypersensitivity Nos (Allergic
reaction/hypersensitivity)
Neutropenia (ANC)
Blood Bilirubin Increased (Bilirubin
(hyperbilirubinemia))
Blood Creatinine Increased (Creatinine)
Fatigue (Fatigue)
Pyrexia (Fever (in absence of
neutropenia))
Haemoglobin Decreased (Hemoglobin)
Hypertension Nos (Hypertension)
Platelet Count Decreased (Platelets)
Proteinuria Present (Proteinuria)
Thrombosis Nos
(Thrombosis/thrombus/embolism)
Vomiting Nos (Vomiting)
Leucopenia Nos (WBC)
MedDRA code
MedDRA code
CTC adverse event term
CTC AE grade
CTC AE grade
CTC AE Attribution Code
Definite (definite)
Possible (possible)
Probable (probably)
Unlikely (unlikely)
Unrelated (unrelated)
CTC AE Attribution Code
Definite (definite)
Possible (possible)
Probable (probably)
Unlikely (unlikely)
Unrelated (unrelated)
Form completed by
Completed by
Date form completed
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CALGB Adverse Event (AE) Addendum
Form
CALGB Adverse Event (AE) Addendum Form
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=4E4F280B-
B2A9-266F-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11546
CALGB Adverse Event (AE)
Addendum Form
Header
CALGB Form (C-1595)
CALGB Study No.
CALGB Patient ID
CTC adverse event report begin date (MM DD
YYYY)
CTC adverse event report end date (MM DD
YYYY)
Are data amended
Yes
No
Patient demographics
Patient Initials (Last, First Middle)
Patient Hospital No.
Institution/Affiliate
Participating Group
Participating Group Study No.
Participating Group Patient ID
Additional Form
Page
Page
Expected Adverse Events
1 / 2
MedDRA Code (Use NCI CTCAE version
specified on study-specific AE form)
CTC adverse event term
CTC AE grade (^2)
CTC AE Attribution Code (^2)
Definite (definite)
Possible (possible)
Probable (probable)
Unlikely (unlikely)
Unrelated (unrelated)
Completed by (Last name, First name)
Date Form Completed
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CALGB 30506 Adverse Event (AE) Form
NCT00863512
CALGB 30506 Adverse Event (AE) Form NCT00863512 
Chemotherapy or Observation in Treating Patients With
Early Stage Non-Small Cell Lung Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=5E92C67F-
D91A-CFB0-E040-BB89AD432DA1
All rights reserved. Please visit https://medical-data-
models.org/forms/11547
CALGB 30506 Adverse Event (AE)
Form NCT00863512
Header
CALGB Form
CALGB Study No
CALGB Patient ID
CTC Adverse Event Report Begin Date (MM DD
YYYY)
CTC Adverse Event Report End Date (MM DD
YYYY)
Are data amended
Yes
No
Patient demographics
Patient Initials (Last, First Middle)
Patient Hospital No.
Institution/Affiliate
Participating Group
Participating Group Study No.
Participating Group Patient ID
Adverse Event Expedited Reporting
System filed?
Has an AdEERS been filed (with Central Office
based on an event reported below)
Yes
1 / 41
No
Cycle Number
Expected Adverse Events
MedDRA Code
CTCAE Term
Abdominal Distention (Abdominal
distension)
Abdominal Infection (Abdominal
infection)
Abdominal Pain (Abdominal pain)
Abdominal Soft Tissue Necrotic Lesion
(Abdominal soft tissue necrosis)
Abducens Nerve Disorder (Abducens
nerve disorder)
Accessory Nerve Disorder (Accessory
nerve disorder)
Acidosis (Acidosis)
Vestibulocochlear Nerve Disorder
(Acoustic nerve disorder NOS)
Prolonged Partial Thromboplastin Time
(Activated partial thromboplastin time
prolonged)
Acute Coronary Syndrome (Acute
coronary syndrome)
Acute Renal Failure (Acute kidney injury)
Adrenal Gland Insufficiency (Adrenal
insufficiency)
Adult Respiratory Distress Syndrome
(Adult respiratory distress syndrome)
Agitation (Agitation)
Akathisia (Akathisia)
Alanine Aminotransferase Increased
(Alanine aminotransferase increased)
Alcohol Intolerance (Alcohol intolerance)
Blood Alkaline Phosphatase Increased
(Alkaline phosphatase increased)
Alkalosis (Alkalosis)
Hypersensitivity (Allergic reaction)
Allergic Rhinitis (Allergic rhinitis)
Alopecia (Alopecia)
Amnesia (Amnesia)
Anorectal Fistula (Anal fistula)
Anal Hemorrhage (Anal hemorrhage)
Anal Mucositis (Anal mucositis)
Anal Necrotic Lesion (Anal necrosis)
Anal Pain (Anal pain)
Anal Stenosis (Anal stenosis)
Anal Ulcer (Anal ulcer)
Anaphylactic Shock (Anaphylaxis)
Anemia (Anemia)
Ankle Fracture (Ankle fracture)
Anorectal Infection (Anorectal infection)
Anorgasmia (Anorgasmia)
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Anxiety (Anxiety)
Aortic Injury (Aortic injury)
Aortic Valve Disorder (Aortic valve
disease)
Aphonia (Aphonia)
Apnea (Apnea)
Acute Appendicitis (Appendicitis)
Acute Perforated Appendicitis
(Appendicitis perforated)
Arachnoiditis (Arachnoiditis)
Arterial Injury (Arterial injury)
Arteritis (Arteritis infective)
Arthritis (Arthritis)
Ascites (Ascites)
Aspartate Aminotransferase Increased
(Aspartate aminotransferase increased)
Aspiration (Aspiration)
Cardiac Arrest (Asystole)
Ataxia (Ataxia)
Atelectasis (Atelectasis)
Atrial Fibrillation (Atrial fibrillation)
Atrial Flutter (Atrial flutter)
Av Block Third Degree (Atrioventricular
block complete)
Av Block First Degree (Atrioventricular
block first degree)
Autoimmune Disease (Autoimmune
disorder)
Bone Necrosis (Avascular necrosis)
Azoospermia (Azoospermia)
Back Pain (Back pain)
Bile Duct Stenosis (Bile duct stenosis)
Biliary Anastomotic Leakage (Biliary
anastomotic leak)
Biliary Fistula (Biliary fistula)
Cholangitis (Biliary tract infection)
Bladder Anastomotic Leakage (Bladder
anastomotic leak)
Cystitis (Bladder infection)
Bladder Perforation (Bladder perforation)
Bladder Spasm (Bladder spasm)
Bloating (Bloating)
Hematopoietic And Lymphoid System
Disorder Other Specify (Blood and
lymphatic system disorders - Other,
specify)
Abnormal Blood Antidiuretic Hormone
(Blood antidiuretic hormone abnormal)
Elevated Bilirubin (Blood bilirubin
increased)
Blood Corticotrophin Decreased (Blood
corticotrophin decreased)
Abnormal Blood Gonadotrophin (Blood
gonadotrophin abnormal)
Abnormal Blood Prolactin (Blood
prolactin abnormal)
Blurred Vision (Blurred vision)
Body Odor (Body odor)
Bone Infection (Bone infection)
Hypocellular Bone Marrow (Bone
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marrow hypocellular)
Bone Pain (Bone pain)
Brachial Plexopathy (Brachial
plexopathy)
Breast Atrophy (Breast atrophy)
Mastitis (Breast infection)
Breast Pain (Breast pain)
Bronchial Fistula (Bronchial fistula)
Bronchitis (Bronchial infection)
Bronchial Obstruction (Bronchial
obstruction)
Bronchial Stricture (Bronchial stricture)
Bronchopleural Fistula (Bronchopleural
fistula)
Bronchial Hemorrhage
(Bronchopulmonary hemorrhage)
Bronchospasm (Bronchospasm)
Bruise (Bruising)
Bullous Dermatitis (Bullous dermatitis)
Burn (Burn)
Buttock Pain (Buttock pain)
Capillary Leak Syndrome Capillary Leak
Syndrome (Capillary leak syndrome)
Decreased Carbon Monoxide Diffusing
Capacity (Carbon monoxide diffusing
capacity decreased)
Cardiac Arrest (Cardiac arrest)
Heart Disorder Other Specify (Cardiac
disorders - Other, specify)
Blood Cardiac Troponin I Increased
(Cardiac troponin I increased)
Blood Cardiac Troponin T Increased
(Cardiac troponin T increased)
Cataract (Cataract)
Catheter-related Infection (Catheter
related infection)
Cd4 Lymphocytes Decreased (CD4
lymphocytes decreased)
Cecal Hemorrhage (Cecal hemorrhage)
Cecal Infection (Cecal infection)
Central Nervous System Necrotic Lesion
(Central nervous system necrosis)
Cerebrospinal Fluid Leakage
(Cerebrospinal fluid leakage)
Infectious Cervicitis (Cervicitis infection)
Cheilitis (Cheilitis)
Angina (Chest pain - cardiac)
Chest Wall Pain (Chest wall pain)
Chills (Chills)
Cholecystitis (Cholecystitis)
Hypercholesterolemia (Cholesterol high)
Chronic Kidney Disease (Chronic kidney
disease)
Chylothorax (Chylothorax)
Cognitive Disturbance (Cognitive
disturbance)
Colitis (Colitis)
Colonic Fistula (Colonic fistula)
Colonic Hemorrhage (Colonic
hemorrhage)
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Colonic Obstruction (Colonic obstruction)
Colonic Perforation (Colonic perforation)
Colonic Stenosis (Colonic stenosis)
Colonic Ulcer (Colonic ulcer)
Concentration Impairment
(Concentration impairment)
Heart Conduction Disorder (Conduction
disorder)
Confusion (Confusion)
Congenital, Familial And Genetic
Disorder Class Other Specify
(Congenital, familial and genetic
disorders - Other, specify)
Conjunctivitis (Conjunctivitis)
Acute Contagious Conjunctivitis
(Conjunctivitis infective)
Constipation (Constipation)
Constrictive Pericarditis (Constrictive
pericarditis)
Keratitis (Corneal infection)
Corneal Ulcer (Corneal ulcer)
Cough (Cough)
Creatine Phosphokinase Increased (CPK
increased)
Cranial Nerve Infection (Cranial nerve
infection)
Cushingoid (Cushingoid)
Non-infectious Cystitis (Cystitis
noninfective)
Cytokine Release Syndrome (Cytokine
release syndrome)
Neonatal Death (Death neonatal)
Death (Death NOS)
Dehydration (Dehydration)
Delayed Orgasm (Delayed orgasm)
Delayed Puberty (Delayed puberty)
Delirium (Delirium)
Delusion (Delusions)
Caries (Dental caries)
Depressed Level Of Consciousness
(Depressed level of consciousness)
Depression (Depression)
Radiation-induced Dermatitis (Dermatitis
radiation)
Prosthesis-related Infection (Device
related infection)
Diarrhea (Diarrhea)
Disseminated Intravascular Coagulation
(Disseminated intravascular coagulation)
Dizziness (Dizziness)
Dry Eye Syndrome (Dry eye)
Xerostomia (Dry mouth)
Dry Skin (Dry Skin)
Duodenal Fistula (Duodenal fistula)
Duodenal Hemorrhage (Duodenal
hemorrhage)
Duodenal Infection (Duodenal infection)
Duodenal Obstruction (Duodenal
obstruction)
Duodenal Perforation (Duodenal
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perforation)
Duodenal Stenosis (Duodenal stenosis)
Duodenal Ulcer (Duodenal ulcer)
Dysarthria (Dysarthria)
Dysesthesia (Dysesthesia)
Dysgeusia (Dysgeusia)
Dysmenorrhea (Dysmenorrhea)
Dyspareunia (Dyspareunia)
Dyspepsia (Dyspepsia)
Dysphagia (Dysphagia)
Dysphasia (Dysphasia)
Ear And Labyrinth Disorder Class Other
Specify (Ear and labyrinth disorders -
Other, specify)
Earache (Ear pain)
Cerebral Edema (Edema cerebral)
Face Edema (Edema face)
Edema Limbs (Edema limbs)
Edema Trunk (Edema trunk)
Ejaculation Disorder (Ejaculation
disorder)
Ejection Fraction Decreased (Ejection
fraction decreased)
Prolonged Qt Interval (Electrocardiogram
QT corrected interval prolonged)
Infectious Encephalitis (Encephalitis
infection)
Infectious Encephalomyelitis
(Encephalomyelitis infection)
Encephalopathy (Encephalopathy)
Infective Endocarditis (Endocarditis
infective)
Endocrine Disorder Other Specify
(Endocrine disorders - Other, specify)
Endophthalmitis (Endophthalmitis)
Enterocolitis (Enterocolitis)
Infectious Enterocolitis (Enterocolitis
infectious)
Enterovesical Fistula (Enterovesical
fistula)
Epistaxis (Epistaxis)
Impotence (Erectile dysfunction)
Erythema Multiforme (Erythema
multiforme)
Erythroderma (Erythroderma)
Esophageal Anastomotic Leakage
(Esophageal anastomotic leak)
Esophageal Fistula (Esophageal fistula)
Esophageal Hemorrhage (Esophageal
hemorrhage)
Esophageal Infection (Esophageal
infection)
Esophageal Necrotic Lesion
(Esophageal necrosis)
Esophageal Obstruction (Esophageal
obstruction)
Esophageal Pain (Esophageal pain)
Perforation Of Esophagus (Esophageal
perforation)
Esophageal Stricture (Esophageal
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stenosis)
Esophageal Ulcer (Esophageal ulcer)
Esophageal Varices Hemorrhage
(Esophageal varices hemorrhage)
Esophagitis (Esophagitis)
Euphoria (Euphoria)
Exostosis (Exostosis)
External Ear Inflammation (External ear
inflammation)
External Ear Pain (External ear pain)
Extraocular Muscle Paresis (Extraocular
muscle paresis)
Extrapyramidal Disorder (Extrapyramidal
disorder)
Eye Disorder Other Specify (Eye
disorders - Other, specify)
Eye Infection (Eye infection)
Eye Pain (Eye pain)
Eyelid Function Disorder (Eyelid function
disorder)
Facial Muscle Weakness (Facial muscle
weakness)
Facial Nerve Disorder (Facial nerve
disorder)
Facial Pain (Facial pain)
Fall (Fall)
Fallopian Tube Anastomotic Leakage
(Fallopian tube anastomotic leak)
Fallopian Tube Obstruction (Fallopian
tube obstruction)
Fallopian Tube Perforation (Fallopian
tube perforation)
Fallopian Tube Stenosis (Fallopian tube
stenosis)
Adipose Tissue Atrophy (Fat atrophy)
Fatigue (Fatigue)
Neutropenic Fever (Febrile neutropenia)
Fecal Incontinence (Fecal incontinence)
Female Genital Tract Fistula (Female
genital tract fistula)
Acquired Feminization (Feminization
acquired)
Intrauterine Fetal Death (Fetal death)
Fetal Growth Retardation (Fetal growth
retardation)
Fever (Fever)
Fibrinogen Decreased (Fibrinogen
decreased)
Deep Connective Tissue Fibrosis
(Fibrosis deep connective tissue)
Flank Pain (Flank pain)
Flasher (Flashing lights)
Flatulence (Flatulence)
Floaters (Floaters)
Flushing (Flushing)
Decreased Forced Expiratory Volume
(Forced expiratory volume decreased)
Fracture (Fracture)
Gait Disturbance (Gait disturbance)
Gallbladder Fistula (Gallbladder fistula)
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Gallbladder Infection (Gallbladder
infection)
Gallbladder Necrotic Lesion (Gallbladder
necrosis)
Gallbladder Obstruction (Gallbladder
obstruction)
Gallbladder Pain (Gallbladder pain)
Gallbladder Perforation (Gallbladder
perforation)
Gastric Anastomotic Leakage (Gastric
anastomotic leak)
Gastric Fistula (Gastric fistula)
Gastric Hemorrhage (Gastric
hemorrhage)
Gastric Necrotic Lesion (Gastric
necrosis)
Gastric Perforation (Gastric perforation)
Gastric Stenosis (Gastric stenosis)
Gastric Ulcer (Gastric ulcer)
Gastritis (Gastritis)
Gastroesophageal Reflux Disease
(Gastroesophageal reflux disease)
Gastrointestinal System Anastomotic
Leakage (Gastrointestinal anastomotic
leak)
Gastrointestinal Disorder Other Specify
(Gastrointestinal disorders - Other,
specify)
Gastrointestinal Fistula (Gastrointestinal
fistula)
Gastrointestinal Pain (Gastrointestinal
pain)
Gastrointestinal Stoma Necrotic Lesion
(Gastrointestinal stoma necrosis)
Gastroparesis (Gastroparesis)
General Disorders And Administration
Site Conditions Class Other Specify
(General disorders and administration
site conditions - Other, specify)
Generalized Muscle Weakness
(Generalized muscle weakness)
Genital Edema (Genital edema)
Gamma-glutamyltransferase Increased
(GGT increased)
Gingival Pain (Gingival pain)
Glaucoma (Glaucoma)
Glossopharyngeal Nerve Disorder
(Glossopharyngeal nerve disorder)
Glucose Intolerance (Glucose
intolerance)
Accelerated Growth (Growth
accelerated)
Abnormal Growth Hormone (Growth
hormone abnormal)
Growth Retardation (Growth
suppression)
Gum Infection (Gum infection)
Gynecomastia (Gynecomastia)
Hallucination (Hallucinations)
Haptoglobin Decreased (Haptoglobin
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decreased)
Head Soft Tissue Necrotic Lesion (Head
soft tissue necrosis)
Headache (Headache)
Heart Failure (Heart failure)
Hematoma (Hematoma)
Hematosalpinx (Hematosalpinx)
Hematuria (Hematuria)
Hemoglobin Increased (Hemoglobin
increased)
Hemoglobinuria (Hemoglobinuria)
Hemolysis (Hemolysis)
Hemolytic Uremic Syndrome (Hemolytic
uremic syndrome)
Hemorrhoidal Hemorrhage
(Hemorrhoidal hemorrhage)
Hemorrhoid (Hemorrhoids)
Hepatic Failure (Hepatic failure)
Hepatic Hemorrhage (Hepatic
hemorrhage)
Hepatic Infection (Hepatic infection)
Hepatic Necrotic Lesion (Hepatic
necrosis)
Hepatic Pain (Hepatic pain)
Viral Hepatitis (Hepatitis viral)
Liver And Biliary Tract Disorder Other
Specify (Hepatobiliary disorders - Other,
specify)
Hiccough (Hiccups)
Hip Fracture (Hip fracture)
Hirsutism (Hirsutism)
Hoarseness (Hoarseness)
Hot Flashes (Hot flashes)
Hydrocephalus (Hydrocephalus)
Hypercalcemia (Hypercalcemia)
Hyperglycemia (Hyperglycemia)
Hyperhidrosis (Hyperhidrosis)
Hyperkalemia (Hyperkalemia)
Hypermagnesemia (Hypermagnesemia)
Hypernatremia (Hypernatremia)
Hyperparathyroidism
(Hyperparathyroidism)
Hypersomnia (Hypersomnia)
Hypertension (Hypertension)
Hyperthyroidism (Hyperthyroidism)
Hypertrichosis (Hypertrichosis)
Hypertriglyceridemia
(Hypertriglyceridemia)
Hyperuricemia (Hyperuricemia)
Hypoalbuminemia (Hypoalbuminemia)
Hypocalcemia (Hypocalcemia)
Hypoglossal Nerve Disorder
(Hypoglossal nerve disorder)
Hypoglycemia (Hypoglycemia)
Hypohidrosis (Hypohidrosis)
Hypokalemia (Hypokalemia)
Hyponatremia (Hyponatremia)
Hypoparathyroidism
(Hypoparathyroidism)
Hypophosphatemia (Hypophosphatemia)
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Hypotension (Hypotension)
Hypothermia (Hypothermia)
Hypothyroidism (Hypothyroidism)
Hypoxia (Hypoxia)
Ileal Fistula (Ileal fistula)
Ileal Hemorrhage (Ileal hemorrhage)
Ileal Obstruction (Ileal obstruction)
Ileal Perforation (Ileal perforation)
Ileal Stenosis (Ileal stenosis)
Ileal Ulcer (Ileal ulcer)
Ileus (Ileus)
Immune System Disorder Other Specify
(Immune system disorders - Other,
specify)
Infection Other Specify (Infections and
infestations - Other, specify)
Infectious Myositis (Infective myositis)
Infusion-related Reaction (Infusion
related reaction)
Infusion Site Extravasation (Infusion site
extravasation)
Injection Site Reaction (Injection site
reaction)
Injury To Carotid Artery (Injury to carotid
artery)
Injury To Inferior Vena Cava (Injury to
inferior vena cava)
Injury To Jugular Vein (Injury to jugular
vein)
Injury To Superior Vena Cava (Injury to
superior vena cava)
Injury, Poisoning And Procedural
Complication Class Other Specify (Injury,
poisoning and procedural complications -
Other, specify)
Inr Increased (INR increased)
Insomnia (Insomnia)
Intestinal Stoma Leakage (Intestinal
stoma leak)
Intestinal Stoma Obstruction (Intestinal
stoma obstruction)
Intestinal Stoma Site Hemorrhage
(Intestinal stoma site bleeding)
Intra-abdominal Hemorrhage (Intra-
abdominal hemorrhage)
Intracranial Hemorrhage (Intracranial
hemorrhage)
Intraoperative Arterial Injury
(Intraoperative arterial injury)
Intraoperative Breast Injury
(Intraoperative breast injury)
Intraoperative Cardiac Injury
(Intraoperative cardiac injury)
Intraoperative Ear Injury (Intraoperative
ear injury)
Intraoperative Endocrine Injury
(Intraoperative endocrine injury)
Intraoperative Gastrointestinal Injury
(Intraoperative gastrointestinal injury)
Intraoperative Head And Neck Injury
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(Intraoperative head and neck injury)
Intraoperative Hemorrhage
(Intraoperative hemorrhage)
Intraoperative Hepatobiliary Injury
(Intraoperative hepatobiliary injury)
Intraoperative Musculoskeletal Injury
(Intraoperative musculoskeletal injury)
Intraoperative Neurological Injury
(Intraoperative neurological injury)
Intraoperative Ocular Injury
(Intraoperative ocular injury)
Intraoperative Renal Injury
(Intraoperative renal injury)
Intraoperative Reproductive System
Injury (Intraoperative reproductive tract
injury)
Intraoperative Respiratory Injury
(Intraoperative respiratory injury)
Intraoperative Skin Injury (Intraoperative
skin injury)
Intraoperative Splenic Injury
(Intraoperative splenic injury)
Intraoperative Urinary System Injury
(Intraoperative urinary injury)
Intraoperative Venous Injury
(Intraoperative venous injury)
Investigation Other Specify
(Investigations - Other, specify)
Iron Overload (Iron overload)
Irregular Menstruation (Irregular
menstruation)
Irritability (Irritability)
Cerebrovascular Ischemia (Ischemia
cerebrovascular)
Trochlear Nerve Disorder (IVth nerve
disorder)
Jejunal Fistula (Jejunal fistula)
Jejunal Hemorrhage (Jejunal
hemorrhage)
Jejunal Obstruction (Jejunal obstruction)
Jejunal Perforation (Jejunal perforation)
Jejunal Stenosis (Jejunal stenosis)
Jejunal Ulcer (Jejunal ulcer)
Joint Effusion (Joint effusion)
Joint Infection (Joint infection)
Joint Range Of Motion Decreased (Joint
range of motion decreased)
Cervical Spine Joint Range Of Motion
Decreased (Joint range of motion
decreased cervical spine)
Lumbar Spine Joint Range Of Motion
Decreased (Joint range of motion
decreased lumbar spine)
Keratitis (Keratitis)
Kidney Anastomotic Leakage (Kidney
anastomotic leak)
Pyelonephritis (Kidney infection)
Kyphosis (Kyphosis)
Lactation Disorder (Lactation disorder)
Large Intestinal Anastomotic Leakage
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(Large intestinal anastomotic leak)
Laryngeal Edema (Laryngeal edema)
Laryngeal Fistula (Laryngeal fistula)
Laryngeal Hemorrhage (Laryngeal
hemorrhage)
Laryngitis (Laryngeal inflammation)
Laryngeal Mucositis (Laryngeal
mucositis)
Laryngeal Obstruction (Laryngeal
obstruction)
Laryngeal Stenosis (Laryngeal stenosis)
Laryngitis (Laryngitis)
Laryngopharyngeal Dysesthesia
(Laryngopharyngeal dysesthesia)
Laryngospasm (Laryngospasm)
Left Ventricular Systolic Dysfunction (Left
ventricular systolic dysfunction)
Lethargy (Lethargy)
Chemotherapy-related Leukemia
(Leukemia secondary to oncology
chemotherapy)
Leukocytosis (Leukocytosis)
Leukoencephalopathy
(Leukoencephalopathy)
Decreased Libido (Libido decreased)
Increased Libido (Libido increased)
Lip Infection (Lip infection)
Lip Pain (Lip pain)
Lipase Increased (Lipase increased)
Lipohypertrophy (Lipohypertrophy)
Localized Edema (Localized edema)
Lordosis (Lordosis)
Lower Gastrointestinal Hemorrhage
(Lower gastrointestinal hemorrhage)
Infectious Lung Disorder (Lung infection)
Lymphadenitis (Lymph gland infection)
Lymph Leakage (Lymph leakage)
Lymph Node Pain (Lymph node pain)
Lymphocele (Lymphocele)
Lymphopenia (Lymphocyte count
decreased)
Lymphocytosis (Lymphocyte count
increased)
Malabsorption Syndrome
(Malabsorption)
Malaise (Malaise)
Mania (Mania)
Mediastinal Hemorrhage (Mediastinal
hemorrhage)
Mediastinitis (Mediastinal infection)
Memory Impairment (Memory
impairment)
Meningismus (Meningismus)
Meningitis (Meningitis)
Menopause (Menopause)
Menorrhagia (Menorrhagia)
Metabolism And Nutrition Disorder Class
Other Specify (Metabolism and nutrition
disorders - Other, specify)
Otitis Media (Middle ear inflammation)
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Mitral Valve Disorder (Mitral valve
disease)
Av Block Second Degree Mobitz Type Ii
(Mobitz (type) II atrioventricular block)
Av Block Second Degree Mobitz Type I
(Mobitz type I)
Involuntary Movements (Movements
involuntary)
Mucosal Infection (Mucosal infection)
Multiple Organ Failure (Multi-organ
failure)
Muscle Weakness Left-sided (Muscle
weakness left-sided)
Muscle Weakness Lower Limb (Muscle
weakness lower limb)
Muscle Weakness Right-sided (Muscle
weakness right-sided)
Muscle Weakness Trunk (Muscle
weakness trunk)
Muscle Weakness Upper Limb (Muscle
weakness upper limb)
Connective And Soft Tissue Disorder
Other Specify (Musculoskeletal and
connective tissue disorder -  Other,
specify)
Musculoskeletal Deformity
(Musculoskeletal deformity)
Myelitis (Myelitis)
Mds (Myelodysplastic syndrome)
Myocardial Infarction (Myocardial
infarction)
Myocarditis (Myocarditis)
Myositis (Myositis)
Nail Discoloration (Nail discoloration)
Nail Infection (Nail infection)
Nail Loss (Nail loss)
Nail Ridging (Nail ridging)
Nasal Congestion (Nasal congestion)
Neck Edema (Neck edema)
Neck Pain (Neck pain)
Neck Soft Tissue Necrotic Lesion (Neck
soft tissue necrosis)
Neoplasm Other Specify (Neoplasms
benign, malignant and unspecified (incl
cysts and polyps) - Other, specify)
Nervous System Disorder Other Specify
(Nervous system disorders - Other,
specify)
Neuralgia (Neuralgia)
Night Blindness (Night blindness)
Nipple Deformity (Nipple deformity)
Non-cardiac Chest Pain (Non-cardiac
chest pain)
Nystagmus (Nystagmus)
Obesity (Obesity)
Gastric Obstruction (Obstruction gastric)
Oculomotor Nerve Disorder (Oculomotor
nerve disorder)
Olfactory Nerve Disorder (Olfactory
nerve disorder)
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Oligospermia (Oligospermia)
Optic Nerve Disorder (Optic nerve
disorder)
Oral Cavity Fistula (Oral cavity fistula)
Burning Mouth Syndrome (Oral
dysesthesia)
Oral Hemorrhage (Oral hemorrhage)
Oral Pain (Oral pain)
Osteonecrosis Of Jaw (Osteonecrosis of
jaw)
Osteoporosis (Osteoporosis)
External Ear Infection (Otitis externa)
Otitis Media (Otitis media)
Ovarian Hemorrhage (Ovarian
hemorrhage)
Ovarian Infection (Ovarian infection)
Ovarian Rupture (Ovarian rupture)
Ovulatory Pain (Ovulation pain)
Pain (Pain)
Pain In Extremity (Pain in extremity)
Skin Pain (Pain of skin)
Palmar-plantar Erythodysthesia (Palmar-
plantar erythrodysesthesia syndrome)
Palpitation (Palpitations)
Pancreatic Infection (Pancreas infection)
Pancreatic Anastomotic Leakage
(Pancreatic anastomotic leak)
Pancreatic Duct Stenosis (Pancreatic
duct stenosis)
Pancreatic Enzymes Decreased
(Pancreatic enzymes decreased)
Pancreatic Fistula (Pancreatic fistula)
Pancreatic Hemorrhage (Pancreatic
hemorrhage)
Pancreatic Necrotic Lesion (Pancreatic
necrosis)
Pancreatitis (Pancreatitis)
Papilledema (Papilledema)
Papulopustular Rash (Papulopustular
rash)
Paresthesia (Paresthesia)
Paronychia (Paronychia)
Paroxysmal Atrial Tachycardia
(Paroxysmal atrial tachycardia)
Pelvic Floor Muscle Weakness (Pelvic
floor muscle weakness)
Pelvic Inflammatory Disease (Pelvic
infection)
Pelvic Pain (Pelvic pain)
Pelvic Soft Tissue Necrotic Lesion
(Pelvic soft tissue necrosis)
Penile Infection (Penile infection)
Penile Pain (Penile pain)
Bile Duct Perforation (Perforation bile
duct)
Pericardial Effusion (Pericardial effusion)
Cardiac Tamponade (Pericardial
tamponade)
Pericarditis (Pericarditis)
Perineal Pain (Perineal pain)
14 / 41
CALGB 30506 Adverse Event (AE) Form NCT00863512
Periodontal Disorder (Periodontal
disease)
Periorbital Edema (Periorbital edema)
Periorbital Infection (Periorbital infection)
Peripheral Ischemia (Peripheral
ischemia)
Peripheral Nervous System Infectious
Disorder (Peripheral nerve infection)
Peripheral Sensory Neuropathy
(Peripheral sensory neuropathy)
Peritoneal Infection (Peritoneal infection)
Peritoneal Necrotic Lesion (Peritoneal
necrosis)
Personality Change (Personality change)
Phantom Pain (Phantom pain)
Pharyngeal Anastomotic Leakage
(Pharyngeal anastomotic leak)
Pharyngeal Fistula (Pharyngeal fistula)
Pharyngeal Hemorrhage (Pharyngeal
hemorrhage)
Pharyngeal Mucositis (Pharyngeal
mucositis)
Pharyngeal Necrotic Lesion (Pharyngeal
necrosis)
Pharyngeal Stenosis (Pharyngeal
stenosis)
Pharyngitis (Pharyngitis)
Pharyngolaryngeal Pain
(Pharyngolaryngeal pain)
Phlebitis (Phlebitis)
Infective Phlebitis (Phlebitis infective)
Photophobia (Photophobia)
Photosensitivity (Photosensitivity)
Thrombocytopenia (Platelet count
decreased)
Pleural Effusion (Pleural effusion)
Hemothorax (Pleural hemorrhage)
Pleural Infection (Pleural infection)
Pleuritic Pain (Pleuritic pain)
Pneumonia (Pneumonitis)
Pneumothorax (Pneumothorax)
Portal Hypertension (Portal
Hypertension)
Portal Vein Thrombosis (Portal vein
thrombosis)
Post-nasal Drip (Postnasal drip)
Postoperative Bleeding (Postoperative
hemorrhage)
Thoracic Procedure Postoperative
Complication (Postoperative thoracic
procedure complication)
Precocious Puberty (Precocious
puberty)
Pregnancy, Puerperium And Perinatal
Condition Class Other Specify
(Pregnancy, puerperium and perinatal
conditions - Other, specify)
Premature Labor (Premature delivery)
Premature Menopause (Premature
menopause)
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Presyncope (Presyncope)
Proctitis (Proctitis)
Productive Cough (Productive cough)
Intestinal Stoma Prolapse (Prolapse of
intestinal stoma)
Urostomy Prolapse (Prolapse of
urostomy)
Prostatic Infection (Prostate infection)
Prostatic Hemorrhage (Prostatic
hemorrhage)
Prostatic Pain (Prostatic pain)
Pruritus (Pruritus)
Psychiatric Disorder Other Specify
(Psychiatric disorders - Other, specify)
Psychosis (Psychosis)
Pulmonary Edema (Pulmonary edema)
Pulmonary Fibrosis (Pulmonary fibrosis)
Pulmonary Fistula (Pulmonary fistula)
Pulmonary Hypertension (Pulmonary
hypertension)
Pulmonary Valve Disorder (Pulmonary
valve disease)
Purpura (Purpura)
Pyramidal Tract Dysfunction (Pyramidal
tract syndrome)
Radiation-recall Dermatitis (Radiation
recall reaction (dermatologic))
Radiculitis (Radiculitis)
Acneiform Dermatitis (Rash acneiform)
Maculopapular Lesion (Rash maculo-
papular)
Papulopustular Rash (Rash pustular)
Rectal Anastomotic Leakage (Rectal
anastomotic leak)
Rectal Fistula (Rectal fistula)
Rectal Hemorrhage (Rectal hemorrhage)
Rectal Mucositis (Rectal mucositis)
Rectal Necrotic Lesion (Rectal necrosis)
Rectal Obstruction (Rectal obstruction)
Rectal Pain (Rectal pain)
Rectal Perforation (Rectal perforation)
Rectal Stenosis (Rectal stenosis)
Rectal Ulcer (Rectal ulcer)
Recurrent Laryngeal Nerve Paralysis
(Recurrent laryngeal nerve palsy)
Urinary Tract Disorder Other Specify
(Renal and urinary disorders - Other,
specify)
Renal Stone (Renal calculi)
Renal Colic (Renal colic)
Renal Hemorrhage (Renal hemorrhage)
Reproductive System And Breast
Disorder Class Other Specify
(Reproductive system and breast
disorders - Other, specify)
Respiratory Failure (Respiratory failure)
Respiratory And Thoracic Disorder Other
Specify (Respiratory, thoracic and
mediastinal disorders - Other, specify)
Restlessness (Restlessness)
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Restrictive Cardiomyopathy (Restrictive
cardiomyopathy)
Retinal Detachment (Retinal
detachment)
Retinal Tear (Retinal tear)
Retinal Vascular Disorder (Retinal
vascular disorder)
Retinoic Acid Syndrome (Retinoic acid
syndrome)
Retinopathy (Retinopathy)
Retroperitoneal Hemorrhage
(Retroperitoneal hemorrhage)
Reversible Posterior
Leukoencephalopathy Syndrome
(Reversible posterior
leukoencephalopathy syndrome)
Infectious Rhinitis (Rhinitis infective)
Right Ventricular Dysfunction (Right
ventricular dysfunction)
Salivary Duct Inflammation (Salivary duct
inflammation)
Salivary Gland Fistula (Salivary gland
fistula)
Salivary Gland Infection (Salivary gland
infection)
Scalp Pain (Scalp pain)
Sclera Disorder (Scleral disorder)
Scoliosis (Scoliosis)
Scrotal Infection (Scrotal infection)
Scrotal Pain (Scrotal pain)
Seizure (Seizure)
Septicemia (Sepsis)
Seroma (Seroma)
Serum Amylase Increased (Serum
amylase increased)
Serum Sickness (Serum sickness)
Sick Sinus Syndrome (Sick sinus
syndrome)
Sinus Bradycardia (Sinus bradycardia)
Paranasal Sinus Disorder (Sinus
disorder)
Sinus Pain (Sinus pain)
Sinus Tachycardia (Sinus tachycardia)
Sinusitis (Sinusitis)
Skin Disorder Other Specify (Skin and
subcutaneous tissue disorders - Other,
specify)
Skin Atrophy (Skin atrophy)
Skin Hyperpigmentation (Skin
hyperpigmentation)
Skin Hypopigmentation (Skin
hypopigmentation)
Skin Induration (Skin induration)
Skin Infection (Skin infection)
Skin Ulcer (Skin ulceration)
Sleep Apnea (Sleep apnea)
Small Intestinal Anastomotic Leakage
(Small intestinal anastomotic leak)
Small Intestinal Mucositis (Small
intestinal mucositis)
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Small Intestinal Obstruction (Small
intestinal obstruction)
Small Intestinal Perforation (Small
intestinal perforation)
Small Intestinal Stenosis (Small intestinal
stenosis)
Small Intestinal Infection (Small intestine
infection)
Small Intestinal Ulcer (Small intestine
ulcer)
Sneezing (Sneezing)
Social Circumstances Other Specify
(Social circumstances - Other, specify)
Soft Tissue Infection (Soft tissue
infection)
Lower Limb Soft Tissue Necrotic Lesion
(Soft tissue necrosis lower limb)
Upper Limb Soft Tissue Necrotic Lesion
(Soft tissue necrosis upper limb)
Somnolence (Somnolence)
Sore Throat (Sore throat)
Spasticity (Spasticity)
Spermatic Cord Anastomotic Leakage
(Spermatic cord anastomotic leak)
Spermatic Cord Hemorrhage (Spermatic
cord hemorrhage)
Spermatic Cord Obstruction (Spermatic
cord obstruction)
Vertebral Fracture (Spinal fracture)
Splenic Disorder (Spleen disorder)
Splenic Infection (Splenic infection)
Gastrointestinal Stoma Stenosis
(Stenosis of gastrointestinal stoma)
Stevens-johnson Syndrome (Stevens-
Johnson syndrome)
Stoma Site Infection (Stoma site
infection)
Stomach Pain (Stomach pain)
Stomal Ulcer (Stomal ulcer)
Stridor (Stridor)
Cerebrovascular Accident (Stroke)
Sudden Cardiac Death (Sudden death
NOS)
Suicidal Ideation (Suicidal ideation)
Suicide Attempt (Suicide attempt)
Superficial Soft Tissue Fibrosis
(Superficial soft tissue fibrosis)
Superficial Thrombophlebitis (Superficial
thrombophlebitis)
Superior Vena Cava Syndrome (Superior
vena cava syndrome)
Supraventricular Tachycardia
(Supraventricular tachycardia)
Intervention Or Procedure Other Specify
(Surgical and medical procedures -
Other, specify)
Syncope (Syncope)
Telangiectasia (Telangiectasia)
Testicular Disorder (Testicular disorder)
Testicular Hemorrhage (Testicular
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hemorrhage)
Testicular Pain (Testicular pain)
Thromboembolism (Thromboembolic
event)
Thrombotic Thrombocytopenic Purpura
(Thrombotic thrombocytopenic purpura)
Tinnitus (Tinnitus)
Dental Developmental Disorder (Tooth
development disorder)
Tooth Discoloration (Tooth discoloration)
Tooth Infection (Tooth infection)
Toothache (Toothache)
Toxic Epidermal Necrolysis (Toxic
epidermal necrolysis)
Tracheal Fistula (Tracheal fistula)
Tracheal Hemorrhage (Tracheal
hemorrhage)
Tracheal Mucositis (Tracheal mucositis)
Tracheal Obstruction (Tracheal
obstruction)
Tracheal Stenosis (Tracheal stenosis)
Tracheitis (Tracheitis)
Tracheostomy Site Bleeding
(Tracheostomy site bleeding)
Transient Ischemic Attack (Transient
ischemic attacks)
Therapy-related Malignant Neoplasm
(Treatment related secondary
malignancy)
Tremor (Tremor)
Tricuspid Valve Disorder (Tricuspid valve
disease)
Trigeminal Nerve Disorder (Trigeminal
nerve disorder)
Trismus (Trismus)
Tumor Lysis Syndrome (Tumor lysis
syndrome)
Tumor Pain (Tumor pain)
Typhlitis (Typhlitis)
Unequal Limb Length (Unequal limb
length)
Unintended Pregnancy (Unintended
pregnancy)
Upper Gastrointestinal Hemorrhage
(Upper gastrointestinal hemorrhage)
Upper Respiratory Tract Infection (Upper
respiratory infection)
Ureteric Anastomotic Leakage (Ureteric
anastomotic leak)
Urethral Anastomotic Leakage (Urethral
anastomotic leak)
Urethral Infection (Urethral infection)
Urinary Tract Fistula (Urinary fistula)
Urinary Frequency (Urinary frequency)
Urinary Incontinence (Urinary
incontinence)
Urinary Retention (Urinary retention)
Urinary Tract Infection (Urinary tract
infection)
Urinary Tract Obstruction (Urinary tract
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obstruction)
Urinary Tract Pain (Urinary tract pain)
Urinary Urgency (Urinary urgency)
Urine Discoloration (Urine discoloration)
Urine Output Decreased (Urine output
decreased)
Urostomy Leakage (Urostomy leak)
Urostomy Obstruction (Urostomy
obstruction)
Urostomy Site Bleeding (Urostomy site
bleeding)
Urostomy Stenosis (Urostomy stenosis)
Urticaria (Urticaria)
Uterine Anastomotic Leakage (Uterine
anastomotic leak)
Uterine Fistula (Uterine fistula)
Uterine Hemorrhage (Uterine
hemorrhage)
Endometritis (Uterine infection)
Uterine Obstruction (Uterine obstruction)
Uterine Pain (Uterine pain)
Uterine Perforation (Uterine perforation)
Uveitis (Uveitis)
Vaginal Anastomotic Leakage (Vaginal
anastomotic leak)
Vaginal Discharge (Vaginal discharge)
Vaginal Dryness (Vaginal dryness)
Vaginal Fistula (Vaginal fistula)
Vaginal Hemorrhage (Vaginal
hemorrhage)
Vaginitis (Vaginal infection)
Vaginitis (Vaginal inflammation)
Vaginal Obstruction (Vaginal obstruction)
Vaginal Pain (Vaginal pain)
Vaginal Perforation (Vaginal perforation)
Vaginal Stricture (Vaginal stricture)
Vaginismus (Vaginismus)
Vagus Nerve Disorder (Vagus nerve
disorder)
Vas Deferens Anastomotic Leakage (Vas
deferens anastomotic leak)
Vascular Access Complication (Vascular
access complication)
Vascular Disorder Other Specify
(Vascular disorders - Other, specify)
Vasculitis (Vasculitis)
Vasovagal Reaction (Vasovagal reaction)
Venous Injury (Venous injury)
Ventricular Arrhythmia (Ventricular
arrhythmia)
Ventricular Fibrillation (Ventricular
fibrillation)
Ventricular Tachycardia (Ventricular
tachycardia)
Vertigo (Vertigo)
Internal Ear Disorder (Vestibular
disorder)
Virilization (Virilization)
Visceral Artery Ischemia (Visceral
arterial ischemia)
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Abnormal Vital Capacity (Vital capacity
abnormal)
Vitreous Hemorrhage (Vitreous
hemorrhage)
Voice Alternation (Voice alteration)
Vulval Infection (Vulval infection)
Watering Eyes (Watering eyes)
Weight Gain (Weight gain)
Weight Loss (Weight loss)
Wheezing (Wheezing)
Leukopenia (White blood cell decreased)
Wolff-parkinson-white Syndrome (Wolff-
Parkinson-White Syndrome)
Wound Complication (Wound
complication)
Wound Dehiscence (Wound dehiscence)
Wound Infection (Wound infection)
Wrist Fracture (Wrist fracture)
CTC AE Grade
Absent Adverse Event (0)
Mild Adverse Event (1)
Moderate Adverse Event (2)
Severe Adverse Event (3)
Life Threatening Adverse Event (4)
Death Related To Adverse Event (5)
CTC AE Attribution Code (2^AE is defined as
adverse event.)
Definite (definite)
Possible (possible)
Probable (probable)
Unlikely (unlikely)
Unrelated (unrelated)
Expected Adverse Events
MedDRA Code
CTCAE Term
Abdominal Distention (Abdominal
distension)
Abdominal Infection (Abdominal
infection)
Abdominal Pain (Abdominal pain)
Abdominal Soft Tissue Necrotic Lesion
(Abdominal soft tissue necrosis)
Abducens Nerve Disorder (Abducens
nerve disorder)
Accessory Nerve Disorder (Accessory
nerve disorder)
Acidosis (Acidosis)
Vestibulocochlear Nerve Disorder
(Acoustic nerve disorder NOS)
Prolonged Partial Thromboplastin Time
(Activated partial thromboplastin time
prolonged)
Acute Coronary Syndrome (Acute
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coronary syndrome)
Acute Renal Failure (Acute kidney injury)
Adrenal Gland Insufficiency (Adrenal
insufficiency)
Adult Respiratory Distress Syndrome
(Adult respiratory distress syndrome)
Agitation (Agitation)
Akathisia (Akathisia)
Alanine Aminotransferase Increased
(Alanine aminotransferase increased)
Alcohol Intolerance (Alcohol intolerance)
Blood Alkaline Phosphatase Increased
(Alkaline phosphatase increased)
Alkalosis (Alkalosis)
Hypersensitivity (Allergic reaction)
Allergic Rhinitis (Allergic rhinitis)
Alopecia (Alopecia)
Amnesia (Amnesia)
Anorectal Fistula (Anal fistula)
Anal Hemorrhage (Anal hemorrhage)
Anal Mucositis (Anal mucositis)
Anal Necrotic Lesion (Anal necrosis)
Anal Pain (Anal pain)
Anal Stenosis (Anal stenosis)
Anal Ulcer (Anal ulcer)
Anaphylactic Shock (Anaphylaxis)
Anemia (Anemia)
Ankle Fracture (Ankle fracture)
Anorectal Infection (Anorectal infection)
Anorgasmia (Anorgasmia)
Anxiety (Anxiety)
Aortic Injury (Aortic injury)
Aortic Valve Disorder (Aortic valve
disease)
Aphonia (Aphonia)
Apnea (Apnea)
Acute Appendicitis (Appendicitis)
Acute Perforated Appendicitis
(Appendicitis perforated)
Arachnoiditis (Arachnoiditis)
Arterial Injury (Arterial injury)
Arteritis (Arteritis infective)
Arthritis (Arthritis)
Ascites (Ascites)
Aspartate Aminotransferase Increased
(Aspartate aminotransferase increased)
Aspiration (Aspiration)
Cardiac Arrest (Asystole)
Ataxia (Ataxia)
Atelectasis (Atelectasis)
Atrial Fibrillation (Atrial fibrillation)
Atrial Flutter (Atrial flutter)
Av Block Third Degree (Atrioventricular
block complete)
Av Block First Degree (Atrioventricular
block first degree)
Autoimmune Disease (Autoimmune
disorder)
Bone Necrosis (Avascular necrosis)
Azoospermia (Azoospermia)
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Back Pain (Back pain)
Bile Duct Stenosis (Bile duct stenosis)
Biliary Anastomotic Leakage (Biliary
anastomotic leak)
Biliary Fistula (Biliary fistula)
Cholangitis (Biliary tract infection)
Bladder Anastomotic Leakage (Bladder
anastomotic leak)
Cystitis (Bladder infection)
Bladder Perforation (Bladder perforation)
Bladder Spasm (Bladder spasm)
Bloating (Bloating)
Hematopoietic And Lymphoid System
Disorder Other Specify (Blood and
lymphatic system disorders - Other,
specify)
Abnormal Blood Antidiuretic Hormone
(Blood antidiuretic hormone abnormal)
Elevated Bilirubin (Blood bilirubin
increased)
Blood Corticotrophin Decreased (Blood
corticotrophin decreased)
Abnormal Blood Gonadotrophin (Blood
gonadotrophin abnormal)
Abnormal Blood Prolactin (Blood
prolactin abnormal)
Blurred Vision (Blurred vision)
Body Odor (Body odor)
Bone Infection (Bone infection)
Hypocellular Bone Marrow (Bone
marrow hypocellular)
Bone Pain (Bone pain)
Brachial Plexopathy (Brachial
plexopathy)
Breast Atrophy (Breast atrophy)
Mastitis (Breast infection)
Breast Pain (Breast pain)
Bronchial Fistula (Bronchial fistula)
Bronchitis (Bronchial infection)
Bronchial Obstruction (Bronchial
obstruction)
Bronchial Stricture (Bronchial stricture)
Bronchopleural Fistula (Bronchopleural
fistula)
Bronchial Hemorrhage
(Bronchopulmonary hemorrhage)
Bronchospasm (Bronchospasm)
Bruise (Bruising)
Bullous Dermatitis (Bullous dermatitis)
Burn (Burn)
Buttock Pain (Buttock pain)
Capillary Leak Syndrome Capillary Leak
Syndrome (Capillary leak syndrome)
Decreased Carbon Monoxide Diffusing
Capacity (Carbon monoxide diffusing
capacity decreased)
Cardiac Arrest (Cardiac arrest)
Heart Disorder Other Specify (Cardiac
disorders - Other, specify)
Blood Cardiac Troponin I Increased
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(Cardiac troponin I increased)
Blood Cardiac Troponin T Increased
(Cardiac troponin T increased)
Cataract (Cataract)
Catheter-related Infection (Catheter
related infection)
Cd4 Lymphocytes Decreased (CD4
lymphocytes decreased)
Cecal Hemorrhage (Cecal hemorrhage)
Cecal Infection (Cecal infection)
Central Nervous System Necrotic Lesion
(Central nervous system necrosis)
Cerebrospinal Fluid Leakage
(Cerebrospinal fluid leakage)
Infectious Cervicitis (Cervicitis infection)
Cheilitis (Cheilitis)
Angina (Chest pain - cardiac)
Chest Wall Pain (Chest wall pain)
Chills (Chills)
Cholecystitis (Cholecystitis)
Hypercholesterolemia (Cholesterol high)
Chronic Kidney Disease (Chronic kidney
disease)
Chylothorax (Chylothorax)
Cognitive Disturbance (Cognitive
disturbance)
Colitis (Colitis)
Colonic Fistula (Colonic fistula)
Colonic Hemorrhage (Colonic
hemorrhage)
Colonic Obstruction (Colonic obstruction)
Colonic Perforation (Colonic perforation)
Colonic Stenosis (Colonic stenosis)
Colonic Ulcer (Colonic ulcer)
Concentration Impairment
(Concentration impairment)
Heart Conduction Disorder (Conduction
disorder)
Confusion (Confusion)
Congenital, Familial And Genetic
Disorder Class Other Specify
(Congenital, familial and genetic
disorders - Other, specify)
Conjunctivitis (Conjunctivitis)
Acute Contagious Conjunctivitis
(Conjunctivitis infective)
Constipation (Constipation)
Constrictive Pericarditis (Constrictive
pericarditis)
Keratitis (Corneal infection)
Corneal Ulcer (Corneal ulcer)
Cough (Cough)
Creatine Phosphokinase Increased (CPK
increased)
Cranial Nerve Infection (Cranial nerve
infection)
Cushingoid (Cushingoid)
Non-infectious Cystitis (Cystitis
noninfective)
Cytokine Release Syndrome (Cytokine
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release syndrome)
Neonatal Death (Death neonatal)
Death (Death NOS)
Dehydration (Dehydration)
Delayed Orgasm (Delayed orgasm)
Delayed Puberty (Delayed puberty)
Delirium (Delirium)
Delusion (Delusions)
Caries (Dental caries)
Depressed Level Of Consciousness
(Depressed level of consciousness)
Depression (Depression)
Radiation-induced Dermatitis (Dermatitis
radiation)
Prosthesis-related Infection (Device
related infection)
Diarrhea (Diarrhea)
Disseminated Intravascular Coagulation
(Disseminated intravascular coagulation)
Dizziness (Dizziness)
Dry Eye Syndrome (Dry eye)
Xerostomia (Dry mouth)
Dry Skin (Dry Skin)
Duodenal Fistula (Duodenal fistula)
Duodenal Hemorrhage (Duodenal
hemorrhage)
Duodenal Infection (Duodenal infection)
Duodenal Obstruction (Duodenal
obstruction)
Duodenal Perforation (Duodenal
perforation)
Duodenal Stenosis (Duodenal stenosis)
Duodenal Ulcer (Duodenal ulcer)
Dysarthria (Dysarthria)
Dysesthesia (Dysesthesia)
Dysgeusia (Dysgeusia)
Dysmenorrhea (Dysmenorrhea)
Dyspareunia (Dyspareunia)
Dyspepsia (Dyspepsia)
Dysphagia (Dysphagia)
Dysphasia (Dysphasia)
Ear And Labyrinth Disorder Class Other
Specify (Ear and labyrinth disorders -
Other, specify)
Earache (Ear pain)
Cerebral Edema (Edema cerebral)
Face Edema (Edema face)
Edema Limbs (Edema limbs)
Edema Trunk (Edema trunk)
Ejaculation Disorder (Ejaculation
disorder)
Ejection Fraction Decreased (Ejection
fraction decreased)
Prolonged Qt Interval (Electrocardiogram
QT corrected interval prolonged)
Infectious Encephalitis (Encephalitis
infection)
Infectious Encephalomyelitis
(Encephalomyelitis infection)
Encephalopathy (Encephalopathy)
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Infective Endocarditis (Endocarditis
infective)
Endocrine Disorder Other Specify
(Endocrine disorders - Other, specify)
Endophthalmitis (Endophthalmitis)
Enterocolitis (Enterocolitis)
Infectious Enterocolitis (Enterocolitis
infectious)
Enterovesical Fistula (Enterovesical
fistula)
Epistaxis (Epistaxis)
Impotence (Erectile dysfunction)
Erythema Multiforme (Erythema
multiforme)
Erythroderma (Erythroderma)
Esophageal Anastomotic Leakage
(Esophageal anastomotic leak)
Esophageal Fistula (Esophageal fistula)
Esophageal Hemorrhage (Esophageal
hemorrhage)
Esophageal Infection (Esophageal
infection)
Esophageal Necrotic Lesion
(Esophageal necrosis)
Esophageal Obstruction (Esophageal
obstruction)
Esophageal Pain (Esophageal pain)
Perforation Of Esophagus (Esophageal
perforation)
Esophageal Stricture (Esophageal
stenosis)
Esophageal Ulcer (Esophageal ulcer)
Esophageal Varices Hemorrhage
(Esophageal varices hemorrhage)
Esophagitis (Esophagitis)
Euphoria (Euphoria)
Exostosis (Exostosis)
External Ear Inflammation (External ear
inflammation)
External Ear Pain (External ear pain)
Extraocular Muscle Paresis (Extraocular
muscle paresis)
Extrapyramidal Disorder (Extrapyramidal
disorder)
Eye Disorder Other Specify (Eye
disorders - Other, specify)
Eye Infection (Eye infection)
Eye Pain (Eye pain)
Eyelid Function Disorder (Eyelid function
disorder)
Facial Muscle Weakness (Facial muscle
weakness)
Facial Nerve Disorder (Facial nerve
disorder)
Facial Pain (Facial pain)
Fall (Fall)
Fallopian Tube Anastomotic Leakage
(Fallopian tube anastomotic leak)
Fallopian Tube Obstruction (Fallopian
tube obstruction)
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Fallopian Tube Perforation (Fallopian
tube perforation)
Fallopian Tube Stenosis (Fallopian tube
stenosis)
Adipose Tissue Atrophy (Fat atrophy)
Fatigue (Fatigue)
Neutropenic Fever (Febrile neutropenia)
Fecal Incontinence (Fecal incontinence)
Female Genital Tract Fistula (Female
genital tract fistula)
Acquired Feminization (Feminization
acquired)
Intrauterine Fetal Death (Fetal death)
Fetal Growth Retardation (Fetal growth
retardation)
Fever (Fever)
Fibrinogen Decreased (Fibrinogen
decreased)
Deep Connective Tissue Fibrosis
(Fibrosis deep connective tissue)
Flank Pain (Flank pain)
Flasher (Flashing lights)
Flatulence (Flatulence)
Floaters (Floaters)
Flushing (Flushing)
Decreased Forced Expiratory Volume
(Forced expiratory volume decreased)
Fracture (Fracture)
Gait Disturbance (Gait disturbance)
Gallbladder Fistula (Gallbladder fistula)
Gallbladder Infection (Gallbladder
infection)
Gallbladder Necrotic Lesion (Gallbladder
necrosis)
Gallbladder Obstruction (Gallbladder
obstruction)
Gallbladder Pain (Gallbladder pain)
Gallbladder Perforation (Gallbladder
perforation)
Gastric Anastomotic Leakage (Gastric
anastomotic leak)
Gastric Fistula (Gastric fistula)
Gastric Hemorrhage (Gastric
hemorrhage)
Gastric Necrotic Lesion (Gastric
necrosis)
Gastric Perforation (Gastric perforation)
Gastric Stenosis (Gastric stenosis)
Gastric Ulcer (Gastric ulcer)
Gastritis (Gastritis)
Gastroesophageal Reflux Disease
(Gastroesophageal reflux disease)
Gastrointestinal System Anastomotic
Leakage (Gastrointestinal anastomotic
leak)
Gastrointestinal Disorder Other Specify
(Gastrointestinal disorders - Other,
specify)
Gastrointestinal Fistula (Gastrointestinal
fistula)
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Gastrointestinal Pain (Gastrointestinal
pain)
Gastrointestinal Stoma Necrotic Lesion
(Gastrointestinal stoma necrosis)
Gastroparesis (Gastroparesis)
General Disorders And Administration
Site Conditions Class Other Specify
(General disorders and administration
site conditions - Other, specify)
Generalized Muscle Weakness
(Generalized muscle weakness)
Genital Edema (Genital edema)
Gamma-glutamyltransferase Increased
(GGT increased)
Gingival Pain (Gingival pain)
Glaucoma (Glaucoma)
Glossopharyngeal Nerve Disorder
(Glossopharyngeal nerve disorder)
Glucose Intolerance (Glucose
intolerance)
Accelerated Growth (Growth
accelerated)
Abnormal Growth Hormone (Growth
hormone abnormal)
Growth Retardation (Growth
suppression)
Gum Infection (Gum infection)
Gynecomastia (Gynecomastia)
Hallucination (Hallucinations)
Haptoglobin Decreased (Haptoglobin
decreased)
Head Soft Tissue Necrotic Lesion (Head
soft tissue necrosis)
Headache (Headache)
Heart Failure (Heart failure)
Hematoma (Hematoma)
Hematosalpinx (Hematosalpinx)
Hematuria (Hematuria)
Hemoglobin Increased (Hemoglobin
increased)
Hemoglobinuria (Hemoglobinuria)
Hemolysis (Hemolysis)
Hemolytic Uremic Syndrome (Hemolytic
uremic syndrome)
Hemorrhoidal Hemorrhage
(Hemorrhoidal hemorrhage)
Hemorrhoid (Hemorrhoids)
Hepatic Failure (Hepatic failure)
Hepatic Hemorrhage (Hepatic
hemorrhage)
Hepatic Infection (Hepatic infection)
Hepatic Necrotic Lesion (Hepatic
necrosis)
Hepatic Pain (Hepatic pain)
Viral Hepatitis (Hepatitis viral)
Liver And Biliary Tract Disorder Other
Specify (Hepatobiliary disorders - Other,
specify)
Hiccough (Hiccups)
Hip Fracture (Hip fracture)
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Hirsutism (Hirsutism)
Hoarseness (Hoarseness)
Hot Flashes (Hot flashes)
Hydrocephalus (Hydrocephalus)
Hypercalcemia (Hypercalcemia)
Hyperglycemia (Hyperglycemia)
Hyperhidrosis (Hyperhidrosis)
Hyperkalemia (Hyperkalemia)
Hypermagnesemia (Hypermagnesemia)
Hypernatremia (Hypernatremia)
Hyperparathyroidism
(Hyperparathyroidism)
Hypersomnia (Hypersomnia)
Hypertension (Hypertension)
Hyperthyroidism (Hyperthyroidism)
Hypertrichosis (Hypertrichosis)
Hypertriglyceridemia
(Hypertriglyceridemia)
Hyperuricemia (Hyperuricemia)
Hypoalbuminemia (Hypoalbuminemia)
Hypocalcemia (Hypocalcemia)
Hypoglossal Nerve Disorder
(Hypoglossal nerve disorder)
Hypoglycemia (Hypoglycemia)
Hypohidrosis (Hypohidrosis)
Hypokalemia (Hypokalemia)
Hyponatremia (Hyponatremia)
Hypoparathyroidism
(Hypoparathyroidism)
Hypophosphatemia (Hypophosphatemia)
Hypotension (Hypotension)
Hypothermia (Hypothermia)
Hypothyroidism (Hypothyroidism)
Hypoxia (Hypoxia)
Ileal Fistula (Ileal fistula)
Ileal Hemorrhage (Ileal hemorrhage)
Ileal Obstruction (Ileal obstruction)
Ileal Perforation (Ileal perforation)
Ileal Stenosis (Ileal stenosis)
Ileal Ulcer (Ileal ulcer)
Ileus (Ileus)
Immune System Disorder Other Specify
(Immune system disorders - Other,
specify)
Infection Other Specify (Infections and
infestations - Other, specify)
Infectious Myositis (Infective myositis)
Infusion-related Reaction (Infusion
related reaction)
Infusion Site Extravasation (Infusion site
extravasation)
Injection Site Reaction (Injection site
reaction)
Injury To Carotid Artery (Injury to carotid
artery)
Injury To Inferior Vena Cava (Injury to
inferior vena cava)
Injury To Jugular Vein (Injury to jugular
vein)
Injury To Superior Vena Cava (Injury to
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superior vena cava)
Injury, Poisoning And Procedural
Complication Class Other Specify (Injury,
poisoning and procedural complications -
Other, specify)
Inr Increased (INR increased)
Insomnia (Insomnia)
Intestinal Stoma Leakage (Intestinal
stoma leak)
Intestinal Stoma Obstruction (Intestinal
stoma obstruction)
Intestinal Stoma Site Hemorrhage
(Intestinal stoma site bleeding)
Intra-abdominal Hemorrhage (Intra-
abdominal hemorrhage)
Intracranial Hemorrhage (Intracranial
hemorrhage)
Intraoperative Arterial Injury
(Intraoperative arterial injury)
Intraoperative Breast Injury
(Intraoperative breast injury)
Intraoperative Cardiac Injury
(Intraoperative cardiac injury)
Intraoperative Ear Injury (Intraoperative
ear injury)
Intraoperative Endocrine Injury
(Intraoperative endocrine injury)
Intraoperative Gastrointestinal Injury
(Intraoperative gastrointestinal injury)
Intraoperative Head And Neck Injury
(Intraoperative head and neck injury)
Intraoperative Hemorrhage
(Intraoperative hemorrhage)
Intraoperative Hepatobiliary Injury
(Intraoperative hepatobiliary injury)
Intraoperative Musculoskeletal Injury
(Intraoperative musculoskeletal injury)
Intraoperative Neurological Injury
(Intraoperative neurological injury)
Intraoperative Ocular Injury
(Intraoperative ocular injury)
Intraoperative Renal Injury
(Intraoperative renal injury)
Intraoperative Reproductive System
Injury (Intraoperative reproductive tract
injury)
Intraoperative Respiratory Injury
(Intraoperative respiratory injury)
Intraoperative Skin Injury (Intraoperative
skin injury)
Intraoperative Splenic Injury
(Intraoperative splenic injury)
Intraoperative Urinary System Injury
(Intraoperative urinary injury)
Intraoperative Venous Injury
(Intraoperative venous injury)
Investigation Other Specify
(Investigations - Other, specify)
Iron Overload (Iron overload)
Irregular Menstruation (Irregular
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menstruation)
Irritability (Irritability)
Cerebrovascular Ischemia (Ischemia
cerebrovascular)
Trochlear Nerve Disorder (IVth nerve
disorder)
Jejunal Fistula (Jejunal fistula)
Jejunal Hemorrhage (Jejunal
hemorrhage)
Jejunal Obstruction (Jejunal obstruction)
Jejunal Perforation (Jejunal perforation)
Jejunal Stenosis (Jejunal stenosis)
Jejunal Ulcer (Jejunal ulcer)
Joint Effusion (Joint effusion)
Joint Infection (Joint infection)
Joint Range Of Motion Decreased (Joint
range of motion decreased)
Cervical Spine Joint Range Of Motion
Decreased (Joint range of motion
decreased cervical spine)
Lumbar Spine Joint Range Of Motion
Decreased (Joint range of motion
decreased lumbar spine)
Keratitis (Keratitis)
Kidney Anastomotic Leakage (Kidney
anastomotic leak)
Pyelonephritis (Kidney infection)
Kyphosis (Kyphosis)
Lactation Disorder (Lactation disorder)
Large Intestinal Anastomotic Leakage
(Large intestinal anastomotic leak)
Laryngeal Edema (Laryngeal edema)
Laryngeal Fistula (Laryngeal fistula)
Laryngeal Hemorrhage (Laryngeal
hemorrhage)
Laryngitis (Laryngeal inflammation)
Laryngeal Mucositis (Laryngeal
mucositis)
Laryngeal Obstruction (Laryngeal
obstruction)
Laryngeal Stenosis (Laryngeal stenosis)
Laryngitis (Laryngitis)
Laryngopharyngeal Dysesthesia
(Laryngopharyngeal dysesthesia)
Laryngospasm (Laryngospasm)
Left Ventricular Systolic Dysfunction (Left
ventricular systolic dysfunction)
Lethargy (Lethargy)
Chemotherapy-related Leukemia
(Leukemia secondary to oncology
chemotherapy)
Leukocytosis (Leukocytosis)
Leukoencephalopathy
(Leukoencephalopathy)
Decreased Libido (Libido decreased)
Increased Libido (Libido increased)
Lip Infection (Lip infection)
Lip Pain (Lip pain)
Lipase Increased (Lipase increased)
Lipohypertrophy (Lipohypertrophy)
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Localized Edema (Localized edema)
Lordosis (Lordosis)
Lower Gastrointestinal Hemorrhage
(Lower gastrointestinal hemorrhage)
Infectious Lung Disorder (Lung infection)
Lymphadenitis (Lymph gland infection)
Lymph Leakage (Lymph leakage)
Lymph Node Pain (Lymph node pain)
Lymphocele (Lymphocele)
Lymphopenia (Lymphocyte count
decreased)
Lymphocytosis (Lymphocyte count
increased)
Malabsorption Syndrome
(Malabsorption)
Malaise (Malaise)
Mania (Mania)
Mediastinal Hemorrhage (Mediastinal
hemorrhage)
Mediastinitis (Mediastinal infection)
Memory Impairment (Memory
impairment)
Meningismus (Meningismus)
Meningitis (Meningitis)
Menopause (Menopause)
Menorrhagia (Menorrhagia)
Metabolism And Nutrition Disorder Class
Other Specify (Metabolism and nutrition
disorders - Other, specify)
Otitis Media (Middle ear inflammation)
Mitral Valve Disorder (Mitral valve
disease)
Av Block Second Degree Mobitz Type Ii
(Mobitz (type) II atrioventricular block)
Av Block Second Degree Mobitz Type I
(Mobitz type I)
Involuntary Movements (Movements
involuntary)
Mucosal Infection (Mucosal infection)
Multiple Organ Failure (Multi-organ
failure)
Muscle Weakness Left-sided (Muscle
weakness left-sided)
Muscle Weakness Lower Limb (Muscle
weakness lower limb)
Muscle Weakness Right-sided (Muscle
weakness right-sided)
Muscle Weakness Trunk (Muscle
weakness trunk)
Muscle Weakness Upper Limb (Muscle
weakness upper limb)
Connective And Soft Tissue Disorder
Other Specify (Musculoskeletal and
connective tissue disorder -  Other,
specify)
Musculoskeletal Deformity
(Musculoskeletal deformity)
Myelitis (Myelitis)
Mds (Myelodysplastic syndrome)
Myocardial Infarction (Myocardial
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infarction)
Myocarditis (Myocarditis)
Myositis (Myositis)
Nail Discoloration (Nail discoloration)
Nail Infection (Nail infection)
Nail Loss (Nail loss)
Nail Ridging (Nail ridging)
Nasal Congestion (Nasal congestion)
Neck Edema (Neck edema)
Neck Pain (Neck pain)
Neck Soft Tissue Necrotic Lesion (Neck
soft tissue necrosis)
Neoplasm Other Specify (Neoplasms
benign, malignant and unspecified (incl
cysts and polyps) - Other, specify)
Nervous System Disorder Other Specify
(Nervous system disorders - Other,
specify)
Neuralgia (Neuralgia)
Night Blindness (Night blindness)
Nipple Deformity (Nipple deformity)
Non-cardiac Chest Pain (Non-cardiac
chest pain)
Nystagmus (Nystagmus)
Obesity (Obesity)
Gastric Obstruction (Obstruction gastric)
Oculomotor Nerve Disorder (Oculomotor
nerve disorder)
Olfactory Nerve Disorder (Olfactory
nerve disorder)
Oligospermia (Oligospermia)
Optic Nerve Disorder (Optic nerve
disorder)
Oral Cavity Fistula (Oral cavity fistula)
Burning Mouth Syndrome (Oral
dysesthesia)
Oral Hemorrhage (Oral hemorrhage)
Oral Pain (Oral pain)
Osteonecrosis Of Jaw (Osteonecrosis of
jaw)
Osteoporosis (Osteoporosis)
External Ear Infection (Otitis externa)
Otitis Media (Otitis media)
Ovarian Hemorrhage (Ovarian
hemorrhage)
Ovarian Infection (Ovarian infection)
Ovarian Rupture (Ovarian rupture)
Ovulatory Pain (Ovulation pain)
Pain (Pain)
Pain In Extremity (Pain in extremity)
Skin Pain (Pain of skin)
Palmar-plantar Erythodysthesia (Palmar-
plantar erythrodysesthesia syndrome)
Palpitation (Palpitations)
Pancreatic Infection (Pancreas infection)
Pancreatic Anastomotic Leakage
(Pancreatic anastomotic leak)
Pancreatic Duct Stenosis (Pancreatic
duct stenosis)
Pancreatic Enzymes Decreased
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(Pancreatic enzymes decreased)
Pancreatic Fistula (Pancreatic fistula)
Pancreatic Hemorrhage (Pancreatic
hemorrhage)
Pancreatic Necrotic Lesion (Pancreatic
necrosis)
Pancreatitis (Pancreatitis)
Papilledema (Papilledema)
Papulopustular Rash (Papulopustular
rash)
Paresthesia (Paresthesia)
Paronychia (Paronychia)
Paroxysmal Atrial Tachycardia
(Paroxysmal atrial tachycardia)
Pelvic Floor Muscle Weakness (Pelvic
floor muscle weakness)
Pelvic Inflammatory Disease (Pelvic
infection)
Pelvic Pain (Pelvic pain)
Pelvic Soft Tissue Necrotic Lesion
(Pelvic soft tissue necrosis)
Penile Infection (Penile infection)
Penile Pain (Penile pain)
Bile Duct Perforation (Perforation bile
duct)
Pericardial Effusion (Pericardial effusion)
Cardiac Tamponade (Pericardial
tamponade)
Pericarditis (Pericarditis)
Perineal Pain (Perineal pain)
Periodontal Disorder (Periodontal
disease)
Periorbital Edema (Periorbital edema)
Periorbital Infection (Periorbital infection)
Peripheral Ischemia (Peripheral
ischemia)
Peripheral Nervous System Infectious
Disorder (Peripheral nerve infection)
Peripheral Sensory Neuropathy
(Peripheral sensory neuropathy)
Peritoneal Infection (Peritoneal infection)
Peritoneal Necrotic Lesion (Peritoneal
necrosis)
Personality Change (Personality change)
Phantom Pain (Phantom pain)
Pharyngeal Anastomotic Leakage
(Pharyngeal anastomotic leak)
Pharyngeal Fistula (Pharyngeal fistula)
Pharyngeal Hemorrhage (Pharyngeal
hemorrhage)
Pharyngeal Mucositis (Pharyngeal
mucositis)
Pharyngeal Necrotic Lesion (Pharyngeal
necrosis)
Pharyngeal Stenosis (Pharyngeal
stenosis)
Pharyngitis (Pharyngitis)
Pharyngolaryngeal Pain
(Pharyngolaryngeal pain)
Phlebitis (Phlebitis)
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Infective Phlebitis (Phlebitis infective)
Photophobia (Photophobia)
Photosensitivity (Photosensitivity)
Thrombocytopenia (Platelet count
decreased)
Pleural Effusion (Pleural effusion)
Hemothorax (Pleural hemorrhage)
Pleural Infection (Pleural infection)
Pleuritic Pain (Pleuritic pain)
Pneumonia (Pneumonitis)
Pneumothorax (Pneumothorax)
Portal Hypertension (Portal
Hypertension)
Portal Vein Thrombosis (Portal vein
thrombosis)
Post-nasal Drip (Postnasal drip)
Postoperative Bleeding (Postoperative
hemorrhage)
Thoracic Procedure Postoperative
Complication (Postoperative thoracic
procedure complication)
Precocious Puberty (Precocious
puberty)
Pregnancy, Puerperium And Perinatal
Condition Class Other Specify
(Pregnancy, puerperium and perinatal
conditions - Other, specify)
Premature Labor (Premature delivery)
Premature Menopause (Premature
menopause)
Presyncope (Presyncope)
Proctitis (Proctitis)
Productive Cough (Productive cough)
Intestinal Stoma Prolapse (Prolapse of
intestinal stoma)
Urostomy Prolapse (Prolapse of
urostomy)
Prostatic Infection (Prostate infection)
Prostatic Hemorrhage (Prostatic
hemorrhage)
Prostatic Pain (Prostatic pain)
Pruritus (Pruritus)
Psychiatric Disorder Other Specify
(Psychiatric disorders - Other, specify)
Psychosis (Psychosis)
Pulmonary Edema (Pulmonary edema)
Pulmonary Fibrosis (Pulmonary fibrosis)
Pulmonary Fistula (Pulmonary fistula)
Pulmonary Hypertension (Pulmonary
hypertension)
Pulmonary Valve Disorder (Pulmonary
valve disease)
Purpura (Purpura)
Pyramidal Tract Dysfunction (Pyramidal
tract syndrome)
Radiation-recall Dermatitis (Radiation
recall reaction (dermatologic))
Radiculitis (Radiculitis)
Acneiform Dermatitis (Rash acneiform)
Maculopapular Lesion (Rash maculo-
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papular)
Papulopustular Rash (Rash pustular)
Rectal Anastomotic Leakage (Rectal
anastomotic leak)
Rectal Fistula (Rectal fistula)
Rectal Hemorrhage (Rectal hemorrhage)
Rectal Mucositis (Rectal mucositis)
Rectal Necrotic Lesion (Rectal necrosis)
Rectal Obstruction (Rectal obstruction)
Rectal Pain (Rectal pain)
Rectal Perforation (Rectal perforation)
Rectal Stenosis (Rectal stenosis)
Rectal Ulcer (Rectal ulcer)
Recurrent Laryngeal Nerve Paralysis
(Recurrent laryngeal nerve palsy)
Urinary Tract Disorder Other Specify
(Renal and urinary disorders - Other,
specify)
Renal Stone (Renal calculi)
Renal Colic (Renal colic)
Renal Hemorrhage (Renal hemorrhage)
Reproductive System And Breast
Disorder Class Other Specify
(Reproductive system and breast
disorders - Other, specify)
Respiratory Failure (Respiratory failure)
Respiratory And Thoracic Disorder Other
Specify (Respiratory, thoracic and
mediastinal disorders - Other, specify)
Restlessness (Restlessness)
Restrictive Cardiomyopathy (Restrictive
cardiomyopathy)
Retinal Detachment (Retinal
detachment)
Retinal Tear (Retinal tear)
Retinal Vascular Disorder (Retinal
vascular disorder)
Retinoic Acid Syndrome (Retinoic acid
syndrome)
Retinopathy (Retinopathy)
Retroperitoneal Hemorrhage
(Retroperitoneal hemorrhage)
Reversible Posterior
Leukoencephalopathy Syndrome
(Reversible posterior
leukoencephalopathy syndrome)
Infectious Rhinitis (Rhinitis infective)
Right Ventricular Dysfunction (Right
ventricular dysfunction)
Salivary Duct Inflammation (Salivary duct
inflammation)
Salivary Gland Fistula (Salivary gland
fistula)
Salivary Gland Infection (Salivary gland
infection)
Scalp Pain (Scalp pain)
Sclera Disorder (Scleral disorder)
Scoliosis (Scoliosis)
Scrotal Infection (Scrotal infection)
Scrotal Pain (Scrotal pain)
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Seizure (Seizure)
Septicemia (Sepsis)
Seroma (Seroma)
Serum Amylase Increased (Serum
amylase increased)
Serum Sickness (Serum sickness)
Sick Sinus Syndrome (Sick sinus
syndrome)
Sinus Bradycardia (Sinus bradycardia)
Paranasal Sinus Disorder (Sinus
disorder)
Sinus Pain (Sinus pain)
Sinus Tachycardia (Sinus tachycardia)
Sinusitis (Sinusitis)
Skin Disorder Other Specify (Skin and
subcutaneous tissue disorders - Other,
specify)
Skin Atrophy (Skin atrophy)
Skin Hyperpigmentation (Skin
hyperpigmentation)
Skin Hypopigmentation (Skin
hypopigmentation)
Skin Induration (Skin induration)
Skin Infection (Skin infection)
Skin Ulcer (Skin ulceration)
Sleep Apnea (Sleep apnea)
Small Intestinal Anastomotic Leakage
(Small intestinal anastomotic leak)
Small Intestinal Mucositis (Small
intestinal mucositis)
Small Intestinal Obstruction (Small
intestinal obstruction)
Small Intestinal Perforation (Small
intestinal perforation)
Small Intestinal Stenosis (Small intestinal
stenosis)
Small Intestinal Infection (Small intestine
infection)
Small Intestinal Ulcer (Small intestine
ulcer)
Sneezing (Sneezing)
Social Circumstances Other Specify
(Social circumstances - Other, specify)
Soft Tissue Infection (Soft tissue
infection)
Lower Limb Soft Tissue Necrotic Lesion
(Soft tissue necrosis lower limb)
Upper Limb Soft Tissue Necrotic Lesion
(Soft tissue necrosis upper limb)
Somnolence (Somnolence)
Sore Throat (Sore throat)
Spasticity (Spasticity)
Spermatic Cord Anastomotic Leakage
(Spermatic cord anastomotic leak)
Spermatic Cord Hemorrhage (Spermatic
cord hemorrhage)
Spermatic Cord Obstruction (Spermatic
cord obstruction)
Vertebral Fracture (Spinal fracture)
Splenic Disorder (Spleen disorder)
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Splenic Infection (Splenic infection)
Gastrointestinal Stoma Stenosis
(Stenosis of gastrointestinal stoma)
Stevens-johnson Syndrome (Stevens-
Johnson syndrome)
Stoma Site Infection (Stoma site
infection)
Stomach Pain (Stomach pain)
Stomal Ulcer (Stomal ulcer)
Stridor (Stridor)
Cerebrovascular Accident (Stroke)
Sudden Cardiac Death (Sudden death
NOS)
Suicidal Ideation (Suicidal ideation)
Suicide Attempt (Suicide attempt)
Superficial Soft Tissue Fibrosis
(Superficial soft tissue fibrosis)
Superficial Thrombophlebitis (Superficial
thrombophlebitis)
Superior Vena Cava Syndrome (Superior
vena cava syndrome)
Supraventricular Tachycardia
(Supraventricular tachycardia)
Intervention Or Procedure Other Specify
(Surgical and medical procedures -
Other, specify)
Syncope (Syncope)
Telangiectasia (Telangiectasia)
Testicular Disorder (Testicular disorder)
Testicular Hemorrhage (Testicular
hemorrhage)
Testicular Pain (Testicular pain)
Thromboembolism (Thromboembolic
event)
Thrombotic Thrombocytopenic Purpura
(Thrombotic thrombocytopenic purpura)
Tinnitus (Tinnitus)
Dental Developmental Disorder (Tooth
development disorder)
Tooth Discoloration (Tooth discoloration)
Tooth Infection (Tooth infection)
Toothache (Toothache)
Toxic Epidermal Necrolysis (Toxic
epidermal necrolysis)
Tracheal Fistula (Tracheal fistula)
Tracheal Hemorrhage (Tracheal
hemorrhage)
Tracheal Mucositis (Tracheal mucositis)
Tracheal Obstruction (Tracheal
obstruction)
Tracheal Stenosis (Tracheal stenosis)
Tracheitis (Tracheitis)
Tracheostomy Site Bleeding
(Tracheostomy site bleeding)
Transient Ischemic Attack (Transient
ischemic attacks)
Therapy-related Malignant Neoplasm
(Treatment related secondary
malignancy)
Tremor (Tremor)
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Tricuspid Valve Disorder (Tricuspid valve
disease)
Trigeminal Nerve Disorder (Trigeminal
nerve disorder)
Trismus (Trismus)
Tumor Lysis Syndrome (Tumor lysis
syndrome)
Tumor Pain (Tumor pain)
Typhlitis (Typhlitis)
Unequal Limb Length (Unequal limb
length)
Unintended Pregnancy (Unintended
pregnancy)
Upper Gastrointestinal Hemorrhage
(Upper gastrointestinal hemorrhage)
Upper Respiratory Tract Infection (Upper
respiratory infection)
Ureteric Anastomotic Leakage (Ureteric
anastomotic leak)
Urethral Anastomotic Leakage (Urethral
anastomotic leak)
Urethral Infection (Urethral infection)
Urinary Tract Fistula (Urinary fistula)
Urinary Frequency (Urinary frequency)
Urinary Incontinence (Urinary
incontinence)
Urinary Retention (Urinary retention)
Urinary Tract Infection (Urinary tract
infection)
Urinary Tract Obstruction (Urinary tract
obstruction)
Urinary Tract Pain (Urinary tract pain)
Urinary Urgency (Urinary urgency)
Urine Discoloration (Urine discoloration)
Urine Output Decreased (Urine output
decreased)
Urostomy Leakage (Urostomy leak)
Urostomy Obstruction (Urostomy
obstruction)
Urostomy Site Bleeding (Urostomy site
bleeding)
Urostomy Stenosis (Urostomy stenosis)
Urticaria (Urticaria)
Uterine Anastomotic Leakage (Uterine
anastomotic leak)
Uterine Fistula (Uterine fistula)
Uterine Hemorrhage (Uterine
hemorrhage)
Endometritis (Uterine infection)
Uterine Obstruction (Uterine obstruction)
Uterine Pain (Uterine pain)
Uterine Perforation (Uterine perforation)
Uveitis (Uveitis)
Vaginal Anastomotic Leakage (Vaginal
anastomotic leak)
Vaginal Discharge (Vaginal discharge)
Vaginal Dryness (Vaginal dryness)
Vaginal Fistula (Vaginal fistula)
Vaginal Hemorrhage (Vaginal
hemorrhage)
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Vaginitis (Vaginal infection)
Vaginitis (Vaginal inflammation)
Vaginal Obstruction (Vaginal obstruction)
Vaginal Pain (Vaginal pain)
Vaginal Perforation (Vaginal perforation)
Vaginal Stricture (Vaginal stricture)
Vaginismus (Vaginismus)
Vagus Nerve Disorder (Vagus nerve
disorder)
Vas Deferens Anastomotic Leakage (Vas
deferens anastomotic leak)
Vascular Access Complication (Vascular
access complication)
Vascular Disorder Other Specify
(Vascular disorders - Other, specify)
Vasculitis (Vasculitis)
Vasovagal Reaction (Vasovagal reaction)
Venous Injury (Venous injury)
Ventricular Arrhythmia (Ventricular
arrhythmia)
Ventricular Fibrillation (Ventricular
fibrillation)
Ventricular Tachycardia (Ventricular
tachycardia)
Vertigo (Vertigo)
Internal Ear Disorder (Vestibular
disorder)
Virilization (Virilization)
Visceral Artery Ischemia (Visceral
arterial ischemia)
Abnormal Vital Capacity (Vital capacity
abnormal)
Vitreous Hemorrhage (Vitreous
hemorrhage)
Voice Alternation (Voice alteration)
Vulval Infection (Vulval infection)
Watering Eyes (Watering eyes)
Weight Gain (Weight gain)
Weight Loss (Weight loss)
Wheezing (Wheezing)
Leukopenia (White blood cell decreased)
Wolff-parkinson-white Syndrome (Wolff-
Parkinson-White Syndrome)
Wound Complication (Wound
complication)
Wound Dehiscence (Wound dehiscence)
Wound Infection (Wound infection)
Wrist Fracture (Wrist fracture)
CTC AE Grade
Absent Adverse Event (0)
Mild Adverse Event (1)
Moderate Adverse Event (2)
Severe Adverse Event (3)
Life Threatening Adverse Event (4)
Death Related To Adverse Event (5)
CTC AE Attribution Code (2^AE is defined as
adverse event.)
Definite (definite)
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Possible (possible)
Probable (probable)
Unlikely (unlikely)
Unrelated (unrelated)
Footer module
Completed by (Last name, First name)
Date Form Completed
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1 / 3
Yes
No
Expected Adverse Events
CTC Adverse Event Term
Blood Creatinine Increased (Creatinine)
Fatigue (Fatigue)
Febrile Neutropenia (fever Of Unknown
Origin Without Clinically Or
Microbiologically Documented Infection)
(anc <1.0 X 10^9/l, Fever >=38.5
Degrees C) (Febrile neutropenia)
Haemoglobin Decreased (Hemoglobin)
Hemorrhage, Pulmonary/upper
Respiratory (Hemorrhage pulmonary -
Select)
Hemorrhage, Gu (Hemorrhage, GU -
Select)
Hypokalaemia (Hypokalemia)
Blood Magnesium Decreased
(Hypomagnesemia)
Peripheral Motor Neuropathy
(Neuropathy-motor)
Peripheral Sensory Neuropathy
(Neuropathy-sensory)
Neutropenia (Neutrophils)
Platelet Count Decreased (Platelets)
Thrombosis Nos
(Thrombosis/thrombus/embolism)
Vomiting Nos (Vomiting)
CTC Select AE
Lung (Lung)
Nose Nos (Nose)
Urinary (Urinary NOS)
CTC adverse event term
CTC adverse event term
CTC AE Attribution Code (^2)
Definite (definite)
Possible (possible)
Probable (probable)
Unlikely (unlikely)
Unrelated (unrelated)
CTC AE Attribution Code (^2)
Definite (definite)
Possible (possible)
Probable (probable)
Unlikely (unlikely)
Unrelated (unrelated)
MedDRA Code (Specify any other events grade 2
or higher that occurred during this time period.
2 / 3
CALGB 90601: Adverse Event (AE) Form NCT00942331
Report secondary malignancies including
AML/MDS here and on Form C-1001)
MedDRA Code (Specify any other events grade 2
or higher that occurred during this time period.
Report secondary malignancies including
AML/MDS here and on Form C-1001)
CTC AE grade (^2)
CTC AE grade (^2)
Completed by (Last name, First name)
Date Form Completed
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CALGB_40302_AE_FRM NCT00390455
CALGB: 40302 ADVERSE EVENT FORM NCT00390455 
Fulvestrant With or Without Lapatinib in Treating
Postmenopausal Women With Stage III or Stage IV Breast
Cancer That is Hormone Receptor-Positive
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=F5A8CF0A-
505E-3C78-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11549
CALGB_40302_AE_FRM
NCT00390455
CALGB clinical trial administrative data
CALGB Form
CALGB Study No
CALGB Patient ID
CTC adverse event report begin date
CTC adverse event report end date
Are data amended
Yes
No
Patient demographics
Patient Initials
Patient Hospital No
Institution/Affiliate
Participating Group
Participating Group Protocol No
Participating Group Patient ID
Adverse Event Expedited Reporting
System filed?
Has an AdEERS been filed (with Central Office
based on an event reported below)
Yes
No
1 / 2
Expected Adverse Events
MedDRA Code
CTC adverse event term
CTC adverse event term
CTC AE Attribution Code (^2)
Definite (definite)
Possible (possible)
Probable (probable)
Unlikely (unlikely)
Unrelated (unrelated)
CTC AE Attribution Code (^2)
Definite (definite)
Possible (possible)
Probable (probable)
Unlikely (unlikely)
Unrelated (unrelated)
MedDRA code (^1)
CTC AE grade (^2)
CTC AE grade (^2)
Completed by
Date form completed
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CALGB_40302_AE_FRM NCT00390455
CALGB 40503 PRE-EXISTING
CONDITIONS FORM NCT00601900
CALGB 40503 PRE-EXISTING CONDITIONS FORM
NCT00601900 
Tamoxifen or Letrozole With or Without Bevacizumab in
Treating Women With Stage III or Stage IV Breast Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=24061909-
3D35-3445-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11550
CALGB 40503 PRE-EXISTING
CONDITIONS FORM NCT00601900
Header
CALGB Form
CALGB Study No
CALGB Patient ID
Date of baseline symptom/event assessment
(MM DD YYYY)
Are data amended
Yes
No
Patient demographics
Patient Initials (Last, First Middle)
Patient Hospital No.
Institution/Affiliate
Participating Group
Participating Group Study No.
Participating Group Patient ID
Expected Adverse Events
CTC Adverse Event Short Name
Hemorrhage, Pulmonary/upper
Respiratory (Hemorrhage pulmonary -
Select)
Hemorrhage, Gi (Hemorrhage, GI -
Select)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
1 / 2
- Select)
Perforation, Gi (Perforation, GI - Select)
CTC Select AE
MedDRA Code
MedDRA Code
CTC adverse event term
CTC adverse event term
CTC AE grade (^2)
CTC AE grade (^2)
Completed by (Last name, First name)
Date form completed (MM DD YYYY)
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NCT00980954 RTOG 0724 F1: Radiation Therapy Oncology Group Phase
III Cervix Chemo RT (+)/(-) Adjuvant Chemotherapy Follow-up Form
NCT00980954 RTOG 0724 F1: Radiation Therapy
Oncology Group Phase III Cervix Chemo RT (+)/(-)
Adjuvant Chemotherapy Follow-up Form
Chemotherapy and Pelvic Radiation Therapy With or
Without Additional Chemotherapy in Treating Patients With
High-Risk Early-Stage Cervical Cancer After Radical
Hysterectomy
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=5C78147E-
D46C-4734-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11552
NCT00980954 RTOG 0724 F1:
Radiation Therapy Oncology Group
Phase III Cervix Chemo RT (+)/(-)
Adjuvant Chemotherapy Follow-up
Form
RTOG clinical trial administrative data
RTOG Study No.
Case #
Institution Name
Institution No.
Patient Initials
RTOG Patient ID
Amended Data
Yes
No
Death Assessment
Date of Last Contact or Death
Vital Status
Alive (Alive)
Dead (Dead)
Primary Cause of Death
Due To Complications Of Non-protocol
Treatment (Due to complications of non-
protocol treatment)
Due To Other Cause (Due to other
cause)
Due To Protocol Treatment (Due to
protocol treatment)
Due To Second Primary Or Other
Malignancy (Due to second primary or
1 / 24
other malignancy)
Due To This Disease (Due to this
disease)
Unknown (Unknown)
Due to other cause specify
Has Patient Been Diagnosed With A New
Progression?
Has the patient had a documented clinical
assessment for this cancer?
No (No)
Unknown (Unknown)
Yes (Yes)
Date of Last Clinical Assessment
Local tumor
Disease Absent (Disease absent)
Disease Present (Disease present)
Unknown (Unknown)
Pelvic lymph nodes
Disease Absent (Disease absent)
Disease Present (Disease present)
Unknown (Unknown)
Para-aortic nodes
Disease Absent (Disease absent)
Disease Present (Disease present)
Unknown (Unknown)
Distant metastasis
Disease Absent (Disease absent)
Disease Present (Disease present)
Unknown (Unknown)
Second primary
Disease Absent (Disease absent)
Disease Present (Disease present)
Unknown (Unknown)
Method of Evaluation
Pathologic (Pathologic)
Physical Exam (Physical Exam)
Radiographic (Radiographic)
Event
Appearance Of Bone Metastasis
(Appearance of bone metastasis)
Appearance Of Distant Nodes
(Appearance of distant nodes)
Appearance Of Liver Metastasis
(Appearance of liver metastasis)
Appearance Of Lung Metastasis
(Appearance of lung metastasis)
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Appearance Of Other Metastasis
(Appearance of other metastasis)
Appearance Of Second Malignancy
(Appearance of second malignancy)
Central Pelvic Mass (Central pelvic
mass)
Common Illiac (Common Illiac)
Complete Response After Recurrence
(other Nodes) (Complete response after
recurrence)
Complete Response After Recurrence
(primary Pelvic Tumor) (Complete
response after recurrence (primary
pelvic tumor))
Complete Response After Recurrence
(regional Nodes) (Complete response
after recurrence (regional nodes))
External Illiac (External Illiac)
Internal Illiac (Internal Illiac)
Obturator Foramen (Obturator)
Para Aortic Nodes/vertebral Body Level
(Para Aortic Nodes/Vertebral Body Level)
Recurrence Upper 1/3 Vagina
(Recurrence upper 1/3 vagina)
Recurrence Upper 2/3 Vagina
(Recurrence upper 2/3 vagina)
Sacral Nodes (Sacral Nodes)
Date
Specify
If there was recurrence of disease, was the
recurrence
Inside The Treatment Field (Inside the
treatment field)
Outside The Treatment Field (Outside
the treatment field)
Did the disease recurrence extend out to the
bony landmarks
Yes
No
Has a new primary cancer or MDS been
diagnosed that has not been previously reported?
No (No)
Unknown (Unknown)
Yes (Yes)
New Primary Site (s)
Aml/mds (AML/MDS)
Bcc (BCC)
Bladder (Bladder)
Brain (Brain)
Colorectal (Colorectal)
Esophageal (Esophageal)
Gastric (Gastric)
Liver (Liver)
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Lung (Lung)
Melanoma (Melanoma)
Nhl (NHL)
None (None)
Other Hematologic, Specify (Other
Hematologic, specify)
Other Solid, Specify (Other solid,
specify)
Pancreatic (Pancreatic)
Renal (Renal)
Squamous-skin (Squamous-Skin)
Unknown Primary (Unknown primary)
Date of diagnosis
Specify
Non-Protocol Therapy
Non-Protocol Therapy Type
Chemotherapy (Chemotherapy)
None (None)
Other Non-protocol Therapy (Other non-
protocol therapy)
Radiation To Other Sites, Specify
(Radiation to other sites)
Radiation To Pelvis (Radiation to pelvis)
Surgery (Surgery)
Surgical Procedure Related To Previous
Rt, Specify (Surgical procedure related
to previous RT, specify)
Unknown (Unknown)
Date of Non-protocol therapy
Specify
Protocol Specific Adverse Event
Evaluation
Any adverse events
No (No)
Unknown (Unknown)
Yes (Yes)
MedDRA disease code
CTCAE Term
Abdominal Distention (Abdominal
distension)
Abdominal Infection (Abdominal
infection)
Abdominal Pain (Abdominal pain)
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Abdominal Soft Tissue Necrotic Lesion
(Abdominal soft tissue necrosis)
Abducens Nerve Disorder (Abducens
nerve disorder)
Accessory Nerve Disorder (Accessory
nerve disorder)
Acidosis (Acidosis)
Vestibulocochlear Nerve Disorder
(Acoustic nerve disorder NOS)
Prolonged Partial Thromboplastin Time
(Activated partial thromboplastin time
prolonged)
Acute Coronary Syndrome (Acute
coronary syndrome)
Acute Renal Failure (Acute kidney injury)
Adrenal Gland Insufficiency (Adrenal
insufficiency)
Adult Respiratory Distress Syndrome
(Adult respiratory distress syndrome)
Agitation (Agitation)
Akathisia (Akathisia)
Alanine Aminotransferase Increased
(Alanine aminotransferase increased)
Alcohol Intolerance (Alcohol intolerance)
Blood Alkaline Phosphatase Increased
(Alkaline phosphatase increased)
Alkalosis (Alkalosis)
Hypersensitivity (Allergic reaction)
Allergic Rhinitis (Allergic rhinitis)
Alopecia (Alopecia)
Amnesia (Amnesia)
Anorectal Fistula (Anal fistula)
Anal Hemorrhage (Anal hemorrhage)
Anal Mucositis (Anal mucositis)
Anal Necrotic Lesion (Anal necrosis)
Anal Pain (Anal pain)
Anal Stenosis (Anal stenosis)
Anal Ulcer (Anal ulcer)
Anaphylactic Shock (Anaphylaxis)
Anemia (Anemia)
Ankle Fracture (Ankle fracture)
Anorectal Infection (Anorectal infection)
Anorexia (Anorexia)
Anorgasmia (Anorgasmia)
Anxiety (Anxiety)
Aortic Injury (Aortic injury)
Aortic Valve Disorder (Aortic valve
disease)
Aphonia (Aphonia)
Apnea (Apnea)
Acute Appendicitis (Appendicitis)
Acute Perforated Appendicitis
(Appendicitis perforated)
Arachnoiditis (Arachnoiditis)
Arterial Injury (Arterial injury)
Arteritis (Arteritis infective)
Arthralgia (Arthralgia)
Arthritis (Arthritis)
Ascites (Ascites)
Aspartate Aminotransferase Increased
5 / 24
NCT00980954 RTOG 0724 F1: Radiation Therapy Oncology Group Phase
III Cervix Chemo RT (+)/(-) Adjuvant Chemotherapy Follow-up Form
(Aspartate aminotransferase increased)
Aspiration (Aspiration)
Cardiac Arrest (Asystole)
Ataxia (Ataxia)
Atelectasis (Atelectasis)
Atrial Fibrillation (Atrial fibrillation)
Atrial Flutter (Atrial flutter)
Av Block Third Degree (Atrioventricular
block complete)
Av Block First Degree (Atrioventricular
block first degree)
Autoimmune Disease (Autoimmune
disorder)
Bone Necrosis (Avascular necrosis)
Azoospermia (Azoospermia)
Back Pain (Back pain)
Bile Duct Stenosis (Bile duct stenosis)
Biliary Anastomotic Leakage (Biliary
anastomotic leak)
Biliary Fistula (Biliary fistula)
Cholangitis (Biliary tract infection)
Bladder Anastomotic Leakage (Bladder
anastomotic leak)
Cystitis (Bladder infection)
Bladder Perforation (Bladder perforation)
Bladder Spasm (Bladder spasm)
Bloating (Bloating)
Hematopoietic And Lymphoid System
Disorder Other Specify (Blood and
lymphatic system disorders - Other,
specify)
Abnormal Blood Antidiuretic Hormone
(Blood antidiuretic hormone abnormal)
Elevated Bilirubin (Blood bilirubin
increased)
Blood Corticotrophin Decreased (Blood
corticotrophin decreased)
Abnormal Blood Gonadotrophin (Blood
gonadotrophin abnormal)
Abnormal Blood Prolactin (Blood
prolactin abnormal)
Blurred Vision (Blurred vision)
Body Odor (Body odor)
Bone Infection (Bone infection)
Hypocellular Bone Marrow (Bone
marrow hypocellular)
Bone Pain (Bone pain)
Brachial Plexopathy (Brachial
plexopathy)
Breast Atrophy (Breast atrophy)
Mastitis (Breast infection)
Breast Pain (Breast pain)
Bronchial Fistula (Bronchial fistula)
Bronchitis (Bronchial infection)
Bronchial Obstruction (Bronchial
obstruction)
Bronchial Stricture (Bronchial stricture)
Bronchopleural Fistula (Bronchopleural
fistula)
Bronchial Hemorrhage
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(Bronchopulmonary hemorrhage)
Bronchospasm (Bronchospasm)
Bruise (Bruising)
Bullous Dermatitis (Bullous dermatitis)
Burn (Burn)
Buttock Pain (Buttock pain)
Capillary Leak Syndrome Capillary Leak
Syndrome (Capillary leak syndrome)
Decreased Carbon Monoxide Diffusing
Capacity (Carbon monoxide diffusing
capacity decreased)
Cardiac Arrest (Cardiac arrest)
Heart Disorder Other Specify (Cardiac
disorders - Other, specify)
Blood Cardiac Troponin I Increased
(Cardiac troponin I increased)
Blood Cardiac Troponin T Increased
(Cardiac troponin T increased)
Cataract (Cataract)
Catheter-related Infection (Catheter
related infection)
Cd4 Lymphocytes Decreased (CD4
lymphocytes decreased)
Cecal Hemorrhage (Cecal hemorrhage)
Cecal Infection (Cecal infection)
Central Nervous System Necrotic Lesion
(Central nervous system necrosis)
Cerebrospinal Fluid Leakage
(Cerebrospinal fluid leakage)
Infectious Cervicitis (Cervicitis infection)
Cheilitis (Cheilitis)
Angina (Chest pain - cardiac)
Chest Wall Pain (Chest wall pain)
Chills (Chills)
Cholecystitis (Cholecystitis)
Hypercholesterolemia (Cholesterol high)
Chronic Kidney Disease (Chronic kidney
disease)
Chylothorax (Chylothorax)
Cognitive Disturbance (Cognitive
disturbance)
Colitis (Colitis)
Colonic Fistula (Colonic fistula)
Colonic Hemorrhage (Colonic
hemorrhage)
Colonic Obstruction (Colonic obstruction)
Colonic Perforation (Colonic perforation)
Colonic Stenosis (Colonic stenosis)
Colonic Ulcer (Colonic ulcer)
Concentration Impairment
(Concentration impairment)
Heart Conduction Disorder (Conduction
disorder)
Confusion (Confusion)
Congenital, Familial And Genetic
Disorder Class Other Specify
(Congenital, familial and genetic
disorders - Other, specify)
Conjunctivitis (Conjunctivitis)
Acute Contagious Conjunctivitis
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(Conjunctivitis infective)
Constipation (Constipation)
Constrictive Pericarditis (Constrictive
pericarditis)
Keratitis (Corneal infection)
Corneal Ulcer (Corneal ulcer)
Cough (Cough)
Creatine Phosphokinase Increased (CPK
increased)
Cranial Nerve Infection (Cranial nerve
infection)
Increased Creatinine (Creatinine
increased)
Cushingoid (Cushingoid)
Non-infectious Cystitis (Cystitis
noninfective)
Cytokine Release Syndrome (Cytokine
release syndrome)
Neonatal Death (Death neonatal)
Death (Death NOS)
Dehydration (Dehydration)
Delayed Orgasm (Delayed orgasm)
Delayed Puberty (Delayed puberty)
Delirium (Delirium)
Delusion (Delusions)
Caries (Dental caries)
Depressed Level Of Consciousness
(Depressed level of consciousness)
Depression (Depression)
Radiation-induced Dermatitis (Dermatitis
radiation)
Prosthesis-related Infection (Device
related infection)
Diarrhea (Diarrhea)
Disseminated Intravascular Coagulation
(Disseminated intravascular coagulation)
Dizziness (Dizziness)
Dry Eye Syndrome (Dry eye)
Xerostomia (Dry mouth)
Dry Skin (Dry Skin)
Duodenal Fistula (Duodenal fistula)
Duodenal Hemorrhage (Duodenal
hemorrhage)
Duodenal Infection (Duodenal infection)
Duodenal Obstruction (Duodenal
obstruction)
Duodenal Perforation (Duodenal
perforation)
Duodenal Stenosis (Duodenal stenosis)
Duodenal Ulcer (Duodenal ulcer)
Dysarthria (Dysarthria)
Dysesthesia (Dysesthesia)
Dysgeusia (Dysgeusia)
Dysmenorrhea (Dysmenorrhea)
Dyspareunia (Dyspareunia)
Dyspepsia (Dyspepsia)
Dysphagia (Dysphagia)
Dysphasia (Dysphasia)
Dyspnea (Dyspnea)
Ear And Labyrinth Disorder Class Other
8 / 24
NCT00980954 RTOG 0724 F1: Radiation Therapy Oncology Group Phase
III Cervix Chemo RT (+)/(-) Adjuvant Chemotherapy Follow-up Form
Specify (Ear and labyrinth disorders -
Other, specify)
Earache (Ear pain)
Cerebral Edema (Edema cerebral)
Face Edema (Edema face)
Edema Limbs (Edema limbs)
Edema Trunk (Edema trunk)
Ejaculation Disorder (Ejaculation
disorder)
Ejection Fraction Decreased (Ejection
fraction decreased)
Prolonged Qt Interval (Electrocardiogram
QT corrected interval prolonged)
Infectious Encephalitis (Encephalitis
infection)
Infectious Encephalomyelitis
(Encephalomyelitis infection)
Encephalopathy (Encephalopathy)
Infective Endocarditis (Endocarditis
infective)
Endocrine Disorder Other Specify
(Endocrine disorders - Other, specify)
Endophthalmitis (Endophthalmitis)
Enterocolitis (Enterocolitis)
Infectious Enterocolitis (Enterocolitis
infectious)
Enterovesical Fistula (Enterovesical
fistula)
Epistaxis (Epistaxis)
Impotence (Erectile dysfunction)
Erythema Multiforme (Erythema
multiforme)
Erythroderma (Erythroderma)
Esophageal Anastomotic Leakage
(Esophageal anastomotic leak)
Esophageal Fistula (Esophageal fistula)
Esophageal Hemorrhage (Esophageal
hemorrhage)
Esophageal Infection (Esophageal
infection)
Esophageal Necrotic Lesion
(Esophageal necrosis)
Esophageal Obstruction (Esophageal
obstruction)
Esophageal Pain (Esophageal pain)
Perforation Of Esophagus (Esophageal
perforation)
Esophageal Stricture (Esophageal
stenosis)
Esophageal Ulcer (Esophageal ulcer)
Esophageal Varices Hemorrhage
(Esophageal varices hemorrhage)
Esophagitis (Esophagitis)
Euphoria (Euphoria)
Exostosis (Exostosis)
External Ear Inflammation (External ear
inflammation)
External Ear Pain (External ear pain)
Extraocular Muscle Paresis (Extraocular
muscle paresis)
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Extrapyramidal Disorder (Extrapyramidal
disorder)
Eye Disorder Other Specify (Eye
disorders - Other, specify)
Eye Infection (Eye infection)
Eye Pain (Eye pain)
Eyelid Function Disorder (Eyelid function
disorder)
Facial Muscle Weakness (Facial muscle
weakness)
Facial Nerve Disorder (Facial nerve
disorder)
Facial Pain (Facial pain)
Fall (Fall)
Fallopian Tube Anastomotic Leakage
(Fallopian tube anastomotic leak)
Fallopian Tube Obstruction (Fallopian
tube obstruction)
Fallopian Tube Perforation (Fallopian
tube perforation)
Fallopian Tube Stenosis (Fallopian tube
stenosis)
Adipose Tissue Atrophy (Fat atrophy)
Fatigue (Fatigue)
Neutropenic Fever (Febrile neutropenia)
Fecal Incontinence (Fecal incontinence)
Female Genital Tract Fistula (Female
genital tract fistula)
Acquired Feminization (Feminization
acquired)
Intrauterine Fetal Death (Fetal death)
Fetal Growth Retardation (Fetal growth
retardation)
Fever (Fever)
Fibrinogen Decreased (Fibrinogen
decreased)
Deep Connective Tissue Fibrosis
(Fibrosis deep connective tissue)
Flank Pain (Flank pain)
Flasher (Flashing lights)
Flatulence (Flatulence)
Floaters (Floaters)
Flu-like Symptoms (Flu like symptoms)
Flushing (Flushing)
Decreased Forced Expiratory Volume
(Forced expiratory volume decreased)
Fracture (Fracture)
Gait Disturbance (Gait disturbance)
Gallbladder Fistula (Gallbladder fistula)
Gallbladder Infection (Gallbladder
infection)
Gallbladder Necrotic Lesion (Gallbladder
necrosis)
Gallbladder Obstruction (Gallbladder
obstruction)
Gallbladder Pain (Gallbladder pain)
Gallbladder Perforation (Gallbladder
perforation)
Gastric Anastomotic Leakage (Gastric
anastomotic leak)
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Gastric Fistula (Gastric fistula)
Gastric Hemorrhage (Gastric
hemorrhage)
Gastric Necrotic Lesion (Gastric
necrosis)
Gastric Perforation (Gastric perforation)
Gastric Stenosis (Gastric stenosis)
Gastric Ulcer (Gastric ulcer)
Gastritis (Gastritis)
Gastroesophageal Reflux Disease
(Gastroesophageal reflux disease)
Gastrointestinal System Anastomotic
Leakage (Gastrointestinal anastomotic
leak)
Gastrointestinal Disorder Other Specify
(Gastrointestinal disorders - Other,
specify)
Gastrointestinal Fistula (Gastrointestinal
fistula)
Gastrointestinal Pain (Gastrointestinal
pain)
Gastrointestinal Stoma Necrotic Lesion
(Gastrointestinal stoma necrosis)
Gastroparesis (Gastroparesis)
General Disorders And Administration
Site Conditions Class Other Specify
(General disorders and administration
site conditions - Other, specify)
Generalized Muscle Weakness
(Generalized muscle weakness)
Genital Edema (Genital edema)
Gamma-glutamyltransferase Increased
(GGT increased)
Gingival Pain (Gingival pain)
Glaucoma (Glaucoma)
Glossopharyngeal Nerve Disorder
(Glossopharyngeal nerve disorder)
Glucose Intolerance (Glucose
intolerance)
Accelerated Growth (Growth
accelerated)
Abnormal Growth Hormone (Growth
hormone abnormal)
Growth Retardation (Growth
suppression)
Gum Infection (Gum infection)
Gynecomastia (Gynecomastia)
Hallucination (Hallucinations)
Haptoglobin Decreased (Haptoglobin
decreased)
Head Soft Tissue Necrotic Lesion (Head
soft tissue necrosis)
Headache (Headache)
Hearing Impairment (Hearing impaired)
Heart Failure (Heart failure)
Hematoma (Hematoma)
Hematosalpinx (Hematosalpinx)
Hematuria (Hematuria)
Hemoglobin Increased (Hemoglobin
increased)
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Hemoglobinuria (Hemoglobinuria)
Hemolysis (Hemolysis)
Hemolytic Uremic Syndrome (Hemolytic
uremic syndrome)
Hemorrhoidal Hemorrhage
(Hemorrhoidal hemorrhage)
Hemorrhoid (Hemorrhoids)
Hepatic Failure (Hepatic failure)
Hepatic Hemorrhage (Hepatic
hemorrhage)
Hepatic Infection (Hepatic infection)
Hepatic Necrotic Lesion (Hepatic
necrosis)
Hepatic Pain (Hepatic pain)
Viral Hepatitis (Hepatitis viral)
Liver And Biliary Tract Disorder Other
Specify (Hepatobiliary disorders - Other,
specify)
Hiccough (Hiccups)
Hip Fracture (Hip fracture)
Hirsutism (Hirsutism)
Hoarseness (Hoarseness)
Hot Flashes (Hot flashes)
Hydrocephalus (Hydrocephalus)
Hypercalcemia (Hypercalcemia)
Hyperglycemia (Hyperglycemia)
Hyperhidrosis (Hyperhidrosis)
Hyperkalemia (Hyperkalemia)
Hypermagnesemia (Hypermagnesemia)
Hypernatremia (Hypernatremia)
Hyperparathyroidism
(Hyperparathyroidism)
Hypersomnia (Hypersomnia)
Hypertension (Hypertension)
Hyperthyroidism (Hyperthyroidism)
Hypertrichosis (Hypertrichosis)
Hypertriglyceridemia
(Hypertriglyceridemia)
Hyperuricemia (Hyperuricemia)
Hypoalbuminemia (Hypoalbuminemia)
Hypocalcemia (Hypocalcemia)
Hypoglossal Nerve Disorder
(Hypoglossal nerve disorder)
Hypoglycemia (Hypoglycemia)
Hypohidrosis (Hypohidrosis)
Hypokalemia (Hypokalemia)
Hypomagnesemia (Hypomagnesemia)
Hyponatremia (Hyponatremia)
Hypoparathyroidism
(Hypoparathyroidism)
Hypophosphatemia (Hypophosphatemia)
Hypotension (Hypotension)
Hypothermia (Hypothermia)
Hypothyroidism (Hypothyroidism)
Hypoxia (Hypoxia)
Ileal Fistula (Ileal fistula)
Ileal Hemorrhage (Ileal hemorrhage)
Ileal Obstruction (Ileal obstruction)
Ileal Perforation (Ileal perforation)
Ileal Stenosis (Ileal stenosis)
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Ileal Ulcer (Ileal ulcer)
Ileus (Ileus)
Immune System Disorder Other Specify
(Immune system disorders - Other,
specify)
Infection Other Specify (Infections and
infestations - Other, specify)
Infectious Myositis (Infective myositis)
Infusion-related Reaction (Infusion
related reaction)
Infusion Site Extravasation (Infusion site
extravasation)
Injection Site Reaction (Injection site
reaction)
Injury To Carotid Artery (Injury to carotid
artery)
Injury To Inferior Vena Cava (Injury to
inferior vena cava)
Injury To Jugular Vein (Injury to jugular
vein)
Injury To Superior Vena Cava (Injury to
superior vena cava)
Injury, Poisoning And Procedural
Complication Class Other Specify (Injury,
poisoning and procedural complications -
Other, specify)
Inr Increased (INR increased)
Insomnia (Insomnia)
Intestinal Stoma Leakage (Intestinal
stoma leak)
Intestinal Stoma Obstruction (Intestinal
stoma obstruction)
Intestinal Stoma Site Hemorrhage
(Intestinal stoma site bleeding)
Intra-abdominal Hemorrhage (Intra-
abdominal hemorrhage)
Intracranial Hemorrhage (Intracranial
hemorrhage)
Intraoperative Arterial Injury
(Intraoperative arterial injury)
Intraoperative Breast Injury
(Intraoperative breast injury)
Intraoperative Cardiac Injury
(Intraoperative cardiac injury)
Intraoperative Ear Injury (Intraoperative
ear injury)
Intraoperative Endocrine Injury
(Intraoperative endocrine injury)
Intraoperative Gastrointestinal Injury
(Intraoperative gastrointestinal injury)
Intraoperative Head And Neck Injury
(Intraoperative head and neck injury)
Intraoperative Hemorrhage
(Intraoperative hemorrhage)
Intraoperative Hepatobiliary Injury
(Intraoperative hepatobiliary injury)
Intraoperative Musculoskeletal Injury
(Intraoperative musculoskeletal injury)
Intraoperative Neurological Injury
(Intraoperative neurological injury)
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Intraoperative Ocular Injury
(Intraoperative ocular injury)
Intraoperative Renal Injury
(Intraoperative renal injury)
Intraoperative Reproductive System
Injury (Intraoperative reproductive tract
injury)
Intraoperative Respiratory Injury
(Intraoperative respiratory injury)
Intraoperative Skin Injury (Intraoperative
skin injury)
Intraoperative Splenic Injury
(Intraoperative splenic injury)
Intraoperative Urinary System Injury
(Intraoperative urinary injury)
Intraoperative Venous Injury
(Intraoperative venous injury)
Investigation Other Specify
(Investigations - Other, specify)
Iron Overload (Iron overload)
Irregular Menstruation (Irregular
menstruation)
Irritability (Irritability)
Cerebrovascular Ischemia (Ischemia
cerebrovascular)
Trochlear Nerve Disorder (IVth nerve
disorder)
Jejunal Fistula (Jejunal fistula)
Jejunal Hemorrhage (Jejunal
hemorrhage)
Jejunal Obstruction (Jejunal obstruction)
Jejunal Perforation (Jejunal perforation)
Jejunal Stenosis (Jejunal stenosis)
Jejunal Ulcer (Jejunal ulcer)
Joint Effusion (Joint effusion)
Joint Infection (Joint infection)
Joint Range Of Motion Decreased (Joint
range of motion decreased)
Cervical Spine Joint Range Of Motion
Decreased (Joint range of motion
decreased cervical spine)
Lumbar Spine Joint Range Of Motion
Decreased (Joint range of motion
decreased lumbar spine)
Keratitis (Keratitis)
Kidney Anastomotic Leakage (Kidney
anastomotic leak)
Pyelonephritis (Kidney infection)
Kyphosis (Kyphosis)
Lactation Disorder (Lactation disorder)
Large Intestinal Anastomotic Leakage
(Large intestinal anastomotic leak)
Laryngeal Edema (Laryngeal edema)
Laryngeal Fistula (Laryngeal fistula)
Laryngeal Hemorrhage (Laryngeal
hemorrhage)
Laryngitis (Laryngeal inflammation)
Laryngeal Mucositis (Laryngeal
mucositis)
Laryngeal Obstruction (Laryngeal
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obstruction)
Laryngeal Stenosis (Laryngeal stenosis)
Laryngitis (Laryngitis)
Laryngopharyngeal Dysesthesia
(Laryngopharyngeal dysesthesia)
Laryngospasm (Laryngospasm)
Left Ventricular Systolic Dysfunction (Left
ventricular systolic dysfunction)
Lethargy (Lethargy)
Chemotherapy-related Leukemia
(Leukemia secondary to oncology
chemotherapy)
Leukocytosis (Leukocytosis)
Leukoencephalopathy
(Leukoencephalopathy)
Decreased Libido (Libido decreased)
Increased Libido (Libido increased)
Lip Infection (Lip infection)
Lip Pain (Lip pain)
Lipase Increased (Lipase increased)
Lipohypertrophy (Lipohypertrophy)
Localized Edema (Localized edema)
Lordosis (Lordosis)
Lower Gastrointestinal Hemorrhage
(Lower gastrointestinal hemorrhage)
Infectious Lung Disorder (Lung infection)
Lymphadenitis (Lymph gland infection)
Lymph Leakage (Lymph leakage)
Lymph Node Pain (Lymph node pain)
Lymphedema (Lymphedema)
Lymphocele (Lymphocele)
Lymphopenia (Lymphocyte count
decreased)
Lymphocytosis (Lymphocyte count
increased)
Malabsorption Syndrome
(Malabsorption)
Malaise (Malaise)
Mania (Mania)
Mediastinal Hemorrhage (Mediastinal
hemorrhage)
Mediastinitis (Mediastinal infection)
Memory Impairment (Memory
impairment)
Meningismus (Meningismus)
Meningitis (Meningitis)
Menopause (Menopause)
Menorrhagia (Menorrhagia)
Metabolism And Nutrition Disorder Class
Other Specify (Metabolism and nutrition
disorders - Other, specify)
Otitis Media (Middle ear inflammation)
Mitral Valve Disorder (Mitral valve
disease)
Av Block Second Degree Mobitz Type Ii
(Mobitz (type) II atrioventricular block)
Av Block Second Degree Mobitz Type I
(Mobitz type I)
Involuntary Movements (Movements
involuntary)
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Mucosal Infection (Mucosal infection)
Stomatitis (Mucositis oral)
Multiple Organ Failure (Multi-organ
failure)
Muscle Weakness Left-sided (Muscle
weakness left-sided)
Muscle Weakness Lower Limb (Muscle
weakness lower limb)
Muscle Weakness Right-sided (Muscle
weakness right-sided)
Muscle Weakness Trunk (Muscle
weakness trunk)
Muscle Weakness Upper Limb (Muscle
weakness upper limb)
Connective And Soft Tissue Disorder
Other Specify (Musculoskeletal and
connective tissue disorder -  Other,
specify)
Musculoskeletal Deformity
(Musculoskeletal deformity)
Myalgia (Myalgia)
Myelitis (Myelitis)
Mds (Myelodysplastic syndrome)
Myocardial Infarction (Myocardial
infarction)
Myocarditis (Myocarditis)
Myositis (Myositis)
Nail Discoloration (Nail discoloration)
Nail Infection (Nail infection)
Nail Loss (Nail loss)
Nail Ridging (Nail ridging)
Nasal Congestion (Nasal congestion)
Nausea (Nausea)
Neck Edema (Neck edema)
Neck Pain (Neck pain)
Neck Soft Tissue Necrotic Lesion (Neck
soft tissue necrosis)
Neoplasm Other Specify (Neoplasms
benign, malignant and unspecified (incl
cysts and polyps) - Other, specify)
Nervous System Disorder Other Specify
(Nervous system disorders - Other,
specify)
Neuralgia (Neuralgia)
Neutrophil Count Decreased (Neutrophil
count decreased)
Night Blindness (Night blindness)
Nipple Deformity (Nipple deformity)
Non-cardiac Chest Pain (Non-cardiac
chest pain)
Nystagmus (Nystagmus)
Obesity (Obesity)
Gastric Obstruction (Obstruction gastric)
Oculomotor Nerve Disorder (Oculomotor
nerve disorder)
Olfactory Nerve Disorder (Olfactory
nerve disorder)
Oligospermia (Oligospermia)
Optic Nerve Disorder (Optic nerve
disorder)
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Oral Cavity Fistula (Oral cavity fistula)
Burning Mouth Syndrome (Oral
dysesthesia)
Oral Hemorrhage (Oral hemorrhage)
Oral Pain (Oral pain)
Osteonecrosis Of Jaw (Osteonecrosis of
jaw)
Osteoporosis (Osteoporosis)
External Ear Infection (Otitis externa)
Otitis Media (Otitis media)
Ovarian Hemorrhage (Ovarian
hemorrhage)
Ovarian Infection (Ovarian infection)
Ovarian Rupture (Ovarian rupture)
Ovulatory Pain (Ovulation pain)
Pain (Pain)
Pain In Extremity (Pain in extremity)
Skin Pain (Pain of skin)
Palmar-plantar Erythodysthesia (Palmar-
plantar erythrodysesthesia syndrome)
Palpitation (Palpitations)
Pancreatic Infection (Pancreas infection)
Pancreatic Anastomotic Leakage
(Pancreatic anastomotic leak)
Pancreatic Duct Stenosis (Pancreatic
duct stenosis)
Pancreatic Enzymes Decreased
(Pancreatic enzymes decreased)
Pancreatic Fistula (Pancreatic fistula)
Pancreatic Hemorrhage (Pancreatic
hemorrhage)
Pancreatic Necrotic Lesion (Pancreatic
necrosis)
Pancreatitis (Pancreatitis)
Papilledema (Papilledema)
Papulopustular Rash (Papulopustular
rash)
Paresthesia (Paresthesia)
Paronychia (Paronychia)
Paroxysmal Atrial Tachycardia
(Paroxysmal atrial tachycardia)
Pelvic Floor Muscle Weakness (Pelvic
floor muscle weakness)
Pelvic Inflammatory Disease (Pelvic
infection)
Pelvic Pain (Pelvic pain)
Pelvic Soft Tissue Necrotic Lesion
(Pelvic soft tissue necrosis)
Penile Infection (Penile infection)
Penile Pain (Penile pain)
Bile Duct Perforation (Perforation bile
duct)
Pericardial Effusion (Pericardial effusion)
Cardiac Tamponade (Pericardial
tamponade)
Pericarditis (Pericarditis)
Perineal Pain (Perineal pain)
Periodontal Disorder (Periodontal
disease)
Periorbital Edema (Periorbital edema)
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Periorbital Infection (Periorbital infection)
Peripheral Ischemia (Peripheral
ischemia)
Peripheral Motor Neuropathy (Peripheral
motor neuropathy)
Peripheral Nervous System Infectious
Disorder (Peripheral nerve infection)
Peripheral Sensory Neuropathy
(Peripheral sensory neuropathy)
Peritoneal Infection (Peritoneal infection)
Peritoneal Necrotic Lesion (Peritoneal
necrosis)
Personality Change (Personality change)
Phantom Pain (Phantom pain)
Pharyngeal Anastomotic Leakage
(Pharyngeal anastomotic leak)
Pharyngeal Fistula (Pharyngeal fistula)
Pharyngeal Hemorrhage (Pharyngeal
hemorrhage)
Pharyngeal Mucositis (Pharyngeal
mucositis)
Pharyngeal Necrotic Lesion (Pharyngeal
necrosis)
Pharyngeal Stenosis (Pharyngeal
stenosis)
Pharyngitis (Pharyngitis)
Pharyngolaryngeal Pain
(Pharyngolaryngeal pain)
Phlebitis (Phlebitis)
Infective Phlebitis (Phlebitis infective)
Photophobia (Photophobia)
Photosensitivity (Photosensitivity)
Thrombocytopenia (Platelet count
decreased)
Pleural Effusion (Pleural effusion)
Hemothorax (Pleural hemorrhage)
Pleural Infection (Pleural infection)
Pleuritic Pain (Pleuritic pain)
Pneumonia (Pneumonitis)
Pneumothorax (Pneumothorax)
Portal Hypertension (Portal
Hypertension)
Portal Vein Thrombosis (Portal vein
thrombosis)
Post-nasal Drip (Postnasal drip)
Postoperative Bleeding (Postoperative
hemorrhage)
Thoracic Procedure Postoperative
Complication (Postoperative thoracic
procedure complication)
Precocious Puberty (Precocious
puberty)
Pregnancy, Puerperium And Perinatal
Condition Class Other Specify
(Pregnancy, puerperium and perinatal
conditions - Other, specify)
Premature Labor (Premature delivery)
Premature Menopause (Premature
menopause)
Presyncope (Presyncope)
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Proctitis (Proctitis)
Productive Cough (Productive cough)
Intestinal Stoma Prolapse (Prolapse of
intestinal stoma)
Urostomy Prolapse (Prolapse of
urostomy)
Prostatic Infection (Prostate infection)
Prostatic Hemorrhage (Prostatic
hemorrhage)
Prostatic Obstruction (Prostatic
obstruction)
Prostatic Pain (Prostatic pain)
Proteinuria (Proteinuria)
Pruritus (Pruritus)
Psychiatric Disorder Other Specify
(Psychiatric disorders - Other, specify)
Psychosis (Psychosis)
Pulmonary Edema (Pulmonary edema)
Pulmonary Fibrosis (Pulmonary fibrosis)
Pulmonary Fistula (Pulmonary fistula)
Pulmonary Hypertension (Pulmonary
hypertension)
Pulmonary Valve Disorder (Pulmonary
valve disease)
Purpura (Purpura)
Pyramidal Tract Dysfunction (Pyramidal
tract syndrome)
Radiation-recall Dermatitis (Radiation
recall reaction (dermatologic))
Radiculitis (Radiculitis)
Acneiform Dermatitis (Rash acneiform)
Maculopapular Lesion (Rash maculo-
papular)
Papulopustular Rash (Rash pustular)
Rectal Anastomotic Leakage (Rectal
anastomotic leak)
Rectal Fistula (Rectal fistula)
Rectal Hemorrhage (Rectal hemorrhage)
Rectal Mucositis (Rectal mucositis)
Rectal Necrotic Lesion (Rectal necrosis)
Rectal Obstruction (Rectal obstruction)
Rectal Pain (Rectal pain)
Rectal Perforation (Rectal perforation)
Rectal Stenosis (Rectal stenosis)
Rectal Ulcer (Rectal ulcer)
Recurrent Laryngeal Nerve Paralysis
(Recurrent laryngeal nerve palsy)
Urinary Tract Disorder Other Specify
(Renal and urinary disorders - Other,
specify)
Renal Stone (Renal calculi)
Renal Colic (Renal colic)
Renal Hemorrhage (Renal hemorrhage)
Reproductive System And Breast
Disorder Class Other Specify
(Reproductive system and breast
disorders - Other, specify)
Respiratory Failure (Respiratory failure)
Respiratory And Thoracic Disorder Other
Specify (Respiratory, thoracic and
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mediastinal disorders - Other, specify)
Restlessness (Restlessness)
Restrictive Cardiomyopathy (Restrictive
cardiomyopathy)
Retinal Detachment (Retinal
detachment)
Retinal Tear (Retinal tear)
Retinal Vascular Disorder (Retinal
vascular disorder)
Retinoic Acid Syndrome (Retinoic acid
syndrome)
Retinopathy (Retinopathy)
Retroperitoneal Hemorrhage
(Retroperitoneal hemorrhage)
Reversible Posterior
Leukoencephalopathy Syndrome
(Reversible posterior
leukoencephalopathy syndrome)
Infectious Rhinitis (Rhinitis infective)
Right Ventricular Dysfunction (Right
ventricular dysfunction)
Salivary Duct Inflammation (Salivary duct
inflammation)
Salivary Gland Fistula (Salivary gland
fistula)
Salivary Gland Infection (Salivary gland
infection)
Scalp Pain (Scalp pain)
Sclera Disorder (Scleral disorder)
Scoliosis (Scoliosis)
Scrotal Infection (Scrotal infection)
Scrotal Pain (Scrotal pain)
Seizure (Seizure)
Septicemia (Sepsis)
Seroma (Seroma)
Serum Amylase Increased (Serum
amylase increased)
Serum Sickness (Serum sickness)
Sick Sinus Syndrome (Sick sinus
syndrome)
Sinus Bradycardia (Sinus bradycardia)
Paranasal Sinus Disorder (Sinus
disorder)
Sinus Pain (Sinus pain)
Sinus Tachycardia (Sinus tachycardia)
Sinusitis (Sinusitis)
Skin Disorder Other Specify (Skin and
subcutaneous tissue disorders - Other,
specify)
Skin Atrophy (Skin atrophy)
Skin Hyperpigmentation (Skin
hyperpigmentation)
Skin Hypopigmentation (Skin
hypopigmentation)
Skin Induration (Skin induration)
Skin Infection (Skin infection)
Skin Ulcer (Skin ulceration)
Sleep Apnea (Sleep apnea)
Small Intestinal Anastomotic Leakage
(Small intestinal anastomotic leak)
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Small Intestinal Mucositis (Small
intestinal mucositis)
Small Intestinal Obstruction (Small
intestinal obstruction)
Small Intestinal Perforation (Small
intestinal perforation)
Small Intestinal Stenosis (Small intestinal
stenosis)
Small Intestinal Infection (Small intestine
infection)
Small Intestinal Ulcer (Small intestine
ulcer)
Sneezing (Sneezing)
Social Circumstances Other Specify
(Social circumstances - Other, specify)
Soft Tissue Infection (Soft tissue
infection)
Lower Limb Soft Tissue Necrotic Lesion
(Soft tissue necrosis lower limb)
Upper Limb Soft Tissue Necrotic Lesion
(Soft tissue necrosis upper limb)
Somnolence (Somnolence)
Sore Throat (Sore throat)
Spasticity (Spasticity)
Spermatic Cord Anastomotic Leakage
(Spermatic cord anastomotic leak)
Spermatic Cord Hemorrhage (Spermatic
cord hemorrhage)
Spermatic Cord Obstruction (Spermatic
cord obstruction)
Vertebral Fracture (Spinal fracture)
Splenic Disorder (Spleen disorder)
Splenic Infection (Splenic infection)
Gastrointestinal Stoma Stenosis
(Stenosis of gastrointestinal stoma)
Stevens-johnson Syndrome (Stevens-
Johnson syndrome)
Stoma Site Infection (Stoma site
infection)
Stomach Pain (Stomach pain)
Stomal Ulcer (Stomal ulcer)
Stridor (Stridor)
Cerebrovascular Accident (Stroke)
Sudden Cardiac Death (Sudden death
NOS)
Suicidal Ideation (Suicidal ideation)
Suicide Attempt (Suicide attempt)
Superficial Soft Tissue Fibrosis
(Superficial soft tissue fibrosis)
Superficial Thrombophlebitis (Superficial
thrombophlebitis)
Superior Vena Cava Syndrome (Superior
vena cava syndrome)
Supraventricular Tachycardia
(Supraventricular tachycardia)
Intervention Or Procedure Other Specify
(Surgical and medical procedures -
Other, specify)
Syncope (Syncope)
Telangiectasia (Telangiectasia)
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Testicular Disorder (Testicular disorder)
Testicular Hemorrhage (Testicular
hemorrhage)
Testicular Pain (Testicular pain)
Thromboembolism (Thromboembolic
event)
Thrombotic Thrombocytopenic Purpura
(Thrombotic thrombocytopenic purpura)
Tinnitus (Tinnitus)
Dental Developmental Disorder (Tooth
development disorder)
Tooth Discoloration (Tooth discoloration)
Tooth Infection (Tooth infection)
Toothache (Toothache)
Toxic Epidermal Necrolysis (Toxic
epidermal necrolysis)
Tracheal Fistula (Tracheal fistula)
Tracheal Hemorrhage (Tracheal
hemorrhage)
Tracheal Mucositis (Tracheal mucositis)
Tracheal Obstruction (Tracheal
obstruction)
Tracheal Stenosis (Tracheal stenosis)
Tracheitis (Tracheitis)
Tracheostomy Site Bleeding
(Tracheostomy site bleeding)
Transient Ischemic Attack (Transient
ischemic attacks)
Therapy-related Malignant Neoplasm
(Treatment related secondary
malignancy)
Tremor (Tremor)
Tricuspid Valve Disorder (Tricuspid valve
disease)
Trigeminal Nerve Disorder (Trigeminal
nerve disorder)
Trismus (Trismus)
Tumor Lysis Syndrome (Tumor lysis
syndrome)
Tumor Pain (Tumor pain)
Typhlitis (Typhlitis)
Unequal Limb Length (Unequal limb
length)
Unintended Pregnancy (Unintended
pregnancy)
Upper Gastrointestinal Hemorrhage
(Upper gastrointestinal hemorrhage)
Upper Respiratory Tract Infection (Upper
respiratory infection)
Ureteric Anastomotic Leakage (Ureteric
anastomotic leak)
Urethral Anastomotic Leakage (Urethral
anastomotic leak)
Urethral Infection (Urethral infection)
Urinary Tract Fistula (Urinary fistula)
Urinary Frequency (Urinary frequency)
Urinary Incontinence (Urinary
incontinence)
Urinary Retention (Urinary retention)
Urinary Tract Infection (Urinary tract
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infection)
Urinary Tract Obstruction (Urinary tract
obstruction)
Urinary Tract Pain (Urinary tract pain)
Urinary Urgency (Urinary urgency)
Urine Discoloration (Urine discoloration)
Urine Output Decreased (Urine output
decreased)
Urostomy Leakage (Urostomy leak)
Urostomy Obstruction (Urostomy
obstruction)
Urostomy Site Bleeding (Urostomy site
bleeding)
Urostomy Stenosis (Urostomy stenosis)
Urticaria (Urticaria)
Uterine Anastomotic Leakage (Uterine
anastomotic leak)
Uterine Fistula (Uterine fistula)
Uterine Hemorrhage (Uterine
hemorrhage)
Endometritis (Uterine infection)
Uterine Obstruction (Uterine obstruction)
Uterine Pain (Uterine pain)
Uterine Perforation (Uterine perforation)
Uveitis (Uveitis)
Vaginal Anastomotic Leakage (Vaginal
anastomotic leak)
Vaginal Discharge (Vaginal discharge)
Vaginal Dryness (Vaginal dryness)
Vaginal Fistula (Vaginal fistula)
Vaginal Hemorrhage (Vaginal
hemorrhage)
Vaginitis (Vaginal infection)
Vaginitis (Vaginal inflammation)
Vaginal Obstruction (Vaginal obstruction)
Vaginal Pain (Vaginal pain)
Vaginal Perforation (Vaginal perforation)
Vaginal Stricture (Vaginal stricture)
Vaginismus (Vaginismus)
Vagus Nerve Disorder (Vagus nerve
disorder)
Vas Deferens Anastomotic Leakage (Vas
deferens anastomotic leak)
Vascular Access Complication (Vascular
access complication)
Vascular Disorder Other Specify
(Vascular disorders - Other, specify)
Vasculitis (Vasculitis)
Vasovagal Reaction (Vasovagal reaction)
Venous Injury (Venous injury)
Ventricular Arrhythmia (Ventricular
arrhythmia)
Ventricular Fibrillation (Ventricular
fibrillation)
Ventricular Tachycardia (Ventricular
tachycardia)
Vertigo (Vertigo)
Internal Ear Disorder (Vestibular
disorder)
Virilization (Virilization)
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Visceral Artery Ischemia (Visceral
arterial ischemia)
Abnormal Vital Capacity (Vital capacity
abnormal)
Vitreous Hemorrhage (Vitreous
hemorrhage)
Voice Alternation (Voice alteration)
Vomiting (Vomiting)
Vulval Infection (Vulval infection)
Watering Eyes (Watering eyes)
Weight Gain (Weight gain)
Weight Loss (Weight loss)
Wheezing (Wheezing)
Leukopenia (White blood cell decreased)
Wolff-parkinson-white Syndrome (Wolff-
Parkinson-White Syndrome)
Wound Complication (Wound
complication)
Wound Dehiscence (Wound dehiscence)
Wound Infection (Wound infection)
Wrist Fracture (Wrist fracture)
CTC AE Grade
CTCAE Begin Date (MM DD YYYY)
Attribution
Definite (Definite)
Possible (Possible)
Probable (Probable)
Unlikely (Unlikely)
Unrelated (Unrelated)
SAE report submitted
No (No)
Unknown (Unknown)
Yes (Yes)
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RTOG clinical trial administrative data
RTOG Study No.
Case #
Institution Name
Institution No.
Patient Initials
RTOG Patient ID
Amended data
Yes
No
Patient status assessment
Time point of this assessment
1 Year From Start Of Treatment (1 year
from start of treatment)
2 Years From Start Of Treatment (2 years
from start of treatment)
3 Months From Start Of Treatment (3
months from start of treatment)
Pretreatment (Pretreatment)
Treatment Start Date
Was patient questionnaire completed
Yes
No
Date patient questionnaire completed
Reason Questionnaire was not Completed
Institution Error (Institutional error)
Not Applicable, Questionnaire Was
Completed (Not applicable,
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questionnaire was completed)
Other Reason (Other reason)
Patient Refused Due To Illness (Patient
refused due to illness)
Patient Refused For Other Reason
(Patient refused for other reason)
Patient Unable To Be Contacted (Patient
unable to be contacted)
Tool Not Availalble In Patient's Language
(Tool not availalble in patient's language)
Unknown (Unknown)
Other reason, specify
Specify method of completion
At Appointment (At appointment)
By Mail (By mail)
By Telephone (By telephone)
Not Applicable (Not applicable)
Unknown (Unknown)
Did the patient require any assistance in
completing the questionnaire?
No (No)
Not Applicable (Not applicable)
Unknown If Assistance Given (Unknown
if assistance given)
Yes (Yes)
Specify the person who assisted the patient
Family (Family)
Not Applicable (Not applicable)
Other (Other)
Staff Member (Staff member)
Unknown (Unknown)
Other, specify
Extent of assistance given
Combination Of Above (Combination of
above)
Interpreted Items For Patient (Interpreted
items for patient)
Marked Items Per Patient's Response
(Marked items per patient's response)
Not Applicable (Not applicable)
Other (Other)
Read Items To Patient (Read items to
patient)
Unknown (Unknown)
Combination of above, specify
Other, specify
MOBILITY
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I Am Confined To Bed (I am confined to
bed)
I Have No Problems In Walking About (I
have no problem in walking about)
I Have Some Problems In Walking About
(I have some problem in walking about)
SELF CARE
I Am Unable To Wash Or Dress Myself (I
am able to wash or dress myself)
I Have No Problem With Self Care (I
have no problem with self care)
I Have Some Problem Washing Or
Dressing Myself (I have some problem
washing or dressing myself)
USUAL ACTIVITIES (e.g. work, study,
housework, family, or leisure activities)
I Am Unable To Perform My Usual
Activities (I am unable to perform my
usual activities)
I Have No Problems With Performing My
Usual Activities (I have no problem with
performing my usual activities)
I Have Some Problems With Performing
My Usual Activities (I have some
problem with performing my usual
activities)
PAIN/DISCOMFORT
I Have Extreme Pain Or Discomfort (I
have extreme pain or discomfort)
I Have Moderate Pain Or Discomfort (I
have moderate pain or discomfort)
I Have No Pain Or Discomfort (I have no
pain or discomfort)
ANXIETY/DEPRESSION (TO THE PATIENT: To
help people say how good or bad a health state
is, we have drawn a scale rather like a
thermometer on which the best state you can
imagine is marked 100 and the worst state you
can imagine is marked 0.)
I Am Extremely Anxious Or Depressed (I
am extremely anxious or depressed)
I Am Moderately Anxious Or Depressed
(I am moderately anxious or depressed)
I Am Not Anxious Or Depressed (I am
not anxious or depressed)
Your own health state today (To help people say
how good or bad a health state is, we - have
drawn a scale rather like a thermometer on which
- the best state you can imagine is marked 100
and the - worst state you can imagine is marked
0.)
Form completed by
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Signature of Person Completing This Form
Date Form Completed
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All rights reserved. Please visit https://medical-data-
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RTOG clinical trial administrative data
RTOG Study
Case #
Institution Name
Institution No.
Patient Initials
Patient Study No.
If this is a revised or corrected form, indicate by
checking box.
Yes (Yes)
Various questionnaire related information
TIME POINT OF ASSESSMENT
(please check box that applies to this
assessment) ((please check box that
applies to this assessment))
1 (1)
12 (12)
24 (24)
3 (3)
36 (36)
6 (6)
Baseline (BASELINE/ PRE RT)
Did the patient complete any items on the
questionnaire?
Yes
No
Date patient filled out questionnaire
1 / 3
Did the patient require any assistance in
completing the questionnaire?
No (No)
Unknown If Assistance Given (Unknown
if assistance given)
Yes (Yes)
Specify the person who assisted the patient and
the extent of the assistance
Family (Family)
Other (Other)
Staff Member (Staff member)
Unknown (Unknown)
Other, specify
Extent of assistance given
Combination Of Above (Combination of
above)
Interpreted Items For Patient (Interpreted
items for patient)
Marked Items Per Patient's Response
(Marked items per patient's response)
Other (Other)
Read Items To Patient (Read items to
patient)
Unknown (Unknown)
Combination of above, specify
Other, specify
Specify method of completion
At Appointment (At appointment)
By Mail (By mail)
By Telephone (By telephone)
Unknown (Unknown)
REASON QUESTIONNAIRE WAS NOT
COMPLETED
Other Reason (Other reason)
Patient Refused (Patient refused)
Patient Refused Due To Illness (Patient
refused due to illness)
Patient Unable To Be Contacted (Patient
unable to be contacted)
Patient Unable To Communicate In
English (Patient unable to communicate
in English)
Questionnaire Not Completed Due To
Institutional Error (Questionnaire not
completed due to institutional error)
Unknown (Unknown)
Other reason, specify
Comments
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Signature
Date
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RTOG-0522 AE: Adverse Event Evaluation
Form NCT00265941
RTOG-0522 AE: Adverse Event Evaluation Form
NCT00265941
Radiation Therapy and Cisplatin With or Without Cetuximab
in Treating Patients With Stage III or Stage IV Head and
Neck Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=F5E8260F-
4A36-157F-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11556
RTOG-0522 AE: Adverse Event
Evaluation Form NCT00265941
RTOG clinical trial administrative data
RTOG Study No.
Case #
Institution Name
Institution No.
Patient Initials
RTOG Patient ID
AMENDED DATA
Yes
No
Report All Continuing Or New Adverse
Events
Date of Last Clinical Assessment
Due date of corresponding form
Type of corresponding form   (Score most severe
grade observed during report period Grade 1-5.)
F1 (F1)
Tf (TF)
MedDRA Code
CTCAE TERM
CTCAE GRADE
CTCAE BEGIN DATE
1 / 2
CTCAE ATTRIBUTION CODE (Attribution to
Protocol Treatment See protocol sections 6 & 7
for definition of "protocol treatment")
Definite (Definite)
Possible (Possible)
Probable (Probable)
Unlikely (Unlikely)
Unrelated (Unrelated)
Serious adverse event report submitted
No (No)
Unknown (Unknown)
Yes (Yes)
CTC Adverse Event Term Specify
AE Description
Person completing form
Form Completion Date
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RTOG-0421 AE: Adverse Event Evaluation
Form NCT00113399
RTOG-0421 AE: Adverse Event Evaluation Form
NCT00113399
Combination Chemotherapy With or Without Radiation
Therapy in Treating Patients With Recurrent Head and
Neck Cancer That Cannot Be Removed By Surgery
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=EB6FBB34-
B48C-4885-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11557
RTOG-0421 AE: Adverse Event
Evaluation Form NCT00113399
RTOG clinical trial administrative data
RTOG Study
Case #
Institution
Institution No.
Participant's Initials
Participant's I.D. No.
AMENDED DATA
Yes
No
Report All Continuing Or New Adverse
Events
Date of assessment
Due date of corresponding form
Type of corresponding form   (INSTRUCTIONS:
the CTC AE Version 3.0 is used to score all
adverse events)
F1 (F1)
Tf (TF)
MedDRA CODE ADVERSE EVENT BASED ON
CTCAE TERM
CTCAE TERM
CTCAE GRADE
1 / 2
CTCAE BEGIN DATE
CTCAE ATTRIBUTION CODE (Attribution to
Protocol Treatment See protocol sections 6 & 7
for definition of "protocol treatment")
Definite (Definite)
Possible (Possible)
Probable (Probable)
Unlikely (Unlikely)
Unrelated (Unrelated)
Serious Adverse Event Report Submitted
No (No)
Unknown (Unknown)
Yes (Yes)
Other CTCAE Term
AE Description
Person completing form
Form completion date
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NCT00533949  RTOG-0617 FA: Radiation Therapy Oncology Group Phase III High-
dose Vs Standard-dose Conformal XRT with Chemotherapy Functinal Assessment
Trial Outcome Index (TOI) Form
NCT00533949  RTOG-0617 FA: Radiation Therapy
Oncology Group Phase III High-dose Vs Standard-dose
Conformal XRT with Chemotherapy Functinal Assessment
Trial Outcome Index (TOI) Form
High-Dose or Standard-Dose Radiation Therapy and
Chemotherapy With or Without Cetuximab in Treating
Patients With Newly Diagnosed Stage III Non-Small Cell
Lung Cancer That Cannot Be Removed by Surgery
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=24E78551-
175E-6260-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11558
NCT00533949  RTOG-0617 FA:
Radiation Therapy Oncology Group
Phase III High-dose Vs Standard-
dose Conformal XRT with
Chemotherapy Functinal
Assessment Trial Outcome Index
(TOI) Form
RTOG clinical trial administrative data
RTOG Study No.
Case #
Institution Name
Institution No.
Patient Initials
RTOG Patient ID
Amended data
Yes
No
Various questionnaire related information
Time point
At Completion Of Chemoradiation (At
completion of chemoradiation)
Pretreatment (Pretreatment)
Three Months From Baseline (Three
months from baseline)
Twelve Months From Baseline (Twelve
months from baseline)
Twenty-four Months From Baseline
(Twenty-four months from baseline)
Was patient questionnaire completed
Yes
No
1 / 6
Date patient questionnaire completed
Reason Questionnaire was not Completed
Institution Error (Institutional error)
Not Applicable, Questionnaire Was
Completed (Not applicable,
questionnaire was completed)
Other Reason (Other reason)
Patient Refused Due To Illness (Patient
refused due to illness)
Patient Refused For Other Reason
(Patient refused for other reason)
Patient Unable To Be Contacted (Patient
unable to be contacted)
Tool Not Availalble In Patient's Language
(Tool not availalble in patient's language)
Unknown (Unknown)
Patient refused for other reason, specify
Other reason, specify
Specify method of completion
At Appointment (At appointment)
By Mail (By mail)
By Telephone (By telephone)
Not Applicable (Not applicable)
Unknown (Unknown)
Did the patient require any assistance in
completing the questionnaire?
Yes
No
Specify the person who assisted the patient
Family (Family)
Other (Other)
Staff Member (Staff member)
Extent of assistance given
Combination Of Above (Combination of
above)
Interpreted Items For Patient (Interpreted
items for patient)
Marked Items Per Patient's Response
(Marked items per patient's response)
Not Applicable (Not applicable)
Other (Other)
Read Items To Patient (Read items to
patient)
Combination of above, specify
Other, specify
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COMMENTS
Signature of Person Completing This Form
Date form originally completed
Physical Well-being
I have a lack of energy
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have nausea
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
Because of my physical condition, I have trouble
meeting the needs of my family
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have pain
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am bothered by side effects of treatment
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I feel ill
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am forced to spend time in bed
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
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Very Much (Very much)
Functional Well-being
I am able to work (include work at home)
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
My work (including work at home) is fulfilling
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am able to enjoy life
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have accepted my illness
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am sleeping well
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am enjoying the things I usually do for fun
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am content with the quality of my life right now
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
Additional Concerns
I have been short of breath
A Little Bit (A little bit)
Not At All (Not at all)
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Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am losing weight
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
My thinking is clear
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I have been coughing
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I am bothered by hair loss.
2 (A little bit)
1 (Not at all)
4 (Quite a bit)
3 (Somewhat)
5 (Very much)
I have a good appetite
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
I feel tightness in my chest
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
Breathing is easy for me
A Little Bit (A little bit)
Not At All (Not at all)
Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
Have you ever smoked?
Yes
No
I regret my smoking
A Little Bit (A little bit)
Not At All (Not at all)
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Quite A Bit (Quite a bit)
Somewhat (Somewhat)
Very Much (Very much)
Footer module
Completed by
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NCT01302834  RTOG 1016 F0: Radiation Therapy Oncology
Group Phase III Head and Neck Cancer Follow-Up Form
NCT01302834  RTOG 1016 F0: Radiation Therapy
Oncology Group Phase III Head and Neck Cancer Follow-
Up Form
Radiation Therapy With Cisplatin or Cetuximab in Treating
Patients With Oropharyngeal Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=9550D538-
F61F-EAB4-E040-BB89AD4377BB
All rights reserved. Please visit https://medical-data-
models.org/forms/11559
NCT01302834  RTOG 1016 F0:
Radiation Therapy Oncology Group
Phase III Head and Neck Cancer
Follow-Up Form
Header
RTOG Study No.
Case #
Institution Name
Institution No.
Patient Initials
RTOG Patient ID
Amended data
Yes
No
Vital status
Date of Last Contact or Death (MM/DD/YYYY)
Patient's Vital Status
Alive (Alive)
Dead (Dead)
Primary Cause of Death
Due To Other Cause (Due to other
cause)
Due To Protocol Treatment (Due to
protocol treatment)
Due To Second Primary Or Other
Malignancy (Due to second primary or
other malignancy)
Due To This Disease (Due to this
disease)
Unknown (Unknown)
Due to protocol treatment, specify
1 / 5
Due to other cause specify
Tumor Measurements At Presentation
Does the patient currently require tube feeding
No (No)
Unknown (Unknown)
Yes (Yes)
Is patient dependent on tube feeding for >50% of
nutritional support  (If yes,)
No (No)
Unknown (Unknown)
Yes (Yes)
Dental gingival health
Life-threatening Dental Condition (Life-
threatening dental condition)
Mild Changes/good Dental Health (Mild
changes/good dental health)
Moderate/fair Dental Health
(Moderate/fair dental health)
Normal (Normal)
Severe Changes In Dental Health
(Severe changes in dental health)
Number of native teeth in place
Has the patient had a documented clinical
assessment for this cancer? (since submission of
the previous follow-up form)
No (No)
Unknown (Unknown)
Yes (Yes)
Date of Last Clinical Assessment
RECURRENCE OR PROGRESSION
Has the patient been diagnosed with first local
recurrence or progression (since submission of
the previous follow-up form)
No (No)
Not Applicable, Patient Has Not Been
Assessed (Not applicable, patient has
not been assessed)
Unknown (Unknown)
Yes (Yes)
Date of First Local Progression (MM DD YYYY)
Has the patient been diagnosed with first regional
recurrence or progression (since submission of
the previous follow-up form)
No (No)
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Not Applicable, Patient Has Not Been
Assessed (Not applicable, patient has
not been assessed)
Unknown (Unknown)
Yes (Yes)
Date of first regional progression (MM DD YYYY)
Has the patient been diagnosed with first distant
recurrence/progression? (since submission of the
previous follow-up form)
No (No)
Not Applicable, Patient Has Not Been
Assessed (Not applicable, patient has
not been assessed)
Unknown (Unknown)
Yes (Yes)
Date of First Distant Progression (MM DD YYYY)
Site(s) of distant progression
Bladder (Bladder)
Brain (Brain)
Colorectal (Colorectal)
Esophageal (Esophageal)
Gastric (Gastric)
Hypopharynx (Hypopharynx)
Larynx (Larynx)
Liver (Liver)
Lung (Lung)
Nasopharynx (Nasopharynx)
None (None)
Oral Cavity (Oral cavity)
Oropharynx (Oropharynx)
Other H + N (Other H + N)
Other Solid (Other solid)
Pancreatic (Pancreatic)
Renal (Renal)
Squamous-skin (Squamous-Skin)
Other solid, specify
New primary cancer
Has a new primary cancer or MDS been
diagnosed that has not been previously reported?
No (No)
Unknown (Unknown)
Yes (Yes)
Site(s) of new primary
Aml/mds (AML/MDS)
Bcc (BCC)
Bladder (Bladder)
Brain (Brain)
Colorectal (Colorectal)
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Esophageal (Esophageal)
Gastric (Gastric)
Hypopharynx (Hypopharynx)
Larynx (Larynx)
Liver (Liver)
Lung (Lung)
Melanoma (Melanoma)
Nasopharynx (Nasopharynx)
Nhl (NHL)
None (None)
Oral Cavity (Oral cavity)
Oropharynx (Oropharynx)
Other H + N (Other H + N)
Other Hematologic (Other Hematologic)
Other Solid (Other solid)
Pancreatic (Pancreatic)
Prostate (Prostate)
Renal (Renal)
Squamous-skin (Squamous-Skin)
Unknown Primary (Unknown primary)
Other Hematologic, specify
Other solid, specify
Date of diagnosis  (MM/DD/YYYY)
NON-PROTOCOL THERAPY
Non-Protocol Therapy Type (for study cancer,
begun since submission of previous follow-up
form)
Biologic/targeted Therapy
(Biologic/targeted therapy)
None (None)
Other Specify (Other)
Radiation To Node(s) (Radiation to
node(s))
Radiation To Other Sites, Specify
(Radiation to other sites)
Radiation To Primary (Radiation to
primary)
Surgery For Other Cancer (Surgery for
other cancer)
Surgery For Study Cancer (Surgery for
study cancer)
Systemic Therapy (Systemic therapy)
Unknown (Unknown)
Non-protocol Therapy Start Date
Details
Protocol Specific Adverse Event
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Evaluation
CTCAE Term
CTC AE Grade
Mild Adverse Event (1)
Moderate Adverse Event (2)
Severe Adverse Event (3)
Life Threatening Adverse Event (4)
Death Related To Adverse Event (5)
CTCAE Begin Date (MM DD YYYY)
CTC AE Attribution Code
Definite (Definite)
Possible (Possible)
Probable (Probable)
Unlikely (Unlikely)
Unrelated (Unrelated)
SAE report submitted
No (No)
Unknown (Unknown)
Yes (Yes)
New or continuing adverse events
New or continuing adverse events (not reported
Q11)
No (No)
Unknown (Unknown)
Yes (Yes)
MedDRA Code
Comments
COMMENTS
Person Completing Form
Form completion date, original (MM DD YYYY)
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USMCI 8214/Z6091:  Adverse Event  -
Medical Form NCT01167725
USMCI 8214/Z6091:  Adverse Event  - Medical Form
NCT01167725
Standard Therapy With or Without Surgery and Mitomycin
C in Treating Patients With Advanced Limited Peritoneal
Dissemination of Colon Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=625EA23A-
C584-1163-E040-BB89AD4327CD
All rights reserved. Please visit https://medical-data-
models.org/forms/11560
USMCI 8214/Z6091:  Adverse Event
- Medical Form NCT01167725
Header Module
Patient ID
Institution No.
Institution Name
Visit
Systemic Therapy (Systemic Therapy)
Date of evaluation
Current Cycle Number
Was the patient hospitalized for 24 hours or
more?
Yes
No
Has an Adverse Event Expedited Report been
submitted?
Yes
No
Adverse event report
CTC Adverse Event Term
Nadir/Worst Date ([Hemoglobin])
Nadir/Worst Value ([Hemoglobin])
CTC Adverse Event Grade
Severe Adverse Event (3)
Life Threatening Adverse Event (4)
Death Related To Adverse Event (5)
Is nadir below LLN?
Yes
No
1 / 2
CTC AE Attribution Code
Definite (Definite)
Possible (Possible)
Probable (Probable)
Unlikely (Unlikely)
Unrelated (Unrelated)
Were any additional adverse events experienced
by the patient
Yes
No
Other, specify
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NCT01349322  RTOG-1005 QP: Radiation Therapy Oncology Group Phase III
Whole Breast Irradiation for Early Stage Breast Cancer Patient Cosmesis
Evaluation Form
NCT01349322  RTOG-1005 QP: Radiation Therapy
Oncology Group Phase III Whole Breast Irradiation for
Early Stage Breast Cancer Patient Cosmesis Evaluation
Form
Higher-Dose Radiation Therapy or Standard Radiation
Therapy in Treating Patients With Early-Stage Breast
Cancer That Was Removed by Surgery
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=9D7B30AD-
FF6E-0FB3-E040-BB89AD435271
All rights reserved. Please visit https://medical-data-
models.org/forms/11561
NCT01349322  RTOG-1005 QP:
Radiation Therapy Oncology Group
Phase III Whole Breast Irradiation for
Early Stage Breast Cancer Patient
Cosmesis Evaluation Form
RTOG clinical trial administrative data
RTOG Study No.
Case #
Institution Name
Institution No.
Patient Initials
RTOG Patient ID
Are data amended
Yes
No
Time point
1 Year Post Rt Completion (1 year post
RT Completion)
3 Years Post Rt Completion (3 years post
RT Completion)
Pretreatment (Pretreatment)
Treatment Start Date
Evaluation performed by
Radiation Oncologist (Radiation
Oncologist)
Surgeon (Surgeon)
Date Questionnaire Completed (MM DD YYYY)
Reason Questionnaire was not Completed
Institution Error (Institutional error)
1 / 4
Not Applicable, Questionnaire Was
Completed (Not applicable,
questionnaire was completed)
Other Reason (Other reason)
Patient Refused Due To Illness (Patient
refused due to illness)
Patient Refused For Other Reason
(Patient refused for other reason)
Patient Unable To Be Contacted (Patient
unable to be contacted)
Patient Withdrew Consent Prior/after
(Patient withdrew consent prior/after)
Unknown (Unknown)
Patient refused for other reason, specify
Other reason, specify
Breast Reconstruction Assessment
Please assess breast cosmesis at this time
Excellent (Excellent)
Fair (Fair)
Good (Good)
Poor (Poor)
Skin telangiectasia
None (None)
Yes, Present And Affects Cosmesis (Yes,
present and affects cosmesis)
Yes, Present But Does Not Affect
Cosmesis (Yes, present but does not
affect cosmesis)
Skin atrophy
None (None)
Yes, Present And Affects Cosmesis (Yes,
present and affects cosmesis)
Yes, Present But Does Not Affect
Cosmesis (Yes, present but does not
affect cosmesis)
Scarring
None (None)
Yes, Present And Affects Cosmesis (Yes,
present and affects cosmesis)
Yes, Present But Does Not Affect
Cosmesis (Yes, present but does not
affect cosmesis)
Pigment change
None (None)
Yes, Present And Affects Cosmesis (Yes,
present and affects cosmesis)
Yes, Present But Does Not Affect
Cosmesis (Yes, present but does not
affect cosmesis)
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Erythema
None (None)
Yes, Present And Affects Cosmesis (Yes,
present and affects cosmesis)
Yes, Present But Does Not Affect
Cosmesis (Yes, present but does not
affect cosmesis)
Fat necrosis
None (None)
Yes, Present And Affects Cosmesis (Yes,
present and affects cosmesis)
Yes, Present But Does Not Affect
Cosmesis (Yes, present but does not
affect cosmesis)
Fibrosis
None (None)
Yes, Present And Affects Cosmesis (Yes,
present and affects cosmesis)
Yes, Present But Does Not Affect
Cosmesis (Yes, present but does not
affect cosmesis)
Retraction or contour defect
None (None)
Yes, Present And Affects Cosmesis (Yes,
present and affects cosmesis)
Yes, Present But Does Not Affect
Cosmesis (Yes, present but does not
affect cosmesis)
Volume loss
None (None)
Yes, Present And Affects Cosmesis (Yes,
present and affects cosmesis)
Yes, Present But Does Not Affect
Cosmesis (Yes, present but does not
affect cosmesis)
Other significant treatment effect
None (None)
Yes, Present And Affects Cosmesis (Yes,
present and affects cosmesis)
Yes, Present But Does Not Affect
Cosmesis (Yes, present but does not
affect cosmesis)
Specify
Footer Module
Comments
Signature
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Evaluation Form
Date
Date Form Completed
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Whole Breast Irradiation for Early Stage Breast Cancer Patient Cosmesis
Evaluation Form
AE1
AE1
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=FF17F5D5-
D70B-0080-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11562
AE1
Miscellaneous Information
Segment
What is the effect on study therapy/intervention
schedule
Dose Modified (Dose Modified)
No Change - Completed (No Change -
Completed)
No Change - Ongoing (No Change -
Ongoing)
Permanently Stopped (Permanently
Stopped)
Temporarily Stopped (Temporarily
Stopped)
Indicate weight at time of the event
Record date transplant center became aware of
the event
If Other, specify reason for deactivation
Report activation status
Deactive - Key field error (Deactive - Key
field error)
Deactive - Other reason (Deactive -
Other reason)
Deactive - Report filed in error (Deactive
- Report filed in error)
Keep report active (Keep report active)
Is there an alternative etiology
Accident, Trauma, or External Factors
(Accident, Trauma, or External Factors)
Concurrent Illness/Condition (Not Pre-
Existing) (Concurrent Illness/Condition
(Not Pre-Existing))
None apparent (None apparent)
Other Pre-Existing Disease or Condition
(Other Pre-Existing Disease or
Condition)
Study Disease (Study Disease)
Date of Onset
Event description
1 / 2
Was this event expected or anticipated
Yes
No
Record the severity of event
Fatal (Fatal)
Life Threatening (Life Threatening)
Mild (Mild)
Moderate (Moderate)
Severe (Severe)
What is the relationship to study
therapy/intervention
Definite (Definite)
Possible (Possible)
Probable (Probable)
Unlikely (Unlikely)
Unrelated (Unrelated)
Record the most severe outcome of the event
Adverse Event Is Ongoing (Persistent
Condition)
Adverse Event Was Fatal (Resolved by
Death)
Adverse Event Is Resolved With
Sequelae (Resolved with Sequelae)
Adverse Event Is Resolved (Resolved,
No Residual Effects)
Record the date of resolution
Was this event associated with
Congenital Anomaly (Congenital
anomaly)
Death (Death)
Disability (Disability)
Hospitalized (Hospitalization (initial or
prolonged))
Life Threatening (Life-threatening event)
None of the following (None of the
following)
Other (Other SAE)
Intervention Required (Required
intervention to prevent permanent
impairment or damage)
Comments
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NCT00655876 F1: Radiation Therapy Oncology
Group Phase III Esophagus Followup Form
NCT00655876 F1: Radiation Therapy Oncology Group
Phase III Esophagus Followup Form
Paclitaxel, Cisplatin, and Radiation Therapy With or Without
Cetuximab in Treating Patients With Locally Advanced
Esophageal Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=2AA3D242-
F366-3171-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11563
NCT00655876 F1: Radiation
Therapy Oncology Group Phase III
Esophagus Followup Form
RTOG clinical trial administrative data
RTOG Study No.
Case #
Institution
Institution No.
Patient Initials
RTOG Patient ID
AMENDED DATA
Yes
No
Patient status
Vital Status
Alive (Alive)
Dead (Dead)
Date of Last Contact or Death
Primary Cause of Death
Due To Other Cause (Due to other
cause)
Due To Protocol Treatment (Due to
protocol treatment)
Due To Second Primary Or Other
Malignancy (Due to second primary or
other malignancy)
Due To This Disease (Due to this
disease)
Unknown (Unknown)
Describe cause of death
Performance Status (Zubrod)
1 / 93
Normal Activity (0)
Symptoms, But Nearly Fully Ambulatory
(1)
Some Bed Time, But Needs To Be In
Bed <50% Of Normal Daytime (2)
Needs To Be In Bed > 50% Of Normal
Daytime (3)
Unable To Get Out Of Bed (4)
Weight (9=unknown)
Kg
Extent of Dysphagia
Asymptomatic (Asymptomatic)
Cannot Swallow (Cannot swallow)
Symptomatic, Liquids Only
(Symptomatic, liquids only)
Symptomatic, Soft Foods Only
(Symptomatic, soft foods only)
Symptomatic, Unrestricted Diet
(Symptomatic, unrestricted diet)
Unknown (Unknown)
Oral alimentation
No (No)
Unknown (Unknown)
Yes (Yes)
Nasogastric tube feeding
No (No)
Unknown (Unknown)
Yes (Yes)
Ostomy feeding
No (No)
Unknown (Unknown)
Yes (Yes)
Intravenous hyperalimentation
No (No)
Unknown (Unknown)
Yes (Yes)
Other
No (No)
Unknown (Unknown)
Yes (Yes)
Other Specify
Disease Assessment
Has the patient had a documented clinical
assessment for this cancer?
No (No)
Unknown (Unknown)
Yes (Yes)
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Date of Last Clinical Assessment (If yes,)
Primary Tumor
Disease Absent (Disease absent)
Disease Present (Disease present)
Unknown (Unknown)
Regional lymph nodes
Disease Absent (Disease absent)
Disease Present (Disease present)
Unknown (Unknown)
Method of Evaluation
Biopsy (Biopsy)
Ct/mri Scan (CT/MRI scan)
Endoscopy With Biopsy (Endoscopy with
biopsy)
Other (Other)
Pet Scan (PET scan)
Distant metastasis including distant nodes
Disease Absent (Disease absent)
Disease Present (Disease present)
Unknown (Unknown)
Second primary
Disease Absent (Disease absent)
Disease Present (Disease present)
Unknown (Unknown)
Disease Events
Event (If no tumor events, code 00 in first box.)
Appearance Of Bone Metastasis
(Appearance of bone metastasis)
Appearance Of Celiac Lymph Nodes
(Appearance of celiac lymph nodes)
Appearance Of Cervical Lymph Nodes
(Appearance of cervical lymph nodes)
Appearance Of Liver Metastasis
(Appearance of liver metastasis)
Appearance Of Lung Metastasis
(Appearance of lung metastasis)
Appearance Of Other Metastasis
(Appearance of other metastasis)
Appearance Of Second Primary
(Appearance of second primary)
Clearance Of Celiac Lymph Nodes
(Clearance of celiac lymph nodes)
Clearance Of Cervical Lymph Nodes
(Clearance of cervical lymph nodes)
Clearance Of Metastasis (Clearance of
metastasis)
Clearance Of Second Primary
(Clearance of second primary)
Recurrence Of Second Primary
(Recurrence of second primary)
Specify
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Date
Method of Evaluation
Biopsy (Biopsy)
Ct/mri Scan (CT/MRI scan)
Endoscopy With Biopsy (Endoscopy with
biopsy)
Other (Other)
Pet Scan (PET scan)
New Primary
Has a new primary cancer or MDS been
diagnosed that has not been previously reported?
No (No)
Unknown (Unknown)
Yes (Yes)
Site(s) of new primary
Aml/mds (AML/MDS)
Bcc (BCC)
Bladder (Bladder)
Brain (Brain)
Colorectal (Colorectal)
Esophageal (Esophageal)
Gastric (Gastric)
Liver (Liver)
Lung (Lung)
Melanoma (Melanoma)
Nhl (NHL)
None (None)
Other Hematologic (Other Hematologic)
Other Solid (Other solid)
Pancreatic (Pancreatic)
Renal (Renal)
Squamous-skin (Squamous-Skin)
Unknown Primary (Unknown primary)
Other Hematologic, specify
Other solid, specify
New Primary Cancer Date
Non-Protocol Therapy Type
Chemotherapy (Chemotherapy)
None (None)
Other Non-protocol Therapy (Other non-
protocol therapy)
Radiation Therapy (Radiation therapy)
Surgery (Surgery)
Unknown (Unknown)
Date of Non-protocol therapy
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Report All Continuing Or New Adverse
Events
MedDRA Code
MedDRA Code
CTC AE Term
Acidosis Nos (Acidosis (metabolic or
respiratory))
Capillary Leak Syndrome (Acute
vascular leak syndrome)
Adrenal Insufficiency (Adrenal
insufficiency)
Adult Respiratory Distress Syndrome
(Adult respiratory distress syndrome
(ARDS))
Blood Albumin Decreased (Albumin,
serum-low (hypoalbuminemia))
Alcohol Intolerance Syndrome
(antabuse-like Syndrome) (Alcohol
intolerance syndrome (antabuse-like
syndrome))
Blood Alkaline Phosphatase Nos
Increased (Alkaline phosphatase)
Alkalosis Nos (Alkalosis (metabolic or
respiratory))
Hypersensitivity Nos (Allergic
reaction/hypersensitivity (including drug
fever))
Rhinitis Allergic Nos (Allergic rhinitis
(including sneezing, nasal stuffiness,
postnasal drip))
Allergy/immunology Other
(Allergy/Immunology-Other (Specify))
Alanine Aminotransferase Increased
(ALT, SGPT (serum glutamic pyruvic
transaminase))
Blood Amylase Increased (Amylase)
Anorexia (Anorexia)
Apnoea (Apnea)
Arachnoiditis
(Arachnoiditis/meningismus/radiculitis)
Arthritis Nos (Arthritis (non-septic))
Ascites (Ascites (non-malignant))
Aspiration (Aspiration)
Aspartate Aminotransferase Increased
(AST, SGOT (serum glutamic oxaloacetic
transaminase))
Ataxia Nec (Ataxia (incoordination))
Atelectasis (Atelectasis)
Atrophy, Skin (Atrophy, skin)
Atrophy, Subcutaneous Fat (Atrophy,
subcutaneous fat)
Auditory/ear Other (Auditory/Ear-Other
(Specify))
Autoimmune Disorder Nos (Autoimmune
reaction)
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Blood Bicarbonate Decreased
(Bicarbonate, serum-low)
Blood Bilirubin Increased (Bilirubin
(hyperbilirubinemia))
Bladder Disorder Nos (Bladder spasms)
Blood/bone Marrow Other (Blood/Bone
Marrow-Other (Specify))
Bone Age (alteration In Bone Age) (Bone
age (alteration in bone age))
Bone Growth: Femoral Head; Slipped
Capital Femoral Epiphysis (Bone growth:
femoral head; slipped capital femoral
epiphysis)
Bone Growth: Limb Length Discrepancy
(Bone growth: limb length discrepancy)
Bone Growth: Spine Kyphosis/lordosis
(Bone growth: spine kyphosis/lordosis)
Bone Marrow Depression Nos (Bone
marrow cellularity)
Bone: Spine-scoliosis (Bone: spine-
scoliosis)
Brachial Plexopathy (Brachial
plexopathy)
Breast Function/lactation (Breast
function/lactation)
Breast Nipple/areolar Deformity (Breast
nipple/areolar deformity)
Breast Volume/hypoplasia (Breast
volume/hypoplasia)
Bronchospasm, Wheezing
(Bronchospasm, wheezing)
Ecchymosis (Bruising (in absence of
grade 3 or 4 thrombocytopenia))
Burn (Burn)
Hypercalcaemia (Calcium, serum-high
(hypercalcemia))
Hypocalcaemia (Calcium, serum-low
(hypocalcemia))
Pulmonary Function Test Nos Decreased
(Carbon monoxide diffusion capacity
(DL(co)))
Arrhythmia Nos (Cardiac Arrhythmia-
Other (Specify))
Cardiac General Other (Cardiac
General-Other (Specify))
Myocardial Ischaemia (Cardiac
ischemia/infarction)
Cardiac Troponin I Increased (Cardiac
troponin I (cTnI))
Cardiac Troponin T Increased (Cardiac
troponin T (cTnT))
Cardiopulmonary Arrest, Cause
Unknown (non-fatal) (Cardiopulmonary
arrest, cause unknown (non-fatal))
Cataract Nec (Cataract)
Cd4 Lymphocytes Decreased (CD4
count)
Cervical Spine-range Of Motion (Cervical
spine-range of motion)
Chelitis (Cheilitis)
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Cholecystitis (Cholecystitis)
Hypercholesteraemia (Cholesterol,
serum-high (hypercholesteremia))
Chyle Or Lymph Leakage (Chyle or
lymph leakage)
Chylothorax (Chylothorax)
Cerebral Ischaemia (CNS
cerebrovascular ischemia)
Cns Necrosis/cystic Progression (CNS
necrosis/cystic progression)
Coagulation Disorder Nos (Coagulation-
Other (Specify))
Learning Disorder Nos (Cognitive
disturbance)
Colitis Nos (Colitis)
Colitis, Infectious (e.g., Clostridium
Difficile) (Colitis, infectious (e.g.,
Clostridium difficile))
Ventricular Asystole (Conduction
abnormality/Atrioventricular heart block -
Asystole)
Conduction Abnormality/atrioventricular
Heart Block (Conduction
abnormality/Atrioventricular heart block -
AV block-first degree)
Conduction Abnormality/atrioventricular
Heart Block - Av Block-second Degree
Mobitz Type I (wenckebach) (Conduction
abnormality/Atrioventricular heart block -
AV block-Second degree Mobitz Type I
(Wenckebach))
Conduction Abnormality/atrioventricular
Heart Block (Conduction
abnormality/Atrioventricular heart block -
AV block-second degree Mobitz Type II)
Conduction Abnormality/atrioventricular
Heart Block (Conduction
abnormality/Atrioventricular heart block -
AV block-third degree (complete AV
block))
Conduction Abnormality/atrioventricular
Heart Block (Conduction
abnormality/Atrioventricular heart block -
Conduction abnormality NOS)
Conduction Abnormality/atrioventricular
Heart Block (Conduction
abnormality/Atrioventricular heart block -
Sick sinus syndrome)
Conduction Abnormality/atrioventricular
Heart Block (Conduction
abnormality/Atrioventricular heart block -
Stokes-Adams syndrome)
Conduction Abnormality/atrioventricular
Heart Block (Conduction
abnormality/Atrioventricular heart block -
Wolff-Parkinson-White syndrome)
Confusion (Confusion)
Constipation (Constipation)
Constitutional Symptoms Other
(Constitutional Symptoms-Other
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(Specify))
Cough (Cough)
Blood Creatine Phosphokinase
Increased (CPK (creatine
phosphokinase))
Blood Creatinine Increased (Creatinine)
Cushingoid (Cushingoid appearance
(e.g., moon face, buffalo hump,
centripetal obesity, cutaneous striae))
Cystitis (Cystitis)
Cytokine Release Syndrome/acute
Infusion Reaction (Cytokine release
syndrome/acute infusion reaction)
Death Not Associated With Ctcae Term
(Death not associated with CTCAE term
- Death NOS)
Death Not Associated With Ctcae Term
(Death not associated with CTCAE term
- Disease progression NOS)
Death Not Associated With Ctcae Term
(Death not associated with CTCAE term
- Multi-organ failure)
Death Not Associated With Ctcae Term
(Death not associated with CTCAE term
- Sudden death)
Dehydration (Dehydration)
Dental: Dentures Or Prosthesis (Dental:
dentures or prosthesis)
Dental: Periodontal Disease (Dental:
periodontal disease)
Dental: Teeth (Dental: teeth)
Dental: Teeth Development (Dental:
teeth development)
Dermal Change Lymphedema,
Phlebolymphedema (Dermal change
lymphedema, phlebolymphedema)
Dermatology/skin Other
(Dermatology/Skin-Other (Specify))
Diarrhoea Nos (Diarrhea)
Disseminated Intravascular Coagulation
(DIC (disseminated intravascular
coagulation))
Distention/bloating, Abdominal
(Distention/bloating, abdominal)
Dizziness (exc Vertigo) (Dizziness)
Dry Eye Nec (Dry eye syndrome)
Dry Mouth (Dry mouth/salivary gland
(xerostomia))
Dry Skin (Dry skin)
Dysphagia (Dysphagia (difficulty
swallowing))
Dyspnoea Nos (Dyspnea (shortness of
breath))
Edema, Larynx (Edema, larynx)
Edema: Head And Neck (Edema: head
and neck)
Oedema Nos (Edema: limb)
Edema: Trunk/genital (Edema:
trunk/genital)
Edema: Viscera (Edema: viscera)
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Ejaculatory Dysfunction (Ejaculatory
dysfunction)
Encephalopathy (Encephalopathy)
Endocrine Other (Endocrine-Other
(Specify))
Enteritis (inflammation Of The Small
Bowel) (Enteritis (inflammation of the
small bowel))
Impotence (Erectile dysfunction)
Oesophagitis Nos (Esophagitis)
Exostosis (Exostosis)
Extrapyramidal Disorder Nec
(Extrapyramidal/involuntary
movement/restlessness)
Extremity-lower (gait/walking) (Extremity-
lower (gait/walking))
Extremity-upper (function) (Extremity-
upper (function))
Eyelid Dysfunction (Eyelid dysfunction)
Fatigue (Fatigue (asthenia, lethargy,
malaise))
Febrile Neutropenia (fever Of Unknown
Origin Without Clinically Or
Microbiologically Documented Infection)
(anc <1.0 X 10^9/l, Fever >=38.5
Degrees C) (Febrile neutropenia)
Feminization (Feminization of male)
Forced Expiratory Volume Decreased
(FEV(1))
Pyrexia (Fever (in the absence of
neutropenia, where neutropenia is
defined as ANC <1.0 x 10^9/L))
Blood Fibrinogen Decreased
(Fibrinogen)
Fibrosis-cosmesis (Fibrosis-cosmesis)
Fibrosis-deep Connective Tissue
(Fibrosis-deep connective tissue)
Fistula, Gi (Fistula, GI - Abdomen NOS)
Anal Fistula (Fistula, GI - Anus)
Fistula, Gi (Fistula, GI - Biliary tree)
Fistula, Gi (Fistula, GI -
Colon/cecum/appendix)
Intestinal Fistula (Fistula, GI -
Duodenum)
Tracheo-oesophageal Fistula Nos
(Fistula, GI - Esophagus)
Fistula, Gi (Fistula, GI - Gallbladder)
Fistula, Gi (Fistula, GI - Ileum)
Fistula, Gi (Fistula, GI - Jejunum)
Fistula, Gi (Fistula, GI - Oral cavity)
Fistula, Gi (Fistula, GI - Pancreas)
Fistula, Gi (Fistula, GI - Pharynx)
Fistula, Gi (Fistula, GI - Rectum)
Fistula, Gi (Fistula, GI - Salivary gland)
Fistula, Gi (Fistula, GI - Small bowel
NOS)
Fistula, Gi (Fistula, GI - Stomach)
Fistula, Gu (Fistula, GU - Bladder)
Fistula, Gu (Fistula, GU - Genital tract-
female)
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Fistula, Gu (Fistula, GU - Kidney)
Fistula, Gu (Fistula, GU - Ureter)
Fistula, Gu (Fistula, GU - Urethra)
Fistula, Gu (Fistula, GU - Uterus)
Urogenital Fistula (Fistula, GU - Vagina)
Fistula, Pulmonary/upper Respiratory
(Fistula, pulmonary/upper respiratory -
Bronchus)
Fistula, Pulmonary/upper Respiratory
(Fistula, pulmonary/upper respiratory -
Larynx)
Fistula, Pulmonary/upper Respiratory
(Fistula, pulmonary/upper respiratory -
Lung)
Fistula, Pulmonary/upper Respiratory
(Fistula, pulmonary/upper respiratory -
Oral cavity)
Fistula, Pulmonary/upper Respiratory
(Fistula, pulmonary/upper respiratory -
Pharynx)
Fistula, Pulmonary/upper Respiratory
(Fistula, pulmonary/upper respiratory -
Pleura)
Fistula, Pulmonary/upper Respiratory
(Fistula, pulmonary/upper respiratory -
Trachea)
Flatulence (Flatulence)
Flu-like Syndrome (Flu-like syndrome)
Flushing (Flushing)
Fracture (Fracture)
Gastritis Nos (Gastritis (including bile
reflux gastritis))
Gastrointestinal Other (Gastrointestinal-
Other (Specify))
Gamma-glutamyltransferase Increased
(GGT (gamma-glutamyl transpeptidase))
Glaucoma Nos (Glaucoma)
Glomerular Filtration Rate (Glomerular
filtration rate)
Hyperglycaemia Nos (Glucose, serum-
high (hyperglycemia))
Hypoglycaemia Nos (Glucose, serum-
low (hypoglycemia))
Growth And Development Other (Growth
and Development-Other (Specify))
Growth Velocity (reduction In Growth
Velocity) (Growth velocity (reduction in
growth velocity))
Gynaecomastia (Gynecomastia)
Alopecia (Hair loss/Alopecia (scalp or
body))
Haptoglobin Decreased (Haptoglobin)
Hearing: Patients With/without Baseline
Audiogram And Enrolled In A Monitoring
Program (Hearing: patients with/without
baseline audiogram and enrolled in a
monitoring program)
Hearing: Patients Without Baseline
Audiogram And Not Enrolled In A
Monitoring Program (Hearing: patients
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without baseline audiogram and not
enrolled in a monitoring program)
Dyspepsia (Heartburn/dyspepsia)
Hematoma (Hematoma)
Haemoglobin Decreased (Hemoglobin)
Haemoglobinuria Present
(Hemoglobinuria)
Hemolysis Nos (Hemolysis (e.g.,
immune hemolytic anemia, drug related
hemolysis))
Haemorrhagic Stroke (Hemorrhage,
CNS)
Melaena (Hemorrhage, GI - Abdomen
NOS)
Hemorrhage, Gi (Hemorrhage, GI -
Anus)
Hemorrhage, Gi (Hemorrhage, GI -
Biliary tree)
Hemorrhage, Gi (Hemorrhage, GI -
Cecum/appendix)
Hemorrhage, Gi (Hemorrhage, GI -
Colon)
Hemorrhage, Gi (Hemorrhage, GI -
Duodenum)
Hemorrhage, Gi (Hemorrhage, GI -
Esophagus)
Hemorrhage, Gi (Hemorrhage, GI -
Ileum)
Hemorrhage, Gi (Hemorrhage, GI -
Jejunum)
Hemorrhage, Gi (Hemorrhage, GI - Liver)
Hemorrhage, Gi (Hemorrhage, GI -
Lower GI NOS)
Hemorrhage, Gi (Hemorrhage, GI - Oral
cavity)
Hemorrhage, Gi (Hemorrhage, GI -
Pancreas)
Hemorrhage, Gi (Hemorrhage, GI -
Peritoneal cavity)
Rectal Bleeding (Hemorrhage, GI -
Rectum)
Hemorrhage, Gi (Hemorrhage, GI -
Stoma)
Haematemesis (Hemorrhage, GI -
Stomach)
Hemorrhage, Gi (Hemorrhage, GI -
Upper GI NOS)
Hemorrhage, Gi (Hemorrhage, GI -
Varices (esophageal))
Hemorrhage, Gi (Hemorrhage, GI -
Varices (rectal))
Hemorrhage, Gu (Hemorrhage, GU -
Bladder)
Hemorrhage, Gu (Hemorrhage, GU -
Fallopian tube)
Hemorrhage, Gu (Hemorrhage, GU -
Kidney)
Hemorrhage, Gu (Hemorrhage, GU -
Ovary)
Hemorrhage, Gu (Hemorrhage, GU -
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Prostate)
Hemorrhage, Gu (Hemorrhage, GU -
Retroperitoneum)
Hemorrhage, Gu (Hemorrhage, GU -
Spermatic cord)
Hemorrhage, Gu (Hemorrhage, GU -
Stoma)
Hemorrhage, Gu (Hemorrhage, GU -
Testes)
Hemorrhage, Gu (Hemorrhage, GU -
Ureter)
Hemorrhage, Gu (Hemorrhage, GU -
Urethra)
Haematuria Present (Hemorrhage, GU -
Urinary NOS)
Hemorrhage, Gu (Hemorrhage, GU -
Uterus)
Vaginal Haemorrhage (Hemorrhage, GU
- Vagina)
Hemorrhage, Gu (Hemorrhage, GU - Vas
deferens)
Hemorrhage, Pulmonary/upper
Respiratory (Hemorrhage,
pulmonary/upper respiratory -
Bronchopulmonary NOS)
Hemorrhage, Pulmonary/upper
Respiratory (Hemorrhage,
pulmonary/upper respiratory - Bronchus)
Hemorrhage, Pulmonary/upper
Respiratory (Hemorrhage,
pulmonary/upper respiratory - Larynx)
Hemorrhage, Pulmonary/upper
Respiratory (Hemorrhage,
pulmonary/upper respiratory - Lung)
Hemorrhage, Pulmonary/upper
Respiratory (Hemorrhage,
pulmonary/upper respiratory -
Mediastinum)
Epistaxis (Hemorrhage, pulmonary/upper
respiratory - Nose)
Hemorrhage, Pulmonary/upper
Respiratory (Hemorrhage,
pulmonary/upper respiratory - Pharynx)
Hemorrhage, Pulmonary/upper
Respiratory (Hemorrhage,
pulmonary/upper respiratory - Pleura)
Haemoptysis (Hemorrhage,
pulmonary/upper respiratory -
Respiratory tract NOS)
Hemorrhage, Pulmonary/upper
Respiratory (Hemorrhage,
pulmonary/upper respiratory - Stoma)
Hemorrhage, Pulmonary/upper
Respiratory (Hemorrhage,
pulmonary/upper respiratory - Trachea)
Post-operative Haemorrhage
(Hemorrhage/bleeding associated with
surgery, intra-operative or post-operative)
Hemorrhage/bleeding Other
(Hemorrhage/Bleeding-Other (Specify))
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Hemorrhoids (Hemorrhoids)
Hepatobiliary/pancreas Other
(Hepatobiliary/Pancreas-Other (Specify))
Hiccups (Hiccoughs (hiccups, singultus))
Menopausal Symptoms (Hot
flashes/flushes)
Hydrocephalus (Hydrocephalus)
Skin Discolouration (Hyperpigmentation)
Hypertension Nos (Hypertension)
Hypopigmentation (Hypopigmentation)
Hypotension Nos (Hypotension)
Hypothermia (Hypothermia)
Hypoxia (Hypoxia)
Ileus (Ileus, GI (functional obstruction of
bowel, i.e., neuroconstipation))
Incontinence, Anal (Incontinence, anal)
Urinary Incontinence (Incontinence,
urinary)
Induration/fibrosis (skin And
Subcutaneous Tissue)
(Induration/fibrosis (skin and
subcutaneous tissue))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Abdomen NOS)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Anal/perianal)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Appendix)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Artery)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Biliary tree)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Bladder (urinary))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
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Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Blood)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Bone (osteomyelitis))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Brain (encephalitis,
infectious))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Brain + Spinal cord
(encephalomyelitis))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Bronchus)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Catheter-related)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Cecum)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Cervix)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Colon)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Conjunctiva)
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Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Cornea)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Dental-tooth)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Duodenum)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Esophagus)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - External ear (otitis externa))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Eye NOS)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Fallopian tube)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Foreign body (e.g., graft,
implant, prosthesis, stent))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Gallbladder (cholecystitis))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
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neutrophils - Heart (endocarditis))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Ileum)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Jejunum)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Joint)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Kidney)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Larynx)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Lens)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Lip/perioral)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Liver)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Lung (pneumonia))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
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neutrophils - Lymphatic)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Mediastinum NOS)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Meninges (meningitis))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Middle ear (otitis media))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Mucosa)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Muscle (infection myositis))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Neck NOS)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Nerve-cranial)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Nerve-peripheral)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Nose)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
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neutrophils - Oral cavity-gums
(gingivitis))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Pancreas)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Paranasal)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Pelvis NOS)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Penis)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Peristomal)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Peritoneal cavity)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Pharynx)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Pleura (empyema))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Prostate)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
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microbiologically) with Grade 3 or 4
neutrophils - Rectum)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Salivary gland)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Scrotum)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Sinus)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Skin (cellulitis))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Small bowel NOS)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Soft tissue NOS)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Spinal cord (myelitis))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Spleen)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Stomach)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
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microbiologically) with Grade 3 or 4
neutrophils - Trachea)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Ungual (nails))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Upper aerodigestive NOS)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Upper airway NOS)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Ureter)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Urethra)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Urinary tract NOS)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Uterus)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Vagina)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Vein)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
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microbiologically) with Grade 3 or 4
neutrophils - Vulva)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Wound)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Abdomen
NOS)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils -
Anal/perianal)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Appendix)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Artery)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Biliary tree)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Bladder
(urinary))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Blood)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Bone
(osteomyelitis))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Brain
(encephalitis, infectious))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Brain +
Spinal cord (encephalomyelitis))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Bronchus)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Catheter-
related)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Cecum)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Cervix)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Colon)
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Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils -
Conjunctiva)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Cornea)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Dental-
tooth)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Duodenum)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Esophagus)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - External ear
(otitis externa))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Eye NOS)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Fallopian
tube)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Foreign
body (e.g., graft, implant, prosthesis,
stent))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Gallbladder
(cholecystitis))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Heart
(endocarditis))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Ileum)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Jejunum)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Joint)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Kidney)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Larynx)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Lens)
Infection With Normal Anc Or Grade 1 Or
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2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Lip/perioral)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Liver)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Lung
(pneumonia))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Lymphatic)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils -
Mediastinum NOS)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Meninges
(meningitis))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Middle ear
(otitis media))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Mucosa)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Muscle
(infection myositis))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Neck NOS)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Nerve-
cranial)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Nerve-
peripheral)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Nose)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Oral cavity-
gums (gingivitis))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Pancreas)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Paranasal)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Pelvis NOS)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
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or Grade 1 or 2 neutrophils - Penis)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Peristomal)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Peritoneal
cavity)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Pharynx)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Pleura
(empyema))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Prostate)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Rectum)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Salivary
gland)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Scrotum)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Sinus)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Skin
(cellulitis))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Small bowel
NOS)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Soft tissue
NOS)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Spinal cord
(myelitis))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Spleen)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Stomach)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Trachea)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Ungual
(nails))
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Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Upper
aerodigestive NOS)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Upper
airway NOS)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Ureter)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Urethra)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Urinary
tract NOS)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Uterus)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Vagina)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Vein)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Vulva)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Wound)
Infection With Unknown Anc (Infection
with unknown ANC - Abdomen NOS)
Infection With Unknown Anc (Infection
with unknown ANC - Anal/perianal)
Infection With Unknown Anc (Infection
with unknown ANC - Appendix)
Infection With Unknown Anc (Infection
with unknown ANC - Artery)
Infection With Unknown Anc (Infection
with unknown ANC - Biliary tree)
Infection With Unknown Anc (Infection
with unknown ANC - Bladder (urinary))
Infection With Unknown Anc (Infection
with unknown ANC - Blood)
Infection With Unknown Anc (Infection
with unknown ANC - Bone
(osteomyelitis))
Infection With Unknown Anc (Infection
with unknown ANC - Brain (encephalitis,
infectious))
Infection With Unknown Anc (Infection
with unknown ANC - Brain + Spinal cord
(encephalomyelitis))
Infection With Unknown Anc (Infection
with unknown ANC - Bronchus)
Implant Infection (Infection with unknown
ANC - Catheter-related)
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Infection With Unknown Anc (Infection
with unknown ANC - Cecum)
Infection With Unknown Anc (Infection
with unknown ANC - Cervix)
Infection With Unknown Anc (Infection
with unknown ANC - Colon)
Infection With Unknown Anc (Infection
with unknown ANC - Conjunctiva)
Infection With Unknown Anc (Infection
with unknown ANC - Cornea)
Infection With Unknown Anc (Infection
with unknown ANC - Dental-tooth)
Infection With Unknown Anc (Infection
with unknown ANC - Duodenum)
Infection With Unknown Anc (Infection
with unknown ANC - Esophagus)
Infection With Unknown Anc (Infection
with unknown ANC - External ear (otitis
externa))
Infection With Unknown Anc (Infection
with unknown ANC - Eye NOS)
Infection With Unknown Anc (Infection
with unknown ANC - Fallopian tube)
Infection With Unknown Anc (Infection
with unknown ANC - Foreign body (e.g.,
graft, implant, prosthesis, stent))
Infection With Unknown Anc (Infection
with unknown ANC - Gallbladder
(cholecystitis))
Infection With Unknown Anc (Infection
with unknown ANC - Heart
(endocarditis))
Infection With Unknown Anc (Infection
with unknown ANC - Ileum)
Infection With Unknown Anc (Infection
with unknown ANC - Jejunum)
Infection With Unknown Anc (Infection
with unknown ANC - Joint)
Infection With Unknown Anc (Infection
with unknown ANC - Kidney)
Infection With Unknown Anc (Infection
with unknown ANC - Larynx)
Infection With Unknown Anc (Infection
with unknown ANC - Lens)
Infection With Unknown Anc (Infection
with unknown ANC - Lip/perioral)
Infection With Unknown Anc (Infection
with unknown ANC - Liver)
Infection With Unknown Anc (Infection
with unknown ANC - Lung (pneumonia))
Infection With Unknown Anc (Infection
with unknown ANC - Lymphatic)
Infection With Unknown Anc (Infection
with unknown ANC - Mediastinum NOS)
Infection With Unknown Anc (Infection
with unknown ANC - Meninges
(meningitis))
Infection With Unknown Anc (Infection
with unknown ANC - Middle ear (otitis
media))
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Infection With Unknown Anc (Infection
with unknown ANC - Mucosa)
Infection With Unknown Anc (Infection
with unknown ANC - Muscle (infection
myositis))
Infection With Unknown Anc (Infection
with unknown ANC - Neck NOS)
Infection With Unknown Anc (Infection
with unknown ANC - Nerve-cranial)
Infection With Unknown Anc (Infection
with unknown ANC - Nerve-peripheral)
Infection With Unknown Anc (Infection
with unknown ANC - Nose)
Infection With Unknown Anc (Infection
with unknown ANC - Oral cavity-gums
(gingivitis))
Infection With Unknown Anc (Infection
with unknown ANC - Pancreas)
Infection With Unknown Anc (Infection
with unknown ANC - Paranasal)
Infection With Unknown Anc (Infection
with unknown ANC - Pelvis NOS)
Infection With Unknown Anc (Infection
with unknown ANC - Penis)
Infection With Unknown Anc (Infection
with unknown ANC - Peristomal)
Infection With Unknown Anc (Infection
with unknown ANC - Peritoneal cavity)
Infection With Unknown Anc (Infection
with unknown ANC - Pharynx)
Infection With Unknown Anc (Infection
with unknown ANC - Pleura (empyema))
Infection With Unknown Anc (Infection
with unknown ANC - Prostate)
Infection With Unknown Anc (Infection
with unknown ANC - Rectum)
Infection With Unknown Anc (Infection
with unknown ANC - Salivary gland)
Infection With Unknown Anc (Infection
with unknown ANC - Scrotum)
Infection With Unknown Anc (Infection
with unknown ANC - Sinus)
Infection With Unknown Anc (Infection
with unknown ANC - Skin (cellulitis))
Infection With Unknown Anc (Infection
with unknown ANC - Small bowel NOS)
Infection With Unknown Anc (Infection
with unknown ANC - Soft tissue NOS)
Infection With Unknown Anc (Infection
with unknown ANC - Spinal cord
(myelitis))
Infection With Unknown Anc (Infection
with unknown ANC - Spleen)
Infection With Unknown Anc (Infection
with unknown ANC - Stomach)
Infection With Unknown Anc (Infection
with unknown ANC - Trachea)
Infection With Unknown Anc (Infection
with unknown ANC - Ungual (nails))
Infection With Unknown Anc (Infection
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with unknown ANC - Upper aerodigestive
NOS)
Infection With Unknown Anc (Infection
with unknown ANC - Upper airway NOS)
Infection With Unknown Anc (Infection
with unknown ANC - Ureter)
Infection With Unknown Anc (Infection
with unknown ANC - Urethra)
Infection With Unknown Anc (Infection
with unknown ANC - Urinary tract NOS)
Infection With Unknown Anc (Infection
with unknown ANC - Uterus)
Infection With Unknown Anc (Infection
with unknown ANC - Vagina)
Infection With Unknown Anc (Infection
with unknown ANC - Vein)
Infection With Unknown Anc (Infection
with unknown ANC - Vulva)
Culture Wound Positive (Infection with
unknown ANC - Wound)
Infection Nos (Infection-Other (Specify))
Infertility/sterility (Infertility/sterility)
Injection Site Reaction Nos (Injection site
reaction/extravasation changes)
Prothrombin Time Prolonged (INR
(International Normalized Ratio of
prothrombin time))
Insomnia Nec (Insomnia)
Intra-operative Injury (Intra-operative
injury - Abdomen NOS)
Intra-operative Injury (Intra-operative
injury - Adrenal gland)
Intra-operative Injury (Intra-operative
injury - Anal sphincter)
Intra-operative Injury (Intra-operative
injury - Anus)
Intra-operative Injury (Intra-operative
injury - Appendix)
Intra-operative Injury (Intra-operative
injury - Artery NOS)
Intra-operative Injury (Intra-operative
injury - Artery-aorta)
Intra-operative Injury (Intra-operative
injury - Artery-carotid)
Intra-operative Injury (Intra-operative
injury - Artery-cerebral)
Intra-operative Injury (Intra-operative
injury - Artery-extremity (lower))
Intra-operative Injury (Intra-operative
injury - Artery-extremity (upper))
Intra-operative Injury (Intra-operative
injury - Artery-hepatic)
Intra-operative Injury (Intra-operative
injury - Artery-major visceral artery)
Intra-operative Injury (Intra-operative
injury - Artery-pulmonary)
Intra-operative Injury (Intra-operative
injury - Biliary tree NOS)
Intra-operative Injury (Intra-operative
injury - Biliary tree-common bile duct)
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Intra-operative Injury (Intra-operative
injury - Biliary tree-common hepatic duct)
Intra-operative Injury (Intra-operative
injury - Biliary tree-left hepatic duct)
Intra-operative Injury (Intra-operative
injury - Biliary tree-right hepatic duct)
Bladder Perforation Postoperative (Intra-
operative injury - Bladder)
Intra-operative Injury (Intra-operative
injury - Bone)
Intra-operative Injury (Intra-operative
injury - Brachial plexus)
Intra-operative Injury (Intra-operative
injury - Brain)
Intra-operative Injury (Intra-operative
injury - Breast)
Intra-operative Injury (Intra-operative
injury - Bronchus)
Intra-operative Injury (Intra-operative
injury - Cartilage)
Intra-operative Injury (Intra-operative
injury - Cecum)
Intra-operative Injury (Intra-operative
injury - Cervix)
Intra-operative Injury (Intra-operative
injury - CN I (olfactory))
Intra-operative Injury (Intra-operative
injury - CN II (optic))
Intra-operative Injury (Intra-operative
injury - CN III (oculomotor))
Intra-operative Injury (Intra-operative
injury - CN IV (trochlear))
Intra-operative Injury (Intra-operative
injury - CN IX (glossopharyngeal) motor
pharynx)
Intra-operative Injury (Intra-operative
injury - CN IX (glossopharyngeal)
sensory ear-pharynx-tongue)
Intra-operative Injury (Intra-operative
injury - CN V (trigeminal) motor)
Intra-operative Injury (Intra-operative
injury - CN V (trigeminal) sensory)
Intra-operative Injury (Intra-operative
injury - CN VI (abducens))
Intra-operative Injury (Intra-operative
injury - CN VII (facial) motor-face)
Intra-operative Injury (Intra-operative
injury - CN VII (facial) sensory-taste)
Intra-operative Injury (Intra-operative
injury - CN VIII (vestibulocochlear))
Intra-operative Injury (Intra-operative
injury - CN X (vagus))
Intra-operative Injury (Intra-operative
injury - CN XI (spinal accessory))
Intra-operative Injury (Intra-operative
injury - CN XII (hypoglossal))
Intra-operative Injury (Intra-operative
injury - Colon)
Intra-operative Injury (Intra-operative
injury - Conjunctiva)
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Intra-operative Injury (Intra-operative
injury - Cornea)
Intra-operative Injury (Intra-operative
injury - Cranial nerve or branch NOS)
Intra-operative Injury (Intra-operative
injury - Duodenum)
Intra-operative Injury (Intra-operative
injury - Esophagus)
Intra-operative Injury (Intra-operative
injury - Extremity-lower)
Intra-operative Injury (Intra-operative
injury - Extremity-upper)
Intra-operative Injury (Intra-operative
injury - Eye NOS)
Intra-operative Injury (Intra-operative
injury - Face NOS)
Intra-operative Injury (Intra-operative
injury - Fallopian tube)
Intra-operative Injury (Intra-operative
injury - Gallbladder)
Intra-operative Injury (Intra-operative
injury - Gingiva)
Intra-operative Injury (Intra-operative
injury - Heart)
Intra-operative Injury (Intra-operative
injury - Ileum)
Intra-operative Injury (Intra-operative
injury - Inner ear)
Intra-operative Injury (Intra-operative
injury - Jejunum)
Intra-operative Injury (Intra-operative
injury - Joint)
Intra-operative Injury (Intra-operative
injury - Kidney)
Intra-operative Injury (Intra-operative
injury - Larynx)
Intra-operative Injury (Intra-operative
injury - Lens)
Intra-operative Injury (Intra-operative
injury - Ligament)
Intra-operative Injury (Intra-operative
injury - Lingual)
Intra-operative Injury (Intra-operative
injury - Lip/perioral area)
Intra-operative Injury (Intra-operative
injury - Liver)
Intra-operative Injury (Intra-operative
injury - Lung)
Intra-operative Injury (Intra-operative
injury - Lung thoracic)
Intra-operative Injury (Intra-operative
injury - Mediastinum)
Intra-operative Injury (Intra-operative
injury - Meninges)
Intra-operative Injury (Intra-operative
injury - Middle ear)
Intra-operative Injury (Intra-operative
injury - Muscle)
Intra-operative Injury (Intra-operative
injury - Nails)
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Intra-operative Injury (Intra-operative
injury - Nasal cavity)
Intra-operative Injury (Intra-operative
injury - Nasopharynx)
Intra-operative Injury (Intra-operative
injury - Neck NOS)
Intra-operative Injury (Intra-operative
injury - Nose)
Intra-operative Injury (Intra-operative
injury - Oral)
Intra-operative Injury (Intra-operative
injury - Oral cavity NOS)
Intra-operative Injury (Intra-operative
injury - Outer ear NOS)
Intra-operative Injury (Intra-operative
injury - Outer ear-pinna)
Intra-operative Injury (Intra-operative
injury - Ovary)
Intra-operative Injury (Intra-operative
injury - Pancreas)
Intra-operative Injury (Intra-operative
injury - Pancreatic duct)
Intra-operative Injury (Intra-operative
injury - Parathyroid)
Intra-operative Injury (Intra-operative
injury - Parotid gland)
Intra-operative Injury (Intra-operative
injury - Pelvis NOS)
Intra-operative Injury (Intra-operative
injury - Penis)
Intra-operative Injury (Intra-operative
injury - Peripheral motor NOS)
Intra-operative Injury (Intra-operative
injury - Peripheral sensory NOS)
Intra-operative Injury (Intra-operative
injury - Peritoneal cavity)
Intra-operative Injury (Intra-operative
injury - Pharynx)
Intra-operative Injury (Intra-operative
injury - Pituitary)
Intra-operative Injury (Intra-operative
injury - Pleura)
Intra-operative Injury (Intra-operative
injury - Prostate)
Intra-operative Injury (Intra-operative
injury - Rectum)
Intra-operative Injury (Intra-operative
injury - Recurrent laryngeal)
Intra-operative Injury (Intra-operative
injury - Retina)
Intra-operative Injury (Intra-operative
injury - Sacral plexus)
Intra-operative Injury (Intra-operative
injury - Salivary duct)
Intra-operative Injury (Intra-operative
injury - Salivary gland)
Intra-operative Injury (Intra-operative
injury - Sciatic)
Intra-operative Injury (Intra-operative
injury - Scrotum)
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Intra-operative Injury (Intra-operative
injury - Sinus)
Intra-operative Injury (Intra-operative
injury - Skin)
Intra-operative Injury (Intra-operative
injury - Small bowel NOS)
Intra-operative Injury (Intra-operative
injury - Soft tissue NOS)
Intra-operative Injury (Intra-operative
injury - Spinal cord)
Intra-operative Injury (Intra-operative
injury - Spleen)
Intra-operative Injury (Intra-operative
injury - Stoma (GI))
Intra-operative Injury (Intra-operative
injury - Stomach)
Intra-operative Injury (Intra-operative
injury - Teeth)
Intra-operative Injury (Intra-operative
injury - Tendon)
Intra-operative Injury (Intra-operative
injury - Testis)
Intra-operative Injury (Intra-operative
injury - Thoracic duct)
Intra-operative Injury (Intra-operative
injury - Thoracodorsal)
Intra-operative Injury (Intra-operative
injury - Thyroid)
Intra-operative Injury (Intra-operative
injury - Tongue)
Intra-operative Injury (Intra-operative
injury - Trachea)
Intra-operative Injury (Intra-operative
injury - Upper aerodigestive NOS)
Intra-operative Injury (Intra-operative
injury - Upper airway NOS)
Intra-operative Injury (Intra-operative
injury - Ureter)
Intra-operative Injury (Intra-operative
injury - Urethra)
Intra-operative Injury (Intra-operative
injury - Urinary conduit)
Intra-operative Injury (Intra-operative
injury - Urinary tract NOS)
Intra-operative Injury (Intra-operative
injury - Uterus)
Intra-operative Injury (Intra-operative
injury - Vagina)
Intra-operative Injury - Vein (Intra-
operative injury - Vein NOS)
Intra-operative Injury (Intra-operative
injury - Vein-extremity (lower))
Intra-operative Injury (Intra-operative
injury - Vein-extremity (upper))
Intra-operative Injury (Intra-operative
injury - Vein-hepatic)
Intra-operative Injury (Intra-operative
injury - Vein-inferior vena cava)
Intra-operative Injury (Intra-operative
injury - Vein-jugular)
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Intra-operative Injury (Intra-operative
injury - Vein-major visceral vein)
Intra-operative Injury (Intra-operative
injury - Vein-portal vein)
Intra-operative Injury (Intra-operative
injury - Vein-pulmonary)
Intra-operative Injury (Intra-operative
injury - Vein-superior vena cava)
Intra-operative Injury (Intra-operative
injury - Vulva)
Intra-operative Injury Other (Intra-
operative Injury-Other (Specify))
Iron Overload (Iron overload)
Menstruation Irregular (Irregular menses
(change from baseline))
Irritability (Irritability (children <3 years of
age))
Joint-effusion (Joint-effusion)
Joint-effusion (Joint-function)
Keratitis Nec (Keratitis (corneal
inflammation/corneal ulceration))
Laryngeal Nerve Dysfunction (Laryngeal
nerve dysfunction)
Leak (including Anastomotic), Gi (Leak
(including anastomotic), GI - Biliary tree)
Leak (including Anastomotic), Gi (Leak
(including anastomotic), GI - Esophagus)
Leak (including Anastomotic), Gi (Leak
(including anastomotic), GI - Large
bowel)
Leak (including Anastomotic), Gi (Leak
(including anastomotic), GI - Leak NOS)
Leak (including Anastomotic), Gi (Leak
(including anastomotic), GI - Pancreas)
Leak (including Anastomotic), Gi (Leak
(including anastomotic), GI - Pharynx)
Leak (including Anastomotic), Gi (Leak
(including anastomotic), GI - Rectum)
Leak (including Anastomotic), Gi (Leak
(including anastomotic), GI - Small
bowel)
Leak (including Anastomotic), Gi (Leak
(including anastomotic), GI - Stoma)
Leak (including Anastomotic), Gi (Leak
(including anastomotic), GI - Stomach)
Leak (including Anastomotic), Gu (Leak
(including anastomotic), GU - Bladder)
Leak (including Anastomotic), Gu (Leak
(including anastomotic), GU - Fallopian
tube)
Leak (including Anastomotic), Gu (Leak
(including anastomotic), GU - Kidney)
Leak (including Anastomotic), Gu (Leak
(including anastomotic), GU - Spermatic
cord)
Leak (including Anastomotic), Gu (Leak
(including anastomotic), GU - Stoma)
Leak (including Anastomotic), Gu (Leak
(including anastomotic), GU - Ureter)
Leak (including Anastomotic), Gu (Leak
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(including anastomotic), GU - Urethra)
Leak (including Anastomotic), Gu (Leak
(including anastomotic), GU - Uterus)
Leak (including Anastomotic), Gu (Leak
(including anastomotic), GU - Vagina)
Leak (including Anastomotic), Gu (Leak
(including anastomotic), GU - Vas
deferens)
Leak, Cerebrospinal Fluid (csf) (Leak,
cerebrospinal fluid (CSF))
Left Ventricular Diastolic Dysfunction
(Left ventricular diastolic dysfunction)
Left Ventricular Failure (Left ventricular
systolic dysfunction)
Leucopenia Nos (Leukocytes (total
WBC))
Encephalopathy Nos
(Leukoencephalopathy (radiolographic
findings))
Libido Decreased (Libido)
Lipase Increased (Lipase)
Hepatic Failure (Liver dysfunction/failure
(clinical))
Local Complication - Device/prosthesis-
related (Local complication -
device/prosthesis-related)
Lumbar Spine-range Of Motion (Lumbar
spine-range of motion)
Lymphatics Other (Lymphatics-Other
(Specify))
Lymphedema-related Fibrosis
(Lymphedema-related fibrosis)
Lymphocele (Lymphocele)
Lymphopenia (Lymphopenia)
Hypermagnesaemia (Magnesium,
serum-high (hypermagnesemia))
Blood Magnesium Decreased
(Magnesium, serum-low
(hypomagnesemia))
Malabsorption (Malabsorption)
Virilism (Masculinization of female)
Amnesia Nec (Memory impairment)
Mental Status (Mental status)
Metabolic/laboratory Other
(Metabolic/Laboratory-Other (Specify))
Mood Alteration - Agitation (Mood
alteration - agitation)
Anxiety Nec (Mood alteration - anxiety)
Depression Nec (Mood alteration -
depression)
Euphoric Mood (Mood alteration -
euphoria)
Mucositis/stomatitis (clinical Exam)
(Mucositis/stomatitis (clinical exam) -
Anus)
Mucositis/stomatitis (clinical Exam)
(Mucositis/stomatitis (clinical exam) -
Esophagus)
Mucositis/stomatitis (clinical Exam)
(Mucositis/stomatitis (clinical exam) -
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Large bowel)
Mucositis/stomatitis (clinical Exam)
(Mucositis/stomatitis (clinical exam) -
Larynx)
Mucositis/stomatitis (clinical Exam)
(Mucositis/stomatitis (clinical exam) -
Oral cavity)
Stomatitis (Mucositis/stomatitis (clinical
exam) - Pharynx)
Mucositis/stomatitis (clinical Exam)
(Mucositis/stomatitis (clinical exam) -
Rectum)
Mucositis/stomatitis (clinical Exam)
(Mucositis/stomatitis (clinical exam) -
Small bowel)
Mucositis/stomatitis (clinical Exam)
(Mucositis/stomatitis (clinical exam) -
Stomach)
Mucositis/stomatitis (clinical Exam)
(Mucositis/stomatitis (clinical exam) -
Trachea)
Mucositis/stomatitis
(functional/symptomatic)
(Mucositis/stomatitis
(functional/symptomatic) - Anus)
Mucositis/stomatitis
(functional/symptomatic)
(Mucositis/stomatitis
(functional/symptomatic) - Esophagus)
Mucositis/stomatitis
(functional/symptomatic)
(Mucositis/stomatitis
(functional/symptomatic) - Large bowel)
Mucositis/stomatitis
(functional/symptomatic)
(Mucositis/stomatitis
(functional/symptomatic) - Larynx)
Mucositis/stomatitis
(functional/symptomatic)
(Mucositis/stomatitis
(functional/symptomatic) - Oral cavity)
Mucositis/stomatitis
(functional/symptomatic)
(Mucositis/stomatitis
(functional/symptomatic) - Pharynx)
Mucositis/stomatitis
(functional/symptomatic)
(Mucositis/stomatitis
(functional/symptomatic) - Rectum)
Mucositis/stomatitis
(functional/symptomatic)
(Mucositis/stomatitis
(functional/symptomatic) - Small bowel)
Mucositis/stomatitis
(functional/symptomatic)
(Mucositis/stomatitis
(functional/symptomatic) - Stomach)
Mucositis/stomatitis
(functional/symptomatic)
(Mucositis/stomatitis
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(functional/symptomatic) - Trachea)
Muscle Weakness, Generalized Or
Specific Area (not Due To Neuropathy)
(Muscle weakness, generalized or
specific area (not due to neuropathy) -
Extraocular)
Muscle Weakness, Generalized Or
Specific Area (not Due To Neuropathy)
(Muscle weakness, generalized or
specific area (not due to neuropathy) -
Extremity-lower)
Muscle Weakness, Generalized Or
Specific Area (not Due To Neuropathy)
(Muscle weakness, generalized or
specific area (not due to neuropathy) -
Extremity-upper)
Muscle Weakness, Generalized Or
Specific Area (not Due To Neuropathy)
(Muscle weakness, generalized or
specific area (not due to neuropathy) -
Facial)
Muscle Weakness, Generalized Or
Specific Area (not Due To Neuropathy)
(Muscle weakness, generalized or
specific area (not due to neuropathy) -
Left-sided)
Muscle Weakness, Generalized Or
Specific Area (not Due To Neuropathy)
(Muscle weakness, generalized or
specific area (not due to neuropathy) -
Ocular)
Muscle Weakness, Generalized Or
Specific Area (not Due To Neuropathy)
(Muscle weakness, generalized or
specific area (not due to neuropathy) -
Pelvic)
Muscle Weakness, Generalized Or
Specific Area (not Due To Neuropathy)
(Muscle weakness, generalized or
specific area (not due to neuropathy) -
Right-sided)
Muscle Weakness, Generalized Or
Specific Area (not Due To Neuropathy)
(Muscle weakness, generalized or
specific area (not due to neuropathy) -
Trunk)
Muscle Weakness Nos (Muscle
weakness, generalized or specific area
(not due to neuropathy) - Whole
body/generalized)
Muscular/skeletal Hypoplasia
(Muscular/skeletal hypoplasia)
Musculoskeletal/soft Tissue Other
(Musculoskeletal/Soft Tissue-Other
(Specify))
Myelitis (Myelitis)
Myelodysplasia (Myelodysplasia)
Myocarditis Nos (Myocarditis)
Myositis (Myositis (inflammation/damage
of muscle))
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Nail Abnormality Nos (Nail changes)
Nasal Cavity/paranasal Sinus Reactions
(Nasal cavity/paranasal sinus reactions)
Nausea (Nausea)
Necrosis, Gi (Necrosis, GI - Anus)
Necrosis, Gi (Necrosis, GI -
Colon/cecum/appendix)
Necrosis, Gi (Necrosis, GI - Duodenum)
Necrosis, Gi (Necrosis, GI - Esophagus)
Necrosis, Gi (Necrosis, GI - Gallbladder)
Necrosis, Gi (Necrosis, GI - Hepatic)
Necrosis, Gi (Necrosis, GI - Ileum)
Necrosis, Gi (Necrosis, GI - Jejunum)
Necrosis, Gi (Necrosis, GI - Oral)
Necrosis, Gi (Necrosis, GI - Pancreas)
Necrosis, Gi (Necrosis, GI - Peritoneal
cavity)
Necrosis, Gi (Necrosis, GI - Pharynx)
Necrosis, Gi (Necrosis, GI - Rectum)
Necrosis, Gi (Necrosis, GI - Small bowel
NOS)
Necrosis, Gi (Necrosis, GI - Stoma)
Necrosis, Gi (Necrosis, GI - Stomach)
Neuroendocrine: Acth Deficiency
(Neuroendocrine: ACTH deficiency)
Inappropriate Adh Secretion
(Neuroendocrine: ADH secretion
abnormality (e.g., SIADH or low ADH))
Neuroendocrine: Gonadotropin Secretion
Abnormality (Neuroendocrine:
gonadotropin secretion abnormality)
Neuroendocrine: Growth Hormone
Secretion Abnormality (Neuroendocrine:
growth hormone secretion abnormality)
Neuroendocrine: Prolactin Hormone
Secretion Abnormality (Neuroendocrine:
prolactin hormone secretion abnormality)
Neurology Other (Neurology-Other
(Specify))
Parosmia (Neuropathy: cranial - CN I
Smell)
Cranial Nerve Injury Nos (Neuropathy:
cranial - CN II Vision)
Neuropathy: Cranial (Neuropathy: cranial
- CN III Pupil, upper eyelid, extra ocular
movements)
Neuropathy: Cranial (Neuropathy: cranial
- CN IV Downward, inward movement of
eye)
Neuropathy: Cranial (Neuropathy: cranial
- CN IX Motor-pharynx; Sensory-ear,
pharynx, tongue)
Neuropathy: Cranial (Neuropathy: cranial
- CN V Motor-jaw muscles; Sensory-
facial)
Neuropathy: Cranial (Neuropathy: cranial
- CN VI Lateral deviation of eye)
Neuropathy: Cranial (Neuropathy: cranial
- CN VII Motor-face; Sensory-taste)
Neuropathy: Cranial (Neuropathy: cranial
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- CN VIII Hearing and balance)
Neuropathy: Cranial (Neuropathy: cranial
- CN X Motor-palate; pharynx, larynx)
Neuropathy: Cranial (Neuropathy: cranial
- CN XI Motor-sternomastoid and
trapezius)
Neuropathy: Cranial (Neuropathy: cranial
- CN XII Motor-tongue)
Peripheral Motor Neuropathy
(Neuropathy: motor)
Peripheral Sensory Neuropathy
(Neuropathy: sensory)
Neutropenia (Neutrophils/granulocytes
(ANC/AGC))
Blindness Night (Night blindness
(nyctalopia))
Nystagmus Nos (Nystagmus)
Obesity (Obesity)
Obstruction, Gi (Obstruction, GI -
Cecum)
Obstruction, Gi (Obstruction, GI - Colon)
Obstruction, Gi (Obstruction, GI -
Duodenum)
Obstruction, Gi (Obstruction, GI -
Esophagus)
Obstruction, Gi (Obstruction, GI -
Gallbladder)
Obstruction, Gi (Obstruction, GI - Ileum)
Obstruction, Gi (Obstruction, GI -
Jejunum)
Obstruction, Gi (Obstruction, GI -
Rectum)
Obstruction, Gi (Obstruction, GI - Small
bowel NOS)
Obstruction, Gi (Obstruction, GI - Stoma)
Obstruction, Gi (Obstruction, GI -
Stomach)
Obstruction, Gu (Obstruction, GU -
Bladder)
Obstruction, Gu (Obstruction, GU -
Fallopian tube)
Obstruction, Gu (Obstruction, GU -
Prostate)
Obstruction, Gu (Obstruction, GU -
Spermatic cord)
Obstruction, Gu (Obstruction, GU -
Stoma)
Obstruction, Gu (Obstruction, GU -
Testes)
Ureteric Obstruction (Obstruction, GU -
Ureter)
Obstruction, Gu (Obstruction, GU -
Urethra)
Obstruction, Gu (Obstruction, GU -
Uterus)
Obstruction, Gu (Obstruction, GU -
Vagina)
Obstruction, Gu (Obstruction, GU - Vas
deferens)
Obstruction/stenosis Of Airway
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(Obstruction/stenosis of airway -
Bronchus)
Obstruction/stenosis Of Airway
(Obstruction/stenosis of airway - Larynx)
Obstruction/stenosis Of Airway
(Obstruction/stenosis of airway -
Pharynx)
Obstruction/stenosis Of Airway
(Obstruction/stenosis of airway -
Trachea)
Conjunctivitis Nec (Ocular surface
disease)
Ocular/visual Other (Ocular/Visual-Other
(Specify))
Odor (patient Odor) (Odor (patient odor))
Diplopia (Ophthalmoplegia/diplopia
(double vision))
Opportunistic Infection Associated With
>=grade 2 Lymphopenia (Opportunistic
infection associated with >=Grade 2
lymphopenia)
Optic Disc Edema (Optic disc edema)
Orgasmic Dysfunction (Orgasmic
dysfunction)
Osteonecrosis (Osteonecrosis (avascular
necrosis))
Osteoporosis (Osteoporosis)
Otitis Externa (exc Boil Of Meatus) Nos
(Otitis, external ear (non-infectious))
Otitis Media Serous Nos (Otitis, middle
ear (non-infectious))
Abdominal Pain Nos (Pain - Abdomen
NOS)
Pain (Pain - Anus)
Pain (Pain - Back)
Pain (Pain - Bladder)
Bone Pain (Pain - Bone)
Pain (Pain - Breast)
Pain (Pain - Buttock)
Pain (Pain - Cardiac/heart)
Pain (Pain - Chest wall)
Chest Pain (Pain - Chest/thorax NOS)
Pain (Pain - Dental/teeth/peridontal)
Pain (Pain - Esophagus)
Earache (Pain - External ear)
Pain (Pain - Extremity-limb)
Pain (Pain - Eye)
Pain (Pain - Face)
Pain (Pain - Gallbladder)
Headache Nos (Pain - Head/headache)
Pain (Pain - Intestine)
Arthralgia (Pain - Joint)
Pain (Pain - Kidney)
Pain (Pain - Larynx)
Pain (Pain - Lip)
Hepatic Pain (Pain - Liver)
Pain (Pain - Lymph node)
Pain (Pain - Middle ear)
Myalgia (Pain - Muscle)
Pain (Pain - Neck)
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Neuralgia Nos (Pain -
Neuralgia/peripheral nerve)
Pain (Pain - Oral cavity)
Pain (Pain - Oral-gums)
Pain (Pain - Ovulatory)
Pain (Pain - Pain NOS)
Pelvic Pain Nos (Pain - Pelvis)
Pain (Pain - Penis)
Pain (Pain - Pericardium)
Pain (Pain - Perineum)
Pain (Pain - Peritoneum)
Pain (Pain - Phantom (pain associated
with missing limb))
Pleuritic Pain (Pain - Pleura)
Pain (Pain - Prostate)
Proctalgia (Pain - Rectum)
Pain (Pain - Scalp)
Pain (Pain - Scrotum)
Pain (Pain - Sinus)
Pain (Pain - Skin)
Pain (Pain - Stomach)
Pain (Pain - Testicle)
Pain (Pain - Throat/pharynx/larynx)
Tumour Pain (Pain - Tumor pain)
Dysuria (Pain - Urethra)
Dysmenorrhoea (Pain - Uterus)
Pain (Pain - Vagina)
Pain Other (Pain-Other (Specify))
Palpitations (Palpitations)
Pancreas, Exocrine Enzyme Deficiency
(Pancreas, exocrine enzyme deficiency)
Pancreatic Endocrine: Glucose
Intolerance (Pancreatic endocrine:
glucose intolerance)
Pancreatitis Nos (Pancreatitis)
Parathyroid Function, Low
(hypoparathyroidism) (Parathyroid
function, low (hypoparathyroidism))
Perforation, Gi (Perforation, GI -
Appendix)
Perforation, Gi (Perforation, GI - Biliary
tree)
Perforation, Gi (Perforation, GI - Cecum)
Perforation, Gi (Perforation, GI - Colon)
Perforation, Gi (Perforation, GI -
Duodenum)
Perforation, Gi (Perforation, GI -
Esophagus)
Perforation, Gi (Perforation, GI -
Gallbladder)
Perforation, Gi (Perforation, GI - Ileum)
Perforation, Gi (Perforation, GI -
Jejunum)
Perforation, Gi (Perforation, GI - Rectum)
Perforation, Gi (Perforation, GI - Small
bowel NOS)
Perforation, Gi (Perforation, GI -
Stomach)
Perforation, Gu (Perforation, GU -
Bladder)
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Perforation, Gu (Perforation, GU -
Fallopian tube)
Perforation, Gu (Perforation, GU -
Kidney)
Perforation, Gu (Perforation, GU - Ovary)
Perforation, Gu (Perforation, GU -
Prostate)
Perforation, Gu (Perforation, GU -
Spermatic cord)
Perforation, Gu (Perforation, GU -
Stoma)
Perforation, Gu (Perforation, GU -
Testes)
Perforation, Gu (Perforation, GU - Ureter)
Perforation, Gu (Perforation, GU -
Urethra)
Perforation, Gu (Perforation, GU -
Uterus)
Perforation, Gu (Perforation, GU -
Vagina)
Perforation, Gu (Perforation, GU - Vas
deferens)
Pericardial Effusion (Pericardial effusion
(non-malignant))
Pericarditis (Pericarditis)
Peripheral Ischaemia Nos (Peripheral
arterial ischemia)
Personality Change
(Personality/behavioral)
Petechiae (Petechiae/purpura
(hemorrhage/bleeding into skin or
mucosa))
Phlebitis Superficial (Phlebitis (including
superficial thrombosis))
Phlebolymphatic Cording
(Phlebolymphatic cording)
Hypophosphataemia (Phosphate, serum-
low (hypophosphatemia))
Photosensitivity Reaction Nos
(Photosensitivity)
Phrenic Nerve Dysfunction (Phrenic
nerve dysfunction)
Platelet Count Decreased (Platelets)
Pleural Effusion (Pleural effusion (non-
malignant))
Pneumonitis Nos
(Pneumonitis/pulmonary infiltrates)
Pneumothorax Nos (Pneumothorax)
Portal Hypertension (Portal vein flow)
Hyperkalaemia (Potassium, serum-high
(hyperkalemia))
Hypokalaemia (Potassium, serum-low
(hypokalemia))
Proctitis Nos (Proctitis)
Prolapse Of Stoma, Gi (Prolapse of
stoma, GI)
Prolapse Of Stoma, Gu (Prolapse of
stoma, GU)
Prolonged Chest Tube Drainage Or Air
Leak After Pulmonary Resection
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(Prolonged chest tube drainage or air
leak after pulmonary resection)
Prolonged Intubation After Pulmonary
Resection (>24 Hrs After Surgery)
(Prolonged intubation after pulmonary
resection (>24 hrs after surgery))
Electrocardiogram Qt Prolonged
(Prolonged QTc interval)
Proptosis/enophthalmos
(Proptosis/enophthalmos)
Proteinuria Present (Proteinuria)
Pruritus Nos (Pruritus/itching)
Delusion Nos (Psychosis
(hallucinations/delusions))
Activated Partial Thromboplastin Time
Prolonged (PTT (Partial thromboplastin
time))
Puberty (delayed) (Puberty (delayed))
Puberty (precocious) (Puberty
(precocious))
Pulmonary Fibrosis (Pulmonary fibrosis
(radiographic changes))
Pulmonary Hypertension (Pulmonary
hypertension)
Pulmonary/upper Respiratory Other
(Pulmonary/Upper Respiratory-Other
(Specify))
Upper Motor Neurone Lesion (Pyramidal
tract dysfunction (e.g., increased tone,
hyperreflexia, positive Babinski,
decreased fine motor coordination))
Rash: Acne/acneiform (Rash:
acne/acneiform)
Radiation Recall Syndrome (Rash:
dermatitis associated with radiation -
Chemoradiation)
Dermatitis Radiation Nos (Rash:
dermatitis associated with radiation -
Radiation)
Erythema Multiforme (Rash: erythema
multiforme (e.g., Stevens-Johnson
syndrome, toxic epidermal necrolysis))
Localised Exfoliation (Rash: hand-foot
skin reaction)
Dermatitis Exfoliative Nos
(Rash/desquamation)
Renal Failure Nos (Renal failure)
Renal/genitourinary Other
(Renal/Genitourinary-Other (Specify))
Restrictive Cardiomyopathy (Restrictive
cardiomyopathy)
Retinal Detachment (Retinal
detachment)
Retinoic Acid Syndrome (Retinoic acid
syndrome)
Retinopathy (Retinopathy)
Right Ventricular Dysfunction (cor
Pulmonale) (Right ventricular dysfunction
(cor pulmonale))
Rigors (Rigors/chills)
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Salivary Gland Disorder Nos (Salivary
gland changes/saliva)
Scleral Necrosis/melt (Scleral
necrosis/melt)
Secondary Malignancy Possibly Related
To Cancer Treatment (Secondary
Malignancy-possibly related to cancer
treatment (Specify))
Convulsions Nos (Seizure)
Seroma (Seroma)
Serum Sickness (Serum sickness)
Sexual/reproductive Function Other
(Sexual/Reproductive Function-Other
(Specify))
Short Stature (Short stature)
Skin Breakdown/decubitus Ulcer (Skin
breakdown/decubitus ulcer)
Hypernatraemia (Sodium, serum-high
(hypernatremia))
Hyponatraemia (Sodium, serum-low
(hyponatremia))
Soft Tissue Necrosis (Soft tissue
necrosis - Abdomen)
Soft Tissue Necrosis (Soft tissue
necrosis - Extremity-lower)
Soft Tissue Necrosis (Soft tissue
necrosis - Extremity-upper)
Soft Tissue Necrosis (Soft tissue
necrosis - Head)
Soft Tissue Necrosis (Soft tissue
necrosis - Neck)
Soft Tissue Necrosis (Soft tissue
necrosis - Pelvic)
Soft Tissue Necrosis (Soft tissue
necrosis - Thorax)
Depressed Level Of Consciousness
(Somnolence/depressed level of
consciousness)
Speech Disorder Nec (Speech
impairment (e.g., dysphasia or aphasia))
Splenic Function (Splenic function)
Striae (Striae)
Stricture/stenosis (including
Anastomotic), Gi (Stricture/stenosis
(including anastomotic), GI - Anus)
Stricture/stenosis (including
Anastomotic), Gi (Stricture/stenosis
(including anastomotic), GI - Biliary tree)
Stricture/stenosis (including
Anastomotic), Gi (Stricture/stenosis
(including anastomotic), GI - Cecum)
Stricture/stenosis (including
Anastomotic), Gi (Stricture/stenosis
(including anastomotic), GI - Colon)
Stricture/stenosis (including
Anastomotic), Gi (Stricture/stenosis
(including anastomotic), GI - Duodenum)
Stricture/stenosis (including
Anastomotic), Gi (Stricture/stenosis
(including anastomotic), GI - Esophagus)
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Stricture/stenosis (including
Anastomotic), Gi (Stricture/stenosis
(including anastomotic), GI - Ileum)
Stricture/stenosis (including
Anastomotic), Gi (Stricture/stenosis
(including anastomotic), GI - Jejunum)
Stricture/stenosis (including
Anastomotic), Gi (Stricture/stenosis
(including anastomotic), GI -
Pancreas/pancreatic duct)
Stricture/stenosis (including
Anastomotic), Gi (Stricture/stenosis
(including anastomotic), GI - Pharynx)
Stricture/stenosis (including
Anastomotic), Gi (Stricture/stenosis
(including anastomotic), GI - Rectum)
Stricture/stenosis (including
Anastomotic), Gi (Stricture/stenosis
(including anastomotic), GI - Small bowel
NOS)
Stricture/stenosis (including
Anastomotic), Gi (Stricture/stenosis
(including anastomotic), GI - Stoma)
Stricture/stenosis (including
Anastomotic), Gi (Stricture/stenosis
(including anastomotic), GI - Stomach)
Stricture/stenosis (including
Anastomotic), Gu (Stricture/stenosis
(including anastomotic), GU - Bladder)
Stricture/stenosis (including
Anastomotic), Gu (Stricture/stenosis
(including anastomotic), GU - Fallopian
tube)
Stricture/stenosis (including
Anastomotic), Gu (Stricture/stenosis
(including anastomotic), GU - Prostate)
Stricture/stenosis (including
Anastomotic), Gu (Stricture/stenosis
(including anastomotic), GU - Spermatic
cord)
Stricture/stenosis (including
Anastomotic), Gu (Stricture/stenosis
(including anastomotic), GU - Stoma)
Stricture/stenosis (including
Anastomotic), Gu (Stricture/stenosis
(including anastomotic), GU - Testes)
Stricture/stenosis (including
Anastomotic), Gu (Stricture/stenosis
(including anastomotic), GU - Ureter)
Stricture/stenosis (including
Anastomotic), Gu (Stricture/stenosis
(including anastomotic), GU - Urethra)
Stricture/stenosis (including
Anastomotic), Gu (Stricture/stenosis
(including anastomotic), GU - Uterus)
Stricture/stenosis (including
Anastomotic), Gu (Stricture/stenosis
(including anastomotic), GU - Vagina)
Stricture/stenosis (including
Anastomotic), Gu (Stricture/stenosis
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(including anastomotic), GU - Vas
deferens)
Supraventricular And Nodal Arrhythmia
(Supraventricular and nodal arrhythmia -
Atrial fibrillation)
Supraventricular And Nodal Arrhythmia
(Supraventricular and nodal arrhythmia -
Atrial flutter)
Supraventricular And Nodal Arrhythmia
(Supraventricular and nodal arrhythmia -
Atrial tachycardia/paroxysmal atrial
tachycardia)
Supraventricular And Nodal Arrhythmia
(Supraventricular and nodal arrhythmia -
Nodal/junctional)
Supraventricular And Nodal Arrhythmia
(Supraventricular and nodal arrhythmia -
Sinus arrhythmia)
Sinus Bradycardia (Supraventricular and
nodal arrhythmia - Sinus bradycardia)
Sinus Tachycardia (Supraventricular and
nodal arrhythmia - Sinus tachycardia)
Supraventricular Arrhythmia Nos
(Supraventricular and nodal arrhythmia -
Supraventricular arrhythmia NOS)
Supraventricular And Nodal Arrhythmia -
Supraventricular Extrasystoles
(premature Atrial Contractions;
Premature Nodal/junctional
Contractions) (Supraventricular and
nodal arrhythmia - Supraventricular
extrasystoles (premature atrial
contractions; premature nodal/junctional
contractions))
Supraventricular And Nodal Arrhythmia
(Supraventricular and nodal arrhythmia -
Supraventricular tachycardia)
Sweating Increased (Sweating
(diaphoresis))
Syncope (Syncope (fainting))
Syndromes Other (Syndromes-Other
(Specify))
Taste Disturbance (Taste alteration
(dysgeusia))
Telangiectasia (Telangiectasia)
Thrombosis/embolism (vascular Access-
related) (Thrombosis/embolism (vascular
access-related))
Thrombosis Nos
(Thrombosis/thrombus/embolism)
Thrombotic Microangiopathy (e.g.,
Thrombotic Thrombocytopenic
Purpura[ttp] Or Hemolytic Uremic
Syndrome[hus]) (Thrombotic
microangiopathy (e.g., thrombotic
thrombocytopenic purpura or hemolytic
uremic syndrome))
Thyroid Function, High (hyperthyroidism,
Thyrotoxicosis) (Thyroid function, high
(hyperthyroidism, thyrotoxicosis))
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Hypothyroidism (Thyroid function, low
(hypothyroidism))
Tinnitus (Tinnitus)
Tremor Nec (Tremor)
Hypertriglyceridaemia (Triglyceride,
serum-high (hypertriglyceridemia))
Trismus (difficulty, Restriction Or Pain
When Opening Mouth) (Trismus
(difficulty, restriction or pain when
opening mouth))
Tumour Flare (Tumor flare)
Tumour Lysis Syndrome (Tumor lysis
syndrome)
Caecitis (Typhlitis (cecal inflammation))
Ulcer, Gi (Ulcer, GI - Anus)
Ulcer, Gi (Ulcer, GI - Cecum)
Ulcer, Gi (Ulcer, GI - Colon)
Duodenal Ulcer (Ulcer, GI - Duodenum)
Ulcer, Gi (Ulcer, GI - Esophagus)
Ulcer, Gi (Ulcer, GI - Ileum)
Ulcer, Gi (Ulcer, GI - Jejunum)
Ulcer, Gi (Ulcer, GI - Rectum)
Ulcer, Gi (Ulcer, GI - Small bowel NOS)
Ulcer, Gi (Ulcer, GI - Stoma)
Gastric Ulcer (Ulcer, GI - Stomach)
Ulceration (Ulceration)
Hyperuricaemia (Uric acid, serum-high
(hyperuricemia))
Fanconi Syndrome (Urinary electrolyte
wasting (e.g., Fanconi's syndrome, renal
tubular acidosis))
Urinary Frequency (Urinary
frequency/urgency)
Urinary Retention (Urinary retention
(including neurogenic bladder))
Urine Discolouration (Urine color
change)
Urticaria Nos (Urticaria (hives, welts,
wheals))
Uveitis (Uveitis)
Vaginal Discharge (non-infectious)
(Vaginal discharge (non-infectious))
Vulvovaginal Dryness (Vaginal dryness)
Vaginal Mucositis (Vaginal mucositis)
Vaginal Stenosis/length (Vaginal
stenosis/length)
Vaginitis (Vaginitis (not due to infection))
Valvular Heart Disease (Valvular heart
disease)
Vascular Other (Vascular-Other
(Specify))
Vasculitis Nos (Vasculitis)
Vasovagal Attack (Vasovagal episode)
Ventricular Arrhythmia (Ventricular
arrhythmia - Bigeminy)
Ventricular Arrhythmia (Ventricular
arrhythmia - Idioventricular rhythm)
Ventricular Arrhythmia (Ventricular
arrhythmia - PVCs)
Ventricular Arrhythmia (Ventricular
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arrhythmia - Torsade de pointes)
Ventricular Arrhythmia (Ventricular
arrhythmia - Trigeminy)
Ventricular Arrhythmia Nos (Ventricular
arrhythmia - Ventricular arrhythmia NOS)
Ventricular Arrhythmia (Ventricular
arrhythmia - Ventricular fibrillation)
Ventricular Arrhythmia (Ventricular
arrhythmia - Ventricular flutter)
Ventricular Arrhythmia (Ventricular
arrhythmia - Ventricular tachycardia)
Vessel Injury-artery (Vessel injury-artery
- Aorta)
Vessel Injury-artery (Vessel injury-artery
- Carotid)
Vessel Injury-artery (Vessel injury-artery
- Extremity-lower)
Vessel Injury-artery (Vessel injury-artery
- Extremity-upper)
Vessel Injury-artery (Vessel injury-artery
- Other NOS)
Vessel Injury-artery (Vessel injury-artery
- Visceral)
Vessel Injury-vein (Vessel injury-vein -
Extremity-lower)
Vessel Injury-vein (Vessel injury-vein -
Extremity-upper)
Vessel Injury-vein (Vessel injury-vein -
IVC)
Vessel Injury-vein (Vessel injury-vein -
Jugular)
Vessel Injury-vein (Vessel injury-vein -
Other NOS)
Vessel Injury-vein (Vessel injury-vein -
SVC)
Vessel Injury-vein (Vessel injury-vein -
Viscera)
Viral Hepatitis (Viral hepatitis)
Visceral Arterial Ischaemia (Visceral
arterial ischemia (non-myocardial))
Vision Blurred (Vision-blurred vision)
Photopsia (Vision-flashing lights/floaters)
Photophobia (Vision-photophobia)
Vital Capacity (Vital capacity)
Vitreous Hemorrhage (Vitreous
hemorrhage)
Dysphonia (Voice changes/dysarthria
(e.g., hoarseness, loss or alteration in
voice, laryngitis))
Vomiting Nos (Vomiting)
Lacrimation Increased (Watery eye
(epiphora, tearing))
Weight Increased (Weight gain)
Weight Decreased (Weight loss)
Culture Wound Negative (Wound
complication, non-infectious)
CTC AE Grade
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CTCAE Begin Date
Adverse Event Reporting to Date
CTC Adverse Event Attribution (Attribution to
Protocol Treatment See protocol sections 6 & 7
for definition of "protocol treatment")
Definite (Definite)
Possible (Possible)
Probable (Probable)
Unlikely (Unlikely)
Unrelated (Unrelated)
Has an AdEERS been filed
No (No)
Unknown (Unknown)
Yes (Yes)
Was this SAE per NCI definitions
Yes
No
Is there a reasonable possibility that the event
may have been caused by the investigational
agent
No (No)
Unknown (Unknown)
Yes (Yes)
Action taken regarding study therapy
Dose Delayed/omitted (Dose
delayed/omitted)
Dose Reduced (Dose reduced)
Agent Stopped (Dose stopped)
Drug Discontinued (Drug discontinued)
Iv Rate Decreased (IV rate decreased)
No Dose Modification (No dose
modification)
Treatment required
Concomitant Medication (Concomitant
medication)
No Treatment Administered (None)
Surgical Procedure (Procedural Surgery)
Present Status
Not Recovered Or Not Resolved (Not
recovered/Not resolved)
Recovered Or Resolved With Sequelae
(Recovered/Resolved with Sequelae)
Recovered Or Resolved Without
Sequelae (Recovered/Resolved without
Sequelae)
Recovering Or Resolving
(Recovering/Resolving)
Report All Continuing Or New Adverse
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Events
New or continuing adverse events
No (No)
Unknown (Unknown)
Yes (Yes)
MedDRA Code
CTC AE Term
Acidosis Nos (Acidosis (metabolic or
respiratory))
Capillary Leak Syndrome (Acute
vascular leak syndrome)
Adrenal Insufficiency (Adrenal
insufficiency)
Adult Respiratory Distress Syndrome
(Adult respiratory distress syndrome
(ARDS))
Blood Albumin Decreased (Albumin,
serum-low (hypoalbuminemia))
Alcohol Intolerance Syndrome
(antabuse-like Syndrome) (Alcohol
intolerance syndrome (antabuse-like
syndrome))
Blood Alkaline Phosphatase Nos
Increased (Alkaline phosphatase)
Alkalosis Nos (Alkalosis (metabolic or
respiratory))
Hypersensitivity Nos (Allergic
reaction/hypersensitivity (including drug
fever))
Rhinitis Allergic Nos (Allergic rhinitis
(including sneezing, nasal stuffiness,
postnasal drip))
Allergy/immunology Other
(Allergy/Immunology-Other (Specify))
Alanine Aminotransferase Increased
(ALT, SGPT (serum glutamic pyruvic
transaminase))
Blood Amylase Increased (Amylase)
Anorexia (Anorexia)
Apnoea (Apnea)
Arachnoiditis
(Arachnoiditis/meningismus/radiculitis)
Arthritis Nos (Arthritis (non-septic))
Ascites (Ascites (non-malignant))
Aspiration (Aspiration)
Aspartate Aminotransferase Increased
(AST, SGOT (serum glutamic oxaloacetic
transaminase))
Ataxia Nec (Ataxia (incoordination))
Atelectasis (Atelectasis)
Atrophy, Skin (Atrophy, skin)
Atrophy, Subcutaneous Fat (Atrophy,
subcutaneous fat)
Auditory/ear Other (Auditory/Ear-Other
(Specify))
Autoimmune Disorder Nos (Autoimmune
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reaction)
Blood Bicarbonate Decreased
(Bicarbonate, serum-low)
Blood Bilirubin Increased (Bilirubin
(hyperbilirubinemia))
Bladder Disorder Nos (Bladder spasms)
Blood/bone Marrow Other (Blood/Bone
Marrow-Other (Specify))
Bone Age (alteration In Bone Age) (Bone
age (alteration in bone age))
Bone Growth: Femoral Head; Slipped
Capital Femoral Epiphysis (Bone growth:
femoral head; slipped capital femoral
epiphysis)
Bone Growth: Limb Length Discrepancy
(Bone growth: limb length discrepancy)
Bone Growth: Spine Kyphosis/lordosis
(Bone growth: spine kyphosis/lordosis)
Bone Marrow Depression Nos (Bone
marrow cellularity)
Bone: Spine-scoliosis (Bone: spine-
scoliosis)
Brachial Plexopathy (Brachial
plexopathy)
Breast Function/lactation (Breast
function/lactation)
Breast Nipple/areolar Deformity (Breast
nipple/areolar deformity)
Breast Volume/hypoplasia (Breast
volume/hypoplasia)
Bronchospasm, Wheezing
(Bronchospasm, wheezing)
Ecchymosis (Bruising (in absence of
grade 3 or 4 thrombocytopenia))
Burn (Burn)
Hypercalcaemia (Calcium, serum-high
(hypercalcemia))
Hypocalcaemia (Calcium, serum-low
(hypocalcemia))
Pulmonary Function Test Nos Decreased
(Carbon monoxide diffusion capacity
(DL(co)))
Arrhythmia Nos (Cardiac Arrhythmia-
Other (Specify))
Cardiac General Other (Cardiac
General-Other (Specify))
Myocardial Ischaemia (Cardiac
ischemia/infarction)
Cardiac Troponin I Increased (Cardiac
troponin I (cTnI))
Cardiac Troponin T Increased (Cardiac
troponin T (cTnT))
Cardiopulmonary Arrest, Cause
Unknown (non-fatal) (Cardiopulmonary
arrest, cause unknown (non-fatal))
Cataract Nec (Cataract)
Cd4 Lymphocytes Decreased (CD4
count)
Cervical Spine-range Of Motion (Cervical
spine-range of motion)
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Chelitis (Cheilitis)
Cholecystitis (Cholecystitis)
Hypercholesteraemia (Cholesterol,
serum-high (hypercholesteremia))
Chyle Or Lymph Leakage (Chyle or
lymph leakage)
Chylothorax (Chylothorax)
Cerebral Ischaemia (CNS
cerebrovascular ischemia)
Cns Necrosis/cystic Progression (CNS
necrosis/cystic progression)
Coagulation Disorder Nos (Coagulation-
Other (Specify))
Learning Disorder Nos (Cognitive
disturbance)
Colitis Nos (Colitis)
Colitis, Infectious (e.g., Clostridium
Difficile) (Colitis, infectious (e.g.,
Clostridium difficile))
Ventricular Asystole (Conduction
abnormality/Atrioventricular heart block -
Asystole)
Conduction Abnormality/atrioventricular
Heart Block (Conduction
abnormality/Atrioventricular heart block -
AV block-first degree)
Conduction Abnormality/atrioventricular
Heart Block - Av Block-second Degree
Mobitz Type I (wenckebach) (Conduction
abnormality/Atrioventricular heart block -
AV block-Second degree Mobitz Type I
(Wenckebach))
Conduction Abnormality/atrioventricular
Heart Block (Conduction
abnormality/Atrioventricular heart block -
AV block-second degree Mobitz Type II)
Conduction Abnormality/atrioventricular
Heart Block (Conduction
abnormality/Atrioventricular heart block -
AV block-third degree (complete AV
block))
Conduction Abnormality/atrioventricular
Heart Block (Conduction
abnormality/Atrioventricular heart block -
Conduction abnormality NOS)
Conduction Abnormality/atrioventricular
Heart Block (Conduction
abnormality/Atrioventricular heart block -
Sick sinus syndrome)
Conduction Abnormality/atrioventricular
Heart Block (Conduction
abnormality/Atrioventricular heart block -
Stokes-Adams syndrome)
Conduction Abnormality/atrioventricular
Heart Block (Conduction
abnormality/Atrioventricular heart block -
Wolff-Parkinson-White syndrome)
Confusion (Confusion)
Constipation (Constipation)
Constitutional Symptoms Other
51 / 93
NCT00655876 F1: Radiation Therapy Oncology Group Phase III
Esophagus Followup Form
(Constitutional Symptoms-Other
(Specify))
Cough (Cough)
Blood Creatine Phosphokinase
Increased (CPK (creatine
phosphokinase))
Blood Creatinine Increased (Creatinine)
Cushingoid (Cushingoid appearance
(e.g., moon face, buffalo hump,
centripetal obesity, cutaneous striae))
Cystitis (Cystitis)
Cytokine Release Syndrome/acute
Infusion Reaction (Cytokine release
syndrome/acute infusion reaction)
Death Not Associated With Ctcae Term
(Death not associated with CTCAE term
- Death NOS)
Death Not Associated With Ctcae Term
(Death not associated with CTCAE term
- Disease progression NOS)
Death Not Associated With Ctcae Term
(Death not associated with CTCAE term
- Multi-organ failure)
Death Not Associated With Ctcae Term
(Death not associated with CTCAE term
- Sudden death)
Dehydration (Dehydration)
Dental: Dentures Or Prosthesis (Dental:
dentures or prosthesis)
Dental: Periodontal Disease (Dental:
periodontal disease)
Dental: Teeth (Dental: teeth)
Dental: Teeth Development (Dental:
teeth development)
Dermal Change Lymphedema,
Phlebolymphedema (Dermal change
lymphedema, phlebolymphedema)
Dermatology/skin Other
(Dermatology/Skin-Other (Specify))
Diarrhoea Nos (Diarrhea)
Disseminated Intravascular Coagulation
(DIC (disseminated intravascular
coagulation))
Distention/bloating, Abdominal
(Distention/bloating, abdominal)
Dizziness (exc Vertigo) (Dizziness)
Dry Eye Nec (Dry eye syndrome)
Dry Mouth (Dry mouth/salivary gland
(xerostomia))
Dry Skin (Dry skin)
Dysphagia (Dysphagia (difficulty
swallowing))
Dyspnoea Nos (Dyspnea (shortness of
breath))
Edema, Larynx (Edema, larynx)
Edema: Head And Neck (Edema: head
and neck)
Oedema Nos (Edema: limb)
Edema: Trunk/genital (Edema:
trunk/genital)
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Edema: Viscera (Edema: viscera)
Ejaculatory Dysfunction (Ejaculatory
dysfunction)
Encephalopathy (Encephalopathy)
Endocrine Other (Endocrine-Other
(Specify))
Enteritis (inflammation Of The Small
Bowel) (Enteritis (inflammation of the
small bowel))
Impotence (Erectile dysfunction)
Oesophagitis Nos (Esophagitis)
Exostosis (Exostosis)
Extrapyramidal Disorder Nec
(Extrapyramidal/involuntary
movement/restlessness)
Extremity-lower (gait/walking) (Extremity-
lower (gait/walking))
Extremity-upper (function) (Extremity-
upper (function))
Eyelid Dysfunction (Eyelid dysfunction)
Fatigue (Fatigue (asthenia, lethargy,
malaise))
Febrile Neutropenia (fever Of Unknown
Origin Without Clinically Or
Microbiologically Documented Infection)
(anc <1.0 X 10^9/l, Fever >=38.5
Degrees C) (Febrile neutropenia)
Feminization (Feminization of male)
Forced Expiratory Volume Decreased
(FEV(1))
Pyrexia (Fever (in the absence of
neutropenia, where neutropenia is
defined as ANC <1.0 x 10^9/L))
Blood Fibrinogen Decreased
(Fibrinogen)
Fibrosis-cosmesis (Fibrosis-cosmesis)
Fibrosis-deep Connective Tissue
(Fibrosis-deep connective tissue)
Fistula, Gi (Fistula, GI - Abdomen NOS)
Anal Fistula (Fistula, GI - Anus)
Fistula, Gi (Fistula, GI - Biliary tree)
Fistula, Gi (Fistula, GI -
Colon/cecum/appendix)
Intestinal Fistula (Fistula, GI -
Duodenum)
Tracheo-oesophageal Fistula Nos
(Fistula, GI - Esophagus)
Fistula, Gi (Fistula, GI - Gallbladder)
Fistula, Gi (Fistula, GI - Ileum)
Fistula, Gi (Fistula, GI - Jejunum)
Fistula, Gi (Fistula, GI - Oral cavity)
Fistula, Gi (Fistula, GI - Pancreas)
Fistula, Gi (Fistula, GI - Pharynx)
Fistula, Gi (Fistula, GI - Rectum)
Fistula, Gi (Fistula, GI - Salivary gland)
Fistula, Gi (Fistula, GI - Small bowel
NOS)
Fistula, Gi (Fistula, GI - Stomach)
Fistula, Gu (Fistula, GU - Bladder)
Fistula, Gu (Fistula, GU - Genital tract-
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female)
Fistula, Gu (Fistula, GU - Kidney)
Fistula, Gu (Fistula, GU - Ureter)
Fistula, Gu (Fistula, GU - Urethra)
Fistula, Gu (Fistula, GU - Uterus)
Urogenital Fistula (Fistula, GU - Vagina)
Fistula, Pulmonary/upper Respiratory
(Fistula, pulmonary/upper respiratory -
Bronchus)
Fistula, Pulmonary/upper Respiratory
(Fistula, pulmonary/upper respiratory -
Larynx)
Fistula, Pulmonary/upper Respiratory
(Fistula, pulmonary/upper respiratory -
Lung)
Fistula, Pulmonary/upper Respiratory
(Fistula, pulmonary/upper respiratory -
Oral cavity)
Fistula, Pulmonary/upper Respiratory
(Fistula, pulmonary/upper respiratory -
Pharynx)
Fistula, Pulmonary/upper Respiratory
(Fistula, pulmonary/upper respiratory -
Pleura)
Fistula, Pulmonary/upper Respiratory
(Fistula, pulmonary/upper respiratory -
Trachea)
Flatulence (Flatulence)
Flu-like Syndrome (Flu-like syndrome)
Flushing (Flushing)
Fracture (Fracture)
Gastritis Nos (Gastritis (including bile
reflux gastritis))
Gastrointestinal Other (Gastrointestinal-
Other (Specify))
Gamma-glutamyltransferase Increased
(GGT (gamma-glutamyl transpeptidase))
Glaucoma Nos (Glaucoma)
Glomerular Filtration Rate (Glomerular
filtration rate)
Hyperglycaemia Nos (Glucose, serum-
high (hyperglycemia))
Hypoglycaemia Nos (Glucose, serum-
low (hypoglycemia))
Growth And Development Other (Growth
and Development-Other (Specify))
Growth Velocity (reduction In Growth
Velocity) (Growth velocity (reduction in
growth velocity))
Gynaecomastia (Gynecomastia)
Alopecia (Hair loss/Alopecia (scalp or
body))
Haptoglobin Decreased (Haptoglobin)
Hearing: Patients With/without Baseline
Audiogram And Enrolled In A Monitoring
Program (Hearing: patients with/without
baseline audiogram and enrolled in a
monitoring program)
Hearing: Patients Without Baseline
Audiogram And Not Enrolled In A
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Monitoring Program (Hearing: patients
without baseline audiogram and not
enrolled in a monitoring program)
Dyspepsia (Heartburn/dyspepsia)
Hematoma (Hematoma)
Haemoglobin Decreased (Hemoglobin)
Haemoglobinuria Present
(Hemoglobinuria)
Hemolysis Nos (Hemolysis (e.g.,
immune hemolytic anemia, drug related
hemolysis))
Haemorrhagic Stroke (Hemorrhage,
CNS)
Melaena (Hemorrhage, GI - Abdomen
NOS)
Hemorrhage, Gi (Hemorrhage, GI -
Anus)
Hemorrhage, Gi (Hemorrhage, GI -
Biliary tree)
Hemorrhage, Gi (Hemorrhage, GI -
Cecum/appendix)
Hemorrhage, Gi (Hemorrhage, GI -
Colon)
Hemorrhage, Gi (Hemorrhage, GI -
Duodenum)
Hemorrhage, Gi (Hemorrhage, GI -
Esophagus)
Hemorrhage, Gi (Hemorrhage, GI -
Ileum)
Hemorrhage, Gi (Hemorrhage, GI -
Jejunum)
Hemorrhage, Gi (Hemorrhage, GI - Liver)
Hemorrhage, Gi (Hemorrhage, GI -
Lower GI NOS)
Hemorrhage, Gi (Hemorrhage, GI - Oral
cavity)
Hemorrhage, Gi (Hemorrhage, GI -
Pancreas)
Hemorrhage, Gi (Hemorrhage, GI -
Peritoneal cavity)
Rectal Bleeding (Hemorrhage, GI -
Rectum)
Hemorrhage, Gi (Hemorrhage, GI -
Stoma)
Haematemesis (Hemorrhage, GI -
Stomach)
Hemorrhage, Gi (Hemorrhage, GI -
Upper GI NOS)
Hemorrhage, Gi (Hemorrhage, GI -
Varices (esophageal))
Hemorrhage, Gi (Hemorrhage, GI -
Varices (rectal))
Hemorrhage, Gu (Hemorrhage, GU -
Bladder)
Hemorrhage, Gu (Hemorrhage, GU -
Fallopian tube)
Hemorrhage, Gu (Hemorrhage, GU -
Kidney)
Hemorrhage, Gu (Hemorrhage, GU -
Ovary)
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Hemorrhage, Gu (Hemorrhage, GU -
Prostate)
Hemorrhage, Gu (Hemorrhage, GU -
Retroperitoneum)
Hemorrhage, Gu (Hemorrhage, GU -
Spermatic cord)
Hemorrhage, Gu (Hemorrhage, GU -
Stoma)
Hemorrhage, Gu (Hemorrhage, GU -
Testes)
Hemorrhage, Gu (Hemorrhage, GU -
Ureter)
Hemorrhage, Gu (Hemorrhage, GU -
Urethra)
Haematuria Present (Hemorrhage, GU -
Urinary NOS)
Hemorrhage, Gu (Hemorrhage, GU -
Uterus)
Vaginal Haemorrhage (Hemorrhage, GU
- Vagina)
Hemorrhage, Gu (Hemorrhage, GU - Vas
deferens)
Hemorrhage, Pulmonary/upper
Respiratory (Hemorrhage,
pulmonary/upper respiratory -
Bronchopulmonary NOS)
Hemorrhage, Pulmonary/upper
Respiratory (Hemorrhage,
pulmonary/upper respiratory - Bronchus)
Hemorrhage, Pulmonary/upper
Respiratory (Hemorrhage,
pulmonary/upper respiratory - Larynx)
Hemorrhage, Pulmonary/upper
Respiratory (Hemorrhage,
pulmonary/upper respiratory - Lung)
Hemorrhage, Pulmonary/upper
Respiratory (Hemorrhage,
pulmonary/upper respiratory -
Mediastinum)
Epistaxis (Hemorrhage, pulmonary/upper
respiratory - Nose)
Hemorrhage, Pulmonary/upper
Respiratory (Hemorrhage,
pulmonary/upper respiratory - Pharynx)
Hemorrhage, Pulmonary/upper
Respiratory (Hemorrhage,
pulmonary/upper respiratory - Pleura)
Haemoptysis (Hemorrhage,
pulmonary/upper respiratory -
Respiratory tract NOS)
Hemorrhage, Pulmonary/upper
Respiratory (Hemorrhage,
pulmonary/upper respiratory - Stoma)
Hemorrhage, Pulmonary/upper
Respiratory (Hemorrhage,
pulmonary/upper respiratory - Trachea)
Post-operative Haemorrhage
(Hemorrhage/bleeding associated with
surgery, intra-operative or post-operative)
Hemorrhage/bleeding Other
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(Hemorrhage/Bleeding-Other (Specify))
Hemorrhoids (Hemorrhoids)
Hepatobiliary/pancreas Other
(Hepatobiliary/Pancreas-Other (Specify))
Hiccups (Hiccoughs (hiccups, singultus))
Menopausal Symptoms (Hot
flashes/flushes)
Hydrocephalus (Hydrocephalus)
Skin Discolouration (Hyperpigmentation)
Hypertension Nos (Hypertension)
Hypopigmentation (Hypopigmentation)
Hypotension Nos (Hypotension)
Hypothermia (Hypothermia)
Hypoxia (Hypoxia)
Ileus (Ileus, GI (functional obstruction of
bowel, i.e., neuroconstipation))
Incontinence, Anal (Incontinence, anal)
Urinary Incontinence (Incontinence,
urinary)
Induration/fibrosis (skin And
Subcutaneous Tissue)
(Induration/fibrosis (skin and
subcutaneous tissue))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Abdomen NOS)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Anal/perianal)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Appendix)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Artery)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Biliary tree)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Bladder (urinary))
Infection (documented Clinically Or
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Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Blood)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Bone (osteomyelitis))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Brain (encephalitis,
infectious))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Brain + Spinal cord
(encephalomyelitis))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Bronchus)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Catheter-related)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Cecum)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Cervix)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Colon)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
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neutrophils - Conjunctiva)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Cornea)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Dental-tooth)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Duodenum)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Esophagus)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - External ear (otitis externa))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Eye NOS)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Fallopian tube)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Foreign body (e.g., graft,
implant, prosthesis, stent))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Gallbladder (cholecystitis))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
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microbiologically) with Grade 3 or 4
neutrophils - Heart (endocarditis))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Ileum)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Jejunum)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Joint)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Kidney)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Larynx)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Lens)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Lip/perioral)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Liver)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Lung (pneumonia))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
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microbiologically) with Grade 3 or 4
neutrophils - Lymphatic)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Mediastinum NOS)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Meninges (meningitis))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Middle ear (otitis media))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Mucosa)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Muscle (infection myositis))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Neck NOS)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Nerve-cranial)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Nerve-peripheral)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Nose)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
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microbiologically) with Grade 3 or 4
neutrophils - Oral cavity-gums
(gingivitis))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Pancreas)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Paranasal)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Pelvis NOS)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Penis)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Peristomal)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Peritoneal cavity)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Pharynx)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Pleura (empyema))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Prostate)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
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(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Rectum)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Salivary gland)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Scrotum)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Sinus)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Skin (cellulitis))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Small bowel NOS)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Soft tissue NOS)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Spinal cord (myelitis))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Spleen)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Stomach)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
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(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Trachea)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Ungual (nails))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Upper aerodigestive NOS)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Upper airway NOS)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Ureter)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Urethra)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Urinary tract NOS)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Uterus)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Vagina)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Vein)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
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(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Vulva)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Wound)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Abdomen
NOS)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils -
Anal/perianal)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Appendix)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Artery)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Biliary tree)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Bladder
(urinary))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Blood)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Bone
(osteomyelitis))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Brain
(encephalitis, infectious))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Brain +
Spinal cord (encephalomyelitis))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Bronchus)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Catheter-
related)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Cecum)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Cervix)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
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or Grade 1 or 2 neutrophils - Colon)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils -
Conjunctiva)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Cornea)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Dental-
tooth)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Duodenum)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Esophagus)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - External ear
(otitis externa))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Eye NOS)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Fallopian
tube)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Foreign
body (e.g., graft, implant, prosthesis,
stent))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Gallbladder
(cholecystitis))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Heart
(endocarditis))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Ileum)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Jejunum)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Joint)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Kidney)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Larynx)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Lens)
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Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Lip/perioral)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Liver)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Lung
(pneumonia))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Lymphatic)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils -
Mediastinum NOS)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Meninges
(meningitis))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Middle ear
(otitis media))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Mucosa)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Muscle
(infection myositis))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Neck NOS)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Nerve-
cranial)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Nerve-
peripheral)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Nose)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Oral cavity-
gums (gingivitis))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Pancreas)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Paranasal)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Pelvis NOS)
Infection With Normal Anc Or Grade 1 Or
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2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Penis)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Peristomal)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Peritoneal
cavity)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Pharynx)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Pleura
(empyema))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Prostate)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Rectum)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Salivary
gland)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Scrotum)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Sinus)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Skin
(cellulitis))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Small bowel
NOS)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Soft tissue
NOS)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Spinal cord
(myelitis))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Spleen)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Stomach)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Trachea)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Ungual
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(nails))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Upper
aerodigestive NOS)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Upper
airway NOS)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Ureter)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Urethra)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Urinary
tract NOS)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Uterus)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Vagina)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Vein)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Vulva)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Wound)
Infection With Unknown Anc (Infection
with unknown ANC - Abdomen NOS)
Infection With Unknown Anc (Infection
with unknown ANC - Anal/perianal)
Infection With Unknown Anc (Infection
with unknown ANC - Appendix)
Infection With Unknown Anc (Infection
with unknown ANC - Artery)
Infection With Unknown Anc (Infection
with unknown ANC - Biliary tree)
Infection With Unknown Anc (Infection
with unknown ANC - Bladder (urinary))
Infection With Unknown Anc (Infection
with unknown ANC - Blood)
Infection With Unknown Anc (Infection
with unknown ANC - Bone
(osteomyelitis))
Infection With Unknown Anc (Infection
with unknown ANC - Brain (encephalitis,
infectious))
Infection With Unknown Anc (Infection
with unknown ANC - Brain + Spinal cord
(encephalomyelitis))
Infection With Unknown Anc (Infection
with unknown ANC - Bronchus)
Implant Infection (Infection with unknown
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ANC - Catheter-related)
Infection With Unknown Anc (Infection
with unknown ANC - Cecum)
Infection With Unknown Anc (Infection
with unknown ANC - Cervix)
Infection With Unknown Anc (Infection
with unknown ANC - Colon)
Infection With Unknown Anc (Infection
with unknown ANC - Conjunctiva)
Infection With Unknown Anc (Infection
with unknown ANC - Cornea)
Infection With Unknown Anc (Infection
with unknown ANC - Dental-tooth)
Infection With Unknown Anc (Infection
with unknown ANC - Duodenum)
Infection With Unknown Anc (Infection
with unknown ANC - Esophagus)
Infection With Unknown Anc (Infection
with unknown ANC - External ear (otitis
externa))
Infection With Unknown Anc (Infection
with unknown ANC - Eye NOS)
Infection With Unknown Anc (Infection
with unknown ANC - Fallopian tube)
Infection With Unknown Anc (Infection
with unknown ANC - Foreign body (e.g.,
graft, implant, prosthesis, stent))
Infection With Unknown Anc (Infection
with unknown ANC - Gallbladder
(cholecystitis))
Infection With Unknown Anc (Infection
with unknown ANC - Heart
(endocarditis))
Infection With Unknown Anc (Infection
with unknown ANC - Ileum)
Infection With Unknown Anc (Infection
with unknown ANC - Jejunum)
Infection With Unknown Anc (Infection
with unknown ANC - Joint)
Infection With Unknown Anc (Infection
with unknown ANC - Kidney)
Infection With Unknown Anc (Infection
with unknown ANC - Larynx)
Infection With Unknown Anc (Infection
with unknown ANC - Lens)
Infection With Unknown Anc (Infection
with unknown ANC - Lip/perioral)
Infection With Unknown Anc (Infection
with unknown ANC - Liver)
Infection With Unknown Anc (Infection
with unknown ANC - Lung (pneumonia))
Infection With Unknown Anc (Infection
with unknown ANC - Lymphatic)
Infection With Unknown Anc (Infection
with unknown ANC - Mediastinum NOS)
Infection With Unknown Anc (Infection
with unknown ANC - Meninges
(meningitis))
Infection With Unknown Anc (Infection
with unknown ANC - Middle ear (otitis
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media))
Infection With Unknown Anc (Infection
with unknown ANC - Mucosa)
Infection With Unknown Anc (Infection
with unknown ANC - Muscle (infection
myositis))
Infection With Unknown Anc (Infection
with unknown ANC - Neck NOS)
Infection With Unknown Anc (Infection
with unknown ANC - Nerve-cranial)
Infection With Unknown Anc (Infection
with unknown ANC - Nerve-peripheral)
Infection With Unknown Anc (Infection
with unknown ANC - Nose)
Infection With Unknown Anc (Infection
with unknown ANC - Oral cavity-gums
(gingivitis))
Infection With Unknown Anc (Infection
with unknown ANC - Pancreas)
Infection With Unknown Anc (Infection
with unknown ANC - Paranasal)
Infection With Unknown Anc (Infection
with unknown ANC - Pelvis NOS)
Infection With Unknown Anc (Infection
with unknown ANC - Penis)
Infection With Unknown Anc (Infection
with unknown ANC - Peristomal)
Infection With Unknown Anc (Infection
with unknown ANC - Peritoneal cavity)
Infection With Unknown Anc (Infection
with unknown ANC - Pharynx)
Infection With Unknown Anc (Infection
with unknown ANC - Pleura (empyema))
Infection With Unknown Anc (Infection
with unknown ANC - Prostate)
Infection With Unknown Anc (Infection
with unknown ANC - Rectum)
Infection With Unknown Anc (Infection
with unknown ANC - Salivary gland)
Infection With Unknown Anc (Infection
with unknown ANC - Scrotum)
Infection With Unknown Anc (Infection
with unknown ANC - Sinus)
Infection With Unknown Anc (Infection
with unknown ANC - Skin (cellulitis))
Infection With Unknown Anc (Infection
with unknown ANC - Small bowel NOS)
Infection With Unknown Anc (Infection
with unknown ANC - Soft tissue NOS)
Infection With Unknown Anc (Infection
with unknown ANC - Spinal cord
(myelitis))
Infection With Unknown Anc (Infection
with unknown ANC - Spleen)
Infection With Unknown Anc (Infection
with unknown ANC - Stomach)
Infection With Unknown Anc (Infection
with unknown ANC - Trachea)
Infection With Unknown Anc (Infection
with unknown ANC - Ungual (nails))
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Infection With Unknown Anc (Infection
with unknown ANC - Upper aerodigestive
NOS)
Infection With Unknown Anc (Infection
with unknown ANC - Upper airway NOS)
Infection With Unknown Anc (Infection
with unknown ANC - Ureter)
Infection With Unknown Anc (Infection
with unknown ANC - Urethra)
Infection With Unknown Anc (Infection
with unknown ANC - Urinary tract NOS)
Infection With Unknown Anc (Infection
with unknown ANC - Uterus)
Infection With Unknown Anc (Infection
with unknown ANC - Vagina)
Infection With Unknown Anc (Infection
with unknown ANC - Vein)
Infection With Unknown Anc (Infection
with unknown ANC - Vulva)
Culture Wound Positive (Infection with
unknown ANC - Wound)
Infection Nos (Infection-Other (Specify))
Infertility/sterility (Infertility/sterility)
Injection Site Reaction Nos (Injection site
reaction/extravasation changes)
Prothrombin Time Prolonged (INR
(International Normalized Ratio of
prothrombin time))
Insomnia Nec (Insomnia)
Intra-operative Injury (Intra-operative
injury - Abdomen NOS)
Intra-operative Injury (Intra-operative
injury - Adrenal gland)
Intra-operative Injury (Intra-operative
injury - Anal sphincter)
Intra-operative Injury (Intra-operative
injury - Anus)
Intra-operative Injury (Intra-operative
injury - Appendix)
Intra-operative Injury (Intra-operative
injury - Artery NOS)
Intra-operative Injury (Intra-operative
injury - Artery-aorta)
Intra-operative Injury (Intra-operative
injury - Artery-carotid)
Intra-operative Injury (Intra-operative
injury - Artery-cerebral)
Intra-operative Injury (Intra-operative
injury - Artery-extremity (lower))
Intra-operative Injury (Intra-operative
injury - Artery-extremity (upper))
Intra-operative Injury (Intra-operative
injury - Artery-hepatic)
Intra-operative Injury (Intra-operative
injury - Artery-major visceral artery)
Intra-operative Injury (Intra-operative
injury - Artery-pulmonary)
Intra-operative Injury (Intra-operative
injury - Biliary tree NOS)
Intra-operative Injury (Intra-operative
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injury - Biliary tree-common bile duct)
Intra-operative Injury (Intra-operative
injury - Biliary tree-common hepatic duct)
Intra-operative Injury (Intra-operative
injury - Biliary tree-left hepatic duct)
Intra-operative Injury (Intra-operative
injury - Biliary tree-right hepatic duct)
Bladder Perforation Postoperative (Intra-
operative injury - Bladder)
Intra-operative Injury (Intra-operative
injury - Bone)
Intra-operative Injury (Intra-operative
injury - Brachial plexus)
Intra-operative Injury (Intra-operative
injury - Brain)
Intra-operative Injury (Intra-operative
injury - Breast)
Intra-operative Injury (Intra-operative
injury - Bronchus)
Intra-operative Injury (Intra-operative
injury - Cartilage)
Intra-operative Injury (Intra-operative
injury - Cecum)
Intra-operative Injury (Intra-operative
injury - Cervix)
Intra-operative Injury (Intra-operative
injury - CN I (olfactory))
Intra-operative Injury (Intra-operative
injury - CN II (optic))
Intra-operative Injury (Intra-operative
injury - CN III (oculomotor))
Intra-operative Injury (Intra-operative
injury - CN IV (trochlear))
Intra-operative Injury (Intra-operative
injury - CN IX (glossopharyngeal) motor
pharynx)
Intra-operative Injury (Intra-operative
injury - CN IX (glossopharyngeal)
sensory ear-pharynx-tongue)
Intra-operative Injury (Intra-operative
injury - CN V (trigeminal) motor)
Intra-operative Injury (Intra-operative
injury - CN V (trigeminal) sensory)
Intra-operative Injury (Intra-operative
injury - CN VI (abducens))
Intra-operative Injury (Intra-operative
injury - CN VII (facial) motor-face)
Intra-operative Injury (Intra-operative
injury - CN VII (facial) sensory-taste)
Intra-operative Injury (Intra-operative
injury - CN VIII (vestibulocochlear))
Intra-operative Injury (Intra-operative
injury - CN X (vagus))
Intra-operative Injury (Intra-operative
injury - CN XI (spinal accessory))
Intra-operative Injury (Intra-operative
injury - CN XII (hypoglossal))
Intra-operative Injury (Intra-operative
injury - Colon)
Intra-operative Injury (Intra-operative
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injury - Conjunctiva)
Intra-operative Injury (Intra-operative
injury - Cornea)
Intra-operative Injury (Intra-operative
injury - Cranial nerve or branch NOS)
Intra-operative Injury (Intra-operative
injury - Duodenum)
Intra-operative Injury (Intra-operative
injury - Esophagus)
Intra-operative Injury (Intra-operative
injury - Extremity-lower)
Intra-operative Injury (Intra-operative
injury - Extremity-upper)
Intra-operative Injury (Intra-operative
injury - Eye NOS)
Intra-operative Injury (Intra-operative
injury - Face NOS)
Intra-operative Injury (Intra-operative
injury - Fallopian tube)
Intra-operative Injury (Intra-operative
injury - Gallbladder)
Intra-operative Injury (Intra-operative
injury - Gingiva)
Intra-operative Injury (Intra-operative
injury - Heart)
Intra-operative Injury (Intra-operative
injury - Ileum)
Intra-operative Injury (Intra-operative
injury - Inner ear)
Intra-operative Injury (Intra-operative
injury - Jejunum)
Intra-operative Injury (Intra-operative
injury - Joint)
Intra-operative Injury (Intra-operative
injury - Kidney)
Intra-operative Injury (Intra-operative
injury - Larynx)
Intra-operative Injury (Intra-operative
injury - Lens)
Intra-operative Injury (Intra-operative
injury - Ligament)
Intra-operative Injury (Intra-operative
injury - Lingual)
Intra-operative Injury (Intra-operative
injury - Lip/perioral area)
Intra-operative Injury (Intra-operative
injury - Liver)
Intra-operative Injury (Intra-operative
injury - Lung)
Intra-operative Injury (Intra-operative
injury - Lung thoracic)
Intra-operative Injury (Intra-operative
injury - Mediastinum)
Intra-operative Injury (Intra-operative
injury - Meninges)
Intra-operative Injury (Intra-operative
injury - Middle ear)
Intra-operative Injury (Intra-operative
injury - Muscle)
Intra-operative Injury (Intra-operative
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injury - Nails)
Intra-operative Injury (Intra-operative
injury - Nasal cavity)
Intra-operative Injury (Intra-operative
injury - Nasopharynx)
Intra-operative Injury (Intra-operative
injury - Neck NOS)
Intra-operative Injury (Intra-operative
injury - Nose)
Intra-operative Injury (Intra-operative
injury - Oral)
Intra-operative Injury (Intra-operative
injury - Oral cavity NOS)
Intra-operative Injury (Intra-operative
injury - Outer ear NOS)
Intra-operative Injury (Intra-operative
injury - Outer ear-pinna)
Intra-operative Injury (Intra-operative
injury - Ovary)
Intra-operative Injury (Intra-operative
injury - Pancreas)
Intra-operative Injury (Intra-operative
injury - Pancreatic duct)
Intra-operative Injury (Intra-operative
injury - Parathyroid)
Intra-operative Injury (Intra-operative
injury - Parotid gland)
Intra-operative Injury (Intra-operative
injury - Pelvis NOS)
Intra-operative Injury (Intra-operative
injury - Penis)
Intra-operative Injury (Intra-operative
injury - Peripheral motor NOS)
Intra-operative Injury (Intra-operative
injury - Peripheral sensory NOS)
Intra-operative Injury (Intra-operative
injury - Peritoneal cavity)
Intra-operative Injury (Intra-operative
injury - Pharynx)
Intra-operative Injury (Intra-operative
injury - Pituitary)
Intra-operative Injury (Intra-operative
injury - Pleura)
Intra-operative Injury (Intra-operative
injury - Prostate)
Intra-operative Injury (Intra-operative
injury - Rectum)
Intra-operative Injury (Intra-operative
injury - Recurrent laryngeal)
Intra-operative Injury (Intra-operative
injury - Retina)
Intra-operative Injury (Intra-operative
injury - Sacral plexus)
Intra-operative Injury (Intra-operative
injury - Salivary duct)
Intra-operative Injury (Intra-operative
injury - Salivary gland)
Intra-operative Injury (Intra-operative
injury - Sciatic)
Intra-operative Injury (Intra-operative
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injury - Scrotum)
Intra-operative Injury (Intra-operative
injury - Sinus)
Intra-operative Injury (Intra-operative
injury - Skin)
Intra-operative Injury (Intra-operative
injury - Small bowel NOS)
Intra-operative Injury (Intra-operative
injury - Soft tissue NOS)
Intra-operative Injury (Intra-operative
injury - Spinal cord)
Intra-operative Injury (Intra-operative
injury - Spleen)
Intra-operative Injury (Intra-operative
injury - Stoma (GI))
Intra-operative Injury (Intra-operative
injury - Stomach)
Intra-operative Injury (Intra-operative
injury - Teeth)
Intra-operative Injury (Intra-operative
injury - Tendon)
Intra-operative Injury (Intra-operative
injury - Testis)
Intra-operative Injury (Intra-operative
injury - Thoracic duct)
Intra-operative Injury (Intra-operative
injury - Thoracodorsal)
Intra-operative Injury (Intra-operative
injury - Thyroid)
Intra-operative Injury (Intra-operative
injury - Tongue)
Intra-operative Injury (Intra-operative
injury - Trachea)
Intra-operative Injury (Intra-operative
injury - Upper aerodigestive NOS)
Intra-operative Injury (Intra-operative
injury - Upper airway NOS)
Intra-operative Injury (Intra-operative
injury - Ureter)
Intra-operative Injury (Intra-operative
injury - Urethra)
Intra-operative Injury (Intra-operative
injury - Urinary conduit)
Intra-operative Injury (Intra-operative
injury - Urinary tract NOS)
Intra-operative Injury (Intra-operative
injury - Uterus)
Intra-operative Injury (Intra-operative
injury - Vagina)
Intra-operative Injury - Vein (Intra-
operative injury - Vein NOS)
Intra-operative Injury (Intra-operative
injury - Vein-extremity (lower))
Intra-operative Injury (Intra-operative
injury - Vein-extremity (upper))
Intra-operative Injury (Intra-operative
injury - Vein-hepatic)
Intra-operative Injury (Intra-operative
injury - Vein-inferior vena cava)
Intra-operative Injury (Intra-operative
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injury - Vein-jugular)
Intra-operative Injury (Intra-operative
injury - Vein-major visceral vein)
Intra-operative Injury (Intra-operative
injury - Vein-portal vein)
Intra-operative Injury (Intra-operative
injury - Vein-pulmonary)
Intra-operative Injury (Intra-operative
injury - Vein-superior vena cava)
Intra-operative Injury (Intra-operative
injury - Vulva)
Intra-operative Injury Other (Intra-
operative Injury-Other (Specify))
Iron Overload (Iron overload)
Menstruation Irregular (Irregular menses
(change from baseline))
Irritability (Irritability (children <3 years of
age))
Joint-effusion (Joint-effusion)
Joint-effusion (Joint-function)
Keratitis Nec (Keratitis (corneal
inflammation/corneal ulceration))
Laryngeal Nerve Dysfunction (Laryngeal
nerve dysfunction)
Leak (including Anastomotic), Gi (Leak
(including anastomotic), GI - Biliary tree)
Leak (including Anastomotic), Gi (Leak
(including anastomotic), GI - Esophagus)
Leak (including Anastomotic), Gi (Leak
(including anastomotic), GI - Large
bowel)
Leak (including Anastomotic), Gi (Leak
(including anastomotic), GI - Leak NOS)
Leak (including Anastomotic), Gi (Leak
(including anastomotic), GI - Pancreas)
Leak (including Anastomotic), Gi (Leak
(including anastomotic), GI - Pharynx)
Leak (including Anastomotic), Gi (Leak
(including anastomotic), GI - Rectum)
Leak (including Anastomotic), Gi (Leak
(including anastomotic), GI - Small
bowel)
Leak (including Anastomotic), Gi (Leak
(including anastomotic), GI - Stoma)
Leak (including Anastomotic), Gi (Leak
(including anastomotic), GI - Stomach)
Leak (including Anastomotic), Gu (Leak
(including anastomotic), GU - Bladder)
Leak (including Anastomotic), Gu (Leak
(including anastomotic), GU - Fallopian
tube)
Leak (including Anastomotic), Gu (Leak
(including anastomotic), GU - Kidney)
Leak (including Anastomotic), Gu (Leak
(including anastomotic), GU - Spermatic
cord)
Leak (including Anastomotic), Gu (Leak
(including anastomotic), GU - Stoma)
Leak (including Anastomotic), Gu (Leak
(including anastomotic), GU - Ureter)
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Leak (including Anastomotic), Gu (Leak
(including anastomotic), GU - Urethra)
Leak (including Anastomotic), Gu (Leak
(including anastomotic), GU - Uterus)
Leak (including Anastomotic), Gu (Leak
(including anastomotic), GU - Vagina)
Leak (including Anastomotic), Gu (Leak
(including anastomotic), GU - Vas
deferens)
Leak, Cerebrospinal Fluid (csf) (Leak,
cerebrospinal fluid (CSF))
Left Ventricular Diastolic Dysfunction
(Left ventricular diastolic dysfunction)
Left Ventricular Failure (Left ventricular
systolic dysfunction)
Leucopenia Nos (Leukocytes (total
WBC))
Encephalopathy Nos
(Leukoencephalopathy (radiolographic
findings))
Libido Decreased (Libido)
Lipase Increased (Lipase)
Hepatic Failure (Liver dysfunction/failure
(clinical))
Local Complication - Device/prosthesis-
related (Local complication -
device/prosthesis-related)
Lumbar Spine-range Of Motion (Lumbar
spine-range of motion)
Lymphatics Other (Lymphatics-Other
(Specify))
Lymphedema-related Fibrosis
(Lymphedema-related fibrosis)
Lymphocele (Lymphocele)
Lymphopenia (Lymphopenia)
Hypermagnesaemia (Magnesium,
serum-high (hypermagnesemia))
Blood Magnesium Decreased
(Magnesium, serum-low
(hypomagnesemia))
Malabsorption (Malabsorption)
Virilism (Masculinization of female)
Amnesia Nec (Memory impairment)
Mental Status (Mental status)
Metabolic/laboratory Other
(Metabolic/Laboratory-Other (Specify))
Mood Alteration - Agitation (Mood
alteration - agitation)
Anxiety Nec (Mood alteration - anxiety)
Depression Nec (Mood alteration -
depression)
Euphoric Mood (Mood alteration -
euphoria)
Mucositis/stomatitis (clinical Exam)
(Mucositis/stomatitis (clinical exam) -
Anus)
Mucositis/stomatitis (clinical Exam)
(Mucositis/stomatitis (clinical exam) -
Esophagus)
Mucositis/stomatitis (clinical Exam)
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(Mucositis/stomatitis (clinical exam) -
Large bowel)
Mucositis/stomatitis (clinical Exam)
(Mucositis/stomatitis (clinical exam) -
Larynx)
Mucositis/stomatitis (clinical Exam)
(Mucositis/stomatitis (clinical exam) -
Oral cavity)
Stomatitis (Mucositis/stomatitis (clinical
exam) - Pharynx)
Mucositis/stomatitis (clinical Exam)
(Mucositis/stomatitis (clinical exam) -
Rectum)
Mucositis/stomatitis (clinical Exam)
(Mucositis/stomatitis (clinical exam) -
Small bowel)
Mucositis/stomatitis (clinical Exam)
(Mucositis/stomatitis (clinical exam) -
Stomach)
Mucositis/stomatitis (clinical Exam)
(Mucositis/stomatitis (clinical exam) -
Trachea)
Mucositis/stomatitis
(functional/symptomatic)
(Mucositis/stomatitis
(functional/symptomatic) - Anus)
Mucositis/stomatitis
(functional/symptomatic)
(Mucositis/stomatitis
(functional/symptomatic) - Esophagus)
Mucositis/stomatitis
(functional/symptomatic)
(Mucositis/stomatitis
(functional/symptomatic) - Large bowel)
Mucositis/stomatitis
(functional/symptomatic)
(Mucositis/stomatitis
(functional/symptomatic) - Larynx)
Mucositis/stomatitis
(functional/symptomatic)
(Mucositis/stomatitis
(functional/symptomatic) - Oral cavity)
Mucositis/stomatitis
(functional/symptomatic)
(Mucositis/stomatitis
(functional/symptomatic) - Pharynx)
Mucositis/stomatitis
(functional/symptomatic)
(Mucositis/stomatitis
(functional/symptomatic) - Rectum)
Mucositis/stomatitis
(functional/symptomatic)
(Mucositis/stomatitis
(functional/symptomatic) - Small bowel)
Mucositis/stomatitis
(functional/symptomatic)
(Mucositis/stomatitis
(functional/symptomatic) - Stomach)
Mucositis/stomatitis
(functional/symptomatic)
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(Mucositis/stomatitis
(functional/symptomatic) - Trachea)
Muscle Weakness, Generalized Or
Specific Area (not Due To Neuropathy)
(Muscle weakness, generalized or
specific area (not due to neuropathy) -
Extraocular)
Muscle Weakness, Generalized Or
Specific Area (not Due To Neuropathy)
(Muscle weakness, generalized or
specific area (not due to neuropathy) -
Extremity-lower)
Muscle Weakness, Generalized Or
Specific Area (not Due To Neuropathy)
(Muscle weakness, generalized or
specific area (not due to neuropathy) -
Extremity-upper)
Muscle Weakness, Generalized Or
Specific Area (not Due To Neuropathy)
(Muscle weakness, generalized or
specific area (not due to neuropathy) -
Facial)
Muscle Weakness, Generalized Or
Specific Area (not Due To Neuropathy)
(Muscle weakness, generalized or
specific area (not due to neuropathy) -
Left-sided)
Muscle Weakness, Generalized Or
Specific Area (not Due To Neuropathy)
(Muscle weakness, generalized or
specific area (not due to neuropathy) -
Ocular)
Muscle Weakness, Generalized Or
Specific Area (not Due To Neuropathy)
(Muscle weakness, generalized or
specific area (not due to neuropathy) -
Pelvic)
Muscle Weakness, Generalized Or
Specific Area (not Due To Neuropathy)
(Muscle weakness, generalized or
specific area (not due to neuropathy) -
Right-sided)
Muscle Weakness, Generalized Or
Specific Area (not Due To Neuropathy)
(Muscle weakness, generalized or
specific area (not due to neuropathy) -
Trunk)
Muscle Weakness Nos (Muscle
weakness, generalized or specific area
(not due to neuropathy) - Whole
body/generalized)
Muscular/skeletal Hypoplasia
(Muscular/skeletal hypoplasia)
Musculoskeletal/soft Tissue Other
(Musculoskeletal/Soft Tissue-Other
(Specify))
Myelitis (Myelitis)
Myelodysplasia (Myelodysplasia)
Myocarditis Nos (Myocarditis)
Myositis (Myositis (inflammation/damage
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of muscle))
Nail Abnormality Nos (Nail changes)
Nasal Cavity/paranasal Sinus Reactions
(Nasal cavity/paranasal sinus reactions)
Nausea (Nausea)
Necrosis, Gi (Necrosis, GI - Anus)
Necrosis, Gi (Necrosis, GI -
Colon/cecum/appendix)
Necrosis, Gi (Necrosis, GI - Duodenum)
Necrosis, Gi (Necrosis, GI - Esophagus)
Necrosis, Gi (Necrosis, GI - Gallbladder)
Necrosis, Gi (Necrosis, GI - Hepatic)
Necrosis, Gi (Necrosis, GI - Ileum)
Necrosis, Gi (Necrosis, GI - Jejunum)
Necrosis, Gi (Necrosis, GI - Oral)
Necrosis, Gi (Necrosis, GI - Pancreas)
Necrosis, Gi (Necrosis, GI - Peritoneal
cavity)
Necrosis, Gi (Necrosis, GI - Pharynx)
Necrosis, Gi (Necrosis, GI - Rectum)
Necrosis, Gi (Necrosis, GI - Small bowel
NOS)
Necrosis, Gi (Necrosis, GI - Stoma)
Necrosis, Gi (Necrosis, GI - Stomach)
Neuroendocrine: Acth Deficiency
(Neuroendocrine: ACTH deficiency)
Inappropriate Adh Secretion
(Neuroendocrine: ADH secretion
abnormality (e.g., SIADH or low ADH))
Neuroendocrine: Gonadotropin Secretion
Abnormality (Neuroendocrine:
gonadotropin secretion abnormality)
Neuroendocrine: Growth Hormone
Secretion Abnormality (Neuroendocrine:
growth hormone secretion abnormality)
Neuroendocrine: Prolactin Hormone
Secretion Abnormality (Neuroendocrine:
prolactin hormone secretion abnormality)
Neurology Other (Neurology-Other
(Specify))
Parosmia (Neuropathy: cranial - CN I
Smell)
Cranial Nerve Injury Nos (Neuropathy:
cranial - CN II Vision)
Neuropathy: Cranial (Neuropathy: cranial
- CN III Pupil, upper eyelid, extra ocular
movements)
Neuropathy: Cranial (Neuropathy: cranial
- CN IV Downward, inward movement of
eye)
Neuropathy: Cranial (Neuropathy: cranial
- CN IX Motor-pharynx; Sensory-ear,
pharynx, tongue)
Neuropathy: Cranial (Neuropathy: cranial
- CN V Motor-jaw muscles; Sensory-
facial)
Neuropathy: Cranial (Neuropathy: cranial
- CN VI Lateral deviation of eye)
Neuropathy: Cranial (Neuropathy: cranial
- CN VII Motor-face; Sensory-taste)
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Neuropathy: Cranial (Neuropathy: cranial
- CN VIII Hearing and balance)
Neuropathy: Cranial (Neuropathy: cranial
- CN X Motor-palate; pharynx, larynx)
Neuropathy: Cranial (Neuropathy: cranial
- CN XI Motor-sternomastoid and
trapezius)
Neuropathy: Cranial (Neuropathy: cranial
- CN XII Motor-tongue)
Peripheral Motor Neuropathy
(Neuropathy: motor)
Peripheral Sensory Neuropathy
(Neuropathy: sensory)
Neutropenia (Neutrophils/granulocytes
(ANC/AGC))
Blindness Night (Night blindness
(nyctalopia))
Nystagmus Nos (Nystagmus)
Obesity (Obesity)
Obstruction, Gi (Obstruction, GI -
Cecum)
Obstruction, Gi (Obstruction, GI - Colon)
Obstruction, Gi (Obstruction, GI -
Duodenum)
Obstruction, Gi (Obstruction, GI -
Esophagus)
Obstruction, Gi (Obstruction, GI -
Gallbladder)
Obstruction, Gi (Obstruction, GI - Ileum)
Obstruction, Gi (Obstruction, GI -
Jejunum)
Obstruction, Gi (Obstruction, GI -
Rectum)
Obstruction, Gi (Obstruction, GI - Small
bowel NOS)
Obstruction, Gi (Obstruction, GI - Stoma)
Obstruction, Gi (Obstruction, GI -
Stomach)
Obstruction, Gu (Obstruction, GU -
Bladder)
Obstruction, Gu (Obstruction, GU -
Fallopian tube)
Obstruction, Gu (Obstruction, GU -
Prostate)
Obstruction, Gu (Obstruction, GU -
Spermatic cord)
Obstruction, Gu (Obstruction, GU -
Stoma)
Obstruction, Gu (Obstruction, GU -
Testes)
Ureteric Obstruction (Obstruction, GU -
Ureter)
Obstruction, Gu (Obstruction, GU -
Urethra)
Obstruction, Gu (Obstruction, GU -
Uterus)
Obstruction, Gu (Obstruction, GU -
Vagina)
Obstruction, Gu (Obstruction, GU - Vas
deferens)
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Obstruction/stenosis Of Airway
(Obstruction/stenosis of airway -
Bronchus)
Obstruction/stenosis Of Airway
(Obstruction/stenosis of airway - Larynx)
Obstruction/stenosis Of Airway
(Obstruction/stenosis of airway -
Pharynx)
Obstruction/stenosis Of Airway
(Obstruction/stenosis of airway -
Trachea)
Conjunctivitis Nec (Ocular surface
disease)
Ocular/visual Other (Ocular/Visual-Other
(Specify))
Odor (patient Odor) (Odor (patient odor))
Diplopia (Ophthalmoplegia/diplopia
(double vision))
Opportunistic Infection Associated With
>=grade 2 Lymphopenia (Opportunistic
infection associated with >=Grade 2
lymphopenia)
Optic Disc Edema (Optic disc edema)
Orgasmic Dysfunction (Orgasmic
dysfunction)
Osteonecrosis (Osteonecrosis (avascular
necrosis))
Osteoporosis (Osteoporosis)
Otitis Externa (exc Boil Of Meatus) Nos
(Otitis, external ear (non-infectious))
Otitis Media Serous Nos (Otitis, middle
ear (non-infectious))
Abdominal Pain Nos (Pain - Abdomen
NOS)
Pain (Pain - Anus)
Pain (Pain - Back)
Pain (Pain - Bladder)
Bone Pain (Pain - Bone)
Pain (Pain - Breast)
Pain (Pain - Buttock)
Pain (Pain - Cardiac/heart)
Pain (Pain - Chest wall)
Chest Pain (Pain - Chest/thorax NOS)
Pain (Pain - Dental/teeth/peridontal)
Pain (Pain - Esophagus)
Earache (Pain - External ear)
Pain (Pain - Extremity-limb)
Pain (Pain - Eye)
Pain (Pain - Face)
Pain (Pain - Gallbladder)
Headache Nos (Pain - Head/headache)
Pain (Pain - Intestine)
Arthralgia (Pain - Joint)
Pain (Pain - Kidney)
Pain (Pain - Larynx)
Pain (Pain - Lip)
Hepatic Pain (Pain - Liver)
Pain (Pain - Lymph node)
Pain (Pain - Middle ear)
Myalgia (Pain - Muscle)
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Pain (Pain - Neck)
Neuralgia Nos (Pain -
Neuralgia/peripheral nerve)
Pain (Pain - Oral cavity)
Pain (Pain - Oral-gums)
Pain (Pain - Ovulatory)
Pain (Pain - Pain NOS)
Pelvic Pain Nos (Pain - Pelvis)
Pain (Pain - Penis)
Pain (Pain - Pericardium)
Pain (Pain - Perineum)
Pain (Pain - Peritoneum)
Pain (Pain - Phantom (pain associated
with missing limb))
Pleuritic Pain (Pain - Pleura)
Pain (Pain - Prostate)
Proctalgia (Pain - Rectum)
Pain (Pain - Scalp)
Pain (Pain - Scrotum)
Pain (Pain - Sinus)
Pain (Pain - Skin)
Pain (Pain - Stomach)
Pain (Pain - Testicle)
Pain (Pain - Throat/pharynx/larynx)
Tumour Pain (Pain - Tumor pain)
Dysuria (Pain - Urethra)
Dysmenorrhoea (Pain - Uterus)
Pain (Pain - Vagina)
Pain Other (Pain-Other (Specify))
Palpitations (Palpitations)
Pancreas, Exocrine Enzyme Deficiency
(Pancreas, exocrine enzyme deficiency)
Pancreatic Endocrine: Glucose
Intolerance (Pancreatic endocrine:
glucose intolerance)
Pancreatitis Nos (Pancreatitis)
Parathyroid Function, Low
(hypoparathyroidism) (Parathyroid
function, low (hypoparathyroidism))
Perforation, Gi (Perforation, GI -
Appendix)
Perforation, Gi (Perforation, GI - Biliary
tree)
Perforation, Gi (Perforation, GI - Cecum)
Perforation, Gi (Perforation, GI - Colon)
Perforation, Gi (Perforation, GI -
Duodenum)
Perforation, Gi (Perforation, GI -
Esophagus)
Perforation, Gi (Perforation, GI -
Gallbladder)
Perforation, Gi (Perforation, GI - Ileum)
Perforation, Gi (Perforation, GI -
Jejunum)
Perforation, Gi (Perforation, GI - Rectum)
Perforation, Gi (Perforation, GI - Small
bowel NOS)
Perforation, Gi (Perforation, GI -
Stomach)
Perforation, Gu (Perforation, GU -
84 / 93
NCT00655876 F1: Radiation Therapy Oncology Group Phase III
Esophagus Followup Form
Bladder)
Perforation, Gu (Perforation, GU -
Fallopian tube)
Perforation, Gu (Perforation, GU -
Kidney)
Perforation, Gu (Perforation, GU - Ovary)
Perforation, Gu (Perforation, GU -
Prostate)
Perforation, Gu (Perforation, GU -
Spermatic cord)
Perforation, Gu (Perforation, GU -
Stoma)
Perforation, Gu (Perforation, GU -
Testes)
Perforation, Gu (Perforation, GU - Ureter)
Perforation, Gu (Perforation, GU -
Urethra)
Perforation, Gu (Perforation, GU -
Uterus)
Perforation, Gu (Perforation, GU -
Vagina)
Perforation, Gu (Perforation, GU - Vas
deferens)
Pericardial Effusion (Pericardial effusion
(non-malignant))
Pericarditis (Pericarditis)
Peripheral Ischaemia Nos (Peripheral
arterial ischemia)
Personality Change
(Personality/behavioral)
Petechiae (Petechiae/purpura
(hemorrhage/bleeding into skin or
mucosa))
Phlebitis Superficial (Phlebitis (including
superficial thrombosis))
Phlebolymphatic Cording
(Phlebolymphatic cording)
Hypophosphataemia (Phosphate, serum-
low (hypophosphatemia))
Photosensitivity Reaction Nos
(Photosensitivity)
Phrenic Nerve Dysfunction (Phrenic
nerve dysfunction)
Platelet Count Decreased (Platelets)
Pleural Effusion (Pleural effusion (non-
malignant))
Pneumonitis Nos
(Pneumonitis/pulmonary infiltrates)
Pneumothorax Nos (Pneumothorax)
Portal Hypertension (Portal vein flow)
Hyperkalaemia (Potassium, serum-high
(hyperkalemia))
Hypokalaemia (Potassium, serum-low
(hypokalemia))
Proctitis Nos (Proctitis)
Prolapse Of Stoma, Gi (Prolapse of
stoma, GI)
Prolapse Of Stoma, Gu (Prolapse of
stoma, GU)
Prolonged Chest Tube Drainage Or Air
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Leak After Pulmonary Resection
(Prolonged chest tube drainage or air
leak after pulmonary resection)
Prolonged Intubation After Pulmonary
Resection (>24 Hrs After Surgery)
(Prolonged intubation after pulmonary
resection (>24 hrs after surgery))
Electrocardiogram Qt Prolonged
(Prolonged QTc interval)
Proptosis/enophthalmos
(Proptosis/enophthalmos)
Proteinuria Present (Proteinuria)
Pruritus Nos (Pruritus/itching)
Delusion Nos (Psychosis
(hallucinations/delusions))
Activated Partial Thromboplastin Time
Prolonged (PTT (Partial thromboplastin
time))
Puberty (delayed) (Puberty (delayed))
Puberty (precocious) (Puberty
(precocious))
Pulmonary Fibrosis (Pulmonary fibrosis
(radiographic changes))
Pulmonary Hypertension (Pulmonary
hypertension)
Pulmonary/upper Respiratory Other
(Pulmonary/Upper Respiratory-Other
(Specify))
Upper Motor Neurone Lesion (Pyramidal
tract dysfunction (e.g., increased tone,
hyperreflexia, positive Babinski,
decreased fine motor coordination))
Rash: Acne/acneiform (Rash:
acne/acneiform)
Radiation Recall Syndrome (Rash:
dermatitis associated with radiation -
Chemoradiation)
Dermatitis Radiation Nos (Rash:
dermatitis associated with radiation -
Radiation)
Erythema Multiforme (Rash: erythema
multiforme (e.g., Stevens-Johnson
syndrome, toxic epidermal necrolysis))
Localised Exfoliation (Rash: hand-foot
skin reaction)
Dermatitis Exfoliative Nos
(Rash/desquamation)
Renal Failure Nos (Renal failure)
Renal/genitourinary Other
(Renal/Genitourinary-Other (Specify))
Restrictive Cardiomyopathy (Restrictive
cardiomyopathy)
Retinal Detachment (Retinal
detachment)
Retinoic Acid Syndrome (Retinoic acid
syndrome)
Retinopathy (Retinopathy)
Right Ventricular Dysfunction (cor
Pulmonale) (Right ventricular dysfunction
(cor pulmonale))
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Rigors (Rigors/chills)
Salivary Gland Disorder Nos (Salivary
gland changes/saliva)
Scleral Necrosis/melt (Scleral
necrosis/melt)
Secondary Malignancy Possibly Related
To Cancer Treatment (Secondary
Malignancy-possibly related to cancer
treatment (Specify))
Convulsions Nos (Seizure)
Seroma (Seroma)
Serum Sickness (Serum sickness)
Sexual/reproductive Function Other
(Sexual/Reproductive Function-Other
(Specify))
Short Stature (Short stature)
Skin Breakdown/decubitus Ulcer (Skin
breakdown/decubitus ulcer)
Hypernatraemia (Sodium, serum-high
(hypernatremia))
Hyponatraemia (Sodium, serum-low
(hyponatremia))
Soft Tissue Necrosis (Soft tissue
necrosis - Abdomen)
Soft Tissue Necrosis (Soft tissue
necrosis - Extremity-lower)
Soft Tissue Necrosis (Soft tissue
necrosis - Extremity-upper)
Soft Tissue Necrosis (Soft tissue
necrosis - Head)
Soft Tissue Necrosis (Soft tissue
necrosis - Neck)
Soft Tissue Necrosis (Soft tissue
necrosis - Pelvic)
Soft Tissue Necrosis (Soft tissue
necrosis - Thorax)
Depressed Level Of Consciousness
(Somnolence/depressed level of
consciousness)
Speech Disorder Nec (Speech
impairment (e.g., dysphasia or aphasia))
Splenic Function (Splenic function)
Striae (Striae)
Stricture/stenosis (including
Anastomotic), Gi (Stricture/stenosis
(including anastomotic), GI - Anus)
Stricture/stenosis (including
Anastomotic), Gi (Stricture/stenosis
(including anastomotic), GI - Biliary tree)
Stricture/stenosis (including
Anastomotic), Gi (Stricture/stenosis
(including anastomotic), GI - Cecum)
Stricture/stenosis (including
Anastomotic), Gi (Stricture/stenosis
(including anastomotic), GI - Colon)
Stricture/stenosis (including
Anastomotic), Gi (Stricture/stenosis
(including anastomotic), GI - Duodenum)
Stricture/stenosis (including
Anastomotic), Gi (Stricture/stenosis
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(including anastomotic), GI - Esophagus)
Stricture/stenosis (including
Anastomotic), Gi (Stricture/stenosis
(including anastomotic), GI - Ileum)
Stricture/stenosis (including
Anastomotic), Gi (Stricture/stenosis
(including anastomotic), GI - Jejunum)
Stricture/stenosis (including
Anastomotic), Gi (Stricture/stenosis
(including anastomotic), GI -
Pancreas/pancreatic duct)
Stricture/stenosis (including
Anastomotic), Gi (Stricture/stenosis
(including anastomotic), GI - Pharynx)
Stricture/stenosis (including
Anastomotic), Gi (Stricture/stenosis
(including anastomotic), GI - Rectum)
Stricture/stenosis (including
Anastomotic), Gi (Stricture/stenosis
(including anastomotic), GI - Small bowel
NOS)
Stricture/stenosis (including
Anastomotic), Gi (Stricture/stenosis
(including anastomotic), GI - Stoma)
Stricture/stenosis (including
Anastomotic), Gi (Stricture/stenosis
(including anastomotic), GI - Stomach)
Stricture/stenosis (including
Anastomotic), Gu (Stricture/stenosis
(including anastomotic), GU - Bladder)
Stricture/stenosis (including
Anastomotic), Gu (Stricture/stenosis
(including anastomotic), GU - Fallopian
tube)
Stricture/stenosis (including
Anastomotic), Gu (Stricture/stenosis
(including anastomotic), GU - Prostate)
Stricture/stenosis (including
Anastomotic), Gu (Stricture/stenosis
(including anastomotic), GU - Spermatic
cord)
Stricture/stenosis (including
Anastomotic), Gu (Stricture/stenosis
(including anastomotic), GU - Stoma)
Stricture/stenosis (including
Anastomotic), Gu (Stricture/stenosis
(including anastomotic), GU - Testes)
Stricture/stenosis (including
Anastomotic), Gu (Stricture/stenosis
(including anastomotic), GU - Ureter)
Stricture/stenosis (including
Anastomotic), Gu (Stricture/stenosis
(including anastomotic), GU - Urethra)
Stricture/stenosis (including
Anastomotic), Gu (Stricture/stenosis
(including anastomotic), GU - Uterus)
Stricture/stenosis (including
Anastomotic), Gu (Stricture/stenosis
(including anastomotic), GU - Vagina)
Stricture/stenosis (including
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Anastomotic), Gu (Stricture/stenosis
(including anastomotic), GU - Vas
deferens)
Supraventricular And Nodal Arrhythmia
(Supraventricular and nodal arrhythmia -
Atrial fibrillation)
Supraventricular And Nodal Arrhythmia
(Supraventricular and nodal arrhythmia -
Atrial flutter)
Supraventricular And Nodal Arrhythmia
(Supraventricular and nodal arrhythmia -
Atrial tachycardia/paroxysmal atrial
tachycardia)
Supraventricular And Nodal Arrhythmia
(Supraventricular and nodal arrhythmia -
Nodal/junctional)
Supraventricular And Nodal Arrhythmia
(Supraventricular and nodal arrhythmia -
Sinus arrhythmia)
Sinus Bradycardia (Supraventricular and
nodal arrhythmia - Sinus bradycardia)
Sinus Tachycardia (Supraventricular and
nodal arrhythmia - Sinus tachycardia)
Supraventricular Arrhythmia Nos
(Supraventricular and nodal arrhythmia -
Supraventricular arrhythmia NOS)
Supraventricular And Nodal Arrhythmia -
Supraventricular Extrasystoles
(premature Atrial Contractions;
Premature Nodal/junctional
Contractions) (Supraventricular and
nodal arrhythmia - Supraventricular
extrasystoles (premature atrial
contractions; premature nodal/junctional
contractions))
Supraventricular And Nodal Arrhythmia
(Supraventricular and nodal arrhythmia -
Supraventricular tachycardia)
Sweating Increased (Sweating
(diaphoresis))
Syncope (Syncope (fainting))
Syndromes Other (Syndromes-Other
(Specify))
Taste Disturbance (Taste alteration
(dysgeusia))
Telangiectasia (Telangiectasia)
Thrombosis/embolism (vascular Access-
related) (Thrombosis/embolism (vascular
access-related))
Thrombosis Nos
(Thrombosis/thrombus/embolism)
Thrombotic Microangiopathy (e.g.,
Thrombotic Thrombocytopenic
Purpura[ttp] Or Hemolytic Uremic
Syndrome[hus]) (Thrombotic
microangiopathy (e.g., thrombotic
thrombocytopenic purpura or hemolytic
uremic syndrome))
Thyroid Function, High (hyperthyroidism,
Thyrotoxicosis) (Thyroid function, high
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(hyperthyroidism, thyrotoxicosis))
Hypothyroidism (Thyroid function, low
(hypothyroidism))
Tinnitus (Tinnitus)
Tremor Nec (Tremor)
Hypertriglyceridaemia (Triglyceride,
serum-high (hypertriglyceridemia))
Trismus (difficulty, Restriction Or Pain
When Opening Mouth) (Trismus
(difficulty, restriction or pain when
opening mouth))
Tumour Flare (Tumor flare)
Tumour Lysis Syndrome (Tumor lysis
syndrome)
Caecitis (Typhlitis (cecal inflammation))
Ulcer, Gi (Ulcer, GI - Anus)
Ulcer, Gi (Ulcer, GI - Cecum)
Ulcer, Gi (Ulcer, GI - Colon)
Duodenal Ulcer (Ulcer, GI - Duodenum)
Ulcer, Gi (Ulcer, GI - Esophagus)
Ulcer, Gi (Ulcer, GI - Ileum)
Ulcer, Gi (Ulcer, GI - Jejunum)
Ulcer, Gi (Ulcer, GI - Rectum)
Ulcer, Gi (Ulcer, GI - Small bowel NOS)
Ulcer, Gi (Ulcer, GI - Stoma)
Gastric Ulcer (Ulcer, GI - Stomach)
Ulceration (Ulceration)
Hyperuricaemia (Uric acid, serum-high
(hyperuricemia))
Fanconi Syndrome (Urinary electrolyte
wasting (e.g., Fanconi's syndrome, renal
tubular acidosis))
Urinary Frequency (Urinary
frequency/urgency)
Urinary Retention (Urinary retention
(including neurogenic bladder))
Urine Discolouration (Urine color
change)
Urticaria Nos (Urticaria (hives, welts,
wheals))
Uveitis (Uveitis)
Vaginal Discharge (non-infectious)
(Vaginal discharge (non-infectious))
Vulvovaginal Dryness (Vaginal dryness)
Vaginal Mucositis (Vaginal mucositis)
Vaginal Stenosis/length (Vaginal
stenosis/length)
Vaginitis (Vaginitis (not due to infection))
Valvular Heart Disease (Valvular heart
disease)
Vascular Other (Vascular-Other
(Specify))
Vasculitis Nos (Vasculitis)
Vasovagal Attack (Vasovagal episode)
Ventricular Arrhythmia (Ventricular
arrhythmia - Bigeminy)
Ventricular Arrhythmia (Ventricular
arrhythmia - Idioventricular rhythm)
Ventricular Arrhythmia (Ventricular
arrhythmia - PVCs)
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Ventricular Arrhythmia (Ventricular
arrhythmia - Torsade de pointes)
Ventricular Arrhythmia (Ventricular
arrhythmia - Trigeminy)
Ventricular Arrhythmia Nos (Ventricular
arrhythmia - Ventricular arrhythmia NOS)
Ventricular Arrhythmia (Ventricular
arrhythmia - Ventricular fibrillation)
Ventricular Arrhythmia (Ventricular
arrhythmia - Ventricular flutter)
Ventricular Arrhythmia (Ventricular
arrhythmia - Ventricular tachycardia)
Vessel Injury-artery (Vessel injury-artery
- Aorta)
Vessel Injury-artery (Vessel injury-artery
- Carotid)
Vessel Injury-artery (Vessel injury-artery
- Extremity-lower)
Vessel Injury-artery (Vessel injury-artery
- Extremity-upper)
Vessel Injury-artery (Vessel injury-artery
- Other NOS)
Vessel Injury-artery (Vessel injury-artery
- Visceral)
Vessel Injury-vein (Vessel injury-vein -
Extremity-lower)
Vessel Injury-vein (Vessel injury-vein -
Extremity-upper)
Vessel Injury-vein (Vessel injury-vein -
IVC)
Vessel Injury-vein (Vessel injury-vein -
Jugular)
Vessel Injury-vein (Vessel injury-vein -
Other NOS)
Vessel Injury-vein (Vessel injury-vein -
SVC)
Vessel Injury-vein (Vessel injury-vein -
Viscera)
Viral Hepatitis (Viral hepatitis)
Visceral Arterial Ischaemia (Visceral
arterial ischemia (non-myocardial))
Vision Blurred (Vision-blurred vision)
Photopsia (Vision-flashing lights/floaters)
Photophobia (Vision-photophobia)
Vital Capacity (Vital capacity)
Vitreous Hemorrhage (Vitreous
hemorrhage)
Dysphonia (Voice changes/dysarthria
(e.g., hoarseness, loss or alteration in
voice, laryngitis))
Vomiting Nos (Vomiting)
Lacrimation Increased (Watery eye
(epiphora, tearing))
Weight Increased (Weight gain)
Weight Decreased (Weight loss)
Culture Wound Negative (Wound
complication, non-infectious)
CTCAE Begin Date
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Adverse Event Reporting to Date
CTC Adverse Event Attribution (Attribution to
Protocol Treatment See protocol sections 6 & 7
for definition of "protocol treatment")
Definite (Definite)
Possible (Possible)
Probable (Probable)
Unlikely (Unlikely)
Unrelated (Unrelated)
Has an AdEERS been filed
No (No)
Unknown (Unknown)
Yes (Yes)
Was this SAE per NCI definitions
Yes
No
Is there a reasonable possibility that the event
may have been caused by the investigational
agent
No (No)
Unknown (Unknown)
Yes (Yes)
Action taken regarding study therapy
Dose Delayed/omitted (Dose
delayed/omitted)
Dose Reduced (Dose reduced)
Agent Stopped (Dose stopped)
Drug Discontinued (Drug discontinued)
Iv Rate Decreased (IV rate decreased)
No Dose Modification (No dose
modification)
Treatment required
Concomitant Medication (Concomitant
medication)
No Treatment Administered (None)
Surgical Procedure (Procedural Surgery)
Present Status
Not Recovered Or Not Resolved (Not
recovered/Not resolved)
Recovered Or Resolved With Sequelae
(Recovered/Resolved with Sequelae)
Recovered Or Resolved Without
Sequelae (Recovered/Resolved without
Sequelae)
Recovering Or Resolving
(Recovering/Resolving)
Footer
Comments
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Investigator Signature (The reported case report
information has been reviewed and confirmed by
the principal investigator)
Date
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RTOG-0534 PQ:  AUA Symptom Score
NCT00567580
RTOG-0534 PQ:  AUA Symptom Score NCT00567580 
Prostate Radiation Therapy or Short-Term Androgen
Deprivation Therapy and Pelvic Lymph Node Radiation
Therapy With or Without Prostate Radiation Therapy in
Treating Patients With a Rising PSA After Surgery for
Prostate Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=40F117E7-
CE30-0BC2-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11564
RTOG-0534 PQ:  AUA Symptom
Score NCT00567580
Header Module
RTOG Study No.
Case #
Institution Name
Institution No.
Patient Initials
RTOG Patient ID
Amended data
Yes
No
Miscellaneous Information
Time point
Month 12 (Month 12)
Month 3 (Month 3)
Month 6 (Month 6)
Other (Other)
Pretreatment (Pretreatment)
Week 6 Of Rt (Week 6 of RT)
Year 1-month 12 (Year 1-Month 12)
Year 1-month 6 (Year 1-Month 6)
Year 10-year 19 (Year 10-Year 19)
Year 2-month 12 (Year 2-Month 12)
Year 2-month 6 (Year 2-Month 6)
Year 3-month 12 (Year 3-Month 12)
Year 3-month 6 (Year 3-Month 6)
Year 4-month 12 (Year 4-Month 12)
Year 4-month 6 (Year 4-Month 6)
Year 5-year 9 (Year 5-Year 9)
Was patient questionnaire completed
Yes
No
Date patient questionnaire completed
1 / 3
Reason Questionnaire was not Completed
Institution Error (Institutional error)
Not Applicable, Questionnaire Was
Completed (Not applicable,
questionnaire was completed)
Other Reason (Other reason)
Patient Refused Due To Illness (Patient
refused due to illness)
Patient Refused For Other Reason
(Patient refused for other reason)
Patient Unable To Be Contacted (Patient
unable to be contacted)
Tool Not Availalble In Patient's Language
(Tool not availalble in patient's language)
Unknown (Unknown)
Patient refused for other reason, specify
Other reason, specify
Specify method of completion
At Appointment (At appointment)
By Mail (By mail)
By Telephone (By telephone)
Not Applicable (Not applicable)
Unknown (Unknown)
Did the patient require any assistance in
completing the questionnaire?
No (No)
Not Applicable (Not applicable)
Unknown If Assistance Given (Unknown
if assistance given)
Yes (Yes)
Specify the person who assisted the patient
Family (Family)
Not Applicable (Not applicable)
Other (Other)
Staff Member (Staff member)
Unknown (Unknown)
Extent of assistance given
Combination Of Above (Combination of
above)
Interpreted Items For Patient (Interpreted
items for patient)
Marked Items Per Patient's Response
(Marked items per patient's response)
Not Applicable (Not applicable)
Other (Other)
Read Items To Patient (Read items to
patient)
Unknown (Unknown)
Combination of above, specify
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Comments
Signature of Person Completing This Form
Date Form Originally Completed
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RTOG clinical trial administrative data
RTOG Study No.
Case #
Institution Name
Institution No.
Patient Initials
RTOG Patient ID
Amended Data (INSTRUCTIONS: Submit this
form at the appropriate follow-up interval and
whenever there is a change in the patient's
status. Dates are recorded mm-dd-yyyy unless
otherwise specified.)
Yes
No
Date of Last Contact or Death (MM/DD/YYYY)
Vital Status
Alive (Alive)
Dead (Dead)
Primary Cause of Death
Due To Complications Of Non-protocol
Treatment (Due to complications of non-
protocol treatment)
Due To Other Cause (Due to other
cause)
Due To Protocol Treatment (Due to
protocol treatment)
Due To Second Primary Or Other
Malignancy (Due to second primary or
other malignancy)
Due To This Disease (Due to this
disease)
Unknown (Unknown)
Specify
1 / 24
Has the patient had a documented clinical
assessment for this cancer?
No (No)
Unknown (Unknown)
Yes (Yes)
Date of Last Clinical Assessment
Current Disease Status
Local tumor
Disease Absent (Disease absent)
Disease Present (Disease present)
Unknown (Unknown)
Regional nodes
Disease Absent (Disease absent)
Disease Present (Disease present)
Unknown (Unknown)
Distant metastasis
Disease Absent (Disease absent)
Disease Present (Disease present)
Unknown (Unknown)
Second primary
Disease Absent (Disease absent)
Disease Present (Disease present)
Unknown (Unknown)
Method of Evaluation
Ct W/contrast (CT w/contrast)
Mri (MRI (NMR))
Pathologic (Pathologic)
Physical Exam (Physical exam)
Events
Event
Appearance Of Bone Metastasis
(Appearance of bone metastasis)
Appearance Of Distant Nodes
(Appearance of distant nodes)
Appearance Of Liver Metastasis
(Appearance of liver metastasis)
Appearance Of Lung Metastasis
(Appearance of lung metastasis)
Appearance Of Other Metastasis
(Appearance of other metastasis)
Appearance Of Second Primary
(Appearance of second primary)
Nodal Progression (Nodal progression)
Progression (Progression)
Date
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Specify
Performance Status
Fully Active, Able To Carry On All Pre-
disease Performance Without
Restriction. (0)
Restricted In Physically Strenuous
Activity But Ambulatory And Able To
Carry Out Work Of A Light Or Sedentary
Nature, E.g., Light Housework, Office
Work. (1)
Ambulatory And Capable Of All Selfcare
But Unable To Carry Out Any Work
Activities. Up And About More Than 50%
Of Waking Hours. (2)
Capable Of Only Limited Selfcare,
Confined To Bed Or Chair More Than
50% Of Waking Hours. (3)
Completely Disabled. Cannot Carry On
Any Selfcare. Totally Confined To Bed Or
Chair. (4)
Dead (5)
Was CA 19-9 drawn during this report period
Yes
No
CA 19-9
Date
New primary cancer
Has a new primary cancer or MDS been
diagnosed that has not been previously reported?
No (No)
Unknown (Unknown)
Yes (Yes)
New Primary Site
Aml/mds (AML/MDS)
Bcc (BCC)
Bladder (Bladder)
Brain (Brain)
Colorectal (Colorectal)
Esophageal (Esophageal)
Gastric (Gastric)
Liver (Liver)
Lung (Lung)
Melanoma (Melanoma)
Nhl (NHL)
None (None)
Other Hematologic, Specify (Other
Hematologic, specify)
Other Solid, Specify (Other solid,
specify)
Pancreatic (Pancreatic)
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Prostate (Prostate)
Renal (Renal)
Squamous-skin (Squamous-Skin)
Unknown Primary (Unknown primary)
Date of diagnosis
Specify
Additional Non Protocol Treatment
Non-Protocol Therapy Type (begun since
submission of previous follow-up form)
Chemotherapy (Chemotherapy)
None (None)
Other Non-protocol Therapy (Other non-
protocol therapy)
Radiation Therapy (Radiation therapy)
Radiation To Other Sites, Specify
(Radiation to other sites)
Surgery (Surgery)
Unknown (Unknown)
Date of Non-protocol therapy
Protocol Specific Adverse Event
Evaluation
Any adverse events
No (No)
Unknown (Unknown)
Yes (Yes)
MedDRA Code
CTC Adverse Event Term
Abdominal Distension (Abdominal
distension)
Abdominal Infection (Abdominal
infection)
Abdominal Pain (Abdominal pain)
Abdominal Soft Tissue Necrosis
(Abdominal soft tissue necrosis)
Abducens Nerve Disorder (Abducens
nerve disorder)
Accessory Nerve Disorder (Accessory
nerve disorder)
Acidosis (Acidosis)
Acoustic Nerve Disorder Nos (Acoustic
nerve disorder NOS)
Activated Partial Thromboplastin Time
Prolonged (Activated partial
thromboplastin time prolonged)
Acute Coronary Syndrome (Acute
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coronary syndrome)
Acute Kidney Injury (Acute kidney injury)
Adrenal Insufficiency (Adrenal
insufficiency)
Adult Respiratory Distress Syndrome
(Adult respiratory distress syndrome)
Agitation (Agitation)
Akathisia (Akathisia)
Alanine Aminotransferase Increased
(Alanine aminotransferase increased)
Alcohol Intolerance (Alcohol intolerance)
Alkaline Phosphatase Increased
(Alkaline phosphatase increased)
Alkalosis (Alkalosis)
Allergic Reaction (Allergic reaction)
Allergic Rhinitis (Allergic rhinitis)
Alopecia (Alopecia)
Amnesia (Amnesia)
Anal Fistula (Anal fistula)
Anal Hemorrhage (Anal hemorrhage)
Anal Mucositis (Anal mucositis)
Anal Necrosis (Anal necrosis)
Anal Pain (Anal pain)
Anal Stenosis (Anal stenosis)
Anal Ulcer (Anal ulcer)
Anaphylaxis (Anaphylaxis)
Anemia (Anemia)
Ankle Fracture (Ankle fracture)
Anorectal Infection (Anorectal infection)
Anorexia (Anorexia)
Anorgasmia (Anorgasmia)
Anxiety (Anxiety)
Aortic Injury (Aortic injury)
Aortic Valve Disease (Aortic valve
disease)
Aphonia (Aphonia)
Apnea (Apnea)
Appendicitis (Appendicitis)
Appendicitis Perforated (Appendicitis
perforated)
Arachnoiditis (Arachnoiditis)
Arterial Injury (Arterial injury)
Arteritis Infective (Arteritis infective)
Arthralgia (Arthralgia)
Arthritis (Arthritis)
Ascites (Ascites)
Aspartate Aminotransferase Increased
(Aspartate aminotransferase increased)
Aspiration (Aspiration)
Asystole (Asystole)
Ataxia (Ataxia)
Atelectasis (Atelectasis)
Atrial Fibrillation (Atrial fibrillation)
Atrial Flutter (Atrial flutter)
Atrioventricular Block Complete
(Atrioventricular block complete)
Atrioventricular Block First Degree
(Atrioventricular block first degree)
Autoimmune Disorder (Autoimmune
disorder)
5 / 24
NCT01013649 RTOG 0848 Phase III Pancreas-Resected + Adjuvant
Treatment Follow-up Form (F1)
Avascular Necrosis (Avascular necrosis)
Azoospermia (Azoospermia)
Back Pain (Back pain)
Bile Duct Stenosis (Bile duct stenosis)
Biliary Anastomotic Leak (Biliary
anastomotic leak)
Biliary Fistula (Biliary fistula)
Biliary Tract Infection (Biliary tract
infection)
Bladder Anastomotic Leak (Bladder
anastomotic leak)
Bladder Infection (Bladder infection)
Bladder Perforation (Bladder perforation)
Bladder Spasm (Bladder spasm)
Bloating (Bloating)
Blood And Lymphatic System Disorders -
Other, Specify (Blood and lymphatic
system disorders - Other, Specify)
Blood Antidiuretic Hormone Abnormal
(Blood antidiuretic hormone abnormal)
Blood Bilirubin Increased (Blood bilirubin
increased)
Blood Corticotrophin Decreased (Blood
corticotrophin decreased)
Blood Gonadotrophin Abnormal (Blood
gonadotrophin abnormal)
Blood Prolactin Abnormal (Blood
prolactin abnormal)
Blurred Vision (Blurred vision)
Body Odor (Body odor)
Bone Infection (Bone infection)
Bone Marrow Hypocellular (Bone
marrow hypocellular)
Bone Pain (Bone pain)
Brachial Plexopathy (Brachial
plexopathy)
Breast Atrophy (Breast atrophy)
Breast Infection (Breast infection)
Breast Pain (Breast pain)
Bronchial Fistula (Bronchial fistula)
Bronchial Infection (Bronchial infection)
Bronchial Obstruction (Bronchial
obstruction)
Bronchial Stricture (Bronchial stricture)
Bronchopleural Fistula (Bronchopleural
fistula)
Bronchopulmonary Hemorrhage
(Bronchopulmonary hemorrhage)
Bronchospasm (Bronchospasm)
Bruising (Bruising)
Bullous Dermatitis (Bullous dermatitis)
Burn (Burn)
Buttock Pain (Buttock pain)
Capillary Leak Syndrome (Capillary leak
syndrome)
Carbon Monoxide Diffusing Capacity
Decreased (Carbon monoxide diffusing
capacity decreased)
Cardiac Arrest (Cardiac arrest)
Cardiac Disorders - Other, Specify
6 / 24
NCT01013649 RTOG 0848 Phase III Pancreas-Resected + Adjuvant
Treatment Follow-up Form (F1)
(Cardiac disorders - Other, Specify)
Cardiac Troponin I Increased (Cardiac
troponin I increased)
Cardiac Troponin T Increased (Cardiac
troponin T increased)
Cataract (Cataract)
Catheter Related Infection (Catheter
related infection)
Cd4 Lymphocytes Decreased (CD4
lymphocytes decreased)
Cecal Hemorrhage (Cecal hemorrhage)
Cecal Infection (Cecal infection)
Central Nervous System Necrosis
(Central nervous system necrosis)
Cerebrospinal Fluid Leakage
(Cerebrospinal fluid leakage)
Cervicitis Infection (Cervicitis infection)
Cheilitis (Cheilitis)
Chest Pain - Cardiac (Chest pain -
cardiac)
Chest Wall Pain (Chest wall pain)
Chills (Chills)
Cholecystitis (Cholecystitis)
Cholesterol High (Cholesterol high)
Chronic Kidney Disease (Chronic kidney
disease)
Chylothorax (Chylothorax)
Cognitive Disturbance (Cognitive
disturbance)
Colitis (Colitis)
Colonic Fistula (Colonic fistula)
Colonic Hemorrhage (Colonic
hemorrhage)
Colonic Obstruction (Colonic obstruction)
Colonic Perforation (Colonic perforation)
Colonic Stenosis (Colonic stenosis)
Colonic Ulcer (Colonic ulcer)
Concentration Impairment
(Concentration impairment)
Conduction Disorder (Conduction
disorder)
Confusion (Confusion)
Congenital, Familial And Genetic
Disorders - Other, Specify (Congenital,
familial and genetic disorders - Other,
Specify)
Conjunctivitis (Conjunctivitis)
Conjunctivitis Infective (Conjunctivitis
infective)
Constipation (Constipation)
Constrictive Pericarditis (Constrictive
pericarditis)
Corneal Infection (Corneal infection)
Corneal Ulcer (Corneal ulcer)
Cough (Cough)
Cpk Increased (CPK increased)
Cranial Nerve Infection (Cranial nerve
infection)
Creatinine Increased (Creatinine
increased)
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Cushingoid (Cushingoid)
Cystitis Noninfective (Cystitis
noninfective)
Cytokine Release Syndrome (Cytokine
release syndrome)
Death Neonatal (Death neonatal)
Death Nos (Death NOS)
Dehydration (Dehydration)
Delayed Orgasm (Delayed orgasm)
Delayed Puberty (Delayed puberty)
Delirium (Delirium)
Delusions (Delusions)
Dental Caries (Dental caries)
Depressed Level Of Consciousness
(Depressed level of consciousness)
Depression (Depression)
Dermatitis Radiation (Dermatitis
radiation)
Device Related Infection (Device related
infection)
Diarrhea (Diarrhea)
Disseminated Intravascular Coagulation
(Disseminated intravascular coagulation)
Dizziness (Dizziness)
Dry Eye (Dry eye)
Dry Mouth (Dry mouth)
Dry Skin (Dry skin)
Duodenal Fistula (Duodenal fistula)
Duodenal Hemorrhage (Duodenal
hemorrhage)
Duodenal Infection (Duodenal infection)
Duodenal Obstruction (Duodenal
obstruction)
Duodenal Perforation (Duodenal
perforation)
Duodenal Stenosis (Duodenal stenosis)
Duodenal Ulcer (Duodenal ulcer)
Dysarthria (Dysarthria)
Dysesthesia (Dysesthesia)
Dysgeusia (Dysgeusia)
Dysmenorrhea (Dysmenorrhea)
Dyspareunia (Dyspareunia)
Dyspepsia (Dyspepsia)
Dysphagia (Dysphagia)
Dysphasia (Dysphasia)
Dyspnea (Dyspnea)
Ear And Labyrinth Disorders - Other,
Specify (Ear and labyrinth disorders -
Other, Specify)
Ear Pain (Ear pain)
Edema Cerebral (Edema cerebral)
Edema Face (Edema face)
Edema Limbs (Edema limbs)
Edema Trunk (Edema trunk)
Ejaculation Disorder (Ejaculation
disorder)
Ejection Fraction Decreased (Ejection
fraction decreased)
Electrocardiogram Qt Corrected Interval
Prolonged (Electrocardiogram QT
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corrected interval prolonged)
Encephalitis Infection (Encephalitis
infection)
Encephalomyelitis Infection
(Encephalomyelitis infection)
Encephalopathy (Encephalopathy)
Endocarditis Infective (Endocarditis
infective)
Endocrine Disorders - Other, Specify
(Endocrine disorders - Other, Specify)
Endophthalmitis (Endophthalmitis)
Enterocolitis (Enterocolitis)
Enterocolitis Infectious (Enterocolitis
infectious)
Enterovesical Fistula (Enterovesical
fistula)
Epistaxis (Epistaxis)
Erectile Dysfunction (Erectile
dysfunction)
Erythema Multiforme (Erythema
multiforme)
Erythroderma (Erythroderma)
Esophageal Anastomotic Leak
(Esophageal anastomotic leak)
Esophageal Fistula (Esophageal fistula)
Esophageal Hemorrhage (Esophageal
hemorrhage)
Esophageal Infection (Esophageal
infection)
Esophageal Necrosis (Esophageal
necrosis)
Esophageal Obstruction (Esophageal
obstruction)
Esophageal Pain (Esophageal pain)
Esophageal Perforation (Esophageal
perforation)
Esophageal Stenosis (Esophageal
stenosis)
Esophageal Ulcer (Esophageal ulcer)
Esophageal Varices Hemorrhage
(Esophageal varices hemorrhage)
Esophagitis (Esophagitis)
Euphoria (Euphoria)
Exostosis (Exostosis)
External Ear Inflammation (External ear
inflammation)
External Ear Pain (External ear pain)
Extraocular Muscle Paresis (Extraocular
muscle paresis)
Extrapyramidal Disorder (Extrapyramidal
disorder)
Eye Disorders - Other, Specify (Eye
disorders - Other, Specify)
Eye Infection (Eye infection)
Eye Pain (Eye pain)
Eyelid Function Disorder (Eyelid function
disorder)
Facial Muscle Weakness (Facial muscle
weakness)
Facial Nerve Disorder (Facial nerve
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disorder)
Facial Pain (Facial pain)
Fall (Fall)
Fallopian Tube Anastomotic Leak
(Fallopian tube anastomotic leak)
Fallopian Tube Obstruction (Fallopian
tube obstruction)
Fallopian Tube Perforation (Fallopian
tube perforation)
Fallopian Tube Stenosis (Fallopian tube
stenosis)
Fat Atrophy (Fat atrophy)
Fatigue (Fatigue)
Febrile Neutropenia (Febrile
neutropenia)
Fecal Incontinence (Fecal incontinence)
Female Genital Tract Fistula (Female
genital tract fistula)
Feminization Acquired (Feminization
acquired)
Fetal Death (Fetal death)
Fetal Growth Retardation (Fetal growth
retardation)
Fever (Fever)
Fibrinogen Decreased (Fibrinogen
decreased)
Fibrosis Deep Connective Tissue
(Fibrosis deep connective tissue)
Flank Pain (Flank pain)
Flashing Lights (Flashing lights)
Flatulence (Flatulence)
Floaters (Floaters)
Flu Like Symptoms (Flu like symptoms)
Flushing (Flushing)
Forced Expiratory Volume Decreased
(Forced expiratory volume decreased)
Fracture (Fracture)
Gait Disturbance (Gait disturbance)
Gallbladder Fistula (Gallbladder fistula)
Gallbladder Infection (Gallbladder
infection)
Gallbladder Necrosis (Gallbladder
necrosis)
Gallbladder Obstruction (Gallbladder
obstruction)
Gallbladder Pain (Gallbladder pain)
Gallbladder Perforation (Gallbladder
perforation)
Gastric Anastomotic Leak (Gastric
anastomotic leak)
Gastric Fistula (Gastric fistula)
Gastric Hemorrhage (Gastric
hemorrhage)
Gastric Necrosis (Gastric necrosis)
Gastric Perforation (Gastric perforation)
Gastric Stenosis (Gastric stenosis)
Gastric Ulcer (Gastric ulcer)
Gastritis (Gastritis)
Gastroesophageal Reflux Disease
(Gastroesophageal reflux disease)
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Gastrointestinal Anastomotic Leak
(Gastrointestinal anastomotic leak)
Gastrointestinal Disorders - Other,
Specify (Gastrointestinal disorders -
Other, Specify)
Gastrointestinal Fistula (Gastrointestinal
fistula)
Gastrointestinal Pain (Gastrointestinal
pain)
Gastrointestinal Stoma Necrosis
(Gastrointestinal stoma necrosis)
Gastroparesis (Gastroparesis)
General Disorders And Administration
Site Conditions - Other, Specify (General
disorders and administration site
conditions - Other, Specify)
Generalized Muscle Weakness
(Generalized muscle weakness)
Genital Edema (Genital edema)
Ggt Increased (GGT increased)
Gingival Pain (Gingival pain)
Glaucoma (Glaucoma)
Glossopharyngeal Nerve Disorder
(Glossopharyngeal nerve disorder)
Glucose Intolerance (Glucose
intolerance)
Growth Accelerated (Growth
accelerated)
Growth Hormone Abnormal (Growth
hormone abnormal)
Growth Suppression (Growth
suppression)
Gum Infection (Gum infection)
Gynecomastia (Gynecomastia)
Hallucinations (Hallucinations)
Haptoglobin Decreased (Haptoglobin
decreased)
Head Soft Tissue Necrosis (Head soft
tissue necrosis)
Headache (Headache)
Hearing Impaired (Hearing impaired)
Heart Failure (Heart failure)
Hematoma (Hematoma)
Hematosalpinx (Hematosalpinx)
Hematuria (Hematuria)
Hemoglobin Increased (Hemoglobin
increased)
Hemoglobinuria (Hemoglobinuria)
Hemolysis (Hemolysis)
Hemolytic Uremic Syndrome (Hemolytic
uremic syndrome)
Hemorrhoidal Hemorrhage
(Hemorrhoidal hemorrhage)
Hemorrhoids (Hemorrhoids)
Hepatic Failure (Hepatic failure)
Hepatic Hemorrhage (Hepatic
hemorrhage)
Hepatic Infection (Hepatic infection)
Hepatic Necrosis (Hepatic necrosis)
Hepatic Pain (Hepatic pain)
11 / 24
NCT01013649 RTOG 0848 Phase III Pancreas-Resected + Adjuvant
Treatment Follow-up Form (F1)
Hepatitis Viral (Hepatitis viral)
Hepatobiliary Disorders - Other, Specify
(Hepatobiliary disorders - Other, Specify)
Hiccups (Hiccups)
Hip Fracture (Hip fracture)
Hirsutism (Hirsutism)
Hoarseness (Hoarseness)
Hot Flashes (Hot flashes)
Hydrocephalus (Hydrocephalus)
Hypercalcemia (Hypercalcemia)
Hyperglycemia (Hyperglycemia)
Hyperhidrosis (Hyperhidrosis)
Hyperkalemia (Hyperkalemia)
Hypermagnesemia (Hypermagnesemia)
Hypernatremia (Hypernatremia)
Hyperparathyroidism
(Hyperparathyroidism)
Hypersomnia (Hypersomnia)
Hypertension (Hypertension)
Hyperthyroidism (Hyperthyroidism)
Hypertrichosis (Hypertrichosis)
Hypertriglyceridemia
(Hypertriglyceridemia)
Hyperuricemia (Hyperuricemia)
Hypoalbuminemia (Hypoalbuminemia)
Hypocalcemia (Hypocalcemia)
Hypoglossal Nerve Disorder
(Hypoglossal nerve disorder)
Hypoglycemia (Hypoglycemia)
Hypohidrosis (Hypohidrosis)
Hypokalemia (Hypokalemia)
Hypomagnesemia (Hypomagnesemia)
Hyponatremia (Hyponatremia)
Hypoparathyroidism
(Hypoparathyroidism)
Hypophosphatemia (Hypophosphatemia)
Hypotension (Hypotension)
Hypothermia (Hypothermia)
Hypothyroidism (Hypothyroidism)
Hypoxia (Hypoxia)
Ileal Fistula (Ileal fistula)
Ileal Hemorrhage (Ileal hemorrhage)
Ileal Obstruction (Ileal obstruction)
Ileal Perforation (Ileal perforation)
Ileal Stenosis (Ileal stenosis)
Ileal Ulcer (Ileal ulcer)
Ileus (Ileus)
Immune System Disorders - Other,
Specify (Immune system disorders -
Other, Specify)
Infections And Infestations - Other,
Specify (Infections and infestations -
Other, Specify)
Infective Myositis (Infective myositis)
Infusion Related Reaction (Infusion
related reaction)
Infusion Site Extravasation (Infusion site
extravasation)
Injection Site Reaction (Injection site
reaction)
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Injury To Carotid Artery (Injury to carotid
artery)
Injury To Inferior Vena Cava (Injury to
inferior vena cava)
Injury To Jugular Vein (Injury to jugular
vein)
Injury To Superior Vena Cava (Injury to
superior vena cava)
Injury, Poisoning And Procedural
Complications - Other, Specify (Injury,
poisoning and procedural complications -
Other, Specify)
Inr Increased (INR increased)
Insomnia (Insomnia)
Intestinal Stoma Leak (Intestinal stoma
leak)
Intestinal Stoma Obstruction (Intestinal
stoma obstruction)
Intestinal Stoma Site Bleeding (Intestinal
stoma site bleeding)
Intra-abdominal Hemorrhage (Intra-
abdominal hemorrhage)
Intracranial Hemorrhage (Intracranial
hemorrhage)
Intraoperative Arterial Injury
(Intraoperative arterial injury)
Intraoperative Breast Injury
(Intraoperative breast injury)
Intraoperative Cardiac Injury
(Intraoperative cardiac injury)
Intraoperative Ear Injury (Intraoperative
ear injury)
Intraoperative Endocrine Injury
(Intraoperative endocrine injury)
Intraoperative Gastrointestinal Injury
(Intraoperative gastrointestinal injury)
Intraoperative Head And Neck Injury
(Intraoperative head and neck injury)
Intraoperative Hemorrhage
(Intraoperative hemorrhage)
Intraoperative Hepatobiliary Injury
(Intraoperative hepatobiliary injury)
Intraoperative Musculoskeletal Injury
(Intraoperative musculoskeletal injury)
Intraoperative Neurological Injury
(Intraoperative neurological injury)
Intraoperative Ocular Injury
(Intraoperative ocular injury)
Intraoperative Renal Injury
(Intraoperative renal injury)
Intraoperative Reproductive Tract Injury
(Intraoperative reproductive tract injury)
Intraoperative Respiratory Injury
(Intraoperative respiratory injury)
Intraoperative Skin Injury (Intraoperative
skin injury)
Intraoperative Splenic Injury
(Intraoperative splenic injury)
Intraoperative Urinary Injury
(Intraoperative urinary injury)
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Intraoperative Venous Injury
(Intraoperative venous injury)
Investigations - Other, Specify
(Investigations - Other, Specify)
Iron Overload (Iron overload)
Irregular Menstruation (Irregular
menstruation)
Irritability (Irritability)
Ischemia Cerebrovascular (Ischemia
cerebrovascular)
Ivth Nerve Disorder (IVth nerve disorder)
Jejunal Fistula (Jejunal fistula)
Jejunal Hemorrhage (Jejunal
hemorrhage)
Jejunal Obstruction (Jejunal obstruction)
Jejunal Perforation (Jejunal perforation)
Jejunal Stenosis (Jejunal stenosis)
Jejunal Ulcer (Jejunal ulcer)
Joint Effusion (Joint effusion)
Joint Infection (Joint infection)
Joint Range Of Motion Decreased (Joint
range of motion decreased)
Joint Range Of Motion Decreased
Cervical Spine (Joint range of motion
decreased cervical spine)
Joint Range Of Motion Decreased
Lumbar Spine (Joint range of motion
decreased lumbar spine)
Keratitis (Keratitis)
Kidney Anastomotic Leak (Kidney
anastomotic leak)
Kidney Infection (Kidney infection)
Kyphosis (Kyphosis)
Lactation Disorder (Lactation disorder)
Large Intestinal Anastomotic Leak (Large
intestinal anastomotic leak)
Laryngeal Edema (Laryngeal edema)
Laryngeal Fistula (Laryngeal fistula)
Laryngeal Hemorrhage (Laryngeal
hemorrhage)
Laryngeal Inflammation (Laryngeal
inflammation)
Laryngeal Mucositis (Laryngeal
mucositis)
Laryngeal Obstruction (Laryngeal
obstruction)
Laryngeal Stenosis (Laryngeal stenosis)
Laryngitis (Laryngitis)
Laryngopharyngeal Dysesthesia
(Laryngopharyngeal dysesthesia)
Laryngospasm (Laryngospasm)
Left Ventricular Systolic Dysfunction (Left
ventricular systolic dysfunction)
Lethargy (Lethargy)
Leukemia Secondary To Oncology
Chemotherapy (Leukemia secondary to
oncology chemotherapy)
Leukocytosis (Leukocytosis)
Leukoencephalopathy
(Leukoencephalopathy)
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Libido Decreased (Libido decreased)
Libido Increased (Libido increased)
Lip Infection (Lip infection)
Lip Pain (Lip pain)
Lipase Increased (Lipase increased)
Lipohypertrophy (Lipohypertrophy)
Localized Edema (Localized edema)
Lordosis (Lordosis)
Lower Gastrointestinal Hemorrhage
(Lower gastrointestinal hemorrhage)
Lung Infection (Lung infection)
Lymph Gland Infection (Lymph gland
infection)
Lymph Leakage (Lymph leakage)
Lymph Node Pain (Lymph node pain)
Lymphedema (Lymphedema)
Lymphocele (Lymphocele)
Lymphocyte Count Decreased
(Lymphocyte count decreased)
Lymphocyte Count Increased
(Lymphocyte count increased)
Malabsorption (Malabsorption)
Malaise (Malaise)
Mania (Mania)
Mediastinal Hemorrhage (Mediastinal
hemorrhage)
Mediastinal Infection (Mediastinal
infection)
Memory Impairment (Memory
impairment)
Meningismus (Meningismus)
Meningitis (Meningitis)
Menopause (Menopause)
Menorrhagia (Menorrhagia)
Metabolism And Nutrition Disorders -
Other, Specify (Metabolism and nutrition
disorders - Other, Specify)
Middle Ear Inflammation (Middle ear
inflammation)
Mitral Valve Disease (Mitral valve
disease)
Mobitz (type) Ii Atrioventricular Block
(Mobitz (type) II atrioventricular block)
Mobitz Type I (Mobitz type I)
Movements Involuntary (Movements
involuntary)
Mucosal Infection (Mucosal infection)
Mucositis Oral (Mucositis oral)
Multi-organ Failure (Multi-organ failure)
Muscle Weakness Left-sided (Muscle
weakness left-sided)
Muscle Weakness Lower Limb (Muscle
weakness lower limb)
Muscle Weakness Right-sided (Muscle
weakness right-sided)
Muscle Weakness Trunk (Muscle
weakness trunk)
Muscle Weakness Upper Limb (Muscle
weakness upper limb)
Musculoskeletal And Connective Tissue
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Disorder - Other, Specify
(Musculoskeletal and connective tissue
disorders - Other, Specify)
Musculoskeletal Deformity
(Musculoskeletal deformity)
Myalgia (Myalgia)
Myelitis (Myelitis)
Myelodysplastic Syndrome
(Myelodysplastic syndrome)
Myocardial Infarction (Myocardial
infarction)
Myocarditis (Myocarditis)
Myositis (Myositis)
Nail Discoloration (Nail discoloration)
Nail Infection (Nail infection)
Nail Loss (Nail loss)
Nail Ridging (Nail ridging)
Nasal Congestion (Nasal congestion)
Nausea (Nausea)
Neck Edema (Neck edema)
Neck Pain (Neck pain)
Neck Soft Tissue Necrosis (Neck soft
tissue necrosis)
Neoplasms Benign, Malignant And
Unspecified (incl Cysts And Polyps) -
Other, Specify (Neoplasms benign,
malignant and unspecified (incl cysts and
polyps) - Other, Specify)
Nervous System Disorders - Other,
Specify (Nervous system disorders -
Other, Specify)
Neuralgia (Neuralgia)
Neutrophil Count Decreased (Neutrophil
count decreased)
Night Blindness (Night blindness)
Nipple Deformity (Nipple deformity)
Non-cardiac Chest Pain (Non-cardiac
chest pain)
Nystagmus (Nystagmus)
Obesity (Obesity)
Obstruction Gastric (Obstruction gastric)
Oculomotor Nerve Disorder (Oculomotor
nerve disorder)
Olfactory Nerve Disorder (Olfactory
nerve disorder)
Oligospermia (Oligospermia)
Optic Nerve Disorder (Optic nerve
disorder)
Oral Cavity Fistula (Oral cavity fistula)
Oral Dysesthesia (Oral dysesthesia)
Oral Hemorrhage (Oral hemorrhage)
Oral Pain (Oral pain)
Osteonecrosis Of Jaw (Osteonecrosis of
jaw)
Osteoporosis (Osteoporosis)
Otitis Externa (Otitis externa)
Otitis Media (Otitis media)
Ovarian Hemorrhage (Ovarian
hemorrhage)
Ovarian Infection (Ovarian infection)
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Ovarian Rupture (Ovarian rupture)
Ovulation Pain (Ovulation pain)
Pain (Pain)
Pain In Extremity (Pain in extremity)
Pain Of Skin (Pain of skin)
Palmar-plantar Erythrodysesthesia
Syndrome (Palmar-plantar
erythrodysesthesia syndrome)
Palpitations (Palpitations)
Pancreas Infection (Pancreas infection)
Pancreatic Anastomotic Leak (Pancreatic
anastomotic leak)
Pancreatic Duct Stenosis (Pancreatic
duct stenosis)
Pancreatic Enzymes Decreased
(Pancreatic enzymes decreased)
Pancreatic Fistula (Pancreatic fistula)
Pancreatic Hemorrhage (Pancreatic
hemorrhage)
Pancreatic Necrosis (Pancreatic
necrosis)
Pancreatitis (Pancreatitis)
Papilledema (Papilledema)
Papulopustular Rash (Papulopustular
rash)
Paresthesia (Paresthesia)
Paronychia (Paronychia)
Paroxysmal Atrial Tachycardia
(Paroxysmal atrial tachycardia)
Pelvic Floor Muscle Weakness (Pelvic
floor muscle weakness)
Pelvic Infection (Pelvic infection)
Pelvic Pain (Pelvic pain)
Pelvic Soft Tissue Necrosis (Pelvic soft
tissue necrosis)
Penile Infection (Penile infection)
Penile Pain (Penile pain)
Perforation Bile Duct (Perforation bile
duct)
Pericardial Effusion (Pericardial effusion)
Pericardial Tamponade (Pericardial
tamponade)
Pericarditis (Pericarditis)
Perineal Pain (Perineal pain)
Periodontal Disease (Periodontal
disease)
Periorbital Edema (Periorbital edema)
Periorbital Infection (Periorbital infection)
Peripheral Ischemia (Peripheral
ischemia)
Peripheral Motor Neuropathy (Peripheral
motor neuropathy)
Peripheral Nerve Infection (Peripheral
nerve infection)
Peripheral Sensory Neuropathy
(Peripheral sensory neuropathy)
Peritoneal Infection (Peritoneal infection)
Peritoneal Necrosis (Peritoneal necrosis)
Personality Change (Personality change)
Phantom Pain (Phantom pain)
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Pharyngeal Anastomotic Leak
(Pharyngeal anastomotic leak)
Pharyngeal Fistula (Pharyngeal fistula)
Pharyngeal Hemorrhage (Pharyngeal
hemorrhage)
Pharyngeal Mucositis (Pharyngeal
mucositis)
Pharyngeal Necrosis (Pharyngeal
necrosis)
Pharyngeal Stenosis (Pharyngeal
stenosis)
Pharyngitis (Pharyngitis)
Pharyngolaryngeal Pain
(Pharyngolaryngeal pain)
Phlebitis (Phlebitis)
Phlebitis Infective (Phlebitis infective)
Photophobia (Photophobia)
Photosensitivity (Photosensitivity)
Platelet Count Decreased (Platelet count
decreased)
Pleural Effusion (Pleural effusion)
Pleural Hemorrhage (Pleural
hemorrhage)
Pleural Infection (Pleural infection)
Pleuritic Pain (Pleuritic pain)
Pneumonitis (Pneumonitis)
Pneumothorax (Pneumothorax)
Portal Hypertension (Portal
hypertension)
Portal Vein Thrombosis (Portal vein
thrombosis)
Postnasal Drip (Postnasal drip)
Postoperative Hemorrhage
(Postoperative hemorrhage)
Postoperative Thoracic Procedure
Complication (Postoperative thoracic
procedure complication)
Precocious Puberty (Precocious
puberty)
Pregnancy, Puerperium And Perinatal
Conditions - Other, Specify (Pregnancy,
puerperium and perinatal conditions -
Other, Specify)
Premature Delivery (Premature delivery)
Premature Menopause (Premature
menopause)
Presyncope (Presyncope)
Proctitis (Proctitis)
Productive Cough (Productive cough)
Prolapse Of Intestinal Stoma (Prolapse
of intestinal stoma)
Prolapse Of Urostomy (Prolapse of
urostomy)
Prostate Infection (Prostate infection)
Prostatic Hemorrhage (Prostatic
hemorrhage)
Prostatic Obstruction (Prostatic
obstruction)
Prostatic Pain (Prostatic pain)
Proteinuria (Proteinuria)
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Pruritus (Pruritus)
Psychiatric Disorders - Other, Specify
(Psychiatric disorders - Other, Specify)
Psychosis (Psychosis)
Pulmonary Edema (Pulmonary edema)
Pulmonary Fibrosis (Pulmonary fibrosis)
Pulmonary Fistula (Pulmonary fistula)
Pulmonary Hypertension (Pulmonary
hypertension)
Pulmonary Valve Disease (Pulmonary
valve disease)
Purpura (Purpura)
Pyramidal Tract Syndrome (Pyramidal
tract syndrome)
Radiation Recall Reaction (dermatologic)
(Radiation recall reaction (dermatologic))
Radiculitis (Radiculitis)
Rash Acneiform (Rash acneiform)
Rash Maculo-papular (Rash maculo-
papular)
Rash Pustular (Rash pustular)
Rectal Anastomotic Leak (Rectal
anastomotic leak)
Rectal Fistula (Rectal fistula)
Rectal Hemorrhage (Rectal hemorrhage)
Rectal Mucositis (Rectal mucositis)
Rectal Necrosis (Rectal necrosis)
Rectal Obstruction (Rectal obstruction)
Rectal Pain (Rectal pain)
Rectal Perforation (Rectal perforation)
Rectal Stenosis (Rectal stenosis)
Rectal Ulcer (Rectal ulcer)
Recurrent Laryngeal Nerve Palsy
(Recurrent laryngeal nerve palsy)
Renal And Urinary Disorders - Other,
Specify (Renal and urinary disorders -
Other, Specify)
Renal Calculi (Renal calculi)
Renal Colic (Renal colic)
Renal Hemorrhage (Renal hemorrhage)
Reproductive System And Breast
Disorders - Other, Specify (Reproductive
system and breast disorders - Other,
Specify)
Respiratory Failure (Respiratory failure)
Respiratory, Thoracic And Mediastinal
Disorders - Other, Specify (Respiratory,
thoracic and mediastinal disorders -
Other, Specify)
Restlessness (Restlessness)
Restrictive Cardiomyopathy (Restrictive
cardiomyopathy)
Retinal Detachment (Retinal
detachment)
Retinal Tear (Retinal tear)
Retinal Vascular Disorder (Retinal
vascular disorder)
Retinoic Acid Syndrome (Retinoic acid
syndrome)
Retinopathy (Retinopathy)
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Retroperitoneal Hemorrhage
(Retroperitoneal hemorrhage)
Reversible Posterior
Leukoencephalopathy Syndrome
(Reversible posterior
leukoencephalopathy syndrome)
Rhinitis Infective (Rhinitis infective)
Right Ventricular Dysfunction (Right
ventricular dysfunction)
Salivary Duct Inflammation (Salivary duct
inflammation)
Salivary Gland Fistula (Salivary gland
fistula)
Salivary Gland Infection (Salivary gland
infection)
Scalp Pain (Scalp pain)
Scleral Disorder (Scleral disorder)
Scoliosis (Scoliosis)
Scrotal Infection (Scrotal infection)
Scrotal Pain (Scrotal pain)
Seizure (Seizure)
Sepsis (Sepsis)
Seroma (Seroma)
Serum Amylase Increased (Serum
amylase increased)
Serum Sickness (Serum sickness)
Sick Sinus Syndrome (Sick sinus
syndrome)
Sinus Bradycardia (Sinus bradycardia)
Sinus Disorder (Sinus disorder)
Sinus Pain (Sinus pain)
Sinus Tachycardia (Sinus tachycardia)
Sinusitis (Sinusitis)
Skin And Subcutaneous Tissue
Disorders - Other, Specify (Skin and
subcutaneous tissue disorders - Other,
Specify)
Skin Atrophy (Skin atrophy)
Skin Hyperpigmentation (Skin
hyperpigmentation)
Skin Hypopigmentation (Skin
hypopigmentation)
Skin Induration (Skin induration)
Skin Infection (Skin infection)
Skin Ulceration (Skin ulceration)
Sleep Apnea (Sleep apnea)
Small Intestinal Anastomotic Leak (Small
intestinal anastomotic leak)
Small Intestinal Mucositis (Small
intestinal mucositis)
Small Intestinal Obstruction (Small
intestinal obstruction)
Small Intestinal Perforation (Small
intestinal perforation)
Small Intestinal Stenosis (Small intestinal
stenosis)
Small Intestine Infection (Small intestine
infection)
Small Intestine Ulcer (Small intestine
ulcer)
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Sneezing (Sneezing)
Social Circumstances - Other, Specify
(Social circumstances - Other, Specify)
Soft Tissue Infection (Soft tissue
infection)
Soft Tissue Necrosis Lower Limb (Soft
tissue necrosis lower limb)
Soft Tissue Necrosis Upper Limb (Soft
tissue necrosis upper limb)
Somnolence (Somnolence)
Sore Throat (Sore throat)
Spasticity (Spasticity)
Spermatic Cord Anastomotic Leak
(Spermatic cord anastomotic leak)
Spermatic Cord Hemorrhage (Spermatic
cord hemorrhage)
Spermatic Cord Obstruction (Spermatic
cord obstruction)
Spinal Fracture (Spinal fracture)
Spleen Disorder (Spleen disorder)
Splenic Infection (Splenic infection)
Stenosis Of Gastrointestinal Stoma
(Stenosis of gastrointestinal stoma)
Stevens-johnson Syndrome (Stevens-
Johnson syndrome)
Stoma Site Infection (Stoma site
infection)
Stomach Pain (Stomach pain)
Stomal Ulcer (Stomal ulcer)
Stridor (Stridor)
Stroke (Stroke)
Sudden Death Nos (Sudden death NOS)
Suicidal Ideation (Suicidal ideation)
Suicide Attempt (Suicide attempt)
Superficial Soft Tissue Fibrosis
(Superficial soft tissue fibrosis)
Superficial Thrombophlebitis (Superficial
thrombophlebitis)
Superior Vena Cava Syndrome (Superior
vena cava syndrome)
Supraventricular Tachycardia
(Supraventricular tachycardia)
Surgical And Medical Procedures -
Other, Specify (Surgical and medical
procedures - Other, Specify)
Syncope (Syncope)
Telangiectasia (Telangiectasia)
Testicular Disorder (Testicular disorder)
Testicular Hemorrhage (Testicular
hemorrhage)
Testicular Pain (Testicular pain)
Thromboembolic Event
(Thromboembolic event)
Thrombotic Thrombocytopenic Purpura
(Thrombotic thrombocytopenic purpura)
Tinnitus (Tinnitus)
Tooth Development Disorder (Tooth
development disorder)
Tooth Discoloration (Tooth discoloration)
Tooth Infection (Tooth infection)
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Toothache (Toothache)
Toxic Epidermal Necrolysis (Toxic
epidermal necrolysis)
Tracheal Fistula (Tracheal fistula)
Tracheal Hemorrhage (Tracheal
hemorrhage)
Tracheal Mucositis (Tracheal mucositis)
Tracheal Obstruction (Tracheal
obstruction)
Tracheal Stenosis (Tracheal stenosis)
Tracheitis (Tracheitis)
Tracheostomy Site Bleeding
(Tracheostomy site bleeding)
Transient Ischemic Attacks (Transient
ischemic attacks)
Treatment Related Secondary
Malignancy (Treatment related
secondary malignancy)
Tremor (Tremor)
Tricuspid Valve Disease (Tricuspid valve
disease)
Trigeminal Nerve Disorder (Trigeminal
nerve disorder)
Trismus (Trismus)
Tumor Lysis Syndrome (Tumor lysis
syndrome)
Tumor Pain (Tumor pain)
Typhlitis (Typhlitis)
Unequal Limb Length (Unequal limb
length)
Unintended Pregnancy (Unintended
pregnancy)
Upper Gastrointestinal Hemorrhage
(Upper gastrointestinal hemorrhage)
Upper Respiratory Infection (Upper
respiratory infection)
Ureteric Anastomotic Leak (Ureteric
anastomotic leak)
Urethral Anastomotic Leak (Urethral
anastomotic leak)
Urethral Infection (Urethral infection)
Urinary Fistula (Urinary fistula)
Urinary Frequency (Urinary frequency)
Urinary Incontinence (Urinary
incontinence)
Urinary Retention (Urinary retention)
Urinary Tract Infection (Urinary tract
infection)
Urinary Tract Obstruction (Urinary tract
obstruction)
Urinary Tract Pain (Urinary tract pain)
Urinary Urgency (Urinary urgency)
Urine Discoloration (Urine discoloration)
Urine Output Decreased (Urine output
decreased)
Urostomy Leak (Urostomy leak)
Urostomy Obstruction (Urostomy
obstruction)
Urostomy Site Bleeding (Urostomy site
bleeding)
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Urostomy Stenosis (Urostomy stenosis)
Urticaria (Urticaria)
Uterine Anastomotic Leak (Uterine
anastomotic leak)
Uterine Fistula (Uterine fistula)
Uterine Hemorrhage (Uterine
hemorrhage)
Uterine Infection (Uterine infection)
Uterine Obstruction (Uterine obstruction)
Uterine Pain (Uterine pain)
Uterine Perforation (Uterine perforation)
Uveitis (Uveitis)
Vaginal Anastomotic Leak (Vaginal
anastomotic leak)
Vaginal Discharge (Vaginal discharge)
Vaginal Dryness (Vaginal dryness)
Vaginal Fistula (Vaginal fistula)
Vaginal Hemorrhage (Vaginal
hemorrhage)
Vaginal Infection (Vaginal infection)
Vaginal Inflammation (Vaginal
inflammation)
Vaginal Obstruction (Vaginal obstruction)
Vaginal Pain (Vaginal pain)
Vaginal Perforation (Vaginal perforation)
Vaginal Stricture (Vaginal stricture)
Vaginismus (Vaginismus)
Vagus Nerve Disorder (Vagus nerve
disorder)
Vas Deferens Anastomotic Leak (Vas
deferens anastomotic leak)
Vascular Access Complication (Vascular
access complication)
Vascular Disorders - Other, Specify
(Vascular disorders - Other, Specify)
Vasculitis (Vasculitis)
Vasovagal Reaction (Vasovagal reaction)
Venous Injury (Venous injury)
Ventricular Arrhythmia (Ventricular
arrhythmia)
Ventricular Fibrillation (Ventricular
fibrillation)
Ventricular Tachycardia (Ventricular
tachycardia)
Vertigo (Vertigo)
Vestibular Disorder (Vestibular disorder)
Virilization (Virilization)
Visceral Arterial Ischemia (Visceral
arterial ischemia)
Vital Capacity Abnormal (Vital capacity
abnormal)
Vitreous Hemorrhage (Vitreous
hemorrhage)
Voice Alteration (Voice alteration)
Vomiting (Vomiting)
Vulval Infection (Vulval infection)
Watering Eyes (Watering eyes)
Weight Gain (Weight gain)
Weight Loss (Weight loss)
Wheezing (Wheezing)
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White Blood Cell Decreased (White
blood cell decreased)
Wolff-parkinson-white Syndrome (Wolff-
Parkinson-White syndrome)
Wound Complication (Wound
complication)
Wound Dehiscence (Wound dehiscence)
Wound Infection (Wound infection)
Wrist Fracture (Wrist fracture)
Grade
Absent Adverse Event (0)
Mild Adverse Event (1)
Moderate Adverse Event (2)
Severe Adverse Event (3)
Life Threatening Adverse Event (4)
Death Related To Adverse Event (5)
CTCAE Begin Date (MM DD YYYY)
CTC AE Attribution Code
Definite (Definite)
Possible (Possible)
Probable (Probable)
Unlikely (Unlikely)
Unrelated (Unrelated)
SAE report submitted
No (No)
Unknown (Unknown)
Yes (Yes)
Footer Module
Comments
Investigator Signature
Date
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NCT00288080 RTOG-0521 AE: Adverse
Event Evaluation Form
NCT00288080 RTOG-0521 AE: Adverse Event Evaluation
Form
Hormone Therapy and Radiation Therapy or Hormone
Therapy and Radiation Therapy Followed by Docetaxel and
Prednisone in Treating Patients With Localized Prostate
Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=F6AEEB67-
8813-18D7-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11566
NCT00288080 RTOG-0521 AE:
Adverse Event Evaluation Form
RTOG clinical trial administrative data
RTOG Study No.
Case #
Institution Name
Institution No.
Patient Initials
RTOG Patient ID
AMENDED DATA
Yes
No
Report All Continuing Or New Adverse
Events
Date of Last Clinical Assessment
Due date of corresponding form
Type of corresponding form
F1 (F1)
Follow-up Form (FO)
Interim Follow-up Form (FS)
Sf (SF)
Radiation Therapy Form (T1)
Tf (TF)
MedDRA Code
CTCAE TERM
CTCAE GRADE
1 / 2
CTCAE BEGIN DATE
CTCAE ATTRIBUTION CODE (Attribution to
Protocol Treatment See protocol sections 6 & 7
for definition of "protocol treatment")
Definite (Definite)
Possible (Possible)
Probable (Probable)
Unlikely (Unlikely)
Unrelated (Unrelated)
Has an Adverse Event Expedited Report been
submitted?
No (No)
Unknown (Unknown)
Yes (Yes)
Other, specify
AE Description
Signature of Person Completing This Form
Date Form Originally Completed
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NCT01302834  RTOG 1016 F1: Radiation Therapy Oncology
Group Phase III Head and Neck Cancer Follow-Up Form
NCT01302834  RTOG 1016 F1: Radiation Therapy
Oncology Group Phase III Head and Neck Cancer Follow-
Up Form
Radiation Therapy With Cisplatin or Cetuximab in Treating
Patients With Oropharyngeal Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=944181D6-
4EF9-82FB-E040-BB89AD43799B
All rights reserved. Please visit https://medical-data-
models.org/forms/11567
NCT01302834  RTOG 1016 F1:
Radiation Therapy Oncology Group
Phase III Head and Neck Cancer
Follow-Up Form
RTOG clinical trial administrative data
RTOG Study No.
Case #
Institution Name
Institution No.
Patient Initials
RTOG Patient ID
Amended data
Yes
No
Patient status assessment
Date of Last Contact or Death (MM/DD/YYYY)
Patient's Vital Status
Alive (Alive)
Dead (Dead)
Primary Cause of Death
Due To Other Cause (Due to other
cause)
Due To Protocol Treatment (Due to
protocol treatment)
Due To Second Primary Or Other
Malignancy (Due to second primary or
other malignancy)
Due To This Disease (Due to this
disease)
Unknown (Unknown)
Due to protocol treatment, specify
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Due to other cause specify
Does the patient currently require tube feeding
No (No)
Unknown (Unknown)
Yes (Yes)
Is patient dependent on tube feeding for >50% of
nutritional support  (If yes,)
No (No)
Unknown (Unknown)
Yes (Yes)
Dental gingival health
Life-threatening Dental Condition (Life-
threatening dental condition)
Mild Changes/good Dental Health (Mild
changes/good dental health)
Moderate/fair Dental Health
(Moderate/fair dental health)
Normal (Normal)
Severe Changes In Dental Health
(Severe changes in dental health)
Number of native teeth in place
Has the patient had a documented clinical
assessment for this cancer? (since submission of
the previous follow-up form)
No (No)
Unknown (Unknown)
Yes (Yes)
Date of Last Clinical Assessment
RECURRENCE OR PROGRESSION
Has the patient been diagnosed with first local
recurrence or progression (since submission of
the previous follow-up form)
No (No)
Not Applicable, Patient Has Not Been
Assessed (Not applicable, patient has
not been assessed)
Unknown (Unknown)
Yes (Yes)
Date of First Local Progression (MM DD YYYY)
Has the patient been diagnosed with first regional
recurrence or progression (since submission of
the previous follow-up form)
No (No)
Not Applicable, Patient Has Not Been
Assessed (Not applicable, patient has
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not been assessed)
Unknown (Unknown)
Yes (Yes)
Date of first regional progression (MM DD YYYY)
Has the patient been diagnosed with first distant
recurrence/progression? (since submission of the
previous follow-up form)
No (No)
Not Applicable, Patient Has Not Been
Assessed (Not applicable, patient has
not been assessed)
Unknown (Unknown)
Yes (Yes)
Date of First Distant Progression (MM DD YYYY)
Site(s) of distant progression
Bladder (Bladder)
Brain (Brain)
Colorectal (Colorectal)
Esophageal (Esophageal)
Gastric (Gastric)
Hypopharynx (Hypopharynx)
Larynx (Larynx)
Liver (Liver)
Lung (Lung)
Nasopharynx (Nasopharynx)
None (None)
Oral Cavity (Oral cavity)
Oropharynx (Oropharynx)
Other H + N (Other H + N)
Other Solid (Other solid)
Pancreatic (Pancreatic)
Renal (Renal)
Squamous-skin (Squamous-Skin)
Other solid, specify
New primary cancer
Has a new primary cancer or MDS been
diagnosed that has not been previously reported?
No (No)
Unknown (Unknown)
Yes (Yes)
Site(s) of new primary
Aml/mds (AML/MDS)
Bcc (BCC)
Bladder (Bladder)
Brain (Brain)
Colorectal (Colorectal)
Esophageal (Esophageal)
Gastric (Gastric)
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Hypopharynx (Hypopharynx)
Larynx (Larynx)
Liver (Liver)
Lung (Lung)
Melanoma (Melanoma)
Nasopharynx (Nasopharynx)
Nhl (NHL)
None (None)
Oral Cavity (Oral cavity)
Oropharynx (Oropharynx)
Other H + N (Other H + N)
Other Hematologic (Other Hematologic)
Other Solid (Other solid)
Pancreatic (Pancreatic)
Prostate (Prostate)
Renal (Renal)
Squamous-skin (Squamous-Skin)
Unknown Primary (Unknown primary)
Other Hematologic, specify
Other solid, specify
Date of diagnosis  (MM/DD/YYYY)
NON-PROTOCOL THERAPY
Non-Protocol Therapy Type (for study cancer,
begun since submission of previous follow-up
form)
Biologic/targeted Therapy
(Biologic/targeted therapy)
None (None)
Other Specify (Other)
Radiation To Node(s) (Radiation to
node(s))
Radiation To Other Sites, Specify
(Radiation to other sites)
Radiation To Primary (Radiation to
primary)
Surgery For Other Cancer (Surgery for
other cancer)
Surgery For Study Cancer (Surgery for
study cancer)
Systemic Therapy (Systemic therapy)
Unknown (Unknown)
Non-protocol Therapy Start Date
Details
Protocol Specific Adverse Event
Evaluation
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CTCAE Term
CTC AE Grade
Mild Adverse Event (1)
Moderate Adverse Event (2)
Severe Adverse Event (3)
Life Threatening Adverse Event (4)
Death Related To Adverse Event (5)
CTCAE Begin Date (MM DD YYYY)
CTC AE Attribution Code
Definite (Definite)
Possible (Possible)
Probable (Probable)
Unlikely (Unlikely)
Unrelated (Unrelated)
SAE report submitted
No (No)
Unknown (Unknown)
Yes (Yes)
New or continuing adverse events
New or continuing adverse events (not reported
Q11)
No (No)
Unknown (Unknown)
Yes (Yes)
MedDRA Code
Comments
COMMENTS
Person Completing Form
Form completion date, original (MM DD YYYY)
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NCT00331773 RTOG-0415 AE: Adverse
Event Evaluation Form
NCT00331773 RTOG-0415 AE: Adverse Event Evaluation
Form
Radiation Therapy in Treating Patients With Stage II
Prostate Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=062815BB-
E53D-47BE-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11568
NCT00331773 RTOG-0415 AE:
Adverse Event Evaluation Form
RTOG clinical trial administrative data
RTOG Study No.
Case #
Institution Name
Institution No.
Patient Initials
RTOG Patient ID
AMENDED DATA
Yes
No
Report All Continuing Or New Adverse
Events
Date of Last Clinical Assessment
Due date of corresponding form
Type of corresponding form
F1 (F1)
Radiation Therapy Form (T1)
MedDRA Code
CTCAE TERM
CTCAE GRADE
CTCAE BEGIN DATE
CTCAE ATTRIBUTION CODE (Attribution to
1 / 2
Protocol Treatment See protocol sections 6 & 7
for definition of "protocol treatment")
Definite (Definite)
Possible (Possible)
Probable (Probable)
Unlikely (Unlikely)
Unrelated (Unrelated)
Has an Adverse Event Expedited Report been
submitted (ADEERS)
No (No)
Unknown (Unknown)
Yes (Yes)
Other, specify
AE Description
Signature of Person Completing This Form
Date Form Originally Completed
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NCT00499174 NCIC-PR.11 Form 4 -
Radical Intervention Form
NCT00499174 NCIC-PR.11 Form 4 - Radical Intervention
Form
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=0EF81226-
86BC-1C56-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11569
NCT00499174 NCIC-PR.11 Form 4 -
Radical Intervention Form
Patient Information
NCIC Patient ID
Patient Initials (first - middle - last)
Patient Medical Record Number (if permitted by
IRB)
Intergroup Patient Serial No
Institution Name
NCI Institution Number (CTEP assigned)
Investigator First Name
Investigator Last Name
Investigator Number (NCI Investigator Number)
Surgery
Protocol Surgery Date (yyyy mmm dd)
Pelvic lymphadenectomy
Yes
No
Laterality of Pelvic Lymphadenectomy (If yes,)
Bilateral (Bilateral)
Unilateral (Unilateral)
Nerve Sparing Surgery
Yes
No
Laterality of Nerve Sparing Surgery (If yes,)
Bilateral (Bilateral)
Unilateral (Unilateral)
T Stage, Pathologic (Pathologic Stage Tumor
Grouping Pathologic Stage)
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Unilateral (pT2a)
Bilateral (pT2b)
Bilateral (pT2c)
Extraprostatic Extension (pT3)
N Stage, Pathologic
No Regional Lymph Node Metastasis
(pN0)
Metastatis In Regional Lymph Node Or
Nodes (see Ajcc Definition) (pN1)
Regional Lymph Nodes Cannot Be
Assessed (pNX)
Gleason Score, Primary Pattern (1-5)
Gleason Score, Secondary Pattern (1-5)
Gleason Score, Combined (sum of the primary
and secondary)
Any tertiary elements of Gleason 4 or 5 pattern?
No (No)
Unknown (Unknown)
Yes (Yes)
Percent (%) (If yes,)
Was percentage of prostate involved with cancer
determined
Not Applicable (N/A)
No (No)
Yes (Yes)
Percentage of prostate involved with cancer (%
[recommended value of N/A on CRF to be
dropped])
Extraprostatic extension (EPE)
No (NO)
Unknown (UNKNOWN)
Yes (YES)
Type of EPE (If yes,)
Established (Established)
Focal (Focal)
Unknown (Unknown)
Invasion of seminal vesicle
No (NO)
Unknown (UNKNOWN)
Yes (YES)
Does the tumor involve the surgical margin
Yes
No
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Location of positive margin (If yes, check all that
apply)
Apex Of The Prostate (Apex or distal
urethral)
Bilateral (Bilateral)
Bladder Neck (Bladder neck)
Peripheral (Peripheral)
Unilateral (Unilateral)
Is there lymphovascular invasion?
Indeterminate (INDETERMINATE)
No (NO)
Unknown (UNKNOWN)
Yes (YES)
Radiation Therapy
Was patient specific Radiotherapy Facility
Questionnaire completed
Yes
No
Radiation Therapy Start Date (External Beam
yyyy mmm dd)
Radiation Therapy End Date (External Beam
yyyy mmm dd)
Total Dose to Prostate (Gy - High Dose Rate
HDRT Temporary Brachytherapy)
Total Number of Fractions Delivered
Where was this dose prescribed
Radiation Therapy Technique
3d Conformal Radiation Therapy (3D
conformal)
Imrt (intensity Modulated Rt) (IMRT)
Other Specify (Other)
Other specify
Were there any unscheduled interruptions in
radiation therapy? (external beam)
No (No)
Yes Due To Adverse Event (Yes, due to
adverse event(s))
Yes, For Other Reasons, Specify (Yes,
for other reasons)
For other reasons specify (Yes)
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Duration of interruption (RECOMMENDED TERM
for Duration of delay - if yes, days)
Date of Implantation (yyyy mmm dd)
Brachytherapy Isotope
Cesium-131 Isotope (Cs-131)
I-125 (I-125)
Other Specify (Other)
Pd-103 (Pd-103)
Other specify
Volume (%) receiving 100% of the dose (V100)
Fraction (4)
Fraction Date (yyyy mmm dd)
Completion Of Radical Intervention
Date of completion of radical intervention (yyyy
mmm dd)
Reason Treatment Ended
Adverse Event/side Effects/complications
(Adverse Event/Side
Effects/Complications)
Death On Study (Death on study)
Other (Other)
Patient Off-treatment For Other
Complicating Disease (Patient off-
treatment for other complicating disease)
Patient Withdrawal Or Refusal After
Beginning Protocol Therapy (Patient
withdrawal/refusal after beginning
protocol therapy)
Patient Withdrawal Or Refusal Before
Beginning Protocol Therapy (Patient
withdrawal/refusal prior to beginning
protocol therapy)
Treatment Completed Per Protocol
Criteria (Treatment completed per
protocol criteria)
Other specify
CTC Adverse Event Term
Grade (Grade according to NCI CTCAE, Version
4.0)
Absent Adverse Event (0)
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Mild Adverse Event (1)
Moderate Adverse Event (2)
Severe Adverse Event (3)
Life Threatening Adverse Event (4)
Death Related To Adverse Event (5)
CTC Adverse Event Attribution Code
(**1=unrelated, 2=unlikely, 3=possible,
4=probable, 5=definite)
Definite (Definite)
Possible (Possible)
Probable (Probable)
Unlikely (Unlikely)
Unrelated (Unrelated)
Androgen Deprivation Therapy For
Prostate Cancer
Non-protocol non-steroidal antiandrogen therapy
Yes
No
Date of First Non-Protocol Therapy (for Prostate
Cancer )
Agent
Non-protocol LHRH analogues
Yes
No
Agent
Other Non-Protocol Therapy (for prostate
cancer?)
Yes
No
Name of Other Non-Protocol Therapy (If yes, for
Prostate Cancer)
Correlative Studies
Was tissue collected for tumor banking
Yes
No
Reason
Quality Of Life Questionnaire
Was QoL Questionnaire completed?
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No: C49487 (No)
Not Applicable (Not Applicable)
Yes: C49488 (Yes)
Date Questionnaire Completed (yyyy mmm dd
Please submit Quality of Life Questionnaires.)
Reason Questionnaire was not Completed
Other Reason (Other reason)
Patient Refused (Patient refused)
Patient Refused Due To Illness (Patient
refused due to illness)
Patient Unable To Be Contacted (Patient
unable to be contacted)
Questionnaire Not Completed Due To
Institutional Error (Questionnaire not
completed due to institutional error)
Other reason, specify
Comments
Comments
Supporting Documentation
Investigator Signature
Person Completing Form, Last Name
Person Completing Form, First Name
Date Form Originally Completed (yyyy - mmm -
dd)
6 / 6
NCT00499174 NCIC-PR.11 Form 4 - Radical Intervention Form
NCIC CTG Standard Form Modules
National Cancer Institute of Canada (NCIC) Clinical Trials
Group (CTG) Standard Form Modules
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=0EE9029D-
F497-2289-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11570
NCIC CTG Standard Form Modules
Patient Information
NCIC Patient ID (NCIC CTG Patient Serial
Number issued at the time of randomization)
Patient Initials
Patient Medical Record Number (if permitted by
IRB)
Institution Name
NCI Institution Number (CTEP assigned)
Investigator First Name
Investigator Last Name
Patient's Date of Birth (yyyy - mmm - dd)
Registered Investigator (NCI Investigator
Number)
Patient Study ID
Month Of Report
Month of report (circle one)
12 (12)
18 (18)
24 (24)
3 (3)
6 (6)
9 (9)
Other Month (OTHER)
Other
Physical Exam
Date of Last Clinical Assessment (yyyy - mmm -
dd)
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ECOG Performance Status (check one)
Fully Active, Able To Carry On All Pre-
disease Performance Without
Restriction. (0)
Restricted In Physically Strenuous
Activity But Ambulatory And Able To
Carry Out Work Of A Light Or Sedentary
Nature, E.g., Light Housework, Office
Work. (1)
Ambulatory And Capable Of All Selfcare
But Unable To Carry Out Any Work
Activities. Up And About More Than 50%
Of Waking Hours. (2)
Capable Of Only Limited Selfcare,
Confined To Bed Or Chair More Than
50% Of Waking Hours. (3)
Completely Disabled. Cannot Carry On
Any Selfcare. Totally Confined To Bed Or
Chair. (4)
Adverse Event Status
Common Toxicity Criteria Adverse Event Short
Name Type
Alopecia (Alopecia)
Diarrhoea Nos (Diarrhea)
Fatigue (Fatigue)
Pain (Pain - Select)
CTCAE Select Term (if applicable)
Abdomen (Abdomen NOS)
Other (Other NOS)
CTC Adverse Event Grade
CTC Adverse Event Attribution Code (*Serious
Adverse Event form required only if malignancy is
thought to be possibly, probably, or definitely
related to protocol therapy. See protocol...)
Definite (Definite)
Possible (Possible)
Probable (Probable)
Unlikely (Unlikely)
Unrelated (Unrelated)
Seriousness Attributed to Adverse Event (Enter
appropriate code as follows: 0=not serious;
1=death; 2=life threatening; 3=hospitalization,
initial or prolonged; 4=disability...)
Congenital Anomaly (Congenital
anomaly)
Death (Death)
Disability (Disability/incapacity)
Hospitalized (Hospitalization, initial or
prolonged)
Life Threatening (Life threatening)
Not Serious (Not serious)
Other (Other)
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Intervention Required (Required
intervention to prevent permanent
impairment/damage)
SAE report submitted (NCIC CTG use only
Default=N enter Y only for adverse events
recorded on SAE report)
Yes
No
Other Malignancies Or Marrow Dysplasia
Has a new primary cancer or MDS been
diagnosed that has not been previously reported?
(myelodysplastic syndrome)
Yes
No
Date of Diagnosis (yyyy-mmm-dd)
Malignancy Type (e.g., bladder)
New Primary Diagnosis
(Histology/Cytopathology)
Comments
Comments
Supporting Documentation
Investigator Signature
Investigator Signature
Person Completing Form, Last Name
Person Completing Form, First Name
Date Form Originally Completed (yyyy - mmm -
dd)
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RTOG-0525 AE: Adverse Event Evaluation
Form NCT00304031
RTOG-0525 AE: Adverse Event Evaluation Form
NCT00304031 
Radiation Therapy and Temozolomide in Treating Patients
With Newly Diagnosed Glioblastoma or Gliosarcoma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=FD9B3E8E-
5C94-635F-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11571
RTOG-0525 AE: Adverse Event
Evaluation Form NCT00304031
RTOG clinical trial administrative data
RTOG Study No.
Case #
Institution Name
Institution No.
Patient Initials
RTOG Patient ID
AMENDED DATA
Yes
No
Report All Continuing Or New Adverse
Events
Date of Last Clinical Assessment
Due date of corresponding form
Type of corresponding form
F1 (F1)
Follow-up Form (FO)
Interim Follow-up Form (FS)
Sf (SF)
Radiation Therapy Form (T1)
Tf (TF)
MedDRA Code
CTC AE Term
CTC AE Grade (Score most severe grade
observed during report period Grade 1-5.)
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CTCAE BEGIN DATE
CTCAE ATTRIBUTION CODE (Attribution to
Protocol Treatment See protocol sections 6 & 7
for definition of "protocol treatment")
Definite (Definite)
Possible (Possible)
Probable (Probable)
Unlikely (Unlikely)
Unrelated (Unrelated)
SAE report submitted
No (No)
Unknown (Unknown)
Yes (Yes)
Other, specify
AE Description
Person completing form
Form Completion Date
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NCT00533949  RTOG-0617 HP: Radiation Therapy Oncology Group Phase III
High-dose Vs Standard-dose Conformal XRT with Chemotherapy Health Utility
Measurement Euro (EQ - 5D)
NCT00533949 RTOG-0617 HP: Radiation Therapy
Oncology Group Phase III High-dose Vs Standard-dose
Conformal XRT with Chemotherapy Health Utility
Measurement Euro (EQ - 5D)
High-Dose or Standard-Dose Radiation Therapy and
Chemotherapy With or Without Cetuximab in Treating
Patients With Newly Diagnosed Stage III Non-Small Cell
Lung Cancer That Cannot Be Removed by Surgery
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=24E6B80C-
368A-3843-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11572
NCT00533949  RTOG-0617 HP:
Radiation Therapy Oncology Group
Phase III High-dose Vs Standard-
dose Conformal XRT with
Chemotherapy Health Utility
Measurement Euro (EQ - 5D)
RTOG clinical trial administrative data
RTOG Study No.
Case #
Institution Name
Institution No.
Patient Initials
RTOG Patient ID
Amended data
Yes
No
Unamed Module 2
Time point
At Completion Of Chemoradiation (At
completion of chemoradiation)
Pretreatment (Pretreatment)
Three Months From Baseline (Three
months from baseline)
Twelve Months From Baseline (Twelve
months from baseline)
Twenty-four Months From Baseline
(Twenty-four months from baseline)
Was patient questionnaire completed
Yes
No
1 / 5
Date patient questionnaire completed
Reason Questionnaire was not Completed
Institution Error (Institutional error)
Not Applicable, Questionnaire Was
Completed (Not applicable,
questionnaire was completed)
Other Reason (Other reason)
Patient Refused Due To Illness (Patient
refused due to illness)
Patient Refused For Other Reason
(Patient refused for other reason)
Patient Unable To Be Contacted (Patient
unable to be contacted)
Tool Not Availalble In Patient's Language
(Tool not availalble in patient's language)
Unknown (Unknown)
Patient refused for other reason, specify
Other reason, specify
Specify method of completion
At Appointment (At appointment)
By Mail (By mail)
By Telephone (By telephone)
Not Applicable (Not applicable)
Unknown (Unknown)
Did the patient require any assistance in
completing the questionnaire?
Yes
No
Specify the person who assisted the patient
Family (Family)
Other (Other)
Staff Member (Staff member)
Extent of assistance given
Combination Of Above (Combination of
above)
Interpreted Items For Patient (Interpreted
items for patient)
Marked Items Per Patient's Response
(Marked items per patient's response)
Not Applicable (Not applicable)
Other (Other)
Read Items To Patient (Read items to
patient)
Combination of above, specify
Other, specify
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High-dose Vs Standard-dose Conformal XRT with Chemotherapy Health Utility
Measurement Euro (EQ - 5D)
Comments
Signature of Person Completing This Form
Date Form Originally Completed
Health Utility Measurement
MOBILITY
I Am Confined To Bed (I am confined to
bed)
I Have No Problems In Walking About (I
have no problem in walking about)
I Have Some Problems In Walking About
(I have some problem in walking about)
SELF CARE
I Am Unable To Wash Or Dress Myself (I
am able to wash or dress myself)
I Have No Problem With Self Care (I
have no problem with self care)
I Have Some Problem Washing Or
Dressing Myself (I have some problem
washing or dressing myself)
USUAL ACTIVITIES (e.g. work, study,
housework, family, or leisure activities)
I Am Unable To Perform My Usual
Activities (I am unable to perform my
usual activities)
I Have No Problems With Performing My
Usual Activities (I have no problem with
performing my usual activities)
I Have Some Problems With Performing
My Usual Activities (I have some
problem with performing my usual
activities)
PAIN/DISCOMFORT
I Have Extreme Pain Or Discomfort (I
have extreme pain or discomfort)
I Have Moderate Pain Or Discomfort (I
have moderate pain or discomfort)
I Have No Pain Or Discomfort (I have no
pain or discomfort)
ANXIETY/DEPRESSION (TO THE PATIENT: To
help people say how good or bad a health state
is, we have drawn a scale rather like a
thermometer on which the best state you can
imagine is marked 100 and the worst state you
can imagine is marked 0.)
I Am Extremely Anxious Or Depressed (I
am extremely anxious or depressed)
I Am Moderately Anxious Or Depressed
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(I am moderately anxious or depressed)
I Am Not Anxious Or Depressed (I am
not anxious or depressed)
Patient status assessment
Your own health state today
HAVE YOU EXPERIENCED SERIOUS ILLNESS
In yourself?
Yes
No
HAVE YOU EXPERIENCED SERIOUS ILLNESS
In your family?
Yes
No
HAVE YOU EXPERIENCED SERIOUS ILLNESS
In caring for others?
Yes
No
WHAT IS YOUR AGE IN YEARS?
ARE YOU A current smoker
Yes
No
ARE YOU An ex-smoker
Yes
No
ARE YOU A never smoker
Yes
No
DO YOU NOW, OR DID YOU EVER, WORK IN
HEALTH OR SOCIAL SERVICES?
Yes
No
IF SO, IN WHAT CAPACITY?
WHICH OF THE FOLLOWING BEST
DESCRIBES YOUR MAIN ACTIVITY?
Homemaker (Housework)
Employed (In employment or self
employment)
Other (Other)
Retired (Retired)
Unemployed (Seeking work)
Student (Student)
Did your education continue after the minimum
school leaving age?
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Measurement Euro (EQ - 5D)
Yes
No
Do you have a degree or equivalent professional
qualification?
Yes
No
IF YOU KNOW YOUR POSTCODE, WOULD
YOU PLEASE WRITE IT HERE
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High-dose Vs Standard-dose Conformal XRT with Chemotherapy Health Utility
Measurement Euro (EQ - 5D)
RTOG 0834: Medical Outcome Scale:
Cognitive NCT00626990
RTOG 0834/EORTC 26053_22054/NCIC CTG CEC.1:
Medical Outcome Scale:  Cognitive NCT00626990 
Radiation Therapy With or Without Temozolomide in
Treating Patients With Anaplastic Glioma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=5AF816A5-
3103-0942-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11573
RTOG 0834: Medical Outcome
Scale:  Cognitive NCT00626990
RTOG clinical trial administrative data
RTOG Study No.
Case #
Institution Name
Institution No.
Patient Initials
RTOG Patient ID
Amended Data
Yes
No
Various questionnaire related information
Time point
Baseline (baseline)
Year 1 (Year 1)
Year 2 (Year 2)
Year 3 (Year 3)
Year 4 (Year 4)
Year 5 (Year 5)
Year 6 (Year 6)
Treatment Begin Date
Was patient questionnaire completed
Yes
No
Date patient questionnaire completed
Reason Questionnaire was not Completed
Institution Error (Institutional error)
Not Applicable, Questionnaire Was
Completed (Not applicable,
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questionnaire was completed)
Other Reason (Other reason)
Patient Refused Due To Illness (Patient
refused due to illness)
Patient Refused For Other Reason
(Patient refused for other reason)
Patient Unable To Be Contacted (Patient
unable to be contacted)
Tool Not Availalble In Patient's Language
(Tool not available in patient's language)
Unknown (Unknown)
Patient refused for other reason, specify
Other reason, specify
Specify method of completion
At Appointment (At appointment)
By Mail (By mail)
By Telephone (By telephone)
Not Applicable (Not applicable)
Unknown (Unknown)
Did the patient require any assistance in
completing the questionnaire?
No (No)
Not Applicable (Not applicable)
Unknown If Assistance Given (Unknown
if assistance given)
Yes (Yes)
Specify the person who assisted the patient
Family (Family)
Not Applicable (Not applicable)
Other (Other)
Staff Member (Staff member)
Unknown (Unknown)
Other, specify
Extent of assistance given
Combination Of Above (Combination of
above)
Interpreted Items For Patient (Interpreted
items for patient)
Marked Items Per Patient's Response
(Marked items per patient's response)
Not Applicable (Not applicable)
Other (Other)
Read Items To Patient (Read items to
patient)
Unknown (Unknown)
Combination of above, specify
Other, specify
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Signature of Person Completing This Form
Date Form Completed
Cognition Quality of Life
How much of the time did you have difficulty
reasoning and solving problems (During the past
month - e.g., difficulty making plans, making
decisions, learning new things)
A Good Bit Of The Time (A good bit of
the time)
A Little Of The Time (A little of the time)
All Of The Time (All of the time)
Most Of The Time (Most of the time)
None Of The Time (None of the time)
Some Of The Time (Some of the time)
How much of the time did you forget (During the
past month - e.g., things that happen recently,
where you put things, appointments)
A Good Bit Of The Time (A good bit of
the time)
A Little Of The Time (A little of the time)
All Of The Time (All of the time)
Most Of The Time (Most of the time)
None Of The Time (None of the time)
Some Of The Time (Some of the time)
How much of the time did you have trouble
keeping your attention on any activity for long
(During the past month)
A Good Bit Of The Time (A good bit of
the time)
A Little Of The Time (A little of the time)
All Of The Time (All of the time)
Most Of The Time (Most of the time)
None Of The Time (None of the time)
Some Of The Time (Some of the time)
How much of the time did you have difficulty
doing activities involving concentration and
thinking (During the past month)
A Good Bit Of The Time (A good bit of
the time)
A Little Of The Time (A little of the time)
All Of The Time (All of the time)
Most Of The Time (Most of the time)
None Of The Time (None of the time)
Some Of The Time (Some of the time)
How much of the time did you become confused
and start several actions at a time (During the
past month)
A Good Bit Of The Time (A good bit of
the time)
A Little Of The Time (A little of the time)
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All Of The Time (All of the time)
Most Of The Time (Most of the time)
None Of The Time (None of the time)
Some Of The Time (Some of the time)
How much of the time did you react slowly to
things that were said and done (During the past
month)
A Good Bit Of The Time (A good bit of
the time)
A Little Of The Time (A little of the time)
All Of The Time (All of the time)
Most Of The Time (Most of the time)
None Of The Time (None of the time)
Some Of The Time (Some of the time)
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ADVL0212: Phase I Weekly Report
NCT00053963
ADVL0212: Phase I Weekly Report NCT00053963 
FR901228 in Treating Children With Refractory or
Recurrent Solid Tumors or Leukemia
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=B1EAF58D-
ABF6-30C9-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/11574
ADVL0212: Phase I Weekly Report
NCT00053963
Header
Study Number
Name
COG Number
Patient Name
Today's date
Reporting Period Number (1. Required field)
Week (1. Required field)
Any dose limiting toxicities this week? (1.
Required field)
Yes
No
Dlt Toxicity Data
Code
Category
Type
Grade
Comment (duration, attribution, etc.)
Results Of Test Completed During This
Weekly Reporting Interval
Test date (MM/DD/YYYY)
1 / 3
Hgb (g/dL)
g/dL
WBC (1. Accepted range is 0.9-50.  A value of
less than 0.9 or greater than 50 generates a
warning on the institutional data receipt, but does
not prevent data entry.)
Laboratory  Unit of Measure
International Units Per Liter (IU/L)
Mu/ml (mU/mL)
Platelets (1. Accepted range is 30-1500.  A value
of less than 30 or greater than 1500 generates a
warning on the institutional data receipt, but does
not prevent data entry.)
Segs (%)
%
Bands (%)
%
Was red cell transfusion given as a result of
CBC? (1. Required field)
No Transfusion (No)
Unknown (Unknown)
Yes (Yes)
Transfusion With Platelets And Red
Blood Cells (Yes, both)
Transfusion With Platelets (Yes,
platelets)
Transfusion With Red Blood Cells (Yes,
red blood cells)
Test date
ALT (acceptable units: IU/L, or mU/mL)
ALT (institutional upper limit of normal)
AST (acceptable units: IU/L, or mU/mL)
AST (institutional upper limit of normal)
T. Bilirubin (mg/dL)
mg/dL
T. Bilirubin (mg/dL- institutional upper limit of
normal)
mg/dL
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Creatinine (mg/dL)
mg/dL
Creatinine (mg/dL- institutional upper limit of
normal)
mg/dL
Comments
General Comments
(MM/DD/YYYY) (1. Required field)
Ccrr Module For Advl0212: Phase I
Weekly Report
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NCT00070122 SOUTHWEST ONCOLOGY
GROUP S0303 ADVERSE EVENT FORM
NCT00070122 SOUTHWEST ONCOLOGY GROUP S0303
ADVERSE EVENT FORM
Combination Chemotherapy and Bevacizumab in Treating
Patients With Locally Advanced, Metastatic, or Recurrent
Colorectal Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=BC630A33-
AF74-10CA-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/11575
NCT00070122 SOUTHWEST
ONCOLOGY GROUP S0303
ADVERSE EVENT FORM
Header
SWOG Patient ID
SWOG Study No.
Registration Step
Patient Initials (L, F M)
Institution/Affiliate
Physician (Groups Other than SWOG)
Group Name
Study No.
Pt. ID
Toxicity
Cycle #
1 (1)
2 (2)
3 (3)
Other (Other)
Reporting period start date
Were toxicities assessed during this time period
Yes
No
Date of most recent toxicity assessment
Adverse event assessment
1 / 2
CTC Adverse Event Term
CTC Adverse Event Grade (1 - 5)
CTC Adverse Event Attribution Code (Attribution
codes)
Definite (definite)
Possible (possible)
Probable (probable)
Unlikely (unlikely)
Unrelated (unrelated)
CTC Adverse Event Term, Other
Comments
Comments
Ccrr Module For Southwest Oncology
Group S0303 Adverse Event Form
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NCT00070122 SOUTHWEST ONCOLOGY GROUP S0303 ADVERSE
EVENT FORM
E5103 Adverse Event Form (CTCAE v3)
NCT00433511
E5103 Adverse Event Form (CTCAE v3) NCT00433511 
Doxorubicin, Cyclophosphamide, and Paclitaxel With or
Without Bevacizumab in Treating Patients With Lymph
Node-Positive or High-Risk, Lymph Node-Negative Breast
Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=22B14F38-
EFAA-6454-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11576
E5103 Adverse Event Form (CTCAE
v3) NCT00433511
ECOG clinical trial administrative data
ECOG Protocol Number
ECOG Patient ID
DCI Name
Registration Step
Patient demographics
Patient Initials (Last, First)
Participating Group Protocol Number
Participating Group Patient ID
Institution/Affiliate
Data amendment
Please mark an 'X' if data have been amended.
Date data amended (s m/d/y)
Reporting Period
On Treatment Report Period (STEP 2 - ARM D
ONLY)
Cycle 10 Step 2 (Cycle 10 Step 2)
Cycle 11 Step 2 (Cycle 11 Step 2)
Cycle 12 Step 2 (Cycle 12 Step 2)
Cycle 13-step 2 (Cycle 13-Step 2)
Cycle 14-step 2 (Cycle 14-Step 2)
Cycle 15 Step 2 (Cycle 15 Step 2)
Cycle 16-step 2 (Cycle 16-Step 2)
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Cycle 17 Step 2 (Cycle 17 Step 2)
Cycle 18-step 2 (Cycle 18-Step 2)
Cycle 9 Step 2 (Cycle 9 Step 2)
Off Treatment Reporting Period
Off Treatment Report Period
12 Months Post-treatment (12 Months
Post-Treatment)
3 Months Post-treatment (3 Months Post-
Treatment)
6 Months Post-treatment (6 Months Post-
Treatment)
9 Months Post-treatment (9 Months Post-
Treatment)
Adverse Events
Were adverse events assessed during this report
period (cycle)
No (No)
Yes, And Reportable Adverse Events
Occurred (Yes, and reportable adverse
events occurred)
Yes, But No Reportable Adverse Events
Occurred (Yes, but no reportable adverse
events occurred)
CTC Adverse Event Report Begin Date (For the
dates below, record the start and end dates of the
time period within current report period in which
patient was assessed for adverse events.)
CTC Adverse Event Report End Date (m/d/y)
I.  METABOLIC - LABS
CTC Adverse Event Term
Hypersensitivity Nos (Allergic
reaction/hypersensitivity (including drug
fever))
Anorexia (Anorexia)
Ataxia Nec (Ataxia (incoordination))
Myocardial Ischaemia (Cardiac
ischemia/infarction)
Cns Necrosis/cystic Progression (CNS
necrosis/cystic progression)
Constipation (Constipation)
Cough (Cough)
Cytokine Release Syndrome/acute
Infusion Reaction (Cytokine release
syndrome/acute infusion reaction)
Diarrhoea Nos (Diarrhea)
Dizziness (exc Vertigo) (Dizziness)
Dyspnoea Nos (Dyspnea (shortness of
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breath))
Fatigue (Fatigue (asthenia, lethargy,
malaise))
Pyrexia (Fever (in the absence of
neutropenia, where neutropenia is
defined as ANC <1.0 x 10^9/L))
Alopecia (Hair loss/Alopecia (scalp or
body))
Dyspepsia (Heartburn/dyspepsia)
Haemorrhagic Stroke (Hemorrhage,
CNS)
Hemorrhage, Gi (Hemorrhage, GI -
Lower GI NOS)
Haematemesis (Hemorrhage, GI -
Stomach)
Hemorrhage, Gi (Hemorrhage, GI -
Upper GI NOS)
Hypertension Nos (Hypertension)
Depression Nec (Mood alteration -
depression)
Mucositis/stomatitis
(functional/symptomatic)
(Mucositis/stomatitis
(functional/symptomatic) - Oral cavity)
Nausea (Nausea)
Chest Pain (Pain - Chest/thorax NOS)
Headache Nos (Pain - Head/headache)
Arthralgia (Pain - Joint)
Myalgia (Pain - Muscle)
Pruritus Nos (Pruritus/itching)
Dermatitis Exfoliative Nos
(Rash/desquamation)
Rigors (Rigors/chills)
Supraventricular And Nodal Arrhythmia
(Supraventricular and nodal arrhythmia -
Sinus arrhythmia)
Taste Disturbance (Taste alteration
(dysgeusia))
Urticaria Nos (Urticaria (hives, welts,
wheals))
Dysphonia (Voice changes/dysarthria
(e.g., hoarseness, loss or alteration in
voice, laryngitis))
Vomiting Nos (Vomiting)
Culture Wound Negative (Wound
complication, non-infectious)
CTC Adverse Event Grade (v3.0)
CTC AE Attribution Code
Definite (definite)
Possible (possible)
Probable (probable)
Unlikely (unlikely)
Unrelated (unrelated)
Action taken for this AE for Chemotherapy
Dose Delayed (Dose delayed)
Dose Delayed And Reduced (Dose
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delayed and reduced)
Dose Held (Dose held)
Dose Reduced (Dose reduced)
Drug Discontinued (Drug discontinued)
Action taken for this AE for Bevacizumab
(/placebo)
Dose Delayed (Dose delayed)
Dose Held (Dose held)
Drug Discontinued (Drug discontinued)
II.  NON-HEMATOLOGIC
III. NON-HEMATOLOGIC (GRADE 2-5)
CTC Adverse Event Short Name (Specify site for
each event)
Febrile Neutropenia (fever Of Unknown
Origin Without Clinically Or
Microbiologically Documented Infection)
(anc <1.0 X 10^9/l, Fever >=38.5
Degrees C) (Febrile neutropenia)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically) - Select)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
- Select)
Infection With Unknown Anc (Infection
with unknown ANC - Select)
CTC Select AE
IV.  Other Adverse Events (GRADE 3-5)
V.  INFECTIONS
Comments
Investigator Signature
Investigator Signature Date
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E1105 Adverse Event Form (CTCAE v3)
NCT00520975
E1105 Adverse Event Form (CTCAE v3) NCT00520975 
First-Line Chemotherapy and Trastuzumab With or Without
Bevacizumab in Treating Patients With Metastatic Breast
Cancer That Overexpresses HER-2/NEU
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=1722503D-
5400-666B-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11577
E1105 Adverse Event Form (CTCAE
v3) NCT00520975
ECOG clinical trial administrative data
ECOG Protocol Number
ECOG Patient ID
DCI Name
Registration Step
Patient demographics
Patient Initials (Last, First)
ECOG Protocol Number
ECOG Patient ID
Participating Group Protocol Number
Participating Group Patient ID
Institution/Affiliate
Data amendment
Please mark an 'X' if data have been amended.
Date data amended
On Treatment
On Treatment Report Period (since start of
treatment)
> Cycle 11 (> Cycle 11)
Cycle 1 (Cycle 1)
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Cycle 10 (Cycle 10)
Cycle 11 (Cycle 11)
Cycle 2 (Cycle 2)
Cycle 3 (Cycle 3)
Cycle 4 (Cycle 4)
Cycle 5 (Cycle 5)
Cycle 6 (Cycle 6)
Cycle 7 (Cycle 7)
Cycle 8 (Cycle 8)
Cycle 9 (Cycle 9)
On Treatment Report Period (since start of
treatment)
> Cycle 11 (> Cycle 11)
Cycle 1 (Cycle 1)
Cycle 10 (Cycle 10)
Cycle 11 (Cycle 11)
Cycle 2 (Cycle 2)
Cycle 3 (Cycle 3)
Cycle 4 (Cycle 4)
Cycle 5 (Cycle 5)
Cycle 6 (Cycle 6)
Cycle 7 (Cycle 7)
Cycle 8 (Cycle 8)
Cycle 9 (Cycle 9)
Specify Cycle (specify)
Off Treatment
Off Treatment Report Period (since registration)
9 Years (108 months post registration)
12 Months Post Randomization (12
Months Post Randomization)
10 Years (120 months post registration)
18 Months Post Randomization (18
Months Post Randomization)
21 Months Post Randomization (21
Months Post Randomization)
24 Months Post Randomization (24
Months Post Randomization)
3 Months Post Randomization (3 Months
Post Randomization)
30 Months Post Randomization (30
Months Post Randomization)
36 Months Post Randomization (36
Months Post Randomization)
42 Months Post Randomization (42
Months Post Randomization)
48 Months Post Randomization (48
Months Post Randomization)
54 Months Post Randomization (54
Months Post Randomization)
6 Months Post Randomization (6 Months
Post Randomization)
60 Months Post Randomization (60
Months Post Randomization)
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6 Years (72 months post registration)
84 Months Post Registration (84 months
post registration)
9 Months Post Randomization (9 Months
Post Randomization)
8 Years (96 months post registration)
Adverse event report
Were adverse events assessed during this report
period
No (No)
Yes, And Reportable Adverse Events
Occurred (Yes, and reportable adverse
events occurred)
Yes, But No Reportable Adverse Events
Occurred (Yes, but no reportable adverse
events occurred)
CTC Adverse Event Report Begin Date
CTC Adverse Event Report End Date
Blood/bone Marrow - Labs
CTC Adverse Event Term
Anorexia (Anorexia)
Constipation (Constipation)
Cough (Cough)
Cytokine Release Syndrome/acute
Infusion Reaction (Cytokine release
syndrome/acute infusion reaction)
Fatigue (Fatigue (asthenia, lethargy,
malaise))
Pyrexia (Fever (in absence of
neutropenia, where neutropenia is
defined as ANC <1000))
Hypertension Nos (Hypertension)
Mucositis/stomatitis
(functional/symptomatic)
(Mucositis/stomatitis
(functional/symptomatic) - Oral cavity)
Muscle Weakness Nos (Muscle
weakness, generalized or specific area
(not due to neuropathy) - Whole
body/generalized)
Myocarditis Nos (Myocarditis)
Nausea (Nausea)
Chest Pain (Pain - Chest/thorax NOS)
Headache Nos (Pain - Head/headache)
Arthralgia (Pain - Joint)
Pneumonitis Nos
(Pneumonitis/pulmonary infiltrates)
Dermatitis Exfoliative Nos
(Rash/desquamation)
Restrictive Cardiomyopathy (Restrictive
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cardiomyopathy)
Rigors (Rigors/chills)
Urticaria Nos (Urticaria (hives, welts,
wheals))
Dysphonia (Voice changes/dysarthria
(e.g., hoarseness, loss or alteration in
voice, laryngitis))
Vomiting Nos (Vomiting)
Culture Wound Negative (Wound
complication, non-infectious)
CTC Adverse Event Grade (v3.0)
CTC Adverse Event Attribution Code
Definite (definite)
Possible (possible)
Probable (probable)
Unlikely (unlikely)
Unrelated (unrelated)
Was this attributed to investigational protocol
treatment
Yes
No
II.  NON-HEMATOLOGIC
CTC Adverse Event Term
Anorexia (Anorexia)
Constipation (Constipation)
Cough (Cough)
Cytokine Release Syndrome/acute
Infusion Reaction (Cytokine release
syndrome/acute infusion reaction)
Fatigue (Fatigue (asthenia, lethargy,
malaise))
Pyrexia (Fever (in absence of
neutropenia, where neutropenia is
defined as ANC <1000))
Hypertension Nos (Hypertension)
Mucositis/stomatitis
(functional/symptomatic)
(Mucositis/stomatitis
(functional/symptomatic) - Oral cavity)
Muscle Weakness Nos (Muscle
weakness, generalized or specific area
(not due to neuropathy) - Whole
body/generalized)
Myocarditis Nos (Myocarditis)
Nausea (Nausea)
Chest Pain (Pain - Chest/thorax NOS)
Headache Nos (Pain - Head/headache)
Arthralgia (Pain - Joint)
Pneumonitis Nos
(Pneumonitis/pulmonary infiltrates)
Dermatitis Exfoliative Nos
(Rash/desquamation)
Restrictive Cardiomyopathy (Restrictive
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cardiomyopathy)
Rigors (Rigors/chills)
Urticaria Nos (Urticaria (hives, welts,
wheals))
Dysphonia (Voice changes/dysarthria
(e.g., hoarseness, loss or alteration in
voice, laryngitis))
Vomiting Nos (Vomiting)
Culture Wound Negative (Wound
complication, non-infectious)
CTC Adverse Event Short Name (Specify site for
each event)
Febrile Neutropenia (fever Of Unknown
Origin Without Clinically Or
Microbiologically Documented Infection)
(anc <1.0 X 10^9/l, Fever >=38.5
Degrees C) (Febrile neutropenia)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically) - Select)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
- Select)
Infection With Unknown Anc (Infection
with unknown ANC - Select)
CTC Select AE
CTC Adverse Event Grade (v3.0)
CTC Adverse Event Grade (v3.0)
CTC Adverse Event Attribution Code
Definite (definite)
Possible (possible)
Probable (probable)
Unlikely (unlikely)
Unrelated (unrelated)
CTC Adverse Event Attribution Code
Definite (definite)
Possible (possible)
Probable (probable)
Unlikely (unlikely)
Unrelated (unrelated)
Was this attributed to investigational protocol
treatment
Yes
No
Was this attributed to investigational protocol
treatment
Yes
No
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III.  NON-HEMATOLOGIC
CTC Adverse Event Term
Anorexia (Anorexia)
Constipation (Constipation)
Cough (Cough)
Cytokine Release Syndrome/acute
Infusion Reaction (Cytokine release
syndrome/acute infusion reaction)
Fatigue (Fatigue (asthenia, lethargy,
malaise))
Pyrexia (Fever (in absence of
neutropenia, where neutropenia is
defined as ANC <1000))
Hypertension Nos (Hypertension)
Mucositis/stomatitis
(functional/symptomatic)
(Mucositis/stomatitis
(functional/symptomatic) - Oral cavity)
Muscle Weakness Nos (Muscle
weakness, generalized or specific area
(not due to neuropathy) - Whole
body/generalized)
Myocarditis Nos (Myocarditis)
Nausea (Nausea)
Chest Pain (Pain - Chest/thorax NOS)
Headache Nos (Pain - Head/headache)
Arthralgia (Pain - Joint)
Pneumonitis Nos
(Pneumonitis/pulmonary infiltrates)
Dermatitis Exfoliative Nos
(Rash/desquamation)
Restrictive Cardiomyopathy (Restrictive
cardiomyopathy)
Rigors (Rigors/chills)
Urticaria Nos (Urticaria (hives, welts,
wheals))
Dysphonia (Voice changes/dysarthria
(e.g., hoarseness, loss or alteration in
voice, laryngitis))
Vomiting Nos (Vomiting)
Culture Wound Negative (Wound
complication, non-infectious)
CTC Adverse Event Grade (v3.0)
CTC Adverse Event Attribution Code
Definite (definite)
Possible (possible)
Probable (probable)
Unlikely (unlikely)
Unrelated (unrelated)
Was this attributed to investigational protocol
treatment
Yes
No
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Other Adverse Events
Other CTC Adverse Event Term not listed
Other, Specify  (site or subterm)
CTC Adverse Event Grade (v3.0)
CTC Adverse Event Attribution Code
Definite (definite)
Possible (possible)
Probable (probable)
Unlikely (unlikely)
Unrelated (unrelated)
Was this attributed to investigational protocol
treatment
Yes
No
V.  INFECTIONS
CTC Adverse Event Short Name (Specify site for
each event)
Febrile Neutropenia (fever Of Unknown
Origin Without Clinically Or
Microbiologically Documented Infection)
(anc <1.0 X 10^9/l, Fever >=38.5
Degrees C) (Febrile neutropenia)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically) - Select)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
- Select)
Infection With Unknown Anc (Infection
with unknown ANC - Select)
CTC Select AE
CTC Adverse Event Grade (v3.0)
CTC Adverse Event Attribution Code
Definite (definite)
Possible (possible)
Probable (probable)
Unlikely (unlikely)
Unrelated (unrelated)
Was this attributed to investigational protocol
treatment
Yes
No
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Comments
Investigator Signature
Investigator Signature Date
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E5202 Adverse Event Form (CTCAE v3.0)
NCT00217737
E5202 Adverse Event Form (CTCAE v3.0) NCT00217737
Oxaliplatin, Leucovorin, and Fluorouracil With or Without
Bevacizumab in Treating Patients Who Have Undergone
Surgery for Stage II Colon Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=EF36966F-
AF72-06D9-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11578
E5202 Adverse Event Form (CTCAE
v3.0) NCT00217737
ECOG clinical trial administrative data
ECOG Protocol Number
ECOG Patient ID
DCI Name
Registration Step
Are data amended (If yes, please circle amended
items in red.)
Yes
No
Patient demographics
Patient Initials
Participating Group Protocol Number
Institution/Affiliate
Participating Group Patient ID
On Treatment
On Treatment Report Period (Arm B Only)
Cycle 18 (Cycle 18)
End Of Second 12 Cycles Of Treatment
(End of Second 12 Cycles of Treatment)
Off Treatment
Off Treatment Report Period (since initial
registration)
9 Years (108 Months Post-Registration)
12 Months (12 Months Post Registration)
10 Years (120 Months Post-Registration)
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15 Months (15 Months Post Registration)
18 Months (18 Months Post Registration)
21 Months Post Registration (21 Months
Post Registration)
2 Years (24 Months Post Registration)
3 Months (3 Months Post Registration)
30 Months (30 Months Post Registration)
3 Years (36 Months Post Registration)
42 Months (42 Months Post Registration)
4 Years (48 Months Post Registration)
54 Months (54 Months Post Registration)
6 Months (6 Months Post Registration)
5 Years (60 Months Post Registration)
6 Years (72 Months Post-Registration)
84 Months Post Registration (84 Months
Post-Registration)
9 Months (9 Months Post Registration)
8 Years (96 Months Post-Registration)
Adverse event assessment
Were adverse events assessed during this report
period (cycle)
No (No)
Yes, And Reportable Adverse Events
Occurred (Yes, and reportable adverse
events occurred)
Yes, But No Reportable Adverse Events
Occurred (Yes, but no reportable adverse
events occurred)
CTC Adverse Event Report Begin Date
CTC Adverse Event Report End Date
CTC Adverse Event Term
Hypersensitivity Nos (Allergic
reaction/hypersensitivity (including drug
fever))
Anorexia (Anorexia)
Arrhythmia Nos (Cardiac Arrhythmia -
Other)
Myocardial Ischaemia (Cardiac
ischemia/infarction)
Cerebral Ischaemia (CNS
cerebrovascular ischemia)
Coagulation Disorder Nos (Coagulation -
Other)
Cough (Cough)
Dehydration (Dehydration)
Diarrhoea Nos (Diarrhea)
Dyspnoea Nos (Dyspnea (shortness of
breath))
Fatigue (Fatigue (asthenia, lethargy,
malaise))
Febrile Neutropenia (fever Of Unknown
Origin Without Clinically Or
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Microbiologically Documented Infection)
(anc <1.0 X 10^9/l, Fever >=38.5
Degrees C) (Febrile neutropenia)
Pyrexia (Fever (in absence of
neutropenia, where neutropenia is
defined as ANC <1000))
Fistula, Gi (Fistula, GI - Rectum)
Alopecia (Hair loss/alopecia (head or
body))
Hearing: Patients Without Baseline
Audiogram And Not Enrolled In A
Monitoring Program (Hearing: patients
without baseline audiogram and not
enrolled in a monitoring program)
Haemoglobin Decreased (Hemoglobin)
Haemorrhagic Stroke (Hemorrhage,
CNS)
Hemorrhage, Gi (Hemorrhage, GI -
Lower GI NOS)
Rectal Bleeding (Hemorrhage, GI -
Rectum)
Hemorrhage, Gi (Hemorrhage, GI -
Stomach)
Hemorrhage, Gi (Hemorrhage, GI -
Upper GI NOS)
Haematuria Present (Hemorrhage, GU -
Urinary NOS)
Epistaxis (Hemorrhage, pulmonary/upper
respiratory - Nose)
Haemoptysis (Hemorrhage,
pulmonary/upper respiratory -
Respiratory tract NOS)
Hemorrhage/bleeding Other
(Hemorrhage/Bleeding - Other)
Hypertension Nos (Hypertension)
Ileus (Ileus, GI (functional obstruction of
bowel, i.e., neuroconstipation))
Leucopenia Nos (Leukocytes (total
WBC))
Mucositis/stomatitis (clinical Exam)
(Mucositis/stomatitis (clinical exam) -
Oral cavity)
Stomatitis (Mucositis/stomatitis (clinical
exam) - Pharynx)
Mucositis/stomatitis
(functional/symptomatic)
(Mucositis/stomatitis
(functional/symptomatic) - Oral cavity)
Mucositis/stomatitis
(functional/symptomatic)
(Mucositis/stomatitis
(functional/symptomatic) - Pharynx)
Nausea (Nausea)
Neurology Other (Neurology - Other)
Peripheral Sensory Neuropathy
(Neuropathy: sensory)
Neutropenia (Neutrophils/granulocytes
(ANC/AGC))
Otitis Media Serous Nos (Otitis, middle
ear (non-infectious))
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Abdominal Pain Nos (Pain - Abdomen
NOS)
Headache Nos (Pain - Head/headache)
Myalgia (Pain - Muscle)
Perforation, Gi (Perforation, GI - Small
bowel NOS)
Phlebitis Superficial (Phlebitis (including
superficial thrombosis))
Platelet Count Decreased (Platelets)
Pneumonitis Nos
(Pneumonitis/pulmonary infiltrates)
Proteinuria Present (Proteinuria)
Pulmonary Fibrosis (Pulmonary fibrosis
(radiographic changes))
Localised Exfoliation (Rash: hand-foot
skin reaction)
Dermatitis Exfoliative Nos
(Rash/desquamation)
Rigors (Rigors/Chills)
Thrombosis/embolism (vascular Access-
related) (Thrombosis/embolism (vascular
access-related))
Thrombosis Nos
(Thrombosis/thrombus/embolism)
Vomiting Nos (Vomiting)
Culture Wound Negative (Wound
complication, non-infectious)
Cardiac Arrhythmia - Other Specify
Coagulation - Other Specify
Hemorrhage/Bleeding - Other Specify
Neurology - Other Specify
CTC Adverse Event Grade (this report period)
CTC Adverse Event Attribution Scale
Definite (definite)
Possible (possible)
Probable (probable)
Unlikely (unlikely)
Unrelated (unrelated)
III. INFECTIONS
Common Toxicity (Specify site for each event)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (CTC
Adverse Event Infection (documented
clinically or microbiologically) with Grade
3 or 4 neutrophils (ANC < 1.0 X 10^9/L) -
Select Grade)
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Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (CTC Adverse Event
Infection with normal ANC or Grade 1 or
2 neutrophils - Select Grade)
Infection With Unknown Anc (Infection
with unknown ANC - Select Grade)
Specify site
Other Adverse Events
Other CTC Adverse Event Term not listed
Other, Specify  (site or subterm)
Comments
Comments
Investigator Signature
Investigator Signature Date
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E1305 Adverse Event Form (CTCAE v4)
NCT00588770
E1305 Adverse Event Form (CTCAE v4) NCT00588770
Chemotherapy With or Without Bevacizumab in Treating
Patients With Recurrent or Metastatic Head and Neck
Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=19FB3923-
297D-35D3-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11579
E1305 Adverse Event Form (CTCAE
v4) NCT00588770
ECOG clinical trial administrative data
ECOG Protocol Number
ECOG Patient ID
DCI Name
Registration Step
Patient demographics
Patient Initials (Last, First)
ECOG Protocol Number
ECOG Patient ID
Participating Group Protocol Number
Participating Group Patient ID
Institution/Affiliate
Data amendment
Please mark an 'X' if data have been amended
(Please circle amended items in red)
Date data amended (M D Y)
On Treatment
On Treatment Report Period (Arm B Only)
> Cycle 19 (> Cycle 19)
Cycle 1 (Cycle 1)
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Cycle 10 (Cycle 10)
Cycle 11 (Cycle 11)
Cycle 12 (Cycle 12)
Cycle 13 (Cycle 13)
Cycle 14 (Cycle 14)
Cycle 15 (Cycle 15)
Cycle 16 (Cycle 16)
Cycle 17 (Cycle 17)
Cycle 18 (Cycle 18)
Cycle 19 (Cycle 19)
Cycle 2 (Cycle 2)
Cycle 3 (Cycle 3)
Cycle 4 (cycle 4)
Cycle 5 (Cycle 5)
Cycle 6 (Cycle 6)
Cycle 7 (Cycle 7)
Cycle 8 (cycle 8)
Cycle 9 (Cycle 9)
Specify Cycle
Off Treatment
Off Treatment Report Period (Choose one)
3 Months Post-treatment (3 Months Post-
Treatment)
Adverse event assessment
Were adverse events assessed during this report
period (cycle)
No (No)
Yes, And Reportable Adverse Events
Occurred (Yes, and reportable adverse
events occurred)
Yes, But No Reportable Adverse Events
Occurred (Yes, but no reportable adverse
events occurred)
CTC Adverse Event Report Begin Date (M D Y)
CTC Adverse Event Report End Date (M D Y)
I. BLOOD/BONE MARROW - LABS
CTC Adverse Event Term
Nervous System Disorders - Other,
Specify (Nervous system disorders -
Other, Specify)
CTC Adverse Event Grade (v4.0 - this
cycle/report period - Report only Grade 3-5)
Severe Adverse Event (3)
Life Threatening Adverse Event (4)
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Death Related To Adverse Event (5)
CTC Adverse Event Attribution Code (highest
attributed to only protocol agent)
Definite (definite)
Possible (possible)
Probable (probable)
Unlikely (unlikely)
Unrelated (unrelated)
Action taken for this AE for Chemotherapy
Dose Delayed (Dose delayed)
Dose Reduced (Dose held and reduced)
Dose Reduced (Dose reduced)
Drug Changed (Drug changed)
Drug Discontinued (Drug discontinued)
Action taken for this AE for Bevacizumab
Dose Delayed (Dose delayed)
Dose Held (Dose held)
Drug Discontinued (Drug discontinued)
II. Non-Hematologic
CTC Adverse Event Term
Nervous System Disorders - Other,
Specify (Nervous system disorders -
Other, Specify)
CTC Adverse Event Grade (v4.0 - this
cycle/report period - Report only Grade 3-5)
Severe Adverse Event (3)
Life Threatening Adverse Event (4)
Death Related To Adverse Event (5)
CTC Adverse Event Attribution Code (highest
attributed to only protocol agent)
Definite (definite)
Possible (possible)
Probable (probable)
Unlikely (unlikely)
Unrelated (unrelated)
Action taken for this AE for Chemotherapy
Dose Delayed (Dose delayed)
Dose Reduced (Dose held and reduced)
Dose Reduced (Dose reduced)
Drug Changed (Drug changed)
Drug Discontinued (Drug discontinued)
Action taken for this AE for Bevacizumab
Dose Delayed (Dose delayed)
Dose Held (Dose held)
Drug Discontinued (Drug discontinued)
Blood/bone Marrow - Labs
CTC Adverse Event Term
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Nervous System Disorders - Other,
Specify (Nervous system disorders -
Other, Specify)
CTC Adverse Event Grade (v4.0 - this
cycle/report period - Report only Grade 3-5)
Severe Adverse Event (3)
Life Threatening Adverse Event (4)
Death Related To Adverse Event (5)
CTC Adverse Event Attribution Code (highest
attributed to only protocol agent)
Definite (definite)
Possible (possible)
Probable (probable)
Unlikely (unlikely)
Unrelated (unrelated)
Action taken for this AE for Chemotherapy
Dose Delayed (Dose delayed)
Dose Reduced (Dose held and reduced)
Dose Reduced (Dose reduced)
Drug Changed (Drug changed)
Drug Discontinued (Drug discontinued)
Action taken for this AE for Bevacizumab
Dose Delayed (Dose delayed)
Dose Held (Dose held)
Drug Discontinued (Drug discontinued)
IV. GI Fistula
CTC Adverse Event Term
Nervous System Disorders - Other,
Specify (Nervous system disorders -
Other, Specify)
CTC Adverse Event Grade (v4.0 - this
cycle/report period - Report only Grade 3-5)
Severe Adverse Event (3)
Life Threatening Adverse Event (4)
Death Related To Adverse Event (5)
CTC Adverse Event Attribution Code (highest
attributed to only protocol agent)
Definite (definite)
Possible (possible)
Probable (probable)
Unlikely (unlikely)
Unrelated (unrelated)
Was this attributed to investigational protocol
treatment
Yes
No
AE Expedited report filed?
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Blood/bone Marrow - Labs
CTC Adverse Event Term
Nervous System Disorders - Other,
Specify (Nervous system disorders -
Other, Specify)
CTC Adverse Event Grade (v4.0 - this
cycle/report period - Report only Grade 3-5)
Severe Adverse Event (3)
Life Threatening Adverse Event (4)
Death Related To Adverse Event (5)
CTC Adverse Event Attribution Code (highest
attributed to only protocol agent)
Definite (definite)
Possible (possible)
Probable (probable)
Unlikely (unlikely)
Unrelated (unrelated)
Was this attributed to investigational protocol
treatment
Yes
No
AE Expedited report filed?
VI. Hemorrhages
CTC Adverse Event Term
Nervous System Disorders - Other,
Specify (Nervous system disorders -
Other, Specify)
CTC Adverse Event Grade (v4.0 - this
cycle/report period - Report only Grade 3-5)
Severe Adverse Event (3)
Life Threatening Adverse Event (4)
Death Related To Adverse Event (5)
CTC Adverse Event Attribution Code (highest
attributed to only protocol agent)
Definite (definite)
Possible (possible)
Probable (probable)
Unlikely (unlikely)
Unrelated (unrelated)
Was this attributed to investigational protocol
treatment
Yes
No
AE Expedited report filed?
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VII. Other Adverse Events (including
Infections)
CTC Adverse Event Term
Nervous System Disorders - Other,
Specify (Nervous system disorders -
Other, Specify)
Other, specify (specific infection or AE CTC
Adverse Event Term not listed)
CTC Adverse Event Grade (v4.0 - this
cycle/report period - Report only Grade 3-5)
Severe Adverse Event (3)
Life Threatening Adverse Event (4)
Death Related To Adverse Event (5)
CTC Adverse Event Attribution Code (highest
attributed to only protocol agent)
Definite (definite)
Possible (possible)
Probable (probable)
Unlikely (unlikely)
Unrelated (unrelated)
Action taken for this AE for Chemotherapy
Dose Delayed (Dose delayed)
Dose Reduced (Dose held and reduced)
Dose Reduced (Dose reduced)
Drug Changed (Drug changed)
Drug Discontinued (Drug discontinued)
Action taken for this AE for Bevacizumab
Dose Delayed (Dose delayed)
Dose Held (Dose held)
Drug Discontinued (Drug discontinued)
Comments
Investigator Signature
Investigator Signature Date
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E2805 Adverse Event Form - (CTCAE v3)
NCT00326898
E2805 Adverse Event Form - (CTCAE v3) NCT00326898 
Sunitinib or Sorafenib in Treating Patients With Kidney
Cancer That Was Removed By Surgery
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=0538F350-
3C05-47A5-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11580
E2805 Adverse Event Form -
(CTCAE v3) NCT00326898
Header
ECOG Protocol Number
ECOG Patient ID
DCI Name
Registration Step
Patient demographics
ECOG Protocol Number
Patient Initials
ECOG Patient ID
Participating Group Protocol Number
Institution/Affiliate
Participating Group Patient ID
Data amendment
Please mark an 'X' if data have been amended.
Date data amended
On Treatment
On Treatment Report Period (Choose one)
Cycle 1 (Cycle 1)
Cycle 2 (Cycle 2)
Cycle 3 (Cycle 3)
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Cycle 4 (Cycle 4)
Cycle 5 (Cycle 5)
Cycle 6 (Cycle 6)
Cycle 7 (Cycle 7)
Cycle 8 (Cycle 8)
Cycle 9 (Cycle 9)
Off Treatment
Off Treatment Report Period (since registration)
9 Years (108 months post registration)
12 Months (12 Months Post Registration)
10 Years (120 months post registration)
15 Months (15 Months Post Registration)
18 Months (18 Months Post Registration)
21 Months Post Registration (21 Months
Post Registration)
2 Years (24 Months Post Registration)
3 Months (3 Months Post Registration)
30 Months (30 Months Post Registration)
3 Years (36 Months Post Registration)
42 Months (42 Months Post Registration)
4 Years (48 Months Post Registration)
54 Months (54 Months Post Registration)
6 Months (6 Months Post Registration)
5 Years (60 Months Post Registration)
6 Years (72 months post registration)
84 Months Post Registration (84 months
post registration)
9 Months (9 Months Post Registration)
8 Years (96 months post registration)
Adverse Event Current Assessment
Were adverse events assessed during this report
period (cycle)
No (No)
Yes, And Reportable Adverse Events
Occurred (Yes, and reportable adverse
events occurred)
Yes, But No Reportable Adverse Events
Occurred (Yes, but no reportable adverse
events occurred)
CTC Adverse Event Report Begin Date
CTC Adverse Event Report End Date
Blood/bone Marrow/metabolic - Labs
CTC Adverse Event Term
Anorexia (Anorexia)
Constipation (Constipation)
Diarrhoea Nos (Diarrhea)
Fatigue (Fatigue (asthenia, lethargy,
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malaise))
Dyspepsia (Heartburn/dyspepsia)
Hypertension Nos (Hypertension)
Hypopigmentation (Hypopigmentation)
Mucositis/stomatitis
(functional/symptomatic)
(Mucositis/stomatitis
(functional/symptomatic) - Pharynx)
Nausea (Nausea)
Localised Exfoliation (Rash: hand-foot
skin reaction)
Dermatitis Exfoliative Nos
(Rash/desquamation)
Hypothyroidism (Thyroid function, low
(hypothyroidism))
Vomiting Nos (Vomiting)
Adverse Event Start Date
Adverse Event End Date
Mark an 'X' if continuing from prior cycle.
CTC Adverse Event Grade (v3.0)
CTC AE Attribution Code
Definite (definite)
Possible (possible)
Probable (probable)
Unlikely (unlikely)
Unrelated (unrelated)
Action Taken at Time of Adverse Event
There Was No Action Taken Based On
The Adverse Event (none)
Other Treatment Was Required As A
Result Of The Adverse Event (other
treatment required)
Protocol Treatment Was Delayed As A
Result Of The Adverse Event (protocol
treatment delayed)
Protocol Treatment Was Discontinued As
A Result Of The Adverse Event (protocol
treatment discontinued)
Study Dose Was Reduced As A Result
Of The Adverse Event (study dose
reduced)
Outcome of Adverse Event
Adverse Event Was Fatal (fatal)
Adverse Event Has Improved (improved)
Adverse Event Is Resolved (resolved)
Adverse Event Is Unchanged
(unchanged)
Adverse Event Is Worse (worsened)
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AE Expedited report filed? (Check box if yes)
NON-HEMATOLOGIC
CTC Adverse Event Term
Anorexia (Anorexia)
Constipation (Constipation)
Diarrhoea Nos (Diarrhea)
Fatigue (Fatigue (asthenia, lethargy,
malaise))
Dyspepsia (Heartburn/dyspepsia)
Hypertension Nos (Hypertension)
Hypopigmentation (Hypopigmentation)
Mucositis/stomatitis
(functional/symptomatic)
(Mucositis/stomatitis
(functional/symptomatic) - Pharynx)
Nausea (Nausea)
Localised Exfoliation (Rash: hand-foot
skin reaction)
Dermatitis Exfoliative Nos
(Rash/desquamation)
Hypothyroidism (Thyroid function, low
(hypothyroidism))
Vomiting Nos (Vomiting)
Adverse Event Start Date
Adverse Event End Date
Mark an 'X' if continuing from prior cycle.
CTC Adverse Event Grade (v3.0)
CTC AE Attribution Code
Definite (definite)
Possible (possible)
Probable (probable)
Unlikely (unlikely)
Unrelated (unrelated)
Action Taken at Time of Adverse Event
There Was No Action Taken Based On
The Adverse Event (none)
Other Treatment Was Required As A
Result Of The Adverse Event (other
treatment required)
Protocol Treatment Was Delayed As A
Result Of The Adverse Event (protocol
treatment delayed)
Protocol Treatment Was Discontinued As
A Result Of The Adverse Event (protocol
treatment discontinued)
Study Dose Was Reduced As A Result
Of The Adverse Event (study dose
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reduced)
Outcome of Adverse Event
Adverse Event Was Fatal (fatal)
Adverse Event Has Improved (improved)
Adverse Event Is Resolved (resolved)
Adverse Event Is Unchanged
(unchanged)
Adverse Event Is Worse (worsened)
AE Expedited report filed? (Check box if yes)
Ii. Infections
CommonToxicity --CTC Adverse Event Short
Name (Specify site for each event)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically) - select)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
- select)
Infection With Unknown Anc (Infection
with unknown ANC - select)
CTC Select AE
CTC Adverse Event Grade (v3.0)
CTC AE Attribution Code
Definite (definite)
Possible (possible)
Probable (probable)
Unlikely (unlikely)
Unrelated (unrelated)
Action Taken at Time of Adverse Event
There Was No Action Taken Based On
The Adverse Event (none)
Other Treatment Was Required As A
Result Of The Adverse Event (other
treatment required)
Protocol Treatment Was Delayed As A
Result Of The Adverse Event (protocol
treatment delayed)
Protocol Treatment Was Discontinued As
A Result Of The Adverse Event (protocol
treatment discontinued)
Study Dose Was Reduced As A Result
Of The Adverse Event (study dose
reduced)
Outcome of Adverse Event
Adverse Event Was Fatal (fatal)
Adverse Event Has Improved (improved)
Adverse Event Is Resolved (resolved)
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Adverse Event Is Unchanged
(unchanged)
Adverse Event Is Worse (worsened)
AE Expedited report filed? (Check box if yes)
Other Adverse Events
Other CTC Adverse Event Term not listed
Other, Specify  (site/sub-term)
CTC Adverse Event Grade (v3.0)
CTC AE Attribution Code
Definite (definite)
Possible (possible)
Probable (probable)
Unlikely (unlikely)
Unrelated (unrelated)
Action Taken at Time of Adverse Event
There Was No Action Taken Based On
The Adverse Event (none)
Other Treatment Was Required As A
Result Of The Adverse Event (other
treatment required)
Protocol Treatment Was Delayed As A
Result Of The Adverse Event (protocol
treatment delayed)
Protocol Treatment Was Discontinued As
A Result Of The Adverse Event (protocol
treatment discontinued)
Study Dose Was Reduced As A Result
Of The Adverse Event (study dose
reduced)
Outcome of Adverse Event
Adverse Event Was Fatal (fatal)
Adverse Event Has Improved (improved)
Adverse Event Is Resolved (resolved)
Adverse Event Is Unchanged
(unchanged)
Adverse Event Is Worse (worsened)
AE Expedited report filed? (Check box if yes)
Comments
Investigator Signature
Investigator Signature Date
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E2905 Adverse Event Form - (CTCAE v4)
NCT00843882
E2905 Adverse Event Form - (CTCAE v4) NCT00843882 
Lenalidomide With or Without Epoetin Alfa in Treating
Patients With Myelodysplastic Syndrome and Anemia
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=0EAAAD8F-
8F89-6BFE-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11581
E2905 Adverse Event Form -
(CTCAE v4) NCT00843882
Header
ECOG Protocol Number
ECOG Patient ID
DCI Name
Registration Step
Patient demographics
ECOG Protocol Number
Patient Initials (Last, First)
ECOG Patient ID
Participating Group Protocol Number
Institution/Affiliate
Participating Group Patient ID
Data amendment
Please mark an 'X' if data have been amended.
(Please circle amended items in red)
Date data amended (MM/DD/YYYY)
On Treatment
On Treatment Report Period (Step 2 - Choose
one x)
>cycle 13-step 2 (>Cycle 13-Step 2)
1 / 4
Cycle 1 Step 2 (Cycle 1 Step 2)
Cycle 10 Step 2 (Cycle 10 Step 2)
Cycle 11 Step 2 (Cycle 11 Step 2)
Cycle 12 Step 2 (Cycle 12 Step 2)
Cycle 13-step 2 (Cycle 13-Step 2)
Cycle 2 Step 2 (Cycle 2 Step 2)
Cycle 3 Step 2 (Cycle 3 Step 2)
Cycle 4 Step 2 (Cycle 4 Step 2)
Cycle 5 Step 2 (Cycle 5 Step 2)
Cycle 6 Step 2 (Cycle 6 Step 2)
Cycle 7 Step 2 (Cycle 7 Step 2)
Cycle 8 Step 2 (Cycle 8 Step 2)
Cycle 9 Step 2 (Cycle 9 Step 2)
On Treatment Report Period (Step 2 - Choose
one x)
>cycle 13-step 2 (>Cycle 13-Step 2)
Cycle 1 Step 2 (Cycle 1 Step 2)
Cycle 10 Step 2 (Cycle 10 Step 2)
Cycle 11 Step 2 (Cycle 11 Step 2)
Cycle 12 Step 2 (Cycle 12 Step 2)
Cycle 13-step 2 (Cycle 13-Step 2)
Cycle 2 Step 2 (Cycle 2 Step 2)
Cycle 3 Step 2 (Cycle 3 Step 2)
Cycle 4 Step 2 (Cycle 4 Step 2)
Cycle 5 Step 2 (Cycle 5 Step 2)
Cycle 6 Step 2 (Cycle 6 Step 2)
Cycle 7 Step 2 (Cycle 7 Step 2)
Cycle 8 Step 2 (Cycle 8 Step 2)
Cycle 9 Step 2 (Cycle 9 Step 2)
Specify Cycle
Specify Cycle
Off Treatment
Off Treatment Report Period (since registration)
9 Years (108 months post registration)
12 Months (12 Months Post Registration)
10 Years (120 months post registration)
15 Months (15 Months Post Registration)
18 Months (18 Months Post Registration)
21 Months Post Registration (21 Months
Post Registration)
2 Years (24 Months Post Registration)
3 Months (3 Months Post Registration)
30 Months (30 Months Post Registration)
3 Years (36 Months Post Registration)
42 Months (42 Months Post Registration)
4 Years (48 Months Post Registration)
54 Months (54 Months Post Registration)
6 Months (6 Months Post Registration)
5 Years (60 Months Post Registration)
6 Years (72 months post registration)
84 Months Post Registration (84 months
post registration)
9 Months (9 Months Post Registration)
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8 Years (96 months post registration)
Adverse Event Current Assessment
Were adverse events assessed during this report
period
No (No)
Yes, And Reportable Adverse Events
Occurred (Yes, and reportable adverse
events occurred)
Yes, But No Reportable Adverse Events
Occurred (Yes, but no reportable adverse
events occurred)
CTC Adverse Event Report Begin Date (For the
dates below, record the start and end dates of the
time period within current period in which patient
was assessed for adversed events. -
MM/DD/YYYY)
CTC Adverse Event Report End Date
(MM/DD/YYYY)
Blood?bone Marrow/metabolic/laboratory
CTC Adverse Event Term (Other CTC Adverse
Event Term not listed)
CTC Adverse Event Grade (v4.0 - this
cycle/report period - Report only Grade 3-5)
Severe Adverse Event (3)
Life Threatening Adverse Event (4)
Death Related To Adverse Event (5)
CTC Adverse Event Attribution Scale
Definite (definite)
Possible (possible)
Probable (probable)
Unlikely (unlikely)
Unrelated (unrelated)
II. NON-HEMATOLOGIC
CTC Adverse Event Term (Other CTC Adverse
Event Term not listed)
CTC Adverse Event Grade (v4.0 - this
cycle/report period - Report only Grade 3-5)
Severe Adverse Event (3)
Life Threatening Adverse Event (4)
Death Related To Adverse Event (5)
CTC Adverse Event Attribution Scale
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Definite (definite)
Possible (possible)
Probable (probable)
Unlikely (unlikely)
Unrelated (unrelated)
III. Other Adverse Events (including
Infections)
CTC Adverse Event Term (Other CTC Adverse
Event Term not listed)
Other, specify (specific infection or AE CTC
Adverse Event Term not listed)
CTC Adverse Event Grade (v4.0 - this
cycle/report period - Report only Grade 3-5)
Severe Adverse Event (3)
Life Threatening Adverse Event (4)
Death Related To Adverse Event (5)
CTC Adverse Event Attribution Scale
Definite (definite)
Possible (possible)
Probable (probable)
Unlikely (unlikely)
Unrelated (unrelated)
Other Adverse Events
CTC Adverse Event Short Name (Specify site for
each event)
CTC Select AE
CTC Adverse Event Grade (v3.0)
CTC Adverse Event Attribution Scale
Definite (definite)
Possible (possible)
Probable (probable)
Unlikely (unlikely)
Unrelated (unrelated)
Comments
Comments
Investigator Signature
Investigator Signature Date
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ECOG-E1505 Adverse Event Form
(CTCAE v4) NCT00324805
ECOG-E1505 Adverse Event Form (CTCAE v4)
NCT00324805 
Chemotherapy With or Without Bevacizumab in Treating
Patients With Stage IB, Stage II, or Stage IIIA Non-Small
Lung Cancer That Was Removed By Surgery
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=07D0D172-
AF48-5791-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11582
ECOG-E1505 Adverse Event Form
(CTCAE v4) NCT00324805
Header
ECOG Protocol Number
DCI Name
Registration Step
ECOG Patient ID
Patient demographics
Patient Initials (Last, First)
ECOG Protocol Number
Participating Group Protocol Number
Institution/Affiliate
ECOG Patient ID
Participating Group Patient ID
Data amendment
Please mark an 'X' if data have been amended
(Please circle amended items in red)
Date data amended (M D Y)
On Treatment
On Treatment Report Period (Arm B Only)
Cycle 10 (Cycle 10)
Cycle 11 (Cycle 11)
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Cycle 12 (Cycle 12)
Cycle 13 (Cycle 13)
Cycle 14 (Cycle 14)
Cycle 15 (Cycle 15)
Cycle 16 (Cycle 16)
Cycle 17 (Cycle 17)
Cycle 5 (Cycle 5)
Cycle 6 (Cycle 6)
Cycle 7 (Cycle 7)
Cycle 8 (cycle 8)
Cycle 9 (Cycle 9)
On Treatment Report Period (Arm B Only)
Cycle 10 (Cycle 10)
Cycle 11 (Cycle 11)
Cycle 12 (Cycle 12)
Cycle 13 (Cycle 13)
Cycle 14 (Cycle 14)
Cycle 15 (Cycle 15)
Cycle 16 (Cycle 16)
Cycle 17 (Cycle 17)
Cycle 5 (Cycle 5)
Cycle 6 (Cycle 6)
Cycle 7 (Cycle 7)
Cycle 8 (cycle 8)
Cycle 9 (Cycle 9)
Off Treatment
Off Treatment Report Period (since initial
registration)
12 Months Post-treatment (12 Months
Post-Treatment)
3 Months Post-treatment (3 Months Post-
Treatment)
6 Months Post-treatment (6 Months Post-
Treatment)
9 Months Post-treatment (9 Months Post-
Treatment)
Adverse Event Current Assessment
Were adverse events assessed during this report
period (cycle)
No (No)
Yes, And Reportable Adverse Events
Occurred (Yes, and reportable adverse
events occurred)
Yes, But No Reportable Adverse Events
Occurred (Yes, but no reportable adverse
events occurred)
CTC Adverse Event Report Begin Date (M D Y)
CTC Adverse Event Report End Date (M D Y)
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Blood/bone Marrow - Labs
CTC Adverse Event Term
Nervous System Disorders - Other,
Specify (Nervous system disorders -
Other, Specify)
CTC Adverse Event Grade (v4.0 - this reporting
period - Report only Grade 3-5)
Severe Adverse Event (3)
Life Threatening Adverse Event (4)
Death Related To Adverse Event (5)
CTC Adverse Event Attribution Code (highest
attributed to only protocol agent)
Definite (definite)
Possible (possible)
Probable (probable)
Unlikely (unlikely)
Unrelated (unrelated)
Action taken for this AE for Chemotherapy
Dose Delayed (Dose delayed)
Dose Delayed And Reduced (Dose
delayed and reduced)
Dose Held (Dose held)
Dose Reduced (Dose reduced)
Drug Discontinued (Drug discontinued)
Action taken for this AE for Bevacizumab
Dose Delayed (Dose delayed)
Dose Held (Dose held)
Drug Discontinued (Drug discontinued)
Blood/bone Marrow - Labs
CTC Adverse Event Term
Nervous System Disorders - Other,
Specify (Nervous system disorders -
Other, Specify)
CTC Adverse Event Grade (v4.0 - this reporting
period - Report only Grade 3-5)
Severe Adverse Event (3)
Life Threatening Adverse Event (4)
Death Related To Adverse Event (5)
CTC Adverse Event Attribution Code (highest
attributed to only protocol agent)
Definite (definite)
Possible (possible)
Probable (probable)
Unlikely (unlikely)
Unrelated (unrelated)
Action taken for this AE for Chemotherapy
Dose Delayed (Dose delayed)
Dose Delayed And Reduced (Dose
delayed and reduced)
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Dose Held (Dose held)
Dose Reduced (Dose reduced)
Drug Discontinued (Drug discontinued)
Action taken for this AE for Bevacizumab
Dose Delayed (Dose delayed)
Dose Held (Dose held)
Drug Discontinued (Drug discontinued)
Blood/bone Marrow - Labs
CTC Adverse Event Term
Nervous System Disorders - Other,
Specify (Nervous system disorders -
Other, Specify)
CTC Adverse Event Grade (v4.0 - this reporting
period - Report only Grade 3-5)
Severe Adverse Event (3)
Life Threatening Adverse Event (4)
Death Related To Adverse Event (5)
CTC Adverse Event Attribution Code (highest
attributed to only protocol agent)
Definite (definite)
Possible (possible)
Probable (probable)
Unlikely (unlikely)
Unrelated (unrelated)
Action taken for this AE for Chemotherapy
Dose Delayed (Dose delayed)
Dose Delayed And Reduced (Dose
delayed and reduced)
Dose Held (Dose held)
Dose Reduced (Dose reduced)
Drug Discontinued (Drug discontinued)
Action taken for this AE for Bevacizumab
Dose Delayed (Dose delayed)
Dose Held (Dose held)
Drug Discontinued (Drug discontinued)
Blood/bone Marrow - Labs
CTC Adverse Event Term
Nervous System Disorders - Other,
Specify (Nervous system disorders -
Other, Specify)
CTC Adverse Event Grade (v4.0 - this reporting
period - Report only Grade 3-5)
Severe Adverse Event (3)
Life Threatening Adverse Event (4)
Death Related To Adverse Event (5)
CTC Adverse Event Attribution Code (highest
attributed to only protocol agent)
Definite (definite)
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Possible (possible)
Probable (probable)
Unlikely (unlikely)
Unrelated (unrelated)
Action taken for this AE for Chemotherapy
Dose Delayed (Dose delayed)
Dose Delayed And Reduced (Dose
delayed and reduced)
Dose Held (Dose held)
Dose Reduced (Dose reduced)
Drug Discontinued (Drug discontinued)
Action taken for this AE for Bevacizumab
Dose Delayed (Dose delayed)
Dose Held (Dose held)
Drug Discontinued (Drug discontinued)
Blood/bone Marrow - Labs
CTC Adverse Event Term
Nervous System Disorders - Other,
Specify (Nervous system disorders -
Other, Specify)
CTC Adverse Event Grade (v4.0 - this reporting
period - Report only Grade 3-5)
Severe Adverse Event (3)
Life Threatening Adverse Event (4)
Death Related To Adverse Event (5)
CTC Adverse Event Attribution Code (highest
attributed to only protocol agent)
Definite (definite)
Possible (possible)
Probable (probable)
Unlikely (unlikely)
Unrelated (unrelated)
Action taken for this AE for Chemotherapy
Dose Delayed (Dose delayed)
Dose Delayed And Reduced (Dose
delayed and reduced)
Dose Held (Dose held)
Dose Reduced (Dose reduced)
Drug Discontinued (Drug discontinued)
Action taken for this AE for Bevacizumab
Dose Delayed (Dose delayed)
Dose Held (Dose held)
Drug Discontinued (Drug discontinued)
Blood/bone Marrow - Labs
CTC Adverse Event Term
Nervous System Disorders - Other,
Specify (Nervous system disorders -
Other, Specify)
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CTC Adverse Event Grade (v4.0 - this reporting
period - Report only Grade 3-5)
Severe Adverse Event (3)
Life Threatening Adverse Event (4)
Death Related To Adverse Event (5)
CTC Adverse Event Attribution Code (highest
attributed to only protocol agent)
Definite (definite)
Possible (possible)
Probable (probable)
Unlikely (unlikely)
Unrelated (unrelated)
Action taken for this AE for Chemotherapy
Dose Delayed (Dose delayed)
Dose Delayed And Reduced (Dose
delayed and reduced)
Dose Held (Dose held)
Dose Reduced (Dose reduced)
Drug Discontinued (Drug discontinued)
Action taken for this AE for Bevacizumab
Dose Delayed (Dose delayed)
Dose Held (Dose held)
Drug Discontinued (Drug discontinued)
Ii. Infections
CTC Adverse Event Term
Nervous System Disorders - Other,
Specify (Nervous system disorders -
Other, Specify)
Other, specify
CTC Adverse Event Grade (v4.0 - this reporting
period - Report only Grade 3-5)
Severe Adverse Event (3)
Life Threatening Adverse Event (4)
Death Related To Adverse Event (5)
CTC Adverse Event Attribution Code (highest
attributed to only protocol agent)
Definite (definite)
Possible (possible)
Probable (probable)
Unlikely (unlikely)
Unrelated (unrelated)
Action taken for this AE for Chemotherapy
Dose Delayed (Dose delayed)
Dose Delayed And Reduced (Dose
delayed and reduced)
Dose Held (Dose held)
Dose Reduced (Dose reduced)
Drug Discontinued (Drug discontinued)
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Action taken for this AE for Bevacizumab
Dose Delayed (Dose delayed)
Dose Held (Dose held)
Drug Discontinued (Drug discontinued)
Comments
Investigator Signature
Investigator Signature Date
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E2603 Adverse Event Form - (CTCAE v3)
(6/05) NCT00110019
E2603 Adverse Event Form - (CTCAE v3) (6/05)
NCT00110019
Carboplatin and Paclitaxel With or Without Sorafenib in
Treating Patients With Unresectable Stage III or Stage IV
Melanoma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=FA0E0E3F-
734F-5246-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11583
E2603 Adverse Event Form -
(CTCAE v3) (6/05) NCT00110019
ECOG clinical trial administrative data
ECOG Protocol Number
ECOG Patient ID
DCI Name
Registration Step
Patient demographics
ECOG Protocol Number
Patient Initials
ECOG Patient ID
Participating Group Protocol Number
Institution/Affiliate
Participating Group Patient ID
Data amendment
Please mark an 'X' if data have been amended.
Date data amended
On Treatment
On Treatment Report Period (Choose one)
> Cycle 10 (> Cycle 10)
Cycle 1 (Cycle 1)
Cycle 10 (Cycle 10)
1 / 4
Cycle 2 (Cycle 2)
Cycle 3 (Cycle 3)
Cycle 4 (Cycle 4)
Cycle 5 (Cycle 5)
Cycle 6 (Cycle 6)
Cycle 7 (Cycle 7)
Cycle 8 (Cycle 8)
Cycle 9 (Cycle 9)
cycle (specify)
Off Treatment
Off Treatment Report Period (since registration)
12 Months (12 Months Post Registration)
15 Months (15 Months Post Registration)
18 Months (18 Months Post Registration)
21 Months Post Registration (21 Months
Post Registration)
2 Years (24 Months Post Registration)
3 Months (3 Months Post Registration)
30 Months (30 Months Post Registration)
3 Years (36 Months Post Registration)
42 Months (42 Months Post Registration)
4 Years (48 Months Post Registration)
54 Months (54 Months Post Registration)
6 Months (6 Months Post Registration)
5 Years (60 Months Post Registration)
9 Months (9 Months Post Registration)
Adverse Event Current Assessment
Were adverse events assessed during this report
period (cycle)
No (No)
Yes, And Reportable Adverse Events
Occurred (Yes, and reportable adverse
events occurred)
Yes, But No Reportable Adverse Events
Occurred (Yes, but no reportable adverse
events occurred)
CTC Adverse Event Report Begin Date
CTC Adverse Event Report End Date
Blood?bone Marrow/metabolic/laboratory
CTC Adverse Event Term Type
Anorexia (Anorexia)
Diarrhoea Nos (Diarrhea)
Fatigue (Fatigue)
Hypertension Nos (Hypertension)
Mucositis/stomatitis
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(functional/symptomatic)
(Mucositis/Stomatitis, Stomach)
Nausea (Nausea)
Peripheral Sensory Neuropathy
(Neuropathy: sensory)
Arthralgia (Pain, Joint)
Myalgia (Pain, Muscle)
Pruritus Nos (Pruritus/itching)
Localised Exfoliation (Rash: hand-foot
skin reaction)
Dermatitis Exfoliative Nos
(Rash/desquamation)
Rigors (Rigors/chills)
Vomiting Nos (Vomiting)
CTC Adverse Event Grade (v3.0)
CTC Adverse Event Attribution Scale
Definite (definite)
Possible (possible)
Probable (probable)
Unlikely (unlikely)
Unrelated (unrelated)
NON-HEMATOLOGIC
CTC Adverse Event Term Type
Anorexia (Anorexia)
Diarrhoea Nos (Diarrhea)
Fatigue (Fatigue)
Hypertension Nos (Hypertension)
Mucositis/stomatitis
(functional/symptomatic)
(Mucositis/Stomatitis, Stomach)
Nausea (Nausea)
Peripheral Sensory Neuropathy
(Neuropathy: sensory)
Arthralgia (Pain, Joint)
Myalgia (Pain, Muscle)
Pruritus Nos (Pruritus/itching)
Localised Exfoliation (Rash: hand-foot
skin reaction)
Dermatitis Exfoliative Nos
(Rash/desquamation)
Rigors (Rigors/chills)
Vomiting Nos (Vomiting)
CTC Adverse Event Grade (v3.0)
CTC Adverse Event Attribution Scale
Definite (definite)
Possible (possible)
Probable (probable)
Unlikely (unlikely)
Unrelated (unrelated)
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Ii. Infections
CTC Adverse Event Short Name (Specify site for
each event)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically) - select)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
- select)
Infection With Unknown Anc (Infection
with unknown ANC - select)
Specify site
CTC Adverse Event Grade (v3.0)
CTC Adverse Event Attribution Scale
Definite (definite)
Possible (possible)
Probable (probable)
Unlikely (unlikely)
Unrelated (unrelated)
Other Adverse Events
Other CTC Adverse Event Term not listed
Other, Specify  (site/sub-term)
CTC Adverse Event Grade (v3.0)
CTC Adverse Event Attribution Scale
Definite (definite)
Possible (possible)
Probable (probable)
Unlikely (unlikely)
Unrelated (unrelated)
Comments
Comments
Investigator Signature
Investigator Signature Date
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E2603 Adverse Event Form - (CTCAE v3)
NCT00110019
E2603 Adverse Event Form - (CTCAE v3) NCT00110019
Carboplatin and Paclitaxel With or Without Sorafenib in
Treating Patients With Unresectable Stage III or Stage IV
Melanoma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=E75AC780-
DB8D-20A4-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11584
E2603 Adverse Event Form -
(CTCAE v3) NCT00110019
Header
ECOG Protocol Number
ECOG Patient ID
DCI Name
Registration Step
Patient demographics
Patient Initials
Participating Group Protocol Number
Institution/Affiliate
Participating Group Patient ID
Data amendment
Please mark an 'X' if data have been amended.
Date data amended
On Treatment
On Treatment Report Period (Choose one)
> Cycle 10 (> Cycle 10)
Cycle 1 (Cycle 1)
Cycle 10 (Cycle 10)
Cycle 2 (Cycle 2)
Cycle 3 (Cycle 3)
Cycle 4 (Cycle 4)
Cycle 5 (Cycle 5)
Cycle 6 (Cycle 6)
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Cycle 7 (Cycle 7)
Cycle 8 (Cycle 8)
Cycle 9 (Cycle 9)
cycle (specify)
Off Treatment
Off Treatment Report Period (since registration)
12 Months (12 Months Post Registration)
15 Months (15 Months Post Registration)
18 Months (18 Months Post Registration)
21 Months Post Registration (21 Months
Post Registration)
2 Years (24 Months Post Registration)
3 Months (3 Months Post Registration)
30 Months (30 Months Post Registration)
3 Years (36 Months Post Registration)
42 Months (42 Months Post Registration)
4 Years (48 Months Post Registration)
54 Months (54 Months Post Registration)
6 Months (6 Months Post Registration)
5 Years (60 Months Post Registration)
9 Months (9 Months Post Registration)
Adverse Event Current Assessment
Were adverse events assessed during this report
period (cycle)
No (No)
Yes, And Reportable Adverse Events
Occurred (Yes, and reportable adverse
events occurred)
Yes, But No Reportable Adverse Events
Occurred (Yes, but no reportable adverse
events occurred)
CTC Adverse Event Report Begin Date
CTC Adverse Event Report End Date
CTC Adverse Event Term Type
Anorexia (Anorexia)
Diarrhoea Nos (Diarrhea)
Fatigue (Fatigue)
Hypertension Nos (Hypertension)
Mucositis/stomatitis
(functional/symptomatic)
(Mucositis/Stomatitis, Stomach)
Nausea (Nausea)
Peripheral Sensory Neuropathy
(Neuropathy: sensory)
Arthralgia (Pain, Joint)
Myalgia (Pain, Muscle)
Pruritus Nos (Pruritus/itching)
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Localised Exfoliation (Rash: hand-foot
skin reaction)
Dermatitis Exfoliative Nos
(Rash/desquamation)
Rigors (Rigors/chills)
Vomiting Nos (Vomiting)
Investigator Term
Mark an 'X' if continuing from prior cycle.
CTC Adverse Event Start Date (Enter Day 1 of
this report period if continuing from previous
report period)
CTC Adverse Event End Date (Leave blank if not
resolved by end of report period)
CTC Adverse Event Grade (v3.0)
CTC Adverse Event Attribution Scale
Definite (definite)
Possible (possible)
Probable (probable)
Unlikely (unlikely)
Unrelated (unrelated)
Action Taken at Time of Adverse Event
There Was No Action Taken Based On
The Adverse Event (none)
Other Treatment Was Required As A
Result Of The Adverse Event (other
treatment required)
Protocol Treatment Was Delayed As A
Result Of The Adverse Event (protocol
treatment delayed)
Protocol Treatment Was Discontinued As
A Result Of The Adverse Event (protocol
treatment discontinued)
Study Dose Was Reduced As A Result
Of The Adverse Event (study dose
reduced)
Outcome of Adverse Event
Adverse Event Was Fatal (death/fatal)
Adverse Event Has Improved (improved)
Adverse Event Is Ongoing (ongoing)
Adverse Event Is Resolved (resolved)
Adverse Event Is Unchanged
(unchanged)
Adverse Event Is Worse (worsened)
Ii. Infections
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Common Toxicity (Specify site for each event)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically) - select)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
- select)
Infection With Unknown Anc (Infection
with unknown ANC - select)
Specify site
Other Adverse Events
Other CTC Adverse Event Term not listed
Other, Specify  (site/sub-term)
Comments
Comments
Investigator Signature
Investigator Signature Date
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E3805 Adverse Event Form - (CTCAE v3)
NCT00309985
E3805 Adverse Event Form - (CTCAE v3) NCT00309985
Androgen Ablation Therapy With or Without Chemotherapy
in Treating Patients With Metastatic Prostate Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=F9FCD590-
0471-30E2-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11585
E3805 Adverse Event Form -
(CTCAE v3) NCT00309985
Header
ECOG Protocol Number
ECOG Patient ID
DCI Name
Registration Step
Patient demographics
ECOG Protocol Number
Patient Initials
ECOG Patient ID
Participating Group Protocol Number
Institution/Affiliate
Participating Group Patient ID
Data amendment
Please mark an 'X' if data have been amended.
Date data amended
On Treatment
On Treatment Report Period (Arm A since start of
treatment)
Completion Of Chemotherapy
(Completion of chemotherapy)
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Off Treatment
Off Treatment Report Period (since registration)
9 Years (108 months post registration)
12 Months (12 Months Post Registration)
10 Years (120 months post registration)
15 Months (15 Months Post Registration)
18 Months (18 Months Post Registration)
21 Months Post Registration (21 Months
Post Registration)
2 Years (24 Months Post Registration)
3 Months (3 Months Post Registration)
30 Months (30 Months Post Registration)
3 Years (36 Months Post Registration)
42 Months (42 Months Post Registration)
4 Years (48 Months Post Registration)
54 Months (54 Months Post Registration)
6 Months (6 Months Post Registration)
5 Years (60 Months Post Registration)
6 Years (72 months post registration)
84 Months Post Registration (84 months
post registration)
9 Months (9 Months Post Registration)
8 Years (96 months post registration)
Adverse Event Current Assessment
Were adverse events assessed during this report
period (cycle)
No (No)
Yes, And Reportable Adverse Events
Occurred (Yes, and reportable adverse
events occurred)
Yes, But No Reportable Adverse Events
Occurred (Yes, but no reportable adverse
events occurred)
CTC Adverse Event Report Begin Date
CTC Adverse Event Report End Date
Blood/bone Marrow - Labs
CTC Adverse Event Term Type
Hypersensitivity Nos (Allergic
reaction/hypersensitivity (including drug
fever))
Anorexia (Anorexia)
Ascites (Ascites (non-malignant))
Colitis Nos (Colitis)
Dermal Change Lymphedema,
Phlebolymphedema (Dermal change
lymphedema, phlebolymphedema)
Diarrhoea Nos (Diarrhea)
Dyspnoea Nos (Dyspnea (shortness of
breath))
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Oedema Nos (Edema: limb)
Enteritis (inflammation Of The Small
Bowel) (Enteritis (inflammation of the
small bowel))
Fatigue (Fatigue)
Febrile Neutropenia (fever Of Unknown
Origin Without Clinically Or
Microbiologically Documented Infection)
(anc <1.0 X 10^9/l, Fever >=38.5
Degrees C) (Febrile neutropenia)
Flushing (Flushing)
Alopecia (Hair loss/Alopecia (scalp or
body))
Hypertension Nos (Hypertension)
Mucositis/stomatitis (clinical Exam)
(Mucositis/stomatitis (clinical exam) -
Oral cavity)
Nail Abnormality Nos (Nail changes)
Nausea (Nausea)
Peripheral Motor Neuropathy
(Neuropathy: motor)
Peripheral Sensory Neuropathy
(Neuropathy: sensory)
Arthralgia (Pain, Joint)
Myalgia (Pain, Muscle)
Pericardial Effusion (Pericardial effusion
(non-malignant))
Phlebitis Superficial (Phlebitis (including
superficial thrombosis))
Pleural Effusion (Pleural effusion (non-
malignant))
Pruritus Nos (Pruritus/itching)
Dermatitis Exfoliative Nos
(Rash/desquamation)
Rigors (Rigors/chills)
Convulsions Nos (Seizure)
Taste Disturbance (Taste alteration
(dysgeusia))
Vomiting Nos (Vomiting)
Lacrimation Increased (Watery eye
(epiphora, tearing))
CTC Adverse Event Grade (v3.0)
CTC Adverse Event Attribution Scale
Definite (definite)
Possible (possible)
Probable (probable)
Unlikely (unlikely)
Unrelated (unrelated)
NON-HEMATOLOGIC
CTC Adverse Event Term Type
Hypersensitivity Nos (Allergic
reaction/hypersensitivity (including drug
fever))
Anorexia (Anorexia)
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Ascites (Ascites (non-malignant))
Colitis Nos (Colitis)
Dermal Change Lymphedema,
Phlebolymphedema (Dermal change
lymphedema, phlebolymphedema)
Diarrhoea Nos (Diarrhea)
Dyspnoea Nos (Dyspnea (shortness of
breath))
Oedema Nos (Edema: limb)
Enteritis (inflammation Of The Small
Bowel) (Enteritis (inflammation of the
small bowel))
Fatigue (Fatigue)
Febrile Neutropenia (fever Of Unknown
Origin Without Clinically Or
Microbiologically Documented Infection)
(anc <1.0 X 10^9/l, Fever >=38.5
Degrees C) (Febrile neutropenia)
Flushing (Flushing)
Alopecia (Hair loss/Alopecia (scalp or
body))
Hypertension Nos (Hypertension)
Mucositis/stomatitis (clinical Exam)
(Mucositis/stomatitis (clinical exam) -
Oral cavity)
Nail Abnormality Nos (Nail changes)
Nausea (Nausea)
Peripheral Motor Neuropathy
(Neuropathy: motor)
Peripheral Sensory Neuropathy
(Neuropathy: sensory)
Arthralgia (Pain, Joint)
Myalgia (Pain, Muscle)
Pericardial Effusion (Pericardial effusion
(non-malignant))
Phlebitis Superficial (Phlebitis (including
superficial thrombosis))
Pleural Effusion (Pleural effusion (non-
malignant))
Pruritus Nos (Pruritus/itching)
Dermatitis Exfoliative Nos
(Rash/desquamation)
Rigors (Rigors/chills)
Convulsions Nos (Seizure)
Taste Disturbance (Taste alteration
(dysgeusia))
Vomiting Nos (Vomiting)
Lacrimation Increased (Watery eye
(epiphora, tearing))
CTC Adverse Event Grade (v3.0)
CTC Adverse Event Attribution Scale
Definite (definite)
Possible (possible)
Probable (probable)
Unlikely (unlikely)
Unrelated (unrelated)
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II. INFECTIONS
CTC Adverse Event Short Name (Specify site for
each event)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically) - select)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
- select)
Infection With Unknown Anc (Infection
with unknown ANC - select)
Specify site
CTC Adverse Event Grade (v3.0)
CTC Adverse Event Attribution Scale
Definite (definite)
Possible (possible)
Probable (probable)
Unlikely (unlikely)
Unrelated (unrelated)
Other Adverse Events
Other CTC Adverse Event Term not listed
Other, Specify  (site/sub-term)
CTC Adverse Event Grade (v3.0)
CTC Adverse Event Attribution Scale
Definite (definite)
Possible (possible)
Probable (probable)
Unlikely (unlikely)
Unrelated (unrelated)
Comments
Comments
Investigator Signature
Investigator Signature Date
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NCT01196390  RTOG 1010 Maintenance
Systemic Treatment Summary Form (SF)
NCT01196390  RTOG 1010 Maintenance Systemic
Treatment Summary Form (SF)
Radiation Therapy, Paclitaxel, and Carboplatin With or
Without Trastuzumab in Treating Patients With Esophageal
Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=870A090F-
64E8-A152-E040-BB89AD430551
All rights reserved. Please visit https://medical-data-
models.org/forms/11586
NCT01196390  RTOG 1010
Maintenance Systemic Treatment
Summary Form (SF)
Header Module
RTOG Study No.
Case #
Institution Name
Institution No.
Patient Initials
RTOG Patient ID
Amended Data
Yes
No
Assessment
Height (CM)
cm
Weight (KG)
Kg
BSA (M^2 [BSA must be taken out to the
hundredth X.XX])
m2
Reporting Period (WHICH CYCLE IS BEING
REPORTED)
Cycle 1 (Cycle 1)
Cycle 2 (Cycle 2)
Cycle 3 (Cycle 3)
Treatment Summary
Agent Name
1 / 4
Date Agent Started (MM DD YYYY)
Date Agent Ended (MM DD YYYY)
Agent Dose (mg)
Total No. of Doses
Agent Total Cumulative Dose (mg)
Dose Modification (Change)
No (No)
Yes, Planned (i.e., The Treatment Was
Changed According To Protocol
Guidelines) (Yes, planned)
Yes, Unplanned (i.e., The Treatment
Change Was Not Part Of Protocol
Guidelines) (Yes, unplanned)
Reason Treatment Ended
Adverse Event/side Effects/complications
(Adverse Event/Side
Effects/Complications)
Alternative Therapy (Alternative therapy)
Death On Study (Death on study)
Disease Progression, Relapse During
Active Treatment (Disease progression,
relapse during active treatment)
Other (Other)
Patient Off-treatment For Other
Complicating Disease (Patient off-
treatment for other complicating disease)
Patient Withdrawal Or Refusal After
Beginning Protocol Therapy (Patient
withdrawal/refusal after beginning
protocol therapy)
Patient Withdrawal Or Refusal Before
Beginning Protocol Therapy (Patient
withdrawal/refusal prior to beginning
protocol therapy)
Treatment Completed Per Protocol
Criteria (Treatment completed per
protocol criteria)
Alternative therapy, specify
Patient off-treatment for other complicating
disease, specify
Other specify
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Form (SF)
Therapy Modification
Details of any treatment modification
Toxicities
Was a MUGA/Echocardiogram Performed During
This Report Period
Yes
No
Incipient CHF (If yes, did the patient experience
defined as asymptomatic >20% decrease in
LVEF or a decrease of LVEF >10% below the
institutions lower limit of normal and required
treatment according to institutional guidelines)
Yes
No
LVEF Status (If a MUGA/echocardiogram was
performed during this report period)
Decrease Of <10% From Baseline And
>=6% Below Lln (Decrease of <10%
from baseline and >=6% below LLN)
Decrease Of <10% From Baseline And
1-5% Below Lln (Decrease of <10% from
baseline and 1-5% below LLN)
Decrease Of >=16% From Baseline And
>=6% Below Lln (Decrease of >=16%
from baseline and >=6% below LLN)
Decrease Of >=16% From Baseline And
1-5% Below Lln (Decrease of >=16%
from baseline and 1-5% below LLN)
Decrease Of 10-15% From Baseline And
>=6% Below Lln (Decrease of 10-15%
from baseline and >=6% below LLN)
Decrease Of 10-15% From Baseline And
1-5% Below Lln (Decrease of 10-15%
from baseline and 1-5% below LLN)
Within Normal Limits (Within normal
limits)
Grade 3 or 4 Restrictive Cardiomyopathy (IF ANY
ANSWERED YES, REPORT COMPLETELY IN
Q#12)
Yes
No
Protocol Specific Adverse Event
Evaluation
Any adverse events
No (No)
Unknown (Unknown)
Yes (Yes)
MedDRA Code
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Form (SF)
CTC Adverse Event Term
CTC AE Grade
Mild Adverse Event (1)
Moderate Adverse Event (2)
Severe Adverse Event (3)
Life Threatening Adverse Event (4)
Death Related To Adverse Event (5)
CTCAE Begin Date (MM DD YYYY)
CTC AE Attribution Code
Definite (Definite)
Possible (Possible)
Probable (Probable)
Unlikely (Unlikely)
Unrelated (Unrelated)
SAE report submitted
No (No)
Unknown (Unknown)
Yes (Yes)
Comments
Comments
Investigator Signature
Date
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Form (SF)
NCT01196390  RTOG 1010 Concurrent
Treatment Summary Form (TF)
NCT01196390  RTOG 1010 Concurrent Treatment
Summary Form (TF)
Radiation Therapy, Paclitaxel, and Carboplatin With or
Without Trastuzumab in Treating Patients With Esophageal
Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=870670E5-
419D-C79B-E040-BB89AD431B2F
All rights reserved. Please visit https://medical-data-
models.org/forms/11587
NCT01196390  RTOG 1010
Concurrent Treatment Summary
Form (TF)
RTOG clinical trial administrative data
RTOG Study No.
Case #
Institution Name
Institution No.
Patient Initials
RTOG Patient ID
Amended Data
Yes
No
Assessment
Height (CM)
cm
Weight (CM)
Kg
BSA (M^2)
m2
Assigned Treatment Arm
Arm 1 (Arm 1)
Arm 2 (Arm 2)
Treatment Summary
Agent Name
Date Agent Started (MM DD YYYY)
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Date Agent Ended (MM DD YYYY)
Agent Dose (mg)
Total No. of Doses
Agent Total Cumulative Dose (mg)
Dose Modification (Change)
No (No)
Yes, Planned (i.e., The Treatment Was
Changed According To Protocol
Guidelines) (Yes, planned)
Yes, Unplanned (i.e., The Treatment
Change Was Not Part Of Protocol
Guidelines) (Yes, unplanned)
Reason Treatment Ended
Adverse Event/side Effects/complications
(Adverse Event/Side
Effects/Complications)
Alternative Therapy (Alternative therapy)
Death On Study (Death on study)
Disease Progression, Relapse During
Active Treatment (Disease progression,
relapse during active treatment)
Other (Other)
Patient Withdrawal Or Refusal After
Beginning Protocol Therapy (Patient
withdrawal/refusal after beginning
protocol therapy)
Patient Withdrawal Or Refusal Before
Beginning Protocol Therapy (Patient
withdrawal/refusal prior to beginning
protocol therapy)
Treatment Completed Per Protocol
Criteria (Treatment completed per
protocol criteria)
Adverse event/side effects/complications specify
Alternative therapy, specify
Other specify
Therapy Modification
Details of any treatment modification
Toxicities
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Grade 3 or 4 Restrictive Cardiomyopathy
Yes
No
Incipient CHF (Defined as asymptomatic >20%
decrease in LVEF or a decrease of LVEF >10%
below the institutions lower limit of normal who
are judged to require treatment according to
institutional guidelines)
Yes
No
Protocol Specific Adverse Event
Evaluation
CTC Adverse Event Term
MedDRA Code
CTC AE Grade
Mild Adverse Event (1)
Moderate Adverse Event (2)
Severe Adverse Event (3)
Life Threatening Adverse Event (4)
Death Related To Adverse Event (5)
CTCAE Begin Date (MM DD YYYY)
AE Resolution Date (TO <= GR2)
CTC AE Attribution Code
Definite (Definite)
Possible (Possible)
Probable (Probable)
Unlikely (Unlikely)
Unrelated (Unrelated)
SAE report submitted
No (No)
Unknown (Unknown)
Yes (Yes)
Protocol Specific Adverse Event
Evaluation
CTC Adverse Event Term
MedDRA Code
CTC AE Grade
Mild Adverse Event (1)
Moderate Adverse Event (2)
Severe Adverse Event (3)
Life Threatening Adverse Event (4)
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Death Related To Adverse Event (5)
CTCAE Begin Date (MM DD YYYY)
AE Resolution Date (TO <= GR2)
CTC AE Attribution Code
Definite (Definite)
Possible (Possible)
Probable (Probable)
Unlikely (Unlikely)
Unrelated (Unrelated)
SAE report submitted
No (No)
Unknown (Unknown)
Yes (Yes)
Protocol Specific Adverse Event
Evaluation
CTC Adverse Event Term
MedDRA Code
CTC AE Grade
Mild Adverse Event (1)
Moderate Adverse Event (2)
Severe Adverse Event (3)
Life Threatening Adverse Event (4)
Death Related To Adverse Event (5)
CTCAE Begin Date (MM DD YYYY)
AE Resolution Date (TO <= GR2)
CTC AE Attribution Code
Definite (Definite)
Possible (Possible)
Probable (Probable)
Unlikely (Unlikely)
Unrelated (Unrelated)
SAE report submitted
No (No)
Unknown (Unknown)
Yes (Yes)
Protocol Specific Adverse Event
Evaluation
CTC Adverse Event Term
4 / 6
NCT01196390  RTOG 1010 Concurrent Treatment Summary Form (TF)
MedDRA Code
CTC AE Grade
Mild Adverse Event (1)
Moderate Adverse Event (2)
Severe Adverse Event (3)
Life Threatening Adverse Event (4)
Death Related To Adverse Event (5)
CTCAE Begin Date (MM DD YYYY)
AE Resolution Date (TO <= GR2)
CTC AE Attribution Code
Definite (Definite)
Possible (Possible)
Probable (Probable)
Unlikely (Unlikely)
Unrelated (Unrelated)
SAE report submitted
No (No)
Unknown (Unknown)
Yes (Yes)
Protocol Specific Adverse Event
Evaluation
CTC Adverse Event Term
MedDRA Code
CTC AE Grade
Mild Adverse Event (1)
Moderate Adverse Event (2)
Severe Adverse Event (3)
Life Threatening Adverse Event (4)
Death Related To Adverse Event (5)
CTCAE Begin Date (MM DD YYYY)
AE Resolution Date (TO <= GR2)
CTC AE Attribution Code
Definite (Definite)
Possible (Possible)
Probable (Probable)
Unlikely (Unlikely)
Unrelated (Unrelated)
SAE report submitted
No (No)
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Unknown (Unknown)
Yes (Yes)
Protocol Specific Adverse Event
Evaluation
Any adverse events
No (No)
Unknown (Unknown)
Yes (Yes)
CTC Adverse Event Term
MedDRA Code
CTC AE Grade
Mild Adverse Event (1)
Moderate Adverse Event (2)
Severe Adverse Event (3)
Life Threatening Adverse Event (4)
Death Related To Adverse Event (5)
CTCAE Begin Date (MM DD YYYY)
CTC AE Attribution Code
Definite (Definite)
Possible (Possible)
Probable (Probable)
Unlikely (Unlikely)
Unrelated (Unrelated)
SAE report submitted
No (No)
Unknown (Unknown)
Yes (Yes)
Comments
Comments
Investigator Signature
Date
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NCT00980954 RTOG 0724 Phase III Cervix Chemo RT (+)/(-) Adjuvant
Chemotherapy: Concurrent Systemic Treatment Summary Form (TF)
NCT00980954 RTOG 0724 Phase III Cervix Chemo RT
(+)/(-) Adjuvant Chemotherapy: Concurrent Systemic
Treatment Summary Form (TF)
Chemotherapy and Pelvic Radiation Therapy With or
Without Additional Chemotherapy in Treating Patients With
High-Risk Early-Stage Cervical Cancer After Radical
Hysterectomy
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=5FE95381-
CD25-390D-E040-BB89AD436907
All rights reserved. Please visit https://medical-data-
models.org/forms/11588
NCT00980954 RTOG 0724 Phase III
Cervix Chemo RT (+)/(-) Adjuvant
Chemotherapy: Concurrent Systemic
Treatment Summary Form (TF)
RTOG clinical trial administrative data
RTOG Study No.
Case #
Institution Name
Institution No.
Patient Initials
RTOG Patient ID
Amended Data (INSTRUCTIONS: Complete form
on web to unblind the protocol treatment arm)
Yes
No
Assessment
Height (CM)
cm
Weight (CM)
Kg
BSA (M2)
m2
Treatment Summary
Agent Name
Start date
1 / 24
Date Agent Ended (MM DD YYYY)
Total No. of Doses
Dose
Total Dose (mg)
Dose Modification (Change)
No (No)
Yes, Planned (i.e., The Treatment Was
Changed According To Protocol
Guidelines) (Yes, planned)
Yes, Unplanned (i.e., The Treatment
Change Was Not Part Of Protocol
Guidelines) (Yes, unplanned)
Reason Treatment Ended
Adverse Event/side Effects/complications
(Adverse Event/Side
Effects/Complications)
Alternative Therapy (Alternative therapy)
Death On Study (Death on study)
Disease Progression, Relapse During
Active Treatment (Disease progression,
relapse during active treatment)
Other (Other)
Patient Off-treatment For Other
Complicating Disease (Patient off-
treatment for other complicating disease)
Patient Withdrawal Or Refusal After
Beginning Protocol Therapy (Patient
withdrawal/refusal after beginning
protocol therapy)
Patient Withdrawal Or Refusal Before
Beginning Protocol Therapy (Patient
withdrawal/refusal prior to beginning
protocol therapy)
Treatment Completed Per Protocol
Criteria (Treatment completed per
protocol criteria)
Alternative therapy, specify
Other Complicating Disease specify
Other specify
Details of any treatment modification
Protocol Specific Adverse Event
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Evaluation
Any adverse events
No (No)
Unknown (Unknown)
Yes (Yes)
MedDRA disease code
CTC Adverse Event Term
Abdominal Distention (Abdominal
distension)
Abdominal Infection (Abdominal
infection)
Abdominal Pain (Abdominal pain)
Abdominal Soft Tissue Necrotic Lesion
(Abdominal soft tissue necrosis)
Abducens Nerve Disorder (Abducens
nerve disorder)
Accessory Nerve Disorder (Accessory
nerve disorder)
Acidosis (Acidosis)
Vestibulocochlear Nerve Disorder
(Acoustic nerve disorder NOS)
Prolonged Partial Thromboplastin Time
(Activated partial thromboplastin time
prolonged)
Acute Coronary Syndrome (Acute
coronary syndrome)
Acute Renal Failure (Acute kidney injury)
Adrenal Gland Insufficiency (Adrenal
insufficiency)
Adult Respiratory Distress Syndrome
(Adult respiratory distress syndrome)
Agitation (Agitation)
Akathisia (Akathisia)
Alanine Aminotransferase Increased
(Alanine aminotransferase increased)
Alcohol Intolerance (Alcohol intolerance)
Blood Alkaline Phosphatase Increased
(Alkaline phosphatase increased)
Alkalosis (Alkalosis)
Hypersensitivity (Allergic reaction)
Allergic Rhinitis (Allergic rhinitis)
Alopecia (Alopecia)
Amnesia (Amnesia)
Anorectal Fistula (Anal fistula)
Anal Hemorrhage (Anal hemorrhage)
Anal Mucositis (Anal mucositis)
Anal Necrotic Lesion (Anal necrosis)
Anal Pain (Anal pain)
Anal Stenosis (Anal stenosis)
Anal Ulcer (Anal ulcer)
Anaphylactic Shock (Anaphylaxis)
Anemia (Anemia)
Ankle Fracture (Ankle fracture)
Anorectal Infection (Anorectal infection)
Anorexia (Anorexia)
Anorgasmia (Anorgasmia)
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Anxiety (Anxiety)
Aortic Injury (Aortic injury)
Aortic Valve Disorder (Aortic valve
disease)
Aphonia (Aphonia)
Apnea (Apnea)
Acute Appendicitis (Appendicitis)
Acute Perforated Appendicitis
(Appendicitis perforated)
Arachnoiditis (Arachnoiditis)
Arterial Injury (Arterial injury)
Arteritis (Arteritis infective)
Arthralgia (Arthralgia)
Arthritis (Arthritis)
Ascites (Ascites)
Aspartate Aminotransferase Increased
(Aspartate aminotransferase increased)
Aspiration (Aspiration)
Cardiac Arrest (Asystole)
Ataxia (Ataxia)
Atelectasis (Atelectasis)
Atrial Fibrillation (Atrial fibrillation)
Atrial Flutter (Atrial flutter)
Av Block Third Degree (Atrioventricular
block complete)
Av Block First Degree (Atrioventricular
block first degree)
Autoimmune Disease (Autoimmune
disorder)
Bone Necrosis (Avascular necrosis)
Azoospermia (Azoospermia)
Back Pain (Back pain)
Bile Duct Stenosis (Bile duct stenosis)
Biliary Anastomotic Leakage (Biliary
anastomotic leak)
Biliary Fistula (Biliary fistula)
Cholangitis (Biliary tract infection)
Bladder Anastomotic Leakage (Bladder
anastomotic leak)
Cystitis (Bladder infection)
Bladder Perforation (Bladder perforation)
Bladder Spasm (Bladder spasm)
Bloating (Bloating)
Hematopoietic And Lymphoid System
Disorder Other Specify (Blood and
lymphatic system disorders - Other,
specify)
Abnormal Blood Antidiuretic Hormone
(Blood antidiuretic hormone abnormal)
Elevated Bilirubin (Blood bilirubin
increased)
Blood Corticotrophin Decreased (Blood
corticotrophin decreased)
Abnormal Blood Gonadotrophin (Blood
gonadotrophin abnormal)
Abnormal Blood Prolactin (Blood
prolactin abnormal)
Blurred Vision (Blurred vision)
Body Odor (Body odor)
Bone Infection (Bone infection)
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Hypocellular Bone Marrow (Bone
marrow hypocellular)
Bone Pain (Bone pain)
Brachial Plexopathy (Brachial
plexopathy)
Breast Atrophy (Breast atrophy)
Mastitis (Breast infection)
Breast Pain (Breast pain)
Bronchial Fistula (Bronchial fistula)
Bronchitis (Bronchial infection)
Bronchial Obstruction (Bronchial
obstruction)
Bronchial Stricture (Bronchial stricture)
Bronchopleural Fistula (Bronchopleural
fistula)
Bronchial Hemorrhage
(Bronchopulmonary hemorrhage)
Bronchospasm (Bronchospasm)
Bruise (Bruising)
Bullous Dermatitis (Bullous dermatitis)
Burn (Burn)
Buttock Pain (Buttock pain)
Capillary Leak Syndrome Capillary Leak
Syndrome (Capillary leak syndrome)
Decreased Carbon Monoxide Diffusing
Capacity (Carbon monoxide diffusing
capacity decreased)
Cardiac Arrest (Cardiac arrest)
Heart Disorder Other Specify (Cardiac
disorders - Other, specify)
Blood Cardiac Troponin I Increased
(Cardiac troponin I increased)
Blood Cardiac Troponin T Increased
(Cardiac troponin T increased)
Cataract (Cataract)
Catheter-related Infection (Catheter
related infection)
Cd4 Lymphocytes Decreased (CD4
lymphocytes decreased)
Cecal Hemorrhage (Cecal hemorrhage)
Cecal Infection (Cecal infection)
Central Nervous System Necrotic Lesion
(Central nervous system necrosis)
Cerebrospinal Fluid Leakage
(Cerebrospinal fluid leakage)
Infectious Cervicitis (Cervicitis infection)
Cheilitis (Cheilitis)
Angina (Chest pain - cardiac)
Chest Wall Pain (Chest wall pain)
Chills (Chills)
Cholecystitis (Cholecystitis)
Hypercholesterolemia (Cholesterol high)
Chronic Kidney Disease (Chronic kidney
disease)
Chylothorax (Chylothorax)
Cognitive Disturbance (Cognitive
disturbance)
Colitis (Colitis)
Colonic Fistula (Colonic fistula)
Colonic Hemorrhage (Colonic
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hemorrhage)
Colonic Obstruction (Colonic obstruction)
Colonic Perforation (Colonic perforation)
Colonic Stenosis (Colonic stenosis)
Colonic Ulcer (Colonic ulcer)
Concentration Impairment
(Concentration impairment)
Heart Conduction Disorder (Conduction
disorder)
Confusion (Confusion)
Congenital, Familial And Genetic
Disorder Class Other Specify
(Congenital, familial and genetic
disorders - Other, specify)
Conjunctivitis (Conjunctivitis)
Acute Contagious Conjunctivitis
(Conjunctivitis infective)
Constipation (Constipation)
Constrictive Pericarditis (Constrictive
pericarditis)
Keratitis (Corneal infection)
Corneal Ulcer (Corneal ulcer)
Cough (Cough)
Creatine Phosphokinase Increased (CPK
increased)
Cranial Nerve Infection (Cranial nerve
infection)
Increased Creatinine (Creatinine
increased)
Cushingoid (Cushingoid)
Non-infectious Cystitis (Cystitis
noninfective)
Cytokine Release Syndrome (Cytokine
release syndrome)
Neonatal Death (Death neonatal)
Death (Death NOS)
Dehydration (Dehydration)
Delayed Orgasm (Delayed orgasm)
Delayed Puberty (Delayed puberty)
Delirium (Delirium)
Delusion (Delusions)
Caries (Dental caries)
Depressed Level Of Consciousness
(Depressed level of consciousness)
Depression (Depression)
Radiation-induced Dermatitis (Dermatitis
radiation)
Prosthesis-related Infection (Device
related infection)
Diarrhea (Diarrhea)
Disseminated Intravascular Coagulation
(Disseminated intravascular coagulation)
Dizziness (Dizziness)
Dry Eye Syndrome (Dry eye)
Xerostomia (Dry mouth)
Dry Skin (Dry Skin)
Duodenal Fistula (Duodenal fistula)
Duodenal Hemorrhage (Duodenal
hemorrhage)
Duodenal Infection (Duodenal infection)
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Duodenal Obstruction (Duodenal
obstruction)
Duodenal Perforation (Duodenal
perforation)
Duodenal Stenosis (Duodenal stenosis)
Duodenal Ulcer (Duodenal ulcer)
Dysarthria (Dysarthria)
Dysesthesia (Dysesthesia)
Dysgeusia (Dysgeusia)
Dysmenorrhea (Dysmenorrhea)
Dyspareunia (Dyspareunia)
Dyspepsia (Dyspepsia)
Dysphagia (Dysphagia)
Dysphasia (Dysphasia)
Dyspnea (Dyspnea)
Ear And Labyrinth Disorder Class Other
Specify (Ear and labyrinth disorders -
Other, specify)
Earache (Ear pain)
Cerebral Edema (Edema cerebral)
Face Edema (Edema face)
Edema Limbs (Edema limbs)
Edema Trunk (Edema trunk)
Ejaculation Disorder (Ejaculation
disorder)
Ejection Fraction Decreased (Ejection
fraction decreased)
Prolonged Qt Interval (Electrocardiogram
QT corrected interval prolonged)
Infectious Encephalitis (Encephalitis
infection)
Infectious Encephalomyelitis
(Encephalomyelitis infection)
Encephalopathy (Encephalopathy)
Infective Endocarditis (Endocarditis
infective)
Endocrine Disorder Other Specify
(Endocrine disorders - Other, specify)
Endophthalmitis (Endophthalmitis)
Enterocolitis (Enterocolitis)
Infectious Enterocolitis (Enterocolitis
infectious)
Enterovesical Fistula (Enterovesical
fistula)
Epistaxis (Epistaxis)
Impotence (Erectile dysfunction)
Erythema Multiforme (Erythema
multiforme)
Erythroderma (Erythroderma)
Esophageal Anastomotic Leakage
(Esophageal anastomotic leak)
Esophageal Fistula (Esophageal fistula)
Esophageal Hemorrhage (Esophageal
hemorrhage)
Esophageal Infection (Esophageal
infection)
Esophageal Necrotic Lesion
(Esophageal necrosis)
Esophageal Obstruction (Esophageal
obstruction)
7 / 24
NCT00980954 RTOG 0724 Phase III Cervix Chemo RT (+)/(-) Adjuvant
Chemotherapy: Concurrent Systemic Treatment Summary Form (TF)
Esophageal Pain (Esophageal pain)
Perforation Of Esophagus (Esophageal
perforation)
Esophageal Stricture (Esophageal
stenosis)
Esophageal Ulcer (Esophageal ulcer)
Esophageal Varices Hemorrhage
(Esophageal varices hemorrhage)
Esophagitis (Esophagitis)
Euphoria (Euphoria)
Exostosis (Exostosis)
External Ear Inflammation (External ear
inflammation)
External Ear Pain (External ear pain)
Extraocular Muscle Paresis (Extraocular
muscle paresis)
Extrapyramidal Disorder (Extrapyramidal
disorder)
Eye Disorder Other Specify (Eye
disorders - Other, specify)
Eye Infection (Eye infection)
Eye Pain (Eye pain)
Eyelid Function Disorder (Eyelid function
disorder)
Facial Muscle Weakness (Facial muscle
weakness)
Facial Nerve Disorder (Facial nerve
disorder)
Facial Pain (Facial pain)
Fall (Fall)
Fallopian Tube Anastomotic Leakage
(Fallopian tube anastomotic leak)
Fallopian Tube Obstruction (Fallopian
tube obstruction)
Fallopian Tube Perforation (Fallopian
tube perforation)
Fallopian Tube Stenosis (Fallopian tube
stenosis)
Adipose Tissue Atrophy (Fat atrophy)
Fatigue (Fatigue)
Neutropenic Fever (Febrile neutropenia)
Fecal Incontinence (Fecal incontinence)
Female Genital Tract Fistula (Female
genital tract fistula)
Acquired Feminization (Feminization
acquired)
Intrauterine Fetal Death (Fetal death)
Fetal Growth Retardation (Fetal growth
retardation)
Fever (Fever)
Fibrinogen Decreased (Fibrinogen
decreased)
Deep Connective Tissue Fibrosis
(Fibrosis deep connective tissue)
Flank Pain (Flank pain)
Flasher (Flashing lights)
Flatulence (Flatulence)
Floaters (Floaters)
Flu-like Symptoms (Flu like symptoms)
Flushing (Flushing)
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Decreased Forced Expiratory Volume
(Forced expiratory volume decreased)
Fracture (Fracture)
Gait Disturbance (Gait disturbance)
Gallbladder Fistula (Gallbladder fistula)
Gallbladder Infection (Gallbladder
infection)
Gallbladder Necrotic Lesion (Gallbladder
necrosis)
Gallbladder Obstruction (Gallbladder
obstruction)
Gallbladder Pain (Gallbladder pain)
Gallbladder Perforation (Gallbladder
perforation)
Gastric Anastomotic Leakage (Gastric
anastomotic leak)
Gastric Fistula (Gastric fistula)
Gastric Hemorrhage (Gastric
hemorrhage)
Gastric Necrotic Lesion (Gastric
necrosis)
Gastric Perforation (Gastric perforation)
Gastric Stenosis (Gastric stenosis)
Gastric Ulcer (Gastric ulcer)
Gastritis (Gastritis)
Gastroesophageal Reflux Disease
(Gastroesophageal reflux disease)
Gastrointestinal System Anastomotic
Leakage (Gastrointestinal anastomotic
leak)
Gastrointestinal Disorder Other Specify
(Gastrointestinal disorders - Other,
specify)
Gastrointestinal Fistula (Gastrointestinal
fistula)
Gastrointestinal Pain (Gastrointestinal
pain)
Gastrointestinal Stoma Necrotic Lesion
(Gastrointestinal stoma necrosis)
Gastroparesis (Gastroparesis)
General Disorders And Administration
Site Conditions Class Other Specify
(General disorders and administration
site conditions - Other, specify)
Generalized Muscle Weakness
(Generalized muscle weakness)
Genital Edema (Genital edema)
Gamma-glutamyltransferase Increased
(GGT increased)
Gingival Pain (Gingival pain)
Glaucoma (Glaucoma)
Glossopharyngeal Nerve Disorder
(Glossopharyngeal nerve disorder)
Glucose Intolerance (Glucose
intolerance)
Accelerated Growth (Growth
accelerated)
Abnormal Growth Hormone (Growth
hormone abnormal)
Growth Retardation (Growth
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suppression)
Gum Infection (Gum infection)
Gynecomastia (Gynecomastia)
Hallucination (Hallucinations)
Haptoglobin Decreased (Haptoglobin
decreased)
Head Soft Tissue Necrotic Lesion (Head
soft tissue necrosis)
Headache (Headache)
Hearing Impairment (Hearing impaired)
Heart Failure (Heart failure)
Hematoma (Hematoma)
Hematosalpinx (Hematosalpinx)
Hematuria (Hematuria)
Hemoglobin Increased (Hemoglobin
increased)
Hemoglobinuria (Hemoglobinuria)
Hemolysis (Hemolysis)
Hemolytic Uremic Syndrome (Hemolytic
uremic syndrome)
Hemorrhoidal Hemorrhage
(Hemorrhoidal hemorrhage)
Hemorrhoid (Hemorrhoids)
Hepatic Failure (Hepatic failure)
Hepatic Hemorrhage (Hepatic
hemorrhage)
Hepatic Infection (Hepatic infection)
Hepatic Necrotic Lesion (Hepatic
necrosis)
Hepatic Pain (Hepatic pain)
Viral Hepatitis (Hepatitis viral)
Liver And Biliary Tract Disorder Other
Specify (Hepatobiliary disorders - Other,
specify)
Hiccough (Hiccups)
Hip Fracture (Hip fracture)
Hirsutism (Hirsutism)
Hoarseness (Hoarseness)
Hot Flashes (Hot flashes)
Hydrocephalus (Hydrocephalus)
Hypercalcemia (Hypercalcemia)
Hyperglycemia (Hyperglycemia)
Hyperhidrosis (Hyperhidrosis)
Hyperkalemia (Hyperkalemia)
Hypermagnesemia (Hypermagnesemia)
Hypernatremia (Hypernatremia)
Hyperparathyroidism
(Hyperparathyroidism)
Hypersomnia (Hypersomnia)
Hypertension (Hypertension)
Hyperthyroidism (Hyperthyroidism)
Hypertrichosis (Hypertrichosis)
Hypertriglyceridemia
(Hypertriglyceridemia)
Hyperuricemia (Hyperuricemia)
Hypoalbuminemia (Hypoalbuminemia)
Hypocalcemia (Hypocalcemia)
Hypoglossal Nerve Disorder
(Hypoglossal nerve disorder)
Hypoglycemia (Hypoglycemia)
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Hypohidrosis (Hypohidrosis)
Hypokalemia (Hypokalemia)
Hypomagnesemia (Hypomagnesemia)
Hyponatremia (Hyponatremia)
Hypoparathyroidism
(Hypoparathyroidism)
Hypophosphatemia (Hypophosphatemia)
Hypotension (Hypotension)
Hypothermia (Hypothermia)
Hypothyroidism (Hypothyroidism)
Hypoxia (Hypoxia)
Ileal Fistula (Ileal fistula)
Ileal Hemorrhage (Ileal hemorrhage)
Ileal Obstruction (Ileal obstruction)
Ileal Perforation (Ileal perforation)
Ileal Stenosis (Ileal stenosis)
Ileal Ulcer (Ileal ulcer)
Ileus (Ileus)
Immune System Disorder Other Specify
(Immune system disorders - Other,
specify)
Infection Other Specify (Infections and
infestations - Other, specify)
Infectious Myositis (Infective myositis)
Infusion-related Reaction (Infusion
related reaction)
Infusion Site Extravasation (Infusion site
extravasation)
Injection Site Reaction (Injection site
reaction)
Injury To Carotid Artery (Injury to carotid
artery)
Injury To Inferior Vena Cava (Injury to
inferior vena cava)
Injury To Jugular Vein (Injury to jugular
vein)
Injury To Superior Vena Cava (Injury to
superior vena cava)
Injury, Poisoning And Procedural
Complication Class Other Specify (Injury,
poisoning and procedural complications -
Other, specify)
Inr Increased (INR increased)
Insomnia (Insomnia)
Intestinal Stoma Leakage (Intestinal
stoma leak)
Intestinal Stoma Obstruction (Intestinal
stoma obstruction)
Intestinal Stoma Site Hemorrhage
(Intestinal stoma site bleeding)
Intra-abdominal Hemorrhage (Intra-
abdominal hemorrhage)
Intracranial Hemorrhage (Intracranial
hemorrhage)
Intraoperative Arterial Injury
(Intraoperative arterial injury)
Intraoperative Breast Injury
(Intraoperative breast injury)
Intraoperative Cardiac Injury
(Intraoperative cardiac injury)
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Intraoperative Ear Injury (Intraoperative
ear injury)
Intraoperative Endocrine Injury
(Intraoperative endocrine injury)
Intraoperative Gastrointestinal Injury
(Intraoperative gastrointestinal injury)
Intraoperative Head And Neck Injury
(Intraoperative head and neck injury)
Intraoperative Hemorrhage
(Intraoperative hemorrhage)
Intraoperative Hepatobiliary Injury
(Intraoperative hepatobiliary injury)
Intraoperative Musculoskeletal Injury
(Intraoperative musculoskeletal injury)
Intraoperative Neurological Injury
(Intraoperative neurological injury)
Intraoperative Ocular Injury
(Intraoperative ocular injury)
Intraoperative Renal Injury
(Intraoperative renal injury)
Intraoperative Reproductive System
Injury (Intraoperative reproductive tract
injury)
Intraoperative Respiratory Injury
(Intraoperative respiratory injury)
Intraoperative Skin Injury (Intraoperative
skin injury)
Intraoperative Splenic Injury
(Intraoperative splenic injury)
Intraoperative Urinary System Injury
(Intraoperative urinary injury)
Intraoperative Venous Injury
(Intraoperative venous injury)
Investigation Other Specify
(Investigations - Other, specify)
Iron Overload (Iron overload)
Irregular Menstruation (Irregular
menstruation)
Irritability (Irritability)
Cerebrovascular Ischemia (Ischemia
cerebrovascular)
Trochlear Nerve Disorder (IVth nerve
disorder)
Jejunal Fistula (Jejunal fistula)
Jejunal Hemorrhage (Jejunal
hemorrhage)
Jejunal Obstruction (Jejunal obstruction)
Jejunal Perforation (Jejunal perforation)
Jejunal Stenosis (Jejunal stenosis)
Jejunal Ulcer (Jejunal ulcer)
Joint Effusion (Joint effusion)
Joint Infection (Joint infection)
Joint Range Of Motion Decreased (Joint
range of motion decreased)
Cervical Spine Joint Range Of Motion
Decreased (Joint range of motion
decreased cervical spine)
Lumbar Spine Joint Range Of Motion
Decreased (Joint range of motion
decreased lumbar spine)
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Keratitis (Keratitis)
Kidney Anastomotic Leakage (Kidney
anastomotic leak)
Pyelonephritis (Kidney infection)
Kyphosis (Kyphosis)
Lactation Disorder (Lactation disorder)
Large Intestinal Anastomotic Leakage
(Large intestinal anastomotic leak)
Laryngeal Edema (Laryngeal edema)
Laryngeal Fistula (Laryngeal fistula)
Laryngeal Hemorrhage (Laryngeal
hemorrhage)
Laryngitis (Laryngeal inflammation)
Laryngeal Mucositis (Laryngeal
mucositis)
Laryngeal Obstruction (Laryngeal
obstruction)
Laryngeal Stenosis (Laryngeal stenosis)
Laryngitis (Laryngitis)
Laryngopharyngeal Dysesthesia
(Laryngopharyngeal dysesthesia)
Laryngospasm (Laryngospasm)
Left Ventricular Systolic Dysfunction (Left
ventricular systolic dysfunction)
Lethargy (Lethargy)
Chemotherapy-related Leukemia
(Leukemia secondary to oncology
chemotherapy)
Leukocytosis (Leukocytosis)
Leukoencephalopathy
(Leukoencephalopathy)
Decreased Libido (Libido decreased)
Increased Libido (Libido increased)
Lip Infection (Lip infection)
Lip Pain (Lip pain)
Lipase Increased (Lipase increased)
Lipohypertrophy (Lipohypertrophy)
Localized Edema (Localized edema)
Lordosis (Lordosis)
Lower Gastrointestinal Hemorrhage
(Lower gastrointestinal hemorrhage)
Infectious Lung Disorder (Lung infection)
Lymphadenitis (Lymph gland infection)
Lymph Leakage (Lymph leakage)
Lymph Node Pain (Lymph node pain)
Lymphedema (Lymphedema)
Lymphocele (Lymphocele)
Lymphopenia (Lymphocyte count
decreased)
Lymphocytosis (Lymphocyte count
increased)
Malabsorption Syndrome
(Malabsorption)
Malaise (Malaise)
Mania (Mania)
Mediastinal Hemorrhage (Mediastinal
hemorrhage)
Mediastinitis (Mediastinal infection)
Memory Impairment (Memory
impairment)
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Meningismus (Meningismus)
Meningitis (Meningitis)
Menopause (Menopause)
Menorrhagia (Menorrhagia)
Metabolism And Nutrition Disorder Class
Other Specify (Metabolism and nutrition
disorders - Other, specify)
Otitis Media (Middle ear inflammation)
Mitral Valve Disorder (Mitral valve
disease)
Av Block Second Degree Mobitz Type Ii
(Mobitz (type) II atrioventricular block)
Av Block Second Degree Mobitz Type I
(Mobitz type I)
Involuntary Movements (Movements
involuntary)
Mucosal Infection (Mucosal infection)
Stomatitis (Mucositis oral)
Multiple Organ Failure (Multi-organ
failure)
Muscle Weakness Left-sided (Muscle
weakness left-sided)
Muscle Weakness Lower Limb (Muscle
weakness lower limb)
Muscle Weakness Right-sided (Muscle
weakness right-sided)
Muscle Weakness Trunk (Muscle
weakness trunk)
Muscle Weakness Upper Limb (Muscle
weakness upper limb)
Connective And Soft Tissue Disorder
Other Specify (Musculoskeletal and
connective tissue disorder -  Other,
specify)
Musculoskeletal Deformity
(Musculoskeletal deformity)
Myalgia (Myalgia)
Myelitis (Myelitis)
Mds (Myelodysplastic syndrome)
Myocardial Infarction (Myocardial
infarction)
Myocarditis (Myocarditis)
Myositis (Myositis)
Nail Discoloration (Nail discoloration)
Nail Infection (Nail infection)
Nail Loss (Nail loss)
Nail Ridging (Nail ridging)
Nasal Congestion (Nasal congestion)
Nausea (Nausea)
Neck Edema (Neck edema)
Neck Pain (Neck pain)
Neck Soft Tissue Necrotic Lesion (Neck
soft tissue necrosis)
Neoplasm Other Specify (Neoplasms
benign, malignant and unspecified (incl
cysts and polyps) - Other, specify)
Nervous System Disorder Other Specify
(Nervous system disorders - Other,
specify)
Neuralgia (Neuralgia)
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Neutrophil Count Decreased (Neutrophil
count decreased)
Night Blindness (Night blindness)
Nipple Deformity (Nipple deformity)
Non-cardiac Chest Pain (Non-cardiac
chest pain)
Nystagmus (Nystagmus)
Obesity (Obesity)
Gastric Obstruction (Obstruction gastric)
Oculomotor Nerve Disorder (Oculomotor
nerve disorder)
Olfactory Nerve Disorder (Olfactory
nerve disorder)
Oligospermia (Oligospermia)
Optic Nerve Disorder (Optic nerve
disorder)
Oral Cavity Fistula (Oral cavity fistula)
Burning Mouth Syndrome (Oral
dysesthesia)
Oral Hemorrhage (Oral hemorrhage)
Oral Pain (Oral pain)
Osteonecrosis Of Jaw (Osteonecrosis of
jaw)
Osteoporosis (Osteoporosis)
External Ear Infection (Otitis externa)
Otitis Media (Otitis media)
Ovarian Hemorrhage (Ovarian
hemorrhage)
Ovarian Infection (Ovarian infection)
Ovarian Rupture (Ovarian rupture)
Ovulatory Pain (Ovulation pain)
Pain (Pain)
Pain In Extremity (Pain in extremity)
Skin Pain (Pain of skin)
Palmar-plantar Erythodysthesia (Palmar-
plantar erythrodysesthesia syndrome)
Palpitation (Palpitations)
Pancreatic Infection (Pancreas infection)
Pancreatic Anastomotic Leakage
(Pancreatic anastomotic leak)
Pancreatic Duct Stenosis (Pancreatic
duct stenosis)
Pancreatic Enzymes Decreased
(Pancreatic enzymes decreased)
Pancreatic Fistula (Pancreatic fistula)
Pancreatic Hemorrhage (Pancreatic
hemorrhage)
Pancreatic Necrotic Lesion (Pancreatic
necrosis)
Pancreatitis (Pancreatitis)
Papilledema (Papilledema)
Papulopustular Rash (Papulopustular
rash)
Paresthesia (Paresthesia)
Paronychia (Paronychia)
Paroxysmal Atrial Tachycardia
(Paroxysmal atrial tachycardia)
Pelvic Floor Muscle Weakness (Pelvic
floor muscle weakness)
Pelvic Inflammatory Disease (Pelvic
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infection)
Pelvic Pain (Pelvic pain)
Pelvic Soft Tissue Necrotic Lesion
(Pelvic soft tissue necrosis)
Penile Infection (Penile infection)
Penile Pain (Penile pain)
Bile Duct Perforation (Perforation bile
duct)
Pericardial Effusion (Pericardial effusion)
Cardiac Tamponade (Pericardial
tamponade)
Pericarditis (Pericarditis)
Perineal Pain (Perineal pain)
Periodontal Disorder (Periodontal
disease)
Periorbital Edema (Periorbital edema)
Periorbital Infection (Periorbital infection)
Peripheral Ischemia (Peripheral
ischemia)
Peripheral Motor Neuropathy (Peripheral
motor neuropathy)
Peripheral Nervous System Infectious
Disorder (Peripheral nerve infection)
Peripheral Sensory Neuropathy
(Peripheral sensory neuropathy)
Peritoneal Infection (Peritoneal infection)
Peritoneal Necrotic Lesion (Peritoneal
necrosis)
Personality Change (Personality change)
Phantom Pain (Phantom pain)
Pharyngeal Anastomotic Leakage
(Pharyngeal anastomotic leak)
Pharyngeal Fistula (Pharyngeal fistula)
Pharyngeal Hemorrhage (Pharyngeal
hemorrhage)
Pharyngeal Mucositis (Pharyngeal
mucositis)
Pharyngeal Necrotic Lesion (Pharyngeal
necrosis)
Pharyngeal Stenosis (Pharyngeal
stenosis)
Pharyngitis (Pharyngitis)
Pharyngolaryngeal Pain
(Pharyngolaryngeal pain)
Phlebitis (Phlebitis)
Infective Phlebitis (Phlebitis infective)
Photophobia (Photophobia)
Photosensitivity (Photosensitivity)
Thrombocytopenia (Platelet count
decreased)
Pleural Effusion (Pleural effusion)
Hemothorax (Pleural hemorrhage)
Pleural Infection (Pleural infection)
Pleuritic Pain (Pleuritic pain)
Pneumonia (Pneumonitis)
Pneumothorax (Pneumothorax)
Portal Hypertension (Portal
Hypertension)
Portal Vein Thrombosis (Portal vein
thrombosis)
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Post-nasal Drip (Postnasal drip)
Postoperative Bleeding (Postoperative
hemorrhage)
Thoracic Procedure Postoperative
Complication (Postoperative thoracic
procedure complication)
Precocious Puberty (Precocious
puberty)
Pregnancy, Puerperium And Perinatal
Condition Class Other Specify
(Pregnancy, puerperium and perinatal
conditions - Other, specify)
Premature Labor (Premature delivery)
Premature Menopause (Premature
menopause)
Presyncope (Presyncope)
Proctitis (Proctitis)
Productive Cough (Productive cough)
Intestinal Stoma Prolapse (Prolapse of
intestinal stoma)
Urostomy Prolapse (Prolapse of
urostomy)
Prostatic Infection (Prostate infection)
Prostatic Hemorrhage (Prostatic
hemorrhage)
Prostatic Obstruction (Prostatic
obstruction)
Prostatic Pain (Prostatic pain)
Proteinuria (Proteinuria)
Pruritus (Pruritus)
Psychiatric Disorder Other Specify
(Psychiatric disorders - Other, specify)
Psychosis (Psychosis)
Pulmonary Edema (Pulmonary edema)
Pulmonary Fibrosis (Pulmonary fibrosis)
Pulmonary Fistula (Pulmonary fistula)
Pulmonary Hypertension (Pulmonary
hypertension)
Pulmonary Valve Disorder (Pulmonary
valve disease)
Purpura (Purpura)
Pyramidal Tract Dysfunction (Pyramidal
tract syndrome)
Radiation-recall Dermatitis (Radiation
recall reaction (dermatologic))
Radiculitis (Radiculitis)
Acneiform Dermatitis (Rash acneiform)
Maculopapular Lesion (Rash maculo-
papular)
Papulopustular Rash (Rash pustular)
Rectal Anastomotic Leakage (Rectal
anastomotic leak)
Rectal Fistula (Rectal fistula)
Rectal Hemorrhage (Rectal hemorrhage)
Rectal Mucositis (Rectal mucositis)
Rectal Necrotic Lesion (Rectal necrosis)
Rectal Obstruction (Rectal obstruction)
Rectal Pain (Rectal pain)
Rectal Perforation (Rectal perforation)
Rectal Stenosis (Rectal stenosis)
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Rectal Ulcer (Rectal ulcer)
Recurrent Laryngeal Nerve Paralysis
(Recurrent laryngeal nerve palsy)
Urinary Tract Disorder Other Specify
(Renal and urinary disorders - Other,
specify)
Renal Stone (Renal calculi)
Renal Colic (Renal colic)
Renal Hemorrhage (Renal hemorrhage)
Reproductive System And Breast
Disorder Class Other Specify
(Reproductive system and breast
disorders - Other, specify)
Respiratory Failure (Respiratory failure)
Respiratory And Thoracic Disorder Other
Specify (Respiratory, thoracic and
mediastinal disorders - Other, specify)
Restlessness (Restlessness)
Restrictive Cardiomyopathy (Restrictive
cardiomyopathy)
Retinal Detachment (Retinal
detachment)
Retinal Tear (Retinal tear)
Retinal Vascular Disorder (Retinal
vascular disorder)
Retinoic Acid Syndrome (Retinoic acid
syndrome)
Retinopathy (Retinopathy)
Retroperitoneal Hemorrhage
(Retroperitoneal hemorrhage)
Reversible Posterior
Leukoencephalopathy Syndrome
(Reversible posterior
leukoencephalopathy syndrome)
Infectious Rhinitis (Rhinitis infective)
Right Ventricular Dysfunction (Right
ventricular dysfunction)
Salivary Duct Inflammation (Salivary duct
inflammation)
Salivary Gland Fistula (Salivary gland
fistula)
Salivary Gland Infection (Salivary gland
infection)
Scalp Pain (Scalp pain)
Sclera Disorder (Scleral disorder)
Scoliosis (Scoliosis)
Scrotal Infection (Scrotal infection)
Scrotal Pain (Scrotal pain)
Seizure (Seizure)
Septicemia (Sepsis)
Seroma (Seroma)
Serum Amylase Increased (Serum
amylase increased)
Serum Sickness (Serum sickness)
Sick Sinus Syndrome (Sick sinus
syndrome)
Sinus Bradycardia (Sinus bradycardia)
Paranasal Sinus Disorder (Sinus
disorder)
Sinus Pain (Sinus pain)
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Sinus Tachycardia (Sinus tachycardia)
Sinusitis (Sinusitis)
Skin Disorder Other Specify (Skin and
subcutaneous tissue disorders - Other,
specify)
Skin Atrophy (Skin atrophy)
Skin Hyperpigmentation (Skin
hyperpigmentation)
Skin Hypopigmentation (Skin
hypopigmentation)
Skin Induration (Skin induration)
Skin Infection (Skin infection)
Skin Ulcer (Skin ulceration)
Sleep Apnea (Sleep apnea)
Small Intestinal Anastomotic Leakage
(Small intestinal anastomotic leak)
Small Intestinal Mucositis (Small
intestinal mucositis)
Small Intestinal Obstruction (Small
intestinal obstruction)
Small Intestinal Perforation (Small
intestinal perforation)
Small Intestinal Stenosis (Small intestinal
stenosis)
Small Intestinal Infection (Small intestine
infection)
Small Intestinal Ulcer (Small intestine
ulcer)
Sneezing (Sneezing)
Social Circumstances Other Specify
(Social circumstances - Other, specify)
Soft Tissue Infection (Soft tissue
infection)
Lower Limb Soft Tissue Necrotic Lesion
(Soft tissue necrosis lower limb)
Upper Limb Soft Tissue Necrotic Lesion
(Soft tissue necrosis upper limb)
Somnolence (Somnolence)
Sore Throat (Sore throat)
Spasticity (Spasticity)
Spermatic Cord Anastomotic Leakage
(Spermatic cord anastomotic leak)
Spermatic Cord Hemorrhage (Spermatic
cord hemorrhage)
Spermatic Cord Obstruction (Spermatic
cord obstruction)
Vertebral Fracture (Spinal fracture)
Splenic Disorder (Spleen disorder)
Splenic Infection (Splenic infection)
Gastrointestinal Stoma Stenosis
(Stenosis of gastrointestinal stoma)
Stevens-johnson Syndrome (Stevens-
Johnson syndrome)
Stoma Site Infection (Stoma site
infection)
Stomach Pain (Stomach pain)
Stomal Ulcer (Stomal ulcer)
Stridor (Stridor)
Cerebrovascular Accident (Stroke)
Sudden Cardiac Death (Sudden death
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NOS)
Suicidal Ideation (Suicidal ideation)
Suicide Attempt (Suicide attempt)
Superficial Soft Tissue Fibrosis
(Superficial soft tissue fibrosis)
Superficial Thrombophlebitis (Superficial
thrombophlebitis)
Superior Vena Cava Syndrome (Superior
vena cava syndrome)
Supraventricular Tachycardia
(Supraventricular tachycardia)
Intervention Or Procedure Other Specify
(Surgical and medical procedures -
Other, specify)
Syncope (Syncope)
Telangiectasia (Telangiectasia)
Testicular Disorder (Testicular disorder)
Testicular Hemorrhage (Testicular
hemorrhage)
Testicular Pain (Testicular pain)
Thromboembolism (Thromboembolic
event)
Thrombotic Thrombocytopenic Purpura
(Thrombotic thrombocytopenic purpura)
Tinnitus (Tinnitus)
Dental Developmental Disorder (Tooth
development disorder)
Tooth Discoloration (Tooth discoloration)
Tooth Infection (Tooth infection)
Toothache (Toothache)
Toxic Epidermal Necrolysis (Toxic
epidermal necrolysis)
Tracheal Fistula (Tracheal fistula)
Tracheal Hemorrhage (Tracheal
hemorrhage)
Tracheal Mucositis (Tracheal mucositis)
Tracheal Obstruction (Tracheal
obstruction)
Tracheal Stenosis (Tracheal stenosis)
Tracheitis (Tracheitis)
Tracheostomy Site Bleeding
(Tracheostomy site bleeding)
Transient Ischemic Attack (Transient
ischemic attacks)
Therapy-related Malignant Neoplasm
(Treatment related secondary
malignancy)
Tremor (Tremor)
Tricuspid Valve Disorder (Tricuspid valve
disease)
Trigeminal Nerve Disorder (Trigeminal
nerve disorder)
Trismus (Trismus)
Tumor Lysis Syndrome (Tumor lysis
syndrome)
Tumor Pain (Tumor pain)
Typhlitis (Typhlitis)
Unequal Limb Length (Unequal limb
length)
Unintended Pregnancy (Unintended
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pregnancy)
Upper Gastrointestinal Hemorrhage
(Upper gastrointestinal hemorrhage)
Upper Respiratory Tract Infection (Upper
respiratory infection)
Ureteric Anastomotic Leakage (Ureteric
anastomotic leak)
Urethral Anastomotic Leakage (Urethral
anastomotic leak)
Urethral Infection (Urethral infection)
Urinary Tract Fistula (Urinary fistula)
Urinary Frequency (Urinary frequency)
Urinary Incontinence (Urinary
incontinence)
Urinary Retention (Urinary retention)
Urinary Tract Infection (Urinary tract
infection)
Urinary Tract Obstruction (Urinary tract
obstruction)
Urinary Tract Pain (Urinary tract pain)
Urinary Urgency (Urinary urgency)
Urine Discoloration (Urine discoloration)
Urine Output Decreased (Urine output
decreased)
Urostomy Leakage (Urostomy leak)
Urostomy Obstruction (Urostomy
obstruction)
Urostomy Site Bleeding (Urostomy site
bleeding)
Urostomy Stenosis (Urostomy stenosis)
Urticaria (Urticaria)
Uterine Anastomotic Leakage (Uterine
anastomotic leak)
Uterine Fistula (Uterine fistula)
Uterine Hemorrhage (Uterine
hemorrhage)
Endometritis (Uterine infection)
Uterine Obstruction (Uterine obstruction)
Uterine Pain (Uterine pain)
Uterine Perforation (Uterine perforation)
Uveitis (Uveitis)
Vaginal Anastomotic Leakage (Vaginal
anastomotic leak)
Vaginal Discharge (Vaginal discharge)
Vaginal Dryness (Vaginal dryness)
Vaginal Fistula (Vaginal fistula)
Vaginal Hemorrhage (Vaginal
hemorrhage)
Vaginitis (Vaginal infection)
Vaginitis (Vaginal inflammation)
Vaginal Obstruction (Vaginal obstruction)
Vaginal Pain (Vaginal pain)
Vaginal Perforation (Vaginal perforation)
Vaginal Stricture (Vaginal stricture)
Vaginismus (Vaginismus)
Vagus Nerve Disorder (Vagus nerve
disorder)
Vas Deferens Anastomotic Leakage (Vas
deferens anastomotic leak)
Vascular Access Complication (Vascular
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access complication)
Vascular Disorder Other Specify
(Vascular disorders - Other, specify)
Vasculitis (Vasculitis)
Vasovagal Reaction (Vasovagal reaction)
Venous Injury (Venous injury)
Ventricular Arrhythmia (Ventricular
arrhythmia)
Ventricular Fibrillation (Ventricular
fibrillation)
Ventricular Tachycardia (Ventricular
tachycardia)
Vertigo (Vertigo)
Internal Ear Disorder (Vestibular
disorder)
Virilization (Virilization)
Visceral Artery Ischemia (Visceral
arterial ischemia)
Abnormal Vital Capacity (Vital capacity
abnormal)
Vitreous Hemorrhage (Vitreous
hemorrhage)
Voice Alternation (Voice alteration)
Vomiting (Vomiting)
Vulval Infection (Vulval infection)
Watering Eyes (Watering eyes)
Weight Gain (Weight gain)
Weight Loss (Weight loss)
Wheezing (Wheezing)
Leukopenia (White blood cell decreased)
Wolff-parkinson-white Syndrome (Wolff-
Parkinson-White Syndrome)
Wound Complication (Wound
complication)
Wound Dehiscence (Wound dehiscence)
Wound Infection (Wound infection)
Wrist Fracture (Wrist fracture)
CTC AE Grade
CTCAE Begin Date (MM DD YYYY)
Attribution
Definite (Definite)
Possible (Possible)
Probable (Probable)
Unlikely (Unlikely)
Unrelated (Unrelated)
SAE report submitted
No (No)
Unknown (Unknown)
Yes (Yes)
Lab results
Units
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Convention (Conventional)
International System Of Units (SI)
Hemoglobin
g/dL
Hematocrit
%
WBC
Platelets (PLT)
1000/uL
Peripheral Neutrophils (%)
%
ANC
Sodium
mmol/L
Potassium
mmol/L
Chloride
mEq/L
BUN
Creatinine
mg/dL
Creatinine Clearance
Total Bilirubin
1000/uL
Alkaline Phosphatase
Lactate Dehydrogenase (LDH)
U/L
SGOT
U/L
SGPT
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Serum Total Protein
Urine Total Protein
Albumin
Uric Acid
mg/dL
Calcium
mg/dL
Glucose
Magnesium
mmol/L
Other
Specify
Footer Module
Comments
Investigator Signature
Date
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NCT00113386  RTOG-0412 AE: Adverse
Event Evaluation Form
NCT00113386  RTOG-0412 AE: Adverse Event Evaluation
Form
Cisplatin and Docetaxel With or Without Radiation Therapy
in Treating Patients Who Are Undergoing Surgery for Newly
Diagnosed Stage III Non-Small Cell Lung Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=E488DFC2-
2D0B-654D-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11589
NCT00113386  RTOG-0412 AE:
Adverse Event Evaluation Form
RTOG clinical trial administrative data
RTOG Study
Case #
Institution
Institution No.
Participant's Initials
Participant's I.D. No.
AMENDED DATA
Yes
No
Report All Continuing Or New Adverse
Events
Date of assessment
Due date of corresponding form
Type of corresponding form   (INSTRUCTIONS:
the CTC AE Version 3.0 is used to score all
adverse events)
F1 (F1)
Tf (TF)
MedDRA CODE ADVERSE EVENT BASED ON
CTCAE TERM
CTCAE TERM
CTCAE GRADE
1 / 3
CTCAE BEGIN DATE
CTCAE ATTRIBUTION CODE (Attribution to
Protocol Treatment See protocol sections 6 & 7
for definition of "protocol treatment")
Definite (Definite)
Possible (Possible)
Probable (Probable)
Unlikely (Unlikely)
Unrelated (Unrelated)
Serious Adverse Event Report Submitted
No (No)
Unknown (Unknown)
Yes (Yes)
IF UNRELATED TO PROTOCOL TREATMENTS
SPECIFY CAUSE
Comments
Laboratory Procedure Date
Date (mm/dd Year)
Treatment Week
Blood
Hgb (gms)
Hct (%)
WBC (x1000)
1000/uL
Platelets (x1000)
1000/uL
Neutrophils/gran (%)
%
ANC
Chemistries
Total Protein
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BUN
Creatinine (mg%)
mg/dL
Calc. Creatinine Clearance
Bilirubin (total mg%)
Alkaline Phosphatase
LDH
U/L
SGOT
SGPT
Uric Acid (mg%)
mg/dL
Albumin (gm%)
Potassium (mg/L)
mmol/L
Calcium (mg/d)
mg/dL
Glucose
Sodium (meq/L)
mmol/L
Other Studies
Other
Normal Range (Remarks use R1, R2, R3, etc.)
Name of person completing this form
Form completion date, original
Comments
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NCT00980954 RTOG 0724 Phase III Cervix Chemo RT
(+)/(-) Adjuvant Chemotherapy:  Adjuvant System
Treatment Summary Form (SF)
Chemotherapy and Pelvic Radiation Therapy With or
Without Additional Chemotherapy in Treating Patients With
High-Risk Early-Stage Cervical Cancer After Radical
Hysterectomy
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=5CFDEE98-
0544-2FA7-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11590
NCT00980954 RTOG 0724 Phase III
Cervix Chemo RT (+)/(-) Adjuvant
Chemotherapy:  Adjuvant System
Treatment Summary Form (SF)
RTOG clinical trial administrative data
RTOG Study No.
Case #
Institution Name
Institution No.
Patient Initials
RTOG Patient ID
Amended Data (INSTRUCTIONS: Complete form
on web to unblind the protocol treatment arm)
Yes
No
Assessment
Height (CM)
cm
Weight (CM)
Kg
BSA
m2
Was dose re-calculated due to elevated serum
creatinine
Yes
No
Dose modification
Yes
No
1 / 24
Treatment Summary
Agent Name
Date Agent Started (MM DD YYYY)
Date Agent Ended (MM DD YYYY)
Total No. of Doses
Dose
Date
Total Dose
Dose Modification (Change)
No (No)
Yes, Planned (i.e., The Treatment Was
Changed According To Protocol
Guidelines) (Yes, planned)
Yes, Unplanned (i.e., The Treatment
Change Was Not Part Of Protocol
Guidelines) (Yes, unplanned)
Reason Treatment Ended
Adverse Event/side Effects/complications
(Adverse Event/Side
Effects/Complications)
Alternative Therapy (Alternative therapy)
Death On Study (Death on study)
Disease Progression, Relapse During
Active Treatment (Disease progression,
relapse during active treatment)
Other (Other)
Patient Off-treatment For Other
Complicating Disease (Patient off-
treatment for other complicating disease)
Patient Withdrawal Or Refusal After
Beginning Protocol Therapy (Patient
withdrawal/refusal after beginning
protocol therapy)
Patient Withdrawal Or Refusal Before
Beginning Protocol Therapy (Patient
withdrawal/refusal prior to beginning
protocol therapy)
Treatment Completed Per Protocol
Criteria (Treatment completed per
protocol criteria)
Alternative therapy, specify
Other Complicating Disease specify
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Other specify
Protocol Specific Adverse Event
Evaluation
Any adverse events
No (No)
Unknown (Unknown)
Yes (Yes)
MedDRA disease code
CTC Adverse Event Term
Abdominal Distention (Abdominal
distension)
Abdominal Infection (Abdominal
infection)
Abdominal Pain (Abdominal pain)
Abdominal Soft Tissue Necrotic Lesion
(Abdominal soft tissue necrosis)
Abducens Nerve Disorder (Abducens
nerve disorder)
Accessory Nerve Disorder (Accessory
nerve disorder)
Acidosis (Acidosis)
Vestibulocochlear Nerve Disorder
(Acoustic nerve disorder NOS)
Prolonged Partial Thromboplastin Time
(Activated partial thromboplastin time
prolonged)
Acute Coronary Syndrome (Acute
coronary syndrome)
Acute Renal Failure (Acute kidney injury)
Adrenal Gland Insufficiency (Adrenal
insufficiency)
Adult Respiratory Distress Syndrome
(Adult respiratory distress syndrome)
Agitation (Agitation)
Akathisia (Akathisia)
Alanine Aminotransferase Increased
(Alanine aminotransferase increased)
Alcohol Intolerance (Alcohol intolerance)
Blood Alkaline Phosphatase Increased
(Alkaline phosphatase increased)
Alkalosis (Alkalosis)
Hypersensitivity (Allergic reaction)
Allergic Rhinitis (Allergic rhinitis)
Alopecia (Alopecia)
Amnesia (Amnesia)
Anorectal Fistula (Anal fistula)
Anal Hemorrhage (Anal hemorrhage)
Anal Mucositis (Anal mucositis)
Anal Necrotic Lesion (Anal necrosis)
Anal Pain (Anal pain)
Anal Stenosis (Anal stenosis)
Anal Ulcer (Anal ulcer)
Anaphylactic Shock (Anaphylaxis)
3 / 24
NCT00980954 RTOG 0724 Phase III Cervix Chemo RT (+)/(-) Adjuvant
Chemotherapy:  Adjuvant System Treatment Summary Form (SF)
Anemia (Anemia)
Ankle Fracture (Ankle fracture)
Anorectal Infection (Anorectal infection)
Anorexia (Anorexia)
Anorgasmia (Anorgasmia)
Anxiety (Anxiety)
Aortic Injury (Aortic injury)
Aortic Valve Disorder (Aortic valve
disease)
Aphonia (Aphonia)
Apnea (Apnea)
Acute Appendicitis (Appendicitis)
Acute Perforated Appendicitis
(Appendicitis perforated)
Arachnoiditis (Arachnoiditis)
Arterial Injury (Arterial injury)
Arteritis (Arteritis infective)
Arthralgia (Arthralgia)
Arthritis (Arthritis)
Ascites (Ascites)
Aspartate Aminotransferase Increased
(Aspartate aminotransferase increased)
Aspiration (Aspiration)
Cardiac Arrest (Asystole)
Ataxia (Ataxia)
Atelectasis (Atelectasis)
Atrial Fibrillation (Atrial fibrillation)
Atrial Flutter (Atrial flutter)
Av Block Third Degree (Atrioventricular
block complete)
Av Block First Degree (Atrioventricular
block first degree)
Autoimmune Disease (Autoimmune
disorder)
Bone Necrosis (Avascular necrosis)
Azoospermia (Azoospermia)
Back Pain (Back pain)
Bile Duct Stenosis (Bile duct stenosis)
Biliary Anastomotic Leakage (Biliary
anastomotic leak)
Biliary Fistula (Biliary fistula)
Cholangitis (Biliary tract infection)
Bladder Anastomotic Leakage (Bladder
anastomotic leak)
Cystitis (Bladder infection)
Bladder Perforation (Bladder perforation)
Bladder Spasm (Bladder spasm)
Bloating (Bloating)
Hematopoietic And Lymphoid System
Disorder Other Specify (Blood and
lymphatic system disorders - Other,
specify)
Abnormal Blood Antidiuretic Hormone
(Blood antidiuretic hormone abnormal)
Elevated Bilirubin (Blood bilirubin
increased)
Blood Corticotrophin Decreased (Blood
corticotrophin decreased)
Abnormal Blood Gonadotrophin (Blood
gonadotrophin abnormal)
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Abnormal Blood Prolactin (Blood
prolactin abnormal)
Blurred Vision (Blurred vision)
Body Odor (Body odor)
Bone Infection (Bone infection)
Hypocellular Bone Marrow (Bone
marrow hypocellular)
Bone Pain (Bone pain)
Brachial Plexopathy (Brachial
plexopathy)
Breast Atrophy (Breast atrophy)
Mastitis (Breast infection)
Breast Pain (Breast pain)
Bronchial Fistula (Bronchial fistula)
Bronchitis (Bronchial infection)
Bronchial Obstruction (Bronchial
obstruction)
Bronchial Stricture (Bronchial stricture)
Bronchopleural Fistula (Bronchopleural
fistula)
Bronchial Hemorrhage
(Bronchopulmonary hemorrhage)
Bronchospasm (Bronchospasm)
Bruise (Bruising)
Bullous Dermatitis (Bullous dermatitis)
Burn (Burn)
Buttock Pain (Buttock pain)
Capillary Leak Syndrome Capillary Leak
Syndrome (Capillary leak syndrome)
Decreased Carbon Monoxide Diffusing
Capacity (Carbon monoxide diffusing
capacity decreased)
Cardiac Arrest (Cardiac arrest)
Heart Disorder Other Specify (Cardiac
disorders - Other, specify)
Blood Cardiac Troponin I Increased
(Cardiac troponin I increased)
Blood Cardiac Troponin T Increased
(Cardiac troponin T increased)
Cataract (Cataract)
Catheter-related Infection (Catheter
related infection)
Cd4 Lymphocytes Decreased (CD4
lymphocytes decreased)
Cecal Hemorrhage (Cecal hemorrhage)
Cecal Infection (Cecal infection)
Central Nervous System Necrotic Lesion
(Central nervous system necrosis)
Cerebrospinal Fluid Leakage
(Cerebrospinal fluid leakage)
Infectious Cervicitis (Cervicitis infection)
Cheilitis (Cheilitis)
Angina (Chest pain - cardiac)
Chest Wall Pain (Chest wall pain)
Chills (Chills)
Cholecystitis (Cholecystitis)
Hypercholesterolemia (Cholesterol high)
Chronic Kidney Disease (Chronic kidney
disease)
Chylothorax (Chylothorax)
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Cognitive Disturbance (Cognitive
disturbance)
Colitis (Colitis)
Colonic Fistula (Colonic fistula)
Colonic Hemorrhage (Colonic
hemorrhage)
Colonic Obstruction (Colonic obstruction)
Colonic Perforation (Colonic perforation)
Colonic Stenosis (Colonic stenosis)
Colonic Ulcer (Colonic ulcer)
Concentration Impairment
(Concentration impairment)
Heart Conduction Disorder (Conduction
disorder)
Confusion (Confusion)
Congenital, Familial And Genetic
Disorder Class Other Specify
(Congenital, familial and genetic
disorders - Other, specify)
Conjunctivitis (Conjunctivitis)
Acute Contagious Conjunctivitis
(Conjunctivitis infective)
Constipation (Constipation)
Constrictive Pericarditis (Constrictive
pericarditis)
Keratitis (Corneal infection)
Corneal Ulcer (Corneal ulcer)
Cough (Cough)
Creatine Phosphokinase Increased (CPK
increased)
Cranial Nerve Infection (Cranial nerve
infection)
Increased Creatinine (Creatinine
increased)
Cushingoid (Cushingoid)
Non-infectious Cystitis (Cystitis
noninfective)
Cytokine Release Syndrome (Cytokine
release syndrome)
Neonatal Death (Death neonatal)
Death (Death NOS)
Dehydration (Dehydration)
Delayed Orgasm (Delayed orgasm)
Delayed Puberty (Delayed puberty)
Delirium (Delirium)
Delusion (Delusions)
Caries (Dental caries)
Depressed Level Of Consciousness
(Depressed level of consciousness)
Depression (Depression)
Radiation-induced Dermatitis (Dermatitis
radiation)
Prosthesis-related Infection (Device
related infection)
Diarrhea (Diarrhea)
Disseminated Intravascular Coagulation
(Disseminated intravascular coagulation)
Dizziness (Dizziness)
Dry Eye Syndrome (Dry eye)
Xerostomia (Dry mouth)
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Dry Skin (Dry Skin)
Duodenal Fistula (Duodenal fistula)
Duodenal Hemorrhage (Duodenal
hemorrhage)
Duodenal Infection (Duodenal infection)
Duodenal Obstruction (Duodenal
obstruction)
Duodenal Perforation (Duodenal
perforation)
Duodenal Stenosis (Duodenal stenosis)
Duodenal Ulcer (Duodenal ulcer)
Dysarthria (Dysarthria)
Dysesthesia (Dysesthesia)
Dysgeusia (Dysgeusia)
Dysmenorrhea (Dysmenorrhea)
Dyspareunia (Dyspareunia)
Dyspepsia (Dyspepsia)
Dysphagia (Dysphagia)
Dysphasia (Dysphasia)
Dyspnea (Dyspnea)
Ear And Labyrinth Disorder Class Other
Specify (Ear and labyrinth disorders -
Other, specify)
Earache (Ear pain)
Cerebral Edema (Edema cerebral)
Face Edema (Edema face)
Edema Limbs (Edema limbs)
Edema Trunk (Edema trunk)
Ejaculation Disorder (Ejaculation
disorder)
Ejection Fraction Decreased (Ejection
fraction decreased)
Prolonged Qt Interval (Electrocardiogram
QT corrected interval prolonged)
Infectious Encephalitis (Encephalitis
infection)
Infectious Encephalomyelitis
(Encephalomyelitis infection)
Encephalopathy (Encephalopathy)
Infective Endocarditis (Endocarditis
infective)
Endocrine Disorder Other Specify
(Endocrine disorders - Other, specify)
Endophthalmitis (Endophthalmitis)
Enterocolitis (Enterocolitis)
Infectious Enterocolitis (Enterocolitis
infectious)
Enterovesical Fistula (Enterovesical
fistula)
Epistaxis (Epistaxis)
Impotence (Erectile dysfunction)
Erythema Multiforme (Erythema
multiforme)
Erythroderma (Erythroderma)
Esophageal Anastomotic Leakage
(Esophageal anastomotic leak)
Esophageal Fistula (Esophageal fistula)
Esophageal Hemorrhage (Esophageal
hemorrhage)
Esophageal Infection (Esophageal
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infection)
Esophageal Necrotic Lesion
(Esophageal necrosis)
Esophageal Obstruction (Esophageal
obstruction)
Esophageal Pain (Esophageal pain)
Perforation Of Esophagus (Esophageal
perforation)
Esophageal Stricture (Esophageal
stenosis)
Esophageal Ulcer (Esophageal ulcer)
Esophageal Varices Hemorrhage
(Esophageal varices hemorrhage)
Esophagitis (Esophagitis)
Euphoria (Euphoria)
Exostosis (Exostosis)
External Ear Inflammation (External ear
inflammation)
External Ear Pain (External ear pain)
Extraocular Muscle Paresis (Extraocular
muscle paresis)
Extrapyramidal Disorder (Extrapyramidal
disorder)
Eye Disorder Other Specify (Eye
disorders - Other, specify)
Eye Infection (Eye infection)
Eye Pain (Eye pain)
Eyelid Function Disorder (Eyelid function
disorder)
Facial Muscle Weakness (Facial muscle
weakness)
Facial Nerve Disorder (Facial nerve
disorder)
Facial Pain (Facial pain)
Fall (Fall)
Fallopian Tube Anastomotic Leakage
(Fallopian tube anastomotic leak)
Fallopian Tube Obstruction (Fallopian
tube obstruction)
Fallopian Tube Perforation (Fallopian
tube perforation)
Fallopian Tube Stenosis (Fallopian tube
stenosis)
Adipose Tissue Atrophy (Fat atrophy)
Fatigue (Fatigue)
Neutropenic Fever (Febrile neutropenia)
Fecal Incontinence (Fecal incontinence)
Female Genital Tract Fistula (Female
genital tract fistula)
Acquired Feminization (Feminization
acquired)
Intrauterine Fetal Death (Fetal death)
Fetal Growth Retardation (Fetal growth
retardation)
Fever (Fever)
Fibrinogen Decreased (Fibrinogen
decreased)
Deep Connective Tissue Fibrosis
(Fibrosis deep connective tissue)
Flank Pain (Flank pain)
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Flasher (Flashing lights)
Flatulence (Flatulence)
Floaters (Floaters)
Flu-like Symptoms (Flu like symptoms)
Flushing (Flushing)
Decreased Forced Expiratory Volume
(Forced expiratory volume decreased)
Fracture (Fracture)
Gait Disturbance (Gait disturbance)
Gallbladder Fistula (Gallbladder fistula)
Gallbladder Infection (Gallbladder
infection)
Gallbladder Necrotic Lesion (Gallbladder
necrosis)
Gallbladder Obstruction (Gallbladder
obstruction)
Gallbladder Pain (Gallbladder pain)
Gallbladder Perforation (Gallbladder
perforation)
Gastric Anastomotic Leakage (Gastric
anastomotic leak)
Gastric Fistula (Gastric fistula)
Gastric Hemorrhage (Gastric
hemorrhage)
Gastric Necrotic Lesion (Gastric
necrosis)
Gastric Perforation (Gastric perforation)
Gastric Stenosis (Gastric stenosis)
Gastric Ulcer (Gastric ulcer)
Gastritis (Gastritis)
Gastroesophageal Reflux Disease
(Gastroesophageal reflux disease)
Gastrointestinal System Anastomotic
Leakage (Gastrointestinal anastomotic
leak)
Gastrointestinal Disorder Other Specify
(Gastrointestinal disorders - Other,
specify)
Gastrointestinal Fistula (Gastrointestinal
fistula)
Gastrointestinal Pain (Gastrointestinal
pain)
Gastrointestinal Stoma Necrotic Lesion
(Gastrointestinal stoma necrosis)
Gastroparesis (Gastroparesis)
General Disorders And Administration
Site Conditions Class Other Specify
(General disorders and administration
site conditions - Other, specify)
Generalized Muscle Weakness
(Generalized muscle weakness)
Genital Edema (Genital edema)
Gamma-glutamyltransferase Increased
(GGT increased)
Gingival Pain (Gingival pain)
Glaucoma (Glaucoma)
Glossopharyngeal Nerve Disorder
(Glossopharyngeal nerve disorder)
Glucose Intolerance (Glucose
intolerance)
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Accelerated Growth (Growth
accelerated)
Abnormal Growth Hormone (Growth
hormone abnormal)
Growth Retardation (Growth
suppression)
Gum Infection (Gum infection)
Gynecomastia (Gynecomastia)
Hallucination (Hallucinations)
Haptoglobin Decreased (Haptoglobin
decreased)
Head Soft Tissue Necrotic Lesion (Head
soft tissue necrosis)
Headache (Headache)
Hearing Impairment (Hearing impaired)
Heart Failure (Heart failure)
Hematoma (Hematoma)
Hematosalpinx (Hematosalpinx)
Hematuria (Hematuria)
Hemoglobin Increased (Hemoglobin
increased)
Hemoglobinuria (Hemoglobinuria)
Hemolysis (Hemolysis)
Hemolytic Uremic Syndrome (Hemolytic
uremic syndrome)
Hemorrhoidal Hemorrhage
(Hemorrhoidal hemorrhage)
Hemorrhoid (Hemorrhoids)
Hepatic Failure (Hepatic failure)
Hepatic Hemorrhage (Hepatic
hemorrhage)
Hepatic Infection (Hepatic infection)
Hepatic Necrotic Lesion (Hepatic
necrosis)
Hepatic Pain (Hepatic pain)
Viral Hepatitis (Hepatitis viral)
Liver And Biliary Tract Disorder Other
Specify (Hepatobiliary disorders - Other,
specify)
Hiccough (Hiccups)
Hip Fracture (Hip fracture)
Hirsutism (Hirsutism)
Hoarseness (Hoarseness)
Hot Flashes (Hot flashes)
Hydrocephalus (Hydrocephalus)
Hypercalcemia (Hypercalcemia)
Hyperglycemia (Hyperglycemia)
Hyperhidrosis (Hyperhidrosis)
Hyperkalemia (Hyperkalemia)
Hypermagnesemia (Hypermagnesemia)
Hypernatremia (Hypernatremia)
Hyperparathyroidism
(Hyperparathyroidism)
Hypersomnia (Hypersomnia)
Hypertension (Hypertension)
Hyperthyroidism (Hyperthyroidism)
Hypertrichosis (Hypertrichosis)
Hypertriglyceridemia
(Hypertriglyceridemia)
Hyperuricemia (Hyperuricemia)
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Hypoalbuminemia (Hypoalbuminemia)
Hypocalcemia (Hypocalcemia)
Hypoglossal Nerve Disorder
(Hypoglossal nerve disorder)
Hypoglycemia (Hypoglycemia)
Hypohidrosis (Hypohidrosis)
Hypokalemia (Hypokalemia)
Hypomagnesemia (Hypomagnesemia)
Hyponatremia (Hyponatremia)
Hypoparathyroidism
(Hypoparathyroidism)
Hypophosphatemia (Hypophosphatemia)
Hypotension (Hypotension)
Hypothermia (Hypothermia)
Hypothyroidism (Hypothyroidism)
Hypoxia (Hypoxia)
Ileal Fistula (Ileal fistula)
Ileal Hemorrhage (Ileal hemorrhage)
Ileal Obstruction (Ileal obstruction)
Ileal Perforation (Ileal perforation)
Ileal Stenosis (Ileal stenosis)
Ileal Ulcer (Ileal ulcer)
Ileus (Ileus)
Immune System Disorder Other Specify
(Immune system disorders - Other,
specify)
Infection Other Specify (Infections and
infestations - Other, specify)
Infectious Myositis (Infective myositis)
Infusion-related Reaction (Infusion
related reaction)
Infusion Site Extravasation (Infusion site
extravasation)
Injection Site Reaction (Injection site
reaction)
Injury To Carotid Artery (Injury to carotid
artery)
Injury To Inferior Vena Cava (Injury to
inferior vena cava)
Injury To Jugular Vein (Injury to jugular
vein)
Injury To Superior Vena Cava (Injury to
superior vena cava)
Injury, Poisoning And Procedural
Complication Class Other Specify (Injury,
poisoning and procedural complications -
Other, specify)
Inr Increased (INR increased)
Insomnia (Insomnia)
Intestinal Stoma Leakage (Intestinal
stoma leak)
Intestinal Stoma Obstruction (Intestinal
stoma obstruction)
Intestinal Stoma Site Hemorrhage
(Intestinal stoma site bleeding)
Intra-abdominal Hemorrhage (Intra-
abdominal hemorrhage)
Intracranial Hemorrhage (Intracranial
hemorrhage)
Intraoperative Arterial Injury
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(Intraoperative arterial injury)
Intraoperative Breast Injury
(Intraoperative breast injury)
Intraoperative Cardiac Injury
(Intraoperative cardiac injury)
Intraoperative Ear Injury (Intraoperative
ear injury)
Intraoperative Endocrine Injury
(Intraoperative endocrine injury)
Intraoperative Gastrointestinal Injury
(Intraoperative gastrointestinal injury)
Intraoperative Head And Neck Injury
(Intraoperative head and neck injury)
Intraoperative Hemorrhage
(Intraoperative hemorrhage)
Intraoperative Hepatobiliary Injury
(Intraoperative hepatobiliary injury)
Intraoperative Musculoskeletal Injury
(Intraoperative musculoskeletal injury)
Intraoperative Neurological Injury
(Intraoperative neurological injury)
Intraoperative Ocular Injury
(Intraoperative ocular injury)
Intraoperative Renal Injury
(Intraoperative renal injury)
Intraoperative Reproductive System
Injury (Intraoperative reproductive tract
injury)
Intraoperative Respiratory Injury
(Intraoperative respiratory injury)
Intraoperative Skin Injury (Intraoperative
skin injury)
Intraoperative Splenic Injury
(Intraoperative splenic injury)
Intraoperative Urinary System Injury
(Intraoperative urinary injury)
Intraoperative Venous Injury
(Intraoperative venous injury)
Investigation Other Specify
(Investigations - Other, specify)
Iron Overload (Iron overload)
Irregular Menstruation (Irregular
menstruation)
Irritability (Irritability)
Cerebrovascular Ischemia (Ischemia
cerebrovascular)
Trochlear Nerve Disorder (IVth nerve
disorder)
Jejunal Fistula (Jejunal fistula)
Jejunal Hemorrhage (Jejunal
hemorrhage)
Jejunal Obstruction (Jejunal obstruction)
Jejunal Perforation (Jejunal perforation)
Jejunal Stenosis (Jejunal stenosis)
Jejunal Ulcer (Jejunal ulcer)
Joint Effusion (Joint effusion)
Joint Infection (Joint infection)
Joint Range Of Motion Decreased (Joint
range of motion decreased)
Cervical Spine Joint Range Of Motion
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Decreased (Joint range of motion
decreased cervical spine)
Lumbar Spine Joint Range Of Motion
Decreased (Joint range of motion
decreased lumbar spine)
Keratitis (Keratitis)
Kidney Anastomotic Leakage (Kidney
anastomotic leak)
Pyelonephritis (Kidney infection)
Kyphosis (Kyphosis)
Lactation Disorder (Lactation disorder)
Large Intestinal Anastomotic Leakage
(Large intestinal anastomotic leak)
Laryngeal Edema (Laryngeal edema)
Laryngeal Fistula (Laryngeal fistula)
Laryngeal Hemorrhage (Laryngeal
hemorrhage)
Laryngitis (Laryngeal inflammation)
Laryngeal Mucositis (Laryngeal
mucositis)
Laryngeal Obstruction (Laryngeal
obstruction)
Laryngeal Stenosis (Laryngeal stenosis)
Laryngitis (Laryngitis)
Laryngopharyngeal Dysesthesia
(Laryngopharyngeal dysesthesia)
Laryngospasm (Laryngospasm)
Left Ventricular Systolic Dysfunction (Left
ventricular systolic dysfunction)
Lethargy (Lethargy)
Chemotherapy-related Leukemia
(Leukemia secondary to oncology
chemotherapy)
Leukocytosis (Leukocytosis)
Leukoencephalopathy
(Leukoencephalopathy)
Decreased Libido (Libido decreased)
Increased Libido (Libido increased)
Lip Infection (Lip infection)
Lip Pain (Lip pain)
Lipase Increased (Lipase increased)
Lipohypertrophy (Lipohypertrophy)
Localized Edema (Localized edema)
Lordosis (Lordosis)
Lower Gastrointestinal Hemorrhage
(Lower gastrointestinal hemorrhage)
Infectious Lung Disorder (Lung infection)
Lymphadenitis (Lymph gland infection)
Lymph Leakage (Lymph leakage)
Lymph Node Pain (Lymph node pain)
Lymphedema (Lymphedema)
Lymphocele (Lymphocele)
Lymphopenia (Lymphocyte count
decreased)
Lymphocytosis (Lymphocyte count
increased)
Malabsorption Syndrome
(Malabsorption)
Malaise (Malaise)
Mania (Mania)
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Mediastinal Hemorrhage (Mediastinal
hemorrhage)
Mediastinitis (Mediastinal infection)
Memory Impairment (Memory
impairment)
Meningismus (Meningismus)
Meningitis (Meningitis)
Menopause (Menopause)
Menorrhagia (Menorrhagia)
Metabolism And Nutrition Disorder Class
Other Specify (Metabolism and nutrition
disorders - Other, specify)
Otitis Media (Middle ear inflammation)
Mitral Valve Disorder (Mitral valve
disease)
Av Block Second Degree Mobitz Type Ii
(Mobitz (type) II atrioventricular block)
Av Block Second Degree Mobitz Type I
(Mobitz type I)
Involuntary Movements (Movements
involuntary)
Mucosal Infection (Mucosal infection)
Stomatitis (Mucositis oral)
Multiple Organ Failure (Multi-organ
failure)
Muscle Weakness Left-sided (Muscle
weakness left-sided)
Muscle Weakness Lower Limb (Muscle
weakness lower limb)
Muscle Weakness Right-sided (Muscle
weakness right-sided)
Muscle Weakness Trunk (Muscle
weakness trunk)
Muscle Weakness Upper Limb (Muscle
weakness upper limb)
Connective And Soft Tissue Disorder
Other Specify (Musculoskeletal and
connective tissue disorder -  Other,
specify)
Musculoskeletal Deformity
(Musculoskeletal deformity)
Myalgia (Myalgia)
Myelitis (Myelitis)
Mds (Myelodysplastic syndrome)
Myocardial Infarction (Myocardial
infarction)
Myocarditis (Myocarditis)
Myositis (Myositis)
Nail Discoloration (Nail discoloration)
Nail Infection (Nail infection)
Nail Loss (Nail loss)
Nail Ridging (Nail ridging)
Nasal Congestion (Nasal congestion)
Nausea (Nausea)
Neck Edema (Neck edema)
Neck Pain (Neck pain)
Neck Soft Tissue Necrotic Lesion (Neck
soft tissue necrosis)
Neoplasm Other Specify (Neoplasms
benign, malignant and unspecified (incl
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cysts and polyps) - Other, specify)
Nervous System Disorder Other Specify
(Nervous system disorders - Other,
specify)
Neuralgia (Neuralgia)
Neutrophil Count Decreased (Neutrophil
count decreased)
Night Blindness (Night blindness)
Nipple Deformity (Nipple deformity)
Non-cardiac Chest Pain (Non-cardiac
chest pain)
Nystagmus (Nystagmus)
Obesity (Obesity)
Gastric Obstruction (Obstruction gastric)
Oculomotor Nerve Disorder (Oculomotor
nerve disorder)
Olfactory Nerve Disorder (Olfactory
nerve disorder)
Oligospermia (Oligospermia)
Optic Nerve Disorder (Optic nerve
disorder)
Oral Cavity Fistula (Oral cavity fistula)
Burning Mouth Syndrome (Oral
dysesthesia)
Oral Hemorrhage (Oral hemorrhage)
Oral Pain (Oral pain)
Osteonecrosis Of Jaw (Osteonecrosis of
jaw)
Osteoporosis (Osteoporosis)
External Ear Infection (Otitis externa)
Otitis Media (Otitis media)
Ovarian Hemorrhage (Ovarian
hemorrhage)
Ovarian Infection (Ovarian infection)
Ovarian Rupture (Ovarian rupture)
Ovulatory Pain (Ovulation pain)
Pain (Pain)
Pain In Extremity (Pain in extremity)
Skin Pain (Pain of skin)
Palmar-plantar Erythodysthesia (Palmar-
plantar erythrodysesthesia syndrome)
Palpitation (Palpitations)
Pancreatic Infection (Pancreas infection)
Pancreatic Anastomotic Leakage
(Pancreatic anastomotic leak)
Pancreatic Duct Stenosis (Pancreatic
duct stenosis)
Pancreatic Enzymes Decreased
(Pancreatic enzymes decreased)
Pancreatic Fistula (Pancreatic fistula)
Pancreatic Hemorrhage (Pancreatic
hemorrhage)
Pancreatic Necrotic Lesion (Pancreatic
necrosis)
Pancreatitis (Pancreatitis)
Papilledema (Papilledema)
Papulopustular Rash (Papulopustular
rash)
Paresthesia (Paresthesia)
Paronychia (Paronychia)
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Paroxysmal Atrial Tachycardia
(Paroxysmal atrial tachycardia)
Pelvic Floor Muscle Weakness (Pelvic
floor muscle weakness)
Pelvic Inflammatory Disease (Pelvic
infection)
Pelvic Pain (Pelvic pain)
Pelvic Soft Tissue Necrotic Lesion
(Pelvic soft tissue necrosis)
Penile Infection (Penile infection)
Penile Pain (Penile pain)
Bile Duct Perforation (Perforation bile
duct)
Pericardial Effusion (Pericardial effusion)
Cardiac Tamponade (Pericardial
tamponade)
Pericarditis (Pericarditis)
Perineal Pain (Perineal pain)
Periodontal Disorder (Periodontal
disease)
Periorbital Edema (Periorbital edema)
Periorbital Infection (Periorbital infection)
Peripheral Ischemia (Peripheral
ischemia)
Peripheral Motor Neuropathy (Peripheral
motor neuropathy)
Peripheral Nervous System Infectious
Disorder (Peripheral nerve infection)
Peripheral Sensory Neuropathy
(Peripheral sensory neuropathy)
Peritoneal Infection (Peritoneal infection)
Peritoneal Necrotic Lesion (Peritoneal
necrosis)
Personality Change (Personality change)
Phantom Pain (Phantom pain)
Pharyngeal Anastomotic Leakage
(Pharyngeal anastomotic leak)
Pharyngeal Fistula (Pharyngeal fistula)
Pharyngeal Hemorrhage (Pharyngeal
hemorrhage)
Pharyngeal Mucositis (Pharyngeal
mucositis)
Pharyngeal Necrotic Lesion (Pharyngeal
necrosis)
Pharyngeal Stenosis (Pharyngeal
stenosis)
Pharyngitis (Pharyngitis)
Pharyngolaryngeal Pain
(Pharyngolaryngeal pain)
Phlebitis (Phlebitis)
Infective Phlebitis (Phlebitis infective)
Photophobia (Photophobia)
Photosensitivity (Photosensitivity)
Thrombocytopenia (Platelet count
decreased)
Pleural Effusion (Pleural effusion)
Hemothorax (Pleural hemorrhage)
Pleural Infection (Pleural infection)
Pleuritic Pain (Pleuritic pain)
Pneumonia (Pneumonitis)
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Pneumothorax (Pneumothorax)
Portal Hypertension (Portal
Hypertension)
Portal Vein Thrombosis (Portal vein
thrombosis)
Post-nasal Drip (Postnasal drip)
Postoperative Bleeding (Postoperative
hemorrhage)
Thoracic Procedure Postoperative
Complication (Postoperative thoracic
procedure complication)
Precocious Puberty (Precocious
puberty)
Pregnancy, Puerperium And Perinatal
Condition Class Other Specify
(Pregnancy, puerperium and perinatal
conditions - Other, specify)
Premature Labor (Premature delivery)
Premature Menopause (Premature
menopause)
Presyncope (Presyncope)
Proctitis (Proctitis)
Productive Cough (Productive cough)
Intestinal Stoma Prolapse (Prolapse of
intestinal stoma)
Urostomy Prolapse (Prolapse of
urostomy)
Prostatic Infection (Prostate infection)
Prostatic Hemorrhage (Prostatic
hemorrhage)
Prostatic Obstruction (Prostatic
obstruction)
Prostatic Pain (Prostatic pain)
Proteinuria (Proteinuria)
Pruritus (Pruritus)
Psychiatric Disorder Other Specify
(Psychiatric disorders - Other, specify)
Psychosis (Psychosis)
Pulmonary Edema (Pulmonary edema)
Pulmonary Fibrosis (Pulmonary fibrosis)
Pulmonary Fistula (Pulmonary fistula)
Pulmonary Hypertension (Pulmonary
hypertension)
Pulmonary Valve Disorder (Pulmonary
valve disease)
Purpura (Purpura)
Pyramidal Tract Dysfunction (Pyramidal
tract syndrome)
Radiation-recall Dermatitis (Radiation
recall reaction (dermatologic))
Radiculitis (Radiculitis)
Acneiform Dermatitis (Rash acneiform)
Maculopapular Lesion (Rash maculo-
papular)
Papulopustular Rash (Rash pustular)
Rectal Anastomotic Leakage (Rectal
anastomotic leak)
Rectal Fistula (Rectal fistula)
Rectal Hemorrhage (Rectal hemorrhage)
Rectal Mucositis (Rectal mucositis)
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Rectal Necrotic Lesion (Rectal necrosis)
Rectal Obstruction (Rectal obstruction)
Rectal Pain (Rectal pain)
Rectal Perforation (Rectal perforation)
Rectal Stenosis (Rectal stenosis)
Rectal Ulcer (Rectal ulcer)
Recurrent Laryngeal Nerve Paralysis
(Recurrent laryngeal nerve palsy)
Urinary Tract Disorder Other Specify
(Renal and urinary disorders - Other,
specify)
Renal Stone (Renal calculi)
Renal Colic (Renal colic)
Renal Hemorrhage (Renal hemorrhage)
Reproductive System And Breast
Disorder Class Other Specify
(Reproductive system and breast
disorders - Other, specify)
Respiratory Failure (Respiratory failure)
Respiratory And Thoracic Disorder Other
Specify (Respiratory, thoracic and
mediastinal disorders - Other, specify)
Restlessness (Restlessness)
Restrictive Cardiomyopathy (Restrictive
cardiomyopathy)
Retinal Detachment (Retinal
detachment)
Retinal Tear (Retinal tear)
Retinal Vascular Disorder (Retinal
vascular disorder)
Retinoic Acid Syndrome (Retinoic acid
syndrome)
Retinopathy (Retinopathy)
Retroperitoneal Hemorrhage
(Retroperitoneal hemorrhage)
Reversible Posterior
Leukoencephalopathy Syndrome
(Reversible posterior
leukoencephalopathy syndrome)
Infectious Rhinitis (Rhinitis infective)
Right Ventricular Dysfunction (Right
ventricular dysfunction)
Salivary Duct Inflammation (Salivary duct
inflammation)
Salivary Gland Fistula (Salivary gland
fistula)
Salivary Gland Infection (Salivary gland
infection)
Scalp Pain (Scalp pain)
Sclera Disorder (Scleral disorder)
Scoliosis (Scoliosis)
Scrotal Infection (Scrotal infection)
Scrotal Pain (Scrotal pain)
Seizure (Seizure)
Septicemia (Sepsis)
Seroma (Seroma)
Serum Amylase Increased (Serum
amylase increased)
Serum Sickness (Serum sickness)
Sick Sinus Syndrome (Sick sinus
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syndrome)
Sinus Bradycardia (Sinus bradycardia)
Paranasal Sinus Disorder (Sinus
disorder)
Sinus Pain (Sinus pain)
Sinus Tachycardia (Sinus tachycardia)
Sinusitis (Sinusitis)
Skin Disorder Other Specify (Skin and
subcutaneous tissue disorders - Other,
specify)
Skin Atrophy (Skin atrophy)
Skin Hyperpigmentation (Skin
hyperpigmentation)
Skin Hypopigmentation (Skin
hypopigmentation)
Skin Induration (Skin induration)
Skin Infection (Skin infection)
Skin Ulcer (Skin ulceration)
Sleep Apnea (Sleep apnea)
Small Intestinal Anastomotic Leakage
(Small intestinal anastomotic leak)
Small Intestinal Mucositis (Small
intestinal mucositis)
Small Intestinal Obstruction (Small
intestinal obstruction)
Small Intestinal Perforation (Small
intestinal perforation)
Small Intestinal Stenosis (Small intestinal
stenosis)
Small Intestinal Infection (Small intestine
infection)
Small Intestinal Ulcer (Small intestine
ulcer)
Sneezing (Sneezing)
Social Circumstances Other Specify
(Social circumstances - Other, specify)
Soft Tissue Infection (Soft tissue
infection)
Lower Limb Soft Tissue Necrotic Lesion
(Soft tissue necrosis lower limb)
Upper Limb Soft Tissue Necrotic Lesion
(Soft tissue necrosis upper limb)
Somnolence (Somnolence)
Sore Throat (Sore throat)
Spasticity (Spasticity)
Spermatic Cord Anastomotic Leakage
(Spermatic cord anastomotic leak)
Spermatic Cord Hemorrhage (Spermatic
cord hemorrhage)
Spermatic Cord Obstruction (Spermatic
cord obstruction)
Vertebral Fracture (Spinal fracture)
Splenic Disorder (Spleen disorder)
Splenic Infection (Splenic infection)
Gastrointestinal Stoma Stenosis
(Stenosis of gastrointestinal stoma)
Stevens-johnson Syndrome (Stevens-
Johnson syndrome)
Stoma Site Infection (Stoma site
infection)
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Stomach Pain (Stomach pain)
Stomal Ulcer (Stomal ulcer)
Stridor (Stridor)
Cerebrovascular Accident (Stroke)
Sudden Cardiac Death (Sudden death
NOS)
Suicidal Ideation (Suicidal ideation)
Suicide Attempt (Suicide attempt)
Superficial Soft Tissue Fibrosis
(Superficial soft tissue fibrosis)
Superficial Thrombophlebitis (Superficial
thrombophlebitis)
Superior Vena Cava Syndrome (Superior
vena cava syndrome)
Supraventricular Tachycardia
(Supraventricular tachycardia)
Intervention Or Procedure Other Specify
(Surgical and medical procedures -
Other, specify)
Syncope (Syncope)
Telangiectasia (Telangiectasia)
Testicular Disorder (Testicular disorder)
Testicular Hemorrhage (Testicular
hemorrhage)
Testicular Pain (Testicular pain)
Thromboembolism (Thromboembolic
event)
Thrombotic Thrombocytopenic Purpura
(Thrombotic thrombocytopenic purpura)
Tinnitus (Tinnitus)
Dental Developmental Disorder (Tooth
development disorder)
Tooth Discoloration (Tooth discoloration)
Tooth Infection (Tooth infection)
Toothache (Toothache)
Toxic Epidermal Necrolysis (Toxic
epidermal necrolysis)
Tracheal Fistula (Tracheal fistula)
Tracheal Hemorrhage (Tracheal
hemorrhage)
Tracheal Mucositis (Tracheal mucositis)
Tracheal Obstruction (Tracheal
obstruction)
Tracheal Stenosis (Tracheal stenosis)
Tracheitis (Tracheitis)
Tracheostomy Site Bleeding
(Tracheostomy site bleeding)
Transient Ischemic Attack (Transient
ischemic attacks)
Therapy-related Malignant Neoplasm
(Treatment related secondary
malignancy)
Tremor (Tremor)
Tricuspid Valve Disorder (Tricuspid valve
disease)
Trigeminal Nerve Disorder (Trigeminal
nerve disorder)
Trismus (Trismus)
Tumor Lysis Syndrome (Tumor lysis
syndrome)
20 / 24
NCT00980954 RTOG 0724 Phase III Cervix Chemo RT (+)/(-) Adjuvant
Chemotherapy:  Adjuvant System Treatment Summary Form (SF)
Tumor Pain (Tumor pain)
Typhlitis (Typhlitis)
Unequal Limb Length (Unequal limb
length)
Unintended Pregnancy (Unintended
pregnancy)
Upper Gastrointestinal Hemorrhage
(Upper gastrointestinal hemorrhage)
Upper Respiratory Tract Infection (Upper
respiratory infection)
Ureteric Anastomotic Leakage (Ureteric
anastomotic leak)
Urethral Anastomotic Leakage (Urethral
anastomotic leak)
Urethral Infection (Urethral infection)
Urinary Tract Fistula (Urinary fistula)
Urinary Frequency (Urinary frequency)
Urinary Incontinence (Urinary
incontinence)
Urinary Retention (Urinary retention)
Urinary Tract Infection (Urinary tract
infection)
Urinary Tract Obstruction (Urinary tract
obstruction)
Urinary Tract Pain (Urinary tract pain)
Urinary Urgency (Urinary urgency)
Urine Discoloration (Urine discoloration)
Urine Output Decreased (Urine output
decreased)
Urostomy Leakage (Urostomy leak)
Urostomy Obstruction (Urostomy
obstruction)
Urostomy Site Bleeding (Urostomy site
bleeding)
Urostomy Stenosis (Urostomy stenosis)
Urticaria (Urticaria)
Uterine Anastomotic Leakage (Uterine
anastomotic leak)
Uterine Fistula (Uterine fistula)
Uterine Hemorrhage (Uterine
hemorrhage)
Endometritis (Uterine infection)
Uterine Obstruction (Uterine obstruction)
Uterine Pain (Uterine pain)
Uterine Perforation (Uterine perforation)
Uveitis (Uveitis)
Vaginal Anastomotic Leakage (Vaginal
anastomotic leak)
Vaginal Discharge (Vaginal discharge)
Vaginal Dryness (Vaginal dryness)
Vaginal Fistula (Vaginal fistula)
Vaginal Hemorrhage (Vaginal
hemorrhage)
Vaginitis (Vaginal infection)
Vaginitis (Vaginal inflammation)
Vaginal Obstruction (Vaginal obstruction)
Vaginal Pain (Vaginal pain)
Vaginal Perforation (Vaginal perforation)
Vaginal Stricture (Vaginal stricture)
Vaginismus (Vaginismus)
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Vagus Nerve Disorder (Vagus nerve
disorder)
Vas Deferens Anastomotic Leakage (Vas
deferens anastomotic leak)
Vascular Access Complication (Vascular
access complication)
Vascular Disorder Other Specify
(Vascular disorders - Other, specify)
Vasculitis (Vasculitis)
Vasovagal Reaction (Vasovagal reaction)
Venous Injury (Venous injury)
Ventricular Arrhythmia (Ventricular
arrhythmia)
Ventricular Fibrillation (Ventricular
fibrillation)
Ventricular Tachycardia (Ventricular
tachycardia)
Vertigo (Vertigo)
Internal Ear Disorder (Vestibular
disorder)
Virilization (Virilization)
Visceral Artery Ischemia (Visceral
arterial ischemia)
Abnormal Vital Capacity (Vital capacity
abnormal)
Vitreous Hemorrhage (Vitreous
hemorrhage)
Voice Alternation (Voice alteration)
Vomiting (Vomiting)
Vulval Infection (Vulval infection)
Watering Eyes (Watering eyes)
Weight Gain (Weight gain)
Weight Loss (Weight loss)
Wheezing (Wheezing)
Leukopenia (White blood cell decreased)
Wolff-parkinson-white Syndrome (Wolff-
Parkinson-White Syndrome)
Wound Complication (Wound
complication)
Wound Dehiscence (Wound dehiscence)
Wound Infection (Wound infection)
Wrist Fracture (Wrist fracture)
CTC AE Grade
CTCAE Begin Date (MM DD YYYY)
Attribution
Definite (Definite)
Possible (Possible)
Probable (Probable)
Unlikely (Unlikely)
Unrelated (Unrelated)
SAE report submitted
No (No)
Unknown (Unknown)
Yes (Yes)
22 / 24
NCT00980954 RTOG 0724 Phase III Cervix Chemo RT (+)/(-) Adjuvant
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Lab results
Units
Convention (Conventional)
International System Of Units (SI)
Hemoglobin
g/dL
Hematocrit
%
WBC
Platelets (PLT)
1000/uL
Peripheral Neutrophils (%)
%
ANC
Sodium
mmol/L
Potassium
mmol/L
Chloride
mEq/L
BUN
Creatinine
mg/dL
Creatinine Clearance
Total Bilirubin
1000/uL
Alkaline Phosphatase
Lactate Dehydrogenase (LDH)
U/L
SGOT
U/L
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SGPT
Serum Total Protein
Urine Total Protein
Albumin
Uric Acid
mg/dL
Calcium
mg/dL
Glucose
Magnesium
mmol/L
Other
Other specify value
Comments
Comments
Investigator Signature
Date
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NCT01013649 RTOG 0848 Phase III Pancreas-Resected +
Adjuvant Treatment Systemic Treatment Summary Form (TF)
NCT01013649 RTOG 0848 Phase III Pancreas-Resected +
Adjuvant Treatment Systemic Treatment Summary Form
(TF)
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=689F0A8D-
3BC3-3BA7-E040-BB89AD434E50
All rights reserved. Please visit https://medical-data-
models.org/forms/11591
NCT01013649 RTOG 0848 Phase III
Pancreas-Resected + Adjuvant
Treatment Systemic Treatment
Summary Form (TF)
RTOG clinical trial administrative data
RTOG Study No.
Case #
Institution Name
Institution No.
Patient Initials
RTOG Patient ID
Amended Data
Yes
No
Assessment
Height (CM)
cm
Weight (CM)
Kg
BSA (M2)
m2
Has the patient smoked at any time during this
report period
Yes
No
What form of tobacco (If yes,)
Cigar (Cigar)
Cigarette (Cigarettes)
Pipe Tobacco (Pipe)
If a cigarette smoker, # of cigarettes a day
Greater Than Or Equal To 16 Cigarettes
1 / 7
Per Day (>=16)
5 Or Fewer Cigarettes Per Day (5 or
fewer)
6 To 15 Cigarettes Per Day (6-15)
Other (Other)
Other, specify
If pipe or cigar smoker, how often
Daily (Daily)
Other (Other)
Weekly (Weekly)
Other, specify
Assigned Treatment Arm
Arm 1 (Arm 1)
Arm 2 (Arm 2)
Total number of cycles of gemcitabine
administered
Total number of cycles of erlotinib administered
Treatment Summary
Agent Name
Date Agent Started (MM DD YYYY)
Date Agent Ended (MM DD YYYY)
Total No. of Doses
Total Dose
Dose Modification (Change)
No (No)
Yes, Planned (i.e., The Treatment Was
Changed According To Protocol
Guidelines) (Yes, planned)
Yes, Unplanned (i.e., The Treatment
Change Was Not Part Of Protocol
Guidelines) (Yes, unplanned)
Reason Treatment Ended
Adverse Event/side Effects/complications
(Adverse Event/Side
Effects/Complications)
Alternative Therapy (Alternative therapy)
Death On Study (Death on study)
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Treatment Systemic Treatment Summary Form (TF)
Disease Progression, Relapse During
Active Treatment (Disease progression,
relapse during active treatment)
Other (Other)
Patient Off-treatment For Other
Complicating Disease (Patient off-
treatment for other complicating disease)
Patient Withdrawal Or Refusal After
Beginning Protocol Therapy (Patient
withdrawal/refusal after beginning
protocol therapy)
Patient Withdrawal Or Refusal Before
Beginning Protocol Therapy (Patient
withdrawal/refusal prior to beginning
protocol therapy)
Treatment Completed Per Protocol
Criteria (Treatment completed per
protocol criteria)
Alternative therapy, specify
Patient off-treatment for other complicating
disease, specify
Other specify
Type of therapy modification
Dose modification
Dose Held (Dose held)
No Dose Modification (No dose
modification)
Non-permanent Reduction (Non-
Permanent Reduction)
Other (Other)
Permanent Reduction (Permanent
Reduction)
Dose Re-escalated (Re-escalated)
Other, specify
Protocol Specific Adverse Event
Evaluation
Any adverse events
No (No)
Unknown (Unknown)
Yes (Yes)
MedDRA disease code
CTC Adverse Event Term
CTC AE Grade
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Treatment Systemic Treatment Summary Form (TF)
CTCAE Begin Date (MM DD YYYY)
CTC AE Attribution Code
Definite (Definite)
Possible (Possible)
Probable (Probable)
Unlikely (Unlikely)
Unrelated (Unrelated)
SAE report submitted
No (No)
Unknown (Unknown)
Yes (Yes)
Baseline Lab Values (hematologic)
ANC
Date (MM DD YYYY)
Hemoglobin
g/dL
Date (MM DD YYYY)
Platelets (PLT)
1000/uL
Date (MM DD YYYY)
Total Bilirubin
Total bilirubin LLN
Total Bilirubin ULN
Date (MM DD YYYY)
SGOT (AST)
SGOT (AST) LLN
SGOT (AST) ULN
Date (MM DD YYYY)
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SGPT
SGPT (ALT) LLN
SGPT (ALT) ULN
Date (MM DD YYYY)
Creatinine
mg/dL
Creatinine LLN
Creatinine ULN
Creatinine Clearance
Date
Date
Lab results
Units
Convention (Conventional)
International System Of Units (SI)
ANC
Hematocrit
%
Hemoglobin
g/dL
WBC
Platelets (PLT)
1000/uL
Peripheral Neutrophils (%)
%
Sodium
mmol/L
5 / 7
NCT01013649 RTOG 0848 Phase III Pancreas-Resected + Adjuvant
Treatment Systemic Treatment Summary Form (TF)
Potassium
mmol/L
Chloride
mEq/L
BUN
Total Bilirubin
1000/uL
SGPT
Alkaline Phosphatase
Lactate Dehydrogenase (LDH)
U/L
SGOT
U/L
Creatinine
mg/dL
Serum Total Protein
Urine Total Protein
Albumin
Uric Acid
mg/dL
Calcium
mg/dL
Creatinine Clearance
Glucose
Magnesium
mmol/L
Other
Other specify value
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Comments
Comments
Investigator Signature
Date
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AMC-052 Adverse Events Form (ADV)
NCT00513526
AMC-052 Adverse Events Form (ADV) NCT00513526 
Human Papillomavirus Vaccine Therapy in Treating Men
With HIV-1 Infection
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=3952E724-
4275-361E-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11592
AMC-052 Adverse Events Form
(ADV) NCT00513526
Header
CTC Adverse Event Category
CTC Adverse Event Term
CTC Adverse Event Grade
Adverse Event Onset Date
Adverse event assessment
MedDRA Code
If other CTC event selected, please provide
description of event
Was this event expected or anticipated
Yes
No
Agent Name
CTC AE Attribution Code
Definite (Definite)
Possible (Possible)
Probable (Probable)
Unlikely (Unlikely)
Unrelated (Unrelated)
Alternative etiology
Accident, Trauma, Or External Factors
(Accident, trauma, or external factors)
Concurrent Illness/condition (not Pre-
existing) (Concurrent illness/condition
(not pre-existing))
None Apparent (None apparent)
Other Pre-existing Disease Or Condition
(Other pre-existing disease or condition)
Study Disease (Study disease)
Action Taken at Time of Adverse Event
1 / 2
Hospitalization For Ae (Hospitalization)
Otc/non-rx (OTC/non-Rx)
Other (Other)
Prescription (Prescription)
Protocol Treatment Was Delayed As A
Result Of The Adverse Event (protocol
treatment delayed)
Protocol Treatment Was Discontinued As
A Result Of The Adverse Event (protocol
treatment discontinued)
Study Dose Was Reduced As A Result
Of The Adverse Event (study dose
reduced)
Other, specify
If modification was made to study therapy, who
initiated modification
Patient Initiated (Patient initiated)
Physician Initiated (Physician initiated)
Outcome of Adverse Event
Adverse Event Is Resolved (Resolved)
Adverse Event Is Resolved With
Sequelae (Resolved with sequelae)
Unresolved At Protocol Completion
(Unresolved at protocol completion)
Unresolved, Protocol Ongoing
(Unresolved, protocol ongoing)
AE Resolution Date
If resolved with sequelae, specify
Seriousness Attributed to Adverse Event
Congenital Anomaly (Congenital
anomaly)
Death (Death)
Disability (Disability/incapacity)
Hospitalized (Hospitalization, initial or
prolonged)
Life Threatening (Life threatening)
Other (Other)
Intervention Required (Required
intervention to prevent permanent
impairment/damage)
Comments
Comments
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AMC-048 Adverse Events Form (ADV)
NCT00392834
AMC-048 Adverse Events Form (ADV) NCT00392834 
Rituximab and Combination Chemotherapy in Treating
Patients With Newly Diagnosed, HIV-Associated Burkitt's
Lymphoma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=32E18FA2-
31FB-4AF2-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11593
AMC-048 Adverse Events Form
(ADV) NCT00392834
Header
CTC Adverse Event Category
CTC Adverse Event Term
CTC Adverse Event Grade
Adverse Event Onset Date
Adverse event assessment
MedDRA Code
If other CTC event selected, please provide
description of event
Was this event expected or anticipated
Yes
No
Agent Name
CTC AE Attribution Code
Definite (Definite)
Possible (Possible)
Probable (Probable)
Unlikely (Unlikely)
Unrelated (Unrelated)
Alternative etiology
Accident, Trauma, Or External Factors
(Accident, trauma, or external factors)
Concurrent Illness/condition (not Pre-
existing) (Concurrent illness/condition
(not pre-existing))
None Apparent (None apparent)
Other Pre-existing Disease Or Condition
(Other pre-existing disease or condition)
Study Disease (Study disease)
Action Taken at Time of Adverse Event
1 / 2
Hospitalization For Ae (Hospitalization)
Otc/non-rx (OTC/non-Rx)
Other (Other)
Prescription (Prescription)
Protocol Treatment Was Delayed As A
Result Of The Adverse Event (protocol
treatment delayed)
Protocol Treatment Was Discontinued As
A Result Of The Adverse Event (protocol
treatment discontinued)
Study Dose Was Reduced As A Result
Of The Adverse Event (study dose
reduced)
Other, specify
If modification was made to study therapy, who
initiated modification
Patient Initiated (Patient initiated)
Physician Initiated (Physician initiated)
Outcome of Adverse Event
Adverse Event Is Resolved (Resolved)
Adverse Event Is Resolved With
Sequelae (Resolved with sequelae)
Unresolved At Protocol Completion
(Unresolved at protocol completion)
Unresolved, Protocol Ongoing
(Unresolved, protocol ongoing)
AE Resolution Date
If resolved with sequelae, specify
Seriousness Attributed to Adverse Event
Congenital Anomaly (Congenital
anomaly)
Death (Death)
Disability (Disability/incapacity)
Hospitalized (Hospitalization, initial or
prolonged)
Life Threatening (Life threatening)
Other (Other)
Intervention Required (Required
intervention to prevent permanent
impairment/damage)
Comments
Comments
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AMC-047 Adverse Events Form (ADV)
NCT00389818
AMC-047 Adverse Events Form (ADV) NCT00389818 
Combination Chemotherapy and Rituximab in Treating
Patients With Newly Diagnosed AIDS-Related B-Cell Non-
Hodgkin's Lymphoma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=21F9E568-
C8BB-253F-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11594
AMC-047 Adverse Events Form
(ADV) NCT00389818
Header
CTC AE Category
CTC Adverse Event Term
CTC Adverse Event Grade
Adverse Event Onset Date
Adverse event assessment
MedDRA Code
If other CTC event selected, please provide
description of event
Was this event expected or anticipated
Yes
No
Agent Name
CTC AE Attribution Code
Definite (Definite)
Possible (Possible)
Probable (Probable)
Unlikely (Unlikely)
Unrelated (Unrelated)
Alternative etiology
Accident, Trauma, Or External Factors
(Accident, trauma, or external factors)
Concurrent Illness/condition (not Pre-
existing) (Concurrent illness/condition
(not pre-existing))
None Apparent (None apparent)
Other Pre-existing Disease Or Condition
(Other pre-existing disease or condition)
Study Disease (Study disease)
Action Taken at Time of Adverse Event
1 / 2
Hospitalization For Ae (Hospitalization)
Otc/non-rx (OTC/non-Rx)
Other (Other)
Prescription (Prescription)
Protocol Treatment Was Delayed As A
Result Of The Adverse Event (protocol
treatment delayed)
Protocol Treatment Was Discontinued As
A Result Of The Adverse Event (protocol
treatment discontinued)
Study Dose Was Reduced As A Result
Of The Adverse Event (study dose
reduced)
Other, specify
If modification was made to study therapy, who
initiated modification
Patient Initiated (Patient initiated)
Physician Initiated (Physician initiated)
Outcome of Adverse Event
Adverse Event Is Resolved (Resolved)
Adverse Event Is Resolved With
Sequelae (Resolved with sequelae)
Unresolved At Protocol Completion
(Unresolved at protocol completion)
Unresolved, Protocol Ongoing
(Unresolved, protocol ongoing)
AE Resolution Date
If resolved with sequelae, specify
Was this considered a Serious Adverse Event
Yes
No
Seriousness Attributed to Adverse Event
Congenital Anomaly (Congenital
anomaly)
Death (Death)
Disability (Disability/incapacity)
Hospitalized (Hospitalization, initial or
prolonged)
Life Threatening (Life threatening)
Other (Other)
Intervention Required (Required
intervention to prevent permanent
impairment/damage)
Comments
Comments
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NCT00265941  RTOG-0522 TF: Radiation Therapy Oncology
Group Phase III Head and Neck Cancer Treatment Summary Form
NCT00265941  RTOG-0522 TF: Radiation Therapy
Oncology Group Phase III Head and Neck Cancer
Treatment Summary Form
Radiation Therapy and Cisplatin With or Without Cetuximab
in Treating Patients With Stage III or Stage IV Head and
Neck Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=F62248A0-
86B5-70AC-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11595
NCT00265941  RTOG-0522 TF:
Radiation Therapy Oncology Group
Phase III Head and Neck Cancer
Treatment Summary Form
RTOG clinical trial administrative data
RTOG Study No.
Case #
Institution Name
Institution No.
Patient Initials
RTOG Patient ID
Amended data
Yes
No
Summary Of Systemic Treatment
Assigned Treatment Arm
Arm 1 (Arm 1)
Arm 2 (Arm 2)
Patient Height (cm)
cm
Arm 2 Only
Patient Weight (kg)
Kg
Body Surface Area (m^2)
Agent Name (pre-populated valid value -> C225)
1 / 16
Date Agent Administered
Agent Total Dose (mg)
Dose per M2
m2
Reason for dose modification (Table of values on
Draft CRF for "Reason for
Termination/Modification" combines values for
2Qs - this must be a separate CDE; not limited to
CDUS values)
Adverse Event/side Effects/complications
(Adverse event/side
effects/complications)
Alternative Therapy (Alternative therapy)
Death On Study (Death on study)
Disease Progression, Relapse During
Active Treatment (Disease progression,
relapse during active treatment)
None (None)
Other (Other)
Other Complicating Disease (Other
complicating disease)
Patient Withdrawal Or Refusal After
Beginning Protocol Therapy (Patient
withdrawal/refusal after beginning
protocol therapy)
Patient Withdrawal Or Refusal Prior To
Beginning Protocol Therapy (Patient
withdrawal/refusal prior to beginning
protocol therapy)
Treatment Completed Per Protocol
Criteria (Treatment completed per
protocol criteria)
Reason Treatment Ended (Table of values on
Draft CRF for "Reason for
Termination/Modification" combines values for
2Qs - this CDE must use CDUS values only)
Adverse Event/side Effects/complications
(Adverse Event/Side
Effects/Complications)
Alternative Therapy (Alternative therapy)
Death On Study (Death on study)
Disease Progression, Relapse During
Active Treatment (Disease progression,
relapse during active treatment)
Other (Other)
Patient Off-treatment For Other
Complicating Disease (Patient off-
treatment for other complicating disease)
Patient Withdrawal Or Refusal After
Beginning Protocol Therapy (Patient
withdrawal/refusal after beginning
protocol therapy)
Patient Withdrawal Or Refusal Before
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Phase III Head and Neck Cancer Treatment Summary Form
Beginning Protocol Therapy (Patient
withdrawal/refusal prior to beginning
protocol therapy)
Treatment Completed Per Protocol
Criteria (Treatment completed per
protocol criteria)
Week 1 - Actual
Patient Weight (kg)
Kg
Body Surface Area (m^2)
If BSA >2.0, was cisplatin dose recalculated
using ideal weight?
Not Applicable (N/A)
No (No)
Yes (Yes)
Week 1
Patient Weight (kg)
Kg
Body Surface Area (m^2)
Agent Name (pre-populated valid value -> C225)
Date Agent Administered
Agent Total Dose (mg)
Dose per M2
m2
Reason for dose modification (Table of values on
Draft CRF for "Reason for
Termination/Modification" combines values for
2Qs - this must be a separate CDE; not limited to
CDUS values)
Adverse Event/side Effects/complications
(Adverse event/side
effects/complications)
Alternative Therapy (Alternative therapy)
Death On Study (Death on study)
Disease Progression, Relapse During
Active Treatment (Disease progression,
relapse during active treatment)
None (None)
Other (Other)
Other Complicating Disease (Other
complicating disease)
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Patient Withdrawal Or Refusal After
Beginning Protocol Therapy (Patient
withdrawal/refusal after beginning
protocol therapy)
Patient Withdrawal Or Refusal Prior To
Beginning Protocol Therapy (Patient
withdrawal/refusal prior to beginning
protocol therapy)
Treatment Completed Per Protocol
Criteria (Treatment completed per
protocol criteria)
Reason Treatment Ended (Table of values on
Draft CRF for "Reason for
Termination/Modification" combines values for
2Qs - this CDE must use CDUS values only)
Adverse Event/side Effects/complications
(Adverse Event/Side
Effects/Complications)
Alternative Therapy (Alternative therapy)
Death On Study (Death on study)
Disease Progression, Relapse During
Active Treatment (Disease progression,
relapse during active treatment)
Other (Other)
Patient Off-treatment For Other
Complicating Disease (Patient off-
treatment for other complicating disease)
Patient Withdrawal Or Refusal After
Beginning Protocol Therapy (Patient
withdrawal/refusal after beginning
protocol therapy)
Patient Withdrawal Or Refusal Before
Beginning Protocol Therapy (Patient
withdrawal/refusal prior to beginning
protocol therapy)
Treatment Completed Per Protocol
Criteria (Treatment completed per
protocol criteria)
Week 2
Patient Weight (kg)
Kg
Body Surface Area (m^2)
Agent Name (pre-populated valid value -> C225)
Date Agent Administered
Agent Total Dose (mg)
Dose per M2
m2
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Reason for dose modification (Table of values on
Draft CRF for "Reason for
Termination/Modification" combines values for
2Qs - this must be a separate CDE; not limited to
CDUS values)
Adverse Event/side Effects/complications
(Adverse event/side
effects/complications)
Alternative Therapy (Alternative therapy)
Death On Study (Death on study)
Disease Progression, Relapse During
Active Treatment (Disease progression,
relapse during active treatment)
None (None)
Other (Other)
Other Complicating Disease (Other
complicating disease)
Patient Withdrawal Or Refusal After
Beginning Protocol Therapy (Patient
withdrawal/refusal after beginning
protocol therapy)
Patient Withdrawal Or Refusal Prior To
Beginning Protocol Therapy (Patient
withdrawal/refusal prior to beginning
protocol therapy)
Treatment Completed Per Protocol
Criteria (Treatment completed per
protocol criteria)
Reason Treatment Ended (Table of values on
Draft CRF for "Reason for
Termination/Modification" combines values for
2Qs - this CDE must use CDUS values only)
Adverse Event/side Effects/complications
(Adverse Event/Side
Effects/Complications)
Alternative Therapy (Alternative therapy)
Death On Study (Death on study)
Disease Progression, Relapse During
Active Treatment (Disease progression,
relapse during active treatment)
Other (Other)
Patient Off-treatment For Other
Complicating Disease (Patient off-
treatment for other complicating disease)
Patient Withdrawal Or Refusal After
Beginning Protocol Therapy (Patient
withdrawal/refusal after beginning
protocol therapy)
Patient Withdrawal Or Refusal Before
Beginning Protocol Therapy (Patient
withdrawal/refusal prior to beginning
protocol therapy)
Treatment Completed Per Protocol
Criteria (Treatment completed per
protocol criteria)
Week 3
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Patient Weight (kg)
Kg
Body Surface Area (m^2)
Agent Name (pre-populated valid value -> C225)
Date Agent Administered
Agent Total Dose (mg)
Dose per M2
m2
Reason for dose modification (Table of values on
Draft CRF for "Reason for
Termination/Modification" combines values for
2Qs - this must be a separate CDE; not limited to
CDUS values)
Adverse Event/side Effects/complications
(Adverse event/side
effects/complications)
Alternative Therapy (Alternative therapy)
Death On Study (Death on study)
Disease Progression, Relapse During
Active Treatment (Disease progression,
relapse during active treatment)
None (None)
Other (Other)
Other Complicating Disease (Other
complicating disease)
Patient Withdrawal Or Refusal After
Beginning Protocol Therapy (Patient
withdrawal/refusal after beginning
protocol therapy)
Patient Withdrawal Or Refusal Prior To
Beginning Protocol Therapy (Patient
withdrawal/refusal prior to beginning
protocol therapy)
Treatment Completed Per Protocol
Criteria (Treatment completed per
protocol criteria)
Reason Treatment Ended (Table of values on
Draft CRF for "Reason for
Termination/Modification" combines values for
2Qs - this CDE must use CDUS values only)
Adverse Event/side Effects/complications
(Adverse Event/Side
Effects/Complications)
Alternative Therapy (Alternative therapy)
Death On Study (Death on study)
Disease Progression, Relapse During
Active Treatment (Disease progression,
relapse during active treatment)
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Other (Other)
Patient Off-treatment For Other
Complicating Disease (Patient off-
treatment for other complicating disease)
Patient Withdrawal Or Refusal After
Beginning Protocol Therapy (Patient
withdrawal/refusal after beginning
protocol therapy)
Patient Withdrawal Or Refusal Before
Beginning Protocol Therapy (Patient
withdrawal/refusal prior to beginning
protocol therapy)
Treatment Completed Per Protocol
Criteria (Treatment completed per
protocol criteria)
Week 4 - Actual
Patient Weight (kg)
Kg
Body Surface Area (m^2)
If BSA >2.0, was cisplatin dose recalculated
using ideal weight?
Not Applicable (N/A)
No (No)
Yes (Yes)
Week 4
Patient Weight (kg)
Kg
Body Surface Area (m^2)
Agent Name (pre-populated valid value -> C225)
Date Agent Administered
Agent Total Dose (mg)
Dose per M2
m2
Reason for dose modification (Table of values on
Draft CRF for "Reason for
Termination/Modification" combines values for
2Qs - this must be a separate CDE; not limited to
CDUS values)
Adverse Event/side Effects/complications
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(Adverse event/side
effects/complications)
Alternative Therapy (Alternative therapy)
Death On Study (Death on study)
Disease Progression, Relapse During
Active Treatment (Disease progression,
relapse during active treatment)
None (None)
Other (Other)
Other Complicating Disease (Other
complicating disease)
Patient Withdrawal Or Refusal After
Beginning Protocol Therapy (Patient
withdrawal/refusal after beginning
protocol therapy)
Patient Withdrawal Or Refusal Prior To
Beginning Protocol Therapy (Patient
withdrawal/refusal prior to beginning
protocol therapy)
Treatment Completed Per Protocol
Criteria (Treatment completed per
protocol criteria)
Reason Treatment Ended (Table of values on
Draft CRF for "Reason for
Termination/Modification" combines values for
2Qs - this CDE must use CDUS values only)
Adverse Event/side Effects/complications
(Adverse Event/Side
Effects/Complications)
Alternative Therapy (Alternative therapy)
Death On Study (Death on study)
Disease Progression, Relapse During
Active Treatment (Disease progression,
relapse during active treatment)
Other (Other)
Patient Off-treatment For Other
Complicating Disease (Patient off-
treatment for other complicating disease)
Patient Withdrawal Or Refusal After
Beginning Protocol Therapy (Patient
withdrawal/refusal after beginning
protocol therapy)
Patient Withdrawal Or Refusal Before
Beginning Protocol Therapy (Patient
withdrawal/refusal prior to beginning
protocol therapy)
Treatment Completed Per Protocol
Criteria (Treatment completed per
protocol criteria)
Week 5
Patient Weight (kg)
Kg
Body Surface Area (m^2)
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Agent Name (pre-populated valid value -> C225)
Date Agent Administered
Agent Total Dose (mg)
Dose per M2
m2
Reason for dose modification (Table of values on
Draft CRF for "Reason for
Termination/Modification" combines values for
2Qs - this must be a separate CDE; not limited to
CDUS values)
Adverse Event/side Effects/complications
(Adverse event/side
effects/complications)
Alternative Therapy (Alternative therapy)
Death On Study (Death on study)
Disease Progression, Relapse During
Active Treatment (Disease progression,
relapse during active treatment)
None (None)
Other (Other)
Other Complicating Disease (Other
complicating disease)
Patient Withdrawal Or Refusal After
Beginning Protocol Therapy (Patient
withdrawal/refusal after beginning
protocol therapy)
Patient Withdrawal Or Refusal Prior To
Beginning Protocol Therapy (Patient
withdrawal/refusal prior to beginning
protocol therapy)
Treatment Completed Per Protocol
Criteria (Treatment completed per
protocol criteria)
Reason Treatment Ended (Table of values on
Draft CRF for "Reason for
Termination/Modification" combines values for
2Qs - this CDE must use CDUS values only)
Adverse Event/side Effects/complications
(Adverse Event/Side
Effects/Complications)
Alternative Therapy (Alternative therapy)
Death On Study (Death on study)
Disease Progression, Relapse During
Active Treatment (Disease progression,
relapse during active treatment)
Other (Other)
Patient Off-treatment For Other
Complicating Disease (Patient off-
treatment for other complicating disease)
Patient Withdrawal Or Refusal After
Beginning Protocol Therapy (Patient
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withdrawal/refusal after beginning
protocol therapy)
Patient Withdrawal Or Refusal Before
Beginning Protocol Therapy (Patient
withdrawal/refusal prior to beginning
protocol therapy)
Treatment Completed Per Protocol
Criteria (Treatment completed per
protocol criteria)
Week 6
Patient Weight (kg)
Kg
Body Surface Area (m^2)
Agent Name (pre-populated valid value -> C225)
Date Agent Administered
Agent Total Dose (mg)
Dose per M2
m2
Reason for dose modification (Table of values on
Draft CRF for "Reason for
Termination/Modification" combines values for
2Qs - this must be a separate CDE; not limited to
CDUS values)
Adverse Event/side Effects/complications
(Adverse event/side
effects/complications)
Alternative Therapy (Alternative therapy)
Death On Study (Death on study)
Disease Progression, Relapse During
Active Treatment (Disease progression,
relapse during active treatment)
None (None)
Other (Other)
Other Complicating Disease (Other
complicating disease)
Patient Withdrawal Or Refusal After
Beginning Protocol Therapy (Patient
withdrawal/refusal after beginning
protocol therapy)
Patient Withdrawal Or Refusal Prior To
Beginning Protocol Therapy (Patient
withdrawal/refusal prior to beginning
protocol therapy)
Treatment Completed Per Protocol
Criteria (Treatment completed per
protocol criteria)
Reason Treatment Ended (Table of values on
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Draft CRF for "Reason for
Termination/Modification" combines values for
2Qs - this CDE must use CDUS values only)
Adverse Event/side Effects/complications
(Adverse Event/Side
Effects/Complications)
Alternative Therapy (Alternative therapy)
Death On Study (Death on study)
Disease Progression, Relapse During
Active Treatment (Disease progression,
relapse during active treatment)
Other (Other)
Patient Off-treatment For Other
Complicating Disease (Patient off-
treatment for other complicating disease)
Patient Withdrawal Or Refusal After
Beginning Protocol Therapy (Patient
withdrawal/refusal after beginning
protocol therapy)
Patient Withdrawal Or Refusal Before
Beginning Protocol Therapy (Patient
withdrawal/refusal prior to beginning
protocol therapy)
Treatment Completed Per Protocol
Criteria (Treatment completed per
protocol criteria)
Week 7
Patient Weight (kg)
Kg
Body Surface Area (m^2)
Agent Name (pre-populated valid value -> C225)
Date Agent Administered
Agent Total Dose (mg)
Dose per M2
m2
Reason for dose modification (Table of values on
Draft CRF for "Reason for
Termination/Modification" combines values for
2Qs - this must be a separate CDE; not limited to
CDUS values)
Adverse Event/side Effects/complications
(Adverse event/side
effects/complications)
Alternative Therapy (Alternative therapy)
Death On Study (Death on study)
Disease Progression, Relapse During
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Active Treatment (Disease progression,
relapse during active treatment)
None (None)
Other (Other)
Other Complicating Disease (Other
complicating disease)
Patient Withdrawal Or Refusal After
Beginning Protocol Therapy (Patient
withdrawal/refusal after beginning
protocol therapy)
Patient Withdrawal Or Refusal Prior To
Beginning Protocol Therapy (Patient
withdrawal/refusal prior to beginning
protocol therapy)
Treatment Completed Per Protocol
Criteria (Treatment completed per
protocol criteria)
Reason Treatment Ended (Table of values on
Draft CRF for "Reason for
Termination/Modification" combines values for
2Qs - this CDE must use CDUS values only)
Adverse Event/side Effects/complications
(Adverse Event/Side
Effects/Complications)
Alternative Therapy (Alternative therapy)
Death On Study (Death on study)
Disease Progression, Relapse During
Active Treatment (Disease progression,
relapse during active treatment)
Other (Other)
Patient Off-treatment For Other
Complicating Disease (Patient off-
treatment for other complicating disease)
Patient Withdrawal Or Refusal After
Beginning Protocol Therapy (Patient
withdrawal/refusal after beginning
protocol therapy)
Patient Withdrawal Or Refusal Before
Beginning Protocol Therapy (Patient
withdrawal/refusal prior to beginning
protocol therapy)
Treatment Completed Per Protocol
Criteria (Treatment completed per
protocol criteria)
Off-protocol treatment
Non-Protocol Supportive Therapy (Was any non-
protocol supportive therapy given during
treatment?)
Yes
No
Type of Supportive Care Given (value for 0=None
must be omitted not CDE Compliant)
Amifostine (Amifostine)
Amifostine And Pilocarpine (Amifostine
and Pilocarpine)
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Pilocarpine (Pilocarpine)
Was the patient hospitalized for any treatment
related complications in this report period?
No (No)
Unknown (Unknown)
Yes (Yes)
Protocol Specific Adverse Event
Evaluation
CTC Adverse Event Term
MedDRA Code
CTC AE Grade
CTCAE Begin Date
CTC AE Attribution Code (A. Attribution to
Protocol Treatment: See protocol sections 6&7 for
definition of "protocol treatment" 1=unrelated;
2=unlikely; 3=possible; 4=probable; 5=definite)
Definite (Definite)
Possible (Possible)
Probable (Probable)
Unlikely (Unlikely)
Unrelated (Unrelated)
Serious adverse event report submitted (B.
Adverse Event report submitted: 1=No; 2=Yes;
9=Unknown)
No (No)
Unknown (Unknown)
Yes (Yes)
Comments
Protocol Specific Adverse Event
Evaluation
New or continuing adverse events (Not reported
in Q6)
No (No)
Unknown (Unknown)
Yes (Yes)
CTC Adverse Event Term
MedDRA Code
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CTC AE Grade
CTCAE Begin Date
CTC AE Attribution Code (A. Attribution to
Protocol Treatment: See protocol sections 6&7 for
definition of "protocol treatment" 1=unrelated;
2=unlikely; 3=possible; 4=probable; 5=definite)
Definite (Definite)
Possible (Possible)
Probable (Probable)
Unlikely (Unlikely)
Unrelated (Unrelated)
Serious adverse event report submitted (B.
Adverse Event report submitted: 1=No; 2=Yes;
9=Unknown)
No (No)
Unknown (Unknown)
Yes (Yes)
Comments
Lab Values Module
Week 7
Patient Weight (kg)
Kg
Body Surface Area (M^2)
m2
Agent Name (pre-populated valid value -> C225)
Date Agent Administered
Agent Total Dose (mg)
Dose per M2
m2
Reason for dose modification (Table of values on
Draft CRF for "Reason for
Termination/Modification" combines values for
2Qs - this must be a separate CDE; not limited to
CDUS values)
Adverse Event/side Effects/complications
(Adverse event/side
effects/complications)
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Alternative Therapy (Alternative therapy)
Death On Study (Death on study)
Disease Progression, Relapse During
Active Treatment (Disease progression,
relapse during active treatment)
None (None)
Other (Other)
Other Complicating Disease (Other
complicating disease)
Patient Withdrawal Or Refusal After
Beginning Protocol Therapy (Patient
withdrawal/refusal after beginning
protocol therapy)
Patient Withdrawal Or Refusal Prior To
Beginning Protocol Therapy (Patient
withdrawal/refusal prior to beginning
protocol therapy)
Treatment Completed Per Protocol
Criteria (Treatment completed per
protocol criteria)
Reason Treatment Ended (Table of values on
Draft CRF for "Reason for
Termination/Modification" combines values for
2Qs - this CDE must use CDUS values only)
Adverse Event/side Effects/complications
(Adverse Event/Side
Effects/Complications)
Alternative Therapy (Alternative therapy)
Death On Study (Death on study)
Disease Progression, Relapse During
Active Treatment (Disease progression,
relapse during active treatment)
Other (Other)
Patient Off-treatment For Other
Complicating Disease (Patient off-
treatment for other complicating disease)
Patient Withdrawal Or Refusal After
Beginning Protocol Therapy (Patient
withdrawal/refusal after beginning
protocol therapy)
Patient Withdrawal Or Refusal Before
Beginning Protocol Therapy (Patient
withdrawal/refusal prior to beginning
protocol therapy)
Treatment Completed Per Protocol
Criteria (Treatment completed per
protocol criteria)
Comments
Comments
Person completing this form
Other (Other)
Urologist Performing Surgery (urologist
performing surgery)
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Form completion date
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NCT01302834  RTOG 1016 TF: Radiation Therapy Oncology
Group Phase III Head and Neck Cancer Treatment Summary Form
NCT01302834  RTOG 1016 TF: Radiation Therapy
Oncology Group Phase III Head and Neck Cancer
Treatment Summary Form
Radiation Therapy With Cisplatin or Cetuximab in Treating
Patients With Oropharyngeal Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=9418B248-
C31D-807C-E040-BB89AD431782
All rights reserved. Please visit https://medical-data-
models.org/forms/11596
NCT01302834  RTOG 1016 TF:
Radiation Therapy Oncology Group
Phase III Head and Neck Cancer
Treatment Summary Form
RTOG clinical trial administrative data
RTOG Study No.
Case #
Institution
Institution No.
Patient Initials
RTOG Patient ID
AMENDED DATA
Yes
No
Header
Assigned Treatment Arm
Arm 1 (Arm 1)
Arm 2 (Arm 2)
Patient Height (cm)
cm
Arm 1 Only - Day 1
Patient Weight (KG, ACTUAL)
Kg
Body Surface Area (M^2, ACTUAL)
m2
Body Surface Area (M^2, VALUE USED TO
CALCULATE DOSE IF ACTUAL BSA > 2)
1 / 8
m2
Agent Name
Date Agent Administered
Agent Total Dose (mg)
Reason for dose modification
Adverse Event/side Effects/complications
(Adverse event/side
effects/complications)
Alternative Therapy (Alternative therapy)
Death On Study (Death on study)
Disease Progression, Relapse During
Active Treatment (Disease progression,
relapse during active treatment)
No Modification (No modification)
Other (Other)
Other Complicating Disease (Other
complicating disease)
Patient Withdrawal Or Refusal After
Beginning Protocol Therapy (Patient
withdrawal/refusal after beginning
protocol therapy)
Patient Withdrawal Or Refusal Prior To
Beginning Protocol Therapy (Patient
withdrawal/refusal prior to beginning
protocol therapy)
Reason Treatment Ended
Adverse Event/side Effects/complications
(Adverse Event/Side
Effects/Complications)
Death On Study (Death on study)
Disease Progression, Relapse During
Active Treatment (Disease progression,
relapse during active treatment)
Other (Other)
Patient Off-treatment For Other
Complicating Disease (Patient off-
treatment for other complicating disease)
Patient Withdrawal Or Refusal After
Beginning Protocol Therapy (Patient
withdrawal/refusal after beginning
protocol therapy)
Patient Withdrawal Or Refusal Before
Beginning Protocol Therapy (Patient
withdrawal/refusal prior to beginning
protocol therapy)
Treatment Completed Per Protocol
Criteria (Treatment completed per
protocol criteria)
Arm 1 Only - Day 1
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Patient Weight (KG, ACTUAL)
Kg
Body Surface Area (M^2, ACTUAL)
m2
Body Surface Area (M^2, VALUE USED TO
CALCULATE DOSE IF ACTUAL BSA > 2)
m2
Agent Name
Date Agent Administered
Agent Total Dose (mg)
Reason for dose modification
Adverse Event/side Effects/complications
(Adverse event/side
effects/complications)
Alternative Therapy (Alternative therapy)
Death On Study (Death on study)
Disease Progression, Relapse During
Active Treatment (Disease progression,
relapse during active treatment)
No Modification (No modification)
Other (Other)
Other Complicating Disease (Other
complicating disease)
Patient Withdrawal Or Refusal After
Beginning Protocol Therapy (Patient
withdrawal/refusal after beginning
protocol therapy)
Patient Withdrawal Or Refusal Prior To
Beginning Protocol Therapy (Patient
withdrawal/refusal prior to beginning
protocol therapy)
Reason Treatment Ended
Adverse Event/side Effects/complications
(Adverse Event/Side
Effects/Complications)
Death On Study (Death on study)
Disease Progression, Relapse During
Active Treatment (Disease progression,
relapse during active treatment)
Other (Other)
Patient Off-treatment For Other
Complicating Disease (Patient off-
treatment for other complicating disease)
Patient Withdrawal Or Refusal After
Beginning Protocol Therapy (Patient
withdrawal/refusal after beginning
protocol therapy)
Patient Withdrawal Or Refusal Before
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Beginning Protocol Therapy (Patient
withdrawal/refusal prior to beginning
protocol therapy)
Treatment Completed Per Protocol
Criteria (Treatment completed per
protocol criteria)
Header
Did patient receive any non-protocol cetuximab
during radiation therapy
No (No)
Unknown (Unknown)
Yes (Yes)
Arm 1 Only - Day 1
Patient Weight (KG, ACTUAL)
Kg
Body Surface Area (M^2, ACTUAL)
m2
Body Surface Area (M^2, VALUE USED TO
CALCULATE DOSE IF ACTUAL BSA > 2)
m2
Agent Name
Date Agent Administered
Agent Total Dose (mg)
Reason for dose modification
Adverse Event/side Effects/complications
(Adverse event/side
effects/complications)
Alternative Therapy (Alternative therapy)
Death On Study (Death on study)
Disease Progression, Relapse During
Active Treatment (Disease progression,
relapse during active treatment)
No Modification (No modification)
Other (Other)
Other Complicating Disease (Other
complicating disease)
Patient Withdrawal Or Refusal After
Beginning Protocol Therapy (Patient
withdrawal/refusal after beginning
protocol therapy)
Patient Withdrawal Or Refusal Prior To
Beginning Protocol Therapy (Patient
withdrawal/refusal prior to beginning
protocol therapy)
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Reason Treatment Ended
Adverse Event/side Effects/complications
(Adverse Event/Side
Effects/Complications)
Death On Study (Death on study)
Disease Progression, Relapse During
Active Treatment (Disease progression,
relapse during active treatment)
Other (Other)
Patient Off-treatment For Other
Complicating Disease (Patient off-
treatment for other complicating disease)
Patient Withdrawal Or Refusal After
Beginning Protocol Therapy (Patient
withdrawal/refusal after beginning
protocol therapy)
Patient Withdrawal Or Refusal Before
Beginning Protocol Therapy (Patient
withdrawal/refusal prior to beginning
protocol therapy)
Treatment Completed Per Protocol
Criteria (Treatment completed per
protocol criteria)
Arm 1 Only - Day 1
Patient Weight (KG, ACTUAL)
Kg
Body Surface Area (M^2, ACTUAL)
m2
Body Surface Area (M^2, VALUE USED TO
CALCULATE DOSE IF ACTUAL BSA > 2)
m2
Agent Name
Date Agent Administered
Agent Total Dose (mg)
Reason for dose modification
Adverse Event/side Effects/complications
(Adverse event/side
effects/complications)
Alternative Therapy (Alternative therapy)
Death On Study (Death on study)
Disease Progression, Relapse During
Active Treatment (Disease progression,
relapse during active treatment)
No Modification (No modification)
Other (Other)
Other Complicating Disease (Other
complicating disease)
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Patient Withdrawal Or Refusal After
Beginning Protocol Therapy (Patient
withdrawal/refusal after beginning
protocol therapy)
Patient Withdrawal Or Refusal Prior To
Beginning Protocol Therapy (Patient
withdrawal/refusal prior to beginning
protocol therapy)
Reason Treatment Ended
Adverse Event/side Effects/complications
(Adverse Event/Side
Effects/Complications)
Death On Study (Death on study)
Disease Progression, Relapse During
Active Treatment (Disease progression,
relapse during active treatment)
Other (Other)
Patient Off-treatment For Other
Complicating Disease (Patient off-
treatment for other complicating disease)
Patient Withdrawal Or Refusal After
Beginning Protocol Therapy (Patient
withdrawal/refusal after beginning
protocol therapy)
Patient Withdrawal Or Refusal Before
Beginning Protocol Therapy (Patient
withdrawal/refusal prior to beginning
protocol therapy)
Treatment Completed Per Protocol
Criteria (Treatment completed per
protocol criteria)
Non-Protocol Therapy
Did patient receive any non-protocol cisplatin
during radiation therapy
No (No)
Unknown (Unknown)
Yes (Yes)
Was any non-protocol supportive therapy given
(during treatment)
No (No)
Unknown (Unknown)
Yes (Yes)
Type of supportive care given, specify (If yes,)
Was the patient hospitalized for any treatment
related complications in this report period?
No (No)
Unknown (Unknown)
Yes (Yes)
Tube feeding
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Does the patient currently require tube feeding
No (No)
Unknown (Unknown)
Yes (Yes)
Is patient dependent on tube feeding for >50% of
nutritional support  (If yes,)
No (No)
Unknown (Unknown)
Yes (Yes)
Dental gingival health
Life-threatening Dental Condition (Life-
threatening dental condition)
Mild Changes/good Dental Health (Mild
changes/good dental health)
Moderate/fair Dental Health
(Moderate/fair dental health)
Normal (Normal)
Severe Changes In Dental Health
(Severe changes in dental health)
Number of native teeth in place (0-32)
Protocol Specific Adverse Event
Evaluation
CTCAE Term
CTC AE Grade
Mild Adverse Event (1)
Moderate Adverse Event (2)
Severe Adverse Event (3)
Life Threatening Adverse Event (4)
Death Related To Adverse Event (5)
CTCAE Begin Date (MM DD YYYY)
CTC AE Attribution Code
Definite (Definite)
Possible (Possible)
Probable (Probable)
Unlikely (Unlikely)
Unrelated (Unrelated)
SAE report submitted
No (No)
Unknown (Unknown)
Yes (Yes)
AE led to discontinuation of treatment
No (No)
Unknown (Unknown)
Yes (Yes)
Protocol Specific Adverse Event
Evaluation
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New or continuing adverse events (not reported
Q9)
No (No)
Unknown (Unknown)
Yes (Yes)
CTCAE Term
MedDRA Code
CTC AE Grade
Mild Adverse Event (1)
Moderate Adverse Event (2)
Severe Adverse Event (3)
Life Threatening Adverse Event (4)
Death Related To Adverse Event (5)
CTCAE Begin Date (MM DD YYYY)
CTC AE Attribution Code
Definite (Definite)
Possible (Possible)
Probable (Probable)
Unlikely (Unlikely)
Unrelated (Unrelated)
SAE report submitted
No (No)
Unknown (Unknown)
Yes (Yes)
AE led to discontinuation of treatment
No (No)
Unknown (Unknown)
Yes (Yes)
Comments
COMMENTS
Person Completing Form
Form completion date, original (MM DD YYYY)
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AMC-051 Adverse Events Form (ADV)
NCT00450320
AMC-051 Adverse Events Form (ADV) NCT00450320 
Sirolimus in Treating Patients With HIV-Related Kaposi's
Sarcoma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=2FDFA89A-
0516-6018-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11597
AMC-051 Adverse Events Form
(ADV) NCT00450320
Header
CTC Adverse Event Category
CTC Adverse Event Term
CTC Adverse Event Grade
Adverse Event Onset Date
Adverse event assessment
MedDRA Code
If other CTC event selected, please provide
description of event
Was this event expected or anticipated
Yes
No
Agent Name
CTC AE Attribution Code
Definite (Definite)
Possible (Possible)
Probable (Probable)
Unlikely (Unlikely)
Unrelated (Unrelated)
Alternative etiology
Accident, Trauma, Or External Factors
(Accident, trauma, or external factors)
Concurrent Illness/condition (not Pre-
existing) (Concurrent illness/condition
(not pre-existing))
None Apparent (None apparent)
Other Pre-existing Disease Or Condition
(Other pre-existing disease or condition)
Study Disease (Study disease)
Action Taken at Time of Adverse Event
1 / 2
Hospitalization For Ae (Hospitalization)
Otc/non-rx (OTC/non-Rx)
Other (Other)
Prescription (Prescription)
Protocol Treatment Was Delayed As A
Result Of The Adverse Event (protocol
treatment delayed)
Protocol Treatment Was Discontinued As
A Result Of The Adverse Event (protocol
treatment discontinued)
Study Dose Was Reduced As A Result
Of The Adverse Event (study dose
reduced)
Other, specify
If modification was made to study therapy, who
initiated modification
Patient Initiated (Patient initiated)
Physician Initiated (Physician initiated)
Outcome of Adverse Event
Adverse Event Is Resolved (Resolved)
Adverse Event Is Resolved With
Sequelae (Resolved with sequelae)
Unresolved At Protocol Completion
(Unresolved at protocol completion)
Unresolved, Protocol Ongoing
(Unresolved, protocol ongoing)
AE Resolution Date
If resolved with sequelae, specify
Seriousness Attributed to Adverse Event
Congenital Anomaly (Congenital
anomaly)
Death (Death)
Disability (Disability/incapacity)
Hospitalized (Hospitalization, initial or
prolonged)
Life Threatening (Life threatening)
Other (Other)
Intervention Required (Required
intervention to prevent permanent
impairment/damage)
Comments
Comments
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RTOG 0825 Phase III GBM Follow-Up Form
(F1) NCT00884741
RTOG 0825 Phase III GBM Follow-Up Form (F1)
NCT00884741 
Temozolomide and Radiation Therapy With or Without
Bevacizumab in Treating Patients With Newly Diagnosed
Glioblastoma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=5A7D0D0E-
5E03-3FE7-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11598
RTOG 0825 Phase III GBM Follow-
Up Form (F1) NCT00884741
RTOG clinical trial administrative data
RTOG Study No.
Case #
Institution Name
Institution No.
Patient Initials
RTOG Patient ID
Amended Data (INSTRUCTIONS: Submit this
form as indicated in the protocol. All dates need
to be recorded as mm-dd-yyyy unless otherwise
specified)
Yes
No
Patient status assessment
Date of Last Contact or Death (MM/DD/YYYY)
Patient Vital Status
Alive (Alive)
Dead (Dead)
Primary Cause of Death
Due To Complications Of Non-protocol
Treatment (Due to complications of non-
protocol treatment)
Due To Other Cause (Due to other
cause)
Glioblastoma (Due to primary/recurrent
glioblastoma)
Due To Protocol Treatment (Due to
protocol treatment)
Unknown (Unknown)
Specify
1 / 6
Due to other cause specify
Karnofsky Performance Status (0-100)
Dead (0)
Moribund, Fatal Processes Progressing
Rapidly (10)
Normal, No Complaints, No Evidence Of
Disease (100)
Very Sick, Hospitalization Indicated.
Death Not Imminent (20)
Severely Disabled, Hospitalization
Indicated. Death Not Imminent (30)
Disabled, Requires Special Care And
Assistance (40)
Requires Considerable Assistance And
Frequent Medical Care (50)
Requires Occasional Assistance, But Is
Able To Care For Most Of His/her Needs
(60)
Cares For Self, Unable To Carry On
Normal Activity Or To Do Active Work
(70)
Normal Activity With Effort; Some Signs
Or Symptoms Of Disease (80)
Able To Carry On Normal Activity; Minor
Signs Or Symptoms Of Disease (90)
Neurologic function
Minor Neurologic Symptoms, Fully Active
At Home/work Without Assistance (Minor
neurologic symptoms, fully active at
home/work without assistance)
Moderate Neurologic Symptoms, Fully
Active At Home/work But Requires
Assistance (Moderate neurologic
symptoms, fully active at home/work but
requires assistance)
Moderate Neurologic Symptoms, Less
Than Fully Active At Home/work And
Requires Assitance (Moderate
neurologic symptoms, less than fully
active at home/work and requires
assistance)
No Neurologic Symptoms, Fully Active At
Home/work Without Assistance (No
neurologic symptoms, fully active at
home/work without assistance)
Severe Neurologic Symptoms, Totally
Inactive Requiring Complete Assistance
At Home Or Institution, Unable To Work
(Severe neurologic symptoms, totally
inactive requiring complete assistance at
home or institution, unable to work)
Unknown (Unknown)
Recurrence Or Progression
Recurrent disease
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No (No)
Unknown (Unknown)
Yes, Ct/mri Scan (Yes, CT/MRI scan)
Non-protocol Therapy To Brain
Non-Protocol Therapy
Yes
No
Extent of Resection
Biopsy (Biopsy)
Not Applicable (Not applicable)
Other (Other)
Subtotal (Subtotal)
Total (gross) (Total (gross))
Other, specify
Date of Resection (MM DD YYYY)
Was there gross evidence of tumor?
No (No)
Undetermined (Undetermined)
Unknown (Unknown)
Yes (Yes)
Was RT necrosis present
No (No)
Undetermined (Undetermined)
Unknown (Unknown)
Yes (Yes)
Non-Protocol Radiation Therapy
Yes
No
Non-protocol Radiation Therapy Start Date (MM
DD YYYY)
RT Total Dose (Gy)
Non-Protocol Radiosurgery?
Yes
No
Radiosurgery date (MM DD YYYY)
Non-Protocol brachytherapy
Yes
No
Brachytherapy Start Date (MM DD YYYY)
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Non-Protocol Chemotherapy (I.E. GLIADEL
WAFER)
Yes
No
Non-Protocol Systemic Treatment
Yes
No
Corticosteroids
Yes
No
Specify
Date of last dose (MM DD YYYY)
Anticonvulsants
Yes
No
Specify
Has the patient taken anticoagulant agents?
Yes
No
Specify
PT (Prothrombin Time Value)
seconds
PT LLN (Institution)
seconds
PT ULN (Institution)
seconds
Date (MM DD YYYY)
INR (International Normalized Ratio of
prothrombin time Value)
INR LLN (Institution)
INR ULN (Institution)
Agents with proarrhythmic potential
Yes
No
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Specify
Herbal Products
Yes
No
Specify
Protocol Specific Adverse Event
Evaluation
Were there any hemorrhage events during this
report period
Yes
No
CTC Adverse Event Term
CTC AE Grade
CTCAE Begin Date (MM DD YYYY)
CTC AE Attribution Code
Definite (Definite)
Possible (Possible)
Probable (Probable)
Unlikely (Unlikely)
Unrelated (Unrelated)
SAE report submitted
No (No)
Unknown (Unknown)
Yes (Yes)
MedDRA Code
PTT (sec) (Partial Thromboplastin Time Value)
PTT LLN (Institution)
seconds
PTT ULN (Institution)
seconds
Platelets (PLT) (Platelets x 1000 cmm Value)
1000/uL
PLT LLN (Institution)
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PLT ULN (Institution)
Protocol Specific Adverse Event
Evaluation
Were there any study-specific adverse events
during this report period
Yes
No
Comments
Comments
Signature of Person Completing This Form
Form Completion Date, Original (MM DD YYYY )
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NSABP PROTOCOL B-38FORM ALERT -
Form ALERT NCT00093795
NSABP PROTOCOL B-38FORM ALERT - Form ALERT
NCT00093795 
Combination Chemotherapy in Treating Women Who Have
Undergone Surgery for Node-Positive Breast Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=DD8A2825-
7101-4099-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/11599
NSABP PROTOCOL B-38FORM
ALERT - Form ALERT
NCT00093795
Patient demographics
Patient Initials
NSABP Patient ID
Institution Name
Affiliate Name
Treating MD, Last Name
Treating MD, First Name
Treating MD, Phone
Person completing Form, Last Name
Person completing Form, First Name
Person completing Form, Phone
Are data amended? (check box if yes, and circle
amended items)
Yes
No
Adverse event report
Date of this Report
Patient's Age at Time of AE
Currrent Cycle Number
Was patient hospitalized for 24 hours or more?
Yes
1 / 2
No
CTCAE v3.0 Short Name
"Select" Term
Specify Type of Adverse Event
Grade 2 Unexpected (Grade 2
unexpected)
Grade 3 Unexpected (Grade 3
unexpected)
Grade 4 Expected (Grade 4 expected)
Grade 4 Unexpected (Grade 4
unexpected)
Grade 5 (Grade 5)
Adverse Event Onset Date
Protocol Therapy
Cyclophosphamide (Cyclophosphamide)
Docetaxel (Docetaxel)
Doxorubicin (Doxorubicin)
Gemcitabine (Gemcitabine)
Paclitaxel (Paclitaxel)
Date of Most Recent Treatment
CTC Adverse Event Attribution Code
Definite (Definite)
Possible (Possible)
Probable (Probable)
Unlikely (Unlikely)
Unrelated (Unrelated)
Briefly describe the AE (provide supporting
documentation)
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NSABP PROTOCOL B-39: FORM ALERT
NCT00103181
NSABP PROTOCOL B-39: FORM ALERT NCT00103181 
Radiation Therapy in Treating Women Who Have
Undergone Surgery For Ductal Carcinoma In Situ or Stage
I or Stage II Breast Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=E6F88B25-
BF25-058C-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11600
NSABP PROTOCOL B-39: FORM
ALERT NCT00103181
Header
Patient Initials
NSABP Patient ID
Institution Name
Affiliated Institution Name
Treating MD Last Name
Treating MD First Name
Treating MD Phone
Person Completing Form Last Name
Person Completing Form First Name
Person Completing Form Phone
Date of This Report
Are data amended (check box if yes, and circle
amended items)
Yes
No
Adverse event
Adverse Event Onset Date
Patient's Age at Time of AE
Was the patient hospitalized for 24 hours or
more?
1 / 2
Yes
No
Protocol Therapy
Partial Breast Irradiation (Partial Breast
Irradiation)
Whole Breast Irradiation (Whole Breast
Irradiation)
Date of Most Recent Treatment (Radiation
Therapy)
Attribution
Definite (Definite)
Possible (Possible)
Probable (Probable)
Unlikely (Unlikely)
Unrelated (Unrelated)
CTCAE v3.0 Short Name
CTCAE v3.0 "Select Term" (if applicable)
CTCAE v3.0 Grade
Briefly describe the AE (provide supporting
documentation)
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NSABP PROTOCOL B-39: FORM ALERT NCT00103181
S1011 Registration Worksheet Step 2
(#8470)
S1011 Registration Worksheet Step 2 (#8470)
Standard or Extended Pelvic Lymphadenectomy in Treating
Patients Undergoing Surgery for Invasive Bladder Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=9386BABC-
0E79-AC8D-E040-BB89AD4309BA
All rights reserved. Please visit https://medical-data-
models.org/forms/11602
S1011 Registration Worksheet Step
2 (#8470)
Header module
Activation Date (MM DD YYYY)
Last Amended Date (MM DD YYYY)
Registration Step
Swog Patient Id
SWOG Patient ID
Registrar's SWOG Roster ID Number
SWOG Investigator Number
SWOG Treating Institution Number
Stratification Questions
Neoadjuvant chemotherapy
Cisplatin Based (1)
Carboplatin Based (2)
Other (3)
None (4)
Clinical stage
T2 (1)
T3 Or T4a (2)
Zubrod performance status
0-1 (1)
2 (2)
Patient Eligibility
Has the SWOG Registration Worksheet been
completed entirely and is the patient eligible
according to the current version of protocol
section 5.0?
1 / 2
Yes
No
Header module
Activation Date (MM DD YYYY)
Last Amended Date (MM DD YYYY)
Registration Step
Swog Patient Id
SWOG Patient ID
Registrar's SWOG Roster ID Number
SWOG Investigator Number
SWOG Treating Institution Number
Stratification Questions
Neoadjuvant chemotherapy
Cisplatin Based (1)
Carboplatin Based (2)
Other (3)
None (4)
Clinical stage
T2 (1)
T3 Or T4a (2)
Zubrod performance status
0-1 (1)
2 (2)
Patient Eligibility
Has the SWOG Registration Worksheet been
completed entirely and is the patient eligible
according to the current version of protocol
section 5.0?
Yes
No
2 / 2
S1011 Registration Worksheet Step 2 (#8470)
AMC-045 Complete Physical Exam Form
(F21) NCT00324415
AMC-045 Complete Physical Exam Form (F21)
NCT00324415 
Cisplatin, Fluorouracil, Cetuximab, and Radiation Therapy
in Treating Patients With HIV and Stage I, Stage II, or
Stage III Anal Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=4428A103-
FC35-0EB3-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11604
AMC-045 Complete Physical Exam
Form (F21) NCT00324415
Header Module
Visit number
Date of evaluation (mm/dd/yyyy)
Physical Exam
Primary site
Abdomen (Abdomen)
Chest (Chest)
Ear (Ears)
Extremities (Extremities)
Eye (Eyes)
Genitalia (Genital)
Head (Head)
Heart (Heart)
Liver (Liver)
Lung (Lungs)
Lymph Node (Lymph Nodes)
Mouth (Mouth)
Neck (Neck)
Neurologic (Neurological)
Other (Other)
Rectal (Rectal)
Skin (Skin)
Spleen (Spleen)
Other, specify
Assessment
Abnormal (Abnormal)
Normal (Normal)
Not Evaluated (Not Evaluated)
Describe abnormal findings
Comments
Comments
1 / 1
AMC-076 Dysplasia Treatment Form (DYS)
NCT01164722
AMC-076 Dysplasia Treatment Form (DYS) NCT01164722 
Infrared Coagulator Ablation or Observation in Preventing
Anal Cancer in HIV-Positive Patients With Anal Neoplasia
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=A8216D81-
B789-F026-E040-BB89AD436DD3
All rights reserved. Please visit https://medical-data-
models.org/forms/11606
AMC-076 Dysplasia Treatment Form
(DYS) NCT01164722
Header Module
Visit number
Dysplasia Treatment
Was dysplasia present
Yes
No
Treatment date (If Yes, mm/dd/yyyy)
Treatment location (If Yes,)
The Intraanal Region (Intraanal)
The Perianal Region (Perianal)
Perianal lesions treated (If perianal, Check all
that apply)
Condyloma (Condyloma)
High-grade Ain (High-grade AIN)
Low-grade Ain (Low-grade AIN)
Other (Other)
Other, specify
Intraanal lesions treated (If intraanal, Check all
that apply)
Condyloma (Condyloma)
Low-grade Flat Anal Intraepithelial
Neoplasia (Low-grade flat AIN)
Other (Other)
Treatment method performed
Cauterization (Cautery)
Cryotherapy (Cryotherapy)
Excision (Excision)
Infrared Photocoagulation Therapy (IRC)
Laser (Laser)
Percentage of perianal or intraanal area treated
5% (<)
> 50% (> 50%)
26-50% (26-50%)
6-25% (6-25%)
1 / 2
Comments
Comments
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AMC-076 Dysplasia Treatment Form (DYS) NCT01164722
AMC-076 HPV On-Study Form (ONS)
NCT01164722
AMC-076 HPV On-Study Form (ONS) NCT01164722
Infrared Coagulator Ablation or Observation in Preventing
Anal Cancer in HIV-Positive Patients With Anal Neoplasia
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=A80C062E-
17BA-F42E-E040-BB89AD432F38
All rights reserved. Please visit https://medical-data-
models.org/forms/11608
AMC-076 HPV On-Study Form
(ONS) NCT01164722
Header Module
Visit number
HIV Status
Date of HIV+ diagnosis (mm/dd/yyyy)
Date of AIDS diagnosis (mm/dd/yyyy)
CDC HIV Risk Group
Hemophilia (Hemophiliac)
Heterosexual Contact (Heterosexual
contact)
Homosexual Or Bisexual Contact
(Homosexual or bisexual contact)
Iv Drug User (IV drug user)
Other (Other)
Transfusion Recipient (Transfusion
recipient)
Other, specify
Condyloma Status
History of anal, perianal, or genital condyloma (If
"Yes", answer the following)
Yes
No
History of penile or genital condyloma
Active Genital Condyloma (Active genital
condyloma)
Active Penile Condyloma (Active penile
condyloma)
No History (No history)
Yes, Resolved With History Of Treatment
(Yes, resolved with history of treatment)
Yes, Resolved Without Treatment (Yes,
resolved without treatment)
History of perianal condyloma
Active Perianal Condyloma (Active
perianal condyloma)
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No History (No history)
Yes, Resolved With History Of Treatment
(Yes, resolved with history of treatment)
Yes, Resolved Without Treatment (Yes,
resolved without treatment)
History of intraanal condlyoma
Active Intraanal Condyloma (Active
intraanal condyloma)
No History (No history)
Yes, Resolved With History Of Treatment
(Yes, resolved with history of treatment)
Yes, Resolved Without Treatment (Yes,
resolved without treatment)
Comments
Comments
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AMC-076 HPV On-Study Form (ONS) NCT01164722
CALGB: BACKGROUND INFORMATION
FORM NCT00041119
CALGB: BACKGROUND INFORMATION FORM
NCT00041119
Comparison of Combination Chemotherapy Regimens in
Treating Older Women Who Have Undergone Surgery for
Breast Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=A50BF263-
C019-2D60-E034-080020C9C0E0
All rights reserved. Please visit https://medical-data-
models.org/forms/11610
CALGB: BACKGROUND
INFORMATION FORM
NCT00041119
Cancer and Leukemia Group B Data
CALGB Form
CALGB Study No
CALGB Patient ID
Amended data?
Yes
No
Patient demographics
Patient's Name
Participating Group
Patient Hospital Number
Participating Group Protocol No.
Main Member Institution/Adjunct
Participating Group Patient No.
Social status
If you do not wish to answer any of the following
questions please mark an X here. (1.)
Today's Date (M)
What is the highest grade you finished in school?
(3.)
1-8 Grades (1-8 grades)
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9-11 Grades (9-11 grades)
Advanced Degree (Advanced degree)
College Degree (b.a./b.s.) (College
degree (B.A./B.S.))
High School Graduate (High School
graduate)
Junior College Degree (Junior college
degree)
Some College (Some college)
Some Post-college Work (Some post-
college work)
What is your marital status? (mark one with an X)
Divorced (Divorced)
Married (Married)
Separated (Separated)
Single, Never Married (Single, never
married)
Widowed (Widowed)
With whom do you live? (mark all that apply with
an X)
Children Aged 18 Years Or Younger
(Children aged 18 years or younger)
Children Aged 19 Years Or Older
(Children aged 19 years or older)
Live Alone (Live alone)
Other Relative, Specify (Other relative,
specify)
Other, Specify (Other, specify)
Parent(s)/parent(s)-in-law
(Parent(s)/Parent(s)-In-Law)
Spouse/partner (Spouse/Partner)
Other relative, specify (with whom you live)
Other, specify (with whom you live) (5.)
What is your current employment status? (mark
all that apply with an X)
Disabled (Disabled)
Employed 32 Hours Or More Per Week
(Employed 32 hours or more per week)
Employed Less Than 32 Hours Per
(Employed less than 32 hours per)
Full-time Student (Full-time student)
Homemaker (Homemaker)
On Medical Leave (On medical leave)
Other, Specify (Other, specify)
Part-time Student (Part-time student)
Retired (Retired)
Unemployed (Unemployed)
Other, specify (current employment status)
Ccrr Module For Calgb: Background
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CALGB: BACKGROUND INFORMATION FORM NCT00041119
Information Form
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CALGB: BACKGROUND INFORMATION FORM NCT00041119
NCT00890747  AMC-061 AIDS and Cancer Specimen
Resource (ACSR) Procurement Form (F37)
NCT00890747  AMC-061 AIDS and Cancer Specimen
Resource (ACSR) Procurement Form (F37)
Sunitinib Malate in Treating HIV-Positive Patients With
Cancer Undergoing Highly Active Antiretroviral Therapy
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=7158429B-
AC2E-967C-E040-BB89AD4302A7
All rights reserved. Please visit https://medical-data-
models.org/forms/11612
NCT00890747  AMC-061 AIDS and
Cancer Specimen Resource (ACSR)
Procurement Form (F37)
Header Module
Visit number
Study Coordinator's name
E-mail
Phone Number (xxx-xxx-xxxx)
Specimen information
Date Specimen Obtained (for previously donated
specimens mm/dd/yyyy)
Specimen(s) obtained for donation to ACSR
Yes
No
Specimen Type (check all that apply)
Peripheral Blood (Blood)
Other (Other)
peripheral Blood Mononuclear Cells
(PBMC)
Plasma (Plasma)
Serum (Serum)
Tissue (Tissue)
Other specify
ACSR site the specimen(s) shipped to
Gwu (GWU)
Jhu (JHU)
Osu (OSU)
Other (Other)
Suny/hscb (SUNY/HSCB)
Ucla (UCLA)
Ucsf (UCSF)
Other, specify
1 / 2
If specimens were not obtained for ACSR, please
indicate reason
Other (Other)
Patient Had Previously Donated
Specimen To Acsr (Patient had
previously donated specimen to ACSR)
Patient Refused To Give Informed
Consent For Acsr Specimen Donation
(Patient refused to give informed consent
for ACSR specimen donation)
Patient Was Not Asked To Consider Acsr
Specimen Donation (Patient was not
asked to consider ACSR specimen
donation)
Other, specify
Comments
Comments
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NCT00890747  AMC-061 AIDS and Cancer Specimen Resource (ACSR)
Procurement Form (F37)
CALGB: 40101 PRE-STUDY ELIGIBILITY
CHECKLIST NCT00041119
CALGB: 40101 PRE-STUDY ELIGIBILITY CHECKLIST
NCT00041119 
Four Versus Six Cycles of Cyclophosphamide/Doxorubicin
or Paclitaxel in Adjuvant Breast Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=A4CFBF75-
6AD3-69D3-E034-080020C9C0E0
All rights reserved. Please visit https://medical-data-
models.org/forms/11614
CALGB: 40101 PRE-STUDY
ELIGIBILITY CHECKLIST
NCT00041119
Header module
CALGB Study No.
CALGB Patient ID
Patient's Name
Participating Group
Patient Hospital Number
Participating Group Protocol No.
Main Member Institution/Adjunct
Participating Group Patient No.
Breast Cancer ELIGIBILITY
Histologically confirmed invasive carcinoma of
the breast
Yes
No
Undergone either modified radical mastectomy or
lumpectomy
Yes
No
Negative tumor margins for invasive cancer and
DCIS in case of mastectomy or lumpectomy
Yes
No
No locally advanced breast cancer, inflammatory
breast cancer or metastatic breast cancer
Yes
No
No involvement of dermal lymphatics on
1 / 3
pathology
Yes
No
"High-risk" node-negative breast cancer
(guidelines are ER/PgR positive primary tumor
>= 1 cm in greatest diameter, or ER/PgR
negative tumor of any size; physician discretion is
allowed)
Yes
No
Negative sentinel node biopsy, and/or an axillary
dissection where at least 6 lymph nodes are
removed and found to be negative
Yes
No
<= 84 days since last major breast surgery
Yes
No
No previous chemotherapy or hormonal therapy
(except for tamoxifen as described in the
protocol) for this malignancy
Yes
No
Age >= 18 years
>= 18
years
Yes
No
CTC Performance status 0-1
Yes
No
Non-pregnant and non-nursing
Yes
No
No active congestive heart failure nor myocardial
infarction within 6 months prior to registration
Yes
No
Disease-free of prior invasive malignancies for >5
years except for curatively treated basal cell or
squamous cell carcinoma of the skin or
carcinoma in situ of the cervix
Yes
No
Willing to stop exogenous hormone therapy,
including oral contraceptives, post-menopausal
hormone replacement therapy, and raloxifene
Yes
No
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CALGB: 40101 PRE-STUDY ELIGIBILITY CHECKLIST NCT00041119
Discontinued tamoxifen at time of enrollment to
study if tamoxifen has been received as breast
cancer preventive agent, or as treatment for this
malignancy for <= 4 weeks. (If latter, indicate
dates below)
Yes
No
Date tamoxifen started
Date tamoxifen discontinued
Meets ALL of the following laboratory criteria
completed within 16 days before registration
Yes
No
ANC >= 1000/mcL
>= 1000
microliter
Yes
No
Date obtained (ANC)
Platelets >= 100,000/mcL
>= 100000
microliter
Yes
No
Date obtained (Platelets)
Creatinine <= 2.0 mg/dL
>= 2
mg/dL
Yes
No
Date obtained (Creatinine)
Total Bilirubin < 1.5 x upper limits of normal of
laboratory (mg/dL)
<= 1,5
mg/dL
Yes
No
Date obtained (Total Bilirubin)
ULN (Total Bilirubin)
Ccrr Module For Calgb: 40101 Pre-study
Eligibility Checklist
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CALGB: 40101 PRE-STUDY ELIGIBILITY CHECKLIST NCT00041119
AMC-061 HIV T-Cell Laboratory Values
Form (F24) NCT00890747
AMC-061 HIV T-Cell Laboratory Values Form (F24)
NCT00890747 
Sunitinib Malate in Treating HIV-Positive Patients With
Cancer Undergoing Highly Active Antiretroviral Therapy
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=715886E9-
A82F-36FE-E040-BB89AD430F6F
All rights reserved. Please visit https://medical-data-
models.org/forms/11616
AMC-061 HIV T-Cell Laboratory
Values Form (F24) NCT00890747
Header Module
Visit number
Sequence number
Date of Evaluation (mm/dd/yyyy)
T-cell Laboratory Values
T-Helper CD4+ %
%
T-Helper CD4+ absolute count
Other, specify
Percent Positive Lymphocytes
%
Absolute Count
Comments
Comments
1 / 1
NSABP B-35 Form ALERT NCT00053898
NSABP B-35 Form ALERT NCT00053898 
Anastrozole or Tamoxifen in Treating Postmenopausal
Women With Ductal Carcinoma in Situ Who Are
Undergoing Lumpectomy and Radiation Therapy
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=A0587E1D-
38C6-3AA5-E034-080020C9C0E0
All rights reserved. Please visit https://medical-data-
models.org/forms/11618
NSABP B-35 Form ALERT
NCT00053898
Patient Demographics
First Three Letters of Patient's Last Name
Patient Study ID
Institution Name
Affiliate Name
Treating MD First Name
Treating MD Last Name
Treating MD Phone
Person Completing Form Last Name
Person Completing Form First Name
Person Completing Form Phone
Are data amended? (If Yes, circle the amended
items in red.)
Yes
No
AE Evaluation
Date of this report (Month Day Year)
Patient's Age at Time of AE
Notify Local IRB?
Yes
No
Institution Number
1 / 2
Specify Type of Adverse Event (AE)
Grade 3 Unexpected* (Grade 3
unexpected*)
Grade 4 Expected (Grade 4 expected)
Grade 4 Unexpected* (Grade 4
unexpected*)
Grade 5** Expected (Grade 5**
expected)
Grade 5** Unexpected* (Grade 5**
unexpected*)
AE (CTC Term)
4-Character NSABP Code
Date of Adverse Event (Month Day Year)
Was the patient hospitalized for 24 hours or
more?
Yes
No
Attribution (relationship) of the AE to protocol
therapy?
Definitely (Related)
Unrelated (Unrelated)
TamoxifenAnastrozole /Start Date (Month Day
Year)
Tamoxifen/Anastrozole Date of Most Recent
Dose (Month Day Year)
Briefly describe the AE (provide supporting
documentation)
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NSABP B-35 Form ALERT NCT00053898
ECOG Second Primary Form (E2100)
ECOG Second Primary Form (E2100)
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=AC346EE2-
C452-2587-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/11619
ECOG Second Primary Form
(E2100)
ECOG data
ECOG Patient ID
Registration Step
Patient's Name
Participating Group Protocol No.
Participating Group Patient ID
Institution/Affiliate
ECOG Protocol No.
Are data amended?
Yes
No
Second Primary Cancers
Date of Diagnosis of Second Primary Cancer (M
D Y)
Site of Second Primary Cancer
Include information on histologic subtype(s).
(Please attach copies of any corroborating
pathology reports.)
Briefly describe cancer therapy the patient has
received prior to the diagnosis of the second
primary and other than that given on ECOG
protocols
Briefly describe treatment planned or given for
the diagnosis of this second primary
1 / 2
Comments
Comments
Investigator Signature
Date
Ccrr Module For Ecog Second Primary
Form (e2100)
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ECOG Second Primary Form (E2100)
CALGB: QOL ASSESSMENT SUMARY
FORM NCT00024102
CALGB: QOL ASSESSMENT SUMARY FORM
NCT00024102 
Comparison of Combination Chemotherapy Regimens in
Treating Older Women Who Have Undergone Surgery for
Breast Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=A50D1BCF-
4910-2EA3-E034-080020C9C0E0
All rights reserved. Please visit https://medical-data-
models.org/forms/11621
CALGB: QOL ASSESSMENT
SUMARY FORM NCT00024102
CALGB Information
CALGB Form
CALGB Study No
CALGB Patient ID
Date Completed (M)
Amended data?
Yes
No
Interviewer or CRA
Assessment Number
Patient data
Patient's Name
Participating Group
Patient Hospital Number
Participating Group Protocol No.
Main Member Institution/Adjunct
Participating Group Patient No.
Physical assessment
Method of assessment (mark one with an X)
Interview In Clinic/hospital (Interview in
clinic/hospital)
Mailed Questionnaire (Mailed
1 / 3
questionnaire)
Self-report Questionnaire Administered
In Clinic/hospital (Self-report
questionnaire administered in
clinic/hospital)
Telephone Interview (Telephone
interview)
date questionnaire was sent to patient (M)
Number of attempts made to contact patient by
telephone and/or mail
Language in which assessment was conducted
(mark one with an X)
English (English)
French (French)
Other, Specify (Other, specify)
Spanish (Spanish)
Other, specify (language in which assessment
was conducted)
Quality of life assessment (mark one with an X)
Completed (Completed)
Not Done (Not done)
Partially Completed (Partially completed)
number of QOL instrument(s) completed
If the assessment was partially completed or not
done, indicate reason(s) below (mark all that
apply with an X)
Assessments Discontinued Due To
Disease Progression Or Relapse, Per
Protocol (Assessments discontinued due
to disease progression or relapse, per
protocol)
Interviewer Forgot To Call Patient Or Mail
Questionnaire (Interviewer forgot to call
patient or mail questionnaire)
Other, Specify (Other, specify)
Patient Died (Patient died)
Patient Does Not Receive Questionnaire
Or Repeatedly Loses Questionnaire And
Does Not Wish To Be Interviewed By
Telephone (Patient does not receive
questionnaire or repeatedly loses
questionnaire and does not wish to be
interviewed by telephone)
Patient Does Not Speak Language In
Which Instruments Are Available (Patient
does not speak language in which
instruments are available)
Patient Does Not Understand Questions
(Patient does not understand questions)
Patient Refuses (Patient refuses)
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CALGB: QOL ASSESSMENT SUMARY FORM NCT00024102
Patient Repeatedly Cancels Interview
Due To Non-medical Reasons (Patient
repeatedly cancels interview due to non-
medical reasons)
Patient Too Medically Ill (Patient too
medically ill)
Unable To Locate Patient (Unable to
locate patient)
Unable To Successfully Reach Patient
(Unable to successfully reach patient)
Other, specify (reason assessment was partially
completed or not done)
Ccrr Module For Calgb: Qol Assessment
Sumary Form
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CALGB: QOL ASSESSMENT SUMARY FORM NCT00024102
NCT00053898 NSABP PROTOCOL B-35 Treatment
of Ipsilateral or Contralateral Breast Event
NCT00053898 NSABP PROTOCOL B-35 Treatment of
Ipsilateral or Contralateral Breast Event
Anastrozole or Tamoxifen in Treating Postmenopausal
Women With Ductal Carcinoma in Situ Who Are
Undergoing Lumpectomy and Radiation Therapy
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=A019BB52-
B911-3D6B-E034-080020C9C0E0
All rights reserved. Please visit https://medical-data-
models.org/forms/11623
NCT00053898 NSABP PROTOCOL
B-35 Treatment of Ipsilateral or
Contralateral Breast Event
Header module
First Three Letters of Patient's Last Name
Patient Study ID
Institution Name
Affiliate Name
Person Completing Form Last Name
Person Completing Form First Name
Person Completing Form Phone
Are data amended? (If Yes, circle the amended
items in red.)
Yes
No
Event for which Treatment is Reported
cst (Cancer in Opposite Breast)
Ipsilateral Breast Tumor Recurrence
(ibtr) (Ipsilateral Breast Tumor
Recurrence (IBTR))
Date of this IBTR or Cancer in Opposite Breast
(month day year If this event has not yet been
reported on a follow-up form, complete and
attach Form F35.)
Breast Cancer Therapeutic Procedure
Total Mastectomy
No (No)
Unknown (Unknown)
Yes (Yes)
Lumpectomy
No (No)
1 / 2
Unknown (Unknown)
Yes (Yes)
Breast Radiation
No (No)
Unknown (Unknown)
Yes (Yes)
Regional Radiation
No (No)
Unknown (Unknown)
Yes (Yes)
Hormonal Therapy
No (No)
Unknown (Unknown)
Yes (Yes)
Chemotherapy
No (No)
Unknown (Unknown)
Yes (Yes)
Other (specify)
No (No)
Unknown (Unknown)
Yes (Yes)
specify
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NCT00053898 NSABP PROTOCOL B-35 Treatment of Ipsilateral or
Contralateral Breast Event
CALGB: Follow-up Solid Tumor Evaluation
Form NCT00053339
CALGB: Follow-up Solid Tumor Evaluation Form
NCT00053339
Trastuzumab With or Without Tamoxifen in Treating Women
With Progressive Stage IV Breast Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=A73D1896-
B650-4751-E034-0003BA0B1A09
All rights reserved. Please visit https://medical-data-
models.org/forms/11625
CALGB: Follow-up Solid Tumor
Evaluation Form NCT00053339
CALGB clinical trial administrative data
CALGB Form
CALGB Study No
CALGB Patient ID
Amended data?
Yes (Yes)
From
To
Patient demographics
Patient Name
Participating Group
Patient Hospital Number
Participating Group Protocol No.
Main Member Institution/Adjunct
Participating Group Patient No.
Target Lesion(s) Follow-up Evaluation
Lesion Number
Site
Date of Evaluation
1 / 3
Method of Evaluation
Bone Scan (Bone scan)
Chest X-ray (chest x-ray)
Clinical Examination (clinical
examination)
Ct Scan (CT scan)
Mri (MRI (NMR))
Not Evaluated (not evaluated)
Other (other)
Spiral Ct Scan (Spiral CT scan)
Ultrasound (Ultrasound)
If other, specify (method of evaluation)
complete response (CR) (complete
response (CR))
insufficient evaluation to determine
response status (insufficient evaluation
to determine response status)
partial response (PR) (partial response
(PR))
progressive disease (PD) (progressive
disease (PD))
stable disease (SD) (stable disease
(SD))
Longest Diameter (cm)
Sum of Longest Diameteres of All Target lesions
(cm)
Response Status at this assessment (Target
Lesion)
Complete Response (complete response
(CR))
Insufficient Evaluation (insufficient
evaluation to determine response status)
Partial Response (partial response (PR))
Partial Response; At Least A 30%
Decrease In The Sum Of Ld Of Target
Lesions Taking As Reference The
Baseline Sum Ld (progressive disease
(PD))
Incomplete Response Or Stable
Disesase (stable disease (SD))
Non-target Lesion(s) Follow-up Evaluation
Are there any non-target lesions?
Yes
No
Site
New Lesion(s) At Follow-up Evaluation
Was the appearance of any new lesions
documented since the baseline evaluation?
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Yes
No
Completed by
Date completed
Ccrr Module For Calgb: Follow-up Solid
Tumor Evaluation Form
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CALGB: Follow-up Solid Tumor Evaluation Form NCT00053339
AMC-061 Enrollment Form (ENR)
NCT00890747
AMC-061 Enrollment Form (ENR) NCT00890747 
Sunitinib Malate in Treating HIV-Positive Patients With
Cancer Undergoing Highly Active Antiretroviral Therapy
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=6DBDC738-
44D1-D324-E040-BB89AD433B23
All rights reserved. Please visit https://medical-data-
models.org/forms/11627
AMC-061 Enrollment Form (ENR)
NCT00890747
Header Module
Projected Start Date of Treatment (mm/dd/yyyy)
Inclusion/exclusion Criteria
Inclusion Criteria
1.5 times ULN AST (SGOT) and ALT
(SGPT) <= 2.5 times the ULN=(if ((If )
Creatinine Within Institutional Normal
Limits Or Glomerular Filtration Rate (gfr)
> 60 Ml/min/m^2 (calculated By The
Cockcroft-gault Equation) (Creatinine
within institutional normal limits or
Glomerular filtration rate (GFR) > 60
mL/min/m^2 (calculated by the
Cockcroft-Gault equation))
Date Informed Consent Obtained (Date
informed consent obtained)
Does The Participant Agree To Employ
An Effective Barrier Method Of Birth
Control Throughout The Study And For
Up To 3 Months Following
Discontinuation Of Study Drug (Does the
participant agree to employ an effective
barrier method of birth control throughout
the study and for up to 3 months
following discontinuation of study drug)
Does The Participant Have A Cd4 Count
> 50 Cells/ul (Does the participant have
a CD4 count > 50 cells/uL)
Does The Participant Have A
Histologically Or Cytologically Confirmed
Nhl, Biopsy-proven Ks Or Solid Tumor Or
Hematological Malignancy (Does the
participant have a histologically or
cytologically confirmed NHL, biopsy-
proven KS or solid tumor or
hematological malignancy)
Does The Participant Have Serologic
Documentation Of Hiv Infection At Any
Time Prior To Study Entry, As Evidenced
By Positive Elisa, Positive Western Blot,
Or Other Federally Approved Licensed
Hiv Test (Does the participant have
serologic documentation of HIV infection
at any time prior to study entry, as
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evidenced by positive ELISA, positive
Western Blot, or other federally approved
licensed HIV test)
Does The Participant Have The Ability
And Willingness To Give Written
Informed Consent (Does the participant
have the ability and willingness to give
written informed consent)
8.0 gm/dL Absolute neutrophil count
(ANC) >= 1500 cells/mm^3 Platelet
count >= 100,000 /mm^3=Does The
Participant Have The Following
Laboratory Parameters Within 7 Days
Prior To Study Entry Hemoglobin >= 8.0
Gm/dl Absolute Neutrophil Count (anc)
>= 1500 Cells/mm^3 Platelet Count >=
100,000 /mm^3 (Does the participant
have the following laboratory parameters
within 7 days prior to study entry
Hemoglobin >)
If The Participant Is Female, And Of
Child-bearing Potential, Has She Had A
Negative Pregnancy Test Within 72
Hours Before Initiation Of Study Drug
Dosing (If the participant is female, and
of child-bearing potential, has she had a
negative pregnancy test within 72 hours
before initiation of study drug dosing)
If Yes, Indicate Cancer Type (see
Protocol Section 4.0 For Specific
Eligibility Criteria) Nhl, Ks, Renal Cell
Cancer, Solid Tumor, Hematologic
Malignancy (If Yes, indicate cancer type
(see protocol section 4.0 for specific
eligibility criteria) NHL, KS, Renal Cell
Cancer, Solid tumor, Hematologic
malignancy)
If Yes, Indicate Haart Regimen Type
Nnrti-based Only, Non Ritonavir Pi-
based Only, Ritonavir Pi-based Only,
Nnrti- And Non Ritonavir Pi-based, Nnrti-
And Ritonavir Pi-based, Neither Pi Nor
Nnrti Based (If Yes, indicate HAART
regimen type NNRTI-based only, Non
ritonavir PI-based only, Ritonavir PI-
based only, NNRTI- and non ritonavir PI-
based, NNRTI- and ritonavir PI-based,
Neither PI nor NNRTI based)
Is The Participant On Stable Anti-
retroviral Therapy For At Least 4 Weeks
With A Pi-based Or Nnrti-based
Regimen Of At Least Three Drugs, With
No Intention To Change The Regimen
Within 8 Weeks After Starting Study
Drug (Is the participant on stable anti-
retroviral therapy for at least 4 weeks
with a PI-based or NNRTI-based
regimen of at least three drugs, with no
intention to change the regimen within 8
weeks after starting study drug)
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Is The Participant, In The Opinion Of The
Investigator, Capable Of Complying With
This Protocol (Is the participant, in the
opinion of the Investigator, capable of
complying with this protocol)
Is The Participant's Life Expectancy 3
Months Or More (Is the participant's life
expectancy 3 months or more)
Karnofsky Performance Status (must Be
> 60%) (Karnofsky Performance Status
(must be > 60%))
Participant's Age (in Years) (Participant's
age (in years))
1.5 times ULN (upper limit of normal) (If
(Total bilirubin <)
Exclusion Criteria
Type of Cancer
Hematologic Malignancy (Hematologic
malignancy)
Kaposi Sarcoma (KS)
Non-hodgkin's Lymphoma (Non-
Hodgkin's lymphoma)
Renal Cell Carcinoma (Renal Cell
Cancer)
Solid Neoplasm (Solid tumor)
Patient HAART regimen type?
Neither Pi Nor Nnrti Based (Neither PI
nor NNRTI based)
Nnrti- And Non-ritonavir Pi-based
(NNRTI- and non-ritonavir PI-based)
Nnrti- And Ritonavir Pi-based (NNRTI-
and ritonavir PI-based)
Nnrti-based Only (NNRTI-based only)
Non-ritonavir Pi-based Only (Non-
ritonavir PI-based only)
Ritonavir Pi-based Only (Ritonavir PI-
based only)
Karnofsky Performance Status (must be > 60%)
>= 60
%
Age (in years)
Date Informed Consent Signed (mm/dd/yyyy)
Exclusion Criteria
Does The Participant Have A Concurrent
Active Opportunistic Infection (Does the
participant have a concurrent active
opportunistic infection)
3 beats in a row)=Does The Participant
Have A History Of Serious Ventricular
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Arrhythmia (ventricular Tachycardia (vt)
Or Ventricular Fibrillation (vf) >= 3 Beats
In A Row) (Does the participant have a
history of serious ventricular arrhythmia
(ventricular tachycardia (VT) or
ventricular fibrillation (VF) >)
Does The Participant Have A Pre-
existing Thyroid Abnormality That
Cannot Be Maintained With Medication
To Keep Measures Of Thyroid
Stimulating Hormone Within The Normal
Range (Does the participant have a pre-
existing thyroid abnormality that cannot
be maintained with medication to keep
measures of thyroid stimulating hormone
within the normal range)
Does The Participant Have A Psychiatric
Illness That Would Limit Compliance
With Study Requirements (Does the
participant have a psychiatric illness that
would limit compliance with study
requirements)
Does The Participant Have A Qtc Interval
> 500 Msec (Does the participant have a
QTc interval > 500 msec)
Does The Participant Have An Abnormal
Left Ventricular Ejection Fraction Per
Institutional Standards (Does the
participant have an abnormal Left
Ventricular Ejection Fraction per
institutional standards)
Does The Participant Have Another
Severe And/or Life-threatening Medical
Disease (Does the participant have
another severe and/or life-threatening
medical disease)
100 mmHg despite optimal medical
therapy) or unstable angina=Does The
Participant Have Clinically Significant
Cardiovascular Disease, Including
Uncontrolled Hypertension (diastolic
Blood Pressure >=100 Mmhg Despite
Optimal Medical Therapy) Or Unstable
Angina (Does the participant have
clinically significant cardiovascular
disease, including uncontrolled
hypertension (diastolic blood pressure >)
Does The Participant Have
Gastrointestinal Tract Disease Resulting
In An Inability To Take Oral Medication
Or A Requirement For Iv Alimentation,
Prior Surgical Procedures Affecting
Absorption, Or Active Peptic Ulcer
Disease (Does the participant have
gastrointestinal tract disease resulting in
an inability to take oral medication or a
requirement for IV alimentation, prior
surgical procedures affecting absorption,
or active peptic ulcer disease)
2=Does The Participant Have Ongoing
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Ventricular Cardiac Dysrhythmias Of Nci
Ctcae Grade >= 2 (Does the participant
have ongoing ventricular cardiac
dysrhythmias of NCI CTCAE grade >)
Does The Participant Have Serious
Cardiac Arrhythmia Requiring Medication
(Does the participant have serious
cardiac arrhythmia requiring medication)
Has The Participant Had A Myocardial
Infarction, Severe/unstable Angina,
Coronary Artery Bypass Graft,
Cerebrovascular Accident, Transient
Ischemic Attack, Or Pulmonary
Embolism Within 6 Months Of Study
Entry (Has the participant had a
myocardial infarction, severe/unstable
angina, coronary artery bypass graft,
cerebrovascular accident, transient
ischemic attack, or pulmonary embolism
within 6 months of study entry)
Has The Participant Had Acute
Treatment For An Infection Or Other
Serious Medical Illness Within 14 Days
Prior To Study Entry (Has the participant
had acute treatment for an infection or
other serious medical illness within 14
days prior to study entry)
Has The Participant Had Major Surgery
Or Radiation Within 3 Weeks Prior To
Study Entry (Has the participant had
major surgery or radiation within 3 weeks
prior to study entry)
Has The Participant Received
Antineoplastic Therapy, Including
Investigational Drug Or Standard
Treatment, Within 2 Weeks Of Study
Entry? (must Be Able To Demonstrate
Adequate Recovery From Prior Therapy-
related Toxicities.) (Has the participant
received antineoplastic therapy, including
investigational drug or standard
treatment, within 2 weeks of study entry?
(Must be able to demonstrate adequate
recovery from prior therapy-related
toxicities.))
If The Participant Is Female, Is She
Pregnant Or Breast-feeding (If the
participant is female, is she pregnant or
breast-feeding)
Will The Participant Undergo Concurrent
Treatment With Medications, Other Than
Antiretroviral Drugs Used To Treat Hiv
Infection, That Are Known To Inhibit Or
Induce Cyp3a4 (Will the participant
undergo concurrent treatment with
medications, other than antiretroviral
drugs used to treat HIV infection, that are
known to inhibit or induce CYP3A4)
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Consent For Participation In
Pharmacogenetics Study And The Use Of
Future Tissue Specimens
Does the participant agree to participate in the
pharmacogenetics study associated with this
protocol
Yes
No
Does the participant agree to have excess
specimens from this study stored for future AIDS-
related research (or leftover)
Yes
No
Comments
Comments
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Leukemia Lab BLOOD/BONE MARROW
EVALUATION FORM 2076614v3.0 NCT00085124
CALGB: DIAGNOSTIC BLOOD/BONE MARROW
EVALUATION FORM
Daunorubicin and Cytarabine With or Without Oblimersen
in Treating Older Patients With Previously Untreated Acute
Myeloid Leukemia
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=B228F576-
D49A-4DCD-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/11628
Leukemia Lab BLOOD/BONE
MARROW EVALUATION FORM
2076614v3.0 NCT00085124
Ccrr Module For Calgb: Diagnostic
Blood/bone Marrow Evaluation Form
Patient`s Name
Patient Hospital Number
Main Member Institution/Adjunct
Participating Group
Participating Group Protocol No.
Participating Group Patient No.
CALGB LabTrak number
Date sample obtained (M D Y)
FAB subtype
Other, specify (diagnosis) (If diagnosed with
AML:)
Did patient have prior MDS?
Yes
No
Is this therapy-related AML?
No (No)
Possibly (Possibly)
Yes (Yes)
Source of specimen submitted (specimens must
be submitted within one week of date sample
obtained)
Bone Marrow (Bone marrow)
Other, Specify (Other, specify)
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Peripheral Blood (Peripheral blood)
Other, specify (source of specimen submitted)
Type of sample
Complete response (Complete
response)
Other, Specify (Other, specify)
Sample Or Specimen Collected Before
Patient Received Treatment For Cancer
(Pretreatment)
Relapse (Relapse)
Other, specify (type of sample) (The following
required reports are attached to this form)
CBC report (including WBC, hemoglobin, platelet
count)
Yes
No
Flow cytometry/immunophenotype report
Yes
No
Pathology report
Yes
No
Cytogenetics report
Yes
No
If any above named required reports are not
submitted, specify reason
Investigator
Completed By
(Print or Type Name)
Date Completed
Phone
Fax
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2076614v3.0 NCT00085124
Follow-up AMLSG 21-13 NCT02013648
Akute myeloische Leukämie (AML)
Randomized Phase III Study of Intensive Chemotherapy
with or without Dasatinib (Sprycel™) in Adult Patients with
Newly Diagnosed Core-Binding Factor Acute Myeloid
Leukemia (CBF-AML) Form derived from original study
material, with friendly permission of Dr. Richard Schlenk,
University Ulm AMLSG Ulm
All rights reserved. Please visit https://medical-data-
models.org/forms/11629
Follow-up AMLSG 21-13
NCT02013648 Akute myeloische
Leukämie (AML)
Follow-up
Consecutive Follow-up Number
Concomitant Disease
Number
Date of Diagnosis
Diagnosis
Therapy
Number
Therapy after end of study
Chemotherapy (1)
Allogenic Transplantation (as mentioned
below) (2)
other (3)
Description of Therapy
Start Date of Therapy
Reason for Therapy
Reinduction (1)
Consolidation (2)
Other (3)
Response before Therapy
CR (1)
CRi (2)
OR (3)
RD (4)
Relapse (5)
Response after Therapy
CR (1)
CRi (2)
PR (3)
RD (4)
Relapse (5)
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Date of evaluation after therapy
Allogenic Transplantation
Date of Transplantation
Transplant
PBSCT (1)
BM (KM) (2)
HLA-Constellation
Full match (0)
1 Mismatch (1)
2 Mismatches (2)
haplo (3)
Donor
family donor (1)
unrelated donor (2)
Donor Comment
Conditioning before transplant
EBMT Identifier
Signature
Date
Name of Investigator
Signature of investigator
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Follow-up AMLSG 21-13 NCT02013648 Akute myeloische Leukämie
(AML)
cancer conference - report
HIS form from Soarian. Urologie Erlangen" with friendly
permission of the urology Erlangen (Prof. Wullich) and the
medical informatics department Erlangen (PD Dr. Bürkle)
All rights reserved. Please visit https://medical-data-
models.org/forms/11630
HIS
Admininstrative Daten
Patient surname *
Patient forename*
Patient title*
former Patient name*
Patient date of birth*
patient age*
Ethnicity / related nationality data*
Street Address*
Patient postal code*
City of residence *
Case Identifier*
Cancer conference
presented from*
Cancer conference Indication*
short Presentation (Kurzvorstellung im
Tumorboard)
normal Presentation (Normalvorstellung
im Tumorboard)
affected Organ*
Urinary Bladder (Harnblase)
Ureter (Harnleiter)
Urethra  (Harnröhre)
Testis (Hoden)
Kidney (Niere)
Renal pelvis  (Nierenbecken)
penis (Penis)
Prostate  (Prostata)
1 / 4
Other  (Sonstige)
Diagnosis*
former Tumortherapy*
Diagnosis
former Tumortherapy*
Cancer conference Decision*
Participants*
Others (Andere)
Internal Medicine Oncology (Intern.
Onkologie)
Nuclear Medicine (Nuklearmedizin)
Palliative medicine (Palliativmedizin)
Pathology (Pathologie)
Radiology (Radiologie)
Radiation oncology (Strahlentherapie)
Urology (Urologie (Vorsitz))
Clinical Protocols*
Cancer conference type*
post-therapeutic (posttherapeut.
Konferenz (Wiederkehrer))
pre-therapeutic (prätherapeut. Konferenz
(Primärpatient))
other (Sonstiges)
planned therapeutic procedure
Operative Surgical Procedures *
Yes
No
Intent *
Curative - procedure intent  (K = kurativ)
Palliative - procedure intent  (P =
palliativ)
Therapeutic radiology procedure *
Yes
No
Intent *
Adjuvant - intent (A = adjuvant)
Curative - procedure intent  (K = kurativ)
Neo-adjuvant - intent  (N = neoadjuvant)
Palliative - procedure intent (P = palliativ)
Chemotherapy Regimen*
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Yes
No
Intent *
Adjuvant - intent (A = adjuvant)
Curative - procedure intent  (K = kurativ)
Neo-adjuvant - intent (N = neoadjuvant)
Palliative - procedure intent  (P =
palliativ)
Endocrine Therapy*
Yes
No
Intent *
Adjuvant - intent  (A = adjuvant)
Curative - procedure intent  (K = kurativ)
Neo-adjuvant - intent  (N = neoadjuvant)
Palliative - procedure intent  (P =
palliativ)
Antibody Therapy *
Yes
No
Intent *
Adjuvant - intent (A = adjuvant)
Curative - procedure intent  (K = kurativ)
Neo-adjuvant - intent  (N = neoadjuvant)
Palliative - procedure intent  (P =
palliativ)
Immunotherapy *
Yes
No
Intent *
Adjuvant - intent (A = adjuvant)
Curative - procedure intent  (K = kurativ)
Neo-adjuvant - intent  (N = neoadjuvant)
Palliative - procedure intent  (P =
palliativ)
Pain management *
Yes
No
oncologic psychotherapy*
Yes
No
wait and see*
Yes
No
acitve surveillance*
Yes
No
further diagnostic*
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Yes
No
Supportive Care*
Yes
No
Intent *
Adjuvant - intent (A = adjuvant)
Curative - procedure intent  (K = kurativ)
Neo-adjuvant - intent (qualifier value)  (N
= neoadjuvant)
Palliative - procedure intent  (P =
palliativ)
Potential Study Subject *
Yes
No
Clinical Trials *
Guideline Adherence*
Yes
No
Reason for Guidelines Adherence*
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AML Material Submission Form Pathology
NCT00049517
E1900 Material Submission Form
Combination Chemotherapy With or Without Monoclonal
Antibody Therapy Followed by Stem Cell Transplant in
Treating Patients With Acute Myeloid Leukemia
NCT00049517 
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=A727E0B4-
B257-2F80-E034-0003BA0B1A09
All rights reserved. Please visit https://medical-data-
models.org/forms/11631
Material Submission Form Pathology
AML E1900 NCT00049517
Header
ECOG Protocol No.
ECOG Patient ID
Registration Step
Patient's Name
Participating Group Protocol No.
Participating Group Patient ID
Institution/Affiliate
Peripheral and Marrow Blast Percentage
%
Sample No.
Investigator signature
Investigator Signature Date
Comments
Completed By Submitting Institutions
Date material(s) sent to central laboratory
Shipped to
Ecog Cytogenetics Laboratory (ECOG
Cytogenetics Laboratory)
Leukemia Immunophenotyping
Reference Library (Leukemia
Immunophenotyping Reference Library)
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Other Central Laboratory (Other Central
Laboratory)
Date Materials collected
Tissue/material type
Other (0)
Peripheral Blood (1)
Bone Marrow Aspirate (2)
Bone Marrow Biopsy (3)
Karyotype (4)
Peripheral Blood Stem Cell Harvest (5)
Type of collection/stain/process
Green Top (heparinized) (green top
(heparinized))
Karyotype (karyotype)
Other (other)
Red Top (red top)
Slide, Unstained, Charged (slide,
unstained, charged)
Slide/air Dried Smear (slide/air dried
smear)
Stem Cell Harvest (stem cell harvest)
Timing of material collection
1 Mo. Post-transplant (1 mo. Post-
transplant)
12 Mos. Post-transplant (12 mos. Post-
transplant)
6 Mos. Post-transplant (6 mos. Post-
transplant)
Baseline/pretreatment
(baseline/pretreatment)
Other (other)
Pre-transplant , Post-consolidation
Chemotherapy (pre-transplant , post-
consolidation chemotherapy)
Pre-transplant Remission Prior To
Consolidation (pre-transplant remission
prior to consolidation)
Relapse (relapse)
Stem Cell Harvest (stem cell harvest)
number of specimens submitted
Leukemia MDS Diagnosis
ALL, Not Otherwise Specified (nos)
(acute lymphocytic leukemia)
AML, Not Otherwise Specified (nos)
(acute myeloid leukemia)
Chronic Lymphocytic Leukemia (CLL)
(chronic lymphocytic leukemia)
Chronic Myelogenous Leukemia, (CML),
Blast Crisis (CML-blast cells)
Chronic Myelogenous Leukemia (CML),
Chronic Phase (CML-chronic phase)
Myelodysplastic Syndrome (MDS) Nos
2 / 3
AML Material Submission Form Pathology NCT00049517
(MDS-myelodysplastic syndrome)
Disease Classified As Specified Other
Leukemia (Other)
Unknown (Unknown)
Absolute blast count
Institution contact name
Principal Investigator name
Institution contact phone number
Institution contact fax number
Completed By Central Lab
Date materials received at central lab
Condition of material(s)
Damaged Or Unusable (not usable as
received)
Useable (usable as received)
Aliquots of sample made
Yes
No
Central Laboratory contact name
contact phone number
Contact fax number
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cancer conference - report
HIS form from Soarian. Urologie Erlangen" with friendly
permission of the urology Erlangen (Prof. Wullich) and the
medical informatics department Erlangen (PD Dr. Bürkle)
All rights reserved. Please visit https://medical-data-
models.org/forms/11632
HIS
Admininstrative Daten
Patient surname *
Patient forename*
Patient title*
former Patient name*
Patient date of birth*
patient age*
Ethnicity / related nationality data*
Street Address*
Patient postal code*
City of residence *
Case Identifier*
Cancer conference
presented from*
Cancer conference Indication*
short Presentation (Kurzvorstellung im
Tumorboard)
normal Presentation (Normalvorstellung
im Tumorboard)
affected Organ*
Urinary Bladder (Harnblase)
Ureter (Harnleiter)
Urethra  (Harnröhre)
Testis (Hoden)
Kidney (Niere)
Renal pelvis  (Nierenbecken)
penis (Penis)
Prostate  (Prostata)
1 / 4
Other  (Sonstige)
Diagnosis*
former Tumortherapy*
Diagnosis
former Tumortherapy*
Cancer conference Decision*
Participants*
Others (Andere)
Internal Medicine Oncology (Intern.
Onkologie)
Nuclear Medicine (Nuklearmedizin)
Palliative medicine (Palliativmedizin)
Pathology (Pathologie)
Radiology (Radiologie)
Radiation oncology (Strahlentherapie)
Urology (Urologie (Vorsitz))
Clinical Protocols*
Cancer conference type*
post-therapeutic (posttherapeut.
Konferenz (Wiederkehrer))
pre-therapeutic (prätherapeut. Konferenz
(Primärpatient))
other (Sonstiges)
planned therapeutic procedure
Operative Surgical Procedures *
Yes
No
Intent *
Curative - procedure intent  (K = kurativ)
Palliative - procedure intent  (P =
palliativ)
Therapeutic radiology procedure *
Yes
No
Intent *
Adjuvant - intent (A = adjuvant)
Curative - procedure intent  (K = kurativ)
Neo-adjuvant - intent  (N = neoadjuvant)
Palliative - procedure intent (P = palliativ)
Chemotherapy Regimen*
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Yes
No
Intent *
Adjuvant - intent (A = adjuvant)
Curative - procedure intent  (K = kurativ)
Neo-adjuvant - intent (N = neoadjuvant)
Palliative - procedure intent  (P =
palliativ)
Endocrine Therapy*
Yes
No
Intent *
Adjuvant - intent  (A = adjuvant)
Curative - procedure intent  (K = kurativ)
Neo-adjuvant - intent  (N = neoadjuvant)
Palliative - procedure intent  (P =
palliativ)
Antibody Therapy *
Yes
No
Intent *
Adjuvant - intent (A = adjuvant)
Curative - procedure intent  (K = kurativ)
Neo-adjuvant - intent  (N = neoadjuvant)
Palliative - procedure intent  (P =
palliativ)
Immunotherapy *
Yes
No
Intent *
Adjuvant - intent (A = adjuvant)
Curative - procedure intent  (K = kurativ)
Neo-adjuvant - intent  (N = neoadjuvant)
Palliative - procedure intent  (P =
palliativ)
Pain management *
Yes
No
oncologic psychotherapy*
Yes
No
wait and see*
Yes
No
acitve surveillance*
Yes
No
further diagnostic*
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Yes
No
Supportive Care*
Yes
No
Intent *
Adjuvant - intent (A = adjuvant)
Curative - procedure intent  (K = kurativ)
Neo-adjuvant - intent (qualifier value)  (N
= neoadjuvant)
Palliative - procedure intent  (P =
palliativ)
Potential Study Subject *
Yes
No
Clinical Trials *
Guideline Adherence*
Yes
No
Reason for Guidelines Adherence*
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aftercare status prostate cancer
HIS form ORBIS.  with friendly permission form urology
(Prof. Semjonow) and medical informatics department (Dr.
Breil)
All rights reserved. Please visit https://medical-data-
models.org/forms/11636
HIS
Patientenaufkleber groß
Admission date*
Patient Identification Number*
Patient sex*
Patient surname *
Patient forename*
Patient date of birth*
Admission hour*
Physician admission*
Medical History
diagnosis*
Date of diagnosis*
Diagnosis ICD code*
ICD10-GM
Therapeutic procedure*
Date treatment started*
Date treatment stopped *
Surgical and medical procedures
OPS-2010
Clinical Trial Subject*
Yes
No
Date last contact*
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Source of follow-up information *
PSA Failure*
PSA Failure (PSA-Rezidiv)
no evidence of recurrence (Rezidivfrei)
Vital Status*
imaging prostate cancer (Bildgebend
PCA)
Lost to follow up (Lost to follow Up)
Check (Prüfen)
non-measurable PSA after PSA failure
(PSA nicht messbar nach PSA Rezidiv)
PSA Failure (PSA-Rezidiv)
no evidence of recurrence (Rezidivfrei)
symptomatic (symptomatisch)
outward therapy completed (Therapie
auswärts - abgeschlossen)
Cause of Death*
other cause of death (sonstiges)
Death by prostate cancer (Tod durch
PCA)
Death of unknown cause  (Tod
unbekannte Ursache)
Death by neoplasm (Tumor)
Death of unknown cause  (unbekannt)
other cause of death*
Date Vital Status*
PSA
Prostate Specific Antigen measurable*
Yes
No
Prostate Specific Antigen not measurable*
Yes
No
Raised prostate specific antigen and suspected
prostate cancer*
Yes
No
Date PSA*
PSA*
comment PSA*
Urinary continence status
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Urinary continence status*
Yes
No
Date continence*
comment continence*
Incontinence appliance*
Frequency of incontinence*
Masculinity/Virility
Masculinity/Virility*
Date virility*
Erection frequency (per week)*
Characteristic of erection*
comment Virilty*
Concomitant Therapy
Concomitant Therapy*
Yes
No
Concomitant Therapy Start Date*
Concomitant Therapy End Date*
none*
Yes
No
Therapeutic radiology procedure*
Yes
No
Start Radiotherapy*
End Radiotherapy*
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Comment radiotherapy*
Antiandrogen Therapy *
Yes
No
Date treatment started*
Date treatment stopped *
Comment Antiandrogen Therapy*
Chemotherapy Regimen*
Yes
No
Date treatment started*
Date treatment stopped *
Comment Chemotherapy*
Other Therapy*
Yes
No
Date treatment started*
Date treatment stopped *
Comment other therapy*
Date*
Investigator*
comment*
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Eligibility Multiple Myeloma NCT01239797
Eligibility NCT01239797 Multiple Myeloma
Phase 3, Randomized, Open Label Trial of
Lenalidomide/Dexamethasone With or Without Elotuzumab
in Relapsed or Refractory Multiple Myeloma
ODM derived from
http://clinicaltrials.gov/show/NCT01239797
All rights reserved. Please visit https://medical-data-
models.org/forms/11637
Eligibility Multiple Myeloma
NCT01239797
Inclusion Criteria
age at least 18 Years*
Yes
No
Multiple Myeloma*
Yes
No
Documented progression from most recent line of
therapy*
Yes
No
1 - 3 prior lines of therapy
Yes
No
Measurable Disease*
Yes
No
Life expectancy >=3 months*
Yes
No
Prior treatment with Lenalidomide permitted if:   *
Yes
No
Best response achieved was ≥ Partial Response
(PR)
Yes
No
Patient was not refractory*
Yes
No
Patient did not discontinue due to a Grade ≥ 3
related adverse event
Yes
No
Subject did not receive >  9 cycles of
Lenalidomide and had at least 9 months between
the last dose of Lenalidomide and progression*
Yes
No
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Exclusion Criteria
Subjects with non-secretory or oligo-secretory or
free light-chain only myeloma*
Yes
No
Active plasma cell leukemia*
Yes
No
Positive for Hepatitis B, C or Human
Immunodeficiency Virus (HIV)*
Yes
No
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Eligibility Psoriasis NCT00216879
Efficacy and Safety of Calcipotriol Plus Betamethasone
Dipropionate Gel for up to a Year in Scalp Psoriasis
ODM derived from
http://clinicaltrials.gov/ct2/show/NCT00148213?term=NCT0
0148213&rank=1
All rights reserved. Please visit https://medical-data-
models.org/forms/11638
Eligibility Psoriasis NCT00216879
Inclusion Criteria
18 Years and older*
Yes
No
Scalp psoriasis amenable to topical treatment
with a maximum of 100 g of study medication per
week*
Yes
No
Clinical signs of psoriasis vulgaris on trunk and/or
limbs, or earlier diagnosed with psoriasis vulgaris
on trunk and/or limbs*
Yes
No
Extent of scalp psoriasis involving more than 10%
of the total scalp area*
Yes
No
Disease severity on the scalp graded as
Moderate, Severe or Very Severe according to
the Investigator's Global Assessment of disease
severity*
Yes
No
Exclusion Criteria
PUVA or Grenz ray therapy anywhere on the
patient within 28 days prior to randomisation*
Yes
No
UVB therapy anywhere on the patient within 14
days prior to randomisation*
Yes
No
Systemic use of biological treatments, whether
marketed or not, directed against or with a
potential effect on, scalp psoriasis (e.g.,
alefacept, efalizumab, etanercept, infliximab)
within 6 months prior to randomisaiton*
Yes
No
Systemic treatments with a potential effect on
scalp psoriasis vulgaris (e.g., corticosteroids,
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retinoids, immunosuppressants) within 28 days
prior to randomisation*
Yes
No
Any topical treatment for scalp psoriasis or any
other skin disease on the scalp (excluding
medicated shampoos, emollients and hair
conditioners) within 14 days prior to
randomisaiton*
Yes
No
Topical treatment for other skin disorders with
very potent WHO group IV corticosteroids within
14 days prior to randomisation*
Yes
No
Planned initiation of, or changes in dose of
concomitant medication that could affect scalp
psoriasis (e.g., beta blockers, antimalarial drugs,
lithium) during the study*
Yes
No
Current diagnosis of guttate, pustular, exfoliative
or erythrodermic psoriasis*
Yes
No
Patients with any of the following conditions
present on the scalp area: viral lesions, fungal
and bacterial skin infections, parasitic infections
and atrophic skin*
Yes
No
Known or suspected severe renal insufficiency or
severe hepatic disorders*
Yes
No
Patiens with history/signs/symptoms suggestive
of an abnormality of calcium homeostasis
associated with clinically significant
hypercalcaemia*
Yes
No
Trial subjects should be using an adequate
method of contraception*
Yes
No
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DAST basic documentation - discharge
ODM form derived from [DAST Entlassung PSYCH UKM]. 
Used as a routine documentation by the University Hospital
Muenster, Germany.
All rights reserved. Please visit https://medical-data-
models.org/forms/11652
DAST basic documentation -
discharge
Patienten Informationen
Name
Aufnahmedatum
Geburtsdatum
Erfassungsdatum
Dokumentierender Behandler
Somatische Therapien
Mehrfachantwort möglich
Keine (1)
Medikamentöse Therapie (2)
EKT (3)
Schlafentzug (4)
Lichttherapie (5)
Sonstige (6)
Psychotherapy session
Psychotherapie
Anzahl der Psychotherapiesitzungen
Keine (1)
Einzeltermine <30 mins (2)
Einzeltermine >30 mins (3)
Gruppentermine (4)
Psychotherapeutisches Hauptverfahren
Psychotherapeutisches Hauptverfahren
Keine Psychotherapie (1)
Unbekannt/Unklar (10)
Supportive Psychotherapie (2)
Tiefenpsychologische Therapie (3)
Kognitive Verhaltenstherapie (4)
Gesprächstherapie nach Rogers (5)
Interpersonelle Psychotherapie (6)
Psychodynamisch-interaktionelle (7)
Gruppentherapie (8)
Sonstige (9)
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Weitere therapeutische Verfahren
(nur wenn Manual-orientiert angewandt,
Mehrfachantwort möglich)
Keine (1)
Psychoedukation (Gruppe/Einzel) (2)
Kognitives Training (Gruppe/Einzel) (3)
Entspannungstraining (Gruppe/Einzel)
(4)
Soziales Kompetenztraining (Gruppe) (5)
Symptommanagementtraining
(Gruppe/Einzel) (6)
Verhaltenstherapeutische
Angehörigengruppe (7)
Sonstige/Anmerkung (8)
Entlassungsmedikation (aus somatischer
Indikation)
Bitte Medikament und Tagesdosis in mg oder ml
angeben
(z.B. Fluanxol 2%, 50 ml alle 14d) - 1 pro Zeile
(aus somatischer Indikation)
Entlassungsmedikation (aus
psychiatrischer Indikation)
Bitte Medikament und Tagesdosis in mg oder ml
angeben
EKG
QTC-Zeit in Sekunden:
sec
Patienten Gewicht
Gewicht in KG
Probleme in der Psychotherapie
Check all that apply
Keine / Entfällt (1)
Mangelnde Änderungsmotivation (2)
Verschlechterung der Symptomatik (3)
Abbruch (durch Therapeut) aus anderen
Gründen: (4)
Sonstige (bitte angeben): (5)
Weiterbehandlung
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(Teil-)stationäre Weiterbehandlung durch:
eigenständige Tagesklinik (1)
nichtstationäre Behandkung (2)
andere psychatrische Klinik  (3)
stationäre Einrichtung für Suchtkranke
(4)
psychotherapeutische/ -somatische
Klinik (5)
Sonsitges (6)
unbekannt/unklar (7)
Weiterversorgung durch
(Mehrfachnennung möglich)
Keine / Unzutreffend (1)
Berufliche Rehabilitation, amb.
Arbeitstraining (2)
Betreute Wohnform (Heim, WG, o.ä.) (3)
Forensik (4)
Tagesstätte (z.B. psychiatr.,
Altentagesstätte) (5)
Sonstiges (6)
Unbekannt / Unklar (7)
Ambulante Nachbetreuung /
Weiterbehandlung durch:
(Mehrfachnennung möglich)
Keine
Hausarzt
Nein (1)
Ja, Kontakt aufgenommen  (2)
Ja, kein Kontakt aufgenommen (3)
Psychiater
Nein (1)
Ja, Kontakt aufgenommen  (2)
Ja, kein Kontakt aufgenommen (3)
Ärztl./Psychol.
Psychotherapeut
Nein (1)
Ja, Kontakt aufgenommen  (2)
Ja, kein Kontakt aufgenommen (3)
Eigene Ambulanz /
Poliklinik
Nein (1)
Ja, Kontakt aufgenommen  (2)
Ja, kein Kontakt aufgenommen (3)
Andere psychiatrische
Ambulanz
Nein (1)
Ja, Kontakt aufgenommen  (2)
Ja, kein Kontakt aufgenommen (3)
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Sozialpsychiatrischer
Dienst
Nein (1)
Ja, Kontakt aufgenommen  (2)
Ja, kein Kontakt aufgenommen (3)
Beratungsstelle
Nein (1)
Ja, Kontakt aufgenommen  (2)
Ja, kein Kontakt aufgenommen (3)
Selbsthilfegruppen / Laiendienste
Nein (1)
Ja, Kontakt aufgenommen  (2)
Ja, kein Kontakt aufgenommen (3)
Ambulanter Pflegedienst
Nein (1)
Ja, Kontakt aufgenommen  (2)
Ja, kein Kontakt aufgenommen (3)
Sonstige
Nein (1)
Ja, Kontakt aufgenommen  (2)
Ja, kein Kontakt aufgenommen (3)
Unbekannt
Nein (1)
Ja, Kontakt aufgenommen  (2)
Ja, kein Kontakt aufgenommen (3)
Psychatrische Entlassungsdiagnosen
ICD-10
DSM-IV
Somatische Entlassungsdiagnosen
Clinical Global Impression
Schweregrad der Krankheit
nicht beurteilbar (0)
Patient ist berhaupt nicht kran (1)
Patient ist ein Grenzfall psychiatrischer
Erkrankungen (2)
Patient ist nur leicht krank (3)
Patient ist mig krank (4)
Patient ist deutlich krank (5)
Patient ist schwer krank (6)
Patient gehrt zu den extrem schwer
Kranken (7)
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Clinical Global Impression Scale of
Change (CGI-C)
Gesamtbeurteilung der Zustandsänderung
nicht beurteilbar (0)
Patient ist berhaupt nicht krank (1)
Patient ist ein Grenzfall psychiatrischer
Erkrankungen (2)
Patient ist nur leicht krank (3)
Patient ist mig krank (4)
Patient ist deutlich krank (5)
Patient ist schwer krank (6)
Patient gehrt zu den extrem schwer
Kranken (7)
Therapeutische Wirksamkeit (gewünschte
Arzneiwirkungen
nicht Beurteilbar (0)
umfassende Besserung. Vollständige
oder fast vollständige (1)
deutliche Besserung. Teilweise
Remission der Symptome (2)
leichte Besserung. Eine weitere
Behandlung des Patienten ist (3)
Zustand unverändert oder verschlechtert
(4)
dennoch nötig (6)
Unerwünschte Wirkungen (Therapie-Risiken)
nicht beurteilbar (0)
Keine (1)
Beeinträchtigen den Patienten nicht
wesentlich (2)
Beeinträchtigen den Patienten
wesentlich (3)
Überwiegen die therapeutische
Wirksamkeit (4)
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Bladder Cancer CALGB 90104
NCT00014534
CALGB: 90104 Chemotherapy Dose Form
Combination Chemotherapy in Treating Patients With
Bladder Cancer
NCT00014534
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=BE1C0B11-
7B76-737C-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/11654
Chemotherapy Dose Form Bladder
Cancer (CALGB 90104)
Chemotherapy Dose Form
CALGB Form
CALGB Study No.
CALGB Patient ID
Patient Initials
Participating group
Patient medical record number
Participating group protocol number
Institution/Affiliate
Participating Group Patient ID
Height
>= 0
cm
Body weight
>= 0
kg
Body surface area
>= 0
m²
Cycle number
Date of First Day of Cycle
Last date Drugs administered
1 / 3
Drug Code
Agent Name
Total dose received this cycle
Units
Gram (grams)
International Unit (international units)
Liter (liters)
Microgram (micrograms)
Meter (milligrams)
Milliliter (milliliters)
Unit (units)
Dose Modified?
No (no)
Yes, Planned (i.e., The Treatment Was
Changed According To Protocol
Guidelines) (yes, planned)
Yes, Unplanned (i.e., The Treatment
Change Was Not Part Of Protocol
Guidelines) (yes, unplanned)
If yes, why
cardiotoxicity (cardiotoxicity)
CNS toxicity (CNS toxicity)
GI toxicity (GI toxicity)
hematologic tox (hematologic tox)
hepatic dys (hepatic dys)
infection/fever (infection/fever)
other (other)
PNS toxicity (PNS toxicity)
pulmonary toxicity (pulmonary toxicity)
renal toxicity (renal toxicity)
Dose Delayed?
No (no)
Yes (yes, planned)
Yes (yes, unplanned)
If yes, why
cardiotoxicity (cardiotoxicity)
CNS toxicity (CNS toxicity)
GI toxicity (GI toxicity)
Cycle Was Delayed Due To Hematologic
Toxicity (hematologic tox)
hepatic dys (hepatic dys)
infection/fever (infection/fever)
other (other)
PNS toxicity (PNS toxicity)
pulmonary toxicity (pulmonary toxicity)
Cycle Was Delayed Due To Renal
Toxicity (renal toxicity)
If why, specify (why dose delayed)
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completed by
date form completed
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Registration Breast Cancer CALGB 40503
NCT00601900
Registration Breast Cancer CALGB 40503 NCT00601900
Registration Breast Cancer CALGB 40503 REGISTRATION
WORKSHEET - 2551888v1.0 NCT00601900
CALGB 40503 REGISTRATION WORKSHEET
Tamoxifen or Letrozole With or Without Bevacizumab in
Treating Women With Stage III or Stage IV Breast Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=24089B14-
3CCA-485C-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11655
Registration Breast Cancer CALGB
40503 NCT00601900
Header Module
Lead Institution*
Inst/Affiliate*
CALGB Patient ID*
Physician of Record*
Participating Group*
Protocol Administration
IRB Approval Date*
MM DD YYYY
Date Informed Consent Signed*
MM DD YYYY
Projected Start Date of Treatment (MM DD
YYYY)*
HIPAA Authorization Date (MM DD YYYY)*
Contact Person at Institution*
Phone*
Fax*
Patient Demographics/pre-treatment
Characteristics
Patient Initials (Last, First Middle)*
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Patient Date of Birth*
MM.DD.YYYY
Patient Social Security Number*
Patient Hospital No.*
Gender*
Female (F)
Male (M)
Race (Mark all that apply)*
A Person Having Origins In Any Of The
Original Peoples Of North And South
America (including Central America),
And Who Maintains Tribal Affiliation Or
Community Attachment. (American
Indian or Alaska Native)
A Person Having Origins In Any Of The
Original Peoples Of The Far East,
Southeast Asia, Or The Indian
Subcontinent Including, For Example,
Cambodia, China, India, Japan, Korea,
Malaysia, Pakistan, The Philippine
Islands, Thailand, And Vietnam. (Asian)
A Person Having Origins In Any Of The
Black Racial Groups Of Africa. Terms
Such As "haitian" Or "negro" Can Be
Used In Addition To "black Or African
American." (Black or African American)
A Person Having Origins In Any Of The
Original Peoples Of Hawaii, Guam,
Samoa, Or Other Pacific Islands. (Native
Hawaiian or other Pacific Islander)
Could Not Be Determined Or Unsure
(Unknown)
A Person Having Origins In Any Of The
Original Peoples Of Europe, The Middle
East, Or North Africa. (White)
Ethnicity (Mark one)*
A Person Of Mexican, Puerto Rican,
Cuban, Central Or South American Or
Other Spanish Culture Or Origin,
Regardless Of Race. (Hispanic or Latino)
A Person Not Meeting The Definition For
Hispanic Or Latino. (Not Hispanic or
Latino)
Could Not Be Determined Or Unsure
(Unknown)
Patient Demographics/pre-treatment
Characteristics2
Performance Status (ECOG/Zubrod scale)*
Fully Active, Able To Carry On All Pre-
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disease Performance Without
Restriction. (0)
Restricted In Physically Strenuous
Activity But Ambulatory And Able To
Carry Out Work Of A Light Or Sedentary
Nature, E.g., Light Housework, Office
Work. (1)
Ambulatory And Capable Of All Selfcare
But Unable To Carry Out Any Work
Activities. Up And About More Than 50%
Of Waking Hours. (2)
Capable Of Only Limited Selfcare,
Confined To Bed Or Chair More Than
50% Of Waking Hours. (3)
Completely Disabled. Cannot Carry On
Any Selfcare. Totally Confined To Bed Or
Chair. (4)
Dead (5)
Height*
cm
Body weight*
>= 0
kg
Body surface area*
>= 0
m²
Disease (Advanced Breast Cancer)*
Stage (IIIB IV)*
Method of Payment (Adminstration USA only
Mark one)*
Medicaid (Medicaid)
Medicaid And Medicare (Medicaid and
Medicare)
Medicare (Medicare)
Medicare And Private Insurance
(Medicare and Private Insurance)
Military Sponsored (including Champus
& Tricare) (Military Sponsored (including
CHAMPUS & TRICARE))
No Means Of Payment (no Insurance)
(No means of payment (no insurance))
Other (Other)
Private Insurance (Private Insurance)
Self Pay (no Insurance) (Self Pay (No
Insurance))
Unknown (Unknown)
Veterans Sponsored (Veterans
Sponsored)
Patient Zip Code*
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Country of Residence (if not USA)*
Certification Of Eligibility And Protocol
Design
In the opinion of the investigator, is the patient
eligible?*
Yes
No
Stratification Factors*
Planned endocrine therapy*
Letrozole (Letrozole)
Tamoxifen (Tamoxifen)
Disease Free Interval (months from initial
diagnosis to first progression)*
<= 24 Months (<= 24 months)
> 24 Months (> 24 months)
Is measurable disease present?*
Yes
No
Assigned Treatment Arm*
Kit number*
Initial Patient Consent For Specimen Use
Patient's Initial Consent given for specimen use
for research on the patient's cancer?*
Yes
No
Patient's initial consent given for specimen use
for genetic research relating to the study
treatment*
Yes
No
Patient's Initial Consent given for specimen kept
for future use in research to learn about, prevent,
or treat cancer*
Yes
No
Patient's initial consent given for specimen(s)
may be kept for use in research to learn about,
prevent, or treat other health problems (for
example:
diabetes, Alzheimer's disease, or heart disease)*
Yes
No
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Patient's initial consent given for further contact to
participate in research on future studies*
Yes
No
Registration Information
CALGB Patient ID*
Registration Date (MM DD YYYY)*
Participating Group Patient ID*
Registrar's Signature*
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VIDE course Ewing Study NCT00824083
EWING 2008, EudraCT 2008-003658-13,
http://clinicaltrials.gov/ct2/show/NCT00824083
All rights reserved. Please visit https://medical-data-
models.org/forms/11658
VIDE course Ewing Study
NCT00824083
Body dimensions
Größe
>= 0
cm
Gewicht
>= 0
kg
Körperoberfläche
>= 0
m²
Körperoberfläche berechnet
>= 0
m²
Patient < 1 Jahr oder < 10 kg
Ja
Nein
VIDE course
Tag 1 dieses Kurses*
Kurs-Nr. (bitte Hinweis lesen!)*
Verzögerung >5 Tage
Nein (0)
Ja, wegen Toxizität des vorhergehenden
Kurses (1)
Ja, aus anderen Gründen (2)
Gleichzeitige Radiotherapie*
Nein (0)
Ja (1)
Protokollabweichung/-modifizierung in diesem
Kurs*
Nein (0)
Ja (1)
Schedule deviation CTC-Code
Grund für Protokollabweichung/-modifizierung
Problem der Medikation (0)
Allgemeinzustand (1)
Post-Transplantations-Kurs (102)
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Arzt-/Klinische Entscheidung (nur
verwenden, wenn kein anderer Code
zutrifft!) (103)
Post Amputation (104)
Tox. Hämoglobin (11)
Tox. Leukozyten (12)
Tox. Granulozyten (13)
Tox. Thrombozyten (14)
Tox. Infektion (21)
Tox. Fieber (22)
Tox. Stomatitis (31)
Tox. Erbrechen (32)
Tox. Diarrhoe (33)
Tox. Hautveränderungen (40)
Tox. Kreatinin (51)
Tox. Proteinurie (52)
Tox. Hämaturie (53)
Tox. Glomeruläre Filtrationsrate (GFR)
(54)
Tox. Tubuläre Phosphatreabsorption (55)
Tox. Bilirubin (61)
Tox. SGOT/SGPT (62)
Tox. Herzfunktion (71)
Tox. ECHO: LV-SF (72)
Tox. Zentrale Neurotoxizität (81)
Tox. Periphere Neurotoxizität (82)
Tox. Sonstige Toxizität (90)
Technische Probleme (93)
Planungsprobleme (94)
Patienten-/Elternablehnung (95)
Zu geringes Gewicht/zu jung (96)
Fehler (97)
Mobilisationskurs (98)
Radiotherapie (99)
VIDE adminstration of chemotherapy
Vincristin (VCR) kumulative Gesamtdosis pro
Kurs*
mg
Vincristin (VCR) kumulative Gesamtdosis pro
Kurs lt. Protokoll*
mg
Ifosfamid (IFO) kumulative Gesamtdosis pro
Kurs*
mg
Ifosfamid (IFO) kumulative Gesamtdosis pro Kurs
lt. Protokoll*
mg
Doxorubicin (DOXO) kumulative Gesamtdosis pro
Kurs*
mg
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Doxorubicin (DOXO) kumulative Gesamtdosis pro
Kurs lt. Protokoll*
mg
Etoposid (ETO) kumulative Gesamtdosis pro
Kurs*
mg
Etoposid (ETO) kumulative Gesamtdosis pro
Kurs lt. Protokoll*
mg
CYC statt IFO*
Nein (0)
Ja (1)
Sonstige Zytostatika-Substitution*
Nein (0)
Ja (1)
VIDE adminstration of CYC
Cyclophosphamid (CYC) kumulative
Gesamtdosis pro Kurs*
mg
Cyclophosphamid (CYC) kumulative
Gesamtdosis pro Kurs lt. Protokoll*
mg
VIDE Other drug substitution
Generischer Wirkstoffname*
Aclarubicin (1)
Erwinia-Asparaginase (NSC-106977,
Porton Asparaginase) (10)
PEG-ASP (11)
Azacytidine (12)
Carmustine (BCNU, 1,3-bis(2-
chloroethyl)-l-nitrosourea) (13)
Bleomycin (14)
Antibody 14G2a (14G2a)
Busulfan (Busulphan, Busulfanum,
Myelosan, BSF) (15)
Carboplatin (CBDCA, JM8, NSC
241240) (16)
Lomustine (17)
Cladribine (CdA, 2-CdA, 2-chloro-2'-
deoxyadenosine, NSC-105014-F) (18)
Chlorambucil (Chlorambucilum, NSC-
3088, WR-139013, Chlorbutinum) (19)
Nimustine (2)
Cyclophosphamide (Cyclo, CPA, CPM,
CTX, CYC, CYT) (20)
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Ciclosporin (Cyclosporin) (21)
Cisplatin, (Cis-platinum, cis-
diamminedichloroplatinum, CDDP, DDP,
CIS, Platinum) (22)
Dexamethasone (23)
Daunorubicin (daunomycin, DNR,
rubidomycin) (24)
Doxorubicin (Adriamycin, Hydroxyl
daunorubicin, Dox, Adria) (25)
Dacarbazine (DIC, Imidazole
carboxamide, dimethyl-triazeno-
imidazole-carboxamide) (26)
Epirubicin (4'-epi-doxorubicin, NSC-
256942, IMI28, epi DX) (27)
Fludarabine (2-F-ara-AMP, FAMP, NSC-
312887, Fludarabine phosphate) (28)
Fluorouracil (5-Fluorouracil, 5FU) (29)
Actinomycin D (Dactinomycin) (3)
G-CSF (30)
GM-CSF (31)
Hydroxyurea (32)
Idarubicin (33)
Interferon ALPHA (34)
Interferon GAMMA (35)
Ifosfamide (36)
Folinic Acid (LV, calcium leucovorin,
calcium folinate, citrovorum factor) (37)
Mechlorethamine (38)
Melphalan (39)
Amsacrine (Acridinyl, Anisidide, m-
AMSA, AMSA, Amsidyl) (4)
Mesna (40)
Mitoxantrone (42)
Mercaptopurine (43)
Methotrexate (44)
Prednisone (45)
Procarbazine (46)
Paclitaxel (47)
Thiotepa (48)
Tioguanine (49)
Cytarabine (Cytosine Arabinoside, Ara-
C, Arabinosylcytosine) (5)
Trofosfamide (50)
Vinblastine (51)
Vincristine (52)
Vindesine (53)
Teniposid (54)
Etoposide (VP-16, VP-16-213, EPEG,
EPE, epipodophyllotoxin) (55)
Daunoxome (56)
Rasburicase (57)
Rituximab (58)
Budesonide (59)
Asparaginase (L-asparaginase,
Colaspase, L-ASP, Crasnitin, Elspar) (6)
Immunglobuline (human) (60)
Treosulfan (61)
Alemtuzumab (62)
Coli Asparaginase (9)
Co-trimoxazol (93)
4 / 5
VIDE course Ewing Study NCT00824083
Hydrocortisone (94)
Anderes (999)
Antithymozyten globuline (ATG)
Tretinoin (ATRA) (ATRA)
Beclomethasone (BEC)
Antibody ch14.18 (CH1418)
Epoetin alfa (Erythropoetin) (ERYPOa)
Epoetin beta (Erythropoetin) (ERYPOb)
Etanercept (ETAN)
Tacrolimus (FK506)
Interleukin 1 (IL1)
Interleukin 12 (IL12)
Interleukin 13 (IL13)
Interleukin 2 (IL2)
Interleukin 3 (IL3)
Interleukin 4 (IL4)
Interleukin 6 (IL6)
Interleukin 7 (IL7)
Interleukin 8 (IL8)
Mitomycin (MIT)
Mycophenolat (MMF)
Monoclonal AB (MonoAB)
Muromonab (OKT3)
Imatinib (STI571)
Topotecan (TOPO)
Falls anderes Generikum, Name*
Kumulative Gesamtdosis pro Kurs*
mg
Supportive drug treatment
G-CSF/GM-CSF*
Nein (0)
Ja (1)
Sonstige Zytokintherapie (z.B. EPO)*
Nein (0)
Ja (1)
Sonstiges Zytokin*
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Registration Worksheet Breast Cancer
Z1041 NCT00513292
Z1041: Registration Worksheet NCT00513292
Combination Chemotherapy and Paclitaxel Plus
Trastuzumab in Treating Women With Palpable Breast
Cancer That Can Be Removed by Surgery
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=211E7BC7-
C479-7160-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11659
Registration Worksheet Breast
Cancer Z1041 NCT00513292
Header Module
Visit
Baseline (Baseline)
Patient ID (Pt. ID issued during registration or
previously issued patient ID)
First
Middle
Last
Institution No.
Institution Name
Registration Date
Has patient previously been registered to an
ACOSOG study
Yes
No
Coordinating Group Protocol Number
Patient Information
Date of Birth
Gender
Female (Female)
Male (Male)
Race (Mark all that apply)
A Person Having Origins In Any Of The
Original Peoples Of North And South
America (including Central America),
And Who Maintains Tribal Affiliation Or
Community Attachment. (American
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Indian or Alaska native)
A Person Having Origins In Any Of The
Original Peoples Of The Far East,
Southeast Asia, Or The Indian
Subcontinent Including, For Example,
Cambodia, China, India, Japan, Korea,
Malaysia, Pakistan, The Philippine
Islands, Thailand, And Vietnam. (Asian)
A Person Having Origins In Any Of The
Black Racial Groups Of Africa. Terms
Such As "haitian" Or "negro" Can Be
Used In Addition To "black Or African
American." (Black or African American)
A Person Having Origins In Any Of The
Original Peoples Of Hawaii, Guam,
Samoa, Or Other Pacific Islands. (Native
Hawaiian or other Pacific Islander)
Could Not Be Determined Or Unsure
(Unknown)
A Person Having Origins In Any Of The
Original Peoples Of Europe, The Middle
East, Or North Africa. (White)
Ethnicity (Mark only one)
A Person Of Mexican, Puerto Rican,
Cuban, Central Or South American Or
Other Spanish Culture Or Origin,
Regardless Of Race. (HISPANIC OR
LATINO)
A Person Not Meeting The Definition For
Hispanic Or Latino. (NOT HISPANIC OR
LATINO)
Could Not Be Determined Or Unsure
(UNKNOWN)
Method of payment (Mark all that apply)
Medicaid (Medicaid)
Medicaid And Medicare (Medicaid and
medicare)
Medicare (Medicare)
Medicare And Private Insurance
(Medicare and private insurance)
Military Or Veterans Sponsored Nos
(Military or veterans sponsored NOS)
Military Sponsored (including Champus
& Tricare) (Military sponsored)
No Means Of Payment (no Insurance)
(No means of payment)
Other (Other)
Private Insurance (Private insurance)
Self Pay (no Insurance) (Self pay)
Veterans Sponsored (Veterans
sponsored)
Other, specify
Body weight
>= 0
kg
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Height
>= 0
cm
Patient Zip Code (USA)
Postal code (Canada)
Other Country Postal Code (Other)
Country of Residence
Date Informed Consent Signed
HIPAA Authorization form
Included In Study Informed Consent
(Included in Study Informed Consent)
HIPAA Authorization Date (If signed as a
separate form,)
Consent
Consent for correlative studies and specimen
banking signed
Yes
No
Date signed (If yes,)
Inclusion Criteria
Inclusion Criteria
Alkaline Phosphatase Must Be <= 2.5 X
Uln For The Lab (Alkaline phosphatase
must be <= 2.5 x ULN for the lab)
Anc Must Be <= 1200/mm^3 (ANC must
be <= 1200/mm^3)
Ast Must Be <= 1.5 X Uln For The Lab
(AST must be <= 1.5 x ULN for the lab)
Breast Cancer Must Be Determined To
Be Her2-positive Prior To Study Entry
(Breast cancer must be determined to be
HER2-positive prior to study entry)
Breast Tumor Must Be Palpable And
Measure >= 2 Cm According To Recist
Criterion (Breast tumor must be palpable
and measure >= 2 cm according to
RECIST criterion)
Diagnosis Of Invasive Adenocarcinoma
Of Breast Must Have Been Made By
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Core Needle Biopsy (Diagnosis of
invasive adenocarcinoma of breast must
have been made by core needle biopsy)
If Patient Had Skeletal Pain Or Alkaline
Phosphatase > Uln But <= 2.5 X Uln,
Bone Scan Must Show No Metastatic
Disease (If patient had skeletal pain or
alkaline phosphatase > ULN but <= 2.5 x
ULN, bone scan must show NO
metastatic disease)
Patient Must Be Female And 18 Years Of
Age Or Older (Patient must be female
and 18 years of age or older)
Patient Must Have An Ecog/ Zubrod
Performance Status Of <= 1 (Patient
must have an ECOG/ Zubrod
performance status of <= 1)
Platelet Count Must Be >=100,000
/mm^3 (Platelet count must be
>=100,000/mm^3)
Serum Creatinine Must Be <= Uln For
The Lab (Serum creatinine must be <=
ULN for the lab)
Total Bilirubin Must Be <= Uln For The
Lab (Total bilirubin must be <= ULN for
the lab)
Within 3 Months Prior To Study Entry,
Patient Must Have A Baseline Left
Ventricular Ejection Fraction (lvef)
Measured By Muga Scan >= 55 (Within
3 months prior to study entry, patient
must have a baseline left ventricular
ejection fraction (LVEF) measured by
MUGA scan >= 55)
Exclusion Criteria
Exclusion Criteria
Patient Had Prior Therapy With
Anthracyclines Or Taxanes For Any
Malignancy (Patient had prior therapy
with anthracyclines or taxanes for any
malignancy)
Patient Has Cardiac Disease That Would
Preclude The Use Of Epirubicin Or
Trastuzumab (Patient has cardiac
disease that would preclude the use of
epirubicin or trastuzumab)
Patient Has Definitive Clinical Or
Radiological Evidence Of Metastatic
Disease (Patient has definitive clinical or
radiological evidence of metastatic
disease)
Patient Has Had Administration Of Any
Investigational Agents Within 30 Days
Prior To Study Entry (Patient has had
administration of any investigational
agents within 30 days prior to study
entry)
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Patient Has Had Surgical Axillary
Staging Procedure Prior To Study Entry
(excluding Fna Of Axillary Nodes)
(Patient has had surgical axillary staging
procedure prior to study entry (excluding
FNA of axillary nodes))
Patient Has History Of Ipsilateral Dcis
Treated With Radiation Therapy (Patient
has history of ipsilateral DCIS treated
with radiation therapy)
Patient Has Ipsilateral Cn2b Or Cn3
Disease (Patient has ipsilateral cN2b or
cN3 disease)
Patient Has Non-malignant Systemic
Disease That Would Preclude Treatment
With Either Regimen (Patient has non-
malignant systemic disease that would
preclude treatment with either regimen)
Patient Has Prior History Of Invasive
Breast Cancer (Patient has prior history
of invasive breast cancer)
Patient Has Psychiatric Or Addictive
Disorder Or Any Other Condition That, In
The Investigator?s Opinion, Precludes
Patient From Meeting Eligibility
Requirements (Patient has psychiatric or
addictive disorder or any other condition
that, in the investigator?s opinion,
precludes patient from meeting eligibility
requirements)
grade 2 as defined by CTCAE
v3.0=Patient Has Sensory/ Motor
Neuropathy >= Grade 2 As Defined By
Ctcae V3.0 (Patient has sensory/ motor
neuropathy >)
Patient Has Synchronous Invasive
Breast Cancer (Patient has synchronous
invasive breast cancer)
Patient Has Tumor Clinically Staged As
T4 (Patient has tumor clinically staged as
T4)
Patient Is Receiving Therapy With Any
Hormonal Agent (excluding Medication
Discontinued Before Study Entry)
(Patient is receiving therapy with ANY
hormonal agent (excluding medication
discontinued before study entry))
Patient Of Child-bearing Potential Does
Not Have Negative Urine/ Serum
Pregnancy Test Within 2 Weeks Of
Registration Or Patient Is Breast Feeding
(Patient of child-bearing potential does
not have negative urine/ serum
pregnancy test within 2 weeks of
registration or patient is breast feeding)
Patient Received Treatment For This
Breast Cancer Prior To Study Entry
(excluding Hormonal Therapy That
Ended Before Study Entry) (Patient
received treatment for this breast cancer
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prior to study entry (excluding hormonal
therapy that ended before study entry))
Eligibility Assessment
Patient meets all eligibility criteria
Yes
No
In the opinion of the investigator, is the patient
eligible?
Yes
No
Assessment Date
Randomization (Please indicate "arm" assigned
as a result of randomization:)
Neoadjuvant Treatment With Fec-75
12w, Followed By Paclitaxel And
Trastuzumab, 12w, Surgery And
Trastuzumab (Neoadjuvant treatment
with FEC-75 12W, followed by Paclitaxel
and Trastuzumab, 12W, surgery and
Trastuzumab)
Neoadjuvant Treatment With Paclitaxel
12w And Trastuzamab 13w Followed By
Fec-75 And Trastuzumab, 12w, Surgery
And Trastuzumab (Neoadjuvant
treatment with Paclitaxel 12W and
Trastuzamab 13W followed by FEC-75
and Trastuzumab, 12W, surgery and
Trastuzumab)
Baseline Performace Status (ECOG/modified
Zubrod scale)
Fully Active, Able To Carry On All Pre-
disease Performance Without Restriction
(0)
Restricted In Physically Strenuous
Activity But Ambulatory And Able To
Carry Out Work Of A Light Or Sedentary
Nature, E.g., Light Housework, Office
Work. (1)
Ambulatory And Capable Of All Selfcare
But Unable To Carry Out Any Work
Activities. Up And About More Than 50%
Of Waking Hours. (2)
Capable Of Only Limited Selfcare,
Confined To Bed Or Chair More Than
50% Of Waking Hours. (3)
Completely Disabled. Cannot Carry On
Any Selfcare. Totally Confined To Bed Or
Chair. (4)
Method of Evaluation
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Method of Evaluation
Contralateral Mammogram (Contralateral
mammogram)
Ipsilateral Axilla Ultrasound (Ipsilateral
Axilla Ultrasound)
Ipsilateral Mammogram (Ipsilateral
mammogram)
Muga Scan (MUGA scan)
Not done
Image date
Left Ventricular Ejection Fraction from MUGA
(LVEF)
%
MUGA LLN (for LVEF)
%
Left Ventricular Ejection Fraction from ECHO
(LVEF)
%
ECHO LLN (for LVEF)
%
Pregnancy Test
Pregnancy test done
Yes
No
Reason pregnancy test not performed
Other (Other)
Postmenopausal (Post-menopausal)
Other, specify
Type of pregnancy test
Serum (Serum)
Urine (Urine)
Date of pregnancy test
Result
Negative (negative)
Positive (positive)
Primary Tumor Biopsy
Method of biopsy
Core Needle Biopsy (Core needle
biopsy)
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Fna (FNA)
Receptor Status, ER (mark one)
Negative (Negative)
Positive (Positive)
Marker Test Method (mark all that apply)
Fluorescence In Situ Hybridization (fish)
(Fluorescence in situ hybridization
(FISH))
Immunohistochemistry (ihc)
(Immunohistochemistry (IHC))
HER-2/neu status (mark one)
Negative (Negative)
Positive (Positive)
PgR Status (mark one)
Negative (Negative)
Positive (Positive)
Histologic Grade
Well Differentiated (Grade I (low))
Moderately Differentiated (Grade II
(intermediate))
Poorly Differentiated (Grade III (high))
Histologic Type
Ductal (Ductal)
Lobular (Lobular (pure > or =90%))
Other Specify (Other)
Other specify
Clinical Stage
Clinical T Stage
No Evidence Of Primary Tumor (T0)
Tumor 2 Cm Or Less In Greatest
Dimension (T1)
Tumor More Than 2 Cm But Not More
Than 5 Cm In Greatest Dimension (T2)
Tumor More Than 5 Cm In Greatest
Dimension (T3)
Tumor Of Any Size With Direct Extension
To (a) Chest Wall Or (b) Skin, Only As
Described Below (T4)
Extension To Chest Wall (T4a)
Edema (including Peau D'orange) Or
Ulceration Of The Skin Of The Breast Or
Satellite Skin Nodules Confined To The
Same Breast (T4b)
Both T4a And T4b (T4c)
Clinical N Stage
No Regional Lymph Node Metastasis
(N0)
Metastasis To Movable Ipsilateral Axillary
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Lymph Node(s) (N1)
Metastasis To Ipsilateral Axillary Lymph
Node(s) Fixed To One Another Or To
Other Structures (N2)
Metastasis To Ipsilateral Mammary
Lymph Node(s) (N3)
Is there a breast lesion >= 2 cm
No (No)
No And Largest Nodal Metastasis < 2
Cm (No and largest nodal metastasis < 2
cm)
No And Largest Nodal Metastasis >= 2
Cm (No and largest nodal metastasis >=
2 cm)
Yes (Yes)
Laboratory Values
Date Specimen collected (if multiple draw dates,
enter first and last)
WBC
ANC
Hemoglobin
g/dL
Platelet count
Total Bilirubin
1000/uL
Total bilirubin (mg/dl), ULN
mg/dL
SGOT (AST)
U/L
SGOT (AST) ULN
Alkaline Phosphatase
Alkaline Phosphatase ULN
Serum creatinine
mg/dL
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Creatinine ULN
History
Hypertension
Yes
No
Smoking
Currently Smoking (Currently smoking)
Never Smoked (Never smoked)
Smoked In The Past (Smoked in the
past)
Cardiac Disease History
Yes
No
Cardiovascular Disease
Yes
No
Diabetes
Yes
No
Hyperlipidemia
Yes
No
Has the patient had a prior history of breast
cancer requiring radiation
Yes
No
Location of tumor (If yes,)
Left Breast: C47855 (Left Breast)
Right Breast: C47856 (Right Breast)
Footer
Did the Investigator sign the CRF indicating
review of all data and certifying data are accurate
and complete to the best of their knowledge
Yes
No
Date of Investigator Signature
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Treatment Form Bladder Cancer CALGB
90601 NCT00942331
CALGB 90601: Treatment Form
Gemcitabine Hydrochloride and Cisplatin With or Without
Bevacizumab in Treating Patients With Advanced Urinary
Tract Cancer
NCT00942331 
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=65402ABE-
C4AA-902C-E040-BB89AD435D5A
All rights reserved. Please visit https://medical-data-
models.org/forms/11660
Treatment Form Bladder Cancer
CALGB 90601 NCT00942331
Header
CALGB Form
CALGB Study No
CALGB Patient ID
Cycle Start Date (MM DD YYYY)
Cycle end date (MM DD YYYY)
Patient Initials (Last, First Middle)
Patient Hospital No.
Institution/Affiliate
Participating Group
Participating Group Study No.
Participating Group Patient ID
Are data amended
Yes
No
Patient has withdrawn consent for clinical follow-
up
Yes
No
Patient has withdrawn consent for survival follow-
up
Yes
No
Withdrawn consent date
1 / 5
Completed by (Last name, First name)
Date form completed (MM DD YYYY)
Clinical Data
Current Cycle Number
Height
>= 0
cm
Body weight
>= 0
kg
Body surface area
>= 0
m²
Gemcitabine
Agent Name
Agent Total Dose (this cycle)
Dose modification
Dose Delayed (Dose delayed)
Dose Delayed And Reduced (Dose
delayed and reduced)
Dose Held (Dose held)
Dose Reduced (Dose reduced)
Drug Discontinued (Drug discontinued)
No Dose Modification (No dose
modification)
Dose Modification Reason
Cardiotoxicity (Cardiotoxicity)
Change In Bsa (Change in BSA)
Cns Toxicity (CNS toxicity)
Dosing Error (Dosing error)
Gi Toxicity (GI toxicity)
Hematologic Toxicity (Hematologic
toxicity)
Hepatic Dysfunction (Hepatic
dysfunction)
Hypersensitivity (Hypersensitivity)
Infection/fever (Infection/fever)
Other (Other)
Patient Refusal/noncompliance (Patient
refusal/noncompliance)
Pns Toxicity (PNS toxicity)
Pulmonary Toxicity (Pulmonary toxicity)
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Renal Toxicity (Renal toxicity)
Scheduling (Scheduling)
If dose modification reason = 99, specify
Cisplatin
Agent Name
Agent Total Dose (this cycle)
Dose modification
Dose Delayed (Dose delayed)
Dose Delayed And Reduced (Dose
delayed and reduced)
Dose Held (Dose held)
Dose Reduced (Dose reduced)
Drug Discontinued (Drug discontinued)
No Dose Modification (No dose
modification)
Dose Modification Reason
Cardiotoxicity (Cardiotoxicity)
Change In Bsa (Change in BSA)
Cns Toxicity (CNS toxicity)
Dosing Error (Dosing error)
Gi Toxicity (GI toxicity)
Hematologic Toxicity (Hematologic
toxicity)
Hepatic Dysfunction (Hepatic
dysfunction)
Hypersensitivity (Hypersensitivity)
Infection/fever (Infection/fever)
Other (Other)
Patient Refusal/noncompliance (Patient
refusal/noncompliance)
Pns Toxicity (PNS toxicity)
Pulmonary Toxicity (Pulmonary toxicity)
Renal Toxicity (Renal toxicity)
Scheduling (Scheduling)
If dose modification reason = 99, specify
Bevacizumab/placebo
Agent Name
Administered
Yes
No
Dose modification
Dose Delayed (Dose delayed)
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Dose Delayed And Reduced (Dose
delayed and reduced)
Dose Held (Dose held)
Dose Reduced (Dose reduced)
Drug Discontinued (Drug discontinued)
No Dose Modification (No dose
modification)
Dose Modification Reason
Cardiotoxicity (Cardiotoxicity)
Change In Bsa (Change in BSA)
Cns Toxicity (CNS toxicity)
Dosing Error (Dosing error)
Gi Toxicity (GI toxicity)
Hematologic Toxicity (Hematologic
toxicity)
Hepatic Dysfunction (Hepatic
dysfunction)
Hypersensitivity (Hypersensitivity)
Infection/fever (Infection/fever)
Other (Other)
Patient Refusal/noncompliance (Patient
refusal/noncompliance)
Pns Toxicity (PNS toxicity)
Pulmonary Toxicity (Pulmonary toxicity)
Renal Toxicity (Renal toxicity)
Scheduling (Scheduling)
If dose modification reason = 99, specify
Was treatment permanently discontinued during
this cycle (Gemcitabine/Cisplatin)
Yes
No
Reason Treatment Ended (Gemcitabine/Cisplatin)
Adverse Event/side Effects/complications
(Adverse Event/Side
Effects/Complications)
Alternative Therapy (Alternative therapy)
Death On Study (Death on study)
Disease Progression, Relapse During
Active Treatment (Disease progression,
relapse during active treatment)
Other (Other)
Patient Off-treatment For Other
Complicating Disease (Patient off-
treatment for other complicating disease)
Patient Withdrawal Or Refusal After
Beginning Protocol Therapy (Patient
withdrawal/refusal after beginning
protocol therapy)
Patient Withdrawal Or Refusal Before
Beginning Protocol Therapy (Patient
withdrawal/refusal prior to beginning
protocol therapy)
Treatment Completed Per Protocol
Criteria (Treatment completed per
protocol criteria)
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Specify
Total number of cycles completed
(Gemcitabine/Cisplatin)
Last dose date (Gemcitabine/Cisplatin)
Gemcitabine/Cisplatin
Was treatment permanently discontinued during
this cycle (Gemcitabine/Cisplatin)
Yes
No
Reason Treatment Ended (Gemcitabine/Cisplatin)
Adverse Event/side Effects/complications
(Adverse Event/Side
Effects/Complications)
Alternative Therapy (Alternative therapy)
Death On Study (Death on study)
Disease Progression, Relapse During
Active Treatment (Disease progression,
relapse during active treatment)
Other (Other)
Patient Off-treatment For Other
Complicating Disease (Patient off-
treatment for other complicating disease)
Patient Withdrawal Or Refusal After
Beginning Protocol Therapy (Patient
withdrawal/refusal after beginning
protocol therapy)
Patient Withdrawal Or Refusal Before
Beginning Protocol Therapy (Patient
withdrawal/refusal prior to beginning
protocol therapy)
Treatment Completed Per Protocol
Criteria (Treatment completed per
protocol criteria)
Specify
Total number of cycles completed
(Gemcitabine/Cisplatin)
Last dose date (Gemcitabine/Cisplatin)
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On-Study Form Glioma N0577
NCT00626990
On-Study Form Glioma N0577 NCT00626990
Brain and Central Nervous System Tumors NCT00887146
On-Study - North Central Cancer Treatment Group N0577
On-Study Form - 2746076v1.0
Radiation Therapy or Radiation Therapy and Temozolomide
or Temozolomide Alone in Treating Patients With Newly
Diagnosed Anaplastic Glioma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=4C0A6585-
AD37-120A-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11661
On-Study Form Glioma N0577
NCT00626990
Header
Protocol Number
Patient ID
Patient Initials (L F M)
Institution Number
Institution
Are data amended (If yes, highlight amended
areas)
Yes
No
Disease History
Date of onset
Date of Procedure
Maximum Diameter Of Tumor On Pre-
operative Scan
Contrast Enhancement
cm
T2 Abnormality on MRI or Low Attenuation on CT
>= 0
cm
Extent Of Resection
Extent of Resection
1 / 3
Biopsy (Biopsy)
Subtotal (Subtotal)
Total (gross) (Total (gross))
Location Of Primary Neoplasm
Site of Lesion
Basal Ganglia (Basal ganglia)
Brainstem (Brainstem)
Cerebellum (Cerebellum)
Fourth Ventricle (Fourth ventricle)
Frontal Lobe (Frontal)
Hypothalamus (Hypothalamus)
Occipital Lobe (Occipital)
Optic Chiasm (Optic chiasm)
Other, Specify (Other specify)
Parietal Lobe (Parietal)
Temporal Lobe (Temporal)
Thalamus (Thalamus)
Third Ventricle (Third ventricle)
Other specify
Side Of Primary Tumor
Side of Primary Tumor
Bilateral (Bilateral)
Left (Left)
Midline (Midline)
Right (Right)
Multifocal Tumors
Yes
No
Has the patient had any prior cancer diagnosed?
Yes
No
Site of Prior Cancer
Prior Cancer Diagnosis Date
Prior Treatment Regimen Type
Descriptive Factors
Family History of Brain Tumor
Yes
No
Relationship
Sister Brother (Brother or sister)
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Child (Child)
Father (Father)
Mother (Mother)
Other (Other)
Other, specify
Corticosteriods
Yes
No
Anticonvulsants
Yes
No
Height
>= 0
cm
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On-Study Form Brain Metastases
NCT00377156
On-Study - North Central Cancer Treatment Group On-
Study Form - 2467371v1.0
Stereotactic Radiation Therapy With or Without Whole-
Brain Radiation Therapy in Treating Patients With Brain
Metastases
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=104D18F2-
219E-2AE1-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11662
On-Study Form Brain Metastases
NCT00377156
Header
NCCTG Protocol Number
NCCTG Patient ID
Patient Initials (L F M)
Institution
Institution Number
Are data amended (If yes, highlight amended
areas)
Yes
No
Description Of Primary Disease
MedDRA Code (primary tumor site: Metastases
to brain parenchyma)
Disease/history
Primary Site (check one)
Bladder (Bladder)
Breast (breast)
Colorectal (Colorectal)
Gynecologic (Gynecologic)
Kidney (Kidney)
Lung (lung)
Other Specify (other)
Prostate Gland (Prostate)
Sarcoma (Sarcoma)
Skin/melanoma (skin/melanoma)
Other, specify
Neurologic Examination
1 / 2
Cranial nerves (check one)
Abnormal (Abnormal)
Normal (Normal)
Sensation (check one)
Abnormal (Abnormal)
Normal (Normal)
Motor (check one)
Abnormal (Abnormal)
Normal (Normal)
Cerebellar (check one)
Abnormal (Abnormal)
Normal (Normal)
Height
Height
>= 0
cm
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Prestudy Form Colorectal Cancer SWOG
S0303 NCT00070122
Prestudy Form Colorectal Cancer SWOG S0303
NCT00070122
SOUTHWEST ONCOLOGY GROUP S0303 Advance GI
Carcinoma Prestudy Form
Advance GI Carcinoma Prestudy Form - 2166748v3.0
Combination Chemotherapy and Bevacizumab in Treating
Patients With Locally Advanced, Metastatic, or Recurrent
Colorectal Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=BC61D627-
95F1-1025-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/11663
Prestudy Form Colorectal Cancer
SWOG S0303 NCT00070122
Header
SWOG Patient ID
SWOG Study No.
Registration Step
Patient Initials (L, F M)
Institution/Affiliate
Physician (Groups Other than SWOG)
Group Name
Study No.
Pt. ID (Instructions: All dates are MONTH, DAY,
YEAR. Explain any blank fields or blank dates in
the Comments section at the end of the form.
Place an X in appropriate boxes. Circle
AMENDED items in red.)
Patient And Disease Description
Height
>= 0
cm
Body weight
>= 0
kg
Performance Status
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Current Disease Status
Initial Diagnosis (initial)
Recurrence (recurrent)
Current Disease Sites
Bone (bone)
Distant Nodes (distant nodes)
Liver (liver)
Lung (lung/pleura)
Other Abdominal (other abdominal)
Other, Specify (Other, specify)
Primary Site/direct Extension (Primary
site/direct extension)
Regional Nodes (regional nodes)
Other, specify (disease site)
Prior systemic therapy
Yes
No
Prior radiation therapy
Yes
No
Prior surgery
Yes
No
Prior immunotherapy
Yes
No
Notes
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Induction Worksheet Intracranial Germ Cell
Tumors NCT00047320
ACNS0122 Induction Worksheet NCT00047320 
Neoadjuvant Chemotherapy With or Without Second-Look
Surgery Followed by Radiation Therapy With or Without
Peripheral Stem Cell Transplantation in Treating Patients
With Intracranial Germ Cell Tumors
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=BD8F3A15-
A2D2-0385-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/11664
Induction Worksheet Intracranial
Germ Cell Tumors NCT00047320
Header
Institution Name
COG Study No
COG Study No
COG Patient ID
Patient Initials
Today's date
Date worksheet entered into RDE
Treatment period
Reporting Period
Cycle 1 (Cycle 1)
Cycle 2 (Cycle 2)
Cycle 3 (Cycle 3)
Cycle 4 (Cycle 4)
Cycle 5 (Cycle 5)
Cycle 6 (Cycle 6)
Reporting Period start date
Reporting Period end date
Height
>= 0
cm
Body weight
>= 0
kg
Body surface area
1 / 6
>= 0
m²
Tumor Evaluation
Type [imaging studies] (Type of imaging studies:)
Mri (MRI of Brain with gadolinium)
Mri (MRI of Brain without gadolinium)
Mri (MRI of Spine with gadolinium)
Mri (MRI of Spine without gadolinium)
Other, Specify (Other (specify))
Specify [other type of imaging study]
Date
Disease Status
Was the patient's disease status evaluated during
this reporting interval?
Yes
No
Type of response
Complete Response (Complete
Response (CR))
Death Prior To Completion Of Protocol
Criteria (Early death)
Incomplete Response Or Stable
Disesase (Incomplete response/SD)
Less than Partial Response (<PR) (Less
than Partial Response (<PR))
Insufficient Evaluation (Not evaluable)
Partial Response (Partial Response
(PR))
Progressive Disease (Progressive
Disease (PD))
Recurrent Disease (Recurrent Disease)
Stable Disease (Stable Disease)
Date
Comments
Evaluations
Was a Neurologic assessment done?
No (No)
Not done/not available (Not done/not
available)
Unknown (Unknown)
Yes (Yes)
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Was endocrinologic evaluation done?
No (No)
Not done/not available (Not done/not
available)
Unknown (Unknown)
Yes (Yes)
Second Look Surgery
Was second look surgery performed after
Induction cycle 6?
Yes
No
date [second look surgery] (If yes,)
why not? [reason second look surgery not
performed] (If no,)
Other (Other)
Patient Refusal (Parent/Patient refusal)
Patient Was In Radiographic Complete
Response (Patient was in radiographic
complete response)
Surgery Contraindicated (Surgery
contraindicated)
If surgery contraindicated, specify the reason
specify [other reason second look surgery not
performed] (If other,)
Significant Events During This Reporting
Period
Were there any dose modifications or
additions/omissions to protocol treatment?
No (No)
Yes (Yes)
Yes, Planned (i.e., The Treatment Was
Changed According To Protocol
Guidelines) (Yes, planned)
Yes, Unplanned (i.e., The Treatment
Change Was Not Part Of Protocol
Guidelines) (Yes, unplanned)
specify [other reason for dose modifications] (If
due to other reason,)
specify [other reason for dose modifications] (If
due to other reason,)
specify [other reason for dose modifications] (If
due to other reason,)
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Has a new primary cancer or MDS been
diagnosed that has not been previously reported?
Yes
No
Date of diagnosis
Is patient off protocol therapy?
Yes
No
date off [protocol therapy] (If yes,)
Reason Treatment Ended
Adverse Event/side Effects/complications
(Adverse Event/Side
Effects/Complications)
Alternative Therapy (Alternative therapy)
Treatment Completed Per Protocol
Criteria (Completion of protocol therapy.)
Cytogenetic Resistance (Cytogenetic
Resistance)
Death On Study (Death on study)
Decision of the patient?s family to
withdraw the patient from protocol
therapy. (Decision of the patient?s family
to withdraw the patient from protocol
therapy.)
Disease Progression Before Active
Treatment (Disease Progression before
Active Treatment)
Lost To Follow-up (Lost to follow-up)
Disease Progression, Relapse During
Active Treatment (Neuraxis
dissemination during or after
chemotherapy)
Disease Progression, Relapse During
Active Treatment (Neuraxis
dissemination or locally progressive
diseases during or after radiation
therapy.)
Other (Other)
Patient Off-treatment For Other
Complicating Disease (Patient off-
treatment for other complicating disease)
Patient refusal or withdrawal from
therapy. (Patient refusal or withdrawal
from therapy.)
Patient Withdrawal Or Refusal After
Beginning Protocol Therapy (Patient
withdrawal or refusal after beginning
protocol therapy)
Patient Withdrawal Or Refusal Before
Beginning Protocol Therapy (Patient
withdrawal or refusal prior to beginning
protocol therapy)
Patient withdrawn from protocol therapy
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due to physician?s choice. (Patient
withdrawn from protocol therapy due to
physician?s choice.)
Vital Status
Alive (Alive)
Dead (Dead)
Was patient unable to be contacted for current
scheduled follow-up?
Yes
No
Was the patient enrolled on another COG
therapeutic study at the end of the reporting
period?
Yes
No
Did the patient withdraw consent for follow-up at
the end of the reporting period?
Yes
No
Is the patient receiving any non-protocol cancer
therapy not previously reported?
Yes
No
Type [non-protocol treatment] (Types of
Treatment)
Bone Marrow Transplant (Bone Marrow
Transplant)
Chemotherapy (Chemotherapy)
Extensive Radiation (Extensive radiation)
Limited Radiation (Limited radiation)
Other Therapy (Other (specify))
External Beam Radiation (Radiation)
Radiation (nos) (Radiation (NOS))
Surgery (Surgery)
Specify [other type of non-protocol treatment]
Start Date [non-protocol treatment]
End Date [non-protocol treatment]
Description (drug, dose, etc.)
Treatment Plan After This Treatment
Period
What is the patient's treatment plan after
chemotherapy?
Conformal Radiation Therapy (Conformal
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Radiation Therapy)
No Further Therapy (No further therapy)
Other Specify (Other, specify)
Second-look Surgery (Second surgery)
please specify [other treatment plan after
chemotherapy] (If 'Other',)
Toxicities
Category
Type
Code
Grade
Attribution
Definite (Definite)
Possible (Possible)
Probable (Probable)
Unlikely (Unlikely)
Unrelated (Unrelated)
Adverse Drug Experience?
Yes
No
Date Onset
Date of test or evaluation showing toxicity
resolved to eligibility requirement or baseline
check box if not resolved
Comments
Comments
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Prestudy Form Acute Promyelocytic
Leukemia NCT00492856
SOUTHWEST ONCOLOGY GROUP Previously Untreated
Acute Promyelocytic Leukemia Prestudy Form (S0521)
2412866v1.0
Combination Chemotherapy With or Without Gemtuzumab
Followed By Tretinoin, Mercaptopurine, and Methotrexate
or Observation in Treating Patients With Acute
Promyelocytic Leukemia
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=01FDEB64-
5CFB-0063-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11665
Prestudy Form Acute Promyelocytic
Leukemia NCT00492856
Header
SWOG Patient ID
SWOG Study No.
Registration Step
Patient Initials (L, F M)
Institution/Affiliate
Physician (Participating Group:)
Participating Group Name
American College Of Surgeons
Oncology Group (ACOSOG)
American College Of Radiology
Oncologic Imaging Network (ACRIN)
Aids-associated Malignancies Clinical
Trials Consortium (AMC)
Cancer And Leukemia Group B (CALGB)
Children's Oncology Group (COG)
Eastern Cooperative Oncology Group
(ECOG)
European Organization For Research
And Treatment Of Cancer (EORTC)
Gynecologic Oncology Group (GOG)
International Breast Cancer Study Group
(IBCSG)
North American Brain Tumor Consortium
(NABTC)
Nabtt Brain Tumor Consortium (NABTT)
North Central Cancer Treatment Group
(NCCTG)
National Cancer Institute Of Canada
Clinical Trials Group (NCIC)
National Surgical Adjuvant Breast And
Bowel Project (NSABP)
Radiation Therapy Oncology Group
(RTOG)
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Southwest Oncology Group (SWOG)
Participating Group Study No.
Participating Group Patient ID (Instructions: All
dates are MONTH, DAY, YEAR. Explain any
blank fields or blank dates in the Comments
section. Place an X in appropriate boxes. Circle
AMENDED items in red and write AMENDED
across the top of the form.)
Patient Characteristics
Performance Status
Fully Active, Able To Carry On All Pre-
disease Performance Without
Restriction. (0)
Restricted In Physically Strenuous
Activity But Ambulatory And Able To
Carry Out Work Of A Light Or Sedentary
Nature, E.g., Light Housework, Office
Work. (1)
Ambulatory And Capable Of All Selfcare
But Unable To Carry Out Any Work
Activities. Up And About More Than 50%
Of Waking Hours. (2)
Capable Of Only Limited Selfcare,
Confined To Bed Or Chair More Than
50% Of Waking Hours. (3)
Completely Disabled. Cannot Carry On
Any Selfcare. Totally Confined To Bed Or
Chair. (4)
Dead (5)
Risk classification at first registration
Intermediate Risk (intermediate)
Low Risk (low)
Specimen for RT-PCR (Pretreatment)
Bone Marrow (bone marrow)
Peripheral Blood (peripheral blood)
Date of marrow specimen collection
Date of blood specimen collection
Did the patient receive ATRA prior to registration
Yes
No
Date ATRA first given
Number of days of ATRA before registration
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Maximum dose of ATRA before registration
mg/m^2/day
Is patient a woman of childbearing potential
(indicator NO for males)
Yes
No
Has a negative pregnancy test been performed
Yes
No
Date of pregnancy test
Patient And Disease Description
Height
>= 0
cm
Date of Initial Pathologic Diagnosis
Patient Disseminated Intravascular Coagulation
Personal Medical History Indicator
No: C0028423 (No)
Yes, With Bleeding (Yes, with bleeding)
Yes, Without Bleeding (Yes, without
bleeding)
Current Laboratory Values
Date Hematology (Blood) Sample Obtained
Time hematology sample obtained
Hemoglobin
Peripheral Platelet Count
1000/uL
Peripheral Blasts
%
Peripheral WBC Count
1000/uL
Peripheral Promyelocytes
%
Peripheral Neutrophils (%)
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%Bone Marrow Biopsy Date
Marrow Blasts (%)
%
Marrow Cellularity (%)
%
Marrow Promyelocytes (%)
%
Marrow Cellularity Status
Cellularity Status Of Bone Marrow Is
Aplasitc (severely Hypocellular) (Aplastic
(severely hypocellular))
Cellularity Status Of Bone Marrow
Unknown, Procedure Resulted In No
Material To Analyze (Dry tap or
inaspirable)
Cellularity Status Of Bone Marrow Is
Hypercellular (Hypercellular)
Cellularity Status Of Bone Marrow Is
Hypocellular (Hypocellular)
Cellularity Status Of Bone Marrow Is
Normocellular (Normocellular)
Cellularity Status Of Bone Marrow Is
Packed (intensely Hypercellular) (Packed
(intensely hypercellular))
Date of Examination for Extramedullary Disease
Extramedullary Disease Involvement
Gingival Hypertrophy (Gingival
hypertrophy)
Mediastinal Mass (Mediastinal mass)
Other Specify (Other)
Peripheral Nervous System (Peripheral
nervous system)
Skin (Skin (cutaneous))
Other, specify
Comments
Comments
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Prestudy Form Adjuvant Melanoma SWOG
S0201
Southwest Oncology Group S0201 Adjuvant Melanoma
Prestudy Form
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=A8B98176-
F2DC-123A-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/11666
Prestudy Form Adjuvant Melanoma
SWOG S0201
SWOG clinical trial administrative data
SWOG Patient ID
Patient Initials (L, F M)
Institution/Affiliate
Physician (Groups other than SWOG)
Group Name
Study No.
Pt. ID
Patient Characteristics
Height
>= 0
cm
Body weight
>= 0
kg
Body surface area
>= 0
m²
Performance Status
Hla Status
HLA Type
A2+ Only (A2+ only)
Both A2+ And C3+ (both A2+ and C3+)
C3+ Only (C3+ only)
Date of HLA typing
Specify HLA tissue typing kit used
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Primary Tumor
Date of initial pathologic diagnosis
Site
Ocular (eye)
Head (head or neck)
Lower Extremity (lower limb)
Trunk (trunk)
Unknown (unknown)
Upper Extremity (upper limb)
Ulceration present?
No (no)
Unknown (unknown)
Yes (yes)
Breslow thickness
Clark level of invasion
I-above Basal Lamina (in Situ) (I)
Ii- Extension Into Papillary Dermis (II)
Iii-interface Papillary-reticular Dermis (III)
Iv-reticular Dermis (IV)
Unknown (Unknown)
V-subcutaneous Fat (V)
Regional Lymph Node Metastases
No (no)
Unknown (unknown)
Yes (yes)
If yes, date of first diagnosis
Total number of nodes examined
Number of positive nodes
Comments
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Eligibility Veno-Occlusive Disease
Prophylactic Use of Defibrotide NCT00272948
Pediatric Trial Investigating the Incidence & Outcome of
Veno-Occlusive Disease With the Prophylactic Use of
Defibrotide (VOD-DF)
ODM derived from
http://clinicaltrials.gov/show/NCT00272948
All rights reserved. Please visit https://medical-data-
models.org/forms/11667
Eligibility Veno-Occlusive Disease
Prophylactic Use of Defibrotide
NCT00272948
Inclusion Criteria
Age below 18 years*
Yes
No
myeloablative conditioning and autologous or
allogeneic stem cell transplantation with at least
one of the following risk factors for VOD: Pre-
existing liver disease, Second myeloablative
HSCT, History of treatment with gemtuzumab
ozogamicin (MYLOTARGO, GO, CMA-676,
Wyeth), Allogeneic HSCT for leukemia beyond
the second relapse, Osteopetrosis (OP),
Conditioning with busulfan and melphalan,
Macrophage activating syndromes (MAS, like
hemophagocytic lymphohistiocytosis, Griscelli,
Chediak-Higashi), Adrenoleukodystrophy (ALD)*
Yes
No
Exclusion Criteria
Pregnant patients*
Yes
No
Patients who are transplanted but do not fulfill
any of the above mentioned criteria*
Yes
No
Medical Concepts
Stem cell transplantation*
Autologous Hematopoietic Stem Cell
Transplantation*
Allogeneic Hematopoietic Stem Cell
Transplantation, HSCT*
Venoocclusive disease*
Liver diseases*
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Gemtuzumab ozogamicin, CMA-676*
leukemia*
Recurrent Disease*
Albers-Schonberg disease*
Myleran*
Melphalan*
Macrophage-Activating Factors*
Hemophagocytic Lymphohistiocytosis*
Chediak-Higashi Syndrome*
Adrenoleukodystrophy*
pregnant*
Transplant procedure*
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Eligibility Veno-Occlusive Disease Prophylactic Use of Defibrotide
NCT00272948
Eligibility Plexus Anesthesia NCT00151112
Comparison of Two Different Procedures for Plexus
Anesthesia
ODM derived from
http://clinicaltrials.gov/ct2/show/record/NCT00151112
All rights reserved. Please visit https://medical-data-
models.org/forms/11668
Eligibility Plexus Anesthesia
NCT00151112
Inclusion Criteria
18 Years and older*
Yes
No
Single shot axillary block*
Yes
No
Exclusion Criteria
Lateral position not possible*
Yes
No
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SPEECH THERAPY CONSULT RESULTS
Form from HIS OpenVistA
All rights reserved. Please visit https://medical-data-
models.org/forms/11669
SPEECH THERAPY CONSULT
RESULTS
General Info
Diagnosis*
Treatment Diagnosis*
Reason for referral*
Prior level of function/Previous S.T. treatments*
Severity Rating Scale (1. Within Normal Limits| 2.
Mild| 3. Moderate| 4. Severe)*
SPEECH-LANGUAGE TESTING
AUDITORY COMPREHENSION *
READING COMPREHENSION *
VERBAL EXPRESSION *
WRITTEN EXPRESSION *
PRAGMATICS*
COGNITION *
SUMMARY*
Severity Rating Scale (1. Within Normal Limits| 2.
Mild| 3. Moderate| 4. Severe)*
SPEECH THERAPY CONSULT RESULTS
PLAN OF CARE, Nursing Care Plan*
Diagnosis*
History of present illness*
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Age*
>= 0
<= 120
years
Gender*
Female (F)
Male (M)
Ethnicity, Ethnic group, Ethnic background*
ADMITTED  WITH*
Admission Date*
Past Medical history*
S.T. ORDER*
Prior Surgery, History of (H/O)  surgery, Past
surgical history*
PRECAUTIONS
Airborne*
Yes
No
Cardiac*
Yes
No
Contact*
Yes
No
Diabetic*
Yes
No
Do not resuscitate (DNR), Do not attempt
resuscitation (DNAR), Not for resuscitation*
Yes
No
Fall Risk, At risk for falling*
Yes
No
Neutropenia*
Yes
No
Other*
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FUNCTIONAL STATUS BEFORE ONSET
FUNCTIONAL STATUS BEFORE ONSET*
SUBJECTIVE
Orientation as to time, place and people*
Pain*
OBJECTIVE
SPEECH PRODUCTION*
SPEECH INTELLIGIBILITY*
ORAL MOTOR FUNCTION*
language ability, verbal ability*
Expressive dysphasia*
Receptive Aphasia, Fluent Aphasia,
Psychosensory Aphasia*
Aphasia, Loss of power of expression or
comprehension*
Voice*
BEDSIDE DYSPHAGIA EVALUATION
ORAL MOTOR FUNCTION*
Dentition*
denture prosthetic device, false teeth*
Reflexes*
Voice quality, vocal quality*
Coughing*
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TRIAL SWALLOW*
Palpation*
Assessment*
Speech Therapy GOALS
Patient will increase speed and accuracy of 4/10
exercises.                 *
Patient will practice slow,exaggerated speech
with an accuracy of                       *
Patient will vary stress and inotation if words and
sentences with an accuracy of          *
Patient will perform confrontational naming with *
Patient will perform word retrieval tasks with
*
Patient will describe sequence of activities using
complete sentences with         *
Patient will be able to carry on an appropriate
conversation with                    *
Patient will follow 1 to 2 stop commands with
*
Patient will demonstrate function of objects with
*
Patient will match pictures to objects with      *
Patient will practice diaphragmatic breathing with
*
Patient will practice relaxation exercises with
*
PROGNOSIS
Prognosis, prediction of outcome*
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SPEECH THERAPY CONSULT RESULTS
S.T. PLAN
S.T. PLAN*
Duration*
Frequency*
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SPEECH THERAPY CONSULT RESULTS
DAST - Basic documentation - Patient
Admission Form
ODM form derived from [DAST Aufnahme PSYCH UKM]. 
Used as a routine documentation by the University Hospital
Muenster, Germany.
All rights reserved. Please visit https://medical-data-
models.org/forms/11672
DAST - Basic documentation -
Patient Admission Form
Patienten Informationen
Name des Patienten
Aufnahmedatum
Geburtsdatum
Erfassungsdatum
Dokumentierender Behandler
Geschlecht
Geschlecht
männlich (1)
weiblich (2)
Alter in Jahren
Alter in Jahren
Familienstand
Familienstand
Kinder
Wie viele Kinder haben Sie?
Wie viele Personen leben in Ihrem
Haushalt?
Kinder
Erwachsene
Gesamt
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In welchem Land sind Sie geboren
(Abstammung)?
Geburtsland
Jahre in Deutschland
Wenn Sie nicht in Deutschland geboren
wurden, seit wievielen Jahren leben Sie in
Deutschland?
In welchem Land sind Ihre Eltern geboren
(Abstammung)?
Mutter
Vater
Schulabschluß
Höchster erreichter Schulabschluß
Anzahl Schuljahre
Wie viele Jahre sind Sie insgesamt zur Schule
gegangen?
Berufsabschluß/ Berufsausbildung
Höchste(r) erreichte(r) Berufsabschluß/
Berufsausbildung
berufliche Situation
Derzeitige berufliche Situation
Psychatrische Erkrankungen bei
Familienangehörigen
Psychatrische Erkrankungen bei Erstgrad-
Familienangehörigen?
Wenn ja, bei WEM und WELCHE
(Vater, Mutter, Schwester, Bruder, Großvater,
Großmutter, Onkel, Tante, andere)
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Vorbehandlung
Vorbehandlungen in den letzten 8 Wochen
vor der jetzigen Aufnahme
Keine (1)
Antidepressive Therapie mit:
(Generikum, mg/d, Dauer in Tagen) (2)
EKT: Anzahl der Einzelstimulationen: (3)
Schlafentzug (4)
Lichttherapie (5)
Psychotherapie: Einzeltherapiesitzungen
(6)
Psychotherapie:
Gruppentherapiesitzungen (7)
Sonstige: (8)
Psychiatrische Aufnahme-Diagnosen
(DSM-IV)
Hauptdiagnose
Nebendiagnose(n)
Körpergröße/-gewicht
Größe in cm
cm
Gewicht in kg
kg
EKG bei Aufnahme
QTC-Zeit in sek
sec
Depressiven Episode
Zeitpunkt der ersten depressiven Episode:
Anzahl der bisherigen depressiven Episoden
Anzahl der bisherigen stationärpsychiatrischen
Krankenhausaufenthalte
Clinical Global Impression (Schweregrad
der Krankheit)
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Punktzahl
nicht beurteilbar (0)
Patient ist überhaupt nicht kran (1)
Patient ist ein Grenzfall psychiatrischer
Erkrankungen (2)
Patient ist nur leicht krank (3)
Patient ist mäßig krank (4)
Patient ist deutlich krank (5)
Patient ist schwer krank (6)
Patient gehört zu den extrem schwer
Kranken (7)
Skala zur globalen Erfassung des
Funktionsniveaus (GAF)
Punktzahl
Unzureichende Informationen (0 )
Ständige Gefahr oder anhaltende
Unfähigkeit. (10-1 )
Optimale Funktion in allen Bereichen.
(100-91 )
Selbst- und Fremdgefährlichkeit. (20-11 )
Leistungsunfähigkeit in fast allen
Bereichen. (30-21 )
Starke Beeinträchtigung in mehreren
Bereichen (40-31 )
Ernsthafte Beeinträchtigung. (50-41 )
Mäßig ausgeprägte Störung. (60-51 )
Leichte Beeinträchtigung. (70-61 )
Höchstens leichte Beeinträchtigungen.
(80-71 )
Gute Leistungsfähigkeit auf allen
Gebieten. (90-81 )
Beurteilungsbogen bei Aufnahme
BDI
liegt vor (1)
Patient/in zu krank (2)
Verweigert (3)
Sonstiges (4)
k.A. (5)
Hamilton Depression Scale (HAMD)
liegt vor (1)
Patient/in zu krank (2)
Verweigert (3)
Sonstiges (4)
k.A. (5)
YMRS-C
liegt vor (1)
Patient/in zu krank (2)
Verweigert (3)
Sonstiges (4)
k.A. (5)
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Sonstiges
5 / 5
DAST - Basic documentation - Patient Admission Form
Prestudy Form Advanced Breast Cancer
NCT00103233
Pre-Study - SOUTHWEST ONCOLOGY GROUP
Advanced Breast Cancer Prestudy Form (S0347) -
2286064v3.0 NCT00103233 
SOUTHWEST ONCOLOGY GROUP Advanced Breast
Cancer Prestudy Form (S0347)
Vinorelbine With or Without Trastuzumab in Treating
Women With Progressive Metastatic Breast Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=DE163996-
0EFD-1EA5-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/11673
Prestudy Form Advanced Breast
Cancer NCT00103233
Header
SWOG Patient ID
SWOG Study No.
Registration Step
Patient Initials (L, F M)
Institution/Affiliate
Physician (Participating Group:)
Group Name
Participating Group Study No.
Participating Group Patient ID (Instructions: All
dates are MONTH, DAY, YEAR. Explain any
blank fields or blank dates in the Comments
section. Place an X in appropriate boxes. Circle
AMENDED items in red and write AMENDED
across the top of the form.)
Patient Characteristics
Height
>= 0
cm
Body weight
>= 0
kg
Performance Status
1 / 5
Fully Active, Able To Carry On All Pre-
disease Performance Without Restriction
(karnofsky 90 - 100) (ecog - 0
Asymptomatic) (0)
Restricted In Physically Strenuous
Activity But Ambulatory (k70 - 80) (ecog -
1 Symptomatic - Fully Ambulatory) (1)
Ambulatory And Capable Of All Selfcare
But Unable To Carry Out Any Work
Activities (k 50 - 60) (ecog - 2
Symptomatic; In Bed , 50% Of The Day)
(2)
Menopausal Status
Menopausal Status
Above Categories Not Applicable And
Age <50 (Above not applicable AND age
< 50)
50=Above Categories Not Applicable
And Age >= 50 (Above not applicable
AND age >)
Post (prior Bilateral Ovariectomy Or >12
Mo Since Lmp With No Prior
Hysterectomy And Not Currently
Receiving Therapy With Lh-rh Analogs
[e.g., Zoladex]) (Post (prior bilateral
ovariectomy OR > 12 mo since LMP with
no prior hysterectomy and not currently
receiving therapy with LH-RH analogs
[e.g. Zoladex]))
Pre (<6 Mo Since Lmp And No Prior
Bilateral Ovariectomy And Not On
Estrogen Replacement) (Pre (< 6 mo
since LMP and no prior bilateral
ovariectomy and not on estrogen
replacement))
Disease Description
SWOG Patient ID
ER Result
Negative (Negative)
Not Done (Never Done or Unknown)
Positive (Positive)
SWOG Study No.
ER Time
At Disease Recurrence (At disease
recurrence)
At Initial Primary Diagnosis (At initial
primary diagnosis)
Other (Other)
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Registration Step
Patient Initials (L, F M)
Other, specify
PgR Result
Negative (Negative)
Never Done Or Unknown (Never Done or
Unknown)
Positive (Positive)
PgR Time
At Disease Recurrence (At disease
recurrence)
At Initial Primary Diagnosis (At initial
primary diagnosis)
Other (Other)
Other, specify
HER-2/neu Status
Equivocal (Equivocal)
Negative (Negative)
Never Done Or Unknown (Never Done or
Unknown)
Positive (Positive)
HER-2/neu Time
At Disease Recurrence (At disease
recurrence)
At Initial Primary Diagnosis (At initial
primary diagnosis)
Other (Other)
Other, specify
Date of initial diagnosis of primary tumor
Date progressive, recurrent or metastatic disease
first diagnosed (radiologic or pathologic)
Involved sites at time of entry (select all involved
sites)
Bone (Bone)
Bone Marrow (Bone marrow)
Brain (Brain)
Distant Lymph Nodes (Distant nodes)
Distant Skin/subcutaneous Tissue
(Distant skin/subcutaneous tissue)
Ipsilateral Supraclavicular Nodes
(ipsilateral supraclavicular nodes)
Liver (Liver)
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Local-regional (Local-regional)
Lung (Lung)
Opposite Breast (Opposite breast)
Other Cns (Other CNS)
Other (Other sites)
Pleura (Pleura)
Other sites, specify
Prior Treatment Related To This Cancer
Other therapy, specify
Radiation (select one)
Extensive Radiation (Extensive RT)
Limited Radiation (Limited RT)
Not Otherwise Specified (Not otherwise
specified)
Has the patient had any of the following prior
treatments? (select ALL that apply)
Anti-retroviral Therapy (Anti-retroviral
therapy)
Antisense (Antisense)
Chemotherapy Multi-agent Systemic,
Adjuvant (Chemotherapy multi-agent
systemic, adjuvant)
Chemotherapy Multi-agent Systemic,
Advanced (Chemotherapy multi-agent
systemic, advanced)
Chemotherapy Non-cytotoxic, Advanced
(Chemotherapy non-cytotoxic, advanced)
Chemotherapy Non-cytoxic, Adjuvant
(Chemotherapy non-cytoxic, adjuvant)
Chemotherapy Other, Adjuvant
(Chemotherapy other, adjuvant)
Chemotherapy Other, Advanced
(Chemotherapy other, advanced)
Chemotherapy Single Agent Systemic,
Adjuvant (Chemotherapy single agent
systemic, adjuvant)
Chemotherapy Single Agent Systemic,
Advanced (Chemotherapy single agent
systemic, advanced)
Gene Transfer (Gene transfer)
Herceptin, Adjuvant (Herceptin, adjuvant)
Herceptin, Advanced (Herceptin,
advanced)
High-dose Chemotherapy With Marrow
Or Stem Cell Support, Adjuvant (High-
dose chemotherapy with marrow or stem
cell support, adjuvant)
High-dose Chemotherapy With Marrow
Or Stem Cell Support, Advanced (High-
dose chemotherapy with marrow or stem
cell support, advanced)
Hormonal Therapy, Adjuvant (Hormonal
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therapy, adjuvant)
Hormonal Therapy, Advanced (Hormonal
therapy, advanced)
Immunotherapy, Adjuvant
(Immunotherapy, adjuvant)
Immunotherapy, Advanced
(Immunotherapy, advanced)
Oncolytic Virotherapy (Oncolytic
virotherapy)
Other Therapy, Adjuvant (Other therapy,
adjuvant)
Other Therapy, Advanced (Other therapy,
advanced)
Surgery (Surgery)
Vaccine (Vaccine)
Number of prior chemotherapy regimens
Number of prior chemotherapy regimens for
metastatic disease
Comments
Comments
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CALGB: BACKGROUND INFORMATION
FORM
CALGB: BACKGROUND INFORMATION FORM
Comparison of Combination Chemotherapy Regimens in
Treating Older Women Who Have Undergone Surgery for
Breast Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=A50BF263-
C019-2D60-E034-080020C9C0E0
All rights reserved. Please visit https://medical-data-
models.org/forms/11674
CALGB: BACKGROUND
INFORMATION FORM
General Administrative Data
CALGB Form
CALGB Study No
CALGB Patient ID
Amended data?
Yes (Yes)
Patient's Name
Participating Group
Patient Hospital Number
Participating Group Protocol No.
Main Member Institution/Adjunct
Participating Group Patient No.
Patient details
If you do not wish to answer any of the following
questions please mark an X here. (1.)
Today's Date (M)
What is the highest grade you finished in school?
(3.)
1-8 Grades (1-8 grades)
9-11 Grades (9-11 grades)
Advanced Degree (Advanced degree)
College Degree (b.a./b.s.) (College
degree (B.A./B.S.))
High School Graduate (High School
graduate)
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Junior College Degree (Junior college
degree)
Some College (Some college)
Some Post-college Work (Some post-
college work)
What is your marital status? (mark one with an X)
Divorced (Divorced)
Married (Married)
Separated (Separated)
Single, Never Married (Single, never
married)
Widowed (Widowed)
With whom do you live? (mark all that apply with
an X)
Children Aged 18 Years Or Younger
(Children aged 18 years or younger)
Children Aged 19 Years Or Older
(Children aged 19 years or older)
Live Alone (Live alone)
Other Relative, Specify (Other relative,
specify)
Other, Specify (Other, specify)
Parent(s)/parent(s)-in-law
(Parent(s)/Parent(s)-In-Law)
Spouse/partner (Spouse/Partner)
Other relative, specify (with whom you live)
Other, specify (with whom you live) (5.)
What is your current employment status? (mark
all that apply with an X)
Disabled (Disabled)
Employed 32 Hours Or More Per Week
(Employed 32 hours or more per week)
Employed Less Than 32 Hours Per
(Employed less than 32 hours per)
Full-time Student (Full-time student)
Homemaker (Homemaker)
On Medical Leave (On medical leave)
Other, Specify (Other, specify)
Part-time Student (Part-time student)
Retired (Retired)
Unemployed (Unemployed)
Other, specify (current employment status)
Ccrr Module For Calgb: Background
Information Form
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Late Radiation Toxicity Form
Late Radiation Toxicity Form
Gemcitabine With or Without Radiation Therapy in Treating
Patients With Pancreatic Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=A65CC822-
2E9B-42C2-E034-0003BA0B1A09
All rights reserved. Please visit https://medical-data-
models.org/forms/11675
Late Radiation Toxicity Form
Administrative Data
ECOG Protocol No.
ECOG Patient ID
Registration Step
Adverse Event Reporting From Date (M D Y)
Adverse Event Reporting To Date (M D Y)
Patient?s Name
Participating Group Protocol No.
Participating Group Patient ID
Institution/Affiliate
Are data amended? (If yes, please circle
amended items in red)
Yes
No
CTC Adverse Events and other Radiation
Unnamed (CTC Adverse Event Term)
CTC Adverse Event Grade
CTC Adverse Event Attribution Code
AE Filed?
Yes
No
Radiation, other; specify
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Comments
Comments
Investigator Signature
Date
Ccrr Module For Late Radiation Toxicity
Form
Has an expedited AE report been filed?
Yes
No
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CALGB: 49808 ON-STUDY FORM
CALGB: 49808 ON-STUDY FORM
Combination Chemotherapy, Surgery, and Radiation
Therapy With or Without Dexrazoxane and Trastuzumab in
Treating Women With Stage III or Stage IV Breast Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=9E35395C-
88BE-227A-E034-080020C9C0E0
All rights reserved. Please visit https://medical-data-
models.org/forms/11689
CALGB: 49808 ON-STUDY FORM
Administrative Data
CALGB Form
CALGB Study No
CALGB Patient ID
Amended data?
Yes (Yes)
Patient's Name
Participating Group
Patient Hospital Number
Participating Group Protocol No.
Main Member Institution/Adjunct
Participating Group Patient No.
Menopausal Status
Menopausal Status (mark one with an X)
Above categories not applicable AND
Age= <50 (Above categories not
applicable AND Age= <50)
Above categories not applicable AND
Age=>50 (Above categories not
applicable AND Age=>50)
Post (Post)
Pre (Pre)
Disease Description
Tumor Laterality (mark one with an X)
Bilateral (Bilateral)
Left (Left)
Right (Right)
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Receptor Status, ER
Negative (Negative)
Positive (Positive)
Receptor Status, PgR
Negative (Negative)
Positive (Positive)
Histologic Grade
High (High)
Intermediate (Intermediate)
Low (Low)
Histologic Subtype  (mark one with an X)
Ductal (Ductal)
Lobular (Lobular)
Mixed Ductal and Lobular (Mixed Ductal
and Lobular)
Other, specify (Other, specify)
Histologic Subtype Other, specify
Type of Primary Biopsy
Core Needle Biopsy (Core needle
biopsy)
Incisional Biopsy (Incisional biopsy)
HER-2 neu Status (mark one with an X)
Dako Herceptest <3+/fish+ (Dako
Herceptest <3+/FISH+)
Dako Herceptest 3+ (Dako Herceptest
3+)
Fish+ (ihc Not Done) (FISH+ (IHC not
done))
Ihc (non-dako Herceptest) Strong
Positive (IHC (non-Dako Herceptest)
strong positive)
Assuming a good or exceptional response to
neoadjuvant treatment, will the patient likely be a
candidate for breast-conserving surgery?
Yes
No
If not, principle reason (mark one with an X)
Diffuse Microcalcifications (Diffuse
Microcalcifications)
Inflammatory Disease (Inflammatory
Disease)
Institutional Norm (Institutional norm)
Multicentric Disease (Multicentric
Disease)
Other, Specify: (Other, specify)
Patient Choice/family History (Patient
choice/Family History)
Specific Anatomy Of Primary (Specific
anatomy of primary)
If not, principle reason, Other, specify
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Disease Assessment
Disease Assessment
Mammogram (Mammogram)
Physical Exam (Physical Exam)
Physician's Final Staging (Physician's
Final Staging)
Ultrasound (Ultrasound)
Primary Tumor Size (cm)
Disease Stage
M (M)
N (N)
T (T)
If the patient was diagnosed with a T4 tumor for
physican's final staging above, indicate the type
of tumor (mark one with an X)
Chest Wall Only (Chest wall only)
Inflammatory (Inflammatory)
Not Applicable (Not applicable)
Skin And Chest Wall (Skin and chest
wall)
Skin Only (Skin only)
Comments
Comments
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CALGB: 80203 On-Study
CALGB: 80203 On-Study
Fluorouracil and Leucovorin Plus Either Irinotecan or
Oxaliplatin With or Without Cetuximab in Treating Patients
With Previously Untreated Metastatic Adenocarcinoma of
the Colon or Rectum
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=B4C3AD14-
5A1C-0716-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/11690
CALGB: 80203 On-Study
Header
CALGB Form
CALGB Study No.
CALGB Patient ID
Start date of first treatment
Are data amended?
Yes
No
Patient details
Patient Initials
Participating Group
Patient Hospital No.
Participating Group Protocol No.
Institution/Affiliate
Participating Group Patient ID
History of primary cancer other than colorectal
Yes
No
Specify type of cancer and year of diagnosis
History of MI in past 6 months, prior CHF, or
significant valvular disease
Yes
No
Performance status
1 / 3
Ambulatory And Capable Of All Selfcare
But Unable To Carry Out Any Work
Activities (k 50 - 60) (ecog - 2
Symptomatic; In Bed , 50% Of The Day)
(Ambulatory and capable of selfcare, but
unable to carry out any work activities)
Capable Of Limited Selfcare, Confined
To Bed Or Chair More Than 50% Of
Waking Hours. (k 30 - 40) (ecog - 3
Symptomatic; In Bed > 50% Of The Day
But Not Bedridden) (Capable of limited
selfcare, confined to bed or chair more
than 50% of waking hours)
Completely Disabled (k10 - 20) (ecog - 4
Bedridden) (Completed disabled)
Fully Active, Able To Carry On All Pre-
disease Performance Without Restriction
(karnofsky 90 - 100) (ecog - 0
Asymptomatic) (Full active, able to carry
on all pre-disease performance without
restriction)
Restricted In Physically Strenuous
Activity But Ambulatory (k70 - 80) (ecog -
1 Symptomatic - Fully Ambulatory)
(Restricted in physically strenous activity
but ambulatory)
Peripheral neutrophil count
Peripheral platelet count
Serum creatinine
mg/dL
SGOT
Bilirubin
SGOT ULN
EGF-R status
Negative (negative)
Positive (positive)
Prior systemic chemotherapy
Yes
No
Agent Name
Reason for chemotherapy
adjuvant (adjuvant)
metastatic (metastatic)
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Date of last dose
Prior radiation therapy
Yes
No
Site(s)
Reason for chemotherapy (means radiation
therapy)
Type Of Radiation Therapy Is Adjuvant
(adjuvant)
Type Of Radiation Therapy Is Other
Specify (metastatic)
Date of last dose
Completed by
Date form completed
Ccrr Module For Calgb: 80203 On-study
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CALGB: 80203 On-Study
SOUTHWEST ONCOLOGY GROUP S0421
TREATMENT FORM: Step 1 Randomization Form
SOUTHWEST ONCOLOGY GROUP S0421 TREATMENT
FORM: Step 1 Randomization Form
Docetaxel and Prednisone With or Without Atrasentan in
Treating Patients With Stage IV Prostate Cancer and Bone
Metastases That Did Not Respond to Previous Hormone
Therapy
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=F15A78DC-
93A4-2746-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11691
SOUTHWEST ONCOLOGY GROUP
S0421 TREATMENT FORM: Step 1
Randomization Form
Header
SWOG Patient ID
SWOG Study No.
Registration Step
Patient Initials (L, F M)
Institution/Affiliate
Physician
Participating Group Name
Participating Study No.
Participating Patient ID (Instructions: Please
complete this form after each cycle 1 cycle = 4
weeks. All dates are MONTH, DAY, YEAR.
Explain any blank dates or fields in a Comments
section. Place an X in appropriate boxes. Circle
AMENDED items in red and write AMENDED
across top of form.)
Status
Vital Status
Alive (Alive)
Dead (Dead)
Date of Last Contact or Death
Has the patient progressed per the definition in
Section 10.0 of the protocol?
1 / 3
Yes
No
Treatment
Were there any dose modifications or
additions/omissions to protocol treatment?
No (No)
Yes, Planned (i.e., The Treatment Was
Changed According To Protocol
Guidelines) (Yes, planned)
Yes, Unplanned (i.e., The Treatment
Change Was Not Part Of Protocol
Guidelines) (Yes, unplanned)
Current cycle number
Treatment start date
Date of last treatment
BSA (First day this cycle - m2)
Weight (kg)
Kg
Alkaline Phosphatase (Total - IU/L)
Hemoglobin (g/dL - cycles 1 & 2 only)
g/dL
Arm 1 + Arm 2
Day 1 (Docetaxel dose)
Was pill taken daily (Prednisone dose)
Yes
No
If no
Was pill taken daily (Atrasentan or matching
placebo)
Yes
No
If no
Comments
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SOUTHWEST ONCOLOGY GROUP S0421 TREATMENT FORM: Step 1
Randomization Form
Comments
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SOUTHWEST ONCOLOGY GROUP S0421 TREATMENT FORM: Step 1
Randomization Form
E5202 Non-Protocol Therapy Form
E5202 Non-Protocol Therapy Form
Oxaliplatin, Leucovorin, and Fluorouracil With or Without
Bevacizumab in Treating Patients Who Have Undergone
Surgery for Stage II Colon Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=EF10CFF6-
E73E-7106-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11692
E5202 Non-Protocol Therapy Form
Header
ECOG Protocol Number
ECOG Patient ID
DCI Name
Registration Step
Time period
Non-protocol Therapy (Non-Protocol
Therapy)
Patient Initials
Patient details
Participating Group Protocol Number
Institution/Affiliate
Participating Group Patient ID
Are data amended (If yes, please circle amended
items in red)
Yes
No
Treatment details
Date of FIRST non-protocol therapy (if given prior
to progression/relapse from protocol therapy)
Non-protocol Chemotherapy
No (No)
Unknown (Unknown)
Yes (Yes)
Non-protocol Hormonal Therapy
No (No)
1 / 2
Unknown (Unknown)
Yes (Yes)
Non-protocol Immunotherapy (Biological
Response Modifiers)
No (No)
Unknown (Unknown)
Yes (Yes)
Non-protocol High Dose Chemotherapy/Stem
Cell Transplant (Autologous or Allogeneic)
No (No)
Unknown (Unknown)
Yes (Yes)
Non-protocol Surgery
No (No)
Unknown (Unknown)
Yes (Yes)
Non-protocol surgery type
Non-protocol Radiation Therapy
No (No)
Unknown (Unknown)
Yes (Yes)
Non-protocol RT type
Other Non-protocol Therapy
No (No)
Unknown (Unknown)
Yes (Yes)
Name of other non-protocol therapy
Was the non-protocol therapy given for the
disease of this protocol (NOTE: Treatment for a
second primary in the same organ site would not
be considered therapy for disease of this
protocol.)
No (No)
Unknown (Unknown)
Yes (Yes)
Comments
Comments
Investigator Signature
Investigator Signature Date
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E4A03 Supplemental Follow-Up Form -
Form 2053
E4A03 Supplemental Follow-Up Form - Form 2053
Lenalidomide and Dexamethasone With or Without
Thalidomide in Treating Patients With Multiple Myeloma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=DC6D87E0-
229D-1046-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/11693
E4A03 Supplemental Follow-Up
Form - Form 2053
Header
ECOG Protocol Number
ECOG Patient ID
DCI Name
Registration Step (Place ID Label Here)
Patient Initials (Last, First)
Participating Group Protocol Number
Participating Group Patient ID
Institution/Affiliate
Report Period (choose one)
Post Treatment 6 Months (Post treatment
6 months)
Are data amended
Yes
No
In The 6 Months Following The End Of All
Protocol Treatment
Date form completed
Did the patient have a peripheral blood stem cell
harvest? (Answer ?no? if patient is preparing for
allogeneic transplant and donor cells were
harvested.)
Yes
No
Date of initial PBSC harvest (If yes:)
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Was stem cell harvest successful?
Yes
No
Did the patient have a stem cell transplant?
Yes
No
Type of transplant (If yes:)
Allogeneic (allogeneic)
Autologous (autologous)
Syngeneic (syngeneic)
Date of stem cell transplant
Did the patient engraft?
No (no)
Unknown (unknown)
Yes (yes)
Comments
Comments
Investigator Signature
Investigator Signature Date
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AE2
AE2
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=FF17FFED-
E72C-015A-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11696
AE2
Averse Events
Segment
Date of Onset
Event description
Relevant Past Medical History
Include any relevant history, including preexisting
medical conditions below
Event Summary
Include clinical history of event, associated signs
or symptoms, alternative etiologies being
considered and medical management below
Initial submitter
Name
Authorized submitter
Name
Date
Date
1 / 1
ECOG Nontarget Lesions Supplemental
Form (E2100)
ECOG Nontarget Lesions Supplemental Form (E2100)
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=AC328486-
403E-246F-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/11697
ECOG Nontarget Lesions
Supplemental Form (E2100)
ECOG clinical trial administrative data
ECOG Protocol No.
ECOG Patient ID
Registration Step
Cycle Number (Use '00' for baseline; leave blank
if off-treatment or N/A)
Patient's Name
Participating Group Protocol No.
Participating Group Patient ID
Institution/Affiliate
Are data amended?
Yes
No
Nontarget Lesions
Lesion Number
Site of Lesion (Multiple nontarget lesions within
an organ may be combined as a single site, but
must be reported in same manner as at
baseline.)
Site Code (Site codes)
Bone (Bone)
Brain (Brain)
Breast (Breast)
Effusion/ascites (Effusion/Ascites)
Gi (GI)
Gu (GU)
Head & Neck (Head & Neck)
Liver (Liver)
Lung (Lung)
Nodes (Nodes)
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Other (specify Site) (Other (specify site))
Skin (Skin)
Method of Evaluation (Method of Evaluation
codes)
Bone Scan (Bone Scan)
Chest X-ray (Chest X-Ray)
Clinical Exam (Clinical Exam)
Ct Scan (CT Scan)
Mri (MRI)
Not Evaluated (Not evaluated)
Other (specify In Comments) (Other
(specify in Comments))
Spiral Ct (Spiral CT)
Ultrasound (Ultrasound)
Date of Evaluation (M D Y)
Follow-up Status of Lesions (Choose one for
each lesion.  Leave blank if baseline.)
Cr (CR)
Incompl. Resp./sd (Incompl. resp./SD)
Pd (PD)
Unequivocal progressive disease in nontarget
lesions is based on: (please describe) (For Site
Code 04 effusion/ascites ONLY:)
Cytology Result
Negative (Negative)
Not Done (Not done)
Positive (Positive)
Comments
Comments
Investigator Signature
Date
Ccrr Module For Ecog Nontarget Lesions
Supplemental Form (e2100)
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Long-Term Follow-up Form NCT00057876
Long-Term Follow-up Form NCT00057876
Gemcitabine With or Without Radiation Therapy in Treating
Patients With Pancreatic Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=A6241793-
87BB-3BE3-E034-0003BA0B1A09
All rights reserved. Please visit https://medical-data-
models.org/forms/11699
Long-Term Follow-up Form
NCT00057876
Header
Registration Step
Patient?s Name
ECOG Protocol No.
ECOG Protocol No.
ECOG Patient ID
ECOG Patient ID
Participating Group Protocol No.
Participating Group Patient ID
Institution/Affiliate
Data amendment
Are data amended? (If yes, please circle
amended items in red)
No (No)
Yes (Yes)
Reporting Period Start Date: (M D Y)
Reporting Period End Date: (M D Y)
Vital Status
Patient's Vital Status
Alive (Alive)
Dead (Dead)
Date of Last Contact or Death (M D Y)
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Primary Cause of Death
Due To Other Cause, Specify (Due to
other cause)
Due To Protocol Treatment (Due to
protocol treatment)
Due To This Disease (Due to this
disease)
Unknown (Unknown)
Describe cause of death
Disease Follow-up Status
Has the patient had a documented clinical
assessment for this cancer (since submission of
the previous follow-up form)?
No (No)
Unknown (Unknown)
Yes (Yes)
Date of last clinical assessment (If yes)
Notice Of Progression
Has the patient developed a first progression that
has not been previously reported?
No (No)
Unknown (Unknown)
Yes (Yes)
Date of progression (If yes)
Site(s) of progression (If yes)
Did a physician make a formal diagnosis of
progressive disease? (If no or unknown, specify
basis of PD in Comments)
No (No)
Unknown (Unknown)
Yes (Yes)
Notice Of New Primary
Has a new primary cancer or MDS been
diagnosed that has not been previously reported?
No (No)
Yes (Yes)
Site(s) of new primary
Toxicity
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Has the patient experienced any severe (Grade
>= 3) long term toxicity that has not been
previously reported?
No (No)
Yes (Yes)
Non-protocol Therapy
Has the patient received any non-protocol cancer
therapy prior to first progression (not previously
reported)?
No (No)
Yes (Yes)
Comments
Comments
Investigator Signature
Date
Ccrr Module For Long-term Follow-up
Form
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E1805 Long-Term Follow-up Form
E1805 Long-Term Follow-up Form
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=0F33ADB9-
78E4-7108-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11701
E1805 Long-Term Follow-up Form
Header
ECOG Protocol Number
ECOG Patient ID
DCI Name
Registration Step
Patient demographics
Patient Initials (Last, First)
ECOG Protocol Number
ECOG Patient ID
Participating Group Protocol Number
Participating Group Patient ID
Institution/Affiliate
Off protocol treatment period
Off Treatment Report Period (since initial
registration)
9 Years (108 Months Post-Registration)
12 Months (12 Months Post Registration)
10 Years (120 Months Post-Registration)
11 Years Post Registration (132 Months
Post Registration)
12 Years Post Registration (144 Months
Post Registration)
15 Months (15 Months Post Registration)
13 Years Post Registration (156 Months
Post Registration)
14 Years Post Registration (168 Months
Post Registration)
18 Months (18 Months Post Registration)
15 Years Post Registration (180 Months
Post Registration)
21 Months Post Registration (21 Months
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Post Registration)
2 Years (24 Months Post Registration)
3 Months (3 Months Post Registration)
30 Months (30 Months Post Registration)
3 Years (36 Months Post Registration)
42 Months (42 Months Post Registration)
4 Years (48 Months Post Registration)
54 Months (54 Months Post Registration)
6 Months (6 Months Post Registration)
5 Years (60 Months Post Registration)
6 Years (72 Months Post-Registration)
84 Months Post Registration (84 Months
Post-Registration)
9 Months (9 Months Post Registration)
8 Years (96 Months Post-Registration)
Data amendment
Please mark an 'X' if data have been amended.
(Please circle amended items in red)
Date data amended (s - MM/DD/YYYY)
Vital Status
Patient Vital Status
Alive (Alive)
Dead (Dead)
Date of last contact or death (MM/DD/YYYY)
Primary Cause of Death (if applicable)
Due To Other Cause (Due to other
cause)
Due To Protocol Treatment (Due to
protocol treatment)
Due To This Disease (Due to this
disease)
Unknown (Unknown)
Describe cause of death
Section II - Reporting Period
Reporting Period Start Date (MM/DD/YYYY)
Reporting Period End Date (MM/DD/YYYY)
Disease Follow-up Status
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Has the patient had a documented clinical
assessment for this cancer (since submission of
the previous follow-up form)
No (No)
Unknown (Unknown)
Yes (Yes)
If unknown, please explain
Date of Last Clinical Assessment (If yes)
Has the patient developed a first progression (or
relapse) that has not been previously reported?
(Notice of Progression)
No (No)
Unknown (Unknown)
Yes (Yes)
If unknown, please explain
Date of Progression (relapse)
Sites of Progression
Did a physician make a formal diagnosis of
progressive disease?
No (No)
Unknown (Unknown)
Yes (Yes)
What was the method used to determine
progression
Biochemical (Biochemical)
Both Clinical And Biochemical (Both
Clinical and Biochemical)
Clinical Examination (Clinical)
Notice Of New Primary (including Second
Colon Primary)
Has a new primary cancer or myelodysplastic
syndrome been diagnosed that has not been
previously reported (MDS)
No (No)
Unknown (Unknown)
Yes (Yes)
Site of New Primary (s)
Adverse Events
Has the patient experienced any severe long
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term toxicity that has not been previously
reported (prior to diagnosis of
progression/relapse)
No (No)
Unknown (Unknown)
Yes (Yes)
Non-protocol Therapy
Has the patient received any non-protocol cancer
therapy prior to first progression (not previously
reported)
No (No)
Unknown (Unknown)
Yes (Yes)
Comments
Investigator Signature
Investigator Signature Date
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Eligibility TRILOGY ACS Acute Coronary
Syndrome NCT00699998
This study will evaluate the relative efficacy and safety of
prasugrel and clopidogrel in a medically managed Unstable
Angina/Non-ST-Elevation Myocardial Infarction
(UA/NSTEMI) acute coronary syndrome (ACS) population
(that is, patients who are not managed with acute coronary
revascularization).
https://clinicaltrials.gov/ct2/show/NCT00699998
All rights reserved. Please visit https://medical-data-
models.org/forms/11703
Eligibility Criteria
Key Inclusion Criteria
Have had a Unstable Angina/Non-ST-Elevation
Myocardial Infarction (UA/NSTEMI) index event
within 10 days prior to randomization
Yes
No
Have had a Unstable Angina/Non-ST-Elevation
Myocardial Infarction (UA/NSTEMI) index event
within 10 days prior to randomization
Yes
No
Had a medical management strategy decision
made with reasonable certainty that neither
percutaneous coronary intervention (PCI) nor
coronary artery bypass graft (CABG) is planned
for treatment of the index event
Yes
No
Had a medical management strategy decision
made with reasonable certainty that neither
percutaneous coronary intervention (PCI) nor
coronary artery bypass graft (CABG) is planned
for treatment of the index event
Yes
No
Had at least 1 of 4 specified high-risk features at
the time of the UA/NSTEMI event
Yes
No
Key Exclusion Criteria
ST-segment elevation myocardial infarction
(STEMI) as the index event
Yes
No
Cardiogenic shock
Yes
No
Refractory ventricular arrhythmias
Yes
No
New York Heart Association (NYHA) Class IV
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congestive heart failure (CHF) within the previous
24 hours
Yes
No
History of ischemic or hemorrhagic stroke
Yes
No
History of transient ischemic attack (TIA)
Yes
No
History of Intracranial neoplasm
Yes
No
arteriovenous malformation
Yes
No
aneurysm
Yes
No
History of spontaneous gastrointestinal (GI) or
non-GI bleeding requiring hospitalization for
treatment, unless definitive treatment has
occurred and there is low likelihood of recurrence
Yes
No
Hemodialysis or peritoneal dialysis
Yes
No
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E2905 Source Document Tracking
Coversheet NCT00843882
E2905 Source Document Tracking Coversheet
NCT00843882 
Lenalidomide With or Without Epoetin Alfa in Treating
Patients With Myelodysplastic Syndrome and Anemia
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=0EA9D5AE-
D3E2-1B14-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11704
E2905 Source Document Tracking
Coversheet NCT00843882
ECOG clinical trial administrative data
ECOG Protocol Number
ECOG Patient ID
DCI Name
Registration Step
Report Period (STEP 2- NOTE: If choosing report
period for end of treatment, select next highest
cycle)
>cycle 13-step 2 (>Cycle 13-Step 2)
Cycle 1 Step 2 (Cycle 1 Step 2)
Cycle 10 Step 2 (Cycle 10 Step 2)
Cycle 11 Step 2 (Cycle 11 Step 2)
Cycle 12 Step 2 (Cycle 12 Step 2)
Cycle 13-step 2 (Cycle 13-Step 2)
Cycle 2 Step 2 (Cycle 2 Step 2)
Cycle 3 Step 2 (Cycle 3 Step 2)
Cycle 4 Step 2 (Cycle 4 Step 2)
Cycle 5 Step 2 (Cycle 5 Step 2)
Cycle 6 Step 2 (Cycle 6 Step 2)
Cycle 7 Step 2 (Cycle 7 Step 2)
Cycle 8 Step 2 (Cycle 8 Step 2)
Cycle 9 Step 2 (Cycle 9 Step 2)
End Of Treatment (End of Treatment)
Specify Cycle
Patient Initials (Last, First)
Participating Group Protocol Number
Participating Group Patient ID
Institution/Affiliate
Document type (Choose one)
1 / 2
Bone Marrow Report (Bone Marrow
Report)
Cytogenetic Report (Cytogenetic Report)
Other (Other)
Patient Pill Diary (Patient pill diary)
Other specify
Report Created Date (List the date the source
document was created below.)
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Eligibility ACCOAST Acute Coronary
Syndrome NCT01015287
The purpose of this trial is to investigate the potential
benefits/risks regarding pretreatment with prasugrel in non-
ST-elevation myocardial infarction (NSTEMI) participants
with elevated troponin scheduled for coronary
angiography/percutaneous coronary intervention (PCI).
https://clinicaltrials.gov/ct2/show/NCT01015287
All rights reserved. Please visit https://medical-data-
models.org/forms/11705
Eligibility criteria
Inclusion Criteria
Have acute coronary syndrome consisting of non-
ST-segment elevation with elevated troponin
Yes
No
Have acute coronary syndrome consisting of non-
ST-segment elevation with elevated troponin
Yes
No
Have acute coronary syndrome consisting of non-
ST-segment elevation with elevated troponin
Yes
No
Scheduled for coronary angiography greater than
or equal to 2 and less than 24 hours from time of
planned randomization, but no more than 48
hours from randomization
Yes
No
Scheduled for coronary PCI greater than or equal
to 2 and less than 24 hours from time of planned
randomization, but no more than 48 hours from
randomization
Yes
No
Must be eligible for treatment with prasugrel
Yes
No
Must be eligible for treatment with aspirin (ASA)
Yes
No
Must be eligible for treatment with a glycoprotein
IIb/IIIa receptor (GPIIb/IIIa) inhibitor
May be on a maintenance dose of clopidogrel 75
mg and must be able to switch to prasugrel
Yes
No
Must be enrolled at a cardiac catheterization
laboratory hospital or at a hospital/ambulance
service affiliated with a cardiac catheterization
laboratory hospital
Yes
No
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Exclusion Criteria
Present with ST-segment elevation myocardial
infarction (STEMI) at the time of entry or
randomization
Yes
No
Have cardiogenic shock
Yes
No
Have refractory ventricular arrhythmias
Yes
No
Have New York Heart Association (NYHA) Class
IV congestive heart failure (CHF)
Have had cardiac arrest within 1 week of entry or
randomization into the study
Yes
No
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Eligibility ACCOAST Acute Coronary Syndrome NCT01015287
Eligibility ALPACS Acute Coronary
Syndrome NCT00728988
This present study is specifically designed to examine the
efficacy and safety of a high pre-treatment dose of
atorvastatin in Asian patients with NSTE-ACS in China and
the Republic of Korea, by using a treatment paradigm
similar to that employed in the ARMYDA-ACS study.
https://clinicaltrials.gov/ct2/show/NCT00728988
All rights reserved. Please visit https://medical-data-
models.org/forms/11707
Eligibility Criteria
Inclusion Criteria
Non-ST elevated ACS
Yes
No
LDL-C > 80 mg/dl
Yes
No
Exclusion Criteria
ST elevated acute myocardial infarction
Yes
No
Previously or currently treated with atorvastatin or
other statins
Yes
No
1 / 1
Eligibility Rivaroxaban Acute Coronary
Syndrome NCT00809965
The purpose of this study is to determine whether
rivaroxaban in addition to standard care reduces the risk of
the composite of cardiovascular death, myocardial
infarction, or stroke in patients with a recent acute coronary
syndrome compared with placebo.
https://clinicaltrials.gov/ct2/show/NCT00809965
All rights reserved. Please visit https://medical-data-
models.org/forms/11708
Elegibility Criteria
Inclusion Criteria
Currently receiving aspirin
Yes
No
Hospitalized with symptoms suggestive of acute
coronary syndrome
Yes
No
Exclusion criteria
Significant renal impairment
Yes
No
Significant liver disease
Yes
No
Need for continued anticoagulant therapy
Yes
No
Any condition that, in the opinion of the
investigator, contraindicates anticoagulant
therapy
Yes
No
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Eligibility ATLAS ACS TIMI 46 Acute
Coronary Syndrome NCT00402597
The purpose of this study is to evaluate the safety of
rivaroxaban in patients with recent acute coronary
syndrome (ACS) and to assess the ability of rivaroxaban to
reduce the occurrence of death, myocardial infarction
(heart attack), repeat myocardial infarctions, stroke, and
ischemia (inadequate blood supply to a local area) in
patients with recent ACS.
https://clinicaltrials.gov/ct2/show/NCT00402597
All rights reserved. Please visit https://medical-data-
models.org/forms/11709
Eligibility criteria
Inclusion Criteria
Have symptoms suggestive of ACS that lasted at
least 10 minutes at rest occurring within 7 days of
randomization
Yes
No
diagnosis of ST-elevation myocardial infarction
Yes
No
diagnosis non-ST elevation myocardial infarction
Yes
No
diagnosis of unstable angina
Yes
No
Exclusion Criteria
Active bleeding
Yes
No
risk of bleeding
Yes
No
intracranial hemorrhage
Yes
No
anticoagulant therapy
Yes
No
Significantly impaired renal function
Yes
No
Significantly impaired hepatic function
Yes
No
cardiogenic shock
Yes
No
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ventricular arrhythmias
Yes
No
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Eligibility ATLAS ACS TIMI 46 Acute Coronary Syndrome NCT00402597
Eligibility Eptifibatide Acute Coronary
Syndrome NCT01863134
Through last couple of years the number of patients treated
for acute coronary event without persistent ST segment
elevation in ECG has been growing. This is probably an
effect of improving diagnostics of myocardial infraction
without persistent ST segment elevation in ECG, due to
routine Troponin serum level evaluation and better primary
prevention. This fact makes the search for the optimal
treatment for patients with acute coronary event without
persistent ST segment elevation in ECG, including both
patients intended for pharmacological and invasive
treatment percutaneous coronary intervention (PCI) or
coronary artery byppass grafting (CABG). Patients
undergoing invasive treatment for acute coronary event,
have higher risk rate, than those with stabile angina
pectoris. The authors of this study want to evaluate,
whether the proportional use of platelet GP IIb/IIIa receptor
antagonist - eptifibatide in patients undergoing CABG
results in improvement of short-, and long time results in
those patients. Eptifibatide ( Integrilin) a cyclic heptapeptide
antagonist of the GP IIb/IIIa integrin receptor, is an
intravenous antagonist with rapid onset and short half-life.
https://clinicaltrials.gov/ct2/show/NCT01863134
All rights reserved. Please visit https://medical-data-
models.org/forms/11710
Eligibility criteria
Inclusion Criteria
Subjects must have a typical anginal pain lasting
at least 20 min., but no longer than 24h.
Yes
No
ECG confirming ischaemia
Yes
No
ST segment depression >= 1,0 mm in at least 2
leads
Yes
No
negative T waves >= 2,0 mm in at least 2 leads
Yes
No
Positive troponin I (TnI)
Yes
No
Subjects must demonstrate their willingness to
participate in the study and comply with its
procedures by signing a written informed consent
and/or parent or legal guardian must have signed
a written informed consent.
Yes
No
Subjects must be ≥ 21 year of age, of either sex
and any race.
Yes
No
Women of childbearing potential (includes
women who are less than 1 year postmenopausal
and women who become sexually active) must be
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using an acceptable method of birth control (e.g.,
hormonal contraceptive, medically prescribed
IUD - intrauterine device, condom in combination
with spermicide) or be surgically sterilized (e.g.,
hysterectomy or tubal ligation).
Yes
No
Exclusion Criteria
Women who are pregnant or nursing.
Yes
No
Angina lasting longer than 24h
Yes
No
ST segment elevation - Pardy wave
Yes
No
age over 75 years
Yes
No
history of revascularization procedure during last
6 months (PTCA, CABG)
Yes
No
chronic heart failure (NYHA III or IV) during pre-
hospitalization period
Yes
No
History of bleeding from gastrointestinal tract
system during last 30 days
Yes
No
History of bleeding from genitourinary system
during last 30 days
Yes
No
history of intracranial lesions or stroke
Yes
No
history of major surgery during last 6 weeks
Yes
No
history of trauma during last 6 weeks
Yes
No
history of hemorrhagic diathesis
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Yes
No
thrombocytopenia < 100 000/mm3
Yes
No
anticoagulant therapy with INR>2,0
Yes
No
significant hepatic failure
Yes
No
significant renal failure with serum creatinine>2,0
mg%
Yes
No
elevated blood pressure: SBP>200mmHg and/or
DBP>110mmHg despite the antihypertensive
treatment
Yes
No
allergy to drugs or any therapeutic agent
Yes
No
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Eligibility Clopidogrel to Prasugrel Acute
Coronary Syndrome NCT01115738
This study will evaluate the use of a prasugrel 60 mg
loading dose (LD) administered during percutaneous
coronary intervention (PCI) with and without a prior LD of
clopidogrel on platelet inhibition in patients presenting with
acute coronary syndrome (ACS). Platelet inhibition
following a prasugrel LD in clopidogrel pretreated patients'
will be determined in a time-dependent manner for two
different prasugrel loading doses (30 mg and 60 mg).
Understanding the effects of this combination on platelet
inhibition will provide guidance to physicians on the use of
prasugrel in patients who have already been pretreated
with clopidogrel.
https://clinicaltrials.gov/ct2/show/NCT01115738
All rights reserved. Please visit https://medical-data-
models.org/forms/11711
Eligibility Criteria
Inclusion Criteria
Participants hospitalized with acute coronary
syndrome (ACS)
Yes
No
anticipated to undergo percutaneous coronary
intervention (PCI)
Yes
No
Participants provide signed informed consent
form (ICF)
Yes
No
Participants weigh at least 60 kilograms (kg) at
the time of screening
Yes
No
test negative for pregnancy at the time of
enrollment based on a urine or serum pregnancy
test
Yes
No
Exclusion Criteria
Have cardiogenic shock at the time of
randomization
Yes
No
Have refractory ventricular arrhythmias
Yes
No
Have New York Heart Association (NYHA) Class
IV congestive heart failure
Yes
No
Have systolic blood pressure greater than 180
mm Hg, or diastolic blood pressure greater than
100 mm Hg on more than 1 assessment at any
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time from participant presentation of ACS
treatment to enrollment
Yes
No
Have systolic blood pressure greater than 180
mm Hg, or diastolic blood pressure greater than
100 mm Hg on more than 1 assessment at any
time from participant presentation of ACS
treatment to enrollment
Yes
No
Have received fibrin-specific fibrinolytic therapy
less than 24 hours prior to randomization
Yes
No
Have active internal bleeding or history of
bleeding diathesis
Yes
No
Have clinical findings associated with an
increased risk of bleeding
Yes
No
Prior history of ischemic or hemorrhagic stroke
Yes
No
Intracranial neoplasm
Yes
No
arteriovenous malformation
Yes
No
aneurysm
Yes
No
Prior history of transient ischemic attack (TIA)
Yes
No
Have an International Normalized Ratio (INR)
known to be greater than 1.5 at the time of
evaluation
Yes
No
Have a platelet count of less than 100,000 per
cubic millimeter (mm^3) at the time of evaluation
Yes
No
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Have anemia [hemoglobin (Hgb) less than 10
grams per deciliter (g/dL)] at the time of
evaluation
Yes
No
Have received 1 or more doses of a
thienopyridine or other adenosine diphosphate
(ADP) receptor inhibitor within 10 days prior to
screening
Yes
No
Have been administered glycoprotein IIb/IIIa
(GPIIb/IIIa) inhibitor within the past 7 days or
planned use of a GPIIb/IIIa inhibitor during PCI
Yes
No
Are receiving or will receive oral anticoagulation
or other antiplatelet therapy, other than aspirin
(ASA), which cannot be safely discontinued for
the duration of the study.
Yes
No
Are receiving daily treatment with nonsteroidal
anti-inflammatory drugs (NSAIDs) or
cyclooxygenase-2 (COX2) inhibitors that cannot
be discontinued during the study
Yes
No
Are women who are known to be pregnant
Yes
No
Breastfeeding
Yes
No
Have known severe hepatic dysfunction (that is,
with cirrhosis or portal hypertension)
Yes
No
Have a history of intolerance or allergy to aspirin
or approved thienopyridines (ticlopidine,
clopidogrel or prasugrel)
Yes
No
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Eligibility EARLY ACS Acute Coronary
Syndrome NCT00089895
The purpose of this study is to see if early INTEGRILIN®
(eptifibatide) therapy in patients with non-ST-segment
elevation acute coronary syndrome (ACS) reduces the
occurence of death, heart attack and urgent cardiac
intervention (surgery) compared to placebo (with delayed
provisional use of eptifibatide).
https://clinicaltrials.gov/ct2/show/NCT00089895
All rights reserved. Please visit https://medical-data-
models.org/forms/11712
Eligibility criteria
Inclusion Criteria
Willing and able to give informed consent and
comply with study procedures and follow-up
through 1 year.
Yes
No
symptoms of cardiac ischemia
Yes
No
60 years of age or more
Yes
No
Electrocardiogram changes
Yes
No
Elevated troponin levels
Yes
No
Elevated CK-MB levels
Yes
No
Prior history of cardiovascular disease
Yes
No
Exclusion criteria
pregnancy (known or suspected)
Yes
No
renal dialysis within 30 days prior to randomizing
in study
Yes
No
Stroke
Yes
No
central nervous system damage
Yes
No
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bleeding disorders
Yes
No
major surgery
Yes
No
major trauma
Yes
No
treatment with heparin
Yes
No
Treatment with eptifibatide
Yes
No
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Eligibility SWAP Acute Coronary Syndrome
NCT00356135
This study will compare the effect of a prasugrel 10-mg
maintenance dose with a clopidogrel 75-mg maintenance
dose on platelet activity, approximately 1 week after the first
dose of study drug, in subjects who have been taking
clopidogrel 75 mg daily following a percutaneous coronary
intervention (PCI) with placement of a stent, performed to
treat acute coronary syndrome (ACS).
https://clinicaltrials.gov/ct2/show/NCT00356135
All rights reserved. Please visit https://medical-data-
models.org/forms/11715
Eligibility Criteria
Inclusion Criteria
Present with a recent history of an ACS event
Yes
No
who state that they are supposed to be taking
daily aspirin
Yes
No
who state that they are supposed to be taking
maintenance dose 75-mg clopidogrel.
Yes
No
Are of a legal age (and at least 18 years of age
but less than 75 years of age)
Yes
No
Are competent mental condition to provide written
informed consent before entering the study.
Yes
No
Exclusion Criteria
Left main coronary artery stent
Yes
No
left anterior descending (LAD) bifurcation stent
Yes
No
Have any form of coronary revascularization
(percutaneous coronary intervention [PCI] or
coronary artery bypass grafting [CABG]) planned
to occur during the study (from signing consent
through the final visit).
Yes
No
Have any form of coronary revascularization
(percutaneous coronary intervention [PCI] or
coronary artery bypass grafting [CABG]) planned
to occur during the study (from signing consent
through the final visit).
Yes
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No
Receiving or will receive oral anticoagulation
(other than aspirin and clopidogrel) that cannot
be safely discontinued for the duration of the
study.
Yes
No
Receiving or will receive other antiplatelet therapy
(other than aspirin and clopidogrel) that cannot
be safely discontinued for the duration of the
study.
Yes
No
Receiving daily treatment with nonsteroidal anti-
inflammatory drugs (NSAIDs) that cannot be
discontinued or are anticipated to require daily
treatment with NSAIDs during the study.
Yes
No
history of ischemic or hemorrhagic stroke
Yes
No
Intracranial neoplasm
Yes
No
Arteriovenous malformation
Yes
No
Aneurysm
Yes
No
History of transient ischemic attack (TIA)
Yes
No
Have a body weight less than 60 kilograms (kg)
Yes
No
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Eligibility Dalteparin Acute Coronary
Syndrome NCT00922766
To collect data on safety and effectiveness of dalteparin in
the management of non-ST segment elevated acute
coronary syndromes in nursing home patients who will be
treated conservatively (without percutaneous corornary
intervention [PCI] or coronary artery bypass graft [CABG]
within 48 hours).
https://clinicaltrials.gov/ct2/show/NCT00922766
All rights reserved. Please visit https://medical-data-
models.org/forms/11716
Eligibility Criteria
Inclusion Criteria
Male or female patients
Yes
No
18 years or more
Yes
No
Presenting with chest pain
Yes
No
No coronary bypass graft
Yes
No
No PCI
Yes
No
Evidence of a personally signed and dated
informed consent document
Yes
No
Recieved Dalteparin
Yes
No
Exclusion Criteria
Dalteparin contraindicated
Yes
No
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Eligibility Aliskiren and Valsartan Acute
Coronary Syndrome NCT00409578
The purpose of this study is to test the hypothesis that the
inhibition of the renin-angiotensin-aldosterone system
(RAAS) with the angiotensin receptor blocker valsartan or
the renin antagonist aliskiren will improve ventricular
hemodynamics, as reflected by a greater reduction in levels
of N-terminal proB-type natriuretic peptide (NT-proBNP)
compared to placebo in subjects stabilized following acute
coronary syndrome (ACS) who are determined to be at
high risk due to an elevated concentration of natriuretic
peptides.
https://clinicaltrials.gov/ct2/show/NCT00409578
All rights reserved. Please visit https://medical-data-
models.org/forms/11717
Eligibility Criteria
Inclusion Criteria
Male or female outpatients
Yes
No
18 years old or older
Yes
No
Final  diagnosis of acute coronary syndrome
Yes
No
ischemic chest discomfort
Yes
No
Elevated concentrations of natriuretic peptide 3-
10 days after admission for their qualifying acute
coronary syndrome event
Yes
No
Exclusion criteria
Presence of clinically overt heart failure
Yes
No
Known evidence of left ventricular systolic
dysfunction
Yes
No
Percutaneous coronary intervention (PCI) less
than 24 hours before randomization
Yes
No
chronic ACEI therapy
Yes
No
chronic ARB therapy
Yes
No
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Eligibility Cardiac Biomarker Assay Acute
Coronary Syndrome NCT01608100
The objective of the study is to evaluate the performance
and intended use of a new cardiac biomarker test, Troponin
I, in an intended use population. Blood specimens will be
tested using the new investigational test that detects the
level of Troponin I. Results will be compared to the
diagnosis of whether or not an acute myocardial infarction
(MI) occurred.
https://clinicaltrials.gov/ct2/show/NCT01608100
All rights reserved. Please visit https://medical-data-
models.org/forms/11718
Eligibility Criteria
Inclusion Criteria
presenting to the Emergency Department with
symptoms consistent with or suggestive of Acute
Coronary Syndrome (ACS) defined as at least 5
minutes of chest pain (or symptoms consistent
with myocardial ischemia) up to 6 hours prior to
initial evaluation.
Yes
No
an Electrocardiogram (ECG) result within 2 hours
of presentation for observation of Acute Coronary
Syndrome (ACS).
Yes
No
greater than 18 years of age.
Yes
No
not known to be pregnant.
Yes
No
Exclusion Criteria
prior participation in this study.
Yes
No
require dialysis for end stage renal disease.
Yes
No
require dialysis for end stage renal disease.
Yes
No
history of a previous heart transplant.
Yes
No
coexisting disorder associated with limited life
expectancy.
Yes
No
currently participating in another investigational
device or drug study.
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Yes
No
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NCT01608100
Eligibility FUTURA/OASIS 8 Acute
Coronary Syndrome NCT00790907
The purpose of this study is to compare the safety of two
different dose regimens of unfractionated heparin (UFH)
during a percutaneous coronary intervention (PCI)
procedure in patients with UA (unstable angina)/NSTEMI
(non ST segment elevation myocardial infarction) who have
been initially treated with fondaparinux.
https://clinicaltrials.gov/ct2/show/NCT00790907
All rights reserved. Please visit https://medical-data-
models.org/forms/11719
Eligibility Criteria
Inclusion Criteria
Presenting or admitted to hospital with symptoms
suspected to represent UA
Yes
No
Presenting or admitted to hospital with symptoms
suspected to represent NSTEMI
Yes
No
Planned coronary angiography, with PCI if
indicated, within 72 hours of enrollment where
possible.
Yes
No
Planned coronary angiography, with PCI if
indicated, within 72 hours of enrollment where
possible.
Yes
No
Age greater than or equal to 60 years
Yes
No
Troponin T above the upper limit of normal for the
local institution;
Yes
No
Troponin I above the upper limit of normal for the
local institution;
Yes
No
CK-MB above the upper limit of normal for the
local institution;
Yes
No
Electrocardiogram (ECG) changes compatible
with ischemia, i.e., ST depression at least 1 mm
in 2 contiguous leads
Yes
No
Electrocardiogram (ECG) changes compatible
with ischemia, i.e., T wave inversion > 3 mm
Yes
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No
Electrocardiogram (ECG) changes compatible
with ischemia, i.e., or any dynamic ST shift or
transient ST elevation
Yes
No
Written informed consent dated and signed
Yes
No
Exclusion Criteria
Age < 21 years
Yes
No
Any contraindication to UFH
Yes
No
Any contraindication to fondaparinux
Yes
No
Contraindication for angiography or PCI at
baseline
Yes
No
Contraindication for angiography at baseline
Yes
No
refractory or recurrent angina associated with
dynamic ST-deviation
Yes
No
heart failure
Yes
No
life-threatening arrhythmias
Yes
No
hemodynamic instability
Yes
No
Subjects already receiving treatment with
enoxaparin for treatment of the qualifying events
Yes
No
Subjects already receiving treatment with LMWH
for treatment of the qualifying events
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Yes
No
Subjects already receiving treatment with
bivalirudin for treatment of the qualifying events
Yes
No
Subjects already receiving treatment with UFH for
treatment of the qualifying events
Yes
No
Hemorrhagic stroke within the last 12 months.
Yes
No
Indication for anti-coagulation other than acute
coronary syndrome (ACS) during the index
hospitalization.
Yes
No
Pregnancy or women of childbearing potential
who are not using an effective method of
contraception.
Yes
No
Co-morbid condition with life expectancy less
than 6 months.
Yes
No
Currently receiving an experimental
pharmacological agent.
Yes
No
Revascularization procedure already performed
for the qualifying event.
Yes
No
Severe renal insufficiency (i.e., estimated
creatinine clearance <20 ml/min)
Yes
No
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Eligibility Bridge Acute Coronary Syndrome
NCT00767507
The purpose of this study is to demonstrate that patients
receiving cangrelor infusion before coronary artery bypass
grafting have an acceptable safety profile and can undergo
surgery without excessive bleeding peri-operatively.
https://clinicaltrials.gov/ct2/show/NCT00767507
All rights reserved. Please visit https://medical-data-
models.org/forms/11720
Eligibility Criteria
Inclusion Criteria
Written informed consent
Yes
No
18 Years of Age
Yes
No
Non emergent coronary bypass graft surgery
Yes
No
Received a thienopyridine within 48 hours prior to
enrollment
Yes
No
Exclusion Criteria
Confirmed or suspected pregnancy
Yes
No
Cerebrovascular accident within one yar
Yes
No
Intracranial neoplasm
Yes
No
History of bleeding diathesis
Yes
No
Thrombocytopenia
Yes
No
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Eligibility ROMICAT-II Acute Coronary
Syndrome NCT01084239
The growing availability of cardiac computed tomography
(CT)* in emergency departments (EDs) across the U.S.
expands the opportunities for its clinical application, but
also heightens the need to define its appropriate use in the
evaluation of patients with acute chest pain. To address this
need, we performed a randomized diagnostic trial (RDT) to
determine whether integrating cardiac CT, along with the
information it provides on coronary artery disease (CAD)
and left ventricular (LV) function, can improve the efficiency
of the management of these patients (i.e. shorten length of
hospital stay, increase direct discharge rates from the ED,
decreasing healthcare costs and improving cost
effectiveness while being safe).
https://clinicaltrials.gov/ct2/show/NCT01084239
All rights reserved. Please visit https://medical-data-
models.org/forms/11722
Eligibility Critera
Inclusion Criteria
Participant had at least five minutes of chest pain
or equivalent (chest tightness; pain radiating to
left, right, or both arms or shoulders, back, neck,
epigastrium, jaw/throat; or unexplained shortness
of breath, syncope/presyncope, generalized
weakness, nausea, or vomiting thought to be of
cardiac origin) at rest or during exercise within 24
hours of ED presentation, warranting further risk
stratification, as determined by an ED attending.
Yes
No
2 or more cardiac risk factors (diabetes,
hypertension, hyperlipidemia, current smoker and
family history of coronary artery disease).
Yes
No
Diabetes
Yes
No
Hypertension
Yes
No
Hyperlipidemia
Yes
No
Current smoker
Yes
No
family history of coronary artery disease
Yes
No
Able to provide a written informed consent.
Yes
No
<75 years of age, but >40 years of age.
Yes
No
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Able to hold breath for at least 10 seconds.
Yes
No
Sinus rhythm.
Yes
No
Exclusion Criteria
New diagnostic ischemic ECG changes in more
than two anatomically adjacent leads or left
bundle branch block
Yes
No
ST-segment elevation or depression > 1 mm
Yes
No
T-wave inversion > 4 mm
Yes
No
Documented or self-reported history of MI
Yes
No
Documented or self-reported history of
percutaneous coronary interventions [PCIs]
Yes
No
Documented or self-reported history of coronary
artery bypass graft [CABG]
Yes
No
Documented or self-reported history of known
significant coronary stenosis [>50%]
Yes
No
Greater than 6 hours since presentation to ED.
Yes
No
BMI >40 kg/m2
Yes
No
Impaired renal function as defined by serum
creatinine >1.5 mg/dL*
Yes
No
Impaired renal function as defined by serum
creatinine >1.5 mg/dL*
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Yes
No
Elevated troponin-T (> 0.09 ng/ml)
Yes
No
Hemodynamically or clinically unstable condition
(BP systolic < 80 mm Hg, atrial or ventricular
arrhythmias, persistent chest pain despite
adequate therapy)
Yes
No
BP systolic < 80 mm Hg
Yes
No
atrial or ventricular arrhythmias
Yes
No
persistent chest pain despite adequate therapy
Yes
No
Known allergy to iodinated contrast agent
Yes
No
Currently symptomatic asthma
Yes
No
Documented or self-reported cocaine use within
the past 48 hours (acute)
Yes
No
On Metformin therapy and unable or unwilling to
discontinue for 48 hours after the CT scan
Yes
No
Contraindication to beta blockers (taking daily
antiasthmatic medication): This exclusion only
applies to patients with a heart rate >65 bpm at
sites using a non-dual source CT scanner
Yes
No
Participant with no telephone or cell phone
numbers or no address (preventing follow-up)
Yes
No
Participant with positive pregnancy test. Women
of childbearing potential, defined as <2 years of
menopause in the absence of hysterectomy or
tube ligation, must have a pregnancy test
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performed within 24 hours before the CT scan.
Yes
No
Participant unwilling to provide a written informed
consent.
Yes
No
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Eligibility MINT Acute Coronary Syndrome
NCT01167582
The purpose of this study is to evaluate two approaches to
red blood cell transfusion in anemic patients with acute
coronary syndrome.
https://clinicaltrials.gov/ct2/show/NCT01167582
All rights reserved. Please visit https://medical-data-
models.org/forms/11723
Eligibility Criteria
Inclusion Criteria
age 18 or older
Yes
No
STEMI (ST segment elevated myocardial
infarction)
Yes
No
NSTEMI (Non ST segment elevation myocardial
infarction)
Yes
No
unstable angina
Yes
No
stable coronary artery disease
Yes
No
undergoing cardiac catheterization during the
index hospitalization
Yes
No
written informed consent has been obtained
Yes
No
hemoglobin concentration less than 10 g/dL at
the time of random allocation.
Yes
No
Exclusion Criteria
bleeding cannot be controlled at the cardiac
catheterization puncture site and/or require
surgery to repair vessel
Yes
No
retroperitoneal bleeding requiring surgery
Yes
No
clinically important hemodynamic instability
based on the judgment of the treating physician
Yes
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No
terminal malignancy or life expectancy less than
6 months
Yes
No
scheduled for cardiac surgery within the next 30
days
Yes
No
declines blood transfusion
Yes
No
history of a clinically significant transfusion
reaction
Yes
No
inability to provide informed consent;
Yes
No
enrolled in a competing study
Yes
No
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Eligibility RegistStents Acute Coronary
Syndrome NCT01171612
The purpose of this study is to evaluate and monitor
perioperative management of patients with coronary stents
undergoing noncardiac surgery.
https://clinicaltrials.gov/ct2/show/NCT01171612
All rights reserved. Please visit https://medical-data-
models.org/forms/11726
Eligibility criteria
Inclusion Criteria
> 18 years old
Yes
No
with coronary stents
Yes
No
American Society of Anaesthesia physical status
II-V
Yes
No
informed consent
Yes
No
Exclusion Criteria
< 18 years old
Yes
No
American Society of Anaesthesia physical status
I
Yes
No
ambulatory surgery
Yes
No
pregnancy
Yes
No
obstetric anaesthesia
Yes
No
endoscopic procedures
Yes
No
cardiac surgery
Yes
No
not informed consent
Yes
No
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Eligibility Vascular Inflammation Acute
Coronary Syndrome NCT00552188
The purpose of this study is to determine the effect of VIA-
2291 as compared to placebo on vascular inflammation
following 24 weeks of dosing.
https://www.clinicaltrials.gov/ct2/show/NCT00552188
All rights reserved. Please visit https://medical-data-
models.org/forms/11727
Eligibility Critera
Inclusion Criteria
Female patients must be of non-childbearing
potential
Yes
No
Recent acute coronary syndrome
Yes
No
Carotid or ascending aorta artery plaque
inflammation Target-to-Background Ratio (TBR) ≥
1.6
Yes
No
Receiving concomitant statin therapy following
the qualifying ACS event for a minimum of 4
weeks, including a stable statin dose regimen for
2 weeks prior to randomization.
Yes
No
Exclusion Criteria
Renal insufficiency defined as creatinine >1.5 x
upper limit of normal (ULN)
Yes
No
Cirrhosis
Yes
No
Recent hepatitis
Yes
No
Alanine aminotransferase (ALT) >1.5 x ULN
Yes
No
Positive screening test for hepatitis B (hepatitis B
surface antigen)
Yes
No
Positive screening test for hepatitis C (by ELISA)
Yes
No
Type I diabetes and uncontrolled Type 2 diabetes
defined as hemoglobin A1c (HbA1c) > 9%
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Yes
No
Heart failure defined by New York Heart
Association Class III or IV
Yes
No
Coronary Artery Bypass Surgery (CABG) within 4
months of randomization
Yes
No
Use of zileuton
Yes
No
Use of montelukast
Yes
No
Use of coumadin
Yes
No
steroids
Yes
No
Acetaminophen use in any form in the 7 days
before enrollment at Visit 1
Yes
No
Allergy to contrast agents
Yes
No
Planned additional cardiac intervention (e.g., PCI,
CABG) within next 6 months
Yes
No
Current atrial fibrillation
Yes
No
Current atrial flutter
Yes
No
Frequent premature ventricular contractions
Yes
No
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Eligibility PLATO Acute Coronary Syndrome
NCT00391872
Ticagrelor is a new, reversible binding, anti-platelet
medication. Anti-platelet medications work to prevent the
formation of blood clots. Ticagrelor is being developed as a
treatment for patients with acute coronary syndrome (ACS).
ACS is a term that is used to describe both heart attacks in
progress or the imminent threat of a heart attack. ACS is
usually caused by the formation of a blood clot in an artery
that partially or totally blocks the blood supply to a portion
of the heart muscle. Ticagrelor will be compared with
clopidogrel to determine which drug, when either is used in
conjunction with aspirin, is better at reducing deaths from
vascular causes, future heart attacks and/or strokes in
patients with ACS.
https://clinicaltrials.gov/ct2/show/NCT00391872
All rights reserved. Please visit https://medical-data-
models.org/forms/11728
Eligibility Criteria
Inclusion Criteria
Male or Female
Yes
No
Age > 18
Yes
No
hospitalised for chest pain
Yes
No
Potential ACS
Yes
No
Exclusion Criteria
moderate or severe liver disease
Yes
No
treated with blood clotting agents that cannot be
stopped
Yes
No
already been treated with an invasive
(angioplasty) procedure
Yes
No
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Eligibility RACS Acute Coronary Syndrome
NCT00521976
The main aim of this trial is to assess the long-term
prognostic value of different types of Factor XIIa in an
unselected, single center series of 871 chest pain patients
admitted to the emergency unit, employing blood samples
collected at admission.
The second purpose of this study is to assess the
incremental prognostic value of B-type natriuretic peptide
(BNP) and high-sensitive C-reactive protein (hsCRP).
A third purpose of this study is to evaluate the prognostic
impact of the Omega-3 Index which is a measure of
eicosapentaenoic acid (EPA) and docosahexaenoic acid
(DHA) relative to other fatty acids in the erythrocyte
membrane.
https://www.clinicaltrials.gov/ct2/show/NCT00521976
All rights reserved. Please visit https://medical-data-
models.org/forms/11731
Eligibility criteria
Inclusion Criteria
adults > 18 years
Yes
No
able to give informed consent
Yes
No
a history of chest pain
Yes
No
other symptoms suggestive of an ACS leading to
admission at the emergency unit
Yes
No
Exclusion Criteria
< 18 years of age
Yes
No
Unwillingness or incapacity to provide informed
consent
Yes
No
Prior admission resulting in inclusion in the
present study
Yes
No
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Treatment Chemotherapy-docetaxel/capecitabine
arm Breast Cancer NCT00433589
Treatment Chemotherapy-docetaxel/capecitabine arm
Breast Cancer NCT00433589
Breast Cancer NCT00433589 Treatment - Chemotherapy-
docetaxel/capecitabine arm - 2499349v1.0
Chemotherapy-docetaxel/capecitabine arm
Genetic Testing or Clinical Assessment in Determining the
Need for Chemotherapy in Women With Breast Cancer
That Involves No More Than 3 Lymph Nodes
NCT00433589
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=196E5474-
4AF3-680E-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
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Treatment Chemotherapy-
docetaxel/capecitabine arm Breast
Cancer NCT00433589
Header
Patient date of birth
DD.MM.YYYY
Patient Hospital Number
Institution Name
Institution No.
Physician of Record
Date
Investigator Signature
Chemotherapy Docetaxel/Capecitabine
arm
Date Chemotherapy Began
Cycle Number
Body weight
>= 0
kg
Body surface area
>= 0
m²
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Performance Status
Fully Active, Able To Carry On All Pre-
disease Performance Without
Restriction. (0)
Restricted In Physically Strenuous
Activity But Ambulatory And Able To
Carry Out Work Of A Light Or Sedentary
Nature, E.g., Light Housework, Office
Work. (1)
Ambulatory And Capable Of All Selfcare
But Unable To Carry Out Any Work
Activities. Up And About More Than 50%
Of Waking Hours. (2)
Capable Of Only Limited Selfcare,
Confined To Bed Or Chair More Than
50% Of Waking Hours. (3)
Completely Disabled. Cannot Carry On
Any Selfcare. Totally Confined To Bed Or
Chair. (4)
Cycle Delayed?
Yes
No
Total Daily Dose of Agent (or Drug)
Were there any dose modifications or
additions/omissions to protocol treatment?
No (No)
Yes, Both Planned And Unplanned (Yes,
both planned and unplanned)
Dose modification
Dose Delayed (Dose delayed)
Dose Delayed And Reduced (Dose
delayed and reduced)
Dose Escalated (Dose escalated)
Dose Held (Dose held)
Dose Reduced (Dose reduced)
Drug Discontinued (Drug discontinued)
No Dose Modification (No dose
modification)
Reason for therapy modification
Hematologic Toxicity (Hematologic
toxicity)
Was treatment modified?
Yes
No
Number of Capecitabine Doses Missed
2 / 2
Treatment Chemotherapy-docetaxel/capecitabine arm Breast Cancer
NCT00433589
Registration Worksheet NSCLC Z4032
NCT00107172
Z4032 Registration Worksheet NCT00107172
Surgery With or Without Internal Radiation Therapy in
Treating Patients With Stage I Non-Small Cell Lung Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=F20F53D3-
C88B-6847-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11740
Registration Worksheet NSCLC
Z4032 NCT00107172
Header Module
Visit
Registration (Registration)
Patient ID (Pt. ID issued during registration or
previously issued patient ID)
Patient Initials
Institution No.
Institution Name
Registration Date
Has patient previously been registered to an
ACOSOG study
Yes
No
Coordinating Group Protocol No.
Patient demographics
Patient date of birth
DD.MM.YYYY
Gender
Female (F)
Male (M)
Race (Mark all that apply)
A Person Having Origins In Any Of The
Original Peoples Of North And South
America (including Central America),
And Who Maintains Tribal Affiliation Or
Community Attachment. (American
Indian or Alaska native)
A Person Having Origins In Any Of The
Original Peoples Of The Far East,
Southeast Asia, Or The Indian
Subcontinent Including, For Example,
1 / 6
Cambodia, China, India, Japan, Korea,
Malaysia, Pakistan, The Philippine
Islands, Thailand, And Vietnam. (Asian)
A Person Having Origins In Any Of The
Black Racial Groups Of Africa. Terms
Such As "haitian" Or "negro" Can Be
Used In Addition To "black Or African
American." (Black)
A Person Having Origins In Any Of The
Original Peoples Of Hawaii, Guam,
Samoa, Or Other Pacific Islands. (Native
Hawaiian or other Pacific Islander)
Could Not Be Determined Or Unsure
(Unknown)
A Person Having Origins In Any Of The
Original Peoples Of Europe, The Middle
East, Or North Africa. (White)
Ethnicity (Mark only one)
A Person Of Mexican, Puerto Rican,
Cuban, Central Or South American Or
Other Spanish Culture Or Origin,
Regardless Of Race. (HISPANIC OR
LATINO)
A Person Not Meeting The Definition For
Hispanic Or Latino. (NOT HISPANIC OR
LATINO)
Could Not Be Determined Or Unsure
(UNKNOWN)
Method of payment (Mark all that apply)
Medicaid (Medicaid)
Medicaid And Medicare (Medicaid and
medicare)
Medicare (Medicare)
Medicare And Private Insurance
(Medicare and private insurance)
Military Or Veterans Sponsored Nos
(Military or veterans sponsored NOS)
Military Sponsored (including Champus
& Tricare) (Military sponsored)
No Means Of Payment (no Insurance)
(No means of payment)
Other (Other)
Private Insurance (Private insurance)
Self Pay (no Insurance) (Self pay)
Veterans Sponsored (Veterans
sponsored)
Other, specify
Body weight
>= 0
kg
Height
>= 0
cm
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Patient Zip Code (USA)
Postal code (Canada)
Other Country Postal Code (Other)
Country of Residence
Date Informed Consent Signed
HIPAA Authorization form (OR)
Included In Study Informed Consent
(Included in Study Informed Consent)
HIPAA Authorization Date (If signed as a
separate form,)
Minor criteria met (check all that apply)
Age >= 75 (Age >= 75)
Modified Medical Research Council
Dyspnea Scale >=3 (Modified Medical
Research Council Dyspnea Scale >=3)
Pco2 > 45 Mmhg (pCO2 > 45 mmHg)
Poor Left Ventricular Function (Poor left
ventricular function)
Pulmonary Hypertension (Pulmonary
hypertension)
Resting Or Exercise Arterial Po2 <= 55
Mmhg Or Spo2 <= 88% (Resting or
exercise arterial pO2 <= 55 mmHg or
SpO2 <= 88%)
Baseline Performace Status (ECOG/modified
Zubrod scale)
Fully Active, Able To Carry On All Pre-
disease Performance Without Restriction
(0)
Restricted In Physically Strenuous
Activity But Ambulatory And Able To
Carry Out Work Of A Light Or Sedentary
Nature, E.g., Light Housework, Office
Work. (1)
Ambulatory And Capable Of All Selfcare
But Unable To Carry Out Any Work
Activities. Up And About More Than 50%
Of Waking Hours. (2)
Capable Of Only Limited Selfcare,
Confined To Bed Or Chair More Than
50% Of Waking Hours. (3)
Completely Disabled. Cannot Carry On
Any Selfcare. Totally Confined To Bed Or
Chair. (4)
Pre-operative Criteria
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Patient must have a suspicious lung nodule for
clinical stage I NSCLC
Yes
No
Patient must have a mass <= 3 cm maximum
diameter by CT size estimate: clinical stage Ia or
selected Ib (i.e., with visceral pleural involvement)
Yes
No
Patient must have a CT scan of the chest with
upper abdomen within 60 days prior to pre-
registration
Yes
No
ECOG performance status (PS) 0, 1, or 2 (Patient
must have an )
Yes
No
Patient must meet at least one major criteria or
meet a minimum or two minor criteria as
described below (Major Criteria - FEV1 <= 50%;
DLCO <= 50%)
Yes
No
Patient must have not had previous intra-thoracic
radiation therapy
Yes
No
Women of child-bearing potential must have
negative serum or urine pregnancy test
N/a (N/A)
No (No)
Yes (Yes)
Patient, or the patient's legally acceptable
representative, must provide a signed and dated
written informed consent PRIOR to registration
and any study-related procedures being
performed
Yes
No
Patient or the patient's legally acceptable
representative must provide written authorization
to allow the use and disclosure of their protected
health information (NOTE: This may be obtained
in either the study-specific informed consent or in
a separate authorization form and must be
obtained from the patient)
Yes
No
No prior invasive malignancies, unless disease-
free for >= 5 years prior to pre-registration.
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(Exceptions: non-melanoma skin cancer, in-situ
cancers)
Yes
No
Ct Scan Of Chest/upper Abdomen
Type of imaging (Mark all that apply)
Ct Scan Of Chest (CT scan of chest)
Ct Scan Of Upper Abdomen, Including
The Liver And Adrenal Glands (CT scan
of upper abdomen, including the liver
and adrenal glands)
Date of CT Scan (chest)
Date of Abdominal CT Assessment (upper
abdomen)
Pregnancy Test
Pregnancy Test done
Yes
No
Date of most recent test
Type of pregnancy test
Serum (Serum)
Urine (Urine)
Pregnancy Test Not Performed Reason
Other (Other)
Patient Is Female But Is Not Of
Childbearing Potential (Patient is female
but is not of childbearing potential)
Patient Is Male (Patient is male)
Other, specify
Size of Nodule on CT scan
> 3.0 Cm (> 3.0 cm)
0 - 1.0 Cm (0 - 1.0 cm)
1.1 - 2.0 Cm (1.1 - 2.0 cm)
2.1 - 3.0 Cm (2.1 - 3.0 cm)
Clinical Stage
Clinical T Stage
Tumor 3 Cm Or Less In Greatest
Dimension, Surrounded By Lung Or
Visceral Pleura, Invasion More Proximal
Than The Lobar Bronchus, (i.e., Not In
The Main Bronchus) (T1)
Tumor With Any Of The Following
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Features Of Size Or Extent: More Than
3cm In Greatest Dimension; Invades The
Visceral Pleura; Associated With
Atelectasis Or Obstructive Pneumonitis
That Extends To The Hilar Region But
Does Not Involve The Entire Lung (T2)
Tumor Of Any Size That Directly Invades
Any Of The Following: Chest Wall
(including Superior Sulcus Tumors),
Diaphragm, Mediastinal Pleura, Parietal
Pericardium; Or Tumor In The Main
Bronchus Less Than 2 Cm Distal To The
Carina, But Without Involvement O* (T3)
Clinical N Stage
No Regional Lymph Node Metastasis
(N0)
Metastasis To Ipsilateral Peribronchial
And/or Ipsilateral Hilar Lymph Nodes,
And Intrapulmonary Nodes Including
Involvement By Direct Extension Of The
Primary Tumor (N1)
Metastasis To Ipsilateral Mediastinal
And/or Subcarinal Lymph Node(s) (N2)
Clinical M Stage
No Distant Metastasis (M0)
Pre-operative Pft's
Forced Expiratory Volume 1 (FEV1)
Forced Expiratory Volume 1 (%Predicted FEV1)
%
Carbon Monoxide Diffusion (DLCO)
%
Forced Vital Capacity (% predicted)
%
Did the Investigator sign the CRF indicating
review of all data and certifying data are accurate
and complete to the best of their knowledge
Yes (Yes)
Date of Investigator Signature
Footer Module
Completed by
Date Form Completed
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CALGB 140503 PRE-REGISTRATION
WORKSHEET
CALGB 140503 PRE-REGISTRATION WORKSHEET
Comparison of Different Types of Surgery in Treating
Patients With Stage IA Non-Small Cell Lung Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=6E4AB7DA-
A34F-776C-E040-BB89AD430B3B
All rights reserved. Please visit https://medical-data-
models.org/forms/11741
CALGB 140503 PRE-
REGISTRATION WORKSHEET
Protocol Administration
Date Informed Consent Signed (MM DD YYYY)
HIPAA Authorization Date (MM DD YYYY)
Projected Start Date of Treatment (surgery - MM
DD YYYY)
Institution/Affiliate
Physician of Record
NCI Investigator Number
NCI Institution No
Patient Demographics/pre-treatment
Characteristics
Patient Initials (Last, First Middle)
Patient date of birth
DD.MM.YYYY
Patient Social Security Number
Patient Hospital No.
Gender
Female (F)
Male (M)
Race (Mark all that apply)
A Person Having Origins In Any Of The
Original Peoples Of North And South
America (including Central America),
And Who Maintains Tribal Affiliation Or
Community Attachment. (American
1 / 2
Indian or Alaska Native)
A Person Having Origins In Any Of The
Original Peoples Of The Far East,
Southeast Asia, Or The Indian
Subcontinent Including, For Example,
Cambodia, China, India, Japan, Korea,
Malaysia, Pakistan, The Philippine
Islands, Thailand, And Vietnam. (Asian)
A Person Having Origins In Any Of The
Black Racial Groups Of Africa. Terms
Such As "haitian" Or "negro" Can Be
Used In Addition To "black Or African
American." (Black or African American)
A Person Having Origins In Any Of The
Original Peoples Of Hawaii, Guam,
Samoa, Or Other Pacific Islands. (Native
Hawaiian or other Pacific Islander)
Could Not Be Determined Or Unsure
(Unknown)
A Person Having Origins In Any Of The
Original Peoples Of Europe, The Middle
East, Or North Africa. (White)
Ethnicity (Mark one)
A Person Of Mexican, Puerto Rican,
Cuban, Central Or South American Or
Other Spanish Culture Or Origin,
Regardless Of Race. (Hispanic or Latino)
A Person Not Meeting The Definition For
Hispanic Or Latino. (Not Hispanic or
Latino)
Could Not Be Determined Or Unsure
(Unknown)
Patient Zip Code
Country of Residence (If not USA)
Notes:
Name of VATS lobectomy credentialed surgeon
(If VATS lobectomy is planned, provide the
following:)
CRA Name
CRA Phone
CRA e-mail
2 / 2
CALGB 140503 PRE-REGISTRATION WORKSHEET
Registration Endometrial Cancer
NCT00063999
Registration Endometrial Cancer NCT00063999 
Registration Form, GOG-0209, Form R
Combination Chemotherapy in Treating Patients With Stage
III, Stage IV, or Recurrent Endometrial Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=B23EF80F-
A3B1-0ED8-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/11742
Registration Endometrial Cancer
NCT00063999
Header Module
Date form originally completed (m d y)
Date form amended (m d y)
Person amending form, last name
Patient Name, Last
Patient Name, First
Patient Study ID
Person Completing Form, Last Name
Tracking Information
Institution name (affiliate)
Treating physician
Patient medical record number
Patient date of birth
DD.MM.YYYY
Patient Social Security Number
Patient's zip code (USA)
Country of residence (if not USA)
Demographic Information
1 / 4
Patient race (mark all that apply)
A Person Having Origins In Any Of The
Original Peoples Of North And South
America (including Central America),
And Who Maintains Tribal Affiliation Or
Community Attachment (American Indian
or Alaska Native)
A Person Having Origins In Any Of The
Original Peoples Of The Far East,
Southeast Asia, Or The Indian
Subcontinent Including, For Example,
Cambodia, China, India, Japan, Korea,
Malaysia, Pakistan, The Philippine
Islands, Thailand, And Vietnam. (Asian)
A Person Having Origins In Any Of The
Black Racial Groups Of Africa. Terms
Such As "haitian" Or "negro" Can Be
Used In Addition To "black Or African
American." (Black or African American)
A Person Having Origins In Any Of The
Original Peoples Of Hawaii, Guam,
Samoa, Or Other Pacific Islands (Native
Hawaiian or other Pacific Islander)
Patient Is Unsure Of Their Race
(Unknown)
A Person Having Origins In Any Of The
Original Peoples Of Europe, The Middle
East, Or North Africa. (White)
Patient ethnicity (check one)
A Person Of Mexican, Puerto Rican,
Cuban, Central Or South American Or
Other Spanish Culture Or Origin,
Regardless Of Race (Hispanic or Latino)
A Person Not Meeting The Definition For
Hispanic Or Latino. (Non-Hispanic)
Patient Is Unsure Of Their Ethnicity
(Unknown)
Method of payment
Medicaid (Medicaid)
Medicaid And Medicare (Medicaid &
Medicare)
Medicare (Medicare)
Medicare And Private Insurance
(Medicare/Private Insurance)
Military Or Veterans Sponsored Nos
(Military or Veterans Sponsored NOS)
Military Sponsored (including Champus
& Tricare) (Military Sponsored (including
CHAMPUS & TRICARE))
No Means Of Payment (no Insurance)
(No means of payment (no insurance))
Other (Other)
Private Insurance (Private Insurance)
Self Pay (no Insurance) (Self pay (no
insurance))
Unknown (Unknown)
Veterans Sponsored (Veterans
Sponsored)
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Height
>= 0
cm
Body weight
>= 0
kg
Performance status (Zubrod)
Fully Active, Able To Carry On All Pre-
disease Performance Without Restriction
(karnofsky 90 - 100) (ecog - 0
Asymptomatic) (0 = Fully active, able to
carry on all pre-disease performance
without restriction (Kamofsky 90-100))
Restricted In Physically Strenuous
Activity But Ambulatory (k70 - 80) (ecog -
1 Symptomatic - Fully Ambulatory) (1 =
Restricted in physically strenuous
activity, but ambulatory (K 70-80))
Ambulatory And Capable Of All Selfcare
But Unable To Carry Out Any Work
Activities (k 50 - 60) (ecog - 2
Symptomatic; In Bed , 50% Of The Day)
(2 = Ambulatory and capable of all
selfcare but unable to carry out any work
activities (K 50-60))
Capable Of Limited Selfcare, Confined
To Bed Or Chair More Than 50% Of
Waking Hours. (k 30 - 40) (ecog - 3
Symptomatic; In Bed > 50% Of The Day
But Not Bedridden) (3 = Capable of only
limited selfcare, confined to bed or chair
for more than 50% of waking hours (K
30-40))
Completely Disabled (k10 - 20) (ecog - 4
Bedridden) (4 = Completely disabled (K
10-20))
Has the patient had any prior cancer diagnosed?
Yes
No
Prior cancer type
Prior cancer diagnosis date
COMMENTS
Footer Module
Participating Group Code
Participating Group Protocol Number
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Registration Endometrial Cancer NCT00063999
Patient Study ID, Participating Group
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Intra-operative Registration/Randomization
Lung Cancer CALGB 140503 NCT00499330
Lung Cancer NCT00499330 Registration - CALGB 140503
INTRA-OPERATIVE REGISTRATION/RANDOMIZATION
WORKSHEET - 2916823v1.0
CALGB 140503 INTRA-OPERATIVE
REGISTRATION/RANDOMIZATION WORKSHEET
Comparison of Different Types of Surgery in Treating
Patients With Stage IA Non-Small Cell Lung Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=6E4AB7DA-
A794-776C-E040-BB89AD430B3B
All rights reserved. Please visit https://medical-data-
models.org/forms/11743
Intra-operative
Registration/Randomization Lung
Cancer CALGB 140503
NCT00499330
Protocol Administration
Date Informed Consent Signed (MM DD YYYY)
HIPAA Authorization Date (MM DD YYYY)
Projected Start Date of Treatment (surgery - MM
DD YYYY)
Institution/Affiliate
Physician of Record
NCI Investigator Number
NCI Institution No
Patient Demographics/pre-treatment
Characteristics
Patient Initials (Last, First Middle)
Patient date of birth
DD.MM.YYYY
Patient Social Security Number
Patient Hospital No.
Gender
Female (FEMALE)
Male (MALE)
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Patient Demographics/pre-treatment
Characteristics2
Performance Status (ECOG/Zubrod scale)
Fully Active, Able To Carry On All Pre-
disease Performance Without
Restriction. (0)
Restricted In Physically Strenuous
Activity But Ambulatory And Able To
Carry Out Work Of A Light Or Sedentary
Nature, E.g., Light Housework, Office
Work. (1)
Ambulatory And Capable Of All Selfcare
But Unable To Carry Out Any Work
Activities. Up And About More Than 50%
Of Waking Hours. (2)
Capable Of Only Limited Selfcare,
Confined To Bed Or Chair More Than
50% Of Waking Hours. (3)
Completely Disabled. Cannot Carry On
Any Selfcare. Totally Confined To Bed Or
Chair. (4)
Dead (5)
Height
>= 0
cm
Body weight
>= 0
kg
Method of Payment (USA only Mark one)
Medicaid (Medicaid)
Medicaid And Medicare (Medicaid and
Medicare)
Medicare (Medicare)
Medicare And Private Insurance
(Medicare and Private Insurance)
Military Sponsored (including Champus
& Tricare) (Military Sponsored (including
CHAMPUS & TRICARE))
No Means Of Payment (no Insurance)
(No means of payment (no insurance))
Other (Other)
Private Insurance (Private Insurance)
Self Pay (no Insurance) (Self Pay (No
Insurance))
Unknown (Unknown)
Veterans Sponsored (Veterans
Sponsored)
Patient Demographics/pre-treatment
Characteristics3
Disease
2 / 3
Intra-operative Registration/Randomization Lung Cancer CALGB 140503
NCT00499330
Certification Of Eligibility
In the opinion of the investigator, is the patient
eligible (Study 580602: Required Imaging
Companion to 140503. All patients will be
registered to study 580602 during registration to
140503.Patients eligible for 140503 are eligible
for 580602)
Yes
No
Protocol Design
Tumor size (based on maximum dimension
determined from preoperative CT scan)
< 1.0 cm (< 1.0 cm)
> 1.5 - 2.0 cm (> 1.5 - 2.0 cm)
1 - 1.5 cm (1 - 1.5 cm)
Histology
Adenocarcinoma (Adenocarcinoma)
Other (Other)
Squamous Cell Carcinoma (Squamous
cell carcinoma)
Smoking Status
Current Smoker (Current)
Former Smoker (Former)
Never Smoked (Never)
Assigned Treatment Arm
Arm A: Lobectomy (Arm A: Lobectomy)
Arm B: Limited Resection (Arm B:
Limited Resection)
Study Companion 580602 (mandatory)
In the opinion of the investigator, is the patient
eligible (Study 580602: Required Imaging
Companion to 140503. All patients will be
registered to study 580602 during registration to
140503.Patients eligible for 140503 are eligible
for 580602)
Yes
No
Notes:
CRA Name
CRA e-mail
CRA Phone
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Intra-operative Registration/Randomization Lung Cancer CALGB 140503
NCT00499330
Registration Cervical Cancer
NCT00262821
Registration Form, Form R, GOG-0219
Cisplatin and Radiation Therapy With or Without
Tirapazamine in Treating Patients With Cervical Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=EF899EC7-
4E6D-0D91-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11744
Registration Cervical Cancer
NCT00262821
Header Module
Date form originally completed
DD.MM.YYYY
Date form amended
DD.MM.YYYY
Person amending form, last name
Patient Name, Last
Patient Name, First
Patient Study ID
Person Completing Form, Last Name
Tracking Information
Institution name (affiliate)
Treating physician
Patient medical record number
Patient date of birth
DD.MM.YYYY
Patient social security number
Patient's zip code (USA)
Country of residence (if not USA)
Demographic Information
1 / 3
Patient race (mark all that apply)
A Person Having Origins In Any Of The
Original Peoples Of North And South
America (including Central America),
And Who Maintains Tribal Affiliation Or
Community Attachment. (American
Indian or Alaska Native)
A Person Having Origins In Any Of The
Original Peoples Of The Far East,
Southeast Asia, Or The Indian
Subcontinent Including, For Example,
Cambodia, China, India, Japan, Korea,
Malaysia, Pakistan, The Philippine
Islands, Thailand, And Vietnam. (Asian)
A Person Having Origins In Any Of The
Black Racial Groups Of Africa. Terms
Such As "haitian" Or "negro" Can Be
Used In Addition To "black Or African
American." (Black or African American)
A Person Having Origins In Any Of The
Original Peoples Of Hawaii, Guam,
Samoa, Or Other Pacific Islands. (Native
Hawaiian or other Pacific Islander)
Could Not Be Determined Or Unsure
(Unknown)
A Person Having Origins In Any Of The
Original Peoples Of Europe, The Middle
East, Or North Africa. (White)
Patient ethnicity (check one)
A Person Of Mexican, Puerto Rican,
Cuban, Central Or South American Or
Other Spanish Culture Or Origin,
Regardless Of Race (Hispanic or Latino)
A Person Not Meeting The Definition For
Hispanic Or Latino. (Non-Hispanic)
Could Not Be Determined Or Unsure
(Unknown)
Method of payment
Medicaid (Medicaid)
Medicaid And Medicare (Medicaid &
Medicare)
Medicare (Medicare)
Medicare And Private Insurance
(Medicare & Private Insurance)
Military Or Veterans Sponsored Nos
(Military or Veterans Sponsored NOS)
Military Sponsored (including Champus
& Tricare) (Military Sponsored (including
Champus & Tricare))
No Means Of Payment (no Insurance)
(No means of payment (no insurance))
Other (Other)
Private Insurance (Private Insurance)
Self Pay (no Insurance) (Self pay (no
insurance))
Unknown (Unknown)
Veterans Sponsored (Veterans
Sponsored)
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Height
>= 0
cm
Body weight
>= 0
kg
Performance status (Zubrod)
Fully Active, Able To Carry On All Pre-
disease Performance Without
Restriction. (0)
Restricted In Physically Strenuous
Activity But Ambulatory And Able To
Carry Out Work Of A Light Or Sedentary
Nature, E.g., Light Housework, Office
Work. (1)
Ambulatory And Capable Of All Selfcare
But Unable To Carry Out Any Work
Activities. Up And About More Than 50%
Of Waking Hours. (2)
Capable Of Only Limited Selfcare,
Confined To Bed Or Chair More Than
50% Of Waking Hours. (3)
Completely Disabled. Cannot Carry On
Any Selfcare. Totally Confined To Bed Or
Chair. (4)
Has the patient had any prior cancer diagnosed?
Yes
No
Prior cancer type
Prior cancer diagnosis date (m d y)
Comments
COMMENTS
Footer Module
Participating Group Code
Participating Group Protocol Number
Participating Group Patient ID
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Registration RF01B Sarcoma, Kaposi
Registration RF01B Sarcoma, Kaposi
Sarcoma, Kaposi xxx Registration - Registration Form
-RF01B - 2267214v3.0
Registration Form -RF01B
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=CCE389FF-
7BB5-4F0D-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/11745
Registration RF01B Sarcoma,
Kaposi
Ccrr Module For Registration Form -rf01b
Has this patient previously participated in an
AMC Study?
Yes
No
Is this an intergroup study?
Yes
No
Protocol Version
Registerer
Phone
Fax
AMC Protocol
Principal Investigator Name
Institution (Site #)
Institution Zip Code
Race
A Person Having Origins In Any Of The
Original Peoples Of North And South
America (including Central America),
And Who Maintains Tribal Affiliation Or
Community Attachment (American Indian
or Alaska Native)
A Person Having Origins In Any Of The
Original Peoples Of The Far East,
Southeast Asia, Or The Indian
Subcontinent Including, For Example,
Cambodia, China, India, Japan, Korea,
Malaysia, Pakistan, The Philippine
Islands, Thailand, And Vietnam. (Asian)
A Person Having Origins In Any Of The
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Black Racial Groups Of Africa. Terms
Such As "haitian" Or "negro" Can Be
Used In Addition To "black Or African
American." (Black, African American,
Haitian)
A Person Having Origins In Any Of The
Original Peoples Of Hawaii, Guam,
Samoa, Or Other Pacific Islands (Native
Hawaiian, Other Pacific Islander)
Patient Is Unsure Of Their Race
(Unknown)
A Person Having Origins In Any Of The
Original Peoples Of Europe, The Middle
East, Or North Africa. (White)
Ethnicity
A Person Of Mexican, Puerto Rican,
Cuban, Central Or South American Or
Other Spanish Culture Or Origin,
Regardless Of Race (Hispanic or Latino)
A Person Not Meeting The Definition For
Hispanic Or Latino. (Non-Hispanic)
Patient Is Unsure Of Their Ethnicity
(Unknown)
Gender
Female (F)
Male (M)
Patient date of birth
DD.MM.YYYY
Age
>= 0
<= 120
years
Patient Initials
Patient Zip Code
Method of Payment
Medicaid (Medicaid)
Medicare (Medicare)
Medicaid And Medicare (Medicare and
Medicaid)
Medicare And Private Insurance
(Medicare and Private Ins)
Military Or Veterans Sponsored Nos
(Military or Veterans Admin Spons)
No Means Of Payment (no Insurance)
(No Means of Payment)
Private Insurance (Private Ins)
Self Pay (no Insurance) (Self Pay/No Ins)
Unknown (Unknown)
Date Informed Consent was Signed
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Date of Enrollment
If Yes, What is the internal ID #?
If Yes, What is the internal ID #?
Record the patient ID # from the coordinating
study
Treatment Assignment
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Demographic A0 HQ Confirmation Prostate
Cancer NCT00288080
A0 HQ Confirmation - Radiation Therapy Oncology Group
PROSTATE:CONFORMAL RT PLUS ANDROGEN
ABLATION
Hormone Therapy and Radiation Therapy or Hormone
Therapy and Radiation Therapy Followed by Docetaxel and
Prednisone in Treating Patients With Localized Prostate
Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=53DF7CA6-
6269-4FBB-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11746
Demographic A0 HQ Confirmation
Prostate Cancer NCT00288080
Module 1
Institutional person randomizing case
Has the eligibility checklist been completed
Yes
No
In the opinion of the investigator, is the patient
eligible?
Yes
No
Date Informed Consent Signed
Patient Initials
Verifying physician
Patient ID
Patient date of birth
DD.MM.YYYY
Race
A Person Having Origins In Any Of The
Original Peoples Of North And South
America (including Central America),
And Who Maintains Tribal Affiliation Or
Community Attachment. (American
Indian or Alaska Native)
A Person Having Origins In Any Of The
Original Peoples Of The Far East,
Southeast Asia, Or The Indian
Subcontinent Including, For Example,
Cambodia, China, India, Japan, Korea,
Malaysia, Pakistan, The Philippine
Islands, Thailand, And Vietnam. (Asian)
A Person Having Origins In Any Of The
Black Racial Groups Of Africa. Terms
Such As "haitian" Or "negro" Can Be
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Used In Addition To "black Or African
American." (Black or African American)
More Than One Race (More than one
race)
A Person Having Origins In Any Of The
Original Peoples Of Hawaii, Guam,
Samoa, Or Other Pacific Islands. (Native
Hawaiian or other Pacific Islander)
Could Not Be Determined Or Unsure
(Unknown)
A Person Having Origins In Any Of The
Original Peoples Of Europe, The Middle
East, Or North Africa. (White)
Ethnicity
A Person Of Mexican, Puerto Rican,
Cuban, Central Or South American Or
Other Spanish Culture Or Origin,
Regardless Of Race. (Hispanic or Latino)
A Person Not Meeting The Definition For
Hispanic Or Latino. (Not Hispanic or
Latino)
Could Not Be Determined Or Unsure
(Unknown)
Male gender
Yes
No
Country of residence
Canada (CA)
Other (Other)
Usa (US)
Patient Zip Code
Method of Payment
Medicaid (Medicaid)
Medicaid And Medicare (Medicaid and
Medicare)
Medicare (Medicare)
Medicare And Private Insurance
(Medicare and Private Insurance)
Military Or Veterans Sponsored Nos
(Military or Veterans Sponsored, Not
Otherwise Specified (NOS))
No Means Of Payment (no Insurance)
(No means of payment (no insurance))
Other (Other)
Private Insurance (Private Insurance)
Self Pay (no Insurance) (Self Pay (No
Insurance))
Unknown (Unknown)
Any care at VA or military hospital
No (No)
Unknown (Unknown)
Yes (Yes)
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Calendar base date
Randomization Date
Medical oncologist's name
Stratification
Gleason Score >=9, Psa Value <=150,
And Any T-stage (Gleason >=9 and PSA
<=150 and any T-stage)
Gleason Score 7 And Psa Value >=20-
150 And Any T-stage (Gleason 7 and
PSA >=20-150 and any T-stage)
Gleason 8 And Psa <20 And >=t2
(Gleason 8 and PSA <20 and >=T2)
Gleason Score 8 And Psa Value >=20-
150 And Any T-stage (Gleason 8 and
PSA >=20-150 and any T-stage)
Gleason Score, Combined
Baseline PSA Value
ng/ml
Clinical T Stage
Clinically Inapparent Tumor Not Palpable
Nor Visible By Imaging (T1)
Tumor Incidental Histologic Finding In
5% Or Less Of Tissue Resected (T1a)
Tumor Incidental Histologic Finding In
More Than 5% Of Tissue Resected
(T1b)
Tumor Identified By Needle Biopsy (eg,
Because Of Elevated Psa) (T1c)
Tumor Confined Within The Prostate (T2)
Tumor Extends Through The Prostate
Capule (T3)
Tumor Is Fixed Or Invades Adjacent
Structures Other Than Seminal Vesicles:
Bladder Neck, External Sphincter, Or
Rectum, Levator Muscles, And/or Pelvic
Wall (T4)
Have you obtained the patient's consent for his or
her tissue to be used for research to learn about,
prevent or treat cancer?
Yes
No
Have you obtained the patient's consent for his or
her tissue to be kept for use research about other
health problems (for example: causes of
diabetes, Alzheimer's disease, and heart
disease)?
Yes
No
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Did patient consent to future contact about more
research?
Yes
No
IMRT
Yes
No
Have you obtained the patient's consent for his or
her blood to be
kept for use in research to learn about, prevent,
treat, or cure cancer?
Yes
No
Have you obtained the patient's consent for his or
her blood to be kept for use in research to learn
about, prevent or treat other health problems (for
example: diabetes, Alzheimer's disease, or heart
disease).
Yes
No
Have you obtained the patient's consent for his or
her blood to be kept for use in future research
Yes
No
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Follow-Up Registry for Sickle Cell Diseases
Register für Sichelzellerkrankungen
Sichel-Reg, 3. Verlaufsdokumentation
Registerzentrale: Dr. Dickerhoff / Dr. Potthoff, Klinik für
Kinder-Onkologie, -Hämatologie und Klinische
Immunologie, Universitätsklinikum Düsseldorf
All rights reserved. Please visit https://medical-data-
models.org/forms/11747
Follow-Up Registry for Sickle Cell
Diseases
Patientendaten
Nachname*
Vorname*
Geburtsname (bei Änderung des Nachnamens)
Geburtsdatum
DD.MM.YYYY
Geschlecht
Female (F)
Male (M)
Meldedatum*
ID Nummer*
Straße*
PLZ*
Stadt*
E-Mail*
Telefon*
Familienstand*
ledig (1)
verheiratet (2)
geschieden (3)
verwitwet (4)
Behandelnde Klinik
Klinik*
Ansprechpartner*
1 / 10
Straße*
PLZ*
Stadt*
E-Mail*
Telefon*
Fax*
Hausarzt
Praxis*
Ansprechpartner*
Straße*
PLZ*
Stadt*
E-Mail*
Telefon*
Fax*
Beruflicher Werdegang
Schulform*
Schulabschluss*
Ausbildung/Studium/Beruf*
Aktuelle Tätigkeit*
Follow-up Status
Verstorben*
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Ja
Nein
Todesdatum*
Todesursache*
Schmerzkrisen (in den vergangenen 12
Monaten)
Schmerzkrise*
nein (0)
bis zu 3 pro Jahr (1)
mehr als 3 pro Jahr (2)
Hand-Fuß-Syndrom*
Ja
Nein
Milzsequestration
Milzsequestration*
Transfusion*
Ja
Nein
Splenektomie*
Nachgewiesene bakterielle Infektionen
Sepsis, Keimnachweis:*
Osteomyelitis, Keimnachweis:*
Meningitis, Keimnachweis:*
Cholelithiasis
Cholelithiasis*
nein (0)
symptomatische Therapie (1)
Cholezystektomie (2)
Aplastische Krise
Aplastische Krise*
Ja
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Nein
niedrigster Hb-Wert*
mg/dl
niedrigster Reti-Wert*
%
Transfusion erforderlich*
Ja
Nein
Parvo Virus Nachweis*
nicht durchgeführt (0)
nein (1)
ja (2)
Zerebraler Infarkt
Zerebraler Infarkt*
Ja
Nein
Diagnose per (MRT, Angio, CT, Andere)*
sofortige Austauschtransfusion (nein: Grund, ja)*
chronisches Transfusionsregime (nein:Grund, ja)*
Hemiparese*
Ja
Nein
Aphasie*
Ja
Nein
Andere neurologische Störung*
Knochenprobleme
Knochenprobleme*
Ja
Nein
Deckplatteneinbrüche*
Ja
Nein
Aseptische Knochennekrosen*
Therapie aseptische Knochennekrosen
(Anbohrung, Osteotomie, Endoprothese,
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Entlastung, Andere)*
weitere Knochenprobleme*
Unterschenkel Ulzera
Unterschenkel Ulzera*
Ja
Nein
Urologische Komplicationen
Urologische Komplicationen*
Ja
Nein
schmerzlose Hämaturie*
Ja
Nein
Enuresis*
Ja
Nein
Priapismus*
Effortil p.os.*
Ja
Nein
Effortil/Methylenblau i.cav.*
Ja
Nein
keine Therapie*
Ja
Nein
weitere Komplikationen*
Akutes Thoraxsyndrom
Akutes Thoraxsyndrom*
Ja
Nein
Transfusion bei Hb below 7g/dl*
Ja
Nein
partieller Austausch bei Hb above 7g/dl*
Ja
Nein
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Transfusionen
Datum der Transfusion*
Indikation der Transfusion*
Chronisches Transfusionsregime*
Ja
Nein
Beginn chronisches Transfusionsregime*
Indikation chronisches Transfusionsregime*
Chelattherapie (ja: name des Chelators, nein)*
Anderes
Aderlasstherapie (nein, ja:Indikation)*
Chirurgische Eingriffe (nein, ja:
Datum/Indikation)*
Knochenmark/Stammzelltransplantation (nein,
ja:Datum/Indikation)*
Besondere Ereignisse (Unfall, Zweiterkrankung
etc.)*
Anzahl der Krankenhaustage in den letzten 12
Monaten*
Medikamente
Penicillin Prophylaxe (nein, ja bis zum 5.
Geburtstag, ja auch nach dem 5. Geburtstag
weil)*
Hydroxycarbamid (Litalir, Siklos, Syrea) seit*
Hydroxycarbamid Dosierung*
mg/Tag
Indikation Hydroxycarbamid*
Klinischer Erfolg Hydroxycarbamid*
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Ja
Nein
Nebenwirkungen Hydroxycarbamid (nein,
ja:welche)*
ACE Hemmer seit*
Indikation für ACE-Hemmer*
Andere Medikamente*
Klinische Untersuchung
Untersuchungsdatum*
Körpergewicht
>= 0
kg
Perzentile des Körpergewichts*
Körperlänge
>= 0
cm
Perzentile der Körperlänge*
Pubertäre Entwicklung altersgerecht*
Ja
Nein
Systolischer Blutdruck*
mmHg
Diastolischer Blutdruck*
mmHg
Labor
Untersuchungsdatum*
Hämoglobin*
mg/dl
MCV*
fl
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Retis*
%
Ferritin*
ng/ml
Erythrozyten*
Tera/l
Leukozyten*
/µl
Thrombozyten*
/µl
Granulozyten*
%
Lymphozyten*
%
Bilirubin gesamt*
mg/dl
Kreatinin*
mg/dl
U-Stix (jährlich ab dem 7. Lebensjahr) Protein*
Ja
Nein
Protein im 24h-Sammelurin*
mg/24h
Sonografie Abdomen
Untersuchungsdatum*
Vergrößerung der Leber über Altersnorm*
Ja
Nein
Strukturauffälligkeiten der Leber*
Ja
Nein
Länge der Leber in der vorderen Axillarlinie*
Gallenblase*
leer (1)
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Gries (2)
Steine (3)
Z.n. Cholezystektomie (4)
Milz*
keine Vergrößerung (1)
Vergrößerung über Altersnorm (2)
Z.n. Splenektomie (3)
Kardiologische Befunde
Untersuchungsdatum*
EKG*
nicht durchgeführt (0)
normal (1)
pathologisch (2)
EKG Rhythmusstörungen*
Ja
Nein
EKG Hypertrophiezeichen*
Ja
Nein
EKG weitere Auffälligkeiten*
Echokardiografie*
nicht durchgeführt (0)
normal (1)
pathologisch (2)
Myokardiale Kontraktilitätsverminderung*
Ja
Nein
V.a. pulmonale Hypertonie*
Ja
Nein
Echokardiografie weitere Auffälligkeiten*
Augenuntersuchung
Untersuchungsdatum*
Funduskopie*
nicht durchgeführt (0)
normal (1)
pathologisch (2)
Retinaablösung*
Ja
Nein
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Proliferative Retinopathie*
Ja
Nein
Glaskörperblutung*
Ja
Nein
Abnormale Fundoskopie*
Intervention*
Visusprüfung*
nicht durchgeführt (0)
normal (1)
pathologisch (2)
Visusprüfung*
Informationen und Bemerkungen
Zu welchen speziellen Problemen wünschen Sie
Informationen?*
Bemerkungen*
Unterschrift
Name des dokumentierenden Arztes*
Datum der Unterschrift*
Unterschrift*
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Test Study
Test Study
All rights reserved. Please visit https://medical-data-
models.org/forms/11752
ODM-Form
Default Itemgroup
test2
1 / 1
base-dataset from ADT - course of
treatment
base-dataset from ADT - course of treatment, ODM derived
from
http://www.tumorzentren.de/tl_files/dokumente/adt_basis.p
df
All rights reserved. Please visit https://medical-data-
models.org/forms/11753
quality management
Patient data
Patientennummer*
Krankenkasse*
Patienten-Telefonnummer*
Patienten-Nachname*
Geburtsname*
Patienten-Vorname*
Patienten-Geschlecht*
weiblich (F)
männlich (M)
Patienten-Geburtsdatum*
DD.MM.YYYY
Nationalität/Staatsangehörigkeit*
Patientenadresse
Straße*
Postleitzahl Patient*
Wohnort*
Anamnese
Untersuchungsdatum*
Aufnahmestatus*
ambulant (ambulant)
stationär (stationär)
Zustand nach Primärtherapie*
Ja
Nein
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Beginn der Primärtherapie*
Zustand nach Rezidivtherapie*
Ja
Nein
Beginn der Rezidivtherapie*
Therapie
Operation
Primärtherapie - Operation*
Ja
Nein
Intent
adjuvant (A)
kurativ (K)
neo-adjuvant (N)
palliativ (P)
Rezidivtherapie - Operation*
Ja
Nein
Intent *
adjuvant (A)
kurativ (K)
neo-adjuvant (N)
palliativ (P)
aktuelle Operation*
Ja
Nein
Intent
adjuvant (A)
kurativ (K)
neo-adjuvant (N)
palliativ (P)
geplante Operation*
Ja
Nein
Intent
adjuvant (A)
kurativ (K)
neo-adjuvant (N)
palliativ (P)
Bestrahlung
Primärtherapie - Bestrahlung*
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Ja
Nein
Intent Bestrahlung
adjuvant (A)
kurativ (K)
neo-adjuvant (N)
palliativ (P)
Rezidivtherapie - Bestrahlung*
Ja
Nein
Intent *
Adjuvant (A = adjuvant)
Kurativ (K = kurativ)
Neoadjuvant (N = neoadjuvant)
Palliativ (P = palliativ)
aktuelle Bestrahlung*
Ja
Nein
Intent *
Adjuvant (A = adjuvant)
Kurativ (K = kurativ)
Neoadjuvant (N = neoadjuvant)
Palliativ (P = palliativ)
geplante Bestrahlung*
Ja
Nein
Intent *
Adjuvant (A = adjuvant)
Kurativ (K = kurativ)
Neoadjuvant (N = neoadjuvant)
Palliativ (P = palliativ)
Chemotherapie
Primärtherapie - Chemotherapie*
Ja
Nein
Intent *
Adjuvant (A = adjuvant)
Kurativ (K = kurativ)
Neoadjuvant (N = neoadjuvant)
Palliativ (P = palliativ)
Rezidivtherapie - Chemotherapie*
Ja
Nein
Intent *
Adjuvant (A = adjuvant)
Kurativ (K = kurativ)
Neoadjuvant (N = neoadjuvant)
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Palliativ (P = palliativ)
aktuelle Chemotherapie*
Ja
Nein
Intent *
Adjuvant (A = adjuvant)
Kurativ (K = kurativ)
Neoadjuvant (N = neoadjuvant)
Palliativ (P = palliativ)
geplante Chemotherapie*
Ja
Nein
Intent *
Adjuvant (A = adjuvant)
Kurativ (K = kurativ)
Neoadjuvant (N = neoadjuvant)
Palliativ (P = palliativ)
Hormon- / endokrine Therapie
Primärtherapie - Hormontherapie*
Ja
Nein
Intent *
Adjuvant (A = adjuvant)
Kurativ (K = kurativ)
Neoadjuvant (N = neoadjuvant)
Palliativ (P = palliativ)
Rezidivtherapie - Hormontherapie*
Ja
Nein
Intent *
Adjuvant (A = adjuvant)
Kurativ (K = kurativ)
Neoadjuvant (N = neoadjuvant)
Palliativ (P = palliativ)
aktuelle Hormontherapie*
Ja
Nein
Intent *
Adjuvant (A = adjuvant)
Kurativ (K = kurativ)
Neoadjuvant (N = neoadjuvant)
Palliativ (P = palliativ)
geplante Hormontherapie*
Ja
Nein
Intent *
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Adjuvant (A = adjuvant)
Kurativ (K = kurativ)
Neoadjuvant (N = neoadjuvant)
Palliativ (P = palliativ)
Knochenmarkstransplantation
Primärtherapie - Knochenmarkstransplantation*
Ja
Nein
Intent *
Adjuvant (A = adjuvant)
Kurativ (K = kurativ)
Neoadjuvant (N = neoadjuvant)
Palliativ (P = palliativ)
Rezidivtherapie - Knochenmarkstransplantation*
Ja
Nein
Intent *
Adjuvant (A = adjuvant)
Kurativ (K = kurativ)
Neoadjuvant (N = neoadjuvant)
Palliativ (P = palliativ)
aktuelle Knochenmarkstransplantation*
Ja
Nein
Intent *
Adjuvant (A = adjuvant)
Kurativ (K = kurativ)
Neoadjuvant (N = neoadjuvant)
Palliativ (P = palliativ)
geplante Knochenmarkstransplantation*
Ja
Nein
Intent *
Adjuvant (A = adjuvant)
Kurativ (K = kurativ)
Neoadjuvant (N = neoadjuvant)
Palliativ (P = palliativ)
Hämopoetische Stammzelltransplantation
Primärtherapie - Stammzelltransplantation*
Ja
Nein
Intent *
Adjuvant (A = adjuvant)
Kurativ (K = kurativ)
Neoadjuvant (N = neoadjuvant)
Palliativ (P = palliativ)
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Rezidivtherapie - Stammzelltransplantation*
Ja
Nein
Intent *
Adjuvant (A = adjuvant)
Kurativ (K = kurativ)
Neoadjuvant (N = neoadjuvant)
Palliativ (P = palliativ)
aktuelle Stammzelltransplantation*
Ja
Nein
Intent *
Adjuvant (A = adjuvant)
Kurativ (K = kurativ)
Neoadjuvant (N = neoadjuvant)
Palliativ (P = palliativ)
geplante Stammzelltransplantation*
Ja
Nein
Intent *
Adjuvant (A = adjuvant)
Kurativ (K = kurativ)
Neoadjuvant (N = neoadjuvant)
Palliativ (P = palliativ)
Immuntherapie
Primärtherapie - Immuntherapie*
Ja
Nein
Intent *
Adjuvant (A = adjuvant)
Kurativ (K = kurativ)
Neoadjuvant (N = neoadjuvant)
Palliativ (P = palliativ)
Rezidivtherapie - Immuntherapie*
Ja
Nein
Intent *
Adjuvant (A = adjuvant)
Kurativ (K = kurativ)
Neoadjuvant (N = neoadjuvant)
Palliativ (P = palliativ)
aktuelle Immuntherapie*
Ja
Nein
Intent *
Adjuvant (A = adjuvant)
Kurativ (K = kurativ)
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Neoadjuvant (N = neoadjuvant)
Palliativ (P = palliativ)
geplante Immuntherapie*
Ja
Nein
Intent *
Adjuvant (A = adjuvant)
Kurativ (K = kurativ)
Neoadjuvant (N = neoadjuvant)
Palliativ (P = palliativ)
Schmerztherapie / Schmerzmanagement
Primärtherapie - Schmerztherapie*
Ja
Nein
Intent *
Adjuvant (A = adjuvant)
Kurativ (K = kurativ)
Neoadjuvant (N = neoadjuvant)
Palliativ (P = palliativ)
Rezidivtherapie - Schmerztherapie*
Ja
Nein
Intent *
Adjuvant (A = adjuvant)
Kurativ (K = kurativ)
Neoadjuvant (N = neoadjuvant)
Palliativ (P = palliativ)
aktuelle Schmerztherapie*
Ja
Nein
Intent *
Adjuvant (A = adjuvant)
Kurativ (K = kurativ)
Neoadjuvant (N = neoadjuvant)
Palliativ (P = palliativ)
geplante Schmerztherapie*
Ja
Nein
Intent *
Adjuvant (A = adjuvant)
Kurativ (K = kurativ)
Neoadjuvant (N = neoadjuvant)
Palliativ (P = palliativ)
Psychoonkologie
Primärtherapie - Psychoonkologie*
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Ja
Nein
Intent *
Adjuvant (A = adjuvant)
Kurativ (K = kurativ)
Neoadjuvant (N = neoadjuvant)
Palliativ (P = palliativ)
Rezidivtherapie - Psychoonkologie*
Ja
Nein
Intent *
Adjuvant (A = adjuvant)
Kurativ (K = kurativ)
Neoadjuvant (N = neoadjuvant)
Palliativ (P = palliativ)
aktuelle Psychoonkologie*
Ja
Nein
Intent *
Adjuvant (A = adjuvant)
Kurativ (K = kurativ)
Neoadjuvant (N = neoadjuvant)
Palliativ (P = palliativ)
geplante Psychoonkologie*
Ja
Nein
Intent *
Adjuvant (A = adjuvant)
Kurativ (K = kurativ)
Neoadjuvant (N = neoadjuvant)
Palliativ (P = palliativ)
supportive Theapie
Primärtherapie - supportive Theapie*
Ja
Nein
Intent *
Adjuvant (A = adjuvant)
Kurativ (K = kurativ)
Neoadjuvant (N = neoadjuvant)
Palliativ (P = palliativ)
Rezidivtherapie - supportive Theapie*
Ja
Nein
Intent *
Adjuvant (A = adjuvant)
Kurativ (K = kurativ)
Neoadjuvant (N = neoadjuvant)
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Palliativ (P = palliativ)
aktuelle supportive Theapie*
Ja
Nein
Intent *
Adjuvant (A = adjuvant)
Kurativ (K = kurativ)
Neoadjuvant (N = neoadjuvant)
Palliativ (P = palliativ)
geplante supportive Theapie*
Ja
Nein
Intent *
Adjuvant (A = adjuvant)
Kurativ (K = kurativ)
Neoadjuvant (N = neoadjuvant)
Palliativ (P = palliativ)
Welche Therapie*
Untersuchungsanlass
Untersuchungsanlass*
medizinische Betreuung (ärztliche
Betreuung/onkologische Beratung)
Diagnostik (Diagnostik)
Nachsorge (Nachsorge)
palliative Betreuung (palliative
Betreuung)
Plan (Planung)
Symptome (Symptome)
Therapie (Therapie)
Zweitmeinung (Zweitmeinung)
Leistungszustand
ECOG Leistungszustand*
Medizinische Untersuchung
Medizinische Untersuchung*
Exploration (Chirurgische Exploration)
Computertomografie (CT)
Doppler-Ultraschall (Doppler)
Endoskopie (Endoskopie)
Histo-/Zytologie (Histo-/Zytologie)
Kernspintomographie
(Kernspintomographie)
körperliche Untersuchung (Körperliche
Untersuchungen)
Labor (Labor)
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Mammographie (Mammographie)
Positronen-Emissions-Tomographie
(PET)
Röntgen (Röntgen)
Sonographie (Sonographie)
Szintigraphie (Szintigraphie)
Tumorstatus
Tumorstatus*
nicht beurteilbar (Beurteilung nicht
möglich)
stable disease (no change)
Tumor Progression (Progression)
Teilremission (Teilremission)
kein Tumor (Tumorfrei)
komplette Remission (Vollremission)
Grund für nicht mögliche Beurteilung*
Tumorausbreitung
Tumorausbreitung*
Ja
Nein
Primärtumor*
fragliches Ergebnis (F = fraglicher
Befund)
kein Nachweis des Tumors (K = kein
Tumornachweis)
Rezidiv (R = Rezidiv)
Tumor vorhanden (T = Tumornachweis)
Medizinische Untersuchung*
Exploration (CH = Chirurgische
Exploration)
Computertomografie (CT )
Doppler-Ultraschall (DO = Doppler)
Endoskopie (EN = Endoskopie)
Histo-/Zytologie (HI = Histo-/Zytologie)
körperliche Untersuchung (KU =
Körperliche Untersuchung)
Labor (LA = Labor)
Mammographie (MA = Mammographie)
Kernspintomographie (NM =
Kernspintomographie)
Positronen-Emissions-Tomographie (PT
= Positronen-Emissions-Tomo.)
Röntgen (RÖ = Röntgen)
Sonographie (SO = Sonographie)
Szintigraphie (SZ = Szintigraphie)
Metastase in regionären Lymphknoten*
fragliches Ergebnis (F = fraglicher
Befund)
kein Nachweis des Tumors (K = kein
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Tumornachweis)
Rezidiv (R = Rezidiv)
Tumor vorhanden (T = Tumornachweis)
Medizinische Untersuchung*
Exploration (CH = Chirurgische
Exploration)
Computertomografie (CT )
Doppler-Ultraschall (DO = Doppler)
Endoskopie (EN = Endoskopie)
Histo-/Zytologie (HI = Histo-/Zytologie)
körperliche Untersuchung (KU =
Körperliche Untersuchung)
Labor (LA = Labor)
Mammographie (MA = Mammographie)
Kernspintomographie (NM =
Kernspintomographie)
Positronen-Emissions-Tomographie (PT
= Positronen-Emissions-Tomo.)
Röntgen (RÖ = Röntgen)
Sonographie (SO = Sonographie)
Szintigraphie (SZ = Szintigraphie)
Metastase in Fern - Lymphknoten*
fragliches Ergebnis (F = fraglicher
Befund)
kein Nachweis des Tumors (K = kein
Tumornachweis)
Rezidiv (R = Rezidiv)
Tumor vorhanden (T = Tumornachweis)
Medizinische Untersuchung*
Exploration (CH = Chirurgische
Exploration)
Computertomografie (CT )
Doppler-Ultraschall (DO = Doppler)
Endoskopie (EN = Endoskopie)
Histo-/Zytologie (HI = Histo-/Zytologie)
körperliche Untersuchung (KU =
Körperliche Untersuchung)
Labor (LA = Labor)
Mammographie (MA = Mammographie)
Kernspintomographie (NM =
Kernspintomographie)
Positronen-Emissions-Tomographie (PT
= Positronen-Emissions-Tomo.)
Röntgen (RÖ = Röntgen)
Sonographie (SO = Sonographie)
Szintigraphie (SZ = Szintigraphie)
Datum der Diagnose*
Metastase in der Lunge*
fragliches Ergebnis (F = fraglicher
Befund)
kein Nachweis des Tumors (K = kein
Tumornachweis)
Rezidiv (R = Rezidiv)
Tumor vorhanden (T = Tumornachweis)
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Medizinische Untersuchung*
Exploration (CH = Chirurgische
Exploration)
Computertomografie (CT )
Doppler-Ultraschall (DO = Doppler)
Endoskopie (EN = Endoskopie)
Histo-/Zytologie (HI = Histo-/Zytologie)
körperliche Untersuchung (KU =
Körperliche Untersuchung)
Labor (LA = Labor)
Mammographie (MA = Mammographie)
Kernspintomographie (NM =
Kernspintomographie)
Positronen-Emissions-Tomographie (PT
= Positronen-Emissions-Tomo.)
Röntgen (RÖ = Röntgen)
Sonographie (SO = Sonographie)
Szintigraphie (SZ = Szintigraphie)
Datum der Diagnose*
Metastase in der Leber*
fragliches Ergebnis (F = fraglicher
Befund)
kein Nachweis des Tumors (K = kein
Tumornachweis)
Rezidiv (R = Rezidiv)
Tumor vorhanden (T = Tumornachweis)
Medizinische Untersuchung*
Exploration (CH = Chirurgische
Exploration)
Computertomografie (CT )
Doppler-Ultraschall (DO = Doppler)
Endoskopie (EN = Endoskopie)
Histo-/Zytologie (HI = Histo-/Zytologie)
körperliche Untersuchung (KU =
Körperliche Untersuchung)
Labor (LA = Labor)
Mammographie (MA = Mammographie)
Kernspintomographie (NM =
Kernspintomographie)
Positronen-Emissions-Tomographie (PT
= Positronen-Emissions-Tomo.)
Röntgen (RÖ = Röntgen)
Sonographie (SO = Sonographie)
Szintigraphie (SZ = Szintigraphie)
Datum der Diagnose*
Metastase im Gehirn*
fragliches Ergebnis (F = fraglicher
Befund)
kein Nachweis des Tumors (K = kein
Tumornachweis)
Rezidiv (R = Rezidiv)
Tumor vorhanden (T = Tumornachweis)
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Medizinische Untersuchung*
Exploration (CH = Chirurgische
Exploration)
Computertomografie (CT )
Doppler-Ultraschall (DO = Doppler)
Endoskopie (EN = Endoskopie)
Histo-/Zytologie (HI = Histo-/Zytologie)
körperliche Untersuchung (KU =
Körperliche Untersuchung)
Labor (LA = Labor)
Mammographie (MA = Mammographie)
Kernspintomographie (NM =
Kernspintomographie)
Positronen-Emissions-Tomographie (PT
= Positronen-Emissions-Tomo.)
Röntgen (RÖ = Röntgen)
Sonographie (SO = Sonographie)
Szintigraphie (SZ = Szintigraphie)
Datum der Diagnose*
Metastase in der Pleura*
fragliches Ergebnis (F = fraglicher
Befund)
kein Nachweis des Tumors (K = kein
Tumornachweis)
Rezidiv (R = Rezidiv)
Tumor vorhanden (T = Tumornachweis)
Medizinische Untersuchung*
Exploration (CH = Chirurgische
Exploration)
Computertomografie (CT )
Doppler-Ultraschall (DO = Doppler)
Endoskopie (EN = Endoskopie)
Histo-/Zytologie (HI = Histo-/Zytologie)
körperliche Untersuchung (KU =
Körperliche Untersuchung)
Labor (LA = Labor)
Mammographie (MA = Mammographie)
Kernspintomographie (NM =
Kernspintomographie)
Positronen-Emissions-Tomographie (PT
= Positronen-Emissions-Tomo.)
Röntgen (RÖ = Röntgen)
Sonographie (SO = Sonographie)
Szintigraphie (SZ = Szintigraphie)
Datum der Diagnose*
Metastase in der Haut*
fragliches Ergebnis (F = fraglicher
Befund)
kein Nachweis des Tumors (K = kein
Tumornachweis)
Rezidiv (R = Rezidiv)
Tumor vorhanden (T = Tumornachweis)
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Medizinische Untersuchung*
Exploration (CH = Chirurgische
Exploration)
Computertomografie (CT )
Doppler-Ultraschall (DO = Doppler)
Endoskopie (EN = Endoskopie)
Histo-/Zytologie (HI = Histo-/Zytologie)
körperliche Untersuchung (KU =
Körperliche Untersuchung)
Labor (LA = Labor)
Mammographie (MA = Mammographie)
Kernspintomographie (NM =
Kernspintomographie)
Positronen-Emissions-Tomographie (PT
= Positronen-Emissions-Tomo.)
Röntgen (RÖ = Röntgen)
Sonographie (SO = Sonographie)
Szintigraphie (SZ = Szintigraphie)
Datum der Diagnose*
Metastase in den Knochen*
fragliches Ergebnis (F = fraglicher
Befund)
kein Nachweis des Tumors (K = kein
Tumornachweis)
Rezidiv (R = Rezidiv)
Tumor vorhanden (T = Tumornachweis)
Medizinische Untersuchung*
Exploration (CH = Chirurgische
Exploration)
Computertomografie (CT )
Doppler-Ultraschall (DO = Doppler)
Endoskopie (EN = Endoskopie)
Histo-/Zytologie (HI = Histo-/Zytologie)
körperliche Untersuchung (KU =
Körperliche Untersuchung)
Labor (LA = Labor)
Mammographie (MA = Mammographie)
Kernspintomographie (NM =
Kernspintomographie)
Positronen-Emissions-Tomographie (PT
= Positronen-Emissions-Tomo.)
Röntgen (RÖ = Röntgen)
Sonographie (SO = Sonographie)
Szintigraphie (SZ = Szintigraphie)
Datum der Diagnose*
Metastase in der Nebenniere*
fragliches Ergebnis (F = fraglicher
Befund)
kein Nachweis des Tumors (K = kein
Tumornachweis)
Rezidiv (R = Rezidiv)
Tumor vorhanden (T = Tumornachweis)
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Medizinische Untersuchung*
Exploration (CH = Chirurgische
Exploration)
Computertomografie (CT )
Doppler-Ultraschall (DO = Doppler)
Endoskopie (EN = Endoskopie)
Histo-/Zytologie (HI = Histo-/Zytologie)
körperliche Untersuchung (KU =
Körperliche Untersuchung)
Labor (LA = Labor)
Mammographie (MA = Mammographie)
Kernspintomographie (NM =
Kernspintomographie)
Positronen-Emissions-Tomographie (PT
= Positronen-Emissions-Tomo.)
Röntgen (RÖ = Röntgen)
Sonographie (SO = Sonographie)
Szintigraphie (SZ = Szintigraphie)
Datum der Diagnose*
Metastase im Peritoneum*
fragliches Ergebnis (F = fraglicher
Befund)
kein Nachweis des Tumors (K = kein
Tumornachweis)
Rezidiv (R = Rezidiv)
Tumor vorhanden (T = Tumornachweis)
Medizinische Untersuchung*
Exploration (CH = Chirurgische
Exploration)
Computertomografie (CT )
Doppler-Ultraschall (DO = Doppler)
Endoskopie (EN = Endoskopie)
Histo-/Zytologie (HI = Histo-/Zytologie)
körperliche Untersuchung (KU =
Körperliche Untersuchung)
Labor (LA = Labor)
Mammographie (MA = Mammographie)
Kernspintomographie (NM =
Kernspintomographie)
Positronen-Emissions-Tomographie (PT
= Positronen-Emissions-Tomo.)
Röntgen (RÖ = Röntgen)
Sonographie (SO = Sonographie)
Szintigraphie (SZ = Szintigraphie)
Datum der Diagnose*
Metastase in der Milz*
fragliches Ergebnis (F = fraglicher
Befund)
kein Nachweis des Tumors (K = kein
Tumornachweis)
Rezidiv (R = Rezidiv)
Tumor vorhanden (T = Tumornachweis)
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Medizinische Untersuchung*
Exploration (CH = Chirurgische
Exploration)
Computertomografie (CT )
Doppler-Ultraschall (DO = Doppler)
Endoskopie (EN = Endoskopie)
Histo-/Zytologie (HI = Histo-/Zytologie)
körperliche Untersuchung (KU =
Körperliche Untersuchung)
Labor (LA = Labor)
Mammographie (MA = Mammographie)
Kernspintomographie (NM =
Kernspintomographie)
Positronen-Emissions-Tomographie (PT
= Positronen-Emissions-Tomo.)
Röntgen (RÖ = Röntgen)
Sonographie (SO = Sonographie)
Szintigraphie (SZ = Szintigraphie)
Datum der Diagnose*
Metastase im Ovar*
fragliches Ergebnis (F = fraglicher
Befund)
kein Nachweis des Tumors (K = kein
Tumornachweis)
Rezidiv (R = Rezidiv)
Tumor vorhanden (T = Tumornachweis)
Medizinische Untersuchung*
Exploration (CH = Chirurgische
Exploration)
Computertomografie (CT )
Doppler-Ultraschall (DO = Doppler)
Endoskopie (EN = Endoskopie)
Histo-/Zytologie (HI = Histo-/Zytologie)
körperliche Untersuchung (KU =
Körperliche Untersuchung)
Labor (LA = Labor)
Mammographie (MA = Mammographie)
Kernspintomographie (NM =
Kernspintomographie)
Positronen-Emissions-Tomographie (PT
= Positronen-Emissions-Tomo.)
Röntgen (RÖ = Röntgen)
Sonographie (SO = Sonographie)
Szintigraphie (SZ = Szintigraphie)
Datum der Diagnose*
Metastase im Knochenmark*
fragliches Ergebnis (F = fraglicher
Befund)
kein Nachweis des Tumors (K = kein
Tumornachweis)
Rezidiv (R = Rezidiv)
Tumor vorhanden (T = Tumornachweis)
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Medizinische Untersuchung*
Exploration (CH = Chirurgische
Exploration)
Computertomografie (CT )
Doppler-Ultraschall (DO = Doppler)
Endoskopie (EN = Endoskopie)
Histo-/Zytologie (HI = Histo-/Zytologie)
körperliche Untersuchung (KU =
Körperliche Untersuchung)
Labor (LA = Labor)
Mammographie (MA = Mammographie)
Kernspintomographie (NM =
Kernspintomographie)
Positronen-Emissions-Tomographie (PT
= Positronen-Emissions-Tomo.)
Röntgen (RÖ = Röntgen)
Sonographie (SO = Sonographie)
Szintigraphie (SZ = Szintigraphie)
Datum der Diagnose*
Fernmestastase (andere Organe)*
fragliches Ergebnis (F = fraglicher
Befund)
kein Nachweis des Tumors (K = kein
Tumornachweis)
Rezidiv (R = Rezidiv)
Tumor vorhanden (T = Tumornachweis)
Medizinische Untersuchung*
Exploration (CH = Chirurgische
Exploration)
Computertomografie (CT )
Doppler-Ultraschall (DO = Doppler)
Endoskopie (EN = Endoskopie)
Histo-/Zytologie (HI = Histo-/Zytologie)
körperliche Untersuchung (KU =
Körperliche Untersuchung)
Labor (LA = Labor)
Mammographie (MA = Mammographie)
Kernspintomographie (NM =
Kernspintomographie)
Positronen-Emissions-Tomographie (PT
= Positronen-Emissions-Tomo.)
Röntgen (RÖ = Röntgen)
Sonographie (SO = Sonographie)
Szintigraphie (SZ = Szintigraphie)
Datum der Diagnose*
anderes Organ, welches?*
Leitlinie
Einhaltung der Leitlinen*
Ja
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Nein
Begründung*
Interdisziplinäre Fallvorstellung  durchgeführt*
Ja
Nein
Begründung*
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Director's Challenge Lung Study Pathology
Evaluation Form
Pathology documentation
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=E6E7E98D-
6ED2-346C-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11754
Director's Challenge Lung Study
Pathology Evaluation Form
Enrollment Requirements
Specimen Identifier Number
Surgery Date
Tumor Size, Largest Dimension (cm)
cm
Histologic Subtype
Histologic Subtype
Acinar Carcinoma (Acinar)
Bronchiolo-alveolar Carcinoma (BAC,
non-invasive)
Mixed Type Bronchiolo-alveolar
Carincoma (Mixed type bronchiolo-
alveolar)
Mucinous Histologic Subtype (Mucinous)
Non-mucinous Histologic Subtype (Non-
mucinous)
Papillary Carcinoma (Papillary)
Signet Ring Cell Carcinoma (Signet Ring
Cell)
Solid (poorly Differentiated) Carcinoma
(Solid (Poorly differentiated))
Component
Major Histologic Subtype (Major)
Minor Histologic Subtype (Minor)
Pure Histologic Subtype (Pure)
Histologic Grade
Histologic Grade Lung Cancer
Moderately differentiated (Moderate)
Poorly differentiated (Poor)
Well differentiated (Well)
Pathological Attributes
Pathological Attribute
Desmoplastic Response (Desmoplastic
response)
Inflammatory Response (Inflammatory
response)
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Lymphatic Invasion (Lymphatic invasion)
Necrosis (Necrosis)
Pleural Invasion (Pleural invasion)
Pleural Surface Involvement (Pleural
surface involvement)
Positive Bronchial Margins (Positive
bronchial margins)
Positive Lymph Nodes (Positive lymph
nodes)
Vascular Invasion (Vascular invasion)
Pathologic Attribute Indicator
No (No)
Unknown (Unknown)
Yes (Yes)
Number of Positive Lymph Nodes
Number of Lymph Nodes Examined
Inflammatory Response Intensity
Intense (Intense)
Mild Intensity (Mild)
Moderate Intensity (Moderate)
Not Applicable (N/A)
Desmoplastic Response Intensity
Intense (Intense)
Mild Intensity (Mild)
Moderate Intensity (Moderate)
Not Applicable (N/A)
Necrosis Intensity
Extensive Necrosis (Extensive)
Focal Necrosis (Focal)
Not Applicable (N/A)
Pathological Attributes Comments
Surgical-pathological Results
Margins of Surgical Resection (Choose one)
All Margins Pathologically Negative (R0)
Microscopically Positive Margins Or
Microscopic Residual Disease (R1)
Macroscopically Positive Margins Or
Gross Residual Disease (R2)
American Joint Committee on Cancer Lung N
Stage Code
No Regional Lymph Nodes Metastasis
(N0)
Metastasis To Ipsilateral Peribronchial
And/or Ipsilateral Hilar Nodes,
Intrapulmonary Nodes, And Direct
Extension Of The Primary Tumor (N1)
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Metastasis To Ipsilateral Mediastinal
And/or Subcarinal Node(s) (N2)
Metastasis To Contralateral Mediastinal,
Contralateral Hilar, Ipsilateral Or
Contralateral Scalene, Or
Supraclavicular Node(s) (N3)
Regional Lymph Nodes Cannot Be
Assessed (NX)
American Joint Committee on Cancer Lung T
Stage Code
No Evidence Of Primary Tumor (T0)
Tumor 3 Cm Or Less In Greatest
Dimension, Surrounded By Lung Or
Visceral Pleura, Not In The Main
Bronchus (T1)
Tumor With Any Of The Following: More
Than 3 Cm Greatest Dimension, Involves
Main Bronchus 2 Cm Or More Distal To
Carina, Invades Visceral Pleura,
Associated With Atelectasis Or
Obstructive Pneumonitis (T2)
Tumor Of Any Size That Directly Invades
Any Of The Following: Chest Wall,
Diaphragm, Mediastinal Pleura, Parietal
Pericardial, Or Main Bronchus Less Than
2 Cm Distal To Carina, Or Associated
Atelectasis Or Obstructive Pneumonitis
Of Entire Lung (T3)
Tumor Of Any Size That Invade Any Of
The Following: Mediastinum, Heart,
Great Vessels, Trachea, Esophagus,
Vertebral Body, Carina; Or Separate
Tumor Nodules In Same Lobe; Or Tumor
With Malignant Pleural Effusion (T4)
Tissue Evaluation
Frozen section histology vs. paraffin section
Concordant Histology (Concordant)
Discordant Histology (Discordant)
If discordant, explain
Percent area tumor cells
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On-Study Advanced Urinary Tract Cancer
CALGB 90601 NCT00942331
CALGB 90601: On-Study Form NCT00942331
Gemcitabine Hydrochloride and Cisplatin With or Without
Bevacizumab in Treating Patients With Advanced Urinary
Tract Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=653FC86F-
74B9-C88B-E040-BB89AD432982
All rights reserved. Please visit https://medical-data-
models.org/forms/11755
On-Study Advanced Urinary Tract
Cancer CALGB 90601
NCT00942331
Header module
CALGB Form (C-1760)
CALGB Study No.
CALGB Patient ID
Are data amended
Yes
No
Patient Initials (Last, First Middle)
Patient Hospital No.
Institution/Affiliate
Participating Group
Participating Group Study No.
Participating Group Patient ID
Initial Diagnosis
Date of initial diagnosis of bladder cancer
T Stage, Clinical
No Evidence Of Primary Tumor (T0)
Tumor Invades Subepithelial Connective
Tissue (T1)
Tumor More Than 2 Cm But Not More
Than 5 Cm In Greatest Dimension (T2)
Tumor More Than 5 Cm In Greatest
Dimension (T3)
Inflammatory Carcinoma (T4)
Noninvasive Papillary Carcinoma (Ta)
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Carcinoma In Situ: "flat Tumor" (Tis)
Primary Tumor Cannot Be Assessed (Tx)
N Stage, Clinical
Metastasis In A Single Lymph Node, 2
Cm Or Less In Greatest Dimension (N1)
Metastasis In A Single Lymph Node,
More Than 2 Cm But Not More Than 5
Cm In Greatest Dimension; Or Multiple
Lymph Nodes, None More Than 5 Cm In
Greatest Dimension (N2)
Metastasis In A Lymph Node More Than
5 Cm In Greatest Dimension (N3)
Regional Lymph Nodes Cannot Be
Assessed (NX)
M Stage, Clinical
No Distant Metastasis (M0)
Distant Metastasis (M1)
Distant Metastasis Cannot Be Assessed
(MX)
Date of diagnosis for recurrent/metastatic disease
or unresectable disease
Bladder
No (No)
Unknown (Unknown)
Yes (Yes)
Renal pelvis
No (No)
Unknown (Unknown)
Yes (Yes)
Ureter
No (No)
Unknown (Unknown)
Yes (Yes)
Urethra
No (No)
Unknown (Unknown)
Yes (Yes)
MedDRA disease code
Was cystectomy performed
Yes
No
Surgery Date
T Stage, Pathologic
No Evidence Of Primary Tumor (T0)
Tumor Invades Subepithelial Connective
Tissue (T1)
Tumor More Than 2 Cm But Not More
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Than 5 Cm In Greatest Dimension (T2)
Tumor More Than 5 Cm In Greatest
Dimension (T3)
Inflammatory Carcinoma (T4)
Noninvasive Papillary Carcinoma (Ta)
Carcinoma In Situ: "flat Tumor" (Tis)
Primary Tumor Cannot Be Assessed (Tx)
N Stage, Pathologic
Metastasis In A Single Lymph Node, 2
Cm Or Less In Greatest Dimension (N1)
Metastasis In A Single Lymph Node,
More Than 2 Cm But Not More Than 5
Cm In Greatest Dimension; Or Multiple
Lymph Nodes, None More Than 5 Cm In
Greatest Dimension (N2)
Metastasis In A Lymph Node More Than
5 Cm In Greatest Dimension (N3)
M Stage, Pathologic
No Distant Metastasis (M0)
Distant Metastasis (M1)
Was nephrectomy and/or ureterectomy
performed
Yes
No
Was an ureterectomy performed
Yes
No
Histologic Grade Bladder Tumor
High Grade (High Grade)
Low Grade (Low Grade)
Histologic Grade (OR)
Grade 1 (Grade 1)
Grade 2 (Grade 2)
Grade 3 (Grade 3)
Prostate
No (NO)
Unknown (UNKNOWN)
Yes (YES)
Uterus
No (NO)
Unknown (UNKNOWN)
Yes (YES)
Vagina
No (NO)
Unknown (UNKNOWN)
Yes (YES)
Pelvic wall
No (NO)
Unknown (UNKNOWN)
Yes (YES)
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Abdominal wall
No (NO)
Unknown (UNKNOWN)
Yes (YES)
Other
No (NO)
Unknown (UNKNOWN)
Yes (YES)
Other specify
Bladder Malignant Neoplasm
Regional Lymph Nodes
Yes
No
Number of positive nodes
Number of Lymph Nodes Examined
Distant metastases present?
Yes
No
Specify sites
Bone (Bone)
Liver (Liver)
Lung/pleura (Lung/pleura)
Nodal/soft Tissue (Nodal/soft tissue)
Other Specify (Other)
Spleen (Spleen)
Other specify
Baseline performance status
Fully Active, Able To Carry On All Pre-
disease Performance Without Restriction
(0)
Restricted In Physically Strenuous
Activity But Ambulatory And Able To
Carry Out Work Of A Light Or Sedentary
Nature, E.g., Light Housework, Office
Work. (1)
Ambulatory And Capable Of All Selfcare
But Unable To Carry Out Any Work
Activities. Up And About More Than 50%
Of Waking Hours. (2)
Capable Of Only Limited Selfcare,
Confined To Bed Or Chair More Than
50% Of Waking Hours. (3)
Completely Disabled. Cannot Carry On
Any Selfcare. Totally Confined To Bed Or
Chair. (4)
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Smoking History
Currently Smoking (Currently smoking)
Never Smoked (Never smoked)
Smoked In The Past (Smoked in the
past)
Number pack years smoked
Laboratory Values
ANC
10^3/mcL
Body surface area
>= 0
m²
Platelets
1000/uL
Bilirubin, total
mg/dL
Bilirubin ULN
mg/dl
ALT (SGPT)
U/L
ALT (SGPT) ULN
U/L
AST (SGOT)
U/L
AST (SGOT) ULN
U/L
Creatinine Clearance
ml/min
Urinalysis
Urine Protein (Mark one with an X.)
0 (0)
1+ (1+)
2+ (2+)
3+ (3+)
4+ (4+)
Protein measurement, urine, quantitative 24 hour
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g/24 hours
Urine Protein/Creatinine Ratio (Or UPC)
Prior Treatment - Systemic Regimens
Prior Treatment
Yes
No
Prior Treatment Regimen Name(s) (s Include all
therapies chemotherapy, hormonal, radiotherapy,
etc.)
Regimen type
Intravesical (Intravesical)
Systemic (Systemic)
Prior Treatment Regimen Start Date (MM DD
YYYY)
Prior Treatment Regimen End Date (MM DD
YYYY)
Ccrr Module For Calgb: 90202 On-study
Completed by (Last Name, First name)
Date Form Completed
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HIS course of treatment and aftercare form
- physician
HIS form from Soarian. Urologie Erlangen" with friendly
permission of the urology Erlangen (Prof. Wullich) and the
medical informatics department Erlangen (PD Dr. Brkle)
All rights reserved. Please visit https://medical-data-
models.org/forms/11756
HIS course of treatment and
aftercare form - physician
Admininstrative Daten
Patienten-Nachname*
Patienten-Vorname*
Patienten-Titel*
früherer Name*
Patienten-Geburtsdatum*
Alter*
>= 0
<= 120
years
Nationalität/Staatsangehörigkeit*
Straße*
Postleitzahl Patient*
Wohnort*
Fallnummer*
Tumordiagnose
Tumordiagnose*
Datum der Diagnose*
Nachsorge
Status Patient*
Primärfall (Primärpatient)
sonstiges (sonstiges)
nicht_kodiert (Wiederkehrer)
Untersuchungsdatum*
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Tumorstatus*
Beurteilung nicht möglich (Beurteilung
nicht möglich)
Tumor Progression (Progression)
stable disease (stable disease)
Teilremission (Teilremission)
kein Tumor (Tumorfrei)
komplette Remission (Vollremission)
Grund für nicht mögliche Beurteilung*
ECOG Leistungszustand*
0 (0)
1 (1)
2 (2)
3 (3)
4 (4)
X (X)
Untersuchungen an der Prostata
digitale rektale Untersuchung*
nicht suspekt (nicht suspekt)
suspekt (suspekt)
unbekannt (unbekannt)
Datum DRU*
PSA unterhalb der Nachweisgrenze*
Ja
Nein
PSA*
Datum PSA*
Auffälligkeiten im Labor
Auffälligkeiten im Labor*
Ja
Nein
Datum Laborauffälligkeit*
Anämie*
Ja
Nein
Niereninsuffizienz*
Ja
Nein
Leukozytopenie*
Ja
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Nein
LDH*
Ja
Nein
CRP*
Ja
Nein
andere*
Ja
Nein
Thrombozytopenie*
Ja
Nein
Bildgebende Diagnostik
Bildgebende Diagnostik*
Ja
Nein
Computertomografie*
Ja (Ja)
Nein (Nein)
unbekannt (unbekannt)
Kernspintomographie*
Ja (Ja)
Nein (Nein)
unbekannt (unbekannt)
Szintigraphie*
Ja
Nein
Positronen-Emissions-Tomographie*
Ja
Nein
Tumorstatus
Tumor Progression*
Ja (ja)
Nein (nein)
unbekannt (unbekannt)
Primärtumor*
fragliches Ergebnis (F = fraglicher
Befund)
kein Nachweis des Tumors (K = kein
Tumornachweis)
Rezidiv (R = Rezidiv)
Tumor vorhanden (T = Tumornachweis)
unbekannt (unbekannt)
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Medizinische Untersuchung*
Exploration (CH = Chirurg. Exploration)
Computertomografie (CT =
Computertomographie)
Doppler-Ultraschall (DO = Doppler)
Endoskopie (EN = Endoskopie)
Histo-/Zytologie (HI = Histo-/Zytologie)
körperliche Untersuchung (KU =
Körperliche Untersuchung)
Labor (LA = Labor)
Kernspintomographie (NM =
Kernspintomographie)
Positronen-Emissions-Tomographie (PT
= Positronen-Emissions-Tomo)
Röntgen (RÖ = Röntgen)
Sonographie (SO = Sonographie)
Szintigraphie (SZ = Szintigraphie)
Metastase in regionären Lymphknoten*
fragliches Ergebnis (F = fraglicher
Befund)
kein Nachweis des Tumors (K = kein
Tumornachweis)
Rezidiv (R = Rezidiv)
Tumor vorhanden (T = Tumornachweis)
unbekannt (unbekannt)
Medizinische Untersuchung*
Exploration (CH = Chirurg. Exploration)
Computertomografie (CT =
Computertomographie)
Doppler-Ultraschall (DO = Doppler)
Endoskopie (EN = Endoskopie)
Histo-/Zytologie (HI = Histo-/Zytologie)
körperliche Untersuchung (KU =
Körperliche Untersuchung)
Labor (LA = Labor)
Kernspintomographie (NM =
Kernspintomographie)
Positronen-Emissions-Tomographie (PT
= Positronen-Emissions-Tomo)
Röntgen (RÖ = Röntgen)
Sonographie (SO = Sonographie)
Szintigraphie (SZ = Szintigraphie)
Metastase
fraglicher Befund=questionable Result (F
)
kein Tumornachweis=No evidence of
neoplasm  (K )
Rezidiv=Recurrent Disease (R )
Tumornachweis=Neoplasm present (T )
unbekannt (unbekannt)
Tumorausbreitung
Lokalisation Fernmetastase*
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Metastase in der Haut*
Ja
Nein
Metastase im Gehirn*
Ja
Nein
Metastase in den Knochen*
Ja
Nein
Metastase im Knochenmark*
Ja
Nein
Metastase in der Leber*
Ja
Nein
Metastase in der Lunge*
Ja
Nein
Metastase im Lymphknoten*
Ja
Nein
Metastase in der Nebenniere*
Ja
Nein
Metastase im Peritoneum*
Ja
Nein
Metastase in der Pleura*
Ja
Nein
Generalisiere Metastasierung*
Ja
Nein
Fernmetastase (andere Organe)*
Ja
Nein
Nachweis durch Medizinische Untersuchung*
Chirurg. Exploration=Exploration (CH )
Computertomographie=Computertomogr
afie (CT )
Doppler=Doppler-Ultraschall (DO )
Endoskopie=Endoskopie (EN )
Histo-/Zytologie=Histo-/Zytologie (HI )
Körperliche Untersuchung=körperliche
Untersuchung (KU )
Labor=Labor (LA )
Kernspintomographie=Kernspintomogra
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phie (NM )
Positronen-Emissions-Tomo=Positronen-
Emissions-Tomographie (PT )
Röntgen=Röntgen (RÖ )
Sonographie=Sonographie (SO )
Szintigraphie=Szintigraphie (SZ )
Datum der Diagnose*
Nebenwirkungen*
Ja
Nein
Spätnebenwirkung während der Beobachtung
des Patienten*
Ja (Ja)
Nein (Nein (allgemein Keine))
unbekannt (unbekannt)
SpätNebenwirkung in Zusammenhang nmit
urologischen Operation*
Harnstauungsnieren
(Harnstauungsnieren)
Hernie (Hernie)
Impotenz (Impotenz)
Urininkontinenz (Inkontinenz)
Lymphocele (Lymphocele)
unbekannt (unbekannt)
Wundheilungsstörungen
(Wundheilungsstörungen)
Spätnebenwirkung in Zusammenhang mit der
Strahlentherapie*
Darmblutung (Darmblutung)
eingeschränkte Blasenfunktion
(eingeschränkte Blasenfunktion)
Harnstauungsnieren
(Harnstauungsnieren)
Impotenz (Impotenz)
Urininkontinenz (Inkontinenz)
unbekannt (unbekannt)
andere Spätnebenwirkungen?*
Ja (Ja)
Nein (Nein)
unbekannt (unbekannt)
Therapie
Radical Prostatectomy*
Ja
Nein
Chemotherapie*
Ja
Nein
Bestrahlung*
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Ja
Nein
Antiandrogen Therapie*
Ja
Nein
Watchful Waiting*
Ja
Nein
Active surveillance *
Ja
Nein
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Hematology/Chemistry Form Melanoma
(Skin) E2603 NCT00110019
Melanoma NCT00110019
E2603 Hematology/Chemistry Form
Carboplatin and Paclitaxel With or Without Sorafenib in
Treating Patients With Unresectable Stage III or Stage IV
Melanoma
Melanoma (Skin) NCT00110019
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=E75AAFAD-
3536-1EBE-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11758
Hematology/Chemistry Form
Melanoma (Skin) E2603
NCT00110019
Header
ECOG Protocol Number
ECOG Patient ID
DCI Name
Registration Step
Patient Initials
Participating Group Protocol Number
Institution/Affiliate
Participating Group Patient ID
Please mark an 'X' if data have been amended.
Date data amended
Comments
Investigator Signature
Investigator Signature Date
On Treatment
On Treatment Report Period (Choose one)
> Cycle 10 (> Cycle 10)
Cycle 1 (Cycle 1)
Cycle 10 (Cycle 10)
1 / 4
Cycle 2 (Cycle 2)
Cycle 3 (Cycle 3)
Cycle 4 (Cycle 4)
Cycle 5 (Cycle 5)
Cycle 6 (Cycle 6)
Cycle 7 (Cycle 7)
Cycle 8 (Cycle 8)
Cycle 9 (Cycle 9)
cycle (specify)
On Treatment Report Period
12 Months (12 Months Post Registration)
15 Months (15 Months Post Registration)
18 Months (18 Months Post Registration)
21 Months Post Registration (21 Months
Post Registration)
2 Years (24 Months Post Registration)
3 Months (3 Months Post Registration)
30 Months (30 Months Post Registration)
3 Years (36 Months Post Registration)
42 Months (42 Months Post Registration)
4 Years (48 Months Post Registration)
54 Months (54 Months Post Registration)
6 Months (6 Months Post Registration)
5 Years (60 Months Post Registration)
9 Months (9 Months Post Registration)
Hematology and Chemistry
Date Hematology Sample Obtained (Blood)
Lab Facility Name
Were hematology/chemistry results obtained this
report period (cycle)
Yes
No
Laboratory Test Not Performed Text
Peripheral WBC Count LLN
Peripheral WBC Count
1000/uL
Peripheral Granulocytes Count LLN
mm3
Peripheral Granulocytes Count
1000/uL
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Peripheral platelet count LLN
Peripheral platelet count
1000/uL
Hemoglobin LLN
g/dL
Hemoglobin
g/dL
Peripheral hematocrit count
%
Peripheral hematocrit count LLN
%
Patient Creatinine Serum ULN
mg/dL
Patient Creatine Serum Value
mg/dL
Total bilirubin (mg/dl), ULN
mg/dL
BUN
Bilirubin, total
mg/dL
SGOT ULN (AST)
SGOT (AST)
U/L
SGPT ULN (ALT)
SGPT (ALT)
U/L
Alkaline Phosphatase ULN
Alkaline Phosphatase
Albumin LLN
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Albumin
Glucose LLN
mg/dL
Glucose ULN
mg/dL
Glucose
Potassium LLN (K)
Potassium ULN
Potassium
mmol/L
Sodium LLN (Na)
Sodium ULN
Sodium
mmol/L
Lactate Dehydrogenase ULN (LDH)
U/L
Lactate Dehydrogenase
U/L
PTT ULN (partial thromboplastin time)
seconds
PTT (partial thromboplastin time)
Amylase ULN
U/L
Amylase
U/L
Lipase ULN
U/L
Lipase
U/L
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Hematology/Chemistry Form Multiple
Myeloma NCT00098475
E4A03 Hematology/Chemistry Form - Form 2057
NCT00098475 
Lenalidomide and Dexamethasone With or Without
Thalidomide in Treating Patients With Multiple Myeloma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=DCFBDEE7-
3B8B-70ED-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/11759
Hematology/Chemistry Form Multiple
Myeloma NCT00098475
Header
ECOG Protocol Number
ECOG Patient ID
DCI Name
Step
Patient Initials
Participating Group Protocol Number
Participating Group Patient ID
Institution/Affiliate
Are data amended
Yes
No
Date Hematology (Blood) Sample Obtained
On Treatment
Cycle # Step # (NOTE: More than one form can
be submitted using the same report period if
necessary.)
Cycle 1 (Cycle 1 Step 2)
Cycle 10 (Cycle 10 Step 2)
Cycle 11 (Cycle 11 Step 2)
Cycle 12 (Cycle 12 Step 2)
Cycle 2 (Cycle 2 Step 2)
Cycle 3 (Cycle 3 Step 2)
Cycle 4 (Cycle 4 Step 2)
Cycle 5 (Cycle 5 Step 2)
Cycle 6 (Cycle 6 Step 2)
Cycle 7 (Cycle 7 Step 2)
Cycle 8 (Cycle 8 Step 2)
1 / 5
Cycle 9 (Cycle 9 Step 2)
Off Treatment
Off Treatment Report Period (Choose one)
12 Months (12 Months Post Registration)
15 Months (15 Months Post Registration)
18 Months (18 Months Post Registration)
21 Months Post Registration (21 Months
Post Registration)
2 Years (24 Months Post Registration)
3 Months (3 Months Post Registration)
30 Months (30 Months Post Registration)
3 Years (36 Months Post Registration)
42 Months (42 Months Post Registration)
4 Years (48 Months Post Registration)
54 Months (54 Months Post Registration)
6 Months (6 Months Post Registration)
5 Years (60 Months Post Registration)
6 Years (72 Months Post Registration)
84 Months Post Registration (84 Months
Post Registration)
9 Months (9 Months Post Registration)
Cycle Number
Were hematology/chemistry results obtained this
report period (cycle)?
Yes
No
Lab results
Lab Facility Name
Peripheral WBC Count LLN (/mm3 x1000)
Peripheral WBC Count
1000/uL
Peripheral Granulocytes Count LLN (* AGC/ANC
/mm3)
mm3
Peripheral Granulocytes Count
1000/uL
Peripheral platelet count LLN (/mm3 x1000)
Peripheral Platelet Count
1000/uL
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Alkaline Phosphatase ULN (U/L)
Alkaline Phosphatase
Bilirubin ULN (mg/dl)
Bilirubin
mg/dl
Creatinine ULN (mg/dl)
Creatinine
mg/dL
Hemoglobin (Hgb) LLN (g/dl)
g/dL
Hemoglobin
g/dL
AST (SGOT) ULN
U/L
AST (SGOT)
U/L
ALT (SGPT) ULN
U/L
SGPT (ALT)
U/L
Calcium LLN
mmol/l
Calcium ULN
mmol/l
Calcium
mmol/l
Glucose LLN
mg/dl
Glucose ULN
mg/dl
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Glucose
mg/dl
Potassium LLN
mmol/l
Potassium ULN
mmol/l
Potassium
mmol/l
Sodium LLN (Na mmol/L)
Sodium ULN
Sodium
mmol/L
Uric acid LLN (mg/dl)
mg/dL
Uric acid ULN
mg/dL
Uric acid
mg/dL
CTC Adverse Event Attribution Scale (CTC
Adverse Event Attribution Scale For each
adverse event, record the attribution to the
protocol treatment as follows: 1=unrelated,
2=unlikely, 3=possible, 4=probable, 5=definite.
Leave attribution box blank if no adverse event.)
Serum Pregnancy Test Results
Result of most recent test
Negative (negative)
Not Applicable, Not Female Of Child-
bearing Potential (not applicable, patient
not female of child-bearing potential)
Not Evaluated (not done)
Positive (positive)
Date of most recent test
Comments
Comments
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Investigator Signature Date
Investigator Signature
5 / 5
Hematology/Chemistry Form Multiple Myeloma NCT00098475
Onstudy Laboratory Form Colorectal
Cancer SWOG S0600 NCT00499369
Lab - Southwest Oncology Group S0600  - 2603916v1.0
Southwest Oncology Group S0600 Onstudy Laboratory
Form
Irinotecan and Cetuximab With or Without Bevacizumab in
Treating Patients With Metastatic Colorectal Cancer That
Progressed During First-Line Therapy
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=2A9122C2-
3489-1DC2-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11760
Onstudy Laboratory Form Colorectal
Cancer SWOG S0600
NCT00499369
Header
SWOG Patient ID
SWOG Study No.
Registration Step
Current Cycle Number
Patient Initials (L, F M)
Institution/Affiliate
Physician
Participating Group Name
Participating Group Study No.
Participating Group Patient ID (Instructions: All
dates are MONTH, DAY, YEAR. Explain any
blank fields or blank dates in the Comments
section.)
Laboratory Values
ANC
1000/ul
Absolute neutrophil count LLN
Peripheral Platelet Count (/mcL)
1000/uL
1 / 4
Peripheral platelet count, LLN
Hemoglobin
g/dL
Hemoglobin (Hgb) LLN (g/dl)
g/dL
International Normalized Ratio
Bilirubin, total
mg/dL
Total bilirubin ULN
mg/dL
AST (SGOT)
U/L
AST (SGOT) ULN
U/L
SGPT (ALT)
U/L
ALT (SGPT) ULN
U/L
Creatinine
mg/dL
Serum Creatinine ULN
mg/dL
Proteinuria
1+ Urine Protein (1+)
2+ Urine Protein (2+)
3+ Urine Protein (3+)
Negative Urine Protein (Negative)
Protein from 24 hour Urine Collection (if > 0.5,
then 24 hour:)
g/24 hours
Ionized serum calcium
Ionized serum calcium, LLN
Calcium
mmol/l
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NCT00499369
Calcium LLN
mmol/l
Magnesium
mmol/L
Magnesium, LLN
Sodium
mmol/L
Sodium LLN
mmol/l
Potassium
mmol/l
Potassium LLN
mmol/l
Bicarbonate
Bicarbonate, LLN
Chloride
mEq/L
Chloride LLN
Collection Date
Collection Date
Collection Date
Collection Date
Collection Date
Collection Date
Collection Date
Collection Date
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Collection Date
Collection Date
Collection Date
Collection Date
Collection Date
Collection Date
Collection Date
Collection Date
Collection Date
Glucose
mg/dl
Glucose LLN
mg/dl
Comments
Comments
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Initial Evaluation Form Prostate Cancer
RTOG 1115 I1 NCT01546987
Prostate Cancer Pre-Study RTOG NCT01546987 
RTOG 1115 I1: Phase III RT + Standard ADT vs RT +
Enhanced ADT + TAK-700 Initial Evaluation Form
Hormone Therapy, Radiation Therapy, and Steroid 17alpha-
monooxygenase TAK-700 in Treating Patients With High-
Risk Prostate Cancer
Prostate Cancer NCT01546987 Pre-Study
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=AEA3B793-
58EB-AE06-E040-BB89AD431781
All rights reserved. Please visit https://medical-data-
models.org/forms/11761
Initial Evaluation Form Prostate
Cancer  RTOG 1115 I1
NCT01546987
Header
RTOG Study No.
Case #
Institution Name
Institution No.
Patient Initials
RTOG Patient ID
Amended Data
Yes
No
Comments
Signature of Person Completing This Form
Date Form Originally Completed
Patient Information
Performance Status (ECOG 0-4)
Fully Active, Able To Carry On All Pre-
disease Performance Without
Restriction. (0)
Restricted In Physically Strenuous
Activity But Ambulatory And Able To
Carry Out Work Of A Light Or Sedentary
Nature, E.g., Light Housework, Office
1 / 13
Work. (1)
Ambulatory And Capable Of All Selfcare
But Unable To Carry Out Any Work
Activities. Up And About More Than 50%
Of Waking Hours. (2)
Capable Of Only Limited Selfcare,
Confined To Bed Or Chair More Than
50% Of Waking Hours. (3)
Completely Disabled. Cannot Carry On
Any Selfcare. Totally Confined To Bed Or
Chair. (4)
History and physical/digital rectal
Yes
No
Date Performed
Has the patient had any prior cancer diagnosed
(invasive other than study site)
Yes
No
Prior malignancy site
Aml/mds (AML/MDS)
Bcc (BCC)
Bladder Is The Site Of Second Primary
Or Recurrent Tumor (bladder)
Brain Is The Site Of Second Primary Or
Recurrent Tumor (brain)
Colorectal (Colorectal)
Esophageal (Esophageal)
Gastric (Gastric)
Liver Is The Site Of Second Primary Or
Recurrent Tumor (liver)
Lung Is The Site Of Second Primary Or
Recurrent Tumor (lung)
Melanoma (Melanoma)
Nhl (NHL)
Other Hematologic (Other hematologic)
Other Solid (Other solid)
Pancreatic (Pancreatic)
Renal (Renal)
Squamous-skin (Squamous-skin)
Unknown Primary (Unknown primary)
Specify
Date Eradicated (mm-yyyy)
Other Patient Disease Type
Heart problems (unstable angina and/or
Congestive heart failure requiring hospitalization
Within the last 6 months)
Yes
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No
Heart problems (transmural myocardial infarction
within the last 6 months)
Yes
No
Infection (acute bacterial or fungal infection
Requiring intravenous antibiotics at the time of
Registration)
Yes
No
COPD exacerbation or other respiratory illness
requiring hospitalization or precluding study
therapy at registration ([within 30 days of
registration])
Yes
No
Hepatic Insufficiency (resulting in clinical
Jaundice and/or coagulation defects)
Yes
No
Does the patient have AIDS (based upon Current
CDC definition)
Yes
No
Cushing Syndrome
Yes
No
Severe chronic renal disease (per study criteria)
Yes
No
Chronic liver disease (per study criteria)
Yes
No
Uncontrolled hypertension (per study criteria)
Yes
No
Prostate: Prior Treatment
Prior surgery (RADICAL PROSTATECTOMY,
CRYOSURGERY [OR HIGH-INTENSITY
FOCUSED ULTRASOUND HIFU])
Yes
No
Prior radiation therapy ([RT INCLUDING
BRACHYTHERAPY, TO THE REGION OF
STUDY THAT WOULD RESULT IN OVERLAP
OF RT FIELDS])
Yes
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No
Prior chemotherapy
Yes
No
Prior Hormonal Therapy (LHRH AGONIST, ANTI-
ANDROGEN THERAPY, ESTOGEN,
TESTOSTERONE OR BILATERAL
ORCHIECTOMY)
Yes
No
Prior testosterone therapy (If yes, administered)
Yes
No
Prior testosterone therapy end date
Is patient receiving brachytherapy (LDR/HDR)
Yes
No
Prostate: Initial Diagnosis
Histologic Type
Adenocarcinoma, Conventional, Not
Otherwise Specified (Adenocarcinoma,
conventional NOS)
Other Specify (Other)
Other specify
Diagnosis Date
Total number of core biopsies taken
Number of positive core biopsies
Total % of positive core biopsies taken
%
Gleason Score, Primary Pattern ([most frequently
seen] 1-5, 9=unknown)
Gleason Score, Secondary Pattern ([second
most frequently seen] 1-5, 9=unknown)
Gleason Score, Worst Pattern ([worst
pathological grade seen in any specimen] 1-5,
9=unknown)
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Gleason Score, Combined
Study Entry Psa Measurements
Baseline PSA Date
Baseline PSA Value
ng/ml
Units
Nanograms Per Deciliter (ng/dL)
Nanograms Per Milliliter (ng/mL)
Not Otherwise Specified (NOS)
Method of Assay
Abbott Labs (Abbott)
Bayer (Bayer)
Dpc (DPC)
Hybritech (Hybritech)
Other (Other)
Unknown (Unknown)
Addtitional PSA Measurements
Pre-diagnostic PSA measurements (Additional
PSA's obtained within 1 year prior to diagnosis if
available)
Yes
No
PSA Date (s)
PSA Value (s)
ng/ml
Disease Information
Was the tumor palpable? (at study entry)
No (No)
Yes, <= 1/2 Of One Lobe (Yes, <= 1/2 of
one lobe)
Yes, > 1/2 Of One Lobe (Yes, > 1/2 of
one lobe)
Yes, Both Lobes (Yes, both lobes)
Yes, Nos (Yes, NOS)
Extracapsular Extension? (by clinical
examination)
Yes
No
T Stage, Clinical (AJCC 7TH EDITION)
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Tumor Incidental Histologic Finding In
5% Or Less Of Tissue Resected (T1a)
Tumor Incidental Histologic Finding In
More Than 5% Of Tissue Resected
(T1b)
Tumor Identified By Needle Biopsy (eg,
Because Of Elevated Psa) (T1c)
Tumor Confined Within The Prostate (T2)
Tumor Involves One-half Of One Lobe Or
Less (T2a)
Tumor Involves More Than One-half Of
One Lobe But Not Both Lobes (T2b)
Tumor Involves Both Lobes (T2c)
Tumor Extends Through The Prostate
Capule (T3)
Extracapsular Extension (unilateral Or
Bilateral) (T3a)
Tumor Invades Seminal Vesicle(s) (T3b)
Tumor Is Fixed Or Invades Adjacent
Structures Other Than Seminal Vesicles:
Such As External Sphincter, Rectum,
Bladder, Levator Muscles, And/or Pelvic
Wall (T4)
Primary Tumor Cannot Be Assessed
(TX)
N Stage, Pathologic
No Positive Regional Nodes (pN0)
Metastases In Regional Node(s) (pN1)
Regional Nodes Not Sampled (pNX)
N Stage, Clinical (RADIOGRAPHIC)
No Regional Lymph Node Metastasis
(N0)
Metastasis In Regional Lymph Node(s)
(N1)
Regional Lymph Nodes Were Not
Assessed (NX)
M Stage, Clinical
No Distant Metastasis (M0)
Distant Metastasis (M1)
Nonregional Lymph Node(s) (M1a)
Bone(s) (M1b)
Other Site(s) With Or Without Bone
Disease (M1c)
Regional lymph node dissection (OR
SAMPLING)
Yes
No
Baseline Lab Values (hematologic)
Date
Sodium
mmol/L
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Sodium LLN
mmol/l
Sodium ULN
mmol/l
Potassium (mEq/L)
mmol/L
Potassium LLN
mmol/l
Potassium ULN
mmol/l
Chloride (mmol/L)
mEq/L
Chloride LLN
mEq/L
Chloride ULN
mEq/L
Bicarbonate
mEq/L
Bicarbonate, LLN
mEq/L
Bicarbonate ULN
mEq/L
BUN
mg/dL
BUN LLN
mg/dl
BUN ULN
mg/dl
Creatinine
mg/dL
Creatinine LLN
mg/dL
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Creatinine ULN
mg/dL
Fasting glucose
mg/dL
Fasting glucose, LLN
mg/dL
Fasting glucose, ULN
mg/dL
Magnesium
mmol/L
Magnesium, LLN
mmol/l
Magnesium, ULN
mmol/L
Phosphorus
mg/dL
Phosphorus LLN
mg/dL
Phosphorus ULN
mg/dL
Liver Panel
Albumin
g/dL
Albumin LLN
g/dL
Albumin ULN
g/dL
AST (SGOT)
U/L
AST (SGOT) ULN
U/L
AST LLN
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U/L
SGPT (ALT)
U/L
ALT LLN
U/L
ALT ULN
U/L
Alkaline Phosphatase
U/L
Alkaline Phosphatase LLN
U/L
Alkaline Phosphatase ULN
U/L
Bilirubin, total
mg/dL
Total bilirubin LLN
mg/dL
Total bilirubin ULN
mg/dL
Direct Bilirubin
mg/dL
Direct Bilirubin LLN
mg/dL
Direct Bilirubin ULN
mg/dL
Fasting Lipid Panel
Cholesterol
mg/dL
Cholesterol LLN
mg/dL
Cholesterol ULN
mg/dL
HDL
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mg/dL
HDL LLN
mg/dL
HDL ULN
mg/dL
LDL
mg/dL
LDL LLN
mg/dL
LDL ULN
mg/dL
Triglycerides
mg/dL
Triglycerides LLN
mg/dL
Triglycerides ULN
mg/dL
Baseline Lab Values (hematologic)
Hemoglobin (gm/dL)
g/dL
Hemoglobin, LLN
g/dL
Hemoglobin, ULN
g/dL
WBC
/ul
WBC LLN
/ul
WBC ULN
/ul
Peripheral Platelet Count
1000/uL
Platelets LLN
1000/ul
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Platelets ULN
1000/ul
ANC
/ul
Absolute neutrophil count LLN
/ul
ANC ULN
/ul
Hemoglobin A1 C (%)
Hemogloblin A1C
%
Hemoglobin A1C LLN
%
Hemoglobin A1C ULN
%
Serum Testosterone
Testosterone
ng/dl
Testosterone LLN
ng/dl
Testosterone ULN
ng/dl
Patient Evaluations
Height
>= 0
cm
Body weight
>= 0
kg
MUGA Scan
Yes
No
Date
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Echocardiogram
Yes
No
Date
Resting ejection fraction
%
Transrectal Ultrasound (Brachytherapy only)
No (No)
Not Applicable (Not Applicable)
Yes (Yes)
Prostate volume
Date performed
CT/MRI abdomen/pelvis
Yes
No
Date Performed
Bone scan
Yes
No
Survivorship
Diabetes
Yes
No
Coronary Artery Disease
Yes
No
Myocardial infarction
Yes
No
Stroke
Yes
No
Pulmonary embolism
Yes
No
Deep vein thrombosis
Yes
No
Osteoporotic fracture
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Yes
No
Concomitant Medications
Concomitant medications
Yes
No
Medication
Dose
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Physical Exam Cancer Prevention
On-Study - Physical Exam - 2803173v1.0
The Division of Cancer Prevention's physical exam case
report form (CRF) template.
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=5C0F9C5A-
FB66-15A0-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11762
Physical Exam Cancer Prevention
Header
DCP Protocol #
Institution Code
Participant ID
Visit Type
Visit Date
Physical Examination
Physical Examination Date
Height
>= 0
cm
Not Obtained
Yes
No
Not Obtained
Yes
No
Not Obtained
Yes
No
Not Obtained
Yes
No
Not Obtained
Yes
No
Body weight
>= 0
kg
Temperature
1 / 3
°C
Pulse
beats/min
Respiratory Rate
/min
Systolic
>= 0
mmHg
Diastolic
>= 0
mmHg
Check here if NO body systems were examined
Yes
No
ECOG Performance Status
Fully Active, Able To Carry On All Pre-
disease Performance Without
Restriction. (0)
Restricted In Physically Strenuous
Activity But Ambulatory And Able To
Carry Out Work Of A Light Or Sedentary
Nature, E.g., Light Housework, Office
Work. (1)
Ambulatory And Capable Of All Selfcare
But Unable To Carry Out Any Work
Activities. Up And About More Than 50%
Of Waking Hours. (2)
Capable Of Only Limited Selfcare,
Confined To Bed Or Chair More Than
50% Of Waking Hours. (3)
Completely Disabled. Cannot Carry On
Any Selfcare. Totally Confined To Bed Or
Chair. (4)
Body System/Site
Abdomen (Abdomen)
Appearance (Appearance)
Breast(s) (Breast(s))
Chest (Chest)
Genitalia (Genitalia)
Heent (H/E/E/N/T)
Heart (Heart)
Lung(s) (Lung(s))
Lymph Nodes (Lymph Nodes)
Musculoskeletal (Musculoskeletal)
Neurological (Neurological)
Pelvis (Pelvis)
Prostate Gland (Prostate)
Rectal (Rectal)
Skin (Skin)
Thyroid (Thyroid)
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Vascular (Vascular)
Body System
Abnormal (Abnormal)
Normal (Normal)
Not Examined (Not Examined)
Comment (Required if Abnormal)
Dcp Template Footer
Protocol Title
Protocol Version
Protocol Date
Page #
Total Page Number
DCP Template Version
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Registration Bladder Cancer CALGB 90104
NCT00014534
Registration Worksheet - 2169258v3.0
CALGB 90104 Registration Worksheet
Combination Chemotherapy in Treating Patients With
Bladder Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=BE1B0241-
438C-6AC6-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/11763
Registration Bladder Cancer CALGB
90104 NCT00014534
Initial Patient Consent For Specimen Use
Patient's Initial Consent given for specimen use
for research on the patient's cancer?
Yes
No
Patient´s Initial Consent given for specimen use
for research unrelated to the patient´s cancer?
Yes
No
Patient's Initial Consent given for further contact
regarding specimen?
Yes
No
assigned CALGB patient ID
Registration date
Assigned Participating Group Patient ID
Registrar's Signature
Ccrr Module For Calgb 90104 Registration
Worksheet
Institution Name
Affiliate Institution
Physician of Record
Participating Group Name
CALGB Patient ID
IRB Approval Date
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Date Informed Consent Signed
Projected Treatment Start Date
HIPAA Authorization Date
Responsible contact
phone
fax
Patient Initials
Patient Social Security Number
Patient date of birth
DD.MM.YYYY
Patient Hospital No.
Gender
Female (F)
Male (M)
Race
American Indian or Alaskan Native
(American Indian or Alaskan Native)
Asian (Asian)
Black or African American (Black or
African American)
Ethnicity (Ethnicity)
Hispanic or Latino (Hispanic or Latino)
Native Hawaiian or Other Pacific Islander
(Native Hawaiian or Other Pacific
Islander)
Non-Hispanic (Non-Hispanic)
Unknown (Unknown)
Unknown (Unknown)
White (White)
Performance Status (ECOG/Zubrod)
Height
>= 0
cm
Body weight
>= 0
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kg
Body surface area
>= 0
m²
Method of Payment
medicaid (medicaid)
medicaid and medicare (medicaid and
medicare)
medicare (medicare)
medicare and private insurance
(medicare and private insurance)
military (including Champus and Tricare)
(military (including Champus and
Tricare))
no means of payment (no insurance) (no
means of payment (no insurance))
other (other)
private insurance (private insurance)
self pay (no insurance) (self pay (no
insurance))
unknown (unknown)
veterans administration sponsored
(veterans administration sponsored)
Patient's zip code
Country of residence (if not USA)
T status
T3 (T3)
T4 (T4)
Lymph node involvement
1 to 5 nodes invovled by tumor (1 to 5
nodes invovled by tumor)
A (A)
absent (absent)
B (B)
greater than or equal to 6 nodes involved
by tumor (greater than or equal to 6
nodes involved by tumor)
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CARDIOLOGY ADMISSION ORDERS -
Mount Sinai Hospital Medical Center
ODM derived from:
http://www.rwjf.org/en/library/research/2008/06/cardiology-
admission-orders-physician-s-order-sheet.html
Mount Sinai Hospital Medical Center
California Avenue at 15th Street
Chicago, IL 60608
All rights reserved. Please visit https://medical-data-
models.org/forms/11765
CARDIOLOGY ADMISSION
ORDERS, PHYSICIAN’S ORDER
SHEET
Admission Details
Admission to
CCU (CCU)
Non-Telemetry (Non-Telemetry)
Telemetry (Telemetry)
Attending Physician
Primary Physician Name
Other Service
Resident Physician Name
Medical History
Heart Failure
Yes
No
NSTEMI
Yes
No
Unstable Angina
Yes
No
CAD
Yes
No
Chest Pain
Yes
No
Other cardiac diagnosis
Allergies
Admission Orders
1 / 7
Vital signs
O2 at 2-4L nasal cannula (maintain O2
saturation >92%) ( O2 at 2-4L nasal
cannula (maintain O2 saturation >92%))
Daily I&O   Daily weights     (Daily I&O
Daily weights    )
Daily pulse oximetry  (Daily pulse
oximetry )
Per unit protocol   (Per unit protocol  )
Diet
Cardiac (no salt, no caffeine)      (Cardiac
(no salt, no caffeine)     )
Low fat/low cholesterol      (Low fat/low
cholesterol     )
Low Sodium (salt substitute)    (Low
Sodium (salt substitute)   )
NPO (NPO)
Renal      (Renal     )
Intravenous Fluids
Fluid Restriction (ml/day)
ml/day
Activity
Bed  rest  with  BR  privileges       (Bed
rest  with  BR  privileges      )
Complete  Bed  rest     (Complete  Bed
rest    )
Other (Other)
Progress  as  tolerated  (Progress  as
tolerated )
Labs
BMP       (BMP      )
BNP      (BNP     )
CBC/diff       (CBC/diff      )
CK-MB (CK-MB)
CMP and Magnesium  (CMP and
Magnesium )
CPK (CPK)
Digoxin level (Digoxin level)
Fasting Lipid Profile in AM (NPO after
midnight)    (Fasting Lipid Profile in AM
(NPO after midnight)   )
HgA1C    (HgA1C   )
INR (INR)
PT  (PT )
PTT    (PTT   )
TFT (thyroid function)       (TFT (thyroid
function)      )
Troponin-1 q 6hrs x 3     (Troponin-1 q
6hrs x 3    )
Urinalysis       (Urinalysis      )
Urine drug screen       (Urine drug screen
)
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ECG times
CXR (PA & Lat) times
Echocardiogram (if LVEF not known)
Yes
No
LVEF (if known)
Consults
Cardiology       (Cardiology      )
Home Health screening         (Home
Health screening        )
Nutrition for education/weight
management        (Nutrition for
education/weight management       )
Pharmacy for education      (Pharmacy
for education     )
PT evaluation       (PT evaluation      )
Smoking Cessation (Smoking Cessation)
Social Services        (Social Services
)
Medication Order
Aspirin 325 mg now (unless documented as
previously given or contraindicated)
Yes
No
Contraindication for Aspirin
Allergy (Allergy)
Bleeding (Bleeding)
Other (Other)
Aspirin daily dose
mg
Aspirin daily dose (frequency)
Metoprolol now (mg)  (unless  documented  as
given  in  ED  or 
contraindicated)
mg
Contraindication for Beta-Blocker
AV block >1st degree     (AV block >1st
degree    )
CHF    (CHF   )
Cocaine use  (Cocaine use )
COPD/Asthma    (COPD/Asthma   )
Decompensated  (Decompensated )
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Other (Other)
Metoprolol dose (mg)
mg
Metroprolol (daily frequency)
Carvedilol (Lopressor) dose (mg)
Carvedilol (Lopressor) (daily frequency)
Metoprolol Extended Release (Toprol XL)  dose
(mg)
mg
Metoprolol Extended Release (Toprol XL) (daily
frequency)
Other Medication
ACE Inhibitor
Contraindications
Allergy    (Allergy   )
Other: (Other:)
Renal insufficiency     (Renal
insufficiency    )
Captopril (Capoten) daily dose (mg) and daily
frequency
daily medication frequency dose
Enalapril (Vasotec) daily dose (mg) and daily
frequency
Lisinopril (Vasotec) daily dose (mg) and daily
frequency
daily medication frequency dose in mg
Ramipril (Altace) daily dose (mg) and daily
frequency
daily medication frequency dose in mg
Other ACE Inhibitor,  daily dose (mg) and daily
frequency
daily medication frequency dose in mg
ANGIOTENSIN RECEPTOR BLOCKER
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Contraindications
Allergy    (Allergy   )
Other: (Other:)
Renal insufficiency      (Renal
insufficiency     )
Irbesartan (Avapro) daily frequency dose in mg
daily medication frequency dose in mg
Valsartan (Diovan) daily frequency dose in mg
daily medication frequency dose in mg
Hydralazine/Nitrates
Hydralazine (Apresoline) daily frequency dose in
mg
daily medication frequency dose in mg
Isosorbide Dinitrate (Isordil, Dilatrate-SR,
Isochron) daily frequency dose in mg
daily medication frequency dose in mg
Isosorbide Mononitrate (Imdur, Ismo, Monoket)
daily frequency dose in mg
daily medication frequency dose in mg
Nitroglycerin Patch (Minitran, Nitrek, Nitro-Dur)
daily frequency dose in mg/hr
daily medication frequency dose in mg/hr
Nitroglycerin (NitroQuick, Nitrostat, Nitro-Tab)
sublingual daily frequency dose in mg
daily medication frequency dose in mg
Diuretics
Furosemide (Lasix) daily frequency dose in mg
daily medication frequency dose in mg
Bumetanide (Bumex) daily frequency dose in mg
daily medication frequency dose in mg
Torsemide (Demadex) daily frequency dose in mg
daily medication frequency dose in mg
Other Diuretics (Dose and Frequency)
ALDOSTERONE ANTAGONIST
Spironolactone (Aldactone)  daily frequency dose
5 / 7
CARDIOLOGY ADMISSION ORDERS - Mount Sinai Hospital Medical
Center
in mg
daily medication frequency dose in mg
DIGITALIS
Digoxin (Lanoxin) daily frequency dose in mg
daily medication frequency dose in mg
ANTICOAGULANT
Warfarin (Coumadin, Jantoven) daily dose in mg,
to be given at 21:00
mg
HMG-CoA REDUCTASE INHIBITOR
Simvastatin (Zocor) daily frequency dose in mg
daily medication frequency dose in mg
Rosuvastatin (Crestor) daily frequency dose in
mg
daily medication frequency dose in mg
Atorvastatin (Lipitor) daily frequency dose in mg
daily medication frequency dose in mg
Further Intravenous MEDICATIONS
Eptifibatide (Integrilin)180 mcg/kg IV bolus, then
2mcg/kg/min IVinfusion for 72 hr
Yes
No
ORAL POTASSIUM REPLACEMENT,
Oral Potassium Dose
10 mEq      (10 mEq     )
20 mEq      (20 mEq     )
40 mEq      (40 mEq     )
60 mEq (60 mEq)
Oral Potassium Daily Frequency
Daily Medication Frequency
ORAL MAGNESIUM REPLACEMENT
Oral Magnesium Dose
400 mg       (400 mg      )
800 mg      (800 mg     )
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other (other)
Oral Magnesium Daily Frequency
Daily Medication Frequency
OTHER MEDICATIONS
Enoxaparin (Lovenox) 1mg/kg SQ every 12
hours.
Yes
No
DVT prophylaxis (use Inpatient Anticoagulation
Orders)
Yes
No
other medication
DISCHARGE PLANNING & EDUCATION
DISCHARGE PLANNING & EDUCATION
⁯Give Smoking Cessation Instructions to
all patients who smoke  ( ⁯ Give Smoking
Cessation Instructions to all patients who
smoke )
⁯Give Myocardial Infarction Patient-
Education Pamphlet  ( ⁯Give Myocardial
Infarction Patient-Education Pamphlet )
⁯Give Post Cardiac Cathetherization
Instruction Sheet  ( ⁯Give Post Cardiac
Cathetherization Instruction Sheet )
⁯Give Post Pacemaker / AICD Instruction
Sheet  (⁯Give Post Pacemaker / AICD
Instruction Sheet )
⁯Given Heart Failure Pamphlet  ( ⁯Given
Heart Failure Pamphlet )
⁯Other ( ⁯Other)
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Tumor board review - Prostate cancer - Protocol of
the pre-therapeutic prostate tumor board review
ODM form derived from Tumorkonferenz -
Prostatakarzinom
Protokoll der prätherapeutischen Prostatakonferenz. 
Used as a routine documentation by the University Hospital
Muenster, Germany.
All rights reserved. Please visit https://medical-data-
models.org/forms/11766
Tumor board review - Prostate
cancer - Protocol of the pre-
therapeutic prostate tumor board
review
Patienten Administration
Tumorkonferenz am
Ort
Benötigte Fachabteilungen
Urologie
Strahlentherapie
Pathologie
Prostatazentrum
Nuklearmedizin
Extern
Hematologie
Psychoonkologie
Thoraxchirugie
Urologie
Name
Zusatz
gesichert (1)
Verdacht (2)
Strahlentherapie
Name
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Zusatz
gesichert (1)
Verdacht (2)
Pathologie
Name
Zusatz
gesichert (1)
Verdacht (2)
Prostatazentrum
Name
Zusatz
gesichert (1)
Verdacht (2)
Nuklearmedizin
Name
Zusatz
gesichert (1)
Verdacht (2)
Hematologie
Name
Zusatz
gesichert (1)
Verdacht (2)
Psychoonkologie
Name
Zusatz
gesichert (1)
Verdacht (2)
Thoraxchirugie
Name
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Zusatz
gesichert (1)
Verdacht (2)
Extern
Name
Zusatz
gesichert (1)
Verdacht (2)
Angaben zum Patienten
PKMS
Erwachsen/ Kind
Geburtsdatum
Diagnose
ECOG
Keine Beschwerden, keine Zeichen der
Krankheit. (0)
Normale Aktivität mit Anstrengung
möglich. Deutliche Symptome. (1)
Einige Hilfestellung nötig, selbständig in
den meisten Bereichen. (2)
Behindert. Qualifizierte Hilfe benötigt. (3)
Schwerkrank. Intensive medizinische
Maßnahmen erforderlich. (4)
Tod (5)
Studie
Bildgebung:
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Checklist for genetic disposition breast
cancer and/or Ovarian cancer
ODM form derived from Humangenetik Senologie UKM.
Used as a routine documentation by the University Hospital
Muenster, Germany.
All rights reserved. Please visit https://medical-data-
models.org/forms/11767
Checklist for genetic disposition
breast cancer and/or Ovarian cancer
Patientenadministration
Geburtsdatum
Fall-Nr.:
Geschlecht
Aufnahme in
Datum
Erfassender Benutzer
A. Patientin und deren Geschwister /
Kinder Auftreten
eines Mamma-Karzinoms bei der Patientin vor
dem 36. LJ
Anzahl  (1)
Gewichtung (2)
Ergebnis (3)
eines unilateralen Mamma-Karzinoms bei der
Patientin vor dem 51. LJ
Anzahl  (1)
Gewichtung (2)
Ergebnis (3)
eines bilateralen Mamma-Karzinoms bei der
Patientin, das erste vor dem 51. LJ
Anzahl  (1)
Gewichtung (2)
Ergebnis (3)
eines uni- oder bilateralen Mamma-Karzinoms
bei der Patientin nach dem 50. LJ
Anzahl  (1)
Gewichtung (2)
Ergebnis (3)
eines Ovarial-/Tubenkarzinoms oder einer
primären Peritonealkarzinose bei der Patientin
Anzahl  (1)
Gewichtung (2)
Ergebnis (3)
eines Mamma-Karzinoms bei
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Schwestern/Töchtern vor dem 36. LJ
Anzahl  (1)
Gewichtung (2)
Ergebnis (3)
eines unilateralen Mamma-Karzinoms bei
Schwestern/Töchtern vor dem 51. LJ
Anzahl  (1)
Gewichtung (2)
Ergebnis (3)
eines bilateralen Mamma-Karzinoms bei
Schwestern/Töchtern, das erste vor dem 51. LJ
Anzahl  (1)
Gewichtung (2)
Ergebnis (3)
eines bilateralen Mamma-Karzinoms bei
Schwestern/Töchtern, das erste nach dem 50. LJ
Anzahl  (1)
Gewichtung (2)
Ergebnis (3)
eines Mamma-Karzinoms bei Brüdern/Söhnen
Anzahl  (1)
Gewichtung (2)
Ergebnis (3)
eines Ovarial-/Tubenkarzinoms oder einer
primären Peritonealkarzinose bei
Schwestern/Töchtern
Anzahl  (1)
Gewichtung (2)
Ergebnis (3)
Summe Patientin Geschwister / Kinder
B. Mütterliche Linie - Auftreten
eines Mamma-Karzinoms bei einer Angehörigen
vor dem 36. LJ
Anzahl  (1)
Gewichtung (2)
Ergebnis (3)
eines unilateralen Mamma-Karzinoms bei einer
Angehörigen vor dem 51. LJ
Anzahl  (1)
Gewichtung (2)
Ergebnis (3)
eines bilateralen Mamma-Karzinoms bei einer
Angehörigen, das erste vor dem 51. LJ
Anzahl  (1)
Gewichtung (2)
Ergebnis (3)
eines uni- oder bilateralen Mamma-Karzinoms
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bei einer Angehörigen nach dem 50. LJ
Anzahl  (1)
Gewichtung (2)
Ergebnis (3)
eines Mamma-Karzinoms bei einem angehörigen
Mann
Anzahl  (1)
Gewichtung (2)
Ergebnis (3)
eines Ovarial-/Tubenkarzinoms oder einer
primären Peritonealkarzinose bei einer
Angehörigen
Anzahl  (1)
Gewichtung (2)
Ergebnis (3)
Total
C. Väterliche Linie
eines Mamma-Karzinoms bei einer Angehörigen
vor dem 36. LJ
Anzahl  (1)
Gewichtung (2)
Ergebnis (3)
eines unilateralen Mamma-Karzinoms bei einer
Angehörigen vor dem 51. LJ
Anzahl  (1)
Gewichtung (2)
Ergebnis (3)
eines bilateralen Mamma-Karzinoms bei einer
Angehörigen, das erste vor dem 51. LJ
Anzahl  (1)
Gewichtung (2)
Ergebnis (3)
eines uni- oder bilateralen Mamma-Karzinoms
bei einer Angehörigen nach dem 50. LJ
Anzahl  (1)
Gewichtung (2)
Ergebnis (3)
eines Mamma-Karzinoms bei einem angehörigen
Mann
Anzahl  (1)
Gewichtung (2)
Ergebnis (3)
eines Ovarial-/Tubenkarzinoms oder einer
primären Peritonealkarzinose bei einer
Angehörigen
Anzahl  (1)
Gewichtung (2)
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Ergebnis (3)
Summe väterliche Linie
D. Der höhere Wert aus B und C
E. Summe aus A und D = Risiko-Score
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Prestudy form NSCLC Stage III
NCT00020709
NCT00020709 
S0023: Combination Chemo Plus RT With or Without
Gefitinib in Treating Patients With Unresectable Stage III
NSCLC
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=9CA62D43-
4AA8-361C-E034-080020C9C0E0
All rights reserved. Please visit https://medical-data-
models.org/forms/11769
Prestudy form NSCLC Stage III
NCT00020709
SWOG clinical trial administrative data
SWOG Patient ID
SWOG Study No.
Registration Step
Patient Initials (L, F M)
Institution / Affiliate
Physician
Group Name (Groups other than SWOG )
Study No. (Groups other than SWOG )
Pt. ID (Groups other than SWOG )
Patient And Disease Description
Height
>= 0
cm
Body weight
>= 0
kg
Body surface area
>= 0
m²
Performance Status
Weight Loss in Previous Six Months
<5% (<5%)
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>=20% (>=20%)
10 - < 20% (10 - < 20%)
5 - < 10% (5 - < 10%)
FEV1
L
DLCO
%
Date of Initial Diagnosis of Primary Tumor
Histologic Type
Adenocarcinoma (Adenocarcinoma)
Bronchioloalveolar (BAC)
(Bronchioloalveolar (BAC))
Large Cell Undifferentiated (Large Cell
Undifferentiated)
NSCLC, NOS (NSCLC, NOS)
Other, Specify (Other, Specify)
Squamous (Squamous)
Other, Specify
Tumor Stage T-status
T1 (T1)
T2 (T2)
T3 (T3)
T4 (T4)
Node Stage N-status
N0 (N0)
N1 (N1)
N2 (N2)
N3 (N3)
Current Laboratory Values (si Units)
Albumin
g/dL
Lactate Dehydrogenase (LDH)
U/L
Lactate Dehydrogenase ULN (LDH)
U/L
Notes
Notes
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Vital Signs Anal Cancer NCT00324415
Anal Cancer NCT00324415 On-Study - AMC-045 Vital
Signs Form (F20) - 2937179v1.0
Cisplatin, Fluorouracil, Cetuximab, and Radiation Therapy
in Treating Patients With HIV and Stage I, Stage II, or
Stage III Anal Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=7285E88F-
E0EF-C8EB-E040-BB89AD437ABB
All rights reserved. Please visit https://medical-data-
models.org/forms/11770
Vital Signs Anal Cancer
NCT00324415
Header Module
Visit number*
Date of evaluation*
DD.MM.YYYY
Time Test Completed*
hh:mm
Vital Signs
Height*
>= 0
cm
Body weight*
>= 0
kg
Body surface area*
>= 0
m²
Systolic*
>= 0
mmHg
Diastolic*
>= 0
mmHg
Heart rate*
>= 0
bpm
Respiratory Rate*
/min
Temperature*
°C
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Karnofsky Performance Status*
%
Dead (0)
Moribund, Fatal Processes Progressing
Rapidly (10)
Normal, No Complaints, No Evidence Of
Disease (100)
Very Sick, Hospitalization Indicated.
Death Not Imminent (20)
Severely Disabled, Hospitalization
Indicated. Death Not Imminent (30)
Disabled, Requires Special Care And
Assistance (40)
Requires Considerable Assistance And
Frequent Medical Care (50)
Requires Occasional Assistance, But Is
Able To Care For Most Of His/her Needs
(60)
Cares For Self, Unable To Carry On
Normal Activity Or To Do Active Work
(70)
Normal Activity With Effort; Some Signs
Or Symptoms Of Disease (80)
Able To Carry On Normal Activity; Minor
Signs Or Symptoms Of Disease (90)
Footer Module
Comments*
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Data quality assurance of stroke acute
treatment Hessen
Quality Assurance Hessen, Eschborn
Document: record stroke acute treatment (phase A)
As of 05/01/2015
File: SA_HE_2015_V04_Bogen
All rights reserved. Please visit https://medical-data-
models.org/forms/11771
Basic / Minimum record
Basisdokumentation
Institutionskennzeichen*
Entlassender Standort*
Betriebsstätten-Nummer
Fachabteilung*
internal medicine (0100)
internal medicine: geriatrics (0102)
internal medicine: cardiology (0103)
internal medicine: nephrology (0104)
internal medicine: hematology and
internal oncology  (0105)
internal medicine: endocrinology (0106)
internal medicine: gastroenterology
(0107)
internal medicine: pneumonology (0108)
internal medicine: rheumatology (0109)
internal medicine: pulmonology (0114)
internal medicine: tumor research (0150)
internal medicine: coloproctology (0151)
internal medicine: infectiology (0152)
internal medicine: diabetes (0153)
internal medicine: naturopathy (0154)
internal medicine: stroke unit (0156)
internal medicine (0190)
geriatry (0200)
geriatry: gynecology  (0224)
geriatry: day unit (for semi-residential
care)   (0260)
geriaty: night unit (for semi-residential
care) (0261)
geriatry (0290)
cardiology (0300)
nephrology (0400)
nephrology: pediatrics (0410)
nephrology: intensive care (0436)
nephrology (0490)
hematology and internal oncology
(0500)
hematology and internal oncology:
pediatrics (0510)
hematology and internal oncology:
gynacology (0524)
hematology and internal oncology:
radiation therapy (0533)
hematology and internal oncology
(0590)
endocrinology (0600)
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endicrinology: gastroenterology (0607)
endocrinology: pediatrics (0610)
endocrinology (0690)
gastroenterology (0700)
gastroenterology: endocrinology (0706)
gastroenterology: pediatrics (0710)
gastroenterology (0790)
pneumology (0800)
rheumatology (0900)
rheumatology: pediatrics (0910)
rheumatology (0990)
pediatrics (1000)
pediatrics: nephrology (1004)
pediatrics: hematology and internal
oncology  (1005)
pediatrics: endocrinology (1006)
pediatrics: gastroenterology (1007)
pediatrics: rheumatology (1009)
pediatrics: pediatric cardiology (1011)
pediatrics: nephrology (1012)
pediatrics: pulmonology (1014)
pediatrics: pediatric neurology (1028)
pediatrics: perinatal medicine (1050)
continuing care for children (1051)
pediatrics (1090)
pediatric cardiology (1100)
pediatric cardiology: intensive care
(1136)
pediatric cardiology (1190)
neonatology (1200)
pediatric surgery (1300)
pulmonology (1400)
pulmonology: pediatrics (1410)
pulmonology (1490)
general surgery (1500)
general surgery: pediatric surgery (1513)
general surgery: trauma surgery (1516)
general surgery: vascular surgery (1518)
general surgery: plastic surgery (1519)
general surgery: thoracic surgery (1520)
general surgery: orthopedics (1523)
general surgery: intensive care (1536)
general surgery: abdominal- and
vascular surgery (1550)
Allgemeine Chirurgie: hand surgery
(1551)
general surgery (1590)
trauma surgery (1600)
neurosurgery (1700)
vascular surgery (1800)
plastic surgery (1900)
thoracic surgery (2000)
thoracic surgery: cardiac surgery (2021)
thoracic surgery: intensive care (2036)
thoracic surgery: cardiac surgery
intensive care (2050)
thoracic surgery (2090)
cardiac surgery (2100)
cardiac surgery: vascular surgery (2118)
cardiac surgery: thoracic surgery (2120)
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cardiac surgery: intensive care (2136)
cardiac surgery: thoracic surgery and
intensive care (2150)
cardiac surgery (2190)
urology (2200)
orthopedics (2300)
orthopedics: rheumatology (2309)
orthopedics: surgery (2315)
orthopedics and trauma surgery (2316)
orthopedics (2390)
gynecology and obstetrics (2400)
gynecology: geriatry (2402)
gynecology: hematology and internal
oncology  (2405)
gynecology: endocrinology (2406)
gynecology (2425)
gynecology and obstetrics (2490)
obstetrics (2500)
otolaryngology (2600)
ophthalmology (2700)
neurology: (2800)
neurology: pediatrics (2810)
neurology: stroke units (2856)
neurology (2890)
general psychiatry: (2900)
general psychiatry: neurology (2928)
general psychiatry: child and adolescent
psychiatry (2930)
general psychiatry: psychosomatics and
psychotherapy (2931)
general psychiatry: addiction treatment
(2950)
general psychiatry: geropsychiatry
(2951)
general psychiatry: forensic treatment
(2952)
general psychiatry: addiction treatment
(day unit) (2953)
general psychiatry: addiction treatment
(night unit) (2954)
general psychiatry: geropsychiatry (day
unit) (2955)
general psychiatry: geropsychiatry (night
unit) (2956)
general psychiatry: day unit (for semi-
residential care) (2960)
general psychiatry: night unit (for semi-
residential care) (2961)
general psychiatry (2990)
child and adolescent psychiatry (3000)
child and adolescent psychiatry: day unit
(for semi-residential care) (3060)
child and adolescent psychiatry: night
unit (for semi-residential care) (3061)
child and adolescent psychiatry (3090)
psychosomatic/psychotherapy (3100)
psychosomatic/psychotherapy: child and
adolescent psychiatry (3110)
psychosomatic/psychotherapy: day unit
(for semi-residential care) (3160)
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psychosomatic/psychotherapy: night unit
(for semi-residential care) (3161)
psychosomatic/psychotherapy (3190)
nuclear medicine (3200)
nuclear medicine: radiation therapy
(3233)
nuclear medicine (3290)
radiation therapy (3300)
radiation therapy: hematology and
internal oncology  (3305)
radiation therapy: radiology (3350)
radiation therapy (3390)
dermatology (3400)
dermatology: day unit (for semi-
residential care) (3460)
dermatology (3490)
dentistry, orthodontics, maxillofacial
surgery (3500)
intensive-care medicine (3600)
intensive-care medicine: internal
medicine (3601)
intensive-care medicine: cardiology
(3603)
intensive-care medicine: pediatrics
(3610)
intensive-care medicine: neurosurgery
(3617)
intensive-care medicine: surgery (3618)
intensive-care medicine: cardiac surgery
(3621)
intensive-care medicine: urology (3622)
intensive-care medicine: gynecology and
obstetrics (3624)
intensive-care medicine: otolaryngology
(3626)
intensive-care medicine: neurology
(3628)
operative intensive-care medicine:
surgery (3650)
intensive-care medicine: thorax-heart
surgery (3651)
intensive-care medicine: heart-thorax
surgery (3652)
intensive-care medicine (3690)
other medical specialty (3700)
angiology (3750)
radiology (3751)
palliative care (3752)
pain therapy (3753)
section for alternative health practice
(3754)
spinal surgery (3755)
addiction medicine (3756)
visceral surgery (3757)
other medical specialty (3790)
Identifikationsnummer des Patienten*
Geburtsdatum*
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Geschlecht*
male (1)
female (2)
Aufnahmedatum Krankenhaus*
Aufnahmezeit Krankenhaus*
Hauptdiagnose*
Minimaldatensatz*
sheet Stroke available (no MDS) (0)
event older than 7 days (1)
Continue laying in another facility within
2 hours after admission (2)
other reason (9)
Erläuterung zum Grund für MDS
Entlassungsdatum Krankenhaus*
Entlassungsgrund*
treatment finished as planned (1)
transferral to nursing facility (10)
discharge to hospice (11)
external transferral to psychiatric
treatment (13)
treatment finished because of other
reasons, postdischarge treatment is
planned (14)
treatment aborted against medical
advice, postdischarge treatment is
planned (15)
internal transferral with change of DRG
payment areas (17)
treatment finished as planned,
postdischarge treatment is planned (2)
case termination (internal transferral)
with change between full- and partial
stationary care (22)
discharge at the end of the year with
admission in previous year (25)
treatment finished because of other
reasons (3)
treatment aborted against medical
advice (4)
change of jurisdiction of insurer or other
payer (5)
transferral to another hospital (6)
death (7)
transferral to another hospital within
cooperative and governmental policies
(8)
transferral to rehabilitation facility (9)
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Stroke/TIA - Admission
Identifikation und Basisdaten
Initialen*
Postleitzahl*
Zeitintervall Ereignis bis Aufnahme*
unknown (0)
<=1h (1)
>1-2h (2)
>2-3h (3)
>3-3,5h (4)
>3,5-4h (5)
>4-6h (6)
>6-24h (7)
>24-48h (8)
>48h-7d (9)
Versorgungssituation vor Akutereignis*
independently at home (1)
home care (2)
care in institution (3)
Einlieferung*
self (1)
contract doctor (2)
rescue Service (3)
transfer from other hospitals (4)
Vorbehandlung
Thrombozytenaggregationshemmer*
Ja
Nein
Antikoagulantien*
no (0)
vitamin K antagonist (1)
NOAC (new oral anticoagulants) (2)
Neurologischer Befund
NIH-Stroke Scale*
Bewusstseinslage*
awake (1)
somnolence / Sopor (2)
coma (3)
Motorische Ausfälle*
monoparesis / -plegie (1)
hemiparesis / -plegie (2)
tetraparesis / -plegie (3)
no (4)
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not evaluable (5)
Dysphagie/Aphasie/Dysarthrie
Dysphagie*
yes (1)
Aphasie*
yes (1)
Dysarthrie*
yes (1)
Keine bzw. nicht beurteilbar*
no (0)
yes (1)
not practicable (2)
Schlucktest nach Protokoll*
no (0)
yes (1)
not practicable (2)
Behinderung
Mod. Rankin-Scale vor Insult*
No symptom (0)
No significant impairment (1)
Mild impairment (2)
Moderately impairment (3)
Moderate impairment (4)
Severe impairment (5)
unknown (9)
Mod. Rankin-Scale 1. Tag nach Aufnahme*
No symptom (0)
No significant impairment (1)
Mild impairment (2)
moderatly impairment (3)
Moderate impairment (4)
Severe impairment (5)
death (6)
Barthel-Index Blasenkontrolle*
incontinent (0)
continent (10)
occasional loss (5)
Barthel-Index Lagewechsel Bett-Stuhl*
completely dependent (0)
low support (10)
completely self (15)
great support (5)
Barthel-Index Fortbewegung*
completely dependent (0)
low support (10)
completely self (15)
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great support (5)
Risikofaktoren
Risikofaktoren*
Ja
Nein
Hypercholesterinämie*
yes (1)
Früherer Schlaganfall*
yes (1)
Vorhofflimmern*
yes, already known (1)
yes, newly diagnosed (2)
Diabetes mellitus*
yes (1)
Arterielle Hypertonie*
yes (1)
Andere(r) Risikofaktor(en)*
yes (1)
Stroke/TIA - Stationary History
Diagnostik
cCT durchgeführt*
Ja
Nein
MRT durchgeführt*
Ja
Nein
Zeitintervall Aufnahme bis erste Bildgebung*
<=0,5h (1)
>0,5-1h (2)
>1-3h (3)
>3-6h (4)
>6h (5)
1. imaging before admission (6)
Erste Bildgebung nach Ereignis im Haus am*
Erste Bildgebung nach Ereignis im Haus um*
Frische Läsion in Bildgebung*
Ja
Nein
Extrakranielle Gefäßdiagnostik nach Ereignis*
no (0)
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<=12h (1)
>12-48h (2)
>48h (3)
Intrakranielle Gefäßdiagnostik nach Ereignis*
no (0)
<=12h (1)
>12-48h (2)
>48h (3)
Langzeit-EKG/-Monitoring über mindestens 24h*
Ja
Nein
Maßnahmen / Therapie
Rekanalisation durchgeführt*
Ja
Nein
Thrombolyse i.v.*
yes (1)
Thrombolyse i.a.*
yes (1)
Mechanische Rekanalisation*
yes (1)
Zeitintervall Aufnahme bis Beginn
Rekanalisation/Thrombolyse*
<=0,5h (1)
>0,5-1h (2)
>1-2h (3)
>2-3h (4)
>3-4h (5)
>4-6h (6)
>6h (7)
Beginn der Thrombolyse am*
Beginn der Thrombolyse um*
Operative Dekompression*
Ja
Nein
Thrombozytenaggregationshemmer innerhalb 48
Std. nach Aufnahme*
Ja
Nein
Heparinisierung*
no (0)
Therapeutic anticoagulation (1)
thromboprophylaxis (2)
9 / 21
Data quality assurance of stroke acute treatment Hessen
Physiotherapie*
no (0)
start <= 2 days after admission (1)
start > 2 days after admission (2)
Logopädie*
no (0)
start <= 2 days after admission (1)
start > 2 days after admission (2)
Mobilisierung*
no (0)
start <= 2 days after admission (1)
start > 2 days after admission (2)
Komplikationen (Nur im Verlauf erworben)
Komplikationen*
Ja
Nein
Intrakranielle Blutung*
yes (1)
Extrakranielle Blutung*
yes (1)
Epileptischer Anfall*
yes (1)
Hirndruck*
yes (1)
Sepsis*
yes (1)
Hydrozephalus*
yes (1)
Pneumonie*
yes (1)
Thrombose / Lungenembolie*
yes (1)
Dekubitus*
yes (1)
Herz-Kreislauf-Dekompensation*
yes (1)
Re-Infarkt*
yes (1)
MRSA*
yes (1)
Harnwegsinfektion*
yes (1)
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Andere Komplikation(en)*
yes (1)
Klinischer Verlauf / Pathogenese
Symptomdauer*
<1h (1)
1 to 24h (2)
>=24h (3)
Kardioembolische Genese*
no (0)
yes (1)
unknown (9)
Stenose carotis interna*
no (0)
<50% (1)
50-<70% (2)
70-99% (3)
100% (4)
not tested (9)
Stroke / TIA - End of Treatment
Sekundärprophylaxe
Sekundärprophylaxe*
Ja
Nein
Thrombozytenaggregationshemmer*
yes (1)
Antihypertensiva*
yes (1)
Statine*
yes (1)
Antikoagulanzien*
vitamin K antagonist (1)
NOAC (new oral anticoagulants) (2)
Antidiabetika*
yes (1)
andere*
yes (1)
Revaskularisierung der ACI*
no (0)
transferred to surgery (1)
transferred to stenting (2)
operation during documented stay (3)
stenting during documented stay (4)
other (9)
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Neurologischer Befund
Bewusstseinslage*
awake (1)
somnolence/sopor (2)
coma (3)
Motorische Ausfälle*
monoparesis / -plegie (1)
hemiparesis / -plegie (2)
tetraparesis / -plegie (3)
no (4)
not evaluable (5)
Dysphagie/Aphasie/Dysarthrie
Dysphagie*
yes (1)
Aphasie*
yes (1)
Dysarthrie*
yes (1)
Keine bzw. nicht beurteilbar*
no (1)
can not be evaluated (2)
Behinderung
Mod. Rankin-Scale*
No symptom (0)
No significant impairment (1)
Mild impairment (2)
Moderately impairment (3)
Moderate impairment (4)
Severe impairment (5)
unknown (9)
Barthel-Index Blasenkontrolle*
incontinent (0)
continent (10)
occasional loss (5)
Barthel-Index Lagewechsel Bett-Stuhl*
completely dependent (0)
low support (10)
completely self (15)
great support (5)
Barthel-Index Fortbewegung*
completely dependent (0)
low support (10)
completely self (15)
great support (5)
Information von Patient und/oder
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Angehörigen vor Entlassung
Information durch Sozial-/Pflegedienst zu
Unterstützungsangeboten*
Ja
Nein
Entlassung
Nummer der Folgeeinrichtung*
Ambulante oder stationäre Rehabilitation
veranlasst*
Ja
Nein
Liegt eine schriftliche Patientenverfügung vor*
Ja
Nein
Behandlung auf Stroke Unit*
Ja
Nein
Dauer der Behandlung auf der Stroke Unit*
days
Beatmung während des stationären Aufenthaltes*
Ja
Nein
Beatmungsdauer*
days
SAB/Intracerebral haemorrhage -
Admission
Identifikation und Basisdaten
Initialen*
Postleitzahl*
Zeitintervall Ereignis bis Aufnahme*
unknown (0)
<=1h (1)
>1-2h (2)
>2-3h (3)
>3-3,5h (4)
>3,5-4h (5)
>4-6h (6)
>6-24h (7)
>24-48h (8)
>48h-7d (9)
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Versorgungssituation vor Akutereignis*
independently at home (1)
home care (2)
care in institution (3)
Einlieferung*
self (1)
contract doctor (2)
rescue Service (3)
transfer from other hospitals (4)
Vorbehandlung
Thrombozytenaggregationshemmer*
Ja
Nein
Antikoagulanzien*
no (0)
vitamin K antagonist (1)
NOAC (new oral anticoagulants) (2)
Neurologischer Befund
Glasgow Coma Scale*
GCS - Augenöffnung*
no (1)
on pain stimulus (2)
on speech (3)
spontaneously (4)
GCS - Beste verbale Reaktion*
no (1)
inarticulate (2)
inadequate (3)
disoriented (4)
oriented (5)
GCS - Beste motorische Reaktion*
no (1)
extensor reaction (2)
flexor reaction (3)
untargeted pain Defence (4)
targeted pain Defence (5)
followed prompts (6)
Motorische Ausfälle*
monoparesis / -plegie (1)
hemiparesis / -plegie (2)
tetraparesis / -plegie (3)
no (4)
not evaluable (5)
Dysphagie/Aphasie/Dysarthrie
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Dysphagie*
yes (1)
Aphasie*
yes (1)
Dysarthrie*
yes (1)
Keine bzw. nicht beurteilbar*
no (1)
can not be evaluated (2)
Schlucktest nach Protokoll*
no (0)
yes (1)
not practicable (2)
Behinderung
Mod. Rankin-Scale vor Insult*
No symptom (0)
No significant impairment (1)
Mild impairment (2)
Moderately impairment (3)
Moderate impairment (4)
Severe impairment (5)
unknown (9)
Mod. Rankin-Scale 1. Tag nach Aufnahme*
No symptom (0)
No significant impairment (1)
Mild impairment (2)
moderatly impairment (3)
Moderate impairment (4)
Severe impairment (5)
death (6)
Barthel-Index Blasenkontrolle*
incontinent (0)
continent (10)
occasional loss (5)
Barthel-Index Lagewechsel Bett-Stuhl*
completely dependent (0)
low support (10)
completely self (15)
great support (5)
Barthel-Index Fortbewegung*
completely dependent (0)
low support (10)
completely self (15)
great support (5)
Risikofaktoren
Risikofaktoren*
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Ja
Nein
Hypercholesterinämie*
yes (1)
Früherer Schlaganfall*
yes (1)
Vorhofflimmern*
yes, already known (1)
yes, newly diagnosed (2)
Diabetes mellitus*
yes (1)
Arterielle Hypertonie*
yes (1)
Andere(r) Risikofaktor(en)*
yes (1)
SAB/Intracerebral haemorrhage -
Stationary History
Diagnostik
cCT durchgeführt*
Ja
Nein
MRT durchgeführt*
Ja
Nein
Zeitintervall Aufnahme bis erste Bildgebung*
1. Imaging before admission (0)
<=3h (1)
>3h (2)
Extrakranielle Gefäßdiagnostik nach Ereignis*
no (0)
<=12h (1)
>12-48h (2)
>48h (3)
Intrakranielle Gefäßdiagnostik nach Ereignis*
no (0)
<=12h (1)
>12-48h (2)
>48h (3)
Langzeit-EKG/-Monitoring über mindestens 24h*
Ja
Nein
Maßnahmen / Therapie
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EVD - externe Ventrikeldrainage*
yes (1)
Operation an Blutung oder Blutungsquelle*
yes (1)
Endovaskuläre Behandlung*
yes (1)
Operative Dekompression*
yes (1)
Keine der vorgenannten Maßnahmen*
yes (1)
Physiotherapie*
no (0)
start <= 2 days after admission (1)
start>2 days after admission (2)
Logopädie*
no (0)
start <= 2 days after admission (1)
start>2 days after admission (2)
Mobilisierung*
no (0)
start <= 2 days after admission (1)
start>2 days after admission (2)
Komplikationen (Nur im Verlauf erworben)
Komplikationen*
Ja
Nein
Re-Blutung*
yes (1)
Sekundäre Ventrikelblutung*
yes (1)
Epileptischer Anfall*
yes (1)
Hirndruck*
yes (1)
Sepsis*
yes (1)
Hydrozephalus*
yes (1)
Pneumonie*
yes (1)
Thrombose / Lungenembolie*
yes (1)
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Dekubitus*
yes (1)
Herz-Kreislauf-Dekompensation*
yes (1)
Hirninfarkt*
yes (1)
MRSA*
yes (1)
Harnwegsinfektion*
yes (1)
Andere Komplikation*
yes (1)
Primärlokalisation
Thalamus*
yes (1)
Stammganglien*
yes (1)
Hirnstamm*
yes (1)
Kleinhirn*
yes (1)
Ventrikel (primär)*
yes (1)
Lobär*
yes (1)
Nicht zuzuordnen*
yes (1)
SAB / Intracerebral haemorrhage -
End of Treatment
Sekundärprophylaxe
Sekundärprophylaxe durchgeführt*
Ja
Nein
Thrombozytenaggregationshemmer*
yes (1)
Antihypertensiva*
yes (1)
Statine*
yes (1)
18 / 21
Data quality assurance of stroke acute treatment Hessen
Antikoagulanzien*
vitamin K antagonist (1)
NOAC (new oral anticoagulants) (2)
Antidiabetika*
yes (1)
andere*
yes (1)
Neurologischer Befund
Glasgow Coma Scale*
GCS - Augenöffnung*
no (1)
on pain stimulus (2)
on speech (3)
spontaneously (4)
GCS - Beste verbale Reaktion*
no (1)
inarticulate (2)
inadequate (3)
disoriented (4)
oriented (5)
GCS - Beste motorische Reaktion*
no (1)
extensor reaction (2)
flexor reaction (3)
untargeted pain Defence (4)
targeted pain Defence (5)
followed prompts (6)
Motorische Ausfälle*
monoparesis / -plegie (1)
hemiparesis / -plegie (2)
tetraparesis / -plegie (3)
no (4)
not evaluable (5)
Dysphagie/Aphasie/Dysarthrie
Dysphagie*
yes (1)
Aphasie*
yes (1)
Dysarthrie*
yes (1)
Keine bzw. nicht beurteilbar*
no (1)
can not be evaluated (2)
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Behinderung
Mod. Rankin-Scale*
No symptom (0)
No significant impairment (1)
Mild impairment (2)
Mäßiggradige impairment (3)
Moderate impairment (4)
Severe impairment (5)
death (6)
Barthel-Index Blasenkontrolle*
incontinent (0)
continent (10)
sporadic loss (5)
Barthel-Index Lagewechsel Bett-Stuhl*
completely dependent (0)
low support (10)
completely self (15)
great support (5)
Barthel-Index Fortbewegung*
completely dependent (0)
low support (10)
completely self (15)
great support (5)
Information von Patient und/oder
Angehörigen vor Entlassung
Information durch Sozial-/Pflegedienst zu
Unterstützungsangeboten*
Ja
Nein
Entlassung
Nummer der Folgeeinrichtung*
Ambulante oder stationäre Rehabilitation
veranlasst*
Ja
Nein
Liegt eine schriftliche Patientenverfügung vor*
Ja
Nein
Behandlung auf Stroke Unit*
Ja
Nein
Dauer der Behandlung auf der Stroke Unit*
days
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Beatmung während des stationären Aufenthaltes*
Ja
Nein
Beatmungsdauer*
days
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Follow-Up 2/2 CML TIGER NCT01657604
Bogen 2 Verlaufsbogen Seite 2 von 2 NCT01657604
Chronic Myeloid Leukemia
Tasigna and Interferon Alpha Evaluation Initiated by the
German Chronic Myeloid Leukemia Study Group - the
TIGER Study
http://clinicaltrials.gov/ct2/show/NCT01657604
All rights reserved. Please visit https://medical-data-
models.org/forms/11772
Follow-Up 2/2 CML TIGER
NCT01657604
Administrative Items
Hospital Identifier*
Patient identifier*
Date of birth
Month of birth*
Day of birth*
Administrative Items
Date of Evaluation*
Number Follow-Up Report*
Sex*
Male (männlich)
Female (weiblich)
Laboratory values
Date laboratory*
Leukocytes*
/ul
Peripheral Blasts
%
Promyelocytes (%)*
Myelocytes, Metamyelocytes (%)*
Neutrophils - band form (%)*
Neutrophils - segmented (%)*
1 / 6
Eosinophils (%)*
Basophils (%)*
Monocytes (%)*
Lymphocytes (%)*
Normoblasts (%)*
Peripheral Platelet Count*
1000/uL
Hemoglobin (mmol/L)*
Hemoglobin*
g/dL
Hematocrit (%)*
Urea
mg/dL
Creatinine
mg/dL
Urate (mg/dL)*
Albumin*
g/dL
Protein*
g/dL
Bilirubin - total (μmol/L)*
Bilirubin, total*
mg/dL
Bilirubin - direct (μmol/L)*
Direct Bilirubin*
mg/dL
Bilirubin - indirect (μmol/L)*
2 / 6
Follow-Up 2/2 CML TIGER NCT01657604
Bilirubin - indirect (mg/dL)*
ALT (SGPT)*
U/L
AST (SGOT)*
U/L
Lactate Dehydrogenase (LDH)*
U/L
Sodium
mmol/L
Calcium*
mmol/l
Phosphate (mmol/L)*
Triacylglycerol lipase (U/L)*
Amylase
U/L
Potassium*
mmol/l
Magnesium (mmol/L)*
Thyrotropin (mU/L)*
Glucose: (mg/dL)*
Glucose (mmol/L)*
Hemogloblin A1C
mmol/mol
Cholesterol*
mg/dL
Cholesterol (mmol/L)*
Quality of Life
Questionaire completed*
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Yes
No
Physical Examination
Date of Physical Examination*
Height*
>= 0
cm
Body weight*
>= 0
kg
Size of Spleen with Palpation*
Size of Spleen with Ultrasound, greatest
diameter*
Blood Pressure
Systolic*
>= 0
mmHg
Diastolic*
>= 0
mmHg
Physical Examination
Heart rate*
>= 0
bpm
Leukaemic infiltration extramedullary *
Yes
No
which (e.g. Lymph node, Skin, etc.)*
Molecular Biology
not performed*
Yes
No
Date of Performance*
Nested-RT-PCR*
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negative (neg.)
positiv (pos.)
BCR-ABL International Scale*
ABL-Transcripts*
/5μL
Material*
Blood  (Blut)
Bone Marrow  (Knochenmark)
Investigator/Place*
Laboratory Number*
Bone Marrow Examination
Not performed*
Yes
No
No Information Available *
Yes
No
Date of Performance*
Cellularity *
aplastic (aplastisch)
hypercellular (hyperzellulär)
hypocellular (hypozellulär)
normocellular (normozellulär)
intense hypercellular (stark hyperzellulär)
Peripheral Blasts*
%
Promyelocytes (%)*
Basophils (%)*
Cytogenetics
evaluted mitosis*
Normal karyotype *
Normal karyotype with addtional aberrations*
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Philadelphia Chromosome*
Philadelphia Chromosome with additional
aberrations*
Chromosome analysis result in ISCN expression
*
unevaluable mitosis*
Investigator/Place*
Laboratory Number*
Signature
Comment*
Hospital*
Date*
Signature*
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consolidation therapy 2 AML in elderly
patients AML-AZA NCT00915252
2. Konsolidierungstherapieblock EudraCT-Nr 2008-004583-
40 Akute myeloische Leukämie(AML) AML alle außer FAB
M3
consolidation therapy 2 AML in elderly patients AML-AZA
NCT00915252
A randomized, multi-center phase II trial to assess the
efficacy of 5-azacytidine added to standard primary therapy
in elderly patients with newly diagnosed AML
Principal Investigator Prof. Dr. Müller-Tidow
All rights reserved. Please visit https://medical-data-
models.org/forms/11773
consolidation therapy 2 AML in
elderly patients AML-AZA
NCT00915252
Patient data
Pat. No.:    -*
Clinical finding
Physical Examination Date:*
ECOG performance status finding:*
ECOG 0 (Normal physical fitness) (0)
ECOG 1 (Outpatient care, easy work
possible) (1)
ECOG 2 (Less than half day bed-ridden,
self-sufficiency possible, but not able to
work) (2)
ECOG 3 (More than half day bed-ridden,
limited self-sufficiency possible) (3)
ECOG 4 (Permanent bed-ridden) (4)
Body weight*
>= 0
kg
Body surface area
>= 0
m²
Differential blood count
Date:*
Hemoglobin*
g/dL
Leukocytes*
/ul
Neutrophil percentage*
1 / 6
Band neutrophil percentage*
[or] Segmented neutrophil percentage*
Lymphocyte percentage*
Monocyte percentage*
Eosinophil percentage*
Basophil percentage*
Blast cell percentage*
Promyelocyte percentage*
Myelocyte percentage*
Metamyelocyte percentage*
Percentage of other cells*
Peripheral Platelet Count*
1000/uL
Clinical Chemistry
Sodium
mmol/L
Potassium*
mmol/l
Total Protein
mg/dL
Uric acid
md/dl
BUN
mg/dL
Creatinine*
mg/dL
Bilirubin, total
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mg/dL
AST (SGOT)
U/L
ALT (SGPT)
U/L
Alkaline Phosphatase
U/L
Lactate Dehydrogenase
U/L
CRP
md/dl
Quick
%
INR
PTT
seconds
Patient randomization in study arm:*
A (5-Azacytidine) (1)
B (Documentation continued on page 31)
(2)
5-Azacytidine
5-Azacytidine dose:*
DL 0: 18 mg/m2 (0)
DL 1: 37,5 mg/m2 (1)
DL 2: 75 mg/m2 (2)
5-Azacytidine
5-Azacytidine - Dose no. 1
Date*
Dose absolute/day (mg)*
Route of administration*
subcutaneous (1)
Reason for not subcutaneous*
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5-Azacytidine - Dose no. 2
Date*
Dose absolute/day (mg)*
Route of administration*
subcutaneous (1)
Reason for not subcutaneous*
5-Azacytidine - Dose no. 3
Date*
Dose absolute/day (mg)*
Route of administration*
subcutaneous (1)
Reason for not subcutaneous*
5-Azacytidine - Dose no. 4
Date*
Dose absolute/day (mg)*
Route of administration*
subcutaneous (1)
Reason for not subcutaneous*
5-Azacytidine - Dose no. 5
Date*
Dose absolute/day (mg)*
Route of administration*
subcutaneous (1)
Reason for not subcutaneous*
5-Azacytidine dose reduction
5-Azacytidine dose reduction*
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Yes
No
yes, reason:*
AE(s) in actual therapy block (1)
AE(s) in a previous therapy block (2)
treatment error (3)
Miscellaneous (4)
Miscellaneous:*
AE-No:*
AE-No:*
Transfusions
How many transfusions did the patient receive in
the period between                  day 1 of the 1st
consolidation chemotherapy AND           day 1 of
the 2nd consolidation chemotherapy?*
Number of transfused erythrocyte concentrates:*
Number of transfused platelet concentrates:*
Chemotherapy
Day 1:*
Ara-C (2 x 1g/sqm over 3 hrs intravenous
day 1,3,5)
Ara-C - dose reduction*
Yes
No
(if yes:) a) Reason:*
(if yes:) b) Absolute total dose in this therapy
block (mg):*
G-CSF dose
Patient did receive G-CSF: *
Yes
No
(if yes:) Start date:*
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(if yes:) End date:*
(if yes:) Pharmaceutical Preparations:*
Neulasta (1)
Neupogen (2)
Granocyte (3)
other (4)
Cytopenia duration
leucocytes <1,0 GPt/l or <1000 /ul
Start date (leucocytes <1,0 GPt/l or <1000 /ul)*
End date (leucocytes >=1,0 GPt/l or >=1000 /ul)*
(or) cytopenia ongoing [leucocytes <1,0 GPt/l or
<1000 /ul] on:*
neutrophils <0,5 GPt/l or <500 /ul
Start date (neutrophils <0,5 GPt/l or <500 /ul)*
End date (neutrophils >=0,5 GPt/l or >=500 /ul)*
(or) cytopenia ongoing [neutrophils <0,5 GPt/l or
<500 /ul] on:*
Start date (platelets <25 GPt/l or <25000
/ul)
Start date (platelets <25 GPt/l or <25000 /ul)*
End date (platelets >=25 GPt/l or >=25000 /ul -
increasing, independent of substitution of
platelets)*
(or) cytopenia ongoing [platelets <25 GPt/l or
<25000 /ul] on:*
Signature
Date:*
Name/Signature study physician*
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PBSC Harvest Worksheet Germ Cell
Tumors ACNS0122 NCT00047320
ACNS0122 PBSC Harvest Worksheet NCT00047320 
Neoadjuvant Chemotherapy With or Without Second-Look
Surgery Followed by Radiation Therapy With or Without
Peripheral Stem Cell Transplantation in Treating Patients
With Intracranial Germ Cell Tumors
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=BD8E5AF7-
9FAF-0089-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/11774
PBSC Harvest Worksheet Germ Cell
Tumors ACNS0122 NCT00047320
Header
COG Study No
Institution Name
COG Patient ID
Patient Initials
Today's date
Date worksheet entered into RDE
Height / Weight
Height
>= 0
cm
Body weight
>= 0
kg
Peripheral stem cell transplantation
Did the patient have PBSC harvest during this
reporting period?
Yes
No
Date [PBSC harvest]
Description (number of cells collected)
Was Bone Marrow harvesting performed?
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Yes
No
date performed (If yes,)
Organ function
Did the patient have adequate CD34+ cells
collected?
Yes
No
Does the patient have adequate bone marrow
function?
Yes
No
Does the patient have adequate renal function?
Yes
No
Does the patient have adequate liver function?
Yes
No
Does the patient have adequate Central Nervous
System function?
Yes
No
Comments
Comments
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Eligibility Acute Myeloid Leukemia
NCT02034227
Safety, Tolerability Study of SG2000 in the Treatment of
Advanced Chronic Lymphocytic Leukemia and Acute
Myeloid Leukemia; ODM derived from:
http://clinicaltrials.gov/show/NCT02034227
All rights reserved. Please visit https://medical-data-
models.org/forms/11787
Eligibility Acute Myeloid Leukemia
NCT02034227
Inclusion Criteria
male or female greater than or equal to 18 years
of age*
Yes
No
have one of the following disease states: acute
myeloid leukemia (aml) (age <60 years) with
relapsed/refractory disease; chronic lymphocytic
leukemia (cll) with relapsed disease following a
fludarabine-based regimen or relapsed disease
following an alkylator-based regimen*
Yes
No
are recovered from the acute adverse effects of
prior therapies (excluding alopecia and grade ≤2
neuropathy).*
Yes
No
have blast counts that can be controlled by the
use of hydroxycarbamide (500 to 3000 mg
daily).*
Yes
No
have adequate hepatic function and renal
function*
Yes
No
have an estimated life expectancy of >3 months*
Yes
No
female subject must have a negative serum
pregnancy result within 7 days before the start of
the study; both men and women must agree to
use a medically acceptable form of contraception
throughout the treatment period and for 3 months
after discontinuation of treatment*
Yes
No
Exclusion Criteria
are eligible for any standard therapy known to be
life prolonging or life saving*
Yes
No
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have diagnosis of aml french-american-british
(fab) classification (fab) m3 (acute promyelocytic
leukemia (apl))*
Yes
No
are receiving concurrent chemotherapy,
radiotherapy, immunotherapy, biological or
hormonal treatment for cancer.*
Yes
No
have undergone anticancer therapy including
chemotherapy (except for hydroxycarbamide at a
maximum daily dose of 3000 mg), endocrine
therapy, immunotherapy, or the use of other
investigational agents within 4 weeks before
study entry.*
Yes
No
prior radiation therapy with volume of bone
marrow treated over 25%.*
Yes
No
use of immunosuppressive therapy, including
systemic steroids within 7 days before the first
dose of sg2000.*
Yes
No
hyperleukocytosis (blast counts >30 000/mm3).*
Yes
No
history of allogeneic stem cell or solid organ
transplantation.*
Yes
No
positive serology for human immunodeficiency
virus (hiv), hepatitis b or hepatitis c or have hiv-
aids, or active hepatitis b or c.*
Yes
No
history of other invasive malignancy within 3
years except for cervical carcinoma in situ,
nonmelanomatous carcinoma of the skin or
ductal carcinoma in situ of the breast that has
been surgically cured.*
Yes
No
have any coexisting medical condition that will
substantially increase the risk associated with the
subject's participation in the study.*
Yes
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No
have psychiatric disorders or altered mental
status precluding understanding of the informed
consent process and/or completion of necessary
studies.*
Yes
No
have persistent grade 2 or greater toxicities from
any cause (except alopecia or peripheral
neuropathy).*
Yes
No
are pregnant or breast-feeding.*
Yes
No
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Physician's discharge letter for Trauma
Surgery Clinic UKM
Items used as routine documentation by  Trauma Surgery
Clinic, University Hostpital Muenster.
ODM derived from original form AB MS UCH POLI.
All rights reserved. Please visit https://medical-data-
models.org/forms/11794
Physician's discharge letter for
Trauma Surgery Clinic UKM
Discharge Header
Patient Name
Date of Birth
Address
We report on the in-patient stay of [Patient Name]
from [Admission Date] to [Discharge Date].
Admission Date
Discharge Date
Recipient
Medical Report
Previous findings
Diagnoses
Therapeutic Procedures
Clinical Course
Planned Procedures
Discharge Medication
Footer
We thank you for your co-operation! Sincerely
yours,
Physician Signature
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RTOG 0825 Phase III GBM Initial
Evaluation Form (I1)
RTOG 0825 Phase III GBM Initial Evaluation Form (I1)
Temozolomide and Radiation Therapy With or Without
Bevacizumab in Treating Patients With Newly Diagnosed
Glioblastoma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=5AE2A23C-
8AD1-6A8B-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11795
RTOG 0825 Phase III GBM Initial
Evaluation Form (I1)
Module 1
RTOG Study No.
RTOG Case #
Institution Name
Institution No.
Patient Initials
RTOG Patient ID
Amended Data (INSTRUCTIONS: Complete form
on web to unblind the protocol treatment arm)
Yes
No
Assessment
Age
>= 0
<= 120
years
Karnofsky Performance Status
Dead (0)
Moribund, Fatal Processes Progressing
Rapidly (10)
Normal, No Complaints, No Evidence Of
Disease (100)
Very Sick, Hospitalization Indicated.
Death Not Imminent (20)
Severely Disabled, Hospitalization
Indicated. Death Not Imminent (30)
Disabled, Requires Special Care And
Assistance (40)
Requires Considerable Assistance And
Frequent Medical Care (50)
Requires Occasional Assistance, But Is
Able To Care For Most Of His/her Needs
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(60)
Cares For Self, Unable To Carry On
Normal Activity Or To Do Active Work
(70)
Normal Activity With Effort; Some Signs
Or Symptoms Of Disease (80)
Able To Carry On Normal Activity; Minor
Signs Or Symptoms Of Disease (90)
Neurologic function
Minor Neurologic Symptoms, Fully Active
At Home/work Without Assistance (Minor
neurologic symptoms, fully active at
home/work without assistance)
Moderate Neurologic Symptoms, Fully
Active At Home/work But Requires
Assistance (Moderate neurologic
symptoms, fully active at home/work but
requires assistance)
Moderate Neurologic Symptoms, Less
Than Fully Active At Home/work And
Requires Assitance (Moderate
neurologic symptoms, less than fully
active at home/work and requires
assistance)
No Neurologic Symptoms, Fully Active At
Home/work Without Assistance (No
neurologic symptoms, fully active at
home/work without assistance)
Severe Neurologic Symptoms, Totally
Inactive Requiring Complete Assistance
At Home Or Institution, Unable To Work
(Severe neurologic symptoms, totally
inactive requiring complete assistance at
home or institution, unable to work)
Disease Information
Initial Diagnosis Date (OF GBM/GLIOSARCOMA
MM DD YYYY)
Extent of Resection
Not Applicable (Not applicable)
Other (Other)
Subtotal (Subtotal)
Total (gross) (Total (gross))
Other specify
Date of Resection (MM DD YYYY)
Central pathology confirmed GBM/gliosarcoma
Yes
No
Sufficient tissue for MGMT/molecular profile
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analysis
Inadequate (Inadequate)
Usable (Usable)
Pre-study Scans
Image date (MM DD YYYY)
Assessment Type
Ct Scan (CT scan)
Mri Scan (MRI scan)
Other (Other)
Other Specify
Dimension 1 (mm)
cm
Dimension 2 (mm)
cm
Pre-study Scans
Image date (MM DD YYYY)
Assessment Type
Ct Scan (CT scan)
Mri Scan (MRI scan)
Other (Other)
Other Specify
Dimension 1 (mm)
cm
Dimension 2 (mm)
cm
Location Of Primary
Site of Lesion
Basal Ganglia (Basal ganglia)
Brainstem (Brainstem)
Cerebellum (Cerebellum)
Corpus Callosum (Corpus callosum)
Frontal Lobe (Frontal)
Occipital Lobe (Occipital)
Other, Specify (Other specify)
Parietal Lobe (Parietal)
Spinal Cord (c1 And Below) (Spinal cord)
Temporal Lobe (Temporal)
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Thalamus (Thalamus)
Other specify
Primary Tumor Laterality
Bilateral (Bilateral)
Left (Left)
Right (Right)
Unknown/not Documented (Unknown)
Baseline Lab Values (hematologic)
ANC
/ul
Date of ANC
DD.MM.YYYY
Peripheral Platelet Count
1000/uL
Date of Platelets
DD.MM.YYYY
Hemoglobin
g/dL
Date of Hemoglobin
DD.MM.YYYY
WBC
/ul
Date of Serum Creatinine
DD.MM.YYYY
Date of Serum Creatinine
DD.MM.YYYY
BUN
mg/dL
BUN date
DD.MM.YYYY
Creatinine
mg/dL
Creatinine ULN
mg/dL
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UPC ratio (RENAL FUNCTION )
Protein from 24 hour Urine Collection (RENAL
FUNCTION If yes mg)
g/24 hours
Bilirubin, total
mg/dL
Total bilirubin, ULN
mg/dL
Date of total Bilirubin
AST (SGOT)
U/L
AST (SGOT) ULN
U/L
AST Date
DD.MM.YYYY
ALT (SGPT)
U/L
ALT ULN
U/L
ALT date
DD.MM.YYYY
PTT
seconds
INR
Non-protocol Therapy To Brain
Has the patient taken anticoagulant agents?
Yes
No
Specify
Agents with proarrhythmic potential
Yes
No
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Specify
Herbal Products
Yes
No
Specify
Corticosteroids
Yes
No
Specify
Anticonvulsants
Yes
No
Specify
Date of Initial Dose (MM DD YYYY)
Date of Initial Dose (MM DD YYYY)
EIAEDS
Yes
No
Date of last dose (MM DD YYYY)
Date of last dose (MM DD YYYY)
Date of last dose (MM DD YYYY)
Date of last dose (MM DD YYYY)
Date of last dose (MM DD YYYY)
NEIAEDS
Yes
No
Severe Active Comorbidity
Unstable angina
Yes
No
Transmural myocardial infaraction
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Yes
No
Infection (Acute bacterial or fungal infection)
Yes
No
Cerebrovascular accident (including stroke)
Yes
No
Peripheral Vascular Disease (PVD)
Yes
No
Coagulation defects
Yes
No
AIDS
Yes
No
Significant vascular disease (e.g. Aortic
Aneurysm, aortic dissection)
Yes
No
Serious nonhealing wound
Yes
No
Footer Module
Comments
Signature of Person Completing This Form
Form Completion Date, Original
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Eligibility Breast Cancer NCCTG N0733
NCT00684983
Breast Cancer NCT00684983 Eligibility - NCCTG N0733
Eligibility Checklist - 2777789v1.0
NCCTG N0733 Eligibility Checklist
Capecitabine and Lapatinib With or Without Cixutumumab
in Treating Patients With Previously Treated HER2-Positive
Stage IIIB, Stage IIIC, or Stage IV Breast Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=555F4502-
A448-6B03-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11797
Eligibility Breast Cancer NCCTG
N0733 NCT00684983
Header
NCCTG Patient ID (provided at time of
Reg/Random)
Patient Hospital No.
Participating Group Code (Cooperative Group
where credit will be applied)
Institution Name (treating location/performance
site)
Institution Code (CTEP assigned number)
Physician of Record
IRB/REB  Approval Date (mm/dd/yyyy)
Date of Registration (mm/dd/yyyy)
Last name
First Name
Phone
Fax
E-mail
Patient Demographics / Pre-treatment
Characteristics
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Last
First
Middle
Gender
Female (FEMALE)
Male (MALE)
Unknown (UNKNOWN)
Ethnicity (U.S. and Canada only)
A Person Of Mexican, Puerto Rican,
Cuban, Central Or South American Or
Other Spanish Culture Or Origin,
Regardless Of Race. (HISPANIC OR
LATINO)
A Person Not Meeting The Definition For
Hispanic Or Latino. (NOT HISPANIC OR
LATINO)
Not Provided Or Available (Not reported)
Could Not Be Determined Or Unsure
(UNKNOWN)
Patient's Date of Birth (mm/dd/yyyy)
Patient Zip Code
Country of residence
Ascension Island (AC)
Andorra (AD)
United Arab Emirates (AE)
Afghanistan (AF)
Antigua And Barbuda (AG)
Anguilla (AI)
Albania (AL)
Armenia (AM)
Netherland Antilles (AN)
Angola (AO)
Antarctica (AQ)
Argentina (AR)
American Samoa (AS)
Austria (AT)
Australia (AU)
Aruba (AW)
Azerbaidjan (AZ)
Bosnia-herzegovina (BA)
Barbados (BB)
Bangladesh (BD)
Belgium (BE)
Burkina Faso (BF)
Bulgaria (BG)
Bahrain (BH)
Burundi (BI)
Benin (BJ)
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Bermuda (BM)
Brunei Darussalam (BN)
Bolivia (BO)
Brazil (BR)
Bahamas (BS)
Bhutan (BT)
Bouvet Island (BV)
Botswana (BW)
Belarus (BY)
Belize (BZ)
Canada (CA)
Cocos Isl. (CC)
Rep. Dem. Congo (CD)
Central African Rep. (CF)
Congo (CG)
Switzerland (CH)
Ivory Coast (CI)
Cook Islands (CK)
Chile (CL)
Cameroon (CM)
China (CN)
Colombia (CO)
Costa Rica (CR)
Cuba (CU)
Cape Verde (CV)
Christmas Island (CX)
Cyprus (CY)
Czech Republic (CZ)
Germany (DE)
Djibouti (DJ)
Denmark (DK)
Dominica (DM)
Dominican Republic (DO)
Algeria (DZ)
Ecuador (EC)
Estonia (EE)
Egypt (EG)
Western Sahara (EH)
Eritrea (ER)
Spain (ES)
Ethiopia (ET)
Finland (FI)
Fiji (FJ)
Falkland Isl. (FK)
Micronesia (FM)
Faroe Islands (FO)
France (FR)
France (european Ter.) (FX)
Gabon (GA)
Great Britain (GB)
Grenada (GD)
Georgia (GE)
Guiana (fr.) (GF)
Guernsey (GG)
Ghana (GH)
Gibraltar (GI)
Greenland (GL)
Gambia (GM)
Guinea (GN)
Guadeloupe (fr.) (GP)
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Equatorial Guinea (GQ)
Greece (GR)
South Georgia And South Sandwich
Islands (GS)
Guatemala (GT)
Guam (us) (GU)
Guinea Bissau (GW)
Guyana (GY)
Hong Kong (HK)
Heard & Mcdonald Isl. (HM)
Honduras (HN)
Croatia (HR)
Haiti (HT)
Hungary (HU)
Indonesia (ID)
Ireland (IE)
Israel (IL)
Isle Of Man (IM)
India (IN)
British Indian O. Ter. (IO)
Iraq (IQ)
Iran (IR)
Iceland (IS)
Italy (IT)
Jersey (JE)
Jamaica (JM)
Jordan (JO)
Japan (JP)
Kenya (KE)
Kyrgyz Republic (KG)
Cambodia (KH)
Kiribati (KI)
Comoros (KM)
St. Kitts Nevis Anguilla (KN)
Korea (north) (KP)
Korea (south) (KR)
Kuwait (KW)
Cayman Islands (KY)
Kazakstan (KZ)
Laos (LA)
Lebanon (LB)
Saint Lucia (LC)
Liechtenstein (LI)
Sri Lanka (LK)
Liberia (LR)
Lesotho (LS)
Lithuania (LT)
Luxembourg (LU)
Latvia (LV)
Libya (LY)
Morocco (MA)
Monaco (MC)
Moldova (MD)
Madagascar (MG)
Marshall Islands (MH)
Macedonia (MK)
Mali (ML)
Myanmar (MM)
Mongolia (MN)
Macau (MO)
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Northern Mariana Isl. (MP)
Martinique (fr.) (MQ)
Mauritania (MR)
Montserrat (MS)
Malta (MT)
Mauritius (MU)
Maldives (MV)
Malawi (MW)
Mexico (MX)
Malaysia (MY)
Mozambique (MZ)
Namibia (NA)
New Caledonia (fr.) (NC)
Niger (NE)
Norfolk Island (NF)
Nigeria (NG)
Nicaragua (NI)
Netherlands (NL)
Norway (NO)
Nepal (NP)
Nauru (NR)
Niue (NU)
New Zealand (NZ)
Oman (OM)
Other (Other)
Panama (PA)
Peru (PE)
Polynesia (fr.) (PF)
Papua New Guinea (PG)
Philippines (PH)
Pakistan (PK)
Poland (PL)
St. Pierre & Miquelon (PM)
Pitcairn (PN)
Puerto Rico (PR)
Portugal (PT)
Palau (PW)
Paraguay (PY)
Qatar (QA)
Reunion (fr.) (RE)
Romania (RO)
Russian Federation (RU)
Rwanda (RW)
Saudi Arabia (SA)
Solomon Islands (SB)
Seychelles (SC)
Sudan (SD)
Sweden (SE)
Singapore (SG)
St. Helena (SH)
Slovenia (SI)
Svalbard & Jan Mayen Isl. (SJ)
Slovakia (SK)
Sierra Leone (SL)
San Marino (SM)
Senegal (SN)
Somalia (SO)
Suriname (SR)
St. Tome And Principe (ST)
Soviet Union (SU)
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El Salvador (SV)
Syria (SY)
Swaziland (SZ)
Turks & Caicos Islands (TC)
Chad (TD)
French Southern Terr. (TF)
Togo (TG)
Thailand (TH)
Tadjikistan (TJ)
Tokelau (TK)
Turkmenistan (TM)
Tunisia (TN)
Tonga (TO)
East Timor (TP)
Turkey (TR)
Trinidad & Tobago (TT)
Tuvalu (TV)
Taiwan (TW)
Tanzania (TZ)
Ukraine (UA)
Uganda (UG)
United Kingdom (UK)
Us Minor Outlying Isl. (UM)
Usa (US)
Uruguay (UY)
Uzbekistan (UZ)
Vatican City State (VA)
St. Vincent & Grenadines (VC)
Venezuela (VE)
Virgin Islands (brit) (VG)
Virgin Islands (us) (VI)
Vietnam (VN)
Vanuatu (VU)
Wallis & Futuna Islands (WF)
Western Samoa (WS)
Yemen (YE)
Mayotte (YT)
Yugoslavia (YU)
South Africa (ZA)
Zambia (ZM)
Dem. Rep. Of Congo (ZR)
Zimbabwe (ZW)
Method of Payment (check oneUSA only)
Medicaid (Medicaid)
Medicaid And Medicare (Medicaid and
Medicare)
Medicare (Medicare)
Medicare And Private Insurance
(Medicare and Private Insurance)
Military Or Veterans Sponsored Nos
(Military or Veterans Sponsored, Not
Otherwise Specified (NOS))
Military Sponsored (including Champus
& Tricare) (Military Sponsored (including
CHAMPUS & TRICARE))
No Means Of Payment (no Insurance)
(No means of payment (no insurance))
Other (Other)
Private Insurance (Private Insurance)
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Self Pay (no Insurance) (Self Pay (No
Insurance))
Unknown (Unknown)
Veterans Sponsored (Veterans
Sponsored)
Race
Race
A Person Having Origins In Any Of The
Original Peoples Of North And South
America (including Central America),
And Who Maintains Tribal Affiliation Or
Community Attachment. (American
Indian or Alaska Native)
A Person Having Origins In Any Of The
Original Peoples Of The Far East,
Southeast Asia, Or The Indian
Subcontinent Including, For Example,
Cambodia, China, India, Japan, Korea,
Malaysia, Pakistan, The Philippine
Islands, Thailand, And Vietnam. (Asian)
A Person Having Origins In Any Of The
Black Racial Groups Of Africa. Terms
Such As "haitian" Or "negro" Can Be
Used In Addition To "black Or African
American." (Black or African American)
A Person Having Origins In Any Of The
Original Peoples Of Hawaii, Guam,
Samoa, Or Other Pacific Islands. (Native
Hawaiian or other Pacific Islander)
Not Provided Or Available (Not
Reported)
Could Not Be Determined Or Unsure
(Unknown)
A Person Having Origins In Any Of The
Original Peoples Of Europe, The Middle
East, Or North Africa. (White)
Pre-treatment Requirements
Age 18 Years and older
Yes
No
Age
>= 0
<= 120
years
Histologically confirmed, locally advanced (a T4
primary tumor and stage IIIB or IIIC disease) or
metastatic breast cancer that has progressed
after treatment with regimens that included
trastuzumab and either an anthracycline or a
taxane or both. (NOTE: Agents need not have
been given concurrently nor in the same regimen.
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NOTE: Prior treatment with trastuzumab is
required unless there is a contraindication for
trastuzumab treatment.)
Yes
No
Prior treatment with trastuzumab in the neo-
adjuvant, adjuvant, or metastatic setting is
required. (NOTE: Prior treatment with
trastuzumab is required unless there is a
contraindication for trastuzumab treatment.   -
NOTE: Concomitant use of trastuzumab is not
allowed in this study.)
Yes
No
Prior chemotherapy allowed in the neo-adjuvant,
adjuvant, or metastatic setting. Unlimited prior
chemotherapy is allowed.
Yes
No
Prior hormonal therapy allowed in the neo-
adjuvant, adjuvant, or metastatic setting.
Unlimited prior hormonal therapy is allowed.
Yes
No
HER2 positive, defined as: Validated IHC assay
score of 3+ (defined as uniform, intense staining
of >30% of invasive tumor cells) -OR- Average
HER2 gene copy number of >6 -OR- Gene
amplified (HER2:D17Z1) ratio >2.20
Yes
No
Must have measurable disease according to
RECIST criteria (See Section 11.0)
Yes
No
Negative pregnancy test done <=7 days prior to
registration, for women of childbearing potential
only. (If not a woman of childbearing potential
check NA)
Yes
No
Negative pregnancy test date (If a woman of
childbearing potential)
The following laboratory values obtained <=7
days prior to registration
Yes
No
Earliest laboratory test date (Note: These dates
pertain to the following labs only.)
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latest laboratory test date
Hemoglobin >9.0 g/dL
Yes
No
Hemoglobin
g/dL
WBC >= 3,000/mL
Yes
No
WBC
/ul
ANC >= 1500/mL
Yes
No
ANC
1000/ul
Platelet Count >= 75,000/mL
Yes
No
Peripheral Platelet Count
1000/uL
Total bilirubin <= 1.5 x ULN
Yes
No
Total Bilirubin
Total Bilirubin ULN
SGOT(AST) and SGPT(ALT) <=2.5 x ULN or
SGOT(AST) and SGPT(ALT) <5 x ULN if
elevations are due to liver metastases.
Yes
No
SGOT(AST) and SGPT(ALT) >2.5 x ULN due to
liver metastases (This question may be answered
"Yes" or "No")
Yes
No
AST (SGOT)
U/L
AST (SGOT) ULN
9 / 16
Eligibility Breast Cancer NCCTG N0733 NCT00684983
U/L
ALT (SGPT)
U/L
ALT (SGPT) ULN
U/L
Serum Creatinine <=1.5 x ULN
Yes
No
Creatinine
mg/dL
Serum Creatinine ULN
mg/dL
Creatinine clearance >=30 mL/min (calculated
according to Cockcroft and Gault - see Appendix
II)
Yes
No
Creatinine Clearance
mL/min
Fasting glucose <120 mg/dL (NOTE: Patients
with diabetes are allowed to participate, provided
that their blood glucose is within the guidelines
above upon enrollment.)
Yes
No
Fasting glucose
mg/dL
International Normalization Ratio (INR) <= 1.5 X
ULN
Yes
No
International Normalization Ratio (INR)
International Normalized Ratio ULN
ECOG performance status 0, 1, or 2
Yes
No
Performance Status
Fully Active, Able To Carry On All Pre-
disease Performance Without
Restriction. (0)
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Restricted In Physically Strenuous
Activity But Ambulatory And Able To
Carry Out Work Of A Light Or Sedentary
Nature, E.g., Light Housework, Office
Work. (1)
Ambulatory And Capable Of All Selfcare
But Unable To Carry Out Any Work
Activities. Up And About More Than 50%
Of Waking Hours. (2)
Capable Of Only Limited Selfcare,
Confined To Bed Or Chair More Than
50% Of Waking Hours. (3)
Completely Disabled. Cannot Carry On
Any Selfcare. Totally Confined To Bed Or
Chair. (4)
Dead (5)
Adequate cardiac function as defined as an
ejection fraction 50% as determined by MUGA or
echocardiogram
Yes
No
Life expectancy >3 months
Yes
No
Has written informed consent been obtained
Yes
No
Willingness to return to an NCCTG or other
participating cooperative group institution for
treatment and follow-up
Yes
No
Patient willing to provide tissue and blood
samples for research purposes (see Sections 6.0
14.0 and 17.0)
Yes
No
Availability of diagnostic material (i.e., diagnostic
slides confirming locally advanced/metastatic
disease and HER2 stained slides) and operative
and pathology reports from diagnosis of locally
advanced or metastatic breast cancer (NOTE:
Biopsy of recurrent disease and submission of
these materials is not required if materials
available from initial diagnosis of locally
advanced/metastatic disease.)
Yes
No
Ability to complete questionnaire(s) by
themselves or with assistance (All responses in
above section must be "Yes" unless specified as
"NA.")
Yes
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No
Exclusion Criteria
Any of the following because this study involves
an investigational agent whose genotoxic,
mutagenic and teratogenic effects on the
developing fetus newborn are unknown: -
Pregnant women - Nursing women - Men or
women of childbearing potential who are
unwilling to employ adequate contraception (as
determined by the treating physician).
Yes
No
Stage III or IV invasive cancer, other than breast
cancer, in <=5 years prior to registration.
Yes
No
Actively being treated for other malignancy,
excepting non-melanotic skin cancer or
carcinoma-in-situ of the cervix (If there is a
history of prior malignancy, they must not be
receiving other specific treatment for their
cancer.)
Yes
No
New York Heart Association class III or IV
cardiovascular disease
Yes
No
Current, active hepatic or biliary disease except
Gilbert's syndrome or asymptomatic gallstones
Yes
No
Evidence of active brain metastasis including
leptomeningeal involvement. CNS metastasis
controlled by prior surgery and/or radiotherapy is
allowed. (NOTE: To be considered controlled,
there must be at least 2 months of no symptoms
or evidence of progression prior to study entry
and corticosteriod therapy must have been
discontinued.)
Yes
No
Major surgery, chemotherapy, or immunologic
therapy <=6 weeks prior to registration
Yes
No
Radiotherapy <=4 weeks prior to registration,
except if to a non-target lesion only. Prior
radiation to a target lesion is permitted only if
there has been clear progression of the lesion
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since radiation was completed. (If patient
receives single dose radiation for palliation or
radiation to non-target lesion, they may
immediately proceed to registration without
waiting 4 weeks. Acute adverse events from
radiation must have resolved to <=CTCAE v3.0
Grade 1.)
Yes
No
Prior treatment with any therapy targeting IGF-I,
IGF-II or its receptors(either monoclonal antibody
or tyrosine kinase inhibitor), including but not
limited to any of the following (which would have
been received on a previous clinical trial):     -
IMC-A12 (cixutumumab) - CP-751,871
(figitumumab) - AMG-479 - INSM-18 - MK0646
(h7C10) - SCH717454 (19D12, robatumumab) -
R1507 - OSI-906 - BMS-754807 - PPP  - NVP-
AEW541 - AVE-1642 - MEDI-573
Yes
No
Prior therapy with any therapy targeting HER1
(EGFR) and/or HER2 (either monoclonal
antibody or tyrosine kinase) other than
trastuzumab, including but not limited to any of
the following: (lapatinib Tykerb, gefitinib Iressa,
erlotinib Tarveca, cetuximab Erbitux,
panitumumab Vectibix)
Yes
No
Currently receiving treatment with any agents that
are contraindicated by study therapies: A) IMC-
A12 - none identified to date B) Lapatinib -
CYPA34 inhibitors and inducers (see Appendix
IV) including grapefruit and grapefruit juice (C
Capecitabine - warfarinCoumadin,
cimetidineTagamet, allopurinolLopurin,
sorivudineUsevir, brivudineBrivex,
ketoconazoleNizoral, itraconazoleSporanox,
ritonavirNorvir, amprenavirAgenerase, or
indinavirCrixivan)
Yes
No
Uncontrolled intercurrent illness (including, but
not limited to: - Poorly controlled diabetes -
Ongoing or active infection - Symptomatic
congestive heart failure - Unstable angina
pectoris - Cardiac arrhythmia - Psychiatric
illness/social situations that would limit
compliance with study requirements)
Yes
No
Co-morbid systemic illnesses or other severe
concurrent disease which, in the judgment of the
investigator, would make the patient inappropriate
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for entry into this study or interfere significantly
with the proper assessment of the safety (of the
prescribed regimens.)
Yes
No
Currently receiving treatment in a different clinical
study in which investigational procedures are
performed or investigational therapies are
administered
Yes
No
Immunocompromised patients (other than that
related to the use of corticosteroids) including
patients known to be HIV positive with an AIDS-
defining illness. (HIV positive patients with CD4
count within institutional normal range and no
history of an AIDS-defining illness are eligible,
however, some antiviral/antiretroviral medications
which have CYP3A4 interactions are prohibited
on this study.)
Yes
No
Registration Check
Consent form signed and dated
Yes
No
Date Informed Consent Signed
Authorization for use and disclosure of protected
health information signed and dated (Non-USA
institution only check NA)
No (No)
Not Applicable (Not Applicable)
Yes (Yes)
Date of authorization
A mandatory translational research component is
part of this study,  patients will automatically be
registered to the translational research
component of this study at the time of
registration. (see Section 14.0 and 17.0)
Yes
No
Treatment cannot begin prior to registration and
must begin <=7 days after registration
Yes
No
Pretreatment tests/procedures must be
completed <= 7 days prior to registration (NOTE:
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The earliest pretreatment test/procedure date
must be less than or equal to the earliest
laboratory test/procedure date and the latest
pretreatment test/procedure date must be greater
than or equal to the latest laboratory
test/procedure date.)
Yes
No
Earliest pretreatment test/procedure date
Latest pretreatment test/procedure date
Earliest exception test date (Tumor
measurement, Chest x-ray or CT, Bone scan,
Brain MRI or CT, must be done <=21 days prior
to registration see Section 4.0.)
latest exception test date
Date of EKG (Electrocardiogram EKG must be
done <=28 days prior to registration see Section
4.0.)
All required baseline symptoms (see Section
10.3) must be documented and graded
Yes
No
Study drug availability checked (Study drug must
be in site pharmacy for this patient prior to
registration)
Yes
No
Blood draw kit availability checked (Site must
have a kit on hand for this patient prior to
registration)
Yes
No
This protocol has a mandatory quality assurance
(QA) audit submission of diagnostic slides and
HER2 stained slides used to make a HER2
positive metastatic breast cancer diagnosis, plus
corresponding operating and pathology reports (If
these materials are not available, the patient is
not eligible for this trial)
Yes
No
Patient QOL booklet availability checked; copies
are not acceptable for this submission (Site must
have booklets on hand for this patient prior to
registration)
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Yes
No
This protocol has mandatory monitoring for the
Safety Cohort - sites must participate in monthly
conference calls (see Section 16.8.4)
Yes
No
At The Time Of
Registration/randomization, The Following
Will Also Be Recorded:
Patient has given permission to keep sample(s)
for use in future research to learn about, prevent,
or treat cancer
Yes
No
Patient has given permission to keep sample(s)
for use in future research to learn about, prevent,
or treat other health problems (for example:
diabetes, Alzheimer's disease, or heart disease)
Yes
No
Patient has given NCCTG permission to give
sample(s) to outside researchers
Yes
No
Stratification Factors
Receptor Status (Hormone)
Er Or Pgr Positive (ER or PgR positive)
Other (Other)
Number of prior chemotherapy regimens in the
metastatic setting
None (None)
One (One)
Two Or More (Two or more)
Subgroup Code
Er/pgr+, Two Prior Regimens (SG01:
ER/PgR+, two prior reg.)
Er/pgr+, One Prior Regimen (SG02:
ER/PgR+, one prior reg.)
Er/pgr+, No Prior Regimens (SG03:
ER/PgR+, no prior reg.)
Other, Two Prior Regimens (SG04:
Other, two prior reg.)
Other, One Prior Regimen (SG05: Other,
one prior reg.)
Other, No Prior Regimen (SG06: Other,
none prior reg.)
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Enrollment Form HIV Anal Cancer AMC-
045 NCT00324415
Cisplatin, Fluorouracil, Cetuximab, and Radiation Therapy
in Treating Patients With HIV and Stage I, Stage II, or
Stage III Anal Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=1CB5F031-
5BC1-01E3-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11798
Enrollment Form HIV Anal Cancer
AMC-045 NCT00324415
General information
Principal Investigator*
Projected Start Date of Treatment*
Karnofsky Performance Status
Dead (0)
Moribund, Fatal Processes Progressing
Rapidly (10)
Normal, No Complaints, No Evidence Of
Disease (100)
Very Sick, Hospitalization Indicated.
Death Not Imminent (20)
Severely Disabled, Hospitalization
Indicated. Death Not Imminent (30)
Disabled, Requires Special Care And
Assistance (40)
Requires Considerable Assistance And
Frequent Medical Care (50)
Requires Occasional Assistance, But Is
Able To Care For Most Of His/her Needs
(60)
Cares For Self, Unable To Carry On
Normal Activity Or To Do Active Work
(70)
Normal Activity With Effort; Some Signs
Or Symptoms Of Disease (80)
Able To Carry On Normal Activity; Minor
Signs Or Symptoms Of Disease (90)
Age*
>= 0
<= 120
years
Inclusion Criteria
Inclusion Criteria*
Date Informed Consent Obtained (Date
informed consent obtained)
Does The Patient Have Adequate
Hematologic Function Within 14 Days Of
Study Enrollment: Hemoglobin >= 10
G/dl, Platelet Count >= 100,000/mm^3,
And Anc >= 1500/mm^3? (Does the
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patient have adequate hematologic
function within 14 days of study
enrollment: Hemoglobin >= 10 g/dl,
Platelet count >= 100,000/mm^3, and
ANC >= 1500/mm^3?)
Does The Patient Have Adequate
Hepatic Function Within 14 Days Of
Study Enrollment: Ast And Alt <= 3 X
Uln, And T. Bili <= 2 X Uln? (if Related To
Antiretroviral Use, Then The Direct
Bilirubin Must Be <= 2 X Uln.) (Does the
patient have adequate hepatic function
within 14 days of study enrollment: AST
and ALT <= 3 X ULN, and T. Bili <= 2 X
ULN? (If related to antiretroviral use,
then the Direct Bilirubin must be <= 2 X
ULN.))
Does The Patient Have Creatinine <= 1.5
X The Upper Limits Of Normal (uln) Or A
Creatinine Clearance Above 60 Ml/min
Within 14 Days Of Study Enrollment?
(Does the patient have creatinine <= 1.5
X the upper limits of normal (ULN) or a
creatinine clearance above 60 mL/min
within 14 days of study enrollment?)
Does The Patient Have Documented Hiv
Infection? (documentation May Be By
Antibody Detection, Culture, Or
Quantitative Assay Of Plasma Hiv Rna.)
(Does the patient have documented HIV
infection? (Documentation may be by
antibody detection, culture, or
quantitative assay of plasma HIV RNA.))
Does The Patient Have Histologically
Proven Stage I-iiib Invasive Anal Canal
Or Perianal (anal Margin) Squamous Cell
Carcinoma? (this May Include Tumors Of
Non-keratinizing Histology Such As
Basoloid, Transitional Cell, Or
Cloacogenic Histology.) (Does the
patient have histologically proven stage
I-IIIB invasive anal canal or perianal
(anal margin) squamous cell carcinoma?
(This may include tumors of non-
keratinizing histology such as basoloid,
transitional cell, or cloacogenic
histology.))
Does The Patient Have The Ability And
Willingness To Give Informed Consent?
(Does the patient have the ability and
willingness to give informed consent?)
Has The Patient Had No Prior
Chemotherapy Or No Prior Irradiation
For This Malignancy? (patients With A
History Of Prior Irradiation To The
Planned Irradiation Field For Another
Condition (eg, Kaposi's Sarcoma) May
Be Eligible After Consultation.) (Has the
patient had no prior chemotherapy or no
prior irradiation for this malignancy?
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(Patients with a history of prior irradiation
to the planned irradiation field for another
condition (eg, Kaposi's sarcoma) may be
eligible after consultation.))
Karnofsky Performance Status (must Be
> 60%) (Karnofsky Performance Status
(must be > 60%))
Patient's Age (in Years) (Patient's age (in
years))
Exclusion Criteria
Exclusion Criteria*
Does The Patient Have A Medical Or
Psychiatric Illness That Precludes Ability
To Give Informed Consent Or Is Likely To
Interfere With The Ability To Comply With
The Protocol Stipulations? (Does the
patient have a medical or psychiatric
illness that precludes ability to give
informed consent or is likely to interfere
with the ability to comply with the
protocol stipulations?)
Does The Patient Have Acute, Active,
Serious, Uncontrolled Opportunistic
Infection? (patients With A Cd4 Count <
50/ul Will Be Excluded If They Have Had
An Opportunistic Infection Within The
Past 6 Months, Or If There Is Evidence
Of Resistance.) (Does the patient have
acute, active, serious, uncontrolled
opportunistic infection? (Patients with a
CD4 count < 50/uL will be excluded if
they have had an opportunistic infection
within the past 6 months, or if there is
evidence of resistance.))
Does The Patient Have Grade 2, 3, 4
Neuropathy? (Does the patient have
Grade 2, 3, 4 neuropathy?)
Does The Patient Have Severe (grade 3
Or 4) Or Poorly Controlled Diarrhea?
(Does the patient have severe (grade 3
or 4) or poorly controlled diarrhea?)
Has The Patient Been Diagnosed With
An Invasive Malignancy Within The Past
24 Months? (excluding In Situ Cervical
Cancer, Anal Dysplasia Or Carcinoma In
Situ, Non-melanoma Skin Carcinoma,
Kaposi's Sarcoma That Has Not
Required Systemic Chemotherapy.) (Has
the patient been diagnosed with an
invasive malignancy within the past 24
months? (excluding in situ cervical
cancer, anal dysplasia or carcinoma in
situ, non-melanoma skin carcinoma,
Kaposi's sarcoma that has not required
systemic chemotherapy.))
If The Patient Is A Female, Is She
Pregnant Or Nursing? (If the patient is a
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female, is she pregnant or nursing?)
Consent Module
Date Informed Consent Signed*
Patient's initial consent given for diagnostic
biopsy specimen use for research on future
studies (This procedure has already been
performed and requires no additional
procedures)*
Yes
No
Patient's initial consent given for anal swab
specimen use for research on future studies (This
procedure requires putting an anal swab in the
anal canal)*
Yes
No
Patient's initial consent given for an additional
diagnostic biopsy for research on future studies
(This will require another biopsy to be done)*
Yes
No
Patient's Initial Consent given for specimen kept
for future use in research to learn about, prevent,
or treat cancer*
Yes
No
Patient's initial consent given for specimen(s)
may be kept for use in research to learn about,
prevent, or treat other health problems (for
example:
diabetes, Alzheimer's disease, or heart disease)*
Yes
No
Patient's initial consent given for further contact to
participate in research on future studies (their
doctor or someone from the AMC)*
Yes
No
Comments Module
Comments*
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Enrollment HIV-Related Kaposi Sarcoma
AMC-051 NCT00450320
Enrollment HIV-Related Kaposi Sarcoma AMC-051
NCT00450320 
Sirolimus in Treating Patients With HIV-Related Kaposi's
Sarcoma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=2FDFA89A-
076B-6018-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11799
Enrollment HIV-Related Kaposi
Sarcoma AMC-051 NCT00450320
Header Module
Principal Investigator
Projected Start Date of Treatment
DD.MM.YYYY
Inclusion/exclusion Criteria
Inclusion Criteria
Date Informed Consent Obtained (Date
informed consent obtained)
Does The Participant Have A Ast (sgot)
And Alt (sgpt) <=2.5 Times The Uln
(Does the participant have a AST
(SGOT) and ALT (SGPT) <=2.5 times the
ULN)
Does The Participant Have A Fasting
Triglyceride Level Of <= 400 Mg/dl (4.5
Mmol/l), And A Total Cholesterol Level Of
<= 300 Mg/dl (7.8 Mmol/l) (Does the
participant have a fasting triglyceride
level of <= 400 mg/dL (4.5 mmol/L), and
a total cholesterol level of <= 300 mg/dL
(7.8 mmol/L))
Does The Participant Have A Total
Bilirubin <= 1.5 Times Upper Limit Of
Normal (uln) (Does the participant have
a Total bilirubin <= 1.5 times upper limit
of normal (ULN))
Does The Participant Have Biopsy-
proven Ks Involving The Skin, Lymph
Nodes, Oral Cavity, Gi Tract And/or
Lungs (gi And Pulmonary Involvement
Must Be Asymptomatic Or Minimally
Symptomatic And Not Require Systemic
Cytotoxic Therapy) (Does the participant
have biopsy-proven KS involving the
skin, lymph nodes, oral cavity, GI tract
and/or lungs (GI and pulmonary
involvement must be asymptomatic or
minimally symptomatic and not require
systemic cytotoxic therapy))
Does The Participant Have Serologic
Documentation Of Hiv Infection At Any
Time Prior To Study Entry, As Evidenced
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By Positive Elisa, Positive Western Blot,
Or Other Federally Approved Licensed
Hiv Test, Or A Detectable Blood Level Of
Hiv Rna (Does the participant have
serologic documentation of HIV infection
at any time prior to study entry, as
evidenced by positive ELISA, positive
Western Blot, or other federally approved
licensed HIV test, or a detectable blood
level of HIV RNA)
Does The Participant Have The Ability
And Willingness To Give Informed
Consent (Does the participant have the
ability and willingness to give informed
consent)
Does The Participant Have The
Following Laboratory Parameters Within
21 Days Prior To Study Entry:
Hemoglobin >= 8.0 Gm/dl; Absolute
Neutrophil Count >= 1000 Cells/mm3;
Platelet Count >= 75,000/mm3 (Does the
participant have the following laboratory
parameters within 21 days prior to study
entry: Hemoglobin >= 8.0 gm/dL;
Absolute neutrophil count >= 1000
cells/mm3; Platelet count >=
75,000/mm3)
Does The Participant, Male Or Female,
Of Reproductive Age, Agree To Employ
An Effective Barrier Method Of Birth
Control Throughout The Study And For
Up To 3 Months Following
Discontinuation Of Study Drug (Does the
participant, male or female, of
reproductive age, agree to employ an
effective barrier method of birth control
throughout the study and for up to 3
months following discontinuation of study
drug)
Gfr > 40 Ml/min (calculated By The
Cockcroft-gault Equation), Calculated As
Follows For Males = 140 - Age [years]) X
(body Weight [kg]) / (72) X (serum
Creatinine [mg/dl]; For Females = 0.85 X
Male Value (GFR > 40 mL/min
(calculated by the Cockcroft-Gault
equation), calculated as follows For
males = 140 - age [years]) x (body
weight [kg]) / (72) x (serum creatinine
[mg/dL]; For females = 0.85 x male
value)
Has The Participant Been On Stable
Anti-retroviral Therapy For At Least 12
Weeks With A Pi-based Or Nnrti-based
Regimen Of At Least Three Drugs, With
No Intention To Change The Regimen
Within 8 Weeks Of Starting Study Drug
(Has the participant been on stable anti-
retroviral therapy for at least 12 weeks
with a PI-based or NNRTI-based
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regimen of at least three drugs, with no
intention to change the regimen within 8
weeks of starting study drug)
Has The Participant Had No Prior
Treatment With Rapamycin (Has the
participant had no prior treatment with
rapamycin)
If The Participant Is Female, Did She
Have A Negative Pregnancy Test Within
72 Hours Before Initiation Of Study Drug
Dosing (If the participant is female, did
she have a negative pregnancy test
within 72 hours before initiation of study
drug dosing)
Is The Participant, In The Opinion Of The
Investigator, Capable Of Complying With
This Protocol (Is the participant, in the
opinion of the Investigator, capable of
complying with this protocol)
Is The Participant's Cd4 Count >50
Cells/ul And Serum Hiv Rna Level <400
Copies/ml (Is the participant's CD4 count
>50 cells/uL and serum HIV RNA level
<400 copies/mL)
Is The Participant's Life Expectancy 3
Months Or More (Is the participant's life
expectancy 3 months or more)
Karnofsky Performance Status (must Be
> 60%) (Karnofsky Performance Status
(must be > 60%))
Participant's Age (in Years) (Participant's
age (in years))
Regarding The Participant's Spot Urine
Protein: Is The Creatinine Ratio <= 0.5
And/or Proteinuria <= 500 Mg/day
(Regarding the participant's spot urine
protein: Is the creatinine ratio <= 0.5
and/or proteinuria <= 500 mg/day)
Exclusion Criteria
Exclusion Criteria
Does The Participant Have A Grade Iii/iv
Cardiac Disease As Defined By The New
York Heart Association Criteria (e.g.,
Congestive Heart Failure, Myocardial
Infarction Within 6 Months Of Study)
(Does the participant have a Grade III/IV
cardiac disease as defined by the New
York Heart Association criteria (e.g.,
congestive heart failure, myocardial
infarction within 6 months of study))
Does The Participant Have A History Of
Prior Or Concurrent Malignancy Except
For Treated Basal Cell Skin Cancer Or A
Cervical Carcinoma In Situ (Does the
participant have a history of prior or
concurrent malignancy except for treated
basal cell skin cancer or a cervical
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carcinoma in situ)
Does The Participant Have An Acute Or
Known Chronic Liver Disease (e.g.,
Chronic Active Hepatitis, Cirrhosis)
(participants With Known Hepatitis C
Infection But With Documentation Of No
Or Minimal Fibrosis On Liver Biopsy May
Be Enrolled) (Does the participant have
an acute or known chronic liver disease
(e.g., chronic active hepatitis, cirrhosis)
(Participants with known Hepatitis C
infection but with documentation of no or
minimal fibrosis on liver biopsy may be
enrolled))
Does The Participant Have Another
Severe And/or Life-threatening Medical
Disease (Does the participant have
another severe and/or life-threatening
medical disease)
Does The Participant Have Any Known
Hypersensitivity To Rapamycin Or Its
Derivatives Or Macrolide Antibiotics
(Does the participant have any known
hypersensitivity to rapamycin or its
derivatives or macrolide antibiotics)
Does The Participant Have Concurrent
Active Opportunistic Infection (oi) (Does
the participant have concurrent active
opportunistic infection (OI))
Has The Participant Had Acute
Treatment For An Infection Or Other
Serious Medical Illness Within 14 Days
Prior To Study Entry; Evidence Of
Infiltrate, Cavitation Or Consolidation On
Chest X-ray Obtained Before Or At The
Time Of The Screening Evaluation (Has
the participant had acute treatment for
an infection or other serious medical
illness within 14 days prior to study entry;
evidence of infiltrate, cavitation or
consolidation on chest x-ray obtained
before or at the time of the screening
evaluation)
Has The Participant Had Antineoplastic
Treatment For Ks (including
Chemotherapy, Radiation Therapy,
Biological Therapy, Or Investigational
Therapy) Within 4 Weeks (6 Weeks For
Nitrosourea Or Mitomycin-c) Of Study
Entry (Has the participant had
antineoplastic treatment for KS (including
chemotherapy, radiation therapy,
biological therapy, or investigational
therapy) within 4 weeks (6 weeks for
nitrosourea or mitomycin-C) of study
entry)
Has The Participant Had Major Surgery
Within 2 Weeks Prior To Study Entry
(Has the participant had major surgery
within 2 weeks prior to study entry)
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Has The Participant Had Previous Local
Therapy Of Any Ks Indicator Lesion
Within 60 Days, Unless The Lesion Has
Progressed Since Treatment (Has the
participant had previous local therapy of
any KS indicator lesion within 60 days,
unless the lesion has progressed since
treatment)
Has The Participant Had Systemic
Corticosteroid Treatment, Other Than
Replacement Doses (Has the participant
had systemic corticosteroid treatment,
other than replacement doses)
Has The Participant Used Any
Investigational Drug Or Treatment Up To
4 Weeks Before Randomization (Has the
participant used any investigational drug
or treatment up to 4 weeks before
randomization)
If The Participant Is Female, Is She
Pregnant Or Breast-feeding (If the
participant is female, is she pregnant or
breast-feeding)
Is The Participant Receiving Treatment
With Agents Or Medications, Other Than
Antiretroviral Drugs Used To Treat Hiv
Infection, Which Would Interfere With
The Metabolism Or Excretion Of
Rapamycin (Is the participant receiving
treatment with agents or medications,
other than antiretroviral drugs used to
treat HIV infection, which would interfere
with the metabolism or excretion of
rapamycin)
Karnofsky Performance Status
%
Dead (0)
Moribund, Fatal Processes Progressing
Rapidly (10)
Normal, No Complaints, No Evidence Of
Disease (100)
Very Sick, Hospitalization Indicated.
Death Not Imminent (20)
Severely Disabled, Hospitalization
Indicated. Death Not Imminent (30)
Disabled, Requires Special Care And
Assistance (40)
Requires Considerable Assistance And
Frequent Medical Care (50)
Requires Occasional Assistance, But Is
Able To Care For Most Of His/her Needs
(60)
Cares For Self, Unable To Carry On
Normal Activity Or To Do Active Work
(70)
Normal Activity With Effort; Some Signs
Or Symptoms Of Disease (80)
Able To Carry On Normal Activity; Minor
Signs Or Symptoms Of Disease (90)
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Age
>= 0
<= 120
years
Informed Consent Date
Select the HAART regimen the participant is
currently receiving
Nnrti-based Haart Regimen (NNRTI-
based HAART Regimen)
Pi-based Haart Regimen (PI-based
HAART Regimen)
Comments
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Enrollment AIDS related NHL AMC-047
NCT00389818
Combination Chemotherapy and Rituximab in Treating
Patients With Newly Diagnosed AIDS-Related B-Cell Non-
Hodgkin's Lymphoma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=1F7A6F51-
F1C3-120A-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11800
Enrollment AIDS related NHL AMC-
047 NCT00389818
Header Module
Principal Investigator
Projected Start Date of Treatment
Inclusion/exclusion Criteria
Inclusion Criteria
Date Informed Consent Obtained (Date
informed consent obtained)
Do The Subject's Granulocytes (anc)
Measure >= 1000 Mm^3 And Platelets
>= 75,000 Dl (unless These Parameters
Are Abnormal Secondary To
Lymphomatous Involvement Of Bone
Marrow, Or Due To Hiv-related
Thrombocytopenia) (Do the subject's
granulocytes (ANC) measure >= 1000
mm^3 and platelets >= 75,000 dL
(unless these parameters are abnormal
secondary to lymphomatous involvement
of bone marrow, or due to HIV-related
thrombocytopenia))
Does The Patient Have The Ability And
Willingness To Give Informed Consent?
(Does the patient have the ability and
willingness to give informed consent?)
Does The Subject Have Documented Hiv
Infection (documentation May Be
Serologic [elisa, Western Blot], Culture,
Or Quantitative Pcr Or Bdna Assays.
Prior Documentation Of Hiv
Seropositivity Is Acceptable) (Does the
subject have documented HIV infection
(Documentation may be serologic
[ELISA, western blot], culture, or
quantitative PCR or bDNA assays. Prior
documentation of HIV seropositivity is
acceptable))
Does The Subject Have Either
Measurable Or Non-measurable Tumor
Parameter(s) Non-measurable Tumor
Parameters Are Defined As Not Having
Bidimensional Measurements But Can
Be Followed For Response By Other
Diagnostic Tests (Does the subject have
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either measurable or non-measurable
tumor parameter(s) Non-measurable
tumor parameters are defined as not
having bidimensional measurements but
can be followed for response by other
diagnostic tests)
Does The Subject Have Previously
Untreated, Histologically Or Cytologically
Documented B-cell Non-hodgkin's
Lymphoma (Does the subject have
previously untreated, histologically or
cytologically documented B-cell non-
Hodgkin's lymphoma)
Does The Subject's Bilirubin Measure <=
2.0 Mg/dl (unless Elevated Secondary To
Lymphomatous Involvement Of Liver Or
Biliary System, Or Due To Other Hiv
Medications [e.g., Indinavir Or
Atazanavir]) (Does the subject's bilirubin
measure <= 2.0 mg/dL (unless elevated
secondary to lymphomatous involvement
of liver or biliary system, or due to other
HIV medications [e.g., indinavir or
atazanavir]))
Does The Subject's Creatinine Measure
<= 2.0 Mg/dl Or Is Creatinine Clearance
>= 60 Ml/min (unless Secondary To
Renal Involvement By Lymphoma) (Does
the subject's creatinine measure <= 2.0
mg/dL or is creatinine clearance >= 60
mL/min (unless secondary to renal
involvement by lymphoma))
If The Subject Is A Male Of Child
Fathering Potential, Does He Agree To
Practice Adequate Birth Control While
Receiving Treatment And For Six Months
After Treatment Is Discontinued (If the
subject is a male of child fathering
potential, does he agree to practice
adequate birth control while receiving
treatment and for six months after
treatment is discontinued)
If The Subject Is Female Capable Of
Childbearing, Does She Agree To
Practice Adequate Birth Control To
Prevent Pregnancy While Receiving
Treatment And For Six Months After
Treatment Is Discontinued (If the subject
is female capable of childbearing, does
she agree to practice adequate birth
control to prevent pregnancy while
receiving treatment and for six months
after treatment is discontinued)
If The Subject Is Female, Has She Had A
Negative Pregnancy Test Within 72
Hours Prior To Study Entry (If the subject
is female, has she had a negative
pregnancy test within 72 hours prior to
study entry)
Is The Disease One Of The Following
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Histologies: Follicular Large-cell (grade
3), Dlbcl, Immunoblastic, Plasmablastic,
Or Primary Effusion Lymphoma (Is the
disease one of the following histologies:
follicular large-cell (Grade 3), DLBCL,
immunoblastic, plasmablastic, or primary
effusion lymphoma)
Is The Subject Receiving Concurrent
Effective Haart (with Any Licensed
Agents, Or Any Agent Available On An
Expanded Access Program) (Is the
subject receiving concurrent effective
HAART (with any licensed agents, or any
agent available on an expanded access
program))
Is The Subject's Left Ventricular Ejection
Fraction (lvef) At Or Above The Lower
Institutional Limits Of Normal, As
Assessed By Muga Scan Or
Echocardiogram, Obtained Within The 6
Weeks Prior To Registration (Is the
subject's left ventricular ejection fraction
(LVEF) at or above the lower institutional
limits of normal, as assessed by MUGA
scan or echocardiogram, obtained within
the 6 weeks prior to registration)
Is The Subject's Lymphoma Cd20-
positive (Is the subject's lymphoma
CD20-positive)
Karnofsky Performance Status (must Be
> 50%) (Karnofsky Performance Status
(must be > 50%))
Patient's Age (in Years) (Patient's age (in
years))
Exclusion Criteria
Exclusion Criteria
Does The Subject Have A History Of
Cytotoxic Chemotherapy Or
Radiotherapy For This Lymphoma (Does
the subject have a history of cytotoxic
chemotherapy or radiotherapy for this
lymphoma)
Does The Subject Have A Second Active
Tumor, Other Than Non-melanomatous
Skin Cancer, Carcinoma In Situ Of The
Cervix Or Kaposi's Sarcoma That Does
Not Require Systemic Therapy (Does the
subject have a second active tumor,
other than non-melanomatous skin
cancer, carcinoma in situ of the cervix or
Kaposi's sarcoma that does not require
systemic therapy)
Does The Subject Have A Serious,
Ongoing, Non-malignant Disease Or
Infection, Which, In The Opinion Of The
Investigator And/or Sponsor, Would
Compromise Protocol Objectives (Does
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the subject have a serious, ongoing, non-
malignant disease or infection, which, in
the opinion of the Investigator and/or
Sponsor, would compromise protocol
objectives)
Does The Subject Have An Acute,
Intercurrent Infection (excluding
Mycobacterium Avium) That May
Interfere With Planned Protocol
Treatment (Does the subject have an
acute, intercurrent infection (excluding
Mycobacterium avium) that may interfere
with planned protocol treatment)
Does The Subject Have History Of
Cutaneous Or Mucocutaneous
Reactions Or Diseases, Due To Any
Cause, Severe Enough To Cause
Hospitalization Or An Inability To Eat Or
Drink For >= 2 Days (Does the subject
have history of cutaneous or
mucocutaneous reactions or diseases,
due to any cause, severe enough to
cause hospitalization or an inability to eat
or drink for >= 2 days)
Does The Subject Have Inadequate
Pulmonary Function (i.e., Shortness Of
Breath At Rest, With Arterial Po\2 < 70
Or Pulse Oximeter-derived O\2
Saturation < 94% On Room Air [unless
Due To Lymphomatous Involvement Of
The Lungs]) (Does the subject have
inadequate pulmonary function (i.e.,
shortness of breath at rest, with arterial
PO\2 < 70 or pulse oximeter-derived O\2
saturation < 94% on room air [unless due
to lymphomatous involvement of the
lungs]))
Does The Subject Have Leptomeningeal
Disease (positive Csf For Lymphoma) Or
A Presence Of Metastatic Disease Of
The Brain In Terms Of Any Mass Lesion
(Does the subject have leptomeningeal
disease (positive CSF for lymphoma) or
a presence of metastatic disease of the
brain in terms of any mass lesion)
Does The Subject Have Primary Cns
Lymphoma (this Includes Parenchymal
Brain Or Spinal Chord Lymphoma) (Does
the subject have primary CNS lymphoma
(this includes parenchymal brain or
spinal chord lymphoma))
Has The Subject Had A Myocardial
Infarction (mi) Within The 6 Months Prior
To Study Entry, New York Heart
Association (nyha) Class Ii Or Greater
Heart Failure, Uncontrolled Angina,
Severe Uncontrolled Ventricular
Arrhythmias, Clinically Significant (Has
the subject had a myocardial infarction
(MI) within the 6 months prior to study
4 / 6
Enrollment AIDS related NHL AMC-047 NCT00389818
entry, New York Heart Association
(NYHA) Class II or greater heart failure,
uncontrolled angina, severe uncontrolled
ventricular arrhythmias, clinically
significant)
Has The Subject Had Any Major Surgery
(excluding Diagnostic Surgery) Within
The 4 Weeks Prior To Study Entry (Has
the subject had any major surgery
(excluding diagnostic surgery) within the
4 weeks prior to study entry)
Has The Subject Received Rituximab
Therapy Within The 12 Months Prior To
Study Entry (Has the subject received
rituximab therapy within the 12 months
prior to study entry)
If The Patient Is A Female, Is She
Pregnant Or Nursing? (If the patient is a
female, is she pregnant or nursing?)
In The Opinion Of The Principal
Investigator, Is The Subject Unable To
Comply With The Requirements Of The
Protocol, Or Unable To Provide
Adequate Informed Consent (In the
opinion of the Principal Investigator, is
the subject unable to comply with the
requirements of the protocol, or unable
to provide adequate informed consent)
Is The Subject Already Receiving
Erythropoietin Or G-csf For Treatment Of
Hiv-related Cytopenia If Yes, Will Growth
Factors Be Discontinued At Least 24
Hours Prior To Chemotherapy (Is the
subject already receiving erythropoietin
or G-CSF for treatment of HIV-related
cytopenia If yes, will growth factors be
discontinued at least 24 hours prior to
chemotherapy)
Is The Subject Receiving Zidovudine As
Part Of The Harrt Regimen (Is the
subject receiving zidovudine as part of
the HARRT regimen)
Is The Subject's Expected Survival < 2
Months (Is the subject's expected
survival < 2 months)
Karnofsky Performance Status
%
Dead (0)
Moribund, Fatal Processes Progressing
Rapidly (10)
Normal, No Complaints, No Evidence Of
Disease (100)
Very Sick, Hospitalization Indicated.
Death Not Imminent (20)
Severely Disabled, Hospitalization
Indicated. Death Not Imminent (30)
Disabled, Requires Special Care And
Assistance (40)
Requires Considerable Assistance And
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Frequent Medical Care (50)
Requires Occasional Assistance, But Is
Able To Care For Most Of His/her Needs
(60)
Cares For Self, Unable To Carry On
Normal Activity Or To Do Active Work
(70)
Normal Activity With Effort; Some Signs
Or Symptoms Of Disease (80)
Able To Carry On Normal Activity; Minor
Signs Or Symptoms Of Disease (90)
Age
>= 0
<= 120
years
Informed Consent Date
Comments
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Enrollment HIV associated Burkitt
Lymphoma AMC-048 NCT00392834
AMC-048 ENR (Enrollment) NCT00392834 
Rituximab and Combination Chemotherapy in Treating
Patients With Newly Diagnosed, HIV-Associated Burkitt's
Lymphoma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=32E18FA2-
33FA-4AF2-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11801
Enrollment HIV associated Burkitt
Lymphoma AMC-048 NCT00392834
Header Module
Principal Investigator
Projected Start Date of Treatment
Inclusion/exclusion Criteria
Inclusion Criteria
Date Informed Consent Obtained (Date
informed consent obtained)
Does The Participant Have A Direct
Bilirubin Level Of <=2.0 Mg/dl (Does the
participant have a direct bilirubin level of
<=2.0 mg/dL)
Does The Participant Have A Histologic
Diagnosis Of Burkitt's Lymphoma (bl) Or
Atypical Burkitt's As Per Who Criteria
(Does the participant have a histologic
diagnosis of Burkitt's lymphoma (BL) or
atypical Burkitt's as per WHO criteria)
Does The Participant Have A Serum
Creatinine <=1.5 Mg/dl (Does the
participant have a serum creatinine
<=1.5 mg/dL)
Does The Participant Have Anc
>=1000/ul And Platelets >=50,000ul
(unless Disease-related) (Does the
participant have ANC >=1000/uL and
platelets >=50,000uL (unless disease-
related))
Does The Participant Have Ast (sgot)
And Alt (sgpt) <=3 X The Upper Limit Of
Normal (Does the participant have AST
(SGOT) and ALT (SGPT) <=3 x the
upper limit of normal)
Does The Participant Have Measurable
Or Nonmeasurable Tumor Parameter(s)
(Does the participant have measurable
or non-measurable tumor parameter(s))
Does The Participant Have Normal
Baseline Cardiac Function Based Upon
Echocardiogram Or Multigated
Acquisition (muga) Blood Pool Scan With
An Ejection Fraction >=50% (Does the
participant have normal baseline cardiac
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function based upon echocardiogram or
multigated acquisition (MUGA) blood
pool scan with an ejection fraction
>=50%)
If The Elevated Bilirubin Is Felt To Be
Secondary To Antiretroviral Therapy, Is
The Participant's Total Bilirubin <=3.5
Mg/dl Provided That The Direct Bilirubin
Is Normal (If the elevated bilirubin is felt
to be secondary to antiretroviral therapy,
is the participant's total bilirubin <=3.5
mg/dL provided that the direct bilirubin is
normal)
If The Participant Is Female Who Is
Premenopausal, Did She Have A
Negative Pregnancy Test (If the
participant is female who is
premenopausal, did she have a negative
pregnancy test)
If The Participant Is Female, Is She Of
Childbearing Age And Using An
Acceptable Form Of Birth Control (If the
participant is female, is she of
childbearing age and using an
acceptable form of birth control)
If The Participant's Creatinine Is >1.5
Mg/dl, Is The Creatinine Clearance >=60
Ml/minute (If the participant's creatinine
is >1.5 mg/dL, is the creatinine clearance
>=60 mL/minute)
Is The Participant (or Their Guardian)
Capable Of Providing Informed Consent
(Is the participant (or their guardian)
capable of providing informed consent)
Is The Participant Hiv Positive
Documented By Enzyme-linked
Immunosorbent Assay [elisa] And
Western Blot, Or Measurable Hiv Viral
Load (Is the participant HIV positive
documented by enzyme-linked
immunosorbent assay [ELISA] and
Western Blot, or measurable HIV viral
load)
Karnofsky Performance Status (must Be
>30%) (Karnofsky performance status
(must be >30%))
Participant's Age (in Years) (Participant's
age (in years))
Exclusion Criteria
Exclusion Criteria
Does The Participant Have A History Of
Any Malignancy For Which The Disease-
free Interval Is <5 Years, Excluding
Curatively Treated Cutaneous Basal Cell
Or Squamous Cell Carcinoma And
Carcinoma In Situ Of The Cervix Or
Cutaneous Ks (Does the participant have
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a history of any malignancy for which the
disease-free interval is <5 years,
excluding curatively treated cutaneous
basal cell or squamous cell carcinoma
and carcinoma in situ of the cervix or
cutaneous KS)
Does The Participant Have Any Medical
Illness Unrelated To Nhl, Which In The
Opinion Of The Attending Physician And
Principal Investigator (pi), Will Preclude
Administration Of Chemotherapy Safely
(Does the participant have any medical
illness unrelated to NHL, which in the
opinion of the attending physician and
Principal Investigator (PI), will preclude
administration of chemotherapy safely)
Has The Participant Received Previous
Therapy For Bl Or Atypical Bl Other Than
Seven Consecutive Days Of Steroids
(Has the participant received previous
therapy for BL or atypical BL other than
seven consecutive days of steroids)
If The Participant Is Female, Is She
Pregnant Or Breast-feeding (If the
participant is female, is she pregnant or
breast-feeding)
If Yes, Will The Growth Factors Be
Discontinued At Least 24 Hours Prior To
Chemotherapy (If yes, will the growth
factors be discontinued at least 24 hours
prior to chemotherapy)
Is The Participant Already Receiving
Erythropoietin Or G-csf For Treatment Of
Hiv-related Cytopenia (Is the participant
already receiving erythropoietin or G-
CSF for treatment of HIV-related
cytopenia)
Informed Consent Date
Karnofsky Performance Status
%
Dead (0)
Moribund, Fatal Processes Progressing
Rapidly (10)
Normal, No Complaints, No Evidence Of
Disease (100)
Very Sick, Hospitalization Indicated.
Death Not Imminent (20)
Severely Disabled, Hospitalization
Indicated. Death Not Imminent (30)
Disabled, Requires Special Care And
Assistance (40)
Requires Considerable Assistance And
Frequent Medical Care (50)
Requires Occasional Assistance, But Is
Able To Care For Most Of His/her Needs
(60)
Cares For Self, Unable To Carry On
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Normal Activity Or To Do Active Work
(70)
Normal Activity With Effort; Some Signs
Or Symptoms Of Disease (80)
Able To Carry On Normal Activity; Minor
Signs Or Symptoms Of Disease (90)
Age
>= 0
<= 120
years
Disease Risk
Modified Ann Arbor Stage
I (I)
Ie (IE)
Ii (II)
Iie (IIE)
Iii (III)
Iiie (IIIE)
Iiie+s (IIIE+S)
Iiis (IIIS)
Iv (IV)
Does the participant have normal LDH
Yes
No
Does the participant have a single focus of
disease that measures <10 cm
Yes
No
Does the participant have intra-abdominal
disease only and total resection
Yes
No
Comments
Comments
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Eligibility Gastroesophageal Reflux
NCT00291746
ODM derived from
http://clinicaltrials.gov/show/NCT00291746
All rights reserved. Please visit https://medical-data-
models.org/forms/11802
Eligibility Gastroesophageal Reflux
NCT00291746
Inclusion Criteria
Age 18 Years to 79 Years*
Yes
No
Subjects who seek medical advice at 
their family doctor (primary care 
physician) for symptoms thought by 
the primary care physician to arise 
from the upper GI tract*
Yes
No
The symptoms thought to pertain to 
the upper GI tract must have been 
present for at least 4 weeks prior to 
Visit 1 and to have occurred at least 
twice a week during that period*
Yes
No
The symptoms thought to pertain to 
the upper GI tract must have been of 
at least mild severity for a minimum 
of 3 days during the week prior to 
Visit 1*
Yes
No
Exclusion Criteria
Upper GI endoscopy performed within 
a year prior to Visit 1*
Yes
No
Previous anti-reflux surgery, surgery for peptic
ulcer or any form of upper gastrointestinal
resective surgery*
Yes
No
Contra-indication to the BravoTM procedure such
as subjects with a history of bleeding diathesis,
strictures anywhere along the GI-tract,
esophageal varices, obstructions, or subjects
equipped with a pacemaker, an implantable
cardiac defibrillator or an implantable
neurostimulator (NB: subjects with severe
esophagitis (grade D) confirmed by endoscopy at
Visit 2 can continue the study without performing
the BravoTM procedure)*
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Yes
No
Medical Concepts
Encounter for medical advice NOS*
General practitioner (GP)*
Upper Gastrointestinal System*
patient encounter*
Severity (qualifier value)*
Endoscopy (procedure)*
Period (temporal concept)*
Anti-reflux surgery*
Peptic Ulcer*
operative procedures*
Resection*
Medical Contraindication*
Esophagus acid reflux test with intraluminal pH
electrode*
Bleeding tendency*
Fibrous stenosis*
Oesophageal Varices *
Obstruction of esophagus*
Artificial cardiac pacemaker*
cardiac defibrillator*
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Neurostimulator*
Esophagitis grade IV*
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Enrollment HIV-Related Kaposi Sarcoma
AMC-059 NCT00686842
PTC299 in Treating Patients With HIV-Related Kaposi
Sarcoma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=546E1FC3-
808C-2E0A-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11803
Enrollment HIV-Related Kaposi
Sarcoma AMC-059 NCT00686842
Header Module
Principal Investigator
Projected Start Date of Treatment
Inclusion/exclusion Criteria
Inclusion Criteria (Each subject must meet all of
the following inclusion criteria to be enrolled in
the study)
Date Informed Consent Obtained (Date
informed consent obtained)
Does The Participant Agree To Employ
An Effective Barrier Method Of Birth
Control Throughout The Study And For
Up To 3 Months Following
Discontinuation Of Study Drug (Does the
participant agree to employ an effective
barrier method of birth control throughout
the study and for up to 3 months
following discontinuation of study drug)
Does The Participant Have A Total
Bilirubin <=1.5 Times Upper Limit Of
Normal (uln) Is The Elevated Bilirubin
Felt To Be Secondary To Indinavir Or
Atazanavir Therapy Is Total Bilirubin <=
3.5 Mg/dl And Is Direct Bilirubin Normal
(Does the participant have a total
bilirubin <=1.5 times upper limit of
normal (ULN) Is the elevated bilirubin felt
to be secondary to Indinavir or
Atazanavir therapy Is total bilirubin <=
3.5 mg/dl and is direct bilirubin normal)
Does The Participant Have At Least Five
Measurable, Previously Non-radiated,
Cutaneous Lesions Present Which Can
Be Used As Indicator Lesions (Does the
participant have at least five measurable,
previously non-radiated, cutaneous
lesions present which can be used as
indicator lesions)
Does The Participant Have Biopsy-
proven Ks Involving The Skin, With Or
Without Lymph Node, Oral Cavity,
Gastrointestinal (gi) Tract And/or Lung
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Involvement (Does the participant have
biopsy-proven KS involving the skin, with
or without lymph node, oral cavity,
gastrointestinal (GI) tract and/or lung
involvement)
Does The Participant Have Four Non-
indicator Cutaneous Lesions Present
Measuring >=4 X 4mm That Are
Accessible For 3 Mm Punch Biopsy
(Does the participant have four non-
indicator cutaneous lesions present
measuring >=4 x 4mm that are
accessible for 3 mm punch biopsy)
Does The Participant Have Serologic
Documentation Of Hiv Infection At Any
Time Prior To Study Entry, As Evidenced
By Positive Elisa, Positive Western Blot,
Or Other Federally Approved Licensed
Hiv Test, Or A Detectable Blood Level Of
Hiv Rna (Does the participant have
serologic documentation of HIV infection
at any time prior to study entry, as
evidenced by positive ELISA, positive
Western Blot, or other federally approved
licensed HIV test, or a detectable blood
level of HIV RNA)
Does The Participant Have The Ability
And Willingness To Give Written
Informed Consent (Does the participant
have the ability and willingness to give
written informed consent)
Does The Participant Have The
Following Laboratory Parameters Within
21 Days Prior To Enrollment: Creatinine
<=2.0 Mg/dl; Ast (sgot) And Alt (sgpt) <=
2.5 X Uln; Inr And Aptt <= Uln; Does The
Participant Have An Inr And Aptt <= Uln;
< 2+ Proteinuria (Does the participant
have the following laboratory parameters
within 21 days prior to enrollment:
creatinine <=2.0 mg/dL; AST (SGOT)
and ALT (SGPT) <= 2.5 x ULN; INR and
aPTT <=  ULN;  does the participant
have an INR and aPTT <= ULN; < 2+
proteinuria)
Does The Participant Have The
Following Laboratory Parameters Within
21 Days Prior To Study Entry:
Hemoglobin >= 8.0 Gm/dl; Absolute
Neutrophil Count >= 1000 Cells/mm3;
Platelet Count >= 75,000/mm3 (Does the
participant have the following laboratory
parameters within 21 days prior to
enrollment: hemoglobin > 8.0 gm/dL;
absolute neutrophil count >= 1000
cells/mm^3; platelet count >=
75,000/mm^3)
Has The Participant Been On Stable
Antiretroviral Therapy For At Least 12
Weeks (Has the participant been on
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stable antiretroviral therapy for at least
12 weeks)
If The Participant Is Female, And Of
Child-bearing Potential, Has She Had A
Negative Pregnancy Test Prior To Study
Entry (If the participant is female, and of
child-bearing potential, has she had a
negative pregnancy test prior to study
entry)
Is The Participant On Antiretroviral
Therapy (Is the participant on
antiretroviral therapy)
Is The Participant, In The Opinion Of The
Investigator, Capable Of Complying With
This Protocol (Is the participant, in the
opinion of the Investigator, capable of
complying with this protocol)
Is The Participant's Life Expectancy 3
Months Or More (Is the participant's life
expectancy 3 months or more)
Karnofsky Performance Status (must Be
> 60%) (Karnofsky Performance Status
(must be > 60%))
Exclusion Criteria
Exclusion Criteria (Subjects meeting any of the
following exclusion criteria are not to be enrolled
in the study)
Does The Participant Have A History Of
Any Of The Following: Myocardial
Infarction, Severe/unstable Angina,
Coronary/peripheral Artery Bypass Graft,
Symptomatic Congestive Heart Failure,
Cerebral Vascular Accident (Does the
participant have a history of any of the
following: myocardial infarction,
severe/unstable angina,
coronary/peripheral artery bypass graft,
symptomatic congestive heart failure,
cerebral vascular accident)
Does The Participant Have A History Of
Any Of The Following: Transient
Ischemic Attack, Pulmonary Embolism,
Deep Vein Thrombosis, Or Other
Significant Thromboembolic Event (Does
the participant have a history of any of
the following: transient ischemic attack,
pulmonary embolism, deep vein
thrombosis, or other significant
thromboembolic event)
Does The Participant Have A Known
Coagulopathy Or Bleeding Diathesis
(Does the participant have a known
coagulopathy or bleeding diathesis)
Does The Participant Have A Prior Or
Ongoing Clinically Significant Illness,
Medical Condition, Surgical History,
Physical Finding, Ecg Finding, Or
3 / 5
Enrollment HIV-Related Kaposi Sarcoma AMC-059 NCT00686842
Laboratory Abnormality (Does the
participant have a prior or ongoing
clinically significant illness, medical
condition, surgical history, physical
finding, ECG finding, or laboratory
abnormality)
Does The Participant Have A Resting
Systolic Blood Pressure >160 Mmhg Or
Diastolic Blood Pressure >100 Mmhg
(Does the participant have a resting
systolic blood pressure >160 mmHg or
diastolic blood pressure >100 mmHg)
Does The Participant Have Any History
Of The Following: Central Nervous
System, Pulmonary, Gastrointestinal, Or
Urinary Bleeding (Does the participant
have any history of the following: central
nervous system, pulmonary,
gastrointestinal, or urinary bleeding)
Does The Participant Have Concurrent
Neoplasia Requiring Cytotoxic Therapy
(Does the participant have concurrent
neoplasia requiring cytotoxic therapy)
Does The Participant Have Concurrent,
Acute, Active Opportunistic Infection
Other Than Oral Thrush Or Genital
Herpes Within 14 Days Of Enrollment
(Does the participant have concurrent,
acute, active opportunistic infection other
than oral thrush or genital herpes within
14 days of enrollment)
Does The Participant Have Symptomatic
Visceral Ks Requiring Cytotoxic Therapy
(Does the participant have symptomatic
visceral KS requiring cytotoxic therapy)
Has The Participant Had Acute
Treatment For An (other Than Oral
Thrush Or Genital Herpes) Or Other
Serious Medical Illness Within 14 Days
Prior To Enrollment (Has the participant
had acute treatment for an (other than
oral thrush or genital herpes) or other
serious medical illness within 14 days
prior to enrollment)
Has The Participant Had Antineoplastic
Treatment For Ks (including
Chemotherapy, Radiation Therapy,
Biological Therapy, Or Investigational
Therapy) Within 4 Weeks Of Study Entry
(Has the participant had antineoplastic
treatment for KS (including
chemotherapy, radiation therapy,
biological therapy, or investigational
therapy) within 4 weeks of study entry)
Has The Participant Had Major Surgery
Within 30 Days Prior To Enrollment, The
Presence Of Unhealed Surgical Wounds
At The Time Of Enrollment Or
Anticipated Need For Surgical
Procedures During The Period Of Study
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Participation (Has the participant had
major surgery within 30 days prior to
enrollment, the presence of unhealed
surgical wounds at the time of enrollment
or anticipated need for surgical
procedures during the period of study
participation)
Has The Participant Had Previous Local
Therapy Of Any Ks Indicator Lesion
Within 60 Days Prior To Enrollment
Unless The Lesion Has Clearly
Progressed Since Treatment (Has the
participant had previous local therapy of
any KS indicator lesion within 60 days
prior to enrollment unless the lesion has
clearly progressed since treatment)
Has The Participant Used Any
Investigational Drug Or Treatment
(excluding Antiretroviral Therapy Or
Agents Available On A Treatment Ind)
Within 28 Days Prior To Enrollment (Has
the participant used any investigational
drug or treatment (excluding antiretroviral
therapy or agents available on a
treatment IND) within 28 days prior to
enrollment)
If The Participant Is Female, Is She
Pregnant Or Breast-feeding (If the
participant is female, is she pregnant or
breast-feeding)
In The Investigator's Opinion, Could
These Factors Affect The Safety Of The
Subject; Alter The Absorption Of The
Study Drug; Or Impair The Assessment
Of Study Results (In the investigator?s
opinion, could these factors affect the
safety of the subject; alter the absorption
of the study drug; or impair the
assessment of study results)
Is The Participant On Ongoing Systemic
Corticosteroid Treatment, Other Than
Replacement Doses (Is the participant
on ongoing systemic corticosteroid
treatment, other than replacement
doses)
Is There Ongoing Use Of Anticoagulant
Therapy, Including Coumadin, Heparin
Or Antiplatelet Drugs (Is there ongoing
use of anticoagulant therapy, including
coumadin, heparin or antiplatelet drugs)
Age
>= 0
<= 120
years
Informed Consent Date
Comments
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Eligibility HIV-1 HPV vaccination AMC-052
NCT00513526
Eligibility HIV-1 HPV vaccination AMC-052 NCT00513526 
Human Papillomavirus Vaccine Therapy in Treating Men
With HIV-1 Infection
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=3BAF52D2-
F5E5-0D56-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11804
Eligibility HIV-1 HPV vaccination
AMC-052 NCT00513526
Inclusion Criteria
Inclusion Criteria
Date Of Informed Consent (Date of
informed consent)
Does The Participant Have
Documentation Of Hiv-1 Infection By Any
Licensed Elisa Test Kit And Confirmed
By Western Blot At Any Time Prior To
Study Entry (Does the participant have
documentation of HIV-1 infection by any
licensed ELISA test kit and confirmed by
Western blot at any time prior to study
entry)
Does The Participant Have The Ability
And Willingness To Give Informed
Consent (Does the participant have the
ability and willingness to give informed
consent)
Participant's Age (in Years) (Participant's
age (in years))
Exclusion Criteria
Age
>= 0
<= 120
years
Informed Consent Date
Exclusion Criteria
Does The Participant Have A History Of
Anal Cytological Result With Hsil,
Atypical Squamous Cells Suggestive Of
Hsil, Or Suggestive Of Carcinoma (Does
the participant have a history of anal
cytological result with HSIL, atypical
squamous cells suggestive of HSIL, or
suggestive of carcinoma)
Does The Participant Have A History Of
Anal Or Perianal Carcinoma (Does the
participant have a history of anal or
perianal carcinoma)
Does The Participant Have A History Of
High Grade Ain (i.e. Ain 2 Or 3) Or High
Grade Perianal Intraepithelial Neoplasia
1 / 2
(Does the participant have a history of
high grade AIN (i.e. AIN 2 or 3) or high
grade perianal intraepithelial neoplasia)
Does The Participant Have Active Drug
Or Alcohol Use Or Dependence That, In
The Opinion Of The Site Investigator,
Would Interfere With Adherence To
Study Requirements (Does the
participant have active drug or alcohol
use or dependence that, in the opinion of
the site investigator, would interfere with
adherence to study requirements)
Does The Participant Have An Allergy To
Yeast Or Any Other Components Of
Gardasil (Does the participant have an
allergy to yeast or any other components
of Gardasil)
Does The Participant Have Hemophilia
(Does the participant have hemophilia)
Has The Participant Ever Received
Gardasil Or Any Other Hpv Vaccine (Has
the participant ever received Gardasil or
any other HPV vaccine)
Has The Participant Undergone A
Splenectomy (Has the participant
undergone a splenectomy)
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Enrollment Cervical Cancer ANZGOG-0902
NCT01414608
ANZGOG-0902 Enrollment
Cisplatin and Radiation Therapy With or Without
Carboplatin and Paclitaxel in Patients With Locally
Advanced Cervical Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=90675395-7527-
57AA-E040-BB89AD43454D
All rights reserved. Please visit https://medical-data-
models.org/forms/11805
Enrollment Cervical Cancer
ANZGOG-0902 NCT01414608
Header
Patient Initials
Patient date of birth
DD.MM.YYYY
Institution Code
Institution
Inclusion Criteria
Stage
Stage Ib1 (IB1)
Stage Ib2 (IB2)
Stage Iia (IIA)
Stage Iib (IIB)
Stage Iiib (IIIB)
Stage Iva (IVA)
Age
>= 0
<= 120
years
ECOG Performance Status
Fully Active, Able To Carry On All Pre-
disease Performance Without
Restriction. (0)
Restricted In Physically Strenuous
Activity But Ambulatory And Able To
Carry Out Work Of A Light Or Sedentary
Nature, E.g., Light Housework, Office
Work. (1)
Ambulatory And Capable Of All Selfcare
But Unable To Carry Out Any Work
Activities. Up And About More Than 50%
Of Waking Hours. (2)
Capable Of Only Limited Selfcare,
Confined To Bed Or Chair More Than
50% Of Waking Hours. (3)
Completely Disabled. Cannot Carry On
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Any Selfcare. Totally Confined To Bed Or
Chair. (4)
Dead (5)
Histologic Type Cervical Cancer
Adenocarcinoma (Adenocarcinoma)
Adenosquamous (Adenosquamous
carcinoma)
Squamous Cell Carcinoma (Squamous
cell carcinoma)
Laboratory Eligibility Data
Date of Assessment
WBC
/ul
ANC
1000/ul
Platelets
1000/uL
Bilirubin
mg/dL
AST (SGOT)
U/L
AST (SGOT) ULN
U/L
ALT (SGPT)
U/L
ALT (SGPT) ULN
U/L
Serum creatinine
mg/dL
Serum Creatinine ULN
mg/dL
Creatinine Clearance
mL/min
Consent
Informed Consent Date
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Consent for correlative studies and specimen
banking signed
Yes
No
Exclusion Criteria
Prior Pelvic Radiation Therapy
Yes
No
Positive para-aortic nodes
Yes
No
Is patient receiving brachytherapy
Yes
No
Prior Chemotherapy
Yes
No
Distant metastasis
Yes
No
Crohn's disease
Yes
No
Patients must not have sensory/motor neuropathy
>= grade 2, as defined by the NCI's Common
Terminology Criteria for Adverse Events Version
3.0
Yes
No
Hysterectomy
Yes
No
Does the patient have a history of the presence
of other invasive malignancies, other than non-
melanoma skin cancer, within the past 5 years?
Yes
No
Is the patient pregnant or nursing
Yes
No
HIV seropositive
Yes
No
Stratification Factors
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Is there lymph node involvement
Yes
No
Lymph Nodes Type
Common Pelvic (common pelvic)
External/internal Iliac (external/internal
iliac)
Other (other)
Method of Evaluation
Biopsy (Biopsy)
Ct/mri Scan (CT/MRI scan)
Pet/ct Scan (PET/CT scan)
Surgery (Surgery)
Footer Module
Investigator Name
Date
Investigator's signature
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Registration Breast Cancer NSABP B-40
NCT00408408
A Randomized Phase III Trial of Neoadjuvant Therapy in
Patients With Palpable and Operable Breast Cancer
Evaluating the Effect on Pathologic Complete Response
(pCR) of Adding Capecitabine or Gemcitabine to Docetaxel
When Administered Before AC With or Without
Bevacizumab and Correlative Science Studies Attempting
to Identify Predictors of High Likelihood for pCR With Each
of the Regimens
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=1B0F2A23-
99E0-5C6F-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11806
Registration Breast Cancer NSABP
B-40 NCT00408408
NSABP REGISTRATION FORM
Patient Initials (Last First Middle)
NSABP Patient ID
Patient's Date of Birth
Patient Social Security Number (USA only)
Institution/Affiliate
Physician of Record
Informed Consent Date
Person Completing Form, Last Name
Person Completing Form, First Name
Person Completing Form, Phone
Person Completing Form, Fax
Race (more than one may be marked)
A Person Having Origins In Any Of The
Original Peoples Of North And South
America (including Central America),
And Who Maintains Tribal Affiliation Or
Community Attachment. (American
Indian or Alaska Native)
A Person Having Origins In Any Of The
Original Peoples Of The Far East,
Southeast Asia, Or The Indian
Subcontinent Including, For Example,
Cambodia, China, India, Japan, Korea,
Malaysia, Pakistan, The Philippine
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Islands, Thailand, And Vietnam. (Asian)
A Person Having Origins In Any Of The
Black Racial Groups Of Africa. Terms
Such As "haitian" Or "negro" Can Be
Used In Addition To "black Or African
American." (Black or African American)
A Person Having Origins In Any Of The
Original Peoples Of Hawaii, Guam,
Samoa, Or Other Pacific Islands. (Native
Hawaiian or other Pacific Islander)
Could Not Be Determined Or Unsure
(Unknown)
A Person Having Origins In Any Of The
Original Peoples Of Europe, The Middle
East, Or North Africa. (White)
Method of Payment (mark primary method only)
Medicaid (Medicaid)
Medicaid And Medicare (Medicaid and
Medicare)
Medicare (Medicare)
Medicare And Private Insurance
(Medicare and Private Insurance)
Military Or Veterans Sponsored Nos
(Military or Veterans Sponsored, Not
Otherwise Specified (NOS))
Military Sponsored (including Champus
& Tricare) (Military Sponsored (including
CHAMPUS & TRICARE))
No Means Of Payment (no Insurance)
(No means of payment (no insurance))
Other (Other)
Private Insurance (Private Insurance)
Self Pay (no Insurance) (Self Pay (No
Insurance))
Unknown (Unknown)
Veterans Sponsored (Veterans
Sponsored)
Ethnicity
A Person Of Mexican, Puerto Rican,
Cuban, Central Or South American Or
Other Spanish Culture Or Origin,
Regardless Of Race. (HISPANIC OR
LATINO)
A Person Not Meeting The Definition For
Hispanic Or Latino. (NOT HISPANIC OR
LATINO)
Could Not Be Determined Or Unsure
(UNKNOWN)
Country of Residence (if not USA)
Canada (CA)
Other (Other)
Puerto Rico (PR)
Usa (US)
Country of Residence
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Patient Zip Code (USA)
Height
>= 0
cm
Body weight
>= 0
kg
How Did The Patient Answer The
Following Questions On The Consent
Form
I agree to have blood samples collected three
times during this study (These samples will be
sent to the NSABP.)
Yes
No
My study doctor (or somone he or she shooses)
may contact me in the future to ask me to take
part in more research. (My study doctor or
someone he or she chooses may contact me in
the future to ask me to take part in more
research.)
Yes
No
Stratification Factors
Lymph Node Involvement
Negative Based On Clinical Evaluation
(clinically negative)
Positive Based On Clinical Evaluation
(clinically positive)
Receptor Status
Er And Pgr Negative (ER and PgR
negative)
Er And/or Pgr Positive (ER and/or PgR
positive)
Age
>= 0
<= 120
years
Certification of Eligibility
In the opinion of the investigator, is the patient
eligible?
Yes
No
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Has the patient authorized the release of
Protected Health Information to the NSABP?
Yes
No
Diagnostic Core Needle Biopsy
Date of procedure (Date of procedure)
Institutional surgical pathology number (core
needle biopsy)
Biopsy Specimens For B-40 Correlative
Studies
Date Specimen collected
PTI Control Number
Target Lesions
Date of Assessment
Number of Target Lesions
Number of Nontarget Lesions [in] Breast
Number of Nontarget Lesions [in] Axilla
Lesion Number ([Target])
Target Lesion Site
Axilla (Axilla)
Breast (Breast)
Longest Diameter of Lesion (s)
cm
Sum of longest diameters of all target lesions
(cm)
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Eligibility CLL N1087 NCT01369849
N1087 Eligibility Checklist
MK2206, Bendamustine Hydrochloride, and Rituximab in
Treating Patients With Relapsed Chronic Lymphocytic
Leukemia or Small Lymphocytic Lymphoma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=A26273FE-
467D-4C3E-E040-BB89AD436F0B
All rights reserved. Please visit https://medical-data-
models.org/forms/11807
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Required Characteristics
18 Years and older
Yes
No
Age
>= 0
<= 120
years
Diagnosis of CLL according to the NCI criteria
(Cheson, Bennett et al. 1996) (Hallek 2008) or
SLL according to the WHO criteria (Harris, 1999).
This includes previous documentation of:
-	Biopsy-proven small lymphocytic lymphoma
(Harris, 1999)
or
-	Diagnosis of CLL according to NCI working
group criteria (Cheson, 1996 and Hallek 2008) as
evidenced by all of the following:
-	Peripheral blood B cell count of >5 x 109/L
consisting of small to moderate size lymphocytes
-	Immunophenotyping consistent with CLL defined
as:
o	The predominant population of lymphocytes
share both B-cell antigens [CD19, CD20 (typically
dim expression), or CD23] as well as CD5 in the
absence of other pan-T-cell markers (CD3, CD2,
etc.)
o	Clonality as evidenced by kappa or lambda; light
chain expression (typically dim immunoglobulin
expression) or other genetic method (e.g. IGHV
analysis)
NOTE:  Splenomegaly, hepatomegaly, or
lymphadenopathy are not required for the
diagnosis of CLL.
-	Before diagnosing CLL or SLL, mantle cell
lymphoma must be excluded by demonstrating a
negative FISH analysis for t(11;14)(IgH/CCND1)
on peripheral blood or tissue biopsy or negative
immunohistochemical stains for cyclin D1 on
involved tissue biopsy
Yes
No
Demonstrated progression after one or two prior
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lines of CLL therapy (Note: Rituximab
monotherapy does not count as a prior line of
therapy)
Yes
No
Progressive disease with any one of the following
characteristics based on standard criteria for
treatment as defined by the NCI-WG 1996
(Cheson, 1996 and Hallek, 2008).  1.
Symptomatic CLL characterized by any one of
the following:   a. Weight loss >=10% within the
previous 6 months   b. Extreme fatigue attributed
to CLL   c. Fevers >100.5 F for 2 weeks without
evidence of infection   d. Drenching night sweats
without evidence of infection  2. Evidence of
progressive bone marrow failure with hemoglobin
<11 g/dL or platelet count <100 x 109/L  3.
Massive or rapidly progressive splenomegaly (>6
cm below left costal margin)  4. Massive (>10 cm)
or rapidly progressive lymphadenopathy
Yes
No
Life expectancy >=12 months
Yes
No
ECOG performance status (PS) 0, 1, or 2
Yes
No
ECOG Performance Status
Fully Active, Able To Carry On All Pre-
disease Performance Without
Restriction. (0)
Restricted In Physically Strenuous
Activity But Ambulatory And Able To
Carry Out Work Of A Light Or Sedentary
Nature, E.g., Light Housework, Office
Work. (1)
Ambulatory And Capable Of All Selfcare
But Unable To Carry Out Any Work
Activities. Up And About More Than 50%
Of Waking Hours. (2)
The following laboratory values obtained <= 14
days prior to registration
Yes
No
Earliest laboratory test date (Note:  These dates
pertain to the following labs only)
Latest laboratory test date (Note:  These dates
pertain to the following labs only)
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Total bilirubin <=1.5 x Institutional Upper Limit of
Normal (ULN) unless due to Gilbert's disease.  If
total bilirubin is >1.5 x ULN, a direct bilirubin
should be performed and must be <1.5 mg/dL for
Gilbert's disease to be diagnosed
Yes
No
Bilirubin, total
mg/dL
Total bilirubin ULN
mg/dL
Is total bilirubin >1.5 x ULN (This question may
be answered yes or no)
Yes
No
Direct Bilirubin
mg/dL
SGOT (AST) <=2.5 x ULN
Yes
No
AST (SGOT)
U/L
AST (SGOT) ULN
U/L
SGPT (ALT) <=2.5 X ULN
Yes
No
ALT (SGPT)
U/L
ALT (SGPT) ULN
U/L
Creatinine <=1.5 x ULN OR creatinine clearance
>=60 mL/min/1.73 m2 for patients with creatinine
levels >1.5 x ULN
Yes
No
Serum creatinine
mg/dL
Creatinine ULN
mg/dL
Is Creatinine >1.5 x ULN (This question may be
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answered yes or no.)
Yes
No
Creatinine Clearance
mL/min
Adequate bone marrow function as defined by:-A
non-transfused platelet count >=30 X 109/L-
Neutrophil count (ANC) >=1 X 109/L-Hemoglobin
(Hgb) >=8g/dL (Note: Cytopenias due to bone
marrow failure are common in patients with
relapsed CLL requiring treatment. Accordingly,
normal bone marrow function is NOT required for
participation)
Yes
No
Negative pregnancy test done <=7 days prior to
registration, for women of childbearing potential
only.
Yes
No
Negative pregnancy test date (If a woman of
childbearing potential)
Ability to complete patient diaries and
questionnaire(s) by themselves or with
assistance
Yes
No
Provide informed written consent
Yes
No
Willing to return to NCCTG enrolling institution for
follow-up
Yes
No
Willing to provide blood samples for correlative
research purposes (see Sections 6.31 and 14.11)
Yes
No
Willing to provide bone marrow aspirate for
correlative research purposes (see Sections 6.31
and 14.11)
Yes
No
Able to swallow whole tablets (NOTE:
Nasogastric or G tube administration is not
allowed. Tablets must not be crushed or chewed.)
Yes
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No
Exclusion Criteria - All Responses In
Section Below Must Be "no."
Prior treatment with bendamustine
Yes
No
Prior treatment with any experimental Akt
inhibitors
Yes
No
More than 1 previous purine nucleoside based-
therapy (i.e., fludarabine, pentostatin, cladribine)
Yes
No
More than 1 previous alkylating agent based-
therapy (i.e. cyclophosphamide, chlorambucil)
Yes
No
More than 2 total prior lines of therapy for CLL
Yes
No
Primary refractory disease as defined by
progression while receiving or within 6 months of
completion of a chemoimmunotherapy regimen
such as fludarabine, cyclophosphamide and
rituximab (FCR) or pentostatin,
cyclophosphamide and rituximab (PCR)
Yes
No
Any of the following because this study involves
an investigational agent whose genotoxic,
mutagenic and teratogenic effects on the
developing fetus and newborn are unknown.
-	Pregnant women
-	Nursing women
-	Men or women of childbearing potential who are
unwilling to employ adequate contraception
Yes
No
Co-morbid systemic illnesses or other severe
concurrent disease which, in the judgment of the
investigator, would make the patient inappropriate
for entry into this study or interfere significantly
with the proper assessment of safety and toxicity
of the prescribed regimens. Including but not
limited to the following: 
-	New York Heart Association Class III or IV heart
disease 
-	Recent myocardial infarction (<1 month) 
-	Uncontrolled infection 
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-	Known infection with the human
immunodeficiency virus (HIV/AIDS) and/or
patients taking HAART as further severe
immunosuppression with this regimen may occur.
-	Infection with known chronic, active Hepatitis C 
-	Positive serology for Hepatitis B (HB) defined as
a positive test for HBsAg. In addition, if negative
for HBsAg but HBcAb positive (regardless of
HBsAb status), a HB DNA test will be performed
and if positive the subject will be excluded. 
-	Uncontrolled diabetes defined as HbA1c >=8 or
fasting blood glucose >=140 mg/dL
Yes
No
Any of the following: 
- History of significant ventricular arrhythmia in
the last 5 years including: ventricular tachycardia
or ventricular fibrillation 
-  QTc prolongation on baseline ECG (defined as
a QTc interval >450 msec for males and QTc
interval >470 msec for females 
- Currently using a medication known to cause
prolonged QTc (See Appendix III) which can not
be discontinued
Note: Other medications with possible risk of
prolonged QTc are allowed but should be used
with caution. Patients using these medications
should be monitored accordingly. See Appendix
IV. 
- Ventricular arrhythmia on baseline ECG
(ventricular tachycardia or ventricular fibrillation
>= 3 beats in a row). 
- Second or third degree heart block
(NOTE: Because QTc prolongation has been
reported in patients taking MK-2206, individuals
with the above characteristics may not be
enrolled in this study.)
Yes
No
Receiving any other investigational agent
concurrently which would be considered as a
treatment for the primary neoplasm
Yes
No
Other active primary malignancy requiring
treatment or limits survival to <24 months
Yes
No
Any major surgery <=28 days prior to registration
Yes
No
Any radiation therapy <=4 weeks prior to
registration
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Yes
No
Current use of corticosteroids (EXCEPTION: Low
doses of steroids <10 mg of prednisone or
equivalent dose of other steroid used for
treatment of non-hematologic medical conditions.
NOTE: Previous use of corticosteroids is
allowed.)
Yes
No
Active hemolytic anemia requiring
immunosuppressive therapy or other
pharmacologic treatment (NOTE: Patients who
have a positive Coombs test but no evidence of
hemolysis are NOT excluded from participation.)
Yes
No
Receiving any medications or substances that
are strong or moderate inhibitors or inducers of
CYP450 3A4. 
-	Use of the following strong or moderate
inhibitors are prohibited <=7 days prior to
registration:
Strong Inhibitors of CYP3A4:
o	Indinavir
o	Nelfinavir
o	Ritonavir
o	Clarithromycin
o	Itraconazole
o	Ketoconazole
o	Nefazodone
o	Saquinavir
o	Telithromycin
Moderate Inhibitors of CYP3A4
o	Aprepitant
o	Erythromycin
o	Fluconazole
o	Grapefruit juice
o	Verapamil
o	Diltiazem
Yes
No
Has patient received any of these strong or
moderate inhibitors of CYP3A4
Yes
No
Latest strong or moderate inhibitor date (P450)
mm/dd/yyyy
Receiving any medications or substances that
are inducers of CYP450 3A4. - Use of the
following inducers is prohibited <=12 days prior to
registration: o Efavirenz o Nevirapine o
Carbamapezine o Modafinil o Phenobarbital o
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Phenytoin o Pioglitazone o Rifabutin o Rifampin o
St. John's wort
Yes
No
Has patient received any of these inducers of
CYP3A4 (This question may be answered yes or
no.)
Yes
No
Latest inducer date (mm/dd/yyyy)
Pre-registration Check
A mandatory correlative research component is
part of this study for all patients, the patient will
be automatically registered onto this component
(see Sections 3.18e, 3.18f and 14.11 and 17.4)
Yes
No
Consent form signed and dated
Yes
No
Informed Consent Date
Authorization for use and disclosure of protected
health information signed and dated (U.S.A,
institutions only If not a USA institution check NA)
Not Applicable (NA)
No (No)
Yes (Yes)
Date of authorization (If a USA institution)
Treatment cannot begin prior to registration and
must begin <=14 days after registration
Yes
No
Pretreatment tests/procedures must be
completed <= 14 days prior to registration (see
Section 4.0)
Yes
No
Earliest pretreatment test/procedure date (NOTE:
The earliest pretreatment test date must be less
than or equal to the earliest laboratory test date
and the latest pretreatment test date must be
greater than or equal to the latest laboratory test
date.)
Latest pretreatment test/procedure date
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Immunophenotyping by flow cytometry date
(Exceptions to the above dates: -
Immunophenotyping by flow cytometry of
Peripheral blood all CLL patients or nodal tissue
SLL only <90 days prior to registration See
Section 4.0.)
Bone marrow biopsy/aspirate date (Baseline
bone marrow biopsy/aspirate <=3 months prior to
registration See Section 4.0.)
CT scan date (CT scan can be performed <=21
days prior to registration.)
Cytogenetic analysis by FISH date (Cytogenetic
analysis by FISH peripheral blood, bone marrow
or nodal tissue <90 days prior to registration See
Section 4.0.)
All required baseline symptoms (see Section
10.3) must be documented and graded
Yes
No
Treatment on this protocol must commence at an
NCCTG institution under the supervision of an
NCCTG member physician
Yes
No
Study drug is available on site
Yes
No
Blood draw kit is available on site
Yes
No
Patient has given permission to store and use
his/her sample(s) for use in future research to
learn about, prevent, or treat cancer (At the time
of registration, the following will be recorded:)
Yes
No
Patient has given permission to store and use
his/her sample(s) for use in future research to
learn about, prevent, or treat other health
problems (for example: diabetes, Alzheimer's
disease, or heart disease) (At the time of
registration, the following will be recorded:)
Yes
No
Patient has given permission for NCCTG to give
his/her sample(s) to outside researchers (At the
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time of registration, the following will be
recorded:)
Yes
No
Patient has agreed to be enrolled on N0392
(NOTE: N0392 must be open at site and offered
to patients. At the time of registration, willingness
to participate will be recorded.  This study is the
"Was It Worth It" study and must be included in
all NCCTG studies. The study must be open and
available at each member site participating in the
N1087 study.  However, a patient can refuse to
go on this study and they are still eligible for
participating in N1087.)
Yes
No
Grouping Factor
Grouping Factor
Phase I (Phase I)
Phase Ii (Phase II)
Subgroup Code
Sg1 - Phase I (SG1 - Phase I)
Sg2 - Phase Ii (SG2 - Phase II)
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Eligibility B-Cell Lymphoma N1085
NCT01334502
N1085 Eligibility Checklist
Everolimus, Rituximab, and Combination Chemotherapy in
Treating Patients With Newly Diagnosed Untreated Diffuse
Large B-Cell Lymphoma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=9EAFF494-
0322-469D-E040-BB89AD43599E
All rights reserved. Please visit https://medical-data-
models.org/forms/11808
Eligibility B-Cell Lymphoma N1085
NCT01334502
Required Characteristics
18 Years and older
Yes
No
Age
>= 0
<= 120
years
Untreated, histological diagnosis of CD20-
positive diffuse large B cell lymphoma
Yes
No
Stage II, III, or IV (Ann Arbor Staging: see
Appendix II)
Yes
No
ECOG performance status (PS) 0, 1, or 2
Yes
No
ECOG Performance Status
Fully Active, Able To Carry On All Pre-
disease Performance Without
Restriction. (0)
Restricted In Physically Strenuous
Activity But Ambulatory And Able To
Carry Out Work Of A Light Or Sedentary
Nature, E.g., Light Housework, Office
Work. (1)
Ambulatory And Capable Of All Selfcare
But Unable To Carry Out Any Work
Activities. Up And About More Than 50%
Of Waking Hours. (2)
The following laboratory values obtained <= 14
days prior to registration
Yes
No
Earliest laboratory test date (NOTE: These dates
pertain to the following labs only)
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Latest laboratory test date (NOTE: These dates
pertain to the following labs only)
Absolute neutrophil count (ANC) >=1500/mm3
Yes
No
ANC
1000/ul
Peripheral platelet count (PLT) >=100,000/mm^3
Yes
No
Peripheral Platelet Count
1000/uL
Hemoglobin >9.0 g/dL
Yes
No
Hemoglobin
g/dL
Total bilirubin <=1.5 x ULN, or if total bilirubin is
>1.5 ULN, the direct bilirubin must be normal
Yes
No
Is total bilirubin >1.5 x ULN (this question may be
answered yes or no)
Yes
No
Direct Bilirubin
mg/dL
Direct Bilirubin ULN
mg/dL
Total Bilirubin
mg/dL
Total bilirubin ULN
mg/dL
Alkaline phosphatase <=3 x ULN, unless
evidence of direct liver involvement by lymphoma,
then <=5 x ULN
Yes
No
Is there liver involvement (This question can be
answered yes or no)
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Yes
No
Alkaline Phosphatase
U/L
Alkaline Phosphatase ULN
U/L
SGOT (AST) <=3 x ULN, unless evidence of
direct liver involvement by lymphoma, then <=5 x
ULN
Yes
No
AST (SGOT)
U/L
AST (SGOT) ULN
U/L
Creatinine <= ULN (mg/dL)
Yes
No
Serum creatinine
mg/dL
Creatinine ULN
mg/dL
Negative pregnancy test done <=7 days prior to
registration, for women of childbearing potential
only. (If not a woman of childbearing potential
check NA)
Yes
No
Negative pregnancy test date (If a woman of
childbearing potential)
Provide informed written consent
Yes
No
Willingness to return to NCCTG enrolling
institution for follow-up
Yes
No
Willing to provide mandatory blood samples for
correlative research purposes (see Sections
6.241, 14.0)
Yes
No
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Willingness to abstain from eating grapefruit or
drinking grapefruit juice for the duration of the
study
Yes
No
Willingness to take everolimus orally, once daily
at the same time every day either consistently
with food or consistently without food
Yes
No
Measurable or assessable disease defined as at
least one of the following: A lymph node or tumor
mass that is >=2.0 cm in at least one dimension
by CT portion of PET/CT, CT or MRI. Diffuse
infiltration of an organ such as the stomach, bone
marrow, peripheral blood, liver, lungs or bowel by
lymphoma without a discrete mass would
constitute assessable, but not measurable,
disease
Yes
No
If diabetic and taking insulin or oral anti-diabetic
therapy, must have HbA1c <=8%, or a fasting
serum glucose <=110% ULN (Note: The
combination of everolimus with five days of
concurrent prednisone at 100 mg/m^2 may cause
significant hyperglycemia)
Yes
No
If HIV positive, CD4 count must be >=400
Yes
No
Exclusion Criteria - All Responses In
Section Below Must Be "no."
Because this study involves an investigational
agent whose genotoxic, mutagenic and
teratogenic effects on the developing fetus and
newborn are unknown, any of the following are
excluded: Pregnant women Nursing women Men
or women of childbearing potential who are
unwilling to employ adequate contraception
throughout the study and for 8 weeks after the
last dose of study drug, by both sexes (Note:
Women of childbearing potential must have a
negative pregnancy test <=14 days prior to
registration)
Yes
No
Co-morbid systemic illnesses or other severe
concurrent disease which, in the judgment of the
investigator, would make the patient inappropriate
for entry into this study or interfere significantly
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with the proper assessment of safety and toxicity
of the prescribed regimens
Yes
No
Immunocompromised patients (other than that
related to the use of corticosteroids) including
patients known to be HIV positive with a CD4
count of <400
Yes
No
Uncontrolled intercurrent illness including, but not
limited to: ongoing or active infection
symptomatic congestive heart failure unstable
angina pectoris cardiac arrhythmia severely
impaired lung function uncontrolled diabetes as
defined by fasting serum glucose >1.5 x ULN
(Note: Optimal glycemic control should be
achieved before starting trial therapy.) psychiatric
illness/social situations that would limit
compliance with study requirements liver disease
such as cirrhosis or severe hepatic impairment
chronic active hepatitis chronic persistent
hepatitis or history of hepatitis B or C
Yes
No
Receiving any other investigational agent which
would be considered as a treatment for the
primary neoplasm
Yes
No
Active other malignancy, excepting non-melanotic
skin cancer or carcinoma-in-situ of the cervix.  If
there is a history of prior malignancy, they must
not be receiving other specific treatment (other
than hormonal therapy) for their cancer
Yes
No
CNS Lymphoma or cerebrospinal fluid
involvement with malignant lymphoma cells
Yes
No
Planned immunization with attenuated live
vaccines <=7 days prior to registration or during
study period (Note: Close contact with those who
have received attenuated live vaccines should be
avoided during treatment with everolimus.
Examples of live vaccines include intranasal
influenza, measles, mumps, rubella, oral polio,
BCG, yellow fever, varicella and TY21a typhoid
vaccines)
Yes
No
Positive hepatitis B antigen (HBsAg) or hepatitis
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C serology (HCV) tests (Note: Hepatitis B surface
antigen Hbs Ag and antibody to Hepatitis B core
anti-HBc; Hepatitis C antibody. All patients must
be screened prior to registration. Those patients
who have evidence of chronic or acute infection
with either hepatitis B or C may not be treated on
this protocol)
Yes
No
Currently on enzyme inducing anti-convulsants or
other strong inducers (efavirenz, nevirapine,
barbiturates, carbamazepine, phenobarbital,
phenytoin, rifabutin, rifampin, pioglitazone) or
strong inhibitors of CYP3A4 (indinavir, nelfinavir,
ritonavir, clarithromycin, itraconazole,
voriconazole, ketoconazole, nefazodone,
saquinavir, telithromycin).  (See
http://medicine.iupui.edu/clinpharm/ddis/table.asp
for an up-to-date list of strong inducers and
inhibitors of CYP3A4.)
Yes
No
Pre-registration Check
A mandatory translational research component is
part of this study,  patients will automatically be
registered to the translational research
component of this study at the time of
registration. (see Sections 3.19a, 14.0, 17.11,
17.2)
Yes
No
Consent form signed and dated
Yes
No
Date Informed Consent Signed
Authorization for use and disclosure of protected
health information signed and dated (U.S.A.
institutions only If not a USA institution check NA)
Not Applicable (NA)
No (No)
Yes (Yes)
Date of authorization (If a USA institution)
Treatment cannot begin prior to registration and
must begin <=14 days after registration
Yes
No
Pretreatment tests/procedures must be
completed <= 14 days prior to registration (see
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Section 4.0)
Yes
No
Earliest pretreatment test/procedure date (NOTE:
The earliest pretreatment test date must be less
than or equal to the earliest laboratory test date
and the latest pretreatment test date must be
greater than or equal to the latest laboratory test
date)
Latest pretreatment test/procedure date
All required baseline symptoms (see Section
10.3) must be documented and graded
Yes
No
Tumor measurement/Evaluation of indicator
lesion must be completed <=28 days prior to
registration (Exceptions to the above dates)
Yes
No
Exception test date
Bone marrow aspirate and biopsy must be
completed <=42 days prior to registration
(Exceptions to the above dates)
Yes
No
Exception test date
Treatment on this protocol must commence at an
NCCTG institution under the supervision of an
NCCTG member physician
Yes
No
Blood draw kit is available on site
Yes
No
Registration Check
Patient has given permission to give his/her blood
sample for research testing (An optional
correlative research component is part of this
study, there will be an option to select if the
patient is to be registered onto this component
Section 17.11, 17.2.)
Yes
No
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Patient has given permission to give his/her
tissue sample for research testing (An optional
correlative research component is part of this
study, there will be an option to select if the
patient is to be registered onto this component
Section 17.11, 17.2.)
Yes
No
Patient has given permission to store and use
his/her sample(s) for use in future research to
learn about, prevent, or treat cancer (At the time
of registration/randomization, the following will
also be recorded)
Yes
No
Patient has given permission to store and use
his/her sample(s) for use in future research to
learn about, prevent, or treat other health
problems (for example: diabetes, Alzheimer's
disease, or heart disease)
Yes
No
Patient has given NCCTG permission to give
sample(s) to outside researchers
Yes
No
Patient has agreed to be enrolled on N0392
(NOTE: N0392 must be open at site and offered
to patient. At time of registration, willingness to
participate will be recorded.)
Yes
No
Grouping Factor
Cohort
Feasibility (Feasibility)
Phase I (Phase I)
8 / 8
Eligibility B-Cell Lymphoma N1085 NCT01334502
Registration Glioma E3F05 NCT00978458
E3F05 Registration Worksheet (step 1)
Radiation Therapy With or Without Temozolomide in
Treating Patients With Low-Grade Glioma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=612A5FBA-
FC8E-B3D3-E040-BB89AD437EF0
All rights reserved. Please visit https://medical-data-
models.org/forms/11809
Registration Glioma E3F05
NCT00978458
Eligibility
First initial
Last initial
Has the eligibility checklist been completed
Yes
No
In the opinion of the investigator, is the patient
eligible?
Yes
No
Age
>= 0
<= 120
years
Karnofsky Performance Status
%
Dead (0)
Moribund, Fatal Processes Progressing
Rapidly (10)
Normal, No Complaints, No Evidence Of
Disease (100)
Very Sick, Hospitalization Indicated.
Death Not Imminent (20)
Severely Disabled, Hospitalization
Indicated. Death Not Imminent (30)
Disabled, Requires Special Care And
Assistance (40)
Requires Considerable Assistance And
Frequent Medical Care (50)
Requires Occasional Assistance, But Is
Able To Care For Most Of His/her Needs
(60)
Cares For Self, Unable To Carry On
Normal Activity Or To Do Active Work
(70)
Normal Activity With Effort; Some Signs
Or Symptoms Of Disease (80)
Able To Carry On Normal Activity; Minor
Signs Or Symptoms Of Disease (90)
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Patient's ECOG sequence number
QOL contact person
Phone
Email address
Name of the institution that will administered the
radiation therapy
Patient Demographics / Pre-treatment
Characteristics
Gender
Female (F)
Male (M)
Patient Birth Date
mm/yy
ZIP Code
Race (check all that apply)
A Person Having Origins In Any Of The
Original Peoples Of North And South
America (including Central America),
And Who Maintains Tribal Affiliation Or
Community Attachment. (American
Indian or Alaska Native)
A Person Having Origins In Any Of The
Original Peoples Of The Far East,
Southeast Asia, Or The Indian
Subcontinent Including, For Example,
Cambodia, China, India, Japan, Korea,
Malaysia, Pakistan, The Philippine
Islands, Thailand, And Vietnam. (Asian)
A Person Having Origins In Any Of The
Black Racial Groups Of Africa. Terms
Such As "haitian" Or "negro" Can Be
Used In Addition To "black Or African
American." (Black or African American)
A Person Having Origins In Any Of The
Original Peoples Of Hawaii, Guam,
Samoa, Or Other Pacific Islands. (Native
Hawaiian or other Pacific Islander)
Not Provided Or Available (Not
Reported)
Could Not Be Determined Or Unsure
(Unknown)
A Person Having Origins In Any Of The
Original Peoples Of Europe, The Middle
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East, Or North Africa. (White)
Patient Ethnicity
A Person Of Mexican, Puerto Rican,
Cuban, Central Or South American Or
Other Spanish Culture Or Origin,
Regardless Of Race. (Hispanic or Latino)
A Person Not Meeting The Definition For
Hispanic Or Latino. (Not Hispanic or
Latino)
Not Provided Or Available (Not reported)
Could Not Be Determined Or Unsure
(Unknown)
Patient Hospital No.
SSN
Method of payment (check one)
Medicaid (Medicaid)
Medicaid And Medicare (Medicaid and
Medicare)
Medicare (Medicare)
Medicare And Private Insurance
(Medicare and Private Insurance)
Military Or Veterans Sponsored Nos
(Military or Veterans Sponsored, Not
Otherwise Specified (NOS))
Military Sponsored (including Champus
& Tricare) (Military Sponsored (including
CHAMPUS & TRICARE))
No Means Of Payment (no Insurance)
(No means of payment (no insurance))
Other (Other)
Private Insurance (Private Insurance)
Self Pay (no Insurance) (Self Pay (No
Insurance))
Unknown (Unknown)
Veterans Sponsored (Veterans
Sponsored)
Attending Physician
Institution contact
Registrar
Country of Residence (if not USA)
Ascension Island (AC)
Andorra (AD)
United Arab Emirates (AE)
Afghanistan (AF)
Antigua And Barbuda (AG)
Anguilla (AI)
Albania (AL)
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Armenia (AM)
Netherland Antilles (AN)
Angola (AO)
Antarctica (AQ)
Argentina (AR)
American Samoa (AS)
Austria (AT)
Australia (AU)
Aruba (AW)
Azerbaidjan (AZ)
Bosnia-herzegovina (BA)
Barbados (BB)
Bangladesh (BD)
Belgium (BE)
Burkina Faso (BF)
Bulgaria (BG)
Bahrain (BH)
Burundi (BI)
Benin (BJ)
Bermuda (BM)
Brunei Darussalam (BN)
Bolivia (BO)
Brazil (BR)
Bahamas (BS)
Bhutan (BT)
Bouvet Island (BV)
Botswana (BW)
Belarus (BY)
Belize (BZ)
Canada (CA)
Cocos Isl. (CC)
Rep. Dem. Congo (CD)
Central African Rep. (CF)
Congo (CG)
Switzerland (CH)
Ivory Coast (CI)
Cook Islands (CK)
Chile (CL)
Cameroon (CM)
China (CN)
Colombia (CO)
Costa Rica (CR)
Cuba (CU)
Cape Verde (CV)
Christmas Island (CX)
Cyprus (CY)
Czech Republic (CZ)
Germany (DE)
Djibouti (DJ)
Denmark (DK)
Dominica (DM)
Dominican Republic (DO)
Algeria (DZ)
Ecuador (EC)
Estonia (EE)
Egypt (EG)
Western Sahara (EH)
Eritrea (ER)
Spain (ES)
Ethiopia (ET)
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Finland (FI)
Fiji (FJ)
Falkland Isl. (FK)
Micronesia (FM)
Faroe Islands (FO)
France (FR)
France (european Ter.) (FX)
Gabon (GA)
Great Britain (GB)
Grenada (GD)
Georgia (GE)
Guiana (fr.) (GF)
Guernsey (GG)
Ghana (GH)
Gibraltar (GI)
Greenland (GL)
Gambia (GM)
Guinea (GN)
Guadeloupe (fr.) (GP)
Equatorial Guinea (GQ)
Greece (GR)
South Georgia And South Sandwich
Islands (GS)
Guatemala (GT)
Guam (us) (GU)
Guinea Bissau (GW)
Guyana (GY)
Hong Kong (HK)
Heard & Mcdonald Isl. (HM)
Honduras (HN)
Croatia (HR)
Haiti (HT)
Hungary (HU)
Indonesia (ID)
Ireland (IE)
Israel (IL)
Isle Of Man (IM)
India (IN)
British Indian O. Ter. (IO)
Iraq (IQ)
Iran (IR)
Iceland (IS)
Italy (IT)
Jersey (JE)
Jamaica (JM)
Jordan (JO)
Japan (JP)
Kenya (KE)
Kyrgyz Republic (KG)
Cambodia (KH)
Kiribati (KI)
Comoros (KM)
St. Kitts Nevis Anguilla (KN)
Korea (north) (KP)
Korea (south) (KR)
Kuwait (KW)
Cayman Islands (KY)
Kazakstan (KZ)
Laos (LA)
Lebanon (LB)
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Saint Lucia (LC)
Liechtenstein (LI)
Sri Lanka (LK)
Liberia (LR)
Lesotho (LS)
Lithuania (LT)
Luxembourg (LU)
Latvia (LV)
Libya (LY)
Morocco (MA)
Monaco (MC)
Moldova (MD)
Madagascar (MG)
Marshall Islands (MH)
Macedonia (MK)
Mali (ML)
Myanmar (MM)
Mongolia (MN)
Macau (MO)
Northern Mariana Isl. (MP)
Martinique (fr.) (MQ)
Mauritania (MR)
Montserrat (MS)
Malta (MT)
Mauritius (MU)
Maldives (MV)
Malawi (MW)
Mexico (MX)
Malaysia (MY)
Mozambique (MZ)
Namibia (NA)
New Caledonia (fr.) (NC)
Niger (NE)
Norfolk Island (NF)
Nigeria (NG)
Nicaragua (NI)
Netherlands (NL)
Norway (NO)
Nepal (NP)
Nauru (NR)
Niue (NU)
New Zealand (NZ)
Oman (OM)
Other (Other)
Panama (PA)
Peru (PE)
Polynesia (fr.) (PF)
Papua New Guinea (PG)
Philippines (PH)
Pakistan (PK)
Poland (PL)
St. Pierre & Miquelon (PM)
Pitcairn (PN)
Puerto Rico (PR)
Portugal (PT)
Palau (PW)
Paraguay (PY)
Qatar (QA)
Reunion (fr.) (RE)
Romania (RO)
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Russian Federation (RU)
Rwanda (RW)
Saudi Arabia (SA)
Solomon Islands (SB)
Seychelles (SC)
Sudan (SD)
Sweden (SE)
Singapore (SG)
St. Helena (SH)
Slovenia (SI)
Svalbard & Jan Mayen Isl. (SJ)
Slovakia (SK)
Sierra Leone (SL)
San Marino (SM)
Senegal (SN)
Somalia (SO)
Suriname (SR)
St. Tome And Principe (ST)
Soviet Union (SU)
El Salvador (SV)
Syria (SY)
Swaziland (SZ)
Turks & Caicos Islands (TC)
Chad (TD)
French Southern Terr. (TF)
Togo (TG)
Thailand (TH)
Tadjikistan (TJ)
Tokelau (TK)
Turkmenistan (TM)
Tunisia (TN)
Tonga (TO)
East Timor (TP)
Turkey (TR)
Trinidad & Tobago (TT)
Tuvalu (TV)
Taiwan (TW)
Tanzania (TZ)
Ukraine (UA)
Uganda (UG)
United Kingdom (UK)
Us Minor Outlying Isl. (UM)
Usa (US)
Uruguay (UY)
Uzbekistan (UZ)
Vatican City State (VA)
St. Vincent & Grenadines (VC)
Venezuela (VE)
Virgin Islands (brit) (VG)
Virgin Islands (us) (VI)
Vietnam (VN)
Vanuatu (VU)
Wallis & Futuna Islands (WF)
Western Samoa (WS)
Yemen (YE)
Mayotte (YT)
Yugoslavia (YU)
South Africa (ZA)
Zambia (ZM)
Dem. Rep. Of Congo (ZR)
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Zimbabwe (ZW)
Comments
8 / 8
Registration Glioma E3F05 NCT00978458
PHARMACY CONSULT RESULTS HIS
Form from HIS OpenVistA
All rights reserved. Please visit https://medical-data-
models.org/forms/11810
PHARMACY CONSULT RESULTS
HIS
ADULT IMMUNIZATION PROTOCOL
Immunization ordered and available on Unit per
protocol*
Yes
No
Influenza immunisation, Flu vaccination*
Yes
No
Pneumococcal vaccination*
Yes
No
GENTAMICIN
Age*
>= 0
<= 120
years
Gender*
Female (F)
Male (M)
Height*
>= 0
cm
Body weight*
>= 0
kg
Serum creatinine*
mg/dL
BUN*
mg/dL
AMINOGLYCOSIDE EXCLUSIONS (14years and
younger, burns over greater than 20% Body
surface area (BSA), Endocarditis, CrCl <=
40ml/hr, Pregnancy, Cystic Fibrosis, Severe liver
disease or ascites)*
TOBRAMYCIN
Age*
>= 0
1 / 4
<= 120
years
Gender*
Female (F)
Male (M)
Height*
>= 0
cm
Body weight*
>= 0
kg
Serum creatinine*
mg/dL
BUN*
mg/dL
AMINOGLYCOSIDE EXCLUSIONS (14years and
younger, burns over greater than 20% BSA,
Endocarditis, CrCl <= 40ml/hr, Pregnancy, Cystic
Fibrosis, Severe liver disease or ascites)*
VANCOMYCIN
VANCOMYCIN ORDER APPROVED
(GUIDELINES FOR RECULTURE:
VANCOMYCIN AFTER 7 DAYS MUST BE
REEVALUATED AND IV THERAPY
DISCONTINUED, IF INDICATED.  RECULTURE
IF NECESSARY 72 HOURS AFTER ANTIBIOTIC
IS STOPPED)*
Yes
No
UNAPPROVED VANCO ORDER, VANCOMYCIN
IS NOT APPROVED FOR THE FOLLOWING
USE:*
Routine surgical prophylaxis other than in a
patient who has a life-threatening condition
Yes
No
Treatment in response to a single blood culture
positive for coagulase-negative staphylococcus, if
other blood cultures drawn in the same time
frame are negative,and if contamination of the
blood culture is likely.*
Yes
No
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Continued empiric use for presumed infections in
patients whose cultures are negative for beta-
lactam-resistant gram-positive microorganisms.*
Yes
No
Systemic or local prophylaxis for infection or
colonization of indwelling central or peripheral
intravascular catheters.*
Yes
No
Selective decontamination of the digestive tract.*
Yes
No
Eradication of MRSA colonization (mupiracin
should be applied topically).*
Yes
No
Primary treatment of antibiotic-associated colitis.*
Yes
No
Routine prophylaxis for very low-birth weight
infants.*
Yes
No
Routine prophylaxis for patients on continuous
ambulatory peritoneal dialysis or hemodialysis.*
Yes
No
Treatment chosen for dosing convenience of
infections due to beta-lactam sensitive gram-
positive microorganisms in patients with renal
failure.*
Yes
No
Use of vancomycin solution for topical application
or irrigation.*
Yes
No
Other
Total Parenteral Nutrition*
Home medications reviewed and printout sent to
floor.*
NURSERY MEDICATION ORDERS PLACED*
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PHYTONADIONE NEONATAL INJ 1MG/0.5ML
IM ONCE (Comments: Administer Vit K in the
anterior thigh)*
Yes
No
ERYTHROMYCIN OINT, OPHTHALMIC ONCE
(Apply to both eyes within 1 hour of birth in L&D)*
Yes
No
TRIPLE DYE PIN POINT APPLICATOR,
TOPICAL ONCE (Apply to cord after first bath)*
Yes
No
HEPATITIS B VACCINE PEDI INJ 5MCG/0.5ML
IM ONCE (Give after consent is signed)*
Yes
No
A&D (VITAMIN A/VITAMIN D) OINT, TOP 60GM
APPLY THIN LAYER PRN (May be used on
perineum as needed)*
Yes
No
OTHER*
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Eligibility Breast Cancer ALTTO NCCTG
NCT00490139
ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment
Optimisation) Study; BIG 2-06/N063D
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=36178CDD-
C8CD-4044-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11811
Eligibility Breast Cancer ALTTO
NCCTG NCT00490139
Header Module
NCCTG Study No.
Central Lab ID Number
Patient Initials
Institution Number
Institution
Are data amended
Yes
No
I. Snap Frozen Tissue
Inclusion Criteria
Informed Consent Has Been Signed And
Dated By The Patient And Person
Obtaining Consent (Informed Consent
has been signed and dated by the
patient and person obtaining consent)
2 cm prior to surgery=Patient's Tumor
Size Is Estimated To Be >= 2 Cm Prior
To Surgery (Patient's tumor size is
estimated to be >)
Tissue Portion Of The Consent Form Is
Complete (Tissue portion of the consent
form is complete)
18 years of age, diagnosed with primary,
invasive breast cancer=Woman Or Man
>= 18 Years Of Age, Diagnosed With
Primary, Invasive Breast Cancer (Woman
or man >)
Age
>= 0
<= 120
years
Authorization for use and disclosure of protected
health information signed and dated
Yes
1 / 2
No
Date of authorization
Patient's Initial Consent given for specimen use
for research unrelated to the patient's cancer?
Yes
No
Patient's initial consent for sharing specimen(s)
with outside researchers.
Yes
No
Protocol Design
Assigned Treatment Arm
Person Registering
CTSU Random. specialist
Investigator Signature
Date of Investigator Signature
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Initial Evaluation Form Esophageal Cancer
RTOG NCT00655876
Paclitaxel, Cisplatin, and Radiation Therapy With or Without
Cetuximab in Treating Patients With Locally Advanced
Esophageal Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=2A16F93C-
C68B-2E25-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11812
Initial Evaluation Form Esophageal
Cancer RTOG NCT00655876
Module 1
RTOG Study No.
RTOG Case #
Institution Name
Institution No.
Patient Initials
RTOG Patient ID
AMENDED DATA
Yes
No
Patient status assessment
Age
>= 0
<= 120
years
Performance Status (Zubrod)
Normal Activity (0)
Symptoms, But Nearly Fully Ambulatory
(1)
Some Bed Time, But Needs To Be In
Bed <50% Of Normal Daytime (2)
Needs To Be In Bed > 50% Of Normal
Daytime (3)
Unable To Get Out Of Bed (4)
History of Prior Malignancy (except non
melanomatous skin cancer)
Yes
No
Site of Prior Cancer
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Prior cancer date eradicated
Weight
Kg
Extent of Dysphagia
Asymptomatic (Asymptomatic)
Cannot Swallow (Cannot swallow)
Symptomatic, Liquids Only
(Symptomatic, liquids only)
Symptomatic, Soft Foods Only
(Symptomatic, soft foods only)
Symptomatic, Unrestricted Diet
(Symptomatic, unrestricted diet)
Unknown (Unknown)
Oral alimentation
No (No)
Unknown (Unknown)
Yes (Yes)
Nasogastric tube feeding
No (No)
Unknown (Unknown)
Yes (Yes)
Ostomy feeding
No (No)
Unknown (Unknown)
Yes (Yes)
Intravenous hyperalimentation
No (No)
Unknown (Unknown)
Yes (Yes)
Other
No (No)
Unknown (Unknown)
Yes (Yes)
Other Specify
Estimate of daily caloric intake
< 1500 Cal/day (< 1500 cal/day)
>= 1500 Cal/day (>= 1500 cal/day)
Prior Treatment
Prior Surgery (for esophageal cancer excludes
diagnostic biopsy)
Yes
No
Prior chemotherapy (for study cancer)
Yes
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No
Prior chemotherapy (for other reasons)
Yes
No
Prior radiation therapy (to chest)
Yes
No
Prior therapy that targeted EGFR pathway
Yes
No
Prior platinum based and/or paclitaxel based
therapy
Yes
No
Study Cancer
Site of study cancer
Cervical Esophagus (Cervical
Esophagus)
Gastroesophageal Junction, Siewert
Type I (Gastroesophageal junction,
Siewert Type I)
Gastroesophageal Junction, Siewert
Type Ii (Gastroesophageal junction,
Siewert Type II)
Lower Thoracic Excludes Ge Junction
(Lower thoracic excludes GE junction)
Mid Thoracic Esophagus (Mid thoracic
esophagus)
Upper Thoracic Esophagus (Upper
thoracic esophagus)
Histologic Type
Adenocarcinoma (Adenocarcinoma)
Squamous Cell Carcinoma (Squamous
cell carcinoma)
Date of initial histologic diagnosis of malignancy
Cervical esophagus
Yes
No
Invasion into the trachea or major bronchi
Yes
No
Evidence of tracheoesophageal fistule
Yes
No
Esophageal Tumor Clinical T Stage
Tumor Invades Lamina Propria Or
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Submucosa (T1)
Tumor Invades Muscularis Propria (T2)
Tumor Invades Adventitia (T3)
Tumor Invades Adjacent Structures (T4)
Is the tumor proximal thoracic
Yes
No
Clinical N Stage
No Regional Lymph Node Metastasis
(N0)
Regional Lymph Node Metastasis (N1)
Clinical M Stage
No Distant Metastasis (M0)
Metastases Present - See Figo And Ajcc
Staging For Complete Details (M1a)
Celiac lymph nodes
Yes
No
Cervical lymph nodes
Yes
No
Supraclavicular lymph nodes
Yes
No
Laboratory Tests
Hemoglobin
g/dL
ANC
1000/ul
Peripheral Platelet Count
1000/uL
Serum creatinine
mg/dL
AST (SGOT)
U/L
AST (SGOT) ULN
U/L
Bilirubin, total
mg/dL
Total bilirubin ULN
mg/dL
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Date
Diagnosis Work-up
History and Physical
Yes
No
CT scan or MRI of the chest or abdomen
Yes
No
Endoscopic biopsy of esophageal tumor
Yes
No
EKG
Yes
No
Bronchoscopy
Yes
No
PET/CT
Yes
No
Date
Co-morbidties
Hospitalized for unstable angina and/or CHF in
last 6 months
Yes
No
Transmural MI in last 6 months
Yes
No
IV antibiotics at time of registration
Yes
No
COPD exacerbation or other respiratory illness
requiring hospitalization or precluding study
therapy at registration
Yes
No
Prior allergic reaction to cisplatin
Yes
No
Prior allergic reaction to C225
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Yes
No
Prior allergic reaction to taxol
Yes
No
Prior severe infusion reaction to a monocolonal
antibody
Yes
No
Footer
Comments
Investigator Signature (The reported case report
information has been reviewed and confirmed by
the principal investigator)
Date
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Initial Evaluation Oropharyngeal Cancer
RTOG 1016 I1NCT01302834
Radiation Therapy With Cisplatin or Cetuximab in Treating
Patients With Oropharyngeal Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=94417A43-
2D71-18EF-E040-BB89AD432749
All rights reserved. Please visit https://medical-data-
models.org/forms/11813
Initial Evaluation Oropharyngeal
Cancer RTOG 1016 I1NCT01302834
Header
RTOG Study No.
RTOG Case #
Institution Name
Institution No.
Patient Initials
RTOG Patient ID
Amended data
Yes
No
Patient demographics
Age
>= 0
<= 120
years
Gender
Female (F)
Male (M)
Performance Status (ZUBROD)
Fully Active, Able To Carry On All Pre-
disease Performance Without
Restriction. (0)
Restricted In Physically Strenuous
Activity But Ambulatory And Able To
Carry Out Work Of A Light Or Sedentary
Nature, E.g., Light Housework, Office
Work. (1)
Ambulatory And Capable Of All Selfcare
But Unable To Carry Out Any Work
Activities. Up And About More Than 50%
Of Waking Hours. (2)
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Capable Of Only Limited Selfcare,
Confined To Bed Or Chair More Than
50% Of Waking Hours. (3)
Completely Disabled. Cannot Carry On
Any Selfcare. Totally Confined To Bed Or
Chair. (4)
Assessment Date
MM DD YYYY
Tumor Measurements At Presentation
Does the patient currently require tube feeding
No (No)
Unknown (Unknown)
Yes (Yes)
Is patient dependent on tube feeding for >50% of
nutritional support  (If yes,)
No (No)
Unknown (Unknown)
Yes (Yes)
Dental gingival health
Life-threatening Dental Condition (Life-
threatening dental condition)
Mild Changes/good Dental Health (Mild
changes/good dental health)
Moderate/fair Dental Health
(Moderate/fair dental health)
Normal (Normal)
Severe Changes In Dental Health
(Severe changes in dental health)
Number of native teeth in place
Diagnostic Work-up
History and Physical
Yes
No
CT of the primary tumor and neck
Yes
No
MRI of the primary tumor and neck
Yes
No
PET/CT of the primary tumor and neck
Yes
No
Chest CT
Yes
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No
Chest PET/CT
Yes
No
ENT or head and neck surgeon examination
Yes
No
Baseline Lab Values (hematologic)
ANC
1000/ul
Date (MM DD YYYY)
Hemoglobin
g/dL
Date (MM DD YYYY)
Peripheral Platelet Count
1000/uL
Date (MM DD YYYY)
Bilirubin, total
mg/dL
Date (MM DD YYYY)
Total bilirubin LLN
mg/dL
Total bilirubin ULN
mg/dL
AST (SGOT)
U/L
Date (MM DD YYYY)
AST LLN
U/L
AST (SGOT) ULN
U/L
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ALT (SGPT)
U/L
Date (MM DD YYYY)
ALT LLN
U/L
ALT (SGPT) ULN
U/L
Creatinine
mg/dL
Date
Creatinine LLN
Creatinine ULN
mg/dL
Creatinine Clearance
mL/min
Laboratory Tests
Histologic Type
Other (Other)
Squamous Cell Carcinoma, Including
Variants (Squamous cell carcinoma,
including variants)
Other specify
Date of initial histologic diagnosis of malignancy
(MM DD YYYY)
Primary Site (If site within region cannot be
determined, specify region)
Base Of Tongue (Base of tongue)
Faucial Arch (Faucial arch)
Oropharynx Nos (OROPHARYNX, NOS)
Other (OTHER)
Pharyngeal Oropharynx (Pharyngeal
Oropharynx)
Soft Palate (Soft Palate)
Tonsillar Fossa Tonsil (Tonsillar fossa,
tonsil)
Other specify
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Indicate other involved sites within region of
origin or extension at study entry (Use previous
codetable Enter "00" for none in #1 only)
Tumor P16 Status
Negative Finding (Negative)
Not Tested (Not Tested)
Positive (Positive)
Tested But Unknown (Tested but
Unknown)
Tumor Measurements At Presentation
Primary Tumor Laterality
Left (Left)
Midline (Midline)
Right (Right)
Clinical T Stage (prior to surgery includes clinical
and radiographic findings)
T0, According To Ajcc Criteria (T0)
T1, According To Ajcc Criteria (T1)
T2, According To Ajcc Criteria (T2)
T3, According To Ajcc Criteria (T3)
T4, According To Ajcc Criteria (T4)
Tis, According To Ajcc Criteria (TIS)
Tx, According To Ajcc Criteria (TX)
Clinical N Stage (prior to surgery includes clinical
and radiographic findings)
N0, According To Ajcc Guidelines (N0)
N1, According To Ajcc Criteria (N1)
N2a, According To Ajcc Guidelines (N2a)
N2b, According To Ajcc Guidelines (N2b)
N2c, According To Ajcc Guidelines (N2c)
N3, According To Ajcc Guidelines (N3)
Nx, According To Ajcc Guidelines (NX)
Clinical N Stage, Right side
N0, According To Ajcc Guidelines (N0)
N1, According To Ajcc Criteria (N1)
N2, According To Ajcc Criteria (N2)
N2a, According To Ajcc Guidelines (N2a)
N2b, According To Ajcc Guidelines (N2b)
N2c, According To Ajcc Guidelines (N2c)
N3, According To Ajcc Guidelines (N3)
Nx, According To Ajcc Guidelines (NX)
Clinical N Stage, Left side
N0, According To Ajcc Guidelines (N0)
N1, According To Ajcc Criteria (N1)
N2, According To Ajcc Criteria (N2)
N2a, According To Ajcc Guidelines (N2a)
N2b, According To Ajcc Guidelines (N2b)
N2c, According To Ajcc Guidelines (N2c)
N3, According To Ajcc Guidelines (N3)
Nx, According To Ajcc Guidelines (NX)
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Clinical M Stage
M0, According To Ajcc Guidelines (M0)
M1, According To Ajcc Staging
Definitions (M1)
Prior Treatment
Prior Surgery (for head and neck cancer)
Yes
No
Date of most recent surgery
Specify
Prior Radiation Therapy (to head and neck that
would result in overlap of RT fields)
Yes
No
Date of Last Treatment (MM DD YYYY)
Prior Chemotherapy (for other reasons)
No (No)
Unknown (Unknown)
Yes (Yes)
Agent Name
Prior allergic reaction to study agent (s or
derivatives)
No (No)
Unknown (Unknown)
Yes (Yes)
Prior cetuximab or other anti-EGFR therapy
No (No)
Unknown (Unknown)
Yes (Yes)
History of Prior Malignancy (INVASIVE OTHER
THAN STUDY SITE)
No (No)
Unknown (Unknown)
Yes (Yes)
Site of Prior Cancer
Prior cancer date eradicated (MM DD YYYY)
Co-morbidities
Unstable angina
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No (No)
Unknown (Unknown)
Yes (Yes)
Congestive heart failure
No (No)
Unknown (Unknown)
Yes (Yes)
Heart problems (transmural MI)
No (No)
Unknown (Unknown)
Yes (Yes)
Infection (requiring IV antibiotics)
No (No)
Unknown (Unknown)
Yes (Yes)
COPD
No (No)
Unknown (Unknown)
Yes (Yes)
Clinical jaundice
No (No)
Unknown (Unknown)
Yes (Yes)
Coagulation defects
No (No)
Unknown (Unknown)
Yes (Yes)
AIDS
No (No)
Unknown (Unknown)
Yes (Yes)
CD4 cell count
/mm^3
Protocol Specific Adverse Event
Evaluation
CTCAE Term
Alopecia (Alopecia)
Anorexia (Anorexia)
Constipation (Constipation)
Cough (Cough)
Diarrhea (Diarrhea)
Dry Mouth (Dry mouth)
Dry Skin (Dry skin)
Dysgeusia (Dysgeusia)
Dyspepsia (Dyspepsia)
Dysphagia (Dysphagia)
Fatigue (Fatigue)
Hearing Impaired (Hearing impaired)
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Insomnia (Insomnia)
Mucositis Oral (Mucositis oral)
Nail Loss (Nail loss)
Nausea (Nausea)
Pain (Pain)
Peripheral Sensory Neuropathy
(Peripheral sensory neuropathy)
Pharyngeal Mucositis (Pharyngeal
mucositis)
Pruritus (Pruritus)
Rash Acneiform (Rash acneiform)
Rash Maculo-papular (Rash maculo-
papular)
Tinnitus (Tinnitus)
Trismus (Trismus)
Vomiting (Vomiting)
CTC AE Grade
Absent Adverse Event (0)
Mild Adverse Event (1)
Moderate Adverse Event (2)
Severe Adverse Event (3)
Life Threatening Adverse Event (4)
Death Related To Adverse Event (5)
CTCAE Begin Date
MM DD YYYY
Comments
Comments
Person Completing Form
Form completion date
MM DD YYYY
8 / 8
Initial Evaluation Oropharyngeal Cancer RTOG 1016 I1NCT01302834
Initial Evaluation recurrent Head and Neck
Cancer RTOG NCT00113399
Radiation Therapy Oncology Group Follow-up Form Phase
III Recurrent Head and Neck Study 
Combination Chemotherapy With or Without Radiation
Therapy in Treating Patients With Recurrent Head and
Neck Cancer That Cannot Be Removed By Surgery
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=EC4F6FCB-
F88D-02BE-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11814
Initial Evaluation recurrent Head and
Neck Cancer RTOG NCT00113399
Header
RTOG Study
Case #
Institution Name
Institution No.
Participant's Initials
Participant's ID No.
Amended data
Yes
No
Age
>= 0
<= 120
years
PERFORMANCE STATUS (ZUBROD)
Ambulatory And Capable Of All Selfcare
But Unable To Carry Out Any Work
Activities (Ambulatory and capable of all
selfcare but unable to carry out any work
activities)
Capable Of Limited Selfcare, Confined
To Bed Or Chair More Than 50% Of
Waking Hours (Capable of limited
selfcare, confined to bed or chair more
than 50% of waking hours)
Completely Disabled (Completely
disabled)
Fully Active, Able To Carry On All Pre-
disease Performance Without Restriction
(Fully active, able to carry on all pre-
disease performance without restriction)
Restricted In Physically Strenuous
Activity But Ambulatory (Restricted in
physically strenuous activity but
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ambulatory)
ANC
1000/ul
Peripheral Platelet Count
1000/uL
Hemoglobin
g/dL
Bilirubin
mg/dL
Bilirubin ULN
mg/dL
AST (SGOT)
U/L
AST (SGOT) ULN
U/L
ALT (SGPT)
U/L
ALT (SGPT) ULN
U/L
Alkaline Phosphatase
U/L
Alkaline Phosphatase ULN
U/L
Creatinine Clearance
mL/min
Calcium
mmol/l
CORRECTED SERUM CALCIUM (mg/dl)
mg/dL
CT OR MRI OF TUMOR SITE
Abnormal (Abnormal)
Normal (Normal)
Not Done (Not done)
CHEST CT
Abnormal (Abnormal)
Normal (Normal)
2 / 7
Initial Evaluation recurrent Head and Neck Cancer RTOG NCT00113399
Not Done (Not done)
ABDOMINAL CT
Abnormal (Abnormal)
Normal (Normal)
Not Done (Not done)
BIOPSY OF TUMOR OR NEEDLE
ASPIRATE/BIOPSY OF METASTATIC LYMPH
NODE
Abnormal (Abnormal)
Normal (Normal)
Not Done (Not done)
PHYSICAL ASSESSMENT OF CAROTID
Yes
No
DOPPLER ULTRASOUND
Yes
No
CT OR MR ANGIOGRAM
Yes
No
CIRCUMFERENTIAL TUMOR INVOLVEMENT
OF CAROTID SHEATH
Yes
No
WAS CAROTID ARTERY STENT PLACED?
Yes
No
IV ANTIBIOTICS AT TIME OF REGISTRATION
Yes
No
HOSPITALIZED FOR COPD OR OTHER
RESPIRATORY ILLNESS IN LAST 6 MONTHS
Yes
No
PREEXISTING GRADE > 2 PERIPHERAL
SENSORY NEUROPATHY
Yes
No
SYMPTOMATIC OR UNCONTROLLED
CARDIAC DISEASE
Yes
No
NEW YORK HEART ASSOCIATION
CLASSIFICATION (If yes,)
No Symptoms With Ordinary Physical
Activity (I)
Symptoms With Ordinary Physical
Activity; Slight Limitation Of Activity (II)
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Symptoms With Less Than Ordinary
Physical Activity; Marked Limitation Of
Activity (III)
Symptoms With Any Physical Activity Or
Even At Rest (IV)
PRIOR SURGERY (FOR HEAD AND NECK
CANCER)
Yes
No
PRIOR SURGERY DATE (MOST RECENT)
PRIOR CHEMOTHERAPY (FOR OTHER
REASONS)
PRIOR CHEMOTHERAPY END DATE
PRIOR DOSE TO THE RECURRENT / NEW
PRIMARY SITE
PRIOR DOSE TO THE SPINAL CORD
PRIOR RADIATION THERAPY END DATE
TYPE OF PATIENT DISEASE (CURRENT
PRESENTATION)
Locally And Regionally Recurrent
(Locally and regionally recurrent)
Locally Recurrent (Locally recurrent)
New Primary (New primary)
Regionally Recurrent (Regionally
recurrent)
T STAGE (of new primary only)
T0, According To Ajcc Criteria (T0)
T1, According To Ajcc Criteria (T1)
T2, According To Ajcc Criteria (T2)
T3, According To Ajcc Criteria (T3)
T4, According To Ajcc Criteria (T4)
Tis, According To Ajcc Criteria (Tis)
Tx, According To Ajcc Criteria (TX)
N STAGE (of new primary only)
N0, According To Ajcc Guidelines (N0)
N1, According To Ajcc Criteria (N1)
N2a, According To Ajcc Guidelines (N2a)
N2b, According To Ajcc Guidelines (N2b)
N2c, According To Ajcc Guidelines (N2c)
N3, According To Ajcc Guidelines (N3)
Nx, According To Ajcc Guidelines (NX)
PRIMARY SITE (CURRENT PRESENTATION)
Aryepiglottic Fold (Aryepiglottic fold)
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Arytenoid (Arytenoid)
Base Of Tongue (Base of tongue)
Buccal Mucosa (Buccal mucosa)
Faucial Arch (Faucial arch)
Floor Of Mouth (Floor of mouth)
Glottic Larynx (GLOTTIC LARYNX,
NOS)
Hard Palate (Hard palate)
Hypopharynx Nos (HYPOPHARYNX,
NOS)
Infrahyoid Epiglottis (Infrahyoid epiglottis)
Lateral Wall (Lateral wall)
Lower Gingiva (Lower gingiva)
Nasopharynx Nos (NASOPHARYNX,
NOS)
Oral Cavity Nos (ORAL CAVITY, NOS)
Oral Tongue (Oral tongue)
Oropharynx Nos (OROPHARYNX, NOS)
Other (OTHER)
Pharyngeal Oropharynx (Pharyngeal
Oropharynx)
Postcricoid Area (Postcricoid area)
Posterior Superior Wall (Posterior
superior wall)
Posterior Wall (Posterior wall)
Pyriform Fossa (Pyriform fossa)
Retromolar Trigone (Retromolar trigone)
Soft Palate (Soft Palate)
Subglottic (Subglottic)
Subglottic (SUBGLOTTIC LARYNX,
NOS)
Supraglottic Larynx (SUPRAGLOTTIC
LARYNX, NOS)
Suprahyoid Epiglottis (Suprahyoid
epiglottis)
Tonsillar Fossa Tonsil (Tonsillar fossa,
tonsil)
Unknown (UNKNOWN)
Upper Gingiva (Upper gingiva)
Ventricular Band (Ventricular band)
Vocal Cords (Vocal cords)
OTHER, SPECIFY
HISTOLOGIC DIAGNOSIS (CURRENT
PRESENTATION)
Other (Other)
Squamous Cell Carcinoma, Including
Variants (Squamous cell carcinoma,
including variants)
HOW MANY RECURRENCES / NEW
PRIMARIES HAS THE PATIENT HAD SINCE
TREATMENT OF THE ORIGINAL HEAD AND
NECK CANCER?
DATE OF FIRST RECURRENCE (OR NEW
PRIMARY)
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LARGEST MEASURABLE LESION
cm
DISTANT METASTASES PRESENT?
Yes
No
DOES THE PATIENT HAVE A HISTORY OF
PRIOR CANCER OTHER THAN THE UPPER
AERO-DIGESTIVE TRACT?
No (No)
Unknown (UNKNOWN)
Yes (Yes)
SITE OF PRIOR CANCER
PRIOR CANCER DATE ERADICATED
WEIGHT LOSS IN PREVIOUS SIX MONTHS
<5% Of Body Weight (< 5% of body
weight)
> Or = 20% Of Body Weight (> or = 20%
of body weight)
10 To <20% Of Body Weight (10 to <
20% of body weight)
5 To <10% Of Body Weight (5 to < 10%
of body weight)
Unknown (Unknown)
DOES THE PATIENT HAVE A PAST HISTORY
OF SWALLOWING PROBLEMS?
No (No)
Unknown (UNKNOWN)
Yes (Yes)
HOW LONG WERE SWALLOWING PROBLEMS
APPARENT? (If yes,)
1 To <7 Months (1 to <7 months)
13 To <19 Months (13 to <19 months)
19 To <24 Months (19 to <24 months)
2 Years Or Longer (2 years or longer)
7 To <13 Months (7 to <13 months)
Less Than 1 Month (Less than 1 month)
Unknown (Unknown)
DOES THE PATIENT CURRENTLY HAVE
SWALLOWING PROBLEMS?
No (No)
Unknown (Unknown)
Yes (Yes)
HOW LONG HAVE SWALLOWING PROBLEMS
BEEN PRESENT? (If yes,)
1 To <7 Months (1 to <7 months)
13 To <19 Months (13 to <19 months)
19 To <24 Months (19 to <24 months)
2 Years Or Longer (2 years or longer)
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7 To <13 Months (7 to <13 months)
Less Than 1 Month (Less than 1 month)
Unknown (Unknown)
DOES THE PATIENT HAVE A PAST HISTORY
OF TUBE FEEDINGS?
No (No)
Unknown (Unknown)
Yes (Yes)
HOW LONG WERE TUBE FEEDINGS GIVEN?
(If yes,)
1 To <7 Months (1 to <7 months)
13 To <19 Months (13 to <19 months)
19 To <24 Months (19 to <24 months)
2 Years Or Longer (2 years or longer)
7 To <13 Months (7 to <13 months)
Less Than 1 Month (Less than 1 month)
Unknown (Unknown)
DOES THE PATIENT CURRENTLY REQUIRE
TUBE FEEDING?
No (No)
Unknown (Unknown)
Yes (Yes)
IS PATIENT DEPENDENT ON TUBE FEEDING
FOR >50% OF NUTRITIONAL SUPPORT? (If
yes,)
No (No)
Unknown (Unknown)
Yes (Yes)
Comments
COMMENTS
Person completing form
Form completion date, original
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Pre-Randomization Colon Cancer Stage III
N0147 NCT00079274
Comparison of Combination Chemotherapy Regimens With
or Without Cetuximab in Treating Patients Who Have
Undergone Surgery For Stage III Colon Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=70E10B08-
8A7D-A35C-E040-BB89AD432A74
All rights reserved. Please visit https://medical-data-
models.org/forms/11815
Pre-Randomization Colon Cancer
Stage III N0147 NCT00079274
Header module
Coordinating Group Protocol Number
Coordinating Group Code
Protocol Title
Patient Study ID
Patient Medical Record Number
Participating Group Code (Cooperative Group
where credit will be applied)
Institution Name (treating locatin/performance
site)
Institution Code (CTEP Assigned number)
Physician of Record
Visit
Reporting Period
Pre-therapy (Pre-treatment)
Protocol Administration
IRB Approval Date
Date Informed Consent Signed
Date of prerandomization
Person Completing Form, Last Name
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Person Completing Form, First Name
Person Completing Form, Phone
Person Completing Form, Fax
Person Completing Form, E-mail
Patient Demographics/pre-treatment
Characteristics
Patient Initials
Patient Birth Date
Patient Gender
Female Gender (FEMALE)
Male Gender (MALE)
Patient Race
A Person Having Origins In Any Of The
Original Peoples Of North And South
America (including Central America),
And Who Maintains Tribal Affiliation Or
Community Attachment. (American
Indian or Alaska Native)
A Person Having Origins In Any Of The
Original Peoples Of The Far East,
Southeast Asia, Or The Indian
Subcontinent Including, For Example,
Cambodia, China, India, Japan, Korea,
Malaysia, Pakistan, The Philippine
Islands, Thailand, And Vietnam. (Asian)
A Person Having Origins In Any Of The
Black Racial Groups Of Africa. Terms
Such As "haitian" Or "negro" Can Be
Used In Addition To "black Or African
American." (Black or African American)
A Person Having Origins In Any Of The
Original Peoples Of Hawaii, Guam,
Samoa, Or Other Pacific Islands. (Native
Hawaiian or other Pacific Islander)
Not Provided Or Available (Not
Reported)
Could Not Be Determined Or Unsure
(Unknown)
A Person Having Origins In Any Of The
Original Peoples Of Europe, The Middle
East, Or North Africa. (White)
Patient Ethnicity
A Person Of Mexican, Puerto Rican,
Cuban, Central Or South American Or
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Other Spanish Culture Or Origin,
Regardless Of Race. (Hispanic or Latino)
A Person Not Meeting The Definition For
Hispanic Or Latino. (Not Hispanic or
Latino)
Not Provided Or Available (Not reported)
Could Not Be Determined Or Unsure
(Unknown)
Patient Zip Code
Country of Residence
Method of Payment
Medicaid (Medicaid)
Medicaid And Medicare (Medicaid and
Medicare)
Medicare (Medicare)
Medicare And Private Insurance
(Medicare and Private Insurance)
Military Or Veterans Sponsored Nos
(Military or Veterans Sponsored, Not
Otherwise Specified (NOS))
Military Sponsored (including Champus
& Tricare) (Military Sponsored (including
CHAMPUS & TRICARE))
No Means Of Payment (no Insurance)
(No means of payment (no insurance))
Other (Other)
Private Insurance (Private Insurance)
Self Pay (no Insurance) (Self Pay (No
Insurance))
Unknown (Unknown)
Veterans Sponsored (Veterans
Sponsored)
Is patient age 70 and over
Yes
No
Kras Results Contact
Last Name
First Name
Phone
Fax
E-mail
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Kras Results Contact
Header
Histologically documented adenocarcinoma of
the colon
Yes
No
At least one pathologically confirmed positive
lymph node identified
Yes
No
There must be no evidence of residual involved
lymph node disease
Yes
No
ECOG performance status (PS) 0, 1, or 2
Yes
No
18 Years and older
Yes
No
Age
>= 0
<= 120
years
Must be willing to provide blood and tissue
samples for eligibility and research purposes, as
described in Sections 14.0 and 17.0
Yes
No
Tumor tissue will be made available to NCCTG
for centralized KRAS testing prior to
registration/randomization
Yes
No
A pre-randomization pathology review is required.
The site has reviewed and understands the
process listed in Section 17.0 and must account
for sufficient time to complete pre-randomization
and registration/randomization steps.
Yes
No
Contraindications
Any of the following:  Pregnant women, Nursing
women, Men or women of childbearing potential
who are unwilling to employ adequate
4 / 7
Pre-Randomization Colon Cancer Stage III N0147 NCT00079274
contraception
Yes
No
Evidence of residual involved lymph node
diseases
Yes
No
Distant metastatic disease at the time of
registration/randomization
Yes
No
Prior chemotherapy or radiation therapy for
treatment of this malignancy
Yes
No
Prior therapy with agent(s) directed against
EGFR
Yes
No
Prior allergic reaction to chimerized or murine
monoclonal antibody therapy or documented
presence of human anti-mouse antibodies
Yes
No
Previous or concurrent malignancy
Yes
No
Any of the following conditions (Uncontrolled high
blood pressure, Unstable angina, Symptomatic
congestive heart failure, Myocardial infarction
less than 6 months prior to randomization, NYHA
class III or IV, Symp pulmonary fibrosis or
intersitial pneumonitis, Active uncontrolled
bacterial, viral, Systemic fungal infection)
Yes
No
Other medical condition which, in the opinion of
the treating physician, would make this protocol
unreasonably hazardous for the patient
Yes
No
Clinically significant peripheral neuropathy at the
time of randomization
Yes
No
Concurrent use of other anti-cancer therapy
including chemotherapy agents, target agents, or
biological agents
Yes
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No
Known allergy to other platinum compounds
Yes
No
History of gastrointestinal bleeding that has not
been appropriately addressed based on
assessment of the enrolling physician
Yes
No
Pre-randomization Check
Request Letter for Immunohistochemistry Test
Results has been given to the patient
Yes
No
Consent form signed and dated
Yes
No
Authorization for use and disclosure of protected
health information signed and dated
No (No)
Not Applicable (Not Applicable)
Yes (Yes)
Date of authorization
Not Applicable
Patient has agreed by signature of consent form
to allow tissue and blood samples to be used for
correlative science studies associated with this
study
Yes
No
Patient will automatically be registered to the
translational research component of this study at
the time of pre-randomization.
Yes
No
Blood draw kit availability checked
Yes
No
The Following Will Also Be Recorded:
Patient has given permission to store blood and
paraffin-embedded tissue for future research of
colorectal cancer
Yes
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No
Patient has given permission to store blood and
paraffin-embedded tissue for future research to
prevent, or treat other health problems
Yes
No
Patient has given NCCTG permission to give their
blood and paraffin-embedded tissue to outside
researchers
Yes
No
The Following Will Also Be Recorded:
Protocol Design
Assigned Treatment
Pre-randomization (Pre-randomization)
Person pre-randomizing
CTSU Random. specialist
Investigator Signature
Date of Investigator Signature
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Initial Evaluation Prostate Cancer Stage II
RTOG-0415 I1 NCT00331773
Radiation Therapy in Treating Patients With Stage II
Prostate Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=06269FC0-
82B9-40C5-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11816
Initial Evaluation Prostate Cancer
Stage II RTOG-0415 I1
NCT00331773
RTOG clinical trial administrative data
RTOG Study No.
RTOG Case #
Institution Name
Institution No.
Patient Initials
RTOG Patient ID
AMENDED DATA
Yes
No
Patient demographics
Age
>= 0
<= 120
years
Performance Status (ZUBROD 0-5)
Fully Active, Able To Carry On All Pre-
disease Performance Without
Restriction. (0)
Restricted In Physically Strenuous
Activity But Ambulatory And Able To
Carry Out Work Of A Light Or Sedentary
Nature, E.g., Light Housework, Office
Work. (1)
Ambulatory And Capable Of All Selfcare
But Unable To Carry Out Any Work
Activities. Up And About More Than 50%
Of Waking Hours. (2)
Capable Of Only Limited Selfcare,
Confined To Bed Or Chair More Than
50% Of Waking Hours. (3)
Completely Disabled. Cannot Carry On
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Any Selfcare. Totally Confined To Bed Or
Chair. (4)
Dead (5)
Has the patient had any prior cancer diagnosed
(other than study site)
Yes
No
Prior malignancy site
Aml/mds (AML/MDS)
Bcc (BCC)
Bladder Is The Site Of Second Primary
Or Recurrent Tumor (bladder)
Brain Is The Site Of Second Primary Or
Recurrent Tumor (brain)
Colorectal (Colorectal)
Esophageal (Esophageal)
Gastric (Gastric)
Liver Is The Site Of Second Primary Or
Recurrent Tumor (liver)
Lung Is The Site Of Second Primary Or
Recurrent Tumor (lung)
Melanoma (Melanoma)
Nhl (NHL)
None (None)
Other Hematologic (Other hematologic)
Other Solid (Other solid)
Pancreatic (Pancreatic)
Renal (Renal)
Squamous-skin (Squamous-skin)
Unknown Primary (Unknown primary)
Specify
DATE ERADICATED (mm-yyyy)
Other Patient Disease Type
Infection (acute bacterial or fungal requiring
intravenous antibiotics at the time of registration)
Yes
No
Does the patient have AIDS
Yes
No
Heart problems (unstable angina and/or CHF
requiring hospitalization within the last 6 months)
Yes
No
Heart problems (Transmural myocardial infarction
within the last 6 months)
Yes
No
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Pulmonary (COPD or other respiratory illness
requiring hospitalization at time of registration)
Yes
No
Hepatic symptoms (hepatic insufficiency resulting
in clinical jaundice and/or coagulation defects)
Yes
No
Prostate: Prior Treatment
Prior Surgery (RADICAL PROSTATECTOMY,
CRYOSURGERY, OR BILATERAL
ORCHIECTOMY)
Yes
No
Prior Radiation Therapy (pelvic)
Yes
No
Prior Chemotherapy
Yes
No
Finasteride (PRIOR HORMONAL THERAPY
TYPE)
Yes
No
Dutasteride (PRIOR HORMONAL THERAPY
TYPE)
Yes
No
Prior Hormonal Therapy End Date (dutasteride)
Prior Hormonal Therapy End Date (dutasteride)
Prior Other Hormonal Therapy (LHRH agonists,
anti-androgens, estrogens)
Yes
No
Other, specify
Prostate: Initial Diagnosis
Date of Initial Diagnosis of Primary Tumor
Total number of core biopsies taken
Number of positive core biopsies
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Histologic Type
Adenocarcinoma, Conventional, Not
Otherwise Specified (Adenocarcinoma,
conventional NOS)
Other Specify (Other)
Other specify
Gleason Score, Primary Pattern ([most frequently
seen] 1-5, 9=unknown)
Gleason Score, Secondary Pattern ([second
most frequently seen] 1-5, 9=unknown)
Gleason Score, Worst Pattern ([worst
pathological grade seen in any specimen] 1-5,
9=unknown)
Gleason Score, Combined ([sum of the primary
and secondary])
Prostate: Disease Description Localized
Was the tumor palpable (at study entry)
No (No)
Yes, <= 1/2 Of One Lobe (Yes, <= 1/2 of
one lobe)
Yes, > 1/2 Of One Lobe (Yes, > 1/2 of
one lobe)
Yes, Both Lobes (Yes, both lobes)
Yes, Nos (Yes, NOS)
Extracapsular Extension (by clinical examination)
Yes
No
Prostate Cancer Staging
Prostate Tumor Clinical Stage
Tumor Incidental Histologic Finding In
5% Or Less Of Tissue Resected (T1a)
Tumor Incidental Histologic Finding In
More Than 5% Of Tissue Resected
(T1b)
Tumor Identified By Needle Biopsy (eg,
Because Of Elevated Psa) (T1c)
Tumor Confined Within The Prostate (T2)
Tumor Involves One Lobe (T2a)
Tumor Involves Both Lobes (T2b)
Tumor Involves Both Lobes (T2c)
Tumor Extends Through The Prostate
Capule (T3)
Extracapsular Extension (unilateral Or
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Bilateral) (T3a)
Tumor Invades Seminal Vesicle(s) (T3b)
Tumor Is Fixed Or Invades Adjacent
Structures Other Than Seminal Vesicles:
Bladder Neck, External Sphincter, Or
Rectum, Levator Muscles, And/or Pelvic
Wall (T4)
Primary Tumor Cannot Be Assessed
(TX)
N Stage, Pathologic
No Regional Lymph Node Metastasis
(pN0)
Metastatis In Regional Lymph Node Or
Nodes (see Ajcc Definition) (pN1)
Regional Lymph Nodes Cannot Be
Assessed (pNX)
N Stage, Clinical (RADIOGRAPHIC)
No Regional Lymph Node Metastasis
(N0)
Metastatis In Regional Lymph Node Or
Nodes (see Ajcc Definition) (N1)
Regional Lymph Nodes Cannot Be
Assessed (NX)
M Stage, Clinical
No Distant Metastasis (M0)
Distant Metastasis (M1)
Nonregional Lymph Node(s) (M1a)
Bone(s) (M1b)
Other Site(s) (M1c)
Distant Metastasis Cannot Be Assessed
(MX)
Study Entry Psa Measurements
Baseline PSA Date
Baseline PSA Value
ng/ml
Pre-diagnostic PSA measurements (Additional
PSA's obtained within 1 year prior to diagnosis if
available)
Yes
No
PSA Date
Prostate-Specific Antigen Value
ng/ml
Method of Assay
Abbott Labs (Abbott)
Bayer (Bayer)
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Dpc (DPC)
Hybritech (Hybritech)
Other (Other)
Method of Assay
Abbott Labs (Abbott)
Bayer (Bayer)
Dpc (DPC)
Hybritech (Hybritech)
Other (Other)
Baseline Lab Values (hematologic)
Hemoglobin
g/dL
ANC
1000/ul
Peripheral Platelet Count
1000/uL
Alkaline Phosphatase
U/L
Alkaline Phosphatase LLN
U/L
Alkaline Phosphatase ULN
U/L
Testosterone
ng/dl
Testosterone LLN
ng/dl
Testosterone ULN
ng/dl
Footer
Comments
Signature of Person Completing This Form
Date Form Originally Completed
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Eligibility Breast Cancer early stage NCIC
MA.32 NCT01101438
NCIC MA.32 Eligibility Worksheet
A Phase III Randomized Trial of Metformin vs Placebo in
Early Stage Breast Cancer
NCT01101438
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=80D63865-
BE43-3FAC-E040-BB89AD4349FC
All rights reserved. Please visit https://medical-data-
models.org/forms/11817
Eligibility Breast Cancer early stage
NCIC MA.32 NCT01101438
Header Module
Institution Code
Patient Initials
Hospital Number (if permitted by REB)
Method of Payment
Medicaid (Medicaid)
Medicaid And Medicare (Medicaid and
Medicare)
Medicare (Medicare)
Medicare And Private Insurance
(Medicare and Private Insurance)
Military Or Veterans Sponsored Nos
(Military or Veterans Sponsored, Not
Otherwise Specified (NOS))
Military Sponsored (including Champus
& Tricare) (Military Sponsored (including
CHAMPUS & TRICARE))
No Means Of Payment (no Insurance)
(No means of payment (no insurance))
Other (Other)
Private Insurance (Private Insurance)
Self Pay (no Insurance) (Self Pay (No
Insurance))
Unknown (Unknown)
Veterans Sponsored (Veterans
Sponsored)
Zip code
Patient Characteristics
Patient Race
A Person Having Origins In Any Of The
Original Peoples Of North And South
America (including Central America),
And Who Maintains Tribal Affiliation Or
Community Attachment. (American
Indian or Alaska Native)
A Person Having Origins In Any Of The
Original Peoples Of The Far East,
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Southeast Asia, Or The Indian
Subcontinent Including, For Example,
Cambodia, China, India, Japan, Korea,
Malaysia, Pakistan, The Philippine
Islands, Thailand, And Vietnam. (Asian)
A Person Having Origins In Any Of The
Black Racial Groups Of Africa. Terms
Such As "haitian" Or "negro" Can Be
Used In Addition To "black Or African
American." (Black or African American)
A Person Having Origins In Any Of The
Original Peoples Of Hawaii, Guam,
Samoa, Or Other Pacific Islands. (Native
Hawaiian or other Pacific Islander)
Not Provided Or Available (Not
Reported)
Could Not Be Determined Or Unsure
(Unknown)
A Person Having Origins In Any Of The
Original Peoples Of Europe, The Middle
East, Or North Africa. (White)
Patient Ethnicity
A Person Of Mexican, Puerto Rican,
Cuban, Central Or South American Or
Other Spanish Culture Or Origin,
Regardless Of Race. (Hispanic or Latino)
A Person Not Meeting The Definition For
Hispanic Or Latino. (Not Hispanic or
Latino)
Not Provided Or Available (Not reported)
Could Not Be Determined Or Unsure
(Unknown)
Eligibility Criteria
Subject has histologically confirmed invasive
breast cancer that has been diagnosed and
completely resected within 12 months prior to
randomization
Yes
No
Tumor Laterality
Bilateral (Bilateral)
Left (Left)
Right (Right)
Date of Initial Diagnosis of Primary Tumor
Histologic Type
Ductal (Ductal)
Lobular (Lobular)
Most extensive definitive surgery
Mastectomy, Nos (Mastectomy NOS)
Partial Mastectomy, Lumpectomy Or
Excisional Biopsy (Partial
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mastectomy/lumpectomy/excisional
biopsy)
Date of Most Extensive Primary Surgery
Is invasive cancer at margin?
Involved, Nos (Involved NOS)
Not Involved, Nos (Not involved NOS)
Is DCIS present? (at resection margin)
Yes
No
Has the subject received adjuvant radiotherapy
Yes
No
Was a boost given? (to the site of residual ductal
in situ disease)
Yes
No
If neoadjuvant, subject has no evidence of clinical
T4 disease prior to chemotherapy and surgery
No (No)
Not Applicable (Not Applicable)
Yes (Yes)
T Stage, Clinical
Tumor 2 Cm Or Less In Greatest
Dimension (T1)
Tumor More Than 2 Cm But Not More
Than 5 Cm In Greatest Dimension (T2)
Tumor More Than 5 Cm In Greatest
Dimension (T3)
Tumor Of Any Size With Direct (T4)
N Stage, Clinical
No Regional Lymph Node Metastasis
(N0)
Metastasis To Movable Ipsilateral Axillary
Lymph Node(s) (N1)
Metastasis To Ipsilateral Axillary Lymph
Node(s) Fixed Or Matted, Or In Clinically
Apparent* Ipsilateral Internal Mammary
Nodes In The Absence Of Clinically
Evident Lymph Node Metastasis (N2)
Metastasis In Ipsilateral Infraclavicular
Lymph Node(s) With Or Without Axillary
Lymph Node Involvement, Or In Clinically
Apparent* Ipsilateral Internal Mammary
Lymph Node(s) And In The Presence Of
Clinically Evident Axillary Lymph Node
Metastasis; Or, Me (N3)
M Stage, Clinical
No Distant Metastases (M0)
Distant Metastasis (M1)
Distant Metastasis Cannot Be Assessed
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(MX)
Subject's TNM Stage (AJCC Version 6) is one of
pT1, pT2, pT3; pN0, pN1, pN2, pN3; M0 and
subject has one of the pT pN combinations
described in protocol section 5.1.4 and subject
has sentinel node biopsy and/or full axillary
lymph node dissection
Yes
No
Pathologic T Stage
No Evidence Of Primary Tumor (T0)
Tumor 2 Cm Or Less In Greatest
Dimension (T1)
Tumor More Than 0.1 Cm But Not More
Than 0.5 Cm In Greatest Dimension
(T1a)
Tumor More Than 0.5 Cm But Not More
Than 1 Cm In Greatest Dimension (T1b)
Tumor More Than 1 Cm But Not More
Than 2 Cm In Greatest Dimension (T1c)
Microinvasion 0.1 Cm Or Less In
Greatest Dimension (T1mic)
Tumor More Than 2 Cm But Not More
Than 5 Cm In Greatest Dimension (T2)
Tumor More Than 5 Cm In Greatest
Dimension (T3)
Tumor Of Any Size With Direct (T4)
Extension To Chest Wall (T4a)
Edema (including Peau D'orange) Or
Ulceration Of The Skin Of The Breast Or
Satellite Skin Nodules Confined To The
Same Breast (T4b)
Both T4a And T4b (T4c)
Inflammatory Carcinoma (T4d)
Carcinoma In Situ: Intraductal
Carcinoma, Lobular Carcinoma In Situ,
Or Paget's Disease Of The Nipple With
No Tumor (Tis)
Ductal Carcinoma In Situ (Tis (DCIS))
Lobular Carcinoma In Situ (Tis (LCIS))
Paget's Disease Of The Nipple With No
Tumor. [note: Paget's Disease
Associated With A Tumor Is Classified
According To The Size Of The Tumor.]
(Tis (Paget's))
Primary Tumor Cannot Be Assessed
(TX)
Pathologic N Stage
No Regional Lymph Node Metastasis
Histologically, No Additional Examination
For Isolated Tumor Cells (itc) (pN0)
No Regional Lymph Node Metastasis
Histologically, Negative Ihc (pN0(i-))
No Regional Lymph Node Metastasis
Histologically, Positive Ihc, No Ihc Cluster
>0.2 Mm (pN0(i+))
No Regional Lymph Node Metastasis
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Histologically, Negative Molecular
Findings (rt-pcr) (pN0(mol-))
No Regionally Lymph Node Metastasis
Histologically, Positive Molecular
Findings (rt-pcr) (pN0(mol+))
Metastasis In 1 To 3 Axillary Lymph
Nodes, And/or In Internal Mammary
Nodes With Microscopic Disease
Detected By Sln Dissection But Not
Clinically Apparent (pN1)
Metastasis In 1 To 3 Axillary Lymph
Nodes (pN1a)
Metastasis In Internal Mammary Nodes
With Microscopic Disease Detected By
Sln Dissection But Not Clinically
Apparent (pN1b)
Metastasis In 1 To 3 Axillary Lymph
Nodes And In Internal Mammary Lymph
Nodes With Microscopic Disease
Detected By Sln Dissection But Not
Clinically Apparent. (pN1c)
Micrometastasis (>0.2 Mm But <=2.0
Mm) (pN1mi)
Metastasis In 4 To 9 Axillary Lymph
Nodes, Or In Clinically Apparent **
Internal Mammary Lymph Nodes In The
Absence Of Axillary Lymph Node
Metastasis To Ipsilateral Axillary Lymph
Node(s) Fixed To Each Other Or To
Other Structures (pN2)
Metastasis In 4 To 9 Axillary Lymph
Nodes (at Least 1 Tumor Deposit >2.0
Mm) (pN2a)
Metastasis In Clinically Apparent*
Internal Mammary Lymph Nodes In The
Absence Of Axillary Lymph Node
Metastasis (pN2b)
Metastasis In >= Axillary Lymph Nodes,
Or In Infraclavicular Lymph Nodes, Or In
Clinically Apparent* Ipsilateral Internal
Mammary Lymph Node(s) In The
Presence Of 1 Or More Positive Axillary
Lymph Node(s); Or, In >3 Axillary Lymph
Nodes With Clinically N (pN3)
Metastasis In >=10 Axillary Lymph
Nodes (at Least 1 Tumor Deposit >2.0
Mm); Or, Metastasis To The
Infraclavicular Lymph Nodes (pN3a)
Metastasis In Clinically Apparent*
Ipsilateral Internal Mammary Lymph
Nodes In The Presence Of >=1 Positive
Axillary Lymph Node(s); Or, In >3
Axillary Lymph Nodes And In Internal
Mammary Lymph Nodes With
Microscopic Disease Detected By
Sentinel Lymph Node (pN3b)
Metastasis In Ipsilateral Supraclavicular
Lymph Nodes (pN3c)
Regional Lymph Nodes Cannot Be
Assessed (e.g., Not Removed For
5 / 13
Eligibility Breast Cancer early stage NCIC MA.32 NCT01101438
Pathologic Study Or Previously
Removed) (pNX)
Pathologic M Stage
No Distant Metastasis (M0)
Distant Metastasis (M1)
Distant Metastasis Cannot Be Assessed
(MX)
Histologic Grade
G1 Low Combined Histologic Grade
(favorable) (G1)
G2 Intermediate Combined Histologic
Grade (moderately Favorable) (G2)
G3 High Combined Histologic Grade
(unfavorable) (G3)
Gx Grade Cannot Be Assessed (GX)
Is there lymphovascular invasion?
No (NO)
Unknown (UNKNOWN)
Yes (YES)
Oncotype DX Recurrence Score
Ki67 Score
Was sentinel node sampling performed
Yes
No
Sentinel Node Biopsy Date
Number of Sentinel Nodes Examined
Number of Positive Sentinel Nodes
Was axillary dissection performed?
Yes
No
Date of Axillary Node Biopsy
Number of axillary nodes examined
Number of positive axillary nodes
Number of Lymph Nodes Examined
Number of Positive Lymph Nodes
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If subject has bilateral breast carcinoma
diagnoses were synchronous - within 3 months of
one another - and at least one of the two breast
carcinomas meet the eligibility criteria and neither
meets the exclusion criteria
No (No)
Not Applicable (Not Applicable)
Yes (Yes)
Chemotherapy, if given, has been completed at
least 4 weeks prior to randomization
No (No)
Not Applicable (Not Applicable)
Not Applicable (Not Applicable)
Yes (Yes)
Prior Adjuvant Chemotherapy
Yes
No
Date Prior Adjuvant Chemotherapy Ended
Estrogen/progesterone receptor status is known
Yes
No
Receptor Status, ER
Negative (Negative)
Positive (Positive)
Receptor Status, PgR
Negative (Negative)
Positive (Positive)
Unknown (Unknown)
HER2 status is known
Yes
No
HER-2/neu status
Negative (Negative)
Positive (Positive)
HER2 test type
Chromogenic In Situ Hybridization
(CISH)
Fluorescence In Situ Hybridization
(FISH)
Immunohistochemistry Staining Method
(IHC)
Other (Other)
Specify (If other,)
Subject has had a bilateral mammogram within
12 months prior to randomization
Yes
No
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Date of mammogram
Subject has ECOG Performance Status of 0, 1 or
2
Yes
No
ECOG Performance Status
Fully Active, Able To Carry On All Pre-
disease Performance Without
Restriction. (0)
Restricted In Physically Strenuous
Activity But Ambulatory And Able To
Carry Out Work Of A Light Or Sedentary
Nature, E.g., Light Housework, Office
Work. (1)
Ambulatory And Capable Of All Selfcare
But Unable To Carry Out Any Work
Activities. Up And About More Than 50%
Of Waking Hours. (2)
Capable Of Only Limited Selfcare,
Confined To Bed Or Chair More Than
50% Of Waking Hours. (3)
Completely Disabled. Cannot Carry On
Any Selfcare. Totally Confined To Bed Or
Chair. (4)
Subject is < 75 years of age and has life
expectancy of at least 5 years
Yes
No
Patient date of birth
DD.MM.YYYY
Age
>= 0
<= 120
years
Subject is accessible for treatment and follow-up
Yes
No
Protocol treatment will begin within 10 working
days after randomization
Yes
No
Most recent REB approved informed consent has
been signed according to local institutional
requirements
Yes
No
Most recent REB approved Tissue and Blood
Collection and Banking informed consent has
been signed and dated by the patient and
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appropriate "I agree/I don't agree" box has been
checked
Yes
No
Date tissue and blood collection and banking
consent signed
Tissue and blood collection and banking consent
version date
Is the subject English or French speaking
Yes
No
Subject has completed the baseline Quality of
Life questionnaire and is willing to complete
future assessments
No (No)
No, The Questionnaire Was Not
Completed But For Reason(s) That Do
Not Affect Eligibility (No, the
questionnaire was not completed but for
reason(s) that do not affect eligibility)
Yes (Yes)
Date Questionnaire Completed
Reason questionnaire was not completed
Illiteracy In English (Illiteracy in English)
Loss Of Sight (Loss of sight)
Other (Other)
Specify
Is the subject English speaking and has s/he
already completed the Quality of Life
questionnaire
Yes
No
Subject has completed the baseline Nurses
Health Study II Physical Activity Questionnaire
and the Block Alive Screener and is willing to
complete future assessments
No (No)
No, The Questionnaire Was Not
Completed But For Reason(s) That Do
Not Affect Eligibility (No, the
questionnaire was not completed but for
reason(s) that do not affect eligibility)
Yes (Yes)
Date patient filled out questionnaires
Investigations, including chest X-ray or CT chest,
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bone scan and abdominal have been performed
no earlier than 4 weeks prior to primary surgery
and no later than the date of randomization and
are negative for metastases
Yes
No
Date of Chest X-ray
Date of CT or MRI of chest
Date of bone scan
Date of bone x-rays
Date Abdominal CT or MRI
Date of liver CT or US scan
Abdominal ultrasound date
Eligibility Labs
Hemoglobin
g/dL
Date
Peripheral Platelet Count
1000/uL
WBC
/ul
Granulocytes
1000/uL
Mean Corpuscular Volume
AST (SGOT)
U/L
AST (SGOT) ULN
U/L
ALT (SGPT)
U/L
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ALT (SGPT) ULN
U/L
Alkaline Phosphatase
U/L
Alkaline Phosphatase ULN
U/L
Creatinine
mg/dL
Serum Creatinine ULN
mg/dL
Bilirubin, total
mg/dL
Ineligibility Criteria
Fasting glucose
mg/dL
Pregnancy Test Result
Negative (negative)
Not Applicable, Not Female Of Child-
bearing Potential (not applicable, not
female of child-bearing potential)
Not Evaluated (not evaluated)
Positive (positive)
Date of pregnancy test
Physical Exam
Date of Pre-entry History & Physical Exam
Height
>= 0
cm
Body weight
>= 0
kg
Body Mass Index
kg/m2
Waist Circumference
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%Hip Circumference
%
Systolic
>= 0
mmHg
Diastolic
>= 0
mmHg
Date of last menstrual period
Menopausal Status
Above Categories Not Applicable And
Age <50 (Above categories not
applicable AND Age < 50)
Above Categories Not Applicable And
Age >= 50 (Above categories not
applicable AND Age >= 50)
Post (prior Bilateral Ovariectomy Or >12
Mo Since Lmp With No Prior
Hysterectomy) (Post (prior bilateral
ovariectomy OR >12 mo since LMP with
no prior hysterectomy))
Pre (<6 Mo Since Lmp And No Prior
Bilateral Ovariectomy And Not On
Estrogen Replacement) (Pre (<6 mo
since LMP AND no prior bilateral
ovariectomy AND not on estrogen
replacement))
Stratification
Hormonal status
Er-negative And Pgr Negative (neither
Tamoxifen Nor Aromatase Inhibitor Is
Permitted)) (ER-negative and PgR
negative (neither tamoxifen nor
aromatase inhibitor is permitted)))
Er-positive And/or Pgr-positive (ER-
positive and/or PgR-positive)
Body Mass Index
<=30 (<=30)
>30 (>30)
Consent
Has this subject given written consent to
participate in MA.32F
Yes
No
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Has informed consent been signed and dated by
patient and person conducting consent form
discussion
Yes
No
Consent form language
English Language (English)
French Language Other (French or
Other)
Consent form version date
Date signed by patient
Name of person conducting the consent form
discussion
Date of signature
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Oncological follow-up - PET-CT
ODM form derived from  PET CT Nachsorge SD Nuk UKM.
Used as a routine documentation by the University Hospital
Muenster, Germany.
All rights reserved. Please visit https://medical-data-
models.org/forms/11819
Oncological follow-up - PET-CT
Primärdiagnose
Tumordiagnose
Lokalisation
rechts (1)
links (2)
beidseits (3)
isthmal (4)
Tumorgröße
cm
unbekannt (1)
unifokal (2)
multifokal (3)
TNM Klassifikation 199
T1a, T1b, T2, T3a, T3b, T4a, T4b, Tx (1)
N0, N1a, N1b, Nx (2)
M0, M1, Mx (3)
TNM Klassifikation 200
T1a, T1b, T2, T3a, T3b, T4a, T4b, Tx (1)
N0, N1a, N1b, Nx (2)
M0, M1, Mx (3)
Ort der Metastasen
Andere (1)
Gehirn (2)
Skelett (3)
Leber (4)
Lunge (5)
Lymphknoten (6)
Histopathologie
anaplastischer Typ (1)
follikulärer Typ (2)
papillärer Typ (3)
medullärer Typ (4)
gering differenziertes Karzinom (5)
Residualtumor
R0 (1)
R1 (2)
R2 (3)
Nebendiagnose
Komplikationen
Recurrensparese
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Ja
Nein
Hypoparathyroidismus
Ja
Nein
Accessoriusparese
Ja
Nein
Horner - Syndrom
Ja
Nein
Primäroperation
1. Operation und Datum
unilateral (1)
bilateral (2)
2. Operation
unilateral (1)
bilateral (2)
Art der Operation
total /near total Resektion (1)
subtotale Resektion (2)
Lymphknotendissektion
Ja
Nein
Rezidivoperation
Ja
Nein
Erste Radiojodtherapie
Datum
Aktivität
GBq
Letzte Radiojodtherapie
Datum
Aktivität
GBq
Applizierte Gesamtaktivität
GBq
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Strahlentherapie
Strahlentherapie
Ja
Nein
Sonstige Therapien
Verlauf
Remission
partiell (1)
komplett (2)
progressiv (3)
stabil (4)
Rezidiv
Ja
Nein
Labor
TSH [μU/ml]
μU/ml
Thyroglobulin
[ng/ml]
Tg-AK [U/ml]
U/ml
Tg-WF
%
rhTSH [0/1]
Datum der Laborwerte
Iod-131-Ganzkörperszintigraphie
Datum
Aktivität
Mbq
Ergebnis
negativ (1)
positiv (2)
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FDG-PET-CT Befund
Hals
negativ (1)
positiv (2)
Thorax
negativ (1)
positiv (2)
Abdomen
negativ (1)
positiv (2)
Skelett
negativ (1)
positiv (2)
Referenz: Lebermittelwert
Datum des FDG-PET-CTs
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Pre-Study Form Prostate Cancer High-Risk
RTOG-0521 I1 NCT00288080
RTOG-0521 I1: Radiation Therapy Oncology Group Phase
III Randomized Study of Localized, High-Risk Prostate
Cancer Initial Evaluation Form NCT00288080 
Hormone Therapy and Radiation Therapy or Hormone
Therapy and Radiation Therapy Followed by Docetaxel and
Prednisone in Treating Patients With Localized Prostate
Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=0C37725E-
C9CF-4EEC-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11820
Pre-Study Form Prostate Cancer
High-Risk RTOG-0521 I1
NCT00288080
RTOG clinical trial administrative data
RTOG Study No.
RTOG Case #
Institution Name
Institution No.
Patient Initials
RTOG Patient ID
Amended Data
Yes
No
Prior malignancy
Age
>= 0
<= 120
years
Performance Status (ZUBROD 0-5)
Fully Active, Able To Carry On All Pre-
disease Performance Without
Restriction. (0)
Restricted In Physically Strenuous
Activity But Ambulatory And Able To
Carry Out Work Of A Light Or Sedentary
Nature, E.g., Light Housework, Office
Work. (1)
Ambulatory And Capable Of All Selfcare
But Unable To Carry Out Any Work
Activities. Up And About More Than 50%
Of Waking Hours. (2)
Capable Of Only Limited Selfcare,
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Confined To Bed Or Chair More Than
50% Of Waking Hours. (3)
Completely Disabled. Cannot Carry On
Any Selfcare. Totally Confined To Bed Or
Chair. (4)
Dead (5)
Has the patient had any prior cancer diagnosed
(other than study site)
Yes
No
Prior malignancy site
Aml/mds (AML/MDS)
Bcc (BCC)
Bladder Is The Site Of Second Primary
Or Recurrent Tumor (bladder)
Brain Is The Site Of Second Primary Or
Recurrent Tumor (brain)
Colorectal (Colorectal)
Esophageal (Esophageal)
Gastric (Gastric)
Liver Is The Site Of Second Primary Or
Recurrent Tumor (liver)
Lung Is The Site Of Second Primary Or
Recurrent Tumor (lung)
Melanoma (Melanoma)
Nhl (NHL)
None (None)
Other Hematologic (Other hematologic)
Other Solid (Other solid)
Pancreatic (Pancreatic)
Renal (Renal)
Squamous-skin (Squamous-skin)
Unknown Primary (Unknown primary)
Specify
Date Eradicated (mm-yyyy)
Other Patient Disease Type
Infection (acute bacterial or fungal requiring
intravenous antibiotics at the time of registration)
Yes
No
Does the patient have AIDS
Yes
No
Allergy (TAXOL)
Yes
No
Heart problems (unstable angina and/or CHF
requiring hospitalization within the last 6 months)
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Yes
No
Heart problems (Transmural myocardial infarction
within the last 6 months)
Yes
No
Prostate: Prior Treatment
Prior Surgery (RADICAL PROSTATECTOMY,
CRYOSURGERY, OR BILATERAL
ORCHIECTOMY)
Yes
No
Prior Radiation Therapy (pelvic)
Yes
No
Prior Chemotherapy
Yes
No
Prior Hormonal Therapy
Yes
No
5 alpha-reductase inhibitor
Yes
No
Prior Hormonal Therapy End Date
Testosterone (PRIOR HORMONAL THERAPY
TYPE)
Yes
No
Prior Other Hormonal Therapy
Yes
No
Other, specify
Date Prior Other Hormonal Therapy Started
Prostate: Initial Diagnosis
Date of Initial Diagnosis of Primary Tumor
Total number of core biopsies taken
Number of positive core biopsies
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Histologic Type
Adenocarcinoma, Conventional, Not
Otherwise Specified (Adenocarcinoma,
conventional NOS)
Other Specify (Other)
Other specify
Gleason Score, Primary Pattern ([most frequently
seen] 1-5, 9=unknown)
Gleason Score, Secondary Pattern ([second
most frequently seen] 1-5, 9=unknown)
Gleason Score, Worst Pattern ([worst
pathological grade seen in any specimen] 1-5,
9=unknown)
Gleason Score, Combined ([sum of the primary
and secondary])
Study Entry Psa Measurements
Baseline PSA Date
Baseline PSA Value
ng/ml
Pre-diagnostic PSA measurements (Additional
PSA's obtained within 1 year prior to diagnosis if
available)
Yes
No
PSA Date
PSA Value
ng/ml
Prostate: Disease Description Localized
Was the tumor palpable (at study entry)
No (No)
Yes, <= 1/2 Of One Lobe (Yes, <= 1/2 of
one lobe)
Yes, > 1/2 Of One Lobe (Yes, > 1/2 of
one lobe)
Yes, Both Lobes (Yes, both lobes)
Yes, Nos (Yes, NOS)
Extracapsular Extension (by clinical examination)
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Yes
No
Prostate Cancer Staging
T Stage, Clinical (AJCC 6TH EDITION)
Tumor Incidental Histologic Finding In
5% Or Less Of Tissue Resected (T1a)
Tumor Incidental Histologic Finding In
More Than 5% Of Tissue Resected
(T1b)
Tumor Identified By Needle Biopsy (eg,
Because Of Elevated Psa) (T1c)
Tumor Confined Within The Prostate (T2)
Tumor Involves One Lobe (T2a)
Tumor Involves Both Lobes (T2b)
Tumor Involves Both Lobes (T2c)
Tumor Extends Through The Prostate
Capule (T3)
Extracapsular Extension (unilateral Or
Bilateral) (T3a)
Tumor Invades Seminal Vesicle(s) (T3b)
Tumor Is Fixed Or Invades Adjacent
Structures Other Than Seminal Vesicles:
Bladder Neck, External Sphincter, Or
Rectum, Levator Muscles, And/or Pelvic
Wall (T4)
Primary Tumor Cannot Be Assessed
(TX)
N Stage, Pathologic
No Regional Lymph Node Metastasis
(pN0)
Metastatis In Regional Lymph Node Or
Nodes (see Ajcc Definition) (pN1)
Regional Lymph Nodes Cannot Be
Assessed (pNX)
N Stage, Clinical (RADIOGRAPHIC)
No Regional Lymph Node Metastasis
(N0)
Metastatis In Regional Lymph Node Or
Nodes (see Ajcc Definition) (N1)
Regional Lymph Nodes Cannot Be
Assessed (NX)
M Stage, Clinical
No Distant Metastasis (M0)
Distant Metastasis (M1)
Nonregional Lymph Node(s) (M1a)
Bone(s) (M1b)
Other Site(s) (M1c)
Distant Metastasis Cannot Be Assessed
(MX)
Baseline Lab Values (hematologic)
Hemoglobin
g/dL
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ANC
1000/ul
Peripheral Platelet Count
1000/uL
ALT (SGPT)
U/L
ALT (SGPT) ULN
U/L
AST (SGOT)
U/L
AST (SGOT) ULN
U/L
Total Bilirubin
mg/dL
Bilirubin ULN
mg/dL
Alkaline Phosphatase
U/L
Alkaline Phosphatase ULN
U/L
Testosterone
ng/dl
Testosterone LLN
ng/dl
Testosterone ULN
ng/dl
Prostate: Treatment Schedule
LHRH agonist
Eligard (Eligard)
Lupron (Lupron)
Not Started (Not started)
Other (Other)
Viadur (Viadur)
Zoladex (Zoladex)
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Other, specify
LHRH agonist start date
Oral antiandrogen taken
Casodex (Casodex)
Eulexin (Eulexin)
Not Started (Not started)
Other (Other)
Other, specify
Oral Antiandrogen Start Date
Footer
Comments
Signature of Person Completing This Form
Date Form Originally Completed
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Pre-Study Form Head and Neck Cancer
Phase III RTOG 0920 I1 NCT00956007
NCT00956007  RTOG 0920 Phase III Head and Neck
Cancer Initial Evaluation Form (I1)
Radiation Therapy With or Without Cetuximab in Treating
Patients Who Have Undergone Surgery for Locally
Advanced Head and Neck Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=5D3AD2F7-
ECBD-0ECD-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11821
Pre-Study Form Head and Neck
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Header
RTOG Study No.
RTOG Case #
Institution Name
Institution No.
Patient Initials
RTOG Patient ID
Patient demographics
Age
>= 0
<= 120
years
Gender
Female (F)
Male (M)
Performance Status (ZUBROD)
Fully Active, Able To Carry On All Pre-
disease Performance Without
Restriction. (0)
Restricted In Physically Strenuous
Activity But Ambulatory And Able To
Carry Out Work Of A Light Or Sedentary
Nature, E.g., Light Housework, Office
Work. (1)
Ambulatory And Capable Of All Selfcare
But Unable To Carry Out Any Work
Activities. Up And About More Than 50%
Of Waking Hours. (2)
Capable Of Only Limited Selfcare,
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Confined To Bed Or Chair More Than
50% Of Waking Hours. (3)
Completely Disabled. Cannot Carry On
Any Selfcare. Totally Confined To Bed Or
Chair. (4)
Tumor Measurements At Presentation
Does the patient currently have swallowing
problems
No (No)
Unknown (Unknown)
Yes (Yes)
How long have swallowing problems been
present (If yes,)
1 To <7 Months (1 to <7 months)
13 To <19 Months (13 to <19 months)
19 To <24 Months (19 to <24 months)
2 Years Or Longer (2 years or longer)
7 To <13 Months (7 to <13 months)
Less Than 1 Month (Less than 1 month)
Unknown (Unknown)
Does the patient currently require tube feeding
No (No)
Unknown (Unknown)
Yes (Yes)
Is patient dependent on tube feeding for >50% of
nutritional support  (If yes,)
No (No)
Unknown (Unknown)
Yes (Yes)
Smoking History
Cigarette Smoker <20 Pack-years
(Cigarette smoker, <20 pack-years)
Cigarette Smoker >40 Pack-years
(Cigarette smoker, >40 pack-years)
Cigarette Smoker 20-40 Pack-years
(Cigarette smoker, 20-40 pack-years)
Never Smoked (Never smoked)
Pipe Or Cigar Smoker Only (Pipe or
cigar smoker only)
Unknown (Unknown)
Does the patient currently smoke (cigarettes)
No (No)
Unknown (Unknown)
Yes (Yes)
Number of Cigarettes per day
14 Or Fewer Per Day (14 or fewer per
day)
15-24 Per Day (15-24 per day)
25 Or More Per Day (25 or more per day)
Unknown (Unknown)
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Time since last cigarette
1 Month To <6 Months (1 month to <6
months)
1 Year To <5 Years (1 year to <5 years)
5 Years To <10 Years (5 years to <10
years)
6 Months To <1 Year (6 months to <1
year)
Less Than 1 Month (Less than 1 month)
More Than 10 Years (More than 10
years)
Never Smoked (Never smoked)
Unknown (Unknown)
Diagnostic Work-up
Basis of Diagnosis
Chest Ct (Chest CT)
Chest Pet/ct (Chest PET/CT)
Chest X-ray (Chest x-ray)
Ct Of The Primary Tumor And Neck (CT
of the primary tumor and neck)
History/physical Examination
(History/physical examination)
Mri Of The Primary Tumor And Neck
(MRI of the primary tumor and neck)
Pet/ct Of The Primary Tumor And Neck
(PET/CT of the primary tumor and neck)
Date of evaluation
DD.MM.YYYY
Baseline Lab Values (hematologic)
ANC
1000/ul
Date
Hemoglobin
g/dL
Date (MM DD YYYY)
Peripheral Platelet Count
1000/uL
Date (MM DD YYYY)
Bilirubin, total
mg/dL
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Total bilirubin LLN
mg/dL
Total Bilirubin ULN
Date (MM DD YYYY)
AST (SGOT)
U/L
AST LLN
U/L
AST (SGOT) ULN
U/L
Date (MM DD YYYY)
ALT (SGPT)
U/L
ALT LLN
U/L
ALT (SGPT) ULN
U/L
Date (MM DD YYYY)
Creatinine
mg/dL
Creatinine LLN
mg/dL
Creatinine ULN
mg/dL
Date
Creatinine Clearance
mL/min
Laboratory Tests
Histologic Type
Other (Other)
Squamous Cell Carcinoma, Including
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Variants (Squamous cell carcinoma,
including variants)
Other specify
Date of initial histologic diagnosis of malignancy
(MM DD YYYY)
Primary Site (If site within region cannot be
determined, specify region)
Aryepiglottic Fold (Aryepiglottic fold)
Arytenoid (Arytenoid)
Base Of Tongue (Base of tongue)
Buccal Mucosa (Buccal mucosa)
Faucial Arch (Faucial arch)
Floor Of Mouth (Floor of mouth)
Glottic Larynx Nos (GLOTTIC LARYNX,
NOS)
Hard Palate (Hard palate)
Infrahyoid Epiglottis (Infrahyoid epiglottis)
Lower Gingiva (Lower gingiva)
Oral Cavity Nos (ORAL CAVITY, NOS)
Oral Tongue (Oral tongue)
Oropharynx Nos (OROPHARYNX, NOS)
Other (OTHER)
Pharyngeal Oropharynx (Pharyngeal
Oropharynx)
Retromolar Trigone (Retromolar trigone)
Soft Palate (Soft Palate)
Subglottic (Subglottic)
Subglottic Larynx Nos (SUBGLOTTIC
LARYNX, NOS)
Supraglottic Larynx Nos
(SUPRAGLOTTIC LARYNX, NOS)
Suprahyoid Epiglottis (Suprahyoid
epiglottis)
Tonsillar Fossa Tonsil (Tonsillar fossa,
tonsil)
Unknown (UNKNOWN)
Upper Gingiva (Upper gingiva)
Ventricular Band (Ventricular band)
Vocal Cords (Vocal cords)
Other specify
Indicate other involved sites within region of
origin or extension at study entry (Use previous
codetable)
Are there multiple primary tumors
Yes
No
Tumor Measurements At Presentation
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Primary Tumor Laterality
Left (Left)
Midline (Midline)
Right (Right)
Clinical T Stage (prior to surgery includes clinical
and radiographic findings)
T0, According To Ajcc Criteria (T0)
T1, According To Ajcc Criteria (T1)
T2, According To Ajcc Criteria (T2)
T3, According To Ajcc Criteria (T3)
T4, According To Ajcc Criteria (T4)
Tis, According To Ajcc Criteria (TIS)
Tx, According To Ajcc Criteria (TX)
Pathologic T Stage (after surgery surgical-
pathologic)
Pt0, According To Ajcc Criteria (pT0)
Pt1, According To Ajcc Criteria (pT1)
Pt2, According To Ajcc Criteria (pT2)
Pt3, According To Ajcc Criteria (pT3)
Pt4, According To Ajcc Criteria (pT4)
Pt4a, According To Ajcc Guidelines
(pT4a)
Pt4b, According To Ajcc Guidelines
(pT4b)
Ptis, According To Ajcc Criteria (pTis)
Ptx, According To Ajcc Criteria (pTX)
Clinical N Stage (prior to surgery includes clinical
and radiographic findings)
N0, According To Ajcc Guidelines (N0)
N1, According To Ajcc Criteria (N1)
N2a, According To Ajcc Guidelines (N2a)
N2b, According To Ajcc Guidelines (N2b)
N2c, According To Ajcc Guidelines (N2c)
N3, According To Ajcc Guidelines (N3)
Nx, According To Ajcc Guidelines (NX)
Clinical N Stage, Right side
N0, According To Ajcc Guidelines (N0)
N1, According To Ajcc Criteria (N1)
N2, According To Ajcc Criteria (N2)
N2a, According To Ajcc Guidelines (N2a)
N2b, According To Ajcc Guidelines (N2b)
N2c, According To Ajcc Guidelines (N2c)
N3, According To Ajcc Guidelines (N3)
Nx, According To Ajcc Guidelines (NX)
Clinical N Stage, Left side
N0, According To Ajcc Guidelines (N0)
N1, According To Ajcc Criteria (N1)
N2, According To Ajcc Criteria (N2)
N2a, According To Ajcc Guidelines (N2a)
N2b, According To Ajcc Guidelines (N2b)
N2c, According To Ajcc Guidelines (N2c)
N3, According To Ajcc Guidelines (N3)
Nx, According To Ajcc Guidelines (NX)
Pathologic N stage (after surgery surgical-
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pathologic)
Pn0, According To Ajcc Guidelines (pN0)
Pn1, According To Ajcc Criteria (pN1)
Pn2, According To Ajcc Criteria (pN2)
Pn2a, According To Ajcc Guidelines
(pN2a)
Pn2b, According To Ajcc Guidelines
(pN2b)
Pn2c, According To Ajcc Guidelines
(pN2c)
Pn3, According To Ajcc Guidelines (pN3)
Pnx, According To Ajcc Guidelines (pNX)
Pathologic N Stage, Right side
Pn0, According To Ajcc Guidelines (pN0)
Pn1, According To Ajcc Criteria (pN1)
Pn2, According To Ajcc Criteria (pN2)
Pn2a, According To Ajcc Guidelines
(pN2a)
Pn2b, According To Ajcc Guidelines
(pN2b)
Pn2c, According To Ajcc Guidelines
(pN2c)
Pn3, According To Ajcc Guidelines (pN3)
Pnx, According To Ajcc Guidelines (pNX)
Pathologic N Stage, Left side
Pn0, According To Ajcc Guidelines (pN0)
Pn1, According To Ajcc Criteria (pN1)
Pn2, According To Ajcc Criteria (pN2)
Pn2a, According To Ajcc Guidelines
(pN2a)
Pn2b, According To Ajcc Guidelines
(pN2b)
Pn2c, According To Ajcc Guidelines
(pN2c)
Pn3, According To Ajcc Guidelines (pN3)
Pnx, According To Ajcc Guidelines (pNX)
Clinical M Stage
M0, According To Ajcc Guidelines (M0)
M1, According To Ajcc Staging
Definitions (M1)
Surgery And Pathologic Risk Factors
Primary Surgery Date
Surgical procedure
Primary Alone (Primary alone)
Primary And Bilateral Neck Dissection
(Primary and bilateral neck dissection)
Primary And Unilateral Neck Dissection
(Primary and unilateral neck dissection)
Serious nonhealing wound
Yes
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No
Was a complete resection of the primary tumor
done
Yes
No
Positive microscopic margins involved on final
specimen
No (NO)
Not Applicable (Not applicable)
Yes (YES)
Extracapsular spread
No (NO)
Not Applicable (Not applicable)
Yes (YES)
Perineural Involvement
No (NO)
Not Applicable (Not applicable)
Yes (YES)
Lymphovascular Invasion
No (NO)
Not Applicable (Not applicable)
Yes (YES)
Simple lymph node >3cm or >= 2 lymph nodes all
< 6cm ([NO EXTRACAPSULAR EXTENSION])
No (NO)
Not Applicable (Not applicable)
Yes (YES)
Close margins of resection (<=5mm)
No (NO)
Not Applicable (Not applicable)
Yes (YES)
T3 or microscopic T4a primary tumor
No (NO)
Not Applicable (Not applicable)
Yes (YES)
T2 oral cavity cancer with > 5mm depth of
invasion
No (NO)
Not Applicable (Not applicable)
Yes (YES)
Number of Lymph Nodes Examined
Number of Positive Lymph Nodes
Prior Treatment
Prior Surgery (other than study cancer)
8 / 11
Pre-Study Form Head and Neck Cancer Phase III RTOG 0920 I1
NCT00956007
Yes
No
Date (of most recent)
Specify (Treatment site)
Prior Radiation Therapy (to head and neck that
would result in overlap of RT fields)
Yes
No
Date of Last Treatment (MM DD YYYY)
Prior Chemotherapy (FOR OTHER REASONS)
No (No)
Unknown (Unknown)
Yes (Yes)
Agent Name
Prior allergic reaction to study agent
No (No)
Unknown (Unknown)
Yes (Yes)
Prior therapy that targeted EGFR pathway (for
other reasons)
No (No)
Unknown (Unknown)
Yes (Yes)
History of Prior Malignancy (INVASIVE OTHER
THAN STUDY SITE)
No (No)
Unknown (Unknown)
Yes (Yes)
Site of Prior Cancer
Prior cancer date eradicated (MM DD YYYY)
Co-morbidities
Unstable angina
No (No)
Unknown (Unknown)
Yes (Yes)
Congestive heart failure
No (No)
Unknown (Unknown)
Yes (Yes)
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Heart problems (Transmural myocardial
infarction)
No (No)
Unknown (Unknown)
Yes (Yes)
Electrolyte abnormalities (CTCAE v 3.0 grade 3-
4)
No (No)
Unknown (Unknown)
Yes (Yes)
Infection (Acute bacterial or fungal requiring IV
antibiotics)
No (No)
Unknown (Unknown)
Yes (Yes)
COPD
No (No)
Unknown (Unknown)
Yes (Yes)
Clinical jaundice
No (No)
Unknown (Unknown)
Yes (Yes)
Coagulation defects
No (No)
Unknown (Unknown)
Yes (Yes)
AIDS
No (No)
Unknown (Unknown)
Yes (Yes)
Pulmonary fibrosis
No (No)
Unknown (Unknown)
Yes (Yes)
Interstitial lung disease
No (No)
Unknown (Unknown)
Yes (Yes)
Protocol Specific Adverse Event
Evaluation
CTC AE Term
Dysphagia (Dysphagia (difficulty
swallowing))
CTC AE Grade
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CTCAE Begin Date
Comments
Comments
Person Completing Form
Form completion date
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Eligibility Breast Cancer N1131
3233760v1.0
Eligibility Breast Cancer N1131 3233760v1.0
N1131 Eligibility Checklist
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=A289006B-
0940-443F-E040-BB89AD430449
All rights reserved. Please visit https://medical-data-
models.org/forms/11822
Eligibility Breast Cancer N1131
3233760v1.0
Required Characteristics
18 Years and older
Yes
No
Age
>= 0
<= 120
years
Histologically or cytologically confirmed estrogen
receptor positive (ER+) (defined as >1% staining)
adenocarcinoma of the breast with clinical
evidence of metastatic disease
Yes
No
Pre-treatment requirements:a.<=2 prior hormonal
treatments in any settingNote: For
premenopausal patients prior therapy must have
included tamoxifen.Note: For postmenopausal
patients prior therapy must have included an
aromatase inhibitor (AI).b.No prior chemotherapy
for metastatic disease.Note: Prior chemotherapy
allowed in neoadjuvant and/or adjuvant setting
only.c.No prior lung radiation therapy.Note: Chest
wall radiation for breast cancer is allowed.
Yes
No
Measurable disease as defined in Section 11.0
Yes
No
Adequate pulmonary function: normal DLCO or
the presence of an asymptomatic Grade 1 DLCO
per grading criteria found in Appendix III (NOTE:
DLCO must be corrected for hemoglobin.)
Yes
No
Negative pregnancy test done <=7 days prior to
registration, for women of childbearing potential
only. If not a woman of childbearing potential or
male (check NA)
N/a (N/A)
No (No)
Yes (Yes)
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Negative pregnancy test date (If a woman of
childbearing potential)
The following laboratory values obtained <=15
days prior to registration
Yes
No
Earliest laboratory test date
Latest laboratory test date (Note:  These dates
pertain to the following labs only.)
Hemoglobin >=9.0 g/dL
Yes
No
Hemoglobin
g/dL
Absolute neutrophil count (ANC) >=1500/mm3
Yes
No
ANC
1000/ul
Peripheral platelet count (PLT) >=100,000/mm3
Yes
No
Peripheral Platelet Count
1000/uL
Total bilirubin <=1.5 x upper limit of normal (ULN)
Yes
No
Bilirubin, total
mg/dL
Total bilirubin ULN
mg/dL
Alkaline phosphatase <=2.5 x ULN or alkaline
phosphatase <=5 x ULN if elevations are due to
liver metastases
Yes
No
Is there liver metastatic involvement (This
question may be answered yes or no)
Yes
No
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Alkaline Phosphatase (if yes <=5 x ULN if no
<=2.5 x ULN)
Alkaline Phosphatase ULN
U/L
SGOT (AST) and SGPT (ALT) <=3 x ULN or
SGOT (AST) and SGPT (ALT) <=5 x ULN if
elevations are due to liver metastases
Yes
No
SGOT (AST) (if yes <=5 x ULN if no <=3 x ULN)
AST (SGOT) ULN
U/L
ALT (SGPT)
U/L
ALT (SGPT) ULN
U/L
Serum creatinine <=1.5 x ULN; if >1.25 x ULN
calculated creatinine clearance must be >=60
ml/min
Yes
No
Creatinine
mg/dL
Serum Creatinine ULN
mg/dL
Is Serum creatinine >1.25 x ULN
Yes (Yes)
Creatinine Clearance
mL/min
ECOG performance status (PS) 0, 1, or 2
Yes
No
ECOG Performance Status
Fully Active, Able To Carry On All Pre-
disease Performance Without
Restriction. (0)
Restricted In Physically Strenuous
Activity But Ambulatory And Able To
Carry Out Work Of A Light Or Sedentary
Nature, E.g., Light Housework, Office
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Work. (1)
Ambulatory And Capable Of All Selfcare
But Unable To Carry Out Any Work
Activities. Up And About More Than 50%
Of Waking Hours. (2)
Life expectancy >3 months
Yes
No
Willingness to return to NCCTG enrolling
institution for treatment and follow-up
Yes
No
Willing to provide tissue and blood samples for
correlative research purposes (see Sections 6.0,
14.0 and 17.0)
Yes
No
Provide informed written consent
Yes
No
Exclusion Criteria
Known standard therapy for the patient's disease
that is potentially curative or definitely capable of
extending life expectancy
Yes
No
Prior thoracic radiotherapy.  Note: Chest wall
radiotherapy for breast cancer is allowed
Yes
No
Symptomatic pulmonary disease
Yes
No
Uncontrolled intercurrent illness including, but not
limited to, ongoing or active infection,
symptomatic congestive heart failure, unstable
angina pectoris, cardiac arrhythmia, or psychiatric
illness/social situations that would limit
compliance with study requirements
Yes
No
Chemotherapy <=3 weeks prior to study entry
(Any of the following prior therapies: If no prior
chemotherapy check NA)
Not Applicable (NA)
No (No)
Yes (Yes)
Last day of chemotherapy (If prior chemotherapy)
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Mitomycin C/nitrosoureas <=6 weeks prior to
study entry (If no prior mitomycin C/nitrosoureas
check NA)
Not Applicable (NA)
No (No)
Yes (Yes)
Last day of mitomycin C/nitrosoureas (If prior
mitomycin C/nitrosoureas)
Immunotherapy <=3 weeks prior to study entry (If
no prior immunotherapy check NA)
Not Applicable (NA)
No (No)
Yes (Yes)
Last day of immunotherapy (If prior
immunotherapy)
Biologic therapy <=3 weeks prior to study entry (If
no prior biologic therapy check NA)
Not Applicable (NA)
No (No)
Yes (Yes)
Last day of biologic therapy (If prior biologic
therapy)
Radiation therapy <=3 weeks prior to study entry
(If no prior radiation therapy check NA)
Not Applicable (NA)
No (No)
Yes (Yes)
Last day of radiation therapy (If prior radiation
therapy NOTES: Prior radiation to a target lesion
is permitted only if there has been clear
progression of the lesion since radiation was
completed. If patient receives single dose
radiation for palliation or radiation to non-target
lesion, they may immediately proceed to
registration without waiting 2 weeks Acute
adverse events from radiation must have resolved
to <=Grade 1 according to the CTEP Active
Version of the CTCAE.)
Failure to fully recover from acute, reversible
effects of prior chemotherapy regardless of
interval since last treatment
Yes
No
Uncontrolled brain metastases including patients
who continue to require glucocorticoids for brain
or leptomeningeal metastases (Note: Patients
with CNS metastases that are stable for at least 8
weeks prior to registration based on imaging,
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clinical assessment, and use of steroids are
eligible.)
Yes
No
Any of the following because this study involves
an investigational agent whose genotoxic,
mutagenic and teratogenic effects on the
developing fetus and newborn are unknown.
-	Pregnant women
-	Nursing women
-	Men or women of childbearing potential who are
unwilling to employ adequate contraception (as
determined by the treating physician) while on
this study and for 30 days after end of treatment
with the study drugs
Yes
No
History of allergy or hypersensitivity to agents
chemically similar to AFP464
Yes
No
Active smokers and those who have smoked
<=30 days prior to registration, and patients
unwilling or unable to completely refrain from
smoking while on study
Yes
No
New York Heart Association class III or IV
cardiovascular disease
Yes
No
Co-morbid systemic illnesses or other severe
concurrent disease which, in the judgment of the
investigator, would make the patient inappropriate
for entry into this study or interfere significantly
with the proper assessment of the safety and
adverse events of the prescribed regimens
Yes
No
Currently receiving treatment in a different clinical
study in which investigational procedures are
performed or investigational therapies are
administered
Yes
No
Immunocompromised patients (other than that
related to the use of corticosteroids) including
patients known to be HIV positive
Yes
No
Other active malignancy <=3 years prior to
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registration. EXCEPTIONS: Non-melanotic skin
cancer or carcinoma-in-situ of the cervix. NOTE:
If there is a history of prior malignancy, they must
not be receiving other specific
treatment (other than hormonal therapy) for their
cancer
Yes
No
Pre-registration Check
Consent form signed and dated
Yes
No
Date Informed Consent Signed
Authorization for use and disclosure of protected
health information signed and dated (U.S.A,
institutions only If not a USA institution check NA)
Not Applicable (NA)
No (No)
Yes (Yes)
Date of authorization (If a USA institution)
A mandatory translational research component is
part of this study,  patients will automatically be
registered to the translational research
component of this study at the time of
registration. (see Sections 3 and 17)
Yes
No
Treatment cannot begin prior to registration and
must begin <=14 days after registration
Yes
No
Pretreatment tests/procedures must be
completed <=15 days prior to registration (see
Section 4.0)
Yes
No
Earliest pretreatment test/procedure date (NOTE:
The earliest pretreatment test date must be less
than or equal to the earliest laboratory test date
and the latest pretreatment test date must be
greater than or equal to the latest laboratory test
date.)
Latest pretreatment test/procedure date
Earliest exception test date (Exceptions to the
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above dates: Tumor measurement, Chest X-ray,
Bone or PET scan, and Brain CT or MRI to be
completed <=22 days prior to registration.)
latest exception test date
All required baseline symptoms (see Section
10.3) must be documented and graded
Yes
No
Treatment on this protocol must commence at an
NCCTG institution under the supervision of an
NCCTG member physician
Yes
No
Blood draw kit is available on site (for this patient)
Yes
No
An optional correlative research component is
part of this study, there will be an option to select
if the patient is to be registered onto this
component (see Section 14)
Yes
No
Patient has given permission to store and use
his/her sample(s) for use in future research to
learn about, prevent, or treat cancer
Yes
No
Patient has given permission to store and use
his/her sample(s) for use in future research to
learn about, prevent, or treat other health
problems (for example: diabetes, Alzheimer's
disease, or heart disease)
Yes
No
Patient has given permission for NCCTG to give
his/her sample(s) to outside researchers
Yes
No
Patient has agreed to be enrolled on N0392
(NOTE: N0392 must be open to site and offered
to patient.  At time of registration, willingness to
participate will be recorded.)
Yes
No
Treatment Decision
Subgroup Code
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Sg1 (SG1)
Assigned Treatment
Afp464 (AFP464)
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Registration Glioblastoma Multiforme
N0874 NCT00731731
N0874 Registration (Step 2) Eligibility Checklist
NCT00731731 
Vorinostat, Temozolomide, and Radiation Therapy in
Treating Patients With Newly Diagnosed Glioblastoma
Multiforme
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=7E51877D-
925A-72BF-E040-BB89AD436E3B
All rights reserved. Please visit https://medical-data-
models.org/forms/11823
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Header
Registration Date (mm/dd/yyyy)
NCCTG Patient ID
Participating Group Code (participant sponsor)
Institution (treating location)
Physician of Record
Patient Medical Record Number
Last name
First Name
Phone
Fax
E-mail
Patient Demographics / Pre-treatment
Characteristics
Patient Initials
Gender
Female (FEMALE)
Male (MALE)
Unknown (UNKNOWN)
Date of Birth
Zip code
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Country of Residence
Method of Payment (check oneUSA only)
Medicaid (Medicaid)
Medicaid And Medicare (Medicaid and
Medicare)
Medicare (Medicare)
Medicare And Private Insurance
(Medicare and Private Insurance)
Military Or Veterans Sponsored Nos
(Military or Veterans Sponsored, Not
Otherwise Specified (NOS))
Military Sponsored (including Champus
& Tricare) (Military Sponsored (including
CHAMPUS & TRICARE))
No Means Of Payment (no Insurance)
(No means of payment (no insurance))
Other (Other)
Private Insurance (Private Insurance)
Self Pay (no Insurance) (Self Pay (No
Insurance))
Unknown (Unknown)
Veterans Sponsored (Veterans
Sponsored)
Race
A Person Having Origins In Any Of The
Original Peoples Of North And South
America (including Central America),
And Who Maintains Tribal Affiliation Or
Community Attachment. (American
Indian or Alaska Native)
A Person Having Origins In Any Of The
Original Peoples Of The Far East,
Southeast Asia, Or The Indian
Subcontinent Including, For Example,
Cambodia, China, India, Japan, Korea,
Malaysia, Pakistan, The Philippine
Islands, Thailand, And Vietnam. (Asian)
A Person Having Origins In Any Of The
Black Racial Groups Of Africa. Terms
Such As "haitian" Or "negro" Can Be
Used In Addition To "black Or African
American." (Black or African American)
A Person Having Origins In Any Of The
Original Peoples Of Hawaii, Guam,
Samoa, Or Other Pacific Islands. (Native
Hawaiian or other Pacific Islander)
Not Provided Or Available (Not
Reported)
Could Not Be Determined Or Unsure
(Unknown)
A Person Having Origins In Any Of The
Original Peoples Of Europe, The Middle
East, Or North Africa. (White)
Ethnicity
A Person Of Mexican, Puerto Rican,
Cuban, Central Or South American Or
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Other Spanish Culture Or Origin,
Regardless Of Race. (HISPANIC OR
LATINO)
A Person Not Meeting The Definition For
Hispanic Or Latino. (NOT HISPANIC OR
LATINO)
Not Provided Or Available (Not reported)
Could Not Be Determined Or Unsure
(UNKNOWN)
Pre-treatment Requirements
18 Years and older
Yes
No
Age
>= 0
<= 120
years
Histologically confirmed glioblastoma multiforme
as determined by pre-registration central
pathology review
Yes
No
Bidimensionally measurable or evaluable disease
by gadolinium MRI or contrast CT scan
Yes
No
Must begin partial brain radiotherapy on the same
day that vorinostat and temozolomide begin.
NOTE: Radiotherapy guidelines are detailed in
Section 7.1.
Yes
No
Karnofsky performance status of >=60 (Appendix
II) or ECOG performance status 0, 1, or 2
(Appendix V). The same scoring system should
be used throughout the study
Yes
No
Which scoring system will be used throughout the
study
Ecog Performance Status (ECOG
Performance Status)
Karnofsky Performance Status
(Karnofsky Performance Status)
Karnofsky Performance Status
%
Dead (0)
Moribund, Fatal Processes Progressing
Rapidly (10)
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Normal, No Complaints, No Evidence Of
Disease (100)
Very Sick, Hospitalization Indicated.
Death Not Imminent (20)
Severely Disabled, Hospitalization
Indicated. Death Not Imminent (30)
Disabled, Requires Special Care And
Assistance (40)
Requires Considerable Assistance And
Frequent Medical Care (50)
Requires Occasional Assistance, But Is
Able To Care For Most Of His/her Needs
(60)
Cares For Self, Unable To Carry On
Normal Activity Or To Do Active Work
(70)
Normal Activity With Effort; Some Signs
Or Symptoms Of Disease (80)
Able To Carry On Normal Activity; Minor
Signs Or Symptoms Of Disease (90)
Performance Status
Fully Active, Able To Carry On All Pre-
disease Performance Without
Restriction. (0)
Restricted In Physically Strenuous
Activity But Ambulatory And Able To
Carry Out Work Of A Light Or Sedentary
Nature, E.g., Light Housework, Office
Work. (1)
Ambulatory And Capable Of All Selfcare
But Unable To Carry Out Any Work
Activities. Up And About More Than 50%
Of Waking Hours. (2)
Capable Of Only Limited Selfcare,
Confined To Bed Or Chair More Than
50% Of Waking Hours. (3)
Completely Disabled. Cannot Carry On
Any Selfcare. Totally Confined To Bed Or
Chair. (4)
Dead (5)
The following laboratory values obtained <= 14
days prior to registration
Yes
No
Earliest laboratory test date (Note: These dates
pertain to the following labs only.)
Latest laboratory test date
ANC >= 1500/mL
Yes
No
ANC
1000/ul
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PLT >= 100,000/mL
Yes
No
Peripheral Platelet Count
1000/uL
WBC >= 3,000/mL
Yes
No
WBC
/ul
HgB >=10.0 g/dL (Note:  This level may be
reached by transfusion)
Yes
No
Hemoglobin
g/dL
Total bilirubin <= 2.0 x ULN
Yes
No
Bilirubin, total
mg/dL
Total bilirubin ULN
mg/dL
SGOT (AST) <= 2.0 X ULN
Yes
No
AST (SGOT)
U/L
AST (SGOT) ULN
U/L
Creatinine <= 1.5 mg/dL
Yes
No
Creatinine
mg/dL
Life expectancy >=12 weeks
Yes
No
Negative pregnancy test done <=7 days prior to
registration, for women of childbearing potential
only. (If not a woman of childbearing potential
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check NA)
Yes
No
Negative serum pregnancy test date (If a woman
of childbearing potential)
Phase II patient only: Willing and able to
complete neurocognitive (see Section 4.2).
Yes
No
Ability to provide informed written consent
Yes
No
Willingness to return to NCCTG or ABTC
enrolling institution for follow-up
Yes
No
Phase II patients: Willing to provide mandatory
tissue samples (slides or blocks) for research
purposes (see Sections 6.1130 and 17.0).
Yes
No
Willing to forego other cytotoxic and non-cytotoxic
drug therapy against the tumor while being
treated with vorinostat and temozolomide
Yes
No
Exclusion Criteria
Any of the following:  Pregnant women, Nursing
women, Men or women of childbearing potential
who are unwilling to employ adequate
contraception throughout the duration of the
study and for 12 weeks after treatment has ended
(Note:  Vorinostat is an investigational agent
whose genotoxic effects on the developing fetus
and newborn are unknown.)
Yes
No
Prior cytotoxic drug therapy, non-cytotoxic drug
therapy, or experimental drug therapy for brain
tumors
Yes
No
Prior cranial RT
Yes
No
Prior Gliadel wafers
Yes
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No
Known hypersensitivity to any of the components
of vorinostat or other agents used in the study
Yes
No
Valproic acid, another histone deacetylase
inhibitor, <=2 weeks prior to registration and
during treatment.
Yes
No
Other active malignancy <=3 years prior to
registration. EXCEPTIONS: Non-melanotic skin
cancer or carcinoma-in-situ of the cervix. NOTE:
If there is a history of prior malignancy, they must
not be receiving other specific
treatment (other than hormonal therapy) for their
cancer
Yes
No
Uncontrolled infection
Yes
No
Immunocompromised patients and patients
known to be HIV positive and currently receiving
antiretroviral therapy.  NOTE: Patients known to
be HIV positive, but without clinical evidence of
an immunocompromised state, are eligible for this
trial.
Yes
No
Co-morbid systemic illnesses or other severe
concurrent disease which, in the judgment of the
investigator, would make the patient inappropriate
for entry into this study or interfere significantly
with the proper assessment of the safety and
adverse events of the prescribed regimens
Yes
No
Uncontrolled intercurrent illness including, but not
limited to, ongoing or active infection, or
psychiatric illness/social situations that would
limit compliance with study requirements
Yes
No
History of myocardial infarction or unstable
angina <=6 months prior to registration or
congestive heart failure(CHF) requiring use of
ongoing maintenance therapy, or life-threatening
ventricular arrhythmias
Yes
No
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Inability to take oral medications
Yes
No
Receiving any other investigational agent which
would be considered as a treatment for the
primary neoplasm
Yes
No
Congenital long QT syndrome
Yes
No
Prolonged QTc interval (>450 msec)
Yes
No
Any of the following Category I drugs that are
generally accepted to have a risk of causing
Torsades de Pointes <=7 days prior to
registration: Quinidine, procainamide,
disopyramide; Amiodarone, sotalol, ibutilide,
dofetilide;  Erythromycin, clarithromycin;
Chlorpromazine, haloperidol, mesoridazine,
thioridazine, pimozide; Cisapride, bepridil,
droperidol, methadone, arsenic, chloroquine,
domperidone, halofantrine, levomethadyl,
pentamidine, sparfloxacin, lidoflazine
Yes
No
Registration Check
Treatment on this protocol must commence at the
accruing membership under the supervision of an
NCCTG or ABTC member physician
Yes
No
Treatment cannot begin prior to registration and
must begin <=15 days after registration
Yes
No
Pretreatment tests/procedures must be
completed <= 21 days prior to registration
Yes
No
Earliest pretreatment test/procedure date
Latest pretreatment test/procedure date
Earliest exception test/procedure date
(Exceptions to the above dates: Hematology &
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Chemistry must be completed <= 14 days prior to
registration see Section 4.0.)
latest exception test/procedure date
All required baseline symptoms must be
documented and graded
Yes
No
Study drug availability checked
Yes
No
Phase II patients: A mandatory translational
research component for tissue (slides or blocks)
is part of this study; the patient will be
automatically registered onto this component
(Sections 3.29d and 17.4).
Yes
No
Grouping Factor
Phase
Tests The Activity Of An Agent In A Set
Of Diseases (II)
Subgroup Code
Sg1 - Phase I (dose Escalation) (SG1 -
Phase I (dose escalation))
Sg2 - Phase I (mtd) (SG2 - Phase I
(MTD))
Sg3 - Phase Ii (SG3 - Phase II)
At The Time Of
Registration/randomization, The Following
Will Also Be Recorded:
Patient has given permission to keep tissue
sample(s) for use in future research to learn
about, prevent, or treat cancer
Yes
No
Patient has given permission to store and use
his/her sample(s) for use in future research to
learn about, prevent, or treat cancer (At the time
of registration, the following will be recorded:)
Yes
No
Patient has given NCCTG permission to give
tissue sample(s) to outside researchers
Yes
No
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Someone may contact me in the future to ask me
to allow other uses of my specimens.
Yes
No
Patient has given permission to keep tissue
sample(s) for use in genetic research
Yes
No
Is this an NCCTG institution
Yes
No
Patient has agreed to be enrolled on N0392
Yes
No
Patient has agreed to be enrolled on 94-72-52
Yes
No
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Initial Evaluation Head and Neck Cancer
Stage III or IV RTOG-0522 I1 NCT00265941
RTOG-0522 I1: Initial Evaluation Form NCT00265941
Radiation Therapy and Cisplatin With or Without Cetuximab
in Treating Patients With Stage III or Stage IV Head and
Neck Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=F64A912E-
BA2D-250A-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11825
Initial Evaluation Head and Neck
Cancer Stage III or IV RTOG-0522 I1
NCT00265941
Header
RTOG Study No.
RTOG Case #
Institution Name
Institution No.
Patient Initials
RTOG Patient ID
Amended data
Yes
No
Patient demographics
Age
>= 0
<= 120
years
Gender
Female (F)
Male (M)
PERFORMANCE STATUS (ZUBROD)
Fully Active, Able To Carry On All Pre-
disease Performance Without
Restriction. (0)
Restricted In Physically Strenuous
Activity But Ambulatory And Able To
Carry Out Work Of A Light Or Sedentary
Nature, E.g., Light Housework, Office
Work. (1)
Ambulatory And Capable Of All Selfcare
But Unable To Carry Out Any Work
Activities. Up And About More Than 50%
Of Waking Hours. (2)
1 / 10
Capable Of Only Limited Selfcare,
Confined To Bed Or Chair More Than
50% Of Waking Hours. (3)
Completely Disabled. Cannot Carry On
Any Selfcare. Totally Confined To Bed Or
Chair. (4)
History of Prior Malignancy (INVASIVE EXCEPT
NON-MELANOMATOUS SKIN CANCER)
Yes
No
Site of Prior Cancer
Prior Cancer Date Eradicated
Prior Treatment
Prior Surgery (FOR HEAD AND NECK CANCER-
EXCLUDES DIAGNOSTIC BIOPSY AND NODAL
SAMPLING)
Yes
No
Prior Chemotherapy (FOR OTHER REASONS)
Yes
No
Prior Radiation Therapy (FOR HEAD AND NECK
CANCER)
Yes
No
Prior therapy that targeted EGFR pathway (Type
shown on CRF - "EGRF")
Yes
No
Co-morbidities
Hospitalized for unstable angina and/or CHF in
last 6 months
Yes
No
Transmural MI in last 6 months
Yes
No
IV antibiotics at time of registration
Yes
No
COPD exacerbation or other respiratory illness
requiring hospitalization or precluding study
therapy at registration
Yes
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No
Prior allergic reaction to Cisplatin
Yes
No
Prior allergic reaction to C225
Yes
No
Diagnostic Work-up
CT scan of tumor site
Abnormal (Abnormal)
Normal (Normal)
Not Done (Not done)
MRI result (of tumor site)
Abnormal (Abnormal)
Normal (Normal)
Not Done (Not done)
PET/CT
Abnormal (Abnormal)
Normal (Normal)
Not Done (Not done)
PET/CT chest
Abnormal (Abnormal)
Normal (Normal)
Not Done (Not done)
Chest X-Ray Result
Abnormal (Abnormal)
Normal (Normal)
Not Done (Not done)
Chest CT
Abnormal (Abnormal)
Normal (Normal)
Not Done (Not done)
ECHO and/or MUGA
Abnormal (Abnormal)
Normal (Normal)
Not Done (Not done)
Baseline LVEF
Abnormal (Abnormal)
Normal (Normal)
Not Done (Not done)
Baseline LVEF
%
Laboratory Tests
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ANC
Abnormal (Abnormal, eligibility not
affected)
Abnormal Not Eligible (Abnormal, not
eligible)
Not Done (Not done)
Normal (Within normal limits)
Platelet Count
Abnormal (Abnormal, eligibility not
affected)
Abnormal Not Eligible (Abnormal, not
eligible)
Not Done (Not done)
Normal (Within normal limits)
Hemoglobin
Abnormal (Abnormal, eligibility not
affected)
Abnormal Not Eligible (Abnormal, not
eligible)
Not Done (Not done)
Normal (Within normal limits)
Hemoglobin
g/dL
Bilirubin
Abnormal (Abnormal, eligibility not
affected)
Abnormal Not Eligible (Abnormal, not
eligible)
Not Done (Not done)
Normal (Within normal limits)
SGOT (AST)
Abnormal (Abnormal, eligibility not
affected)
Abnormal Not Eligible (Abnormal, not
eligible)
Not Done (Not done)
Normal (Within normal limits)
SGPT (ALT)
Abnormal (Abnormal, eligibility not
affected)
Abnormal Not Eligible (Abnormal, not
eligible)
Not Done (Not done)
Normal (Within normal limits)
Serum Creatinine
Abnormal (Abnormal, eligibility not
affected)
Abnormal Not Eligible (Abnormal, not
eligible)
Not Done (Not done)
Normal (Within normal limits)
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Creatinine Clearance
Abnormal (Abnormal, eligibility not
affected)
Abnormal Not Eligible (Abnormal, not
eligible)
Not Done (Not done)
Normal (Within normal limits)
Serum Calcium
Abnormal (Abnormal, eligibility not
affected)
Abnormal Not Eligible (Abnormal, not
eligible)
Not Done (Not done)
Normal (Within normal limits)
Corrected Serum Calcium
Abnormal (Abnormal, eligibility not
affected)
Abnormal Not Eligible (Abnormal, not
eligible)
Not Done (Not done)
Normal (Within normal limits)
Ionized Serum Calcium
Abnormal (Abnormal, eligibility not
affected)
Abnormal Not Eligible (Abnormal, not
eligible)
Not Done (Not done)
Normal (Within normal limits)
Magnesium
Abnormal (Abnormal, eligibility not
affected)
Abnormal Not Eligible (Abnormal, not
eligible)
Not Done (Not done)
Normal (Within normal limits)
Primary Site (If site within region cannot be
determined, specify region)
Antrum (Antrum)
Aryepiglottic Fold (Aryepiglottic fold)
Arytenoid (Arytenoid)
Base Of Tongue (Base of tongue)
Buccal Mucosa (Buccal mucosa)
Ethmoid (Ethmoid)
Faucial Arch (Faucial arch)
Floor Of Mouth (Floor of mouth)
Frontal (Frontal)
Glottic Larynx Nos (GLOTTIC LARYNX,
NOS)
Hard Palate (Hard palate)
Hypopharynx Nos (HYPOPHARYNX,
NOS)
Infrahyoid Epiglottis (Infrahyoid epiglottis)
Lateral Wall (Lateral wall)
Lower Gingiva (Lower gingiva)
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Nasal Cavity (Nasal cavity)
Nasopharynx Nos (NASOPHARYNX,
NOS)
Nose Nos (NOSE, NOS)
Oral Cavity Nos (ORAL CAVITY, NOS)
Oral Tongue (Oral tongue)
Oropharynx Nos (OROPHARYNX, NOS)
Other (OTHER)
Paranasal Sinuses Nos (PARANASAL
SINUSES, NOS)
Pharyngeal Oropharynx (Pharyngeal
Oropharynx)
Postcricoid Area (Postcricoid area)
Posterior Superior Wall (Posterior
superior wall)
Posterior Wall (Posterior wall)
Pyriform Fossa (Pyriform fossa)
Retromolar Trigone (Retromolar trigone)
Soft Palate (Soft Palate)
Sphenoid (Sphenoid)
Subglottic (Subglottic)
Subglottic Larynx Nos (SUBGLOTTIC
LARYNX, NOS)
Supraglottic Larynx Nos
(SUPRAGLOTTIC LARYNX, NOS)
Suprahyoid Epiglottis (Suprahyoid
epiglottis)
Tonsillar Fossa Tonsil (Tonsillar fossa,
tonsil)
Unknown (UNKNOWN)
Upper Gingiva (Upper gingiva)
Ventricular Band (Ventricular band)
Vocal Cords (Vocal cords)
Other specify
Indicate other involved sites within region of
origin or extension at study entry (Use previous
codetable)
Antrum (Antrum)
Aryepiglottic Fold (Aryepiglottic fold)
Arytenoid (Arytenoid)
Base Of Tongue (Base of tongue)
Buccal Mucosa (Buccal mucosa)
Ethmoid (Ethmoid)
Faucial Arch (Faucial arch)
Floor Of Mouth (Floor of mouth)
Frontal (Frontal)
Glottic Larynx Nos (GLOTTIC LARYNX,
NOS)
Hard Palate (Hard palate)
Hypopharynx Nos (HYPOPHARYNX,
NOS)
Infrahyoid Epiglottis (Infrahyoid epiglottis)
Lateral Wall (Lateral wall)
Lower Gingiva (Lower gingiva)
Nasal Cavity (Nasal cavity)
Nasopharynx Nos (NASOPHARYNX,
NOS)
6 / 10
Initial Evaluation Head and Neck Cancer Stage III or IV RTOG-0522 I1
NCT00265941
Nose Nos (NOSE, NOS)
Oral Cavity Nos (ORAL CAVITY, NOS)
Oral Tongue (Oral tongue)
Oropharynx Nos (OROPHARYNX, NOS)
Other (OTHER)
Paranasal Sinuses Nos (PARANASAL
SINUSES, NOS)
Pharyngeal Oropharynx (Pharyngeal
Oropharynx)
Postcricoid Area (Postcricoid area)
Posterior Superior Wall (Posterior
superior wall)
Posterior Wall (Posterior wall)
Pyriform Fossa (Pyriform fossa)
Retromolar Trigone (Retromolar trigone)
Soft Palate (Soft Palate)
Sphenoid (Sphenoid)
Subglottic (Subglottic)
Subglottic Larynx Nos (SUBGLOTTIC
LARYNX, NOS)
Supraglottic Larynx Nos
(SUPRAGLOTTIC LARYNX, NOS)
Suprahyoid Epiglottis (Suprahyoid
epiglottis)
Tonsillar Fossa Tonsil (Tonsillar fossa,
tonsil)
Unknown (UNKNOWN)
Upper Gingiva (Upper gingiva)
Ventricular Band (Ventricular band)
Vocal Cords (Vocal cords)
Other specify
Tumor Measurements At Presentation
Histologic Type
Other (Other)
Squamous Cell Carcinoma, Including
Variants (Squamous cell carcinoma,
including variants)
Tumor diameter
>= 0
cm
Nodal mass (cm)
Primary Tumor Laterality
Left (Left)
Right (Right)
Clinical T Stage
T0, According To Ajcc Criteria (T0)
T1, According To Ajcc Criteria (T1)
T2, According To Ajcc Criteria (T2)
T3, According To Ajcc Criteria (T3)
T4, According To Ajcc Criteria (T4)
7 / 10
Initial Evaluation Head and Neck Cancer Stage III or IV RTOG-0522 I1
NCT00265941
Tis, According To Ajcc Criteria (TIS)
Tx, According To Ajcc Criteria (TX)
Clinical N Stage (OVERALL)
N0, According To Ajcc Guidelines (N0)
N1, According To Ajcc Criteria (N1)
N2a, According To Ajcc Guidelines (N2a)
N2b, According To Ajcc Guidelines (N2b)
N2c, According To Ajcc Guidelines (N2c)
N3, According To Ajcc Guidelines (N3)
Nx, According To Ajcc Guidelines (NX)
Clinical N Stage, Right side
N0, According To Ajcc Guidelines (N0)
N1, According To Ajcc Criteria (N1)
N2a, According To Ajcc Guidelines (N2a)
N2b, According To Ajcc Guidelines (N2b)
N2c, According To Ajcc Guidelines (N2c)
N3, According To Ajcc Guidelines (N3)
Nx, According To Ajcc Guidelines (NX)
Clinical N Stage, Left side
N0, According To Ajcc Guidelines (N0)
N1, According To Ajcc Criteria (N1)
N2a, According To Ajcc Guidelines (N2a)
N2b, According To Ajcc Guidelines (N2b)
N2c, According To Ajcc Guidelines (N2c)
N3, According To Ajcc Guidelines (N3)
Nx, According To Ajcc Guidelines (NX)
Clinical M Stage
M0, According To Ajcc Guidelines (M0)
M1, According To Ajcc Staging
Definitions (M1)
Weight Loss in Previous Six Months
<5% Of Body Weight (< 5% of body
weight)
> Or = 20% Of Body Weight (> or = 20%
of body weight)
10 To <20% Of Body Weight (10 to <
20% of body weight)
5 To <10% Of Body Weight (5 to < 10%
of body weight)
Unknown (Unknown)
Does the patient have a past history of
swallowing problems
No (No)
Unknown (Unknown)
Yes (Yes)
How long were swallowing problems apparent (If
yes,)
1 To <7 Months (1 to <7 months)
13 To <19 Months (13 to <19 months)
19 To <24 Months (19 to <24 months)
2 Years Or Longer (2 years or longer)
7 To <13 Months (7 to <13 months)
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Less Than 1 Month (Less than 1 month)
Unknown (Unknown)
Does the patient currently have swallowing
problems
No (No)
Unknown (Unknown)
Yes (Yes)
How long have swallowing problems been
present (If yes,)
1 To <7 Months (1 to <7 months)
13 To <19 Months (13 to <19 months)
19 To <24 Months (19 to <24 months)
2 Years Or Longer (2 years or longer)
7 To <13 Months (7 to <13 months)
Less Than 1 Month (Less than 1 month)
Unknown (Unknown)
Does the patient have a past history of tube
feedings
No (No)
Unknown (Unknown)
Yes (Yes)
How long were tube feedings given (If yes,)
1 To <7 Months (1 to <7 months)
13 To <19 Months (13 to <19 months)
19 To <24 Months (19 to <24 months)
2 Years Or Longer (2 years or longer)
7 To <13 Months (7 to <13 months)
Less Than 1 Month (Less than 1 month)
Unknown (Unknown)
Does the patient currently require tube feeding
No (No)
Unknown (Unknown)
Yes (Yes)
Is patient dependent on tube feeding for >50% of
nutritional support  (If yes,)
No (No)
Unknown (Unknown)
Yes (Yes)
Smoking History
Cigarette Smoker <20 Pack-years
(Cigarette smoker, <20 pack-years)
Cigarette Smoker >40 Pack-years
(Cigarette smoker, >40 pack-years)
Cigarette Smoker 20-40 Pack-years
(Cigarette smoker, 20-40 pack-years)
Never Smoked (Never smoked)
Pipe Or Cigar Smoker Only (Pipe or
cigar smoker only)
Unknown (Unknown)
Does the patient currently smoke (cigarettes)
No (No)
Patient Refused To Answer (Patient
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Refused to Answer)
Unknown (Unknown)
Yes (Yes)
Number of Cigarettes per day (Need to add this
new question to CRF to capture value for current
smokers - values need to match existing CDE)
14 Or Fewer (14 or fewer)
15-24 (15-24)
25 Or More (25 or more)
Unknown (Unknown)
Smoking Discontinued Duration
1 Month To <6 Months (1 month to <6
months)
1 Year To <5 Years (1 year to <5 years)
5 Years To <10 Years (5 years to <10
years)
6 Months To <1 Year (6 months to <1
year)
Less Than 1 Month (Less than 1 month)
More Than 10 Years (More than 10
years)
Never Smoked (Never smoked)
Unknown (Unknown)
Protocol Specific Adverse Event
Evaluation
CTC Adverse Event Term
Dysphagia (Dysphagia (difficulty
swallowing))
MedDRA Code
CTC AE Grade
CTCAE Begin Date
Comments
Comments
COMMENTS
Person completing form
Form completion date, original
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Treatment Summary NSCLC Stage III
RTOG NCT00533949
NCT00533949  TF: Radiation Therapy Oncology Group
Phase III High-dose Vs Standard-dose Conformal XRT with
Chemotherapy Treatment Summary Form
High-Dose or Standard-Dose Radiation Therapy and
Chemotherapy With or Without Cetuximab in Treating
Patients With Newly Diagnosed Stage III Non-Small Cell
Lung Cancer That Cannot Be Removed by Surgery
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=24FB4F78-
9A8F-669C-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11826
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RTOG clinical trial administrative data
RTOG Study No.
RTOG Case #
Institution
Institution No.
Patient Initials
RTOG Patient ID
AMENDED DATA
Yes
No
Assessment of Chemotherapy
Height
>= 0
cm
Body weight
>= 0
kg
Body surface area
>= 0
m²
Treatment Phase
Chemoradiation (Chemoradiation)
Consolidation (Consolidation)
Gender
Female (F)
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Male (M)
Age
>= 0
<= 120
years
Agent Name
Agent Start Date (FOR  CYCLES BEING
REPORTED)
Agent End Date (FOR  CYCLES BEING
REPORTED)
Agent Total Cumulative Dose (for cycles being
reported)
Total number of doses
Reason for Treatment Modification
Adverse Event/side Effects/complications
(Adverse event/side
effects/complications)
Alternative Therapy (Alternative therapy)
Death On Study (Death on study)
Disease Progression, Relapse During
Active Treatment (Disease progression,
relapse during active treatment)
None (None)
Other (Other)
Other Complicating Disease (Other
complicating disease)
Patient Withdrawal Or Refusal After
Beginning Protocol Therapy (Patient
withdrawal/refusal after beginning
protocol therapy)
Patient Withdrawal Or Refusal Prior To
Beginning Protocol Therapy (Patient
withdrawal/refusal prior to beginning
protocol therapy)
Treatment Completed Per Protocol
Criteria (Treatment completed per
protocol criteria)
Reason Treatment Ended
Adverse Event/side Effects/complications
(Adverse Event/Side
Effects/Complications)
Alternative Therapy (Alternative therapy)
Death On Study (Death on study)
Disease Progression, Relapse During
Active Treatment (Disease progression,
relapse during active treatment)
Other (Other)
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Patient Off-treatment For Other
Complicating Disease (Patient off-
treatment for other complicating disease)
Patient Withdrawal Or Refusal After
Beginning Protocol Therapy (Patient
withdrawal/refusal after beginning
protocol therapy)
Patient Withdrawal Or Refusal Before
Beginning Protocol Therapy (Patient
withdrawal/refusal prior to beginning
protocol therapy)
Treatment Completed Per Protocol
Criteria (Treatment completed per
protocol criteria)
Alternative therapy, specify alternative therapy
Other complicating disease, specify complicating
disease
Other, specify
Comments
Person completing form
Form completion date, original
Report All Continuing Or New Adverse
Events
New or continuing adverse events
No (No)
Unknown (Unknown)
Yes (Yes)
MedDRA Code
CTC Adverse Event Term
Acidosis Nos (Acidosis (metabolic or
respiratory))
Capillary Leak Syndrome (Acute
vascular leak syndrome)
Adrenal Insufficiency (Adrenal
insufficiency)
Adult Respiratory Distress Syndrome
(Adult respiratory distress syndrome
(ARDS))
Blood Albumin Decreased (Albumin,
serum-low (hypoalbuminemia))
Alcohol Intolerance Syndrome
(antabuse-like Syndrome) (Alcohol
intolerance syndrome (antabuse-like
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syndrome))
Blood Alkaline Phosphatase Nos
Increased (Alkaline phosphatase)
Alkalosis Nos (Alkalosis (metabolic or
respiratory))
Hypersensitivity Nos (Allergic
reaction/hypersensitivity (including drug
fever))
Rhinitis Allergic Nos (Allergic rhinitis
(including sneezing, nasal stuffiness,
postnasal drip))
Allergy/immunology Other
(Allergy/Immunology-Other (Specify))
Alanine Aminotransferase Increased
(ALT, SGPT (serum glutamic pyruvic
transaminase))
Blood Amylase Increased (Amylase)
Anorexia (Anorexia)
Apnoea (Apnea)
Arachnoiditis
(Arachnoiditis/meningismus/radiculitis)
Arthritis Nos (Arthritis (non-septic))
Ascites (Ascites (non-malignant))
Aspiration (Aspiration)
Aspartate Aminotransferase Increased
(AST, SGOT (serum glutamic oxaloacetic
transaminase))
Ataxia Nec (Ataxia (incoordination))
Atelectasis (Atelectasis)
Atrophy, Skin (Atrophy, skin)
Atrophy, Subcutaneous Fat (Atrophy,
subcutaneous fat)
Auditory/ear Other (Auditory/Ear-Other
(Specify))
Autoimmune Disorder Nos (Autoimmune
reaction)
Blood Bicarbonate Decreased
(Bicarbonate, serum-low)
Blood Bilirubin Increased (Bilirubin
(hyperbilirubinemia))
Bladder Disorder Nos (Bladder spasms)
Blood/bone Marrow Other (Blood/Bone
Marrow-Other (Specify))
Bone Age (alteration In Bone Age) (Bone
age (alteration in bone age))
Bone Growth: Femoral Head; Slipped
Capital Femoral Epiphysis (Bone growth:
femoral head; slipped capital femoral
epiphysis)
Bone Growth: Limb Length Discrepancy
(Bone growth: limb length discrepancy)
Bone Growth: Spine Kyphosis/lordosis
(Bone growth: spine kyphosis/lordosis)
Bone Marrow Depression Nos (Bone
marrow cellularity)
Bone: Spine-scoliosis (Bone: spine-
scoliosis)
Brachial Plexopathy (Brachial
plexopathy)
Breast Function/lactation (Breast
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function/lactation)
Breast Nipple/areolar Deformity (Breast
nipple/areolar deformity)
Breast Volume/hypoplasia (Breast
volume/hypoplasia)
Bronchospasm, Wheezing
(Bronchospasm, wheezing)
Ecchymosis (Bruising (in absence of
grade 3 or 4 thrombocytopenia))
Burn (Burn)
Hypercalcaemia (Calcium, serum-high
(hypercalcemia))
Hypocalcaemia (Calcium, serum-low
(hypocalcemia))
Pulmonary Function Test Nos Decreased
(Carbon monoxide diffusion capacity
(DL(co)))
Arrhythmia Nos (Cardiac Arrhythmia-
Other (Specify))
Cardiac General Other (Cardiac
General-Other (Specify))
Myocardial Ischaemia (Cardiac
ischemia/infarction)
Cardiac Troponin I Increased (Cardiac
troponin I (cTnI))
Cardiac Troponin T Increased (Cardiac
troponin T (cTnT))
Cardiopulmonary Arrest, Cause
Unknown (non-fatal) (Cardiopulmonary
arrest, cause unknown (non-fatal))
Cataract Nec (Cataract)
Cd4 Lymphocytes Decreased (CD4
count)
Cervical Spine-range Of Motion (Cervical
spine-range of motion)
Chelitis (Cheilitis)
Cholecystitis (Cholecystitis)
Hypercholesteraemia (Cholesterol,
serum-high (hypercholesteremia))
Chyle Or Lymph Leakage (Chyle or
lymph leakage)
Chylothorax (Chylothorax)
Cerebral Ischaemia (CNS
cerebrovascular ischemia)
Cns Necrosis/cystic Progression (CNS
necrosis/cystic progression)
Coagulation Disorder Nos (Coagulation-
Other (Specify))
Learning Disorder Nos (Cognitive
disturbance)
Colitis Nos (Colitis)
Colitis, Infectious (e.g., Clostridium
Difficile) (Colitis, infectious (e.g.,
Clostridium difficile))
Ventricular Asystole (Conduction
abnormality/Atrioventricular heart block -
Asystole)
Conduction Abnormality/atrioventricular
Heart Block (Conduction
abnormality/Atrioventricular heart block -
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AV block-first degree)
Conduction Abnormality/atrioventricular
Heart Block - Av Block-second Degree
Mobitz Type I (wenckebach) (Conduction
abnormality/Atrioventricular heart block -
AV block-Second degree Mobitz Type I
(Wenckebach))
Conduction Abnormality/atrioventricular
Heart Block (Conduction
abnormality/Atrioventricular heart block -
AV block-second degree Mobitz Type II)
Conduction Abnormality/atrioventricular
Heart Block (Conduction
abnormality/Atrioventricular heart block -
AV block-third degree (complete AV
block))
Conduction Abnormality/atrioventricular
Heart Block (Conduction
abnormality/Atrioventricular heart block -
Conduction abnormality NOS)
Conduction Abnormality/atrioventricular
Heart Block (Conduction
abnormality/Atrioventricular heart block -
Sick sinus syndrome)
Conduction Abnormality/atrioventricular
Heart Block (Conduction
abnormality/Atrioventricular heart block -
Stokes-Adams syndrome)
Conduction Abnormality/atrioventricular
Heart Block (Conduction
abnormality/Atrioventricular heart block -
Wolff-Parkinson-White syndrome)
Confusion (Confusion)
Constipation (Constipation)
Constitutional Symptoms Other
(Constitutional Symptoms-Other
(Specify))
Cough (Cough)
Blood Creatine Phosphokinase
Increased (CPK (creatine
phosphokinase))
Blood Creatinine Increased (Creatinine)
Cushingoid (Cushingoid appearance
(e.g., moon face, buffalo hump,
centripetal obesity, cutaneous striae))
Cystitis (Cystitis)
Cytokine Release Syndrome/acute
Infusion Reaction (Cytokine release
syndrome/acute infusion reaction)
Death Not Associated With Ctcae Term
(Death not associated with CTCAE term
- Death NOS)
Death Not Associated With Ctcae Term
(Death not associated with CTCAE term
- Disease progression NOS)
Death Not Associated With Ctcae Term
(Death not associated with CTCAE term
- Multi-organ failure)
Death Not Associated With Ctcae Term
(Death not associated with CTCAE term
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- Sudden death)
Dehydration (Dehydration)
Dental: Dentures Or Prosthesis (Dental:
dentures or prosthesis)
Dental: Periodontal Disease (Dental:
periodontal disease)
Dental: Teeth (Dental: teeth)
Dental: Teeth Development (Dental:
teeth development)
Dermal Change Lymphedema,
Phlebolymphedema (Dermal change
lymphedema, phlebolymphedema)
Dermatology/skin Other
(Dermatology/Skin-Other (Specify))
Diarrhoea Nos (Diarrhea)
Disseminated Intravascular Coagulation
(DIC (disseminated intravascular
coagulation))
Distention/bloating, Abdominal
(Distention/bloating, abdominal)
Dizziness (exc Vertigo) (Dizziness)
Dry Eye Nec (Dry eye syndrome)
Dry Mouth (Dry mouth/salivary gland
(xerostomia))
Dry Skin (Dry skin)
Dysphagia (Dysphagia (difficulty
swallowing))
Dyspnoea Nos (Dyspnea (shortness of
breath))
Edema, Larynx (Edema, larynx)
Edema: Head And Neck (Edema: head
and neck)
Oedema Nos (Edema: limb)
Edema: Trunk/genital (Edema:
trunk/genital)
Edema: Viscera (Edema: viscera)
Ejaculatory Dysfunction (Ejaculatory
dysfunction)
Encephalopathy (Encephalopathy)
Endocrine Other (Endocrine-Other
(Specify))
Enteritis (inflammation Of The Small
Bowel) (Enteritis (inflammation of the
small bowel))
Impotence (Erectile dysfunction)
Oesophagitis Nos (Esophagitis)
Exostosis (Exostosis)
Extrapyramidal Disorder Nec
(Extrapyramidal/involuntary
movement/restlessness)
Extremity-lower (gait/walking) (Extremity-
lower (gait/walking))
Extremity-upper (function) (Extremity-
upper (function))
Eyelid Dysfunction (Eyelid dysfunction)
Fatigue (Fatigue (asthenia, lethargy,
malaise))
Febrile Neutropenia (fever Of Unknown
Origin Without Clinically Or
Microbiologically Documented Infection)
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(anc <1.0 X 10^9/l, Fever >=38.5
Degrees C) (Febrile neutropenia)
Feminization (Feminization of male)
Forced Expiratory Volume Decreased
(FEV(1))
Pyrexia (Fever (in the absence of
neutropenia, where neutropenia is
defined as ANC <1.0 x 10^9/L))
Blood Fibrinogen Decreased
(Fibrinogen)
Fibrosis-cosmesis (Fibrosis-cosmesis)
Fibrosis-deep Connective Tissue
(Fibrosis-deep connective tissue)
Fistula, Gi (Fistula, GI - Abdomen NOS)
Anal Fistula (Fistula, GI - Anus)
Fistula, Gi (Fistula, GI - Biliary tree)
Fistula, Gi (Fistula, GI -
Colon/cecum/appendix)
Intestinal Fistula (Fistula, GI -
Duodenum)
Tracheo-oesophageal Fistula Nos
(Fistula, GI - Esophagus)
Fistula, Gi (Fistula, GI - Gallbladder)
Fistula, Gi (Fistula, GI - Ileum)
Fistula, Gi (Fistula, GI - Jejunum)
Fistula, Gi (Fistula, GI - Oral cavity)
Fistula, Gi (Fistula, GI - Pancreas)
Fistula, Gi (Fistula, GI - Pharynx)
Fistula, Gi (Fistula, GI - Rectum)
Fistula, Gi (Fistula, GI - Salivary gland)
Fistula, Gi (Fistula, GI - Small bowel
NOS)
Fistula, Gi (Fistula, GI - Stomach)
Fistula, Gu (Fistula, GU - Bladder)
Fistula, Gu (Fistula, GU - Genital tract-
female)
Fistula, Gu (Fistula, GU - Kidney)
Fistula, Gu (Fistula, GU - Ureter)
Fistula, Gu (Fistula, GU - Urethra)
Fistula, Gu (Fistula, GU - Uterus)
Urogenital Fistula (Fistula, GU - Vagina)
Fistula, Pulmonary/upper Respiratory
(Fistula, pulmonary/upper respiratory -
Bronchus)
Fistula, Pulmonary/upper Respiratory
(Fistula, pulmonary/upper respiratory -
Larynx)
Fistula, Pulmonary/upper Respiratory
(Fistula, pulmonary/upper respiratory -
Lung)
Fistula, Pulmonary/upper Respiratory
(Fistula, pulmonary/upper respiratory -
Oral cavity)
Fistula, Pulmonary/upper Respiratory
(Fistula, pulmonary/upper respiratory -
Pharynx)
Fistula, Pulmonary/upper Respiratory
(Fistula, pulmonary/upper respiratory -
Pleura)
Fistula, Pulmonary/upper Respiratory
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(Fistula, pulmonary/upper respiratory -
Trachea)
Flatulence (Flatulence)
Flu-like Syndrome (Flu-like syndrome)
Flushing (Flushing)
Fracture (Fracture)
Gastritis Nos (Gastritis (including bile
reflux gastritis))
Gastrointestinal Other (Gastrointestinal-
Other (Specify))
Gamma-glutamyltransferase Increased
(GGT (gamma-glutamyl transpeptidase))
Glaucoma Nos (Glaucoma)
Glomerular Filtration Rate (Glomerular
filtration rate)
Hyperglycaemia Nos (Glucose, serum-
high (hyperglycemia))
Hypoglycaemia Nos (Glucose, serum-
low (hypoglycemia))
Growth And Development Other (Growth
and Development-Other (Specify))
Growth Velocity (reduction In Growth
Velocity) (Growth velocity (reduction in
growth velocity))
Gynaecomastia (Gynecomastia)
Alopecia (Hair loss/Alopecia (scalp or
body))
Haptoglobin Decreased (Haptoglobin)
Hearing: Patients With/without Baseline
Audiogram And Enrolled In A Monitoring
Program (Hearing: patients with/without
baseline audiogram and enrolled in a
monitoring program)
Hearing: Patients Without Baseline
Audiogram And Not Enrolled In A
Monitoring Program (Hearing: patients
without baseline audiogram and not
enrolled in a monitoring program)
Dyspepsia (Heartburn/dyspepsia)
Hematoma (Hematoma)
Haemoglobin Decreased (Hemoglobin)
Haemoglobinuria Present
(Hemoglobinuria)
Hemolysis Nos (Hemolysis (e.g.,
immune hemolytic anemia, drug related
hemolysis))
Haemorrhagic Stroke (Hemorrhage,
CNS)
Melaena (Hemorrhage, GI - Abdomen
NOS)
Hemorrhage, Gi (Hemorrhage, GI -
Anus)
Hemorrhage, Gi (Hemorrhage, GI -
Biliary tree)
Hemorrhage, Gi (Hemorrhage, GI -
Cecum/appendix)
Hemorrhage, Gi (Hemorrhage, GI -
Colon)
Hemorrhage, Gi (Hemorrhage, GI -
Duodenum)
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Hemorrhage, Gi (Hemorrhage, GI -
Esophagus)
Hemorrhage, Gi (Hemorrhage, GI -
Ileum)
Hemorrhage, Gi (Hemorrhage, GI -
Jejunum)
Hemorrhage, Gi (Hemorrhage, GI - Liver)
Hemorrhage, Gi (Hemorrhage, GI -
Lower GI NOS)
Hemorrhage, Gi (Hemorrhage, GI - Oral
cavity)
Hemorrhage, Gi (Hemorrhage, GI -
Pancreas)
Hemorrhage, Gi (Hemorrhage, GI -
Peritoneal cavity)
Rectal Bleeding (Hemorrhage, GI -
Rectum)
Hemorrhage, Gi (Hemorrhage, GI -
Stoma)
Haematemesis (Hemorrhage, GI -
Stomach)
Hemorrhage, Gi (Hemorrhage, GI -
Upper GI NOS)
Hemorrhage, Gi (Hemorrhage, GI -
Varices (esophageal))
Hemorrhage, Gi (Hemorrhage, GI -
Varices (rectal))
Hemorrhage, Gu (Hemorrhage, GU -
Bladder)
Hemorrhage, Gu (Hemorrhage, GU -
Fallopian tube)
Hemorrhage, Gu (Hemorrhage, GU -
Kidney)
Hemorrhage, Gu (Hemorrhage, GU -
Ovary)
Hemorrhage, Gu (Hemorrhage, GU -
Prostate)
Hemorrhage, Gu (Hemorrhage, GU -
Retroperitoneum)
Hemorrhage, Gu (Hemorrhage, GU -
Spermatic cord)
Hemorrhage, Gu (Hemorrhage, GU -
Stoma)
Hemorrhage, Gu (Hemorrhage, GU -
Testes)
Hemorrhage, Gu (Hemorrhage, GU -
Ureter)
Hemorrhage, Gu (Hemorrhage, GU -
Urethra)
Haematuria Present (Hemorrhage, GU -
Urinary NOS)
Hemorrhage, Gu (Hemorrhage, GU -
Uterus)
Vaginal Haemorrhage (Hemorrhage, GU
- Vagina)
Hemorrhage, Gu (Hemorrhage, GU - Vas
deferens)
Hemorrhage, Pulmonary/upper
Respiratory (Hemorrhage,
pulmonary/upper respiratory -
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Bronchopulmonary NOS)
Hemorrhage, Pulmonary/upper
Respiratory (Hemorrhage,
pulmonary/upper respiratory - Bronchus)
Hemorrhage, Pulmonary/upper
Respiratory (Hemorrhage,
pulmonary/upper respiratory - Larynx)
Hemorrhage, Pulmonary/upper
Respiratory (Hemorrhage,
pulmonary/upper respiratory - Lung)
Hemorrhage, Pulmonary/upper
Respiratory (Hemorrhage,
pulmonary/upper respiratory -
Mediastinum)
Epistaxis (Hemorrhage, pulmonary/upper
respiratory - Nose)
Hemorrhage, Pulmonary/upper
Respiratory (Hemorrhage,
pulmonary/upper respiratory - Pharynx)
Hemorrhage, Pulmonary/upper
Respiratory (Hemorrhage,
pulmonary/upper respiratory - Pleura)
Haemoptysis (Hemorrhage,
pulmonary/upper respiratory -
Respiratory tract NOS)
Hemorrhage, Pulmonary/upper
Respiratory (Hemorrhage,
pulmonary/upper respiratory - Stoma)
Hemorrhage, Pulmonary/upper
Respiratory (Hemorrhage,
pulmonary/upper respiratory - Trachea)
Post-operative Haemorrhage
(Hemorrhage/bleeding associated with
surgery, intra-operative or post-operative)
Hemorrhage/bleeding Other
(Hemorrhage/Bleeding-Other (Specify))
Hemorrhoids (Hemorrhoids)
Hepatobiliary/pancreas Other
(Hepatobiliary/Pancreas-Other (Specify))
Hiccups (Hiccoughs (hiccups, singultus))
Menopausal Symptoms (Hot
flashes/flushes)
Hydrocephalus (Hydrocephalus)
Skin Discolouration (Hyperpigmentation)
Hypertension Nos (Hypertension)
Hypopigmentation (Hypopigmentation)
Hypotension Nos (Hypotension)
Hypothermia (Hypothermia)
Hypoxia (Hypoxia)
Ileus (Ileus, GI (functional obstruction of
bowel, i.e., neuroconstipation))
Incontinence, Anal (Incontinence, anal)
Urinary Incontinence (Incontinence,
urinary)
Induration/fibrosis (skin And
Subcutaneous Tissue)
(Induration/fibrosis (skin and
subcutaneous tissue))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
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Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Abdomen NOS)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Anal/perianal)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Appendix)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Artery)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Biliary tree)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Bladder (urinary))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Blood)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Bone (osteomyelitis))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Brain (encephalitis,
infectious))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Brain + Spinal cord
(encephalomyelitis))
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Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Bronchus)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Catheter-related)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Cecum)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Cervix)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Colon)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Conjunctiva)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Cornea)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Dental-tooth)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Duodenum)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Esophagus)
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Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - External ear (otitis externa))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Eye NOS)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Fallopian tube)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Foreign body (e.g., graft,
implant, prosthesis, stent))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Gallbladder (cholecystitis))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Heart (endocarditis))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Ileum)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Jejunum)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Joint)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
14 / 47
Treatment Summary NSCLC Stage III RTOG NCT00533949
neutrophils - Kidney)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Larynx)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Lens)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Lip/perioral)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Liver)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Lung (pneumonia))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Lymphatic)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Mediastinum NOS)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Meninges (meningitis))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Middle ear (otitis media))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
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neutrophils - Mucosa)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Muscle (infection myositis))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Neck NOS)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Nerve-cranial)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Nerve-peripheral)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Nose)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Oral cavity-gums
(gingivitis))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Pancreas)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Paranasal)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Pelvis NOS)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
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microbiologically) with Grade 3 or 4
neutrophils - Penis)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Peristomal)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Peritoneal cavity)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Pharynx)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Pleura (empyema))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Prostate)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Rectum)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Salivary gland)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Scrotum)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Sinus)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
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microbiologically) with Grade 3 or 4
neutrophils - Skin (cellulitis))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Small bowel NOS)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Soft tissue NOS)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Spinal cord (myelitis))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Spleen)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Stomach)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Trachea)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Ungual (nails))
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Upper aerodigestive NOS)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Upper airway NOS)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
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microbiologically) with Grade 3 or 4
neutrophils - Ureter)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Urethra)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Urinary tract NOS)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Uterus)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Vagina)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Vein)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Vulva)
Infection (documented Clinically Or
Microbiologically) With Grade 3 Or 4
Neutrophils (anc <1.0 X 10^9/l) (Infection
(documented clinically or
microbiologically) with Grade 3 or 4
neutrophils - Wound)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Abdomen
NOS)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils -
Anal/perianal)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Appendix)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Artery)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
19 / 47
Treatment Summary NSCLC Stage III RTOG NCT00533949
or Grade 1 or 2 neutrophils - Biliary tree)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Bladder
(urinary))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Blood)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Bone
(osteomyelitis))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Brain
(encephalitis, infectious))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Brain +
Spinal cord (encephalomyelitis))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Bronchus)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Catheter-
related)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Cecum)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Cervix)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Colon)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils -
Conjunctiva)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Cornea)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Dental-
tooth)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Duodenum)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Esophagus)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - External ear
(otitis externa))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Eye NOS)
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Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Fallopian
tube)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Foreign
body (e.g., graft, implant, prosthesis,
stent))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Gallbladder
(cholecystitis))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Heart
(endocarditis))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Ileum)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Jejunum)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Joint)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Kidney)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Larynx)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Lens)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Lip/perioral)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Liver)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Lung
(pneumonia))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Lymphatic)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils -
Mediastinum NOS)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Meninges
(meningitis))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Middle ear
(otitis media))
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Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Mucosa)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Muscle
(infection myositis))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Neck NOS)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Nerve-
cranial)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Nerve-
peripheral)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Nose)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Oral cavity-
gums (gingivitis))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Pancreas)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Paranasal)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Pelvis NOS)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Penis)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Peristomal)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Peritoneal
cavity)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Pharynx)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Pleura
(empyema))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Prostate)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Rectum)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Salivary
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gland)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Scrotum)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Sinus)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Skin
(cellulitis))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Small bowel
NOS)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Soft tissue
NOS)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Spinal cord
(myelitis))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Spleen)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Stomach)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Trachea)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Ungual
(nails))
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Upper
aerodigestive NOS)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Upper
airway NOS)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Ureter)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Urethra)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Urinary
tract NOS)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Uterus)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Vagina)
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Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Vein)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Vulva)
Infection With Normal Anc Or Grade 1 Or
2 Neutrophils (Infection with normal ANC
or Grade 1 or 2 neutrophils - Wound)
Infection With Unknown Anc (Infection
with unknown ANC - Abdomen NOS)
Infection With Unknown Anc (Infection
with unknown ANC - Anal/perianal)
Infection With Unknown Anc (Infection
with unknown ANC - Appendix)
Infection With Unknown Anc (Infection
with unknown ANC - Artery)
Infection With Unknown Anc (Infection
with unknown ANC - Biliary tree)
Infection With Unknown Anc (Infection
with unknown ANC - Bladder (urinary))
Infection With Unknown Anc (Infection
with unknown ANC - Blood)
Infection With Unknown Anc (Infection
with unknown ANC - Bone
(osteomyelitis))
Infection With Unknown Anc (Infection
with unknown ANC - Brain (encephalitis,
infectious))
Infection With Unknown Anc (Infection
with unknown ANC - Brain + Spinal cord
(encephalomyelitis))
Infection With Unknown Anc (Infection
with unknown ANC - Bronchus)
Implant Infection (Infection with unknown
ANC - Catheter-related)
Infection With Unknown Anc (Infection
with unknown ANC - Cecum)
Infection With Unknown Anc (Infection
with unknown ANC - Cervix)
Infection With Unknown Anc (Infection
with unknown ANC - Colon)
Infection With Unknown Anc (Infection
with unknown ANC - Conjunctiva)
Infection With Unknown Anc (Infection
with unknown ANC - Cornea)
Infection With Unknown Anc (Infection
with unknown ANC - Dental-tooth)
Infection With Unknown Anc (Infection
with unknown ANC - Duodenum)
Infection With Unknown Anc (Infection
with unknown ANC - Esophagus)
Infection With Unknown Anc (Infection
with unknown ANC - External ear (otitis
externa))
Infection With Unknown Anc (Infection
with unknown ANC - Eye NOS)
Infection With Unknown Anc (Infection
with unknown ANC - Fallopian tube)
Infection With Unknown Anc (Infection
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with unknown ANC - Foreign body (e.g.,
graft, implant, prosthesis, stent))
Infection With Unknown Anc (Infection
with unknown ANC - Gallbladder
(cholecystitis))
Infection With Unknown Anc (Infection
with unknown ANC - Heart
(endocarditis))
Infection With Unknown Anc (Infection
with unknown ANC - Ileum)
Infection With Unknown Anc (Infection
with unknown ANC - Jejunum)
Infection With Unknown Anc (Infection
with unknown ANC - Joint)
Infection With Unknown Anc (Infection
with unknown ANC - Kidney)
Infection With Unknown Anc (Infection
with unknown ANC - Larynx)
Infection With Unknown Anc (Infection
with unknown ANC - Lens)
Infection With Unknown Anc (Infection
with unknown ANC - Lip/perioral)
Infection With Unknown Anc (Infection
with unknown ANC - Liver)
Infection With Unknown Anc (Infection
with unknown ANC - Lung (pneumonia))
Infection With Unknown Anc (Infection
with unknown ANC - Lymphatic)
Infection With Unknown Anc (Infection
with unknown ANC - Mediastinum NOS)
Infection With Unknown Anc (Infection
with unknown ANC - Meninges
(meningitis))
Infection With Unknown Anc (Infection
with unknown ANC - Middle ear (otitis
media))
Infection With Unknown Anc (Infection
with unknown ANC - Mucosa)
Infection With Unknown Anc (Infection
with unknown ANC - Muscle (infection
myositis))
Infection With Unknown Anc (Infection
with unknown ANC - Neck NOS)
Infection With Unknown Anc (Infection
with unknown ANC - Nerve-cranial)
Infection With Unknown Anc (Infection
with unknown ANC - Nerve-peripheral)
Infection With Unknown Anc (Infection
with unknown ANC - Nose)
Infection With Unknown Anc (Infection
with unknown ANC - Oral cavity-gums
(gingivitis))
Infection With Unknown Anc (Infection
with unknown ANC - Pancreas)
Infection With Unknown Anc (Infection
with unknown ANC - Paranasal)
Infection With Unknown Anc (Infection
with unknown ANC - Pelvis NOS)
Infection With Unknown Anc (Infection
with unknown ANC - Penis)
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Infection With Unknown Anc (Infection
with unknown ANC - Peristomal)
Infection With Unknown Anc (Infection
with unknown ANC - Peritoneal cavity)
Infection With Unknown Anc (Infection
with unknown ANC - Pharynx)
Infection With Unknown Anc (Infection
with unknown ANC - Pleura (empyema))
Infection With Unknown Anc (Infection
with unknown ANC - Prostate)
Infection With Unknown Anc (Infection
with unknown ANC - Rectum)
Infection With Unknown Anc (Infection
with unknown ANC - Salivary gland)
Infection With Unknown Anc (Infection
with unknown ANC - Scrotum)
Infection With Unknown Anc (Infection
with unknown ANC - Sinus)
Infection With Unknown Anc (Infection
with unknown ANC - Skin (cellulitis))
Infection With Unknown Anc (Infection
with unknown ANC - Small bowel NOS)
Infection With Unknown Anc (Infection
with unknown ANC - Soft tissue NOS)
Infection With Unknown Anc (Infection
with unknown ANC - Spinal cord
(myelitis))
Infection With Unknown Anc (Infection
with unknown ANC - Spleen)
Infection With Unknown Anc (Infection
with unknown ANC - Stomach)
Infection With Unknown Anc (Infection
with unknown ANC - Trachea)
Infection With Unknown Anc (Infection
with unknown ANC - Ungual (nails))
Infection With Unknown Anc (Infection
with unknown ANC - Upper aerodigestive
NOS)
Infection With Unknown Anc (Infection
with unknown ANC - Upper airway NOS)
Infection With Unknown Anc (Infection
with unknown ANC - Ureter)
Infection With Unknown Anc (Infection
with unknown ANC - Urethra)
Infection With Unknown Anc (Infection
with unknown ANC - Urinary tract NOS)
Infection With Unknown Anc (Infection
with unknown ANC - Uterus)
Infection With Unknown Anc (Infection
with unknown ANC - Vagina)
Infection With Unknown Anc (Infection
with unknown ANC - Vein)
Infection With Unknown Anc (Infection
with unknown ANC - Vulva)
Culture Wound Positive (Infection with
unknown ANC - Wound)
Infection Nos (Infection-Other (Specify))
Infertility/sterility (Infertility/sterility)
Injection Site Reaction Nos (Injection site
reaction/extravasation changes)
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Prothrombin Time Prolonged (INR
(International Normalized Ratio of
prothrombin time))
Insomnia Nec (Insomnia)
Intra-operative Injury (Intra-operative
injury - Abdomen NOS)
Intra-operative Injury (Intra-operative
injury - Adrenal gland)
Intra-operative Injury (Intra-operative
injury - Anal sphincter)
Intra-operative Injury (Intra-operative
injury - Anus)
Intra-operative Injury (Intra-operative
injury - Appendix)
Intra-operative Injury (Intra-operative
injury - Artery NOS)
Intra-operative Injury (Intra-operative
injury - Artery-aorta)
Intra-operative Injury (Intra-operative
injury - Artery-carotid)
Intra-operative Injury (Intra-operative
injury - Artery-cerebral)
Intra-operative Injury (Intra-operative
injury - Artery-extremity (lower))
Intra-operative Injury (Intra-operative
injury - Artery-extremity (upper))
Intra-operative Injury (Intra-operative
injury - Artery-hepatic)
Intra-operative Injury (Intra-operative
injury - Artery-major visceral artery)
Intra-operative Injury (Intra-operative
injury - Artery-pulmonary)
Intra-operative Injury (Intra-operative
injury - Biliary tree NOS)
Intra-operative Injury (Intra-operative
injury - Biliary tree-common bile duct)
Intra-operative Injury (Intra-operative
injury - Biliary tree-common hepatic duct)
Intra-operative Injury (Intra-operative
injury - Biliary tree-left hepatic duct)
Intra-operative Injury (Intra-operative
injury - Biliary tree-right hepatic duct)
Bladder Perforation Postoperative (Intra-
operative injury - Bladder)
Intra-operative Injury (Intra-operative
injury - Bone)
Intra-operative Injury (Intra-operative
injury - Brachial plexus)
Intra-operative Injury (Intra-operative
injury - Brain)
Intra-operative Injury (Intra-operative
injury - Breast)
Intra-operative Injury (Intra-operative
injury - Bronchus)
Intra-operative Injury (Intra-operative
injury - Cartilage)
Intra-operative Injury (Intra-operative
injury - Cecum)
Intra-operative Injury (Intra-operative
injury - Cervix)
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Intra-operative Injury (Intra-operative
injury - CN I (olfactory))
Intra-operative Injury (Intra-operative
injury - CN II (optic))
Intra-operative Injury (Intra-operative
injury - CN III (oculomotor))
Intra-operative Injury (Intra-operative
injury - CN IV (trochlear))
Intra-operative Injury (Intra-operative
injury - CN IX (glossopharyngeal) motor
pharynx)
Intra-operative Injury (Intra-operative
injury - CN IX (glossopharyngeal)
sensory ear-pharynx-tongue)
Intra-operative Injury (Intra-operative
injury - CN V (trigeminal) motor)
Intra-operative Injury (Intra-operative
injury - CN V (trigeminal) sensory)
Intra-operative Injury (Intra-operative
injury - CN VI (abducens))
Intra-operative Injury (Intra-operative
injury - CN VII (facial) motor-face)
Intra-operative Injury (Intra-operative
injury - CN VII (facial) sensory-taste)
Intra-operative Injury (Intra-operative
injury - CN VIII (vestibulocochlear))
Intra-operative Injury (Intra-operative
injury - CN X (vagus))
Intra-operative Injury (Intra-operative
injury - CN XI (spinal accessory))
Intra-operative Injury (Intra-operative
injury - CN XII (hypoglossal))
Intra-operative Injury (Intra-operative
injury - Colon)
Intra-operative Injury (Intra-operative
injury - Conjunctiva)
Intra-operative Injury (Intra-operative
injury - Cornea)
Intra-operative Injury (Intra-operative
injury - Cranial nerve or branch NOS)
Intra-operative Injury (Intra-operative
injury - Duodenum)
Intra-operative Injury (Intra-operative
injury - Esophagus)
Intra-operative Injury (Intra-operative
injury - Extremity-lower)
Intra-operative Injury (Intra-operative
injury - Extremity-upper)
Intra-operative Injury (Intra-operative
injury - Eye NOS)
Intra-operative Injury (Intra-operative
injury - Face NOS)
Intra-operative Injury (Intra-operative
injury - Fallopian tube)
Intra-operative Injury (Intra-operative
injury - Gallbladder)
Intra-operative Injury (Intra-operative
injury - Gingiva)
Intra-operative Injury (Intra-operative
injury - Heart)
28 / 47
Treatment Summary NSCLC Stage III RTOG NCT00533949
Intra-operative Injury (Intra-operative
injury - Ileum)
Intra-operative Injury (Intra-operative
injury - Inner ear)
Intra-operative Injury (Intra-operative
injury - Jejunum)
Intra-operative Injury (Intra-operative
injury - Joint)
Intra-operative Injury (Intra-operative
injury - Kidney)
Intra-operative Injury (Intra-operative
injury - Larynx)
Intra-operative Injury (Intra-operative
injury - Lens)
Intra-operative Injury (Intra-operative
injury - Ligament)
Intra-operative Injury (Intra-operative
injury - Lingual)
Intra-operative Injury (Intra-operative
injury - Lip/perioral area)
Intra-operative Injury (Intra-operative
injury - Liver)
Intra-operative Injury (Intra-operative
injury - Lung)
Intra-operative Injury (Intra-operative
injury - Lung thoracic)
Intra-operative Injury (Intra-operative
injury - Mediastinum)
Intra-operative Injury (Intra-operative
injury - Meninges)
Intra-operative Injury (Intra-operative
injury - Middle ear)
Intra-operative Injury (Intra-operative
injury - Muscle)
Intra-operative Injury (Intra-operative
injury - Nails)
Intra-operative Injury (Intra-operative
injury - Nasal cavity)
Intra-operative Injury (Intra-operative
injury - Nasopharynx)
Intra-operative Injury (Intra-operative
injury - Neck NOS)
Intra-operative Injury (Intra-operative
injury - Nose)
Intra-operative Injury (Intra-operative
injury - Oral)
Intra-operative Injury (Intra-operative
injury - Oral cavity NOS)
Intra-operative Injury (Intra-operative
injury - Outer ear NOS)
Intra-operative Injury (Intra-operative
injury - Outer ear-pinna)
Intra-operative Injury (Intra-operative
injury - Ovary)
Intra-operative Injury (Intra-operative
injury - Pancreas)
Intra-operative Injury (Intra-operative
injury - Pancreatic duct)
Intra-operative Injury (Intra-operative
injury - Parathyroid)
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Intra-operative Injury (Intra-operative
injury - Parotid gland)
Intra-operative Injury (Intra-operative
injury - Pelvis NOS)
Intra-operative Injury (Intra-operative
injury - Penis)
Intra-operative Injury (Intra-operative
injury - Peripheral motor NOS)
Intra-operative Injury (Intra-operative
injury - Peripheral sensory NOS)
Intra-operative Injury (Intra-operative
injury - Peritoneal cavity)
Intra-operative Injury (Intra-operative
injury - Pharynx)
Intra-operative Injury (Intra-operative
injury - Pituitary)
Intra-operative Injury (Intra-operative
injury - Pleura)
Intra-operative Injury (Intra-operative
injury - Prostate)
Intra-operative Injury (Intra-operative
injury - Rectum)
Intra-operative Injury (Intra-operative
injury - Recurrent laryngeal)
Intra-operative Injury (Intra-operative
injury - Retina)
Intra-operative Injury (Intra-operative
injury - Sacral plexus)
Intra-operative Injury (Intra-operative
injury - Salivary duct)
Intra-operative Injury (Intra-operative
injury - Salivary gland)
Intra-operative Injury (Intra-operative
injury - Sciatic)
Intra-operative Injury (Intra-operative
injury - Scrotum)
Intra-operative Injury (Intra-operative
injury - Sinus)
Intra-operative Injury (Intra-operative
injury - Skin)
Intra-operative Injury (Intra-operative
injury - Small bowel NOS)
Intra-operative Injury (Intra-operative
injury - Soft tissue NOS)
Intra-operative Injury (Intra-operative
injury - Spinal cord)
Intra-operative Injury (Intra-operative
injury - Spleen)
Intra-operative Injury (Intra-operative
injury - Stoma (GI))
Intra-operative Injury (Intra-operative
injury - Stomach)
Intra-operative Injury (Intra-operative
injury - Teeth)
Intra-operative Injury (Intra-operative
injury - Tendon)
Intra-operative Injury (Intra-operative
injury - Testis)
Intra-operative Injury (Intra-operative
injury - Thoracic duct)
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Intra-operative Injury (Intra-operative
injury - Thoracodorsal)
Intra-operative Injury (Intra-operative
injury - Thyroid)
Intra-operative Injury (Intra-operative
injury - Tongue)
Intra-operative Injury (Intra-operative
injury - Trachea)
Intra-operative Injury (Intra-operative
injury - Upper aerodigestive NOS)
Intra-operative Injury (Intra-operative
injury - Upper airway NOS)
Intra-operative Injury (Intra-operative
injury - Ureter)
Intra-operative Injury (Intra-operative
injury - Urethra)
Intra-operative Injury (Intra-operative
injury - Urinary conduit)
Intra-operative Injury (Intra-operative
injury - Urinary tract NOS)
Intra-operative Injury (Intra-operative
injury - Uterus)
Intra-operative Injury (Intra-operative
injury - Vagina)
Intra-operative Injury - Vein (Intra-
operative injury - Vein NOS)
Intra-operative Injury (Intra-operative
injury - Vein-extremity (lower))
Intra-operative Injury (Intra-operative
injury - Vein-extremity (upper))
Intra-operative Injury (Intra-operative
injury - Vein-hepatic)
Intra-operative Injury (Intra-operative
injury - Vein-inferior vena cava)
Intra-operative Injury (Intra-operative
injury - Vein-jugular)
Intra-operative Injury (Intra-operative
injury - Vein-major visceral vein)
Intra-operative Injury (Intra-operative
injury - Vein-portal vein)
Intra-operative Injury (Intra-operative
injury - Vein-pulmonary)
Intra-operative Injury (Intra-operative
injury - Vein-superior vena cava)
Intra-operative Injury (Intra-operative
injury - Vulva)
Intra-operative Injury Other (Intra-
operative Injury-Other (Specify))
Iron Overload (Iron overload)
Menstruation Irregular (Irregular menses
(change from baseline))
Irritability (Irritability (children <3 years of
age))
Joint-effusion (Joint-effusion)
Joint-effusion (Joint-function)
Keratitis Nec (Keratitis (corneal
inflammation/corneal ulceration))
Laryngeal Nerve Dysfunction (Laryngeal
nerve dysfunction)
Leak (including Anastomotic), Gi (Leak
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(including anastomotic), GI - Biliary tree)
Leak (including Anastomotic), Gi (Leak
(including anastomotic), GI - Esophagus)
Leak (including Anastomotic), Gi (Leak
(including anastomotic), GI - Large
bowel)
Leak (including Anastomotic), Gi (Leak
(including anastomotic), GI - Leak NOS)
Leak (including Anastomotic), Gi (Leak
(including anastomotic), GI - Pancreas)
Leak (including Anastomotic), Gi (Leak
(including anastomotic), GI - Pharynx)
Leak (including Anastomotic), Gi (Leak
(including anastomotic), GI - Rectum)
Leak (including Anastomotic), Gi (Leak
(including anastomotic), GI - Small
bowel)
Leak (including Anastomotic), Gi (Leak
(including anastomotic), GI - Stoma)
Leak (including Anastomotic), Gi (Leak
(including anastomotic), GI - Stomach)
Leak (including Anastomotic), Gu (Leak
(including anastomotic), GU - Bladder)
Leak (including Anastomotic), Gu (Leak
(including anastomotic), GU - Fallopian
tube)
Leak (including Anastomotic), Gu (Leak
(including anastomotic), GU - Kidney)
Leak (including Anastomotic), Gu (Leak
(including anastomotic), GU - Spermatic
cord)
Leak (including Anastomotic), Gu (Leak
(including anastomotic), GU - Stoma)
Leak (including Anastomotic), Gu (Leak
(including anastomotic), GU - Ureter)
Leak (including Anastomotic), Gu (Leak
(including anastomotic), GU - Urethra)
Leak (including Anastomotic), Gu (Leak
(including anastomotic), GU - Uterus)
Leak (including Anastomotic), Gu (Leak
(including anastomotic), GU - Vagina)
Leak (including Anastomotic), Gu (Leak
(including anastomotic), GU - Vas
deferens)
Leak, Cerebrospinal Fluid (csf) (Leak,
cerebrospinal fluid (CSF))
Left Ventricular Diastolic Dysfunction
(Left ventricular diastolic dysfunction)
Left Ventricular Failure (Left ventricular
systolic dysfunction)
Leucopenia Nos (Leukocytes (total
WBC))
Encephalopathy Nos
(Leukoencephalopathy (radiolographic
findings))
Libido Decreased (Libido)
Lipase Increased (Lipase)
Hepatic Failure (Liver dysfunction/failure
(clinical))
Local Complication - Device/prosthesis-
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related (Local complication -
device/prosthesis-related)
Lumbar Spine-range Of Motion (Lumbar
spine-range of motion)
Lymphatics Other (Lymphatics-Other
(Specify))
Lymphedema-related Fibrosis
(Lymphedema-related fibrosis)
Lymphocele (Lymphocele)
Lymphopenia (Lymphopenia)
Hypermagnesaemia (Magnesium,
serum-high (hypermagnesemia))
Blood Magnesium Decreased
(Magnesium, serum-low
(hypomagnesemia))
Malabsorption (Malabsorption)
Virilism (Masculinization of female)
Amnesia Nec (Memory impairment)
Mental Status (Mental status)
Metabolic/laboratory Other
(Metabolic/Laboratory-Other (Specify))
Mood Alteration - Agitation (Mood
alteration - agitation)
Anxiety Nec (Mood alteration - anxiety)
Depression Nec (Mood alteration -
depression)
Euphoric Mood (Mood alteration -
euphoria)
Mucositis/stomatitis (clinical Exam)
(Mucositis/stomatitis (clinical exam) -
Anus)
Mucositis/stomatitis (clinical Exam)
(Mucositis/stomatitis (clinical exam) -
Esophagus)
Mucositis/stomatitis (clinical Exam)
(Mucositis/stomatitis (clinical exam) -
Large bowel)
Mucositis/stomatitis (clinical Exam)
(Mucositis/stomatitis (clinical exam) -
Larynx)
Mucositis/stomatitis (clinical Exam)
(Mucositis/stomatitis (clinical exam) -
Oral cavity)
Stomatitis (Mucositis/stomatitis (clinical
exam) - Pharynx)
Mucositis/stomatitis (clinical Exam)
(Mucositis/stomatitis (clinical exam) -
Rectum)
Mucositis/stomatitis (clinical Exam)
(Mucositis/stomatitis (clinical exam) -
Small bowel)
Mucositis/stomatitis (clinical Exam)
(Mucositis/stomatitis (clinical exam) -
Stomach)
Mucositis/stomatitis (clinical Exam)
(Mucositis/stomatitis (clinical exam) -
Trachea)
Mucositis/stomatitis
(functional/symptomatic)
(Mucositis/stomatitis
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(functional/symptomatic) - Anus)
Mucositis/stomatitis
(functional/symptomatic)
(Mucositis/stomatitis
(functional/symptomatic) - Esophagus)
Mucositis/stomatitis
(functional/symptomatic)
(Mucositis/stomatitis
(functional/symptomatic) - Large bowel)
Mucositis/stomatitis
(functional/symptomatic)
(Mucositis/stomatitis
(functional/symptomatic) - Larynx)
Mucositis/stomatitis
(functional/symptomatic)
(Mucositis/stomatitis
(functional/symptomatic) - Oral cavity)
Mucositis/stomatitis
(functional/symptomatic)
(Mucositis/stomatitis
(functional/symptomatic) - Pharynx)
Mucositis/stomatitis
(functional/symptomatic)
(Mucositis/stomatitis
(functional/symptomatic) - Rectum)
Mucositis/stomatitis
(functional/symptomatic)
(Mucositis/stomatitis
(functional/symptomatic) - Small bowel)
Mucositis/stomatitis
(functional/symptomatic)
(Mucositis/stomatitis
(functional/symptomatic) - Stomach)
Mucositis/stomatitis
(functional/symptomatic)
(Mucositis/stomatitis
(functional/symptomatic) - Trachea)
Muscle Weakness, Generalized Or
Specific Area (not Due To Neuropathy)
(Muscle weakness, generalized or
specific area (not due to neuropathy) -
Extraocular)
Muscle Weakness, Generalized Or
Specific Area (not Due To Neuropathy)
(Muscle weakness, generalized or
specific area (not due to neuropathy) -
Extremity-lower)
Muscle Weakness, Generalized Or
Specific Area (not Due To Neuropathy)
(Muscle weakness, generalized or
specific area (not due to neuropathy) -
Extremity-upper)
Muscle Weakness, Generalized Or
Specific Area (not Due To Neuropathy)
(Muscle weakness, generalized or
specific area (not due to neuropathy) -
Facial)
Muscle Weakness, Generalized Or
Specific Area (not Due To Neuropathy)
(Muscle weakness, generalized or
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specific area (not due to neuropathy) -
Left-sided)
Muscle Weakness, Generalized Or
Specific Area (not Due To Neuropathy)
(Muscle weakness, generalized or
specific area (not due to neuropathy) -
Ocular)
Muscle Weakness, Generalized Or
Specific Area (not Due To Neuropathy)
(Muscle weakness, generalized or
specific area (not due to neuropathy) -
Pelvic)
Muscle Weakness, Generalized Or
Specific Area (not Due To Neuropathy)
(Muscle weakness, generalized or
specific area (not due to neuropathy) -
Right-sided)
Muscle Weakness, Generalized Or
Specific Area (not Due To Neuropathy)
(Muscle weakness, generalized or
specific area (not due to neuropathy) -
Trunk)
Muscle Weakness Nos (Muscle
weakness, generalized or specific area
(not due to neuropathy) - Whole
body/generalized)
Muscular/skeletal Hypoplasia
(Muscular/skeletal hypoplasia)
Musculoskeletal/soft Tissue Other
(Musculoskeletal/Soft Tissue-Other
(Specify))
Myelitis (Myelitis)
Myelodysplasia (Myelodysplasia)
Myocarditis Nos (Myocarditis)
Myositis (Myositis (inflammation/damage
of muscle))
Nail Abnormality Nos (Nail changes)
Nasal Cavity/paranasal Sinus Reactions
(Nasal cavity/paranasal sinus reactions)
Nausea (Nausea)
Necrosis, Gi (Necrosis, GI - Anus)
Necrosis, Gi (Necrosis, GI -
Colon/cecum/appendix)
Necrosis, Gi (Necrosis, GI - Duodenum)
Necrosis, Gi (Necrosis, GI - Esophagus)
Necrosis, Gi (Necrosis, GI - Gallbladder)
Necrosis, Gi (Necrosis, GI - Hepatic)
Necrosis, Gi (Necrosis, GI - Ileum)
Necrosis, Gi (Necrosis, GI - Jejunum)
Necrosis, Gi (Necrosis, GI - Oral)
Necrosis, Gi (Necrosis, GI - Pancreas)
Necrosis, Gi (Necrosis, GI - Peritoneal
cavity)
Necrosis, Gi (Necrosis, GI - Pharynx)
Necrosis, Gi (Necrosis, GI - Rectum)
Necrosis, Gi (Necrosis, GI - Small bowel
NOS)
Necrosis, Gi (Necrosis, GI - Stoma)
Necrosis, Gi (Necrosis, GI - Stomach)
Neuroendocrine: Acth Deficiency
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(Neuroendocrine: ACTH deficiency)
Inappropriate Adh Secretion
(Neuroendocrine: ADH secretion
abnormality (e.g., SIADH or low ADH))
Neuroendocrine: Gonadotropin Secretion
Abnormality (Neuroendocrine:
gonadotropin secretion abnormality)
Neuroendocrine: Growth Hormone
Secretion Abnormality (Neuroendocrine:
growth hormone secretion abnormality)
Neuroendocrine: Prolactin Hormone
Secretion Abnormality (Neuroendocrine:
prolactin hormone secretion abnormality)
Neurology Other (Neurology-Other
(Specify))
Parosmia (Neuropathy: cranial - CN I
Smell)
Cranial Nerve Injury Nos (Neuropathy:
cranial - CN II Vision)
Neuropathy: Cranial (Neuropathy: cranial
- CN III Pupil, upper eyelid, extra ocular
movements)
Neuropathy: Cranial (Neuropathy: cranial
- CN IV Downward, inward movement of
eye)
Neuropathy: Cranial (Neuropathy: cranial
- CN IX Motor-pharynx; Sensory-ear,
pharynx, tongue)
Neuropathy: Cranial (Neuropathy: cranial
- CN V Motor-jaw muscles; Sensory-
facial)
Neuropathy: Cranial (Neuropathy: cranial
- CN VI Lateral deviation of eye)
Neuropathy: Cranial (Neuropathy: cranial
- CN VII Motor-face; Sensory-taste)
Neuropathy: Cranial (Neuropathy: cranial
- CN VIII Hearing and balance)
Neuropathy: Cranial (Neuropathy: cranial
- CN X Motor-palate; pharynx, larynx)
Neuropathy: Cranial (Neuropathy: cranial
- CN XI Motor-sternomastoid and
trapezius)
Neuropathy: Cranial (Neuropathy: cranial
- CN XII Motor-tongue)
Peripheral Motor Neuropathy
(Neuropathy: motor)
Peripheral Sensory Neuropathy
(Neuropathy: sensory)
Neutropenia (Neutrophils/granulocytes
(ANC/AGC))
Blindness Night (Night blindness
(nyctalopia))
Nystagmus Nos (Nystagmus)
Obesity (Obesity)
Obstruction, Gi (Obstruction, GI -
Cecum)
Obstruction, Gi (Obstruction, GI - Colon)
Obstruction, Gi (Obstruction, GI -
Duodenum)
Obstruction, Gi (Obstruction, GI -
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Esophagus)
Obstruction, Gi (Obstruction, GI -
Gallbladder)
Obstruction, Gi (Obstruction, GI - Ileum)
Obstruction, Gi (Obstruction, GI -
Jejunum)
Obstruction, Gi (Obstruction, GI -
Rectum)
Obstruction, Gi (Obstruction, GI - Small
bowel NOS)
Obstruction, Gi (Obstruction, GI - Stoma)
Obstruction, Gi (Obstruction, GI -
Stomach)
Obstruction, Gu (Obstruction, GU -
Bladder)
Obstruction, Gu (Obstruction, GU -
Fallopian tube)
Obstruction, Gu (Obstruction, GU -
Prostate)
Obstruction, Gu (Obstruction, GU -
Spermatic cord)
Obstruction, Gu (Obstruction, GU -
Stoma)
Obstruction, Gu (Obstruction, GU -
Testes)
Ureteric Obstruction (Obstruction, GU -
Ureter)
Obstruction, Gu (Obstruction, GU -
Urethra)
Obstruction, Gu (Obstruction, GU -
Uterus)
Obstruction, Gu (Obstruction, GU -
Vagina)
Obstruction, Gu (Obstruction, GU - Vas
deferens)
Obstruction/stenosis Of Airway
(Obstruction/stenosis of airway -
Bronchus)
Obstruction/stenosis Of Airway
(Obstruction/stenosis of airway - Larynx)
Obstruction/stenosis Of Airway
(Obstruction/stenosis of airway -
Pharynx)
Obstruction/stenosis Of Airway
(Obstruction/stenosis of airway -
Trachea)
Conjunctivitis Nec (Ocular surface
disease)
Ocular/visual Other (Ocular/Visual-Other
(Specify))
Odor (patient Odor) (Odor (patient odor))
Diplopia (Ophthalmoplegia/diplopia
(double vision))
Opportunistic Infection Associated With
>=grade 2 Lymphopenia (Opportunistic
infection associated with >=Grade 2
lymphopenia)
Optic Disc Edema (Optic disc edema)
Orgasmic Dysfunction (Orgasmic
dysfunction)
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Osteonecrosis (Osteonecrosis (avascular
necrosis))
Osteoporosis (Osteoporosis)
Otitis Externa (exc Boil Of Meatus) Nos
(Otitis, external ear (non-infectious))
Otitis Media Serous Nos (Otitis, middle
ear (non-infectious))
Abdominal Pain Nos (Pain - Abdomen
NOS)
Pain (Pain - Anus)
Pain (Pain - Back)
Pain (Pain - Bladder)
Bone Pain (Pain - Bone)
Pain (Pain - Breast)
Pain (Pain - Buttock)
Pain (Pain - Cardiac/heart)
Pain (Pain - Chest wall)
Chest Pain (Pain - Chest/thorax NOS)
Pain (Pain - Dental/teeth/peridontal)
Pain (Pain - Esophagus)
Earache (Pain - External ear)
Pain (Pain - Extremity-limb)
Pain (Pain - Eye)
Pain (Pain - Face)
Pain (Pain - Gallbladder)
Headache Nos (Pain - Head/headache)
Pain (Pain - Intestine)
Arthralgia (Pain - Joint)
Pain (Pain - Kidney)
Pain (Pain - Larynx)
Pain (Pain - Lip)
Hepatic Pain (Pain - Liver)
Pain (Pain - Lymph node)
Pain (Pain - Middle ear)
Myalgia (Pain - Muscle)
Pain (Pain - Neck)
Neuralgia Nos (Pain -
Neuralgia/peripheral nerve)
Pain (Pain - Oral cavity)
Pain (Pain - Oral-gums)
Pain (Pain - Ovulatory)
Pain (Pain - Pain NOS)
Pelvic Pain Nos (Pain - Pelvis)
Pain (Pain - Penis)
Pain (Pain - Pericardium)
Pain (Pain - Perineum)
Pain (Pain - Peritoneum)
Pain (Pain - Phantom (pain associated
with missing limb))
Pleuritic Pain (Pain - Pleura)
Pain (Pain - Prostate)
Proctalgia (Pain - Rectum)
Pain (Pain - Scalp)
Pain (Pain - Scrotum)
Pain (Pain - Sinus)
Pain (Pain - Skin)
Pain (Pain - Stomach)
Pain (Pain - Testicle)
Pain (Pain - Throat/pharynx/larynx)
Tumour Pain (Pain - Tumor pain)
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Dysuria (Pain - Urethra)
Dysmenorrhoea (Pain - Uterus)
Pain (Pain - Vagina)
Pain Other (Pain-Other (Specify))
Palpitations (Palpitations)
Pancreas, Exocrine Enzyme Deficiency
(Pancreas, exocrine enzyme deficiency)
Pancreatic Endocrine: Glucose
Intolerance (Pancreatic endocrine:
glucose intolerance)
Pancreatitis Nos (Pancreatitis)
Parathyroid Function, Low
(hypoparathyroidism) (Parathyroid
function, low (hypoparathyroidism))
Perforation, Gi (Perforation, GI -
Appendix)
Perforation, Gi (Perforation, GI - Biliary
tree)
Perforation, Gi (Perforation, GI - Cecum)
Perforation, Gi (Perforation, GI - Colon)
Perforation, Gi (Perforation, GI -
Duodenum)
Perforation, Gi (Perforation, GI -
Esophagus)
Perforation, Gi (Perforation, GI -
Gallbladder)
Perforation, Gi (Perforation, GI - Ileum)
Perforation, Gi (Perforation, GI -
Jejunum)
Perforation, Gi (Perforation, GI - Rectum)
Perforation, Gi (Perforation, GI - Small
bowel NOS)
Perforation, Gi (Perforation, GI -
Stomach)
Perforation, Gu (Perforation, GU -
Bladder)
Perforation, Gu (Perforation, GU -
Fallopian tube)
Perforation, Gu (Perforation, GU -
Kidney)
Perforation, Gu (Perforation, GU - Ovary)
Perforation, Gu (Perforation, GU -
Prostate)
Perforation, Gu (Perforation, GU -
Spermatic cord)
Perforation, Gu (Perforation, GU -
Stoma)
Perforation, Gu (Perforation, GU -
Testes)
Perforation, Gu (Perforation, GU - Ureter)
Perforation, Gu (Perforation, GU -
Urethra)
Perforation, Gu (Perforation, GU -
Uterus)
Perforation, Gu (Perforation, GU -
Vagina)
Perforation, Gu (Perforation, GU - Vas
deferens)
Pericardial Effusion (Pericardial effusion
(non-malignant))
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Pericarditis (Pericarditis)
Peripheral Ischaemia Nos (Peripheral
arterial ischemia)
Personality Change
(Personality/behavioral)
Petechiae (Petechiae/purpura
(hemorrhage/bleeding into skin or
mucosa))
Phlebitis Superficial (Phlebitis (including
superficial thrombosis))
Phlebolymphatic Cording
(Phlebolymphatic cording)
Hypophosphataemia (Phosphate, serum-
low (hypophosphatemia))
Photosensitivity Reaction Nos
(Photosensitivity)
Phrenic Nerve Dysfunction (Phrenic
nerve dysfunction)
Platelet Count Decreased (Platelets)
Pleural Effusion (Pleural effusion (non-
malignant))
Pneumonitis Nos
(Pneumonitis/pulmonary infiltrates)
Pneumothorax Nos (Pneumothorax)
Portal Hypertension (Portal vein flow)
Hyperkalaemia (Potassium, serum-high
(hyperkalemia))
Hypokalaemia (Potassium, serum-low
(hypokalemia))
Proctitis Nos (Proctitis)
Prolapse Of Stoma, Gi (Prolapse of
stoma, GI)
Prolapse Of Stoma, Gu (Prolapse of
stoma, GU)
Prolonged Chest Tube Drainage Or Air
Leak After Pulmonary Resection
(Prolonged chest tube drainage or air
leak after pulmonary resection)
Prolonged Intubation After Pulmonary
Resection (>24 Hrs After Surgery)
(Prolonged intubation after pulmonary
resection (>24 hrs after surgery))
Electrocardiogram Qt Prolonged
(Prolonged QTc interval)
Proptosis/enophthalmos
(Proptosis/enophthalmos)
Proteinuria Present (Proteinuria)
Pruritus Nos (Pruritus/itching)
Delusion Nos (Psychosis
(hallucinations/delusions))
Activated Partial Thromboplastin Time
Prolonged (PTT (Partial thromboplastin
time))
Puberty (delayed) (Puberty (delayed))
Puberty (precocious) (Puberty
(precocious))
Pulmonary Fibrosis (Pulmonary fibrosis
(radiographic changes))
Pulmonary Hypertension (Pulmonary
hypertension)
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Pulmonary/upper Respiratory Other
(Pulmonary/Upper Respiratory-Other
(Specify))
Upper Motor Neurone Lesion (Pyramidal
tract dysfunction (e.g., increased tone,
hyperreflexia, positive Babinski,
decreased fine motor coordination))
Rash: Acne/acneiform (Rash:
acne/acneiform)
Radiation Recall Syndrome (Rash:
dermatitis associated with radiation -
Chemoradiation)
Dermatitis Radiation Nos (Rash:
dermatitis associated with radiation -
Radiation)
Erythema Multiforme (Rash: erythema
multiforme (e.g., Stevens-Johnson
syndrome, toxic epidermal necrolysis))
Localised Exfoliation (Rash: hand-foot
skin reaction)
Dermatitis Exfoliative Nos
(Rash/desquamation)
Renal Failure Nos (Renal failure)
Renal/genitourinary Other
(Renal/Genitourinary-Other (Specify))
Restrictive Cardiomyopathy (Restrictive
cardiomyopathy)
Retinal Detachment (Retinal
detachment)
Retinoic Acid Syndrome (Retinoic acid
syndrome")
Retinopathy (Retinopathy)
Right Ventricular Dysfunction (cor
Pulmonale) (Right ventricular dysfunction
(cor pulmonale))
Rigors (Rigors/chills)
Salivary Gland Disorder Nos (Salivary
gland changes/saliva)
Scleral Necrosis/melt (Scleral
necrosis/melt)
Secondary Malignancy Possibly Related
To Cancer Treatment (Secondary
Malignancy-possibly related to cancer
treatment (Specify))
Convulsions Nos (Seizure)
Seroma (Seroma)
Serum Sickness (Serum sickness)
Sexual/reproductive Function Other
(Sexual/Reproductive Function-Other
(Specify))
Short Stature (Short stature)
Skin Breakdown/decubitus Ulcer (Skin
breakdown/decubitus ulcer)
Hypernatraemia (Sodium, serum-high
(hypernatremia))
Hyponatraemia (Sodium, serum-low
(hyponatremia))
Soft Tissue Necrosis (Soft tissue
necrosis - Abdomen)
Soft Tissue Necrosis (Soft tissue
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necrosis - Extremity-lower)
Soft Tissue Necrosis (Soft tissue
necrosis - Extremity-upper)
Soft Tissue Necrosis (Soft tissue
necrosis - Head)
Soft Tissue Necrosis (Soft tissue
necrosis - Neck)
Soft Tissue Necrosis (Soft tissue
necrosis - Pelvic)
Soft Tissue Necrosis (Soft tissue
necrosis - Thorax)
Depressed Level Of Consciousness
(Somnolence/depressed level of
consciousness)
Speech Disorder Nec (Speech
impairment (e.g., dysphasia or aphasia))
Splenic Function (Splenic function)
Striae (Striae)
Stricture/stenosis (including
Anastomotic), Gi (Stricture/stenosis
(including anastomotic), GI - Anus)
Stricture/stenosis (including
Anastomotic), Gi (Stricture/stenosis
(including anastomotic), GI - Biliary tree)
Stricture/stenosis (including
Anastomotic), Gi (Stricture/stenosis
(including anastomotic), GI - Cecum)
Stricture/stenosis (including
Anastomotic), Gi (Stricture/stenosis
(including anastomotic), GI - Colon)
Stricture/stenosis (including
Anastomotic), Gi (Stricture/stenosis
(including anastomotic), GI - Duodenum)
Stricture/stenosis (including
Anastomotic), Gi (Stricture/stenosis
(including anastomotic), GI - Esophagus)
Stricture/stenosis (including
Anastomotic), Gi (Stricture/stenosis
(including anastomotic), GI - Ileum)
Stricture/stenosis (including
Anastomotic), Gi (Stricture/stenosis
(including anastomotic), GI - Jejunum)
Stricture/stenosis (including
Anastomotic), Gi (Stricture/stenosis
(including anastomotic), GI -
Pancreas/pancreatic duct)
Stricture/stenosis (including
Anastomotic), Gi (Stricture/stenosis
(including anastomotic), GI - Pharynx)
Stricture/stenosis (including
Anastomotic), Gi (Stricture/stenosis
(including anastomotic), GI - Rectum)
Stricture/stenosis (including
Anastomotic), Gi (Stricture/stenosis
(including anastomotic), GI - Small bowel
NOS)
Stricture/stenosis (including
Anastomotic), Gi (Stricture/stenosis
(including anastomotic), GI - Stoma)
Stricture/stenosis (including
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Anastomotic), Gi (Stricture/stenosis
(including anastomotic), GI - Stomach)
Stricture/stenosis (including
Anastomotic), Gu (Stricture/stenosis
(including anastomotic), GU - Bladder)
Stricture/stenosis (including
Anastomotic), Gu (Stricture/stenosis
(including anastomotic), GU - Fallopian
tube)
Stricture/stenosis (including
Anastomotic), Gu (Stricture/stenosis
(including anastomotic), GU - Prostate)
Stricture/stenosis (including
Anastomotic), Gu (Stricture/stenosis
(including anastomotic), GU - Spermatic
cord)
Stricture/stenosis (including
Anastomotic), Gu (Stricture/stenosis
(including anastomotic), GU - Stoma)
Stricture/stenosis (including
Anastomotic), Gu (Stricture/stenosis
(including anastomotic), GU - Testes)
Stricture/stenosis (including
Anastomotic), Gu (Stricture/stenosis
(including anastomotic), GU - Ureter)
Stricture/stenosis (including
Anastomotic), Gu (Stricture/stenosis
(including anastomotic), GU - Urethra)
Stricture/stenosis (including
Anastomotic), Gu (Stricture/stenosis
(including anastomotic), GU - Uterus)
Stricture/stenosis (including
Anastomotic), Gu (Stricture/stenosis
(including anastomotic), GU - Vagina)
Stricture/stenosis (including
Anastomotic), Gu (Stricture/stenosis
(including anastomotic), GU - Vas
deferens)
Supraventricular And Nodal Arrhythmia
(Supraventricular and nodal arrhythmia -
Atrial fibrillation)
Supraventricular And Nodal Arrhythmia
(Supraventricular and nodal arrhythmia -
Atrial flutter)
Supraventricular And Nodal Arrhythmia
(Supraventricular and nodal arrhythmia -
Atrial tachycardia/paroxysmal atrial
tachycardia)
Supraventricular And Nodal Arrhythmia
(Supraventricular and nodal arrhythmia -
Nodal/junctional)
Supraventricular And Nodal Arrhythmia
(Supraventricular and nodal arrhythmia -
Sinus arrhythmia)
Sinus Bradycardia (Supraventricular and
nodal arrhythmia - Sinus bradycardia)
Sinus Tachycardia (Supraventricular and
nodal arrhythmia - Sinus tachycardia)
Supraventricular Arrhythmia Nos
(Supraventricular and nodal arrhythmia -
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Supraventricular arrhythmia NOS)
Supraventricular And Nodal Arrhythmia -
Supraventricular Extrasystoles
(premature Atrial Contractions;
Premature Nodal/junctional
Contractions) (Supraventricular and
nodal arrhythmia - Supraventricular
extrasystoles (premature atrial
contractions; premature nodal/junctional
contractions))
Supraventricular And Nodal Arrhythmia
(Supraventricular and nodal arrhythmia -
Supraventricular tachycardia)
Sweating Increased (Sweating
(diaphoresis))
Syncope (Syncope (fainting))
Syndromes Other (Syndromes-Other
(Specify))
Taste Disturbance (Taste alteration
(dysgeusia))
Telangiectasia (Telangiectasia)
Thrombosis/embolism (vascular Access-
related) (Thrombosis/embolism (vascular
access-related))
Thrombosis Nos
(Thrombosis/thrombus/embolism)
Thrombotic Microangiopathy (e.g.,
Thrombotic Thrombocytopenic
Purpura[ttp] Or Hemolytic Uremic
Syndrome[hus]) (Thrombotic
microangiopathy (e.g., thrombotic
thrombocytopenic purpura or hemolytic
uremic syndrome))
Thyroid Function, High (hyperthyroidism,
Thyrotoxicosis) (Thyroid function, high
(hyperthyroidism, thyrotoxicosis))
Hypothyroidism (Thyroid function, low
(hypothyroidism))
Tinnitus (Tinnitus)
Tremor Nec (Tremor)
Hypertriglyceridaemia (Triglyceride,
serum-high (hypertriglyceridemia))
Trismus (difficulty, Restriction Or Pain
When Opening Mouth) (Trismus
(difficulty, restriction or pain when
opening mouth))
Tumour Flare (Tumor flare)
Tumour Lysis Syndrome (Tumor lysis
syndrome)
Caecitis (Typhlitis (cecal inflammation))
Ulcer, Gi (Ulcer, GI - Anus)
Ulcer, Gi (Ulcer, GI - Cecum)
Ulcer, Gi (Ulcer, GI - Colon)
Duodenal Ulcer (Ulcer, GI - Duodenum)
Ulcer, Gi (Ulcer, GI - Esophagus)
Ulcer, Gi (Ulcer, GI - Ileum)
Ulcer, Gi (Ulcer, GI - Jejunum)
Ulcer, Gi (Ulcer, GI - Rectum)
Ulcer, Gi (Ulcer, GI - Small bowel NOS)
Ulcer, Gi (Ulcer, GI - Stoma)
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Gastric Ulcer (Ulcer, GI - Stomach)
Ulceration (Ulceration)
Hyperuricaemia (Uric acid, serum-high
(hyperuricemia))
Fanconi Syndrome (Urinary electrolyte
wasting (e.g., Fanconi's syndrome, renal
tubular acidosis))
Urinary Frequency (Urinary
frequency/urgency)
Urinary Retention (Urinary retention
(including neurogenic bladder))
Urine Discolouration (Urine color
change)
Urticaria Nos (Urticaria (hives, welts,
wheals))
Uveitis (Uveitis)
Vaginal Discharge (non-infectious)
(Vaginal discharge (non-infectious))
Vulvovaginal Dryness (Vaginal dryness)
Vaginal Mucositis (Vaginal mucositis)
Vaginal Stenosis/length (Vaginal
stenosis/length)
Vaginitis (Vaginitis (not due to infection))
Valvular Heart Disease (Valvular heart
disease)
Vascular Other (Vascular-Other
(Specify))
Vasculitis Nos (Vasculitis)
Vasovagal Attack (Vasovagal episode)
Ventricular Arrhythmia (Ventricular
arrhythmia - Bigeminy)
Ventricular Arrhythmia (Ventricular
arrhythmia - Idioventricular rhythm)
Ventricular Arrhythmia (Ventricular
arrhythmia - PVCs)
Ventricular Arrhythmia (Ventricular
arrhythmia - Torsade de pointes)
Ventricular Arrhythmia (Ventricular
arrhythmia - Trigeminy)
Ventricular Arrhythmia Nos (Ventricular
arrhythmia - Ventricular arrhythmia NOS)
Ventricular Arrhythmia (Ventricular
arrhythmia - Ventricular fibrillation)
Ventricular Arrhythmia (Ventricular
arrhythmia - Ventricular flutter)
Ventricular Arrhythmia (Ventricular
arrhythmia - Ventricular tachycardia)
Vessel Injury-artery (Vessel injury-artery
- Aorta)
Vessel Injury-artery (Vessel injury-artery
- Carotid)
Vessel Injury-artery (Vessel injury-artery
- Extremity-lower)
Vessel Injury-artery (Vessel injury-artery
- Extremity-upper)
Vessel Injury-artery (Vessel injury-artery
- Other NOS)
Vessel Injury-artery (Vessel injury-artery
- Visceral)
Vessel Injury-vein (Vessel injury-vein -
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Extremity-lower)
Vessel Injury-vein (Vessel injury-vein -
Extremity-upper)
Vessel Injury-vein (Vessel injury-vein -
IVC)
Vessel Injury-vein (Vessel injury-vein -
Jugular)
Vessel Injury-vein (Vessel injury-vein -
Other NOS)
Vessel Injury-vein (Vessel injury-vein -
SVC)
Vessel Injury-vein (Vessel injury-vein -
Viscera)
Viral Hepatitis (Viral hepatitis)
Visceral Arterial Ischaemia (Visceral
arterial ischemia (non-myocardial))
Vision Blurred (Vision-blurred vision)
Photopsia (Vision-flashing lights/floaters)
Photophobia (Vision-photophobia)
Vital Capacity (Vital capacity)
Vitreous Hemorrhage (Vitreous
hemorrhage)
Dysphonia (Voice changes/dysarthria
(e.g., hoarseness, loss or alteration in
voice, laryngitis))
Vomiting Nos (Vomiting)
Lacrimation Increased (Watery eye
(epiphora, tearing))
Weight Increased (Weight gain)
Weight Decreased (Weight loss)
Culture Wound Negative (Wound
complication, non-infectious)
CTC AE Grade
CTCAE Begin Date
CTC Adverse Event Attribution (Attribution to
Protocol Treatment See protocol sections 6 & 7
for definition of "protocol treatment")
Definite (Definite)
Possible (Possible)
Probable (Probable)
Unlikely (Unlikely)
Unrelated (Unrelated)
Has an Adverse Event Expedited Report been
submitted? (AdEERS)
No (No)
Unknown (Unknown)
Yes (Yes)
Form completion date
Comments
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Person completing form
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Pre-Study Form Colorectal Cancer SWOG
S0600 NCT00499369
Southwest Oncology Group S0600 Prestudy Form
Irinotecan and Cetuximab With or Without Bevacizumab in
Treating Patients With Metastatic Colorectal Cancer That
Progressed During First-Line Therapy
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=153FB385-
1447-52C3-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11828
Pre-Study Form Colorectal Cancer
SWOG S0600 NCT00499369
Header
SWOG Patient ID
SWOG Study No.
Registration Step
Patient Initials (L, F M)
Institution/Affiliate
Physician
Participating Group Name
Participating Group Study No.
Participating Group Patient ID (Place an X in
appropriate boxes. Circle AMENDED items in red
and write AMENDED across the top of the form.)
Comments
Disease Description
Performance Status
Fully Active, Able To Carry On All Pre-
disease Performance Without
Restriction. (0)
Restricted In Physically Strenuous
Activity But Ambulatory And Able To
Carry Out Work Of A Light Or Sedentary
Nature, E.g., Light Housework, Office
Work. (1)
Ambulatory And Capable Of All Selfcare
But Unable To Carry Out Any Work
Activities. Up And About More Than 50%
Of Waking Hours. (2)
1 / 5
Capable Of Only Limited Selfcare,
Confined To Bed Or Chair More Than
50% Of Waking Hours. (3)
Completely Disabled. Cannot Carry On
Any Selfcare. Totally Confined To Bed Or
Chair. (4)
Dead (5)
Date of progression on first-line chemotherapy
Site of Involvement (s - select all that apply for
current disease:)
Bone (Bone)
Distant Lymph Nodes (Distant lymph
nodes)
Liver (Liver)
Lung (Lung)
Other Specify (Other)
Other Abdominal (Other abdominal)
Pleura (Pleura)
Primary Site/direct Extension (Primary
site/direct extension)
Regional Lymph Nodes (Regional lymph
nodes)
Laboratory Values
ANC
1000/ul
Absolute neutrophil count LLN
/ul
Collection Date
Peripheral Platelet Count
1000/uL
Platelets LLN
1000/ul
Hemoglobin
g/dL
Hemoglobin, LLN
g/dL
Patient receiving full-dose anticoagulants
Yes
No
INR
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Liver metastases (Hepatic:)
Yes
No
Total Bilirubin
mg/dL
Total bilirubin ULN
mg/dL
AST (SGOT)
U/L
AST (SGOT) ULN
U/L
ALT (SGPT)
U/L
ALT (SGPT) ULN
U/L
Serum creatinine
mg/dL
Serum Creatinine ULN
mg/dL
Creatinine Clearance measured
mL/min
Creatinine Clearance estimated
mL/min
UPC ratio
Protein from 24 hour Urine Collection (if > 0.5,
then 24 hour:)
g/24 hours
Ionized serum calcium
mmol/L
Ionized serum calcium LLN
mmol/L
Calcium
mmol/l
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Calcium LLN
mmol/l
Magnesium
mmol/L
Magnesium, LLN
mmol/l
Sodium
mmol/L
Sodium LLN
mmol/l
Potassium
mmol/l
Potassium LLN
mmol/l
Bicarbonate
mmol/L
Bicarbonate LLN
mmol/L
Chloride
mmol/L
Chloride LLN
mmol/L
Systolic
>= 0
mmHg
Diastolic
>= 0
mmHg
Prior Treatment Related To This Cancer
Prior Therapy Type (select ALL that apply)
Chemotherapy Multiple Agents Systemic
(Chemotherapy multiple agents
systemic)
Chemotherapy Non-cytotoxic
(Chemotherapy non-cytotoxic)
Chemotherapy Nos (Chemotherapy
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NOS)
Chemotherapy Single Agent Systemic
(Chemotherapy single agent systemic)
Other (Other)
Radiotherapy (Radiotherapy)
Surgery (Surgery)
Number of prior chemotherapy regimens
Date Prior Chemotherapy Ended
Date prior bevacizumab ended
Front-line chemotherapy regimen (select one)
Fluorouracil/leucovorin
Calcium/oxaliplatin (FOLFOX)
First-line Therapy With Folfox-bev, Xelox-
bev, Or Flox-bev With Discontinuation Of
Oxaliplatin And Then Addition Of
Fluoropyrimidine (OPTIMOX)
Capecitabine/oxaliplatin/bevacizumab
(xelox) (XELOX)
Prior radiation therapy stop date (if applicable)
Date of Most Recent Surgery (major if applicable)
Other therapy, specify
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Advanced Chronic Myelogenous Leukemia
(CML) NCT00123487- End of Treatment
Study documentation part: End of treatment.
This is a phase III study of BMS-354825 in subjects with
chronic myelogenous leukemia in accelerated phase, or in
myeloid or lymphoid blast phase or with Philadelphia
chromosome positive (Ph+) acute lymphoblastic leukemia
who are resistant or intolerant to imatinib mesylate
(Gleevec).Trial Number: NCT00123487. Drug: dasatinib.
Phase 3
All rights reserved. Please visit https://medical-data-
models.org/forms/11830
Advanced Chronic Myelogenous
Leukemia (CML) NCT00123487-
End of Treatment
SUBJECT DETAILS
Subject number :
Subject initial:
Visit date:
Site number:
VITAL SIGNS
Were vital signs taken?
Yes
No
Date:
Position:
Sitting (1)
Standing (2)
Supine (3)
Blood pressure systolic (in mm Hg):
mmHg
Blood pressure diastolic (in mm Hg):
mmHg
Heart rate (in bpm):
bpm
PHYSICAL MEASUREMENTS
Were any physical measurements taken?
Yes
No
Date of measurement:
1 / 15
Weight (in Kg):
Kg
Performance status (ECOG):
EXTRAMEDULLARY INVOLVEMENT
Date of assessment:
Is extramedullary disease present?
Yes
No
f yes, please provide the side code(s) from below:
1=Skin/ Soft tissue, 2=Bone, 3=Visceral (lung),
4=Visceral (liver), 5=Visceral  (other), 6=Lymph
node, 8=Bone marrow, 9=CNS, 10=Mediastinum,
14=Effusion, 16=Spleen, 18= Intestine, 19=
Ascites, 25= Pelvis, 26=Peritoneum, 34= Ovary,
36= Pleura, 37= Gastric, 98= Other
PROGRESSION
Did the subject progress?
Yes
No
Date of progression:
Reason for progression:
10 Loss of hematologic response (CHR,
NEL or RTC) (1)
12 Development of blast phase CML (2)
9 No decrease from baseline percent
blasts despite maximum dose (3)
18 Development of new extra- medullary
sites (other than liver or spleen) (4)
BEST OVERALL HEMATOLOGIC
RESPONSE
Was the hematologic response confirmed?
Yes
No
Complete hematologic response (CHR):
Yes
No
If yes, date of CHR:
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No evidence of leukemia (NEL):
Yes
No
If yes, date of NEL:
Return to chronic phase (RTC):
Yes
No
If yes, date of RTC:
Minor hematologic response (MiHR):
Yes
No
No hematologic response:
Yes
No
Unable to determine:
Early death attributed to toxicity. (1)
Early discontinuation attributed to
toxicity. (2)
No assessment due to reason other than
toxicity or progression (Specify) (3)
Please specify "The reason other than toxicity or
progression":
BEST OVERALL CYTOGENETIC
RESPONSE
Date of best cytogenetic response:
Best cytogenetic response:
Complete cytogenetic response (CCyR)
(1)
Partial cytogenetic response (PCyR) (2)
Minor cytogenetic response (3)
Minimal cytogenetic response (4)
No cytogenetic response:
Yes
No
Unable to determine:
Early death attributed to toxicity. (1)
Early discontinuation attributed to
toxicity. (2)
No assessment due to reason other than
toxicity or progression (Specify) (3)
Please specify "The reason other than toxicity or
progression":
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EXTERNAL DATA TRACKING
Were any of the following protocol specified
activities performed?
Yes
No
If yes, provide date and time:
Mutation analysis:
Yes
No
END OF TREATMENT STATUS
Date of subject off treatment:
Reason for discontinuing:
Disease progression (1)
Study drug toxicity (Specify) (2)
Adverse event unrelated to study drug
(Specify) (3)
Subject request (4)
Investigator request (5)
Other (Specify) (6)
For the reasons with "Specify", please mention
the details:
SUBJECT STATUS
Will the subject continue to be followed?
Yes
No
If no, please indicate the primary reason:
Subject withdrew consent (Specify) (1)
Death (2)
Lost to follow-up (3)
Other (Specify) (4)
In case of "Lost to follow-up", please mention the
date of last contact:
For the reasons with "Specify", please mention
the details:
Pharmacokinetics
DOSE ADMINISTRATION
Date and time administered (Day 7):
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Last dose received on day 7 (in mg):
mg
Date and time administered (Day 8):
Morning dose received on day 8 (in mg):
mg
Date and time administered (Day 14):
Last dose received on day 14 (in mg):
mg
Date and time administered (Day 15):
Morning dose received on day 15 (in mg):
mg
BLOOD PHARMACOKINETICS (DAY 8)
Were any samples collected?
Yes
No
Pharmacokinetic sample:
Actual date and time during the phase predose:
Actual date and time during the interval of 1- 3 hr:
Actual date and time during the interval of 5- 8 hr:
BLOOD PHARMACOKINETICS (DAY 15)
Were any samples collected?
Yes
No
Pharmacokinetic sample label:
Actual date and time during the phase predose:
Actual date and time during the interval of 3- 4 hr
(post dose):
Comments:
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CSF PHARMACOKINETICS
Were any samples collected?
Yes
No
Actual date and time on day 15:
Actual date and time on day 15 (3- 4 hours post
dose):
Comments:
Follow- Up
FOLLOW-UP
Date of last contact:
Subject disease status:
Alive, no evidence of disease (1)
Alive, with disease (2)
Alive, disease status unknown (3)
Lost to follow-up (4)
Dead (5)
Does subject still have a prior toxicity related to
study drug?
Yes
No
Did the subject's disease progress since the last
report?
Yes
No
Date of recent progression:
SUBJECT STATUS
Will the subject continue to be followed?
Yes
No
If no, please indicate the primary reason:
Subject withdrew consent (Specify) (1)
Death (2)
Lost to follow-up (3)
Other (Specify) (4)
In case of "Lost to follow-up", please mention the
date of last contact:
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For the reasons with "Specify", please mention
the details:
Evaluation of EQ-5D:
DRUG ACCOUNTABILITY
Medication name:
Serious Adverse Event (SAE)- Form
GENERAL INFORMATION
Date to submitted to BMS:*
Name of institution:
Address:
Country:
Date of birth:
Gender at birth:
Female (1)
Male (2)
Race:
White (1)
Black (2)
Asian (3)
American indian or Alaska native (4)
Native Hawaiian or other pacific islander
(5)
Other race (6)
If "Other", please specify:
SERIOUS ADVERSE EVENT (SAE)-
INITIAL REPORT
Ctc code:
Event:
Death (1)
Life threatening (2)
Cancer (3)
Congenital anomaly (4)
Hospitalization/ Prolongation (5)
Persistent/ Significant disability (6)
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Important medical event (7)
Drug dependency/ Abuse (8)
Other (9)
If "Other", please specify:
Onset date and time:
Resolution date and time:
CTC grade:
Relationship to study drug:
Certain (1)
Probable (2)
Possible (3)
Not likely (4)
Not related (5)
Action taken regarding study drug
None (1)
Reduced (2)
Increased (3)
Interrupted (4)
Discontinued (5)
Outcome:
Did not resolve (1)
Resolved (2)
Resolved W/ Sequela (3)
Unknown (4)
Death (5)
Treatment required?
Yes
No
Date of death:
Cause of death:
SERIOUS ADVERSE EVENT (SAE)-
FOLLOW-UP REPORT
Description of serious adverse event/ relevant
medical history; If unrelated to study drug, specify
cause:
Study drug:
Phase:
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Lead in (1)
Blinded (2)
Open (3)
Suspect drug:
Yes
No
Therapy start date:
Therapy stop date:
Total dose daily:
No of course:
Route:
Concomitant medication (exclude any medication
used to treat the SAE):
Concomitant medication therapy start date:
Concomitant medication therapy stop date:
Laboratory test (Relevant to SAE only):
Date of test:
Results:
Baseline:
Supplemental page
EXCEPTION
Was an exception granted?
Yes (1)
No  (2)
Not applicable (3)
Date exception granted:
Inclusion number:
Exclusion number:
Exception granted by (Personnel):
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Comments:
Please see https://medical-data-
models.org/forms/11515 (Previous and
current medications)
Please see https://medical-data-
models.org/forms/11515 (Pre- treatment
events)
Please see https://medical-data-
models.org/forms/11783 (On- Treatment
1)
Please see https://medical-data-
models.org/forms/11515 (Medical tests
and examinations)
Please see https://medical-data-
models.org/forms/11515 (General Medical
History)
Please see https://medical-data-
models.org/forms/11783 (On- Treatment
1)
FLUORESCENT IN SITU
HYBRIDIZATION (FISH)
Was a FISH analysis performed?
Yes
No
Date:
Sample type:
Peripheral blood (1)
Bone marrow (2)
Extramedullary (3)
For extramedullary site, please mention the site
from the followings, 1=Skin/ Soft tissue, 2=Bone,
3=Visceral (lung), 4=Visceral (liver), 5=Visceral
(other), 6=Lymph node, 8=Bone marrow, 9=CNS,
10=Mediastinum, 14=Effusion, 16=Spleen, 18=
Intestine, 19= Ascites, 25= Pelvis,
26=Peritoneum, 34= Ovary, 36= Pleura, 37=
Gastric, 98= Other:
10 / 15
Advanced Chronic Myelogenous Leukemia (CML) NCT00123487- End of
Treatment
Please see https://medical-data-
models.org/forms/11783 (On- Treatment
8)
LABORATORY TEST RESULTS
Were laboratory tests performed?
Yes
No
Name of laboratory:
Date of hematology specimen collection:
Differential:
% (1)
Absolute (2)
Hemoglobin:
Hematocrit:
Red blood cells:
White blood cells:
Platelet count:
Neutrophils:
Bands:
Lymphocytes:
Monocytes:
Eosinophils:
Basophils:
Blasts:
Promyelocytes:
Myelocytes:
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Metamyelocytes:
Other, please specify:
Date of coagulation specimen collection:
International normalized ratio:
Other, please specify:
Was the subject fasting?
Yes (1)
No (2)
Unknown (3)
Date of chemistry specimen collection:
AST (SGOT):
ALT (SGPT):
Total bilirubin:
Alkaline phosphatase:
Lactate dehydrogenase (LDH):
Creatinine:
Blood urea nitrogen (BUN):
Urea:
Potassium:
Uric acid
Ionized calcium:
Calcium:
Phosphorus:
Magnesium:
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Sodium:
Please see https://medical-data-
models.org/forms/11783 (On- Treatment
8)
Please see https://medical-data-
models.org/forms/11783 (On- Treatment
1)
Please see https://medical-data-
models.org/forms/11783 (On- Treatment
6)
Please see https://medical-data-
models.org/forms/11783 (On- Treatment
6)
DEATH DATA
Did the subject die?
Yes
No
Date of death:
Cause of death:
Disease (Specify) (1)
Study drug toxicity (Specify) (2)
Infection (Specify) (3)
Other malignancy/ Neoplasm (Specify)
(4)
Cardiovascular disease (Specify) (5)
Fatal bleeding (Specify) (6)
Unknown (7)
Other (Specify) (8)
For the causes asking for specification, please
mention details:
ENROLLMENT IN PREVIOUS BMS
CA180 PROTOCOL
Previous protocol number:
Previous site number:
Previous subject number:
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Date subject or legally authorized representative
signed informed consent for previous protocol?
DOSE ADMINISTRATION FOR
UNSCHEDULED CSF
Date and time of dose administration (Day prior
to CSF ):
Last dose received (in mg):
mg
Date and time of dose administration (Day of
CSF):
Morning dose received (in mg):
mg
CSF PHARMACOKINETICS
Were any samples collected?
Yes
No
Actual date and time (3- 4 hours post dose):
Pharmacokinetic sample label:
Comments:
BLOOD PHARMACOKINETICS
Were any samples collected?
Yes
No
Pharmacokinetic sample label:
Actual date and time (3-4 hr post dose):
Comments:
DOSE ADMINISTRATION
Date and time of dose administration:
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Last dose received (in mg):
mg
PLEURAL OR OTHER BODY FLUID
PHARMACOKINETICS
Were any samples collected?
Yes
No
Actual date and time of sample collection:
Pharmacokinetic sample label:
Comments
DIAGNOSTIC PROCEDURES
Did the subject have any non protocol specified
diagnostic procedures performed?
Yes
No
Procedure:
Date of procedure:
Reason:
Adverse event (1)
Other (2)
Findings:
15 / 15
Advanced Chronic Myelogenous Leukemia (CML) NCT00123487- End of
Treatment
Advanced Chronic Myelogenous Leukemia
(CML) NCT00123487 – On- Treatment
Study documentation part: On- Treatment
This is a phase III study of BMS-354825 in subjects with
chronic myelogenous leukemia in accelerated phase, or in
myeloid or lymphoid blast phase or with Philadelphia
chromosome positive (Ph+) acute lymphoblastic leukemia
who are resistant or intolerant to imatinib mesylate
(Gleevec).Trial Number: NCT00123487. Drug: dasatinib.
Phase 3
All rights reserved. Please visit https://medical-data-
models.org/forms/11831
Advanced Chronic Myelogenous
Leukemia (CML) NCT00123487 –
On- Treatment
SUBJECT DETAILS
Subject number:
Subject initial:
Visit date:
On-Treatment 1
VITAL SIGNS (DAY 1)
Were vital signs taken?
Yes
No
Date:
Position:
Sitting (1)
Standing (2)
Supine (3)
Blood pressure systolic (in mm Hg):
mmHg
Blood pressure diastolic (in mm Hg):
mmHg
Heart rate (in bpm):
bpm
PHYSICAL MEASUREMENTS (DAY 1)
Were any physical measurements taken?
Yes
No
Date of measurement:
Weight (in Kg):
1 / 42
Kg
Performance status (ECOG):
EXTRAMEDULLARY INVOLVEMENT
(DAY 1)
Date of assessment:
Is extramedullary disease presen?
Yes
No
If yes, please provide the side code(s) from
below: 1=Skin/ Soft tissue, 2=Bone, 3=Visceral
(lung), 4=Visceral (liver), 5=Visceral  (other),
6=Lymph node, 8=Bone marrow, 9=CNS,
10=Mediastinum, 14=Effusion, 16=Spleen, 18=
Intestine, 19= Ascites, 25= Pelvis,
26=Peritoneum, 34= Ovary, 36= Pleura, 37=
Gastric, 98= Other
VITAL SIGNS (END OF MONTH 1)
Were vital signs taken?
Yes
No
Date:
Position:
Sitting (1)
Standing (2)
Supine (3)
Blood pressure systolic (in mm Hg):
mmHg
Blood pressure diastolic (in mm Hg):
mmHg
Heart rate (in bpm):
bpm
PHYSICAL MEASUREMENTS (END OF
MONTH 1)
Were any physical measurements taken?
Yes
No
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Date of measurement:
Weight (in Kg):
Kg
Performance status (ECOG):
EXTRAMEDULLARY INVOLVEMENT
(END OF MONTH 1)
Date of assessment:
Is extramedullary disease present?
Yes
No
If yes, please provide the side code(s) from
below: 1=Skin/ Soft tissue, 2=Bone, 3=Visceral
(lung), 4=Visceral (liver), 5=Visceral  (other),
6=Lymph node, 8=Bone marrow, 9=CNS,
10=Mediastinum, 14=Effusion, 16=Spleen, 18=
Intestine, 19= Ascites, 25= Pelvis,
26=Peritoneum, 34= Ovary, 36= Pleura, 37=
Gastric, 98= Other
CHEST X-RAY
Was a chest X-ray performed?
Yes
No
Date of chest X-ray:
Interpretation of X-ray report:
Normal  (1)
Abnormal (2)
If Abnormal, please specify clinically relevant
abnormalities:
TRANSFUSION
Did the subject recieve any transfusion(s) since
the last data collection?
Yes
No
Date of transfusion:
Type of transfusion(s), provide all that apply from
below: 1= Paked cells, 3= Plasma, 5=Platelets,
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98= Other
EXTERNAL DATA TRACKING
Were any of the following protocol specified
activities performed?
Yes
No
If yes, provide date and time:
ELECTROCARDIOGRAM
Was an Electrocardiogram done?
Yes
No
Date and time:
Heart rate (in bpm):
bpm
PR Interval (in sec):
sec
QRS Width (in sec):
sec
QT Interval (in sec):
Bazett's QTc (in msec):
msec
Fridericia's QTc (in msec):
msec
Electrocardiogram interpretation:
Normal (1)
Abnormal (2)
If abnormal, ECG corresponds to Hypertrophy?
Provide from the following: 1= Left atrial
hypertrophy, 2= Right atrial hypertrophy, 3= Left
ventricular hypertrophy, 4= Right ventricular
hypertrophy
If abnormal, ECG corresponds to infarction?
Provide from the following: 5= Acute infarction, 6=
Subacute infarction (Recent), 7= Old infarction
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If abnormal, ECG corresponds to ST/T
Morphology? Provide from the following: 8=
Myocardial ischemia, 9= Digitalis effect, 10=
Symmetrical T- Wave inversions, 12= Other non-
specific ST/T
If abnormal, ECG corresponds to disorders of
Rhythm? Provide from the following: 13= Sinus
tachycardia, 14= Sinus bradycardia, 15=
Supraventricular premature beat, 17=
Supraventricular tachycardia, 19= Atrial
fibrillation, 20= Atrial flutter, 16= Ventricular
premature beat, 18= Ventricular tachycardia, 73=
Ventricular fibrillation, 55=Torsade de pointes,
21= Other rhythm abnormalities, 22= Pacemaker
rhythm
If abnormal, ECG corresponds to disorders of
conduction? Provide from the following: 23=  1°
A-V Block, 24= 2°  A-V Block, 25= 3°  A-V Block,
26= LBB Block, 27= RBB Block, 29= Other
intraventricular conduction defect, 28= Pre-
excitation syndrom
Other abnormalities? 30= Left axis deviation, 98=
Other (in this case specify please)
BONE MARROW BIOPSY/ ASPIRATE
Was a bone marrow procedure performed?
Yes
No
Date of procedure:
Indicate procedure:
31 Aspirate (1)
16 Biopsy (2)
89 Both (Aspirate and Biopsy) (3)
Was cytogenetic analysis performed?
Yes
No
Number of metaphases examined:
Number of metaphases positive for philadelphia
chromosome:
Was the specimen adequate for light microscopic
analysis?
Yes
No
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Number of blasts:
%
Number of promyelocytes:
%
Number of basophils:
%
Cellularity form:
Clot (1)
Biopsy (2)
Cellularity results:
1 Absent (1)
2 Hypocellular (less than 20%) (2)
3 Normal (20-40%) (3)
4 Hypercellular (41-100%) (4)
95 Not done (5)
If "Not done", please specify:
DRUG DISPENSATION
Was drug dispensed?
Yes
No
Date of dispensation:
Container number:
BMS-354825 DOSING
Start date:
Stop date:
Actual dose taken per day (in mg):
Reason for dose modification:
3 Hematologic toxicity (specify) (1)
4 Non hematologic toxicity (specify) (2)
56 Dosing error (3)
57 Raising % blasts (4)
59 Loss of response (5)
66 No CHR, NEL or RTC within 6 weeks
(6)
67 NoCCyR after 6 months (7)
68 No MCyR after 3 months (8)
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98 Other (specify) (9)
For the reasons asking for specification, please
explain the cause:
CONCOMITANT MEDICATIONS
Were any additions or changes made to
concomitant medications since the last data
collection?
Yes
No
Medication name:
Date started:
Date stopped:
Reason:
3 Adverse event (1)
98 Other (2)
NON-SERIOUS ADVERSE EVENTS
Did the subject experience any new or changed
non- serious adverse events since the last
collection?
Yes
No
CTC code:
CTC grade:
Onset date:
Resolution date:
Relationship to study drug:
Certain (1)
Probable (2)
Possible (3)
Not likely (4)
Not related (5)
Action taken regarding study drug:
None (1)
Reduced (2)
Increased (3)
Interrupted (4)
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Discontinued (5)
Treatment required?
Yes
No
On-Treatment 2
VITAL SIGNS (END OF MONTH 2)
Were vital signs taken?
Yes
No
Date:
Position:
Sitting (1)
Standing (2)
Supine (3)
Blood pressure systolic (in mm Hg):
mmHg
Blood pressure diastolic (in mm Hg):
mmHg
Heart rate (in bpm):
bpm
PHYSICAL MEASUREMENTS (END OF
MONTH 2)
Were any physical measurements taken?
Yes
No
Date of measurement:
Weight (in Kg):
Kg
Performance status (ECOG):
EXTRAMEDULLARY INVOLVEMENT
(END OF MONTH 2)
Date of assessment:
Is extramedullary disease present?
Yes
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No
If yes, please provide the side code(s) from
below: 1=Skin/ Soft tissue, 2=Bone, 3=Visceral
(lung), 4=Visceral (liver), 5=Visceral  (other),
6=Lymph node, 8=Bone marrow, 9=CNS,
10=Mediastinum, 14=Effusion, 16=Spleen, 18=
Intestine, 19= Ascites, 25= Pelvis,
26=Peritoneum, 34= Ovary, 36= Pleura, 37=
Gastric, 98= Other
CHEST X-RAY
Was a chest X-ray performed?
Yes
No
Date of chest X-ray:
Interpretation of X-ray report:
Normal  (1)
Abnormal (2)
If Abnormal, please specify clinically relevant
abnormalities:
TRANSFUSIONS
Did the subject recieve any transfusion(s) since
the last data collection?
Yes
No
Date of transfusion:
Type of transfusion(s), provide all that apply from
below: 1= Paked cells, 3= Plasma, 5=Platelets,
98= Other
EXTERNAL DATA TRACKING
Were any of the following protocol specified
activities performed?
Yes
No
If yes, provide date and time:
BONE MARROW BIOPSY/ ASPIRATE
Was a bone marrow procedure performed?
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Yes
No
Date of procedure:
Indicate procedure:
31 Aspirate (1)
16 Biopsy (2)
89 Both (Aspirate and Biopsy) (3)
Was cytogenetic analysis performed?
Yes
No
Number of metaphases examined:
Number of metaphases positive for philadelphia
chromosome:
Was the specimen adequate for light microscopic
analysis?
Yes
No
Number of blasts:
%
Number of promyelocytes:
%
Number of basophils:
%
Cellularity form:
Clot (1)
Biopsy (2)
Cellularity results:
1 Absent (1)
2 Hypocellular (less than 20%) (2)
3 Normal (20-40%) (3)
4 Hypercellular (41-100%) (4)
95 Not done (specify) (5)
If "Not done", please specify:
DRUG DISPENSATION
Was drug dispensed?
Yes
No
Date of dispensation:
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Container number:
BMS-354825 DOSING
Start date:
Stop date:
Actual dose taken per day (in mg):
Reason for dose modification:
3 Hematologic toxicity (specify) (1)
4 Non hematologic toxicity (specify) (2)
56 Dosing error (3)
57 Raising % blasts (4)
59 Loss of response (5)
66 No CHR, NEL or RTC within 6 weeks
(6)
67 NoCCyR after 6 months (7)
68 No MCyR after 3 months (8)
98 Other (specify) (9)
For the reasons asking for specification, please
explain the cause:
CONCOMITANT MEDICATIONS
Were any additions or changes made to
concomitant medications since the last data
collection?
Yes
No
Medication name:
Date started:
Date stopped:
Reason:
3 Adverse event (1)
98 Other (2)
NON-SERIOUS ADVERSE EVENTS
Did the subject experience any new or changed
non- serious adverse events since the last
collection?
Yes
No
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CTC code:
CTC grade:
Onset date:
Resolution date:
Relationship to study drug:
Certain (1)
Probable (2)
Possible (3)
Not likely (4)
Not related (5)
Action taken regarding study drug:
None (1)
Reduced (2)
Increased (3)
Interrupted (4)
Discontinued (5)
Treatment required?
Yes
No
PREGNANCY TEST (END OF MONTH 2)
Was a pregnancy test performed?
Yes
No
Date of test:
If no test was performed, specify reason:
1 Post-menopausal (Amenorrhea>= 12
months) (1)
2 Surgically sterile (2)
5 Male (3)
6 Pre-menarche (4)
If a test was performed, please specify result:
Positive (1)
Negative (2)
Specify test:
Urine HCG (1)
Serum HCG (2)
EQ-5D
EQ-5D evaluation:
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On-Treatment 3
VITAL SIGNS (END OF MONTH 3)
Were vital signs taken?
Yes
No
Date:
Position:
Sitting (1)
Standing (2)
Supine (3)
Blood pressure systolic (in mm Hg):
mmHg
Blood pressure diastolic (in mm Hg):
mmHg
Heart rate (in bpm):
bpm
PHYSICAL MEASUREMENTS (END OF
MONTH 3)
Were any physical measurements taken?
Yes
No
Date of measurement:
Weight (in Kg):
Kg
Performance status (ECOG):
EXTRAMEDULLARY INVOLVEMENT
(END OF MONTH 3)
Date of assessment:
Is extramedullary disease present?
Yes
No
If yes, please provide the side code(s) from
below: 1=Skin/ Soft tissue, 2=Bone, 3=Visceral
(lung), 4=Visceral (liver), 5=Visceral  (other),
6=Lymph node, 8=Bone marrow, 9=CNS,
10=Mediastinum, 14=Effusion, 16=Spleen, 18=
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Intestine, 19= Ascites, 25= Pelvis,
26=Peritoneum, 34= Ovary, 36= Pleura, 37=
Gastric, 98= Other
CHEST X-RAY
Was a chest X-ray performed?
Yes
No
Date of chest X-ray:
Interpretation of X-ray report:
Normal  (1)
Abnormal (2)
If Abnormal, please specify clinically relevant
abnormalities:
TRANSFUSIONS
Did the subject recieve any transfusion(s) since
the last data collection?
Yes
No
Date of transfusion:
Type of transfusion(s), provide all that apply from
below: 1= Paked cells, 3= Plasma, 5=Platelets,
98= Other
EXTERNAL DATA TRACKING
Were any of the following protocol specified
activities performed?
Yes
No
If yes, provide date and time:
BONE MARROW BIOPSY/ ASPIRATE
Was a bone marrow procedure performed?
Yes
No
Date of procedure:
Indicate procedure:
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31 Aspirate (1)
16 Biopsy (2)
89 Both (Aspirate and Biopsy) (3)
Was cytogenetic analysis performed?
Yes
No
Number of metaphases examined:
Number of metaphases positive for philadelphia
chromosome:
Was the specimen adequate for light microscopic
analysis?
Yes
No
Number of blasts:
%
Number of promyelocytes:
%
Number of basophils:
%
Cellularity form:
Clot (1)
Biopsy (2)
Cellularity results:
1 Absent (1)
2 Hypocellular (less than 20%) (2)
3 Normal (20-40%) (3)
4 Hypercellular (41-100%) (4)
95 Not done (5)
If "Not done", please specify:
DRUG DISPENSATION
Was drug dispensed?
Yes
No
Date of dispensation:
Container number:
BMS-354825 DOSING
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Start date:
Stop date:
Actual dose taken per day (in mg):
Reason for dose modification:
3 Hematologic toxicity (specify) (1)
4 Non hematologic toxicity (specify) (2)
56 Dosing error (3)
57 Raising % blasts (4)
59 Loss of response (5)
66 No CHR, NEL or RTC within 6 weeks
(6)
67 NoCCyR after 6 months (7)
68 No MCyR after 3 months (8)
98 Other (specify) (9)
For the reasons asking for specification, please
explain the cause:
CONCOMITANT MEDICATIONS
Were any additions or changes made to
concomitant medications since the last data
collection?
Yes
No
Medication name:
Date started:
Date stopped:
Reason:
3 Adverse event (1)
98 Other (2)
NON-SERIOUS ADVERSE EVENTS
Did the subject experience any new or changed
non- serious adverse events since the last
collection?
Yes
No
CTC code:
CTC grade:
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Onset date:
Resolution date:
Relationship to study drug:
Certain (1)
Probable (2)
Possible (3)
Not likely (4)
Not related (5)
Action taken regarding study drug:
None (1)
Reduced (2)
Increased (3)
Interrupted (4)
Discontinued (5)
Treatment required?
Yes
No
On-Treatment 4
VITAL SIGNS (END OF MONTH 6)
Were vital signs taken?
Yes
No
Date:
Position:
Sitting (1)
Standing (2)
Supine (3)
Blood pressure systolic (in mm Hg):
mmHg
Blood pressure diastolic (in mm Hg):
mmHg
Heart rate (in bpm):
bpm
PHYSICAL MEASUREMENTS (END OF
MONTH 6)
Were any physical measurements taken?
Yes
No
Date of measurement:
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Weight (in Kg):
Kg
Performance status (ECOG):
EXTRAMEDULLARY INVOLVEMENT
(END OF MONTH 6)
Date of assessment:
Is extramedullary disease present?
Yes
No
If yes, please provide the side code(s) from
below: 1=Skin/ Soft tissue, 2=Bone, 3=Visceral
(lung), 4=Visceral (liver), 5=Visceral  (other),
6=Lymph node, 8=Bone marrow, 9=CNS,
10=Mediastinum, 14=Effusion, 16=Spleen, 18=
Intestine, 19= Ascites, 25= Pelvis,
26=Peritoneum, 34= Ovary, 36= Pleura, 37=
Gastric, 98= Other
TRANSFUSIONS
Did the subject recieve any transfusion(s) since
the last data collection?
Yes
No
Date of transfusion:
Type of transfusion(s), provide all that apply from
below: 1= Paked cells, 3= Plasma, 5=Platelets,
98= Other
EXTERNAL DATA TRACKING
Were any of the following protocol specified
activities performed?
Yes
No
If yes, provide date and time:
BONE MARROW BIOPSY/ ASPIRATE
Was a bone marrow procedure performed?
Yes
No
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Date of procedure:
Indicate procedure:
31 Aspirate (1)
16 Biopsy (2)
89 Both (Aspirate and Biopsy) (3)
Was cytogenetic analysis performed?
Yes
No
Number of metaphases examined:
Number of metaphases positive for philadelphia
chromosome:
Was the specimen adequate for light microscopic
analysis?
Yes
No
Number of blasts:
%
Number of promyelocytes:
%
Number of basophils:
%
Cellularity form:
Clot (1)
Biopsy (2)
Cellularity results:
1 Absent (1)
2 Hypocellular (less than 20%) (2)
3 Normal (20-40%) (3)
4 Hypercellular (41-100%) (4)
95 Not done (5)
If "Not done", please specify:
DRUG DISPENSATION
Was drug dispensed?
Yes
No
Date of dispensation:
Container number:
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BMS-354825 DOSING
Start date:
Stop date:
Actual dose taken per day (in mg):
mg
Reason for dose modification:
3 Hematologic toxicity (specify) (1)
4 Non hematologic toxicity (specify) (2)
56 Dosing error (3)
57 Raising % blasts (4)
59 Loss of response (5)
66 No CHR, NEL or RTC within 6 weeks
(6)
67 NoCCyR after 6 months (7)
68 No MCyR after 3 months (8)
98 Other (specify) (9)
For the reasons asking for specification, please
explain the cause:
CONCOMITANT MEDICATIONS
Were any additions or changes made to
concomitant medications since the last data
collection?
Yes
No
Medication name:
Date started:
Date stopped:
Reason:
3 Adverse event (1)
98 Other (2)
NON-SERIOUS ADVERSE EVENTS
Did the subject experience any new or changed
non- serious adverse events since the last
collection?
Yes
No
CTC code:
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CTC grade:
Onset date:
Resolution date:
Relationship to study drug:
Certain (1)
Probable (2)
Possible (3)
Not likely (4)
Not related (5)
Action taken regarding study drug:
None (1)
Reduced (2)
Increased (3)
Interrupted (4)
Discontinued (5)
Treatment required?
Yes
No
PREGNANCY TEST (END OF MONTH 4)
Was a pregnancy test performed?
Yes
No
Date of test:
If no test was performed, specify reason:
1 Post-menopausal (Amenorrhea>= 12
months) (1)
2 Surgically sterile (2)
5 Male (3)
6 Pre-menarche (4)
If a test was performed, please specify result:
Positive (1)
Negative (2)
Specify test
Urine HCG (1)
Serum HCG (2)
PREGNANCY TEST (END OF MONTH 6)
Was a pregnancy test performed?
Yes
No
Date of test:
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If no test was performed, specify reason:
1 Post-menopausal (Amenorrhea>= 12
months) (1)
2 Surgically sterile (2)
5 Male (3)
6 Pre-menarche (4)
If a test was performed, please specify result:
Positive (1)
Negative (2)
Specify test:
Urine HCG (1)
Serum HCG (2)
On-Treatment 5
VITAL SIGNS (END OF MONTH 9)
Were vital signs taken?
Yes
No
Date:
Position:
Sitting (1)
Standing (2)
Supine (3)
Blood pressure systolic (in mm Hg):
mmHg
Blood pressure diastolic (in mm Hg):
mmHg
Heart rate (in bpm):
bpm
PHYSICAL MEASUREMENTS (END OF
MONTH 9)
Were any physical measurements taken?
Yes
No
Date of measurement:
Weight (in Kg):
Kg
Performance status (ECOG):
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EXTRAMEDULLARY INVOLVEMENT
(END OF MONTH 9)
Date of assessment:
Is extramedullary disease present?
Yes
No
If yes, please provide the side code(s) from
below: 1=Skin/ Soft tissue, 2=Bone, 3=Visceral
(lung), 4=Visceral (liver), 5=Visceral  (other),
6=Lymph node, 8=Bone marrow, 9=CNS,
10=Mediastinum, 14=Effusion, 16=Spleen, 18=
Intestine, 19= Ascites, 25= Pelvis,
26=Peritoneum, 34= Ovary, 36= Pleura, 37=
Gastric, 98= Other
TRANSFUSIONS
Did the subject recieve any transfusion(s) since
the last data collection?
Yes
No
Date of transfusion:
Type of transfusion(s), provide all that apply from
below: 1= Paked cells, 3= Plasma, 5=Platelets,
98= Other
EXTERNAL DATA TRACKING
Were any of the following protocol specified
activities performed?
Yes
No
If yes, provide date and time:
BONE MARROW BIOPSY/ ASPIRATE
Was a bone marrow procedure performed?
Yes
No
Date of procedure:
Indicate procedure:
31 Aspirate (1)
16 Biopsy (2)
89 Both (Aspirate and Biopsy) (3)
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Was cytogenetic analysis performed?
Yes
No
Number of metaphases examined:
Number of metaphases positive for philadelphia
chromosome:
Was the specimen adequate for light microscopic
analysis?
Yes
No
Number of blasts:
%
Number of promyelocytes:
%
Number of basophils:
%
Cellularity form:
Clot (1)
Biopsy (2)
Cellularity results:
1 Absent (1)
2 Hypocellular (less than 20%) (2)
3 Normal (20-40%) (3)
4 Hypercellular (41-100%) (4)
95 Not done (5)
If "Not done", please specify:
DRUG DISPENSATION
Was drug dispensed?
Yes
No
Date of dispensation:
Container number:
BMS-354825 DOSING
Start date:
Stop date:
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Actual dose taken per day (in mg):
mg
Reason for dose modification:
3 Hematologic toxicity (specify) (1)
4 Non hematologic toxicity (specify) (2)
56 Dosing error (3)
57 Raising % blasts (4)
59 Loss of response (5)
66 No CHR, NEL or RTC within 6 weeks
(6)
67 NoCCyR after 6 months (7)
68 No MCyR after 3 months (8)
98 Other (specify) (9)
For the reasons asking for specification, please
explain the cause:
CONCOMITANT MEDICATIONS
Were any additions or changes made to
concomitant medications since the last data
collection?
Yes
No
Medication name:
Date started:
Date stopped:
Reason:
3 Adverse event (1)
98 Other (2)
NON-SERIOUS ADVERSE EVENTS
Did the subject experience any new or changed
non- serious adverse events since the last
collection?
Yes
No
CTC code:
CTC grade:
Onset date:
Resolution date:
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Relationship to study drug:
Certain (1)
Probable (2)
Possible (3)
Not likely (4)
Not related (5)
Action taken regarding study drug:
None (1)
Reduced (2)
Increased (3)
Interrupted (4)
Discontinued (5)
Treatment required?
Yes
No
PREGNANCY TEST (END OF MONTH 8)
Was a pregnancy test performed?
Yes
No
Date of test:
If no test was performed, specify reason:
1 Post-menopausal (Amenorrhea>= 12
months) (1)
2 Surgically sterile (2)
5 Male (3)
6 Pre-menarche (4)
If a test was performed, please specify result:
Positive (1)
Negative (2)
Specify test:
Urine HCG (1)
Serum HCG (2)
On-Treatment 6
VITAL SIGNS (END OF MONTH 12)
Were vital signs taken?
Yes
No
Date:
Position:
Sitting (1)
Standing (2)
Supine (3)
Blood pressure systolic (in mm Hg):
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mmHg
Blood pressure diastolic (in mm Hg):
mmHg
Heart rate (in bpm):
bpm
PHYSICAL MEASUREMENTS (END OF
MONTH 12)
Were any physical measurements taken?
Yes
No
Date of measurement:
Weight (in Kg):
Kg
Performance status (ECOG):
EXTRAMEDULLARY INVOLVEMENT
(END OF MONTH 12)
Date of assessment:
Is extramedullary disease present?
Yes
No
If yes, please provide the side code(s) from
below: 1=Skin/ Soft tissue, 2=Bone, 3=Visceral
(lung), 4=Visceral (liver), 5=Visceral  (other),
6=Lymph node, 8=Bone marrow, 9=CNS,
10=Mediastinum, 14=Effusion, 16=Spleen, 18=
Intestine, 19= Ascites, 25= Pelvis,
26=Peritoneum, 34= Ovary, 36= Pleura, 37=
Gastric, 98= Other
TRANSFUSIONS
Did the subject recieve any transfusion(s) since
the last data collection?
Yes
No
Date of transfusion:
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Type of transfusion(s), provide all that apply from
below: 1= Paked cells, 3= Plasma, 5=Platelets,
98= Other
EXTERNAL DATA TRACKING
Were any of the following protocol specified
activities performed?
Yes
No
If yes, provide date and time:
BONE MARROW BIOPSY/ ASPIRATE
Was a bone marrow procedure performed?
Yes
No
Date of procedure:
Indicate procedure:
31 Aspirate (1)
16 Biopsy (2)
89 Both (Aspirate and Biopsy) (3)
Was cytogenetic analysis performed?
Yes
No
Number of metaphases examined:
Number of metaphases positive for philadelphia
chromosome:
Was the specimen adequate for light microscopic
analysis?
Yes
No
Number of blasts:
%
Number of promyelocytes:
%
Number of basophils:
%
Cellularity form:
Clot (1)
Biopsy (2)
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Cellularity results:
1 Absent (1)
2 Hypocellular (less than 20%) (2)
3 Normal (20-40%) (3)
4 Hypercellular (41-100%) (4)
95 Not done (5)
If "Not done", please specify:
DRUG DISPENSATION
Was drug dispensed?
Yes
No
Date of dispensation:
Container number:
BMS-354825 DOSING
Start date:
Stop date:
Actual dose taken per day (in mg):
mg
Reason for dose modification:
3 Hematologic toxicity (specify) (1)
4 Non hematologic toxicity (specify) (2)
56 Dosing error (3)
57 Raising % blasts (4)
59 Loss of response (5)
66 No CHR, NEL or RTC within 6 weeks
(6)
67 NoCCyR after 6 months (7)
68 No MCyR after 3 months (8)
98 Other (specify) (9)
For the reasons asking for specification, please
explain the cause:
CONCOMITANT MEDICATIONS
Were any additions or changes made to
concomitant medications since the last data
collection?
Yes
No
Medication name:
29 / 42
Advanced Chronic Myelogenous Leukemia (CML) NCT00123487 – On-
Treatment
Date started:
Date stopped:
Reason:
3 Adverse event (1)
98 Other (2)
NON-SERIOUS ADVERSE EVENTS
Did the subject experience any new or changed
non- serious adverse events since the last
collection?
Yes
No
CTC code:
CTC grade:
Onset date:
Resolution date:
Relationship to study drug:
Certain (1)
Probable (2)
Possible (3)
Not likely (4)
Not related (5)
Action taken regarding study drug:
None (1)
Reduced (2)
Increased (3)
Interrupted (4)
Discontinued (5)
Treatment required?
Yes
No
PREGNANCY TEST (END OF MONTH 1
0)
Was a pregnancy test performed?
Yes
No
Date of test:
If no test was performed, specify reason:
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1 Post-menopausal (Amenorrhea>= 12
months) (1)
2 Surgically sterile (2)
5 Male (3)
6 Pre-menarche (4)
If a test was performed, please specify result:
Positive (1)
Negative (2)
Specify test:
Urine HCG (1)
Serum HCG (2)
PREGNANCY TEST (END OF MONTH
12)
Was a pregnancy test performed?
Yes
No
Date of test:
If no test was performed, specify reason:
1 Post-menopausal (Amenorrhea>= 12
months) (1)
2 Surgically sterile (2)
5 Male (3)
6 Pre-menarche (4)
If a test was performed, please specify result:
Positive (1)
Negative (2)
Specify test:
Urine HCG (1)
Serum HCG (2)
On-Treatment 7
VITAL SIGNS (END OF MONTH 18)
Were vital signs taken?
Yes
No
Date:
Position:
Sitting (1)
Standing (2)
Supine (3)
Blood pressure systolic (in mm Hg):
mmHg
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Blood pressure diastolic (in mm Hg):
mmHg
Heart rate (in bpm):
bpm
PHYSICAL MEASUREMENTS (END OF
MONTH 18)
Were any physical measurements taken?
Yes
No
Date of measurement:
Weight (in Kg):
Kg
Performance status (ECOG):
EXTRAMEDULLARY INVOLVEMENT
(END OF MONTH 18)
Date of assessment:
Is extramedullary disease present?
Yes
No
If yes, please provide the side code(s) from
below: 1=Skin/ Soft tissue, 2=Bone, 3=Visceral
(lung), 4=Visceral (liver), 5=Visceral  (other),
6=Lymph node, 8=Bone marrow, 9=CNS,
10=Mediastinum, 14=Effusion, 16=Spleen, 18=
Intestine, 19= Ascites, 25= Pelvis,
26=Peritoneum, 34= Ovary, 36= Pleura, 37=
Gastric, 98= Other
TRANSFUSIONS
Did the subject recieve any transfusion(s) since
the last data collection?
Yes
No
Date of transfusion:
Type of transfusion(s), provide all that apply from
below: 1= Paked cells, 3= Plasma, 5=Platelets,
98= Other
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EXTERNAL DATA TRACKING
Were any of the following protocol specified
activities performed?
Yes
No
If yes, provide date:
BONE MARROW BIOPSY/ ASPIRATE
Was a bone marrow procedure performed?
Yes
No
Date of procedure:
Indicate procedure:
31 Aspirate (1)
16 Biopsy (2)
89 Both (Aspirate and Biopsy) (3)
Was cytogenetic analysis performed?
Yes
No
Number of metaphases examined:
Number of metaphases positive for philadelphia
chromosome:
Was the specimen adequate for light microscopic
analysis?
Yes
No
Number of blasts:
%
Number of promyelocytes:
%
Number of basophils:
%
Cellularity form:
Clot (1)
Biopsy (2)
Cellularity results:
1 Absent (1)
2 Hypocellular (less than 20%) (2)
3 Normal (20-40%) (3)
4 Hypercellular (41-100%) (4)
95 Not done (5)
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If "Not done", please specify:
DRUG DISPENSATION
Was drug dispensed?
Yes
No
Date of dispensation:
Container number:
BMS-354825 DOSING
Start date:
Stop date:
Actual dose taken per day (in mg):
mg
Reason for dose modification:
3 Hematologic toxicity (specify) (1)
4 Non hematologic toxicity (specify) (2)
56 Dosing error (3)
57 Raising % blasts (4)
59 Loss of response (5)
66 No CHR, NEL or RTC within 6 weeks
(6)
67 NoCCyR after 6 months (7)
68 No MCyR after 3 months (8)
98 Other (specify) (9)
For the reasons asking for specification, please
explain the cause:
CONCOMITANT MEDICATIONS
Were any additions or changes made to
concomitant medications since the last data
collection?
Yes
No
Medication name:
Date started:
Date stopped:
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Reason:
3 Adverse event (1)
98 Other (2)
NON-SERIOUS ADVERSE EVENTS
Did the subject experience any new or changed
non- serious adverse events since the last
collection?
Yes
No
CTC code:
CTC grade:
Onset date:
Resolution date:
Relationship to study drug:
Certain (1)
Probable (2)
Possible (3)
Not likely (4)
Not related (5)
Action taken regarding study drug:
None (1)
Reduced (2)
Increased (3)
Interrupted (4)
Discontinued (5)
Treatment required?
Yes
No
PREGNANCY TEST (END OF MONTH
14)
Was a pregnancy test performed?
Yes
No
Date of test:
If no test was performed, specify reason:
1 Post-menopausal (Amenorrhea>= 12
months) (1)
2 Surgically sterile (2)
5 Male (3)
6 Pre-menarche (4)
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If a test was performed, please specify result:
Positive (1)
Negative (2)
Specify test:
Urine HCG (1)
Serum HCG (2)
PREGNANCY TEST (END OF MONTH
16)
Was a pregnancy test performed?
Yes
No
Date of test:
If no test was performed, specify reason:
1 Post-menopausal (Amenorrhea>= 12
months) (1)
2 Surgically sterile (2)
5 Male (3)
6 Pre-menarche (4)
If a test was performed, please specify result:
Positive (1)
Negative (2)
Specify test:
Urine HCG (1)
Serum HCG (2)
PREGNANCY TEST (END OF MONTH
18)
Was a pregnancy test performed?
Yes
No
Date of test:
If no test was performed, specify reason:
1 Post-menopausal (Amenorrhea>= 12
months) (1)
2 Surgically sterile (2)
5 Male (3)
6 Pre-menarche (4)
If a test was performed, please specify result:
Positive (1)
Negative (2)
Specify test:
Urine HCG (1)
Serum HCG (2)
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On-Treatment 8
VITAL SIGNS (END OF MONTH 24}
Were vital signs taken?
Yes
No
Date:
Position:
Sitting (1)
Standing (2)
Supine (3)
Blood pressure systolic (in mm Hg):
mmHg
Blood pressure diastolic (in mm Hg):
mmHg
Heart rate (in bpm):
bpm
PHYSICAL MEASUREMENTS (END OF
MONTH 24)
Were any physical measurements taken?
Yes
No
Date of measurement:
Weight (in Kg):
Kg
Performance status (ECOG):
EXTRAMEDULLARY INVOLVEMENT
(END OF MONTH 24)
Date of assessment:
Is extramedullary disease present?
Yes
No
If yes, please provide the side code(s) from
below: 1=Skin/ Soft tissue, 2=Bone, 3=Visceral
(lung), 4=Visceral (liver), 5=Visceral  (other),
6=Lymph node, 8=Bone marrow, 9=CNS,
10=Mediastinum, 14=Effusion, 16=Spleen, 18=
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Intestine, 19= Ascites, 25= Pelvis,
26=Peritoneum, 34= Ovary, 36= Pleura, 37=
Gastric, 98= Other
TRANSFUSIONS
Did the subject recieve any transfusion(s) since
the last data collection?
Yes
No
Date of transfusion:
Type of transfusion(s), provide all that apply from
below: 1= Paked cells, 3= Plasma, 5=Platelets,
98= Other
EXTERNAL DATA TRACKING
Were any of the following protocol specified
activities performed?
Yes
No
If yes, provide date:
BONE MARROW BIOPSY/ ASPIRATE
Was a bone marrow procedure performed?
Yes
No
Date of procedure:
Indicate procedure:
31 Aspirate (1)
16 Biopsy (2)
89 Both (Aspirate and Biopsy) (3)
Was cytogenetic analysis performed?
Yes
No
Number of metaphases examined:
Number of metaphases positive for philadelphia
chromosome:
Was the specimen adequate for light microscopic
analysis?
Yes
No
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Number of blasts:
%
Number of promyelocytes:
%
Number of basophils:
%
Cellularity form:
Clot (1)
Biopsy (2)
Cellularity results:
1 Absent (1)
2 Hypocellular (less than 20%) (2)
3 Normal (20-40%) (3)
4 Hypercellular (41-100%) (4)
95 Not done (5)
If "Not done", please specify:
DRUG DISPENSATION
Was drug dispensed?
Yes
No
Date of dispensation:
Container number:
BMS-354825 DOSING
Start date:
Stop date:
Actual dose taken per day (in mg):
mg
Reason for dose modification:
3 Hematologic toxicity (specify) (1)
4 Non hematologic toxicity (specify) (2)
56 Dosing error (3)
57 Raising % blasts (4)
59 Loss of response (5)
66 No CHR, NEL or RTC within 6 weeks
(6)
67 NoCCyR after 6 months (7)
68 No MCyR after 3 months (8)
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98 Other (specify) (9)
For the reasons asking for specification, please
explain the cause:
CONCOMITANT MEDICATIONS
Were any additions or changes made to
concomitant medications since the last data
collection?
Yes
No
Medication name:
Date started:
Date stopped:
Reason:
3 Adverse event (1)
98 Other (2)
NON-SERIOUS ADVERSE EVENTS
Did the subject experience any new or changed
non- serious adverse events since the last
collection?
Yes
No
CTC code:
CTC grade:
Onset date:
Resolution date:
Relationship to study drug:
Certain (1)
Probable (2)
Possible (3)
Not likely (4)
Not related (5)
Action taken regarding study drug:
None (1)
Reduced (2)
Increased (3)
Interrupted (4)
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Discontinued (5)
Treatment required?
Yes
No
PREGNANCY TEST (END OF MONTH
20)
Was a pregnancy test performed?
Yes
No
Date of test:
If no test was performed, specify reason:
1 Post-menopausal (Amenorrhea>= 12
months) (1)
2 Surgically sterile (2)
5 Male (3)
6 Pre-menarche (4)
If a test was performed, please specify result:
Positive (1)
Negative (2)
Specify test:
Urine HCG (1)
Serum HCG (2)
PREGNANCY TEST (END OF MONTH
22
Was a pregnancy test performed?
Yes
No
Date of test:
If no test was performed, specify reason:
1 Post-menopausal (Amenorrhea>= 12
months) (1)
2 Surgically sterile (2)
5 Male (3)
6 Pre-menarche (4)
If a test was performed, please specify result:
Positive (1)
Negative (2)
Specify test:
Urine HCG (1)
Serum HCG (2)
PREGNANCY TEST (END OF MONTH
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24)
Was a pregnancy test performed?
Yes
No
Date of test:
If no test was performed, specify reason:
1 Post-menopausal (Amenorrhea>= 12
months) (1)
2 Surgically sterile (2)
5 Male (3)
6 Pre-menarche (4)
If a test was performed, please specify result:
Positive (1)
Negative (2)
Specify test:
Urine HCG (1)
Serum HCG (2)
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Advanced Chronic Myelogenous Leukemia
(CML) NCT00123487 –  Pre-Treatment
Study documentation part: Pre-Treatment
This is a phase III study of BMS-354825 in subjects with
chronic myelogenous leukemia in accelerated phase, or in
myeloid or lymphoid blast phase or with Philadelphia
chromosome positive (Ph+) acute lymphoblastic leukemia
who are resistant or intolerant to imatinib mesylate
(Gleevec).Trial Number: NCT00123487. Drug: dasatinib.
Phase 3.
All rights reserved. Please visit https://medical-data-
models.org/forms/11832
Advanced Chronic Myelogenous
Leukemia (CML) NCT00123487 –
Pre-Treatment
Subject details
Subject number:
Subject initial:
Visit date:
General Medical History
SYSTEM
Head, eyes, ears, nose and throat:
No (1)
Yes (2)
Unknown (3)
Cardiovascular:
No (1)
Yes (2)
Unknown (3)
Peripheral Vascular:
No (1)
Yes (2)
Unknown (3)
Respiratory:
No (1)
Yes (2)
Unknown (3)
Gastrointestinal
No (1)
Yes (2)
Unknown (3)
Hepatobiliary:
No (1)
Yes (2)
Unknown (3)
Renal:
No (1)
Yes (2)
Unknown (3)
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Genitourinary:
No (1)
Yes (2)
Unknown (3)
Endocrine-Metabolic:
No (1)
Yes (2)
Unknown (3)
Hematologic- Lymphatic:
No (1)
Yes (2)
Unknown (3)
Musculoskeletal:
No (1)
Yes (2)
Unknown (3)
Dermatologic:
No (1)
Yes (2)
Unknown (3)
Neurologic:
No (1)
Yes (2)
Unknown (3)
Psychiatric:
No (1)
Yes (2)
Unknown (3)
Allergies:
No (1)
Yes (2)
Unknown (3)
Neoplasia:
No (1)
Yes (2)
Unknown (3)
Alcohol use:
No (1)
Yes (2)
Unknown (3)
Tobacco use:
No (1)
Yes (2)
Unknown (3)
Drug abuse:
No (1)
Yes (2)
Unknown (3)
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Other:
No (1)
Yes (2)
Unknown (3)
Please specify (only for the systems answered
with yes):
INITIAL LEUKEMIA DIAGNOSIS
Date of initial CML diagnosis:
Date of initial Ph + ALL Diagnosis:
Date of onset of advanced phase:
CURRENT DISEASE STATUS
Accelerated Phase CML:
Yes
No
Ph+ ALL:
Yes
No
Myeloid Blast CML:
Yes
No
Lymphoid blast CML:
Yes
No
Chronic phase with history of accelerated or blast
phase:
Yes
No
Chronic phase with clonal evolution:
Yes
No
EXTRAMEDULLARY INVOLVEMENT
Date of Assessment:
Is extramedullary disease present?
Yes
No
If yes, provide site code(s) from below:
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1 = SKIN/SOFT TISSUE  2 = BONE  3 =
VISCERAL, LUNG  4 = VISCERAL, LIVER  5 =
VISCERAL, OTHER
6 = LYMPH NODE  8 = BONE MARROW  9 =
CNS  10 = MEDIASTINUM  14 = EFFUSION
16 = SPLEEN  18 = INTESTINE  19 = ASCITES
25 = PELVIS  26 = PERITONEUM
34 = OVARY  36 = PLEURA  37 = GASTRIC  98
= OTHER
CHEST X-RAY
Was a chest X-ray performed?
Yes
No
Date of chest X- ray, if performed already:
Interpretation of chest X- ray:
Normal (1)
Abnormal (2)
Specify clinical relevant abnormalities:
Imatinib Mesylate
PRIOR IMATINIB MESYLATE HISTORY
Date of first dose of imatinib mesylate received:
Date of last dose of imatinib mesylate received:
Highest dose of imatinib mesylate received (in
mg):
mg
Subject is eligible due to:
Primary resistance (1)
Acquired resistance (2)
Intolerance (3)
Has the subject ever tolerated a dose of imatinib
mesylate greater than or equal to 600mg?
Yes
No
Reasons for intolerance:
Fluid retention (1)
Gastrointestinal symptoms (2)
Arthralgia/ Myalgia (3)
Rash (4)
Other (5)
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If other, please specify:
BEST HEMATOLOGIC RESPONSE TO
IMATINIB MESYLATE
Best hematologic response to imatinib mesylate:
Complete hematologic response (CHR)
(1)
Return to chronic phase (RTC) (2)
No evidence of Leukemia (NEL) (3)
No response to imatinib mesylate (4)
Date of most recent hematologic progression
while on imatinib mesylate:
Imatinib mesylate dose at time of most recent
hematologic progression (in mg):
mg
BEST CYTOGENETIC RESPONSE TO
IMATINIB MESYLATE
Best cytogenetic response to imatinib mesylate:
Complete cytogenetic response (CCyR)
(1)
Partial cytogenetic response (PCyR) (2)
Minor cytogenetic response (3)
Minimal cytogenetic respose (4)
No response to Imatinib mesylate (5)
Date of most recent cytogenetic progression
while on imatinib mesylate:
Imatinib mesylate dose at time of most recent
cytogenetic progression (in mg):
mg
Previous and current therapies for
leukemia
PREVIOUS AND CURRENT THERAPIES
FOR LEUKEMIA
Therapy:
Date stopped:
STEM CELL TRANSPLANT
Did the subject have a stem cell transplant for
5 / 12
Advanced Chronic Myelogenous Leukemia (CML) NCT00123487 –  Pre-
Treatment
CML?
Yes
No
DATE  OF LAST TRANSPLANT:
PRIOR RADIOTHERAPY FOR
LEUKEMIA
Site of radiotherapy:
Therapy stop date:
EXTERNAL DATA TRACKING
Pre- treatment mutation analysis:
Yes
No
Date of pre-treatment mutation analysis:
Pre- treatment lab:
Yes
No
Date of pre-treatment lab:
Previous and current medications
PREVIOUS AND CURRENT
MEDICATIONS
Medication name:
Date started:
Date stopped:
Medical tests and examinations
VITAL SIGNS
Date:
Position:
Sitting (1)
Standing (2)
Supine (3)
Systolic blood pressure (in mm Hg):
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mmHg
Diastolic blood pressure (in mm Hg):
mmHg
Heart rate (bpm):
bpm
PHYSICAL MEASUREMENTS
Date of measurement:
Height:
Weight:
Performance status (ECOG):
PREGNANCY TEST
Was a pregnancy test performed?
Yes
No
If "No", specify reason:
Post- Menopausal (1)
Surgically sterile (2)
Male (3)
Pre- Menarche (4)
If "Yes", specify test:
Urine HCG (1)
Serum HCG (2)
Test result:
Positive (1)
Negative (2)
Date of test:
PHYSICAL EXAMINATION
Date of examination:
General appearance:
Normal (1)
Abnormal (2)
Not done (3)
7 / 12
Advanced Chronic Myelogenous Leukemia (CML) NCT00123487 –  Pre-
Treatment
Head, eyes, ears, nose, throat:
Normal (1)
Abnormal (2)
Not done (3)
Neck:
Normal (1)
Abnormal (2)
Not done (3)
Cardiovascular:
Normal (1)
Abnormal (2)
Not done (3)
Lungs:
Normal (1)
Abnormal (2)
Not done (3)
Abdomen:
Normal (1)
Abnormal (2)
Not done (3)
Lymph nodes:
Normal (1)
Abnormal (2)
Not done (3)
Genitourinary:
Normal (1)
Abnormal (2)
Not done (3)
Extremities:
Normal (1)
Abnormal (2)
Not done (3)
Neurological:
Normal (1)
Abnormal (2)
Not done (3)
Skin:
Normal (1)
Abnormal (2)
Not done (3)
Musculoskeletal:
Normal (1)
Abnormal (2)
Not done (3)
Others:
Normal (1)
Abnormal (2)
Not done (3)
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For systems with "Abnormal" as result, please
specify:
ELECTROCARDIOGRAM
Date and time of ECG:
Heart rate (bpm):
bpm
QRS width (sec):
sec
Bazett's QTc (msec):
msec
PR interval  (sec):
sec
Fridericia's QTc (msec):
msec
QT Interval (sec):
sec
Interpretation of ECG tracing:
Normal (1)
Abnormal (2)
Any Hypertrophy, when ECG interpretation
abnormal?
Left atrial hypertrophy (1)
Right atrial hypertrophy (2)
Left ventricular hypertrophy (3)
Right ventricular hypertrophy (4)
If ECG interpretation abnormal, any infarction?
Acute (1)
Subacute (recent) (2)
Old (3)
If ECG interpretation abnormal, any ST/ T
Morphology?
Myocardial ischemia (1)
Digitalis effect (2)
Symmetrical T-wave inversions (3)
Other non-specific ST/ T (4)
If ECG interpretation abnormal, any rhythm
abnormalities?
Sinus tachycardia (1)
Torsade de pointes (10)
Other rhythm abnormalities (11)
Pacemaker rhythm (12)
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Sinus bradycardia (2)
Supraventricular premature beat (3)
Supraventricular tachycardia (4)
Atrial fibrillation (5)
Atrial flutter (6)
Ventricular premature beat (7)
Ventricular tachycardia (8)
Ventricular fibrillation (9)
If ECG interpretation abnormal, any conduction
abnormalities?
1° A-V Block (1)
2° A-V Block (2)
3° A-V Block (3)
LBB Block (4)
RBB Block (5)
Other intraventricular conduction defect
(6)
Pre-excitation syndrom (7)
Other abnormalities:
Left axis deviation (1)
Other (2)
Pre- Treatment events
PRE-TREATMENT EVENTS
CTC CODE:
Onset date:
CTC grade:
Treatment required:
Yes
No
BONE MARROW BIOPSY I ASPIRATE
Date of procedure:
Indicate procedure:
Aspirate (1)
Biopsy (2)
Both (Aspirate and biopsy) (3)
Was cytogenetic analysis performed?
Yes
No
Number of metaphases examined:
Number of metaphases positive for philadelphia
chromosome:
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Was the specimen adequate for light microscopic
analysis?
Yes
No
Number of blasts:
%
Number of promyelocytes:
%
Number of basophils:
%
Cellularity form:
Clot (1)
Biopsy (2)
Cellularity results:
Absent (1)
Hypocellular (Less than 20%) (2)
Normal (20-40%) (3)
Hypercellular (41-100%) (4)
Not done (5)
Is the subject eligible based on clonal evolution?
Yes
No
If yes, specify additional clones
EQ-5D
Evaluation of EQ-5D:
Pre- treatment status
PRE-TREATMENT STATUS
Will the subject enter the treatment phase of this
study?
Yes
No
PRIMARY REASON FOR NOT
ENTERING THE TREATMENT PHASE
OF THIS STUDY (Fill only if study entry is
denied)
Adverse event:
Yes
No
Subject withdrew consent (specify):
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Death:
Yes
No
Lost to Follow-up (Date of last contact):
Poor/ Non- compliance (specify):
Pregnancy:
Yes
No
Subject no longer meets study criteria (specify):
Administrative reason by sponsor:
Yes
No
Others (Specify):
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Breast Cancer DataMart Common Data
Elements for Adjuvant Clinical Trials
Treatment - Breast Cancer DataMart Common Data
Elements for Adjuvant Clinical Trials - 2719861v1.0
Breast Cancer DataMart Common Data Elements for
Adjuvant Clinical Trials
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=43B3F0AE-
1119-0B42-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11834
Breast Cancer DataMart Common
Data Elements for Adjuvant Clinical
Trials
Patient Characteristics
Patient ID (protocol ID + sequentially assigned
number based on order of registration )
Age
>= 0
<= 120
years
Menopausal Status
Above Categories Not Applicable And
Age <50 (1)
Above Categories Not Applicable And
Age >= 50 (2)
Post (prior Bilateral Ovariectomy Or >12
Mo Since Lmp With No Prior
Hysterectomy And Not Currently
Receiving Therapy With Lh-rh Analogs
[e.g., Zoladex]) (3)
Post (prior Bilateral Ovariectomy Or >12
Mo Since Lmp With No Prior
Hysterectomy) (4)
Pre (<6 Mo Since Lmp And No Prior
Bilateral Ovariectomy And Not On
Estrogen Replacement) (5)
Vital Status
Alive (Alive)
Dead (Dead)
Lost To Follow-up (Lost to follow-up)
Primary Cause of Death
Accident (Accidental)
Due To Other Cause (Due to other
cause)
Due To Protocol Treatment (Due to
protocol treatment)
Due To This Disease (Due to this
disease)
Not Applicable (Not applicable)
Suicide (Suicide)
Describe cause of death
1 / 30
Patient Performance Status
ECOG Performance Status
Fully Active, Able To Carry On All Pre-
disease Performance Without
Restriction. (0)
Restricted In Physically Strenuous
Activity But Ambulatory And Able To
Carry Out Work Of A Light Or Sedentary
Nature, E.g., Light Housework, Office
Work. (1)
Ambulatory And Capable Of All Selfcare
But Unable To Carry Out Any Work
Activities. Up And About More Than 50%
Of Waking Hours. (2)
Capable Of Only Limited Selfcare,
Confined To Bed Or Chair More Than
50% Of Waking Hours. (3)
Completely Disabled. Cannot Carry On
Any Selfcare. Totally Confined To Bed Or
Chair. (4)
Dead (5)
Karnofsky Performance Status
%
Dead (0)
Moribund, Fatal Processes Progressing
Rapidly (10)
Normal, No Complaints, No Evidence Of
Disease (100)
Very Sick, Hospitalization Indicated.
Death Not Imminent (20)
Severely Disabled, Hospitalization
Indicated. Death Not Imminent (30)
Disabled, Requires Special Care And
Assistance (40)
Requires Considerable Assistance And
Frequent Medical Care (50)
Requires Occasional Assistance, But Is
Able To Care For Most Of His/her Needs
(60)
Cares For Self, Unable To Carry On
Normal Activity Or To Do Active Work
(70)
Normal Activity With Effort; Some Signs
Or Symptoms Of Disease (80)
Able To Carry On Normal Activity; Minor
Signs Or Symptoms Of Disease (90)
Protocol Design
Stratification Factors (protocol specific)
Assigned Treatment Arm (protocol specific)
Treatment Assignment Code (protocol specific)
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NSC Number (Please check the CTEP Home
Page for a list of agent NSC numbers.)
Agent Name
Agent Dose
Units
Billion Pfu (billion pfu)
Cells (cells)
Centigrays (cGy)
Curie (Ci)
Centimeter (cm)
Deciliter (dL)
Decimeter (dm)
Gram-equivalent Weight (Eq)
Gram (g)
Gravity (in Centrifugation) (gravity)
Grays (Gy)
Hertz (Hz)
International Unit (IU)
Joules Per Centimeter Square (J/cm^2)
Kilo-electron Volt (keV)
Kilogram (kg)
Kilohertz (kHz)
Kilopascal (kPa)
Liter (L)
Meter (m)
Microcurie (mcCi)
Microgram (mcg)
Millicurie (mCi)
Microliter (mcL)
Micrometer (mcm)
Micromole (mcmol)
Milliequivalent (mEq)
Million Electron Volts (MeV)
Milligram (mg)
Megahertz (MHz)
Million International Units (million IU)
Million Pfu (million pfu)
Milliunit (milliunit)
Milliliter (mL)
Millimeter (mm)
Milligrams Per Milliliter Per Minute
(MMM)
Millimole (mmol)
Gram-molecular Weight (mole) (mol)
Milliosmole (mOsmol)
Megarad (Mrad)
Million Unit (MU)
Millivolt (mV)
Million Viral Particles (mVP)
Not Applicable (N/A)
Nanocurie (nCi)
Nanogram (ng)
Nanometer (nm)
Nanometers Of Light (nm light)
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Osmole (Osmol)
Pascal (Pa)
Percent (percent)
Plaque Forming Unit (pfu)
Picogram (pg)
Pounds Per Square Inch (psi)
Tissue Culture Infections Dose (TCID)
Unit (unit)
Viral Particles (VP)
Route
Intramuscular (IM)
Intravenous (IV)
Nasal (Nasal)
Oral (PO)
Subcutaneous (Subcutaneous)
Topical (Topical)
Transdermal (Transdermal)
Vaginal (vaginal)
Frequency
After Meals (p.c.) (after meals (P.C.))
Am (AM)
As Needed (p.r.n) (as needed (P.R.N))
At Bedtime Or Hour Of Sleep (h.s.) (at
bedtime or hour of sleep (H.S.))
Before Meals (a.c.) (before meals (A.C.))
Daily (Daily)
Every 1 To 2 Hours (Every 1 to 2 hours)
Every 10 Hours (Every 10 hours)
Every 11 Hours (Every 11 hours)
Every 12 Hours (q12hr) (every 12 hours
(Q12hr))
Every 13 Hours (Every 13 hours)
Every 14 Hours (Every 14 hours)
Every 15 Hours (Every 15 hours)
Every 16 Hours (Every 16 hours)
Every 17 Hours (Every 17 hours)
Every 18 Hours (Every 18 hours)
Every 19 Hours (Every 19 hours)
Every 2 Hours (Every 2 hours)
Every 20 Hours (Every 20 hours)
Every 21 Hours (Every 21 hours)
Every 22 Hours (Every 22 hours)
Every 23 Hours (Every 23 hours)
Every 24 Hours (Every 24 hours)
Every 3 Hours (Every 3 hours)
Every 3 To 4 Hours (Every 3 to 4 hours)
Every 4 Hours (q4hr) (every 4 hours
(Q4hr))
Every 4 To 5 Hours (Every 4 to 5 hours)
Every 4 To 6 Hours (Every 4 to 6 hours)
Every 5 Hours (Every 5 hours)
Every 6 Hours (Every 6 hours)
Every 6 Hours (q6hr) (every 6 hours
(Q6hr))
Every 7 Hours (Every 7 hours)
Every 8 Hours (q8hr) (every 8 hours
(Q8hr))
Every 9 Hours (Every 9 hours)
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Every Day (q.d.) (every day (Q.D.))
Every Evening (Every evening)
Every Hour (Every hour)
Every Morning (Every morning)
Every Other Day (q.o.d.) (every other day
(Q.O.D.))
Five Times Daily (Five times daily)
Four Times A Day (q.i.d) (four times a
day (Q.I.D))
Immediately (stat) (immediately (Stat))
Monthly (Monthly)
Not Specified (Not specified)
Once A Day (q.d.) (Once a day (Q.D.))
Other (Other)
Pm/bedtime (PM/bedtime)
Three Times A Day (t.i.d) (three times a
day (T.I.D))
Three Times A Week (t.i.w) (three times
a week (T.I.W))
Twice A Day (b.i.d) (twice a day (B.I.D))
Twice A Week (b.i.w) (twice a week
(B.I.W))
Unknown (Unknown)
Weekly (Weekly)
Schedule
Surgical Procedures
Surgery Site
Axilla (Axilla)
Breast (Breast)
Internal Mammary Lymph Node (Internal
Mammary Lymph Node)
Most extensive definitive surgery
Mastectomy, Nos (Mastectomy NOS)
Partial Mastectomy, Lumpectomy Or
Excisional Biopsy (Partial
mastectomy/lumpectomy/excisional
biopsy)
Radical Mastectomy (Radical
Mastectomy)
Pathologic Disease Classification
Is measurement gross or microscopic?
Gross (Gross)
Microscopic (Microscopic)
Not Directly Measurable (Not directly
measurable)
Tumor Laterality
Left (L)
Right (R)
Is metastatic breast cancer present
Yes
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No
Is patient unresectable or inoperable
Yes
No
Histologic Type
90%)=Adenoid Cystic (Adenoid cystic
(pure > or )
90%)=Adenosquamous
(Adenosquamous (pure > or )
Apocrine (Apocrine)
90%)=Apocrine (Apocrine (pure > or )
Atypical Ductal Hyperplasia (Atypical
ductal hyperplasia (ADH))
Atypical Lobular Hyperplasia (Atypical
lobular hyperplasia (ALH))
Benign Phyllodes Tumor (Benign
Phyllodes tumor)
Borderline Phyllodes Tumor (Borderline
Phyllodes tumor)
Carcinoma With Cartilaginous/osseous
Metaplasia (Carcinoma with metaplasia,
cartilaginous/osseous type)
Carcinoma With Mixed Metaplasia
(Carcinoma with metaplasia, mixed type)
Carcinoma With Spindle Cell Metaplasia
(Carcinoma with metaplasia, spindle cell
type)
Carcinoma With Squamous Metaplasia
(Carcinoma with metaplasia, squamous
type)
Carcinosarcoma (Carcinosarcoma)
Clinging (Clinging)
Comedo (Comedo)
Complex Sclerosing Lesion (Complex
sclerosing lesion)
Cribriform (Cribriform)
90%)=Cribriform (Cribriform (pure > or )
Ductal (Ductal)
Ductal Hyperplasia, Usual Type (Ductal
hyperplasia, usual type (florid, not
atypical))
Ductal Nos (Ductal NOS)
Eluca-caps (expanded Lobular Unit With
Columnar Alteration; Columnar Alteration
With Prominent Snouts) (ELUCA-CAPS)
Fibroadenoma (Fibroadenoma)
Fibrocystic Change, Blunt Duct Adenosis
(Fibrocystic change, blunt duct adenosis)
Fibrocystic Change, Duct Ectasia
(Fibrocystic change, duct ectasia)
Fibrocystic Change, Nos (Fibrocystic
change, NOS)
Fibrocystic Change, Papillary Or
Apocrine (Fibrocystic change, papillary
or apocrine)
Fibromatosis (Fibromatosis)
Hypersecretory Atypia (Hypersecretory
atypia)
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Intra-cystic (encysted Papillary) (Intra-
cystic (encysted papillary))
Intraductal Papilloma (Intraductal
papilloma)
Invasive Micropapillary (Invasive
micropapillary)
Invasive Nos (Invasive NOS)
Lactational Changes (Lactational
changes)
Lobular (Lobular)
90%)=Lobular (Lobular (pure > or )
Mastitis (Mastitis)
Medullary Carcinoma (Medullary)
90%)=Medullary (Medullary (pure > or )
Metaplastic Carcinoma (carcinoma With
Metaplasia) (Metaplastic carcinoma
(carcinoma with metaplasia))
Micropapillary (Micropapillary)
Micropapilloma (Micropapilloma)
Mixed Ductal And Lobular (Mixed ductal
and lobular)
Mucinous Adenocarcinoma (Mucinous)
90%)=Mucinous Adenocarcinoma
(Mucinous (pure > or )
No Specific Pathologic Change (No
specific pathologic change)
Other Specify (Other)
90%)=Papillary (Papillary (pure > or )
Papillary Carcinoma In Situ (papillary)
(Papillary carcinoma in situ (papillary))
Radial Scar (Radial scar)
Reactive Spindle Cell Nodule (Reactive
spindle cell nodule)
Sclerosing Adenosis (Sclerosing
adenosis)
90%)=Secretory (Secretory (juvenile;
pure > or )
Solid (Solid)
90%)=Squamous (Squamous (pure > or
)
Tubular Adenocarcinoma (Tubular)
90%)=Tubular (Tubular (pure > or )
Tubulolobular (Tubulolobular)
90%)=Tubulolobular (Tubulolobular (pure
> or )
Unknown (Unknown)
Tumor size
Histologic Grade
High (High)
Intermediate (Intermediate)
Low (Low)
Unknown (Unknown)
AJCC Cancer Staging Handbook edition
First Edition (1st)
Second Edition (published 1983) (2nd)
Third Edition (published 1988) (3rd)
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Fourth Edition (published 1992) (4th)
Fifth Edition (published 1997 (5th)
Sixth Edition (published 2002) (6th)
Pathologic T Stage
No Evidence Of Primary Tumor (T0)
Tumor 2 Cm Or Less In Greatest
Dimension (T1)
Tumor More Than 0.1 Cm But Not More
Than 0.5 Cm In Greatest Dimension
(T1a)
Tumor More Than 0.5 Cm But Not More
Than 1 Cm In Greatest Dimension (T1b)
Tumor More Than 1 Cm But Not More
Than 2 Cm In Greatest Dimension (T1c)
Microinvasion 0.1 Cm Or Less In
Greatest Dimension (T1mic)
Tumor More Than 2 Cm But Not More
Than 5 Cm In Greatest Dimension (T2)
Tumor More Than 5 Cm In Greatest
Dimension (T3)
Tumor Of Any Size With Direct (T4)
Extension To Chest Wall (T4a)
Edema (including Peau D'orange) Or
Ulceration Of The Skin Of The Breast Or
Satellite Skin Nodules Confined To The
Same Breast (T4b)
Both T4a And T4b (T4c)
Inflammatory Carcinoma (T4d)
Carcinoma In Situ: Intraductal
Carcinoma, Lobular Carcinoma In Situ,
Or Paget's Disease Of The Nipple With
No Tumor (Tis)
Ductal Carcinoma In Situ (Tis (DCIS))
Lobular Carcinoma In Situ (Tis (LCIS))
Paget's Disease Of The Nipple With No
Tumor. [note: Paget's Disease
Associated With A Tumor Is Classified
According To The Size Of The Tumor.]
(Tis (Paget's))
Primary Tumor Cannot Be Assessed
(TX)
Pathologic N Stage
No Regional Lymph Node Metastasis
Histologically, No Additional Examination
For Isolated Tumor Cells (itc) (pN0)
No Regional Lymph Node Metastasis
Histologically, Negative Ihc (pN0(i-))
No Regional Lymph Node Metastasis
Histologically, Positive Ihc, No Ihc Cluster
>0.2 Mm (pN0(i+))
No Regional Lymph Node Metastasis
Histologically, Negative Molecular
Findings (rt-pcr) (pN0(mol-))
No Regionally Lymph Node Metastasis
Histologically, Positive Molecular
Findings (rt-pcr) (pN0(mol+))
Metastasis In 1 To 3 Axillary Lymph
Nodes, And/or In Internal Mammary
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Nodes With Microscopic Disease
Detected By Sln Dissection But Not
Clinically Apparent (pN1)
Metastasis In 1 To 3 Axillary Lymph
Nodes (pN1a)
Metastasis In Internal Mammary Nodes
With Microscopic Disease Detected By
Sln Dissection But Not Clinically
Apparent (pN1b)
Metastasis In 1 To 3 Axillary Lymph
Nodes And In Internal Mammary Lymph
Nodes With Microscopic Disease
Detected By Sln Dissection But Not
Clinically Apparent. (pN1c)
Micrometastasis (>0.2 Mm But <=2.0
Mm) (pN1mi)
Metastasis In 4 To 9 Axillary Lymph
Nodes, Or In Clinically Apparent **
Internal Mammary Lymph Nodes In The
Absence Of Axillary Lymph Node
Metastasis To Ipsilateral Axillary Lymph
Node(s) Fixed To Each Other Or To
Other Structures (pN2)
Metastasis In 4 To 9 Axillary Lymph
Nodes (at Least 1 Tumor Deposit >2.0
Mm) (pN2a)
Metastasis In Clinically Apparent*
Internal Mammary Lymph Nodes In The
Absence Of Axillary Lymph Node
Metastasis (pN2b)
Metastasis In >= Axillary Lymph Nodes,
Or In Infraclavicular Lymph Nodes, Or In
Clinically Apparent* Ipsilateral Internal
Mammary Lymph Node(s) In The
Presence Of 1 Or More Positive Axillary
Lymph Node(s); Or, In >3 Axillary Lymph
Nodes With Clinically N (pN3)
Metastasis In >=10 Axillary Lymph
Nodes (at Least 1 Tumor Deposit >2.0
Mm); Or, Metastasis To The
Infraclavicular Lymph Nodes (pN3a)
Metastasis In Clinically Apparent*
Ipsilateral Internal Mammary Lymph
Nodes In The Presence Of >=1 Positive
Axillary Lymph Node(s); Or, In >3
Axillary Lymph Nodes And In Internal
Mammary Lymph Nodes With
Microscopic Disease Detected By
Sentinel Lymph Node (pN3b)
Metastasis In Ipsilateral Supraclavicular
Lymph Nodes (pN3c)
Regional Lymph Nodes Cannot Be
Assessed (e.g., Not Removed For
Pathologic Study Or Previously
Removed) (pNX)
Pathologic M Stage
No Distant Metastasis (M0)
Distant Metastasis (M1)
Distant Metastasis Cannot Be Assessed
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(MX)
Pathology: Assessment Of Lymph Nodes
Was sentinel node sampling performed
No (No)
Unknown (Unknown)
Yes (Yes)
Sentinel Node Site
Axillary (Axillary)
Internal Mammary (Internal Mammary)
Supraclavicular (Supraclavicular)
Unknown (Unknown)
Number of Sentinel Nodes Examined (If yes,)
Sentinel Node Biopsy Date
Number of Positive Sentinel Nodes
Number of Positive Sentinel Nodes by H&E
Number of Positive Sentinel Nodes by
Immunohistochemistry (IHC) only
Measurement of Largest Metastasis
< 2 Mm (< 2 mm)
> Or = 2 Mm (> or = 2 mm)
Fine Needle Aspiration or Biopsy performed for
axillary lymph nodes
Yes
No
Was axillary dissection performed?
Yes
No
Date of Axillary Dissection
Number of Lymph Nodes Examined (If yes,)
Number of Positive Lymph Nodes (For each
type,)
Number of Lymph Nodes without
Micrometastases
Number of Lymph Nodes with Micrometastases
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Lymph Nodes Type
Axillary (axillary)
Infraclavicular (infraclavicular)
Internal Mammary (internal mammary)
Supraclavicular (supraclavicular)
Lymph Node Involvement
Equivocal (equivocal)
Negative (negative)
Not Evaluated (not evaluated)
Positive (positive)
Unknown (unknown)
Diameter of largest positive lymph node
metastasis
Extracapsular Extension?
No (No)
Unknown (Unknown)
Yes (Yes)
Margins
Does the tumor involve the surgical margin
Yes
No
Estrogen Status
Marker Test Method
Elisa (ELISA)
Fluorescence In Situ Hybridization (fish)
(Fluorescence in situ hybridization
(FISH))
Immunohistochemistry (ihc)
(Immunohistochemistry (IHC))
Ligand Binding Assay (Ligand Binding
Assay)
Other, Specify (Other)
Rtpcr, Rt-pcr, Reverse Transcriptase-
polymerase Chain Reaction (RT-PCR)
Serum Extracellular Domain (ecd) Test
(Serum ECD test)
Other specify
Receptor Status, ER
Negative (Negative)
Not Done (NOT DONE)
Positive (Positive)
Unknown (Unknown)
Timing of Assay
At Recurrence (At recurrence)
Initial Diagnosis (Initial diagnosis)
Other (Other)
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ER Timing, Other, Specify
ER cells stained positive
%
Estrogen receptor value
Other specify
Antigen Retrieval
No (No)
Unknown (Unknown)
Yes (Yes)
Yes specify
Percentage of Invasive Tumor Cells with Nuclear
Staining
Percentage of DCIS Cells with Nuclear Staining
Intensity of Stained Malignant Nuclei Description
Intense (Intense)
Intermediate (Intermediate)
Negative (Negative)
Scant (Scant)
Unknown (Unknown)
Intensity of Stained Malignant Nuclei Scaled
Allred score
Were specimens submitted for central pathology
review
Yes
No
Was marker status changed by central pathology
review
Yes
No
ER status by central pathology review
Negative (Negative)
Not Done (NOT DONE)
Positive (Positive)
Unknown (Unknown)
Estrogen Status
Receptor Status, PgR
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Negative (Negative)
Not Done (NOT DONE)
Positive (Positive)
Unknown (Unknown)
PgR Timing, Other, specify
PgR % cells stained positive
Progesterone receptor value
Allred score
PgR status by central pathology review
Negative (Negative)
Not Done (NOT DONE)
Positive (Positive)
Unknown (Unknown)
Pathology: Breast Tumor Markers
Marker Name (s)
Her2/neu (HER2/neu)
Other Specify (Other)
Other specify
Method of Evaluation
Bone Scan (Bone scan)
Chest X-ray (Chest x-ray)
Clinical Examination (pe) (Clinical
examination)
Ct Scan (CT scan)
Cytology (Cytology)
Mri (MRI (NMR))
Not Evaluated (Not evaluated)
Other (Other)
Spiral Ct Scan (Spiral CT scan)
Ultrasound (Ultrasound)
Other Specify
Staining Antibody
Cb-11 Other (CB-11 other)
Cb-11/ventana Kit (CB-11/Ventana Kit)
Dako Herceptest [tm] (DAKO Herceptest
[TM])
Other Specify (Other)
Tab-250 (TAB-250)
Percentage of Invasive Tumor Cells with
Membrane Staining
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Herceptest Score
0 (0)
1+ (1+)
2+ (2+)
3+ (3+)
Ventana Scoring System (Score)
0 (0)
1+ (1+)
2+ (2+)
3+ (3+)
IHC Lab Value
+1 (+1)
+2 (+2)
+3 (+3)
0 (0)
Kit or Test Type (If FISH,)
Other Specify (Other, specify)
Ventana/oncorprobe[tm]
(Ventana/Oncorprobe)
Vysis/path Vysion[tm] (Vysis/PathVysion)
Other, specify
FISH Result
Amplified (Amplified)
Not Amplified (Not amplified)
FISH HER2/neu chromosome 17 Ratio
Mean Number of HER2/neu Signals/Cell (Note:
Enter 99.9 or 999 if unknown)
Amplification Cutpoint
Final Diagnosis with HER2/neu
Equivocal (Equivocal)
Negative (Negative)
Positive (Positive)
HER-2/neu time
At Disease Recurrence (At disease
recurrence)
At Initial Primary Diagnosis (At initial
primary diagnosis)
Other (Other)
Pathology: Assessment Of Ductal
Carcinoma In Situ (dcis)
Is DCIS present?
Yes
No
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Is DCIS present with invasive cancer?
Yes
No
Is an extensive intraductal component (EIC)
present
Yes
No
Is cancerization of lobules present?
Yes
No
Dominant Histologic Type
Aprocrine (Aprocrine)
Clinging (Clinging)
Comedo (Comedo)
Cribriform (Cribriform)
Intra-cystic (encysted Papillary) (Intra-
cystic (encysted papillary))
Micropapillary (Micropapillary)
Other, Specify (Other, specify)
Papillary Carcinoma In Situ (papillary)
(Papillary carcinoma in situ (papillary))
Solid (Solid)
Other specify
Is DCIS at margin?
> Or = 1 Mm To 10 Mm (> or = 1 mm to
10 mm)
Greater Than 10 Mm (Greater than 10
mm)
Involved, Not Otherwise Specified
(Involved NOS)
Less Than 1 Mm (Less than 1 mm)
Not Involved, Not Otherwise Specified
(Not involved NOS)
Transected (Transected)
Unknown (Unknown)
Is Paget's disease of the nipple present?
No (NO)
Unknown (UNKNOWN)
Yes (YES)
Is microinvasive cancer present?
No (NO)
Unknown (UNKNOWN)
Yes (YES)
Pathology: Assessment Of Lobular
Carcinoma In Situ (lcis)
Is LCIS present?
Yes
No
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Is LCIS present with invasive cancer?
Yes
No
Extent of LCIS
Extensive (Extensive)
Focal (Focal)
Not Specified (Not specified)
Is LCIS at margin?
> Or = 1 Mm To 10 Mm (> or = 1 mm to
10 mm)
Greater Than 10 Mm (Greater than 10
mm)
Involved, Not Otherwise Specified
(Involved NOS)
Less Than 1 Mm (Less than 1 mm)
Not Involved, Not Otherwise Specified
(Not involved NOS)
Transected (Transected)
Unknown (Unknown)
Endpoints
Time from registration to
Biologic Therapy Start (Biologic therapy
start)
Biologic Therapy Stop (Biologic therapy
stop)
Chemotherapy Start (Chemotherapy
start)
Chemotherapy Stop (Chemotherapy
stop)
Contralateral Dcis (Contralateral DCIS)
Contralateral Invasive Disease
(Contralateral invasive disease)
Contralateral Lcis (Contralateral LCIS)
Death From Any Cause (Death from any
cause)
Distant Recurrence (Distant invasive
recurrence)
First Randomization (First
randomization)
Hormone Therapy Start (Hormonal
therapy start)
Hormonal Therapy Stop (Hormonal
therapy stop)
Ipsilateral Dcis (Ipsilateral DCIS)
Ipsilateral Invasive Recurrence
(Ipsilateral invasive recurrence)
Ipsilateral Lcis (Ipsilateral LCIS)
Last Assessment (Last assessment)
Last Contact Or Death (Last Contact or
Death)
Local/regional Recurrence
(Local/regional invasive recurrence)
Local/regional Recurrence
(Local/regional recurrence)
Most Extensive Primary Surgery (Most
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extensive primary surgery)
Radiation Therapy Start (Radiation
therapy start)
Radiation Therapy Stop (Radiation
therapy stop)
Second Randomization (Second
randomization)
Secondary Non-breast Primary Cancer
(Secondary non-breast primary cancer)
Third Randomization (Third
randomization)
Time from randomization to
Biologic Therapy Start (Biologic therapy
start)
Biologic Therapy Stop (Biologic therapy
stop)
Chemotherapy Start (Chemotherapy
start)
Chemotherapy Stop (Chemotherapy
stop)
Contralateral Dcis (Contralateral DCIS)
Contralateral Invasive Disease
(Contralateral invasive disease)
Contralateral Lcis (Contralateral LCIS)
Death From Any Cause (Death from any
cause)
Distant Recurrence (Distant invasive
recurrence)
First Randomization (First
randomization)
Hormone Therapy Start (Hormonal
therapy start)
Hormonal Therapy Stop (Hormonal
therapy stop)
Ipsilateral Dcis (Ipsilateral DCIS)
Ipsilateral Invasive Recurrence
(Ipsilateral invasive recurrence)
Ipsilateral Lcis (Ipsilateral LCIS)
Last Assessment (Last assessment)
Last Contact Or Death (Last Contact or
Death)
Local/regional Recurrence
(Local/regional invasive recurrence)
Local/regional Recurrence
(Local/regional recurrence)
Most Extensive Primary Surgery (Most
extensive primary surgery)
Radiation Therapy Start (Radiation
therapy start)
Radiation Therapy Stop (Radiation
therapy stop)
Second Randomization (Second
randomization)
Secondary Non-breast Primary Cancer
(Secondary non-breast primary cancer)
Third Randomization (Third
randomization)
Time from most extensive surgery to
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Biologic Therapy Start (Biologic therapy
start)
Biologic Therapy Stop (Biologic therapy
stop)
Chemotherapy Start (Chemotherapy
start)
Chemotherapy Stop (Chemotherapy
stop)
Contralateral Dcis (Contralateral DCIS)
Contralateral Invasive Disease
(Contralateral invasive disease)
Contralateral Lcis (Contralateral LCIS)
Death From Any Cause (Death from any
cause)
Distant Recurrence (Distant invasive
recurrence)
First Randomization (First
randomization)
Hormone Therapy Start (Hormonal
therapy start)
Hormonal Therapy Stop (Hormonal
therapy stop)
Ipsilateral Dcis (Ipsilateral DCIS)
Ipsilateral Invasive Recurrence
(Ipsilateral invasive recurrence)
Ipsilateral Lcis (Ipsilateral LCIS)
Last Assessment (Last assessment)
Last Contact Or Death (Last Contact or
Death)
Local/regional Recurrence
(Local/regional invasive recurrence)
Local/regional Recurrence
(Local/regional recurrence)
Most Extensive Primary Surgery (Most
extensive primary surgery)
Radiation Therapy Start (Radiation
therapy start)
Radiation Therapy Stop (Radiation
therapy stop)
Second Randomization (Second
randomization)
Secondary Non-breast Primary Cancer
(Secondary non-breast primary cancer)
Third Randomization (Third
randomization)
Duration
Tumor Response
Pathologic complete response in the primary
tumor
Yes
No
Target Lesion Response Status
Complete Response (Complete
Response)
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Incomplete Response Or Stable Disease
(Incomplete Response or Stable
Disease)
Insufficient Evaluation To Determine
Response Status (Insufficient evaluation
to determine response status)
Partial Response (Partial Response)
Progressive Disease (Progressive
Disease)
Stable Disease (Stable Disease)
Non-Target Lesion Response Status
Complete Response (Complete
Response)
Incomplete Response/sd (Incomplete
Response/SD)
Insufficient Evaluation To Determine
Response Status (Insufficient evaluation
to determine response status)
Progressive Disease (Progressive
Disease)
Overall response
Complete Response (Complete
Response)
Incomplete Response (Incomplete
Response)
Insufficient Evaluation To Determine
Response Status (Insufficient evaluation
to determine response status)
Partial Response (Partial Response)
Progressive Disease (Progressive
Disease)
Sites Of Progression
First recurrence/progression
Distant (Distant)
Local (Local)
Regional (Regional)
Site of First Local-Regional Progression
Axilla (Axilla)
Axillary Nodes (Axillary nodes)
Chest Wall (Chest wall)
Infraclavicular Nodes (Infraclavicular
nodes)
Internal Mammary Nodes (Internal
mammary nodes)
Ipsilateral Breast (Ipsilateral breast)
Other (Other)
Supraclavicular Nodes (Supraclavicular
nodes)
Site of First Distant Progression
Bone (Bone)
Brain (Brain)
Central Nervous System (Central
nervous system)
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Distant Lymph Nodes (Distant nodes)
Liver (Liver)
Lung (Lung)
Lymph Nodes (Lymph nodes)
None Or None Known (None or none
known)
Other Cns (Other CNS)
Other, Generalized, Nos, Carcinomatosis
(Other generalized NOS, carcinomatosis)
Other Nos (Other NOS)
Other Soft Tissue (Other Soft Tissue)
Other Visceral (Other Visceral)
Peritoneum (Peritoneum)
Pleura (Pleura)
Skin (Skin)
Other specify
Progressive Disease Documentation
Progressive Disease Defined By New
Lesions (Appearance of one or more
new lesions)
Nontarget Lesions (unequivocal
Progression Of Existing Nontarget
Lesions) (Nontarget Lesions)
Other, Specify (Other)
Target Lesions (at Least A 20% Increase
In The Sum Of Longest Diameters Of
Target Lesions, Taking As Reference The
Smallest Sum Recorded Since The
Treatment Started) (Target Lesions)
Other specify
Notice Of New Primary
Has a new primary cancer or MDS been
diagnosed that has not been previously reported?
No (No)
Unknown (Unknown)
Yes (Yes)
Primary Site
C00 - Lip (excludes Skin Of Lip C44.0)
(C00)
C00-c14 - Lip, Oral Cavity And Pharynx
(C00-C14)
C00.0 - External Upper Lip (C00.0)
C00.1 - External Lower Lip (C00.1)
C00.2 - External Lip, Nos (C00.2)
C00.3 - Mucosa Of Upper Lip (C00.3)
C00.4 - Mucosa Of Lower Lip (C00.4)
C00.5 - Mucosa Of Lip, Nos (C00.5)
C00.6 - Commissure Of Lip (C00.6)
C00.8 - Overlapping Lesion Of Lip
(C00.8)
C00.9 - Lip, Nos (excludes Skin Of Lip
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C44.0) (C00.9)
C01 - Base Of Tongue (C01)
C01.9 - Base Of Tongue, Nos (C01.9)
C02 - Other And Unspecified Parts Of
Tongue (C02)
C02.0 - Dorsal Surface Of Tongue, Nos
(C02.0)
C02.1 - Border Of Tongue (C02.1)
C02.2 - Ventral Surface Of Tongue, Nos
(C02.2)
C02.3 - Anterior 2/3 Of Tongue, Nos
(C02.3)
C02.4 - Lingual Tonsil (C02.4)
C02.8 - Overlapping Lesion Of Tongue
(C02.8)
C02.9 - Tongue, Nos (C02.9)
C03 - Gum (C03)
C03.0 - Upper Gum (C03.0)
C03.1 - Lower Gum (C03.1)
C03.9 - Gum, Nos (C03.9)
C04 - Floor Of Mouth (C04)
C04.0 - Anterior Floor Of Mouth (C04.0)
C04.1 - Lateral Floor Of Mouth (C04.1)
C04.8 - Overlapping Lesion Of Floor Of
Mouth (C04.8)
C04.9 - Floor Of Mouth, Nos (C04.9)
C05 - Palate (C05)
C05.0 - Hard Palate (C05.0)
C05.1 - Soft Palate, Nos (excludes
Nasopharyngeal Surface Of Soft Palate
C11.3) (C05.1)
C05.2 - Uvula (C05.2)
C05.8 - Overlapping Lesion Of Palate
(see Note Page 45) (C05.8)
C05.9 - Palate, Nos (C05.9)
C06 - Other And Unspecified Parts Of
Mouth (C06)
C06.0 - Cheek Mucosa (C06.0)
C06.1 - Vestibule Of Mouth (C06.1)
C06.2 - Retromolar Area (C06.2)
C06.8 - Overlapping Lesion Of Other
And Unspecified Parts Of Mouth (C06.8)
C06.9 - Mouth, Nos (C06.9)
C07 - Parotid Gland (C07)
C07.9 - Parotid Gland (C07.9)
C08 - Other And Unspecified Major
Salivary Glands (C08)
C08.0 - Submandibular Gland (C08.0)
C08.1 - Sublingual Gland (C08.1)
C08.8 - Overlapping Lesion Of Major
Salivary Glands (C08.8)
C08.9 - Major Salivary Gland, Nos
(C08.9)
C09 - Tonsil (C09)
C09.0 - Tonsillar Fossa (C09.0)
C09.1 - Tonsillar Pillar (C09.1)
C09.8 - Overlapping Lesion Of Tonsil
(C09.8)
C09.9 - Tonsil, Nos (excludes Lingual
Tonsil C02.4 And Pharyngeal Tonsil
21 / 30
Breast Cancer DataMart Common Data Elements for Adjuvant Clinical
Trials
C11.1) (C09.9)
C10 - Oropharynx (C10)
C10.0 - Vallecula (C10.0)
C10.1 - Anterior Surface Of Epiglottis
(C10.1)
C10.2 - Lateral Wall Of Oropharynx
(C10.2)
C10.3 - Posterior Wall Of Oropharynx
(C10.3)
C10.4 - Branchial Cleft (site Of
Neoplasm) (C10.4)
C10.8 - Overlapping Lesion Of
Oropharynx (C10.8)
C10.9 - Oropharynx, Nos (C10.9)
C11 - Nasopharynx (C11)
C11.0 - Superior Wall Of Nasopharynx
(C11.0)
C11.1 - Posterior Wall Of Nasopharynx
(C11.1)
C11.2 - Lateral Wall Of Nasopharynx
(C11.2)
C11.3 - Anterior Wall Of Nasopharynx
(C11.3)
C11.8 - Overlapping Lesion Of
Nasopharynx (C11.8)
C11.9 - Nasopharynx, Nos (C11.9)
C12 - Pyriform Sinus (C12)
C12.9 - Pyriform Sinus (C12.9)
C13 - Hypopharynx (C13)
C13.0 - Postcricoid Region (C13.0)
C13.1 - Hypopharyngeal Aspect Of
Aryepiglottic Fold (C13.1)
C13.2 - Posterior Wall Of Hypopharynx
(C13.2)
C13.8 - Overlapping Lesion Of
Hypopharynx (C13.8)
C13.9 - Hypopharynx, Nos (C13.9)
C14 - Other And Ill-defined Sites In Lip,
Oral Cavity And Pharynx (C14)
C14.0 - Pharynx, Nos (C14.0)
C14.2 - Waldeyer Ring (C14.2)
C14.8 - Overlapping Lesion Of Lip, Oral
Cavity And Pharynx (C14.8)
C15 - Esophagus (C15)
C15-c26 - Digestive Organs (C15-C26)
C15.0 - Cervical Esophagus (C15.0)
C15.1 - Thoracic Esophagus (C15.1)
C15.2 - Abdominal Esophagus (C15.2)
C15.3 - Upper Third Of Esophagus
(C15.3)
C15.4 - Middle Third Of Esophagus
(C15.4)
C15.5 - Lower Third Of Esophagus
(C15.5)
C15.8 - Overlapping Lesion Of
Esophagus (C15.8)
C15.9 - Esophagus, Nos (C15.9)
C16 - Stomach (C16)
C16.0 - Cardia, Nos Gastric Cardia
(C16.0)
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C16.1 - Fundus Of Stomach (C16.1)
C16.2 - Body Of Stomach (C16.2)
C16.3 - Gastric Antrum (C16.3)
C16.4 - Pylorus (C16.4)
C16.5 - Lesser Curvature Of Stomach,
Nos (not Classifiable To C16.1 To C16.4)
(C16.5)
C16.6 - Greater Curvature Of Stomach,
Nos (not Classifiable To C16.0 To C16.4)
(C16.6)
C16.8 - Overlapping Lesion Of Stomach
(C16.8)
C16.9 - Stomach, Nos (C16.9)
C17 - Small Intestine (C17)
C17.0 - Duodenum (C17.0)
C17.1 - Jejunum (C17.1)
C17.2 - Ileum (excludes Ileocecal Valve
C18.0) (C17.2)
C17.3 - Meckel Diverticulum (site Of
Neoplasm) (C17.3)
C17.8 - Overlapping Lesion Of Small
Intestine (C17.8)
C17.9 - Small Intestine, Nos (C17.9)
C18 - Colon (C18)
C18.0 - Cecum (C18.0)
C18.1 - Appendix (C18.1)
C18.2 - Ascending Colon (C18.2)
C18.3 - Hepatic Flexure Of Colon
(C18.3)
C18.4 - Transverse Colon (C18.4)
C18.5 - Splenic Flexure Of Colon
(C18.5)
C18.6 - Descending Colon (C18.6)
C18.7 - Sigmoid Colon (C18.7)
C18.8 - Overlapping Lesion Of Colon
(see Note Page 45) (C18.8)
C18.9 - Colon, Nos (C18.9)
C19 - Rectosigmoid Junction (C19)
C19.9 - Rectosigmoid Junction (C19.9)
C20 - Rectum (C20)
C20.9 - Rectum, Nos (C20.9)
C21 - Anus And Anal Canal (C21)
C21.0 - Anus, Nos (excludes Skin Of
Anus And Perianal Skin C44.5) (C21.0)
C21.1 - Anal Canal (C21.1)
C21.2 - Cloacogenic Zone (C21.2)
C21.8 - Overlapping Lesion Of Rectum,
Anus And Anal Canal (C21.8)
C22 - Liver And Intrahepatic Bile Ducts
(C22)
C22.0 - Liver (C22.0)
C22.1 - Intrahepatic Bile Duct (C22.1)
C23 - Gallbladder (C23)
C23.9 - Gallbladder (C23.9)
C24 - Other And Unspecified Parts Of
Biliary Tract (C24)
C24.0 - Extrahepatic Bile Duct (C24.0)
C24.1 - Ampulla Of Vater (C24.1)
C24.8 - Overlapping Lesion Of Biliary
Tract (C24.8)
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C24.9 - Biliary Tract, Nos (C24.9)
C25 - Pancreas (C25)
C25.0 - Head Of Pancreas (C25.0)
C25.1 - Body Of Pancreas (C25.1)
C25.2 - Tail Of Pancreas (C25.2)
C25.3 - Pancreatic Duct (C25.3)
C25.4 - Islets Of Langerhans (C25.4)
C25.7 - Other Specified Parts Of
Pancreas (C25.7)
C25.8 - Overlapping Lesion Of Pancreas
(C25.8)
C25.9 - Pancreas, Nos (C25.9)
C26 - Other And Ill-defined Digestive
Organs (C26)
C26.0 - Intestinal Tract, Nos (C26.0)
C26.8 - Overlapping Lesion Of Digestive
System (C26.8)
C26.9 - Gastrointestinal Tract, Nos
(C26.9)
C30 - Nasal Cavity And Middle Ear (C30)
C30-c39 Respiratory System And
Intrathoracic Organs (C30-C39)
C30.0 - Nasal Cavity (excludes Nose,
Nos C76.0) (C30.0)
C30.1 - Middle Ear (C30.1)
C31 - Accessory Sinuses (C31)
C31.0 - Maxillary Sinus (C31.0)
C31.1 - Ethmoid Sinus (C31.1)
C31.2 - Frontal Sinus (C31.2)
C31.3 - Sphenoid Sinus (C31.3)
C31.8 - Overlapping Lesion Of
Accessory Sinuses (C31.8)
C31.9 - Accessory Sinus, Nos (C31.9)
C32 - Larynx (C32)
C32.0 - Glottis (C32.0)
C32.1 - Supraglottis (C32.1)
C32.2 - Subglottis (C32.2)
C32.3 - Laryngeal Cartilage (C32.3)
C32.8 - Overlapping Lesion Of Larynx
(C32.8)
C32.9 - Larynx, Nos (C32.9)
C33 - Trachea (C33)
C33.9 - Trachea (C33.9)
C34 - Bronchus And Lung (C34)
C34.0 - Main Bronchus (C34.0)
C34.1 - Upper Lobe, Lung (C34.1)
C34.2 - Middle Lobe, Lung (C34.2)
C34.3 - Lower Lobe, Lung (C34.3)
C34.8 - Overlapping Lesion Of Lung
(C34.8)
C34.9 - Lung, Nos (C34.9)
C37 - Thymus (C37)
C37.9 - Thymus (C37.9)
C38 - Heart, Mediastinum, And Pleura
(C38)
C38.0 - Heart (C38.0)
C38.1 - Anterior Mediastinum (C38.1)
C38.2 - Posterior Mediastinum (C38.2)
C38.3 - Mediastinum, Nos (C38.3)
C38.4 - Pleura, Nos (C38.4)
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C38.8 - Overlapping Lesion Of Heart,
Mediastinum, And Pleura (C38.8)
C39 - Other And Ill-defined Sites Within
Respiratory System Ad Intrathoracic
Organs (C39)
C39.0 - Upper Respiratory Tract, Nos
(C39.0)
C39.8 - Overlapping Lesion Of
Respiratory System And Intrathoracic
Organs (C39.8)
C39.9 - Ill-defined Sites Within
Respiratory System (C39.9)
C40 - Bones, Joints And Articular
Cartilage Of Limbs (C40)
C40-c41 - Bones, Joints And Articular
Cartilage (C40-C41)
C40.0 - Long Bones Of Upper Limb,
Scapula And Associated Joints (C40.0)
C40.1 - Short Bones Of Upper Limb And
Associated Joints (C40.1)
C40.2 - Long Bones Of Lower Limb And
Associated Joints (C40.2)
C40.3 - Short Bones Of Lower Limb And
Associated Joints (C40.3)
C40.8 - Overlapping Lesion Of Bones,
Joints And Articular Cartilage Of Limbs
(C40.8)
C40.9 - Bone Of Limb, Nos (C40.9)
C41 - Bones, Joints And Articular
Cartilage Of Other And Unspecified Sites
(C41)
C41.0 - Bones Of Skull And Face And
Associated Joints (excludes Mandible
C41.1) (C41.0)
C41.1 - Mandible (C41.1)
C41.2 - Vertebral Column (excludes
Sacrum And Coccyx C41.4) (C41.2)
C41.3 - Rib, Sternum, Clavicle And
Associated Joints (C41.3)
C41.4 - Pelvic Bones, Sacrum, Coccyx
And Associated Joints (C41.4)
C41.8 - Overlapping Lesion Of Bones,
Joints And Articular Cartilage (C41.8)
C41.9 - Bone, Nos (C41.9)
C42 - Hematopoietic And
Reticuloendothelial Systems (C42)
C42.0 - Blood (C42.0)
C42.1 - Bone Marrow (C42.1)
C42.2 - Spleen (C42.2)
C42.3 - Reticuloendothelial System, Nos
(C42.3)
C42.4 - Hematopoietic System, Nos
(C42.4)
C44 - Skin (excludes Skin Of Vulva
C51._, Skin Of Penis C60.9, Skin Of
Scrotum C63.2) (C44)
C44.0 - Skin Of Lip, Nos (C44.0)
C44.1 - Eyelid (C44.1)
C44.2 - External Ear (C44.2)
C44.3 - Skin Of Other And Unspecified
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Parts Of Face (C44.3)
C44.4 - Skin Of Scalp And Neck (C44.4)
C44.5 - Skin Of Trunk (C44.5)
C44.6 - Skin Of Upper Limb And
Shoulder (C44.6)
C44.7 - Skin Of Lower Limb And Hip
(C44.7)
C44.8 - Overlapping Lesion Of Skin
(C44.8)
C44.9 - Skin, Nos (excludes Skin Of
Labia Majora C51.0, Skin Of Vulva
C51.9, Skin Of Penis C60.9 And Skin Of
Scrotum C63.2) (C44.9)
C47 - Peripheral Nerves And Autonomic
Nervous System (includes Autonomic
Nervous System, Ganglia, Nerve,
Parasympathetic Nervous System,
Peripheral Nerve, Spinal Nerve,
Sympathetic Nervous System) (C47)
C47.0 - Peripheral Nerves And
Autonomic Nervous System Of Head,
Face, And Neck (excludes Peripheral
Nerves And Autonomic Nervous System
Of Orbit C69.6) (C47.0)
C47.1 - Peripheral Nerves And
Autonomic Nervous System Of Upper
Limb And Shoulder (C47.1)
C47.2 - Peripheral Nerves And
Autonomic Nervous System Of Lower
Limb And Hip (C47.2)
C47.3 - Peripheral Nerves And
Autonomic Nervous System Of Thorax
(C47.3)
C47.4 - Peripheral Nerves And
Autonomic Nervous System Of Abdomen
(C47.4)
C47.5 - Peripheral Nerves And
Autonomic Nervous System Of Pelvis
(C47.5)
C47.6 - Peripheral Nerves And
Autonomic Nervous System Of Trunk,
Nos (C47.6)
C47.8 - Overlapping Lesion Of
Peripheral Nerves And Autonomic
Nervous System (C47.8)
C47.9 - Autonomic Nervous System, Nos
(C47.9)
C48 - Retroperitoneum And Peritoneum
(C48)
C48.0 - Retroperitoneum (C48.0)
C48.1 - Specified Parts Of Peritoneum
(C48.1)
C48.2 - Peritoneum, Nos (C48.2)
C48.8 - Overlapping Lesion Of
Retroperitoneum And Peritoneum
(C48.8)
C49 - Connective, Subcutaneous And
Other Soft Tissu (C49)
C49.0 - Connective, Subcutaneous And
Other Soft Tissues Of Head, Face, And
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Neck (excludes Connective Tissue Of
Orbit C69.6 And Nasal Cartilage C30.0)
(C49.0)
C49.1 - Connective, Subcutaneous And
Other Soft Tissues Of Upper Limb And
Shoulder (C49.1)
C49.2 - Connective, Subcutaneous And
Other Soft Tissues Of Lower Limb And
Hip (C49.2)
C49.3 - Connective, Subcutaneous And
Other Soft Tissues Of Thorax (excludes
Thymus C37.9, Heart And Mediastinum
C38._) (C49.3)
C49.4 - Connective, Subcutaneous And
Other Soft Tissues Of Abdomen (C49.4)
C49.5 - Connective, Subcutaneous And
Other Soft Tissues Of Pelvis (C49.5)
C49.6 - Connective, Subcutaneous And
Other Soft Tissues Of Trunk, Nos
(C49.6)
C49.8 - Overlapping Lesion Of
Connective, Subcutaneous And Other
Soft Tissues (C49.8)
C49.9 - Connective, Subcutaneous And
Other Soft Tissues, Nos (C49.9)
C50 - Breast (excludes Skin Of Breast
C44.5) (C50)
C50.0 - Nipple (C50.0)
C50.1 - Central Portion Of Breast
(C50.1)
C50.2 - Upper-inner Quadrant Of Breast
(C50.2)
C50.3 - Lower-inner Quadrant Of Breast
(C50.3)
C50.4 - Upper-outer Quadrant Of Breast
(C50.4)
C50.5 - Lower-outer Quadrant Of Breast
(C50.5)
C50.6 - Axillary Tail Of Breast (C50.6)
C50.8 - Overlapping Lesion Of Breast
(C50.8)
C50.9 - Breast, Nos (C50.9)
C51 - Vulva (C51)
C51-c58 - Female Genital Organs (C51-
C58)
C51.0 - Labium Majus (C51.0)
C51.1 - Labium Minus (C51.1)
C51.2 - Clitoris (C51.2)
C51.8 - Overlapping Lesion Of Vulva
(C51.8)
C51.9 - Vulva, Nos (C51.9)
C52 - Vagina (C52)
C52.9 - Vagina, Nos (C52.9)
C53 - Cervix Uteri (C53)
C53.0 - Endocervix (C53.0)
C53.1 - Exocervix (C53.1)
C53.8 - Overlapping Lesion Of Cervix
Uteri (C53.8)
C53.9 - Cervix Uteri (C53.9)
C54 - Corpus Uteri (C54)
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C54.0 - Isthmus Uteri (C54.0)
C54.1 - Endometrium (C54.1)
C54.2 - Myometrium (C54.2)
C54.3 - Fundus Uteri (C54.3)
C54.8 - Overlapping Lesion Of Corpus
Uteri (C54.8)
C54.9 - Corpus Uteri (C54.9)
C55 - Uterus, Nos (C55)
C55.9 - Uterus, Nos (C55.9)
C56 - Ovary (C56)
C56.9 - Ovary (C56.9)
C57 - Other And Unspecified Female
Genital Organs (C57)
C57.0 - Fallopian Tube (C57.0)
C57.1 - Broad Ligament (C57.1)
C57.2 - Round Ligament (C57.2)
C57.3 - Parametrium (C57.3)
C57.4 - Uterine Adnexa (C57.4)
C57.7 - Other Specified Parts Of Female
Genital Organs (C57.7)
C57.8 - Overlapping Lesion Of Female
Genital Organs (C57.8)
C57.9 - Female Genital Tract, Nos
(C57.9)
C58 - Placenta (C58)
C58.9 - Placenta (C58.9)
C60 - Penis (C60)
C60-c63 - Male Genital Organs (C60-
C63)
C60.0 - Prepuce (C60.0)
C60.1 - Glans Penis (C60.1)
C60.2 - Body Of Penis (C60.2)
C60.8 - Overlapping Lesion Of Penis
(C60.8)
C60.9 - Penis, Nos (C60.9)
C61 - Prostate Gland (C61)
C61.9 - Prostate Gland (C61.9)
C62 - Testis (C62)
C62.0 - Undescended Testis (site Of
Neoplasm) (C62.0)
C62.1 - Descended Testis (C62.1)
C62.9 - Testis, Nos (C62.9)
C63 - Other And Unspecified Male
Genital Organs (C63)
C63.0 - Epididymis (C63.0)
C63.1 - Spermatic Cord (C63.1)
C63.2 - Scrotum, Nos (C63.2)
C63.7 - Other Specified Parts Of Male
Genital Organs (C63.7)
C63.8 - Overlapping Lesion Of Male
Genital Organs (C63.8)
C63.9 - Male Genital Organs, Nos
(C63.9)
C64 - Kidney (C64)
C64-c68 - Urinary Tract (C64-C68)
C64.9 - Kidney, Nos (C64.9)
C65 - Renal Pelvis (C65)
C65.9 - Renal Pelvis (C65.9)
C66 - Ureter (C66)
C66.9 - Ureter (C66.9)
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C67 - Bladder (C67)
C67.0 - Trigone Of Bladder (C67.0)
C67.1 - Dome Of Bladder (C67.1)
C67.2 - Lateral Wall Of Bladder (C67.2)
C67.3 - Anterior Wall Of Bladder (C67.3)
C67.4 - Posterior Wall Of Bladder
(C67.4)
C67.5 - Bladder Neck (C67.5)
C67.6 - Ureteric Orifice (C67.6)
C67.7 - Urachus (C67.7)
C67.8 - Overlapping Lesion Of Bladder
(C67.8)
C67.9 - Bladder, Nos (C67.9)
C68 - Other And Unspecified Urinary
Organs (C68)
C68.0 - Urethra (C68.0)
C68.1 - Paraurethral Gland (C68.1)
C68.8 - Overlapping Lesion Of Urinary
Organs (C68.8)
C68.9 - Urinary System, Nos (C68.9)
C69 - Eye And Adnexa (C69)
C69-c72 - Eye, Brain And Other Parts Of
Central Nervous System (C69-C72)
C69.0 - Conjunctiva (C69.0)
C69.1 - Cornea, Nos (C69.1)
C69.2 - Retina (C69.2)
C69.3 - Choroid (C69.3)
C69.4 - Ciliary Body (C69.4)
C69.5 - Lacrimal Gland (C69.5)
C69.6 - Orbit, Nos (C69.6)
C69.8 - Overlapping Lesion Of Eye And
Adnexa (see Note Page 45) (C69.8)
C69.9 - Eye, Nos (C69.9)
C70 - Meninges (C70)
C70.0 - Cerebral Meninges (C70.0)
C70.1 - Spinal Meninges (C70.1)
C70.9 - Meninges, Nos (C70.9)
C71 - Brain (C71)
C71.0 - Cerebrum (C71.0)
C71.1 - Frontal Lobe (C71.1)
C71.2 - Temporal Lobe (C71.2)
C71.3 - Parietal Lobe (C71.3)
C71.4 - Occipital Lobe (C71.4)
C71.5 - Ventricle, Nos (C71.5)
C71.6 - Cerebellum, Nos (C71.6)
C71.7 - Brain Stem (C71.7)
C71.8 - Overlapping Lesion Of Brain
(C71.8)
C71.9 - Brain, Nos (C71.9)
C72 - Spinal Cord, Cranial Nerves,and
Other Parts Of Central Nervous System
(excludes Peripheral Nerves,
Sympathetic And Parasympathetic
Nerves And Ganglia C47) (C72)
C72.0 - Spinal Cord (C72.0)
C72.1 - Cauda Equina (C72.1)
C72.2 - Olfactory Nerve (C72.2)
C72.3 - Optic Nerve (C72.3)
C72.4 - Acoustic Nerve (C72.4)
C72.5 - Cranial Nerve, Nos (C72.5)
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C72.8 - Overlapping Lesion Of Brain And
Central Nervous System (C72.8)
C72.9 - Nervous System, Nos (C72.9)
C73 - Thyroid Gland (C73)
C73-c75 - Thyroid And Other Endocrine
Glands (C73-C75)
C73.9 - Thyroid Gland (C73.9)
C74 - Adrenal Gland (C74)
C74.0 - Cortex Of Adrenal Gland (C74.0)
C74.1 - Medulla Of Adrenal Gland
(C74.1)
C74.9 - Adrenal Gland, Nos (C74.9)
C75 - Other Endocrine Glands And
Related Structures (C75)
C75.0 - Parathyroid Gland (C75.0)
C75.1 - Pituitary Gland (C75.1)
C75.2 - Craniopharyngeal Duct (C75.2)
C75.3 - Pineal Gland (C75.3)
C75.4 - Carotid Body (C75.4)
C75.5 - Aortic Body And Other
Paraganglia (C75.5)
C75.8 - Overlapping Lesion Of
Endocrine Glands And Related
Structures (C75.8)
C75.9 - Endocrine Gland, Nos (C75.9)
C76 - Other And Ill-defined Sites (C76)
C76.0 - Head, Face Or Neck, Nos
(C76.0)
C76.1 - Thorax, Nos (C76.1)
C76.2 - Abdomen, Nos (C76.2)
C76.3 - Pelvis, Nos (C76.3)
C76.4 - Upper Limb, Nos (C76.4)
C76.5 - Lower Limb, Nos (C76.5)
C76.7 - Other Ill-defined Sites (C76.7)
C76.8 - Overlapping Lesion Of Ill-defined
Sites (C76.8)
C77 - Lymph Nodes (C77)
C77.0 - Lymph Nodes Of Head, Face
And Neck (C77.0)
C77.1 - Intrathoracic Lymph Nodes
(C77.1)
C77.2 - Intra-abdominal Lymph Nodes
(C77.2)
C77.3 - Lymph Nodes Of Axilla Or Arm
(C77.3)
C77.4 - Lymph Nodes Of Inguinal
Region Or Leg (C77.4)
C77.5 - Pelvic Lymph Nodes (C77.5)
C77.8 - Lymph Nodes Of Multiple
Regions (C77.8)
C77.9 - Lymph Node, Nos (C77.9)
C80 - Unknown Primary Site (C80)
C80.9 - Unknown Primary Site (C80.9)
Site of New Primary
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Eligibility Acute Myeloid Leukemia
NCT02310243
Study of Palbociclib in MLL-rearranged Acute Leukemias;
ODM derived from:
http://clinicaltrials.gov/show/NCT02310243
All rights reserved. Please visit https://medical-data-
models.org/forms/11838
Eligibility Acute Myeloid Leukemia
NCT02310243
Inclusion Criteria
patients with confirmed diagnosis of acute
leukemia with mll rearrangement according to the
2008 who classification*
Yes
No
patients with mll-rearranged leukemia who are
refractory to standard induction therapy and not
immediate candidates for allogeneic hsct (bridge
to transplant is allowed)*
Yes
No
patients with mll-rearranged leukemia who
relapsed after standard first-line treatment and
are not immediate candidates for allogeneic hsct
(bridge to transplant is allowed)*
Yes
No
patients with newly diagnosed mll-rearranged
leukemia who are not eligible for intensive first-
line therapy*
Yes
No
genetic assessment in the amlsg central
laboratory*
Yes
No
age ≥ 18 years, no upper age limit*
Yes
No
who performance status of ≤ 2*
Yes
No
no prior chemotherapy two weeks before study
entry except hydroxyurea to control
hyperleukocytosis*
Yes
No
non-pregnant and non-nursing. women of child-
bearing potential must have a negative serum or
urine pregnancy test with a sensitivity of at least
25 miu/ml within 72 hours prior to registration
(wocbp is defined as a sexually active mature
woman who has not undergone a hysterectomy
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or who has had menses at any time in the
preceding 24 months).*
Yes
No
female patients in the reproductive age and male
patients must agree to avoid getting pregnant or
to father a child while on therapy and for three
months after the last dose of therapy.*
Yes
No
women of child-bearing potential must either
commit to continued abstinence from
heterosexual intercourse or begin one acceptable
method of birth control (iud, tubal ligation, or
partner's vasectomy). hormonal contraception is
an inadequate method of birth control.*
Yes
No
men must agree not to father a child and must
use a latex condom during any sexual contact
with wocbp while receiving therapy and for three
months after therapy is stopped, even if they have
undergone successful vasectomy.*
Yes
No
signed written informed consent*
Yes
No
Exclusion Criteria
prior treatment with palbociclib*
Yes
No
performance status > 2 according to who criteria*
Yes
No
organ insufficiency: creatinine > 1.5 x upper
normal serum level; bilirubin, ast, or ap > 2.5 x
upper normal serum level; heart failure nyha iii/iv;
uncontrolled hypertension; unstable angina;
serious cardiac arrhythmia; severe obstructive or
restrictive ventilation disorder*
Yes
No
uncontrolled infection*
Yes
No
patients with a "currently active" second
malignancy other than non-melanoma skin
cancer. patients are not considered to have a
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"currently active" malignancy if they have
completed therapy and are considered by their
physician to be at less than 30% risk of relapse
within one year.*
Yes
No
severe neurologic or psychiatric disorder
interfering with ability of giving informed consent*
Yes
No
known or suspected active alcohol or drug
abuse*
Yes
No
known positivity for hiv, active hav, hbv, or hcv
infection*
Yes
No
bleeding disorder unrelated to leukemia*
Yes
No
uncontrolled cns involvement (treatment for cns-
involvement prior to inclusion is allowed)*
Yes
No
qtc > 470 msec (based on the mean value of
triplicate ecgs), family or personal history of long
or short qt syndrome, brugada syndrome, or
known history of qtc prolongation or torsade de
pointes*
Yes
No
uncontrolled electrolyte disorders that can
aggravate the effects of a qtc-prolonging drug
(e.g., hypocalcemia, hypokalemia,
hypomagnesemia)*
Yes
No
no consent for registration, storage, and
processing of individual disease characteristics,
information on the course of the disease, and
information obtained from the family physician
and/or other physicians involved in the treatment
of the patient about study participation*
Yes
No
no consent for biobanking*
Yes
No
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Hypertension Status Form Breast Cancer
E1105 NCT00520975
E1105 Hypertension Status Form
First-Line Chemotherapy and Trastuzumab With or Without
Bevacizumab in Treating Patients With Metastatic Breast
Cancer That Overexpresses HER-2/NEU
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=3DA5CD22-
EF9E-0E6A-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11840
Hypertension Status Form Breast
Cancer E1105 NCT00520975
General information
ECOG Protocol Number*
DCI Name*
Registration Step*
Patient Initials (Last, First)*
Participating Group Protocol Number*
Institution/Affiliate*
ECOG Patient ID*
Participating Group Patient ID*
Please mark an 'X' if data have been amended.
(Please circle amended items in red)*
Date data amended (M D Y)*
Off Treatment Report Period (since registration)*
9 Years (108 months post registration)
12 Months Post Randomization (12
Months Post Randomization)
10 Years (120 months post registration)
18 Months Post Randomization (18
Months Post Randomization)
21 Months Post Randomization (21
Months Post Randomization)
24 Months Post Randomization (24
Months Post Randomization)
3 Months Post Randomization (3 Months
Post Randomization)
30 Months Post Randomization (30
Months Post Randomization)
36 Months Post Randomization (36
Months Post Randomization)
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42 Months Post Randomization (42
Months Post Randomization)
48 Months Post Randomization (48
Months Post Randomization)
54 Months Post Randomization (54
Months Post Randomization)
6 Months Post Randomization (6 Months
Post Randomization)
60 Months Post Randomization (60
Months Post Randomization)
6 Years (72 months post registration)
84 Months Post Registration (84 months
post registration)
9 Months Post Randomization (9 Months
Post Randomization)
8 Years (96 months post registration)
Reporting Period
On Treatment Report Period (Maintenance 1
cycle = 3 weeks)*
> Cycle 12 (> Cycle 12)
Cycle 1 (Cycle 1)
Cycle 10 (Cycle 10)
Cycle 11 (Cycle 11)
Cycle 12 (Cycle 12)
Cycle 2 (Cycle 2)
Cycle 3 (Cycle 3)
Cycle 4 (cycle 4)
Cycle 5 (Cycle 5)
Cycle 6 (Cycle 6)
Cycle 7 (Cycle 7)
Cycle 8 (cycle 8)
Cycle 9 (Cycle 9)
Systolic*
>= 0
mmHg
Diastolic*
>= 0
mmHg
Mark an 'X' if not done (during this reporting
period)*
Date of Assessment (most recent)*
Anti-Hypertensive Drugs*
ACE Inhibitor (ACE inhibitors)
Angiotensin II Receptor Blocker
(Angiotensin II inhibitors)
Beta Blocker (Beta blockers)
Calcium Channel Blocker (Calcium
channel blockers)
Diuretic (Diuretics)
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No Medication Given (No medication
given)
Other (Other)
Other, specify
Comments
Investigator Signature*
Investigator Signature Date*
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Hypertension Status Form Lung Cancer
E1505 NCT00324805
E1505 Hypertension Status Form
Chemotherapy With or Without Bevacizumab in Treating
Patients With Stage IB, Stage II, or Stage IIIA Non-Small
Lung Cancer That Was Removed By Surgery
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=1C55F49C-
6CD4-6958-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11841
Hypertension Status Form Lung
Cancer E1505 NCT00324805
General information
ECOG Protocol Number*
ECOG Patient ID*
DCI Name*
Registration Step*
Patient Initials (Last, First)*
Participating Group Protocol Number*
Institution/Affiliate*
Participating Group Patient ID*
Please mark an 'X' if data have been amended.
(Please circle amended items in red)*
Date data amended (M D Y)*
Reporting Period
Systolic*
>= 0
mmHg
Diastolic*
>= 0
mmHg
Mark an 'X' if not done (during this reporting
period)*
Date of Assessment (most recent)*
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Anti-Hypertensive Drugs*
ACE Inhibitor (ACE inhibitors)
Angiotensin II Receptor Blocker
(Angiotensin II inhibitors)
Beta Blocker (Beta blockers)
Calcium Channel Blocker (Calcium
channel blockers)
Diuretic (Diuretics)
No Medication Given (No medication
given)
Other (Other)
Other, specify
Reporting Period*
Baseline (Baseline)
Cycle 1 (Cycle 1)
Cycle 10 (Cycle 10)
Cycle 11 (Cycle 11)
Cycle 12 (Cycle 12)
Cycle 13 (Cycle 13)
Cycle 14 (Cycle 14)
Cycle 15 (Cycle 15)
Cycle 16 (Cycle 16)
Cycle 17 (Cycle 17)
Cycle 2 (Cycle 2)
Cycle 3 (Cycle 3)
Cycle 4 (Cycle 4)
Cycle 5 (Cycle 5)
Cycle 6 (Cycle 6)
Cycle 7 (Cycle 7)
Cycle 8 (Cycle 8)
Cycle 9 (Cycle 9)
Off Treatment Report Period*
12 Months Post-treatment (12 Months
Post-Treatment)
3 Months Post-treatment (3 Months Post-
Treatment)
6 Months Post-treatment (6 Months Post-
Treatment)
9 Months Post-treatment (9 Months Post-
Treatment)
Comments
Investigator Signature*
Investigator Signature Date*
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Treatment Form Breast Cancer Early Stage
NCIC MA.32 NCT01101438
NCIC MA.32 Treatment Report Form
A Phase III Randomized Trial of Metformin vs Placebo in
Early Stage Breast Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=80FC65BF-
C111-5459-E040-BB89AD430BEC
All rights reserved. Please visit https://medical-data-
models.org/forms/11842
Treatment Form Breast Cancer Early
Stage NCIC MA.32 NCT01101438
Patient Information
NCIC Patient ID (NCIC CTG Patient Serial
Number issued at the time of randomization)
Patient Initials (first-middle-last)
Patient Hospital No. (if permitted by REB)
Investigator No.
Investigator First Name
Investigator Middle Name
Investigator Last Name
Timing Of Report
Date
On Treatment Reporting Period
12 Months (12 months)
24 Months (24 months)
36 Months (36 months)
48 Months (48 months)
6 Months (6 months)
Physical Exam
Date of Physical Exam (yyyy-mmm-dd)
Body weight
>= 0
kg
Body Mass Index
kg/m2
1 / 30
Waist Circumference
cm
Hip Circumference
cm
Systolic
>= 0
mmHg
Diastolic
>= 0
mmHg
Disease Status
Status of Most Recent Clinical Assessment
Cancer Present (Cancer present)
No Evidence Of Disease (No evidence of
disease)
In Situ Disease Follow-up
Since the last report has there been a biopsy
proven diagnosis of DCIS
Yes
No
Tumor Laterality
Left (L)
Right (R)
Date of radiologic detection of DCIS (If yes,)
Date of histologic DCIS diagnosis (If yes,)
Kit Return - Question
Have any treatment kits been returned this
reporting period
Yes
No
Kit Return
Kit number
Number of pills returned
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Kit Dispension - Question
Have any treatment kits been dispensed this
reporting period
Yes
No
Kit Dispensation
Date dispensed
Metformin/placebo Administration - Ramp-
up
Date of Initial Dose
Date subject scheduled to begin full dose
Date subject reports full dose begun
Metformin/placebo Administration
Has subject taken protocol medication every day
Yes
No
How many pills does the subject report having
missed (If no,)
Dose Modification Reason (If no, please enter the
reasons for dose modifications in the table
below:)
Adverse Event (Adverse event)
Dosing Error (Dosing error)
Hold For Procedure (Hold for procedure)
Intercurrent Illness (Intercurrent illness)
Other (Other)
Patient Forgot (Patient forgot)
Patient Request (Patient request)
Specify
Was this dose modification or addition/omission
as per protocol guidelines
Yes
No
Radiology Investigations - Question
Was a mammogram performed
3 / 30
Treatment Form Breast Cancer Early Stage NCIC MA.32 NCT01101438
No (No)
Not Applicable (Not Applicable)
Yes (Yes)
Mammogram laterality
Bilateral (Bilateral)
Unilateral (unilateral)
Specify side
Left (Left)
Right (Right)
Was imaging done to assess for recurrence
(other than mammogram)
Yes
No
Radiology Investigations
Type of imaging
Mammography (Mammography)
Magnetic Resonance Imaging (MRI)
Other (Other)
Scan - Bone (Scan - bone)
Scan - Ct Abdomen (Scan - CT
abdomen)
Scan - Ct Brain (Scan - CT brain)
Scan - Ct Chest (Scan - CT chest)
Scan - Ct Pelvis (Scan - CT pelvis)
Ultrasound - Abdomen (Ultrasound -
abdomen)
Ultrasound - Pelvis (Ultrasound - pelvis)
Xray - Chest (Xray - chest)
Specify
Date of test
Result
Abnormal, Malignant (Abnormal,
malignant)
Abnormal, Non-malignant (Abnormal,
non-malignant)
Normal (Normal)
Hematology
Lab, Hematology, Sample Collection Date
Date
Was sample obtained
Yes
No
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Hemoglobin
g/dL
Hemoglobin LLN
g/dL
Hemoglobin ULN
g/dL
Peripheral Platelet Count
1000/uL
Platelets LLN
1000/ul
Platelets ULN
1000/ul
WBC
/ul
WBC LLN
/ul
WBC ULN
/ul
Peripheral Granulocytes Count
1000/uL
Peripheral Granulocytes Count LLN
1000/ul
Peripheral Granulocytes Count ULN
1000/ul
Mean Corpuscular Volume
fl
Mean Corpuscular Volume LLN
fl
Mean Corpuscular Volume ULN
fl
Biochemistry
Date Specimen collected (biochemical
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investigations)
Was sample obtained
Yes
No
Alkaline Phosphatase
U/L
Alkaline Phosphatase LLN
U/L
Alkaline Phosphatase ULN
U/L
ALT (SGPT)
U/L
ALT LLN
U/L
ALT (SGPT) ULN
U/L
AST (SGOT)
U/L
AST LLN
U/L
AST (SGOT) ULN
U/L
Total Bilirubin
mg/dL
Total bilirubin LLN
mg/dL
Total bilirubin ULN
mg/dL
Creatinine
mg/dL
Creatinine LLN
mg/dL
Serum Creatinine ULN
mg/dL
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Serum Vitamin B12
pg/ml
Serum Vitamin B12 LLN
pg/ml
Serum Vitamin B12 ULN
pg/ml
Fasting glucose
mg/dL
Fasting glucose, LLN
mg/dL
Fasting glucose, ULN
mg/dL
Serious Adverse Event - Question
Did the patient experience a Serious Adverse
Event, as defined in protocol section 11, during
this reporting period
Yes
No
Adverse Events On Treatment - Question
Were any additional adverse events experienced
by the patient
No (No)
Not Assessed (Not assessed)
Yes (Yes)
Has a new primary cancer or MDS been
diagnosed that has not been previously reported?
Yes
No
Has there been a new diagnosis of diabetes
since the last report
Yes
No
Adverse Events
Would you like to carry forward the adverse
events (indicated as continuing) from the previous
reporting period
Yes
No
CTCAE Term
Abdominal Distention (Abdominal
distension)
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Abdominal Infection (Abdominal
infection)
Abdominal Pain (Abdominal pain)
Abdominal Soft Tissue Necrotic Lesion
(Abdominal soft tissue necrosis)
Abducens Nerve Disorder (Abducens
nerve disorder)
Accessory Nerve Disorder (Accessory
nerve disorder)
Acidosis (Acidosis)
Vestibulocochlear Nerve Disorder
(Acoustic nerve disorder NOS)
Prolonged Partial Thromboplastin Time
(Activated partial thromboplastin time
prolonged)
Acute Coronary Syndrome (Acute
coronary syndrome)
Acute Renal Failure (Acute kidney injury)
Adrenal Gland Insufficiency (Adrenal
insufficiency)
Adult Respiratory Distress Syndrome
(Adult respiratory distress syndrome)
Agitation (Agitation)
Akathisia (Akathisia)
Alanine Aminotransferase Increased
(Alanine aminotransferase increased)
Alcohol Intolerance (Alcohol intolerance)
Blood Alkaline Phosphatase Increased
(Alkaline phosphatase increased)
Alkalosis (Alkalosis)
Hypersensitivity (Allergic reaction)
Allergic Rhinitis (Allergic rhinitis)
Alopecia (Alopecia)
Amnesia (Amnesia)
Anorectal Fistula (Anal fistula)
Anal Hemorrhage (Anal hemorrhage)
Anal Mucositis (Anal mucositis)
Anal Necrotic Lesion (Anal necrosis)
Anal Pain (Anal pain)
Anal Stenosis (Anal stenosis)
Anal Ulcer (Anal ulcer)
Anaphylactic Shock (Anaphylaxis)
Anemia (Anemia)
Ankle Fracture (Ankle fracture)
Anorectal Infection (Anorectal infection)
Anorexia (Anorexia)
Anorgasmia (Anorgasmia)
Anxiety (Anxiety)
Aortic Injury (Aortic injury)
Aortic Valve Disorder (Aortic valve
disease)
Aphonia (Aphonia)
Apnea (Apnea)
Acute Appendicitis (Appendicitis)
Acute Perforated Appendicitis
(Appendicitis perforated)
Arachnoiditis (Arachnoiditis)
Arterial Injury (Arterial injury)
Arteritis (Arteritis infective)
Arthralgia (Arthralgia)
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Arthritis (Arthritis)
Ascites (Ascites)
Aspartate Aminotransferase Increased
(Aspartate aminotransferase increased)
Aspiration (Aspiration)
Cardiac Arrest (Asystole)
Ataxia (Ataxia)
Atelectasis (Atelectasis)
Atrial Fibrillation (Atrial fibrillation)
Atrial Flutter (Atrial flutter)
Av Block Third Degree (Atrioventricular
block complete)
Av Block First Degree (Atrioventricular
block first degree)
Autoimmune Disease (Autoimmune
disorder)
Bone Necrosis (Avascular necrosis)
Azoospermia (Azoospermia)
Back Pain (Back pain)
Bile Duct Stenosis (Bile duct stenosis)
Biliary Anastomotic Leakage (Biliary
anastomotic leak)
Biliary Fistula (Biliary fistula)
Cholangitis (Biliary tract infection)
Bladder Anastomotic Leakage (Bladder
anastomotic leak)
Cystitis (Bladder infection)
Bladder Perforation (Bladder perforation)
Bladder Spasm (Bladder spasm)
Bloating (Bloating)
Hematopoietic And Lymphoid System
Disorder Other Specify (Blood and
lymphatic system disorders - Other,
specify)
Abnormal Blood Antidiuretic Hormone
(Blood antidiuretic hormone abnormal)
Elevated Bilirubin (Blood bilirubin
increased)
Blood Corticotrophin Decreased (Blood
corticotrophin decreased)
Abnormal Blood Gonadotrophin (Blood
gonadotrophin abnormal)
Abnormal Blood Prolactin (Blood
prolactin abnormal)
Blurred Vision (Blurred vision)
Body Odor (Body odor)
Bone Infection (Bone infection)
Hypocellular Bone Marrow (Bone
marrow hypocellular)
Bone Pain (Bone pain)
Brachial Plexopathy (Brachial
plexopathy)
Breast Atrophy (Breast atrophy)
Mastitis (Breast infection)
Breast Pain (Breast pain)
Bronchial Fistula (Bronchial fistula)
Bronchitis (Bronchial infection)
Bronchial Obstruction (Bronchial
obstruction)
Bronchial Stricture (Bronchial stricture)
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Bronchopleural Fistula (Bronchopleural
fistula)
Bronchial Hemorrhage
(Bronchopulmonary hemorrhage)
Bronchospasm (Bronchospasm)
Bruise (Bruising)
Bullous Dermatitis (Bullous dermatitis)
Burn (Burn)
Buttock Pain (Buttock pain)
Capillary Leak Syndrome Capillary Leak
Syndrome (Capillary leak syndrome)
Decreased Carbon Monoxide Diffusing
Capacity (Carbon monoxide diffusing
capacity decreased)
Cardiac Arrest (Cardiac arrest)
Heart Disorder Other Specify (Cardiac
disorders - Other, specify)
Blood Cardiac Troponin I Increased
(Cardiac troponin I increased)
Blood Cardiac Troponin T Increased
(Cardiac troponin T increased)
Cataract (Cataract)
Catheter-related Infection (Catheter
related infection)
Cd4 Lymphocytes Decreased (CD4
lymphocytes decreased)
Cecal Hemorrhage (Cecal hemorrhage)
Cecal Infection (Cecal infection)
Central Nervous System Necrotic Lesion
(Central nervous system necrosis)
Cerebrospinal Fluid Leakage
(Cerebrospinal fluid leakage)
Infectious Cervicitis (Cervicitis infection)
Cheilitis (Cheilitis)
Angina (Chest pain - cardiac)
Chest Wall Pain (Chest wall pain)
Chills (Chills)
Cholecystitis (Cholecystitis)
Hypercholesterolemia (Cholesterol high)
Chronic Kidney Disease (Chronic kidney
disease)
Chylothorax (Chylothorax)
Cognitive Disturbance (Cognitive
disturbance)
Colitis (Colitis)
Colonic Fistula (Colonic fistula)
Colonic Hemorrhage (Colonic
hemorrhage)
Colonic Obstruction (Colonic obstruction)
Colonic Perforation (Colonic perforation)
Colonic Stenosis (Colonic stenosis)
Colonic Ulcer (Colonic ulcer)
Concentration Impairment
(Concentration impairment)
Heart Conduction Disorder (Conduction
disorder)
Confusion (Confusion)
Congenital, Familial And Genetic
Disorder Class Other Specify
(Congenital, familial and genetic
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disorders - Other, specify)
Conjunctivitis (Conjunctivitis)
Acute Contagious Conjunctivitis
(Conjunctivitis infective)
Constipation (Constipation)
Constrictive Pericarditis (Constrictive
pericarditis)
Keratitis (Corneal infection)
Corneal Ulcer (Corneal ulcer)
Cough (Cough)
Creatine Phosphokinase Increased (CPK
increased)
Cranial Nerve Infection (Cranial nerve
infection)
Increased Creatinine (Creatinine
increased)
Cushingoid (Cushingoid)
Non-infectious Cystitis (Cystitis
noninfective)
Cytokine Release Syndrome (Cytokine
release syndrome)
Neonatal Death (Death neonatal)
Death (Death NOS)
Dehydration (Dehydration)
Delayed Orgasm (Delayed orgasm)
Delayed Puberty (Delayed puberty)
Delirium (Delirium)
Delusion (Delusions)
Caries (Dental caries)
Depressed Level Of Consciousness
(Depressed level of consciousness)
Depression (Depression)
Radiation-induced Dermatitis (Dermatitis
radiation)
Prosthesis-related Infection (Device
related infection)
Diarrhea (Diarrhea)
Disseminated Intravascular Coagulation
(Disseminated intravascular coagulation)
Dizziness (Dizziness)
Dry Eye Syndrome (Dry eye)
Xerostomia (Dry mouth)
Dry Skin (Dry Skin)
Duodenal Fistula (Duodenal fistula)
Duodenal Hemorrhage (Duodenal
hemorrhage)
Duodenal Infection (Duodenal infection)
Duodenal Obstruction (Duodenal
obstruction)
Duodenal Perforation (Duodenal
perforation)
Duodenal Stenosis (Duodenal stenosis)
Duodenal Ulcer (Duodenal ulcer)
Dysarthria (Dysarthria)
Dysesthesia (Dysesthesia)
Dysgeusia (Dysgeusia)
Dysmenorrhea (Dysmenorrhea)
Dyspareunia (Dyspareunia)
Dyspepsia (Dyspepsia)
Dysphagia (Dysphagia)
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Dysphasia (Dysphasia)
Dyspnea (Dyspnea)
Ear And Labyrinth Disorder Class Other
Specify (Ear and labyrinth disorders -
Other, specify)
Earache (Ear pain)
Cerebral Edema (Edema cerebral)
Face Edema (Edema face)
Edema Limbs (Edema limbs)
Edema Trunk (Edema trunk)
Ejaculation Disorder (Ejaculation
disorder)
Ejection Fraction Decreased (Ejection
fraction decreased)
Prolonged Qt Interval (Electrocardiogram
QT corrected interval prolonged)
Infectious Encephalitis (Encephalitis
infection)
Infectious Encephalomyelitis
(Encephalomyelitis infection)
Encephalopathy (Encephalopathy)
Infective Endocarditis (Endocarditis
infective)
Endocrine Disorder Other Specify
(Endocrine disorders - Other, specify)
Endophthalmitis (Endophthalmitis)
Enterocolitis (Enterocolitis)
Infectious Enterocolitis (Enterocolitis
infectious)
Enterovesical Fistula (Enterovesical
fistula)
Epistaxis (Epistaxis)
Impotence (Erectile dysfunction)
Erythema Multiforme (Erythema
multiforme)
Erythroderma (Erythroderma)
Esophageal Anastomotic Leakage
(Esophageal anastomotic leak)
Esophageal Fistula (Esophageal fistula)
Esophageal Hemorrhage (Esophageal
hemorrhage)
Esophageal Infection (Esophageal
infection)
Esophageal Necrotic Lesion
(Esophageal necrosis)
Esophageal Obstruction (Esophageal
obstruction)
Esophageal Pain (Esophageal pain)
Perforation Of Esophagus (Esophageal
perforation)
Esophageal Stricture (Esophageal
stenosis)
Esophageal Ulcer (Esophageal ulcer)
Esophageal Varices Hemorrhage
(Esophageal varices hemorrhage)
Esophagitis (Esophagitis)
Euphoria (Euphoria)
Exostosis (Exostosis)
External Ear Inflammation (External ear
inflammation)
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External Ear Pain (External ear pain)
Extraocular Muscle Paresis (Extraocular
muscle paresis)
Extrapyramidal Disorder (Extrapyramidal
disorder)
Eye Disorder Other Specify (Eye
disorders - Other, specify)
Eye Infection (Eye infection)
Eye Pain (Eye pain)
Eyelid Function Disorder (Eyelid function
disorder)
Facial Muscle Weakness (Facial muscle
weakness)
Facial Nerve Disorder (Facial nerve
disorder)
Facial Pain (Facial pain)
Fall (Fall)
Fallopian Tube Anastomotic Leakage
(Fallopian tube anastomotic leak)
Fallopian Tube Obstruction (Fallopian
tube obstruction)
Fallopian Tube Perforation (Fallopian
tube perforation)
Fallopian Tube Stenosis (Fallopian tube
stenosis)
Adipose Tissue Atrophy (Fat atrophy)
Fatigue (Fatigue)
Neutropenic Fever (Febrile neutropenia)
Fecal Incontinence (Fecal incontinence)
Female Genital Tract Fistula (Female
genital tract fistula)
Acquired Feminization (Feminization
acquired)
Intrauterine Fetal Death (Fetal death)
Fetal Growth Retardation (Fetal growth
retardation)
Fever (Fever)
Fibrinogen Decreased (Fibrinogen
decreased)
Deep Connective Tissue Fibrosis
(Fibrosis deep connective tissue)
Flank Pain (Flank pain)
Flasher (Flashing lights)
Flatulence (Flatulence)
Floaters (Floaters)
Flu-like Symptoms (Flu like symptoms)
Flushing (Flushing)
Decreased Forced Expiratory Volume
(Forced expiratory volume decreased)
Fracture (Fracture)
Gait Disturbance (Gait disturbance)
Gallbladder Fistula (Gallbladder fistula)
Gallbladder Infection (Gallbladder
infection)
Gallbladder Necrotic Lesion (Gallbladder
necrosis)
Gallbladder Obstruction (Gallbladder
obstruction)
Gallbladder Pain (Gallbladder pain)
Gallbladder Perforation (Gallbladder
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perforation)
Gastric Anastomotic Leakage (Gastric
anastomotic leak)
Gastric Fistula (Gastric fistula)
Gastric Hemorrhage (Gastric
hemorrhage)
Gastric Necrotic Lesion (Gastric
necrosis)
Gastric Perforation (Gastric perforation)
Gastric Stenosis (Gastric stenosis)
Gastric Ulcer (Gastric ulcer)
Gastritis (Gastritis)
Gastroesophageal Reflux Disease
(Gastroesophageal reflux disease)
Gastrointestinal System Anastomotic
Leakage (Gastrointestinal anastomotic
leak)
Gastrointestinal Disorder Other Specify
(Gastrointestinal disorders - Other,
specify)
Gastrointestinal Fistula (Gastrointestinal
fistula)
Gastrointestinal Pain (Gastrointestinal
pain)
Gastrointestinal Stoma Necrotic Lesion
(Gastrointestinal stoma necrosis)
Gastroparesis (Gastroparesis)
General Disorders And Administration
Site Conditions Class Other Specify
(General disorders and administration
site conditions - Other, specify)
Generalized Muscle Weakness
(Generalized muscle weakness)
Genital Edema (Genital edema)
Gamma-glutamyltransferase Increased
(GGT increased)
Gingival Pain (Gingival pain)
Glaucoma (Glaucoma)
Glossopharyngeal Nerve Disorder
(Glossopharyngeal nerve disorder)
Glucose Intolerance (Glucose
intolerance)
Accelerated Growth (Growth
accelerated)
Abnormal Growth Hormone (Growth
hormone abnormal)
Growth Retardation (Growth
suppression)
Gum Infection (Gum infection)
Gynecomastia (Gynecomastia)
Hallucination (Hallucinations)
Haptoglobin Decreased (Haptoglobin
decreased)
Head Soft Tissue Necrotic Lesion (Head
soft tissue necrosis)
Headache (Headache)
Hearing Impairment (Hearing impaired)
Heart Failure (Heart failure)
Hematoma (Hematoma)
Hematosalpinx (Hematosalpinx)
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Hematuria (Hematuria)
Hemoglobin Increased (Hemoglobin
increased)
Hemoglobinuria (Hemoglobinuria)
Hemolysis (Hemolysis)
Hemolytic Uremic Syndrome (Hemolytic
uremic syndrome)
Hemorrhoidal Hemorrhage
(Hemorrhoidal hemorrhage)
Hemorrhoid (Hemorrhoids)
Hepatic Failure (Hepatic failure)
Hepatic Hemorrhage (Hepatic
hemorrhage)
Hepatic Infection (Hepatic infection)
Hepatic Necrotic Lesion (Hepatic
necrosis)
Hepatic Pain (Hepatic pain)
Viral Hepatitis (Hepatitis viral)
Liver And Biliary Tract Disorder Other
Specify (Hepatobiliary disorders - Other,
specify)
Hiccough (Hiccups)
Hip Fracture (Hip fracture)
Hirsutism (Hirsutism)
Hoarseness (Hoarseness)
Hot Flashes (Hot flashes)
Hydrocephalus (Hydrocephalus)
Hypercalcemia (Hypercalcemia)
Hyperglycemia (Hyperglycemia)
Hyperhidrosis (Hyperhidrosis)
Hyperkalemia (Hyperkalemia)
Hypermagnesemia (Hypermagnesemia)
Hypernatremia (Hypernatremia)
Hyperparathyroidism
(Hyperparathyroidism)
Hypersomnia (Hypersomnia)
Hypertension (Hypertension)
Hyperthyroidism (Hyperthyroidism)
Hypertrichosis (Hypertrichosis)
Hypertriglyceridemia
(Hypertriglyceridemia)
Hyperuricemia (Hyperuricemia)
Hypoalbuminemia (Hypoalbuminemia)
Hypocalcemia (Hypocalcemia)
Hypoglossal Nerve Disorder
(Hypoglossal nerve disorder)
Hypoglycemia (Hypoglycemia)
Hypohidrosis (Hypohidrosis)
Hypokalemia (Hypokalemia)
Hypomagnesemia (Hypomagnesemia)
Hyponatremia (Hyponatremia)
Hypoparathyroidism
(Hypoparathyroidism)
Hypophosphatemia (Hypophosphatemia)
Hypotension (Hypotension)
Hypothermia (Hypothermia)
Hypothyroidism (Hypothyroidism)
Hypoxia (Hypoxia)
Ileal Fistula (Ileal fistula)
Ileal Hemorrhage (Ileal hemorrhage)
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Ileal Obstruction (Ileal obstruction)
Ileal Perforation (Ileal perforation)
Ileal Stenosis (Ileal stenosis)
Ileal Ulcer (Ileal ulcer)
Ileus (Ileus)
Immune System Disorder Other Specify
(Immune system disorders - Other,
specify)
Infection Other Specify (Infections and
infestations - Other, specify)
Infectious Myositis (Infective myositis)
Infusion-related Reaction (Infusion
related reaction)
Infusion Site Extravasation (Infusion site
extravasation)
Injection Site Reaction (Injection site
reaction)
Injury To Carotid Artery (Injury to carotid
artery)
Injury To Inferior Vena Cava (Injury to
inferior vena cava)
Injury To Jugular Vein (Injury to jugular
vein)
Injury To Superior Vena Cava (Injury to
superior vena cava)
Injury, Poisoning And Procedural
Complication Class Other Specify (Injury,
poisoning and procedural complications -
Other, specify)
Inr Increased (INR increased)
Insomnia (Insomnia)
Intestinal Stoma Leakage (Intestinal
stoma leak)
Intestinal Stoma Obstruction (Intestinal
stoma obstruction)
Intestinal Stoma Site Hemorrhage
(Intestinal stoma site bleeding)
Intra-abdominal Hemorrhage (Intra-
abdominal hemorrhage)
Intracranial Hemorrhage (Intracranial
hemorrhage)
Intraoperative Arterial Injury
(Intraoperative arterial injury)
Intraoperative Breast Injury
(Intraoperative breast injury)
Intraoperative Cardiac Injury
(Intraoperative cardiac injury)
Intraoperative Ear Injury (Intraoperative
ear injury)
Intraoperative Endocrine Injury
(Intraoperative endocrine injury)
Intraoperative Gastrointestinal Injury
(Intraoperative gastrointestinal injury)
Intraoperative Head And Neck Injury
(Intraoperative head and neck injury)
Intraoperative Hemorrhage
(Intraoperative hemorrhage)
Intraoperative Hepatobiliary Injury
(Intraoperative hepatobiliary injury)
Intraoperative Musculoskeletal Injury
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(Intraoperative musculoskeletal injury)
Intraoperative Neurological Injury
(Intraoperative neurological injury)
Intraoperative Ocular Injury
(Intraoperative ocular injury)
Intraoperative Renal Injury
(Intraoperative renal injury)
Intraoperative Reproductive System
Injury (Intraoperative reproductive tract
injury)
Intraoperative Respiratory Injury
(Intraoperative respiratory injury)
Intraoperative Skin Injury (Intraoperative
skin injury)
Intraoperative Splenic Injury
(Intraoperative splenic injury)
Intraoperative Urinary System Injury
(Intraoperative urinary injury)
Intraoperative Venous Injury
(Intraoperative venous injury)
Investigation Other Specify
(Investigations - Other, specify)
Iron Overload (Iron overload)
Irregular Menstruation (Irregular
menstruation)
Irritability (Irritability)
Cerebrovascular Ischemia (Ischemia
cerebrovascular)
Trochlear Nerve Disorder (IVth nerve
disorder)
Jejunal Fistula (Jejunal fistula)
Jejunal Hemorrhage (Jejunal
hemorrhage)
Jejunal Obstruction (Jejunal obstruction)
Jejunal Perforation (Jejunal perforation)
Jejunal Stenosis (Jejunal stenosis)
Jejunal Ulcer (Jejunal ulcer)
Joint Effusion (Joint effusion)
Joint Infection (Joint infection)
Joint Range Of Motion Decreased (Joint
range of motion decreased)
Cervical Spine Joint Range Of Motion
Decreased (Joint range of motion
decreased cervical spine)
Lumbar Spine Joint Range Of Motion
Decreased (Joint range of motion
decreased lumbar spine)
Keratitis (Keratitis)
Kidney Anastomotic Leakage (Kidney
anastomotic leak)
Pyelonephritis (Kidney infection)
Kyphosis (Kyphosis)
Lactation Disorder (Lactation disorder)
Large Intestinal Anastomotic Leakage
(Large intestinal anastomotic leak)
Laryngeal Edema (Laryngeal edema)
Laryngeal Fistula (Laryngeal fistula)
Laryngeal Hemorrhage (Laryngeal
hemorrhage)
Laryngitis (Laryngeal inflammation)
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Laryngeal Mucositis (Laryngeal
mucositis)
Laryngeal Obstruction (Laryngeal
obstruction)
Laryngeal Stenosis (Laryngeal stenosis)
Laryngitis (Laryngitis)
Laryngopharyngeal Dysesthesia
(Laryngopharyngeal dysesthesia)
Laryngospasm (Laryngospasm)
Left Ventricular Systolic Dysfunction (Left
ventricular systolic dysfunction)
Lethargy (Lethargy)
Chemotherapy-related Leukemia
(Leukemia secondary to oncology
chemotherapy)
Leukocytosis (Leukocytosis)
Leukoencephalopathy
(Leukoencephalopathy)
Decreased Libido (Libido decreased)
Increased Libido (Libido increased)
Lip Infection (Lip infection)
Lip Pain (Lip pain)
Lipase Increased (Lipase increased)
Lipohypertrophy (Lipohypertrophy)
Localized Edema (Localized edema)
Lordosis (Lordosis)
Lower Gastrointestinal Hemorrhage
(Lower gastrointestinal hemorrhage)
Infectious Lung Disorder (Lung infection)
Lymphadenitis (Lymph gland infection)
Lymph Leakage (Lymph leakage)
Lymph Node Pain (Lymph node pain)
Lymphedema (Lymphedema)
Lymphocele (Lymphocele)
Lymphopenia (Lymphocyte count
decreased)
Lymphocytosis (Lymphocyte count
increased)
Malabsorption Syndrome
(Malabsorption)
Malaise (Malaise)
Mania (Mania)
Mediastinal Hemorrhage (Mediastinal
hemorrhage)
Mediastinitis (Mediastinal infection)
Memory Impairment (Memory
impairment)
Meningismus (Meningismus)
Meningitis (Meningitis)
Menopause (Menopause)
Menorrhagia (Menorrhagia)
Metabolism And Nutrition Disorder Class
Other Specify (Metabolism and nutrition
disorders - Other, specify)
Otitis Media (Middle ear inflammation)
Mitral Valve Disorder (Mitral valve
disease)
Av Block Second Degree Mobitz Type Ii
(Mobitz (type) II atrioventricular block)
Av Block Second Degree Mobitz Type I
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(Mobitz type I)
Involuntary Movements (Movements
involuntary)
Mucosal Infection (Mucosal infection)
Stomatitis (Mucositis oral)
Multiple Organ Failure (Multi-organ
failure)
Muscle Weakness Left-sided (Muscle
weakness left-sided)
Muscle Weakness Lower Limb (Muscle
weakness lower limb)
Muscle Weakness Right-sided (Muscle
weakness right-sided)
Muscle Weakness Trunk (Muscle
weakness trunk)
Muscle Weakness Upper Limb (Muscle
weakness upper limb)
Connective And Soft Tissue Disorder
Other Specify (Musculoskeletal and
connective tissue disorder -  Other,
specify)
Musculoskeletal Deformity
(Musculoskeletal deformity)
Myalgia (Myalgia)
Myelitis (Myelitis)
Mds (Myelodysplastic syndrome)
Myocardial Infarction (Myocardial
infarction)
Myocarditis (Myocarditis)
Myositis (Myositis)
Nail Discoloration (Nail discoloration)
Nail Infection (Nail infection)
Nail Loss (Nail loss)
Nail Ridging (Nail ridging)
Nasal Congestion (Nasal congestion)
Nausea (Nausea)
Neck Edema (Neck edema)
Neck Pain (Neck pain)
Neck Soft Tissue Necrotic Lesion (Neck
soft tissue necrosis)
Neoplasm Other Specify (Neoplasms
benign, malignant and unspecified (incl
cysts and polyps) - Other, specify)
Nervous System Disorder Other Specify
(Nervous system disorders - Other,
specify)
Neuralgia (Neuralgia)
Neutrophil Count Decreased (Neutrophil
count decreased)
Night Blindness (Night blindness)
Nipple Deformity (Nipple deformity)
Non-cardiac Chest Pain (Non-cardiac
chest pain)
Nystagmus (Nystagmus)
Obesity (Obesity)
Gastric Obstruction (Obstruction gastric)
Oculomotor Nerve Disorder (Oculomotor
nerve disorder)
Olfactory Nerve Disorder (Olfactory
nerve disorder)
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Oligospermia (Oligospermia)
Optic Nerve Disorder (Optic nerve
disorder)
Oral Cavity Fistula (Oral cavity fistula)
Burning Mouth Syndrome (Oral
dysesthesia)
Oral Hemorrhage (Oral hemorrhage)
Oral Pain (Oral pain)
Osteonecrosis Of Jaw (Osteonecrosis of
jaw)
Osteoporosis (Osteoporosis)
External Ear Infection (Otitis externa)
Otitis Media (Otitis media)
Ovarian Hemorrhage (Ovarian
hemorrhage)
Ovarian Infection (Ovarian infection)
Ovarian Rupture (Ovarian rupture)
Ovulatory Pain (Ovulation pain)
Pain (Pain)
Pain In Extremity (Pain in extremity)
Skin Pain (Pain of skin)
Palmar-plantar Erythodysthesia (Palmar-
plantar erythrodysesthesia syndrome)
Palpitation (Palpitations)
Pancreatic Infection (Pancreas infection)
Pancreatic Anastomotic Leakage
(Pancreatic anastomotic leak)
Pancreatic Duct Stenosis (Pancreatic
duct stenosis)
Pancreatic Enzymes Decreased
(Pancreatic enzymes decreased)
Pancreatic Fistula (Pancreatic fistula)
Pancreatic Hemorrhage (Pancreatic
hemorrhage)
Pancreatic Necrotic Lesion (Pancreatic
necrosis)
Pancreatitis (Pancreatitis)
Papilledema (Papilledema)
Papulopustular Rash (Papulopustular
rash)
Paresthesia (Paresthesia)
Paronychia (Paronychia)
Paroxysmal Atrial Tachycardia
(Paroxysmal atrial tachycardia)
Pelvic Floor Muscle Weakness (Pelvic
floor muscle weakness)
Pelvic Inflammatory Disease (Pelvic
infection)
Pelvic Pain (Pelvic pain)
Pelvic Soft Tissue Necrotic Lesion
(Pelvic soft tissue necrosis)
Penile Infection (Penile infection)
Penile Pain (Penile pain)
Bile Duct Perforation (Perforation bile
duct)
Pericardial Effusion (Pericardial effusion)
Cardiac Tamponade (Pericardial
tamponade)
Pericarditis (Pericarditis)
Perineal Pain (Perineal pain)
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Periodontal Disorder (Periodontal
disease)
Periorbital Edema (Periorbital edema)
Periorbital Infection (Periorbital infection)
Peripheral Ischemia (Peripheral
ischemia)
Peripheral Motor Neuropathy (Peripheral
motor neuropathy)
Peripheral Nervous System Infectious
Disorder (Peripheral nerve infection)
Peripheral Sensory Neuropathy
(Peripheral sensory neuropathy)
Peritoneal Infection (Peritoneal infection)
Peritoneal Necrotic Lesion (Peritoneal
necrosis)
Personality Change (Personality change)
Phantom Pain (Phantom pain)
Pharyngeal Anastomotic Leakage
(Pharyngeal anastomotic leak)
Pharyngeal Fistula (Pharyngeal fistula)
Pharyngeal Hemorrhage (Pharyngeal
hemorrhage)
Pharyngeal Mucositis (Pharyngeal
mucositis)
Pharyngeal Necrotic Lesion (Pharyngeal
necrosis)
Pharyngeal Stenosis (Pharyngeal
stenosis)
Pharyngitis (Pharyngitis)
Pharyngolaryngeal Pain
(Pharyngolaryngeal pain)
Phlebitis (Phlebitis)
Infective Phlebitis (Phlebitis infective)
Photophobia (Photophobia)
Photosensitivity (Photosensitivity)
Thrombocytopenia (Platelet count
decreased)
Pleural Effusion (Pleural effusion)
Hemothorax (Pleural hemorrhage)
Pleural Infection (Pleural infection)
Pleuritic Pain (Pleuritic pain)
Pneumonia (Pneumonitis)
Pneumothorax (Pneumothorax)
Portal Hypertension (Portal
Hypertension)
Portal Vein Thrombosis (Portal vein
thrombosis)
Post-nasal Drip (Postnasal drip)
Postoperative Bleeding (Postoperative
hemorrhage)
Thoracic Procedure Postoperative
Complication (Postoperative thoracic
procedure complication)
Precocious Puberty (Precocious
puberty)
Pregnancy, Puerperium And Perinatal
Condition Class Other Specify
(Pregnancy, puerperium and perinatal
conditions - Other, specify)
Premature Labor (Premature delivery)
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Premature Menopause (Premature
menopause)
Presyncope (Presyncope)
Proctitis (Proctitis)
Productive Cough (Productive cough)
Intestinal Stoma Prolapse (Prolapse of
intestinal stoma)
Urostomy Prolapse (Prolapse of
urostomy)
Prostatic Infection (Prostate infection)
Prostatic Hemorrhage (Prostatic
hemorrhage)
Prostatic Obstruction (Prostatic
obstruction)
Prostatic Pain (Prostatic pain)
Proteinuria (Proteinuria)
Pruritus (Pruritus)
Psychiatric Disorder Other Specify
(Psychiatric disorders - Other, specify)
Psychosis (Psychosis)
Pulmonary Edema (Pulmonary edema)
Pulmonary Fibrosis (Pulmonary fibrosis)
Pulmonary Fistula (Pulmonary fistula)
Pulmonary Hypertension (Pulmonary
hypertension)
Pulmonary Valve Disorder (Pulmonary
valve disease)
Purpura (Purpura)
Pyramidal Tract Dysfunction (Pyramidal
tract syndrome)
Radiation-recall Dermatitis (Radiation
recall reaction (dermatologic))
Radiculitis (Radiculitis)
Acneiform Dermatitis (Rash acneiform)
Maculopapular Lesion (Rash maculo-
papular)
Papulopustular Rash (Rash pustular)
Rectal Anastomotic Leakage (Rectal
anastomotic leak)
Rectal Fistula (Rectal fistula)
Rectal Hemorrhage (Rectal hemorrhage)
Rectal Mucositis (Rectal mucositis)
Rectal Necrotic Lesion (Rectal necrosis)
Rectal Obstruction (Rectal obstruction)
Rectal Pain (Rectal pain)
Rectal Perforation (Rectal perforation)
Rectal Stenosis (Rectal stenosis)
Rectal Ulcer (Rectal ulcer)
Recurrent Laryngeal Nerve Paralysis
(Recurrent laryngeal nerve palsy)
Urinary Tract Disorder Other Specify
(Renal and urinary disorders - Other,
specify)
Renal Stone (Renal calculi)
Renal Colic (Renal colic)
Renal Hemorrhage (Renal hemorrhage)
Reproductive System And Breast
Disorder Class Other Specify
(Reproductive system and breast
disorders - Other, specify)
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Respiratory Failure (Respiratory failure)
Respiratory And Thoracic Disorder Other
Specify (Respiratory, thoracic and
mediastinal disorders - Other, specify)
Restlessness (Restlessness)
Restrictive Cardiomyopathy (Restrictive
cardiomyopathy)
Retinal Detachment (Retinal
detachment)
Retinal Tear (Retinal tear)
Retinal Vascular Disorder (Retinal
vascular disorder)
Retinoic Acid Syndrome (Retinoic acid
syndrome)
Retinopathy (Retinopathy)
Retroperitoneal Hemorrhage
(Retroperitoneal hemorrhage)
Reversible Posterior
Leukoencephalopathy Syndrome
(Reversible posterior
leukoencephalopathy syndrome)
Infectious Rhinitis (Rhinitis infective)
Right Ventricular Dysfunction (Right
ventricular dysfunction)
Salivary Duct Inflammation (Salivary duct
inflammation)
Salivary Gland Fistula (Salivary gland
fistula)
Salivary Gland Infection (Salivary gland
infection)
Scalp Pain (Scalp pain)
Sclera Disorder (Scleral disorder)
Scoliosis (Scoliosis)
Scrotal Infection (Scrotal infection)
Scrotal Pain (Scrotal pain)
Seizure (Seizure)
Septicemia (Sepsis)
Seroma (Seroma)
Serum Amylase Increased (Serum
amylase increased)
Serum Sickness (Serum sickness)
Sick Sinus Syndrome (Sick sinus
syndrome)
Sinus Bradycardia (Sinus bradycardia)
Paranasal Sinus Disorder (Sinus
disorder)
Sinus Pain (Sinus pain)
Sinus Tachycardia (Sinus tachycardia)
Sinusitis (Sinusitis)
Skin Disorder Other Specify (Skin and
subcutaneous tissue disorders - Other,
specify)
Skin Atrophy (Skin atrophy)
Skin Hyperpigmentation (Skin
hyperpigmentation)
Skin Hypopigmentation (Skin
hypopigmentation)
Skin Induration (Skin induration)
Skin Infection (Skin infection)
Skin Ulcer (Skin ulceration)
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Sleep Apnea (Sleep apnea)
Small Intestinal Anastomotic Leakage
(Small intestinal anastomotic leak)
Small Intestinal Mucositis (Small
intestinal mucositis)
Small Intestinal Obstruction (Small
intestinal obstruction)
Small Intestinal Perforation (Small
intestinal perforation)
Small Intestinal Stenosis (Small intestinal
stenosis)
Small Intestinal Infection (Small intestine
infection)
Small Intestinal Ulcer (Small intestine
ulcer)
Sneezing (Sneezing)
Social Circumstances Other Specify
(Social circumstances - Other, specify)
Soft Tissue Infection (Soft tissue
infection)
Lower Limb Soft Tissue Necrotic Lesion
(Soft tissue necrosis lower limb)
Upper Limb Soft Tissue Necrotic Lesion
(Soft tissue necrosis upper limb)
Somnolence (Somnolence)
Sore Throat (Sore throat)
Spasticity (Spasticity)
Spermatic Cord Anastomotic Leakage
(Spermatic cord anastomotic leak)
Spermatic Cord Hemorrhage (Spermatic
cord hemorrhage)
Spermatic Cord Obstruction (Spermatic
cord obstruction)
Vertebral Fracture (Spinal fracture)
Splenic Disorder (Spleen disorder)
Splenic Infection (Splenic infection)
Gastrointestinal Stoma Stenosis
(Stenosis of gastrointestinal stoma)
Stevens-johnson Syndrome (Stevens-
Johnson syndrome)
Stoma Site Infection (Stoma site
infection)
Stomach Pain (Stomach pain)
Stomal Ulcer (Stomal ulcer)
Stridor (Stridor)
Cerebrovascular Accident (Stroke)
Sudden Cardiac Death (Sudden death
NOS)
Suicidal Ideation (Suicidal ideation)
Suicide Attempt (Suicide attempt)
Superficial Soft Tissue Fibrosis
(Superficial soft tissue fibrosis)
Superficial Thrombophlebitis (Superficial
thrombophlebitis)
Superior Vena Cava Syndrome (Superior
vena cava syndrome)
Supraventricular Tachycardia
(Supraventricular tachycardia)
Intervention Or Procedure Other Specify
(Surgical and medical procedures -
24 / 30
Treatment Form Breast Cancer Early Stage NCIC MA.32 NCT01101438
Other, specify)
Syncope (Syncope)
Telangiectasia (Telangiectasia)
Testicular Disorder (Testicular disorder)
Testicular Hemorrhage (Testicular
hemorrhage)
Testicular Pain (Testicular pain)
Thromboembolism (Thromboembolic
event)
Thrombotic Thrombocytopenic Purpura
(Thrombotic thrombocytopenic purpura)
Tinnitus (Tinnitus)
Dental Developmental Disorder (Tooth
development disorder)
Tooth Discoloration (Tooth discoloration)
Tooth Infection (Tooth infection)
Toothache (Toothache)
Toxic Epidermal Necrolysis (Toxic
epidermal necrolysis)
Tracheal Fistula (Tracheal fistula)
Tracheal Hemorrhage (Tracheal
hemorrhage)
Tracheal Mucositis (Tracheal mucositis)
Tracheal Obstruction (Tracheal
obstruction)
Tracheal Stenosis (Tracheal stenosis)
Tracheitis (Tracheitis)
Tracheostomy Site Bleeding
(Tracheostomy site bleeding)
Transient Ischemic Attack (Transient
ischemic attacks)
Therapy-related Malignant Neoplasm
(Treatment related secondary
malignancy)
Tremor (Tremor)
Tricuspid Valve Disorder (Tricuspid valve
disease)
Trigeminal Nerve Disorder (Trigeminal
nerve disorder)
Trismus (Trismus)
Tumor Lysis Syndrome (Tumor lysis
syndrome)
Tumor Pain (Tumor pain)
Typhlitis (Typhlitis)
Unequal Limb Length (Unequal limb
length)
Unintended Pregnancy (Unintended
pregnancy)
Upper Gastrointestinal Hemorrhage
(Upper gastrointestinal hemorrhage)
Upper Respiratory Tract Infection (Upper
respiratory infection)
Ureteric Anastomotic Leakage (Ureteric
anastomotic leak)
Urethral Anastomotic Leakage (Urethral
anastomotic leak)
Urethral Infection (Urethral infection)
Urinary Tract Fistula (Urinary fistula)
Urinary Frequency (Urinary frequency)
Urinary Incontinence (Urinary
25 / 30
Treatment Form Breast Cancer Early Stage NCIC MA.32 NCT01101438
incontinence)
Urinary Retention (Urinary retention)
Urinary Tract Infection (Urinary tract
infection)
Urinary Tract Obstruction (Urinary tract
obstruction)
Urinary Tract Pain (Urinary tract pain)
Urinary Urgency (Urinary urgency)
Urine Discoloration (Urine discoloration)
Urine Output Decreased (Urine output
decreased)
Urostomy Leakage (Urostomy leak)
Urostomy Obstruction (Urostomy
obstruction)
Urostomy Site Bleeding (Urostomy site
bleeding)
Urostomy Stenosis (Urostomy stenosis)
Urticaria (Urticaria)
Uterine Anastomotic Leakage (Uterine
anastomotic leak)
Uterine Fistula (Uterine fistula)
Uterine Hemorrhage (Uterine
hemorrhage)
Endometritis (Uterine infection)
Uterine Obstruction (Uterine obstruction)
Uterine Pain (Uterine pain)
Uterine Perforation (Uterine perforation)
Uveitis (Uveitis)
Vaginal Anastomotic Leakage (Vaginal
anastomotic leak)
Vaginal Discharge (Vaginal discharge)
Vaginal Dryness (Vaginal dryness)
Vaginal Fistula (Vaginal fistula)
Vaginal Hemorrhage (Vaginal
hemorrhage)
Vaginitis (Vaginal infection)
Vaginitis (Vaginal inflammation)
Vaginal Obstruction (Vaginal obstruction)
Vaginal Pain (Vaginal pain)
Vaginal Perforation (Vaginal perforation)
Vaginal Stricture (Vaginal stricture)
Vaginismus (Vaginismus)
Vagus Nerve Disorder (Vagus nerve
disorder)
Vas Deferens Anastomotic Leakage (Vas
deferens anastomotic leak)
Vascular Access Complication (Vascular
access complication)
Vascular Disorder Other Specify
(Vascular disorders - Other, specify)
Vasculitis (Vasculitis)
Vasovagal Reaction (Vasovagal reaction)
Venous Injury (Venous injury)
Ventricular Arrhythmia (Ventricular
arrhythmia)
Ventricular Fibrillation (Ventricular
fibrillation)
Ventricular Tachycardia (Ventricular
tachycardia)
Vertigo (Vertigo)
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Internal Ear Disorder (Vestibular
disorder)
Virilization (Virilization)
Visceral Artery Ischemia (Visceral
arterial ischemia)
Abnormal Vital Capacity (Vital capacity
abnormal)
Vitreous Hemorrhage (Vitreous
hemorrhage)
Voice Alternation (Voice alteration)
Vomiting (Vomiting)
Vulval Infection (Vulval infection)
Watering Eyes (Watering eyes)
Weight Gain (Weight gain)
Weight Loss (Weight loss)
Wheezing (Wheezing)
Leukopenia (White blood cell decreased)
Wolff-parkinson-white Syndrome (Wolff-
Parkinson-White Syndrome)
Wound Complication (Wound
complication)
Wound Dehiscence (Wound dehiscence)
Wound Infection (Wound infection)
Wrist Fracture (Wrist fracture)
AE Ongoing
No (No)
Not Assessed (Not assessed)
Yes (Yes)
Grade
Seriousness Attributed to Adverse Event
Congenital Anomaly (Congenital
anomaly)
Death (Death)
Disability (Disability/incapacity)
Hospitalized (Hospitalization, initial or
prolonged)
Life Threatening (Life threatening)
Not Serious (Not serious)
Intervention Required (Required
intervention to prevent permanent
impairment/damage)
Attribution
Definite (Definite)
Possible (Possible)
Probable (Probable)
Unlikely (Unlikely)
Unrelated (Unrelated)
Cardiovascular Morbidity - Question
Has there been a hospitalization for a
cardiovascular event since the last report
Yes
No
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Cardiovascular Mobidity
Problem, cardiovascular
Angina Requiring Coronary Artery
Bypass Graft (Angina requiring coronary
artery bypass graft)
Angina Requiring Transluminal Coronary
Angioplasty (Angina requiring
transluminal coronary angioplasty)
Myocardial Infarction (Myocardial
Infarction)
New Or Worsening Angina (New or
worsening angina)
Other (Other)
Transient Ischemic Attack
Cerebrovascular Accident (Stroke /
transient inschemic attack TIA)
Thromboembolism (Thromboembolic
Event)
Specify
Date of hospital admission
Cancer Treatment Since Last Report ¿
Question
Has patient received any new treatment for
breast cancer since the last report
No (No)
Unknown (Unknown)
Yes (Yes)
Cancer Treatment Since Last Report
Non-Protocol Therapy Type
Other Specify (Other)
Radiation Therapy (Radiation therapy)
Surgery (Surgery)
Systemic Therapy (Systemic therapy)
Specify
Name of Other Non-Protocol Therapy
Non protocol surgery
Non-protocol Therapy Start Date
Major Medical Problems
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Concomitant Diseases and/or Relevant Medical
Conditions
Quality Of Life Questionnaire
Was this subject one of the sub-set of subjects
who completed questionnaires at baseline
Yes
No
Date patient filled out questionnaire
Questionnaire
Block Alive Screener (Block Alive
screener)
Nhs Ii - Physical Activity (NHS II -
Physical Activity)
Quality Of Life (Quality of Life)
Done
Yes
No
Reason questionnaire was not completed
Other Reason (Other reason)
Patient Could Not Be Contacted (Patient
could not be contacted)
Patient Did Not Keep Appointment
(Patient did not keep appointment)
Patient Kept Appointment For
Examination, But Could Not Complete
Questionnaire Due To Illness (Patient
kept appointment for examination, but
could not complete questionnaire due to
illness)
Patient Kept Appointment For
Examination, But Refused To Complete
Questionnaire For Reasons Other Than
Illness (Patient kept appointment for
examination, but refused to complete
questionnaire for reasons other)
Test Omitted Due To
Institution/investigator Error
(Questionnaire not administered due to
institutional error)
Specify
Comments
Comments
Contact Information
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CRA Name
Phone number
Fax Number
Institution Name
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On-Study Form Breast Cancer ALTTO BIG 2-
06 NCCTG N063D EGF106708 NCT00490139
ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment
Optimisation) Study; BIG 2-06/N063D
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=31CB3D80-
4488-2AD0-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11843
On-Study Form Breast Cancer
ALTTO BIG 2-06 NCCTG N063D
EGF106708 NCT00490139
Header Module
Centre No.
Subject No.
Patient Status
Date of Physical Exam
Not done
Are there any changes since the previous
assessment
Yes
No
Are there any changes since the previous
assessment
Adverse Event (Adverse Event)
Death (Death)
Lost To Follow-up (Lost To Follow-up)
Patient Withdrew Study Consent (Patient
withdrew study consent)
Recurrence Of Disease (Recurrence of
disease)
Second Primary Malignancy Or
Contralateral Breast Cancer (Second
primary malignancy or contralateral
breast cancer)
Significant Cardiac Disease (Significant
cardiac disease)
Date of Last Contact
ECOG Performance Status
Fully Active, Able To Carry On All Pre-
disease Performance Without
Restriction. (0)
Restricted In Physically Strenuous
Activity But Ambulatory And Able To
Carry Out Work Of A Light Or Sedentary
Nature, E.g., Light Housework, Office
1 / 4
Work. (1)
Ambulatory And Capable Of All Selfcare
But Unable To Carry Out Any Work
Activities. Up And About More Than 50%
Of Waking Hours. (2)
Capable Of Only Limited Selfcare,
Confined To Bed Or Chair More Than
50% Of Waking Hours. (3)
Completely Disabled. Cannot Carry On
Any Selfcare. Totally Confined To Bed Or
Chair. (4)
Dead (5)
Systolic
>= 0
mmHg
Diastolic
>= 0
mmHg
Cardiac Monitoring
Date of LVEF
Left Ventricular Ejection Fraction
%
Method of Evaluation
Echocardiogram (Echocardiogram)
Muga Scan (MUGA scan)
LVEF Status
Normal (1)
Abnormal - Not Clinically Significant (2)
Abnormal - Clinically Significant (3)
Symptomatic CHF
Yes
No
New York Heart Association Classification
Patients With Cardiac Disease But
Without Resulting Limitation Of Physical
Activity. Ordinary Physical Activity Does
Not Cause Undue Fatigue, Palpitation,
Dyspnea Or Anginal Pain. (Class I)
Patients With Cardiac Disease Resulting
In Slight Limitation Of Physical Activity.
They Are Comfortable At Rest. Ordinary
Physical Activity Results In Fatigue,
Palpitation, Dyspnea Or Anginal Pain.
(Class II)
Patients With Cardiac Disease Resulting
In Marked Limitation Of Physical Activity.
They Are Comfortable At Rest. Less
Than Ordinary Activity Causes Fatigue,
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Palpitation, Dyspnea Or Anginal Pain.
(Class III)
Patients With Cardiac Disease Resulting
In Inability To Carry On Any Physical
Activity Without Discomfort. Symptoms
Of Heart Failure Or The Anginal
Syndrome May Be Present Even At
Rest. If Any Physical Activity Is
Undertaken, Discomfort Increases.
(Class IV)
Hematology And Biochemistry
Date Collected
Result
Abnormal - Clinically Significant
(Abnormal - Clinically significant)
Abnormal - Not Clinically Significant
(Abnormal - Not clinically significant)
Normal (Normal)
Radiological examination
Type of radiological examination
Abdominal Ct-scan (Abdominal CT-scan)
Bilateral Mammogram (Bilateral
mammogram)
Bone Scan (Bone scan (scintigraphy))
Bone X-ray (Bone X-ray)
Ct Scan Of Chest (Chest CT-scan)
Chest X-ray (Chest X-Ray)
Left Mammogram, Only (Left
mammogram, only)
Right Mammogram, Only (Right
mammogram, only)
Date of test
Are there any clinically significant abnormalities
Yes
No
Specify
Type of radiological examination (Other
examinations)
Bone Scan (Bone scan)
Computed Tomography (CT scan)
Endoscopy (Endoscopy)
Lymphangiogram (Lymphangiogram)
Mammography (Mammography)
Magnetic Resonance Imaging (MRI)
Nuclear Scan (Nuclear scan)
Other (Other)
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Positron Emission Tomography (PET
scan)
Pet/ct Scan (PET/CT scan)
Transvaginal Ultrasound (Transvaginal
Ultrasound)
Ultrasound (Ultrasound)
X-ray (X-ray)
Specify
Anatomical site
Abdomen (Abdomen)
Abdomen/abdominal Wall
(Abdomen/abdominal wall)
Bladder (Bladder)
Bone (Bone)
Breast (Breast)
Cervix Uteri (Cervix)
Chest (Chest)
Central Nervous System (CNS)
Colon (Colon)
Colorectal (Colorectal)
Esophagus (Esophagus/Oesophagus)
Head And Neck (Head and Neck)
Heart (Heart)
Kidney (Kidney)
Liver (Liver)
Lung (Lung)
Lymph Node (Lymph Node)
Mouth (Oral Cavity)
Other (Other)
Ovary (Ovary)
Pancreas (Pancreas)
Pelvis (Pelvis)
Peritoneum (Peritoneum)
Pleura (Pleura)
Prostate Gland (Prostate)
Rectum (Rectum)
Skin (Skin)
Small Intestine (Small Intestine)
Spleen (Spleen)
Stomach (Stomach)
Testis (Testicle)
Thyroid Gland (Thyroid)
Translational Research (appendix 5)
Type of tissue
Additional Blood Sample For Ctc
(circulating Tumor Cells) (Additional
blood sample for CTC (circulating tumor
cells))
Additional Blood Sample For Proteomics
(Additional blood sample for Proteomics)
Was sample obtained
Yes
No
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On-Study Form Week 25 Breast Cancer ALTTO BIG
2-06 NCCTG N063D EGF106708 NCT00490139
BIG 2-06 / NCCTG N063D / EGF106708 - Week 25
ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment
Optimisation) Study; BIG 2-06/N063D
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=32A4CF7B-
C387-422A-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11844
On-Study Form Week 25 Breast
Cancer ALTTO BIG 2-06 NCCTG
N063D EGF106708 NCT00490139
Header Module
Centre No.
Subject No.
Patient Status
Physical Examination Date
Not done
Are there any changes since the previous
assessment
Yes
No
Are there any changes since the previous
assessment
Adverse Event (Adverse Event)
Death (Death)
Lost To Follow-up (Lost To Follow-up)
Patient Withdrew From Treatment And
Will Continue With Follow-up (Patient
withdrew from treatment and will
continue with follow-up)
Patient Withdrew Study Consent (Patient
withdrew study consent)
Recurrence Of Disease (Recurrence of
disease)
Second Primary Malignancy Or
Contralateral Breast Cancer (Second
primary malignancy or contralateral
breast cancer)
Significant Cardiac Disease (Significant
cardiac disease)
Date of Last Contact
Body weight
>= 0
kg
1 / 3
ECOG Performance Status
Fully Active, Able To Carry On All Pre-
disease Performance Without
Restriction. (0)
Restricted In Physically Strenuous
Activity But Ambulatory And Able To
Carry Out Work Of A Light Or Sedentary
Nature, E.g., Light Housework, Office
Work. (1)
Ambulatory And Capable Of All Selfcare
But Unable To Carry Out Any Work
Activities. Up And About More Than 50%
Of Waking Hours. (2)
Capable Of Only Limited Selfcare,
Confined To Bed Or Chair More Than
50% Of Waking Hours. (3)
Completely Disabled. Cannot Carry On
Any Selfcare. Totally Confined To Bed Or
Chair. (4)
Dead (5)
Systolic
>= 0
mmHg
Diastolic
>= 0
mmHg
Cardiac Monitoring
Date of LVEF
Left Ventricular Ejection Fraction
%
Method of Evaluation
Echocardiogram (Echocardiogram)
Muga Scan (MUGA scan)
LVEF Status
Normal (1)
Abnormal - Not Clinically Significant (2)
Abnormal - Clinically Significant (3)
Symptomatic congestive heart failure
Yes
No
New York Heart Association Classification
Patients With Cardiac Disease But
Without Resulting Limitation Of Physical
Activity. Ordinary Physical Activity Does
Not Cause Undue Fatigue, Palpitation,
Dyspnea Or Anginal Pain. (Class I)
Patients With Cardiac Disease Resulting
In Slight Limitation Of Physical Activity.
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They Are Comfortable At Rest. Ordinary
Physical Activity Results In Fatigue,
Palpitation, Dyspnea Or Anginal Pain.
(Class II)
Patients With Cardiac Disease Resulting
In Marked Limitation Of Physical Activity.
They Are Comfortable At Rest. Less
Than Ordinary Activity Causes Fatigue,
Palpitation, Dyspnea Or Anginal Pain.
(Class III)
Patients With Cardiac Disease Resulting
In Inability To Carry On Any Physical
Activity Without Discomfort. Symptoms
Of Heart Failure Or The Anginal
Syndrome May Be Present Even At
Rest. If Any Physical Activity Is
Undertaken, Discomfort Increases.
(Class IV)
Hematology And Biochemistry
Date of blood specimen collection
Result
Abnormal - Clinically Significant
(Abnormal - Clinically significant)
Abnormal - Not Clinically Significant
(Abnormal - Not clinically significant)
Normal (Normal)
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On-Study Form Week 13 Breast Cancer ALTTO BIG
2-06 NCCTG N063D EGF106708 NCT00490139
BIG 2-06 / NCCTG N063D / EGF106708 - Week 13
ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment
Optimisation) Study; BIG 2-06/N063D
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=32A4BA27-
3C91-3F3A-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11845
On-Study Form Week 13 Breast
Cancer ALTTO BIG 2-06 NCCTG
N063D EGF106708 NCT00490139
Header Module
Centre No.
Subject No.
Patient Status
Physical Examination Date
Not done
Are there any changes since the previous
assessment
Yes
No
Are there any changes since the previous
assessment
Adverse Event (Adverse Event)
Death (Death)
Lost To Follow-up (Lost To Follow-up)
Patient Withdrew From Treatment And
Will Continue With Follow-up (Patient
withdrew from treatment and will
continue with follow-up)
Patient Withdrew Study Consent (Patient
withdrew study consent)
Recurrence Of Disease (Recurrence of
disease)
Second Primary Malignancy Or
Contralateral Breast Cancer (Second
primary malignancy or contralateral
breast cancer)
Significant Cardiac Disease (Significant
cardiac disease)
Last Contact Date
Body weight
>= 0
kg
1 / 3
ECOG Performance Status
Fully Active, Able To Carry On All Pre-
disease Performance Without
Restriction. (0)
Restricted In Physically Strenuous
Activity But Ambulatory And Able To
Carry Out Work Of A Light Or Sedentary
Nature, E.g., Light Housework, Office
Work. (1)
Ambulatory And Capable Of All Selfcare
But Unable To Carry Out Any Work
Activities. Up And About More Than 50%
Of Waking Hours. (2)
Capable Of Only Limited Selfcare,
Confined To Bed Or Chair More Than
50% Of Waking Hours. (3)
Completely Disabled. Cannot Carry On
Any Selfcare. Totally Confined To Bed Or
Chair. (4)
Dead (5)
Systolic
>= 0
mmHg
Diastolic
>= 0
mmHg
Cardiac Monitoring
Date of LVEF
Left Ventricular Ejection Fraction
%
Method of Evaluation
Echocardiogram (Echocardiogram)
Muga Scan (MUGA scan)
LVEF Status
Normal (1)
Abnormal - Not Clinically Significant (2)
Abnormal - Clinically Significant (3)
Symptomatic congestive heart failure
Yes
No
New York Heart Association Classification
Patients With Cardiac Disease But
Without Resulting Limitation Of Physical
Activity. Ordinary Physical Activity Does
Not Cause Undue Fatigue, Palpitation,
Dyspnea Or Anginal Pain. (Class I)
Patients With Cardiac Disease Resulting
In Slight Limitation Of Physical Activity.
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They Are Comfortable At Rest. Ordinary
Physical Activity Results In Fatigue,
Palpitation, Dyspnea Or Anginal Pain.
(Class II)
Patients With Cardiac Disease Resulting
In Marked Limitation Of Physical Activity.
They Are Comfortable At Rest. Less
Than Ordinary Activity Causes Fatigue,
Palpitation, Dyspnea Or Anginal Pain.
(Class III)
Patients With Cardiac Disease Resulting
In Inability To Carry On Any Physical
Activity Without Discomfort. Symptoms
Of Heart Failure Or The Anginal
Syndrome May Be Present Even At
Rest. If Any Physical Activity Is
Undertaken, Discomfort Increases.
(Class IV)
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On-Study Form Months 15, 21, 30, 42, and 54 Breast Cancer
ALTTO BIG 2-06 NCCTG N063D EGF106708 NCT00490139
BIG 2-06 / NCCTG N063D / EGF106708 - Months 15, 21,
30, 42, and 54
ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment
Optimisation) Study; BIG 2-06/N063D
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=31CACBF0-
6868-37A9-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11846
On-Study Form Months 15, 21, 30,
42, and 54 Breast Cancer ALTTO
BIG 2-06 NCCTG N063D
EGF106708 NCT00490139
Header Module
Centre No.
Subject No.
Patient Status
Physical Examination Date
Not done
Are there any changes since the previous
assessment
Yes
No
Are there any changes since the previous
assessment
Adverse Event (Adverse Event)
Death (Death)
Lost To Follow-up (Lost To Follow-up)
Patient Withdrew Study Consent (Patient
withdrew study consent)
Recurrence Of Disease (Recurrence of
disease)
Second Primary Malignancy Or
Contralateral Breast Cancer (Second
primary malignancy or contralateral
breast cancer)
Significant Cardiac Disease (Significant
cardiac disease)
Date of Last Contact
Body weight
>= 0
kg
ECOG Performance Status
1 / 2
Fully Active, Able To Carry On All Pre-
disease Performance Without
Restriction. (0)
Restricted In Physically Strenuous
Activity But Ambulatory And Able To
Carry Out Work Of A Light Or Sedentary
Nature, E.g., Light Housework, Office
Work. (1)
Ambulatory And Capable Of All Selfcare
But Unable To Carry Out Any Work
Activities. Up And About More Than 50%
Of Waking Hours. (2)
Capable Of Only Limited Selfcare,
Confined To Bed Or Chair More Than
50% Of Waking Hours. (3)
Completely Disabled. Cannot Carry On
Any Selfcare. Totally Confined To Bed Or
Chair. (4)
Dead (5)
Systolic
>= 0
mmHg
Diastolic
>= 0
mmHg
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On-Study Form Month 24 Breast Cancer ALTTO BIG
2-06 NCCTG N063D EGF106708 NCT00490139
ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment
Optimisation) Study; BIG 2-06/N063D
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=32A2E66F-
28A2-0578-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11847
On-Study Form Month 24 Breast
Cancer ALTTO BIG 2-06 NCCTG
N063D EGF106708 NCT00490139
Header Module
Centre No.
Subject No.
Patient Status
Physical Examination Date
Not done
Are there any changes since the previous
assessment
Yes
No
Are there any changes since the previous
assessment
Adverse Event (Adverse Event)
Death (Death)
Lost To Follow-up (Lost To Follow-up)
Patient Withdrew Study Consent (Patient
withdrew study consent)
Recurrence Of Disease (Recurrence of
disease)
Second Primary Malignancy Or
Contralateral Breast Cancer (Second
primary malignancy or contralateral
breast cancer)
Significant Cardiac Disease (Significant
cardiac disease)
Last Contact Date
Body weight
>= 0
kg
ECOG Performance Status
Fully Active, Able To Carry On All Pre-
disease Performance Without
1 / 5
Restriction. (0)
Restricted In Physically Strenuous
Activity But Ambulatory And Able To
Carry Out Work Of A Light Or Sedentary
Nature, E.g., Light Housework, Office
Work. (1)
Ambulatory And Capable Of All Selfcare
But Unable To Carry Out Any Work
Activities. Up And About More Than 50%
Of Waking Hours. (2)
Capable Of Only Limited Selfcare,
Confined To Bed Or Chair More Than
50% Of Waking Hours. (3)
Completely Disabled. Cannot Carry On
Any Selfcare. Totally Confined To Bed Or
Chair. (4)
Dead (5)
Systolic
>= 0
mmHg
Diastolic
>= 0
mmHg
Cardiac Monitoring
Date of LVEF
Left Ventricular Ejection Fraction
%
Method of Evaluation
Echocardiogram (Echocardiogram)
Muga Scan (MUGA scan)
LVEF Status
Normal (1)
Abnormal - Not Clinically Significant (2)
Abnormal - Clinically Significant (3)
Symptomatic congestive heart failure
Yes
No
NYHA classification
Patients With Cardiac Disease But
Without Resulting Limitation Of Physical
Activity. Ordinary Physical Activity Does
Not Cause Undue Fatigue, Palpitation,
Dyspnea Or Anginal Pain. (Class I)
Patients With Cardiac Disease Resulting
In Slight Limitation Of Physical Activity.
They Are Comfortable At Rest. Ordinary
Physical Activity Results In Fatigue,
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Palpitation, Dyspnea Or Anginal Pain.
(Class II)
Patients With Cardiac Disease Resulting
In Marked Limitation Of Physical Activity.
They Are Comfortable At Rest. Less
Than Ordinary Activity Causes Fatigue,
Palpitation, Dyspnea Or Anginal Pain.
(Class III)
Patients With Cardiac Disease Resulting
In Inability To Carry On Any Physical
Activity Without Discomfort. Symptoms
Of Heart Failure Or The Anginal
Syndrome May Be Present Even At
Rest. If Any Physical Activity Is
Undertaken, Discomfort Increases.
(Class IV)
Hematology And Biochemistry
Date Collected
Result
Abnormal - Clinically Significant
(Abnormal - Clinically significant)
Abnormal - Not Clinically Significant
(Abnormal - Not clinically significant)
Normal (Normal)
Radiological examination
Type of radiological examination
Abdominal Ct-scan (Abdominal CT-scan)
Bilateral Mammogram (Bilateral
mammogram)
Bone Scan (Bone scan (scintigraphy))
Bone X-ray (Bone X-ray)
Ct Scan Of Chest (Chest CT-scan)
Chest X-ray (Chest X-Ray)
Left Mammogram, Only (Left
mammogram, only)
Right Mammogram, Only (Right
mammogram, only)
Not done
Date of test
Date of test
Are there any clinically significant abnormalities
Yes
No
Are there any clinically significant abnormalities
Yes
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No
Specify
Specify
Type of radiological examination (Other
examinations)
Bone Scan (Bone scan)
Computed Tomography (CT scan)
Endoscopy (Endoscopy)
Lymphangiogram (Lymphangiogram)
Mammography (Mammography)
Magnetic Resonance Imaging (MRI)
Nuclear Scan (Nuclear scan)
Other (Other)
Positron Emission Tomography (PET
scan)
Pet/ct Scan (PET/CT scan)
Transvaginal Ultrasound (Transvaginal
Ultrasound)
Ultrasound (Ultrasound)
X-ray (X-ray)
Specify
Anatomical site
Abdomen (Abdomen)
Abdomen/abdominal Wall
(Abdomen/abdominal wall)
Bladder (Bladder)
Bone (Bone)
Breast (Breast)
Cervix Uteri (Cervix)
Chest (Chest)
Central Nervous System (CNS)
Colon (Colon)
Colorectal (Colorectal)
Esophagus (Esophagus/Oesophagus)
Head And Neck (Head and Neck)
Heart (Heart)
Kidney (Kidney)
Liver (Liver)
Lung (Lung)
Lymph Node (Lymph Node)
Mouth (Oral Cavity)
Other (Other)
Ovary (Ovary)
Pancreas (Pancreas)
Pelvis (Pelvis)
Peritoneum (Peritoneum)
Pleura (Pleura)
Prostate Gland (Prostate)
Rectum (Rectum)
Skin (Skin)
Small Intestine (Small Intestine)
Spleen (Spleen)
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Stomach (Stomach)
Testis (Testicle)
Thyroid Gland (Thyroid)
Translational Research (appendix 5)
Type of tissue
Additional Blood Sample For Ctc
(circulating Tumor Cells) (Additional
blood sample for CTC (circulating tumor
cells))
Additional Blood Sample For Proteomics
(Additional blood sample for Proteomics)
Date Collected
Was sample obtained
Yes
No
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On-Study Form Week 52 Breast Cancer ALTTO BIG
2-06 NCCTG N063D EGF106708 NCT00490139
ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment
Optimisation) Study; BIG 2-06/N063D
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=32A2C760-
5699-01DF-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11848
On-Study Form Week 52 Breast
Cancer ALTTO BIG 2-06 NCCTG
N063D EGF106708 NCT00490139
Header Module
Centre No.
Subject No.
Patient Status
Physical Examination Date
Not done
Are there any changes since the previous
assessment
Yes
No
Are there any changes since the previous
assessment
Adverse Event (Adverse Event)
Death (Death)
Lost To Follow-up (Lost To Follow-up)
Patient Withdrew Study Consent (Patient
withdrew study consent)
Recurrence Of Disease (Recurrence of
disease)
Second Primary Malignancy Or
Contralateral Breast Cancer (Second
primary malignancy or contralateral
breast cancer)
Significant Cardiac Disease (Significant
cardiac disease)
Last Contact Date
Body weight
>= 0
kg
ECOG Performance Status
Fully Active, Able To Carry On All Pre-
disease Performance Without
Restriction. (0)
1 / 5
Restricted In Physically Strenuous
Activity But Ambulatory And Able To
Carry Out Work Of A Light Or Sedentary
Nature, E.g., Light Housework, Office
Work. (1)
Ambulatory And Capable Of All Selfcare
But Unable To Carry Out Any Work
Activities. Up And About More Than 50%
Of Waking Hours. (2)
Capable Of Only Limited Selfcare,
Confined To Bed Or Chair More Than
50% Of Waking Hours. (3)
Completely Disabled. Cannot Carry On
Any Selfcare. Totally Confined To Bed Or
Chair. (4)
Dead (5)
Systolic
>= 0
mmHg
Diastolic
>= 0
mmHg
Cardiac Monitoring
Date Left Ventricular Ejection Fraction
Left Ventricular Ejection Fraction
%
Method of Evaluation
Echocardiogram (Echocardiogram)
Muga Scan (MUGA scan)
LVEF Status
Normal (1)
Abnormal - Not Clinically Significant (2)
Abnormal - Clinically Significant (3)
Symptomatic congestive heart failure
Yes
No
New York Heart Association Classification
Patients With Cardiac Disease But
Without Resulting Limitation Of Physical
Activity. Ordinary Physical Activity Does
Not Cause Undue Fatigue, Palpitation,
Dyspnea Or Anginal Pain. (Class I)
Patients With Cardiac Disease Resulting
In Slight Limitation Of Physical Activity.
They Are Comfortable At Rest. Ordinary
Physical Activity Results In Fatigue,
Palpitation, Dyspnea Or Anginal Pain.
(Class II)
Patients With Cardiac Disease Resulting
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In Marked Limitation Of Physical Activity.
They Are Comfortable At Rest. Less
Than Ordinary Activity Causes Fatigue,
Palpitation, Dyspnea Or Anginal Pain.
(Class III)
Patients With Cardiac Disease Resulting
In Inability To Carry On Any Physical
Activity Without Discomfort. Symptoms
Of Heart Failure Or The Anginal
Syndrome May Be Present Even At
Rest. If Any Physical Activity Is
Undertaken, Discomfort Increases.
(Class IV)
Hematology And Biochemistry
Date Collected
Result
Abnormal - Clinically Significant
(Abnormal - Clinically significant)
Abnormal - Not Clinically Significant
(Abnormal - Not clinically significant)
Normal (Normal)
Radiological examination
Type of radiological examination
Abdominal CT-scan (Abdominal CT-
scan)
Bilateral Mammogram (Bilateral
mammogram)
Bone Scan (Bone scan (scintigraphy))
Bone X-ray (Bone X-ray)
Ct Scan Of Chest (Chest CT-scan)
Chest X-ray (Chest X-Ray)
Left Mammogram, Only (Left
mammogram, only)
Right Mammogram, Only (Right
mammogram, only)
Imaging Date
Are there any clinically significant abnormalities
Yes
No
Specify
Type of radiological examination (Other
examinations)
Bone Scan (Bone scan)
Computed Tomography (CT scan)
Endoscopy (Endoscopy)
Lymphangiogram (Lymphangiogram)
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Mammography (Mammography)
Magnetic Resonance Imaging (MRI)
Nuclear Scan (Nuclear scan)
Other (Other)
Positron Emission Tomography (PET
scan)
Pet/CT Scan (PET/CT scan)
Transvaginal Ultrasound (Transvaginal
Ultrasound)
Ultrasound (Ultrasound)
X-ray (X-ray)
Specify
Anatomical site
Abdomen (Abdomen)
Abdomen/abdominal Wall
(Abdomen/abdominal wall)
Bladder (Bladder)
Bone (Bone)
Breast (Breast)
Cervix Uteri (Cervix)
Chest (Chest)
Central Nervous System (CNS)
Colon (Colon)
Colorectal (Colorectal)
Esophagus (Esophagus/Oesophagus)
Head And Neck (Head and Neck)
Heart (Heart)
Kidney (Kidney)
Liver (Liver)
Lung (Lung)
Lymph Node (Lymph Node)
Mouth (Oral Cavity)
Other (Other)
Ovary (Ovary)
Pancreas (Pancreas)
Pelvis (Pelvis)
Peritoneum (Peritoneum)
Pleura (Pleura)
Prostate Gland (Prostate)
Rectum (Rectum)
Skin (Skin)
Small Intestine (Small Intestine)
Spleen (Spleen)
Stomach (Stomach)
Testis (Testicle)
Thyroid Gland (Thyroid)
Translational Research
Type of tissue
Additional Blood Sample For CTC
(circulating Tumor Cells) (1)
Additional Blood Sample For Proteomics
(2)
Was sample obtained
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Yes
No
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On-Study Form Week 37 Breast Cancer ALTTO BIG
2-06 NCCTG N063D EGF106708 NCT00490139
ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment
Optimisation) Study; BIG 2-06/N063D
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=32A4A72C-
3292-3DF0-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11849
On-Study Form Week 37 Breast
Cancer ALTTO BIG 2-06 NCCTG
N063D EGF106708 NCT00490139
Header Module
Centre No.
Subject No.
Patient Status
Physical Examination
Not done
Are there any changes since the previous
assessment
Yes
No
Are there any changes since the previous
assessment
Adverse Event (Adverse Event)
Death (Death)
Lost To Follow-up (Lost To Follow-up)
Patient Withdrew From Treatment And
Will Continue With Follow-up (Patient
withdrew from treatment and will
continue with follow-up)
Patient Withdrew Study Consent (Patient
withdrew study consent)
Recurrence Of Disease (Recurrence of
disease)
Second Primary Malignancy Or
Contralateral Breast Cancer (Second
primary malignancy or contralateral
breast cancer)
Significant Cardiac Disease (Significant
cardiac disease)
Last Contact Date
Body weight
>= 0
kg
1 / 3
ECOG Performance Status
Fully Active, Able To Carry On All Pre-
disease Performance Without
Restriction. (0)
Restricted In Physically Strenuous
Activity But Ambulatory And Able To
Carry Out Work Of A Light Or Sedentary
Nature, E.g., Light Housework, Office
Work. (1)
Ambulatory And Capable Of All Selfcare
But Unable To Carry Out Any Work
Activities. Up And About More Than 50%
Of Waking Hours. (2)
Capable Of Only Limited Selfcare,
Confined To Bed Or Chair More Than
50% Of Waking Hours. (3)
Completely Disabled. Cannot Carry On
Any Selfcare. Totally Confined To Bed Or
Chair. (4)
Dead (5)
Systolic
>= 0
mmHg
Diastolic
>= 0
mmHg
Menopausal Status
Menopausal Status
Above Categories Not Applicable And
Age <50 (Above categories not
applicable AND Age < 50)
50=Above Categories Not Applicable
And Age >= 50 (Above categories not
applicable AND Age >)
Post (prior Bilateral Ovariectomy Or >12
Mo Since Lmp With No Prior
Hysterectomy And Not Currently
Receiving Therapy With Lh-rh Analogs
[e.g., Zoladex]) (Post (prior bilateral
ovariectomy OR >12 mo since LMP with
no prior hysterectomy AND not currently
receiving therapy with LH-RH analogs
(e.g., Zoladex)))
Post (prior Bilateral Ovariectomy Or >12
Mo Since Lmp With No Prior
Hysterectomy) (Post (prior bilateral
ovariectomy OR >12 mo since LMP with
no prior hysterectomy))
Date of last menstrual period
Cardiac Monitoring
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Date Left Ventricular Ejection Fraction
Left Ventricular Ejection Fraction
%
Method of Evaluation
Echocardiogram (Echocardiogram)
Muga Scan (MUGA scan)
LVEF Status
Normal (1)
Abnormal - Not Clinically Significant (2)
Abnormal - Clinically Significant (3)
Symptomatic CHF
Yes
No
New York Heart Association Classification
Patients With Cardiac Disease But
Without Resulting Limitation Of Physical
Activity. Ordinary Physical Activity Does
Not Cause Undue Fatigue, Palpitation,
Dyspnea Or Anginal Pain. (Class I)
Patients With Cardiac Disease Resulting
In Slight Limitation Of Physical Activity.
They Are Comfortable At Rest. Ordinary
Physical Activity Results In Fatigue,
Palpitation, Dyspnea Or Anginal Pain.
(Class II)
Patients With Cardiac Disease Resulting
In Marked Limitation Of Physical Activity.
They Are Comfortable At Rest. Less
Than Ordinary Activity Causes Fatigue,
Palpitation, Dyspnea Or Anginal Pain.
(Class III)
Patients With Cardiac Disease Resulting
In Inability To Carry On Any Physical
Activity Without Discomfort. Symptoms
Of Heart Failure Or The Anginal
Syndrome May Be Present Even At
Rest. If Any Physical Activity Is
Undertaken, Discomfort Increases.
(Class IV)
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Eligibility Chemotherapy-induced
Symptomatic Anemia NCT02140736
Epoetin Alfa Biosimilar in the Management of
Chemotherapy-Induced Symptomatic Anemia in
Haematology and Oncology; ODM derived from:
https://clinicaltrials.gov/show/NCT02140736
All rights reserved. Please visit https://medical-data-
models.org/forms/11850
Eligibility Chemotherapy-induced
Symptomatic Anemia NCT02140736
Inclusion Criteria
patients of more than 18 years of age*
Yes
No
patients presenting with anemia following
chemotherapy*
Yes
No
patients suffer from solid tumours, malignant
hemopathies, lymphomas or myelomas and
presenting with anemia following chemotherapy*
Yes
No
- the patients may be included regardless of their
chemotherapy cycle (from the first cycle until the
last cycle)*
Yes
No
patients eligible for epoetin alfa biosimilar
treatment*
Yes
No
Exclusion Criteria
patients are not receiving chemotherapy*
Yes
No
patients already included in an epoetin zeta trial*
Yes
No
patients presenting with a contraindication to
epoetin zeta*
Yes
No
patients presenting with hypersensitivity to the
active principle or any of the excipients*
Yes
No
patient with erythroblastopenia or acquired pure
red cell aplasia (aprca)*
Yes
No
1 / 2
patient with uncontrollable arterial hypertension*
Yes
No
patients who cannot receive adequate
prophylaxis by antithrombotic agents*
Yes
No
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Eligibility Chemotherapy-induced Symptomatic Anemia NCT02140736
Quality Assurance Coronary Angiography and
Percuteanous Intervention (PCI) - Basic (AQUA)
Documentation form for quality assurance in German
Health Care by the Institute for Applied Quality
Improvement and Research in Health Care (Aqua),
https://www.aqua-institut.de/en/home. Internal Aqua form
version: 21-3-B Specification 2015 V02
All rights reserved. Please visit https://medical-data-
models.org/forms/11851
Quality assurance Coronary
Angiography and Percuteanous
Intervention (PCI) - Basic (AQUA)
Basic documentation
Healthcare Facility Identifier *
Zip Code of Discharge*
Facility's Section Identifier
Hospital admission date (DD.MM.YYYY)*
Medical specialty*
internal medicine (0100)
internal medicine: geriatrics (0102)
internal medicine: cardiology (0103)
internal medicine: nephrology (0104)
internal medicine: hematology and
internal oncology  (0105)
internal medicine: endocrinology (0106)
internal medicine: gastroenterology
(0107)
internal medicine: pneumonology (0108)
internal medicine: rheumatology (0109)
internal medicine: pulmonology (0114)
internal medicine: tumor research (0150)
internal medicine: coloproctology (0151)
internal medicine: infectiology (0152)
internal medicine: diabetes (0153)
internal medicine: naturopathy (0154)
internal medicine: stroke unit (0156)
internal medicine (0190)
geriatry (0200)
geriatry: gynecology  (0224)
geriatry: day unit (for semi-residential
care)   (0260)
geriaty: night unit (for semi-residential
care) (0261)
geriatry (0290)
cardiology (0300)
nephrology (0400)
nephrology: pediatrics (0410)
nephrology: intensive care (0436)
nephrology (0490)
hematology and internal oncology
(0500)
hematology and internal oncology:
pediatrics (0510)
hematology and internal oncology:
gynacology (0524)
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hematology and internal oncology:
radiation therapy (0533)
hematology and internal oncology
(0590)
endocrinology (0600)
endicrinology: gastroenterology (0607)
endocrinology: pediatrics (0610)
endocrinology (0690)
gastroenterology (0700)
gastroenterology: endocrinology (0706)
gastroenterology: pediatrics (0710)
gastroenterology (0790)
pneumology (0800)
rheumatology (0900)
rheumatology: pediatrics (0910)
rheumatology (0990)
pediatrics (1000)
pediatrics: nephrology (1004)
pediatrics: hematology and internal
oncology  (1005)
pediatrics: endocrinology (1006)
pediatrics: gastroenterology (1007)
pediatrics: rheumatology (1009)
pediatrics: pediatric cardiology (1011)
pediatrics: nephrology (1012)
pediatrics: pulmonology (1014)
pediatrics: pediatric neurology (1028)
pediatrics: perinatal medicine (1050)
continuing care for children (1051)
pediatrics (1090)
pediatric cardiology (1100)
pediatric cardiology: intensive care
(1136)
pediatric cardiology (1190)
neonatology (1200)
pediatric surgery (1300)
pulmonology (1400)
pulmonology: pediatrics (1410)
pulmonology (1490)
general surgery (1500)
general surgery: pediatric surgery (1513)
general surgery: trauma surgery (1516)
general surgery: vascular surgery (1518)
general surgery: plastic surgery (1519)
general surgery: thoracic surgery (1520)
general surgery: orthopedics (1523)
general surgery: intensive care (1536)
general surgery: abdominal- and
vascular surgery (1550)
Allgemeine Chirurgie: hand surgery
(1551)
general surgery (1590)
trauma surgery (1600)
neurosurgery (1700)
vascular surgery (1800)
plastic surgery (1900)
thoracic surgery (2000)
thoracic surgery: cardiac surgery (2021)
thoracic surgery: intensive care (2036)
thoracic surgery: cardiac surgery
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intensive care (2050)
thoracic surgery (2090)
cardiac surgery (2100)
cardiac surgery: vascular surgery (2118)
cardiac surgery: thoracic surgery (2120)
cardiac surgery: intensive care (2136)
cardiac surgery: thoracic surgery and
intensive care (2150)
cardiac surgery (2190)
urology (2200)
orthopedics (2300)
orthopedics: rheumatology (2309)
orthopedics: surgery (2315)
orthopedics and trauma surgery (2316)
orthopedics (2390)
gynecology and obstetrics (2400)
gynecology: geriatry (2402)
gynecology: hematology and internal
oncology  (2405)
gynecology: endocrinology (2406)
gynecology (2425)
gynecology and obstetrics (2490)
obstetrics (2500)
otolaryngology (2600)
ophthalmology (2700)
neurology: (2800)
neurology: pediatrics (2810)
neurology: stroke units (2856)
neurology (2890)
general psychiatry: (2900)
general psychiatry: neurology (2928)
general psychiatry: child and adolescent
psychiatry (2930)
general psychiatry: psychosomatics and
psychotherapy (2931)
general psychiatry: addiction treatment
(2950)
general psychiatry: geropsychiatry
(2951)
general psychiatry: forensic treatment
(2952)
general psychiatry: addiction treatment
(day unit) (2953)
general psychiatry: addiction treatment
(night unit) (2954)
general psychiatry: geropsychiatry (day
unit) (2955)
general psychiatry: geropsychiatry (night
unit) (2956)
general psychiatry: day unit (for semi-
residential care) (2960)
general psychiatry: night unit (for semi-
residential care) (2961)
general psychiatry (2990)
child and adolescent psychiatry (3000)
child and adolescent psychiatry: day unit
(for semi-residential care) (3060)
child and adolescent psychiatry: night
unit (for semi-residential care) (3061)
child and adolescent psychiatry (3090)
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psychosomatic/psychotherapy (3100)
psychosomatic/psychotherapy: child and
adolescent psychiatry (3110)
psychosomatic/psychotherapy: day unit
(for semi-residential care) (3160)
psychosomatic/psychotherapy: night unit
(for semi-residential care) (3161)
psychosomatic/psychotherapy (3190)
nuclear medicine (3200)
nuclear medicine: radiation therapy
(3233)
nuclear medicine (3290)
radiation therapy (3300)
radiation therapy: hematology and
internal oncology  (3305)
radiation therapy: radiology (3350)
radiation therapy (3390)
dermatology (3400)
dermatology: day unit (for semi-
residential care) (3460)
dermatology (3490)
dentistry, orthodontics, maxillofacial
surgery (3500)
intensive-care medicine (3600)
intensive-care medicine: internal
medicine (3601)
intensive-care medicine: cardiology
(3603)
intensive-care medicine: pediatrics
(3610)
intensive-care medicine: neurosurgery
(3617)
intensive-care medicine: surgery (3618)
intensive-care medicine: cardiac surgery
(3621)
intensive-care medicine: urology (3622)
intensive-care medicine: gynecology and
obstetrics (3624)
intensive-care medicine: otolaryngology
(3626)
intensive-care medicine: neurology
(3628)
operative intensive-care medicine:
surgery (3650)
intensive-care medicine: thorax-heart
surgery (3651)
intensive-care medicine: heart-thorax
surgery (3652)
intensive-care medicine (3690)
other medical specialty (3700)
angiology (3750)
radiology (3751)
palliative care (3752)
pain therapy (3753)
section for alternative health practice
(3754)
spinal surgery (3755)
addiction medicine (3756)
visceral surgery (3757)
other medical specialty (3790)
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Healthcare facility is the provider of this
procedure (The facility for documenting the
procedure and the facility for providing the
procedure are not identical)*
Yes
No
Patient identification number*
Date of Birth (DD.MM.YYYY)*
Gender*
male (1)
female (2)
Patient
diagnostic coronary angiography before this stay*
no (0)
yes (1)
unknown (9)
Catheteral intervention before this stay*
no (0)
yes (1)
unknown (9)
Patient post coronary bypass operation*
no (0)
yes (1)
unknown (9)
Left ventricular ejection fraction under 40%*
no (0)
yes (1)
questionable (2)
unknown (9)
Diabetes mellitus*
no (0)
yes, non-insulin-dependent (1)
yes, insulin-dependent (2)
unknown (9)
Kidney failure*
no (0)
yes, dependence on dialysis (1)
yes, non-dependent on dialysis (2)
unknown (9)
Current cardiac medical history (before
first procedure)
acute coronary syndrome (STEMI or NSTEMI,
but with positive lab values or instable angina
pectoris (rest angina))*
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Yes
No
Stable angina - according to CCS
nein (0)
CCS I (angina only during strenuous
physical activity) (1)
CCS II (angina during ordinary activity )
(2)
CCS III (angina during less-than-ordinary
activity) (3)
objective (apparatus-based) signs of ischemia   -
exercise ecg or other non-invasive tests
no (0)
yes (1)
questionable (2)
unknown (9)
Clinical course
postprocedural myocardial infarction*
no (0)
yes, until 36 hours after the previous
procedure (1)
yes, more than 36 hours after the
previous procedure (until discharge from
the hospital) (2)
other  postprocedural events - e.g. Sepsis*
no (0)
yes, until 36 hours after the previous
procedure (1)
yes, more than 36 hours after the
previous procedure (until discharge from
the hospital) (2)
Pseudoaneurysm with new compression (at site
of punctutre)*
no (0)
yes, until 36 hours after the previous
procedure (1)
yes, more than 36 hours after the
previous procedure (until discharge from
the hospital) (2)
Vascular thrombosis (close to punction site)*
no (0)
yes, until 36 hours after the previous
procedure (1)
yes, more than 36 hours after the
previous procedure (until discharge from
the hospital) (2)
Therapy of hemarrage at puncture site
injection of thrombin (1)
transfusion (2)
surgical intervention at the puncture site
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(3)
Severe hemorrhage at puncture site*
no (0)
yes, until 36 hours after the previous
procedure (1)
yes, more than 36 hours after the
previous procedure (until discharge from
the hospital) (2)
postprocedural transferral or admission to
emergency CABG surgery*
no (0)
yes, until 36 hours after the previous
procedure (1)
yes, more than 36 hours after the
previous procedure (until discharge from
the hospital) (2)
postprocedural Emergency-PCI at the same
vessel*
no (0)
yes, until 36 hours after the previous
procedure (1)
yes, more than 36 hours after the
previous procedure (until discharge from
the hospital) (2)
postprocedural TIA/Stroke*
no (0)
yes, until 36 hours after the previous
procedure (1)
yes, more than 36 hours after the
previous procedure (until discharge from
the hospital) (2)
Death - every Deathcase independent from
cause*
no (0)
yes, until 36 hours after the previous
procedure (1)
yes, more than 36 hours after the
previous procedure (until discharge from
the hospital) (2)
Discharge
Did the patient stay at heart surgery or has
he/she been transferred there for elective
purposes ?
Yes
No
Hostpital discharge date  (DD.MM.YYYY)*
Reason for Discharge*
treatment finished as planned (1)
transferral to nursing facility (10)
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discharge to hospice (11)
external transferral to psychiatric
treatment (13)
treatment finished because of other
reasons, postdischarge treatment is
planned (14)
treatment aborted against medical
advice, postdischarge treatment is
planned (15)
internal transferral with change of DRG
payment Areas (17)
treatment finished as planned,
postdischarge treatment is planned (2)
case termination (internal transferral)
with change between full- and partial
stationary care (22)
discharge at the end of the year with
admission in previous year  (25)
treatment finished because of other
reasons (3)
treatment aborted against medical
advice (4)
change of jurisdiction of insurer or other
payer (5)
transferral to another hospital (6)
death (7)
transferral to another hospital within
cooperative and governmental policies
(8)
transferral to rehabilitation facility (9)
Discharge diagnoses - ICD codes*
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Test task
Test task
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models.org/forms/11898
Patient admission form
Personal information
Patient First Name*
Patient Last Name*
Patient title*
Patient date of birth*
DD.MM.YYYY
Patient gender*
male (1)
female (2)
Street Address*
City*
Patient postal code*
Telephone
Mobile phone*
Country*
Ethnicity
Caucasian (1)
Filipino (10)
Roma (11)
Other (12)
Not Known (13)
South Asian (2)
North African (3)
Sub-Saharan African (4)
Afro-Carribean (5)
Turk (6)
Kurd (7)
Latin American (8)
Chinese (9)
Health Insurance Number*
Primary Care Physician's name
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Primary Care Physician's Address
Contact person
Length of body*
cm
Body Weight*
kg
Body Mass Index*
kg/m2
Age*
>= 0
<= 120
years
Admission information
Date and time of admission*
Emergency admission?*
Yes
No
Complaints
Chief complaints
Chief complaint appearance time
Chief complaint duration
>= 1
hours, days
Other health complains
Chest symptom/complaint
Chest Pain
Yes
No
Chest pain appearance time
Duration of chest pain
hours
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Evaluate chest pain
Coughing
Yes
No
Chronic cough
Yes
No
Productive cough
Yes
No
Sputum color
clear sputum (1)
green sputum (2)
yellow sputum (3)
sputum with blood (4)
Dyspnea
Yes
No
Dyspnea type
Inspiratory dyspnea (1)
Expiratory dyspnea (2)
Nocturnal dyspnea (3)
Palpitations
Yes
No
Duration of palpitations
>= 1
hours, days
Abdominal symptoms
Abdominal Pain
acute (1)
chronic (2)
not present (3)
Site of abdominal pain
Right hypochondriac region (1)
Epigastric region (2)
Left hypochondriac region (3)
Right lumbar region (4)
Umbilical region (5)
Left lumbar region (6)
Right iliac region (7)
Hypogastric region (8)
Left iliac region (9)
Abdominal pain intensity
not present (0)
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1 (1)
most severe symptoms (10)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
7 (7)
8 (8)
9 (9)
Diarrhea
Yes
No
Constipation
Yes
No
Diarrhea duration
>= 1
days
Genitourinary system complaints
Yes
No
Dysuria
Chronic	 (1)
Intermittent (2)
Nocturia
Yes
No
Hematuria
Musculoskeletal System complaints
Arthralgia
Not present (1)
1 joint involved (2)
polyarthralgia (3)
Localized joint pain
Joint swelling
Myalgia
Not present (1)
Muscle pain chronic (2)
Generalized acute muscle pain  (3)
Localized muscle pain (4)
Neurologic Symptoms
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Hearing problem
Not present (1)
Congenital hearing disorder (2)
Hearing Loss, Sudden (3)
Hearing Loss, Bilateral (4)
Hearing Loss, Central (5)
Conductive hearing loss (6)
Noise-induced hearing loss (7)
Visual Impairment
Not present (1)
Binocular vision disorder (2)
Color vision defect (3)
Low Vision (4)
Visual Suppression (5)
Low vision associated with AIDS (6)
Weak vision (7)
Blurred vision (8)
Sleep disorders
Yes
No
Memory Disorders
Yes
No
Vertigo
Yes
No
Emesis*
Yes
No
Nausea*
Yes
No
Heartburn*
Yes
No
Headache*
Yes
No
Headache grade
None (Grade 0) (1)
Mild pain not interfering with function
(Grade 1) (2)
Moderate pain interfering with function
but not ADL (Grade 2) (3)
Severe pain severly interfering with ADL
(Grade 3) (4)
Disabling (Grade 4) (5)
Physical examination
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Mitral valve auscultation*
No murmurs (1)
Systolic murmur (2)
Diastolic murmur (3)
Systolic and dyastolic murmur (4)
Aortic valve auscultation*
No murmurs (1)
Systolic murmur (2)
Diastolic murmur (3)
Systolic and dyastolic murmur (4)
Pulmonary valve auscultation*
No murmurs (1)
Systolic murmur (2)
Diastolic murmur (3)
Systolic and dyastolic murmur (4)
Tricuspid valve auscultation*
No murmurs (1)
Systolic murmur (2)
Diastolic murmur (3)
Systolic and dyastolic murmur (4)
Percussion of heart borders*
Normal (1)
Left border extended (2)
Right border extended (3)
Both borders extended (4)
Auscultation of lungs*
Vesicular breathing (1)
Decreased breath sounds (2)
Inspiratory wheezing (3)
Expiratory wheezing (4)
Rales (5)
Inspiratory crepitation (6)
Rhonchi (7)
Chest percussion*
Normal percutor sound (1)
Dull percutor sound (2)
Chest auscultation finding
Chest percussion finding
Palpation of chest*
Palpation of abdomen*
Soft and painless (1)
Tenderness (location?) (2)
Site of abdominal tenderness
Right hypochondriac region (1)
Epigastric region (2)
Left hypochondriac region (3)
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Right lumbar region (4)
Umbilical region (5)
Left lumbar region (6)
Right iliac region (7)
Hypogastric region (8)
Left iliac region (9)
Liver size by percussion*
cm
Heart rate*
bpm
Pulse*
bpm
Heart rate rhythmic?*
Yes
No
Pulse rhythmic?*
Yes
No
Respiratory rate*
cpm
Body temperature*
grad C
Level of consciousness*
Body position*
Active (1)
Compelled (2)
Muscle Development
Normal (1)
Hypotrophy (2)
Hypertrophy (3)
Bone Development
Normal (1)
Defiguration (2)
Deformation (3)
Joints
Normal (1)
Defiguration (2)
Deformation (3)
Skin
Normal color and clear (1)
Jaundice (2)
Cyanosis (3)
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Hyperemia (4)
Erythema (5)
Eyes Sclera
Normal color (1)
Sclera icteris (2)
Visible mucous membranes
Normal color (1)
Jaundice (2)
Cyanosis (3)
Thyroid gland*
Normal (1)
Hyperthyreoidism I stage (2)
Hyperthyreoidism II stage (3)
Hyperthyreoidism III stage (4)
Leg Swelling*
Yes
No
Past medical history
Diabetes Mellitus
Type 1 (1)
Type 2 (2)
Diabetes Mellitus management
yes, only set dietary (1)
yes, medical controlled (2)
yes, insulin dependent (3)
Diabetes Mellitus duration
>= 1
years
Tuberculosis
Sexually Transmitted Diseases
Viral hepatitis
HIV/AIDS
Prior myocadial infarction
Prior myocadial infarction localization
Old posterior myocardial infarction (1)
Old anterior myocardial infarction (2)
Old lateral myocardial infarction (3)
Prior stroke
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Prior Stroke localization
Anterior cerebral artery occlusion (1)
Posterior cerebral artery occlusion (2)
Basilar artery occlusion with cerebral
infarction (3)
Allergic reactions*
Smoking
Alcohol abuse
Drug abuse
Operative Surgical Procedures
Prior traumas
Family history*
Family social history*
Prior or current Pharmacotherapy
Diagnosis
Principal diagnosis*
Secondary diagnosis
ICD Codes*
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modified from http://www.d2d.de/ .
Einrichtungsübergreifende elektronische Fallakte (eEFA). 
(EFA / eEFA Düren)
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CDA Header Physician Letter
Patient
Vorname
Nachname
Geschlecht
Weiblich (F)
Männlich (M)
Geburtsdatum
Straße
Hausnummer
Postleitzahl Patient
Stadt
Patient-Nr.
Versichertennummer
Krankenversicherung
Ja
Nein
Versicherungsnehmer
Behandelnder Arzt
Arzt
Adresse (Arzt)
Telefonnummer (Arzt)
Fax (Arzt)
Erzeugt am
1 / 3
Unterschrift
Kopie an
CDA body Physician letter
Anamnese
Datum
Anamnese
Allergien und allergische Reaktionen
Datum
Allergien und allergische Reaktionen
Befund
Datum
Befund
Laborwerte
Datum
Labortest
Labortest - Langtext
Wert
Einheit
Normwert
Uncodierte Diagnosen
Datum
Uncodierte Diagnose
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Diagnosen mit ICD 10
Datum
Diagnose mit ICD 10
Diagnosetext
Lokalisation
Diagnosezusatz
Medikation
Datum
Medikation
Medikation Entlassung
Datum
Medikation Entlassung
Pflege
Datum
Pflegestufe
Pflegeklassifizierung
Pflegehilfsmittel verordnet
Ja
Nein
Pflegehilfsmittel verordnet seit
Epikrise
Datum
Epikrise
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Heart failure summary record - Fixed
components
Derived from public deliverables of SemanticHealthNet
(http://www.semantichealthnet.eu/index.cfm/deliverables/)
http://www.semantichealthnet.eu/SemanticHealthNet/asset
s/File/SHN%20288408%20D%201_2%20v2%20with%20A
nnexes.pdf
All rights reserved. Please visit https://medical-data-
models.org/forms/11907
Heart failure summary record - Fixed
components
Fixed components
Patient Identifiers
Date of birth
Sex
female (f)
male (m)
Height
>= 0
cm
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Heart failure summary record - Occasional
Updates
Derived from public deliverables of SemanticHealthNet
(http://www.semantichealthnet.eu/index.cfm/deliverables/)
http://www.semantichealthnet.eu/SemanticHealthNet/asset
s/File/SHN%20288408%20D%201_2%20v2%20with%20A
nnexes.pdf
All rights reserved. Please visit https://medical-data-
models.org/forms/11908
Heart failure summary record -
Occasional Updates
Social Circumstances
Housing
Lives Alone (1)
Lives with Partner (2)
Lives with Relative (3)
Lives with Friend (4)
Other (5)
Social network
Accomodation (suitable for mobility)
Lifestyle
Smoking
Never Smoked (1)
Current Smoker (2)
stopped in last year (3)
stopped >1 year (4)
Alcohol
<= 20
units per week
Exercise
Diet
Dietary Supplements
Medicine Management by Patient
poor (1)
moderate (2)
good (3)
Cognitive function
Quality of life score
Mood Assessment
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Comorbidity
Hyperlipidaemia start of therapy
Hypertension start of therapy
Diabetes mellitus start of therapy
Chronic Kidney Disease Year of Diagnosis
Atrial Fibrillation Year of Onset
Myocardial Infarction, most recent date
Coronary artery bypass
Yes
No
Valve surgery
Yes
No
Other Cardiac Surgery
Yes
No
Date of most recent Cardiac Surgery
Percutaneous Transluminal Coronary Angioplasty
Yes
No
Percutaneous valvuloplasty
Yes
No
Other percutaneous vascular procedure
Yes
No
Coronary Artery Disease other than myocardial
infarction
Yes
No
Cardiomyopathy
Dilated (1)
Hypertrophic (2)
Other (3)
Cardiomyopathy date of first diagnosis
2 / 6
Heart failure summary record - Occasional Updates
Valve disease (specify valve and whether
dominant stenosis or regurgitation or mixed)
Valve disease date of first diagnosis
Other Comorbidity
Primary Cause of Heart Failure
Primary Cause of Heart Failure
Myocardial Infarction (1)
Coronary Artery Disease (2)
Cardiomyopathy (3)
Valve Disease (4)
Hypertension (5)
Atrial Fibrillation (6)
Other (7)
Primary Case of Heart Failure
Cardiac Phenotype
Left Ventricular Ejection Fraction
%
Left ventricular systolic dysfunction
no (1)
mild (2)
moderate (3)
severe (4)
Left ventricular end-diastolic dimension
mm
Left atrial dimension
mm
Right ventricular dysfunction
Yes
No
Tricuspid annular plane systolic excursion
mm
Aortic Valve
normal (1)
mild stenosis (2)
moderate stenosis (3)
severe stenosis (4)
mild regurgitation (5)
moderate regurgitation (6)
severe regurgitation (7)
biological prosthetic valve (8)
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mechanical prosthetic valve (9)
Mitral Valve
normal (1)
mild stenosis (2)
moderate stenosis (3)
severe stenosis (4)
mild regurgitation (5)
moderate regurgitation (6)
severe regurgitation (7)
biological prosthetic valve (8)
mechanical prosthetic valve (9)
Pulmonary Valve
normal (1)
mild stenosis (2)
moderate stenosis (3)
severe stenosis (4)
mild regurgitation (5)
moderate regurgitation (6)
severe regurgitation (7)
Tricuspid Valve
normal (1)
mild stenosis (2)
moderate stenosis (3)
severe stenosis (4)
mild regurgitation (5)
moderate regurgitation (6)
severe regurgitation (7)
Peak velocity of tricuspid regurgitation
Inferior Vena Cava Diameter
cm
Percentage collapse of IVCD with sniffing
%
Diastolic function impaired
no (1)
mild (2)
moderate (3)
severe (4)
don’t know (5)
not done (6)
Left ventricular hypertrophy
no (1)
mild (2)
moderate (3)
severe (4)
don't know (5)
not done (6)
Mitral E-wave velocity
Mitral A-wave velocity
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Mitral e´-velocity
Left ventricular ejection time
Aortic pre-ejection period
Pulmonary pre ejection period
Electrocardiogram
Heart Rhythm
Sinus rhythm (1)
Atrial fibrillation (2)
Other (3)
QRS duration
ms
QRS morphology
left bundle branch block (BBB) (1)
right bundle branch block (2)
indeterminate bundle branch block (3)
PR interval
ms
Atrial fibrillation periods
min/24hrs
Ventricular tachycardia, bursts
consecutive beats
Chest X-ray
Chest X-ray finding
Spirometry
FEV1
L
Forced vital capacity
L
Forced expired volume in one second/forced vital
capacity ratio
%
Specialised Tests
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Other Cardiac Imaging Tests
Cardiac catheterisation
Electrophysiology study
Device Therapy
Pacemaker
Cardiac Resynchronisation Therapy
Implantable Cardiac Defibrillator
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Heart failure summary record - Frequent
Updates (Monitoring)
Derived from public deliverables of SemanticHealthNet
(http://www.semantichealthnet.eu/index.cfm/deliverables/)
http://www.semantichealthnet.eu/SemanticHealthNet/asset
s/File/SHN%20288408%20D%201_2%20v2%20with%20A
nnexes.pdf
All rights reserved. Please visit https://medical-data-
models.org/forms/11909
Heart failure summary record -
Frequent Updates (Monitoring)
Symptoms
Breathlessness (relationship to exertion, severity,
at night)
Ankle swelling
Chest pain
Fatigue
Palpitations
Dizziness
Blackouts/Syncope
Signs
NYHA Class
I (1)
II (2)
III (3)
IV (4)
Body weight changes
kg
Temperature
°C
Heart Rhythm
Sinus rhythm (1)
Atrial fibrillation (2)
Other (3)
Heart rate
>= 0
bpm
Systolic
>= 0
mmHg
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Diastolic
>= 0
mmHg
Jugular Venous Pressure
Peripheral Oedema
Third Heart Sound
Lung Crepitations
Transcutaneous Oxygen Saturation
%
Blood tests
Haemoglobin
g/dL
Mean Corpuscular Volume
fl
Mean corpuscular hemoglobin concentration
g/dL
WBC
/ul
Peripheral Platelet Count
1000/uL
Sodium
mmol/L
Potassium
mmol/l
Urea
mg/dL
Creatinine
mg/dL
Albumin
g/dL
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Bilirubin, total
mg/dL
AST (SGOT)
U/L
ALT (SGPT)
U/L
Alkaline Phosphatase
U/L
INR
B-type Natriuretic Peptide
<= 100
pg/ml
BNPT
<= 400
pg/ml
Blood Glucose
mg/dL
Troponin
ng/mL
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Peripheral Atherosclerotic Vascular Disease
EHR key data elements
2012 ACCF / AHA Data Standard
Peripheral Atherosclerotic Disease (PAD)
General data elements
see
http://www.ncbi.nlm.nih.gov/pubmed/22144570
All rights reserved. Please visit https://medical-data-
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Peripheral Atherosclerotic Disease
(PAD) - General data elements
Allgemeine Datenelemente
Geschlecht*
Männlich (1)
Weiblich (2)
Geburtsdatum*
Ethnizität*
American Indian or Alaska Native (1)
Asian (2)
Black or African American (3)
Native Hawaiian or Other Pacific Islander
(4)
White (5)
Other (specify) (6)
Hispanic ethnicity*
Ja
Nein
Patient ZIP code*
Healthcare facility*
Insurance payer*
Government (government-reimbursed
care) (1)
Commercial (2)
Health maintenance organization (3)
none (4)
Date and time of presentation to healthcare
facility*
Encounter type*
Emergency admission for stroke (1)
Planned admission for noncardiovascular
problem (10)
Regularly scheduled outpatient visit (11)
Urgent or other unscheduled outpatient
visit (12)
Emergency admission for TIA (2)
Emergency admission for limb ischemia
(3)
Emergency admission for other
cardiovascular problem (4)
Planned admission for
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evaluation/treatment of carotid artery
disease (5)
Planned admission for
evaluation/treatment of PAD (6)
Planned admission for
evaluation/treatment of aortic aneurysm
(7)
Planned admission for
evaluation/treatment of renal/mesenteric
artery disease (8)
Planned admission for other
cardiovascular problem (9)
Reason for encounter*
Symptoms related to carotid artery
disease (1)
Symptoms related to PAD (2)
Symptoms related to aortic aneurysmal
disease (3)
Symptoms related to renal artery
disease (4)
Symptoms related to mesenteric artery
disease (5)
Symptoms related to other
cardiovascular disease (6)
Noncardiovascular symptoms (7)
Admission location*
ICU/stroke unit (1)
Step-down unit (2)
Unmonitored hospital floor (3)
Observation/holding unit in emergency
department (4)
Outpatient (5)
Patient Transport*
Self/family/friend/caregiver (1)
Taxi/public transportation (2)
Ambulance (3)
Mobile ICU (4)
Air or ambulance transfer from another
facility (5)
Encounter location*
Caregiver office: primary care or
specialist (1)
Urgent care facility (2)
Inpatient hospital (3)
Outpatient hospital (4)
Emergency department (5)
Ambulatory surgery center (6)
Inpatient rehabilitation facility (7)
SNF (8)
Mobile unit (9)
Anamnese
Hoher Blutdruck in der Anamnese?*
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Diabetes in der Anamnese?*
History of Dyslipidemia*
History of Smoking*
Current every day smoker (indicate pack
years) (1)
Current some days smoker (indicate
pack years) (2)
Former smoker (indicate pack years) (3)
Never smoker (4)
Smoker, current status unknown (5)
Unknown if ever smoked (6)
History of alcohol consumption*
History of illicit drug use*
Ja
Nein
History of Myocardial Infarction*
Myocardial infarction within the past 6 weeks*
Ja
Nein
History of angina pectoris*
History of CABG surgery*
History of Percutaneous Coronary Intervention
(PCI)*
History of Peripheral Artery Disease (PAD)*
Ja
Nein
History of aortic aneurysm*
Ja
Nein
History of renal or mesenteric artery disease*
Ja
Nein
History of TIA*
History of stroke*
History of Congestive Heart Failure*
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NYHA classification*
without limitations of physical activity.
Ordinary physical activity does not cause
undue fatigue, palpitations, or dyspnea.
(I)
slight limitation of physical activity. The
patient is comfortable at rest. Ordinary
physical activity results in fatigue,
palpitations, or dyspnea. (II)
marked limitation of physical activity. The
patient is comfortable at rest. Less than
ordinary activity causes fatigue,
palpitations, or dyspnea. (III)
inability to carry on any physical activity
without discomfort. Heart failure
symptoms are present even at rest or
with minimal exertion. (IV)
History of pulmonary insufficiency*
Ja
Nein
History of chronic kidney disease*
Körperliche Untersuchung
Körpergröße*
>= 0
cm
Gewicht*
>= 0
kg
BMI*
kg/m2
Systolischer Blutdruck*
>= 0
mmHg
Diastolischer Blutdruck*
>= 0
mmHg
Herzfrequenz*
>= 0
bpm
Cardiac rhythm*
Normal sinus rhythm (1)
Atrial fibrillation (2)
Other (3)
peripheral vascular exam*
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Cardiac examination*
Peripheral edema*
Laboruntersuchungen
Blutbild*
Hämoglobin*
g/dL
Hämatokrit*
%
Glukose*
mg/dl
BUN*
mg/dL
Kreatinine*
mg/dL
GFR*
ml/(min*1,73m2)
Natrium*
mmol/L
Kalium*
mmol/l
HbA1c*
%
Prothrombin time*
s
PTT*
s
Total cholesterol*
mg/dL
LDL*
mg/dL
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HDL*
mg/dL
Triglyzeride*
mg/dL
CRP*
ESR*
Kalzium*
mmol/l
Phosphorus*
Magnesium*
TSH*
BNP*
AST*
U/L
ALT*
U/L
CK*
Troponin T*
Troponin I*
Homocysteine*
Vitamin B12*
Folic acid*
Prothrombin gene (20210) screen*
Protein C Activity Test*
Protein S activity*
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Antithrombin III*
Anticardiolipin antibody*
Lupus anticoagulant*
Aktuelle pharmakologische Therapie
Aspirin*
Clopidogrel*
Prasugrel*
P2Y12 antagonists*
Dipyridamole*
Other antiplatelet drugs*
Unfractionated Heparin*
Heparin (Low-Molecular-Weight)*
Fondaparinux*
Other factor Xa inhibitor*
Direct thrombin inhibitor*
Warfarin*
Anticoagulants (other)*
Antihypertensive drugs*
Statins*
Drugs used in Diabetes*
Smoking cessation therapy*
Antiarrhythmic drugs*
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Heart failure medications*
Drugs for symptoms of PAD*
Noncardiovascular medications*
Drug Allergy*
Medication side effect*
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2. Induction AML-AZA elderly patients
NCT00915252
2. Induktionstherapieblock EudraCT-Nr 2008-004583-40
Akute myeloische Leukmie(AML) AML alle auer FAB M3
(5-Azacytidin plus Standardtherapie bei älteren AML-
Patienten
Efficacy of 5-azacytidine Added to Standard Primary
Therapy in Elderly Patients With Newly Diagnosed Acute
Myeloid Leukemia (AML) (AML-AZA)
NCT00915252
Principal Investigator Prof. Dr. Müller-Tidow
All rights reserved. Please visit https://medical-data-
models.org/forms/11912
2. Induction AML-AZA elderly
patients NCT00915252
Patient data
Pat. No.:    -*
Clinical finding
Physical Examination Date:*
ECOG performance status finding*
ECOG 0 (Normal physical fitness) (0)
ECOG 1 (Outpatient care, easy work
possible) (1)
ECOG 2 (Less than half day bed-ridden,
self-sufficiency possible, but not able to
work) (2)
ECOG 3 (More than half day bed-ridden,
limited self-sufficiency possible) (3)
ECOG 4 (Permanent bed-ridden) (4)
Body weight*
>= 0
kg
Body surface area*
>= 0
m²
Differential blood count
Date:*
Hemoglobin*
g/dL
Leukocytes*
/µl
Neutrophil percentage*
Band neutrophil percentage*
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[or] Segmented neutrophil percentage*
Lymphocyte percentage*
Monocyte percentage*
Eosinophil percentage*
Basophil percentage*
Blast cell percentage*
Promyelocyte percentage*
Myelocyte percentage*
Metamyelocyte percentage*
Percentage of other cells*
Platelets*
1000/uL
Clinical Chemistry
Sodium
mmol/L
Potassium*
mmol/l
Total Protein*
mg/dL
Uric acid*
md/dl
BUN*
mg/dL
Creatinine*
mg/dL
Bilirubin, total*
mg/dL
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AST (SGOT)*
U/L
ALT (SGPT)*
U/L
Alkaline Phosphatase*
U/L
Lactate Dehydrogenase (LDH)*
U/L
CRP*
md/dl
Quick's value (in percent)*
%
INR*
PTT*
seconds
Patient randomization in study arm:*
A (5-Azacytidine) (1)
B (Documentation continued on page 16)
(2)
5-Azacytidine
5-Azacytidine dose:*
DL 1: 37,5 mg/m2 (1)
DL 2: 75 mg/m2 (2)
5-Azacytidine - Dose no. 1
Date*
Dose absolute/day (mg)*
Route of administration*
Bolus Infusion (1)
not intravenous (2)
Reason for not intravenous*
5-Azacytidine - Dose no. 2
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Date*
Dose absolute/day*
mg
Route of administration*
Bolus Infusion (1)
not intravenous (2)
Reason for not intravenous*
5-Azacytidine - Dose no. 3
Date*
Dose absolute/day (mg)*
mg
Route of administration*
Bolus Infusion (1)
not intravenous (2)
Reason for not intravenous*
5-Azacytidine - Dose no. 4
Date*
Dose absolute/day (mg)*
mg
Route of administration*
Bolus Infusion (1)
not intravenous (2)
Reason for not intravenous*
5-Azacytidine - Dose no. 5
Date*
Dose absolute/day (mg)*
Route of administration*
Bolus Infusion (1)
not intravenous (2)
Reason for not intravenous*
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5-Azacytidine dose reduction
5-Azacytidine dose reduction*
Yes
No
yes, reason:*
AE(s) in actual therapy block (1)
AE(s) in a previous therapy block (2)
treatment error (3)
Miscellaneous (4)
Miscellaneous:*
AE-No:*
AE-No:*
Transfusions
How many transfusions did the patient receive in
the period between day 1 of the 1st induction
chemotherapy and day 1 of the 2nd induction
chemotherapy?*
Number of transfused erythrocyte concentrates:*
Number of transfused platelet concentrates:*
Chemotherapy
Day 1:*
Ara-C (100mg/sqm over 24 hrs
intravenous day 1-7)
Ara-C - dose reduction*
Yes
No
(if yes:) a) Reason:*
(if yes:) b) Absolute total dose in this therapy
block (mg):*
Daunorubicin (60mg/sqm over 1-2 hrs
intravenous day 3-5)
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Daunorubicin (60mg/sqm over 1-2 hrs
intravenous day 3-5) - dose reduction*
Yes
No
(if yes:) a) Reason:*
(if yes:) b) Absolute total dose in this therapy
block (mg):*
G-CSF dose
Patient did receive G-CSF: *
Yes
No
(if yes:) Start date:*
(if yes:) End date:*
(if yes:) Pharmaceutical Preparations:*
Neulasta (1)
Neupogen (2)
Granocyte (3)
other (4)
Cytopenia duration
leucocytes <1,0 GPt/l or <1000 /ul
Start date (leucocytes <1,0 GPt/l or <1000 /ul)*
End date (leucocytes >=1,0 GPt/l or >=1000 /ul)*
(or) cytopenia ongoing [leucocytes <1,0 GPt/l or
<1000 /ul] on:*
neutrophils <0,5 GPt/l or <500 /ul
Start date (neutrophils <0,5 GPt/l or <500 /ul)*
End date (neutrophils >=0,5 GPt/l or >=500 /ul)*
(or) cytopenia ongoing [neutrophils <0,5 GPt/l or
<500 /ul] on:*
Start date (platelets <25 GPt/l or <25000
/ul)
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Start date (platelets <25 GPt/l or <25000 /ul)*
End date (platelets >=25 GPt/l or >=25000 /ul -
increasing, independent of substitution of
platelets)*
(or) cytopenia ongoing [platelets <25 GPt/l or
<25000 /ul] on:*
Signature
Date:*
Name/Signature study physician*
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On Study Breast Cancer CALGB_40301
Randomized Placebo-Controlled Phase III Trial of Letrozole
Alone or Letrozole and Tipifarnib (Zarnestra, R115777) for
Postmenopausal women with ER/PR+ Tamoxifen resistant
MBC
CALGB_40301_ON_STUDY_FORM
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=E53B0CD1-
788E-25B9-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11913
On Study Breast Cancer
CALGB_40301
Header
CALGB Form
CALGB Study No
CALGB Patient ID
Are data amended
Yes
No
Patient demographics
Patient Initials
Patient Hospital No
Institution/Affiliate
Participating Group
Participating Group Study No
Participating Group Patient ID
Patient Characteristics
Post menopausal
Yes
No
Is patient on ovarian suppression with GnRH-A
agonist
Yes
No
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Disease Description
ER status (Mark one with an X.)
Negative (Negative)
Positive (Positive)
Unknown (Unknown)
Other, specify
PgR status  (Mark one with an X.)
Negative (Negative)
Positive (Positive)
Unknown (Unknown)
Timing of assay  (Mark one with an X.)
At Recurrence (At recurrence)
Initial Diagnosis (Initial diagnosis)
Other (Other)
Timing of assay  (Mark one with an X.)
At Recurrence (At recurrence)
Initial Diagnosis (Initial diagnosis)
Other (Other)
Other, specify
Date of initial diagnosis of primary tumor
Date progressive or metastatic disease first
diagnosed
Site Of Progression Or Recurrence
Site of progression (s)
Bone (Bone)
Bone Marrow (Bone marrow)
Brain (Brain)
Distant Lymph Nodes (Distant nodes)
Distant Skin/subcutaneous Tissue
(Distant skin/subcutaneous skin)
Ipsilateral Supraclavicular Nodes
(Ipsilateral supraclavicular nodes)
Liver (Liver)
Local-regional (including Ipsilateral
Breast; Chest Wall; Axillary, Internal
Mammary, And Infraclavicular Nodes;
Local-regional Skin And Subcutaneous
Tissue) (Local-regional)
Lung, Nos (Lung)
Contralateral Breast (Opposite breast)
Other (Other)
Other Cns (Other CNS)
Pleura (Pleura)
Other, specify:
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Prior Systemic Therapy
Prior adjuvant hormonal therapy (Do not include
steroids given with chemotherapy.)
Yes
No
Prior endocrine therapy for metastasis or
recurrence (Do not include steroids given with
chemotherapy.)
Yes
No
Prior adjuvant chemotherapy (Include pre-op
chemotherapy at diagnosis.)
Yes
No
Prior chemotherapy for metastasis or recurrence
Yes
No
Prior adjuvant high dose
chemotherapy/Autologous stem cell transplant
(HDC/ASCT )
Yes
No
Prior High-Dose Chemotherapy with Autologous
Stem Cell Transplant for metastasis or recurrence
Yes
No
Prior adjuvant immunotherapy
Yes
No
Prior immunotherapy for metastasis or recurrence
Yes
No
Prior adjuvant other therapy
Yes
No
Prior other adjuvant therapy
Prior other therapy for metastasis or recurrence
Yes
No
Prior therapy for metastatic or recurrent disease
Prior Systemic Regimens
Prior treatment regimen name (s)
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Start date
End date
Prior treatment regimen type
Adjuvant (Adjuvant)
Advanced (Advanced)
Required Laboratory Values
Granulocytes
1000/uL
Platelet count
1000/uL
Creatinine
mg/dL
Bilirubin, total
mg/dL
Bilirubin ULN
mg/dL
ALT (SGPT)
U/L
ALT (SGPT) ULN
U/L
AST (SGOT)
U/L
AST (SGOT) ULN
U/L
Was tumor marker information available for the
following (Mark all that apply with an X.)
CEA (1)
CA 15-3 (2)
CA 27-29 (3)
Carcinoembryonic Antigen
<= 2.5
µg/L
CA 15-3
<= 25
kU/L
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CA 27-29
<= 38
U/ml
Completed by
Date form completed
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Eligibility Multiple Sclerosis
Betaferon/Betaseron NCT00099502
BEYOND: Betaferon/Betaseron Efficacy Yielding Outcomes
of a New Dose in Multiple Sclerosis (MS) Patients
https://clinicaltrials.gov/ct2/show/NCT00099502
The purpose of this study is to determine
-  whether treatment with Betaferon / Betaseron (interferon
beta-1b)  500 micrograms safe,
tolerable and more efficacious than treatment with
interferon beta-1b  250 micrograms
-  whether  treatment with Betaferon / Betaseron (interferon
beta-1b) tolerable and more
efficacious than treatment with Copaxone  (Glatiramer
Acetate) 20 mg
All rights reserved. Please visit https://medical-data-
models.org/forms/11914
Eligibility Multiple Sclerosis
Betaferon/Betaseron NCT00099502
Inclusion criteria
Female and male patients*
Yes
No
Aged 18-55 years*
>= 18
<= 55
Yes
No
Diagnosis of RRMS (Relapsing-Remitting
Multiple Sclerosis)*
Yes
No
EDSS score of 0 to 5.0*
>= 0
<= 5
Yes
No
Treatment-naive to IFNB or Copaxone*
Yes
No
Exclusion criteria
Neurological progression at disease onset or
between relapses*
Yes
No
Serious or acute heart diseases*
Yes
No
History of severe depression or suicide attempt*
Yes
No
Serious or acute liver, renal or bone marrow
dysfunction*
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Yes
No
Monoclonal gammopathy*
Yes
No
Known allergy to Gadolinium-DTPA, to IFNs
(Interferons), to glatiramer acetate, to human
albumin or to mannitol*
Yes
No
Pregnancy or lactation*
Yes
No
Medical Concepts
Betaferon*
Copaxone*
Depression*
Suicide attempt*
Red blood cell count*
White blood cell count*
Platelet count - finding*
Creatinine*
Liver Dysfunction*
Glutamate oxaloacetate transaminase (GOT) =
Aspartate Transaminase (AST)*
Aspartate aminotransferase:Catalytic
Concentration:Point in
time:Serum/Plasma:Quantitative*
Glutamate Pyruvate Transaminase (GPT) =
Alanine Transaminase (ALT)*
Alanine aminotransferase:Catalytic
Concentration:Point in
time:Serum/Plasma:Quantitative*
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Gamma-glutamyl transferase*
Gamma glutamyl transferase:Catalytic
Concentration:Point in
time:Serum/Plasma:Quantitative*
Glutamate Dehydrogenase*
Glutamate dehydrogenase:Catalytic
Concentration:Point in
time:Serum/Plasma:Quantitative*
Monoclonal Gammapathies*
Hypersensitivity*
Magnetic resonance imaging contrast media
allergy*
Interferons allergy*
Drug Allergy*
Albumin solution allergy*
Mannitol (substance)*
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EUMDS registry laboratory NCT00600860
http://www.eumds.org/
All rights reserved. Please visit https://medical-data-
models.org/forms/11915
Laboratory data EUMDS registry
NCT00600860
Laboratory data
Blood date
Peripheral blasts
%
Hb
Hb unit
WBC
WBC unit
Platelets
Platelets unit
RBC
10E12/l
MCV
fl
Neutrophils
%
Lymphocytes
%
Monocytes
%
Eosinophils
%
Basophils
%
Erythropoeitin
iU/l
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LDH
iU/l
ALT (SGPT)
U/L
AST (SGOT)
U/L
Serum Creatinine
Serum Creatinine unit
Creatinine clearance (calculated by database)
Serum glucose
Serum glucose unit
Serum Iron
Serum Iron unit
Iron binding capacity
Iron binding capacity unit
Ferritin
Ferritin unit
Transferrin sat. level (calculated by database)
Urinanalysis (protein)
neg (-)
pos (+)
trace (t)
Blood for biological correlative studies?
Yes
No
Urine for biological correlative studies?
Yes
No
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On-Study Form Bladder Cancer
NCT00014534 CALGB-90104
On-Study Form Bladder Cancer NCT00014534 CALGB-
90104
NCT00014534
NCI Cooperative Group On-Study Form-Revised (CALGB-
90104)
Combination Chemotherapy in Treating Patients With
Bladder Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=BE1B6E9C-
942E-7181-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/11916
On-Study Form Bladder Cancer
NCT00014534 CALGB-90104
Muscle Invasive Bladder Disease: Prior
Treatment Affecting The Bladder
Prior Intravesical Therapy (Note: If no, skip to
Prior Surgery below)
Yes
No
Type of Prior Immunotherapy
BCG (BCG)
Interferon (Interferon)
Other (Other)
Number of Courses
Specify agent
Agent Start Date
Agent End Date
Type of Prior Chemotherapy
Mmc (MMC)
Other (Other)
Thiotepa (Thiotepa)
Number of Courses
Specify agent
Prior Surgery (for urothelial disease)
Yes
No
Prior Surgery Type
Patient Previously Had Other Surgery,
Specify (Other, specify)
Patient Previosly Had A Partial
Cystectomy (Partial cystectomy)
Patient Previosly Had A Radical
1 / 5
Cystectomy (radical cystectomy)
Patient Previosly Had A Turbt (TURBT)
Other, specify
TURBT, specify number
Prior surgery date
Any Other Prior Therapy
Yes
No
Prior Therapy Name
Prior Therapy Date
Chest X-ray assessment date
Chest X-ray results
Equivocal (equivocal)
Negative (negative)
Positive (positive)
Abdominal/pelvic CT assessment date
CT results
Abnormal-disease Related (abnormal-
disease related)
Abnormal-not Disease Related
(abnormal-not disease related)
Equivocal (equivocal)
Normal (normal)
Not Done (not done)
Unknown (unknown)
ANC
1000/ul
Peripheral Platelet Count
1000/uL
Bilirubin, total
mg/dL
Bilirubin ULN
mg/dL
Creatinine
mg/dL
Creatinine Clearance
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mL/min
Alkaline Phosphatase
U/L
Alkaline Phosphatase ULN
U/L
AST (SGOT)
U/L
AST (SGOT) ULN
U/L
Completed by
Date form completed
Ccrr Module For Nci Cooperative Group
On-study Form-revised (calgb-90104)
CALGB Form
CALGB Study No.
CALGB Patient ID
Are data amended?
Yes (Yes)
Patient Initials
Participating group
Patient medical record number
Participating group protocol number
Institution/Affiliate
Participating Group Patient ID
Date of Initial Symptom
Has the patient had a prior history of superficial
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disease?
Yes
No
Number of Prior Occurrences of Papillary
Number of Prior Occurrence of CIS
Date of Initial Pathologic Diagnosis of muscle
invasive bladder cancer
Date of Initial Pathologic Diagnosis of muscle
invasive bladder cancer
Date of Current pathologic diagnosis for muscle
invasive bladder cancer
Date of Most recent prior recurrence for muscle
invasive bladder cancer
Histologic Type (mark all that apply)
Other Specify (Other, specify)
Transitional Cell Carcinoma (Transitional
cell carcinoma)
Other, specify
Histologic Grade (check the highest grade)
Well Differentiated (G1)
Moderately Differentiated (G2)
Poorly Differentiated (G3)
Tumor Grade Cannot Be Assessed (GX)
Pathologic T Stage (Indicate highest stage at the
current presentation of disease)
No Evidence Of Primary Tumor (T0)
Tumor Invades Subepithelial Connective
Tissue (T1)
Tumor Invades Superficial Muscles (inner
Half) (T2a)
Tumor Invades Deep Muscles (outer
Half) (T2b)
Tumor Invades Perivesical Tissue
Microscopically (T3a)
Tumor Invades Perivesical Tissue
Macroscopically (extravesical Mass)
(T3b)
Inflammatory Carcinoma (T4)
Pathologic N Stage (Distant Metastasis)
No Regional Lymph Node Metastasis
(N0)
Metastasis In A Single Lymph Node, 2
Cm Or Less In Greatest Dimension (N1)
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Metastasis In A Single Lymph Node,
More Than 2 Cm But Not More Than 5
Cm In Greatest Dimension; Or Multiple
Lymph Nodes, None More Than 5 Cm In
Greatest Dimension (N2)
Metastasis In A Lymph Node More Than
5 Cm In Greatest Dimension (N3)
Regional Lymph Nodes Cannot Be
Assessed (Nx)
Pathologic M Stage
M0, According To Ajcc Staging
Definitions (M0)
Lymph Node Type (unnamed)
Common Iliac (Common Iliac)
External Iliac (External Iliac)
Hypogastric (Hypogastric)
Internal Iliac (Internal Iliac)
Other, Specify (Other, specify)
Para-aortic (Para-aortic)
Other, specify
Lymph Node Involvement (unnamed)
Lymph Nodes Were Evaluated For
Involvement, And They Were Equivocal
(equivocal)
Lymph Nodes Were Evaluated For
Involvement, And They Were Negative
(negative)
Lymph Nodes Were Not Evaluated For
Involvement (not evaluated)
Lymph Nodes Were Evaluated For
Involvement, And They Were Positive
(positive)
Unknown Whether The Lymph Nodes
Were Evaluated For Involvement
(unknown)
Number of Lymph Nodes Examined
Number of Positive Lymph Nodes
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Drug Administration Form DA3 Lymphoma
AMC-075 NCT01193842
AMC-075 Study Drug Administration Form (DA3)
Vorinostat and Combination Chemotherapy With Rituximab
in Treating Patients With Previously Untreated HIV-Related
Diffuse Large B-Cell Non-Hodgkin Lymphoma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=9F024D4D-
B085-7931-E040-BB89AD4333FF
All rights reserved. Please visit https://medical-data-
models.org/forms/11920
Drug Administration Form DA3
Lymphoma AMC-075 NCT01193842
Header Module
Visit number
Comments
Enter Total Dose Of Study Drug Received
This Cycle And Dose Modification Codes
Cycle Start Date
DD.MM.YYYY
Body surface area
>= 0
m²
Agent Name
Dose Modification
Dose Delayed (Dose delayed)
Dose Delayed And Reduced (Dose
delayed and reduced)
Dose Escalated (Dose escalated)
Dose Reduced (Dose reduced)
Drug Discontinued (Drug discontinued)
No Dose Modification (No dose
modification)
Total Dose of Agents/Drugs for this Cycle
mg/cycle
Number of Doses Missed
Agent Start Date
Agent End Date
Duration Delay
days
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Treatment form Cervical Cancer SWOG
S0227 NCT00057928
SOUTHWEST ONCOLOGY GROUP S0227 TREATMENT
FORM (S0227)
S0227 Comparison of Cisplatin Combined With Either
Paclitaxel or Gemcitabine in Treating Patients With
Recurrent, Persistent, or Metastatic Cervical Cancer
NCT00057928
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=AA4D01C2-
8134-3CDA-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/11921
Treatment form Cervical Cancer
SWOG S0227 NCT00057928
SWOG clinical trial administrative data
SWOG Patient ID
SWOG Study No.
Registration Step
Patient Initials (L, F M)
Cycle #
Institution / Affiliate
Physician (Groups other than SWOG)
Group Name
Study No.
Pt. ID
Status
Date of Last Contact or Death
Vital Status
Alive (Alive)
Dead (Dead)
First Cycle Of Treatment
Cycle start date (same as treatment start date)
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Cycle end date (Date immediately prior to the
date next cycle begins, or date decision made to
discontinue patient from protocol treatment if last
cycle)
Weight (First day of this cycle)
Body surface area
>= 0
m²
Were there any dose modifications or
additions/omissions to protocol treatment
No (No)
(i.e., The Treatment Was Changed
According To Protocol Guidelines) (Yes,
planned, specify in comments)
(i.e., The Treatment Change Was Not
Part Of Protocol Guidelines) (Yes,
unplanned, specify in comments)
Total dose for this cycle: gemcitabine (Arm 2
only)
CONCOMITANT MEDICATIONS / MEDICAL
INTERVENTIONS
Others, specify
Start Date
Stop Date
Comments
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Drug Dose Form Cervical Cancer GOG
NCT00064077
GOG Cycle Dose Drug Form
Comparison of Four Combination Chemotherapy Regimens
Using Cisplatin in Treating Patients With Stage IVB,
Recurrent, or Persistent Cancer of the Cervix
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=ABA3A924-
559C-246C-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/11922
Drug Dose Form Cervical Cancer
GOG NCT00064077
Header Module
Date form originally completed (m d y)
Date form amended (m d y)
Person amending form, last name
Patient Name, Last
Patient Name, First
Patient Study ID
Person Completing Form, Last Name
Treatment Cycle And Modification
Cycle start date (Day 1 m d y)
Current cycle number
Cycle delayed
Yes
No
Number of days treatment course was delayed
Agent Name
Dose level
Dose modification (change) (* P = Planned, U =
Unplanned)
No (No)
(i.e., The Treatment Was Changed
According To Protocol Guidelines)
(Planned)
1 / 3
(i.e., The Treatment Change Was Not
Part Of Protocol Guidelines) (Unplanned)
Total dose of agents/drugs for this cycle
Units
Body weight
>= 0
kg
Body surface area
>= 0
m²
Performance status
Ambulatory and capable of all selfcare
but unable to carry out any work
activities (K 50 - 60) (Ambulatory and
capable of all selfcare but unable to carry
out any work activities (K 50 - 60))
Capable of only limited selfcare, confined
to bed or chair more than 50% of waking
hours (K 30 - 40) (Capable of only limited
selfcare, confined to bed or chair more
than 50% of waking hours (K 30 - 40))
Completely disabled  (K 10 - 20)
(Completely disabled  (K 10 - 20))
Fully active, able to carry on all pre-
disease performance without restriction
(Karnofsky 90 - 100) (Fully active, able to
carry on all pre-disease performance
without restriction (Karnofsky 90 - 100))
Restricted in physically strenuous activity
but ambulatory (K 70 -     80) (Restricted
in physically strenuous activity but
ambulatory (K 70 -     80))
Assessment date (m d y Pretreatment
hematology and chemistry values Specify
individual dates when assessment dates differ)
Hemoglobin
g/dL
Peripheral hematocrit count (1000/L)
WBC
/ul
ANC
1000/ul
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Peripheral Platelet Count
1000/uL
BUN
mg/dL
Creatinine
mg/dL
Creatinine Clearance
mL/min
AST (SGOT)
U/L
Bilirubin, total
mg/dL
Result of CA125 (IU/ml)
Other (1st Lab Test), specify
Other (1st Lab Value), specify
Other (2nd Lab Test), specify
Other (2nd Lab Value), specify
Comments
COMMENTS
Footer Module
Participating Group Code
Participating Group Protocol Number
Participating Patient Study ID
Ccrr Module For Gog Cycle Dose Drug
Form
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Treatment Neuroendocrine Carcinoma
SWOG S0518 NCT00569127
Southwest Oncology Group S0518 Treatment Form
NCT00569127
Octreotide and Interferon Alfa-2b or Bevacizumab in
Treating Patients With Metastatic or Locally Advanced,
High-Risk Neuroendocrine Tumor
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=0F23B84D-
2C40-70EC-E044-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11923
Treatment Neuroendocrine
Carcinoma SWOG S0518
NCT00569127
Administrative documentation
SWOG Patient ID*
SWOG Study No.*
Registration Step*
Current Cycle Number*
Patient Initials (L, F M)*
Institution/Affiliate*
Physician*
Participating Group Name*
Participating Study No.*
Participating Patient ID*
Status
Date of Last Contact or Death*
Vital Status*
Dead (0)
Alive (1)
Has the patient progressed?*
Yes
No
Treatment for This Cycle
1 / 3
Assigned Treatment Arm*
Arm 1: Octreotide + Bevacizumab (Arm
1: Octreotide + Bevacizumab)
Arm 1: Octreotide + Interferon Alpha 2b
(Arm 1: Octreotide + Interferon alpha 2b)
Cycle Start Date*
Date of last treatment for this cycle*
Body weight*
>= 0
kg
Body surface area*
>= 0
m²
Were there any dose modifications or
additions/omissions to protocol treatment?*
No (No)
Yes, Planned (i.e., The Treatment Was
Changed According To Protocol
Guidelines) (Yes, planned)
Yes, Unplanned (i.e., The Treatment
Change Was Not Part Of Protocol
Guidelines) (Yes, unplanned)
Agent Name*
Total Dose (this cycle)*
Units*
Dose modification*
Dose Delayed (Dose delayed)
Dose Delayed And Reduced (Dose
delayed and reduced)
Dose Held (Dose held)
Dose Reduced (Dose reduced)
Drug Discontinued (Drug discontinued)
No Dose Modification (No dose
modification)
Dose Modification Reason*
Adverse Event (Adverse event)
Alternative Therapy For Other Reason
(Alternative therapy for other reason)
Death (Death)
Disease Progression (Disease
progression)
Dosing Error (Dosing error)
Other (Other)
Patient Refusal/noncompliance (Patient
refusal/noncompliance)
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Scheduling (Scheduling)
Other, specify*
Modification due to Adverse Event*
Arterial Thrombotic Event (Arterial
Thrombotic Event)
Gi Toxicity (GI toxicity)
Hematologic Toxicity (Hematologic
toxicity)
Hepatic Toxicity (Hepatic Toxicity)
Other (Other)
Renal Toxicity (Renal toxicity)
Venous Thrombosis/embolism (Venous
Thrombosis/Embolism)
Other, specify*
Cycle 1 Only, All Patients
Comments
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Cycle Dose Drug Form (D2R) GOG-0241
GOG-0241 Cycle Dose Drug Form (D2R)
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=
All rights reserved. Please visit https://medical-data-
models.org/forms/11924
Cycle Dose Drug Form (D2R) GOG-
0241
Header Module
Date form originally completed (m d y)
Date form amended (m d y)
Person amending form, last name
Patient Initials (First, Middle, Last)
Patient Study ID
Person Completing Form, Last Name
Comments
Treatment Cycle And Modification
Current Cycle Number
Cycle Delayed?
Yes
No
Number of days treatment cycle was delayed
Cycle delayed reason
Non Protocol Illness (Non protocol
illness)
Patient Refusal (Patient refusal)
Personal Reasons (Personal reasons)
Protocol Related Ae (Protocol related
AE)
Scheduling (Scheduling)
Cycle start date (Day 1 m d y)
Agent Name
Agent Dose level (e.g. 175 mg/m^2)
1 / 3
Dose modification status
Dose Modification (Change)
No (No)
Yes, Planned (i.e., The Treatment Was
Changed According To Protocol
Guidelines) (Yes, planned)
Yes, Unplanned (i.e., The Treatment
Change Was Not Part Of Protocol
Guidelines) (Yes, unplanned)
Dose Modification Reason
Adverse Event
Agent Total Dose
Units (e.g. kgs)
Body weight
>= 0
kg
Body surface area
>= 0
m²
ECOG performance status grade
Fully Active, Able To Carry On All Pre-
disease Performance Without
Restriction. (0) (0)
Restricted In Physically Strenuous
Activity But Ambulatory And Able To
Carry Out Work Of A Light Or Sedentary
Nature, E.g., Light Housework, Office
Work. (1) (1)
Ambulatory And Capable Of All Selfcare
But Unable To Carry Out Any Work
Activities. Up And About More Than 50%
Of Waking Hours. (2) (2)
Capable Of Only Limited Selfcare,
Confined To Bed Or Chair More Than
50% Of Waking Hours. (3) (3)
Completely Disabled. Cannot Carry On
Any Selfcare. Totally Confined To Bed Or
Chair. (4) (4)
Dead (5) (5)
Pretreatment Hematology And Chemistry
Values
Assessment Date (m d y)
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Hemoglobin
g/dL
Peripheral Hematocrit Count (1000/L)
WBC
/ul
ANC
1000/ul
Peripheral Platelet Count
1000/uL
PT (sec)
seconds
PTT
seconds
UPCR
BUN
mg/dL
Creatinine
mg/dL
Creatinine Clearance
mL/min
AST (SGOT)
U/L
Bilirubin, total
mg/dL
Alkaline Phosphatase
U/L
Result of CA125 (IU/ml)
INR
Other, specify test
Other specify value
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Cycle Dose Drug Form (D2R) GOG-0262
Cycle Dose Drug Form (D2R) GOG-0262
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=
All rights reserved. Please visit https://medical-data-
models.org/forms/11925
Cycle Dose Drug Form (D2R) GOG-
0262
Header Module
Date form originally completed (m d y)
Date form amended (m d y)
Person amending form, last name
Patient Initials (First, Middle, Last)
Patient Study ID
Person Completing Form, Last Name
COMMENTS
Treatment Cycle And Modification
Current Cycle Number
Cycle Delayed?
Yes
No
Number of days treatment cycle was delayed
Cycle delayed reason
Non Protocol Illness (Non protocol
illness)
Patient Refusal (Patient refusal)
Personal Reasons (Personal reasons)
Protocol Related Ae (Protocol related
AE)
Scheduling (Scheduling)
Cycle start date (Day 1 m d y)
Agent Name
Agent Dose level (e.g. mg/m^2)
1 / 3
Were there any dose modifications or
additions/omissions to protocol treatment (1=Yes,
planned; 2 =Yes, unplanned; 3=No)
No (No)
Yes, Planned (i.e., The Treatment Was
Changed According To Protocol
Guidelines) (Yes, planned)
Yes, Unplanned (i.e., The Treatment
Change Was Not Part Of Protocol
Guidelines) (Yes, unplanned)
Total dose of agents/drugs for this cycle
Units (eg. mg, kg)
Body weight
>= 0
kg
Body surface area
>= 0
m²
ECOG performance status grade
Fully Active, Able To Carry On All Pre-
disease Performance Without
Restriction. (0) (0)
Restricted In Physically Strenuous
Activity But Ambulatory And Able To
Carry Out Work Of A Light Or Sedentary
Nature, E.g., Light Housework, Office
Work. (1) (1)
Ambulatory And Capable Of All Selfcare
But Unable To Carry Out Any Work
Activities. Up And About More Than 50%
Of Waking Hours. (2) (2)
Capable Of Only Limited Selfcare,
Confined To Bed Or Chair More Than
50% Of Waking Hours. (3) (3)
Completely Disabled. Cannot Carry On
Any Selfcare. Totally Confined To Bed Or
Chair. (4) (4)
Dead (5) (5)
Pretreatment Hematology And Chemistry
Values
Assessment Date (m d y)
Hemoglobin
g/dL
Peripheral Hematocrit Count (1000/L)
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WBC
/ul
ANC
1000/ul
Peripheral Platelet Count
1000/uL
PT (sec)
seconds
PTT
seconds
BUN
mg/dL
Creatinine
mg/dL
Creatinine Clearance
mL/min
AST (SGOT)
U/L
Bilirubin, total
mg/dL
Alkaline Phosphatase
U/L
Result of CA125 (IU/ml)
INR
Other, specify test
Other specify value
Comments
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Emergency protocol- Module Basis
Emergency protocol by the DIVI (Deutsche Interdisziplinre
Vereinigung für Intensiv- und Notfallmedizin). ODM derived
from "Notaufnahmeprotokoll Modul Basis V2015.1".
All rights reserved. Please visit https://medical-data-
models.org/forms/11927
Emergency protocol- Module Basis
PATIENTENINFORMATIONEN
Patienten-ID:*
Name des Patienten:*
Anschrift:
Telefon:
Geburtsdatum:*
Versicherung:*
GKV (1)
BG (2)
UTV (3)
P (4)
Geschlecht:
männlich  (1)
weiblich (2)
Aufnahmedatum und Aufnahmezeit:
Vital signs and other informations
VITALPARAMETER
Atemfrequenz:
/min
Sauerstoffsättigung
%
Systolischer Blutdruck:
mmHg
Herzfrequenz:
bpm
Körperkerntemperatur:
°C
Glasgow-Koma-Skala:
Rechte Pupillenweite:
1 / 6
weit (1)
mittel (2)
eng (3)
Linke Pupillenweite:
weit (1)
mittel (2)
eng (3)
Lichtreaktion (rechts):
prompt (1)
träge (2)
keine (3)
Lichtreaktion (links):
prompt (1)
träge (2)
keine (3)
Schmerzskala:
>= 0
<= 10
ANDERE INFORMATIONEN
Manchester-Triage-System/ Emergency Severity
Index (MTS/ ESI):
Schwanger:
ja (1)
nein (2)
unbekannt (3)
Tetanusschutz:
ja (1)
nein (2)
unbekannt (3)
Rankin-Skala:
>= 0
<= 5
Isolation:
Nein (1)
Multiresistenter Keim (2)
Gastroenteritis (3)
Tuberkulose (4)
Meningitis (5)
Umkehriso (6)
Andere (7)
Multiresistente Keime:
Nein (1)
Ja Andere (10)
V.a. Andere (11)
Ja MRSA (2)
V.a. MRSA (3)
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Ja 3-MRGN (4)
V.a. 3-MRGN (5)
Ja 4-MRGN (6)
V.a. 4-MRGN (7)
Ja VRE (8)
V.a. VRE (9)
Zuweisung:
Ohne (1)
Vertragsarzt/ Praxis (2)
KV-Notdienst am KH (3)
KV-Notdienst außerhalb KH (4)
Rettungsdienst (5)
Notarzt (6)
Klinik/ Verlegung (7)
Andere (8)
Transportmittel:
Ohne (1)
KTW (2)
RTW (3)
NAW/NEF/ITW (4)
RTH/ITH (5)
Anderes (6)
Diagnostics
DIAGNOSTIK:
Labor:
ja (1)
nein (2)
opB ja (3)
opB nein (4)
Labor Zeit:
Blutgasanalyse:
ja (1)
nein (2)
opB ja (3)
opB nein (4)
Blutgasanalyse Zeit:
U-Stix:
ja (1)
nein (2)
opB ja (3)
opB nein (4)
U-Stix Zeit:
EKG:
ja (1)
nein (2)
opB ja (3)
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opB nein (4)
EKG Zeit:
Sono:
ja (1)
nein (2)
opB ja (3)
opB nein (4)
Sono Zeit:
Echo:
ja (1)
nein (2)
opB ja (3)
opB nein (4)
Echo Zeit:
CCT:
ja (1)
nein (2)
opB ja (3)
opB nein (4)
CCT Zeit:
CT:
ja (1)
nein (2)
opB ja (3)
opB nein (4)
CT Zeit:
Traumascan:
ja (1)
nein (2)
opB ja (3)
opB nein (4)
Traumascan Zeit:
MRT:
ja (1)
nein (2)
opB ja (3)
opB nein (4)
MRT Zeit:
Rö. WS:
ja (1)
nein (2)
4 / 6
Emergency protocol- Module Basis
opB ja (3)
opB nein (4)
Rö. WS Zeit:
Rö. Thorax:
ja (1)
nein (2)
opB ja (3)
opB nein (4)
Rö. Thorax Zeit:
Rö. Becken:
ja (1)
nein (2)
opB ja (3)
opB nein (4)
Rö. Becken Zeit:
Rö. Extremität:
ja (1)
nein (2)
opB ja (3)
opB nein (4)
Rö. Extremität Zeit:
Rö. Sonstiges:
ja (1)
nein (2)
opB ja (3)
opB nein (4)
Rö. Sonstiges Zeit:
Anamnesis
NOTFALLANAMNESE
Leitsymptom:
Körperliche Untersuchung:
Relevante Eigenmedikation:
Leitsymptom seit:
Erster Arztkontakt seit:
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Allergien:
Befunde:
Verlauf / durchgeführte Therapie:
Initiierung Therapie seit:
Abschlussdiagnosen:
ICD 10:
Weiteres Procedere /Therapieempfehlung /
Weiterbehandler:
Verlegung intern Funktion (OP, HKL, oä)
(1)
Abbruch durch Pat. (10)
Kein Arztkontakt  (11)
Sonstige Entlassung (12)
Tod (13)
Verlegung intern Überwachung (ITS,
IMC, oä) (2)
Verlegung intern Normalstation (3)
Verlegung extern Funktion (OP, HKL, oä)
(4)
Verlegung extern Überwachung (ITS,
IMC, oä) (5)
Verlegung extern Normalstation (6)
Entlassung nach Hause (7)
Entlassung zu weiterbehandl. Arzt (8)
Entlassung gegen ärztl. Rat (9)
Zeitpunkt Verlegung/Entlasssung:
Kommentare:
Zusatzmodule (Überwachung, Trauma, Konsil,
Neurologie, Anästhesie), bitte die passenden
Module eintragen
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Emergency protocol- Module Trauma
Emergency protocol by the DIVI (Deutsche Interdisziplinre
Vereinigung fr Intensiv- und Notfallmedizin).  ODM derived
from "Notaufnahmeprotokoll Modul Trauma".
All rights reserved. Please visit https://medical-data-
models.org/forms/11929
Patienteninformation und
Stammdaten
PATIENTENINFORMATIONEN
Name des Patienten:*
Patienten-ID:*
Geburtsdatum:*
Geschlecht:
männlich (1)
weiblich (2)
STAMMDATEN
Angemeldetes Verletzungsmuster:
Unfalldatum und Unfallzeit:
ASA vor Trauma:
I (1)
II (2)
III (3)
IV (4)
V (5)
Unfallursache:
Trauma (1)
V.a. Gewaltverbrechen (2)
V.a. Suizid (3)
Unfallmechanismus:
stumpf (1)
penetrierend (2)
Unfallart (Verkehr):
PKW/LKW Insasse mit Helm/ Gurt (1)
PKW/LKW Insasse ohne Helm/ Gurt (2)
Motorradfahrer mit Helm/ Gurt (3)
Motorradfahrer ohne Helm/ Gurt (4)
Fahrradfahrer mit Helm/ Gurt (5)
Fahrradfahrer ohne Helm/ Gurt (6)
Fußgänger (7)
sonstiger VU (8)
Unfallart (Sturz):
unter 3m (1)
über 3m (2)
1 / 12
Unfallart (Sonstiges):
Schlag (1)
Schuss (2)
Stich (3)
Andere (4)
Für ,,Andere" bitte erwähnen:
Preclinical information
PRÄKLINIK
Alarmierungszeit:
Uhr
Eintreffzeit:
Uhr
Beginn Transport:
Uhr
ERSTE VITALWERTE
Atemfrequenz:
/min
Sauerstoffsättigung:
%
etCO2:
mmHg
Systolischer Blutdruck:
mmHg
Herzfrequenz:
bpm
Glasgow-Koma-Skala:
Rechte Pupillenweite:
weit (1)
mittel (2)
eng (3)
Linke Pupillenweite:
weit (1)
mittel (2)
eng (3)
Lichtreaktion (rechts):
prompt (1)
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träge (2)
keine (3)
Lichtreaktion (links):
prompt (1)
träge (2)
keine (3)
Intoxikation:
Kein (1)
Alkohol (2)
Drogen (3)
Temperatur:
°C
Schmerzskala:
<= 10
>= 0
PRÄKLINISCHE THERAPIE
HWS-Immobilisierung:
Ja
Nein
Intubation:
Ja
Nein
Supraglottische Atemwegshilfe:
Ja
Nein
Chirurgischer Atemweg:
Ja
Nein
Rechte Thoraxdrainage:
Ja
Nein
Linke Thoraxdrainage:
Ja
Nein
Sauerstoff:
Ja
Nein
Rechter venöser Zugang:
Ja
Nein
Linker venöser Zugang:
Ja
Nein
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Rechter arterieller Zugang (radial):
Ja
Nein
Linker arterieller Zugang (radial):
Ja
Nein
Rechter arterieller Zugang (femoral):
Ja
Nein
Linker arterieller Zugang (femoral):
Ja
Nein
ZVK:
subclavia (rechts) (1)
subclavia (links) (2)
jugularis (rechts) (3)
jugularis (links) (4)
femoral (rechts) (5)
femoral (links) (6)
nein (7)
Rechter IO Zugang:
Ja
Nein
Linker IO Zugang:
Ja
Nein
Kristalloide:
ml
Kolloide:
ml
Small Volume Resuscitation:
Ja
Nein
Herzdruckmassage:
Ja
Nein
Defibrillation:
Ja
Nein
Katecholamine:
Ja
Nein
Blutstillung:
Druckverband (1)
Hämostyptika (2)
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Tourniquet (3)
Fraktur:
reponiert (1)
achsengerecht gelagert (2)
immobilisiert (3)
Beckengurt:
Ja
Nein
Tranexamsäure:
Ja
Nein
FAST (Focused assessment with ultrasonography
for trauma):
Analgosedierung:
Ja
Nein
Thermoprotektion:
Ja
Nein
PRÄKLINISCHE DIAGNOSE
Schädel-Hirn:
keine (1)
leicht (2)
mittel (3)
Schwer (4)
Gesicht
keine (1)
leicht (2)
mittel (3)
Schwer (4)
Thorax:
keine (1)
leicht (2)
mittel (3)
Schwer (4)
Abdomen:
keine (1)
leicht (2)
mittel (3)
Schwer (4)
Wirbelsäule:
keine (1)
leicht (2)
mittel (3)
Schwer (4)
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Becken:
keine (1)
leicht (2)
mittel (3)
Schwer (4)
Obere Extremität
keine (1)
leicht (2)
mittel (3)
Schwer (4)
Untere Extremität:
keine (1)
leicht (2)
mittel (3)
Schwer (4)
Weichteil
keine (1)
leicht (2)
mittel (3)
Schwer (4)
NACA-Score:
Bemerkung:
Clinical information
ERSTE VITALWERTE (Bitte siehe
Basismodul https://medical-data-
models.org/forms/11927)
FiO2:
%
SCHOCKRAUM DIAGNOSTIK/
ADJUNCTS
FAST (Focused assessment with ultrasonography
for trauma):
Ja (1)
Nein (2)
opB (3)
freie Flüssigkeit (4)
FAST Zeit:
Uhr
Relevanter gefühlter Blutverlust?
Ja
Nein
AUFNAHMELABOR
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pH:
Base Excess:
mmol/l
PaO2
mmHg
Hb:
g/dl
Thrombozyten:
gpt/l
Quick:
%
PTT:
sek
INR:
Fibrinogen:
g/l
Calcium (io):
mmol/l
Ethanol:
mg/dl
ROTEM Zeit:
Uhr
EXTEM MCF:
mm
EXTEM CT:
sek
FIBTEM A10:
mm
BILDGEBUNG
Ergebnisse Bildgebung
Teleradiologie:
Ja
7 / 12
Emergency protocol- Module Trauma
Nein
Schockraum Therapie und
verschiedene
SCHOCKRAUM THERAPIE
HWS-Immobilisierung:
Ja
Nein
HWS-Immobilisierung Zeit:
Uhr
Intubation:
Ja
Nein
Intubation Zeit:
Uhr
Supraglottische Atemwegshilfe:
Ja
Nein
Supraglottische Atemwegshilfe Zeit:
Uhr
Chirurgischer Atemweg:
Ja
Nein
Chirurgischer Atemweg Zeit:
Uhr
Rechte Thoraxdrainage:
Ja
Nein
Rechte Thoraxdrainage Zeit:
Uhr
Linke Thoraxdrainage:
Ja
Nein
Linke Thoraxdrainage Zeit:
Uhr
Sauerstoff:
Ja
Nein
Sauerstoff Zeit:
Uhr
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Venöser Zugang:
rechts (1)
links (2)
keine (3)
Venöser Zugang Zeit:
Uhr
Arterieller Zugang (radial):
rechts (1)
links (2)
keine (3)
Arterieller Zugang (radial) Zeit:
Uhr
Arterieller Zugang (femoral):
rechts (1)
links (2)
keine (3)
Arterieller Zugang (femoral) Zeit:
Uhr
ZVK:
subclavia (rechts)  (1)
subclavia (links)  (2)
jugularis (rechts)  (3)
jugularis (links)  (4)
femoral (rechts)  (5)
femoral (links)  (6)
keine (7)
ZVK Zeit:
Uhr
IO Zugang:
rechts (1)
links (2)
keine (3)
Kristalloide:
ml
Kristalloide Zeit:
Uhr
Kolloide:
ml
Kolloide Zeit:
Uhr
Small Volume Resuscitation:
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Ja
Nein
Small Volume Resuscitation Zeit:
Uhr
Herzdruckmassage:
Ja
Nein
Herzdruckmassage Zeit:
Uhr
Defibrillation:
Ja
Nein
Defibrillation Zeit:
Uhr
Katecholamine:
Ja
Nein
Katecholamine Zeit:
Uhr
Blutstillung:
Druckverband  (1)
Hämostyptika  (2)
Tourniquet (3)
Blutstillung Zeit:
Uhr
Fraktur:
reponiert  (1)
achsengerecht gelagert  (2)
immobilisiert (3)
Fraktur Zeit:
Uhr
Beckengurt:
Ja
Nein
Beckengurt Zeit:
Uhr
Analgosedierung:
Ja
Nein
Analgosedierung Zeit:
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Uhr
Aktiver Wärmeerhalt:
Ja
Nein
Aktiver Wärmeerhalt Zeit:
Uhr
Emergency intervention times
time
Uhr
time
Uhr
time
Uhr
time
Uhr
time
Uhr
time
Uhr
time
Uhr
time
Uhr
Anticoagulation Therapy
Anticoagulation Therapy
CodelistItem 724270 (1)
CodelistItem 724271 (2)
CodelistItem 724272 (3)
CodelistItem 724273 (4)
CodelistItem 724274 (5)
CodelistItem 724275 (6)
PHYSICAL EXAMINATION
PHYSICAL EXAMINATION
final diagnoses
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final diagnoses
diagnosis
Ja
Nein
shock room diagnosis
Ja
Nein
Further procedures
Further procedures
Team members
Anesthetist
surgeon
Central Interdisciplinary Emergency Department
radiologist
Medical Assistant Radiology
Other
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Emergency protocol- Module Case
conference
Emergency protocol by the DIVI (Deutsche Interdisziplinäre
Vereinigung für Intensiv- und Notfallmedizin).  ODM derived
from “Notaufnahmeprotokoll Modul Konsil”
All rights reserved. Please visit https://medical-data-
models.org/forms/11931
Emergency protocol- Module Case
conference
PATIENTENINFORMATIONEN
Name des Patienten:*
Patienten-ID:*
Geburtsdatum:*
Geschlecht:
männlich (1)
weiblich (2)
KONSIL
Fachrichtung:
Angefordert um:
Uhr
Eingetroffen um:
Uhr
Anordnungen:
Anordnungen Zeitpunkt:
Uhr
Durchgeführt von:
Durchgeführt um:
Uhr
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epSOS Illnesses and Disorders
Illnesses and Disorders
Cholera (A00)
Typhus abdominalis und Paratyphus
(A01)
Sonstige Salmonelleninfektionen (A02)
Shigellose [Bakterielle Ruhr] (A03)
Sonstige bakterielle Darminfektionen
(A04)
Sonstige bakteriell bedingte
Lebensmittelvergiftungen, anderenorts
nicht klassifiziert (A05)
Amöbiasis (A06)
Sonstige Darmkrankheiten durch
Protozoen (A07)
Virusbedingte und sonstige näher
bezeichnete Darminfektionen (A08)
Sonstige und nicht näher bezeichnete
Gastroenteritis und Kolitis infektiösen
und nicht näher bezeichneten Ursprungs
(A09)
Tuberkulose der Atmungsorgane,
bakteriologisch, molekularbiologisch
oder histologisch gesichert (A15)
Tuberkulose der Atmungsorgane, weder
bakteriologisch, molekularbiologisch
noch histologisch gesichert (A16)
Tuberkulose des Nervensystems (A17)
Tuberkulose sonstiger Organe (A18)
Miliartuberkulose (A19)
Pest (A20)
Tularämie (A21)
Anthrax [Milzbrand] (A22)
Brucellose (A23)
Rotz [Malleus] und Melioidose
[Pseudorotz] (A24)
Rattenbisskrankheiten (A25)
Erysipeloid (A26)
Leptospirose (A27)
Sonstige bakterielle Zoonosen,
anderenorts nicht klassifiziert (A28)
Lepra [Aussatz] (A30)
Infektion durch sonstige Mykobakterien
(A31)
Listeriose (A32)
Tetanus neonatorum (A33)
Tetanus während der Schwangerschaft,
der Geburt und des Wochenbettes (A34)
Sonstiger Tetanus (A35)
Diphtherie (A36)
Keuchhusten (A37)
Scharlach (A38)
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Meningokokkeninfektion (A39)
Streptokokkensepsis (A40)
Sonstige Sepsis (A41)
Aktinomykose (A42)
Nokardiose (A43)
Bartonellose (A44)
Erysipel [Wundrose] (A46)
Sonstige bakterielle Krankheiten,
anderenorts nicht klassifiziert (A48)
Bakterielle Infektion nicht näher
bezeichneter Lokalisation (A49)
Syphilis connata (A50)
Frühsyphilis (A51)
Spätsyphilis (A52)
Sonstige und nicht näher bezeichnete
Syphilis (A53)
Gonokokkeninfektion (A54)
Lymphogranuloma inguinale (venereum)
durch Chlamydien (A55)
Sonstige durch Geschlechtsverkehr
übertragene Chlamydienkrankheiten
(A56)
Ulcus molle (venereum) (A57)
Granuloma venereum (inguinale) (A58)
Trichomoniasis (A59)
Infektionen des Anogenitalbereiches
durch Herpesviren [Herpes simplex]
(A60)
Sonstige vorwiegend durch
Geschlechtsverkehr übertragene
Krankheiten, anderenorts nicht
klassifiziert (A63)
Durch Geschlechtsverkehr übertragene
Krankheiten, nicht näher bezeichnet
(A64)
Nichtvenerische Syphilis (A65)
Frambösie (A66)
Pinta [Carate] (A67)
Rückfallfieber (A68)
Sonstige Spirochäteninfektionen (A69)
Infektionen durch Chlamydia psittaci
(A70)
Trachom (A71)
Sonstige Krankheiten durch Chlamydien
(A74)
Fleckfieber (A75)
Zeckenbissfieber [Rickettsiosen, durch
Zecken übertragen] (A77)
Q-Fieber (A78)
Sonstige Rickettsiosen (A79)
Akute Poliomyelitis [Spinale
Kinderlähmung] (A80)
Atypische Virusinfektionen des
Zentralnervensystems (A81)
Tollwut [Rabies] (A82)
Virusenzephalitis, durch Moskitos
[Stechmücken] übertragen (A83)
Virusenzephalitis, durch Zecken
übertragen (A84)
Sonstige Virusenzephalitis, anderenorts
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nicht klassifiziert (A85)
Virusenzephalitis, nicht näher bezeichnet
(A86)
Virusmeningitis (A87)
Sonstige Virusinfektionen des
Zentralnervensystems, anderenorts nicht
klassifiziert (A88)
Virusinfektion des Zentralnervensystems,
nicht näher bezeichnet (A89)
Dengue-Fieber [Klassische Dengue]
(A90)
Hämorrhagisches Dengue-Fieber (A91)
Sonstige durch Moskitos [Stechmücken]
übertragene Viruskrankheiten (A92)
Sonstige durch Arthropoden übertragene
Viruskrankheiten, anderenorts nicht
klassifiziert (A93)
Durch Arthropoden übertragene
Viruskrankheit, nicht näher bezeichnet
(A94)
Gelbfieber (A95)
Hämorrhagisches Fieber durch
Arenaviren (A96)
Sonstige hämorrhagische
Viruskrankheiten, anderenorts nicht
klassifiziert (A98)
Nicht näher bezeichnete hämorrhagische
Viruskrankheit (A99)
Infektionen durch Herpesviren [Herpes
simplex] (B00)
Varizellen [Windpocken] (B01)
Zoster [Herpes zoster] (B02)
Pocken (B03)
Affenpocken (B04)
Masern (B05)
Röteln [Rubeola] [Rubella] (B06)
Viruswarzen (B07)
Sonstige Virusinfektionen, die durch
Haut- und Schleimhautläsionen
gekennzeichnet sind, anderenorts nicht
klassifiziert (B08)
Nicht näher bezeichnete Virusinfektion,
die durch Haut- und
Schleimhautläsionen gekennzeichnet ist
(B09)
Akute Virushepatitis A (B15)
Akute Virushepatitis B (B16)
Sonstige akute Virushepatitis (B17)
Chronische Virushepatitis (B18)
Nicht näher bezeichnete Virushepatitis
(B19)
Infektiöse und parasitäre Krankheiten
infolge HIV-Krankheit [Humane
Immundefizienz-Viruskrankheit] (B20)
Bösartige Neubildungen infolge HIV-
Krankheit [Humane Immundefizienz-
Viruskrankheit] (B21)
Sonstige näher bezeichnete Krankheiten
infolge HIV-Krankheit [Humane
Immundefizienz-Viruskrankheit] (B22)
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Sonstige Krankheitszustände infolge
HIV-Krankheit [Humane Immundefizienz-
Viruskrankheit] (B23)
Nicht näher bezeichnete HIV-Krankheit
[Humane Immundefizienz-
Viruskrankheit] (B24)
Zytomegalie (B25)
Mumps (B26)
Infektiöse Mononukleose (B27)
Viruskonjunktivitis (B30)
Sonstige Viruskrankheiten, anderenorts
nicht klassifiziert (B33)
Viruskrankheit nicht näher bezeichneter
Lokalisation (B34)
Dermatophytose [Tinea] (B35)
Sonstige oberflächliche Mykosen (B36)
Kandidose (B37)
Kokzidioidomykose (B38)
Histoplasmose (B39)
Blastomykose (B40)
Parakokzidioidomykose (B41)
Sporotrichose (B42)
Chromomykose und chromomykotischer
Abszess (B43)
Aspergillose (B44)
Kryptokokkose (B45)
Zygomykose (B46)
Myzetom (B47)
Sonstige Mykosen, anderenorts nicht
klassifiziert (B48)
Nicht näher bezeichnete Mykose (B49)
Malaria tropica durch Plasmodium
falciparum (B50)
Malaria tertiana durch Plasmodium vivax
(B51)
Malaria quartana durch Plasmodium
malariae (B52)
Sonstige parasitologisch bestätigte
Malaria (B53)
Malaria, nicht näher bezeichnet (B54)
Leishmaniose (B55)
Afrikanische Trypanosomiasis (B56)
Chagas-Krankheit (B57)
Toxoplasmose (B58)
Pneumozystose (B59)
Sonstige Protozoenkrankheiten,
anderenorts nicht klassifiziert (B60)
Nicht näher bezeichnete
Protozoenkrankheit (B64)
Schistosomiasis [Bilharziose] (B65)
Befall durch sonstige Trematoden [Egel]
(B66)
Echinokokkose (B67)
Taeniasis (B68)
Zystizerkose (B69)
Diphyllobothriose und Sparganose (B70)
Befall durch sonstige Zestoden (B71)
Drakunkulose (B72)
Onchozerkose (B73)
Filariose (B74)
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Trichinellose (B75)
Hakenwurm-Krankheit (B76)
Askaridose (B77)
Strongyloidiasis (B78)
Trichuriasis (B79)
Enterobiasis (B80)
Sonstige intestinale Helminthosen,
anderenorts nicht klassifiziert (B81)
Nicht näher bezeichneter intestinaler
Parasitismus (B82)
Sonstige Helminthosen (B83)
Pedikulose [Läusebefall] und Phthiriasis
[Filzläusebefall] (B85)
Skabies (B86)
Myiasis (B87)
Sonstiger Parasitenbefall der Haut (B88)
Nicht näher bezeichnete parasitäre
Krankheit (B89)
Folgezustände der Tuberkulose (B90)
Folgezustände der Poliomyelitis (B91)
Folgezustände der Lepra (B92)
Folgezustände sonstiger und nicht näher
bezeichneter infektiöser und parasitärer
Krankheiten (B94)
Streptokokken und Staphylokokken als
Ursache von Krankheiten, die in anderen
Kapiteln klassifiziert sind (B95)
Sonstige näher bezeichnete Bakterien
als Ursache von Krankheiten, die in
anderen Kapiteln klassifiziert sind (B96)
Viren als Ursache von Krankheiten, die
in anderen Kapiteln klassifiziert sind
(B97)
Sonstige und nicht näher bezeichnete
Infektionskrankheiten (B99)
Bösartige Neubildung der Lippe (C00)
Bösartige Neubildung des
Zungengrundes (C01)
Bösartige Neubildung sonstiger und
nicht näher bezeichneter Teile der Zunge
(C02)
Bösartige Neubildung des Zahnfleisches
(C03)
Bösartige Neubildung des Mundbodens
(C04)
Bösartige Neubildung des Gaumens
(C05)
Bösartige Neubildung sonstiger und
nicht näher bezeichneter Teile des
Mundes (C06)
Bösartige Neubildung der Parotis (C07)
Bösartige Neubildung sonstiger und
nicht näher bezeichneter großer
Speicheldrüsen (C08)
Bösartige Neubildung der Tonsille (C09)
Bösartige Neubildung des Oropharynx
(C10)
Bösartige Neubildung des Nasopharynx
(C11)
Bösartige Neubildung des Recessus
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piriformis (C12)
Bösartige Neubildung des Hypopharynx
(C13)
Bösartige Neubildung sonstiger und
ungenau bezeichneter Lokalisationen
der Lippe, der Mundhöhle und des
Pharynx (C14)
Bösartige Neubildung des Ösophagus
(C15)
Bösartige Neubildung des Magens (C16)
Bösartige Neubildung des Dünndarmes
(C17)
Bösartige Neubildung des Kolons (C18)
Bösartige Neubildung am Rektosigmoid,
Übergang (C19)
Bösartige Neubildung des Rektums
(C20)
Bösartige Neubildung des Anus und des
Analkanals (C21)
Bösartige Neubildung der Leber und der
intrahepatischen Gallengänge (C22)
Bösartige Neubildung der Gallenblase
(C23)
Bösartige Neubildung sonstiger und
nicht näher bezeichneter Teile der
Gallenwege (C24)
Bösartige Neubildung des Pankreas
(C25)
Bösartige Neubildung sonstiger und
ungenau bezeichneter
Verdauungsorgane (C26)
Bösartige Neubildung der Nasenhöhle
und des Mittelohres (C30)
Bösartige Neubildung der
Nasennebenhöhlen (C31)
Bösartige Neubildung des Larynx (C32)
Bösartige Neubildung der Trachea (C33)
Bösartige Neubildung der Bronchien und
der Lunge (C34)
Bösartige Neubildung des Thymus (C37)
Bösartige Neubildung des Herzens, des
Mediastinums und der Pleura (C38)
Bösartige Neubildung sonstiger und
ungenau bezeichneter Lokalisationen
des Atmungssystems und sonstiger
intrathorakaler Organe (C39)
Bösartige Neubildung des Knochens und
des Gelenkknorpels der Extremitäten
(C40)
Bösartige Neubildung des Knochens und
des Gelenkknorpels sonstiger und nicht
näher bezeichneter Lokalisationen (C41)
Bösartiges Melanom der Haut (C43)
Sonstige bösartige Neubildungen der
Haut (C44)
Mesotheliom (C45)
Kaposi-Sarkom [Sarcoma idiopathicum
multiplex haemorrhagicum] (C46)
Bösartige Neubildung der peripheren
Nerven und des autonomen
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Nervensystems (C47)
Bösartige Neubildung des
Retroperitoneums und des Peritoneums
(C48)
Bösartige Neubildung sonstigen
Bindegewebes und anderer
Weichteilgewebe (C49)
Bösartige Neubildung der Brustdrüse
[Mamma] (C50)
Bösartige Neubildung der Vulva (C51)
Bösartige Neubildung der Vagina (C52)
Bösartige Neubildung der Cervix uteri
(C53)
Bösartige Neubildung des Corpus uteri
(C54)
Bösartige Neubildung des Uterus, Teil
nicht näher bezeichnet (C55)
Bösartige Neubildung des Ovars (C56)
Bösartige Neubildung sonstiger und
nicht näher bezeichneter weiblicher
Genitalorgane (C57)
Bösartige Neubildung der Plazenta
(C58)
Bösartige Neubildung des Penis (C60)
Bösartige Neubildung der Prostata (C61)
Bösartige Neubildung des Hodens (C62)
Bösartige Neubildung sonstiger und
nicht näher bezeichneter männlicher
Genitalorgane (C63)
Bösartige Neubildung der Niere,
ausgenommen Nierenbecken (C64)
Bösartige Neubildung des
Nierenbeckens (C65)
Bösartige Neubildung des Ureters (C66)
Bösartige Neubildung der Harnblase
(C67)
Bösartige Neubildung sonstiger und
nicht näher bezeichneter Harnorgane
(C68)
Bösartige Neubildung des Auges und der
Augenanhangsgebilde (C69)
Bösartige Neubildung der Meningen
(C70)
Bösartige Neubildung des Gehirns (C71)
Bösartige Neubildung des
Rückenmarkes, der Hirnnerven und
anderer Teile des Zentralnervensystems
(C72)
Bösartige Neubildung der Schilddrüse
(C73)
Bösartige Neubildung der Nebenniere
(C74)
Bösartige Neubildung sonstiger
endokriner Drüsen und verwandter
Strukturen (C75)
Bösartige Neubildung sonstiger und
ungenau bezeichneter Lokalisationen
(C76)
Sekundäre und nicht näher bezeichnete
bösartige Neubildung der Lymphknoten
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(C77)
Sekundäre bösartige Neubildung der
Atmungs- und Verdauungsorgane (C78)
Sekundäre bösartige Neubildung an
sonstigen und nicht näher bezeichneten
Lokalisationen (C79)
Bösartige Neubildung ohne Angabe der
Lokalisation (C80)
Hodgkin-Lymphom
[Lymphogranulomatose] (C81)
Follikuläres Lymphom (C82)
Nicht follikuläres Lymphom (C83)
Reifzellige T/NK-Zell-Lymphome (C84)
Sonstige und nicht näher bezeichnete
Typen des Non-Hodgkin-Lymphoms
(C85)
Bösartige immunproliferative Krankheiten
(C88)
Plasmozytom und bösartige
Plasmazellen-Neubildungen (C90)
Lymphatische Leukämie (C91)
Myeloische Leukämie (C92)
Monozytenleukämie (C93)
Sonstige Leukämien näher bezeichneten
Zelltyps (C94)
Leukämie nicht näher bezeichneten
Zelltyps (C95)
Sonstige und nicht näher bezeichnete
bösartige Neubildungen des
lymphatischen, blutbildenden und
verwandten Gewebes (C96)
Bösartige Neubildungen als
Primärtumoren an mehreren
Lokalisationen (C97)
Carcinoma in situ der Mundhöhle, des
Ösophagus und des Magens (D00)
Carcinoma in situ sonstiger und nicht
näher bezeichneter Verdauungsorgane
(D01)
Carcinoma in situ des Mittelohres und
des Atmungssystems (D02)
Melanoma in situ (D03)
Carcinoma in situ der Haut (D04)
Carcinoma in situ der Brustdrüse
[Mamma] (D05)
Carcinoma in situ der Cervix uteri (D06)
Carcinoma in situ sonstiger und nicht
näher bezeichneter Genitalorgane (D07)
Carcinoma in situ sonstiger und nicht
näher bezeichneter Lokalisationen (D09)
Gutartige Neubildung des Mundes und
des Pharynx (D10)
Gutartige Neubildung der großen
Speicheldrüsen (D11)
Gutartige Neubildung des Kolons, des
Rektums, des Analkanals und des Anus
(D12)
Gutartige Neubildung sonstiger und
ungenau bezeichneter Teile des
Verdauungssystems (D13)
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Gutartige Neubildung des Mittelohres
und des Atmungssystems (D14)
Gutartige Neubildung sonstiger und nicht
näher bezeichneter intrathorakaler
Organe (D15)
Gutartige Neubildung des Knochens und
des Gelenkknorpels (D16)
Gutartige Neubildung des Fettgewebes
(D17)
Hämangiom und Lymphangiom (D18)
Gutartige Neubildung des mesothelialen
Gewebes (D19)
Gutartige Neubildung des
Weichteilgewebes des Retroperitoneums
und des Peritoneums (D20)
Sonstige gutartige Neubildungen des
Bindegewebes und anderer
Weichteilgewebe (D21)
Melanozytennävus (D22)
Sonstige gutartige Neubildungen der
Haut (D23)
Gutartige Neubildung der Brustdrüse
[Mamma] (D24)
Leiomyom des Uterus (D25)
Sonstige gutartige Neubildungen des
Uterus (D26)
Gutartige Neubildung des Ovars (D27)
Gutartige Neubildung sonstiger und nicht
näher bezeichneter weiblicher
Genitalorgane (D28)
Gutartige Neubildung der männlichen
Genitalorgane (D29)
Gutartige Neubildung der Harnorgane
(D30)
Gutartige Neubildung des Auges und der
Augenanhangsgebilde (D31)
Gutartige Neubildung der Meningen
(D32)
Gutartige Neubildung des Gehirns und
anderer Teile des Zentralnervensystems
(D33)
Gutartige Neubildung der Schilddrüse
(D34)
Gutartige Neubildung sonstiger und nicht
näher bezeichneter endokriner Drüsen
(D35)
Gutartige Neubildung an sonstigen und
nicht näher bezeichneten Lokalisationen
(D36)
Neubildung unsicheren oder
unbekannten Verhaltens der Mundhöhle
und der Verdauungsorgane (D37)
Neubildung unsicheren oder
unbekannten Verhaltens des Mittelohres,
der Atmungsorgane und der
intrathorakalen Organe (D38)
Neubildung unsicheren oder
unbekannten Verhaltens der weiblichen
Genitalorgane (D39)
Neubildung unsicheren oder
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unbekannten Verhaltens der männlichen
Genitalorgane (D40)
Neubildung unsicheren oder
unbekannten Verhaltens der Harnorgane
(D41)
Neubildung unsicheren oder
unbekannten Verhaltens der Meningen
(D42)
Neubildung unsichereen oder
unbekannten Verhaltens des Gehirns
und des Zentralnervensystems (D43)
Neubildung unsicheren oder
unbekannten Verhaltens der endokrinen
Drüsen (D44)
Polycythaemia vera (D45)
Myelodysplastische Syndrome (D46)
Sonstige Neubildungen unsicheren oder
unbekannten Verhaltens des
lymphatischen, blutbildenden und
verwandten Gewebes (D47)
Neubildung unsicheren oder
unbekannten Verhaltens an sonstigen
und nicht näher bezeichneten
Lokalisationen (D48)
Eisenmangelanämie (D50)
Vitamin-B12-Mangelanämie (D51)
Folsäure-Mangelanämie (D52)
Sonstige alimentäre Anämien (D53)
Anämie durch Enzymdefekte (D55)
Thalassämie (D56)
Sichelzellenkrankheiten (D57)
Sonstige hereditäre hämolytische
Anämien (D58)
Erworbene hämolytische Anämien (D59)
Erworbene isolierte aplastische Anämie
[Erythroblastopenie] [pure red cell
aplasia] (D60)
Sonstige aplastische Anämien (D61)
Akute Blutungsanämie (D62)
Anämie bei chronischen, anderenorts
klassifizierten Krankheiten (D63)
Sonstige Anämien (D64)
Disseminierte intravasale Gerinnung
[Defibrinationssyndrom] (D65)
Hereditärer Faktor-VIII-Mangel (D66)
Hereditärer Faktor-IX-Mangel (D67)
Sonstige Koagulopathien (D68)
Purpura und sonstige hämorrhagische
Diathesen (D69)
Agranulozytose und Neutropenie (D70)
Funktionelle Störungen der neutrophilen
Granulozyten (D71)
Sonstige Krankheiten der Leukozyten
(D72)
Krankheiten der Milz (D73)
Methämoglobinämie (D74)
Sonstige Krankheiten des Blutes und der
blutbildenden Organe (D75)
Bestimmte Krankheiten mit Beteiligung
des lymphoretikulären Gewebes und des
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retikulohistiozytären Systems (D76)
Sonstige Krankheiten des Blutes und der
blutbildenden Organe bei anderenorts
klassifizierten Krankheiten (D77)
Immundefekt mit vorherrschendem
Antikörpermangel (D80)
Kombinierte Immundefekte (D81)
Immundefekt in Verbindung mit anderen
schweren Defekten (D82)
Variabler Immundefekt [common variable
immunodeficiency] (D83)
Sonstige Immundefekte (D84)
Sarkoidose (D86)
Sonstige Störungen mit Beteiligung des
Immunsystems, anderenorts nicht
klassifiziert (D89)
Angeborenes Jodmangelsyndrom (E00)
Jodmangelbedingte
Schilddrüsenkrankheiten und verwandte
Zustände (E01)
Subklinische Jodmangel-Hypothyreose
(E02)
Sonstige Hypothyreose (E03)
Sonstige nichttoxische Struma (E04)
Hyperthyreose [Thyreotoxikose] (E05)
Thyreoiditis (E06)
Sonstige Krankheiten der Schilddrüse
(E07)
Diabetes mellitus, Typ 1 (E10)
Diabetes mellitus, Typ 2 (E11)
Diabetes mellitus in Verbindung mit Fehl-
oder Mangelernährung [Malnutrition]
(E12)
Sonstiger näher bezeichneter Diabetes
mellitus (E13)
Nicht näher bezeichneter Diabetes
mellitus (E14)
Hypoglykämisches Koma,
nichtdiabetisch (E15)
Sonstige Störungen der inneren
Sekretion des Pankreas (E16)
Hypoparathyreoidismus (E20)
Hyperparathyreoidismus und sonstige
Krankheiten der Nebenschilddrüse (E21)
Überfunktion der Hypophyse (E22)
Unterfunktion und andere Störungen der
Hypophyse (E23)
Cushing-Syndrom (E24)
Adrenogenitale Störungen (E25)
Hyperaldosteronismus (E26)
Sonstige Krankheiten der Nebenniere
(E27)
Ovarielle Dysfunktion (E28)
Testikuläre Dysfunktion (E29)
Pubertätsstörungen, anderenorts nicht
klassifiziert (E30)
Polyglanduläre Dysfunktion (E31)
Krankheiten des Thymus (E32)
Sonstige endokrine Störungen (E34)
Störungen der endokrinen Drüsen bei
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anderenorts klassifizierten Krankheiten
(E35)
Kwashiorkor (E40)
Alimentärer Marasmus (E41)
Kwashiorkor-Marasmus (E42)
Nicht näher bezeichnete erhebliche
Energie- und Eiweißmangelernährung
(E43)
Energie- und Eiweißmangelernährung
mäßigen und leichten Grades (E44)
Entwicklungsverzögerung durch Energie-
und Eiweißmangelernährung (E45)
Nicht näher bezeichnete Energie- und
Eiweißmangelernährung (E46)
Vitamin-A-Mangel (E50)
Thiaminmangel [Vitamin-B1-Mangel]
(E51)
Niazinmangel [Pellagra] (E52)
Mangel an sonstigen Vitaminen des
Vitamin-B-Komplexes (E53)
Ascorbinsäuremangel (E54)
Vitamin-D-Mangel (E55)
Sonstige Vitaminmangelzustände (E56)
Alimentärer Kalziummangel (E58)
Alimentärer Selenmangel (E59)
Alimentärer Zinkmangel (E60)
Mangel an sonstigen Spurenelementen
(E61)
Sonstige alimentäre Mangelzustände
(E63)
Folgen von Mangelernährung oder
sonstigen alimentären Mangelzuständen
(E64)
Lokalisierte Adipositas (E65)
Adipositas (E66)
Sonstige Überernährung (E67)
Folgen der Überernährung (E68)
Störungen des Stoffwechsels
aromatischer Aminosäuren (E70)
Störungen des Stoffwechsels
verzweigter Aminosäuren und des
Fettsäurestoffwechsels (E71)
Sonstige Störungen des
Aminosäurestoffwechsels (E72)
Laktoseintoleranz (E73)
Sonstige Störungen des
Kohlenhydratstoffwechsels (E74)
Störungen des Sphingolipidstoffwechsels
und sonstige Störungen der
Lipidspeicherung (E75)
Störungen des Glykosaminoglykan-
Stoffwechsels (E76)
Störungen des
Glykoproteinstoffwechsels (E77)
Störungen des Lipoproteinstoffwechsels
und sonstige Lipidämien (E78)
Störungen des Purin- und
Pyrimidinstoffwechsels (E79)
Störungen des Porphyrin- und
Bilirubinstoffwechsels (E80)
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Störungen des Mineralstoffwechsels
(E83)
Zystische Fibrose (E84)
Amyloidose (E85)
Volumenmangel (E86)
Sonstige Störungen des Wasser- und
Elektrolythaushaltes sowie des Säure-
Basen-Gleichgewichts (E87)
Sonstige Stoffwechselstörungen (E88)
Endokrine und Stoffwechselstörungen
nach medizinischen Maßnahmen,
anderenorts nicht klassifiziert (E89)
Ernährungs- und Stoffwechselstörungen
bei anderenorts klassifizierten
Krankheiten (E90)
Demenz bei Alzheimer-Krankheit (F00)
Vaskuläre Demenz (F01)
Demenz bei anderenorts klassifizierten
Krankheiten (F02)
Nicht näher bezeichnete Demenz (F03)
Organisches amnestisches Syndrom,
nicht durch Alkohol oder andere
psychotrope Substanzen bedingt (F04)
Delir, nicht durch Alkohol oder andere
psychotrope Substanzen bedingt (F05)
Andere psychische Störungen aufgrund
einer Schädigung oder Funktionsstörung
des Gehirns oder einer körperlichen
Krankheit (F06)
Persönlichkeits- und Verhaltensstörung
aufgrund einer Krankheit, Schädigung
oder Funktionsstörung des Gehirns
(F07)
Nicht näher bezeichnete organische oder
symptomatische psychische Störung
(F09)
Psychische und Verhaltensstörungen
durch Alkohol (F10)
Psychische und Verhaltensstörungen
durch Opioide (F11)
Psychische und Verhaltensstörungen
durch Cannabinoide (F12)
Psychische und Verhaltensstörungen
durch Sedativa oder Hypnotika (F13)
Psychische und Verhaltensstörungen
durch Kokain (F14)
Psychische und Verhaltensstörungen
durch andere Stimulanzien,
einschließlich Koffein (F15)
Psychische und Verhaltensstörungen
durch Halluzinogene (F16)
Psychische und Verhaltensstörungen
durch Tabak (F17)
Psychische und Verhaltensstörungen
durch flüchtige Lösungsmittel (F18)
Psychische und Verhaltensstörungen
durch multiplen Substanzgebrauch und
Konsum anderer psychotroper
Substanzen (F19)
Schizophrenie (F20)
13 / 53
epSOS Illnesses and Disorders
Schizotype Störung (F21)
Anhaltende wahnhafte Störungen (F22)
Akute vorübergehende psychotische
Störungen (F23)
Induzierte wahnhafte Störung (F24)
Schizoaffektive Störungen (F25)
Sonstige nichtorganische psychotische
Störungen (F28)
Nicht näher bezeichnete nichtorganische
Psychose (F29)
Manische Episode (F30)
Bipolare affektive Störung (F31)
Depressive Episode (F32)
Rezidivierende depressive Störung (F33)
Anhaltende affektive Störungen (F34)
Andere affektive Störungen (F38)
Nicht näher bezeichnete affektive
Störung (F39)
Phobische Störungen (F40)
Andere Angststörungen (F41)
Zwangsstörung (F42)
Reaktionen auf schwere Belastungen
und Anpassungsstörungen (F43)
Dissoziative Störungen
[Konversionsstörungen] (F44)
Somatoforme Störungen (F45)
Andere neurotische Störungen (F48)
Essstörungen (F50)
Nichtorganische Schlafstörungen (F51)
Sexuelle Funktionsstörungen, nicht
verursacht durch eine organische
Störung oder Krankheit (F52)
Psychische oder Verhaltensstörungen im
Wochenbett, anderenorts nicht
klassifiziert (F53)
Psychologische Faktoren oder
Verhaltensfaktoren bei anderenorts
klassifizierten Krankheiten (F54)
Schädlicher Gebrauch von
nichtabhängigkeitserzeugenden
Substanzen (F55)
Nicht näher bezeichnete
Verhaltensauffälligkeiten bei körperlichen
Störungen und Faktoren (F59)
Spezifische Persönlichkeitsstörungen
(F60)
Kombinierte und andere
Persönlichkeitsstörungen (F61)
Andauernde Persönlichkeitsänderungen,
nicht Folge einer Schädigung oder
Krankheit des Gehirns (F62)
Abnorme Gewohnheiten und Störungen
der Impulskontrolle (F63)
Störungen der Geschlechtsidentität
(F64)
Störungen der Sexualpräferenz (F65)
Psychische und Verhaltensstörungen in
Verbindung mit der sexuellen
Entwicklung und Orientierung (F66)
Andere Persönlichkeits- und
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Verhaltensstörungen (F68)
Nicht näher bezeichnete Persönlichkeits-
und Verhaltensstörung (F69)
Leichte Intelligenzminderung (F70)
Mittelgradige Intelligenzminderung (F71)
Schwere Intelligenzminderung (F72)
Schwerste Intelligenzminderung (F73)
Andere Intelligenzminderung (F78)
Nicht näher bezeichnete
Intelligenzminderung (F79)
Umschriebene Entwicklungsstörungen
des Sprechens und der Sprache (F80)
Umschriebene Entwicklungsstörungen
schulischer Fertigkeiten (F81)
Umschriebene Entwicklungsstörung der
motorischen Funktionen (F82)
Kombinierte umschriebene
Entwicklungsstörungen (F83)
Tief greifende Entwicklungsstörungen
(F84)
Andere Entwicklungsstörungen (F88)
Nicht näher bezeichnete
Entwicklungsstörung (F89)
Hyperkinetische Störungen (F90)
Störungen des Sozialverhaltens (F91)
Kombinierte Störung des
Sozialverhaltens und der Emotionen
(F92)
Emotionale Störungen des Kindesalters
(F93)
Störungen sozialer Funktionen mit
Beginn in der Kindheit und Jugend (F94)
Ticstörungen (F95)
Andere Verhaltens- und emotionale
Störungen mit Beginn in der Kindheit und
Jugend (F98)
Psychische Störung ohne nähere
Angabe (F99)
Bakterielle Meningitis, anderenorts nicht
klassifiziert (G00)
Meningitis bei anderenorts klassifizierten
bakteriellen Krankheiten (G01)
Meningitis bei sonstigen anderenorts
klassifizierten infektiösen und
parasitären Krankheiten (G02)
Meningitis durch sonstige und nicht
näher bezeichnete Ursachen (G03)
Enzephalitis, Myelitis und
Enzephalomyelitis (G04)
Enzephalitis, Myelitis und
Enzephalomyelitis bei anderenorts
klassifizierten Krankheiten (G05)
Intrakranielle und intraspinale Abszesse
und Granulome (G06)
Intrakranielle und intraspinale Abszesse
und Granulome bei anderenorts
klassifizierten Krankheiten (G07)
Intrakranielle und intraspinale Phlebitis
und Thrombophlebitis (G08)
Folgen entzündlicher Krankheiten des
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Zentralnervensystems (G09)
Chorea Huntington (G10)
Hereditäre Ataxie (G11)
Spinale Muskelatrophie und verwandte
Syndrome (G12)
Systematrophien, vorwiegend das
Zentralnervensystem betreffend, bei
anderenorts klassifizierten Krankheiten
(G13)
Primäres Parkinson-Syndrom (G20)
Sekundäres Parkinson-Syndrom (G21)
Parkinson-Syndrom bei anderenorts
klassifizierten Krankheiten (G22)
Sonstige degenerative Krankheiten der
Basalganglien (G23)
Dystonie (G24)
Sonstige extrapyramidale Krankheiten
und Bewegungsstörungen (G25)
Extrapyramidale Krankheiten und
Bewegungsstörungen bei anderenorts
klassifizierten Krankheiten (G26)
Alzheimer-Krankheit (G30)
Sonstige degenerative Krankheiten des
Nervensystems, anderenorts nicht
klassifiziert (G31)
Sonstige degenerative Krankheiten des
Nervensystems bei anderenorts
klassifizierten Krankheiten (G32)
Multiple Sklerose [Encephalomyelitis
disseminata] (G35)
Sonstige akute disseminierte
Demyelinisation (G36)
Sonstige demyelinisierende Krankheiten
des Zentralnervensystems (G37)
Epilepsie (G40)
Status epilepticus (G41)
Migräne (G43)
Sonstige Kopfschmerzsyndrome (G44)
Zerebrale transitorische Ischämie und
verwandte Syndrome (G45)
Zerebrale Gefäßsyndrome bei
zerebrovaskulären Krankheiten (G46)
Schlafstörungen (G47)
Krankheiten des N. trigeminus [V.
Hirnnerv] (G50)
Krankheiten des N. facialis [VII. Hirnnerv]
(G51)
Krankheiten sonstiger Hirnnerven (G52)
Krankheiten der Hirnnerven bei
anderenorts klassifizierten Krankheiten
(G53)
Krankheiten von Nervenwurzeln und
Nervenplexus (G54)
Kompression von Nervenwurzeln und
Nervenplexus bei anderenorts
klassifizierten Krankheiten (G55)
Mononeuropathien der oberen Extremität
(G56)
Mononeuropathien der unteren
Extremität (G57)
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Sonstige Mononeuropathien (G58)
Mononeuropathie bei anderenorts
klassifizierten Krankheiten (G59)
Hereditäre und idiopathische
Neuropathie (G60)
Polyneuritis (G61)
Sonstige Polyneuropathien (G62)
Polyneuropathie bei anderenorts
klassifizierten Krankheiten (G63)
Sonstige Krankheiten des peripheren
Nervensystems (G64)
Myasthenia gravis und sonstige
neuromuskuläre Krankheiten (G70)
Primäre Myopathien (G71)
Sonstige Myopathien (G72)
Krankheiten im Bereich der
neuromuskulären Synapse und des
Muskels bei anderenorts klassifizierten
Krankheiten (G73)
Infantile Zerebralparese (G80)
Hemiparese und Hemiplegie (G81)
Paraparese und Paraplegie, Tetraparese
und Tetraplegie (G82)
Sonstige Lähmungssyndrome (G83)
Krankheiten des autonomen
Nervensystems (G90)
Hydrozephalus (G91)
Toxische Enzephalopathie (G92)
Sonstige Krankheiten des Gehirns (G93)
Sonstige Krankheiten des Gehirns bei
anderenorts klassifizierten Krankheiten
(G94)
Sonstige Krankheiten des
Rückenmarkes (G95)
Sonstige Krankheiten des
Zentralnervensystems (G96)
Krankheiten des Nervensystems nach
medizinischen Maßnahmen, anderenorts
nicht klassifiziert (G97)
Sonstige Krankheiten des
Nervensystems, anderenorts nicht
klassifiziert (G98)
Sonstige Krankheiten des
Nervensystems bei anderenorts
klassifizierten Krankheiten (G99)
Hordeolum und Chalazion (H00)
Sonstige Entzündung des Augenlides
(H01)
Sonstige Affektionen des Augenlides
(H02)
Affektionen des Augenlides bei
anderenorts klassifizierten Krankheiten
(H03)
Affektionen des Tränenapparates (H04)
Affektionen der Orbita (H05)
Affektionen des Tränenapparates und
der Orbita bei anderenorts klassifizierten
Krankheiten (H06)
Konjunktivitis (H10)
Sonstige Affektionen der Konjunktiva
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(H11)
Affektionen der Konjunktiva bei
anderenorts klassifizierten Krankheiten
(H13)
Affektionen der Sklera (H15)
Keratitis (H16)
Hornhautnarben und -trübungen (H17)
Sonstige Affektionen der Hornhaut (H18)
Affektionen der Sklera und der Hornhaut
bei anderenorts klassifizierten
Krankheiten (H19)
Iridozyklitis (H20)
Sonstige Affektionen der Iris und des
Ziliarkörpers (H21)
Affektionen der Iris und des Ziliarkörpers
bei anderenorts klassifizierten
Krankheiten (H22)
Cataracta senilis (H25)
Sonstige Kataraktformen (H26)
Sonstige Affektionen der Linse (H27)
Katarakt und sonstige Affektionen der
Linse bei anderenorts klassifizierten
Krankheiten (H28)
Chorioretinitis (H30)
Sonstige Affektionen der Aderhaut (H31)
Chorioretinale Affektionen bei
anderenorts klassifizierten Krankheiten
(H32)
Netzhautablösung und Netzhautriss
(H33)
Netzhautgefäßverschluss (H34)
Sonstige Affektionen der Netzhaut (H35)
Affektionen der Netzhaut bei anderenorts
klassifizierten Krankheiten (H36)
Glaukom (H40)
Glaukom bei anderenorts klassifizierten
Krankheiten (H42)
Affektionen des Glaskörpers (H43)
Affektionen des Augapfels (H44)
Affektionen des Glaskörpers und des
Augapfels bei anderenorts klassifizierten
Krankheiten (H45)
Neuritis nervi optici (H46)
Sonstige Affektionen des N. opticus [II.
Hirnnerv] und der Sehbahn (H47)
Affektionen des N. opticus [II. Hirnnerv]
und der Sehbahn bei anderenorts
klassifizierten Krankheiten (H48)
Strabismus paralyticus (H49)
Sonstiger Strabismus (H50)
Sonstige Störungen der
Blickbewegungen (H51)
Akkommodationsstörungen und
Refraktionsfehler (H52)
Sehstörungen (H53)
Blindheit und Sehbeeinträchtigung (H54)
Nystagmus und sonstige abnorme
Augenbewegungen (H55)
Sonstige Affektionen des Auges und der
Augenanhangsgebilde (H57)
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Sonstige Affektionen des Auges und der
Augenanhangsgebilde bei anderenorts
klassifizierten Krankheiten (H58)
Affektionen des Auges und der
Augenanhangsgebilde nach
medizinischen Maßnahmen, anderenorts
nicht klassifiziert (H59)
Otitis externa (H60)
Sonstige Krankheiten des äußeren
Ohres (H61)
Krankheiten des äußeren Ohres bei
anderenorts klassifizierten Krankheiten
(H62)
Nichteitrige Otitis media (H65)
Eitrige und nicht näher bezeichnete Otitis
media (H66)
Otitis media bei anderenorts
klassifizierten Krankheiten (H67)
Entzündung und Verschluss der Tuba
auditiva (H68)
Sonstige Krankheiten der Tuba auditiva
(H69)
Mastoiditis und verwandte Zustände
(H70)
Cholesteatom des Mittelohres (H71)
Trommelfellperforation (H72)
Sonstige Krankheiten des Trommelfells
(H73)
Sonstige Krankheiten des Mittelohres
und des Warzenfortsatzes (H74)
Sonstige Krankheiten des Mittelohres
und des Warzenfortsatzes bei
anderenorts klassifizierten Krankheiten
(H75)
Otosklerose (H80)
Störungen der Vestibularfunktion (H81)
Schwindelsyndrome bei annderenorts
klassifizierten Krankheiten (H82)
Sonstige Krankheiten des Innenohres
(H83)
Hörverlust durch Schallleitungs- oder
Schallempfindungsstörung (H90)
Sonstiger Hörverlust (H91)
Otalgie und Ohrenfluss (H92)
Sonstige Krankheiten des Ohres,
anderenorts nicht klassifiziert (H93)
Sonstige Krankheiten des Ohres bei
anderenorts klassifizierten Krankheiten
(H94)
Krankheiten des Ohres und des
Warzenfortsatzes nach medizinischen
Maßnahmen, anderenorts nicht
klassifiziert (H95)
Rheumatisches Fieber ohne Angabe
einer Herzbeteiligung (I00)
Rheumatisches Fieber mit
Herzbeteiligung (I01)
Rheumatische Chorea (I02)
Rheumatische Mitralklappenkrankheiten
(I05)
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Rheumatische
Aortenklappenkrankheiten (I06)
Rheumatische
Trikuspidalklappenkrankheiten (I07)
Krankheiten mehrerer Herzklappen (I08)
Sonstige rheumatische Herzkrankheiten
(I09)
Essentielle (primäre) Hypertonie (I10)
Hypertensive Herzkrankheit (I11)
Hypertensive Nierenkrankheit (I12)
Hypertensive Herz- und Nierenkrankheit
(I13)
Sekundäre Hypertonie (I15)
Angina pectoris (I20)
Akuter Myokardinfarkt (I21)
Rezidivierender Myokardinfarkt (I22)
Bestimmte akute Komplikationen nach
akutem Myokardinfarkt (I23)
Sonstige akute ischämische
Herzkrankheit (I24)
Chronische ischämische Herzkrankheit
(I25)
Lungenembolie (I26)
Sonstige pulmonale Herzkrankheiten
(I27)
Sonstige Krankheiten der Lungengefäße
(I28)
Akute Perikarditis (I30)
Sonstige Krankheiten des Perikards (I31)
Perikarditis bei anderenorts
klassifizierten Krankheiten (I32)
Akute und subakute Endokarditis (I33)
Nichtrheumatische
Mitralklappenkrankheiten (I34)
Nichtrheumatische
Aortenklappenkrankheiten (I35)
Nichtrheumatische
Trikuspidalklappenkrankheiten (I36)
Pulmonalklappenkrankheiten (I37)
Endokarditis, Herzklappe nicht näher
bezeichnet (I38)
Endokarditis und
Herzklappenkrankheiten bei anderenorts
klassifizierten Krankheiten (I39)
Akute Myokarditis (I40)
Myokarditis bei anderenorts
klassifizierten Krankheiten (I41)
Kardiomyopathie (I42)
Kardiomyopathie bei anderenorts
klassifizierten Krankheiten (I43)
Atrioventrikulärer Block und
Linksschenkelblock (I44)
Sonstige kardiale
Erregungsleitungsstörungen (I45)
Herzstillstand (I46)
Paroxysmale Tachykardie (I47)
Vorhofflimmern und Vorhofflattern (I48)
Sonstige kardiale Arrhythmien (I49)
Herzinsuffizienz (I50)
Komplikationen einer Herzkrankheit und
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ungenau beschriebene Herzkrankheit
(I51)
Sonstige Herzkrankheiten bei
anderenorts klassifizierten Krankheiten
(I52)
Subarachnoidalblutung (I60)
Intrazerebrale Blutung (I61)
Sonstige nichttraumatische intrakranielle
Blutung (I62)
Hirninfarkt (I63)
Schlaganfall, nicht als Blutung oder
Infarkt bezeichnet (I64)
Verschluss und Stenose präzerebraler
Arterien ohne resultierenden Hirninfarkt
(I65)
Verschluss und Stenose zerebraler
Arterien ohne resultierenden Hirninfarkt
(I66)
Sonstige zerebrovaskuläre Krankheiten
(I67)
Zerebrovaskuläre Störungen bei
anderenorts klassifizierten Krankheiten
(I68)
Folgen einer zerebrovaskulären
Krankheit (I69)
Atherosklerose (I70)
Aortenaneurysma und -dissektion (I71)
Sonstiges Aneurysma und sonstige
Dissektion (I72)
Sonstige periphere Gefäßkrankheiten
(I73)
Arterielle Embolie und Thrombose (I74)
Sonstige Krankheiten der Arterien und
Arteriolen (I77)
Krankheiten der Kapillaren (I78)
Krankheiten der Arterien, Arteriolen und
Kapillaren bei anderenorts klassifizierten
Krankheiten (I79)
Thrombose, Phlebitis und
Thrombophlebitis (I80)
Pfortaderthrombose (I81)
Sonstige venöse Embolie und
Thrombose (I82)
Varizen der unteren Extremitäten (I83)
Haemorrhoiden (I84)
Ösophagusvarizen (I85)
Varizen sonstiger Lokalisationen (I86)
Sonstige Venenkrankheiten (I87)
Unspezifische Lymphadenitis (I88)
Sonstige nichtinfektiöse Krankheiten der
Lymphgefäße und Lymphknoten (I89)
Hypotonie (I95)
Kreislaufkomplikationen nach
medizinischen Maßnahmen, anderenorts
nicht klassifiziert (I97)
Sonstige Störungen des
Kreislaufsystems bei anderenorts
klassifizierten Krankheiten (I98)
Sonstige und nicht näher bezeichnete
Krankheiten des Kreislaufsystems (I99)
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Akute Rhinopharyngitis
[Erkältungsschnupfen] (J00)
Akute Sinusitis (J01)
Akute Pharyngitis (J02)
Akute Tonsillitis (J03)
Akute Laryngitis und Tracheitis (J04)
Akute obstruktive Laryngitis [Krupp] und
Epiglottitis (J05)
Akute Infektionen an mehreren oder
nicht näher bezeichneten Lokalisationen
der oberen Atemwege (J06)
Grippe durch bestimmte nachgewiesene
Influenzaviren (J09)
Grippe durch sonstige nachgewiesene
Influenzaviren (J10)
Grippe, Viren nicht nachgewiesen (J11)
Viruspneumonie, anderenorts nicht
klassifiziert (J12)
Pneumonie durch Streptococcus
pneumoniae (J13)
Pneumonie durch Haemophilus
influenzae (J14)
Pneumonie durch sonstige
Infektionserreger, anderenorts nicht
klassifiziert (J16)
Pneumonie bei anderenorts
klassifizierten Krankheiten (J17)
Pneumonie, Erreger nicht näher
bezeichnet (J18)
Akute Bronchitis (J20)
Akute Bronchiolitis (J21)
Akute Infektion der unteren Atemwege,
nicht näher bezeichnet (J22)
Vasomotorische und allergische
Rhinopathie (J30)
Chronische Rhinitis, Rhinopharyngitis
und Pharyngitis (J31)
Chronische Sinusitis (J32)
Nasenpolyp (J33)
Sonstige Krankheiten der Nase und der
Nasennebenhöhlen (J34)
Chronische Krankheiten der
Gaumenmandeln und der
Rachenmandel (J35)
Peritonsillarabszess (J36)
Chronische Laryngitis und
Laryngotracheitis (J37)
Krankheiten der Stimmlippen und des
Kehlkopfes, anderenorts nicht
klassifiziert (J38)
Sonstige Krankheiten der oberen
Atemwege (J39)
Bronchitis, nicht als akut oder chronisch
bezeichnet (J40)
Einfache und schleimig-eitrige
chronische Bronchitis (J41)
Nicht näher bezeichnete chronische
Bronchitis (J42)
Emphysem (J43)
Sonstige chronische obstruktive
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Lungenkrankheit (J44)
Asthma bronchiale (J45)
Status asthmaticus (J46)
Bronchiektasen (J47)
Kohlenbergarbeiter-Pneumokoniose
(J60)
Pneumokoniose durch Asbest und
sonstige anorganische Fasern (J61)
Pneumokoniose durch Quarzstaub (J62)
Pneumokoniose durch sonstige
anorganische Stäube (J63)
Nicht näher bezeichnete Pneumokoniose
(J64)
Pneumokoniose in Verbindung mit
Tuberkulose (J65)
Krankheit der Atemwege durch
spezifischen organischen Staub (J66)
Allergische Alveolitis durch organischen
Staub (J67)
Krankheiten der Atmungsorgane durch
Einatmen von chemischen Substanzen,
Gasen, Rauch und Dämpfen (J68)
Pneumonie durch feste und flüssige
Substanzen (J69)
Krankheiten der Atmungsorgane durch
sonstige exogene Substanzen (J70)
Atemnotsyndrom des Erwachsenen
[ARDS] (J80)
Lungenödem (J81)
Eosinophiles Lungeninfiltrat, anderenorts
nicht klassifiziert (J82)
Sonstige interstitielle Lungenkrankheiten
(J84)
Abszess der Lunge und des
Mediastinums (J85)
Pyothorax (J86)
Pleuraerguss, anderenorts nicht
klassifiziert (J90)
Pleuraerguss bei anderenorts
klassifizierten Krankheiten (J91)
Pleuraplaques (J92)
Pneumothorax (J93)
Sonstige Krankheitszustände der Pleura
(J94)
Krankheiten der Atemwege nach
medizinischen Maßnahmen, anderenorts
nicht klassifiziert (J95)
Respiratorische Insuffizienz, anderenorts
nicht klassifiziert (J96)
Sonstige Krankheiten der Atemwege
(J98)
Krankheiten der Atemwege bei
anderenorts klassifizierten Krankheiten
(J99)
Störungen der Zahnentwicklung und des
Zahndurchbruchs (K00)
Retinierte und impaktierte Zähne (K01)
Zahnkaries (K02)
Sonstige Krankheiten der
Zahnhartsubstanzen (K03)
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Krankheiten der Pulpa und des
periapikalen Gewebes (K04)
Gingivitis und Krankheiten des
Parodonts (K05)
Sonstige Krankheiten der Gingiva und
des zahnlosen Alveolarkammes (K06)
Dentofaziale Anomalien [einschließlich
fehlerhafter Okklusion] (K07)
Sonstige Krankheiten der Zähne und des
Zahnhalteapparates (K08)
Zysten der Mundregion, anderenorts
nicht klassifiziert (K09)
Sonstige Krankheiten der Kiefer (K10)
Krankheiten der Speicheldrüsen (K11)
Stomatitis und verwandte Krankheiten
(K12)
Sonstige Krankheiten der Lippe und der
Mundschleimhaut (K13)
Krankheiten der Zunge (K14)
Ösophagitis (K20)
Gastroösophageale Refluxkrankheit
(K21)
Sonstige Krankheiten des Ösophagus
(K22)
Krankheiten des Ösophagus bei
anderenorts klassifizierten Krankheiten
(K23)
Ulcus ventriculi (K25)
Ulcus duodeni (K26)
Ulcus pepticum, Lokalisation nicht näher
bezeichnet (K27)
Ulcus pepticum jejuni (K28)
Gastritis und Duodenitis (K29)
Funktionelle Dyspepsie (K30)
Sonstige Krankheiten des Magens und
des Duodenums (K31)
Akute Appendizitis (K35)
Sonstige Appendizitis (K36)
Nicht näher bezeichnete Appendizitis
(K37)
Sonstige Krankheiten der Appendix
(K38)
Hernia inguinalis (K40)
Hernia femoralis (K41)
Hernia umbilicalis (K42)
Hernia ventralis (K43)
Hernia diaphragmatica (K44)
Sonstige abdominale Hernien (K45)
Nicht näher bezeichnete abdominale
Hernie (K46)
Crohn-Krankheit [Enteritis regionalis]
[Morbus Crohn] (K50)
Colitis ulcerosa (K51)
Sonstige nichtinfektiöse Gastroenteritis
und Kolitis (K52)
Gefäßkrankheiten des Darmes (K55)
Paralytischer Ileus und intestinale
Obstruktion ohne Hernie (K56)
Divertikulose des Darmes (K57)
Reizdarmsyndrom (K58)
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Sonstige funktionelle Darmstörungen
(K59)
Fissur und Fistel in der Anal- und
Rektalregion (K60)
Abszess in der Anal- und Rektalregion
(K61)
Sonstige Krankheiten des Anus und des
Rektums (K62)
Sonstige Krankheiten des Darmes (K63)
Peritonitis (K65)
Sonstige Krankheiten des Peritoneums
(K66)
Krankheiten des Peritoneums bei
anderenorts klassifizierten
Infektionskrankheiten (K67)
Alkoholische Leberkrankheit (K70)
Toxische Leberkrankheit (K71)
Chronische Hepatitis, anderenorts nicht
klassifiziert (K73)
Fibrose und Zirrhose der Leber (K74)
Sonstige entzündliche Leberkrankheiten
(K75)
Sonstige Krankheiten der Leber (K76)
Leberkrankheiten bei anderenorts
klassifizierten Krankheiten (K77)
Cholelithiasis (K80)
Cholezystitis (K81)
Sonstige Krankheiten der Gallenblase
(K82)
Sonstige Krankheiten der Gallenwege
(K83)
Akute Pankreatitis (K85)
Sonstige Krankheiten des Pankreas
(K86)
Krankheiten der Gallenblase, der
Gallenwege und des Pankreas bei
anderenorts klassifizierten Krankheiten
(K87)
Intestinale Malabsorption (K90)
Krankheiten des Verdauungssystems
nach medizinischen Maßnahmen,
anderenorts nicht klassifiziert (K91)
Sonstige Krankheiten des
Verdauungssystems (K92)
Krankheiten sonstiger
Verdauungsorgane bei anderenorts
klassifizierten Krankheiten (K93)
Staphylococcal scalded skin syndrome
[SSS-Syndrom] (L00)
Impetigo (L01)
Hautabszess, Furunkel und Karbunkel
(L02)
Phlegmone (L03)
Akute Lymphadenitis (L04)
Pilonidalzyste (L05)
Sonstige lokale Infektionen der Haut und
der Unterhaut (L08)
Pemphiguskrankheiten (L10)
Sonstige akantholytische Dermatosen
(L11)
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Pemphigoidkrankheiten (L12)
Sonstige bullöse Dermatosen (L13)
Bullöse Dermatosen bei anderenorts
klassifizierten Krankheiten (L14)
Atopisches [endogenes] Ekzem (L20)
Seborrhoisches Ekzem (L21)
Windeldermatitis (L22)
Allergische Kontaktdermatitis (L23)
Toxische Kontaktdermatitis (L24)
Nicht näher bezeichnete
Kontaktdermatitis (L25)
Exfoliative Dermatitis (L26)
Dermatitis durch oral, enteral oder
parenteral aufgenommene Substanzen
(L27)
Lichen simplex chronicus und Prurigo
(L28)
Pruritus (L29)
Sonstige Dermatitis (L30)
Psoriasis (L40)
Parapsoriasis (L41)
Pityriasis rosea (L42)
Lichen ruber planus (L43)
Sonstige papulosquamöse
Hautkrankheiten (L44)
Papulosquamöse Hautkrankheiten bei
anderenorts klassifizierten Krankheiten
(L45)
Urtikaria (L50)
Erythema exsudativum multiforme (L51)
Erythema nodosum (L52)
Sonstige erythematöse Krankheiten
(L53)
Erythem bei anderenorts klassifizierten
Krankheiten (L54)
Dermatitis solaris acuta (L55)
Sonstige akute Hautveränderungen
durch Ultraviolettstrahlen (L56)
Hautveränderungen durch chronische
Exposition gegenüber nichtionisierender
Strahlung (L57)
Radiodermatitis (L58)
Sonstige Krankheiten der Haut und der
Unterhaut durch Strahleneinwirkung
(L59)
Krankheiten der Nägel (L60)
Krankheiten der Nägel bei anderenorts
klassifizierten Krankheiten (L62)
Alopecia areata (L63)
Alopecia androgenetica (L64)
Sonstiger Haarausfall ohne
Narbenbildung (L65)
Narbige Alopezie [Haarausfall mit
Narbenbildung] (L66)
Anomalien der Haarfarbe und des
Haarschaftes (L67)
Hypertrichose (L68)
Akne (L70)
Rosazea (L71)
Follikuläre Zysten der Haut und der
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Unterhaut (L72)
Sonstige Krankheiten der Haarfollikel
(L73)
Krankheiten der ekkrinen
Schweißdrüsen (L74)
Krankheiten der apokrinen
Schweißdrüsen (L75)
Vitiligo (L80)
Sonstige Störungen der
Hautpigmentierung (L81)
Seborrhoische Keratose (L82)
Acanthosis nigricans (L83)
Hühneraugen und Horn- (Haut-)
Schwielen (L84)
Sonstige Epidermisverdickung (L85)
Keratom bei anderenorts klassifizierten
Krankheiten (L86)
Störungen der transepidermalen
Elimination (L87)
Pyoderma gangraenosum (L88)
Dekubitalgeschwür und Druckzone (L89)
Atrophische Hautkrankheiten (L90)
Hypertrophe Hautkrankheiten (L91)
Granulomatöse Krankheiten der Haut
und der Unterhaut (L92)
Lupus erythematodes (L93)
Sonstige lokalisierte Krankheiten des
Bindegewebes (L94)
Anderenorts nicht klassifizierte
Vaskulitis, die auf die Haut begrenzt ist
(L95)
Ulcus cruris, anderenorts nicht
klassifiziert (L97)
Sonstige Krankheiten der Haut und der
Unterhaut, anderenorts nicht klassifiziert
(L98)
Sonstige Krankheiten der Haut und der
Unterhaut bei anderenorts klassifizierten
Krankheiten (L99)
Eitrige Arthritis (M00)
Direkte Gelenkinfektionen bei
anderenorts klassifizierten infektiösen
und parasitären Krankheiten (M01)
Reaktive Arthritiden (M02)
Postinfektiöse und reaktive Arthritiden
bei anderenorts klassifizierten
Krankheiten (M03)
Seropositive chronische Polyarthritis
(M05)
Sonstige chronische Polyarthritis (M06)
Arthritis psoriatica und Arthritiden bei
gastrointestinalen Grundkrankheiten
(M07)
Juvenile Arthritis (M08)
Juvenile Arthritis bei anderenorts
klassifizierten Krankheiten (M09)
Gicht (M10)
Sonstige Kristall-Arthropathien (M11)
Sonstige näher bezeichnete
Arthropathien (M12)
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Sonstige Arthritis (M13)
Arthropathien bei sonstigen anderenorts
klassifizierten Krankheiten (M14)
Polyarthrose (M15)
Koxarthrose [Arthrose des Hüftgelenkes]
(M16)
Gonarthrose [Arthrose des
Kniegelenkes] (M17)
Rhizarthrose [Arthrose des
Daumensattelgelenkes] (M18)
Sonstige Arthrose (M19)
Erworbene Deformitäten der Finger und
Zehen (M20)
Sonstige erworbene Deformitäten der
Extremitäten (M21)
Krankheiten der Patella (M22)
Binnenschädigung des Kniegelenkes
[internal derangement] (M23)
Sonstige näher bezeichnete
Gelenkschädigungen (M24)
Sonstige Gelenkkrankheiten,
anderenorts nicht klassifiziert (M25)
Panarteriitis nodosa und verwandte
Zustände (M30)
Sonstige nekrotisierende Vaskulopathien
(M31)
Systemischer Lupus erythematodes
(M32)
Dermatomyositis-Polymyositis (M33)
Systemische Sklerose (M34)
Sonstige Krankheiten mit
Systembeteiligung des Bindegewebes
(M35)
Systemkrankheiten des Bindegewebes
bei anderenorts klassifizierten
Krankheiten (M36)
Kyphose und Lordose (M40)
Skoliose (M41)
Osteochondrose der Wirbelsäule (M42)
Sonstige Deformitäten der Wirbelsäule
und des Rückens (M43)
Spondylitis ankylosans (M45)
Sonstige entzündliche Spondylopathien
(M46)
Spondylose (M47)
Sonstige Spondylopathien (M48)
Spondylopathien bei anderenorts
klassifizierten Krankheiten (M49)
Zervikale Bandscheibenschäden (M50)
Sonstige Bandscheibenschäden (M51)
Sonstige Krankheiten der Wirbelsäule
und des Rückens, anderenorts nicht
klassifiziert (M53)
Rückenschmerzen (M54)
Myositis (M60)
Kalzifikation und Ossifikation von
Muskeln (M61)
Sonstige Muskelkrankheiten (M62)
Muskelkrankheiten bei anderenorts
klassifizierten Krankheiten (M63)
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Synovitis und Tenosynovitis (M65)
Spontanruptur der Synovialis und von
Sehnen (M66)
Sonstige Krankheiten der Synovialis und
der Sehnen (M67)
Krankheiten der Synovialis und der
Sehnen bei anderenorts klassifizierten
Krankheiten (M68)
Krankheiten des Weichteilgewebes im
Zusammenhang mit Beanspruchung,
Überbeanspruchung und Druck (M70)
Sonstige Bursopathien (M71)
Fibromatosen (M72)
Krankheiten des Weichteilgewebes bei
anderenorts klassifizierten Krankheiten
(M73)
Schulterläsionen (M75)
Enthesopathien der unteren Extremität
mit Ausnahme des Fußes (M76)
Sonstige Enthesopathien (M77)
Sonstige Krankheiten des
Weichteilgewebes, anderenorts nicht
klassifiziert (M79)
Osteoporose mit pathologischer Fraktur
(M80)
Osteoporose ohne pathologische Fraktur
(M81)
Osteoporose bei anderenorts
klassifizierten Krankheiten (M82)
Osteomalazie im Erwachsenenalter
(M83)
Veränderungen der Knochenkontinuität
(M84)
Sonstige Veränderungen der
Knochendichte und -struktur (M85)
Osteomyelitis (M86)
Knochennekrose (M87)
Osteodystrophia deformans [Paget-
Krankheit] (M88)
Sonstige Knochenkrankheiten (M89)
Osteopathien bei anderenorts
klassifizierten Krankheiten (M90)
Juvenile Osteochondrose der Hüfte und
des Beckens (M91)
Sonstige juvenile Osteochondrosen
(M92)
Sonstige Osteochondropathien (M93)
Sonstige Knorpelkrankheiten (M94)
Sonstige erworbene DDeformitäten des
Muskel-Skelett-Systems und des
Bindegewebes (M95)
Krankheiten des Muskel-Skelett-Systems
nach medizinischen Maßnahmen,
anderenorts nicht klassifiziert (M96)
Biomechanische Funktionsstörungen,
anderenorts nicht klassifiziert (M99)
Akutes nephritisches Syndrom (N00)
Rapid-progressives nephritisches
Syndrom (N01)
Rezidivierende und persistierende
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Hämaturie (N02)
Chronisches nephritisches Syndrom
(N03)
Nephrotisches Syndrom (N04)
Nicht näher bezeichnetes nephritisches
Syndrom (N05)
Isolierte Proteinurie mit Angabe
morphologischer Veränderungen (N06)
Hereditäre Nephropathie, anderenorts
nicht klassifiziert (N07)
Glomeruläre Krankheiten bei
anderenorts klassifizierten Krankheiten
(N08)
Akute tubulointerstitielle Nephritis (N10)
Chronische tubulointerstitielle Nephritis
(N11)
Tubulointerstitielle Nephritis, nicht als
akut oder chronisch bezeichnet (N12)
Obstruktive Uropathie und
Refluxuropathie (N13)
Arzneimittel- und schwermetallinduzierte
tubulointerstitielle und tubuläre
Krankheitszustände (N14)
Sonstige tubulointerstitielle
Nierenkrankheiten (N15)
Tubulointerstitielle Nierenkrankheiten bei
anderenorts klassifizierten Krankheiten
(N16)
Akutes Nierenversagen (N17)
Chronische Nierenkrankheit (N18)
Nicht näher bezeichnete
Niereninsuffizienz (N19)
Nieren- und Ureterstein (N20)
Stein in den unteren Harnwegen (N21)
Harnstein bei anderenorts klassifizierten
Krankheiten (N22)
Nicht näher bezeichnete Nierenkolik
(N23)
Krankheiten infolge Schädigung der
tubulären Nierenfunktion (N25)
Schrumpfniere, nicht näher bezeichnet
(N26)
Kleine Niere unbekannter Ursache (N27)
Sonstige Krankheiten der Niere und des
Ureters, anderenorts nicht klassifiziert
(N28)
Sonstige Krankheiten der Niere und des
Ureters bei anderenorts klassifizierten
Krankheiten (N29)
Zystitis (N30)
Neuromuskuläre Dysfunktion der
Harnblase, anderenorts nicht klassifiziert
(N31)
Sonstige Krankheiten der Harnblase
(N32)
Krankheiten der Harnblase bei
anderenorts klassifizierten Krankheiten
(N33)
Urethritis und urethrales Syndrom (N34)
Harnröhrenstriktur (N35)
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Sonstige Krankheiten der Harnröhre
(N36)
Krankheiten der Harnröhre bei
anderenorts klassifizierten Krankheiten
(N37)
Sonstige Krankheiten des Harnsystems
(N39)
Prostatahyperplasie (N40)
Entzündliche Krankheiten der Prostata
(N41)
Sonstige Krankheiten der Prostata (N42)
Hydrozele und Spermatozele (N43)
Hodentorsion und Hydatidentorsion
(N44)
Orchitis und Epididymitis (N45)
Sterilität beim Mann (N46)
Vorhauthypertrophie, Phimose und
Paraphimose (N47)
Sonstige Krankheiten des Penis (N48)
Entzündliche Krankheiten der
männlichen Genitalorgane, anderenorts
nicht klassifiziert (N49)
Sonstige Krankheiten der männlichen
Genitalorgane (N50)
Krankheiten der männlichen
Genitalorgane bei anderenorts
klassifizierten Krankheiten (N51)
Gutartige Mammadysplasie
[Brustdrüsendysplasie] (N60)
Entzündliche Krankheiten der Mamma
[Brustdrüse] (N61)
Hypertrophie der Mamma [Brustdrüse]
(N62)
Nicht näher bezeichnete Knoten in der
Mamma [Brustdrüse] (N63)
Sonstige Krankheiten der Mamma
[Brustdrüse] (N64)
Salpingitis und Oophoritis (N70)
Entzündliche Krankheit des Uterus,
ausgenommen der Zervix (N71)
Entzündliche Krankheit der Cervix uteri
(N72)
Sonstige entzündliche Krankheiten im
weiblichen Becken (N73)
Entzündung im weiblichen Becken bei
anderenorts klassifizierten Krankheiten
(N74)
Krankheiten der Bartholin-Drüsen (N75)
Sonstige entzündliche Krankheit der
Vagina und Vulva (N76)
Vulvovaginale Ulzeration und
Entzündung bei anderenorts
klassifizierten Krankheiten (N77)
Endometriose (N80)
Genitalprolaps bei der Frau (N81)
Fisteln mit Beteiligung des weiblichen
Genitaltraktes (N82)
Nichtentzündliche Krankheiten des
Ovars, der Tuba uterina und des Lig.
latum uteri (N83)
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Polyp des weiblichen Genitaltraktes
(N84)
Sonstige nichtentzündliche Krankheiten
des Uterus, ausgenommen der Zervix
(N85)
Erosion und Ektropium der Cervix uteri
(N86)
Dysplasie der Cervix uteri (N87)
Sonstige nichtentzündliche Krankheiten
der Cervix uteri (N88)
Sonstige nichtentzündliche Krankheiten
der Vagina (N89)
Sonstige nichtentzündliche Krankheiten
der Vulva und des Perineums (N90)
Ausgebliebene, zu schwache oder zu
seltene Menstruation (N91)
Zu starke, zu häufige oder
unregelmäßige Menstruation (N92)
Sonstige abnorme Uterus- oder
Vaginalblutung (N93)
Schmerz und andere Zustände im
Zusammenhang mit den weiblichen
Genitalorganen und dem
Menstruationszyklus (N94)
Klimakterische Störungen (N95)
Neigung zu habituellem Abort (N96)
Sterilität der Frau (N97)
Komplikationen im Zusammenhang mit
künstlicher Befruchtung (N98)
Krankheiten des Urogenitalsystems nach
medizinischen Maßnahmen, anderenorts
nicht klassifiziert (N99)
Extrauteringravidität (O00)
Blasenmole (O01)
Sonstige abnorme Konzeptionsprodukte
(O02)
Spontanabort (O03)
Ärztlich eingeleiteter Abort (O04)
Sonstiger Abort (O05)
Nicht näher bezeichneter Abort (O06)
Misslungene Aborteinleitung (O07)
Komplikationen nach Abort,
Extrauteringravidität und
Molenschwangerschaft (O08)
Vorher bestehende Hypertonie, die
Schwangerschaft, Geburt und
Wochenbett kompliziert (O10)
Vorher bestehende chronische
Hypertonie mit aufgepfropfter
Präeklampsie, die Schwangerschaft,
Geburt und Wochenbett kompliziert
(O11)
Gestationsödeme und
Gestationsproteinurie
[schwangerschaftsinduziert] ohne
Hypertonie (O12)
Gestationshypertonie
[schwangerschaftsinduzierte Hypertonie]
(O13)
Präeklampsie (O14)
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Eklampsie (O15)
Nicht näher bezeichnete Hypertonie der
Mutter (O16)
Blutung in der Frühschwangerschaft
(O20)
Übermäßiges Erbrechen während der
Schwangerschaft (O21)
Venenkrankheiten und Hämorrhoiden als
Komplikationen in der Schwangerschaft
(O22)
Infektionen des Urogenitaltraktes in der
Schwangerschaft (O23)
Diabetes mellitus in der
Schwangerschaft (O24)
Fehl- und Mangelernährung in der
Schwangerschaft (O25)
Betreuung der Mutter bei sonstigen
Zuständen, die vorwiegend mit der
Schwangerschaft verbunden sind (O26)
Abnorme Befunde bei der
Screeninguntersuchung der Mutter zur
pränatalen Diagnostik (O28)
Komplikationen bei Anästhesie in der
Schwangerschaft (O29)
Mehrlingsschwangerschaft (O30)
Komplikationen, die für eine
Mehrlingsschwangerschaft spezifisch
sind (O31)
Betreuung der Mutter bei festgestellter
oder vermuteter Lage- und
Einstellungsanomalie des Feten (O32)
Betreuung der Mutter bei festgestelltem
oder vermutetem Missverhältnis
zwischen Fetus und Becken (O33)
Betreuung der Mutter bei festgestellter
oder vermuteter Anomalie der
Beckenorgane (O34)
Betreuung der Mutter bei festgestellter
oder vermuteter Anomalie oder
Schädigung des Feten (O35)
Betreuung der Mutter wegen sonstiger
festgestellter oder vermuteter
Komplikationen beim Feten (O36)
Polyhydramnion (O40)
Sonstige Veränderungen des
Fruchtwassers und der Eihäute (O41)
Vorzeitiger Blasensprung (O42)
Pathologische Zustände der Plazenta
(O43)
Placenta praevia (O44)
Vorzeitige Plazentalösung [Abruptio
placentae] (O45)
Präpartale Blutung, anderenorts nicht
klassifiziert (O46)
Frustrane Kontraktionen [Unnütze
Wehen] (O47)
Übertragene Schwangerschaft (O48)
Vorzeitige Wehen und Entbindung (O60)
Misslungene Geburtseinleitung (O61)
Abnorme Wehentätigkeit (O62)
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Protrahierte Geburt (O63)
Geburtshindernis durch Lage-, Haltungs-
und Einstellungsanomalien des Feten
(O64)
Geburtshindernis durch Anomalie des
mütterlichen Beckens (O65)
Sonstiges Geburtshindernis (O66)
Komplikationen bei Wehen und
Entbindung durch intrapartale Blutung,
anderenorts nicht klassifiziert (O67)
Komplikationen bei Wehen und
Entbindung durch fetalen Distress [fetal
distress] [fetaler Gefahrenzustand] (O68)
Komplikationen bei Wehen und
Entbindung durch
Nabelschnurkomplikationen (O69)
Dammriss unter der Geburt (O70)
Sonstige Verletzungen unter der Geburt
(O71)
Postpartale Blutung (O72)
Retention der Plazenta und der Eihäute
ohne Blutung (O73)
Komplikationen bei Anästhesie während
der Wehentätigkeit und bei der
Entbindung (O74)
Sonstige Komplikationen bei
Wehentätigkeit und Entbindung,
anderenorts nicht klassifiziert (O75)
Spontangeburt eines Einlings (O80)
Geburt eines Einlings durch Zangen-
oder Vakuumextraktion (O81)
Geburt eines Einlings durch
Schnittentbindung [Sectio caesarea]
(O82)
Puerperalfieber (O85)
Sonstige Wochenbettinfektionen (O86)
Venenkrankheiten und Hämorrhoiden als
Komplikationen im Wochenbett (O87)
Embolie während der Gestationsperiode
(O88)
Komplikationen bei Anästhesie im
Wochenbett (O89)
Wochenbettkomplikationen, anderenorts
nicht klassifiziert (O90)
Infektionen der Mamma [Brustdrüse] im
Zusammenhang mit der Gestation (O91)
Sonstige Krankheiten der Mamma
[Brustdrüse] im Zusammenhang mit der
Gestation und Laktationsstörungen
(O92)
Folgen von Komplikationen während
Schwangerschaft, Geburt und
Wochenbett (O94)
Sterbefall während der
Gestationsperiode nicht näher
bezeichneter Ursache (O95)
Tod infolge jeder gestationsbedingten
Ursache nach mehr als 42 Tagen bis
unter einem Jahr nach der Entbindung
(O96)
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Tod an den Folgen gestationsbedingter
Ursachen (O97)
Infektiöse und parasitäre Krankheiten der
Mutter, die anderenorts klassifizierbar
sind, die jedoch Schwangerschaft,
Geburt und Wochenbett komplizieren
(O98)
Sonstige Krankheiten der Mutter, die
anderenorts klassifizierbar sind, die
jedoch Schwangerschaft, Geburt und
Wochenbett komplizieren (O99)
Schädigung des Feten und
Neugeborenen durch Zustände der
Mutter, die zur vorliegenden
Schwangerschaft keine Beziehung
haben müssen (P00)
Schädigung des Feten und
Neugeborenen durch mütterliche
Schwangerschaftskomplikationen (P01)
Schädigung des Feten und
Neugeborenen durch Komplikationen
von Plazenta, Nabelschnur und Eihäuten
(P02)
Schädigung des Feten und
Neugeborenen durch sonstige
Komplikationen bei Wehen und
Entbindung (P03)
Schädigung des Feten und
Neugeborenen durch Noxen, die
transplazentar oder mit der Muttermilch
übertragen werden (P04)
Intrauterine Mangelentwicklung und
fetale Mangelernährung (P05)
Störungen im Zusammenhang mit kurzer
Schwangerschaftsdauer und niedrigem
Geburtsgewicht, anderenorts nicht
klassifiziert (P07)
Störungen im Zusammenhang mit langer
Schwangerschaftsdauer und hohem
Geburtsgewicht (P08)
Intrakranielle Verletzung und Blutung
durch Geburtsverletzung (P10)
Sonstige Geburtsverletzungen des
Zentralnervensystems (P11)
Geburtsverletzung der behaarten
Kopfhaut (P12)
Geburtsverletzung des Skeletts (P13)
Geburtsverletzung des peripheren
Nervensystems (P14)
Sonstige Geburtsverletzungen (P15)
Intrauterine Hypoxie (P20)
Asphyxie unter der Geburt (P21)
Atemnot [Respiratory distress] beim
Neugeborenen (P22)
Angeborene Pneumonie (P23)
Aspirationssyndrome beim
Neugeborenen (P24)
Interstitielles Emphysem und verwandte
Zustände mit Ursprung in der
Perinatalperiode (P25)
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Lungenblutung mit Ursprung in der
Perinatalperiode (P26)
Chronische Atemwegskrankheit mit
Ursprung in der Perinatalperiode (P27)
Sonstige Störungen der Atmung mit
Ursprung in der Perinatalperiode (P28)
Kardiovaskuläre Krankheiten mit
Ursprung in der Perinatalperiode (P29)
Angeborene Viruskrankheiten (P35)
Bakterielle Sepsis beim Neugeborenen
(P36)
Sonstige angeborene infektiöse und
parasitäre Krankheiten (P37)
Omphalitis beim Neugeborenen mit oder
ohne leichte Blutung (P38)
Sonstige Infektionen, die für die
Perinatalperiode spezifisch sind (P39)
Fetaler Blutverlust (P50)
Nabelblutung beim Neugeborenen (P51)
Intrakranielle nichttraumatische Blutung
beim Feten und Neugeborenen (P52)
Hämorrhagische Krankheit beim Feten
und Neugeborenen (P53)
Sonstige Blutungen beim Neugeborenen
(P54)
Hämolytische Krankheit beim Feten und
Neugeborenen (P55)
Hydrops fetalis durch hämolytische
Krankheit (P56)
Kernikterus (P57)
Neugeborenenikterus durch sonstige
gesteigerte Hämolyse (P58)
Neugeborenenikterus durch sonstige
und nicht näher bezeichnete Ursachen
(P59)
Disseminierte intravasale Gerinnung
beim Feten und Neugeborenen (P60)
Sonstige hämatologische Krankheiten in
der Perinatalperiode (P61)
Transitorische Störungen des
Kohlenhydratstoffwechsels, die für den
Feten und das Neugeborene spezifisch
sind (P70)
Transitorische Störungen des Kalzium-
und Magnesiumstoffwechsels beim
Neugeborenen (P71)
Sonstige transitorische endokrine
Krankheiten beim Neugeborenen (P72)
Sonstige transitorische Störungen des
Elektrolythaushaltes und des
Stoffwechsels beim Neugeborenen (P74)
Mekoniumileus bei zystischer Fibrose
(P75)
Sonstiger Darmverschluss beim
Neugeborenen (P76)
Enterocolitis necroticans beim Feten und
Neugeborenen (P77)
Sonstige Krankheiten des
Verdauungssystems in der
Perinatalperiode (P78)
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Hypothermie beim Neugeborenen (P80)
Sonstige Störungen der
Temperaturregulation beim
Neugeborenen (P81)
Sonstige Krankheitszustände mit
Beteiligung der Haut, die für den Feten
und das Neugeborene spezifisch sind
(P83)
Krämpfe beim Neugeborenen (P90)
Sonstige zerebrale Störungen beim
Neugeborenen (P91)
Ernährungsprobleme beim
Neugeborenen (P92)
Reaktionen und Intoxikationen durch
Arzneimittel oder Drogen, die dem Feten
und Neugeborenen verabreicht wurden
(P93)
Störungen des Muskeltonus beim
Neugeborenen (P94)
Fetaltod nicht näher bezeichneter
Ursache (P95)
Sonstige Zustände, die ihren Ursprung in
der Perinatalperiode haben (P96)
Anenzephalie und ähnliche
Fehlbildungen (Q00)
Enzephalozele (Q01)
Mikrozephalie (Q02)
Angeborener Hydrozephalus (Q03)
Sonstige angeborene Fehlbildungen des
Gehirns (Q04)
Spina bifida (Q05)
Sonstige angeborene Fehlbildungen des
Rückenmarks (Q06)
Sonstige angeborene Fehlbildungen des
Nervensystems (Q07)
Angeborene Fehlbildungen des
Augenlides, des Tränenapparates und
der Orbita (Q10)
Anophthalmus, Mikrophthalmus und
Makrophthalmus (Q11)
Angeborene Fehlbildungen der Linse
(Q12)
Angeborene Fehlbildungen des vorderen
Augenabschnittes (Q13)
Angeborene Fehlbildung des hinteren
Augenabschnittes (Q14)
Sonstige angeborene Fehlbildungen des
Auges (Q15)
Angeborene Fehlbildungen des Ohres,
die eine Beeinträchtigung des
Hörvermögens verursachen (Q16)
Sonstige angeborene Fehlbildungen des
Ohres (Q17)
Sonstige angeborene Fehlbildungen des
Gesichtes und des Halses (Q18)
Angeborene Fehlbildungen der
Herzhöhlen und verbindender Strukturen
(Q20)
Angeborene Fehlbildungen der
Herzsepten (Q21)
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Angeborene Fehlbildungen der
Pulmonal- und der Trikuspidalklappe
(Q22)
Angeborene Fehlbildungen der Aorten-
und der Mitralklappe (Q23)
Sonstige angeborene Fehlbildungen des
Herzens (Q24)
Angeborene Fehlbildungen der großen
Arterien (Q25)
Angeborene Fehlbildungen der großen
Venen (Q26)
Sonstige angeborene Fehlbildungen des
peripheren Gefäßsystems (Q27)
Sonstige angeborene Fehlbildungen des
Kreislaufsystems (Q28)
Angeborene Fehlbildungen der Nase
(Q30)
Angeborene Fehlbildungen des
Kehlkopfes (Q31)
Angeborene Fehlbildungen der Trachea
und der Bronchien (Q32)
Angeborene Fehlbildungen der Lunge
(Q33)
Sonstige angeborene Fehlbildungen des
Atmungssystems (Q34)
Gaumenspalte (Q35)
Lippenspalte (Q36)
Gaumenspalte mit Lippenspalte (Q37)
Sonstige angeborene Fehlbildungen der
Zunge, des Mundes und des Rachens
(Q38)
Angeborene Fehlbildungen des
Ösophagus (Q39)
Sonstige angeborene Fehlbildungen des
oberen Verdauungstraktes (Q40)
Angeborene(s) Fehlen, Atresie und
Stenose des Dünndarmes (Q41)
Angeborene(s) Fehlen, Atresie und
Stenose des Dickdarmes (Q42)
Sonstige angeborene Fehlbildungen des
Darmes (Q43)
Angeborene Fehlbildungen der
Gallenblase, der Gallengänge und der
Leber (Q44)
Sonstige angeborene Fehlbildungen des
Verdauungssystems (Q45)
Angeborene Fehlbildungen der Ovarien,
der Tubae uterinae und der Ligg. lata
uteri (Q50)
Angeborene Fehlbildungen des Uterus
und der Cervix uteri (Q51)
Sonstige angeborene Fehlbildungen der
weiblichen Genitalorgane (Q52)
Nondescensus testis (Q53)
Hypospadie (Q54)
Sonstige angeborene Fehlbildungen der
männlichen Genitalorgane (Q55)
Unbestimmtes Geschlecht und
Pseudohermaphroditismus (Q56)
Nierenagenesie und sonstige
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Reduktionsdefekte der Niere (Q60)
Zystische Nierenkrankheit (Q61)
Angeborene obstruktive Defekte des
Nierenbeckens und angeborene
Fehlbildungen des Ureters (Q62)
Sonstige angeborene Fehlbildungen der
Niere (Q63)
Sonstige angeborene Fehlbildungen des
Harnsystems (Q64)
Angeborene Deformitäten der Hüfte
(Q65)
Angeborene Deformitäten der Füße
(Q66)
Angeborene Muskel-Skelett-
Deformitäten des Kopfes, des Gesichtes,
der Wirbelsäule und des Thorax (Q67)
Sonstige angeborene Muskel-Skelett-
Deformitäten (Q68)
Polydaktylie (Q69)
Syndaktylie (Q70)
Reduktionsdefekte der oberen Extremität
(Q71)
Reduktionsdefekte der unteren
Extremität (Q72)
Reduktionsdefekte nicht näher
bezeichneter Extremität(en) (Q73)
Sonstige angeborene Fehlbildungen der
Extremität(en) (Q74)
Sonstige angeborene Fehlbilldungen der
Schädel- und Gesichtsschädelknochen
(Q75)
Angeborene Fehlbildungen der
Wirbelsäule und des knöchernen Thorax
(Q76)
Osteochondrodysplasie mit
Wachstumsstörungen der
Röhrenknochen und der Wirbelsäule
(Q77)
Sonstige Osteochondrodysplasien (Q78)
Angeborene Fehlbildungen des Muskel-
Skelett-Systems, anderenorts nicht
klassifiziert (Q79)
Ichthyosis congenita (Q80)
Epidermolysis bullosa (Q81)
Sonstige angeborene Fehlbildungen der
Haut (Q82)
Angeborene Fehlbildungen der Mamma
[Brustdrüse] (Q83)
Sonstige angeborene Fehlbildungen des
Integumentes (Q84)
Phakomatosen, anderenorts nicht
klassifiziert (Q85)
Angeborene Fehlbildungssyndrome
durch bekannte äußere Ursachen,
anderenorts nicht klassifiziert (Q86)
Sonstige näher bezeichnete angeborene
Fehlbildungssyndrome mit Beteiligung
mehrerer Systeme (Q87)
Sonstige angeborene Fehlbildungen,
anderenorts nicht klassifiziert (Q89)
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Down-Syndrom (Q90)
Edwards-Syndrom und Patau-Syndrom
(Q91)
Sonstige Trisomien und partielle
Trisomien der Autosomen, anderenorts
nicht klassifiziert (Q92)
Monosomien und Deletionen der
Autosomen, anderenorts nicht
klassifiziert (Q93)
Balancierte Chromosomen-
Rearrangements und Struktur-Marker,
anderenorts nicht klassifiziert (Q95)
Turner-Syndrom (Q96)
Sonstige Anomalien der Gonosomen bei
weiblichem Phänotyp, anderenorts nicht
klassifiziert (Q97)
Sonstige Anomalien der Gonosomen bei
männlichem Phänotyp, anderenorts nicht
klassifiziert (Q98)
Sonstige Chromosomenanomalien,
anderenorts nicht klassifiziert (Q99)
Störungen des Herzschlages (R00)
Herzgeräusche und andere Herz-
Schallphänomene (R01)
Gangrän, anderenorts nicht klassifiziert
(R02)
Abnormer Blutdruckwert ohne Diagnose
(R03)
Blutung aus den Atemwegen (R04)
Husten (R05)
Störungen der Atmung (R06)
Hals- und Brustschmerzen (R07)
Sonstige Symptome, die das
Kreislaufsystem und das
Atmungssystem betreffen (R09)
Bauch- und Beckenschmerzen (R10)
Übelkeit und Erbrechen (R11)
Sodbrennen (R12)
Dysphagie (R13)
Flatulenz und verwandte Zustände (R14)
Stuhlinkontinenz (R15)
Hepatomegalie und Splenomegalie,
anderenorts nicht klassifiziert (R16)
Gelbsucht, nicht näher bezeichnet (R17)
Aszites (R18)
Sonstige Symptome, die das
Verdauungssystem und das Abdomen
betreffen (R19)
Sensibilitätsstörungen der Haut (R20)
Hautausschlag und sonstige
unspezifische Hauteruptionen (R21)
Lokalisierte Schwellung, Raumforderung
und Knoten der Haut und der Unterhaut
(R22)
Sonstige Hautveränderungen (R23)
Abnorme unwillkürliche Bewegungen
(R25)
Störungen des Ganges und der Mobilität
(R26)
Sonstige Koordinationsstörungen (R27)
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Sonstige Symptome, die das
Nervensystem und das Muskel-Skelett-
System betreffen (R29)
Schmerzen beim Wasserlassen (R30)
Nicht näher bezeichnete Hämaturie
(R31)
Nicht näher bezeichnete
Harninkontinenz (R32)
Harnverhaltung (R33)
Anurie und Oligurie (R34)
Polyurie (R35)
Ausfluss aus der Harnröhre (R36)
Sonstige Symptome, die das
Harnsystem betreffen (R39)
Somnolenz, Sopor und Koma (R40)
Sonstige Symptome, die das
Erkennungsvermögen und das
Bewusstsein betreffen (R41)
Schwindel und Taumel (R42)
Störungen des Geruchs- und
Geschmackssinnes (R43)
Sonstige Symptome, die die
Sinneswahrnehmungen und das
Wahrnehmungsvermögen betreffen
(R44)
Symptome, die die Stimmung betreffen
(R45)
Symptome, die das äußere
Erscheinungsbild und das Verhalten
betreffen (R46)
Sprech- und Sprachstörungen,
anderenorts nicht klassifiziert (R47)
Dyslexie und sonstige
Werkzeugstörungen, anderenorts nicht
klassifiziert (R48)
Störungen der Stimme (R49)
Fieber sonstiger und unbekannter
Ursache (R50)
Kopfschmerz (R51)
Schmerz, anderenorts nicht klassifiziert
(R52)
Unwohlsein und Ermüdung (R53)
Senilität (R54)
Synkope und Kollaps (R55)
Krämpfe, anderenorts nicht klassifiziert
(R56)
Schock, anderenorts nicht klassifiziert
(R57)
Blutung, anderenorts nicht klassifiziert
(R58)
Lymphknotenvergrößerung (R59)
Ödem, anderenorts nicht klassifiziert
(R60)
Hyperhidrose (R61)
Ausbleiben der erwarteten normalen
physiologischen Entwicklung (R62)
Symptome, die die Nahrungs- und
Flüssigkeitsaufnahme betreffen (R63)
Kachexie (R64)
Sonstige Allgemeinsymptome (R68)
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Unbekannte und nicht näher bezeichnete
Krankheitsursachen (R69)
Beschleunigte
Blutkörperchensenkungsreaktion und
Veränderungen der Plasmaviskosität
(R70)
Veränderung der Erythrozyten (R71)
Veränderung der Leukozyten,
anderenorts nicht klassifiziert (R72)
Erhöhter Blutglukosewert (R73)
Abnorme Serumenzymwerte (R74)
Laborhinweis auf Humanes
Immundefizienz-Virus [HIV] (R75)
Sonstige abnorme immunologische
Serumbefunde (R76)
Sonstige Veränderungen der
Plasmaproteine (R77)
Nachweis von Drogen und anderen
Substanzen, die normalerweise nicht im
Blut vorhanden sind (R78)
Sonstige abnorme Befunde der
Blutchemie (R79)
Isolierte Proteinurie (R80)
Glukosurie (R81)
Sonstige abnorme Urinbefunde (R82)
Abnorme Liquorbefunde (R83)
Abnorme Befunde in
Untersuchungsmaterialien aus
Atemwegen und Thorax (R84)
Abnorme Befunde in
Untersuchungsmaterialien aus
Verdauungsorganen und Bauchhöhle
(R85)
Abnorme Befunde in
Untersuchungsmaterialien aus den
männlichen Genitalorganen (R86)
Abnorme Befunde in
Untersuchungsmaterialien aus den
weiblichen Genitalorganen (R87)
Abnorme Befunde in
Untersuchungsmaterialien aus anderen
Körperorganen, -systemen und
-geweben (R89)
Abnorme Befunde bei der bildgebenden
Diagnostik des Zentralnervensystems
(R90)
Abnorme Befunde bei der bildgebenden
Diagnostik der Lunge (R91)
Abnorme Befunde bei der bildgebenden
Diagnostik der Mamma [Brustdrüse]
(R92)
Abnorme Befunde bei der bildgebenden
Diagnostik sonstiger Körperstrukturen
(R93)
Abnorme Ergebnisse von
Funktionsprüfungen (R94)
Plötzlicher Kindstod (R95)
Sonstiger plötzlicher Tod unbekannter
Ursache (R96)
Tod ohne Anwesenheit anderer
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Personen (R98)
Sonstige ungenau oder nicht näher
bezeichnete Todesursachen (R99)
Oberflächliche Verletzung des Kopfes
(S00)
Offene Wunde des Kopfes (S01)
Fraktur des Schädels und der
Gesichtsschädelknochen (S02)
Luxation, Verstauchung und Zerrung von
Gelenken und Bändern des Kopfes (S03)
Verletzung von Hirnnerven (S04)
Verletzung des Auges und der Orbita
(S05)
Intrakranielle Verletzung (S06)
Zerquetschung des Kopfes (S07)
Traumatische Amputation von Teilen des
Kopfes (S08)
Sonstige und nicht näher bezeichnete
Verletzungen des Kopfes (S09)
Oberflächliche Verletzung des Halses
(S10)
Offene Wunde des Halses (S11)
Fraktur im Bereich des Halses (S12)
Luxation, Verstauchung und Zerrung von
Gelenken und Bändern in Halshöhe
(S13)
Verletzung der Nerven und des
Rückenmarkes in Halshöhe (S14)
Verletzung von Blutgefäßen in Halshöhe
(S15)
Verletzung von Muskeln und Sehnen in
Halshöhe (S16)
Zerquetschung des Halses (S17)
Traumatische Amputation in Halshöhe
(S18)
Sonstige und nicht näher bezeichnete
Verletzungen des Halses (S19)
Oberflächliche Verletzung des Thorax
(S20)
Offene Wunde des Thorax (S21)
Fraktur der Rippe(n), des Sternums und
der Brustwirbelsäule (S22)
Luxation, Verstauchung und Zerrung von
Gelenken und Bändern im Bereich des
Thorax (S23)
Verletzung der Nerven und des
Rückenmarkes in Thoraxhöhe (S24)
Verletzung von Blutgefäßen des Thorax
(S25)
Verletzung des Herzens (S26)
Verletzung sonstiger und nicht näher
bezeichneter intrathorakaler Organe
(S27)
Zerquetschung des Thorax und
traumatische Amputation von Teilen des
Thorax (S28)
Sonstige und nicht näher bezeichnete
Verletzungen des Thorax (S29)
Oberflächliche Verletzung des
Abdomens, der Lumbosakralgegend und
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des Beckens (S30)
Offene Wunde des Abdomens, der
Lumbosakralgegend und des Beckens
(S31)
Fraktur der Lendenwirbelsäule und des
Beckens (S32)
Luxation, Verstauchung und Zerrung von
Gelenken und Bändern der
Lendenwirbelsäule und des Beckens
(S33)
Verletzung der Nerven und des lumbalen
Rückenmarkes in Höhe des Abdomens,
der Lumbosakralgegend und des
Beckens (S34)
Verletzung von Blutgefäßen in Höhe des
Abdomens, der Lumbosakralgegend und
des Beckens (S35)
Verletzung von intraabdominalen
Organen (S36)
Verletzung der Harnorgane und der
Beckenorgane (S37)
Zerquetschung und traumatische
Amputation von Teilen des Abdomens,
der Lumbosakralgegend und des
Beckens (S38)
Sonstige und nicht näher bezeichnete
Verletzungen des Abdomens, der
Lumbosakralgegend und des Beckens
(S39)
Oberflächliche Verletzung der Schulter
und des Oberarmes (S40)
Offene Wunde der Schulter und des
Oberarmes (S41)
Fraktur im Bereich der Schulter und des
Oberarmes (S42)
Luxation, Verstauchung und Zerrung von
Gelenken und Bändern des
Schultergürtels (S43)
Verletzung von Nerven in Höhe der
Schulter und des Oberarmes (S44)
Verletzung von Blutgefäßen in Höhe der
Schulter und des Oberarmes (S45)
Verletzung von Muskeln und Sehnen in
Höhe der Schulter und des Oberarmes
(S46)
Zerquetschung der Schulter und des
Oberarmes (S47)
Traumatische Amputation an Schulter
und Oberarm (S48)
Sonstige und nicht näher bezeichnete
Verletzungen der Schulter und des
Oberarmes (S49)
Oberflächliche Verletzung des
Unterarmes (S50)
Offene Wunde des Unterarmes (S51)
Fraktur des Unterarmes (S52)
Luxation, Verstauchung und Zerrung des
Ellenbogengelenkes und von Bändern
des Ellenbogens (S53)
Verletzung von Nerven in Höhe des
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Unterarmes (S54)
Verletzung von Blutgefäßen in Höhe des
Unterarmes (S55)
Verletzung von Muskeln und Sehnen in
Höhe des Unterarmes (S56)
Zerquetschung des Unterarmes (S57)
Traumatische Amputation am Unterarm
(S58)
Sonstige und nicht näher bezeichnete
Verletzungen des Unterarmes (S59)
Oberflächliche Verletzung des
Handgelenkes und der Hand (S60)
Offene Wunde des Handgelenkes und
der Hand (S61)
Fraktur im Bereich des Handgelenkes
und der Hand (S62)
Luxation, Verstauchung und Zerrung von
Gelenken und Bändern in Höhe des
Handgelenkes und der Hand (S63)
Verletzung von Nerven in Höhe des
Handgelenkes und der Hand (S64)
Verletzung von Blutgefäßen in Höhe des
Handgelenkes und der Hand (S65)
Verletzung von Muskeln und Sehnen in
Höhe des Handgelenkes und der Hand
(S66)
Zerquetschung des Handgelenkes und
der Hand (S67)
Traumatische Amputation an
Handgelenk und Hand (S68)
Sonstige und nicht näher bezeichnete
Verletzungen des Handgelenkes und der
Hand (S69)
Oberflächliche Verletzung der Hüfte und
des Oberschenkels (S70)
Offene Wunde der Hüfte und des
Oberschenkels (S71)
Fraktur des Femurs (S72)
Luxation, Verstauchung und Zerrung des
Hüftgelenkes und von Bändern der Hüfte
(S73)
Verletzung von Nerven in Höhe der Hüfte
und des Oberschenkels (S74)
Verletzung von Blutgefäßen in Höhe der
Hüfte und des Oberschenkels (S75)
Verletzung von Muskeln und Sehnen in
Höhe der Hüfte und des Oberschenkels
(S76)
Zerquetschung der Hüfte und des
Oberschenkels (S77)
Traumatische Amputation an Hüfte und
Oberschenkel (S78)
Oberflächliche Verletzung des
Unterschenkels (S80)
Offene Wunde des Unterschenkels (S81)
Fraktur des Unterschenkels,
einschließlich des oberen
Sprunggelenkes (S82)
Luxation, Verstauchung und Zerrung des
Kniegelenkes und von Bändern des
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Kniegelenkes (S83)
Verletzung von Nerven in Höhe des
Unterschenkels (S84)
Verletzung von Blutgefäßen in Höhe des
Unterschenkels (S85)
Verletzung von Muskeln und Sehnen in
Höhe des Unterschenkels (S86)
Zerquetschung des Unterschenkels
(S87)
Traumatische Amputation am
Unterschenkel (S88)
Sonstige und nicht näher bezeichnete
Verletzungen des Unterschenkels (S89)
Oberflächliche Verletzung der
Knöchelregion und des Fußes (S90)
Offene Wunde der Knöchelregion und
des Fußes (S91)
Fraktur des Fußes [ausgenommen
oberes Sprunggelenk] (S92)
Luxation, Verstauchung und Zerrung der
Gelenke und Bänder in Höhe des oberen
Sprunggelenkes und des Fußes (S93)
Verletzung von Nerven in Höhe des
Knöchels und des Fußes (S94)
Verletzung von Blutgefäßen in Höhe des
Knöchels und des Fußes (S95)
Verletzung von Muskeln und Sehnen in
Höhe des Knöchels und des Fußes
(S96)
Zerquetschung des oberen
Sprunggelenkes und des Fußes (S97)
Traumatische Amputation am oberen
Sprunggelenk und Fuß (S98)
Sonstige und nicht näher bezeichnete
Verletzungen der Knöchelregion und des
Fußes (S99)
Oberflächliche Verletzungen mit
Beteiligung mehrerer Körperregionen
(T00)
Offene Wunden mit Beteiligung mehrerer
Körperregionen (T01)
Frakturen mit Beteiligung mehrerer
Körperregionen (T02)
Luxationen, Verstauchungen und
Zerrungen mit Beteiligung mehrerer
Körperregionen (T03)
Zerquetschungen mit Beteiligung
mehrerer Körperregionen (T04)
Traumatische Amputationen mit
Beteiligung mehrerer Körperregionen
(T05)
Sonstige Verletzungen mit Beteiligung
mehrerer Körperregionen, anderenorts
nicht klassifiziert (T06)
Nicht näher bezeichnete multiple
Verletzungen (T07)
Fraktur der Wirbelsäule, Höhe nicht
näher bezeichnet (T08)
Sonstige Verletzungen der Wirbelsäule
und des Rumpfes, Höhe nicht näher
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bezeichnet (T09)
Fraktur der oberen Extremität, Höhe
nicht näher bezeichnet (T10)
Sonstige Verletzungen der oberen
Extremität, Höhe nicht näher bezeichnet
(T11)
Fraktur der unteren Extremität, Höhe
nicht näher bezeichnet (T12)
Sonstige Verletzungen der unteren
Extremität, Höhe nicht näher bezeichnet
(T13)
Verletzung an einer nicht näher
bezeichneten Körperregion (T14)
Fremdkörper im äußeren Auge (T15)
Fremdkörper im Ohr (T16)
Fremdkörper in den Atemwegen (T17)
Fremdkörper im Verdauungstrakt (T18)
Fremdkörper im Urogenitaltrakt (T19)
Verbrennung oder Verätzung des Kopfes
und des Halses (T20)
Verbrennung oder Verätzung des
Rumpfes (T21)
Verbrennung oder Verätzung der
Schulter und des Armes, ausgenommen
Handgelenk und Hand (T22)
Verbrennung oder Verätzung des
Handgelenkes und der Hand (T23)
Verbrennung oder Verätzung der Hüfte
und des Beines, ausgenommen
Knöchelregion und Fuß (T24)
Verbrennung oder Verätzung der
Knöchelregion und des Fußes (T25)
Verbrennung oder Verätzung, begrenzt
auf das Auge und seine Anhangsgebilde
(T26)
Verbrennung oder Verätzung der
Atemwege (T27)
Verbrennung oder Verätzung sonstiger
innerer Organe (T28)
Verbrennungen oder Verätzungen
mehrerer Körperregionen (T29)
Verbrennung oder Verätzung,
Körperregion nicht näher bezeichnet
(T30)
Verbrennungen, klassifiziert nach dem
Ausmaß der betroffenen
Körperoberfläche (T31)
Verätzungen, klassifiziert nach dem
Ausmaß der betroffenen
Körperoberfläche (T32)
Oberflächliche Erfrierung (T33)
Erfrierung mit Gewebsnekrose (T34)
Erfrierung mit Beteiligung mehrerer
Körperregionen und nicht näher
bezeichnete Erfrierung (T35)
Vergiftung durch systemisch wirkende
Antibiotika (T36)
Vergiftung durch sonstige systemisch
wirkende Antiinfektiva und Antiparasitika
(T37)
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Vergiftung durch Hormone und deren
synthetische Ersatzstoffe und
Antagonisten, anderenorts nicht
klassifiziert (T38)
Vergiftung durch nichtopioidhaltige
Analgetika, Antipyretika und
Antirheumatika (T39)
Vergiftung durch Betäubungsmittel und
Psychodysleptika [Halluzinogene] (T40)
Vergiftung durch Anästhetika und
therapeutische Gase (T41)
Vergiftung durch Antiepileptika, Sedativa,
Hypnotika und Antiparkinsonmittel (T42)
Vergiftung durch psychotrope
Substanzen, anderenorts nicht
klassifiziert (T43)
Vergiftung durch primär auf das
autonome Nervensystem wirkende
Arzneimittel (T44)
Vergiftung durch primär systemisch und
auf das Blut wirkende Mittel, anderenorts
nicht klassifiziert (T45)
Vergiftung durch primär auf das Herz-
Kreislaufsystem wirkende Mittel (T46)
Vergiftung durch primär auf den Magen-
Darmtrakt wirkende Mittel (T47)
Vergiftung durch primär auf die glatte
Muskulatur, die Skelettmuskulatur und
das Atmungssystem wirkende Mittel
(T48)
Vergiftung durch primär auf Haut und
Schleimhäute wirkende und in der
Augen-, der Hals-Nasen-Ohren- und der
Zahnheilkunde angewendete Mittel zur
topischen Anwendung (T49)
Vergiftung durch Diuretika und sonstige
und nicht näher bezeichnete
Arzneimittel, Drogen und biologisch
aktive Substanzen (T50)
Toxische Wirkung von Alkohol (T51)
Toxische Wirkung von organischen
Lösungsmitteln (T52)
Toxische Wirkung von halogenierten
aliphatischen und aromatischen
Kohlenwasserstoffen (T53)
Toxische Wirkung von ätzenden
Substanzen (T54)
Toxische Wirkung von Seifen und
Detergenzien (T55)
Toxische Wirkung von Metallen (T56)
Toxische Wirkung von sonstigen
anorganischen Substanzen (T57)
Toxische Wirkung von Kohlenmonoxid
(T58)
Toxische Wirkung sonstiger Gase,
Dämpfe oder sonstigen Rauches (T59)
Toxische Wirkung von
Schädlingsbekämpfungsmitteln
[Pestiziden] (T60)
Toxische Wirkung schädlicher
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Substanzen, die mit essbaren
Meerestieren aufgenommen wurden
(T61)
Toxische Wirkung sonstiger schädlicher
Substanzen, die mit der Nahrung
aufgenommen wurden (T62)
Toxische Wirkung durch Kontakt mit
giftigen Tieren (T63)
Toxische Wirkung von Aflatoxin und
soonstigem Mykotoxin in kontaminierten
Lebensmitteln (T64)
Toxische Wirkung sonstiger und nicht
näher bezeichneter Substanzen (T65)
Nicht näher bezeichnete Schäden durch
Strahlung (T66)
Schäden durch Hitze und Sonnenlicht
(T67)
Hypothermie (T68)
Sonstige Schäden durch niedrige
Temperatur (T69)
Schäden durch Luft- und Wasserdruck
(T70)
Erstickung (T71)
Schäden durch sonstigen Mangel (T73)
Missbrauch von Personen (T74)
Schäden durch sonstige äußere
Ursachen (T75)
Unerwünschte Nebenwirkungen,
anderenorts nicht klassifiziert (T78)
Bestimmte Frühkomplikationen eines
Traumas, anderenorts nicht klassifiziert
(T79)
Komplikationen nach Infusion,
Transfusion oder Injektion zu
therapeutischen Zwecken (T80)
Komplikationen bei Eingriffen,
anderenorts nicht klassifiziert (T81)
Komplikationen durch Prothesen,
Implantate oder Transplantate im Herzen
und in den Gefäßen (T82)
Komplikationen durch Prothesen,
Implantate oder Transplantate im
Urogenitaltrakt (T83)
Komplikationen durch orthopädische
Endoprothesen, Implantate oder
Transplantate (T84)
Komplikationen durch sonstige interne
Prothesen, Implantate oder
Transplantate (T85)
Versagen und Abstoßung von
transplantierten Organen und Geweben
(T86)
Komplikationen, die für Replantation und
Amputation bezeichnend sind (T87)
Sonstige Komplikationen bei
chirurgischen Eingriffen und
medizinischer Behandlung, anderenorts
nicht klassifiziert (T88)
Folgen von Verletzungen des Kopfes
(T90)
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Folgen von Verletzungen des Halses und
des Rumpfes (T91)
Folgen von Verletzungen der oberen
Extremität (T92)
Folgen von Verletzungen der unteren
Extremität (T93)
Folgen von Verletzungen mehrerer oder
nicht näher bezeichneter Körperregionen
(T94)
Folgen von Verbrennungen, Verätzungen
oder Erfrierungen (T95)
Folgen einer Vergiftung durch
Arzneimittel, Drogen und biologisch
aktive Substanzen (T96)
Folgen toxischer Wirkungen von
vorwiegend nicht medizinisch
verwendeten Substanzen (T97)
Folgen sonstiger und nicht näher
bezeichneter Wirkungen äußerer
Ursachen (T98)
Schweres akutes respiratorisches
Syndrom [SARS] (U04)
Erreger mit bestimmten
Antibiotikaresistenzen, die besondere
therapeutische oder hygienische
Maßnahmen erfordern (U80)
Bakterien mit Multiresistenz gegen
Antibiotika (U81)
Allgemeinuntersuchung und Abklärung
bei Personen ohne Beschwerden oder
angegebene Diagnose (Z00)
Sonstige spezielle Untersuchungen und
Abklärungen bei Personen ohne
Beschwerden oder angegebene
Diagnose (Z01)
Untersuchung und Konsultation aus
administrativen Gründen (Z02)
Ärztliche Beobachtung und Beurteilung
von Verdachtsfällen (Z03)
Untersuchung und Beobachtung aus
sonstigen Gründen (Z04)
Nachuntersuchung nach Behandlung
wegen bösartiger Neubildung (Z08)
Nachuntersuchung nach Behandlung
wegen anderer Krankheitszustände
außer bösartigen Neubildungen (Z09)
Allgemeine Reihenuntersuchung
bestimmter Bevölkerungsgruppen (Z10)
Spezielle Verfahren zur Untersuchung
auf infektiöse und parasitäre Krankheiten
(Z11)
Spezielle Verfahren zur Untersuchung
auf Neubildungen (Z12)
Spezielle Verfahren zur Untersuchung
auf sonstige Krankheiten oder Störungen
(Z13)
Kontakt mit und Exposition gegenüber
übertragbaren Krankheiten (Z20)
Asymptomatische HIV-Infektion
[Humane Immundefizienz-Virusinfektion]
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(Z21)
Keimträger von Infektionskrankheiten
(Z22)
Notwendigkeit der Impfung
[Immunisierung] gegen einzelne
bakterielle Krankheiten (Z23)
Notwendigkeit der Impfung
[Immunisierung] gegen bestimmte
einzelne Viruskrankheiten (Z24)
Notwendigkeit der Impfung
[Immunisierung] gegen andere einzelne
Viruskrankheiten (Z25)
Notwendigkeit der Impfung
[Immunisierung] gegen andere einzelne
Infektionskrankheiten (Z26)
Notwendigkeit der Impfung
[Immunisierung] gegen Kombinationen
von Infektionskrankheiten (Z27)
Nicht durchgeführte Impfung
[Immunisierung] (Z28)
Notwendigkeit von anderen
prophylaktischen Maßnahmen (Z29)
Kontrazeptive Maßnahmen (Z30)
Fertilisationsfördernde Maßnahmen
(Z31)
Untersuchung und Test zur Feststellung
einer Schwangerschaft (Z32)
Schwangerschaftsfeststellung als
Nebenbefund (Z33)
Überwachung einer normalen
Schwangerschaft (Z34)
Überwachung einer
Risikoschwangerschaft (Z35)
Pränatales Screening (Z36)
Resultat der Entbindung (Z37)
Lebendgeborene nach dem Geburtsort
(Z38)
Postpartale Betreuung und
Untersuchung der Mutter (Z39)
Prophylaktische Operation (Z40)
Maßnahmen aus anderen Gründen als
der Wiederherstellung des
Gesundheitszustandes (Z41)
Nachbehandlung unter Anwendung
plastischer Chirurgie (Z42)
Versorgung künstlicher Körperöffnungen
(Z43)
Versorgen mit und Anpassen einer
Ektoprothese (Z44)
Anpassung und Handhabung eines
implantierten medizinischen Gerätes
(Z45)
Versorgen mit und Anpassen von
anderen medizinischen Geräten oder
Hilfsmitteln (Z46)
Andere orthopädische Nachbehandlung
(Z47)
Andere Nachbehandlung nach
chirurgischem Eingriff (Z48)
Dialysebehandlung (Z49)
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Rehabilitationsmaßnahmen (Z50)
Sonstige medizinische Behandlung (Z51)
Spender von Organen oder Geweben
(Z52)
Personen, die Einrichtungen des
Gesundheitswesens wegen spezifischer
Maßnahmen aufgesucht haben, die aber
nicht durchgeführt wurden (Z53)
Rekonvaleszenz (Z54)
Kontaktanlässe mit Bezug auf die
Ausbildung (Z55)
Kontaktanlässe mit Bezug auf das
Berufsleben (Z56)
Berufliche Exposition gegenüber
Risikofaktoren (Z57)
Kontaktanlässe mit Bezug auf die
physikalische Umwelt (Z58)
Kontaktanlässe mit Bezug auf das
Wohnumfeld oder die wirtschaftliche
Lage (Z59)
Kontaktanlässe mit Bezug auf die soziale
Umgebung (Z60)
Kontaktanlässe mit Bezug auf
Kindheitserlebnisse (Z61)
Andere Kontaktanlässe mit Bezug auf
die Erziehung (Z62)
Andere Kontaktanlässe mit Bezug auf
den engeren Familienkreis (Z63)
Kontaktanlässe mit Bezug auf bestimmte
psychosoziale Umstände (Z64)
Kontaktanlässe mit Bezug auf andere
psychosoziale Umstände (Z65)
Beratung in Bezug auf Sexualeinstellung,
-verhalten oder -orientierung (Z70)
Personen, die das Gesundheitswesen
zum Zwecke anderer Beratung oder
ärztlicher Konsultation in Anspruch
nehmen, anderenorts nicht klassifiziert
(Z71)
Probleme mit Bezug auf die
Lebensführung (Z72)
Probleme mit Bezug auf Schwierigkeiten
bei der Lebensbewältigung (Z73)
Probleme mit Bezug auf
Pflegebedürftigkeit (Z74)
Probleme mit Bezug auf medizinische
Betreuungsmöglichkeiten oder andere
Gesundheitsversorgung (Z75)
Personen, die das Gesundheitswesen
aus sonstigen Gründen in Anspruch
nehmen (Z76)
Bösartige Neubildung in der
Familienanamnese (Z80)
Psychische Krankheiten oder
Verhaltensstörungen in der
Familienanamnese (Z81)
Bestimmte Behinderungen oder
chronische Krankheiten in der
Familienanamnese, die zu Schädigung
oder Behinderung führen (Z82)
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Andere spezifische Krankheiten in der
Familienanamnese (Z83)
Andere Krankheiten oder Zustände in
der Familienanamnese (Z84)
Bösartige Neubildung in der
Eigenanamnese (Z85)
Bestimmte andere Krankheiten in der
Eigenanamnese (Z86)
Andere Krankheiten oder Zustände in
der Eigenanamnese (Z87)
Allergie gegenüber Arzneimitteln,
Drogen oder biologisch aktiven
Substanzen in der Eigenanamnese (Z88)
Extremitätenverlust (Z89)
Verlust von Organen, anderenorts nicht
klassifiziert (Z90)
Risikofaktoren in der Eigenanamnese,
anderenorts nicht klassifiziert (Z91)
Medizinische Behandlung in der
Eigenanamnese (Z92)
Vorhandensein einer künstlichen
Körperöffnung (Z93)
Zustand nach Organ- oder
Gewebetransplantation (Z94)
Vorhandensein von kardialen oder
vaskulären Implantaten oder
Transplantaten (Z95)
Vorhandensein von anderen
funktionellen Implantaten (Z96)
Vorhandensein anderer medizinischer
Geräte oder Hilfsmittel (Z97)
Sonstige Zustände nach chirurgischem
Eingriff (Z98)
Langzeitige Abhängigkeit von
unterstützenden Apparaten,
medizinischen Geräten oder Hilfsmitteln,
anderenorts nicht klassifiziert (Z99)
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ATC 2nd level
ATC 2nd level
ATC 2nd level
ALIMENTÄRES SYSTEM UND
STOFFWECHSEL (A)
STOMATOLOGIKA (A01)
MITTEL BEI SÄURE BEDINGTEN
ERKRANKUNGEN (A02)
MITTEL BEI FUNKTIONELLEN
GASTROINTESTINALEN STÖRUNGEN
(A03)
ANTIEMETIKA UND MITTEL GEGEN
ÜBELKEIT (A04)
GALLEN- UND LEBERTHERAPIE (A05)
MITTEL GEGEN OBSTIPATION (A06)
ANTIDIARRHOIKA UND INTESTINALE
ANTIPHLOGISTIKA/ANTIINFEKTIVA
(A07)
ANTIADIPOSITA, EXKL. DIÄTETIKA
(A08)
DIGESTIVA, INKL. ENZYME (A09)
ANTIDIABETIKA (A10)
VITAMINE (A11)
MINERALSTOFFE (A12)
TONIKA (A13)
ANABOLIKA ZUR SYSTEMISCHEN
ANWENDUNG (A14)
APPETIT STIMULIERENDE MITTEL
(A15)
ANDERE MITTEL FÜR DAS
ALIMENTÄRE SYSTEM UND DEN
STOFFWECHSEL (A16)
BLUT UND BLUTBILDENDE ORGANE
(B)
ANTITHROMBOTISCHE MITTEL (B01)
ANTIHÄMORRHAGIKA (B02)
ANTIANÄMIKA (B03)
BLUTERSATZMITTEL UND
PERFUSIONSLÖSUNGEN (B05)
ANDERE HÄMATOLOGIKA (B06)
KARDIOVASKULÄRES SYSTEM (C)
HERZTHERAPIE (C01)
ANTIHYPERTONIKA (C02)
DIURETIKA (C03)
PERIPHERE VASODILATATOREN (C04)
VASOPROTEKTOREN (C05)
BETA-ADRENOZEPTOR-
ANTAGONISTEN (C07)
CALCIUMKANALBLOCKER (C08)
MITTEL MIT WIRKUNG AUF DAS
RENIN-ANGIOTENSIN-SYSTEM (C09)
MITTEL, DIE DEN
LIPIDSTOFFWECHSEL
BEEINFLUSSEN (C10)
DERMATIKA (D)
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ANTIMYKOTIKA ZUR
DERMATOLOGISCHEN ANWENDUNG
(D01)
EMOLLIENTIA UND
HAUTSCHUTZMITTEL (D02)
ZUBEREITUNGEN ZUR BEHANDLUNG
VON WUNDEN UND GESCHWÜREN
(D03)
ANTIPRURIGINOSA, INKL.
ANTIHISTAMINIKA, ANÄSTHETIKA
ETC. (D04)
ANTIPSORIATIKA (D05)
ANTIBIOTIKA UND
CHEMOTHERAPEUTIKA ZUR
DERMATOLOGISCHEN ANWENDUNG
(D06)
CORTICOSTEROIDE,
DERMATOLOGISCHE
ZUBEREITUNGEN (D07)
ANTISEPTIKA UND
DESINFEKTIONSMITTEL (D08)
MEDIZINISCHE VERBÄNDE (D09)
AKNEMITTEL (D10)
ANDERE DERMATIKA (D11)
UROGENITALSYSTEM UND
SEXUALHORMONE (G)
GYNÄKOLOGISCHE ANTIINFEKTIVA
UND ANTISEPTIKA (G01)
ANDERE GYNÄKOLOGIKA (G02)
SEXUALHORMONE UND
MODULATOREN DES
GENITALSYSTEMS (G03)
UROLOGIKA (G04)
SYSTEMISCHE HORMONPRÄPARATE,
EXKL. SEXUALHORMONE UND
INSULINE (H)
HYPOPHYSEN- UND
HYPOTHALAMUSHORMONE UND
ANALOGA (H01)
CORTICOSTEROIDE ZUR
SYSTEMISCHEN ANWENDUNG (H02)
SCHILDDRÜSENTHERAPIE (H03)
PANKREASHORMONE (H04)
CALCIUMHOMÖOSTASE (H05)
ANTIINFEKTIVA ZUR SYSTEMISCHEN
ANWENDUNG (J)
ANTIBIOTIKA ZUR SYSTEMISCHEN
ANWENDUNG (J01)
ANTIMYKOTIKA ZUR SYSTEMISCHEN
ANWENDUNG (J02)
MITTEL GEGEN MYKOBAKTERIEN
(J04)
ANTIVIRALE MITTEL ZUR
SYSTEMISCHEN ANWENDUNG (J05)
IMMUNSERA UND IMMUNGLOBULINE
(J06)
IMPFSTOFFE (J07)
ANTINEOPLASTISCHE UND
IMMUNMODULIERENDE MITTEL (L)
ANTINEOPLASTISCHE MITTEL (L01)
2 / 4
ATC 2nd level
ENDOKRINE THERAPIE (L02)
IMMUNSTIMULANZIEN (L03)
IMMUNSUPPRESSIVA (L04)
MUSKEL- UND SKELETTSYSTEM (M)
ANTIPHLOGISTIKA UND
ANTIRHEUMATIKA (M01)
TOPISCHE MITTEL GEGEN GELENK-
UND MUSKELSCHMERZEN (M02)
MUSKELRELAXANZIEN (M03)
GICHTMITTEL (M04)
MITTEL ZUR BEHANDLUNG VON
KNOCHENERKRANKUNGEN (M05)
ANDERE MITTEL GEGEN
STÖRUNGEN DES MUSKEL- UND
SKELETTSYSTEMS (M09)
NERVENSYSTEM (N)
ANÄSTHETIKA (N01)
ANALGETIKA (N02)
ANTIEPILEPTIKA (N03)
ANTIPARKINSONMITTEL (N04)
PSYCHOLEPTIKA (N05)
PSYCHOANALEPTIKA (N06)
ANDERE MITTEL FÜR DAS
NERVENSYSTEM (N07)
ANTIPARASITÄRE MITTEL,
INSEKTIZIDE UND REPELLENZIEN (P)
MITTEL GEGEN PROTOZOEN-
ERKRANKUNGEN (P01)
ANTHELMINTIKA (P02)
MITTEL GEGEN EKTOPARASITEN,
INKL. ANTISCABIOSA, INSEKTIZIDE
UND REPELLENZIEN (P03)
RESPIRATIONSTRAKT (R)
RHINOLOGIKA (R01)
HALS- UND RACHENTHERAPEUTIKA
(R02)
MITTEL BEI OBSTRUKTIVEN
ATEMWEGSERKRANKUNGEN (R03)
HUSTEN- UND ERKÄLTUNGSMITTEL
(R05)
ANTIHISTAMINIKA ZUR
SYSTEMISCHEN ANWENDUNG (R06)
ANDERE MITTEL FÜR DEN
RESPIRATIONSTRAKT (R07)
SINNESORGANE (S)
OPHTHALMIKA (S01)
OTOLOGIKA (S02)
OPHTHALMOLOGISCHE UND
OTOLOGISCHE ZUBEREITUNGEN
(S03)
VARIA (V)
ALLERGENE (V01)
ALLE ÜBRIGEN THERAPEUTISCHEN
MITTEL (V03)
DIAGNOSTIKA (V04)
ALLGEMEINE DIÄTETIKA (V06)
ALLE ÜBRIGEN
NICHTTHERAPEUTISCHEN MITTEL
(V07)
KONTRASTMITTEL (V08)
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RADIODIAGNOSTIKA (V09)
RADIOTHERAPEUTIKA (V10)
WUNDVERBÄNDE (V20)
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ePrescription epSOS
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ePrescription epSOS
Rezept
Rezept Nummer*
Medizinprodukt Code
Datum des Rezepts*
Handelsname*
Wirkstoff*
Wirkstoff Code
WHO ATC
Stärke*
Packungsgröße
Darreichungsform*
Oral drops, solution (10101000)
Oral drops, suspension (10102000)
Oral drops, emulsion (10103000)
Oral liquid (10104000)
Oral solution (10105000)
Oral suspension (10106000)
Oral emulsion (10107000)
Oral gel (10108000)
Oral paste (10109000)
Powder for oral solution (10110000)
Powder for oral suspension (10111000)
Granules for oral solution (10112000)
Granules for oral suspension (10113000)
Powder and solvent for oral solution
(10114000)
Powder and solvent for oral suspension
(10115000)
Lyophilisate for suspension (10116000)
Syrup (10117000)
Powder for syrup (10118000)
Granules for syrup (10119000)
Soluble tablet (10120000)
Dispersible tablet (10121000)
Herbal tea (10122000)
Oral powder (10201000)
Instant herbal tea (10202000)
Effervescent powder (10203000)
Granules (10204000)
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Effervescent granules (10205000)
Gastro-resistant granules (10206000)
Prolonged-release granules (10207000)
Modified-release granules (10208000)
Cachet (10209000)
Capsule, hard (10210000)
Capsule, soft (10211000)
Gastro-resistant capsule, hard
(10212000)
Gastro-resistant capsule, soft
(10213000)
Chewable capsule, soft (10214000)
Prolonged-release capsule, hard
(10215000)
Prolonged-release capsule, soft
(10216000)
Modified-release capsule, hard
(10217000)
Modified-release capsule, soft
(10218000)
Tablet (10219000)
Coated tablet (10220000)
Film-coated tablet (10221000)
Effervescent tablet (10222000)
Orodispersible tablet (10223000)
Oral lyophilisate (10224000)
Gastro-resistant tablet (10225000)
Prolonged-release tablet (10226000)
Modified-release tablet (10227000)
Chewable tablet (10228000)
Medicated chewing-gum (10229000)
Oral gum (10230000)
Pillules (10231000)
Orodispersible film (10236100)
Gargle (10301000)
Concentrate for gargle (10302000)
Gargle, powder for solution (10303000)
Gargle, tablet for solution (10304000)
Oromucosal solution (10305000)
Oromucosal suspension (10306000)
Oromucosal drops (10307000)
Oromucosal spray (10308000)
Sublingual spray (10309000)
Mouthwash (10310000)
Mouthwash, tablet for solution
(10311000)
Gingival solution (10312000)
Oromucosal gel (10313000)
Oromucosal paste (10314000)
Oromucosal ointment (10314005)
Oromucosal cream (10314010)
Buccal film (10314011)
Gingival gel (10315000)
Gingival paste (10316000)
Oromucosal capsule (10317000)
Sublingual tablet (10318000)
Muco-adhesive buccal tablet (10319000)
Buccal tablet (10320000)
Lozenge (10321000)
Compressed lozenge (10322000)
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Pastille (10323000)
Periodontal powder (10401000)
Dental gel (10402000)
Dental stick (10403000)
Dental insert (10404000)
Dental powder (10405000)
Dental solution (10406000)
Dental suspension (10407000)
Dental emulsion (10408000)
Toothpaste (10409000)
Periodontal gel (10410000)
Periodontal insert (10411000)
Bath additive (10501000)
Cream (10502000)
Gel (10503000)
Ointment (10504000)
Cutaneous paste (10505000)
Medicated plaster (10506000)
Cutaneous foam (10507000)
Shampoo (10508000)
Cutaneous spray, solution (10509000)
Cutaneous spray, suspension
(10510000)
Cutaneous spray, powder (10511000)
Cutaneous liquid (10512000)
Cutaneous solution (10513000)
Concentrate for cutaneous solution
(10514000)
Cutaneous suspension (10515000)
Cutaneous emulsion (10516000)
Cutaneous powder (10517000)
Cutaneous patch (10517500)
Solution for iontophoresis (10518000)
Transdermal patch (10519000)
Collodion (10520000)
Medicated nail lacquer (10521000)
Nail solution (10521500)
Poultice (10522000)
Cutaneous stick (10523000)
Cutaneous sponge (10524000)
Impregnated dressing (10525000)
Scrub (10539500)
Transdermal spray, solution (10546500)
Transdermal system (10547000)
Solution for skin-prick test (10548000)
Solution for skin-scratch test (10549000)
Plaster for provocation test (10550000)
Eye cream (10601000)
Eye gel (10602000)
Eye ointment (10603000)
Eye drops, solution (10604000)
Eye drops, emulsion (10604500)
Eye drops, suspension (10605000)
Eye drops, powder and solvent for
solution (10606000)
Eye drops, powder and solvent for
suspension (10607000)
Eye drops, solvent for reconstitution
(10608000)
Eye drops, prolonged-release
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(10609000)
Eye lotion (10610000)
Eye lotion, solvent for reconstitution
(10611000)
Ophthalmic insert (10612000)
Ophthalmic strip (10613000)
Ear cream (10701000)
Ear gel (10702000)
Ear ointment (10703000)
Ear drops, solution (10704000)
Ear drops, suspension (10705000)
Ear drops, emulsion (10706000)
Ear drops, powder and solvent for
suspension (10707000)
Ear powder (10708000)
Ear spray, solution (10709000)
Ear spray, suspension (10710000)
Ear spray, emulsion (10711000)
Ear wash, solution (10712000)
Ear wash, emulsion (10713000)
Ear tampon (10714000)
Ear stick (10715000)
Nasal cream (10801000)
Nasal gel (10802000)
Nasal ointment (10803000)
Nasal drops, solution (10804000)
Nasal drops, suspension (10805000)
Nasal drops, emulsion (10806000)
Nasal powder (10807000)
Nasal spray, solution (10808000)
Nasal spray, suspension (10809000)
Nasal spray, emulsion (10810000)
Nasal wash (10811000)
Nasal stick (10812000)
Intravaginal ring (10900500)
Vaginal cream (10901000)
Vaginal gel (10902000)
Vaginal ointment (10903000)
Vaginal foam (10904000)
Vaginal solution (10905000)
Vaginal suspension (10906000)
Vaginal emulsion (10907000)
Tablet for vaginal solution (10908000)
Pessary (10909000)
Vaginal capsule, hard (10910000)
Vaginal capsule, soft (10911000)
Vaginal tablet (10912000)
Effervescent vaginal tablet (10913000)
Medicated vaginal tampon (10914000)
Vaginal delivery system (10915000)
Vaginal sponge (10916000)
Rectal cream (11001000)
Rectal gel (11002000)
Rectal ointment (11003000)
Rectal foam (11004000)
Rectal solution (11005000)
Rectal suspension (11006000)
Rectal emulsion (11007000)
Concentrate for rectal solution
(11008000)
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Powder for rectal solution (11009000)
Oral drops (11010)
Powder for rectal suspension (11010000)
Tablet for rectal solution (11011000)
Tablet for rectal suspension (11012000)
Suppository (11013000)
Rectal capsule (11014000)
Rectal tampon (11015000)
Oral liquid (11050)
Nebuliser solution (11101000)
Nebuliser suspension (11102000)
Powder for nebuliser suspension
(11103000)
Powder for nebuliser solution (11104000)
Nebuliser emulsion (11105000)
Pressurised inhalation, solution
(11106000)
Pressurised inhalation, suspension
(11107000)
Pressurised inhalation, emulsion
(11108000)
Inhalation powder (11109000)
Inhalation powder, hard capsule
(11110000)
Inhalation powder, pre-dispensed
(11111000)
Inhalation vapour, powder (11112000)
Inhalation vapour, capsule (11113000)
Inhalation vapour, solution (11114000)
Inhalation vapour, tablet (11115000)
Inhalation vapour, ointment (11116000)
Inhalation vapour, liquid (11117000)
Inhalation gas (11118000)
Solution for injection (11201000)
Suspension for injection (11202000)
Emulsion for injection (11203000)
Gel for injection (11204000)
Powder for solution for injection
(11205000)
Powder for suspension for injection
(11206000)
Powder and solvent for solution for
injection (11207000)
Powder and solvent for suspension for
injection (11208000)
Concentrate for solution for injection
(11209000)
Solution for infusion (11210000)
Solution for infusion in administration
system (11210500)
Emulsion for infusion (11211000)
Powder for solution for infusion
(11212000)
Concentrate for solution for infusion
(11213000)
Powder and solvent for solution for
infusion (11214000)
Lyophilisate and solvent for solution for
injection (11214500)
Lyophilisate for solution for infusion
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(11215000)
Solvent for parenteral use (11216000)
Lyophilisate for solution for injection
(11217000)
Lyophilisate for suspension for injection
(11218000)
Implant (11301000)
Implantation tablet (11302000)
Implantation chain (11303000)
Implantation suspension (11303500)
Powder and solvent for implantation
paste (11304000)
Solution for peritoneal dialysis
(11401000)
Solution for haemofiltration (11402000)
Solution for haemodiafiltration
(11403000)
Solution for haemodialysis (11404000)
Concentrate for haemodialysis solution
(11405000)
Solution for intravesical use (11501000)
Bladder irrigation (11502000)
Powder for bladder irrigation (11503000)
Urethral gel (11504000)
Urethral stick (11505000)
Endotracheopulmonary instillation,
solution (11601000)
Endotracheopulmonary instillation,
powder for solution (11602000)
Endotracheopulmonary instillation,
suspension (11603000)
Endotracheopulmonary instillation,
powder and solvent for solution
(11604000)
Endocervical gel (11701000)
Powder and solvent for endocervical gel
(11702000)
Intrauterine delivery system (11901000)
Intrauterine solution (11902000)
Intrauterine suspension (11903000)
Intrauterine emulsion (11904000)
Intrauterine tablet (11905000)
Intrauterine capsule (11906000)
Nebulisation solution (12004000)
Capsule (12100)
Absorbable coated sponge (12100500)
Denture lacquer (12101000)
Anticoagulant and preservative solution
for blood (12102000)
Solution for blood fraction modification
(12103000)
Wound stick (12104000)
Radiopharmaceutical precursor
(12105000)
Radionuclide generator (12106000)
Kit for radiopharmaceutical preparation
(12107000)
Gastroenteral solution (12108000)
Dispersion (12109000)
Fibrin sealant-powder and solvent for
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fibrin sealant (12109500)
Gastroenteral suspension (12110000)
Gastroenteral emulsion (12111000)
Solution for organ preservation
(12112000)
Irrigation solution (12113000)
Stomach irrigation (12114000)
Sealant (12115000)
Solution of perfusion of organs
(12115500)
Powder and solvent for sealant
(12116000)
Impregnated pad (12117000)
Living tissue equivalent (12118000)
Medicated sponge (12119000)
Gastro-resistant capsule (12120)
Intestinal gel (12120000)
Medicated thread (12130000)
Solution for provocation test (12131000)
Prolonged-release capsule (12150)
Tablet (12200)
Medicinal gas, compressed (12301000)
Medicinal gas, cryogenic (12302000)
Medicinal gas, liquefied (12303000)
Oromucosal liquid (13050)
Lozenge (13220)
Dental liquid (14050)
Cutaneous spray (15090)
Cutaneous liquid (15130)
Eye drops (16040)
Ear drops (17040)
Ear spray (17090)
Ear wash (17120)
Nasal drops (18040)
Nasal spray (18080)
Vaginal liquid (19050)
Vaginal capsule (19100)
Enema (20050)
Nebuliser liquid (21010)
Pressurised inhalation (21060)
Inhalation powder (21100)
Inhalation vapour (21140)
Injection (22010)
Powder for injection (22050)
Sterile concentrate (22090)
Infusion (22100)
Powder for infusion (22120)
Endotracheopulmonary instillation
(26010)
Intrauterine liquid (29020)
Pouch (30047500)
Blood fraction modifier (31030)
Gastroenteral liquid (31080)
Chewable/dispersible tablet (50001000)
Coated granules in sachet (50001250)
Concentrate and diluent for solution for
infusion (50001500)
Concentrate and solvent for concentrate
for solution for infusion (50002000)
Concentrate and solvent for cutaneous
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solution (50003000)
Concentrate and solvent for cutaneous
use (50004000)
Concentrate and solvent for injection
(50005000)
Concentrate and solvent for solution for
infusion (50006000)
Concentrate and solvent for solution for
injection (50007000)
Concentrate and solvent for suspension
for injection (50008000)
Concentrate for cutaneous spray,
emulsion (50009000)
Concentrate for dispersion for infusion
(50009300)
Concentrate for emulsion for infusion
(50009500)
Concentrate for oral solution (50010000)
Concentrate for oral/rectal solution
(50011000)
Concentrate for peritoneal dialysis
solution (50012000)
Concentrate for solution for intravesical
use (50013000)
Concentrate for spray emulsion
(50013500)
Concentrate for suspension for infusion
(50014000)
Cutaneous and nasal ointment
(50015000)
Cutaneous/oromucosal/oral solution
(50015300)
Cutaneous/oromucosal spray
(50015400)
Cutaneous spray, emulsion (50015500)
Cutaneous spray, ointment (50016000)
Dental paste (50017000)
Ear/eye drops, solution (50018000)
Ear/eye oinment (50019000)
Ear/eye/nose drops, solution (50020000)
Effervescent buccal tablet (50020500)
Emulsion for injection/infusion
(50021000)
Emulsion and suspension for emulsion
for injection (50021500)
Endosinusial wash, suspension
(50022000)
Eye drops, solution in single-dose
container (50023000)
Film coated gastro-resistant tablet
(50023500)
Gargle/mouthwash (50024000)
Gastro-resistant coated tablet
(50025000)
Gastro-resistant granules for oral
suspension (50026000)
Gastro-resistant prolonged-release tablet
(50026250)
Granules and solvent for oral suspension
(50026500)
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Granules and solvent for suspension for
injection (50027000)
Granules for oral and rectal suspension
(50028000)
Granules for oral drops, solution
(50029000)
Granules for use in drinking water
(50029250)
Granules for vaginal solution (50029500)
Hard capsule with gastro-resistant
pellets (50029600)
Herbal tea in bag (50029700)
Inhalation powder, tablet (50030000)
Inhalation vapour, effervescent tablet
(50031000)
Inhalation vapour, emulsion (50032000)
Inhalation vapour, impregnated pad
(50033000)
Intrauterine foam (50033300)
Intravitreal implant in applicator
(50033500)
Liquefied gas for dental use (50034000)
Modified-release film-coated tablet
(50035000)
Modified-release granules for oral
suspension (50036000)
Muco-adhesive buccal prolonged-release
tablet (50036100)
Nasal/oromucosal solution (50036500)
Nasal spray and oromucosal solution
(50037000)
Nasal spray, solution in single-dose
container (50037250)
Oral drops, liquid (50037750)
Oral/rectal suspension (50038000)
Oral solution/concentrate for nebuliser
solution (50038500)
Oromucosal patch (50039000)
Oromucosal powder in pouch
(50039300)
Oromucosal/laryngopharyngeal solution
(50039500)
Oromucosal/laryngopharyngeal
solution/spray (50040000)
Pillules in single-dose container
(50041000)
Powder and solution for solution for
injection (50041500)
Powder and solvent for concentrate for
solution for infusion (50042000)
Powder for concentrate for solution for
infusion (50043000)
Powder and solvent for cutaneous
solution (50044000)
Powder and solvent for dispersion for
injection (50044500)
Powder and solvent for endosinusial
solution (50045000)
Powder and solvent for epilesional
solution (50045500)
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Powder and solvent for gingival gel
(50046000)
Powder and solvent for instillation
solution for intraocular use (50047000)
Powder and solvent for intravesical
solution (50047500)
Powder and solvent for nebuliser solution
(50047700)
Powder and solvent for prolonged-
release suspension for injection
(50048000)
Powder and solvent for solution for
injection in pre-filled syringe (50048250)
Powder and solvent for suspension for
injection in pre-filled syringe (50048300)
Powder and suspension for suspension
for injection (50048500)
Powder, dispersion and solvent for
concentrate for dispersion for injection
(50048600)
Powder for concentrate for dispersion for
infusion (50048750)
Powder for concentrate for
haemodialysis solution, (50049000)
Powder for concentrate for intravesical
suspension (50049100)
Powder for concentrate for solution for
injection/infusion (50049250)
Powder for dental solution (50049270)
Powder for epilesional solution
(50049300)
Powder for implantation suspension
(50049500)
Powder for   intravesical soluution
(50050000)
Powder for mouth wash (50051100)
Powder foor oral/rectal suspension
(50052000)
Powder for solution for injection or
infusion (50053000)
Powder for solution for injection/infusion
(50053500)
Powder for solution for intravesical use
(50054000)
Powder for solution for nasal spray
(50055000)
Powder for intravesical suspension
(500551000)
Prolonged-release film-coated tablet
(50055500)
Prolonged-release granules for oral
suspension (50056000)
Radiopharmaceutical precursor, solution
(50056500)
Solution for
haemodialysis/haemofiltration
(50057000)
Solution for infusion and oral solution
(50058000)
Solution for injection/concentrate for
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solution for infusion (50059000)
Solution for injection/infusion (50060000)
Solution for injection in cartridge
(50060100)
Solution for injection in pre-filled pen
(50060200)
Solution for injection in pre-filled syringe
(50060300)
Solution for injection in pre-filled syringe
with automatic needle guard (50060400)
Solution for injection/infusion in pre-filled
syringe (50060500)
Solution for intraperitoneal use
(50061000)
Solution for use in drinking water
(50061300)
Solution for sealant (50061500)
Solvent for nasal use (50061600)
Suspension and effervescent granules
for oral suspension (50062000)
Suspension and solution for spray
(50062500)
Suspension for infusion (50063000)
Suspension for injection in cartridge
(50063100)
Suspension for injection in pre-filled pen
(50063200)
Suspension for injection in pre-filled
syringe (50063300)
Suspension for use in drinking water
(50063500)
Tablet and solvent for rectal suspension
(50064000)
Tablet and powder for oral solution
(50065000)
Tablet for oral suspension (50066000)
Oral suspension for use in drinking water
(50070000)
Powder and solvent for dental gel
(50071000)
Powder for use in drinking water
(50072000)
Powder for solution for intraocular
irrigation (50073000)
Solvent for solution for intraocular
irrigation (50074000)
Solvent for solution for infusion
(50076000)
Dispersion for injection (50077000)
Gas and solvent for dispersion for
injection/infusion (50078000)
Concentrate for solution for
injection/infusion (50079000)
Powder and solvent for solution for
injection/infusion (50080000)
Inhalation solution (50081000)
Oral drops, powder for suspension
(50082000)
Anzahl der Packungen
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Anzahl der Einheiten pro Verabreichung
Häufigkeit der Verabreichung*
Duration of treatment
Behandlungsbeginn
Verabreichungsweg*
aurikulär (20001000)
bukkal (20002500)
kutan (20003000)
dental (20004000)
endocervikal (20006000)
endosinusal (20007000)
endotracheopulmonal (20008000)
epidural (20009000)
Epilesional use (20010000)
Extraamniotic use (20011000)
Extracorporeal use (20011500)
Gastroenteral use (20013000)
Gastric use (20013500)
Gingival use (20014000)
Hämodialyse (20015000)
Implantation (20015500)
Inhalation use (20020000)
Intestinal use (20021000)
Intraamniotic use (20022000)
Intraarterial use (20023000)
Intraarticular use (20024000)
Intrabursal use (20025000)
Intracardiac use (20026000)
Intracartilaginous use (20026500)
Intracavernous use (20027000)
Intracerebral use (20027010)
Intracervical use (20028000)
Intracisternal use (20028500)
Intracoronary use (20029000)
intradermal (20030000)
Intradiscal use (20031000)
Intraepidermal use (20031500)
Intralesional use (20032000)
Intralymphatic use (20033000)
intramuskulär (20035000)
Intraocular use (20036000)
Intraosseous use (20036500)
Intrapericardial use (20037000)
Intraperitoneal use (20038000)
Intrapleural use (20039000)
Intraprostatic use (20039500)
Intrasternal use (20041000)
Intrathecal use (20042000)
Intratumoral use (20043000)
Intrauterine use (20044000)
intravenös (20045000)
Intravesical use (20046000)
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Intravitreal use (20047000)
Iontophoresis (20047500)
Laryngopharyngeal use (20048000)
nasal (20049000)
Nebulisation use (20050000)
Ocular use (20051000)
oral (20053000)
Oromucosal use (20054000)
Oropharyngeal use (20055000)
Paravertebral use (20056000)
Periarticular use (20057000)
Perineural use (20058000)
Periodontal use (20059000)
Periosseous use (20059300)
Posterior juxtascleral use (20059500)
rektal (20061000)
retrobulbär (20061500)
Route of administration not applicable
(20062000)
Subconjunctival use (20065000)
subkutan (20066000)
sublingual (20067000)
Submucosal use (20067500)
transdermal (20070000)
Urethral use (20071000)
Vaginal use (20072000)
Anweisungen für Patient
Hinweis für Apotheke
Verschreibende Person
Beruf der verschreibenden Person
Health professionals (22)
Medical doctors (221)
Generalist medical practitioners (2211)
Specialist medical practitioners (2212)
Nursing and midwifery professionals
(222)
Nursing professionals (2221)
Midwifery professionals (2222)
Traditional and complementary medicine
professionals (223)
Paramedical practitioners (224)
Veterinarians (225)
Other health professionals (226)
Dentists (2261)
Pharmacists (2262)
Environmental and occupational health
and hygiene professionals (2263)
Physiotherapists (2264)
Dieticians and nutritionists (2265)
Audiologists and speech therapists
(2266)
Optometrists and ophthalmic opticians
(2267)
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Health professionals not elsewhere
classified (2269)
Health associate professionals (32)
Medical and pharmaceutical technicians
(321)
Medical imaging and therapeutic
equipment technicians (3211)
Medical and pathology laboratory
technicians (3212)
Pharmaceutical technicians and
assistants (3213)
Medical and dental prosthetic
technicians (3214)
Nursing and midwifery associate
professionals (322)
Nursing associate professionals (3221)
Midwifery associate professionals (3222)
Traditional and complementary medicine
associate professionals (323)
Other health associate professionals
(325)
Dental assistants and therapists (3251)
Medical records and health information
technicians (3252)
Community health workers (3253)
Dispensing opticians (3254)
Physiotherapy technicians and assistants
(3255)
Medical assistants (3256)
Environmental and occupational health
inspectors and associates (3257)
Ambulance workers (3258)
Health associate professionals not
elsewhere classified (3259)
Fachgebiet der verschreibenden Person
Zeitpunkt der Verschreibung
ID der verschreibenden Person
Vollständiger Name der verschreibenden Person
Telefonnummer der verschreibenden Person
E-Mail der verschreibenden Person
Einrichtung der verschreibenden Person
Aufsichtsorganisation der verschreibenden
Person
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ICD10 Chapters
ODM derived from
http://www.who.int/classifications/icd/en/
https://www.dimdi.de/static/de/klassi/icd-10-who/
All rights reserved. Please visit https://medical-data-
models.org/forms/11940
ICD10 Chapters
ICD10 Kapitel
ICD10 Kapitel
Bestimmte infektiöse und parasitäre
Krankheiten (A00-B99) (01)
Neubildungen (C00-D48) (02)
Krankheiten des Blutes und der
blutbildenden Organe sowie bestimmte
Störungen mit Beteiligung des
Immunsystems (D50-D89) (03)
Endokrine, Ernährungs- und
Stoffwechselkrankheiten (E00-E90) (04)
Psychische und Verhaltensstörungen
(F00-F99) (05)
Krankheiten des Nervensystems (G00-
G99) (06)
Krankheiten des Auges und der
Augenanhangsgebilde (H00-H59) (07)
Krankheiten des Ohres und des
Warzenfortsatzes (H60-H95) (08)
Krankheiten des Kreislaufsystems (I00-
I99) (09)
Krankheiten des Atmungssystems (J00-
J99) (10)
Krankheiten des Verdauungssystems
(K00-K93) (11)
Krankheiten der Haut und der Unterhaut
(L00-L99) (12)
Krankheiten des Muskel-Skelett-Systems
und des Bindegewebes (M00-M99) (13)
Krankheiten des Urogenitalsystems
(N00-N99) (14)
Schwangerschaft, Geburt und
Wochenbett (O00-O99) (15)
Bestimmte Zustände, die ihren Ursprung
in der Perinatalperiode haben (P00-P96)
(16)
Angeborene Fehlbildungen,
Deformitäten und
Chromosomenanomalien (Q00-Q99)
(17)
Symptome und abnorme klinische und
Laborbefunde, die anderenorts nicht
klassifiziert sind (R00-R99) (18)
Verletzungen, Vergiftungen und
bestimmte andere Folgen äußerer
Ursachen (S00-T98) (19)
Äußere Ursachen von Morbidität und
Mortalität (V01-Y98) (20)
Faktoren, die den Gesundheitszustand
beeinflussen und zur Inanspruchnahme
des Gesundheitswesens führen (Z00-
Z99) (21)
Schlüsselnummern für besondere
Zwecke (U00-U89) (22)
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End of Study Psoriasis MIPSO EudraCT
2014-003022-40
MIPSO Vergleichende Untersuchung der bakteriellen
Mikrobiota in der Haut sowie dem Darm von Psoriasis-
Patienten vor und nach systemischer Behandlung mit
Adalimumab bzw. Ustekinumab oder Ciclosporin
(EudraCT 2014-003022-40)
Principal Investigator: Prof. Dr. Dr. h.c. Thomas A. Luger
All rights reserved. Please visit https://medical-data-
models.org/forms/11954
End of Study Psoriasis MIPSO
EudraCT 2014-003022-40
Studienende/-abbruch
Patientennummer (derived)
Studienende / Studienabbruch Datum
Studienende / Studienabbruch Datum Status
T (1)
TM (2)
M (3)
Studienende / Studienabbruch
reguläres Studienende (1)
vorzeitiger Studienabbruch (2)
Studienabbruch Grund 1
Wechsel der Behandlung erforderlich (1)
Studienabbruch Grund 2
Patientenwunsch (1)
Studienabbruch Grund 3
Ein/Aus verletzt vor Therapie (1)
Studienabbruch Grund 4
Ein/Aus verletzt bei Studienpatient (1)
Studienabbruch Grund 5
Eintreten einer Schwangerschaft (1)
Studienabbruch Grund 6
Nicht zulässige Begleitmedikation (1)
Studienabbruch Grund 7
Weitere Teilnahme ärztlich nicht
vertrebar (1)
Studienabbruch Grund 8
Zeitfenster für Visiten nicht eingehalten
(1)
Studienabbruch Grund 9
Mangelnde Compliance des Patienten
(1)
Studienabbruch Grund 10
Abbruch der gesamten Studie (1)
Studienabbruch Grund 11
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Anderer Grund (9)
Studienabbruch Grund 11 (Beschreibung)
Studienende/-abbruch: Datum der Unterschrift
Studienende/-abbruch: Datum Unterschrift Status
T (1)
TM (2)
M (3)
Studienende/-abbruch: Unterschrift Prüfer vorh.
nein (0)
ja (1)
Kommentar Studienende/-abbruch
Studienabbruch Grund RQG
Studienabbruch verletztes Ein/Aus
EIN01 (1)
AUS05 (10)
AUS06 (11)
AUS07 (12)
AUS08 (13)
AUS09 (14)
AUS10 (15)
AUS11 (16)
AUS12 (17)
AUS13 (18)
AUS14 (19)
EIN02 (2)
AUS15 (20)
AUS16 (21)
AUS17 (22)
AUS18 (23)
AUS19 (24)
AUS20 (25)
AUS21 (26)
AUS22 (27)
AUS23 (28)
AUS24 (29)
EIN03 (3)
AUS25 (30)
AUS26 (31)
AUS27 (32)
AUS28 (33)
AUS29 (34)
AUS30 (35)
AUS31 (36)
AUS32 (37)
AUS33 (38)
AUS34 (39)
EIN04 (4)
AUS35 (40)
AUS36 (41)
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AUS37 (42)
AUS38 (43)
AUS39 (44)
AUS40 (45)
AUS41 (46)
AUS42 (47)
AUS43 (48)
AUS44 (49)
EIN05 (5)
AUS45 (50)
AUS46 (51)
AUS01 (6)
AUS02 (7)
AUS03 (8)
AUS04 (9)
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1. Induction Acute Myeloid Leukemia =60
years (AML2003) NCT00180102
AML2003 - Standard-Therapy vs Intensified Therapy for
Adult Acute Myeloid Leukemia Patients <= 60 Years
http://clinicaltrials.gov/show/NCT00180102
Prospektive, randomisierte, multizentrische
Therapieoptimierungsstudie - Studienprotokoll AML2003
All rights reserved. Please visit https://medical-data-
models.org/forms/11959
1. Induction Acute Myeloid Leukemia
<=60 years (AML2003)
NCT00180102
Allgemeine Angaben
Klinik-Nr.:*
Patienten-Nr.: 2-*
Patienten-Initialen: (Nachname/Vorname)*
Beginn:*
Ende:*
Größe*
>= 0
cm
Gewicht*
>= 0
kg
Körperoberfläche*
>= 0
m²
Daunorubicin
Tag - tatsächlich (vorgesehen 3-5)*
Daunorubicin Tagesdosis - tatsächlich
(vorgesehen 60 mg/qm über 2h i.v.)*
Gesamtdosis absolut*
mg
Dosisreduktion*
Ja
Nein
Ara-C
Tag - tatsächlich (vorgesehen 1-7)*
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Ara-C Tagesdosis - tatsächlich (vorgesehen 100
mg/qm über 24h i.v.)*
Gesamtdosis absolut*
mg
Dosisreduktion*
Ja
Nein
G-CSF-Gabe:
Beginn:*
Ende:*
Handelsname:*
Gesamtdosis*
µg
Zytopeniedauer
Beginn Leukozyten <1,0 GPt/l bzw. <1000 /ul:*
Ende (3x Leukozyten >1,0 GPt/l bzw. >=1000
/ul):*
Zytopenie andauernd*
Ja
Nein
Beginn Neutrophile <0,5 GPt/l bzw. <500 /ul:*
Ende (3x Neutrophile >0,5 GPt/l bzw. >=500 /ul):*
Zytopenie andauernd*
Ja
Nein
Beginn Thrombozyten <20 GPt/l bzw. <20000
/ul:*
Ende (3x Thrombozyten >20 GPt/l bzw. >=20000
/ul):*
Zytopenie andauernd*
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Ja
Nein
Transfusionen
Anzahl Erythrozyten-Transfusionen*
andauernde Erythrozyten-Transfusionen*
Ja
Nein
Anzahl Thrombozyten-Transfusionen
(Einzelspender)*
andauernde Thrombozyten-Transfusionen*
Ja
Nein
Anzahl Thrombozyten-Transfusionen (gepoolt)*
andauernde Thrombozyten-Transfusionen*
Ja
Nein
Unterschrift
Datum*
Name des Studienarztes/Unterschrift*
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Pre-Study Breast Cancer SWOG S0307
NCT00127205
SOUTHWEST ONCOLOGY GROUP S0307 PRESTUDY
FORM
Zoledronate, Clodronate, or Ibandronate in Treating Women
Who Have Undergone Surgery for Stage I, Stage II, or
Stage III Breast
SOUTHWEST ONCOLOGY GROUP S0307 PRESTUDY
FORM Zoledronate, Clodronate, or Ibandronate in Treating
Women Who Have Undergone Surgery for Stage I, Stage
II, or Stage III Breast
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=DEA0B902-
CDD3-54E6-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/11960
Pre-Study Breast Cancer SWOG
S0307 NCT00127205
Administrative documentation
SWOG Patient ID*
SWOG Study No.*
Registration Step*
Patient Initials (L, F M)
Institution/Affiliate*
Physician*
Participating Group Name*
Participating Group Study No.*
Participating Group Patient ID*
Comments
Disease Description
Performance Status
Fully Active, Able To Carry On All Pre-
disease Performance Without
Restriction. (0)
Restricted In Physically Strenuous
Activity But Ambulatory And Able To
Carry Out Work Of A Light Or Sedentary
Nature, E.g., Light Housework, Office
Work. (1)
Ambulatory And Capable Of All Selfcare
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But Unable To Carry Out Any Work
Activities. Up And About More Than 50%
Of Waking Hours. (2)
Histologically confirmed primary invasive
adenocarcinoma of the breast*
Stage I (Stage I)
Stage Ii (Stage II)
Stage Iii (Stage III)
Laboratory Values
Serum creatinine*
mg/dL
Creatinine ULN*
mg/dL
Collection Date (mm/dd/yyyy)*
Previous bisphosphonate*
Intravenous: C13346 (IV)
None: C41132 (None)
Oral (Oral)
Date of dental examination (mm/dd/yyyy)*
Bone Pain
Yes
No
Bone Metastasis
Yes
No
Consent For Submission And Banking
Consent for submission and banking*
Accepted Serum Submission (Accepted
serum submission)
Accepted Tissue Submission (Accepted
tissue submission)
Declined Serum Submission (Declined
serum submission)
Declined Tissue Submission (Declined
tissue submission)
Patient Characteristics
Menopausal status  (select one:)*
Above Categories Not Applicable And
Age <50 (Above not applicable AND age
< 50)
Above Categories Not Applicable And
Age >= 50 (Above not applicable AND
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age >=50)
Post (prior Bilateral Ovariectomy Or >12
Mo Since Lmp With No Prior
Hysterectomy) (Post (prior bilateral
ovariectomy OR > 12 mo since LMP with
no prior hysterectomy))
Pre (<6 Mo Since Lmp And No Prior
Bilateral Ovariectomy And Not On
Estrogen Replacement) (Pre (< 6 mo
since LMP and no prior bilateral
ovariectomy and not on estrogen
replacement))
Height
>= 0
cm
Body weight
>= 0
kg
Body surface area
>= 0
m²
Disease Description
Date of Initial Diagnosis of Primary Tumor*
Tumor Laterality (select one:)
Bilateral (Bilateral)
Left (Left)
Right (Right)
Pathologic Primary Tumor Size (cm.)
cm
Number of Positive Lymph Nodes (If sentinel
node biopsy and axillary node dissection were
performed, enter the sum of positive nodes.)
ER Status
Negative (ER-)
Positive (ER+)
PgR Status
Negative (PgR-)
Positive (PgR+)
Was HER-2/neu status determined?
Yes
No
If Yes, HER2/neu final diagnosis
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Equivocal (Equivocal)
Negative (Negative)
Positive (Positive)
Treatment With Statins
Is the patient currently taking a statin
(atorvastatin Lipitor, pravastatin Pravachol,
simvastatin Zocor, lovastatin Mevacor, fluvastatin
Lescol, rosuvastatin Crestor?)
Yes
No
Length of time on statin*
< 1 Yr (< 1 yr)
>4 Yrs (>4 yrs)
1-2 Yrs (1-2 yrs)
2-3 Yrs (2-3 yrs)
3-4 Yrs (3-4 yrs)
Patient Preference
If oral and intravenous bisphosphonates are
equally effective in preventing breast cancer
recurrence in the bone, which would the patient
prefer to receive? (Note that the answer to this
question will not in any way affect which
treatment the patient is randomly assigned to on
this study.)*
Intravenous (Intravenous)
Oral (Oral)
Prior Treatment Related To This Cancer
Most Extensive Primary Surgery  (select one:)*
Mastectomy, Nos (Mastectomy, NOS)
Partial Mastectomy, Lumpectomy Or
Excisional Biopsy (Partial
mastectomy/lumpectomy/excisional
biopsy)
Date of surgery*
Was sentinel node sampling performed?*
Yes
No
Sentinel Node Biopsy Date*
Sentinel Node Biopsy Results*
Negative (Negative)
Positive (Positive)
Was axillary dissection performed?*
Yes
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No
Date of Axillary Dissection*
Systemic Treatment For This Cancer
Chemotherapy (select one:)*
Completed (Completed)
Currently Receiving (Currently receiving)
Not Planned (Not planned)
Planned (Planned)
Date chemotherapy completed (If completed,)*
Hormone therapy (select one:)*
Currently Receiving (Currently receiving)
Not Planned (Not planned)
Planned (Planned)
If currently receiving*
Aromatase Inhibitor (Aromatase inhibitor)
Ovarian Suppression (Ovarian
suppression)
Serm (SERM)
5 / 5
Pre-Study Breast Cancer SWOG S0307 NCT00127205
Emergency protocol- Module Observation
Emergency protocol by the DIVI (Deutsche Interdisziplinäre
Vereinigung für Intensiv- und Notfallmedizin).  ODM derived
from “Notaufnahmeprotokoll Modul Überwachung”
All rights reserved. Please visit https://medical-data-
models.org/forms/11964
Emergency protocol- Module
Observation
PATIENTENINFORMATIONEN
Name des Patienten:*
Patienten-ID:*
Geburtsdatum:*
Geschlecht:
männlich  (1)
weiblich (2)
Bemerkung / Notizen / Verlauf:
ANORDNUNGEN
Anordnungen:
Anordnungen Zeitpunkt:
Uhr
Durchgeführt von:
Durchgeführt um:
Uhr
Bemerkung / Notizen / Verlauf:
BLUT UND GERINNUNG/
INVASIVITÄTEN/ BEATMUNG
Beatmung:
Spontanatmung (1)
unterstützte Spontanatmung (2)
kontrollierte Beatmung (3)
sonstige Beatmungsform (4)
Invasivitäten:
venös (1)
arteriell (2)
ZVK (3)
IO (4)
Blasenkatheter (5)
1 / 4
Gerinnung:
Tranexamsäure (1)
Fibrinogen (2)
Faktor XIII  (3)
Calcium (4)
PPSB (5)
Beginn Gerinungstherapie:
Uhr
Erythrozyten-Konzentrate (EK):
>= 1
<= 12
Zeitpunkt erste Gabe des EK:
Uhr
Gefrierfrischplasma (FFP):
>= 1
<= 12
Zeitpunkt erste Gabe des FFP:
Uhr
Thrombozyten-Konzentrate (TK)
>= 1
<= 12
Zeitpunkt erste Gabe des TK:
Uhr
Pflege durch:
Pflege von- bis:
Arzt:
Arzt von- bis:
ÜBERWACHUNG
Zeit:
Uhr
Blutdruck:
mmHg
Defibrillation:
Ja
Nein
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In-/ Extubation:
Ja
Nein
Narkose:
Ja
Nein
Gewicht:
Kg
Größe:
cm
Medikamente:
Dosis:
Infusionen:
Dosis:
Perfusoren:
Dosis:
Sauerstoff:
l/min
FiO2:
%
etCO2:
mmHg
Ateminutenvolumen (AMV):
Residualvolumen (VR):
l
VP max:
Positiver endexspiratorischer Druck (PEEP):
AF:
Atemzüge/min
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Sauerstoffsättigung (SpO2):
mmHg
Systolischer Blutdruck:
mmHg
Herzfrequenz (HF):
/min
Temperatur:
°C
GCS:
Thoraxschmerz:
Urin:
Kalium:
Gefühl:
Anästhesiologischen Verlaufs- Beobachtung
(AVB):
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Emergency protocol- Module Anesthesia
Emergency protocol by the DIVI (Deutsche Interdisziplinäre
Vereinigung für Intensiv- und Notfallmedizin).  ODM derived
from “Notaufnahmeprotokoll Modul Anästhesie”.
All rights reserved. Please visit https://medical-data-
models.org/forms/11965
Anesthesia
PATIENTENINFORMATIONEN
Name des Patienten:*
Geburtsdatum:*
Patienten-ID:*
Geschlecht:
männlich  (1)
weiblich (2)
RISIKO-EINSCHÄTZUNG
Blutdruck:
kein path. Befund (1)
path. Befund ohne Relevanz für
Anästhesie (2)
path. Befund mit Relevanz für
Anästhesie (3)
Befunde nicht erhoben (4)
Myokard:
kein path. Befund (1)
path. Befund ohne Relevanz für
Anästhesie (2)
path. Befund mit Relevanz für
Anästhesie (3)
Befunde nicht erhoben (4)
Koronarfunktion:
kein path. Befund (1)
path. Befund ohne Relevanz für
Anästhesie (2)
path. Befund mit Relevanz für
Anästhesie (3)
Befunde nicht erhoben (4)
EKG:
kein path. Befund (1)
path. Befund ohne Relevanz für
Anästhesie (2)
path. Befund mit Relevanz für
Anästhesie (3)
Befunde nicht erhoben (4)
Gefäßsystem:
kein path. Befund (1)
path. Befund ohne Relevanz für
Anästhesie (2)
path. Befund mit Relevanz für
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Anästhesie (3)
Befunde nicht erhoben (4)
Lunge/Atemweg:
kein path. Befund (1)
path. Befund ohne Relevanz für
Anästhesie (2)
path. Befund mit Relevanz für
Anästhesie (3)
Befunde nicht erhoben (4)
Rö-Thorax:
kein path. Befund (1)
path. Befund ohne Relevanz für
Anästhesie (2)
path. Befund mit Relevanz für
Anästhesie (3)
Befunde nicht erhoben (4)
Bewusstsein:
kein path. Befund (1)
path. Befund ohne Relevanz für
Anästhesie (2)
path. Befund mit Relevanz für
Anästhesie (3)
Befunde nicht erhoben (4)
Neurologie:
kein path. Befund (1)
path. Befund ohne Relevanz für
Anästhesie (2)
path. Befund mit Relevanz für
Anästhesie (3)
Befunde nicht erhoben (4)
Muskulatur:
kein path. Befund (1)
path. Befund ohne Relevanz für
Anästhesie (2)
path. Befund mit Relevanz für
Anästhesie (3)
Befunde nicht erhoben (4)
Endokrinium:
kein path. Befund (1)
path. Befund ohne Relevanz für
Anästhesie (2)
path. Befund mit Relevanz für
Anästhesie (3)
Befunde nicht erhoben (4)
Leber:
kein path. Befund (1)
path. Befund ohne Relevanz für
Anästhesie (2)
path. Befund mit Relevanz für
Anästhesie (3)
Befunde nicht erhoben (4)
Niere:
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kein path. Befund (1)
path. Befund ohne Relevanz für
Anästhesie (2)
path. Befund mit Relevanz für
Anästhesie (3)
Befunde nicht erhoben (4)
Anatomie:
kein path. Befund (1)
path. Befund ohne Relevanz für
Anästhesie (2)
path. Befund mit Relevanz für
Anästhesie (3)
Befunde nicht erhoben (4)
Allergie:
kein path. Befund (1)
path. Befund ohne Relevanz für
Anästhesie (2)
path. Befund mit Relevanz für
Anästhesie (3)
Befunde nicht erhoben (4)
Elektrolyte:
kein path. Befund (1)
path. Befund ohne Relevanz für
Anästhesie (2)
path. Befund mit Relevanz für
Anästhesie (3)
Befunde nicht erhoben (4)
Säure-Basen-H.:
kein path. Befund (1)
path. Befund ohne Relevanz für
Anästhesie (2)
path. Befund mit Relevanz für
Anästhesie (3)
Befunde nicht erhoben (4)
Hämatologie:
kein path. Befund (1)
path. Befund ohne Relevanz für
Anästhesie (2)
path. Befund mit Relevanz für
Anästhesie (3)
Befunde nicht erhoben (4)
Gerinnung:
kein path. Befund (1)
path. Befund ohne Relevanz für
Anästhesie (2)
path. Befund mit Relevanz für
Anästhesie (3)
Befunde nicht erhoben (4)
Ernährungszustand:
kein path. Befund (1)
path. Befund ohne Relevanz für
Anästhesie (2)
path. Befund mit Relevanz für
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Anästhesie (3)
Befunde nicht erhoben (4)
Zahnstatus:
kein path. Befund (1)
path. Befund ohne Relevanz für
Anästhesie (2)
path. Befund mit Relevanz für
Anästhesie (3)
Befunde nicht erhoben (4)
VERSCHIEDENE
ASA:
Dienstart:
RD (1)
BD (2)
ÜS (3)
Dringlichkeit:
geplant (1)
dringlich (2)
Notfall (3)
Größe:
cm
Körpergewicht:
Kg
Letzte Mahlzeit (fest) um:
Uhr
Letzte Mahlzeit (flüssig) um:
Uhr
Alkohol:
g/d
Nikotin:
py
RCRI:
MET:
Mallampati:
Reklination:
gut (1)
eingeschränkt (2)
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unmöglich (3)
Zahnstatus
Vollprothese:
oben (1)
unten (2)
Teilprothese:
oben (1)
unten (2)
Fachrichtung:
Prämedikationserfolg:
gering (1)
gut (2)
tief schlafend (3)
PM nicht vorgesehen (4)
PM nicht erhalten (5)
Cormack:
OPS-301:
Anästhesie Verlaufsbeobachtung (AVB):
Durchführung/Verlauf/Besonderheiten:
Anordnungen für AWR/Station:
Ende AWR um:
Uhr
BTM-Abrechnung:
Anaesthesia technique
ANÄSTHESIETECHNIK
Einleitung:
inhalativ geplant (1)
inhalativ durchgeführt (2)
intravenös geplant (3)
intravenös durchgeführt (4)
Aufrechterhaltung:
inhalativ geplant (1)
inhalativ durchgeführt (2)
intravenös geplant (3)
intravenös durchgeführt (4)
balanciert geplant (5)
balanciert durchgeführt (6)
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Regionalanästhesie:
SPA geplant (1)
IVRA durchgeführt (10)
sonstige geplant (11)
sonstige durchgeführt (12)
periphere Blockade geplant (13)
periphere Blockade durchgeführt (14)
mit Katheter geplant (15)
mit Katheter durchgeführt (16)
Kombinationsnarkose geplant (17)
Kombinationsnarkose durchgeführt (18)
SPA durchgeführt (2)
PDA lumbal geplant (3)
PDA lumbal durchgeführt (4)
PDA thorakal geplant (5)
PDA thorakal durchgeführt (6)
Plexus geplant (7)
Plexus durchgeführt (8)
IVRA geplant (9)
Sonstige Verfahren:
Standby geplant (1)
Standby durchgeführt (2)
Sedierung geplant (3)
Sedierung durchgeführt (4)
Atemwegszugang:
orale ITN geplant (1)
Doppellumentubus durchgeführt (10)
Jet geplant (11)
Jet durchgeführt (12)
Trachealkanüle geplant (13)
Trachealkanüle durchgeführt (14)
sonstige geplant (15)
sonstige durchgeführt (16)
orale ITN durchgeführt (2)
nasale ITN geplant (3)
nasale ITN durchgeführt (4)
Maske geplant (5)
Maske durchgeführt (6)
SGA geplant (7)
SGA durchgeführt (8)
Doppellumentubus geplant (9)
Measures in recovery room
MAßNAHMEN IN AWR
Zentraler Venenkatheter (ZVK):
Ja
Nein
Periduralanästhesie (PDA):
Ja
Nein
Patientengesteuerte Analgesie (PCA):
Ja
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Nein
Urin-Ableitung:
Ja
Nein
Nachbeatmung:
Ja
Nein
Labor:
Ja
Nein
Transfusion:
Ja
Nein
Cell-Saver:
Ja
Nein
Pneumonieprophylax:
Ja
Nein
Spritzenpumpe:
Ja
Nein
Magensonde:
Ja
Nein
Mobilisierung:
Ja
Nein
Sonstiges:
Ja
Nein
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On-Study Form Adjuvant Melanoma Stage
III or IV E1609 NCT01274338
E1609 Adjuvant Melanoma On-Study Form NCT01274338
Ipilimumab or High-Dose Interferon Alfa-2b in Treating
Patients With High-Risk Stage III or Stage IV Melanoma
That Has Been Removed by Surgery Source
E1609 Adjuvant Melanoma On-Study Form NCT01274338
Ipilimumab or High-Dose Interferon Alfa-2b in Treating
Patients With High-Risk Stage III or Stage IV Melanoma
That Has Been Removed by Surgery
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=9774AE71-
6A1A-F871-E040-BB89AD4322F8
All rights reserved. Please visit https://medical-data-
models.org/forms/11966
On-Study Form Adjuvant Melanoma
Stage III or IV E1609 NCT01274338
Header
ECOG Protocol Number
ECOG Patient ID
DCI Name
Registration Step
Report period
Baseline (Baseline)
Please mark an 'X' if data have been amended.
Data Amended Date
Patient demographics
Patient Initials
Participating Group Protocol Number
Institution/Affiliate
Participating Group Patient ID
Patient status assessment
Height
>= 0
cm
ECOG Performance status
Fully Active, Able To Carry On All Pre-
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disease Performance Without Restriction
(karnofsky 90 - 100) (ecog - 0
Asymptomatic) (0=)
Restricted In Physically Strenuous
Activity But Ambulatory (k70 - 80) (ecog -
1 Symptomatic - Fully Ambulatory) (1=)
Ambulatory And Capable Of All Selfcare
But Unable To Carry Out Any Work
Activities (k 50 - 60) (ecog - 2
Symptomatic; In Bed , 50% Of The Day)
(2=)
Capable Of Limited Selfcare, Confined
To Bed Or Chair More Than 50% Of
Waking Hours. (k 30 - 40) (ecog - 3
Symptomatic; In Bed > 50% Of The Day
But Not Bedridden) (3=)
Completely Disabled (k10 - 20) (ecog - 4
Bedridden) (4=)
Was BRAF Gene Analysis performed (If yes,
submit E1609 Source Document Tracking
Coversheet)
Yes
No
BRAF Mutation Result (If Yes:)
Other (Other)
Unknown (Unknown)
V600e (V600E)
V600k (V600K)
Wild Type (Wild Type)
Specify
Date of Test (BRAF Mutation)
Prior Treatment For This Disease
Prior Immunotherapy (for melanoma at any time)
Yes
No
Yes specify (if)
Date (if applicable)
Prior Treatment For This Disease
Initial biopsy of primary
No (No)
Unknown (Unknown)
Yes (Yes)
Resection of primary
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No (No)
Unknown (Unknown)
Yes (Yes)
Resection of local skin recurrence (w/in 5 cm of
primary_)
No (No)
Unknown (Unknown)
Yes (Yes)
Lymphatic mapping
No (No)
Unknown (Unknown)
Yes (Yes)
Sentinel lymph node biopsy
No (No)
Unknown (Unknown)
Yes (Yes)
Regional lymph node dissection
No (No)
Unknown (Unknown)
Yes (Yes)
Resection of recurrence in regional lymph node
basin
No (No)
Unknown (Unknown)
Yes (Yes)
Resection of recurrence in the form of in-transit or
satellite metastases
No (No)
Unknown (Unknown)
Yes (Yes)
Resection of recurrence in the form of distant
skin/subcutaneous metastases
No (No)
Unknown (Unknown)
Yes (Yes)
Resection of recurrence in the form of lung
metastases
No (No)
Unknown (Unknown)
Yes (Yes)
Date (if applicable)
Prior Treatment For This Disease
Resection of cutaneous and subcutaneous
metastases
No (No)
Unknown (Unknown)
Yes (Yes)
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Resection of nodal (lymphatic) metastases
No (No)
Unknown (Unknown)
Yes (Yes)
Resection of lung metastases
No (No)
Unknown (Unknown)
Yes (Yes)
Prior Treatment For This Disease
Prior radiation therapy for melanoma
No (No)
Unknown (Unknown)
Yes (Yes)
Date (if applicable)
Description Of Disease At Initial Diagnosis
Date of initial pathologic diagnosis
Pathologic T Stage
Tumor 1.0 Mm Or Less In Thickness And
Clark?s Level Ii Or Iii, No Ulceration
(T1a)
Tumor 1.0 Mm Or Less In Thickness And
Clark?s Level Iv Or V Or With Ulceration
(T1b)
Tumor More Than 1.0 Mm But Not More
Than 2.0 Mm In Thickness, No
Ulceration (T2a)
Tumor More Than 1.0 Mm But Not More
Than 2.0 Mm In Thickness, With
Ulceration (T2b)
Tumor More Than 2.0 Mm But Not More
Than 4 Mm In Thickness, No Ulceration
(T3a)
Tumor More Than 2.0 Mm But Not More
Than 4 Mm In Thickness, With
Ulceration. (T3b)
Tumor More Than 4.0 Mm In Thickness,
No Ulceration. (T4a)
Tumor More Than 4.0 Mm In Thickness,
With Ulceration. (T4b)
Primary Tumor Cannot Be Assessed
(e.g., Shave Biopsy Or Regressed
Melanoma) (TX)
Mark an 'X' if unknown
Pathologic N Stage
No Regional Lymph Node Metastasis
(N0)
4 / 9
On-Study Form Adjuvant Melanoma Stage III or IV E1609 NCT01274338
Metastasis To One Lymph Node.
Clinically Occult (microscopic)
Metastasis (N1a)
Metastasis To One Lymph Node.
Clinically Apparent (macroscopic)
Metastasis (N1b)
Metastasis To 2 Or 3 Regional Nodes Or
Intralymphatic Regional Metastasis
Without Nodal Metastases. Clinically
Occult (microscopic) Metastasis
Clinically Occult (microscopic)
Metastasis (N2a)
Metastasis To 2 Or 3 Regional Nodes Or
Intralymphatic Regional Metastasis
Without Nodal Metastases. Clinically
Apparent (macroscopic) Metastasis
(N2b)
Metastasis To 2 Or 3 Regional Nodes Or
Intralymphatic Regional Metastasis
Without Nodal Metastases. Satellite Or
In-transit Metastasis Without Nodal
Metastasis (N2c)
Metastasis To 2 Or 3 Regional Nodes Or
Intralymphatic Regional Metastasis
Without Nodal Metastases. Satellite Or
In-transit Metastasis Without Nodal
Metastasis (N3)
Regional Lymph Nodes Cannot Be
Assessed (NX)
Pathologic M Stage
No Distant Metastases (M0)
Metastasis To Skin, Subcutaneous
Tissues, Or Distant Lymph Nodes (M1a)
Metastasis To Lung (M1b)
Metastasis To All Other Visceral Sites Or
Distant Metastasis At Any Site
Associated With An Elevated Serum
Lactic Dehydrogenase (M1c)
Distant Metastasis Cannot Be Assessed
(MX)
Breslow thickness
Primary Site
Acral (acral)
Anogenital (non-mucosal) (Anogenital
(non-mucosal))
Cutaneous (Cutaneous)
Head (Head)
Lower Extremity (Lower extremity)
Mucosal (Mucosal)
Neck (Neck)
Ocular (Ocular)
Other Specify (Other)
Trunk (Trunk)
Unknown (Unknown)
Upper Extremity (Upper extremity)
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Other specify (If)
Status of Primary Tumor
Not Recurrent, Resected, No Residual
Tumor (Not recurrent, resected, no
residual tumor)
Not Recurrent, Resected, Residual
Tumor (Not recurrent, resected, residual
tumor)
Primary Tumor Is Unknown (primary
tumor is unknown)
Recurrent (Recurrent)
Unresected (Unresected)
Ulceration
No (no)
Unknown (Unknown)
Yes (yes)
Clark level
Above Basal Lamina (in Situ) (above
basal lamina)
Extension Into Papillary Dermis
(extension into papillary dermis)
Interface Papillary-reticular Dermis
(interface papillary-reticular dermis)
Reticular Dermis (reticular dermis)
Subcutaneous Fat (subcutaneous fat)
unknown (unknown)
Pattern of involvement
Acral Lentiginous (acral lentiginous)
Lentigo Maligna Melanoma (lentigo
maligna melanoma)
Mucosal (Mucosal)
Nodular (nodular)
Other, Specify (other)
Superficial Spreading (superficial
spreading)
unknown (unknown)
Other specify
Mitotic rate
0 Per Square Millimeter (0 per square
millimeter)
1 Per Square Millimeter (1 per square
millimeter)
10 Or More Per Square Millimeter (10 or
more per square millimeter)
2 Per Square Millimeter (2 per square
millimeter)
3 Per Square Millimeter (3 per square
millimeter)
4 Per Square Millimeter (4 per square
millimeter)
5-10 Per Square Millimeter (5-10 per
square millimeter)
Unknown (Unknown)
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Gross extracapsular extension at primary
presentation (Regional Lymph Nodes/Intrasit
Metastases)
No (no)
Unknown (unknown)
Yes (yes)
Micro Extracapsular extension at primary
presentation
No (no)
Unknown (unknown)
Yes (yes)
Macroscopic (Involvement of nodes)
No (No)
Unknown (Unknown)
Yes (Yes)
Microscopic (Involvement of nodes)
No (No)
Unknown (Unknown)
Yes (Yes)
Intransit metastases or satellite lesions (at
primary presentation)
No (No)
Unknown (Unknown)
Yes (Yes)
Matted Lymph Nodes
No (No)
Unknown (Unknown)
Yes (Yes)
Were lymph nodes examined at the primary
presentation?
No (No)
Unknown (Unknown)
Yes (Yes)
Number of Lymph Nodes Examined (If yes:)
Number of Positive Lymph Nodes
Distant metastases
Cutaneous (Cutaneous)
Lung (Lung)
Nodal (Nodal)
History Of Disease
Newly diagnosed primary cutaneous melanoma
along with
Yes
No
Newly diagnosed primary cutaneous melanoma
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along with (If Yes:)
Distant Cutaneous/nodal Disease
(distant cutaneous/nodal disease)
Distant Lung Disease (distant lung
disease)
Regional Nodal And Satellite/in-transit
Disease (regional nodal and satellite/in-
transit disease)
Regional Nodal Without Satellite/in-
transit Disease (regional nodal without
satellite/in-transit disease)
Regional Satellite/in-transit Disease
Without Lymph Nodes Involvement
(regional satellite/in-transit disease
without lymph nodes involvement)
Specify the classification (If answered 1,)
Melanoma Stage Iiib (IIIB)
Melanoma Stage Iiic (IIIC)
Melanoma M1a (M1a)
Previously diagnosed primary cutaneous
melanoma with subsequent
Yes
No
Previously diagnosed primary cutaneous
melanoma with subsequent (If Yes:)
Distant Cutaneous/nodal Disease
(distant cutaneous/nodal disease)
Distant Lung Disease (distant lung
disease)
Regional Nodal And Satellite/in-transit
Disease (regional nodal and satellite/in-
transit disease)
Regional Nodal Without Satellite/in-
transit Disease (regional nodal without
satellite/in-transit disease)
Regional Satellite/in-transit Disease
Without Lymph Nodes Involvement
(regional satellite/in-transit disease
without lymph nodes involvement)
Unknown primary melanoma presenting with
Yes
No
Unknown primary melanoma presenting with (If
Yes:)
Cutaneous Or Nodal Disease (cutaneous
or nodal disease)
Lung Disease (lung disease)
Baseline Abnormalities
CTC AE Term
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CTC Adverse Event Grade (v4.0 Use grade 1-4
per CTCAE)
Mild Adverse Event (1)
Moderate Adverse Event (2)
Severe Adverse Event (3)
Life Threatening Adverse Event (4)
Comments
Comments
Investigator Signature
Investigator Signature Date
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On-Study Form Advanced Melanoma
E2603 NCT00110019
E2603 Advanced Melanoma On-Study Form
NCT00110019 Carboplatin and Paclitaxel With or Without
Sorafenib in Treating Patients With Unresectable Stage III
or Stage IV Melanoma
E2603 Advanced Melanoma On-Study Form
NCT00110019
Carboplatin and Paclitaxel With or Without Sorafenib in
Treating Patients With Unresectable Stage III or Stage IV
Melanoma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=E75E3DD6-
DB7A-4ABA-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/11968
On-Study Form Advanced Melanoma
E2603 NCT00110019
Header
ECOG Protocol Number
ECOG Patient ID
DCI Name
Registration Step
Report period
Baseline (Baseline)
Patient demographics
Patient Initials
Participating Group Protocol Number
Institution/Affiliate
Participating Group Patient ID
Data amendment
Please mark an 'X' if data have been amended.
Data Amended Date
ECOG Performance status
Fully Active, Able To Carry On All Pre-
disease Performance Without Restriction
(karnofsky 90 - 100) (ecog - 0
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Asymptomatic) (0=)
Restricted In Physically Strenuous
Activity But Ambulatory (k70 - 80) (ecog -
1 Symptomatic - Fully Ambulatory) (1=)
Ambulatory And Capable Of All Selfcare
But Unable To Carry Out Any Work
Activities (k 50 - 60) (ecog - 2
Symptomatic; In Bed , 50% Of The Day)
(2=)
Capable Of Limited Selfcare, Confined
To Bed Or Chair More Than 50% Of
Waking Hours. (k 30 - 40) (ecog - 3
Symptomatic; In Bed > 50% Of The Day
But Not Bedridden) (3=)
Completely Disabled (k10 - 20) (ecog - 4
Bedridden) (4=)
Height
>= 0
cm
Description Of Disease At Initial Diagnosis
Date of initial pathologic diagnosis
Mark an'X' if N/A
Pathologic T stage Number (1-4)
1 (1)
2 (2)
3 (3)
4 (4)
T1a, According To Ajcc Guidelines (T1a)
T1b, According To Ajcc Guidelines (T1b)
T2a, According To Ajcc Guidelines (T2a)
T2b, According To Ajcc Guidelines (T2b)
T3a, According To Ajcc Guidelines (T3a)
T3b, According To Ajcc Guidelines (T3b)
T4a, According To Ajcc Guidelines (T4a)
T4b, According To Ajcc Guidelines (T4b)
Pathologic T stage Letter
a (a)
b (b)
Pathologic N Stage Number (1-3)
1 (1)
2 (2)
3 (3)
N0, According To Ajcc Guidelines (N0)
N1a, According To Ajcc Guidelines (N1a)
N1b, According To Ajcc Guidelines (N1b)
N2a, According To Ajcc Guidelines (N2a)
N2b, According To Ajcc Guidelines (N2b)
N2c, According To Ajcc Guidelines (N2c)
N3, According To Ajcc Guidelines (N3)
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Pathologic N Stage Letter
a (a)
b (b)
c (c)
Pathologic M stage Number
M1a, According To Ajcc Guidelines
(M1a)
M1b, According To Ajcc Guidelines
(M1b)
M1c, According To Ajcc Guidelines (M1c)
Pathologic M stage Letter
a (a)
b (b)
c (c)
Breslow thickness
Ulceration
No (no)
Unknown (Unknown)
Yes (yes)
Clark level
Above Basal Lamina (in Situ) (above
basal lamina)
Extension Into Papillary Dermis
(extension into papillary dermis)
Interface Papillary-reticular Dermis
(interface papillary-reticular dermis)
Reticular Dermis (reticular dermis)
Subcutaneous Fat (subcutaneous fat)
unknown (unknown)
Primary Site (If other:)
Anogenital (non-mucosal) (anogenital)
Head (head)
Lower Extremity (lower extremity)
Mucosal (mucosal)
Neck (neck)
Ocular (ocular)
other (other)
Subungual (subungual)
Trunk (trunk)
Unknown (unknown)
Upper Extremity (upper extremity)
Specify other primary site
Pattern of involvement
Acral Lentiginous (acral lentiginous)
Lentigo Maligna Melanoma (lentigo
maligna melanoma)
Mucosal (Mucosal)
Nodular (nodular)
Other, Specify (other)
Superficial Spreading (superficial
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spreading)
unknown (unknown)
Specify other primary site
Primary tumor size measurement
Primary tumor size measurement
Primary tumor size measurement
cm
Melanocytes present
No (no)
Unknown (Unknown)
Yes (yes)
Lymphoid infiltration of primary tumor
Absent (absent)
Dense Or Prominent (dense or
prominent)
Sparse Focal Infiltrate (sparse focal
infiltrate)
Unknown (unknown)
Gross extracapsular extension at primary
presentation
No (no)
Unknown (unknown)
Yes (yes)
Micro Extracapsular extension at primary
presentation
No (no)
Unknown (unknown)
Yes (yes)
Intransit metastases or satellite lesions (at
primary presentation?)
No (no)
Unknown (unknown)
Yes (yes)
Matted Lymph Nodes
No (no)
Unknown (unknown)
Yes (yes)
Number of lymph nodes examined
Number of positive lymph nodes
History Of Disease
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Date of first diagnosis of regional lymph node
involvement
Intransit metastasis first diagnosis date
Date of first diagnosis of distant metastasis
Description Of Current Disease
Status of primary tumor
Not Recurrent, Resected, No Residual
Tumor (not recurrent, resected, no
residual tumor)
Not Recurrent, Resected, Residual
Tumor (not recurrent, resected, residual
tumor)
Recurrent (recurrent)
Unresected (unresected)
Were lymph nodes examined at the primary
presentation?
No (No)
Unknown (Unknown)
Yes (Yes)
Number of sentinel nodes examined
Number of positive sentinel nodes
Number of organ sites involved (*)
Lung
No (no)
Unknown (unknown)
Yes (yes)
Liver
No (no)
Unknown (unknown)
Yes (yes)
Brain
No (no)
Unknown (unknown)
Yes (yes)
Bone
No (no)
Unknown (unknown)
Yes (yes)
Distant soft tissue metastasis
No (no)
Unknown (unknown)
Yes (yes)
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Distant skin/subcutaneous tissue
No (no)
Unknown (unknown)
Yes (yes)
Distant lymph nodes
No (no)
Unknown (unknown)
Yes (yes)
Other CNS
No (no)
Unknown (unknown)
Yes (yes)
Other visceral
No (no)
Unknown (unknown)
Yes (yes)
Other non-visceral
No (no)
Unknown (unknown)
Yes (yes)
Specify other visceral
Specify other non-visceral
Comments
Comments
Investigator Signature
Investigator Signature Date
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Pharmacodynamics Form Sarcoma, Kaposi
Protocol #40 - PR4003
Pharmacodynamics Form for Protocol #40 - PR4003
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=CCE4149D-
4174-4BF9-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/11970
Pharmacodynamics Form Sarcoma,
Kaposi Protocol #40 - PR4003
Patient data
Patient Initials
20 hours post-initiation of flavopiridol infusion,
date
60 minutes post-initiation of flavopiridol infusion,
time
60 minutes post-initiation of flavopiridol infusion,
date
At completion of flavopiridol infusion, time
At completion of flavopiridol infusion, date
Just prior to the start of flavopiridol, time
Just prior to the start of flavopiridol, date
Total Flavopiridol dose for the cycle
Body surface area
>= 0
m²
Body weight
>= 0
kg
Height
>= 0
cm
Visit date
Cycle#
ID#
1 / 2
Site#
Study#
20 hours post-initiation of flavopiridol infusion,
time
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Eligibility Heart Failure EVEREST
NCT00071331
EVEREST: Efficacy of Vasopressin Antagonism in hEart
failuRE: Outcome Study With Tolvaptan
NCT00071331
All rights reserved. Please visit https://medical-data-
models.org/forms/11971
Eligibility Heart Failure EVEREST
NCT00071331
Inclusion criteria
Age greater than or equal to 18 years*
Yes
No
Current hospitalization for chronic congestive
heart failure with admission up to 48 hours prior
to randomization. Chronic heart failure is defined
as requiring treatment for a minimum of 30 days
prior to hospitalization. The subject must have
signs of extracellular volume expansion, defined
as two or more of the following: a) jugular venous
distention; b) pitting edema (>1+); or c) dyspnea*
Yes
No
NYHA Class III or IV at the time of
hospitalization*
Yes
No
Left Ventricular Ejection Fraction <= 40% within
one year*
<= 40
%
Yes
No
Exclusion criteria
Women who will not adhere to the reproductive
precautions as outlined in the Informed Consent
form*
Yes
No
Positive urine pregnancy test*
Yes
No
Inability to provide written informed consent*
Yes
No
Cardiac surgery within 60 days of potential study
enrollment, excluding percutaneous coronary
interventions*
Yes
No
Planned revascularization procedures,
electrophysiologic (EP) device implantation,
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cardiac mechanical support implantation, cardiac
transplantation, or other cardiac surgery within 30
days following study enrollment*
Yes
No
Subjects who are on cardiac mechanical support*
Yes
No
History of bi-ventricular pacer placement within
the last 60 days*
Yes
No
Co-morbid condition with an expected survival
less than six months*
Yes
No
Subjects with acute ST segment elevation
myocardial infarction at the time of
hospitalization*
Yes
No
History of sustained ventricular tachycardia or
ventricular fibrillation within 30 days, unless in the
presence of an automatic implantable
cardioverter defibrillator*
Yes
No
History of a cerebrovascular accident within the
last 30 days*
Yes
No
Hemodynamically significant uncorrected primary
cardiac valvular disease*
Yes
No
Hypertrophic cardiomyopathy (obstructive or non-
obstructive)*
Yes
No
CHF due to uncorrected thyroid disease, active
myocarditis or known amyloid cardiomyopathy*
Yes
No
Subjects with progressive or episodic
neurological disease such as multiple sclerosis or
history of multiple strokes*
Yes
No
History of primary significant liver disease or
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acute hepatic failure, as defined by the
investigator*
Yes
No
History of poorly controlled diabetes mellitus*
Yes
No
Morbid obesity, defined as > 159 kg (or 350 lbs)
or BMI > 40*
Yes
No
Supine systolic arterial blood pressure < 90
mmHg*
Yes
No
Serum creatinine > 3.5 mg/dL or > 309.4 mmol/L*
Yes
No
Serum potassium > 5.5 mEq/L or > 5.5 mmol/L*
Yes
No
Hemoglobin < 9 g/dL or < 90 g/L*
Yes
No
History of hypersensitivity and/or idiosyncratic
reaction to benzazepine derivatives (such as
benazapril)*
Yes
No
History of drug or medication abuse within the
past year, or current alcohol abuse*
Yes
No
Inability to take oral medications*
Yes
No
Participation in another clinical drug or device
trial within the past 30 days*
Yes
No
Previous participation in this or any other
tolvaptan clinical trial*
Yes
No
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ENDOSCOPY PRE PROCEDURE ID
RECORD
Form from HIS OpenVistA
All rights reserved. Please visit https://medical-data-
models.org/forms/11972
HIS
Allgemeine Informationen
Datum und Zeit des Eintreffens*
Allergie*
Medikation*
STATUS des Patienten*
HOW ARRIVED*
ACCOMPANIED BY*
Zustand bei Ankunft*
stabil (1)
instabil (2)
Bewusstseinslage*
stuporös (0)
sediert (1)
lethargisch (2)
wach (3)
CONSENT SIGNED BY*
PATIENT ID BAND ON WITH CORRECT NAME,
DOB AND PHYSICIAN*
Ja
Nein
NOTES Patient ID*
Behandelnder Arzt*
Behandelnder Arzt*
ASSISTED BY*
Anästhesist*
Anamnese*
LANGUAGE BARRIER*
Ja
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Nein
TRANSLATOR (yes, N/A)*
Ja
Nein
NOTES*
PHYSICAL DISABILITIES   *
Ja
Nein
Körperliche Behinderung*
Zahnstatus*
Vollprothese (1)
Partielle Prothese (2)
Eigenes Gebiss intakt (3)
Hören*
links vermindert (DL)
rechts vermindert (DR)
normal (WNL)
Visual (WNL,Glasses, Contacts)*
normal (1)
Brille (2)
Kontaktlinsen (3)
NOTES*
Vitalzeichen bei Aufnahme*
Oximetrie*
%
Gewicht*
>= 0
kg
Größe*
>= 0
cm
NPO SINCE*
Prep (Fleet Enema, Fleet Prep Kit, Golytely, Half-
Lightly, MAG Citrate, MOVI Prep, Nulytely, OSMO
Prep)*
PREP COMMENTS*
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Präoperative Diagnosen
Abnormal GI Xray*
Ja
Nein
Bauchschmerzen*
Ja
Nein
abnormaler Gewichtsverlust*
Ja
Nein
Achalasie*
Ja
Nein
Anämie*
Ja
Nein
Aszites*
Ja
Nein
Irregular bowel habits*
Ja
Nein
Leberzirrhose*
Ja
Nein
Screening für Kolonkarzinom*
Ja
Nein
Common Bile Duct Leak*
Ja
Nein
Common Bile Duct Stone*
Ja
Nein
Verstopfung*
Ja
Nein
Diarrhö*
Ja
Nein
Dyspepsie*
Ja
Nein
Dysphagie*
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Ja
Nein
Elevated Liver Function Tests*
Ja
Nein
Ösophagusvarizen*
Ja
Nein
Familienanamnese Kolonkarzinom*
Ja
Nein
Family History of Polyps*
Ja
Nein
Family History of Polyposis*
Ja
Nein
Foreign Body in Colon*
Ja
Nein
Foreign Body in Esophagus*
Ja
Nein
Foreign Body in Stomach*
Ja
Nein
Peptic Ulcer*
Ja
Nein
Gastroesophageal reflux disease (GERD)*
Ja
Nein
Gastrointestinale Blutung*
Ja
Nein
Hämatemesis*
Ja
Nein
History of Barrett's*
Ja
Nein
History of Cholangiocarcinoma*
Ja
Nein
History of Colon Cancer*
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Ja
Nein
History of Crohn's Disease*
Ja
Nein
History of Diverticulosis*
Ja
Nein
History of Esophageal Cancer*
Ja
Nein
History of Esophageal/ Gastric Varicies*
Ja
Nein
History of Gastric Cancer*
Ja
Nein
History of Pancreatic Cancer*
Ja
Nein
History of Peptic Ulcer Disease*
Ja
Nein
History of Polyps*
Ja
Nein
History of Ulcerative Colitis*
Ja
Nein
Blut im Stuhl*
Ja
Nein
Eisenmangelanämie*
Ja
Nein
Ikterus*
Ja
Nein
Teerstuhl*
Ja
Nein
Übelkeit*
Ja
Nein
Erbrechen*
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Ja
Nein
Occult/Guaiac Positive Stool*
Ja
Nein
Pankreatitis*
Ja
Nein
Portale Hypertension*
Ja
Nein
gastric reflux*
Ja
Nein
abnormaler Gewichtsverlust*
Ja
Nein
Sonstig*
PRE-PROCEDURE ALDRETE  SCORE
Aktivität*
cannot move extremities (0)
2 extremities move voluntarily or on
command (1)
all 4 extremities move voluntarily or on
command (2)
Atmung*
apnea or SAO2 <90% (0)
dyspnea or limited breathing (1)
able to deep breath, cough freely (2)
Blutdruck*
BP +/- 50% pre-procedure level (0)
BP +/- 21-49% pre-procedure level (1)
BP +/- 20% of pre-procedure level (2)
Bewusstseinslage*
nicht oder schwer erweckbar (0)
leicht erweckbar (1)
Wach und reagiert adäquat (2)
Hautzustand*
Patient is cyanotic (0)
Skin is pale-dusky-blotchy- jaundice (1)
Skin is pink-warm- dry (2)
ALDRETE Gesamtscore*
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Kerala ACS Registry
Acute Coronary Syndrome Quality Improvement in Kerala
(ACS QUIK) Cluster Randomized, Stepped Wedge Multi-
center implementation of a Locally-Developed Quality
Improvement Toolkit.
(http://www.csikerala.org/acsregistry.php)
All rights reserved. Please visit https://medical-data-
models.org/forms/11973
Kerala ACS Registry
Demographics
Name
Age
Sex
Occupation
Height
Weight
Waist Circumference
Address
Telephone
Email
Education
Socio economic status
Thatched House (1)
Tiled House (2)
Concrete House (3)
Symptom
C3177142
Chest Pain (1)
Dyspnea (2)
Others (3)
Date & Time of onset
Date & Time of first level contact
Date & Time of arrival at Enrolling hospital
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Last episode of chest pain
Transfer from another hospital
Yes
No
Physical examination
HR
SBP
DBP
Killip Class
ST elevation
2,3 AVF (1)
1 AVL (2)
V1-V6 (3)
V1-V4 (4)
V4-V6 (5)
ST depression
2,3 AVF (1)
1 AVL (2)
V1-V6 (3)
V1-V4 (4)
V4-V6 (5)
T inversion
2,3 AVF (1)
1 AVL (2)
V1-V6 (3)
V1-V4 (4)
V4-V6 (5)
LBBB
Yes
No
History
Hypertension
Yes
No
Diabetes
Yes
No
Smoking
Yes
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No
Other forms of Tobacco
Yes
No
Prior MI
Yes
No
Stroke
Yes
No
Prior PCI/CABG
Yes
No
Investigations and Treatment
Troponin
CKMB
CPK
FBS
RBS
Hemoglobin
Creatinine
TG
LDL
HDL
TC
EF
Final Diagnosis
STEMI (1)
NSTEMI (2)
Unstable Angina (3)
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Thrombolysis
SK (1)
UK (2)
Dose
mUnits
Presentation to needle time
minutes
Medication
Nitrates
Previous Medication (1)
In Hospital (2)
At discharge (3)
ACE/ARB
Previous Medication (1)
In Hospital (2)
At discharge (3)
Betablocker
Previous Medication (1)
In Hospital (2)
At discharge (3)
Aspirin
Previous Medication (1)
In Hospital (2)
At discharge (3)
Clopidogrel
Previous Medication (1)
In Hospital (2)
At discharge (3)
Statin
Previous Medication (1)
In Hospital (2)
At discharge (3)
CCB
Previous Medication (1)
In Hospital (2)
At discharge (3)
UFH/LMWH
Previous Medication (1)
In Hospital (2)
At discharge (3)
2b 3 A blocker
Previous Medication (1)
In Hospital (2)
At discharge (3)
4 / 5
Kerala ACS Registry
In Hospital Procedure
TPI
Yes
No
PPI
Yes
No
IABP
Yes
No
PCI
Yes
No
CABG
Yes
No
CAG
Yes
No
Outcome
Reinfarction
Yes
No
Cardiogenic shock
Yes
No
Heart Failure
Yes
No
Stroke
Yes
No
Death
Yes
No
Referal to other hospital
Yes
No
Follow up Event
Death (1)
Stroke (2)
Heart failure (3)
PCI/CABG (4)
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CARDIAC REHAB CONSULT RESULTS
INTERDISCIPLINARY NOTE
Form from HIS OpenVistA
All rights reserved. Please visit https://medical-data-
models.org/forms/11976
HIS
Date, Diagnosis, BMI
DATE REFERRAL RECEIVED*
ADMISSION DATE TO CARDIAC
REHABILITATION*
Diagnosis*
Weight*
>= 0
kg
Height*
cm
Body Mass Index*
kg/m2
SYMPTOM(S) ON ADMISSION
SYMPTOM(S) ON ADMISSION*
PAST CARDIAC HISTORY
PAST CARDIAC HISTORY*
PAST Medical HISTORY
Acute Renal Failure/Dialysis*
Arthritis*
Asthma*
Malignant Neoplasms*
Chronic Obstructive Pulmonary Disease*
Depression*
Orthopedic Limitation     *
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Thyroid Disease*
Other*
History of Hypertension*
History of Diabetes*
Cholesterol History*
LIPID VALUES THIS ADMISSION*
Physical activity*
PERTINENT SOCIAL HISTORY
Family Status*
PATIENT LIVES*
Employment status*
Family history (FH) of*
Stress*
PATIENT APPEARS (Behavior)*
Smoking History
Smoker
HOW MUCH Smoking*
Quit at time of hospitalization*
Former smoker(not smoked more than 6
months)*
Quit smoking in*
Never Smoked*
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NARRATIVE*
Procedure Date and Results
Heart catheterization*
CARDIAC CATHETERIZATION DATE*
Cardiac ejection fraction*
LV FUNCTION*
MARK WITH % OCCLUSIONS*
LM*
LAD*
DIAGONAL*
CX*
ADDITIONAL COMMENTS*
PTCI / STENT*
PTCI DATE*
PTCA
STENT
ATHERECTOMY*
IIB/IIA INHIBITOR*
MARK WITH APPROPRIATE LETTER: PTCA-
(P), STENT-(S), ATHERECTOMY-(A)*
LM*
LAD
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DIAGONAL*
CX*
ADDITIONAL COMMENTS*
SURGERY*
Coronary Artery Bypass Surgery*
DATE CABG*
MIDCAB*
AVR*
MVR*
OTHER PROCEDURES*
CARDIOVASCULAR RISK FACTOR*
CORRELATE A NUMBER WITH GRAFT ORIGIN
SITE*
DONOR AREA TO*
LIMA*
RIMA*
RADIAL*
SVG*
RPD*
PATIENT/FAMILY EDUCATION
BOOKLET(S) GIVEN*
DATE BOOKLET(S) given*
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BOOKLET VERSIONS*
VIDEO(S) SHOWN*
DATE VIDEO(S) shown*
VIDEO VERSION*
LEARNER*
PATIENT'S PHYSICAL READINESS TO LEARN*
PSYCHOLOGICALLY WILLING TO LEARN*
EDUCATIONAL TOPICS: 1.Description of
Cardiac Catheterization and site care, 2.Heart
structure and function, 3.Myocardial Infarction
symptoms and interventions, 4.Unstable Angina
symptoms and interventons, 5.Congestive Heart
Failure and importance of daily weights, 6.PTCI
(Angioplasty,Stent), 7.Open Heart Surgery*
EDUCATIONAL TOPICS CORONARY RISK AND
MODIFICATION: 1.Tobacco Cessation,
2.Exercise guidelines, aerobic exercise for
minimum of 30 minutes, 3.Dietary Modifications,
4.Stress Management, 5.Cholesterol and
Triglycerides, 6.Diabetes Management, 7.Obesity,
8.Medication,  9.Hypertension*
DISCHARGE SPECIFIC INSTRUCTIONS:
1.Activity, 2.Site / Incision care, 3.Daily Weight,
4.Returning to work, 5.Driving,  6.Recurrent
Chest Pain, 7.Psychosocial, 8.Coumadin, 9.Sex*
CARDIAC REHAB NARRATIVE*
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CARDIAC REHAB CONSULT RESULTS INTERDISCIPLINARY NOTE
Initial assessment Leukemia AML-AZA in
elderly patients NCT00915252
A randomized, multi-center phase II trial to assess the
efficacy of 5-azacytidine added to standard primary therapy
in elderly patients with newly diagnosed AML
NCT00915252
Principal Investigator Prof. Dr. Müller-Tidow
All rights reserved. Please visit https://medical-data-
models.org/forms/11977
Initial assessment Leukemia AML-
AZA in elderly patients
NCT00915252
Patient data
Pat. No.:    -*
Birth date:*
Gender:*
male (1)
female (2)
Medical History*
CodelistItem 729085 (1)
CodelistItem 729086 (2)
CodelistItem 729087 (3)
CodelistItem 729088 (4)
CodelistItem 729089 (5)
Date of diagnosis MDS*
Date of diagnosis MPS*
Year chemotherapy*
Regimen*
Year radiotherapy*
Clinical findings
Physical Examination Date*
ECOG status at study inclusion:*
ECOG performance status - grade 0
(Normal physical fitness) (0)
ECOG performance status - grade 1
(Outpatient care, easy work possible) (1)
ECOG performance status - grade 2
(Less than half day bed-ridden, self-
sufficiency possible, but not able to work)
(2)
ECOG performance status - grade 3
(More than half day bed-ridden, limited
self-sufficiency possible) (3)
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ECOG performance status - grade 4
(Permanent bed-ridden) (4)
Size*
>= 0
cm
Weight*
>= 0
kg
Body surface area*
>= 0
m²
Extramedullary AML manifestation*
yes (1)
no (2)
unknown (3)
if yes, localization:*
CNS (1)
Other: (2)
Other:*
Clinically relevant pre-existing conditions
and comorbidities
Clinically relevant pre-existing conditions and
comorbidities*
Present (1)
Absent (2)
Disease*
Onset (Month)*
Onset (Year)*
ongoing*
Yes
No
Differential blood count
Date:*
Hemoglobin*
g/dL
2 / 7
Initial assessment Leukemia AML-AZA in elderly patients NCT00915252
Leukocytes*
/ul
Neutrophil percentage*
Band neutrophil percentage*
[or] Segmented neutrophil percentage*
Lymphocyte percentage*
Monocyte percentage*
Eosinophil percentage*
Basophil percentage*
Blast cell percentage*
Promyelocyte percentage*
Myelocyte percentage*
Metamyelocyte percentage*
Percentage of other cells*
Peripheral Platelet Count*
1000/uL
Clinical Chemistry
Sodium*
mmol/L
Potassium*
mmol/l
Total Protein*
mg/dL
Uric acid*
md/dl
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BUN*
mg/dL
Urea*
mg/dL
Creatinine*
mg/dL
Bilirubin, total*
mg/dL
AST (SGOT)*
U/L
ALT (SGPT)*
U/L
Alkaline Phosphatase*
U/L
Lactate Dehydrogenase*
U/L
CRP*
md/dl
Quick*
%
INR*
PTT*
seconds
Fibrinogen*
g/l
AT III percentage*
%
Bone marrow examination
Date:*
Obligatory materials shipping (bone marrow +
blood) for determination of methylation status to:*
Munster (1)
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Dresden (2)
Frankfurt (3)
no shipping because (kein Versand weil)
no shipping because*
Shipping of an iliac crest biopsy to:*
Munster (1)
Dresden (2)
Frankfurt (3)
no shipping because (kein Versand weil)
no shipping because*
Cytology
Blast percentage*
<5% (1)
>=5% (2)
cannot be assessed (3)
If >=5%, please specify [%]*
Dysplasia sign:*
Unilineage Dysplasia Present (1)
AML with Multilineage Dysplasia (2)
Absent (3)
Not examined for (4)
cannot be assessed (5)
FAB
FAB:*
FAB type M0 (1)
FAB type M1 (2)
FAB type M2 (3)
FAB type M4 (4)
FAB type M4eo (5)
FAB type M5 (6)
FAB type M5a (6a)
FAB type M5b (6b)
FAB type M6 (7)
FAB type M7 (8)
unknown (9)
Cytogenetics (Please attach copy of findings!)*
Normal karyotype (1)
-5/5q- (10)
t(3;3) (11)
11q23 - aberrations (12)
t(8;21) (2)
t(16;16) (3)
-7/7q- (4)
t(6;9) (5)
+8 as single aberration (6)
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+8 with an additional aberration (except
t(9;11)) (7)
Complex karyotype (>= 3 lesions) (8)
inv(16) (9)
other aberrations:*
Molecular Genetic Analysis (Please attach
copy of findings!)
AML1/ETO:*
yes (1)
no (2)
Not examined for (3)
PML/RARa:*
yes (1)
no (2)
Not examined for (3)
CBFbeta/MYH11:*
yes (1)
no (2)
Not examined for (3)
C/EBPalpha:*
yes (1)
no (2)
Not examined for (3)
NPM1(mut):*
yes (1)
Not examined for (1)
no (2)
Not examined for (3)
IDH mutation:*
yes (1)
no (2)
Not examined for (3)
FLT3 point mutation:*
yes (1)
no (2)
Not examined for (3)
FLT3-ITD:*
yes (1)
no (2)
Not examined for (3)
Flt3-ITD-ratio*
Flt3-ITD Percentage*
Other:*
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Signature
Date:*
Name/Signature study physician*
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Eligibility Alzheimer Disease NCT01255046
Study of STA-1 as an Add-on Treatment to Donepezil; ODM
derived from: https://clinicaltrials.gov/show/NCT01255046
All rights reserved. Please visit https://medical-data-
models.org/forms/11979
Eligibility Alzheimer Disease
NCT01255046
Inclusion Criteria
male or female patient aged ≥ 50 years;*
Yes
No
probable alzheimer's disease diagnosed by the
national institute of neurological and
communicative disorders and stroke and the
alzheimer's disease and related disorders
association (nincds-adrda) criteria;*
Yes
No
mmse score between 10-26, inclusive;*
Yes
No
patient has been treated with donepezil 10 mg
per day for at least 3 months prior to screening;*
Yes
No
patient able to participate in all study evaluations
and ingest oral medication as indicated;*
Yes
No
patient has a responsible caregiver who will
accompany the patient to all clinic visits during
the study;*
Yes
No
patient and the responsible caregiver have
provided written informed consent before
undergoing any study procedures.*
Yes
No
Exclusion Criteria
brain image (computed tomography (ct) scan or
magnetic resonance imaging (mri) done within
past 12 months prior to the study) and laboratory
tests to exclude secondary dementia or non-
alzheimer's dementia;*
Yes
No
patient with significant clinically central nervous
system illness other than ad (e.g. parkinson's
disease, human immunodeficiency virus (hiv)
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induced dementia, hachinski ischaemic score
(his) >4) or dementia complicated by other
organic disease or delirium;*
Yes
No
patient with a severe or uncontrolled diagnostic
and statistical manual of mental disorders (dsm-
iv) axis i disorder other than alzheimer's disease,
including amnestic disorders, schizophrenia or
schizoaffective disorder, bipolar disorder, current
major depressive episode, psychosis, panic, or
post-traumatic stress disorder;*
Yes
No
patient suffering from cerebral disturbances
following a stroke or a cerebral trauma (if the
event occurred within the last 6 months);*
Yes
No
patient with a history of hypersensitivity to study
drugs;*
Yes
No
patient who has a history or evidence of a
medical condition that would expose them to an
undue risk of a significant adverse event or
interfere with assessments of safety or efficacy
during the course of the trial, including but not
limited to hepatic, renal, respiratory,
cardiovascular, endocrine (e.g., addison's
disease), immune, neurologic, or hematologic
disease as determined by the clinical judgment of
the investigator;*
Yes
No
participation in any research study within the last
30 days;*
Yes
No
patient with significant alcohol or drug abuse as
judged by the investigator.*
Yes
No
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Eligibility Breast Neoplasms NCT02013726
MBI and Breast Tomosynthesis Screening Accuracies in
Patients With Dense Breast Tissue; ODM derived from:
https://clinicaltrials.gov/show/NCT02013726
All rights reserved. Please visit https://medical-data-
models.org/forms/11982
Eligibility Breast Neoplasms
NCT02013726
Inclusion Criteria
women over 25 years of age with normal or
increased risk of breast cancer.*
Yes
No
women with type 3 or 4 breast density as
determined by a breast imaging radiologist on a
current unilateral (women with prior mastectomy)
or bilateral mammography (within prior 6 weeks).*
Yes
No
no contraindications to breast mbi or breast
tomosynthesis.*
Yes
No
Exclusion Criteria
women under the age of 25.*
Yes
No
women who are or may be pregnant.*
Yes
No
women who are currently lactating or have
discontinued breast feeding < 2 months prior to
the study.*
Yes
No
male patients are excluded as subjects.*
Yes
No
those unable or unwilling to provide informed
consent.*
Yes
No
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Eligibility Hypoglycemia NCT01980914
Hypoglycemia (Low Blood Sugar) and the Heart; ODM
derived from: https://clinicaltrials.gov/show/NCT01980914
Principal Investigator:	Graydon S Meneilly, MD	University of
British Columbia	
All rights reserved. Please visit https://medical-data-
models.org/forms/11990
Eligibility Hypoglycemia
NCT01980914
Inclusion Criteria
70 years old and over*
Yes
No
had type 2 diabetes for at least 5 years*
Yes
No
treated with insulin glargine*
Yes
No
BMI of between 20 and 35 Kg/M2*
Yes
No
A1c between 7 and 8.5 %*
Yes
No
well controlled hypertension and hyperlipidemia.*
Yes
No
Exclusion Criteria
cannot speak english or give informed consent,
or cognitive impairment*
Yes
No
glomerular filtration rate (GFR) less than
40ml/min*
Yes
No
poorly controlled Chronic Heart Failure*
Yes
No
active coronary artery disease*
Yes
No
active cerebrovascular disease although a past
history of CAD or stroke will not results in
exclusion*
Yes
No
1 / 1
Eligibility Lymphoma NCT01528865
Safety & Efficacy of Lamivudine & Tenofovir to Lower
Plasma Level of Viral RNA in Lymphoma; ODM derived
from: https://clinicaltrials.gov/show/NCT01528865
Principal Investigator: Scott D Gitlin, MD
All rights reserved. Please visit https://medical-data-
models.org/forms/11991
Eligibility Lymphoma NCT01528865
Inclusion Criteria
Patients must have a histologically confirmed
diagnosis of non-Hodgkin lymphoma (NHL)*
Yes
No
Must have HERV-K(HML2) viral load of ≥1x103
using a gag primer reverse transcriptase
polymerase chain reaction (RT-PCR) assay.*
Yes
No
Must have bi-dimensionally measurable disease.*
Yes
No
Patients with lymphomas that are felt to be
incurable with any therapy and for whom there
are no standard treatments that would be
anticipated to be necessary or beneficial within
the next 5 months. These patients can have
received any amount of prior chemotherapy to
enter this trial.*
Yes
No
All previous therapies must have been
discontinued at least 4 weeks prior to initiation of
the administration of this study's drugs.*
Yes
No
HIV negative by standard blood testing.*
Yes
No
Have an expected life expectancy of at least 5
months.*
Yes
No
Have an Eastern Cooperative Oncology Group
(ECOG) performance scale status of 0 - 2l) Must
have a serum creatinine <2.0 and creatinine
clearance >30 ml/min/m2. Other organ
dysfunction is eligible at the discretion of the PI.*
Yes
No
Agree to use a reliable method of birth control
prior to drug initiation and for the duration of their
study participation.*
Yes
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No
Exclusion Criteria
a) Have received chemotherapy or radiotherapy
within 4 weeks*
Yes
No
Have not recovered from the adverse effects or
toxicities of lymphoma therapy most recently
administered.*
Yes
No
Currently receiving any other investigational
medication or therapy.*
Yes
No
Patients with a second malignancy that might
interfere with interpretation of the results of this
study.*
Yes
No
Patients with known allergic reaction to
lamivudine or tenofovir disoproxil fumarate (DF).*
Yes
No
Patients on drugs that interfere with renal function
or drugs that compete with tenofovir for active
binding sites (i.e. intravenous cidofovir, acyclovir,
ganciclovir, and valganciclovir).*
Yes
No
Uncontrolled concurrent illnesses, including, but
not limited to, active/ongoing infection,
symptomatic congestive heart failure, unstable
angina pectoris.*
Yes
No
Women who are pregnant, become pregnant, or
are breast-feeding.*
Yes
No
Standard blood tests that are positive for HIV
infection*
Yes
No
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Eligibility Major Depressive Disorder
NCT02311725
Storytelling Video Intervention for Depressed Primary Care
Patients - Pilot Trial; ODM derived from:
https://clinicaltrials.gov/show/NCT02311725
Principal Investigator:	Lisa Uebelacker, PhD	Butler
Hospital/Brown University and Brandon Gaudiano, PhD
Butler Hospital/Brown University
All rights reserved. Please visit https://medical-data-
models.org/forms/11992
Eligibility Major Depressive Disorder
NCT02311725
Inclusion Criteria
1. Meets DSM-5 criteria for current or lifetime
major depressive disorder.*
Yes
No
2. No Lifetime diagnosis of bipolar disorder,
schizophrenia, or chronic psychotic condition.*
Yes
No
3. No current hazardous illicit drug or alcohol
use.*
Yes
No
4. No suicidal ideation or behavior requiring
immediate attention.*
Yes
No
5. Depression symptom severity: a Quick
Inventory of Depressive Symptoms (QIDS) score
>11.*
Yes
No
6. Taking an antidepressant medication for at
least 6 weeks; prescribed by their primary care
provider.*
Yes
No
7. Not in psychotherapy during the study period.*
Yes
No
8. Have a PCP at our enrollment site.*
Yes
No
9. If pregnant, less than 24 weeks gestation.*
Yes
No
10. English speaking.*
Yes
No
11. Aged 18 or older.*
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Yes
No
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Eligibility Multiple Sclerosis NCT02149706
A Study of NeuroVax, a Novel Therapeutic TCR Peptide
Vaccine for SPMS of Multiple Sclerosis; ODM derived from:
https://clinicaltrials.gov/show/NCT02149706
Principal Investigator:	Dennis Bourdette, MD F.A.A.N.
Oregon Health and Science University
All rights reserved. Please visit https://medical-data-
models.org/forms/11993
Eligibility Multiple Sclerosis
NCT02149706
Inclusion Criteria
Ages Eligible for Study: 18 Years to 70 Years*
Yes
No
Genders Eligible for Study: Both*
Yes
No
Accepts Healthy Volunteers: No Criteria*
Yes
No
Subject is between 18 and 70 years of age,
inclusive.*
Yes
No
Definite MS by the revised McDonald criteria
(2005) (Appendix A), with a Secondary
Progressive course.*
Yes
No
Expanded Disability Status Scale (EDSS)
>=score 3.5 (Appendix B).*
Yes
No
Two or more documented clinical relapses of MS
in the preceding 24 months OR one documented
clinical relapse of MS in the preceding 1 2
months prior to screening .*
Yes
No
Laboratory values within the following limits:*
Yes
No
Creatinine 1 . 5 x high normal.*
Yes
No
Hemoglobin*
Yes
No
Exclusion Criteria
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Subjects currently prescribed Campath or
Lemtrada*
Yes
No
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Eligibility Multiple Sclerosis NCT02200718
A Study of NeuroVax, a Novel Therapeutic TCR Peptide
Vaccine for Pediatric Multiple Sclerosis; ODM derived from:
https://clinicaltrials.gov/show/NCT02200718
Principal Investigator: Dennis Bourdette, MD F.A.A.N.
All rights reserved. Please visit https://medical-data-
models.org/forms/11994
Eligibility Multiple Sclerosis
NCT02200718
Inclusion Criteria
Ages Eligible for Study: 5 Years to 17 Years*
Yes
No
Genders Eligible for Study: Both*
Yes
No
Accepts Healthy Volunteers: No Criteria*
Yes
No
Subject is between 5 and 17 years of age,
inclusive*
Yes
No
Clinically diagnosed Pediatric MS*
Yes
No
Definite Pediatric MS by the revised McDonald
criteria (2005) (Appendix A), with a pediatric MS
course*
Yes
No
Expanded Disability Status Scale (EDSS) <=
score 6.5 (Appendix B) Two or more documented
clinical relapses of MS in the preceding 24
months OR one documented clinical relapse of
MS in the preceding 12 months prior to
screening*
Yes
No
Laboratory values within the following limits:*
Yes
No
Creatinine 1 . 5 x high normal*
Yes
No
Hemoglobin*
Yes
No
Exclusion Criteria
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Subjects currently prescribed Campath or
Lemtrada*
Yes
No
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Eligibility Muscle Spasticity Due to Multiple
Sclerosis NCT01649050
Efficacy of 5 Weeks of Treatment With BGG492 in Patients
With Spasticity Due to Multiple Sclerosis; ODM derived
from: https://clinicaltrials.gov/show/NCT01649050
All rights reserved. Please visit https://medical-data-
models.org/forms/11995
Eligibility Muscle Spasticity Due to
Multiple Sclerosis NCT01649050
Inclusion Criteria
Diagnosis of multiple sclerosis (MS) of any type.*
Yes
No
MS diagnosis at least 6 months prior to
screening.*
Yes
No
Stable MS with no relapse within 3 months prior
to screening.*
Yes
No
Treated or untreated spasticity due to MS for at
least 3 months prior to screening, not wholly
relieved with antispasticity medications.*
Yes
No
Exclusion Criteria
Patients with symptoms of spasticity not due to
MS.*
Yes
No
Patients taking three or more different anti-
spasticity medications.*
Yes
No
Acute MS exacerbation requiring treatment within
3 months of the Screening Visit.*
Yes
No
Initiation of, or the discontinuation of interferon
beta or any other disease modifying therapy for
MS within 3 months of the Screening Visit.*
Yes
No
Use of baclofen pump at any time.*
Yes
No
Wheelchair or bed-bound patients.*
Yes
No
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Eligibility Myocardial Infarction
NCT01950130
Prophylactic IABP in High-risk Patients Undergoing CABG;
ODM derived from:
https://clinicaltrials.gov/show/NCT01950130
Principal Investigator: Philippe Grieshaber, MD
All rights reserved. Please visit https://medical-data-
models.org/forms/11996
Eligibility Myocardial Infarction
NCT01950130
Inclusion Criteria
Age >18 years*
Yes
No
Isolated CABG planned*
Yes
No
Informed consent in trial participation given*
Yes
No
Any left ventricular functional impairment
(regional wall motion abnormality or global
LVEF<55%) assessed via ventriculography or
transthoracic or transeophageal
echocardiography*
Yes
No
Elevated cardiac biomarkers (CK-MB > 6% of
total-CK, Troponin I > 3-fold of specific test
reference) or myocardial infarction (NSTEMI or
STEMI) within the last 4 days.*
Yes
No
Exclusion Criteria
Contraindications for IABP*
Yes
No
Cardiogenic shock*
Yes
No
Shock of any other cause*
Yes
No
Critical preoperative state according to
EuroSCORE II-criteria*
Yes
No
Cardiac surgical procedure other than CABG
planned*
Yes
No
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Severe comorbidity with life expectancy < 6
months*
Yes
No
Incapability of giving informed consent*
Yes
No
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Eligibility Non Small Cell Lung Cancer
NCT02470065
Neoadjuvant Afatinib in Early Stage Non Small Cell Lung
Cancer.; ODM derived from:
https://clinicaltrials.gov/show/NCT02470065
Principal Investigator:	Sanjay Popat, PhD  Royal Marsden
NHS Foundation Trust
All rights reserved. Please visit https://medical-data-
models.org/forms/11997
Eligibility Non Small Cell Lung
Cancer NCT02470065
Inclusion Criteria
histological or cytological diagnosis of nsclc;*
Yes
No
Patients considered operable and with resectable
tumor with curative intent (anatomical resection
and systematic lymph node dissection) based on
evaluation by a thoracic multi-disciplinary team
composed of at least a thoracic surgeon,
oncologist and radiologist;*
Yes
No
Stage I-III (T1a-3, N0-1, M0 according to UICC
version 7) NSCLC by local staging criteria
potentially treatable by radical (curative) surgery.
Patients with T1 tumor at baseline will be limited
to 20%;*
Yes
No
Radiologically measurable disease according to
RECIST criteria 1.1; assessed by chest and
upper abdomen CT scan within 2 weeks (+1
week) prior to registration); brain CT scan or MRI
according to local practice*
Yes
No
No prior treatment for NSCLC is allowed*
Yes
No
Adequate tissue in terms of quality and quantity
for EGFR local testing.*
Yes
No
Exclusion Criteria
no adequate bone marrow function within 2
weeks prior to randomization*
Yes
No
no adequate liver function. Patients with Gilbert's
syndrome total bilirubin must be below 4 times
institutional upper limit of normal; within 2 weeks
prior to randomization*
Yes
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No
no adequate renal function within 2 weeks prior
to randomization*
Yes
No
known positivity to human immunodeficiency
virus (hiv), hepatitis b or hepatitis c*
Yes
No
known history of allergic reactions attributed to
compounds of similar chemical or biological
composition;*
Yes
No
history of a hematologic or primary solid tumor
malignancy, unless no evidence of that disease
for 5 years, except pT1-2 prostatic cancer
Gleason score < 6, superficial bladder cancer,
non melanoma skin cancer or carcinoma in situ
of the cervix;*
Yes
No
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Eligibility Osteoarthritis, Degenerative
NCT02034409
A Pilot Trial to Assess Low-Intensity Ultrasound in
Osteoarthritis; ODM derived from:
https://clinicaltrials.gov/show/NCT02034409.
Principal Investigator:	Daniel O Clegg, MD	VA Salt Lake City
Health Care System, Salt Lake City, UT.
All rights reserved. Please visit https://medical-data-
models.org/forms/12007
Eligibility Osteoarthritis,
Degenerative NCT02034409
Inclusion Criteria
40 years of age or older*
Yes
No
Clinical symptoms of osteoarthritis for at least 6
months*
Yes
No
Pain in the index knee on motion or weight
bearing for the majority of days during the month
before screening*
Yes
No
Clinical diagnosis of primary osteoarthritis of the
knee based on clinical and radiographic criteria*
Yes
No
American Rheumatism Association Functional
Class I, II, or III*
Yes
No
Females of childbearing potential must be willing
to use a reliable form of medically acceptable
contraception*
Yes
No
Exclusion Criteria
Concurrent medical/arthritis condition(s), or any
other illness per the opinion of the investigator,
that could interfere with the evaluation of pain or
efficacy*
Yes
No
Spine or hip pain of significant magnitude*
Yes
No
History of significant ligament or meniscal injury
of the index joint*
Yes
No
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Arthroscopy of the index knee within 6 months of
study entry*
Yes
No
Unable to undergo MRI of the knee*
Yes
No
Pregnancy or lactation*
Yes
No
Corticosteroid treatment within 1 to 3 months
prior to study entry*
Yes
No
Intra-articular injection of hyaluronic acid or
congeners to the index knee within 6 months of
study entry*
Yes
No
Use of excluded therapy(ies) prior to study entry*
Yes
No
Use of disease modifying anti-rheumatic
medications and chronic tetracycline or its
derivatives*
Yes
No
Exposure to glucosamine, chondroitin sulfate, or
any other investigational treatment, within 1
month of study entry*
Yes
No
Use of any medical therapy, complementary or
alternative regimens for the treatment of
osteoarthritis within 7 days prior to study entry*
Yes
No
Initiation of any other medical or physical therapy,
or muscle conditioning program, within 2 months
prior to or during the study*
Yes
No
Unlikely to comply with study requirements*
Yes
No
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Blood Chemistry AML CALGB 10603
NCT00651261
CALGB: 10603 Lab Results - Blood Chemistry
NCT00651261 Daunorubicin, Cytarabine, and Midostaurin
in Treating Patients With Newly Diagnosed Acute Myeloid
Leukemia 
NCT00651261 
Daunorubicin, Cytarabine, and Midostaurin in Treating
Patients With Newly Diagnosed Acute Myeloid Leukemia
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=62302100-
240B-35C1-E040-BB89AD431366
All rights reserved. Please visit https://medical-data-
models.org/forms/12011
Blood Chemistry AML CALGB 10603
NCT00651261
Header
CALGB Form
CALGB Study No.
CALGB Patient ID
Reporting Period Start Date (MM DD YYYY)
Reporting Period End Date (MM DD YYYY)
Are data amended
Yes
No
Patient demographics
Patient Initials (Last, First Middle)
Patient Hospital No.
Institution/Affiliate
Participating Group
Participating Group Study No.
Participating Group Patient ID
Lab data
Name of Laboratory
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Laboratory ID (provided by CALGB)
Treatment Phase
Baseline (Baseline)
Consolidation #1 (Consolidation #1)
Consolidation #2 (Consolidation #2)
Consolidation #3 (Consolidation #3)
Consolidation #4 (Consolidation #4)
Continuation (Continuation)
Induction #1 (Induction #1)
Induction #2 (Induction #2)
Post-therapy (Post-therapy follow-up)
Lab collection time point (Mark one with an X)
A Regularly Scheduled Time Point (A
regularly scheduled time point)
An Additional Time Point (An additional
time point)
Lab results
Magnesium
mmol/L
Calcium
mmol/l
Sodium
mmol/L
Potassium
mmol/l
Chloride
mmol/L
Glucose
mg/dl
Uric acid
md/dl
Serum creatinine
mg/dL
BUN
mg/dL
Total Bilirubin
mg/dL
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AST (SGOT)
U/L
ALT (SGPT)
U/L
Alkaline Phosphatase
U/L
Albumin
g/dL
Total Protein
mg/dL
CTC Adverse Event Grade
Overall Response
Completed by (print or type name)
Date Form Completed (MM DD YYYY)
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Eligibility Parkinson's Syndrome
NCT01950468
A Cross-Over, Multi-Center Trial to Evaluate the Diagnostic
Efficacy and Safety of [123I]NAV5001 as an Imaging Agent
to Aid in the Diagnosis of Parkinsonian Syndromes; ODM
derived from: https://clinicaltrials.gov/show/NCT01950468
Principal Investigator: Stephen Flitman, M.D and  Ira
Goodman, M.D
All rights reserved. Please visit https://medical-data-
models.org/forms/12026
Eligibility Parkinson's Syndrome
NCT01950468
Inclusion Criteria
Subject has provided written informed consent
before the initiation of any study related
procedures and continues to give willing consent
for participation*
Yes
No
Age ≥ 40 years*
Yes
No
Have had upper extremity tremor for < 3 years
duration, regardless of presumed diagnosis or
etiology*
Yes
No
Have a UPDRS part III score upon entry of ≤ 16*
Yes
No
Exclusion Criteria
Any clinically significant or unstable physical or
psychological illness based on medical history or
physical examination at screening, as determined
by the investigator*
Yes
No
Structural brain abnormality affecting the entire
brain (e.g., normal pressure hydrocephalus) or
the striatum (e.g., local tumor or stroke)*
Yes
No
Any clinically significant abnormal laboratory
results obtained at screening and as determined
by the investigator*
Yes
No
Any clinically significant abnormal
electrocardiogram (ECG) results obtained at
screening and as determined by the investigator*
Yes
No
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Any history of drug, narcotic, or alcohol abuse
within 2 years before the date of informed
consent, as defined by the Diagnostic and
Statistical Manual of the American Psychiatric
Association, Fourth Edition, revised (DSM-IV-TR
[American Psychiatric Association, 1994])*
Yes
No
Positive urine drug screen for opiates, cocaine, or
amphetamines at screening*
Yes
No
Positive pregnancy test before imaging*
Yes
No
Participation in an investigational drug or device
clinical trial within 30 days before the date of
informed consent*
Yes
No
Previous scan with any DAT imaging agent (e.g.
[123I]NAV5001, Altropane, DaTscan,
DOPASCAN)*
Yes
No
Any exposure to radiopharmaceuticals within 30
days before the date of informed consent*
Yes
No
Breast-feeding*
Yes
No
Inability to lie supine for 1 hour*
Yes
No
Any thyroid disease other than adequately
treated hypothyroidism*
Yes
No
Known sensitivity or allergy to iodine or iodine
containing products*
Yes
No
Treatment within the 30 days before the date of
imaging with amoxapine, amphetamine,
benztropine, bupropion, buspirone, cocaine,
mazindol, methamphetamine, methylphenidate,
norephedrine, phentermine,
phenylpropanolamine, selegiline, and sertraline,
paroxetine, or citalopram.*
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Eligibility Parkinson's Syndrome NCT01950468
Yes
No
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Eligibility Paroxysmal Atrial Fibrillation
NCT01877486
PVI Using Cryoablation Alone in Paroxysmal AF Patients
Converted From Persistent AF With Dofetilide; ODM
derived from: https://clinicaltrials.gov/show/NCT01877486
Principal Investigator:	Jonathan S Steinberg, MD	University
of Rochester	
All rights reserved. Please visit https://medical-data-
models.org/forms/12027
Eligibility Paroxysmal Atrial
Fibrillation NCT01877486
Inclusion Criteria
Aged 18 to 80 years*
Yes
No
Able and willing to give written informed consent*
Yes
No
Paroxysmal AF, defined as recurrent AF ( ≥ 2
episodes in 1 month) that terminates within 7
days as assessed by ECG recordings*
Yes
No
Prior persistent AF, defined as sustained beyond
seven days and up to one year, successfully
converted to paroxysmal AF by dofetilide*
Yes
No
Exclusion Criteria
Previous ablation for AF*
Yes
No
Left atrial size larger than 60mm (parasternal
view on transthoracic echocardiogram)*
Yes
No
Patients who have AF episodes triggered by
another uniform arrhythmia (e.g. atrial flutter or
atrial tachycardia)*
Yes
No
Presence of severe valvular disease with the
need for surgical correction*
Yes
No
AF deemed secondary to a transient or
correctable abnormality including electrolyte
imbalance, trauma, recent surgery, infection, toxic
ingestion, and endocrinopathy*
Yes
No
Pregnant women or women of child bearing
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potential and not on reliable methods of birth
control*
Yes
No
Second or third degree AV block, sinus pause > 3
seconds, resting heart rate< 30 bpm without
permanent pacemaker*
Yes
No
History of drug-induced Torsades de Pointes or
congenital long QT syndrome*
Yes
No
Uninterrupted AF for more than 12 months prior
to randomization unless sinus rhythm maintained
for ≥ 24 hours after cardioversion.*
Yes
No
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Eligibility Prostatic Neoplasms
NCT01976962
Functional MR-guided Stereotactic Body Radiation Therapy
of Prostate Cancer; ODM derived from:
https://clinicaltrials.gov/show/NCT01976962
Principal Investigator:	Harvey Quon, MD	CancerCare
Manitoba	
All rights reserved. Please visit https://medical-data-
models.org/forms/12028
Eligibility Prostatic Neoplasms
NCT01976962
Inclusion Criteria
Informed consent*
Yes
No
Age >18 years*
Yes
No
Histologically confirmed and centrally reviewed
prostate adenocarcinoma based*
Yes
No
PSA within 60 days*
Yes
No
High risk prostate cancer defined as any one of:
clinical stage >= T3, Gleason score >= 8, or PSA
>=20 and <50 ng/mL.*
Yes
No
Exclusion Criteria
Evidence of lymph node metastasis*
Yes
No
Evidence of distant metastases*
Yes
No
Prior pelvic radiotherapy or brachytherapy*
Yes
No
Previous radical prostatectomy, cryotherapy, or
high-frequency ultrasound*
Yes
No
Unable to undergo gold seed insertion*
Yes
No
Immunosuppressive medications*
Yes
No
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Inflammatory bowel disease*
Yes
No
Unable to undergo MRI*
Yes
No
Previous bilateral orchiectomy*
Yes
No
Previous hormonal therapy including LHRH
agonists (leuprolide, goserelin), LHRH
antagonists (degarelix), anti-androgens
(bicalutamide, flutamide, nilutamide), surgical
castration, and estrogens*
Yes
No
Previous finasteride within 14 days.*
Yes
No
Previous dutasteride within 180 days.*
Yes
No
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Eligibility Pulmonary Arterial Hypertension
With Congenital Cardiac Shunt NCT02138708
Evaluation of the Pulmonary Vascular Reactivity Test in
Patients With Pulmonary Arterial Hypertension and a
Cardiac Shunt; ODM derived from:
https://clinicaltrials.gov/show/NCT02138708
All rights reserved. Please visit https://medical-data-
models.org/forms/12029
Eligibility Pulmonary Arterial
Hypertension With Congenital
Cardiac Shunt NCT02138708
Inclusion Criteria
Patient child or adult, (regardless of age and
weight) , which presents with heart disease with a
shunt,*
Yes
No
Patient who requires, during current care, a
hemodynamic exploration by catheterization to
assess pulmonary vascular resistance (due to
doubt on the operability of the patient on the
usual clinical and echo cardiographic data) .*
Yes
No
Informed consent signed by the patient or at least
one holder of parental authority, and the
investigator*
Yes
No
Patient affiliated or benefiting from a social
security scheme*
Yes
No
Exclusion Criteria
Patient with a specific treatment for PAH (the
prostacyclin derivatives, antagonists of
endothelium receptors and inhibitors of
phosphodiesterase 5).*
Yes
No
Patient participating in another research with
exclusion period*
Yes
No
Known allergy to acetylcholine or adenosine*
Yes
No
Contraindication to the use of KRENOSIN
(adenosine)*
Yes
No
Atrioventricular block second or third degree, with
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the exception of patients with cardiac
pacemaker.*
Yes
No
Dysfunction sinoatrial (the headset disease)
except patients with a pacemaker*
Yes
No
Chronic obstructive pulmonary disease with
bronchospasm (eg bronchial asthma)*
Yes
No
Long qt syndrome*
Yes
No
Severe arterial hypotension*
Yes
No
Known adenosine hypersensitivity*
Yes
No
Pregnant or patient of childbearing potential not
using an  effective contraception*
Yes
No
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Shunt NCT02138708
Eligibility Relapsing Remitting Multiple
Sclerosis NCT01714089
Proof of Concept Study Evaluating RNS60 in the Treatment
of Relapsing Remitting Multiple Sclerosis; ODM derived
from: https://clinicaltrials.gov/show/NCT01714089
Principal Investigator:	Fred Lublin, MD, PhD	Mt. Sinai School
of Medicine
All rights reserved. Please visit https://medical-data-
models.org/forms/12030
Eligibility Relapsing Remitting
Multiple Sclerosis NCT01714089
Inclusion Criteria
1. Males or females, aged between 18 and 50
years.*
Yes
No
2. Diagnosis of RR-MS according to McDonald
2010 diagnostic criteria with a prior brain MRI
that demonstrates lesions consistent with RRMS,
both within the past year.*
Yes
No
3.No evidence of relapse during the 60 days prior
to enrollment.*
Yes
No
4. EDSS score of 0-5 at screening.*
Yes
No
5. Women of childbearing potential who have a
negative pregnancy test (serum HCG) at
screening.*
Yes
No
6. Men or women of reproductive potential who
commit to use adequate contraception during the
study and for 1 month following the last day of
treatment.*
Yes
No
7. Subjects must be capable of understanding the
purpose and risks of the study and provide
written, informed consent.*
Yes
No
Exclusion Criteria
1. Diagnosis of Secondary Progressive MS,
Primary Progressive MS or Progressive
Relapsing MS.*
Yes
No
2.Normal baseline brain MRI.*
Yes
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No
3. History of any clinically significant autoimmune
disease: inflammatory bowel disease, diabetes,
lupus or severe asthma.*
Yes
No
4. Current or prior malignancies (excluding non-
melanoma skin carcinoma or in situ carcinoma of
the cervix that has been adequately treated.)*
Yes
No
5. Significant organ dysfunction, including
cardiac, renal (eGFR ≤ 60 ml/min.), liver, central
nervous system, pulmonary, vascular,
gastrointestinal, endocrine, or metabolic (e.g.,
creatinine ≥ 1.6 mg/dL; ALT or AST ≥ 1.5x the
upper limit of normal), history of myocardial
infarction, congestive heart failure, or arrhythmias
within 6 months prior to enrollment.the upper limit
of normal), history of myocardial infarction,
congestive heart failure, or arrhythmias within 6
months prior to enrollment.*
Yes
No
6. Steroid therapy within 60 days prior to
enrollment, with the exception of corticosteroids
or ACTH for relapse treatment during the course
of the study.*
Yes
No
7. Known allergy to Gadolinium-DTPA*
Yes
No
8. Therapy with any immunomodulatory drugs
within 3 months prior to enrollment, including but
not limited to interferons, glatiramir acetate, BG-
12, teriflunomide, laquinimod and IV
immunoglobulin.*
Yes
No
9. Treatment at any time with immunosuppressive
drugs such as cladribine, total lymphoid
irradiation, monoclonal antibody treatment,
mitoxantrone, Tysabri, fingolimod, cytoxan,
methotrexate.*
Yes
No
10. Participation in any investigational therapy
within one year prior to enrollment, unless given
approval by PI.*
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Yes
No
11. Known or suspected current or past alcohol
or drug abuse within one year prior to
enrollment.*
Yes
No
12. Any medical, psychiatric or other condition
that could result in a subject not being able to
comply with protocol requirements.*
Yes
No
3 / 3
Eligibility Relapsing Remitting Multiple Sclerosis NCT01714089
Eligibility Schizophrenia NCT02420015
Mobile Health Technology to Enhance Abstinence in
Smokers With Schizophrenia; ODM derived from:
https://clinicaltrials.gov/show/NCT02420015
Principal Investigator:	Jean C Beckham, Ph.D.	Duke
University
All rights reserved. Please visit https://medical-data-
models.org/forms/12031
Eligibility Schizophrenia
NCT02420015
Inclusion Criteria
currently smoke at least ten cigarettes a day*
Yes
No
have been smoking for at least one year*
Yes
No
meet criteria for schizophrenia, schizoaffective
disorder, or another psychotic disorder based on
structured clinical interview*
Yes
No
can speak and write fluent conversational
english*
Yes
No
are between 18 and 70 years of age*
Yes
No
are willing to make a smoking cessation attempt*
Yes
No
score 26 or higher on the montreal cognitive
assessment*
Yes
No
Exclusion Criteria
have a history of myocardial infarction in the past
6 months*
Yes
No
have a contraindication to NRT with no medical
clearance from the primary care provider or study
physician*
Yes
No
use and unwillingness to stop use of other forms
of nicotine such as cigars, pipes, or chewing
tobacco*
Yes
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No
are pregnant*
Yes
No
meet criteria for a current manic episode based
on structured clinical interview*
Yes
No
are currently enrolled in another smoking
cessation trial*
Yes
No
are currently imprisoned or in psychiatric
hospitalization*
Yes
No
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Eligibility Schizophrenia NCT02512367
Evaluate the Efficacy of a Global Dental Health Promotion
Program on Dental Hygiene in Patients With
Schizophrenia.; ODM derived from:
https://clinicaltrials.gov/show/NCT02512367
All rights reserved. Please visit https://medical-data-
models.org/forms/12032
Eligibility Schizophrenia
NCT02512367
Inclusion Criteria
patients with a confirmed diagnosis of
schizophrenia according to the diagnostic and
statistical manual of mental disorders 5th edition
(DSM V)*
Yes
No
managed at a specialized establishment
(teaching or non-teaching hospital)*
Yes
No
in-patients or out-patients*
Yes
No
older than 18 years*
Yes
No
who have provided written informed consent to
take part in the study*
Yes
No
Exclusion Criteria
patients who are unstable from a psychiatric poit
of view or who suffer from delirium.*
Yes
No
patients under forced hospitalization*
Yes
No
patients with no teeth*
Yes
No
patients with a risk of infectious endocarditis or a
major risk of superinfection*
Yes
No
patients on long-term treatment with antibiotics
(impact of antibiotherapy on oral flora)*
Yes
No
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patients treated with chemotherapy*
Yes
No
pregnant or breastfeeding women*
Yes
No
patients without national health insurance cover.*
Yes
No
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Eligibility Type 2 Diabetes NCT01516320
Mechanisms of Diabetes Relapse After Bariatric Surgery;
ODM derived from:
https://clinicaltrials.gov/show/NCT01516320
All rights reserved. Please visit https://medical-data-
models.org/forms/12039
Eligibility Type 2 Diabetes
NCT01516320
Inclusion Criteria: Post GBP Subjects
Must be able to attend 4 study visits at St. Luke's
Roosevelt Hospital Center in Manhattan, New
York City*
Yes
No
At least 1 year post GBP surgery*
Yes
No
History of Type 2 Diabetes before surgery*
Yes
No
Inclusion Criteria: Non-Operated
Overweight to Moderately Obese Controls
Must be able to attend 4 study visits at St. Luke's
Roosevelt Hospital Center in Manhattan, New
York City*
Yes
No
No personal or family history of Type 1, Type 2 or
Gestational Diabetes*
Yes
No
BMI between ~24-42*
Yes
No
Exclusion Criteria
Active cancer, unstable angina, recent stroke.*
Yes
No
Current therapy with medications that may affect
glucose metabolism such as glucocorticoids,
adrenergic agents, etc.*
Yes
No
Evidence of a medical condition that might alter
results or compromise the elimination of the
peptide, including active infection, kidney failure,
severe liver dysfunction, severe respiratory or
cardiac failure*
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Yes
No
Pregnancy: A pregnancy test will be done prior to
enrollment and to each procedure in all
premenopausal women.*
Yes
No
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Eligibility Type 2 Diabetes NCT01939782
Metabolic Clock Genes During Fasting and After Food
Intake in Type 2 Diabetics; ODM derived from:
https://clinicaltrials.gov/show/NCT01939782
Principal Investigator:	Daniela Jakubowicz, MD	Diabetes
Unit E. Wolfson Medical Center. Tel Aviv University
All rights reserved. Please visit https://medical-data-
models.org/forms/12040
Eligibility Type 2 Diabetes
NCT01939782
INCLUSION CRITERIA FOR PATIENTS
WITH TYPE 2 DIABETES
Type 2 diabetic patients
Yes
No
HbA1C > 6.5%
Yes
No
Duration of diabetes: 0.5 to 30 years
Yes
No
Subjects ≥ 26 and ≤ 65 years of age
Yes
No
BMI: > 26 kg/m2
Yes
No
All oral antidiabetic treatments and will be
allowed, not insulin treatment
Yes
No
Normal liver and kidney function
Yes
No
Normal thyroid function
Yes
No
Stable physical activity pattern during the three
months immediately preceding study
Yes
No
No metabolic disease other than diabetes
Yes
No
Usually wakes up between 06:00 and 07:00 and
goes to sleep between 22:00 and 24:00.
Yes
No
Normal TSH and FT4 levels
Yes
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No
No shift work within 5 years of the study
Yes
No
Did not cross time zones within 1 month of the
study
Yes
No
Acceptable health beside diabetes based on
interview, medical history, physical examination,
and laboratory tests
Yes
No
Read and understood the informed consent form
and signed it voluntarily
Yes
No
INCLUSION CRITERIA FOR HEALTHY
NON-DIABETIC PATIENTS
Healthy non diabetic, and not known as diabetic
Yes
No
Fasting glucose <100 mg/dl
Yes
No
HbA1C <5.7 %
Yes
No
Not taking any antidiabetic drugs
Yes
No
Subjects ≥ 26 and ≤ 65 years of age
Yes
No
BMI: <26 kg/m2
Yes
No
Normal liver and kidney function
Yes
No
Normal TSH and FT4 levels
Yes
No
Usually wakes up between 06:00 and 07:00 and
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goes to sleep between 22:00 and 24:00.
Yes
No
No shift work within 5 years of the study
Yes
No
Did not cross time zones within 1 month of the
study
Yes
No
Acceptable health based on interview, medical
history, physical examination, and laboratory
tests
Yes
No
Read and understood the informed consent form
and signed it voluntarily
Yes
No
EXCLUSION CRITERIA FOR ALL 2
GROUPS (HEALTHY AND DIABETICS)
Clinically significant pulmonary, cardiac, renal,
hepatic, neurologic, psychiatric, infectious,
malignant disease
Yes
No
Type 1 diabetes
Yes
No
Treatment with Insulin
Yes
No
Serum creatinin level > 1.5 mg/dl
Yes
No
Pregnancy or lactation
Yes
No
Illicit drug abuse or alcoholism
Yes
No
Subjects on steroid treatment
Yes
No
Subjects known by the principal investigator to be
unable to cooperate for any reason.
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Yes
No
Abnormal liver function tests defined as an
increase by a factor of at least 2 above the upper
normal limit of alanine aminotransferase (ALT)
and/or aspartate aminotransferase (AST)
Yes
No
Night or rotating shift work
Yes
No
Jet lag during the 2 week period immediately
prior to study onset
Yes
No
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Eligibility Parkinsons Disease
NCT02318927
A Responsive Closed-Loop Approach to Treat Freezing of
Gait in Parkinson's Disease; ODM derived from:
https://clinicaltrials.gov/show/NCT02318927
All rights reserved. Please visit https://medical-data-
models.org/forms/12041
Eligibility Parkinsons Disease
NCT02318927
Inclusion Criteria
1. A clinical diagnosis of idiopathic PD, without a
previous DBS operation
Yes
No
2. Must be deemed appropriate for a GPi DBS
operation by the interdisciplinary screening team
(GPi must be the target chosen as most
appropriate for treatment of their PD to qualify for
this study)
Yes
No
3. Age 30-75 years (must meet UK Brain Bank
criteria for diagnosis of idiopathic Parkinson's
disease).
Yes
No
4. Experiencing significant gait and postural
instability despite optimal pharmacologic
management (Hoehn and Yahr Stage II or greater
in the on state).
Yes
No
5. Best medication "on" does not reveal
meaningful improvement in posture scores (Pull
Test). Patients must be challenged in person with
a suprathreshold dose of levodopa (1.5 times
optimized regular dose of levodopa) and must
have poor or no improvement in postural stability.
Yes
No
6. Patients must possess a clinical history of gait
freezing > 2 episodes per month, to be included,
participants must also score > 1 on item #3 of the
Freezing of Gait (FOG) Questionnaire and exhibit
five or more FoG episodes during the provocation
protocol in on or off state.
Yes
No
7. L-dopa responsive with clearly defined "on"
periods.
Yes
No
8. Willingness and ability to cooperate during
conscious operative procedure, as well as during
post-surgical evaluations, adjustments of
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medications and stimulator settings.
Yes
No
Exclusion Criteria
1. Clinically significant medical disease that
would increase the risk of developing pre- or
postoperative complications. Clinically significant
medical disease includes uncontrolled systemic
hypertension with values above 170/100mmHg;
cardiac or pulmonary disease; uncorrected
coagulation abnormalities or need for therapeutic
anticoagulation which cannot be interrupted; any
condition that would render the patient unable to
safely cooperate with the study tests as judged
by the screening physician.
Yes
No
2. Evidence of secondary or atypical
parkinsonism.
Yes
No
3. Other neurological and musculoskeletal
impairments that would negatively influence
postural stability
Yes
No
4. Past MRI scan with significant evidence of
brain atrophy or other abnormalities.
Yes
No
5. Dementia as evidenced by impairment in two
neuropsychological domains and a Mattis
Dementia Score <130.
Yes
No
6. A major untreated psychiatric disorder as
revealed on psychiatric exam at screening, and a
Beck Depression Inventory Score >14.
Yes
No
7. Subjects with a history of seizures.
Yes
No
8. Subjects who may require repeat MRI scans
Yes
No
9. Subjects with a history of a cranial
neurosurgical procedure.
Yes
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No
10. Subjects with metal in the head or another
implanted stimulator (e.g. vagus nerve stimulator,
spinal cord stimulator, pacemaker, cochlear
implant, etc).
Yes
No
11. Subjects who require treatment with
Electroconvulsive therapy (ECT) or repetitive
Transcranial Magnetic Stimulation (rTMS).
Yes
No
12. Pregnant or nursing women or women who
wish to become pregnant will be excluded.
Yes
No
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Eligibility Severe Asthma NCT01961258
"SEVERE ASTHMA" in the COMMUNITY; ODM derived
from: https://clinicaltrials.gov/show/NCT01961258
All rights reserved. Please visit https://medical-data-
models.org/forms/12042
Inclusion Criteria
Inclusion Criteria
Age 20-70 years old
Yes
No
A computerized diagnosis-title of "bronchial
asthma", at any stage of severity.
Yes
No
Sub-group: Severe asthma (according to
the ATS workshop consensus definition of
severe/refractory asthma, based on the
level of prescribed medication criteria
2000)
An obligatory criteria of at least 12 month inhaler-
therapy prescription of a combination of high
dose corticosteroid +LABA (at least 12 inhalers of
Symbicort 160/4.5 mcg OR at least 10 inhalers of
Seretide 500 mcg, a year)
Yes
No
Prescription of SABA, either Ventolin OR Bricalin
inhalers at least once a quarter of a year or at
least 4 inhalers in 12 months OR at least one
prescription a month of inhalation-solution of
Ventolin or Bricalin a month.
Yes
No
Prescription of an oral or IM corticosteroid, at
least twice in the last 12 months.
Yes
No
Sub-group: Treatment resistant severe
asthma (Asthmatics that potentially have
"difficult to treat severe asthma" due to co-
morbidities or potential triggering factors).
Having computerized title-diagnosis of COPD,
congestive heart failure, smoking, bronchiectasis,
interstitial lung disease.
Yes
No
Prescription of an oral or topical (ocular) beta-
blockers.
Yes
No
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Exclusion Criteria
Exclusion Criteria
Age <20 or >70 years old.
Yes
No
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OPS Chapter 1 Diagnostic Procedures
derived from:
German Procedure Classification
https://www.dimdi.de/static/en/klassi/ops/index.htm [DIMDI
Operationen- und Prozedurenschlüssel (OPS)]
DIMDI publishes the OPS classification on behalf of the
Federal Ministry of Health; it is in the public domain. Its use
in inpatient care is laid down in § 301 Volume V of the
German Social Security Code (SGB V) and for surgical
procedures in the outpatient sector in § 295 SGB V.
All rights reserved. Please visit https://medical-data-
models.org/forms/12043
OPS Chapter 1 Diagnostic
Procedures
DIAGNOSTISCHE MASSNAHMEN
DIAGNOSTISCHE MASSNAHMEN
Klinische Untersuchung (1-10)
Klinische Untersuchung in
Allgemeinanästhesie (1-100)
Neurologische Untersuchungen (1-20)
Diagnostik zur Feststellung des
Hirntodes (1-202)
Invasive Funktionsdiagnostik des
Nervensystems (1-203)
Untersuchung des Liquorsystems (1-
204)
Elektromyographie (EMG) (1-205)
Neurographie (1-206)
Elektroenzephalographie (EEG) (1-207)
Registrierung evozierter Potentiale (1-
208)
Komplexe Diagnostik bei Spina bifida (1-
209)
Andere neurophysiologische
Untersuchungen (1-20a)
Magnetenzephalographie (MEG) (1-20b)
Navigierte transkranielle
Magnetstimulation (nTMS) (1-20c)
Epilepsiediagnostik (1-21)
Nicht invasive Video-EEG-
Intensivdiagnostik zur Klrung eines
Verdachts auf Epilepsie oder einer
epilepsiechirurgischen
Operationsindikation (1-210)
Invasive Video-EEG-Intensivdiagnostik
bei Epilepsie zur Klrung einer
epilepsiechirurgischen
Operationsindikation (1-211)
Invasive intraoperative
Epilepsiediagnostik (1-212)
Syndromdiagnose bei komplizierten
Epilepsien (1-213)
Untersuchungen der Augen (1-22)
Messung des Augeninnendrucks (1-220)
Untersuchungen im HNO-Bereich (1-24)
Audiometrie (1-242)
Phoniatrie (1-243)
Rhinomanometrie (1-245)
Olfaktometrie und Gustometrie (1-247)
Untersuchungen der
elektrophysiologischen Aktivitt des
Herzens (1-26)
1 / 11
Elektrophysiologische Untersuchung des
Herzens, kathetergesttzt (1-265)
Elektrophysiologische Untersuchung des
Herzens, nicht kathetergesttzt (1-266)
Kardiales Mapping (1-268)
Magnetokardiographie (1-269)
Diagnostische Katheteruntersuchung an
Herz und Kreislauf (1-27)
Rechtsherz-Katheteruntersuchung (1-
273)
Transseptale Linksherz-
Katheteruntersuchung (1-274)
Transarterielle Linksherz-
Katheteruntersuchung (1-275)
Angiokardiographie als selbständige
Maßnahme (1-276)
Herzkatheteruntersuchung bei
funktionell/morphologisch
univentrikulärem Herzen (1-277)
Andere diagnostische
Katheteruntersuchung an Herz und
Gefäßen (1-279)
Funktionsuntersuchungen des
Verdauungstraktes (1-31)
Ösophagusmanometrie (1-313)
Manometrie der Gallen- und
Pankreasgänge (1-314)
Anorektale Manometrie (1-315)
pH-Metrie des Ösophagus (1-316)
pH-Metrie des Magens (1-317)
Dünndarmmanometrie (1-318)
Dickdarmmanometrie (1-319)
Untersuchung des Harntraktes (1-33)
Urodynamische Untersuchung (1-334)
Messung des Urethradruckprofils (1-335)
Harnröhrenkalibrierung (1-336)
Biopsie ohne Inzision an Nervensystem
und endokrinen Organen (1-40)
Perkutane Biopsie an intrakraniellem
Gewebe mit Steuerung durch
bildgebende Verfahren (1-401)
Perkutane (Nadel-)Biopsie an
intraspinalem Gewebe (1-404)
Perkutane (Nadel-)Biopsie an peripheren
Nerven (1-405)
Perkutane (Nadel-)Biopsie an
endokrinen Organen (1-406)
Perkutane Biopsie an endokrinen
Organen mit Steuerung durch
bildgebende Verfahren (1-407)
Endosonographische Biopsie an
endokrinen Organen (1-408)
Biopsie ohne Inzision an Auge, Ohr,
Nase und Haut von Gesicht und Kopf (1-
41)
Biopsie ohne Inzision an der Ohrmuschel
(1-410)
Biopsie ohne Inzision am äußeren
Gehörgang durch Otoskopie (1-411)
Biopsie ohne Inzision an Augenlid und
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Augenbraue (1-412)
Biopsie ohne Inzision an Konjunktiva und
Kornea (1-413)
Biopsie ohne Inzision an der Nase (1-
414)
Biopsie ohne Inzision an der
Gesichtshaut (1-415)
Biopsie ohne Inzision an Mund,
Mundhöhle, Larynx, Pharynx und
blutbildenden Organen (1-42)
Biopsie ohne Inzision an Mund und
Mundhöhle (1-420)
Biopsie ohne Inzision am Larynx (1-421)
Biopsie ohne Inzision am Pharynx (1-
422)
Biopsie ohne Inzision am Knochenmark
(1-424)
(Perkutane) (Nadel-)Biopsie an
Lymphknoten, Milz und Thymus (1-425)
(Perkutane) Biopsie an Lymphknoten,
Milz und Thymus mit Steuerung durch
bildgebende Verfahren (1-426)
Biopsie ohne Inzision an respiratorischen
Organen (1-43)
Endoskopische Biopsie an
respiratorischen Organen (1-430)
Perkutane (Nadel-)Biopsie an
respiratorischen Organen (1-431)
Perkutane Biopsie an respiratorischen
Organen mit Steuerung durch
bildgebende Verfahren (1-432)
Biopsie ohne Inzision an den
Verdauungsorganen (1-44)
Endoskopische Biopsie an oberem
Verdauungstrakt, Gallengängen und
Pankreas (1-440)
Perkutane (Nadel-)Biopsie an
hepatobiliärem System und Pankreas (1-
441)
Perkutane Biopsie an hepatobiliärem
System und Pankreas mit Steuerung
durch bildgebende Verfahren (1-442)
Endoskopische Biopsie am unteren
Verdauungstrakt (1-444)
Endosonographische Feinnadelpunktion
am oberen Verdauungstrakt (1-445)
Endosonographische Feinnadelpunktion
am unteren Verdauungstrakt (1-446)
Endosonographische Feinnadelpunktion
am Pankreas (1-447)
Endosonographische Feinnadelpunktion
am hepatobiliären System (1-448)
Andere Biopsie ohne Inzision an
anderen Verdauungsorganen (1-449)
Biopsie ohne Inzision an Harnorganen
und männlichen Geschlechtsorganen (1-
46)
Transurethrale Biopsie an Harnorganen
und Prostata (1-460)
Perkutan-nephroskopische Biopsie an
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Harnorganen (1-461)
Perkutan-zystoskopische Biopsie an
Harnorganen und Prostata (1-462)
Perkutane (Nadel-)Biopsie an
Harnorganen und männlichen
Geschlechtsorganen (1-463)
Transrektale Biopsie an männlichen
Geschlechtsorganen (1-464)
Perkutane Biopsie an Harnorganen und
männlichen Geschlechtsorganen mit
Steuerung durch bildgebende Verfahren
(1-465)
Biopsie ohne Inzision an weiblichen
Geschlechtsorganen (1-47)
Perkutane (Nadel-)Biopsie an weiblichen
Geschlechtsorganen (1-470)
Biopsie ohne Inzision am Endometrium
(1-471)
Biopsie ohne Inzision an der Cervix uteri
(1-472)
Biopsie ohne Inzision am graviden
Uterus mit Steuerung durch bildgebende
Verfahren (1-473)
Perkutane Biopsie an weiblichen
Geschlechtsorganen mit Steuerung
durch bildgebende Verfahren (1-474)
Biopsie ohne Inzision an Knochen und
Gelenken (1-48)
Perkutane (Nadel-)Biopsie an Knochen
(1-480)
Biopsie ohne Inzision an Knochen mit
Steuerung durch bildgebende Verfahren
(1-481)
Arthroskopische Biopsie an Gelenken (1-
482)
Perkutane (Nadel-)Biopsie an Gelenken
und Schleimbeuteln (1-483)
Perkutane Biopsie an Gelenken und
Schleimbeuteln mit Steuerung durch
bildgebende Verfahren (1-484)
Biopsie ohne Inzision an anderen
Organen und Geweben (1-49)
Biopsie ohne Inzision an Haut und
Unterhaut (1-490)
Perkutane (Nadel-)Biopsie an Muskeln
und Weichteilen (1-491)
Perkutane Biopsie an Muskeln und
Weichteilen mit Steuerung durch
bildgebende Verfahren (1-492)
Perkutane (Nadel-)Biopsie an anderen
Organen und Geweben (1-493)
(Perkutane) Biopsie an anderen
Organen und Geweben mit Steuerung
durch bildgebende Verfahren (1-494)
Transvenöse oder transarterielle Biopsie
(1-497)
Biopsie an Mamma, Knochen und
Muskeln durch Inzision (1-50)
Biopsie der Mamma durch Inzision (1-
501)
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Biopsie an Muskeln und Weichteilen
durch Inzision (1-502)
Biopsie an Knochen durch Inzision (1-
503)
Biopsie an Gelenken und
Schleimbeuteln durch Inzision (1-504)
Biopsie an Nervengewebe, Hypophyse,
Corpus pineale durch Inzision und
Trepanation von Schädelknochen (1-51)
Biopsie an intrakraniellem Gewebe durch
Inzision und Trepanation von
Schädelknochen (1-510)
Stereotaktische Biopsie an
intrakraniellem Gewebe (1-511)
Biopsie an intraspinalem Gewebe durch
Inzision (1-512)
Biopsie an peripheren Nerven durch
Inzision (1-513)
Biopsie an Hypophyse und Corpus
pineale durch Inzision (1-514)
Stereotaktische Biopsie an Hypophyse
und Corpus pineale (1-515)
Biopsie an Augen und
Augenanhangsgebilden durch Inzision
(1-52)
Biopsie am Augenlid durch Inzision (1-
520)
Biopsie an Tränendrüse und
Tränendrüsenausführungsgang durch
Inzision (1-522)
Biopsie an anderen Teilen des Auges
durch Inzision (1-529)
Biopsie an Ohr und Nase durch Inzision
(1-53)
Biopsie am äußeren Gehörgang durch
Inzision (1-531)
Biopsie an anderen Teilen des Ohres
durch Inzision (1-532)
Biopsie am Naseninnenraum durch
Inzision (1-537)
Biopsie an den Nasennebenhöhlen
durch Inzision (1-538)
Biopsie an anderen Teilen der Nase
durch Inzision (1-539)
Biopsie an Mund, Mundhöhle und
Pharynx durch Inzision (1-54)
Biopsie an Speicheldrüse und
Speicheldrüsenausführungsgang durch
Inzision (1-542)
Biopsie an anderen Strukturen des
Mundes und der Mundhöhle durch
Inzision (1-545)
Biopsie am Oropharynx durch Inzision
(1-546)
Biopsie am Hypopharynx durch Inzision
(1-547)
Biopsie am Nasopharynx durch Inzision
(1-548)
Biopsie am Larynx durch Inzision (1-549)
Biopsie an anderen Verdauungsorganen,
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Zwerchfell und (Retro-)Peritoneum durch
Inzision (1-55)
Biopsie am Zwerchfell durch Inzision (1-
550)
Biopsie an der Leber durch Inzision (1-
551)
Biopsie an Gallenblase und
Gallengängen durch Inzision (1-552)
Biopsie am Pankreas durch Inzision (1-
553)
Biopsie am Magen durch Inzision (1-554)
Biopsie am Dünndarm durch Inzision (1-
555)
Biopsie am Kolon durch Inzision (1-556)
Biopsie an Rektum und perirektalem
Gewebe durch Inzision (1-557)
Biopsie an anderen Verdauungsorganen,
Peritoneum und retroperitonealem
Gewebe durch Inzision (1-559)
Biopsie an Harnwegen und männlichen
Geschlechtsorganen durch Inzision (1-
56)
Biopsie an Niere und perirenalem
Gewebe durch Inzision (1-560)
Biopsie an Urethra und periurethralem
Gewebe durch Inzision (1-561)
Biopsie an anderen Harnorganen durch
Inzision (1-562)
Biopsie an Prostata und
periprostatischem Gewebe durch
Inzision (1-563)
Biopsie am Penis durch Inzision (1-564)
Biopsie am Hoden durch Inzision (1-565)
Biopsie am männlichen Perineum durch
Inzision (1-566)
Biopsie an anderen männlichen
Geschlechtsorganen durch Inzision (1-
569)
Biopsie an weiblichen
Geschlechtsorganen durch Inzision (1-
57)
Biopsie an Ovar, Tuba(e) uterina(e) und
Ligamenten des Uterus durch Inzision
(1-570)
Biopsie an Uterus und Cervix uteri durch
Inzision (1-571)
Biopsie an der Vagina durch Inzision (1-
572)
Biopsie an der Vulva durch Inzision (1-
573)
Biopsie am weiblichen Perineum durch
Inzision (1-574)
Biopsie an anderen weiblichen
Geschlechtsorganen durch Inzision (1-
579)
Biopsie an anderen Organen durch
Inzision (1-58)
Biopsie an Herz und Perikard durch
Inzision (1-580)
Biopsie am Mediastinum und anderen
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intrathorakalen Organen durch Inzision
(1-581)
Biopsie an Schilddrüse und
Nebenschilddrüsen durch Inzision (1-
582)
Biopsie an anderen Organen des Halses
durch Inzision (1-583)
Biopsie an der Nebenniere durch
Inzision (1-584)
Biopsie an anderen intraabdominalen
Organen durch Inzision (1-585)
Biopsie an Lymphknoten durch Inzision
(1-586)
Biopsie an Blutgefäßen durch Inzision
(1-587)
Biopsie an anderen Organen und
Geweben durch Inzision (1-589)
Diagnostische Endoskopie der oberen
Atemwege (1-61)
Diagnostische Laryngoskopie (1-610)
Diagnostische Pharyngoskopie (1-611)
Diagnostische Rhinoskopie (1-612)
Evaluation des Schluckens mit flexiblem
Endoskop (1-613)
Diagnostische Tracheobronchoskopie (1-
62)
Diagnostische Tracheobronchoskopie (1-
620)
Diagnostische Endoskopie des oberen
Verdauungstraktes (1-63)
Diagnostische Ösophagoskopie (1-630)
Diagnostische Ösophagogastroskopie
(1-631)
Diagnostische
Ösophagogastroduodenoskopie (1-632)
Diagnostische Jejunoskopie (1-635)
Diagnostische Intestinoskopie
(Endoskopie des tiefen Jejunums und
Ileums) (1-636)
Diagnostische Endoskopie des oberen
Verdauungstraktes über ein Stoma (1-
638)
Kapselendoskopie des Dünndarms (1-
63a)
Chromoendoskopie des oberen
Verdauungstraktes (1-63b)
Diagnostische Endoskopie der Gallen-
und Pankreaswege (1-64)
Diagnostische retrograde Darstellung der
Gallenwege (1-640)
Diagnostische retrograde Darstellung der
Pankreaswege (1-641)
Diagnostische retrograde Darstellung der
Gallen- und Pankreaswege (1-642)
Diagnostische direkte Endoskopie der
Gallenwege (duktale Endoskopie)
(POCS) (1-643)
Diagnostische direkte Endoskopie des
Pankreasganges (duktale Endoskopie)
(POPS) (1-644)
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Zugang durch retrograde Endoskopie (1-
645)
Diagnostische Endoskopie des unteren
Verdauungstraktes (1-65)
Diagnostische Koloskopie (1-650)
Diagnostische Sigmoideoskopie (1-651)
Diagnostische Endoskopie des Darmes
über ein Stoma (1-652)
Diagnostische Proktoskopie (1-653)
Diagnostische Rektoskopie (1-654)
Chromoendoskopie des unteren
Verdauungstraktes (1-655)
Kapselendoskopie des Kolons (1-656)
(Ileo-)Koloskopie durch Push-and-pull-
back-Technik (1-657)
Diagnostische Endoskopie der
Harnwege (1-66)
Diagnostische Urethroskopie (1-660)
Diagnostische Urethrozystoskopie (1-
661)
Diagnostische Urethrozystoskopie einer
augmentierten Harnblase (1-663)
Diagnostische Ureterorenoskopie (1-
665)
Diagnostische Endoskopie einer
Harnableitung (1-666)
Diagnostische Endoskopie der
Harnwege über ein Stoma (1-668)
Diagnostische Endoskopie der
weiblichen Geschlechtsorgane (1-67)
Diagnostische Vaginoskopie (1-670)
Diagnostische Kolposkopie (1-671)
Diagnostische Hysteroskopie (1-672)
Diagnostische Hysterosalpingoskopie (1-
673)
Diagnostische Embryofetoskopie (1-674)
Andere diagnostische Endoskopie (1-68)
Diagnostische Endoskopie der
Tränenwege (1-681)
Diagnostische Endoskopie der
Milchgänge (1-682)
Diagnostische Sialendoskopie der
Glandula submandibularis oder der
Glandula parotis (1-683)
Diagnostische Endoskopie durch Inzision
und intraoperativ (1-69)
Diagnostische Bronchoskopie und
Tracheoskopie durch Inzision und
intraoperativ (1-690)
Diagnostische Thorakoskopie und
Mediastinoskopie (1-691)
Diagnostische Endoskopie der
Harnwege durch Inzision und
intraoperativ (1-693)
Diagnostische Laparoskopie
(Peritoneoskopie) (1-694)
Diagnostische Endoskopie des
Verdauungstraktes durch Inzision und
intraoperativ (1-695)
Diagnostische Endoskopie des
8 / 11
OPS Chapter 1 Diagnostic Procedures
Douglasraumes (Kuldoskopie) (1-696)
Diagnostische Arthroskopie (1-697)
Diagnostische Endoskopie durch
Punktion, Inzision und intraoperativ am
Zentralnervensystem (1-698)
Andere diagnostische Endoskopie durch
Punktion, Inzision und intraoperativ (1-
699)
Provokationstestung (1-70)
Spezifische allergologische
Provokationstestung (1-700)
Pneumologische
Funktionsuntersuchungen (1-71)
Ganzkörperplethysmographie (1-710)
Bestimmung der CO-Diffusionskapazität
(1-711)
Spiroergometrie (1-712)
Messung der funktionellen
Residualkapazität [FRC] mit der Helium-
Verdünnungsmethode (1-713)
Messung der bronchialen Reaktivität (1-
714)
Sechs-Minuten-Gehtest nach Guyatt (1-
715)
Metabolische Funktionsuntersuchung (1-
76)
Belastungstest mit Substanzen zum
Nachweis einer Stoffwechselstörung (1-
760)
Pankreasfunktionstest mit Aspiration von
Duodenalsaft über eine Duodenalsonde
(1-761)
Leberfunktionstest mit intravenöser
Applikation eines C13-markierten
Substrates (1-762)
Palliativmedizinische, geriatrische und
frührehabilitative Funktionsuntersuchung
(1-77)
Multidimensionales geriatrisches
Screening und Minimalassessment (1-
770)
Standardisiertes geriatrisches
Basisassessment (GBA) (1-771)
Multidimensionales
palliativmedizinisches Screening und
Minimalassessment (1-773)
Standardisiertes palliativmedizinisches
Basisassessment (PBA) (1-774)
Frührehabilitationsassessment von
Patienten mit Kopf-Hals-Tumoren (1-775)
Physiologische Funktionstests (1-79)
Kardiorespiratorische Polysomnographie
(1-790)
Kardiorespiratorische Polygraphie (1-
791)
Multipler Schlaflatenztest
(MSLT)/multipler Wachbleibetest (MWT)
(1-795)
Komplexe endokrinologische
Funktionsuntersuchung (1-797)
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Instrumentelle 3D-Ganganalyse (1-798)
Instrumentelle 3D-Funktionsanalyse der
Wirbelsäule (1-799)
Ballon-Okklusionstest einerr Arterie (1-
79a)
Diagnostische Punktion und Aspiration
(1-84)
Diagnostische Punktion an Auge und
Augenanhangsgebilden (1-840)
Diagnostische Punktion und Aspiration
eines intrakraniellen Hohlraumes (1-841)
Diagnostische Punktion des Perikardes
[Perikardiozentese] (1-842)
Diagnostische Aspiration aus dem
Bronchus (1-843)
Diagnostische perkutane Punktion der
Pleurahöhle (1-844)
Diagnostische perkutane Punktion und
Aspiration der Leber (1-845)
Diagnostische perkutane Punktion von
Harnorganen (1-846)
Diagnostische perkutane Punktion und
Aspiration der männlichen
Geschlechtsorgane (1-847)
Andere diagnostische Punktion und
Aspiration (1-85)
Diagnostische perkutane Aspiration einer
Zyste, n.n.bez. (1-850)
Diagnostische (perkutane) Punktion des
Ovars (1-851)
Diagnostische Amniozentese
[Amnionpunktion] (1-852)
Diagnostische (perkutane) Punktion und
Aspiration der Bauchhöhle (1-853)
Diagnostische perkutane Punktion eines
Gelenkes oder Schleimbeutels (1-854)
Andere diagnostische Punktion und
Aspiration (1-859)
Psychosomatische,
psychotherapeutische, (neuro-
)psychologische, psychosoziale und
testpsychologische Untersuchung (1-90)
Psychosomatische und
psychotherapeutische Diagnostik (1-900)
(Neuro-)psychologische und
psychosoziale Diagnostik (1-901)
Testpsychologische Diagnostik (1-902)
Diagnostik bei chronischen
Schmerzzuständen (1-91)
Multidisziplinäre algesiologische
Diagnostik (1-910)
Erweiterte apparativ-überwachte
interventionelle Schmerzdiagnostik mit
standardisierter Erfolgskontrolle (1-911)
Neurophysiologische apparative
Testverfahren zur Schmerzdiagnostik (1-
912)
Medizinische Evaluation zur
Transplantation (1-92)
Medizinische Evaluation und
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Entscheidung über die Indikation zur
Transplantation (1-920)
Infektiologisches Monitoring (1-93)
Infektiologisches Monitoring (1-930)
Komplexe Diagnostik (1-94)
Komplexe Diagnostik bei
hämatologischen und onkologischen
Erkrankungen bei Kindern und
Jugendlichen (1-940)
Komplexe Diagnostik bei Leukämien (1-
941)
Komplexe neuropädiatrische Diagnostik
(1-942)
Komplexe Diagnostik bei Verdacht auf
Lungenerkrankungen bei Kindern und
Jugendlichen (1-943)
Basisdiagnostik bei unklarem
Symptomkomplex bei Neugeborenen
und Säuglingen (1-944)
Diagnostik bei Verdacht auf Gefährdung
von Kindeswohl und Kindergesundheit
(1-945)
Andere diagnostische Maßnahmen (1-
99)
Ex-vivo-Zellkultursystem zur
prätherapeutischen
Chemosensibilitätstestung (1-990)
Molekulares Monitoring der
Resttumorlast [MRD] (1-991)
Durchführung von
Genmutationsanalysen und
Genexpressionsanalysen bei soliden
bösartigen Neubildungen (1-992)
Automatisierte Anreicherung mit
immunzytochemischer Detektion
zirkulierender Tumorzellen [CTC] (1-993)
In-vitro-Bestimmung des
Genexpressionsprofils mittels RNA aus
Monozyten des peripheren Blutes bei
Zustand nach Transplantation (1-994)
Zusatzinformationen zu diagnostischen
Maßnahmen (1-999)
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Emergency protocol- Module Neurology
Emergency protocol by the DIVI (Deutsche Interdisziplinäre
Vereinigung für Intensiv- und Notfallmedizin).  ODM derived
from “Notaufnahmeprotokoll Modul Neurologie”.
All rights reserved. Please visit https://medical-data-
models.org/forms/12045
Emergency protocol- Module
Neurology
PATIENTENINFORMATIONEN
Name des Patienten:*
Patienten-ID:*
Geburtsdatum:*
Geschlecht:
männlich  (1)
weiblich (2)
ARBEITSDIAGNOSE/
SCHLÜSSELSYMPTOME
Arbeitsdiagnose / Schlüsselsymptome:
Zeit:
Versorgungsituation:
unabhängig zu Hause (1)
Pflege zu Hause (2)
Institution (3)
Zeit von Symptombeginn bis Eintreffen ZNA:
0-3 (1)
3-4,5 (2)
4,5-6 (3)
6-12 (4)
12-24 (5)
24-72 (6)
>72 (7)
Dauer der Schlüsselsymptome:
<1h (1)
1-24h (2)
>24h (3)
Gegenwärtig anhaltend (4)
Bewusstsein:
wach (1)
somnolent  (2)
soporös (3)
komatös (4)
Amnesie:
anterograd (1)
retrograd (2)
1 / 12
Altgedächtnis (3)
Neugedächtnis (4)
ORIENTIERT
Ort:
Ja
Nein
Zeit:
Ja
Nein
Person:
Ja
Nein
Situation:
Ja
Nein
NOSOLOGISCHE EINORDNUNG
Meningitis / Enzephalitis:
bakteriell  (1)
viral (2)
autoimmun (3)
Schlaganfall / Ischämie:
Ischämie (1)
ICB (2)
SDH (3)
EDH (4)
SAB (5)
Kopfschmerz:
Rückenschmerz:
VAS Schmerz-Skala:
Schwindel:
Ja
Nein
Neuromuskuläre Erkrankungen:
Myasthenia gravis  (1)
Guillain Barré (2)
Besinger Score:
Epileptische Anfälle:
Fokal (1)
Komplex partiell  (2)
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Generalisiert (3)
Status (4)
Medikament gegen epileptische Anfälle:
Medikamentös durchbrochen:
Ja
Nein
Metabolisch / Toxisch / Enzephalopathisch:
Renal (1)
Hepatisch (2)
Septisch (3)
Ethyltoxisch (4)
Andere (5)
Andere:
KOMORBIDITÄT
Infektion:
Ja
Nein
CRP:
mg/l
Leukozyten:
10^9/l
Diabetes mellitus:
Ja
Nein
Arterielle Hypertonie:
Ja
Nein
Koronare Herzkrankheit:
Ja
Nein
Demenz:
Ja
Nein
Früherer Apoplex:
Ja
Nein
Tumorleiden:
Ja
Nein
SPRACHE/ NEUROPSYCHOLOGIE
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Sprache/Neuropsychologie:
klar und flüssig (1)
nicht-flüssige Aphasie (2)
globale Aphasie (3)
verwaschen (4)
flüssige Aphasie (5)
Neglect  (6)
Wortfindungsstörung (7)
Apraxie (8)
KOPF
Kopf frei beweglich:
Ja
Nein
Meningismus:
ja (1)
nein (2)
endgradig (3)
Nackenrigor:
positiv (1)
negativ (2)
Druckdolenz:
positiv (1)
negativ (2)
Nervenaustrittspunkt (N. supraorbitalis):
positiv (1)
negativ (2)
Nervenaustrittspunkt (N. infraorbitalis):
positiv (1)
negativ (2)
Nervenaustrittspunkt (N. mentalis):
positiv (1)
negativ (2)
HIRNNERVEN
Geruchsempfinden anamnestisch intakt:
Ja
Nein
Visus:
unkorrigiert (1)
korrigiert (2)
Visusverlust:
Ja
Nein
Gesichtsfeld fingerperimetrisch intakt (rechts):
Ja
Nein
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Gesichtsfeld fingerperimetrisch intakt (links):
Ja
Nein
Oculomotorik intakt (rechts):
Ja
Nein
Oculomotorik intakt (links):
Ja
Nein
Doppelbilder:
Ja
Nein
Ptosis:
Ja
Nein
Horner:
Ja
Nein
Konvergenz:
Ja
Nein
Nystagmus:
rechts (1)
links (2)
Pupillenweite (rechts):
eng (1)
mittel (2)
weit (3)
Linke Pupillenweite:
weit (1)
mittel (2)
eng (3)
Gesichtssensibilität intakt (rechts):
Ja
Nein
Gesichtssensibilität intakt (links):
Ja
Nein
Oculocephaler Reflex (Bei Bewußtlosigkeit):
vorhanden (rechts) (1)
vorhanden (links) (2)
vorhanden (3)
pathologisch (4)
Cornealreflex (rechts):
normal (1)
abgeschwächt (2)
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Cornealreflex (links):
normal (1)
abgeschwächt (2)
Mimische Muskulatur (rechts):
opB (1)
vermindert (2)
Mimische Muskulatur (links):
opB (1)
vermindert (2)
Augenschluss gestört (rechts):
Ja
Nein
Augenschluss gestört (links):
Ja
Nein
Gehör subjektiv (rechts):
Hypakusis (1)
opB (2)
Gehör subjektiv (links):
Hypakusis (1)
opB (2)
Gaumensegel symmetrisch:
Ja
Nein
Schluckakt subjektiv unbehindert:
Ja
Nein
Zunge frei beweglich:
Ja
Nein
REFLEXSTATUS
Bicepsreflex (rechts):
normal (1)
fehlt (2)
vermindert (3)
gesteigert (4)
Bicepsreflex (links):
normal (1)
fehlt (2)
vermindert (3)
gesteigert (4)
Tricepsreflex (rechts):
normal (1)
fehlt (2)
vermindert (3)
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gesteigert (4)
Tricepsreflex (links):
normal (1)
fehlt (2)
vermindert (3)
gesteigert (4)
Quadricepsreflex (rechts):
normal (1)
fehlt (2)
vermindert (3)
gesteigert (4)
Quadricepsreflex (links):
normal (1)
fehlt (2)
vermindert (3)
gesteigert (4)
Adduktorenreflex (rechts):
normal (1)
fehlt (2)
vermindert (3)
gesteigert (4)
Adduktorenreflex (links):
normal (1)
fehlt (2)
vermindert (3)
gesteigert (4)
Achillessehnenreflex (rechts):
normal (1)
fehlt (2)
vermindert (3)
gesteigert (4)
Achillessehnenreflex (links):
normal (1)
fehlt (2)
vermindert (3)
gesteigert (4)
Bauchhautreflex (rechts):
normal (1)
fehlt (2)
vermindert (3)
gesteigert (4)
Bauchhautreflex (links):
normal (1)
fehlt (2)
vermindert (3)
gesteigert (4)
Trömnerzeichen (rechts):
normal (1)
fehlt (2)
vermindert (3)
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gesteigert (4)
Trömnerzeichen (links)
normal (1)
fehlt (2)
vermindert (3)
gesteigert (4)
Babinski (rechts):
positiv (1)
negativ (2)
Babinski (links):
positiv (1)
negativ (2)
MOTORIK
Hemiparese:
Ja
Nein
Armbetont:
rechts (1)
links (2)
Beinbetont:
rechts (1)
links (2)
Pronation (rechts):
Ja
Nein
Pronation (links):
Ja
Nein
Paraparese:
Ja
Nein
Höhe:
Isolierte Muskelatrophie:
Ja
Nein
Wenn ja, wo?
Lasègue (rechts):
°
Lasègue (links):
°
Faszikulationen:
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Ja
Nein
Wenn ja, wo?
Tonus:
unauffällig (1)
erhöht (2)
Wo ist Tonus erhöht?
Rigor:
Ja
Nein
Wenn ja, wo?
KOORDINATION
Gangbild:
Trendelenburg:
rechts (1)
links (2)
Sensibel ataktisch:
Ja
Nein
Spastisch:
Ja
Nein
Romberg:
sicher (1)
Fallneigung rechts (2)
Fallneigung links (3)
Unterberger:
unauffällig (1)
Abweichung (2)
Wenn ,,Abweichung", bitte Details angeben:
Finger-Nase:
sicher (1)
dysmetrisch (2)
Tremor:
Unwillkürliche Bewegung:
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SENSIBILITÄT
Berührungsempfinden:
Schmerzempfinden:
Hypästhesie:
Hyperpathie:
Allodynie:
Reithosenareal:
Neglect:
Ja
Nein
Vibrationsempfinden (rechts):
Vibrationsempfinden (links):
BILDGEBUNG
Bildgebung:
CT (1)
CTA (2)
MRT (3)
DSA (4)
Zeit vom Eintreffen in ZNA bis Bildgebung:
<1h (1)
1-3h (2)
>3h (3)
Weitere Diagnostik:
Labor (1)
Ultraschall/Doppler (2)
EEG/el. Physiologie (3)
LP (4)
Befund Bildgebung / Diagnostik:
ICB / SAB / SDH / EDH
Ventrikeleinbruch:
Ja
Nein
Seitenventrikel:
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rechts (1)
links (2)
3. Ventrikel:
Ja
Nein
4. Ventrikel:
Ja
Nein
GRAEB Score:
ICB Volumen:
0-15 ml (1)
15-30 ml  (2)
>30 ml (3)
Aneurysma/AVM:
Ja
Nein
WFNS- Skala:
Hunt & Hess:
Neurochirurgische / Neuroradiologische
Intervention:
CEREBRALE ISCHÄMIE
Cerebrale Ischämie:
Ja
Nein
NIHSS:
Gewicht:
Kg
Blutzucker (BZ):
mg/dl
INR:
Thrombos:
10^9/l
CT- FRÜHZEICHEN
11 / 12
Emergency protocol- Module Neurology
Hypodensitäten:
Ja
Nein
MCA Territorium:
<1/3 (1)
>1/3 (2)
HCMAS:
rechts (1)
links (2)
ASPECTS Score:
0-7 (1)
8-10 (2)
THROMBOLYSE
Thrombolyse:
IV-Lyse (1)
IA-Lyse (2)
Door-to-Needle-Time:
0-30 min (1)
30-60 min (2)
60-120 min (3)
>120 min (4)
Substanz:
Dosis
Device:
Diagnose / Bemerkungen:
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Eligibility Severe Asthma NCT01961258
"SEVERE ASTHMA" in the COMMUNITY; ODM derived
from: https://clinicaltrials.gov/show/NCT01961258
All rights reserved. Please visit https://medical-data-
models.org/forms/12046
Eligibility Severe Asthma
NCT01961258
Inclusion Criteria
age 20-70 years old*
Yes
No
a computerized diagnosis-title of "bronchial
asthma", at any stage of severity.*
Yes
No
a subgroup of the above asthmatic patients will
be considered as having "severe asthma"
according to the ats workshop consensus
definition of severe/refractory asthma, based on
the level of prescribed medication criteria 2000:*
Yes
No
an obligatory criteria of at least 12 month inhaler-
therapy prescription of a combination of high
dose corticosteroid +laba (at least 12 inhalers of
symbicort 160/4.5 mcg or at least 10 inhalers of
seretide 500 mcg, a year)*
Yes
No
plus at least one of the following criteria:*
Yes
No
prescription of saba, either ventolin or bricalin
inhalers at least once a quarter of a year or at
least 4 inhalers in 12 months or at least one
prescription a month of inhalation-solution of
ventolin or bricalin a month.*
Yes
No
prescription of an oral or im corticosteroid, at
least twice in the last 12 months.*
Yes
No
the fulfilment of the above mentioned criteria
indicates that these asthmatic patients are not
conrolled, according to the gina definition of
controlled asthma.*
Yes
No
asthmatics that potentially have "difficult to treat
severe asthma" due to co-morbidities or potential
triggering factors will be sub-grouped according
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to these criteria (criteria for potential exclusion of
having "treatment resistant severe asthma"):*
Yes
No
having computerized title-diagnosis of copd,
congestive heart failure, smoking, bronchiectasis,
interstitial lung disease.*
Yes
No
prescription of an oral or topical (ocular) beta-
blockers.*
Yes
No
Exclusion Criteria
age <20 or >70 years old.*
Yes
No
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Eligibility Alzheimer's Disease
NCT02080364
Evaluation of the Efficacy and Safety of Azeliragon
(TTP488) in Patients With Mild Alzheimer's Disease; ODM
derived from: https://clinicaltrials.gov/show/NCT02080364
All rights reserved. Please visit https://medical-data-
models.org/forms/12047
Eligibility Alzheimer's Disease
NCT02080364
Inclusion Criteria
diagnosis of probable alzheimer disease (ad) with
documented evidence of progression of disease*
Yes
No
mini mental state examination (mmse) score of
21-26, inclusive*
Yes
No
clinical dementia rating global score of 0.5 or 1*
Yes
No
rosen-modified hachinski ischemia score less
than or equal to 4*
Yes
No
brain magnetic resonance imaging (mri)
consistent with the diagnosis of probable ad*
Yes
No
concurrent use of cholinesterase inhibitor or
memantine with stable dose for at least 3 months
prior to randomization*
Yes
No
caregiver willing to participate and be able to
attend clinic visits with patient*
Yes
No
ability to ingest oral medications*
Yes
No
Exclusion Criteria
significant neurological or psychiatric disease
other than alzheimer's disease*
Yes
No
participants with evidence or history of severe
drug allergies (resulting in dyspnea or severe
rash).*
Yes
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No
any contraindications to mri  (e.g., clinically
significant claustrophobia, non-removable
ferromagnetic implants). patients with
contraindications to mri may undergo computed
tomography (ct) on approval by sponsor.*
Yes
No
any contraindications to the fdg-pet study (e.g.
allergy to any component of the fdg dose) in the
cohort undergoing a pet scan.*
Yes
No
previous exposure to investigational or non-
investigational therapies for alzheimer's disease
within 6 months of screening*
Yes
No
history of cancer within the last 5 years except
adequately treated cervical carcinoma in-situ,
cutaneous basal cell or squamous cell cancer, or
non-progressive prostate cancer not requiring
treatment*
Yes
No
women of childbearing potential*
Yes
No
uncontrolled blood pressure and/or blood
pressure above 160/100*
Yes
No
prescription medical food intended for dietary
management of the metabolic processes
associated with alzheimer's disease.*
Yes
No
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OPS Chapter 3 Diagnostic Imaging
derived from:
OPS - German Procedure Classification
https://www.dimdi.de/static/en/klassi/ops/index.htm
DIMDI publishes the OPS classification on behalf of the
Federal Ministry of Health; it is in the public domain. Its use
in inpatient care is laid down in  301 Volume V of the
German Social Security Code (SGB V) and for surgical
procedures in the outpatient sector in  295 SGB V.
All rights reserved. Please visit https://medical-data-
models.org/forms/12050
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BILDGEBENDE DIAGNOSTIK
BILDGEBENDE DIAGNOSTIK
Komplexe differenzialdiagnostische
Sonographie mit digitaler Bild- und
Videodokumentation (3-03)
Komplexe differenzialdiagnostische
Sonographie mit Kontrastmittel (3-030)
Komplexe differenzialdiagnostische
transthorakale Stress-Echokardiographie
(3-031)
Komplexe sonographische Erkrankungs-
und Fehlbildungsdiagnostik bei Feten (3-
032)
Komplexe differenzialdiagnostische
Sonographie bei Neugeborenen und
Kleinkindern (3-033)
Komplexe differenzialdiagnostische
Sonographie mittels Tissue Doppler
Imaging [TDI] und Verformungsanalysen
von Gewebe [Speckle Tracking] (3-034)
Komplexe differenzialdiagnostische
Sonographie des Gefäßsystems mit
quantitativer Auswertung (3-035)
Komplexe differenzialdiagnostische
Sonographie bei Weichteiltumoren mit
quantitativer Vermessung (3-036)
Endosonographie (3-05)
Endosonographie von Mundhöhle und
Hypopharynx (3-050)
Endosonographie des Ösophagus (3-
051)
Transösophageale Echokardiographie
[TEE] (3-052)
Endosonographie des Magens (3-053)
Endosonographie des Duodenums (3-
054)
Endosonographie der Gallenwege (3-
055)
Endosonographie des Pankreas (3-056)
Endosonographie des Kolons (3-057)
Endosonographie des Rektums (3-058)
Endosonographie der Bauchhöhle
[Laparoskopische Sonographie] (3-059)
Endosonographie des
Retroperitonealraumes (3-05a)
Endosonographie der Harnblase und der
Urethra (3-05b)
Endosonographie der männlichen
Geschlechtsorgane (3-05c)
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Endosonographie der weiblichen
Geschlechtsorgane (3-05d)
Endosonographie der Blutgefäße (3-05e)
Transbronchiale Endosonographie (3-
05f)
Endosonographie des Herzens (3-05g)
Andere Endosonographie (3-05x)
Projektionsradiographie mit
Spezialverfahren (3-10)
Mammographie (3-100)
Projektionsradiographie mit
Kontrastmittelverfahren (3-13)
Myelographie (3-130)
Diskographie (3-131)
Pharyngographie (3-134)
Bronchographie (3-135)
Galaktographie (3-136)
Ösophagographie (3-137)
Gastrographie (3-138)
Isolierte Dünndarmdarstellung
[Enteroklysma] (3-139)
Kolonkontrastuntersuchung (3-13a)
Magen-Darm-Passage (fraktioniert) (3-
13b)
Cholangiographie (3-13c)
Urographie (3-13d)
Miktionszystourethrographie (3-13e)
Zystographie (3-13f)
Urethrographie (3-13g)
Hysterosalpingographie (3-13h)
Vasovesikulographie (3-13j)
Arthrographie (3-13k)
Fistulographie (3-13m)
Sinugraphie (3-13n)
Projektionsradiographie der Leber mit
Kontrastmittel (3-13p)
Andere Projektionsradiographie mit
Kontrastmittelverfahren (3-13x)
Computertomographie (CT), nativ (3-20)
Native Computertomographie des
Schädels (3-200)
Native Computertomographie des
Halses (3-201)
Native Computertomographie des
Thorax (3-202)
Native Computertomographie von
Wirbelsäule und Rückenmark (3-203)
Native Computertomographie des
Herzens (3-204)
Native Computertomographie des
Muskel-Skelett-Systems (3-205)
Native Computertomographie des
Beckens (3-206)
Native Computertomographie des
Abdomens (3-207)
Native Computertomographie der
peripheren Gefäße (3-208)
Andere native Computertomographie (3-
20x)
Computertomographie (CT) mit
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Kontrastmittel (3-22)
Computertomographie des Schädels mit
Kontrastmittel (3-220)
Computertomographie des Halses mit
Kontrastmittel (3-221)
Computertomographie des Thorax mit
Kontrastmittel (3-222)
Computertomographie von Wirbelsäule
und Rückenmark mit Kontrastmittel (3-
223)
Computertomographie des Herzens mit
Kontrastmittel (3-224)
Computertomographie des Abdomens
mit Kontrastmittel (3-225)
Computertomographie des Beckens mit
Kontrastmittel (3-226)
Computertomographie des Muskel-
Skelett-Systems mit Kontrastmittel (3-
227)
Computertomographie der peripheren
Gefäße mit Kontrastmittel (3-228)
Andere Computertomographie mit
Kontrastmittel (3-22x)
Computertomographie (CT),
Spezialverfahren (3-24)
CT-Ventrikulographie (3-240)
CT-Myelographie (3-241)
Andere Computertomographie-
Spezialverfahren (3-24x)
Elektronenstrahltomographie (EBT) (3-
26)
Elektronenstrahltomographie des
Gehirns (3-260)
Elektronenstrahltomographie des
Herzens (3-261)
Elektronenstrahltomographie der
peripheren Gefäße (3-262)
Andere Elektronenstrahltomographie (3-
26x)
Optische laserbasierte Verfahren (3-30)
Optische Kohärenztomographie [OCT]
(3-300)
Konfokale Mikroskopie (3-301)
3D-Oberflächenvermessung durch
Laserscanning (3-302)
Andere laserbasierte Verfahren mit
digitaler Bildverarbeitung (3-30x)
Andere optische Verfahren (3-31)
Optische foto- und videogestützte
Verfahren zur metrischen Form- und
Oberflächendarstellung (3-310)
Arteriographie (3-60)
Arteriographie der intrakraniellen Gefäße
(3-600)
Arteriographie der Gefäße des Halses
(3-601)
Arteriographie des Aortenbogens (3-602)
Arteriographie der thorakalen Gefäße (3-
603)
Arteriographie der Gefäße des
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Abdomens (3-604)
Arteriographie der Gefäße des Beckens
(3-605)
Arteriographie der Gefäße der oberen
Extremitäten (3-606)
Arteriographie der Gefäße der unteren
Extremitäten (3-607)
Superselektive Arteriographie (3-608)
Arteriographie der Rückenmarkgefäße
(Spinale Arteriographie) (3-60a)
Andere Arteriographie (3-60x)
Phlebographie (3-61)
Phlebographie der intrakraniellen Gefäße
(3-610)
Phlebographie der Gefäße von Hals und
Thorax (3-611)
Phlebographie der Gefäße von Abdomen
und Becken (3-612)
Phlebographie der Gefäße einer
Extremität (3-613)
Phlebographie der Gefäße einer
Extremität mit Darstellung des
Abflussbereiches (3-614)
Kavernosographie (3-615)
Andere Phlebographie (3-61x)
Lymphographie (3-62)
Lymphographie einer Extremität (3-620)
Lymphographie von zwei Extremitäten
(3-621)
Andere Lymphographie (3-62x)
Andere Darstellung des Gefäßsystems
(3-69)
Angiographie am Auge (3-690)
Szintigraphie (3-70)
Szintigraphie von Gehirn und
Liquorräumen (3-700)
Szintigraphie der Schilddrüse (3-701)
Szintigraphie anderer endokriner Organe
(3-702)
Szintigraphie der Lunge (3-703)
Radionuklidventrikulographie des
Herzens (3-704)
Szintigraphie des Muskel-Skelett-
Systems (3-705)
Szintigraphie der Nieren (3-706)
Szintigraphie des Gastrointestinaltraktes
(3-707)
Szintigraphie der Blutgefäße (3-708)
Szintigraphie des Lymphsystems (3-709)
Szintigraphie des hämatopoetischen
Systems (3-70a)
Resorptions- und Exkretionstests mit
Radionukliden (3-70b)
Ganzkörper-Szintigraphie zur
Lokalisationsdiagnostik (3-70c)
Teilkörper-Szintigraphie zur
Lokalisationsdiagnostik (3-70d)
Andere Szintigraphien (3-70x)
Single-Photon-
Emissionscomputertomographie
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(SPECT) (3-72)
Single-Photon-
Emissionscomputertomographie des
Gehirns (3-720)
Single-Photon-
Emissionscomputertomographie des
Herzens (3-721)
Single-Photon-
Emissionscomputertomographie der
Lunge (3-722)
Teilkörper-Single-Photon-
Emissionscomputertomographie
ergänzend zur planaren Szintigraphie (3-
724)
Andere Single-Photon-
Emissionscomputertomographie (3-72x)
Single-Photon-
Emissionscomputertomographie mit
Computertomographie (SPECT/CT) (3-
73)
Single-Photon-
Emissionscomputertomographie mit
Computertomographie (SPECT/CT) des
Gehirns (3-730)
Single-Photon-
Emissionscomputertomographie mit
Computertomographie (SPECT/CT) des
Herzens (3-731)
Single-Photon-
Emissionscomputertomographie mit
Computertomographie (SPECT/CT) der
Lunge (3-732)
Single-Photon-
Emissionscomputertomographie mit
Computertomographie (SPECT/CT) des
Skelettsystems (3-733)
Andere Single-Photon-
Emissionscomputertomographie mit
Computertomographie (SPECT/CT) (3-
73x)
Positronenemissionstomographie (PET)
mit Vollring-Scanner (3-74)
Positronenemissionstomographie des
Gehirns (3-740)
Positronenemissionstomographie des
Herzens (3-741)
Positronenemissionstomographie des
gesamten Körperstammes (3-742)
Andere Positronenemissionstomographie
(3-74x)
Positronenemissionstomographie mit
Computertomographie (PET/CT) (3-75)
Positronenemissionstomographie mit
Computertomographie (PET/CT) des
Gehirns (3-750)
Positronenemissionstomographie mit
Computertomographie (PET/CT) des
Herzens (3-751)
Positronenemissionstomographie mit
Computertomographie (PET/CT) des
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gesamten Körperstammes (3-752)
Positronenemissionstomographie mit
Computertomographie (PET/CT) des
ganzen Körpers (3-753)
Positronenemissionstomographie mit
Computertomographie (PET/CT) des
gesamten Körperstammes und des
Kopfes (3-754)
Andere Positronenemissionstomographie
mit Computertomographie (PET/CT) (3-
75x)
Sondenmessungen und
Inkorporationsmessungen (3-76)
Sondenmessung im Rahmen der SLNE
(Sentinel Lymphnode Extirpation) (3-
760)
Sondenmessung bei der
Parathyreoidektomie (3-761)
Sondenmessung zur Tumorlokalisation
(3-762)
Teilkörper-Inkorporationsmessungen (3-
763)
Ganzkörpermessungen mit dem
Ganzkörper-Inkorporationsmessplatz (3-
764)
Sondenmessung zur intraoperativen
Leckageüberwachung bei isolierter bzw.
hyperthermer Extremitätenperfusion (3-
765)
Magnetresonanztomographie (MRT),
nativ (3-80)
Native Magnetresonanztomographie des
Schädels (3-800)
Native Magnetresonanztomographie des
Halses (3-801)
Native Magnetresonanztomographie von
Wirbelsäule und Rückenmark (3-802)
Native Magnetresonanztomographie des
Herzens (3-803)
Native Magnetresonanztomographie des
Abdomens (3-804)
Native Magnetresonanztomographie des
Beckens (3-805)
Native Magnetresonanztomographie des
Muskel-Skelett-Systems (3-806)
Native Magnetresonanztomographie der
Mamma (3-807)
Native Magnetresonanztomographie der
peripheren Gefäße (3-808)
Native Magnetresonanztomographie des
Thorax (3-809)
Native Magnetresonanztomographie des
Feten (3-80b)
Andere native
Magnetresonanztomographie (3-80x)
Magnetresonanztomographie (MRT) mit
Kontrastmittel (3-82)
Magnetresonanztomographie des
Schädels mit Kontrastmittel (3-820)
Magnetresonanztomographie des Halses
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mit Kontrastmittel (3-821)
Magnetresonanztomographie des
Thorax mit Kontrastmittel (3-822)
Magnetresonanztomographie von
Wirbelsäule und Rückenmark mit
Kontrastmittel (3-823)
Magnetresonanztomographie des
Herzens mit Kontrastmittel (3-824)
Magnetresonanztomographie des
Abdomens mit Kontrastmittel (3-825)
Magnetresonanztomographie des
Muskel-Skelett-Systems mit
Kontrastmittel (3-826)
Magnetresonanztomographie der
Mamma mit Kontrastmittel (3-827)
Magnetresonanztomographie der
peripheren Gefäße mit Kontrastmittel (3-
828)
Magnetresonanztomographie des
Beckens mit Kontrastmittel (3-82a)
Magnetresonanztomographie des Feten
mit Kontrastmittel (3-82b)
Andere Magnetresonanztomographie mit
Kontrastmittel (3-82x)
Magnetresonanztomographie (MRT),
Spezialverfahren (3-84)
Magnetresonanz-Ventrikulographie (3-
840)
Magnetresonanz-Myelographie (3-841)
Magnetresonanz-Sialographie (3-842)
Magnetresonanz-
Cholangiopankreatikographie [MRCP] (3-
843)
Magnetresonanz-Arthrographie (3-844)
Magnetresonanz-Elastographie (3-845)
Magnetresonanztomographie der Leber
zur Bestimmung des Eisengehaltes (3-
846)
Andere Magnetresonanz-
Spezialverfahren (3-84x)
Andere bildgebende Verfahren (3-90)
Knochendichtemessung (alle Verfahren)
(3-900)
Elektroimpedanzspektroskopie der Haut
(3-901)
Radiofrequenzspektroskopie von
Brustgewebe (3-902)
Zusatzinformationen zu bildgebenden
Verfahren (3-99)
Computergestützte Bilddatenanalyse mit
3D-Auswertung (3-990)
Computergestützte Bilddatenanalyse mit
4D-Auswertung (3-991)
Intraoperative Anwendung der Verfahren
(3-992)
Quantitative Bestimmung von
Parametern (3-993)
Virtuelle 3D-Rekonstruktionstechnik (3-
994)
Dosimetrie zur Therapieplanung (3-995)
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Anwendung eines 3D-Bildwandlers (3-
996)
Computertechnische Bildfusion
verschiedener bildgebender Modalitäten
(3-997)
Serieller Vergleich von mehr als zwei
PET- oder PET/CT-Untersuchungen (3-
998)
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ATC A - Alimentary Tract and Metabolism
modified from epSOS value set
1.3.6.1.4.1.12559.11.10.1.3.1.42.24
http://www.epsos.eu
http://www.whocc.no/atc_ddd_index/
WHO Collaborating Centre for Drug Statistics Methodology,
ATC classification index with DDDs 2015. Oslo, Norway
2014
Copyright ATC index: WHO Collaborating Centre for Drug
Statistics Methodology, Oslo, Norway
Copying and distribution for commercial purposes is not
allowed. 
German ATC Codes: Datenquelle des amtlichen ATC-Index
mit DDD-Angaben: GKV-Arzneimittelindex im
Wissenschaftlichen Institut der AOK (WIdO), AOK
Bundesverband GbR Stand September 2015. Nur nicht-
kommerzielle Nutzung zulässig
All rights reserved. Please visit https://medical-data-
models.org/forms/12052
ATC A - Alimentary Tract and
Metabolism
ALIMENTÄRES SYSTEM UND
STOFFWECHSEL
ALIMENTÄRES SYSTEM UND
STOFFWECHSEL
ALIMENTÄRES SYSTEM UND
STOFFWECHSEL (A)
STOMATOLOGIKA (A01)
STOMATOLOGIKA (A01A)
Mittel zur Kariesprophylaxe (A01AA)
Natriumfluorid (A01AA01)
Natriummonofluorphosphat (A01AA02)
Olaflur (A01AA03)
Zinn(II)-fluorid (A01AA04)
Kombinationen (A01AA30)
Natriumfluorid, Kombinationen
(A01AA51)
Antiinfektiva und Antiseptika zur oralen
Lokalbehandlung (A01AB)
Wasserstoffperoxid (A01AB02)
Chlorhexidin (A01AB03)
Amphotericin B (A01AB04)
Polynoxylin (A01AB05)
Domiphen (A01AB06)
Oxychinolin (A01AB07)
Neomycin (A01AB08)
Miconazol (A01AB09)
Natamycin (A01AB10)
Verschiedene (A01AB11)
Hexetidin (A01AB12)
Tetracyclin (A01AB13)
Benzoxoniumchlorid (A01AB14)
Tibezoniumiodid (A01AB15)
Mepartricin (A01AB16)
Metronidazol (A01AB17)
Clotrimazol (A01AB18)
Natriumperborat (A01AB19)
Chlortetracyclin (A01AB21)
Doxycyclin (A01AB22)
Minocyclin (A01AB23)
Corticosteroide zur oralen
Lokalbehandlung (A01AC)
Triamcinolon (A01AC01)
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Dexamethason (A01AC02)
Hydrocortison (A01AC03)
Prednisolon, Kombinationen (A01AC54)
Andere Mittel zur oralen
Lokalbehandlung (A01AD)
Epinephrin (A01AD01)
Benzydamin (A01AD02)
Acetylsalicylsäure (A01AD05)
Adrenalon (A01AD06)
Amlexanox (A01AD07)
Becaplermin (A01AD08)
Verschiedene (A01AD11)
MITTEL BEI SÄURE BEDINGTEN
ERKRANKUNGEN (A02)
ANTACIDA (A02A)
Magnesium-haltige Verbindungen
(A02AA)
Magnesiumcarbonat (A02AA01)
Magnesiumoxid (A02AA02)
Magnesiumperoxid (A02AA03)
Magnesiumhydroxid (A02AA04)
Magnesiumsilikat (A02AA05)
Kombinationen (A02AA10)
Aluminium-haltige Verbindungen
(A02AB)
Aluminiumhydroxid (A02AB01)
Algeldrat (A02AB02)
Aluminiumphosphat (A02AB03)
Dihydroxyaluminiumnatriumcarbonat
(Carbaldrat) (A02AB04)
Aluminiumacetoacetat (A02AB05)
Aloglutamol (A02AB06)
Aluminiumglycinat (A02AB07)
Kombinationen (A02AB10)
Calcium-haltige Verbindungen (A02AC)
Calciumcarbonat (A02AC01)
Calciumsilikat (A02AC02)
Kombinationen (A02AC10)
Kombinationen und Komplexe von
Aluminium-, Calcium- und Magnesium-
haltigen Verbindungen (A02AD)
Einfache Salzkombinationen (A02AD01)
Magaldrat (A02AD02)
Almagat (A02AD03)
Hydrotalcit (A02AD04)
Almasilat (A02AD05)
Antacida mit Karminativa (A02AF)
Magaldrat und Karminativa (A02AF01)
Einfache Salzkombinationen und
Karminativa (A02AF02)
Antacida mit Spasmolytika (A02AG)
Antacida mit Natriumbicarbonat (A02AH)
Antacida, andere Kombinationen
(A02AX)
MITTEL BEI PEPTISCHEM ULKUS
UND GASTROESOPHAGEALER
REFLUXKRANKHEIT (A02B)
Histamin-H2-Rezeptorantagonisten
(A02BA)
Cimetidin (A02BA01)
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Ranitidin (A02BA02)
Famotidin (A02BA03)
Nizatidin (A02BA04)
Niperotidin (A02BA05)
Roxatidin (A02BA06)
Ranitidinbismutcitrat (A02BA07)
Lafutidin (A02BA08)
Cimetidin, Kombinationen (A02BA51)
Famotidin, Kombinationen (A02BA53)
Prostaglandine (A02BB)
Misoprostol (A02BB01)
Enprostil (A02BB02)
Protonenpumpenhemmer (A02BC)
Omeprazol (A02BC01)
Pantoprazol (A02BC02)
Lansoprazol (A02BC03)
Rabeprazol (A02BC04)
Esomeprazol (A02BC05)
Kombinationen zur Eradikation von
Helicobacter pylori (A02BD)
Omeprazol, Amoxicillin und Metronidazol
(A02BD01)
Lansoprazol, Tetracyclin und
Metronidazol (A02BD02)
Lansoprazol, Amoxicillin und
Metronidazol (A02BD03)
Pantoprazol, Amoxicillin und
Clarithromycin (A02BD04)
Omeprazol, Amoxicillin und
Clarithromycin (A02BD05)
Esomeprazol, Amoxicillin und
Clarithromycin (A02BD06)
Lansoprazol, Amoxicillin und
Clarithromycin (A02BD07)
Andere Mittel bei peptischem Ulkus und
gastrooesophagealer Refluxkrankheit
(A02BX)
Carbenoxolon (A02BX01)
Sucralfat (A02BX02)
Pirenzepin (A02BX03)
Methiosulfoniumchlorid (A02BX04)
Bismutsubcitrat (A02BX05)
Proglumid (A02BX06)
Gefarnat (A02BX07)
Sulglicotid (A02BX08)
Acetoxolon (A02BX09)
Zolimidin (A02BX10)
Troxipid (A02BX11)
Bismutsubnitrat (A02BX12)
Alginsäure (A02BX13)
Carbenoxolon, Kombinationen exkl.
Psycholeptika (A02BX51)
Carbenoxolon, Kombinationen mit
Psycholeptika (A02BX71)
Gefarnat, Kombinationen mit
Psycholeptika (A02BX77)
ANDERE MITTEL BEI SÄURE
BEDINGTEN ERKRANKUNGEN (A02X)
MITTEL BEI FUNKTIONELLEN
GASTROINTESTINALEN STÖRUNGEN
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(A03)
MITTEL BEI FUNKTIONELLEN
GASTROINTESTINALEN STÖRUNGEN
(A03A)
Synthetische Anticholinergika, Ester mit
tertiären Aminogruppen (A03AA)
Oxyphencyclimin (A03AA01)
Camylofin (A03AA03)
Mebeverin (A03AA04)
Trimebutin (A03AA05)
Rociverin (A03AA06)
Dicycloverin (A03AA07)
Dihexyverin (A03AA08)
Difemerin (A03AA09)
Piperidolat (A03AA30)
Synthetische Anticholinergika, quartäre
Ammonium-Verbindungen (A03AB)
Benzilon (A03AB01)
Glycopyrronium (A03AB02)
Oxyphenonium (A03AB03)
Penthienat (A03AB04)
Propanthelin (A03AB05)
Otiloniumbromid (A03AB06)
Methanthelinium (A03AB07)
Tridihexethyl (A03AB08)
Isopropamid (A03AB09)
Hexocyclium (A03AB10)
Poldin (A03AB11)
Mepenzolat (A03AB12)
Bevonium (A03AB13)
Pipenzolat (A03AB14)
Diphemanil (A03AB15)
(2-
Benzhydryloxyethyl)diethylmethylammon
iumiodid (A03AB16)
Tiemoniumiodid (A03AB17)
Prifiniumbromid (A03AB18)
Timepidiumbromid (A03AB19)
Fenpiverinium (A03AB21)
Oxyphenonium, Kombinationen
(A03AB53)
Synthetische Spasmolytika, Amide mit
tertiären Aminen (A03AC)
Dimethylaminopropionylphenothiazin
(A03AC02)
Nicofetamid (A03AC04)
Tiropramid (A03AC05)
Papaverin und Derivate (A03AD)
Papaverin (A03AD01)
Drotaverin (A03AD02)
Moxaverin (A03AD30)
Serotonin-Rezeptor-Antagonisten
(A03AE)
Alosetron (A03AE01)
tegaserod (A03AE02)
Cilansetron (A03AE03)
prucalopride (A03AE04)
Andere Mittel bei funktionellen
gastrointestinalen Störungen (A03AX)
Fenpipran (A03AX01)
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Diisopromin (A03AX02)
Chlorbenzoxamin (A03AX03)
Pinaverium (A03AX04)
Fenoverin (A03AX05)
Idanpramin (A03AX06)
Proxazol (A03AX07)
Alverin (A03AX08)
Trepibuton (A03AX09)
Isomethepten (A03AX10)
Caroverin (A03AX11)
Phloroglucinol (A03AX12)
Silikone (A03AX13)
Trimethyldiphenylpropylamin (A03AX30)
Alverin, Kombinationen (A03AX58)
BELLADONNA UND DERIVATE, REIN
(A03B)
Belladonna-Alkaloide, tertiäre Amine
(A03BA)
Atropin (A03BA01)
Hyoscyamin (A03BA03)
Belladonna-Gesamtalkaloide (A03BA04)
Belladonna-Alkaloide, halbsynthetisch,
quartäre Ammonium-Verbindungen
(A03BB)
Butylscopolamin (A03BB01)
Methylatropin (A03BB02)
Methylscopolamin (A03BB03)
Fentonium (A03BB04)
Cimetropiumbromid (A03BB05)
SPASMOLYTIKA IN KOMBINATION MIT
PSYCHOLEPTIKA (A03C)
Synthetische Anticholinergika in
Kombination mit Psycholeptika (A03CA)
Isopropamid und Psycholeptika
(A03CA01)
Clidinium und Psycholeptika (A03CA02)
Oxyphencyclimin und Psycholeptika
(A03CA03)
Otiloniumbromid und Psycholeptika
(A03CA04)
Glycopyrronium und Psycholeptika
(A03CA05)
Bevonium und Psycholeptika (A03CA06)
Ambutonium und Psycholeptika
(A03CA07)
Diphemanil und Psycholeptika
(A03CA08)
Emepronium und Psycholeptika
(A03CA30)
Propanthelin und Psycholeptika
(A03CA34)
Belladonna und Derivate in Kombination
mit Psycholeptika (A03CB)
Methylscopolamin und Psycholeptika
(A03CB01)
Belladonna-Gesamtalkaloide und
Psycholeptika (A03CB02)
Atropin und Psycholeptika (A03CB03)
Methylhomatropin und Psycholeptika
(A03CB04)
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Hyoscyamin und Psycholeptika
(A03CB31)
Andere Spasmolytika in Kombination mit
Psycholeptika (A03CC)
SPASMOLYTIKA IN KOMBINATION MIT
ANALGETIKA (A03D)
Synthetische Anticholinergika in
Kombination mit Analgetika (A03DA)
Tropenzilon und Analgetika (A03DA01)
Pitofenon und Analgetika (A03DA02)
Bevonium und Analgetika (A03DA03)
Ciclonium und Analgetika (A03DA04)
Camylofin und Analgetika (A03DA05)
Trospium und Analgetika (A03DA06)
Tiemoniumiodid und Analgetika
(A03DA07)
Belladonna und Derivate in Kombination
mit Analgetika (A03DB)
Butylscopolamin und Analgetika
(A03DB04)
Andere Spasmolytika in Kombination mit
Analgetika (A03DC)
SPASMOLYTIKA UND
ANTICHOLINERGIKA IN KOMBINATION
MIT ANDEREN MITTELN (A03E)
Spasmolytika, Psycholeptika und
Analgetika in Kombination (A03EA)
Spasmolytika in Kombination mit
anderen Mitteln (A03ED)
PROKINETIKA (A03F)
Prokinetika (A03FA)
Metoclopramid (A03FA01)
Cisaprid (A03FA02)
Domperidon (A03FA03)
Bromoprid (A03FA04)
Alizaprid (A03FA05)
Cleboprid (A03FA06)
ANTIEMETIKA UND MITTEL GEGEN
ÜBELKEIT (A04)
ANTIEMETIKA UND MITTEL GEGEN
ÜBELKEIT (A04A)
Serotonin-5HT3-Antagonisten (A04AA)
Ondansetron (A04AA01)
Granisetron (A04AA02)
Tropisetron (A04AA03)
Dolasetron (A04AA04)
Palonosetron (A04AA05)
Andere Antiemetika (A04AD)
Scopolamin (A04AD01)
Ceriumoxalat (A04AD02)
Chlorbutanol (A04AD04)
Metopimazin (A04AD05)
Dronabinol (A04AD10)
Nabilon (A04AD11)
Aprepitant, Fosaprepitant (A04AD12)
Casopitant (A04AD13)
Scopolamin, Kombinationen (A04AD51)
Chlorbutanol, Kombinationen (A04AD54)
GALLEN- UND LEBERTHERAPIE (A05)
GALLENTHERAPIE (A05A)
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Gallensäure-haltige Zubereitungen
(A05AA)
Chenodeoxycholsäure (A05AA01)
Ursodeoxycholsäure (A05AA02)
Cholsäure (A05AA03)
Zubereitungen zur Gallentherapie
(A05AB)
N-(Hydroxymethyl)nicotinamid
(A05AB01)
Andere Mittel zur Gallentherapie
(A05AX)
Piprozolin (A05AX01)
Hymecromon (A05AX02)
Cyclobutyrol (A05AX03)
LEBERTHERAPIE, LIPOTROPE
SUBSTANZEN (A05B)
Lebertherapie (A05BA)
Argininglutamat (A05BA01)
silymarin (A05BA03)
Citiolon (A05BA04)
Epomediol (A05BA05)
Ornithinoxoglurat (A05BA06)
Tidiacicarginin (A05BA07)
Glycyrrhizinsäure (A05BA08)
MITTEL ZUR GALLENTHERAPIE UND
LIPOTROPE SUBSTANZEN IN
KOMBINATION (A05C)
MITTEL GEGEN OBSTIPATION (A06)
MITTEL GEGEN OBSTIPATION (A06A)
Gleitmittel, Emollientia (A06AA)
Dickflüssiges Paraffin (A06AA01)
Docusat-Natrium (A06AA02)
Dickflüssiges Paraffin, Kombinationen
(A06AA51)
Kontaktlaxanzien (A06AB)
Oxyphenisatin (A06AB01)
Bisacodyl (A06AB02)
Dantron (A06AB03)
Phenolphthalein (A06AB04)
Rizinusöl (A06AB05)
Sennoside (A06AB06)
Cascara (A06AB07)
Natriumpicosulfat (A06AB08)
Bisoxatin (A06AB09)
Kontaktlaxanzien in Kombination
(A06AB20)
Kontaktlaxanzien in Kombination mit
Belladonna-Alkaloiden (A06AB30)
Bisacodyl, Kombinationen (A06AB52)
Dantron, Kombinationen (A06AB53)
Sennoside, Kombinationen (A06AB56)
Cascara, Kombinationen (A06AB57)
Natriumpicosulfat, Kombinationen
(A06AB58)
Quellmittel (A06AC)
Ispaghula (Flohsamen) (A06AC01)
Ethulose (A06AC02)
Sterculia (A06AC03)
Leinsamen (A06AC05)
Methylcellulose (A06AC06)
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Triticum (Weizenkleie) (A06AC07)
Polycarbophil-Calcium (A06AC08)
Ispaghula, Kombinationen (A06AC51)
Sterculia, Kombinationen (A06AC53)
Leinsamen, Kombinationen (A06AC55)
Osmotisch wirkende Laxanzien (A06AD)
Magnesiumcarbonat (A06AD01)
Magnesiumoxid (A06AD02)
Magnesiumperoxid (A06AD03)
Magnesiumsulfat (A06AD04)
Mineralsalze in Kombination (A06AD10)
Lactulose (A06AD11)
Lactitol (A06AD12)
Natriumsulfat (A06AD13)
Pentaerythrityl (A06AD14)
Macrogol (A06AD15)
Mannitol (A06AD16)
Natriumphosphat (A06AD17)
Sorbitol (A06AD18)
Magnesiumcitrat (A06AD19)
Natriumtartrat (A06AD21)
Lactulose, Kombinationen (A06AD61)
Macrogol, Kombinationen (A06AD65)
Klysmen (A06AG)
Natriumphosphat (A06AG01)
Bisacodyl (A06AG02)
Dantron, inkl. Kombinationen (A06AG03)
Glycerol (A06AG04)
Öl (A06AG06)
Sorbitol (A06AG07)
Docusat-Natrium, inkl. Kombinationen
(A06AG10)
Laurylsulfat, inkl. Kombinationen
(A06AG11)
Kombinationen (A06AG20)
Periphere Opioidrezeptor-Antagonisten
(A06AH)
Methylnaltrexon bromid (A06AH01)
Alvimopan (A06AH02)
Andere Mittel gegen Obstipation
(A06AX)
Glycerol (A06AX01)
Kohlendioxid freisetzende Mittel
(A06AX02)
Lubiproston (A06AX03)
ANTIDIARRHOIKA UND INTESTINALE
ANTIPHLOGISTIKA/ANTIINFEKTIVA
(A07)
INTESTINALE ANTIINFEKTIVA (A07A)
Antibiotika (A07AA)
Neomycin (A07AA01)
Nystatin (A07AA02)
Natamycin (A07AA03)
Streptomycin (A07AA04)
Polymyxin B (A07AA05)
Paromomycin (A07AA06)
Amphotericin B (A07AA07)
Kanamycin (A07AA08)
Vancomycin (A07AA09)
Colistin (A07AA10)
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Rifaximin (A07AA11)
Neomycin, Kombinationen (A07AA51)
Streptomycin, Kombinationen (A07AA54)
Sulfonamide (A07AB)
Phthalylsulfathiazol (A07AB02)
Sulfaguanidin (A07AB03)
Succinylsulfathiazol (A07AB04)
Imidazol-Derivate (A07AC)
Miconazol (A07AC01)
Andere intestinale Antiinfektiva (A07AX)
Broxychinolin (A07AX01)
Acetarsol (A07AX02)
Nifuroxazid (A07AX03)
Nifurzid (A07AX04)
INTESTINALE ADSORBENZIEN (A07B)
Kohle-haltige Zubereitungen (A07BA)
Medizinische Kohle (A07BA01)
Medizinische Kohle, Kombinationen
(A07BA51)
Bismut-haltige Zubereitungen (A07BB)
Andere intestinale Adsorbenzien
(A07BC)
Pektin (A07BC01)
Kaolin (A07BC02)
Crospovidon (A07BC03)
Attapulgit (A07BC04)
Diosmectit (A07BC05)
Kombinationen (A07BC30)
Attapulgit, Kombinationen (A07BC54)
ELEKTROLYTE MIT
KOHLENHYDRATEN (A07C)
Elektrolyte zur oralen Rehydrierung
(A07CA)
MOTILITÄTSHEMMER (A07D)
Motilitätshemmer (A07DA)
Diphenoxylat (A07DA01)
Opium (A07DA02)
Loperamid (A07DA03)
Difenoxin (A07DA04)
Loperamidoxid (A07DA05)
Morphin, Kombinationen (A07DA52)
Loperamid, Kombinationen (A07DA53)
INTESTINALE ANTIPHLOGISTIKA
(A07E)
Corticosteroide mit lokaler Wirkung
(A07EA)
Prednisolon (A07EA01)
Hydrocortison (A07EA02)
Prednison (A07EA03)
Betamethason (A07EA04)
Tixocortol (A07EA05)
Budesonid (A07EA06)
Beclometason (A07EA07)
Antiallergika, exkl. Corticosteroide
(A07EB)
Cromoglicinsäure (A07EB01)
Aminosalicylsäure und ähnliche Mittel
(A07EC)
Sulfasalazin (A07EC01)
Mesalazin (A07EC02)
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Olsalazin (A07EC03)
Balsalazid (A07EC04)
MIKROBIELLE ANTIDIARRHOIKA
(A07F)
Mikrobielle Antidiarrhoika (A07FA)
Milchsäurebildner (A07FA01)
Saccharomyces boulardii (A07FA02)
Milchsäurebildner, Kombinationen
(A07FA51)
ANDERE ANTIDIARRHOIKA (A07X)
Andere Antidiarrhoika (A07XA)
Albumintannat (A07XA01)
ceratonia (A07XA02)
Calcium-haltige Verbindungen
(A07XA03)
Racecadotril (A07XA04)
Albumintannat, Kombinationen
(A07XA51)
ANTIADIPOSITA, EXKL. DIÄTETIKA
(A08)
ANTIADIPOSITA, EXKL. DIÄTETIKA
(A08A)
Zentral wirkende Antiadiposita (A08AA)
Phentermin (A08AA01)
Fenfluramin (A08AA02)
Amfepramon (A08AA03)
Dexfenfluramin (A08AA04)
Mazindol (A08AA05)
Etilamfetamin (A08AA06)
Cathin (A08AA07)
Clobenzorex (A08AA08)
Mefenorex (A08AA09)
Sibutramin (A08AA10)
Ephedrin, Kombinationen (A08AA56)
Peripher wirkende Antiadiposita (A08AB)
Orlistat (A08AB01)
Andere Antiadiposita (A08AX)
Rimonabant (A08AX01)
DIGESTIVA, INKL. ENZYME (A09)
DIGESTIVA, INKL. ENZYME (A09A)
Enzym-haltige Zubereitungen (A09AA)
Diastase (A09AA01)
Multienzyme (Lipase, Protease etc.)
(A09AA02)
Pepsin (A09AA03)
Tilactase (A09AA04)
Säure-haltige Zubereitungen (A09AB)
Glutaminsäurehydrochlorid (A09AB01)
Betainhydrochlorid (A09AB02)
Salzsäure (A09AB03)
Zitronensäure (A09AB04)
Enzym- und Säure-haltige
Zubereitungen, Kombinationen (A09AC)
Pepsin- und Säure-haltige Zubereitungen
(A09AC01)
Multienzyme und Säure-haltige
Zubereitungen (A09AC02)
ANTIDIABETIKA (A10)
INSULINE UND ANALOGA (A10A)
Insuline und Analoga zur Injektion,
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schnell wirkend (A10AB)
Insulin (human) (A10AB01)
Insulin (Rind) (A10AB02)
Insulin (Schwein) (A10AB03)
Insulin lispro (A10AB04)
Insulin aspart (A10AB05)
Insulin glulisin (A10AB06)
Kombinationen (A10AB30)
Insuline und Analoga zur Injektion,
intermediär wirkend (A10AC)
Insulin (human) (A10AC01)
Insulin (Rind) (A10AC02)
Insulin (Schwein) (A10AC03)
Insulin lispro (A10AC04)
Kombinationen (A10AC30)
Insuline und Analoga zur Injektion,
intermediär oder lang wirkend kombiniert
mit schnell wirkend (A10AD)
Insulin (human) (A10AD01)
Insulin (Rind) (A10AD02)
Insulin (Schwein) (A10AD03)
Insulin lispro (A10AD04)
Insulin aspart (A10AD05)
Kombinationen (A10AD30)
Insuline und Analoga zur Injektion, lang
wirkend (A10AE)
Insulin (human) (A10AE01)
Insulin (Rind) (A10AE02)
Insulin (Schwein) (A10AE03)
Insulin glargin (A10AE04)
Insulin detemir (A10AE05)
Kombinationen (A10AE30)
Insuline und Analoga zur Inhalation
(A10AF)
Insulin (human) (A10AF01)
ANTIDIABETIKA, EXKL. IINSULINE
(A10B)
Phenformin (A10BA01)
Metformin (A10BA02)
Buformin (A10BA03)
Sulfonylharnstoff-Derivate (A10BB)
Glibenclamid (A10BB01)
Chlorpropamid (A10BB02)
Tolbutamid (A10BB03)
Glibornurid (A10BB04)
Tolazamid (A10BB05)
Carbutamid (A10BB06)
Glipizid (A10BB07)
Gliquidon (A10BB08)
Gliclazid (A10BB09)
Metahexamid (A10BB10)
Glisoxepid (A10BB11)
Glimepirid (A10BB12)
Acetohexamid (A10BB31)
Sulfonamide (heterozyklisch) (A10BC)
Glymidin (A10BC01)
Kombinationen mit oralen Antidiabetika
(A10BD)
Phenformin und Sulfonamide (A10BD01)
Metformin und Sulfonamide (A10BD02)
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Metformin und Rosiglitazon (A10BD03)
Glimepirid und Rosiglitazon (A10BD04)
Metformin und Pioglitazon (A10BD05)
Glimepirid und Pioglitazon (A10BD06)
Metformin und Sitagliptin (A10BD07)
Metformin und Vildagliptin (A10BD08)
Pioglitazon und Alogliptin (A10BD09)
Alpha-Glukosidasehemmer (A10BF)
Acarbose (A10BF01)
Miglitol (A10BF02)
Voglibose (A10BF03)
Thiazolidindione (A10BG)
Troglitazon (A10BG01)
Rosiglitazon (A10BG02)
Pioglitazon (A10BG03)
Dipeptidyl-Peptidase-4-Inhibitoren
(A10BH)
Sitagliptin (A10BH01)
Vildagliptin (A10BH02)
Saxagliptin (A10BH03)
Alogliptin (A10BH04)
Andere Antidiabetika, exkl. Insuline
(A10BX)
guar gum (A10BX01)
Repaglinid (A10BX02)
Nateglinid (A10BX03)
Exenatid (A10BX04)
Pramlintid (A10BX05)
Benfluorex (A10BX06)
Liraglutid (A10BX07)
Mitiglinid (A10BX08)
ANDERE ANTIDIABETIKA (A10X)
Aldosereduktasehemmer (A10XA)
Tolrestat (A10XA01)
VITAMINE (A11)
MULTIVITAMINE, KOMBINATIONEN
(A11A)
Multivitamine mit Mineralstoffen (A11AA)
Multivitamine und Eisen (A11AA01)
Multivitamine und Calcium (A11AA02)
Multivitamine und andere Mineralstoffe,
inkl. Kombinationen (A11AA03)
Multivitamine und Spurenelemente
(A11AA04)
Multivitamine, andere Kombinationen
(A11AB)
MULTIVITAMINE, REIN (A11B)
Multivitamine, rein (A11BA)
VITAMIN A UND D, INKL. DEREN
KOMBINATIONEN (A11C)
Vitamin A, rein (A11CA)
Retinol (Vitamin A) (A11CA01)
Betacaroten (A11CA02)
Vitamin A und D in Kombination (A11CB)
Vitamin D und Analoga (A11CC)
Ergocalciferol (A11CC01)
Dihydrotachysterol (A11CC02)
Alfacalcidol (A11CC03)
Calcitriol (A11CC04)
Colecalciferol (A11CC05)
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Calcifediol (A11CC06)
Kombinationen (A11CC20)
VITAMIN B1, REIN UND IN
KOMBINATION MIT VITAMIN B6 UND
VITAMIN B12 (A11D)
Vitamin B1, rein (A11DA)
Thiamin (Vitamin B1) (A11DA01)
Sulbutiamin (A11DA02)
Benfotiamin (A11DA03)
Vitamin B1 in Kombination mit Vitamin
B6 und/oder Vitamin B12 (A11DB)
VITAMIN-B-KOMPLEX, INKL.
KOMBINATIONEN (A11E)
Vitamin-B-Komplex, rein (A11EA)
Vitamin-B-Komplex mit Vitamin C
(A11EB)
Vitamin-B-Komplex mit Mineralstoffen
(A11EC)
Vitamin-B-Komplex mit anabolen
Steroiden (A11ED)
Vitamin-B-Komplex, andere
Kombinationen (A11EX)
ASCORBINSÄURE (VITAMIN C), INKL.
KOMBINATIONEN (A11G)
Ascorbinsäure (Vitamin C), rein (A11GA)
Ascorbinsäure (Vitamin C) (A11GA01)
Ascorbinsäure (Vitamin C),
Kombinationen (A11GB)
Ascorbinsäure (Vitamin C) und Calcium
(A11GB01)
ANDERE VITAMINPRÄPARATE, REIN
(A11H)
Andere Vitaminpräparate, rein (A11HA)
Nicotinamid (A11HA01)
Pyridoxin (Vitamin B6) (A11HA02)
Tocopherol (Vitamin E) (A11HA03)
Riboflavin (Vitamin B2) (A11HA04)
Biotin (A11HA05)
Pyridoxalphosphat (A11HA06)
Inositol (A11HA07)
Tocofersolan (A11HA08)
Dexpanthenol (A11HA30)
Calciumpantothenat (A11HA31)
Pantethin (A11HA32)
ANDERE VITAMINPRÄPARATE,
KOMBINATIONEN (A11J)
Kombinationen von Vitaminen (A11JA)
Vitamine mit Mineralstoffen (A11JB)
Vitamine, andere Kombinationen
(A11JC)
MINERALSTOFFE (A12)
CALCIUM (A12A)
Calcium (A12AA)
Calciumphosphat (A12AA01)
Calciumglubionat (A12AA02)
Calciumgluconat (A12AA03)
Calciumcarbonat (A12AA04)
Calciumlactat (A12AA05)
Calciumlactogluconat (A12AA06)
Calciumchlorid (A12AA07)
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Calciumglycerylphosphat (A12AA08)
Calciumcitratlysin-Komplex (A12AA09)
Calciumglucoheptonat (A12AA10)
Calciumpangamat (A12AA11)
Calciumacetat, wasserfrei (A12AA12)
Calcium (verschiedene Salze in
Kombination) (A12AA20)
Calciumlaevulat (A12AA30)
Calcium, Kombinationen mit Vitamin D
und/oder anderen Mitteln (A12AX)
KALIUM (A12B)
Kalium (A12BA)
Kaliumchlorid (A12BA01)
Kaliumcitrat (A12BA02)
Kaliumhydrogentartrat (A12BA03)
Kaliumhydrogencarbonat (A12BA04)
Kaliumgluconat (A12BA05)
Kombinationen (A12BA30)
Kaliumchlorid, Kombinationen
(A12BA51)
ANDERE MINERALSTOFFE (A12C)
Natrium (A12CA)
Natriumchlorid (A12CA01)
Natriumsulfat (A12CA02)
Zink (A12CB)
Zinksulfat (A12CB01)
Zinkgluconat (A12CB02)
Zinkprotein-Komplex (A12CB03)
Magnesium (A12CC)
Magnesiumchlorid (A12CC01)
Magnesiumsulfat (A12CC02)
Magnesiumgluconat (A12CC03)
Magnesiumcitrat (A12CC04)
Magnesiumaspartat (A12CC05)
Magnesiumlactat (A12CC06)
Magnesiumlevulinat (A12CC07)
Magnesiumpidolat (A12CC08)
Magnesiumorotat (A12CC09)
Magnesiumoxid (A12CC10)
Magnesium (verschiedene Salze in
Kombination) (A12CC30)
Fluorid (A12CD)
Natriumfluorid (A12CD01)
Natriummonofluorphosphat (A12CD02)
Natriumfluorid, Kombinationen
(A12CD51)
Selen (A12CE)
Natriumselenat (A12CE01)
Natriumselenit (A12CE02)
Andere Mineralstoff-haltige
Zubereitungen (A12CX)
TONIKA (A13)
TONIKA (A13A)
ANABOLIKA ZUR SYSTEMISCHEN
ANWENDUNG (A14)
ANABOLE STEROIDE (A14A)
Androstan-Derivate (A14AA)
Androstanolon (A14AA01)
Stanozolol (A14AA02)
Metandienon (A14AA03)
14 / 15
ATC A - Alimentary Tract and Metabolism
Metenolon (A14AA04)
Oxymetholon (A14AA05)
Quinbolon (A14AA06)
Prasteron (A14AA07)
Oxandrolon (A14AA08)
Norethandrolon (A14AA09)
Estren-Derivate (A14AB)
Nandrolon (A14AB01)
Ethylestrenol (A14AB02)
Oxaboloncipionat (A14AB03)
ANDERE ANABOLIKA (A14B)
APPETIT STIMULIERENDE MITTEL
(A15)
ANDERE MITTEL FÜR DAS
ALIMENTÄRE SYSTEM UND DEN
STOFFWECHSEL (A16)
ANDERE MITTEL FÜR DAS
ALIMENTÄRE SYSTEM UND DEN
STOFFWECHSEL (A16A)
Aminosäuren und Derivate (A16AA)
Levocarnitin (A16AA01)
Ademetionin (A16AA02)
Glutamin (A16AA03)
Mercaptamin (A16AA04)
Carglumsäure (A16AA05)
Betain (A16AA06)
Enzyme (A16AB)
Alglucerase (A16AB01)
Imiglucerase (A16AB02)
Agalsidase alfa (A16AB03)
Agalsidase beta (A16AB04)
Laronidase (A16AB05)
Sacrosidase (A16AB06)
Alglucosidase alfa (A16AB07)
Galsulfase (A16AB08)
Idursulfase (A16AB09)
Sonstige Mittel für das alimentäre
System und den Stoffwechsel (A16AX)
Alpha-Liponsäure (Thioctsäure)
(A16AX01)
Anetholtrithion (A16AX02)
Natriumphenylbutyrat (A16AX03)
Nitisinon (A16AX04)
Zinkacetat (A16AX05)
Miglustat (A16AX06)
Sapropterin (A16AX07)
Biguanide (AA10BA)
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ATC B - Blood and blood forming
organs
BLUT UND BLUTBILDENDE ORGANE
BLUT UND BLUTBILDENDE ORGANE
BLUT UND BLUTBILDENDE ORGANE
(B)
ANTITHROMBOTISCHE MITTEL (B01)
ANTITHROMBOTISCHE MITTEL (B01A)
Vitamin-K-Antagonisten (B01AA)
Dicoumarol (B01AA01)
Phenindion (B01AA02)
Warfarin (B01AA03)
Phenprocoumon (B01AA04)
Acenocoumarol (B01AA07)
Ethylbiscoumacetat (B01AA08)
Clorindion (B01AA09)
Diphenadion (B01AA10)
Tioclomarol (B01AA11)
Heparingruppe (B01AB)
Heparin (B01AB01)
Antithrombin III, Antithrombin alfa
(B01AB02)
Dalteparin (B01AB04)
Enoxaparin (B01AB05)
Nadroparin (B01AB06)
Parnaparin (B01AB07)
Reviparin (B01AB08)
Danaparoid (B01AB09)
Tinzaparin (B01AB10)
Sulodexid (B01AB11)
Bemiparin (B01AB12)
Heparin, Kombinationen (B01AB51)
Thrombozytenaggregationshemmer,
exkl. Heparin (B01AC)
Ditazol (B01AC01)
Cloricromen (B01AC02)
Picotamid (B01AC03)
Clopidogrel (B01AC04)
Ticlopidin (B01AC05)
Acetylsalicylsäure (B01AC06)
Dipyridamol (B01AC07)
Carbasalat calcium (B01AC08)
Epoprostenol (B01AC09)
Indobufen (B01AC10)
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Iloprost (B01AC11)
Abciximab (B01AC13)
Aloxiprin (B01AC15)
Eptifibatid (B01AC16)
Tirofiban (B01AC17)
Triflusal (B01AC18)
Beraprost (B01AC19)
Treprostinil (B01AC21)
Prasugrel (B01AC22)
Kombinationen (B01AC30)
Enzyme (B01AD)
Streptokinase (B01AD01)
Alteplase (B01AD02)
Anistreplase (B01AD03)
Urokinase (B01AD04)
Fibrinolysin (B01AD05)
Brinase (B01AD06)
Reteplase (B01AD07)
Saruplase (B01AD08)
Ancrod (B01AD09)
Drotrecogin alfa (aktiviert) (B01AD10)
Tenecteplase (B01AD11)
Protein C (B01AD12)
Direkte Thrombininhibitoren (B01AE)
Desirudin (B01AE01)
Lepirudin (B01AE02)
Argatroban (B01AE03)
Melagatran (B01AE04)
Ximelagatran (B01AE05)
Bivalirudin (B01AE06)
Dabigatran etexilat (B01AE07)
Andere antithrombotische Mittel (B01AX)
Defibrotid (B01AX01)
Chondroitinsulfat B (B01AX04)
Fondaparinux (B01AX05)
Rivaroxaban (B01AX06)
ANTIHÄMORRHAGIKA (B02)
ANTIFIBRINOLYTIKA (B02A)
Aminosäuren (B02AA)
Aminocapronsäure (B02AA01)
Tranexamsäure (B02AA02)
Aminomethylbenzoesäure (B02AA03)
Proteinasehemmer (B02AB)
Aprotinin (B02AB01)
Alfa1-Antitrypsin (B02AB02)
c1-inhibitor (B02AB03)
Camostat (B02AB04)
VITAMIN K UND ANDERE
HÄMOSTATIKA (B02B)
Vitamin K (B02BA)
Phytomenadion (B02BA01)
Menadion (B02BA02)
Fibrinogene (B02BB)
Fibrinogen, human (B02BB01)
Lokale Hämostatika (B02BC)
Absorbierbarer Gelatineschwamm
(B02BC01)
Oxidierte Zellulose (B02BC02)
Tetragalacturonsäurehydroxymethylester
(B02BC03)
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Adrenalon (B02BC05)
Thrombin (B02BC06)
Kollagen (B02BC07)
Calciumalginat (B02BC08)
Epinephrin (B02BC09)
Fibrinogen, human (B02BC10)
Kombinationen (B02BC30)
Blutgerinnungsfaktoren (B02BD)
Gerinnungsfaktoren IX, II, VII und X in
Kombination (B02BD01)
Gerinnungsfaktor VIII (B02BD02)
Faktor-VIII-Inhibitor-bypass-Aktivität
(B02BD03)
Gerinnungsfaktor IX (B02BD04)
Gerinnungsfaktor VII (B02BD05)
Von Willebrand-Faktor und
Gerinnungsfaktor VIII in Kombination
(B02BD06)
Gerinnungsfaktor XIII (B02BD07)
Eptacog alfa (aktiviert) (B02BD08)
Nonacog alfa (B02BD09)
Thrombin (B02BD30)
Andere systemische Hämostatika
(B02BX)
Etamsylat (B02BX01)
Carbazochrom (B02BX02)
Batroxobin (B02BX03)
Romiplostim (B02BX04)
Eltrombopag (B02BX05)
ANTIANÄMIKA (B03)
EISEN-HALTIGE ZUBEREITUNGEN
(B03A)
Eisen zweiwertig, orale Zubereitungen
(B03AA)
Eisen(II)glycinsulfat (B03AA01)
Eisen(II)fumarat (B03AA02)
Eisen(II)gluconat (B03AA03)
Eisen(II)carbonat (B03AA04)
Eisen(II)chlorid (B03AA05)
Eisen(II)succinat (B03AA06)
Eisen(II)sulfat (B03AA07)
Eisen(II)tartrat (B03AA08)
Eisen(II)aspartat (B03AA09)
Eisen(II)ascorbat (B03AA10)
Eisen(II)iodat (B03AA11)
Eisen dreiwertig, orale Zubereitungen
(B03AB)
Eisen(III)natrium-citrat (B03AB01)
Eisen(III)oxid-Saccharose-Komplex
(B03AB02)
Natriumferedetat (B03AB03)
Eisen(III)hydroxid (B03AB04)
Eisen(III)hydroxid-Polymaltose-Komplex
(B03AB05)
Eisen(III)citrat (B03AB06)
Chondroitinsulfat-Eisen(III)-Komplex
(B03AB07)
Eisen(III)acetyltransferrin (B03AB08)
Eisen(III)proteinsuccinylat (B03AB09)
Eisen, parenterale Zubereitungen
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(B03AC)
Eisen(III)hydroxid-Polymaltose-Komplex
(B03AC01)
Eisen(III)oxid-Saccharose-Komplex
(B03AC02)
Eisen(III)sorbit-Zitronensäure-Komplex
(B03AC03)
Eisen(III)sorbit-Gluconsäure-Komplex
(B03AC05)
Eisen(III)hydroxid-Dextran-Komplex
(B03AC06)
Eisen(III)natrium-Gluconat-Komplex
(B03AC07)
Eisen in Kombination mit Folsäure
(B03AD)
Eisen-Aminosäure-Komplex (B03AD01)
Eisen(II)fumarat (B03AD02)
Eisen(II)sulfat (B03AD03)
Eisen(III)hydroxid-Polymaltose-Komplex
(B03AD04)
Eisen in anderen Kombinationen
(B03AE)
Eisen, Vitamin B12 und Folsäure
(B03AE01)
Eisen, Multivitamine und Folsäure
(B03AE02)
Eisen und Multivitamine (B03AE03)
Eisen, Multivitamine und Mineralstoffe
(B03AE04)
Verschiedene Kombinationen (B03AE10)
VITAMIN B12 UND FOLSÄURE (B03B)
Vitamin B12 (Cyanocobalamin und
Analoga) (B03BA)
Cyanocobalamin (B03BA01)
Cyanocobalamin-Tannin-Komplex
(B03BA02)
Hydroxocobalamin (B03BA03)
Cobamamid (B03BA04)
Mecobalamin (B03BA05)
Cyanocobalamin, Kombinationen
(B03BA51)
Hydroxocobalamin, Kombinationen
(B03BA53)
Folsäure und Derivate (B03BB)
Folsäure (B03BB01)
Folsäure, Kombinationen (B03BB51)
ANDERE ANTIANÄMIKA (B03X)
Andere Antianämika (B03XA)
Erythropoietin (B03XA01)
Darbepoetin alfa (B03XA02)
Methoxy-Polyethylenglycol-Epoetin beta
(B03XA03)
BLUTERSATZMITTEL UND
PERFUSIONSLÖSUNGEN (B05)
BLUT UND VERWANDTE PRODUKTE
(B05A)
Blutersatzmittel und
Plasmaproteinfraktionen (B05AA)
Albumin (B05AA01)
Andere Plasmaproteinfraktionen
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(B05AA02)
Fluorocarbon-Blutersatzmittel (B05AA03)
Dextran (B05AA05)
Gelatine-haltige Mittel (B05AA06)
Hydroxyethylstärke (B05AA07)
Hämoglobin crosfumaril (B05AA08)
Hämoglobin raffimer (B05AA09)
Hämoglobin glutamer (Rind) (B05AA10)
Andere Blutprodukte (B05AX)
Erythrozyten (B05AX01)
Thrombozyten (B05AX02)
Blutplasma (B05AX03)
Stammzellen aus Nabelschnurblut
(B05AX04)
I.V.-LÖSUNGEN (B05B)
Lösungen zur parenteralen Ernährung
(B05BA)
Aminosäuren (B05BA01)
Fett-Emulsionen (B05BA02)
Kohlenhydrate (B05BA03)
Proteinhydrolysate (B05BA04)
Kombinationen (B05BA10)
Lösungen mit Wirkung auf den
Elektrolythaushalt (B05BB)
Elektrolyte (B05BB01)
Elektrolyte mit Kohlenhydraten
(B05BB02)
Trometamol (B05BB03)
Osmodiuretika (B05BC)
Mannitol (B05BC01)
Harnstoff (B05BC02)
SPÜLLÖSUNGEN (B05C)
Antiinfektiva (B05CA)
Cetylpyridinium (B05CA01)
Chlorhexidin (B05CA02)
Nitrofural (B05CA03)
Sulfamethizol (B05CA04)
Taurolidin (B05CA05)
Mandelsäure (B05CA06)
Noxytiolin (B05CA07)
Ethacridinlactat (B05CA08)
Neomycin (B05CA09)
Kombinationen (B05CA10)
Salzlösungen (B05CB)
Natriumchlorid (B05CB01)
Natriumcitrat (B05CB02)
Magnesiumcitrat (B05CB03)
Natriumbicarbonat (B05CB04)
Kombinationen (B05CB10)
Andere Spüllösungen (B05CX)
Glucose (B05CX01)
Sorbitol (B05CX02)
Glycin (B05CX03)
Mannitol (B05CX04)
Kombinationen (B05CX10)
LÖSUNGEN ZUR
PERITONEALDIALYSE (B05D)
Isotone Lösungen (B05DA)
Hypertone Lösungen (B05DB)
ADDITIVA ZU I.V.-LÖSUNGEN (B05X)
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Elektrolytlösungen (B05XA)
Kaliumchlorid (B05XA01)
Natriumbicarbonat (B05XA02)
Natriumchlorid (B05XA03)
Ammoniumchlorid (B05XA04)
Magnesiumsulfat (B05XA05)
Kaliumphosphat, inkl. Kombinationen mit
anderen Kaliumsalzen (B05XA06)
Calciumchlorid (B05XA07)
Natriumacetat (B05XA08)
Natriumphosphat (B05XA09)
Magnesiumphosphat (B05XA10)
Magnesiumchlorid (B05XA11)
Zinkchlorid (B05XA12)
Salzsäure (B05XA13)
Dinatrium-1-glycerinphosphat
(B05XA14)
Kaliumlactat (B05XA15)
Kardioplege Lösungen (B05XA16)
Kaliumacetat (B05XA17)
Kombinationen von Elektrolyten
(B05XA30)
Elektrolyte in Kombination mit anderen
Mitteln (B05XA31)
Aminosäuren (B05XB)
Argininhydrochlorid (B05XB01)
Alanylglutamin (B05XB02)
Lysin (B05XB03)
Vitamine (B05XC)
Andere Additiva zu i.v.-Lösungen
(B05XX)
Trometamol (B05XX02)
HÄMODIALYSEKONZENTRATE UND
HÄMOFILTRATE (B05Z)
Hämodialysekonzentrate (B05ZA)
Hämofiltrate (B05ZB)
ANDERE HÄMATOLOGIKA (B06)
ANDERE HÄMATOLOGIKA (B06A)
Enzyme (B06AA)
Fibrinolysin und Desoxyribonuclease
(B06AA02)
Hyaluronidase (B06AA03)
Chymotrypsin (B06AA04)
Trypsin (B06AA07)
Desoxyribonuclease (B06AA10)
Bromelains (B06AA11)
Streptokinase, Kombinationen
(B06AA55)
Andere Hämprodukte (B06AB)
Hematin (B06AB01)
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ATC C - Cardiovascular System
KARDIOVASKULÄRES SYSTEM
KARDIOVASKULÄRES SYSTEM
KARDIOVASKULÄRES SYSTEM (C)
HERZTHERAPIE (C01)
HERZGLYKOSIDE (C01A)
Digitalisglykoside (C01AA)
Acetyldigitoxin (C01AA01)
Acetyldigoxin (C01AA02)
Digitalisblätter (C01AA03)
Digitoxin (C01AA04)
Digoxin (C01AA05)
Lanatosid C (C01AA06)
Deslanosid (C01AA07)
Metildigoxin (C01AA08)
Gitoformat (C01AA09)
Acetyldigoxin, Kombinationen
(C01AA52)
Scillaglykoside (C01AB)
Proscillaridin (C01AB01)
Proscillaridin, Kombinationen (C01AB51)
Strophantusglykoside (C01AC)
g-Strophanthin (C01AC01)
Cymarin (C01AC03)
Andere Herzglykoside (C01AX)
Peruvosid (C01AX02)
ANTIARRHYTHMIKA, KLASSE I UND III
(C01B)
Antiarrhythmika, Klasse Ia (C01BA)
Chinidin (C01BA01)
Procainamid (C01BA02)
Disopyramid (C01BA03)
Spartein (C01BA04)
Ajmalin (C01BA05)
Prajmalin (C01BA08)
Lorajmin (C01BA12)
Chinidin, Kombinationen exkl.
Psycholeptika (C01BA51)
Chinidin, Kombinationen mit
Psycholeptika (C01BA71)
Antiarrhythmika, Klasse Ib (C01BB)
Lidocain (C01BB01)
Mexiletin (C01BB02)
Tocainid (C01BB03)
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Aprindin (C01BB04)
Antiarrhythmika, Klasse Ic (C01BC)
Propafenon (C01BC03)
Flecainid (C01BC04)
Lorcainid (C01BC07)
Encainid (C01BC08)
Antiarrhythmika, Klasse III (C01BD)
Amiodaron (C01BD01)
Bretyliumtosilat (C01BD02)
Bunaftin (C01BD03)
Dofetilid (C01BD04)
Ibutilid (C01BD05)
Tedisamil (C01BD06)
Andere Antiarrhythmika, Klasse I und III
(C01BG)
Moracizin (C01BG01)
Cibenzolin (C01BG07)
KARDIOSTIMULANZIEN, EXKL.
HERZGLYKOSIDE (C01C)
Adrenerge und dopaminerge Mittel
(C01CA)
Etilefrin (C01CA01)
Isoprenalin (C01CA02)
Norepinephrin (C01CA03)
Dopamin (C01CA04)
Norfenefrin (C01CA05)
Phenylephrin (C01CA06)
Dobutamin (C01CA07)
Oxedrin (C01CA08)
Metaraminol (C01CA09)
Methoxamin (C01CA10)
Mephentermin (C01CA11)
Dimetofrin (C01CA12)
Prenalterol (C01CA13)
Dopexamin (C01CA14)
Gepefrin (C01CA15)
Ibopamin (C01CA16)
Midodrin (C01CA17)
Octopamin (C01CA18)
Fenoldopam (C01CA19)
Cafedrin (C01CA21)
Arbutamin (C01CA22)
Theodrenalin (C01CA23)
Epinephrin (C01CA24)
Kombinationen (C01CA30)
Etilefrin, Kombinationen (C01CA51)
Phosphodiesterasehemmer (C01CE)
Amrinon (C01CE01)
Milrinon (C01CE02)
Enoximon (C01CE03)
Bucladesin (C01CE04)
Andere Kardiostimulanzien (C01CX)
Angiotensinamid (C01CX06)
Xamoterol (C01CX07)
Levosimendan (C01CX08)
BEI HERZERKRANKUNGEN
EINGESETZTE VASODILATATOREN
(C01D)
Organische Nitrate (C01DA)
Glyceroltrinitrat (C01DA02)
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Methylpropylpropanedioldinitrat
(C01DA04)
Pentaerythrityltetranitrat (C01DA05)
Propatylnitrat (C01DA07)
Isosorbiddinitrat (C01DA08)
Trolnitrat (C01DA09)
Erythrityltetranitrat (C01DA13)
Isosorbidmononitrat (C01DA14)
Organische Nitrate in Kombination
(C01DA20)
Tenitramin (C01DA38)
Glyceroltrinitrat, Kombinationen
(C01DA52)
Methylpropylpropanedioldinitrat,
Kombinationen (C01DA54)
Pentaerythrityltetranitrat, Kombinationen
(C01DA55)
Propatylnitrat, Kombinationen
(C01DA57)
Isosorbiddinitrat, Kombinationen
(C01DA58)
Trolnitrat, Kombinationen (C01DA59)
Erythrityltetranitrat, Kombinationen
(C01DA63)
Organische Nitrate in Kombination mit
Psycholeptika (C01DA70)
Chinolon-Vasodilatatoren (C01DB)
Flosequinan (C01DB01)
Andere bei Herzerkrankungen
eingesetzte Vasodilatatoren (C01DX)
Itramintosilat (C01DX01)
Prenylamin (C01DX02)
Oxyfedrin (C01DX03)
Benziodaron (C01DX04)
Carbocromen (C01DX05)
Hexobendin (C01DX06)
Etafenon (C01DX07)
Heptaminol (C01DX08)
Imolamin (C01DX09)
Dilazep (C01DX10)
Trapidil (C01DX11)
Molsidomin (C01DX12)
Efloxat (C01DX13)
Cinepazet (C01DX14)
Cloridarol (C01DX15)
Nicorandil (C01DX16)
Linsidomin (C01DX18)
Nesiritid (C01DX19)
Itramintosilat, Kombinationen (C01DX51)
Prenylamin, Kombinationen (C01DX52)
Oxyfedrin, Kombinationen (C01DX53)
Benziodaron, Kombinationen (C01DX54)
ANDERE HERZMITTEL (C01E)
Prostaglandine (C01EA)
Alprostadil (C01EA01)
Andere Herzmittel (C01EB)
Campher (C01EB02)
Indometacin (C01EB03)
crataegus glycosides (C01EB04)
Creatinolfosfat (C01EB05)
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Fosfocreatin (C01EB06)
Fructose-1,6-diphosphat (C01EB07)
Ubidecarenon (C01EB09)
Adenosin (C01EB10)
Tiracizin (C01EB11)
Acadesin (C01EB13)
Trimetazidin (C01EB15)
Ibuprofen (C01EB16)
Ivabradin (C01EB17)
Ranolazin (C01EB18)
icatibant (C01EB19)
Regadenoson (C01EB21)
Andere Herzmittel, Kombinationen
(C01EX)
ANTIHYPERTONIKA (C02)
ANTIADRENERGE MITTEL, ZENTRAL
WIRKEND (C02A)
Rauwolfia-Alkaloide (C02AA)
Rescinnamin (C02AA01)
Reserpin (C02AA02)
Kombinationen von Rauwolfia-Alkaloiden
(C02AA03)
Rauwolfia-Alkaloide, ganze Wurzel
(C02AA04)
Deserpidin (C02AA05)
Methoserpidin (C02AA06)
Bietaserpin (C02AA07)
Reserpin, Kombinationen (C02AA52)
Kombinationen von Rauwolfia-
Alkaloiden, Kombinationen (C02AA53)
Bietaserpin, Kombinationen (C02AA57)
Methyldopa (C02AB)
Methyldopa (linksdrehend) (C02AB01)
Methyldopa (racemisch) (C02AB02)
Imidazolin-Rezeptoragonisten (C02AC)
Clonidin (C02AC01)
Guanfacin (C02AC02)
Tolonidin (C02AC04)
Moxonidin (C02AC05)
Rilmenidin (C02AC06)
ANTIADRENERGE MITTEL,
GANGLIENBLOCKER (C02B)
Sulfonium-Derivate (C02BA)
Trimetaphan (C02BA01)
Sekundäre und tertiäre Amine (C02BB)
Mecamylamin (C02BB01)
Bisquartäre Ammonium-Verbindungen
(C02BC)
ANTIADRENERGE MITTEL, PERIPHER
WIRKEND (C02C)
Alpha-Adrenozeptor-Antagonisten
(C02CA)
Prazosin (C02CA01)
Indoramin (C02CA02)
Trimazosin (C02CA03)
Doxazosin (C02CA04)
Urapidil (C02CA06)
Guanidin-Derivate (C02CC)
Betanidin (C02CC01)
Guanethidin (C02CC02)
4 / 16
ATC C - Cardiovascular System
Guanoxan (C02CC03)
Debrisoquin (C02CC04)
Guanoclor (C02CC05)
Guanazodin (C02CC06)
Guanoxabenz (C02CC07)
MITTEL MIT WIRKUNG AUF DIE
ARTERIELLE GEFÄSSMUSKULATUR
(C02D)
Thiazid-Derivate (C02DA)
Diazoxid (C02DA01)
Hydrazinophthalazin-Derivate (C02DB)
Dihydralazin (C02DB01)
Hydralazin (C02DB02)
Endralazin (C02DB03)
Cadralazin (C02DB04)
Pyrimidin-Derivate (C02DC)
Minoxidil (C02DC01)
Nitroferrocyanid-Derivate (C02DD)
Nitroprussid (C02DD01)
Guanidin-Derivate (C02DG)
Pinacidil (C02DG01)
ANDERE ANTIHYPERTONIKA (C02K)
Alkaloide, exkl. Rauwolfia (C02KA)
Veratrum (C02KA01)
Tyrosinhydroxylasehemmer (C02KB)
Metirosin (C02KB01)
MAO-Hemmer (C02KC)
Pargylin (C02KC01)
Serotonin-Antagonisten (C02KD)
Ketanserin (C02KD01)
Antihypertonika zur Behandlung der
pulmonalen arteriellen Hypertonie
(C02KX)
Bosentan (C02KX01)
Ambrisentan (C02KX02)
Sitaxentan (C02KX03)
ANTIHYPERTONIKA UND DIURETIKA
IN KOMBINATION (C02L)
Rauwolfia-Alkaloide und Diuretika in
Kombination (C02LA)
Reserpin und Diuretika (C02LA01)
Rescinnamin und Diuretika (C02LA02)
Deserpidin und Diuretika (C02LA03)
Methoserpidin und Diuretika (C02LA04)
Bietaserpin und Diuretika (C02LA07)
Rauwolfia-Alkaloide, ganze Wurzel und
Diuretika (C02LA08)
Syrosingopin und Diuretika (C02LA09)
Kombinationen von Rauwolfia-Alkaloiden
und Diuretika inkl. andere Kombinationen
(C02LA50)
Reserpin und Diuretika, Kombinationen
mit anderen Mitteln (C02LA51)
Rescinnamin und Diuretika,
Kombinationen mit anderen Mitteln
(C02LA52)
Reserpin und Diuretika, Kombinationen
mit Psycholeptika (C02LA71)
Methyldopa und Diuretika in Kombination
(C02LB)
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Methyldopa (linksdrehend) und Diuretika
(C02LB01)
Imidazolin-Rezeptoragonisten in
Kombination mit Diuretika (C02LC)
Clonidin und Diuretika (C02LC01)
Moxonidin und Diuretika (C02LC05)
Clonidin und Diuretika, Kombinationen
mit anderen Mitteln (C02LC51)
Alpha-Adrenozeptor-Antagonisten und
Diuretika (C02LE)
Prazosin und Diuretika (C02LE01)
Guanidin-Derivate und Diuretika (C02LF)
Guanethidin und Diuretika (C02LF01)
Hydrazinophthalazin-Derivate und
Diuretika (C02LG)
Dihydralazin und Diuretika (C02LG01)
Hydralazin und Diuretika (C02LG02)
Picodralazin und Diuretika (C02LG03)
Dihydralazin und Diuretika,
Kombinationen mit anderen Mitteln
(C02LG51)
Picodralazin und Diuretika,
Kombinationen mit Psycholeptika
(C02LG73)
Alkaloide, exkl. Rauwolfia, in
Kombination mit Diuretika (C02LK)
Veratrum und Diuretika (C02LK01)
MAO-Hemmer und Diuretika (C02LL)
Pargylin und Diuretika (C02LL01)
Serotonin-Antagonisten und Diuretika
(C02LN)
Andere Antihypertonika und Diuretika
(C02LX)
Pinacidil und Diuretika (C02LX01)
KOMBINATIONEN VON
ANTIHYPERTENSIVEN WIRKSTOFFEN
AUS ATC-GRUPPE C02 (C02N)
DIURETIKA (C03)
LOW-CEILING-DIURETIKA, THIAZIDE
(C03A)
Thiazide, rein (C03AA)
Bendroflumethiazid (C03AA01)
Hydroflumethiazid (C03AA02)
Hydrochlorothiazid (C03AA03)
Chlorothiazid (C03AA04)
Polythiazid (C03AA05)
Trichlormethiazid (C03AA06)
Cyclopenthiazid (C03AA07)
Methylclothiazid (C03AA08)
Cyclothiazid (C03AA09)
Mebutizid (C03AA13)
Thiazide und Kalium in Kombination
(C03AB)
Bendroflumethiazid und Kalium
(C03AB01)
Hydroflumethiazid und Kalium
(C03AB02)
Hydrochlorothiazid und Kalium
(C03AB03)
Chlorothiazid und Kalium (C03AB04)
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Polythiazid und Kalium (C03AB05)
Trichlormethiazid und Kalium (C03AB06)
Cyclopenthiazid und Kalium (C03AB07)
Methylclothiazid und Kalium (C03AB08)
Cyclothiazid und Kalium (C03AB09)
Thiazide, Kombinationen mit
Psycholeptika und/oder Analgetika
(C03AH)
Chlorothiazid, Kombinationen
(C03AH01)
Hydroflumethiazid, Kombinationen
(C03AH02)
Thiazide, Kombinationen mit anderen
Mitteln (C03AX)
Hydrochlorothiazid, Kombinationen
(C03AX01)
LOW-CEILING-DIURETIKA, EXKL.
THIAZIDE (C03B)
Sulfonamide, rein (C03BA)
Quinethazon (C03BA02)
Clopamid (C03BA03)
Chlortalidon (C03BA04)
Mefrusid (C03BA05)
Clofenamid (C03BA07)
Metolazon (C03BA08)
Meticran (C03BA09)
Xipamid (C03BA10)
Indapamid (C03BA11)
Clorexolon (C03BA12)
Fenquizon (C03BA13)
Clorexolon, Kombinationen mit
Psycholeptika (C03BA82)
Sulfonamide und Kalium in Kombination
(C03BB)
Quinethazon und Kalium (C03BB02)
Clopamid und Kalium (C03BB03)
Chlortalidon und Kalium (C03BB04)
Mefrusid und Kalium (C03BB05)
Clofenamid und Kalium (C03BB07)
Quecksilber-haltige Diuretika (C03BC)
Mersalyl (C03BC01)
Xanthin-Derivate (C03BD)
Theobromin (C03BD01)
Sulfonamide, Kombinationen mit
anderen Mitteln (C03BK)
Andere Low-ceiling-Diuretika (C03BX)
Cicletanin (C03BX03)
HIGH-CEILING-DIURETIKA (C03C)
Sulfonamide, rein (C03CA)
Furosemid (C03CA01)
Bumetanid (C03CA02)
Piretanid (C03CA03)
Torasemid (C03CA04)
Sulfonamide und Kalium in Kombination
(C03CB)
Furosemid und Kalium (C03CB01)
Bumetanid und Kalium (C03CB02)
Aryloxyessigsäure-Derivate (C03CC)
Etacrynsäure (C03CC01)
Tienilinsäure (C03CC02)
7 / 16
ATC C - Cardiovascular System
Pyrazolon-Derivate (C03CD)
Muzolimin (C03CD01)
Andere High-ceiling-Diuretika (C03CX)
Etozolin (C03CX01)
KALIUM SPARENDE MITTEL (C03D)
Aldosteron-Antagonisten (C03DA)
Spironolacton (C03DA01)
Kaliumcanrenoat (C03DA02)
Canrenon (C03DA03)
Eplerenon (C03DA04)
Andere Kalium sparende Mittel (C03DB)
Amilorid (C03DB01)
Triamteren (C03DB02)
DIURETIKA UND KALIUM SPARENDE
MITTEL IN KOMBINATION (C03E)
Low-ceiling-Diuretika und Kalium
sparende Mittel (C03EA)
Hydrochlorothiazid und Kalium sparende
Mittel (C03EA01)
Trichlormethiazid und Kalium sparende
Mittel (C03EA02)
Epitizid und Kalium sparende Mittel
(C03EA03)
Altizid und Kalium sparende Mittel
(C03EA04)
Mebutizid und Kalium sparende Mittel
(C03EA05)
Chlortalidon und Kalium sparende Mittel
(C03EA06)
Cyclopenthiazid und Kalium sparende
Mittel (C03EA07)
Metolazon und Kalium sparende Mittel
(C03EA12)
Bendroflumethiazid und Kalium
sparende Mittel (C03EA13)
Butizid und Kalium sparende Mittel
(C03EA14)
High-ceiling-Diuretika und Kalium
sparende Diuretika (C03EB)
Furosemid und Kalium sparende Mittel
(C03EB01)
Bumetanid und Kalium sparende Mittel
(C03EB02)
ANDERE DIURETIKA (C03X)
Vasopressin-Antagonisten (C03XA)
Tolvaptan (C03XA01)
Conivaptan (C03XA02)
PERIPHERE VASODILATATOREN (C04)
PERIPHERE VASODILATATOREN
(C04A)
2-Amino-1-phenylethanol-Derivate
(C04AA)
Isoxsuprin (C04AA01)
Buphenin (C04AA02)
Bamethan (C04AA31)
Imidazolin-Derivate (C04AB)
Phentolamin (C04AB01)
Tolazolin (C04AB02)
Nicotinsäure und Derivate (C04AC)
Nicotinsäure (C04AC01)
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Nicotinylalkohol (Pyridylcarbinol)
(C04AC02)
Inositolnicotinat (C04AC03)
Ciclonicat (C04AC07)
Purin-Derivate (C04AD)
Pentifyllin (C04AD01)
Xantinolnicotinat (C04AD02)
Pentoxifyllin (C04AD03)
Etofyllinnicotinat (C04AD04)
Mutterkorn-Alkaloide (C04AE)
Ergoloidmesylat (C04AE01)
Nicergolin (C04AE02)
Dihydroergocristin (C04AE04)
Ergoloidmesylat, Kombinationen
(C04AE51)
Dihydroergocristin, Kombinationen
(C04AE54)
Enzyme (C04AF)
Kallidinogenase (C04AF01)
Andere periphere Vasodilatatoren
(C04AX)
Cyclandelat (C04AX01)
Phenoxybenzamin (C04AX02)
Vincamin (C04AX07)
Moxisylyt (C04AX10)
Bencyclan (C04AX11)
Vinburnin (C04AX17)
Suloctidil (C04AX19)
Buflomedil (C04AX20)
Naftidrofuryl (C04AX21)
Butalamin (C04AX23)
Visnadin (C04AX24)
Cetiedil (C04AX26)
Cinepazid (C04AX27)
Ifenprodil (C04AX28)
Azapetin (C04AX30)
Fasudil (C04AX32)
VASOPROTEKTOREN (C05)
MITTEL ZUR BEHANDLUNG VON
HÄMORRHOIDEN UND
ANALFISSUREN ZUR TOPISCHEN
ANWENDUNG (C05A)
Corticosteroide (C05AA)
Hydrocortison (C05AA01)
Prednisolon (C05AA04)
Betamethason (C05AA05)
Fluorometholon (C05AA06)
Fluocortolon (C05AA08)
Dexamethason (C05AA09)
Fluocinolon acetonid (C05AA10)
Fluocinonid (C05AA11)
Antibiotika (C05AB)
Lokalanästhetika (C05AD)
Lidocain (C05AD01)
Tetracain (C05AD02)
Benzocain (C05AD03)
Cinchocain (C05AD04)
Procain (C05AD05)
Oxetacain (C05AD06)
Pramocain (C05AD07)
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Muskelrelaxanzien (C05AE)
Glyceroltrinitrat (C05AE01)
Isosorbiddinitrat (C05AE02)
Andere Mittel zur Behandlung von
Hämorrhoiden und Analfissuren zur
topischen Anwendung (C05AX)
Aluminium-haltige Zubereitungen
(C05AX01)
Bismutpräparate, Kombinationen
(C05AX02)
Andere Hämorrhoidenmittel,
Kombinationen (C05AX03)
Zinkpräparate (C05AX04)
Tribenosid (C05AX05)
ANTIVARIKOSA (C05B)
Heparine oder Heparinoide zur
topischen Anwendung (C05BA)
Heparinoide (C05BA01)
Natriumapolat (C05BA02)
Heparin (C05BA03)
Natriumpentosanpolysulfat (C05BA04)
Heparinoid, Kombinationen (C05BA51)
Heparin, Kombinationen (C05BA53)
Sklerosierende Mittel zur lokalen
Injektion (C05BB)
Monoethanolaminoleat (C05BB01)
Polidocanol (Lauromacrogol 400)
(C05BB02)
Invertzucker (C05BB03)
Natriumtetradecylsulfat (C05BB04)
Phenol (C05BB05)
Glucose, Kombinationen (C05BB56)
Andere sklerosierende Mittel (C05BX)
Calciumdobesilat (C05BX01)
Calciumdobesilat, Kombinationen
(C05BX51)
KAPILLARSTABILISIERENDE MITTEL
(C05C)
Bioflavonoide (C05CA)
Rutoside (C05CA01)
Monoxerutin (C05CA02)
Diosmin (C05CA03)
Troxerutin (C05CA04)
Hidrosmin (C05CA05)
Rutosid, Kombinationen (C05CA51)
Diosmin, Kombinationen (C05CA53)
Troxerutin, Kombinationen (C05CA54)
Andere kapillarstabilisierende Mittel
(C05CX)
Tribenosid (C05CX01)
BETA-ADRENOZEPTOR-
ANTAGONISTEN (C07)
BETA-ADRENOZEPTOR-
ANTAGONISTEN (C07A)
Beta-Adrenozeptor-Antagonisten,
nichtselektiv (C07AA)
Alprenolol (C07AA01)
Oxprenolol (C07AA02)
Pindolol (C07AA03)
Propranolol (C07AA05)
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Timolol (C07AA06)
Sotalol (C07AA07)
Nadolol (C07AA12)
Mepindolol (C07AA14)
Carteolol (C07AA15)
Tertatolol (C07AA16)
Bopindolol (C07AA17)
Bupranolol (C07AA19)
Penbutolol (C07AA23)
Cloranolol (C07AA27)
Sotalol, Kombinationen (C07AA57)
Beta-Adrenozeptor-Antagonisten,
selektiv (C07AB)
Practolol (C07AB01)
Metoprolol (C07AB02)
Atenolol (C07AB03)
Acebutolol (C07AB04)
Betaxolol (C07AB05)
Bevantolol (C07AB06)
Bisoprolol (C07AB07)
Celiprolol (C07AB08)
Esmolol (C07AB09)
Epanolol (C07AB10)
S-Atenolol (C07AB11)
Nebivolol (C07AB12)
Talinolol (C07AB13)
Metoprolol, Kombinationen (C07AB52)
Bisoprolol, Kombinationen (C07AB57)
Alpha- und Beta-Adrenozeptor-
Antagonisten (C07AG)
Labetalol (C07AG01)
Carvedilol (C07AG02)
BETA-ADRENOZEPTOR-
ANTAGONISTEN UND THIAZIDE
(C07B)
Beta-Adrenozeptor-Antagonisten,
nichtselektiv, und Thiazide (C07BA)
Oxprenolol und Thiazide (C07BA02)
Propranolol und Thiazide (C07BA05)
Timolol und Thiazide (C07BA06)
Sotalol und Thiazide (C07BA07)
Nadolol und Thiazide (C07BA12)
Metipranolol und Thiazide,
Kombinationen (C07BAA68)
Beta-Adrenozeptor-Antagonisten,
selektiv, und Thiazide (C07BB)
Metoprolol und Thiazide (C07BB02)
Atenolol und Thiazide (C07BB03)
Acebutolol und Thiazide (C07BB04)
Bevantolol und Thiazide (C07BB06)
Bisoprolol und Thiazide (C07BB07)
Metoprolol und Thiazide, Kombinationen
(C07BB52)
Alpha- und Beta-Adrenozeptor-
Antagonisten und Thiazide (C07BG)
Labetalol und Thiazide (C07BG01)
BETA-ADRENOZEPTOR-
ANTAGONISTEN UND ANDERE
DIURETIKA (C07C)
Beta-Adrenozeptor-Antagonisten,
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nichtselektiv, und andere Diuretika
(C07CA)
Oxprenolol und andere Diuretika
(C07CA02)
Pindolol und andere Diuretika
(C07CA03)
Bopindolol und andere Diuretika
(C07CA17)
Penbutolol und andere Diuretika
(C07CA23)
Beta-Adrenozeptor-Antagonisten,
selektiv, und andere Diuretika (C07CB)
Metoprolol und andere Diuretika
(C07CB02)
Atenolol und andere Diuretika
(C07CB03)
Atenolol und andere Diuretika,
Kombinationen (C07CB53)
Alpha- und Beta-Adrenozeptor-
Antagonisten und andere Diuretika
(C07CG)
Labetalol und andere Diuretika
(C07CG01)
BETA-ADRENOZEPTOR-
ANTAGONISTEN, THIAZIDE UND
ANDERE DIURETIKA (C07D)
Beta-Adrenozeptor-Antagonisten,
nichtselektiv, Thiazide und andere
Diuretika (C07DA)
Timolol, Thiazide und andere Diuretika
(C07DA06)
Beta-Adrenozeptor-Antagonisten,
selektiv, Thiazide und andere Diuretika
(C07DB)
Atenolol, Thiazide und andere Diuretika
(C07DB01)
BETA-ADRENOZEPTOR-
ANTAGONISTEN UND
VASODILATATOREN (C07E)
Beta-Adrenozeptor-Antagonisten,
nichtselektiv, und Vasodilatatoren
(C07EA)
Beta-Adrenozeptor-Antagonisten,
selektiv, und Vasodilatatoren (C07EB)
BETA-ADRENOZEPTOR-
ANTAGONISTEN UND ANDERE
ANTIHYPERTONIKA (C07F)
Beta-Adrenozeptor-Antagonisten,
nichtselektiv, und andere Antihypertonika
(C07FA)
Propranolol und andere Antihypertonika
(C07FA05)
Beta-Adrenozeptor-Antagonisten,
selektiv, und andere Antihypertonika
(C07FB)
Metoprolol und andere Antihypertonika
(C07FB02)
Atenolol und andere Antihypertonika
(C07FB03)
CALCIUMKANALBLOCKER (C08)
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SELEKTIVE
CALCIUMKANALBLOCKER MIT
VORWIEGENDER GEFÄSSWIRKUNG
(C08C)
Dihydropyridin-Derivate (C08CA)
Amlodipin (C08CA01)
Felodipin (C08CA02)
Isradipin (C08CA03)
Nicardipin (C08CA04)
Nifedipin (C08CA05)
Nimodipin (C08CA06)
Nisoldipin (C08CA07)
Nitrendipin (C08CA08)
Lacidipin (C08CA09)
Nilvadipin (C08CA10)
Manidipin (C08CA11)
Barnidipin (C08CA12)
Lercanidipin (C08CA13)
Cilnidipin (C08CA14)
Benidipin (C08CA15)
Nifedipin, Kombinationen (C08CA55)
Andere selektive Calciumkanalblocker
mit vorwiegender Gefäßwirkung (C08CX)
Mibefradil (C08CX01)
SELEKTIVE
CALCIUMKANALBLOCKER MIT
VORWIEGENDER HERZWIRKUNG
(C08D)
Phenylalkylamin-Derivate (C08DA)
Verapamil (C08DA01)
Gallopamil (C08DA02)
Verapamil, Kombinationen (C08DA51)
Benzothiazepin-Derivate (C08DB)
Diltiazem (C08DB01)
NICHTSELEKTIVE
CALCIUMKANALBLOCKER (C08E)
Phenylalkylamin-Derivate (C08EA)
Fendilin (C08EA01)
Bepridil (C08EA02)
Andere nichtselektive
Calciumkanalblocker (C08EX)
Lidoflazin (C08EX01)
Perhexilin (C08EX02)
CALCIUMKANALBLOCKER UND
DIURETIKA (C08G)
Calciumkanalblocker und Diuretika
(C08GA)
Nifedipin und Diuretika (C08GA01)
MITTEL MIT WIRKUNG AUF DAS
RENIN-ANGIOTENSIN-SYSTEM (C09)
ACE-HEMMER, REIN (C09A)
ACE-Hemmer, rein (C09AA)
Captopril (C09AA01)
Enalapril (C09AA02)
Lisinopril (C09AA03)
Perindopril (C09AA04)
Ramipril (C09AA05)
Quinapril (C09AA06)
Benazepril (C09AA07)
Cilazapril (C09AA08)
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Fosinopril (C09AA09)
Trandolapril (C09AA10)
Spirapril (C09AA11)
Delapril (C09AA12)
Moexipril (C09AA13)
Temocapril (C09AA14)
Zofenopril (C09AA15)
Imidapril (C09AA16)
ACE-HEMMER, KOMBINATIONEN
(C09B)
ACE-Hemmer und Diuretika (C09BA)
Captopril und Diuretika (C09BA01)
Enalapril und Diuretika (C09BA02)
Lisinopril und Diuretika (C09BA03)
Perindopril und Diuretika (C09BA04)
Ramipril und Diuretika (C09BA05)
Quinapril und Diuretika (C09BA06)
Benazepril und Diuretika (C09BA07)
Cilazapril und Diuretika (C09BA08)
Fosinopril und Diuretika (C09BA09)
Delapril und Diuretika (C09BA12)
Moexipril und Diuretika (C09BA13)
Zofenopril und Diuretika (C09BA15)
ACE-Hemmer und Calciumkanalblocker
(C09BB)
Enalapril und Lercanidipin (C09BB02)
Lisinopril und Amlodipin (C09BB03)
Perindopril und Amlodipin (C09BB04)
Ramipril und Felodipin (C09BB05)
Trandolapril und Verapamil (C09BB10)
Delapril und Manidipin (C09BB12)
ANGIOTENSIN-II-ANTAGONISTEN,
REIN (C09C)
Angiotensin-II-Antagonisten, rein
(C09CA)
Losartan (C09CA01)
Eprosartan (C09CA02)
Valsartan (C09CA03)
Irbesartan (C09CA04)
Tasosartan (C09CA05)
Candesartan (C09CA06)
Telmisartan (C09CA07)
Olmesartan medoxomil (C09CA08)
ANGIOTENSIN-II-ANTAGONISTEN,
KOMBINATIONEN (C09D)
Angiotensin-II-Antagonisten und
Diuretika (C09DA)
Losartan und Diuretika (C09DA01)
Eprosartan und Diuretika (C09DA02)
Valsartan und Diuretika (C09DA03)
Irbesartan und Diuretika (C09DA04)
Candesartan und Diuretika (C09DA06)
Telmisartan und Diuretika (C09DA07)
Olmesartan medoxomil und Diuretika
(C09DA08)
Angiotensin-II-Antagonisten und
Calciumkanalblocker (C09DB)
Valsartan und Amlodipin (C09DB01)
Olmesartan medoxomil und Amlodipin
(C09DB02)
14 / 16
ATC C - Cardiovascular System
Telmisartan und Amlodipin (C09DB04)
Angiotensin-II-Antagonisten, andere
Kombinationen (C09DX)
Valsartan, Amlodipin und
Hydrochlorothiazid (C09DX01)
Valsartan und Aliskiren (C09DX02)
ANDERE MITTEL MIT WIRKUNG AUF
DAS RENIN-ANGIOTENSIN-SYSTEM
(C09X)
Renin-Inhibitoren (C09XA)
Remikiren (C09XA01)
Aliskiren (C09XA02)
Aliskiren und Hydrochlorothiazid
(C09XA52)
MITTEL, DIE DEN
LIPIDSTOFFWECHSEL
BEEINFLUSSEN (C10)
MITTEL, DIE DEN
LIPIDSTOFFWECHSEL
BEEINFLUSSEN, REIN (C10A)
HMG-CoA-Reduktasehemmer (C10AA)
Simvastatin (C10AA01)
Lovastatin (C10AA02)
Pravastatin (C10AA03)
Fluvastatin (C10AA04)
Atorvastatin (C10AA05)
Cerivastatin (C10AA06)
Rosuvastatin (C10AA07)
Pitavastatin (C10AA08)
Fibrate (C10AB)
Clofibrat (C10AB01)
Bezafibrat (C10AB02)
Aluminiumclofibrat (C10AB03)
Gemfibrozil (C10AB04)
Fenofibrat (C10AB05)
Simfibrat (C10AB06)
Ronifibrat (C10AB07)
Ciprofibrat (C10AB08)
Etofibrat (C10AB09)
Clofibrid (C10AB10)
Gallensäure bindende Mittel (C10AC)
Colestyramin (C10AC01)
Colestipol (C10AC02)
Colextran (C10AC03)
Colesevelam (C10AC04)
Nicotinsäure und Derivate (C10AD)
Niceritrol (C10AD01)
Nicotinsäure (C10AD02)
Nicofuranose (C10AD03)
Aluminiumnicotinat (C10AD04)
Nicotinylalkohol (Pyridylcarbinol)
(C10AD05)
Acipimox (C10AD06)
Nicotinsäure, Kombinationen (C10AD52)
Andere Mittel, die den Lipidstoffwechsel
beeinflussen (C10AX)
Dextrothyroxin (C10AX01)
Probucol (C10AX02)
Tiadenol (C10AX03)
Meglutol (C10AX05)
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Omega-3-Fettsäuren inkl. andere Ester
und Säuren (C10AX06)
Magnesiumpyridoxal-5-
phosphatglutamat (C10AX07)
Policosanol (C10AX08)
Ezetimib (C10AX09)
Alipogen tiparvovec (C10AX10)
MITTEL, DIE DEN
LIPIDSTOFFWECHSEL
BEEINFLUSSEN, KOMBINATIONEN
(C10B)
HMG-CoA-Reduktasehemmer in
Kombination mit anderen Mitteln, die den
Lipidstoffwechsel beeinflussen (C10BA)
Lovastatin und Nicotinsäure (C10BA01)
Simvastatin und Ezetimib (C10BA02)
Pravastatin und Fenofibrat (C10BA03)
HMG-CoA-Reduktasehemmer, andere
Kombinationen (C10BX)
Simvastatin und Acetylsalicylsäure
(C10BX01)
Pravastatin und Acetylsalicylsäure
(C10BX02)
Atorvastatin und Amlodipin (C10BX03)
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ATC D - Dermatologicals
DERMATIKA
DERMATIKA
DERMATIKA (D)
ANTIMYKOTIKA ZUR
DERMATOLOGISCHEN ANWENDUNG
(D01)
ANTIMYKOTIKA ZUR TOPISCHEN
ANWENDUNG (D01A)
Antibiotika (D01AA)
Nystatin (D01AA01)
Natamycin (D01AA02)
Hachimycin (D01AA03)
Pecilocin (D01AA04)
Mepartricin (D01AA06)
Pyrrolnitrin (D01AA07)
Griseofulvin (D01AA08)
Kombinationen (D01AA20)
Imidazol- und Triazol-Derivate (D01AC)
Clotrimazol (D01AC01)
Miconazol (D01AC02)
Econazol (D01AC03)
Chlormidazol (D01AC04)
Isoconazol (D01AC05)
Tiabendazol (D01AC06)
Tioconazol (D01AC07)
Ketoconazol (D01AC08)
Sulconazol (D01AC09)
Bifonazol (D01AC10)
Oxiconazol (D01AC11)
Fenticonazol (D01AC12)
Omoconazol (D01AC13)
Sertaconazol (D01AC14)
Fluconazol (D01AC15)
Flutrimazol (D01AC16)
Kombinationen (D01AC20)
Miconazol, Kombinationen (D01AC52)
Bifonazol, Kombinationen (D01AC60)
Andere Antimykotika zur topischen
Anwendung (D01AE)
Bromchlorsalicylanilid (D01AE01)
Methylrosanilin (D01AE02)
Tribrommetacresol (D01AE03)
Undecylensäure (D01AE04)
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Polynoxylin (D01AE05)
2-(4-Chlorphenoxy)ethanol (D01AE06)
Chlorphenesin (D01AE07)
Ticlaton (D01AE08)
Sulbentin (D01AE09)
Ethylhydroxybenzoat (D01AE10)
Haloprogin (D01AE11)
Salicylsäure (D01AE12)
Selendisulfid (D01AE13)
Ciclopirox (D01AE14)
Terbinafin (D01AE15)
Amorolfin (D01AE16)
Dimazol (D01AE17)
Tolnaftat (D01AE18)
Tolciclat (D01AE19)
Kombinationen (D01AE20)
Flucytosin (D01AE21)
Naftifin (D01AE22)
Butenafin (D01AE23)
Undecylensäure, Kombinationen
(D01AE54)
ANTIMYKOTIKA ZUR SYSTEMISCHEN
ANWENDUNG (D01B)
Antimykotika zur systemischen
Anwendung (D01BA)
Griseofulvin (D01BA01)
Terbinafin (D01BA02)
EMOLLIENTIA UND
HAUTSCHUTZMITTEL (D02)
EMOLLIENTIA UND
HAUTSCHUTZMITTEL (D02A)
Silikon-haltige Mittel (D02AA)
Zink-haltige Mittel (D02AB)
Vaseline und Fett-haltige Mittel (D02AC)
Flüssige Pflaster (D02AD)
Harnstoff-haltige Mittel (D02AE)
Harnstoff (D02AE01)
Harnstoff, Kombinationen (D02AE51)
Salicylsäure-haltige Zubereitungen
(D02AF)
Andere Emollientia und Hautschutzmittel
(D02AX)
PROTEKTIVA GEGEN UV-
STRAHLUNG (D02B)
Protektiva gegen UV-Strahlung zur
topischen Anwendung (D02BA)
Aminobenzoesäure (D02BA01)
Octinoxat (D02BA02)
Protektiva gegen UV-Strahlung zur
systemischen Anwendung (D02BB)
Betacaroten (D02BB01)
ZUBEREITUNGEN ZUR BEHANDLUNG
VON WUNDEN UND GESCHWÜREN
(D03)
WUNDBEHANDLUNGSMITTEL (D03A)
Lebertransalben (D03AA)
Andere Wundbehandlungsmittel
(D03AX)
Cadexomer-Iod (D03AX01)
Dextranomer (D03AX02)
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Dexpanthenol (D03AX03)
Calciumpantothenat (D03AX04)
Hyaluronsäure (D03AX05)
Becaplermin (D03AX06)
Crilanomer (D03AX09)
Enoxolon (D03AX10)
ENZYME (D03B)
Proteolytische Enzyme (D03BA)
Trypsin (D03BA01)
Kollagenase (D03BA02)
Kollagenase, Kombinationen (D03BA52)
ANTIPRURIGINOSA, INKL.
ANTIHISTAMINIKA, ANÄSTHETIKA
ETC. (D04)
ANTIPRURIGINOSA, INKL.
ANTIHISTAMINIKA, ANÄSTHETIKA
ETC. (D04A)
Antihistaminika zur topischen
Anwendung (D04AA)
Thonzylamin (D04AA01)
Mepyramin (D04AA02)
Thenalidin (D04AA03)
Tripelennamin (D04AA04)
Chloropyramin (D04AA09)
Promethazin (D04AA10)
Tolpropamin (D04AA12)
Dimetinden (D04AA13)
Clemastin (D04AA14)
Bamipin (D04AA15)
Isothipendyl (D04AA22)
Diphenhydramin (D04AA32)
Diphenhydraminmethylbromid
(D04AA33)
Chlorphenoxamin (D04AA34)
Lokalanästhetika (D04AB)
Lidocain (D04AB01)
Cinchocain (D04AB02)
Oxybuprocain (D04AB03)
Benzocain (D04AB04)
Chinisocain (D04AB05)
Tetracain (D04AB06)
Pramocain (D04AB07)
Andere Antipruriginosa (D04AX)
ANTIPSORIATIKA (D05)
ANTIPSORIATIKA ZUR TOPISCHEN
ANWENDUNG (D05A)
Teere (D05AA)
Anthracen-Derivate (D05AC)
Dithranol (D05AC01)
Dithranol, Kombinationen (D05AC51)
Psoralene zur topischen Anwendung
(D05AD)
Trioxysalen (D05AD01)
Methoxsalen (D05AD02)
Andere Antipsoriatika zur topischen
Anwendung (D05AX)
Fumarsäure (D05AX01)
Calcipotriol (D05AX02)
Calcitriol (D05AX03)
Tacalcitol (D05AX04)
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Tazaroten (D05AX05)
Calcipotriol, Kombinationen (D05AX52)
ANTIPSORIATIKA ZUR
SYSTEMISCHEN ANWENDUNG
(D05B)
Psoralene zur systemischen Anwendung
(D05BA)
Trioxysalen (D05BA01)
Methoxsalen (D05BA02)
Bergapten (D05BA03)
Retinoide zur Behandlung der Psoriasis
(D05BB)
Etretinat (D05BB01)
Acitretin (D05BB02)
Andere Antipsoriatika zur systemischen
Anwendung (D05BX)
Fumarsäure-Derivate, Kombinationen
(D05BX51)
ANTIBIOTIKA UND
CHEMOTHERAPEUTIKA ZUR
DERMATOLOGISCHEN ANWENDUNG
(D06)
ANTIBIOTIKA ZUR TOPISCHEN
ANWENDUNG (D06A)
Tetracyclin und Derivate (D06AA)
Demeclocyclin (D06AA01)
Chlortetracyclin (D06AA02)
Oxytetracyclin (D06AA03)
Tetracyclin (D06AA04)
Andere Antibiotika zur topischen
Anwendung (D06AX)
Fusidinsäure (D06AX01)
Chloramphenicol (D06AX02)
Neomycin (D06AX04)
Bacitracin (D06AX05)
Gentamicin (D06AX07)
Tyrothricin (D06AX08)
Mupirocin (D06AX09)
Virginiamycin (D06AX10)
Rifaximin (D06AX11)
Amikacin (D06AX12)
Retapamulin (D06AX13)
CHEMOTHERAPEUTIKA ZUR
TOPISCHEN ANWENDUNG (D06B)
Sulfonamide (D06BA)
Sulfadiazin-Silber (D06BA01)
Sulfathiazol (D06BA02)
Mafenid (D06BA03)
Sulfamethizol (D06BA04)
Sulfanilamid (D06BA05)
Sulfamerazin (D06BA06)
Sulfadiazin-Silber, Kombinationen
(D06BA51)
Antivirale Mittel (D06BB)
Idoxuridin (D06BB01)
Tromantadin (D06BB02)
Aciclovir (D06BB03)
Podophyllotoxin (D06BB04)
Inosin (D06BB05)
Penciclovir (D06BB06)
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Lysozym (D06BB07)
Ibacitabin (D06BB08)
Edoxudin (D06BB09)
Imiquimod (D06BB10)
Docosanol (D06BB11)
Aciclovir, Kombinationen (D06BB53)
Andere Chemotherapeutika (D06BX)
Metronidazol (D06BX01)
ANTIBIOTIKA UND
CHEMOTHERAPEUTIKA,
KOMBINATIONEN (D06C)
CORTICOSTEROIDE,
DERMATOLOGISCHE
ZUBEREITUNGEN (D07)
CORTICOSTEROIDE, REIN (D07A)
Corticosteroide, schwach wirksam
(Gruppe I) (D07AA)
Methylprednisolon (D07AA01)
Hydrocortison (D07AA02)
Prednisolon (D07AA03)
Corticosteroide, mittelstark wirksam
(Gruppe II) (D07AB)
Clobetason (D07AB01)
Hydrocortisonbutyrat (D07AB02)
Flumetason (D07AB03)
Fluocortin (D07AB04)
Fluperolon (D07AB05)
Fluorometholon (D07AB06)
Flupredniden (D07AB07)
Desonid (D07AB08)
Triamcinolon (D07AB09)
Alclometason (D07AB10)
Hydrocortisonbuteprat (D07AB11)
Dexamethason (D07AB19)
Clocortolon (D07AB21)
Kombinationen mittelstark wirksamer
Corticosteroide (D07AB30)
Corticosteroide, stark wirksam (Gruppe
III) (D07AC)
Betamethason (D07AC01)
Fluclorolon (D07AC02)
Desoximetason (D07AC03)
Fluocinolon acetonid (D07AC04)
Fluocortolon (D07AC05)
Diflucortolon (D07AC06)
Fludroxycortid (D07AC07)
Fluocinonid (D07AC08)
Budesonid (D07AC09)
Diflorason (D07AC10)
Amcinonid (D07AC11)
Halometason (D07AC12)
Mometason (D07AC13)
Methylprednisolonaceponat (D07AC14)
Beclometason (D07AC15)
Hydrocortisonaceponat (D07AC16)
Fluticason (D07AC17)
Prednicarbat (D07AC18)
Difluprednat (D07AC19)
Ulobetasol (D07AC21)
Corticosteroide, sehr stark wirksam
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(Gruppe IV) (D07AD)
Clobetasol (D07AD01)
Halcinonid (D07AD02)
CORTICOSTEROIDE,
KOMBINATIONEN MIT ANTISEPTIKA
(D07B)
Corticosteroide, schwach wirksam,
Kombinationen mit Antiseptika (D07BA)
Prednisolon und Antiseptika (D07BA01)
Hydrocortison und Antiseptika
(D07BA04)
Corticosteroide, mittelstark wirksam,
Kombinationen mit Antiseptika (D07BB)
Flumetason und Antiseptika (D07BB01)
Desonid und Antiseptika (D07BB02)
Triamcinolon und Antiseptika (D07BB03)
Hydrocortisonbutyrat und Antiseptika
(D07BB04)
Corticosteroide, stark wirksam,
Kombinationen mit Antiseptika (D07BC)
Betamethason und Antiseptika
(D07BC01)
Fluocinolon acetonid und Antiseptika
(D07BC02)
Fluocortolon und Antiseptika (D07BC03)
Diflucortolon und Antiseptika (D07BC04)
Corticosteroide, sehr stark wirksam,
Kombinationen mit Antiseptika (D07BD)
CORTICOSTEROIDE,
KOMBINATIONEN MIT ANTIBIOTIKA
(D07C)
Corticosteroide, schwach wirksam,
Kombinationen mit Antibiotika (D07CA)
Hydrocortison und Antibiotika
(D07CA01)
Methylprednisolon und Antibiotika
(D07CA02)
Prednisolon und Antibiotika (D07CA03)
Corticosteroide, mittelstark wirksam,
Kombinationen mit Antibiotika (D07CB)
Triamcinolon und Antibiotika (D07CB01)
Flupredniden und Antibiotika (D07CB02)
Fluorometholon und Antibiotika
(D07CB03)
Dexamethason und Antibiotika
(D07CB04)
Flumetason und Antibiotika (D07CB05)
Corticosteroide, stark wirksam,
Kombinationen mit Antibiotika (D07CC)
Betamethason und Antibiotika
(D07CC01)
Fluocinolon acetonid und Antibiotika
(D07CC02)
Fludroxycortid und Antibiotika
(D07CC03)
Beclometason und Antibiotika
(D07CC04)
Fluocinonid und Antibiotika (D07CC05)
Fluocortolon und Antibiotika (D07CC06)
Corticosteroide, sehr stark wirksam,
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Kombinationen mit Antibiotika (D07CD)
Clobetasol und Antibiotika (D07CD01)
CORTICOSTEROIDE, ANDERE
KOMBINATIONEN (D07X)
Corticosteroide, schwach wirksam,
andere Kombinationen (D07XA)
Hydrocortison (D07XA01)
Prednisolon (D07XA02)
Corticosteroide, mittelstark wirksam,
andere Kombinationen (D07XB)
Flumetason (D07XB01)
Triamcinolon (D07XB02)
Flupredniden (D07XB03)
Fluorometholon (D07XB04)
Dexamethason (D07XB05)
Kombinationen mittelstark wirksamer
Corticosteroide (D07XB30)
Corticosteroide, stark wirksam, andere
Kombinationen (D07XC)
Betamethason (D07XC01)
Desoximetason (D07XC02)
Mometason (D07XC03)
Diflucortolon (D07XC04)
Corticosteroide, sehr stark wirksam,
andere Kombinationen (D07XD)
ANTISEPTIKA UND
DESINFEKTIONSMITTEL (D08)
ANTISEPTIKA UND
DESINFEKTIONSMITTEL (D08A)
Acridin-Derivate (D08AA)
Ethacridinlactat (D08AA01)
Aminoacridin (D08AA02)
Euflavin (D08AA03)
Aluminium-haltige Mittel (D08AB)
Biguanide und Amidine (D08AC)
Dibrompropamidin (D08AC01)
Chlorhexidin (D08AC02)
Propamidin (D08AC03)
Hexamidin (D08AC04)
Polihexanid (D08AC05)
Chlorhexidin, Kombinationen (D08AC52)
Borsäure-haltige Mittel (D08AD)
Phenol und Derivate (D08AE)
Hexachlorophen (D08AE01)
Policresulen (D08AE02)
Phenol (D08AE03)
Triclosan (D08AE04)
Chloroxylenol (D08AE05)
Biphenylol (D08AE06)
Nitrofuran-Derivate (D08AF)
Nitrofural (D08AF01)
Iod-haltige Mittel (D08AG)
Iodoctylphenoxypolyglycolether
(D08AG01)
Povidon-Iod (D08AG02)
Iod (D08AG03)
Diiodhydroxypropan (D08AG04)
Chinolin-Derivate (D08AH)
Dequalinium (D08AH01)
Chlorquinaldol (D08AH02)
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Oxichinolin (D08AH03)
Clioquinol (D08AH30)
Quartäre Ammonium-Verbindungen
(D08AJ)
Benzalkonium (D08AJ01)
Cetrimonium (D08AJ02)
Cetylpyridinium (D08AJ03)
Cetrimid (D08AJ04)
Benzoxoniumchlorid (D08AJ05)
Didecyldimethylammoniumchlorid
(D08AJ06)
Benzethoniumchlorid (D08AJ08)
Octenidin, Kombinationen (D08AJ57)
Benzethoniumchlorid, Kombinationen
(D08AJ58)
Dodecloniumbromid, Kombinationen
(D08AJ59)
Quecksilber-haltige Mittel (D08AK)
Quecksilberamidochlorid (D08AK01)
Phenylmercuriborat (D08AK02)
Quecksilberchlorid (D08AK03)
Merbromin (D08AK04)
Metallisches Quecksilber (D08AK05)
Thiomersal (D08AK06)
Quecksilberiodid (D08AK30)
Silber-haltige Verbindungen (D08AL)
Silbernitrat (D08AL01)
Silber (D08AL30)
Andere Antiseptika und
Desinfektionsmittel (D08AX)
Wasserstoffperoxid (D08AX01)
Eosin (D08AX02)
Propanol (D08AX03)
Tosylchloramid-Natrium (D08AX04)
Isopropanol (D08AX05)
Kaliumpermanganat (D08AX06)
Natriumhypochlorit (D08AX07)
Ethanol (D08AX08)
Propanol, Kombinationen (D08AX53)
MEDIZINISCHE VERBÄNDE (D09)
MEDIZINISCHE VERBÄNDE (D09A)
Medizinische Verbände mit Antiinfektiva
(D09AA)
Framycetin (D09AA01)
Fusidinsäure (D09AA02)
Nitrofural (D09AA03)
Phenylquecksilbernitrat (D09AA04)
Benzododecinium (D09AA05)
Triclosan (D09AA06)
Cetylpyridinium (D09AA07)
Aluminiumhydroxychlorid (D09AA08)
Povidon-Iod (D09AA09)
Clioquinol (D09AA10)
Benzalkonium (D09AA11)
Chlorhexidin (D09AA12)
Iodoform (D09AA13)
Zink-haltige Verbände (D09AB)
Zink-haltige Verbände ohne Zusätze
(D09AB01)
Zink-haltige Verbände mit Zusätzen
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(D09AB02)
Vaselin-haltige Verbände (D09AX)
AKNEMITTEL (D10)
AKNEMITTEL ZUR TOPISCHEN
ANWENDUNG (D10A)
Corticosteroide, Kombinationen zur
Behandlung der Akne (D10AA)
Fluorometholon (D10AA01)
Methylprednisolon (D10AA02)
Dexamethason (D10AA03)
Schwefel-haltige Mittel (D10AB)
Bithionol (D10AB01)
Schwefel (D10AB02)
Tioxolon (D10AB03)
Mesulfen (D10AB05)
Retinoide zur topischen Anwendung bei
Akne (D10AD)
Tretinoin (D10AD01)
Retinol (D10AD02)
Adapalen (D10AD03)
Isotretinoin (D10AD04)
Motretinid (D10AD05)
Tretinoin, Kombinationen (D10AD51)
Adapalen, Kombinationen (D10AD53)
Isotretinoin, Kombinationen (D10AD54)
Peroxide (D10AE)
Benzoylperoxid (D10AE01)
Benzoylperoxid, Kombinationen
(D10AE51)
Antiinfektiva zur Behandlung der Akne
(D10AF)
Clindamycin (D10AF01)
Erythromycin (D10AF02)
Chloramphenicol (D10AF03)
Meclocyclin (D10AF04)
Clindamycin, Kombinationen (D10AF51)
Erythromycin, Kombinationen (D10AF52)
Andere Aknemittel zur topischen
Anwendung (D10AX)
Aluminiumchlorid (D10AX01)
Resorcin (D10AX02)
Azelainsäure (D10AX03)
Aluminiumoxid (D10AX04)
Dapson (D10AX05)
Verschiedene Kombinationen (D10AX30)
AKNEMITTEL ZUR SYSTEMISCHEN
ANWENDUNG (D10B)
Retinoide zur Behandlung der Akne
(D10BA)
Isotretinoin (D10BA01)
Andere Aknemittel zur systemischen
Anwendung (D10BX)
Natriumbituminosulfonat (D10BX01)
ANDERE DERMATIKA (D11)
ANDERE DERMATIKA (D11A)
Antihidrotika (D11AA)
Medizinische Haarwaschmittel (D11AC)
Cetrimid (D11AC01)
Cadmium-haltige Verbindungen
(D11AC02)
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Selen-haltige Verbindungen (D11AC03)
Povidon-Iod (D11AC06)
Schwefel-haltige Verbindungen
(D11AC08)
Xenysalat (D11AC09)
Verschiedene (D11AC30)
Androgene zur topischen Anwendung
(D11AE)
Metandienon (D11AE01)
Warzenmittel und Keratolytika (D11AF)
Mittel zur Behandlung der Dermatitis,
exkl. Corticosteroide (D11AH)
Tacrolimus (D11AH01)
Pimecrolimus (D11AH02)
Cromoglicinsäure (D11AH03)
Andere Dermatika (D11AX)
Minoxidil (D11AX01)
Gamolensäure (D11AX02)
Calciumgluconat (D11AX03)
Lithiumsuccinat (D11AX04)
Magnesiumsulfat (D11AX05)
Mequinol (D11AX06)
Tiratricol (D11AX08)
Oxaceprol (D11AX09)
Finasterid (D11AX10)
Hydrochinon (D11AX11)
Pyrithion Zink (D11AX12)
Monobenzon (D11AX13)
Eflornithin (D11AX16)
Diclofenac (D11AX18)
Alitretinoin (D11AX19)
Gamolensäure, Kombinationen
(D11AX52)
Kollagen, Kombinationen (D11AX57)
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ATC G - Genito urinary system and sex
hormones
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ATC G - Genito urinary system and
sex hormones
UROGENITALSYSTEM UND
SEXUALHORMONE
UROGENITALSYSTEM UND
SEXUALHORMONE
UROGENITALSYSTEM UND
SEXUALHORMONE (G)
GYNÄKOLOGISCHE ANTIINFEKTIVA
UND ANTISEPTIKA (G01)
ANTIINFEKTIVA UND ANTISEPTIKA,
EXKL. KOMBINATIONEN MIT
CORTICOSTEROIDEN (G01A)
Antibiotika (G01AA)
Nystatin (G01AA01)
Natamycin (G01AA02)
Amphotericin B (G01AA03)
Candicidin (G01AA04)
Chloramphenicol (G01AA05)
Hachimycin (G01AA06)
Oxytetracyclin (G01AA07)
Carfecillin (G01AA08)
Mepartricin (G01AA09)
Clindamycin (G01AA10)
Pentamycin (G01AA11)
Nystatin, Kombinationen (G01AA51)
Arsen-haltige Verbindungen (G01AB)
Acetarsol (G01AB01)
Chinolin-Derivate (G01AC)
Diiodhydroxychinolin (G01AC01)
Clioquinol (G01AC02)
Chlorquinaldol (G01AC03)
Dequalinium (G01AC05)
Broxychinolin (G01AC06)
Oxychinolin (G01AC30)
Organische Säuren (G01AD)
Milchsäure (G01AD01)
Essigsäure (G01AD02)
Ascorbinsäure (G01AD03)
Sulfonamide (G01AE)
Sulfatolamid (G01AE01)
Kombinationen von Sulfonamiden
(G01AE10)
Imidazol-Derivate (G01AF)
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Metronidazol (G01AF01)
Clotrimazol (G01AF02)
Miconazol (G01AF04)
Econazol (G01AF05)
Ornidazol (G01AF06)
Isoconazol (G01AF07)
Tioconazol (G01AF08)
Ketoconazol (G01AF11)
Fenticonazol (G01AF12)
Azanidazol (G01AF13)
Propenidazol (G01AF14)
Butoconazol (G01AF15)
Omoconazol (G01AF16)
Oxiconazol (G01AF17)
Flutrimazol (G01AF18)
Kombinationen von Imidazol-Derivaten
(G01AF20)
Triazol-Derivate (G01AG)
Terconazol (G01AG02)
Andere Antiinfektiva und Antiseptika
(G01AX)
Clodantoin (G01AX01)
Inosin (G01AX02)
Policresulen (G01AX03)
Nifuratel (G01AX05)
Furazolidon (G01AX06)
Methylrosanilin (G01AX09)
Povidon-Iod (G01AX11)
Ciclopirox (G01AX12)
Protiofat (G01AX13)
Lactobacillus-Ferment (G01AX14)
Kupferusnat (G01AX15)
Octenidin, Kombinationen (G01AX66)
ANTIINFEKTIVA/ANTISEPTIKA IN
KOMBINATION MIT
CORTICOSTEROIDEN (G01B)
Antibiotika und Corticosteroide (G01BA)
Chinolin-Derivate und Corticosteroide
(G01BC)
Antiseptika und Corticosteroide (G01BD)
Sulfonamide und Corticosteroide
(G01BE)
Imidazol-Derivate und Corticosteroide
(G01BF)
ANDERE GYNÄKOLOGIKA (G02)
WEHEN FÖRDERNDE MITTEL (G02A)
Mutterkorn-Alkaloide (G02AB)
Methylergometrin (G02AB01)
Mutterkorn-Alkaloide (G02AB02)
Ergometrin (G02AB03)
Mutterkorn-Alkaloide und Oxytocin inkl.
Derivate, in Kombination (G02AC)
Methylergometrin und Oxytocin
(G02AC01)
Prostaglandine (G02AD)
Dinoprost (G02AD01)
Dinoproston (G02AD02)
Gemeprost (G02AD03)
Carboprost (G02AD04)
Sulproston (G02AD05)
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Misoprostol (G02AD06)
Andere Wehen fördernde Mittel (G02AX)
KONTRAZEPTIVA ZUR LOKALEN
ANWENDUNG (G02B)
Intrauterine Kontrazeptiva (G02BA)
Plastik-IUP (G02BA01)
Plastik-IUP mit Kupfer (G02BA02)
Plastik-IUP mit Gestagen (G02BA03)
Intravaginale Kontrazeptiva (G02BB)
Vaginalring mit Gestagenen und
Estrogenen (G02BB01)
ANDERE GYNÄKOLOGIKA (G02C)
Sympathomimetika, Wehen hemmend
(G02CA)
Ritodrin (G02CA01)
Buphenin (G02CA02)
Fenoterol (G02CA03)
Prolactinhemmer (G02CB)
Bromocriptin (G02CB01)
Lisurid (G02CB02)
Cabergolin (G02CB03)
Quinagolid (G02CB04)
Metergolin (G02CB05)
Tergurid (G02CB06)
Antiphlogistika zur vaginalen Anwendung
(G02CC)
Ibuprofen (G02CC01)
Naproxen (G02CC02)
Benzydamin (G02CC03)
Flunoxaprofen (G02CC04)
Andere Gynäkologika (G02CX)
Atosiban (G02CX01)
SEXUALHORMONE UND
MODULATOREN DES
GENITALSYSTEMS (G03)
HORMONELLE KONTRAZEPTIVA ZUR
SYSTEMISCHEN ANWENDUNG
(G03A)
Gestagene und Estrogene, fixe
Kombinationen (G03AA)
Etynodiol und Ethinylestradiol
(G03AA01)
Quingestanol und Ethinylestradiol
(G03AA02)
Lynestrenol und Ethinylestradiol
(G03AA03)
Megestrol und Ethinylestradiol
(G03AA04)
Norethisteron und Ethinylestradiol
(G03AA05)
Norgestrel und Ethinylestradiol
(G03AA06)
Levonorgestrel und Ethinylestradiol
(G03AA07)
Medroxyprogesteron und Ethinylestradiol
(G03AA08)
Desogestrel und Ethinylestradiol
(G03AA09)
Gestoden und Ethinylestradiol
(G03AA10)
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Norgestimat und Ethinylestradiol
(G03AA11)
Drospirenon und Ethinylestradiol
(G03AA12)
Norelgestromin und Ethinylestradiol
(G03AA13)
Nomegestrol und Estradiol (G03AA14)
Gestagene und Estrogene,
Sequenzialpräparate (G03AB)
Megestrol und Ethinylestradiol
(G03AB01)
Lynestrenol und Ethinylestradiol
(G03AB02)
Levonorgestrel und Ethinylestradiol
(G03AB03)
Norethisteron und Ethinylestradiol
(G03AB04)
Desogestrel und Ethinylestradiol
(G03AB05)
Gestoden und Ethinylestradiol
(G03AB06)
Chlormadinon und Ethinylestradiol
(G03AB07)
Gestagene (G03AC)
Norethisteron (G03AC01)
Lynestrenol (G03AC02)
Levonorgestrel (G03AC03)
Quingestanol (G03AC04)
Megestrol (G03AC05)
Medroxyprogesteron (G03AC06)
Norgestrienon (G03AC07)
Etonogestrel (G03AC08)
Desogestrel (G03AC09)
ANDROGENE (G03B)
3-Oxoandrosten-4-Derivate (G03BA)
Fluoxymesteron (G03BA01)
Methyltestosteron (G03BA02)
Testosteron (G03BA03)
5-Androstanon-3-Derivate (G03BB)
Mesterolon (G03BB01)
Androstanolon (G03BB02)
ESTROGENE (G03C)
Natürliche und halbsynthetische
Estrogene, rein (G03CA)
Ethinylestradiol (G03CA01)
Estradiol (G03CA03)
Estriol (G03CA04)
Chlorotrianisen (G03CA06)
Estron (G03CA07)
Promestrien (G03CA09)
Estradiol, Kombinationen (G03CA53)
Konjugierte Estrogene (G03CA57)
Synthetische Estrogene, rein (G03CB)
Dienestrol (G03CB01)
Diethylstilbestrol (G03CB02)
Methallenestril (G03CB03)
Moxestrol (G03CB04)
Estrogene, Kombinationen mit anderen
Mitteln (G03CC)
Dienestrol (G03CC02)
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Methallenestril (G03CC03)
Estron (G03CC04)
Diethylstilbestrol (G03CC05)
Estriol (G03CC06)
Andere Estrogene (G03CX)
Tibolon (G03CX01)
GESTAGENE (G03D)
Pregnen-4-Derivate (G03DA)
Gestonoron (G03DA01)
Medroxyprogesteron (G03DA02)
Hydroxyprogesteron (G03DA03)
Progesteron (G03DA04)
Pregnadien-Derivate (G03DB)
Dydrogesteron (G03DB01)
Megestrol (G03DB02)
Medrogeston (G03DB03)
Nomegestrol (G03DB04)
Demegeston (G03DB05)
Chlormadinon (G03DB06)
Promegeston (G03DB07)
Estren-Derivate (G03DC)
Allylestrenol (G03DC01)
Norethisteron (G03DC02)
Ethisteron (G03DC04)
Etynodiol (G03DC06)
Methylestrenolon (G03DC31)
Lynestrenol (G03DDC03)
ANDROGENE UND WEIBLICHE
SEXUALHORMONE IN KOMBINATION
(G03E)
Androgene und Estrogene (G03EA)
Methyltestosteron und Estrogen
(G03EA01)
Testosteron und Estrogen (G03EA02)
Prasteron und Estrogen (G03EA03)
Androgen, Gestagen und Estrogen in
Kombination (G03EB)
Androgene und weibliche
Sexualhormone in Kombination mit
anderen Mitteln (G03EK)
Methyltestosteron (G03EK01)
GESTAGENE UND ESTROGENE IN
KOMBINATION (G03F)
Gestagene und Estrogene, fixe
Kombinationen (G03FA)
Norethisteron und Estrogen (G03FA01)
Hydroxyprogesteron und Estrogen
(G03FA02)
Ethisteron und Estrogen (G03FA03)
Progesteron und Estrogen (G03FA04)
Methylnortestosteron und Estrogen
(G03FA05)
Etynodiol und Estrogen (G03FA06)
Lynestrenol und Estrogen (G03FA07)
Megestrol und Estrogen (G03FA08)
Noretynodrel und Estrogen (G03FA09)
Norgestrel und Estrogen (G03FA10)
Levonorgestrel und Estrogen (G03FA11)
Medroxyprogesteron und Estrogen
(G03FA12)
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Norgestimat und Estrogen (G03FA13)
Dydrogesteron und Estrogen (G03FA14)
Dienogest und Estrogen (G03FA15)
Trimegeston und Estrogen (G03FA16)
Drospirenon und Estrogen (G03FA17)
Gestagene und Estrogene,
Sequenzialpräparate (G03FB)
Norgestrel und Estrogen (G03FB01)
Lynestrenol und Estrogen (G03FB02)
Chlormadinon und Estrogen (G03FB03)
Megestrol und Estrogen (G03FB04)
Norethisteron und Estrogen (G03FB05)
Medroxyprogesteron und Estrogen
(G03FB06)
Medrogeston und Estrogen (G03FB07)
Dydrogesteron und Estrogen (G03FB08)
Levonorgestrel und Estrogen (G03FB09)
Desogestrel und Estrogen (G03FB10)
Trimegeston und Estrogen (G03FB11)
GONADOTROPINE UND ANDERE
OVULATIONSAUSLÖSER (G03G)
Gonadotropine (G03GA)
Choriongonadotrophin (G03GA01)
Humanes menopausales Gonadotrophin
(G03GA02)
Serumgonadotrophin (G03GA03)
Urofollitropin (G03GA04)
Follitropin alfa (G03GA05)
Follitropin beta (G03GA06)
Lutropin alfa (G03GA07)
Choriongonadotropin alfa (G03GA08)
Corifollitropin alfa (G03GA09)
Kombinationen (G03GA30)
Ovulationsauslöser, synthetisch
(G03GB)
Cyclofenil (G03GB01)
Clomifen (G03GB02)
Epimestrol (G03GB03)
ANTIANDROGENE (G03H)
Antiandrogene, rein (G03HA)
Cyproteron (G03HA01)
Antiandrogene und Estrogene (G03HB)
Cyproteron und Estrogen (G03HB01)
ANDERE SEXUALHORMONE UND
MODULATOREN DES
GENITALSYSTEMS (G03X)
Antigonadotropine und ähnliche Mittel
(G03XA)
Danazol (G03XA01)
Gestrinon (G03XA02)
Progesteron-Rezeptor-Modulatoren
(G03XB)
Mifepriston (G03XB01)
Selektive Estrogenrezeptor-Modulatoren
(G03XC)
Raloxifen (G03XC01)
Bazedoxifen (G03XC02)
UROLOGIKA (G04)
UROLOGIKA (G04B)
Harn ansäuernde Mittel (G04BA)
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Ammoniumchlorid (G04BA01)
Calciumchlorid (G04BA03)
Harnkonkrement lösende Mittel (G04BC)
Mittel bei häufiger Blasenentleerung und
Harninkontinenz (G04BD)
Emepronium (G04BD01)
Flavoxat (G04BD02)
Meladrazin (G04BD03)
Oxybutynin (G04BD04)
Terodilin (G04BD05)
Propiverin (G04BD06)
Tolterodin (G04BD07)
Solifenacin (G04BD08)
Trospium (G04BD09)
Darifenacin (G04BD10)
Fesoterodin (G04BD11)
Mittel bei erektiler Dysfunktion (G04BE)
Alprostadil (G04BE01)
Papaverin (G04BE02)
Sildenafil (G04BE03)
Yohimbin (G04BE04)
Phentolamin (G04BE05)
Moxisylyt (G04BE06)
Apomorphin (G04BE07)
Tadalafil (G04BE08)
Vardenafil (G04BE09)
Kombinationen (G04BE30)
Papaverin, Kombinationen (G04BE52)
Andere Urologika (G04BX)
Magnesiumhydroxid (G04BX01)
Acetohydroxamsäure (G04BX03)
Phenazopyridin (G04BX06)
Succinimid (G04BX10)
Kollagen (G04BX11)
Phenylsalicylat (G04BX12)
Dimethylsulfoxid (G04BX13)
Dapoxetin (G04BX14)
MITTEL BEI BENIGNER
PROSTATAHYPERPLASIE (G04C)
Alpha-Adrenozeptor-Antagonisten
(G04CA)
Alfuzosin (G04CA01)
Tamsulosin (G04CA02)
Terazosin (G04CA03)
Silodosin (G04CA04)
Alfuzosin und Finasterid (G04CA51)
Tamsulosin und Dutasterid (G04CA52)
Testosteron-5-alpha-Reduktasehemmer
(G04CB)
Finasterid (G04CB01)
Dutasterid (G04CB02)
Andere Mittel bei benigner
Prostatahyperplasie (G04CX)
Pygeum africanum (G04CX01)
Serenoa repens (G04CX02)
Mepartricin (G04CX03)
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ATC H - Systemic hormonal
preparations, excl. sex hormones
and insulins
SYSTEMISCHE HORMONPRÄPARATE,
EXKL. SEXUALHORMONE UND
INSULINE
SYSTEMISCHE HORMONPRÄPARATE, EXKL.
SEXUALHORMONE UND INSULINE
SYSTEMISCHE HORMONPRÄPARATE,
EXKL. SEXUALHORMONE UND
INSULINE (H)
HYPOPHYSEN- UND
HYPOTHALAMUSHORMONE UND
ANALOGA (H01)
HYPOPHYSENVORDERLAPPENHORM
ONE UND ANALOGA (H01A)
ACTH (H01AA)
Corticotropin (H01AA01)
Tetracosactid (H01AA02)
Thyrotropin (H01AB)
Thyrotropin alfa (H01AB01)
Somatropin und Somatropin-Agonisten
(H01AC)
Somatropin (H01AC01)
Somatrem (H01AC02)
Mecasermin (H01AC03)
Sermorelin (H01AC04)
Mecasermin rinfabat (H01AC05)
Andere
Hypophysenvorderlappenhormone und
Analoga (H01AX)
Pegvisomant (H01AX01)
HYPOPHYSENHINTERLAPPENHORM
ONE (H01B)
Vasopressin und Analoga (H01BA)
Vasopressin (H01BA01)
Desmopressin (H01BA02)
Lypressin (H01BA03)
Terlipressin (H01BA04)
Ornipressin (H01BA05)
Argipressin (H01BA06)
Oxytocin und Analoga (H01BB)
Demoxytocin (H01BB01)
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Oxytocin (H01BB02)
Carbetocin (H01BB03)
HYPOTHALAMUSHORMONE (H01C)
Gonadotropin-Releasing-Hormone
(H01CA)
Gonadorelin (H01CA01)
Nafarelin (H01CA02)
Histrelin (H01CA03)
Somatostatin und Analoga (H01CB)
Somatostatin (H01CB01)
Octreotid (H01CB02)
Lanreotid (H01CB03)
Vapreotid (H01CB04)
Gonadotropin-Releasing-Hormon-
Antagonisten (H01CC)
Ganirelix (H01CC01)
Cetrorelix (H01CC02)
CORTICOSTEROIDE ZUR
SYSTEMISCHEN ANWENDUNG (H02)
CORTICOSTEROIDE ZUR
SYSTEMISCHEN ANWENDUNG, REIN
(H02A)
Mineralocorticoide (H02AA)
Aldosteron (H02AA01)
Fludrocortison (H02AA02)
Desoxycorton (H02AA03)
Glucocorticoide (H02AB)
Betamethason (H02AB01)
Dexamethason (H02AB02)
Fluocortolon (H02AB03)
Methylprednisolon (H02AB04)
Paramethason (H02AB05)
Prednisolon (H02AB06)
Prednison (H02AB07)
Triamcinolon (H02AB08)
Hydrocortison (H02AB09)
Cortison (H02AB10)
Prednyliden (H02AB11)
Rimexolon (H02AB12)
Deflazacort (H02AB13)
Cloprednol (H02AB14)
Meprednison (H02AB15)
Cortivazol (H02AB17)
CORTICOSTEROIDE ZUR
SYSTEMISCHEN ANWENDUNG,
KOMBINATIONEN (H02B)
Corticosteroide zur systemischen
Anwendung, Kombinationen (H02BX)
Methylprednisolon, Kombinationen
(H02BX01)
NEBENNIERENHEMMSTOFFE (H02C)
Anticorticosteroide (H02CA)
Trilostan (H02CA01)
SCHILDDRÜSENTHERAPIE (H03)
SCHILDDRÜSENPRÄPARATE (H03A)
Schilddrüsenhormone (H03AA)
Levothyroxin-Natrium (H03AA01)
Liothyronin-Natrium (H03AA02)
Kombinationen von Levothyroxin und
Liothyronin (H03AA03)
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Tiratricol (H03AA04)
Zubereitungen aus Schilddrüsengewebe
(H03AA05)
THYREOSTATIKA (H03B)
Thiouracile (H03BA)
Methylthiouracil (H03BA01)
Propylthiouracil (H03BA02)
Benzylthiouracil (H03BA03)
Schwefel-haltige Imidazol-Derivate
(H03BB)
Carbimazol (H03BB01)
Thiamazol (H03BB02)
Thiamazol, Kombinationen (H03BB52)
Perchlorate (H03BC)
Kaliumperchlorat (H03BC01)
Andere Thyreostatika (H03BX)
Diiodtyrosin (H03BX01)
Dibromtyrosin (H03BX02)
IODTHERAPIE (H03C)
Iodtherapie (H03CA)
PANKREASHORMONE (H04)
GLYKOGENOLYTISCHE HORMONE
(H04A)
Glykogenolytische Hormone (H04AA)
Glucagon (H04AA01)
CALCIUMHOMÖOSTASE (H05)
NEBENSCHILDDRÜSENHORMONE
UND ANALOGA (H05A)
Nebenschilddrüsenhormone und
Analoga (H05AA)
Nebenschilddrüsenextrakt (H05AA01)
Teriparatid (H05AA02)
Parathyroid Hormon (H05AA03)
NEBENSCHILDDRÜSEN-
ANTAGONISTEN (H05B)
Calcitonin-haltige Zubereitungen
(H05BA)
Calcitonin (Lachs, synthetisch)
(H05BA01)
Calcitonin (Schwein, natürlich)
(H05BA02)
Calcitonin (Mensch, synthetisch)
(H05BA03)
Elcatonin (H05BA04)
Andere Nebenschilddrüsen-Antagonisten
(H05BX)
Cinacalcet (H05BX01)
Paricalcitol (H05BX02)
Doxercalciferol (H05BX03)
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ATC J - Antiinfectives for systemic
use
ANTIINFEKTIVA ZUR SYSTEMISCHEN
ANWENDUNG
ANTIINFEKTIVA ZUR SYSTEMISCHEN
ANWENDUNG
B-Pertussis-Poliomyelitis-Tetanus (B-
Pertussis-Poliomyelitis-Tetanus)
B-Pertussis-Poliomyelitis-Tetanus-
Hepatitis B (B-Pertussis-Poliomyelitis-
Tetanus-Hepatitis B)
B-Pertussis-Tetanus-Hepatitis B (B-
Pertussis-Tetanus-Hepatitis B)
B-Pertussis-Tetanus-Hepatitis B-
Meningokokken  A + C (B-Pertussis-
Tetanus-Hepatitis B-Meningokokken  A +
C)
gereinigtes Polysaccharid-Antigen
(gereinigtes Polysaccharid-Antigen)
ANTIINFEKTIVA ZUR SYSTEMISCHEN
ANWENDUNG (J)
ANTIBIOTIKA ZUR SYSTEMISCHEN
ANWENDUNG (J01)
TETRACYCLINE (J01A)
Tetracycline (J01AA)
Demeclocyclin (J01AA01)
Doxycyclin (J01AA02)
Chlortetracyclin (J01AA03)
Lymecyclin (J01AA04)
Metacyclin (J01AA05)
Oxytetracyclin (J01AA06)
Tetracyclin (J01AA07)
Minocyclin (J01AA08)
Rolitetracyclin (J01AA09)
Penimepicyclin (J01AA10)
Clomocyclin (J01AA11)
Tigecyclin (J01AA12)
Kombinationen von Tetracyclinen
(J01AA20)
Oxytetracyclin, Kombinationen
(J01AA56)
AMPHENICOLE (J01B)
Amphenicole (J01BA)
Chloramphenicol (J01BA01)
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Thiamphenicol (J01BA02)
Thiamphenicol, Kombinationen
(J01BA52)
BETALACTAM-ANTIBIOTIKA,
PENICILLINE (J01C)
Penicilline mit erweitertem
Wirkungsspektrum (J01CA)
Ampicillin (J01CA01)
Pivampicillin (J01CA02)
Carbenicillin (J01CA03)
Amoxicillin (J01CA04)
Carindacillin (J01CA05)
Bacampicillin (J01CA06)
Epicillin (J01CA07)
Pivmecillinam (J01CA08)
Azlocillin (J01CA09)
Mezlocillin (J01CA10)
Mecillinam (J01CA11)
Piperacillin (J01CA12)
Ticarcillin (J01CA13)
Metampicillin (J01CA14)
Talampicillin (J01CA15)
Sulbenicillin (J01CA16)
Temocillin (J01CA17)
Hetacillin (J01CA18)
Kombinationen (J01CA20)
Ampicillin, Kombinationen (J01CA51)
Beta-Lactamase-sensitive Penicilline
(J01CE)
Benzylpenicillin (J01CE01)
Phenoxymethylpenicillin (J01CE02)
Propicillin (J01CE03)
Azidocillin (J01CE04)
Pheneticillin (J01CE05)
Penamecillin (J01CE06)
Clometocillin (J01CE07)
Benzylpenicillin-Benzathin (J01CE08)
Benzylpenicillin-Procain (J01CE09)
Phenoxymethylpenicillin-Benzathin
(J01CE10)
Kombinationen (J01CE30)
Beta-Lactamase-resistente Penicilline
(J01CF)
Dicloxacillin (J01CF01)
Cloxacillin (J01CF02)
Meticillin (J01CF03)
Oxacillin (J01CF04)
Flucloxacillin (J01CF05)
Beta-Lactamase-Inhibitoren (J01CG)
Sulbactam (J01CG01)
Tazobactam (J01CG02)
Kombinationen von Penicillinen, inkl.
Beta-Lactamase-Inhibitoren (J01CR)
Ampicillin und Enzym-Inhibitoren
(J01CR01)
Amoxicillin und Enzym-Inhibitoren
(J01CR02)
Ticarcillin und Enzym-Inhibitoren
(J01CR03)
Sultamicillin (J01CR04)
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Piperacillin und Enzym-Inhibitoren
(J01CR05)
Kombinationen von Penicillinen
(J01CR50)
ANDERE BETA-LACTAM-ANTIBIOTIKA
(J01D)
Cephalosporine der 1. Generation
(J01DB)
Cefalexin (J01DB01)
Cefaloridin (J01DB02)
Cefalotin (J01DB03)
Cefazolin (J01DB04)
Cefadroxil (J01DB05)
Cefazedon (J01DB06)
Cefatrizin (J01DB07)
Cefapirin (J01DB08)
Cefradin (J01DB09)
Cefacetril (J01DB10)
Cefroxadin (J01DB11)
Ceftezol (J01DB12)
Cephalosporine der 2. Generation
(J01DC)
Cefoxitin (J01DC01)
Cefuroxim (J01DC02)
Cefamandol (J01DC03)
Cefaclor (J01DC04)
Cefotetan (J01DC05)
Cefonicid (J01DC06)
Cefotiam (J01DC07)
Loracarbef (J01DC08)
Cefmetazol (J01DC09)
Cefprozil (J01DC10)
Ceforanid (J01DC11)
Cephalosporine der 3. Generation
(J01DD)
Cefotaxim (J01DD01)
Ceftazidim (J01DD02)
Cefsulodin (J01DD03)
Ceftriaxon (J01DD04)
Cefmenoxim (J01DD05)
Latamoxef (J01DD06)
Ceftizoxim (J01DD07)
Cefixim (J01DD08)
Cefodizim (J01DD09)
Cefetamet (J01DD10)
Cefpiramid (J01DD11)
Cefoperazon (J01DD12)
Cefpodoxim (J01DD13)
Ceftibuten (J01DD14)
Cefdinir (J01DD15)
Cefditoren (J01DD16)
Cefcapen (J01DD17)
Ceftriaxon, Kombinationen (J01DD54)
Cefoperazon, Kombinationen (J01DD62)
Cephalosporine der 4. Generation
(J01DE)
Cefepim (J01DE01)
Cefpirom (J01DE02)
Cefozopran (J01DE03)
Monobactame (J01DF)
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Aztreonam (J01DF01)
Carbapeneme (J01DH)
Meropenem (J01DH02)
Ertapenem (J01DH03)
Doripenem (J01DH04)
Biapenem (J01DH05)
Imipenem und Enzym-Inhibitoren
(J01DH51)
Panipenem und Betamipron (J01DH55)
Andere Cephalosporine und Peneme
(J01DI)
Ceftobiprol medocaril (J01DI01)
SULFONAMIDE UND TRIMETHOPRIM
(J01E)
Trimethoprim und Derivate (J01EA)
Trimethoprim (J01EA01)
Brodimoprim (J01EA02)
Iclaprim (J01EA03)
Kurz wirkende Sulfonamide (J01EB)
Sulfaisodimidin (J01EB01)
Sulfamethizol (J01EB02)
Sulfadimidin (J01EB03)
Sulfapyridin (J01EB04)
Sulfafurazol (J01EB05)
Sulfanilamid (J01EB06)
Sulfathiazol (J01EB07)
Sulfathiourea (J01EB08)
Kombinationen (J01EB20)
Mittellang wirkende Sulfonamide
(J01EC)
Sulfamethoxazol (J01EC01)
Sulfadiazin (J01EC02)
Sulfamoxol (J01EC03)
Kombinationen (J01EC20)
Lang wirkende Sulfonamide (J01ED)
Sulfadimethoxin (J01ED01)
Sulfalen (J01ED02)
Sulfametomidin (J01ED03)
Sulfametoxydiazin (J01ED04)
Sulfamethoxypyridazin (J01ED05)
Sulfaperin (J01ED06)
Sulfamerazin (J01ED07)
Sulfaphenazol (J01ED08)
Sulfamazon (J01ED09)
Kombinationen (J01ED20)
Kombinationen von Sulfonamiden und
Trimethoprim, inkl. Derivate (J01EE)
Sulfamethoxazol und Trimethoprim
(J01EE01)
Sulfadiazin und Trimethoprim (J01EE02)
Sulfametrol und Trimethoprim (J01EE03)
Sulfamoxol und Trimethoprim (J01EE04)
Sulfadimidin und Trimethoprim
(J01EE05)
Sulfadiazin und Tetroxoprim (J01EE06)
Sulfamerazin und Trimethoprim
(J01EE07)
MAKROLIDE, LINCOSAMIDE UND
STREPTOGRAMINE (J01F)
Makrolide (J01FA)
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Erythromycin (J01FA01)
Spiramycin (J01FA02)
Midecamycin (J01FA03)
Oleandomycin (J01FA05)
Roxithromycin (J01FA06)
Josamycin (J01FA07)
Troleandomycin (J01FA08)
Clarithromycin (J01FA09)
Azithromycin (J01FA10)
Miocamycin (J01FA11)
Rokitamycin (J01FA12)
Dirithromycin (J01FA13)
Flurithromycin (J01FA14)
Telithromycin (J01FA15)
Lincosamide (J01FF)
Clindamycin (J01FF01)
Lincomycin (J01FF02)
Streptogramine (J01FG)
Pristinamycin (J01FG01)
Quinupristin/Dalfopristin (J01FG02)
AMINOGLYKOSID-ANTIBIOTIKA (J01G)
Streptomycine (J01GA)
Streptomycin (J01GA01)
Streptoduocin (J01GA02)
Andere Aminoglykoside (J01GB)
Tobramycin (J01GB01)
Gentamicin (J01GB03)
Kanamycin (J01GB04)
Neomycin (J01GB05)
Amikacin (J01GB06)
Netilmicin (J01GB07)
Sisomicin (J01GB08)
Dibekacin (J01GB09)
Ribostamycin (J01GB10)
Isepamicin (J01GB11)
Arbekacin (J01GB12)
CHINOLONE (J01M)
Fluorchinolone (J01MA)
Ofloxacin (J01MA01)
Ciprofloxacin (J01MA02)
Pefloxacin (J01MA03)
Enoxacin (J01MA04)
Temafloxacin (J01MA05)
Norfloxacin (J01MA06)
Lomefloxacin (J01MA07)
Fleroxacin (J01MA08)
Sparfloxacin (J01MA09)
Rufloxacin (J01MA10)
Grepafloxacin (J01MA11)
Levofloxacin (J01MA12)
Trovafloxacin (J01MA13)
Moxifloxacin (J01MA14)
Gemifloxacin (J01MA15)
Gatifloxacin (J01MA16)
Prulifloxacin (J01MA17)
Pazufloxacin (J01MA18)
Garenoxacin (J01MA19)
Andere Chinolone (J01MB)
Rosoxacin (J01MB01)
Nalidixinsäure (J01MB02)
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Piromidsäure (J01MB03)
Pipemidsäure (J01MB04)
Oxolinsäure (J01MB05)
Cinoxacin (J01MB06)
Flumequin (J01MB07)
KOMBINATIONEN VON ANTIBIOTIKA
(J01R)
Kombinationen von Antibiotika (J01RA)
Penicilline, Kombination mit anderen
Antibiotika (J01RA01)
Sulfonamide, Kombination mit anderen
Antibiotika (exkl. Trimethoprim)
(J01RA02)
Cefuroxim, Kombination mit anderen
Antibiotika (J01RA03)
Spiramycin, Kombination mit anderen
Antibiotika (J01RA04)
ANDERE ANTIBIOTIKA (J01X)
Glycopeptid-Antibiotika (J01XA)
Vancomycin (J01XA01)
Teicoplanin (J01XA02)
Telavancin (J01XA03)
Dalbavancin (J01XA04)
Oritavancin (J01XA05)
Polymyxine (J01XB)
Colistin (J01XB01)
Polymyxin B (J01XB02)
Steroid-Antibiotika (J01XC)
Fusidinsäure (J01XC01)
Imidazol-Derivate (J01XD)
Metronidazol (J01XD01)
Tinidazol (J01XD02)
Ornidazol (J01XD03)
Nitrofuran-Derivate (J01XE)
Nitrofurantoin (J01XE01)
Nifurtoinol (J01XE02)
Andere Antibiotika (J01XX)
Fosfomycin (J01XX01)
Xibornol (J01XX02)
Clofoctol (J01XX03)
Spectinomycin (J01XX04)
Methenamin (J01XX05)
Mandelsäure (J01XX06)
Nitroxolin (J01XX07)
Linezolid (J01XX08)
Daptomycin (J01XX09)
Bacitracin (J01XX10)
ANTIMYKOTIKA ZUR SYSTEMISCHEN
ANWENDUNG (J02)
ANTIMYKOTIKA ZUR SYSTEMISCHEN
ANWENDUNG (J02A)
Antibiotika (J02AA)
Amphotericin B (J02AA01)
Hachimycin (J02AA02)
Imidazol-Derivate (J02AB)
Miconazol (J02AB01)
Ketoconazol (J02AB02)
Triazol-Derivate (J02AC)
Fluconazol (J02AC01)
Itraconazol (J02AC02)
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Voriconazol (J02AC03)
Posaconazol (J02AC04)
Andere Antimykotika zur systemischen
Anwendung (J02AX)
Flucytosin (J02AX01)
Caspofungin (J02AX04)
Micafungin (J02AX05)
Anidulafungin (J02AX06)
MITTEL GEGEN MYKOBAKTERIEN
(J04)
MITTEL ZUR BEHANDLUNG DER
TUBERKULOSE (J04A)
Aminosalicylsäure und Derivate (J04AA)
Aminosalicylsäure (J04AA01)
Natriumaminosalicylat (J04AA02)
Calciumaminosalicylat (J04AA03)
Antibiotika (J04AB)
Cycloserin (J04AB01)
Rifampicin (J04AB02)
Rifamycin (J04AB03)
Rifabutin (J04AB04)
Rifapentin (J04AB05)
Capreomycin (J04AB30)
Hydrazide (J04AC)
Isoniazid (J04AC01)
Isoniazid, Kombinationen (J04AC51)
Thiocarbamid-Derivate (J04AD)
Protionamid (J04AD01)
Tiocarlid (J04AD02)
Ethionamid (J04AD03)
Andere Mittel zur Behandlung der
Tuberkulose (J04AK)
Pyrazinamid (J04AK01)
Ethambutol (J04AK02)
Terizidon (J04AK03)
Morinamid (J04AK04)
Kombinationen von Mitteln zur
Behandlung der Tuberkulose (J04AM)
Streptomycin und Isoniazid (J04AM01)
Rifampicin und Isoniazid (J04AM02)
Ethambutol und Isoniazid (J04AM03)
Thioacetazon und Isoniazid (J04AM04)
Rifampicin, Pyrazinamid und Isoniazid
(J04AM05)
Rifampicin, Pyrazinamid, Ethambutol und
Isoniazid (J04AM06)
MITTEL ZUR BEHANDLUNG DER
LEPRA (J04B)
Mittel zur Behandlung der Lepra (J04BA)
Clofazimin (J04BA01)
Dapson (J04BA02)
Aldesulfonnatrium (J04BA03)
ANTIVIRALE MITTEL ZUR
SYSTEMISCHEN ANWENDUNG (J05)
DIREKT WIRKENDE ANTIVIRALE
MITTEL (J05A)
Thiosemicarbazone (J05AA)
Metisazon (J05AA01)
Nukleoside und Nukleotide, exkl.
Inhibitoren der Reversen Transkriptase
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(J05AB)
Aciclovir (J05AB01)
Idoxuridin (J05AB02)
Vidarabin (J05AB03)
Ribavirin (J05AB04)
Ganciclovir (J05AB06)
Famciclovir (J05AB09)
Valaciclovir (J05AB11)
Cidofovir (J05AB12)
Penciclovir (J05AB13)
Valganciclovir (J05AB14)
Brivudin (J05AB15)
Cyclische Amine (J05AC)
Rimantadin (J05AC02)
Tromantadin (J05AC03)
Phosphonsäure-Derivate (J05AD)
Foscarnet (J05AD01)
Fosfonet (J05AD02)
Proteasehemmer (J05AE)
Saquinavir (J05AE01)
Indinavir (J05AE02)
Ritonavir (J05AE03)
Nelfinavir (J05AE04)
Amprenavir (J05AE05)
Lopinavir (J05AE06)
Fosamprenavir (J05AE07)
Atazanavir (J05AE08)
Tipranavir (J05AE09)
Darunavir (J05AE10)
Nukleosidale und nukleotidale Inhibitoren
der Reversen Transkriptase (J05AF)
Zidovudin (J05AF01)
Didanosin (J05AF02)
Zalcitabin (J05AF03)
Stavudin (J05AF04)
Lamivudin (J05AF05)
Abacavir (J05AF06)
Tenofovir disoproxil (J05AF07)
Adefovir dipivoxil (J05AF08)
Emtricitabin (J05AF09)
Entecavir (J05AF10)
Telbivudin (J05AF11)
Clevudin (J05AF12)
Nicht-Nukleosidale Inhibitoren der
Reversen Transkriptase (J05AG)
Nevirapin (J05AG01)
Delavirdin (J05AG02)
Efavirenz (J05AG03)
Etravirin (J05AG04)
Neuraminidasehemmer (J05AH)
Zanamivir (J05AH01)
Oseltamivir (J05AH02)
Antivirale Mittel zur Behandlung von HIV
Infektionen, Kombinationen (J05AR)
Zidovudin und Lamivudin (J05AR01)
Lamivudin und Abacavir (J05AR02)
Tenofovir disoproxil und Emtricitabin
(J05AR03)
Zidovudin, Lamivudin und Abacavir
(J05AR04)
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Zidovudin, Lamivudin und Nevirapin
(J05AR05)
Emtricitabin, Tenofovir disoproxil und
Efavirenz (J05AR06)
Stavudin, Lamivudin und Nevirapin
(J05AR07)
Andere antivirale Mittel (J05AX)
Moroxydin (J05AX01)
Lysozym (J05AX02)
Inosin pranobex (J05AX05)
Pleconaril (J05AX06)
Enfuvirtid (J05AX07)
Raltegravir (J05AX08)
Maraviroc (J05AX09)
Maribavir (J05AX10)
IMMUNSERA UND IMMUNGLOBULINE
(J06)
IMMUNSERA (J06A)
Immunsera (J06AA)
Diphtherie-Antitoxin (J06AA01)
Tetanus-Antitoxin (J06AA02)
Schlangengift-Antiserum (J06AA03)
Botulismus-Antitoxin (J06AA04)
Gasbrand-Serum (J06AA05)
Tollwut-Serum (J06AA06)
IMMUNGLOBULINE (J06B)
Immunglobuline, normal human (J06BA)
Immunglobuline, normal human, zur
extravasalen Anwendung (J06BA01)
Immunglobuline, normal human, zur
intravasalen Anwendung (J06BA02)
Spezifische Immunglobuline (J06BB)
Anti-D(rh)-Immunglobulin (J06BB01)
Tetanus-Immunglobulin (J06BB02)
Varicella/Zoster-Immunglobulin
(J06BB03)
Hepatitis-B-Immunglobulin (J06BB04)
Tollwut-Immunglobulin (J06BB05)
Röteln-Immunglobulin (J06BB06)
Kuhpocken-Immunglobulin (J06BB07)
Staphylococcus-Immunglobulin
(J06BB08)
Cytomegalievirus-Immunglobulin
(J06BB09)
Diphtherie-Immunglobulin (J06BB10)
Hepatitis-A-Immunglobulin (J06BB11)
FSME-Immunglobulin (J06BB12)
Pertussis-Immunglobulin (J06BB13)
Masern-Immunglobulin (J06BB14)
Mumps-Immunglobulin (J06BB15)
Palivizumab (J06BB16)
Kombinationen (J06BB30)
Andere Immunglobuline (J06BC)
Nebacumab (J06BC01)
IMPFSTOFFE (J07)
BAKTERIELLE IMPFSTOFFE (J07A)
Milzbrand-Impfstoffe (J07AC)
Anthrax-Antigen (J07AC01)
Brucellose-Impfstoffe (J07AD)
Brucella-Antigen (J07AD01)
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Cholera-Impfstoffe (J07AE)
Cholera, inaktiviert, ganze Zelle
(J07AE01)
Cholera, lebend abgeschwächt
(J07AE02)
Cholera, Kombinationen mit Typhus-
Impfstoff, inaktiviert, ganze Zelle
(J07AE51)
Diphtherie-Impfstoffe (J07AF)
Diphtherie-Toxoid (J07AF01)
Haemophilus influenzae B-Impfstoffe
(J07AG)
Haemophilus influenzae B, gereinigtes
Antigen konjugiert (J07AG01)
Haemophilus influenzae B,
Kombinationen mit Toxoiden (J07AG51)
Haemophilus influenzae B,
Kombinationen mit Pertussis und
Toxoiden (J07AG52)
Haemophilus influenzae B,
Kombinationen mit Meningokokken C,
(J07AG53)
Meningokokken-Impfstoffe (J07AH)
Meningokokken A, gereinigtes
Polysaccharid-Antigen (J07AH01)
Andere Meningokokken monovalent,
(J07AH02)
Meningokokken bivalent (A, C),
gereinigtes Polysaccharid-Antigen
(J07AH03)
Meningokokken tetravalent (A, C, Y, W-
135), gereinigtes Polysaccharid-Antigen
(J07AH04)
Andere Meningokokken polyvalent,
gereinigtes Polysaccharid-Antigen
(J07AH05)
Meningokokken B-Polysaccharid-
Impfstoff, monovalent (J07AH06)
Meningokokken C, gereinigtes
Polysaccharid-Antigen, konjugiert
(J07AH07)
Meningokokken tetravalent (A, C, Y, W-
135), gereinigtes Polysaccharid-Antigen,
konjugiert (J07AH08)
Pertussis-Impfstoffe (J07AJ)
Pertussis, inaktiviert, ganze Zelle
(J07AJ01)
Pertussis, gereinigtes Antigen (J07AJ02)
Pertussis, inaktiviert, ganze Zelle,
Kombinationen mit Toxoiden (J07AJ51)
Pertussis, gereinigtes Antigen,
Kombinationen mit Toxoiden (J07AJ52)
Pest-Impfstoffe (J07AK)
Pest, inaktiviert, ganze Zelle (J07AK01)
Pneumokokken-Impfstoffe (J07AL)
Pneumokokken, gereinigtes
Polysaccharid-Antigen (J07AL01)
Pneumokokken, gereinigtes
Polysaccharid-Antigen, konjugiert
(J07AL02)
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Pneumokokken, gereinigtes
Polysaccharid-Antigen und Haemophilus
influenzae B, konjugiert (J07AL52)
Tetanus-Impfstoffe (J07AM)
Tetanus-Toxoid (J07AM01)
Tetanus-Toxoid, Kombinationen mit
Diphtherie-Toxoid (J07AM51)
Tetanus-Toxoid, Kombinationen mit
Tetanus-Immunglobulin (J07AM52)
Tuberkulose-Impfstoffe (J07AN)
Tuberkulose, lebend abgeschwächt
(J07AN01)
Typhus-Impfstoffe (J07AP)
Typhus, oral, lebend abgeschwächt
(J07AP01)
Typhus, inaktiviert, ganze Zelle
(J07AP02)
Typhus, gereinigtes Polysaccharid-
Antigen (J07AP03)
Typhus, Kombinationen mit
Paratyphustypen (J07AP10)
Typhus (exanthematicus)-Impfstoffe
(J07AR)
Typhus exanthematicus, inaktiviert,
ganze Zelle (J07AR01)
Andere bakterielle Impfstoffe (J07AX)
VIRALE IMPFSTOFFE (J07B)
Encephalitis-Impfstoffe (J07BA)
FSME, inaktiviert, ganzes Virus
(J07BA01)
Encephalitis, japanische, inaktiviert,
ganzes Virus (J07BA02)
Influenza-Impfstoffe (J07BB)
Influenza, inaktiviert, ganzes Virus
(J07BB01)
Influenza, inaktiviert, Spaltvirus oder
Oberflächenantigen (J07BB02)
Influenza, lebend abgeschwächt
(J07BB03)
Hepatitis-Impfstoffe (J07BC)
Hepatitis B, gereinigtes Antigen
(J07BC01)
Hepatitis A, inaktiviert, ganzes Virus
(J07BC02)
Kombinationen (J07BC20)
Masern-Impfstoffe (J07BD)
Masern, lebend abgeschwächt
(J07BD01)
Masern, Kombinationen mit Mumps,
lebend abgeschwächt (J07BD51)
Masern, Kombinationen mit Mumps und
Röteln, lebend abgeschwächt (J07BD52)
Masern, Kombinationen  mit Röteln,
lebend abgeschwächt (J07BD53)
Masern, Kombinationen mit Mumps,
Röteln und Varicella, lebend
abgeschwächt (J07BD54)
Mumps-Impfstoffe (J07BE)
Mumps, lebend abgeschwächt
(J07BE01)
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Poliomyelitis-Impfstoffe (J07BF)
Poliomyelitis, oral, monovalent, lebend
abgeschwächt (J07BF01)
Poliomyelitis, oral, trivalent, lebend
abgeschwächt (J07BF02)
Poliomyelitis, trivalent, inaktiviert, ganzes
Virus (J07BF03)
Tollwut-Impfstoffe (J07BG)
Tollwut, inaktiviert, ganzes Virus
(J07BG01)
Rotavirus-Diarrhoe-Impfstoffe (J07BH)
Rotavirus, lebend abgeschwächt
(J07BH01)
Rotavirus, pentavalent, lebend,
Reassortanten (J07BH02)
Röteln-Impfstoffe (J07BJ)
Röteln, lebend abgeschwächt (J07BJ01)
Röteln, Kombinationen mit Mumps,
lebend abgeschwächt (J07BJ51)
Varicella Zoster Impfstoffe (J07BK)
Varicella, lebend abgeschwächt
(J07BK01)
Zoster Virus, lebend abgeschwächt
(J07BK02)
Gelbfieber-Impfstoffe (J07BL)
Gelbfieber, lebend abgeschwächt
(J07BL01)
Papillomvirus-Impfstoffe (J07BM)
Humaner Papillomvirus-Impfstoff (Typen
6,11,16,18) (J07BM01)
Humaner Papillomvirus-Impfstoff (Typen
16,18) (J07BM02)
Andere virale Impfstoffe (J07BX)
BAKTERIELLE UND VIRALE
IMPFSTOFFE, KOMBINIERT (J07C)
Bakterielle und virale Impfstoffe,
kombiniert (J07CA)
Diphtherie-Poliomyelitis-Tetanus
(J07CA01)
Diphtherie-Pertussis-Poliomyelitis-
Tetanus (J07CA02)
Diphtherie-Röteln-Tetanus (J07CA03)
Haemophilus influenzae B und
Poliomyelitis (J07CA04)
Diphtherie-Hepatitis B-Pertussis-Tetanus
(J07CA05)
Diphtherie-Haemophilus influenzae
(J07CA06)
Diphtherie-Hepatitis B-Tetanus
(J07CA07)
Haemophilus influenzae B und Hepatitis
B (J07CA08)
Diphtherie-Haemophilus influenzae
(J07CA09)
Typhus-Hepatitis A (J07CA10)
Diphtherie-Haemophilus influenzae
(J07CA11)
Diphtherie-Pertussis-Poliomyelitis-
Tetanus-Hepatitis B (J07CA12)
Diphtherie-Haemophilus influenzae
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(J07CA13)
ANDERE IMPFSTOFFE (J07X)
konjugiert (konjugiert)
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ATC L - Antineoplastic and
immunomodulating agents
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ATC L - Antineoplastic and
immunomodulating agents
ANTINEOPLASTISCHE UND
IMMUNMODULIERENDE MITTEL
ANTINEOPLASTISCHE UND
IMMUNMODULIERENDE MITTEL
ANTINEOPLASTISCHE UND
IMMUNMODULIERENDE MITTEL (L)
ANTINEOPLASTISCHE MITTEL (L01)
ALKYLIERENDE MITTEL (L01A)
Stickstofflost-Analoga (L01AA)
Cyclophosphamid (L01AA01)
Chlorambucil (L01AA02)
Melphalan (L01AA03)
Chlormethin (L01AA05)
Ifosfamid (L01AA06)
Trofosfamid (L01AA07)
Prednimustin (L01AA08)
Bendamustin (L01AA09)
Alkylsulfonate (L01AB)
Busulfan (L01AB01)
Treosulfan (L01AB02)
Mannosulfan (L01AB03)
Ethylenimine (L01AC)
Thiotepa (L01AC01)
Triaziquon (L01AC02)
Carboquon (L01AC03)
Nitrosoharnstoffe (L01AD)
Carmustin (L01AD01)
Lomustin (L01AD02)
Semustin (L01AD03)
Streptozocin (L01AD04)
Fotemustin (L01AD05)
Nimustin (L01AD06)
Ranimustin (L01AD07)
Epoxide (L01AG)
Etoglucid (L01AG01)
Andere alkylierende Mittel (L01AX)
Mitobronitol (L01AX01)
Pipobroman (L01AX02)
Temozolomid (L01AX03)
Dacarbazin (L01AX04)
ANTIMETABOLITEN (L01B)
Folsäure-Analoga (L01BA)
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Methotrexat (L01BA01)
Raltitrexed (L01BA03)
Pemetrexed (L01BA04)
Pralatrexat (L01BA05)
Purin-Analoga (L01BB)
Mercaptopurin (L01BB02)
Tioguanin (L01BB03)
Cladribin (L01BB04)
Fludarabin (L01BB05)
Clofarabin (L01BB06)
Nelarabin (L01BB07)
Pyrimidin-Analoga (L01BC)
Cytarabin (L01BC01)
Fluorouracil (L01BC02)
Tegafur (L01BC03)
Carmofur (L01BC04)
Gemcitabin (L01BC05)
Capecitabin (L01BC06)
Azacitidin (L01BC07)
Decitabin (L01BC08)
Fluorouracil, Kombinationen (L01BC52)
Tegafur, Kombinationen (L01BC53)
PFLANZLICHE ALKALOIDE UND
ANDERE NATÜRLICHE MITTEL (L01C)
Vinka-Alkaloide und Analoga (L01CA)
Vinblastin (L01CA01)
Vincristin (L01CA02)
Vindesin (L01CA03)
Vinorelbin (L01CA04)
Vinflunin (L01CA05)
Podophyllotoxin-Derivate (L01CB)
Etoposid (L01CB01)
Teniposid (L01CB02)
Colchicin-Derivate (L01CC)
Demecolcin (L01CC01)
Taxane (L01CD)
Paclitaxel (L01CD01)
Docetaxel (L01CD02)
Paclitaxel poliglumex (L01CD03)
Andere pflanzliche Alkaloide und
natürliche Mittel (L01CX)
Trabectedin (L01CX01)
ZYTOTOXISCHE ANTIBIOTIKA UND
VERWANDTE SUBSTANZEN (L01D)
Actinomycine (L01DA)
Dactinomycin (L01DA01)
Anthracycline und verwandte
Substanzen (L01DB)
Doxorubicin (L01DB01)
Daunorubicin (L01DB02)
Epirubicin (L01DB03)
Aclarubicin (L01DB04)
Zorubicin (L01DB05)
Idarubicin (L01DB06)
Mitoxantron (L01DB07)
Pirarubicin (L01DB08)
Valrubicin (L01DB09)
Andere zytotoxische Antibiotika (L01DC)
Bleomycin (L01DC01)
Plicamycin (L01DC02)
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Mitomycin (L01DC03)
Ixabepilon (L01DC04)
ANDERE ANTINEOPLASTISCHE
MITTEL (L01X)
Platin-haltige Verbindungen (L01XA)
Cisplatin (L01XA01)
Carboplatin (L01XA02)
Oxaliplatin (L01XA03)
Satraplatin (L01XA04)
Methylhydrazine (L01XB)
Procarbazin (L01XB01)
Monoklonale Antikörper (L01XC)
Edrecolomab (L01XC01)
Rituximab (L01XC02)
Trastuzumab (L01XC03)
Alemtuzumab (L01XC04)
Gemtuzumab (L01XC05)
Cetuximab (L01XC06)
Bevacizumab (L01XC07)
Panitumumab (L01XC08)
Catumaxomab (L01XC09)
Ofatumumab (L01XC10)
Sensibilisatoren für die
photodynamische/Radio-Therapie
(L01XD)
Porfimer natrium (L01XD01)
Methylaminolevulinat (L01XD03)
Aminolevulinsäure (L01XD04)
Temoporfin (L01XD05)
Efaproxiral (L01XD06)
Proteinkinase-Inhibitoren (L01XE)
Imatinib (L01XE01)
Gefitinib (L01XE02)
Erlotinib (L01XE03)
Sunitinib (L01XE04)
Sorafenib (L01XE05)
Dasatinib (L01XE06)
Lapatinib (L01XE07)
Nilotinib (L01XE08)
Temsirolimus (L01XE09)
Everolimus (L01XE10)
Pazopanib (L01XE11)
Andere antineoplastische Mittel (L01XX)
Amsacrin (L01XX01)
Asparaginase (L01XX02)
Altretamin (L01XX03)
Hydroxycarbamid (L01XX05)
Lonidamin (L01XX07)
Pentostatin (L01XX08)
Miltefosin (L01XX09)
Masoprocol (L01XX10)
Estramustin (L01XX11)
Tretinoin (L01XX14)
Mitoguazon (L01XX16)
Topotecan (L01XX17)
Tiazofurin (L01XX18)
Irinotecan (L01XX19)
Alitretinoin (L01XX22)
Mitotan (L01XX23)
Pegaspargase (L01XX24)
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Bexaroten (L01XX25)
Arsentrioxid (L01XX27)
Denileukin diftitox (L01XX29)
Bortezomib (L01XX32)
Celecoxib (L01XX33)
Anagrelid (L01XX35)
Oblimersen (L01XX36)
Sitimagen ceradenovec (L01XX37)
Vorinostat (L01XX38)
Romidepsin (L01XX39)
Kombinationen von antineoplastischen
Mitteln (L01XY)
ENDOKRINE THERAPIE (L02)
HORMONE UND VERWANDTE MITTEL
(L02A)
Estrogene (L02AA)
Diethylstilbestrol (L02AA01)
Polyestradiolphosphat (L02AA02)
Ethinylestradiol (L02AA03)
Fosfestrol (L02AA04)
Gestagene (L02AB)
Megestrol (L02AB01)
Medroxyprogesteron (L02AB02)
Gestonoron (L02AB03)
Gonadotropin-Releasing-Hormon-
Analoga (L02AE)
Buserelin (L02AE01)
Leuprorelin (L02AE02)
Goserelin (L02AE03)
Triptorelin (L02AE04)
Andere Hormone (L02AX)
HORMONANTAGONISTEN UND
VERWANDTE MITTEL (L02B)
Antiestrogene (L02BA)
Tamoxifen (L02BA01)
Toremifen (L02BA02)
Fulvestrant (L02BA03)
Antiandrogene (L02BB)
Flutamid (L02BB01)
Nilutamid (L02BB02)
Bicalutamid (L02BB03)
Aromatase-Inhibitoren (L02BG)
Aminoglutethimid (L02BG01)
Formestan (L02BG02)
Anastrozol (L02BG03)
Letrozol (L02BG04)
Vorozol (L02BG05)
Exemestan (L02BG06)
Andere Hormonantagonisten und
verwandte Mittel (L02BX)
Abarelix (L02BX01)
Degarelix (L02BX02)
IMMUNSTIMULANZIEN (L03)
IMMUNSTIMULANZIEN (L03A)
Koloniestimulierende Faktoren (L03AA)
Filgrastim (L03AA02)
Molgramostim (L03AA03)
Sargramostim (L03AA09)
Lenograstim (L03AA10)
Ancestim (L03AA12)
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Pegfilgrastim (L03AA13)
Interferone (L03AB)
Interferon alfa, natürlich (L03AB01)
Interferon beta, natürlich (L03AB02)
Interferon gamma (L03AB03)
Interferon alfa-2a (L03AB04)
Interferon alfa-2b (L03AB05)
Interferon alfa-n1 (L03AB06)
Interferon beta-1a (L03AB07)
Interferon beta-1b (L03AB08)
Interferon alfacon-1 (L03AB09)
Peginterferon alfa-2b (L03AB10)
Peginterferon alfa-2a (L03AB11)
Peginterferon alfa-2b, Kombinationen
(L03AB60)
Peginterferon alfa-2a, Kombinationen
(L03AB61)
Interleukine (L03AC)
Aldesleukin (L03AC01)
Oprelvekin (L03AC02)
Andere Immunstimulanzien (L03AX)
Lentinan (L03AX01)
Roquinimex (L03AX02)
BCG-Impfstoff (L03AX03)
Pegademase (L03AX04)
Pidotimod (L03AX05)
Poly I:C (L03AX07)
Poly ICLC (L03AX08)
Thymopentin (L03AX09)
Immunocyanin (L03AX10)
Tasonermin (L03AX11)
Melanom-Impfstoff (L03AX12)
Glatirameracetat (L03AX13)
Histamin dihydrochlorid (L03AX14)
Mifamurtid (L03AX15)
Plerixafor (L03AX16)
IMMUNSUPPRESSIVA (L04)
IMMUNSUPPRESSIVA (L04A)
Selektive Immunsuppressiva (L04AA)
Muromonab-CD3 (L04AA02)
Antilymphozytäres Immunglobulin (Pferd)
(L04AA03)
Antithymozytäres Immunglobulin
(Kaninchen) (L04AA04)
Mycophenolsäure (L04AA06)
Sirolimus (L04AA10)
Leflunomid (L04AA13)
Alefacept (L04AA15)
Everolimus (L04AA18)
Gusperimus (L04AA19)
Efalizumab (L04AA21)
Abetimus (L04AA22)
Natalizumab (L04AA23)
Abatacept (L04AA24)
Eculizumab (L04AA25)
Tumornekrosefaktor alpha(TNF-alpha)-
Inhibitoren (L04AB)
Etanercept (L04AB01)
Infliximab (L04AB02)
Afelimomab (L04AB03)
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Adalimumab (L04AB04)
Certolizumab pegol (L04AB05)
Golimumab (L04AB06)
Interleukin-Inhibitoren (L04AC)
Daclizumab (L04AC01)
Basiliximab (L04AC02)
Anakinra (L04AC03)
Rilonacept (L04AC04)
Ustekinumab (L04AC05)
Mepolizumab (L04AC06)
Tocilizumab (L04AC07)
Canakinumab (L04AC08)
Calcineurin-Inhibitoren (L04AD)
Ciclosporin (L04AD01)
Tacrolimus (L04AD02)
Andere Immunsuppressiva (L04AX)
Azathioprin (L04AX01)
Thalidomid (L04AX02)
Methotrexat (L04AX03)
Lenalidomid (L04AX04)
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ATC M - Musculo-skeletal System
MUSKEL- UND SKELETTSYSTEM
MUSKEL- UND SKELETTSYSTEM
MUSKEL- UND SKELETTSYSTEM (M)
ANTIPHLOGISTIKA UND
ANTIRHEUMATIKA (M01)
NICHTSTEROIDALE
ANTIPHLOGISTIKA UND
ANTIRHEUMATIKA (M01A)
Butylpyrazolidine (M01AA)
Phenylbutazon (M01AA01)
Mofebutazon (M01AA02)
Oxyphenbutazon (M01AA03)
Clofezon (M01AA05)
Kebuzon (M01AA06)
Essigsäure-Derivate und verwandte
Substanzen (M01AB)
Indometacin (M01AB01)
Sulindac (M01AB02)
Tolmetin (M01AB03)
Zomepirac (M01AB04)
Diclofenac (M01AB05)
Alclofenac (M01AB06)
Bumadizon (M01AB07)
Etodolac (M01AB08)
Lonazolac (M01AB09)
Fentiazac (M01AB10)
Acemetacin (M01AB11)
Difenpiramid (M01AB12)
Oxametacin (M01AB13)
Proglumetacin (M01AB14)
Ketorolac (M01AB15)
Aceclofenac (M01AB16)
Bufexamac (M01AB17)
Indometacin, Kombinationen (M01AB51)
Diclofenac, Kombinationen (M01AB55)
Oxicame (M01AC)
Piroxicam (M01AC01)
Tenoxicam (M01AC02)
Droxicam (M01AC04)
Lornoxicam (M01AC05)
Meloxicam (M01AC06)
Propionsäure-Derivate (M01AE)
Ibuprofen (M01AE01)
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Naproxen (M01AE02)
Ketoprofen (M01AE03)
Fenoprofen (M01AE04)
Fenbufen (M01AE05)
Benoxaprofen (M01AE06)
Suprofen (M01AE07)
Pirprofen (M01AE08)
Flurbiprofen (M01AE09)
Indoprofen (M01AE10)
Tiaprofensäure (M01AE11)
Oxaprozin (M01AE12)
Ibuproxam (M01AE13)
Dexibuprofen (M01AE14)
Flunoxaprofen (M01AE15)
Alminoprofen (M01AE16)
Dexketoprofen (M01AE17)
Ibuprofen, Kombinationen (M01AE51)
Ketoprofen, Kombinationen (M01AE53)
Fenamate (M01AG)
Mefenaminsäure (M01AG01)
Tolfenaminsäure (M01AG02)
Flufenaminsäure (M01AG03)
Meclofenaminsäure (M01AG04)
Coxibe (M01AH)
Celecoxib (M01AH01)
Rofecoxib (M01AH02)
Valdecoxib (M01AH03)
Parecoxib (M01AH04)
Etoricoxib (M01AH05)
Lumiracoxib (M01AH06)
Andere nichtsteroidale Antiphlogistika
und Antirheumatika (M01AX)
Nabumeton (M01AX01)
Nifluminsäure (M01AX02)
Azapropazon (M01AX04)
Glucosamin (M01AX05)
Benzydamin (M01AX07)
Glukosaminoglycanpolysulfat (M01AX12)
Proquazon (M01AX13)
Orgotein (M01AX14)
Nimesulid (M01AX17)
Feprazon (M01AX18)
Diacerein (M01AX21)
Morniflumat (M01AX22)
Tenidap (M01AX23)
Oxaceprol (M01AX24)
Chondroitinsulfat (M01AX25)
Feprazon, Kombinationen (M01AX68)
ANTIPHLOGISTIKA/ANTIRHEUMATIKA
IN KOMBINATION (M01B)
Antiphlogistika/Antirheumatika in
Kombination mit Corticosteroiden
(M01BA)
Phenylbutazon und Corticosteroide
(M01BA01)
Dipyrocetyl und Corticosteroide
(M01BA02)
Acetylsalicylsäure und Corticosteroide
(M01BA03)
Andere Antiphlogistika/Antirheumatika in
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Kombination mit anderen Mitteln
(M01BX)
SPEZIFISCHE ANTIRHEUMATIKA
(M01C)
Chinoline (M01CA)
Oxycinchophen (M01CA03)
Gold-Verbindungen (M01CB)
Natrium aurothiomalat (M01CB01)
Natrium aurothiosulfat (M01CB02)
Auranofin (M01CB03)
Aurothioglucose (M01CB04)
Aurotioprol (M01CB05)
Penicillamin und ähnliche Mittel (M01CC)
Penicillamin (M01CC01)
Bucillamin (M01CC02)
Andere spezifische Antirheumatika
(M01CX)
TOPISCHE MITTEL GEGEN GELENK-
UND MUSKELSCHMERZEN (M02)
TOPISCHE MITTEL GEGEN GELENK-
UND MUSKELSCHMERZEN (M02A)
Nichtsteroidale Antiphlogistika zur
topischen Anwendung (M02AA)
Phenylbutazon (M02AA01)
Mofebutazon (M02AA02)
Clofezon (M02AA03)
Oxyphenbutazon (M02AA04)
Benzydamin (M02AA05)
Etofenamat (M02AA06)
Piroxicam (M02AA07)
Felbinac (M02AA08)
Bufexamac (M02AA09)
Ketoprofen (M02AA10)
Bendazac (M02AA11)
Naproxen (M02AA12)
Ibuprofen (M02AA13)
Fentiazac (M02AA14)
Diclofenac (M02AA15)
Feprazon (M02AA16)
Nifluminsäure (M02AA17)
Meclofenaminsäure (M02AA18)
Flurbiprofen (M02AA19)
Tolmetin (M02AA21)
Suxibuzon (M02AA22)
Indometacin (M02AA23)
Nifenazon (M02AA24)
Aceclofenac (M02AA25)
Capsaicin und ähnliche Mittel (M02AB)
Capsaicin (M02AB01)
Zucapsaicin (M02AB02)
Zubereitungen mit Salicylsäure-
Derivaten (M02AC)
Andere topische Mittel gegen Gelenk-
und Muskelschmerzen (M02AX)
Tolazolin (M02AX02)
Dimethylsulfoxid (M02AX03)
Verschiedene (M02AX10)
MUSKELRELAXANZIEN (M03)
MUSKELRELAXANZIEN, PERIPHER
WIRKENDE MITTEL (M03A)
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Curare-Alkaloide (M03AA)
Alcuronium (M03AA01)
Tubocurarin (M03AA02)
Dimethyltubocurarin (M03AA04)
Cholin-Derivate (M03AB)
Suxamethonium (M03AB01)
Andere quartäre Ammonium-
Verbindungen (M03AC)
Pancuronium (M03AC01)
Gallamin (M03AC02)
Vecuronium (M03AC03)
Atracurium (M03AC04)
Hexafluronium (M03AC05)
Pipecuroniumbromid (M03AC06)
Doxacuriumchlorid (M03AC07)
Fazadiniumbromid (M03AC08)
Rocuroniumbromid (M03AC09)
Mivacuriumchlorid (M03AC10)
Cisatracurium (M03AC11)
Andere Muskelrelaxanzien, peripher
wirkende Mittel (M03AX)
Botulinumtoxin (M03AX01)
MUSKELRELAXANZIEN, ZENTRAL
WIRKENDE MITTEL (M03B)
Carbaminsäureester (M03BA)
Phenprobamat (M03BA01)
Carisoprodol (M03BA02)
Methocarbamol (M03BA03)
Styramat (M03BA04)
Febarbamat (M03BA05)
Phenprobamat, Kombinationen exkl.
Psycholeptika (M03BA51)
Carisoprodol, Kombinationen exkl.
Psycholeptika (M03BA52)
Methocarbamol, Kombinationen exkl.
Psycholeptika (M03BA53)
Phenprobamat, Kombinationen mit
Psycholeptika (M03BA71)
Carisoprodol, Kombinationen mit
Psycholeptika (M03BA72)
Methocarbamol, Kombinationen mit
Psycholeptika (M03BA73)
Oxazol-, Thiazin- und Triazin-Derivate
(M03BB)
Chlormezanon (M03BB02)
Chlorzoxazon (M03BB03)
Chlormezanon, Kombinationen exkl.
Psycholeptika (M03BB52)
Chlorzoxazon, Kombinationen exkl.
Psycholeptika (M03BB53)
Chlormezanon, Kombinationen mit
Psycholeptika (M03BB72)
Chlorzoxazon, Kombinationen mit
Psycholeptika (M03BB73)
Ether, chemisch den Antihistaminika
verwandt (M03BC)
Orphenadrin(citrat) (M03BC01)
Orphenadrin, Kombinationen (M03BC51)
Andere zentral wirkende Mittel (M03BX)
Baclofen (M03BX01)
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Tizanidin (M03BX02)
Pridinol (M03BX03)
Tolperison (M03BX04)
Thiocolchicosid (M03BX05)
Mephenesin (M03BX06)
Tetrazepam (M03BX07)
Cyclobenzaprin (M03BX08)
Eperison (M03BX09)
Fenyramidol (M03BX30)
MUSKELRELAXANZIEN, DIREKT
WIRKENDE MITTEL (M03C)
Dantrolen und Derivate (M03CA)
Dantrolen (M03CA01)
GICHTMITTEL (M04)
GICHTMITTEL (M04A)
Urikostatika (M04AA)
Allopurinol (M04AA01)
Tisopurin (M04AA02)
Febuxostat (M04AA03)
Allopurinol, Kombinationen (M04AA51)
Urikosurika (M04AB)
Probenecid (M04AB01)
Sulfinpyrazon (M04AB02)
Benzbromaron (M04AB03)
Isobromindion (M04AB04)
Gichtmittel ohne Effekt auf den
Harnsäuremetabolismus (M04AC)
Colchicin (M04AC01)
Cinchophen (M04AC02)
Andere Gichtmittel (M04AX)
Uratoxidase (M04AX01)
Pegloticase (M04AX02)
MITTEL ZUR BEHANDLUNG VON
KNOCHENERKRANKUNGEN (M05)
MITTEL MIT EINFLUSS AUF DIE
KNOCHENSTRUKTUR UND DIE
MINERALISATION (M05B)
Bisphosphonate (M05BA)
Etidronsäure (M05BA01)
Clodronsäure (M05BA02)
Pamidronsäure (M05BA03)
Alendronsäure (M05BA04)
Tiludronsäure (M05BA05)
Ibandronsäure (M05BA06)
Risedronsäure (M05BA07)
Zoledronsäure (M05BA08)
Bisphosphonate, Kombinationen
(M05BB)
Etidronsäure und Calcium,
Sequenzialpräparate (M05BB01)
Risedronsäure und Calcium,
Sequenzialpräparate (M05BB02)
Alendronsäure und Colecalciferol
(M05BB03)
Risedronsäure, Calcium und
Colecalciferol, Sequenzialpräparate
(M05BB04)
Knochenmorphogene Proteine (M05BC)
Dibotermin alfa (M05BC01)
Eptotermin alfa (M05BC02)
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Andere Mittel mit Einfluss auf die
Knochenstruktur und die Mineralisation
(M05BX)
Ipriflavon (M05BX01)
Aluminiumhydroxychlorid (M05BX02)
Strontium ranelat (M05BX03)
Denosumab (M05BX04)
ANDERE MITTEL GEGEN
STÖRUNGEN DES MUSKEL- UND
SKELETTSYSTEMS (M09)
ANDERE MITTEL GEGEN
STÖRUNGEN DES MUSKEL- UND
SKELETTSYSTEMS (M09A)
Chinin und Derivate (M09AA)
Hydrochinin (M09AA01)
Chinin, Kombinationen mit Psycholeptika
(M09AA72)
Enzyme (M09AB)
Chymopapain (M09AB01)
Trypsin, Kombinationen (M09AB52)
Andere Mittel gegen Störungen des
Muskel- und Skelettsystems (M09AX)
Hyaluronsäure (M09AX01)
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ATC P - Antiparasitic products,
insecticides and repellents
ANTIPARASITÄRE MITTEL,
INSEKTIZIDE UND REPELLENZIEN
ANTIPARASITÄRE MITTEL, INSEKTIZIDE UND
REPELLENZIEN
ANTIPARASITÄRE MITTEL,
INSEKTIZIDE UND REPELLENZIEN (P)
MITTEL GEGEN PROTOZOEN-
ERKRANKUNGEN (P01)
MITTEL GEGEN AMÖBIASIS UND
ANDERE PROTOZOEN-
ERKRANKUNGEN (P01A)
Hydroxychinolin-Derivate (P01AA)
Broxychinolin (P01AA01)
Clioquinol (P01AA02)
Chlorquinaldol (P01AA04)
Tilbroquinol (P01AA05)
Clioquinol, Kombinationen (P01AA52)
Nitroimidazol-Derivate (P01AB)
Metronidazol (P01AB01)
Tinidazol (P01AB02)
Ornidazol (P01AB03)
Azanidazol (P01AB04)
Propenidazol (P01AB05)
Nimorazol (P01AB06)
Secnidazol (P01AB07)
Dichloracetamid-Derivate (P01AC)
Diloxanid (P01AC01)
Clefamid (P01AC02)
Etofamid (P01AC03)
Teclosan (P01AC04)
Arsen-haltige Verbindungen (P01AR)
Arsthinol (P01AR01)
Difetarson (P01AR02)
Glycobiarsol (P01AR03)
Glycobiarsol, Kombinationen (P01AR53)
Andere Mittel gegen Amöbiasis und
andere Protozoen-Erkrankungen
(P01AX)
Chiniofon (P01AX01)
Emetin (P01AX02)
Phanquinon (P01AX04)
Mepacrin (P01AX05)
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Atovaquon (P01AX06)
Trimetrexat (P01AX07)
Tenonitrozol (P01AX08)
Dehydroemetin (P01AX09)
Fumagillin (P01AX10)
Nitazoxanid (P01AX11)
Emetin, Kombinationen (P01AX52)
MALARIAMITTEL (P01B)
Aminochinoline (P01BA)
Chloroquin (P01BA01)
Hydroxychloroquin (P01BA02)
Primaquin (P01BA03)
Amodiaquin (P01BA06)
Biguanide (P01BB)
Proguanil (P01BB01)
Cycloguanilembonat (P01BB02)
Proguanil, Kombinationen (P01BB51)
Methanolchinoline (P01BC)
Chinin (P01BC01)
Mefloquin (P01BC02)
Diaminopyrimidine (P01BD)
Pyrimethamin (P01BD01)
Pyrimethamin, Kombinationen
(P01BD51)
Artemisinin und Derivate, rein (P01BE)
Artemisinin (P01BE01)
Artemether (P01BE02)
Artesunat (P01BE03)
Artemotil (P01BE04)
Artenimol (Dihydroartemisinin)
(P01BE05)
artemether, combinations (P01BE52)
Andere Malariamittel (P01BX)
Halofantrin (P01BX01)
MITTEL GEGEN LEISHMANIASIS UND
TRYPANOSOMIASIS (P01C)
Nitroimidazol-Derivate (P01CA)
Benznidazol (P01CA02)
Antimon-haltige Verbindungen (P01CB)
Megluminantimonat (P01CB01)
Natriumstibogluconat (P01CB02)
Nitrofuran-Derivate (P01CC)
Nifurtimox (P01CC01)
Nitrofural (P01CC02)
Arsen-haltige Verbindungen (P01CD)
Melarsoprol (P01CD01)
Acetarsol (P01CD02)
Andere Mittel gegen Leishmaniasis und
Trypanosomiasis (P01CX)
Pentamidindiisetionat (P01CX01)
Suramin natrium (P01CX02)
Eflornithin (P01CX03)
ANTHELMINTIKA (P02)
TREMATODENMITTEL (P02B)
Chinolin-Derivate und verwandte
Substanzen (P02BA)
Praziquantel (P02BA01)
Oxamniquin (P02BA02)
Organophosphat-Verbindungen (P02BB)
Metrifonat (P02BB01)
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Andere Trematodenmittel (P02BX)
Bithionol (P02BX01)
Niridazol (P02BX02)
Stibophen (P02BX03)
Triclabendazol (P02BX04)
NEMATODENMITTEL (P02C)
Benzimidazol-Derivate (P02CA)
Mebendazol (P02CA01)
Tiabendazol (P02CA02)
Albendazol (P02CA03)
Ciclobendazol (P02CA04)
Flubendazol (P02CA05)
Fenbendazol (P02CA06)
Mebendazol, Kombinationen (P02CA51)
Piperazin und Derivate (P02CB)
Piperazin (P02CB01)
Diethylcarbamazin (P02CB02)
Tetrahydropyrimidin-Derivate (P02CC)
Pyrantel (P02CC01)
Oxantel (P02CC02)
Imidazothiazol-Derivate (P02CE)
Levamisol (P02CE01)
Avermektine (P02CF)
Ivermectin (P02CF01)
Andere Nematodenmittel (P02CX)
Pyrvinium (P02CX01)
Bephenium (P02CX02)
BANDWURMMITTEL (P02D)
Salicylsäure-Derivate (P02DA)
Niclosamid (P02DA01)
Andere Bandwurmmittel (P02DX)
Desaspidin (P02DX01)
Dichlorophen (P02DX02)
MITTEL GEGEN EKTOPARASITEN,
INKL. ANTISCABIOSA, INSEKTIZIDE
UND REPELLENZIEN (P03)
MITTEL GEGEN EKTOPARASITEN,
INKL. ANTISCABIOSA (P03A)
Schwefel-haltige Mittel (P03AA)
Dixanthogen (P03AA01)
Kaliumpolysulfid (P03AA02)
Mesulfen (P03AA03)
Disulfiram (P03AA04)
Thiram (P03AA05)
Disulfiram, Kombinationen (P03AA54)
Chlor-haltige Mittel (P03AB)
Clofenotan (P03AB01)
Lindan (P03AB02)
Clofenotan, Kombinationen (P03AB51)
Pyrethrine, inkl. synthetische
Verbindungen (P03AC)
pyrethrum (P03AC01)
Bioallethrin (P03AC02)
Phenothrin (P03AC03)
Permethrin (P03AC04)
pyrethrum, combinations (P03AC51)
Bioallethrin, Kombinationen (P03AC52)
Phenothrin, Kombinationen (P03AC53)
Permethrin, Kombinationen (P03AC54)
Andere Mittel gegen Ektoparasiten, inkl.
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Antiscabiosa (P03AX)
Benzylbenzoat (P03AX01)
Kupferoleat (P03AX02)
Malathion (P03AX03)
quassia (P03AX04)
INSEKTIZIDE UND REPELLENZIEN
(P03B)
Pyrethrine (P03BA)
Cyfluthrin (P03BA01)
Cypermethrin (P03BA02)
Decamethrin (P03BA03)
Tetramethrin (P03BA04)
Andere Insektizide und Repellenzien
(P03BX)
Diethyltoluamid (P03BX01)
Dimethylphthalat (P03BX02)
Dibutylphthalat (P03BX03)
Dibutylsuccinat (P03BX04)
Dimethylcarbat (P03BX05)
Etohexadiol (P03BX06)
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ATC N - Nervous System
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ATC N - Nervous System
NERVENSYSTEM
NERVENSYSTEM
NERVENSYSTEM (N)
ANÄSTHETIKA (N01)
ALLGEMEINANÄSTHETIKA (N01A)
Ether (N01AA)
Diethylether (N01AA01)
Vinylether (N01AA02)
Halogenierte Kohlenwasserstoffe
(N01AB)
Halothan (N01AB01)
Chloroform (N01AB02)
Enfluran (N01AB04)
Trichlorethylen (N01AB05)
Isofluran (N01AB06)
Desfluran (N01AB07)
Sevofluran (N01AB08)
Barbiturate, rein (N01AF)
Methohexital (N01AF01)
Hexobarbital (N01AF02)
Thiopental (N01AF03)
Barbiturate in Kombination mit anderen
Mitteln (N01AG)
Narcobarbital (N01AG01)
Opioidanästhetika (N01AH)
Fentanyl (N01AH01)
Alfentanil (N01AH02)
Sufentanil (N01AH03)
Phenoperidin (N01AH04)
Anileridin (N01AH05)
Remifentanil (N01AH06)
Fentanyl, Kombinationen (N01AH51)
Andere Allgemeinanästhetika (N01AX)
Droperidol (N01AX01)
Ketamin (N01AX03)
Propanidid (N01AX04)
Alfaxalon (N01AX05)
Etomidate (N01AX07)
Propofol (N01AX10)
Natriumoxybat (N01AX11)
Distickstoffmonoxid (N01AX13)
Esketamin (N01AX14)
Xenon (N01AX15)
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Distickstoffmonoxid, Kombinationen
(N01AX63)
LOKALANÄSTHETIKA (N01B)
Ester der Aminobenzoesäure (N01BA)
Metabutethamin (N01BA01)
Procain (N01BA02)
Tetracain (N01BA03)
Chloroprocain (N01BA04)
Benzocain (N01BA05)
Procain, Kombinationen (N01BA52)
Amide (N01BB)
Bupivacain (N01BB01)
Lidocain (N01BB02)
Mepivacain (N01BB03)
Prilocain (N01BB04)
Butanilicain (N01BB05)
Cinchocain (N01BB06)
Etidocain (N01BB07)
Articain (N01BB08)
Ropivacain (N01BB09)
Levobupivacain (N01BB10)
Kombinationen (N01BB20)
Bupivacain, Kombinationen (N01BB51)
Lidocain, Kombinationen (N01BB52)
Mepivacain, Kombinationen (N01BB53)
Prilocain, Kombinationen (N01BB54)
Etidocain, Kombinationen (N01BB57)
Articain, Kombinationen (N01BB58)
Ester der Benzoesäure (N01BC)
Cocain (N01BC01)
Andere Lokalanästhetika (N01BX)
Ethylchlorid (N01BX01)
Dyclonin (N01BX02)
Phenol (N01BX03)
Capsaicin (N01BX04)
ANALGETIKA (N02)
OPIOIDE (N02A)
Natürliche Opium-Alkaloide (N02AA)
Morphin (N02AA01)
Opium (N02AA02)
Hydromorphon (N02AA03)
Nicomorphin (N02AA04)
Oxycodon (N02AA05)
Dihydrocodein (N02AA08)
Diamorphin (N02AA09)
Papaveretum (N02AA10)
Morphin, Kombinationen (N02AA51)
Oxycodon, Kombinationen (N02AA55)
Dihydrocodein, Kombinationen
(N02AA58)
Codein, Kombinationen exkl.
Psycholeptika (N02AA59)
Codein, Kombinationen mit
Psycholeptika (N02AA79)
Phenylpiperidin-Derivate (N02AB)
Ketobemidon (N02AB01)
Pethidin (N02AB02)
Fentanyl (N02AB03)
Pethidin, Kombinationen exkl.
Psycholeptika (N02AB52)
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Pethidin, Kombinationen mit
Psycholeptika (N02AB72)
Diphenylpropylamin-Derivate (N02AC)
Dextromoramid (N02AC01)
Piritramid (N02AC03)
Dextropropoxyphen (N02AC04)
Bezitramid (N02AC05)
Methadon, Kombinationen exkl.
Psycholeptika (N02AC52)
Dextropropoxyphen, Kombinationen exkl.
Psycholeptika (N02AC54)
Dextropropoxyphen, Kombinationen mit
Psycholeptika (N02AC74)
Benzomorphan-Derivate (N02AD)
Pentazocin (N02AD01)
Phenazocin (N02AD02)
Oripavin-Derivate (N02AE)
Buprenorphin (N02AE01)
Morphinan-Derivate (N02AF)
Butorphanol (N02AF01)
Nalbufin (N02AF02)
Opioide in Kombination mit Spasmolytika
(N02AG)
Morphin mit Spasmolytika (N02AG01)
Ketobemidon mit Spasmolytika
(N02AG02)
Pethidin mit Spasmolytika (N02AG03)
Hydromorphon mit Spasmolytika
(N02AG04)
Andere Opioide (N02AX)
Tilidin (N02AX01)
Tramadol (N02AX02)
Dezocin (N02AX03)
Meptazinol (N02AX05)
Tapentadol (N02AX06)
Tramadol, Kombinationen (N02AX52)
ANDERE ANALGETIKA UND
ANTIPYRETIKA (N02B)
Salicylsäure und Derivate (N02BA)
Acetylsalicylsäure (N02BA01)
Aloxiprin (N02BA02)
Cholinsalicylat (N02BA03)
Natriumsalicylat (N02BA04)
Salicylamid (N02BA05)
Salsalat (N02BA06)
Ethenzamid (N02BA07)
Morpholinsalicylat (N02BA08)
Dipyrocetyl (N02BA09)
Benorilat (N02BA10)
Diflunisal (N02BA11)
Kaliumsalicylat (N02BA12)
Guacetisal (N02BA14)
Carbasalat calcium (N02BA15)
Imidazolsalicylat (N02BA16)
Acetylsalicylsäure, Kombinationen exkl.
Psycholeptika (N02BA51)
Salicylamid, Kombinationen exkl.
Psycholeptika (N02BA55)
Ethenzamid, Kombinationen exkl.
Psycholeptika (N02BA57)
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Dipyrocetyl, Kombinationen exkl.
Psycholeptika (N02BA59)
Carbasalat calcium, Kombinationen exkl.
Psycholeptika (N02BA65)
Acetylsalicylsäure, Kombinationen mit
Psycholeptika (N02BA71)
Salicylamid, Kombinationen mit
Psycholeptika (N02BA75)
Ethenzamid, Kombinationen mit
Psycholeptika (N02BA77)
Dipyrocetyl, Kombinationen mit
Psycholeptika (N02BA79)
Pyrazolone (N02BB)
Phenazon (N02BB01)
Metamizol-Natrium (N02BB02)
Aminophenazon (N02BB03)
Propyphenazon (N02BB04)
Nifenazon (N02BB05)
Phenazon, Kombinationen exkl.
Psycholeptika (N02BB51)
Metamizol-Natrium, Kombinationen exkl.
Psycholeptika (N02BB52)
Aminophenazon, Kombinationen exkl.
Psycholeptika (N02BB53)
Propyphenazon, Kombinationen exkl.
Psycholeptika (N02BB54)
Phenazon, Kombinationen mit
Psycholeptika (N02BB71)
Metamizol-Natrium, Kombinationen mit
Psycholeptika (N02BB72)
Aminophenazon, Kombinationen mit
Psycholeptika (N02BB73)
Propyphenazon, Kombinationen mit
Psycholeptika (N02BB74)
Anilide (N02BE)
Paracetamol (N02BE01)
Phenacetin (N02BE03)
Bucetin (N02BE04)
Propacetamol (N02BE05)
Paracetamol, Kombinationen exkl.
Psycholeptika (N02BE51)
Phenacetin, Kombinationen exkl.
Psycholeptika (N02BE53)
Bucetin, Kombinationen exkl.
Psycholeptika (N02BE54)
Paracetamol, Kombinationen mit
Psycholeptika (N02BE71)
Phenacetin, Kombinationen mit
Psycholeptika (N02BE73)
Bucetin, Kombinationen mit
Psycholeptika (N02BE74)
Andere Analgetika und Antipyretika
(N02BG)
Rimazolium (N02BG02)
Glafenin (N02BG03)
Floctafenin (N02BG04)
Viminol (N02BG05)
Nefopam (N02BG06)
Flupirtin (N02BG07)
Ziconotid (N02BG08)
4 / 13
ATC N - Nervous System
Methoxyfluran (N02BG09)
Cannabinoide (N02BG10)
MIGRÄNEMITTEL (N02C)
Mutterkorn-Alkaloide (N02CA)
Dihydroergotamin (N02CA01)
Ergotamin (N02CA02)
Methysergid (N02CA04)
Lisurid (N02CA07)
Dihydroergotamin, Kombinationen
(N02CA51)
Ergotamin, Kombinationen exkl.
Psycholeptika (N02CA52)
Ergotamin, Kombinationen mit
Psycholeptika (N02CA72)
Corticosteroid-Derivate (N02CB)
Flumedroxon (N02CB01)
Selektive Serotonin-5HT1-Agonisten
(N02CC)
Sumatriptan (N02CC01)
Naratriptan (N02CC02)
Zolmitriptan (N02CC03)
Rizatriptan (N02CC04)
Almotriptan (N02CC05)
Eletriptan (N02CC06)
Frovatriptan (N02CC07)
Andere Migränemittel (N02CX)
Pizotifen (N02CX01)
Clonidin (N02CX02)
Iprazochrom (N02CX03)
Dimetotiazin (N02CX05)
Oxetoron (N02CX06)
ANTIEPILEPTIKA (N03)
ANTIEPILEPTIKA (N03A)
Barbiturate und Derivate (N03AA)
Methylphenobarbital (N03AA01)
Phenobarbital (N03AA02)
Primidon (N03AA03)
Barbexaclon (N03AA04)
Metharbital (N03AA30)
Hydantoin-Derivate (N03AB)
Ethotoin (N03AB01)
Phenytoin (N03AB02)
Amino(diphenylhydantoin)valeriansäure
(N03AB03)
Mephenytoin (N03AB04)
Fosphenytoin (N03AB05)
Phenytoin, Kombinationen (N03AB52)
Mephenytoin, Kombinationen (N03AB54)
Oxazolidin-Derivate (N03AC)
Paramethadion (N03AC01)
Trimethadion (N03AC02)
Ethadion (N03AC03)
Succinimid-Derivate (N03AD)
Ethosuximid (N03AD01)
Phensuximid (N03AD02)
Mesuximid (N03AD03)
Ethosuximid, Kombinationen (N03AD51)
Benzodiazepin-Derivate (N03AE)
Clonazepam (N03AE01)
Carboxamid-Derivate (N03AF)
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Carbamazepin (N03AF01)
Oxcarbazepin (N03AF02)
Rufinamid (N03AF03)
Eslicarbazepin (N03AF04)
Fettsäure-Derivate (N03AG)
Valproinsäure (N03AG01)
Valpromid (N03AG02)
Aminobuttersäure (N03AG03)
Vigabatrin (N03AG04)
Progabid (N03AG05)
Tiagabin (N03AG06)
Andere Antiepileptika (N03AX)
Sultiam (N03AX03)
Phenacemid (N03AX07)
Lamotrigin (N03AX09)
Felbamat (N03AX10)
Topiramat (N03AX11)
Gabapentin (N03AX12)
Pheneturid (N03AX13)
Levetiracetam (N03AX14)
Zonisamid (N03AX15)
Pregabalin (N03AX16)
Stiripentol (N03AX17)
Lacosamid (N03AX18)
Carisbamat (N03AX19)
Beclamid (N03AX30)
ANTIPARKINSONMITTEL (N04)
ANTICHOLINERGIKA (N04A)
Tertiäre Amine (N04AA)
Trihexyphenidyl (N04AA01)
Biperiden (N04AA02)
Metixen (N04AA03)
Procyclidin (N04AA04)
Profenamin (N04AA05)
Dexetimid (N04AA08)
Phenglutarimid (N04AA09)
Mazaticol (N04AA10)
Bornaprin (N04AA11)
Tropatepin (N04AA12)
Ether, chemisch den Antihistaminika
verwandt (N04AB)
Etanautin (N04AB01)
Orphenadrin(chlorid) (N04AB02)
Tropinether oder Tropin-Derivate
(N04AC)
Benzatropin (N04AC01)
Etybenzatropin (N04AC30)
DOPAMINERGE MITTEL (N04B)
Dopa und Dopa-Derivate (N04BA)
Levodopa (N04BA01)
Levodopa und Decarboxylasehemmer
(N04BA02)
Levodopa, Decarboxylasehemmer und
COMT-Hemmer (N04BA03)
Melevodopa (N04BA04)
Melevodopa und Decarboxylasehemmer
(N04BA05)
Etilevodopa und Decarboxylasehemmer
(N04BA06)
Adamantan-Derivate (N04BB)
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Amantadin (N04BB01)
Dopamin-Agonisten (N04BC)
Bromocriptin (N04BC01)
Pergolid (N04BC02)
Dihydroergocryptinmesilat (N04BC03)
Ropinirol (N04BC04)
Pramipexol (N04BC05)
Cabergolin (N04BC06)
Apomorphin (N04BC07)
Piribedil (N04BC08)
Rotigotin (N04BC09)
Monoaminoxidase-B-Hemmer (N04BD)
Selegilin (N04BD01)
Rasagilin (N04BD02)
Andere dopaminerge Mittel (N04BX)
Tolcapon (N04BX01)
Entacapon (N04BX02)
Budipin (N04BX03)
PSYCHOLEPTIKA (N05)
ANTIPSYCHOTIKA (N05A)
Phenothiazine mit aliphatischer
Seitenkette (N05AA)
Chlorpromazin (N05AA01)
Levomepromazin (N05AA02)
Promazin (N05AA03)
Acepromazin (N05AA04)
Triflupromazin (N05AA05)
Cyamemazin (N05AA06)
Chlorproethazin (N05AA07)
Phenothiazine mit Piperazinstruktur
(N05AB)
Dixyrazin (N05AB01)
Fluphenazin (N05AB02)
Perphenazin (N05AB03)
Prochlorperazin (N05AB04)
Thiopropazat (N05AB05)
Trifluoperazin (N05AB06)
Acetophenazin (N05AB07)
Thioproperazin (N05AB08)
Butaperazin (N05AB09)
Perazin (N05AB10)
Phenothiazine mit Piperidinstruktur
(N05AC)
Periciazin (N05AC01)
Thioridazin (N05AC02)
Mesoridazin (N05AC03)
Pipotiazin (N05AC04)
Butyrophenon-Derivate (N05AD)
Haloperidol (N05AD01)
Trifluperidol (N05AD02)
Melperon (N05AD03)
Moperon (N05AD04)
Pipamperon (N05AD05)
Bromperidol (N05AD06)
Benperidol (N05AD07)
Droperidol (N05AD08)
Fluanison (N05AD09)
Indol-Derivate (N05AE)
Oxypertin (N05AE01)
Molindon (N05AE02)
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Sertindol (N05AE03)
Ziprasidon (N05AE04)
Thioxanthen-Derivate (N05AF)
Flupentixol (N05AF01)
Clopenthixol (N05AF02)
Chlorprothixen (N05AF03)
Tiotixen (N05AF04)
Zuclopenthixol (N05AF05)
Diphenylbutylpiperidin-Derivate (N05AG)
Fluspirilen (N05AG01)
Pimozid (N05AG02)
Penfluridol (N05AG03)
Diazepine, Oxazepine, Thiazepine und
Oxepine (N05AH)
Loxapin (N05AH01)
Clozapin (N05AH02)
Olanzapin (N05AH03)
Quetiapin (N05AH04)
Asenapin (N05AH05)
Clotiapin (N05AH06)
Benzamide (N05AL)
Sulpirid (N05AL01)
Sultoprid (N05AL02)
Tiaprid (N05AL03)
Remoxiprid (N05AL04)
Amisulprid (N05AL05)
Veraliprid (N05AL06)
Levosulpirid (N05AL07)
Lithium (N05AN)
Lithium (N05AN01)
Andere Antipsychotika (N05AX)
Prothipendyl (N05AX07)
Risperidon (N05AX08)
Mosapramin (N05AX10)
Zotepin (N05AX11)
Aripiprazol (N05AX12)
Paliperidon (N05AX13)
ANXIOLYTIKA (N05B)
Benzodiazepin-Derivate (N05BA)
Diazepam (N05BA01)
Chlordiazepoxid (N05BA02)
Medazepam (N05BA03)
Oxazepam (N05BA04)
Dikaliumclorazepat (N05BA05)
Lorazepam (N05BA06)
Adinazolam (N05BA07)
Bromazepam (N05BA08)
Clobazam (N05BA09)
Ketazolam (N05BA10)
Prazepam (N05BA11)
Alprazolam (N05BA12)
Halazepam (N05BA13)
Pinazepam (N05BA14)
Camazepam (N05BA15)
Nordazepam (N05BA16)
Fludiazepam (N05BA17)
Ethylloflazepat (N05BA18)
Etizolam (N05BA19)
Clotiazepam (N05BA21)
Cloxazolam (N05BA22)
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Tofisopam (N05BA23)
Lorazepam, Kombinationen (N05BA56)
Diphenylmethan-Derivate (N05BB)
Hydroxyzin (N05BB01)
Captodiam (N05BB02)
Hydroxyzin, Kombinationen (N05BB51)
Carbamate (N05BC)
Meprobamat (N05BC01)
Emylcamat (N05BC03)
Mebutamat (N05BC04)
Meprobamat, Kombinationen (N05BC51)
Dibenzo-bicyclo-octadien-Derivate
(N05BD)
Benzoctamin (N05BD01)
Azaspirodecandion-Derivate (N05BE)
Buspiron (N05BE01)
Andere Anxiolytika (N05BX)
Mephenoxalon (N05BX01)
Gedocarnil (N05BX02)
Etifoxin (N05BX03)
HYPNOTIKA UND SEDATIVA (N05C)
Barbiturate, rein (N05CA)
Pentobarbital (N05CA01)
Amobarbital (N05CA02)
Butobarbital (N05CA03)
Barbital (N05CA04)
Aprobarbital (N05CA05)
Secobarbital (N05CA06)
Talbutal (N05CA07)
Vinylbital (N05CA08)
Vinbarbital (N05CA09)
Cyclobarbital (N05CA10)
Heptabarbital (N05CA11)
Reposal (N05CA12)
Methohexital (N05CA15)
Hexobarbital (N05CA16)
Thiopental (N05CA19)
Etallobarbital (N05CA20)
Allobarbital (N05CA21)
Proxibarbal (N05CA22)
Barbiturate, Kombinationen (N05CB)
Kombinationen von Barbituraten
(N05CB01)
Barbiturate in Kombination mit anderen
Mitteln (N05CB02)
Aldehyde und Derivate (N05CC)
Chloralhydrat (N05CC01)
Chloralodol (N05CC02)
Acetylglycinamidchloralhydrat
(N05CC03)
Dichloralphenazon (N05CC04)
Paraldehyd (N05CC05)
Benzodiazepin-Derivate (N05CD)
Flurazepam (N05CD01)
Nitrazepam (N05CD02)
Flunitrazepam (N05CD03)
Estazolam (N05CD04)
Triazolam (N05CD05)
Lormetazepam (N05CD06)
Temazepam (N05CD07)
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Midazolam (N05CD08)
Brotizolam (N05CD09)
Quazepam (N05CD10)
Loprazolam (N05CD11)
Doxefazepam (N05CD12)
Cinolazepam (N05CD13)
Piperidindion-Derivate (N05CE)
Glutethimid (N05CE01)
Methyprylon (N05CE02)
Pyrithyldion (N05CE03)
Benzodiazepin-verwandte Mittel (N05CF)
Zopiclon (N05CF01)
Zolpidem (N05CF02)
Zaleplon (N05CF03)
Eszopiclon (N05CF04)
Melatonin-Rezeptor-Agonisten (N05CH)
Melatonin (N05CH01)
Ramelteon (N05CH02)
Andere Hypnotika und Sedativa
(N05CM)
Methaqualon (N05CM01)
Clomethiazol (N05CM02)
Bromisoval (N05CM03)
Carbromal (N05CM04)
Scopolamin (N05CM05)
Propiomazin (N05CM06)
Triclofos (N05CM07)
Ethchlorvynol (N05CM08)
Valerian (N05CM09)
Hexapropymate (N05CM10)
Bromide (N05CM11)
Apronal (N05CM12)
Valnoctamid (N05CM13)
Methylpentynol (N05CM15)
Niaprazin (N05CM16)
Dexmedetomidin (N05CM18)
Hypnotika und Sedativa in Kombination,
exkl. Barbiturate (N05CX)
Meprobamat, Kombinationen (N05CX01)
Methaqualon, Kombinationen (N05CX02)
Methylpentynol, Kombinationen
(N05CX03)
Clomethiazol, Kombinationen (N05CX04)
Emepronium, Kombinationen (N05CX05)
Dipiperonylaminoethanol, Kombinationen
(N05CX06)
PSYCHOANALEPTIKA (N06)
ANTIDEPRESSIVA (N06A)
Nichtselektive Monoamin-
Wiederaufnahmehemmer (N06AA)
Desipramin (N06AA01)
Imipramin (N06AA02)
Imipraminoxid (N06AA03)
Clomipramin (N06AA04)
Opipramol (N06AA05)
Trimipramin (N06AA06)
Lofepramin (N06AA07)
Dibenzepin (N06AA08)
Amitriptylin (N06AA09)
Nortriptylin (N06AA10)
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Protriptylin (N06AA11)
Doxepin (N06AA12)
Iprindol (N06AA13)
Melitracen (N06AA14)
Butriptylin (N06AA15)
Dosulepin (N06AA16)
Amoxapin (N06AA17)
Dimetacrin (N06AA18)
Amineptin (N06AA19)
Maprotilin (N06AA21)
Quinupramin (N06AA23)
Selektive Serotonin-
Wiederaufnahmehemmer (N06AB)
Zimeldin (N06AB02)
Fluoxetin (N06AB03)
Citalopram (N06AB04)
Paroxetin (N06AB05)
Sertralin (N06AB06)
Alaproclat (N06AB07)
Fluvoxamin (N06AB08)
Etoperidon (N06AB09)
Escitalopram (N06AB10)
Monoaminoxidasehemmer, nichtselektiv
(N06AF)
Isocarboxazid (N06AF01)
Nialamid (N06AF02)
Phenelzin (N06AF03)
Tranylcypromin (N06AF04)
Iproniazid (N06AF05)
Iproclozid (N06AF06)
Monoaminoxidase-A-Hemmer (N06AG)
Moclobemid (N06AG02)
Toloxaton (N06AG03)
Andere Antidepressiva (N06AX)
Oxitriptan (N06AX01)
Tryptophan (N06AX02)
Mianserin (N06AX03)
Nomifensin (N06AX04)
Trazodon (N06AX05)
Nefazodon (N06AX06)
Minaprin (N06AX07)
Bifemelan (N06AX08)
Viloxazin (N06AX09)
Oxaflozan (N06AX10)
Mirtazapin (N06AX11)
Bupropion (N06AX12)
Medifoxamin (N06AX13)
Tianeptin (N06AX14)
Pivagabin (N06AX15)
Venlafaxin (N06AX166)
Milnacipran (N06AX17)
Reboxetin (N06AX18)
Gepiron (N06AX19)
Duloxetin (N06AX21)
Agomelatin (N06AX22)
Desvenlafaxin (N06AX23)
PSYCHOSTIMULANZIEN, MITTEL FÜR
DIE ADHD UND NOOTROPIKA (N06B)
Zentral wirkende Sympathomimetika
(N06BA)
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Amfetamin (N06BA01)
Dexamfetamin (N06BA02)
Metamfetamin (N06BA03)
Methylphenidat (N06BA04)
Pemolin (N06BA05)
Fencamfamin (N06BA06)
Modafinil (N06BA07)
Fenozolon (N06BA08)
Atomoxetin (N06BA09)
Fenetyllin (N06BA10)
Dexmethylphenidat (N06BA11)
Xanthin-Derivate (N06BC)
Coffein (N06BC01)
Propentofyllin (N06BC022)
Andere Psychostimulanzien und
Nootropika (N06BX)
Meclofenoxat (N06BX01)
Pyritinol (N06BX02)
Piracetam (N06BX03)
Deanol (N06BX04)
Fipexid (N06BX05)
Citicolin (N06BX06)
Oxiracetam (N06BX07)
Pirisudanol (N06BX08)
Linopirdin (N06BX09)
Nizofenon (N06BX10)
Aniracetam (N06BX11)
Acetylcarnitin (N06BX12)
Idebenon (N06BX13)
Prolintan (N06BX14)
Pipradrol (N06BX15)
Pramiracetam (N06BX16)
Adrafinil (N06BX17)
Vinpocetin (N06BX18)
PSYCHOLEPTIKA UND
PSYCHOANALEPTIKA IN
KOMBINATION (N06C)
Antidepressiva in Kombination mit
Psycholeptika (N06CA)
Amitriptylin und Psycholeptika
(N06CA01)
Melitracen und Psycholeptika
(N06CA02)
Psychostimulanzien in Kombination mit
Psycholeptika (N06CB)
ANTIDEMENTIVA (N06D)
Cholinesterasehemmer (N06DA)
Tacrin (N06DA01)
Donepezil (N06DA02)
Rivastigmin (N06DA03)
Galantamin (N06DA04)
Andere Antidementiva (N06DX)
Memantin (N06DX01)
Ginkgo biloba (N06DX02)
ANDERE MITTEL FÜR DAS
NERVENSYSTEM (N07)
PARASYMPATHOMIMETIKA (N07A)
Cholinesterasehemmer (N07AA)
Neostigmin (N07AA01)
Pyridostigmin (N07AA02)
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Distigmin (N07AA03)
Ambenonium (N07AA30)
Neostigmin, Kombinationen (N07AA51)
Cholinester (N07AB)
Carbachol (N07AB01)
Bethanechol (N07AB02)
Andere Parasympathomimetika (N07AX)
Pilocarpin (N07AX01)
Cholinalfoscerat (N07AX02)
Cevimelin (N07AX03)
MITTEL ZUR BEHANDLUNG VON
SUCHTERKRANKUNGEN (N07B)
Mittel zur Behandlung der
Nikotinabhängigkeit (N07BA)
Nicotin (N07BA01)
Vareniclin (N07BA03)
Mittel zur Behandlung der
Alkoholabhängigkeit (N07BB)
Disulfiram (N07BB01)
Calcium carbimid (N07BB02)
Acamprosat (N07BB03)
Naltrexon (N07BB04)
Mittel zur Behandlung der
Opiatabhängigkeit (N07BC)
Buprenorphin (N07BC01)
Methadon (N07BC02)
Levacetylmethadol (N07BC03)
Lofexidin (N07BC04)
Buprenorphin, Kombinationen
(N07BC51)
ANTIVERTIGINOSA (N07C)
Antivertiginosa (N07CA)
Betahistin (N07CA01)
Cinnarizin (N07CA02)
Flunarizin (N07CA03)
Acetylleucin (N07CA04)
Cinnarizin, Kombinationen (N07CA52)
ANDERE MITTEL FÜR DAS
NERVENSYSTEM (N07X)
Ganglioside und Gangliosid-Derivate
(N07XA)
Andere Mittel für das Nervensystem
(N07XX)
Tirilazad (N07XX01)
Riluzol (N07XX02)
Xaliproden (N07XX03)
Natriumoxybat (N07XX04)
Amifampridin (N07XX05)
Tetrabenazin (N07XX06)
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ATC R - Respiratory System
RESPIRATIONSTRAKT
RESPIRATIONSTRAKT
RESPIRATIONSTRAKT (R)
RHINOLOGIKA (R01)
DEKONGESTIVA UND ANDERE
RHINOLOGIKA ZUR TOPISCHEN
ANWENDUNG (R01A)
Sympathomimetika, rein (R01AA)
Cyclopentamin (R01AA02)
Ephedrin (R01AA03)
Phenylephrin (R01AA04)
Oxymetazolin (R01AA05)
Tetryzolin (R01AA06)
Xylometazolin (R01AA07)
Naphazolin (R01AA08)
Tramazolin (R01AA09)
Metizolin (R01AA10)
Tuaminoheptan (R01AA11)
Fenoxazolin (R01AA12)
Tymazolin (R01AA13)
Epinephrin (R01AA14)
Sympathomimetika, Kombinationen exkl.
Corticosteroide (R01AB)
Phenylephrin (R01AB01)
Naphazolin (R01AB02)
Tetryzolin (R01AB03)
Ephedrin (R01AB05)
Xylometazolin (R01AB06)
Oxymetazolin (R01AB07)
Tuaminoheptan (R01AB08)
Antiallergika, exkl. Corticosteroide
(R01AC)
Cromoglicinsäure (R01AC01)
Levocabastin (R01AC02)
Azelastin (R01AC03)
Antazolin (R01AC04)
Spagluminsäure (R01AC05)
Thonzylamin (R01AC06)
Nedocromil (R01AC07)
Olopatadin (R01AC08)
Cromoglicinsäure, Kombinationen
(R01AC51)
Corticosteroide (R01AD)
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Beclometason (R01AD01)
Prednisolon (R01AD02)
Dexamethason (R01AD03)
Flunisolid (R01AD04)
Budesonid (R01AD05)
Betamethason (R01AD06)
Tixocortol (R01AD07)
Fluticason (R01AD08)
Mometason (R01AD09)
Triamcinolon (R01AD11)
Fluticason furoat (R01AD12)
Prednisolon, Kombinationen (R01AD52)
Dexamethason, Kombinationen
(R01AD53)
Tixocortol, Kombinationen (R01AD57)
Hydrocortison, Kombinationen
(R01AD60)
Andere Rhinologika (R01AX)
Calciumhexaminthiocyanat (R01AX01)
Retinol (R01AX02)
Ipratropium bromid (R01AX03)
Ritiometan (R01AX05)
Mupirocin (R01AX06)
Hexamidin (R01AX07)
Framycetin (R01AX08)
Hyaluronsäure (R01AX09)
Verschiedene (R01AX10)
Kombinationen (R01AX30)
NASALE DEKONGESTIVA ZUR
SYSTEMISCHEN ANWENDUNG
(R01B)
Sympathomimetika (R01BA)
Phenylpropanolamin (R01BA01)
Pseudoephedrin (R01BA02)
Phenylephrin (R01BA03)
Phenylpropanolamin, Kombinationen
(R01BA51)
Pseudoephedrin, Kombinationen
(R01BA52)
Phenylephrin, Kombinationen (R01BA53)
HALS- UND RACHENTHERAPEUTIKA
(R02)
HALS- UND RACHENTHERAPEUTIKA
(R02A)
Antiseptika (R02AA)
Ambazon (R02AA01)
Dequalinium (R02AA02)
Dichlorbenzylalkohol (R02AA03)
Chlorhexidin (R02AA05)
Cetylpyridinium (R02AA06)
Benzethonium (R02AA09)
Myristylbenzalkonium (R02AA10)
Chlorquinaldol (R02AA11)
Hexylresorcinol (R02AA12)
Acriflaviniumchlorid (R02AA13)
Oxychinolin (R02AA14)
Povidon-Iod (R02AA15)
Benzalkonium (R02AA16)
Cetrimonium (R02AA17)
Hexamidin (R02AA18)
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Phenol (R02AA19)
Verschiedene (R02AA20)
Antibiotika (R02AB)
Neomycin (R02AB01)
Tyrothricin (R02AB02)
Fusafungin (R02AB03)
Bacitracin (R02AB04)
Gramicidin (R02AB30)
Lokalanästhetika (R02AD)
Benzocain (R02AD01)
Lidocain (R02AD02)
Cocain (R02AD03)
Dyclonin (R02AD04)
Andere Hals- und Rachentherapeutika
(R02AX)
Flurbiprofen (R02AX01)
MITTEL BEI OBSTRUKTIVEN
ATEMWEGSERKRANKUNGEN (R03)
INHALATIVE SYMPATHOMIMETIKA
(R03A)
Alpha- und Beta-Adrenozeptor-
Agonisten (R03AA)
Epinephrin (R03AA01)
Nichtselektive Beta-Adrenozeptor-
Agonisten (R03AB)
Isoprenalin (R03AB02)
Orciprenalin (R03AB03)
Selektive Beta2-Adrenozeptor-Agonisten
(R03AC)
Salbutamol (R03AC02)
Terbutalin (R03AC03)
Fenoterol (R03AC04)
Rimiterol (R03AC05)
Hexoprenalin (R03AC06)
Isoetarin (R03AC07)
Pirbuterol (R03AC08)
Tretoquinol (R03AC09)
Carbuterol (R03AC10)
Tulobuterol (R03AC11)
Salmeterol (R03AC12)
Formoterol (R03AC13)
Clenbuterol (R03AC14)
Reproterol (R03AC15)
Procaterol (R03AC16)
Bitolterol (R03AC17)
Indacaterol (R03AC18)
Kombinationen von Sympathomimetika
(R03AH)
Sympathomimetika in Kombination mit
Corticosteroiden oder anderen Mitteln,
exkl. Anticholinergika (R03AK)
Epinephrin und andere Mittel bei
obstruktiven Atemwegserkrankungen
(R03AK01)
Isoprenalin und andere Mittel bei
obstruktiven Atemwegserkrankungen
(R03AK02)
Fenoterol und Cromoglicinsäure,
Dinatriumsalz (R03AK03)
Salbutamol und Cromoglicinsäure,
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Dinatriumsalz (R03AK04)
Reproterol und Cromoglicinsäure,
Dinatriumsalz (R03AK05)
Salmeterol und Fluticason (R03AK06)
Formoterol und Budesonid (R03AK07)
ANDERE INHALATIVE MITTEL BEI
OBSTRUKTIVEN
ATEMWEGSERKRANKUNGEN (R03B)
Glucocorticoide (R03BA)
Beclometason (R03BA01)
Budesonid (R03BA02)
Flunisolid (R03BA03)
Betamethason (R03BA04)
Fluticason (R03BA05)
Triamcinolon (R03BA06)
Mometason (R03BA07)
Ciclesonid (R03BA08)
Anticholinergika (R03BB)
Ipratropium bromid (R03BB01)
Oxitropium bromid (R03BB02)
Stechapfel-haltige Zubereitungen
(R03BB03)
Tiotropium bromid (R03BB04)
Antiallergika, exkl. Corticosteroide
(R03BC)
Cromoglicinsäure (R03BC01)
Nedocromil (R03BC03)
Andere inhalative Mittel bei obstruktiven
Atemwegserkrankungen (R03BX)
Fenspirid (R03BX01)
SYMPATHOMIMETIKA ZUR
SYSTEMISCHEN ANWENDUNG
(R03C)
Alpha- und Beta-Adrenozeptor-
Agonisten (R03CA)
Ephedrin (R03CA02)
Nichtselektive Beta-Adrenozeptor-
Agonisten (R03CB)
Isoprenalin (R03CB01)
Methoxyphenamin (R03CB02)
Orciprenalin (R03CB03)
Isoprenalin, Kombinationen (R03CB51)
Orciprenalin, Kombinationen (R03CB53)
Selektive Beta2-Adrenozeptor-Agonisten
(R03CC)
Salbutamol (R03CC02)
Terbutalin (R03CC03)
Fenoterol (R03CC04)
Hexoprenalin (R03CC05)
Isoetarin (R03CC06)
Pirbuterol (R03CC07)
Procaterol (R03CC08)
Tretoquinol (R03CC09)
Carbuterol (R03CC10)
Tulobuterol (R03CC11)
Bambuterol (R03CC12)
Clenbuterol (R03CC13)
Reproterol (R03CC14)
Terbutalin, Kombinationen (R03CC53)
Sympathomimetika und andere Mittel bei
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obstruktiven Atemwegserkrankungen
(R03CK)
ANDERE MITTEL BEI OBSTRUKTIVEN
ATEMWEGSERKRANKUNGEN ZUR
SYSTEMISCHEN ANWENDUNG
(R03D)
Xanthine (R03DA)
Diprophyllin (R03DA01)
Cholintheophyllinat (R03DA02)
Proxyphyllin (R03DA03)
Theophyllin (R03DA04)
Aminophyllin (R03DA05)
Etamiphyllin (R03DA06)
Theobromin (R03DA07)
Bamifyllin (R03DA08)
Acefyllinpiperazin (R03DA09)
Bufyllin (R03DA10)
Doxofyllin (R03DA11)
Kombinationen von Xanthinen
(R03DA20)
Diprophyllin, Kombinationen (R03DA51)
Theophyllin, Kombinationen exkl.
Psycholeptika (R03DA54)
Aminophyllin, Kombinationen (R03DA55)
Theobromin, Kombinationen (R03DA57)
Theophyllin, Kombinationen mit
Psycholeptika (R03DA74)
Xanthine und Sympathomimetika
(R03DB)
Diprophyllin und Sympathomimetika
(R03DB01)
Cholintheophyllinat und
Sympathomimetika (R03DB02)
Proxyphyllin und Sympathomimetika
(R03DB03)
Theophyllin und Sympathomimetika
(R03DB04)
Aminophyllin und Sympathomimetika
(R03DB05)
Etamiphyllin und Sympathomimetika
(R03DB06)
Leukotrienrezeptor-Antagonisten
(R03DC)
Zafirlukast (R03DC01)
Pranlukast (R03DC02)
Montelukast (R03DC03)
Ibudilast (R03DC04)
Andere Mittel bei obstruktiven
Atemwegserkrankungen zur
systemischen Anwendung (R03DX)
Amlexanox (R03DX01)
Eprozinol (R03DX02)
Fenspirid (R03DX03)
Omalizumab (R03DX05)
Seratrodast (R03DX06)
Roflumilast (R03DX07)
HUSTEN- UND ERKÄLTUNGSMITTEL
(R05)
EXPEKTORANZIEN, EXKL.
KOMBINATIONEN MIT ANTITUSSIVA
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(R05C)
Expektoranzien (R05CA)
Tyloxapol (R05CA01)
Kaliumiodid (R05CA02)
Guaifenesin (R05CA03)
ipecacuanha (R05CA04)
althea root (R05CA05)
senega (R05CA06)
Antimonpentasulfid (R05CA07)
Kreosot (R05CA08)
Guajacolsulfonat (R05CA09)
Kombinationen (R05CA10)
Levoverbenon (R05CA11)
Mukolytika (R05CB)
Acetylcystein (R05CB01)
Bromhexin (R05CB02)
Carbocistein (R05CB03)
Eprazinon (R05CB04)
Mesna (R05CB05)
Ambroxol (R05CB06)
Sobrerol (R05CB07)
Domiodol (R05CB08)
Letostein (R05CB09)
Kombinationen (R05CB10)
Stepronin (R05CB11)
Tiopronin (R05CB12)
Dornase alfa (Desoxyribonuclease)
(R05CB13)
Neltenexin (R05CB14)
Erdostein (R05CB15)
ANTITUSSIVA, EXKL.
KOMBINATIONEN MIT
EXPEKTORANZIEN (R05D)
Opium-Alkaloide und Derivate (R05DA)
Ethylmorphin (R05DA01)
Hydrocodon (R05DA03)
Codein (R05DA04)
Opium-Alkaloide mit Morphin (R05DA05)
Normethadon (R05DA06)
Noscapin (R05DA07)
Pholcodin (R05DA08)
Dextromethorphan (R05DA09)
Thebacon (R05DA10)
Dimemorfan (R05DA11)
Acetyldihydrocodein (R05DA12)
Kombinationen (R05DA20)
Andere Antitussiva (R05DB)
Benzonatat (R05DB01)
Benproperin (R05DB02)
Clobutinol (R05DB03)
Isoaminil (R05DB04)
Pentoxyverin (R05DB05)
Oxolamin (R05DB07)
Oxeladin (R05DB09)
Clofedanol (R05DB10)
Pipazetat (R05DB11)
Bibenzoniumbromid (R05DB12)
Butamirat (R05DB13)
Fedrilat (R05DB14)
Zipeprol (R05DB15)
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Dibunat (R05DB16)
Droxypropin (R05DB17)
Prenoxdiazin (R05DB18)
Dropropizin (R05DB19)
Kombinationen (R05DB20)
Cloperastin (R05DB21)
Meprotixol (R05DB22)
Piperidion (R05DB23)
Tipepidin (R05DB24)
Morclofon (R05DB25)
Nepinalon (R05DB26)
Levodropropizin (R05DB27)
Dimethoxanat (R05DB28)
ANTITUSSIVA UND
EXPEKTORANZIEN, KOMBINATIONEN
(R05F)
Opium-Derivate und Expektoranzien
(R05FA)
Opium-Derivate und Mukolytika
(R05FA01)
Opium-Derivate und Expektoranzien
(R05FA02)
Andere Antitussiva und Expektoranzien
(R05FB)
Antitussiva und Mukolytika (R05FB01)
Antitussiva und Expektoranzien
(R05FB02)
ANDERE ZUBEREITUNGEN GEGEN
ERKÄLTUNGSKRANKHEITEN (R05X)
ANTIHISTAMINIKA ZUR
SYSTEMISCHEN ANWENDUNG (R06)
ANTIHISTAMINIKA ZUR
SYSTEMISCHEN ANWENDUNG
(R06A)
Aminoalkylether (R06AA)
Bromazin (R06AA01)
Diphenhydramin (R06AA02)
Clemastin (R06AA04)
Chlorphenoxamin (R06AA06)
Diphenylpyralin (R06AA07)
Carbinoxamin (R06AA08)
Doxylamin (R06AA09)
Diphenhydramin, Kombinationen
(R06AA52)
Clemastin, Kombinationen (R06AA54)
Chlorphenoxamin, Kombinationen
(R06AA56)
Diphenylpyralin, Kombinationen
(R06AA57)
Substituierte Alkylamine (R06AB)
Brompheniramin (R06AB01)
Dexchlorpheniramin (R06AB02)
Dimetinden (R06AB03)
Chlorphenamin (R06AB04)
Pheniramin (R06AB05)
Dexbrompheniramin (R06AB06)
Talastin (R06AB07)
Brompheniramin, Kombinationen
(R06AB51)
Dexchlorpheniramin, Kombinationen
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(R06AB52)
Chlorphenamin, Kombinationen
(R06AB54)
Dexbrompheniramin, Kombinationen
(R06AB56)
Substituierte Ethylendiamine (R06AC)
Mepyramin (R06AC01)
Histapyrrodin (R06AC02)
Chloropyramin (R06AC03)
Tripelennamin (R06AC04)
Methapyrilen (R06AC05)
Thonzylamin (R06AC06)
Histapyrrodin, Kombinationen
(R06AC52)
Chloropyramin, Kombinationen
(R06AC53)
Phenothiazin-Derivate (R06AD)
Alimemazin (R06AD01)
Promethazin (R06AD02)
Thiethylperazin (R06AD03)
Methdilazin (R06AD04)
Hydroxyethylpromethazin (R06AD05)
Thiazinam (R06AD06)
Mequitazin (R06AD07)
Oxomemazin (R06AD08)
Isothipendyl (R06AD09)
Promethazin, Kombinationen (R06AD52)
Hydroxyethylpromethazin,
Kombinationen (R06AD55)
Piperazin-Derivate (R06AE)
Buclizin (R06AE01)
Cyclizin (R06AE03)
Chlorcyclizin (R06AE04)
Meclozin (R06AE05)
Oxatomid (R06AE06)
Cetirizin (R06AE07)
Levocetirizin (R06AE09)
Buclizin, Kombinationen (R06AE51)
Cyclizin, Kombinationen (R06AE53)
Meclozin, Kombinationen (R06AE55)
Kombinationen von Antihistaminika
(R06AK)
Andere Antihistaminika zur systemischen
Anwendung (R06AX)
Bamipin (R06AX01)
Cyproheptadin (R06AX02)
Thenalidin (R06AX03)
Phenindamin (R06AX04)
Antazolin (R06AX05)
Triprolidin (R06AX07)
Pyrrobutamin (R06AX08)
Azatadin (R06AX09)
Astemizol (R06AX11)
Terfenadin (R06AX12)
Loratadin (R06AX13)
Mebhydrolin (R06AX15)
Deptropin (R06AX16)
Ketotifen (R06AX17)
Acrivastin (R06AX18)
Azelastin (R06AX19)
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Tritoqualin (R06AX21)
Ebastin (R06AX22)
Pimethixen (R06AX23)
Epinastin (R06AX24)
Mizolastin (R06AX25)
Fexofenadin (R06AX26)
Desloratadin (R06AX27)
Rupatadin (R06AX28)
Thenalidin, Kombinationen (R06AX53)
Pyrrobutamin, Kombinationen
(R06AX58)
ANDERE MITTEL FÜR DEN
RESPIRATIONSTRAKT (R07)
ANDERE MITTEL FÜR DEN
RESPIRATIONSTRAKT (R07A)
Surfactant-Präparate (R07AA)
Colfoscerilpalmitat (R07AA01)
natural phospholipids (R07AA02)
Kombinationen (R07AA30)
Atemstimulanzien (R07AB)
Doxapram (R07AB01)
Nikethamid (R07AB02)
Pentetrazol (R07AB03)
Etamivan (R07AB04)
Bemegrid (R07AB05)
Prethcamid (R07AB06)
Almitrin (R07AB07)
Dimeflin (R07AB08)
Mepixanox (R07AB09)
Nikethamid, Kombinationen (R07AB52)
Pentetrazol, Kombinationen (R07AB53)
Andere Mittel für den Respirationstrakt
(R07AX)
Stickoxid (R07AX01)
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ATC S - Sensory Organs
SINNESORGANE
SINNESORGANE
SINNESORGANE (S)
OPHTHALMIKA* (S01)
ANTIINFEKTIVA (S01A)
Antibiotika (S01AA)
Chloramphenicol (S01AA01)
Chlortetracyclin (S01AA02)
Neomycin (S01AA03)
Oxytetracyclin (S01AA04)
Tyrothricin (S01AA05)
Framycetin (S01AA07)
Tetracyclin (S01AA09)
Natamycin (S01AA10)
Gentamicin (S01AA11)
Tobramycin (S01AA12)
Fusidinsäure (S01AA13)
Benzylpenicillin (S01AA14)
Dihydrostreptomycin (S01AA15)
Rifamycin (S01AA16)
Erythromycin (S01AA17)
Polymyxin B (S01AA18)
Ampicillin (S01AA19)
Antibiotika in Kombination mit anderen
Mitteln (S01AA20)
Amikacin (S01AA21)
Micronomicin (S01AA22)
Netilmicin (S01AA23)
Kanamycin (S01AA24)
Azidamfenicol (S01AA25)
Azithromycin (S01AA26)
Kombinationen von Antibiotika
(S01AA30)
Sulfonamide (S01AB)
Sulfamethizol (S01AB01)
Sulfafurazol (S01AB02)
Sulfadicramid (S01AB03)
Sulfacetamid (S01AB04)
Sulfaphenazol (S01AB05)
Antivirale Mittel (S01AD)
Idoxuridin (S01AD01)
Trifluridin (S01AD02)
Aciclovir (S01AD03)
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Interferon (S01AD05)
Vidarabin (S01AD06)
Famciclovir (S01AD07)
Fomivirsen (S01AD08)
Ganciclovir (S01AD09)
Andere Antiinfektiva (S01AX)
Quecksilber-haltige Verbindungen
(S01AX01)
Silber-haltige Verbindungen (S01AX02)
Zink-haltige Verbindungen (S01AX03)
Nitrofural (S01AX04)
Bibrocathol (S01AX05)
Resorcin (S01AX06)
Natriumborat (S01AX07)
Hexamidin (S01AX08)
Chlorhexidin (S01AX09)
Natriumpropionat (S01AX10)
ofloxacin (S01AX11)
norfloxacin (S01AX12)
ciprofloxacin (S01AX13)
Dibrompropamidin (S01AX14)
Propamidin (S01AX15)
Picloxydin (S01AX16)
lomefloxacin (S01AX17)
Povidon-Iod (S01AX18)
levofloxacin (S01AX19)
gatifloxacin (S01AX21)
moxifloxacin (S01AX22)
ANTIPHLOGISTIKA (S01B)
Corticosteroide, rein (S01BA)
Dexamethason (S01BA01)
Hydrocortison (S01BA02)
Cortison (S01BA03)
Prednisolon (S01BA04)
Triamcinolon (S01BA05)
Betamethason (S01BA06)
Fluorometholon (S01BA07)
Medryson (S01BA08)
Clobetason (S01BA09)
Alclometason (S01BA10)
Desonid (S01BA11)
Formocortal (S01BA12)
Rimexolon (S01BA13)
Loteprednol (S01BA14)
Fluocinolon acetonid (S01BA15)
Corticosteroide und Mydriatika in
Kombination (S01BB)
Hydrocortison und Mydriatika (S01BB01)
Prednisolon und Mydriatika (S01BB02)
Fluorometholon und Mydriatika
(S01BB03)
Betamethason und Mydriatika
(S01BB04)
Nichtsteroidale Antiphlogistika (S01BC)
Indometacin (S01BC01)
Oxyphenbutazon (S01BC02)
Diclofenac (S01BC03)
Flurbiprofen (S01BC04)
Ketorolac (S01BC05)
Piroxicam (S01BC06)
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Bendazac (S01BC07)
Salicylsäure (S01BC08)
Pranoprofen (S01BC09)
Nepafenac (S01BC10)
Bromfenac (S01BC11)
ANTIPHLOGISTIKA UND
ANTIINFEKTIVA IN KOMBINATION
(S01C)
Corticosteroide und Antiinfektiva in
Kombination (S01CA)
Dexamethason und Antiinfektiva
(S01CA01)
Prednisolon und Antiinfektiva (S01CA02)
Hydrocortison und Antiinfektiva
(S01CA03)
Fluocortolon und Antiinfektiva
(S01CA04)
Betamethason und Antiinfektiva
(S01CA05)
Fludrocortison und Antiinfektiva
(S01CA06)
Fluorometholon und Antiinfektiva
(S01CA07)
Methylprednisolon und Antiinfektiva
(S01CA08)
Chlorprednison und Antiinfektiva
(S01CA09)
Fluocinolon acetonid und Antiinfektiva
(S01CA10)
Clobetason und Antiinfektiva (S01CA11)
Corticosteroide/Antiinfektiva/Mydriatika
in Kombination (S01CB)
Dexamethason (S01CB01)
Prednisolon (S01CB02)
Hydrocortison (S01CB03)
Betamethason (S01CB04)
Fluorometholon (S01CB05)
Nichtsteroidale Antiphlogistika und
Antiinfektiva in Kombination (S01CC)
Diclofenac und Antiinfektiva (S01CC01)
GLAUKOMMITTEL UND MIOTIKA
(S01E)
Sympathomimetika in der
Glaukomtherapie (S01EA)
Epinephrin (S01EA01)
Dipivefrin (S01EA02)
Apraclonidin (S01EA03)
Clonidin (S01EA04)
Brimonidin (S01EA05)
Epinephrin, Kombinationen (S01EA51)
Parasympathomimetika (S01EB)
Pilocarpin (S01EB01)
Carbachol (S01EB02)
Ecothiopat (S01EB03)
Demecarium (S01EB04)
Physostigmin (S01EB05)
Neostigmin (S01EB06)
Fluostigmin (S01EB07)
Aceclidin (S01EB08)
Acetylcholin (S01EB09)
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Paraoxon (S01EB10)
Pilocarpin, Kombinationen (S01EB51)
Aceclidin, Kombinationen (S01EB58)
Carboanhydrasehemmer (S01EC)
Acetazolamid (S01EC01)
Diclofenamid (S01EC02)
Dorzolamid (S01EC03)
Brinzolamid (S01EC04)
Methazolamid (S01EC05)
Beta-Adrenozeptor-Antagonisten
(S01ED)
Timolol (S01ED01)
Betaxolol (S01ED02)
Levobunolol (S01ED03)
Metipranolol (S01ED04)
Carteolol (S01ED05)
Befunolol (S01ED06)
Timolol, Kombinationen (S01ED51)
Betaxolol, Kombinationen (S01ED52)
Metipranolol, Kombinationen (S01ED54)
Carteolol, Kombinationen (S01ED55)
Prostaglandin-Analoga (S01EE)
Latanoprost (S01EE01)
Unoproston (S01EE02)
Bimatoprost (S01EE03)
Travoprost (S01EE04)
Tafluprost (S01EE05)
Andere Glaukommittel (S01EX)
Guanethidin (S01EX01)
Dapiprazol (S01EX02)
MYDRIATIKA UND ZYKLOPLEGIKA
(S01F)
Anticholinergika (S01FA)
Atropin (S01FA01)
Scopolamin (S01FA02)
Methylscopolamin (S01FA03)
Cyclopentolat (S01FA04)
Homatropin (S01FA05)
Tropicamid (S01FA06)
Tropicamid, Kombinationen (S01FA56)
Sympathomimetika, exkl. Glaukommittel
(S01FB)
Phenylephrin (S01FB01)
Ephedrin (S01FB02)
Ibopamin (S01FB03)
DEKONGESTIVA UND
ANTIALLERGIKA (S01G)
Sympathomimetika als Dekongestiva
(S01GA)
Naphazolin (S01GA01)
Tetryzolin (S01GA02)
Xylometazolin (S01GA03)
Oxymetazolin (S01GA04)
Phenylephrin (S01GA05)
Oxedrin (S01GA06)
Naphazolin, Kombinationen (S01GA51)
Tetryzolin, Kombinationen (S01GA52)
Xylometazolin, Kombinationen
(S01GA53)
Phenylephrin, Kombinationen
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(S01GA55)
Oxedrin, Kombinationen (S01GA56)
Andere Antiallergika (S01GX)
Cromoglicinsäure (S01GX01)
Levocabastin (S01GX02)
Spagluminsäure (S01GX03)
Nedocromil (S01GX04)
Lodoxamid (S01GX05)
Emedastin (S01GX06)
Azelastin (S01GX07)
Ketotifen (S01GX08)
Olopatadin (S01GX09)
Epinastin (S01GX10)
Cromoglicinsäure, Kombinationen
(S01GX51)
LOKALANÄSTHETIKA (S01H)
Lokalanästhetika (S01HA)
Cocain (S01HA01)
Oxybuprocain (S01HA02)
Tetracain (S01HA03)
Proxymetacain (S01HA04)
Procain (S01HA05)
Cinchocain (S01HA06)
Lidocain (S01HA07)
Kombinationen (S01HA30)
DIAGNOSTIKA (S01J)
Farbstoffe (S01JA)
Fluorescein (S01JA01)
Bengalrosa-Natrium (S01JA02)
Fluorescein, Kombinationen (S01JA51)
Andere ophthalmologische Diagnostika
(S01JX)
CHIRURGISCHE HILFSMITTEL (S01K)
Viskoelastische Substanzen (S01KA)
Hyaluronsäure (S01KA01)
Hypromellose (S01KA02)
Hyaluronsäure, Kombinationen
(S01KA51)
Andere chirurgische Hilfsmittel (S01KX)
Chymotrypsin (S01KX01)
MITTEL GEGEN VASKULÄRE
AUGENERKRANKUNGEN (S01L)
Antineovaskuläre Mittel (S01LA)
Verteporfin (S01LA01)
Anecortav (S01LA02)
Pegaptanib (S01LA03)
Ranibizumab (S01LA04)
ANDERE OPHTHALMIKA (S01X)
Andere Ophthalmika (S01XA)
Guajazulen (S01XA01)
Retinol (S01XA02)
Natriumchlorid, hyperton (S01XA03)
Kaliumiodid (S01XA04)
Natriumedetat (S01XA05)
Ethylmorphin (S01XA06)
Alaun (S01XA07)
Acetylcystein (S01XA08)
Iodoheparinat (S01XA09)
Inosin (S01XA10)
Nandrolon (S01XA11)
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Dexpanthenol (S01XA12)
Alteplase (S01XA13)
Heparin (S01XA14)
Ascorbinsäure (S01XA15)
Ciclosporin (S01XA18)
Künstliche Tränen und andere
indifferente Mittel (S01XA20)
OTOLOGIKA (S02)
ANTIINFEKTIVA (S02A)
Antiinfektiva (S02AA)
Chloramphenicol (S02AA01)
Nitrofural (S02AA02)
Borsäure (S02AA03)
Aluminiumacetattartrat (S02AA04)
Clioquinol (S02AA05)
Hydrogenperoxid (S02AA06)
Neomycin (S02AA07)
Tetracyclin (S02AA08)
Chlorhexidin (S02AA09)
Essigsäure (S02AA10)
Polymyxin B (S02AA11)
Rifamycin (S02AA12)
Miconazol (S02AA13)
Gentamicin (S02AA14)
Ciprofloxacin (S02AA15)
Ofloxacin (S02AA16)
Antiinfektiva, Kombinationen (S02AA30)
CORTICOSTEROIDE (S02B)
Corticosteroide (S02BA)
Hydrocortison (S02BA01)
Prednisolon (S02BA03)
Dexamethason (S02BA06)
Betamethason (S02BA07)
Fluocinolon acetonid (S02BA08)
CORTICOSTEROIDE UND
ANTIINFEKTIVA IN KOMBINATION
(S02C)
Corticosteroide und Antiinfektiva in
Kombination (S02CA)
Prednisolon und Antiinfektiva (S02CA01)
Flumetason und Antiinfektiva (S02CA02)
Hydrocortison und Antiinfektiva
(S02CA03)
Triamcinolon und Antiinfektiva
(S02CA04)
Fluocinolon acetonid und Antiinfektiva
(S02CA05)
Dexamethason und Antiinfektiva
(S02CA06)
Fludrocortison und Antiinfektiva
(S02CA07)
ANDERE OTOLOGIKA (S02D)
Analgetika und Anästhetika (S02DA)
Lidocain (S02DA01)
Cocain (S02DA02)
Phenazon (S02DA03)
Kombinationen (S02DA30)
Indifferente Zubereitungen (S02DC)
OPHTHALMOLOGISCHE UND
OTOLOGISCHE ZUBEREITUNGEN
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(S03)
ANTIINFEKTIVA (S03A)
Antiinfektiva (S03AA)
Neomycin (S03AA01)
Tetracyclin (S03AA02)
Polymyxin B (S03AA03)
Chlorhexidin (S03AA04)
Hexamidin (S03AA05)
Gentamicin (S03AA06)
Ciprofloxacin (S03AA07)
Chloramphenicol (S03AA08)
Antiinfektiva, Kombinationen (S03AA30)
CORTICOSTEROIDE (S03B)
Corticosteroide (S03BA)
Dexamethason (S03BA01)
Prednisolon (S03BA02)
Betamethason (S03BA03)
CORTICOSTEROIDE UND
ANTIINFEKTIVA IN KOMBINATION
(S03C)
Corticosteroide und Antiinfektiva in
Kombination (S03CA)
Dexamethason und Antiinfektiva
(S03CA01)
Prednisolon und Antiinfektiva (S03CA02)
Hydrocortison und Antiinfektiva
(S03CA04)
Fludrocortison und Antiinfektiva
(S03CA05)
Betamethason und Antiinfektiva
(S03CA06)
ANDERE OPHTHALMOLOGISCHE
UND OTOLOGISCHE
ZUBEREITUNGEN (S03D)
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ATC V - Various
VARIA
VARIA
VARIA (V)
ALLERGENE (V01)
ALLERGENE (V01A)
Allergen-Extrakte (V01AA)
Federn (V01AA01)
Gräserpollen (V01AA02)
Hausstaubmilben (V01AA03)
Schimmel- und Hefepilze (V01AA04)
Baumpollen (V01AA05)
Insekten (V01AA07)
Nahrungsmittel (V01AA08)
Textilien (V01AA09)
Blüten (V01AA10)
Tiere (V01AA11)
Verschiedene (V01AA20)
ALLE ÜBRIGEN THERAPEUTISCHEN
MITTEL (V03)
ALLE ÜBRIGEN THERAPEUTISCHEN
MITTEL (V03A)
Antidote (V03AB)
Ipecacuanha (V03AB01)
Nalorphin (V03AB02)
Edetate (V03AB03)
Pralidoxim (V03AB04)
Prednisolon und Promethazin
(V03AB05)
Thiosulfat (V03AB06)
Natriumnitrit (V03AB08)
Dimercaprol (V03AB09)
Obidoxim (V03AB13)
Protamin (V03AB14)
Naloxon (V03AB15)
Ethanol (V03AB16)
Methylthioniniumchlorid (V03AB17)
Kaliumpermanganat (V03AB18)
Physostigmin (V03AB19)
Kupfersulfat (V03AB20)
Kaliumiodid (V03AB21)
Amylnitrit (V03AB22)
Acetylcystein (V03AB23)
Digitalis-Antitoxin (V03AB24)
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Flumazenil (V03AB25)
Methionin (V03AB26)
4-Dimethylaminophenol (V03AB27)
Cholinesterase (V03AB29)
Eisen(III)hexacyanoferrat(II) (V03AB31)
Glutathion (V03AB32)
Hydroxocobalamin (V03AB33)
Fomepizol (V03AB34)
Sugammadex (V03AB35)
Eisen-Chelatbildner (V03AC)
Deferoxamin (V03AC01)
Deferipron (V03AC02)
Deferasirox (V03AC03)
Mittel zur Behandlung der Hyperkaliämie
und Hyperphosphatämie (V03AE)
Polystyrolsulfonat (V03AE01)
Sevelamer (V03AE02)
Lanthan(III)-carbonat (V03AE03)
Calciumacetat und Magnesiumcarbonat
(V03AE04)
Entgiftungsmittel für die Behandlung mit
Zytostatika (V03AF)
Mesna (V03AF01)
Dexrazoxan (V03AF02)
Calciumfolinat (V03AF03)
Calciumlevofolinat (V03AF04)
Amifostin (V03AF05)
Natriumfolinat (V03AF06)
Rasburicase (V03AF07)
Palifermin (V03AF08)
Glucarpidase (V03AF09)
Natriumlevofolinat (V03AF10)
Mittel zur Behandlung der
Hyperkalzämie (V03AG)
Natriumcellulosephosphat (V03AG01)
Mittel zur Behandlung der Hypoglykämie
(V03AH)
Diazoxid (V03AH01)
Gewebekleber (V03AK)
Mittel zur Embolisation (V03AM)
Medizinische Gase (V03AN)
Sauerstoff (V03AN01)
Kohlendioxid (V03AN02)
Helium (V03AN03)
Stickstoff (V03AN04)
Medizinische Luft (V03AN05)
Andere therapeutische Mittel (V03AX)
Nalfurafin (V03AX02)
Nerven dämpfende Mittel (V03AZ)
Ethanol (V03AZ01)
DIAGNOSTIKA (V04)
URIN-TESTS (V04B)
ANDERE DIAGNOSTIKA (V04C)
Diabetes-Tests (V04CA)
Tolbutamid (V04CA01)
Glucose (V04CA02)
Fettabsorptions-Tests (V04CB)
Vitamin-A-Konzentrate (V04CB01)
Gallenfluss-Tests (V04CC)
Sorbitol (V04CC01)
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Magnesiumsulfat (V04CC02)
Sincalid (V04CC03)
Ceruletid (V04CC04)
Hypophysenfunktions-Tests (V04CD)
Metyrapon (V04CD01)
Sermorelin (V04CD03)
Corticoliberin (V04CD04)
Somatorelin (V04CD05)
Leberfunktions-Tests (V04CE)
Galactose (V04CE01)
Bromsulfalein (V04CE02)
Tuberkulose-Diagnostika (V04CF)
Tuberkulin (V04CF01)
Magensäuresekretions-Tests (V04CG)
Kationenaustauscherharze (V04CG01)
Betazol (V04CG02)
Histaminphosphat (V04CG03)
Pentagastrin (V04CG04)
Methylthioniniumchlorid (V04CG05)
Coffein und Natriumbenzoat (V04CG30)
Nierenfunktionstests und Tests auf
Harnleiterverletzungen (V04CH)
Inulin und andere Polyfructosane
(V04CH01)
Indigokarmin (V04CH02)
Phenolsulfonphthalein (V04CH03)
Alsactid (V04CH04)
Aminohippursäure (V04CH30)
Schilddrüsenfunktions-Tests (V04CJ)
Thyrotropin (V04CJ01)
Protirelin (V04CJ02)
Pankreasfunktions-Tests (V04CK)
Sekretin (V04CK01)
Pankreozymin (Cholecystokinin)
(V04CK02)
Bentiromid (V04CK03)
Allergie-Tests (V04CL)
Fertilitäts-Tests (V04CM)
Gonadorelin (V04CM01)
Andere Diagnostika (V04CX)
ALLGEMEINE DIÄTETIKA (V06)
DIÄTETIKA ZUR BEHANDLUNG DER
ADIPOSITAS (V06A)
Niedrigkalorische Diäten (V06AA)
PROTEINZUSATZNAHRUNG (V06B)
SÄUGLINGSNAHRUNG (V06C)
Diätetika ohne Phenylalanin (V06CA)
ANDERE DIÄTETIKA (V06D)
Kohlenhydrate/Proteine/Mineralstoffe/Vit
amine, Kombinationen (V06DA)
Fette/Kohlenhydrate/Proteine/Mineralstof
fe/Vitamine, Kombinationen (V06DB)
Kohlenhydrate (V06DC)
Glucose (V06DC01)
Fructose (V06DC02)
Aminosäuren, inkl. Kombinationen mit
Polypeptiden (V06DD)
Aminosäuren/Kohlenhydrate/Mineralstoff
e/Vitamine, Kombinationen (V06DE)
Milchersatzstoffe (V06DF)
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Andere Diätetika-Kombinationen
(V06DX)
ALLE ÜBRIGEN
NICHTTHERAPEUTISCHEN MITTEL
(V07)
ALLE ÜBRIGEN
NICHTTHERAPEUTISCHEN MITTEL
(V07A)
Pflaster (V07AA)
Lösungs- und Verdünnungsmittel, inkl.
Spüllösungen (V07AB)
Bluttransfusionen, Hilfsstoffe (V07AC)
Blut-Tests, Hilfsmittel (V07AD)
Inkontinenz-Artikel (V07AN)
Sensitivitäts-Tests, Plättchen und
Tabletten (V07AR)
Stoma-Artikel (V07AS)
Kosmetika (V07AT)
Technische Desinfektionsmittel (V07AV)
Waschsubstanzen etc. (V07AX)
Andere nichttherapeutische Hilfsmittel
(V07AY)
Chemikalien und Reagenzien zur
Analyse (V07AZ)
KONTRASTMITTEL (V08)
RÖNTGENKONTRASTMITTEL, IOD-
HALTIG (V08A)
Wasserlösliche nephrotrope
hochosmolare Röntgenkontrastmittel
(V08AA)
Amidotrizoesäure (V08AA01)
Metrizoesäure (V08AA02)
Iodamid (V08AA03)
Iotalaminsäure (V08AA04)
Ioxitalaminsäure (V08AA05)
Ioglicinsäure (V08AA06)
Acetrizoinsäure (V08AA07)
Iocarminsäure (V08AA08)
Methiodal (V08AA09)
Diodon (V08AA10)
Wasserlösliche nephrotrope
niederosmolare Röntgenkontrastmittel
(V08AB)
Metrizamid (V08AB01)
Iohexol (V08AB02)
Ioxaglinsäure (V08AB03)
Iopamidol (V08AB04)
Iopromid (V08AB05)
Iotrolan (V08AB06)
Ioversol (V08AB07)
Iopentol (V08AB08)
Iodixanol (V08AB09)
Iomeprol (V08AB10)
Iobitridol (V08AB11)
Ioxilan (V08AB12)
Wasserlösliche hepatotrope
Röntgenkontrastmittel (V08AC)
Iodoxaminsäure (V08AC01)
Iotroxinsäure (V08AC02)
Ioglycaminsäure (V08AC03)
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Adipiodon (V08AC04)
Iobenzaminsäure (V08AC05)
Iopansäure (V08AC06)
Iocetaminsäure (V08AC07)
Natriumiopodat (V08AC08)
Tyropansäure (V08AC09)
Calciumiopodat (V08AC10)
Wasserunlösliche Röntgenkontrastmittel
(V08AD)
Ethylester iodierter Fettsäuren
(V08AD01)
Iopydol (V08AD02)
Propyliodon (V08AD03)
Iofendylat (V08AD04)
RÖNTGENKONTRASTMITTEL, NICHT
IOD-HALTIG (V08B)
Bariumsulfat-haltige
Röntgenkontrastmittel (V08BA)
Bariumsulfat mit Suspensionsmittel
(V08BA01)
Bariumsulfat ohne Suspensionsmittel
(V08BA02)
KONTRASTMITTEL FÜR DIE
MAGNETRESONANZTOMOGRAPHIE
(V08C)
Paramagnetische Kontrastmittel (V08CA)
Gadopentetsäure (V08CA01)
Gadotersäure (V08CA02)
Gadodiamid (V08CA03)
Gadoteridol (V08CA04)
Mangafodipir (V08CA05)
Gadoversetamid (V08CA06)
Ammoniumeisen(III)citrat (V08CA07)
Gadobensäure (V08CA08)
Gadobutrol (V08CA09)
Gadoxetsäure (V08CA10)
Gadofosveset (V08CA11)
Superparamagnetische Kontrastmittel
(V08CB)
Ferumoxsil (V08CB01)
Ferristen (V08CB02)
Eisenoxid, Nanopartikel (V08CB03)
Andere Kontrastmittel für die
Magnetresonanztomographie (V08CX)
Perflubron (V08CX01)
ULTRASCHALL-KONTRASTMITTEL
(V08D)
Ultraschall-Kontrastmittel (V08DA)
Humanalbumin-Mikrosphären
(V08DA01)
Galactose-Mikropartikel (V08DA02)
Perflenapent (V08DA03)
Phospholipid-Mikrosphären (V08DA04)
Schwefelhexafluorid (V08DA05)
RADIODIAGNOSTIKA (V09)
ZENTRALES NERVENSYSTEM (V09A)
[99mTc]Technetium-Verbindungen
(V09AA)
[99mTc]Technetium-Exametazim
(V09AA01)
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[99mTc]Technetium-Bicisat (V09AA02)
[123I]Iod-Verbindungen (V09AB)
[123I]Iod-Iofetamin (V09AB01)
[123I]Iod-Ioloprid (V09AB02)
[123I]Iod-Ioflupan (V09AB03)
Andere Radiodiagnostika für das
zentrale Nervensystem (V09AX)
[111In]Indium(III) pentetat (V09AX01)
[124I]Iod-2 beta-carboxymethyl-3 beta-
(4-iodphenyl)-tropan (V09AX03)
SKELETT (V09B)
[99mTc]Technetium-Verbindungen
(V09BA)
[99mTc]Technetium-Oxidronat
(V09BA01)
[99mTc]Technetium-Medronat
(V09BA02)
[99mTc]Technetium-Pyrophosphat
(V09BA03)
[99mTc]Technetium-Butedronat
(V09BA04)
NIERENSYSTEM (V09C)
[99mTc]Technetium-Verbindungen
(V09CA)
[99mTc]Technetium-Pentetat (V09CA01)
[99mTc]Technetium-Succimer
(V09CA02)
[99mTc]Technetium-Mertiatid (V09CA03)
[99mTc]Technetium-Glucoheptonat
(V09CA04)
[99mTc]Technetium-Gluconat
(V09CA05)
Andere Radiodiagnostika für das
Nierensystem (V09CX)
Natrium iodhippurat[123I] (V09CX01)
Natrium iodhippurat[131I] (V09CX02)
Natrium iodtalamat[125I] (V09CX03)
[51Cr]Chromedetat (V09CX04)
LEBER- UND
RETIKULOENDOTHELIALSYSTEM
(V09D)
[99mTc]Technetium-Verbindungen
(V09DA)
[99mTc]Technetium-Disofenin
(V09DA01)
[99mTc]Technetium-Etifenin (V09DA02)
[99mTc]Technetium-Lidofenin
(V09DA03)
[99mTc]Technetium-Mebrofenin
(V09DA04)
[99mTc]Technetium-Galtifenin
(V09DA05)
[99mTc]Technetium, Partikel und
Kolloide (V09DB)
[99mTc]Technetium-Nanokolloid
(V09DB01)
[99mTc]Technetium-Mikrokolloid
(V09DB02)
[99mTc]Technetium-Millimikrosphären
(V09DB03)
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[99mTc]Technetium-Zinn-Kolloid
(V09DB04)
[99mTc]Technetium-Schwefel-Kolloid
(V09DB05)
[99mTc]Technetium-Rheniumsulfid-
Kolloid (V09DB06)
[99mTc]Technetium-Phytat (V09DB07)
Andere Radiodiagnostika für das Leber-
und Retikuloendothelialsystem (V09DX)
[75Se]Selenium-Tauroselcholinat
(V09DX01)
RESPIRATIONSTRAKT (V09E)
[99mTc]Technetium, Inhalate (V09EA)
[99mTc]Technetium-Pentetat (V09EA01)
[99mTc]Technetium, Technegas
(V09EA02)
[99mTc]Technetium-Nanokolloid
(V09EA03)
[99mTc]Technetium, Partikel zur
Injektion (V09EB)
[99mTc]Technetium-Macrosalb
(V09EB01)
[99mTc]Technetium-Mikrosphären
(V09EB02)
Andere Radiodiagnostika für den
Respirationstrakt (V09EX)
[81mKr]Kryptongas (V09EX01)
[127Xe]Xenongas (V09EX02)
[133Xe]Xenongas (V09EX03)
SCHILDDRÜSE (V09F)
Verschiedene Radiodiagnostika für die
Schilddrüse (V09FX)
[99mTc]Technetium-Pertechnetat
(V09FX01)
[123I]Natriumiodid (V09FX02)
[131I]Natriumiodid (V09FX03)
[124I]Natriumiodid (V09FX04)
KARDIOVASKULÄRES SYSTEM
(V09G)
[99mTc]Technetium-Verbindungen
(V09GA)
[99mTc]Technetium-Sestamibi
(V09GA01)
[99mTc]Technetium-Tetrofosmin
(V09GA02)
[99mTc]Technetium-Teboroxim
(V09GA03)
[99mTc]Technetium-Humanalbumin
(V09GA04)
[99mTc]Technetium-Furifosmin
(V09GA05)
[99mTc]Technetium-Zinn-markierte
Zellen (V09GA06)
[99mTc]Technetium-Apcitid (V09GA07)
[125I]Iod-Verbindungen (V09GB)
[125I]Fibrinogen (V09GB01)
[125I]Iod-Humanalbumin (V09GB02)
Andere Radiodiagnostika für das
kardiovaskuläre System (V09GX)
[201Tl]Thallium(I)-chlorid (V09GX01)
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[111In]Indium-Imciromab (V09GX02)
[51Cr]Chromchromat-markierte Zellen
(V09GX03)
ENTZÜNDUNGS- UND
INFEKTIONSERKENNUNG (V09H)
[99mTc]Technetium-Verbindungen
(V09HA)
[99mTc]Technetium-
Humanimmunglobulin (V09HA01)
[99mTc]Technetium-Exametazim-
markierte Zellen (V09HA02)
[99mTc]Technetium-Antigranulozyten-
Antikörper (V09HA03)
[99mTc]Technetium-Sulesomab
(V09HA04)
[111In]Indium-Verbindungen (V09HB)
[111In]Indiumoxinat-markierte Zellen
(V09HB01)
[111In]Indiumtropolonat-markierte Zellen
(V09HB02)
Andere Radiodiagnostika zur Erkennung
von Entzündungen und Infektionen
(V09HX)
Gallium[67Ga]citrat (V09HX01)
TUMORERKENNUNG (V09I)
[99mTc]Technetium-Verbindungen
(V09IA)
[99mTc]Technetium-
Anticarcinoembryoantigen-Antikörper
(V09IA01)
[99mTc]Technetium-Antimelanom-
Antikörper (V09IA02)
[99mTc]Technetium-Succimer,
pentavalent (V09IA03)
[99mTc]Technetium-Votumumab
(V09IA04)
[99mTc]Technetium-Depreotid (V09IA05)
[99mTc]Technetium-Arcitumomab
(V09IA06)
[111In]Indium-Verbindungen (V09IB)
[111In]Indium-Pentetreotid (V09IB01)
[111In]Indium Satumomab pendetid
(V09IB02)
[111In]Indium-Antiovariumkarzinom-
Antikörper (V09IB03)
[111In]Indium-Capromab-Pendetid
(V09IB04)
Andere Radiodiagnostika zur
Tumorerkennung (V09IX)
Iobenguan[123I] (V09IX01)
Iobenguan[131I] (V09IX02)
[125I]Iod-CC49-Monoklonaler Antikörper
(V09IX03)
Fludeoxyglucose[18F] (V09IX04)
Fluorodopa[18F] (V09IX05)
Natrium[18F]fluorid (V09IX06)
Fluoromethylcholin[18F] (V09IX07)
ANDERE RADIODIAGNOSTIKA (V09X)
[131I]Iod-Verbindungen (V09XA)
[131I]Iodnorcholesterol (V09XA01)
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[131I]Iodcholesterol (V09XA02)
[131I]Iod-Humanalbumin (V09XA03)
Verschiedene Radiodiagnostika (V09XX)
[57Co]Cobaltcyanocobalamin (V09XX01)
[58Co]Cobaltcyanocobalamin (V09XX02)
[75Se]Selennorcholesterol (V09XX03)
[59Fe]Eisen(III)citrat (V09XX04)
RADIOTHERAPEUTIKA (V10)
ENTZÜNDUNGSHEMMENDE MITTEL
(V10A)
[90Y]Yttrium-Verbindungen (V10AA)
[90Y]Yttriumcitrat-Kolloid (V10AA01)
[90Y]Yttrium-Eisen(III)hydroxid-Kolloid
(V10AA02)
[90Y]Yttriumsilicat-Kolloid (V10AA03)
Andere entzündungshemmende
Radiotherapeutika (V10AX)
Chrom(III)-[32P]phosphat-Kolloid
(V10AX01)
[153Sm]Samariumhydroxyapatit-Kolloid
(V10AX02)
[165Dy]Dysprosium-Kolloid (V10AX03)
[169Er]Erbiumcitrat-Kolloid (V10AX04)
[186Re]Rheniumsulfid-Kolloid
(V10AX05)
[198Au]Gold-Kolloid (V10AX06)
SCHMERZLINDERUNG
(KNOCHENMETASTASEN) (V10B)
Verschiedene Radiopharmaka zur
Schmerzlinderung (V10BX)
[89Sr]Strontiumchlorid (V10BX01)
Samarium[153Sm]lexidronam
(V10BX02)
[186Re]Rhenium-Etidronat (V10BX03)
ANDERE RADIOTHERAPEUTIKA
(V10X)
[131I]Iod-Verbindungen (V10XA)
[131I]Natriumiodid (V10XA01)
Iobenguan[131I] (V10XA02)
Tositumomab/[131I]Iod tositumomab
(V10XA53)
Verschiedene Radiotherapeutika
(V10XX)
Natriumphosphat[32P] (V10XX01)
[90Y]Ibritumomab tiuxetan (V10XX02)
WUNDVERBÄNDE (V20)
9 / 9
ATC V - Various
Notaufnahmeprotokoll - Basismodul
Emergency protocol by the DIVI (Deutsche Interdisziplinre
Vereinigung für Intensiv- und Notfallmedizin). ODM derived
from "Notaufnahmeprotokoll Modul Basis".
All rights reserved. Please visit https://medical-data-
models.org/forms/12067
Emergency protocol- Module Basis
PATIENTENINFORMATIONEN
Patienten-ID:*
Name des Patienten:*
Anschrift:
Telefon:
Geburtsdatum:*
Versicherung:*
GKV (1)
BG (2)
UTV (3)
P (4)
Geschlecht:
männlich  (1)
weiblich (2)
Aufnahmedatum und Aufnahmezeit:
Vital signs and other informations
VITALPARAMETER
Atemfrequenz:
/min
Sauerstoffsättigung
%
Systolischer Blutdruck:
mmHg
Herzfrequenz:
bpm
Körperkerntemperatur:
°C
Glasgow-Koma-Skala:
Rechte Pupillenweite:
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weit (1)
mittel (2)
eng (3)
Linke Pupillenweite:
weit (1)
mittel (2)
eng (3)
Lichtreaktion (rechts):
prompt (1)
träge (2)
keine (3)
Lichtreaktion (links):
prompt (1)
träge (2)
keine (3)
Schmerzskala:
>= 0
<= 10
ANDERE INFORMATIONEN
Manchester-Triage-System/ Emergency Severity
Index (MTS/ ESI):
Schwanger:
ja (1)
nein (2)
unbekannt (3)
Tetanusschutz:
ja (1)
nein (2)
unbekannt (3)
Rankin-Skala:
>= 0
<= 5
Isolation:
Nein (1)
Multiresistenter Keim (2)
Gastroenteritis (3)
Tuberkulose (4)
Meningitis (5)
Umkehriso (6)
Andere (7)
Multiresistente Keime:
Nein (1)
Ja Andere (10)
V.a. Andere (11)
Ja MRSA (2)
V.a. MRSA (3)
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Ja 3-MRGN (4)
V.a. 3-MRGN (5)
Ja 4-MRGN (6)
V.a. 4-MRGN (7)
Ja VRE (8)
V.a. VRE (9)
Zuweisung:
Ohne (1)
Vertragsarzt/ Praxis (2)
KV-Notdienst am KH (3)
KV-Notdienst außerhalb KH (4)
Rettungsdienst (5)
Notarzt (6)
Klinik/ Verlegung (7)
Andere (8)
Transportmittel:
Ohne (1)
KTW (2)
RTW (3)
NAW/NEF/ITW (4)
RTH/ITH (5)
Anderes (6)
Diagnostics
DIAGNOSTIK:
Labor:
ja (1)
nein (2)
opB ja (3)
opB nein (4)
Labor Zeit:
Blutgasanalyse:
ja (1)
nein (2)
opB ja (3)
opB nein (4)
Blutgasanalyse Zeit:
U-Stix:
ja (1)
nein (2)
opB ja (3)
opB nein (4)
U-Stix Zeit:
EKG:
ja (1)
nein (2)
opB ja (3)
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opB nein (4)
EKG Zeit:
Sono:
ja (1)
nein (2)
opB ja (3)
opB nein (4)
Sono Zeit:
Echo:
ja (1)
nein (2)
opB ja (3)
opB nein (4)
Echo Zeit:
CCT:
ja (1)
nein (2)
opB ja (3)
opB nein (4)
CCT Zeit:
CT:
ja (1)
nein (2)
opB ja (3)
opB nein (4)
CT Zeit:
Traumascan:
ja (1)
nein (2)
opB ja (3)
opB nein (4)
Traumascan Zeit:
MRT:
ja (1)
nein (2)
opB ja (3)
opB nein (4)
MRT Zeit:
Rö. WS:
ja (1)
nein (2)
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opB ja (3)
opB nein (4)
Rö. WS Zeit:
Rö. Thorax:
ja (1)
nein (2)
opB ja (3)
opB nein (4)
Rö. Thorax Zeit:
Rö. Becken:
ja (1)
nein (2)
opB ja (3)
opB nein (4)
Rö. Becken Zeit:
Rö. Extremität:
ja (1)
nein (2)
opB ja (3)
opB nein (4)
Rö. Extremität Zeit:
Rö. Sonstiges:
ja (1)
nein (2)
opB ja (3)
opB nein (4)
Rö. Sonstiges Zeit:
Anamnesis
NOTFALLANAMNESE
Leitsymptom:
Körperliche Untersuchung:
Relevante Eigenmedikation:
Leitsymptom seit:
Erster Arztkontakt seit:
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Allergien:
Befunde:
Verlauf / durchgeführte Therapie:
Initiierung Therapie seit:
Abschlussdiagnosen:
ICD 10:
Weiteres Procedere /Therapieempfehlung /
Weiterbehandler:
Verlegung intern Funktion (OP, HKL, oä)
(1)
Abbruch durch Pat. (10)
Kein Arztkontakt  (11)
Sonstige Entlassung (12)
Tod (13)
Verlegung intern Überwachung (ITS,
IMC, oä) (2)
Verlegung intern Normalstation (3)
Verlegung extern Funktion (OP, HKL, oä)
(4)
Verlegung extern Überwachung (ITS,
IMC, oä) (5)
Verlegung extern Normalstation (6)
Entlassung nach Hause (7)
Entlassung zu weiterbehandl. Arzt (8)
Entlassung gegen ärztl. Rat (9)
Zeitpunkt Verlegung/Entlasssung:
Kommentare:
Zusatzmodule (Überwachung, Trauma, Konsil,
Neurologie, Anästhesie), bitte die passenden
Module eintragen
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Preoperative Anesthesia Assessment DIVI
(EXTRACT)
Used only for teaching purposes at GMDS Conference
2015.
Short extract of Preoperative Anesthesia Assessment
based on Anesthesia Documentation by
"Anästhesie V2015.1 Stand 18.12.14 © Sektion
Notaufnahmeprotokoll der DIVI
(Deutsche Interdisziplinäre Vereinigung für Intensiv- und
Notfallmedizin)"
All rights reserved. Please visit https://medical-data-
models.org/forms/12068
Preoperative Anesthesia
Assessment DIVI (EXTRACT)
Administrative Data
Patient First Name
Patient Surname
Gender
Female (FEMALE)
Male (MALE)
Preoperative Assessment
ASA
A normal healthy patient (1)
A patient with mild systemic disease (2)
A patient with severe systemic disease
(3)
A patient with severe systemic disease
that is a constant threat to life (4)
A moribund patient who is not expected
to survive without the operation (5)
Urgency of procedure
elective (elective)
emergency (emergent)
urgent (urgent)
Height (cm)
cm
Weight (kg)
kg
Mallampati score
The soft palate, uvula, fauces, and pillars
are visible (Class 1)
The soft palate, uvula and fauces are
visible (Class 2)
The soft palate and base of uvula are
visible (Class 3)
The hard palate only is visible (Class 4)
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OPS Chapter 5 SURGERIES
derived from:
OPS - German Procedure Classification
https://www.dimdi.de/static/en/klassi/ops/index.htm
DIMDI publishes the OPS classification on behalf of the
Federal Ministry of Health; it is in the public domain. Its use
in inpatient care is laid down in  301 Volume V of the
German Social Security Code (SGB V) and for surgical
procedures in the outpatient sector in  295 SGB V.
All rights reserved. Please visit https://medical-data-
models.org/forms/12078
OPS Chapter 5 SURGERIES
OPERATIONEN
OPERATIONEN
Inzision (Trepanation) und Exzision an
Schädel, Gehirn und Hirnhäuten (5-01)
Schädeleröffnung über die Kalotte (5-
010)
Zugang durch die Schädelbasis (5-011)
Inzision der Schädelknochen
[Kraniotomie und Kraniektomie] (5-012)
Inzision von Gehirn und Hirnhäuten (5-
013)
Stereotaktische Operationen an Schädel,
Gehirn und Hirnhäuten (5-014)
Exzision und Destruktion von erkranktem
intrakraniellem Gewebe (5-015)
Exzision und Destruktion von erkranktem
Gewebe der Schädelknochen (5-016)
Inzision, Resektion und Destruktion an
intrakraniellen Anteilen von Hirnnerven
und Ganglien (5-017)
Mikrovaskuläre Dekompression von
intrakraniellen Nerven (5-018)
Andere Operationen an Schädel, Gehirn
und Hirnhäuten (5-02)
Kranioplastik (5-020)
Rekonstruktion der Hirnhäute (5-021)
Inzision am Liquorsystem (5-022)
Anlegen eines Liquorshuntes [Shunt-
Implantation] (5-023)
Revision und Entfernung von
Liquorableitungen (5-024)
Inzision, Exzision, Destruktion und
Verschluss von intrakraniellen
Blutgefäßen (5-025)
Rekonstruktion von intrakraniellen
Blutgefäßen (5-026)
Anlegen eines Bypasses und
Transposition von intrakraniellen
Blutgefäßen (5-027)
Funktionelle Eingriffe an Schädel, Gehirn
und Hirnhäuten (5-028)
Andere Operationen an Schädel, Gehirn
und Hirnhäuten (5-029)
Operationen an Rückenmark,
Rückenmarkhäuten und Spinalkanal (5-
03)
Zugang zum kraniozervikalen Übergang
und zur Halswirbelsäule (5-030)
Zugang zur Brustwirbelsäule (5-031)
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Zugang zur Lendenwirbelsäule, zum Os
sacrum und zum Os coccygis (5-032)
Inzision des Spinalkanals (5-033)
Inzision von Rückenmark und
Rückenmarkhäuten (5-034)
Exzision und Destruktion von erkranktem
Gewebe des Rückenmarkes und der
Rückenmarkhäute (5-035)
Plastische Operationen an Rückenmark
und Rückenmarkhäuten (5-036)
Operationen an intraspinalen
Blutgefäßen (5-037)
Operationen am spinalen Liquorsystem
(5-038)
Andere Operationen an Rückenmark und
Rückenmarkstrukturen (5-039)
Operationen an Nerven und
Nervenganglien (5-04)
Inzision von Nerven (5-040)
Exzision und Destruktion von
(erkranktem) Gewebe von Nerven (5-
041)
Exzision eines Nerven zur
Transplantation (5-042)
Sympathektomie (5-043)
Epineurale Naht eines Nerven und
Nervenplexus, primär (5-044)
Interfaszikuläre Naht eines Nerven und
Nervenplexus, primär (5-045)
Epineurale Naht eines Nerven und
Nervenplexus, sekundär (5-046)
Interfaszikuläre Naht eines Nerven und
Nervenplexus, sekundär (5-047)
Epineurale Naht eines Nerven und
Nervenplexus mit Transplantation (5-048)
Interfaszikuläre Naht eines Nerven und
Nervenplexus mit Transplantation (5-049)
Perkutane Sympathikolyse mit
Steuerung durch bildgebende Verfahren
(5-04a)
Andere Operationen an Nerven und
Nervenganglien (5-05)
Epineurale Naht eines Nerven und
Nervenplexus mit Transposition, primär
(5-050)
Interfaszikuläre Naht eines Nerven und
Nervenplexus mit Transposition, primär
(5-051)
Epineurale Naht eines Nerven und
Nervenplexus mit Transposition,
sekundär (5-052)
Interfaszikuläre Naht eines Nerven und
Nervenplexus mit Transposition,
sekundär (5-053)
Epineurale Naht eines Nerven und
Nervenplexus mit Transplantation und
Transposition (5-054)
Interfaszikuläre Naht eines Nerven und
Nervenplexus mit Transplantation und
Transposition (5-055)
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Neurolyse und Dekompression eines
Nerven (5-056)
Neurolyse und Dekompression eines
Nerven mit Transposition (5-057)
Andere Rekonstruktion eines Nerven
und Nervenplexus (5-058)
Andere Operationen an Nerven und
Ganglien (5-059)
Operationen an Schilddrüse und
Nebenschilddrüse (5-06)
Inzision im Gebiet der Schilddrüse (5-
060)
Hemithyreoidektomie (5-061)
Andere partielle Schilddrüsenresektion
(5-062)
Thyreoidektomie (5-063)
Operationen an der Schilddrüse durch
Sternotomie (5-064)
Exzision des Ductus thyreoglossus (5-
065)
Partielle Nebenschilddrüsenresektion (5-
066)
Parathyreoidektomie (5-067)
Operationen an der Nebenschilddrüse
durch Sternotomie (5-068)
Andere Operationen an Schilddrüse und
Nebenschilddrüsen (5-069)
Operationen an anderen endokrinen
Drüsen (5-07)
Exploration der (Umgebung der)
Nebenniere (5-070)
Partielle Adrenalektomie (5-071)
Adrenalektomie (5-072)
Andere Operationen an der Nebenniere
(5-073)
Exzision und Resektion von erkranktem
Gewebe des Corpus pineale (5-074)
Exzision und Resektion von erkranktem
Gewebe der Hypophyse (5-075)
Andere Operationen an der Hypophyse
(5-076)
Exzision und Resektion des Thymus (5-
077)
Andere Operationen am Thymus (5-078)
Operationen an anderen endokrinen
Drüsen (5-079)
Operationen an Tränendrüse und
Tränenwegen (5-08)
Inzision der Tränendrüse (5-080)
Exzision von (erkranktem) Gewebe der
Tränendrüse (5-081)
Andere Operationen an der Tränendrüse
(5-082)
Inzision von Tränensack und sonstigen
Tränenwegen (5-084)
Exzision von erkranktem Gewebe an
Tränensack und sonstigen Tränenwegen
(5-085)
Rekonstruktion des Tränenkanals und
Tränenpunktes (5-086)
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Dakryozystorhinostomie (5-087)
Andere Rekonstruktion der Tränenwege
(5-088)
Andere Operationen an den
Tränenwegen (5-089)
Operationen an den Augenlidern (5-09)
Inzision des (erkrankten) Augenlides (5-
090)
Exzision und Destruktion von
(erkranktem) Gewebe des Augenlides (5-
091)
Operationen an Kanthus und Epikanthus
(5-092)
Korrekturoperation bei Entropium und
Ektropium (5-093)
Korrekturoperation bei Blepharoptosis (5-
094)
Naht des Augenlides (5-095)
Andere Rekonstruktion der Augenlider
(5-096)
Blepharoplastik (5-097)
Vertikale Lidverlängerung (5-098)
Andere Operationen am Augenlid (5-
099)
Operationen an den Augenmuskeln (5-
10)
Verstärkende Eingriffe an einem geraden
Augenmuskel (5-10a)
Schwächende Eingriffe an einem
geraden Augenmuskel (5-10b)
Chirurgie der Abrollstrecke (Faden-
Operation, Myopexie) (5-10c)
Transposition eines geraden
Augenmuskels (5-10d)
Andere Operationen an den geraden
Augenmuskeln (5-10e)
Verstärkende Eingriffe an einem
schrägen Augenmuskel (5-10f)
Schwächende Eingriffe an einem
schrägen Augenmuskel (5-10g)
Transposition eines schrägen
Augenmuskels (5-10h)
Andere Operationen an den schrägen
Augenmuskeln (5-10j)
Kombinierte Operationen an den
Augenmuskeln (5-10k)
Andere Operationen an den
Augenmuskeln (5-10m)
Operationen an der Konjunktiva (5-11)
Operative Entfernung eines
Fremdkörpers aus der Konjunktiva (5-
110)
Exzision und Destruktion von
(erkranktem) Gewebe der Konjunktiva (5-
112)
Konjunktivaplastik (5-113)
Lösung von Adhäsionen zwischen
Konjunktiva und Augenlid (5-114)
Naht der Konjunktiva (5-115)
Andere Operationen an der Konjunktiva
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(5-119)
Operationen an der Kornea (5-12)
Operative Entfernung eines
Fremdkörpers aus der Kornea (5-120)
Inzision der Kornea (5-121)
Operationen bei Pterygium (5-122)
Exzision und Destruktion von
(erkranktem) Gewebe der Kornea (5-
123)
Naht der Kornea (5-124)
Hornhauttransplantation und
Keratoprothetik (5-125)
Refraktive Keratoplastik und andere
Rekonstruktion der Kornea (5-126)
Andere Operationen an der Kornea (5-
129)
Operationen an Iris, Corpus ciliare,
vorderer Augenkammer und Sklera (5-
13)
Operative Entfernung eines
Fremdkörpers aus der vorderen
Augenkammer (5-130)
Senkung des Augeninnendruckes durch
filtrierende Operationen (5-131)
Senkung des Augeninnendruckes durch
Operationen am Corpus ciliare (5-132)
Senkung des Augeninnendruckes durch
Verbesserung der
Kammerwasserzirkulation (5-133)
Senkung des Augeninnendruckes durch
nicht filtrierende Operationen (5-134)
Exzision und Destruktion von erkranktem
Gewebe an Iris, Corpus ciliare und
Sklera (5-135)
Andere Iridektomie und Iridotomie (5-
136)
Andere Operationen an der Iris (5-137)
Operationen an der Sklera (5-138)
Andere Operationen an Sklera, vorderer
Augenkammer, Iris und Corpus ciliare (5-
139)
Operationen an der Linse (5-14)
Entfernung eines Fremdkörpers aus der
Augenlinse (5-140)
Kapsulotomie der Linse (5-142)
Intrakapsuläre Extraktion der Linse (5-
143)
Extrakapsuläre Extraktion der Linse
[ECCE] (5-144)
Andere Linsenextraktionen (5-145)
(Sekundäre) Einführung und Wechsel
einer alloplastischen Linse (5-146)
Revision und Entfernung einer
alloplastischen Linse (5-147)
Andere Operationen an der Linse (5-
149)
Operationen an Retina, Choroidea und
Corpus vitreum (5-15)
Entfernung eines Fremdkörpers aus dem
hinteren Augenabschnitt (5-150)
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Fixation der Netzhaut durch eindellende
Operationen (5-152)
Revision, Wechsel und Entfernung einer
Cerclage oder Plombe, die zur Fixation
der Netzhaut angelegt wurde (5-153)
Andere Operationen zur Fixation der
Netzhaut (5-154)
Destruktion von erkranktem Gewebe an
Retina und Choroidea (5-155)
Andere Operationen an der Retina (5-
156)
Andere Operationen an der Choroidea
(5-157)
Pars-plana-Vitrektomie (5-158)
Vitrektomie über anderen Zugang und
andere Operationen am Corpus vitreum
(5-159)
Operationen an Orbita und Augapfel (5-
16)
Orbitotomie (5-160)
Entfernung eines Fremdkörpers aus
Orbita und Augapfel, n.n.bez. (5-161)
Entfernung des Augeninhaltes
[Eviszeration] (5-162)
Entfernung des Augapfels [Enukleation]
(5-163)
Andere Exzision, Destruktion und
Exenteration der Orbita und
Orbitainnenhaut (5-164)
Sekundäre Einführung, Revision und
Entfernung eines Orbitaimplantates (5-
165)
Revision und Rekonstruktion von Orbita
und Augapfel (5-166)
Rekonstruktion der Orbitawand (5-167)
Operationen am N. opticus (5-168)
Andere Operationen an Orbita, Auge und
Augapfel (5-169)
Operationen an Ohrmuschel und
äußerem Gehörgang (5-18)
Inzision am äußeren Ohr (5-180)
Exzision und Destruktion von erkranktem
Gewebe des äußeren Ohres (5-181)
Resektion der Ohrmuschel (5-182)
Wundversorgung am äußeren Ohr (5-
183)
Plastische Korrektur abstehender Ohren
(5-184)
Konstruktion und Rekonstruktion des
äußeren Gehörganges (5-185)
Plastische Rekonstruktion von Teilen der
Ohrmuschel (5-186)
Plastische Rekonstruktion der gesamten
Ohrmuschel (5-187)
Andere Rekonstruktion des äußeren
Ohres (5-188)
Andere Operationen am äußeren Ohr (5-
189)
Mikrochirurgische Operationen am
Mittelohr (5-19)
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Revision einer Stapedektomie (5-192)
Andere Operationen an den
Gehörknöchelchen (5-193)
Myringoplastik [Tympanoplastik Typ I] (5-
194)
Tympanoplastik (Verschluss einer
Trommelfellperforation und
Rekonstruktion der Gehörknöchelchen)
(5-195)
Stapesplastik (5-197)
Fensterungsoperation des Promotoriums
(5-198)
Andere mikrochirurgische Operationen
am Mittelohr (5-199)
Andere Operationen an Mittel- und
Innenohr (5-20)
Parazentese [Myringotomie] (5-200)
Entfernung einer Paukendrainage (5-
201)
Inzision an Warzenfortsatz und Mittelohr
(5-202)
Mastoidektomie (5-203)
Rekonstruktion des Mittelohres (5-204)
Andere Exzisionen an Mittel- und
Innenohr (5-205)
Inzision [Eröffnung] und Destruktion
[Ausschaltung] des Innenohres (5-208)
Andere Operationen am Mittel- und
Innenohr (5-209)
Operationen an der Nase (5-21)
Operative Behandlung einer
Nasenblutung (5-210)
Inzision der Nase (5-211)
Exzision und Destruktion von erkranktem
Gewebe der Nase (5-212)
Resektion der Nase (5-213)
Submuköse Resektion und plastische
Rekonstruktion des Nasenseptums (5-
214)
Operationen an der unteren
Nasenmuschel [Concha nasalis] (5-215)
Reposition einer Nasenfraktur (5-216)
Plastische Rekonstruktion der äußeren
Nase (5-217)
Plastische Rekonstruktion der inneren
und äußeren Nase [Septorhinoplastik]
(5-218)
Andere Operationen an der Nase (5-219)
Operationen an den Nasennebenhöhlen
(5-22)
Nasennebenhöhlenpunktion (5-220)
Operationen an der Kieferhöhle (5-221)
Operation am Siebbein und an der
Keilbeinhöhle (5-222)
Operationen an der Stirnhöhle (5-223)
Operationen an mehreren
Nasennebenhöhlen (5-224)
Plastische Rekonstruktion der
Nasennebenhöhlen (5-225)
Andere Operationen an den
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Nasennebenhöhlen (5-229)
Entfernung und Wiederherstellung von
Zähnen (5-23)
Zahnextraktion (5-230)
Operative Zahnentfernung (durch
Osteotomie) (5-231)
Zahnsanierung durch Füllung (5-232)
Prothetischer Zahnersatz (5-233)
Replantation, Transplantation,
Implantation und Stabilisierung eines
Zahnes (5-235)
Entfernung eines transplantierten
Zahnes (5-236)
Wurzelspitzenresektion und
Wurzelkanalbehandlung (5-237)
Operationen an Zahnfleisch, Alveolen
und Kiefer (5-24)
Inzision des Zahnfleisches und
Osteotomie des Alveolarkammes (5-240)
Gingivaplastik (5-241)
Andere Operationen am Zahnfleisch (5-
242)
Exzision einer odontogenen
pathologischen Veränderung des Kiefers
(5-243)
Alveolarkammplastik und
Vestibulumplastik (5-244)
Zahnfreilegung (5-245)
Andere Operationen und Maßnahmen an
Gebiss, Zahnfleisch und Alveolen (5-
249)
Operationen an der Zunge (5-25)
Inzision, Exzision und Destruktion von
erkranktem Gewebe der Zunge (5-250)
Partielle Glossektomie (5-251)
Glossektomie (5-252)
Rekonstruktion der Zunge (5-253)
Andere Operationen an der Zunge (5-
259)
Operationen an Speicheldrüsen und
Speicheldrüsenausführungsgängen (5-
26)
Inzision und Schlitzung einer
Speicheldrüse und eines
Speicheldrüsenausführungsganges (5-
260)
Exzision von erkranktem Gewebe einer
Speicheldrüse und eines
Speicheldrüsenausführungsganges (5-
261)
Resektion einer Speicheldrüse (5-262)
Rekonstruktion einer Speicheldrüse und
eines
Speicheldrüsenausführungsganges (5-
263)
Andere Operationen an Speicheldrüse
und Speicheldrüsenausführungsgang (5-
269)
Andere Operationen an Mund und
Gesicht (5-27)
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Äußere Inzision und Drainage im Mund-,
Kiefer- und Gesichtsbereich (5-270)
Inzision des harten und weichen
Gaumens (5-271)
Exzision und Destruktion des
(erkrankten) harten und weichen
Gaumens (5-272)
Inzision, Exzision und Destruktion in der
Mundhöhle (5-273)
Mundbodenplastik (5-274)
Palatoplastik (5-275)
Plastische Rekonstruktion einer
(angeborenen) Lippenspalte und Lippen-
Kieferspalte (5-276)
Resektion des Mundbodens mit
plastischer Rekonstruktion (5-277)
Resektion der Wange mit plastischer
Rekonstruktion (5-278)
Andere Operationen am Mund (5-279)
Operationen im Bereich des Naso- und
Oropharynx (5-28)
Transorale Inzision und Drainage eines
pharyngealen oder parapharyngealen
Abszesses (5-280)
Tonsillektomie (ohne Adenotomie) (5-
281)
Tonsillektomie mit Adenotomie (5-282)
Exzision und Destruktion einer
Zungengrundtonsille (5-284)
Adenotomie (ohne Tonsillektomie) (5-
285)
Andere Operationen an Gaumen- und
Rachenmandeln (5-289)
Operationen am Pharynx (5-29)
Pharyngotomie (5-290)
Operationen an Kiemengangsresten (5-
291)
Exzision und Destruktion von erkranktem
Gewebe des Pharynx (5-292)
Pharyngoplastik (5-293)
Andere Rekonstruktionen des Pharynx
(5-294)
Partielle Resektion des Pharynx
[Pharynxteilresektion] (5-295)
Radikale Resektion des Pharynx
[Pharyngektomie] (5-296)
Andere Operationen am Pharynx (5-299)
Exzision und Resektion am Larynx (5-
30)
Exzision und Destruktion von erkranktem
Gewebe des Larynx (5-300)
Hemilaryngektomie (5-301)
Andere partielle Laryngektomie (5-302)
Laryngektomie (5-303)
Andere Larynxoperationen und
Operationen an der Trachea (5-31)
Larynxverengende Eingriffe (5-310)
Temporäre Tracheostomie (5-311)
Permanente Tracheostomie (5-312)
Inzision des Larynx und andere
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Inzisionen der Trachea (5-313)
Exzision, Resektion und Destruktion (von
erkranktem Gewebe) der Trachea (5-
314)
Rekonstruktion des Larynx (5-315)
Rekonstruktion der Trachea (5-316)
Andere Operationen an Larynx und
Trachea (5-319)
Exxzision und Resektion an Lunge und
Bronchus (5-32)
Exzision und Destruktion von erkranktem
Gewebe eines Bronchus (5-320)
Andere Exzision und Resektion eines
Bronchus (ohne Resektion des
Lungenparenchyms) (5-321)
Atypische Lungenresektion (5-322)
Segmentresektion und
Bisegmentresektion der Lunge (5-323)
Einfache Lobektomie und Bilobektomie
der Lunge (5-324)
Erweiterte Lobektomie und Bilobektomie
der Lunge (5-325)
Einfache (Pleuro-)Pneum(on)ektomie (5-
327)
Erweiterte (Pleuro-)Pneum(on)ektomie
(5-328)
Andere Exzisionen an Lunge und
Bronchus (5-329)
Andere Operationen an Lunge und
Bronchus (5-33)
Inzision eines Bronchus (5-330)
Inzision der Lunge (5-331)
Adhäsiolyse an Lunge und Brustwand
(5-333)
Rekonstruktion an Lunge und Bronchien
(5-334)
Lungentransplantation (5-335)
Andere Operationen an Lunge und
Bronchien (5-339)
Operationen an Brustwand, Pleura,
Mediastinum und Zwerchfell (5-34)
Inzision von Brustwand und Pleura (5-
340)
Inzision des Mediastinums (5-341)
Exzision und Destruktion von erkranktem
Gewebe des Mediastinums (5-342)
Exzision und Destruktion von
(erkranktem) Gewebe der Brustwand (5-
343)
Pleurektomie (5-344)
Pleurodese [Verödung des
Pleuraspaltes] (5-345)
Plastische Rekonstruktion der Brustwand
(5-346)
Operationen am Zwerchfell (5-347)
Andere Operationen am Thorax (5-349)
Operationen an Klappen und Septen des
Herzens und herznaher Gefäße (5-35)
Valvulotomie (5-350)
Ersatz von Herzklappen durch Prothese
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(5-351)
Wechsel von Herzklappenprothesen (5-
352)
Valvuloplastik (5-353)
Andere Operationen an Herzklappen (5-
354)
Herstellung und Vergrößerung eines
Septumdefektes des Herzens (5-355)
Plastische Rekonstruktion des
Herzseptums bei angeborenen
Herzfehlern (5-356)
Operationen bei kongenitalen
Gefäßanomalien (5-357)
Operationen bei kongenitalen
Klappenanomalien des Herzens (5-358)
Andere Operationen am Herzen bei
kongenitalen Anomalien (5-359)
Minimalinvasive Operationen an
Herzklappen (5-35a)
Operationen an den Koronargefäßen (5-
36)
Desobliteration (Endarteriektomie) der
Koronararterien (5-360)
Anlegen eines aortokoronaren Bypass
(5-361)
Anlegen eines aortokoronaren Bypass
durch minimalinvasive Technik (5-362)
Andere Revaskularisation des Herzens
(5-363)
Anwendung eines mechanischen
Anastomosensystems bei Operationen
an den Koronargefäßen (5-364)
Andere Operationen an den
Koronargefäßen (5-369)
Rhythmuschirurgie und andere
Operationen an Herz und Perikard (5-37)
Perikardiotomie und Kardiotomie (5-370)
Chirurgische ablative Maßnahmen bei
Tachyarrhythmie (5-371)
Exzision und Destruktion von erkranktem
Gewebe des Perikardes und
Perikardektomie (5-372)
Exzision und Destruktion von erkranktem
Gewebe des Herzens (5-373)
Rekonstruktion des Perikardes und des
Herzens (5-374)
Herz- und Herz-Lungen-Transplantation
(5-375)
Implantation und Entfernung eines
herzunterstützenden Systems, offen
chirurgisch (5-376)
Implantation eines Herzschrittmachers,
Defibrillators und Ereignis-Rekorders (5-
377)
Entfernung, Wechsel und Korrektur eines
Herzschrittmachers und Defibrillators (5-
378)
Andere Operationen an Herz und
Perikard (5-379)
Minimalinvasive Rekonstruktion des
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Perikardes und des Herzens (5-37a)
Offen chirurgische Implantation und
Entfernung von Kanülen für die
Anwendung eines extrakorporalen (herz-
und) lungenunterstützenden Systems mit
Gasaustausch (5-37b)
Inzision, Exzision und Verschluss von
Blutgefäßen (5-38)
Inzision, Embolektomie und
Thrombektomie von Blutgefäßen (5-380)
Endarteriektomie (5-381)
Resektion von Blutgefäßen mit
Reanastomosierung (5-382)
Resektion und Ersatz (Interposition) von
(Teilen von) Blutgefäßen (5-383)
Resektion und Ersatz (Interposition) an
der Aorta (5-384)
Unterbindung, Exzision und Stripping
von Varizen (5-385)
Andere Exzision von (erkrankten)
Blutgefäßen und Transplantatentnahme
(5-386)
Ligatur und Teilverschluss der Vena cava
(5-387)
Naht von Blutgefäßen (5-388)
Anderer operativer Verschluss an
Blutgefäßen (5-389)
Endovaskuläre Implantation von Stent-
Prothesen (5-38a)
Endoskopische Entnahme von
Blutgefäßen zur Transplantation (5-38b)
Offen chirurgische Implantation von nicht
großlumigen ungecoverten Stents (5-
38c)
Offen chirurgische Implantation von nicht
großlumigen gecoverten Stents (5-38d)
Offen chirurgische Implantation von
großlumigen ungecoverten Stents (5-
38e)
Offen chirurgische Angioplastie (Ballon)
(5-38f)
Selektive offene intravasale Lyse (5-38g)
Andere Operationen an Blutgefäßen (5-
39)
Shuntoperationen zwischen großem und
kleinem Kreislauf [Links-Rechts-Shunt]
(5-390)
Anlegen eines intraabdominalen
venösen Shuntes (5-391)
Anlegen eines arteriovenösen Shuntes
(5-392)
Anlegen eines anderen Shuntes und
Bypasses an Blutgefäßen (5-393)
Revision einer Blutgefäßoperation (5-
394)
Patchplastik an Blutgefäßen (5-395)
Transposition von Blutgefäßen (5-396)
Andere plastische Rekonstruktion von
Blutgefäßen (5-397)
Operationen am Glomus caroticum und
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anderen Paraganglien (5-398)
Andere Operationen an Blutgefäßen (5-
399)
Operationen am Lymphgewebe (5-40)
Inzision von Lymphknoten und
Lymphgefäßen (5-400)
Exzision einzelner Lymphknoten und
Lymphgefäße (5-401)
Regionale Lymphadenektomie
(Ausräumung mehrerer Lymphknoten
einer Region) als selbständiger Eingriff
(5-402)
Radikale zervikale Lymphadenektomie
[Neck dissection] (5-403)
Radikale (systematische)
Lymphadenektomie als selbständiger
Eingriff (5-404)
Operationen am Ductus thoracicus (5-
405)
Regionale Lymphadenektomie
(Ausräumung mehrerer Lymphknoten
einer Region) im Rahmen einer anderen
Operation (5-406)
Radikale (systematische)
Lymphadenektomie im Rahmen einer
anderen Operation (5-407)
Andere Operationen am
Lymphgefäßsystem (5-408)
Operationen an Milz und Knochenmark
(5-41)
Entnahme von hämatopoetischen
Stammzellen aus Knochenmark und
peripherem Blut zur Transplantation (5-
410)
Transplantation von hämatopoetischen
Stammzellen aus dem Knochenmark (5-
411)
Inzision der Milz (5-412)
Splenektomie (5-413)
Andere Operationen am Knochenmark
(5-418)
Andere Operationen an der Milz (5-419)
Operationen am Ösophagus (5-42)
Inzision des Ösophagus (5-420)
Ösophagostomie als selbständiger
Eingriff (5-421)
Lokale Exzision und Destruktion von
erkranktem Gewebe des Ösophagus (5-
422)
Partielle Ösophagusresektion ohne
Wiederherstellung der Kontinuität (5-423)
Partielle Ösophagusresektion mit
Wiederherstellung der Kontinuität (5-424)
(Totale) Ösophagektomie ohne
Wiederherstellung der Kontinuität (5-425)
(Totale) Ösophagektomie mit
Wiederherstellung der Kontinuität (5-426)
Rekonstruktion der Ösophaguspassage
(als selbständiger Eingriff) (5-427)
Rekonstruktion der Ösophaguspassage
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bei Atresie und Versorgung einer
kongenitalen ösophagotrachealen Fistel
(5-428)
Andere Operationen am Ösophagus (5-
429)
Inzision, Exzision und Resektion am
Magen (5-43)
Gastrotomie (5-430)
Gastrostomie (5-431)
Operationen am Pylorus (5-432)
Lokale Exzision und Destruktion von
erkranktem Gewebe des Magens (5-433)
Atypische partielle Magenresektion (5-
434)
Partielle Magenresektion (2/3-Resektion)
(5-435)
Subtotale Magenresektion (4/5-
Resektion) (5-436)
(Totale) Gastrektomie (5-437)
(Totale) Gastrektomie mit
Ösophagusresektion (5-438)
Andere Inzision, Exzision und Resektion
am Magen (5-439)
Andere Operationen am Magen (5-44)
Vagotomie (5-444)
Gastroenterostomie ohne
Magenresektion [Bypassverfahren] (5-
445)
Revision nach Magenresektion (5-447)
Andere Rekonstruktion am Magen (5-
448)
Andere Operationen am Magen (5-449)
Inzision, Exzision, Resektion und
Anastomose an Dünn- und Dickdarm (5-
45)
Inzision des Darmes (5-450)
Lokale Exzision und Destruktion von
erkranktem Gewebe des Dünndarmes
(5-451)
Lokale Exzision und Destruktion von
erkranktem Gewebe des Dickdarmes (5-
452)
Ausschaltung eines Darmsegmentes als
selbständiger Eingriff (z.B. bei
zweizeitigen plastischen Operationen)
(5-453)
Resektion des Dünndarmes (5-454)
Partielle Resektion des Dickdarmes (5-
455)
(Totale) Kolektomie und
Proktokolektomie (5-456)
Bypass-Anastomose des Darmes (5-
459)
Andere Operationen an Dünn- und
Dickdarm (5-46)
Anlegen eines Enterostomas,
doppelläufig, als selbständiger Eingriff
(5-460)
Anlegen eines Enterostomas,
endständig, als selbständiger Eingriff (5-
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461)
Anlegen eines Enterostomas (als
protektive Maßnahme) im Rahmen eines
anderen Eingriffes (5-462)
Anlegen anderer Enterostomata (5-463)
Revision und andere Eingriffe an einem
Enterostoma (5-464)
Rückverlagerung eines doppelläufigen
Enterostomas (5-465)
Wiederherstellung der Kontinuität des
Darmes bei endständigen Enterostomata
(5-466)
Andere Rekonstruktion des Darmes (5-
467)
Intraabdominale Manipulation am Darm
(5-468)
Andere Operationen am Darm (5-469)
Operationen an der Appendix (5-47)
Appendektomie (5-470)
Simultane Appendektomie (5-471)
Andere Operationen an der Appendix (5-
479)
Operationen am Rektum (5-48)
Inzision des Rektums (5-480)
Peranale lokale Exzision und Destruktion
von erkranktem Gewebe des Rektums
(5-482)
Rektumresektion unter
Sphinktererhaltung (5-484)
Rektumresektion ohne
Sphinktererhaltung (5-485)
Rekonstruktion des Rektums (5-486)
Andere Operation am Rektum (5-489)
Operationen am Anus (5-49)
Inzision und Exzision von Gewebe der
Perianalregion (5-490)
Operative Behandlung von Analfisteln (5-
491)
Exzision und Destruktion von erkranktem
Gewebe des Analkanals (5-492)
Operative Behandlung von
Hämorrhoiden (5-493)
Durchtrennung des Sphincter ani
[Sphinkterotomie] (5-494)
Primäre plastische Rekonstruktion bei
anorektalen Anomalien (5-495)
Rekonstruktion des Anus und des
Sphinkterapparates (5-496)
Andere Operationen am Anus (5-499)
Operationen an der Leber (5-50)
Inzision der Leber (5-500)
Lokale Exzision und Destruktion von
erkranktem Gewebe der Leber
(atypische Leberresektion) (5-501)
Anatomische (typische) Leberresektion
(5-502)
Leberteilresektion und Hepatektomie
(zur Transplantation) (5-503)
Lebertransplantation (5-504)
Rekonstruktion der Leber (5-505)
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Implantation, Wechsel und Entfernung
eines Katheterverweilsystems in
Leberarterie und Pfortader (zur
Chemotherapie) (5-506)
Andere Operationen an der Leber (5-
509)
Operationen an Gallenblase und
Gallenwegen (5-51)
Cholezystotomie und Cholezystostomie
(5-510)
Cholezystektomie (5-511)
Biliodigestive Anastomose (von Ductus
hepaticus, Ductus choledochus und
Leberparenchym) (5-512)
Endoskopische Operationen an den
Gallengängen (5-513)
Andere Operationen an den
Gallengängen (5-514)
Exzision und Resektion von erkranktem
Gewebe der Gallengänge (5-515)
Andere Rekonstruktion der Gallengänge
(5-516)
Einlegen oder Wechseln von
selbstexpandierenden Stents und Stent-
Prothesen in die Gallengänge (5-517)
Operationen an Sphincter Oddi und
Papilla duodeni major (5-518)
Andere Operationen an Gallenblase und
Gallengängen (5-519)
Operationen am Pankreas (5-52)
Inzision des Pankreas (5-520)
Lokale Exzision und Destruktion von
erkranktem Gewebe des Pankreas (5-
521)
Marsupialisation einer Pankreaszyste (5-
522)
Innere Drainage des Pankreas (5-523)
Partielle Resektion des Pankreas (5-524)
(Totale) Pankreatektomie (5-525)
Endoskopische Operationen am
Pankreasgang (5-526)
Anastomose des Ductus pancreaticus
(5-527)
Transplantation von Pankreas(gewebe)
(5-528)
Andere Operationen am Pankreas und
am Pankreasgang (5-529)
Verschluss abdominaler Hernien (5-53)
Verschluss einer Hernia inguinalis (5-
530)
Verschluss einer Hernia femoralis (5-
531)
Verschluss einer Hernia umbilicalis (5-
534)
Verschluss einer Hernia epigastrica (5-
535)
Verschluss einer Narbenhernie (5-536)
Verschluss kongenitaler
Bauchwanddefekte (Omphalozele,
Laparoschisis) (5-537)
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Verschluss einer Hernia diaphragmatica
(5-538)
Verschluss anderer abdominaler Hernien
(5-539)
Andere Operationen in der Bauchregion
(5-54)
Inzision der Bauchwand (5-540)
Laparotomie und Eröffnung des
Retroperitoneums (5-541)
Exzision und Destruktion von erkranktem
Gewebe der Bauchwand (5-542)
Exzision und Destruktion von
peritonealem Gewebe (5-543)
Verschluss von Bauchwand und
Peritoneum (5-545)
Plastische Rekonstruktion von
Bauchwand und Peritoneum (5-546)
Resektion von Gewebe in der
Bauchregion ohne sichere
Organzuordnung (5-547)
Andere Bauchoperationen (5-549)
Operationen an der Niere (5-55)
Perkutan-transrenale Nephrotomie,
Nephrostomie, Steinentfernung,
Pyeloplastik und ureterorenoskopische
Steinentfernung (5-550)
Offen chirurgische Nephrotomie,
Nephrostomie, Pyelotomie und
Pyelostomie (5-551)
Exzision und Destruktion von
(erkranktem) Gewebe der Niere (5-552)
Partielle Resektion der Niere (5-553)
Nephrektomie (5-554)
Nierentransplantation (5-555)
Rekonstruktion der Niere (5-557)
Andere Operationen an der Niere (5-
559)
Operationen am Ureter (5-56)
Transurethrale und perkutan-transrenale
Erweiterung des Ureters (5-560)
Inzision, Resektion und (andere)
Erweiterung des Ureterostiums (5-561)
Ureterotomie, perkutan-transrenale und
transurethrale Steinbehandlung (5-562)
Exzision und Destruktion von erkranktem
Gewebe des Ureters, Ureterresektion
und Ureterektomie (5-563)
Kutane Harnableitung durch
Ureterokutaneostomie (nicht kontinentes
Stoma) (5-564)
Kutane Harnableitung mit
Darminterponat [Conduit] (nicht
kontinentes Stoma) (5-565)
Kutane Harnableitung mit Darmreservoir
(kontinentes Stoma) (5-566)
Interne Harnableitung über den Darm (5-
567)
Rekonstruktion des Ureters (5-568)
Andere Operationen am Ureter (5-569)
Operationen an der Harnblase (5-57)
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Endoskopische Entfernung von Steinen,
Fremdkörpern und Tamponaden der
Harnblase (5-570)
Zystotomie [Sectio alta] (5-571)
Zystostomie (5-572)
Transurethrale Inzision, Exzision,
Destruktion und Resektion von
(erkranktem) Gewebe der Harnblase (5-
573)
Offen chirurgische und laparoskopische
Exzision und Destruktion von
(erkranktem) Gewebe der Harnblase (5-
574)
Partielle Harnblasenresektion (5-575)
Zystektomie (5-576)
Ersatz der Harnblase (5-577)
Andere plastische Rekonstruktion der
Harnblase (5-578)
Andere Operationen an der Harnblase
(5-579)
Operationen an der Urethra (5-58)
Offen chirurgische Urethrotomie und
Urethrostomie (5-580)
Plastische Meatotomie der Urethra (5-
581)
Exzision, Destruktion und Resektion von
(erkranktem) Gewebe der Urethra (5-
582)
Urethrektomie als selbständiger Eingriff
(5-583)
Rekonstruktion der Urethra (5-584)
Transurethrale Inzision von (erkranktem)
Gewebe der Urethra (5-585)
Andere Operationen an Urethra und
periurethralem Gewebe (5-589)
Andere Operationen an den
Harnorganen (5-59)
Inzision und Exzision von
retroperitonealem Gewebe (5-590)
Inzision und Exzision von perivesikalem
Gewebe (5-591)
Raffung des urethrovesikalen
Überganges (5-592)
Transvaginale Suspensionsoperation
[Zügeloperation] (5-593)
Suprapubische (urethrovesikale)
Zügeloperation [Schlingenoperation] (5-
594)
Abdominale retropubische und
paraurethrale Suspensionsoperation (5-
595)
Andere Harninkontinenzoperationen (5-
596)
Eingriffe bei artifiziellem
Harnblasensphinkter (5-597)
Suspensionsoperation [Zügeloperation]
bei Harninkontinenz des Mannes (5-598)
Andere Operationen am Harntrakt (5-
599)
Operationen an Prostata und Vesiculae
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seminales (5-60)
Inzision der Prostata (5-600)
Transurethrale Exzision und Destruktion
von Prostatagewebe (5-601)
Transrektale und perkutane Destruktion
von Prostatagewebe (5-602)
Exzision und Destruktion von
Prostatagewebe (5-603)
Radikale Prostatovesikulektomie (5-604)
Andere Exzision und Destruktion von
Prostatagewebe (5-605)
Operationen an den Vesiculae seminales
(5-606)
Inzision und Exzision von
periprostatischem Gewebe (5-607)
Andere Operationen an der Prostata (5-
609)
Operationen an Skrotum und Tunica
vaginalis testis (5-61)
Inzision an Skrotum und Tunica vaginalis
testis (5-610)
Operation einer Hydrocele testis (5-611)
Exzision und Destruktion von erkranktem
Skrotumgewebe (5-612)
Plastische Rekonstruktion von Skrotum
und Tunica vaginalis testis (5-613)
Andere Operationen an Skrotum und
Tunica vaginalis testis (5-619)
Operationen am Hoden (5-62)
Inzision des Hodens (5-620)
Exzision und Destruktion von erkranktem
Gewebe des Hodens (5-621)
Orchidektomie (5-622)
Orchidopexie (5-624)
Exploration bei Kryptorchismus (5-625)
Operative Verlagerung eines
Abdominalhodens (5-626)
Rekonstruktion des Hodens (5-627)
Implantation, Wechsel und Entfernung
einer Hodenprothese (5-628)
Andere Operationen am Hoden (5-629)
Operationen an Funiculus spermaticus,
Epididymis und Ductus deferens (5-63)
Operative Behandlung einer Varikozele
und einer Hydrocele funiculi spermatici
(5-630)
Exzision im Bereich der Epididymis (5-
631)
Epididymektomie (5-633)
Rekonstruktion des Funiculus
spermaticus (5-634)
Vasotomie des Ductus deferens (5-635)
Destruktion, Ligatur und Resektion des
Ductus deferens (5-636)
Rekonstruktion von Ductus deferens und
Epididymis (5-637)
Andere Operationen an Funiculus
spermaticus,  Epididymis und Ductus
deferens (5-639)
Operationen am Penis (5-64)
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Operationen am Präputium (5-640)
Lokale Exzision und Destruktion von
erkranktem Gewebe des Penis (5-641)
Amputation des Penis (5-642)
Plastische Rekonstruktion des Penis (5-
643)
Plastische Rekonstruktion bei
männlicher Epispadie (5-644)
Plastische Rekonstruktion bei
männlicher Hypospadie (5-645)
Operationen zur
Geschlechtsumwandlung (5-646)
Andere Operationen am Penis (5-649)
Operationen am Ovar (5-65)
Inzision des Ovars (5-650)
Lokale Exzision und Destruktion von
Ovarialgewebe (5-651)
Ovariektomie (5-652)
Salpingoovariektomie (5-653)
Plastische Rekonstruktion des Ovars (5-
656)
Adhäsiolyse an Ovar und Tuba uterina
ohne mikrochirurgische Versorgung (5-
657)
Adhäsiolyse an Ovar und Tuba uterina
mit mikrochirurgischer Versorgung (5-
658)
Andere Operationen am Ovar (5-659)
Operationen an der Tuba uterina (5-66)
Salpingotomie (5-660)
Salpingektomie (5-661)
Destruktion und Verschluss der Tubae
uterinae [Sterilisationsoperation] (5-663)
Exzision und Destruktion von erkranktem
Gewebe der Tuba uterina (5-665)
Plastische Rekonstruktion der Tuba
uterina (5-666)
Insufflation der Tubae uterinae (5-667)
Andere Operationen an der Tuba uterina
(5-669)
Operationen an der Cervix uteri (5-67)
Dilatation des Zervikalkanals (5-670)
Konisation der Cervix uteri (5-671)
Andere Exzision und Destruktion von
erkranktem Gewebe der Cervix uteri (5-
672)
Amputation der Cervix uteri (5-673)
Rekonstruktion der Cervix uteri in der
Gravidität (5-674)
Andere Rekonstruktion der Cervix uteri
(5-675)
Andere Operationen an der Cervix uteri
(5-679)
Inzision, Exzision und Exstirpation des
Uterus (5-68)
Inzision des Uterus [Hysterotomie] (5-
680)
Exzision und Destruktion von erkranktem
Gewebe des Uterus (5-681)
Subtotale Uterusexstirpation (5-682)
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Uterusexstirpation [Hysterektomie] (5-
683)
Zervixstumpfexstirpation (5-684)
Radikale Uterusexstirpation (5-685)
Radikale Zervixstumpfexstirpation (5-
686)
Exenteration [Eviszeration] des
weiblichen kleinen Beckens (5-687)
Andere Inzision und Exzision des Uterus
(5-689)
Andere Operationen am Uterus und
Operationen an den Parametrien (5-69)
Therapeutische Kürettage [Abrasio uteri]
(5-690)
Entfernung eines intrauterinen
Fremdkörpers (5-691)
Exzision und Destruktion von erkranktem
Gewebe der Parametrien (5-692)
Plastische Rekonstruktion der
Parametrien (bei Lagekorrektur des
Uterus) (5-693)
Parazervikale Uterusdenervation (5-694)
Rekonstruktion des Uterus (5-695)
Andere Operationen an Uterus und
Parametrien (5-699)
Operationen an Vagina und
Douglasraum (5-70)
Kuldotomie (5-700)
Inzision der Vagina (5-701)
Lokale Exzision und Destruktion von
erkranktem Gewebe der Vagina und des
Douglasraumes (5-702)
Verschluss und (sub-)totale Exstirpation
der Vagina (5-703)
Vaginale Kolporrhaphie und
Beckenbodenplastik (5-704)
Konstruktion und Rekonstruktion der
Vagina (5-705)
Andere plastische Rekonstruktion der
Vagina (5-706)
Plastische Rekonstruktion des kleinen
Beckens und des Douglasraumes (5-
707)
Andere Operationen an Vagina und
Douglasraum (5-709)
Operationen an der Vulva (5-71)
Inzision der Vulva (5-710)
Operationen an der Bartholin-Drüse
(Zyste) (5-711)
Andere Exzision und Destruktion von
erkranktem Gewebe der Vulva (5-712)
Operationen an der Klitoris (5-713)
Vulvektomie (5-714)
Radikale Vulvektomie (5-715)
Konstruktion und Rekonstruktion der
Vulva (und des Perineums) (5-716)
Andere Operationen an der Vulva (5-
718)
Andere Operationen an den weiblichen
Geschlechtsorganen (5-719)
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Entbindung aus Beckenendlage und
instrumentelle Entbindung (5-72)
Zangenentbindung (5-720)
Drehung des kindlichen Kopfes mit
Zange (5-724)
Extraktion bei Beckenendlage (5-725)
Spontane und vaginale operative
Entbindung bei Beckenendlage (5-727)
Vakuumentbindung (5-728)
Andere instrumentelle Entbindung (5-
729)
Andere Operationen zur
Geburtseinleitung und unter der Geburt
(5-73)
Künstliche Fruchtblasensprengung
[Amniotomie] (5-730)
Andere operative Geburtseinleitung (5-
731)
Innere und kombinierte Wendung ohne
und mit Extraktion (5-732)
Misslungene vaginale operative
Entbindung (5-733)
Operative Maßnahmen am Feten zur
Geburtserleichterung (5-734)
Episiotomie und Naht (5-738)
Andere Operationen zur Unterstützung
der Geburt (5-739)
Sectio caesarea und Entwicklung des
Kindes (5-74)
Klassische Sectio caesarea (5-740)
Sectio caesarea, suprazervikal und
korporal (5-741)
Sectio caesarea extraperitonealis (5-
742)
Entfernung eines intraperitonealen
Embryos (5-743)
Operationen bei Extrauteringravidität (5-
744)
Andere Sectio caesarea (5-749)
Andere geburtshilfliche Operationen (5-
75)
Intraamniale Injektion zur Beendigung
der Schwangerschaft (5-750)
Kürettage zur Beendigung der
Schwangerschaft [Abruptio] (5-751)
Andere Operationen zur Beendigung
einer Schwangerschaft (5-752)
Therapeutische Amniozentese
[Amnionpunktion] (5-753)
Intrauterine Therapie des Feten (5-754)
Andere intrauterine Operationen am
Feten (5-755)
Entfernung zurückgebliebener Plazenta
(postpartal) (5-756)
Uterusexstirpation, geburtshilflich (5-
757)
Rekonstruktion weiblicher
Geschlechtsorgane nach Ruptur, post
partum [Dammriss] (5-758)
Andere geburtshilfliche Operationen (5-
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759)
Operationen bei
Gesichtsschädelfrakturen (5-76)
Reposition einer lateralen
Mittelgesichtsfraktur (5-760)
Reposition einer zentralen
Mittelgesichtsfraktur (5-761)
Reposition einer zentrolateralen
Mittelgesichtsfraktur (5-762)
Reposition anderer kombinierter
Mittelgesichtsfrakturen (Mehrfachfraktur)
(5-763)
Reposition einer Fraktur des Corpus
mandibulae und des Processus
alveolaris mandibulae (5-764)
Reposition einer Fraktur des Ramus
mandibulae und des Processus
articularis mandibulae (5-765)
Reposition einer Orbitafraktur (5-766)
Reposition einer Stirnhöhlenwandfraktur
(5-767)
Reosteotomien disloziert verheilter
Gesichtsschädelfrakturen (5-768)
Andere Operationen bei
Gesichtsschädelfrakturen (5-769)
Andere Operationen an
Gesichtsschädelknochen (5-77)
Inzision (Osteotomie), lokale Exzision
und Destruktion (von erkranktem
Gewebe) eines
Gesichtsschädelknochens (5-770)
Partielle und totale Resektion eines
Gesichtsschädelknochens (5-771)
Partielle und totale Resektion der
Mandibula (5-772)
Arthroplastik am Kiefergelenk (5-773)
Plastische Rekonstruktion und
Augmentation der Maxilla (5-774)
Plastische Rekonstruktion und
Augmentation der Mandibula (5-775)
Osteotomie zur Verlagerung des
Untergesichtes (5-776)
Osteotomie zur Verlagerung des
Mittelgesichtes (5-777)
Rekonstruktion der Weichteile im Gesicht
(5-778)
Andere Operationen an Kiefergelenk und
Gesichtsschädelknochen (5-779)
Implantatversorgung für die
Rekonstruktion mit Gesichtsepithesen
(5-77a)
Knochentransplantation und
-transposition an Kiefer- und
Gesichtsschädelknochen (5-77b)
Operationen an anderen Knochen (5-78)
Inzision am Knochen, septisch und
aseptisch (5-780)
Osteotomie und Korrekturosteotomie (5-
781)
Exzision und Resektion von erkranktem
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Knochengewebe (5-782)
Entnahme eines Knochentransplantates
(5-783)
Knochentransplantation und
-transposition (5-784)
Implantation von alloplastischem
Knochenersatz (5-785)
Osteosyntheseverfahren (5-786)
Entfernung von Osteosynthesematerial
(5-787)
Operationen an Metatarsale und
Phalangen des Fußes (5-788)
Andere Operationen am Knochen (5-
789)
Reposition von Fraktur und Luxation (5-
79)
Geschlossene Reposition einer Fraktur
oder Epiphysenlösung mit
Osteosynthese (5-790)
Offene Reposition einer einfachen
Fraktur im Schaftbereich eines langen
Röhrenknochens (5-791)
Offene Reposition einer Mehrfragment-
Fraktur im Schaftbereich eines langen
Röhrenknochens (5-792)
Offene Reposition einer einfachen
Fraktur im Gelenkbereich eines langen
Röhrenknochens (5-793)
Offene Reposition einer Mehrfragment-
Fraktur im Gelenkbereich eines langen
Röhrenknochens (5-794)
Offene Reposition einer einfachen
Fraktur an kleinen Knochen (5-795)
Offene Reposition einer Mehrfragment-
Fraktur an kleinen Knochen (5-796)
Offene Reposition einer Fraktur an Talus
und Kalkaneus (5-797)
Offene Reposition einer Beckenrand-
und Beckenringfraktur (5-798)
Offene Reposition einer Azetabulum-
und Hüftkopffraktur mit Osteosynthese
(5-799)
Geschlossene Reposition einer
Gelenkluxation mit Osteosynthese (5-
79a)
Offene Reposition einer Gelenkluxation
(5-79b)
Andere Reposition von Fraktur und
Luxation (5-79c)
Offen chirurgische Gelenkoperationen
(5-80)
Offen chirurgische Operation eines
Gelenkes (5-800)
Offen chirurgische Operation am
Gelenkknorpel und an den Menisken (5-
801)
Offen chirurgische Refixation und Naht
am Kapselbandapparat des
Kniegelenkes (5-802)
Offen chirurgische Bandplastik am
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Kniegelenk (5-803)
Offen chirurgische Operationen an der
Patella und ihrem Halteapparat (5-804)
Offen chirurgische Refixation und Plastik
am Kapselbandapparat des
Schultergelenkes (5-805)
Offen chirurgische Refixation und Plastik
am Kapselbandapparat des
Sprunggelenkes (5-806)
Offen chirurgische Refixation am
Kapselbandapparat anderer Gelenke (5-
807)
Arthrodese (5-808)
Andere offen chirurgische
Gelenkoperationen (5-809)
Arthroskopische Gelenkoperationen (5-
81)
Arthroskopische Gelenkoperation (5-
810)
Arthroskopische Operation an der
Synovialis (5-811)
Arthroskopische Operation am
Gelenkknorpel und an den Menisken (5-
812)
Arthroskopische Refixation und Plastik
am Kapselbandapparat des
Kniegelenkes (5-813)
Arthroskopische Refixation und Plastik
am Kapselbandapparat des
Schultergelenkes (5-814)
Arthroskopische Entfernung und
arthroskopischer Wechsel eines
Bandersatzes am Kniegelenk (5-815)
Arthroskopische Operationen am
Labrum acetabulare (5-816)
Andere arthroskopische Operationen (5-
819)
Endoprothetischer Gelenk- und
Knochenersatz (5-82)
Implantation einer Endoprothese am
Hüftgelenk (5-820)
Revision, Wechsel und Entfernung einer
Endoprothese am Hüftgelenk (5-821)
Implantation einer Endoprothese am
Kniegelenk (5-822)
Revision, Wechsel und Entfernung einer
Endoprothese am Kniegelenk (5-823)
Implantation einer Endoprothese an
Gelenken der oberen Extremität (5-824)
Revision, Wechsel und Entfernung einer
Endoprothese an Gelenken der oberen
Extremität (5-825)
Implantation einer Endoprothese an
Gelenken der unteren Extremität (5-826)
Revision, Wechsel und Entfernung einer
Endoprothese an Gelenken der unteren
Extremität (5-827)
Implantation, Revision, Wechsel und
Entfernung eines Knochenteilersatzes
und Knochentotalersatzes (5-828)
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Andere gelenkplastische Eingriffe (5-
829)
Operationen an der Wirbelsäule (5-83)
Inzision von erkranktem Knochen- und
Gelenkgewebe der Wirbelsäule (5-830)
Exzision von erkranktem
Bandscheibengewebe (5-831)
Exzision von erkranktem Knochen- und
Gelenkgewebe der Wirbelsäule (5-832)
Knochenersatz an der Wirbelsäule (5-
835)
Spondylodese (5-836)
Wirbelkörperersatz und komplexe
Rekonstruktion der Wirbelsäule (5-837)
Andere komplexe Rekonstruktionen der
Wirbelsäule (5-838)
Andere Operationen an der Wirbelsäule
(5-839)
Minimalinvasive Behandlungsverfahren
an der Wirbelsäule (zur
Schmerztherapie) (5-83a)
Osteosynthese (dynamische
Stabilisierung) an der Wirbelsäule (5-
83b)
Zusatzinformationen zu Operationen an
der Wirbelsäule (5-83w)
Operationen an der Hand (5-84)
Operationen an Sehnen der Hand (5-
840)
Operationen an Bändern der Hand (5-
841)
Operationen an Faszien der Hohlhand
und der Finger (5-842)
Operationen an Muskeln der Hand (5-
843)
Operation an Gelenken der Hand (5-844)
Synovialektomie an der Hand (5-845)
Arthrodese an Gelenken der Hand (5-
846)
Resektionsarthroplastik an Gelenken der
Hand (5-847)
Operationen bei kongenitalen Anomalien
der Hand (5-848)
Andere Operationen an der Hand (5-
849)
Operationen an Muskeln, Sehnen,
Faszien und Schleimbeuteln (5-85)
Inzision an Muskel, Sehne und Faszie
(5-850)
Durchtrennung von Muskel, Sehne und
Faszie (5-851)
Exzision an Muskel, Sehne und Faszie
(5-852)
Rekonstruktion von Muskeln (5-853)
Rekonstruktion von Sehnen (5-854)
Naht und andere Operationen an
Sehnen und Sehnenscheide (5-855)
Rekonstruktion von Faszien (5-856)
Plastische Rekonstruktion mit lokalen
Lappen an Muskeln und Faszien (5-857)
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Entnahme und Transplantation von
Muskel, Sehne und Faszie mit
mikrovaskulärer Anastomosierung (5-
858)
Andere Operationen an Muskeln,
Sehnen, Faszien und Schleimbeuteln (5-
859)
Replantation, Exartikulation und
Amputation von Extremitäten und andere
Operationen an den Bewegungsorganen
(5-86)
Replantation obere Extremität (5-860)
Replantation untere Extremität (5-861)
Amputation und Exartikulation obere
Extremität (5-862)
Amputation und Exartikulation Hand (5-
863)
Amputation und Exartikulation untere
Extremität (5-864)
Amputation und Exartikulation Fuß (5-
865)
Revision eines Amputationsgebietes (5-
866)
Operationen bei kongenitalen Anomalien
des Fußes (5-867)
Operationen bei anderen kongenitalen
Anomalien des Bewegungsapparates (5-
868)
Andere Operationen an den
Bewegungsorganen (5-869)
Zusatzinformationen zu Operationen an
den Bewegungsorganen (5-86a)
Exzision und Resektion der Mamma (5-
87)
Partielle (brusterhaltende) Exzision der
Mamma und Destruktion von
Mammagewebe (5-870)
(Modifizierte radikale) Mastektomie (5-
872)
Erweiterte (radikale) Mastektomie mit
Resektion an den Mm. pectorales
majores et minores und
Thoraxwandteilresektion (5-874)
Subkutane Mastektomie und
hautsparende Mastektomieverfahren (5-
877)
Andere Exzision und Resektion der
Mamma (5-879)
Andere Operationen an der Mamma (5-
88)
Inzision der Mamma (5-881)
Operationen an der Brustwarze (5-882)
Plastische Operationen zur
Vergrößerung der Mamma (5-883)
Mammareduktionsplastik (5-884)
Plastische Rekonstruktion der Mamma
mit Haut- und Muskeltransplantation (5-
885)
Andere plastische Rekonstruktion der
Mamma (5-886)
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Andere Operationen an der Mamma (5-
889)
Operationen an Haut und Unterhaut (5-
89)
Tätowieren und Einbringen von
Fremdmaterial in Haut und Unterhaut (5-
890)
Inzision eines Sinus pilonidalis (5-891)
Andere Inzision an Haut und Unterhaut
(5-892)
Lokale Exzision von erkranktem Gewebe
an Haut und Unterhaut (5-894)
Radikale und ausgedehnte Exzision von
erkranktem Gewebe an Haut und
Unterhaut (5-895)
Chirurgische Wundtoilette
[Wunddebridement] mit Entfernung von
erkranktem Gewebe an Haut und
Unterhaut (5-896)
Exzision und Rekonstruktion eines Sinus
pilonidalis (5-897)
Operationen am Nagelorgan (5-898)
Andere Exzision an Haut und Unterhaut
(5-899)
Operative Wiederherstellung und
Rekonstruktion von Haut und Unterhaut
(5-90)
Einfache Wiederherstellung der
Oberflächenkontinuität an Haut und
Unterhaut (5-900)
Freie Hauttransplantation,
Entnahmestelle (5-901)
Freie Hauttransplantation,
Empfängerstelle (5-902)
Lokale Lappenplastik an Haut und
Unterhaut (5-903)
Lappenplastik an Haut und Unterhaut,
Entnahmestelle (5-904)
Lappenplastik an Haut und Unterhaut,
Empfängerstelle (5-905)
Kombinierte plastische Eingriffe an Haut
und Unterhaut (5-906)
Revision einer Hautplastik (5-907)
Plastische Operation an Lippe und
Mundwinkel (5-908)
Andere Wiederherstellung und
Rekonstruktion von Haut und Unterhaut
(5-909)
Andere Operationen an Haut und
Unterhaut (5-91)
Straffungsoperation am Gesicht (5-910)
Gewebereduktion an Haut und Unterhaut
(5-911)
Haartransplantation und
Haartransposition (5-912)
Entfernung oberflächlicher
Hautschichten (5-913)
Chemochirurgie der Haut (5-914)
Destruktion von erkranktem Gewebe an
Haut und Unterhaut (5-915)
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Temporäre Weichteildeckung (5-916)
Syndaktylie- und Polydaktyliekorrektur
der Finger (5-917)
Syndaktylie- und Polydaktyliekorrektur
der Zehen (5-918)
Operative Versorgung von
Mehrfachtumoren an einer Lokalisation
der Haut in einer Sitzung (5-919)
Andere Operationen an Haut und
Unterhaut (5-91a)
Operationen an Haut und Unterhaut bei
Verbrennungen und Verätzungen (5-92)
Inzision an Haut und Unterhaut bei
Verbrennungen und Verätzungen (5-920)
Chirurgische Wundtoilette
[Wunddebridement] und Entfernung von
erkranktem Gewebe an Haut und
Unterhaut bei Verbrennungen und
Verätzungen (5-921)
Wunddebridement an Muskel, Sehne
und Faszie bei Verbrennungen und
Verätzungen (5-922)
Temporäre Weichteildeckung bei
Verbrennungen und Verätzungen (5-923)
Freie Hauttransplantation und
Lappenplastik an Haut und Unterhaut bei
Verbrennungen und Verätzungen,
Entnahmestelle (5-924)
Freie Hauttransplantation und
Lappenplastik an Haut und Unterhaut bei
Verbrennungen und Verätzungen,
Empfängerstelle (5-925)
Lokale Lappenplastik an Haut und
Unterhaut bei Verbrennungen und
Verätzungen (5-926)
Kombinierte plastische Eingriffe an Haut
und Unterhaut bei Verbrennungen und
Verätzungen (5-927)
Primärer Wundverschluss der Haut und
Revision einer Hautplastik bei
Verbrennungen und Verätzungen (5-928)
Andere Operationen bei Verbrennungen
und Verätzungen (5-929)
Angaben zum Transplantat und zu
verwendeten Materialien (5-93)
Art dees Transplantates (5-930)
Art des verwendeten Knochenersatz-
und Osteosynthesematerials (5-931)
Art des verwendeten Materials für
Gewebeersatz und Gewebeverstärkung
(5-932)
Verwendung einer Kunststoff- oder
biologischen Membran zur Prophylaxe
von Adhäsionen (5-933)
Verwendung von MRT-fähigem Material
(5-934)
Verwendung von beschichtetem
Osteosynthesematerial (5-935)
Verwendung von Arzneimitteln für
neuartige Therapien (5-936)
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Verwendung von thermomechanischem
Osteosynthesematerial (5-937)
Spezielle Operationstechniken und
Operationen bei speziellen
Versorgungssituationen (5-98)
Versorgung bei Mehrfachverletzung (5-
981)
Versorgung bei Polytrauma (5-982)
Reoperation (5-983)
Mikrochirurgische Technik (5-984)
Lasertechnik (5-985)
Minimalinvasive Technik (5-986)
Anwendung eines OP-Roboters (5-987)
Anwendung eines Navigationssystems
(5-988)
Fluoreszenzgestützte Therapieverfahren
(5-989)
Hybridtherapie (5-98a)
Anwendung eines flexiblen
Ureterorenoskops (5-98b)
Anwendung eines Klammernahtgerätes
(5-98c)
Verwendung von patientenindividuell
hergestelltem Instrumentarium (5-98d)
Intraoperative Blutflussmessung in
Gefäßen (5-98e)
Einsatz von Shavertechnik zur Weichteil-
und Knochenabtragung bei Operationen
an Nase, Nasennebenhöhlen und
Gesichtsschädelknochen (5-98f)
Vorzeitiger Abbruch einer Operation (5-
99)
Vorzeitiger Abbruch einer Operation
(Eingriff nicht komplett durchgeführt) (5-
995)
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MEDIKAMENTE
MEDIKAMENTE
Applikation von Medikamenten (6-00)
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(6-001)
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Applikation von Medikamenten, Liste 7
(6-007)
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OPS Chapter 8 NON-OPERATIVE
THERAPEUTIC PROCEDURES
NICHTOPERATIVE THERAPEUTISCHE
MASSNAHMEN
NICHTOPERATIVE THERAPEUTISCHE
MASSNAHMEN
Applikation von Medikamenten und
Nahrung (8-01)
Applikation von Medikamenten und
Elektrolytlösungen über das
Gefäßsystem bei Neugeborenen (8-010)
Intrathekale und intraventrikuläre
Applikation von Medikamenten durch
Medikamentenpumpen (8-011)
Enterale Ernährungstherapie als
medizinische Hauptbehandlung (8-015)
Parenterale Ernährungstherapie als
medizinische Hauptbehandlung (8-016)
Enterale Ernährung als medizinische
Nebenbehandlung (8-017)
Komplette parenterale Ernährung als
medizinische Nebenbehandlung (8-018)
Therapeutische Injektion (8-02)
Therapeutische Injektion (8-020)
Immuntherapie (8-03)
Spezifische allergologische
Immuntherapie (8-030)
Fremdkörperentfernung (8-10)
Fremdkörperentfernung durch
Endoskopie (8-100)
Fremdkörperentfernung ohne Inzision (8-
101)
Fremdkörperentfernung aus der Haut
ohne Inzision (8-102)
Extrakorporale Stoßwellentherapie (8-
11)
Extrakorporale Stoßwellenlithotripsie
[ESWL] von Steinen in den Harnorganen
(8-110)
Extrakorporale Stoßwellenlithotripsie
[ESWL] von Steinen in Gallenblase und
Gallengängen (8-111)
Extrakorporale Stoßwellenlithotripsie
[ESWL] von Steinen in sonstigen
Organen (8-112)
Extrakorporale Stoßwellentherapie am
Stütz- und Bewegungsapparat (8-115)
Andere extrakorporale
Stoßwellentherapie (8-119)
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Manipulationen am Verdauungstrakt (8-
12)
Magenspülung (8-120)
Darmspülung (8-121)
Desinvagination (8-122)
Wechsel und Entfernung eines
Gastrostomiekatheters (8-123)
Wechsel und Entfernung eines
Jejunostomiekatheters (8-124)
Anlegen und Wechsel einer duodenalen
oder jejunalen Ernährungssonde (8-125)
Transanale Irrigation (8-126)
Endoskopisches Einlegen und
Entfernung eines Magenballons (8-127)
Anwendung eines Stuhldrainagesystems
(8-128)
Applikation einer
Spenderstuhlsuspension (8-129)
Manipulationen am Harntrakt (8-13)
Manipulationen an der Harnblase (8-132)
Wechsel und Entfernung eines
suprapubischen Katheters (8-133)
Einlegen, Wechsel und Entfernung einer
Ureterschiene [Ureterkatheter] (8-137)
Wechsel und Entfernung eines
Nephrostomiekatheters (8-138)
Andere Manipulationen am Harntrakt (8-
139)
Andere Formen von therapeutischer
Katheterisierung und Kanüleneinlage (8-
14)
Therapeutische Drainage der
Pleurahöhle (8-144)
Therapeutische Drainage von Organen
des Bauchraumes (8-146)
Therapeutische Drainage von
Harnorganen (8-147)
Therapeutische Drainage von anderen
Organen und Geweben (8-148)
Andere therapeutische Katheterisierung
und Kanüleneinlage (8-149)
Therapeutische Aspiration und
Entleerung durch Punktion (8-15)
Therapeutische perkutane Punktion des
Zentralnervensystems und des Auges
(8-151)
Therapeutische perkutane Punktion von
Organen des Thorax (8-152)
Therapeutische perkutane Punktion der
Bauchhöhle (8-153)
Therapeutische perkutane Punktion von
Organen des Bauchraumes (8-154)
Therapeutische perkutane Punktion von
Harnorganen (8-155)
Therapeutische perkutane Punktion von
männlichen Geschlechtsorganen (8-156)
Therapeutische perkutane Punktion von
weiblichen Geschlechtsorganen (8-157)
Therapeutische perkutane Punktion
eines Gelenkes (8-158)
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Andere therapeutische perkutane
Punktion (8-159)
Spülung (Lavage) (8-17)
Therapeutische Spülung (Lavage) des
Auges (8-170)
Therapeutische Spülung (Lavage) des
Ohres (8-171)
Therapeutische Spülung (Lavage) der
Nasennebenhöhlen (8-172)
Therapeutische Spülung (Lavage) der
Lunge und der Pleurahöhle (8-173)
Therapeutische Spülung des
Bauchraumes bei liegender Drainage
und temporärem
Bauchdeckenverschluss (8-176)
Therapeutische Spülung des
Retroperitonealraumes bei liegender
Drainage und temporärem
Bauchdeckenverschluss (8-177)
Therapeutische Spülung eines Gelenkes
(8-178)
Andere therapeutische Spülungen (8-
179)
Verbände und Entfernung von
erkranktem Gewebe an Haut und
Unterhaut (8-19)
Spezielle Verbandstechniken (8-190)
Verband bei großflächigen und
schwerwiegenden Hauterkrankungen (8-
191)
Entfernung von erkranktem Gewebe an
Haut und Unterhaut ohne Anästhesie (im
Rahmen eines Verbandwechsels) bei
Vorliegen einer Wunde (8-192)
Geschlossene Reposition einer Fraktur
und Gelenkluxation ohne Osteosynthese
(8-20)
Geschlossene Reposition einer Fraktur
ohne Osteosynthese (8-200)
Geschlossene Reposition einer
Gelenkluxation ohne Osteosynthese (8-
201)
Geschlossene Reposition einer Fraktur
oder Gelenkluxation an der Wirbelsäule
ohne Osteosynthese (8-202)
Forcierte Korrektur von Adhäsionen und
Deformitäten (8-21)
Brisement force (8-210)
Redressierende Verfahren (8-211)
Quengelbehandlung (8-212)
Osteoklasie (8-213)
Herstellung und Anpassung von
Gesichtsepithesen (8-22)
Herstellung und Anpassung von
Gesichtsepithesen mit Klebe- oder
Brillen-Fixation (8-220)
Herstellung und Anpassung von
Gesichtsepithesen mit Implantat-Fixation
(8-221)
Immobilisation mit Gipsverband (8-31)
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Aufwendige Gipsverbände (8-310)
Lagerungsbehandlung (8-39)
Lagerungsbehandlung (8-390)
Extension am Skelett (8-40)
Extension durch Knochennagelung
(Steinmann-Nagel) (8-400)
Extension durch Knochendrahtung
(Kirschner-Draht) (8-401)
Extension der Wirbelsäule (8-41)
Extension an der Schädelkalotte (8-410)
Andere Extension der Halswirbelsäule
(8-411)
Extension der Lendenwirbelsäule (8-412)
Andere Extension der Wirbelsäule (8-
419)
Kontrolle von Blutungen durch
Tamponaden (8-50)
Tamponade einer Nasenblutung (8-500)
Tamponade einer Ösophagusblutung (8-
501)
Tamponade einer Rektumblutung (8-502)
Tamponade einer nicht geburtshilflichen
Uterusblutung (8-503)
Tamponade einer vaginalen Blutung (8-
504)
Wechsel und Entfernung einer
Tamponade bei Blutungen (8-506)
Manipulation an Fetus oder Uterus
während der Gravidität oder direkt
postpartal (8-51)
Manipulation am Fetus vor der Geburt
(8-510)
Partus mit Manualhilfe (8-515)
Manuelle postpartale Korrektur einer
Inversio uteri (8-516)
Strahlentherapie (8-52)
Oberflächenstrahlentherapie (8-520)
Orthovoltstrahlentherapie (8-521)
Hochvoltstrahlentherapie (8-522)
Andere Hochvoltstrahlentherapie (8-523)
Brachytherapie mit umschlossenen
Radionukliden (8-524)
Sonstige Brachytherapie mit
umschlossenen Radionukliden (8-525)
Radioaktive Moulagen (8-526)
Konstruktion und Anpassung von
Fixations- und Behandlungshilfen bei
Strahlentherapie (8-527)
Bestrahlungssimulation für externe
Bestrahlung und Brachytherapie (8-528)
Bestrahlungsplanung für perkutane
Bestrahlung und Brachytherapie (8-529)
Protonentherapie (8-52a)
Kohlenstoffionentherapie (8-52b)
Andere Schwerionentherapie (8-52c)
Intraoperative Strahlentherapie mit
Röntgenstrahlung (8-52d)
Nuklearmedizinische Therapie (8-53)
Therapie mit offenen Radionukliden (8-
530)
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Radiojodtherapie (8-531)
Andere nuklearmedizinische Therapie
(8-539)
Zytostatische Chemotherapie,
Immuntherapie und antiretrovirale
Therapie (8-54)
Instillation von und lokoregionale
Therapie mit zytotoxischen Materialien
und Immunmodulatoren (8-541)
Nicht komplexe Chemotherapie (8-542)
Mittelgradig komplexe und intensive
Blockchemotherapie (8-543)
Hochgradig komplexe und intensive
Blockchemotherapie (8-544)
Hypertherme Chemotherapie (8-546)
Andere Immuntherapie (8-547)
Hochaktive antiretrovirale Therapie
[HAART] (8-548)
Perkutane geschlossene Organperfusion
mit Chemotherapeutika (8-549)
Frührehabilitative Komplexbehandlung
(8-55)
Geriatrische frührehabilitative
Komplexbehandlung (8-550)
Neurologisch-neurochirurgische
Frührehabilitation (8-552)
Frührehabilitative Komplexbehandlung
von Patienten mit Kopf-Hals-Tumoren (8-
553)
Fachübergreifende und andere
Frührehabilitation (8-559)
Physikalisch-therapeutische
Einzelmaßnahmen (8-56)
Lichttherapie (8-560)
Funktionsorientierte physikalische
Therapie (8-561)
Physikalisch-medizinische
Komplexbehandlung (8-563)
Hyperthermie und Hypothermie (8-60)
Lokoregionale Hyperthermie im Rahmen
einer onkologischen Therapie (8-600)
Teilkörperhyperthermie im Rahmen einer
onkologischen Therapie (8-601)
Ganzkörperhyperthermie im Rahmen
einer onkologischen Therapie (8-602)
Interstitielle und intrakavitäre
Hyperthermie im Rahmen einer
onkologischen Therapie (8-603)
Computergestützte Planung einer
Hyperthermie (8-604)
Hypothermiebehandlung (8-607)
Elektrostimulation des Nervensystems
(8-63)
Elektrokrampftherapie [EKT] (8-630)
Neurostimulation (8-631)
Repetitive transkranielle
Magnetstimulation [rTMS] (8-632)
Pharyngeale elektrische Stimulation
[PES] (8-633)
Elektrische Konversion des
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Herzrhythmus (8-64)
Externe elektrische Defibrillation
(Kardioversion) des Herzrhythmus (8-
640)
Temporäre externe elektrische
Stimulation des Herzrhythmus (8-641)
Temporäre interne elektrische
Stimulation des Herzrhythmus (8-642)
Elektrische Stimulation des
Herzrhythmus, intraoperativ (8-643)
Elektrotherapie (8-65)
Elektrotherapie (8-650)
Thermotherapie mit magnetischen
Nanopartikeln (8-651)
Dauer der Behandlung durch
fokussierten Ultraschall (8-66)
Dauer der Behandlung durch
Magnetresonanz-gesteuerten
fokussierten Ultraschall [MRgFUS] (8-
660)
Zugang bei maschineller Beatmung und
Maßnahmen zum Offenhalten der
Atemwege (8-70)
Offenhalten der oberen Atemwege (8-
700)
Einfache endotracheale Intubation (8-
701)
Intubation mit Doppellumentubus (8-704)
Anlegen einer Maske zur maschinellen
Beatmung (8-706)
Maschinelle Beatmung und
Atemunterstützung über Maske oder
Tubus (8-71)
Maschinelle Beatmung und
Atemunterstützung bei Neugeborenen
und Säuglingen (8-711)
Maschinelle Beatmung und
Atemunterstützung bei Kindern und
Jugendlichen (8-712)
Maschinelle Beatmung und
Atemunterstützung bei Erwachsenen (8-
713)
Spezialverfahren zur maschinellen
Beatmung bei schwerem Atemversagen
(8-714)
Einstellung einer häuslichen
maschinellen Beatmung (8-716)
Einstellung einer nasalen oder
oronasalen Überdrucktherapie bei
schlafbezogenen Atemstörungen (8-717)
Zusatzinformationen zur maschinellen
Beatmung (8-719)
Sauerstoffzufuhr (8-72)
Sauerstoffzufuhr bei Neugeborenen (8-
720)
Hyperbare Oxygenation [HBO] (8-721)
Maßnahmen im Rahmen der
Reanimation (8-77)
Kardiale oder kardiopulmonale
Reanimation (8-771)
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Operative Reanimation (8-772)
Andere Reanimationsmaßnahmen (8-
779)
Transfusion von Blutzellen (8-80)
Transfusion von Vollblut,
Erythrozytenkonzentrat und
Thrombozytenkonzentrat (8-800)
Austauschtransfusion (8-801)
Transfusion von Leukozyten (8-802)
Gewinnung und Transfusion von
Eigenblut (8-803)
Transfusion von peripher gewonnenen
hämatopoetischen Stammzellen (8-805)
Transfusion von Plasma,
Plasmabestandteilen und Infusion von
Volumenersatzmitteln (8-81)
Transfusion von Plasmabestandteilen
und gentechnisch hergestellten
Plasmaproteinen (8-810)
Infusion von Volumenersatzmitteln bei
Neugeborenen (8-811)
Transfusion von Plasma und anderen
Plasmabestandteilen und gentechnisch
hergestellten Plasmaproteinen (8-812)
Plasmapherese und Immunadsorption
(8-82)
Therapeutische Plasmapherese (8-820)
Immunadsorption (8-821)
LDL-Apherese (8-822)
Zellapherese (8-823)
Photopherese (8-824)
Spezielle Zellaphereseverfahren (8-825)
Doppelfiltrationsplasmapherese (DFPP)
(8-826)
Apherese der löslichen, FMS-ähnlichen
Tyrosinkinase 1 [sFlt-1-Apherese] (8-
827)
Therapeutische Katheterisierung und
Kanüleneinlage in Gefäße (8-83)
Legen und Wechsel eines Katheters in
zentralvenöse Gefäße (8-831)
Legen und Wechsel eines Katheters in
die A. pulmonalis (8-832)
Ablative Maßnahmen bei
Tachyarrhythmie (8-835)
Perkutan-transluminale
Gefäßintervention (8-836)
Perkutan-transluminale
Gefäßintervention an Herz und
Koronargefäßen (8-837)
Perkutan-transluminale
Gefäßintervention an Gefäßen des
Lungenkreislaufes (8-838)
Andere therapeutische Katheterisierung
und Kanüleneinlage in Herz und
Blutgefäße (8-839)
Dauer der Behandlung mit einem
herzunterstützenden System (8-83a)
Zusatzinformationen zu Materialien (8-
83b)
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Andere perkutan-transluminale
Gefäßintervention (8-83c)
Andere perkutan-transluminale
Gefäßintervention an Herz und
Koronargefäßen (8-83d)
Perkutan-transluminale Stentimplantation
(8-84)
Perkutan-transluminale Implantation von
nicht medikamentenfreisetzenden Stents
(8-840)
Perkutan-transluminale Implantation von
medikamentenfreisetzenden Stents (8-
841)
Perkutan-transluminale Implantation von
nicht medikamentenfreisetzenden
gecoverten Stents (Stent-Graft) (8-842)
Perkutan-transluminale Implantation von
bioresorbierbaren Stents (8-843)
Perkutan-transluminale Implantation von
selbstexpandierenden Mikrostents (8-
844)
Perkutan-transluminale Implantation von
ungecoverten Cheatham-Platinum-
Stents [CP-Stent] (8-845)
Perkutan-transluminale Implantation von
gecoverten Cheatham-Platinum-Stents
[CP-Stent] (8-846)
Perkutan-transluminale Implantation
eines Wachstumsstents (8-847)
Perkutan-transluminale Implantation von
medikamentenfreisetzenden gecoverten
Stents (Stent-Graft) (8-848)
Perkutan-transluminale Implantation von
sonstigen ungecoverten großlumigen
Stents (8-849)
Perkutan-transluminale Implantation von
sonstigen gecoverten großlumigen
Stents (8-84a)
Perkutan-transluminale Implantation von
Stents zur Strömungslaminierung bei
Aneurysmen (8-84b)
Perkutan-transluminale Implantation
eines selbstexpandierenden
Bifurkationsstents, intrakraniell (8-84c)
Extrakorporale Zirkulation und
Behandlung von Blut (8-85)
Operativer äußerer Kreislauf (bei
Anwendung der Herz-Lungen-Maschine)
(8-851)
Extrakorporaler Gasaustausch ohne und
mit Herzunterstützung und Prä-ECMO-
Therapie (8-852)
Hämofiltration (8-853)
Hämodialyse (8-854)
Hämodiafiltration (8-855)
Hämoperfusion (8-856)
Peritonealdialyse (8-857)
Extrakorporale Leberersatztherapie
[Leberdialyse] (8-858)
Isolierte Extremitätenperfusion (8-859)
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Dialyseverfahren wegen mangelnder
Funktionsaufnahme und Versagen eines
Nierentransplantates (8-85a)
Anwendung von Blutegeln zur Sicherung
des venösen Blutabstroms bei
Lappenplastiken oder replantierten
Gliedmaßenabschnitten (8-85b)
Autogene und allogene
Stammzelltherapie und lokale Therapie
mit Blutbestandteilen und Hepatozyten
(8-86)
Autogene Stammzelltherapie (8-860)
Entnahme, Aufbereitung und Applikation
von Blutbestandteilen zur lokalen
Anwendung (8-861)
Hepatozytentransplantation (8-862)
Allogene Stammzelltherapie (8-863)
Anästhesie (8-90)
Intravenöse Anästhesie (8-900)
Inhalationsanästhesie (8-901)
Balancierte Anästhesie (8-902)
(Analgo-)Sedierung (8-903)
Schmerztherapie (8-91)
Epidurale Injektion und Infusion zur
Schmerztherapie (8-910)
Subarachnoidale Injektion und Infusion
zur Schmerztherapie (8-911)
Injektion eines Medikamentes an
extrakranielle Hirnnerven zur
Schmerztherapie (8-913)
Injektion eines Medikamentes an
Nervenwurzeln und wirbelsäulennahe
Nerven zur Schmerztherapie (8-914)
Injektion und Infusion eines
Medikamentes an andere periphere
Nerven zur Schmerztherapie (8-915)
Injektion eines Medikamentes an das
sympathische Nervensystem zur
Schmerztherapie (8-916)
Injektion eines Medikamentes in Gelenke
der Wirbelsäule zur Schmerztherapie (8-
917)
Multimodale Schmerztherapie (8-918)
Komplexe Akutschmerzbehandlung (8-
919)
Multimodale schmerztherapeutische
Kurzzeitbehandlung (8-91b)
Teilstationäre Multimodale
Schmerztherapie (8-91c)
Neurologisches Monitoring (8-92)
EEG-Monitoring (mindestens 2 Kanäle)
für mehr als 24 h (8-920)
Monitoring mittels evoozierter Potentiale
(8-921)
Monitoring der hirnvenösen
Sauerstoffsättigung (8-923)
Invasives neurologisches Monitoring (8-
924)
Intraoperatives neurophysiologisches
Monitoring (8-925)
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Monitoring von Atmung, Herz und
Kreislauf (8-93)
Monitoring von Atmung, Herz und
Kreislauf ohne Messung des
Pulmonalarteriendruckes und des
zentralen Venendruckes (8-930)
Monitoring von Atmung, Herz und
Kreislauf mit Messung des zentralen
Venendruckes (8-931)
Monitoring von Atmung, Herz und
Kreislauf mit Messung des
Pulmonalarteriendruckes (8-932)
Funkgesteuerte kardiologische
Telemetrie (8-933)
Multimodale Komplexbehandlung (8-97)
Multimodale dermatologische
Komplexbehandlung (8-971)
Komplexbehandlung bei
schwerbehandelbarer Epilepsie (8-972)
Komplexbehandlung bei Spina bifida (8-
973)
Multimodale Komplexbehandlung bei
sonstiger chronischer Erkrankung (8-
974)
Naturheilkundliche und
anthroposophisch-medizinische
Komplexbehandlung (8-975)
Komplexbehandlung bei
Querschnittlähmung (8-976)
Multimodal-nichtoperative
Komplexbehandlung des
Bewegungssystems (8-977)
Aufrechterhaltung der Homöostase für
die postmortale Organspende (8-978)
Stationäre Behandlung vor
Transplantation (8-979)
Multimodale intensivmedizinische
Überwachung und Behandlung bei
zerebrovaskulären Vasospasmen (8-97a)
Multimodale intensivmedizinische
Überwachung und Behandlung bei
neuromuskulären Erkrankungen (8-97b)
Stationäre Behandlung bei erfolgter
Aufnahme auf die Warteliste zur
Organtransplantation (8-97c)
Multimodale Komplexbehandlung bei
Morbus Parkinson und atypischem
Parkinson-Syndrom (8-97d)
Behandlung des Morbus Parkinson in
der Spätphase mit Arzneimittelpumpen
(8-97e)
Sonstige multimodale
Komplexbehandlung (8-98)
Intensivmedizinische
Komplexbehandlung (Basisprozedur) (8-
980)
Neurologische Komplexbehandlung des
akuten Schlaganfalls (8-981)
Palliativmedizinische
Komplexbehandlung (8-982)
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Multimodale rheumatologische
Komplexbehandlung (8-983)
Multimodale Komplexbehandlung bei
Diabetes mellitus (8-984)
Motivationsbehandlung
Abhängigkeitskranker [Qualifizierter
Entzug] (8-985)
Multimodale kinder- und
jugendrheumatologische
Komplexbehandlung (8-986)
Komplexbehandlung bei Besiedelung
oder Infektion mit multiresistenten
Erregern [MRE] (8-987)
Spezielle Komplexbehandlung der Hand
(8-988)
Chirurgische Komplexbehandlung bei
schweren Infektionen (8-989)
Teilstationäre geriatrische
Komplexbehandlung (8-98a)
Andere neurologische
Komplexbehandlung des akuten
Schlaganfalls (8-98b)
Intensivmedizinische
Komplexbehandlung im Kindesalter
(Basisprozedur) (8-98d)
Spezialisierte stationäre
palliativmedizinische
Komplexbehandlung (8-98e)
Aufwendige intensivmedizinische
Komplexbehandlung (Basisprozedur) (8-
98f)
Komplexbehandlung bei Besiedelung
oder Infektion mit nicht multiresistenten
isolationspflichtigen Erregern (8-98g)
Zusatzinformationen zu nicht operativen
therapeutischen Maßnahmen (8-99)
Anwendung eines Navigationssystems
(8-990)
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OPS Chapter 9 ADDITIONAL
PROCEDURES
derived from:
OPS - German Procedure Classification
https://www.dimdi.de/static/en/klassi/ops/index.htm
DIMDI publishes the OPS classification on behalf of the
Federal Ministry of Health; it is in the public domain. Its use
in inpatient care is laid down in  301 Volume V of the
German Social Security Code (SGB V) and for surgical
procedures in the outpatient sector in  295 SGB V.
All rights reserved. Please visit https://medical-data-
models.org/forms/12081
OPS Chapter 9 ADDITIONAL
PROCEDURES
ERGÄNZENDE MASSNAHMEN
ERGÄNZENDE MASSNAHMEN
Hochaufwendige Pflege von Patienten
(9-20)
Hochaufwendige Pflege von
Erwachsenen (9-200)
Hochaufwendige Pflege von Kindern und
Jugendlichen (9-201)
Hochaufwendige Pflege von Kleinkindern
(9-202)
Geburtsbegleitende Maßnahmen (9-26)
Überwachung und Leitung einer
normalen Geburt (9-260)
Überwachung und Leitung einer
Risikogeburt (9-261)
Postnatale Versorgung des
Neugeborenen (9-262)
Überwachung und Leitung der isolierten
Geburt der Plazenta (9-263)
Überwachung und Leitung einer Geburt,
n.n.bez. (9-268)
Behandlung wegen Infertilität (9-27)
Künstliche Insemination (9-270)
Follikelpunktion und Ovumaspiration,
intratubärer Gametentransfer (GIFT) (9-
271)
In-vitro-Fertilisation (IVF) und
Embryotransfer (9-272)
Andere Behandlung der weiblichen
Infertilität (9-278)
Behandlung während der
Schwangerschaft (9-28)
Stationäre Behandlung vor Entbindung
während desselben Aufenthalts (9-280)
Phoniatrische und pädaudiologische
Komplexbehandlung (9-31)
Phoniatrische Komplexbehandlung
organischer und funktioneller Störungen
der Sprache, des Sprechens, der
Stimme und des Schluckens (9-310)
Integrierte phoniatrisch-
psychosomatische Komplexbehandlung
von Störungen der Sprache, des
Sprechens, der Stimme, des Schluckens
und des Hörens (9-311)
Integrierte pädaudiologische
Komplexbehandlung (9-312)
Therapie von Stimm-, Sprach-, Sprech-,
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Schluckstörungen und Hörstörungen (9-
32)
Therapie organischer und funktioneller
Störungen der Sprache, des Sprechens,
der Stimme und des Schluckens (9-320)
Psychosoziale, psychosomatische und
neuropsychologische Therapie (9-40)
Psychosoziale Interventionen (9-401)
Psychosomatische Therapie (9-402)
Sozialpädiatrische, neuropädiatrische
und pädiatrisch-psychosomatische
Therapie (9-403)
Neuropsychologische Therapie (9-404)
Psychotherapie (9-41)
Einzeltherapie (9-410)
Gruppentherapie (9-411)
Multimodale psychotherapeutische
Komplexbehandlung im Liaisondienst (9-
412)
Präventive Maßnahmen (9-50)
Patientenschulung (9-500)
Multimodale stationäre Behandlung zur
Tabakentwöhnung (9-501)
Ergänzende kommunikative Maßnahmen
(9-51)
Einsatz von
Gebärdensprachdolmetschern (9-510)
Regelbehandlung bei psychischen und
psychosomatischen Störungen und
Verhaltensstörungen bei Erwachsenen
(9-60)
Regelbehandlung bei psychischen und
psychosomatischen Störungen und
Verhaltensstörungen bei Erwachsenen
(9-607)
Intensivbehandlung bei psychischen und
psychosomatischen Störungen und
Verhaltensstörungen bei Erwachsenen
(9-61)
Intensivbehandlung bei psychischen und
psychosomatischen Störungen und
Verhaltensstörungen bei erwachsenen
Patienten mit 1 Merkmal (9-617)
Intensivbehandlung bei psychischen und
psychosomatischen Störungen und
Verhaltensstörungen bei erwachsenen
Patienten mit 2 Merkmalen (9-618)
Intensivbehandlung bei psychischen und
psychosomatischen Störungen und
Verhaltensstörungen bei erwachsenen
Patienten mit 3 Merkmalen (9-619)
Intensivbehandlung bei psychischen und
psychosomatischen Störungen und
Verhaltensstörungen bei erwachsenen
Patienten mit 4 Merkmalen (9-61a)
Intensivbehandlung bei psychischen und
psychosomatischen Störungen und
Verhaltensstörungen bei erwachsenen
Patienten mit 5 und mehr Merkmalen (9-
61b)
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Psychotherapeutische
Komplexbehandlung bei psychischen
und psychosomatischen Störungen und
Verhaltensstörungen bei Erwachsenen
(9-62)
Psychotherapeutische
Komplexbehandlung bei psychischen
und psychosomatischen Störungen und
Verhaltensstörungen bei Erwachsenen
(9-626)
Psychosomatisch-psychotherapeutische
Komplexbehandlung bei psychischen
und psychosomatischen Störungen und
Verhaltensstörungen bei Erwachsenen
(9-63)
Psychosomatisch-psychotherapeutische
Komplexbehandlung bei psychischen
und psychosomatischen Störungen und
Verhaltensstörungen bei Erwachsenen
(9-634)
Zusatzinformationen zur Behandlung bei
psychischen und psychosomatischen
Störungen und Verhaltensstörungen bei
Erwachsenen (9-64)
Erhöhter Betreuungsaufwand bei
psychischen und psychosomatischen
Störungen und Verhaltensstörungen bei
Erwachsenen (9-640)
Kriseninterventionelle Behandlung bei
psychischen und psychosomatischen
Störungen und Verhaltensstörungen bei
Erwachsenen (9-641)
Integrierte klinisch-psychosomatisch-
psychotherapeutische
Komplexbehandlung bei psychischen
und psychosomatischen Störungen und
Verhaltensstörungen bei Erwachsenen
(9-642)
Psychiatrisch-psychotherapeutische
Behandlung im besonderen Setting
(Mutter/Vater-Kind-Setting) (9-643)
Erbringung von
Behandlungsmaßnahmen im
stationsersetzenden Umfeld und als
halbtägige tagesklinische Behandlung
bei Erwachsenen (9-644)
Indizierter komplexer
Entlassungsaufwand bei psychischen
und psychosomatischen Störungen und
Verhaltensstörungen bei Erwachsenen
(9-645)
Erhöhter Aufwand bei drohender oder
bestehender psychosozialer Notlage bei
Erwachsenen (9-646)
Spezifische qualifizierte
Entzugsbehandlung
Abhängigkeitskranker bei Erwachsenen
(9-647)
Erhöhter therapieprozessorientierter
patientenbezogener
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Supervisionsaufwand bei psychischen
und psychosomatischen Störungen und
Verhaltensstörungen bei Erwachsenen
(9-648)
Anzahl der Therapieeinheiten pro Woche
bei Erwachsenen (9-649)
Psychiatrisch-psychosomatische
Regelbehandlung bei psychischen und
psychosomatischen Störungen und
Verhaltensstörungen bei Kindern (9-65)
Regelbehandlung bei psychischen und
psychosomatischen Störungen und
Verhaltensstörungen bei Kindern (9-656)
Psychiatrisch-psychosomatische
Regelbehandlung bei psychischen und
psychosomatischen Störungen und
Verhaltensstörungen bei Jugendlichen
(9-66)
Regelbehandlung bei psychischen und
psychosomatischen Störungen und
Verhaltensstörungen bei Jugendlichen
(9-666)
Psychiatrisch-psychosomatische
Intensivbehandlung bei psychischen und
psychosomatischen Störungen und
Verhaltensstörungen bei Kindern und
Jugendlichen (9-67)
Psychiatrisch-psychosomatische
Intensivbehandlung bei psychischen und
psychosomatischen Störungen und
Verhaltensstörungen bei Kindern und
Jugendlichen (9-672)
Psychiatrisch-psychosomatische
Behandlung im besonderen Setting
(Eltern-Kind-Setting) bei psychischen
und psychosomatischen Störungen und
Verhaltensstörungen bei Kindern und
Jugendlichen (9-68)
Psychiatrisch-psychosomatische
Behandlung im besonderen Setting
(Eltern-Kind-Setting) bei psychischen
und psychosomatischen Störungen und
Verhaltensstörungen bei Kindern und
Jugendlichen (9-686)
Zusatzinformationen zur Behandlung bei
psychischen und psychosomatischen
Störungen und Verhaltensstörungen bei
Kindern und Jugendlichen (9-69)
Kriseninterventionelle Behandlung bei
psychischen und psychosomatischen
Störungen und Verhaltensstörungen bei
Kindern und Jugendlichen (9-690)
Erbringung von
Behandlungsmaßnahmen im
stationsersetzenden Umfeld und als
halbtägige tagesklinische Behandlung
bei Kindern und Jugendlichen (9-691)
Indizierter komplexer
Entlassungsaufwand bei psychischen
und psychosomatischen Störungen und
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Verhaltensstörungen bei Kindern und
Jugendlichen (9-692)
Intensive Beaufsichtigung mit
Überwachung in einer Kleinstgruppe
oder Einzelbetreuung bei psychischen
und psychosomatischen Störungen und
Verhaltensstörungen bei Kindern und
Jugendlichen (9-693)
Spezifische Behandlung im besonderen
Setting bei substanzbedingten
Störungen bei Kindern und Jugendlichen
(9-694)
Erhöhter therapieprozessorientierter
patientenbezogener
Supervisionsaufwand bei psychischen
und psychosomatischen Störungen und
Verhaltensstörungen bei Kindern und
Jugendlichen (9-695)
Anzahl der Therapieeinheiten pro Woche
bei Kindern und Jugendlichen (9-696)
Behandlung in Einrichtungen, die im
Anwendungsbereich der Psychiatrie-
Personalverordnung liegen, und
Pflegebedürftigkeit (9-98)
Behandlung von Erwachsenen in
Einrichtungen, die im
Anwendungsbereich der Psychiatrie-
Personalverordnung liegen, Allgemeine
Psychiatrie (9-980)
Behandlung von Erwachsenen in
Einrichtungen, die im
Anwendungsbereich der Psychiatrie-
Personalverordnung liegen,
Abhängigkeitskranke (9-981)
Behandlung von Erwachsenen in
Einrichtungen, die im
Anwendungsbereich der Psychiatrie-
Personalverordnung liegen,
Gerontopsychiatrie (9-982)
Behandlung von Kindern und
Jugendlichen in Einrichtungen, die im
Anwendungsbereich der Psychiatrie-
Personalverordnung liegen, Kinder- und
Jugendpsychiatrie (9-983)
Pflegebedürftigkeit (9-984)
Obduktion (9-99)
Klinische Obduktion bzw. Obduktion zur
Qualitätssicherung (9-990)
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Therapeutic algorithm for adult patients with
primary MDS and and low IPSS risk score
Derived from:
Malcovati L, Hellström-Lindberg E, Bowen D, Adès L,
Cermak J, Del Cañizo C,
Della Porta MG, Fenaux P, Gattermann N, Germing U,
Jansen JH, Mittelman M, Mufti 
G, Platzbecker U, Sanz GF, Selleslag D, Skov-Holm M,
Stauder R, Symeonidis A, van
de Loosdrecht AA, de Witte T, Cazzola M; European
Leukemia Net. Diagnosis and
treatment of primary myelodysplastic syndromes in adults:
recommendations from
the European LeukemiaNet. Blood. 2013 Oct
24;122(17):2943-64
http://www.ncbi.nlm.nih.gov/pubmed/23980065
All rights reserved. Please visit https://medical-data-
models.org/forms/12095
Therapeutic algorithm for adult
patients with primary MDS and and
low IPSS risk score
Adult patient with primary MDS and and
low IPSS risk score
1. Low IPSS risk
Asymptomatic cytopenia -> Watchful
waiting (1)
Symptomatic anemia -> step 2 (2)
2. Symptomatic anemia
sEpo < 500 mU/mL and/or RBC units <
2/month -> rHuEpo +/- G-CSF (2)
MDS del(5q) -> step 3 (3)
RBC transfusion and iron chelation
therapy (4)
Age < 60 years, BM blasts < 5%, normal
cytogenetics, transfusion-dependency
(hypocellular bone marrow) ->
Immunosuppressive therapy with ATG
plus CSA (5)
3. MDS del(5q)
sEpo >=500 mU/mL and RBC units
>=2/month -> Lenalidomide (within
prospective registry) (3)
sEpo < 500 mU/mL and/or RBC units
<2/month -> rHuEpo +/- G-CSF ->
Lenalidomide (within prospective
registry) (4)
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Eligibility Idiopathic Parkinson's Disease
NCT02352363
Randomized Safety Study of CVT-301 Compared to an
Observational Control Group; ODM derived from:
https://clinicaltrials.gov/show/NCT02352363
All rights reserved. Please visit https://medical-data-
models.org/forms/12099
Eligibility Idiopathic Parkinson's
Disease NCT02352363
Inclusion Criteria
has signed and dated an internal review
board/independent ethics committee (irb/iec)-
approved informed consent form before any
protocol-specific screening procedures are
performed.*
Yes
No
women of child-bearing potential must use
protocol-defined contraceptive measures and
must have a negative serum human chorionic
gonadotropin (hcg) test at screening. these
patients must be willing to remain on their current
form of contraception for the duration of the
study.*
Yes
No
patients who have idiopathic pd (i.e., not induced
by drugs or other diseases) as defined by fulfilling
steps 1 and 2 of the united kingdom (uk) brain
bank criteria, diagnosed after the age of 30
years.*
Yes
No
patients who are classified as stage 1 to 3 (in the
on state) on the modified hoehn and yahr scale
for staging of pd severity.*
Yes
No
patients who have experienced motor fluctuations
for a minimum of 2 hours of average daily off time
per waking day (excluding early morning off time)
by self-report and confirmed by the pd diary (on 3
consecutive days) during the screening period.*
Yes
No
Exclusion Criteria
patients who have dyskinesia of a severity that
would significantly interfere with their ability to
participate or perform study procedures.*
Yes
No
pregnant or lactating females or females wishing
to become pregnant.*
Yes
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No
patients who have any known contraindication to
the use of levodopa (ld), including a history of
malignant melanoma or a history of narrow-angle
glaucoma.*
Yes
No
patients who have had previous surgery for pd
(including but not limited to deep brain stimulation
[dbs] or cell transplantation).*
Yes
No
patients with a history of psychotic symptoms
requiring treatment, or suicide ideation or attempt
within the prior 12 months (stable regimens [for at
least 4 weeks prior to screening visit 1 (sv1)] of
anti-depressant and certain low-dose atypical
antipsychotic medications are permitted).*
Yes
No
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Eligibility Idiopathic Parkinson's Disease NCT02352363
Eligibility Leukemia NCT02141477
Omacetaxine and Decitabine in Acute Myelogenous
Leukemia (AML) and Myelodysplastic Syndrome (MDS);
ODM derived from:
https://clinicaltrials.gov/show/NCT02141477
All rights reserved. Please visit https://medical-data-
models.org/forms/12100
Eligibility Leukemia NCT02141477
Inclusion Criteria
1. previously untreated aml (>/= 20% blasts) or
aml m6. patients with high-risk (intermediate-2 or
high by ipss or >/= 10% blasts) mds will also be
eligible. prior therapy with hydroxyurea, biological
or targeted therapy (e.g. flt3 inhibitors, other
kinase inhibitors, azacitidine), or hematopoietic
growth factors is allowed. no prior chemotherapy
is allowed except for a single or a two day dose of
cytarabine (up to 3 g/m2) for emergency use is
also allowed as prior therapy.*
Yes
No
2. age >/= 70 years.*
Yes
No
3. ecog performance status </= 2.*
Yes
No
4. adequate hepatic (serum total bilirubin </= 1.5
x uln, sgpt and/or sgot </= 2.5 x uln) and renal
function (creatinine </= 2.0 mg/dl).*
Yes
No
5. patients must be willing and able to review,
understand, and provide written consent before
starting therapy.*
Yes
No
6. men of childbearing potential who agree to use
contraception prior to study entry and for the
duration of participation.*
Yes
No
Exclusion Criteria
1. nyha class iii or iv heart disease, active
ischemia or any other uncontrolled cardiac
condition such as angina pectoris, clinically
significant cardiac arrhythmia and requiring
therapy, uncontrolled hypertension (blood
pressure >/= 160 systolic and >/= 110 diastolic
not responsive to antihypertensive medication),
uncontrolled diabetes mellitus, or congestive
heart failure.*
Yes
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No
2. myocardial infarction in the previous 12 weeks
(from the start of treatment).*
Yes
No
3. active and uncontrolled disease/infection as
judged by the treating physician.*
Yes
No
4. acute promyelocytic leukemia (apl).*
Yes
No
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Eligibility Leukemia NCT02225275
Combination of Lenalidomide and Obinutuzumab (GA101)
in Patients With Recurrent Chronic Lymphocytic
Leukemia/Small Lymphocytic Lymphoma (CLL/SLL); ODM
derived from: https://clinicaltrials.gov/show/NCT02225275
All rights reserved. Please visit https://medical-data-
models.org/forms/12103
Eligibility Leukemia NCT02225275
Inclusion Criteria
1. age 18 years or older at the time of signing
informed consent. able to understand and to
provide voluntarily informed consent;*
Yes
No
2. have documented cll/sll according to nci
criteria;*
Yes
No
3. recurrent or refractory disease according to nci
criteria;*
Yes
No
4. patient are eligible if they have received one or
more prior treatment;*
Yes
No
5. ecog performance status of 0-2 (appendix 1);*
Yes
No
6. life expectancy > 6 months;*
Yes
No
7. adequate renal function indicated by serum
creatinine less or equal to 2 mg/dl;*
Yes
No
8. adequate hepatic function indicated as total
bilirubin less or equal to 2 mg/dl and alt/gpt less
or equal to two times the upper normal limit;*
Yes
No
9. disease free of prior malignancies for 3 years
with exception of currently treated basal cell
squamous cell carcinoma of the skin, or
carcinoma "in situ" of the cervix or breast.
patients with malignancies with indolent behavior
such as prostate cancer treated with radiation or
surgery can be enrolled in the study as long as
they have a reasonable expectation to have been
cured with the treatment modality received*
Yes
No
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10. no prior history of myelodysplastic syndrome
or other myeloid malignancy;*
Yes
No
11. all participants must be registered into the
mandatory revlimid rems® program, and be
willing and able to comply with the requirements
of the revlimid rems ®;*
Yes
No
12. females of childbearing potential (fcbp) must
have a negative serum and/or urine pregnancy
test with a sensitive of at least 50 miu/ml within
10-14 days and again within 24 hours prior to
prescribe lenalidomide for cycle 1 (prescriptions
must be filled within 7 days as required by
revlimid rems) and must either commit to
continued abstinence from heterosexual
intercourse or begin two acceptable methods of
birth control, one highly effective method and one
additional effective method at the same time, at
least 28 days before she starts taking
lenalidomide. fcbp must also agree to ongoing
pregnancy testing. men must agree to use a latex
condom during sexual contact with a fcbp even if
they have had a successful vasectomy.*
Yes
No
Exclusion Criteria
1. known sensitivity to lenalidomide or other
thalidomide derivatives or anti cd20;*
Yes
No
2. documented prolymphocytic leukemia
(prolymphocytes more than 55% in the blood);*
Yes
No
3. known history of infection with human
immunodeficiency virus (hiv) or human t cell
leukemia virus 1 (htlv-1);*
Yes
No
4. serologic status reflecting active hepatitis b or
c. patients with hepatitis b (hbv) antibody positive
but who have positivity for hepatitis b surface
antigen (hbsag) or anti hepatitis b core antibody
(anti-hbc) and patients who are positive for anti-
hcv will need to have a negative pcr (viral hbv
dna or hcv rna) result prior to enrollment. those
who are hbsag positive or hbv dna positive and
those who are positive for hcv (rna) will be
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excluded;*
Yes
No
5. pregnant or breast feeding females;*
Yes
No
6. history of tuberculosis treated within the last
five years or recent exposure to tuberculosis;*
Yes
No
7. any serious medical condition, laboratory
abnormality, or psychiatric illness that places the
subject unacceptable risk if he/she were to
participate to the study;*
Yes
No
8. patients with a recent history of deep vein
thrombosis or pulmonary embolus, in the six
months prior to enrollment are not eligible for this
study.*
Yes
No
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Eligibility Lung Cancer NCT02225405
Induction Study of Cisplatin, Docetaxel, and Nintedanib
Stage IB-IIIA Non-Small Cell Lung Cancer (NCLC); ODM
derived from: https://clinicaltrials.gov/show/NCT02225405
All rights reserved. Please visit https://medical-data-
models.org/forms/12104
Eligibility Lung Cancer
NCT02225405
Inclusion Criteria
1. age 18 years and older*
Yes
No
2. histologically or cytologically confirmed non-
small cell lung cancer. patients with a suspected
lung cancer are eligible, but pathology must be
confirmed prior to initiating treatment on study.
neuroendocrine carcinomas are not eligible.
carcinomas with neuroendocrine differentiation
are eligible.*
Yes
No
3. stage ib (with a primary tumor >/= 4cm), iia, iib,
or iiia (according to ajcc 7th edition). patients with
stage iiia must not have more than one
mediastinal lymph node station involved by
tumor.*
Yes
No
4. all patients must have lymph node evaluation
of contralateral stations 2 and/or 4 to exclude n3
disease.*
Yes
No
5. the patient must be a suitable candidate for
surgery, in the opinion of the treating physician.*
Yes
No
6. ecog performance status score 0-1*
Yes
No
7. signed and dated written informed consent
prior to admission to the study in accordance with
ich-gcp guidelines and to the local legislation*
Yes
No
Exclusion Criteria
1. prior systemic therapy or radiation therapy for
treatment of the current lung cancer*
Yes
No
2. known hypersensitivity to the trial drugs or to
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their excipients*
Yes
No
3. centrally located tumors with radiographic
evidence (ct or mri) of local invasion of major
blood vessels*
Yes
No
4. radiographic evidence of cavitary or necrotic
tumor*
Yes
No
5. major injuries within the past 10 days prior to
start of study treatment with incomplete wound
healing*
Yes
No
6. history of clinically significant haemorrhagic or
thromboembolic event in the past 6 months*
Yes
No
7. known inherited predisposition to bleeding or
thrombosis*
Yes
No
8. significant cardiovascular diseases (i.e.
uncontrolled hypertension, unstable angina,
history of infarction within the past 12 months
prior to start of study treatment, congestive heart
failure > nyha ii, serious cardiac arrhythmia,
pericardial effusion)*
Yes
No
9. creatinine > 1.5 institutional upper limit of
normal. patients with creatinine > 1.5 the
institutional upper limit of normal who have
creatinine clearance >/= 60 cc/min (calculated
using the cockcroft and gault equation) are
eligible*
Yes
No
10. hepatic function: total bilirubin > institutional
upper limit of normal or ast > 1.5 x institutional
upper limit of normal*
Yes
No
11. coagulation parameters: international
normalised ratio (inr) > 2, prothrombin time (pt)
and partial thromboplastin time (ptt) > 50% of
deviation of institutional uln*
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Yes
No
12. absolute neutrophil count ( anc) < 1500/ml,
and/or platelets < 100000/ml*
Yes
No
13. prior malignancy requiring systemic therapy
or radiation therapy within 1 year of
randomization*
Yes
No
14. active serious infections in particular if
requiring systemic antibiotic or antimicrobial
therapy*
Yes
No
15. active or chronic hepatitis c and/or b
infection*
Yes
No
16. gastrointestinal disorders or abnormalities
that would interfere with absorption of the study
drug*
Yes
No
17. serious illness or concomitant non-
oncological disease such as neurologic,
psychiatric, infectious disease or laboratory
abnormality that may increase the risk associated
with study participation or study drug
administration and in the judgment of the
investigator would make the patient inappropriate
for entry into the study*
Yes
No
18. patients who are sexually active, with
preserved reproductive capacity, and unwilling to
use a medically acceptable method of
contraception (e.g. such as implants, injectables,
combined oral contraceptives, some intrauterine
devices or vasectomized partner for participating
females, condoms for participating males) during
the trial and for at least three months after end of
active therapy*
Yes
No
19. pregnancy or breast feeding.*
Yes
No
20. psychological, familial, sociological or
geographical factors potentially hampering
compliance with the study protocol and follow-up
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schedule.*
Yes
No
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Eligibility Liver Metastasis NCT02218801
A Prospective Colorectal Liver Metastasis Database With
an Integrated Quality Assurance Program; ODM derived
from: https://clinicaltrials.gov/show/NCT02218801
All rights reserved. Please visit https://medical-data-
models.org/forms/12105
Eligibility Liver Metastasis
NCT02218801
Inclusion Criteria
with histologically proven colorectal
adenocarcinoma with liver metastasis.*
Yes
No
with unresectable, borderline or initially
unresectable liver metastasis from a colorectal
cancer assessed by a clinician or by a multi-
disciplinary tumor board (mdt).*
Yes
No
participants of the mdt must include at least one
liver surgeon, one radiologist and one oncologist.
they will determine the resectability of the crlm
according to local practice.*
Yes
No
With a surgical procedure (resection with or
without portal vein embolization, intraoperative
local ablative technique or a combined approach)
must be planned (if indicated after preoperative
systemic treatment) during the mdt.*
Yes
No
age ≥ 18 years.*
Yes
No
before patient registration, written informed
consent must be given according to ich/gcp, and
national/local regulations.*
Yes
No
Exclusion Criteria
any psychological, familial, or sociological
condition potentially hampering understanding of
the research project.*
Yes
No
any other malignancy other than in situ
carcinoma of the cervix or non-melanoma skin
cancer (unless there has been a disease-free
interval of at least 5 years)*
Yes
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1. induction therapy adverse events AML
NCT00180102
Randomisierter Vergleich zwischen Standard- und
intensivierter Therapiestrategie der akuten myeloischen
Leukämie des Erwachsenen im Alter von <= 60 Jahren
Prospektive, randomisierte, multizentrische
Therapieoptimierungsstudie - Studienprotokoll AML2003
http://www.clinicaltrials.gov/ct2/show/NCT00180102
All rights reserved. Please visit https://medical-data-
models.org/forms/12109
1. induction therapy adverse events
AML NCT00180102
Allgemeine Angaben
Klinik-Nr.:*
Patienten-Nr.: 2-*
Patienten-Initialen: (Nachname/Vorname)*
allergische Reaktion
allergische Reaktion*
Ja
Nein
Beginn:*
Ende:*
Intensität*
leicht (1)
mäßig (2)
schwer (3)
lebensbedrohlich (4)
Kausalität (mit Studienmedikation)*
unbekannt (0)
nein (1)
möglich (2)
ja (sicher) (3)
Hämoglobin
Hämoglobin*
Ja
Nein
Beginn:*
Ende:*
Intensität*
leicht (1)
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mäßig (2)
schwer (3)
lebensbedrohlich (4)
Kausalität (mit Studienmedikation)*
unbekannt (0)
nein (1)
möglich (2)
ja (sicher) (3)
Leukozyten
Leukozyten*
Ja
Nein
Beginn:*
Ende:*
Intensität*
leicht (1)
mäßig (3)
schwer (3)
lebensbedrohlich (4)
Kausalität (mit Studienmedikation)*
unbekannt (0)
nein (1)
möglich (2)
ja (sicher) (3)
Neutrophile
Neutrophile*
Ja
Nein
Beginn:*
Ende:*
Intensität*
leicht (1)
mäßig (2)
schwer (3)
lebensbedrohlich (4)
Kausalität (mit Studienmedikation)*
unbekannt (0)
nein (1)
möglich (2)
ja (sicher) (3)
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Thrombozyten
Thrombozyten*
Ja
Nein
Beginn:*
Ende:*
Intensität*
leicht (1)
mäßig (3)
schwer (3)
lebensbedrohlich (4)
Kausalität (mit Studienmedikation)*
unbekannt (0)
nein (1)
möglich (2)
ja (sicher) (3)
Arrhythmien
Arrhythmien*
Ja
Nein
Beginn:*
Ende:*
Intensität*
leicht (1)
mäßig (3)
schwer (3)
lebensbedrohlich (4)
Kausalität (mit Studienmedikation)*
unbekannt (0)
nein (1)
möglich (2)
ja (sicher) (3)
kardiale Ischämie/Myokardinfarkt
kardiale Ischämie/Myokardinfarkt*
Ja
Nein
Beginn:*
Ende:*
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Intensität*
leicht (1)
mäßig (3)
schwer (3)
lebensbedrohlich (4)
Kausalität (mit Studienmedikation)*
unbekannt (0)
nein (1)
möglich (2)
ja (sicher) (3)
Hypertonie
Hypertonie*
Ja
Nein
Beginn:*
Ende:*
Intensität*
leicht (1)
mäßig (3)
schwer (3)
lebensbedrohlich (4)
Kausalität (mit Studienmedikation)*
unbekannt (0)
nein (1)
möglich (2)
ja (sicher) (3)
Hypotonie
Hypotonie*
Ja
Nein
Beginn:*
Ende:*
Intensität*
leicht (1)
mäßig (3)
schwer (3)
lebensbedrohlich (4)
Kausalität (mit Studienmedikation)*
unbekannt (0)
nein (1)
möglich (2)
ja (sicher) (3)
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linksventrik. systolische Dysfunktion
linksventrik. systolische Dysfunktion*
Ja
Nein
Beginn:*
Ende:*
Intensität*
leicht (1)
mäßig (3)
schwer (3)
lebensbedrohlich (4)
Kausalität (mit Studienmedikation)*
unbekannt (0)
nein (1)
möglich (2)
ja (sicher) (3)
Perikarditis
Perikarditis*
Ja
Nein
Beginn:*
Ende:*
Intensität*
leicht (1)
mäßig (3)
schwer (3)
lebensbedrohlich (4)
Kausalität (mit Studienmedikation)*
unbekannt (0)
nein (1)
möglich (2)
ja (sicher) (3)
pulmonale Hypertonie
pulmonale Hypertonie*
Ja
Nein
Beginn:*
Ende:*
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Intensität*
leicht (1)
mäßig (3)
schwer (3)
lebensbedrohlich (4)
Kausalität (mit Studienmedikation)*
unbekannt (0)
nein (1)
möglich (2)
ja (sicher) (3)
DIC
DIC*
Ja
Nein
Beginn:*
Ende:*
Intensität*
leicht (1)
mäßig (3)
schwer (3)
lebensbedrohlich (4)
Kausalität (mit Studienmedikation)*
unbekannt (0)
nein (1)
möglich (2)
ja (sicher) (3)
Fibrinogen
Fibrinogen*
Ja
Nein
Beginn:*
Ende:*
Intensität*
leicht (1)
mäßig (3)
schwer (3)
lebensbedrohlich (4)
Kausalität (mit Studienmedikation)*
unbekannt (0)
nein (1)
möglich (2)
ja (sicher) (3)
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Fieber (Neutrophile > 1,0 GPt/l)
Fieber (Neutrophile > 1,0 GPt/l)*
Ja
Nein
Beginn:*
Ende:*
Intensität*
leicht (1)
mäßig (3)
schwer (3)
lebensbedrohlich (4)
Kausalität (mit Studienmedikation)*
unbekannt (0)
nein (1)
möglich (2)
ja (sicher) (3)
neutropenisches Fieber >= 38,5 °C
(Neutrophile <= 1,0 GPt/l)
neutropenisches Fieber >= 38,5 °C (Neutrophile
<= 1,0 GPt/l)*
Ja
Nein
Beginn:*
Ende:*
Intensität*
leicht (1)
mäßig (3)
schwer (3)
lebensbedrohlich (4)
Kausalität (mit Studienmedikation)*
unbekannt (0)
nein (1)
möglich (2)
ja (sicher) (3)
Ausschlag/Schuppung
Ausschlag/Schuppung*
Ja
Nein
Beginn:*
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Ende:*
Intensität*
leicht (1)
mäßig (3)
schwer (3)
lebensbedrohlich (4)
Kausalität (mit Studienmedikation)*
unbekannt (0)
nein (1)
möglich (2)
ja (sicher) (3)
Pankreas endokrin (Glukoseintoleranz)
Pankreas endokrin (Glukoseintoleranz)*
Ja
Nein
Beginn:*
Ende:*
Intensität*
leicht (1)
mäßig (3)
schwer (3)
lebensbedrohlich (4)
Kausalität (mit Studienmedikation)*
unbekannt (0)
nein (1)
möglich (2)
ja (sicher) (3)
Diarrhoe
Diarrhoe*
Ja
Nein
Beginn:*
Ende:*
Intensität*
leicht (1)
mäßig (3)
schwer (3)
lebensbedrohlich (4)
Kausalität (mit Studienmedikation)*
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unbekannt (0)
nein (1)
möglich (2)
ja (sicher) (3)
Dysphagie/Ösophagitis/Gastritis/Ileus
Dysphagie/Ösophagitis/Gastritis/Ileus*
Ja
Nein
Beginn:*
Ende:*
Intensität*
leicht (1)
mäßig (3)
schwer (3)
lebensbedrohlich (4)
Kausalität (mit Studienmedikation)*
unbekannt (0)
nein (1)
möglich (2)
ja (sicher) (3)
Enteritis
Enteritis*
Ja
Nein
Beginn:*
Ende:*
Intensität*
leicht (1)
mäßig (3)
schwer (3)
lebensbedrohlich (4)
Kausalität (mit Studienmedikation)*
unbekannt (0)
nein (1)
möglich (2)
ja (sicher) (3)
Mukositis/Stomatitis
Mukositis/Stomatitis*
Ja
Nein
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Beginn:*
Ende:*
Intensität*
leicht (1)
mäßig (3)
schwer (3)
lebensbedrohlich (4)
Kausalität (mit Studienmedikation)*
unbekannt (0)
nein (1)
möglich (2)
ja (sicher) (3)
Übelkeit/Erbrechen
Übelkeit/Erbrechen*
Ja
Nein
Beginn:*
Ende:*
Intensität*
leicht (1)
mäßig (3)
schwer (3)
lebensbedrohlich (4)
Kausalität (mit Studienmedikation)*
unbekannt (0)
nein (1)
möglich (2)
ja (sicher) (3)
Blutung
Blutung*
Ja
Nein
Beginn:*
Ende:*
Intensität*
leicht (1)
mäßig (3)
schwer (3)
lebensbedrohlich (4)
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Kausalität (mit Studienmedikation)*
unbekannt (0)
nein (1)
möglich (2)
ja (sicher) (3)
Pankreatitis
Pankreatitis*
Ja
Nein
Beginn:*
Ende:*
Intensität*
leicht (1)
mäßig (3)
schwer (3)
lebensbedrohlich (4)
Kausalität (mit Studienmedikation)*
unbekannt (0)
nein (1)
möglich (2)
ja (sicher) (3)
Infektion
Infektion*
Ja
Nein
Beginn:*
Ende:*
Intensität*
leicht (1)
mäßig (3)
schwer (3)
lebensbedrohlich (4)
Kausalität (mit Studienmedikation)*
unbekannt (0)
nein (1)
möglich (2)
ja (sicher) (3)
Alkalische Phosphatase
Alkalische Phosphatase*
Ja
Nein
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Beginn:*
Ende:*
Intensität*
leicht (1)
mäßig (3)
schwer (3)
lebensbedrohlich (4)
Kausalität (mit Studienmedikation)*
unbekannt (0)
nein (1)
möglich (2)
ja (sicher) (3)
ALAT, GPT
ALAT, GPT*
Ja
Nein
Beginn:*
Ende:*
Intensität*
leicht (1)
mäßig (3)
schwer (3)
lebensbedrohlich (4)
Kausalität (mit Studienmedikation)*
unbekannt (0)
nein (1)
möglich (2)
ja (sicher) (3)
ASAT, GOT
ASAT, GOT*
Ja
Nein
Beginn:*
Ende:*
Intensität*
leicht (1)
mäßig (3)
schwer (3)
lebensbedrohlich (4)
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Kausalität (mit Studienmedikation)*
unbekannt (0)
nein (1)
möglich (2)
ja (sicher) (3)
Bilirubin
Beginn:*
Ende:*
Intensität*
leicht (1)
mäßig (3)
schwer (3)
lebensbedrohlich (4)
Kausalität (mit Studienmedikation)*
unbekannt (0)
nein (1)
möglich (2)
ja (sicher) (3)
Kreatinin
Kreatinin*
Ja
Nein
Beginn:*
Ende:*
Intensität*
leicht (1)
mäßig (3)
schwer (3)
lebensbedrohlich (4)
Kausalität (mit Studienmedikation)*
unbekannt (0)
nein (1)
möglich (2)
ja (sicher) (3)
GGT
GGT*
Ja
Nein
Beginn:*
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Ende:*
Intensität*
leicht (1)
mäßig (3)
schwer (3)
lebensbedrohlich (4)
Kausalität (mit Studienmedikation)*
unbekannt (0)
nein (1)
möglich (2)
ja (sicher) (3)
Ataxie
Ataxie*
Ja
Nein
Beginn:*
Ende:*
Intensität*
leicht (1)
mäßig (3)
schwer (3)
lebensbedrohlich (4)
Kausalität (mit Studienmedikation)*
unbekannt (0)
nein (1)
möglich (2)
ja (sicher) (3)
motorische Neuropathie
motorische Neuropathie*
Ja
Nein
Beginn:*
Ende:*
Intensität*
leicht (1)
mäßig (3)
schwer (3)
lebensbedrohlich (4)
Kausalität (mit Studienmedikation)*
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unbekannt (0)
nein (1)
möglich (2)
ja (sicher) (3)
sensorische Neuropathie
sensorische Neuropathie*
Ja
Nein
Beginn:*
Ende:*
Intensität*
leicht (1)
mäßig (3)
schwer (3)
lebensbedrohlich (4)
Kausalität (mit Studienmedikation)*
unbekannt (0)
nein (1)
möglich (2)
ja (sicher) (3)
Krampfanfälle
Krampfanfälle*
Ja
Nein
Beginn:*
Ende:*
Intensität*
leicht (1)
mäßig (3)
schwer (3)
lebensbedrohlich (4)
Kausalität (mit Studienmedikation)*
unbekannt (0)
nein (1)
möglich (2)
ja (sicher) (3)
Nystagmus
Nystagmus*
Ja
Nein
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Beginn:*
Ende:*
Intensität*
leicht (1)
mäßig (3)
schwer (3)
lebensbedrohlich (4)
Kausalität (mit Studienmedikation)*
unbekannt (0)
nein (1)
möglich (2)
ja (sicher) (3)
Augenerkrankung
Augenerkrankung*
Ja
Nein
Beginn:*
Ende:*
Intensität*
leicht (1)
mäßig (3)
schwer (3)
lebensbedrohlich (4)
Kausalität (mit Studienmedikation)*
unbekannt (0)
nein (1)
möglich (2)
ja (sicher) (3)
Schmerzen
Schmerzen*
Ja
Nein
Beginn:*
Ende:*
Intensität*
leicht (1)
mäßig (3)
schwer (3)
lebensbedrohlich (4)
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Kausalität (mit Studienmedikation)*
unbekannt (0)
nein (1)
möglich (2)
ja (sicher) (3)
Dyspnoe
Dyspnoe*
Ja
Nein
Beginn:*
Ende:*
Intensität*
leicht (1)
mäßig (3)
schwer (3)
lebensbedrohlich (4)
Kausalität (mit Studienmedikation)*
unbekannt (0)
nein (1)
möglich (2)
ja (sicher) (3)
Hypoxie
Hypoxie*
Ja
Nein
Beginn:*
Ende:*
Intensität*
leicht (1)
mäßig (3)
schwer (3)
lebensbedrohlich (4)
Kausalität (mit Studienmedikation)*
unbekannt (0)
nein (1)
möglich (2)
ja (sicher) (3)
Pleuraerguss - ohne maligne Genese
Pleuraerguss - ohne maligne Genese*
Ja
Nein
17 / 20
1. induction therapy adverse events AML NCT00180102
Beginn:*
Ende:*
Intensität*
leicht (1)
mäßig (3)
schwer (3)
lebensbedrohlich (4)
Kausalität (mit Studienmedikation)*
unbekannt (0)
nein (1)
möglich (2)
ja (sicher) (3)
Pneumonitis/Lungeninfiltrate
Pneumonitis/Lungeninfiltrate*
Ja
Nein
Beginn:*
Ende:*
Intensität*
leicht (1)
mäßig (3)
schwer (3)
lebensbedrohlich (4)
Kausalität (mit Studienmedikation)*
unbekannt (0)
nein (1)
möglich (2)
ja (sicher) (3)
Zystitis
Zystitis*
Ja
Nein
Beginn:*
Ende:*
Intensität*
leicht (1)
mäßig (3)
schwer (3)
lebensbedrohlich (4)
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Kausalität (mit Studienmedikation)*
unbekannt (0)
nein (1)
möglich (2)
ja (sicher) (3)
Tumorlyse-Syndrom
Tumorlyse-Syndrom*
Ja
Nein
Beginn:*
Ende:*
Intensität*
leicht (1)
mäßig (3)
schwer (3)
lebensbedrohlich (4)
Kausalität (mit Studienmedikation)*
unbekannt (0)
nein (1)
möglich (2)
ja (sicher) (3)
Thrombose/Embolie
Thrombose/Embolie*
Ja
Nein
Beginn:*
Ende:*
Intensität*
leicht (1)
mäßig (3)
schwer (3)
lebensbedrohlich (4)
Kausalität (mit Studienmedikation)*
unbekannt (0)
nein (1)
möglich (2)
ja (sicher) (3)
Sonstige
Sonstige:*
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Beginn:*
Ende:*
Intensität*
leicht (1)
mäßig (3)
schwer (3)
lebensbedrohlich (4)
Kausalität (mit Studienmedikation)*
unbekannt (0)
nein (1)
möglich (2)
ja (sicher) (3)
Unterschrift
Datum*
Name des Studienarztes/Unterschrift*
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Baseline Laboratory test form pancreatic
cancer SWOG S0205 NCT00075686
BASELINE LABORATORY TEST RESULT FORM -
2307541v3.0
SOUTHWEST ONCOLOGY GROUP S0205 BASELINE
LABORATORY TEST RESULT FORM S0205 Gemcitabine
With or Without Cetuximab as First-Line Therapy in
Treating Patients With Locally Advanced Unresectable or
Metastatic Adenocarcinoma of the Pancreas Source Form:
NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=F2FD3D46-
E071-663C-E034-0003BA3F9857
All rights reserved. Please visit https://medical-data-
models.org/forms/12110
Baseline Laboratory test form
pancreatic cancer SWOG S0205
NCT00075686
Header
SWOG Patient ID
SWOG Study No.
Registration Step
Patient Initials
Date form completed
Institution/Affiliate
Physician
Comments
Baseline Lab Test Results
Hemoglobin
g/dL
Hemoglobin, LLN
g/dL
Hematology lab collected date
Peripheral platelet count
1000/uL
Peripheral platelet count, LLN
Peripheral WBC count
1000/uL
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Peripheral WBC count, LLN
Peripheral Granulocytes Count
1000/uL
Peripheral Granulocytes Count LLN
/mm3
Alkaline Phosphatase
U/L
Alkaline Phosphatase ULN
U/L
Chemistry lab collected date
Creatinine
mg/dL
Creatinine, ULN
mg/dL
Creatinine Clearance
Calculated Creatinine Clearance (Calc
creatinine clearance)
Measured Creatinine Clearance
(Measured creatinine clearance)
Calculated creatinine clearance
Calculated creatinine clearance, ULN
Measured creatinine clearance
Measured creatinine clearance, ULN
Bilirubin, total
mg/dL
Total bilirubin ULN
mg/dL
AST (SGOT)
U/L
AST (SGOT) ULN
U/L
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ALT (SGPT)
U/L
ALT (SGPT) ULN
U/L
Albumin
Albumin ULN
g/dL
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NCT00075686
Registration/Randomization Eligibility
Checklist Colon Cancer N0147 NCT00079274
Comparison of Combination Chemotherapy Regimens With
or Without Cetuximab in Treating Patients Who Have
Undergone Surgery For Stage III Colon Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=70E2C30D-
79F3-2C30-E040-BB89AD435E55
All rights reserved. Please visit https://medical-data-
models.org/forms/12111
Registration/Randomization Eligibility
Checklist Colon Cancer N0147
NCT00079274
Header module
Coordinating Group Protocol Number
Coordinating Group Code
Protocol Title
Patient Study ID
Patient Medical Record Number
Participating Group Code (Cooperative Group
where credit will be applied)
Institution Name (treating locatin/performance
site)
Institution Code (CTEP Assigned number)
Physician of Record
Assigned Treatment Arm
A) Oxaliplatin + Fluorouracil/leucovorin
Regimen (folfox) (A) Oxaliplatin +
Fluorouracil/Leucovorin Regimen
(FOLFOX))
D) Oxaliplatin + Fluorouracil/leucovorin
Regimen (folfox) + C225 (D) Oxaliplatin +
Fluorouracil/Leucovorin Regimen
(FOLFOX) + C225)
Locally-directed Therapy (G) Locally-
Directed Therapy)
Required Characteristics
Randomization must occur =< 56 days post
surgery
Yes
No
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KRAS wild-type status determined by central
testing
Yes
No
Laboratory values obtained <= 28 days prior to
randomization
Yes
No
Earliest laboratory test date
Latest laboratory test date
Hgb >=9 g/dL
Yes
No
Hgb
Absolute neutrophil count >= LLN
Yes
No
Absolute neutrophil count
Absolute neutrophil count LLN
Platelet count >= 100,000/mcL
Yes
No
Platelet count
Serum Creatinine <=1.5 x ULN
<= 1.5 x ULN
Yes
No
Creatinine
mg/dL
Creatinine ULN
mg/dL
Total bilirubin <= 1.5 x ULN
<= 1.5 x ULN
Yes
No
Total Bilirubin
mg/dL
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Total bilirubin ULN
mg/dL
Is patient a woman of childbearing potential
Yes
No
Negative serum pregnancy test
Yes
No
Negative pregnancy test date
Registration/randomization Check
KRAS mutant status determined by central
testing, or KRAS status not evaluable
Yes
No
Must collect translational research blood sample
for Section 14.2 following pre-randomization, but
prior to registration/randomization
Yes
No
Study drug availability checked
Yes
No
Treatment on this protocol must commence at the
accruing membership under the supervision of a
CTSU member physician
Yes
No
Treatment cannot begin prior to randomization
and must begin <= 14 days after randomization
Yes
No
Pretreatment tests must be completed within the
guidelines specified on the test schedule
Yes
No
All required baseline symptoms must be
documented and graded in the patient's medical
record
Yes
No
Patient Instructions for Prevention and Treating
Diarrhea and Patient and Physician Fact Sheet
have been given to the patient; treating physician
has discussed their contents with the patient
Yes
3 / 4
Registration/Randomization Eligibility Checklist Colon Cancer N0147
NCT00079274
No
Stratification Factors At The Time Of
Randomization
Positive lymph node involvement
>=4 (>=4)
1-3 (1-3)
Histology
High (High)
Low (Low)
Clinical T Stage
T1 Or T2 (T1 or T2)
T3 Stage Finding (T3)
T4 Stage Finding (T4)
Descriptive Factors At The Time Of
Registration/randomization
Perforation
Yes
No
Obstruction
No (NO)
Unknown (UNKNOWN)
Yes (YES)
Adherence
No (NO)
Unknown (UNKNOWN)
Yes (YES)
Baseline stools reported
No, Patient Has A Colostomy/ileostomy
(No, patient has a colostomy/ileostomy)
Yes (Yes)
Baseline number of stools per day
Protocol Design
Person Registering
CTSU Random. specialist
Investigator Signature
Date of Investigator Signature
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Eligibility Metastatic/Advanced Renal Cell
Carcinoma NCT02187042
Evaluation Of The Impact Of A Call Center In Management
Of Metastatic And/Or Advanced Renal Cell Carcinoma
Patients Treated With Sunitinib (Sutent) In First Line; ODM
derived from: https://clinicaltrials.gov/show/NCT02187042
All rights reserved. Please visit https://medical-data-
models.org/forms/12112
Eligibility Metastatic/Advanced Renal
Cell Carcinoma NCT02187042
Inclusion Criteria
metastatic and/or advanced renal cell carcinoma
patients treated with sunitinib in first line
according to the summary of product
characteristics*
Yes
No
resolution of all adverse event (grade ≤ 1
according to the common terminology criteria for
adverse events v 4.3 of june 2010) from a prior
treatment by radiotherapy and/or surgery*
Yes
No
patient who can be followed for 6 months*
Yes
No
patient who has signed a consent form*
Yes
No
patient affiliated to a national health service*
Yes
No
sexually active fertile subjects and their partners
must agree to use medically accepted methods of
contraception during the course of the study and
for 28 days after the last dose of study treatment*
Yes
No
Exclusion Criteria
patient who is participating in another clinical
study*
Yes
No
patient taken in charge by a home help service*
Yes
No
patient with brain metastases not treated or
symptomatic*
Yes
No
patient with an eastern cooperative oncology
group at inclusion > 2*
1 / 2
Yes
No
patient with a rate of serum creatinine > 1.5 times
the upper limit normal*
Yes
No
patient with a rate of bilirubin > 2 mg/dl*
C1278039
Yes
No
patient with a rate of aspartate transaminase
(asat) or alanine transaminase (alat) > 2.5 times
the upper limit normal or > 5 times the upper limit
normal for patients with hepatic metastases*
Yes
No
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Registration Leukemia COG AALL08B1
NCT01142427
COG AALL08B1 OPEN Registration Worksheet
NCT01142427
Risk-Based Classification System of Patients With Newly
Diagnosed Acute Lymphoblastic Leukemia
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=ADF3C25C-
AD44-CFB2-E040-BB89AD4343C8
All rights reserved. Please visit https://medical-data-
models.org/forms/12113
Registration Leukemia COG
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Stratification
ADVL0912 Stratum
Patients With Relapsed Or Refractory
Neuroblastoma, With Or Without Bone
Marrow Involvement, Who Are Not
Eligible For Part A1 Or A2 Or Cannot
Enroll On Part A1 Because Of Stratum
Suspension Or Lack Of Available Slots
(Patients with relapsed or refractory
neuroblastoma, with or without bone
marrow involvement, who are not eligible
for Part A1 or A2 or cannot enroll on Part
A1 because of stratum suspension or
lack of available slots)
Patients With Relapsed/refractory Solid
Tumors (including Cns Tumors), And
Anaplastic Large Cell Lymphoma (alcl)
With Or Without Bone Marrow
Involvement (Patients with
relapsed/refractory solid tumors
(including CNS tumors), and anaplastic
large cell lymphoma (ALCL) WITH OR
WITHOUT bone marrow involvement)
Patients With Relapsed/refractory Solid
Tumors (including Cns Tumors), And
Anaplastic Large Cell Lymphoma (alcl)
Without Bone Marrow Involvement
(Patients with relapsed/refractory solid
tumors (including CNS tumors), and
anaplastic large cell lymphoma (ALCL)
WITHOUT bone marrow involvement)
Treatment Start Date
Comments
Patient Criteria
Does the patient have newly diagnosed acute
leukemia suspected to be acute lymphoblastic
leukemia (See Section 3.2.3 for eligibility
requirements)
Yes
No
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Did patient have a bone marrow evaluation just
prior to study entry (See section 3.2 and 3.2.1 for
eligibility requirements)
Yes
No
Was the patient in the indicated age range at time
of study enrollment (To be eligible, patient must
be greater than 12 months and less than or equal
to 21 years of age at the time of study
enrollment.)
Yes
No
Will all required diagnostic samples be sent to the
local and COG Reference Laboratories as per
indicated documents (Indicated documents
include Appendix I-V. Adequate samples MUST
be sent to a COG-APPROVED Cytogenetic
Laboratory and COG Reference Laboratory per
Section 4.1 so that the data needed for risk-
adjusted post-Induction therapy are available)
Yes
No
Has the patient received Prior Treatment with
cytotoxic chemotherapy (Patients may not have
received prior cytotoxic therapy except for
intrathecal chemotherapy or steroids See
sections 3.2.6 and 3.3.1. PATIENTS MUST BE
ENROLLED ON AALL08B1 BEFORE
TREATMENT BEGINS with the exception of the
first dose of intrathecal chemotherapy or selected
cases of steroid pretreatment)
Yes
No
Does patient have the indicated type of leukemia
(Indicated type of leukemia is secondary ALL that
developed after treatment of a prior malignancy
with cytotoxic chemotherapy)
Yes
No
Date Informed Consent Signed
Have all institutional, FDA, and NCI requirements
for human studies been met? (To be eligible, all
institutional, FDA, and NCI requirements for
human studies must be met)
Yes
No
Consent For Research Studies
Was consent signed for Pharmacokinetics
Yes
No
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Does the participant agree to participate in the
pharmacogenetics study associated with this
protocol
Yes
No
Patient consents to tissue submission
Yes
No
Patient consents to blood submission
Yes
No
Signature
Exclusion Criteria
Pregnancy test done
Yes
No
Is patient pregnant
Yes
No
Is patient nursing
Yes
No
Has patient agreed to use an effective
contraceptive method
N/a, Patient Is Not Of Reproductive
Potential (N/A, patient is not of
reproductive potential)
No (No)
Yes (Yes)
Is the patient receiving corticosteroids?
Yes
No
Has patient been on a stable or decreasing dose
of corticosteroids for the indicated period
Yes
No
Is patient currently receiving any other anticancer
or experimental drug therapy
Yes
No
Does patient have an uncontrolled infection?
Yes
No
Is patient, in the opinion of the investigator, able
to comply with the safety monitoring requirements
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of the study
Yes
No
Is patient receiving CYP3A4 substrates with
narrow therapeutic indices
Yes
No
Did patient receive CYP3A4 inhibitor during the
indicated period
Yes
No
Did patient receive CYP3A4 inducer during the
indicated period
Yes
No
Organ Function - Non Hematological
Does patient have adequate renal function?
Yes
No
Date of Creatinine Clearance
Creatinine
mg/dL
What is the GFR for the indicated period
(ml/min/1.73m2)
mL/Min/1.73m2
Does patient have adequate liver function?
Yes
No
Date
Total Bilirubin
mg/dL
Total bilirubin ULN
mg/dL
ALT (SGPT)
U/L
Albumin
g/dL
Is patient able to swallow capsules or a liquid
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suspension
Yes
No
Organ Function - Hematological
Does patient have bone marrow involvement
Yes
No
Does patient have adequate bone marrow
function?
Yes
No
Lab, Hematology, Sample Collection Date
WBC
/ul
ANC
1000/ul
Segs
%
Bands
%
Peripheral Platelet Count
1000/uL
Hemoglobin
g/dL
Were transfusions given
No Transfusion (No)
Unknown (Unknown)
Transfusion With Platelets And Red
Blood Cells (Yes, both)
Transfusion With Platelets (Yes,
platelets)
Transfusion With Red Blood Cells (Yes,
red blood cells)
Inclusion Criteria
Were tests to determine eligibility performed
during the indicated period
Yes
No
Does patient have a BSA (body surface area)
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greater than or equal to the indicated value (BSA
Dose Level 0 and 1 only: To be eligible, patients
must have a BSA >= 0.4 at the time of study
enrollment. - )
Yes
No
Body surface area
>= 0
m²
Does patient have histologic verification of the
malignancy at the indicated time point
Yes
No
Does patient have neuroblastoma
Yes
No
Does patient have ALCL (anaplastic large cell
lymphoma)
Yes
No
Does patient have histologic verification of the
malignancy at the indicated time point
Yes
No
Did patient have ALK molecular abnormality
verified by a Clinical Laboratory Improvement
Amendments (CLIA) certified laboratory
Yes
No
Does patient have histologic verification of the
malignancy at the indicated time point
Yes
No
Does patient meet the disease status
requirement (To be eligible, patient must have
either measurable and/or evaluable disease.  -  -
Note:  See Protocol Sections 12.2 and 12.3 and
12.6 for definitions.)
Yes
No
Is patient's current disease state one for which
there is no known curative therapy available or
therapy proven to prolong survival with an
acceptable quality of life
Yes
No
Karnofsky Status
Dead. (0)
Moribund; fatal processes progressing
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rapidly. (10)
Normal - no complaints; no evidence of
disease. (100)
Very sick; hospital admission is
necessary; active supportive treament
necessary. (20)
Severely disabled; hospital admission is
indicated although death not imminent.
(30)
Disabled; requires special care and
assistance. (40)
Requires considerable assistance and
frequent medical care. (50)
Requires occasional assistance, but is
able to care for most personal needs.
(60)
Care for self; unable to carry on normal
activity or to do active work. (70)
Normal activity; minor sign of symptoms
of disease. (80)
Able to carry on normal activity; minor
sign or symptoms of disease. (90)
Lansky
10%: Completely disabled, not even
passive play (10)
100%: Fully active (100)
20%: Limited to very passive activity
initiated by others (20)
30%: Needs considerable assistance for
quiet activities (30)
40%: Able to initiate quiet activities (40)
50%: Considerable assistance required
for any active play; fully able to engage in
quiet play (50)
60%: Ambulatory up to 50% of time,
limited active play with
assistance/supervision (60)
70%: Both greater restriction of, and less
time spent in active play (70)
80%: Restricted in strenuous play, tires
more easily, otherwise active (80)
90%: Minor restriction in physically
strenuous play (90)
Has patient fully recovered from the acute toxic
effects of all prior chemotherapy, immunotherapy,
or radiotherapy prior to entering this study
Yes
No
Prior therapy type
Hematopoietic Growth Factor
(Hematopoietic Growth Factor)
Chemotherapy Myelosuppressive
Therapy (Myelosuppressive
Chemotherapy)
No Previous Exposure To Drug (nos) (No
prior therapy)
Prior Therapy (nos) (Prior therapy NOS)
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Targeted Ionizing Radiation Therapy
Utilizing Radioactive Implants Or Seeds
(Radiation therapy)
Autologous Stem Cell Rescue Stem Cell
Transplantation (Stem Cell Transplant or
Rescue without TBI)
Did patient receive nitrosourea
Yes
No
Last Treatment Date (prior to enrolling on this
study)
Has patient previously received any of the
indicated agents (To be eligible, patients must not
have received prior therapy with PF-02341066.)
Yes
No
Stratification
AALL08B1 Stratum
All Patients (All Patients)
Consent For Research Studies
Did patient or parent agree to allow the indicated
specimen(s) to be banked for future scientific
research related to this protocol (Indicated
specimens include bone marrow and peripheral
blood Instruction # 1 - research on genetic
variation - model consent)
Yes
No
Has the patient given permission for optional
sample banking for future cancer research
studies (Instruction # 2 - model consent)
Yes
No
Did patient/parent/guardian agree to have
patients' specimen banked for use in research to
learn about, prevent, or treat cancer (Instruction #
3 - model consent)
Yes
No
Patient's Initial Consent given for specimen use
for research unrelated to the patient's cancer
(Instruction # 4 - model consent)
Yes
No
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Registration Brain and Central Nervous System
Tumors COG ADVL0912 NCT00939770
COG ADVL0912 OPEN Registration Worksheet
NCT00939770
Crizotinib in Treating Young Patients With Relapsed or
Refractory Solid Tumors or Anaplastic Large Cell
Lymphoma
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=A54DD196-
B288-B398-E040-BB89AD432E23
All rights reserved. Please visit https://medical-data-
models.org/forms/12114
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Nervous System Tumors COG
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Stratification
ADVL0912 Stratum
Patients With Relapsed Or Refractory
Neuroblastoma, With Or Without Bone
Marrow Involvement, Who Are Not
Eligible For Part A1 Or A2 Or Cannot
Enroll On Part A1 Because Of Stratum
Suspension Or Lack Of Available Slots
(Patients with relapsed or refractory
neuroblastoma, with or without bone
marrow involvement, who are not eligible
for Part A1 or A2 or cannot enroll on Part
A1 because of stratum suspension or
lack of available slots)
Patients With Relapsed/refractory Solid
Tumors (including Cns Tumors), And
Anaplastic Large Cell Lymphoma (alcl)
With Or Without Bone Marrow
Involvement (Patients with
relapsed/refractory solid tumors
(including CNS tumors), and anaplastic
large cell lymphoma (ALCL) WITH OR
WITHOUT bone marrow involvement)
Patients With Relapsed/refractory Solid
Tumors (including Cns Tumors), And
Anaplastic Large Cell Lymphoma (alcl)
Without Bone Marrow Involvement
(Patients with relapsed/refractory solid
tumors (including CNS tumors), and
anaplastic large cell lymphoma (ALCL)
WITHOUT bone marrow involvement)
Treatment Start Date
Patient Criteria
Were tests to determine eligibility performed
during the indicated period (Indicated period
refers to prior to enrollment. -  - Note:  All studies
to determine eligibility must be performed within 7
days prior to enrollment unless otherwise
indicated.  Please see section 4.0 of the protocol
for instructions on required repeated eligibility
studies if more than 7 calendar days elapse
between labs and start of therapy. - )
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Yes
No
Was the patient in the indicated age range at time
of study enrollment (To be eligible, patient must
be greater than 12 months and less than or equal
to 21 years of age at the time of study
enrollment.)
Yes
No
Does patient have a BSA (body surface area)
greater than or equal to the indicated value (BSA
Dose Level 0 and 1 only: To be eligible, patients
must have a BSA >= 0.4 at the time of study
enrollment. - )
Yes
No
BSA (In m2;)
m2
Does patient have histologic verification of the
malignancy at the indicated time point (Indicated
time point refers to original diagnosis or relapse. -
- To be eligible, patient must have histologic
verification of malignancy at original diagnosis or
relapse. -  - Patients with relapsed or refractory
solid tumors, CNS tumors or anaplastic large cell
lymphoma excluding patients with primary
cutaneous ALCL.  -  - Please note: The
requirement for histologic verification does not
apply to patients with diffuse intrinsic brain stem
tumors, optic pathway tumors, or patients with
pineal region tumors with elevations of serum or
CSF tumor markers e.g., alpha-fetoprotein or
beta-HCG.)
Yes
No
Does patient have neuroblastoma
Yes
No
Does patient have ALCL (anaplastic large cell
lymphoma)
Yes
No
Does patient have histologic verification of the
malignancy at the indicated time point (For
patients with ALK fusion proteins, ALK mutations
or ALK amplification defined as greater than 4-
fold increase in the ALK signal number as
compared to reference signal number on
chromosome 2q arm. -   - Indicated time point
refers to original diagnosis or relapse. -  - Patients
must have had histologic verification of
malignancy at original diagnosis or relapse. -  - To
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be eligible, patients must have confirmed ALK
protein, mutations and/or amplification defined as
greater than 4-fold increase in the ALK signal
number as compared to reference signal number
on chromosome 2q arm. Testing for eligibility
purposes must be performed as a CLIA certified
assay.)
Yes
No
Did patient have ALK molecular abnormality
verified by a Clinical Laboratory Improvement
Amendments (CLIA) certified laboratory (For
patients with ALK fusion proteins, ALK mutations,
or ALK amplification defined as greater than 4-
fold increase in the ALK signal number as
compared to reference signal number on
chromosome 2q arm. -  - To be eligible, patients
must have confirmed ALK protein, mutation
and/or amplification. Testing for eligibility
purposes must be performed as a CLIA certified
assay. )
Yes
No
Does patient have histologic verification of the
malignancy at the indicated time point (For Part
A3 patients -  - Indicated time point refers to
original diagnosis or relapse. -  - To be eligible,
patient must have histologic verification of
malignancy at original diagnosis or relapse. -  - To
be eligible, patients must have relapsed or
refractory neuroblastoma, with or without bone
marrow involvement, who are not eligible for Part
A1 or A2 or cannot enroll on Part A1 because of
Part suspension or lack of available slots. These
patients will be enrolled at one dose level below
the dose level at which patients on Part A1 are
actively enrolling.)
Yes
No
Does patient meet the disease status
requirement
Yes
No
Is patient's current disease state one for which
there is no known curative therapy available or
therapy proven to prolong survival with an
acceptable quality of life (To be eligible, patient's
current disease state must be one for which there
is no known curative therapy or therapy proven to
prolong survival with an acceptable quality of life.)
Yes
No
Karnofsky Performance Status Score (To be
eligible, patients greater than 16 years of age
must have a Karnofsky performance score
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greater than or equal to 50. -  - Note: Neurologic
deficits in patients with CNS tumors must have
been relatively stable for a minimum of 1 week
prior to study enrollment. Patients who are unable
to walk because of paralysis, but who are up in a
wheelchair, will be considered ambulatory for the
purpose of assessing the performance score.
See Appendix I)
Dead (0)
Moribund, Fatal Processes Progressing
Rapidly (10)
Normal, No Complaints, No Evidence Of
Disease (100)
Very Sick, Hospitalization Indicated.
Death Not Imminent (20)
Severely Disabled, Hospitalization
Indicated. Death Not Imminent (30)
Disabled, Requires Special Care And
Assistance (40)
Requires Considerable Assistance And
Frequent Medical Care (50)
Requires Occasional Assistance, But Is
Able To Care For Most Of His/her Needs
(60)
Cares For Self, Unable To Carry On
Normal Activity Or To Do Active Work
(70)
Normal Activity With Effort; Some Signs
Or Symptoms Of Disease (80)
Able To Carry On Normal Activity; Minor
Signs Or Symptoms Of Disease (90)
Lansky Performance Status Score (To be eligible,
patients less than or equal to 16 years of age
must have a Lansky play score greater than or
equal to 50. -  - Note: Neurologic deficits in
patients with CNS tumors must have been
relatively stable for a minimum of 1 week prior to
study enrollment. Patients who are unable to walk
because of paralysis, but who are up in a
wheelchair, will be considered ambulatory for the
purpose of assessing the performance score.
See Appendix I - )
Unresponsive (0)
No Play; Does Not Get Out Of Bed. (10)
Fully Active, Normal (100)
Often Sleeping; Play Entirely Limited To
Very Passive Activities. (20)
In Bed; Needs Assistance Even For
Quiet Play. (30)
Mostly In Bed; Participates In Quiet
Activities. (40)
Gets Dressed, But Lies Around Much Of
The Day; No Active Play, Able To
Participate In All Quiet Play And
Activities. (50)
Up And Around, But Minimal Active Play;
Keeps Busy With Quieter Activities. (60)
Both Greater Restriction Of And Less
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Time Spent In Play Activity (70)
Active, But Tires More Quickly (80)
Minor Restrictions In Physically
Strenuous Activity (90)
Has patient fully recovered from the acute toxic
effects of all prior chemotherapy, immunotherapy,
or radiotherapy prior to entering this study (-
Myelosuppressive chemotherapy:  Solid Tumors:
Patients with solid tumors must not have received
within 3 weeks of enrollment onto this study 6
weeks if prior nitrosourea.  - Lymphoma: Patients
with lymphoma who relapse during standard
maintenance therapy are eligible at time of
relapse. For patients with ALCL who relapse
while they are receiving cytotoxic therapy, at least
14 days must have elapsed since the completion
of cytotoxic therapy. Note: Cytoreduction with
hydroxyurea can be initiated and continued for up
to 24 hours prior to the start of PF-02341066. -  -
-	Hematopoietic growth factors: At least 7 days
since the completion of therapy with a growth
factor. -   - -	Biologic anti-neoplastic agent:  At
least 7 days since the completion of therapy with
a biologic agent.  For agents that have known
adverse events occurring beyond 7 days after
administration, this period must be extended
beyond the time during which adverse events are
known to occur.  The duration of this interval must
be discussed with the Study Chair. -  - -
Monoclonal antibodies:  At least 7 days or 3 half-
lives, whichever is longer, must have elapsed
since prior treatment with a monoclonal antibody.
-  - -	XRT:  >= 2 wks for local palliative XRT small
port; >= 6 weeks must have elapsed since
treatment with therapeutic doses of MIBG; >= 6
months must have elapsed if prior TBI,
craniospinal XRT or >= 50% radiation of pelvis;
>= 6 wks must have elapsed if other substantial
BM radiation. -  - -	Bone Marrow/Stem Cell
Transplant or Rescue without TBI:  -  - Part A1 or
Part C: No evidence of active graft vs. host
disease and >= 3 months must have elapsed
since stem cell transplant or infusion. -  - Part A2,
Part A3, or Part B: No evidence of active graft vs.
host disease and >= 6 weeks must have elapsed
since stem cell transplant or infusion. -  - )
Yes
No
Prior therapy type
Hematopoietic Growth Factor
(Hematopoietic Growth Factor)
Chemotherapy Myelosuppressive
Therapy (Myelosuppressive
Chemotherapy)
No Previous Exposure To Drug (nos) (No
prior therapy)
Prior Therapy (nos) (Prior therapy NOS)
5 / 9
Registration Brain and Central Nervous System Tumors COG ADVL0912
NCT00939770
Targeted Ionizing Radiation Therapy
Utilizing Radioactive Implants Or Seeds
(Radiation therapy)
Autologous Stem Cell Rescue Stem Cell
Transplantation (Stem Cell Transplant or
Rescue without TBI)
Did patient receive nitrosourea (If prior therapy
was myelosuppressive chemotherapy -  - To be
eligible, patients with solid tumors must not have
received within 6 weeks of enrollment onto this
study if prior nitrosourea.)
Yes
No
Last Treatment Date (prior to enrolling on this
study)
Has patient previously received any of the
indicated agents (To be eligible, patients must not
have received prior therapy with PF-02341066.)
Yes
No
Organ Function - Hematological
Does patient have bone marrow involvement
Yes
No
Does patient have adequate bone marrow
function?
Yes
No
Lab, Hematology, Sample Collection Date
WBC
Absolute neutrophil count (ANC)
Segs
%
Bands
%
Peripheral Platelet Count
Hemoglobin
Were transfusions given
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No Transfusion (No)
Unknown (Unknown)
Transfusion With Platelets And Red
Blood Cells (Yes, both)
Transfusion With Platelets (Yes,
platelets)
Transfusion With Red Blood Cells (Yes,
red blood cells)
Organ Function - Non Hematological
Does patient have adequate renal function?
Yes
No
Date of Creatinine Clearance
Creatinine
mg/dL
What is the GFR for the indicated period
(ml/min/1.73m2)
mL/Min/1.73m2
Does patient have adequate liver function?
Yes
No
Date
Total Bilirubin
mg/dL
Total bilirubin ULN
mg/dL
SGPT
Albumin (Serum)
Is patient able to swallow capsules or a liquid
suspension
Yes
No
Exclusion Criteria
Pregnancy test done
Yes
No
Is patient pregnant
Yes
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No
Is patient nursing
Yes
No
Has patient agreed to use an effective
contraceptive method
N/a, Patient Is Not Of Reproductive
Potential (N/A, patient is not of
reproductive potential)
No (No)
Yes (Yes)
Is the patient receiving corticosteroids?
Yes
No
Has patient been on a stable or decreasing dose
of corticosteroids for the indicated period
Yes
No
Is patient currently receiving any other anticancer
or experimental drug therapy
Yes
No
Does patient have an uncontrolled infection?
Yes
No
Is patient, in the opinion of the investigator, able
to comply with the safety monitoring requirements
of the study
Yes
No
Is patient receiving CYP3A4 substrates with
narrow therapeutic indices
Yes
No
Did patient receive CYP3A4 inhibitor during the
indicated period
Yes
No
Did patient receive CYP3A4 inducer during the
indicated period
Yes
No
Consent For Research Studies
Date Informed Consent Signed
Was consent signed for Pharmacokinetics
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Yes
No
Does the participant agree to participate in the
pharmacogenetics study associated with this
protocol
Yes
No
Patient consents to tissue submission
Yes
No
Patient consents to blood submission
Yes
No
Comments
Signature
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Eligibility Breast Cancer Panobinostat and
Letrozole NCT01105312 N093B 3303518v1.0
Eligibility Breast Cancer Panobinostat and Letrozole
NCT01105312 N093B 3303518v1.0
Breast Cancer NCT01105312 Eligibility - NCCTG Eligibility
Checklist N093B - 3303518v1.0
NCCTG Eligibility Checklist N093B
Panobinostat and Letrozole in Treating Patients With
Metastatic Breast Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=B1C93F5C-
1300-C2C0-E040-BB89AD4348C9
All rights reserved. Please visit https://medical-data-
models.org/forms/12115
Eligibility Breast Cancer
Panobinostat and Letrozole
NCT01105312 N093B 3303518v1.0
Pre-treatment Requirements
Age >= 18 years
>= 18
years
Yes
No
Age
Histologic proof of metastatic breast cancer that
is unresected at registration (with no intention of
resecting tumors during this study). Evidence of
metastatic breast cancer confirmed by
radiological imaging
Yes
No
Measurable disease (see Section 11.21 for
definition of measurable disease)
Yes
No
Metastatic site(s) must be amenable to biopsy
Yes
No
Post-menopausal according to any one of the
following criteria:
a. Age >60 years old
b. Age >45 years old with last menstrual period
>12 months prior to registration and estriadiol
and folliclestimulating
hormone (FSH) levels in postmenopausal range
(per institutional normal limits)
c. Bilateral oophorectomy
If male (check NA).
Not Available (NA)
No (No)
Yes (Yes)
Tumor estrogen, progesterone and HER2 [tested
by IHC or FISH (fluorescent in situ hybridization)]
status from the metastatic site. If not available,
the results from the original tumor diagnosing the
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primary breast cancer may be used.- Triple
negative disease only [ER- (defined as =<1% by
IHC), PR- (defined as =<1% by IHC), and HER2-]
Patients with triple negative breast cancer are
allowed if there is clinical or radiographic
evidence of tumor progression in the adjuvant or
metastatic setting. (Note: If HER2 result by IHC is
2+ equivocal, the tumor must be confirmed to be
HER2- by FISH.)
Yes
No
Prior treatments allowed: 0 or 1 prior
chemotherapy regimens for breast cancer. <=2
prior aromatase inhibitor regimens (including
letrozole)
Yes
No
The following laboratory values obtained <= 14
days prior to registration
Yes
No
Earliest laboratory test date (Note: These dates
pertain to the following labs only.)
Latest laboratory test date (Note: These dates
pertain to the following labs only.)
ANC >= 1,500/mm^3
Yes
No
ANC
1000/ul
Platelet count >= 100,000/mm^3
Yes
No
Peripheral Platelet Count
1000/uL
Total bilirubin =< upper limit of normal (ULN)
Yes
No
Total Bilirubin
mg/dL
Total bilirubin ULN
mg/dL
SGPT (ALT) <=3 x ULN or SGPT (ALT) <=5 x
ULN if elevations are due to liver metastasis
Yes
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No
Is there liver involvement
Yes
No
SGPT (ALT) (<=5 x ULN if evalations are due to
liver metastasis - <=3 x ULN)
SGPT (ALT) ULN
SGOT (AST) <=3 x ULN or SGOT (AST) <=5 x
ULN if elevations are due to liver metastasis
Yes
No
SGOT (AST) (<=5 x ULN if evalations are due to
liver metastasis - <=3 x ULN)
U/L
SGOT (AST) ULN
TSH <= ULN
Yes
No
TSH
TSH ULN
Creatinine <= 1.5 x ULN
<= 1.5
ULN
Yes
No
Creatinine
mg/dL
Creatinine ULN
mg/dL
ECOG performance status (PS) 0, 1, or 2
Yes
No
ECOG performance status grade
Fully Active, Able To Carry On All Pre-
disease Performance Without
Restriction. (0) (0)
Restricted In Physically Strenuous
Activity But Ambulatory And Able To
Carry Out Work Of A Light Or Sedentary
Nature, E.g., Light Housework, Office
Work. (1) (1)
Ambulatory And Capable Of All Selfcare
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But Unable To Carry Out Any Work
Activities. Up And About More Than 50%
Of Waking Hours. (2) (2)
Capable Of Only Limited Selfcare,
Confined To Bed Or Chair More Than
50% Of Waking Hours. (3) (3)
Completely Disabled. Cannot Carry On
Any Selfcare. Totally Confined To Bed Or
Chair. (4) (4)
Dead (5) (5)
Ability to provide informed written consent
Yes
No
Willing to return to NCCTG enrolling institution for
follow-up
Yes
No
Life expectancy >=12 weeks
Yes
No
Willing to provide tissue samples for correlative
research purposes (see Sections 4.0, 6.25, and
17.1)
Yes
No
Exclusion Criteria - All Responses In
Section Below Must Be "no."
Known standard therapy for the patient's disease
that is potentially curative or definitely capable of
extending life expectancy
Yes
No
>1prior chemotherapy regimen for breast cancer.
>2 prior aromatase inhibitor regimens
Yes
No
Uncontrolled intercurrent illness including, but not
limited to, ongoing or active infection,
symptomatic congestive heart failure, unstable
angina pectoris, cardiac arrhythmia, or psychiatric
illness/social situations that would limit
compliance with study requirements
Yes
No
Chemotherapy <=4 weeks prior to registration
(Any of the following prior therapies: If no prior
chemotherapy check NA)
Not Applicable (NA)
No (No)
Yes (Yes)
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Last day of chemotherapy (If prior chemotherapy)
Radiation therapy <=4 weeks prior to registration
(If no prior radiation therapy check NA)
Not Applicable (NA)
No (No)
Yes (Yes)
Last day of radiation therapy (If prior radiation
therapy)
Radiation to >25% of bone marrow
Yes
No
Failure to fully recover from acute, reversible
effects of prior chemotherapy regardless of
interval since last treatment
Yes
No
New York Heart Association class III or IV
cardiovascular disease
Yes
No
Any of the following because this study involves
an investigational agent whose genotoxic,
mutagenic and teratogenic effects on the
developing fetus and newborn are unknown.
-	Pregnant women
-	Nursing women
-	Men or women of childbearing potential who are
unwilling to employ adequate contraception
(as determined by the treating physician)
Yes
No
Receiving any other investigational agent
concurrently which would be considered as a
treatment for the primary neoplasm
Yes
No
Co-morbid systemic illnesses or other severe
concurrent disease which, in the judgment of the
investigator, would make the patient inappropriate
for entry into this study or interfere significantly
with the proper assessment of safety and toxicity
of the prescribed regimens
Yes
No
Immunocompromised patients (other than that
related to the use of corticosteroids) including
patients known to be HIV positive
Yes
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No
History of other malignancy <=5 years with the
exception of non-melanoma skin cancer or
carcinoma in-situ of the cervix
Yes
No
History of myocardial infarction or unstable
angina <=6 months prior to registration or
congestive heart failure (CHF) requiring use of
ongoing maintenance therapy, or life-threatening
ventricular arrhythmias
Yes
No
Receiving CYP3A4 inhibitors and inducers or any
other contraindicated agent listed in Appendix III
Yes
No
Congenital long QT syndrome or QTcF>450
msec on screening ECG:- Complete left bundle
block or use of a permanent cardiac pacemaker,
history or presence of ventricular
tachyarrhythmias, clinically significant resting
bradycardia (<50 beats per minute)- Right bundle
branch block + left anterior hemiblock
(bifascicular block
Yes
No
Registration Check
Consent form signed and dated
Yes
No
Date Informed Consent Signed
Authorization for use and disclosure of protected
health information signed and dated (Non-USA
institution only check NA)
Not Applicable (NA)
No (No)
Yes (Yes)
Date of authorization
A mandatory correlative research component is
part of this study for all patients, the patient will
be automatically registered onto this component
(see Section 3.19c, 4.0 and/or 17.1)
Yes
No
Treatment on this protocol must commence at the
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accruing membership under the supervision of an
NCCTG member physician
Yes
No
Treatment cannot begin prior to registration and
must begin <=14 days after registration
Yes
No
Pretreatment tests/procedures must be
completed <= 14 days prior to registration (see
Section 4.0 - NOTE: The earliest pretreatment
test/procedure date must be less than or equal to
the earliest laboratory test/procedure date and
the latest pretreatment test/procedure date must
be greater than or equal to the latest laboratory
test/procedure date.)
Yes
No
Earliest pretreatment test/procedure date
Latest pretreatment test/procedure date
All required baseline symptoms (see Section
10.3) must be documented and graded
Yes
No
Study drug availability checked
Yes
No
Blood draw kit availability checked (Blood kit must
be available on site)
Yes
No
Patient has given permission to give his/her blood
sample for research testing
Yes
No
Patient has given permission to store and use
his/her blood/plasma sample for future research
to learn about, prevent, or treat cancer
Yes
No
Patient has given permission to store and use
his/her blood/plasma sample for use in future
research to learn about, prevent, or treat other
health problems (for example: diabetes,
Alzheimer's disease, or heart disease)
Yes
No
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Patient has given NCCTG permission to give
blood to outside researchers
Yes
No
Patient has given permission to store and use
his/her sample(s) for use in future research to
learn about, prevent, or treat cancer
Yes
No
Patient has given permission to store and use
his/her tissue(s) sample for use in future research
to learn about, prevent, or treat other health
problems (for example: diabetes, Alzheimer's
disease, or heart disease)
Yes
No
Patient has given NCCTG permission to give
tissue(s) to outside researchers
Yes
No
Is this an NCCTG institution (NCCTG Institutions
only: N0932 must be open at site and offered to
patient. - This question may be answered yes or
no.)
Yes
No
Patient has agreed to be enrolled on N0932 (At
time of registration, the following will be
recorded:)
Yes
No
Grouping Factor (Patient Cohort)
Phase Ii (Phase II)
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Treatment form Colorectal Cancer NSABP
R-04 NCT00058474
NSABP PROTOCOL R-04: TREATMENT FORM -
2082638v3.0
Radiation Therapy and Either Capecitabine or Fluorouracil
With or Without Oxaliplatin Before Surgery in Treating
Patients With Resectable Rectal Cancer
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=B7822823-
8FBF-24ED-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/12116
Treatment form Colorectal Cancer
NSABP R-04 NCT00058474
Treatment
First Three Letters of Patients Last Name
Patient Study ID
Institution Name / Affiliate Name
Person Completing Form, Last Name
Person Completing Form, First Name
Person Completing Form, Phone
Are Data Amended?
Yes
No
Number of days any capecitabine taken
First day of infusion
Last day of infusion
Total cumulative dose
First day pills taken
Last day pills taken
CEA Date
CEA Value
Reason 5-FU or Capecitabine was discontinued
or never started
Alternative Therapy (alternative therapy)
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Adverse Event/side Effects/complications
(complications of radiation therapy)
Death On Study (death on study)
Disease Progression, Relapse During
Active Treatment (disease
progression/treatment failure)
Other (other complicating disease)
Other (other, specify)
Patient Withdrawal Or Refusal After
Beginning Protocol Therapy (patient
withdrawal or refusal)
second primary (second primary)
toxicity/side effects/complications
(toxicity/side effects/complications)
Treatment Completed Per Protocol
Criteria (treatment completed per
protocol)
Other complicating disease, specify
other, specify
Were any treatments delayed or skipped?
Yes
No
What was the reason for the treatment
modification?
Dose Reduction (dose reduction)
Dose Reduction Or Interruption Due To
Non-medical Reason (dose reduction or
interruption due to non-medical reason)
Dose Reduction Or Interruption Due To
Other Medical Reason (dose reduction
or interruption due to other medical
reason)
Interruption In Treatment Due To Toxicity
(interruption in treatment due to toxicity)
Other, Specify (other, specify)
dose reduction or interruption due to other
medical reason, specify
dose reduction or interruption due to non-medical
reason, specify
other, specify
Specify type of toxicity
Chemotherapy-associated
(chemotherapy-associated)
Radiation-associated (radiation-
associated)
Unknown (unknown)
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date of first injection
date of last injection
Was epoetin alfa discontinued while the patient
was still receiving chemotherapy or radiation?
Yes
No
If yes, mark reason
Excessively High Hemoglobin
(excessively high hemoglobin)
Other, Specify (other, specify)
Patient Refused Epoetin Alfa (patient
refused epoetin alfa)
other, specify (reason)
Date of chemistries
Total Bilirubin
mg/dL
Total bilirubin ULN
mg/dL
Alkaline Phosphatase
U/L
Alkaline Phosphatase ULN
U/L
AST (SGOT)
U/L
AST (SGOT) ULN
U/L
Creatinine
mg/dL
Serum Creatinine, Upper limit of lab normal
BUN
mg/dL
BUN ULN
mg/dl
WBC
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/ul
WBC LLN
/ul
AGC/ANC
AGC/ANC, Lower limit of lab normal
Peripheral Platelet Count
1000/uL
Platelets LLN
1000/ul
HGB
g/dL
Hemoglobin, LLN
g/dL
Date of hematologies
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Eligibility Myocardial Ischemia
NCT02469740
Peripheral Endothelial Function Assessment of Patients on
Ticagrelor vs. Clopidogrel Who Have Undergone PCI; ODM
derived from: https://clinicaltrials.gov/show/NCT02469740
All rights reserved. Please visit https://medical-data-
models.org/forms/12117
Eligibility Myocardial Ischemia
NCT02469740
Inclusion Criteria
subjects must be able and willing to give written
informed consent and to comply with the
requirements of this study protocol*
Yes
No
subjects must be male or female, aged 18 years
or above at baseline*
Yes
No
diagnosed with coronary artery disease and
undergone pci*
Yes
No
female subjects of child bearing potential must be
willing to ensure that they or their partner use
effective contraception during the study and for
12 months (as per guidelines on patients
undergoing pci who are on antiplatelet therapy).*
Yes
No
female subjects' urine pregnancy test performed
at the baseline visit must be negative (which is
required by local hospital policy in order to
undergo pci).*
Yes
No
Exclusion Criteria
allergy/hypersensitivity to study medications or
their ingredients*
Yes
No
contraindications to either clopidogrel or
ticagrelor:*
Yes
No
ticagrelor contraindications - active bleeding,
history of intracranial haemorrhage, moderate to
severe hepatic impairment, dialysis, uric acid
nephropathy, co-administration of a strong
cyp3a4 inhibitor (e.g. ketoconazole,
clarithromycin, nefazodone, ritonavir and
atazanavir), history of sick sinus syndrome or
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high degree av block without pacemaker
protection*
Yes
No
clopidogrel contraindications - severe hepatic
impairment, active bleeding*
Yes
No
on treatment with oral anticoagulant (vitamin k
antagonist, dabigatran, rivaroxaban, apixaban)*
Yes
No
unable to follow up in research centre (for
example, due to logistic difficulties)*
Yes
No
female subjects who are pregnant or breast-
feeding, or considering becoming pregnant
during the study.*
Yes
No
subjects who have participated in another study
and received any other investigational agent
within the previous 12 months*
Yes
No
subjects unable to provide written informed
consent within 24 hours of pci (for example,
intubated patients)*
Yes
No
subjects who have a history of drug or alcohol
use that, in the opinion of the investigator, would
interfere with adherence to study requirements.*
Yes
No
use of both left and right radial access for pci*
Yes
No
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Eligibility Nasopharyngeal Carcinoma
NCT02460887
The Role of Induction Gemcitabine and Cisplatin in
Locoregionally Advanced Nasopharyngeal Carcinoma in
the Era of IMRT; ODM derived from:
https://clinicaltrials.gov/show/NCT02460887
All rights reserved. Please visit https://medical-data-
models.org/forms/12119
Eligibility Nasopharyngeal
Carcinoma NCT02460887
Inclusion Criteria
patients with newly histologically confirmed non-
keratinizing nasopharyngeal carcinoma (including
who ii or iii).*
Yes
No
tumor staged as t1-4n2-3或t3-4n0-1m0
(according to the 7th ajcc edition).*
Yes
No
satisfactory performance status:  karnofsky scale
(kps) ≥ 70.*
Yes
No
adequate marrow: leucocyte count ≥ 4000/μl,
hemoglobin ≥ 90g/l and platelet count ≥*
Yes
No
adequate liver function: alanine aminotransferase
(alt), aspartate aminotransferase (ast) <
1.5×upper limit of normal (uln) concomitant with
alkaline phosphatase (alp) ≤ 2.5×uln*
Yes
No
and bilirubin ≤1.5×uln.*
Yes
No
adequate renal function: creatinine clearance ≥
60 ml/min.*
Yes
No
patients must be informed of the investigational
nature of this study and give written informed
consent.*
Yes
No
Exclusion Criteria
who type keratinizing squamous cell carcinoma
or basaloid squamous cell carcinoma.*
Yes
No
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treatment with palliative intent.*
Yes
No
prior malignancy except adequately treated basal
cell or squamous cell skin cancer, in situ cervical
cancer.*
Yes
No
pregnancy or lactation (consider pregnancy test
in women of child-bearing age and emphasize
effective contraception during the treatment
period).*
Yes
No
history of previous rt (except for non-
melanomatous skin cancers outside intended rt
treatment volume).*
Yes
No
prior chemotherapy or surgery (except
diagnostic) to primary tumor or nodes.*
Yes
No
any severe intercurrent disease, which may bring
unacceptable risk or affect the compliance of the
trial, for example, unstable cardiac disease
requiring treatment, renal disease, chronic
hepatitis, diabetes with poor control (fasting
plasma glucose > 1.5×uln), and emotional
disturbance.*
Yes
No
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Eligibility Neoadjuvant Operable Breast
Cancer NCT02400567
Efficacy of Letrozole + Palbociclib Combination as
Neoadjuvant Treatment of Stage II-IIIA PAM 50 ROR-
defined Low or Intermediate Risk Luminal Breast Cancer, in
Postmenopausal Women; ODM derived from:
https://clinicaltrials.gov/show/NCT02400567
All rights reserved. Please visit https://medical-data-
models.org/forms/12121
Eligibility Neoadjuvant Operable
Breast Cancer NCT02400567
Inclusion Criteria
1. aged  18 years, post-menopausal women*
Yes
No
2. newly diagnosed and operable unilateral
invasive breast cancer,  not candidate or
uncertain for breast conservation - note:
multicentric/multifocal tumors are allowed
provided a maximum of 3 lesions are present,
and all share the same characteristics: er allred
4, her2- (pam50 will be performed in the largest
lesion)*
Yes
No
3. stage ii-iiia*
Yes
No
4. assessment of nodal status available
(ultrasound guided fna or biopsy if necessary)*
Yes
No
5. non metastatic, m0*
Yes
No
6. er-positive by ihc (allred score≥4)*
Yes
No
7. her2-negative by ihc (score 0 or 1+) and/or
fish/cish*
Yes
No
8. either luminal a and proven nodal involvement
(cytology or histology), or luminal b through
pam50 ror (prosigna™) centralized evaluation*
Yes
No
9. ecog 0-1*
Yes
No
10. no prior systemic therapy for the present
tumor*
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Yes
No
11. adequate renal, hepatic, and hematopoietic
functions as defined by the following criteria:
absolute neutrophil count (anc) ≥1,500/mm3 or
≥1.5 x 109/l*
Yes
No
platelets ≥100,000/mm3 or ≥100 x 109/l*
Yes
No
hemoglobin ≥9 g/dl*
Yes
No
serum aspartate transaminase (ast) and serum
alanine aminotransferase transaminase (alt) ≤2.5
x upper limit of normal (uln)*
Yes
No
alkaline phosphatase ≤2.5 x uln*
Yes
No
total serum bilirubin ≤1 x uln*
Yes
No
serum creatinine ≤1.5 x uln or estimated
creatinine clearance ≥ 60 ml/min as calculated
using the method standard for the institution*
Yes
No
12 adequate cardiac functions, including: lead
electrocardiogram (ecg) with normal tracing or
non clinically significant changes that do not
require medical intervention.*
Yes
No
qtc interval ≤480 msec*
Yes
No
no  history of torsades de pointes or other
symptomatic qtc abnormality.*
Yes
No
13. willingness and ability to comply with
scheduled visits, treatment plan, laboratory tests,
and other trial procedures*
Yes
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No
14. signed informed consent and health
insurance coverage*
Yes
No
Exclusion Criteria
1. non operable, bilateral, t4 or metastatic breast
cancer*
Yes
No
2. limited t2 breast cancer immediately accessible
to conservative surgery*
Yes
No
3. previous homolateral breast cancer (including
in situ carcinoma), and/or contralateral breast
cancer except if treated by surgery +/- radiation
therapy alone without any systemic treatment*
Yes
No
4. previous hormone replacement therapy (hrt)
stopped less than 2 weeks before beginning of
treatment*
Yes
No
5. previous use of serms such as raloxifene*
Yes
No
6. any surgery (not including minor procedures
such as lymph node biopsy, primary tumor core
biopsy, fine needle aspiration) within 4 weeks of
start of study treatment; or not fully recovered
from any side effects of previous procedures.*
Yes
No
7. diagnosis of any previous malignancy within
the last 5 years, except for adequately treated
basal cell carcinoma, or squamous cell skin
carcinoma, or in situ cervical carcinoma*
Yes
No
8. history of any previous anti-cancer
chemotherapy  and any previous treatment using
ai*
Yes
No
9. concurrent administration of herbal
preparations as complementary medicine.*
3 / 4
Eligibility Neoadjuvant Operable Breast Cancer NCT02400567
Yes
No
10. any clinically significant gastrointestinal
abnormalities, which may impair intake, transit or
absorption of the study drugs, such as the
inability to take oral medication in tablet form and
malabsorption syndrome*
Yes
No
11. patient with any psychological, familial, social
or geographical condition which could potentially
hamper compliance with the study protocol and
follow-up schedule; those conditions should be
discussed with the patient before registration in
the trial.*
Yes
No
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Eligibility Neonatal Diabetes Secondary to
Mutation in the Potassium Channel NCT02375828
Glibentek in Patients With Neonatal Diabetes Secondary to
Mutations in K+-ATP Channels; ODM derived from:
https://clinicaltrials.gov/show/NCT02375828
All rights reserved. Please visit https://medical-data-
models.org/forms/12122
Eligibility Neonatal Diabetes
Secondary to Mutation in the
Potassium Channel NCT02375828
Inclusion Criteria
age below 18 years*
Yes
No
neonatal diabetes secondary to documented
mutation in one of the 2 sub units of potassium
channels*
Yes
No
patients already treated by glibenclamide pills*
Yes
No
signed consent*
Yes
No
Exclusion Criteria
families unable to fill in the questionnaries*
Yes
No
patients unable to answer to the visual hedonic
squale*
Yes
No
patients unable to take the oral solution*
Yes
No
known allergy to sulfonylureas or to other
antidiabetic or antibiotic sulfamides*
Yes
No
insulin therapy associated to glibenclamide*
Yes
No
miconazole therapy*
Yes
No
porphyria*
Yes
No
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breast feeding*
Yes
No
severe renal failure (creatinine clearance below
30 ml/mn)*
Yes
No
liver failure (prothombine time below 70)*
Yes
No
not affiliated to the health care system*
Yes
No
2 / 2
Eligibility Neonatal Diabetes Secondary to Mutation in the Potassium
Channel NCT02375828
Eligibility Non-Small Cell Lung Cancer
NCT02109653
Efficacy and Safety of LGX818 in Patients With Advanced
or Metastatic BRAF V600 Mutant NSCLC; ODM derived
from: https://clinicaltrials.gov/show/NCT02109653
All rights reserved. Please visit https://medical-data-
models.org/forms/12125
Eligibility Non-Small Cell Lung
Cancer NCT02109653
Inclusion Criteria
presence of braf v600e mutation in tumor tissue*
Yes
No
histologically or cytologically confirmed diagnosis
of stage iiib or iv nsclc*
Yes
No
at least one measurable lesion as defined by
recist v1.1*
Yes
No
patients must have progressed during or after at
least one previous systemic, anti-cancer
treatment for locally advanced or metastatic
nsclc.*
Yes
No
eastern cooperative oncology group (ecog)/world
health organization (who) performance status 0-
2*
Yes
No
Exclusion Criteria
patients with symptomatic central nervous
system (cns) metastases*
Yes
No
history of leptomeningeal metastases*
Yes
No
prior therapy with a braf inhibitor*
Yes
No
patients taking prohibited medication listed in the
protocol*
Yes
No
presence or history of a malignant disease other
than nsclc that has been diagnosed and/or
required therapy within the past 3 years.*
Yes
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No
impaired cardiovascular function or clinically
significant cardiovascular diseases*
Yes
No
pregnant or lactating women or woman of
childbearing potential*
Yes
No
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Eligibility Osteoarthritis NCT02128555
Total Ankle Replacement Versus Arthrodesis Trial; ODM
derived from: https://clinicaltrials.gov/show/NCT02128555
All rights reserved. Please visit https://medical-data-
models.org/forms/12127
Eligibility Osteoarthritis
NCT02128555
Inclusion Criteria
diagnosis of end-stage ankle osteoarthritis*
Yes
No
aged 50-85 years inclusive*
Yes
No
the surgeon believes the patient is suitable for
both tar and arthrodesis (having considered
deformity, stability, bone quality, soft tissue
envelope, and neurovascular status)*
Yes
No
the patient is able to read and understand the
patient information sheet (pis) and trial
procedures*
Yes
No
the patient is willing and able to provide written
informed consent*
Yes
No
Exclusion Criteria
previous ipsilateral talonavicular, subtalar or
calcaneocuboid fusion or surgery planned within
1 year of index procedure*
Yes
No
more than 4 lower limb joints fused (including
contralateral limb, but excluding proximal
interphalangeal joint fusions)*
Yes
No
• unable to have mri/ct scan (e.g. severe
claustrophobia or contraindication for either
scan)*
Yes
No
history of local bone or joint infection*
Yes
No
any co-morbidity, which, in the opinion of the
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investigator, is severe enough to; interfere with
the patient's ability to complete the study
assessments or; presents an unacceptable risk to
the patient's safety*
Yes
No
participant in another clinical trial that would
materially impact on their participation in this
study*
Yes
No
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ALTTO (Adjuvant Lapatinib And/Or Trastuzumab
Treatment Optimisation) Study; BIG 2-06/N063D
A Randomised, Multi-centre, Open-label, Phase III Study of
Adjuvant Lapatinib, Trastuzumab, Their Sequence and
Their Combination in Patients With HER2/ErbB2 Positive
Primary Breast Cancer
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study documentation
Pre-Registration Eligibility Checklist -
Cover Sheet/Demographics (N063D)
Header Module
Studie Nr.*
Labor Nr*
Institutions-Nr.*
Patienteninitialien*
Institution*
Registration Header
Gruppen-Protokoll Nr.*
Gruppen-Code*
Protocol Titel*
Nr. Krankenakte*
Gruppen-Code Teilnehmer*
veränderte Daten*
Ja
Nein
Unnamed 1
Registrierungs-Typ*
erste Einreichung (First Submission)
zweite Einrichung (Second Submission )
erste Einreichung*
Pre-Registration Eligibility Checklist
Cover Sheet/Demographics (1)
Eligibility Checklist (2)
Contact Person For Pathology Results
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Nachname*
Vorname*
Telefon*
Fax*
E-Mail*
Patient Demographics
Patienten-Geschlecht*
Female (1)
Male (2)
Unknown (3)
Patienten-Geburtsdatum*
Postleitzahl Patient*
Wohnort*
Method of Payment*
Rasse*
amerikaner Ureinwohner (American
Indian or Alaska Native)
Asiate (Asian)
Afroamerikaner (Black or African
American)
Pazifikinsulaner (Native Hawaiian or
other Pacific Islander)
Nicht berichtet (Not Reported)
Unbekannt (Unknown)
Kaukasier (White)
Ethnische Gruppe*
Hispanoamerikanische Herkunft
(HISPANIC OR LATINO)
keine Hispanoamerikanische Herkunft
(NOT HISPANIC OR LATINO)
Nicht berichtet (Not reported)
Unbekannt (Unknown)
Eligibility Screening Form
Einschlusskriterien*
Alter >= 18  (Age >= 18 years)
Baseline Lvef > 50% Measured By
Echocardiography Or Muga Scan After
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Completion Of All Anthracycline-based
(neo-) Adjuvant Chemotherapy And Prior
To The Targeted Therapy(ies) (Baseline
LVEF > 50% measured by
echocardiography or MUGA scan after
completion of all anthracycline-based
(neo-) adjuvant chemotherapy and prior
to the targeted therapy(ies)
Completion Of All Necessary Baseline
Laboratory And Radiological
Investigations (Completion of all
necessary baseline laboratory and
radiological investigations)
Eastern Cooperative Oncology Group
(ecog) Performance Status < 1  (Eastern
Cooperative Oncology Group (ECOG)
performance status < 1)
Hormon Rezeptor Status
(Östrogen/Progesteron oder Östrogen
alleine) (Known hormone receptor status
(ER/PgR or ER alone))
Must Have Received At Least Four
Cycles Of An Approved Anthracycline-
based (neo-) Adjuvant Chemotherapy
Regimen  (Must have received at least
four cycles of an approved anthracycline-
based (neo-) adjuvant chemotherapy
regimen)
nicht metastasiertes operables Mamma-
Karzinom (Non-metastatic operable
primary invasive adenocarcinoma of the
breast)
Her2Neu positives Mamma-Karzinom
(Overexpression and/or amplification of
HER2 in the invasive component of the
primary tumor)
Einverständniserklärung unterschrieben
(Signed written informed consent)
Ausschlusskriterien*
(neo-) Or Adjuvant Chemotherapy Using
Peripheral Stem Cell Or Bone Marrow
Stem Cell Support  ((Neo-) or adjuvant
chemotherapy using peripheral stem cell
or bone marrow stem cell support)
klinisches T4 Stadium (Any clinically
staged T4 tumor, including inflammatory
breast cancer)
Any Of The Following Abnormal
Laboratory Tests Immediately Prior To
Randomization  (Any of the following
abnormal laboratory tests immediately
prior to randomization (see list in
instructions))
Any Prior Mediastinal Irradiation Except
Internal Mammary Node Irradiation For
The Present Breast Cancer  (Any prior
mediastinal irradiation except internal
mammary node irradiation for the
present)
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beidseitige Tumoren (Bilateral tumors)
Concomitant Use Of Cyp3a4 Inhibitors
Or Inducers  (Concomitant use of
CYP3A4 inhibitors or inducers)
Concurrent Anti-cancer Treatment In
Another Investigational Trial With
Hormone Therapy Or Immunotherapy
(Concurrent anti-cancer treatment in
another investigational trial with hormone
therapy or immunotherapy)
gleichzeitige Tumor-Therapie, außer
Hormontherapie (Concurrent anti-cancer
treatment, except hormonal therapy)
Mammakarzinom in der Vorgeschichte
(History of any prior (ipsi- and/or
contralateral) invasive breast carcinoma)
Malabsorption Syndrome, Disease
Significantly Affecting Gastrointestinal
Function, Or Resection Of The Stomach
Or Small Bowel, Or Person Unable To
Swallow Oral Medication  (Malabsorption
syndrome, disease significantly affecting
gastrointestinal function, or resection of
the stomach or small bowel, or person
unable to swallow oral medication)
Maximum Cumulative Dose Of
Doxorubicin >360mg/m2 Or Maximum
Cumulative Dose Of Epirubicin
>720mg/m2 Or Any Prior Anthracyclines
Unrelated To The Present Breast Cancer
(Maximum cumulative dose of
doxorubicin >360mg/m2 or maximum
cumulative dose of epirubicin
>720mg/m2 or any prior anthracyclines
unrelated to the present breast cancer)
multifokaler Tumor (Multifocal tumors)
Other Concurrent Serious Diseases That
May Interfere With Planned Treatment
Including Severe Pulmonary
Conditions/illness  (Other concurrent
serious diseases that may interfere with
planned treatment including severe
pulmonary conditions/illness)
Past Or Current History Of Malignant
Neoplasms, Except For Curatively
Treated Basal And Squamous Cell
Carcinoma Of The Skin Or Carcinoma In
Situ Of The Cervix  (Past or current
history of malignant neoplasms, except
for curatively treated basal and
squamous cell carcinoma of the skin or
carcinoma in situ of the cervix)
Patients With Positive Or Suspicious
Internal Mammary Nodes Identified By
Sentinel Node Technique Which Have
Not Been Irradiated Or Will Not Be
Irradiated, Or Patients With
Supraclavicular Lymph Node
Involvement  (Patients with positive or
suspicious internal mammary nodes
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identified by sentinel node technique
which have not been irradiated or will not
be irradiated, or patients with
supraclavicular lymph node involvement)
Schwanger oder stillende Frau (Pregnant
or lactating women)
Prior Use Of Anti-her2 Therapy For Any
Reason Or Other Prior Biologic Or
Immunotherapy For Breast Cancer (Prior
use of anti-HER2 therapy for any reason
or other prior biologic or immunotherapy
for breast cancer)
Serious Cardiac Illness Or Medical
Conditions  (Serious cardiac illness or
medical conditions (including...))
Unresolved Or Unstable Serious Adverse
Event From Prior Adjuvant
Chemotherapy Or Radiotherapy
(Unresolved or unstable serious adverse
event from prior adjuvant chemotherapy
or radiotherapy)
Women Of Childbearing Potential
Including Women Whose Last Menstrual
Period Was <1 Year Ago Who Are
Unable Or Unwilling To Use Adequate
Contraceptive Measures During Study
Treatment  (Women of childbearing
potential including women whose last
menstrual period was <1 year ago who
are unable or unwilling to use adequate
contraceptive measures during study
treatment)
Randomization
Date of Randomization*
Assigned Treatment Arm*
Lapatinib  (Lapatinib alone)
Lapatinib In Combination With
Trastuzumab  (Lapatinib in combination
with Trastuzumab)
Trastuzumab  (Trastuzumab alone)
Trastuzumab Followed By Lapatinib
(Trastuzumab followed by Lapatinib)
Informed consent
Datum Einverstädniserklärung*
Datum Einverstädniserklärung für
Pharmakogenetische Tests*
Datum Einverstädniserklärung für Blutproben*
Ja
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Nein
Datum Einverstädniserklärung für Tumorgewebe*
Ja
Nein
Datum Einverstädniserklärung für zusätzliche
Blutproben*
Ja
Nein
Datum Einverstädniserklärung für gefrorene
Proben*
Ja
Nein
Unnamed 1
Menopausenstatus*
Kategorien nicht anwendbar, Alter unter
50 (Above categories not applicable AND
Age < 50)
Kategorien nicht anwendbar, älter als 50
(Above categories not applicable AND
Age >= 50)
Postmenopause (Post (prior bilateral
ovariectomy OR >12 mo since LMP with
no prior hysterectomy))
Prämenopause (Pre (<6 mo since LMP
AND no prior bilateral ovariectomy AND
not on estrogen replacement))
Datum letzte Menstruation*
Datum Schwangerschaftstest*
Schwangerschaftstest*
negativ (negative)
nicht anwendbar (not applicable, not
female of child-bearing potential)
positiv (positive)
Hatte die Patientin eine Hysterektomie?*
Ja
Nein
Datum Hysterektomie*
Einseitige Ovarektomie*
Ja
Nein
Seite Ovarektomie*
links (Left)
rechts (Right)
6 / 28
ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation)
Study; BIG 2-06/N063D
Datum Einseitige Ovarektomie*
Patient Status
Datum körperliche Untersuchung*
körperliche Untersuchung*
auffällig, klinisch signifikant (Abnormal -
Clinically significant)
auffällig, klinisch nicht signifikant
(Abnormal - Not clinically significant)
unauffällig (Normal)
Größe*
Körpergewicht*
Körperoberfläche*
Systolischer Blutdruck*
Diastolischer Blutdruck*
Herzfrequenz*
ECOG Leistungszustand*
0 (0)
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
ECG
date of ECG*
Result*
Normal (1)
Abnormal - Clinically significant (2)
Abnormal - Not clinically significant (3)
Cardiac Monitoring
Datum Linksventrikuläre Ejektionsfraktion*
Linksventrikuläre Ejektionsfraktion*
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Echokardiographie*
Ja
Nein
Radionuklidventrikulographie *
Ja
Nein
Ergebnis*
auffällig, klinisch signifikant (Abnormal -
Clinically significant)
auffällig, klinisch nicht signifikant
(Abnormal - Not clinically significant)
unauffällig (Normal)
Symptomatic CHF*
Ja
Nein
NYHA Classification*
Patients With Cardiac Disease But
Without Resulting Limitation Of Physical
Activity. Ordinary Physical Activity Does
Not Cause Undue Fatigue, Palpitation,
Dyspnea Or Anginal Pain. (Class I)
(Class I)
Patients With Cardiac Disease Resulting
In Slight Limitation Of Physical Activity.
They Are Comfortable At Rest. Ordinary
Physical Activity Results In Fatigue,
Palpitation, Dyspnea Or Anginal Pain.
(Class II) (Class II)
Patients With Cardiac Disease Resulting
In Marked Limitation Of Physical Activity.
They Are Comfortable At Rest. Less
Than Ordinary Activity Causes Fatigue,
Palpitation, Dyspnea Or Anginal Pain.
(Class III) (Class III)
Patients With Cardiac Disease Resulting
In Inability To Carry On Any Physical
Activity Without Discomfort. Symptoms
Of Heart Failure Or The Anginal
Syndrome May Be Present Even At
Rest. If Any Physical Activity Is
Undertaken, Discomfort Increases.
(Class IV) (Class IV)
Local Her2 Results
Staining Antibody*
nicht_sinnvoll_für_Untersuchung (Cb-
11/ventana Kit )
nicht_sinnvoll_für_Untersuchung (Dako
A0485 )
nicht_sinnvoll_für_Untersuchung (Dako
Herceptest [tm] )
nicht_sinnvoll_für_Untersuchung (Ncl-c-
erbb2-316 )
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nicht_sinnvoll_für_Untersuchung (other)
nicht_sinnvoll_für_Untersuchung (Tab-
250 )
nicht_sinnvoll_für_Untersuchung*
Her2/Neu Status *
fraglich (Equivocal )
negativ (Negative )
Nicht auswertbar (Non-interpretable )
positiv (Positive )
Percentage of invasive tumor cells with complete
membrane staining*
FISH Kit or Test Type*
nicht_sinnvoll_für_Untersuchung (Other)
nicht_sinnvoll_für_Untersuchung
(Vysis/path Vysion[tm] )
nicht_sinnvoll_für_Untersuchung*
FisH-Test*
positiv (Amplified )
fraglich (Equivocal )
negativ (Not Amplified )
FISH HER2/neu chromosome 17 Ratio*
Chromosome 17 copy number*
Monosomy  (Monosomy )
Normal  (Normal )
Polysomy  (Polysomy )
Test Datum*
nicht durchgeführt*
CISH Kit or Test Type*
nicht_sinnvoll_für_Untersuchung (Other)
nicht_sinnvoll_für_Untersuchung
(Ventana Inform)
nicht_sinnvoll_für_Untersuchung*
CISH*
positiv (Amplified )
fraglich (Equivocal )
negativ (Not Amplified )
Chromosome 17 copy number*
Monosomy  (Monosomy )
Normal  (Normal )
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Polysomy  (Polysomy )
Hormonal Receptor Status
Östrogenrezeptor-positive Zellen %*
Progesteronrezeptor-positive Zellen %*
History Of Primary Breast Cancer
Diagnosedatum*
Körperseite Tumor*
links (Left)
rechts (Right)
klinische Tumorgröße*
N - Stadium der regionalen Lymphknoten*
N0 Stadium  (N0)
N1 Stadium  (N1)
N2 Stadium (N2)
N3 Stadium (N3)
Tumorgröße*
Schnittrand infiltiert durch Tumor*
Ja
Nein
histologischer Typ*
apokrin (Apocrine )
Cribriform  (Cribriform )
Duktales Karzinom (Ductal NOS)
invasives Karzinom (Invasive NOS)
invasives lobuläre Karzinom (Lobular )
Medulläres Karzinom (Medullary)
Mikropapillär (Micropapillary )
Gemischt, duktal und lobulär (Mixed
ductal and lobular)
Muzinöses Adenokarzinom (Mucinous)
andere (other)
tubulär (Tubular (pure > or =90%))
Tubulolobulär  (Tubulolobular )
andere*
Carcinoma in Situ *
Ja
Nein
histologischer Typ*
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DCIS (DCIS)
lobuläres Carcinoma in situ (LCIS)
Gemischt, duktales und lobuläres CIS
(Mixed DCIS & LCIS)
Morbus Paget der Mamille*
Ja
Nein
Histopathologisches Grading*
G1 gut differenziert (G1)
G2 mäßig differenziert (G2)
G3 schlecht differenziert (G3)
nicht bestimmbar (GX)
Lymphknotenbefall*
>= 4 Positive Nodes, No Neoadjuvant
Chemotherapy (>= 4 positive nodes, no
neoadjuvant chemotherapy)
1-3 Positive Nodes, No Neoadjuvant
Chemotherapy  (1-3 positive nodes, no
neoadjuvant chemotherapy)
Node Negative, No Neoadjuvant
Chemotherapy  (Node negative, no
neoadjuvant chemotherapy)
nicht anwendbar (Not Applicable)
Timing of chemotherapy*
Concurrent  (Concurrently with targeted
therapy)
Sequential  (Sequentially)
Hematology And Biochemistry*
Date of blood specimen collection*
Result*
Normal (1)
Abnormal - Clinically significant (2)
Abnormal - Not clinically significant (3)
History Of Primary Cancer (continued)
Name Labor*
Östrogen-Rezeptor*
negativ (Negative )
positiv (Positive )
unbekannt (Unknown)
Stauts Östrogenrezeptor im Tumor*
Ja
Nein
Wert Östrogenrezeptor*
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H-Score*
Allred-Score*
Remmle score*
other*
Method*
Range*
Progesteron-Rezeptor*
negativ (Negative )
positiv (Positive )
unbekannt (Unknown)
Stauts Progesteronrezeptor im Tumor*
Ja
Nein
Wert Progesteronrezeptor*
H-Score*
Allred-Score*
Remmle score*
other*
Method*
Range*
Sentinel Node Sampling
Durchführung Sentinellymphknotenbiopsie*
Ja
Nein
Datum Sentinellymphknotenbiopsie*
Körperseite*
rechts (Left)
links (Right)
Sentinellymphknoten Biospie Axilla*
negativ (Negative)
12 / 28
ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation)
Study; BIG 2-06/N063D
positiv (Positive )
Sentinel Biopsie der internen Brustlymphknoten*
negativ (Negative)
positiv (Positive )
nicht durchgeführt*
Most Extensive Primary Surgery
Operation*
Lumpektomie (Lumpectomy )
nicht_kodiert (Modified Radical
Mastectomy )
andere (Other )
Paritielle Mastektomie (Partial
Mastectomy )
Segmentale Mastektomie
(Quandrantectomy / Segmentectomy)
nicht_kodiert (Radical Mastectomy )
genauere Bezeichnung*
Seite*
links (Left)
rechts (Right)
Datum der OP*
Axilladissektion
Datum Axilladissektion*
Seite*
links (Left)
rechts (Right)
Anzahl der untersuchten Lymphknoten*
Anzahl der beteiligten Lymphknoten *
Largest tumor deposit*
Isolated Tumor Cells Alone (Isolated
Tumor Cells Alone)
Macrometastases  (Macrometastases)
Micromets  (Micrometastases)
None Detected  (None Detected )
Not Measured  (Not Measured )
nicht durchgeführt*
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Chemotherapy
Chemotherapie Substanz*
kumulative Dosis*
erste Dosis*
Zyklen geplant*
Intention - letzte Chemotherapie*
Adjuvant (Adjuvant)
Neoadjuvant (Neoadjuvant)
Datum Beginn*
Datum Ende*
Previous Or Current Cardiovascular
Disease
nicht_sinnvoll_für_Untersuchung*
Ja
Nein
nicht_sinnvoll_für_Untersuchung*
nicht_sinnvoll_für_Untersuchung*
nicht_sinnvoll_für_Untersuchung
(Current)
nicht_sinnvoll_für_Untersuchung
(Resolved)
nicht_sinnvoll_für_Untersuchung*
Ja
Nein
nicht_sinnvoll_für_Untersuchung*
Ja
Nein
ECG
nicht_sinnvoll_für_Untersuchung*
nicht_sinnvoll_für_Untersuchung
(Abdominal CT-scan)
nicht_sinnvoll_für_Untersuchung
(Bilateral mammogram)
nicht_sinnvoll_für_Untersuchung (Bone
scan (scintigraphy))
nicht_sinnvoll_für_Untersuchung (Bone
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X-ray)
nicht_sinnvoll_für_Untersuchung (Chest
CT-scan)
nicht_sinnvoll_für_Untersuchung (Chest
X-Ray)
nicht_sinnvoll_für_Untersuchung (CT
Scan)
nicht_sinnvoll_für_Untersuchung
(Endoscopy )
nicht_sinnvoll_für_Untersuchung (Left
mammogram, only)
nicht_sinnvoll_für_Untersuchung
(Lymphangiogram )
nicht_sinnvoll_für_Untersuchung
(Mammography )
nicht_sinnvoll_für_Untersuchung (MRI)
nicht_sinnvoll_für_Untersuchung
(Nuclear Scan )
nicht_sinnvoll_für_Untersuchung (Other )
nicht_sinnvoll_für_Untersuchung (PET
Scan)
nicht_sinnvoll_für_Untersuchung
(PET/CT scan)
nicht_sinnvoll_für_Untersuchung (Right
mammogram, only)
nicht_sinnvoll_für_Untersuchung
(Transvaginal Ultrasound)
nicht_sinnvoll_für_Untersuchung
(Ultrasound )
nicht_sinnvoll_für_Untersuchung (X-ray)
nicht_sinnvoll_für_Untersuchung*
nicht_sinnvoll_für_Untersuchung*
nicht_sinnvoll_für_Untersuchung
(Abdomen )
nicht_sinnvoll_für_Untersuchung
(Abdomen/abdominal Wall )
nicht_sinnvoll_für_Untersuchung
(Bladder )
nicht_sinnvoll_für_Untersuchung (Bone )
nicht_sinnvoll_für_Untersuchung (Breast
)
nicht_sinnvoll_für_Untersuchung
(Central Nervous System (CNS))
nicht_sinnvoll_für_Untersuchung (Cervix
Uteri )
nicht_sinnvoll_für_Untersuchung (Chest
)
nicht_sinnvoll_für_Untersuchung (Colon
)
nicht_sinnvoll_für_Untersuchung
(Colorectal )
nicht_sinnvoll_für_Untersuchung
(Esophagus )
nicht_sinnvoll_für_Untersuchung (Head
And Neck )
nicht_sinnvoll_für_Untersuchung (Heart )
nicht_sinnvoll_für_Untersuchung (Kidney
)
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nicht_sinnvoll_für_Untersuchung (Liver )
nicht_sinnvoll_für_Untersuchung (Lung )
nicht_sinnvoll_für_Untersuchung (Lymph
Node )
nicht_sinnvoll_für_Untersuchung (Mouth
(Oral Cavity))
nicht_sinnvoll_für_Untersuchung (Other )
nicht_sinnvoll_für_Untersuchung (Ovary
)
nicht_sinnvoll_für_Untersuchung
(Pancreas )
nicht_sinnvoll_für_Untersuchung (Pelvis
)
nicht_sinnvoll_für_Untersuchung
(Peritoneum )
nicht_sinnvoll_für_Untersuchung (Pleura
)
nicht_sinnvoll_für_Untersuchung
(Prostate Gland )
nicht_sinnvoll_für_Untersuchung
(Rectum )
nicht_sinnvoll_für_Untersuchung (Skin )
nicht_sinnvoll_für_Untersuchung (Small
Intestine)
nicht_sinnvoll_für_Untersuchung (Spleen
)
nicht_sinnvoll_für_Untersuchung
(Stomach )
nicht_sinnvoll_für_Untersuchung (Testis
(Testicle))
nicht_sinnvoll_für_Untersuchung
(Thyroid Gland (Thyroid))
nicht_sinnvoll_für_Untersuchung*
nicht_sinnvoll_für_Untersuchung*
Ja
Nein
nicht_sinnvoll_für_Untersuchung*
nicht_sinnvoll_für_Untersuchung*
Translational Research
nicht_sinnvoll_für_Untersuchung*
nicht_sinnvoll_für_Untersuchung
(Additional Blood Sample For Ctc
(circulating Tumor Cells) (Additional
blood sample for CTC (circulating tumor
cells)))
nicht_sinnvoll_für_Untersuchung
(Additional Blood Sample For
Proteomics (Additional blood sample for
Proteomics))
nicht_sinnvoll_für_Untersuchung
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(Additional Fresh Frozen Tumor Samples
(Additional fresh frozen tumor samples))
nicht_sinnvoll_für_Untersuchung (Blood
Sample For Pgx)
nicht_sinnvoll_für_Untersuchung (FFPE
tumor block)
nicht_sinnvoll_für_Untersuchung (Tumor
Tissue For Pgx)
nicht_sinnvoll_für_Untersuchung*
nicht_sinnvoll_für_Untersuchung*
Ja
Nein
Central Her2 Testing Form - FISH
Percentage greater than or equal to 3
Chromosome 17 signals*
NACA (No apparent Chromosome 17 anomaly)*
Ja
Nein
Why no result*
nicht_sinnvoll_für_Untersuchung
(Hybridization Failure)
nicht_sinnvoll_für_Untersuchung
(Insufficient Tissue )
nicht_sinnvoll_für_Untersuchung
(Interductal Only )
nicht_sinnvoll_für_Untersuchung (No
Cancer Tissue )
nicht_sinnvoll_für_Untersuchung (Other)
Specify*
Other features*
nicht_sinnvoll_für_Untersuchung
(Duplication Of Her2 )
nicht_sinnvoll_für_Untersuchung (Most
Cells With No Centromere 17 )
nicht_sinnvoll_für_Untersuchung
(Negative Her2 )
nicht_sinnvoll_für_Untersuchung
(Normal Her2 )
nicht_sinnvoll_für_Untersuchung (Not A
Small Clone )
nicht_sinnvoll_für_Untersuchung (Other )
nicht_sinnvoll_für_Untersuchung (Small
Clone Of Amplification )
Central Her2 Testing Form - IHC
nicht_sinnvoll_für_Untersuchung*
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Uniformity of staining*
Absent (Absent)
Present (Present)
Homogeneous dark circumferential pattern*
Absent (Absent)
Present (Present)
Her-2/neu*
borderline (Equivocal - 2+)
positiv (Equivocal - 3+)
nicht ausreichend Gewebe (Insufficient
tissue/hybridization failure)
negativ (Negative - 0)
negativ (Negative - 1+)
positiv (Positive - 3+)
Gefäßinvasion*
Ja
Nein
Suitable for TMA*
Ja
Nein
Radiotherapy
Strahlentherapie durchgeführt*
Ja
Nein
Ort der Bestrahlung*
Körperseite*
links (Left)
rechts (Right)
Gesamtdosis*
Dosis - Einheit*
Centigray (cGy)
Gray (Gy)
Rad (Rad)
Beginn Strahlentherapie*
Ende Strahlentherapie*
Hormonetherapy
Hormon- / endokrine Therapie*
Ja
Nein
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Therapieart*
Einzeldosis*
Einheit*
Milligramm (mg)
nicht anwendbar (N/A)
Datum Therapiebeginn - endokrine Therapie*
Datum Therapieende - endokrine Therapie*
fortlaufend am Studienende*
Ja (Yes)
Concomitant Treatment
Name Nebentherapie*
Intention *
Kurativ (Curative)
Prävention (Prophylaxis)
Datum Therapiebeginn*
Datum Ende*
fortlaufend*
Ja (Yes)
Administration of Study Drug
Date Agent Administered*
Einzeldosis*
kumulative Dosis*
Was treatment delayed*
Ja
Nein
Specify code*
Administrative Reasons  (Administrative
Reasons )
Adverse Event Other Than Hematologic
Or Cardiac  (Adverse Event Other Than
Hematologic Or Cardiac )
Cardiac Adverse Event (Cardiac Adverse
Event)
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Dosing Error  (Dosing Error )
Hematologic Adverse Event
(Hematologic Adverse Event )
Other  (Other )
Subject Non-compliance (Subject Non-
compliance)
specify*
Dosislevel der Chemotherapie reduziert*
Ja
Nein
Specify code*
Administrative Reasons  (Administrative
Reasons )
Adverse Event Other Than Hematologic
Or Cardiac  (Adverse Event Other Than
Hematologic Or Cardiac )
Cardiac Adverse Event (Cardiac Adverse
Event)
Dosing Error  (Dosing Error )
Hematologic Adverse Event
(Hematologic Adverse Event )
Other  (Other )
Subject Non-compliance (Subject Non-
compliance)
specify*
Post-Event-Treatment
Chemotherapy
Rezidivtherapie - Chemotherapie*
Ja
Nein
Agent Name*
Total No. Cycles*
initial dose*
Dose UOM*
Miligram per Meter squared (mg/m2)
Date started*
Date stopped*
Targeted Therapy
AdditionalTargetTherapy*
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Ja
Nein
Agent Name*
Total No. Cycles*
initial dose*
Dose UOM*
Miligram per Meter squared (mg/m2)
Date started*
Date stopped*
Hormonetherapy
Rezidivtherapie - Hormontherapie*
Ja
Nein
Agent Name*
Total No. Cycles*
initial dose*
Dose UOM*
Miligram per Meter squared (mg/m2)
Not Applicable (N/A)
Date started*
Date stopped*
Radiotherapy
Rezidivtherapie - Bestrahlung*
Ja
Nein
Radiation Therapy Site*
Side*
Left (Left)
Right (Right)
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Total Dose*
Dose UOM*
Miligram per Meter squared (mg/m2)
Radiation Therapy Start Date*
Radiation Therapy End Date*
Surgery
Rezidivtherapie - Operation*
Ja
Nein
Surgical site*
Surgery Date*
Adverse Event (AE)
Name Adverse Event*
Alanin-Transaminase (Alanine
Aminotransferase Increased (ALT, SGPT
(serum glutamic pyruvic transaminase)))
Allergie (Allergy/immunology Other
(Allergy/Immunology-Other (Specify)))
Haar (Alopecia (Hair loss/Alopecia (scalp
or body)))
Herzrhythmus (Arrhythmia Nos (Cardiac
Arrhythmia-Other (Specify)))
Aspartat-Transaminase (Aspartate
Aminotransferase Increased (AST, SGOT
(serum glutamic oxaloacetic
transaminase)))
Sinnesorgane (Auditory/ear Other
(Auditory/Ear-Other (Specify)))
Alkalische Phosphatase (Blood Alkaline
Phosphatase Nos Increased (Alkaline
phosphatase))
Bilirubin (Blood Bilirubin Increased
(Bilirubin (hyperbilirubinemia)))
Kreatinin (Blood Creatinine Increased
(Creatinine))
Herz, allgemein (Cardiac General Other
(Cardiac General-Other (Specify)))
Obstipation (Constipation (Constipation))
Allgemeinsymptome (Constitutional
Symptoms Other (Constitutional
Symptoms-Other (Specify)))
Zystitis (Cystitis (Cystitis))
Bewusstsein (Depressed Level Of
Consciousness (Somnolence/depressed
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level of consciousness))
Haut (Dermatology/skin Other
(Dermatology/Skin-Other (Specify)))
Diarrhoe (Diarrhoea Nos (Diarrhea))
Dyspnoe (Dyspnoea Nos (Dyspnea
(shortness of breath)))
Endokrines System (Endocrine Other
(Endocrine-Other (Specify)))
Hämaturie (Haematuria Present
(Hemorrhage, GU - Urinary NOS))
Hämoglobin (Haemoglobin Decreased
(Hemoglobin))
Blutungen (Hemorrhage/bleeding Other
(Hemorrhage/Bleeding-Other (Specify)))
Infektion (Infection Nos (Infection-Other
(Specify)))
Leukozyten (Leucopenia Nos
(Leukocytes (total WBC)))
Laborwerte (Metabolic/laboratory Other
(Metabolic/Laboratory-Other (Specify)))
Übelkeit (Nausea (Nausea))
Peripherer Nerv (Neuralgia Nos (Pain -
Neuralgia/peripheral nerve))
Urogenital-System (Niere/Blase)
Schmerzen (Pain Other (Pain-Other
(Specify)))
Perikarditis (Pericarditis (Pericarditis))
Thrombozyten (Platelet Count
Decreased (Platelets))
Proteinurie (Proteinuria Present
(Proteinuria))
Lunge/Kehlkopf (Pulmonary/upper
Respiratory Other (Pulmonary/Upper
Respiratory-Other (Specify)))
Fieber (Pyrexia (Fever (in the absence of
neutropenia, where neutropenia is
defined as ANC <1.0 x 10^9/L)))
Gastrointestinaltrakt (Renal/genitourinary
Other (Renal/Genitourinary-Other
(Specify)))
Vomiting (Vomiting Nos (Vomiting))
1024 more adverse events*
SAE reported*
Ja
Nein
CTCAE Begin Date*
CTCAE End Date*
Grad der Nebenwirkung*
CTC Adverse Event Outcomme*
Adverse Event Was Fatal  (fatal)
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Adverse Event Has Improved  (improved)
Adverse Event Is Ongoing  (ongoing)
Adverse Event Is Resolved  (resolved)
Adverse Event Is Resolved With
Sequelae  (resolved with sequelae)
Action Taken at Time of Adverse Event*
There Was No Action Taken Based On
The Adverse Event  (none)
Other Treatment Was Required As A
Result Of The Adverse Event  (other
treatment required)
Protocol Treatment Was Delayed As A
Result Of The Adverse Event  (protocol
treatment delayed)
Protocol Treatment Was Discontinued As
A Result Of The Adverse Event
(protocol treatment discontinued)
Study Dose Was Reduced As A Result
Of The Adverse Event  (study dose
reduced)
relation to study drug*
Ja
Nein
Second Primary Malignancy and
Contralateral Breast Cancer
Rezdivtumor*
Date of First Recurrence or Progression*
Medizinische Untersuchung*
körperliche Untersuchung (Clinical)
radiologisch (Radiological)
Biopsie*
Ja
Nein
Datum Biopsie*
histologischer Typ*
On Study - Years 6, 7, 8, 9, and 10
Patient Status
körperliche Untersuchung*
nicht durchgeführt*
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Are there any changes since the previous
assessment*
Ja
Nein
Are there any changes since the previous
assessment*
Adverse Event  (Adverse Event)
Patient verstorben (Death )
keine Nachuntersuchung erfolgt (Lost To
Follow-up)
Patient Withdrew Study Consent
(Patient withdrew study consent)
Rezdivtumor (Recurrence of disease)
Zweittumor (Second primary malignancy
or contralateral breast cancer)
Herzerkrankung (Significant cardiac
disease)
Datum des letzten Kontaktes*
ECOG Leistungszustand*
0 (0)
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
Systolischer Blutdruck*
Diastolischer Blutdruck*
Cardiac Monitoring
Datum Linksventrikuläre Ejektionsfraktion*
Linksventrikuläre Ejektionsfraktion*
Echokardiographie*
Ja
Nein
Radionuklidventrikulographie *
Ja
Nein
Ergebnis*
auffällig, klinisch signifikant (Abnormal -
Clinically significant)
auffällig, klinisch nicht signifikant
(Abnormal - Not clinically significant)
unauffällig (Normal)
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Symptomatic CHF*
Ja
Nein
New York Heart Association*
Patients With Cardiac Disease But
Without Resulting Limitation Of Physical
Activity. Ordinary Physical Activity Does
Not Cause Undue Fatigue, Palpitation,
Dyspnea Or Anginal Pain. (Class I)
(Class I)
Patients With Cardiac Disease Resulting
In Slight Limitation Of Physical Activity.
They Are Comfortable At Rest. Ordinary
Physical Activity Results In Fatigue,
Palpitation, Dyspnea Or Anginal Pain.
(Class II) (Class II)
Patients With Cardiac Disease Resulting
In Marked Limitation Of Physical Activity.
They Are Comfortable At Rest. Less
Than Ordinary Activity Causes Fatigue,
Palpitation, Dyspnea Or Anginal Pain.
(Class III) (Class III)
Patients With Cardiac Disease Resulting
In Inability To Carry On Any Physical
Activity Without Discomfort. Symptoms
Of Heart Failure Or The Anginal
Syndrome May Be Present Even At
Rest. If Any Physical Activity Is
Undertaken, Discomfort Increases.
(Class IV) (Class IV)
Mammogram
Mammogramm*
beidseits (Bilateral)
links (Left)
rechts (Right)
Untersuchungsdatum*
nicht durchgeführt*
Are there any clinically significant abnormalites*
Ja
Nein
specify*
Hematoly and Biochemistry
Date of blood specimen collection*
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Result*
auffällig, klinisch signifikant (Abnormal -
Clinically significant)
auffällig, klinisch nicht signifikant
(Abnormal - Not clinically significant)
unauffällig (Normal)
Survival Follow-Up
Vitalstatus*
lebend (Alive)
tot (Dead)
keine Nachuntersuchung erfolgt (Lost To
Follow-up)
Todesdatum*
Datum letzter Kontakt*
Unterschrift Untersuchuer*
Datum*
Treatment Completion
nicht_sinnvoll_für_Untersuchung*
nicht_sinnvoll_für_Untersuchung (No)
nicht_sinnvoll_für_Untersuchung (Not
Applicable)
nicht_sinnvoll_für_Untersuchung (Yes)
nicht_sinnvoll_für_Untersuchung*
nicht_sinnvoll_für_Untersuchung (No)
nicht_sinnvoll_für_Untersuchung (Not
Applicable)
nicht_sinnvoll_für_Untersuchung (Yes)
nicht_sinnvoll_für_Untersuchung*
nicht_sinnvoll_für_Untersuchung (No)
nicht_sinnvoll_für_Untersuchung (Not
Applicable)
nicht_sinnvoll_für_Untersuchung (Yes)
Grund für Therapeabbruch*
Adverse Event  (Adverse Event)
kontrallaterales Mammakarzinom
(contralateral breast cancer)
Patient verstorben (Death )
keine Nachuntersuchung erfolgt (Lost to
follow-up)
Verletzung des Protokolls (Protocol
violation)
Rediziverkrankung (Recurrence of
disease)
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Zweittumor (second primary malignancy)
Subject Decided To Withdraw From
Investigational Product But Is Continuing
To Be Followed Per Protocol  (Subject
decided to withdraw from investigational
product but is continuing to be followed
per protocol)
Subject Decided To Withdraw From The
Study  (Subject decided to withdraw from
the study)
Datum letzter Kontakt während
Behandlungsperiode*
Additional Comments
CRF Page Number*
Kommentar*
Unterschrift Untersuchuer*
Datum*
Death Form
Todesdatum*
Todesursache*
Adverse Event während Studie (Adverse
event during study)
Adverse Event während Therapie des
Rezidiv (Adverse event during treatment
given after recurrence)
Tumor Progression (Breast cancer
progression)
Todesursache tumorbedingt (Malignant
disease other than breast cancer)
andere Todesursache (Other)
andere Todesursache*
Autopsie*
Nein (No)
unbekannt (unknown)
Ja (Yes)
Please summarize findings*
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06/N063D NCT00490139
A Randomised, Multi-centre, Open-label, Phase III Study of
Adjuvant Lapatinib, Trastuzumab, Their Sequence and
Their Combination in Patients With HER2/ErbB2 Positive
Primary Breast Cancer
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Outcome of Pregnancy Breast
Cancer NCT00490139
Header Module
NCCTG Study No*
Central Lab ID Number*
Institution Number*
Patient Initials*
Institution*
Registration Header
Coordinating Group Protocol Number (N063D)*
Coordinating Group Code (NCCTG)*
Protocol Title (ALTTO: Adjuvant Lapatinib and/or
Trastuzumab Treatment Optimisation Trial)*
Patient Medical Record Number*
Participating Group Code*
amended data*
Yes
No
Submission Details
Registration Type*
First Submission (First Submission)
Second Submission  (Second
Submission )
First Submission*
Pre-Registration Eligibility Checklist
Cover Sheet/Demographics (1)
Eligibility Checklist (2)
1 / 30
Contact Person For Pathology Results
Last Name*
Forename*
Phone*
Fax*
E-Mail*
Patient Demographics
Patient sex*
Female (1)
Male (2)
Unknown (3)
Patient date of birth*
Patient postal code*
Country of Residence*
Method of Payment*
Race*
A Person Having Origins In Any Of The
Original Peoples Of North And South
America (including Central America),
And Who Maintains Tribal Affiliation Or
Community Attachment.  (American
Indian or Alaska Native)
A Person Having Origins In Any Of The
Original Peoples Of The Far East,
Southeast Asia, Or The Indian
Subcontinent Including, For Example,
Cambodia, China, India, Japan, Korea,
Malaysia, Pakistan, The Philippine
Islands, Thailand, And Vietnam.  (Asian)
A Person Having Origins In Any Of The
Black Racial Groups Of Africa. Terms
Such As "haitian" Or "negro" Can Be
Used In Addition To "black Or African
American."  (Black or African American)
A Person Having Origins In Any Of The
Original Peoples Of Hawaii, Guam,
Samoa, Or Other Pacific Islands.  (Native
Hawaiian or other Pacific Islander)
Not Provided Or Available  (Not
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Reported)
Could Not Be Determined Or Unsure
(Unknown)
A Person Having Origins In Any Of The
Original Peoples Of Europe, The Middle
East, Or North Africa.  (White)
Ethnic group *
A Person Of Mexican, Puerto Rican,
Cuban, Central Or South American Or
Other Spanish Culture Or Origin,
Regardless Of Race.  (HISPANIC OR
LATINO)
A Person Not Meeting The Definition For
Hispanic Or Latino.  (NOT HISPANIC OR
LATINO)
Not Provided Or Available  (Not reported)
Could Not Be Determined Or Unsure
(Unknown)
Eligibility Screening Form
Inclusion Criteria *
>= 18 Years Of Age  (Age >= 18 years)
Baseline Lvef > 50% Measured By
Echocardiography Or Muga Scan After
Completion Of All Anthracycline-based
(neo-) Adjuvant Chemotherapy And Prior
To The Targeted Therapy(ies) (Baseline
LVEF > 50% measured by
echocardiography or MUGA scan after
completion of all anthracycline-based
(neo-) adjuvant chemotherapy and prior
to the targeted therapy(ies)
Completion Of All Necessary Baseline
Laboratory And Radiological
Investigations (Completion of all
necessary baseline laboratory and
radiological investigations)
Eastern Cooperative Oncology Group
(ecog) Performance Status < 1  (Eastern
Cooperative Oncology Group (ECOG)
performance status < 1)
Known Hormone Receptor Status (er/pgr
Or Er Alone)  (Known hormone receptor
status (ER/PgR or ER alone))
Must Have Received At Least Four
Cycles Of An Approved Anthracycline-
based (neo-) Adjuvant Chemotherapy
Regimen  (Must have received at least
four cycles of an approved anthracycline-
based (neo-) adjuvant chemotherapy
regimen)
Non-metastatic Operable Primary
Invasive Adenocarcinoma Of The Breast
(Non-metastatic operable primary
invasive adenocarcinoma of the breast)
Overexpression And/or Amplification Of
Her2 In The Invasive Component Of The
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Primary Tumor  (Overexpression and/or
amplification of HER2 in the invasive
component of the primary tumor)
Signed Written Informed Consent
(Signed written informed consent)
Exclusion criteria*
(neo-) Or Adjuvant Chemotherapy Using
Peripheral Stem Cell Or Bone Marrow
Stem Cell Support  ((Neo-) or adjuvant
chemotherapy using peripheral stem cell
or bone marrow stem cell support)
Any Clinically Staged T4 Tumor,
Including Inflammatory Breast Cancer
(Any clinically staged T4 tumor, including
inflammatory breast cancer)
Any Of The Following Abnormal
Laboratory Tests Immediately Prior To
Randomization  (Any of the following
abnormal laboratory tests immediately
prior to randomization (see list in
instructions))
Any Prior Mediastinal Irradiation Except
Internal Mammary Node Irradiation For
The Present Breast Cancer  (Any prior
mediastinal irradiation except internal
mammary node irradiation for the
present)
Bilateral Tumors  (Bilateral tumors)
Concomitant Use Of Cyp3a4 Inhibitors
Or Inducers  (Concomitant use of
CYP3A4 inhibitors or inducers)
Concurrent Anti-cancer Treatment In
Another Investigational Trial With
Hormone Therapy Or Immunotherapy
(Concurrent anti-cancer treatment in
another investigational trial with hormone
therapy or immunotherapy)
Concurrent Anti-cancer Treatment,
Except Hormonal Therapy  (Concurrent
anti-cancer treatment, except hormonal
therapy)
History Of Any Prior (ipsi- And/or
Contralateral) Invasive Breast Carcinoma
(History of any prior (ipsi- and/or
contralateral) invasive breast carcinoma)
Malabsorption Syndrome, Disease
Significantly Affecting Gastrointestinal
Function, Or Resection Of The Stomach
Or Small Bowel, Or Person Unable To
Swallow Oral Medication  (Malabsorption
syndrome, disease significantly affecting
gastrointestinal function, or resection of
the stomach or small bowel, or person
unable to swallow oral medication)
Maximum Cumulative Dose Of
Doxorubicin >360mg/m2 Or Maximum
Cumulative Dose Of Epirubicin
>720mg/m2 Or Any Prior Anthracyclines
Unrelated To The Present Breast Cancer
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(Maximum cumulative dose of
doxorubicin >360mg/m2 or maximum
cumulative dose of epirubicin
>720mg/m2 or any prior anthracyclines
unrelated to the present breast cancer)
Multifocal Tumors  (Multifocal tumors)
Other Concurrent Serious Diseases That
May Interfere With Planned Treatment
Including Severe Pulmonary
Conditions/illness  (Other concurrent
serious diseases that may interfere with
planned treatment including severe
pulmonary conditions/illness)
Past Or Current History Of Malignant
Neoplasms, Except For Curatively
Treated Basal And Squamous Cell
Carcinoma Of The Skin Or Carcinoma In
Situ Of The Cervix  (Past or current
history of malignant neoplasms, except
for curatively treated basal and
squamous cell carcinoma of the skin or
carcinoma in situ of the cervix)
Patients With Positive Or Suspicious
Internal Mammary Nodes Identified By
Sentinel Node Technique Which Have
Not Been Irradiated Or Will Not Be
Irradiated, Or Patients With
Supraclavicular Lymph Node
Involvement  (Patients with positive or
suspicious internal mammary nodes
identified by sentinel node technique
which have not been irradiated or will not
be irradiated, or patients with
supraclavicular lymph node involvement)
Pregnant Or Lactating Women
(Pregnant or lactating women)
Prior Use Of Anti-her2 Therapy For Any
Reason Or Other Prior Biologic Or
Immunotherapy For Breast Cancer (Prior
use of anti-HER2 therapy for any reason
or other prior biologic or immunotherapy
for breast cancer)
Serious Cardiac Illness Or Medical
Conditions  (Serious cardiac illness or
medical conditions (including...))
Unresolved Or Unstable Serious Adverse
Event From Prior Adjuvant
Chemotherapy Or Radiotherapy
(Unresolved or unstable serious adverse
event from prior adjuvant chemotherapy
or radiotherapy)
Women Of Childbearing Potential
Including Women Whose Last Menstrual
Period Was <1 Year Ago Who Are
Unable Or Unwilling To Use Adequate
Contraceptive Measures During Study
Treatment  (Women of childbearing
potential including women whose last
menstrual period was <1 year ago who
are unable or unwilling to use adequate
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contraceptive measures during study
treatment)
Randomization
Date of Randomization*
Assigned Treatment Arm*
Lapatinib  (Lapatinib alone)
Lapatinib In Combination With
Trastuzumab  (Lapatinib in combination
with Trastuzumab)
Trastuzumab  (Trastuzumab alone)
Trastuzumab Followed By Lapatinib
(Trastuzumab followed by Lapatinib)
Informed consent
Date Informed consent signed*
Date of consent [for] pharmacogenetic research*
Did the patient consent to donate blood sample*
Yes
No
Did the patient consent to tumor tissue*
Yes
No
Did the patient consent to donate additional blood
sample*
Yes
No
Did the patient consent to donate fresh/frozen
tissue*
Yes
No
Gynecological status
Menopausal Status*
Above Categories Not Applicable And
Age <50  (Above categories not
applicable AND Age < 50)
Above Categories Not Applicable And
Age >= 50  (Above categories not
applicable AND Age >= 50)
Post (prior Bilateral Ovariectomy Or >12
Mo Since Lmp With No Prior
Hysterectomy)  (Post (prior bilateral
ovariectomy OR >12 mo since LMP with
no prior hysterectomy))
Pre (<6 Mo Since Lmp And No Prior
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Bilateral Ovariectomy And Not On
Estrogen Replacement)  (Pre (<6 mo
since LMP AND no prior bilateral
ovariectomy AND not on estrogen
replacement))
Date last menstrual cycle*
Date of pregnancy test*
Pregnancy test*
positive (1)
negative (2)
Not Applicable, Not Female Of Child-
bearing Potential (3)
Has the patient had a hysterectomy?*
Yes
No
Date Hysterectomy*
Unilateral Oophorectomy*
Yes
No
Side Ovariectomy *
Left (Left)
Right (Right)
Date Unilateral Oophorectomy*
Patient Status
Date of Physical exam*
Physical Examination*
Abnormal - Clinically Significant
(Abnormal - Clinically significant)
Abnormal - Not Clinically Significant
(Abnormal - Not clinically significant)
Normal (Normal)
Height
>= 0
cm
Body weight*
>= 0
kg
Body surface area
>= 0
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m²
Systolic blood pressure
mmHg
Diastolic blood pressure
mmHg
Heart rate
>= 0
bpm
ECOG performance status grade *
Fully Active, Able To Carry On All Pre-
disease Performance Without
Restriction. (0) (0)
Restricted In Physically Strenuous
Activity But Ambulatory And Able To
Carry Out Work Of A Light Or Sedentary
Nature, E.g., Light Housework, Office
Work. (1) (1)
Ambulatory And Capable Of All Selfcare
But Unable To Carry Out Any Work
Activities. Up And About More Than 50%
Of Waking Hours. (2) (2)
Capable Of Only Limited Selfcare,
Confined To Bed Or Chair More Than
50% Of Waking Hours. (3) (3)
Completely Disabled. Cannot Carry On
Any Selfcare. Totally Confined To Bed Or
Chair. (4) (4)
Dead (5) (5)
ECG
date of ECG*
Result*
Abnormal - Clinically significant
(Abnormal - Clinically significant)
Abnormal - Not clinically significant
(Abnormal - Not clinically significant)
Normal (Normal)
Cardiac Monitoring
Date Left Ventricular Ejection Fraction
Left Ventricular Ejection Fraction
%
Echocardiography*
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Yes
No
Radionuclide Ventriculogram Scan*
Yes
No
Result*
Abnormal - Clinically Significant
(Abnormal - Clinically significant)
Abnormal - Not Clinically Significant
(Abnormal - Not clinically significant)
Normal (Normal)
Symptomatic CHF*
Yes
No
NYHA Classification
Patients With Cardiac Disease But
Without Resulting Limitation Of Physical
Activity. Ordinary Physical Activity Does
Not Cause Undue Fatigue, Palpitation,
Dyspnea Or Anginal Pain. (Class I)
(Class I)
Patients With Cardiac Disease Resulting
In Slight Limitation Of Physical Activity.
They Are Comfortable At Rest. Ordinary
Physical Activity Results In Fatigue,
Palpitation, Dyspnea Or Anginal Pain.
(Class II) (Class II)
Patients With Cardiac Disease Resulting
In Marked Limitation Of Physical Activity.
They Are Comfortable At Rest. Less
Than Ordinary Activity Causes Fatigue,
Palpitation, Dyspnea Or Anginal Pain.
(Class III) (Class III)
Patients With Cardiac Disease Resulting
In Inability To Carry On Any Physical
Activity Without Discomfort. Symptoms
Of Heart Failure Or The Anginal
Syndrome May Be Present Even At
Rest. If Any Physical Activity Is
Undertaken, Discomfort Increases.
(Class IV) (Class IV)
Local Her2 Results
t*
not_useful_for_research (Cb-11/ventana
Kit )
not_useful_for_research (Dako A0485 )
not_useful_for_research (Dako
Herceptest [tm] )
not_useful_for_research (Ncl-c-erbb2-
316 )
Other Specify  (other)
not_useful_for_research (Tab-250 )
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not_useful_for_research*
Her2/Neu Status *
Equivocal  (Equivocal )
Negative  (Negative )
Non-interpretable  (Non-interpretable )
Positive  (Positive )
Percentage of invasive tumor cells with complete
membrane staining*
FISH Kit or Test Type*
Other Specify (Other)
not_useful_for_research (Vysis/path
Vysion[tm] )
not_useful_for_research*
FisH-Test*
Positive Finding  (Amplified )
Equivocal  (Equivocal )
Negative Finding  (Not Amplified )
FISH HER2/neu chromosome 17 Ratio*
Chromosome 17 copy number*
Monosomy  (Monosomy )
Normal  (Normal )
Polysomy  (Polysomy )
Test Date*
Not done*
CISH Kit or Test Type*
Other Specify  (Other)
not_useful_for_research (Ventana
Inform)
not_useful_for_research*
CISH*
Positive Finding  (Amplified )
Equivocal  (Equivocal )
Negative Finding  (Not Amplified )
Chromosome 17 copy number*
Monosomy  (Monosomy )
Normal  (Normal )
Polysomy  (Polysomy )
Hormonal Receptor Status
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ER % cells stained positive*
PgR % cells stained positive*
History Of Primary Breast Cancer
Date of diagnosis*
Tumor Laterality*
Left (Left)
Right (Right)
Clinical Size of Tumor*
N - Regional lymph node stage*
No Regional Lymph Node Metastasis
(N0) (N0)
Metastasis To Movable Ipsilateral Axillary
Lymph Node(s) (N1) (N1)
Metastasis To Ipsilateral Axillary Lymph
Node(s) Fixed Or Matted, Or In Clinically
Apparent* Ipsilateral Internal Mammary
Nodes In The Absence Of Clinically
Evident Lymph Node Metastasis (N2)
(N2)
Metastasis In Ipsilateral Infraclavicular
Lymph Node(s) With Or Without Axillary
Lymph Node Involvement, Or In Clinically
Apparent* Ipsilateral Internal Mammary
Lymph Node(s) And In The Presence Of
Clinically Evident Axillary Lymph Node
Metastasis; Or, Me (N3) (N3)
Tumor size*
Surgical margin involved by malignant neoplasm*
Yes
No
Histologic Type*
Apocrine  (Apocrine )
Cribriform  (Cribriform )
Ductal Nos  (Ductal NOS)
Invasive Nos  (Invasive NOS)
Lobular  (Lobular )
Medullary Carcinoma  (Medullary)
Micropapillary  (Micropapillary )
Mixed Ductal And Lobular  (Mixed ductal
and lobular)
Mucinous Adenocarcinoma  (Mucinous)
Other Specify  (other)
Tubular (Tubular (pure > or =90%))
Tubulolobular  (Tubulolobular )
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other*
Carcinoma in Situ *
Yes
No
Histologic Type*
Ductal Breast Carcinoma In Situ  (DCIS)
Lobular carcinoma in situ of breast
(LCIS)
Mixed Ductal And Lobular CIS (Mixed
DCIS & LCIS)
Paget's Disease of the Nipple*
Yes
No
Histologic Grade*
G1 Low Combined Histologic Grade
(favorable) (G1) (G1)
G2 Intermediate Combined Histologic
Grade (moderately Favorable) (G2) (G2)
G3 High Combined Histologic Grade
(unfavorable) (G3) (G3)
Gx Grade Cannot Be Assessed (GX)
(GX)
Lymphnode involvement*
>= 4 Positive Nodes, No Neoadjuvant
Chemotherapy (>= 4 positive nodes, no
neoadjuvant chemotherapy)
1-3 Positive Nodes, No Neoadjuvant
Chemotherapy  (1-3 positive nodes, no
neoadjuvant chemotherapy)
Node Negative, No Neoadjuvant
Chemotherapy  (Node negative, no
neoadjuvant chemotherapy)
Not Applicable (Not Applicable)
Timing of chemotherapy*
Concurrent  (Concurrently with targeted
therapy)
Sequential  (Sequentially)
Hematology And Biochemistry*
Date of blood specimen collection*
Result*
Abnormal - Clinically significant
(Abnormal - Clinically significant)
Abnormal - Not clinically significant
(Abnormal - Not clinically significant)
Normal (Normal)
History Of Primary Cancer (continued)
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Laboratory Name*
Estrogen Receptor*
negative (Negative )
positive (Positive )
unknown (Unknown)
Status of estrogen receptors of neoplasm *
Yes
No
Estrogen receptor value*
H-Score*
Allred-Score*
Remmle score*
other*
Method*
Range*
progesterone receptor*
negative (Negative )
positive (Positive )
unknown (Unknown)
Status of progesterone receptors of neoplasm *
Yes
No
Progesterone receptor value*
H-Score*
Allred-Score*
Remmle score*
other*
Method*
Range*
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Sentinel Node Sampling
Was sentinel node sampling performed*
Yes
No
Sentinel Node Biopsy Date*
Side *
Right (Left)
Left (Right)
Axillary sentinel node biopsy*
Negative Finding  (Negative)
Positive Finding  (Positive )
Internal sentinel mammary nodes biopsy*
Negative Finding  (Negative)
Positive Finding  (Positive )
Not done*
Most Extensive Primary Surgery
Operative Surgical Procedures *
Lumpectomy  (Lumpectomy )
not_coded (Modified Radical
Mastectomy )
Other  (Other )
Partial Mastectomy  (Partial Mastectomy
)
Quandrantectomy / Segmentectomy
(Quandrantectomy / Segmentectomy)
not_coded (Radical Mastectomy )
Specify*
Laterality*
Left (Left)
Right (Right)
Date of surgery*
Axillary Lymph Node Dissection
Date of Axillary Dissection*
Laterality*
Left (Left)
Right (Right)
Number of lymph nodes examined*
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Number of lymph nodes involved by malignant
neoplasm *
Largest tumor deposit*
Isolated Tumor Cells Alone (Isolated
Tumor Cells Alone)
Macrometastases  (Macrometastases)
Micromets  (Micrometastases)
None Detected  (None Detected )
Not Measured  (Not Measured )
Not done*
Chemotherapy
Chemotherapeutic agent*
Cumulative Dose*
initial dose*
planned cycles*
Intent - prior chemotherapy*
Adjuvant - intent (Adjuvant)
Neo-adjuvant - intent  (Neoadjuvant)
Date treatment started*
Date treatment stopped *
Previous Or Current Cardiovascular
Disease
not_useful_for_research*
Yes
No
not_useful_for_research*
not_useful_for_research*
not_useful_for_research (Current)
not_useful_for_research (Resolved)
not_useful_for_research*
Yes
No
not_useful_for_research*
Yes
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No
ECG
not_useful_for_research*
Abdominal Ct-scan  (Abdominal CT-
scan)
Bilateral Mammogram  (Bilateral
mammogram)
Bone Scan  (Bone scan (scintigraphy))
Bone X-ray  (Bone X-ray)
Ct Scan Of Chest  (Chest CT-scan)
Chest X-ray  (Chest X-Ray)
Computed Tomography  (CT Scan)
Endoscopy  (Endoscopy )
Left Mammogram, Only  (Left
mammogram, only)
Lymphangiogram  (Lymphangiogram )
Mammography  (Mammography )
Magnetic Resonance Imaging  (MRI)
Nuclear Scan  (Nuclear Scan )
Other  (Other )
Positron Emission Tomography  (PET
Scan)
Pet/ct Scan  (PET/CT scan)
Right Mammogram, Only  (Right
mammogram, only)
Transvaginal Ultrasound  (Transvaginal
Ultrasound)
Ultrasound  (Ultrasound )
X-ray (X-ray)
not_useful_for_research*
not_useful_for_research*
not_useful_for_research (Abdomen )
not_useful_for_research
(Abdomen/abdominal Wall )
not_useful_for_research (Bladder )
not_useful_for_research (Bone )
not_useful_for_research (Breast )
not_useful_for_research (Central
Nervous System (CNS))
not_useful_for_research (Cervix Uteri )
not_useful_for_research (Chest )
not_useful_for_research (Colon )
not_useful_for_research (Colorectal )
not_useful_for_research (Esophagus )
not_useful_for_research (Head And
Neck )
not_useful_for_research (Heart )
not_useful_for_research (Kidney )
not_useful_for_research (Liver )
not_useful_for_research (Lung )
not_useful_for_research (Lymph Node )
not_useful_for_research (Mouth (Oral
Cavity))
not_useful_for_research (Other )
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not_useful_for_research (Ovary )
not_useful_for_research (Pancreas )
not_useful_for_research (Pelvis )
not_useful_for_research (Peritoneum )
not_useful_for_research (Pleura )
not_useful_for_research (Prostate Gland
)
not_useful_for_research (Rectum )
not_useful_for_research (Skin )
not_useful_for_research (Small
Intestine)
not_useful_for_research (Spleen )
not_useful_for_research (Stomach )
not_useful_for_research (Testis
(Testicle))
not_useful_for_research (Thyroid Gland
(Thyroid))
not_useful_for_research*
not_useful_for_research*
Yes
No
not_useful_for_research*
not_useful_for_research*
Translational Research
not_useful_for_research*
not_useful_for_research (Additional
Blood Sample For Ctc (circulating Tumor
Cells) (Additional blood sample for CTC
(circulating tumor cells)))
not_useful_for_research (Additional
Blood Sample For Proteomics
(Additional blood sample for
Proteomics))
not_useful_for_research (Additional
Fresh Frozen Tumor Samples (Additional
fresh frozen tumor samples))
not_useful_for_research (Blood Sample
For Pgx)
not_useful_for_research (FFPE tumor
block)
not_useful_for_research (Tumor Tissue
For Pgx)
not_useful_for_research*
not_useful_for_research*
Yes
No
Central Her2 Testing Form - FISH
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Percentage greater than or equal to 3
Chromosome 17 signals*
NACA (No apparent Chromosome 17 anomaly)*
Yes
No
Why no result*
Hybridization Failure (Hybridization
Failure)
Insufficient Tissue  (Insufficient Tissue )
Interductal Only  (Interductal Only )
No Cancer Tissue  (No Cancer Tissue )
Other (Other)
Specify*
Other features*
Duplication Of Her2  (Duplication Of
Her2 )
Most Cells With No Centromere 17
(Most Cells With No Centromere 17 )
Negative Her2  (Negative Her2 )
Normal Her2  (Normal Her2 )
Not A Small Clone  (Not A Small Clone )
Other  (Other )
Small Clone Of Amplification  (Small
Clone Of Amplification )
Central Her2 Testing Form - IHC
not_useful_for_research*
Uniformity of staining*
Absent (Absent)
Present (Present)
Homogeneous dark circumferential pattern*
Absent (Absent)
Present (Present)
Her-2/neu*
Weak To Moderate Staining, Complete
>10% Cells (Weak to moderate staining,
complete >10% cells ) (Equivocal - 2+)
Strong Staining, Complete >10% <=30%
Cells (Strong staining, complete >10%
<=30% cells ) (Equivocal - 3+)
Insufficient Tissue/hybridization Failure
(Insufficient tissue/hybridization failure)
No Staining Or Membranous Staining
<=10% Cells (No staining or
membranous staining <=10% cells )
(Negative - 0)
Faint Membrane Staining, Partial >10%
Cells (Faint membrane staining, partial
>10% cells ) (Negative - 1+)
Strong Staining, Complete >30% Cells
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(Strong staining, complete >30% cells )
(Positive - 3+)
Is there vascular invasion*
Yes
No
Suitable for TMA*
Yes
No
Radiotherapy
prior Radiation Therapy*
Yes
No
RT Site*
Side *
Left (Left)
Right (Right)
Total radiation dose *
Dose UOM*
Centigray (cGy)
Gray (Gy)
Radiation Absorbed Dose (Rad)
Start Radiotherapy*
End Radiotherapy*
Hormone therapy
Has the patient received hormone therapy before
or during the trial
Yes
No
Therapeutic procedure *
Single dose characteristic *
Unit type (qualifier value) *
Milligram (mg)
Not Applicable (N/A)
Date treatment started - endocrine therapy*
Date treatment stopped - endocrine therapy*
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ongoing at time of study completion*
Yes (Yes)
Concomitant Treatment
Name of concomitant treatment*
Intent*
Curative treatment (Curative)
Prevention (Prophylaxis)
Date treatment started*
Date stopped*
Ongoing*
Yes (Yes)
Administration of Study Drug
Date Agent Administered*
Single dose characteristic *
Cumulative Dose*
Was treatment delayed*
Yes
No
Specify code*
Administrative Reasons  (Administrative
Reasons )
Adverse Event Other Than Hematologic
Or Cardiac  (Adverse Event Other Than
Hematologic Or Cardiac )
Cardiac Adverse Event (Cardiac Adverse
Event)
Dosing Error  (Dosing Error )
Hematologic Adverse Event
(Hematologic Adverse Event )
Other  (Other )
Subject Non-compliance (Subject Non-
compliance)
specify*
Chemotherapeutic drug level decreased*
Yes
No
Specify code*
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Administrative Reasons  (Administrative
Reasons )
Adverse Event Other Than Hematologic
Or Cardiac  (Adverse Event Other Than
Hematologic Or Cardiac )
Cardiac Adverse Event (Cardiac Adverse
Event)
Dosing Error  (Dosing Error )
Hematologic Adverse Event
(Hematologic Adverse Event )
Other  (Other )
Subject Non-compliance (Subject Non-
compliance)
specify*
Chemotherapy
relapse treatment - chemotherapy*
Yes
No
Agent Name*
Total No. Cycles*
initial dose*
Dose UOM*
Miligram per Meter squared (mg/m2)
Date started*
Date stopped*
Targeted Therapy
Did the patient receive additional target therapy
after recurrence of breast cancer or second
primary malignancy of contralateral breast
cancer*
Yes
No
Agent Name*
Total No. Cycles*
initial dose*
21 / 30
Breast Cancer ALTTO Study BIG 2-06/N063D NCT00490139
Dose UOM*
Miligram per Meter squared (mg/m2)
Date started*
Date stopped*
Hormonetherapy
relapse treatment - endocrine therapy*
Yes
No
Agent Name*
Total No. Cycles*
initial dose*
Dose UOM*
Miligram per Meter squared (mg/m2)
Not Applicable (N/A)
Date started*
Date stopped*
Radiotherapy
relapse treatment - radiotherapy*
Yes
No
Radiation Therapy Site*
Side*
Left (Left)
Right (Right)
Total Dose*
Dose UOM*
Miligram per Meter squared (mg/m2)
Radiation Therapy Start Date*
Radiation Therapy End Date*
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Surgery
relapse treatment - Operative Surgical
Procedures*
Yes
No
Surgical site*
Surgery Date*
Adverse Event (AE)
AE Name*
Laboratory Values*
Yes
No
Gastrointestinal system *
Yes
No
Genitourinary system *
Yes
No
Skin*
Yes
No
Allergic Reaction*
Yes
No
Fever *
Yes
No
Infection*
Yes
No
Entire sensory organ*
Yes
No
General symptom*
Yes
No
Lung/Larynx*
Yes
No
Endocrine system *
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Yes
No
Cardiac General Other *
Yes
No
Hemoglobin*
Yes
No
Aspartate Transaminase *
Yes
No
Alanine Transaminase*
Yes
No
Creatinine*
Yes
No
Peripheral Nerves *
Yes
No
Hemorrhage *
Yes
No
Bilirubin *
Yes
No
Leukocytes*
Yes
No
Alkaline Phosphatase *
Yes
No
Proteinuria*
Yes
No
Hair *
Yes
No
Obstipation *
Yes
No
Diarrhea*
Yes
No
Hematuria*
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Yes
No
Pain *
Yes
No
Blood Platelets *
Yes
No
Nausea *
Yes
No
Heart Rhythm *
Yes
No
Pericarditis *
Yes
No
Conscious*
Yes
No
Dyspnea*
Yes
No
Cystitis*
Yes
No
Erbrechen*
Yes
No
1024 more adverse events*
SAE reported*
Yes
No
CTCAE Begin Date*
CTCAE End Date*
CTC Adverse Event Grade*
CTC Adverse Event Outcomme*
Adverse Event Was Fatal  (fatal)
Adverse Event Has Improved  (improved)
Adverse Event Is Ongoing  (ongoing)
Adverse Event Is Resolved  (resolved)
Adverse Event Is Resolved With
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Sequelae  (resolved with sequelae)
Action Taken at Time of Adverse Event*
There Was No Action Taken Based On
The Adverse Event  (none)
Other Treatment Was Required As A
Result Of The Adverse Event  (other
treatment required)
Protocol Treatment Was Delayed As A
Result Of The Adverse Event  (protocol
treatment delayed)
Protocol Treatment Was Discontinued As
A Result Of The Adverse Event
(protocol treatment discontinued)
Study Dose Was Reduced As A Result
Of The Adverse Event  (study dose
reduced)
relation to study drug*
Yes
No
Second Primary Malignancy and
Contralateral Breast Cancer
Recurrence Tumor*
Date of First Recurrence or Progression*
Medical Examination *
Physical Examination (Clinical)
Radiology (Radiological)
Biopsy*
Yes
No
Biopsy Date*
histologic type*
Patient Status
Physical Examination*
Not done*
Are there any changes since the previous
assessment*
Yes
No
Are there any changes since the previous
assessment*
26 / 30
Breast Cancer ALTTO Study BIG 2-06/N063D NCT00490139
Adverse Event  (Adverse Event)
Patient died (Death )
Lost to follow up (Lost To Follow-up)
Patient Withdrew Study Consent
(Patient withdrew study consent)
Recurrence Of Disease  (Recurrence of
disease)
Second Primary Malignancy Or
Contralateral Breast Cancer  (Second
primary malignancy or contralateral
breast cancer)
Significant Cardiac Disease  (Significant
cardiac disease)
Date last contact*
ECOG performance status grade *
Fully Active, Able To Carry On All Pre-
disease Performance Without
Restriction. (0) (0)
Restricted In Physically Strenuous
Activity But Ambulatory And Able To
Carry Out Work Of A Light Or Sedentary
Nature, E.g., Light Housework, Office
Work. (1) (1)
Ambulatory And Capable Of All Selfcare
But Unable To Carry Out Any Work
Activities. Up And About More Than 50%
Of Waking Hours. (2) (2)
Capable Of Only Limited Selfcare,
Confined To Bed Or Chair More Than
50% Of Waking Hours. (3) (3)
Completely Disabled. Cannot Carry On
Any Selfcare. Totally Confined To Bed Or
Chair. (4) (4)
Dead (5) (5)
Systolic Blood Pressure*
Diastolic Blood Pressure *
Cardiac Monitoring
Date Left Ventricular Ejection Fraction *
Left Ventricular Ejection Fraction *
Echocardiography*
Yes
No
Radionuclide Ventriculogram Scan*
Yes
No
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Result*
Abnormal - Clinically Significant
(Abnormal - Clinically significant)
Abnormal - Not Clinically Significant
(Abnormal - Not clinically significant)
Normal (Normal)
Symptomatic CHF*
Yes
No
New York Heart Association*
Patients With Cardiac Disease But
Without Resulting Limitation Of Physical
Activity. Ordinary Physical Activity Does
Not Cause Undue Fatigue, Palpitation,
Dyspnea Or Anginal Pain. (Class I)
(Class I)
Patients With Cardiac Disease Resulting
In Slight Limitation Of Physical Activity.
They Are Comfortable At Rest. Ordinary
Physical Activity Results In Fatigue,
Palpitation, Dyspnea Or Anginal Pain.
(Class II) (Class II)
Patients With Cardiac Disease Resulting
In Marked Limitation Of Physical Activity.
They Are Comfortable At Rest. Less
Than Ordinary Activity Causes Fatigue,
Palpitation, Dyspnea Or Anginal Pain.
(Class III) (Class III)
Patients With Cardiac Disease Resulting
In Inability To Carry On Any Physical
Activity Without Discomfort. Symptoms
Of Heart Failure Or The Anginal
Syndrome May Be Present Even At
Rest. If Any Physical Activity Is
Undertaken, Discomfort Increases.
(Class IV) (Class IV)
Mammogram
Mammogram*
Bilateral (Bilateral)
Left (Left)
Right (Right)
Date of Test*
Not done*
Are there any clinically significant abnormalites*
Yes
No
specify*
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Hematoly and Biochemistry
Date of blood specimen collection*
Result*
Abnormal - Clinically significant
(Abnormal - Clinically significant)
Abnormal - Not clinically significant
(Abnormal - Not clinically significant)
Normal (Normal)
Survival Follow-Up
Vital status*
Alive (Alive)
Dead (Dead)
Lost to follow up (Lost To Follow-up)
Dead*
Date of last contact*
Investigator Signature*
Date*
Treatment Completion
not_useful_for_research*
not_useful_for_research (No)
not_useful_for_research (Not Applicable)
not_useful_for_research (Yes)
not_useful_for_research*
not_useful_for_research (No)
not_useful_for_research (Not Applicable)
not_useful_for_research (Yes)
not_useful_for_research*
not_useful_for_research (No)
not_useful_for_research (Not Applicable)
not_useful_for_research (Yes)
Reasons for treatment discontinuation*
Adverse Event  (Adverse Event)
contralateral breast cancer (contralateral
breast cancer)
Death (Death )
Lost To Follow-up: C48227  (Lost to
follow-up)
Protocol Violation  (Protocol violation)
Recurrence of disease (Recurrence of
disease)
second primary malignancy (second
primary malignancy)
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Subject Decided To Withdraw From
Investigational Product But Is Continuing
To Be Followed Per Protocol  (Subject
decided to withdraw from investigational
product but is continuing to be followed
per protocol)
Subject Decided To Withdraw From The
Study  (Subject decided to withdraw from
the study)
Date of last contact within treatment period*
Additional Comments
CRF Page Number*
Comments*
Investigator Signature*
Date*
Death Form
Date of death*
Cause of death*
Adverse Event During Study  (Adverse
event during study)
Adverse Event During Treatment Given
After Recurrence  (Adverse event during
treatment given after recurrence)
Breast Cancer Progression  (Breast
cancer progression)
Malignant Disease Other Than Breast
Cancer  (Malignant disease other than
breast cancer)
other cause of death (Other)
other cause of death*
Was autopsy performed*
unknown (0)
Yes (1)
No (2)
Please summarize findings*
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ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment
Optimisation) Study; BIG 2-06/N063D NCT00490139
A Randomised, Multi-centre, Open-label, Phase III Study of
Adjuvant Lapatinib, Trastuzumab, Their Sequence and
Their Combination in Patients With HER2/ErbB2 Positive
Primary Breast Cancer
NCT00490139
All rights reserved. Please visit https://medical-data-
models.org/forms/12130
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Header Module
Studie Nr*
Labor Nr*
Institutions-Nr.*
Patienteninitialien*
Institution*
Registration Header
Gruppen-Protokoll Nr*
Gruppen-Code*
Protocol Titel*
Nr. Krankenakte*
Gruppen-Code Teilnehmer*
amended data*
Ja
Nein
Registrierungs-Typ
erste Einreichung (First Submission)
zweite Einrichung (Second Submission )
erste Einreichung
Pre-Registration Eligibility Checklist
Cover Sheet/Demographics (1)
Eligibility Checklist (2)
Contact Person For Pathology Results
Nachname*
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Vorname*
Telefon*
Fax*
E-Mail*
Patient Demographics
Patienten-Geschlecht*
Female (1)
Male (2)
Unknown (3)
Patienten-Geburtsdatum*
Postleitzahl Patient*
Wohnort*
Method of Payment*
Rasse*
amerikaner Ureinwohner (American
Indian or Alaska Native)
Asiate (Asian)
Afroamerikaner (Black or African
American)
Pazifikinsulaner (Native Hawaiian or
other Pacific Islander)
Nicht berichtet (Not Reported)
Unbekannt (Unknown)
Kaukasier (White)
Ethnische Gruppe*
Hispanoamerikanische Herkunft
(HISPANIC OR LATINO)
keine Hispanoamerikanische Herkunft
(NOT HISPANIC OR LATINO)
Nicht berichtet (Not reported)
Unbekannt (Unknown)
Eligibility Screening Form
Einschlusskriterien*
Alter mindestens 18  (Age at least 18
years)
Baseline Lvef above 50% Measured By
Echocardiography Or Muga Scan After
Completion Of All Anthracycline-based
(neo-) Adjuvant Chemotherapy And Prior
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To The Targeted Therapy(ies) (Baseline
LVEF above 50% measured by
echocardiography or MUGA scan after
completion of all anthracycline-based
(neo-) adjuvant chemotherapy and prior
to the targeted therapy(ies)
Completion Of All Necessary Baseline
Laboratory And Radiological
Investigations (Completion of all
necessary baseline laboratory and
radiological investigations)
Eastern Cooperative Oncology Group
(ecog) Performance Status < 1  (Eastern
Cooperative Oncology Group (ECOG)
performance status < 1)
Hormon Rezeptor Status
(Östrogen/Progesteron oder Östrogen
alleine) (Known hormone receptor status
(ER/PgR or ER alone))
Must Have Received At Least Four
Cycles Of An Approved Anthracycline-
based (neo-) Adjuvant Chemotherapy
Regimen  (Must have received at least
four cycles of an approved anthracycline-
based (neo-) adjuvant chemotherapy
regimen)
nicht metastasiertes operables Mamma-
Karzinom (Non-metastatic operable
primary invasive adenocarcinoma of the
breast)
Her2Neu positives Mamma-Karzinom
(Overexpression and/or amplification of
HER2 in the invasive component of the
primary tumor)
Einverständniserklärung unterschrieben
(Signed written informed consent)
Ausschlusskriterien*
(neo-) Or Adjuvant Chemotherapy Using
Peripheral Stem Cell Or Bone Marrow
Stem Cell Support  ((Neo-) or adjuvant
chemotherapy using peripheral stem cell
or bone marrow stem cell support)
klinisches T4 Stadium (Any clinically
staged T4 tumor, including inflammatory
breast cancer)
Any Of The Following Abnormal
Laboratory Tests Immediately Prior To
Randomization  (Any of the following
abnormal laboratory tests immediately
prior to randomization (see list in
instructions))
Any Prior Mediastinal Irradiation Except
Internal Mammary Node Irradiation For
The Present Breast Cancer  (Any prior
mediastinal irradiation except internal
mammary node irradiation for the
present)
beidseitige Tumoren (Bilateral tumors)
Concomitant Use Of Cyp3a4 Inhibitors
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Or Inducers  (Concomitant use of
CYP3A4 inhibitors or inducers)
Concurrent Anti-cancer Treatment In
Another Investigational Trial With
Hormone Therapy Or Immunotherapy
(Concurrent anti-cancer treatment in
another investigational trial with hormone
therapy or immunotherapy)
gleichzeitige Tumor-Therapie, außer
Hormontherapie (Concurrent anti-cancer
treatment, except hormonal therapy)
Mammakarzinom in der Vorgeschichte
(History of any prior (ipsi- and/or
contralateral) invasive breast carcinoma)
Malabsorption Syndrome, Disease
Significantly Affecting Gastrointestinal
Function, Or Resection Of The Stomach
Or Small Bowel, Or Person Unable To
Swallow Oral Medication  (Malabsorption
syndrome, disease significantly affecting
gastrointestinal function, or resection of
the stomach or small bowel, or person
unable to swallow oral medication)
Maximum Cumulative Dose Of
Doxorubicin above 360mg/m2 Or
Maximum Cumulative Dose Of Epirubicin
above 720mg/m2 Or Any Prior
Anthracyclines Unrelated To The Present
Breast Cancer  (Maximum cumulative
dose of doxorubicin above 360mg/m2 or
maximum cumulative dose of epirubicin
above 720mg/m2 or any prior
anthracyclines unrelated to the present
breast cancer)
multifokaler Tumor (Multifocal tumors)
Other Concurrent Serious Diseases That
May Interfere With Planned Treatment
Including Severe Pulmonary
Conditions/illness  (Other concurrent
serious diseases that may interfere with
planned treatment including severe
pulmonary conditions/illness)
Past Or Current History Of Malignant
Neoplasms, Except For Curatively
Treated Basal And Squamous Cell
Carcinoma Of The Skin Or Carcinoma In
Situ Of The Cervix  (Past or current
history of malignant neoplasms, except
for curatively treated basal and
squamous cell carcinoma of the skin or
carcinoma in situ of the cervix)
Patients With Positive Or Suspicious
Internal Mammary Nodes Identified By
Sentinel Node Technique Which Have
Not Been Irradiated Or Will Not Be
Irradiated, Or Patients With
Supraclavicular Lymph Node
Involvement  (Patients with positive or
suspicious internal mammary nodes
identified by sentinel node technique
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which have not been irradiated or will not
be irradiated, or patients with
supraclavicular lymph node involvement)
Schwanger oder stillende Frau (Pregnant
or lactating women)
Prior Use Of Anti-her2 Therapy For Any
Reason Or Other Prior Biologic Or
Immunotherapy For Breast Cancer (Prior
use of anti-HER2 therapy for any reason
or other prior biologic or immunotherapy
for breast cancer)
Serious Cardiac Illness Or Medical
Conditions  (Serious cardiac illness or
medical conditions (including...))
Unresolved Or Unstable Serious Adverse
Event From Prior Adjuvant
Chemotherapy Or Radiotherapy
(Unresolved or unstable serious adverse
event from prior adjuvant chemotherapy
or radiotherapy)
Women Of Childbearing Potential
Including Women Whose Last Menstrual
Period Was <1 Year Ago Who Are
Unable Or Unwilling To Use Adequate
Contraceptive Measures During Study
Treatment  (Women of childbearing
potential including women whose last
menstrual period was <1 year ago who
are unable or unwilling to use adequate
contraceptive measures during study
treatment)
Randomization
Date of Randomization*
Assigned Treatment Arm*
Lapatinib  (Lapatinib alone)
Lapatinib In Combination With
Trastuzumab  (Lapatinib in combination
with Trastuzumab)
Trastuzumab  (Trastuzumab alone)
Trastuzumab Followed By Lapatinib
(Trastuzumab followed by Lapatinib)
Informed consent
Datum Einverstädniserklärung*
Datum Einverstädniserklärung für
Pharmakogenetische Tests*
Datum Einverstädniserklärung für Blutproben*
Ja
Nein
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Datum Einverstädniserklärung für Tumorgewebe*
Ja
Nein
Datum Einverstädniserklärung für zusätzliche
Blutproben*
Ja
Nein
Datum Einverstädniserklärung für gefrorene
Proben*
Ja
Nein
Patient Status
Datum körperliche Untersuchung*
körperliche Untersuchung*
auffällig, klinisch signifikant (Abnormal -
Clinically significant)
auffällig, klinisch nicht signifikant
(Abnormal - Not clinically significant)
unauffällig (Normal)
Größe*
Körpergewicht*
Körperoberfläche*
Systolischer Blutdruck*
Diastolischer Blutdruck*
Herzfrequenz*
ECOG Leistungszustand*
0 (0)
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
Menopausenstatus
Kategorien nicht anwendbar, Alter unter
50 (Above categories not applicable AND
Age < 50)
Kategorien nicht anwendbar, älter als 50
(Above categories not applicable AND
Age at least 50)
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Postmenopause (Post (prior bilateral
ovariectomy OR more than 12 mo since
LMP with no prior hysterectomy))
Prämenopause (Pre (<6 mo since LMP
AND no prior bilateral ovariectomy AND
not on estrogen replacement))
Datum letzte Menstruation
Datum Schwangerschaftstest
Schwangerschaftstest
negativ (negative)
nicht anwendbar (not applicable, not
female of child-bearing potential)
positiv (positive)
Hatte die Patientin eine Hysterektomie?
Ja
Nein
Datum Hysterektomie
Einseitige Ovarektomie
Ja
Nein
Seite Ovarektomie
links (Left)
rechts (Right)
Datum Einseitige Ovarektomie
ECG
date of ECG*
Result*
auffällig, klinisch signifikant (Abnormal -
Clinically significant)
auffällig, klinisch nicht signifikant
(Abnormal - Not clinically significant)
unauffällig (Normal)
Cardiac Monitoring
Datum Linksventrikuläre Ejektionsfraktion*
Linksventrikuläre Ejektionsfraktion*
Echokardiographie*
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Ja
Nein
Radionuklidventrikulographie *
Ja
Nein
Ergebnis*
auffällig, klinisch signifikant (Abnormal -
Clinically significant)
auffällig, klinisch nicht signifikant
(Abnormal - Not clinically significant)
unauffällig (Normal)
Symptomatic CHF*
Ja
Nein
NYHA Classification*
Patients With Cardiac Disease But
Without Resulting Limitation Of Physical
Activity. Ordinary Physical Activity Does
Not Cause Undue Fatigue, Palpitation,
Dyspnea Or Anginal Pain. (Class I)
(Class I)
Patients With Cardiac Disease Resulting
In Slight Limitation Of Physical Activity.
They Are Comfortable At Rest. Ordinary
Physical Activity Results In Fatigue,
Palpitation, Dyspnea Or Anginal Pain.
(Class II) (Class II)
Patients With Cardiac Disease Resulting
In Marked Limitation Of Physical Activity.
They Are Comfortable At Rest. Less
Than Ordinary Activity Causes Fatigue,
Palpitation, Dyspnea Or Anginal Pain.
(Class III) (Class III)
Patients With Cardiac Disease Resulting
In Inability To Carry On Any Physical
Activity Without Discomfort. Symptoms
Of Heart Failure Or The Anginal
Syndrome May Be Present Even At
Rest. If Any Physical Activity Is
Undertaken, Discomfort Increases.
(Class IV) (Class IV)
Local Her2 Results
Staining Antibody*
nicht_sinnvoll_für_Untersuchung (Cb-
11/ventana Kit )
nicht_sinnvoll_für_Untersuchung (Dako
A0485 )
nicht_sinnvoll_für_Untersuchung (Dako
Herceptest [tm] )
nicht_sinnvoll_für_Untersuchung (Ncl-c-
erbb2-316 )
nicht_sinnvoll_für_Untersuchung (other)
nicht_sinnvoll_für_Untersuchung (Tab-
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250 )
nicht_sinnvoll_für_Untersuchung*
Her2/Neu Status *
fraglich (Equivocal )
negativ (Negative )
Nicht auswertbar (Non-interpretable )
positiv (Positive )
Percentage of invasive tumor cells with complete
membrane staining*
FISH Kit or Test Type*
nicht_sinnvoll_für_Untersuchung (Other)
nicht_sinnvoll_für_Untersuchung
(Vysis/path Vysion[tm] )
nicht_sinnvoll_für_Untersuchung*
FisH-Test*
positiv (Amplified )
fraglich (Equivocal )
negativ (Not Amplified )
FISH HER2/neu chromosome 17 Ratio*
Chromosome 17 copy number*
Monosomy  (Monosomy )
Normal  (Normal )
Polysomy  (Polysomy )
Test Datum*
nicht durchgeführt*
CISH Kit or Test Type*
nicht_sinnvoll_für_Untersuchung (Other)
nicht_sinnvoll_für_Untersuchung
(Ventana Inform)
nicht_sinnvoll_für_Untersuchung*
CISH*
positiv (Amplified )
fraglich (Equivocal )
negativ (Not Amplified )
Chromosome 17 copy number*
Monosomy  (Monosomy )
Normal  (Normal )
Polysomy  (Polysomy )
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Hormonal Receptor Status
Östrogenrezeptor-positive Zellen %*
Progesteronrezeptor-positive Zellen %*
History Of Primary Breast Cancer
Diagnosedatum*
Körperseite Tumor*
links (Left)
rechts (Right)
klinische Tumorgröße*
N - Stadium der regionalen Lymphknoten*
N0 Stadium  (N0)
N1 Stadium  (N1)
N2 Stadium (N2)
N3 Stadium (N3)
Tumorgröße*
Schnittrand infiltiert durch Tumor*
Ja
Nein
histologischer Typ*
apokrin (Apocrine )
Cribriform  (Cribriform )
Duktales Karzinom (Ductal NOS)
invasives Karzinom (Invasive NOS)
invasives lobuläre Karzinom (Lobular )
Medulläres Karzinom (Medullary)
Mikropapillär (Micropapillary )
Gemischt, duktal und lobulär (Mixed
ductal and lobular)
Muzinöses Adenokarzinom (Mucinous)
andere (other)
tubulär (Tubular (pure at least 90%))
Tubulolobulär  (Tubulolobular )
andere*
Carcinoma in Situ *
Ja
Nein
histologischer Typ*
DCIS (DCIS)
lobuläres Carcinoma in situ (LCIS)
Gemischt, duktales und lobuläres CIS
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(Mixed DCIS & LCIS)
Morbus Paget der Mamille*
Ja
Nein
Histopathologisches Grading*
G1 gut differenziert (G1)
G2 mäßig differenziert (G2)
G3 schlecht differenziert (G3)
nicht bestimmbar (GX)
Lymphknotenbefall*
1-3 Positive Nodes, No Neoadjuvant
Chemotherapy  (1-3 positive nodes, no
neoadjuvant chemotherapy)
at least 4 Positive Nodes, No
Neoadjuvant Chemotherapy (at least 4
positive nodes, no neoadjuvant
chemotherapy)
Node Negative, No Neoadjuvant
Chemotherapy  (Node negative, no
neoadjuvant chemotherapy)
nicht anwendbar (Not Applicable)
Timing of chemotherapy*
Concurrent  (Concurrently with targeted
therapy)
Sequential  (Sequentially)
Hematology And Biochemistry*
Date of blood specimen collection*
Result*
auffällig, klinisch signifikant (Abnormal -
Clinically significant)
auffällig, klinisch nicht signifikant
(Abnormal - Not clinically significant)
unauffällig (Normal)
History Of Primary Cancer (continued)
Name Labor*
Östrogen-Rezeptor*
negativ (Negative )
positiv (Positive )
unbekannt (Unknown)
Stauts Östrogenrezeptor im Tumor*
Ja
Nein
Wert Östrogenrezeptor*
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H-Score*
Allred-Score*
Remmle score*
other*
Method*
Range*
Progesteron-Rezeptor*
negativ (Negative )
positiv (Positive )
unbekannt (Unknown)
Stauts Progesteronrezeptor im Tumor*
Ja
Nein
Wert Progesteronrezeptor*
H-Score*
Allred-Score*
Remmle score*
other*
Method*
Range*
Sentinel Node Sampling
Durchführung Sentinellymphknotenbiopsie*
Ja
Nein
Datum Sentinellymphknotenbiopsie*
Körperseite*
rechts (Left)
links (Right)
Sentinellymphknoten Biospie Axilla*
negativ (Negative)
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positiv (Positive )
Sentinel Biopsie der internen Brustlymphknoten*
negativ (Negative)
positiv (Positive )
nicht durchgeführt*
Most Extensive Primary Surgery
Operation*
Lumpektomie (Lumpectomy )
nicht_kodiert (Modified Radical
Mastectomy )
andere (Other )
Paritielle Mastektomie (Partial
Mastectomy )
Segmentale Mastektomie
(Quandrantectomy / Segmentectomy)
nicht_kodiert (Radical Mastectomy )
genauere Bezeichnung*
Seite*
links (Left)
rechts (Right)
Datum der OP*
Axilladissektion
Datum Axilladissektion*
Seite*
links (Left)
rechts (Right)
Anzahl der untersuchten Lymphknoten*
Anzahl der beteiligten Lymphknoten *
Largest tumor deposit*
Isolated Tumor Cells Alone (Isolated
Tumor Cells Alone)
Macrometastases  (Macrometastases)
Micromets  (Micrometastases)
None Detected  (None Detected )
Not Measured  (Not Measured )
nicht durchgeführt*
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Chemotherapy
Chemotherapie Substanz*
kumulative Dosis*
erste Dosis*
Zyklen geplant*
Intention - letzte Chemotherapie*
Adjuvant (Adjuvant)
Neoadjuvant (Neoadjuvant)
Datum Beginn*
Datum Ende*
Previous Or Current Cardiovascular
Disease
nicht_sinnvoll_für_Untersuchung*
Ja
Nein
nicht_sinnvoll_für_Untersuchung*
nicht_sinnvoll_für_Untersuchung*
nicht_sinnvoll_für_Untersuchung
(Current)
nicht_sinnvoll_für_Untersuchung
(Resolved)
nicht_sinnvoll_für_Untersuchung*
Ja
Nein
nicht_sinnvoll_für_Untersuchung*
Ja
Nein
ECG
nicht_sinnvoll_für_Untersuchung*
nicht_sinnvoll_für_Untersuchung
(Abdominal CT-scan)
nicht_sinnvoll_für_Untersuchung
(Bilateral mammogram)
nicht_sinnvoll_für_Untersuchung (Bone
scan (scintigraphy))
nicht_sinnvoll_für_Untersuchung (Bone
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X-ray)
nicht_sinnvoll_für_Untersuchung (Chest
CT-scan)
nicht_sinnvoll_für_Untersuchung (Chest
X-Ray)
nicht_sinnvoll_für_Untersuchung (CT
Scan)
nicht_sinnvoll_für_Untersuchung
(Endoscopy )
nicht_sinnvoll_für_Untersuchung (Left
mammogram, only)
nicht_sinnvoll_für_Untersuchung
(Lymphangiogram )
nicht_sinnvoll_für_Untersuchung
(Mammography )
nicht_sinnvoll_für_Untersuchung (MRI)
nicht_sinnvoll_für_Untersuchung
(Nuclear Scan )
nicht_sinnvoll_für_Untersuchung (Other )
nicht_sinnvoll_für_Untersuchung (PET
Scan)
nicht_sinnvoll_für_Untersuchung
(PET/CT scan)
nicht_sinnvoll_für_Untersuchung (Right
mammogram, only)
nicht_sinnvoll_für_Untersuchung
(Transvaginal Ultrasound)
nicht_sinnvoll_für_Untersuchung
(Ultrasound )
nicht_sinnvoll_für_Untersuchung (X-ray)
nicht_sinnvoll_für_Untersuchung*
nicht_sinnvoll_für_Untersuchung*
nicht_sinnvoll_für_Untersuchung
(Abdomen )
nicht_sinnvoll_für_Untersuchung
(Abdomen/abdominal Wall )
nicht_sinnvoll_für_Untersuchung
(Bladder )
nicht_sinnvoll_für_Untersuchung (Bone )
nicht_sinnvoll_für_Untersuchung (Breast
)
nicht_sinnvoll_für_Untersuchung
(Central Nervous System (CNS))
nicht_sinnvoll_für_Untersuchung (Cervix
Uteri )
nicht_sinnvoll_für_Untersuchung (Chest
)
nicht_sinnvoll_für_Untersuchung (Colon
)
nicht_sinnvoll_für_Untersuchung
(Colorectal )
nicht_sinnvoll_für_Untersuchung
(Esophagus )
nicht_sinnvoll_für_Untersuchung (Head
And Neck )
nicht_sinnvoll_für_Untersuchung (Heart )
nicht_sinnvoll_für_Untersuchung (Kidney
)
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nicht_sinnvoll_für_Untersuchung (Liver )
nicht_sinnvoll_für_Untersuchung (Lung )
nicht_sinnvoll_für_Untersuchung (Lymph
Node )
nicht_sinnvoll_für_Untersuchung (Mouth
(Oral Cavity))
nicht_sinnvoll_für_Untersuchung (Other )
nicht_sinnvoll_für_Untersuchung (Ovary
)
nicht_sinnvoll_für_Untersuchung
(Pancreas )
nicht_sinnvoll_für_Untersuchung (Pelvis
)
nicht_sinnvoll_für_Untersuchung
(Peritoneum )
nicht_sinnvoll_für_Untersuchung (Pleura
)
nicht_sinnvoll_für_Untersuchung
(Prostate Gland )
nicht_sinnvoll_für_Untersuchung
(Rectum )
nicht_sinnvoll_für_Untersuchung (Skin )
nicht_sinnvoll_für_Untersuchung (Small
Intestine)
nicht_sinnvoll_für_Untersuchung (Spleen
)
nicht_sinnvoll_für_Untersuchung
(Stomach )
nicht_sinnvoll_für_Untersuchung (Testis
(Testicle))
nicht_sinnvoll_für_Untersuchung
(Thyroid Gland (Thyroid))
nicht_sinnvoll_für_Untersuchung*
nicht_sinnvoll_für_Untersuchung*
Ja
Nein
nicht_sinnvoll_für_Untersuchung*
nicht_sinnvoll_für_Untersuchung*
Translational Research
nicht_sinnvoll_für_Untersuchung*
nicht_sinnvoll_für_Untersuchung
(Additional Blood Sample For Ctc
(circulating Tumor Cells) (Additional
blood sample for CTC (circulating tumor
cells)))
nicht_sinnvoll_für_Untersuchung
(Additional Blood Sample For
Proteomics (Additional blood sample for
Proteomics))
nicht_sinnvoll_für_Untersuchung
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(Additional Fresh Frozen Tumor Samples
(Additional fresh frozen tumor samples))
nicht_sinnvoll_für_Untersuchung (Blood
Sample For Pgx)
nicht_sinnvoll_für_Untersuchung (FFPE
tumor block)
nicht_sinnvoll_für_Untersuchung (Tumor
Tissue For Pgx)
nicht_sinnvoll_für_Untersuchung*
nicht_sinnvoll_für_Untersuchung*
Ja
Nein
Central Her2 Testing Form - FISH
Percentage greater than or equal to 3
Chromosome 17 signals*
NACA (No apparent Chromosome 17 anomaly)*
Ja
Nein
Why no result*
nicht_sinnvoll_für_Untersuchung
(Hybridization Failure)
nicht_sinnvoll_für_Untersuchung
(Insufficient Tissue )
nicht_sinnvoll_für_Untersuchung
(Interductal Only )
nicht_sinnvoll_für_Untersuchung (No
Cancer Tissue )
nicht_sinnvoll_für_Untersuchung (Other)
Specify*
Other features*
nicht_sinnvoll_für_Untersuchung
(Duplication Of Her2 )
nicht_sinnvoll_für_Untersuchung (Most
Cells With No Centromere 17 )
nicht_sinnvoll_für_Untersuchung
(Negative Her2 )
nicht_sinnvoll_für_Untersuchung
(Normal Her2 )
nicht_sinnvoll_für_Untersuchung (Not A
Small Clone )
nicht_sinnvoll_für_Untersuchung (Other )
nicht_sinnvoll_für_Untersuchung (Small
Clone Of Amplification )
Central Her2 Testing Form - IHC
nicht_sinnvoll_für_Untersuchung*
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Uniformity of staining*
Absent (Absent)
Present (Present)
Homogeneous dark circumferential pattern*
Absent (Absent)
Present (Present)
Her-2/neu*
borderline (Equivocal - 2+)
positiv (Equivocal - 3+)
nicht ausreichend Gewebe (Insufficient
tissue/hybridization failure)
negativ (Negative - 0)
negativ (Negative - 1+)
positiv (Positive - 3+)
Gefäßinvasion*
Ja
Nein
Suitable for TMA*
Ja
Nein
Radiotherapy
Strahlentherapie durchgeführt*
Ja
Nein
Ort der Bestrahlung*
Körperseite*
links (Left)
rechts (Right)
Gesamtdosis*
Dosis - Einheit*
Centigray (cGy)
Gray (Gy)
Rad (Rad)
Beginn Strahlentherapie*
Ende Strahlentherapie*
Hormonetherapy
Hormon- / endokrine Therapie*
Ja
Nein
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Therapieart*
Einzeldosis*
Einheit*
Milligramm (mg)
nicht anwendbar (N/A)
Datum Therapiebeginn - endokrine Therapie*
Datum Therapieende - endokrine Therapie*
fortlaufend am Studienende*
Ja (Yes)
Concomitant Treatment
Name Nebentherapie*
Intention *
Kurativ (Curative)
Prävention (Prophylaxis)
Datum Therapiebeginn*
Datum Ende*
fortlaufend*
Ja (Yes)
Administration of Study Drug
Date Agent Administered*
Einzeldosis*
kumulative Dosis*
Was treatment delayed*
Ja
Nein
Specify code*
Administrative Reasons  (Administrative
Reasons )
Adverse Event Other Than Hematologic
Or Cardiac  (Adverse Event Other Than
Hematologic Or Cardiac )
Cardiac Adverse Event (Cardiac Adverse
Event)
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Dosing Error  (Dosing Error )
Hematologic Adverse Event
(Hematologic Adverse Event )
Other  (Other )
Subject Non-compliance (Subject Non-
compliance)
specify*
Dosislevel der Chemotherapie reduziert*
Ja
Nein
Specify code*
Administrative Reasons  (Administrative
Reasons )
Adverse Event Other Than Hematologic
Or Cardiac  (Adverse Event Other Than
Hematologic Or Cardiac )
Cardiac Adverse Event (Cardiac Adverse
Event)
Dosing Error  (Dosing Error )
Hematologic Adverse Event
(Hematologic Adverse Event )
Other  (Other )
Subject Non-compliance (Subject Non-
compliance)
specify*
Chemotherapy
Rezidivtherapie - Chemotherapie*
Ja
Nein
Agent Name*
Total No. Cycles*
initial dose*
Dose UOM*
Miligram per Meter squared (mg/m2)
Date started*
Date stopped*
Targeted Therapy
Did the patient receive additional target therapy
after recurrence of breast cancer or second
primary malignancy of contralateral breast
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cancer*
Ja
Nein
Agent Name*
Total No. Cycles*
initial dose*
Dose UOM*
Miligram per Meter squared (mg/m2)
Date started*
Date stopped*
Hormonetherapy
Rezidivtherapie - Hormontherapie*
Ja
Nein
Agent Name*
Total No. Cycles*
initial dose*
Dose UOM*
Miligram per Meter squared (mg/m2)
Not Applicable (N/A)
Date started*
Date stopped*
Radiotherapy
Rezidivtherapie - Bestrahlung*
Ja
Nein
Radiation Therapy Site*
Side*
Left (Left)
Right (Right)
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Total Dose*
Dose UOM*
Miligram per Meter squared (mg/m2)
Radiation Therapy Start Date*
Radiation Therapy End Date*
Surgery
Rezidivtherapie - Operation*
Ja
Nein
Surgical site*
Surgery Date*
Adverse Event (AE)
Name Adverse Event*
Laborwerte*
Ja
Nein
Gastrointestinaltrakt*
Ja
Nein
Urogenital-System*
Ja
Nein
Haut*
Ja
Nein
Allergie*
Ja
Nein
Fieber*
Ja
Nein
Infektion*
Ja
Nein
Sinnesorgane*
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Ja
Nein
Allgemeinsymptome*
Ja
Nein
Lunge/Kehlkopf*
Ja
Nein
Endokrines System*
Ja
Nein
Herz, allgemein*
Ja
Nein
Hämoglobin*
Ja
Nein
Aspartat-Transaminase*
Ja
Nein
Alanin-Transaminase*
Ja
Nein
Kreatinin*
Ja
Nein
Peripherer Nerv*
Ja
Nein
Blutungen*
Ja
Nein
Bilirubin*
Ja
Nein
Leukozyten*
Ja
Nein
Alkalische Phosphatase*
Ja
Nein
Proteinurie*
Ja
Nein
Haar*
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Ja
Nein
Obstipation*
Ja
Nein
Diarrhoe*
Ja
Nein
Hämaturie*
Ja
Nein
Schmerzen*
Ja
Nein
Thrombozyten*
Ja
Nein
Übelkeit*
Ja
Nein
Herzrhythmus*
Ja
Nein
Perikarditis*
Ja
Nein
Bewusstsein*
Ja
Nein
Dyspnoe*
Ja
Nein
Zystitis*
Ja
Nein
Vomiting*
Ja
Nein
1024 more adverse events*
SAE reported*
Ja
Nein
CTCAE Begin Date*
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CTCAE End Date*
Grad der Nebenwirkung*
CTC Adverse Event Outcomme*
Adverse Event Was Fatal  (fatal)
Adverse Event Has Improved  (improved)
Adverse Event Is Ongoing  (ongoing)
Adverse Event Is Resolved  (resolved)
Adverse Event Is Resolved With
Sequelae  (resolved with sequelae)
Action Taken at Time of Adverse Event*
There Was No Action Taken Based On
The Adverse Event  (none)
Other Treatment Was Required As A
Result Of The Adverse Event  (other
treatment required)
Protocol Treatment Was Delayed As A
Result Of The Adverse Event  (protocol
treatment delayed)
Protocol Treatment Was Discontinued As
A Result Of The Adverse Event
(protocol treatment discontinued)
Study Dose Was Reduced As A Result
Of The Adverse Event  (study dose
reduced)
relation to study drug*
Ja
Nein
Second Primary Malignancy and
Contralateral Breast Cancer
Rezdivtumor*
Date of First Recurrence or Progression*
Medizinische Untersuchung*
körperliche Untersuchung (Clinical)
radiologisch (Radiological)
Biopsie*
Ja
Nein
Datum Biopsie*
histologischer Typ*
Patient Status
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körperliche Untersuchung*
nicht durchgeführt*
Are there any changes since the previous
assessment*
Ja
Nein
Are there any changes since the previous
assessment*
Adverse Event  (Adverse Event)
Patient verstorben (Death )
keine Nachuntersuchung erfolgt (Lost To
Follow-up)
Patient Withdrew Study Consent
(Patient withdrew study consent)
Rezdivtumor (Recurrence of disease)
Zweittumor (Second primary malignancy
or contralateral breast cancer)
Herzerkrankung (Significant cardiac
disease)
Datum des letzten Kontaktes*
ECOG Leistungszustand*
0 (0)
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
Systolischer Blutdruck*
Diastolischer Blutdruck*
Cardiac Monitoring
Datum Linksventrikuläre Ejektionsfraktion*
Linksventrikuläre Ejektionsfraktion*
Echokardiographie*
Ja
Nein
Radionuklidventrikulographie *
Ja
Nein
Ergebnis*
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auffällig, klinisch signifikant (Abnormal -
Clinically significant)
auffällig, klinisch nicht signifikant
(Abnormal - Not clinically significant)
unauffällig (Normal)
Symptomatic CHF*
Ja
Nein
New York Heart Association*
Patients With Cardiac Disease But
Without Resulting Limitation Of Physical
Activity. Ordinary Physical Activity Does
Not Cause Undue Fatigue, Palpitation,
Dyspnea Or Anginal Pain. (Class I)
(Class I)
Patients With Cardiac Disease Resulting
In Slight Limitation Of Physical Activity.
They Are Comfortable At Rest. Ordinary
Physical Activity Results In Fatigue,
Palpitation, Dyspnea Or Anginal Pain.
(Class II) (Class II)
Patients With Cardiac Disease Resulting
In Marked Limitation Of Physical Activity.
They Are Comfortable At Rest. Less
Than Ordinary Activity Causes Fatigue,
Palpitation, Dyspnea Or Anginal Pain.
(Class III) (Class III)
Patients With Cardiac Disease Resulting
In Inability To Carry On Any Physical
Activity Without Discomfort. Symptoms
Of Heart Failure Or The Anginal
Syndrome May Be Present Even At
Rest. If Any Physical Activity Is
Undertaken, Discomfort Increases.
(Class IV) (Class IV)
Mammogram
Mammogramm*
beidseits (Bilateral)
links (Left)
rechts (Right)
Untersuchungsdatum*
nicht durchgeführt*
Are there any clinically significant abnormalites*
Ja
Nein
specify*
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Hematology and Biochemistry
Date of blood specimen collection*
Result*
auffällig, klinisch signifikant (Abnormal -
Clinically significant)
auffällig, klinisch nicht signifikant
(Abnormal - Not clinically significant)
unauffällig (Normal)
Survival Follow-Up
Vitalstatus*
lebend (Alive)
tot (Dead)
keine Nachuntersuchung erfolgt (Lost To
Follow-up)
Todesdatum*
Datum letzter Kontakt*
Unterschrift Untersuchuer*
Datum*
Treatment Completion
nicht_sinnvoll_für_Untersuchung*
nicht_sinnvoll_für_Untersuchung (No)
nicht_sinnvoll_für_Untersuchung (Not
Applicable)
nicht_sinnvoll_für_Untersuchung (Yes)
nicht_sinnvoll_für_Untersuchung*
nicht_sinnvoll_für_Untersuchung (No)
nicht_sinnvoll_für_Untersuchung (Not
Applicable)
nicht_sinnvoll_für_Untersuchung (Yes)
nicht_sinnvoll_für_Untersuchung*
nicht_sinnvoll_für_Untersuchung (No)
nicht_sinnvoll_für_Untersuchung (Not
Applicable)
nicht_sinnvoll_für_Untersuchung (Yes)
Grund für Therapeabbruch*
Adverse Event  (Adverse Event)
kontrallaterales Mammakarzinom
(contralateral breast cancer)
Patient verstorben (Death )
keine Nachuntersuchung erfolgt (Lost to
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follow-up)
Verletzung des Protokolls (Protocol
violation)
Rediziverkrankung (Recurrence of
disease)
Zweittumor (second primary malignancy)
Subject Decided To Withdraw From
Investigational Product But Is Continuing
To Be Followed Per Protocol  (Subject
decided to withdraw from investigational
product but is continuing to be followed
per protocol)
Subject Decided To Withdraw From The
Study  (Subject decided to withdraw from
the study)
Datum letzter Kontakt während
Behandlungsperiode*
Additional Comments
CRF Page Number*
Kommentar*
Unterschrift Untersuchuer*
Datum*
Death Form
Todesdatum*
Todesursache*
Adverse Event während Studie (Adverse
event during study)
Adverse Event während Therapie des
Rezidiv (Adverse event during treatment
given after recurrence)
Tumor Progression (Breast cancer
progression)
Todesursache tumorbedingt (Malignant
disease other than breast cancer)
andere Todesursache (Other)
andere Todesursache*
Autopsie*
Nein (No)
unbekannt (unknown)
Ja (Yes)
Please summarize findings*
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Eligibility Metastatic Colorectal Carcinoma FOLFOX6
or FOLFIRI Combined With Sorafenib NCT00889343
A Controlled Randomized Double-blind Multi-center Phase
II Study of FOLFOX6 or FOLFIRI Combined With Sorafenib
Versus Placebo in Second-line Metastatic Colorectal
Carcinoma NCT00889343
ODM derived from
http://clinicaltrials.gov/show/NCT00889343
All rights reserved. Please visit https://medical-data-
models.org/forms/12131
Eligibility Metastatic Colorectal
Carcinoma FOLFOX6 or FOLFIRI
Combined With Sorafenib
NCT00889343
Einschlusskriterien
Alter mindestens 18 Jahre*
Ja
Nein
ECOG Performance Status of 0 to 2*
Ja
Nein
Life expectancy of at least 12 weeks.*
Ja
Nein
Subjects with at least one uni-dimensional
(RECIST) measurable lesion of metastatic
colorectal carcinoma after first-line chemotherapy
with an Oxaliplatin- or Irinotecan based
Fluoropyrimidine containing regimen ±
bevacizumab and had a progression
subsequently. Lesions must be measured by CT-
scan or MRI.*
Ja
Nein
Adequate bone marrow, liver and renal function
as assessed by the following laboratory
requirements to be conducted within 7 days prior
to screening:*
Ja
Nein
Hämoglobin*
Ja
Nein
Absolute Neutrophil Count, ANC*
Ja
Nein
Platelet count 100,000 microliter Total bilirubin <
1.5 times the upper limit of normal*
Ja
Nein
ALT and AST < 2.5 x upper limit of normal (< 5 x
upper limit of normal for patients with liver
involvement of their cancer)*
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Ja
Nein
Alkaline phosphatase < 4 x upper limit of normal*
Ja
Nein
PT-INR/PTT < 1.5 x upper limit of normal
[Patients who are being therapeutically
anticoagulated with an agent such as coumadin
or heparin will be allowed to participate provided
that no prior evidence of underlying abnormality
in these parameters exists.]*
Ja
Nein
Serum creatinine < 1.5 x upper limit of normal*
Ja
Nein
Signed and dated informed consent before the
start of specific protocol procedures *
Ja
Nein
Ausschlusskriterien
History of cardiac disease: congestive heart
failure >NYHA class 2. Active CAD (MI more than
6 mo prior to study entry is allowed). Cardiac
arrythmias requiring anti-arrythmic therapy (beta
blockers or digoxin are permitted) or uncontrolled
hypertension*
Ja
Nein
History of HIV infection or chronic hepatitis B or
C*
Ja
Nein
Active clinically serious infections (> grade 2 NCI-
CTC version 3.0)*
Ja
Nein
Symptomatic metastatic brain or meningeal
tumors (unless the patient is > 6 months from
definitive therapy, has a negative imaging study
within 4 weeks of study entry and is clinically
stable with respect to the tumor at the time of
study entry)*
Ja
Nein
Patients with seizure disorder requiring
medication (such as steroids or anti-epileptics)*
Ja
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Nein
History of organ allograft*
Ja
Nein
Blutungsneigung*
Ja
Nein
Nierendialyse*
Ja
Nein
Dihydroptyridindehydrogenase-Mangel*
Ja
Nein
Contraindications for the use of atropine in
patients receiving FOLFIRI*
Ja
Nein
Previous or concurrent cancer that is distinct in
primary site or histology from the cancer being
evaluated in this study EXCEPT cervical
carcinoma in situ, treated basal cell carcinoma,
superficial bladder tumors [Ta, Tis & T1] or any
cancer curatively treated > 3 years prior to study
entry.*
Ja
Nein
Peripheral sensory neuropathy > CTC grade 2*
Ja
Nein
Chronic inflammatory bowel disease. Ileus.
Genetic fructose intolerance*
Ja
Nein
Pregnant or breast-feeding patients.*
Ja
Nein
Women of childbearing potential must have a
negative pregnancy test performed within 7 days
before the start of treatment. Fertile women and
men (<2 years after last menstruation in women)
must use effective means of contraception
(intrauterine contraceptive device, contraceptive
implants, injectables (hormonal depot),
transdermal hormonal contraception
(contraceptive patch), sexual abstinence or
vasectomised partner) during treatment and for at
least 6 months after last administration of
medication.*
Ja
Nein
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Substance abuse, medical, psychological or
social conditions that may interfere with the
patient's participation in the study or evaluation of
the study results*
Ja
Nein
Any condition that is unstable or could jeopardize
the safety of the patient and their compliance in
the study *
Ja
Nein
Patients unable to swallow oral medications.*
Ja
Nein
Any other anticancer chemotherapy or
immunotherapy during the study or within 4
weeks of study entry.*
Ja
Nein
Radiotherapy during study or within 3 weeks of
start of study drug. (Palliative radiotherapy will be
allowed). *
Ja
Nein
major surgery*
Ja
Nein
Autologous bone marrow transplant or stem cell
rescue within 4 months prior to study treatment*
Ja
Nein
Use of biologic response modifiers, such as G-
CSF, within 3 week of study entry. [G-CSF and
other hematopoietic growth factors may be used
in the management of acute toxicity such as
febrile neutropenia when clinically indicated or at
the discretion of the investigator, however, they
may not be substituted for a required dose
reduction.] [Patients taking chronic erythropoietin
are permitted provided no dose adjustment is
undertaken within 2 months prior to the study or
during the study]*
Ja
Nein
Investigational drug therapy outside of this trial
during or within 4 weeks of study entry*
Ja
Nein
Prior exposure to the study drug.*
Ja
Nein
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Any St. John´s wort containing remedy*
Ja
Nein
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Eligibility Prostate Cancer NCT02181192
Point in Time of Radiotherapy for Patients With Biochemical
Recurrent Prostate Carcinoma; ODM derived from:
https://clinicaltrials.gov/show/NCT02181192
All rights reserved. Please visit https://medical-data-
models.org/forms/12132
Eligibility Prostate Cancer
NCT02181192
Inclusion Criteria
postoperative, biochemical recurrent prostate
carcinoma with psa value  between 0.2 to 0.99
ng/ml*
Yes
No
prior irradiation*
Yes
No
comprehension of study protocol content and
signed  informed consent form*
Yes
No
minimum age 18 years*
Yes
No
Exclusion Criteria
primary therapy of prostate carcinoma*
Yes
No
psa value >= 1 ng/ml*
Yes
No
diagnosed distant metastases before
randomisation (osseous or systemic)*
Yes
No
performed pet/ct before randomisation*
Yes
No
malignant slave tumor*
Yes
No
potent men that are not willing or are unable to
apply consequent contraception*
Yes
No
ongoing drug- and/or alcohol abuse*
Yes
No
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patients that are not willing or able to cooperate
according to protocol*
Yes
No
patients in care*
Yes
No
patients that are not able to understand german
language*
Yes
No
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Admission Order Form Internal Medicine
descriptions
All rights reserved. Please visit https://medical-data-
models.org/forms/12160
Admission Order Form Internal
Medicine
UA1
Do you have Diabetes Mellitus?
D.M. Typ 1 (1)
D.M. Typ 2 (2)
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Eligibility Prostate Cancer NCT02269982
Development of Circulating Molecular Predictors of
Chemotherapy and Novel Hormonal Therapy Benefit in
Men With Metastatic Castration Resistant Prostate Cancer
(mCRPC) (PCF); ODM derived from:
https://clinicaltrials.gov/show/NCT02269982
All rights reserved. Please visit https://medical-data-
models.org/forms/12166
Eligibility Prostate Cancer
NCT02269982
Inclusion Criteria
1. histologically confirmed diagnosis of
adenocarcinoma of the prostate.  pure small cell
or neuroendocrine tumors of the prostate are not
permitted.*
Yes
No
2. clinical or radiographic evidence of metastatic
disease.*
Yes
No
3. planned therapy with either enzalutamide
and/or abiraterone acetate within the coming 6
weeks*
Yes
No
4. castrate levels of testosterone (<50 ng/dl) at
most recent assessment.*
Yes
No
5. evidence of disease progression on or
following most recent therapy as evidenced by
the following:
• radiographic evidence of disease progression
as defined by one or more new bone scan lesions
that is not consistent with flare/healing, or growth
of soft tissue/visceral metastases to greater than
one centimeter (cm) in longest diameter (2 cm
shortest diameter for lymph nodes).*
Yes
No
6. at least two of the following high risk features
during screening for rapid disease progression:*
Yes
No
1. anemia with a hemoglobin <12.0 g/dl*
Yes
No
2. elevated alkaline phosphatase above the
institution upper limit of normal*
Yes
No
3. high lactate dehydrogenase (ldh) above the
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upper limit of normal*
Yes
No
4. prior therapy with either enzalutamide or
abiraterone acetate in patients planned to receive
the converse therapy.  patients are not permitted
if they are continuing on the same therapy or
restarting a therapy that they have been exposed
to in the past.*
Yes
No
5. presence of visceral metastasis on imaging*
Yes
No
6. presence of clinically significant pain requiring
opioid analgesia*
Yes
No
7. patients with a cellsearch ctc > 5 cells per 7.5
ml whole blood (if available as standard of care)
are eligible without additional high risk features*
Yes
No
8. psa doubling time under 3 months on most
recent therapy*
Yes
No
7. age > 18 years.*
Yes
No
8. ability to understand and the willingness to
sign a written informed consent document.*
Yes
No
Exclusion Criteria
1. history of intercurrent or past medical or
psychiatric illness that would make participation
in a blood drawing protocol difficult or not feasible
at the discretion of the principal investigator or
co-investigator(s).*
Yes
No
2. treatment with an anthracycline or
mitoxantrone within 1 week of ctc collection*
Yes
No
3. prior docetaxel in the castration resistant
metastatic setting.  patients treated with
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docetaxel for metastatic castration sensitive
disease will be eligible.*
Yes
No
4. unwillingness to be followed longitudinally for
serial ctc biomarker studies.*
Yes
No
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Inclusion and exclusion criteria Stem-Cell
Transplantation CASLAMB NCT00148148
A Study of Caspofungin, Liposomal Amphotericin B or the
Combination of Both for Patients After Stem-Cell
Transplantation
NCT00148148
All rights reserved. Please visit https://medical-data-
models.org/forms/12175
Inclusion and exclusion criteria
Stem-Cell Transplantation CASLAMB
NCT00148148
Einschlusskriterien
Erwachsener Patient (≥ 18 Jahre) mit
Granulozytopenie (absolute Zahl neutrophiler
Granulozyten: ≤500/μL) und Zustand nach
allogener hämatopoetischer
Stammzelltransplantation und Immunsuppression
mit Cyclosporin A
Ja
Nein
Patient mit persistierendem bzw.
wiederauftretendem Fieber (orale Temperatur
≥38.0°C) und Granulozytopenie (absolute Zahl
neutrophiler Granulozyten ≤500/μL) und
adäquater antibakterieller Therapie für ≥36-48
Stunden, der einer empirischen antimykotischen
Therapie bedarf
Ja
Nein
Liegender, mindestens doppellumiger
zentralvenöser Katheter zur Verabreichung von
Medikamenten und zur Gewinnung von
Plasmaproben
Ja
Nein
Für Patientinnen im gebärfähigen Alter: Vorliegen
eines negativen Schwangerschaftstests innerhalb
von 7 Tagen vor Behandlungsbeginn und
ausreichende Kontrazeption während der
Studienteilnahme
Ja
Nein
Lebenserwartung ≥5 Tage
Ja
Nein
Behandlung in einem der genannten Prüfzentren
Ja
Nein
Ausreichende renale und hepatische Funktion
gemäß den folgenden Defi -
nitionen:
Bilirubin gesamt: ≤ 3x oberer Referenzwert
SGOT oder SGPT: ≤ 3x oberer Referenzwert
Alkalische Phosphatase: ≤ 5x oberer
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Referenzwert
Kreatinin i. S.: ≤ 2x oberer Referenzwert
Ja
Nein
Bilirubin gesamt: ≤ 3x oberer Referenzwert
Ja
Nein
SGOT oder SGPT: ≤ 3x oberer Referenzwert
Ja
Nein
Alkalische Phosphatase: ≤ 5x oberer
Referenzwert
Ja
Nein
Kreatinin i. S.: ≤ 2x oberer Referenzwert
Ja
Nein
Vorliegen einer schriftlichen
Einverständniserklärung des Patienten/der
Patientin bzw. des gesetzlichen Vertreters nach
vorheriger Aufklärung
Ja
Nein
Ausschlusskriterien
Teilnahme an dieser Studie zu einem früheren
Zeitpunkt
Ja
Nein
Schwerwiegende psychiatrische Vor-
/Begleiterkrankung
Ja
Nein
Schwangerschaft oder Stillzeit
Ja
Nein
Frauen im gebärfähigen Alter mit unzureichender
oder nicht gesicherter
Kontrazeption
Ja
Nein
Nachweis einer wahrscheinlichen bzw.
nachgewiesenen aktiven invasiven
Pilzinfektion zum Zeitpunkt des
Studieneinschlusses
(siehe EORTC/MSG-Defi nition)
Ja
Nein
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Patient mit pathologischen Funktionsparametern
der Leber- und Nierenfunktion
Bilirubin gesamt: > 3x oberer Referenzwert
SGOT oder SGPT: > 3x oberer Referenzwert
Alkalische Phosphatase: > 5x oberer
Referenzwert
Kreatinin i. S.: > 2x oberer Referenzwert
Ja
Nein
Bilirubin gesamt: > 3x oberer Referenzwert
Ja
Nein
SGOT oder SGPT: > 3x oberer Referenzwert
Ja
Nein
Alkalische Phosphatase: > 5x oberer
Referenzwert
Ja
Nein
Kreatinin i. S.: > 2x oberer Referenzwert
Ja
Nein
Klinischer und/oder laborchemischer Hinweis auf
eine aktive Venenverschluss-Erkrankung. VOD ist
gekennzeichnet durch eine Erhöhung der Serum-
Transaminasen und nachfolgend einer
persistierenden Erhöhung des Serum-Bilirubins
sowie Leberdruckschmerz, Gewichtszunahme
und Aszites
Ja
Nein
Hämodynamisch instablier Patient bzw. Patient
mit einer antizipierten Überlebensdauer von <5
Tagen
Ja
Nein
Gleichzeitige Einnahme von Rifampicin,
Phenytoin, Carbamazepin, Phenobarbital,
Dexamethason, Efavirenz und Nevirapin
Ja
Nein
Patient mit anamnestischer Unverträglichkeit von
Echinocandin-Antimykotika oder dokumentierten
allergischen Reaktionen gegenüber Amphotericin
B
Ja
Nein
Jegliche andere Bedingung oder Umstand, die
nach Meinung des behandelnden Arztes ein
Risiko für den Patienten bedeuten, die
protokollgerechte Therapie des Patienten
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beeinträchtigen, und die Zielsetzung der Studie
beeinträchtigen könnte
Ja
Nein
Fehlendes oder inkomplettes Einverständnis
Ja
Nein
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SteffisAMICA
Test Study
All rights reserved. Please visit https://medical-data-
models.org/forms/12177
ODM-Form
Persönliche Daten
Alter des Patienten
>= 0
<= 110
Jahre
Geschlecht des Patienten
männlich (1)
weiblich (2)
Größe des Patienten
>= 130
<= 220
cm
Gewicht des Patienten
>= 30
<= 400
kg
Seit wann befindet sich der Patient im
Krankenhaus?
Wie lange befand sich der Patient im
Krankenhaus, bevor er in die Studie
eingeschlossen wurde?
>= 0
<= 300
Tage
Wie lange befand sich der Patient auf der
Intensivstation, bevor er in die Studie
eingeschlossen wurde?
>= 0
<= 300
Tage
Wie häufig befand sich der Patient innerhalb der
letzten 12 Monate im Krankenhaus?
>= 0
<= 100
Art der Operation
Bitte geben sie die Art der Operation an. Treffen
mehrere Angaben zu, wählen sie bitte diejenige
mit der größten klinischen Relevanz
Transplantation eines soliden Organs (1)
ossärer Eingriff (orthopädische, unfall-,
wirbelsäulen-, kieferchirurgische
Operation) (2)
Intraabdominelle Eingriffe (allgemein-
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,viszeralchirurgische, urologische oder
gynäkologische Operation) (3)
intrathorakaler Eingriff (Herz-,
Lungenoperation, Mediastinaleingriff) (4)
Intrazerebraler Eingriff (5)
Transplantation eines soliden Organs
Wann wurde die Transplantation durchgeführt
(Datum des Beginns der OP)?
???
Welche(s) Organ(e) wurde(n) transplantiert
Herz (1)
Lunge (2)
Niere (3)
Leber (4)
Pankreas (5)
Dünndarm (6)
Handelt es sich um eine Retransplantation?
Yes
No
Wie oft wurde eine Retransplantation
durchgeführt?
>= 1
<= 20
Hat der Patient vor dieser Transplantation bereits
einmal ein anderes Organ transplantiert
bekommen, das nicht im Rahmen der aktuellen
Transplantation transplantiert wurde?
Yes
No
Welche anderen Organe wurden dem Patienten
vor der aktuellen Transplantation transplantiert?
Herz (1)
Lunge (2)
Niere (3)
Leber (4)
Pankreas (5)
Dünndarm (6)
Wann wurden dem Patienten das/die andere(n)
Organ(e) transplantiert?
Transplantationsdatum
Organspender
Größe des Organspenders
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>= 130
<= 220
cm
Gewicht des Organspenders
>= 30
<= 400
kg
Wie lange befand sich er Organspender vor der
Explantation auf der Intensivstation?
>= 0
<= 200
Tage
Liegt für den Organspender ein Erregernachweis
für Pilze vor?
Yes
No
Welche Pilze wurden beim Organspender
nachgewiesen?
Liste einfügen (1)
Wurde der Patient vor der Explantation mit
Antimykotika behandelt?
Yes
No
Mit welchen Antimykotika ist der Organspender
vor der Explantation behandelt worden?
Antimykotikaliste einfügen (1)
Wie lange ist der Organspender vor der
Explantation mit Antimykotika behandelt worden?
>= 1
<= 200
Tage
Wie war die Qualität des Spenderorgans
(Chirurgische Einschätzung)
sehr gut (1)
gut (2)
ausreichend (3)
Allgemeines zu Nicht-Transplantationen
Wann fand der Eingriff statt?
???
Handelte es sich bei dem primären Eingriff um
einen Elektiveingriff?
Yes
No
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Gab es nach der pimären Operation weitere
Folge-oder Revisionseingriffe?
Yes
No
Wieviele Folge- oder Revisionseingriffe gab es?
>= 1
<= 100
Wann war der letzte Folge- oder
Revisionseingriff?
???
Handelte es sich bei der primären Operation um
einen Tumoreingriff?
Yes
No
Handelte es sich um einen malignen Tumor?
Yes
No
War ein Polytrauma Grund für den Eingriff?
Yes
No
Wie lange dauerte es vom Eintritt des
Ereignisses bis zum Beginn der Operation?
>= 0
<= 400
Stunden
Wie war der allererste festgestellte GCS-Wert?
>= 3
<= 15
Wurde bei dem Ereigniss die Haut großflächig
verletzt (z.B. i.S. eines Decollement)?
Yes
No
Kam es zu einer Pfählungsverletzung oder einer
vergleichbatren Verletzung?
Yes
No
Waren Verbrennungen Grund für den Eingriff?
Yes
No
Welches war der schwerste Grad der
Verbrennung?
>= 1
<= 4
4 / 16
SteffisAMICA
Wieviel Prozent der  Körperoberfläche waren
verbrannt?
>= 1
<= 100
Prozent KOF
Gab oder gibt es nach der Operation Weichteile,
die großflächig nicht von intakter Haut bedeckt
sind?
Yes
No
War der Patient vor der Operation medikamentös
oder aus anderen Gründen immunsuppremiert?
Yes
No
Warum war der Patient immunsuppremiert?
Warum war der Patient immunsuppremiert?
Chemotherapie (1)
Malignom (2)
Z.n. Transplantation (3)
Autoimmunerkrankung (4)
sonstige (5)
Ossäre Eingriffe
Welcher Knochentyp wurde überwiegend
operiert?
lange Röhrenknochen (1)
kurze Knochen (2)
Wirbelsäule (3)
Plattenknochen (4)
Wurden (außer Nahtmaterial) Fremdkörper
eigebracht, die planmäßig im Patienten
verbleiben?
Yes
No
Ist das Material mit Antiinfektiva beschichtet?
Yes
No
Waren Knochen oder Teile davon vor Beginn der
Operation nicht von Weichteilgewebe
umschlossen (i.S.e. offenen Fraktur)?
Yes
No
Waren Weichteile vor oder im Rahmen der
Operation ischämisch (auch latent durch
Blutsperre)?
Yes
No
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Intraabdominelle Eingriffe
Gab es eine Perforation von Magen oder Darm?
Yes
No
Bestand oder besteht eine Gallenleckage?
Yes
No
Bestand während der OP das klinische Bild einer
Peritonitis?
Yes
No
Bestand während der OP das klinische Bild der
akuten Pankreatitis?
Yes
No
Zeigten  Magen und/oder Darm vor oder während
der Operation Anzeichen einer Ischämie?
Yes
No
Intrathorakale Eingriffe
An welchem Organ erfolgte die Operation?
Herz (1)
Lunge (2)
Thymus (3)
Gefäße (4)
Weichteile (5)
Wurde im Rahmen der Operation eine Herz-
Lungen-Maschine eingesetzt?
Yes
No
Wie lange war die Maschine im Einsatz?
>= 1
<= 300
Minuten
Intrazerebrale Eingriffe
Wurde eine Operation am Gehirn (auch
Sondenanlagen) durchgeführt?
Yes
No
Zustand des Patienten
Wie hoch ist die Körpertemperatur?
>= 20
<= 45
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°C
Wie hoch ist der mittlere arterielle Blutdruck
(MAP)?
>= 0
<= 200
mmHg
Wie hoch ist die Herzfrequenz?
>= 0
<= 200
pro Minute
SAPS ll Score
>= 0
<= 163
APACHE ll Score
>= 0
<= 71
Besteht ein akutes Nierenversagen? AKIN-
Score?
>= 0
<= 3
Labor/Mikrobiologie
atueller PCT
aktuelles CRP
aktueller IL-6 Spiegel
Liegt eine Granulozytopenie vor?
Ja (1)
Nein (2)
Unbekannt (3)
Hatten sie den Verdacht auf eine Mykose der
Lunge?
Yes
No
Auf welcher Grundlage haben Sie den Verdacht
gestellt?
Verdacht aufgrund von Röntgen-Thorax-
Aufnahme (1)
Verdacht aufgrund eines Thorax-CTs (2)
Konnten Sie Aspergillen-Antigen nachweisen?
Ja (1)
Nein (2)
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nicht erhoben (3)
Wo konnten sie das Antigen nachweisen?
Positiv im Liquor (1)
Positiv im Serum (2)
Positiv in BAL (3)
Konnten Sie Candida-Antigen nachweisen?
Ja (1)
Nein (2)
nicht erhoben (3)
Wo konnten Sie das Antigen nachweisen?
Positiv im Liquor (1)
Positiv im Serum (2)
Positiv in BAL (3)
Konnten sie Aspergillen-Antikörper nachweisen?
Ja (1)
Nein (2)
nicht erhoben (3)
Welche Antikörper konnten Sie in welcher
Konzentration nachweisen?
IgM (1)
IgA (2)
IgG (3)
Konnten Sie Candida-Antikörper nachweisen?
Ja (1)
Nein (2)
nicht erhoben (3)
Welche Antikörper konnten Sie in welcher
Konzentration nachweisen?
IgM (1)
IgA (2)
IgG (3)
Bitte geben Sie ein, welche Proben sie gewonnen
haben und welchen Keimnachweis sie erhalten
haben.
Art der Probe
Blutkultur (1)
Abstrich (2)
BAL (3)
Trachealsekret (4)
Liquor (5)
Urin (6)
Punktion (7)
Präparat (Pathologie) (8)
andere (9)
Art des Abstrichs
oberflächlich (Haut) (1)
oral (2)
rektal (3)
vaginal (4)
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Wunde (oberflächlich) (5)
Wunde (tief) (6)
OP-Gebiet (7)
andere (8)
Art des Punktionssekrets
Gelenk (1)
andere (10)
Perikard (2)
Pleura (3)
Serom (4)
Abszess (5)
Zyste (6)
Aszites (7)
Hämatom (8)
Liquor (9)
Wann haben Sie die Probe(n) entnommen?
??
Wann haben Sie den Befund der Probe
bekommen?
??
Welche Erreger wurden nachgewiesen?
noch einfügen (1)
Welche Resistenzen wurden nachgewiesen?
keine (1)
noch einfügen (2)
Gibt es den zusätzlichen Nachweis von
multiresistenten Bakterien?
Yes
No
Welche multiresistenten erreger wurden
nachgewiesen?
MRSA (1)
VRE (2)
3-MRGN (3)
4-MRGN (4)
ESBL (5)
andere (6)
Aktuelle Therapie
Wird der Patient aktuell kontrolliert beatmet?
Yes
No
Seit wann wird der Patient kontrolliert beatmet?
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Wird der Patient aktuell parenteral ernährt?
Yes
No
Bekommt der Patient aktuell Immunsuppressiva?
Yes
No
Welche Immunsuppressiva bekommt der Patient?
Liste einfügen (1)
Bekommt der Patient aktuell Antiinfektiva
(Antibiotika oder Antimykotika)?
Yes
No
Welche Antiinfektiva bekommt der Patient
aktuell?
Liste einfügen (1)
In welcher Dosierung bekommt der Patient
aktuell die ausgewählten Antiinfektiva?
Seit wann bekommt der Patient die Antiinfektiva?
???
Hat der Patient im Rahmen des aktuellen
Krankenhausaufenthaltes eine
Breitspektrumantibiose erhalten, die aktuell nicht
mehr gegeben wird?
Yes
No
Welche Vasopressoren bekommt der Patient?
keine (1)
Norepinephrin (2)
Epinephrin (3)
Vasopressin (4)
Dobutamin (5)
Dopamin (6)
In welcher Dosierung bekommt der Patient die
ausgewählten Vasopressoren?
eingeben
???
Wird der Patient hämodialysiert?
Yes
No
Entscheidungsparameter
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Welche der folgenden Parameter hat ihre
Entscheidung, ein Antimykotikum zu
verabreichen, maßgeblich beeinflusst?
kulturelle bzw. molekularer Nachweis von
Hefen (1)
Katecholaminpflichtigkeit (10)
prophylaktish aufgrund des individuelen
Risikoprofils (11)
prophylaktisch aufgrund eines
Klinikstandards (12)
Sonstiges (13)
serologischer Befund mit Hinweis auf
Hefeinfektion (2)
kultureller bzw. molekularer Nachweis
von Schimelpilzen (3)
serologischer Befund mit Hinweis auf
Schimmelpilzinfektion (4)
Fieber (5)
CRP-Wert (6)
PCT-Wert (7)
Blutdruck (8)
Herzfrequenz (9)
Tag 3 und Folgetage
Der Patient
liegt weiter auf der Intensivstation (1)
wurde auf eine nachgeordnete Station
verlegt (2)
ist verstorben (3)
ist aus dem Krankenhaus entlassen  (4)
wurde in eine nachgeordnete Klinik/Reha
verlegt (5)
Wann?
Folgedatumerhebung???
Auf welcher Station wird der Patient derzeit
behandelt? Bitte nennen sie uns die
Kontaktdaten des für diese Station zuständigen
Kollegen
Zustand des Patienten
Wurden seit dem (Tag der letzten Eintragung)
Revisions-OPs durchgeführt?
Yes
No
Wie oft wurden Revisions-OPs durchgeführt?
>= 0
<= 200
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Labor/Mikrobiologie
aktueller PCT
aktuelles CRP
aktueller IL-6 Spiegel
aktuelle Leukozytenzahl
Liegt eine Granulozytopenie vor?
Ja (1)
Nein (2)
Unbekannt (3)
Hatten Sie den Verdacht auf eine Mykose der
Lunge?
Yes
No
Auf welcher Grundlage haben Sie den Verdacht
gestellt?
Verdacht aufgrund von Röntgen-Thorax-
Aufnahme (1)
Verdacht aufgrund eines Thorax-CTs (2)
Konnten Sie Aspergillen-Antigen nachweisen?
Ja (1)
Nein (2)
nicht erhoben (3)
Wo konnten Sie das Aspergillen-Antigen
nachweisen?
Positiv im Liquor (1)
Positiv im Serum (2)
Positiv in BAL (3)
Konnten sie Candida-Antigen nachweisen?
Ja (1)
Nein (2)
nicht erhoben (3)
Wo konnten Sie das Candida-Antigen
nachweisen?
Positiv im Liquor (1)
Positiv im Serum (2)
Positiv in BAL (3)
Konnten Sie Aspergillen-Antikörper nachweisen?
Ja (1)
Nein (2)
nicht erhoben (3)
Welche Antikörper konnten Sie in welcher
Konzentration nachweisen?
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IgM (1)
IgA (2)
IgG (3)
Konnten Sie Candida-Antikörper nachweisen?
Ja (1)
Nein (2)
nicht erhoben (3)
Welche Antikörper konnten Sie in welcher
Konzentration nachweisen?
IgM (1)
IgA (2)
IgG (3)
Welche der folgenden Nachweise oder
Verhärtungsfälle einer Pilzinfektion sind seit dem
(Tag der letzten Eintragung Tag 0, Tag 3, Tag 7)
neu hinzugekommen?
Art der Probe
Blutkultur (1)
Abstrich (2)
BAL (3)
Trachealsekret (4)
Liquor (5)
Urin (6)
Punktion (7)
Präparat (Pathologie) (8)
andere (9)
Art des Abstrichs
oberflächlich (Haut) (1)
oral (2)
rektal (3)
vaginal (4)
Wunde (oberflächlich) (5)
Wunde (tief) (6)
OP-Gebiet (7)
andere (8)
Artz des Punktionssekrets
Gelenk (1)
andere (10)
Perikard (2)
Pleura (3)
Serom (4)
Abszess (5)
Zyste (6)
Aszites (7)
Hämatom (8)
Liquor (9)
Entnahmedatum der Probe
Probendatum (Entnahme) (relativ)???
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Probenergebnisdatum (Befunddatum)
??? (relativ)
Welche Erreger wurden nachgewiesen?
noch einfügen (1)
Welche Resistenzen wurden bei dem Erreger
achgewiesen?
noch einfügen (1)
Gibt es einen zusätzlichen Nachweis von
multiresistenten Bakterien?
MRSA (1)
VRE (2)
3-MRGN (3)
4-MRGN (4)
ESBL (5)
andere (6)
Aktuelle Therapie
Wird der Patient aktuell kontrolliert beatmet?
Yes
No
Seit wann wird der Patient kontrolliert beatmet?
Wird der Patient aktuell parenteral ernährt?
Yes
No
Bekommt der Patient aktuell Immunsuppressiva?
Yes
No
Welche Immunsuppressiva bekommt der Patient?
Liste einfügen (1)
Bekommt der Patient aktuell Antiinfektiva
(Antibiotika oder Antimykotika)?
Yes
No
Welche Antiinfektiva bekommt der Patient
aktuell?
Liste einfügen (1)
In welcher Dosierung bekommt der Patient
aktuell die ausgewählten Antiinfektiva?
Seit wann bekommt der Patient die Antiinfektiva?
???
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Welche Vasopressoren bekommt der Patient?
keine (1)
Norepinephrin (2)
Epinephrin (3)
Vasopressin (4)
Dobutamin (5)
Dopamin (6)
In welcher Dosierung bekommt der Patient die
ausgewählten Vasopressoren?
???
Wird der Patient hämodialysiert?
Yes
No
Beendigung der Antimykotikatherapie
Wann haben sie die antimykotische Tehrapie
beendet?
???Zeitpunkt Tehrapieende (relativ)
Was war der primäre Grund für das Ende der
antimykotischen Therapie?
Verdacht auf eine Mykose hat sich nicht
bestätigt (1)
Abbruch wegen Nebenwirkungen (2)
Die Therapie war erfolgreich und konnte
beendet werden (3)
andere Erklärung der Befunde (4)
keine Erhärtung des Verdachts einer
Infektion mit Pilzen (5)
7 Tage keine positive Blutkultur (6)
14 Tage Therapie nach Konversion von
positiven Befunden (7)
Freitext (8)
Auto-Auswertung: Antimykotikum geändert
Wann wurde die antimykotische Therapie
umgestellt?
???Zeitpunkt Therapieumstellung (relativ)
Was war der Grund für den Therapiewechsel?
Resistogramm (1)
Nebenwirkungen (2)
Anpassung an
Grunderkrankungen/Nebendiagnosen
(3)
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Nichtanschlagen der Therapie (4)
Anschlagen der Therapie und
Deeskalation (5)
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Eligibility Relapsing Forms of Multiple
Sclerosis NCT02097849
Vaccination Response in Tecfidera-Treated Versus
Interferon-Treated Participants With Relapsing Forms of
Multiple Sclerosis.; ODM derived from:
https://clinicaltrials.gov/show/NCT02097849
All rights reserved. Please visit https://medical-data-
models.org/forms/12178
Eligibility Relapsing Forms of
Multiple Sclerosis NCT02097849
Criteria
must have a confirmed diagnosis of rrms per the
2010 mcdonald criteria.*
Yes
No
must have a known tetanus immunization history
with most recent tetanus vaccination given 2 to
15 years prior to screening and an anti-tetanus
igg titer at screening that is less than or equal to
one-half the upper limit of detection for the
assay.*
Yes
No
must have been on a stable approved dose of
tecfidera (240 mg twice daily [bid]) [group 1] for
≥6 months or on a stable approved dose of a
non-pegylated ifn (e.g., avonex, betaseron, rebif,
extavia) [group 2] for ≥3 months prior to day 1.*
Yes
No
Exclusion criteria
clinical relapse requiring treatment within 30 days
prior to day 1.
Yes
No
pneumococcal vaccination within 5 years prior to
screening.
Yes
No
previous exposure to meningococcal vaccines.
Yes
No
known hypersensitivity to td, ppsv23, or mcv4 or
their components.
Yes
No
note: other protocol-defined inclusion/exclusion
criteria may apply.
Yes
No
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Eligibility Renal Insufficiency, Chronic
NCT02097550
Primary Care eHealth Intervention for Improved Outcomes
in Chronic Kidney Disease; ODM derived from:
https://clinicaltrials.gov/show/NCT02097550
All rights reserved. Please visit https://medical-data-
models.org/forms/12186
Eligibility Renal Insufficiency, Chronic
NCT02097550
Inclusion Criteria
adults 18 years or older*
Yes
No
egfr 30-49*
Yes
No
not pregnant at study assessment.*
Yes
No
the ability to use a computer or smartphone*
Yes
No
the ability to understand english*
Yes
No
Exclusion Criteria
if patient's ckd care is being delivered by a
nephrologist (not the primary care provider)*
Yes
No
severe hypertriglyceridemia (tg>500 mg/dl)*
Yes
No
hyperkalemia (k>5.0 meq/l)*
Yes
No
serious illness likely to preclude study
completion*
Yes
No
pregnancy*
Yes
No
intolerance/allergy to all indicated ckd
medications*
Yes
No
plans to change primary care site.*
Yes
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TestinfoName
Description
All rights reserved. Please visit https://medical-data-
models.org/forms/12187
Subformularname
Section2
Height
>= 0
cm
Do you have D.M. ?
D.M. Type 1 (1)
D.M. Type 2 (2)
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Eligibility Arthritis NCT02223858
Staying Positive With Arthritis Study; ODM derived from:
https://clinicaltrials.gov/show/NCT02223858
All rights reserved. Please visit https://medical-data-
models.org/forms/12188
Eligibility Arthritis NCT02223858
Inclusion Criteria
the target population will be african american (aa)
and white (wh) veterans with symptomatic knee
arthritis. specific inclusion criteria include:*
Yes
No
age 50 years or older*
Yes
No
receive primary care at a participating study site*
Yes
No
self-report as non-hispanic black/aa or non-
hispanic wh*
Yes
No
frequent, symptomatic knee pain identified using
questions from the oa initiative*
Yes
No
pain level of 4 or higher on a 0-10 numeric rating
scale*
Yes
No
can speak, read, and write in english*
Yes
No
Exclusion Criteria
patients will be excluded if they:*
Yes
No
report serious problems with hearing, eyesight, or
memory*
Yes
No
report having been diagnosed any type of
arthritis other than osteoarthritis or degenerative
arthritis*
Yes
No
report that they have been treated for cancer in
the last 3 years*
Yes
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No
report having had a steroid injection into one or
both knees in the past 3 months*
Yes
No
report that there is a reason they cannot
complete the study procedures, which include
telephone calls and program activities that involve
reading and writing*
Yes
No
do not have a telephone number where they can
receive telephone calls from research staff*
Yes
No
screen positive for cognitive impairment*
Yes
No
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Eligibility Asthma NCT02347462
Bilevel Positive Airway Pressure (BiPAP) for the Treatment
of Moderate to Severe Acute Asthma Exacerbations; ODM
derived from: https://clinicaltrials.gov/show/NCT02347462
All rights reserved. Please visit https://medical-data-
models.org/forms/12189
Eligibility Asthma NCT02347462
Inclusion Criteria
2-18 years old*
Yes
No
admitted to bc children's hospital with a clinical
diagnosis of an acute asthma exacerbation*
Yes
No
pram score of >3 following initial treatment with
three rounds of inhaled salbutamol and
ipratropium bromide, and one dose of systemic
steroid*
Yes
No
parents willing and able to sign consent*
Yes
No
children over the age of 6 willing to provide
assent*
Yes
No
Exclusion Criteria
clinical suspicion of co-existing bacterial
pneumonia: focal crackles or bronchial breathing,
and/or major chest x-ray findings*
Yes
No
impending respiratory failure at presentation
requiring direct picu admission*
Yes
No
receiving maintenance dose of oral steroid at
time of hospital admission*
Yes
No
any contraindication to bipap use including
altered mental status, recent bowel surgery,
intractable vomiting, or inability to protect airway*
Yes
No
current tracheostomy, home ventilation (ippv or
nippv) or home oxygen requirement*
Yes
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No
history of congenital heart disease or chronic
respiratory disease (including bronchopulmonary
dysplasia, cystic fibrosis, pulmonary
hypertension)*
Yes
No
craniofacial abnormality precluding the use of a
tight fitting facial mask*
Yes
No
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Eligibility Breast Cancer NCT02101320
Hand-held Gamma Camera in the SNOLL Procedure; ODM
derived from: https://clinicaltrials.gov/show/NCT02101320
All rights reserved. Please visit https://medical-data-
models.org/forms/12190
Eligibility Breast Cancer
NCT02101320
Inclusion Criteria
patients older than 18 years*
Yes
No
patients undergoing snoll procedure for breast
non palpable invasive cancer (ultrasound image
target) confirmed by biopsy before surgery*
Yes
No
clinical t0n0 stage*
Yes
No
before the snoll procedure, patients will be
informed on all this procedure*
Yes
No
a free and informed consent must be obtained*
Yes
No
Exclusion Criteria
mulitifocal breast cancer, diffuse
microcalcifications
Yes
No
non-palpable breast cancer without ultrasound
target
Yes
No
isolated in situ cancer or invasive cancer
associated with extended in situ carcinoma
Yes
No
patients who underwent neoadjuvant
chemotherapy
Yes
No
palpable axillary nodes on clinical examination or
with a suspicious or positive cytology
Yes
No
pregnant patient
Yes
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No
history of axillary surgery or mammoplasty
Yes
No
allergy to any component of the tracking
technique
Yes
No
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Eligibility Breast Neoplasms NCT02187718
Ambulatory SNP Under Local Anaesthesia in a Subgroup
of Breast Cancer Patients - Trial; ODM derived from:
https://clinicaltrials.gov/show/NCT02187718
All rights reserved. Please visit https://medical-data-
models.org/forms/12191
Eligibility Breast Neoplasms
NCT02187718
Inclusion Criteria
female*
Yes
No
age 18-60 years*
Yes
No
diagnosis of invasive bc (established with core
needle biopsy of the breast lesion)*
Yes
No
breast carcinoma measures > 20 mm
ultrasonographically*
Yes
No
pre-operative us+fnac is negative or inconclusive*
Yes
No
no evidence of distant metastases*
Yes
No
asa classification i-iii*
Yes
No
signed informed consent*
Yes
No
Exclusion Criteria
history of previous breast surgery in the affected
breast*
Yes
No
history of previous axillary surgery in the
ipsilateral axilla*
Yes
No
history of radiation therapy (ipsilateral breast or
axilla)*
Yes
No
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history of neo-adjuvant therapy (for the bc)*
Yes
No
known allergy to lidocain*
Yes
No
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Eligibility Carcinoma, Squamous Cell
NCT02438995
Super-Selective Intraarterial Infusion of Cetuximab
(Erbitux) With or Without Radiation Thereapy for the
Treatment of Unrespectable Recurrent Squamous Cell
Carcinoma of the Head and Neck; ODM derived from:
https://clinicaltrials.gov/show/NCT02438995
All rights reserved. Please visit https://medical-data-
models.org/forms/12192
Eligibility Carcinoma, Squamous Cell
NCT02438995
Inclusion Criteria
1. male or female patients of 18 years of age.*
Yes
No
2. patients with a documented diagnosis of
recurrent head and neck squamous cell
carcinoma patients must have at least one
confirmed and evaluable tumor site.* the
recurrence must have bidimensional
measurements by clinical examination or ct scan.
a confirmed  recurrence site may also be biopsy-
proven*
Yes
No
3. tumor recurrence which is surgically
unresectable (appendix)*
Yes
No
4. patients must have a karnofsky performance
status ≥70% (or the equivalent ecog level of 0-2)
(see appendix performance status evaluation)
and an expected survival of ≥ three months.*
Yes
No
5. patients must have adequate hematologic
reserve with wbc≥3000/mm3, absolute
neutrophils ≥1500/mm3 and platelets ≥100,000/
mm3. patients who are on coumadin must have a
platelet count of ≥150,000/ mm3*
Yes
No
6. pre-enrollment chemistry parameters must
show: bilirubin<1.5x the institutional upper limit of
normal (iunl); ast or alt<2.5x iunl and
creatinine<1.5x iunl.*
Yes
No
7. pre-enrollment coagulation parameters (pt and
ptt) must be ≤1.5x the iunl.*
Yes
No
8. patients must agree to use a medically
effective method of contraception during and for a
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period of three months after the treatment period.
a pregnancy test will be performed on each
premenopausal female of childbearing potential
immediately prior to entry into the research
study.*
Yes
No
9. patients must be able to understand and give
written informed consent. informed consent must
be obtained at the time of patient screening.*
Yes
No
10. patients who refuse surgery.*
Yes
No
Exclusion Criteria
1. women who are pregnant or lactating.*
Yes
No
2. women of childbearing potential and fertile
men will be informed as to the potential risk of
procreation while participating in this research
trial and will be advised that they must use
effective contraception during and for a period of
three months after the treatment period.*
Yes
No
3. patients with significant intercurrent medical or
psychiatric conditions that would place them at
increased risk or affect their ability to receive or
comply with treatment or post-treatment clinical
monitoring.*
Yes
No
4. pre-existing cardiac or respiratory disorders*
Yes
No
5. unrelated malignancy within 3 years*
Yes
No
6. history of hypersensitivity reactions to other
egfr inhibitors*
Yes
No
7. metastatic disease*
Yes
No
8. less than 6 months from prior radiation therapy
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(arm 1)*
Yes
No
9. previous exposure to cetuximab*
Yes
No
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Eligibility Congestive Heart Failure
NCT02394470
BioImpedentiometry, Lung UltraSound and cONgestion in
Heart Failure; ODM derived from:
https://clinicaltrials.gov/show/NCT02394470
All rights reserved. Please visit https://medical-data-
models.org/forms/12193
Eligibility Congestive Heart Failure
NCT02394470
Inclusion Criteria
signed informed consent*
Yes
No
group-specific inclusion criteria:*
Yes
No
1. group 1  (acute heart failure - ahf), patient
admitted to the hospital for acute heart failure
(de-novo or exacerbation of chronic heart failure),
who have at least two of the following congestion
criteria:*
Yes
No
weight gain ≥ 2 kg over the three days prior to
hospitalization*
Yes
No
physical findings or radiographic signs of
pulmonary congestion (crackles, semi-
orthopnea)*
Yes
No
hepatomegaly > 2 cm from the arch rib or
ascites*
Yes
No
jugular turgor or central venous pressure > 10 cm
h20*
Yes
No
ankle swelling*
Yes
No
2. group 2  (chronic heart failure - chf):
outpatients with chronic heart failure (chf) with
characters of clinical stability*
Yes
No
no hospitalization in the previous six months*
Yes
No
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symptoms stable for at least 4 weeks*
Yes
No
oral therapy stable for at least 4 weeks*
Yes
No
no involuntary weight variations greater than 2 kg
in the last 4 weeks*
Yes
No
absence of signs of congestion*
Yes
No
3. group 3  (advanced chronic heart failure - ad-
chf) patients on optimal medical therapy for hf
and treated with periodic infusions of
levosimendan (every 4 weeks) according to the
following criteria*
Yes
No
systolic dysfunction (lvef <35%)*
Yes
No
nyha class iiib-iv and/or level intermacs 4, 5, 6*
Yes
No
≥2 admissions or access to the emergency
department for acute hf exacerbation in the
previous 12 months*
Yes
No
Exclusion Criteria
uremia in dialysis treatment*
Yes
No
invasive mechanical ventilation*
Yes
No
mechanical circulatory support*
Yes
No
cardiac cachexia defined as weight loss ≥ 5% in
the prior 12 months or body mass index <20
kg/m2 and hypoalbuminemia (albumin <3.2 g/dl)
or anemia (hemoglobin <12 g/l)*
Yes
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Eligibility Depression NCT01906476
Stepped Telemental Health Care Intervention for
Depression; ODM derived from:
https://clinicaltrials.gov/show/NCT01906476
All rights reserved. Please visit https://medical-data-
models.org/forms/12194
Eligibility Depression NCT01906476
Inclusion Criteria
has a dsm-iv diagnosis of non-psychotic major
depressive disorder (mdd) as assessed using the
mini international neuropsychiatric interview
(mini), plus a score of 12 or greater on the quick
inventory of depressive symptomatology -
clinician rated (qids-c)*
Yes
No
has a phone, access to the internet, and basic
internet skills*
Yes
No
is at least 18 years of age*
Yes
No
is able to speak and read english*
Yes
No
if currently taking an antidepressant medication,
participant must have been on a stable dose for
at least 10 days, and have no plans to change the
dose*
Yes
No
Exclusion Criteria
has visual, hearing, voice, or motor impairment
that would prevent completion of study
procedures*
Yes
No
is diagnosed with a psychotic disorder, bipolar
disorder, dissociative disorder, substance use or
other diagnosis for which participation in this trial
is either inappropriate or dangerous*
Yes
No
is severely suicidal (has ideation, plan, and
intent)*
Yes
No
is currently receiving or planning to begin
psychotherapy during the study treatment period*
Yes
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Eligibility Depression NCT01912664
Online Peer Networked Collaborative Learning for
Managing Depressive Symptoms; ODM derived from:
https://clinicaltrials.gov/show/NCT01912664
All rights reserved. Please visit https://medical-data-
models.org/forms/12195
Eligibility Depression NCT01912664
Inclusion Criteria
phq-9 of 10 or higher.*
Yes
No
has a dsm-iv diagnosis of major depressive
episode assessed using the quick inventory of
depressive symptomatology (qids).*
Yes
No
has a telephone, e-mail account, computer, and
broadband access to the internet.*
Yes
No
is able to speak and read english.*
Yes
No
is at least 19 years of age.*
Yes
No
is able to give informed consent.*
Yes
No
Exclusion Criteria
has hearing or voice impairment that would
prevent participation in psychotherapy*
Yes
No
has visual impairment that would prevent use of
the workbook and completion of assessment
materials.*
Yes
No
is diagnosed with a psychotic disorder, bipolar
disorder, dissociative disorder, current post-
traumatic stress disorder (ptsd), current
substance abuse, or other diagnosis for which
participation in a clinical trial of psychotherapy
may be either inappropriate or dangerous.
patients with substance abuse diagnoses who
have been clean and sober for 3 months will be
admitted if otherwise eligible.*
Yes
No
1 / 2
is currently receiving individual psychotherapy or
planning to receive psychotherapy during the 10-
week treatment phase of the study (social
networking site only)*
Yes
No
is planning to be out of town or unavailable for
treatment for 4 weeks or more during the
scheduled treatment time.*
Yes
No
exhibits severe suicidality, including ideation,
plan, and intent.*
Yes
No
has initiated treatment with an antidepressant in
past 10 days.  once patients have been on a
stable dose for 10 days and do not have an
appointment with a physician or psychiatrist to
change this dose, the patient will be eligible
based on this criterion (social networking site
only).*
Yes
No
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Eligibility DEPRESSION NCT02376491
Efficacy of Intermittent ThetaBurst Stimulation Compared to
10 Hz Stimulation on Dorsolateral Prefrontal Cortex in
Treatment Resistant Major Depressive Disorder: a Double-
blind Randomized Study; ODM derived from:
https://clinicaltrials.gov/show/NCT02376491
All rights reserved. Please visit https://medical-data-
models.org/forms/12196
Eligibility DEPRESSION
NCT02376491
Inclusion Criteria
age 18 years  to 75 years*
Yes
No
both gender eligible*
Yes
No
volontary and able to give consent*
Yes
No
major depressive episode (madrs > 20) single or
recurrent*
Yes
No
resistance to at least 2 antidepressants ,*
Yes
No
treated by antidepressant at efficient stable
posology since more than 4 weeks*
Yes
No
Exclusion Criteria
initiation or modification of antidepressant drug*
Yes
No
neurodegenerative disease*
Yes
No
bipolar i, ii disorder*
Yes
No
schizophrenia, schizoaffective disorder,
schizophreniform, delusional disorder, or current
psychotic symptoms*
Yes
No
substance abuse in past 15 days*
Yes
No
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substance dependence not weaned*
Yes
No
benzodiazepine and any anticonvulsant during
rtms treatment course*
Yes
No
ect failure in medical history*
Yes
No
contra-indication to rtms and mri*
Yes
No
pregnancy*
Yes
No
difficulty to obtain informed consent*
Yes
No
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Eligibility DEPRESSION NCT02376491
Eligibility Depression, Normobaric
Hyperoxia. NCT02149563
Oxygen Therapy in Depression; ODM derived from:
https://clinicaltrials.gov/show/NCT02149563
All rights reserved. Please visit https://medical-data-
models.org/forms/12197
Eligibility Depression, Normobaric
Hyperoxia. NCT02149563
Inclusion Criteria
men and women aged 18-65 years diagnosed
with mild to moderate depression.*
Yes
No
Exclusion Criteria
patients with oxygen saturation below 95%;*
Yes
No
an unstable mental (psychiatric) condition*
Yes
No
a psychiatric condition that requires a change in
pharmacotherapy (importantly - medications will
not be changed in patients who will be enrolled to
the study)*
Yes
No
acute or chronic respiratory disease*
Yes
No
any severe physical illness*
Yes
No
suicidal thoughts or attempts*
Yes
No
drug abuse*
Yes
No
obesity (bmi over 30)*
Yes
No
inability to cease smoking during night hours
while participants are supposed to be using the
oxygen/air supplementing machine.*
Yes
No
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Eligibility Schizophrenia NCT01971073
Transcranial Direct Current Stimulation Influences on
Cognitive Inhibition in Schizophrenia; ODM derived from:
https://clinicaltrials.gov/show/NCT01971073
All rights reserved. Please visit https://medical-data-
models.org/forms/12206
Eligibility Schizophrenia
NCT01971073
Inclusion Criteria
must be 18 years old or above.*
Yes
No
clinical diagnosis of schizophrenia or
schizoaffective disorder*
Yes
No
must be with a stable mental status as
demonstrated by a stable positive and-negative
symptom score (panss) score over a period of 2
weeks.*
Yes
No
must have no medication changes in the 2 weeks
prior to obtaining informed consent.*
Yes
No
must be able to give informed consent for the
trial.*
Yes
No
Exclusion Criteria
unwilling or unable, in the opinion of the
investigator, to comply with study instructions*
Yes
No
pregnant or breast-feeding.*
Yes
No
current dsm-v substance or alcohol abuse.*
Yes
No
concurrent delirium*
Yes
No
mental retardation*
Yes
No
drug-induced psychosis*
Yes
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No
history of clinically significant brain trauma
documented by ct or mri.*
Yes
No
epilepsy or had seizures 6 months prior the
beginning of the study*
Yes
No
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Eligibility Diabetes Mellitus NCT02399657
Effect of Dexamethasone Implant in Hard Exudate
Complicated With Diabetic Macular Edema; ODM derived
from: https://clinicaltrials.gov/show/NCT02399657
All rights reserved. Please visit https://medical-data-
models.org/forms/12207
Eligibility Diabetes Mellitus
NCT02399657
Inclusion Criteria
1. patients diagnosed with csme (clinically
significant macular edema) with hard exudates
within 1500 micrometer from foveal center*
Yes
No
2. those who have a bcva (best corrected visual
acuity) of study eye between 0.06(20/320) and
0.5(20/40)*
Yes
No
3. those who have a central macular thickness on
oct over 300 micrometer*
Yes
No
4. if both eyes are eligible, eye having more hard
exudates is selected (contralateral eye should be
treated with corticosteroid other than ozurdex or
focal laser photocoagulation, anti-vegf (vascular
endothelial growth factor) injection is not allowed
in contralateral eye)*
Yes
No
Exclusion Criteria
1. those who have csme without hard exudates*
Yes
No
2. those who have macular edema not related
with diabetic retinopathy (e.g. amd (age-related
macular degeneration), uveitis, retinal vein
occlusion and untreated malignant hypertension)*
Yes
No
3. those who have a history of intraocular surgery
(e.g. cataract surgery) within 3 months*
Yes
No
4. those who have a visual acuity of contralateral
eye less than 0.1 (10/100)*
Yes
No
5. those who received  focal laser treatment on
macula within 3 months*
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Yes
No
6. those who had intravitreal anti-vegf agent
injection within 3 months*
Yes
No
7. those who had intravitreal triamcinolone
injection within 6 months*
Yes
No
8. those  who have other ophthalmologic disease
affecting visual acuity (e.g. central corneal
opacity, cataract change at lens center)*
Yes
No
9. those who have severe systemic disease (e.g.
uncontrolled dm, hypertension, cardiovascular
disease, cerebrovascular disease)*
Yes
No
10. those who refuse to submit written consent*
Yes
No
11. those who cannot understand the contents of
the clinical study and cooperate in the clinical
trial*
Yes
No
12. those who are pregnant or lactating women*
Yes
No
13. those who have a history of vitrectomy*
Yes
No
14. those who require systemic corticosteroid or
immunosuppressive agent treatment*
Yes
No
15. those who are banned from using ozurdex*
Yes
No
ocular infection or periocular infection*
Yes
No
advanced glaucoma*
Yes
No
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Eligibility Diabetes Mellitus NCT02399657
hypersensitivity to dexamethasone or other
component of ozurdex*
Yes
No
posterior lens capsule rupture or aphakia*
Yes
No
anterior chamber intraocular lens or posterior
capsule rupture*
Yes
No
3 / 3
Eligibility Diabetes Mellitus NCT02399657
Eligibility Diabetes Mellitus, Type 2
NCT02312063
Dietary Impacts on Glucose-lowering Effects of Sitagliptin
in Type 2 Diabetes; ODM derived from:
https://clinicaltrials.gov/show/NCT02312063
All rights reserved. Please visit https://medical-data-
models.org/forms/12208
Eligibility Diabetes Mellitus, Type 2
NCT02312063
Inclusion Criteria
japanese t2dm patients, who are oad nave or
receive 4-week wash out of one oad (glinides,
alpha-gi, metformin) before randomization.*
Yes
No
hba1c:6.0-8.0 %*
Yes
No
bmi:18-30 kg/m2*
Yes
No
age:20-75 years old*
Yes
No
crcl: > 60ml/min*
Yes
No
Exclusion Criteria
patients on dpp-4 inhibitors or glimepiride*
Yes
No
patients treated with pioglitazone*
Yes
No
patients with moderate/severe renal impairments*
Yes
No
patients with insulin or glp-1 receptor agonists*
Yes
No
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Eligibility Diabetes Mellitus, Type 2
NCT02390050
A Dose Range Finding Study to Evaluate the Effect of
Bexagliflozin Tablets in Subjects With Type 2 Diabetes
Mellitus; ODM derived from:
https://clinicaltrials.gov/show/NCT02390050
All rights reserved. Please visit https://medical-data-
models.org/forms/12209
Eligibility Diabetes Mellitus, Type 2
NCT02390050
Inclusion Criteria
1. men or women  20 years of age at screening.
women of childbearing potential must test
negative by urine pregnancy test.*
Yes
No
2. treatment naïve or currently taking one oral
anti-diabetic medication in combination with diet
and exercise*
Yes
No
3. diagnosed with t2dm with hba1c levels at
screening between 7.0% and 8.5% (inclusive) if
treatment naïve or with hba1c levels between 6.5
and 8.5% (inclusive) if on one oral anti-diabetic
medication*
Yes
No
4. currently having a body mass index (bmi) ≤ 40
kg/m2*
Yes
No
5. taking stable doses of medication for
hypertension or hyperlipidemia that has not
changed for at least 30 days prior to screening (if
applicable)*
Yes
No
6. able to comprehend the study participation
requirements and willing to provide written
informed consent in accordance with institutional
and regulatory guidelines*
Yes
No
7. able to maintain adequate glycemic control at
the run-in visit (for subjects who complete the
washout)*
Yes
No
8. having an hba1c between 7.0 and 8.5%
(inclusive) prior to randomization (day -3 to-5)*
Yes
No
9. capable of adhering to the investigational
1 / 4
product administration requirements as
evidenced by omission of no more than one dose
of run-in medication*
Yes
No
Exclusion Criteria
1. a diagnosis of type 1 diabetes mellitus or
maturity-onset diabetes of the young*
Yes
No
2. current use of parenteral therapy for treatment
of diabetes*
Yes
No
3. pregnancy or current breastfeeding status*
Yes
No
4. hemoglobinopathy or carrier status for
hemoglobin alleles that affect hba1c
measurement*
Yes
No
5. genitourinary tract infection within 6 weeks of
screening or history of ≥3 genitourinary infections
requiring treatment within 6 months of screening*
Yes
No
6. estimated glomerular filtration rate (egfr)  < 60
ml/min/1.73 m2 at screening.*
Yes
No
7. uncontrolled hypertension at screening*
Yes
No
8. a positive result on hepatitis b surface antigen,
hepatitis c, or positive result from screen for
drugs of abuse*
Yes
No
9. history of human immunodeficiency virus
infection*
Yes
No
10. life expectancy < 2 years*
Yes
No
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11. history of new york heart association class 4
heart failure within 3 months of screening*
Yes
No
12. history of myocardial infarction, unstable
angina, stroke, or hospitalization for heart failure
within 3 months of screening*
Yes
No
13. history of treatment with an investigational
drug within 30 days or within 7 half lives of the
investigational drug, whichever is longer*
Yes
No
14. previous treatment with bexagliflozin or study
drug egt0001474*
Yes
No
15. currently or within 6 months of taking any
sodium glucose transporter 2 (sglt2) inhibitors
from screening*
Yes
No
16. currently participating in another
interventional trial*
Yes
No
17. not able to comply with the study scheduled
visits*
Yes
No
18. affected by any condition, disease, disorder,
or clinically relevant abnormality that, in the
opinion of the investigator, would jeopardize the
subject's appropriate participation in this study.*
Yes
No
19. liver function tests resulting in alanine
transaminase (alt) or aspartate transaminase
(ast) ≥ 2.5 x upper limit of normal (uln) or total
bilirubin ≥ 1.5 x uln, with the exception of isolated
gilbert's syndrome ,at screening*
Yes
No
20. exhibiting fasting plasma glucose ≥ 250 mg/dl
(13.9 mmol/l) on two or more consecutive days
prior to randomization or exhibiting severe clinical
signs or symptoms of hyperglycemia during the
washout or run-in periods, including weight loss,
blurred vision, increased thirst, or increased
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urination, or fatigue*
Yes
No
21. fasting plasma glucose ≥ 250 mg/dl at
randomization*
Yes
No
22. prior renal transplantation or evidence of
nephrotic syndrome, defined as a urine albumin-
to-creatinine ratio (uacr) > 2000 mg/g at
screening*
Yes
No
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Eligibility Diabetes NCT02439177
Evaluating System Accuracy and User Performance of
Omnitest® Blood Glucose Monitoring Systems for Self-
testing in Managing Diabetes Mellitus; ODM derived from:
https://clinicaltrials.gov/show/NCT02439177
All rights reserved. Please visit https://medical-data-
models.org/forms/12211
Eligibility Diabetes NCT02439177
Inclusion Criteria
male or female subjects with type 1 or type 2
diabetes, for the evaluation of system accuracy
also healthy subjects*
Yes
No
age ≥ 18*
Yes
No
signed and dated informed consent form*
Yes
No
for small modifications of the insulin doses to
achieve certain blood glucose values (system
accuracy evaluation): male or female subjects
with diabetes mellitus type 1 with intensified
insulin therapy (intensified conventional therapy -
i.c.t.) or insulin pump therapy (continuous
subcutaneous insulin infusion - c.s.i.i.)*
Yes
No
Exclusion Criteria
pregnancy or lactation period*
Yes
No
severe acute illness that, in the opinion of the
investigating physician, might confound the
results of the test or which could result in a risk to
the subject caused by the test.*
Yes
No
severe chronic illness besides diabetes mellitus
as assessed by the investigating physician that
might confound the results of the test or which
could result in a risk to the subject caused by the
test.*
Yes
No
mental incapacity or language barriers precluding
adequate compliance with the test procedures*
Yes
No
legal incompetence or limited legal competence*
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Yes
No
dependency from the sponsor or the clinical
investigator (e.g. co-workers of the sponsor or the
clinical research centre)*
Yes
No
for user performance evaluation: subjects having
participated in a study with omnitest® 5 before.*
Yes
No
for system accuracy evaluation: subjects intended
to provide blood samples with glucose
concentrations between 50 and 80 mg/dl must
not have coronary heart disease, myocardial
infarction in history, cerebral events in history,
peripheral artery occlusive disease or impaired
hypoglycaemia awareness*
Yes
No
anamnestically relevant amounts of interfering
substances in the blood, following labelling in the
instructions for use as reviewed and evaluated by
a physician during screening.*
Yes
No
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Eligibility Diabetes, Type 2 NCT02222623
The Inova Type 2 Diabetes Mellitus Study; ODM derived
from: https://clinicaltrials.gov/show/NCT02222623
All rights reserved. Please visit https://medical-data-
models.org/forms/12212
Eligibility Diabetes, Type 2
NCT02222623
Inclusion Criteria
1. adult patients ages18-75 admitted to a general
medicine or surgical department of medicine
hospitalist services.*
Yes
No
2. a known history of t2dm, receiving either diet
alone, low dose insulin (≤0.4 units/kg/day), oads,
glp1 analogs, or in any combination of oads, glp1
analogs and low dose insulin (≤0.4 units/kg/day).*
Yes
No
3. subjects must have a bg >140 mg/dl and ≤240
mg/dl before randomization without laboratory
evidence of diabetic ketoacidosis or
hyperglycemic hyperosmolar nonketotic
syndrome (bicarbonate <18 meq/l, ph <7.30, or
positive serum or urinary ketones, bg >240
mg/dl).*
Yes
No
Exclusion Criteria
1. patients with a diagnosis of type 1 diabetes
mellitus.*
Yes
No
2. patients using nutritional bolus insulin at
home.*
Yes
No
3. patients with increased blood glucose
concentration, but without a known history of
diabetes.*
Yes
No
4. patients with a history of diabetic ketoacidosis,
hyperglycemic hyperosmolar nonketotic
syndrome, or ketonuria.*
Yes
No
5. patients admitted to or expected to require
admission to any intensive care unit (icu) or
intermediate care unit (imc).*
Yes
No
1 / 2
6. patients who are receiving or are anticipated to
receive enteral or parenteral nutrition.*
Yes
No
7. patients admitted for cardiac surgery.*
Yes
No
8. patients receiving continuous insulin infusion.*
Yes
No
9. patients with clinically relevant hepatic disease
(diagnosed liver cirrhosis and portal
hypertension), corticosteroid therapy, or impaired
renal function (creatinine ≥ 3.5 mg/dl).*
Yes
No
10. persons with decisional incapacity (mental
condition rendering the subject unable to
understand the nature, scope, and possible
consequences of the study).*
Yes
No
11. female subjects who are pregnant or
immediately (same hospitalization) post partum
at time of enrollment into the study.*
Yes
No
12. patients with recognized or suspected
endocrine disorders associated with increased
insulin resistance, acromegaly, or
hyperthyroidism.*
Yes
No
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Eligibility Head and Neck Squamous Cell
Carcinoma NCT02143622
Study of Efficacy and Safety of LJM716 and Cetuximab in
Head and Neck Squamous Cell Carcinoma Patients; ODM
derived from: https://clinicaltrials.gov/show/NCT02143622
All rights reserved. Please visit https://medical-data-
models.org/forms/12213
Eligibility Head and Neck Squamous
Cell Carcinoma NCT02143622
Inclusion Criteria
most recent regimen contains both platinum and
cetuximab (phase ii, group b).*
Yes
No
ecog performance status (ps) ≤ 2.*
Yes
No
recovery from all aes of previous anti-cancer
therapies, to baseline or to ctcae grade ≤ 1,
except for alopecia.*
Yes
No
measurable disease as determined by recist
v1.1.*
Yes
No
Exclusion Criteria
previous anti-her3 antibody treatment.*
Yes
No
symptomatic brain metastasis.*
Yes
No
prior systemic anti-cancer treatment, within a
period of time that is shorter than the cycle length
used for that treatment prior to starting study
treatment.*
Yes
No
prior anaphylactic or other severe infusion
reaction to human immunoglobulin or antibody
formulations.*
Yes
No
inadequate end organ function.*
Yes
No
ongoing diarrhea ctcae grade ≥ 2. other protocol-
defined inclusion/exclusion criteria may apply*
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No
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Eligibility Heart Rate Control in ICD Patients
With Heart Failure NCT01868880
Effect of Ivabradine and Beta-blockers Combination Versus
Beta-blockers Up-titration on Right Ventricular Pacing; ODM
derived from: https://clinicaltrials.gov/show/NCT01868880
All rights reserved. Please visit https://medical-data-
models.org/forms/12214
Eligibility Heart Rate Control in ICD
Patients With Heart Failure
NCT01868880
Inclusion Criteria
age ≥ 18 years.*
Yes
No
patients with stable chronic heart failure
implanted with mono-cameral or bicameral icd
with a home monitoring remote control.*
Yes
No
moderate to severe left ventricular dysfunction (fe
≤ 40%).*
Yes
No
any cause of heart failure was allowed apart
congenital heart disease.*
Yes
No
bicameral icd programmed in ddd or aai/ddd with
av interval < 300 msec.*
Yes
No
rest ecg heart rate ≥70 bpm;*
Yes
No
sinus rhythm.*
Yes
No
in therapy with low-dose of beta-blocker
(bisoprolol 1,25-2,5 mg) and with the maximum
dose tolerated of angiotensin-converting enzyme
inhibitor or blockade of angiotensin ii receptor,
mineralocorticoid antagonist, antiplatelet and
lipid-lowering therapy, unless contraindicated.*
Yes
No
Exclusion Criteria
inability of providing informed consent;*
Yes
No
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age < 18 years.*
Yes
No
state of pregnancy or lactation.*
Yes
No
recent (<2 months) myocardial infarction;*
Yes
No
contraindications to beta-blockers and
ivabradine;*
Yes
No
rest ecg heart rate < 70 bpm;*
Yes
No
no sinus rhythm.*
Yes
No
administration of non-dihydropyridinic calcium
channels antagonists, digitalis, class i
antiarrhythmic drugs, strong inhibitors of
cytochrome p450 3a4 at the time of enrollment.*
Yes
No
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NCT01868880
Eligibility Hepatocellular Carcinoma
NCT02487017
DC-CIK Combined With TACE in the Treatment of
Hepatocellular Carcinoma; ODM derived from:
https://clinicaltrials.gov/show/NCT02487017
All rights reserved. Please visit https://medical-data-
models.org/forms/12215
Eligibility Hepatocellular Carcinoma
NCT02487017
Inclusion Criteria
18-80 years old;*
Yes
No
histologically confirmed with hepatocellular
carcinoma at stage i-ii;*
Yes
No
patients who can accept transcatheter arterial
chemoembolization ;*
Yes
No
patients who have a life expectancy of at least 3
months;*
Yes
No
patients who have a child-pugh:a/b; .eastern
cooperative oncology group (ecog) performance
status was 0-2.*
Yes
No
Exclusion Criteria
white blood cell ＜3 x 10^9/l,platelet count ＜75 x
10^9/l;bun and cr more than normal limits on 3.0
times ;*
Yes
No
known or suspected allergy to the investigational
agent or any agent given in association with this
trial;*
Yes
No
pregnant or lactating patients;*
Yes
No
known history of human immunodeficiency virus
(hiv), hepatitis c virus (hcv) or treponemapallidun
(tp) infection;*
Yes
No
patients who are suffering from serious
autoimmune disease;*
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Yes
No
patients who had used long time or are using
immunosuppressant;*
Yes
No
patients who had active infection;*
Yes
No
prior use of any anti-cancer treatment in 30
days;*
Yes
No
now or recently will join another experimental
clinical study ;*
Yes
No
history of organ allograft;*
Yes
No
other situations that the researchers considered
unsuitable for this study*
Yes
No
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Eligibility Hypertension NCT02391779
Flaxseed Lignan Supplementation in Elderly Participants
With Stage I Hypertension; ODM derived from:
https://clinicaltrials.gov/show/NCT02391779
All rights reserved. Please visit https://medical-data-
models.org/forms/12216
Eligibility Hypertension
NCT02391779
Inclusion Criteria
high normal blood pressure (130/85 - 139/89) or
stage i hypertension (140/90 - 150/90)*
Yes
No
ability to follow simple instructions*
Yes
No
Exclusion Criteria
age below 60 years.*
Yes
No
individuals living in long term care homes.*
Yes
No
individuals unable to walk for 30 minutes.*
Yes
No
unstable diabetes, or diabetics taking insulin
(note: eligible diabetic participants will undergo
additional testing during the study ).*
Yes
No
current cancer or diagnosed with cancer in the
past 2 years.*
Yes
No
significant liver or other gastrointestinal disorder
including inflammatory bowel disease. (while
constipation is the most common gastrointestinal
problem in the elderly, it would not be a
contraindication)*
Yes
No
significant kidney disorder.*
Yes
No
have taken oral antibiotics in the past three
months*
Yes
No
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unstable or severe cardiac disease, recent
myocardial infarction, or stroke (either in past 6
months or significantly affecting physical
mobility).*
Yes
No
unstable other medical disease including, but not
limited to, pulmonary disorder, epilepsy and
genitourinary disorder.*
Yes
No
migraine with aura within the last year (as this is
a risk factor for stroke).*
Yes
No
current diagnosis of a bleeding condition, or at
risk of bleeding.*
Yes
No
significant immune-compromise.*
Yes
No
current use of hormone replacement therapy
(except thyroid).*
Yes
No
current use of blood pressure medications and/or
diuretics*
Yes
No
current use of flax seed supplement*
Yes
No
participation in any other clinical trial with an
investigational agent within one month prior to
randomization.*
Yes
No
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Eligibility Diabetes NCT02230618
Post Marketing Surveillance (PMS) Study of Ryzodeg™
(Insulin Degludec /Insulin Aspart) in Patients With Diabetes
Mellitus in Routine Clinical Practice in India; ODM derived
from: https://clinicaltrials.gov/show/NCT02230618
All rights reserved. Please visit https://medical-data-
models.org/forms/12219
Eligibility Diabetes NCT02230618
Inclusion Criteria
informed consent obtained before any study-
related activities. (study-related activities are any
procedures that are related to recording of data
according to the protocol). the historical data
including the data before informed consent
obtained (e.g., hba1c (glycated haemoglobin ),
fpg (fasting plasma glucose), pppg (postprandial
plasma glucose), severe hypoglycaemia before
the start of ryzodeg therapy) can be used for
baseline data*
Yes
No
patients with insulin requiring diabetes mellitus
and who are scheduled to start treatment with
ryzodeg™ based on the clinical judgment of their
treating physician*
Yes
No
Exclusion Criteria
known or suspected allergy to ryzodeg™ any of
the active substances or any of the excipients*
Yes
No
previous participation in this study*
Yes
No
mental incapacity, unwillingness or language
barriers precluding adequate understanding or
cooperation*
Yes
No
patients who are or have previously been on
ryzodeg™ therapy*
Yes
No
patients who are participating in other studies or
clinical trials*
Yes
No
patients who are pregnant, breast feeding or have
the intention of becoming pregnant within the
following 12 months*
Yes
1 / 2
No
2 / 2
Eligibility Diabetes NCT02230618
nfdm
nfdm of eGK
All rights reserved. Please visit https://medical-data-
models.org/forms/12226
Der Notfalldatensatz der eGK
Notfalldatensatz
Letzte_Aktualisierung*
Versionskennung*
Zusätzliche_Information
Freitext*
Diagnose_1
Diagnose_Code*
Diagnosesicherheit*
Seitenlokalisation*
Text_Diagnose*
Zeitpunkt_Diagnosestellung*
Fremdbefund*
Ja
Nein
Identifier_Codiersystem_Diagnose_1
Versionskennung*
Diagnose_2
Diagnose_Code*
Diagnosesicherheit*
Seitenlokalisation*
Text_Diagnose*
Zeitpunkt_Diagnosestellung*
1 / 17
Fremdbefund*
Ja
Nein
Identifier_Codiersystem_Diagnose_2
Versionskennung*
Diagnose_3
Diagnose_Code*
Diagnosesicherheit*
Seitenlokalisation*
Text_Diagnose*
Zeitpunkt_Diagnosestellung*
Fremdbefund*
Ja
Nein
Identifier_Codiersystem_Diagnose_3
Versionskennung*
Diagnose_4
Diagnose_Code*
Diagnosesicherheit*
Seitenlokalisation*
Text_Diagnose*
Zeitpunkt_Diagnosestellung*
Fremdbefund*
Ja
Nein
Identifier_Codiersystem_Diagnose_4
Versionskennung*
2 / 17
nfdm
Diagnose_5
Diagnose_Code*
Diagnosesicherheit*
Seitenlokalisation*
Text_Diagnose*
Zeitpunkt_Diagnosestellung*
Fremdbefund*
Ja
Nein
Identifier_Codiersystem_Diagnose_5
Versionskennung*
Diagnose_6
Diagnose_Code*
Diagnosesicherheit*
Seitenlokalisation*
Text_Diagnose*
Zeitpunkt_Diagnosestellung*
Fremdbefund*
Ja
Nein
Identifier_Codiersystem_Diagnose_6
Versionskennung*
Diagnose_7
Diagnose_Code*
Diagnosesicherheit*
3 / 17
nfdm
Seitenlokalisation*
Text_Diagnose*
Zeitpunkt_Diagnosestellung*
Fremdbefund*
Ja
Nein
Identifier_Codiersystem_Diagnose_7
Versionskennung*
Diagnose_8
Diagnose_Code*
Diagnosesicherheit*
Seitenlokalisation*
Text_Diagnose*
Zeitpunkt_Diagnosestellung*
Fremdbefund*
Ja
Nein
Identifier_Codiersystem_Diagnose_8
Versionskennung*
Diagnose_9
Diagnose_Code*
Diagnosesicherheit*
Seitenlokalisation*
Text_Diagnose*
4 / 17
nfdm
Zeitpunkt_Diagnosestellung*
Fremdbefund*
Ja
Nein
Identifier_Codiersystem_Diagnose_9
Versionskennung*
Diagnose_10
Diagnose_Code*
Diagnosesicherheit*
Seitenlokalisation*
Text_Diagnose*
Zeitpunkt_Diagnosestellung*
Fremdbefund*
Ja
Nein
Identifier_Codiersystem_Diagnose_10
Versionskennung*
Diagnose_11
Diagnose_Code*
Diagnosesicherheit*
Seitenlokalisation*
Text_Diagnose*
Zeitpunkt_Diagnosestellung*
Fremdbefund*
Ja
Nein
5 / 17
nfdm
Identifier_Codiersystem_Diagnose_11
Versionskennung*
Diagnose_12
Diagnose_Code*
Diagnosesicherheit*
Seitenlokalisation*
Text_Diagnose*
Zeitpunkt_Diagnosestellung*
Fremdbefund*
Ja
Nein
Identifier_Codiersystem_Diagnose_12
Versionskennung*
Diagnose_13
Diagnose_Code*
Diagnosesicherheit*
Seitenlokalisation*
Text_Diagnose*
Zeitpunkt_Diagnosestellung*
Fremdbefund*
Ja
Nein
Identifier_Codiersystem_Diagnose_13
Versionskennung*
Diagnose_14
Diagnose_Code*
6 / 17
nfdm
Diagnosesicherheit*
Seitenlokalisation*
Text_Diagnose*
Zeitpunkt_Diagnosestellung*
Fremdbefund*
Ja
Nein
Identifier_Codiersystem_Diagnose_14
Versionskennung*
Diagnose_15
Diagnose_Code*
Diagnosesicherheit*
Seitenlokalisation*
Text_Diagnose*
Zeitpunkt_Diagnosestellung*
Fremdbefund*
Ja
Nein
Identifier_Codiersystem_Diagnose_15
Versionskennung*
Diagnose_16
Diagnose_Code*
Diagnosesicherheit*
Seitenlokalisation*
7 / 17
nfdm
Text_Diagnose*
Zeitpunkt_Diagnosestellung*
Fremdbefund*
Ja
Nein
Identifier_Codiersystem_Diagnose_16
Versionskennung*
Diagnose_17
Diagnose_Code*
Diagnosesicherheit*
Seitenlokalisation*
Text_Diagnose*
Zeitpunkt_Diagnosestellung*
Fremdbefund*
Ja
Nein
Identifier_Codiersystem_Diagnose_17
Versionskennung*
Diagnose_18
Diagnose_Code*
Diagnosesicherheit*
Seitenlokalisation*
Text_Diagnose*
Zeitpunkt_Diagnosestellung*
8 / 17
nfdm
Fremdbefund*
Ja
Nein
Identifier_Codiersystem_Diagnose_18
Versionskennung*
Diagnose_19
Diagnose_Code*
Diagnosesicherheit*
Seitenlokalisation*
Text_Diagnose*
Zeitpunkt_Diagnosestellung*
Fremdbefund*
Ja
Nein
Identifier_Codiersystem_Diagnose_19
Versionskennung*
Diagnose_20
Diagnose_Code*
Diagnosesicherheit*
Seitenlokalisation*
Text_Diagnose*
Zeitpunkt_Diagnosestellung*
Fremdbefund*
Ja
Nein
Identifier_Codiersystem_Diagnose_20
Versionskennung*
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Allergie_Unverträglichkeiten_1
Text_Allergie_Unverträglichkeit*
Arzneimittel*
Reaktion*
Fremdbefund*
Ja
Nein
Allergie_Unverträglichkeiten_2
Text_Allergie_Unverträglichkeit*
Arzneimittel*
Reaktion*
Fremdbefund*
Ja
Nein
Allergie_Unverträglichkeiten_3
Text_Allergie_Unverträglichkeit*
Arzneimittel*
Reaktion*
Fremdbefund*
Ja
Nein
Allergie_Unverträglichkeiten_4
Text_Allergie_Unverträglichkeit*
Arzneimittel*
Reaktion*
Fremdbefund*
Ja
Nein
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Allergie_Unverträglichkeiten_5
Text_Allergie_Unverträglichkeit*
Arzneimittel*
Reaktion*
Fremdbefund*
Ja
Nein
Allergie_Unverträglichkeiten_6
Text_Allergie_Unverträglichkeit*
Arzneimittel*
Reaktion*
Fremdbefund*
Ja
Nein
Allergie_Unverträglichkeiten_7
Text_Allergie_Unverträglichkeit*
Arzneimittel*
Reaktion*
Fremdbefund*
Ja
Nein
Allergie_Unverträglichkeiten_8
Text_Allergie_Unverträglichkeit*
Arzneimittel*
Reaktion*
Fremdbefund*
Ja
Nein
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Allergie_Unverträglichkeiten_9
Text_Allergie_Unverträglichkeit*
Arzneimittel*
Reaktion*
Fremdbefund*
Ja
Nein
Allergie_Unverträglichkeiten_10
Text_Allergie_Unverträglichkeit*
Arzneimittel*
Reaktion*
Fremdbefund*
Ja
Nein
Behandelnder_Arzt_Institution_1
Vorname_Arzt*
Name_Arzt*
Institutionsbezeichnung*
Telefonnummer*
Behandelnder_Arzt_Institution_2
Vorname_Arzt*
Name_Arzt*
Institutionsbezeichnung*
Telefonnummer*
Behandelnder_Arzt_Institution_3
12 / 17
nfdm
Vorname_Arzt*
Name_Arzt*
Institutionsbezeichnung*
Telefonnummer*
Einverständniserklärung_Arzt
Vorname*
Name*
Adresse*
Zu_benachrichtigende_Person_Institution
_1
Vorname*
Name*
Telefonnummer*
Zu_benachrichtigende_Person_Institution
_2
Vorname*
Name*
Telefonnummer*
Zu_benachrichtigende_Person_Institution
_3
Vorname*
Name*
Telefonnummer*
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Versicherter
Versicherter_ID*
Vorname*
Name*
Vorsatzwort*
Namenzusatz*
Titel*
Geburtsdatum*
Besondere_Hinweise
Schwangerschaft*
Ja
Nein
Kommunikationsstörungen_1*
Kommunikationsstörungen_2*
Kommunikationsstörungen_3*
Kommunikationsstörungen_4*
Kommunikationsstörungen_5*
Weglaufgefährdung*
Sonstige_Hinweise*
Schwangerschaft
Errechneter_Entbindungstermin*
Implantate_1
Implantate*
Typenbezeichnung*
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Fremdbefund*
Ja
Nein
Datum_Implantation*
Implantate_2
Implantate*
Typenbezeichnung*
Fremdbefund*
Ja
Nein
Datum_Implantation*
Implantate_3
Implantate*
Typenbezeichnung*
Fremdbefund*
Ja
Nein
Datum_Implantation*
Implantate_4
Implantate*
Typenbezeichnung*
Fremdbefund*
Ja
Nein
Datum_Implantation*
Implantate_5
Implantate*
Typenbezeichnung*
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Fremdbefund*
Ja
Nein
Datum_Implantation*
Implantate_6
Implantate*
Typenbezeichnung*
Fremdbefund*
Ja
Nein
Datum_Implantation*
Implantate_7
Implantate*
Typenbezeichnung*
Fremdbefund*
Ja
Nein
Datum_Implantation*
Implantate_8
Implantate*
Typenbezeichnung*
Fremdbefund*
Ja
Nein
Datum_Implantation*
Implantate_9
Implantate*
Typenbezeichnung*
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Fremdbefund*
Ja
Nein
Datum_Implantation*
Implantate_10
Implantate*
Typenbezeichnung*
Fremdbefund*
Ja
Nein
Datum_Implantation*
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CLL Eligibility BO17072 NCT00090051
An open-label, multicenter, randomized, comparative,
phase III study to evaluate the efficacy and safety of
rituximab plus fludarabine and cyclophosphamide (FCR)
versus fludarabine and cyclophosphamide alone (FC) in
previously treated patients with CD20 positive B-cell
chronic lymphocytic leukemia (CLL).
FCR Versus FC Alone in the Treatment of Chronic
Lymphocytic Leukemia (CLL) in Relapsed Patients
NCT00090051
Roche BO17072
All rights reserved. Please visit https://medical-data-
models.org/forms/12228
Eligibility Chronic Lymphocytic
Leukemia NCT00090051
Inclusion Criteria
Age 18 years or older
>= 18
years
Yes
No
Established diagnosis of B-cell CLL by NCI
Working Group criteria
Yes
No
Patients with CD20-positive B-cell CLL (NCI
criteria) who have been previously treated with
one of the following chemotherapy regimens:
-	single agent chlorambucil +/-
prednisone/prednisolone,
-	single agent fludarabine (or other nucleoside
analogue),
-	alkylator-containing combination therapy (e.g.
CHOP/CVP).
Yes
No
Life expectancy > 6 months
>= 6
months
Yes
No
ECOG performance status 0-1
Yes
No
ANC >= 1 x 10E9/L
>= 1
10^9/L
Yes
No
Platelet count >= 50 x 10E9/L
>= 50
10^9/L
Yes
No
Creatinine clearance, calculated according to the
formula of Cockroft and Gault >= 50 ml/min
1 / 4
>= 50
ml/min
Yes
No
Total bilirubin <= 2 x ULN
Yes
No
Alkaline phosphatase and transaminases <= 2 x
ULN
Yes
No
A negative serum pregnancy test one week prior
to treatment must be available both for pre-
menopausal women and for women who are < 2
years after the onset of menopause
Yes
No
Written informed consent
Yes
No
Exclusion Criteria
Patients who have received prior combination
treatment with cyclophosphamide and fludarabine
either concurrently or sequentially.
Yes
No
Patients who are refractory to fludarabine (or any
nucleoside analogue).
Refractory is defined as not achieving at least a
PR for a minimum duration of 6 months.
Yes
No
Patients who have had prior treatment with
interferon, rituximab or another monoclonal
antibody
Yes
No
Patients who have had a prior allogeneic BMT or
autologous BMT or peripheral stem cell
transplant (PBSCT) or patients who are
considered to be candidates for allogeneic or
autologous BMT or PSCT as assessed by his/her
treating physician
Yes
No
Fertile men or women of childbearing potential
not using adequate contraception (oral
contraceptives, intrauterine device or barrier
method of contraception in conjunction with
2 / 4
CLL Eligibility BO17072 NCT00090051
spermicidal jelly or surgically sterile).
Yes
No
Severe grade 3 or 4 non-hematological toxicity or
prolonged (> 2 weeks) cytopenia on prior
fludarabine regimen
Yes
No
Patients with a history of Fludarabine-induced or
clinically significant autoimmune cytopenia as
assessed by his/her treating physician (Coombs-
positive patients without clinical signs of
autoimmune hemolytic anemia are eligible for
study entry)
Yes
No
Patients with a history of other malignancies
within 2 years prior to study entry, except for
adequately treated carcinoma in situ of the
cervix; basal or squamous cell skin cancer; low
grade, early stage localized prostate cancer
treated surgically with curative intent; good
prognosis DCIS of the breast treated with
lumpectomy alone with curative intent
Yes
No
Patients with co - morbid conditions that would
require long term use (> 1 month) of systemic
corticosteroids during study treatment (e.g.
chronic obstructive pulmonary disease [COPD]).
Steroid use <= 1 month is permissible
Yes
No
Patients with active bacterial, viral, or fungal
infection requiring systemic therapy
Yes
No
Patients with a history of severe cardiac disease;
e.g. NYHA Functional Class III or IV heart failure,
myocardial infarction within 6 months, ventricular
tachyarrythmias requiring ongoing treatment, or
unstable angina
Yes
No
Seizure disorders requiring anticonvulsant
therapy
Yes
No
Severe chronic obstructive pulmonary disease
with hypoxemia
Yes
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No
Uncontrolled diabetes mellitus
Yes
No
Uncontrolled hypertension
Yes
No
Transformation to aggressive B-cell malignancy
(e.g., large B-cell lymphoma, Richter’s syndrome,
or prolymphocytic leukemia (PLL) )
Yes
No
Known infection with HIV, hepatitis B or hepatitis
C
Yes
No
Treatment with any other investigational agent, or
participating in another clinical trial within 30 days
prior to entering this study
Yes
No
Known hypersensitivity or anaphylactic reactions
to murine antibodies or proteins
Yes
No
Any co-existing medical or psychological
condition that would preclude participation in the
study or compromise ability to give informed
consent
Yes
No
Eligibility summary
Will the patient participate in the trial?
Yes
No
Date of consent
specify reason
Investigator signature
Investigator Signature Date
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CLL History BO17072 NCT00090051
An open-label, multicenter, randomized, comparative,
phase III study to evaluate the efficacy and safety of
rituximab plus fludarabine and cyclophosphamide (FCR)
versus fludarabine and cyclophosphamide alone (FC) in
previously treated patients with CD20 positive B-cell
chronic lymphocytic leukemia (CLL). FCR Versus FC Alone
in the Treatment of Chronic Lymphocytic Leukemia (CLL) in
Relapsed Patients NCT00090051 Roche BO17072
All rights reserved. Please visit https://medical-data-
models.org/forms/12231
History of Chronic lymphocytic
leukemia NCT0090051
Vital signs and physical measurements
Weight
kg
Height
cm
Temperature
°C
after al least 5 minutes rest
systolic
mmHg
diastolic
mmHg
Pulse rate
bpm
"B" symptoms
Fever
Yes
No
Night sweats
Yes
No
Weight loss
Yes
No
General physical examination
Perform a standard physical examination but
specify only abnormalities not related to CLL.
ECG
1 / 2
Date ECG performed
dd/mm/yy
Are there any abnormalities noted in the ECG?
Yes
No
Specification of abnormalities
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CLL Lab BO17072 NCT00090051
An open-label, multicenter, randomized, comparative,
phase III study to evaluate the efficacy and safety of
rituximab plus fludarabine and cyclophosphamide (FCR)
versus fludarabine and cyclophosphamide alone (FC) in
previously treated patients with CD20 positive B-cell
chronic lymphocytic leukemia (CLL). FCR Versus FC Alone
in the Treatment of Chronic Lymphocytic Leukemia (CLL) in
Relapsed Patients NCT00090051 Roche BO17072
All rights reserved. Please visit https://medical-data-
models.org/forms/12232
Laboratories of Chronic lymphocytic
leukemia NCT0090051
Laboratory analysis
Sample collection date
dd/mm/yy
Lab ID number
Hematology
Hemoglobin
Hematocrit
Red Blood Cells
Leukocytes (total)
Neutrophils
Basophils
Eosinophils
Lymphocytes
Monocytes
Other cells
Platelets
Prothrombin time
Please comment on any abnormal other cells and
specify white cell morphology
1 / 4
Coombs tests indirect/direct
Sample collection date
dd/mm/yy
Indirect Coombs tests
negative (1)
positive (2)
Direct Coombs tests
negative (1)
positive (2)
Blood chemistry
Aspartate transaminase (Serum glutamic
oxaloacetic transaminase)
Alanine transaminase (Serum glutamate-pyruvate
transaminase)
Alk. phosphatase
Bilirubin total
Urea (BUN)
Serum creatinine
Estimated creatinine clearance
Lactate dehydrogenase
Total protein
Albumin
Blood glucose (random)
beta-2-microglobulin
Electrocytes
Sodium
Calcium
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Potassium
Phosphate
Lymphocyte immunophenotyping (local
lab)
Sample collection date
dd/mm/yy
Lymphocytes
%
Monocytes
%
Neutrophils
%
Lymphocyte immunophenotyping (local
lab)
Lymphocyte immunophenotyping Lab value
%
CD3+ (1)
kappa (10)
lambda (11)
CD5+/CD19 (2)
CD19+ (3)
CD5+/CD20 (4)
CD20+ (5)
CD79b (6)
CD23 (7)
CD38 (8)
FMC7/lgG1 (SMIG) weak (9)
Lymphocyte immunophenotyping Lab parameter
gated (1)
total (2)
Comments
Blood sampling for molecular analyses
Sample number
Sample collection date (1)
Remarks (2)
Blood sampling for VH mutation status
and chromosome abnormalities
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Sample number 401
Sample collection date (1)
Remarks (2)
Bone marrow examination
Date of examination
dd/mm/yy
Result of Bone marrow examination
Result of Bone marrow examination normal result
Yes
No
Result of Bone marrow examination abnormal
result
normocellular (1)
hypocellular (2)
hypercellular (3)
Is bone marrow involved with CLL?
Percentage of bone marrow involvement
Percentage of bone marrow involved with
CLL (1)
diffuse pattern of involvement (2)
nodular pattern of involvement (3)
no involvement
Yes
No
Lymphoid nodules in bone marrow?
Yes
No
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CLL Cycle 1 FCR vs FC BO17072
NCT00090051
An open-label, multicenter, randomized, comparative,
phase III study to evaluate the efficacy and safety of
rituximab plus fludarabine and cyclophosphamide (FCR)
versus fludarabine and cyclophosphamide alone (FC) in
previously treated patients with CD20 positive B-cell
chronic lymphocytic leukemia (CLL).
FCR Versus FC Alone in the Treatment of Chronic
Lymphocytic Leukemia (CLL) in Relapsed Patients
NCT00090051
Roche BO17072
All rights reserved. Please visit https://medical-data-
models.org/forms/12234
Chemotherapy Cycle 1 of Chronic
Lymphocytic Leukemia
NCT00090051 BO17072
Randomization
Date of visit
dd/mm/yy
Date of Randomization
dd/mm/yy
Randomization number
Treatment arm
FCR (1)
FC (2)
Reason why randomized but not treated
Pharmacokinetic assessments
Participation in pharmacokinetic sampling
Yes
No
Vital signs and physical measurements
Weight
kg
Height
cm
Temperature
°C
Sitting measurements after al least 5
minutes rest
Blood pressure systolic
mmHg
Blood pressure diastolic
kg
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Pulse rate
bpm
"B" symptoms
Fever
Yes
No
Night sweats
Yes
No
Weight loss
Yes
No
General physical examination
Perform a standard physical examination but
specify only abnormalities not related to CLL.
ECG
Date ECG performed
dd/mm/yy
Are there any abnormalities noted in the ECG?
Yes
No
Specification of abnormalities
Was ECG performed?
Yes
No
Laboratory analysis
Sample collection date
dd/mm/yy
Lab ID number
Hematology
Hemoglobin
Hematocrit
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Red Blood Cells
Leukocytes (total)
Neutrophils
Basophils
Eosinophils
Lymphocytes
Monocytes
Other cells
Platelets
Prothrombin time
Please comment on any abnormal other cells and
specify white cell morphology
Blood chemistry
Aspartate transaminase (Serum glutamic
oxaloacetic transaminase)
Alanine transaminase (Serum glutamate-pyruvate
transaminase)
Alk. phosphatase
Bilirubin total
Urea (BUN)
Serum creatinine
Lactate dehydrogenase
Total protein
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Albumin
Blood glucose (random)
beta-2-microglobulin
Electrocytes
Sodium
Calcium
Potassium
Phosphate
Administration of Rituximab
Date of first dose
dd/mm/yy
Start time of first dose
hh:mm
End time of first dose
hh:mm
Actual Dose of Rituximab
mg
Interrupted infusion
Yes
No
Reason of interruption
Decrease of infusion rate
Yes
No
Reason of decrease
Completion of infusion
Yes
No
Reason of incomplete infusion
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Administration of Fludarabine
Delay of Fludarabine medication
Yes
No
Reason for delay
laboratory (1)
adverse event (2)
other (3)
Specify other reason
Fludarabine Medication
Date
dd/mm/yy
Start time
hh:mm
End time
hh:mm
Actual dose
mg
Dose adjustment
Yes
No
Reason for dose adjustment
laboratory (1)
adverse event (2)
other (3)
Specify other reason
Administration of Cyclophosphamide
Delay of Cyclophosphamide
Yes
No
Reson for delay
laboratory (1)
adverse event (2)
other (3)
Specify other reason
Cyclophosphamide Medication
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Date
dd/mm/yy
Start time
hh:mm
End time
hh:mm
Actual dose
mg
Dose adjustment
Yes
No
Reason for dose adjustment
laboratory (1)
adverse event (2)
other (3)
Specify other reason
6 / 6
CLL Cycle 1 FCR vs FC BO17072 NCT00090051
CLL Cycle 3-6 FCR vs FC BO17072
NCT00090051
An open-label, multicenter, randomized, comparative,
phase III study to evaluate the efficacy and safety of
rituximab plus fludarabine and cyclophosphamide (FCR)
versus fludarabine and cyclophosphamide alone (FC) in
previously treated patients with CD20 positive B-cell
chronic lymphocytic leukemia (CLL).
FCR Versus FC Alone in the Treatment of Chronic
Lymphocytic Leukemia (CLL) in Relapsed Patients
NCT00090051
Roche BO17072
All rights reserved. Please visit https://medical-data-
models.org/forms/12239
Chemotherapy Cycle 3-6 of Chronic
Lymphocytic Leukemia
NCT00090051 BO17072
Administration of Rituximab
Rituximab should be administered on the same
day as Fludarabine and Cyclophosphamide
administration.
Was administration of Rituximab delayed?
Yes
No
Reason for delay
laboratory (1)
adverse event (2)
other (3)
Specify other reason
Date of first dose
dd/mm/yy
Start time of first dose
hh:mm
End time of first dose
hh:mm
Actual Dose of Rituximab
mg
Interrupted infusion
Yes
No
Reason of interruption
Decrease of infusion rate
Yes
No
Reason of decrease
Completion of infusion
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Yes
No
Reason of incomplete infusion
Administration of Rituximab
Rituximab should be administered on the same
day as Fludarabine and Cyclophosphamide
Does the patient have a lymphocyte count of >
25x10e9/L?
Yes
No
Is the Rituximab dose being split over 2 days?
Yes
No
Day 1
Delay of Rituximab medication
Yes
No
Reason for delay
laboratory (1)
adverse event (2)
other (3)
Specify other reason
Date
dd/mm/yy
Start time
hh:mm
End time
hh:mm
Actual Dose
mg
Infusion interrupted
Yes
No
Specify reason
Decrease of infusion rate
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Yes
No
Specify reason
Infusion completed
Yes
No
Specify Reason
Day 2
Delay of Rituximab medication
Yes
No
Reason for delay
laboratory (1)
adverse event (2)
other (3)
Specify other reason
Date
dd/mm/yy
Start time
hh:mm
End time
hh:mm
Actual Dose
mg
Infusion interrupted
Yes
No
Specify reason
Decrease of infusion rate
Yes
No
Specify reason
Infusion completed
Yes
No
Specify Reason
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Administration of Fludarabine
Delay of Fludarabine medication
Yes
No
Reason for delay
laboratory (1)
adverse event (2)
other (3)
Specify other reason
Fludarabine Medication
Date
dd/mm/yy
Start time
hh:mm
End time
hh:mm
Actual dose
mg
Dose adjustment
Yes
No
Reason for dose adjustment
laboratory (1)
adverse event (2)
other (3)
Specify other reason
Administration of Cyclophosphamide
Delay of Cyclophosphamide
Yes
No
Reson for delay
laboratory (1)
adverse event (2)
other (3)
Specify other reason
Cyclophosphamide Medication
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Date
dd/mm/yy
Start time
hh:mm
End time
hh:mm
Actual dose
mg
Dose adjustment
Yes
No
Reason for dose adjustment
laboratory (1)
adverse event (2)
other (3)
Specify other reason
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CLL Tumor assessment FCR vs FC
BO17072 NCT00090051
An open-label, multicenter, randomized, comparative,
phase III study to evaluate the efficacy and safety of
rituximab plus fludarabine and cyclophosphamide (FCR)
versus fludarabine and cyclophosphamide alone (FC) in
previously treated patients with CD20 positive B-cell
chronic lymphocytic leukemia (CLL). 
FCR Versus FC Alone in the Treatment of Chronic
Lymphocytic Leukemia (CLL) in Relapsed Patients
NCT00090051
Roche BO17072
All rights reserved. Please visit https://medical-data-
models.org/forms/12240
Tumor assessment of Chronic
Lymphocytic Leukemia
NCT00090051 BO17072
Tumor assessment at screening
Date of Assessment
dd/mm/yy
Indicator lesions
Code of origin
extra nodal or other specification
Side of lesion
Dimensions
mm x mm
Method of assessment
Other specification
Non-indicator lesions
Code of origin
extra nodal or other specification
Side of lesion
Liver and spleen examination
Date of Assessment
dd/mm/yy
Examination type
CT scan (1)
1 / 4
physical examination (2)
other (3)
specify other examination
Hepatomegaly
Yes
No
Splenomegaly
Yes
No
Tumor assessment after Cycle 3 and 6
Assessment Date
dd/mm/yy
Indicator lesions
Code of origin
extra nodal or other specification
Side of lesion
Dimensions
mm x mm
Method of assessment
Other specification
Non-indicator lesions
Code of origin
extra nodal or other specification
Side of lesion
Presence
Yes
No
Liver and spleen examination after Cycle 3
and 6
Date of Assessment
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dd/mm/yy
Examination type
CT scan (1)
physical examination (2)
other (3)
specify other examination
Hepatomegaly
Yes
No
Status since last visit
no change (1)
decrease (2)
increase (3)
Splenomegaly
Yes
No
Status since last visit
no change (1)
decrease (2)
increase (3)
Response assessment after cycle 3
Date of Assessment
dd/mm/yy
Are there any new lesions?
Yes
No
Was there unequivocal progression in the size of
non-indicator lesions?
Yes
No
Overall response
complete response (1)
partial response (2)
stable disease (3)
pregressive disease (4)
Does patient fulfill the criteria for a CR but have
persistent anemia or thrombocytopenia?
Yes
No
Response assessment	after Cycle 6
Assessment Date
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dd/mm/yy
Are there any new lesions?
Yes
No
Was there unequivocal progression in the size of
non-indicator lesions?
Yes
No
Overall response
complete response (1)
partial response (2)
stable disease (3)
pregressive disease (4)
Was complete response confirmed with a bone
marrow biopsy?
yes (1)
no (2)
not applicable (3)
Is patient in complete remission but has bone
marrow nodules that can be identified
histologically?
yes (1)
no (2)
not applicable (3)
Does patient fulfill the criteria for a CR but have
persistent anemia or thrombocytopenia?
Yes
No
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CLL Adverse Event BO17072
NCT00090051
An open-label, multicenter, randomized, comparative,
phase III study to evaluate the efficacy and safety of
rituximab plus fludarabine and cyclophosphamide (FCR)
versus fludarabine and cyclophosphamide alone (FC) in
previously treated patients with CD20 positive B-cell
chronic lymphocytic leukemia (CLL). 
FCR Versus FC Alone in the Treatment of Chronic
Lymphocytic Leukemia (CLL) in Relapsed Patients
NCT00090051
Roche BO17072
All rights reserved. Please visit https://medical-data-
models.org/forms/12241
Adverse event or intercurrent illness
Chronic Lymphocytic Leukemia
NCT00090051 BO17072
Adverse event
Name adverse event
Date of Onset
dd/mm/yy
Serious Adverse Event
Yes
No
Did this event start during a MabThera®
infusion?
Yes
No
Did this event start within 24 hours of finishing a
MabThera® infusion?
Yes
No
CTCAE grade
CTCAE grade 1 (1)
CTCAE grade 2 (2)
CTCAE grade 3 (3)
CTCAE grade 4 (4)
Test drug adjustment
none (1)
dosage modified/interrupted (2)
discontinued (3)
Was treatment given for this event
Yes
No
Most extreme intensity CTCAE grade
CTCAE grade 1 (1)
CTCAE grade 2 (2)
CTCAE grade 3 (3)
CTCAE grade 4 (4)
Adverse event
unrelated (1)
remote (2)
1 / 2
possible (3)
probable (4)
Adverse Event Outcome
resolved, no sequelae (1)
resolved, with sequelae (2)
unresoved (3)
death (4)
Resolved Date
dd/mm/yy
Adverse Event Comment
Adverse event treatments
Name of treatment
Treatment Start Date
dd/mm/yy
Treatment End Date
dd/mm/yy
Treatment Ongoing
Yes
No
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CLL Unscheduled Lab BO17072
NCT00090051
An open-label, multicenter, randomized, comparative,
phase III study to evaluate the efficacy and safety of
rituximab plus fludarabine and cyclophosphamide (FCR)
versus fludarabine and cyclophosphamide alone (FC) in
previously treated patients with CD20 positive B-cell
chronic lymphocytic leukemia (CLL). FCR Versus FC Alone
in the Treatment of Chronic Lymphocytic Leukemia (CLL) in
Relapsed Patients NCT00090051 Roche BO17072
All rights reserved. Please visit https://medical-data-
models.org/forms/12243
Unscheduled Laboratories of
Chronic lymphocytic leukemia
NCT0090051
Unscheduled laboratory analysis
Date Sample Collection
dd/mm/yy
Lab ID number
Lab parameter
Lab result
Laboratory analysis
Sample collection date
dd/mm/yy
Lab ID number
Hematology
Hemoglobin
Hematocrit
Red Blood Cells
Leukocytes (total)
Neutrophils
Basophils
Eosinophils
Lymphocytes
Monocytes
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Other cells
Platelets
Prothrombin time
Please comment on any abnormal other cells and
specify white cell morphology
Blood chemistry
Aspartate transaminase (Serum glutamic
oxaloacetic transaminase)
Alanine transaminase (Serum glutamate-pyruvate
transaminase)
Alk. phosphatase
Bilirubin total
Urea (BUN)
Serum creatinine
Lactate dehydrogenase
Total protein
Albumin
Blood glucose (random)
Electrocytes
Sodium
Calcium
Potassium
Phosphate
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CLL Hospitalization BO17072
NCT00090051
An open-label, multicenter, randomized, comparative,
phase III study to evaluate the efficacy and safety of
rituximab plus fludarabine and cyclophosphamide (FCR)
versus fludarabine and cyclophosphamide alone (FC) in
previously treated patients with CD20 positive B-cell
chronic lymphocytic leukemia (CLL). FCR Versus FC Alone
in the Treatment of Chronic Lymphocytic Leukemia (CLL) in
Relapsed Patients NCT00090051 Roche BO17072
All rights reserved. Please visit https://medical-data-
models.org/forms/12245
MRU-Hospitalization of Chronic
lymphocytic leukemia NCT0090051
Hospitalization
Admission date
dd/mm/yy
Discharge date
dd/mm/yy
Total number of days in ICU
days
Principal reason for hospitalization
1 / 1
CLL Pharmacokinetics BO17072
NCT00090051
An open-label, multicenter, randomized, comparative,
phase III study to evaluate the efficacy and safety of
rituximab plus fludarabine and cyclophosphamide (FCR)
versus fludarabine and cyclophosphamide alone (FC) in
previously treated patients with CD20 positive B-cell
chronic lymphocytic leukemia (CLL). FCR Versus FC Alone
in the Treatment of Chronic Lymphocytic Leukemia (CLL) in
Relapsed Patients NCT00090051 Roche BO17072
All rights reserved. Please visit https://medical-data-
models.org/forms/12246
Pharmacokinetics Cycle 1 and 3 of
Chronic lymphocytic leukemia
NCT0090051
Blood sampling for pharmacokinetics
(Rituximab)
Scheduled sampling time
h
Scheduled sampling date
dd/mm/yy
Sample number
Sample collection date
dd/mm/yy
Sample collection time
hh:mm
Remarks
If patient takes Rituximab on day 1, then
start of Fludarabine and
Cyclophosphamide pharmacokinetic
sampling starts on day 2, immediately
prior the infusion.
Scheduled sampling time
h
Sampling number
Sample collection date
dd/mm/yy
Sample collection time
hh:mm
Remarks
1 / 1
CLL Completion BO17072 NCT00090051
An open-label, multicenter, randomized, comparative,
phase III study to evaluate the efficacy and safety of
rituximab plus fludarabine and cyclophosphamide (FCR)
versus fludarabine and cyclophosphamide alone (FC) in
previously treated patients with CD20 positive B-cell
chronic lymphocytic leukemia (CLL).
NCT00090051
All rights reserved. Please visit https://medical-data-
models.org/forms/12247
Treatment phase completion Chronic
Lymphocytic Leukemia BO17072
NCT00090051
Death of Patient
Date of Death
dd/mm/yy
Cause of Death
Cause of death
Death related to test drugs
unrelated (1)
remote (2)
possible (3)
probable (4)
Was autopsy performed?
Yes
No
Autopsy findings
Comments
Treatment phase completion
Date of last dosing
dd/mm/yy
Did the patient complete the study up to the end
of the treatment phase?
Yes
No
Reason for no completion
adverse event/intercurrent illness (1)
death (complete death page) (2)
insufficient therapeutic response (3)
failure to return (4)
violation of selection criteria at entry (5)
other protocol violation (6)
refused treatment/did not
cooperate/withdrew consent (7)
early improvement (8)
1 / 2
administrative/other (9)
Specify violation of selection criteria
Specify other protocol violation
Specify other reason
Additional observations
Additional observations
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CLL Completion BO17072 NCT00090051
CLL Follow-Up BO17072 NCT00090051
An open-label, multicenter, randomized, comparative,
phase III study to evaluate the efficacy and safety of
rituximab plus fludarabine and cyclophosphamide (FCR)
versus fludarabine and cyclophosphamide alone (FC) in
previously treated patients with CD20 positive B-cell
chronic lymphocytic leukemia (CLL).
NCT00090051 BO17072
All rights reserved. Please visit https://medical-data-
models.org/forms/12248
Follow-Up Study completion Chronic
Lymphocytic Leukemia BO17072
NCT00090051
Complete response confirmation
Info
Bone marrow sampling for molecular
response
Date of 1st confirmation
dd/mm/yy
Remarks of 1st confirmation
Date of 2nd Confirmation
dd/mm/yy
Remarks of 2nd confirmation
Blood sampling for molecular response
Date of 1st confirmation
dd/mm/yy
Remarks of 1st confirmation
Date of 2nd confirmation
dd/mm/yy
Remarks of 2nd confirmation
Completion of follow-up period
Did the patient complete the study up to the end
of 5 year follow-up?
Yes
No
Study completion
Date of last contact
dd/mm/yy
1 / 2
Did the patient complete the study up to the end
of the treatment phase?
Yes
No
Reason for no completion
adverse event/intercurrent illness (1)
death (complete death page) (2)
insufficient therapeutic response (3)
failure to return (4)
did not cooperate/withdrew consent (5)
administrative/other (6)
Specify violation of selection criteria
Specify other protocol violation
Specify other reason
Survival visit
Date of contact
dd/mm/yy
Survival status
alive (1)
death (2)
lost to follow-up (3)
Date of death
dd/mm/yy
Date last contact
dd/mm/yy
Cause of death
progressive disease (1)
other (2)
not known (3)
Specify other cause of death
Did the patient’s disease progress after coming
off study?
yes (1)
no (2)
not known (3)
not applicable (progressive disease
already documented) (4)
Date of progressive disease
dd/mm/yy
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CLL Follow-Up BO17072 NCT00090051
CLL Follow-Up Treatments NCT00090051
BO17072
An open-label, multicenter, randomized, comparative,
phase III study to evaluate the efficacy and safety of
rituximab plus fludarabine and cyclophosphamide (FCR)
versus fludarabine and cyclophosphamide alone (FC) in
previously treated patients with CD20 positive B-cell
chronic lymphocytic leukemia (CLL).
NCT00090051 BO17072
All rights reserved. Please visit https://medical-data-
models.org/forms/12249
Follow-Up Subsequent treatments for
Chronic Lymphocytic Leukemia
NCT00090051 BO17072
Subsequent treatments/medical
procedures/chemotherapy related to CLL
Name of treatment
Start date
dd/mm/yy
End date
dd/mm/yy
Best response
CR (1)
PR (2)
SD (3)
PD (4)
NK/NA (5)
Ongoing
Yes
No
Subsequent treatments radiotherapy
site of radiotherapy
Total dose
Gy
Start date
dd/mm/yy
End date
dd/mm/yy
Ongoing
Yes
No
Surgery
Surgical procedure
1 / 2
Date of surgery
dd/mm/yy
Other treatment
Name of treatment
Start date
dd/mm/yy
End date
dd/mm/yy
Ongoing
Yes
No
2 / 2
CLL Follow-Up Treatments NCT00090051 BO17072
CLL Follow-Up Month 9 BO17072
NCT00090051
An open-label, multicenter, randomized, comparative,
phase III study to evaluate the efficacy and safety of
rituximab plus fludarabine and cyclophosphamide (FCR)
versus fludarabine and cyclophosphamide alone (FC) in
previously treated patients with CD20 positive B-cell
chronic lymphocytic leukemia (CLL).
NCT00090051 BO17072
All rights reserved. Please visit https://medical-data-
models.org/forms/12250
Follow-Up Month 9 Chronic
Lymphocytic Leukemia
NCT00090051 BO17072
Bone marrow examination
Date of examination
dd/mm/yy
Result of Bone marrow examination
normal result
Yes
No
abnormal result
normocellular (1)
hypocellular (2)
hypercellular (3)
Is bone marrow involved with CLL?
Percentage of bone marrow involvement
%
Percentage of bone marrow involved with
CLL (1)
diffuse pattern of involvement (2)
nodular pattern of involvement (3)
Bone marrow no involvement
Yes
No
Lymphoid nodules in bone marrow?
Yes
No
Tumor assessment
Date of Assessment
dd/mm/yy
Indicator lesions
Code of origin
extra nodal or other specification
1 / 3
Side of lesion
Dimensions
mm x mm
Method of assessment
Other specification
Non-indicator lesions
Code of origin
extra nodal or other specification
Site of lesion
Present
Yes
No
Liver and spleen examination
Date of Assessment
dd/mm/yy
Examination type
CT scan (1)
physical examination (2)
other (3)
specify other examination
Hepatomegaly
Yes
No
Splenomegaly
Yes
No
Response assessment
Assessment Date
dd/mm/yy
Are there any new lesions?
Yes
No
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CLL Follow-Up Month 9 BO17072 NCT00090051
Was there unequivocal progression in the size of
non-indicator lesions?
Yes
No
Overall response
complete response (1)
partial response (2)
stable disease (3)
pregressive disease (4)
Was complete response confirmed with a bone
marrow biopsy?
yes (1)
no (2)
not applicable (3)
Is patient in complete remission but has bone
marrow nodules that can be identified
histologically?
Percentage of bone marrow involved with
CLL (1)
diffuse pattern of involvement (2)
nodular pattern of involvement (3)
Does patient fulfill the criteria for a CR but have
persistent anemia or Thrombocytopenia?
Yes
No
3 / 3
CLL Follow-Up Month 9 BO17072 NCT00090051
CLL Follow-Up Disease tranformation
BO17072 NCT00090051
An open-label, multicenter, randomized, comparative,
phase III study to evaluate the efficacy and safety of
rituximab plus fludarabine and cyclophosphamide (FCR)
versus fludarabine and cyclophosphamide alone (FC) in
previously treated patients with CD20 positive B-cell
chronic lymphocytic leukemia (CLL). FCR Versus FC Alone
in the Treatment of Chronic Lymphocytic Leukemia (CLL) in
Relapsed Patients NCT00090051 Roche BO17072
All rights reserved. Please visit https://medical-data-
models.org/forms/12251
Follow-Up Disease tranformation of
Chronic lymphocytic leukemia
NCT0090051
Progressive disease due to transformation
to an more aggressive histology
Date of transformation
dd/mm/yy
Diagnosis
PLL (>55% prolymphocytes) (1)
Richter's Syndrome (see below) (2)
Richter syndrome
Diffuse large B cell lymphoma (1)
Hodgkin’s disease (2)
Clinical diagnosis only (3)
Other, specify (4)
Epstein-Barr virus
negative (1)
positive (2)
not done (3)
1 / 1
CLL Concomitant Treatments BO17072
NCT00090051
An open-label, multicenter, randomized, comparative,
phase III study to evaluate the efficacy and safety of
rituximab plus fludarabine and cyclophosphamide (FCR)
versus fludarabine and cyclophosphamide alone (FC) in
previously treated patients with CD20 positive B-cell
chronic lymphocytic leukemia (CLL). 
FCR Versus FC Alone in the Treatment of Chronic
Lymphocytic Leukemia (CLL) in Relapsed Patients
NCT00090051
Roche BO17072
Treatments given for an adverse event should be recorded
on the appropriate “Adverse event” page.
Treatments given for prophylaxis or treatment of abnormal
laboratory values (e.g. blood cells, potassium supplements,
etc.) should be recorded on this page.
List any treatments continuing at screen or that have begun
since screen (or medical procedures performed) that are
not recorded on Adverse event pages.
All rights reserved. Please visit https://medical-data-
models.org/forms/12252
Concomitant Treatmants Chronic
Lymphocytic Leukemia BO17072
NCT00090051
Concomitant treatments (or medical
procedures) other than for CLL
Treatments given for an adverse event should be
recorded on the appropriate “Adverse event”
page.
Treatments given for prophylaxis or treatment of
abnormal laboratory values (e.g. blood cells,
potassium supplements, etc.) should be recorded
on this page.
List any treatments continuing at screen or that
have begun since screen (or medical procedures
performed) that are not recorded on Adverse
event pages.
Name of concomitant treatment
Total Daily Dose of Agent (or Drug)
mg
Start date
dd/mm/yy
End Date
dd/mm/yy
Ongoing
Yes
No
Concomitant Medication Use Reason
1 / 1
CLL Cycle 2 FCR vs FC BO17072
NCT00090051
An open-label, multicenter, randomized, comparative,
phase III study to evaluate the efficacy and safety of
rituximab plus fludarabine and cyclophosphamide (FCR)
versus fludarabine and cyclophosphamide alone (FC) in
previously treated patients with CD20 positive B-cell
chronic lymphocytic leukemia (CLL).
FCR Versus FC Alone in the Treatment of Chronic
Lymphocytic Leukemia (CLL) in Relapsed Patients
NCT00090051
Roche BO17072
All rights reserved. Please visit https://medical-data-
models.org/forms/12253
Chemotherapy Cycle 2 of Chronic
Lymphocytic Leukemia
NCT00090051 BO17072
Vital signs and physical measurements
Weight
kg
Height
cm
Temperature
°C
after al least 5 minutes rest
systolic
mmHg
diastolic
kg
Pulse rate
kg
"B" symptoms
Fever
Yes
No
Night sweats
Yes
No
Weight loss
Yes
No
General physical examination
General physical examination
normal (1)
1 / 5
abnormal (2)
"If abnormal: Post Baseline adverse
change in patient’s state is to be
recorded on an “Adverse event“ page in
case of abnormalities not related to CLL.
Record spleen and liver examination and
CLL related lesions in the tumor
assessment section, if changed as
compared to previous examination." (3)
Administration of Rituximab
Rituximab should be administered on the same
day as Fludarabine and Cyclophosphamide
Does the patient have a lymphocyte count of >
25x10e9/L?
Yes
No
Is the Rituximab dose being split over 2 days?
Yes
No
Day 1
Delay of Rituximab medication
Yes
No
Reason for delay
laboratory (1)
adverse event (2)
other (3)
Specify other reason
Date
dd/mm/yy
Start time
hh:mm
End time
hh:mm
Actual Dose
mg
Infusion interrupted
Yes
No
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CLL Cycle 2 FCR vs FC BO17072 NCT00090051
Specify reason
Decrease of infusion rate
Yes
No
Specify reason
Infusion completed
Yes
No
Specify Reason
Day 2
Delay of Rituximab medication
Yes
No
Reason for delay
laboratory (1)
adverse event (2)
other (3)
Specify other reason
Date
dd/mm/yy
Start time
hh:mm
End time
hh:mm
Actual Dose
mg
Infusion interrupted
Yes
No
Specify reason
Decrease of infusion rate
Yes
No
Specify reason
Infusion completed
3 / 5
CLL Cycle 2 FCR vs FC BO17072 NCT00090051
Yes
No
Specify Reason
Administration of Fludarabine
Delay of Fludarabine medication
Yes
No
Reason for delay
laboratory (1)
adverse event (2)
other (3)
Specify other reason
Fludarabine Medication
Date
dd/mm/yy
Start time
hh:mm
End time
hh:mm
Actual dose
mg
Dose adjustment
Yes
No
Reason for dose adjustment
laboratory (1)
adverse event (2)
other (3)
Specify other reason
Administration of Cyclophosphamide
Delay of Cyclophosphamide
Yes
No
Reson for delay
laboratory (1)
adverse event (2)
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CLL Cycle 2 FCR vs FC BO17072 NCT00090051
other (3)
Specify other reason
Cyclophosphamide Medication
Date
dd/mm/yy
Start time
hh:mm
End time
hh:mm
Actual dose
mg
Dose adjustment
Yes
No
Reason for dose adjustment
laboratory (1)
adverse event (2)
other (3)
Specify other reason
5 / 5
CLL Cycle 2 FCR vs FC BO17072 NCT00090051
Dissection of Staphylococcus Aureus Infection From Colonization
in Cystic Fibrosis Patients (StaphCI) NCT00669760  Basic Data
Study documentation part: Basic Data. Dissection of
staphylococcus aureus infection from colonization in cystic
fibrosis patients, a non-interventional, prospective,
longitudinal multicenter study.  Trial number:
NCT00669760.
All rights reserved. Please visit https://medical-data-
models.org/forms/12274
Dissection of Staphylococcus Aureus
Infection From Colonization in Cystic
Fibrosis Patients (StaphCI)
NCT00669760 <e2><80><93> Basic
Data
Basisdaten
Zentrums-Nr.:
Pat.-Nr.:
Einschlusskriterien
Patient mit diagnostizierter Mukoviszidose (CF)
Ja
Nein
Alter mindestens 6 Jahre
Ja
Nein
Positiver Nachweis von Staphylococcus aureus-
Kolonisation oder Infektion über einen Zeitraum
von mehr als 6 Monaten im letzten Jahr vor
Studienbeginn
Ja
Nein
Patient ist in der Lage, einen Lungenfunktionstest
durchzuführen
Ja
Nein
Ausschlusskriterium
Pseudomonas aeruginosa und / oder
Burkholderia cepacia Kolonisation oder Infektion
über einen Zeitraum von mehr als 6 Monaten im
letzten Jahr vor Studienbeginn
Ja
Nein
Demographie
Geschlecht:
männlich (1)
weiblich (2)
Geburtsdatum:
1 / 2
CF-Genotyp:
∆F508 homozygot (1)
∆F508 heterozygot (2)
nicht bekannt (3)
andere (4)
Bei anderen, bitte erwähnen:
Einverständniserklärung unterzeichnet am:
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Dissection of Staphylococcus Aureus Infection From Colonization in
Cystic Fibrosis Patients (StaphCI) NCT00669760  Basic Data
Dissection of Staphylococcus Aureus Infection From Colonization in Cystic
Fibrosis Patients (StaphCI) NCT00669760- Outpatient Department Visit 1-8
Study documentation part: Outpatient Department Visit 1 -
8. Dissection of staphylococcus aureus infection from
colonization in cystic fibrosis patients, a non-interventional,
prospective, longitudinal multicenter study.  Trial number:
NCT00669760.
All rights reserved. Please visit https://medical-data-
models.org/forms/12276
Dissection of Staphylococcus Aureus
Infection From Colonization in Cystic
Fibrosis Patients (StaphCI)
NCT00669760- Outpatient
Department Visit 1-8
Ambulanzbesuch
Zentrums-Nr.:
Pat.-Nr.:
Datum:
Grund:
Routinebesuch (1)
Exazerbation (2)
Ambulanzbesuch Nr.:
Erkrankungen (Bitte nur Neuerkrankungen
seit dem letzten Ambulanzbesuch mit
Datum dokumentieren)
Pankreasinsuffizienz
Ja
Nein
Beginn Datum:
Therapiepflichtige diabetische Stoffwechsellage
Ja
Nein
Beginn Datum:
Allergische ABPA mit Kortison- therapie
Ja
Nein
Beginn Datum:
Chronische P. aeruginosa Kolonisation/Infektion
(>6 Monate) in der Vergangenheit
Ja
Nein
1 / 6
Vitalparameter / Lungenfunktion
Größe:
cm
Gewicht:
Kg
FEV1
%
MEF25:
%
VC:
%
Klinischer Status
Krankheitsgefühl, Müdigkeit, Abgeschlagenheit
nicht vorhanden (1)
schwach ausgeprägt (2)
mittel (3)
stark ausgeprägt (4)
Sinusitis
Ja
Nein
Kopfschmerz
Ja
Nein
Nasensekret
klar (1)
gelb/grün (2)
kein (3)
Vermehrter produktiver Husten
Ja
Nein
Hämoptysis
Ja
Nein
Sputum
Ja
Nein
Sputum Volumen
wenig (1)
viel (2)
Physikalische Zeichen einer Infektion
2 / 6
Dissection of Staphylococcus Aureus Infection From Colonization in Cystic
Fibrosis Patients (StaphCI) NCT00669760- Outpatient Department Visit 1-8
Ja
Nein
progrediente obstruktive Atemgeräusche
Ja
Nein
progrediente Rasselgeräusche
Ja
Nein
Anzahl der Fehltage (Schule oder Beruf):
Röntgenthorax durchgeführt?
Ja
Nein
Wenn durchgeführt, Zeichen einer frischen
Infektion?
Ja
Nein
Pleuraerguß (Vermehrt im Vergleich zu früheren
Untersuchungen)?
Ja
Nein
Atelektase (Vermehrt im Vergleich zu früheren
Untersuchungen)?
Ja
Nein
Infiltrate(Vermehrt im Vergleich zu früheren
Untersuchungen)?
Ja
Nein
Vorliegen einer frischen Infektion (Beurteilung
durch Prüfarzt)?
ja (1)
nein (2)
nicht sicher beurteilbar (3)
Antibiotische Therapie
(Antistaphylokokken-Therapie)
Cotrimoxazol:
Ja
Nein
Therapiebeginn:
Therapieende:
Indikation:
Prophylaxe (1)
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Dissection of Staphylococcus Aureus Infection From Colonization in Cystic
Fibrosis Patients (StaphCI) NCT00669760- Outpatient Department Visit 1-8
bei Nachweis von S. aureus (2)
Klinische Indikation (3)
Flucloxacillin:
Ja
Nein
Therapiebeginn:
Therapieende:
Indication:
Prophylaxe (1)
bei Nachweis von S. aureus (2)
Klinische Indikation (3)
Cefaclor:
Ja
Nein
Therapiebeginn:
Therapieende:
Indikation:
Prophylaxe (1)
bei Nachweis von S. aureus (2)
Klinische Indikation (3)
Wenn andere, bitte erwähnen :
Therapiebeginn:
Therapieende:
Indikation:
Prophylaxe (1)
bei Nachweis von S. aureus (2)
Klinische Indikation (3)
Therapie mit Azithromycin
Therapie mit Azithromycin?
Ja
Nein
Therapiebeginn:
Therapieende:
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Dissection of Staphylococcus Aureus Infection From Colonization in Cystic
Fibrosis Patients (StaphCI) NCT00669760- Outpatient Department Visit 1-8
Inhalative Antibiotika-Therapie seit dem
letzten Ambulanzbesuch
Polymyxin:
Ja
Nein
Anzahl Zyklen:
Mittlere Therapiedauer pro Zyklus:
Tobramycin:
Ja
Nein
Anzahl Zyklen:
Mittlere Therapiedauer pro Zyklus:
Weitere Antibiotika-Therapie seit dem
letzten Ambulanzbesuch
Medikation:
Gabe:
oral (1)
i.v. (2)
Therapiebeginn:
Therapiedauer :
Tage
Entnahme von Probenmaterial
Ambulanzbesuch freitags oder vor einem
Feiertag? (Wenn ja, Entnahme von
Probenmaterial muß entfallen, da dieses nicht
über mehrere Tage haltbar ist)
Ja
Nein
Sputum:
Ja
Nein
Nasenabstrich:
Ja
Nein
Rachenabstrich:
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Dissection of Staphylococcus Aureus Infection From Colonization in Cystic
Fibrosis Patients (StaphCI) NCT00669760- Outpatient Department Visit 1-8
Ja
Nein
Serummonovette:
Ja
Nein
EDTA-Blut:
Ja
Nein
Versand
Gekühltes Probenmaterial und CRF Seiten
dieses Ambulanzbesuches + Basisdaten per
Express versenden:
nein, da Freitag oder Feiertag (1)
nein, andere Gründe (2)
ja (3)
nur Versand der CRF-Seiten (4)
Bitte erwähnen, wenn andere:
6 / 6
Dissection of Staphylococcus Aureus Infection From Colonization in Cystic
Fibrosis Patients (StaphCI) NCT00669760- Outpatient Department Visit 1-8
Dissection of Staphylococcus Aureus Infection From Colonization in Cystic Fibrosis
Patients (StaphCI) NCT00669760- Outpatient Department Visit (Undefined)
Study documentation part: Outpatient Department Visit
(Undefined and with microbiology part). Dissection of
staphylococcus aureus infection from colonization in cystic
fibrosis patients, a non-interventional, prospective,
longitudinal multicenter study.  Trial number:
NCT00669760.
All rights reserved. Please visit https://medical-data-
models.org/forms/12278
Dissection of Staphylococcus Aureus
Infection From Colonization in Cystic
Fibrosis Patients (StaphCI)
NCT00669760- Outpatient
Department Visit (Undefined)
Ambulanzbesuch
Zentrums-Nr.:
Pat.-Nr.:
Datum:
Grund:
Routinebesuch (1)
Exazerbation (2)
Ambulanzbesuch Nr.:
Erkrankungen (Bitte nur Neuerkrankungen
seit dem letzten Ambulanzbesuch mit
Datum dokumentieren)
Pankreasinsuffizienz:
Ja
Nein
Beginn Datum:
Therapiepflichtige diabetische Stoffwechsellage:
Ja
Nein
Beginn Datum:
Allergische ABPA mit Kortison-therapie:
Ja
Nein
Beginn Datum:
Chronische P. aeruginosa Kolonisation/Infektion
(>6 Monate) in der Vergangenheit:
Ja
Nein
1 / 11
Vitalparameter / Lungenfunktion
Größe:
cm
Gewicht:
Kg
FEV1
%
MEF25:
%
VC:
%
Klinischer Status (bitte aktuellen Befund
am Tag des Ambulanzbesuches
eintragen)
Krankheitsgefühl, Müdigkeit, Abgeschlagenheit:
nicht vorhanden (1)
schwach ausgeprägt (2)
mittel (3)
stark ausgeprägt (4)
Sinusitis:
Ja
Nein
Kopfschmerz:
Ja
Nein
Nasensekret:
klar (1)
gelb/grün (2)
kein (3)
Vermehrter produktiver Husten:
Ja
Nein
Hämoptysis:
Ja
Nein
Sputum:
Ja
Nein
Sputum Volumen:
wenig (1)
viel (2)
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Dissection of Staphylococcus Aureus Infection From Colonization in Cystic Fibrosis
Patients (StaphCI) NCT00669760- Outpatient Department Visit (Undefined)
Physikalische Zeichen einer Infektion:
Ja
Nein
progrediente obstruktive Atemgeräusche:
Ja
Nein
progrediente Rasselgeräusche:
Ja
Nein
Anzahl der Fehltage (Schule oder Beruf):
Röntgenthorax durchgeführt?
Ja
Nein
Wenn durchgeführt,Zeichen einer frischen
Infektion?
Ja
Nein
Pleuraerguß (Vermehrt im Vergleich zu früheren
Untersuchungen)?
Ja
Nein
Atelektase (Vermehrt im Vergleich zu früheren
Untersuchungen)?
Ja
Nein
Infiltrate (Vermehrt im Vergleich zu früheren
Untersuchungen)?
Ja
Nein
Vorliegen einer frischen Infektion (Beurteilung
durch Prüfarzt)?
ja (1)
nein (2)
nicht sicher beurteilbar (3)
Antistaphylokokken-Therapie
Cotrimoxazol:
Ja
Nein
Therapiebeginn:
Therapieende:
Indikation:
Prophylaxe (1)
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Dissection of Staphylococcus Aureus Infection From Colonization in Cystic Fibrosis
Patients (StaphCI) NCT00669760- Outpatient Department Visit (Undefined)
bei Nachweis von S. aureus (2)
Klinische Indikation (3)
Flucloxacillin:
Ja
Nein
Therapiebeginn:
Therapieende:
Indikation:
Prophylaxe (1)
bei Nachweis von S. aureus (2)
Klinische Indikation (3)
Cefaclor:
Ja
Nein
Therapiebeginn:
Therapieende:
Indikation:
Prophylaxe (1)
bei Nachweis von S. aureus (2)
Klinische Indikation (3)
Andere:
Therapiebeginn:
Therapieende:
Indikation:
prophylaxis (1)
by proof of S. aureus (2)
clinical indication (3)
Therapie mit Azithromycin
Therapie mit Azithromycin:
Ja
Nein
Therapiebeginn:
Therapieende:
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Dissection of Staphylococcus Aureus Infection From Colonization in Cystic Fibrosis
Patients (StaphCI) NCT00669760- Outpatient Department Visit (Undefined)
Inhalative Antibiotika-Therapie seit dem
letzten Ambulanzbesuch
Polymyxin:
Ja
Nein
Anzahl Zyklen:
Mittlere Therapiedauer pro Zyklus:
Tobramycin:
Ja
Nein
Anzahl Zyklen:
Mittlere Therapiedauer pro Zyklus:
Weitere Antibiotika-Therapie seit dem
letzten Ambulanzbesuch
Medikation:
Gabe:
oral (1)
i.v. (2)
Therapiebeginn:
Therapiedauer:
days
Entnahme von Probenmaterial
Ambulanzbesuch freitags oder vor einem
Feiertag? (Wenn ja, Entnahme von
Probenmaterial muß entfallen, da dieses nicht
über mehrere Tage haltbar ist)
Ja
Nein
Sputum:
Ja
Nein
Nasenabstrich
Ja
Nein
Rachenabstrich
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Dissection of Staphylococcus Aureus Infection From Colonization in Cystic Fibrosis
Patients (StaphCI) NCT00669760- Outpatient Department Visit (Undefined)
Ja
Nein
Serummonovette
Ja
Nein
EDTA blut:
Ja
Nein
Versand
Gekühltes Probenmaterial und CRF Seiten
dieses Ambulanzbesuches per Express
versenden
nein, da Freitag oder Feiertag (1)
nein, andere Gründe (2)
ja (3)
nur Versand der CRF-Seiten (4)
other
Microbiology- Staphylococcus
aureus characteristics
Basisdaten
Zentrums-Nr.:
Pat.-Nr.:
Datum:
Probenmaterial:
Nasenabstrich (1)
Rachenabstrich (2)
Sputum (3)
nasale Lavage (4)
Labornummer:
S. aureus Morphotyp:
Kryobox-Nr.:
Blut Agar
Hämolyse (0-4):
β-Toxin:
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Dissection of Staphylococcus Aureus Infection From Colonization in Cystic Fibrosis
Patients (StaphCI) NCT00669760- Outpatient Department Visit (Undefined)
Ja
Nein
Pigmentierung:
weiß (1)
grau (2)
gelb (3)
glasig (4)
Größe:
winzig < 1 mm (1)
klein  1 mm (2)
groß > 1mm (3)
SCV (4)
normal (5)
Spiegeleiförmig (6)
Konsistenz:
trocken (1)
feucht (2)
schleimig (3)
Schaedler Agar
Hämolyse (0-4):
β-Toxin:
Ja
Nein
Pigmentierung:
weiß (1)
grau (2)
gelb (3)
glasig (4)
Größe:
winzig < 1 mm (1)
klein  1 mm (2)
groß > 1mm (3)
SCV (4)
normal (5)
Spiegeleiförmig (6)
Konsistenz:
trocken (1)
feucht (2)
schleimig (3)
Ergebnisse der Resistenztestung
PSSA:
Ja
Nein
MSSA:
Ja
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Nein
MLSB:
Ja
Nein
MRSA:
Ja
Nein
Aminoglykoside:
Ja
Nein
Gyrasehemmer:
Ja
Nein
TMP/SMX:
Ja
Nein
Biochemische Differenzierung
Katalase:
positiv (1)
negativ (2)
Röhrchen Koagulase:
positiv (1)
negativ (2)
Pastorex:
positiv (1)
negativ (2)
Vitek:
Ja
Nein
PCR:
Ja
Nein
Microbiology- Sputum, Serum and
EDTA blood
Sputum
Labornummer:
Grampositive Kokken:
ja + (1 bis 10 KBE/GF) (1)
ja ++ (10 bis 100 KBE/GF ) (2)
ja +++ (> 100 KBE/GF ) (3)
nein (4)
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Gramnegative Stäbchen:
ja + (1 bis 10 KBE/GF) (1)
ja ++ (10 bis 100 KBE/GF ) (2)
ja +++ (> 100 KBE/GF ) (3)
nein (4)
Neutrophile Granulozyten:
%
Plattenepithelien:
%
S 100 A12 :
ng/ml
IL-8:
pg/ml
Myeloperoxidase:
ng/ml
Kryobox-Nr.:
Serum
Labornummer:
Kryobox-Nr.:
EDTA-Blut
Labornummer:
Kryobox-Nr.:
Microbiology- Summary sheet
Basisdaten
Datum:
Probenmaterial:
Nasenabstrich (1)
Rachenabstrich  (2)
Sputum  (3)
nasale lavage (4)
Labornummer:
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Staphylococcus aureus
Staphylococcus aureus:
negativ (1)
+ (2)
++ (3)
+++ (4)
Keimzahl:
Anzahl der Morphotypen:
Davon normal:
SCVs:
Andere Erreger
Andere Erreger:
negativ (1)
+ (2)
++ (3)
+++ (4)
Keimzahl (gramnegativ):
Spezies:
H. influenzae (1)
S. maltophilia (2)
E. coli (3)
P. aeruginosa (4)
andere (5)
Wenn andere, bitte erwähnen:
Begleitflora
nicht hämolysierende Streptokokken:
Ja
Nein
vergrünende Streptokokken:
Ja
Nein
apathogene Neisserien:
Ja
Nein
Candida albicans:
Ja
Nein
Candida glabrata:
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Ja
Nein
Candida dubliniensis:
Ja
Nein
Candida parapsilosis:
Ja
Nein
Andere Candida:
Aspergillus fumigatus:
Ja
Nein
Aspergillus niger:
Ja
Nein
andere Aspergillus Arten:
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Dissection of Staphylococcus Aureus Infection From Colonization in
Cystic Fibrosis Patients (StaphCI) NCT00669760 – (Centre-Log)
Study documentation part: (Centre-Log).  Dissection of
staphylococcus aureus infection from colonization in cystic
fibrosis patients, a non-interventional, prospective,
longitudinal multicenter study.  Trial number:
NCT00669760.
All rights reserved. Please visit https://medical-data-
models.org/forms/12280
Dissection of Staphylococcus Aureus
Infection From Colonization in Cystic
Fibrosis Patients (StaphCI)
NCT00669760 – (Centre-Log)
Zentrums-Log
Zentrum:
Zentrums-Nr.:
Leitender Prüfer:
Pat.-Nr.:
Name:
Vorname:
Geburtsdatum:
Studienbeginn:
Studienende/-abbruch:
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Cystic Fibrosis Patients (StaphCI) NCT00669760 – (Patient Log)
Study documentation part: (Patient Log).  Dissection of
staphylococcus aureus infection from colonization in cystic
fibrosis patients, a non-interventional, prospective,
longitudinal multicenter study.  Trial number:
NCT00669760.
All rights reserved. Please visit https://medical-data-
models.org/forms/12284
Dissection of Staphylococcus Aureus
Infection From Colonization in Cystic
Fibrosis Patients (StaphCI)
NCT00669760 – (Patient Log)
Patient Log
Centre name:
Patient number:
Patient name:
Date of birth:
Experiment Start Date:
Experiment End Date:
Outpatient department visit number:
Reason for visiting outpatient department:
Routine  (1)
Exacerbation (2)
Specimen dispatch:
Sputum (1)
Nasal swab (2)
Throat swab (3)
Serum (4)
EDTA blood (5)
Case report form dispatch:
Yes
No
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Pharmacokinetic Study of Doxorubicin in
Children With Cancer NCT01095926
Official Title: 	Phase II Pharmacokinetic Study to Assess the
Age-dependency in the Clearance of Doxorubicin in
Paediatric Patients With Solid Tumours and Leukaemia
Analyze pharmacokinetics of doxorubicin in children with
cancer. Furthermore investigate the predictive role of
troponin and natriuretic peptides for anthracycline-induced
cardiotoxicity.
https://clinicaltrials.gov/ct2/show/NCT01095926
NCT01095926
All rights reserved. Please visit https://medical-data-
models.org/forms/12285
Registration
Registration
Date of birth
Date of consent first parent
Date of consent second parent (UK: not
necessary)
Sex
male (1)
female (2)
Consent for blood sample for pharmacogenetic
analysis
yes (1)
no (2)
"If yes, please document date of blood
sample on page 39 „Pharmacogenetics“
(4)
Date of diagnosis
Tumour type
Wilms tumour
AVD (1)
High Risk (2)
Neuroblastoma
N4 (1)
N6 (2)
TVD (3)
CADO (4)
Ewing
sarcoma
VIDE (1)
VAC (2)
VAI (3)
Soft tissue
sarcoma
10 - VAIA III (CWS (e.g. CWS-2002-P) )
11 - High risk (EpSSG-
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Rhabdomyosarcoma (e.g. RMS 2005) )
12 - IA (EpSSG-Soft tissue sarcoma
(e.g. NRSTS 2005) )
ALL
I-BFM (e.g. ALL-BFM 2000) = 13 -
Protocol II (1)
AIEOP (e.g. LLA 2000) = 14 - Protocol II
(2)
AIEOP/I-BFM (AIEOP-BFM ALL2009) =
15 - Protocol II (3)
SFCE (FRALLE 2000) = 16 -
Consolidation ; 17 - Intensification (4)
MRC (e.g. UKALL 2003) = 18 - Delayed
Intensification (5)
Other
To include a patient with another tumour
type is only possible if the patient is
younger than 3 years! (1)
Please contact the national study
manager to verify if patient is eligible. (2)
Doxorubicin administration: time of
infusion
Is the planned infusion time in accordance with
the above listed infusion time
(taken from the protocol)?
Yes (protocol specific sampling sheets
will be provided) (1)
No, deviations are planned (one of three
flexible standard sheets will be provided)
(2)
If no: administered infusion time: ≤ 0.5 h;
> 0.5 h - < 12 h; ≥ 12 h (3)
Inclusion criteria
Patient ≤ 17 years of age
Yes
No
Patient shall receive at least two cycles of
doxorubicin
Yes
No
Patient, parent(s) or legal representative
has/have provided written informed
consent to participate in the trial according to
national regulations
Yes
No
Patient is enrolled in a national or European
protocol - run by one of the
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study groups listed in the protocol - for treatment
of Wilms tumours,
neuroblastoma, soft tissue sarcoma, Ewing
sarcoma or acute lymphatic leukaemia
and is treated with doxorubicin according to that
protocol
Or
Patient < 3 years enrolled or listed in any national
or European study protocol
for any paediatric malignancy. Treatment with
doxorubicin has to be
according to that protocol
Yes
No
Life expectancy of at least 3 month
Yes
No
Karnofsky performance status of ≥ 70%
Yes
No
Additional blood withdrawal is acceptable for the
patient
Yes
No
Assent of patient, if patient is able to
(if not able: please enter „N.A.“)
Yes (1)
No (2)
N.A. (3)
If assent is given: Date of patient assent
(4)
Exclusion criterion
Prior cardiac problems
Yes
No
Footer module
Date of
registration
Name Investigator
Signature Investigator
1st Sampling period
Physical Examination
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Physical Examination Date
Height
cm
Weight
kg
BSA
m2
Karnofsky
Index
%
Determination of cardiac function (before
sampling period)
Date
Blood
pressure
mm Hg
sys  (1)
dia (2)
Heart
rate
/min
Echocardiography
LVEDD (1)
IVS (2)
LVSF (3)
LVESD (4)
LVPW (5)
LVEF (6)
Electrocardiography (optional)
Not done (1)
Date: (2)
ECG findings (3)
If abnormal, please specify (4)
Clinical chemistry
Date
Bilirubin
(total)
mg/dL
4 / 14
Pharmacokinetic Study of Doxorubicin in Children With Cancer
NCT01095926
Serum
creatinine
mg/dL
Serum
albumin
mg/dL
GOT / AST
U/L
GPT / ALT
U/L
GFR
mL/min
GFR estimated: (1)
By radioactivity measurement (2)
By urine collection (3)
From a single measurement of serum-
creatinine (4)
Haematology
Date
Haemoglobin
g/dL
Haematocrit
%
Neutrophils
/μL
Leucocytes
/μL
Platelets
/μL
Agents that are known to interact with
doxorubicin according to SmPCs
administered?
Carbamazepine
Yes
No
Cimetidine
Yes
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No
Cyclosporine
Yes
No
Phenobarbital
Yes
No
Phenytoin
Yes
No
Progesterone
Yes
No
Rifampicin
Ritonavir
Yes
No
Sulfamethoxazole
Yes
No
Verapamil
Yes
No
Antiemetic agents administered?
Granisetron
Yes
No
Metoclopramid
Yes
No
Ondansetron
Yes
No
Other 5-HT3-receptor antagonists
Yes
No
Aprepitant
Yes
No
Alizapride
Yes
No
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Dexamethason administered?
Yes
No
Dimenhydrinate administered?
Yes
No
Domperidone administered?
Yes
No
Lorazepam administered?
Yes
No
Other
Yes
No
Cardioprotective agents administered?
Dexrazoxane
Yes
No
Other(s)
If other(s): (INN name) (1)
Systemic antimycotic agents
Azole antimycotics
Yes
No
Other(s)
If other(s): (INN name) (1)
Other agents administered?
Antibiotic agents
Yes
No
Anticonvulsive agents
Yes
No
Cardioactive agents
Yes
No
Proton pump inhibitors
Yes
No
Contraceptive agents
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Yes
No
Systemic antiviral agents
Yes
No
Actual protocol block
Wilms tumour
AVD (1)
High Risk (2)
Neuroblastoma
N4 (1)
N6 (2)
TVD (3)
CADO (4)
Ewing
sarcoma
VIDE (1)
VAC (2)
VAI (3)
Soft tissue
sarcoma
VAIA III (1)
High risk (2)
IA (3)
ALL
Protocol II (1)
Consolidation (2)
Intensification (3)
Delayed Intensification (4)
Other:
Start of actual protocol block
Without delay
With delay of
Due to toxicity of previous protocol block
(1)
Due to other reasons (2)
Chemotherapy in actual protocol block
administered ?
Actinomycine D
No (1)
Yes, per protocol (2)
Yes, but not per protocol (3)
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Asparaginase
No (1)
Yes, per protocol (2)
Yes, but not per protocol (3)
Cyclophosphamide
No (1)
Yes, per protocol (2)
Yes, but not per protocol (3)
Dacarbazine
No (1)
Yes, per protocol (2)
Yes, but not per protocol (3)
Dexamethasone
No (1)
Yes, per protocol (2)
Yes, but not per protocol (3)
Etoposide
No (1)
Yes, per protocol (2)
Yes, but not per protocol (3)
Ifosfamide
No (1)
Yes, per protocol (2)
Yes, but not per protocol (3)
Topotecan
No (1)
Yes, per protocol (2)
Yes, but not per protocol (3)
Vincristine
No (1)
Yes, per protocol (2)
Yes, but not per protocol (3)
Other:
(INN name)
No (1)
Yes, per protocol (2)
Yes, but not per protocol (3)
Previous anthracycline treatment
Cumulative doxorubicin dose
mg
Other anthracyclines administered
Daunorubicin (1)
Epirubicin (2)
Idarubicin (3)
Mitoxantrone (4)
Cumulative dose of other anthracyclines
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mg
Doxorubicin treatment in 1st sampling
period
Brand name
Adriblastin(e)/Adriblastina®(Pfizer/Pharm
acia) (1)
Doxorubicin (Hydrochloride) (TEVA) (2)
Adrimedac® (Medac)  (3)
Ribodoxo® (Hikma) (4)
DOXO-Cell® (Cell Pharm)  (5)
Other (6)
Haematological toxicity of actual protocol
block
Leucocytes
10^3/μL
Nadir (1)
Date of nadir (2)
Date of recovery (3)
Platelets
10^3/μL
Nadir  (1)
Date of nadir  (2)
Date of recovery (3)
Haemoglobin
g/dL
Nadir  (1)
Date of nadir  (2)
Date of recovery (3)
Transfusions
Number of days with platelets transfusions
Number of days with erythrocytes transfusions
Determination of cardiac function (end of
sampling period)
Date
Blood
pressure
mm Hg
sys  (1)
dia (2)
Electrocardiography (optional)
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within 28 days after doxorubicin
administration
Not done: (1)
Date: (2)
Routine practice (3)
Adverse Event (4)
Control of preknown condition (5)
Other (6)
ECG findings (7)
If abnormal, please specify (8)
Echocardiography
LVEDD (1)
IVS (2)
LVSF (3)
LVESD (4)
LVPW (5)
LVEF (6)
Adverse events
Haemoglobin
g/dL
Grade 0 - 2 (1)
Grade 3  (2)
Grade 4  (3)
Grade 5 (SAE-Report) (4)
Leucocytes
(total WBC)
/mm3
Grade 0 - 2 (1)
Grade 3  (2)
Grade 4  (3)
Grade 5 (SAE-Report) (4)
Neutrophils /
granulocytes
Grade 0 - 2 (1)
Grade 3  (2)
Grade 4  (3)
Grade 5 (SAE-Report) (4)
Platelets
Grade 0 - 2 (1)
Grade 3  (2)
Grade 4  (3)
Grade 5 (SAE-Report) (4)
Cardiac
arrhythmia
Symptomatic and incompletely controlled
medically or controlled with device (e.g.
defibrillator) (1)
Life-threatening (e.g. arrhythmia
associated with CHF, hypotension,
syncope, shock) (2)
Left ventricular
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systolic
dysfunction
Symptomatic CHF responsive to
intervention; EF < 40-20% SF < 15% (1)
Refractory CHF or poorly controlled; EF
< 20%; intervention such as ventricular
assist device, ventricular reduction
surgery, or heart transplant indicated (2)
Left ventricular
diastolic
dysfunction
Symptomatic CHF responsive to
intervention (1)
Refractory CHF, poorly controlled;
intervention such as ventricular assist
device or heart transplant indicated (2)
Prolonged
QT c interval
QT c > 0.50 second (1)
QT c > 0.5 second; life-threatening signs
or symptoms (e.g. arrhythmia, CHF,
hypotension, shock syncope); Torsade
de pointes (2)
Pericarditis
Pericarditis with physiologic
consequences (e.g. pericardial
constriction) (1)
Life-threatening consequences;
emergency intervention indicated (2)
Myocarditis
CHF responsive to intervention (1)
Severe or refractory CHF (2)
Hypertension
Requiring more than one drug or more
intensive therapy than previously (1)
Life-threatening (e.g. hypertensive crisis)
(2)
Hypotension
Sustained (≥ 24 h) therapy, resolves
without persisting physiologic
consequences (1)
Shock (e.g. acidaemia; impairment of
vital organ function) (2)
Infections
Specify: (1)
Constitutional Symptoms
> 40.0°C (> 104.0°F) for ≤ 24 hrs (1)
> 40.0°C (> 104.0°F) for > 24 hrs (2)
Mucositis /
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Stomatitis
(functional /
symptomatic)
Upper aerodigestive tract sites:
Symptomatic and unable to adequately
aliment or hydrate orally; respiratory
symptoms interfering with ADL Lower GI
sites: Stool incontinence or other
symptoms interfering with ADL (1)
Symptoms associated with life-
threatening consequences (2)
Vomiting
(no. of episodes
in 24 h)
≥ 6 episodes in 24 hrs; IV fluids, or TPN
indicated ≥ 24 hrs (1)
Life-threatening consequences (2)
Diarrhoea
Increase of ≥ 7 stools per day over
baseline; incontinence; IV fluids ≥ 24 hrs;
hospitalization; severe increase in
ostomy output compared to baseline;
interfering with ADL (1)
Life-threatening consequences (e.g.
haemodynamic collapse) (2)
Glomerular filtration
rate (GFR)
< 25% LLN, chronic dialysis not
indicated (1)
Chronic dialysis or renal transplant
indicated (2)
Proteinuria
4+ or > 3.5 g/24 hrs (1)
Nephrotic syndrome (2)
Bilirubin
> 3.0 – 10.0 x ULN  (1)
> 10.0 x ULN (2)
AST, SGOT
> 5.0 – 20.0 x ULN  (1)
> 20.0 x ULN (2)
ALT, SGPT
> 5.0 – 20.0 x ULN  (1)
> 20.0 x ULN (2)
Other adverse events
Please specify:
Grade 0 - 2 (1)
Grade 3  (2)
Grade 4  (3)
Grade 5 (SAE-Report) (4)
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Start of next protocol block
Without delay
With delay of days
Due to other reasons (Due to other
reasons)
Due to toxicity of previous protocol block
(Due to toxicity of previous protocol
block)
Footer module
Date
Name Investigator
Signature Investigator
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CLL History BO17072 NCT00090051
An open-label, multicenter, randomized, comparative,
phase III study to evaluate the efficacy and safety of
rituximab plus fludarabine and cyclophosphamide (FCR)
versus fludarabine and cyclophosphamide alone (FC) in
previously treated patients with CD20 positive B-cell
chronic lymphocytic leukemia (CLL). FCR Versus FC Alone
in the Treatment of Chronic Lymphocytic Leukemia (CLL) in
Relapsed Patients NCT00090051 Roche BO17072
All rights reserved. Please visit https://medical-data-
models.org/forms/12292
History of Chronic lymphocytic
leukemia NCT0090051
History of CLL
Date of first diagnosis
dd/mm/yy
Is Binet stage at diagnosis known?
yes (-> specify below) (1)
no (2)
Binet stage at diagnosis
A (1)
B (2)
C (3)
Date of last progression
dd/mm/yy
Site of progression (tick all that apply)
peripheral blood (1)
lymph nodes (2)
bone marrow (3)
other (-> specify below) (4)
Other progression
Binet stage at screening
Stage at screening
A (1)
B (2)
C (3)
Previous chemotherapy
Type of previous chemotherapy
1 (1)
2 (2)
3 (3)
Previous chemotherapy
Amendment C onwards
1 (1)
2 (2)
3 (3)
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BO17072 NCT00090051
An open-label, multicenter, randomized, comparative,
phase III study to evaluate the efficacy and safety of
rituximab plus fludarabine and cyclophosphamide (FCR)
versus fludarabine and cyclophosphamide alone (FC) in
previously treated patients with CD20 positive B-cell
chronic lymphocytic leukemia (CLL).
NCT00090051
Roche BO17072
FCR Versus FC Alone in the Treatment of Chronic
Lymphocytic Leukemia (CLL) in Relapsed Patients
All rights reserved. Please visit https://medical-data-
models.org/forms/12294
Demographics and Medical History
Chronic Lymphocytic Leukemia
NCT00090051
Demographics
Date of visit
ddmmyy
Patient initials
FML
Birth Date
ddmmyy
Sex
female (f)
male (m)
Female reproductive status
childbearing potential without
contraceptive protection (-> exclusion)
(1)
childbearing potential with contraceptive
protection (-> specify) (2)
surgically sterilized (3)
postmenopausal (4)
contraceptive protection, specify
Race
caucasian/white (1)
black (2)
oriental (3)
other (specify) (4)
Specify race
Serum pregnancy test (only females of
childbearing potential)
Date of pregnancy test
ddmmyy
Pregnancy Test
1 / 3
negative (0)
positive (-> patient must be excluded
from study) (1)
Previous or current diseases other than
CLL
Are there any diseases (including allergies) that
are clinically significant or for which the patient is
under
treatment (list treatments on treatment form)
other than CLL?
no (0)
yes -> specify (1)
Disease
active
Yes
No
Previous treatments not associated with
CLL
Have there been any previous drug treatments
(or medical procedures) not associated with CLL
completed
in the last month?
no (0)
yes (->specify) (1)
Name of treatment (or medical procedure)
Previous treatments/medical
procedures/chemotherapy related to CLL
Name of treatment
Start date
dd/mm/yy
End date
Best response
CR (1)
PR (2)
SD (3)
PD (4)
NK/NA (5)
Previous treatments radiotherapy
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site of radiotherapy
Total dose
Gy
Start date
dd/mm/yy
End date
dd/mm/yy
Surgery
Surgical procedure
Date of Surgery
dd/mm/yy
Other treatment
Name of treatment
Start date
dd/mm/yy
End date
dd/mm/yy
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Riliva_CRF_EudraCT - Nr. 2012-000108-
13- Screening
Study documentation part: Screening. This is a phase II
multicenter trial with Rivaroxaban in the treatment of
livedoid vasculopathy assessing the pain on a visual analog
scale (VAS).  Principal Investigator PD Dr. Tobias Görge,
University Hospital of Münster. EudraCT - Nr. 2012-
000108-13.
All rights reserved. Please visit https://medical-data-
models.org/forms/12355
Screening I
Basic data
Centre number:
Date of birth:
Gender:
male (1)
female (2)
Date informed consent signed:
Assessment date:
Inclusion Criteria
1) Secured livedo vasculopathy
Yes
No
2) Age ≥ 18 years and ≤ 80 years
Yes
No
3) 40 points on the pain VAS at least one day
within the last 7 days before beginning therapy
Yes
No
4) In women: secured contraception
(Requirement: Pearl Index <1) (in case of men
please  choose "No")
Yes
No
5) Adequate communication skills in the German
language
Yes
No
6) Patient must be able to recognize the nature,
significance and scope of the clinical trial and to
align his will hereafter
Yes
No
Exclusion Criteria
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1) Participation in another intervention study
within the last 30 days before beginning therapy
Yes
No
2) Known allergy to the study medication
Yes
No
3) Known problems of galactose intolerance,
deficit of lactase or glucose-galactose
malabsorption
Yes
No
4) Pregnancy
Yes
No
5) Lactation
Yes
No
6) Known renal impairment (creatinine clearance
<30ml/min)
Yes
No
7) Known liver disease (Child-Pugh score B and
C)
Yes
No
8) Known ulcerative gastrointestinal disorders
within the last 30 days prior to initiation of therapy
or during
Yes
No
9) Uncontrolled, severe arterial hypertension
Yes
No
10) Artificial heart valves
Yes
No
11) Acute pulmonary embolism
Yes
No
12) Known bronchiectasis or pulmonary bleeding
Yes
No
13) Known vascular retinopathy
Yes
No
14) Intracranial or intracerebral haemorrhage
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within the last 30 days before beginning of
therapy or during therapy
Yes
No
15) Brain, spinal cord or eye surgery within the
last 30 days before beginning of therapy or during
therapy
Yes
No
16) Spinal or epidural anaesthesia or puncture
within the last 2 weeks before beginning of
therapy or during therapy
Yes
No
17) Application of systemic heparin within 1 day
before beginning of therapy
Yes
No
18) Intake of NSARs or thrombocyte aggregation
inhibitors within 1 day before beginning of therapy
or during therapy
Yes
No
19) Intake of vitamin-K-antagonists (marcumar,
warfarin) and/or thrombin inhibitor (dabigatran)
within 7 days before beginning of therapy or
during therapy
Yes
No
20) Concomitant use of CYP3A4 inducers (e.g.
rifampicin, phenytoin, carbamazepine,
phenobarbital or St. John’s Wort)
Yes
No
21) Concomitant systemic treatment with azole-
antimycotics (such as ketoconazole, itraconazole,
voriconazole and posaconazole)
Yes
No
22) Concomitant systemic treatment with HIV-
protease inhibitors (e.g. ritonavir)
Yes
No
23) Concomitant systemic treatment with
dronedarone
Yes
No
24) Presence of malignant neoplasms at high risk
of bleeding
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Yes
No
25) Recent brain or spinal injury
Yes
No
26) Known or suspected oesophageal varices
Yes
No
27) Known arteriovenous malformations
Yes
No
28) Known vascular aneurysms
Yes
No
29) Known major intraspinal or intracerebral
vascular abnormalities
Yes
No
Urine pregnancy test
Date of urine pregnancy test:
Result of urine pregnancy test:
positive (1)
negative (2)
not performed as the subject is male (3)
other (4)
Please mention details when other:
Patient meets all the inclusion criteria and none
of the exclusion criteria is present:
Yes, approval for treatment with study
medication according to the study
protocol (1)
No, unapproved for the treatment with
study medication according to the study
protocol (2)
No, the inclusion or the exclusion criteria
can not be met in future, so end of the
study (screening failure) (3)
Screening II
Basic data
Centre number:
Date of renewed assessment of the inclusion and
the exclusion criteria:
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Inclusion Criteria
1) Secured livedo vasculopathy
Yes
No
2) Age ≥ 18 years and ≤ 80 years
Yes
No
3) 40 points on the pain VAS at least one day
within the last 7 days before beginning therapy
Yes
No
4)In women: secured contraception
(Requirement: Pearl Index <1) (in case of men
please choose "No")
Yes
No
5) Adequate communication skills in the German
language
Yes
No
6) Patient must be able to recognize the nature,
significance and scope of the clinical trial and to
align his will hereafter
Yes
No
Exclusion Criteria
1) Participation in another intervention study
within the last 30 days before beginning therapy
Yes
No
2) Known allergy to the study medication
Yes
No
3) Known problems of galactose intolerance,
deficit of lactase or glucose-galactose
malabsorption
Yes
No
4) Pregnancy
Yes
No
5) Lactation
Yes
No
6) Known renal impairment (creatinine clearance
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<30ml/min)
Yes
No
7) Known liver disease (Child-Pugh score B and
C)
Yes
No
8) Known ulcerative gastrointestinal disorders
within the last 30 days prior to initiation of therapy
or during
Yes
No
9) Uncontrolled, severe arterial hypertension
Yes
No
10) Artificial heart valves
Yes
No
11) Acute pulmonary embolism
Yes
No
12) Known bronchiectasis or pulmonary bleeding
Yes
No
13) Known vascular retinopathy
Yes
No
14) Intracranial or intracerebral haemorrhage
within the last 30 days before beginning of
therapy or during therapy
Yes
No
15) Brain, spinal cord or eye surgery within the
last 30 days before beginning of therapy or during
therapy
Yes
No
16) Spinal or epidural anaesthesia or puncture
within the last 2 weeks before beginning of
therapy or during therapy
Yes
No
17) Application of systemic heparin within 1 day
before beginning of therapy
Yes
No
18) Intake of NSARs or thrombocyte aggregation
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inhibitors within 1 day before beginning of therapy
or during therapy
Yes
No
19) Intake of vitamin-K-antagonists (marcumar,
warfarin) and/or thrombin inhibitor (dabigatran)
within 7 days before beginning of therapy or
during therapy
Yes
No
20) Concomitant use of CYP3A4 inducers (e.g.
rifampicin, phenytoin, carbamazepine,
phenobarbital or St. John’s Wort)
Yes
No
21) Concomitant systemic treatment with azole-
antimycotics (such as ketoconazole, itraconazole,
voriconazole and posaconazole)
Yes
No
22) Concomitant systemic treatment with HIV-
protease inhibitors (e.g. ritonavir)
Yes
No
23) Concomitant systemic treatment with
dronedarone
Yes
No
24) Presence of malignant neoplasms at high risk
of bleeding
Yes
No
25) Recent brain or spinal injury
Yes
No
26) Known or suspected oesophageal varices
Yes
No
27) Known arteriovenous malformations
Yes
No
28) Known vascular aneurysms
Yes
No
29) Known major intraspinal or intracerebral
vascular abnormalities
Yes
No
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Urine pregnancy test
Date of urine pregnancy test:
Result of urine pregnancy test:
positive  (1)
negative  (2)
not performed as the subject is male  (3)
other (4)
Please mention details when other:
Patient meets all the inclusion criteria and none
of the exclusion criteria is present:
Yes, approval for treatment with study
medication according to the study
protocol  (1)
No, end of study (Screening failure) (2)
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Riliva_CRF_EudraCT - Nr. 2012-000108-
13-Study termination
Study description: Study documentation part- Study
termination. This is a phase II multicenter trial with
Rivaroxaban in the treatment of livedoid vasculopathy
assessing the pain on a visual analog scale (VAS).
Principal Investigator PD Dr. Tobias Grge, University
Hospital of Mnster. EudraCT - Nr. 2012-000108-13.
All rights reserved. Please visit https://medical-data-
models.org/forms/12357
Riliva_CRF_EudraCT - Nr. 2012-
000108-13-Study termination
Studienabbruch
Datum des Studienabbruchs:
Zentrum Nr.:
Primärer Grund für Studienabbruch:
Widerruf der Einwilligungserklärung
durch Patient (1)
Vorzeitiges Schließen der gesamten
Studie (2)
Mangelnde Compliance des Patienten
(3)
Abfall des Hämoglobin Wertes von über
2 Einheiten [g/dl] vom Ausgangswert und
Blutungsquelle kann nicht gestoppt
werden (4)
Entscheidung des Prüfarztes, dass eine
weitere Teilnahme des Patienten an der
Studie nicht vertretbar ist (5)
Verletzung von Ein- bzw.
Ausschlusskriterien nach 1. Gabe
Prüfmedikation (6)
Bitte die verletzten Kriterium erläutern:
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Pharmacokinetic Study of Doxorubicin in
Children With Cancer NCT01095926
Official Title: Phase II Pharmacokinetic Study to Assess the
Age-dependency in the Clearance of Doxorubicin in
Paediatric Patients With Solid Tumours and Leukaemia
Analyze pharmacokinetics of doxorubicin in children with
cancer. Furthermore investigate the predictive role of
troponin and natriuretic peptides for anthracycline-induced
cardiotoxicity.
https://clinicaltrials.gov/ct2/show/NCT01095926
NCT01095926
All rights reserved. Please visit https://medical-data-
models.org/forms/12358
2st Sampling period NCT01095926
Physical Examination
Physical Examination Date
Height
cm
Weight
kg
BSA
m2
Karnofsky
Index
%
Determination of cardiac function (before
sampling period)
Date
Blood
pressure
mm Hg
sys  (1)
dia (2)
Heart
rate
/min
Echocardiography
LVEDD (1)
IVS (2)
LVSF (3)
LVESD (4)
LVPW (5)
LVEF (6)
Electrocardiography (optional)
Not done (1)
Date: (2)
ECG findings (3)
If abnormal, please specify (4)
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Clinical chemistry
Date
Bilirubin
(total)
mg/dL
Serum
creatinine
mg/dL
Serum
albumin
mg/dL
GOT / AST
U/L
GPT / ALT
U/L
GFR
mL/min
GFR estimated: (1)
By radioactivity measurement (2)
By urine collection (3)
From a single measurement of serum-
creatinine (4)
Haematology
Date
Haemoglobin
g/dL
Haematocrit
%
Neutrophils
/μL
Leucocytes
/μL
Platelets
/μL
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Agents that are known to interact with
doxorubicin according to SmPCs
administered?
Carbamazepine
Yes
No
Cimetidine
Yes
No
Cyclosporine
Yes
No
Phenobarbital
Yes
No
Phenytoin
Yes
No
Progesterone
Yes
No
Rifampicin
Ritonavir
Yes
No
Sulfamethoxazole
Yes
No
Verapamil
Yes
No
Antiemetic agents administered?
Granisetron
Yes
No
Metoclopramid
Yes
No
Ondansetron
Yes
No
Other 5-HT3-receptor antagonists
Yes
No
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Aprepitant
Yes
No
Alizapride
Yes
No
Dexamethason administered?
Yes
No
Dimenhydrinate administered?
Yes
No
Domperidone administered?
Yes
No
Lorazepam administered?
Yes
No
Other
Yes
No
Cardioprotective agents administered?
Dexrazoxane
Yes
No
Other(s)
If other(s): (INN name) (1)
Systemic antimycotic agents
Azole antimycotics
Yes
No
Other(s)
If other(s): (INN name) (1)
Other agents administered?
Antibiotic agents
Yes
No
Anticonvulsive agents
Yes
No
Cardioactive agents
Yes
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No
Proton pump inhibitors
Yes
No
Contraceptive agents
Yes
No
Systemic antiviral agents
Yes
No
Actual protocol block
Wilms tumour
AVD (1)
High Risk (2)
Neuroblastoma
N4 (1)
N6 (2)
TVD (3)
CADO (4)
Ewing
sarcoma
VIDE (1)
VAC (2)
VAI (3)
Soft tissue
sarcoma
VAIA III (1)
High risk (2)
IA (3)
ALL
Protocol II (1)
Consolidation (2)
Intensification (3)
Delayed Intensification (4)
Other:
Start of actual protocol block
Without delay
With delay of
Due to toxicity of previous protocol block
(1)
Due to other reasons (2)
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Chemotherapy in actual protocol block
administered ?
Actinomycine D
No (1)
Yes, per protocol (2)
Yes, but not per protocol (3)
Reduced due to toxicity of actual /
previous protocol block? (4)
Asparaginase
No (1)
Yes, per protocol (2)
Yes, but not per protocol (3)
Reduced due to toxicity of actual /
previous protocol block? (4)
Cyclophosphamide
No (1)
Yes, per protocol (2)
Yes, but not per protocol (3)
Reduced due to toxicity of actual /
previous protocol block? (4)
Dacarbazine
No (1)
Yes, per protocol (2)
Yes, but not per protocol (3)
Reduced due to toxicity of actual /
previous protocol block? (4)
Dexamethasone
No (1)
Yes, per protocol (2)
Yes, but not per protocol (3)
Etoposide
No (1)
Yes, per protocol (2)
Yes, but not per protocol (3)
Reduced due to toxicity of actual /
previous protocol block? (4)
Ifosfamide
No (1)
Yes, per protocol (2)
Yes, but not per protocol (3)
Reduced due to toxicity of actual /
previous protocol block? (4)
Topotecan
No (1)
Yes, per protocol (2)
Yes, but not per protocol (3)
Reduced due to toxicity of actual /
previous protocol block? (4)
Vincristine
No (1)
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Yes, per protocol (2)
Yes, but not per protocol (3)
Reduced due to toxicity of actual /
previous protocol block? (4)
Other:
(INN name)
No (1)
Yes, per protocol (2)
Yes, but not per protocol (3)
Reduced due to toxicity of actual /
previous protocol block? (4)
Previous anthracycline treatment
Cumulative doxorubicin dose
mg
Other anthracyclines administered
Daunorubicin (1)
Epirubicin (2)
Idarubicin (3)
Mitoxantrone (4)
Cumulative dose of other anthracyclines
mg
Doxorubicin treatment in 2st sampling
period
Brand name
Adriblastin(e)/Adriblastina®(Pfizer/Pharm
acia) (1)
Doxorubicin (Hydrochloride) (TEVA) (2)
Adrimedac® (Medac)  (3)
Ribodoxo® (Hikma) (4)
DOXO-Cell® (Cell Pharm)  (5)
Other (6)
Haematological toxicity of actual protocol
block
Leucocytes
10^3/μL
Nadir (1)
Date of nadir (2)
Date of recovery (3)
Platelets
10^3/μL
Nadir  (1)
Date of nadir  (2)
Date of recovery (3)
Haemoglobin
g/dL
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Nadir  (1)
Date of nadir  (2)
Date of recovery (3)
Transfusions
Number of days with platelets transfusions
Number of days with erythrocytes transfusions
Determination of cardiac function (end of
sampling period)
Date
Blood
pressure
mm Hg
sys  (1)
dia (2)
Electrocardiography (optional)
within 28 days after doxorubicin
administration
Not done: (1)
Date: (2)
Routine practice (3)
Adverse Event (4)
Control of preknown condition (5)
Other (6)
ECG findings (7)
If abnormal, please specify (8)
Echocardiography
LVEDD (1)
IVS (2)
LVSF (3)
LVESD (4)
LVPW (5)
LVEF (6)
Adverse events
Haemoglobin
g/dL
Grade 0 - 2 (1)
Grade 3  (2)
Grade 4  (3)
Grade 5 (SAE-Report) (4)
Leucocytes
(total WBC)
/mm3
Grade 0 - 2 (1)
8 / 12
Pharmacokinetic Study of Doxorubicin in Children With Cancer
NCT01095926
Grade 3  (2)
Grade 4  (3)
Grade 5 (SAE-Report) (4)
Neutrophils /
granulocytes
Grade 0 - 2 (1)
Grade 3  (2)
Grade 4  (3)
Grade 5 (SAE-Report) (4)
Platelets
Grade 0 - 2 (1)
Grade 3  (2)
Grade 4  (3)
Grade 5 (SAE-Report) (4)
Cardiac
arrhythmia
Symptomatic and incompletely controlled
medically or controlled with device (e.g.
defibrillator) (1)
Life-threatening (e.g. arrhythmia
associated with CHF, hypotension,
syncope, shock) (2)
Left ventricular
systolic
dysfunction
Symptomatic CHF responsive to
intervention; EF < 40-20% SF < 15% (1)
Refractory CHF or poorly controlled; EF
< 20%; intervention such as ventricular
assist device, ventricular reduction
surgery, or heart transplant indicated (2)
Left ventricular
diastolic
dysfunction
Symptomatic CHF responsive to
intervention (1)
Refractory CHF, poorly controlled;
intervention such as ventricular assist
device or heart transplant indicated (2)
Prolonged
QT c interval
QT c > 0.50 second (1)
QT c > 0.5 second; life-threatening signs
or symptoms (e.g. arrhythmia, CHF,
hypotension, shock syncope); Torsade
de pointes (2)
Pericarditis
Pericarditis with physiologic
consequences (e.g. pericardial
constriction) (1)
Life-threatening consequences;
emergency intervention indicated (2)
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Myocarditis
CHF responsive to intervention (1)
Severe or refractory CHF (2)
Hypertension
Requiring more than one drug or more
intensive therapy than previously (1)
Life-threatening (e.g. hypertensive crisis)
(2)
Hypotension
Sustained (≥ 24 h) therapy, resolves
without persisting physiologic
consequences (1)
Shock (e.g. acidaemia; impairment of
vital organ function) (2)
Infections
Specify: (1)
Constitutional Symptoms
> 40.0°C (> 104.0°F) for ≤ 24 hrs (1)
> 40.0°C (> 104.0°F) for > 24 hrs (2)
Mucositis /
Stomatitis
(functional /
symptomatic)
Upper aerodigestive tract sites:
Symptomatic and unable to adequately
aliment or hydrate orally; respiratory
symptoms interfering with ADL Lower GI
sites: Stool incontinence or other
symptoms interfering with ADL (1)
Symptoms associated with life-
threatening consequences (2)
Vomiting
(no. of episodes
in 24 h)
≥ 6 episodes in 24 hrs; IV fluids, or TPN
indicated ≥ 24 hrs (1)
Life-threatening consequences (2)
Diarrhoea
Increase of ≥ 7 stools per day over
baseline; incontinence; IV fluids ≥ 24 hrs;
hospitalization; severe increase in
ostomy output compared to baseline;
interfering with ADL (1)
Life-threatening consequences (e.g.
haemodynamic collapse) (2)
Glomerular filtration
rate (GFR)
< 25% LLN, chronic dialysis not
indicated (1)
Chronic dialysis or renal transplant
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indicated (2)
Proteinuria
4+ or > 3.5 g/24 hrs (1)
Nephrotic syndrome (2)
Bilirubin
> 3.0 – 10.0 x ULN  (1)
> 10.0 x ULN (2)
AST, SGOT
> 5.0 – 20.0 x ULN  (1)
> 20.0 x ULN (2)
ALT, SGPT
> 5.0 – 20.0 x ULN  (1)
> 20.0 x ULN (2)
Other adverse events
Please specify:
Grade 0 - 2 (1)
Grade 3  (2)
Grade 4  (3)
Grade 5 (SAE-Report) (4)
Start of next protocol block
Without delay
With delay of days
Due to other reasons (Due to other
reasons)
Due to toxicity of previous protocol block
(Due to toxicity of previous protocol
block)
Actual protocol block is last block of
chemotherapy
Yes
No
Start of next protocol block
within 28 days after
doxorubicin administration
Yes
No
Pharmacogenetics
Date of blood sample for pharmacogenetic
analysis
End of study / Withdrawal
Date
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Regular end of patient’s participation in the study
Yes
No
Withdrawal
Reason for withdrawal
Death (1)
Other: (10)
Patient, parent(s) or legal representative
decided to withdraw from the study (2)
Changes in the patient’s condition render
the patient unacceptable for further study
participation in the judgement of the
investigator (3)
CodelistItem 762101 (4)
Please give reason: Discontinuation of
doxorubicin treatment Due to: (5)
Disease progression/relapse (6)
Refractory disease (7)
Cardiotoxicity (8)
Other unacceptable adverse events (9)
Footer module
Date
Name Investigator
Signature Investigator
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Eligibility Chronic Kidney Disease Stage 1
NCT01561222
Effect of Vitamin D Supplement on Osteoprotegin
Expression and Disease Progression in Patients With
Chronic Kidney Disease Stage 1 and 2; ODM derived from:
https://clinicaltrials.gov/show/NCT01561222
All rights reserved. Please visit https://medical-data-
models.org/forms/12416
Eligibility Chronic Kidney Disease
Stage 1 NCT01561222
Inclusion Criteria
clinical diagnosis of ckd stage 1 and 2*
Yes
No
age >18 years*
Yes
No
ability to provide informed consent*
Yes
No
Exclusion Criteria
on vitamin d in past 4 weeks*
Yes
No
plans to relocate out of taixing city in the next one
year*
Yes
No
serum phosphate >5.5 mg/dl in past 3 months*
Yes
No
serum calcium >10.0 mg/dl in past 3 months*
Yes
No
cancer*
Yes
No
transplanted organ*
Yes
No
rapidly deteriorating kidney function with the
expectation for initiation of dialysis in less than 6
months*
Yes
No
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Eligibility Coronary Artery Disease
NCT02110303
DIAMOND - Dual Antiplatelet Therapy to Reduce
Myocardial Injury; ODM derived from:
https://clinicaltrials.gov/show/NCT02110303
All rights reserved. Please visit https://medical-data-
models.org/forms/12417
Eligibility Coronary Artery Disease
NCT02110303
Inclusion Criteria
patients aged 40 years with angiographically
proven multivessel coronary artery disease
defined as at least two major epicardial vessels
with any combination of either (a) >50% luminal
stenosis, or (b) previous revascularization
(percutaneous coronary intervention or coronary
artery bypass graft surgery).*
Yes
No
provision of informed consent prior to any study
specific procedures*
Yes
No
Exclusion Criteria
an acute coronary syndrome within the last 12
months*
Yes
No
an indication for dual anti-platelet therapy, such
as drug eluting stent*
Yes
No
inability to take aspirin*
Yes
No
receiving thienopyridine therapy such as
clopidogrel or prasugrel*
Yes
No
percutaneous coronary intervention or coronary
artery bypass graft surgery within the last 3
months*
Yes
No
inability or unwilling to give informed consent*
Yes
No
woman with child-bearing potential and who are
breastfeeding will not be enrolled into the trial
(woman who have experienced menarche, are
pre-menopausal, have not been sterilised or who
are currently pregnant)*
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Yes
No
known hypersensitivity to ticagrelor or one of its
excipients*
Yes
No
active pathological bleeding or bleeding
diathesis*
Yes
No
significant thrombocytopenia: <100 x 10^9 /l*
Yes
No
history of intracranial haemorrhage*
Yes
No
moderate to severe liver impairment (child's
grade b or c)*
Yes
No
maintenance therapy with strong cytochrome
p450 3a4 (cyp3a4) inhibitors, such as
ketoconazole, nefazodone, ritonavir, indinavir,
atazanavir, or clarithromycin*
Yes
No
major intercurrent illness or life expectancy <1
year*
Yes
No
renal dysfunction (egfr ≤30 ml/min/1.73 m2)*
Yes
No
contraindication to iodinated contrast agents*
Yes
No
planned coronary revascularization or major non-
cardiac surgery in the next 12 months*
Yes
No
maintenance therapy with simvastatin at doses
greater than 40mg daily*
Yes
No
receiving oral anticoagulants including warfarin,
rivaroxaban, dabigatran or apixaban.*
Yes
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Eligibility Diabetes Mellitus Type 2
NCT02160639
Evaluating the Impact of Year Long, Augmented Diabetes
Self Management Support; ODM derived from:
https://clinicaltrials.gov/show/NCT02160639
All rights reserved. Please visit https://medical-data-
models.org/forms/12418
Eligibility Diabetes Mellitus Type 2
NCT02160639
Inclusion Criteria
english or spanish speaking*
Yes
No
diagnosis of type 2 diabetes mellitus*
Yes
No
hba1c > 8*
Yes
No
have not completed a diabetes self management
education program in the past year*
Yes
No
Exclusion Criteria
current engagement in cancer treatment*
Yes
No
diagnosis of end-stage renal disease*
Yes
No
pregnant*
Yes
No
receiving immunosuppressant therapy following
transplant*
Yes
No
diagnosis of serious mental illness*
Yes
No
undergoing systemic treatment with prednisone*
Yes
No
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Eligibility Diabetes NCT02117622
A Non-interventional, Post Marketing Surveillance (PMS)
Study of Tresiba® (Insulin Degludec) to Evaluate Long
Term Safety and Efficacy in Patients With Diabetes Mellitus
in Routine Clinical Practice in India; ODM derived from:
https://clinicaltrials.gov/show/NCT02117622
All rights reserved. Please visit https://medical-data-
models.org/forms/12420
Eligibility Diabetes NCT02117622
Inclusion Criteria
informed consent obtained before any study-
related activities (study related activities are any
procedure related to recording of data according
to the protocol). the historical data including the
data before informed consent obtained (e.g.
glycosylated haemoglobin (hba1c), fasting
plasma glucose (fpg), severe hypoglycaemia
before the start of tresiba therapy) can be used
for baseline data*
Yes
No
patients with insulin requiring diabetes mellitus
and who is scheduled to start treatment with
tresiba® based on the clinical judgment of their
treating physician*
Yes
No
Exclusion Criteria
known or suspected allergy to tresiba®, the
active substance or any of the excipients*
Yes
No
previous participation in this study*
Yes
No
mental incapacity, unwillingness or language
barriers precluding adequate understanding or
cooperation*
Yes
No
patients who are or have previously been on
tresiba® therapy*
Yes
No
patients who are participating in other studies or
clinical trials*
Yes
No
patients who are pregnant, breast feeding or have
the intention of becoming pregnant within the
following 12 months*
Yes
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Eligibility Hepatitis B NCT02135666
Evaluation of the Long-term Hepatitis A and B Antibody
Persistence in Healthy Adult Subjects, Primed 16 to 20
Years Earlier With GSK Biologicals' Combined Hepatitis A
and B Vaccine, Twinrix® (SB208127) in Study HAB-084
(208127/084); ODM derived from:
https://clinicaltrials.gov/show/NCT02135666
All rights reserved. Please visit https://medical-data-
models.org/forms/12422
Eligibility Hepatitis B NCT02135666
Inclusion Criteria
subjects who, in the opinion of the investigator,
can and will comply with the requirements of the
protocol.*
Yes
No
a male or female who received two/three doses of
twinrix according to his/her group allocation in
study hab-084 (208127/084), and received no
further dose of any hepatitis a and/or b vaccine
since then.*
Yes
No
written informed consent obtained from the
subject.*
Yes
No
Exclusion Criteria
chronic administration (defined as more than 14
days in total) of immunosuppressants or other
immune-modifying drugs within six months prior
to study entry. inhaled and topical steroids are
allowed.*
Yes
No
administration of long-acting immune-modifying
drugs within six months prior to the study entry.*
Yes
No
concurrently participating in another clinical
study, at any time during the study period, in
which the subject has been or will be exposed to
an investigational or a non-investigational
vaccine/product (pharmaceutical product or
device).*
Yes
No
administration of any hepatitis a and/or b vaccine
at any time since completion of the primary
vaccination series in hab-084 (208127/084)
study, including a challenge dose of the study
vaccine, as a part of the study procedures, during
the long-term persistence phase.*
Yes
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No
documented history of hepatitis a or b disease
since completion of the primary vaccination
series in hab-084 (208127/084) study.*
Yes
No
any confirmed or suspected immunosuppressive
or immunologic deficiency syndromes, based on
medical history and physical examination (no
laboratory testing required).*
Yes
No
administration of immunoglobulins within six
months prior to study entry.*
Yes
No
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Eligibility Lymphoma NCT02106988
Concurrent Chemotherapy and Radiation Therapy for
Newly Diagnosed Nasal NK Cell Lymphoma; ODM derived
from: https://clinicaltrials.gov/show/NCT02106988
All rights reserved. Please visit https://medical-data-
models.org/forms/12423
Eligibility Lymphoma NCT02106988
Inclusion Criteria
1. patients with newly diagnosed stage i and ii
nasal nk cell lymphoma.*
Yes
No
2. adequate blood cell counts (i.e. anc > 1000) at
baseline, or willingness to accept supportive
measures such as transfusions, filgrastim, and
epoetin.*
Yes
No
3. patients must have adequate liver function as
indicated by: *bilirubin </= 1.5 times the upper
limit of normal (uln), * alanine transaminase (alt)
</= 2 times the (uln) or aspartate transaminase
(ast) </= 2 times the uln, *these values must be
obtained within two weeks before protocol entry.*
Yes
No
4. patients are required to have a serum
creatinine </= 2.0 mg/dl. this value must be
obtained within two weeks before protocol entry.*
Yes
No
5. left ventricular ejection fraction must be
evaluated by nuclear medicine scan or
echocardiography and measure >/= 50%.*
Yes
No
6. male patients must agree to use a barrier
method of contraception or agree to abstain from
heterosexual activity for the duration of the
study.*
Yes
No
7. female patients must be willing to use two
adequate barrier methods of contraception to
prevent pregnancy or agree to abstain from
heterosexual activity throughout the study or be
post menopausal (free from menses > two years
or surgically sterilized).*
Yes
No
8. female patients of childbearing potential must
have a negative serum pregnancy test (bhcg)
within 2 weeks of protocol entry.*
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Yes
No
9. patients must have the ability to give informed
consent.*
Yes
No
Exclusion Criteria
1. patients with active hepatitis b and/or hepatitis
c infection.*
Yes
No
2. patients with active infections requiring specific
anti-infective therapy are not eligible until all signs
of infections are resolved.*
Yes
No
3. patients known to be hiv positive.*
Yes
No
4. patients with pre-existing cardiovascular
disease requiring ongoing treatment. this
includes: a) congestive heart failure class iii/iv chf
per new york heart association (nyha) criteria. b)
cardiomyopathy, c) uncontrolled cardiac
arrhythmia, d) unstable angina pectoris, e) recent
mi (within 6 months).*
Yes
No
5. patients who are pregnant or breast-feeding.*
Yes
No
6. patients with psychiatric illness and/or social
situations that would limit compliance with the
study medication and requirements.*
Yes
No
7. prior radiation to the site of current primary
disease, if re-treatment would lead to violation of
known radiation dose tolerance limits for that
site.*
Yes
No
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EBMT Total Body Irradiation
ODM derived from HSCT forms on http://www.ebmt.org/
All rights reserved. Please visit https://medical-data-
models.org/forms/12424
EBMT Total Body Irradiation
To be completed by the haematology unit
EBMT Centre Identification Code (CIC) of
haematology unit
Hospital
Unit
Hospital Patient Number
UIC (if known)
Initials
Date of birth:
Date of transplant
Date conditioning chemo started
To be completed by the radiophysicist
group
EBMT Centre Identification Code (CIC) of
radiophysicist unit (if CIC exists
Hospital
Unit
Telephone
Fax
TARGET VOLUME defined as WHOLE
BODY (including the skin)
T.B.I. DOSE
Gy
TRANSVERSE +
%
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NORMAL TISSUE LUNG, ORGAN MOST
AT RISK
TRANSVERSE -
%
LONGITUDINAL +
%
LONGITUDINAL -
%
Doses spleen
%
RIB CAGE
%
Doses Others
%
NORMAL TISSUE LUNG, ORGAN MOST
AT RISK
LUNG DOSE
Gy
SHIELDED PHYSICAL VOLUME IRRADIATED
%
Fractions
STARTING DATE
MIN.TIME GAP
DOSE-RATE
Gy/min
MAXIMUM DOSE RATE
Gy/min
NORMAL TISSUE OTHER ORGANS AT
RISK
Doses EYES LENSE
%
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EBMT Total Body Irradiation
doses KIDNEYS
%
doses CNS
%
other doses
%
COMMENTS
COMMENTS e.g. irregular parameters, if
parameters vary or not constant
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EBMT Total Body Irradiation
Admission and Eligiblity Form Hyperthermia
Treatment Study
Hyper-PEI-protocol:a programme with regional deep
hyperthermia(RHT)in combination with PEI-
chemotherapy.The Hyper-PEI protocol is offered in place of
the 
intensive  standard  chemotherapy  for  high-risk  patie
nts  with  malignant,  extracranial  tumors. 
Patients  have  a  measurable  relapsed  tumor,or a primary
tumor that did not respond sufficiently to treatment
according to standard protocols.  
Responsible MD:
PD Dr. med. R Wessalowski,
Clinic for pediatric oncology,haematology and immunology
UKD, Moorenstr. 5, 40225 Dusseldorf
Form has to be completed by cooperating center or clinic
and sent to the Hyper-PEI director. Confirmation or denial
of admittance will be sent to the cooperating center and
GPOH study coordinator by head of protocol.
All rights reserved. Please visit https://medical-data-
models.org/forms/12427
Admission and Eligibility
Patient Identification
Patient Name
Date
Date
Inclusion criteria
Histologically significant malignant solid
extracerebral and extrapulmonary tumor
Yes
No
No metastases
Yes
No
Documented evidence of metastatic disease
Yes
No
Recent, complete Staging
Yes
No
No participiation in any other experimental
studies within past 4 weeks
Yes
No
Age ≥ 25 years at time of diagnosis
Yes
No
Informed Consent given and signed
Yes
No
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Lansky/Karnovsky score ≥70
Yes
No
Life expectancy ≥ 3 months
Yes
No
Blood count Hb  8 g/dl (or transfusion)
Yes
No
Platelets count must be ≥ 50.000 (or transfusion)
Yes
No
Creatinine no greater than 1,5 times ULN
Yes
No
Creatinine clearance > 50 mml/min/1.73m2
Yes
No
Transaminases < 2 times ULN
Yes
No
Bilirubin total <1,5 mg/dl
Yes
No
Normal coagulation
Yes
No
Leukapheresis or bone marrow aspiration
possible
Yes
No
Comments
Exclusion criteria
Cardiac pacemaker
Yes
No
Implant or other metallic device in area of
hyperthermia
Yes
No
Metastatic malignant disease
Yes
No
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Currently Pregnant or breast feeding
Yes
No
Hepatitis B/C infection
Yes
No
HIV positivity
Yes
No
Comment
Attachment
Diagnostic Imaging of staging
Yes
No
Correctness of information confirmed
Date
Responsible physician
Signature
Inclusion of Patient into Hyper-PEI
Protocol
Date
Signature Head of Hyper-PEI Dusseldorf
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Admission and Eligiblity Form Hyperthermia Treatment Study
Eligibility Low Dose Methotrexate in Severe
Chronic Asthma NCT02124226
Low-dose Methotrexate for Reduction GINA 5 Medications
in Chronic Severe Asthma; ODM derived from:
https://clinicaltrials.gov/show/NCT02124226
All rights reserved. Please visit https://medical-data-
models.org/forms/12428
Eligibility Low Dose Methotrexate in
Severe Chronic Asthma
NCT02124226
Inclusion Criteria
1. patients with a diagnosis of csa taking gina
step 5 medications (i.e. regular ocs and/or
omalizumab for a minimum of 6 months);*
Yes
No
2. failure in weaning patients completely from
step 5 medications during run-in;*
Yes
No
3. male and female individuals age 18 - 75
years;*
Yes
No
4. patients must be able to provide consent;*
Yes
No
Exclusion Criteria
1. use of immunomodulatory therapies in the
preceding 3 months;*
Yes
No
2. recent or current history of alcoholism;*
Yes
No
3. high liver enzyme levels (greater than 2.5 times
the upper limit of the normal range);*
Yes
No
4. serum creatinine levels greater than 2.0 mg/dl*
Yes
No
5. acute illness within 15 days of study
medication administration;*
Yes
No
6. leucopenia (below 3.0x109/l) and/or
thrombocytopenia (below 100x109/l).*
Yes
No
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7. pregnancy or planning to become pregnant;*
Yes
No
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Eligibility Low Dose Methotrexate in Severe Chronic Asthma
NCT02124226
Eligibility Hepatitis A NCT02124785
Evaluation of the Long-term Persistence of Hepatitis A
Antibodies in Healthy Adults Who Were Vaccinated 21-25
Years Earlier With GlaxoSmithKline (GSK) Biologicals'
Hepatitis A Vaccine, Havrix®; ODM derived from:
https://clinicaltrials.gov/show/NCT02124785
All rights reserved. Please visit https://medical-data-
models.org/forms/12429
Eligibility Hepatitis A NCT02124785
Inclusion Criteria
a male or female who received two doses of
havrix in study hav-112 (208109/108) or hav-123
(208109/114), and received no further booster
dose since then.*
Yes
No
subjects who, in the opinion of the investigator,
can and will comply with the requirements of the
protocol (e.g. return for follow-up visits).*
Yes
No
written informed consent obtained from the
subject.*
Yes
No
Exclusion Criteria
history of hepatitis a disease since completion of
the primary vaccination series in studies hav-112
(208109/108) or hav-123 (208109/114).*
Yes
No
administration of a hepatitis a vaccine at any time
since completion of the primary vaccination
series in studies hav-112 (208109/108) or hav-
123 (208109/114) including a challenge dose of
the study vaccine, as a part of the study
procedures, during the long-term persistence
phase.*
Yes
No
any confirmed or suspected immunosuppressive
or immunodeficient condition, based on medical
history.*
Yes
No
administration of hepatitis a immunoglobulins
and/or any blood products and/or long-acting
immune-modifying drugs within six months prior
to study entry.*
Yes
No
chronic administration of immunosuppressants or
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other immune-modifying drugs within six months
prior to study entry. for corticosteroids, this will
mean prednisone ≥ 20 mg/day, or equivalent.
inhaled and topical steroids are allowed.*
Yes
No
administration of long-acting immune-modifying
drugs within six months prior to study entry (e.g.
infliximab).*
Yes
No
concurrently participating in another clinical study
during the period starting 30 days before and
ending 30 days after each study visit, in which the
subject has been or will be exposed to an
investigational or a non-investigational
vaccine/product (pharmaceutical product or
device).*
Yes
No
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Eligibility Breast Cancer NCT01817374
Breast VCEUS to Evaluate Early Response to Neoadjuvant
Chemotherapy; ODM derived from:
https://clinicaltrials.gov/show/NCT01817374
All rights reserved. Please visit https://medical-data-
models.org/forms/12430
Eligibility Breast Cancer
NCT01817374
Inclusion Criteria
1. adult patients (age 19 years or older).*
Yes
No
2. patients with newly diagnosed and untreated
stage ii and iii breast cancer scheduled to
undergo neoadjuvant chemotherapy.*
Yes
No
3. patients with signed informed consent.*
Yes
No
Exclusion Criteria
1. any history of prior radiation or chemotherapy
for breast cancer.*
Yes
No
2. patients who only have non-measurable
disease.*
Yes
No
3. patients who are medically unstable.*
Yes
No
4. patients with other primary cancers requiring
systemic treatment.*
Yes
No
5. patients with cardiac shunts.*
Yes
No
6. patients with unstable cardiopulmonary
conditions.*
Yes
No
7. patients with known pulmonary hypertension.*
Yes
No
8. patients with known hypersensitivity to any
component of definity (r) microbubble contrast.*
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Yes
No
9. patients who are pregnant, breast-feeding or
are planning to become pregnant during the
study duration.*
Yes
No
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Initial Visit Hyperthermia Treatment Study
Hyper-PEI-protocol:a programme with regional deep
hyperthermia(RHT)in combination with PEI-
chemotherapy.The Hyper-PEI protocol is offered in place of
the 
intensive  standard  chemotherapy  for  high-risk  patie
nts  with  malignant,  extracranial  tumors. 
Patients  have  a  measurable  relapsed  tumor,or a primary
tumor that did not respond sufficiently to treatment
according to standard protocols.  
Responsible MD:
PD Dr. med. R Wessalowski,
Clinic for pediatric oncology,haematology and immunology
UKD, Moorenstr. 5, 40225 Dusseldorf
Form has to be completed by cooperating center or clinic
after inclusion and sent to the Hyper-PEI director.
All rights reserved. Please visit https://medical-data-
models.org/forms/12441
Initial Visit Hyperthermia Treatment
Study
Patient Identification
Patient Name
Inclusion confirmation
Inclusion confirmed by Hyper-PEI leader
Yes
No
Date
Initial Therapy
Treatment Regimen
Start date
dd/mm/yy
End date
dd/mm/yy
Radiotherapy
yes no=no not known=not known (yes)
Surgery
yes no=no not known=not known (yes)
Response
Complete remission (CR)
yes no=no not known=not known (yes)
Partial Response (PR)
yes no=no not known=not known (yes)
Low Response
yes no=no not known=not known (yes)
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Stable Disease
yes no=no not known=not known (yes)
Progression
yes no=no not known=not known (yes)
Progression Treatment
Treatment Regimen
Start date
dd/mm/yy
End date
dd/mm/yy
Radiotherapy
yes no=no not known=not known (yes)
Surgery
yes no=no not known=not known (yes)
Response
Complete remission (CR)
yes no=no not known=not known (yes)
Partial Response
yes no=no not known=not known (yes)
Low Response
yes no=no not known=not known (yes)
Stable Disease
yes no=no not known=not known (yes)
Progression
yes no=no not known=not known (yes)
Diagnostic Radiology
Localisation
Dimension 1
cm
Dimension 2
cm
Measurement Method
x-ray, 2=CT, 3=MRI, 4=Ultrasound (1)
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Is there evidence of metastasis
yes , no=no , not known=not known (yes)
Dimension 1
cm
Dimension 2
cm
Measurement Method
X-ray , 2=CT , 3=MRI , 4=Ultrasound (1)
Patient History
Date
Has the childhood development been normal
before diagnose
Body Height
yes , no=no , not know=not known (yes)
Development of Weight
yes , no=no , not known=not known (yes)
Psychomotor Development
yes , no=no , not known=not known (yes)
Sexual Development
yes , no=no , not known=not known (yes)
History of childhood diseases
Rubeola
yes , no=no, not known=not known (yes)
Measles
yes , no=no , not know=not known (yes)
Mumps
yes , no=no , not known=not known (yes)
Pertussis
yes , no=no , not known=not known (yes)
TBC
yes , no=no , not known=not known (yes)
scarlet fever
yes , no=no , not known=not known (yes)
Chickenpox
yes , no=no , not known=not known (yes)
Any current side effects of tumor treatment
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yes , no=no, not known=not known (yes)
If yes, please specify
Other relevant diseases
yes , no=no, not known=not known (yes)
If yes, please specify
operative procedures other than tumor surgery
yes , no=no, not known=not known (yes)
If yes, please specify
Vaccinations
Measles
yes , no=no , not known=not known (yes)
Mumps
yes , no=no , not known=not known (yes)
Rubeola
yes , no=no, not known=not known (yes)
Pertussis
yes , no=no, not known=not known (yes)
Tuberculosis
yes , no=no, not known=not known (yes)
Polio
yes , no=no, not known=not known (yes)
Diphteria
yes , no=no, not known=not known (yes)
Tetanus
yes , no=no, not known=not known (yes)
HIB
yes , no=no, not known=not known (yes)
Type B viral hepatitis
yes , no=no, not known=not known (yes)
Virological Diagnostics
Findings should be enclosed, no older than 4
weeks
Human immunodeficiency virus
infection (1)
immunity (2)
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negative (3)
not known (4)
Type B viral hepatitis
infection 2= immunity 3= negative 4= not
known (1)
Viral hepatitis C
infection 2= immunity 3= negative 4= not
known (1)
HSV IgG
infection 2= immunity 3= negative 4= not
known (1)
CMV
infection 2= immunity 3= negative 4= not
known (1)
EBV status
infection 2= immunity 3= negative 4= not
known (1)
HHV6
infection 2= immunity 3= negative 4= not
known (1)
VZV
infection 2= immunity 3= negative 4= not
known (1)
Adenovirus
infection 2= immunity 3= negative 4= not
known (1)
Parvovirus B 19
infection 2= immunity 3= negative 4= not
known (1)
Microbiological Diagnostics
Findings should be enclosed, no older than 4
weeks
Toxoplasma Antibodies
infection 2= immunity 3= negative 4= not
known (1)
Mycoplasma Antibodies
infection 2= immunity 3= negative 4= not
known (1)
Syphilis Antibodies
infection 2= immunity 3= negative 4= not
known (1)
Confirmation of correctness
5 / 6
Initial Visit Hyperthermia Treatment Study
Date
Treating Physician
Signature
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Treatment Form Hyperthermia treatment
Study
Hyper-PEI-protocol:a programme with regional deep
hyperthermia(RHT)in combination with PEI-
chemotherapy.The Hyper-PEI protocol is offered in place of
the 
intensive  standard  chemotherapy  for  high-risk  patie
nts  with  malignant,  extracranial  tumors. 
Patients  have  a  measurable  relapsed  tumor,or a primary
tumor that did not respond sufficiently to treatment
according to standard protocols.  
Responsible MD:
PD Dr. med. R Wessalowski,
Clinic for pediatric oncology,haematology and immunology
UKD, Moorenstr. 5, 40225 Dusseldorf
Purpose of this form is to document Hyperthermia
treatment.This form has to be filled in by the Hyperthermia-
Specialists of UKD.
All rights reserved. Please visit https://medical-data-
models.org/forms/12442
Treatment Form Day 1 to 4
Patient Identification
Hyper-PEI-UPN
Date
Body weight
>= 0
kg
Height
>= 0
cm
BSA
>= 0
m²
Technical Specifications
Maximum Output
Watt
Frequency
MHz
Focus
_ , Y=_ (X)
Process of Hyperthermia
Organ
T max °C , 2=T min °C , 3=T90 °C ,
4=T50 °C , 5=T20 °C , 6=CEMT90 min
(1)
Tumor Probe
T max °C , 2=T min °C , 3=T90 °C ,
4=T50 °C , 5=T20 °C , 6=CEMT90 min
(1)
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Urinary Bladder
T max °C , 2=T min °C , 3=T90 °C ,
4=T50 °C , 5=T20 °C , 6=CEMT90 min
(1)
Rectum
T max °C , 2=T min °C , 3=T90 °C ,
4=T50 °C , 5=T20 °C , 6=CEMT90 min
(1)
Vagina
T max °C , 2=T min °C , 3=T90 °C ,
4=T50 °C , 5=T20 °C , 6=CEMT90 min
(1)
Skin
T max °C , 2=T min °C , 3=T90 °C ,
4=T50 °C , 5=T20 °C , 6=CEMT90 min
(1)
Vital signs
Pulse
beats/min
Start warm up , 2=10min , 3=Start
Hyperthermia , 4=15min , 5=30min ,
6=45min , 7=60min (1)
Oxygen saturation (SaO2):
Start warm up , 2=10min , 3=Start
Hyperthermia , 4=15min , 5=30min ,
6=45min , 7=60min (1)
Blood pressure (RR)
Start warm up , 2=10min , 3=Start
Hyperthermia , 4=15min , 5=30min ,
6=45min , 7=60min (1)
Chemotherapy
Cycle Number
Day of Treatment
Day 1 , 2=Day 4 (1)
Total amount of medication given
Total amount of cisplatin administered this
reporting period
mg
Total amount of Carboplatin administerd
mg
Total amount of Etoposide administered
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mg
Total amount of Mesna-Bolus administered
mg
Total amount of Ifosfamide administered
mg
Total amount of Cyclophosphamide administered
mg
Total amount of Mesna administered
mg
Total amount of medication given for sedation
mg
Any other Medication administered
Correctness of information confirmed
Date
Treating Physician
Signature
Chemotherapy
Cycle number
Day of Treatment
Day 2 , 2=Day 3 (1)
Total amount of medication administered
Total amount of Etoposide administered
mg
Total amount of Ifosfamide administered
mg
Total amount of Cyclophosphamide administered
mg
Total amount of Mesna administered
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mg
Any other medication administered
Correctness of information confirmed
Date
Treating Physician
Signature
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Severe adverse Events (SAE)  Form
Hyperthermia Treatment Study
Hyper-PEI-protocol:a programme with regional deep
hyperthermia(RHT)in combination with PEI-
chemotherapy.The Hyper-PEI protocol is offered in place of
the 
intensive  standard  chemotherapy  for  high-risk  patie
nts  with  malignant,  extracranial  tumors. 
Patients  have  a  measurable  relapsed  tumor,or a primary
tumor that did not respond sufficiently to treatment
according to standard protocols.  
Responsible MD:
PD Dr. med. R Wessalowski,
Clinic for pediatric oncology,haematology and immunology
UKD, Moorenstr. 5, 40225 Dusseldorf
Only to be filled in if current SAE have been observed. To
be faxed workdays to Study-coordinator within 24h after
observation. 0211-811-9198
Study-coordinator will inform BfArM and ethics committee
about any deaths after inquiry within 7 days. Any other SAE
will be related within 14 days.
All rights reserved. Please visit https://medical-data-
models.org/forms/12443
Severe adverse Events (SAE) Hyper-
PEI
Identification
Patient ID
Hyper-PEI-UPN
Observed SAE
Death within 30 days of treatment
Yes
No
Lifethreatening adverse event (i.e Toxicity-level 4
WHO)
Yes
No
Permanently disabling or crippling adverse event
Yes
No
AE requires or prolongs hospitalization
Yes
No
Secondary Neoplasm
Yes
No
SAE associated with overdose causing
symptoms
Yes
No
Specify
Correctness of information confirmed
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Date
Treating Physician
Signature
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Registration Form Hyperthermia Treatment
Study
Hyper-PEI-protocol:a programme with regional deep
hyperthermia(RHT)in combination with PEI-
chemotherapy.The Hyper-PEI protocol is offered in place of
the 
intensive  standard  chemotherapy  for  high-risk  patie
nts  with  malignant,  extracranial  tumors. 
Patients  have  a  measurable  relapsed  tumor,or a primary
tumor that did not respond sufficiently to treatment
according to standard protocols.  
Responsible MD:
PD Dr. med. R Wessalowski,
Clinic for pediatric oncology,haematology and immunology
UKD, Moorenstr. 5, 40225 Dsseldorf
All rights reserved. Please visit https://medical-data-
models.org/forms/12445
Registration Form HYPER-PEI
General Information
Weight*
kg
Height*
cm
Diagnosis
Date of diagnosis
Localisation
Primary Neoplasm
No (No)
no information (no information)
Yes (Yes)
1. Relapse
yes, No=No, not known=not known (Yes)
2./3./... Relapse
Yes, No=No, not known=not known (Yes)
Metastasis
No  (No)
not known (not known)
Yes  (Yes)
metastasis unifocal
No  (No)
not known (not known)
Yes  (Yes)
Metastasis multifocal
No  (No)
not known (not known)
Yes  (Yes)
Transferring Hospital
Hospital Name
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Date
Treating Physician
Signature
Email
Phone Number
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Toxicity- Form Hyperthermia treatment
Study
Hyper-PEI-protocol:a programme with regional deep
hyperthermia(RHT)in combination with PEI-
chemotherapy.The Hyper-PEI protocol is offered in place of
the 
intensive  standard  chemotherapy  for  high-risk  patie
nts  with  malignant,  extracranial  tumors. 
Patients  have  a  measurable  relapsed  tumor,or a primary
tumor that did not respond sufficiently to treatment
according to standard protocols.  
Responsible MD:
PD Dr. med. R Wessalowski,
Clinic for pediatric oncology,haematology and immunology
UKD, Moorenstr. 5, 40225 Dusseldorf
This form belongs to Primary CRF, inpatient
surveillance,documentation of adverse and serious adverse
events. Attachment 14 is used for documentation of therapy
toxicity.
All rights reserved. Please visit https://medical-data-
models.org/forms/12446
Toxicity-Form Hyper-PEI (modified
WHO CTC)
Patient Identification
Patient Name
Hyper-PEI-UPN
Attachment
To be enclosed to
Date
Treating Physician
Signature
G-CSF and Transfusion
Administering of G-CSF
Start time
hh:mm
End time
hh:mm
Specify medication used:
Dosage
mg
Amount of erythrocyte concentrate administered
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Date of latest Transfusion
Amount of Platelet concentrate administered
Date of latest platelet transfusion
Toxicity Levels
Allergic reaction or hypersensitivity
none , 1=transient erythema/drug fever
<38°C , 2=urticaria/drug fever ≤ 38°C
/mild bronchial spasm 3=serum
sickness/bronchial spasms/parenteral
therapy necessary , 4=anaphylaxis (0)
Other
1 , 2=2, 3=3, 4=4 (1)
Light Sensitivity
normal , 2=symptoms without
impairment of ADL , 3=symptoms, ADL
impaired (0)
Hearing
normal , 1=hearing loss only to be
determined audiometrically , 2=moderate
symptoms of tinnitus,mild hypacusis in
audiometric testing , 3=severely
impairing hearing loss,hearing aid
required , 4=irreversible deafness (0)
Audiometry
no hearing loss (0)
≤ 15dB at ≤ 2kHz (1)
16-30dB at ≤ 2kHz (2)
31-60dB at ≤ 2kHz (3)
>60dB at ≤ 2kHz (4)
Cushingoid symptoms
Yes
No
Hypothyroidism
none , 1=asymptomatic/no treatment
required , 2=symptomatic/treatment
required , 3=hospitalization associated
with hypothyroidism , 4=myxedema
coma (0)
Inappropriate ADH Syndrome
Yes
No
Nausea
none (0)
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almost normal eating (1)
severely reduced food intake but still
eating (2)
almost no food intake (3)
Emesis
none (0)
1 episode/24h (1)
2-5 episodes/24h (2)
6-10 episodes/24h (3)
>10 episodes/24h or parenteral
antiemesis (4)
Diarrhea
none (0)
>2-3 bowel movements/day  (1)
≥4-6 bowel movements/day, nightly
tenesmus,moderate tenesmus at
daytime (2)
≥7-9 bowel movements/day, severe
tenesmus,incontinence (3)
≥10 bowel movements/day, bloody
diarrhea, i.v infusions required (4)
Taste perception
normal (0)
slightly altered (1)
severly altered (2)
irreversibly altered (4)
Smell perception
normal (0)
slightly altered (1)
severly altered (2)
irreversibly altered (4)
Constipation
Not At All (0)
A Little Bit (1)
Somewhat (2)
Quite A Bit (3)
Ileus>96h (4)
Proctitis
none (0)
increased frequency of bowel
movement,blood spots (1)
increased frequency of bowel
movement,bloody feces (2)
diarrhea,severly bloody and mucous
feces, parenteral substitution required (3)
perforation,bleeding,necrosis,other life
threatening complication (4)
Bleeding
none (0)
mild, no pRBC´s required (1)
pRBC required (3)
life threatening bleeding,ICU required (4)
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PTT (partial thromboplastin time)
normal (0)
≤ 1.66 ULN (1)
≤ 2.33 ULN (2)
≤ 3.00 ULN (3)
>3.00 ULN (4)
Petechiae or purpura
none (0)
some (1)
petechiae and purpura in larger area (2)
generalised petechiae and purpura in
skin and/or mucous membrane (4)
Quick
normal (0)
≤ 1.25 ULN (1)
≤ 1.50 ULN (2)
≤ 2.00 ULN (3)
> 2.00 ULN (4)
Leucocytes
/μL
≥4000 (0)
3.0-3.900 (1)
2.0-2.900 (2)
1.0-1.900 (3)
<1000 (4)
Platelets
/μL
normal (0)
≥75.000 (1)
<75.000 (2)
<50.000 (3)
<25.000 (4)
Hemoglobin
g/dl
normal (0)
≥10 (1)
<10 (2)
<8 (3)
<6,5 (4)
Lymphocytes
/μL
≥ 2.000 (0)
< 2.000 (1)
< 1.500 (2)
< 1.000 (3)
< 500 (4)
Granulocytes
/μL
> 2.000 1=< 2.000 2=< 1.500 3=< 1.000
4=< 500 (0)
Hemorrhage
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none (0)
little,no pRBC required (1)
severe,1-2 pRBC/episode (2)
very severe, 3-4 pRBC/episode (3)
massive,>4 pRBC/episode (4)
Alopecia
none (0)
local (1)
severe/complete (2)
Rash/Desquamation
none (0)
macular/papular exanthema (1)
macular/papular erythema with pruritus
on 50% of body surface (2)
generalised erythroderma/macular-
papular or vesicular eruptions >50%
body surface (3)
generalised exfoliative/ulcerative
dermatitis (4)
Stomatitis
none (0)
painless ulceration/erythema (1)
painful erythema/edema/ulceration, but
still able to eat (2)
painful erythema/edema/ulceration,
unable to eat (3)
parenteral or enteral nutrition required
(4)
Urticaria
none (0)
no treatment required (1)
topical or systemic treatment < 24h
required (2)
systemic treatment > 24h required (3)
Wound infection
none (0)
cellulitis (1)
superficial infection (2)
iv antibiotics required (3)
necrotizing fasciitis (4)
Impaired healing
none (0)
suture dehiscence (1)
suture hernia (2)
fasciotomy (3)
fasciotomy with exposure of inner organs
(4)
Burn Injury
none (0)
°I (painful rash and swelling) (1)
°II (blistering,exuding skin-lesion) (2)
°III (blistering,white-grey necrosis of
dermis and subdermis,no pain,no
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epithelial regeneration (3)
°IV (no regeneration, charring) (4)
Burns classified according to percentage of body
surface involved or size of burn blister
%
0 (0)
1 (1)
2 (2)
3 (3)
4 (4)
Arrhythmia
normal (0)
asymtomatic,transient,no treatment
required (1)
reoccuring or persisting,no treatment
required (2)
antiarrhythmical treatment required (3)
hypotension, ventricular
tachycardy,ventricular fibrillation (4)
Cardiac output
normal (0)
asymptomatic reduction of resting ef
<20% from baseline (1)
asymptomatic reduction of resting ef
>20% from baseline (2)
moderate heart failure, not refractory to
treatment (3)
severe heart failure (4)
Hypotension
none (0)
asymptomatic (1)
treatment required but no hospitalization
(2)
hospitalization,no long-term effects (3)
shock (4)
Edema
none (0)
asymptomatic (1)
treatment required (2)
difficult treatment, impairing (3)
anasarca (4)
Pericardial effusion or Pericarditis
none (0)
asymptomatic effusion, no intervention
required (1)
Pericarditis (pain,ecg-alterations...) (2)
symptomatic effusion,drainage required
(3)
pericardial tamponade, immediate
intervention required (4)
Catheter related infection
none (0)
minor, no treatment required (1)
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local infection,local or oral treatment
sufficient (2)
severe,systemic infection, iv
antibiotics/antimycotics required,
hospitalization (3)
life threatening sepsis (4)
Infection of unknown anc
none (0)
minor (1)
major (2)
severe (3)
lifethreatening sepsis (4)
Alkalosis
normal (0)
pH≤ normal but >7,3 (1)
pH<7,3 (3)
pH<7,3 and lifethreatening (4)
Acidosis
normal (0)
≥ normal but < 7,5 (1)
pH < 7,5 (3)
< 7,5 and lifethreatening (4)
Hyperglycemia
mg/dl
<116 (0)
≤160 (1)
≤250 (2)
≤500 (3)
>500 (4)
Hypoglycemia
mg/dl
>64 (0)
≤64 (1)
≤54 (2)
≤39 (3)
<30 (4)
Hypercalcemia
<10,6 (0)
10,0-11,5 (1)
11,6-12,5 (2)
12,6-13,4 (3)
13,5 (4)
Hypocalcemia
>8,4 (0)
8,4-7,8 (1)
7,7-7,0 (2)
6,9-6,1 (3)
6,0 (4)
Hypomagnesemia
>1,4 (0)
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1,4-1,2 (1)
1,1-0,9 (2)
0,8-0,6 (3)
0,5 (4)
Hypernatremia
0 (0)
ULN-150mmol/l (1)
>150-155mmol/l (2)
>155-160mmol/l (3)
>160mmol/l (4)
Hyponatremia
LSV-130mmol/l (1)
120-130mmol/l (3)
<120mmol/l (4)
Hyperkalemia
>ULN-5,5mmol/l (1)
>5,5-6,0mmol/l (2)
>6,0-7,0mmol/l (3)
>7,0mmol/l (4)
Hypokalemia
<LSV-3,0 mmol/l (1)
2,5-<3,0 mmol/l (3)
<2,5 mmol/l (4)
Pulmonary function
unchanged (0)
asymptomatic,change in functional
parameter (1)
minor dyspnea on exertion (2)
severe dyspnea on exertion (3)
dyspnea at rest (4)
Lymphatic system
normal (0)
minor lymph edema (1)
major lymph edema, compression
required (2)
severe lymph edema, functional
impairment (3)
severe lymph edema, functional
impairment,ulceration (4)
Creatinine
normal (0)
<1,5 times ULN (1)
>1,5 times ULN (2)
> 3 times ULN (3)
>6 times ULN (4)
Proteinuria
none (0)
<0,3g/l (1)
3-10g/l (2)
>10g/l (3)
nephrotic syndrome (4)
8 / 10
Toxicity- Form Hyperthermia treatment Study
Hematuria
none (0)
microhaematuria (1)
haematuria or blood clots (2)
haematuria with blood clots (3)
pRBC required (4)
Tumor pain
none (0)
minor pain,no functional impairment (1)
distinct pain,functional impairment, no
impairment of ADL (2)
severe pain,impairment to ADL (3)
bed-ridden (4)
Sensory function status
unchanged (0)
mild paresthesia,loss of deep tendon
reflexes (1)
moderate objective sensory
deficit,moderate paresthesia (2)
severe objective sensory deficit or
paresthesia with functional impairment
(3)
Motor function
unchanged (0)
subjective weakness without objective
finding (1)
moderate objective weakness without
significant functional impairment (2)
objective weakness with functional
impairment (3)
paralysis (4)
Mood and Psyche
unchanged (0)
minor anxiety or depression (1)
moderate anxiety or depression (2)
severe anxiety or depression (3)
suicidal (4)
Headache
none (0)
minor (1)
moderate or transient (2)
permantly and severely (3)
Other
0 (0)
1 (1)
2 (2)
3 (3)
4 (4)
General Condition
Activity
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normal , 1=weariness without
impairment of ADL , 2=abnormal
fatigue,impaired ADL (20%
Lansky/Karnofsky) , 3=severe fatigue or
loss of skills (40% Lansky/Karnofsky) ,
4= bed-ridden (0)
Fever
°C
none , 1=38-39 , 2=39.1-40 , 3=>40<24h
, 4=>40>24h (0)
Febrile Neutropenia
°C
none , 1=38-39 , 2=39.1-40 , 3=>40<24h
, 4=>40>24h (0)
Fever with signs of infection
none , 1=38-39 , 2=39.1-40 , 3=>40<24h
, 4=>40>24h (0)
Weight loss
<5% , 1=5-10% , 2=10-20% , 3=>20%
(0)
Weight gain
<5% , 1=5-10% , 2=10-20% , 3=>20%
(0)
Shivering
none , 1=mild/symptomatic therapy
sufficient , 2= severe/anesthesia required
, 3=no response to anesthesia (0)
Perspiration
normal , 1=little/sometimes ,
2=severe/frequently ,
3=severe/permanently (0)
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Control group: Multicenter trial of hemolysis
as diagnostic test for cystic fibrosis (HemCF)
Controlled, multicenter trial of hemolysis as diagnostic test
for cystic fibrosis (HemCF).
Documentation part for control group.
Principal Investigator PD Dr. Hermann Schillers, University
Hospital of Muenster
All rights reserved. Please visit https://medical-data-
models.org/forms/12453
Controlled multicenter trial of
hemolysis as diagnostic test for
cystic fibrosis (HemCF)
Patienteninformationen
Zentrum
Pat.-Nr.:
Name des Patienten:
Date of informed consent
Einschlusskriterien
Vorliegen einer unterschriebenen
Einverständniserklärung
Ja
Nein
Ausschlusskriterien
Infektionen der Atemwege innerhalb der letzten 4
Wochen
Ja
Nein
Teilnahme an Medikamentenstudie innerhalb der
letzten 30 Tage
Ja
Nein
Klinischer Hinweis auf eine Mukoviszidose
Ja
Nein
Gruppeneinteilung
Gruppeneinteilung
Healthy individual with CFTR-mutation
(delF508) (Healthy individual with CFTR-
mutation (delF508))
Healthy individual with CFTR-mutation
(without delF508) (Healthy individual with
CFTR-mutation (without delF508))
Healthy individual, related to CF-patient,
without confirmed CFTR-mutation
(Healthy individual, related to CF-patient,
without confirmed CFTR-mutation)
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Healthy individual,without confirmed
CFTR-mutation (Healthy
individual,without confirmed CFTR-
mutation)
Patient with Malabsorption (Patient with
Malabsorption)
Diagnose wenn Patient mit Malabsorption
Demographie
Geburtsdatum:
Geschlecht
male (1)
female (2)
Körpergewicht
kg
Größe:
cm
Hämolysetest
Datum Blutentnahme
Laboruntersuchung
Ergebnis
Control 75 (Control 75)
Gd3+ (Gd3+)
Gd3+ + Zn2+ (Gd3+ + Zn2+)
Weitere Laborergebnisse
Erythrozyten
/μL
Vitamin E
mg/dl
Retikulozyten
Einheit Laborergebnis Retikulozyten
/nl (/nl)
% (%)
Zink
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fibrosis (HemCF)
Masseinheit Zink
μg/dl (μg/dl)
μmol/l (μmol/l)
Begleitmedikation der letzten 4 Wochen
Begleitmedikation der letzten 4 Wochen
Ja
Nein
wenn Begleitmedikation in den letzten 4 Wochen
auftraten
Datum
Unterschrift Prüfer
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Eligibility Schizophrenia NCT02146547
European Long-acting Antipsychotics in Schizophrenia
Trial; ODM derived from:
https://clinicaltrials.gov/show/NCT02146547
All rights reserved. Please visit https://medical-data-
models.org/forms/12454
Eligibility Schizophrenia
NCT02146547
Inclusion Criteria
1. diagnosis of schizophrenia as defined by dsm-
iv-r (diagnostic and statistical manual) as
determined by the m.i.n.i.plus*
Yes
No
2. age 18 or older.*
Yes
No
3. the first psychosis occurred at least one year
and no more than 7 years ago.*
Yes
No
4. if patients are using an antipsychotic drug, a
medication switch is currently under
consideration.*
Yes
No
5. capable of providing written informed consent*
Yes
No
Exclusion Criteria
1. intolerance / hypersensitivity to one of the
drugs (including active substances, metabolites
and excipients) in this study including oral
paliperidone and aripiprazole and/or
hypersensitivity to risperidone.*
Yes
No
2. pregnancy or lactation.*
Yes
No
3. patients who are currently using clozapine.*
Yes
No
4. patients who do not fully comprehend the
purpose or are not competent to make a rational
decision whether or not to participate.*
Yes
No
5. patients with a documented history of
intolerance to any of the study medications
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and/or a documented history of non-response to
a treatment with one of the study drugs of at least
6 weeks within the registered dose range.*
Yes
No
6. forensic patients.*
Yes
No
7. patients who have been treated with an
investigational drug within 30 days prior to
screening.*
Yes
No
8. simultaneous participation in another
intervention study (neither medication or
psychosocial intervention).*
Yes
No
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Eligibility Comparison of Prasugrel and Clopidogrel
Acute Coronary Syndrome NCT00097591
The sponsors of this investigational drug are developing
prasugrel (also known as CS-747) as a possible treatment
for patients with acute coronary syndrome (heart attack or
chest pain) who need, or are expected to need, a
percutaneous coronary intervention (PCI; also called a
balloon angioplasty). Prasugrel was compared with
Clopidogrel to determine which drug is better at reducing
deaths, future heart attacks, or stroke.
(https://clinicaltrials.gov/ct2/show/NCT00097591)
All rights reserved. Please visit https://medical-data-
models.org/forms/12455
Eligiblity Criteria
Inclusion Criteria
A person who has been diagnosed with acute
coronary syndrome
Yes
No
A person who is to undergo a percutaneous
coronary intervention.
Yes
No
A person who is of the legal age of 18
Yes
No
A person who is mentally competent to provide a
signed written informed consent.
Yes
No
If a woman is of childbearing potential (i.e.,
before menopause), she must test negative for
pregnancy
Yes
No
If a woman is of childbearing potential (i.e.,
before menopause), she must agree to use a
reliable method of birth control.
Yes
No
Exclusion Criteria
A person who has had an ischemic stroke within
the last 3 months or a hemorrhagic stroke at any
time in the past.
Yes
No
A person who has active internal bleeding or has
a history of a bleeding disorder.
Yes
No
Individuals who are at an increased risk of
bleeding based on laboratory criteria evaluated
by the treatment physician or on medication that
can cause bleeding.
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Yes
No
A person who has liver disease; for example,
cirrhosis.
Yes
No
A person who has a condition such as alcoholism
Yes
No
mental illness
Yes
No
drug dependent
Yes
No
A person who has cardiogenic shock
Yes
No
refractory ventricular arrhythmia
Yes
No
congestive heart failure (class IV)
Yes
No
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Eligibility Comparison of Prasugrel and Clopidogrel Acute Coronary
Syndrome NCT00097591
Eligibility Relapsing-Remitting Multiple
Sclerosis NCT02090348
Study to Evaluate Fatigue in Participants With Relapsing
Remitting Multiple Sclerosis When Treated With Dimethyl
Fumarate; ODM derived from:
https://clinicaltrials.gov/show/NCT02090348
All rights reserved. Please visit https://medical-data-
models.org/forms/12456
Eligibility Relapsing-Remitting
Multiple Sclerosis NCT02090348
Criteria
have a confirmed diagnosis of rrms and satisfies
the therapeutic indication as described in the
local label.*
Yes
No
have a stable edss (as assessed by the
investigator) and been on the same (type and
dosage) standard of care (soc) first-line treatment
for at least 6 months.*
Yes
No
if taking antidepressants, amphetamine,
modafinil, or fampridine (fampyra), subject must
be assessed as having been clinically stable for
at least 3 months prior to the baseline visit.*
Yes
No
fsmc total score ≥43 (mild fatigue) at baseline.*
Yes
No
as perceived by the investigator, have the ability
to comply with all requirements of the study
protocol.*
Yes
No
key exclusion criteria:*
Yes
No
diagnosis of major depression, as identified by
the investigator.*
Yes
No
diagnosis of primary progressive, secondary
progressive, or progressive relapsing multiple
sclerosis.*
Yes
No
history of malignancy (except for basal cell
carcinoma that had been completely excised prior
to study entry), severe allergic or anaphylactic
reactions or known drug hypersensitivity,
abnormal laboratory results indicative of any
significant disease, and/or a major disease that
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would preclude participation in a clinical trial.*
Yes
No
treatment of ms relapse within 90 days prior to
study enrollment.*
Yes
No
history of a positive test result for human
immunodeficiency virus, hepatitis c virus
antibody, or hepatitis b virus (defined as positive
for hepatitis b surface antigen or hepatitis b core
antibody.*
Yes
No
impaired hepatic or renal function, as perceived
by the investigator.*
Yes
No
any prior treatment with dmf (or other fumarate
derivative), total lymphoid irradiation, cladribine,
fingolimod, t cell or t-cell receptor vaccination, or
any therapeutic monoclonal antibody.*
Yes
No
current enrollment in any other clinical studies.*
Yes
No
known to suffer from narcolepsy or another
significant sleep disorder.*
Yes
No
comorbidity that may have an impact on fatigue.*
Yes
No
other unspecified reasons that, in the opinion of
the investigator or biogen idec, make the subject
unsuitable for enrollment.*
Yes
No
note:  other protocol-defined inclusion/exclusion
criteria may apply*
Yes
No
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Eligibility Antiplatelet Therapy Acute
Coronary Syndrome NCT00830960
The study will compare the safety and efficacy of prasugrel,
administered at different doses with clopidogrel in the
treatment of Asian participants with acute coronary
syndrome (ACS) undergoing percutaneous coronary
intervention.
(https://clinicaltrials.gov/ct2/show/NCT00830960)
All rights reserved. Please visit https://medical-data-
models.org/forms/12457
Eligibiltiy Critera
Inclusion Criteria
A person who has been diagnosed with acute
coronary syndrome (ACS) and is to undergo a
percutaneous coronary intervention (PCI)
Yes
No
A person who has been diagnosed with acute
coronary syndrome (ACS) and is to undergo a
percutaneous coronary intervention (PCI)
Yes
No
A person who is of East or Southeast Asian
descent
Yes
No
A person who is of the legal age of 18 (or age 21
in Singapore)
Yes
No
Is mentally competent to provide a signed written
informed consent before entering the study
Yes
No
If a woman is of childbearing potential, she must
test negative for pregnancy
Yes
No
agree to use a reliable method of birth control
Yes
No
Exclusion Criteria
cardiogenic shock
Yes
No
ventricular arrhythmias
Yes
No
congestive heart failure
Yes
No
A person who is at an increased risk of bleeding
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(e.g. active internal bleeding, history of bleeding
disorder, recent fibrinolytic therapy before
randomization into the study)
Yes
No
History of ischemic or hemorrhagic stroke
Yes
No
intracranial neoplasm
Yes
No
arteriovenous malformation
Yes
No
aneurysm
Yes
No
prior history of transient ischemic attack (TIA)
Yes
No
A person who needs to take other antiplatelet
therapy other than Aspirin for the duration of the
study
Yes
No
A person who receives daily treatment with
nonsteroidal anti-inflammatory drugs (NSAIDs) or
cyclooxygenase-2 (COX2) inhibitors that cannot
be discontinued
Yes
No
A person who has a severe liver disease, such as
cirrhosis
Yes
No
Alcoholism
Yes
No
mental illness
Yes
No
drug dependence
Yes
No
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Eligibility Neoplasms, Colorectal
NCT01157052
Oxaliplatin Pharmacokinetics With and Without
Ca2+/MG2+ Infusion in Colorectal Cancer Patients; ODM
derived from: https://clinicaltrials.gov/show/NCT01157052
All rights reserved. Please visit https://medical-data-
models.org/forms/12458
Eligibility Neoplasms, Colorectal
NCT01157052
Inclusion Criteria
patients must have metastatic colorectal cancer
(stage iv)*
Yes
No
patients who were treated with 5fu and leucovorin
in the adjuvant setting or with 5fu and leucovorin
(lv)or/and folfiri regimen for metastatic setting
may be eligible for this trial.*
Yes
No
patients must be ≥ 18 years*
Yes
No
patients must have an eastern cooperative
oncology group (ecog) performance status of 0 to
2*
Yes
No
patients must have adequate renal function of
creatinine < 1.5mg/dl and a creatinine clearance
> 45ml/min. patients must have adequate hepatic
function with a bilirubin > 1.5 mg/dl and ast
(normal range 0-14/l) and alt (normal range 0-49
u/l) in the absence of liver metastasis or </= 5x
the upper limit of normal of ast and alt in the
presence of liver metastasis.*
Yes
No
patients must have adequate bone marrow
function with absolute neutrophil count(anc)≥*
Yes
No
1,500/цl and platelets ≥ 100,000/цl and a
hemoglobin ≥ 10g/d.*
Yes
No
patients must be willing and able to comply with
the study protocol for the study duration and
patients must give written informed consent prior
to any study-specific screening procedures with
the understanding that the patient may withdraw
consent at any time without prejudice.*
Yes
No
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women of childbearing potential must have a
negative serum pregnancy test performed within
7 days prior to the start of treatment. also,women
of childbearing potential and men must agree to
use adequate contraception prior to study entry
and for the duration of study participation. the
investigator is requested to advise the patient
how to achieve an adequate contraception.*
Yes
No
life expectancy longer that 6 months*
Yes
No
Exclusion Criteria
patients who have received oxaliplatin previously*
Yes
No
patients with known peripheral neuropathy ≥
grade 2 according to the who scale*
Yes
No
patients who have tested positive for hiv*
Yes
No
patients with other significant medical, psychiatric
disorders that, in the opinion of the investigator,
will exclude the patient from the study for
compliance of safety reasons.*
Yes
No
patients who cannot swallow*
Yes
No
history of known allergy to oxaliplatin or other
platinum compounds,to 5-fu, to lv, or to any
ingredients in the formulations or the containers*
Yes
No
participation in another clinical trial with any
investigational drug within 30 days prior to study
screening*
Yes
No
pernicious anemia or other megaloblastic anemia
with vitamin b12 deficiency*
Yes
No
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patient with concomitant treatment with
drugs/ingredients reported to have a potential
activity to prevent peripheral sensory neuropathy
(psn)*
Yes
No
patients who haven't successfully completed local
therapy for previously treated cns metastases &
who haven't been discontinued with corticosteroid
for >4kws before starting chemotherapy. patients
with asymptomatic brain mets who have no
evidence of midline shift on ct/mri may be
enrolled without initiation of local therapy for the
cns mets. repeat scan must be performed < 4wks
to ensure no progression.*
Yes
No
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Eligibility Nephropathy NCT02118714
Atrasentan Spermatogenesis and Testicular Function; ODM
derived from: https://clinicaltrials.gov/show/NCT02118714
All rights reserved. Please visit https://medical-data-
models.org/forms/12459
Eligibility Nephropathy
NCT02118714
Inclusion Criteria
males 30 to 75 years of age*
Yes
No
type 1 or 2 diabetes and has been treated with at
least one anti-hyperglycemic medication and
angiotensin-converting enzyme inhibitors
(acei)/angiotensin receptor blockers (arb) (renin-
angiotensin system [ras] inhibitor) for at least 2
months prior to screening*
Yes
No
estimated glomerular filtration rate (egfr) equal to
or greater than 50 ml/min with the chronic kidney
disease epidemiology collaboration (ckd-epi)
formula and urine albumin-to-creatinine ratio
(uacr) equal to or greater than 30 and  less than
5,000 mg/g creatinine.*
Yes
No
able to provide a semen specimen at the required
intervals.*
Yes
No
baseline sperm concentration ≥ 30 million per
ml.*
Yes
No
Exclusion Criteria
treatment with hormone suppressive agents or
cancer chemotherapy within the past 6 months or
planned during the study.*
Yes
No
history of moderate or severe peripheral edema,
pulmonary edema or facial edema unrelated to
trauma or history of myxedema in the prior 6
months to screening.*
Yes
No
history of pulmonary hypertension requiring
either oxygen therapy and/or endothelin receptor
antagonist or phosphodiesterase therapy or any
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lung disease requiring oxygen therapy.*
Yes
No
documented diagnosis of heart failure, previous
hospitalization for heart failure or current or
constellation of symptoms (dyspnea on exertion,
pedal edema, orthopnea, paroxysmal nocturnal
dyspnea) felt to be compatible with heart failure,
that was not explained by other causes, and for
which there was a change in medication or other
management directed at heart failure.*
Yes
No
history of hormone replacement therapy.*
Yes
No
subject has evidence or history of
hypogonadism.*
Yes
No
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Baseline-Lab Stem-Cell Transplantation
CASLAMB NCT00148148
A Study of Caspofungin, Liposomal Amphotericin B or the
Combination of Both for Patients After Stem-Cell
Transplantation
NCT00148148
All rights reserved. Please visit https://medical-data-
models.org/forms/12461
Lab
Dokumentationsdatum
Datum
Elektrolyte
Natrium
Calcium
Kalium
Magnesium
Stoffwechsel
Glucose
Harnsäure
Leber
Gesamteiweiss
SGOT
Gesamtbilirubin
SGPT
Alkal.
Phosphatase
gGT
LDH
Pankreas
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Amylase
Lipase
Niere
Harnstoff
Kreatininclearance
nach Cockroft & Gault
Kreatinin
Infektion
CRP (optional)
Gerinnung (optional)
TPZ
TZ
Fibrinogen
Hämatologie
Datum der Probeentnahme
Erythrozyten
Hämoglobin
Hämatokrit
Thrombozyten
Leukozyten
Neutrophile Granulozyten
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Hämatologie (optional, Absolutwerte)
Lymphozyten
Monozyten
Eosinophile
Basophile
Sonstige
Urin-Status
Datum der Probeentnahme
Leukozyten
positiv (1)
negativ (2)
Nitrit
positiv (1)
negativ (2)
Eiweiß
positiv (1)
negativ (2)
Ketonkörper
positiv (1)
negativ (2)
pH
spezifisches
Gewicht
Urobilinogen
normal (1)
abnormal (2)
Bilirubin
positiv (1)
negativ (2)
Erythrozyten
positiv (1)
negativ (2)
Glucose
normal (1)
abnormal (2)
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Pregnancy Test
Schwangerschafts-Schnelltest
Schwangerschaft
Ja
Nein
Datum
Ergebnis
Ja
Nein
Antikonzeption durch Leuprorelinazetat o.ä. und
negativer Schwangerschafts-Test bei Aufnahme
Ja
Nein
Microbiology
Blutkulturen
Datum
Befund
nein (1)
ja (2)
findings
Fakultative Mikrobiologische
Untersuchungen
Verfahren
Datum
Erregernachweis
nein (1)
ja (2)
pathogen detection
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Eligibility HouYi Acute Coronary Syndrome
NCT01864005
The purpose of this study is to test the hypothesis that the
onset of the antiplatelet effect of ticagrelor is more rapid
and greater than clopidogrel in Chinese patients with ACS.
https://clinicaltrials.gov/ct2/show/NCT01864005
All rights reserved. Please visit https://medical-data-
models.org/forms/12464
Eligibility criteria
Inclusion Criteria
Provision of informed consent prior to any study
specific procedures
Yes
No
Female or male
Yes
No
Aged at least 18 years
Yes
No
Females of child-bearing potential must have a
negative urine pregnancy test at enrolment
Yes
No
Females of child-bearing potential must be willing
to use reliable contraception
Yes
No
Index event of non-ST or ST segment elevation
ACS.
Yes
No
Exclusion Criteria
Contraindication or other reason that clopidogrel
should not be administered
Yes
No
Contraindication or other reason that ticagrelor
should not be administered
Yes
No
Oral anticoagulation therapy within 30 days prior
to randomisation or cannot be stopped
Yes
No
GP IIb/IIIa receptor antagonists therapy within 30
days prior to randomisation or cannot be stopped
Yes
No
Ticagrelor within 14 days prior to randomisation
Yes
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No
Clopidogrel within 14 days prior to randomisation
Yes
No
P2Y12 inhibitors within 14 days prior to
randomisation
Yes
No
Requires dialysis
Yes
No
Nonselective non-steroidal anti-inflammatory
drugs therapy that cannot be stopped
Yes
No
prostacyclins (PGI2) therapy that cannot be
stopped
Yes
No
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Eligibility Rosuvastatin Acute Coronary
Syndrome NCT01241903
The central hypothesis for this work is that platelet -
leukocyte interactions play a critical role in the
pathogenesis of acute ischemic events. The primary
objective of the study is to determine if early, high-dose
administration of the HMG-CoA reductase inhibitor
rosuvastatin in the setting of acute coronary syndrome and
percutaneous coronary intervention exerts beneficial
vascular effects by reducing platelet - leukocyte
interactions.
https://clinicaltrials.gov/ct2/show/NCT01241903
All rights reserved. Please visit https://medical-data-
models.org/forms/12465
Eligibility Critera
Inclusion Criteria
Subjects must be between 18 and 80 years old.
Yes
No
Subjects must be willing and able to give
informed consent
Yes
No
A woman of child-bearing potential who is
currently sexually active must agree to use a
medically accepted method of contraception
while receiving protocol-specified medication and
for up to 30 days after enrollment.
Yes
No
Subjects must have symptoms of acute coronary
syndrome
Yes
No
Subjects must be statin naive or currently only on
low dose statin (Simvastatin 20mg, Pravastatin
40mg, or Atorvastatin 10mg)
Yes
No
Exclusion criteria
Use of Crestor in the past 30 days
Yes
No
GFR (estimated) <30 ml/min
Yes
No
Hemodialysis
Yes
No
History of liver failure
Yes
No
Unexplained liver function abnormalities
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Yes
No
Current or planned use of cyclosporine
Yes
No
Current or planned use of gemfibrozil
Yes
No
Sepsis
Yes
No
Hypotension
Yes
No
Dehydration
Yes
No
Trauma
Yes
No
Recent (within the last 2 weeks) or planned (in
the next month) major surgery
Yes
No
HIV/AIDS with current of planned use of HIV
protease inhibitors
Yes
No
Metabolic abnormality
Yes
No
electrolyte abnormality
Yes
No
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Eligibility TIMACS Acute Coronary
Syndrome NCT00552513
The timing of intervention study is a prospective,
randomized, international, multicentre comparison of the
relative efficacy, safety, and cost effectiveness of a
management strategy of coronary angiography and
intervention performed within 24 hours of randomization
versus delayed coronary angiography and intervention in
patients after 36 hours with acute coronary syndromes
(ACS).
https://clinicaltrials.gov/ct2/show/NCT00552513
All rights reserved. Please visit https://medical-data-
models.org/forms/12466
Eligibility Criteria
Inclusion Criteria
Patients presenting or admitted to hospital with
symptoms suspected to represent an acute
coronary syndrome (unstable angina or MI
without persistent ST elevation)
Yes
No
Able to randomise within 24 hours of the onset of
the most recent episode of symptoms
Yes
No
Age more than or equal to 60 years
Yes
No
Troponin T above the upper limit of normal for the
local institution
Yes
No
Troponin I above the upper limit of normal for the
local institution
Yes
No
Creatine Kinase - Myocardial Bands (CK-MB)
above the upper limit of normal for the local
institution
Yes
No
Written informed consent dated and signed
Yes
No
Exclusion Criteria
Age less than 21 years
Yes
No
Not a suitable candidate for revascularisation
Yes
No
Co-morbid condition with life expectancy less
1 / 2
than six months
Yes
No
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Eligibility Mojito Study Acute Coronary
Syndrome NCT01992523
The aim of the Mashed Or Just Integral pill of TicagrelOr
(MOJITO) study is to evaluate the superiority of Ticagrelor
180 mg LD mashed pill versus Ticagrelor 180 mg LD
integral pill both orally administrated in decreasing residual
platelet reactivity 1 hour after the administration among 70
patients with STEMI (ST segment elevation myocardial
infarction) undergoing PPCI (primary percutaneous
coronary intervention) with bivalirudin monotherapy.
https://clinicaltrials.gov/ct2/show/NCT01992523
All rights reserved. Please visit https://medical-data-
models.org/forms/12467
Eligibility Criteria
Inclusion Criteria
Patients presenting within 12 hours from the
onset of symptoms with STEMI
Yes
No
Informed, written consent
Yes
No
Exclusion Criteria
Age < 18 years or Age > 75 years
Yes
No
Active bleeding
Yes
No
bleeding diathesis
Yes
No
coagulopathy
Yes
No
Increased risk of bradycardiac events
Yes
No
History of gastrointestinal bleeding <2 months
Yes
No
History of genitourinary bleeding <2 months
Yes
No
Major surgery in the last 6 weeks
Yes
No
History of intracranial bleeding or structural
abnormalities
Yes
No
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Suspected aortic dissection
Yes
No
Administration in the week before the index event
of clopidogrel
Yes
No
Administration in the week before the index event
of ticlopidine
Yes
No
Administration in the week before the index event
of prasugrel
Yes
No
Administration in the week before the index event
of ticagrelor
Yes
No
Administration in the week before the index event
of thrombolytics
Yes
No
Administration in the week before the index event
of bivalirudin
Yes
No
Administration in the week before the index event
of low-molecular weight heparin
Yes
No
Administration in the week before the index event
of fondaparinux
Yes
No
Concomitant oral or IV therapy with strong
CYP3A inhibitors
Yes
No
Concomitant oral or IV therapy with strong
CYP3A inducers
Yes
No
Known relevant hematological deviations: Hb <10
g/dl
Yes
No
Known relevant hematological deviations:
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Thrombi. <100x10^9/l
Yes
No
Use of coumadin derivatives within the last 7
days
Yes
No
Known severe liver disease
Yes
No
severe renal failure
Yes
No
Known allergy to the study medications
Yes
No
Pregnancy
Yes
No
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Eligibility MEDICATION Acute Coronary
Syndrome NCT00903032
We propose to test the effectiveness of a multi-faceted
patient-centered adherence intervention among veterans
following ACS hospitalization to improve adherence to
cardioprotective medications (primary aim). Secondary
aims will assess whether the intervention improves
achievement of secondary prevention blood pressure (BP)
and low density lipoprotein (LDL)-cholesterol goals,
reduces cardiac endpoints (myocardial infarction ) MI
hospitalization, coronary revascularization, all-cause
mortality) and is cost-effective.
https://clinicaltrials.gov/ct2/show/NCT00903032
All rights reserved. Please visit https://medical-data-
models.org/forms/12468
Eligibility Criteria
Inclusion Criteria
acute coronary syndrome (ACS) as the primary
reason for hospital admission
Yes
No
symptoms of ischemia
Yes
No
ECG change indicative of new ischemia (new ST-
T changes or new left bundle branch block);
Yes
No
development of pathological Q waves in the ECG
Yes
No
Exclusion Criteria
planned discharge to nursing home or skilled
nursing facility
Yes
No
lack of telephone/cell phone
Yes
No
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Eligibility Chest Pain Diagnostic Acute
Coronary Syndrome NCT01035047
Clinical decision units (CDUs) improve resource utilization
and are a recommended care option by the American
College of Cardiology / American Heart Association, but
are underutilized in non-low risk chest pain patients due to
weaknesses of traditional cardiac testing. Cardiac magnetic
resonance imaging (CMR) is sensitive and specific for
ischemia, can simultaneously assess cardiac function and
myocardial perfusion, and could revolutionize the diagnostic
process for intermediate risk patients with chest pain. The
primary objective of this trial is to measure the efficiency
and safety of a combined CDU-CMR care pathway
compared to inpatient care among patients with non-low
risk acute chest pain.
https://clinicaltrials.gov/ct2/show/NCT01035047
All rights reserved. Please visit https://medical-data-
models.org/forms/12469
Eligibility Criteria
Inclusion Criteria
Age greater than or equal to 21 years of age at
the time of enrollment
Yes
No
Chest discomfort or other symptoms consistent
with possible ACS as indicated by the treating
physician after obtaining an ECG and cardiac
biomarkers for the patient's evaluation
Yes
No
Thrombolysis in myocardial infarction (TIMI) risk
score >/= 2 or physician impression of
intermediate or high likelihood symptoms
represent ACS
Yes
No
Patient requires an inpatient or CDU evaluation
for their chest pain
Yes
No
Exclusion criteria
Elevated cardiac biomarkers
Yes
No
New ST-segment elevation on any
electrocardiogram (>/= 1 mV)
Yes
No
New ST-segment depression on any
electrocardiogram (>/= 2 mV)
Yes
No
Known inducible cardiac ischemia without
subsequent revascularization
Yes
No
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Unable to lie flat
Yes
No
Symptomatic hypotension at the time of
enrollment (systolic < 90 mm Hg)
Yes
No
Contra-indications to MRI (examples: Pacemaker,
defibrillator, cerebral aneurysm clips, metallic
ocular foreign body, implanted devices, severe
claustrophobia)
Yes
No
Terminal diagnosis with life expectancy less than
3 months
Yes
No
Currently Pregnant
Yes
No
Creatinine clearance < 45 ml/min at the time of
enrollment or clinical concern for acute kidney
injury
Yes
No
Chronic liver disease with a creatinine clearance
of <60 ml/min at the time of enrollment
Yes
No
Hepato-renal syndrome
Yes
No
History of liver transplant
Yes
No
History of heart transplant
Yes
No
History of kidney transplant
Yes
No
Confirmed angioplasty
Yes
No
Confirmed stent placement within the last 6
months
Yes
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No
Confirmed coronary artery bypass grafting
(CABG) within the last 6 months
Yes
No
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Eligibility RE-DEEM Acute Coronary
Syndrome NCT00621855
The purpose of this trial is to evaluate the safety and
indicators of efficacy of up to 4 doses of orally administered
dabigatran etexilate, administered twice daily, compared to
placebo when given in addition to dual antiplatelet
treatment in patients with an index event (MI) at high risk
for new ischaemic cardiovascular events.
https://www.clinicaltrials.gov/ct2/show/NCT00621855
All rights reserved. Please visit https://medical-data-
models.org/forms/12470
Eligibility criteria
Inclusion criteria
Patients with acute coronary syndromes
Yes
No
with at least one additional risk factor for
cardiovascular complications
Yes
No
Exclusion criteria
Long term treatment with any other oral
anticoagulant
Yes
No
Severe/disabling stroke within last 6 months
Yes
No
Conditions associated with increased bleeding
risk
Yes
No
Anaemia
Yes
No
Thrombocytopenia
Yes
No
Severe renal impairment
Yes
No
Liver disease
Yes
No
Positive pregnancy test
Yes
No
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Eligibility Ticagrelor Versus Clopidogrel
Acute Coronary Syndrome NCT01294462
The purpose of the study is to assess the efficacy
(prevention of vascular events) and safety (especially
bleedings) of Ticagrelor (AZD6140) compared with
Clopidogrel, both given on top of low dose aspirin, in
Asian/Japanese patients with acute coronary syndrome
and a planned percutaneous coronary intervention (PCI).
https://clinicaltrials.gov/ct2/show/NCT01294462
All rights reserved. Please visit https://medical-data-
models.org/forms/12471
Eligibility criteria
Inclusion Criteria
Provision of signed informed consent
Yes
No
Index event of ST segment elevation ACS
Yes
No
Index event of non-ST segment elevation ACS
Yes
No
Exclusion criteria
Index event is an acute complication of
percutaneous coronary intervention
Yes
No
Patient has undergone Percutaneous Coronary
Intervention (PCI) after the index event before the
first dose of study treatment
Yes
No
Oral anticoagulation therapy that cannot be
stopped
Yes
No
The conditions associated with increased risk of
bradycardiac events
Yes
No
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Eligibility SWITCHIII Acute Coronary
Syndrome NCT00464087
The primary objective of this clinical trial is to evaluate
safety of switching from fondaparinux to either
unfractionated heparin or bivalirudin for patients
experiencing acute coronary syndrome undergoing
percutaneous coronary angioplasty.
https://clinicaltrials.gov/ct2/show/NCT00464087
All rights reserved. Please visit https://medical-data-
models.org/forms/12472
Eligibility Criteria
Inclusion Criteria
The patient is, male or female
Yes
No
> 18 years of age
Yes
No
The patient presents with coronary syndrome
Yes
No
The patient presents with coronary syndrome
Yes
No
unstable angina
Yes
No
non ST segment elevated myocardial infarction
(NSTEMI)
Yes
No
The patient is scheduled for angiography, with
possible angioplasty, evaluation of their coronary
disease
Yes
No
The patient is able and willing to conform to the
requirements of the study and voluntarily signs
an Informed Consent.
Yes
No
Exclusion criteria
ST elevated myocardial infarction within the
preceding 48 hours
Yes
No
Patient weighs more than 400 lbs (181.2 kg) or
less than 110 lbs (50 kg)
Yes
No
Patients presenting on or received bivalirudin
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within the preceding 24 hours;
Yes
No
Patients presenting on or received GP IIb/IIIa
inhibitors within the preceding 24 hours;
Yes
No
Patients presenting on or received low-molecular
weight heparin within the preceding 24 hours
Yes
No
Patients that received unfractionated heparin less
than or equal to 90 minutes prior to fondaparinux
administration.
Yes
No
Patients with known conditions of bleeding
diathesis
Yes
No
Patients with actively bleeding within the previous
6 months (GI bleed etc.);
Yes
No
Known diagnosis of acute bacterial endocarditis;
Yes
No
Patients with cardiogenic shock
Yes
No
Required intra-aortic balloon pump (IABP)
Yes
No
If patient is on warfarin (Coumadin) therapy
Yes
No
Patients who had a major or minor stroke (CVA or
TIA)
Yes
No
Patients who had a major surgery within the past
6 months;
Yes
No
Known impaired renal function (creatinine ≥ 3.0
mg/dL (265.2 μmol/L)
Yes
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No
status post renal transplant
Yes
No
patients on chronic dialysis
Yes
No
creatinine clearance ≤ 30 ml/min
Yes
No
A platelet count of less than 100,000 cells/mm3;
Yes
No
Known allergies to fondaparinux, aspirin,
clopidogrel bisulfate (PlavixR), ticlopidine
(TiclidR), heparin, bivalirudin, that cannot be
medically managed;
Yes
No
Known allergies to contrast that cannot be
medically managed;
Yes
No
Prior angioplasty within the previous 30 days;
Yes
No
Contraindication to low-molecular weight heparin
Yes
No
Contraindication to unfractionated heparin
Yes
No
Contraindication to bivalirudin;
Yes
No
Pregnant or lactating women;
Yes
No
Pregnant or lactating women;
Yes
No
Currently participating in an investigational drug
or another device study.
Yes
No
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Eligibility Prasugrel vs Clopidogrel Acute
Coronary Syndrome NCT00385944
This is a multicenter, randomized, double-blind, cross-over
study to compare the pharmacodynamic response in
subjects with Acute Coronary Syndrome receiving a 10-mg
maintenance dose (MD) of prasugrel compared with a 150-
mg maintenance dose of clopidogrel, following a 900-mg
loading dose (LD) of clopidogrel.
https://clinicaltrials.gov/ct2/show/NCT00385944
All rights reserved. Please visit https://medical-data-
models.org/forms/12473
Eligiblity Criteria
Inclusion Criteria
Present with acute coronary syndrome (ACS)
Yes
No
Have planned treatment with a one-time 900-mg
loading dose of commercially available
clopidogrel
Yes
No
Are between the ages of 18 and 85 years.
Yes
No
Willing and able to sign informed consent.
Yes
No
Exclusion Criteria
Have overt ST-segment elevation myocardial
infarction (STEMI).
Yes
No
Have cardiogenic shock.
Yes
No
Have refractory ventricular arrhythmias.
Yes
No
Have New York Heart Association (NYHA) Class
IV congestive heart failure.
Yes
No
Have severe and uncontrolled hypertension.
Yes
No
Have active internal bleeding or history of
bleeding diathesis.
Yes
No
Have an increased risk of bleeding.
Yes
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No
Have history of cerebrovascular accidents.
Yes
No
Have certain abnormal blood level values.
Yes
No
Are currently receiving chemotherapy
Yes
No
Are currently receiving radiation therapy.
Yes
No
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NCT00385944
Eligibility Vorapaxar Acute Coronary
Syndrome NCT00684203
The study is designed to assess safety and effects of
vorapaxar, when added to standard of care (aspirin and
clopidigrel), in Japanese subjects with acute coronary
syndrome. The study may also provide information about
the effect of vorapaxar on preventing heart attack and
stroke in this subject population.
https://clinicaltrials.gov/ct2/show/NCT00684203
All rights reserved. Please visit https://medical-data-
models.org/forms/12474
Eligibility criteria
Inclusion Criteria
Men and women aged 18 years or more
Yes
No
with history of cardiac ischemia related chest
discomfort of > 10 minutes duration < 24 hours
prior to randomization
Yes
No
with history of cardiac ischemia related chest
discomfort of > 10 minutes duration < 24 hours
prior to randomization
Yes
No
Participants who are planned to undergo PCI will
be the target participants
Yes
No
Elevated troponin I
Yes
No
creatinine kinase MB isozyme greater than the
site's upper limit of normal (ULN)
Yes
No
ST segment depression >= 0.1 mV (>=1 mm)
Yes
No
transient (<30 minutes) ST segment elevation >=
0.1 mV (>=1 mm) in at least 2 contiguous leads
Yes
No
Willing to give appropriate informed consent and
complete all study-related procedures, and able
to adhere to dosing and all visit schedules.
Yes
No
Women of child-bearing potential (all
postmenarchal women who are <1 years
menopausal or who have not had surgical
sterilization or a hysterectomy are considered to
be women of child-bearing potential) must agree
to use a medically accepted method of
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contraception while receiving protocol-specified
medication, and for 60 days after stopping the
medication.
Yes
No
Exclusion Criteria
Pregnant and nursing mothers (premenopausal
women should have a negative pregnancy test
result confirmed before enrollment)
Yes
No
known hypersensitivity to any component of the
current investigational product;
Yes
No
Participation in a study of experimental therapy or
use of any investigational drug within 30 days
before enrollment
Yes
No
History of a bleeding diathesis
Yes
No
evidence of active abnormal bleeding within 30
days before enrollment
Yes
No
History of a hemorrhagic stroke at any time
Yes
No
Severe hypertension (systolic blood pressure
>200 mm Hg or diastolic blood pressure >110
mm Hg) while receiving therapy;
Yes
No
Major surgery within 2 weeks prior to enrollment
Yes
No
Known platelet count <100,000/mm^3
Yes
No
Uncontrolled cardiac arrhythmia;
Yes
No
Known impairment of renal function (serum
creatinine >2.0 mg/dL [>176.8 umol/L]),
dysproteinemia, nephrotic syndrome, or other
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renal disease;
Yes
No
Active or chronic hepatobiliary or hepatic disease
Yes
No
Anticipated staged PCI
Yes
No
Anticipated intracoronary brachytherapy
Yes
No
Concurrent or anticipated treatment with warfarin
Yes
No
Concurrent or anticipated treatment with factor
Xa inhibitor after enrollment
Yes
No
Concurrent or anticipated treatment with direct
thrombin inhibitor after enrollment
Yes
No
Concurrent or anticipated treatment with or
antiplatelet agents after enrollment
Yes
No
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Eligibility CHAMPION PHOENIX Acute
Coronary Syndrome NCT01156571
The study is designed to compare the efficacy and safety
profile of cangrelor to standard of care in patients require
percutaneous coronary intervention (PCI).
https://clinicaltrials.gov/ct2/show/NCT01156571
All rights reserved. Please visit https://medical-data-
models.org/forms/12475
Eligibility Criteria
Inclusion Criteria
Male or non-pregnant female
Yes
No
non-pregnant female
Yes
No
at least 18 years of age
Yes
No
Patients undergoing percutaneous coronary
intervention (PCI)
Yes
No
Stable angina (SA) patients
Yes
No
with diagnostic coronary angiography
Yes
No
Non-ST-Segment Elevation Acute Coronary
Syndrome (NSTE-ACS) patients with diagnostic
coronary angiography within 72 hours prior to
randomization demonstrating atherosclerosis
Yes
No
Non-ST-Segment Elevation Acute Coronary
Syndrome (NSTE-ACS) patients with diagnostic
coronary angiography within 72 hours prior to
randomization demonstrating atherosclerosis
Yes
No
ST-segment elevation myocardial infarction
(STEMI) patients (diagnostic angiography not
required)
Yes
No
Provide written informed consent
Yes
No
Exclusion Criteria
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Receipt of any P2Y12 inhibitor at any time in the
7 days preceding randomization
Yes
No
Eptifibatide usage within 12 hours preceding
randomization (most recent dose must have been
administered ≥12 hours prior to randomization)
Yes
No
Tirofiban usage within 12 hours preceding
randomization (most recent dose must have been
administered ≥12 hours prior to randomization)
Yes
No
Abciximab usage within 7 days preceding
randomization
Yes
No
Receipt of fibrinolytic therapy in the 12 hours
preceding randomization
Yes
No
Increased bleeding risk
Yes
No
ischemic stroke within the last year or any
previous hemorrhagic stroke
Yes
No
tumor
Yes
No
cerebral arteriovenous malformation
Yes
No
intracranial aneurysm
Yes
No
recent (<1 month) trauma
Yes
No
major surgery (including bypass surgery)
Yes
No
currently receiving warfarin
Yes
No
2 / 3
Eligibility CHAMPION PHOENIX Acute Coronary Syndrome
NCT01156571
active bleeding
Yes
No
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NCT01156571
CF-Patient, multicenter trial of hemolysis as
diagnostic test for cystic fibrosis (HemCF)
CF-Patient, multicenter trial of hemolysis as diagnostic test
for cystic fibrosis (HemCF)
Principal Investigator PD Dr. Hermann Schillers, University
Hospital of Mnster
All rights reserved. Please visit https://medical-data-
models.org/forms/12487
CF-Patient, multicenter trial of
hemolysis as diagnostic test for
cystic fibrosis (HemCF)
Patienteninformationen
Study site number
Patienentennummer
Name des Patienten:
Datum der Einverständniserklärung
Einschlusskriterien
Vorliegen einer unterschriebenen
Einverständniserklärung
Ja
Nein
Ausschlusskriterien
Infektionen der Atemwege innerhalb der letzten 4
Wochen
Ja
Nein
Teilnahme an Medikamentenstudie innerhalb der
letzten 30 Tage
Ja
Nein
Klinischer Hinweis auf eine Mukoviszidose
Ja
Nein
Gruppeneinteilung
Typischer CF-Patient und delF508 homozygot
Ja
Nein
Typischer CF-Patient und nicht delF508
homozygot
Ja
Nein
Atypischer CF-Patient
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Ja
Nein
Datum:
fecal elastase >200
>= 200
μg/g
Ja
Nein
CFTR-Mutationen
CFTR-Mutationen
Ja
Nein
Allel 1
1717-1G→A  (1717-1G→A )
2184dA (2184dA)
3849+10kb C→T (3849+10kb C→T)
A455E (A455E)
delF508  (delF508 )
dl507  (dl507 )
G542X  (G542X )
G551D  (G551D )
N1303K  (N1303K )
R1162X (R1162X)
R117H (R117H)
R347P S549N 621+1G→T (R347P
S549N 621+1G→T)
R553X  (R553X )
R560T  (R560T )
W1282X  (W1282X )
Allel 2
1717-1G→A  (1717-1G→A )
2184dA (2184dA)
3849+10kb C→T (3849+10kb C→T)
A455E (A455E)
delF508  (delF508 )
dl507  (dl507 )
G542X  (G542X )
G551D  (G551D )
N1303K  (N1303K )
R1162X (R1162X)
R117H (R117H)
R347P S549N 621+1G→T (R347P
S549N 621+1G→T)
R553X  (R553X )
R560T  (R560T )
W1282X  (W1282X )
Allel 1 und 2
1717-1G→A  (1717-1G→A )
2184dA (2184dA)
3849+10kb C→T (3849+10kb C→T)
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A455E (A455E)
delF508  (delF508 )
dl507  (dl507 )
G542X  (G542X )
G551D  (G551D )
N1303K  (N1303K )
R1162X (R1162X)
R117H (R117H)
R347P S549N 621+1G→T (R347P
S549N 621+1G→T)
R553X  (R553X )
R560T  (R560T )
W1282X  (W1282X )
Andere Mutation Allel 1
Andere Mutation Allel 2
Shwachman-Score ohne Röntgen
Schweißchlorid
<30 mmol/l  (<30 mmol/l )
>60 mmol/l (>60 mmol/l)
≥30 und ≤60 mmol/l  (≥30 und ≤60
mmol/l )
Datum
Datum unbekannt
Ja
Nein
Lungenfunktionstests
Lungenfunktionstests durchgeführt
Ja
Nein
Datum Lungenfunktionstest
FEV1
%
FVC
%
Demographie
Geburtsdatum:
Geschlecht:
männlich  (1)
weiblich (2)
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Körpergewicht
kg
Größe:
cm
Hämolysetest
Datum Blutentnahme
Datum Laboruntersuchung
Ergebnis Kontrolle 75
%
Ergebnis Gd3
%
Ergebnis Gd3+ + Zn2
%
Weitere Laborergebnisse
Erythrozyten
/μl
Vitamin E
mg/l
Retikulozyten
Masseinheit Retikulozyten
% (1)
/nl (2)
Zink
Masseinheit Zink
μg/dl (1)
μmol/l (2)
Begleitmedikation der letzten 4 Wochen
keine Begleitmedikation
Ja
Nein
Inhalativ
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Budesonid (Budesonid)
Colistin (Colistin)
Dornase (Dornase)
Fluticason/Salmeterol
(Fluticason/Salmeterol)
Formoterol (Formoterol)
hypertonic saline solution (hypertonic
saline solution)
Ipratropiumbromid/Fenoterol
(Ipratropiumbromid/Fenoterol)
Salbutamol (Salbutamol)
Salmeterol (Salmeterol)
Tobramycin (Tobramycin)
PO
ambroxole (ambroxole)
Azithromycin (Azithromycin)
Beta carotene (Beta carotene)
Cefaclor (Cefaclor)
Cefadroxil (Cefadroxil)
Cefuroxim (Cefuroxim)
Ciprofloxacin (Ciprofloxacin)
Lipase, Amylase, (Lipase, Amylase,)
Multivitamin (Multivitamin)
N-Acetylcysteine (N-Acetylcysteine)
Omeprazole (Omeprazole)
Protease (Protease)
Selenium (Selenium)
sulfamethoxazole (sulfamethoxazole)
trimethoprim (trimethoprim)
UDCA (UDCA)
Vitamin A (Vitamin A)
Vitamin D (Vitamin D)
Vitamin E (Vitamin E)
Vitamin K (Vitamin K)
Zinc (Zinc)
andere Begleitmedikation
Datum
Unterschrift Prüfer
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Riliva_CRF_EudraCT - Nr. 2012-000108-
13- Anamnesis
Study documentation part: Anamnesis. This is a phase II
multicenter trial with Rivaroxaban in the treatment of
livedoid vasculopathy assessing the pain on a visual analog
scale (VAS).  Principal Investigator PD Dr. Tobias Görge,
University Hospital of Münster. EudraCT - Nr. 2012-
000108-13.
All rights reserved. Please visit https://medical-data-
models.org/forms/12496
Anamnesis
Livedovaskulopathie Anamnese
Auftreten erster Symptome
Auftreten erster Ulzerationen
Diagnosestellung
Zeitpunkt der ersten Behandlung mit
Antikoagulantien
Anzahl Schübe innerhalb der letzten 6 Monate
Sind bisher oberflächliche Venenthrombosen
aufgetreten?
Ja
Nein
Sind bisher tiefe Venenthrombosen aufgetreten?
Ja
Nein
Datum 1. Auftreten
Lokalisation: Armvene
Ja
Nein
Lokalisation:Bein-/Wadenvene
Ja
Nein
Lokalisation:Beckenvene
Ja
Nein
Lokalisation:Oberschenkelvene
Ja
Nein
Lokalisation: Kniegelenksvene
Ja
Nein
Lokalisation:Leberpfortader
Ja
Nein
1 / 7
Andere Lokalisation
Auftreten von Gerinnungsstörungen
ja (1)
nein (2)
nicht bekannt (3)
Faktor-V-Leiden-Mutation
Ja
Nein
Mangel an Protein C und Protein S
Ja
Nein
Prothrombin G20210A-Mutation
Ja
Nein
Hyperhomocysteinämie
Ja
Nein
Antithrombin-III-Mangel
Ja
Nein
Antikardiolipin-Antikörper
Ja
Nein
Erhöhter Plasminogen-Aktivator-Inhibitor-1-
Spiegel (Störungen der Fibrinolyse)
Ja
Nein
Andere
Bisherige Therapieformen der
Livedovaskulopathie
Heparin, diese Therapie müssen mind. 1 Tag vor
Therapiebeginn abgesetzt werden
(Ausschlusskriterien)!
Ja
Nein
Beginn
Ende
Therapieansprechen
sehr gut (1)
gut (2)
mittelmäßig (3)
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schlecht (4)
gar nicht (5)
unbekannt (6)
NSAR, diese Therapie müssen mind. 1 Tag vor
Therapiebeginn abgesetzt werden
(Ausschlusskriterien)!
Ja
Nein
Beginn
Ende
Therapieansprechen
sehr gut (1)
gut (2)
mittelmäßig (3)
schlecht (4)
gar nicht (5)
unbekannt (6)
Thrombozytenaggregationshemmer, diese
Therapie müssen mind. 1 Tag vor
Therapiebeginn abgesetzt werden
(Ausschlusskriterien)!
Ja
Nein
Beginn
Ende
Therapieansprechen
sehr gut (1)
gut (2)
mittelmäßig (3)
schlecht (4)
gar nicht (5)
unbekannt (6)
Vitamin K- Antagonisten, diese Therapie muss
mind. 7 Tage vor Therapiebeginn abgesetzt
werden (Ausschlusskriterium)!
Ja
Nein
Beginn
Ende
Therapieansprechen
sehr gut (1)
gut (2)
mittelmäßig (3)
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schlecht (4)
gar nicht (5)
unbekannt (6)
Immunglobuline
Ja
Nein
Beginn
Ende
Therapieansprechen
sehr gut (1)
gut (2)
mittelmäßig (3)
schlecht (4)
gar nicht (5)
unbekannt (6)
Steroide
Ja
Nein
Beginn
Ende
Therapieansprechen
sehr gut (1)
gut (2)
mittelmäßig (3)
schlecht (4)
gar nicht (5)
unbekannt (6)
Weitere
Beginn
Ende
Therapieansprechen
sehr gut (1)
gut (2)
mittelmäßig (3)
schlecht (4)
gar nicht (5)
unbekannt (6)
Chronische Begleiterkrankungen
Chronische Begleiterkrankungen
Ja
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Nein
Erkrankung
Beginn
Livedovaskulopathie- Familienanamnese
Auftreten der Livedovaskulopathie in eigene
Kinder und Eltern
nicht bekannt (1)
nein (2)
ja, männlich (3)
ja, weiblich (4)
Auftreten der Livedovaskulopathie in Großeltern,
Enkelkinder, Geschwister
nicht bekannt (1)
nein (2)
ja, männlich (3)
ja, weiblich (4)
Auftreten der Livedovaskulopathie in Onkel,
Tante, Neffen, Nichten
nicht bekannt (1)
nein (2)
ja, männlich (3)
ja, weiblich (4)
Gerinnungsstörungen in der
Verwandtschaft
Faktor-V-Leiden-Mutation
ja (1)
nein (2)
nicht bekannt (3)
Mangel an Protein C und Protein S
ja (1)
nein (2)
nicht bekannt (3)
Prothrombin G20210A-Mutation
ja (1)
nein (2)
nicht bekannt (3)
Hyperhomocysteinämie
ja (1)
nein (2)
nicht bekannt (3)
Antithrombin-III-Mangel
ja (1)
nein (2)
nicht bekannt (3)
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Antikardiolipin-Antikörper
ja (1)
nein (2)
nicht bekannt (3)
Erhöhter Plasminogen-Aktivator-Inhibitor-1-
Spiegel (Störungen der Fibrinolyse)
ja (1)
nein (2)
nicht bekannt (3)
Andere
Laboratory values
LV-assoziierte Laborwerte
Kryoglobulin Messwert
titer
Datum
Kryofibrinogen Messwert
titer
Datum
Kälteagglutinin Messwert
titer
Datum
Homozystein (nüchtern) Messwert
µmol/l
Datum
Vitamin B6 Messwert
ng/ml
Datum
Vitamin B12 Messwert
pg/ml
Datum
Folsäure Messwert
ng/ml
6 / 7
Riliva_CRF_EudraCT - Nr. 2012-000108-13- Anamnesis
Datum
Protein C Messwert
%
Datum
Protein S (gesamt) Messwert
%
Datum
Anti-Thrombin-III Messwert
%
Datum
Antinukleäre Antikörper
positiv (1)
negativ (2)
Datum
Lupus-Antikoagulans Messwert
sec
Datum
Antikardiolipinantikörper (IgG) Messwert
U/ml
Datum
β2-Glykoprotein-1-Antikörper (IgG) Messwert
U/ml
Datum
Lipoprotein(a) Messwert
mg/dl
Datum
Weitere
Datum
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Riliva_CRF_EudraCT - Nr. 2012-000108-
13- Adverse event
Study documentation part: Adverse event. This is a phase
II multicenter trial with Rivaroxaban in the treatment of
livedoid vasculopathy assessing the pain on a visual analog
scale (VAS).  Principal Investigator PD Dr. Tobias Görge,
University Hospital of Münster. EudraCT - Nr. 2012-
000108-13.
All rights reserved. Please visit https://medical-data-
models.org/forms/12498
Riliva_CRF_EudraCT - Nr. 2012-
000108-13- Adverse event
Unerwünschtes Ereignis  (AE)
Unerwünschtes Ereignis (AE)
Beginn AE Datum
Schwerwiegend
Ja
Nein
Intensität
leicht: keine Auswirkung auf
Alltagsaktivitäten (z.B. Kochen,
Einkaufen) (1)
mittel: Alltagsaktivitäten beeinträchtigt (2)
schwer: Alltagsaktivitäten oder Arbeit
nicht möglich (3)
Zusammenhang mit Prüfmedikation:
keine begründete Möglichkeit eines
Zusammenhangs (1)
begründete Möglichkeit eines
Zusammenhangs (2)
Maßnahmen bzgl. Prüfmedikation
keine (1)
Dosisreduktion (2)
Dosiserhöhung (3)
vorübergehend abgesetzt (4)
endgültig abgesetzt (5)
unbekannt (6)
nicht zutreffend (7)
AE führt zum Studienabbruch
Ja
Nein
Ende AE Datum
Ausgang des AE
wiederhergestellt (1)
gebessert (2)
noch nicht gebessert (3)
wiederhergestellt mit bleibendem
Schaden (4)
Tod (5)
unbekannt (6)
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Days 2-5 Physical Examination Stem-Cell
Transplantation CASLAMB NCT00148148
A Study of Caspofungin, Liposomal Amphotericin B or the
Combination of Both for Patients After Stem-Cell
Transplantation
NCT00148148
All rights reserved. Please visit https://medical-data-
models.org/forms/12499
Days 2-5 Physical Examination
Stem-Cell Transplantation CASLAMB
NCT00148148
Körperliche Untersuchung
Datum der Untersuchung
Medical history
Kopf und Hals (Beschreibung)
Lymphknoten
normal (1)
abnormal (2)
not known (3)
not done (4)
Kardiovaskuläres System
normal (1)
abnormal (2)
not known (3)
not done (4)
Lunge
normal (1)
abnormal (2)
not known (3)
not done (4)
Abdomen
normal (1)
abnormal (2)
not known (3)
not done (4)
Genital / Rektal
normal (1)
abnormal (2)
not known (3)
not done (4)
Muskuloskeletal /
Extremitäten
normal (1)
abnormal (2)
not known (3)
not done (4)
Haut
normal (1)
abnormal (2)
not known (3)
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not done (4)
Nervensystem
normal (1)
abnormal (2)
not known (3)
not done (4)
Other Examination
Sonstiges
normal (1)
abnormal (2)
not known (3)
not done (4)
Vitalparameter
Größe
Gewicht
>= 0
kg
KOF berechnet
>= 0
m²
Körpertemperatur
°C
Herzfrequenz
>= 0
bpm
Atemfrequenz
/min
Blutdruck systolisch
mmHg
Diastolischer Blutdruck
mmHg
Karnofsky Index
%
Mukositis, Grad WHO
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NCT00148148
Eligibility Colorectal Cancer NCT00609310
Dietary Bioflavonoid Supplementation for the Prevention of
Neoplasia Recurrence; ODM derived from:
https://clinicaltrials.gov/show/NCT00609310
All rights reserved. Please visit https://medical-data-
models.org/forms/12500
Eligibility Colorectal Cancer
NCT00609310
Inclusion Criteria
patient who had a recent surgical resection of
colorectal cancer with pathologically proven stage
2 or stage 3 (without adjuvant chemotherapy or
after completion of adjuvant chemotherapy)
according to uicc. the time interval for recruitment
should be within 3-12 month after surgery.*
Yes
No
male or female*
Yes
No
caucasian*
Yes
No
50  to 75 years old*
Yes
No
broca-index: between -20 and +25%*
Yes
No
who are willing and capable to confirm written
consent to enrolment after ample information has
been provided*
Yes
No
who are in a stable condition that it can be
expected that no changes in relevant medical
conditions will occur during the study*
Yes
No
Exclusion Criteria
subjects with any major relevant clinical
abnormality (as based on extensive medical
history, physi-cal examination, vital signs)*
Yes
No
subjects with active cancer*
Yes
No
subjects with any major clinically relevant
laboratory abnormality.*
1 / 2
Yes
No
subjects who participated in another trial with any
investigational substance within the last 4 weeks*
Yes
No
subjects who are known or suspected to be
(social) drug dependent, incl. those drinking more
than moderately and who are not willing to
abstain from alcohol abuse during the active
study phase*
Yes
No
subjects who adhere to a extreme diet or lifestyle
that might interfere with the investigation*
Yes
No
subjects who are known or suspected not to
comply with the study directives and/or who are
known or suspected not to be reliable or
trustworthy*
Yes
No
subjects who are known or suspected not to be
capable of understanding and evaluating the in-
formation that is given to them as part of the
formal information policy (informed consent), in
par-ticular regarding the risks and discomfort to
which they would agree to be exposed*
Yes
No
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Emergency background: Emergency
Physicians protocol DIVI
DIVI-Protocol for documentation purposes of emergency
medical response by emergency physicians (Version 5.1
2015) Deutsche interdisziplinaere Vereinigung fuer Intensiv
und Notfallmedizin DIVI (German interdisciplinary
association for intensive and emergeny medical care)
All rights reserved. Please visit https://medical-data-
models.org/forms/12501
Emergency background and medical
history
Emergency background
General condition before emergency
healthy (1)
ill, not impaired (2)
slightly impaired (3)
severely impaired (4)
life threatening illness (5)
unknown (6)
first aid (layman)
sufficient (1)
insufficient (2)
none (3)
Emergency responder at the site
Yes
No
Time of arrival of emergency responder (if
applicable)
Please describe emergency situation
Medical history
Prior medication
Prior treatment
emergency preliminary evaluation
Colonization with MRSA
open (1)
covered (2)
no (no)
yes (yes)
Neurological preliminary assessment
Time of neurological assessment
Normal assessment finding
Yes
No
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GCS Eye opening
no reaction (1)
on pain stimulus (2)
on request (3)
spontaneously (4)
GCS best verbal response
no verbal response (1)
incomprehensible sounds (2)
inadequate utterance (3)
conversational confused (4)
conversational oriented (5)
Best motor response
None (1)
Extension to pain (2)
Flexion to pain (3)
Withdraws (4)
Localize to pain (5)
Obeys command (6)
best motor response left arm
best motor response left leg
best motor response right arm
best motor response right leg
Glasgow coma score total
Use of Extremities,right arm
normal (1)
slightly reduced movements (2)
severely reduced movement (3)
Use of extremities,right leg
normal (1)
slightly reduced movement (2)
severely reduced movement (3)
Use of extremities, left arm
normal (1)
slightly reduced movement (2)
severely reduced movement (3)
Use of extremities, left leg
normal (1)
slightly reduced movement (2)
severely reduced movement (3)
Awareness
state of consciousness
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alert (1)
sleepy (2)
unconscious (3)
response to verbal stimulus (4)
response to pain stimulus (5)
anesthetized (6)
can not be assessed (7)
Neurological Abnormality
Neurological examination findings
normal (0)
can not be assessed (1)
prior known neurological deficit (10)
other (11)
hemiplegic symptoms (2)
no smiling (3)
blurred vision (4)
paraplegia (5)
babinski sign positive (6)
disturbance of speech (7)
dementia (8)
meningism (9)
Size of right Pupil
small (1)
medium (2)
large (3)
irregular (4)
Size of left Pupil
small (1)
medium (2)
large (3)
irregular (4)
Pupil reaction to light (left)
prompt (1)
indolent (2)
none (3)
Pupil reaction to light (right)
prompt (1)
indolent (2)
none (3)
Initial vital signs
Have vital signs been taken?
Yes
No
Pain scale
0 no pain at all (0)
1 (1)
10 unbearable pain (10)
2 (2)
3 (3)
4 (4)
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5 (5)
6 (6)
7 (7)
8 (8)
9 (9)
Blood pressure (BP)
mmHg
Heart rate (in bpm):
bpm
Cardiac rhythm type
rhythmical (1)
arrhythmical (2)
Blood Glucose
Unit used for measuring blood glucose
mg/dl (1)
mmol/l (2)
Respiratory Rate
/min
Oxygen saturation
SaO2
SaO2
at room air (1)
with oxygen insufflation (2)
Body Temperature
°C
etCO2
ECG
Yes
No
ECG findings
sinus rhthm (1)
small complex tachycardia (10)
wide complex tachycardia (11)
SVES/VES monomorph (12)
VES polymorph (13)
arrhythmia absoluta (2)
AV-block II° (3)
AV-block III° (4)
pacemaker (5)
artrial fibrillation (6)
electro-mechanical dissociation (7)
asystole (8)
STEMI (9)
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Respiratory pattern
not examined (0)
without pathological finding (1)
hyperventilation (10)
choking (11)
rattling sound (12)
Dyspnea (2)
gasping (3)
Apnea (4)
artificial ventilation (5)
other pathological breathing pattern (6)
stridor (7)
cyanosis (8)
spasticity (9)
Skin status
not examined (0)
normal (1)
abnormal (2)
dehydrated (standing skin fold) (3)
bedsore (4)
exanthema (5)
edema (6)
cold and clammy (7)
psychiatric evaluation
not examined (0)
without pathological finding (1)
retarded/stuporous (10)
euphorical (11)
motorical restless (12)
can not be assessed (2)
delusional (3)
agitated (4)
depressed (5)
confused (6)
aggressiv (7)
anxious (8)
suicidal (9)
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Patient Identification Emergency Physician
protocol DIVI
DIVI-Protocol for documentation purposes of emergency
medical response by emergency physicians (Version 5.1
2015) Deutsche interdisziplinaere Vereinigung fuer Intensiv
und Notfallmedizin DIVI (German interdisciplinary
association for intensive and emergeny medical care)
All rights reserved. Please visit https://medical-data-
models.org/forms/12502
EMS protocol Patient Identification
Patient Identification
Patient surname
Patient Name
Date of birth
Street Adress
Postal Code (Patient Residence)
City of residence
Health Insurance Name
Insurance number
Patient sex
male (1)
female (2)
Body Mass Index
kg/m2
>40 (1)
≤40 (2)
Age
years
Age younger than 1 month
days
1-7 (1)
8-28 (2)
Emergency response Number
Patient number
Personnel Number
EMS Station
license plate number
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Technical Specifications Emergency
Physician protocol DIVI
DIVI-Protocol for documentation purposes of emergency
medical response by emergency physicians (Version 5.1
2015) Deutsche interdisziplinaere Vereinigung fuer Intensiv
und Notfallmedizin DIVI (German interdisciplinary
association for intensive and emergeny medical care)
All rights reserved. Please visit https://medical-data-
models.org/forms/12503
Technical Specifications Emergency
Physician protocol DIVI
Technical Specifications
Date of emergency
Emergency site
Home of patient (1)
major event (10)
public space (11)
street (12)
other (13)
sport fields (2)
Hospital (3)
maternity home (4)
workplace (5)
medical practice (6)
school (7)
retirement home (8)
educational institution (9)
Please specify emergency site
Category of emergency response
primary emergency medical response (1)
secondary (i.e. Patient transfer) (2)
emergency physician supplemental claim
(3)
corollary emergency (4)
unnecessary call-out (5)
precautionary provision (6)
Why was the call-out unnecessary?
no patient (1)
cancelled (2)
patient already removed (3)
willful alarm (4)
cancelled due to technical problems (5)
cancelled due to adverse weather (6)
cancelled for other reasons (7)
Destination of transport
Advance notification
stroke unit (1)
intracardiac catheter lab (2)
trauma care (3)
Name of emergency physician
Assistant
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paramedic (1)
emergency medical technician (2)
intensive care nurse (3)
certified first responder (4)
Name of Assistant
First response team
Treating Physician
doctor in further training (1)
medical specialist (2)
Medical specialty
anesthesiology (1)
surgery (2)
internal medicine (3)
pediatrics (4)
general practitioner (5)
intensive care (6)
Call number of emergency vehicle
involved emergency vehicles
emergency physician response car (1)
casualty response team (emergency
physician,paramedic,EMT)  (2)
mobile intensive care unit (3)
ambulance (4)
Helicopter SAR (5)
intensive care transport helicopter (6)
mountain rescue (7)
water rescue (8)
other (9)
Symptom onset
Onset longer than 24h ago
Yes
No
witnessed syncope/collapse
Yes
No
Time of Alarm
Arrival
arrival at patient
Departure
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Patient Transfer
Ready for Standby
End of mission
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Baseline Inspection_Riliva_CRF_EudraCT -
Nr. 2012-000108-13
Study documentation part: Baseline Inspection. This is a
phase II multicenter trial with Rivaroxaban in the treatment
of livedoid vasculopathy assessing the pain on a visual
analog scale (VAS).  Principal Investigator PD Dr. Tobias
Görge, University Hospital of Münster. EudraCT - Nr. 2012-
000108-13.
All rights reserved. Please visit https://medical-data-
models.org/forms/12504
Baseline
Inspection_Riliva_CRF_EudraCT -
Nr. 2012-000108-13
Vitalparameter
Visite konnte durchgeführt werden
ja (1)
nein Studienabbruch, sofern seit der
Einwilligung des Patienten
Unerwünschte Ereignisse (AE´s)
aufgetreten  (2)
sind, bitte auf AE-Bogen dokumentieren.
(sind, bitte auf AE-Bogen
dokumentieren.)
Datum der Visite = 1. Tag der Gabe
Prüfmedikation
Größe
cm
Gewicht
kg
Puls
beats/min
Dosierung Notfallmedikation, Enoxaparin-Natrium
mg
20 mg (1)
40 mg (2)
60 mg (3)
80 mg (4)
100 mg (5)
Systolischer Blutdruck Arm links
mmHg
Diastolischer Blutdruck Arm links
mmHg
Systolischer Blutdruck Arm rechts
mmHg
Diastolischer Blutdruck Arm rechts
mmHg
Systolischer Blutdruck Unterschenkel/Knöchel
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links
mmHg
Diastolischer Blutdruck Unterschenkel/Knöchel
links
mmHg
Systolischer Blutdruck Unterschenkel/Knöchel
rechts
mmHg
Diastolischer Blutdruck Unterschenkel/Knöchel
rechts
mmHg
Chronisch venöse Insuffizienz nach Widmer
nein (1)
ja, Grad I (2)
ja, Grad II (3)
ja, Grad III (4)
Hämoglobin
g/dL
Thrombozyten-Transfusionen in den letzten 30
Tagen?
Ja
Nein
Hautuntersuchung (linker Unterschenkel /
Fuß)
Anzahl der aktiven Läsionen
Unterschenkelrückseite proximal
Anzahl der Läsionen in Abheilung
Unterschenkelrückseite proximal
Anzahl der aktiven Läsionen
Unterschenkelrückseite distal
Anzahl der Läsionen in Abheilung
Unterschenkelrückseite distal
Anzahl der aktiven Läsionen
Unterschenkelvorderseite proximal
Anzahl der Läsionen in Abheilung
Unterschenkelvorderseite proximal
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Anzahl der aktiven Läsionen
Unterschenkelvorderseite distal
Anzahl der Läsionen in Abheilung
Unterschenkelvorderseite distal
Anzahl der aktiven Läsionen Sprunggelenk lateral
Anzahl der Läsionen in Abheilung Sprunggelenk
lateral
Anzahl der aktiven Läsionen Sprunggelenk
medial
Anzahl der Läsionen in Abheilung Sprunggelenk
medial
Anzahl der aktiven Läsionen Fußrücken
Anzahl der Läsionen in Abheilung Fußrücken
Anzahl Atrophie blanche Herde linker
Unterschenkel / Fuß
Hautuntersuchung (rechter Unterschenkel
/ Fuß)
Anzahl der aktiven Läsionen
Unterschenkelrückseite proximal
Anzahl der Läsionen in Abheilung
Unterschenkelrückseite proximal
Anzahl der aktiven Läsionen
Unterschenkelrückseite distal
Anzahl der Läsionen in Abheilung
Unterschenkelrückseite distal
Anzahl der aktiven Läsionen
Unterschenkelvorderseite proximal
Anzahl der Läsionen in Abheilung
Unterschenkelvorderseite proximal
Anzahl der aktiven Läsionen
Unterschenkelvorderseite distal
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Anzahl der Läsionen in Abheilung
Unterschenkelvorderseite distal
Anzahl der aktiven Läsionen Sprunggelenk lateral
Anzahl der Läsionen in Abheilung Sprunggelenk
lateral
Anzahl der aktiven Läsionen Sprunggelenk
medial
Anzahl der Läsionen in Abheilung Sprunggelenk
medial
Anzahl der aktiven Läsionen Fußrücken
Anzahl der Läsionen in Abheilung Fußrücken
Anzahl Atrophie blanche Herde rechter
Unterschenkel / Fuß
LV - Score (adaptiert n. Kreuter)
Erythema Score
kein Erythem (1)
leicht (2)
mittel (3)
schwer (4)
Schmerz Score
kein Schmerz (1)
leicht (2)
mittel (3)
schwer (4)
Ulzeration Score
keine Ulzeration (1)
Kruste (2)
Ulzeration ohne Kruste (3)
tiefe Ulzeration (4)
Hautuntersuchung - Livedo racemosa
Livedo racemosa Oberarm
Ja
Nein
Livedo racemosa Unterarm
Ja
Nein
Livedo racemosa Hand
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Ja
Nein
Livedo racemosa Oberschenkel
Ja
Nein
Livedo racemosa Unterschenkel
Ja
Nein
Livedo racemosa Fuß
Ja
Nein
Livedo racemosa Stamm
Ja
Nein
Schmerzstärke auf der Visuellen Analog Skala
(VAS)
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Diseases documentation Emergency
Physician protocol DIVI
DIVI-Protocol for documentation purposes of emergency
medical response by emergency physicians (Version 5.1
2015) Deutsche interdisziplinaere Vereinigung fuer Intensiv
und Notfallmedizin DIVI (German interdisciplinary
association for intensive and emergeny medical care)
All rights reserved. Please visit https://medical-data-
models.org/forms/12507
Diseases documentation Emergency
Physician protocol DIVI
Diseases
Central nervous system
none (0)
Stroke/TIA/ICB (1)
eligible for lysis (2)
seizure  (3)
status epilepticus (4)
Meningitis/Encephalitis (5)
syncope (6)
other (7)
Circulatory system
none (0)
ACS (1)
heart failure (10)
pulmonary edema (11)
hypertensive crisis (12)
cardiogenic shock (13)
pacemaker/ICD malfunction (14)
other (15)
STEMI (2)
Anterior myocardial infarction (3)
posterior myocardial infarction (4)
Arrhythmia (5)
Tachycardia (6)
Bradycardia (7)
pulmonary embolism (8)
orthostatic dysfunction (9)
respiratory system
none (0)
asthma (1)
other (10)
status asthmaticus (2)
COPD (3)
home care artificial ventilation (4)
home care oxygen insufflation (5)
pneumonia/bronchitis (6)
hyperventilation syndrome (7)
aspiration (8)
hemoptysis (9)
Abdomen
none (0)
acute abdomen (1)
gastro-intestinal bleeding (2)
upper GI-bleeding (3)
lower GI-bleeding (4)
colic (i.e renal, gall bladder...) (5)
enteritis (6)
other (7)
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Psychiatry
none (0)
psychosis,mania,state of overexcitement
(1)
(tried)suicide (10)
psychosocial crisis (11)
other (12)
anxiousness,depression (2)
intoxication (3)
accidental intoxication (4)
intoxication with alcohol (5)
intoxication with drugs (6)
intoxication with prescription drugs (7)
other substance (8)
withdrawal,abstinence delirium (9)
Metabolic diseases
none (0)
hypoglycaemia (1)
hyperglycaemia (2)
dehydration (3)
uremia/acute kidney injury (4)
requiring dialysis (5)
other (6)
pediatric patient
none (0)
febrile seizure (1)
acute spasmodic laryngitis (2)
SIDS/near-SIDS (3)
other (4)
Gynecology
none (0)
gravidity (1)
labor/imminent birth (2)
prehospital birth (3)
(pre)-Eclampsia (4)
vaginal bleeding (5)
other (6)
Other conditions
none (0)
anaphylactic reaction I°-II° (1)
social problem (no psychiatric disorder)
(10)
medical treatment complication (11)
other (12)
anaphylactic reaction  III°-VI° (2)
heat exhaustion/heatstroke (3)
hypothermia/frostbite (4)
sepsis/septic shock/high febrile infection
(5)
influenza (6)
Hepatitis/HIV (7)
acute lumbago (8)
epistaxis (9)
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Injuries
Injury due to sporting activity
Yes
No
Injury due to work-related activity
Yes
No
Polytrauma
Yes
No
Craniocerebral trauma
none (0)
minor (1)
moderate (2)
severe (3)
decked (4)
open (5)
Facial trauma or injury
none  (0)
minor  (1)
moderate  (2)
severe  (3)
decked  (4)
open (5)
Neck injuries
none  (0)
minor  (1)
moderate  (2)
severe  (3)
decked  (4)
open (5)
Thoracic injuries
none  (0)
minor  (1)
moderate  (2)
severe  (3)
decked  (4)
open (5)
Abdominal injuries
none  (0)
minor  (1)
moderate  (2)
severe  (3)
decked  (4)
open (5)
spinal injuries
none  (0)
minor  (1)
moderate  (2)
severe  (3)
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decked  (4)
open (5)
pelvic injuries
none  (0)
minor  (1)
moderate  (2)
severe  (3)
decked  (4)
open (5)
arm injuries
none  (0)
minor  (1)
moderate  (2)
severe  (3)
decked  (4)
open (5)
Leg injuries
none  (0)
minor  (1)
moderate  (2)
severe  (3)
decked  (4)
open (5)
Soft tissue injuries
none  (0)
minor  (1)
moderate  (2)
severe  (3)
decked  (4)
open (5)
Mechanism of injury
blunt (1)
penetrating (2)
Fall
m
<3 (1)
>3 (2)
Traffic accident
pedestrian (1)
motorcyclist (2)
cyclist (3)
inside car/truck (4)
other (5)
Violence
blunt force (1)
stabbing (2)
shooting (3)
other (4)
violent crime (5)
Burn/scalding injuries
%
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I° (__)
II° (__)
III° (__)
IV° (__)
chemical burn
Yes
No
Burial alive
Yes
No
Patient was jammed
Yes
No
Inhalation injury
Yes
No
Electrical injury
Yes
No
Near drowning
Yes
No
scuba accident
Yes
No
Hemorrhagic Shock
Yes
No
Other injuries
Initial diagnosis
Please specify initial Diagnosis
Injury-illness index
I° negligible (1)
II° minor (2)
III° moderate (3)
IV° threat to life cannot be ruled out (4)
V° acute threat to life (5)
VI° resuscitation (6)
VII° Death (7)
palliative situation (8)
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Chronological development description
Emergency Physician protocol DIVI
DIVI-Protocol for documentation purposes of emergency
medical response by emergency physicians (Version 5.1
2015) Deutsche interdisziplinaere Vereinigung fuer Intensiv
und Notfallmedizin DIVI (German interdisciplinary
association for intensive and emergeny medical care)
All rights reserved. Please visit https://medical-data-
models.org/forms/12508
Chronological development
description Emergency Physician
protocol DIVI
Development description
Heart rate
>= 0
bpm
Heart rate Time
Blood pressure (BP)
mmHg
Blood pressure time
Start cardiopulmonary resuscitation
End cardiopulmonary resuscitation
Defibrillation
Defibrillation joule
Intubation
tracheal Extubation
Adrenaline during resuscitation
Amiodarone during resuscitation
Patient transport
Oxygen flow rate
l/min
Oxygen saturation
SaO2%
etCO2
mmHg
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Medication Emergency Physician protocol
DIVI
DIVI-Protocol for documentation purposes of emergency
medical response by emergency physicians (Version 5.1
2015) Deutsche interdisziplinaere Vereinigung fuer Intensiv
und Notfallmedizin DIVI (German interdisciplinary
association for intensive and emergeny medical care)
All rights reserved. Please visit https://medical-data-
models.org/forms/12509
Medication Emergency Physician
protocol DIVI
Medication given
No medication given
Yes
No
Medication name
Medication Dose
Lysis
befor cardiac arrest (1)
during cardiac arrest (2)
after ROSC (3)
Start of Lysis
Medication given by paramedic
Epinephrine
Yes
No
Amiodarone
Yes
No
Glucose
Yes
No
Inhaled bronchodilator therapy
Yes
No
Analgesics
Yes
No
Benzodiazepines
Yes
No
Nitroglycerin
Yes
No
Any other Medication administered
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Yes
No
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Resuscitation Emergency Physician
protocol DIVI
DIVI-Protocol for documentation purposes of emergency
medical response by emergency physicians (Version 5.1
2015) Deutsche interdisziplinaere Vereinigung fuer Intensiv
und Notfallmedizin DIVI (German interdisciplinary
association for intensive and emergeny medical care)
All rights reserved. Please visit https://medical-data-
models.org/forms/12510
Resuscitation Emergency Physician
protocol DIVI
Resuscitation/Death/determination of
death
Resuscitation
ROSC during resuscitation (1)
no ROSC (2)
futile (3)
Resuscitation started by
first aid  (1)
first responder (2)
emergency medical service (3)
emergency physician (4)
No Resuscitation
not wanted/patients provision (1)
too late (2)
terminal disease (3)
other (4)
Hospital admission
ROSC (1)
ongoing resuscitation (2)
Death
Yes
No
Determination of death
natural cause (1)
not natural (2)
undetermined (3)
Time of Death
Time of Death unknown
Yes
No
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Study Completion-Further Examinations Stem-
Cell Transplantation CASLAMB NCT00148148
A Study of Caspofungin, Liposomal Amphotericin B or the
Combination of Both for Patients After Stem-Cell
Transplantation NCT00148148
All rights reserved. Please visit https://medical-data-
models.org/forms/12518
Study Completion-Further
Examinations Stem-Cell
Transplantation CASLAMB
NCT00148148
Optional Microbiological tests
Microbiological method
Date
Pathogen Detection
nein (1)
ja (2)
Other examinations
Case conference
Diagnosis
date
Case conference
Case conference
diagnosis
date
Detection of infection status
Existence of a probable or secured invasive
fungal disease according to MSG EORTC criteria
Yes
No
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Study Completion - Discontinuation Stem-Cell
Transplantation CASLAMB NCT00148148
A Study of Caspofungin, Liposomal Amphotericin B or the
Combination of Both for Patients After Stem-Cell
Transplantation
NCT00148148
All rights reserved. Please visit https://medical-data-
models.org/forms/12520
Study Completion - Discontinuation
Stem-Cell Transplantation CASLAMB
NCT00148148
Kriterien Beendigung – Abbruch
Date
dd/mm/yyyy
Reguläres Ende der Studienteilnahme
Detection of engraftment
Ja
Nein
Persistent defervescence
Ja
Nein
Vorzeitiger Abbruch
Withdrawal of consent
Ja
Nein
Inclusion criteria not complied
Ja
Nein
Non-haematological event (grade 3/4)
Ja
Nein
Proof of fungal infection
Ja
Nein
Need for medication listed under the Exclusion
criteria
Ja
Nein
Pregnancy
Ja
Nein
Participation is not best interest for patient or
study
Ja
Nein
Death
Ja
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Nein
Comments
Abschluss
Infection Status
Ja
Nein
Fungal Infection
Survival Status
Ja
Nein
Survival Status
dd/mm/yyyy
Engraftment
Ja
Nein
Engraftment
dd/mm/yyyy
Graft failure
Ja
Nein
Graft failure
Graft-versus-host disease
I (1)
II (2)
III (3)
IV (4)
Study Completion
Ende der regulären Behandlung (1)
Vorzeitiger Abbruch (2)
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NCT00148148
Study Completion-Physical Examination Stem-
Cell Transplantation CASLAMB NCT00148148
A Study of Caspofungin, Liposomal Amphotericin B or the
Combination of Both for Patients After Stem-Cell
Transplantation
NCT00148148
All rights reserved. Please visit https://medical-data-
models.org/forms/12523
Study Completion-Physical
Examination Stem-Cell
Transplantation CASLAMB
NCT00148148
körperliche Untersuchung
Datum der Untersuchung
Medical history
Kopf und Hals (Beschreibung)
Lymphknoten
normal (1)
abnormal (2)
not known (3)
not done (4)
Kardiovaskuläres System
normal (1)
abnormal (2)
not known (3)
not done (4)
Lunge
normal (1)
abnormal (2)
not known (3)
not done (4)
Abdomen
normal (1)
abnormal (2)
not known (3)
not done (4)
Genital / Rektal
normal (1)
abnormal (2)
not known (3)
not done (4)
Muskuloskeletal /
Extremitäten
normal (1)
abnormal (2)
not known (3)
not done (4)
Haut
normal (1)
abnormal (2)
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not known (3)
not done (4)
Nervensystem
normal (1)
abnormal (2)
not known (3)
not done (4)
Other Examination
Vitalparameter
Größe
Gewicht
>= 0
kg
KOF berechnet
>= 0
m²
Körpertemperatur
°C
Herzfrequenz
>= 0
bpm
Atemfrequenz
/min
Blutdruck
mmHg
Karnofsky Index
%
Mukositis, Grad WHO
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CASLAMB NCT00148148
Procedures Emergency Physician protocol
DIVI
DIVI-Protocol for documentation purposes of emergency
medical response by emergency physicians (Version 5.1
2015) Deutsche interdisziplinaere Vereinigung fuer Intensiv
und Notfallmedizin DIVI (German interdisciplinary
association for intensive and emergeny medical care)
All rights reserved. Please visit https://medical-data-
models.org/forms/12525
Procedures Emergency Physician
protocol DIVI
Venipuncture
peripheral venous access
Yes
No
intraosseous needle
Yes
No
transnasal approach
Yes
No
Location of devices
size size of devices
Type of devices
Number of devices applied
difficult venipuncture
>2 tries (1)
impossible,change of approach (2)
Airway
Oxygen
l/min
Preoxygenation
Yes
No
Suction of patient
Yes
No
bag valve mask ventilation
demand valve (1)
controlled (2)
impossible (3)
supraglottic airway device
larynx mask (1)
larynx tube (2)
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other (3)
Endotracheal intubation
orally (1)
nasal (2)
Size of endotracheal tube
Flexible fiberoptic intubation laryngoscope
Yes
No
cricothyrotomy
Yes
No
other airway device
Yes
No
Difficult intubation number of tries
artificial ventilation
manually (1)
mechanical (2)
controlled (3)
assistive (4)
NIV (5)
FiO2
Respiratory Rate
/min
Mandatory Minute volume
Positive endexpiratory pressure
Intravesical pressure at maximum flow
Defibrillation
AED
first aid (1)
first responder (2)
emergency medical service (3)
physician (4)
Defibrillator
monophasic (1)
biphasic (2)
1. Defibrillation Time
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1. Rosc time
Total number of defibrillations
maximum energy for defibrillation
joule
Resuscitation
Cardiac resuscitation massage
manually (0)
feedback system (1)
mechanically assisted chest
compression device (2)
Start of cardiac resuscitation massage
Active cooling of patient
cold Infusion (1)
cold packs (2)
cooling units (3)
CPR instruction by phone
Yes
No
Other measures taken
Special positioning of the patient
recovery position (1)
sitting up position (10)
thermoregulation measures (11)
incubator (12)
other (13)
Cervical spine support (2)
vacuum splint (3)
vacuum mattress (4)
scoop stretcher (5)
spineboard (6)
shock position (7)
head of bed elevation (8)
supine position (9)
12 lead ecg
Yes
No
Infusion pump
Yes
No
wound dressing
Yes
No
pleural drainage system
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right side (1)
left side (2)
Nasogastric intubation
Yes
No
Home childbirth
Yes
No
telemetry of ecg
Yes
No
external cardiac pacemaker
Yes
No
invasive blood pressure
Yes
No
repositioning of fracture
Yes
No
Ultrasound
Yes
No
Cardioversion
Yes
No
Pelvic support
Yes
No
urinary catheterization
Yes
No
Crisis intervention
Yes
No
other
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Days 2-5 Imaging Stem-Cell
Transplantation CASLAMB NCT00148148
A Study of Caspofungin, Liposomal Amphotericin B or the
Combination of Both for Patients After Stem-Cell
Transplantation
NCT00148148
All rights reserved. Please visit https://medical-data-
models.org/forms/12528
Days 2-5 Imaging Stem-Cell
Transplantation CASLAMB
NCT00148148
Weitere Verfahren
Verfahren
Ergebnis
Datum des Verfahrens
weitere Verfahren
Ja
Nein
Konsiliaruntersuchungen
Konsil
Diagnose
Datum
Erfassung des Infektionsstatus
Vorliegen einer wahrscheinlichen bzw.
gesicherten
invasiven Pilzinfektion nach MSG-EORTC-
Kriterien
Ja
Nein
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Patient referral Emergency Physician
protocol DIVI
DIVI-Protocol for documentation purposes of emergency
medical response by emergency physicians (Version 5.1
2015) Deutsche interdisziplinaere Vereinigung fuer Intensiv
und Notfallmedizin DIVI (German interdisciplinary
association for intensive and emergeny medical care)
All rights reserved. Please visit https://medical-data-
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Patient referral Emergency Physician
protocol DIVI
Vital signs at patient referral
Time of transfer
GCS at transfer time
Blood pressure
mmHg
Heart rate
>= 0
bpm
Heart Rate
rhythmical (1)
arrhythmical (2)
Blood Glucose
Unit used for measuring blood glucose
mg/dl (1)
mmol/l (2)
Blood Glucose low
Yes
No
Blood glucose high
Yes
No
Respiratory rate
/min
SaO2
Body Temperature
°C
etCO2
mmHg
Pain scale
0 no pain at all (0)
1 (1)
10 unbearable pain (10)
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2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
7 (7)
8 (8)
9 (9)
ECG findings
not done (0)
sinus rhthm (1)
small complex tachycardia (10)
wide complex tachycardia (11)
SVES/VES monomorph (12)
VES polymorph (13)
arrhythmia absoluta (2)
AV-block II° (3)
AV-block III° (4)
pacemaker (5)
artrial fibrillation (6)
electro-mechanical dissociation (7)
asystole (8)
STEMI (9)
Respiratory pattern
not examined (0)
without pathological finding (1)
hyperventilation (10)
choking (11)
rattling sound (12)
Dyspnea (2)
gasping (3)
Apnea (4)
artificial ventilation (5)
other pathological breathing pattern (6)
stridor (7)
cyanosis (8)
spasticity (9)
state of consciousness
not examined (0)
alert (1)
sleepy (2)
unconscious (3)
response to verbal stimulus (4)
response to pain stimulus (5)
anesthetized (6)
can not be assessed (7)
Mission development particularities
Referral from emergency vehicle with emergency
physician
Yes
No
Referral to emergency vehicle with emergency
physician
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Yes
No
Transport mode to hospital
with physician attendance (1)
by helicopter (2)
at least one hospital declines patient (3)
forced referral to hospital (4)
compulsory care (5)
examination and treatment without transport
patient declines transport (1)
patient not fit for transport (2)
treatment abandoned/limited (deliberate)
(3)
Increased cleaning effort
Yes
No
difficult patient access
Yes
No
Technical rescue required
Yes
No
Heavy transport required
Yes
No
Mass casualties
Yes
No
Coordinating emergency physician on site
Yes
No
Treatment of more than one patient
Yes
No
Patient referral
Patient remitted to
none (0)
at site (1)
cardiac catheter lab (10)
chest pain unit (11)
general ward (12)
other (13)
emergency room (2)
stroke unit (3)
intensive care (4)
surgical theater (5)
doctors office (6)
general practitioner (7)
3 / 4
Patient referral Emergency Physician protocol DIVI
special outpatient service (8)
resuscitation room (9)
receiving caregiver name
Comments
Further comments
Signature
Signature of emergency physician
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Medical History/ Concomitant Diseases  Stem-
Cell Transplantation CASLAMB NCT00148148
A Study of Caspofungin, Liposomal Amphotericin B or the
Combination of Both for Patients After Stem-Cell
Transplantation
NCT00148148
All rights reserved. Please visit https://medical-data-
models.org/forms/12535
Medical History/ Concomitant
Diseases  Stem-Cell Transplantation
CASLAMB NCT00148148
Tag der Erhebung
Datum der Erhebung der Begleiterkrankungen
Keine Krankengeschichte
Ja
Nein
Vor-/Begleiterkrankungen
Körpersystem-Code
Ophthalmologisch   (1)
Neurologisch (10)
Urogenital  (11)
Hmatologisch (12)
Immunologisch (13)
Psychiatrisch (14)
Otorhinolaryngologisch (2)
Arzneimittelallergien   (3)
Endokrinol ogisch  (4)
Dermatologisch (5)
Pulmonal (6)
Cardiovaskulr (7)
Gastrointestinal  (8)
Muskuloskeletal (9)
Diagnose
Status
restored (1)
stable (2)
unstable (3)
Kommentare
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Days 2-5 Medication Stem-Cell
Transplantation CASLAMB NCT00148148
A Study of Caspofungin, Liposomal Amphotericin B or the
Combination of Both for Patients After Stem-Cell
Transplantation
NCT00148148
All rights reserved. Please visit https://medical-data-
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Days 2-5 Medication Stem-Cell
Transplantation CASLAMB
NCT00148148
Medication Days 2-5
Datum Medikation
Biposomal Amphotericin B
Biposomal Amphotericin B
Ja
Nein
Soll-Dosis (3 mg/kg KG)
mg / kg
Kumulative Dosis
Infusionsbeginn
Infusionsende
Caspofungin
Caspofungin
Ja
Nein
Kumulative Dosis
Infusionsbeginn
Infusionsende
Begleitmedikation
Concomitant medication log and adverse event
log updated?
Ja
Nein
Are the termination criteria fulfilled ?
Ja
Nein
Tag 4: Blutentnahmen für die Analyse der
Plasmakonzentrationen
1 / 2
Blood sample 1
Blood sample 2
Blood sample 3
Blood sample 4
Blood sample 5
Datum und Unterschrift
Datum, Unterschrift
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Days 2-5 Medication Stem-Cell Transplantation CASLAMB
NCT00148148
Baseline-Imaging Stem-Cell Transplantation
CASLAMB NCT00148148
A Study of Caspofungin, Liposomal Amphotericin B or the
Combination of Both for Patients After Stem-Cell
Transplantation
NCT00148148
All rights reserved. Please visit https://medical-data-
models.org/forms/12537
Baseline-Imaging Stem-Cell
Transplantation CASLAMB
NCT00148148
Röntgen-Thorax
Date
Pathology
ohne pathologischen Befund (1)
Befund vereinbar mit einer Pilzinfektion
(2)
anderer Befund (3)
Other pathology
HR-CT der Lungen
Date
Finding
ohne pathologischen Befund (1)
Befund vereinbar mit einer Pilzinfektion
(2)
anderer Befund (3)
Other pathology
CT Scan not performed
Reason (1)
Weitere Verfahren
Verfahren
Ergebnis
Datum des Verfahrens
weitere Verfahren
Ja
Nein
Konsiliaruntersuchungen
Konsil
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Diagnose
Datum
Erfassung des Infektionsstatus
Vorliegen einer wahrscheinlichen bzw.
gesicherten invasiven Pilzinfektion nach MSG-
EORTC-Kriterien
Ja
Nein
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Day of last Dose-Physical Examination Stem-
Cell Transplantation CASLAMB NCT00148148
A Study of Caspofungin, Liposomal Amphotericin B or the
Combination of Both for Patients After Stem-Cell
Transplantation
NCT00148148
All rights reserved. Please visit https://medical-data-
models.org/forms/12540
Day of last Dose-Physical
Examination Stem-Cell
Transplantation CASLAMB
NCT00148148
Physical examination
Physical Examination Date
Medical History
Head and neck
Lymph nodes
normal (1)
abnormal (2)
not known (3)
not done (4)
Cardiovascular examination
normal (1)
abnormal (2)
not known (3)
not done (4)
Lung
normal (1)
abnormal (2)
not known (3)
not done (4)
Abdomen
normal (1)
abnormal (2)
not known (3)
not done (4)
Genital / Rectal
normal (1)
abnormal (2)
not known (3)
not done (4)
Musculoskeletal system physical examination
normal (1)
abnormal (2)
not known (3)
not done (4)
Examination of skin
normal (1)
abnormal (2)
not known (3)
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not done (4)
Neurologic Examination
normal (1)
abnormal (2)
not known (3)
not done (4)
Other Examination
Vital Signs
Body Height
cm
Weight
>= 0
kg
BSA calculated
>= 0
m²
Body Temperature
°C
Heart rate
>= 0
bpm
respiratory rate
/min
Blood Pressure
mmHg
systolic (1)
diastolic (2)
Karnofsky Index
%
Mukositis, Grad WHO
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Day of last Dose-Physical Examination Stem-Cell Transplantation
CASLAMB NCT00148148
Day of last Dose-Medication Stem-Cell
Transplantation CASLAMB NCT00148148
A Study of Caspofungin, Liposomal Amphotericin B or the
Combination of Both for Patients After Stem-Cell
Transplantation
NCT00148148
All rights reserved. Please visit https://medical-data-
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Day of last Dose-Medication Stem-
Cell Transplantation CASLAMB
NCT00148148
Medikation am Tag der letzten Gabe
Datum Medikation
Biposomal Amphotericin B
Biposomal Amphotericin B
Ja
Nein
Soll-Dosis (3 mg/kg KG)
Absolute -Dosis
Infusionsbeginn
Infusionsende
caspofungin
caspofungin
Ja
Nein
absolute dose
Infusionsbeginn
Infusionsende
Begleitmedikation
Begleitmedikations-Log und Adverse Event-Log
ausgefüllt?
Ja
Nein
Abbruchkriterien erfüllt?
Ja
Nein
Datum und Unterschrift
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Datum, Unterschrift
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Day of last Dose-Medication Stem-Cell Transplantation CASLAMB
NCT00148148
Eligibility 11q-deleted Relapsed/Refractory Chronic
Lymphocytic Leukaemia (CLL), NCT01955668
AZD6738 First Time in Patient Multiple Ascending Dose
Study; ODM derived from:
https://clinicaltrials.gov/show/NCT01955668
All rights reserved. Please visit https://medical-data-
models.org/forms/12543
Eligibility 11q-deleted
Relapsed/Refractory Chronic
Lymphocytic Leukaemia (CLL),
NCT01955668
Inclusion Criteria
Signed informed consent*
Yes
No
b cell malignancy*
Yes
No
refractory cll*
Yes
No
Performance status (ECOG):*
Yes
No
Not positive with Communicable diseases*
Yes
No
females of childbearing potential must be using
adequate contraceptive measures and not be
breastfeeding*
Yes
No
Postmenopausal*
Yes
No
irreversible surgical sterilisation*
Yes
No
Hormone levels in postmenopausal range and
amenorrhoeic for 12 months*
Yes
No
ability to swallow and retain oral medication*
Yes
No
Exclusion Criteria
cancer treatment during 4 weeks prior to study
entry*
Yes
No
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Concomitant Medication with corticosteroids*
>= 10
mg
Yes
No
Hypersensitivity to the trial drug or the excipients*
Yes
No
Subject Participation Status in Clinical Study
within 28 days prior to IC*
Yes
No
Concomitant Medication modulating cyp3a4 or
pgp activity*
Yes
No
impaired hepatic function*
albumin < 33g/l (1)
ast or alt > 2.5 x uln (2)
total bilirubin > 1.5 x uln (3)
alkaline phosphatase > 2.5 x uln (4)
Impaired renal function*
glomerular filtration rate (gfr) < 50 ml/min
(1)
serum creatinine > 1.5 x uln 	 (2)
haematuria: +++ on microscopy or
dipstick (3)
Unstable or worsening liver or renal dysfunction*
Yes
No
inr > 1.5 or other evidence of impaired hepatic
synthesis function*
Yes
No
cns involvement with malignancy*
Yes
No
cardiac dysfunction*
myocardial infarction (1)
nyha class ii/iii/iv heart failure (2)
unstable angina (3)
unstable cardiac arrhythmias (4)
reduced lvef < 55% (5)
any of the following cardiac criteria*
mean resting corrected qt interval (qtc)
>470 msec obtained from 3
electrocardiograms (ecgs) in 24 hours
(1)
any clinically important abnormalities in
rhythm (2)
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Eligibility 11q-deleted Relapsed/Refractory Chronic Lymphocytic
Leukaemia (CLL), NCT01955668
any clinically important abnormalities in
conduction (3)
any clinically important abnormalities in
morphology (4)
risk of qtc prolongation or risk of arrhythmic
events*
Yes
No
patients at risk of brain perfusion problems*
Yes
No
hypotension*
Yes
No
uncontrolled hypertension*
Yes
No
any other malignancy which has been active or
treated within the past three years, with the
exception of cervical intra-epithelial neoplasia
and non-melanoma skin cancer*
Yes
No
Comorbidity that would preclude adequate
absorption of azd6738*
Yes
No
patients with uncontrolled seizures*
Yes
No
active infection requiring systemic antibiotics,
antifungal or antiviral drugs*
Yes
No
concurrent severe and/or uncontrolled medical
condition (e.g., severe copd, severe parkinson's
disease, active inflammatory bowel disease) or
psychiatric condition*
Yes
No
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Eligibility 11q-deleted Relapsed/Refractory Chronic Lymphocytic
Leukaemia (CLL), NCT01955668
Eligibility Abdominal Obesity NCT00992641
The Effect of Nordic Recommended Diet on the Features of
Metabolic Syndrome - Multicentre Study; ODM derived
from: https://clinicaltrials.gov/show/NCT00992641
All rights reserved. Please visit https://medical-data-
models.org/forms/12544
Eligibility Abdominal Obesity
NCT00992641
Inclusion Criteria
Age*
>= 30
<= 65
years
Yes
No
Body Mass Index*
>= 27
<= 38
kg/m2
Yes
No
two other idf criteria for metabolic syndrome*
Yes
No
anti-hypertensives and lipid-lowering medication
are allowed*
Exclusion Criteria
fasting plasma glucose*
>= 7.0 mmol/l
Yes
No
fasting plasma triglycerides*
>= 3.0 mmol/l
Yes
No
fasting plasma total cholesterol*
>= 6.5 mmol/l
Yes
No
blood pressure*
>= 160/100
mmHg
Yes
No
Weight loss or weight change*
>= 5
%
Yes
No
any disease or condition that may hamper the
successful participation of the intervention*
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Yes
No
alcohol abuse*
>= 40
g/day
Yes
No
oral corticosteroid therapy*
Yes
No
severe psychiatric disorders*
Yes
No
cancer under treatment*
Yes
No
coeliac disease*
Yes
No
exceptional diets*
Yes
No
binge eating*
Yes
No
unwillingness to discontinue the use of dietary
supplements*
Yes
No
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Eligibility - Parkinson's Disease
NCT01792843
Cognitive Phenotypes in Parkinson's Disease; ODM
derived from: https://clinicaltrials.gov/show/NCT01792843
All rights reserved. Please visit https://medical-data-
models.org/forms/12545
Eligibility - Parkinson's Disease
NCT01792843
Inclusion Criteria
Patient sex*
Female (Female)
Male (Male)
Age 18-80*
<= 80
>= 18
Yes
No
Parkinson disease as classified in international
standarts*
Yes
No
Patients without neurological comorbidity*
Yes
No
Patients with health insurance*
Yes
No
Signed informed consent*
Yes
No
Exclusion Criteria
pregnant or breastfeeding women*
Yes
No
parkinsonian syndrome other than pd*
Yes
No
currently participating in another clinical trial or
study;*
Yes
No
patient whose physical or mental condition is
incompatible with the study assessments*
Yes
No
provided for by legal guardian*
Yes
No
subjects with claustrophobia*
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Yes
No
MRI contraindication*
Yes
No
pd patients treated by deep brain stimulation*
Yes
No
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Eligibility Abdominal Obesity NCT02343107
E-coaching for Type 2 Diabetes; ODM derived from:
https://clinicaltrials.gov/show/NCT02343107
All rights reserved. Please visit https://medical-data-
models.org/forms/12546
Eligibility Abdominal Obesity
NCT02343107
Inclusion criteria
Age and Consent
>= 18
<= 75
Yes
No
Abdominal obesity defined by waist
circumference
men≥ 102cm (1)
women≥ 88cm (2)
Diabetes mellitus and hba1c measurement the
month prior to selection
>= 5,6
<= 8,5
hba1c
Yes
No
Must have already received a standard nutrition
education
Yes
No
estimated average calorie intake between 1200
and 4000 calories
>= 1200
<= 4000
Kcal
Yes
No
Under stable treatment for at least 3 months
Yes
No
Weight change of no more than 4kg 3 months
prior to enlistment and without restrictive diet
Yes
No
Having Health Insurance or comparable health
coverage
Yes
No
access to internet and usual use, possession of
an email address
Yes
No
understanding and reading french
Yes
No
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Exclusion criteria
Alcohol abuse
>= 30
g/day
Yes
No
symptomatic cardiovascular disease
Yes
No
subject receiving general or local treatment that
may interfere with the assessment of the primary
endpoint
Yes
No
situation requiring rapid equilibration of diabetes
Yes
No
subject with any severe or acute illness which
may influence the results of the study or to life-
threatening
Yes
No
subject in a situation which, in the opinion of the
investigator, would interfere with the optimal
participation in the study or be a particular risk to
the patient
Yes
No
patient who underwent obesity surgery to the
exclusion of a gastric band, loosened or removed
for more than a year
Yes
No
for female subjects: pregnancy or lactation, or
subject may become pregnant during the study
Yes
No
for female subjects: subject may change hormone
treatment under study (contraceptive or hormone
replacement)
Yes
No
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Eligibility Acromioclavicular Joint Arthritis
NCT01040065
Distal Clavicle Resection With Rotator Cuff Repair; ODM
derived from: https://clinicaltrials.gov/show/NCT01040065
All rights reserved. Please visit https://medical-data-
models.org/forms/12547
Eligibility Acromioclavicular Joint
Arthritis NCT01040065
Inclusion Criteria
rotator-cuff tear requiring repair*
Yes
No
acromioclavicular joint tenderness more than
moderate(pain visual analogue scale 4-7)*
Yes
No
acromioclavicular arthritis(petersson grade ii-iii)*
Yes
No
Exclusion Criteria
arthritic changes of glenohumeral joint*
Yes
No
combined infection*
Yes
No
Prior mini-open, open procedures*
Yes
No
complete subscapularis tear*
Yes
No
incomplete repair*
Yes
No
neurologic abnormality including axillary nerve*
Yes
No
adhesive capsulitis*
Yes
No
prior surgery, trauma, or infection on shoulder
girdle*
Yes
No
slap lesion or biceps tendon lesion without
rotator-cuff tear or impingement syndrome*
Yes
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No
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Eligibility Actinic Cheilitis NCT00868088
Photodynamic Therapy to Treat Actinic Damage in Patients
With Squamous Cell Carcinoma (SCC) of the Lip; ODM
derived from: https://clinicaltrials.gov/show/NCT00868088
All rights reserved. Please visit https://medical-data-
models.org/forms/12548
Eligibility Actinic Cheilitis
NCT00868088
Inclusion Criteria
biopsy proven squamous cell carcinoma of the
lip*
Yes
No
more than half of lip affected by actinic cheilitis by
physical exam at time of initial evaluation.*
Yes
No
patients > 18 years of age*
Yes
No
patients must be able to provide informed
consent*
Yes
No
Exclusion Criteria
patients with history of photosensitivity*
Yes
No
patients with medical conditions associated with
photosensitivity, such as cutaneous porphyria or
a collagen vascular disease*
Yes
No
patients taking medications known to cause
photosensitivity*
Yes
No
patients with hypersensitivity to porphyrins.*
Yes
No
women who are pregnant or nursing*
Yes
No
patients who have received anti-neoplastic
treatment to the lips within 30 days of enrolling in
this study.*
Yes
No
patients simultaneously participating in another
1 / 2
research study for management of scc or actinic
cheilitis*
Yes
No
subjects that plan to use other forms of ac
treatment prior to mohs.*
Yes
No
subjects that have an scc requiring urgent (and
sooner) mohs surgery, including those tumors
that are large (> 2cm or at the discretion of the
principle investigator) and those subjects that
have palpable lymph nodes.*
Yes
No
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Eligibility Actinic Keratosis NCT01260987
Fractional CO2 Laser Assisted Photodynamic Therapy;
ODM derived from:
https://clinicaltrials.gov/show/NCT01260987
All rights reserved. Please visit https://medical-data-
models.org/forms/12549
Eligibility Actinic Keratosis
NCT01260987
Inclusion Criteria
age 18 or older*
>= 18
yrs
must be skin type I-III*
Yes
No
fertile women using secure birth control*
moderate to severe actinic keratoses in the face
or on the hands,*
Yes
No
difficult to treat nodular basal cell carcinomas in
the face*
Yes
No
Exclusion Criteria
Must not be pregnant or breast feeding*
Yes
No
patients with porphyria*
Yes
No
patients with gorlins syndrome*
Yes
No
patients with a tendency to produce hypertrophic
scars or keloids*
Yes
No
patients with known allergy to metvix*
Yes
No
patients who are not considered able to follow the
treatment protocol*
Yes
No
patients with pigmented or morphea basal cell
carcinomas*
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Yes
No
known herpes simplex virus infection in treatment
areas*
Yes
No
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Eligibility Active Rheumatoid Arthritis;
Rheumatoid Arthritis NCT01480388
A Dose Range Finding Study of JNJ-39758979 in Patients
With Active Rheumatoid Arthritis Currently Treated With
Methotrexate; ODM derived from:
https://clinicaltrials.gov/show/NCT01480388
All rights reserved. Please visit https://medical-data-
models.org/forms/12555
Eligibility Active Rheumatoid
Arthritis; Rheumatoid Arthritis
NCT01480388
Inclusion Criteria
has a diagnosis of rheumatoid arthritis (ra) for at
least 6 months before screening.*
Yes
No
positive test for either anti-cyclic citrullinated
peptide (anti-ccp) antibody or rheumatoid factor
(rf) in serum at screening.*
Yes
No
has active ra defined as persistent disease
activity with the following criteria: at least 6
swollen and 6 tender joints, and serum crp ≥ 0.70
mg/dl at screening.*
Yes
No
has been treated with and tolerated methotrexate
(mtx) treatment at dosages of 10 to 25 mg/week
for a minimum of 6 months prior to screening and
must be on a stable dose for a minimum of 8
weeks prior to screening*
Yes
No
must be post-menopausal or if pre-menopausal,
must use an acceptable form of birth control*
Yes
No
has completed at least 5 days of daily pain diary
in the 10 days prior to randomization.*
Yes
No
Exclusion Criteria
has inflammatory diseases other than ra, such as
lupus.*
Yes
No
is currently receiving treatment for ra other than
methotrexate, nsaids, or oral corticosteroids such
as prednisone, or pain medicines.*
Yes
No
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has ever received any biologic agent for a
rheumatic indication.*
Yes
No
has current signs or symptoms of liver
insufficiency or cardiac, vascular, pulmonary,
gastrointestinal, endocrine, neurologic,
hematologic, psychiatric, or metabolic
disturbances that are severe, progressive, or
uncontrolled.*
Yes
No
has moderate or severe renal insufficiency*
Yes
No
has a recent (within 2 months) serious infection*
Yes
No
has had an opportunistic infection.*
Yes
No
has had cancer within the past 5 years (except
certain skin or cervical conditions)*
Yes
No
has abused substances or alcohol within the past
2 years*
Yes
No
has active hepatitis b or c infection*
Yes
No
has had active tuberculosis*
Yes
No
has had exposure to  tuberculosis without
preventative treatment*
Yes
No
2 / 2
Eligibility Active Rheumatoid Arthritis; Rheumatoid Arthritis
NCT01480388
Examination_Riliva_CRF_EudraCT - Nr.
2012-000108-13
Study documentation part: Examination Week- 4, 8 and 12.
This is a phase II multicenter trial with Rivaroxaban in the
treatment of livedoid vasculopathy assessing the pain on a
visual analog scale (VAS).  Principal Investigator PD Dr.
Tobias Grge, University Hospital of Mnster. EudraCT - Nr.
2012-000108-13.
All rights reserved. Please visit https://medical-data-
models.org/forms/12557
Examination_Riliva_CRF_EudraCT -
Nr. 2012-000108-13
Vitalparameter
Untersuchung Woche Nr.
Woche 4 (1)
Woche 8 (2)
Woche 12 (3)
Visite konnte durchgeführt werden
ja (1)
nein Studienabbruch, sofern seit der
Einwilligung des Patienten
Unerwünschte Ereignisse (AE´s)
aufgetreten  (2)
sind, bitte auf AE-Bogen dokumentieren.
(sind, bitte auf AE-Bogen
dokumentieren.)
Datum der Visite = 1. Tag der Gabe
Prüfmedikation
Größe
cm
Gewicht
kg
Puls
beats/min
Dosierung Notfallmedikation, Enoxaparin-Natrium
mg
20 mg (1)
40 mg (2)
60 mg (3)
80 mg (4)
100 mg (5)
Systolischer Blutdruck Arm links
mmHg
Diastolischer Blutdruck Arm links
mmHg
Systolischer Blutdruck Arm rechts
mmHg
Diastolischer Blutdruck Arm rechts
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mmHg
Systolischer Blutdruck Unterschenkel/Knöchel
links
mmHg
Diastolischer Blutdruck Unterschenkel/Knöchel
links
mmHg
Systolischer Blutdruck Unterschenkel/Knöchel
rechts
mmHg
Diastolischer Blutdruck Unterschenkel/Knöchel
rechts
mmHg
Chronisch venöse Insuffizienz nach Widmer
nein (1)
ja, Grad I (2)
ja, Grad II (3)
ja, Grad III (4)
Hämoglobin
g/dL
Thrombozyten-Transfusionen in den letzten 30
Tagen?
Ja
Nein
Hautuntersuchung (linker Unterschenkel /
Fuß)
Anzahl der aktiven Läsionen
Unterschenkelrückseite proximal
Anzahl der Läsionen in Abheilung
Unterschenkelrückseite proximal
Anzahl der aktiven Läsionen
Unterschenkelrückseite distal
Anzahl der Läsionen in Abheilung
Unterschenkelrückseite distal
Anzahl der aktiven Läsionen
Unterschenkelvorderseite proximal
Anzahl der Läsionen in Abheilung
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Unterschenkelvorderseite proximal
Anzahl der aktiven Läsionen
Unterschenkelvorderseite distal
Anzahl der Läsionen in Abheilung
Unterschenkelvorderseite distal
Anzahl der aktiven Läsionen Sprunggelenk lateral
Anzahl der Läsionen in Abheilung Sprunggelenk
lateral
Anzahl der aktiven Läsionen Sprunggelenk
medial
Anzahl der Läsionen in Abheilung Sprunggelenk
medial
Anzahl der aktiven Läsionen Fußrücken
Anzahl der Läsionen in Abheilung Fußrücken
Anzahl Atrophie blanche Herde linker
Unterschenkel / Fuß
Hautuntersuchung (rechter Unterschenkel
/ Fuß)
Anzahl der aktiven Läsionen
Unterschenkelrückseite proximal
Anzahl der Läsionen in Abheilung
Unterschenkelrückseite proximal
Anzahl der aktiven Läsionen
Unterschenkelrückseite distal
Anzahl der Läsionen in Abheilung
Unterschenkelrückseite distal
Anzahl der aktiven Läsionen
Unterschenkelvorderseite proximal
Anzahl der Läsionen in Abheilung
Unterschenkelvorderseite proximal
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Anzahl der aktiven Läsionen
Unterschenkelvorderseite distal
Anzahl der Läsionen in Abheilung
Unterschenkelvorderseite distal
Anzahl der aktiven Läsionen Sprunggelenk lateral
Anzahl der Läsionen in Abheilung Sprunggelenk
lateral
Anzahl der aktiven Läsionen Sprunggelenk
medial
Anzahl der Läsionen in Abheilung Sprunggelenk
medial
Anzahl der aktiven Läsionen Fußrücken
Anzahl der Läsionen in Abheilung Fußrücken
Anzahl Atrophie blanche Herde rechter
Unterschenkel / Fuß
LV - Score (adaptiert n. Kreuter)
Erythema Score
kein Erythem (1)
leicht (2)
mittel (3)
schwer (4)
Schmerz Score
kein Schmerz (1)
leicht (2)
mittel (3)
schwer (4)
Ulzeration Score
keine Ulzeration (1)
Kruste (2)
Ulzeration ohne Kruste (3)
tiefe Ulzeration (4)
Hautuntersuchung - Livedo racemosa
Livedo racemosa Oberarm
Ja
Nein
Livedo racemosa Unterarm
Ja
Nein
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Livedo racemosa Hand
Ja
Nein
Livedo racemosa Oberschenkel
Ja
Nein
Livedo racemosa Unterschenkel
Ja
Nein
Livedo racemosa Fuß
Ja
Nein
Livedo racemosa Stamm
Ja
Nein
Schmerzstärke auf der Visuellen Analog Skala
(VAS)
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Eligibility Active Systemic Onset JIA
NCT00570661
Phase II, Open Label, International, Multicentre Clinical
Trial to Investigate Safety and Efficacy of Oral ITF2357 in
Patients With Active Systemic Onset Juvenile Idiopathic
Arthritis (SOJIA); ODM derived from:
https://clinicaltrials.gov/show/NCT00570661
All rights reserved. Please visit https://medical-data-
models.org/forms/12559
Eligibility Active Systemic
NCT00570661
Inclusion Criteria
established diagnosis of systemic sojia according
to ilar criteria for at least six months before the
study entry, with inadequate response or
intolerance to standard therapy with oral steroids
and/or methotrexate, with or without previously
used biologic agents.*
Yes
No
active disease for at least one month prior to
enrolment as defined by the following criteria:*
Yes
No
presence of arthritis plus at least one of the
following:*
Yes
No
fever, defined as a body temperature >= 37,5 c
degree at least once a day during at least five
consecutive days or presence of typical sojia
intermittent temperature chart*
Yes
No
rash, defined by presence of typical sojia salmon
pink rash on the trunk and elsewhere during the
febrile episodes*
Yes
No
serositis (pericarditis, pleuritis, peritonitis)
confirmed by ultrasound and/or x-ray exploration
or by presence of typical ecg findings in the case
of pericarditis*
Yes
No
lymphadenopathy, defined by lymph nodes
enlargement to 1,5 cm or more localized
anywhere within the body,  and/or hepatomegaly
and/or splenomegaly,  confirmed by ultrasound
evaluation and established after comparison  to
age standards for organ size*
Yes
No
esr >= 20 mm/h (first hour) and/or crp >= 10 mg/l.
in the absence of arthritis, two definite or one
1 / 4
definite and one probable diagnostic criteria  plus
esr >=20 mm/h (first hour) and/or crp >=10 mg/l*
Yes
No
age at enrolment between  2 and 25 years*
>= 2
<= 25
Yes
No
age at first sojia diagnosis < 16 years*
<= 16
Yes
No
previously introduced standard treatment of
disease with steroids without satisfactory effect
and concomitant treatment with oral steroids at a
dose equivalent to >= 0,2 mg/kg/day of
prednisolone, unmodified for at least four weeks
before patient's enrolment*
Yes
No
6. in case of concomitant methotrexate treatment,
it has to be on stable dose >= 10mg/m2 weekly
for al least 4 weeks before pt enrollment*
Yes
No
previous treatment with biologics, if any, during at
least three months without satisfactory effect or
with drug intolerability, discontinued for at least
the period specified below before patient's
enrolment:*
Yes
No
two months for etanercept*
Yes
No
six months for infliximab*
Yes
No
other disease-modifying anti-rheumatic drugs
possibly previously introduced have to be
discontinued for a period of at least five half lives*
Yes
No
concomitant nonsteroidal anti-inflammatory
drugs, if any, on a stable dose for at least four
weeks before patient's enrolment*
Yes
No
female of childbearing potential, using safe
contraceptive measures*
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Yes
No
signed written informed consent before starting
any study procedure*
Yes
No
Exclusion Criteria
ongoing clinical relevant viral infection*
Yes
No
history of macrophage activation syndrome*
Yes
No
clinically significant illness i.e. any condition
(including laboratory abnormalities) that in the
opinion of the investigator places the patient to
unacceptable risk for adverse outcome if he/she
were to participate in the study*
Yes
No
4. psychiatric illness/social situations that would
limit compliance with study medication and
protocol requirements*
Yes
No
congenital heart and/or central nervous system
disorders*
Yes
No
inherited metabolic diseases*
Yes
No
positive serological testing for anti hcv, anti hiv
and hbsag (to be performed at screening)*
Yes
No
pregnant or lactating women*
Yes
No
presence of malignancy*
Yes
No
any previous evidence, irrespective of its severity,
of coronary disease, cardiac rhythm
abnormalities or congestive heart failure*
Yes
No
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qtc interval > 450 msec at screening evaluation*
>= 450
msec
Yes
No
serum magnesium and potassium below the lln at
screening*
Yes
No
unavoidable concomitant treatment with any drug
known for potential risk of causing torsades de
pointes*
Yes
No
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Eligibility Active, Moderate to Severe
Rheumatoid Arthritis NCT00642629
A Randomized, Double-blind, Placebo-controlled Clinical
Study of the Oral IL-12/23 Inhibitor, STA-5326 Mesylate,
Administered to Patients With Rheumatoid Arthritis to
Determine Safety, Tolerability, Pharmacokinetic and
Synovial Tissue Outcomes; ODM derived from:
https://clinicaltrials.gov/show/NCT00642629
All rights reserved. Please visit https://medical-data-
models.org/forms/12560
Eligibility Active, Moderate to Severe
Rheumatoid Arthritis NCT00642629
Inclusion Criteria
male or female 18 years of age or older.*
Yes
No
has diagnosis of ra in conformance with the
american college of rheumatology (acr) criteria
for at least 6 months.*
Yes
No
has at least one knee, wrist, or ankle that has
active synovitis and is amenable to arthroscopic
procedures for the acquisition of synovial tissue
via biopsy.*
Yes
No
must be taking methotrexate for a minimum of 4
months prior to day 1, with a stable dose regimen
for at least 2 months, and*
Yes
No
have plans to remain on the stable dose regimen
of methotrexate for the duration of this study.*
Yes
No
if female of childbearing potential, must be
neither pregnant nor breast feeding, and*
Yes
No
must have a negative pregnancy test (serum β
-hcg) within 1 week of day 1. must be willing to
use "double-barrier" contraception methods for
the duration of the study.*
Yes
No
Exclusion Criteria
is taking any disease-modifying anti-rheumatic
drug (dmard) other than mtx concomitantly or
within 1 month prior to day 1.*
Yes
No
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a positive (≥10 mm) tuberculin (ppd) skin test,
unless the patient has had prior bcg
immunization or has received prior suppressive
treatment such as 1 year of inh.*
Yes
No
has received any investigational drug or
experimental procedure for the treatment of ra
within 3 months of day 1 for a biologic compound
or within 1 month of day 1 for a non-biologic
compound.*
Yes
No
has any clinically significant disease  that, in the
opinion of the investigator, would make the
patient an unsuitable candidate for this trial.*
Yes
No
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Eligibility Acute Alcoholic Hepatitis
NCT01809132
Efficacy Study of Anakinra, Pentoxifylline, and Zinc
Compared to Methylprednisolone in Severe Acute Alcoholic
Hepatitis; ODM derived from:
https://clinicaltrials.gov/show/NCT01809132
All rights reserved. Please visit https://medical-data-
models.org/forms/12562
Eligibility Acute Alcoholic Hepatitis
NCT01809132
Inclusion Criteria
ability to provide informed consent by subject or
appropriate family member*
Yes
No
age between 21-70 years*
>= 21
<= 70
Yes
No
3. recent alcohol consumption > 50 g/d for > 6
months, continuing within two months before
enrollment*
>= 50
g/day
Yes
No
at least 2 of the following symptoms of acute
alcoholic hepatitis: anorexia, nausea, right upper
quadrant pain, jaundice, leukocytosis,
hepatomegaly and*
Yes
No
5. elevation of ast > 80 u/l within 3 days of
baseline, but < 500 u/l; ast > alt and alt < 200 u/l;
total bilirubin > 3 mg/dl.*
Yes
No
liver biopsy showing alcoholic hepatitis
(steatohepatitis) or ultrasound of liver showing
increased echogenicity or ct scan showing
decreased attenuation of liver compared to
spleen or mri showing fatty liver (decreased
signaling intensity on t1 weighted images) if liver
biopsy confirms diagnosis of alcoholic hepatitis
then requirement for ast elevation > 80 is waived.
the liver biopsy must be done within 60 days of
study enrollment.*
Yes
No
model for end-stage liver disease (meld) ≥ 20 and
maddrey df ≥ 32.*
Yes
No
willingness to utilize two reliable forms of
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contraception from screening through the first 6
weeks of the study.*
Yes
No
Exclusion Criteria
hypotension with bp < 80/50 after volume
repletion*
Yes
No
pregnancy; incarceration; inability to provide
consent or lack of appropriate family member*
Yes
No
signs of uncontrolled systemic infection: fever >
38°c and positive blood or ascites cultures and on
appropriate antibiotic therapy for ≥ 3 days within 3
days of inclusion*
Yes
No
acute gastrointestinal bleeding requiring >2 units
blood transfusion within the previous 4 days*
Yes
No
5. undue risk from immunosuppression: positive
hbsag; a positive skin ppd skin test, a positive
quantiferon, or history of treatment for
tuberculosis; history of any malignancy except
skin cancer but including hepatocellular
carcinoma within the last five years; hiv infection*
Yes
No
recent previous treatment with corticosteroids or
other immunosuppressive medications. including
specific anti-tnf therapy (not including
pentoxifylline), calcineurin inhibitors within the
previous 3 months.  treatment with
corticosteroids for ≤3 days prior to baseline is
acceptable.*
Yes
No
7. evidence of acute pancreatitis: ct evidence or
amylase or lipase > 5 x upper limit of normal
(uln).*
Yes
No
serious cardiac, respiratory or neurologic disease
or evidence of other liver diseases such as
autoimmune hepatitis, primary biliary cirrhosis,
primary sclerosing cholangitis, wilson disease,
2 / 3
Eligibility Acute Alcoholic Hepatitis NCT01809132
hemochromatosis, secondary iron overload due
to chronic hemolysis, alpha-1-antitrypsin
deficiency*
Yes
No
9. acute or chronic kidney injury with serum
creatinine > 3.0 mg/dl.*
Yes
No
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Eligibility Acute Asthma Exacerbation
NCT01011452
Acute Montelukast in Asthma; ODM derived from:
https://clinicaltrials.gov/show/NCT01011452
All rights reserved. Please visit https://medical-data-
models.org/forms/12563
Eligibility Acute Asthma
Exacerbation NCT01011452
Inclusion Criteria
acute asthma exacerbation requiring
hospitalisation*
Yes
No
Exclusion Criteria
smoking history greater than or equal to 10 pack
years*
Yes
No
presenting pefr greater than or equal to 75
percent predicted best*
Yes
No
failure to demonstrate greater than or equal to 15
percent variability in pefr or  fev during the study*
Yes
No
any significant and active pulmonary pathology
other than asthma*
Yes
No
pregnancy or breastfeeding*
Yes
No
intended pregnancy or inability to take adequate
precautions against conception*
Yes
No
patient already on montelukast*
Yes
No
patient already on phenobarbitone*
Yes
No
patient already on rifampicin*
Yes
No
patient already on phenytoin*
Yes
No
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chronic airflow limitation*
Yes
No
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Eligibility Acute Asthma NCT00922350
Heliox and Posture in Patients With Asthma; ODM derived
from: https://clinicaltrials.gov/show/NCT00922350
All rights reserved. Please visit https://medical-data-
models.org/forms/12564
Eligibility Acute Asthma
NCT00922350
Inclusion Criteria
reversibility of bronchial obstruction after
administration of bronchodilator drugs for at least
10 percent in fev1*
Yes
No
a clinical diagnosis of acute severe asthma*
Yes
No
a history of asthma over 1 year*
Yes
No
duration of the crisis of current asthma lasting
less than seven days*
Yes
No
Exclusion Criteria
were unable to understand or perform the
spirometric maneuver*
Yes
No
smoking with a higher consumption of 100
cigarettes/year*
Yes
No
other pulmonary comorbidities of lower to upper
airways*
Yes
No
heart failure*
Yes
No
heart rate greater than 150 bpm*
Yes
No
systolic pressure below 90 mmhg or greater than
150 mhg*
Yes
No
pregnancy*
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Yes
No
inability to stay inline with the trunk forward*
Yes
No
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Eligibility Acute Asthma NCT01079000
Emergency Department (ED)-Directed Interventions to
Improve Asthma Outcomes; ODM derived from:
https://clinicaltrials.gov/show/NCT01079000
All rights reserved. Please visit https://medical-data-
models.org/forms/12565
Eligibility Acute Asthma
NCT01079000
Inclusion Criteria
age 17-55 years old;*
>= 17
<= 55
Yes
No
patients treated and discharged from one of the
four study sites with acute asthma during the
study period;*
Yes
No
patients must have had a previous physician-
diagnosis of asthma and an exacerbation
diagnosed by the ed physician (e.g., past asthma
history, recorded response to β-agonists in the
ed, and increased asthma symptoms). in the
event of a new diagnosis, the patient is still
eligible for the study if the treating physician feels
that the history is compatible with a diagnosis of
asthma;*
Yes
No
patients must have evidence of airflow
obstruction on presentation at the ed, defined as
an fev1 or pef <80 percent of predicted;*
Yes
No
patients must not have a history of more than 20
pack-years of smoking;*
Yes
No
all patients should have a pcp  with whom to
follow-up or attempts will be made to find one for
them.*
Yes
No
Exclusion Criteria
these criteria ensure the exclusion of suspected
copd patients and patients who require different
treatments:*
Yes
No
patients with asthma who are primarily cared for
by a respirologist/pulmonologist;*
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Yes
No
patients not seen by an emergency physician in
the ed*
Yes
No
physician diagnosis of acute copd*
Yes
No
radiologically confirmed pneumonia during the 10
days preceding trial entry;*
Yes
No
patients with an active history of bronchiectasis,
cystic fibrosis, or lung cancer;*
Yes
No
clinically confirmed congestive heart failure at ed
presentation;*
Yes
No
patients not able/unwilling to perform spirometry
assessment*
Yes
No
inability to provide informed consent or comply
with the study protocol due to cognitive
impairment, language barrier, or no contact
details;*
Yes
No
patient has previously participated in the study;*
Yes
No
patients who in the opinion of the investigator are
unsuitable for enrolment.*
Yes
No
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Eligibility Acute Asthma NCT01403467
Impact of Continuous Positive Airway Pressure on the
Treatment of Acute Asthma Exacerbation; ODM derived
from: https://clinicaltrials.gov/show/NCT01403467
All rights reserved. Please visit https://medical-data-
models.org/forms/12566
Eligibility Acute Asthma
NCT01403467
Inclusion Criteria
Must be 18 years and older*
>= 18
Yes
No
known asthmatic patients visiting ed with acute
exacerbation*
Yes
No
had given their written informed consent.*
Yes
No
Exclusion Criteria
smoking history*
Yes
No
chronic obstructive pulmonary disease*
Yes
No
required intubation*
Yes
No
instability of hemodynamic or arrhythmia*
Yes
No
unable to perform pefr*
Yes
No
facial abnormality*
Yes
No
pulmonary infiltration*
Yes
No
pregnancy.*
Yes
No
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Eligibility Acute Asthma NCT01429415
Magnesium Nebulization Utilization in Management of
Pediatric Asthma; ODM derived from:
https://clinicaltrials.gov/show/NCT01429415
All rights reserved. Please visit https://medical-data-
models.org/forms/12567
Eligibility Acute Asthma
NCT01429415
Inclusion Criteria
2-17 years of age*
>= 2
<= 17
Yes
No
diagnosis of asthma/reactive airways/viral
wheeze, defined as this diagnosis made by a
physician and at least one prior acute episode of
wheezing with cough or dyspnea treated with
inhaled ß2 agonists or oral corticosteroids.*
Yes
No
persistent moderate to severe airway obstruction
after 3 doses of salbutamol and ipratropium,
defined as a pram 5 or higher.*
Yes
No
Exclusion Criteria
no previous history of wheezing or bronchodilator
therapy.*
Yes
No
patients who have already received iv mg therapy
during the index visit.*
Yes
No
critically ill children requiring immediate
intubation. these children need immediate icu
management and hospitalization.*
Yes
No
children who in the opinion of the treating
physician require a chest radiograph due to
atypical clinical presentation and are found to
have radiologist-confirmed pneumonia. these rare
patients may have to be hospitalized primarily for
treatment of the infection and may not respond to
magnesium.*
Yes
No
known co-existent renal, chronic pulmonary,
neurologic, cardiac or systemic disease. these
conditions may influence the response to mg and
hospitalization.*
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Yes
No
transfers from other institutions. these patients
would have received initial therapy well before
arrival, potentially represent a different stage of
their acute disease and may respond differently
to mg therapy.*
Yes
No
known hypersensitivity to mg sulfate.*
Yes
No
patients previously enrolled in the study.*
Yes
No
insufficient command of the english language.*
Yes
No
lack of a home or cellular telephone*
Yes
No
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Eligibility Acute Biphenotypic Leukemia
NCT01804101
Liposomal Cytarabine-Daunorubicin CPX-351 in Treating
Patients With Untreated Myelodysplastic Syndrome or
Acute Myeloid Leukemia; ODM derived from:
https://clinicaltrials.gov/show/NCT01804101
All rights reserved. Please visit https://medical-data-
models.org/forms/12574
Eligibility Acute Biphenotypic
Leukemia NCT01804101
Inclusion Criteria
Diagnosis of untreated high-risk myelodysplastic
syndrome (>= 10% blasts) or aml*
Yes
No
prior hydroxyurea for aml is permitted but should
be discontinued prior to start of cpx-351
treatment*
Yes
No
azacitidine, decitabine, lenalidomide, and growth
factors are permitted for low-risk mds (< 10%
blasts); all treatments for mds should be
discontinued prior to start of cpx-351 treatment*
Yes
No
treatment-related mortality (trm) score >= 13.1 as
calculated with simplified model*
Yes
No
bilirubin < 2.0 mg/ml x upper limit of normal; this
requirement reflects the excretion of cpx-351 by
the liver*
Yes
No
aspartate aminotransferase (ast)/alanine
aminotransferase (alt) < 4.0 x upper limit of
normal; this requirement reflects the excretion of
cpx-351 by the liver*
Yes
No
left ventricular ejection fraction (lvef) >= 40%,
assessed within 28 days prior to registration, e.g.
by multi gated acquisition (muga) scan or
echocardiography, or other appropriate diagnostic
modality*
Yes
No
patients with symptoms/signs of
hyperleukocytosis or white blood cell count (wbc)
> 100,000/ul can be treated with leukapheresis
prior to enrollment*
Yes
No
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provide signed written informed consent*
Yes
No
Exclusion Criteria
refractory/relapsing blast crisis of chronic
myelogenous leukemia (cml)*
Yes
No
concomitant illness associated with a likely
survival of < 1 year*
Yes
No
active systemic fungal, bacterial, viral, or other
infection, unless under treatment with anti-
microbials and controlled/stable, as defined as
being afebrile and hemodynamically stable for
24-48 hours*
Yes
No
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Eligibility Acute Decompensated Heart
Failure (ADHF) NCT01885403
Acute Congestive Heart Failure; ODM derived from:
https://clinicaltrials.gov/show/NCT01885403
All rights reserved. Please visit https://medical-data-
models.org/forms/12575
Eligibility Acute Decompensated
Heart Failure (ADHF) NCT01885403
Inclusion Criteria
males and females, ages 18-75*
>= 18
<= 75
Yes
No
able and willing to provide written informed
consent or not able to give informed consent
because of mechanical respiration*
Yes
No
diagnosis of acute or chronic decompensated
heart failure with pulmonary congestion or
edema*
Yes
No
systolic blood pressure >80 mm hg at time of
enrollment*
>= 80
mmHg
Yes
No
resting pulse oximetry (spo2) at the time of
enrollment of at least 88 percent at 21 percent
iron oxides (feo2)*
Yes
No
agreement to be measured with the study
devices according to study protocol by patient or
legal representative*
Yes
No
left ventricular ejection fraction (lvef) < 40 percent
in 3d- echocardiography*
>= 40
%
Yes
No
Exclusion Criteria
active participation in another interventional
research study*
Yes
No
surgery of the upper airway, nose, sinus or middle
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ear within the last 90 days*
Yes
No
major medical or psychiatric condition that would
interfere with the demands of the study or the
ability to complete the study.*
Yes
No
unable to use pap therapies due to physical
issues (e.g. facial structural abnormalities) or
cognitive issues (e.g. dementia)*
Yes
No
participants in whom positive airway pressure
(pap) therapy is medically contraindicated.*
Yes
No
uncontrolled hypertension (systolic ≥200 mm
hg/diastolic ≥120 mm hg)*
Yes
No
pregnancy*
Yes
No
lactation*
Yes
No
implanted pacemaker / cardiac resynchronization
therapy (crt) / implantable cardioverter-
defibrillator (icd) except for medtronic devices
with opti vol algorithm*
Yes
No
incompetent patients or patients who, in the
judgment of the investigator, are too unstable or
are otherwise not capable of performing study
procedures*
Yes
No
postpartum cardiomyopathy*
Yes
No
Hypertrophic cardiomyopathy (obstructive or non-
obstructive)*
Yes
No
primary mitral valve stenosis*
Yes
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No
patients requiring more than 50 percent
supplemental oxygen or patients requiring more
than 4 lpm oxygen*
Yes
No
patients with persistent ventricular arrhythmias*
Yes
No
patients chronically classified (prior to admission)
as new york heart association (nyha) class iv or
american heart association class d heart failure*
Yes
No
patients with glomerular filtration rate (gfr) <30 or
obligatory dialysis*
Yes
No
resting respiratory rate >30 breaths per minute*
Yes
No
patients requiring mechanical ventilation or
patients with an artificial airway (endotracheal or
tracheostomy tube)*
Yes
No
patients with carbon monoxide toxicity*
Yes
No
patients with severe sepsis*
Yes
No
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Eligibility Acute Decompensated Heart
Failure NCT00693745
Neutrophil Gelatinase-Associated Lipcalin (NGAL)
Evaluation Along With B-Type Natriuretic Peptide in Acutely
Decompensated HF; ODM derived from:
https://clinicaltrials.gov/show/NCT00693745
All rights reserved. Please visit https://medical-data-
models.org/forms/12578
Eligibility Acute Decompensated
Heart Failure NCT00693745
Inclusion Criteria
male or female 18 years of age or older.*
Yes
No
patients presenting to the emergency department
/ hospital with symptoms of new or
decompensated heart failure and who will be
treated with at least one dose of iv diuretic;*
Yes
No
ability to draw blood samples for baseline ngal,
bnp and creatinine levels either prior to the
administration of the first dose of iv diuretic or
within 1 hour after the first dose of an iv diuretic*
Yes
No
ability to provide written informed consent from
subject or their authorized representative.*
Yes
No
Exclusion Criteria
acute myocardial infarction or active ischemia ;*
Yes
No
patients who are intubated or otherwise  not able
to communicate or comply with study
assessments*
Yes
No
cardiogenic shock or any other clinical condition
that would contraindicate the administration of an
iv agent with potent vasodilating properties*
Yes
No
known history of  marked renal insufficiency (e.g.,
usual serum creatinine ≥ 3.0 mg/dl), on dialysis
(either acute of chronic) or in imminent need of
dialysis at enrollment;*
Yes
No
prisoners or other institutionalized or vulnerable
individuals;*
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Yes
No
participation in an interventional clinical study
within the previous 30 days;*
Yes
No
unlikely to be willing or able to comply with study
procedures, including the follow-up at 30 and 90
days .*
Yes
No
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Eligibility Acute Decompensated Heart
Failure NCT00699712
Study to Assess Hemodynamic Effects, Safety and
Tolerability of Chimeric Natriuretic Peptide (CD-NP) in
Patients With Stabilized Acute Heart Failure (AHF); ODM
derived from: https://clinicaltrials.gov/show/NCT00699712
All rights reserved. Please visit https://medical-data-
models.org/forms/12579
Eligibility Acute Decompensated
Heart Failure NCT00699712
Inclusion criteria
hospitalization for acute heart failure*
Yes
No
in need of hemodynamic monitoring*
Yes
No
Exclusion criteria
administration of intravenous radiographic
contrast agent within 7 days prior to screening  or
planned iv contrast media administration in the 4
days after screening or acute contrast-induced
nephropathy at the time of screening
Yes
No
current  or planned treatment with any iv
therapies, including diuretics, vasodilators
(including nesiritide), vasopressin antagonists,
positive inotropic agents and vasopressors, or
mechanical support
Yes
No
current or planned ultrafiltration, hemofiltration, or
dialysis within 7 days of screening
Yes
No
significant pulmonary disease
Yes
No
known valvular heart disease
Yes
No
any organ transplant recipient or patient currently
listed for transplant or admitted for any
transplantation.
Yes
No
major surgery within 30 days of screening
Yes
No
other major disability or disease with expected
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survival less than 6 months.
Yes
No
major neurologic event, including cerebrovascular
events, in the 60 days prior to screening
Yes
No
clinical diagnosis of acute coronary syndrome
within 45 days of screening
Yes
No
troponin t ≥ 3 times the upper limit of normal at
screening
Yes
No
significant arrhythmias
Yes
No
acute myocarditis or hypertrophic obstructive,
restrictive, or constrictive cardiomyopathy
Yes
No
liver function abnormality
Yes
No
administration of an investigational drug or
implantation of investigational device, or
participation in another trial, within 30 days prior
to screening
Yes
No
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Eligibility Acute Decompensated Heart Failure NCT00699712
Day of last Dose-Imaging Stem-Cell
Transplantation CASLAMB NCT00148148
A Study of Caspofungin, Liposomal Amphotericin B or the
Combination of Both for Patients After Stem-Cell
Transplantation
NCT00148148
All rights reserved. Please visit https://medical-data-
models.org/forms/12580
Day of last Dose-Imaging Stem-Cell
Transplantation CASLAMB
NCT00148148
Röntgen-Thorax
Datum
Pathology
ohne pathologischen Befund (1)
Befund vereinbar mit einer Pilzinfektion
(2)
anderer Befund (3)
sonstiger pathologischer Befund
HR-CT der Lungen
Datum
Pathologischer Befund
ohne pathologischen Befund (1)
Befund vereinbar mit einer Pilzinfektion
(2)
anderer Befund (3)
sonstiger Befund
kein CT durchgeführt
Ja
Nein
Reason
Weitere Verfahren
Verfahren
Ergebnis
Datum des Verfahrens
weitere Verfahren
Ja
Nein
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Konsiliaruntersuchungen
Konsil
Diagnose
Datum
Erfassung des Infektionsstatus
Vorliegen einer wahrscheinlichen bzw.
gesicherten invasiven Pilzinfektion nach MSG-
EORTC-Kriterien
Ja
Nein
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Day of last Dose-Imaging Stem-Cell Transplantation CASLAMB
NCT00148148
Eligibility Acute Decompensated Heart
Failure NCT00842023
Assessment of Biomarkers and Cardiorenal Syndrome in
Acute Decompensated Heart Failure With Vasodilator
Therapy; ODM derived from:
https://clinicaltrials.gov/show/NCT00842023
All rights reserved. Please visit https://medical-data-
models.org/forms/12582
Eligibility Acute Decompensated
Heart Failure NCT00842023
Inclusion Criteria
at least 18 years of age.*
Yes
No
subject must be able to understand the potential
risks and benefits associated with the study.*
Yes
No
baseline systolic blood pressure ≥ 90 mm hg at
the time of enrollment.*
>= 90
mmHg
Yes
No
clinical symptoms of dyspnea and laboratory
admission bnp levels > 500 pg/ml.*
Yes
No
neither pregnant or breastfeeding at the time of
enrollment.*
Yes
No
authorization of patient's enrollment by patient's
medical provider.*
Yes
No
Exclusion Criteria
younger than 18 years of age*
>= 18
yrs
Yes
No
denies written informed consent*
Yes
No
pregnant or lactating.*
Yes
No
baseline systolic bp < 90 mmhg or cardiogenic
shock*
Yes
1 / 2
No
no symptoms of congestion or admission bnp <
500 pg/ml*
Yes
No
known allergy to e.coli-derived products, or any
history of anaphylactic reactions to nesiritide.*
Yes
No
receiving dialysis at the time of enrollment.*
Yes
No
serum creatinine > 2.5 mg/dl at the time of
enrollment.*
>= 2.5
mg/dl
Yes
No
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Eligibility Acute Decompensated Heart
Failure NCT01060293
Dopamine in Acute Decompensated Heart Failure II; ODM
derived from: https://clinicaltrials.gov/show/NCT01060293
All rights reserved. Please visit https://medical-data-
models.org/forms/12583
Eligibility Acute Decompensated
Heart Failure NCT01060293
Inclusion Criteria
patients with new york heart association (nyha)
functional class iv heart failure according to the
american heart association (aha) classification,
namely dyspnea on minimal exertion or rest
dyspnea, orthopnea, and paroxysmal nocturnal
dyspnea,*
Yes
No
signs of congestion,*
Yes
No
pulmonary congestion on chest x-ray,*
Yes
No
serum b-type natriuretic peptide levels > 400
pg/ml or nt-probnp > 1500 pg/ml,*
Yes
No
echocardiographic documentation of systolic or
diastolic dysfunction,*
Yes
No
age >18 years old,*
>= 18
yrs
Yes
No
on medical therapy with an ace-inhibitor and/or a
β-blocker,*
Yes
No
experiencing an acute decompensation of known
chronic hf,*
Yes
No
baseline oxygen saturation <90 percent on
admission arterial blood gas*
>= 90
%
Yes
No
Exclusion Criteria
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acute de novo heart failure*
Yes
No
severe renal failure (serum creatinine >200 μmol/l
or gfr <30 ml/min/1.73m2)*
Yes
No
admission systolic blood pressure <90 mm hg;*
Yes
No
severe valvular disease;*
Yes
No
known adverse reactions to furosemide or
dopamine;*
Yes
No
hf secondary to congenital heart disease;*
Yes
No
a scheduled procedure with a need for iv contrast
dye;*
Yes
No
a scheduled cardiac surgery within 6 months*
Yes
No
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Eligibility Acute Decompensated Heart
Failure NCT01138683
Cardiorenal Interactions During Treatment of Acute
Decompensated Heart Failure: Diuretics Versus
Ultrafiltration; ODM derived from:
https://clinicaltrials.gov/show/NCT01138683
All rights reserved. Please visit https://medical-data-
models.org/forms/12584
Eligibility Acute Decompensated
Heart Failure NCT01138683
Inclusion Criteria
>18 years old*
Yes
No
severe systolic heart failure with ejection fraction
<40%*
Yes
No
hospitalisation for decompensated heart failure*
Yes
No
new york heart association (nyha) iii or iv*
Yes
No
Diagnosis*
jugular vein distension>6cm (1)
tissue doppler mitral annulus lateral>12
or medial>15 (2)
chest x-ray: pulmonary edema or pleural
effusion (3)
Exclusion Criteria
need for inotropic or vasopressive agents*
Yes
No
use of intravenous (iv) contrast media*
Yes
No
acute coronary syndrome*
Yes
No
need of dialysis*
Yes
No
severe co-morbidity*
Yes
No
contra-indications for anticoagulation*
Yes
No
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pregnancy*
Yes
No
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Eligibility Acute Decompensated Heart Failure NCT01138683
Eligibility Acute Decompensated Heart
Failure NCT01837849
A Comparison of Recombinant Human Brain Natriuretic
Peptide and Dobutamine; ODM derived from:
https://clinicaltrials.gov/show/NCT01837849
All rights reserved. Please visit https://medical-data-
models.org/forms/12585
Eligibility Acute Decompensated
Heart Failure NCT01837849
Inclusion Criteria
patients were classified as nyha class iii-iv*
Yes
No
ejection fraction <40%*
Yes
No
Exclusion Criteria
intravenous administration with rhbnp or
dobutamine in the 2 weeks before study entry*
Yes
No
acute myocardial infarction*
Yes
No
significant valvular stenosis*
Yes
No
serious ventricular arrhythmia (frequent
ventricular premature beat of >5 bpm,
nonsustained and sustained ventricular
tachycardia)*
Yes
No
blood pressure <95/60 mmhg or >140/90 mmhg*
Yes
No
shock*
Yes
No
hypovolemia*
Yes
No
hepatic or renal impairment*
Yes
No
pregnant and lactating women.*
Yes
No
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Eligibility Acute Decompensated Heart
Failure NCT01863511
Tolvaptan/Ultrafiltration in the Treatment of Acute Heart
Failure; ODM derived from:
https://clinicaltrials.gov/show/NCT01863511
All rights reserved. Please visit https://medical-data-
models.org/forms/12586
Eligibility Acute Decompensated
Heart Failure NCT01863511
Inclusion Criteria
2 of 3 physical exam findings of volume overload
(rales, jvp over 5 cm and   edema)*
Yes
No
bnp over 300*
Yes
No
no contraindication to ultrafiltration (line insertion,
heparin use)*
Yes
No
Exclusion Criteria
serum creatinine > 3mg/dl or na > 145*
Yes
No
inotrope or vasopressor dependency*
Yes
No
active infection, including urinary tract*
Yes
No
resynchronization therapy or coronary
intervention in past 30 days*
Yes
No
life expectancy less than 6 months*
Yes
No
hypertrophic obstructive cardiomyopathy with
peak resting gradient > 20 mmhg*
Yes
No
iv contrast or nsaid use in the past 1 week (ungal
related requirement)*
Yes
No
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Eligibility Acute Decompensated Heart
Failure NCT01960218
Gas Exchange for Predicting Hospital Heart Failure
Readmissions; ODM derived from:
https://clinicaltrials.gov/show/NCT01960218
All rights reserved. Please visit https://medical-data-
models.org/forms/12587
Eligibility Acute Decompensated
Heart Failure NCT01960218
Inclusion Criteria
subject is 18 years and older*
>= 18
yrs
Yes
No
subject is hospitalized for acute decompensated
heart failure (adhf)*
Yes
No
subject is stage c:class ii/iii/iv systolic or diastolic
heart failure*
Yes
No
subject is willing and to provide appropriate
informed consent*
Yes
No
subject is willing and able to comply with the
requirements of the protocol, including follow-up
evaluations and schedule*
Yes
No
subject is willing to use the shape-hf
cardiopulmonary exercise testing system*
Yes
No
Exclusion Criteria
the subject is pregnant (verified in a manner
consistent with institution's standard of care)*
Yes
No
subject is currently participating in another
investigational device or drug trial*
Yes
No
subject is a prisoner, a minor or unable to
adequately give informed consent due to mental
or physical condition*
Yes
No
subject is unwilling or unable to return for the
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required follow-up after test*
Yes
No
subject has left ventricular assist device (lvad)*
Yes
No
subject is listed for transplant*
Yes
No
subject has a clinical diagnosis of acute
myocardial infarction (ami) on admission (note: if
troponin measurements have been collected and
are elevated but not due to an mi subject is still
eligible for study)*
Yes
No
subject has a pulmonary embolism (pe) on
admission*
Yes
No
subject is dialysis dependent*
Yes
No
subject has a cardiac resynchronization device
(crt) which has been re-programmed at any time
during the study*
Yes
No
subject has chronic obstructive pulmonary
disease (copd) who is oxygen or steroid
dependent*
Yes
No
subject has severe hypertension > 180 millimeter
of mercury (mmhg) resting systolic at time of test*
Yes
No
subject has severe heart failure with renal
insufficiency (with creatinine clearance rate (crcl)
of 30 or less) and/or on iv inotropic therapy
and/or enrolling in hospice*
Yes
No
2 / 2
Eligibility Acute Decompensated Heart Failure NCT01960218
Eligibility Acute Decompensated Heart
Failure NCT01966601
A Study to Explore the Efficacy of TRV027 in Patients
Hospitalized for Acute Decompensated Heart Failure; ODM
derived from: https://clinicaltrials.gov/show/NCT01966601
All rights reserved. Please visit https://medical-data-
models.org/forms/12588
Eligibility Acute Decompensated
Heart Failure NCT01966601
Inclusion Criteria
men or women aged ≥21 years and ≤ 85 years*
>= 21
<= 85
yrs
Yes
No
able to provide written informed consent*
Yes
No
pre-existing diagnosis of heart failure*
Yes
No
systolic blood pressure ≥120 mmhg and ≤ 200
mmhg within 30 minutes of  randomization*
Yes
No
ventricular rate ≤125 bpm. patients with rate-
controlled persistent or permanent atrial
fibrillation (afib) at screening are permitted.*
Yes
No
presence of adhf defined by*
Yes
No
bnp > 400 pg/ml or nt-probnp > 1600 pg/ml*
Yes
No
for patients with bmi >30 kg/m2: bnp > 200 pg/ml
or nt-probnp > 800 pg/ml*
Yes
No
for patients with rate-controlled persistent or
permanent afib: bnp > 600 pg/ml or nt-probnp >
2400 pg/ml*
Yes
No
and at least two (2) of the following*
Yes
No
congestion on chest radiograph (cxr)*
Yes
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No
rales by chest auscultation*
Yes
No
edema ≥ +1 on a 0-3 + scale, indicating
indentation of skin with mild digital pressure that
requires 10 or more seconds to resolve in any
dependent area including extremities or sacral
region.*
Yes
No
elevated jugular venous pressure (≥8 cm h2o)*
Yes
No
receipt of a iv loop diuretic at a minimum dose 40
mg furosemide (or equivalent loop diuretic) for
the treatment of dyspnea due to adhf at least 1
hour prior to anticipated  randomization and the
initiation of study medication*
Yes
No
patient report of dyspnea at rest or upon minimal
exertion during screening at least one hour after
administration of iv loop diuretic*
Yes
No
Exclusion Criteria
women who are pregnant or breast-feeding*
Yes
No
acs in the 3 months prior to screening or planned
during current admission.*
Yes
No
temperature >38.5oc*
Yes
No
clinically significant anemia*
Yes
No
current or planned ultrafiltration, paracentesis,
hemofiltration or dialysis at time of screening*
Yes
No
any mechanical ventilation*
Yes
2 / 4
Eligibility Acute Decompensated Heart Failure NCT01966601
No
cpap/bipap discontinued less than 1 hour prior to
randomization*
Yes
No
history of primary pulmonary hypertension*
Yes
No
history or current use of left ventricular assist
devices (lvads) or intra-aortic balloon pumps
(iabps)*
Yes
No
intravenous radiographic contrast agent within 72
hours prior to screening or presence of acute
contrast induced nephropathy at the time of
screening*
Yes
No
presence of clinically significant arrhythmia*
Yes
No
nitroprusside or nesiritide*
Yes
No
intravenous nitrates*
Yes
No
use of inotropes*
Yes
No
use of arbs within 7 days of prior to
randomization*
Yes
No
use of any investigational medication within 30
days*
Yes
No
clinically significant hypersensitivity or allergy to,
or intolerance of, angiotensin receptor blockers*
Yes
No
major surgery within 8 weeks prior to screening*
Yes
No
stroke within 3 months prior to screening*
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Yes
No
egfr (smdrd) <20 ml/min/1.73m2 or >75
ml/min/1.73m2 between presentation and
randomization*
Yes
No
post cardiac or renal transplant*
Yes
No
listed for renal transplant or cardiac transplant
with anticipated transplant time to transplant < 6
months*
Yes
No
history of severe left ventricular outlet obstruction
(either valvular or sub-valvular), severe mitral
valve stenosis or severe aortic regurgitation*
Yes
No
cardiac valvular abnormality that requires surgical
correction*
Yes
No
complex congenital heart disease*
Yes
No
hypertrophic or restrictive cardiomyopathy*
Yes
No
significant pulmonary or hepatic disease that
could interfere with the evaluation of safety or
efficacy of trv027*
Yes
No
life expectancy of less than 6 months*
Yes
No
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Eligibility Acute Decompensated Heart
Failure NCT02440971
Adaptive Servo Ventilation (ASV) in Heart Failure; ODM
derived from: https://clinicaltrials.gov/show/NCT02440971
All rights reserved. Please visit https://medical-data-
models.org/forms/12589
Eligibility Acute Decompensated
Heart Failure NCT02440971
Inclusion Criteria
admitted to the hospital with a primary diagnosis
of adhf*
Yes
No
stable off oxygen for 24 hours*
Yes
No
informed consent*
Yes
No
age ≥ 18 years*
Yes
No
Exclusion Criteria
age < 18 years*
Yes
No
pregnant women, breastfeeding mothers*
Yes
No
anyone not capable of giving informed consent*
Yes
No
contraindications to positive airway pressure*
Yes
No
severe bullous lung disease*
Yes
No
dehydration*
Yes
No
cerebrospinal fluid leak*
Yes
No
acute sinusitis or otitis media*
Yes
No
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epistaxis (severe nose bleeds) causing a risk of
pulmonary aspiration*
Yes
No
conditions predisposing to a risk of vomiting into
mask*
Yes
No
impaired ability to clear secretions*
Yes
No
hypotension (defined as systolic bp < 100mmhg)
or significant intravascular volume depletion*
Yes
No
pneumothorax or pneumomediastinum*
Yes
No
recent cranial trauma or surgery.*
Yes
No
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Eligibility Acute Depression NCT02378415
Subanesthetic IV Bolus Ketamine in the Treatment of Acute
Depression; ODM derived from:
https://clinicaltrials.gov/show/NCT02378415
All rights reserved. Please visit https://medical-data-
models.org/forms/12590
Eligibility Acute Depression
NCT02378415
Inclusion Criteria
bss greater than 4*
Yes
No
bhs greater than 8*
Yes
No
bdi greater than 19*
Yes
No
ability to give informed consent.*
Yes
No
active duty military status.*
Yes
No
verified negative qualitative pregnancy test.*
Yes
No
all participants must be accepted for psychiatric
admission to the hospital prior to consideration
for enrollment in this study.*
Yes
No
Exclusion Criteria
psychosis or bipolar disorder.*
Yes
No
pregnancy*
Yes
No
involuntary status on presentation to the ed.*
Yes
No
uds positive for illicit drugs of abuse.*
Yes
No
blood alcohol level greater than zero*
Yes
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No
previous enrollees in this treatment protocol will
be excluded from repeat participation.*
Yes
No
any patient brought for command directed
psychiatric evaluation.*
Yes
No
specific contraindications to the use of ketamine
are as follows and under such circumstances or
conditions, personnel with the following should be
excluded from participation in this study:*
Yes
No
patients with elevated intracranial pressure,
uncontrolled hypertension, coronary artery
disease, aneurysms, thyrotoxicosis, chf, a recent
history of head or eye injury, or angina.*
Yes
No
all personnel in whom a significant elevation of
blood pressure would constitute a serious hazard
to their overall health and well-being.*
Yes
No
patients currently utilizing the following
medications: conivaptan, disatinib, peginterferon
alfa-2b, quazepam, tocilizumab*
Yes
No
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Eligibility Acute Gouty Arthritis
NCT01356602
Safety and Efficacy of Canakinumab Prefilled Syringes in
Frequently Flaring Acute Gouty Arthritis Patients; ODM
derived from: https://clinicaltrials.gov/show/NCT01356602
All rights reserved. Please visit https://medical-data-
models.org/forms/12591
Eligibility Acute Gouty Arthritis
NCT01356602
Inclusion Criteria
3 or more gout flares within last year*
Yes
No
contraindication, intolerance or lack of efficacy for
nsaids and/or colchicine*
Yes
No
body mass index of less than or equal to 45
kg/m2*
Yes
No
Exclusion Criteria
use of the following therapies (within varying
protocol defined timeframes): corticosteroids,
narcotics, topical ice/cold packs, chronic opiate
treatment, nsaids (such as aspirin), colchicine.*
Yes
No
hemodialysis*
Yes
No
live vaccine within 3 months before first dose*
Yes
No
donation or loss of 400 ml or more within 3
months before first dose*
Yes
No
gout brought on by other factors such as
chemotherapy, lead, transplant, etc.*
Yes
No
presence of other acute inflammatory arthritis
such as rheumatoid arthritis*
Yes
No
any conditions or significant medical problems
that puts the patient at an unacceptable
immunological  risk to receive this type of therapy
such as hiv, hepatitis, tuberculosis and other
infections/conditions*
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Yes
No
significant cardiovascular conditions such as
uncontrolled hypertension*
Yes
No
significant medical diseases such as uncontrolled
diabetes, thyroid disease*
Yes
No
history of malignancy of any organ system within
the past 5 years*
Yes
No
women who are pregnant or nursing*
Yes
No
other protocol-defined inclusion/exclusion criteria
may apply*
Yes
No
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Eligibility Acute Heart Failure
NCT00449423
Metabolic Modulation as Treatment in Acute Heart Failure;
ODM derived from:
https://clinicaltrials.gov/show/NCT00449423
All rights reserved. Please visit https://medical-data-
models.org/forms/12592
Eligibility Acute Heart Failure
NCT00449423
Inclusion Criteria
acute heart failure*
Yes
No
nyha class iii - iv.*
Yes
No
ejection fraction <35*
Yes
No
Exclusion Criteria
age <18 or >85*
Yes
No
allergy*
Yes
No
renal failure*
Yes
No
recently developed  brady- or tachy-arrythmias*
Yes
No
serious infection*
Yes
No
heart failure due to restrictive or hypertrophic
cardiomyopathy or stenotic valvular heart
disease*
Yes
No
recent myocardial infarction (<6 weeks)*
Yes
No
pulmonary wedge pressure >30 mm hg*
Yes
No
diabetes mellitus treated with insulin*
Yes
No
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peptic ulcer*
Yes
No
pregnancy*
Yes
No
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Eligibility Acute Heart Failure
NCT00512759
Goal-directed Afterload Reduction in Acute Congestive
Cardiac Decompensation Study; ODM derived from:
https://clinicaltrials.gov/show/NCT00512759
All rights reserved. Please visit https://medical-data-
models.org/forms/12593
Eligibility Acute Heart Failure
NCT00512759
Inclusion Criteria
acute hf expressed by acute dyspnea new york
heart association (nyha) class iii or iv, and a bnp-
level  500 pg/ml.*
Yes
No
Exclusion Criteria
cardiopulmonary resuscitation < 7 days*
Yes
No
cardiogenic shock, st-elevation myocardial
infarction, or other clinical conditions that require
immediate icu admission or urgent ptca*
Yes
No
systolic blood pressure lower than 100 mmhg at
presentation*
Yes
No
primary rhythmogenic cause of acute
decompensation (ventricular tachycardia, reentry
tachycardia, atrial fibrillation or atrial flutter with a
ventricular rate exceeding 140 beats per minute)*
Yes
No
nstemi as primary diagnosis*
Yes
No
severe aortic stenosis*
Yes
No
adult congenital heart disease as primary cause
of acute hf*
Yes
No
hypertrophic obstructive cardiomyopathy*
Yes
No
chronic kidney disease with creatinin levels > 250
µmol/l*
Yes
No
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bilateral renal artery stenosis*
Yes
No
severe sepsis or other causes of high output
failure*
Yes
No
cirrhosis of the liver child class c*
Yes
No
previous adverse reactions to nitrates*
Yes
No
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Eligibility Acute Decompensated Heart
Failure NCT00699712
Study to Assess Hemodynamic Effects, Safety and
Tolerability of Chimeric Natriuretic Peptide (CD-NP) in
Patients With Stabilized Acute Heart Failure (AHF); ODM
derived from: https://clinicaltrials.gov/show/NCT00699712
All rights reserved. Please visit https://medical-data-
models.org/forms/12594
Eligibility Acute Decompensated
Heart Failure NCT00699712
Inclusion criteria
hospitalization for ahf*
Yes
No
in need of hemodynamic monitoring*
Yes
No
Exclusion criteria
administration of intravenous radiographic
contrast agent within 7 days prior to screening  or
planned iv contrast media administration in the 4
days after screening or acute contrast-induced
nephropathy at the time of screening
Yes
No
current  or planned treatment with any iv
therapies, including diuretics, vasodilators
(including nesiritide), vasopressin antagonists,
positive inotropic agents and vasopressors, or
mechanical support
Yes
No
current or planned ultrafiltration, hemofiltration, or
dialysis within 7 days of screening
Yes
No
significant pulmonary disease
Yes
No
known valvular heart disease
Yes
No
any organ transplant recipient or patient currently
listed for transplant or admitted for any
transplantation.
Yes
No
major surgery within 30 days of screening
Yes
No
other major disability or disease with expected
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survival less than 6 months.
Yes
No
major neurologic event, including cerebrovascular
events, in the 60 days prior to screening
Yes
No
clinical diagnosis of acute coronary syndrome
within 45 days of screening
Yes
No
troponin t ≥ 3 times the upper limit of normal at
screening
Yes
No
significant arrhythmias
Yes
No
acute myocarditis or hypertrophic obstructive,
restrictive, or constrictive cardiomyopathy
Yes
No
liver function abnormality
Yes
No
administration of an investigational drug or
implantation of investigational device, or
participation in another trial, within 30 days prior
to screening
Yes
No
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Eligibility Acute Heart Failure
NCT00561483
Sequential Cystatin C Levels and Renal Impairment in
Acute Heart Failure; ODM derived from:
https://clinicaltrials.gov/show/NCT00561483
All rights reserved. Please visit https://medical-data-
models.org/forms/12596
Eligibility Acute Heart Failure
NCT00561483
Inclusion Criteria
hospital admission within 48 hours for adhf, with
an expected stay over 24 hours.*
Yes
No
evidence of fluid overload, including jugular
venous distention, pulmonary rales, peripheral
edema, and/or ascites receiving diuretic therapy*
Yes
No
Exclusion Criteria
heart failure due to congenital heart disease or
critical aortic stenosis (potentially different cardio-
renal pathophysiology)*
Yes
No
acute myocardial infarction or unstable acute
coronary syndromes*
Yes
No
end-stage renal insufficiency on renal
replacement therapy (already has underlying
advanced renal failure).*
Yes
No
patients with active cancer (cystatin c has been
shown to be produced by some tumors)*
Yes
No
known exposure to nephrotoxic agents (such as
contrast dye) or planned surgery during
hospitalization at the time of enrollment*
Yes
No
hemoglobin < 9 mg/dl or clinically significant
active bleeding.*
Yes
No
unable to comply with protocol or unable to have
informed consent*
Yes
No
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NCT00922402
Heart & Diabetes - Feasibility Study; ODM derived from:
https://clinicaltrials.gov/show/NCT00922402
All rights reserved. Please visit https://medical-data-
models.org/forms/12597
Eligibility Acute Heart Failure
NCT00922402
Inclusion criteria
acute heart failure, defined according to current
esc guidelines*
Yes
No
hba1c > 7.5 percent  at admission in cardiology
unit*
Yes
No
Hyperglycemia > 180 mg/dl at admission in
cardiology unit*
Yes
No
the patients signed the informed consent*
Yes
No
Exclusion criteria
heart failure in acute infarction or cardiogenic
shock
Yes
No
creatinine > 3.5 mg/dl at admission or in
hemodialytic therapy
Yes
No
cirrhosis
Yes
No
acute infective pathology
Yes
No
cardiac revascularization during the
hospitalization or in the preceding 3 months
Yes
No
life expectance < 12 months
Yes
No
age < 18 years
Yes
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No
pregnant women
Yes
No
informed consent not signed
Yes
No
subject included in other protocols
Yes
No
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Eligibility Acute Heart Failure
NCT01065077
BAY58-2667 Dose Finding Trial Investigating Fixed Doses
in Patients With Acute Decompensated Chronic Congestive
Heart Failure (ADHF); ODM derived from:
https://clinicaltrials.gov/show/NCT01065077
All rights reserved. Please visit https://medical-data-
models.org/forms/12598
Eligibility Acute Heart Failure
NCT01065077
Inclusion Criteria
male and female subjects, age >/= 18 years of
age*
>= 18
yrs
Yes
No
Postmenopausal women aged 18 years or older.
Yes
No
women with bilateral tubal ligation, women with
bilateral ovariectomy, and women with a
hysterectomy
Yes
No
subjects must have the clinical diagnosis of chf
made at least three months prior to enrollment*
Yes
No
subjects must experience worsening of both of
the symptoms below leading to hospitalization at
the time of entry into the study:*
Yes
No
dyspnea*
Yes
No
clinical evidence of volume overload*
Yes
No
Exclusion Criteria
Pregnancy or breastfeeding
Yes
No
acute de-novo heart failure*
Yes
No
acute myocardial infarction and/or myocardial
infarction within 30 days*
Yes
No
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valvular heart disease requiring surgical
intervention during the course of the study*
Yes
No
heart failure due to or associated with
uncorrected primary valvular disease,
malfunctioning artificial heart valve, or
uncorrected congenital heart disease*
Yes
No
primary hypertrophic cardiomyopathy*
Yes
No
acute inflammatory heart disease,eg, acute
myocarditis*
Yes
No
unstable angina requiring angiography*
Yes
No
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Glioblastoma multiforme N0874
N0874 Pre-Registration (Step 1) Eligibility Checklist
Vorinostat, Temozolomide, and Radiation Therapy in
Treating Patients With Newly Diagnosed Glioblastoma
Multiforme
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=7F194A19-
97CE-83E0-E040-BB89AD431393
All rights reserved. Please visit https://medical-data-
models.org/forms/12599
Eligibility Glioblastoma multiforme
N0874 Pre-Registration Step 1
Header
Pre-Registration date
NCCTG Patient ID
Participating Group Code (participant sponsor)
Institution (treating location)
Physician of Record
Patient Medical Record Number
Last name
First Name
Phone
Fax
E-mail
Patient Demographics / Pre-treatment
Characteristics
Patient Initials
Gender
Female (FEMALE)
Male (MALE)
Unknown (UNKNOWN)
Date of Birth
Zip code
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Country of Residence
Method of Payment (check oneUSA only)
Medicaid (Medicaid)
Medicaid And Medicare (Medicaid and
Medicare)
Medicare (Medicare)
Medicare And Private Insurance
(Medicare and Private Insurance)
Military Or Veterans Sponsored Nos
(Military or Veterans Sponsored, Not
Otherwise Specified (NOS))
Military Sponsored (including Champus
& Tricare) (Military Sponsored (including
CHAMPUS & TRICARE))
No Means Of Payment (no Insurance)
(No means of payment (no insurance))
Other (Other)
Private Insurance (Private Insurance)
Self Pay (no Insurance) (Self Pay (No
Insurance))
Unknown (Unknown)
Veterans Sponsored (Veterans
Sponsored)
Race
A Person Having Origins In Any Of The
Original Peoples Of North And South
America (including Central America),
And Who Maintains Tribal Affiliation Or
Community Attachment. (American
Indian or Alaska Native)
A Person Having Origins In Any Of The
Original Peoples Of The Far East,
Southeast Asia, Or The Indian
Subcontinent Including, For Example,
Cambodia, China, India, Japan, Korea,
Malaysia, Pakistan, The Philippine
Islands, Thailand, And Vietnam. (Asian)
A Person Having Origins In Any Of The
Black Racial Groups Of Africa. Terms
Such As "haitian" Or "negro" Can Be
Used In Addition To "black Or African
American." (Black or African American)
A Person Having Origins In Any Of The
Original Peoples Of Hawaii, Guam,
Samoa, Or Other Pacific Islands. (Native
Hawaiian or other Pacific Islander)
Not Provided Or Available (Not
Reported)
Could Not Be Determined Or Unsure
(Unknown)
A Person Having Origins In Any Of The
Original Peoples Of Europe, The Middle
East, Or North Africa. (White)
Ethnicity
A Person Of Mexican, Puerto Rican,
Cuban, Central Or South American Or
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Other Spanish Culture Or Origin,
Regardless Of Race. (HISPANIC OR
LATINO)
A Person Not Meeting The Definition For
Hispanic Or Latino. (NOT HISPANIC OR
LATINO)
Not Provided Or Available (Not reported)
Could Not Be Determined Or Unsure
(UNKNOWN)
Intensity modulated radiation therapy
Is your site using IMRT for this study?
Yes
No
If yes, is your site certified?
Neurocognitive Testing Certification
Is at least one individual at your site certified for
Neurocognitive testing
Yes
No
Eligibility Check
Central pathology review submission. This review
is mandatory prior to registration to confirm
eligibility. It should be initiated as soon after
surgery as possible.
Yes
No
Treatment should begin >=2 weeks and <=5
weeks following surgery
Yes
No
Pre-registration Check
Consent form signed and dated
Yes
No
Date Informed Consent Signed
Authorization for use and disclosure of protected
health information signed and dated (If not a USA
institution check NA)
Not Applicable (NA)
No (No)
Yes (Yes)
Date of authorization (If a USA institution)
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The site has reviewed and understands the
process listed in Section 17.0 and must account
for sufficient time to complete pre-registration and
registration steps
Yes
No
An NCCTG or ABTC approved radiation
oncologist has seen the patient and confirms the
patient is a suitable candidate for this study
Yes
No
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Eligibility Acute Heart Failure
NCT01067859
A Phase IIb Study to Investigate the Efficacy and
Tolerability of Lower Doses Cinaciguat (25 µg/h, 10 µg/h)
Given Intravenously to Patients With Acute Decompensated
Chronic Congestive Heart Failure (ADHF); ODM derived
from: https://clinicaltrials.gov/show/NCT01067859
All rights reserved. Please visit https://medical-data-
models.org/forms/12600
Eligibility Acute Heart Failure
NCT01067859
Inclusion Criteria
male and female subjects, age >/= 18 years of
age;*
Yes
No
Postmenopausal women aged 18 years or older.
Yes
No
women with bilateral tubal ligation, women with
bilateral ovariectomy, and women with a
hysterectomy
Yes
No
subjects must have the clinical diagnosis of
congestive heart failure (chf) made at least three
months prior to enrollment*
Yes
No
subjects must experience worsening of both of
the symptoms below leading to hospitalization at
the time of entry into the study:*
Yes
No
dyspnea*
Yes
No
clinical evidence of volume overload*
Yes
No
Exclusion Criteria
Pregnancy or breastfeeding
Yes
No
acute de-novo heart failure*
Yes
No
acute myocardial infarction and/or myocardial
infarction within 30 days*
Yes
No
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valvular heart disease requiring surgical
intervention during the course of the study*
Yes
No
heart failure due to or associated with
uncorrected primary valvular disease,
malfunctioning artificial heart valve, or
uncorrected congenital heart disease*
Yes
No
primary hypertrophic cardiomyopathy*
Yes
No
acute inflammatory heart disease, eg, acute
myocarditis*
Yes
No
unstable angina requiring angiography*
Yes
No
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Eligibility Acute Heart Failure
NCT01127945
Study to Evaluate the Effectiveness of High Dose Statin
Loading in Acute Heart Failure Patients; ODM derived from:
https://clinicaltrials.gov/show/NCT01127945
All rights reserved. Please visit https://medical-data-
models.org/forms/12601
Eligibility Acute Heart Failure
NCT01127945
Inclusion Criteria
dyspnea at rest or minimal activity*
Yes
No
tachypnea (respiratory rate > 20/min)*
Yes
No
rales or pulmonary edema on chest x-ray
Exclusion Criteria
acute coronary syndrome*
Yes
No
hospitalization plan for ptca or cabg*
Yes
No
cardiogenic shock (systolic blood pressure <
80mmhg)*
Yes
No
uncontrolled hypertension (systolic blood
pressure > 180mmhg)*
Yes
No
allergy, adverse drug reaction, hypersensitivity to
statin*
Yes
No
troponin > 5 times upper limit of normal (uln)*
Yes
No
creatinine kinase-mb level > 3 times uln*
Yes
No
ast, alt > 3 times uln or acute hepatitis*
Yes
No
current or past history of muscle disease,
rhabdomyolysis*
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Yes
No
life expectancy < 6 months (e.g. metastatic
malignancy, liver cirrhosis)*
Yes
No
pregnancy or women at age of childbearing
potential*
Yes
No
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Eligibility Acute Heart Failure
NCT01301313
Efficacy and Safety of Levosimendan in Severe Acute
Heart Failure in Critical Children; ODM derived from:
https://clinicaltrials.gov/show/NCT01301313
All rights reserved. Please visit https://medical-data-
models.org/forms/12602
Eligibility Acute Heart Failure
NCT01301313
Inclusion Criteria
patients who give written consent to participate in
the study and for the transfer of material for
cellular and molecular studies.*
Yes
No
understand the purpose of the study and to be
available to perform the procedures written in the
protocol.*
Yes
No
any child of 1 day old to 18 years old, admitted to
the paediatric intensive care unit due to severe
acute heart failure of any etiology.*
Yes
No
Exclusion Criteria
Patients who express their wish of not to
participate in the protocol*
Yes
No
hypertrophic or restrictive cardiomyopathy*
Yes
No
aortic stenosis*
Yes
No
allergy to any drug used in the study*
Yes
No
it is not possible to prescribe the study
medication because it is contraindicated
according to the summary of the product
characteristic or according to the criteria of the
physician responsible for patient*
Yes
No
Pregnancy*
Yes
No
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NCT01800968
Functional Impact of GLP-1 for Heart Failure Treatment
(FIGHT); ODM derived from:
https://clinicaltrials.gov/show/NCT01800968
All rights reserved. Please visit https://medical-data-
models.org/forms/12603
Eligibility Acute Heart Failure
NCT01800968
Inclusion Criteria
age  18 years*
Yes
No
ahfs as defined by the presence of at least 1
symptom (dyspnea, orthopnea, or edema) and 1
sign (rales on auscultation, peripheral edema,
ascites, pulmonary vascular congestion on chest
radiography)*
Yes
No
ahfs is the primary cause of hospitalization*
Yes
No
prior clinical diagnosis of hf*
Yes
No
left ventricular ejection fraction(lvef) ≤ 40 percent
during the preceding 3 months (if no echo within
the preceding 3 months, an lvef ≤ 30 percent
during the preceding three years is acceptable)*
Yes
No
on evidence-based medication for hf (including
beta-blocker and ace-inhibitor/arb) or previously
deemed intolerant*
Yes
No
use of at least 80 mg or furosemide total daily
dose (or equivalent) prior to admission for ahfs (a
lower dose of a loop diuretic combined with a
thiazide will count as an "equivalent")*
Yes
No
willingness to provide informed consent*
Yes
No
Exclusion Criteria
ahfs due to acute myocarditis or acute myocardial
infarction*
Yes
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No
2. ongoing hemodynamically significant
arrhythmias contributing to hf decompensation*
Yes
No
inotrope, intra-aortic balloon pump (iabp) or other
mechanical circulatory support use at the time of
consent. prior use will not exclude a patient.*
Yes
No
4. current or planned left ventricular assist device
therapy in next 180 days*
Yes
No
united network for organ sharing status 1a or 1b*
Yes
No
b-type natriuretic peptide(bnp)< 250 or nt-
probnp<1,000 (not required per protocol but if
available and too low would be an exclusion;
within 48 hours of consent)*
Yes
No
hemoglobin (hgb) < 8.0 g/dl*
Yes
No
8. glomerular filtration rate(gfr) < 20 ml/min/1.73
m2 within 48 hours of consent*
Yes
No
systolic blood pressure < 80 mmhg at consent*
Yes
No
resting heart rate > 110 at consent*
Yes
No
acute coronary syndrome within 4 weeks as
defined by electrocardiographic (ecg) changes
and biomarkers of myocardial necrosis (e.g.
troponin) in an appropriate clinical setting (chest
discomfort or anginal equivalent)*
Yes
No
percutaneous coronary intervention, coronary
artery bypass grafting or new biventricular pacing
within past 4 weeks*
Yes
No
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primary hypertrophic cardiomyopathy*
Yes
No
infiltrative cardiomyopathy*
Yes
No
constrictive pericarditis or tamponade*
Yes
No
complex congenital heart disease*
Yes
No
non-cardiac pulmonary edema*
Yes
No
more than moderate aortic or mitral stenosis*
Yes
No
intrinsic (prolapse, rheumatic) valve disease with
severe mitral, aortic or tricuspid regurgitation*
Yes
No
sepsis, active infection (excluding cystitis) or
other comorbidity driving the hf decompensation*
Yes
No
acute or chronic severe liver disease as
evidenced by any of the following:
encephalopathy, variceal bleeding, international
normalized ration (inr) > 1.7 in the absence of
anticoagulation treatment*
Yes
No
terminal illness (other than hf) with expected
survival of less than 1 year*
Yes
No
previous adverse reaction to the study drug*
Yes
No
receipt of any investigational product in the
previous 30 days.*
Yes
No
enrollment or planned enrollment in another
randomized therapeutic clinical trial in next 6
months.*
3 / 5
Eligibility Acute Heart Failure NCT01800968
Yes
No
inability to comply with planned study
procedures*
Yes
No
pregnancy or breastfeeding mothers*
Yes
No
women of reproductive age not on adequate
contraception*
Yes
No
history of acute or chronic pancreatitis*
Yes
No
history of symptomatic gastroparesis*
Yes
No
familial or personal history of medullary thyroid
cancer or multiple endocrine neoplasia type-2
(men2)*
Yes
No
prior weight-loss surgery (i.e., roux-en-y gastric
bypass) or other gastric surgery associated with
increased endogenous glp-1 production*
Yes
No
prior or ongoing treatment with glp-1 receptor
agonists*
Yes
No
ongoing treatment with dipeptidyl peptide-iv
inhibitors (1 week washout required)*
Yes
No
ongoing treatment with thiazolidinedione*
Yes
No
oxygen-dependent chronic obstructive pulmonary
disease*
Yes
No
diabetic patients with history of 2 or more severe
hypoglycemia, diabetic ketoacidosis(dka) or
hyperglycemic, hyperosmotic nonketotic coma in
the preceding 12 months.*
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Yes
No
diagnosis of type 1 diabetes mellitus*
Yes
No
if diabetic, inadequate glycemic control with
glucose level > 300 mg/dl within 24 hours of
randomization*
Yes
No
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Eligibility Acute Heart Failure
NCT01822808
Bi Treatment With Hydralazine/Nitrates Versus Placebo in
Africans Admitted With Acute Heart Failure; ODM derived
from: https://clinicaltrials.gov/show/NCT01822808
All rights reserved. Please visit https://medical-data-
models.org/forms/12604
Eligibility Acute Heart Failure
NCT01822808
Inclusion Criteria
> 18 years of age*
Yes
No
hospital admission for acute heart failure as
defined by the presence of acute dyspnea and
the presence of clinical signs of heart failure on
physical examination.*
Yes
No
where available, nt-probnp >900 pg/ml, >1800
pg/ml if the patient has atrial fibrillation at
screening or >450 pg/ml if bmi > 35 kg/m2, lvef
<45 percent assessed by echocardiography or
other method within the previous 12 months*
Yes
No
background therapy with at least ace-inhibitor or
angiotensin receptor blocker (arb) and beta-
blocker (unless beta-blocker is contraindicated
due to severe volume overload, low output heart
failure, or cardiogenic shock)*
Yes
No
available for regular follow up*
Yes
No
Exclusion Criteria
currently being treated with hydralazine and/or
nitrates or a history of intolerance to oral therapy
with either hydralazine or nitrates.*
Yes
No
any intravenous treatment for heart failure, except
iv furosemide (eg. iv inotropes, pressors, nitrates
or nesiritide) at the time of screening.*
Yes
No
systolic blood pressure <100 mmhg*
Yes
No
plan for revascularization*
Yes
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No
greater than 96 hours after admission*
Yes
No
reversible etiology of acute heart failure such as
myocarditis, acute myocardial infarction,
arrhythmia. acute mi is defined as symptoms and
major electrocardiogram (ecg) changes(i.e., st
segment elevations), and arrhythmia includes
unstable heart rates above 120/min or below
50/min.*
Yes
No
hypertrophic obstructive cardiomyopathy,
constrictive cardiomyopathy, endomyocardial
fibroelastosis*
Yes
No
known severe congenital heart disease (such as
uncorrected tetralogy of fallot or transposition of
the aorta)*
Yes
No
severe aortic or mitral stenosis or severe
rheumatic mitral regurgitation.*
Yes
No
renal impairment (defined by creatinine >3 mg/dl)
at screening or on any type of dialysis.*
Yes
No
known hepatic impairment (total bilirubin
>3mg/dl) or increased ammonia levels at
screening.*
Yes
No
history of systemic lupus erythematous.*
Yes
No
stroke or tia within 2 weeks from screening.*
Yes
No
women who are pregnant or lactating.*
Yes
No
allergy to organic nitrates*
Yes
No
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history or presence of any other diseases (ie.
including malignancies or aids) with a life
expectancy of < 12 months*
Yes
No
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Eligibility Acute Heart Failure
NCT01834833
Consultation at 8 Days to Reduce Hospitalisations in Heart
Failure Patient; ODM derived from:
https://clinicaltrials.gov/show/NCT01834833
All rights reserved. Please visit https://medical-data-
models.org/forms/12605
Eligibility Acute Heart Failure
NCT01834833
Inclusion criteria
patient with decompensated heart failure
hospitalized in the hospital bichat,*
Yes
No
eligible for discharge*
Yes
No
being able to return for a consultation to the
hospital*
Yes
No
having nt-probnp at time of release ≥ 3500 ng /l
and/or a non optimized treatment of at time of
release -according to the responsible physician*
Yes
No
having signed the consent form by participation in
the study.*
Yes
No
Exclusion criteria
age < 18 years,
Yes
No
no membership in a national insurance scheme
or in the universal health
Yes
No
coverage (cmu)(free universal health care)(a
patient benefiting from the medical aid of the
state (ame) cannot be included)
Yes
No
participation to another protocol of research,
Yes
No
not being reachable by telephone in 6 months
Yes
No
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NCT02002702
Study of Safety, Tolerability and Pharmacokinetics of
Serelaxin in Japanese Acute Heart Failure (AHF) Patients;
ODM derived from:
https://clinicaltrials.gov/show/NCT02002702
All rights reserved. Please visit https://medical-data-
models.org/forms/12606
Eligibility Acute Heart Failure
NCT02002702
Inclusion Criteria
written informed consent must be obtained before
any study-specific assessment is performed.*
Yes
No
male or female ≥20 years of age*
Yes
No
hospitalized for ahf; ahf is defined as including all
of the followings measured at any time between
presentation (including the emergency
department) and the end of screening:*
Yes
No
dyspnea at rest or with minimal exertion*
Yes
No
pulmonary congestion on chest x-ray,*
Yes
No
bnp ≥350 pg/ml or nt-probnp ≥1,400 pg/ml*
Yes
No
sbp ≥125 mmhg at the start and at the end of
screening*
Yes
No
able to be randomized within 16 hours from
presentation to the hospital, including the
emergency department*
Yes
No
received intravenous (iv) furosemide of at least
40 mg (or equivalent) at any time between
presentation (this include outpatient clinic,
ambulance, or hospital including emergency
department) and the start of screening for the
study for the treatment of the current acute heart
failure (hf) episode.*
Yes
No
impaired renal function defined as an estimated
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glomerular filtration rate (egfr) between
presentation and randomization of ≥ 25 and≤ 75
ml/min/1.73 m2, calculated using the japanese
formula*
Yes
No
with body weight ≥30 kg and ≤160 kg
Exclusion Criteria
dyspnea primarily due to non-cardiac causes*
Yes
No
temperature >38.5°c (oral or equivalent) or sepsis
or active infection requiring iv anti-microbial
treatment*
Yes
No
clinical evidence of acute coronary syndrome
currently or within 30 days prior to enrollment.*
Yes
No
ahf due to significant arrhythmias, which include
any of the following: sustained ventricular
tachycardia, bradycardia with sustained
ventricular rate <45 beats per minute, or atrial
fibrillation/flutter with sustained ventricular
response of >130 beats per minute.*
Yes
No
other protocol defined inclusion/exclusion criteria
may apply.*
Yes
No
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Eligibility Acute Heart Failure
NCT02007720
Efficacy, Safety and Tolerability of Sexelaxin When Added
to Standard Therapy in AHF; ODM derived from:
https://clinicaltrials.gov/show/NCT02007720
All rights reserved. Please visit https://medical-data-
models.org/forms/12607
Eligibility Acute Heart Failure
NCT02007720
Inclusion Criteria
male or female  ≥ 18 years of age,*
Yes
No
hospitalized for ahf; ahf is defined as including all
of the followings measured at any time between
presentation (including the emergency
department) and the end of screening:*
Yes
No
dyspnea at rest or with minimal exertion*
Yes
No
pulmonary congestion on chest x-ray,*
Yes
No
brain natriuretic peptide (bnp) ≥350 pg/ml or nt-
probnp ≥1,400 pg/ml*
Yes
No
systolic bp ≥125 mmhg at the start and at the end
of screening*
Yes
No
able to be randomized within 16 hours from
presentation to the hospital, including the
emergency department and outpatient clinic*
Yes
No
received intravenous furosemide of at least 40
mg total (or equivalent) at any time between
presentation (this includes outpatient clinic,
ambulance, or hospital including emergency
department) and the start of screening for the
study for the treatment of the current acute hf
episode*
Yes
No
renal impairment defined as an estimate
glomerular filtration rate using the  between
presentation and randomization of ≥ 25 and
≤75ml/min/1.73m2, calculated using the
modification of diet in renal disease formula (or
1 / 3
modified smdrd formula according to specific
ethnic groups and local practice guidelines).*
Yes
No
with body weight  ≤ 160 kg
Yes
No
Exclusion Criteria
dyspnea primarily due to non-cardiac causes*
Yes
No
temperature >38.5°c (oral or equivalent),  sepsis,
active and clinically significant infection requiring
iv anti-microbial treatment or known presence or
evidence of human immunodeficiency virus (hiv)
infection (based on history and/or clinical
findings, including laboratory results obtained
during screening period).*
Yes
No
clinical evidence of acute coronary syndrome
currently or within 30 days prior to enrollment*
Yes
No
ahf due to significant arrhythmias, which include
any of the following: sustained ventricular
tachycardia, bradycardia with sustained
ventricular rate <45 beats per minute, or atrial
fibrillation/flutter with sustained ventricular
response of >130 beats per minute*
Yes
No
hepatic disease unrelated to heart failure etiology
and as determined by any one of the following:
ast and/or alt values exceeding 3 x uln and/or
bilirubin > 1.5 x uln at screening or  history of
hepatic encephalopathy, esophageal varices, or
portacaval shunt, or a diagnosis of cirrhosis by
any means, or evidence of chronic hepatitis b
(presence of hepatitis b surface antigen
production: positive hbsag), or chronic hepatitis c
infection (presence of hepatitis c genetic
replication: positive hepatitis c viral  rna, based
on history and/or clinical findings, including
laboratory results obtained during screening
period).*
Yes
No
significant uncorrected left ventricular outflow
obstruction, such as obstructive hypertrophic
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cardiomyopathy or severe aortic stenosis (i.e.,
aortic valve area <1.0 cm2 or mean gradient >50
mmhg on prior or current echocardiogram), and
severe mitral stenosis*
Yes
No
history of malignancy of any organ system (other
than localized basal cell carcinoma of the skin),
treated or untreated, within the past year with a
life expectancy less than 1 year*
Yes
No
other protocol defined inclusion/exclusion criteria
may apply.*
Yes
No
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Eligibility Acute Heart Failure
NCT02135835
A Study to Evaluate the Efficacy and Safety of Shenfu
Zhusheye in Patients With Acute Heart Failure; ODM
derived from: https://clinicaltrials.gov/show/NCT02135835
All rights reserved. Please visit https://medical-data-
models.org/forms/12608
Eligibility Acute Heart Failure
NCT02135835
Inclusion Criteria
clinical diagnosis of  acute heart failure according
to guidelines for the diagnosis and treatment of
acute heart failure 2010 of chinese medical
association(participants whose heart function
grade of nyha is ).*
Yes
No
lvef≤40%.*
Yes
No
nt-pro-bnp ≥1400 pg/ml or bnp ≥ 350pg/ml.*
Yes
No
ages 18-80, male or female.*
Yes
No
all participants signed the informed consent.*
Yes
No
Exclusion Criteria
participants with abnormal liver function (alt, ast
≥3 times of upper limit of normal) or abnormal
kidney function( cr≥1.5 times of upper limit of
normal or cr >3.0 mg/dl (> 265 µmol/l)).*
Yes
No
sbp ≥ 150mmhg.*
Yes
No
participants with severe chronic asthmatic
bronchitis or acute episode of lung diseases.*
Yes
No
participants with acute coronary syndrome,
cardiogenic shock, aortic dissection, pulmonary
embolism, severe ventricular arrhythmias,
complete atrioventricular block without cardiac
pacemaker, hypertrophic obstructive
cardiomyopathy, restrictive cardiomyopathy and
severe valvular disease without surgery.*
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Yes
No
participants with advanced cancer.*
Yes
No
breastfeeding, pregnant and potentially fertile
women participant.*
Yes
No
participants with insanity*
Yes
No
known allergies with shenfu zhusheye or its
ingredients in the past.*
Yes
No
participants who have taken part in other clinical
trials in last month.*
Yes
No
participants who abuse alcohol or other drugs in
last year.*
Yes
No
participants who are not suitable for clinical trial
under doctors' consideration.*
Yes
No
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Eligibility AIDS Related Lymphoma
NCT00001563
EPOCH Chemotherapy +/- IL-12 for Previously Untreated
and EPOCH Plus Rituximab for Previously Treated Patients
With AIDS-Associated Lymphoma; ODM derived from:
https://clinicaltrials.gov/show/NCT00001563
All rights reserved. Please visit https://medical-data-
models.org/forms/12617
Eligibility AIDS Related Lymphoma
NCT00001563
Criteria
aggressive cd20 + nhl confirmed by pathology,
dcs.*
hiv + serology.*
Yes
No
all stages (i-iv) of disease.*
Yes
No
nhl previously treated with up to two
chemotherapy regimens and evaluable disease.*
Yes
No
age greater than or equal to 18 years.*
Yes
No
laboratory test: (abnormalities are allowed if due
to organ involvement by lymphoma).*
Yes
No
creatinine less than or equal to 1.7.*
Yes
No
bilirubin must be less than 2.0 mg/dl, or total
bilirubin less than or equal to 3.7 mg/dl with direct
fraction less than or equal to 0.2 mg/dl and
indirect fraction of less than or equal 3.5 mg/dl in
patients for whom these abnormalities are felt to
be due to protease inhibitor therapy.*
Yes
No
ast and alt less than or equal to 3 times uln (ast
and alt less than or equal to 6 times uln for
patients on hyperalimentation for whom these
abnormalities are felt to be due to the
hyperalimentation).*
Yes
No
anc greater than or equal 1000/mm(3).*
Yes
No
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platelets must be greater than or equal to
75,000/mm(3) (patients with itp platelets greater
than or equal to 30,000/mm(3).*
Yes
No
signed informed consent and durable power of
attorney.*
Yes
No
Exclusion Criteria
Pregnancy or nursing*
Yes
No
history of clinical heart failure or symptomatic
ischemic heart disease.*
Yes
No
serious underlying medical condition or infection
other than hiv that would contraindicate epoch.*
Yes
No
concurrent anti-retroviral therapy during epoch
therapy.*
Yes
No
primary cns lymphoma.*
Yes
No
2 / 2
Eligibility AIDS Related Lymphoma NCT00001563
Study Completion-Toxicity Stem-Cell
Transplantation CASLAMB NCT00148148
A Study of Caspofungin, Liposomal Amphotericin B or the
Combination of Both for Patients After Stem-Cell
Transplantation
NCT00148148
All rights reserved. Please visit https://medical-data-
models.org/forms/12622
Study Completion-Toxicity Stem-Cell
Transplantation CASLAMB
NCT00148148
Allergien
Allergische Reaktionen / Überempfindlichkeit
Grad 0 (none) (1)
Grad 1 (transient rash, drug fever <38C)
(2)
Grad 2 (urticaria, drug fever 38C, and/or
asymptomatic bronchospasm) (3)
Grad 3 (symptomatic bronchospasm,
requiring parenteral medication/s, with or
without urticaria; allergy-related
edema/angioedema) (4)
Grad 4 (anaphylaxis) (5)
Verfassung
Fieber
Grad 0 (none) (1)
Grad 1 (38.0-39.0 °C) (2)
Grad 2 (39.1-40.0 °C) (3)
Grad 3 (>40.0 °C for <24 hrs) (4)
Grad 4 (>40.0 °C for >24 hrs) (5)
Rigor, Schüttelfrost
Grad 0 (none) (1)
Grad 1 (mild, requiring symptomatic
treatment (e.g., blanket) or non-narcotic
medication) (2)
Grad 2 (severe and/or prolonged,
requiring narcotic medication) (3)
Grad 3 (not responsive to narcotic
medication) (4)
Grad 4 (-) (5)
Haut
Ausschlag
Grad 0 (none) (1)
Grad 1 (macular or papular eruption or
erythema without associated symptoms)
(2)
Grad 2 (macular or papular eruption or
erythema with pruritus or other
associated symptoms covering <50% of
body surface or localized desquamation
or other lesions covering <50% of body
surface area) (3)
Grad 3 (symptomatic generalized
erythroderma or macular, papular or
vesicular eruption or desquamation
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covering ≥50% of body surface area) (4)
Grad 4 (generalized exfoliative dermatitis
or ulcerative dermatitis) (5)
Nesselausschlag
Grad 0 (none) (1)
Grad 1 (requiring no medication) (2)
Grad 2 (requiring PO or topical treatment
or IV medication or steroids for <24 hrs)
(3)
Grad 3 (requiring IV medication or
steroids for ≥24 hrs) (4)
Grad 4 (-) (5)
Magen-Darm
Übelkeit
Grad 0 (none) (1)
Grad 1 (able to eat) (2)
Grad 2 (oral intake significantly
decreased) (3)
Grad 3 (no significant intake, requiring IV
fluids) (4)
Grad 4 (-) (5)
Erbrechen
Grad 0 (none) (1)
Grad 1 (1 episode in 24 hours over
pretreatment) (2)
Grad 2 (2-5 episodes in 24 hours over
pretreatment) (3)
Grad 3 (≥6 episodes in 24 hours over
pretreatment; or need for IV fluids) (4)
Grad 4 (requiring parenteral nutrition; or
physiologic consequences requiring
intensive care; hemodynamic collapse)
(5)
Leber
Alkalische Phosphatase
Grad 0 (WNL) (1)
Grad 1 (>ULN - 2.5 x ULN) (2)
Grad 2 (>2.5 - 5.0 x ULN) (3)
Grad 3 (>5.0 - 20.0 x ULN) (4)
Grad 4 (>20.0 x ULN) (5)
Bilirubin
Grad 0 (WNL) (1)
Grad 1 (>ULN - 1.5 x ULN) (2)
Grad 2 (>1.5 - 3.0 x ULN) (3)
Grad 3 (>3.0 - 10.0 x ULN) (4)
Grad 4 (>10.0 x ULN) (5)
SGOT
Grad 0 (WNL) (1)
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Grad 1 (>ULN - 2.5 x ULN) (2)
Grad 2 (>2.5 - 5.0 x ULN) (3)
Grad 3 (>5.0 - 20.0 x ULN) (4)
Grad 4 (>20.0 x ULN) (5)
SGPT
Grad 0 (WNL) (1)
Grad 1 (>ULN - 2.5 x ULN) (2)
Grad 2 (>2.5 - 5.0 x ULN) (3)
Grad 3 (>5.0 - 20.0 x ULN) (4)
Grad 4 (>20.0 x ULN) (5)
Metabolisch / Labor
Übersäuerung
Grad 0 (normal) (1)
Grad 1 (pH <normal, but ≥7.3) (2)
Grad 2 (-) (3)
Grad 3 (pH <7.3) (4)
Grad 4 (pH <7.3 with lifethreatening
physiologic consequences) (5)
Amylase
Grad 0 (WNL) (1)
Grad 1 (>ULN - 1.5 x ULN) (2)
Grad 2 (>1.5 - 2.0 x ULN) (3)
Grad 3 (>2.0 - 5.0 x ULN) (4)
Grad 4 (>5.0 x ULN) (5)
Hypokaliämie
Grad 0 (WNL) (1)
Grad 1 (<LLN - 3.0 mmol/L) (2)
Grad 2 (-) (3)
Grad 3 (2.5 - <3.0 mmol/L) (4)
Grad 4 (<2.5 mmol/L) (5)
Hypomagnesiämie
Grad 0 (WNL) (1)
Grad 1 (<LLN - 1.2 mg/dL; <LLN - 0.5
mmol/L) (2)
Grad 2 (0.9 - <1.2 mg/dL; 0.4 - <0.5
mmol/L) (3)
Grad 3 (0.7 - <0.9 mg/dL; 0.3 - <0.4
mmol/L) (4)
Grad 4 (<0.7 mg/dL; <0.3 mmol/L) (5)
Lipase
Grad 0 (WNL) (1)
Grad 1 (>ULN - 1.5 x ULN) (2)
Grad 2 (>1.5 - 2.0 x ULN) (3)
Grad 3 (>2.0 - 5.0 x ULN) (4)
Grad 4 (>5.0 x ULN) (5)
Lungen
Kurzatmigkeit
Grad 0 (normal) (1)
Grad 1 (-) (2)
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Grad 2 (dyspnea on exertion) (3)
Grad 3 (dyspnea at normal level of
activity) (4)
Grad 4 (dyspnea at rest or requiring
ventilator support) (5)
Schmerz
Bauchschmerzen
Grad 0 (none) (1)
Grad 1 (mild pain not interfering with
function) (2)
Grad 2 (moderate pain: pain or
analgesics interfering with function, but
not interfering with activities of daily
living) (3)
Grad 3 (severe pain: pain or analgesics
severely interfering with activities of daily
living) (4)
Grad 4 (disabling) (5)
Brustschmerz
Grad 0 (none) (1)
Grad 1 (mild pain not interfering with
function) (2)
Grad 2 (moderate pain: pain or
analgesics interfering with function, but
not interfering with activities of daily
living) (3)
Grad 3 (severe pain: pain or analgesics
severely interfering with activities of daily
living) (4)
Grad 4 (disabling) (5)
Kopfschmerz
Grad 0 (none) (1)
Grad 1 (mild pain not interfering with
function) (2)
Grad 2 (moderate pain: pain or
analgesics interfering with function, but
not interfering with activities of daily
living) (3)
Grad 3 (severe pain: pain or analgesics
severely interfering with activities of daily
living) (4)
Grad 4 (disabling) (5)
Myalgie
Grad 0 (none) (1)
Grad 1 (mild pain not interfering with
function) (2)
Grad 2 (moderate pain: pain or
analgesics interfering with function, but
not interfering with activities of daily
living) (3)
Grad 3 (severe pain: pain or analgesics
severely interfering with activities of daily
living) (4)
Grad 4 (disabling) (5)
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Renal / Urogenitalsystem
Kreatinin
Grad 0 (WNL) (1)
Grad 1 (>ULN - 1.5 x ULN) (2)
Grad 2 (>1.5 - 3.0 x ULN) (3)
Grad 3 (>3.0 - 6.0 x ULN) (4)
Grad 4 (>6.0 x ULN) (5)
Nierenversagen
Grad 0 (none) (1)
Grad 1 (-) (2)
Grad 2 (-) (3)
Grad 3 (requiring dialysis, but reversible)
(4)
Grad 4 (requiring dialysis and
irreversible) (5)
Anhang VI: BMT-Komplex
Abstoßung des Transplantat (graft failure)
Grad 0 (absent) (1)
Grad 1 (mild) (2)
Grad 2 (moderate) (3)
Grad 3 (severe) (4)
Grad 4 (life-threatening) (5)
GVHD
Grad 0 (absent) (1)
Grad 1 (mild) (2)
Grad 2 (moderate) (3)
Grad 3 (severe) (4)
Grad 4 (life-threatening) (5)
Venenverschlusskrankheit
Grad 0 (absent) (1)
Grad 1 (mild) (2)
Grad 2 (moderate) (3)
Grad 3 (severe) (4)
Grad 4 (life-threatening) (5)
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Days 2-5 Toxicity Stem-Cell Transplantation
CASLAMB NCT00148148
A Study of Caspofungin, Liposomal Amphotericin B or the
Combination of Both for Patients After Stem-Cell
Transplantation
NCT00148148
All rights reserved. Please visit https://medical-data-
models.org/forms/12623
Days 2-5 Toxicity Stem-Cell
Transplantation CASLAMB
NCT00148148
Allergien
Allergische Reaktionen/
Überempfindlichkeit
Grad 0 (none) (1)
Grad 1 (transient rash, drug fever <38C)
(2)
Grad 2 (urticaria, drug fever 38C, and/or
asymptomatic bronchospasm) (3)
Grad 3 (symptomatic bronchial spasm,
requiring parenteral medication/s, with or
without urticaria; allergy-related
edema/angioedema) (4)
Grad 4 (anaphylaxis) (5)
Verfassung
Fieber
Grad 0 (none) (1)
Grad 1 (38.0-39.0 °C) (2)
Grad 2 (39.1-40.0 °C) (3)
Grad 3 (>40.0 °C for <24 hrs) (4)
Grad 4 (>40.0 °C for >24 hrs) (5)
Schüttelfrost
Grad 0 (none) (1)
Grad 1 (mild, requiring symptomatic
treatment (e.g., blanket) or non-narcotic
medication) (2)
Grad 2 (severe and/or prolonged,
requiring narcotic medication) (3)
Grad 3 (not responsive to narcotic
medication) (4)
Grad 4 (-) (5)
Haut
Ausschlag
Grad 0 (none) (1)
Grad 1 (macular or papular eruption or
erythema without associated symptoms)
(2)
Grad 2 (macular or papular eruption or
erythema with pruritus or other
associated symptoms covering <50% of
body surface or localized desquamation
or other lesions covering <50% of body
surface area) (3)
Grad 3 (symptomatic generalized
erythroderma or macular, papular or
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vesicular eruption or desquamation
covering ≥50% of body surface area) (4)
Grad 4 (generalized exfoliative dermatitis
or ulcerative dermatitis) (5)
Nesselausschlag
Grad 0 (none) (1)
Grad 1 (requiring no medication) (2)
Grad 2 (requiring PO or topical treatment
or IV medication or steroids for <24 hrs)
(3)
Grad 3 (requiring IV medication or
steroids for ≥24 hrs) (4)
Grad 4 (-) (5)
Magen-Darm
Übelkeit
Grad 0 (none) (1)
Grad 1 (able to eat) (2)
Grad 2 (oral intake significantly
decreased) (3)
Grad 3 (no significant intake, requiring IV
fluids) (4)
Grad 4 (-) (5)
Erbrechen
Grad 0 (none) (1)
Grad 1 (1 episode in 24 hours over
pretreatment) (2)
Grad 2 (2-5 episodes in 24 hours over
pretreatment) (3)
Grad 3 (≥6 episodes in 24 hours over
pretreatment; or need for IV fluids) (4)
Grad 4 (requiring parenteral nutrition; or
physiologic consequences requiring
intensive care; hemodynamic collapse)
(5)
Leber
Alkalische Phosphatase
Grad 0 (WNL) (1)
Grad 1 (>ULN - 2.5 x ULN) (2)
Grad 2 (>2.5 - 5.0 x ULN) (3)
Grad 3 (>5.0 - 20.0 x ULN) (4)
Grad 4 (>20.0 x ULN) (5)
Bilirubin
Grad 0 (WNL) (1)
Grad 1 (>ULN - 1.5 x ULN) (2)
Grad 2 (>1.5 - 3.0 x ULN) (3)
Grad 3 (>3.0 - 10.0 x ULN) (4)
Grad 4 (>10.0 x ULN) (5)
SGOT
Grad 0 (WNL) (1)
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Grad 1 (>ULN - 2.5 x ULN) (2)
Grad 2 (>2.5 - 5.0 x ULN) (3)
Grad 3 (>5.0 - 20.0 x ULN) (4)
Grad 4 (>20.0 x ULN) (5)
SGPT
Grad 0 (WNL) (1)
Grad 1 (>ULN - 2.5 x ULN) (2)
Grad 2 (>2.5 - 5.0 x ULN) (3)
Grad 3 (>5.0 - 20.0 x ULN) (4)
Grad 4 (>20.0 x ULN) (5)
Metabolisch / Labor
Übersäuerung
Grad 0 (normal) (1)
Grad 1 (pH <normal, but ≥7.3) (2)
Grad 2 (-) (3)
Grad 3 (pH <7.3) (4)
Grad 4 (pH <7.3 with lifethreatening
physiologic consequences) (5)
Amylase
Grad 0 (WNL) (1)
Grad 1 (>ULN - 1.5 x ULN) (2)
Grad 2 (>1.5 - 2.0 x ULN) (3)
Grad 3 (>2.0 - 5.0 x ULN) (4)
Grad 4 (>5.0 x ULN) (5)
Hypokaliämie
Grad 0 (WNL) (1)
Grad 1 (<LLN - 3.0 mmol/L) (2)
Grad 2 (-) (3)
Grad 3 (2.5 - <3.0 mmol/L) (4)
Grad 4 (<2.5 mmol/L) (5)
Hypomagnesiämie
Grad 0 (WNL) (1)
Grad 1 (<LLN - 1.2 mg/dL; <LLN - 0.5
mmol/L) (2)
Grad 2 (0.9 - <1.2 mg/dL; 0.4 - <0.5
mmol/L) (3)
Grad 3 (0.7 - <0.9 mg/dL; 0.3 - <0.4
mmol/L) (4)
Grad 4 (<0.7 mg/dL; <0.3 mmol/L) (5)
Lipase
Grad 0 (WNL) (1)
Grad 1 (>ULN - 1.5 x ULN) (2)
Grad 2 (>1.5 - 2.0 x ULN) (3)
Grad 3 (>2.0 - 5.0 x ULN) (4)
Grad 4 (>5.0 x ULN) (5)
Lunge
Kurzatmigkeit
Grad 0 (normal) (1)
Grad 1 (-) (2)
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Grad 2 (dyspnea on exertion) (3)
Grad 3 (dyspnea at normal level of
activity) (4)
Grad 4 (dyspnea at rest or requiring
ventilator support) (5)
Schmerz
Bauchschmerzen
Grad 0 (none) (1)
Grad 1 (mild pain not interfering with
function) (2)
Grad 2 (moderate pain: pain or
analgesics interfering with function, but
not interfering with activities of daily
living) (3)
Grad 3 (severe pain: pain or analgesics
severely interfering with activities of daily
living) (4)
Grad 4 (disabling) (5)
Brustschmerz
Grad 0 (none) (1)
Grad 1 (mild pain not interfering with
function) (2)
Grad 2 (moderate pain: pain or
analgesics interfering with function, but
not interfering with activities of daily
living) (3)
Grad 3 (severe pain: pain or analgesics
severely interfering with activities of daily
living) (4)
Grad 4 (disabling) (5)
Kopfschmerz
Grad 0 (none) (1)
Grad 1 (mild pain not interfering with
function) (2)
Grad 2 (moderate pain: pain or
analgesics interfering with function, but
not interfering with activities of daily
living) (3)
Grad 3 (severe pain: pain or analgesics
severely interfering with activities of daily
living) (4)
Grad 4 (disabling) (5)
Myalgie
Grad 0 (none) (1)
Grad 1 (mild pain not interfering with
function) (2)
Grad 2 (moderate pain: pain or
analgesics interfering with function, but
not interfering with activities of daily
living) (3)
Grad 3 (severe pain: pain or analgesics
severely interfering with activities of daily
living) (4)
Grad 4 (disabling) (5)
4 / 5
Days 2-5 Toxicity Stem-Cell Transplantation CASLAMB NCT00148148
Renal / Urogenitalsystem
Kreatinin
Grad 0 (WNL) (1)
Grad 1 (>ULN - 1.5 x ULN) (2)
Grad 2 (>1.5 - 3.0 x ULN) (3)
Grad 3 (>3.0 - 6.0 x ULN) (4)
Grad 4 (>6.0 x ULN) (5)
Nierenversagen
Grad 0 (none) (1)
Grad 1 (-) (2)
Grad 2 (-) (3)
Grad 3 (requiring dialysis, but reversible)
(4)
Grad 4 (requiring dialysis and
irreversible) (5)
Anhang VI: BMT-Komplex
Abstoßung des Transplantat (graft failure)
Grad 0 (absent) (1)
Grad 1 (mild) (2)
Grad 2 (moderate) (3)
Grad 3 (severe) (4)
Grad 4 (life-threatening) (5)
GVHD
Grad 0 (absent) (1)
Grad 1 (mild) (2)
Grad 2 (moderate) (3)
Grad 3 (severe) (4)
Grad 4 (life-threatening) (5)
Venenverschlusskrankheit
Grad 0 (absent) (1)
Grad 1 (mild) (2)
Grad 2 (moderate) (3)
Grad 3 (severe) (4)
Grad 4 (life-threatening) (5)
5 / 5
Days 2-5 Toxicity Stem-Cell Transplantation CASLAMB NCT00148148
Study completion-Lab Stem-Cell
Transplantation CASLAMB NCT00148148
A Study of Caspofungin, Liposomal Amphotericin B or the
Combination of Both for Patients After Stem-Cell
Transplantation
NCT00148148
All rights reserved. Please visit https://medical-data-
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Study completion-Lab Stem-Cell
Transplantation CASLAMB
NCT00148148
Dokumentationsdatum
Datum
Elektrolyte
Natrium
Calcium
Unit (1)
Kalium
Unit (1)
Magnesium
Unit (1)
Stoffwechsel
Glucose
Harnsäure
Leber
Gesamteiweiss
SGOT
Gesamtbilirubin
SGPT
Alkal.
Phosphatase
gGT
LDH
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Pankreas
Amylase
Lipase
Niere
Harnstoff
Kreatininclearance
nach Cockroft & Gault
Kreatinin
Infektion
CRP (optional)
Gerinnung (optional)
TPZ
TZ
Fibrinogen
Hämatologie
Datum der Probeentnahme
Erythrozyten
Hämoglobin
Hämatokrit
Thrombozyten
Leukozyten
Neutrophile Granulozyten
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Hämatologie (optional, Absolutwerte)
Lymphozyten
Monozyten
Eosinophile
Basophile
Sonstige
Urin-Status
Datum der Probeentnahme
Leukozyten
positiv (1)
negativ (2)
Nitrit
positiv (1)
negativ (2)
Eiweiß
positiv (1)
negativ (2)
Ketonkörper
positiv (1)
negativ (2)
pH
spezifisches
Gewicht
Urobilinogen
normal (1)
abnormal (2)
Bilirubin
positiv (1)
negativ (2)
Erythrozyten
positiv (1)
negativ (2)
Glucose
normal (1)
abnormal (2)
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Eligibility Acute Heart Failure
NCT02141607
Evolution of Molecular Biomarkers in Acute Heart Failure
Induced by Shock; ODM derived from:
https://clinicaltrials.gov/show/NCT02141607
All rights reserved. Please visit https://medical-data-
models.org/forms/12627
Eligibility Acute Heart Failure
NCT02141607
Inclusion Criteria
for patients in septic shock, severity: sofa score >
5*
Yes
No
for patients in cardiogenic shock, severity: sofa
score > 5*
Yes
No
first blood sample available within 16 hours from
admission to the icu.*
Yes
No
only community medical acquired septic shock.
we include patients with shock symptoms and
shock diagnosis occurring within the first 48
hours from hospital admission*
Yes
No
informed consent available*
Yes
No
Exclusion Criteria
risk of rapidly fatal illness and death within 24
hours*
Yes
No
patients already enrolled in other interventional
studies*
Yes
No
n > 4 units of red blood cells transfused*
Yes
No
patients treated with plasma or whole blood*
Yes
No
active hematological malignancy*
Yes
No
metastatic cancer*
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Yes
No
immunodepression, including transplant patients:
hiv+, constitutive immune system deficiency,
immunosuppressive therapy, systemic
corticosteroids (aerosols allowed)*
Yes
No
patients with pre-existing end stage renal disease
needing renal replacement therapy (rrt). the
introduction of continuous veno-venous
hemofiltration (cvvh), from the day of admission
onward is allowed.*
Yes
No
cardiac surgery patients*
Yes
No
cirrhosis child c*
Yes
No
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Eligibility Acute Heart Failure
NCT02151383
Pharmacokinetics & Safety of Serelaxin on Top of Standard
of Care Therapy in Pediatric Patients With Acute Heart
Failure; ODM derived from:
https://clinicaltrials.gov/show/NCT02151383
All rights reserved. Please visit https://medical-data-
models.org/forms/12630
Eligibility Acute Heart Failure
NCT02151383
Inclusion Criteria
body weight ≥2.5 kg to ≤120 kg*
Yes
No
hospitalization in an intensive care unit or step-
down unit with the following:*
Yes
No
signs and symptoms of acute heart failure of any
etiology*
Yes
No
stable dose of vasoactive and/or inotropic drugs*
Yes
No
for non-surgical patients echocardiographic
evidence of reduced ventricular function (ejection
fraction <50 percent or fractional shortening <28
percent)*
Yes
No
systolic blood pressure (sbp) ≥25th percentile
sbp for age and gender.*
Yes
No
Exclusion Criteria
moderate to severe left ventricular outflow tract,
mitral stenosis, or aortic arch obstruction*
Yes
No
single ventricle physiology*
Yes
No
fixed pulmonary hypertension*
Yes
No
blood lactate levels >5 mmol/l at screening*
Yes
No
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birth < 36 weeks post-conceptual age (for
patients <1year old)*
Yes
No
confirmed or clinically suspected systemic
infection or severe localized infection*
Yes
No
dyspnea or acute lung injury primarily due to non-
cardiac causes*
Yes
No
patients with severe renal impairment, those
known to have significant renal disease and
those having renal replacement therapy*
Yes
No
high use of inotropic and/or vasoactive agents at
screening*
Yes
No
electrocardiographic abnormalities*
Yes
No
solid organ transplant recipient within 1 year of
transplantation or one who presents with severe
organ rejection*
Yes
No
other protocol defined inclusion/exclusion criteria
may apply.*
Yes
No
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Eligibility Acute Heart Failure
NCT02350114
An Observational Study of the Functional Capacity of Heart
Failure; ODM derived from:
https://clinicaltrials.gov/show/NCT02350114
All rights reserved. Please visit https://medical-data-
models.org/forms/12631
Eligibility Acute Heart Failure
NCT02350114
Inclusion Criteria
have a left ventricular ejection fraction (lvef) 40
percent, as assessed by any method, e.g.,
echocardiography, a multigated acquisition
(muga) scan or magnetic resonance imaging
(mri);*
Yes
No
present with signs and symptoms considered to
be primarily due to ahf and be admitted to the
hospital for ahf;*
Yes
No
confirmation verbally that the patient was
ambulatory, i.e., able to walk >30m, prior to
developing symptoms of ahf leading to the
current admission;*
Yes
No
be capable of understanding the nature of the
trial; be willing and able to comply with the
inpatient and outpatient study protocol
requirements for the duration of the study; and be
willing to participate, as documented by written
informed consent.*
Yes
No
Exclusion Criteria
have a systolic blood pressure <90mmhg or
>170mmhg at baseline;*
Yes
No
have an anticipated  need for an invasive
procedure within 3 days of study enrollment, e.g.,
due to  hemodynamic or cardiac rhythm
instability, or acute coronary syndrome, requiring
procedures including, but not limited to, cardiac
catheterization, placement of a
defibrillator/pacemaker, or placement of a
pulmonary artery catheter;*
Yes
No
have a primary hf etiology attributable to either
restrictive/obstructive cardiomyopathy, idiopathic
hypertrophic cardiomyopathy (as defined by any
1 / 2
wall thickness > 1.8cm) that is obstructive, or
uncorrected severe valvular disease (except
mitral regurgitation);*
Yes
No
have any other comorbidities that limit ambulation
more than the patient's heart failure, e.g.,
symptomatic peripheral arterial disease, copd,
arthritis or other condition, as confirmed verbally
with the patient;*
Yes
No
have severe renal insufficiency (defined as a gfr
<30ml/min/1.73m2 according to the mdrd
equation);*
Yes
No
have an anticipated survival of less than 90 days,
for any reason;*
Yes
No
have received an investigational agent (drug,
device or biologic product) within 30 days (or, if
longer, 5 half-lives for a drug or biologic agent)
prior to study entry, or be planning to receive an
investigational agent at any time throughout the
full duration of the study until at least study day
35;*
Yes
No
have any other clinically significant laboratory
abnormality, medical condition or social
circumstance that, in the investigators opinion,
makes it inappropriate for the patient to
participate in this clinical trial.*
Yes
No
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Day of last Dose-Toxicity Stem-Cell
Transplantation CASLAMB NCT00148148
A Study of Caspofungin, Liposomal Amphotericin B or the
Combination of Both for Patients After Stem-Cell
Transplantation
NCT00148148
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Day of last Dose-Toxicity Stem-Cell
Transplantation CASLAMB
NCT00148148
Allergien
Allergische Reaktionen / Überempfindlichkeit
Grad 0 (none) (1)
Grad 1 (transient rash, drug fever <38C)
(2)
Grad 2 (urticaria, drug fever 38C, and/or
asymptomatic bronchospasm) (3)
Grad 3 (symptomatic bronchospasm,
requiring parenteral medication/s, with or
without urticaria; allergy-related
edema/angioedema) (4)
Grad 4 (anaphylaxis) (5)
Verfassung
Fieber
Grade 0 (none) (1)
Grade 1 (38.0-39.0 °C) (2)
Grade 2 (39.1-40.0 °C) (3)
Grade 3 (>40.0 °C for <24 hrs) (4)
Grade 4 (>40.0 °C for >24 hrs) (5)
Schüttelfrost
Grade 0 (none) (1)
Grade 1 (mild, requiring symptomatic
treatment (e.g., blanket) or non-narcotic
medication) (2)
Grade 2 (severe and/or prolonged,
requiring narcotic medication) (3)
Grade 3 (not responsive to narcotic
medication) (4)
Grade 4 (-) (5)
Haut
Ausschlag
Grade 0 (none) (1)
Grade 1 (macular or papular eruption or
erythema without associated symptoms)
(2)
Grade 2 (macular or papular eruption or
erythema with pruritus or other
associated symptoms covering <50% of
body surface or localized desquamation
or other lesions covering <50% of body
surface area) (3)
Grade 3 (symptomatic generalized
erythroderma or macular, papular or
vesicular eruption or desquamation
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covering ≥50% of body surface area) (4)
Grade 4 (generalized exfoliative
dermatitis or ulcerative dermatitis) (5)
Nesselausschlag
Grade 0 (none) (1)
Grade 1 (requiring no medication) (2)
Grade 2 (requiring PO or topical
treatment or IV medication or steroids for
<24 hrs) (3)
Grade 3 (requiring IV medication or
steroids for ≥24 hrs) (4)
Grade 4 (-) (5)
Magen-Darm
Übelkeit
Grade 0 (none) (1)
Grade 1 (able to eat) (2)
Grade 2 (oral intake significantly
decreased) (3)
Grade 3 (no significant intake, requiring
IV fluids) (4)
Grade 4 (-) (5)
Erbrechen
Grade 0 (none) (1)
Grade 1 (1 episode in 24 hours over
pretreatment) (2)
Grade 2 (2-5 episodes in 24 hours over
pretreatment) (3)
Grade 3 (≥6 episodes in 24 hours over
pretreatment; or need for IV fluids) (4)
Grade 4 (requiring parenteral nutrition; or
physiologic consequences requiring
intensive care; hemodynamic collapse)
(5)
Leber
Alkalische Phosphatase
Grade 0 (WNL) (1)
Grade 1 (>ULN - 2.5 x ULN) (2)
Grade 2 (>2.5 - 5.0 x ULN) (3)
Grade 3 (>5.0 - 20.0 x ULN) (4)
Grade 4 (>20.0 x ULN) (5)
Bilirubin
Grade 0 (WNL) (1)
Grade 1 (>ULN - 1.5 x ULN) (2)
Grade 2 (>1.5 - 3.0 x ULN) (3)
Grade 3 (>3.0 - 10.0 x ULN) (4)
Grade 4 (>10.0 x ULN) (5)
SGOT
Grade 0 (WNL) (1)
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Grade 1 (>ULN - 2.5 x ULN) (2)
Grade 2 (>2.5 - 5.0 x ULN) (3)
Grade 3 (>5.0 - 20.0 x ULN) (4)
Grade 4 (>20.0 x ULN) (5)
SGPT
Grade 0 (WNL) (1)
Grade 1 (>ULN - 2.5 x ULN) (2)
Grade 2 (>2.5 - 5.0 x ULN) (3)
Grade 3 (>5.0 - 20.0 x ULN) (4)
Grade 4 (>20.0 x ULN) (5)
Metabolisch / Labor
Übersäuerung
Grade 0 (normal) (1)
Grade 1 (pH <normal, but ≥7.3) (2)
Grade 2 (-) (3)
Grade 3 (pH <7.3) (4)
Grade 4 (pH <7.3 with lifethreatening
physiologic consequences) (5)
Amylase
Grade 0 (WNL) (1)
Grade 1 (>ULN - 1.5 x ULN) (2)
Grade 2 (>1.5 - 2.0 x ULN) (3)
Grade 3 (>2.0 - 5.0 x ULN) (4)
Grade 4 (>5.0 x ULN) (5)
Hypokaliämie
Grade 0 (WNL) (1)
Grade 1 (<LLN - 3.0 mmol/L) (2)
Grade 2 (-) (3)
Grade 3 (2.5 - <3.0 mmol/L) (4)
Grade 4 (<2.5 mmol/L) (5)
Hypomagnesiämie
Grade 0 (WNL) (1)
Grade 1 (<LLN - 1.2 mg/dL; <LLN - 0.5
mmol/L) (2)
Grade 2 (0.9 - <1.2 mg/dL; 0.4 - <0.5
mmol/L) (3)
Grade 3 (0.7 - <0.9 mg/dL; 0.3 - <0.4
mmol/L) (4)
Grade 4 (<0.7 mg/dL; <0.3 mmol/L) (5)
Lipase
Grade 0 (WNL) (1)
Grade 1 (>ULN - 1.5 x ULN) (2)
Grade 2 (>1.5 - 2.0 x ULN) (3)
Grade 3 (>2.0 - 5.0 x ULN) (4)
Grade 4 (>5.0 x ULN) (5)
Lungen
Dyspnoe
Grade 0 (normal) (1)
Grade 1 (-) (2)
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Grade 2 (dyspnea on exertion) (3)
Grade 3 (dyspnea at normal level of
activity) (4)
Grade 4 (dyspnea at rest or requiring
ventilator support) (5)
Schmerz
Bauchschmerzen
Grade 0 (none) (1)
Grade 1 (mild pain not interfering with
function) (2)
Grade 2 (moderate pain: pain or
analgesics interfering with function, but
not interfering with activities of daily
living) (3)
Grade 3 (severe pain: pain or analgesics
severely interfering with activities of daily
living) (4)
Grade 4 (disabling) (5)
Brustschmerz
Grade 0 (none) (1)
Grade 1 (mild pain not interfering with
function) (2)
Grade 2 (moderate pain: pain or
analgesics interfering with function, but
not interfering with activities of daily
living) (3)
Grade 3 (severe pain: pain or analgesics
severely interfering with activities of daily
living) (4)
Grade 4 (disabling) (5)
Kopfschmerz
Grade 0 (none) (1)
Grade 1 (mild pain not interfering with
function) (2)
Grade 2 (moderate pain: pain or
analgesics interfering with function, but
not interfering with activities of daily
living) (3)
Grade 3 (severe pain: pain or analgesics
severely interfering with activities of daily
living) (4)
Grade 4 (disabling) (5)
Myalgie
Grade 0 (none) (1)
Grade 1 (mild pain not interfering with
function) (2)
Grade 2 (moderate pain: pain or
analgesics interfering with function, but
not interfering with activities of daily
living) (3)
Grade 3 (severe pain: pain or analgesics
severely interfering with activities of daily
living) (4)
Grade 4 (disabling) (5)
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Renal / Genitourinary
Kreatinin
Grade 0 (WNL) (1)
Grade 1 (>ULN - 1.5 x ULN) (2)
Grade 2 (>1.5 - 3.0 x ULN) (3)
Grade 3 (>3.0 - 6.0 x ULN) (4)
Grade 4 (>6.0 x ULN) (5)
Nierenversagen
Grade 0 (none) (1)
Grade 1 (-) (2)
Grade 2 (-) (3)
Grade 3 (requiring dialysis, but
reversible) (4)
Grade 4 (requiring dialysis and
irreversible) (5)
Anhang VI: BMT-Komplex
Abstoßung des Transplantats (graft failure)
Grade 0 (absent) (1)
Grade 1 (mild) (2)
Grade 2 (moderate) (3)
Grade 3 (severe) (4)
Grade 4 (life-threatening) (5)
GVHD
Grade 0 (absent) (1)
Grade 1 (mild) (2)
Grade 2 (moderate) (3)
Grade 3 (severe) (4)
Grade 4 (life-threatening) (5)
Venenverschlusskrankheit
Grade 0 (absent) (1)
Grade 1 (mild) (2)
Grade 2 (moderate) (3)
Grade 3 (severe) (4)
Grade 4 (life-threatening) (5)
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Baseline-Toxicity Stem-Cell
Transplantation CASLAMB
NCT00148148
Allergien
Allergie
Grad 0 (none) (1)
Grade 1 (transient rash, drug fever
<38°C) (2)
Grade 2 (urticaria, drug fever ≥38°C,
and/or asymptomatic bronchospasm) (3)
Grade 3 (symptomatic bronchospasm,
requiring parenteral medication/s, with or
without urticaria; allergy-related
edema/angioedema) (4)
Grade 4 (anaphylaxis) (5)
Verfassung des Patienten
Fieber
°C
Grad 0 (none) (1)
Grad 1 (38.0-39.0 °C) (2)
Grad 2 (39.1-40.0 °C) (3)
Grad 3 (>40.0 °C for <24 hrs) (4)
Grad 4 (>40.0 °C for >24 hrs) (5)
Schüttelfrost
Grad 0 (none) (1)
Grad 1 (mild, requiring symptomatic
treatment (e.g., blanket) or non-narcotic
medication) (2)
Grad 2 (severe and/or prolonged,
requiring narcotic medication) (3)
Grad 3 (not responsive to narcotic
medication) (4)
Grad 4 (-) (5)
Haut
Ausschlag
Grad 0 (none) (1)
Grad 1 (macular or papular eruption or
erythema without associated symptoms)
(2)
Grad 2 (macular or papular eruption or
erythema with pruritus or other
associated symptoms covering <50% of
body surface or localized desquamation
or other lesions covering <50% of body
surface area) (3)
Grad 3 (symptomatic generalized
erythroderma or macular, papular or
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vesicular eruption or desquamation
covering ≥50% of body surface area) (4)
Grad 4 (generalized exfoliative dermatitis
or ulcerative dermatitis) (5)
Nesselausschlag
Grad 0 (none) (1)
Grad 1 (requiring no medication) (2)
Grad 2 (requiring PO or topical treatment
or IV medication or steroids for <24 hrs)
(3)
Grad 3 (requiring IV medication or
steroids for ≥24 hrs) (4)
Grad 4 (-) (5)
Magen-Darm
Übelkeit
Grade 0 (none) (1)
Grade 1 (able to eat) (2)
Grade 2 (oral intake significantly
decreased) (3)
Grade 3 (no significant intake, requiring
IV fluids) (4)
Grade 4 (-) (5)
Erbrechen
Grade 0 (none) (1)
Grade 1 (1 episode in 24 hours over
pretreatment) (2)
Grade 2 (2-5 episodes in 24 hours over
pretreatment) (3)
Grade 3 (≥6 episodes in 24 hours over
pretreatment; or need for IV fluids) (4)
Grade 4 (requiring parenteral nutrition; or
physiologic consequences requiring
intensive care; hemodynamic collapse)
(5)
Leber
Alkalische Phosphatase
Grad 0 (WNL) (1)
Grad 1 (>ULN - 2.5 x ULN) (2)
Grad 2 (>2.5 - 5.0 x ULN) (3)
Grad 3 (>5.0 - 20.0 x ULN) (4)
Grad 4 (>20.0 x ULN) (5)
Bilirubin
Grad 0 (WNL) (1)
Grad 1 (>ULN - 1.5 x ULN) (2)
Grad 2 (>1.5 - 3.0 x ULN) (3)
Grad 3 (>3.0 - 10.0 x ULN) (4)
Grad 4 (>10.0 x ULN) (5)
SGOT
Grad 0 (WNL) (1)
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Grad 1 (>ULN - 2.5 x ULN) (2)
Grad 2 (>2.5 - 5.0 x ULN) (3)
Grad 3 (>5.0 - 20.0 x ULN) (4)
Grad 4 (>20.0 x ULN) (5)
SGPT
Grad 0 (WNL) (1)
Grad 1 (>ULN - 2.5 x ULN) (2)
Grad 2 (>2.5 - 5.0 x ULN) (3)
Grad 3 (>5.0 - 20.0 x ULN) (4)
Grad 4 (>20.0 x ULN) (5)
Metabolisch / Labor
Übersäuerung
Grad 0 (normal) (1)
Grad 1 (pH <normal, but ≥7.3) (2)
Grad 2 (-) (3)
Grad 3 (pH <7.3) (4)
Grad 4 (pH <7.3 with lifethreatening
physiologic consequences) (5)
Amylase
Grad 0 (WNL) (1)
Grad 1 (>ULN - 1.5 x ULN) (2)
Grad 2 (>1.5 - 2.0 x ULN) (3)
Grad 3 (>2.0 - 5.0 x ULN) (4)
Grad 4 (>5.0 x ULN) (5)
Hypokaliämie
Grad 0 (WNL) (1)
Grad 1 (<LLN - 3.0 mmol/L) (2)
Grad 2 (-) (3)
Grad 3 (2.5 - <3.0 mmol/L) (4)
Grad 4 (<2.5 mmol/L) (5)
Hypomagnesiämie
Grad 0 (WNL) (1)
Grad 1 (<LLN - 1.2 mg/dL; <LLN - 0.5
mmol/L) (2)
Grad 2 (0.9 - <1.2 mg/dL; 0.4 - <0.5
mmol/L) (3)
Grad 3 (0.7 - <0.9 mg/dL; 0.3 - <0.4
mmol/L) (4)
Grad 4 (<0.7 mg/dL; <0.3 mmol/L) (5)
Lipase
Grad 0 (WNL) (1)
Grad 1 (>ULN - 1.5 x ULN) (2)
Grad 2 (>1.5 - 2.0 x ULN) (3)
Grad 3 (>2.0 - 5.0 x ULN) (4)
Grad 4 (>5.0 x ULN) (5)
Lungen
Kurzatmigkeit
Grad 0 (normal) (1)
Grad 1 (-) (2)
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Grad 2 (dyspnea on exertion) (3)
Grad 3 (dyspnea at normal level of
activity) (4)
Grad 4 (dyspnea at rest or requiring
ventilator support) (5)
Schmerz
Bauchschmerzen
Grad 0 (none) (1)
Grad 1 (mild pain not interfering with
function) (2)
Grad 2 (moderate pain: pain or
analgesics interfering with function, but
not interfering with activities of daily
living) (3)
Grad 3 (severe pain: pain or analgesics
severely interfering with activities of daily
living) (4)
Grad 4 (disabling) (5)
Brustschmerz
Grad 0 (none) (1)
Grad 1 (mild pain not interfering with
function) (2)
Grad 2 (moderate pain: pain or
analgesics interfering with function, but
not interfering with activities of daily
living) (3)
Grad 3 (severe pain: pain or analgesics
severely interfering with activities of daily
living) (4)
Grad 4 (disabling) (5)
Kopfschmerz
Grad 0 (none) (1)
Grad 1 (mild pain not interfering with
function) (2)
Grad 2 (moderate pain: pain or
analgesics interfering with function, but
not interfering with activities of daily
living) (3)
Grad 3 (severe pain: pain or analgesics
severely interfering with activities of daily
living) (4)
Grad 4 (disabling) (5)
Myalgie
Grad 0 (none) (1)
Grad 1 (mild pain not interfering with
function) (2)
Grad 2 (moderate pain: pain or
analgesics interfering with function, but
not interfering with activities of daily
living) (3)
Grad 3 (severe pain: pain or analgesics
severely interfering with activities of daily
living) (4)
Grad 4 (disabling) (5)
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Niere / Urogenital
Kreatinin
Grade 0 (WNL) (1)
Grade 1 (>ULN - 1.5 x ULN) (2)
Grade 2 (>1.5 - 3.0 x ULN) (3)
Grade 3 (>3.0 - 6.0 x ULN) (4)
Grade 4 (>6.0 x ULN) (5)
Nierenversagen
Grad 0 (none) (1)
Grad 1 (-) (2)
Grad 2 (-) (3)
Grad 3 (requiring dialysis, but reversible)
(4)
Grad 4 (requiring dialysis and
irreversible) (5)
Anhang VI: BMT-Komplex
Abstoßung des Transplantats (graft failure)
Grade 0 (absent) (1)
Grade 1 (mild) (2)
Grade 2 (moderate) (3)
Grade 3 (severe) (4)
Grade 4 (life-threatening) (5)
GVHD
Grade 0 (absent) (1)
Grade 1 (mild) (2)
Grade 2 (moderate) (3)
Grade 3 (severe) (4)
Grade 4 (life-threatening) (5)
Venenverschlusskrankheit
Grade 0 (absent) (1)
Grade 1 (mild) (2)
Grade 2 (moderate) (3)
Grade 3 (severe) (4)
Grade 4 (life-threatening) (5)
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Baseline-Medication Stem-Cell
Transplantation CASLAMB NCT00148148
A Study of Caspofungin, Liposomal Amphotericin B or the
Combination of Both for Patients After Stem-Cell
Transplantation
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Baseline-Medication Stem-Cell
Transplantation CASLAMB
NCT00148148
Medikation
Datum Medikation Tag 1
Biposomal Amphotericin B
Biposomal Amphotericin B
Ja
Nein
Soll-Dosis (3 mg/kg KG)
mg / kg
Absolut-Dosis
Infusionsbeginn
Infusionsende
caspofungin
Caspofungin
Ja
Nein
absolute dose
Infusionsbeginn
Infusionsende
Blutentnahmen für die Analyse der
Plasmakonzentrationen
Blutprobe 1
Blood sample 2
Blood sample 3
Blood sample 4
1 / 2
Blood sample 5
Datum und Unterschrift
Datum, Unterschrift
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Eligibility Acute Leukaemia NCT01521611
Targeted Radiotherapy in HSCT for Poor Risk
Haematological Malignancy; ODM derived from:
https://clinicaltrials.gov/show/NCT01521611
All rights reserved. Please visit https://medical-data-
models.org/forms/12636
Eligibility Acute Leukaemia
NCT01521611
Inclusion Criteria
an underlying haematological malignancy
including acute myeloid leukaemia in cr1 but with
poor prognostic features or in >cr1 or in relapse;
acute lymphoblastic leukaemia; transformed
myelodysplasia, chronic myeloid leukaemia
(accelerated phase or blast transformation, poor
response or intolerance of tyrosine kinase
inhibitors), myeloma. patients may be in
remission, partial remission or relapse.*
Yes
No
no concurrent or recent (within 3 weeks)
chemotherapy for the underlying haematological
condition*
Yes
No
for patients with relapsed leukaemia, bm blasts
must represent < 20 percent of bm nucleated
cells.*
Yes
No
although the bm remission status is not
important, patients must have cellularity > 10
percent.*
Yes
No
as malignant plasma cells may or may not
express cd66 antigens, patients with myeloma
must have less than 30 percent plasma cells (as
a percentage of total nucleated cells) in the bm at
the time of the study.*
Yes
No
age = or >18 yrs.*
Yes
No
who performance status of 0, 1 or 2 (appendix
5).*
Yes
No
predicted life-expectancy of greater than four
months.*
Yes
No
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patients must be negative for human anti-mouse
antibodies (hama).*
Yes
No
wbc   < 30 x 109/l (absolute neutrophil count >0.5
x 109/l) platelets > 50 x 109/l (platelet support is
permitted)*
Yes
No
plasma creatinine < 120 micromol/l (or creatinine
clearance or edta clearance > 50 ml/min) plasma
bilirubin  < 30 micromol/l ast no more than 2.5 x
upper limit of the normal range.*
Yes
No
patient must be able to provide written informed
consent.*
Yes
No
Exclusion Criteria
any serious intercurrent disease.*
Yes
No
patients with bm cellularity < 10%.*
Yes
No
history of atopic asthma, eczema or allergy to
rodent protein, confirmed history of severe
allergic reactions to penicillin or streptomycin.*
Yes
No
positive hama.*
Yes
No
patients unable to provide informed consent or
who are unable to co-operate for reasons of poor
mental or physical health.*
Yes
No
pregnancy*
Yes
No
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Eligibility Acute Leukemia NCT01020175
Peripheral Blood (PB) Versus Bone Marrow (BM) in
Allogeneic Stem Cell Transplantation; ODM derived from:
https://clinicaltrials.gov/show/NCT01020175
All rights reserved. Please visit https://medical-data-
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Eligibility Acute Leukemia
NCT01020175
Inclusion Criteria
patients with either diagnosis of aml in first or
second remission, in first untreated relapse (blast
count in marrow < 30 percent); all in first or
second remission, in first untreated relapse (blast
count in marrow < 30 percent); cml in first chronic
phase, in first accelerated phase (total blast and
promyelocytes in marrow and or peripheral blood
< 30 percent) or mds (excluding raeb-t).*
Yes
No
age between 18 and 55 years.*
Yes
No
ecog performance status between 0,1 or 2.*
Yes
No
hla-identical sibling donor.*
Yes
No
written informed consent.*
Yes
No
Exclusion Criteria
serum creatinine more than 10 percent above the
normal range for the centre.*
Yes
No
left ventricular size and function abnormal.*
Yes
No
dlco < 50 percent.*
Yes
No
bilirubin > 2mg/dl (34.2 µmol/l).*
Yes
No
splenectomised or splenic irradiation.*
Yes
No
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psychiatric, addictive, or any other disorder,
which compromises ability to give truly informed
consent for participation in this study.*
Yes
No
currently receiving non-licensed drugs which may
affect gvhd or engraftment.*
Yes
No
pregnant or lactating women.*
Yes
No
known sensitivity to e.coli derived products.*
Yes
No
hiv positive.*
Yes
No
previously received bm/pbpc transplant.*
Yes
No
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Eligibility Acute Leukemia NCT01036009
A Study of Withdrawal of Immunosuppression and Donor
Lymphocyte Infusions Following Allogeneic Transplant for
Pediatric Hematologic Malignancies; ODM derived from:
https://clinicaltrials.gov/show/NCT01036009
All rights reserved. Please visit https://medical-data-
models.org/forms/12641
Eligibility Acute Leukemia
NCT01036009
Inclusion Criteria
age 6 months - 25 years.*
Yes
No
diagnoses of acute leukemia (aml, all,
biphenotypic leukemia), pre-leukemic syndromes
(monosomy 7 or other bone marrow clonal
malformations), jmml, myelodysplastic
syndromes or cml.*
Yes
No
undergoing an allogeneic transplant as standard
care.*
Yes
No
performance status: karnofsky/lansky>60%.*
Yes
No
availability of pre-transplant recipient's dna and
donor's dna for chimerism testing. this could be
dna or material from which dna could be
extracted. frozen blood would be preferred. for
some patients, post transplant specimens that
are not infiltrated with donor cells may be used.*
Yes
No
bone marrow or pbmtc as stem cell source.hla
matching: donor and recipient should be matched
at a minimum of 7/8 antigens (a,b,c and drb1) for
bone marrow and pbmtc transplants.*
Yes
No
no history of ≥grade iii acute gvhd.*
Yes
No
Exclusion Criteria
treatment on other experimental protocols, if
withdrawal of immunosuppression interferes with
procedures of follow-up on the primary study.*
Yes
No
leukemia relapse defined as > 5 percent blasts on
1 / 2
bone marrow exam or >1 percent leukemia cells
by immunoflow mrd, or presence of
extramedullary leukemia.*
Yes
No
history of acute gvhd ≥ stage iii or  with any
degree of active acute or cgvhd.*
Yes
No
on steroids for any reason.*
Yes
No
any condition that compromises compliance with
the objectives and procedures of this protocol, as
judged by the principal investigator.*
Yes
No
cells for dli cannot be obtained from the donor.*
Yes
No
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Molecular Monitoring Survey EUREKA
European survey on the assessment of deep molecular
Response in chronic phase CML patients after at least two
years of therapy with tyrosine KinAse inhibitors - major
component of the Path to Cure Pillar of EUTOS III.
ODM derived from:
http://www.eutos.org/content/path_to_cure/eureka/index_e
ng.html
All rights reserved. Please visit https://medical-data-
models.org/forms/12643
Case Report Form (CRF)
Blood Sample Collection
Date of sample
Physician Information
Name
Affiliation
academic (1)
regional hospital (2)
office based hematologist (3)
City
Country
Patient Information
Initials
Date of Birth
Sex
Male (1)
Female (2)
Ethnicity
Caucasian (1)
Black (2)
Hispanic (3)
Oriental/Asian (4)
Other (5)
Date of informed consent
Type of BCR-ABL transcript at diagnosis
b2a2 (e13a2) (1)
Other (10)
b3a2 (e14a2) (2)
b2a2 + b3a2 (e13a2 + e14a2) (3)
e1a2 (4)
b2a3 (e13a3) (5)
b3a3  (e14a3) (6)
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e6a2 (7)
e19a2 (8)
unknown (9)
Eutos Score (at diagnosis)
high (1)
low (2)
Sokal Score (at diagnosis)
high (high)
intermediate (intermediate)
low (low)
Euro (Hasford) Score (at diagnosis)
low (1)
intermediate (2)
high (3)
CML Diagnosis, Treatment
CML Diagnosis
First line TKI
Imatinib (1)
Nilotinib (2)
Dasatinib  (3)
Bosutinib  (4)
Ponatinib (5)
Second line TKI
Imatinib (1)
Nilotinib (2)
Dasatinib (3)
Bosutinib (4)
Ponatinib (5)
Third line TKI
Imatinib (1)
Nilotinib  (2)
Dasatinib  (3)
Bosutinib  (4)
Ponatinib (5)
Current treatment
mg/day
Imatinib  (1)
Nilotinib (2)
Dasatinib (3)
Bosutinib (4)
Ponatinib (5)
Other (6)
Most recent molecular result from the local lab
No MMR (1)
MMR (2)
MR4 (3)
MR4.5 (4)
MR5 (5)
CMR (6)
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Date & Signature
Date
Sign./Physician Stamp
Addresses of reference laboratories
How to send samples
Universitätsklinikum Jena
Universitätsklinikum Leipzig
Universtitätsklinik Mannheim
Universitätsklinikum Schleswig-Holstein, Campus
Kiel
3 / 3
Molecular Monitoring Survey EUREKA
Eligibility Acute Leukemia NCT01362985
Analysis of Data Collected in the European Group for Blood
and Marrow Transplantation (EBMT) Registry for Off-Label
Transplant Use of Plerixafor; ODM derived from:
https://clinicaltrials.gov/show/NCT01362985
All rights reserved. Please visit https://medical-data-
models.org/forms/12644
Eligibility Acute Leukemia
NCT01362985
Criteria
background disease other than lymphoma or
multiple myeloma (mm)*
Yes
No
are younger than 18 years of age.*
Yes
No
received transplant using ex vivo plerixafor-
mobilised cells (umbilical cord cell, peripheral
blood (pb), bone marrow (bm) cell collection)*
Yes
No
received treatment with plerixafor alone (i.e.,
without granulocyte colony stimulating factor (g-
csf))*
Yes
No
contraindication for g-csf*
Yes
No
transplants using plerixafor-mobilised cells from
allogeneic donor*
Yes
No
received transplant using plerixafor-mobilised
bone marrow cells*
Yes
No
routes of plerixafor administration other than
subcutaneous*
Yes
No
patients whose cells do not mobilize poorly*
Yes
No
other*
Yes
No
Exclusion Criteria
1 / 2
adults diagnosed with lymphoma or multiple
myeloma (mm) and have been treated with
plerixafor according to the european union (eu)
label.*
Yes
No
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Eligibility Acute Leukemia NCT02246907
Exercise and Quality of Life in Leukemia Patients; ODM
derived from: https://clinicaltrials.gov/show/NCT02246907
All rights reserved. Please visit https://medical-data-
models.org/forms/12645
Eligibility Acute Leukemia
NCT02246907
Inclusion Criteria
newly diagnosed with acute leukemia by
pathology report*
Yes
No
admitted for induction chemotherapy within in the
previous 96 hours or +/- 3 days from initiation of
induction chemotherapy*
Yes
No
an expected hospital stay of 3-4 weeks or longer*
Yes
No
participation in the study must be approved by
the physician directly responsible for the patient's
care while at university of north carolina
-hospitals*
Yes
No
age >21 years of age*
Yes
No
willing and able to provide, signed informed
consent*
Yes
No
willing and able to use a computer to complete
study questionnaires*
Yes
No
ability to understand and speak english*
Yes
No
Exclusion Criteria
cardiovascular disease (unless the disease would
not compromise the patient's ability to participate
in the exercise rehabilitation program)*
Yes
No
acute or chronic respiratory disease that would
compromise the patient's ability to participate in
the exercise rehabilitation program*
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Yes
No
acute or chronic bone, joint, or muscular
abnormalities that would compromise the
patient's ability to participate in the exercise
rehabilitation program*
Yes
No
inability to understand and speak english*
Yes
No
dementia, altered mental status, or any
psychiatric condition that would prohibit the
understanding or rendering of informed consent*
Yes
No
another active malignancy*
Yes
No
patients will also be excluded if they have active
bleeding, acute thrombosis, ischemia,
hemodynamically unstable, and uncontrolled
pain.*
Yes
No
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Eligibility Acute Leukemias NCT01339988
Busulfan and Cyclophosphamide Instead of Total Boby
Irradiation (TBI) and Cyclophosphamide for Hematological
Malignancies Hematocrit (HCT); ODM derived from:
https://clinicaltrials.gov/show/NCT01339988
All rights reserved. Please visit https://medical-data-
models.org/forms/12647
Eligibility Acute Leukemias
NCT01339988
Inclusion Criteria
suitable cord blood from matched unrelated or
related donor.*
Yes
No
cardiac (echo/ekg): shortening fraction ≥ 27
percent*
Yes
No
electrolytes within normal cchmc limits.*
Yes
No
pulmonary function tests: dlco ≥ 50%*
Yes
No
renal: creatinine clearance/gfr ≥ 60
ml/minute/1.73m2*
Yes
No
lumbar puncture: no leukemic infiltrate.*
Yes
No
cbc: anc ≥ 1000ml and unsupported platelet
count of ≥ 50,000/ml*
Yes
No
documented hsv and cmv titers, hepatitis b
surface antigen, hepatitis c by serology, hiv by
serology: all negative.*
Yes
No
hepatic transaminases < 2.5x normal; total
bilirubin < 2 mg/dl patients who do not meet
above organ function criteria (liver, cardiac,
renal), due to the presence of a tumor
compromising these organs, may have exception
made for these criteria and remain eligible for
treatment plan after consultation with program
director of blood and marrow transplant*
Yes
No
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Exclusion Criteria
patients with neoplastic or non-neoplastic
disease of any major organ system that would
compromise their ability to withstand the pre-
transplant conditioning regimen.*
Yes
No
patients with uncontrolled (culture or biopsy
positive) infections requiring intravenous
antivirals, antibiotics, or antifungals.  patients on
prolonged antifungal therapy with a history of
fungal infection should be considered for a non-
myeloablative protocol.*
Yes
No
patients who are pregnant or lactating.  patients
of childbearing potential must practice an
effective method of birth control while
participating on this treatment plan.*
Yes
No
hiv seropositive patients*
Yes
No
2 / 2
Eligibility Acute Leukemias NCT01339988
Eligibility Acute Lymphoblastic Leukaemia
NCT01251809
Trial of Oncaspar® and Three Doses of Pegylated
Recombinant Asparaginase in Adult Patients With Newly
Diagnosed Acute Lymphoblastic Leukaemia; ODM derived
from: https://clinicaltrials.gov/show/NCT01251809
All rights reserved. Please visit https://medical-data-
models.org/forms/12648
Eligibility Acute Lymphoblastic
Leukaemia NCT01251809
Inclusion Criteria
previously untreated acute lymphoblastic
leukaemia (pro-b, common, pre-b, early t, thymic
t, mature t)*
Yes
No
age 18 years - 55 years*
Yes
No
treatment according to german multicenter trials
for adult acute lymphoblastic leukaemia (gmall)
07/2003 protocol or subsequent gmall protocols
for patients with de novo all*
Yes
No
written informed consent*
Yes
No
women of child-bearing potential or partner of
men with child-bearing potential must use a
highly effective method of contraception*
Yes
No
negative pregnancy test for women of child-
bearing potential*
Yes
No
Exclusion Criteria
patients with philadelphia chromosome (bcr-abl)
positive all*
Yes
No
severe comorbidity or leukaemia-associated
complications*
Yes
No
known hypersensitivity to asparaginase*
Yes
No
history of severe pancreatitis*
Yes
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No
history of thrombosis or pulmonary embolism*
Yes
No
pre-existing clinically relevant coagulopathy*
Yes
No
liver dysfunction (e.g. acute or current hepatitis,
alcohol or drug abuse) or history of clinically
relevant liver disease*
Yes
No
bilirubin > 1.5 x upper limit norm (uln)*
Yes
No
other current malignancies*
Yes
No
severe psychiatric illness or other circumstances
which may compromise the cooperation of the
patient or the ability to give informed consent*
Yes
No
body mass index > 30 kg/m²*
Yes
No
known pregnancy, breast feeding*
Yes
No
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Eligibility Acute Lymphoblastic Leukaemia
NCT01949129
Allogeneic Stem Cell Transplantation for Children and
Adolescents With Acute Lymphoblastic Leukaemia; ODM
derived from: https://clinicaltrials.gov/show/NCT01949129
All rights reserved. Please visit https://medical-data-
models.org/forms/12649
Eligibility Acute Lymphoblastic
Leukaemia NCT01949129
Inclusion Criteria
patients with all (except for patients with b-all)
who fulfil the following criteria:*
Yes
No
age at time of screening less than 18 years*
Yes
No
indication for allogeneic hsct*
Yes
No
complete remission (cr) before hsct*
Yes
No
written consent of the parents (legal guardian)
and, if necessary, the minor patient via "informed
consent form"*
Yes
No
no pregnancy*
Yes
No
no secondary malignancy*
Yes
No
no previous hsct*
Yes
No
hsct is performed in a study participating centre*
Yes
No
Exclusion Criteria
patients who do not fulfil the inclusion criteria*
Yes
No
non hodgkin-lymphoma*
Yes
No
all with extramedullary  involvement with
1 / 2
indication for tbi*
Yes
No
cns involvement at the timepoint of screening*
Yes
No
trisomy 21*
Yes
No
the whole protocol or essential parts are declined
either by patient himself/herself or the respective
legal guardian*
Yes
No
no consent is given for saving and propagation of
anonymous  medical data for study reasons*
Yes
No
severe concomitant disease that does not allow
treatment according to the protocol at the
investigators discretion (e.g. malformation
syndromes, cardiac malformations, metabolic
disorders)*
Yes
No
karnofsky / lansky score < 50*
%
Yes
No
subjects unwilling or unable to comply with the
study procedures*
Yes
No
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Eligibility Acute Lymphoblastic Leukemia
(ALL) NCT00840853
Multi-virus CTLs Expressing CD19 Chimeric Receptors,
CD19 Positive Malignancies Post SCT, MULTIPRAT; ODM
derived from: https://clinicaltrials.gov/show/NCT00840853
All rights reserved. Please visit https://medical-data-
models.org/forms/12650
Eligibility Acute Lymphoblastic
Leukemia (ALL) NCT00840853
Inclusion Criteria
any patient regardless of sex or age with cd19+
b-all undergoing allogeneic hsct (group a)*
Yes
No
or any patient regardless of sex or age with
cd19+ b-cll or nhl undergoing allogeneic hsct
(group b).*
Yes
No
with minimal residual disease (mrd) or relapse
post-hsct (for the phase i dose escalation)*
Yes
No
with no evidence of all or cll/nhl post-hsct (to be
included in the expansion cohort*
Yes
No
patients with life expectancy greater than or equal
to 6 weeks*
Yes
No
patients with a karnofsky/lansky score greater
than or equal to 50*
Yes
No
donor hiv negative*
Yes
No
5. patient or parent/guardian capable of providing
informed consent*
Yes
No
patients with bilirubin 2x normal or less, ast 3x
normal or less, creatinine less than or equal to 2x
normal for age and hgb greater than 8.0*
Yes
No
pulse oximetry of greater than 90 percent on
room air*
Yes
No
sexually active patients must be willing to utilize
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one of the more effective birth control methods
for 6 months after the ctl infusion. the male
partner should use a condom.*
Yes
No
available allogeneic cd19car transduced tri-virus-
specific cytotoxic t lymphocytes with greater than
or equal to 15 percent expression of cd19car
determined by flow-cytometry and greater than
10 percent killing of one or more viral antigen
pulsed targets in a cytotoxicity assay at an
effector:target ratio of 20:1.**
Yes
No
patients should have been off other
investigational antiviral or antitumor therapy for
one month prior to entry in this study.*
Yes
No
note: cell dose is based on total cell numbers and
not individual antivirus or antileukemic cell
numbers.*
Yes
No
Exclusion Criteria
severe intercurrent infection*
Yes
No
evidence of graft versus host disease >grade ii*
Yes
No
pregnant or lactating*
Yes
No
history of hypersensitivity reactions to murine
protein-containing products.*
Yes
No
currently taking corticosteroids for therapy of
gvhd.*
Yes
No
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Eligibility Acute Lymphoblastic Leukemia
(ALL) NCT01439347
A Phase 3 Study to Evaluate Marqibo® in the Treatment of
Subjects _ 60 Years Old With Newly Diagnosed ALL; ODM
derived from: https://clinicaltrials.gov/show/NCT01439347
All rights reserved. Please visit https://medical-data-
models.org/forms/12651
Eligibility Acute Lymphoblastic
Leukemia (ALL) NCT01439347
Inclusion Criteria
have provided written, signed, and dated
informed consent to participate in the study, in
accordance with the ich gcp guideline e6 and all
applicable local regulations.are age >or=60 years
(at the time of providing informed consent).*
Yes
No
have newly diagnosed, histologically proven,
untreated philadelphia chromosome-negative
(ph-) all, with >or= 5% bone marrow blasts.*
Yes
No
have an eastern cooperative oncology group
(ecog) performance status of 0-2. have a life
expectancy >or= 3 months.*
Yes
No
have renal and liver function as defined below
within 14 days, inclusive, prior to study
enrollment, unless the abnormality is considered
attributable to leukemia:*
Yes
No
total bilirubin ≤ 2.0 x the upper limit of normal
(uln), unless the subject has a known diagnosis
of gilbert's disease aspartate transaminase (ast,
sgot) or alanine transaminase (alt, sgpt) ≤ 3 x uln
serum creatinine ≤ 1.5 x uln. not have had major
surgery within 4 weeks before the planned start
of treatment.*
Yes
No
if female, are post-menopausal, surgically
sterilized, or willing to use acceptable methods of
birth control (eg, hormonal contraceptive, intra-
uterine device, diaphragm with spermicide,
condom with spermicide, or abstinence) from the
screening visit through 30 days after the last dose
of any protocol defined chemotherapeutic
agents.*
Yes
No
if male and sexually active with a partner of child-
bearing potential, agree to use an acceptable
barrier method for contraception from the
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screening visit through 30 days after the last dose
of any protocol defined chemotherapeutic
agents.*
Yes
No
have the ability and willingness to fully comply
with study procedures and restrictions.*
Yes
No
Exclusion Criteria
has had prior systemic chemotherapy (for all or
other malignancy). has had prior vincristine for
any reason. is planning to undergo stem cell
transplantation (sct) as any part of first-line
therapy for all.*
Yes
No
has burkitts lymphoma/leukemia. has
philadelphia chromosome-positive (ph+) all
and/or bcr/abl rearrangements documented by
fluorescent in-situ hybridization (fish),
cytogenetics, or polymerase chain reaction (pcr).*
Yes
No
has active central nervous system (cns) disease.
has ongoing neuropathy of any etiology > grade
1. has a history of persistent active neurologic
disorders including demyelinating form of
charcot-marie-tooth syndrome, acquired
demyelinating disorders, and other demyelinating
conditions.*
Yes
No
prior hydroxyurea (hydrea®) for the management
of any condition other than leukocytosis or prior
hydroxyurea of >7 days duration for the
management of leukocytosis (hydroxyurea for the
management of leukocytosis must be planned to
be tapered off before or on day 5 of induction).*
Yes
No
has received prior steroids within 7 days before
beginning protocol-specified induction therapy for
reasons other than leukocytosis (steroids for the
management of leukocytosis are allowed but
must be planned to be tapered off before or on
day 5 of induction).*
Yes
No
has an active serious infection not controlled by
oral or iv antibiotics or antifungals.*
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Yes
No
has received any investigational therapy within 28
days before beginning any protocol-defined
chemotherapeutic treatment.*
Yes
No
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Eligibility Acute Lymphoblastic Leukemia
NCT00130195
Study of Imatinib-Combined Chemotherapy for BCR-ABL-
Positive Acute Lymphoblastic Leukemia (ALL); ODM
derived from: https://clinicaltrials.gov/show/NCT00130195
All rights reserved. Please visit https://medical-data-
models.org/forms/12654
Eligibility Acute Lymphoblastic
Leukemia NCT00130195
Inclusion Criteria
previously untreated bcr-abl-positive all*
Yes
No
age between 15 and 64 years*
Yes
No
performance status between 0 and 3 (ecog
criteria)*
Yes
No
adequate functioning of the liver (serum bilirubin
level < 2.0 mg/dl), kidneys (serum creatinine level
< 2.0 mg/dl), and heart (left ventricular ejection
fraction greater than 50 percent and no severe
abnormalities detected on electrocardiograms
and echocardiographs)*
Yes
No
written informed consent to participate in the trial*
Yes
No
Exclusion Criteria
uncontrolled active infection*
Yes
No
another severe and/or life-threatening disease*
Yes
No
positive for hiv antibody and/or hepatitis b surface
(hbs) antigen tests*
Yes
No
another primary malignancy which is clinically
active and/or requires medical interventions*
Yes
No
pregnant and/or lactating women*
Yes
No
past history of renal failure*
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Yes
No
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Eligibility Acute Lymphoblastic Leukemia
NCT00136435
A Study in Adults With Untreated Acute Lymphoblastic
Leukemia; ODM derived from:
https://clinicaltrials.gov/show/NCT00136435
All rights reserved. Please visit https://medical-data-
models.org/forms/12656
Eligibility Acute Lymphoblastic
Leukemia NCT00136435
Inclusion Criteria
patients must have pathologically documented
acute lymphoblastic leukemia, excluding mature
b-cell all.*
Yes
No
no prior therapy for leukemia with the following
exceptions*
Yes
No
up to one week of steroids;*
Yes
No
emergent leukapheresis;*
Yes
No
emergency treatment for hyperleukocytosis with
hydroxyurea;*
Yes
No
cranial rt for cns leukostasis (one dose only);*
Yes
No
emergent radiation therapy to the mediastinum.*
Yes
No
eastern cooperative oncology group (ecog)
performance status 0 to 2.*
Yes
No
between the ages of 18 to 50 years.*
Yes
No
Exclusion Criteria
uncontrolled active infection.*
Yes
No
pregnant or breastfeeding*
Yes
No
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prior history of pancreatitis.*
Yes
No
prior history of a cerebrovascular accident or
hemorrhage*
Yes
No
evidence of infection with the human
immunodeficiency virus.*
Yes
No
active psychiatric or mental illness making
informed consent or careful clinical follow-up
unlikely.*
Yes
No
the treating physician should consider all relevant
medical and other considerations when deciding
whether this protocol is appropriate for a
particular patient.*
Yes
No
2 / 2
Eligibility Acute Lymphoblastic Leukemia NCT00136435
Eligibility Acute Lymphoblastic Leukemia
NCT00144963
Liposomal Vincristine Plus Dexamethasone in Patients With
Relapsed or Refractory Acute Lymphoblastic Leukemia;
ODM derived from:
https://clinicaltrials.gov/show/NCT00144963
All rights reserved. Please visit https://medical-data-
models.org/forms/12658
Eligibility Acute Lymphoblastic
Leukemia NCT00144963
Inclusion Criteria
previously treated, relapsed or refractory all
(including lymphoblastic lymphoma and burkitt's
subtypes) with measurable disease.*
Yes
No
performance status ≤3 (ecog).*
Yes
No
all ages are eligible. those aged 12 years or older
may be counted towards the mtd in the phase i
portion of the trial. pediatric patients are eligible,
but must be treated at a dose level previously
tested in an adult (one full course).*
Yes
No
adequate liver function (bilirubin ≤2 x upper limit
normal), and renal function (creatinine ≤2 x upper
limit normal).*
Yes
No
negative pregnancy test in females of
childbearing potential.*
Yes
No
patients with prior history of stem cell transplant
are eligible if they meet all other eligibility
requirements.*
Yes
No
Exclusion Criteria
active serious infection not controlled by oral or
intravenous antibiotics.*
Yes
No
treatment with any investigational agents or
chemotherapy agents in the last 21 days before
study entry, unless full recovery from side effects
has occurred or the patient has rapidly
progressive disease judged to be life threatening
by the investigator.*
Yes
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No
concurrent treatment with other anti-cancer
agents other than dexamethasone.*
Yes
No
known cns leukemia or lymphoma requiring
intrathecal or craniospinal radiation therapy or
with cns neuropathy limiting evaluation of study
drug. patients with controlled cns disease (no
progression signs or symptoms at the time of
study entry) may be eligible after approval by the
principal investigator. lumbar puncture not
required in asymptomatic patients.*
Yes
No
prior history of grade 3 or 4 sensory or motor
neuropathy related to chemotherapeutic
treatment, or persistent grade 2 or greater active
neuropathy.*
Yes
No
history of active neurologic disorders unrelated to
chemotherapy (including familial neurologic
diseases and acquired demyelinating disorders).*
Yes
No
prior history of hypersensitivity reactions to
vincristine or any of the other components of
vsli.*
Yes
No
pregnant and/or lactating women; or fertile men
or women not willing to use contraception.*
Yes
No
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Eligibility Acute Lymphoblastic Leukemia
NCT00165087
Treatment of Childhood Acute Lymphoblastic Leukemia;
ODM derived from:
https://clinicaltrials.gov/show/NCT00165087
All rights reserved. Please visit https://medical-data-
models.org/forms/12661
Eligibility Acute Lymphoblastic
Leukemia NCT00165087
Inclusion Criteria
acute lymphoblastic leukemia, excluding known
mature b-cell all*
Yes
No
< 18 years of age*
Yes
No
patients who are leukopheresed or exchanged
are eligible for study only after completion of the
pheresis or exchange transfusion*
Yes
No
absence of a t(8,14) (q24; q32), t (8,22), t(2,8)*
Yes
No
total bilirubin < 1.4mg/dl*
Yes
No
Exclusion Criteria
known hiv positive*
Yes
No
prior steroid therapy within 30 days of diagnosis*
Yes
No
septic shock*
Yes
No
ongoing intracranial hemorrhage*
Yes
No
clinical evidence of cns or lung leukostasis*
Yes
No
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Diagnostic - AMLSG 21-13 NCT02013648
Akute myeloische Leukämie AML
Randomized Phase III Study of Intensive Chemotherapy
with or without Dasatinib (Sprycel™) in Adult Patients
with Newly Diagnosed Core-Binding Factor
Acute Myeloid Leukemia (CBF-AML)
All rights reserved. Please visit https://medical-data-
models.org/forms/12668
Diagnostic (1)
Patient data
Gender
m (1)
f (2)
How tall is the patient?
cm
Ethnic origin
Caucasian (1)
Asian (2)
North African/Arabian/Turk (3)
Other African (4)
Other, please specify (5)
Other ethnic origin
General condition (WHO/ECOG)
0 (0)
1 (1)
2 (2)
3 (3)
Temperature
Degree Celcius
LDH
U/l
Tissue typing done
Yes
No
Number of siblings
Number HLA-identic siblings
Diagnosis
Date of initial diagnosis
FAB-classification of AML
Type of AML
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de Novo AML (1)
therapy induced AML (2)
secondary AML after MDS/MPS (3)
Previous hematological disease (MDS/MPS)
no (0)
yes (please specify) (1)
Date of initial diagnosis
Initial Diagnosis
Initial Therapy
Previous oncological disease
Yes
No
Date of initial diagnosis
Diagnosis
Therapy
previous diseases
and Baseline symptoms
Exposure to toxic agents, if yes please specify
Smoking or smoking history
Yes
No
Cigarettes per day
Number of smoking years
years
Previous Chemotherapy or radiation
Yes
No
Extramedullary Manifestatation
no (0)
Skin (1)
CNS (2)
Liver (3)
Spleen (4)
lymphatic (5)
Hyperplasia of gingiva (6)
multiple (please specify) (7)
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AML
other (please specify) (8)
Splenomegaly
Yes
No
Maximal spleen diameter, sonographic
cm
Spleen position under costal arch
cm
Hepatomegaly
Yes
No
Liver-diameter
cm
Liver size below costal arch
cm
Baseline Examinations
Blood pressure
mm Hg
Pulse
bpm
Chest X-ray done
Yes
No
Date of chest X-ray
Abnormal chest X-ray
Yes
No
ECG done?
Yes
No
ECG Abnormalities
Yes
No
Echocardiography done?
Yes
No
Ejection fraction
%
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AML
Echocardiography abnormal
Yes
No
Urinalysis done?
Yes
No
Urine pH
pH
Urine protein
normal (0)
+ (1)
++ (2)
+++ (3)
++++ (4)
Urinalysis glucose
normal (0)
+ (1)
++ (2)
+++ (3)
++++ (4)
Pregnancy test done?
Yes
No
Pregnancy test result
negative (0)
positive (no study participation!) (1)
Hepatitis A Test done?
Yes
No
Hepatitis A test positive
negativ (0)
positive (1)
Evidence of acute Hepatitis
Yes
No
Hepatitis B Test done?
Yes
No
Hepatitis B test result
negative (0)
positive (1)
Evidence of acute Hepatitis
Yes
No
Evicence of chronic hepatitis
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Yes
No
Hepatitis C test done?
Yes
No
Hepatitis C test result
negative (0)
positive (1)
Evidence of acute Hepatitis
Yes
No
Evicence of chronic hepatitis
Yes
No
HIV test done?
Yes
No
HIV test result
negative (0)
positive (1)
Cytogenetic examination done?
Yes
No
Number of analysed Metaphases
Karyotype
Concomitant Medication
Did Patient take any concomitant medication
during time form informed consent till start of
Induction I ?
If yes please specify on special form
Yes
No
ADVERSE EVENTS
Did any Adverse events occure during time from
signed informed consent to the start of Induction
I? If yes specify on Adverse Events form
Yes
No
Signature
Date
5 / 6
Diagnostic - AMLSG 21-13 NCT02013648 Akute myeloische Leukämie
AML
Name of Investigator
Signature of investigator
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Patient identification Stem-Cell
Transplantation CASLAMB NCT00148148
A Study of Caspofungin, Liposomal Amphotericin B or the
Combination of Both for Patients After Stem-Cell
Transplantation
NCT00148148
All rights reserved. Please visit https://medical-data-
models.org/forms/12682
Patient identification Stem-Cell
Transplantation CASLAMB
NCT00148148
Patient demographics
Patient Initials
Patient date of birth
Gender
male (1)
female (2)
Informed Consent Date
Study Registration Date
Study Arm
Arm A (1)
Arm B (2)
Arm C (3)
Information about primary diseases
Primary disease
ALL (1)
CML (2)
AML (3)
other (4)
Other primary disorders
Date of first diagnosis
Recurrence date
Remission status prior to transplantation
in Remission  (1)
not in Remission (2)
Date of transplantation
Transplant type
HLA-matched+related (1)
HLA-mismatched or unrelated (2)
Conditioning scheme
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Beginning of neutropenia
Steroids administered
Yes
No
GvHD
Yes
No
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Eligibility Isolated Systolic Hypertension
NCT02088450
Systolic Hypertension in Europe; ODM derived from:
https://clinicaltrials.gov/show/NCT02088450
All rights reserved. Please visit https://medical-data-
models.org/forms/12723
Eligibility Isolated Systolic
Hypertension NCT02088450
Inclusion Criteria
at least 60 years old*
Yes
No
sitting systolic blood pressure on masked
placebo, during run-in phase of     160  to 219
mmhg, with a sitting diastolic blood pressure
below 95 mmhg and a standing systolic blood
pressure of  at least 140 mmhg*
Yes
No
informed consent must be obtained*
Yes
No
Exclusion Criteria
systolic hypertension is secondary to a disorder
that needed specific medical or surgical
treatment*
Yes
No
retinal haemorrhage or papilloedema*
Yes
No
congestive heart failure*
Yes
No
dissecting aortic aneurysm*
Yes
No
serum creatinine concentration at presentation of
180µmol/l or more*
history of severe nose bleeds*
Yes
No
stroke or myocardial infarction in the year before
the study*
Yes
No
dementia*
Yes
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No
substance abuse*
Yes
No
any disorder prohibiting a sitting or standing
position*
Yes
No
any severe concomitant cardiovascular or non-
cardiovascular disease*
Yes
No
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Eligibility Isolated Systolic Hypertension NCT02088450
Eligibility Hypertension NCT00888355
MK0954 Versus Placebo for Treatment of Mild to Moderate
Hypertension; ODM derived from:
https://clinicaltrials.gov/show/NCT00888355
All rights reserved. Please visit https://medical-data-
models.org/forms/12724
Eligibility Hypertension
NCT00888355
Inclusion Criteria
patient has been diagnosed with mild to
moderate hypertension*
Yes
No
patient has no treatment or active medical
problem, other than hypertension that might
affect the patients blood pressure*
Yes
No
Exclusion Criteria
pregnant or lactating female patients*
Yes
No
secondary hypertension or history of malignant
hypertension*
Yes
No
sitting systolic blood pressure > 210 mmhg*
Yes
No
history of stroke*
Yes
No
history of myocardial infarction with in the past
year*
Yes
No
current of prior history of heart failure*
Yes
No
known hypersensitivity to losartan*
Yes
No
obesity*
Yes
No
patients known to be hiv positive or known to be
positive for hepatitis b*
Yes
No
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absence of one kidney*
Yes
No
patient is abusing or previously abused alcohol or
drugs with in past two years*
Yes
No
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Eligibility Hypertension NCT00888355
Eligibility Acute Myelogenous Leukemia
NCT00136448
High Dose Ara-C (HDAC) and Interleukin-2 (IL-2) for
Patients With Acute Myelogenous Leukemia (AML); ODM
derived from: https://clinicaltrials.gov/show/NCT00136448
All rights reserved. Please visit https://medical-data-
models.org/forms/12725
Eligibility Acute Myelogenous
Leukemia NCT00136448
Inclusion Criteria
patients must have aml based on french-
american-british (fab) criteria.*
Yes
No
patients must have a total bilirubin of < 2.0 mg/dl,
sgot < 90 iu/ml, alkaline phosphatase < 250 u/ml
and a serum creatinine < 2.0 mg/dl.*
Yes
No
age 18 years or greater.*
Yes
No
Exclusion Criteria
history of an antecedent hematologic malignancy
such as myelodysplastic syndromes (mds).*
Yes
No
uncontrolled infection*
Yes
No
history of a previous or concomitant malignancy
other than non-melanoma skin cancer.*
Yes
No
evidence of central nervous system (cns)
leukemia.*
Yes
No
current use of corticosteroids.*
Yes
No
prior treatment for aml, other than hydroxyurea.*
Yes
No
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Eligibility Asthma NCT01313585
Device Mixing in Asthma, a General Practice Research
Database Study; ODM derived from:
https://clinicaltrials.gov/show/NCT01313585
All rights reserved. Please visit https://medical-data-
models.org/forms/12726
Eligibility Asthma NCT01313585
Inclusion Criteria
aged: 4-80 years:*
Yes
No
evidence of asthma a diagnostic code for
asthma*
Yes
No
2 prescriptions for asthma at different points in
time during the prior year and/ or  2 prescriptions
for asthma therapies during the outcome year,
including 1 ics prescription (in addition to that
received at ipd) - ipdi cohort only;
be on current asthma therapy (for the ipda cohort
only): 1 ics prescription in the prior year, and 1
other asthma prescription during the baseline
year. have at least one year of up-to-standard
(uts) baseline data (prior to the ipd) and at least
one year of uts outcome data (following the ipd).*
Yes
No
Exclusion Criteria
had a COPD read code at any time*
Yes
No
received a combination inhaler in addition to a
separate ics inhaler in the baseline year*
Yes
No
received a long-acting beta2-agonsist (laba) in
addition to a separate ics inhaler in the baseline
year*
Yes
No
received ics therapy during baseline year via dpi
(in ipda cohort only).*
Yes
No
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Eligibility Breast Cancer NCT00026845
Comparison of Surgeries, With or Without Radiation
Therapy, in Treating Women With Stage I or Stage II Breast
Cancer; ODM derived from:
https://clinicaltrials.gov/show/NCT00026845
All rights reserved. Please visit https://medical-data-
models.org/forms/12727
Eligibility Breast Cancer
NCT00026845
Inclusion Criteria
histologically confirmed invasive breast cancer
(Stage I or II (T1-2, N0-1, M0))*
Yes
No
sex: female*
Yes
No
prior concurrent therapy:  biologic therapy*
Yes
No
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Bone marrow + Blood count AMLSG 21-13
NCT02013648 Akute myeloische Leukämie (AML)
AMLSG 21-13 NCT02013648
Randomized Phase III Study of Intensive Chemotherapy
with or without Dasatinib (Sprycel™) in Adult Patients
with Newly Diagnosed Core-Binding Factor
Acute Myeloid Leukemia (CBF-AML)
All rights reserved. Please visit https://medical-data-
models.org/forms/12729
Bone Marrow + Blood Count AMLSG
21-13 NCT02013648 Akute
myeloische Leukämie (AML)
Bone marrow
Point in time
Diagnostic (0)
Induction (1)
Induction II (optional) (2)
Consolid. (3)
Consolid. II (4)
Consolid III (5)
Consolid IV (6)
Maintenance (7)
Follow up (8)
If Maintanance: which Month?
after 12 Months (12)
after 3 Months (3)
after 6 Months (6)
after 9 Months (9)
If Follow-up: consecutive Follow-up Nr:
Which kind of bone marrow examination took
place?
BM-Cytology (1)
BM-Histology (due to punctio sicca) (2)
No bone marrow evaluation done (3)
Date
Cellularity
punctio sicca (0)
hypocellular (1)
normocellular (2)
hypercellular (3)
not evaluable (4)
Blasts
%
Megakaryocytes
none (0)
reduced (1)
normal (2)
increased (3)
not evaluable (4)
Auer rods
none (0)
present (1)
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Dyserythropoesis
Yes
No
Dysmegakaryopoesis
Yes
No
Dysgranulopoesis
Yes
No
Blood count
Date
Hemoglobin
[g/dl]
Erythrocytes
[Tera/l]
Platelets
[Giga/l]
Leukocyteses
[Giga/l]
Blasts
%
Promyelocytes
%
Myelocytes
%
Metamyelocytes
%
Neutrophiles
%
Eosinophiles
%
Basophiles
%
Lymphocytes
%
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Bone marrow + Blood count AMLSG 21-13 NCT02013648 Akute
myeloische Leukämie (AML)
Monocytes
%
Other bloodcells(please specify)
%
Patient data
Study site
Patient ID
Date
Investigator
Signature investigator
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Bone marrow + Blood count AMLSG 21-13 NCT02013648 Akute
myeloische Leukämie (AML)
Family history
Form from HIS OpenVistA
All rights reserved. Please visit https://medical-data-
models.org/forms/12730
HIS
Maternal Family History
Mutter lebt*
Ja
Nein
Hypertonie*
Ja
Nein
Diabetes mellitus*
Ja
Nein
Schlaganfall*
Ja
Nein
Herzinfarkt*
Ja
Nein
Early Coronary Vascular Disease*
Ja
Nein
Brustkrebs*
Ja
Nein
Darmkrebs*
Ja
Nein
Other*
FH: Age at death*
Todesursache (Mutter)*
Kommentar*
Paternal Family History
Vater lebt*
Ja
Nein
Hypertonie*
Ja
Nein
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Diabetes mellitus*
Ja
Nein
Schlaganfall*
Ja
Nein
Herzinfarkt*
Ja
Nein
Early Coronary Vascular Disease*
Ja
Nein
Prostatakrebs*
Ja
Nein
Darmkrebs*
Ja
Nein
Other*
FH: Age at death*
Todesursache (Vater)*
Kommentar*
Siblings Family History
Geschwister ohne signifikante Erkrankung*
Geschwister mit signifikanter Erkrankung*
Ja
Nein
Hypertonie*
Ja
Nein
Schlaganfall*
Ja
Nein
Herzinfarkt*
Ja
Nein
Diabetes mellitus*
Ja
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Family history
Nein
Early Coronary Vascular Disease*
Ja
Nein
Darmkrebs*
Ja
Nein
Other*
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Family history
Adverse Event AMLSG 21-13 NCT02013648
Akute myeloische Leukämie (AML)
Randomized Phase III Study of Intensive Chemotherapy
with or without Dasatinib (Sprycel(TM)) in Adult Patients
with Newly Diagnosed Core-Binding Factor
Acute Myeloid Leukemia (CBF-AML)
All rights reserved. Please visit https://medical-data-
models.org/forms/12732
Adverse Event AMLSG 21-13
NCT02013648 Akute myeloische
Leukämie (AML)
Adverse Event
Point in time
Diagnostic (0)
Induction I (1)
Induction II (optional) (2)
Consolid. I (3)
Consolid. II (4)
Consolid. III (5)
Consolid. IV (6)
Maintenance (7)
If Maintenance: Month
after 1 Month (1)
after 10 Months (10)
after 11 Months (11)
after 12 Months (12)
after 2 Months (2)
after 3 Months (3)
after 4 Months (4)
after 5 Months (5)
after 6 Months (6)
after 7 Months (7)
after 8 Months (8)
after 9Months (9)
Description of Adverse Event
Adverse Event Term
Serious Adverse Event
Yes
No
Grade of Adverse Event
Mild  (1)
Moderate (2)
Severe (3)
Life-Threatening (4)
Death related to AE (5)
Outcome
recovered (1)
not yet recovered (2)
recovered with sequelae (3)
Death (4)
unknown (5)
Treatment/Action taken
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Adverse Event Start Date
Adverse Event End Date
Adverse Event related to
Cytarabine
definitely (1)
probably (2)
possible (3)
unlikely (4)
not related (5)
Medication not administered (6)
Daunorubicin
definitely (1)
probably (2)
possible (3)
unlikely (4)
not related (5)
Medication not administered (6)
Dasatinib
definitely (1)
probably (2)
possible (3)
unlikely (4)
not related (5)
Medication not administered (6)
Underlying Disease
recovered (1)
not yet recovered (2)
recovered with sequelae (3)
Death (4)
unknown (5)
Concomitant medication
definitely (1)
probably (2)
possible (3)
unlikely (4)
not related (5)
Medication not administered (6)
Other
recovered (1)
not yet recovered (2)
recovered with sequelae (3)
Death (4)
unknown (5)
Signature
Date
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Adverse Event AMLSG 21-13 NCT02013648 Akute myeloische
Leukämie (AML)
Name of Investigator
Signature of investigator
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Adverse Event AMLSG 21-13 NCT02013648 Akute myeloische
Leukämie (AML)
Eligibility Acute Lymphoblastic Leukemia
NCT02070523
Pegylated Liposomal Doxorubicin Versus Daunorubicin to
Treat Acute Lymphoblastic Leukemia:; ODM derived from:
https://clinicaltrials.gov/show/NCT02070523
All rights reserved. Please visit https://medical-data-
models.org/forms/12737
Eligibility Acute Lymphoblastic
Leukemia NCT02070523
Inclusion Criteria
eligible men or women were age over 14，but
less than 60 years;*
Yes
No
eastern cooperative oncology group performance
status of 0 to2;*
Yes
No
diagnosed with all (who classification, the
primitive cells ≥ 20%);*
Yes
No
previous untreated all patients had not received
chemotherapy before (excluding dexamethasone,
prednisone, and hydroxyurea). history of
receiving blood transfusion, hematopoietic growth
factors, vitamin, and palliative measures such as
leukocyte removal, dexamethasone, prednisone,
hydroxyurea (0.5-3g daily, more than three days)
is allowed;*
Yes
No
the levels of lscs in bone marrow were measured
with flow cytometry before treatment;*
Yes
No
subjects must be able to provide written informed
consent.*
Yes
No
Exclusion Criteria
mixed type of all patients;*
Yes
No
clinically significant active infections;*
Yes
No
nursing (breastfeeding) or intending to be nursing
during the study；*
Yes
No
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pregnancy, or intending to become pregnant
during the study;*
Yes
No
patients with cardiac dysfunction currently
(especially congestive heart failure) or history of
congestive heart failure;*
Yes
No
patients with severe liver failure (alt ≥ 5 times the
upper limit of normal (uln), total bilirubin ≥
3mg/dl)*
Yes
No
patients with renal insufficiency, creatinine
clearance <30ml/min, creatinine clearance rate is
calculated as follows: men: ccr (ml / min) = (140 -
age) × weight (kg) / [0.8136 ×serum creatinine (
μmol / l )] female: ccr (ml / min) = (140 - age) ×
weight (kg) × 0.85 /[0.8136 × serum creatinine (
μmol / l)];*
Yes
No
patients did not or will not participate in other
trials of drugs 30 days before or 90 days after the
beginning of this study,*
Yes
No
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Eligibility Acute Lymphoblastic Leukemia NCT02070523
Eligibility Acute Lymphoblastic Leukemia
NCT02185781
Phase I Study of Adoptive Immunotherapy With Enriched
and Expanded Autologous Natural Killer (NK) Cells for
Patients With Ph+ Acute Lymphoblastic Leukemia (ALL);
ODM derived from:
https://clinicaltrials.gov/show/NCT02185781
All rights reserved. Please visit https://medical-data-
models.org/forms/12738
Eligibility Acute Lymphoblastic
Leukemia NCT02185781
Inclusion Criteria
adult subjects with ph+ all in chr (1st or 2nd) with
mrd positivity confirmed at baseline, older or
equal to 60 years or not eligible for other post-chr
treatment modalities.*
Yes
No
who score 0-1.*
Yes
No
hematopoietic, liver and renal normal functions
defined as follows:wbc bigger or equal to
2.000/mm3 lymphocytes bigger or equal to
500/mm3 neutrophils bigger or equal to
1.000/mm3 platelets bigger or equal to
50.000/mm3 hb bigger or equal to 9 g/dl
creatinine fewer or equal to 1.5 x uln bilirubin
fewer or equal to 1.5 x uln ast and alt less than 3
times the upper limit of normal. ldh less than 2
times the upper limit of normal.*
Yes
No
for male and female subjects of childbearing
potential, agreement to use effective
contraception.*
Yes
No
authorization by istituto superiore di sanità (iss)
according to dm 2 march 2004.*
Yes
No
signed written informed consent according to
ich/eu/gcp and national local regulations.*
Yes
No
Exclusion Criteria
concurrent chemotherapy or immunotherapy (tki
maintenance is permitted).*
Yes
No
any contraindications to perform a leukapheretic
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procedure for mononuclear cell collection.*
Yes
No
active or chronic infection, including treponema,
hiv, hbv and/or hcv unless antigen/pcr negative.*
Yes
No
presence of autoimmune symptoms.*
Yes
No
pregnant or lactating females.*
Yes
No
simultaneous participation in another clinical
trial.*
Yes
No
any physical or psychological impediment in a
patient that could lead the investigator to suspect
his/her poor compliance to the protocol.*
Yes
No
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Eligibility Acute Lymphoblastic Leukemia NCT02185781
Eligibility Acute Lymphoblastic Leukemia
NCT02186860
Chimeric Antigen Receptor (CAR)-Modified T Cell Therapy
in Treating Patients With Acute Lymphoblastic Leukemia;
ODM derived from:
https://clinicaltrials.gov/show/NCT02186860
All rights reserved. Please visit https://medical-data-
models.org/forms/12739
Eligibility Acute Lymphoblastic
Leukemia NCT02186860
Inclusion Criteria
age: 18-65 years*
Yes
No
patients with cluster of differentiation 19 (cd19)
positive b cell malignancies as confirmed by flow
cytometry*
Yes
No
refractory or relapsed b cell-acute lymphoblastic
leukemia*
Yes
No
no available curative treatment options (such as
hematopoietic stem cell transplantation)*
Yes
No
stage iii-iv disease*
Yes
No
creatinine < 2.5 mg/dl*
Yes
No
aspartate transaminase-alanine transaminase
ratio < 3x normal*
Yes
No
bilirubin < 2.0 mg/dl*
Yes
No
karnofsky performance status >= 60*
Yes
No
expected survival time > 3 months*
Yes
No
adequate venous access for apheresis*
Yes
No
ability to understand and provide informed
consent*
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Yes
No
Exclusion Criteria
pregnant or lactating women*
Yes
No
patients requiring t cell immunosuppressive
therapy*
Yes
No
active central nervous system leukemia*
Yes
No
any concurrent active malignancies*
Yes
No
patients with a history of a seizure disorder or
cardiac disorder*
Yes
No
previous treatment with any immunotherapy
products*
Yes
No
patients with human immunodeficiency virus,
hepatitis b or c infection*
Yes
No
uncontrolled active infection*
Yes
No
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Eligibility Acute Lymphoblastic Leukemia NCT02186860
NINDS CDE Participant/Subject
Characteristics Amyotrophic Lateral Sclerosis
NINDS Common Data Elements (Participant/Subject
Characteristics Amyotrophic Lateral Sclerosis)
Used from the National Institute of Neurological Disorders
and Stroke Common Data Elements
(https://www.commondataelements.ninds.nih.gov/)
References:
Grinnon ST, Miller K, Marler JR, Lu Y, Stout A, Odenkirchen
J, Kunitz S. National Institute of Neurological Disorders and
Stroke Common Data Element Project - approach and
methods. Clin Trials. 2012;9(3):322-9.
All rights reserved. Please visit https://medical-data-
models.org/forms/12742
Demographics and Social Status
Demographics
Gender
female (1)
male (2)
unknown (3)
unspecified (4)
not reported (5)
Date of birth
Ethnicity
Hispanic or Latino (1)
not Hispanic or Latino (2)
Not Reported (3)
Unknown (4)
Race
American Indian/Alaska Native (1)
Unknown (10)
Not Reported (11)
African - Black (i.e., south of the Sahara)
(2)
African - North (i.e., Sahara or north of
the Sahara: e.g., Algeria, Egypt,
Morocco, Tunisia, etc.) (3)
American - Black (i.e., people of African
descent whose area of origin is within
the Americas: e.g., Canada, Caribbean,
Brazil, US, etc.) (4)
Asian - East (i.e., China, Japan, Korea,
etc.) (5)
Asian - West (i.e., Bangladesh, India,
Iran, Iraq, Pakistan, etc.) (6)
Caucasian (e.g., United Kingdom,
Germany, Peninsular Spain, Latin
America, France, Italy, (7)
Native Hawaiian or other Pacific Islander
(8)
Other (i.e., if none of the above
categories reflects your area of origin,
then specify as precisely as possible) (9)
Ireland, Sweden, etc.) (Ireland, Sweden,
etc.))
Fathers country(s) of origin
Mothers country(s)of origin
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Social Status
Religion
None (1)
Christian (2)
Buddhist (3)
Hindu (4)
Jewish (5)
Muslim (6)
Sikh (7)
Other (please specify) (8)
Years of education
>= 0
<= 30
yrs
Highest education level attained
Never attended/ Kindergarten only (1)
9th Grade (10)
10th Grade (11)
11th Grade (12)
12th Grade, no diploma (13)
High school graduate (14)
GED or equivalent (15)
Some college, no degree  (16)
Associate degree: occupational,
technical, or vocational program (17)
Associate degree: academic program
(18)
Bachelor's degree (e.g., BA, AB, BS,
BBA) (19)
1st Grade (2)
Master's degree (e.g., MA, MS, MEng,
MEd, MBA) (20)
Professional school degree (e.g., MD,
DDS, DVM, JD) (21)
Doctoral degree (e.g., PhD, EdD) (22)
Unknown (23)
2nd Grade (3)
3rd Grade (4)
4th Grade (5)
5th Grade (6)
6th Grade (7)
7th Grade (8)
8th Grade (9)
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NINDS CDE Participant/Subject Characteristics Amyotrophic Lateral
Sclerosis
Secondary Primary Malignancy Form HOVON
132 AML/SAKK 30/13 EudraCT 2013-002843-26
Randomized study with a run-in dose-selection phase to
assess the added value of Lenalidomide in combination
with standard remission-induction chemotherapy and post-
remission treatment in patients aged 18-65 years with
previously untreated acute myeloid leukemia (AML) or high
risk myelodysplasia (MDS) (IPSS-R risk score> 4.5)
Description of Form: Secondary Primary Malignancy Form
With friendly permission of HOVON-Group, Prof. G.
Ossenkoppele
All rights reserved. Please visit https://medical-data-
models.org/forms/12749
Secondary Primary Malignancy
Form (Secondary Primary
Malignancy Form HOVON 132
AML/SAKK 30/13 EudraCT 2013-
002843-26)
Report Information
Type of report
Initial report (1)
Follow up report (2)
Final report (3)
Date report
dd/mm/yyyy
Date of birth
dd/mm/yyyy
Second Primary Malignancy Information
Second primary malignancy
acute leukemia* (1)
MDS* (2)
lymphoma* (3)
solid skin tumour* (4)
solid tumour (excl. skin)* (5)
other* (8)
*Specify
Date of diagnosis
dd/mm/yyyy
Date clinical diagnosis
dd/mm/yyyy
Diagnosed during study phase
before start protocol treatment  (0)
induction cycle I  (1)
maintenance (1-6)*  (11-16)
follow up  (17)
other* (18)
induction cycle II (2)
post induction cycle III  (3)
autoHSCT  (4)
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alloHSCT  (5)
Cycle Number
Specify
Pathology Result
Pathology Result (Please send in copy of report if
available)
Report Information
Type of Report
Initial report (1)
Follow up report (2)
Final report (3)
Date Report
dd/mm/yyyy
Treatment Second Primary Malignancy
Treatment given
no  (0)
chemotherapy only  (1)
surgery (2)
radiotherapy  (3)
monoclonal antibodies  (4)
combination*  (5)
other, please specify* (8)
*Specify
Date of start treatment
dd/mm/yyyy
Response second primary malignancy
CR  (1)
PR  (2)
stable disease (3)
progressive disease (4)
other, please specify* (8)
*Specify
Date response achieved
dd/mm/yyyy
Date last contact
dd/mm/yyyy
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Secondary Primary Malignancy Form HOVON 132 AML/SAKK 30/13
EudraCT 2013-002843-26
Survival status
alive  (0)
dead (1)
External/environmental exposures (Please
provide any information about external /
environmental exposures that might be
risk factors for the reported SPM. If no
information is available, fill out as...
Tobacco
no (0)
yes (1)
unknown (9)
Alcohol
no (0)
yes (1)
unknown (9)
Exposure to chemicals
no (0)
yes (1)
unknown (9)
Occupation / hobbies
no (0)
yes (1)
unknown (9)
Sun exposure
no (0)
yes (1)
unknown (9)
Previous chemo or radiation therapy
no (0)
yes (1)
unknown (9)
Other
no (0)
yes (1)
unknown (9)
*Specify
Report Information
Type of report
Initial report (1)
Follow up report (2)
Final report (3)
Date report
dd/mm/yyyy
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Secondary Primary Malignancy Form HOVON 132 AML/SAKK 30/13
EudraCT 2013-002843-26
Relevants Family's History (please provide
relevant family’s medical history (such as
known genetic mutations for breast
cancer, prostate cancer, etc. or family
member(s) – such as parents siblings,...
Relevant family's history
no (0)
yes (1)
unknown (9)
*Specify
Comments
Comments
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Secondary Primary Malignancy Form HOVON 132 AML/SAKK 30/13
EudraCT 2013-002843-26
Eligibility Diabetes Mellitus, Type 2
NCT01147692
A Drug Interaction Study of Simvastatin and Albiglutide;
ODM derived from:
https://clinicaltrials.gov/show/NCT01147692
All rights reserved. Please visit https://medical-data-
models.org/forms/12753
Eligibility Diabetes Mellitus, Type 2
NCT01147692
Inclusion Criteria
no clinically significant diseases or clinically
significant abnormal laboratory values*
Yes
No
females must be of non-childbearing potential*
Yes
No
body mass index (bmi) is >/=18 kg and ≤30
kg/m2*
Yes
No
nonsmoker*
Yes
No
negative drug screen*
Yes
No
Exclusion Criteria
positive test results for hepatitis b, hepatitis c or
human immunodeficiency virus (hiv)*
Yes
No
any clinically relevant abnormality*
Yes
No
female subject is pregnant or breast-feeding*
Yes
No
history of any anaphylactic reaction to any drug*
Yes
No
history of significant cardiovascular or pulmonary
dysfunction*
Yes
No
current or chronic history of liver disease*
Yes
No
history of alcohol or substance abuse*
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Yes
No
history of thyroid dysfunction or disease*
Yes
No
history of gastrointestinal surgery or disease*
Yes
No
history of pancreatitis*
Yes
No
previously received any glp-1 mimetic compound
(e.g., exenatide)*
Yes
No
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Eligibility Diabetes Mellitus, Type 2 NCT01147692
Eligibility Acute Lymphoblastic Leukemia, in
Relapse NCT01518517
GRASPA (Erythrocytes Encapsulating L-asparaginase) in
Patients With Relapse of Acute Lymphoblastic Leukemia;
ODM derived from:
https://clinicaltrials.gov/show/NCT01518517
All rights reserved. Please visit https://medical-data-
models.org/forms/12754
Eligibility Acute Lymphoblastic
Leukemia, in Relapse NCT01518517
Inclusion Criteria
patient from 1 to 55 years old (children and
adolescents from 1 to 17 years/ adults from 18 to
55 years)*
Yes
No
patients with 1st all relapse, which could be either
isolated bone marrow relapse, or combined
(medullary and extra-medullary) relapse, or extra-
medullary isolated relapse; or lymphoblastic
lymphoma (excepted burkitt lymphoma) or failure
to all first line treatment (no complete remission
obtained)*
Yes
No
patient previously treated with free e.coli l-
asparaginase form or pegylated one*
Yes
No
performance status ≤ 2 (who score)*
Yes
No
patient informed and consent provided (the 2
parents need to consent when children are below
18)*
Yes
No
Exclusion Criteria
all t(9;22) and/or bcr-abl positive (philadelphia
chromosome positive)*
Yes
No
patient with 2nd relapse and over*
Yes
No
women of childbearing potential without effective
contraception as well as pregnant or breast
feeding women*
Yes
No
patient unable to receive treatments used in
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global chemotherapy protocols, due to general or
visceral conditions such as:severe cardiac
impairment (nyha grade 3 or 4
cardiomyopathy)/serum creatinine 2 x uln unless
related to all /alt or ast 5 x uln unless related to all
/pancreatitis history /other malignancy that all /
severe infection, hiv positive, active hepatitis
related to b or c virus infection / trisomy 21 / other
serious conditions according to investigator's
opinion*
Yes
No
known grade 4 allergic reaction to e.coli l-
asparaginase (according nci-ctcae, version 3.0)*
Yes
No
history of grade 3 transfusional incident*
Yes
No
presence of specific anti-erythrocyte antibodies
preventing from getting a compatible erythrocyte
concentrate for the patient*
Yes
No
patient under concomitant treatment likely to
cause hemolysis*
Yes
No
patient undergoing yellow fever vaccination*
Yes
No
patient under phenytoin treatment*
Yes
No
patient included in previous clinical study less
than 6 weeks ago*
Yes
No
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Eligibility Acute Lymphoblastic Leukemia, in Relapse NCT01518517
Eligibility Acute Myeloid Leukemia
NCT00488709
Fludarabine, Cytarabine, Topotecan in Treating Patients
With Relapsed or Refractory Acute Myeloid Leukemia;
ODM derived from:
https://clinicaltrials.gov/show/NCT00488709
All rights reserved. Please visit https://medical-data-
models.org/forms/12755
Eligibility Acute Myeloid Leukemia
NCT00488709
Inclusion Criteria
1. subjects of 18 years of age or major, with
diagnosis of primary or secondary aml, confirmed
cytologically, that fulfill one of the following
conditions:*
Yes
No
do not reach a cr after the conventional
treatment.*
Yes
No
relapse in the first 12 months after a cr. during
remission, patients can have be treated by a
transplant. the relapse is defined as the presence
of blasts in peripheric blood or the presence of >5
% of blasts in mo.*
Yes
No
not participation in a  clinical trial.*
Yes
No
2. ecog < o = 2*
Yes
No
3. considered suitable patients for an intensive
chemotherapy*
Yes
No
4. informed consent*
Yes
No
Exclusion Criteria
1. pelvic or spinal radiotherapy in 4 weeks before
the incorporation in the protocol.*
Yes
No
2. acute promyelocytic leukaemia*
Yes
No
3. first line chemotherapy for aml which has
contained fludarabine or topotecan.*
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Yes
No
4. active or chronic hepatitis or hepatic cirrhosis.*
Yes
No
5. positivity known to the virus of the human
immunodeficiency (hiv)*
Yes
No
6. pregnant or breastfeeding patients.*
Yes
No
7. patients with deterioration of the functions
hepatic or renal, defined for the following values
base them of laboratory:*
Yes
No
ast or alt >2,5 times the top limit of the normality
of the center (lsnc)*
Yes
No
alkaline phosphatase >2,5 times the lsnc*
Yes
No
total bilirubin value >2 times the lsnc*
Yes
No
creatinine value >2 times the lsnc after a suitable
hydration*
Yes
No
8. precedents of intervention of major surgery in
2 weeks before the incorporation in the protocol.*
Yes
No
9. patients with disease serious or not controlled
(for example not controlled diabetes, infection,
hypertension, etc.).*
Yes
No
10. patients who have received other cytotoxic
drugs (except hydroxyurea to reduce the
leucocytosis) as treatment of the current relapse
or of the resistance, in 4 weeks before the
protocol.*
Yes
No
11. patients with hypersensitivity known to
someone of the drugs of the protocol.*
2 / 3
Eligibility Acute Myeloid Leukemia NCT00488709
Yes
No
12. patients treated previously with growth factors
with purposes of sensibilization.*
Yes
No
13. patients with psychological, intellectual or
sensitive dysfunction that can reduce his capacity
of comprehension and fulfillment of the protocol.*
Yes
No
14. patients treated before with flat.*
Yes
No
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Eligibility Acute Myeloid Leukemia NCT00488709
Eligibility Alzheimer's Disease
NCT02127476
A Study of Single and Multiple Doses of KHK6640 in
Subjects With Prodromal or Mild to Moderate Alzheimer's
Disease; ODM derived from:
https://clinicaltrials.gov/show/NCT02127476
All rights reserved. Please visit https://medical-data-
models.org/forms/12756
Eligibility Alzheimer's Disease
NCT02127476
Inclusion Criteria
patients with prodromal ad or mild to moderate
ad*
Yes
No
clinical dementia rating (cdr) score of 0.5, 1.0, or
2.0*
Yes
No
have a cognitive impairment*
Yes
No
low aβ and high tau in cerebrospinal fluid (csf)*
Yes
No
mini mental state examination (mmse) score > 16
at screening*
Yes
No
Exclusion Criteria
previous active treatment with an ad
immunotherapy in an investigational study*
Yes
No
use of another investigational drug within 30 days
of screening*
Yes
No
history or presence of clinically significant
seizures, brain trauma, transient ischemic attack,
and/or cerebrovascular disease*
Yes
No
presence of a neurological condition that could
be contributing to cognitive impairment above
and beyond that caused by the subject's ad*
Yes
No
evidence of infection, tumor, or other clinically
significant lesions that could indicate a dementia
diagnosis other than ad*
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Yes
No
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Eligibility Alzheimer's Disease NCT02127476
Eligibility Arthritis, Rheumatoid
NCT01604343
A Study of CNTO 136 (Sirukumab), Administered
Subcutaneously, in Patients With Active Rheumatoid
Arthritis Despite Disease-Modifying Antirheumatic Drug
(DMARD) Therapy (SIRROUND-D); ODM derived from:
https://clinicaltrials.gov/show/NCT01604343
All rights reserved. Please visit https://medical-data-
models.org/forms/12757
Eligibility Arthritis, Rheumatoid
NCT01604343
Inclusion Criteria
have a diagnosis of rheumatoid arthritis (ra) for at
least 3 months before screening*
Yes
No
have moderately to severely active ra with at least
6 of 68 tender joints and 6 of 66 swollen joints, at
screening and at baseline*
Yes
No
have been unresponsive to single-agent or
combination disease-modifying antirheumatic
drugs (dmard) therapy that includes methotrexate
(mtx) or sulfasalazine (ssz) due to lack of benefit
after at least 12 weeks of dmard, as assessed by
the treating physician*
Yes
No
if using oral corticosteroids, must be on a stable
dose equivalent to less than or equal to 10
mg/day of prednisone for at least 2 weeks prior to
the first administration of study agent. if currently
not using corticosteroids, must not have received
oral corticosteroids for at least 2 weeks prior to
the first administration of study agent*
Yes
No
if using non nonsteroidal anti-inflammatory drug
(nsaids) or other analgesics for ra, must be on a
stable dose for at least 2 weeks prior to the first
administration of study agent*
Yes
No
if using non-biologic dmard such as mtx, ssz,
hydroxychloroquine, chloroquine, or bucillamine,
must be on a stable dose for at least 4 weeks
prior to the first administration of study agent and
should have no serious toxic side effects
attributable to the dmard*
Yes
No
Exclusion Criteria
has a history of intolerance to at least 2 or
1 / 3
inadequate response to at least 1 anti-tumor
necrosis factor alpha agent after 3 months of
therapy*
Yes
No
has received infliximab, golimumab, adalimumab,
or certolizumab pegol within 3 months of the first
study agent administration*
Yes
No
has received etanercept or yisaipu within 6 weeks
of the first study agent administration*
Yes
No
has a history of intolerance to tocilizumab that
precluded further treatment with it, or inadequate
response to 3 months of tocilizumab (anti-il-6
receptor) therapy*
Yes
No
has used b-cell-depleting therapy (eg, rituximab)
within 7 months of first study agent administration
or have evidence during screening of abnormally
low b cell level caused by previous b-cell
depletion therapy*
Yes
No
has used anakinra within 4 weeks of first study
agent administration*
Yes
No
has used any other biologic therapy for the
treatment of ra within 3 months of the first study
agent administration*
Yes
No
has received intra-articular (ia), intramuscular
(im), or intravenous (iv) corticosteroids for ra,
including adrenocorticotrophic hormone during
the 4 weeks prior to first study agent
administration-*
Yes
No
has received leflunomide within 24 months before
the first study agent administration and have not
undergone a drug elimination procedure, unless
the m1 metabolite is measured and is
undetectable. if a drug elimination procedure is
performed during screening, the m1 metabolite
should be measured and found to be
undetectable*
2 / 3
Eligibility Arthritis, Rheumatoid NCT01604343
Yes
No
has a history of cyclophosphamide or cytotoxic
agent use*
Yes
No
has received cyclosporine a, azathioprine,
tacrolimus, mycophenolate mofetil, oral or
parenteral gold, or d-penicillamine within 4 weeks
of the first study agent administration*
Yes
No
has received an investigational drug (including
investigational vaccines) or used an
investigational medical device within 3 months or
5 half lives, whichever is longer, before the first
study agent administration*
Yes
No
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Eligibility Arthritis, Rheumatoid NCT01604343
Eligibility Asthma NCT00130351
A 3-week Study Investigating Patient Use and Functionality
of Formoterol in a Novel Inhalation Device in Patients With
Asthma; ODM derived from:
https://clinicaltrials.gov/show/NCT00130351
All rights reserved. Please visit https://medical-data-
models.org/forms/12758
Eligibility Asthma NCT00130351
Inclusion Criteria
patients who are capable of understanding the
directions for device usage, evaluating device
function and completing the patient diary*
Yes
No
patients who have a current diagnosis of asthma*
Yes
No
patients who have a documented forced
expiratory volume at 1 second (fev1) reversibility
of at least 12% over baseline value following
administration of a bronchodilator (i.e. "historical"
reversibility) or demonstrate a >12% increase in
fev1 over their baseline value within 30 minutes
after inhalation of up to 360 µg (4 puffs) of
albuterol at visit 1.  the administration of albuterol
for the reversibility test must be within 30 minutes
after baseline spirometry.*
Yes
No
Exclusion Criteria
patients who were enrolled in study cfor258f2304
or cfor258f2306, or who have any experience
using the certihaler® device.*
Yes
No
qtc above 450 milliseconds for males and 470
milliseconds for females, or any findings on the
screening electrocardiogram (ecg) that in the
opinion of the investigator would present a safety
hazard for continuation in the study*
Yes
No
patients who have a known history of untoward
reactions to sympathomimetic amines or to
inhaled medications or to any of the individual
components in those therapies*
Yes
No
other protocol-defined inclusion and exclusion
criteria apply*
Yes
No
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Eligibility Asthma NCT00920621
Randomized Trial: Maternal Vitamin D Supplementation to
Prevent Childhood Asthma (VDAART); ODM derived from:
https://clinicaltrials.gov/show/NCT00920621
All rights reserved. Please visit https://medical-data-
models.org/forms/12759
Eligibility Asthma NCT00920621
Inclusion Criteria
personal history of asthma, eczema, allergic
rhinitis or a history of asthma, eczema, allergic
rhinitis in the biological father of the child*
Yes
No
gestational age between 10 and 18 weeks at the
time of randomization*
Yes
No
maternal age between 18 and 39 years*
Yes
No
not a current smoker*
Yes
No
english or spanish speaking*
Yes
No
intent to participate for the full 4 years (through
pregnancy and then until the 3rd birthday of the
child)*
Yes
No
Exclusion Criteria
not meeting inclusion criteria*
Yes
No
gestational age greater than 18 weeks*
Yes
No
presence of chronic medical conditions*
Yes
No
taking vitamin d supplements containing more
than 2000 iu/day of vitamin d3*
Yes
No
multiple gestation pregnancy (twins, triplets)*
Yes
No
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pregnancy achieved by assisted reproduction
techniques (e.g., iui, ivf)*
Yes
No
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Eligibility Asthma NCT00920621
Eligibility Atrial Fibrillation NCT00070655
Evaluating the Use of SR34006 Compared to Warfarin or
Acenocoumarol in Patients With Atrial Fibrillation
(AMADEUS); ODM derived from:
https://clinicaltrials.gov/show/NCT00070655
All rights reserved. Please visit https://medical-data-
models.org/forms/12760
Eligibility Atrial Fibrillation
NCT00070655
Inclusion Criteria
ecg-documented atrial fibrillation (af) and an
indication for long-term vitamin k antagonist (vka)
therapy based on the presence of at least one of
the following risk factors:*
Yes
No
1. previous ischemic stroke, transient ischemic
attack (tia) or systemic embolism*
Yes
No
2. hypertension requiring drug treatment*
Yes
No
3. left ventricular dysfunction (left ventricular
ejection fraction <45% or symptomatic congestive
heart failure)*
Yes
No
4. age >75 years*
Yes
No
5. age between 65-75 years plus diabetes
mellitus, or*
Yes
No
6. age between 65-75 years plus symptomatic
coronary artery disease (previous myocardial
infarction (mi) or angina pectoris)*
Yes
No
written informed consent*
Yes
No
Exclusion Criteria
legal lower age limitations (country specific)*
Yes
No
indication for vka other than af, including
prosthetic heart valves, venous
thromboembolism, and planned cardioversion*
Yes
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No
transient af caused by a reversible disorder*
Yes
No
active bleeding or high risk of bleeding*
Yes
No
recent (<15 days) or anticipated invasive
procedures with potential for uncontrolled
bleeding, including major surgery*
Yes
No
participation in another pharmacotherapeutic
study within the prior 30 days*
Yes
No
creatinine clearance <10 ml/min, severe hepatic
disease, or bacterial endocarditis*
Yes
No
uncontrolled hypertension: systolic blood
pressure > 180 mm hg and/or diastolic blood
pressure > 110 mm hg*
Yes
No
pregnancy or childbearing potential without
proper contraceptive measures*
Yes
No
breastfeeding*
Yes
No
any other contraindication listed in the labeling of
warfarin or acenocoumarol*
Yes
No
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Eligibility Atrial Fibrillation NCT00070655
Eligibility Atrial Fibrillation NCT00352560
Electrophysiological Effects of Irbesartan in Patients With
Paroxysmal Atrial Fibrillation (AF); ODM derived from:
https://clinicaltrials.gov/show/NCT00352560
All rights reserved. Please visit https://medical-data-
models.org/forms/12761
Eligibility Atrial Fibrillation
NCT00352560
Inclusion Criteria
recurrent paf with indication for catheter ablation*
Yes
No
Exclusion Criteria
struct. cardiopathy*
Yes
No
mitral valve disease*
Yes
No
vef<40%*
Yes
No
myocardiopathy*
Yes
No
lvh*
Yes
No
cardiac surgery*
Yes
No
af reversible*
Yes
No
qt c>450*
Yes
No
recent mi/stroke, severe htn*
Yes
No
requirement of acei/arbs*
Yes
No
coronary synd., hta, liver disease*
Yes
No
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Eligibility Atrial Fibrillation NCT01213368
Dose Ranging Study of Dronedarone for the Control of
Ventricular Rate in Japanese Patients With Permanent
Atrial Fibrillation; ODM derived from:
https://clinicaltrials.gov/show/NCT01213368
All rights reserved. Please visit https://medical-data-
models.org/forms/12762
Eligibility Atrial Fibrillation
NCT01213368
Inclusion Criteria
patients of aged 20 years or more.*
Yes
No
permanent atrial fibrillation [af] (defined as
duration of af > 6 months) for which cardioversion
is not considered and with resting ventricular
heart rate ≥ 80 bpm at screening.*
Yes
No
Exclusion Criteria
unstable angina pectoris.*
Yes
No
history of torsades de pointes.*
Yes
No
prolonged qt corrected interval (≥ 500 ms).*
Yes
No
third degree atrioventricular block (avb) on the
screening ecg while in af or, documentation on
previous ecgs while in sinus rhythm of pr-interval
> 0.28 sec or high degree avb (2nd degree or
higher) or, significant sinus node disease
(documented pause ≥ 3 sec) - without a
permanent pacemaker implanted.*
Yes
No
congestive heart failure (chf) of new york heart
association classification (nyha) class iv or recent
(within 1 month prior to randomization) unstable
nyha class iii.*
Yes
No
treatment with other class i or iii anti-arrhythmic
drugs.*
Yes
No
patients treated with amiodarone during the 4
weeks preceding randomization.*
Yes
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No
clinically relevant haematologic, hepatic, gastro-
intestinal, renal, pulmonary, endocrinologic (in
particular thyroid) or psychiatric disease.*
Yes
No
hypokalemia and hypomagnesemia must be
corrected before randomization.*
Yes
No
the above information is not intended to contain
all considerations relevant to a patient's potential
participation in a clinical trial.*
Yes
No
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Eligibility Atrial Fibrillation NCT01213368
Eligibility Autosomal Dominant Polycystic
Kidney Disease NCT01810614
A New Diet for Patients With Autosomal Dominant
Polycystic Disease (ADPKD); ODM derived from:
https://clinicaltrials.gov/show/NCT01810614
All rights reserved. Please visit https://medical-data-
models.org/forms/12763
Eligibility Autosomal Dominant
Polycystic Kidney Disease
NCT01810614
Inclusion Criteria
have not been prescribed dietary restrictions or
enhancements*
Yes
No
blood pressure <135/85 mmhg with or without
specific treatment*
Yes
No
willingness to participate for at least one month*
Yes
No
diet history consistent with the excretion of >30
meq nae / day based on usual dietary intake*
Yes
No
Exclusion Criteria
other active diseases requiring pharmacologic
agents*
Yes
No
unstable weight (+/- 2 kg) for 3 months prior to
enrollment*
Yes
No
food allergies*
Yes
No
pregnancy or lactating*
Yes
No
confounding medications, i.e. bicarbonate,
citrate*
Yes
No
individuals who do not consume meat for
personal, religious, or health reasons.*
Yes
No
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Eligibility Breast Cancer NCT00062400
Assessing Women's Attitudes About the Risk of Infertility
Related to Adjuvant Therapy for Early Breast Cancer; ODM
derived from: https://clinicaltrials.gov/show/NCT00062400
All rights reserved. Please visit https://medical-data-
models.org/forms/12764
Eligibility Breast Cancer
NCT00062400
Criteria
histologically or cytologically confirmed prior or
current diagnosis of breast cancer- Stage I or II,
No relapsed disease*
Yes
No
no evidence of infertility: regular menses or
regular hormonal contraception use for the past 3
months*
Yes
No
hormonal status: Not specified*
Yes
No
patient characteristics: Age 35 and under at
diagnosis*
Yes
No
Sex: female*
Yes
No
menopausal status: premenopausal*
Yes
No
performance status: Not specified*
Yes
No
life expectancy: Not specified*
Yes
No
hematopoietic: Not specified*
Yes
No
hepatic: Not specified*
Yes
No
renal: Not specified*
Yes
No
Other: No psychological, familial, sociological, or
geographical condition that would preclude study
compliance*
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Yes
No
prior concurrent therapy:*
Yes
No
biologic therapy:not specified*
Yes
No
chemotherapy: Not specified*
Yes
No
endocrine therapy: See Disease Characteristics*
Yes
No
radiotherapy: Not specified*
Yes
No
surgery: Not specified*
Yes
No
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Eligibility Breast Cancer NCT00062400
Eligibility Breast Cancer NCT00754312
A Phase I, Multicenter, Open Label Study on the Effects of
SNDX-275 on Expression of Biomarkers in Subjects With
Newly Diagnosed Breast Cancer; ODM derived from:
https://clinicaltrials.gov/show/NCT00754312
All rights reserved. Please visit https://medical-data-
models.org/forms/12765
Eligibility Breast Cancer
NCT00754312
Inclusion Criteria
is scheduled for breast biopsy due to a
suspicious mass palpable or ≥1 cm on
mammogram*
Yes
No
must be able to receive two doses of study
medication 7 days apart prior to surgery*
Yes
No
has histologically confirmed invasive breast
cancer with er positive, er and/or pr negative
histology or triple negative (for er, pr, her-2)
histology*
Yes
No
has an ecog performance status ≤ 2*
Yes
No
has no clinically significant laboratory or cardiac
abnormalities*
Yes
No
has a negative serum pregnancy test at
screening as is either post menopausal, sterile or
willing to use an approved method of
contraception.*
Yes
No
is able to swallow and retain oral medication*
Yes
No
Exclusion Criteria
has a concomitant medical condition that
precludes adequate study treatment compliance
or assessment, such as:  a. bleeding disorders
that would increase risks of additional core
biopsy for biomarkers, b. morbid obesity*
Yes
No
is currently receiving treatment with a medication
on the prohibited medication list*
Yes
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No
has allergy to benzamides or inactive
components of study drug*
Yes
No
is participating in another clinical trial or has
received another investigational agent within 30
days prior to informed consent*
Yes
No
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Eligibility Breast Cancer NCT00754312
Eligibility Breast Cancer NCT01728506
An Internet-based Weight Loss and Exercise Intervention
for Breast Cancer Survivors; ODM derived from:
https://clinicaltrials.gov/show/NCT01728506
All rights reserved. Please visit https://medical-data-
models.org/forms/12766
Eligibility Breast Cancer
NCT01728506
Inclusion Criteria
breast cancer diagnosis*
Yes
No
completion of surgery, chemotherapy +/- radiation
for stage i, ii, or iii breast cancer 2-12 months
prior to study initiation*
Yes
No
bmi between 27 and 50*
Yes
No
patient self-report of ability to walk for 10 minutes
without interruption or pain*
Yes
No
access to computer and the internet*
Yes
No
Exclusion Criteria
metastatic disease*
Yes
No
prior receipt of chemotherapy for other
malignancy*
Yes
No
pregnancy at the time of study entry*
Yes
No
limited food choices due to celiac sprue or
inflammatory bowel disease*
Yes
No
illiteracy*
Yes
No
non-english speaking*
Yes
No
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Eligibility Bronchial Asthma NCT00142025
Study of Efficacy of Oxcarbazepine in Therapy of Bronchial
Asthma; ODM derived from:
https://clinicaltrials.gov/show/NCT00142025
All rights reserved. Please visit https://medical-data-
models.org/forms/12767
Eligibility Bronchial Asthma
NCT00142025
Inclusion Criteria
bronchial asthma has been known at least for 1
year*
Yes
No
absence of long-term remissions of asthma
(lasting more than 1 month)*
Yes
No
poorly controlled asthma, due to various reasons*
Yes
No
non-smokers*
Yes
No
Exclusion Criteria
presence of concomitant severe diseases*
Yes
No
allergy or adverse reactions to carbamazepine or
oxcarbazepine*
Yes
No
abnormal baseline haematology, blood chemistry
or urinalysis*
Yes
No
current use of long-acting beta-agonists*
Yes
No
age younger than 16 years old*
Yes
No
long-term history of smoking*
Yes
No
pregnancy or lactating*
Yes
No
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Eligibility Cancer NCT01162551
Trial of Sirolimus and Methotrexate in Relapsed/Refractory
Lymphoblastic Leukemia and Lymphoma; ODM derived
from: https://clinicaltrials.gov/show/NCT01162551
All rights reserved. Please visit https://medical-data-
models.org/forms/12768
Eligibility Cancer NCT01162551
Inclusion Criteria
patients </= 25 years of age, at time of
enrollment, with second or greater relapse of all
or nhl. for all must have histologic diagnosis with
>10% blasts in the marrow and for lymphoblastic
lymphoma or peripheral t-cell lymphoma must
have radiologic or physical evidence of
recurrence.*
Yes
No
lansky > 50%  or karnofsky > 50%*
Yes
No
negative pregnancy test*
Yes
No
creatinine clearance or radioisotope gfr >
70ml/min/m2 or serum creatinine based on age
/gender*
Yes
No
pulse ox >94%*
Yes
No
total bilirubin <1.5 x normal for age*
Yes
No
alt < 5 x normal for age*
Yes
No
albumin > 2g/dl*
Yes
No
shortening fraction by echo > 28% or ejection
fraction > 50% by gated radionuclide study*
Yes
No
Exclusion Criteria
patient has known allergies to sirolimus,fk-506 or
mtor inhibitors*
Yes
No
patient is taking other investigational anti-
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neoplastic drugs*
Yes
No
patient received no myelosuppressive chemo
within 14 days*
Yes
No
< 14 days have elapsed since local palliative xrt
(small port) < 28 days since prior craniospinal xrt
or 50% radiation of pelvis <28 days if other
substantial bm radiation*
Yes
No
hematopoietic growth factors within 7 days of
entry (except erythropoietin.)*
Yes
No
patient has taken any biologic agents within 14
days*
Yes
No
post bmt/sct - evidence of active gvhd, at least >
3 months must have elapsed*
Yes
No
patient has uncontrolled infection (if patients with
fungal disease, stable for < 14 days and patients
with bacteremia without negative blood culture*
Yes
No
existing non-hematologic toxicities > grade 2*
Yes
No
use of steroids or hydroxyurea is permitted upto
14 days prior to entry.*
Yes
No
2 / 2
Eligibility Cancer NCT01162551
Eligibility Carcinoma, Non-small Cell Lung
NCT00385996
Pilot Study of Preoperative Tarceva (Erlotinib) for Stages I/II
Non-Small Cell Lung Cancer; ODM derived from:
https://clinicaltrials.gov/show/NCT00385996
All rights reserved. Please visit https://medical-data-
models.org/forms/12769
Eligibility Carcinoma, Non-small Cell
Lung NCT00385996
Inclusion Criteria
biopsy proven stage i/ii non-small cell lung cancer
who are candidates for  surgical resection*
Yes
No
ambulatory and capable of all self-care but may
be unable to carry out any work activities.*
Yes
No
preoperative and postoperative high resolution ct
scans done at nyph-weill cornell medical center
for purposes of volumetric measurements.*
Yes
No
acceptable cardiac, breathing, kidney, liver, and
bone marrow functions.*
Yes
No
18 years and older.*
Yes
No
women of child-bearing potential must be taking
adequate contraceptive precautions prior to study
entry and for the duration of study participation. a
negative serum or urine pregnancy test is
required within 7-10 days of tarceva®
administration. men and premenopausal women
of child bearing potential will follow an approved,
medically accepted birth control regimen or agree
to abstain from heterosexual intercourse while
taking study drug and for 30 days following the
last dose of study drug.*
Yes
No
Exclusion Criteria
cannot be on any other anti-cancer treatment
during this study.*
Yes
No
prior treatment with any egfr inhibitor.*
Yes
No
patients who had prior treatment with
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chemotherapy or radiation for this disease.*
Yes
No
other active cancers.*
Yes
No
tumors with a mixed histology of small cell and
non-small cell carcinoma as well as patients with
pulmonary carcinoid tumors.*
Yes
No
gastro-intestinal abnormalities, including active
peptic ulcer or inflammatory bowel disease.*
Yes
No
hypersensitivity to compounds similar in chemical
composition to tarceva®.*
Yes
No
active infection or serious underlying medical
conditions which would impair protocol
treatment.*
Yes
No
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Eligibility Carcinoma, Non-small Cell Lung NCT00385996
Eligibility Cardiovascular Disease
NCT00441714
Effect of Ischemic Postconditioning on Targeting of Annexin
A5 After Forearm Exercise; ODM derived from:
https://clinicaltrials.gov/show/NCT00441714
All rights reserved. Please visit https://medical-data-
models.org/forms/12770
Eligibility Cardiovascular Disease
NCT00441714
Inclusion Criteria
age 18-50 years*
Yes
No
no physical limitation to perform ischemic
exercise*
Yes
No
informed consent*
Yes
No
Exclusion Criteria
diabetes (fasting glucose > 7,0mmol/l, or random
glucose >11,0mmol/l)*
Yes
No
hyperlipidemia (random total cholesterol > 6.5
mmol/l)*
Yes
No
hypertension (supine sbp/dbp > 140/90 mmhg at
screening)*
Yes
No
any cardiovascular disease*
Yes
No
drug abuse*
Yes
No
concomitant chronic use of medication*
Yes
No
administration of radioactivity in research setting
during the last 5 years*
Yes
No
participation to any drug-investigation during the
previous month as checked with vip check
according to crcn standard procedures.*
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Yes
No
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Eligibility Cardiovascular Disease NCT00441714
Eligibility Cardiovascular Disease
NCT01230606
Same Day Versus Next Day Discharge: Ambulatory
Closure Device Percutaneous Intervention; ODM derived
from: https://clinicaltrials.gov/show/NCT01230606
All rights reserved. Please visit https://medical-data-
models.org/forms/12771
Eligibility Cardiovascular Disease
NCT01230606
Inclusion Criteria
1.   <75 years of age at the time of procedure.*
Yes
No
2.      patient has a type a or b lesion(s)*
Yes
No
3.      femoral access site is amenable to closure
with a vascular closure device.*
Yes
No
4.      over 2 hours since the completion of the pci
procedure (at least 2 hours must elapse from
completion of the pci before subjects become
eligible).*
Yes
No
Exclusion Criteria
1. patient has a life expectancy less than 12
months.*
Yes
No
2. patient has recent evidence of an acute
coronary syndrome (mi)*
Yes
No
3. femoral access is difficult or site is not
amenable to closure device*
Yes
No
4. anticoagulants other than unfractionated
heparin or bivalirudin were used during the
procedure (i.e. enoxaparin).*
Yes
No
5. patient has sub optimal angiographic outcome
or clinical complication(s) during pci*
Yes
No
6. the pci occurred in something other than a
native coronary artery*
Yes
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No
7. angiographic evidence of thrombus*
Yes
No
8. patient has more than 3 stents implanted
during this pci*
Yes
No
9. patient has an inr >2, platelet count <100,000
or hematocrit <25*
Yes
No
10. occlusion of major side branch during pci of
>1.5mm*
Yes
No
11. patient has ejection fraction ≤30%*
Yes
No
12. known allergy to pci procedural medications*
Yes
No
13. patient reports living further than 30 minutes
from a hospital by ambulance.*
Yes
No
14. patient provides informed consent and agrees
to the follow-up schedule.*
Yes
No
15. evidence of  vascular complication(s) (e.g.
dissection, hematoma, bleeding) peri-procedure*
Yes
No
16. patient is pregnant*
Yes
No
17. evidence of infection (e.g. fever, pus, swelling)
peri-procedure*
Yes
No
18. patients with chronic renal insufficiency (e.g.
serum creatinine ≥1.5 mg/dl)*
Yes
No
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Eligibility Childhood Asthma NCT02451709
STudy of Asthma Adherence Reminders; ODM derived
from: https://clinicaltrials.gov/show/NCT02451709
All rights reserved. Please visit https://medical-data-
models.org/forms/12772
Eligibility Childhood Asthma
NCT02451709
Inclusion Criteria
doctor diagnosed asthma.*
Yes
No
on at least bts stage 2, which means they will be
on regular inhaled steroids.*
Yes
No
no change in regular asthma treatment in the last
1 month (on regular inhaled steroids, no change
in steroid dose for*
Yes
No
1 month, no change in add on therapy in the last
month).*
Yes
No
acq (asthma control questionnaire) score more
than or equal to 1.5.*
Yes
No
can speak and understand english.*
Yes
No
Exclusion Criteria
bts stage 5 asthma (complex issues, too
unstable).*
Yes
No
recent changes to asthma treatment within the
last month. (see above)*
Yes
No
acq (asthma control questionnaire) score < 1.5.*
Yes
No
another chronic health condition (eg diabetes,
congenital heart disease, cystic fibrosis).*
Yes
No
can't speak or understand english.*
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Yes
No
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Eligibility Childhood Asthma NCT02451709
Eligibility Diabetes Mellitus, Type 2
NCT01472367
A Study of the Safety and Efficacy of MK-0431A in Pediatric
Participants With Type 2 Diabetes Mellitus (MK-0431A-
170); ODM derived from:
https://clinicaltrials.gov/show/NCT01472367
All rights reserved. Please visit https://medical-data-
models.org/forms/12773
Eligibility Diabetes Mellitus, Type 2
NCT01472367
Inclusion Criteria
has type 2 diabetes mellitus (t2dm)*
Yes
No
is on metformin monotherapy (≥1500 mg/day) for
≥12 weeks with a1c ≥6.5% and ≤10.0% or is on
stable doses of metformin (≥1500 mg/day) and
insulin for ≥12 weeks with an a1c ≥7.0% and
≤10%. note: participants on a daily dose of
metformin greater than or equal to 1000 mg/day,
but less than 1500 mg/day may be eligible if there
is documentation that higher doses are not
tolerated.*
Yes
No
between 10 and 17 years of age on day of
signing informed consent with randomization to
occur prior to 18th birthday.*
Yes
No
participant and a family member or adult closely
involved in the daily activities will participate in
the participant's treatment and study protocol
(i.e., available for telephone calls, study visits and
administration of study medication as needed).*
Yes
No
Exclusion Criteria
known type 1 diabetes mellitus or documented
evidence of positive diabetes auto-antibodies (if
performed when participant was diagnosed with
diabetes).*
Yes
No
known monogenic diabetes, secondary diabetes,
or a genetic syndrome or disorder known to affect
glucose tolerance other than diabetes.*
Yes
No
symptomatic hyperglycemia and/or moderate to
large ketonuria requiring immediate initiation of
another antihyperglycemic agent.*
Yes
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No
participant has previously taken a dipeptidyl
peptidase-iv (dpp-4) inhibitor (such as sitagliptin,
vildagliptin, alogliptin, or saxagliptin) or glucagon-
like peptide-1 (glp-1) receptor agonist (such as
exenatide or liraglutide).*
Yes
No
exhibits abnormal growth patterns or is being
treated with growth hormone.*
Yes
No
history of idiopathic acute pancreatitis or chronic
pancreatitis.*
Yes
No
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Eligibility Diabetes Mellitus, Type II
NCT00554697
Diabetes Mellitus Type II and Tissue Oxygenation; ODM
derived from: https://clinicaltrials.gov/show/NCT00554697
All rights reserved. Please visit https://medical-data-
models.org/forms/12774
Eligibility Diabetes Mellitus, Type II
NCT00554697
Inclusion Criteria
we will include 30 patients who have more than a
five-year history of insulin-dependent type-2
diabetes mellitus and 30 non-diabetic patients
meeting the following criteria:*
Yes
No
35 - 65 yrs old*
Yes
No
bmi < 30*
Yes
No
asa class i - iii*
Yes
No
abdominal surgery scheduled to last between 2-
4 hours*
Yes
No
for non- diabetic group: previous bmp within the
last year demonstrating glucose < 126mg/dl*
Yes
No
dmii defined as fasting plasma glucose of > 126
mg/dl at time of diagnosis, now requiring insulin*
Yes
No
at least one diabetes associated vasculopathy:
coronary artery disease, diabetic nephropathy,
hypertension, diabetic retinopathy, diffuse
neuropathy, peripheral vascular disease, or a
history of stroke*
Yes
No
Exclusion Criteria
pregnant*
Yes
No
immunocompromised: hiv/aids, on
immunosuppressant therapy for any reason, or
post-organ transplantation.*
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Yes
No
infection or fever, or on glucocorticoids*
Yes
No
malignancy currently requiring radiation or
chemotherapy*
Yes
No
liver or renal failure*
Yes
No
pancreatic insufficiency, dysautonomia, thyroid
disease, raynaud's syndrome, pathologic allen-
test, or any coagulopathies*
Yes
No
respiratory disease affecting ability to reach pao2
of 300mmhg: copd, emphysema, cystic fibrosis,
asthma, pneumonia, pe*
Yes
No
smoker within the past 6 months or current
alcohol abuse*
Yes
No
allergy to local anesthetic*
Yes
No
for diabetics: dmi, other specific subtype, and
gestational diabetics*
Yes
No
we will also exclude patients with epidural
catheter, to avoid the influence of regional
anesthesia on tissue oxygenation [37, 38].*
Yes
No
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Eligibility Diabetes NCT00789711
An Observational Study to Compare the Safety and
Effectiveness of NovoMix® 30 and Levemir™ for the
Treatment of Diabetes; ODM derived from:
https://clinicaltrials.gov/show/NCT00789711
All rights reserved. Please visit https://medical-data-
models.org/forms/12775
Eligibility Diabetes NCT00789711
Inclusion Criteria
patients diagnosed with type 1 or type 2 diabetes
mellitus*
Yes
No
patients uncontrolled on oral antidiabetic drugs*
Yes
No
insulin naïve patients or patients currently on
human insulin*
Yes
No
Exclusion Criteria
subjects who are unlikely to comply with protocol
requirements*
Yes
No
subjects who are previously enrolled in novomix®
30 and levemir™ study*
Yes
No
subjects on novomix® 30 and levemir™ therapy*
Yes
No
subjects with hypersensitivity to novomix® 30  or
to any of the excipients*
Yes
No
subjects with hypersensitivity to levemir™ or to
any of the excipients*
Yes
No
females of child bearing potential who are
pregnant, breast feeding or intend to become
pregnant or are not using adequate contraceptive
methods (adequate contraceptive measures are
required by local law or practice*
Yes
No
contraindications and warnings specified in the
current prescribing information*
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Yes
No
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Eligibility Diastolic Heart Failure
NCT02254382
Positive Airway Pressure Therapy Study in Sleep Apnea
and Diastolic Heart Failure; ODM derived from:
https://clinicaltrials.gov/show/NCT02254382
All rights reserved. Please visit https://medical-data-
models.org/forms/12776
Eligibility Diastolic Heart Failure
NCT02254382
Inclusion Criteria
clinical signs and symptoms of heart failure
according to the esc guidelines*
Yes
No
echocardiographic evidence of diastolic
dysfunction*
Yes
No
polysomnographic evidence of at least moderate
sleep-disordered breathing (apnea-hypopnea
index (ahi) ≥ 15 / h)*
Yes
No
bnp ≥ 300 pg / ml*
Yes
No
nyha class ii or iii*
Yes
No
patient tolerates the ventilation treatment (1h
sample ventilation)*
Yes
No
stable drug therapy in the last 4 weeks prior to
randomization (no iv diuretic therapy or
increasing the dose of diuretics to> 100%)*
Yes
No
minimum age of patients of 18 years*
Yes
No
Exclusion Criteria
oxygen saturation (so2) <92% of the days in
peace without o2 therapy, measured baseline
(start time) in the pulse oximetry or
polysomnography in a cape. bga (the
measurement must be max. lie back 1 week)*
Yes
No
patients, who have a risk professional with
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symptomatic sleep apnea*
Yes
No
known copd with fev1 <70%*
Yes
No
advanced herzklappenvitien*
Yes
No
pericardial diseases*
Yes
No
existing apap or bi-level therapy (including
adaptive servo-ventilation) in the last 3 months*
Yes
No
acute cardiac event in the last 3 months*
Yes
No
bmi ≥ 35kg / m²*
Yes
No
pregnant or lactating women*
Yes
No
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Eligibility Osteoarthritis NCT00104312
Osteoarthritis: Weakness From Inflammation; ODM derived
from: https://clinicaltrials.gov/show/NCT00104312
All rights reserved. Please visit https://medical-data-
models.org/forms/12777
Eligibility Osteoarthritis
NCT00104312
Inclusion Criteria
50 years of age or older*
Yes
No
normal body weight (a body mass index (bmi) of
30 or less)*
Yes
No
osteoarthritis of the knee (prior to knee surgery)*
Yes
No
planning to have knee surgery at a medstar
hospital*
Yes
No
Exclusion Criteria
history of a stroke*
Yes
No
history of muscle weakness or paralysis*
Yes
No
history of rheumatoid arthritis or*
Yes
No
inflammatory joint disease*
Yes
No
history of a bleeding disorder*
Yes
No
history of gout*
Yes
No
diabetes for which you take insulin*
Yes
No
polymyalgia rheumatica (total body muscle
aching/stiffness)*
Yes
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No
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Eligibility Rheumatoid Arthritis
NCT01600521
A Clinical Study of a Natural Remedy for Rheumatoid
Arthritis vs. Commonly Used Conventional Medications;
ODM derived from:
https://clinicaltrials.gov/show/NCT01600521
All rights reserved. Please visit https://medical-data-
models.org/forms/12778
Eligibility Rheumatoid Arthritis
NCT01600521
Inclusion Criteria
age of 18 years or older*
Yes
No
active ra, defined by at least 8 swollen joints and
at least 10 tender joints (excluding distal
interphalangeal joints)*
Yes
No
an erythrocyte sedimentation rate (esr) of at least
28 mm per hour*
Yes
No
the 1987 revised american college of
rheumatology (acr) criteria for diagnosis of ra for
at least 6 months*
Yes
No
not use of nsaids within two weeks*
Yes
No
agreement to participate in this study.*
Yes
No
Exclusion Criteria
poor compliance*
Yes
No
severe medical conditions*
Yes
No
abnormalities in liver, or kidney function, or in
haematological parameters,*
Yes
No
pregnancy or breast feeding*
Yes
No
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Eligibility Rheumatoid Arthritis
NCT01665430
A Long-Term Extension Study to WA19926 of
RoActemra/Actemra (Tocilizumab) in Patients With Early,
Moderate to Severe Rheumatoid Arthritis; ODM derived
from: https://clinicaltrials.gov/show/NCT01665430
All rights reserved. Please visit https://medical-data-
models.org/forms/12779
Eligibility Rheumatoid Arthritis
NCT01665430
Inclusion Criteria
adult patients, >/= 18 years of age*
Yes
No
patients who complete wa19926 core study (visit
at week 104 and two follow-up telephone visits)
and who may benefit from study drug treatment
according to the investigator's assessment*
Yes
No
no current or recent adverse event or laboratory
finding preventing the use of the study drug dose
of roactemra/actemra 8 mg/kg at baseline visit*
Yes
No
receiving treatment on an outpatient basis*
Yes
No
females of child-bearing potential must agree to
use at least one adequate method of
contraception as defined by protocol during the
treatment period*
Yes
No
Exclusion Criteria
pregnant women*
Yes
No
patients who have prematurely withdrawn from
the wa19926 study for any reason*
Yes
No
treatment with any investigational agent or cell
depleting therapies since last administration of
study drug in the wa 19926 core study*
Yes
No
treatment with an anti-tumor necrosis factor (tnf)
or anti-interleukin (il)1 agent, or a t-cell
costimulation modulator since the last
administration of the study drug in the wa19926
core study*
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Yes
No
immunization with a live/attenuated vaccine since
the last administration of study drug in the
wa19926 core study*
Yes
No
diagnosis since visit at week 104 of the core
wa19926 study of rheumatic autoimmune disease
other than rheumatoid arthritis*
Yes
No
diagnosis since visit at week 104 of the core
wa19926 study of inflammatory joint disease
other than rheumatoid arthritis*
Yes
No
evidence of serious uncontrolled concomitant
disease or disorder*
Yes
No
known active or history of recurrent infection*
Yes
No
current liver disease as determined by
investigator*
Yes
No
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Eligibility Sarcoidosis NCT00581607
Double Blind, Randomized Trial of Bosentan for Sarcoidosis
Associated Pulmonary Hypertension; ODM derived from:
https://clinicaltrials.gov/show/NCT00581607
All rights reserved. Please visit https://medical-data-
models.org/forms/12780
Eligibility Sarcoidosis NCT00581607
Inclusion Criteria
patients with known sarcoidosis 21.*
Yes
No
age 18 or greater*
Yes
No
patients with documented pulmonary
hypertension with a pa mean > 25 mm hg as
measured by cardiac catheterization within six
months of entry into the study. pulmonary artery
occluding pressure and or left ventricular end
diastolic pressure must be less than 15 mm hg.*
Yes
No
patients with who class ii or iii*
Yes
No
six minute walk distance of between 100 to 500
meters*
Yes
No
patients on stable immunotherapy for their
sarcoidosis, including prednisone, methotrexate,
azathioprine, hydroxychloroquine,
cyclophosphamide, thalidomide, and/or
infliximab*
Yes
No
patients able to provide written consent*
Yes
No
Exclusion Criteria
patients on pulmonary vasodilator drugs (flolan,
remodulin, bosentan, sildenafil) n the prior 28
days. patients on stable dose of calcium channel
blocker for more than 1 month prior to right heart
catheterization can be continued on the calcium
channel blocker.*
Yes
No
patients with severe airway obstruction as defined
by fev1/fvc of less than 35%*
Yes
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No
patients with world health organization (who)
class iv status.*
Yes
No
patients who are pregnant or breast feeding*
Yes
No
patients with significant left ventricular
dysfunction with a left ventricular ejection fraction
of less than 35%*
Yes
No
cardiac index < 2.0 liters and/or right atrial
pressure >15 mm hg*
Yes
No
significant liver dysfunction not due to
sarcoidosis.*
Yes
No
patients with severe other organ disease felt by
investigators to impact on survival during the
course of the study.*
Yes
No
patients unable to perform the 6 minute walk
study*
Yes
No
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Eligibility Schizophrenia NCT00159081
One Year Drug Treatment in First-Episode Schizophrenia;
ODM derived from:
https://clinicaltrials.gov/show/NCT00159081
All rights reserved. Please visit https://medical-data-
models.org/forms/12781
Eligibility Schizophrenia
NCT00159081
Inclusion Criteria
after the acute treatment of the first-episode in
schizophrenia (according icd-10 f20)*
Yes
No
age between 18 and 55*
Yes
No
informed consent*
Yes
No
Exclusion Criteria
residence outside of the catchment area*
Yes
No
legal reasons*
Yes
No
insufficient knowledge of the german language*
Yes
No
substance abuse or addiction*
Yes
No
pregnancy*
Yes
No
serious physical illness*
Yes
No
organic brain disease*
Yes
No
contraindication to neuroleptic treatment*
Yes
No
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NINDS CDE Family History Amyotrophic
Lateral Sclerosis
NINDS Common Data Elements (Family History
Amyotrophic Lateral Sclerosis)
Used from the National Institute of Neurological Disorders
and Stroke Common Data Elements
(https://www.commondataelements.ninds.nih.gov/)
References:
Grinnon ST, Miller K, Marler JR, Lu Y, Stout A, Odenkirchen
J, Kunitz S. National Institute of Neurological Disorders and
Stroke Common Data Element Project - approach and
methods. Clin Trials. 2012;9(3):322-9.
All rights reserved. Please visit https://medical-data-
models.org/forms/12782
General Health History
Family History
Are you adopted?
Yes
No
Are your parents, cousins, or otherwise
biologically related to each other?
Yes
No
Has anyone in your family ever been diagnosed
with Amyotrophic Lateral Sclerosis (ALS) or
Frontotemporal Dementia (FTD)?
Yes
No
Has your mother been diagnosed with
ALS/FTD/other neurological diseases?
ALS (1)
FTD (2)
other neurological disease (please
specify) (3)
None (4)
Are there tissue samples of your mother in
repository?
Yes (please give specimen ID) (1)
No (2)
Unknown (3)
Has your father been diagnosed with
ALS/FTD/other neurological diseases?
ALS (1)
FTD (2)
other neurological diseases (please
specify) (3)
None (4)
Are there tissue samples of your father in
repository?
Yes (please give specimen ID) (1)
No (2)
Unknown (3)
How many siblings does the patient have?
Has one of your siblings been diagnosed with
ALS/FTD/other neurological diseases?
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ALS (1)
FTD (2)
other neurological disease (please
specify) (3)
None (4)
Are there tissue samples of your sibling in
repository?
Yes (please give specimen ID) (1)
No (2)
Unknown (3)
How many half siblings does the patient have?
Has one of your half siblings been diagnosed with
ALS/FTD/other neurological diseases?
ALS (1)
FTD (2)
other neurological disease (please
specify) (3)
None (4)
Are there tissue samples of your half sibling in
repository?
Yes (please give specimen ID) (1)
No (2)
Unknown (3)
Has your maternal grandmother been diagnosed
with ALS/FTD/other neurological diseases?
ALS (1)
FTD (2)
other neurological diseases (please
specify) (3)
None (4)
Are there tissue samples of your maternal
grandmother in repository?
Yes (please give specimen ID) (1)
No (2)
Unknown (3)
Has your maternal grandfather been diagnosed
with ALS/FTD/other neurological diseases?
ALS (1)
FTD (2)
other neurological diseases (please
specify) (3)
None (4)
Are there tissue samples of your maternal
grandfather in repository?
yes (please give specimen ID) (1)
No (2)
Unknown (3)
Has your paternal grandmother been diagnosed
with ALS/FTD/other neurological diseases?
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ALS (1)
FTD (2)
other neurological diseases (please
specify) (3)
None (4)
Are there tissue samples of your paternal
grandmother in repository?
Yes (please give specimen ID) (1)
No (2)
Unknown (3)
Has your paternal grandfather been diagnosed
with ALS/FTD/other neurological diseases?
ALS (1)
FTD (2)
other neurological diseases (please
specify) (3)
None (4)
Are there tissue samples of your paternal
grandfather in repository?
yes (please give specimen ID) (1)
No (2)
Unknown (3)
How many maternal aunts does the patient have?
Has your maternal aunt been diagnosed with
ALS/FTD/other neurological diseases?
ALS (1)
FTD (2)
other neurological disease (please
specify) (3)
None (4)
Are there tissue samples of your maternal aunt in
repository?
Yes (please give specimen ID) (1)
No (2)
Unknown (3)
How many maternal uncles does the patient
habe?
Has your maternal uncle been diagnosed with
ALS/FTD/other neurological diseases?
ALS (1)
FTD (2)
other neurological diseases (please
specify) (3)
None (4)
Are there tissue samples of your maternal uncle
in repository?
Yes (please give specimen ID) (1)
No (2)
Unknown (3)
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How many paternal aunts does the patient have?
Has your paternal aunt been diagnosed with
ALS/FTD/other neurological diseases?
ALS (1)
FTD (2)
other neurological diseases (please
specify) (3)
None (4)
Are there tissue samples of your paternal aunt in
repository?
Yes (please give specimen ID) (1)
No (2)
Unknown (3)
How many paternal uncles does the patient
have?
Has your paternal uncle been diagnosed with
ALS/FTD/other neurologfical diseases?
ALS (1)
FTD (2)
other neurological diseases (please
specify) (3)
None (4)
Are there tissue samples of your paternal uncle in
repository?
Yes (please give specimen ID) (1)
No (2)
Unknown (3)
How many maternal cousins does the patient
have?
Has your maternal cousin been diagnosed with
ALS/FTD/other neurological diseases?
ALS (1)
FTD (2)
other neurological diseases (please
specify) (3)
None (4)
Are there tissue samples of your maternal cousin
in repository?
Yes (please give specimen ID) (1)
No (2)
Unknown (3)
How many paternal cousins does the patient
have?
Has your paternal cousin been diagnosed with
ALS/FTD/other neurological diseases?
ALS (1)
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FTD (2)
other neurological diseases (please
specify) (3)
None (4)
Are there tissue samples of your paternal cousin
in repository?
Yes (please give specimen ID) (1)
No (2)
Unknown (3)
Other relative, please specify
Has your relative been diagnosed with
ALS/FTD/other neurological diseases?
ALS (1)
FTD (2)
other neurological diseases (please
specify) (3)
None (4)
Are there tissue samples of your relative in
repository?
Yes (please give specimen ID) (1)
No (2)
Unknown (3)
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Eligibility Acute Lymphoblastic Leukemia
NCT00368355
T Cell Depletion for Recipients of HLA Haploidentical
Related Donor Stem Cell Grafts; ODM derived from:
https://clinicaltrials.gov/show/NCT00368355
All rights reserved. Please visit https://medical-data-
models.org/forms/12783
Eligibility Acute Lymphoblastic
Leukemia NCT00368355
Inclusion Criteria
lack of suitable conventional donor (i.e. 5/6 or 6/6
related or 5/6 or 6/6 unrelated donor) or presence
of a rapidly progressive disease not permitting
time to identify an unrelated donor*
Yes
No
age less than or equal to 55 years of age*
Yes
No
patients with high risk all in cr1 or all or high
grade (stage iii or iv) nhl after first relapse or with
primary refractory disease or minimal residual
diseases.*
Yes
No
myelodysplastic syndrome*
Yes
No
patients with high risk aml in cr1 (complement
receptor 1) or after first relapse or with primary
refractory disease or minimal residual disease.*
Yes
No
cml*
Yes
No
hemophagocytic lymphohistiocytosis (hlh),
familial hemophagocytic lymphohistiocytosis (flh),
viral-associated hemophagocytic syndrome
(vahs), x-linked lymphoproliferative disease (xlp),
severe chronic active epstein barr virus infection
(scaebv) with predilection for t- or nk-cell
malignancy*
Yes
No
donor cells should be collected and frozen before
conditioning starts*
Yes
No
Exclusion Criteria
patients with a life expectancy (< / = 6 weeks)
limited by diseases other than leukemia*
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Yes
No
patients with symptomatic cardiac disease, or
evidence of significant cardiac disease by
echocardiogram (i.e., shortening fraction < 25%)*
Yes
No
patients with severe renal disease (i.e., creatinine
clearance less than 40 cc/1.73 m^2)*
Yes
No
patients with pre-existing severe restrictive
pulmonary disease (fvc less than 40 percent of
predicted)*
Yes
No
patients with severe hepatic disease (direct
bilirubin greater than 3 ug/dl or sgpt (serum
glutamic-pyruvic transaminase) greater than 500
ug/dl)*
Yes
No
patients with severe personality disorder or
mental illness*
Yes
No
patients with a severe infection that on evaluation
by the principal investigator precludes ablative
chemotherapy or successful transplantation*
Yes
No
patients with documented hiv positivity*
Yes
No
'high risk' all or aml refers to those acute
leukemias identified by the presence of specific
biologic features, which predict high likelihood of
failure to conventional chemotherapy.  as biologic
features of high risk disease evolve with
improvement of conventional chemotherapy, it is
not practical to define this indication with any
further specificity.  therefore, high risk aml/all will
be determined by the primary physician.*
Yes
No
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Eligibility Acute Lymphoblastic Leukemia
NCT00376467
STI 571 (GLIVEC) in the Treatment of Adult Acute
Lymphoblastic Leukemia; ODM derived from:
https://clinicaltrials.gov/show/NCT00376467
All rights reserved. Please visit https://medical-data-
models.org/forms/12784
Eligibility Acute Lymphoblastic
Leukemia NCT00376467
Inclusion Criteria
patients with ph +ve and/or bcr/abl +ve all, either
in 1st chr (independently from the molecular
status) for study a, or at diagnosis and untreated
for study b;*
Yes
No
age >18 years and <60 for study a, >60 for study
b;*
Yes
No
written voluntary informed consent.*
Yes
No
Exclusion Criteria
patients of childbearing potential without a
negative pregnancy test prior to the initiation of
study. barrier contraceptive precautions are to be
used throughout the trial in both sexes;*
Yes
No
pretreatment with steroids for more than 10 days
in study b;*
Yes
No
serum bilirubin and creatinine values >3 the
upper limit of normal range;*
Yes
No
sgot and sgpt values >3 the upper limit of the
normal range;*
Yes
No
patients who had received any other
investigational agent within 4 weeks before the
enrollment;*
Yes
No
patients with cardiovascular diseases grade >3
according to the new york heart association (see
appendix 1);*
Yes
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No
patients with a history of non compliance to
medical regimen or who are considered
potentially unreliable;*
Yes
No
patients with moderate/severe mood or
psychiatric disorders;*
Yes
No
concomitant neoplasia.*
Yes
No
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Eligibility Acute Lymphoblastic Leukemia
NCT00388895
Glivec in Ph Positive Lymphoblastic Leukemia; ODM
derived from: https://clinicaltrials.gov/show/NCT00388895
All rights reserved. Please visit https://medical-data-
models.org/forms/12785
Eligibility Acute Lymphoblastic
Leukemia NCT00388895
Inclusion Criteria
new diagnosis lla ph+ (bcr/abl) patients ≤65 years
old*
Yes
No
fertile age women must do a pregnancy test in
the 7 days previous at the beginning of clinical
trial medication*
Yes
No
performance status 0-2 (appendix b); is allowed
performance status > 2 because of lla*
Yes
No
patients without organ alteration: hepatic
function: global bilirubin, ast, alt, gamma-gt and
alkaline phosphatase less than 2 times lsn; renal
function: creatinine < 1,5 mg/dl o clearance
creatinine > 60 ml/min; anormal renal function
caused by lla ; normal heart function (appendix
b):          fev > 50%; no chronic respiratory illness.
if the anormal values are secondary of the
experimental illness the investigator can decide
himself if the patient can be included at the
clinical trial.*
Yes
No
negative hiv serology*
Yes
No
written, oral or with witness informed consent. in
patients < 18 years old must be signed written
and legal representative informed consent.*
Yes
No
Exclusion Criteria
no experimental chemotherapy or other
experimental treatment. allowed to begin
induction chemotherapy from the diagnosis to
confirm ph. no major surgical process in the
previous 14 days of the treatment start.
Yes
No
other lla variability*
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Yes
No
previous history of coronary valvular,
hypertensive cardiopathy illness*
Yes
No
chronic hepatic illness*
Yes
No
chronic respiratory insufficiency*
Yes
No
renal insufficiency not caused by lla*
Yes
No
severe neurological problems not caused by lla*
Yes
No
severe affection of the performance status (grade
3-4 oms gradation) not caused by lla*
Yes
No
pregnancy and breastfeeding*
Yes
No
blastic crisis cml*
Yes
No
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Eligibility Acute Lymphoblastic Leukemia
NCT00494897
PETHEMA LAL-RI/96: Treatment for Patients With
Standard Risk Acute Lymphoblastic Leukemia; ODM
derived from: https://clinicaltrials.gov/show/NCT00494897
All rights reserved. Please visit https://medical-data-
models.org/forms/12786
Eligibility Acute Lymphoblastic
Leukemia NCT00494897
Inclusion Criteria
adults (over 15 years) with all standard risk no
prior antiblastic chemotherapy*
>= 15
yrs
Yes
No
Exclusion Criteria
mature b-all (fabl3) or with cytogenetic all "burkitt-
like" alterations (t[8;14], t[2;8], t[8;22])*
Yes
No
mixed forms of all*
Yes
No
acute leukemia no differentiate*
Yes
No
patients with coronary disorders, valvular or
hypertensive cardiopathy*
Yes
No
patients with chronic liver disorders*
Yes
No
chronic pulmonary disorders*
Yes
No
renal insufficiency*
Yes
No
neurologic dysfunctions*
Yes
No
ecog 3 and 4*
Yes
No
no signed consent form*
Yes
No
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Eligibility Acute Lymphoblastic Leukemia
NCT00529360
Allogeneic Stem Cell Transplant With Clofarabine, Ara-C
and TBI for AML and ALL; ODM derived from:
https://clinicaltrials.gov/show/NCT00529360
All rights reserved. Please visit https://medical-data-
models.org/forms/12787
Eligibility Acute Lymphoblastic
Leukemia NCT00529360
Inclusion Criteria
age: patients must be <30 years of age.*
Yes
No
disease status:  all in relapse, induction failure,
cr3, or cr3p (part a only); aml in relapse,
induction failure, cr3, or cr3p (part a only); all in
cr3 or cr3p (part a and part b); aml in cr3 or   cr3p
(part a  and bonly); cr3/cr3p must be documented
by bone marrow and cns assessment within 14
days of initiation of the pre-transplant conditioning
regimen.*
Yes
No
creatinine clearance  >40 ml/min/m2 or >60
ml/min/1.73 m2 or an equivalent radioisotope
glomerular filtration rate (gfr) as determined by
the institutional normal range or serum creatinine
based on age*
Yes
No
adequate liver function defined as: total bilirubin
<2.5 mg/dl l, or sgot (ast) or sgpt (alt) <5 x upper
limit of normal*
Yes
No
adequate cardiac function defined as: shortening
fraction >27 percent by echocardiogram, or
ejection fraction of >50 percent by radionuclide
angiogram or echocardiogram.*
Yes
No
adequate pulmonary function defined as:
corrected dlco >60 percent by pulmonary function
test; for children who are uncooperative, no
evidence of dyspnea at rest, no exercise
intolerance, and a pulse oximetry >94 percent on
room air.*
Yes
No
performance status: for patients age 1-16 years,
lansky score of >60; for patients > 16 years,
karnofsky score of >60.*
Yes
No
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patients must have received a minimum of one
round of re-induction and one round of
consolidation chemotherapy after relapse #2*
Yes
No
Exclusion Criteria
patients with prior myeloablative allogeneic stem
cell transplantation and /or tbi.*
Yes
No
females who are pregnant (positive hcg) or
lactating.*
Yes
No
karnofsky <60 percent or lansky <60 percent if
less than 16 years of age*
Yes
No
age >30 years of age*
Yes
No
any patient with uncontrolled infection prior to
study entry*
Yes
No
patients with evidence of active disease.*
Yes
No
patients with down syndrome are excluded*
Yes
No
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Eligibility Acute Lymphoblastic Leukemia
NCT00710892
CASPALLO: Allodepleted T Cells Transduced With
Inducible Caspase 9 Suicide Gene; ODM derived from:
https://clinicaltrials.gov/show/NCT00710892
All rights reserved. Please visit https://medical-data-
models.org/forms/12788
Eligibility Acute Lymphoblastic
Leukemia NCT00710892
Inclusion Criteria
at the time of transplant:*
Yes
No
patients (up to 65 years of age) with:*
Yes
No
all or high grade nhl that is stage iii or iv and has
relapsed or is considered to be primary refractory
disease.*
Yes
No
myelodysplastic syndrome.*
Yes
No
aml after first relapse or with primary refractory
disease.*
Yes
No
cml*
Yes
No
hemophagocytic lymphohistiocytosis (hlh);
familial hemophagocytic lymphohistiocytosis (flh);
viral-associated hemophagocytic syndrome
(vahs); patients with severe chronic active epstein
barr virus infection (scaebv) with predilection for t
or nk cell malignancy; x-linked lymphoproliferative
disease (xlp)*
Yes
No
lack of suitable conventional donor (i.e. 5/6 or 6/6
related, or 5/6 or 6/6 unrelated donor) or
presence of a rapidly progressive disease not
permitting time to identify an unrelated donor.*
Yes
No
at the time of allodepleted t cell infusion:*
Yes
No
engrafted with anc greater than 500.*
Yes
No
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must have greater than or equal to 50 percent
donor chimerism in either peripheral blood or
bone marrow, or relapse of their original disease.*
Yes
No
life expectancy greater than 30 days*
Yes
No
lansky/karnofsky scores greater than or equal to
60*
Yes
No
absence of severe renal disease (creatinine
greater than 2x normal for age)*
Yes
No
absence of severe hepatic disease (direct
bilirubin greater than 2 mg/dl, or sgot greater than
200*
Yes
No
oxygen saturation greater than 94 percent on
room air*
Yes
No
patient/guardian able to give informed consent*
Yes
No
Exclusion Criteria
at the time of transplant:*
Yes
No
pregnancy*
Yes
No
at the time of allodepleted t cell infusion:*
Yes
No
gvhd*
Yes
No
severe intercurrent infection*
Yes
No
pregnancy*
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Yes
No
other investigational drugs in the prior 30 days*
Yes
No
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Eligibility Acute Lymphoblastic Leukemia
NCT00726934
The Effectiveness of the Neutropenic Diet in Pediatric
Oncology Patients; ODM derived from:
https://clinicaltrials.gov/show/NCT00726934
All rights reserved. Please visit https://medical-data-
models.org/forms/12789
Eligibility Acute Lymphoblastic
Leukemia NCT00726934
Inclusion Criteria
patients between the ages of 1 and 30 years
with:*
Yes
No
acute lymphoblastic leukemia/lymphoma*
Yes
No
malignant brain tumor*
Yes
No
non-cns solid tumors*
Yes
No
acute myeloblastic leukemia*
Yes
No
non-hodgkin's lymphoma hodgkin's disease*
Yes
No
head and neck tumors*
Yes
No
patients must also be ready to receive a cycle of
chemotherapy that predictably renders
neutropenia at least 70 percent of the time or has
a risk of febrile neutropenia of at least 20 percent.
this can be any cycle number, it does not need to
be the first cycle of chemotherapy they are to
receive.*
Yes
No
Exclusion Criteria
patients receiving myeloablative chemotherapy in
preparation for allogeneic or autologous bone
marrow or stem cell transplant.*
Yes
No
co-morbidity with immunosuppressive disease
such as aids.*
Yes
No
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asplenia.*
Yes
No
patients with documented infection at time of
enrollment.*
Yes
No
patients who are not fed orally (g-tube
dependant, tpn-dependant).*
Yes
No
patients actively receiving radiation to the brain or
gastrointestinal tract for sarcoma.*
Yes
No
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Eligibility Acute Lymphoblastic Leukemia
NCT00766311
Aerobic and Strengthening Exercise for Acute Leukemia;
ODM derived from:
https://clinicaltrials.gov/show/NCT00766311
All rights reserved. Please visit https://medical-data-
models.org/forms/12790
Eligibility Acute Lymphoblastic
Leukemia NCT00766311
Inclusion Criteria
diagnosed with childhood all when age greater
than 1 and less than 10 at diagnosis, white blood
cell count less than 50,000 cells/microliter and
receiving continuation/maintenance therapy
based on the original disease classification*
Yes
No
in first remission*
Yes
No
maintenance phase of therapy (eligibility extends
from day 0 of maintenance therapy up to six
months prior to the completion of therapy)*
Yes
No
current age 5-10 years*
Yes
No
modified lansky performance scale must score 60
or higher at time of enrollment*
Yes
No
written informed consent*
Yes
No
Exclusion Criteria
lower extremity amputation or congenital
deformity of lower limb*
Yes
No
history of pre-existing neuron-motor or neuro-
developmental disorder prior to diagnosis of
childhood all, such as mental retardation, down
syndrome, cerebral palsy, and traumatic brain
injury*
Yes
No
pre-existing heart or lung disease by clinical
history*
Yes
No
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children with specific contraindications to exercise
will be offered enrollment after this transient
condition is resolved: severe anemia (hemoglobin
less than 8 g/dl), fever greater than 38 degrees
centigrade, platelets less than 50*109/ul,
neutrophil counts less than 0.5*109/ul.*
Yes
No
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Eligibility Acute Lymphoblastic Leukemia
NCT00784017
Comparative Efficacy and Safety of Two Asparaginase
Preparations in Children With Previously Untreated Acute
Lymphoblastic Leukaemia; ODM derived from:
https://clinicaltrials.gov/show/NCT00784017
All rights reserved. Please visit https://medical-data-
models.org/forms/12791
Eligibility Acute Lymphoblastic
Leukemia NCT00784017
Inclusion Criteria
previously untreated t-lineage or precursor b-
lineage all*
Yes
No
patients must have morphological proof of all and
diagnosis must be made from bone marrow
morphology with more than 25 percent blasts*
Yes
No
written informed consent*
Yes
No
treatment according to dcog all 10 protocol*
Yes
No
Exclusion Criteria
mature b-lineage all*
Yes
No
patients with secondary all*
Yes
No
known allergy to any asnase preparation*
Yes
No
general health status according to karnofsky /
lansky score < 40 percent*
Yes
No
pre-existing known coagulopathy (e.g.
haemophilia)*
Yes
No
pre-existing pancreatitis*
Yes
No
liver insufficiency (bilirubin > 50 µmol/l; sgot/sgpt
> 10 x uln)*
Yes
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No
other current malignancies*
Yes
No
pregnancy (planned or existent), breast feeding*
Yes
No
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Eligibility Acute Lymphoblastic Leukemia
NCT00816049
ALL2008 Protocol for Childhood Acute Lymphoblastic
Leukemia (ALL) - 6MP Consolidation Therapy; ODM
derived from: https://clinicaltrials.gov/show/NCT00816049
All rights reserved. Please visit https://medical-data-
models.org/forms/12792
Eligibility Acute Lymphoblastic
Leukemia NCT00816049
Inclusion Criteria
childhood all*
Yes
No
all mandatory biological data are available*
Yes
No
written informed consent has been obtained*
Yes
No
Exclusion Criteria
mixed lineage all*
Yes
No
pre-treatment with glucocorticosteroids or other
antileukemic agents for more than 1 week*
Yes
No
all predisposition syndromes*
Yes
No
previous cancer*
Yes
No
off protocol administration of additional
chemotherapy during induction therapy*
Yes
No
sexually active females not using contraception*
Yes
No
tpmt-deficiency*
Yes
No
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Eligibility Acute Lymphoblastic Leukemia
NCT00819351
ALL2008 Protocol for Childhood Acute Lymphoblastic
Leukemia Intermittent Versus Continuous PEG
Asparaginase; ODM derived from:
https://clinicaltrials.gov/show/NCT00819351
All rights reserved. Please visit https://medical-data-
models.org/forms/12793
Eligibility Acute Lymphoblastic
Leukemia NCT00819351
Inclusion Criteria
childhood all*
Yes
No
all mandatory biological data are available*
Yes
No
written informed consent has been obtained*
Yes
No
Exclusion Criteria
bilineage all*
Yes
No
pre-treatment with glucocorticosteroids or other
antileukemic agents for more than 1 week*
Yes
No
all predisposition syndromes*
Yes
No
previous cancer*
Yes
No
off protocol administration of additional
chemotherapy during induction therapy*
Yes
No
sexually active females not using contraception*
Yes
No
no allergic reactions to peg asparaginase*
Yes
No
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NCT00853008
Treatment of High Risk Adult Acute Lymphoblastic
Leukemia; ODM derived from:
https://clinicaltrials.gov/show/NCT00853008
All rights reserved. Please visit https://medical-data-
models.org/forms/12794
Eligibility Acute Lymphoblastic
Leukemia NCT00853008
Inclusion Criteria
high risk all adult patients (age> 15 years)
previously untreated*
Yes
No
high-risk all*
Yes
No
one or more of the following*
Yes
No
age 30-60 yr.*
>= 30
<= 60
yrs
Yes
No
wbc count >25x109/l*
Yes
No
11q23 or all1/af4*
Yes
No
very high-risk all*
Yes
No
hr all and one of the following*
Yes
No
slow cytologic response (>10 percent blasts in
bm on d14 of induction therapy).*
Yes
No
mrd>0.05 percent (by flow cytometry) at the end
of consolidation*
Yes
No
Exclusion Criteria
l3 all or b mature(sig +) or t(8;14), t(2;8), t(8;22).*
Yes
No
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all ph (bcr/abl) positive.*
Yes
No
biphenotypic all as egil criteria.*
Yes
No
undifferentiated all.*
Yes
No
patients with cardiac pathology*
Yes
No
patients with chronic liver disease in activity
phase*
Yes
No
pulmonary disease*
Yes
No
renal insufficiency not due to all*
Yes
No
neurological disorders not due to all*
Yes
No
ecog ps (grades 3 and 4) not due to all.*
Yes
No
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Eligibility Acute Lymphoblastic Leukemia
NCT00861679
Therapy Protocol Acute Lymphoblastic Leukemia Stem Cell
Transplantation International; ODM derived from:
https://clinicaltrials.gov/show/NCT00861679
All rights reserved. Please visit https://medical-data-
models.org/forms/12795
Eligibility Acute Lymphoblastic
Leukemia NCT00861679
Inclusion Criteria
all patients with all who fulfil the following
criteria:*
Yes
No
age at time of initial diagnosis or relapse
diagnosis, respectively ≤18 years*
Yes
No
indication for allogeneic hsct*
Yes
No
complete remission (cr) is achieved before sct*
Yes
No
written consent of the parents (legal guardian)
and, if indicated, the minor patient via "informed
consent form"*
Yes
No
no pregnancy*
Yes
No
no secondary malignancy*
Yes
No
no previous hsct*
Yes
No
hsct is performed in a study participating centre.*
Yes
No
Exclusion Criteria
patients with b-all
informed consent not signed by parents (legal
guardian)*
Yes
No
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pregnancy*
Yes
No
secondary malignancy*
Yes
No
previous hsct*
Yes
No
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Eligibility Acute Lymphoblastic Leukemia
NCT00874562
Rapamycin in Relapsed Acute Lymphoblastic Leukemia;
ODM derived from:
https://clinicaltrials.gov/show/NCT00874562
All rights reserved. Please visit https://medical-data-
models.org/forms/12796
Eligibility Acute Lymphoblastic
Leukemia NCT00874562
Inclusion Criteria
documented acute lymphoblastic leukemia (l1 or
l2 subtypes)*
Yes
No
first or subsequent relapse*
Yes
No
365 days of age or older*
Yes
No
greater than 7 days from any chemotherapy or
immunotherapy, with the exception of intrathecal
chemotherapy*
Yes
No
absolute peripheral leukemia blast count of 1000
cells/ul or greater*
Yes
No
patient (or parent/guardian if patient is less than
18 years of age) must sign informed consent*
Yes
No
Exclusion Criteria
burkitts leukemia (acute lymphoblastic leukemia
l3 subtype)*
Yes
No
uncontrolled active infection*
Yes
No
pregnancy or mothers who are nursing*
Yes
No
patient currently taking rapamycin*
Yes
No
patients with significant liver dysfunction as
outlined in protocol*
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Yes
No
severe concurrent disease, which in the judgment
of the investigator, would make the patient
inappropriate for entry into the study*
Yes
No
active psychiatric disease, substance abuse, or
mental illness that would interfere with
cooperation with the requirements of the trial*
Yes
No
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Eligibility Acute Lymphoblastic Leukemia
NCT00388895
Glivec in Ph Positive Lymphoblastic Leukemia; ODM
derived from: https://clinicaltrials.gov/show/NCT00388895
All rights reserved. Please visit https://medical-data-
models.org/forms/12797
Eligibility Acute Lymphoblastic
Leukemia NCT00388895
Inclusion Criteria
new diagnosis all ph+ (bcr/abl) patients ≤ 65
years old*
Yes
No
fertile age women must do a pregnancy test in
the 7 days previous at the beginning of clinical
trial medication*
Yes
No
performance status 0-2 (appendix b); is allowed
performance status > 2 because of lla*
Yes
No
patients without organ alteration: hepatic
function: global bilirubin, ast, alt, gamma-gt and
alkaline phosphatase less than 2 times lsn; renal
function: creatinine < 1,5 mg/dl o clearance
creatinine > 60 ml/min; anormal renal function
caused by lla ; normal heart function (appendix
b):fev > 50 percent; no chronic respiratory illness.
if the anormal values are secondary of the
experimental illness the investigator can decide
himself if the patient can be included at the
clinical trial.*
Yes
No
negative hiv serology*
Yes
No
written, oral or with witness informed consent. in
patients < 18 years old must be signed written
and legal representative informed consent.*
Yes
No
no experimental chemotherapy or other
experimental treatment. allowed to begin
induction chemotherapy from the diagnosis to
confirm ph. no major surgical process in the
previous 14 days of the treatment start.*
Yes
No
Exclusion Criteria
other all variability*
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Yes
No
previous history of coronary valvular,
hypertensive cardiopathy illness*
Yes
No
chronic hepatic illness*
Yes
No
chronic respiratory insufficiency*
Yes
No
renal insufficiency not caused by lla*
Yes
No
severe neurological problems not caused by lla*
Yes
No
severe affection of the performance status (grade
3-4 oms gradation) not caused by lla*
Yes
No
pregnancy and breastfeeding women*
Yes
No
blastic crisis cml*
Yes
No
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Eligibility Acute Lymphoblastic Leukemia
NCT00930098
A Phase II, Open-Label Study of Clofarabine in Paediatric
Patients With Refractory/Relapsed Acute Lymphoblastic
Leukaemia; ODM derived from:
https://clinicaltrials.gov/show/NCT00930098
All rights reserved. Please visit https://medical-data-
models.org/forms/12798
Eligibility Acute Lymphoblastic
Leukemia NCT00930098
Inclusion Criteria
have a diagnosis of all and confirmed by
pathologic assessment.*
Yes
No
be ≤ 21 years old at time of initial diagnosis.*
Yes
No
eligible patients must have: primary refractory
disease; or relapsed or refractory disease after a
minimum of 2 prior blocks of treatment.*
Yes
No
must not be eligible for therapy of higher curative
potential.*
Yes
No
have a karnofsky performance status of ≥ 50 or
lansky performance scale of ≥ 30.*
Yes
No
provide a signed, written informed consent from
parent or guardian or young adult patients.*
Yes
No
be able to comply with study procedures and
follow-up examinations.*
Yes
No
have adequate cardiac function without
treatment.*
Yes
No
have adequate organ function as indicated by the
laboratory values for serum creatinine, serum
bilirubin, ast and alt, obtained within 7 days prior
to registration.*
Yes
No
Exclusion Criteria
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received previous treatment with clofarabine.*
Yes
No
patients with isolated extramedullary disease.*
Yes
No
have received prior bmt or pbsct within the last 6
months.*
Yes
No
have received prior bmt or pbsct more than 6
months ago, but now has compromised organ
function.*
Yes
No
have an active, uncontrolled systemic infection.*
Yes
No
are pregnant or lactating.  male and female
patients who are fertile must agree to use an
effective means of birth control to avoid
pregnancy.*
Yes
No
have a psychiatric disorder that would interfere
with consent, study participation, or follow-up.*
Yes
No
have received any other chemotherapy within the
previous 2 weeks and must have recovered from
acute toxicity oa all previous therapy prior to
enrollment.*
Yes
No
have any other severe concurrent disease.*
Yes
No
have recent history of significant renal, hepatic or
pulmonary dysfunction, or cardiac dysfunction or
on treatment to support cardiac function.*
Yes
No
have cns disease.*
Yes
No
2 / 2
Eligibility Acute Lymphoblastic Leukemia NCT00930098
Eligibility Acute Lymphoblastic Leukemia
NCT00957320
Study of Sirolimus With PEG-Asparaginase in Acute
Lymphoblastic Leukemia (ALL); ODM derived from:
https://clinicaltrials.gov/show/NCT00957320
All rights reserved. Please visit https://medical-data-
models.org/forms/12799
Eligibility Acute Lymphoblastic
Leukemia NCT00957320
Inclusion Criteria
less than 21 years old.*
Yes
No
acute lymphoblastic leukemia.*
Yes
No
second or greater bone marrow relapse or 1st
relapse and refractory to at least 2 attempts at re-
induction.*
Yes
No
life expectancy of at least 8 weeks.*
Yes
No
fully recovered from the acute toxic effects of all
prior therapy.*
Yes
No
appropriate organ function.*
Yes
No
Exclusion Criteria
patients with a documented history of ≥ grade 3
local or systemic reactions to peg-asparaginase.*
Yes
No
patients with a documented history of anti-e. coli
asparaginase antibodies.*
Yes
No
patients with a history of ≥ grade 3 pancreatitis.*
Yes
No
patients with an active and uncontrolled
infection.*
Yes
No
patients s/p allogeneic bone marrow
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transplantation, who are still on
immunosuppressants.*
Yes
No
pregnant or lactating females.  women of
childbearing age will agree to use contraception
during the protocol.*
Yes
No
patients currently receiving other investigational
agents, medications, or supplements with a
known anti-leukemic effect.*
Yes
No
other concomitant medications that may alter the
metabolism of sirolimus (see section 7.2).*
Yes
No
patients who, in the opinion of the investigator,
will not be able to comply with safety monitoring
requirements of the study.*
Yes
No
patients with a history of a documented thrombus
from previous asparaginase therapy.*
Yes
No
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Eligibility Acute Lymphoblastic Leukemia
NCT00973752
Treatment of Older Adults With Acute Lymphoblastic
Leukemia; ODM derived from:
https://clinicaltrials.gov/show/NCT00973752
All rights reserved. Please visit https://medical-data-
models.org/forms/12800
Eligibility Acute Lymphoblastic
Leukemia NCT00973752
Inclusion Criteria
acute lymphoblastic leukemia*
Yes
No
patients with lymphoblastic lymphoma are also
eligible*
Yes
No
no prior anti-leukemic therapy except <1 week of
steroids, and/or emergent radiation therapy to the
mediastinum, or hydroxyurea or emergent
leukopheresis. longer steroid use for diseases
other than leukemia is permitted.*
Yes
No
age 51-75 years*
Yes
No
ejection fraction > 45 percent*
Yes
No
creatinine < 2.0 mg/dl*
Yes
No
total bilirubin < 3.0 mg/dl*
Yes
No
ecog performance status of 0, 1, 2*
Yes
No
non-pregnant and non lactating*
Yes
No
Exclusion Criteria
known mature b-cell all by the presence of any of
the following: surface immunoglobulin, l3
morphology, t(8;14)(q24;q32), t(8;22), or t(2;8)
known hiv positive*
Yes
No
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comorbid medical condition, in the investigator's
opinion, would make participation in this trial and
adherence to the protocol guidelines difficult*
Yes
No
active psychiatric or mental illness making
informed consent or careful clinical follow-up
unlikely*
Yes
No
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Eligibility Acute Lymphoblastic Leukemia
NCT00983528
Alemtuzumab and Clofarabine for Relapsed or Refractory
Acute Lymphoblastic Leukemia; ODM derived from:
https://clinicaltrials.gov/show/NCT00983528
All rights reserved. Please visit https://medical-data-
models.org/forms/12801
Eligibility Acute Lymphoblastic
Leukemia NCT00983528
Inclusion Criteria
provide signed written informed consent.  if a
patient is under 18 years of age the parent or the
guardian will also need to provide written
informed consent.*
Yes
No
diagnosis of all (b or t lineage) who have received
therapy with at least 1 but not more than 3 prior
different induction regimens and have been
deemed to have relapse or refractory disease.
the phase ii component of the study enrollment
will be limited to 2 different prior induction
regimens if patients are older than 30 years.*
Yes
No
all lymphoblasts with cd52 expression on at least
10 percent on lymphoblasts.*
Yes
No
age >= 16 years of age.*
Yes
No
ecog ps 0-2.*
Yes
No
have adequate renal and hepatic functions.*
Yes
No
subject or their patient or guardian is capable of
understanding the investigational nature,
potential risks and benefits of the study, and able
to provide valid informed consent.*
Yes
No
female patients of childbearing potential must
have a negative serum pregnancy test within 2
weeks prior to enrollment.*
Yes
No
male and female patients must use an effective
contraceptive method during the study and for a
minimum of 6 months after study treatment.
subjects 16 and 17 years old must also adhere to
effective contraception methods or abstinence
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during the study and for a minimum of 6 months
after study and the nature of contraception or
abstinence must be documented.*
Yes
No
cmv pcr negative prior to enrollment*
Yes
No
Exclusion Criteria
current concomitant chemotherapy, radiation
therapy, or immunotherapy other than as
specified in the protocol.*
Yes
No
use of investigational agents within 30 days or
any anticancer therapy within 2 weeks before
study entry with the exception of hydroxyurea,
cns treatment or prophylaxis, or tyrosine kinase
inhibitors for individuals with philadelphia
chromosome positive all.  the patient must have
recovered from all acute toxicities from any
previous therapy.*
Yes
No
lack of bone marrow or blood involvement by
leukemia such as a documented cns or testicular
only relapse.*
Yes
No
have any other severe concurrent disease, or
have a history of serious organ dysfunction or
disease involving the heart, kidney, liver, or other
organ system that may place the patient at undue
risk to undergo treatment.*
Yes
No
patients with any known or suspected hepatitis b,
c and hiv infections.*
Yes
No
patients with a systemic fungal, bacterial, viral, or
other infection not controlled (defined as
exhibiting ongoing signs/symptoms related to the
infection and without improvement, despite
appropriate antibiotics or other treatment).*
Yes
No
pregnant or lactating patients.*
Yes
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No
any significant concurrent disease, illness, or
psychiatric disorder that would compromise
patient safety or compliance, interfere with
consent, study participation, follow up, or
interpretation of study results.*
Yes
No
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Eligibility Acute Lymphoblastic Leukemia
NCT00991744
Liposomal Cytarabine for Central Nervous System (CNS)-
Treatment in High-risk Acute Lymphoblastic Leukemia
(ALL); ODM derived from:
https://clinicaltrials.gov/show/NCT00991744
All rights reserved. Please visit https://medical-data-
models.org/forms/12802
Eligibility Acute Lymphoblastic
Leukemia NCT00991744
Inclusion Criteria
high risk acute lymphoblastic leukemia*
Yes
No
not eligible for bone marrow transplantation*
Yes
No
age 1-18*
Yes
No
written informed consent has been obtained*
Yes
No
Exclusion Criteria
persistent nci grade 3-4 neurotoxicity from
previous treatments*
Yes
No
bilineage all*
Yes
No
leukemia predisposing syndromes (e.g. downs
syndrome, ataxia telangiectasia)*
Yes
No
previous cancer*
Yes
No
known intolerance to nopho all 2008 anticancer
agents*
Yes
No
sexually active females will use safe
contraceptives*
Yes
No
previous treatment with intrathecal liposomal
cytarabine*
Yes
No
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NCT01134575
CMC-544 in Relapsed Refractory Acute Lymphoblastic
Leukemia (ALL); ODM derived from:
https://clinicaltrials.gov/show/NCT01134575
All rights reserved. Please visit https://medical-data-
models.org/forms/12803
Eligibility Acute Lymphoblastic
Leukemia NCT01134575
Inclusion Criteria
previously treated all (including burkitt's
lymphoma and lymphoblastic lymphoma) in
relapse or primary refractory. patients in first
relapse will be eligible regardless of the first
remission duration. at least 10 patients in salvage
1-2 will be treated to assess anti-all response
more precisely.*
Yes
No
age 16 years or older. pediatric patients (<16
years old) will be allowed into the study after
safety is established, that is at least 10 adult
patients having received 1 or more cycles each.*
Yes
No
zubrod performance status 0-3.*
Yes
No
adequate liver function (bilirubin </= 1.5 mg/dl
and sgpt or sgot </= 3 x upper limit of normal
[uln], unless considered due to tumor), and renal
function (creatinine </= 2 mg/dl). even if organ
function abnormalities are considered due to
tumor, the upper limit for bilirubin is </= 2.0 mg/dl
and creatinine </= 3 mg/dl.*
Yes
No
male and female patients who are of childbearing
potential agree to use an effective barrier method
of birth control (e.g., latex condom, diaphragm,
cervical cap, etc.) to avoid pregnancy. female
patients need a negative serum or urine
pregnancy test within 14 days of study start
(applies only if patient is of childbearing potential.
non-childbearing is defined as >/= 1 year
postmenopausal or surgically sterilized).*
Yes
No
Exclusion Criteria
patient with active heart disease (nyha class >/=
3 as assessed by history and physical
examination).*
Yes
No
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patients with a cardiac ejection fraction (as
measured by either muga or echocardiogram) <
45 percent are excluded.*
Yes
No
patients who receive other chemotherapy.
patients must have been off previous therapy for
>/= 2 weeks and must have recovered from acute
toxicity (to grade 1 or less) of all previous therapy
prior to enrollment (consent signing). (concurrent
therapy for central nervous system [cns]
prophylaxis or treatment for cns relapse is
permitted). treatment may start earlier if
necessitated by the patient's medical condition
(e.g. rapidly progressive disease) following
discussion with the principal investigator.*
Yes
No
prior allogeneic stem cell transplant in previous 4
months.*
Yes
No
peripheral lymphoblasts > 50 x 10^9/l.*
Yes
No
pregnant and breast-feeding patients are
excluded.*
Yes
No
patients with known hepatitis b are excluded.*
Yes
No
2 / 2
Eligibility Acute Lymphoblastic Leukemia NCT01134575
Eligibility Acute Lymphoblastic Leukemia
NCT01354457
Safety and Efficacy of Radio-immunotherapy (RIT) for
Patients With Relapse or Refractory Acute Lymphoblastic
Leukaemia (ALL) B CD22+; ODM derived from:
https://clinicaltrials.gov/show/NCT01354457
All rights reserved. Please visit https://medical-data-
models.org/forms/12804
Eligibility Acute Lymphoblastic
Leukemia NCT01354457
Inclusion Criteria
age 18-70 years*
Yes
No
b-all (oms) with >=20 percent of blasts in bone
marrow*
Yes
No
cd22+ expression >=70 percent of the blast
population*
Yes
No
all previously treated all patients who have
experienced relapse or treatment failure*
Yes
No
at least 15 days since previous treatment*
Yes
No
performance status 0 - 2*
Yes
No
creatinine clearance >= 50 ml/min (cockroft
formula).*
Yes
No
serum bilirubin  <= 30 mmol/l*
Yes
No
written informed consent*
Yes
No
Exclusion Criteria
t-all*
Yes
No
meningeal involvement*
Yes
No
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cd22 expression on tumor cells or < 70 percent*
Yes
No
hiv positive*
Yes
No
active hepatitis b or c*
Yes
No
active infection within 7 days of starting
treatment*
Yes
No
left ventricular ejection fraction < 50 percent.*
Yes
No
contra-indication to 90y-dota-hll2*
Yes
No
previous or concurrent second malignancy except
for adequately treated basal cell carcinoma of the
skin, curatively treated in situ carcinoma of the
cervix, curatively treated solid cancer, with no
evidence of disease for at least 5 years*
Yes
No
any psychological, familial, sociological or
geographical condition potentially hampering
compliance with the study protocol and follow-up
schedule*
Yes
No
participation at the same time in another study in
which investigational drugs are used*
Yes
No
absence of written informed consent*
Yes
No
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Eligibility Acute Lymphoblastic Leukemia
NCT01506453
Therapeutic Interventions For Pain Induced By Vincristine
Treatment For Childhood Acute Lymphoblastic Leukemia
(ALL); ODM derived from:
https://clinicaltrials.gov/show/NCT01506453
All rights reserved. Please visit https://medical-data-
models.org/forms/12805
Eligibility Acute Lymphoblastic
Leukemia NCT01506453
Inclusion Criteria
participant is enrolled on total xvi*
Yes
No
participant is 1 year of age or older*
Yes
No
participant has symptoms of np/pn with onset no
more than 7 days after one of the following
vincristine doses:  protocol week 1, week 2
(induction), week 7 (reinduction i), or week 17
(reinduction ii).*
Yes
No
patient is expected to receive 2 doses of
vincristine in weekly intervals as outlined by the
total xvi protocol while on study drug (i.e. no
known dosage reductions or planned missed
doses).*
Yes
No
participant is able and willing to take oral
medications.*
Yes
No
Exclusion Criteria
previous participation in this study*
Yes
No
participant is receiving gabapentin for another
indication at the time of diagnosis of np/pn or has
received gabapentin previously.*
Yes
No
pregnancy. female participants of childbearing
potential must have documented negative urine
or serum pregnancy test result not older than 7
days. male patients with reproductive potential
will be counseled not to procreate during the
study.*
Yes
No
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impaired renal function: decreased egfr
(<60ml/min/1.73m^2 as estimated by the revised
schwartz equation)*
Yes
No
participant has allergy or other contraindication
for either morphine or gabapentin therapy.*
Yes
No
inability or unwillingness of research participant
or legal guardian/representative to give written
informed consent.*
Yes
No
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Eligibility Acute Lymphoblastic Leukemia
NCT01523782
Administration of GRASPA (Suspension of Erythrocytes
Encapsulating L-asparaginase) in Elderly Patients With
First Line Acute Lymphoblastic Leukemia; ODM derived
from: https://clinicaltrials.gov/show/NCT01523782
All rights reserved. Please visit https://medical-data-
models.org/forms/12806
Eligibility Acute Lymphoblastic
Leukemia NCT01523782
Inclusion Criteria
aged  ≥ 55 years*
Yes
No
newly diagnosed all without prior treatment*
Yes
No
patient capable to receive polychemotherapy
(who  < 2)*
Yes
No
with or without meningeal disease*
Yes
No
signed informed consent forms*
Yes
No
subscribed to social security insurance*
Yes
No
Exclusion Criteria
all t(9;22) and/or bcr-abl positive*
Yes
No
general state incompatible with chemotherapy
treatment (who>2)*
Yes
No
presenting with a general or visceral
contraindication to intensive treatment*
Yes
No
patient with another cancer other than all*
Yes
No
severe evolutive infection or hiv seropositive or
active hepatitis related to b or c viral infection*
Yes
No
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prior treatment with l-asparaginase (irrespective
of the form)*
Yes
No
history of grade 3 transfusional incident (life
threatening)*
Yes
No
presenting rare and/or dangerous anti-
erythrocyte antibodies thus leading to the
unavailable of a phenotype compatible red blood
cells*
Yes
No
included in another clinical trial during the last
4weeks.*
Yes
No
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Eligibility Acute Lymphoblastic Leukemia
NCT01593488
Liposomal Cytarabine in the Treatment of Central Nervous
System Resistant or Relapsed Acute Lymphoblastic
Leukemia in Children; ODM derived from:
https://clinicaltrials.gov/show/NCT01593488
All rights reserved. Please visit https://medical-data-
models.org/forms/12807
Eligibility Acute Lymphoblastic
Leukemia NCT01593488
Inclusion Criteria
age < 18 years*
Yes
No
diagnosis of acute lymphoblastic leukemia (all)*
Yes
No
central nervous system involvement with
malignant cells present in cerebrospinal fluid*
Yes
No
cns involvement may be refractive to prior
systemic therapy, a first recurrence after prior
systemic and intrathecal therapy or a second
recurrence*
Yes
No
cns involvement may be an isolated lesion or
present with other sites of disease*
Yes
No
ecog performance status 0-2*
Yes
No
life expectancy of at least 8 weeks*
Yes
No
absence of severe organ dysfunction*
Yes
No
informed consent*
Yes
No
Exclusion Criteria
eligibility for aieop studies of first recurrence of
all,and receiving therapy in a center participating
in the aieop studies*
Yes
No
concurrent treatment with experimental
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therapies*
Yes
No
severe neurologic toxicities from previous
chemotherapy*
Yes
No
severe coagulopathy at time of recurrence*
Yes
No
sepsis*
Yes
No
intrathecal therapy within 1 week of planned
study therapy*
Yes
No
total body or head and spine radiation within 8
weeks of enrolment*
Yes
No
bone marrow transplant within 8 weeks of start of
study therapy.*
Yes
No
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Eligibility Schizophrenia NCT01051531
A Safety, Tolerability, and Treatment Response Study of
Paliperidone Palmitate Administered to Patients With
Schizophrenia; ODM derived from:
https://clinicaltrials.gov/show/NCT01051531
All rights reserved. Please visit https://medical-data-
models.org/forms/12808
Eligibility Schizophrenia
NCT01051531
Inclusion Criteria
signed informed consent to participate in the
study obtained*
Yes
No
signed informed consent to participate in the
optional pharmacogenomic component of the
study obtained (refusal to give consent for the
pharmacogenomic component of the study does
not exclude a patient from participation in the
clinical study)*
Yes
No
confirmation of diagnosis of schizophrenia
according to the diagnostic and statistical manual
of mental disorders, 4th edition (dsm-iv) within 5
years prior to screening*
Yes
No
patient is willing and able to fill out self-
administered questionnaires during the study*
Yes
No
confirmation that patient has been given an
adequate dose of an appropriate oral
antipsychotic for an adequate period of time
before enrollment, but previous treatment is
considered unsuccessful due to one or more of
the following reasons: lack of efficacy, lack of
tolerability or safety, lack of compliance and/or
other reasons to switch to another antipsychotic
medication*
Yes
No
Exclusion Criteria
the patient's psychiatric diagnosis is due to the
direct pharmacological effects of a drug of abuse
substance or medication, or is due to a general
medical condition (eg, clinically notable
hypothyroidism)*
Yes
No
the patient is treatment resistant in the judgment
of the investigator*
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Yes
No
the patient meets the dsm-iv definition of
substance dependence (except for nicotine and
caffeine) within 6 months prior to entry*
Yes
No
the patient has a previously defined
hypersensitivity (anaphylaxis-type reaction) to
risperidone or paliperidone or excipients*
Yes
No
the patient has received treatment with a long-
acting injectable antipsychotic within 3 injection
cycles prior to baseline, received clozapine within
3 months prior to screening, received treatment
with other investigational agents within 30 days of
the screening visit, has participated in more than
one investigational drug study in the past 12
months, or has planned use of other
investigational drugs during the time frame of the
study*
Yes
No
history or current symptoms of tardive dyskinesia,
history of neuroleptic malignant syndrome, or
evidence of clinically significant cardiovascular,
renal, hepatic, gastrointestinal, neurological,
endocrine, metabolic or pulmonary disease in the
past 6 months*
Yes
No
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Eligibility Acute Lymphoblastic Leukemia
NCT01685411
Busulfan and Cyclophosphamide Followed By ALLO BMT;
ODM derived from:
https://clinicaltrials.gov/show/NCT01685411
All rights reserved. Please visit https://medical-data-
models.org/forms/12809
Eligibility Acute Lymphoblastic
Leukemia NCT01685411
Inclusion Criteria
diagnosis of acute lymphoblastic leukemia (all),
acute myeloid leukemia (aml) or myelodysplastic
syndrome (mds) and current in complete
remission meeting one of the following:*
Yes
No
<45 years of age who are at least 6 months after
initial hematopoietic stem cell transplant (hsct)*
Yes
No
<45 years of age and have received sufficient
radiation treatment to be ineligible for total body
irradiation (tbi) containing preparative therapy*
Yes
No
karnofsky performance status >70 percent or if
<16 years of age, a lansky play score >50*
Yes
No
adequate major organ function including:*
Yes
No
cardiac: left ventricular ejection fraction >45
percent by echocardiogram (echo/muga)*
Yes
No
renal: creatinine clearance >40 ml/min/1.73m^2*
Yes
No
hepatic: no clinical evidence of hepatic failure
(e.g., coagulopathy, ascites)*
Yes
No
an acceptable source of stem cells according to
current university of minnesota bone marrow
transplant program guidelines. acceptable stem
cell sources include:*
Yes
No
hla-matched related or unrelated donor bone
marrow (6/6 or 5/6 antigen match)*
Yes
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No
hla-matched related or unrelated donor
peripheral blood stem cells*
Yes
No
related or single or double unrelated donor
umbilical cord blood (6/6, 5/6 or 4/6 match)*
Yes
No
women of childbearing age must have a negative
pregnancy test and all sexually active participants
must agree to use effective contraception during
study treatment*
Yes
No
written consent (adult or parent/guardian)*
Yes
No
Exclusion Criteria
eligible for tbi containing preparative regimen*
Yes
No
active uncontrolled infection within one week of
study enrollment*
Yes
No
pregnant or lactating female*
Yes
No
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Eligibility Acute Lymphoblastic Leukemia
NCT01744223
Safety Study of Gene Modified Donor T-cells Following
Partially Mismatched Stem Cell Transplant; ODM derived
from: https://clinicaltrials.gov/show/NCT01744223
All rights reserved. Please visit https://medical-data-
models.org/forms/12810
Eligibility Acute Lymphoblastic
Leukemia NCT01744223
Inclusion Criteria
lack of suitable conventional donor (i.e. 7/8 or 8/8
related or 7/8 or 8/8 unrelated donor) or presence
of rapidly progressive disease not permitting time
to identify an unrelated donor*
Yes
No
hla typing will be performed at high resolution
(allele level) for the hla-a, -b, cw, and drbl, and
loci.  a minimum match of 5/10 is required.   the
donor and recipient must be identical, as
determined by high resolution typing, at least one
allele of each of the following genetic loci: hla-a,
hla-b, hla-cw, and hla- drb1.*
Yes
No
subjects with adequate physical function as
measured by:a)cardiac: left ventricular ejection
fraction at rest must be >35 percent, or
shortening fraction > 25percent. b)hepatic:
bilirubin < 2.5 mg/dl; and alt, ast, and alkaline
phosphatase < 5 x uln. c)renal: serum creatinine
within normal range for age, or creatinine
clearance or gfr > 40 ml/min/1.73m2.
d)pulmonary: fev 1, fvc, dlco (diffusion capacity) >
50 percent predicted (corrected for hemoglobin);
or 02 saturation > 92 percent on room air.*
Yes
No
clinical diagnosis of one of the following: acute
lymphoblastic leukemia, acute myelogenous
leukemia, lymphoma*
Yes
No
subjects must have received cytotoxic
chemotherapy within 3 months of consent date
(measured from the start date of chemotherapy).*
Yes
No
performance status:  karnofsky/lansky score > 60
percent.*
Yes
No
Exclusion Criteria
hla-matched, related or 7-or 8/8 allele matched
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(hla-a,-b,-cw,-drbl) unrelated donor able to
donate.*
Yes
No
autologous hematopoietic stem cell transplant < 3
months prior to enrollment.*
Yes
No
pregnancy or breast-feeding.*
Yes
No
evidence of hiv infection or known hiv positive
serology.*
Yes
No
current uncontrolled bacterial, viral or fungal
infection (currently taking medication with
evidence of progression of clinical symptoms or
radiologic findings).*
Yes
No
non-hematologic malignancy within prior three (3)
years.*
Yes
No
prior allogeneic hematopoietic stem cell
transplant.*
Yes
No
subjects with a history of primary idiopathic
myelofibrosis.*
Yes
No
bovine product allergy.*
Yes
No
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Eligibility Acute Lymphoblastic Leukemia
NCT01810120
Trial to Assess the Efficacy of a TCR Alfa Beta Depleted
Graft in Pediatric Affected by ALL or AML and Receiving an
HSCT; ODM derived from:
https://clinicaltrials.gov/show/NCT01810120
All rights reserved. Please visit https://medical-data-
models.org/forms/12811
Eligibility Acute Lymphoblastic
Leukemia NCT01810120
Inclusion Criteria
patients aged ≥ 3 months and < 21 years*
Yes
No
patients diagnosed with malignant hemopathies
(acute lymphoblastic leukemia   (all), acute
myeloid leukemia (aml), non-hodgkin lymphoma
(nhl)) in complete morphological remission or
myelodysplastic syndromes (mds), solid tumors
or non malignant hematological disorders (scid,
acquired and congenital aplastic anemia, other
primary immunodeficiencies, life-threatening
cytopenia) eligible for an allogeneic
transplantation and lacking a related or unrelated
hla-matched donor*
Yes
No
patients displaying an hla-partially matched family
donor*
Yes
No
lansky/karnofsky score  > 40, who > 4*
Yes
No
signed written informed consent*
Yes
No
Exclusion Criteria
grade >ii acute gvhd or chronic extensive gvhd at
the time of inclusion*
Yes
No
patient receiving an immunosuppressive
treatment for gvhd treatment at the time of
inclusion*
Yes
No
dysfunction of liver (alt/ast > 5 times normal
value, or bilirubin > 3 times normal value), or of
renal function (creatinine clearance < 30 ml /
min)*
Yes
No
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severe cardiovascular disease (arrhythmias
requiring chronic treatment, congestive heart
failure or left ventricular ejection fraction
<40percent)*
Yes
No
current active infectious disease (including
positive hiv serology or viral rna)*
Yes
No
serious concurrent uncontrolled medical disorder*
Yes
No
pregnant or breast feeding female patient*
Yes
No
lack of parents' informed consent.*
Yes
No
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Eligibility Acute Lymphoblastic Leukemia
NCT02010931
Retrospective Analysis of Survival in Adult MRD Positive
Acute Lymphoblastic Leukemia Patients; ODM derived
from: https://clinicaltrials.gov/show/NCT02010931
All rights reserved. Please visit https://medical-data-
models.org/forms/12812
Eligibility Acute Lymphoblastic
Leukemia NCT02010931
Inclusion Criteria
patients with philadelphia-negative b-precursor
acute lyphmoblastic leukemia in complete
hematological remission defined as less than 5
percent blasts in bone marrow after at least 3
intensive chemotherapy blocks (i.e. any standard
or investigational regimen according to adult
protocols as long as 3 age appropriate
chemotherapy blocks were given, this also
includes relapse treatment*
Yes
No
detection of minimal  residual disease (molecular
failure or molecular relapse) at a level of greater
than or equal to 10*(-4) by pcr or greater than or
equal to 10*(-3) by flow cytometry at a reference
lab*
Yes
No
age 15 or greater at time of initial diagnosis with
acute lymphoblastic leukemia. for patients aged
15-17 treatment according to adult protocols is
required*
Yes
No
initial diagnosis in the year 2000 or later*
Yes
No
history of acute lymphoblastic leukemia treatment
(including response to first therapy, number of
prior relapses) is available*
Yes
No
relapse status and disease follow up after
timepoint of minimal residual disease detection is
available*
Yes
No
Exclusion Criteria
patients with extramedullary disease at timepoint
of minimal residual disease detection*
Yes
No
use of blinatumomab within 18 months of minimal
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residual disease detection*
Yes
No
allogeneic hematopoietic stem cell
transplantation prior to minimal residual disease
detection at the required level*
Yes
No
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Eligibility Acute Lymphoblastic Leukemia
NCT02042690
Haplo-identical HSCT Versus Chemotherapy for Adult
Acute Lymphoblastic Leukemia Patients; ODM derived
from: https://clinicaltrials.gov/show/NCT02042690
All rights reserved. Please visit https://medical-data-
models.org/forms/12813
Eligibility Acute Lymphoblastic
Leukemia NCT02042690
Inclusion Criteria
acute lymphoblastic leukemia*
Yes
No
18-39 years old*
Yes
No
in first complete remission*
Yes
No
adequate hepatic function defined as: total
bilirubin ≤2.0 times the institutional upper limit of
normal (uln); alanine aminotransferase (alt) and
aspartate aminotransferase(ast) ≤2.5 times the
institutional uln -*
Yes
No
adequate renal function defined as creatinine ≤3
times the institutional uln*
Yes
No
no uncontrollable infection*
Yes
No
performance status(ps)score 0-2(who)*
Yes
No
subjects able to provide written informed
consent*
Yes
No
Exclusion Criteria
having hla-matched donor*
Yes
No
high-risk all: (1)ph+all (2)hypodiploidy
(3)t(v;11q23) (4) complex karyotype（≥5
chromosome abnormalities）（5）high white
blood cell (wbc) count (b-all≥30×109/l;t-all
≥100×109/l).*
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Yes
No
pregnancy*
Yes
No
loss of ability to freely provide consent due to
psychiatric or physical illness*
Yes
No
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Eligibility Schizophrenia NCT01662310
An Efficacy Study of Paliperidone for the Prevention of
Relapse in Participants With Schizophrenia; ODM derived
from: https://clinicaltrials.gov/show/NCT01662310
All rights reserved. Please visit https://medical-data-
models.org/forms/12814
Eligibility Schizophrenia
NCT01662310
Inclusion Criteria
have a diagnosis of schizophrenia according to
diagnostic and statistical manual of mental
disorders, 4th edition (dsm-iv)*
Yes
No
have experienced an acute episode, with a
positive and negative syndrome  scale (panss)
total score between 70 and 120 inclusive, at
screening and baseline*
Yes
No
women must be postmenopausal (for at least 1
year), surgically sterile (have had a hysterectomy
or bilateral oophorectomy, tubal ligation, or
otherwise be incapable of pregnancy), practicing
a highly effective method of birth control, if
sexually active*
Yes
No
men must be using a highly effective method of
birth control and must not donate sperm during
the study and for 3 months after receiving the last
dose of study drug*
Yes
No
be willing and capable to complete the
questionnaires and able to take oral medications
independently*
Yes
No
Exclusion Criteria
has drug dependence diagnosis according to
dsm-iv (excluding nicotine and caffeine
dependence) within 6 months before screening*
Yes
No
participants with crohn's disease and hepatic or
renal diseases*
Yes
No
has had relevant history of any significant and/or
unstable cardiovascular, respiratory, neurologic
(including seizures or significant cerebrovascular
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dysfunction), renal, hepatic, endocrine, or
immunologic diseases*
Yes
No
has had history of neuroleptic malignant
syndrome (the disorder caused by antipsychotic
drugs with symptoms of  fever, muscle rigidity
and delirium)*
Yes
No
has had known or suspected stevens johnson
syndrome (an immune disease with symptoms of
fever, sore throat, ulcers and conjunctivitis) after
exposure to phenytoin, carbamazepine,
barbiturates, or lamotrigine*
Yes
No
had been treated with clozapine for treatment
refractory or treatment resistant schizophrenia*
Yes
No
has significant risk of suicide or homicidal
behavior, or significant risk of deliberate self harm
or harm to others*
Yes
No
has taken isocarboxazid, phenelzine, selegiline
and tranylcypromine within 4 weeks before
screening*
Yes
No
has received electroconvulsive therapy within 60
days before screening*
Yes
No
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Eligibility Severe Alcoholic Hepatitis
NCT02485106
Rifaximin Use in Severe Alcoholic Hepatitis; ODM derived
from: https://clinicaltrials.gov/show/NCT02485106
All rights reserved. Please visit https://medical-data-
models.org/forms/12815
Eligibility Severe Alcoholic Hepatitis
NCT02485106
Inclusion Criteria
heavy alcohol drinking within 3 months (over 40
g/day)*
Yes
No
maddrey's discriminant function ≥ 32*
Yes
No
ast/alt ration ≥ 2*
Yes
No
bilirubin level ≥ 5mg/dl*
Yes
No
any one of the following additional criteria :
hepatic encephalopathy, enlarged, tender liver, or
peripheral leucocytosis*
Yes
No
age : 19-75*
Yes
No
jaundice within 3 months*
Yes
No
Exclusion Criteria
other causes of chronic liver disease (hbv, hcv, or
autoimmune hepatitis)*
Yes
No
antibiotics or probiotics use within 8 weeks*
Yes
No
drug induced hepatotoxicity*
Yes
No
acute viral hepatitis (hav or hev)*
Yes
No
hepatic abscess or cholagitis*
Yes
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No
hepatocellular carcinoma of modified uicc stage
ii, iii or iv*
Yes
No
malignant tumor other than hcc*
Yes
No
pregnancy*
Yes
No
severe chronic extrahepatic disease*
Yes
No
type i hepatorenal syndrome*
Yes
No
hepatic encephalopathy grade ii or iv*
Yes
No
severe infection*
Yes
No
2 / 2
Eligibility Severe Alcoholic Hepatitis NCT02485106
Eligibility Sexual Dysfunction.
NCT02091765
KIS Study: a Study Evaluating the Effectiveness of an
Internet-based Therapy Program for Sexuality and Intimacy
Problems in Women Treated for Breast Cancer; ODM
derived from: https://clinicaltrials.gov/show/NCT02091765
All rights reserved. Please visit https://medical-data-
models.org/forms/12816
Eligibility Sexual Dysfunction.
NCT02091765
Inclusion Criteria
woman.*
Yes
No
between 18 and 65 years of age.*
Yes
No
diagnosis of histologically confirmed primary
breast cancer.*
Yes
No
received treatment in one of the participating
hospitals.*
Yes
No
completed treatment for breast cancer(with the
exception of endocrine therapy).*
Yes
No
diagnosis of breast cancer between 6 months
and 5 years prior to study entry.*
Yes
No
disease-free at time of study entry.*
Yes
No
presence of sexuality and intimacy problems.*
Yes
No
Exclusion Criteria
lacks basic proficiency in dutch.*
Yes
No
no access to the internet.*
Yes
No
serious cognitive or psychiatric problems (i.e.
depression, alcohol dependency, or psychotic
disorders).*
Yes
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No
severe relationship problems for which the
internet-based program is not designed (and
which need to be addressed prior to undergoing
sex therapy).*
Yes
No
participation in a concurrent therapy program to
alleviate sexuality/intimacy problems.*
Yes
No
treated for another type of cancer beside breast
cancer (with the exception of cervical carcinoma
in situ and basal cell carcinoma).*
Yes
No
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Eligibility Skin Cancer NCT00836342
Correlation Between Skin Carotenoid Levels and Previous
History of Skin Cancer; ODM derived from:
https://clinicaltrials.gov/show/NCT00836342
All rights reserved. Please visit https://medical-data-
models.org/forms/12817
Eligibility Skin Cancer NCT00836342
Inclusion Criteria
subjects between 50 and 75 years old without
history of previous scc or bcc.*
Yes
No
fitzpatrick skin types i-iv.*
Yes
No
willing and able to understand and sign informed
consent.*
Yes
No
able to complete study and comply with study
procedures*
Yes
No
Exclusion Criteria
regular ingestion of supplements containing
carotenoids or vitamin a in the past 4 weeks.*
Yes
No
use of topical retinoids in the past 4 weeks.*
Yes
No
treatment with systemic retinoids in the past 6
months.*
Yes
No
dermatologic conditions that require the use of
interfering topical or systemic therapy or that
might interfere with study assessments such as,
but not limited to, palmar psoriasis, hand
dermatitis or palmo-plantar keratoderma.*
Yes
No
previous history of psoriasis.*
Yes
No
clinically significant abnormal findings or
conditions, which might, in the opinion of the
principal investigator, interfere with study
evaluations or pose a risk to subject safety during
the study.*
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Yes
No
subjects who are known to be pregnant or
planning a pregnancy.*
Yes
No
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Eligibility Squamous Cell Carcinoma
NCT02088515
Nedaplatin (Jiebaishu®) Combined With Docetaxel for
Advanced Lung Squamous Cell Carcinoma; ODM derived
from: https://clinicaltrials.gov/show/NCT02088515
All rights reserved. Please visit https://medical-data-
models.org/forms/12818
Eligibility Squamous Cell Carcinoma
NCT02088515
Inclusion Criteria
1. primary lung squamous carcinoma confirmed
by cytology and histology, excluding sputum
examination.*
Yes
No
2. iiib-no radiotherapy indication /iv phased by
aslc 2009 tnm criteria.*
Yes
No
3. at least one measurable tumor based on recist
( longest diameter: ≥20 mm by ct scan or 10 mm
by spiral ct )*
Yes
No
4. male or female, age≥18 or ≤75 years old*
Yes
No
5. ecog ps: 0 or 1*
Yes
No
6. estimated time of survival: ≥12 weeks*
Yes
No
7. suitable hematologic function: anc≥2×109/l,
plc≥100×109/l and hb≥9 g/dl*
Yes
No
8. suitable liver function: total bilirubin≤normal
uln, ast and alt≤2.5×normal uln, alp≤5×normal
uln.*
Yes
No
9. suitable renal function: cr≤normal uln,or ccr≥60
ml/min*
Yes
No
10. no history of chemotherapy*
Yes
No
11. at the enrollment, the past operation has
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been over 4 weeks and the subject recovered.*
Yes
No
12. for the female subject with the intact uterus, if
amenorrhea is less than 24 months, pregnancy
test must be negative within 28 days of
enrollment. if pregnancy test has been past 7
days at the time of initial chemotherapy, urine
pregnancy test must be done.*
Yes
No
13. the authorized icf must be signed*
Yes
No
Exclusion Criteria
1. having the other cancer in the recent five
years, cured skin basal cell carcinoma and
cervical  carcinoma excluded.*
Yes
No
2. having the evidence of cns metastasis, no
matter if treated; if being suspicious of cns
metastasis, cns mri or enhanced ct scan must be
done within 28 days of enrollment.*
Yes
No
3. ast and /or alt＞2.5×normal uln, and alp
＞5×normal uln.*
Yes
No
4. radiotherapy in the past (excluding palliative
radiotherapy for pain relief and the measurable
tumor outside the radio field)*
Yes
No
5. chemotherapy in the past (excluding
bisphosphonates )*
Yes
No
6. having the other uncontrolled diseases.*
Yes
No
7. the female in pregnancy or feeding.*
Yes
No
8. the subjects with the productivity capacity, but
refusal to use the effective contraception
measure.*
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Yes
No
9. participating in other clinical trial and at the
time of treatment period.*
Yes
No
10. allergy to the tested drugs*
Yes
No
11. having the other uncontrolled diseases*
Yes
No
12. bmt had been done.*
Yes
No
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Follow Up Form HOVON 132 AML/SAKK
30/13 EudraCT 2013-002843-26
Description of Form: Follow Up Form
All rights reserved. Please visit https://medical-data-
models.org/forms/12829
Follow Up Form
Default Itemgroup
Date last known to be alive or death
dd/mm/yyyy
Patient status
Survival status
alive  (0)
dead* (1)
*Cause of death
leukemia  (1)
pneumonia  (2)
other infection  (3)
hemorrhage (4)
veno-occlusive disease*  (5)
other* (8)
Specify
Remission Status
Remission status
no CR(i)  (0)
CR  (1)
CRi (2)
Date of relapse
dd/mm/yyyy
Second malignancy (not previously reported)
no (0)
yes* (please complete SPM form (22)
and SAE form) (1)
Specify
Date of diagnosis
dd/mm/yyyy
GvHD
Acute GvHD (not previously reported)
none  (0)
Grade I  (1)
Grade II (2)
Grade III  (3)
Grade IV (4)
1 / 3
not applicable, no alloHSCT (8 )
Chronic GvHD (not previously reported)
none (0)
limited (1)
extensive (2)
too early (3)
not applicable, no alloHSCT (8)
AML/MDS Treatment Given after End of
Protocol
Treatment given off protocol
no (leave boxes 15 to 20 empty)  (0)
chemotherapy only (1)
autoHSCT** (2)
alloHSCT**   (3)
DLI** (4)
other* (8)
Specify
Date of start treatment
dd/mm/yyyy
Was CR(i) achieved after off protocol treatment
no  (0)
yes, CR*  (1)
yes, CRi* (2)
achieved before  (3)
unknown (9)
Date CR(i)
dd/mm/yyyy
Comments
Comments
Fill in this Page in Case of autoHSCT,
alloHSCT or DLI (Given after End of
Protocol)
Conditioning Therapy
no conditioning  (0)
non-myelo ablative (1)
myelo ablative (2)
other* (8)
Specify
Date of Transplant
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dd/mm/yyyy
Source of stem cells (actually infused)
bone marrow  (1)
peripheral blood (2)
BM + PB (3)
cord blood (4)
Number of nucleated cells infused
10^8/kg
Number of CD34+ cells infused
10^6/kg
T-cell depletion
Yes
No
Number of T-cells infused
10^4/kg
Donor
Donor sex
male (1)
female (2)
Donor date of birth
Relation with patient
monozygotic twin (1)
HLA identical sibling (2)
HLA identical parent (3)
1-antigen-mismatched related donor (4)
2-or more-antigen mismatched related
donor (haplo-identical) (5)
matched unrelated donor# (6)
mismatched unrelated donor## (7)
cord blood unit identified (8)
unknown (9)
Comments 2
Comments
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Eligibility Alzheimer's Disease
NCT00001972
PET Scan of Brain Metabolism in Relation to Age and
Disease; ODM derived from:
https://clinicaltrials.gov/show/NCT00001972
All rights reserved. Please visit https://medical-data-
models.org/forms/12832
Eligibility Alzheimer's Disease
NCT00001972
Criteria
age between 18 and 90 years.*
Yes
No
no past or current medical condition that would
interfere with brain function.*
Yes
No
no occupational exposure to metal slivers or
shavings.*
Yes
No
no females who are pregnant or breast feeding.*
Yes
No
age between 18 and 90 years.*
Yes
No
diagnosis of possible or probably alzheimer
disease according to nincds-adrda criteria.*
Yes
No
aside from alzheimer disease, no past or current
medical condition that would interfere with brain
function.*
Yes
No
no history of alcoholism, psychiatric or
neurological illness, head trauma with loss of
consciousness, history of exposure to central
nervous system toxin; history of central nervous
system infection, metabolic, endocrine,
connective tissue diseases; hypertension or other
cardiovascular disorder; abnormal renal, liver or
pulmonary function; blood or coagulation
disease; malignancy; psychopharmacological
treatment.*
Yes
No
neurodegenerative or neurodevelopmental
disorder; stroke; epilepsy; subjects requiring
regular medication, and subjects demonstrated
by drug screening to have taken a controlled
substance.
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Yes
No
no females who are pregnant or breast feeding.*
Yes
No
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Eligibility Alzheimer's Disease NCT00001972
Eligibility Breast Cancer NCT00156052
Hypofractionated Radiotherapy Post-Lumpectomy in
Women With Node Negative Breast Cancer; ODM derived
from: https://clinicaltrials.gov/show/NCT00156052
All rights reserved. Please visit https://medical-data-
models.org/forms/12833
Eligibility Breast Cancer
NCT00156052
Inclusion Criteria
1. the female patient has a histological diagnosis
of invasive carcinoma of the breast, and no
evidence of metastatic disease.*
Yes
No
2. has had a lumpectomy (including segmental
resection and partial mastectomy), that is,
surgical excision of the tumour with a rim of
normal tissue.*
Yes
No
3. patient has not had an axillary dissection, or
for patients who have had an axillary dissection,
all nodes are negative for metastatic disease.*
Yes
No
Exclusion Criteria
1. tumour greater than 5 cm in greatest diameter
on pathological examination.*
Yes
No
2. the presence of invasive or intraductal
(noninvasive) breast cancer involving the surgical
margins.*
Yes
No
3. clinical evidence prior to surgery of infiltration
of the skin of the involved breast such as edema,
ulceration, or fixation of the tumour to underlying
muscle, or inflammatory breast cancer.*
Yes
No
4. bilateral malignancy of the breast
(synchronous or metachronous).*
Yes
No
5. more than one primary invasive tumour in the
same breast.*
Yes
No
6. previous surgery for breast cancer.*
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Yes
No
7. pathological status of axilla is unknown.*
Yes
No
8. status for adjuvant systemic therapy not
determined.*
Yes
No
9. for patients not treated with adjuvant
chemotherapy:  unable to commence radiation
therapy within 16 weeks of last surgical
procedure on the breast.*
Yes
No
10. for patients treated with adjuvant
chemotherapy:  unable to commence radiation
therapy within 8 weeks of the last dose of
chemotherapy.*
Yes
No
11. serious nonmalignant disease (eg.
cardiovascular, renal, etc.) which would preclude
surgical or radiation treatment.*
Yes
No
12. currently pregnant or lactating.*
Yes
No
13. breast deemed too large to permit
satisfactory radiation (ie. separation > 25 cm).*
Yes
No
14. previous concomitant malignancies of any
type except squamous, or basal cell carcinomas
of the skin, or carcinoma in situ of the cervix
which have been effectively treated.*
Yes
No
15. geographic inaccessibility for follow-up.*
Yes
No
16. psychiatric or addictive disorders which
preclude obtaining informed consent or
adherence to the protocol.*
Yes
No
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Eligibility Breast Cancer NCT00156052
Eligibility Breast Cancer NCT00291096
Protocol for Women at Increased Risk of Developing Breast
Cancer; ODM derived from:
https://clinicaltrials.gov/show/NCT00291096
All rights reserved. Please visit https://medical-data-
models.org/forms/12834
Eligibility Breast Cancer
NCT00291096
Inclusion Criteria
women with at least 2 times the normal risk of
developing breast cancer*
Yes
No
between the ages of 30-65 (or within 10 years of
youngest age at diagnosis in first degree
relative)*
Yes
No
greater than six months from ingestion of
antihormonal therapy*
Yes
No
greater than 1 year from pregnancy, lactation, or
chemotherapy*
Yes
No
willing to have a mammogram within six months
prior to rpfna*
Yes
No
willing to discontinue NSAIDs or herbal
supplements*
Yes
No
willing to have blood drawn*
Yes
No
Exclusion Criteria
no metastatic malignancy of any kind*
Yes
No
no breast implants or tram flap reconstructions*
Yes
No
no radiation to both breasts*
Yes
No
no women who have a current mammogram or
clinical breast exam suspicious for cancer*
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Yes
No
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Eligibility Breast Cancer NCT00291096
Eligibility Breast Neoplasms NCT00001338
A Prospective, Randomized, Phase III Trial of FLAC (5-
Fluorouracil, Leucovorin, Adriamycin, Cytoxan)
Chemotherapy With GM-CSF (Granulocyte-Macrophage
Colony-Stimulating Factor) Versus PIXY 321 in Advanced
Breast Cancer; ODM derived from:
https://clinicaltrials.gov/show/NCT00001338
All rights reserved. Please visit https://medical-data-
models.org/forms/12835
Eligibility Breast Neoplasms
NCT00001338
Criteria
patients who have had prior radiation therapy
providing there was not more than  20% of the
bone marrow has been irradiated.*
Yes
No
patients who have received less than or equal to
360mg/m2 of adriamycin as adjuvant therapy.*
Yes
No
patients must be previously untreated with
chemotherapy for metastatic disease.*
Yes
No
there must be no history of previous malignancy
except for cured non-melanoma skin cancer
(basal or squamous cell carcinoma), cervical
cancer in situ, or a past malignancy that has
been inactive for over 5 years.*
Yes
No
performance status (karnofsky scale) must be
greater than 70; ecog 0-2.*
Yes
No
absolute granulocyte count greater than 1500
microliters and platelet count greater than
100,000/mm3.*
Yes
No
liver function tests (sgot, and total bilirubin)
should be less than 2x the upper limits of normal
unless there is evidence of hepatic involvement
with tumor.  serum creatinine should be less than
1.7 or creatinine clearance should be greater
than 45 ml/min.*
Yes
No
patients must be greater than or equal to 18
years of age.*
Yes
No
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the patient must be able to give informed
consent, and to return to nci for treatment and
adequate follow-up for the period the protocol
requires.*
Yes
No
no patients who are poor medical or psychiatric
risks because of nonmalignant systemic disease
which would preclude them from being subjected
to any treatments in this protocol.*
Yes
No
patients should not currently require therapy for
cardiac arrhythmias, congestive heart failure, or
coronary artery disease.  patients who have
received prior adriamycin or have any history of
cardiac disease must have a lvef greater than 45
percent by muga.*
Yes
No
no history of cns metastasis, or know seizure
disorder.*
Yes
No
no allergy to any study medication.*
Yes
No
no pregnant or lactating women.*
Yes
No
no patients requiring ongoing therapy for
asthma.*
Yes
No
no patients with bleeding disorders for study entry
as are patients requiring chronic anticoagulation.*
Yes
No
no patients with active infection or are known to
be hiv positive.*
Yes
No
2 / 2
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Eligibility Lymphoma NCT00002481
Combination Chemotherapy and Radiation Therapy Plus
Bone Marrow Transplantation in Treating Patients With
Relapsed or Refractory Non-Hodgkin's Lymphoma; ODM
derived from: https://clinicaltrials.gov/show/NCT00002481
All rights reserved. Please visit https://medical-data-
models.org/forms/12836
Eligibility Lymphoma NCT00002481
Criteria
age: 16 and over*
Yes
No
performance status: calgb 0-2 karnofsky 70-
100%
Yes
No
life expectancy: more than 2 months
Yes
No
hematopoietic: neutrophil count at least
1,500/mm3 platelet count at least 100,000/mm3
Yes
No
hepatic: bilirubin less than 3 times normal sgot
and sgpt less than 3 times normal alkaline
phosphatase less than 3 times normal hepatitis b
surface antigen negative
Yes
No
renal function
Yes
No
cardiovascular: cardiac ejection fraction normal
by muga scan no uncontrolled or severe
cardiovascular disease, including the following:
myocardial infarction within the past 6 months
congestive heart failure symptomatic angina
(despite optimal medical management) life-
threatening arrhythmia or hypertension
Yes
No
pulmonary: pulmonary function tests (dlco and
spirometry) greater than 60% predicted
Yes
No
other: hiv negative no serious organ dysfunction
(unless caused by lymphoma) no active bacterial,
viral, or fungal infection no active peptic ulcer
disease no uncontrolled diabetes mellitus no
other malignancy except curatively treated
carcinoma in situ of the cervix or basal cell or
squamous cell skin cancer no other serious
medical or psychiatric illness that would preclude
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study
Yes
No
not pregnant
Yes
No
chemotherapy: see disease characteristics prior
nitrosourea allowed if cumulative dose no more
than 600 mg/m2 prior bleomycin allowed if
cumulative dose no more than 300 units/m2 prior
doxorubicin allowed if cumulative dose no more
than 450 mg/m2 no prior high-dose etoposide
(more than 1,800 mg/m2) no prior high-dose
cyclophosphamide (more than 100 mg/kg) no
chemotherapy within 4 weeks (no melphalan,
nitrosourea, or mitomycin within 6 weeks) prior to
bone marrow collection*
Yes
No
no prior salvage therapy  radiotherapy: see
disease characteristics no prior radiotherapy to
liver or lung prior other radiotherapy allowed if
doses do not exceed the following limits: 1,400
cgy to the mediastinum 1,400 cgy to the whole
abdomen 4,000 cgy to the cns
Yes
No
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Eligibility Lymphoma, Non-Hodgkin
NCT01536561
Study of Radiolabeled Monoclonal Antibody Anti-B1 for the
Treatment of B-Cell Lymphomas and Extended Study to
Determine the Safety and Efficacy of Coulter Clone®
131Iodine-B1 Radioimmunotherapy of Advanced Non-
Hodgkin's Lymphoma; ODM derived from:
https://clinicaltrials.gov/show/NCT01536561
All rights reserved. Please visit https://medical-data-
models.org/forms/12837
Eligibility Lymphoma, Non-Hodgkin
NCT01536561
Inclusion Criteria
subjects had histologically-confirmed nhl.*
Yes
No
subjects with low-, intermediate-, or high-grade
histologies, according to the international working
formulation.*
Yes
No
subjects had relapsed after or had failed to
respond to at least 1 prior chemotherapy
regimen.*
Yes
No
subjects had evidence that their tumor tissue
expressed the CD20 antigen.*
Yes
No
Exclusion Criteria
≥25% bone marrow involvement.*
Yes
No
absolute granulocyte count ≥1500 cells/mm3 or
platelet count ≤100,000 platelets/mm3.*
Yes
No
creatinine ≥2.0 mg/dl, bilirubin ≥2.0 mg/dl.*
Yes
No
cytotoxic chemotherapy, radiation therapy,
immunosuppressants, or cytokine treatment
within 4 weeks of study entry.*
Yes
No
active infection, collagen vascular disease,
vasculitis, glomerulonephritis, new york heart
association class ii or iv heart disease and/or
serious illness.*
Yes
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No
prior external beam radiation therapy such that
the maximum tolerated dose level for any normal
organ would be exceeded by additional
irradiation.*
Yes
No
pregnancy*
Yes
No
allergy to iodine or previous sensitization to
mouse protein as documented by positive anti-
mouse antibody elisa test.*
Yes
No
known brain metastases*
Yes
No
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Eligibility Metastatic Breast Cancer
NCT00584766
Intensive Combo Chemo With Autologous BM Rescue for
Metastatic Breast Cancer; ODM derived from:
https://clinicaltrials.gov/show/NCT00584766
All rights reserved. Please visit https://medical-data-
models.org/forms/12838
Eligibility Metastatic Breast Cancer
NCT00584766
Inclusion Criteria
breast carcinoma at first clinical evidence of
metastatic disease*
Yes
No
must have measurable disease by physical exam,
x-ray, or scan*
Yes
No
age < or equal to 55*
Yes
No
performance status 0-2*
Yes
No
Exclusion Criteria
can't have had more than one prior
chemotherapy regimen*
Yes
No
can't have had concurrent hormonal therapy*
Yes
No
no brain metastases*
Yes
No
no previous pelvic radiation*
Yes
No
no history of another malignancy*
Yes
No
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Eligibility Multiple Sclerosis NCT00004814
Phase III Randomized, Double-Blind, Placebo-Controlled
Study of Copolymer 1 for Relapsing-Remitting Multiple
Sclerosis; ODM derived from:
https://clinicaltrials.gov/show/NCT00004814
All rights reserved. Please visit https://medical-data-
models.org/forms/12839
Eligibility Multiple Sclerosis
NCT00004814
Criteria
clinically or laboratory-supported definite multiple
sclerosis*
Yes
No
neurologically stable for at least 30 days prior to
entry expanded disability status scale score no
greater than 5*
Yes
No
at least 2 documented relapses within 2 years
prior to entry onset of first relapse at least 1 year
prior to randomization*
Yes
No
biologic therapy: no prior copolymer 1*
Yes
No
immunosuppressive therapy: no prior cytotoxic
immunosuppressives, i.e.: azathioprine
cyclophosphamide cyclosporine at least 30 days
since corticosteroids*
Yes
No
radiotherapy: no prior lymphoid irradiation*
Yes
No
not hiv or htlv-i seropositive no insulin-dependent
diabetes mellitus no lyme disease no requirement
for aspirin or chronic nonsteroidal anti-
inflammatory drugs no pregnant or nursing
women adequate contraception required of fertile
women*
Yes
No
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Eligibility Neoplasm, Prostate
NCT01819285
Early Compared With Delayed Hormone Therapy in
Treating Patients With Nonmetastatic Prostate Cancer;
ODM derived from:
https://clinicaltrials.gov/show/NCT01819285
All rights reserved. Please visit https://medical-data-
models.org/forms/12840
Eligibility Neoplasm, Prostate
NCT01819285
Inclusion Criteria
histologically or cytologically proven, newly
diagnosed asymptomatic (with the exception of
voiding disturbances) carcinoma of the prostate
t0-4 n0-2 m0 which is not suitable for local
treatment with curative intent (radical
prostatectomy, radiation therapy)*
Yes
No
all t stages are acceptable (uicc 1982). the stage
is determined by rectal palpation.*
Yes
No
patients with regional lymph node metastases
smaller than 5 cm (n0-2), determined either by ct
or ultrasonography, preferable with cytologic
confirmation.*
Yes
No
life expectancy of at least six months.*
Yes
No
WHO performance status score 0-1.*
Yes
No
informed consent. patients must be prepared to
undergo an orchiectomy or continuous treatment
with a depot lhrh analogue.*
Yes
No
continuous follow-up until death if possible.*
Yes
No
Exclusion Criteria
other malignancies diagnosed during the last 10
years, apart from treated basal cell carcinoma of
the skin.*
Yes
No
prostate cancer known for longer than one month
before entering the study.*
Yes
1 / 2
No
pain caused by the prostate cancer or its
metastases*
Yes
No
any previous treatment for prostate cancer
(radical prostatectomy, radiation therapy,
endocrine treatment, etc.) note: tur-p for voiding
disturbances is allowed at any time and is not an
exclusion criterion.*
Yes
No
patients with ureteric obstruction caused by local
infiltration of prostatic cancer and other evidence
of locally advanced disease which could cause
fatal complications if untreated (e.g. rectal
stenosis, thrombosis of pelvic veins).*
Yes
No
patients with palpable or juxtaregional lymph
node metastasis (paraaortic, supraclavicular,
inguinal, n3-4).*
Yes
No
patients with evidence of distant metastases
(bone, lung, liver).*
Yes
No
age over 80 years. performance status who score
2, 3 and 4 (any reason).*
Yes
No
patient who refuses orchiectomy or longterm
subcutaneous implants of lhrh analogue in two
monthly intervals.*
Yes
No
expected difficulties with follow-up for any
reason.*
Yes
No
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Eligibility Non-Insulin-dependent Diabetes
Mellitus NCT01582282
Study of Metamucil on Blood Glucose and HbA1c in Type II
NIDDM Subjects; ODM derived from:
https://clinicaltrials.gov/show/NCT01582282
All rights reserved. Please visit https://medical-data-
models.org/forms/12841
Eligibility Non-Insulin-dependent
Diabetes Mellitus NCT01582282
Inclusion Criteria
have a clinical diagnosis of type ii diabetes
mellitus, controlled by diet and/or second
generation oral hypoglycemic drugs, with the
onset of the disease after age 35.*
Yes
No
are between 0 and 50% above "normal" body
weight (adjusted by frame) according to the
metropolitan life insurance tables*
Yes
No
are male or female, aged 36-80 years with a
diagnosis made at least 1 year prior to
enrollment.*
Yes
No
have an hba1c level between 6 and 10%*
Yes
No
have a fasting serum glucose level between 120-
220 mg/dl and not vary by more than ±20%
during the month prior to entering the treatment
phase and hba1c levels not vary by more than
±10% during the month prior to entering the
treatment phase. serum glucose level must have
been between 120-220mg/dl and the subject's
hba1c between 6 and 10% at week 0.*
Yes
No
have been on a "stable" diet consistent with ada-
recommended dietary guidelines with intake of
total dietary fiber < 15g/1000 calories and were
willing to maintain this diet during the 20-week
study.*
Yes
No
have maintained a constant body weight (±5%)
during the month prior to entering the treatment
phase*
Yes
No
Exclusion Criteria
1 / 2
have a condition that would interfere with
evaluation*
Yes
No
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Eligibility Osteoarthritis NCT00000434
Impact of Exercise on Older Persons With Osteoarthritis;
ODM derived from:
https://clinicaltrials.gov/show/NCT00000434
All rights reserved. Please visit https://medical-data-
models.org/forms/12842
Eligibility Osteoarthritis
NCT00000434
Inclusion Criteria
60 years of age or older*
Yes
No
presence of osteoarthritis of the lower extremities
with an american college of rheumatology
functional class rating of i, ii, or iii*
Yes
No
no other contraindication from a personal
physician for participation in the fitness walking*
Yes
No
lack of moderate-to-severe cognitive impairment
as assessed by the short portable mental status
questionnaire*
Yes
No
Exclusion Criteria
under 60 years of age*
Yes
No
lack of osteoarthritis of the lower extremities*
Yes
No
contraindication from a personal physician for
participation in fitness walking*
Yes
No
presence of moderate-to-severe cognitive
impairment as assessed by the short portable
mental status questionnaire*
Yes
No
steroid injections in either hip or knee within the
previous 6 months*
Yes
No
uncomplicated knee or hip surgery within
previous year*
Yes
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No
complicated knee or hip surgery within previous
year*
Yes
No
plans for total knee or hip replacement within the
next year*
Yes
No
rheumatoid arthritis or other systemic
inflammatory arthritis*
Yes
No
diabetes that is not under control*
Yes
No
current participation in a structured aerobic
exercise program*
Yes
No
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Eligibility Prostate Cancer NCT00002511
Radiation Therapy Compared With No Further Treatment
Following Surgery in Treating Patients With Prostate
Cancer; ODM derived from:
https://clinicaltrials.gov/show/NCT00002511
All rights reserved. Please visit https://medical-data-
models.org/forms/12843
Eligibility Prostate Cancer
NCT00002511
Criteria
histologically documented invasive
adenocarcinoma of the prostate staged pt3 pn0
after radical prostatectomy*
Yes
No
preoperative staging must have been t0-3 n0 m0
based on physical exam, chest x-ray, bone scan,
ct or mri of entire pelvis and abdomen, and
serum psa*
Yes
No
at least 1 of the following features must be
present:
complete capsule invasion (i.e., perforation)
positive surgical margins (microscopic or gross)
seminal vesicle invasion*
Yes
No
radiotherapy must begin within 16 weeks
following surgery, after recovery of urinary
function*
Yes
No
age: 75 and under*
Yes
No
performance status: who 0-2*
Yes
No
no other malignancies*
Yes
No
endocrine therapy: no more than 4 months of
preoperative hormonal therapy*
Yes
No
surgery: radical prostatectomy required within 12
weeks with recovery of urinary function*
Yes
No
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Eligibility Prostate Cancer NCT00548600
Radical Radiotherapy by External Beam Radiation Versus
Radical Radiotherapy With Temporary Iridium Implant Plus
External Beam Radiation in Carcinoma of the Prostate;
ODM derived from:
https://clinicaltrials.gov/show/NCT00548600
All rights reserved. Please visit https://medical-data-
models.org/forms/12844
Eligibility Prostate Cancer
NCT00548600
Inclusion Criteria
all patients must have histologically proven
adenocarcinoma of the prostate*
Yes
No
the primary tumour should be staged clinically b2
or c as classified by a.j.c. staging system*
Yes
No
Exclusion Criteria
patients requiring transurethral prostatectomy
(turp) prior to diagnosis*
Yes
No
presence of metastases identified by bone scan,
chest x-ray or ct scan of the abdomen and pelvis,
or staging lymphadenectomy*
Yes
No
karnofsky performance status less than 80*
Yes
No
inadequate laboratory results: i.e. hb < 12
gm/litre, wbc < 3.5 x 10 per litre, platelets < 100 x
10/litre, urea > 13 mmol/litre, creatinine > 220
mmol/litre*
Yes
No
unfit for surgery for other medical reasons*
Yes
No
age above 75 years*
Yes
No
failure to provide written informed consent*
Yes
No
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Eligibility Prostatic Neoplasm
NCT00001266
A Phase II Trial of Leuprolide + Flutamide + Suramin in
Untreated Poor Prognosis Prostate Carcinoma; ODM
derived from: https://clinicaltrials.gov/show/NCT00001266
All rights reserved. Please visit https://medical-data-
models.org/forms/12845
Eligibility Prostatic Neoplasm
NCT00001266
Inclusion Criteria
patients must have a histologic diagnosis of
carcinoma of the prostate and must not have had
a trial of hormonal therapy or chemotherapy.*
Yes
No
patients must be 18 years of age*
Yes
No
an sgot/sgpt within 2 times of normal.
Yes
No
patients must have stage d2 prostate carcinoma
or state d1 disease with a gleason grade 7 or
above (poorly differentiated).*
Yes
No
no other malignancy except curatively treated
basal cell cancer of the skin.*
Yes
No
performance status ecog of 0-3.*
Yes
No
ability to give informed consent.*
Yes
No
no history of bleeding diathesis.  patients with a
history of peptic ulcer disease will be eligible if
the ulcer is shown to be resolved by a barium
study.*
Yes
No
no history of cerebrovascular event, either
thrombotic or hemorrhagic.*
Yes
No
no current clinical signs of congestive heart
failure, angina pectoris or myocardial infarction.
patient cannot be on calcium channel blockers
such as nifedipine, diltiazem, or verapamil.*
Yes
No
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no clinical or radiographic evidence of brain
metastases.*
Yes
No
patients with extensive liver replacement (greater
than 50%) by tumor will be ineligible.*
Yes
No
patients must have a creatinine lest than or equal
2.5 mg/dl or creatinine clearance of greater than
or equal to 40 ml/min.*
Yes
No
patients must have adequate hepatic function
(bilirubin less than 1.5mg%).*
Yes
No
if the patient has white cells in his urinalysis or
other evidence of a urinary tract infection, this
must be evaluated and appropriate therapy
initiation prior to the initiation of therapy.*
Yes
No
patients must not have received chemotherapy.*
Yes
No
an absolute granulocyte count greater than
1,500; platelet count greater than 100,000;
fibrinogen greater than 200 mg/dl; hgb greater
than or equal to 9 gm/dl.*
Yes
No
reliability of the patient to take oral medication, go
home and return for follow-up and treatment.*
Yes
No
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Eligibility Type 2 Diabetes NCT00471549
Simvastatin Reduces Circulating Osteoprotegerin Levels in
Patients With Type 2 Diabetes; ODM derived from:
https://clinicaltrials.gov/show/NCT00471549
All rights reserved. Please visit https://medical-data-
models.org/forms/12846
Eligibility Type 2 Diabetes
NCT00471549
Inclusion Criteria
type 2 diabetes*
Yes
No
persistent microalbuminuria*
Yes
No
fasting plasma cholesterol > 5.5 mmol/liter*
Yes
No
fasting plasma triglycerides < 4.5 mmol/liter*
Yes
No
fasting hba1c < 10 %*
Yes
No
fasting serum c-peptide > 0.49 nmol/liter*
Yes
No
blood pressure < 155/95*
Yes
No
Exclusion Criteria
signs of primary kidney disease*
Yes
No
signs of primary hepatic disease*
Yes
No
signs of insufficiently treated cardiac disease*
Yes
No
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Molecular Monitoring Survey EUREKA
EUropean survey on the assessment of deep molecular
REsponse in chronic phase CML patients after at least two
years of therapy with tyrosine KinAse inhibitors - major
component of the Path to Cure Pillar of EUTOS III.
ODM derived from:
http://www.eutos.org/content/path_to_cure/eureka/index_e
ng.html
All rights reserved. Please visit https://medical-data-
models.org/forms/12858
Informed Consent Form
Patienteninformation
Patienteninformation
Ziel des EUREKA-Registers
Ziel des EUREKA-Registers
Ablauf der Datenerhebung
Ablauf der Datenerhebung
Ablauf der Biomaterialgewinnung
Ablauf der Biomaterialgewinnung
Möglicher Nutzen und mögliche Risiken
Möglicher Nutzen und mögliche Risiken
Informationen zum Datenschutz
Informationen zum Datenschutz
Freiwilligkeit und Zurückziehen der
Einwilligung
Freiwilligkeit und Zurückziehen der Einwilligung
Weitere Informationen
Weitere Informationen
Weitere Fragen
Weitere Fragen
Name des/der behandelnden
Arztes/Ärztin:  (1)
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Fax: 03641 932 4202 (10)
cml@med.uni-jena.de (11)
Telefonnummer: (2)
oder an die (3)
CML-Studienzentrale (4)
Prof. Dr. Andreas Hochhaus (5)
Universitätsklinikum Jena, Klinik für
Innere Medizin II (6)
Erlanger Allee 101 (7)
07740 Jena (8)
Tel.: 03641 932 4201 (9)
Patienteneinverständniserklärung
Patienteneinverständniserklärung
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Molecular Monitoring Survey EUREKA
Eligibility Squamous Cell Carcinoma of the
Head and Neck NCT01528163
Study Comparing Two Treatments in Patients With
Recurrent or Metastatic Squamous Cell Carcinoma of the
Head and Neck; ODM derived from:
https://clinicaltrials.gov/show/NCT01528163
All rights reserved. Please visit https://medical-data-
models.org/forms/12859
Eligibility Squamous Cell Carcinoma
of the Head and Neck NCT01528163
Inclusion Criteria
1. recurrent and/or metastatic head and neck
squamous cell carcinoma not amenable to
curative treatment with surgery and/or
chemotherapy and/or radiation.*
Yes
No
2. at least one measurable lesion by mri or ct-
scan according to recist 1.1.*
Yes
No
3. progressive disease within 1 year after first line
platinum-based chemotherapy given either as a
part of the multimodal curative treatment or in the
palliative setting.*
Yes
No
4. ecog performance status 0 -2, in stable
medical condition*
Yes
No
5. patients must have an expected survival of at
least 3 months*
Yes
No
6. paraffin-embedded tumor tissue available for
immunohistochemistry but not mandatory*
Yes
No
7. patients must be over 18 years old and must
be able to give written informed consent.*
Yes
No
8. women of child-bearing age or sexually active
female patients with reproductive potential must
have a negative pregnancy test (serum or urine
within the 7 days prior to enrollment).*
Yes
No
9. patients must have adequate organ function
(hemoglobin ≥ 9 g/100 ml, neutrophils ≥
1,500/mm3, platelets ≥ 100,000/mm3,  total
bilirubin <1  time the upper limit of normal (uln)
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for age, serum alanine aminotransferase (alt) <
1.5 1.5 x uln  for age, aspartate aminotransferase
(ast) < 1.5  ´ uln for age , serum creatinine <1.5 x
uln for age.*
Yes
No
10. signed informed consent prior to beginning
protocol specific procedure.*
Yes
No
11. sexually active patients must use effective
contraception during the period of therapy and up
to 150 days after the last treatment dose.
acceptable contraception includes, but is not
limited to: oral hormone therapy, partner
vasectomy, or double barrier contraception (which
is defined as a male condom plus spermicide in
combination with either a female condom, or
diaphragm, or cervical cap or intrauterine
device)*
Yes
No
Exclusion Criteria
1. non-squamous head and neck cancer*
Yes
No
2. nasopharynx cancer*
Yes
No
3. more than two lines of chemotherapy for
palliative treatment*
Yes
No
4. surgery or investigational drugs or
chemotherapy within 4 weeks before study
inclusion. curative radiation therapy (60-70 gy)
within 8 weeks. for palliative radiation therapy (i.e
8 gy on a painful lesion) no delay is needed.*
Yes
No
5. previous treatment with cabazitaxel*
Yes
No
6. significant active cardiac disease including:
uncontrolled high blood pressure according to the
ctcae 4 grading, unstable angina, congestive
heart failure, myocardial infarction within the
previous 6 months, or serious cardiac
arrhythmias*
Yes
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No
7. other uncontrolled illnesses (active infections
requiring antibiotics, bleeding disorders,
uncontrolled diabetes …)*
Yes
No
8. previous malignancy from which the patient
has been disease-free for < 5years, as other than
scchn.*
Yes
No
9. previous treatments with taxanes and/or anti-
egfr therapy are not an exclusion criteria.*
Yes
No
10. active grade > 2 peripheral neuropathy*
Yes
No
11. active grade > 2 stomatitis*
Yes
No
12. known brain or leptomeningeal involvement*
Yes
No
13. history of severe hypersensitivity reaction (>
grade 3) to polysorbate 80 containing drugs*
Yes
No
14. concurrent or planned treatment with strong
inhibitors of cytochrome p450 3a/5. a one-week
washout period is necessary for patients who are
already on these treatments.*
Yes
No
15. organic brain syndrome or significant
psychiatric abnormality that would preclude
participation in the full protocol and follow up.*
Yes
No
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Eligibility Patients Undergoing Open Resection
of Colorectal Tumours NCT02136277
Vascular Changes During Colorectal Surgery; ODM derived
from: https://clinicaltrials.gov/show/NCT02136277
All rights reserved. Please visit https://medical-data-
models.org/forms/12860
Eligibility Patients Undergoing Open
Resection of Colorectal Tumours
NCT02136277
Inclusion Criteria
Patient age*
>= 18
<= 80
colorectal cancer*
Yes
No
Surgery*
Yes
No
No Neoplasm Metastasis*
Yes
No
Informed consent*
Yes
No
Exclusion Criteria
metastatic disease*
Yes
No
Esophageal Varices*
Yes
No
Patients with recent acute coronary syndrome
(symptoms involving the heart) or unstable
ischaemic cardiac disease (reduced blood supply
to the heart);*
Yes
No
Patients known to have right-to-left shunts
(abnormal movement of blood within the heart),
severe pulmonary hypertension (high blood
pressure in the pulmonary artery, the blood
vessel that leads from the heart to the lungs),
uncontrolled hypertension (high blood pressure)
or adult respiratory distress syndrome (severe
fluid build-up in both lungs);*
Yes
No
Pregnant or breast-feeding women*
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Yes
No
Known sensitivity to sonovue*
Yes
No
Long QT Syndrome*
Yes
No
2 / 2
Eligibility Patients Undergoing Open Resection of Colorectal Tumours
NCT02136277
Eligibility Stage II Prostate Carcinoma
NCT01618838
Endoscopic Evaluation of Late Rectal Injury Following
CyberKnife Radiosurgery for Prostate Cancer; ODM
derived from: https://clinicaltrials.gov/show/NCT01618838
All rights reserved. Please visit https://medical-data-
models.org/forms/12861
Eligibility Stage II Prostate
Carcinoma NCT01618838
Inclusion Criteria
histologically confirmed adenocarcinoma of the
prostate (biopsy within one year of enrollment)*
Yes
No
signed study-specific consent*
Yes
No
psa within 60 days of registration*
Yes
No
baseline aua/ ipss score of < 20*
Yes
No
candidate for screening colonoscopy*
Yes
No
pretreatment colonoscopy/lower endoscopy
done*
Yes
No
Exclusion Criteria
prior pelvic radiotherapy*
Yes
No
prior radical prostate surgery*
Yes
No
recent (within 5 years) or concurrent cancers
other than non-melanoma skin cancer*
Yes
No
implanted hardware adjacent to the prostate that
would prohibit appropriate treatment planning
and/or treatment delivery*
Yes
No
inflammatory bowel disease*
Yes
No
1 / 1
Eligibility Stage IIIB or IV Non-Small Cell
Lung Cancer NCT00473889
A Clinical Trial of Vorinostat (MK0683, SAHA) in
Combination With FDA Approved Cancer Drugs in Patients
With Advanced Non-Small Cell Lung Cancer
(NSCLC)(0683-056); ODM derived from:
https://clinicaltrials.gov/show/NCT00473889
All rights reserved. Please visit https://medical-data-
models.org/forms/12862
Eligibility Stage IIIB or IV Non-Small
Cell Lung Cancer NCT00473889
Inclusion Criteria
males and females at least 18 years of age who
have confirmed diagnosis of non-small cell lung
cancer*
Yes
No
patients with no systemic prior systemic
treatment for lung cancer except patients at least
12 months from prior adjuvant therapy*
Yes
No
adequate bone marrow,kidney and liver function*
Yes
No
must be recovered and at least 4 weeks from
major surgery or radiation*
Yes
No
ecog (eastern cooperative oncology group)
performance status of 0 or 1*
Yes
No
men and women must agree to use birth control
during the study*
Yes
No
women able to have children must have a
negative pregnancy test 14 days before study
enrollment*
Yes
No
Exclusion Criteria
patients with prior treatment with other
investigational agents less than 4 weeks before
study enrollment*
Yes
No
pregnant or nursing female patients*
Yes
No
patients who are hiv positive*
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Yes
No
patients who have hepatitis a, b, or c*
Yes
No
patients unable to take study medication by
mouth*
Yes
No
patients with untreated brain cancer*
Yes
No
patient eligible for treatment with bevacizumab
and for whom bevacizumab is available*
Yes
No
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Eligibility T-cell Lymphoma NCT02424045
Bendamustine, Carboplatin and Dexamethasone (BCD) for
Refractory or Relapsed Peripheral T-cell Lymphoma; ODM
derived from: https://clinicaltrials.gov/show/NCT02424045
All rights reserved. Please visit https://medical-data-
models.org/forms/12863
Eligibility T-cell Lymphoma
NCT02424045
Inclusion Criteria
1. histologically proven aggressive t-cell non-
hodgkin's lymphoma (nhl)*
Yes
No
2. age 18 -75 years*
Yes
No
3. ann arbor stage ii, iii and iv (appendix a)*
Yes
No
4. relapsed or refractory cases to previous
treatments*
Yes
No
5. performance status (ecog) ≤ 2 (appendix b)*
Yes
No
6. at least one or more bidimensionally
measurable lesion(s)*
Yes
No
≥ 2 cm by conventional ct*
Yes
No
≥ 1 cm by spiral ct*
Yes
No
skin lesion (photographs should be taken) ≥ 2
cm*
Yes
No
measurable lesion by physical examination ≥ 2
cm*
Yes
No
7. cardiac ejection fraction ≥ 50 % as measured
by muga or 2decho without clinically significant
abnormalities*
Yes
No
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8. adequate renal function: serum creatinine level
< 2 mg/dl (177 μmol/l)*
Yes
No
9. adequate liver functions: transaminase (ast/alt)
< 3 x upper normal value (or < 5 x uln in the
presence of dlbcl involvement of the liver),
bilirubin < 2 x upper normal value (or < 5 x uln in
the presence of ptcl involvement of the liver)*
Yes
No
10. adequate bm functions: hemoglobin ≥ 9 g/dl
absolute neutrophil count (anc) ≥ 1,500/μl and
platelet count ≥ 75,000/μl, unless abnormalities
are due to bone marrow involvement by
lymphoma*
Yes
No
11. a negative serum or urine pregnancy test
prior to treatment must be available both for pre-
menopausal women and for women who are <
1years after the onset of menopause.*
Yes
No
12. informed consent*
Yes
No
Exclusion Criteria
1. alk-positive anaplastic large cell lymphoma and
sezary syndrome.*
Yes
No
2. cns or testis involvement.*
Yes
No
3. previously treated with the regimen containing
bendamustine or platinum agents.*
Yes
No
4. any other malignancies within the past 5 years
except curatively treated non-melanoma skin
cancer or in situ carcinoma of cervix uteri*
Yes
No
5. pregnant or lactating women, women of
childbearing potential not employing adequate
contraception*
Yes
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No
6. other serious illness or medical conditions*
Yes
No
7. unstable cardiac disease despite treatment,
myocardial infarction within 6 months prior to
study entry*
Yes
No
8. history of significant neurologic or psychiatric
disorders including dementia or seizures*
Yes
No
9. active uncontrolled infection (viral, bacterial or
fungal infection)*
Yes
No
10. other serious medical illnesses*
Yes
No
11. known hypersensitivity to any of the study
drugs or its ingredients*
Yes
No
12. concomitant administration of any other
experimental drug under investigation, or
concomitant chemotherapy, hormonal therapy, or
immunotherapy.*
Yes
No
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Eligibility Treatment-resistant Depression
NCT02417064
A Study to Evaluate the Efficacy, Safety, and Tolerability of
Fixed Doses of Intranasal Esketamine Plus an Oral
Antidepressant in Adult Participants With Treatment-
resistant Depression; ODM derived from:
https://clinicaltrials.gov/show/NCT02417064
All rights reserved. Please visit https://medical-data-
models.org/forms/12868
Eligibility Treatment-resistant
Depression NCT02417064
Inclusion Criteria
at the time of signing the informed consent form
(icf), participant must be a man or woman 18 (or
older if the minimum legal age of consent in the
country in which the study is taking place is
greater than [>]18) to 64 years of age, inclusive*
Yes
No
at the start of the screening/prospective
observational phase, participant must meet the
diagnostic and statistical manual of mental
disorders (dsm-5) diagnostic criteria for single-
episode major depressive disorder (mdd) (if
single-episode mdd, the duration must be greater
than or equal to [>=] 2 years) or recurrent mdd,
without psychotic features, based upon clinical
assessment and confirmed by the mini-
international neuropsychiatric interview (mini)*
Yes
No
at the start of the screening/prospective
observational phase, participant must have an
inventory of depressive symptomatology-clinician
rated ( ids-c30) total score of greater than or
equal to (>=) 34*
Yes
No
at the start of the screening/prospective
observational phase, participants must have had
nonresponse to >=2 but less than or equal to (<=)
5 oral antidepressant treatments taken at
adequate dosage and for adequate duration, as
assessed using the massachusetts general
hospital - antidepressant treatment response
questionnaire (mgh-atrq) and documented by
medical history and pharmacy/prescription
records, for the current episode of depression.
participant must be taking an oral antidepressant
treatment with nonresponse at the start of the
screening/prospective observational phase.*
Yes
No
the participant's current major depressive
episode and treatment response to
antidepressant treatments used in the current
depressive episode (retrospectively assessed)
must be deemed valid for participation in a
clinical study based on a site-independent
1 / 2
qualification assessment*
Yes
No
Exclusion Criteria
participants who have previously demonstrated
nonresponse of depressive symptoms to
esketamine or ketamine in the current major
depressive episode, to all 4 of the oral
antidepressant treatment options available for the
double-blind induction phase (i.e, duloxetine,
escitalopram, sertraline, and venlafaxine
extended release [xr]) in the current major
depressive episode (based on mgh-atrq), or an
adequate course of treatment with
electroconvulsive therapy (ect) in the current
major depressive episode, defined as at least 7
treatments with unilateral ect*
Yes
No
participant currently has an implant for vagal
nerve stimulation (vns) or has received deep
brain stimulation (dbs) in the current episode of
depression*
Yes
No
participant has a current or prior dsm-5 diagnosis
of a psychotic disorder or mdd with psychosis,
bipolar or related disorders (confirmed by the
mini), comorbid obsessive compulsive disorder,
intellectual disability (only dsm-5 diagnostic code
319), borderline personality disorder, antisocial
personality disorder, histrionic personality
disorder, or narcissistic personality disorder*
Yes
No
participant has homicidal ideation/intent, per the
investigator's clinical judgment, or has suicidal
ideation with some intent to act within 6 months
prior to the start of the screening/prospective
observational phase, per the investigator's clinical
judgment or based on the columbia suicide
severity rating scale  (c-ssrs)*
Yes
No
participants with history of moderate or severe
substance or alcohol use disorder according to
dsm-5 criteria*
Yes
No
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Eligibility Type 1 Diabetes Mellitus
NCT02144337
Physical Activity in Children With Type 1 Diabetes Study;
ODM derived from:
https://clinicaltrials.gov/show/NCT02144337
All rights reserved. Please visit https://medical-data-
models.org/forms/12869
Eligibility Type 1 Diabetes Mellitus
NCT02144337
Inclusion Criteria
be aged between 9 and 11 years*
Yes
No
have a clinical diagnosis of type 1 diabetes
mellitus for at least 3 months*
Yes
No
be willing and able to comply with the study
protocol*
Yes
No
be physically able to participate in physical
activity*
Yes
No
have a parent/carer who provides informed
consent*
Yes
No
Exclusion Criteria
be under the age of 9 years and over the age of
11 years*
Yes
No
have been diagnosed with type 1 diabetes
mellitus for less than 3 months*
Yes
No
have an injury or physical health condition that
precludes their participation in physical activity*
Yes
No
have a psychiatric disorder that interferes with
provision of assent, completion of measurements,
intervention, or follow-up*
Yes
No
insufficient proficiency in english to comply with
treatment or provide data*
Yes
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No
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Eligibility Type 2 Diabetes Mellitus
NCT00942318
Efficacy of Continuous Subcutaneous Insulin Infusion
Versus Basal-bolus Multiple Daily Injections Regimen in
Type 2 Diabetes; ODM derived from:
https://clinicaltrials.gov/show/NCT00942318
All rights reserved. Please visit https://medical-data-
models.org/forms/12870
Eligibility Type 2 Diabetes Mellitus
NCT00942318
Inclusion Criteria
type 2 diabetes mellitus*
Yes
No
age > 18 years*
Yes
No
patients treated for at least 6 months by multiple
daily insulin injections associating long acting
insulin (at least 1 long acting insulin analog
injection-glargine or detemir- or at least 2 nph
insulin injections) plus mealtimes rapid acting
insulin injections (human or analogs) +/- oral
hypoglycemic agents.*
Yes
No
7,5% ≤ hba1c ≤ 10%*
Yes
No
patients able to perform self-monitoring blood
glucose (smbg) measurement and insulin
injections.*
Yes
No
smbg > 3/day*
Yes
No
Exclusion Criteria
diabetic retinopathy contraindicating glycemic
control intensification*
Yes
No
situation or pathology not allowing therapeutic
education program (blindness, deafness, low
language fluency…)*
Yes
No
situation or pathology not allowing insulin therapy
self-management and / or portable insulin pump
use (rheumatologic pathology, low visual acuity,
…)*
Yes
No
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recent (<3 month) serious pathology*
Yes
No
planned treatment or therapy able to induce long-
term glycemic control worsening*
Yes
No
long lasting (> 2 month) planned treatment with
glucocorticoids, octreotide, lanreotide or danazol*
Yes
No
pregnancy wish or ongoing pregnancy*
Yes
No
known haemoglobinopathy.*
Yes
No
creatinin clearance <30ml/min (mdrd formula).*
Yes
No
organ transplant.*
Yes
No
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Eligibility Type 2 Diabetes NCT00641251
DSS: Diabetes Surgery Study - Intensive Medical
Management of Type 2 Diabetes, With and Without Gastric
Bypass Surgery; ODM derived from:
https://clinicaltrials.gov/show/NCT00641251
All rights reserved. Please visit https://medical-data-
models.org/forms/12871
Eligibility Type 2 Diabetes
NCT00641251
Inclusion Criteria
1. age 30 to 67 years at eligibility visit.*
Yes
No
2. diagnosed with t2dm at least 6 months prior to
enrollment, under the active care of a doctor for
at least the six months prior to enrollment, and
hba1c ≥ 8.0 %.*
Yes
No
3. body mass index (bmi) ≥ 30.0 kg/m2 and ≤
39.9 kg/m2 at eligibility visit.*
Yes
No
4. willingness to accept random assignment to
either treatment group.*
Yes
No
5. expect to live or work within approximately one
hour's traveling time from the study clinic for the
duration of the two-year trial.*
Yes
No
6. willingness to comply with the follow-up
protocol and successful completion of the run-in
(described below).*
Yes
No
7. written informed consent.*
Yes
No
Exclusion Criteria
1. cardiovascular event (myocardial infarction,
acute coronary syndrome, coronary artery
angioplasty or bypass, stroke) in the past six
months.*
Yes
No
2. current evidence of congestive heart failure,
angina pectoris, or symptomatic peripheral
vascular disease.*
Yes
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No
3. cardiac stress test indicating that surgery or
imm would not be safe.*
Yes
No
4. pulmonary embolus or thrombophlebitis in the
past six months.*
Yes
No
5. cancer of any kind (except basal cell skin
cancer or cancer in situ) unless documented to
be disease-free for five years.*
Yes
No
6. significant anemia (hemoglobin 1.0 g or more
below normal range) or history of coagulopathy.*
Yes
No
7. serum creatinine ≥ 1.5 mg/dl.*
Yes
No
8. hba1c > 14.0%.*
Yes
No
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Eligibility Uncontrolled Hypertension
NCT01628172
Renal Sympathetic Denervation for the Management of
Chronic Hypertension; ODM derived from:
https://clinicaltrials.gov/show/NCT01628172
All rights reserved. Please visit https://medical-data-
models.org/forms/12872
Eligibility Uncontrolled Hypertension
NCT01628172
Inclusion Criteria
≥ 18 and ≤ 85 years of age*
Yes
No
uncontrolled hypertension (defined as sbp ≥ 140
mmhg during 24hr ambulatory bp monitoring)*
Yes
No
current treatment with ≥ 3 anti-hypertensive
drugs (including at least one diuretic)*
Yes
No
accessibility of renal vasculature*
Yes
No
ability to understand the requirements of the
study*
Yes
No
willingness to adhere to study restrictions and
comply with all post-procedural follow-up
requirements*
Yes
No
Exclusion Criteria
secondary cause of hypertension*
Yes
No
white coat hypertension*
Yes
No
estimated gfr < 45*
Yes
No
type 1 diabetes*
Yes
No
known renovascular abnormalities (eg, renal
artery stenosis, previous renal artery stenting or
angioplasty)*
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Yes
No
life expectancy <1 year for any medical condition*
Yes
No
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Eligibility Uncontrolled Hypertension
NCT01996033
EnligHTN German Observational Study; ODM derived
from: https://clinicaltrials.gov/show/NCT01996033
All rights reserved. Please visit https://medical-data-
models.org/forms/12873
Eligibility Uncontrolled Hypertension
NCT01996033
Inclusion Criteria
subject is planned to undergo a renal denervation
procedure for the treatment of hypertension*
Yes
No
subject is ≥18 years of age at time of consent*
Yes
No
subject must be able and willing to provide written
informed consent*
Yes
No
subject must be able and willing to comply with
the required follow-up schedule*
Yes
No
subject has office systolic blood pressure (sbp) ≥
140 mmhg*
Yes
No
subject has established hypertension (diagnosed
≥12 months prior to baseline) and is on a
guideline based drug regimen at a stable (≥ 14
days) and a fully tolerated dose consisting of ≥3
anti-hypertensive medications (including 1
diuretic), or subject has documented drug
intolerance to 2 or more of the 4 major classes of
anti-hypertensives (ace-i/ angiotensin receptor
blocker (arb), calcium channel blockers, beta
blockers, or diuretic) and is unable to take 3 anti-
hypertensive drugs*
Yes
No
Exclusion Criteria
subject has known significant renovascular
abnormalities such as renal artery stenosis >
30%*
Yes
No
subject has undergone prior renal angioplasty,
renal denervation, indwelling renal stents, and/or
abdominal aortic stent grafts*
Yes
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No
subject has a history of hemodynamically
significant valvular heart disease*
Yes
No
subject has blood clotting abnormalities*
Yes
No
subject life expectancy is < 12 months, as
determined by the study investigator*
Yes
No
subject is participating in another clinical study
which has the potential*
Yes
No
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Eligibility Unipolar Depression
NCT00369915
The Antidepressant Efficacy of the Anticholinergic
Scopolamine; ODM derived from:
https://clinicaltrials.gov/show/NCT00369915
All rights reserved. Please visit https://medical-data-
models.org/forms/12875
Eligibility Unipolar Depression
NCT00369915
Criteria
two groups of subjects will be recruited for
studies under this protocol: unipolar depressives
and bipolar depressives. subjects with unipolar or
bipolar depression appear to exhibit abnormal
cholinergic function during the depressed phase,
and no differences are hypothesized to exist
between mdd and bd depressives herein.
however, while bd subjects are more difficult to
recruit, the evidence for cholinergic abnormalities
has been particularly compelling for bd.
moreover, observations from our pilot study
suggest that scopolamine will improve symptoms
in both mdd and bd, a particularly persuasive
observation given bd notoriously has been
difficult to treat.  thus, the magnitude of this
serious clinical problem justifies the inclusion of
bd subjects.  therefore both groups will be
recruited.  however, bd type i subjects will be
included only if they are currently stable on
lithium or valproate to reduce the risks associated
with possible precipitation of mania.*
Yes
No
the presence of inclusion and exclusion criteria
will be established using both an unstructured
clinical interview with a psychiatrist and the
structured clinical interview for dsm-iv (scid).
family history of mental illness will be obtained
from the subject using the family interview of
genetic studies.  we will recruit 24 subjects per
group.*
Yes
No
depressed samples:  subjects (ages 18-55)
currently suffering from a major depressive
episode falling into one of the following
subgroups:*
Yes
No
1. .  major depressive disorder (mdd):  subjects
will be selected with primary mdd and are
currently depressed as defined by dsm-iv criteria
for recurrent mdd and current madrs score in the
moderately-to-severely depressed range (greater
than or equal to 20).  the duration of the index
episode is greater than or equal to four weeks.*
Yes
No
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2. .  bipolar disorder type ii (bd):  subjects will be
selected who meet dsm-iv criteria for bipolar
disorder type i or ii and are currently depressed,
with madrs score in the moderately-to-severely
depressed range (greater than or equal to 20).
the duration of the index episode is greater than
or equal to four weeks.*
Yes
No
Exclusion Criteria
subjects will be recruited who are drug-naive or
who have not received psychotropic drugs for at
least 3 weeks (8 weeks for fluoxetine) prior to
screening.  subjects also will be excluded if they
have: a) serious suicidal ideation or behavior, or
current delusions or hallucinations, b) inability to
provide informed consent, c) serious, unstable
illnesses including hepatic, renal,
gastroenterologic, respiratory, cardiovascular
(including ischemic heart disease,
endocrinologic, neurologic, immunologic, or
hematologic disease, d) a history of drug or
alcohol abuse within 6 months or alcohol or drug
dependence in the last five years (dsm iv criteria),
e) not using a medically accepted means of
contraception and are a woman of childbearing
potential, f) current pregnancy (documented by
pregnancy testing prior to each brain scan to
avoid exposing a fetus to radiation or to a
research mri scan that is not medically
necessary), g) current breast feeding, h) history
of ulcerative colitis or toxic megacolon, i) vision
and/or hearing problems severe enough to
interfere with testing, j) electrocardiographic
evidence of ischemia, arrhythmia, conduction
defect, or myocardial infarction, k) current blood
pressure of greater than 160 mm hg or less than
90 mm hg systolic, or greater than 90 mm hg
diastolic, l) clinically significant cerebrovascular or
cardiovascular disease, hypertension, congestive
heart disease, angina pectoris, clinic evidence of
cerebrovascular disease, gross neurological
impairment, hyperthyroidism, known
hypersensitivity or idiosyncracy to anticholinergic
agents (e.g. skin rashes), glaucoma, renal or
hepatic impairment,  m) current nicotine use or
nicotine dependence within last six months (due
to the effects of nicotine on the cholinergic
system)  n) narrow angle glaucoma (due to the
possibility of exacerbation of this condition by
scopolamine) o) age greater than 55 years (to
reduce the biological heterogeneity
encompassed by the mdd and bd criteria, since
subjects with a late age-at onset for depression
have a far greater likelihood of having mri
correlates of cerebrovascular disease than age-
matched, healthy controls or age-matched, early-
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onset depressives), p) exposure within two weeks
to medications likely to affect mood or cognition
or likely to interact with scopolamine (e.g.
narcotics or anti-cholinergic agents)- as verified
by history and urine drug screen, q) hiv positive
status, r) history of gastric or intestinal
obstructions, s) history of urinary retention or
bladder obstruction.  during the course of this
study, participants will be unable to take some
medications, including antidepressant or
antianxiety agents, sleep aids, diphenhydramine
(e.g. benedryl) or cough/cold preparations that
contain diphenhydramine or antihistamines. a
detailed list of allowed and not allowed
medications is provided in appendix b in the
protocol.*
Yes
No
we are not excluding comorbid anxiety disorders.
exclusion of patients with comorbid anxiety
disorders would affect the generalizability of our
findings since a substantial percentage of
patients with major depression have these
comorbid diagnoses.  instead, we will exclude
patients with this comorbid diagnosis only if it is
believed to be of clinical significance.  allowing
participation by patients with histories of
comorbid anxiety disorders broadens the
inclusion criteria to more closely approximate
patients seen in real world settings.*
Yes
No
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Eligibility Valvular Heart Disease
NCT02303795
RIvaroxaban for Valvular Heart disease and atRial
Fibrillation Trial -RIVER Trial; ODM derived from:
https://clinicaltrials.gov/show/NCT02303795
All rights reserved. Please visit https://medical-data-
models.org/forms/12876
Eligibility Valvular Heart Disease
NCT02303795
Inclusion Criteria
1. male and female patients aged >18 and < 80
years at time of inclusion*
Yes
No
2. patients with persistent or paroxysmal atrial
fibrillation  with bioprosthetic mitral valves.*
Yes
No
the patient must be able to give informed
consent*
Yes
No
Exclusion Criteria
1. cardiovascular-related conditions as known
presence of cardiac thrombus or tumor*
Yes
No
active endocarditis*
Yes
No
uncontrolled hypertension*
Yes
No
2. hemorrhage risk-related criteria*
Yes
No
active internal bleeding*
Yes
No
history of, or condition associated with, increased
bleeding risk*
Yes
No
3. concomitant conditions and therapies*
Yes
No
history of previous thromboembolism with high
risk of bleeding:*
Yes
No
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severe, disabling stroke (modified rankin score of
4-5, inclusive) within 3 months*
Yes
No
acute thromboembolic events or thrombosis
(venous/arterial) within the last 14 days prior to
randomization*
Yes
No
acute mi within the last 14 days prior to
randomization*
Yes
No
treatment with: chronic aspirin therapy > 100 mg
daily or dual antiplatelet therapy; intravenous
antiplatelets; fibrinolytics; anticipated need for
long-term treatment with a nonsteroidal
antiinflammatory drug; systemic treatment with a
strong inhibitor of cytochrome p450 3a4, such as
ketoconazole or protease inhibitors; treatment
with a strong inducer of cytochrome p450 3a4,
such as rifampicin, phenytoin, phenobarbital, or
carbamazepine.*
Yes
No
anemia*
Yes
No
pregnancy or breastfeeding or women of
reproductive age not using effective contraceptive
methods*
Yes
No
calculated creatinine clearance b30 ml/min*
Yes
No
known significant liver disease or alanine
aminotransferase n3× the upper limit of normal*
Yes
No
previous participation in this study.*
Yes
No
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Eligibility Venous Thromboembolism
NCT01119261
EUropean Pharmacogenetics of AntiCoagulant Therapy -
Acenocoumarol; ODM derived from:
https://clinicaltrials.gov/show/NCT01119261
All rights reserved. Please visit https://medical-data-
models.org/forms/12877
Eligibility Venous Thromboembolism
NCT01119261
Inclusion Criteria
patients with either venous thromboembolism
(vte) or atrial fibrillation (af) requiring coumarin
therapy for at least 12 weeks and a target inr in
the low intensity range (inr range 2-3 in the united
kingdom, sweden, germany, austria and greece
and inr 2.5-3.5 in the netherlands)*
Yes
No
age ≥ 18 years*
Yes
No
ability to attend scheduled visits*
Yes
No
signed informed consent*
Yes
No
Exclusion Criteria
presence of a mechanical heart valve*
Yes
No
severe cognitive impairment*
Yes
No
known genotype cyp2c9 or vkorc1 at start of the
study*
Yes
No
previous or current treatment with any coumarin*
Yes
No
pregnancy or lactation*
Yes
No
non-eligible subject*
Yes
No
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Eligibility Ventricular Tachycardia
NCT00787800
The Use of Dual Chamber ICD With Special Programmed
Features to Lower the Risk of Inappropriate Shock; ODM
derived from: https://clinicaltrials.gov/show/NCT00787800
All rights reserved. Please visit https://medical-data-
models.org/forms/12878
Eligibility Ventricular Tachycardia
NCT00787800
Inclusion Criteria
candidates for icd for primary prevention
according to  american heart
association/american college of cardiology
(aha/acc) guidelines who have a clinical
indication for icd implantation for ventricular
arrhythmia or sudden death prevention.*
Yes
No
the ability to understand the scope of the study,
provide written informed consent, and a
willingness to complete all study visits and
associated procedures.*
Yes
No
Exclusion Criteria
pregnant women*
Yes
No
age <18 years old*
Yes
No
inability to provide consent*
Yes
No
on a heart transplant waiting list*
Yes
No
life expectancy <1 year*
Yes
No
indication for pacing*
Yes
No
atrioventricular (av) node ablation*
Yes
No
permanent atrial fibrillation or atrial flutter*
Yes
No
indication for cardiac resynchronization*
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Yes
No
preexisting, separate pacemaker pulse generator
that won't be explanted*
Yes
No
intra-aortic balloon pump or other device*
Yes
No
inotropic drug (not digitalis) necessary for
hemodynamic support*
Yes
No
chronic serious bacterial infection*
Yes
No
inability to receive pectoral non-thoracotomy lead
icd*
Yes
No
inability to program device according to protocol*
Yes
No
history of out of hospital cardiac arrest (ohca) or
sustained ventricular tachycardia as an indication
for icd (secondary prevention indication)*
Yes
No
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Eligibility Ventricular Tachycardia NCT00787800
Eligibility Viral Hepatitis B NCT01953458
Therapeutic Option for Hepatitis B and C: a French Cohort;
ODM derived from:
https://clinicaltrials.gov/show/NCT01953458
All rights reserved. Please visit https://medical-data-
models.org/forms/12879
Eligibility Viral Hepatitis B
NCT01953458
Inclusion Criteria
hbv-positive patients*
Yes
No
chronic hepatitis b defined by a positive hbsag (
surface antigen of the hepatitis b virus) for at
least 6 months*
Yes
No
acute hepatitis b defined as a recent appearance
(<6 months) of detectable hbs ag,*
Yes
No
chronic hepatitis b with serological remission
hbsag-negative , hb dna-negative,*
Yes
No
with or without association with acute or chronic
hepatitis d.*
Yes
No
hcv-positive patients*
Yes
No
chronic hepatitis c defined by the positivity for
anti-hcv antibodies for at least 6 months and
positive hcv-rna*
Yes
No
acute hepatitis c defined by the recent
appearance of hcv rna (less than 6 months) in
patients with risk factors (with or without positive
antibodies)*
Yes
No
patients with cured hepatitis c defined by long-
term eradication, either spontaneous, a positive
anti-hcv antibodies associated to a negative rna
at two collection - 6 months interval time; either
treatment defined by negative viremia 3 month
after end of treatment.*
Yes
No
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Exclusion Criteria
hiv co-infected patients are not eligible to the
cohort.*
Yes
No
so-called vulnerable populations (minors, people
under guardianship or protection, or a private
individual under protection from making legal or
administrative decisions)*
Yes
No
treatment ongoing   during or stopped since less
than 3 months*
Yes
No
patients end of life*
Yes
No
woman whose pregnancy is known*
Yes
No
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Eligibility Viral Hepatitis B NCT01953458
Eligibility Acute Asthma NCT01079000
Emergency Department (ED)-Directed Interventions to
Improve Asthma Outcomes; ODM derived from:
https://clinicaltrials.gov/show/NCT01079000
All rights reserved. Please visit https://medical-data-
models.org/forms/12884
Eligibility Acute Asthma
NCT01079000
Inclusion Criteria
1. age 17-55 years old;*
Yes
No
2. patients treated and discharged from one of
the four study sites with acute asthma (not simply
for a prescription refill) during the study period;*
Yes
No
3. patients must have had a previous physician-
diagnosis of asthma and an exacerbation
diagnosed by the ed physician (e.g., past asthma
history, recorded response to β-agonists in the
ed, and increased asthma symptoms). in the
event of a new diagnosis, the patient is still
eligible for the study if the treating physician feels
that the history is compatible with a diagnosis of
asthma;*
Yes
No
4. patients must have evidence of airflow
obstruction on presentation at the ed, defined as
an fev1 or pef <80% of predicted;*
Yes
No
5. patients must not have a history of more than
20 pack-years of smoking;*
Yes
No
6. all patients should have a pcp (fp, nurse
practitioner or internist) with whom to follow-up or
attempts will be made to find one for them.*
Yes
No
Exclusion Criteria
these criteria ensure the exclusion of suspected
copd patients and patients who require different
treatments:*
Yes
No
1. patients with asthma who are primarily cared
for by a respirologist/pulmonologist;*
Yes
No
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2. patients not seen by an emergency physician
in the ed (e.g., direct referrals);*
Yes
No
3. physician diagnosis of acute copd (e.g., failure
of fev1 or pef to respond to ed treatment and a
fev1/fvc ratio ≤ 70%);*
Yes
No
4. radiologically confirmed pneumonia during the
10 days preceding trial entry;*
Yes
No
5. patients with an active history of
bronchiectasis, cystic fibrosis, or lung cancer;*
Yes
No
6. clinically confirmed congestive heart failure at
ed presentation;*
Yes
No
7. patients not able/unwilling to perform
spirometry assessment;*
Yes
No
8. inability to provide informed consent or comply
with the study protocol due to cognitive
impairment, language barrier, or no contact
details;*
Yes
No
9. patient has previously participated in the
study;*
Yes
No
10. patients who in the opinion of the investigator
are unsuitable for enrolment.*
Yes
No
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Eligibility Acute Asthma NCT01079000
Eligibility Alzheimer's Disease
NCT01454453
Optimisation of Antipsychotic Drug Use in Older People;
ODM derived from:
https://clinicaltrials.gov/show/NCT01454453
All rights reserved. Please visit https://medical-data-
models.org/forms/12885
Eligibility Alzheimer's Disease
NCT01454453
Inclusion Criteria
treatment and control (antipsychotic free) group*
Yes
No
schizophrenia*
Yes
No
meet diagnostic criteria for schizophrenia-like
illness*
Yes
No
aged between 60 and 95 years of age*
Yes
No
score <6 on the geriatric depression scale*
Yes
No
alzheimer's*
Yes
No
meet diagnostic criteria for ad*
Yes
No
score <=4 on the  modified hachinski ischaemia
scale*
Yes
No
score < 8 on a modified version of the updrs*
Yes
No
aged between 60 and 95 years of age*
Yes
No
score <6 on the geriatric depression scale*
Yes
No
Exclusion Criteria
treatment group*
Yes
No
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schizophrenia*
Yes
No
current or past history of addiction, traumatic
brain injury or epilepsy*
Yes
No
prescribed any drug that interferes with brain
dopamine in past 2 weeks (6 weeks if depot
antipsychotic medication).*
Yes
No
medical conditions that might affect ability to
tolerate a brain scan*
Yes
No
unable to give informed consent*
Yes
No
alzheimer's*
Yes
No
current or past history of psychiatric illness,
traumatic brain injury or epilepsy*
Yes
No
prescribed an antipsychotic or other oral drug
that interferes with brain dopamine function within
the past 2 weeks (6 weeks if depot antipsychotic
medication).*
Yes
No
medical conditions that might affect a person's
ability to tolerate a brain scan*
Yes
No
control (antipsychotic free) group*
Yes
No
schizophrenia*
Yes
No
prescribed psychotropic medication*
Yes
No
unable to give informed consent*
Yes
No
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Eligibility Alzheimer's Disease NCT01454453
alzheimer's*
Yes
No
• prescribed psychotropic medication*
Yes
No
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Eligibility Alzheimer's Disease NCT01454453
Eligibility Acute Myelogenous Leukemia
NCT00136422
Study of Vaccination With Autologous Acute Myeloblastic
Leukemia Cells in Patients With Advanced Myelodysplasia
or Acute Myelogenous Leukemia; ODM derived from:
https://clinicaltrials.gov/show/NCT00136422
All rights reserved. Please visit https://medical-data-
models.org/forms/12899
Eligibility Acute Myelogenous
Leukemia NCT00136422
Inclusion Criteria
patients must have pathologically documented
myelodysplasia or acute myelogenous leukemia.*
Yes
No
the patients with myelodysplasia must also have:
french-american-british (fab) subtype refractory
anemia with excess blasts (raeb) or refractory
anemia with excess blasts in transformation
(raeb-t), or normal or hypercellular bone marrow.*
Yes
No
the patients with acute myelogenous leukemia
must also: not be candidates for
myelosuppressive chemotherapy due to age or
comorbid disease, or have relapsed acute
myelogenous leukemia or be refractory to
standard therapy and not likely to require
cytoreductive therapy within 60 days*
Yes
No
eastern cooperative oncology group (ecog)
performance status 0 or 1.*
Yes
No
estimated life expectancy of 6 months or greater.*
Yes
No
age at least 18 years.*
Yes
No
greater than 4 weeks from any chemotherapy,
radiotherapy, immunotherapy, or systemic
glucocorticoid therapy (non-glucocorticoid
hormonal therapy allowed).*
Yes
No
greater than 2 months following bone marrow or
peripheral blood stem cell transplantation or
treatment with donor lymphocyte infusion (dli).*
Yes
No
Exclusion Criteria
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uncontrolled active infection.*
Yes
No
pregnancy or nursing mothers.*
Yes
No
previous participation in an adenovirus based
trial.*
Yes
No
the patients with myelodysplasia who have either:
fab subtype refractory anemia (ra), refractory
anemia with ringed sideroblasts (rars), chronic
myelomonocytic leukemia (cmml), or the
presence of hypocellular bone marrow.*
Yes
No
chemotherapy, radiotherapy, immunotherapy, or
systemic steroid therapy within the last 4 weeks.*
Yes
No
active central nervous system (cns) disease.*
Yes
No
evidence of infection with the human
immunodeficiency virus.*
Yes
No
active psychiatric or mental illness making
informed consent or careful clinical follow-up
unlikely.*
Yes
No
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Eligibility Arthritis NCT00153673
Effect of Selective COX-2 Inhibition on Ulcer Healing; ODM
derived from: https://clinicaltrials.gov/show/NCT00153673
All rights reserved. Please visit https://medical-data-
models.org/forms/12901
Eligibility Arthritis NCT00153673
Inclusion Criteria
gastric ulcers confirmed by endoscopy*
Yes
No
stop taking nsaids for 1 week prior to endoscopy*
Yes
No
age 18*
Yes
No
h. pylori negative*
Yes
No
informed written consent*
Yes
No
Exclusion Criteria
actively bleeding ulcers*
Yes
No
ulcers showing dysplasia or malignancy*
Yes
No
renal failure (serum creatinine >200umol/l)*
Yes
No
previous gastric surgery*
Yes
No
moribund or terminal malignancy*
Yes
No
concomitant use of proton pump inhibitor,
misoprostol, aspirin, steroid or anticoagulant*
Yes
No
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Eligibility Alzheimer Disease NCT00304629
Long-term Safety and Efficacy of Galantamine in
Alzheimer's Disease; ODM derived from:
https://clinicaltrials.gov/show/NCT00304629
All rights reserved. Please visit https://medical-data-
models.org/forms/12902
Eligibility Alzheimer Disease
NCT00304629
Inclusion Criteria
patients must have taken trial medication during
the 24-month trial period of gal-int-8 and should
be enrolled within 1 month after completion*
Yes
No
patients and their primary caregiver give informed
consent for the participation in the trial*
Yes
No
patients must have remained in good health, as
determined by medical history, complete physical
examination and laboratory tests*
Yes
No
Exclusion Criteria
if a patient developed, during the trial gal-int-8,
symptoms of other neurological or psychiatric
diseases that might contribute to dementia, the
subject cannot be enrolled.  this includes subjects
developing neurodegenerative disorders such as
parkinson's disease, pick's disease or
huntington's chorea, or creutzfeldt-jacob disease,
and subjects with cognitive impairment resulting
from stroke, acute cerebral trauma, hypoxic
cerebral damage, infection or primary or
metastatic cerebral neoplasia*
Yes
No
subjects with the following co-existing medical
conditions: a) any history of epilepsy or
convulsions except for febrile convulsions during
childhood b) peptic ulcer: if the ulcer is
considered to be still "active", i.e., if treatment for
this condition started <3 months ago or if
treatment is not successful (symptoms still
present), the subject is not eligible. c) clinically
significant hepatic, renal, pulmonary, metabolic or
endocrine disturbances*
Yes
No
patients with current, clinically significant
cardiovascular disease that would be expected to
limit the subject's ability to complete a 12-month
trial.  the following would usually be considered
clinically significant cardiovascular disease: a)
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unstable angina*
Yes
No
angina or coronary artery disease that required a
change in medication (anti-angina or digitalis)
within the last 3 months b) decompensated
congestive heart failure i.e. when symptoms
occur in a subject on stable medication during
rest or light exercise (nyha iii and iv).  note: if the
only signs of decompensation are pretibial or
malleolar oedema and the exercise tolerance is
still reasonable (absence of dyspnoea) the
subject should not be excluded c) cardiac
disease potentially resulting in syncope, near
syncope or other alterations of mental status*
Yes
No
in addition, the following conditions should lead to
exclusion: atrial fibrillation without prophylactic
treatment to prevent thromboembolic stroke,
bradycardia <50 beats/min., atrioventricular block
> first degree. d)  severe mitral or aortic valvular
disease e) hypotension or treatment for
hypotension f) systolic blood pressure greater
than 170 mmhg or diastolic blood pressure
greater than 110 mmhg*
Yes
No
patients using any agent for the treatment of
dementia (approved, experimental, including over
the counter agents), including, but not limited to
nootropic agents, cholinomimetic agents, choline,
oestrogens taken without medical need, chronic
nsaids (30 consecutive days), vitamin e more
than 30 iu daily, and deprenyl*
Yes
No
conditions that could interfere with the absorption
of the compound or with the evaluation of the
disease*
Yes
No
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Eligibility Arrhythmia NCT00627328
The Atrial High Rate Episodes in Pacemaker Patients;
ODM derived from:
https://clinicaltrials.gov/show/NCT00627328
All rights reserved. Please visit https://medical-data-
models.org/forms/12903
Eligibility Arrhythmia NCT00627328
Inclusion Criteria
patients undergoing a medtronic kappa dr 700 or
medtronic kappa 900 dr implant, for approved
indications*
Yes
No
no previous history of pacemaker implantation*
Yes
No
patients 50 years of age or older*
Yes
No
Exclusion Criteria
patients with a history of atrial tachyarrhythmias
(primary arm of study)*
Yes
No
patients with medical conditions that would limit
study participation*
Yes
No
patients inaccessible for follow-up at the study
center*
Yes
No
patients incapable of providing informed consent*
Yes
No
patients with nyha classification of iv*
Yes
No
patients with a history of neurocardiogenic
syncope, long qt syndrome, or hypertrophic
obstructive cardiomyopathy (hocm)*
Yes
No
patients taking sotalol or amiodorone*
Yes
No
patients with a history of a prior icd or pacemaker
implantation.*
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Yes
No
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Eligibility Arrhythmia NCT00627328
Eligibility Asthma NCT01161303
An Investigation of Tumor Necrosis Factor (TNF)-Alpha in
Asthma Using Biopsy Explants and Primary Bronchial
Epithelial Cell Cultures; ODM derived from:
https://clinicaltrials.gov/show/NCT01161303
All rights reserved. Please visit https://medical-data-
models.org/forms/12904
Eligibility Asthma NCT01161303
Inclusion Criteria
moderately severe asthmatics*
Yes
No
male or female*
Yes
No
uses inhaled beclomethasone 400-1000 mcg or
equivalent*
Yes
No
documented positive skin test to common
allergens and*
Yes
No
fev1 of >60% predicted*
Yes
No
Exclusion Criteria
smokers*
Yes
No
subjects with an acute asthmatic episode in the
last 6 weeks*
Yes
No
other significant clinical illnesses*
Yes
No
pregnant women*
Yes
No
those sensitive to lignocaine*
Yes
No
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Eligibility Breast Cancer NCT00005908
Primary Chemotherapy With Docetaxel-Capecitabine and
Doxorubicin-Cyclophosphamide in Breast Cancer; ODM
derived from: https://clinicaltrials.gov/show/NCT00005908
All rights reserved. Please visit https://medical-data-
models.org/forms/12935
Eligibility Breast Cancer
NCT00005908
Criteria
stage ii or iii breast cancer with a tumor size of
greater than 2 cm.  patients with a previous
biopsy are eligible provided adequate tumor
tissue remains for biopsy in this study.*
Yes
No
at least 18 years of age.*
Yes
No
adequate hematopoietic function as defined by
absolute neutrophil count greater than
1200/mm^3 and platelet count greater than
100,000/mm^3.*
Yes
No
adequate renal function as defined by creatinine
less than 1.6 mg/dl.*
Yes
No
adequate hepatic function as defined by total (t.)
bilirubin less than 1.4 mg/dl and serum glutamic
oxaloacetic transaminase (sgot)/serum glutamic
pyruvic transaminase (sgpt) less than 1.5 times
the upper limit of normal and alkaline
phosphatase less than 2.5 times upper limit of
normal*
Yes
No
zubrod performance status 0-2.*
Yes
No
Exclusion Criteria
medical or psychiatric condition that, in the
opinion of the principal investigator, would
preclude chemotherapy administration.  patients
may be evaluated by psychiatry or medical
subspecialties as appropriate.*
Yes
No
pregnant or lactating women*
Yes
No
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known bleeding disorders*
Yes
No
hypersensitivity to tween 80 (polysorbate)*
Yes
No
cardiac ejection fraction below normal limits,
myocardial infarction within the past 12 months,
or symptomatic arrhythmia requiring medical
intervention.*
Yes
No
prior chemotherapy or hormonal therapy for
breast cancer.  patients treated with hormonal
chemoprevention (tamoxifen or raloxifene) will be
eligible.*
Yes
No
active malignancy diagnosed within the last 5
years.  (cervical cancer or non-melanomatous
skin cancer that has been treated with curative
intent will be eligible).*
Yes
No
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Eligibility Breast Cancer NCT00005605
Tamoxifen to Prevent Bone Loss and Heart Disease in
Premenopausal Women Receiving Chemotherapy for
Stage I or Stage II Breast Cancer; ODM derived from:
https://clinicaltrials.gov/show/NCT00005605
All rights reserved. Please visit https://medical-data-
models.org/forms/12936
Eligibility Breast Cancer
NCT00005605
Criteria
histologically proven stage i or ii breast cancer*
Yes
No
must be scheduled to receive adjuvant
chemotherapy with or without tamoxifen*
Yes
No
age: 35 to 50*
Yes
No
sex: female*
Yes
No
menopausal status: premenopausal by follicle-
stimulating hormone and estradiol levels*
Yes
No
not pregnant*
Yes
No
prior concurrent therapy:*
Yes
No
chemotherapy: see disease characteristics*
Yes
No
endocrine therapy: see disease characteristics*
Yes
No
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Eligibility Breast Cancer NCT00006346
Stress Reduction in Older Women With Stage II, Stage III,
or Stage IV Breast Cancer; ODM derived from:
https://clinicaltrials.gov/show/NCT00006346
All rights reserved. Please visit https://medical-data-
models.org/forms/12957
Eligibility Breast Cancer
NCT00006346
Criteria
diagnosis of stage ii, iii, or iv breast cancer*
Yes
No
no brain or cns metastases*
Yes
No
age: 55 and over*
Yes
No
sex: female*
Yes
No
performance status: ecog 0-2*
Yes
No
life expectancy: more than 3 months*
Yes
No
no non-cancer life-threatening illness*
Yes
No
no history of major psychiatric disorders*
Yes
No
no drug abuse dependency disorder*
Yes
No
prior concurrent therapy:*
Yes
No
1 / 1
Eligibility Breast Cancer NCT00006346
Stress Reduction in Older Women With Stage II, Stage III,
or Stage IV Breast Cancer; ODM derived from:
https://clinicaltrials.gov/show/NCT00006346
All rights reserved. Please visit https://medical-data-
models.org/forms/12958
Eligibility Breast Cancer
NCT00006346
Criteria
diagnosis of stage ii, iii, or iv breast cancer*
Yes
No
no brain or cns metastases*
Yes
No
age: 55 and over*
Yes
No
sex: female*
Yes
No
performance status: ecog 0-2*
Yes
No
life expectancy: more than 3 months*
Yes
No
no non-cancer life-threatening illness*
Yes
No
no history of major psychiatric disorders*
Yes
No
no drug abuse dependency disorder*
Yes
No
prior concurrent therapy:*
Yes
No
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Eligibility Breast Cancer NCT00033514
Trastuzumab and Erlotinib as First-Line Therapy in Treating
Women With Metastatic Breast Cancer Associated With
HER2/Neu Overexpression; ODM derived from:
https://clinicaltrials.gov/show/NCT00033514
All rights reserved. Please visit https://medical-data-
models.org/forms/12959
Eligibility Breast Cancer
NCT00033514
Inclusion Criteria
women aged > 18 years*
Yes
No
histologically documents metastatic breast
cancer*
Yes
No
her2 positive using fish*
Yes
No
for phase i, patients who have previously received
treatment for their metastatic disease are allowed
to participate.*
Yes
No
for the phase ii portion of the study, patients must
have measureable disease (> 2 cm; > 1 cm on
spiral ct scan)*
Yes
No
ecog performance status of 0 to 2*
Yes
No
a life expectancy of  > 3 months*
Yes
No
use of effective means of contraception*
Yes
No
Exclusion Criteria
for phase ii, prior cytotoxic chemotherapy and/or
prior herceptin for their metastatic disease.  prior
treatment in the adjuvant setting is allowed.*
Yes
No
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Eligibility Breast Cancer NCT00193024
Epirubicin and Docetaxel in the Treatment of Patients With
Metastatic Breast Cancer; ODM derived from:
https://clinicaltrials.gov/show/NCT00193024
All rights reserved. Please visit https://medical-data-
models.org/forms/12961
Eligibility Breast Cancer
NCT00193024
Inclusion Criteria
metastatic breast cancer confirmed by biopsy.*
Yes
No
received no previous chemotherapy for metastatic
breast cancer.*
Yes
No
prior hormonal therapy is acceptable.*
Yes
No
measurable or evaluable disease.*
Yes
No
able to perform activities of daily living without
considerable assistance*
Yes
No
adequate bone marrow, liver and kidney function*
Yes
No
must be able to understand the nature of this
study and give written informed consent.*
Yes
No
Exclusion Criteria
age < 18 years.*
Yes
No
cardiac ejection fraction < 45%.*
Yes
No
women who are pregnant or lactating.*
Yes
No
patients with meningeal metastases are
ineligible.*
Yes
No
moderate peripheral neuropathy*
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Yes
No
history of hypersensitivity reaction to taxotere*
Yes
No
males with metastatic breast cancer*
Yes
No
please note:  there are additional
inclusion/exclusion criteria.  the study center will
determine if you meet all of the criteria.  if you do
not qualify for the trial, study personnel will
explain the reasons.  if you do qualify, study
personnel will explain the trial in detail and
answer any questions you may have.*
Yes
No
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Eligibility Breast Cancer NCT00193037
Doxorubicin HCI Liposome Injection Versus Weekly
Docetaxel in Patients First Relapse Metastatic Breast
Cancer; ODM derived from:
https://clinicaltrials.gov/show/NCT00193037
All rights reserved. Please visit https://medical-data-
models.org/forms/12962
Eligibility Breast Cancer
NCT00193037
Inclusion Criteria
metastatic breast cancer confirmed by biopsy*
Yes
No
prior adjuvant/neoadjuvant treatment allowed*
Yes
No
measurable disease*
Yes
No
able to perform activities of daily living with
minimal assistance*
Yes
No
age 18 years or older*
Yes
No
adequate bone marrow, liver and kidney function*
Yes
No
normal heart function*
Yes
No
written informed consent*
Yes
No
Exclusion Criteria
pre-existing moderate peripheral neuropathy*
Yes
No
history of significant heart disease*
Yes
No
meningeal metastases.*
Yes
No
prior chemotherapy for metastatic breast cancer*
Yes
No
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no measurable disease (including bone only,
pleural effusions, etc.)*
Yes
No
receiving herceptin therapy.*
Yes
No
women who are pregnant or lactating.*
Yes
No
please note:  there are additional
inclusion/exclusion criteria.  the study center will
determine if you meet all of the criteria.  if you do
not qualify for the trial, study personnel will
explain the reasons.  if you do qualify, study
personnel will explain the trial in detail and
answer any questions you may have.*
Yes
No
2 / 2
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Eligibility Breast Cancer NCT00193050
Weekly Gemcitabine, Epirubicin, and Docetaxel in Locally
Advanced or Inflammatory Breast Cancer; ODM derived
from: https://clinicaltrials.gov/show/NCT00193050
All rights reserved. Please visit https://medical-data-
models.org/forms/12963
Eligibility Breast Cancer
NCT00193050
Inclusion Criteria
adenocarcinoma of the breast confirmed by
biopsy*
Yes
No
female patients >18 years of age*
Yes
No
normal cardiac function*
Yes
No
ability to perform activities of daily living with
minimal assistance*
Yes
No
chemotherapy naïve or have received prior
chemotherapy > 5 years ago*
Yes
No
adequate bone marrow, liver and kidney function*
Yes
No
be informed of the investigational nature of this
study*
Yes
No
sign an informed consent form*
Yes
No
sentinel lymph node and/or axillary dissection
prior to enrollment*
Yes
No
Exclusion Criteria
life expectancy of < than 6 months*
Yes
No
history of significant heart disease*
Yes
No
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prior chemotherapy or hormonal therapy*
Yes
No
concurrent trastuzumab therapy*
Yes
No
history of significant psychiatric disorders*
Yes
No
history of active uncontrolled infection*
Yes
No
please note:  there are additional
inclusion/exclusion criteria.  the study center will
determine if you meet all of the criteria.  if you do
not qualify for the trial, study personnel will
explain the reasons.  if you do qualify, study
personnel will explain the trial in detail and
answer any questions you may have.*
Yes
No
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Eligibility Breast Cancer NCT00193063
Weekly Gemcitabine and Trastuzumab in the Treatment of
Patients With Human Epidermal Growth Factor Receptor 2
(HER2) Positive Metastatic Breast Cancer; ODM derived
from: https://clinicaltrials.gov/show/NCT00193063
All rights reserved. Please visit https://medical-data-
models.org/forms/12964
Eligibility Breast Cancer
NCT00193063
Inclusion Criteria
her-2 positive metastatic breast cancer confirmed
by biopsy*
Yes
No
measurable disease*
Yes
No
able to perform activities of daily living without
considerable*
Yes
No
no previous chemotherapy with gemcitabine*
Yes
No
no more than one prior chemotherapy regimen
for metastatic breast cancer*
Yes
No
adequate bone marrow, liver and renal function*
Yes
No
normal heart function*
Yes
No
give written informed consent prior to entering
this study.*
Yes
No
Exclusion Criteria
received previous treatment with gemcitabine*
Yes
No
history of brain metastases*
Yes
No
serious underlying medical conditions*
Yes
No
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please note:  there are additional
inclusion/exclusion criteria.  the study center will
determine if you meet all of the criteria.  if you do
not qualify for the trial, study personnel will
explain the reasons.  if you do qualify, study
personnel will explain the trial in detail and
answer any questions you may have.*
Yes
No
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Eligibility Breast Cancer NCT00193089
Docetaxel, Vinorelbine and Trastuzumab in the Treatment
of Patients With Metastatic Her-2 Positive Breast Cancer;
ODM derived from:
https://clinicaltrials.gov/show/NCT00193089
All rights reserved. Please visit https://medical-data-
models.org/forms/12965
Eligibility Breast Cancer
NCT00193089
Inclusion Criteria
metastatic breast cancer confirmed by biopsy*
Yes
No
overexpression of the her-2 oncogene*
Yes
No
age > 18 years*
Yes
No
measurable disease*
Yes
No
able to perform activities of daily living with
minimal assistance*
Yes
No
no previous chemotherapy for metastatic
disease*
Yes
No
one or more previous hormonal therapies for
metastatic disease.*
Yes
No
adequate bone marrow, liver and kidney function*
Yes
No
patients with < grade 1 peripheral neuropathy are
eligible.*
Yes
No
must give written informed consent prior to
entering this study.*
Yes
No
Exclusion Criteria
abnormal heart function*
Yes
No
1 / 2
previous treatment with trastuzumab*
Yes
No
brain metastases untreated*
Yes
No
pre-existing symptomatic peripheral neuropathy*
Yes
No
serious underlying medical conditions*
Yes
No
please note:  there are additional
inclusion/exclusion criteria.  the study center will
determine if you meet all of the criteria.  if you do
not qualify for the trial, study personnel will
explain the reasons.  if you do qualify, study
personnel will explain the trial in detail and
answer any questions you may have.*
Yes
No
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ACNS0122 Neurologic Assessment
Worksheet NCT00047320
ACNS0122 Neurologic Assessment Worksheet
NCT00047320 
Neoadjuvant Chemotherapy With or Without Second-Look
Surgery Followed by Radiation Therapy With or Without
Peripheral Stem Cell Transplantation in Treating Patients
With Intracranial Germ Cell Tumors
Source Form: NCI FormBuilder:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsActio
n.do?method=getFormDetails&formIdSeq=BE457FF2-
45E3-1E0F-E034-0003BA12F5E7
All rights reserved. Please visit https://medical-data-
models.org/forms/12967
ACNS0122 Neurologic Assessment
Worksheet NCT00047320
Header
Institution Name
COG Study No.
COG Study No.
COG Patient ID
Patient Initials
Today's date
Date worksheet entered into RDE
Neurologic Assessment
Neurologic Assessment performed
Off Treatment (End of Ttherapy)
Follow-up (Follow-up)
Not Done (Not Done)
On Study (On Study)
Other, Specify (Other, specify)
What is the date of the examination?
Mental Status
Level of consciousness
Abnormal (Abnormal)
Normal (Normal)
Unknown/not Tested (Unknown/Not
tested)
Global cognitive function
Abnormal (Abnormal)
Normal (Normal)
Unknown/not Tested (Unknown/Not
tested)
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Speech and language
Abnormal (Abnormal)
Normal (Normal)
Unknown/not Tested (Unknown/Not
tested)
Personality Change
No (No)
Unknown (Unknown/Not tested)
Yes (Yes)
Cranial Nerves
Visual
Abnormal (Abnormal)
Normal (Normal)
Unknown/not Tested (Unknown/Not
tested)
Eye movement
Abnormal (Abnormal)
Normal (Normal)
Unknown/not Tested (Unknown/Not
tested)
Facial sensation
Abnormal (Abnormal)
Normal (Normal)
Unknown/not Tested (Unknown/Not
tested)
Hearing
Abnormal (Abnormal)
Normal (Normal)
Unknown/not Tested (Unknown/Not
tested)
Gag
Abnormal (Abnormal)
Normal (Normal)
Unknown/not Tested (Unknown/Not
tested)
Tongue
Abnormal (Abnormal)
Normal (Normal)
Unknown/not Tested (Unknown/Not
tested)
Motor
Strength
Abnormal (Abnormal)
Normal (Normal)
Unknown/not Tested (Unknown/Not
tested)
Tone
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Abnormal (Abnormal)
Normal (Normal)
Unknown/not Tested (Unknown/Not
tested)
Reflexes
Abnormal (Abnormal)
Normal (Normal)
Unknown/not Tested (Unknown/Not
tested)
Sensory function
Abnormal (Abnormal)
Normal (Normal)
Unknown/not Tested (Unknown/Not
tested)
Cerebellar/Basal Ganglia
Abnormal (Abnormal)
Normal (Normal)
Unknown/not Tested (Unknown/Not
tested)
Comments
Comments
3 / 3
ACNS0122 Neurologic Assessment Worksheet NCT00047320
Eligibility Breast Cancer NCT00109785
PET Scans in Patients With Locally Advanced Breast
Cancer; ODM derived from:
https://clinicaltrials.gov/show/NCT00109785
All rights reserved. Please visit https://medical-data-
models.org/forms/12976
Eligibility Breast Cancer
NCT00109785
Criteria
histologically confirmed locally advanced breast
carcinoma*
Yes
No
stage t3 t4, n2 or n3 disease*
Yes
No
18 and over*
Yes
No
male or female*
Yes
No
karnofsky 80-100%*
Yes
No
no history of psychiatric illness that would
preclude giving informed consent*
Yes
No
not pregnant*
Yes
No
fertile patients must use effective contraception*
Yes
No
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Eligibility Breast Neoplasms NCT00138814
Boost Use in Breast Conservation Radiotherapy; ODM
derived from: https://clinicaltrials.gov/show/NCT00138814
All rights reserved. Please visit https://medical-data-
models.org/forms/12977
Eligibility Breast Neoplasms
NCT00138814
Inclusion Criteria
histologically proven carcinoma of the breast, t1-2
(0-5cm) n0-1, m0.*
Yes
No
pure ductal carcinoma in situ accepted if
completely excised.*
Yes
No
any receptor status.*
Yes
No
extensive intraductal cancer (eic) accepted if
completely excised.*
Yes
No
Exclusion Criteria
unable to consent*
Yes
No
vascular/collagen disorder*
Yes
No
prior malignancy except minor skin squamous
cell or basal cell carcinoma or carcinoma in-situ
of the cervix .*
Yes
No
gross multifocal disease*
Yes
No
involvement of margins.*
Yes
No
bilateral breast cancer*
Yes
No
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Eligibility Breast Cancer NCT00193102
Thalidomide in Combination With Capecitabine in Patients
With Metastatic Breast Cancer; ODM derived from:
https://clinicaltrials.gov/show/NCT00193102
All rights reserved. Please visit https://medical-data-
models.org/forms/12978
Eligibility Breast Cancer
NCT00193102
Inclusion Criteria
metastatic breast cancer confirmed by biopsy*
Yes
No
measurable or evaluable disease*
Yes
No
females > 18 years*
Yes
No
able to perform activities of daily living with
minimal assistance*
Yes
No
life expectancy > 3 months*
Yes
No
adequate bone marrow, liver and kidney function*
Yes
No
all patients must give written informed consent in
order to participate.*
Yes
No
Exclusion Criteria
women who are pregnant or lactating.*
Yes
No
received more than 3 prior chemotherapy
regimens in the metastatic setting.*
Yes
No
received continuous infusion 5-fluorouracil lasting
> 120 hours.*
Yes
No
received thalidomide or capecitabine as their last
prior regimen.*
Yes
No
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preexisting moderate to severe neuropathy*
Yes
No
please note:  there are additional
inclusion/exclusion criteria.  the study center will
determine if you meet all of the criteria.  if you do
not qualify for the trial, study personnel will
explain the reasons.  if you do qualify, study
personnel will explain the trial in detail and
answer any questions you may have.*
Yes
No
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Eligibility Breast Cancer NCT00198250
Venlafaxine for Hot Flashes After Breast Cancer; ODM
derived from: https://clinicaltrials.gov/show/NCT00198250
All rights reserved. Please visit https://medical-data-
models.org/forms/12979
Eligibility Breast Cancer
NCT00198250
Inclusion Criteria
women at least 21 years of age*
Yes
No
willing and able to provide informed consent*
Yes
No
first time diagnosis of breast cancer*
Yes
No
no other history of cancer*
Yes
No
considered disease free at time of study
enrollment*
Yes
No
at least four weeks post-completion of surgery,
radiation, and/or chemotherapy for non-
metastatic cancer*
Yes
No
experiencing daily hot flashes*
Yes
No
desirous of treatment for hot flashes, but not
concurrently using any other hot flash treatments*
Yes
No
living within 60 miles of indianapolis*
Yes
No
able to read, write and speak english*
Yes
No
Exclusion Criteria
current treatment with antidepressants for
depression, neuropathic pain or hot flashes*
Yes
No
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diagnosis of metastatic breast cancer (stage iv)*
Yes
No
treatment for hot flashes within the past four
weeks, including (a) soy supplements; (b)
botanicals, such as dong quai (angelica sinensis),
black cohosh, ginseng, gotu kola, licorice root,
chaste tree, sage, or  wild yam root; (c) vitamin e;
or (d) prescription medications, such as clonidine
hydrochloride  or megestrol acetate.*
Yes
No
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Eligibility Breast Cancer, Metastatic
NCT00167414
Study for Using Radiosurgery on Limited Metastases of
Breast Cancer; ODM derived from:
https://clinicaltrials.gov/show/NCT00167414
All rights reserved. Please visit https://medical-data-
models.org/forms/12980
Eligibility Breast Cancer, Metastatic
NCT00167414
Inclusion Criteria
age: no limit*
Yes
No
karnofsky performance status (kps) ≥ 70*
Yes
No
no more than 5 metastatic sites involving one or
more different organs (liver, lung or bone).*
Yes
No
the size of the lesion must be such that it can be
safely treated to sterilizing radiation doses
according to the rules in the protocol.*
Yes
No
previously treated lesions are not eligible unless
the prescribed dose can be safely delivered.*
Yes
No
concurrent therapy is allowed and recommended.
the chemotherapy protocol type and schedule are
at the discretion of the medical oncologist.*
Yes
No
informed consent must be obtained.*
Yes
No
pregnancy test must be negative for women of
child bearing potential*
Yes
No
Exclusion Criteria
inability of patient to be followed longitudinally as
specified by protocol.*
Yes
No
technical inability to achieve required dose based
on safe dose constraints required for
radiosurgery.*
Yes
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No
women who are pregnant or nursing.*
Yes
No
failure to meet requirements in inclusion criteria*
Yes
No
contraindications to radiation.*
Yes
No
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Eligibility Breast Neoplasms NCT00301548
Perioperative Chemotherapy After Primary Chemotherapy
for Locally Advanced Breast Cancer; ODM derived from:
https://clinicaltrials.gov/show/NCT00301548
All rights reserved. Please visit https://medical-data-
models.org/forms/12982
Eligibility Breast Neoplasms
NCT00301548
Inclusion Criteria
patients with  breast cancer histologically proven
> 2 cm, er and pgr <20% or any er and pgr
absent (t2,t3 n0-2, m0)*
Yes
No
no treatment  with  previous
chemotherapy/hormonotherapy*
Yes
No
performance status 0-2 (ecog scale, appendix 2)*
Yes
No
measurable or evaluable lesions*
Yes
No
age between 18-70 years*
Yes
No
no significant intercurrent illness such as
diabetes, cardiovascular,     renal or neurologic
impairments*
Yes
No
absence of psychiatric illness*
Yes
No
wbc > 4,000/mm3; plts > 100,000/mm3*
Yes
No
ast, alt, ldh, gamma-gt < 2.5 x upper limit of
normal and      bilirubin < 3 mg/100 ml*
Yes
No
informed consent obtained*
Yes
No
pregnancy test (in fertile women). an effective
contraceptive      method must be utilized by
fertile women.*
Yes
No
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baseline examinations (chest x ray, ct scan, ecg
etc) performed     within one month prior initiation
to therapy*
Yes
No
Exclusion Criteria
uncontrolled infection and metabolite disease*
Yes
No
distant metastases*
Yes
No
active peripheric and/or central neurological
disease*
Yes
No
active cardiac disease defined as chf (nyha iii-iv)
significant arrhytmias, bilateral bundle branch
block or recent (less than 3 months) history of
myocardial infarction*
Yes
No
history of second malignancy (exception in situ
carcinoma of the uterine cervix and basal or
squamous cell carcinoma of the skin)*
Yes
No
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Eligibility Carcinoma Breast NCT01849133
Randomized Trial on Intraoperative Radiotherapy Full Dose
Vs External Radiotherapy; ODM derived from:
https://clinicaltrials.gov/show/NCT01849133
All rights reserved. Please visit https://medical-data-
models.org/forms/12983
Eligibility Carcinoma Breast
NCT01849133
Inclusion Criteria
age ≥ 48 and < 75*
Yes
No
clinical mammographic/ultrasound diagnosis of
unicentric carcinoma, with ultrasound diameter
≤2.5 cm. advisable, but not mandatory, the
execution of mammoscintigraphy with mdp-99mtc
(methyl diphosphonate technetium-99m) : this
procedure allows the bone staging and the
mapping of eventual multi-focality/multi-centricity
of the breast neoplasm.*
Yes
No
no previous therapy (biopsy included) for breast
cancer in other institutions.*
Yes
No
patients with non-palpable lesions will undergo
preoperative centering and stereotactic and/or
ultrasound-guided cytology (the execution of this
last procedure is not mandatory).*
Yes
No
adequate information to the patient and informed
consent.*
Yes
No
Exclusion Criteria
ductal or lobular non-infiltrating carcinoma.*
Yes
No
paget disease.*
Yes
No
tumor in close proximity to the skin.*
Yes
No
tumor in the axillary tail.*
Yes
No
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documented multi-centricity/multi-focality of the
tumor.*
Yes
No
patients who underwent excisional biopsy in other
institutions.*
Yes
No
histology different from carcinoma.*
Yes
No
personal anamnesis positive for malignancy
(basocellular carcinoma, in situ carcinoma of the
cervix, contralateral breast cancer free of disease
after 15 years of follow-up excluded).*
Yes
No
general contraindications to regular follow-up or
radiotherapy.*
Yes
No
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Eligibility Carcinoma NCT00034879
Iressa Expanded Access Program (EAP); ODM derived
from: https://clinicaltrials.gov/show/NCT00034879
All rights reserved. Please visit https://medical-data-
models.org/forms/12984
Eligibility Carcinoma NCT00034879
Inclusion Criteria
previous documented histologically or
cytologically confirmed non-small cell lung
cancer;*
Yes
No
locally advanced and/or metastatic non-operable
non-small cell lung cancer (stage iii or iv)patients
who have received at least one course of
standard systemic chemotherapy or radiation
therapy or are ineligible for chemotherapy or
radiotherapy or are ineligible or not a candidate
for enrollment on another zd1839 trial or who, in
the investigator's opinion, are not medically
suitable for chemotherapy.*
Yes
No
age 18 years or older;*
Yes
No
written informed consent to participate in the
trial.*
Yes
No
Exclusion Criteria
receiving concurrent radiotherapy, chemotherapy,
or other systemic anti-cancer medication or any
other investigational agent.    * non-cytotoxic or
hormonal therapies for the adjuvant treatment of
cancer or for previously treated cancers may be
allowed per astrazeneca permission;*
Yes
No
patients eligible for or previously enrolled on a
zd1839 blinded clinical trial protocol. patients
eligible for or previously enrolled on an open-label
or unblinded zd1839 clinical trial may be
considered for acceptance into the expanded
access program with astrazeneca permission;*
Yes
No
having other active malignancies;*
Yes
No
incomplete healing from previous oncologic or
1 / 2
other major surgery;*
Yes
No
evidence of any other significant clinical disorder
or laboratory finding that makes it undesirable for
the patient to participate in the trial;*
Yes
No
pregnancy or breast feeding (women of child-
bearing potential).*
Yes
No
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Eligibility Carcinoma of Unknown Primary
NCT00148135
Combination of Carboplatin, Gemcitabine, and
Capecitabine in Patients With Carcinoma of Unknown
Primary Site; ODM derived from:
https://clinicaltrials.gov/show/NCT00148135
All rights reserved. Please visit https://medical-data-
models.org/forms/12985
Eligibility Carcinoma of Unknown
Primary NCT00148135
Inclusion Criteria
histologic or cytologic diagnosis of carcinoma,
with clinical evidence of metastasis and the
primary site not clear after the following work-up:*
Yes
No
complete history and physical*
Yes
No
laboratory evaluation including serum beta-
human chorionic gonadotropin (hcg), serum
alpha-fetoprotein for undifferentiated or poorly
differentiated carcinomas and serum prostate
specific antigen (psa) in men.*
Yes
No
directed radiologic evaluation including, at a
minimum, computerized tomography (ct) of chest,
abdomen and pelvis and bilateral mammography
for female patients.*
Yes
No
pathologic immunohistochemistry studies of the
surgical or biopsy specimen, including studies for
estrogen receptor/progesterone receptor and psa
stains when clinically appropriate.*
Yes
No
patients must be at least 18 years of age and
have a zubrod performance   status 0-2.*
Yes
No
adequate organ function, defined as absolute
neutrophil count (anc) > 1500/ul, platelet count of
> 100,000/ul, serum creatinine less than or equal
to 2.0 mg/dl, serum bilirubin less than or equal to
1.5 mg/dl.*
Yes
No
patients must have measurable disease. (partial
response [pr] - at least a 30% decrease in the
sum of ld of target lesions taking as reference the
baseline sum ld.)*
Yes
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No
patients may be previously untreated or have
received one chemotherapy regimen provided it
did not include carboplatin, gemcitabine or
capecitabine.*
Yes
No
patients must have no serious intercurrent
medical or psychiatric illness that would limit their
ability to provide informed consent or receive
protocol therapy.*
Yes
No
patients must be informed of the investigational
nature of this study and provide written informed
consent in accordance with institutional and
federal guidelines prior to the initiation of
therapy.*
Yes
No
Exclusion Criteria
patients with previous invasive malignancy within
the preceding 5 years are ineligible unless
clinicopathologic information regarding the
current neoplasm is clearly discordant from prior
disease.  patients with non-melanoma skin
cancer or in situ cancer of any site are eligible.*
Yes
No
patients with brain metastasis are not eligible.*
Yes
No
no concurrent chemotherapy, biological or
radiotherapy is allowed.*
Yes
No
pregnant or lactating women are not eligible.
women and men of  childbearing potential must
agree to use effective contraception throughout
the treatment period, and for six months after
treatment has been discontinued.*
Yes
No
the following groups of patients will not be eligible
for the study as they represent populations of
patients with cup for whom more specific
treatment approaches are available:*
Yes
No
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1. patients presenting with squamous carcinoma
isolated to middle and   high cervical lymph
nodes*
Yes
No
2. women presenting with isolated axillary
lymphadenopathy*
Yes
No
3. women presenting with predominant peritoneal
carcinomatosis*
Yes
No
4. men < 50 years of age presenting with
predominant mediastinal and/or retroperitoneal
nodal involvement and biopsy showing
undifferentiated or poorly differentiated
carcinoma.*
Yes
No
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Eligibility Chronic Heart Failure
NCT00343902
Hawthorn Extract Randomized Blinded Chronic Heart
Failure (HERB CHF) Trial; ODM derived from:
https://clinicaltrials.gov/show/NCT00343902
All rights reserved. Please visit https://medical-data-
models.org/forms/12986
Eligibility Chronic Heart Failure
NCT00343902
Inclusion Criteria
ambulatory individuals 18 years and older who
had been diagnosed with chf (nyha functional
classes ii-iv) for > 3 months*
Yes
No
left ventricular ejection fraction (lvef) of ≤ 40
percent*
Yes
No
receiving indicated standard therapy (if not
contraindicated or intolerant for > 3 months)
defined as a diuretic, an ace-inhibitor or an
angiotensin receptor blocker (arb) and a beta-
blocke*
Yes
No
patients with nyha class iii or iv symptoms were
also required to receive spironolactone.  doses of
these drugs had to be stable for ≥ 3 months,
except for diuretics, for which ≥ 1 month of
stability was required.*
Yes
No
Exclusion Criteria
hemodynamically severe uncorrected primary
valvular disease*
Yes
No
active myocarditis*
Yes
No
hypertrophic cardiomyopathy*
Yes
No
restrictive cardiomyopathy*
Yes
No
myocardial infarction, stroke, unstable angina,
coronary artery bypass    graft surgery, valvular
surgery, or angioplasty < 3 months before
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randomization*
Yes
No
symptomatic or sustained ventricular tachycardia
not controlled by antiarrhythmic drugs or an
implantable cardioverter-defibrillator*
Yes
No
any condition other than heart failure that would
be expected to limit exercise (e.g., angina,
peripheral vascular disease, pulmonary disease,
arthritis, or an orthopedic problem severe enough
to limit exercise)*
Yes
No
nursing mothers, pregnant women and those
planning a pregnancy during the study period*
Yes
No
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Eligibility Chronic Hepatitis C
NCT00006164
Long Term Interferon for Patients Who Did Not Clear
Hepatitis C Virus With Standard Treatment; ODM derived
from: https://clinicaltrials.gov/show/NCT00006164
All rights reserved. Please visit https://medical-data-
models.org/forms/12987
Eligibility Chronic Hepatitis C
NCT00006164
Inclusion Criteria
age at entry at least 18 years.*
Yes
No
positive for hepatitis c.*
Yes
No
previous treatment with any interferon or
interferon and ribavirin for at least 3 months.*
Yes
No
documented non-response to treatment with
interferon.*
Yes
No
a liver biopsy demonstrating significant liver
scarring.*
Yes
No
Exclusion Criteria
no other liver disease.*
Yes
No
no unstable major medical diseases or
conditions.*
Yes
No
no major complications of cirrhosis.*
Yes
No
no recent abuse of alcohol or illicit drugs.*
Yes
No
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Eligibility Chronic Lymphocytic Leukemia
NCT00073489
A Pilot Study of OSI-461 in Patients With Chronic
Lymphocytic Leukemia (CLL); ODM derived from:
https://clinicaltrials.gov/show/NCT00073489
All rights reserved. Please visit https://medical-data-
models.org/forms/12988
Eligibility Chronic Lymphocytic
Leukemia NCT00073489
Inclusion Criteria
diagnosis of cll established by bone marrow
aspiration and biopsy or flow cytometry of
peripheral blood.*
Yes
No
no previous therapy for cll.*
Yes
No
expected remaining life span greater than or
equal to six months.*
Yes
No
18 years or older.*
Yes
No
willingness and ability to sign an informed
consent.*
Yes
No
Exclusion Criteria
other active malignancy or history of treatment of
any malignancy (excluding non-melanoma skin
cancer) within the previous three years.*
Yes
No
history of other malignancy which could affect the
diagnosis or assessment of osi-461.*
Yes
No
previous therapy for cll.*
Yes
No
use of an investigational medication or device
within one month of initiating study therapy.*
Yes
No
concurrent immunotherapy.*
Yes
No
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use of steroids at the time of enrollment (patients
who require steroids after enrollment may remain
on study).*
Yes
No
any condition or any medication which may
interfere with the conduct of the study.*
Yes
No
serious uncontrolled intercurrent medical or
psychiatric illness, including serious infection.*
Yes
No
evidence of cns involvement.*
Yes
No
pregnant or nursing women.*
Yes
No
2 / 2
Eligibility Chronic Lymphocytic Leukemia NCT00073489
Eligibility Cocaine Dependence
NCT00227812
Integrated Treatment for Cocaine and Mood Disorders - 1;
ODM derived from:
https://clinicaltrials.gov/show/NCT00227812
All rights reserved. Please visit https://medical-data-
models.org/forms/12989
Eligibility Cocaine Dependence
NCT00227812
Inclusion Criteria
generally physically healthy*
Yes
No
aged 18-55*
Yes
No
meets cocaine dependence by dsm-iv criteria*
Yes
No
meets major depressive disorder or substance-
induced depression disorder by dsm-iv criteria.*
Yes
No
willing and able to participate in the 12 week
treatment study and one year follow up.*
Yes
No
Exclusion Criteria
pregnant or breastfeeding.*
Yes
No
taking medications that interact with the study
medication (mao inhibitors, anticonvulsants,
haloperidol, phenothiazines,selegiline,
anesthetics*
Yes
No
have other psychiatric diagnoses requiring
therapy or medication.*
Yes
No
physically dependent on opiates or alcohol.*
Yes
No
currently being treated with bupropion
hydrochloride (e.g. zyban).*
Yes
No
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Eligibility Asthma NCT00001759
Assessment of Lung Inflammation in Patients With Atopic
Asthma Using Positron Emission Tomography; ODM
derived from: https://clinicaltrials.gov/show/NCT00001759
All rights reserved. Please visit https://medical-data-
models.org/forms/12990
Eligibility Asthma NCT00001759
Criteria
negative pregnancy test within two days of the
scan and willingness to adhere to reliable birth
control until the completion of the protocol.*
Yes
No
subjects must be able to give informed consent.*
Yes
No
subjects in the negative control group must have
no history of asthma or other lung disease.*
Yes
No
control subjects must have negative prick skin
tests to the allergens used.*
Yes
No
asthmatic subjects must have asthma as defined
in this study.*
Yes
No
asthmatic subjects must have positive prick skin
tests to one or more allergens used.*
Yes
No
subjects must have access to a primary medical
care provider outside of the nih.*
Yes
No
subjects must weigh less than 136 kg.*
Yes
No
no breast feeding.*
Yes
No
no smoking in the last 3 years, or greater than 6
months of smoking in the past ten years.*
Yes
No
no antihistamines one week prior to the skin test
on the first visit.*
Yes
No
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no history of coronary artery disease.*
Yes
No
no evidence of lung disease other than asthma;
no evidence of autoimmune or inflammatory
disease which could affect lung function such as
lupus erythematosus (except for the control
subjects with wegener's granulomatosis).*
Yes
No
no evidence of either acute (e.g., bacterial or viral
pneumonia) or chronic (e.g., bronchiectasis) lung
infection.*
Yes
No
no diabetes, or history of glucose intolerance
(e.g., gestational diabetes).*
Yes
No
no allergy to methacholine.*
Yes
No
no beta-adrenergic blocking medication.*
Yes
No
control subjects must not have a history of
asthma, atopic rhinitis or atopic dermatitis.*
Yes
No
control subjects must not have any response to
inhaled methacholine with a fall in fev1 in excess
of 20% to less than or equal to 25 mg/ml.*
Yes
No
asthmatic subjects must not have chronic
bronchitis or a diagnosis of chronic obstructive
lung disease (copd).*
Yes
No
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Eligibility B-Cell Lymphoma NCT00162656
Treatment of Mature B-cell Lymphoma/Leukaemia; ODM
derived from: https://clinicaltrials.gov/show/NCT00162656
All rights reserved. Please visit https://medical-data-
models.org/forms/12991
Eligibility B-Cell Lymphoma
NCT00162656
Inclusion Criteria
newly diagnosed b lineage non-hodgkin's
lymphoma with revised european american
lymphoma (real) ii 9 (diffuse large cell
lymphoma), 10 (burkitt's lymphoma), or 11 (high
grade b cell lymphoma, burkitt's like) or bone
marrow > 5% l3 blasts.*
Yes
No
pre treatment imaging studies adequate to
document murphy disease stage*
Yes
No
group b and c patients are eligible for
randomization (therapy stratification by group :
group a=completely resected stage i or
completely resected abdominal stage ii lesions,
group b= all cases not eligible for group a or
group c, group c= any cns involvement and/or
bone marrow involvement ³ 25% blasts)*
Yes
No
patients should be available for a minimum follow
up of 36 months*
Yes
No
informed consent prior to study entry*
Yes
No
Exclusion Criteria
anaplastic large cell ki 1 positive lymphomas*
Yes
No
previous chemotherapy.*
Yes
No
congenital immunodeficiency*
Yes
No
prior organ transplantation*
Yes
No
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previous malignancy of any type*
Yes
No
known hiv positivity*
Yes
No
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Eligibility Bladder Neoplasms
NCT00001381
A Phase I Trial Using Suramin to Treat Superficial
Transitional Cell Carcinoma of the Bladder; ODM derived
from: https://clinicaltrials.gov/show/NCT00001381
All rights reserved. Please visit https://medical-data-
models.org/forms/12992
Eligibility Bladder Neoplasms
NCT00001381
Criteria
histologically confirmed superficial transitional
cell carcinoma of the bladder pathologically
staged as tis, ta, or t1. visible tumors at time of
treatment not required. no metastatic disease or
muscle invasion.*
Yes
No
clinically useful pretreatment bladder function
required.*
Yes
No
no significant prostatic obstructive symptoms
associated with impaired or incomplete bladder
emptying.*
Yes
No
no active urinary tract infection.*
Yes
No
at least 1 course of prior standard intravesical
therapy required.*
Yes
No
at least 4 weeks since intravesical treatment, with
resolution of any local or systemic toxicity.*
Yes
No
age: 18 and over.*
Yes
No
performance status:  ecog 0 or 1.*
Yes
No
wbc at least 3,300;*
Yes
No
hemoglobin at least 10 g/dl.*
Yes
No
bilirubin no greater than 1.5 mg/dl;*
Yes
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No
ast and alt no greater than 2 times normal.*
Yes
No
renal: creatinine no greater than 1.5 mg/dl.*
Yes
No
medically able to undergo cystoscopy.*
Yes
No
no pregnant women.*
Yes
No
2 / 2
Eligibility Bladder Neoplasms NCT00001381
Eligibility Breast Cancer NCT00001384
A Pilot Trial of AC (Adriamycin, Cyclophosphamide)
Chemotherapy With G-CSF (Granulocyte Colony-
Stimulating Factor) Followed by Infusional Taxol (Paclitaxel)
as Adjuvant Treatment for High Risk Stage II and Stage III
Breast Cancer Patients; ODM derived from:
https://clinicaltrials.gov/show/NCT00001384
All rights reserved. Please visit https://medical-data-
models.org/forms/12993
Eligibility Breast Cancer
NCT00001384
Criteria
patients will be eligible for study either before or
after receiving adjuvant radiation therapy.*
Yes
No
patients with stage iii disease will be eligible to
receive this regimen as neo-adjuvant
chemotherapy or as adjuvant therapy if surgery
was performed prior to patient referral.*
Yes
No
patients must be previously untreated with
chemotherapy.*
Yes
No
there must be no history of previous malignancy
except for cured non-melanoma skin cancer
(basal or squamous cell carcinoma), cervical
cancer in situ, or a past malignancy that has
been inactive for over 5 years.  patients with a
prior history of lower stage contralateral breast
cancer, treated with surgery, and/or radiation, but
not chemotherapy, are eligible for this study.*
Yes
No
performance status (karnofsky scale) must be
greater than 70; ecog 0 to 2.*
Yes
No
absolute granulocyte count greater than 1500 per
microliter and platelet count greater than 100,000
per mm(3).*
Yes
No
liver function tests (sgot, and total bilirubin)
should be less than 2x upper limits of normal.
serum creatinine should be less than 1.7 or
creatinine clearance should be greater than 45 ml
per min.*
Yes
No
the patient must be able to give an informed
consent, and to return to nci for treatment and
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adequate follow-up for the period the protocol
requires.*
Yes
No
patients must be greater than or equal to 18
years of age.*
Yes
No
patients and/or their partners must be willing to
practice a non-hormonal method of contraception
during therapy and for 6 months following
therapy.*
Yes
No
patients who are poor medical or psychiatric risks
because of nonmalignant systemic disease which
would preclude them from being subjected to any
treatments in this protocol are excluded.*
Yes
No
patients must have a normal ejection fraction by
muga scan and have no angina.  patients should
not currently require therapy for cardiac
arrhythmias, congestive heart failure, or coronary
artery disease.*
Yes
No
no patients with a history of symptomatic cns
disease.*
Yes
No
no patients with allergy to any study medication.*
Yes
No
no pregnant or lactating women.*
Yes
No
patients with bleeding disorders are ineligible for
study entry as are patients requiring chronic
anticoagulation.*
Yes
No
2 / 2
Eligibility Breast Cancer NCT00001384
Eligibility Breast Cancer NCT00002720
Surgery With or Without Lymph Node Removal in Treating
Older Women With Stage I Breast Cancer; ODM derived
from: https://clinicaltrials.gov/show/NCT00002720
All rights reserved. Please visit https://medical-data-
models.org/forms/12994
Eligibility Breast Cancer
NCT00002720
Criteria
histologically proven stage i, invasive breast
cancer*
Yes
No
estrogen receptor positive*
Yes
No
Age: 65 to 80*
Yes
No
Sex: female*
Yes
No
postmenopausal*
Yes
No
no serious disease that would preclude surgery*
Yes
No
no other prior or concurrent malignancy except
basal cell carcinoma or carcinoma in situ of the
cervix*
Yes
No
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Eligibility Breast Cancer NCT00003016
Prolonged Tamoxifen Compared With Shorter Tamoxifen in
Treating Patients Who Have Breast Cancer; ODM derived
from: https://clinicaltrials.gov/show/NCT00003016
All rights reserved. Please visit https://medical-data-
models.org/forms/12995
Eligibility Breast Cancer
NCT00003016
Criteria
curatively treated carcinoma of the breast*
Yes
No
currently taking adjuvant tamoxifen*
Yes
No
must be substantial uncertainty as to whether or
not to continue tamoxifen (i.e., no clear indication
or definite contraindication to further treatment
with tamoxifen)*
Yes
No
not pregnant or nursing*
Yes
No
no contraindications to receiving tamoxifen*
Yes
No
no other serious medical problems*
Yes
No
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Eligibility Breast Cancer NCT00003088
Combination Chemotherapy in Treating Patients With
Breast Cancer; ODM derived from:
https://clinicaltrials.gov/show/NCT00003088
All rights reserved. Please visit https://medical-data-
models.org/forms/12996
Eligibility Breast Cancer
NCT00003088
Criteria
1.1 patients with operable, histologically
confirmed adenocarcinoma of the female breast
and positive lymph nodes. node positivity may be
determined by either an axillary node dissection
or a positive sentinel node finding by
immunohistochemistry or histology. this includes
any patient with one or more positive lymph
nodes whose tumors are t0, t1, 2 or 3 and n1, n2,
mo. patients with metaplastic carcinoma are
eligible. bilateral disease does not exclude
patients from entry.*
Yes
No
1.2 tumors that are locally advanced at diagnosis
are not eligible. this is left to investigator
judgment. patients with tumors fixed to the chest
wall, peau d'orange skin changes, skin
ulcerations, or clinical inflammatory changes (t4
disease) are excluded from this study. dermal
lymphatic involvement noted on pathology without
clinical inflammatory changes will not exclude a
patient from this study.*
Yes
No
1.3 patients with any erp/pgr status are eligible.*
Yes
No
2.1 <84 days from mastectomy or within 84 days
of axillary dissection if the patient's most
extensive breast surgery was a breast sparing
procedure.*
Yes
No
2.2 surgical resection margins - all tumor should
be removed by either a modified radical
mastectomy or a segmental mastectomy. node
dissection: patients may have had either an
axillary node dissection or sentinel lymph node
biopsy before beginning treatment on protocol.*
Yes
No
mastectomy:  there should be no evidence of
gross or microscopic tumor at the surgical
resection margins noted in the final surgery or
pathology reports for patients who have had a
modified radical mastectomy. patients with close
margins (tumor < 1 mm from margin) are
1 / 2
eligible.*
Yes
No
segmental mastectomy (lumpectomy): although
clear margins are preferable, dcis or lcis at the
surgical resection margin will not render a patient
who has undergone a segmental mastectomy
ineligible for this study. invasive tumor at the final
resection margin will render a patient ineligible.*
Yes
No
2.3  no prior chemotherapy.*
Yes
No
2.4  no prior radiation therapy for this malignancy.
patients who received radiation to the breast for
dcis are eligible. patients who have had
segmental mastectomy will be treated with
radiotherapy according to standard procedures in
the treating physician's institution after
completion of all chemotherapy. patients who
have had modified radical mastectomy may also
receive radiotherapy at the discretion of the
treating physician according to institutional
guidelines.*
Yes
No
2.5 patients may receive up to four weeks of
tamoxifen therapy for this malignancy and still be
eligible for study entry. patients who received
tamoxifen for purposes of chemoprevention (e.g.,
breast cancer prevention trial) or for other
indications (including previous breast cancer) are
eligible. tamoxifen therapy should be discontinued
before the patient is enrolled on this study.*
Yes
No
3. age > 18. there is no upper age limit for
enrollment on this study.*
Yes
No
granulocyte count > 1000/mm3*
Yes
No
platelet count > 100,000/mm3*
Yes
No
bilirubin within upper limits of normal*
Yes
No
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Eligibility Breast Cancer NCT00003577
Combination Chemotherapy With or Without Epirubicin in
Treating Women With Stage I or Stage II Breast Cancer;
ODM derived from:
https://clinicaltrials.gov/show/NCT00003577
All rights reserved. Please visit https://medical-data-
models.org/forms/12997
Eligibility Breast Cancer
NCT00003577
Criteria
histological confirmation of invasive, early stage
breast cancer*
Yes
No
prior complete excision of tumor required (wide
local excision or mastectomy)*
Yes
No
Hormone receptor status: not specified*
Yes
No
sex: female*
Yes
No
adequate bone marrow function*
Yes
No
adequate hepatic function*
Yes
No
renal:*
Yes
No
adequate renal function*
Yes
No
no prior cancer except for basal cell carcinoma or
carcinoma in situ*
Yes
No
not pregnant or nursing*
Yes
No
fertile patients must use effective contraception*
Yes
No
no prior chemotherapy*
Yes
No
concurrent hormone therapy allowed*
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Yes
No
no prior radiotherapy but concurrent radiotherapy
allowed*
Yes
No
surgery: see disease characteristics*
Yes
No
no more than 6 weeks since prior surgery to the
breast*
Yes
No
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Eligibility Breast Cancer NCT00156039
Randomized Trial of Follow-up Strategies in Breast Cancer;
ODM derived from:
https://clinicaltrials.gov/show/NCT00156039
All rights reserved. Please visit https://medical-data-
models.org/forms/12998
Eligibility Breast Cancer
NCT00156039
Inclusion Criteria
women with breast cancer on well follow-up at
regional cancer centres in ontario and manitoba*
Yes
No
diagnosed at least 12 months previously (range
9-15 months)*
Yes
No
without evidence of active disease (i.e., stages
iiib and iv excluded)*
Yes
No
free from any primary treatment complications*
Yes
No
Exclusion Criteria
primary treatment at least 3 months previously,
except for continued use of tamoxifen*
Yes
No
still experiencing complications of primary
treatment (patients will become eligible once
complications resolve provided they are within
the 6 month window)*
Yes
No
unable to identify an acceptable family physician
to provide follow-up*
Yes
No
language or literacy skills inconsistent with
completing questionnaires*
Yes
No
unable to comply with study protocol including
completion of questionnaires*
Yes
No
previously enrolled in a study which requires
continued follow-up in specialist or peripheral
clinics*
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Yes
No
actively followed at a cancer centre for another
primary cancer*
Yes
No
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Eligibility Colon Cancer NCT00695201
Hepatic Arterial Infusion With Floxuridine and
Dexamethasone in Combination With Intravenous
Oxaliplatin Plus Irinotecan in Patients With Unresectable
Hepatic Metastases From Colorectal Cancer; ODM derived
from: https://clinicaltrials.gov/show/NCT00695201
All rights reserved. Please visit https://medical-data-
models.org/forms/12999
Eligibility Colon Cancer
NCT00695201
Inclusion Criteria
history of histologically confirmed colorectal
adenocarcinoma metastatic to the liver with no
clinical or radiographic evidence of extrahepatic
disease.*
Yes
No
confirmation of diagnosis must be performed at
mskcc.*
Yes
No
patient's liver metastases must be deemed
unresectable and comprise <70% of the liver
parenchyma.*
Yes
No
a patient may have had prior chemotherapy or be
previously untreated.*
Yes
No
patient may not have received prior treatment
with fudr or >2 doses of oxaliplatin.*
Yes
No
kps > or = to 60%.*
Yes
No
wbc > or = to 3,000 cells/mm3 and platelet count
> or = to 100,000 cells/mm3 within 14 days of
registration.*
Yes
No
creatinine < or = to 1.5 mg/dl within 14 days of
registration.*
Yes
No
total serum bilirubin < or = 2.0 mg/dl within 14
days of registration.*
Yes
No
Exclusion Criteria
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no active concurrent malignancies: except a
patient's potentially resectable colorectal
primary.*
Yes
No
patient must not have obstruction of gi or gu
tract.*
Yes
No
patient must not have current, symptomatic
peripheral sensory neuropathy.*
Yes
No
no prior radiation to liver.*
Yes
No
no active infection, ascites, or hepatic
encephalopathy.*
Yes
No
age ≥ 18 years.*
Yes
No
female patients cannot be pregnant or lactating.*
Yes
No
signed informed consent.*
Yes
No
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Eligibility Colorectal Cancer NCT00041652
Safety Study of hMN14 to Treat Either Colorectal or Breast
Cancer; ODM derived from:
https://clinicaltrials.gov/show/NCT00041652
All rights reserved. Please visit https://medical-data-
models.org/forms/13000
Eligibility Colorectal Cancer
NCT00041652
Criteria
histologic or cytologic diagnosis or either, colonic,
rectal, or breast carcinoma*
Yes
No
measurable lesion diagnosed by ct scan*
Yes
No
recurrent/metastatic disease considered
surgically unresectable.*
Yes
No
prior/concurrent therapy:*
Yes
No
chemotherapy: patients who either have failed at
least one regimen of standard systemic therapy,
or are clinically asymptomatic and are not
presently being considered for chemotherapy
(enrollment must occur at least 4 weeks beyond
last treatment)*
Yes
No
other: prior treatment with investigational agents
is excluded unless follow-up is completed and
patient is off study*
Yes
No
performance status: patients with a karnofsky
performance status > 70% (or equivalent, ecog 0-
1) and expected survival of at least 3 months.*
Yes
No
hematopoietic: wbc >/= 3000 mm3, neutrophils
>/= 1500 mm3, platelets >/= 75,000, cea < 300
ng/ml*
Yes
No
hepatic: serum bilirubin </= 2.0 mg/dl, alt < 2.5 x
iuln*
Yes
No
cardiovascular: patients with lvef >/= 40% by
required muga/2d-echo study.*
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Yes
No
pulmonary: patients with fev1 >/= 60% by
required pulmonary function tests*
Yes
No
other: patients agreeing to use a medically
effective method of contraception during and for a
period of 3 months after the treatment period.  a
pregnancy test will be preformed on each
premenopausal female of childbearing potential
immediately prior to entry into the study.  patients
able to understand and give written informed
consent. patients with a significant concurrent
medical condition that could affect the patient's
ability to tolerate or complete the study.*
Yes
No
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Eligibility Colorectal Cancer NCT02223078
Two Center Study to Determine Effect of G17DT on Plasma
Gastrin Levels in Patients With Colorectal Cancer.; ODM
derived from: https://clinicaltrials.gov/show/NCT02223078
All rights reserved. Please visit https://medical-data-
models.org/forms/13001
Eligibility Colorectal Cancer
NCT02223078
Inclusion Criteria
patients with histologically confirmed colorectal
carcinoma for whom no other anti-cancer
treatment was anticipated during the three month
period of study.*
Yes
No
patients taking a proton pump inhibitor at a fixed
daily dose which had remained unchanged for at
least six weeks preceding screening and was not
anticipated to change during the study.*
Yes
No
proton pump inhibitor compliance of ~70% (to be
measured between screening and baseline (week
0)).*
Yes
No
male or female patients from 18 to 65 years of
age.*
Yes
No
patients with a life expectancy of over three
months.*
Yes
No
world health organisation (who) performance
status of 0 to 1.*
Yes
No
written informed consent given.*
Yes
No
Exclusion Criteria
patients in receipt of histamine h2-receptor (h2
receptor) antagonists or any other antacid
therapy, other than a proton pump inhibitor at a
stable dose.*
Yes
No
patients with any other factor likely to alter intra-
gastric acidity e.g. previous gastric surgery,
including vagotomy or anatomically abnormal
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upper gastrointestinal tract.*
Yes
No
history of other malignant disease within the
previous five years, except non-*
Yes
No
melanomatous skin cancer or in situ carcinoma of
the uterine cervix.*
Yes
No
previous use within the last four weeks,
concomitant use or anticipated use in the period
of the study of radiotherapy or chemotherapy.*
Yes
No
concomitant use of immunosuppressants,
including systemic (i .e. oral or injected)
corticosteroids.*
Yes
No
females who were pregnant, planning to become
pregnant or lactating. women, who in the opinion
of the investigator were of child bearing potential,
were to have a negative pregnancy test before
study drug administration.*
Yes
No
patients taking part in another study involving an
investigational or licensed drug or device in the
three months preceding enrolment or during the
study.*
Yes
No
previous g 17dt treatment.*
Yes
No
haematological indicators: haemoglobin <10.0
g/dl white blood cell count <4.0 x 109/l platelets <
100 x 1 09/l*
Yes
No
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Eligibility Colorectal Neoplasms
NCT00677586
I Phase Surgery Versus Staged Surgery for Synchronous
Liver Metastasis of Colorectal Cancer; ODM derived from:
https://clinicaltrials.gov/show/NCT00677586
All rights reserved. Please visit https://medical-data-
models.org/forms/13002
Eligibility Colorectal Neoplasms
NCT00677586
Inclusion Criteria
age <= 75 years*
Yes
No
resectable primary colorectal tumor*
Yes
No
remnant liver volume >= 70%*
Yes
No
without other organ metastasis or peritoneum
metastasis*
Yes
No
without contradiction of cardiac and pulmonary
diseases*
Yes
No
Exclusion Criteria
age > 75 years*
Yes
No
unresectable primary colorectal tumor*
Yes
No
remnant liver volume < 70%*
Yes
No
with other organ metastasis or peritoneum
metastasis*
Yes
No
with contradiction of cardiac and pulmonary
diseases*
Yes
No
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Moxaverine 200mg p.o. in patients with
central nervous vertigo Visit 4
Placebo controlled,double blind and randomized parallel
group trial to verify effectivity and tolerability of moxaverine
p.o. in patients with central nervous vertigo. Sponsor:
URSAPHARM Industriestrasse 66129 Saarbrücken Phone
06805-9292-0 Fax 06805- 929288 Head of clinical trial:
Univ.-Prof.Dr.med. Ralph Mösges Medical Faculty,
University of Cologne Phone 0221-4783456 Fax 0221-
4783465
All rights reserved. Please visit https://medical-data-
models.org/forms/13030
Case report form Visit 4
Patient Identification
Patient number
Study site number
Date of completion of this form
otorhinolaryngologic examination
Otoscopy
normal (1)
abnormal (2)
Please specify findings of Otoscopy
Rinne test
normal (1)
abnormal (2)
Please specify findings of Rinne test
Webers test
normal (1)
abnormal (2)
Please specify findings of Webers test
direction of eye movement with frenzel lens
eyeglasses
horizontal (1)
vertical (2)
rotating (3)
amplitude of eye movement with frenzel lens
eyeglasses
small (1)
medium (2)
heavy (3)
Frequency of eye movement with frenzel lens
eyeglasses
little (1)
medium (2)
high (3)
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Dizziness with frenzel lens eyeglasses
little (1)
distinctly (2)
severe (3)
Posturography
Any significant findings during computerized
dynamic posturography procedure
None (1)
Yes (2)
Please specify findings during computerized
dynamic posturography procedure
Tasks of investigator during this visit
DHI-Questionnaire given to patient
Yes
No
Remaining trial medication retrieved from
patient?
Yes
No
Number of tablets of trial medication retrieved
from patient
Any questions the patient might have have been
answered.
Yes
No
Please note questions and answers given
Signature date
Signature
Comorbidities and concomitant Medication
Have comorbidities changed?
Yes
No
Please specify comorbidities by ICD-Code
Has concomitant medication been subject to
change?
Yes
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No
Please specify medication name,dose,start and
end date of therapy
additional comments
General impression regarding the trial
General tolerance of trial substance
very good (1)
good (2)
fair (3)
poor (4)
General therapeutic effectiveness
very good (1)
good (2)
fair (3)
poor (4)
Signature date
Signature
Adverse reactions
During this trial period,have there been adverse
reactions to the study drug?
Yes
No
Please specify the adverse event or reaction
Severity of adverse event or reaction
Mild (1)
Moderate (2)
Severe (3)
Life-threatening (4)
Treatment of AE
None (1)
dose reduction (2)
dose omission (3)
discontinuation (4)
antidote (5)
concomitant medication changed (6)
other (7)
Development of adverse event or reaction
subsided (1)
decreased (2)
persistent (3)
increased (4)
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fatal (5)
unknown (6)
other (7)
Association with trial substance
by underlying disease (1)
none (2)
possible (3)
likely (4)
affirmative (5)
Please give further information about
countermeasures, development,outcome and
judgment of the AE
Date
Signature
Final report
Reason for discontinuation
planned end of trial (0)
lack of efficacy (1)
discontinuation of patient due to
administrative or other reasons (10)
other (11)
Allergy/Hypersensitivity (2)
Allergy to trial substance (3)
Other SAE´s (4)
informed consent withdrawn (5)
Use of prohibited drugs/substances (6)
lack of compliance (7)
exclusion criteria occurred (8)
violation of protocol (9)
Please specify other reasons for discontinuation
of the patient
Date and time of discontinuation
Participation discontinued by
Patient (1)
Investigator (2)
Study Director (3)
Discontinuation of whole trial
Yes
No
Date of discontinuation of trial
Trial discontinued by
4 / 5
Moxaverine 200mg p.o. in patients with central nervous vertigo Visit 4
Sponsor (1)
Study Director (2)
Date of completion of this form
Signature
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Eligibility Coronary Artery Disease
NCT00264043
The Study to Evaluate Patient Outcome Using Distal
Protection Combined With the BX Velocity.; ODM derived
from: https://clinicaltrials.gov/show/NCT00264043
All rights reserved. Please visit https://medical-data-
models.org/forms/13031
Eligibility Coronary Artery Disease
NCT00264043
Inclusion Criteria
unstable angina pectoris (braunwald classification
b & c, i-ii-iii, native vessels)*
Yes
No
or lesion located in the svg;*
Yes
No
single de novo or restenotic lesion requiring
treatment in a major native coronary artery or
saphenous vein graft;*
Yes
No
the vessel diameter to place the angioguard™
device in must be > 3 and < 5.5 mm (6.5 when
the 7mm angioguard™ is available);*
Yes
No
target lesion stenosis is >50% and <100% (timi
1).*
Yes
No
Exclusion Criteria
a q-wave or non-q-wave myocardial infarction
within the preceding 72 hours unless the ck and
ck-mb enzymes are back to normal;*
Yes
No
more than one coronary artery is 100%
occluded;*
Yes
No
patient has unprotected left main coronary
disease with > 50% stenosis;*
Yes
No
patient has an ostial target lesion;*
Yes
No
significant (>50%) untreated stenosis proximal or
distal to the target lesion that will be treated
during the procedure, since this may require
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revascularization or impede runoff;*
Yes
No
ejection fraction <30%;*
Yes
No
totally occluded vessel (timi 0 level).*
Yes
No
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Eligibility Coronary Artery Disease
NCT00385242
PET and Recovery Following Revascularization (PARR 2);
ODM derived from:
https://clinicaltrials.gov/show/NCT00385242
All rights reserved. Please visit https://medical-data-
models.org/forms/13032
Eligibility Coronary Artery Disease
NCT00385242
Inclusion Criteria
patient is > 18 years of age.*
Yes
No
documented ejection fraction of <35% attributable
to cad.*
Yes
No
documented cad*
Yes
No
any patient being considered for
revascularization, transplant/heart failure work up
or where, in the opinion of the attending physician
or surgeon, viability imaging would be considered
useful in ongoing clinical management
decisions.*
Yes
No
Exclusion Criteria
other co-morbid conditions making survival
unlikely*
Yes
No
< 6 weeks post myocardial infarction*
Yes
No
cad unsuitable for revascularization*
Yes
No
emergency revascularization is required.*
Yes
No
severe valvular disease that requires surgery.*
Yes
No
geographically inaccessible*
Yes
No
lack of informed consent.*
Yes
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No
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Eligibility Dementia NCT00010803
Ginkgo Biloba Prevention Trial in Older Individuals; ODM
derived from: https://clinicaltrials.gov/show/NCT00010803
All rights reserved. Please visit https://medical-data-
models.org/forms/13033
Eligibility Dementia NCT00010803
Inclusion Criteria
non-demented participants*
Yes
No
willing to participate in a seven-year follow-up trial
of ginkgo biloba*
Yes
No
english is their usual language*
Yes
No
willing informant who has frequent contact with
the participant*
Yes
No
Exclusion Criteria
currently on anticoagulant therapy*
Yes
No
cancer diagnosed and treated within the past two
years (except for skin cancer)*
Yes
No
participant with class iii - iv congestive heart
failure*
Yes
No
currently being treated with
psychopharmacological drugs for depression*
Yes
No
hospitalized for depression within the last year*
Yes
No
taking aricept (or similar agents) for cognitive
problems or dementia*
Yes
No
baseline blood creatinine >2*
Yes
No
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baseline sggt is a marker of liver function (3 x
normal>or=90 iu)*
Yes
No
baseline hematocrit<30*
Yes
No
baseline white blood count>or=15,000*
Yes
No
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Eligibility Depression NCT00026637
Depression and Health Outcomes in Refractory Epilepsy;
ODM derived from:
https://clinicaltrials.gov/show/NCT00026637
All rights reserved. Please visit https://medical-data-
models.org/forms/13034
Eligibility Depression NCT00026637
Criteria
must have a seizure disorder.*
Yes
No
must meet the dsm-iv criteria for major
depression.*
Yes
No
must be willing to provide written informed
consent.*
Yes
No
must be age 21 to 75 years old.*
Yes
No
must be compliant, cooperative, reliable, and able
to follow instructions, and to visit the clinic on
schedule.*
Yes
No
Exclusion Criteria
have active suicidal or homicidal ideation.
Yes
No
have current alcohol or other substance abuse
disorders or a history of bipolar depression or any
psychotic disorder.
Yes
No
are pregnant or lactating.
Yes
No
are known to be hypersensitive to sertraline.
Yes
No
have a progressive central nervous system
disorder (such as a tumor or multiple sclerosis),
or severe hepatic or renal disease (serum
creatinine >3 mg/dl).
Yes
No
currently taking an antidepressant medication or
seeing a therapist regularly.
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Yes
No
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Eligibility Breast Cancer NCT00287534
Effectiveness of Combination of Arimidex and Nolvadex in
Adjuvant Therapy of Breast Carcinoma in Postmenopausal
Women.; ODM derived from:
https://clinicaltrials.gov/show/NCT00287534
All rights reserved. Please visit https://medical-data-
models.org/forms/13035
Eligibility Breast Cancer
NCT00287534
Inclusion Criteria
signed informed consent,*
Yes
No
post-menopausal women ≤75 years,*
Yes
No
histologically confirmed invasive breast
carcinoma (no distant metastases),*
Yes
No
positive hormone receptor status,*
Yes
No
continuous 2-year adjuvant tamoxifen therapy 20
mg/30 mg with 4 weeks after primary surgery*
Yes
No
Exclusion Criteria
menopause status maintained by medication,*
Yes
No
pre-operative chemotherapy or hormone therapy
or radiation therapy,*
Yes
No
relapse or second carcinoma or previous
cancerous disease,*
Yes
No
breast carcinoma in situ,*
Yes
No
simultaneous carcinoma of the opposite side or
secondary breast,*
Yes
No
10 or more tumour-infiltrated lymph nodes.*
Yes
No
serious accompanying diseases*
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No
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Eligibility Breast Cancer NCT02450058
Adjuvant FEC Versus EP in Breast Cancer (MIG5); ODM
derived from: https://clinicaltrials.gov/show/NCT02450058
All rights reserved. Please visit https://medical-data-
models.org/forms/13036
Eligibility Breast Cancer
NCT02450058
Inclusion Criteria
women with histologically confirmed breast
cancer who had undergone radical mastectomy
or breast-conserving surgery in addition to full
ipsilateral axillary lymph node dissection*
Yes
No
lymph node-positive disease with less than 10
involved axillary lymph nodes*
Yes
No
surgery performed not more than 5 weeks before
randomization*
Yes
No
ecog performance status 0*
Yes
No
absolute neutrophil count ≥ 2,000/mm³*
Yes
No
wbc ≥ 3,000/mm³*
Yes
No
platelet count ≥ 100,000/mm³*
Yes
No
bilirubin ≤ 1.5 times upper limit of normal (uln)*
Yes
No
ast and alt ≤ 1.5 times uln*
Yes
No
postoperative regional radiotherapy limited to the
remaining breast admitted for patients who
received breast-conserving surgery*
Yes
No
written informed consent*
Yes
No
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Exclusion Criteria
prior or concurrent ipsilateral or contralateral
invasive breast carcinoma within the last 10
years*
Yes
No
metastatic disease, including metastasis in the
ipsilateral supraclavicular lymph nodes*
Yes
No
prior chemotherapy or prior cytotoxic regimens or
prior hormonal therapy*
Yes
No
pregnant or nursing*
Yes
No
other serious medical illness requiring
medication, uncontrolled infections*
Yes
No
other malignancy except adequately treated,
cone-biopsied in situ carcinoma of the cervix or
basal cell or squamous cell carcinoma of the
skin*
Yes
No
recent myocardial infarction, congestive heart
failure, or serious arrhythmia*
Yes
No
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Eligibility Depression NCT00118404
Cognitive Therapy for Recurrent Depression; ODM derived
from: https://clinicaltrials.gov/show/NCT00118404
All rights reserved. Please visit https://medical-data-
models.org/forms/13037
Eligibility Depression NCT00118404
Inclusion Criteria
recurrent unipolar major depressive disorder*
Yes
No
have experienced at least two episodes of major
depression*
Yes
No
have experienced at least one period of recovery
during a depressive episode or have a history of
dysthymia (a mood disorder characterized by
depression) prior to the onset of current or past
depressive episodes*
Yes
No
willing and able to comply with all study
requirements*
Yes
No
able to speak and read english*
Yes
No
Exclusion Criteria
active alcohol or other substance dependence
within 6 months prior to study entry*
Yes
No
currently at risk for suicide*
Yes
No
mood disorders due to a medical condition or
substance abuse*
Yes
No
bipolar, schizoaffective, obsessive compulsive, or
eating disorders*
Yes
No
schizophrenia*
Yes
No
unable to stop mood-altering medications*
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Yes
No
current use of medication or diagnosis of a
medical disorder that may cause depression
(e.g., diabetes, head injury, stroke, cancer,
multiple sclerosis)*
Yes
No
previous failure to experience a reduction in
depressive symptoms after 8 weeks of cognitive
therapy with a certified therapist*
Yes
No
previous failure to experience a reduction in
depressive symptoms after 6 weeks of 40 mg of
prozac*
Yes
No
pregnancy or plan to become pregnant in the
next 11-12 months*
Yes
No
unable to attend clinic twice weekly during
business hours*
Yes
No
unable to complete questionnaires*
Yes
No
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Eligibility Depression NCT00332787
Determining Optimal Continuation Treatment Duration for
Depressed Children and Adolescents; ODM derived from:
https://clinicaltrials.gov/show/NCT00332787
All rights reserved. Please visit https://medical-data-
models.org/forms/13038
Eligibility Depression NCT00332787
Inclusion Criteria
currently being treated on an outpatient basis*
Yes
No
currently attending school*
Yes
No
diagnosis of non-psychotic major depressive
disorder (mdd)*
Yes
No
duration of illness is at least 4 weeks*
Yes
No
in good general medical health*
Yes
No
normal intelligence*
Yes
No
Exclusion Criteria
lifetime history of any psychotic disorder,
including psychotic depression*
Yes
No
diagnosis of bipolar i or ii disorder*
Yes
No
history of alcohol or substance abuse or
dependence within 6 months of study entry*
Yes
No
lifetime history of anorexia nervosa or bulimia*
Yes
No
pregnant or breastfeeding*
Yes
No
does not agree to use an effective form of
contraception (i.e., iud, birth control pills, or
barrier devices)*
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Yes
No
any chronic medical illness requiring regular
medication*
Yes
No
currently taking medication with psychotropic
effects (i.e., anticonvulsants, steroids, etc.), other
than stable stimulant treatment*
Yes
No
a first degree relative has bipolar i disorder*
Yes
No
previous adequate treatment with fluoxetine was
ineffective (defined as at least 20 mg/day for 4
weeks)*
Yes
No
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Eligibility Breast Neoplasm NCT00001507
Chemotherapy and Progenitor Cell Transplantation to Treat
Inflammatory Breast Cancer; ODM derived from:
https://clinicaltrials.gov/show/NCT00001507
All rights reserved. Please visit https://medical-data-
models.org/forms/13040
Eligibility Breast Neoplasm
NCT00001507
Criteria
Inclusion Criteria
age greater or equal to 18 years.*
Yes
No
all patients must have a histologically confirmed
diagnosis of inflammatory breast carcinoma
stage iii b.  patients with no clinical inflammatory
signs but with tumor invasion of dermal lymphatic
on histology are eligible.  patients with metastatic
disease and inflammatory breast carcinoma are
not eligible.  all pathologic material must be
reviewed and confirmed by the department of
pathology of the treating institution prior to
treatment (there will be no central pathology
review).*
Yes
No
patients may be untreated or may have received
prior induction chemotherapy outside the nci.  if
patients received prior induction chemotherapy,
they may not have been unresponsive to it.  they
may have received chemotherapy either before
(neo-adjuvant setting) or after local surgery
(adjuvant setting).*
Yes
No
karnofsky performance status of greater than
70% (ecog 0 or 1).*
Yes
No
ejection fraction by muga or 2-d echocardiogram
within institution normal limits.*
Yes
No
creatinine clearance of greater than 60 cc/mm.*
Yes
No
ast and alt less than 3 times the upper limit of
normal.*
Yes
No
bilirubin less than 1.5 (except in cases of gilbert's
disease).*
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Yes
No
anc greater than l000/mm(3).*
Yes
No
platelet count greater than 90,000/mm(3).*
Yes
No
dlco greater than 50%.*
Yes
No
no history of medical or psychiatric disease which
would preclude safe treatment in the view of the
principal investigator.*
Yes
No
no history of abnormal bleeding tendency or
predisposition to repeated infections.*
Yes
No
patients must be able to give informed consent.*
Yes
No
Exclusion Criteria
patients with inflammatory breast cancer but with
metastatic disease.*
Yes
No
any patient may be excluded from this study at
the discretion of the principal investigator if it is
deemed that allowing participation would
represent an unacceptable medical or psychiatric
risk.*
Yes
No
any patient with a need for chronic steroids or
anticoagulation will be ineligible.*
Yes
No
any patient testing positive for hiv (aids) or
hepatitis b or c will be ineligible.*
Yes
No
any female patient known or found to be pregnant
will be considered ineligible.  patients of
childbearing potential unwilling to practice
contraception will be ineligible.*
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Yes
No
any patient with an active second malignancy
(excluding treated skin cancers or carcinoma in
situ) will be ineligible.*
Yes
No
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Eligibility Depressive Disorder
NCT02231268
Observational Study to Assess a 6-months Treatment With
Gladem; ODM derived from:
https://clinicaltrials.gov/show/NCT02231268
All rights reserved. Please visit https://medical-data-
models.org/forms/13042
Eligibility Depressive Disorder
NCT02231268
Inclusion Criteria
men and women at least 18 years old*
Yes
No
de novo prescription of gladem*
Yes
No
treatment with gladem  intended for at least 6
months*
Yes
No
depressive disorders*
Yes
No
Exclusion Criteria
known hypersensitivity against sertraline*
Yes
No
concomitant treatment with monoamine oxidase
(mao)-inhibitors, selegiline, moclobemide
(washout for at least 14 days necessary)*
Yes
No
concomitant treatment  with other serotoninergic
substances like tryptophan or fenfluramine*
Yes
No
instable epilepsy*
Yes
No
according to product information (october 1998)
gladem prescription was  possible with
precautions in the following  cases:*
Yes
No
patients with stable epilepsy*
Yes
No
patients with restricted liver functions*
Yes
No
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suicidal patients*
Yes
No
patients in emotional state and marked sleeping
disorders*
Yes
No
according to product information (october 1998)
gladem should only be prescribed during
pregnancy and lactation period, if the expected
benefit was greater than the risk. women of
childbearing age should use gladem only in
combination with sufficient contraception.*
Yes
No
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Eligibility Carcinoma, Basal Cell
NCT00218829
DMSO-PDT of BCC - A 6 Year Follow Up; ODM derived
from: https://clinicaltrials.gov/show/NCT00218829
All rights reserved. Please visit https://medical-data-
models.org/forms/13045
Eligibility Carcinoma, Basal Cell
NCT00218829
Inclusion Criteria
histological verified bcc.*
Yes
No
one or two pdt treatments with treatment interval
no longer than two weeks.*
Yes
No
lesion complete response three months after
therapy.*
Yes
No
Exclusion Criteria
pregnant.*
Yes
No
gorlin's syndrome*
Yes
No
morpheaform or pigmented bcc.*
Yes
No
histology older than one year.*
Yes
No
tumour infiltration more than four mm.*
Yes
No
previous pdt treated lesions.*
Yes
No
1 / 1
Eligibility Carcinoma, Non-Small-Cell Lung
NCT00001499
Phase II Neoadjuvant Trial of a Continuous Infusion of
Paclitaxel Plus Cisplatin Followed by Chest Radiotherapy
for Patients With Stage III Non-Small Cell Lung Cancer;
ODM derived from:
https://clinicaltrials.gov/show/NCT00001499
All rights reserved. Please visit https://medical-data-
models.org/forms/13046
Eligibility Carcinoma, Non-Small-Cell
Lung NCT00001499
Criteria
histologically confirmed non-small cell lung
cancer of the following histologies: squamous cell
carcinoma, adenocarcinoma, large cell
carcinoma, no mixed small/non-small cell
carcinoma with predominant small cell
component.*
Yes
No
unresectable stage iiia/b disease confined to
thorax including:*
Yes
No
microscopic disease involvement following
attempted surgery and limited to anatomic areas
corresponding to stage iii disease (n2-3, t3-4).*
Yes
No
surgically treated stage i/ii disease with histologic
or cytologic proof of relapse and limited to
anatomic areas corresponding to stage iii disease
(n2-3, t3-4).*
Yes
No
t3, n0 tumor extending directly to the chest wall
considered resectable and not eligible.*
Yes
No
no stage iiib disease with pleural effusion visible
on chest x-ray unless related to a previous
thoracotomy.*
Yes
No
no typical carcinoid or mesothelioma.*
Yes
No
measurable disease preferred but not required.*
Yes
No
no prior chemotherapy or thoracic radiotherapy.*
Yes
No
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age: 18 and over.*
Yes
No
performance status: ecog 0-2.*
Yes
No
agc greater than 2,000.*
Yes
No
platelets greater than 100,000.*
Yes
No
hepatic: bilirubin no greater than 1.5 mg/dl.*
Yes
No
renal: creatinine no greater than 1.5 mg/dl.*
Yes
No
no symptomatic heart disease including: less
than fully compensated congestive cardiac
failure, significant arrhythmias e.g.:  greater than
first-degree heart block, uncontrolled and
symptomatic atrial dysrhythmia except sinus,
bradycardia or sustained ventricular tachycardia,
myocardial infarction within 3 months.*
Yes
No
pulmonary: no major uncontrolled active infection
(unless due to obstructed bronchus).*
Yes
No
no major active psychiatric problem requiring
hospitalization or psychotropic medication such
as phenothiazines.*
Yes
No
no prior second malignancy within 5 years
except:  nonmelanomatous skin cancer, in situ
carcinoma of the cervix.*
Yes
No
no pregnant or nursing women.*
Yes
No
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Eligibility Carcinoma, Renal Cell
NCT00502034
Low-dose IL-2 Plus IFN-alpha Immunotherapy as Adjuvant
Treatment of Renal Carcinoma.; ODM derived from:
https://clinicaltrials.gov/show/NCT00502034
All rights reserved. Please visit https://medical-data-
models.org/forms/13048
Eligibility Carcinoma, Renal Cell
NCT00502034
Inclusion Criteria
diagnosis histologically confirmed of renal cells
carcinoma (every histotype);*
Yes
No
age < 75 years*
Yes
No
radical surgical removal of the tumor: total or
partial nephrectomy  within previous 3 months*
Yes
No
patient classified as t1 (with diameter > 2,5 cm),
t2, t3 a-b-c; in presence of involvement of loco-
regional  lymph-nodes (staging n1, n2, n3, tnm
class.), metastases should have been completely
removed during nephrectomy*
Yes
No
absence of distant metastases;*
Yes
No
written informed consent*
Yes
No
Exclusion Criteria
tumor diameter equal or less than 2,5 cm;*
Yes
No
previous chemotherapy or ormonotherapy o
immunotherapy;*
Yes
No
renal insufficiency >3 mg/dl);*
Yes
No
no symptomatic arrhythmias or autoimmune
disease*
Yes
No
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Moxaverine 200mg p.o. in patients with
central nervous vertigo 2
Placebo controlled,double blind and randomized parallel
group trial to verify effectivity and tolerability of moxaverine
p.o. in patients with central nervous vertigo. Sponsor:
URSAPHARM Industriestrasse 66129 Saarbrücken Phone
06805-9292-0 Fax 06805- 929288 Head of clinical trial:
Univ.-Prof.Dr.med. Ralph Mösges Medical Faculty,
University of Cologne Phone 0221-4783456 Fax 0221-
4783465
All rights reserved. Please visit https://medical-data-
models.org/forms/13049
Case report form Visit 2
Patient Identification
Patient Number
Study site number
Date of completion of this form
otorhinolaryngologic examination
Otoscopy
normal (1)
findings (2)
Rinne test
normal (1)
findings (2)
Webers test
normal (1)
findings (2)
Direction of eye movement with frenzel lens
eyeglasses
horizontal (1)
vertical (2)
rotating (3)
Amplitude of eye movement with frenzel-lens
eyeglasses
small (1)
medium (2)
heavy (3)
Frequency of eye movement with frenzel lens
eyeglasses
little (1)
medium (2)
high (3)
Dizziness
little (1)
distinctly (2)
severe (3)
Please specify findings of Otoscopy
1 / 4
Please specify findings of Rinne test
Please specify findings of Webers test
Posturography
Any significant findings during computerized
dynamic posturography procedure
None (1)
Yes (2)
Please specify findings during computerized
dynamic posturography procedure
Tasks of investigator during this visit
DHI-Questionnaire given to patient
Yes
No
Remaining trial medication retrieved from
patient?
Yes
No
Number of tablets of trial medication retrieved
from patient
Following package of trial medication given to
patient
Yes
No
Any questions the patient might have have been
answered.
Yes
No
Please note questions and answers given
Signature date
Signature
Comorbidities and concomitant Medication
Have comorbidities changed?
Yes
No
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Please specify comorbidities by ICD-Code
Has concomitant medication been subject to
change?
Yes
No
Please specify medication name,dose,start and
end date
or
Therapy
additional comments
General impression regarding the trial
General tolerance of trial substance
very good (1)
good (2)
fair (3)
poor (4)
General therapeutic effectiveness
Very good (1)
Good (2)
Fair (3)
Poor (4)
Signature Date
Signature
Adverse reactions
During this trial period,have there been adverse
reactions to the study drug?
Yes
No
Please specify the adverse event or reaction
Severity of adverse event or reaction
Mild (1)
Moderate (2)
Severe (3)
Life threatening (4)
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Treatment of AE
None (1)
dose reduction (2)
dose omission (3)
discontinuation (4)
antidote (5)
concomitant medication changed (6)
other (7)
Development of adverse event or reaction
subsided (1)
decreased (2)
persistent (3)
increased (4)
fatal (5)
unknown (6)
other (7)
Association with trial substance
by underlying disease (1)
none (2)
possible (3)
likely (4)
affirmative (5)
Please give further information about
countermeasures, development,outcome and
judgment of the AE
Signature Date
Signature
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Eligibility Chronic Heart Failure
NCT00501514
Effects of Growth Hormone on Exercise Capacity; ODM
derived from: https://clinicaltrials.gov/show/NCT00501514
All rights reserved. Please visit https://medical-data-
models.org/forms/13050
Eligibility Chronic Heart Failure
NCT00501514
Inclusion Criteria
ejection fraction < 40%*
Yes
No
left ventricular internal dimension >58 mm*
Yes
No
ii-iii nyha class*
Yes
No
stable hemodynamic condition during the
previous three months*
Yes
No
sinus rhythm*
Yes
No
Exclusion Criteria
ima or cabg or ptca in the previous six months*
Yes
No
unstable angina*
Yes
No
major arrhythmias (lown class> iv)*
Yes
No
diseases limiting exercise capacity*
Yes
No
insulin treated diabetes mellitus*
Yes
No
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central nervous vertigo 3
Placebo controlled,double blind and randomized parallel
group trial to verify effectivity and tolerability of moxaverine
p.o. in patients with central nervous vertigo. Sponsor:
URSAPHARM Industriestrasse 66129 Saarbrücken Phone
06805-9292-0 Fax 06805- 929288 Head of clinical trial:
Univ.-Prof.Dr.med. Ralph Mösges Medical Faculty,
University of Cologne Phone 0221-4783456 Fax 0221-
4783465
All rights reserved. Please visit https://medical-data-
models.org/forms/13051
Case report form Visit 3
Demographic Information
Patient Number
Study site number
Date of completion of this form
otorhinolaryngologic examination
Otoscopy
normal (1)
abnormal (2)
Please specify findings of Otoscopy
Rinne test
normal (1)
abnormal (2)
Please specify findings of Rinne test
Webers test
normal (1)
abnormal (2)
Please specify findings of Webers test
Direction of eye movement with frenzel lens
eyeglasses
horizontal (1)
vertical (2)
rotating (3)
Amplitude of eye movement with frenzel lens
eyeglasses
small (1)
medium (2)
heavy (3)
Frequency of eye movement with frenzel lens
eyeglasses
little (1)
medium (2)
high (3)
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Dizziness with frenzel lens eyeglasses
little (1)
distinctly (2)
severe (3)
Posturography
Any significant findings during computerized
dynamic posturography procedure
None (1)
Yes (2)
Please specify findings during computerized
dynamic posturography procedure
Tasks of investigator during this visit
DHI-Questionnaire given to patient
Yes
No
Remaining trial medication retrieved from
patient?
Yes
No
Number of tablets of trial medication retrieved
from patient
Following package of trial medication given to
patient
Yes
No
Any questions the patient might have have been
answered.
Yes
No
Please note questions and answers given
Signature Date
Signature
Comorbidities and concomitant Medication
Have comorbidities changed?
Yes
No
Please specify comorbidities by ICD-Code
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Has concomitant medication been subject to
change?
Yes
No
Please specify medication name,dose,start and
end date of therapy
additional comments
General impression regarding the trial
General tolerance of trial substance
very good (1)
good (2)
fair (3)
poor (4)
General therapeutic effectiveness
very good (1)
good (2)
fair (3)
poor (4)
Signature date
Signature
Adverse reactions
During this trial period,have there been adverse
reactions to the study drug?
Yes
No
Please specify the adverse event or reaction
Severity of adverse event or reaction
Mild (1)
Moderate (2)
Severe (3)
Life-threatening (4)
Treatment of AE
None (1)
dose reduction (2)
dose omission (3)
discontinuation (4)
antidote (5)
concomitant medication changed (6)
other (7)
Development of adverse event or reaction
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subsided (1)
decreased (2)
persistent (3)
increased (4)
fatal (5)
unknown (6)
other (7)
Association with trial substance
by underlying disease (1)
none (2)
possible (3)
likely (4)
affirmative (5)
Please give further information about
countermeasures, development,outcome and
judgment of the AE
Signature date
Signature
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Moxaverine 200mg p.o. in patients with
central nervous vertigo Pharmacovigilance
Placebo controlled,double blind and randomized parallel
group trial to verify effectivity and tolerability of moxaverine
p.o. in patients with central nervous vertigo. Sponsor:
URSAPHARM Industriestrasse 66129 Saarbrücken Phone
06805-9292-0 Fax 06805- 929288 Head of clinical trial:
Univ.-Prof.Dr.med. Ralph Mösges Medical Faculty,
University of Cologne Phone 0221-4783456 Fax 0221-
4783465
All rights reserved. Please visit https://medical-data-
models.org/forms/13052
Case Report Form
Pharmacovigilance
Demographic Information
Patient number
Study Site number
Visit number
Week as outlined in Follow-up schedule
Patient Initials: first three characters of given and
last name
Patient age
Patient Gender
Female (f)
Male (m)
Body height
>= 0
cm
Body weight
>= 0
kg
Pharmacovigilance 1
Please give the date the Adverse Event occurred
Please give a detailed discription of the AE
Plasma concentration of trial substance
determinated?
Yes
No
Laboratory Procedure Date
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Please specify plasma concentration of trial
substance
Please specify any medication used starting with
trial substance
Please specify dose of applied substance,
frequency and route of administration
Date the medication was started
Date medication was stopped
Please specify any Indication for medications
administered using ICD Codes
Signature Date
Signature
Pharmacovigilance 2
Date of first occurrence of the AE
Has the trial substance been discontinued?
Yes
No
Event resulted in a hospitalization
Yes
No
Date of hospitalization due to the AE
Has the hospitalization of an inpatient been
prolonged due to the AE?
Yes
No
Please give a detailed description of actions
taken
Please give your opinion on the correlation of the
reported AE with the trial
no obvious correlation with the study (1)
questionable influence of trial substance
(2)
possible influence of trial substance (3)
likely influence of trial substance (4)
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Pharmacovigilance
cannot be determined at this point (5)
Please list all enclosed documents
Please give name and qualification of completing
health care professional
Signature Date
Signature
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Pharmacovigilance
Eligibility Lymphoma, Non-Hodgkin
NCT00938041
Retreatment of Patients With Non-Hodgkin's Lymphoma
Who Have Previously Responded to Iodine-131 Anti B1
Antibody; ODM derived from:
https://clinicaltrials.gov/show/NCT00938041
All rights reserved. Please visit https://medical-data-
models.org/forms/13055
Eligibility Lymphoma, Non-Hodgkin
NCT00938041
Inclusion Criteria
patients with histologically confirmed initial
diagnosis of non-hodgkin's b-cell lymphoma*
Yes
No
patients must have previously responded with a
duration of response of at least 3 months to
iodine-131 anti-b1 antibody therapy*
Yes
No
patients must have evidence that their tumor
tissue had cd20 expression*
Yes
No
patients must have performance status of at least
60% on the karnofsky scale and an anticipated
survival of at least 3 months*
Yes
No
patients must have absolute granulocyte count
(anc) greater than 1,500 cells/mm3 and platelet
count greater than 100,000 cells/mm3 within 14
days of study entry without support of
hematopoietic cytokines or transfusion of blood
products*
Yes
No
patients must have adequate renal  (serum
creatine less than 1.5 x upper limit of normal) and
hepatic function (total bilirubin less than 1.5 x
upper limit of normal and hepatic transaminases,
ast and alt, less than 5 x upper limit of normal)
within 14 days of study entry*
Yes
No
patients must have bi-dimensionally measurable
disease with a least one lesion greater than or
equal to 2 cm x 2 cm by ct scan*
Yes
No
patients must be at least 18 years of age*
Yes
No
patients must give written informed consent and
sign an institutional review board/ethics
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committee- approved informed consent form prior
to study entry*
Yes
No
Exclusion Criteria
patients with more than 25% bone marrow
involvement*
Yes
No
patients who have received cytotoxic
chemotherapy, radiation therapy,
immunosuppressants, or cytokine treatment
within 4 weeks prior to study entry or who exhibit
persistent clinical evidence of toxicity.  the use of
systemic steroids much be discontinued at least 1
week prior to study entry.*
Yes
No
patients with active obstructive hydronephoresis*
Yes
No
patients with evidence of active infection requiring
iv antibiotics at time of study entry*
Yes
No
patients with new york heart association class iii
or iv heart disease or other serious illness that
would preclude evaluation*
Yes
No
patients with prior malignancy other than
lymphoma, except for adequately treated skin
cancer, in situ cervical cancer, or other cancer for
which the patient has been disease free for 5
years*
Yes
No
patients with known hiv infection*
Yes
No
patients with known brain or leptomeningeal
metasteses*
Yes
No
patients who are pregnant or nursing*
Yes
No
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Efficacy and tolerability of subcutaneous hyposensitization with
CLUSTOID in Patients with allergic rhinoconjunctivitis 1.0
Prospective,multicentric,double blind and placebo-
controlled Phase III clinical trial to determine efficacy and
tolerability of subcutaneous hyposensitization with
CLUSTOID in patients with allergic rhinoconjunctivits
caused by grass or rye pollen.
EudraCT-Nr. 2008-000513-29
Study-code:CLU-2008-001
Sponsor:
ROXALL Medizin GmbH
Carl-Petersen-Straße 4
20535 Hamburg
Phone:040-8972520
Fax:040-89725223
Project coordinator:
Dr.Jenny Uhlig
ROXALL Medizin GmbH
Head of clinical investigation:
Prof.Dr.med.Ludger Klimek
An den Quellen 10
65183 Wiesbaden
Phone:0611-8904381
Fax:0611-3082360
Monitoring,data management and statistical evaluation:
IMSIE- Institut for medical statistics,computer sciences and
epidemiology
University hospital Cologne
Lindenburger Allee 42
50931 Cologne
Phone:0221-4783456
Fax:0221-4783465
All rights reserved. Please visit https://medical-data-
models.org/forms/13067
Case report form Visit 1
Inclusion criteria
Male or female between 18 and 75 years of age
Yes
No
Allergic rhinitis or rhinoconjunctivitis with or
without controlled seasonal asthma due to
allergen-exposure
Yes
No
Sensitization to grass and/or rye pollen
Yes
No
The majority of symptoms is experienced during
grass pollen season
Yes
No
Positive scratch test for grass pollen with
minimum diameter of rash 3mm
Yes
No
Planned treatment for allergies and/or asthma
with at least one of the following substances
local cromoglycate (eye,nose) (1)
oral antihistamine (2)
nasal steroid (3)
oral leukotriene antagonist (4)
total symptom score of equal to or higher than 8
during previous pollen season
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Yes
No
Patient is willing and able to keep track of
symptoms and antiallergic medication with a
patient diary
Yes
No
Signed informed consent
Yes
No
All laboratory results are within normal range or
to be considered not relevant
Yes
No
Exclusion criteria
Participation in any other clinical trial at the same
time
Yes
No
Hyposensitization with grass or rye pollen extract
within 3 years prior to enrollment
Yes
No
Predominantly perennial allergic rhinitis
Yes
No
Poorly or not controlled Asthma (GINA Guidelines
2007)
Yes
No
Inflammation or Infection of targeted organs
Yes
No
Irreversible secondary changes to the targeted
organ like emphysema or bronchiectasis (FEV <
70 percent of predicted value)
Yes
No
Active tuberculosis
Yes
No
Autoimmune diseases
Yes
No
Severe chronic inflammatory diseases
Yes
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No
Malignancies
Yes
No
Alcohol abuse
Yes
No
Prior or continuing treatment with psychotropic
drugs or tranquilizer
Yes
No
Prior or continuing treatment with Anti-IgE
Antibodies
Yes
No
Treatment with adrenergic beta receptor
antagonists (including locally applied eye drops)
or other contraindicated drugs
Yes
No
Any contraindication to the use of Adrenaline
Yes
No
Women of childbearing potential, pregnancy or
breastfeeding
Yes
No
Female of childbearing potential, not using safe
contraceptive measures
Yes
No
Ability to understand directions or protocol limited
due to comorbidity or language barrier
Yes
No
Suspected poor compliance or other
contraindications to enrollment to the discretion
of the investigator
Yes
No
Dependency from the sponsor or the clinical
investigator
Yes
No
Medical History and documentation of first
Dose of trial substance
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CLUSTOID in Patients with allergic rhinoconjunctivitis 1.0
Date of visit 1
Date of informed consent
Please give Patient ID composed of Study site Nr
and Patient Nr
Patient date of birth
DD.MM.YYYY
Patient gender
male (1)
female (2)
Please state the patient´s ethnicity
caucasian (1)
asian (2)
negroid (3)
other (4)
Please specify other ethnicity
Female of childbearing potential, using safe
contraceptive measures
Yes
No
Was a pregnancy test performed?
Yes
No
Please specify the date of the pregnancy test
Result of pregnancy test
positive-> exclusion from trial (1)
negative->safe contraception throughout
the trial (2)
Blood pressure (BP)
mmHg
Body height
cm
Body weight
kg
Heart rate
bpm
Edema
none (0)
little (1)
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severe (2)
secretion
none (0)
clear fluid (1)
congested/mucous (2)
Redness
none (0)
little (1)
severe (2)
Sensitization against grass pollen
Yes
No
Sensitization against rye pollen
Yes
No
Sensitization against other allergen,please
specify
Clinical symptoms of Rhinits
yes (1)
No-> exclusion from trial (2)
Symptoms of Rhinitis are mainly:
seasonal (1)
perennial-> exclusion from trial (2)
Year Rhinitis occurred for the first time
Clinical symptoms of rhinoconjunctivitis present?
Yes
No
Year rhinoconjunctivitis occurred for the first time
Has the patient been diagnosed with allergic
asthma?
Yes
No
Please state the year allergic asthma has been
diagnosed
Asthma symptoms are mainly
seasonal (1)
perennial -> exclusion from trial (2)
Symptoms are
controlled (1)
partially controlled ->exclusion from trial
(2)
uncontrolled -> exclusion from trial (3)
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Please specify planned antiallergic treatment
local cromoglycat (1)
oral antihistamine (2)
nasal steroid (3)
Please specify prior illnesses,vaccinations and
antibiotic treatment of the past 10 years
Are there any comorbidities?
Yes
No
Comorbidities
active tuberculosis -> exclusion (1)
autoimmune diseases -> exclusion (2)
severe chronic inflammatory diseases ->
exclusion (3)
malignancies -> exclusion (4)
irreversible secondary changes to the
targeted organ -> exclusion (5)
severe hypertension -> exclusion (6)
other (7)
Please specify other comorbidities
Does the patient use any other medication?
Yes
No
Does the patient use any of the above mentioned
medications?
yes -> exclusion (1)
no (2)
Please specify any other concomitant agent
Examination of cardiovascular system
normal (1)
abnormal (2)
Please specify findings during examination of the
cardiovascular system
Respiratory system
Normal (1)
Abnormal (2)
Please specify findings during examination of the
respiratory system
Gastrointestinal system
normal (1)
abnormal (2)
Please specify findings during examination of the
gastrointestinal system
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CLUSTOID in Patients with allergic rhinoconjunctivitis 1.0
Examination of the eyes
Normal (1)
Abnormal (2)
Please specify findings during examination of the
eyes
Physical examination of the nose
Normal (1)
Abnormal (2)
Please specify findings during examination of the
nose
Physical examination of the ears
Normal (1)
Abnormal (2)
Please specify findings during examination of the
ears
Physical examination of the throat
Normal (1)
Abnormal (2)
Please specify findings during examination of the
throat
Examination of the endocrine system
Normal (1)
Abnormal (2)
Please specify findings during testing of the
endocrine system
Examination of the musculoskeletal system
Normal (1)
Abnormal (2)
Please specify findings during examination of the
musculoskeletal system
Examination of the central nervous system
Normal (1)
Abnormal (2)
Please specify findings during the examination of
the central nervous system
Examination of the genitourinary tract
Normal (1)
Abnormal (2)
Please specify findings during examination of the
genitourinary tract
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Efficacy and tolerability of subcutaneous hyposensitization with
CLUSTOID in Patients with allergic rhinoconjunctivitis 1.0
Examination of the lymphatic system
Normal (1)
Abnormal (2)
Please specify findings during examination of the
lymphatic system
Please specify any other finding during the
physical examination
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Efficacy and tolerability of subcutaneous hyposensitization with
CLUSTOID in Patients with allergic rhinoconjunctivitis 1.0
Eligibility Diabetes Mellitus, Type 1
NCT00190502
Polyclonal Anti-T-Lymphocyte Globulin (ATG) in Type 1
Diabetes; ODM derived from:
https://clinicaltrials.gov/show/NCT00190502
All rights reserved. Please visit https://medical-data-
models.org/forms/13093
Eligibility Diabetes Mellitus, Type 1
NCT00190502
Inclusion Criteria
type 1 diabetes*
Yes
No
body mass index up to 32 kg/m2*
Yes
No
exclusion of gravidity in women*
Yes
No
known diagnosis of diabetes of less than 6
weeks*
Yes
No
insulin dose of up to 40 iu per day for no longer
than 1 month*
Yes
No
positive for at least one autoantibody (gad, ia2,
ica)*
Yes
No
c-peptide level ≥ 0.3 pmol/ml 4 min. following
intravenous (iv) administration of 1 ml glucagon*
Yes
No
no concurrent severe infection*
Yes
No
granulocyte count ≥ 2 x 10^9/l*
Yes
No
platelet count ≥ 120 x 10^9/l*
Yes
No
Exclusion Criteria
other non-diabetes related autoimmune disease*
Yes
No
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previous immunosuppressive therapy*
Yes
No
any clinical impairment precluding
immunosuppressive therapy*
Yes
No
leucopenia or thrombocytopenia*
Yes
No
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Eligibility Diabetes Mellitus, Type 1 NCT00190502
Eligibility Diabetes Mellitus, Type 1
NCT00623610
Beta-Cell Transplantation in Pre-Uremic Patients With Type
1 Diabetes; ODM derived from:
https://clinicaltrials.gov/show/NCT00623610
All rights reserved. Please visit https://medical-data-
models.org/forms/13094
Eligibility Diabetes Mellitus, Type 1
NCT00623610
Inclusion Criteria
type 1 insulin-dependent diabetic patients in
relatively good general condition*
Yes
No
non-smoker*
Yes
No
body weight < 80 kg*
Yes
No
c-peptide < 0.03 nmol/l (<0.09 µg/l) 6 min. after
glucagon iv (1mg) (glycemia > 180 mg/dl)*
Yes
No
ebv antibody positive*
Yes
No
cooperative and reliable patient giving informed
consent by signature;  the patient should be
informed in sufficient detail on the content and
procedure of the protocol, indicating potential
risks of intervention and of immunosuppressive
therapy; the patient should also be informed that
withdrawal of immunosuppressive therapy in
patients with persistent plasma c-peptide
positivity may result in subsequent loss of ß-cell
graft function; the ß cell implant should be
identified as a clinical trial.*
Yes
No
Exclusion Criteria
history of thrombosis or pulmonary embolism*
Yes
No
abnormal liver function*
Yes
No
hla antibodies*
Yes
No
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Eligibility Diabetes NCT00811044
Regulation of Hepatic Insulin Extraction; ODM derived
from: https://clinicaltrials.gov/show/NCT00811044
All rights reserved. Please visit https://medical-data-
models.org/forms/13095
Eligibility Diabetes NCT00811044
Inclusion Criteria
ages 18-65*
Yes
No
non-diabetic*
Yes
No
diabetes controlled with diet or with pills*
Yes
No
no family history of diabetes*
Yes
No
family history of type 2 diabetes*
Yes
No
personal history of gestational diabetes*
Yes
No
Exclusion Criteria
< 18 or > 65 years of age*
Yes
No
medications that affect glucose (sugar) levels*
Yes
No
kidney disease*
Yes
No
liver disease*
Yes
No
heart/cardiovascular disease*
Yes
No
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Eligibility Early Rheumatoid Arthritis
NCT00195663
Efficacy and Safety of Adalimumab and Methotrexate
(MTX) Versus MTX Monotherapy in Subjects With Early
Rheumatoid Arthritis; ODM derived from:
https://clinicaltrials.gov/show/NCT00195663
All rights reserved. Please visit https://medical-data-
models.org/forms/13096
Eligibility Early Rheumatoid Arthritis
NCT00195663
Inclusion Criteria
subject was age 18 or older and in good health
(investigator discretion) with a recent stable
medical history.*
Yes
No
diagnosis of rheumatoid arthritis (ra) as defined
by the 1987-revised american college of
rheumatology (acr) criteria, with a disease
duration less than 3 years, at least 8 swollen
joints out of the 66 joints assessed, at least 10
tender joints out of the 68 joints assessed, at
least 1 joint erosion or rheumatoid factor (rf)
positivity, erythrocyte sedimentation rate (esr) >=
28 mm/1h or c-reactive protein (crp) >= 1.5
mg/dl*
Yes
No
Exclusion Criteria
chronic arthritis diagnosed before the age of 16*
Yes
No
preceding treatment with mtx, cyclophosphamide,
cyclosporin, azathioprine or more than 2 other
disease-modifying anti-rheumatic drugs
(dmards)*
Yes
No
subject previously received anti-tumor necrosis
factor (tnf) therapy*
Yes
No
permanently wheelchair-bound or bedridden
patients*
Yes
No
subject considered by the investigator, for any
reason, to be an unsuitable candidate for the
study*
Yes
No
female subject who is pregnant or breast-feeding
or considering becoming pregnant*
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Yes
No
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Eligibility Follicular Lymphoma
NCT00115700
Radiotherapy Versus Radiotherapy Plus Chemotherapy in
Early Stage Follicular Lymphoma; ODM derived from:
https://clinicaltrials.gov/show/NCT00115700
All rights reserved. Please visit https://medical-data-
models.org/forms/13097
Eligibility Follicular Lymphoma
NCT00115700
Inclusion Criteria
adult patients (≥ 18 years old) with histologically
documented "follicular lymphoma, grade 1",
grade 2", or "follicular lymphoma, grade 3a"
diagnosed following an excisional, incisional or
generous core biopsy. (i.e. an fna alone is
insufficient.)*
Yes
No
disease limited to stages i and ii after   adequate
staging*
Yes
No
anticipated life expectancy > 5 years*
Yes
No
given written informed consent*
Yes
No
been assessed by a radiation oncologist and a
medical oncologist/ haematologist*
Yes
No
wcc > 3.0 x 10^9/l, platelet count > 100 x 10^9/l,
serum creatinine < 0.15 mmol/l*
Yes
No
ability to commence radiotherapy within 6 weeks
of randomisation*
Yes
No
women using effective contraception, are not
pregnant and agree not to become pregnant
during participating in the trial and during the 12
months thereafter. men agree not to father a child
during participation in the trial and during the 12
months thereafter.*
Yes
No
Exclusion Criteria
received previous systemic cytotoxic
chemotherapy.*
Yes
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No
received previous radiotherapy, (except
superficial radiation therapy for non-melanoma
skin cancers).*
Yes
No
received previous immunotherapy.*
Yes
No
a medical contraindication to radiotherapy,
chemotherapy, or rituximab.*
Yes
No
any previous or concurrent malignancy other than
curatively treated non-melanoma skin cancer,
level 1 malignant melanoma, or in situ cervical
cancer, unless disease and treatment-free for 5
years.*
Yes
No
such extensive involvement of the thorax that
treatment with radiation therapy alone would be
hazardous because of excessive lung irradiation,
even if a shrinking field technique were
employed.*
Yes
No
suspected or confirmed pregnancy. must not be
lactating.*
Yes
No
patients who have known human immuno-
deficiency virus (hiv) infection or active hepatitis b
(hbv).*
Yes
No
treatment within a clinical study within 30 days
prior to study entry.*
Yes
No
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Eligibility Colorectal Cancer NCT00003225
Amifostine Plus Irinotecan in Treating Patients With
Metastatic Colorectal Cancer; ODM derived from:
https://clinicaltrials.gov/show/NCT00003225
All rights reserved. Please visit https://medical-data-
models.org/forms/13100
Eligibility Colorectal Cancer
NCT00003225
Inclusion Criteria
18 years of age or older*
Yes
No
ecog 0-2*
Yes
No
life expectancy of at least 12 weeks*
Yes
No
pathologically confirmed diagnosis of metastatic
colorectal cancer*
Yes
No
measureable disease*
Yes
No
have not received therapy for cancer within 4
weeks of enrollment on study*
Yes
No
prior radiation therapy to the pelvis for treatment
of colorectal cancer is allowed. radiation therapy
delivered elsewhere is allowed as long as the
patient has been off treatment for at least six
weeks and measurable lesions are present
outside the radiation field*
Yes
No
pretreatment granulocyte count of > 1500/mm3,
hemoglobin > 9.0 g/dl (without transfusion), and
platelet count of > 100,000/um*
Yes
No
serum creatinine < 2.0 mg/dl*
Yes
No
adequate hepatic function as documented by a
serum bilirubin < 2.0 mg/dl regardless of whether
patients have liver involvement secondary to
tumor.  ast must be < 3x the upper limit of normal
unless the liver is involved with tumor, in which
case the ast must be < 5x institutional upper limit
of normal*
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Yes
No
Exclusion Criteria
prior therapy with irinotecan*
Yes
No
patients with any active or uncontrolled infection*
Yes
No
patients with psychiatric disorders that would
interfere with consent or follow-up*
Yes
No
patients with a history of myocardial infarction
within the previous six months, congestive heart
failure, or cerebrovascular disease*
Yes
No
history of prior malignancy except for adequately
treated basal cell or squamous cell skin cancer,
in situ cervical cancer, or other cancer for which
the patient has been disease-free for at least five
years*
Yes
No
presence of clinically apparent central nervous
system metastases or carcinomatous meningitis*
Yes
No
patients with uncontrolled diabetes mellitus*
Yes
No
any other sever concurrent disease which, in the
judgment of the investigator, would make the
patient inappropriate for entry into this study*
Yes
No
patients unable to stop taking antihypertensive
medication 24 hour prior to administration of
ethyol (off x 1 day)*
Yes
No
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Eligibility Colorectal Cancer NCT02228785
A Study of the Safety and Tolerance of Three Doses of
G17DT in Metastatic Colorectal Cancer; ODM derived
from: https://clinicaltrials.gov/show/NCT02228785
All rights reserved. Please visit https://medical-data-
models.org/forms/13101
Eligibility Colorectal Cancer
NCT02228785
Inclusion Criteria
patients aged 18 years or over with histologically
verified adenocarcinoma of colon or rectum.*
Yes
No
recurrent of metastatic disease not amenable to
curative surgery and/or radiotherapy.*
Yes
No
life expectancy greater than 3 months.*
Yes
No
karnofsky index score greater than or equal to
50%.*
Yes
No
written informed consent obtained.*
Yes
No
Exclusion Criteria
neoplastic lesions other than colorectal cancer
(except treated basal cell carcinoma of the skin or
cancer of the uterine cervix, through stage i.*
Yes
No
acute intercurrent illness.*
Yes
No
patient considered to be a medical risk because
of non-malignant systemic disease or grossly
abnormal laboratory results.*
Yes
No
patients who had received any other anticancer
therapy within 3 months.*
Yes
No
factor liable to alter the serum gastrin
concentration or affect intra-gastric acidity, for
instance concomitant therapy with h2 receptor
antagonist drugs, proton pump inhibitors, or
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previous gastric surgery.*
Yes
No
patients immunologically compromised including
those on corticosteroid therapy.*
Yes
No
women of child-bearing age.*
Yes
No
positive immediate hypersensitivity reaction to
skin testing with study medication.*
Yes
No
patients unable to complete the diary book*
Yes
No
haematogical status haemoglobin count less than
10g/dl white blood cell count less than 4.0 x
10^9/l platelet count less than 100 x 10^9/l*
Yes
No
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Eligibility Colorectal Cancer NCT02228785
Eligibility Colorectal Neoplasm
NCT00001576
A Phase I Study of Isolated Hepatic Perfusion With
Escalating Dose Melphalan Followed by Postoperative
Hepatic Arterial Floxuridine and Leucovorin for Metastatic
Unresectable Colorectal Cancers of the Liver; ODM derived
from: https://clinicaltrials.gov/show/NCT00001576
All rights reserved. Please visit https://medical-data-
models.org/forms/13102
Eligibility Colorectal Neoplasm
NCT00001576
Criteria
patients must not have been previously treated
with intrahepatic artery infusional therapy using
fudr.*
Yes
No
patients mush have had no chemotherapy,
radiotherapy or biologic therapy for their
malignancy in the month prior to the liver
perfusion and must have recovered from all side
effects.*
Yes
No
patients must have an ecog performance
standard of 0, 1 or 2 on the day prior to
treatment.*
Yes
No
patients must have adequate hepatic function as
evidence by bilirubin less than 2.0 and a pt and
ptt that are within 1-2 seconds of the upper
normal limit.*
Yes
No
patients must not have biopsy proven cirrhosis or
evidence of significant portal hypertension by
history, endoscopy, or radiologic studies.*
Yes
No
patients must not have a history of congestive
heart failure with an lvef less than 40%.*
Yes
No
patients must not have copd or other chronic
pulmonary disease with pft's less than 50%
predicted for age.*
Yes
No
patients must be 18 years of age or older.*
Yes
No
patients must have a platelet count greater than
100,000 a hct greater than 27.0, a white blood
1 / 2
count greater than 3000/micro liters, and a
creatinine less than or equal to 1.5 or a creatinine
clearance of greater than 60 ml/min.*
Yes
No
patients must not be pregnant or nursing.*
Yes
No
patients must not be taking immunosuppressive
drugs or on chronic anticoagulation.*
Yes
No
patients must not have an active infection.*
Yes
No
patients must not have severe allergic reactions
to iodine contrast which can not be controlled by
premedication with antihistamines and steroids.*
Yes
No
patients must not have hiv disease.*
Yes
No
patients must be aware of the neoplastic nature
of his/her illness, the experimental nature of the
therapy, alternative treatments, potential benefits,
and risks.  the patient must be willing to sign an
informed consent.*
Yes
No
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Eligibility Lung Cancer NCT00003053
Combination Chemotherapy in Treating Patients With Stage
I, II, or IIIA Non-small Cell Lung Cancer That Has Been
Surgically Removed; ODM derived from:
https://clinicaltrials.gov/show/NCT00003053
All rights reserved. Please visit https://medical-data-
models.org/forms/13103
Eligibility Lung Cancer
NCT00003053
Criteria
histologically proven stage i, ii, or iiia non-small
cell lung cancer after radical surgery*
Yes
No
no evidence of lymphonodal enlargement during
postsurgical chest ct scan*
Yes
No
70 and under*
Yes
No
ecog performance status: 0-2*
Yes
No
wbc at least 3,500/mm3*
Yes
No
platelet count at least 100,000/mm3*
Yes
No
creatinine no greater than 1.5 times the upper
limit of normal*
Yes
No
fev1 at least 1 liter*
Yes
No
less than 10% weight loss in the past 3 months*
Yes
No
no prior malignancy except nonmelanoma skin
cancer or carcinoma in situ of the cervix*
Yes
No
radical surgery required*
Yes
No
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Eligibility Non-Insulin-Dependent Diabetes
Mellitus NCT00825383
Effect of Dietary Fiber on Glucose & Lipids in Non Insulin
Dependent Diabetes Mellitus (NIDDM); ODM derived from:
https://clinicaltrials.gov/show/NCT00825383
All rights reserved. Please visit https://medical-data-
models.org/forms/13104
Eligibility Non-Insulin-Dependent
Diabetes Mellitus NCT00825383
Inclusion Criteria
niddm*
Yes
No
age 35 to 80 years*
Yes
No
stable oral hypoglycemic treatment for at least
one month*
Yes
No
fasting triglycerides < 500 mg/dl*
Yes
No
Exclusion Criteria
insulin dependent niddm*
Yes
No
insulin dependent diabetes*
Yes
No
hepatic disease*
Yes
No
significant hepatic dysfunction*
Yes
No
signifiacnt renal dysfunction*
Yes
No
presence of significant hematological,
neurological, cardiovascular or gastrointestinal
disorder, unless stable for past 6 months,*
Yes
No
serious intercurrent illness or anticipated major
surgery*
Yes
No
female pregnant or likely to become pregnant*
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Yes
No
chronic drug abuse, alcoholism or psychaitric
disorder within the past 2 years*
Yes
No
treated with  beta adrenergic blockers*
Yes
No
on lipid lowering drugs*
Yes
No
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Eligibility Non-Insulin-Dependent Diabetes Mellitus NCT00825383
Eligibility Prostate Cancer NCT00959023
Study of Blood and Tumor Samples From Men With an
Inherited Risk of Prostate Cancer; ODM derived from:
https://clinicaltrials.gov/show/NCT00959023
All rights reserved. Please visit https://medical-data-
models.org/forms/13105
Eligibility Prostate Cancer
NCT00959023
Criteria
meets 1 of the following criteria:*
Yes
No
diagnosis of prostate cancer meeting any of the
following criteria:*
Yes
No
attending prostate clinics at the royal marsden
nhs foundation trust*
Yes
No
any age at diagnosis*
Yes
No
not attending prostate clinics at the royal
marsden nhs foundation trust, meeting 1 of the
following criteria:*
Yes
No
no older than 60 years at diagnosis*
Yes
No
diagnosis in two relatives where one is ≤ 65 years
at diagnosis*
Yes
No
at any age in a cluster with 3 or more cases*
Yes
No
any unaffected male relatives of men who are
already taking part in the study*
Yes
No
able to understand the information sheet and give
informed consent*
Yes
No
no man who is too ill to take part*
Yes
No
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Eligibility Follicular Lymphoma
NCT00393107
Safety and Efficacy of Fludarabine and Cyclophosphamide
+ Rituximab; ODM derived from:
https://clinicaltrials.gov/show/NCT00393107
All rights reserved. Please visit https://medical-data-
models.org/forms/13106
Eligibility Follicular Lymphoma
NCT00393107
Inclusion Criteria
histologically documented who grade 1-2
,cd20+,follicular lymphoma*
Yes
No
relapsed follicular lymphoma*
Yes
No
stage iii or iv disease*
Yes
No
stage ii patients are eligible if they present with b
symptoms or bulky disease*
Yes
No
to have a need for therapy in the opinion of
treating clinician*
Yes
No
measurable disease*
Yes
No
expected survival of 6 months or more*
Yes
No
age 18 to 70 years*
Yes
No
to have undergone < 3 lines of chemotherapy*
Yes
No
performance status of 0 to 2*
Yes
No
Exclusion Criteria
known hiv infections*
Yes
No
known hepatitis b or c*
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Yes
No
cns lymphoma*
Yes
No
previous malignancies, or cardiac, renal, hepatic,
or respiratory failure*
Yes
No
pregnant or lactating women and patients of child
bearing potential unless using birth control
measures*
Yes
No
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Eligibility Prostate Carcinoma
NCT00002540
Screening for Prostate Cancer in Older Patients (PLCO
Screening Trial); ODM derived from:
https://clinicaltrials.gov/show/NCT00002540
All rights reserved. Please visit https://medical-data-
models.org/forms/13107
Eligibility Prostate Carcinoma
NCT00002540
Exclusion Criteria
men who at the time of randomization are less
than 55 or greater than or equal to 75 years of
age*
Yes
No
individuals undergoing treatment for cancer at
this time, excluding basal-cell and squamous-cell
skin cancer*
Yes
No
individuals with known prior cancer of the colon,
rectum, lung, prostate*
Yes
No
this includes primary or metastatic plco cancers*
Yes
No
individuals with previous surgical removal of the
entire colon, one lung, or the entire prostate*
Yes
No
individuals who are participating in another
cancer screening or cancer primary prevention
trial*
Yes
No
males who have taken
proscar/propecia/finasteride in the past 6
months*
Yes
No
note: individuals who are already enrolled in the
trial when their physician prescribes finasteride
are not prevented from taking this medication. as
a result, these participants will continue to be
screened and followed just as those participants
who are not on finasteride.*
Yes
No
note: men who are taking tamoxifen are not
excluded from any part of the plco screening
trial.*
Yes
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No
individuals who are unwilling or unable to sign the
informed consent form*
Yes
No
males who have had more than one psa blood
test in the past three years*
Yes
No
individuals who have had a colonoscopy,
sigmoidoscopy, or barium enema in the past
three years*
Yes
No
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Eligibility Follicular Lymphoma
NCT00696735
High-Dose Therapy Treatment in Patients With Follicular
Lymphoma; ODM derived from:
https://clinicaltrials.gov/show/NCT00696735
All rights reserved. Please visit https://medical-data-
models.org/forms/13108
Eligibility Follicular Lymphoma
NCT00696735
Inclusion Criteria
age 18-60 years old*
Yes
No
follicular lymphoma b, c or d (working
formulation)*
Yes
No
no previous treatment*
Yes
No
seronegativity hiv*
Yes
No
ecog performance status less than or 2*
Yes
No
eligible for autologous stem-cell transplantation*
Yes
No
stage ii , iii or iv ann arbor classification*
Yes
No
criterias of high tumor burden*
Yes
No
patient's written informed consent*
Yes
No
Exclusion Criteria
age less than 18 years old or more than 60 years
old*
Yes
No
other type of lymphoma*
Yes
No
stage less than 3 or iii-iv (faible masse)*
Yes
No
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seropositivity hiv*
Yes
No
patients with a history of another malignancy
except basal cell skin cancer or in situ uterus
cancer*
Yes
No
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Eligibility Glucose Intolerance
NCT00005760
Health Effects of Liposuction in Overweight Women With
Elevated Insulin Levels, Impaired Glucose Tolerance and/or
Type 2 Diabetes; ODM derived from:
https://clinicaltrials.gov/show/NCT00005760
All rights reserved. Please visit https://medical-data-
models.org/forms/13109
Eligibility Glucose Intolerance
NCT00005760
Criteria
obesity:  defined as subjects having a body mass
index greater than 30 kg/m(2).  weight must be
less than 300 lb (136 kg) because of limits
related to the dxa and ct scanners.*
Yes
No
patients with type 2 diabetes, impaired glucose
tolerance, or hyperinsulinemia are eligible.*
Yes
No
patients' age must be greater than or equal to 18
years at the start of the study.*
Yes
No
patients must be planning to undergo large
volume liposuction.*
Yes
No
premenopausal women participating in the study
must have a negative pregnancy test at the start
of the study and will be required to remain on
some form of effective contraception for the
duration of the study.*
Yes
No
patients recruited for the pilot study will be
required to have all four grandparents and both
parents to be either all non-hispanic caucasians
or non-hispanic african-american.*
Yes
No
volunteers with the presence of significant,
unstable or evolving renal disease are not
eligible.  subjects must not have calculated (age
and weight corrected) creatinine clearances
below 50 ml/min or significant worsening of
serum creatinine levels during the course of the
study (greater than 30% increase from baseline).*
Yes
No
volunteers with the presence of significant,
unstable or evolving hepatic disease associated
with sgot and/or sgpt greater than 2.5 times
normal are not eligible.*
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Yes
No
volunteers with the presence of significant,
evolving or unstable cardiac disease are not
eligible.  subjects with nyha stage 3 or 4 disease
will be excluded from the study.*
Yes
No
volunteers with the presence of significant,
evolving or unstable pulmonary disease including
uncontrolled bronchial asthma and/or chronic
bronchitis are not eligible.*
Yes
No
volunteers with the presence of other
uncontrolled or unstable medical conditions
including uncontrolled thyroid disease, cushing's
syndrome, autoimmune or gastrointestinal
disease are not eligible.*
Yes
No
volunteers who are pregnant are not eligible.*
Yes
No
volunteers must not have uncontrolled type 2
diabetes as evidenced by recent coma or pre-
coma states, frequent episodes of hypoglycemia,
predominantly severe hyperglycemia (plasma
glucose greater than 400 mg/dl) in the past three
months prior to study commencement, a
glycosylated hemoglobin (hba1c) value greater
than 10 in the past three months prior to the
study commencement, and frequent or recurrent
episodes of ketosis (ketonuria and/or
ketonemia).*
Yes
No
volunteers with uncontrolled, significant or
evolving psychiatric/psychological syndromes
which in the opinion of the investigators would
place the patient at increased risk during the
course of the study or would impede competence
and/or ability to complete the study are not
eligible.*
Yes
No
volunteers with current history of illicit substance
abuse and/or alcoholism based on reported
history and the cage questionnaire are not
eligible.*
Yes
No
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volunteers must not have a recent use (within the
preceding 6 months) of anorexiant medications or
medications that would affect nutrient absorption
such as orlistat or acarbose.*
Yes
No
volunteers must not be receiving treatment with
an insulin-sensitizing medication such as
metformin or the thiazolidinediones.  use of
insulin, meglitides or the sulphonylureas will not
constitute an exclusion.*
Yes
No
volunteers with an absence of spontaneous
menses for greater than 1 year are not eligible.*
Yes
No
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Eligibility Glucose Intolerance
NCT00006162
Lifestyle Interventions to Reduce Diabetes Risk; ODM
derived from: https://clinicaltrials.gov/show/NCT00006162
All rights reserved. Please visit https://medical-data-
models.org/forms/13110
Eligibility Glucose Intolerance
NCT00006162
Inclusion Criteria
japanese american*
Yes
No
confirmed impaired glucose tolerance*
Yes
No
able to fill out questionnaires*
Yes
No
Exclusion Criteria
significant exercise-restricting disease*
Yes
No
poorly controlled hypertension*
Yes
No
psychiatric disease or dementia*
Yes
No
already on unusually restrictive diet*
Yes
No
use of hypolipidemic drugs*
Yes
No
use of tobacco*
Yes
No
abnormal blood screening tests*
Yes
No
ecg evidence of ischemic heart disease at rest*
Yes
No
abnormal maximal bruce treadmill test*
Yes
No
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Eligibility Healthy NCT00006173
Magnetic Resonance Imaging for Evaluating Kidney
Function; ODM derived from:
https://clinicaltrials.gov/show/NCT00006173
All rights reserved. Please visit https://medical-data-
models.org/forms/13111
Eligibility Healthy NCT00006173
Inclusion Criteria
healthy volunteers or patients with significant
clinical suspicion of renovascular hypertension.*
Yes
No
subjects  able to understand the informed
consent for this study.*
Yes
No
subjects must be able to hold their breath for 20
second intervals.*
Yes
No
patients must be clinically stable and be judged
by their physician able to tolerate the mr study of
1.5-2 hour duration.*
Yes
No
Exclusion Criteria
any contraindication for mr study including:
pacemaker or other implanted electronic device;
cochlear implants; metal in the eye; embedded
shrapnel fragments; cerebral aneurysm clips; or
medical infusion pumps.*
Yes
No
allergy to gadolinium, iodinated contrast media,
aceis, or sulphur-containing medication.*
Yes
No
patients have a hematocrit at or below 30.
severe anemia may predispose to hypotension
after captopril.*
Yes
No
patients with hyperkalemia (plasma potassium:
above 5.0 mmol/l), because of the risk of
arrhythmia.*
Yes
No
clinically unstable patients and those unable to
tolerate a 1-2 hour mr study.  examples of
medical conditions that would lead to exclusion
include unstable angina, dyspnea at rest, severe
pain at rest, or severe back pain.*
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Yes
No
pregnancy.*
Yes
No
nursing mothers.*
Yes
No
subjects who are claustrophobic and are unable
to tolerate mr imaging.*
Yes
No
patients with a serum creatinine concentration
above 4mg/dl.*
Yes
No
bilateral renal stents.*
Yes
No
healthy subjects must not have an abnormality
detected on dipstick urinalysis, or a systolic bp
above 140 mmhg or a diastolic bp above 90
mmhg on screening examination or an abnormal
bun or creatinine level in the blood.*
Yes
No
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Eligibility Healthy NCT00001413
Bone Mineral Density in Women With Major Depression;
ODM derived from:
https://clinicaltrials.gov/show/NCT00001413
All rights reserved. Please visit https://medical-data-
models.org/forms/13112
Eligibility Healthy NCT00001413
Criteria
Inclusion Criteria
a history of current or past major depression of at
least four months duration, or a history of two or
more brief depressive episodes will be the
primary criterion for inclusion.*
Yes
No
patients with bipolar disorder will be eligible if
they meet the depressive episode criterion.*
Yes
No
no specific inclusion criteria are set for normal
volunteers.*
Yes
No
Exclusion Criteria
depressed subjects:*
Yes
No
pregnant women will not be eligible to
participate.*
Yes
No
known medical causes of osteoporosis, other
than depression.*
Yes
No
current or past history of eating disorders, or
schizophrenia, as per dsm-iv.*
Yes
No
chronic use of oral or parenteral steroids (daily
use for 3 months or longer).*
Yes
No
healthy subjects:*
Yes
No
pregnant women will not be eligible to
participate.*
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Yes
No
known medical causes of osteoporosis.*
Yes
No
any history of dsm-iv diagnosis, including
depression, eating disorders, and alcohol or drug
abuse.*
Yes
No
history or current evidence of any significant
clinical or laboratory abnormalities.*
Yes
No
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Eligibility Healthy NCT00025857
Brain Function in Mentally Ill Adolescents; ODM derived
from: https://clinicaltrials.gov/show/NCT00025857
All rights reserved. Please visit https://medical-data-
models.org/forms/13113
Eligibility Healthy NCT00025857
Criteria
all subjects 7-18 (adolescents).*
Yes
No
consent: can give consent/assent.*
Yes
No
iq: all subjects will have iq greater than 70.*
Yes
No
subjects currently on antidepressants or
benzodiazepines medication.*
Yes
No
subjects suffering from adhd and currently on
stimulants.*
Yes
No
subjects with major depression: 
diagnosis: current diagnosis of mdd. clinical
impairment: cgas less than 60.*
Yes
No
subjects with ptsd:
diagnosis: current diagnosis of ptsd. clinical
impairment: cgas of less than 60.*
Yes
No
subjects with history of trauma:
trauma (i.e., sexual or physical abuse, exposure
to an accident, etc.) will be defined according to
the ksads, the child trauma questionnaire, the life
events survey and the history of adoption.*
Yes
No
Exclusion Criteria
any medical condition that increases risk for mri
(e.g. pacemaker, metallic foreign material in
eye).*
Yes
No
any medical condition that increases risk for
fluoxetine treatment for patients with mdd/ptsd.*
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Yes
No
pregnancy.*
Yes
No
participants suffering from acute psychosis or
suicidal ideation; current abuse/dependency to
alcohol or drugs.*
Yes
No
currently in an abusive situation at home.*
Yes
No
weight that is 15% more or less than ideal body
weight for sex and height.*
Yes
No
current tobacco use.*
Yes
No
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Eligibility Heart Diseases NCT01805492
Global Profiling of Gene and Protein Expression
Associated With Coronary Heart Disease Reversal; ODM
derived from: https://clinicaltrials.gov/show/NCT01805492
All rights reserved. Please visit https://medical-data-
models.org/forms/13114
Eligibility Heart Diseases
NCT01805492
Inclusion Criteria
diagnosis of coronary artery disease (cad)*
Yes
No
stable angina*
Yes
No
angioplasty*
Yes
No
evidence of >50% luminal narrowing on coronary
angiogram*
Yes
No
acute myocardial infarction*
Yes
No
bypass surgery*
Yes
No
stent placement or*
Yes
No
two or more cad risk factors*
Yes
No
systolic pressure >140 mm hg or diastolic
pressure >90 mm hg)*
Yes
No
high total cholesterol (>200 mg/dl)*
Yes
No
physician diagnosed diabetes*
Yes
No
body mass index (bmi) >30*
Yes
No
family history of heart disease in parents or
siblings*
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Yes
No
21 years of age or older*
Yes
No
mentally competent to provide informed consent*
Yes
No
Exclusion Criteria
known history of autoimmune disease*
Yes
No
systemic/chronic disease requiring chemotherapy
or long term treatment*
Yes
No
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Eligibility Heart Failure NCT01156337
Sodium Management in Acute and Chronic Heart Failure;
ODM derived from:
https://clinicaltrials.gov/show/NCT01156337
All rights reserved. Please visit https://medical-data-
models.org/forms/13115
Eligibility Heart Failure
NCT01156337
Inclusion Criteria
decompensated hf due to ischemic or
nonischemic cardiomyopathy,*
Yes
No
>18 years of age,*
Yes
No
hf according to framingham criteria*
Yes
No
nyha functional class iii*
Yes
No
ef <40%,*
Yes
No
serum creatinine <2,5 mg/dl*
Yes
No
bun <60 mg/dl,*
Yes
No
Exclusion Criteria
nyha class > iii or < iii,*
Yes
No
cerebral vascular disease,*
Yes
No
dementia,*
Yes
No
cancer,*
Yes
No
uncompensated diabetes,*
Yes
No
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severe hepatic disease*
Yes
No
patients requiring pacemaker*
Yes
No
previous rct implantation*
Yes
No
alcoholic habit*
Yes
No
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Eligibility Hepatitis C NCT00005657
Genetics of Hepatitis C Virus Infection; ODM derived from:
https://clinicaltrials.gov/show/NCT00005657
All rights reserved. Please visit https://medical-data-
models.org/forms/13116
Eligibility Hepatitis C NCT00005657
Criteria
patients who have recovered from past hcv
exposure (positive anti-hcv but negative hcv
viremia and absent liver disease).*
Yes
No
patients with asymptomatic hcv infection (positive
anti-hcv and hcv viremia, but persistently normal
or minimally elevated alt and normal or mild
disease on liver biopsy).*
Yes
No
patients with active liver disease (positive anti-hcv
and hcv viremia, persistently elevated alt and/or
moderate disease on liver biopsy).*
Yes
No
patients with active extrahepatic manifestations of
hcv infection (cryoglobulinemia,
glomerulonephritis, vasculitis, etc.).*
Yes
No
patients with rapidly progressive, severe liver
disease and/or hepatocellular carcinoma.*
Yes
No
patients who have undergone or are undergoing
treatment.*
Yes
No
patients from a single-source outbreak of hcv
infections (in which the viral factors should be
identical and the patients are often from a
homogeneous population with less genetic
variability).*
Yes
No
hcv infected family members and twins.*
Yes
No
patients with other forms of liver disease
including hbv infection, primary biliary cirrhosis,
autoimmune hepatitis, nonalcoholic
steatohepatitis, hemochromatosis, and wilson's
disease, as well as normal volunteers.*
Yes
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No
Exclusion Criteria
adult subjects with a hct of less than 30 or
pediatric subjects less than 25 will be excluded.*
Yes
No
children with hcv infection younger than 2 years
of age will be excluded.*
Yes
No
unaffected healthy volunteers who are minors are
not eligible for this study.*
Yes
No
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Eligibility Hepatitis NCT00287469
A Safety and Efficacy Study of the Hepatitis E Vaccine in
Nepal.; ODM derived from:
https://clinicaltrials.gov/show/NCT00287469
All rights reserved. Please visit https://medical-data-
models.org/forms/13117
Eligibility Hepatitis NCT00287469
Inclusion Criteria
a male or female 18 years of age or older at the
time of the first vaccination.*
Yes
No
written or oral witnessed (if the subject was
illiterate) informed consent obtained from the
subject*
Yes
No
free of obvious health problems as established by
medical history before entering into the study*
Yes
No
if the subject was female, she must have a
negative serum pregnancy test within 48 hours
prior to each vaccination and must agree to avoid
becoming pregnant during the course of
vaccination and until 30 days after the last dose
of vaccine.*
Yes
No
Exclusion Criteria
use of any investigational or non-registered drug
or vaccine other than the study vaccine(s) within
30 days preceding the first dose of study vaccine,
or planned use during the study period.*
Yes
No
administration of chronic (defined as more than
14 days) immunosuppressants or other immune
modifying drugs within six months of vaccination.
for corticosteroids, this will mean prednisone, or
equivalent, * 0.5 mg/kg/day. inhaled and topical
steroids are allowed.*
Yes
No
any chronic drug therapy to be continued during
the study period with the exception of
contraceptive agents, homeopathic remedies,
vitamins, minerals and any other dietary
supplements or other drug therapy at the
discretion of the investigator.*
Yes
No
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planned administration/administration of a
vaccine not foreseen by the study protocol within
30 days of the first dose of study vaccine,
excluding tetanus toxoid or rabies vaccine.*
Yes
No
any confirmed or suspected immunosuppressive
or immunodeficient condition, including human
immunodeficiency virus (hiv) infection, as
reported by the volunteer (testing for hiv will not
be performed).*
Yes
No
history of allergic disease or reactions likely to be
exacerbated by any component of the vaccine.*
Yes
No
major congenital defects or serious chronic
illness.*
Yes
No
history of any neurologic disorders or seizures.*
Yes
No
acute disease at the time of enrollment. acute
disease was defined as the presence of a
moderate or severe illness with or without fever.
all vaccines could be administered to persons
with a minor illness such as diarrhea, mild upper
respiratory infection with or without low-grade
febrile illness, i.e., oral temperature < 38.0°c
(100.4°f).*
Yes
No
acute or chronic, clinically significant pulmonary,
cardiovascular, hepatic or renal functional
abnormality, as determined by history.*
Yes
No
administration of immunoglobulins and/or any
blood products within the three months preceding
the first dose of study vaccine or planned
administration during the study period.*
Yes
No
pregnant female.*
Yes
No
history of chronic alcohol consumption (defined
as the consumption of the equivalent of 4 or more
12 ounce beers 4 or more times a week) and/or
2 / 3
Eligibility Hepatitis NCT00287469
intravenous drug abuse.*
Yes
No
antibodies to rhev (* 20 wr u/ml).*
Yes
No
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Eligibility Hormone-Refractory Prostate
Cancer NCT01133704
Immunotherapy With APC8015 (Sipuleucel-T, Provenge) for
Asymptomatic, Metastatic, Hormone-Refractory Prostate
Cancer; ODM derived from:
https://clinicaltrials.gov/show/NCT01133704
All rights reserved. Please visit https://medical-data-
models.org/forms/13118
Eligibility Hormone-Refractory
Prostate Cancer NCT01133704
Inclusion Criteria
histologically documented adenocarcinoma of the
prostate*
Yes
No
metastatic disease as evidenced by soft tissue
and/or bony metastases*
Yes
No
prostate-specific antigen value of at least 5
ng/ml*
Yes
No
tumor progression while on hormonal therapy*
Yes
No
castration levels of testosterone (defined as less
than 50 ng/dl)*
Yes
No
life expectancy of at least 16 weeks*
Yes
No
adequate hematologic, renal, and liver function*
Yes
No
Exclusion Criteria
visceral organ metastases*
Yes
No
metastatic disease expected to be in need of
radiation therapy within 4 months.*
Yes
No
concurrent therapy with experimental agents*
Yes
No
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Eligibility Hypertension NCT00122811
The Hypertension in the Very Elderly Trial (HYVET); ODM
derived from: https://clinicaltrials.gov/show/NCT00122811
All rights reserved. Please visit https://medical-data-
models.org/forms/13125
Eligibility Hypertension
NCT00122811
Inclusion Criteria
aged 80 or older*
Yes
No
sitting systolic bp 160-199 mmhg and sitting
diastolic bp < 110 mmhg*
Yes
No
Exclusion Criteria
known accelerated hypertension (retinal
haemorrhages or exudates or papilloedema).*
Yes
No
overt clinical congestive heart failure requiring
treatment with a diuretic or angiotensin
converting enzyme inhibitor. subjects allowed if
treated with digoxin only.*
Yes
No
renal failure (serum creatinine of more than 150
µmol/l).*
Yes
No
previous documented cerebral or subarachnoid
haemorrhage in the last 6 months. (ischaemic
cerebral and cardiac events do not exclude,
although the patient must be neurologically and
cardiologically stable.)*
Yes
No
condition expected to severely limit survival, e.g.
terminal illness.*
Yes
No
known secondary hypertension (e.g. renal artery
stenosis, chronic renal insufficiency, and
endocrine cause).*
Yes
No
gout.*
Yes
No
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clinical diagnosis of dementia.*
Yes
No
resident in a nursing home, i.e. where the
dependency and care requirements of the
patients are such that they require the regular
input of qualified nurses and therefore the
majority of staff in the home are nurses (other
forms of residential care are acceptable).*
Yes
No
unable to stand up or walk*
Yes
No
participation in a drug trial within the past month
preceding selection.*
Yes
No
alcohol or drug abuse.*
Yes
No
less than 2 months placebo run-in.*
Yes
No
contraindications to use of trial drugs*
Yes
No
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Eligibility Inflammatory Tissue Disorder
NCT00765362
Mobile - Bearing Knee Study; ODM derived from:
https://clinicaltrials.gov/show/NCT00765362
All rights reserved. Please visit https://medical-data-
models.org/forms/13127
Eligibility Inflammatory Tissue
Disorder NCT00765362
Inclusion Criteria
skeletal maturity*
Yes
No
less than 70 on preoperative knee society score
(rating score)*
Yes
No
sufficient bone stock, as judged by radiographs,
to support primary knee implant*
Yes
No
patients with inflammatory tissue disorders,
osteoarthritis, post-traumatic arthritis, secondary
arthritis, or avascular necrosis of the femoral
condyles*
Yes
No
patient is not pregnant*
Yes
No
primary total knee replacement*
Yes
No
sufficient collateral ligaments to support device,
as judged by physician during stability testing
(varus/valgus and flexion/extension)*
Yes
No
varus deformity <45 or valgus deformity <45 or
fixed flexion deformity <90*
Yes
No
patient is likely to be available for evaluation for
the duration of the study*
Yes
No
able and willing to sign the informed consent and
follow study procedures*
Yes
No
Exclusion Criteria
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skeletal immaturity*
Yes
No
greater than or equal to 70 on preoperative knee
society score (rating scale)*
Yes
No
previous knee surgery that has adversely
affected bone stock or prior total knee
replacement*
Yes
No
post patellectomy*
Yes
No
patient is pregnant*
Yes
No
insufficient collateral ligaments, as judged by the
physician*
Yes
No
neurological conditions that might hinder patient's
ability to follow study procedures (i.e., any that
restrict physical activities such as parkinson's
disease, multiple sclerosis, previous stroke which
affects lower extremity).*
Yes
No
varus deformity >45 or valgus deformity >45 or
fixed flexion deformity >90.*
Yes
No
mental conditions that may interfere with ability to
give an informed consent or willingness to fulfill
the study requirements (i.e., severe mental
retardation such that the patient cannot
understand the informed consent process, global
dementia, prior strokes that interfere the with
patient's cognitive abilities, senile dementia, and
alzheimer's disease).*
Yes
No
prisoners*
Yes
No
conditions that place excessive demand on the
implant (i.e. charcot's joints, muscle deficiencies,
refusal to modify postoperative physical activities,
skeletal immaturity).*
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Yes
No
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Eligibility Invasive Breast Cancer
NCT00983684
Comparison of Intra-operative Radiotherapy With Post-
operative Radiotherapy for Women With Early Breast
Cancer; ODM derived from:
https://clinicaltrials.gov/show/NCT00983684
All rights reserved. Please visit https://medical-data-
models.org/forms/13128
Eligibility Invasive Breast Cancer
NCT00983684
Inclusion Criteria
age 45 years or older*
Yes
No
operable invasive breast cancer (t1 and small t2,
n0-1, m0) confirmed by cytological or histological
examination*
Yes
No
suitable for breast conserving surgery*
Yes
No
previously diagnosed and treated contralateral
breast cancer may be entered but will be
randomised to a separate stratum.*
Yes
No
available for regular follow-up for at least ten
years.*
Yes
No
note: individual centres may wish to restrict entry
to a more exactly defined subset of patients, in
which case, only patients with these
characteristics may be entered by that particular
centre.  for example, centres may decide at
outset to recruit only women over 50 or even over
65 years of age.  such policies must be pre-
defined in writing and approved by the
international steering committee.*
Exclusion Criteria
more than one obvious cancer in the same breast
as diagnosed by clinical examination,
mammography or ultrasonography.*
Yes
No
bilateral breast cancer at the time of diagnosis.*
Yes
No
ipsilateral breast had a previous cancer and/or
irradiation.*
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Yes
No
patients known to have brca2 gene mutations, but
testing for gene mutations is not required*
Yes
No
lobular cancer or extensive intraductal component
(eic =>25% of the tumour is intraductal) on core
biopsy or initial pathology (if performed)*
Yes
No
patients undergoing primary medical treatment
(hormones or chemotherapy) as initial treatment
with neoadjuvant intent of reducing tumour size
should be excluded; those given short duration
(up to 4 weeks) systemic therapy can be
included.*
Yes
No
patients presenting with gross nodal disease,
considered to be clinically malignant or proven
cytologically or by scanning. in general, 4 or more
positive nodes or extranodal spread are not
suitable for targit alone and should receive ebrt
as well. however, individual centres may decide
that anything more than micrometastasis should
receive ebrt.*
Yes
No
patients with any severe concomitant disease that
may limit their life expectancy.*
Yes
No
previous history of malignant disease does not
preclude entry if the expectation of relapse-free
survival at 10 years is 90% or greater.*
Yes
No
any factor included as exclusion criterion in the
local centre's treatment policy. this is particularly
relevant to patients entered into the post
pathology stratum.*
Yes
No
no more than 30 days can have elapsed between
last breast cancer surgery (not axillary) and entry
into the trial for patients in the post-pathology
stratification.*
Yes
No
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Eligibility Leukemia NCT00004857
Fludarabine Followed by Alemtuzumab in Treating Patients
With Chronic Lymphocytic Leukemia; ODM derived from:
https://clinicaltrials.gov/show/NCT00004857
All rights reserved. Please visit https://medical-data-
models.org/forms/13143
Eligibility Leukemia NCT00004857
Criteria
1.1 an absolute lymphocytosis of > 5,000/µl*
Yes
No
1.1.1 morphologically, the lymphocytes must
appear mature with < 55% prolymphocytes.*
Yes
No
1.1.2 bone marrow examination must include at
least a unilateral aspirate and biopsy. the aspirate
smear must show > 30% of all nucleated cells to
be lymphoid or the bone marrow core biopsy
must show lymphoid infiltrates compatible with
marrow involvement by cll. the overall cellularity
must be normocellular or hypercellular.*
Yes
No
1.1.3 local institution lymphocyte phenotype must
reveal a predominant b-cell monoclonal
population sharing a b-cell marker (cd19, cd20,
cd23, cd24) with the cd5 antigen, in the absence
of other pan-t-cell markers. additionally, the b-
cells must be monoclonal with regard to
expression of either κ or λ and have surface
immunoglobulin expression of low density.
patients with bright surface immunoglobulin levels
must have cd23 co-expression.*
Yes
No
1.2  staging*
Yes
No
1.2.1 patients must be in the intermediate- or
high-risk categories of the modified three-stage
rai staging system (i.e., stages i, ii, iii, or iv) per
the protocol.*
Yes
No
1.2.2 patients in the intermediate-risk group must
have evidence of active disease as demonstrated
by at least one of the following criteria:*
Yes
No
massive or progressive splenomegaly and/or
lymphadenopathy*
Yes
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No
presence of weight loss > 10% over the
preceding 6 month period;*
Yes
No
grade 2 or 3 fatigue*
Yes
No
fevers > 100.5°c or night sweats for greater than
2 weeks without evidence of infection*
Yes
No
progressive lymphocytosis with an increase of >
50% over a 2 month period or an anticipated
doubling time of less than 6 months.*
Yes
No
2. prior treatment: no prior therapy for cll
including corticosteroids for autoimmune
complications that have developed since the
initial diagnosis of cll.*
Yes
No
3. no medical condition requiring chronic use of
oral corticosteroids.*
Yes
No
4. age ≥18 years.*
Yes
No
5. performance status 0 - 2.*
Yes
No
6. no hiv disease. due to alterations in host
immunity, patients with hiv may not be enrolled.*
Yes
No
7. non-pregnant and non-nursing. due to the
unknown teratogenic potential of campath-1h,
pregnant or nursing women may not be enrolled.
women and men of reproductive potential should
agree to use an effective means of birth control.*
Yes
No
8. initial required laboratory values:*
Yes
No
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creatinine  <1.5 x upper limit of institutional
normal value coomb's testing negative*
Yes
No
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Eligibility Leukemia NCT00004933
Homoharringtonine Compared With Hydroxyurea for
Chronic Myelogenous Leukemia That Has Not Responded
to Interferon Alfa; ODM derived from:
https://clinicaltrials.gov/show/NCT00004933
All rights reserved. Please visit https://medical-data-
models.org/forms/13144
Eligibility Leukemia NCT00004933
Criteria
1.1 diagnosis of chronic myelogenous leukemia
(cml) in chronic phase. patients in either
accelerated or blastic phases are not eligible.
clonal cytogenetic evolution alone does not
exclude patients. see appendix i for definitions of
accelerated and blastic phases of cml.*
Yes
No
1.2 patients in whom a philadelphia chromosome
[t(9;22)] is not detectable by cytogenetic studies
are eligible if they meet one of the following
criteria:*
Yes
No
bcr/abl protein detectable by immunoblotting*
Yes
No
bcr/abl rearrangement detectable by southern
blot analysis*
Yes
No
polymerase chain reaction (pcr) positive fusion
transcripts for bcr/abl*
Yes
No
bcr/abl translocation present by fluorescence in
situ hybridization (fish).*
Yes
No
2. prior treatment:*
Yes
No
2.1 no previous therapy with homoharringtonine
(hht)*
Yes
No
2.2 no more than six months cumulative (<180
days) of prior hydroxyurea (hu) therapy. however,
patients may not have received more than 60
days of hu treatment after failing interferon.
patients with previous intolerance or failure to
respond to hu are not eligible.*
Yes
No
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2.3  patients must have failed an adequate trial
(5m units/m2/day) of alpha-interferon (ifn) or
ifn/ara-c to be eligible, as defined below (any one
of the following):*
Yes
No
failure to achieve a complete hematologic
response after 6 months of ifn therapy.*
Yes
No
failure to achieve any cytogenetic response (i.e.,
still 100% ph+) after 12 months of ifn therapy.*
Yes
No
intolerable adverse effects of ifn therapy after at
least one month of ifn treatment. significant
documented toxicity of ≥ grade 3 (using nci
common toxicity criteria guidelines) due to ifn is
required.*
Yes
No
loss of a prior hematologic remission or
cytogenetic response to ifn.*
Yes
No
a two-fold increase in wbc count when compared
to wbc count when ifn therapy was initiated.*
Yes
No
3. age ≥ 16 years*
Yes
No
4. patients with uncontrolled tachyarrhythmias
(such as, atrial fibrillation, paroxysmal
supraventricular tachycardia, and ventricular
tachycardias not adequately controlled) are not
eligible.*
Yes
No
5. non-pregnant and non-nursing. treatment
under this protocol would expose an unborn child
to significant risks. women and men of
reproductive potential should agree to use an
effective means of birth control.*
Yes
No
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Eligibility Leukemia NCT00005596
Combination Chemotherapy in Treating Children With
Newly Diagnosed Acute Lymphoblastic Leukemia; ODM
derived from: https://clinicaltrials.gov/show/NCT00005596
All rights reserved. Please visit https://medical-data-
models.org/forms/13145
Eligibility Leukemia NCT00005596
Criteria
confirmed diagnosis of newly diagnosed b-
precursor acute lymphocytic leukemia*
Yes
No
standard risk (not low, high, or very high risk)*
Yes
No
prior registration and treatment on pog 9900
classification study*
Yes
No
age: 1 to 21 at diagnosis*
Yes
No
not pregnant or nursing*
Yes
No
fertile patients must use effective contraception*
Yes
No
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Eligibility Leukemia,Myeloid, Chronic
NCT00027144
Study Using Vaccination With Heat Shock Protein 70
(HSP70) for the Treatment of CML in Chronic Phase; ODM
derived from: https://clinicaltrials.gov/show/NCT00027144
All rights reserved. Please visit https://medical-data-
models.org/forms/13146
Eligibility Leukemia,Myeloid, Chronic
NCT00027144
Inclusion Criteria
ecog performance score(ps) less than 2.*
Yes
No
must be at least 18 years of age and capable of
giving informed consent.*
Yes
No
must be less than three years from the original
diagnosis of philadelphia chromosome positive
cml in chronic phase.*
Yes
No
patient is not in cytogenetic remission.*
Yes
No
no anticipation of bone marrow or stem cell
transplant for six months unless these therapies
are deemed necessary by a treatment physician
due to the evolution of the disease;*
Yes
No
concurrent treatment with hydroxyurea or gleevec
is allowed.past treatment with ifn alpha, ara-c or
other cytoxic agents is allowed*
Yes
No
must not have any serious illness such that their
medical condition might be compromised by
participation in the study.*
Yes
No
must have adequate renal function (serum
creatinine < 2.0), hepatic function (bilirubin and
transaminase less than 2.0 x of the upper normal
limit).*
Yes
No
must not be on corticosteroid therapy, or other
immunosuppressive medications.*
Yes
No
Exclusion criteria
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patients with an ecog performance score greater
than or equal to 2.
Yes
No
patient is greater than or equal to 3 years out
from the original diagnosis.
Yes
No
significant anemia (hemoglobin < 10 g/dl) and
thrombocytopenia (platelet < 20,000/ml) requiring
transfusion.
Yes
No
peripheral blast count is over 10%.
Yes
No
positive urine or blood pregnancy test.
Yes
No
impaired renal function (serum creatinine > 2.0),
hepatic function (bilirubin and transaminase more
than 2.0 x of the upper normal limit).
Yes
No
patient with significant active infection requiring
hospitalization at the time of enrollment.
Yes
No
patient with significant behavioral or
psychological problems that prevent adequate
follow-up.
Yes
No
concurrent treatment with ifn alpha ara-c or other
cytotoxic agents (gleevec and hydroxyurea are
allowed.
Yes
No
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Eligibility Lung Cancer NCT00193310
Preoperative or Postoperative Therapy of Patients With
Stages IB, II, IIIA Non-Small Cell Lung Cancer; ODM
derived from: https://clinicaltrials.gov/show/NCT00193310
All rights reserved. Please visit https://medical-data-
models.org/forms/13147
Eligibility Lung Cancer
NCT00193310
Inclusion Criteria
non-small cell  lung cancer*
Yes
No
neoadjuvant candidates must have potentially
resectable disease*
Yes
No
adjuvant candidates must have had complete
resection*
Yes
No
clinical stage ib, ii, or iiia non-small cell lung
cancer*
Yes
No
ecog performance status 0 or 1*
Yes
No
adequate bone marrow, liver and kidney function*
Yes
No
no previous chemotherapy or radiation therapy for
non-small cell lung cancer.*
Yes
No
give written informed consent.*
Yes
No
Exclusion Criteria
stage iiia with n2 nodes > 6 cm*
Yes
No
stage iiib or iv disease*
Yes
No
age <18 years*
Yes
No
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ecog performance status 2 or higher*
Yes
No
considered inoperable based on general medical
condition*
Yes
No
history of prior malignancy within five years*
Yes
No
women who are pregnant or lactating*
Yes
No
please note:  there are additional
inclusion/exclusion criteria.  the study center will
determine if you meet all of the criteria.  if you do
not qualify for the trial, study personnel will
explain the reasons.  if you do qualify, study
personnel will explain the trial in detail and
answer any questions you may have.*
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Eligibility Lung Cancer NCT00653250
Celecoxib in Treating Patients With Stage I, Stage II, or
Stage IIIA Non-Small Cell Lung Cancer; ODM derived from:
https://clinicaltrials.gov/show/NCT00653250
All rights reserved. Please visit https://medical-data-
models.org/forms/13148
Eligibility Lung Cancer
NCT00653250
Criteria
presumed histological or cytological diagnosis of
non-small cell lung cancer*
Yes
No
diagnosis to be confirmed upon study entry to
collect biopsy material for correlative studies*
Yes
No
stage i-iiia disease*
Yes
No
ecog performance status of 0-2*
Yes
No
serum creatinine ≤ 1.5 mg/dl*
Yes
No
granulocytes ≥ 1,500/mm^3*
Yes
No
platelets ≥ 100,000/mm^3*
Yes
No
ast ≤ 3 times normal*
Yes
No
bilirubin ≤ 1.5 mg/dl*
Yes
No
not pregnant or nursing*
Yes
No
fertile patients must use effective contraception*
Yes
No
no active unresolved infection*
Yes
No
prior concurrent therapy:*
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Yes
No
at least 7 days since prior and no concurrent non-
steroidal anti-inflammatory agents or other cyclo-
oxygenase-2 inhibitors*
Yes
No
at least 7 days since prior parenteral antibiotics*
Yes
No
no prior systemic chemotherapy or radiotherapy*
Yes
No
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Eligibility Lung Cancer NCT00955175
Hypofractionated 3-Dimensional Radiation Therapy in
Treating Patients With Newly Diagnosed Stage I, Stage II,
or Stage III Non-Small Cell Lung Cancer. ICORG 99-09;
ODM derived from:
https://clinicaltrials.gov/show/NCT00955175
All rights reserved. Please visit https://medical-data-
models.org/forms/13149
Eligibility Lung Cancer
NCT00955175
Criteria
histologically or cytologically confirmed newly
diagnosed non-small cell lung cancer meeting 1
of the following stage criteria:*
Yes
No
stage i or ii disease*
Yes
No
medically inoperable or patient refused surgery*
Yes
No
stage iiia or iiib disease (no pleural effusions)*
Yes
No
radiation dose parameters must satisfy the
required study dose-volume constraints*
Yes
No
karnofsky performance status 70-100%*
Yes
No
weight loss ≤ 10% within 3 months before
diagnosis*
Yes
No
no other malignancy within the past 5 years,
except nonmelanoma skin cancer*
Yes
No
no clinically significant cardiovascular disease
(e.g., hypertension [blood pressure > 150/100
mm hg], myocardial infarction or stroke within the
past 6 months, or unstable angina)*
Yes
No
prior concurrent therapy:*
Yes
No
no concurrent chemotherapy*
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Efficacy and tolerability of subcutaneous hyposensitization with
CLUSTOID in Patients with allergic rhinoconjunctivitis 1.1
Prospective,multicentric,double blind and placebo-
controlled Phase III clinical trial to determine efficacy and
tolerability of subcutaneous hyposensitization with
CLUSTOID in patients with allergic rhinoconjunctivits
caused by grass or rye pollen. EudraCT-Nr. 2008-000513-
29 Study-code:CLU-2008-001 Sponsor: ROXALL Medizin
GmbH Carl-Petersen-Straße 4 20535 Hamburg Phone:040-
8972520 Fax:040-89725223 Project coordinator: Dr.Jenny
Uhlig ROXALL Medizin GmbH Head of clinical
investigation: Prof.Dr.med.Ludger Klimek An den Quellen
10 65183 Wiesbaden Phone:0611-8904381 Fax:0611-
3082360 Monitoring,data management and statistical
evaluation: IMSIE- Institut for medical statistics,computer
sciences and epidemiology University hospital Cologne
Lindenburger Allee 42 50931 Cologne Phone:0221-
4783456 Fax:0221-4783465
All rights reserved. Please visit https://medical-data-
models.org/forms/13150
Case report form Visit1 part 2
Medical History and documentation of first
Dose of trial substance
Please give Patient ID composed of Study site Nr
and Patient Nr
Has a skin prick test been performed?
yes (1)
no (2)
waiting for washout of Antihistamine or
Steroids (3)
Date Skin prick test was performed
Reaction to grass:please give the diameter of the
resulting rash
Reaction to rye: diameter of rash
Reaction to birch:diameter of rash
Reaction to artemisia:diameter of rash
Reaction to dust mite:diameter of rash
Reaction to cat hair:diameter of rash
Reaction to dog hair:diameter of rash
Reaction to mold:diameter of rash
Reaction to histamin-hydrochloride:diameter of
rash
Reaction to phenolic glycerine-saline solution
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Please give FVC spirometry result
liter
Please give FEV1 result of spirometry
liter
Please give FEV1/FVC spirometry results
%
Peak expiratory flow measurement 1
liter
Peak expiratory flow measurement 2
liter
Peak expiratory flow measurement 3
liter
Peak expiratory flow measurement: optimum at
Visit 1
liter
Baseline value of nasal irritation
0 sneezing 0-2 times (0)
1 sneezing 3-5 times (1)
2 >5 times (2)
blank value of nasal irritation
0 sneezing 0-2 times (0)
1 sneezing 3-5 times (1)
2 sneezing >5 times (2)
First provocation value of nasal irritation
0 sneezing 0-2 times (0)
1 sneezing 3-5 times (1)
2 sneezing >5 times (2)
second provocation value of nasal irritation
0 sneezing 0-2 times (0)
1 sneezing 3-5 times (1)
2 sneezing >5 times (2)
Baseline value of nasal secretion provocation
0 no secretion (0)
1 little secretion (1)
2 heavy secretion (2)
Blank value of nasal secretion provocation
0 no secretion (0)
1 little secretion (1)
2 heavy secretion (2)
First provocation value of nasal secretion
0 no secretion (0)
1 little secretion (1)
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2 heavy secretion (2)
Second provocation value of nasal secretion
0 no secretion (0)
1 little secretion (1)
2 heavy secretion (2)
Baseline value of remote symptom provocation
0 none (0)
1 lacrimation and/or itching of
palate/ears (1)
2 conjunctivitis and/or urticaria and/or
coughing and/or shortness of breath (2)
Blank value of remote symptom provocation
0 none (0)
1 lacrimation and/or itching of
palate/ears (1)
2 conjunctivitis and/or urticaria and/or
coughing and/or shortness of breath (2)
First provocation value of remote symptoms
0 none  (0)
1 lacrimation and/or itching of
palate/ears  (1)
2 conjunctivitis and/or urticaria and/or
coughing and/or shortness of breath (2)
second provocation value of remote symptoms
0 none  (0)
1 lacrimation and/or itching of
palate/ears  (1)
2 conjunctivitis and/or urticaria and/or
coughing and/or shortness of breath (2)
Sum of nasal provocation test symptom scores:
baseline value
<= 6
Sum of nasal provocation test symptom scores:
blank value
<= 6
Sum of nasal provocation test symptom
scores:first provocation value
<= 6
Sum of nasal provocation test symptom
scores:second provocation value
<= 6
Flow volume in cm3/sec baseline value
cm3
Flow volume in cm3/sec blank value
cm3
3 / 10
Efficacy and tolerability of subcutaneous hyposensitization with
CLUSTOID in Patients with allergic rhinoconjunctivitis 1.1
Flow volume in cm3/sec first provocation value
cm3
Flow volume in cm3/sec second provocation
value
cm3
Percentage of flow reduction:blank value
%
Percentage of flow reduction:first provocation
value
%
Percentage of flow reduction:second provocation
value
%
Rhinoscopic evaluation after provocation
tests:Edema
none (0)
little (1)
severe (2)
Rhinoscopic evaluation after provocation test:
secretion
none (0)
clear fluid (1)
thick mucous (2)
Rhinoscopic evaluation after provocation
tests:redness
none (0)
little (1)
severe (2)
radioallergosorbent test categories for timothy
grass
<0,35 (0)
0,35-069 (I)
0,70-3,49 (II)
3,50-17,49 (III)
17,5-49,99 (IV)
50-100 (V)
>100 (VI)
Please specify RAST-Category [kU/L] for Timothy
grass
kU/L
Radioallergosorbent test categories for rye
<0,35 I= 0,35-069 II= 0,70-3,49 III= 3,50-
17,49 IV= 17,5-49,99 V= 50-100 VI=
>100 (0)
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Please specify RAST-Category [kU/L] for rye
pollen
kU/L
Total IgE [kU/L]
kU/L
Verification of specific IgG4 RAST cetagories:
timothy grass
<0,35 I= 0,35-069 II= 0,70-3,49 III= 3,50-
17,49 IV= 17,5-49,99 V= 50-100 VI=
>100 (0)
Please specify RAST-Category [kU/L] for Timothy
grass
kU/L
Radioallergosorbent test categories for rye
<0,35 I= 0,35-069 II= 0,70-3,49 III= 3,50-
17,49 IV= 17,5-49,99 V= 50-100 VI=
>100 (0)
Please specify RAST-Category [kU/L] for rye
pollen
kU/L
Please specify measured hemoglobine and units
used
Please specify measured amount of erythrocytes
and units used
Please specify measured amount of leucocytes
and units used
Please specify measured amount of neutrophils
and units used
Please specify measured amount of eosinophils
and units used
Please specify measured amount of basophils
and units used
Please specify measured amount of monocytes
and units used
Please specify measured amount of lymphocytes
and units used
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Please specify measured hematocrit and units
used
Please specify measured amount of
thrombocytes and units used
Please specify measured amount of total bilirubin
and units used
Please specify the measured SGPT and units
used
Please specify the measurement of LDH and
units used
Please specify the measurement of creatinine
and units used
Please specify the measurement of serum
glutamate-oxaloacetate transaminase and units
used
Please specify the measurement of CRP and
units used
Subcutaneous desensitization
Dose one of desensitization substance
administered?
Yes
No
Please give the hour the first dose was
administered
If the dose has not been administered, please
specify the reason why
Administered Dose of trial substance
0,1 ml according to protocol (1)
adjusted dose (2)
If dose of trial substance has been adjusted,
please specify the reason why and how much
has actually been administered
ml
Please specify wich arm has been used for
injection
right arm (1)
left arm (2)
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30 min after injection, has the patient
experienced any local, gastrointestinal, systemic
or other symptoms
Yes
No
Have any of the following symptoms occured?If
yes please do not forget to fill in AE report
local reaction of the
skin:swelling,itching,rash,or burning
sensation (1)
gastrointestinal
symptoms:nausea,vomiting,dyspepsia,fla
tulence,diarrhea (2)
systemic reactions (3)
unspecified symptoms like headache,
discomfort (3.1)
minor systemic symptoms like rhinitis,or
minor asthmatic symptoms (3.2)
non-life-threatening systemic symptoms
like urticaria, angioedema,severe
asthmatic symptoms (3.3)
severe systemic symptoms like
anaphylactic shock [extended
documentation as SAE] (3.4)
other (4)
Please specify any other symptoms that occured
within 30 min after injection
Have severe local, gastrointestinal or systemic
symptoms occured? If yes, the SAE sheet has to
be filled in and sent to the sponsor within 24
hours.
Yes
No
What measures have been taken in response to
the SAE?
termination of study -> please fill in study
completion form (1)
adjustment of dose during next course of
desensitization (2)
Has the quality of life form for patients with
rhinoconjunctivits been filled in be the patient?
Yes
No
Has the second dose of desensitization been
administered?
Yes
No
Please give the time, the second dose has been
administered
If the second dose has not been administered,
please specify the reason why
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How much of the trial substance has been
titrated?
ml
0,2ml (1)
adjusted dose (2)
If the dose of trial substance has been adjusted,
please specify the reason why and how much
has actually been administered
Please specify which arm has been used for
injection, please don´t use the same arm as
during the first round of desensitization
right arm (1)
left arm (2)
30 min after injection, has the patient
experienced any local, gastrointestinal, systemic
or other symptoms
Yes
No
Have any of the following symptoms occured?If
yes please do not forget to fill in AE report
local reaction of the
skin:swelling,itching,rash,or burning
sensation (1)
gastrointestinal
symptoms:nausea,vomiting,dyspepsia,fla
tulence,diarrhea (2)
systemic reactions (3)
unspecified symptoms like headache,
discomfort (3.1)
minor systemic symptoms like rhinitis,or
minor asthmatic symptoms (3.2)
non-life-threatening systemic symptoms
like urticaria, angioedema,severe
asthmatic symptoms (3.3)
severe systemic symptoms like
anaphylactic shock [extended
documentation as SAE] (3.4)
other (4)
Please specify any other symptoms that occured
within 30 min after injection of second
desensitization
Have severe local, gastrointestinal or systemic
symptoms occured during second
desensitization? If yes, the SAE sheet has to be
filled in and sent to the sponsor within 24 hours.
Yes
No
What measures have been taken in response to
the SAE?
termination of study -> please fill in study
completion form 2=adjustment of dose
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during next course of desensitization (1)
Adverse Events
Did any Adverse Events occur?
Yes
No
Have these been serious adverse events?
Yes
No
Please describe the AE
Adverse Event Start Date
Adverse Event End Date
How often did the event occur?
once (1)
regularly (2)
continuing (3)
Please give your opinion to the severity of the AE
minor (1)
moderate (2)
severe (3)
Adverse Event Outcome
Recovered (1)
Subsiding (2)
Continuing (3)
resolved with sequelae (4)
increased symptoms (5)
fatal (6)
What actions have been taken regarding the trial
substance?
not applicable (1)
no adjustment in dose (2)
adjustment of dose (3)
suspension of treatment (4)
discontinuation of treatment (5)
other (6)
What other actions have been taken in response
to the AE?
none (1)
change of concomitant medication (2)
hospitalization/prolonged stay in hospital
(3)
further therapeutic and diagnostic
measures (4)
Is the AE related to the trial substance?
undecided/incomplete (1)
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inconclusive (2)
without context to trial substance (3)
unlikely (4)
possible (5)
probable (6)
confirmed (7)
Please agree to a date for follow up within next
month
Date of completion of this form
Signature
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Efficacy and tolerability of subcutaneous hyposensitization with
CLUSTOID in Patients with allergic rhinoconjunctivitis Visit 2
Prospective,multicentric,double blind and placebo-
controlled Phase III clinical trial to determine efficacy and
tolerability of subcutaneous hyposensitization with
CLUSTOID in patients with allergic rhinoconjunctivits
caused by grass or rye pollen. EudraCT-Nr. 2008-000513-
29 Study-code:CLU-2008-001 Sponsor: ROXALL Medizin
GmbH Carl-Petersen-Straße 4 20535 Hamburg Phone:040-
8972520 Fax:040-89725223 Project coordinator: Dr.Jenny
Uhlig ROXALL Medizin GmbH Head of clinical
investigation: Prof.Dr.med.Ludger Klimek An den Quellen
10 65183 Wiesbaden Phone:0611-8904381 Fax:0611-
3082360 Monitoring,data management and statistical
evaluation: IMSIE- Institut for medical statistics,computer
sciences and epidemiology University hospital Cologne
Lindenburger Allee 42 50931 Cologne Phone:0221-
4783456 Fax:0221-4783465
All rights reserved. Please visit https://medical-data-
models.org/forms/13151
Case report form Visit 2
Visit 2 Titration Visit
Please give Patient ID composed of Study site Nr
and Patient Nr
Date of visit 2
Have all Laboratory results not readily available
during visit 1 been added?
Yes
No
Date of completion of laboratory results
Is the patient still participating in this trial? If no,
please fill in study completion form
Yes
No
Female of childbearing potential, using safe
contraceptive measures? If no please fill in study
completion form
Yes
No
Peak flow best value during visit 1
l/min
Please take 3 consecutive peak flow
measurements
l/min
Second peak flow measurement
l/min
Third peak flow measurement
l/min
Peak flow best value during visit 2
l/min
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If peak flow measurement is > 80% of expected
best value, continue with allergen exposure, if no
suspend next exposure to allergen and repeat
peak flow measurement
Yes
No
First peak flow measurement after suspension
l/min
Second peak flow measurement after suspension
l/min
third peak flow measurement after suspension
l/min
Blood pressure measurement
mm/Hg
Heart rate count
bpm
Body height
cm
Body weight
kg
Rhinoscopic evaluation:Edema
none (0)
little (1)
severe (2)
Rhinoscopic evaluation: secretion
none (0)
clear fluid (1)
thick mucous (2)
Rhinoscopic evaluation:redness
none (0)
little (1)
severe (2)
Has concomitant medication been subject to
change?
Yes
No
Please specify any changes of therapy and
review for exclusion criteria
Have comorbidities changed?
Yes
No
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If comorbidities have changed,please specify and
review for exclusion criteria
Subcutaneous desensitization
Has the third dose of desensitization been
administered?
Yes
No
Please give the date and time, the third dose has
been administered
If the third dose has not been administered,
please specify the reason why
How much of the trial substance has been
titrated?
ml
0,3ml (1)
adjusted dose (2)
If the dose of trial substance has been adjusted,
please specify the reason why and how much
has actually been administered
Please specify which arm has been used for
injection
right arm (1)
left arm (2)
30 min after injection, has the patient
experienced any local, gastrointestinal, systemic
or other symptoms
Yes
No
Have any of the following symptoms occured?If
yes please do not forget to fill in AE report
local reaction of the
skin:swelling,itching,rash,or burning
sensation (1)
gastrointestinal
symptoms:nausea,vomiting,dyspepsia,fla
tulence,diarrhea (2)
systemic reactions (3)
unspecified symptoms like headache,
discomfort (3.1)
minor systemic symptoms like rhinitis,or
minor asthmatic symptoms (3.2)
non-life-threatening systemic symptoms
like urticaria, angioedema,severe
asthmatic symptoms (3.3)
severe systemic symptoms like
anaphylactic shock [extended
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documentation as SAE] (3.4)
other (4)
Please specify any other symptoms that occured
within 30 min after injection of third
desensitization
Has the fourth dose of desensitization been
administered?
Yes
No
Please give the date and time the fourth dose has
been administered
If the fourth dose has not been administered,
please specify the reason why
How much of the trial substance has been
titrated?
ml
0,5ml (1)
adjusted dose (2)
If the dose of trial substance has been adjusted,
please specify the reason why and how much
has actually been administered
Please specify which arm has been used for
injection, please don´t use the same arm as
during the previous round of desensitization
right arm (1)
left arm (2)
30 min after injection, has the patient
experienced any local, gastrointestinal, systemic
or other symptoms
Yes
No
Have any of the following symptoms occured?If
yes please do not forget to fill in AE report
local reaction of the
skin:swelling,itching,rash,or burning
sensation (1)
gastrointestinal
symptoms:nausea,vomiting,dyspepsia,fla
tulence,diarrhea (2)
systemic reactions (3)
unspecified symptoms like headache,
discomfort (3.1)
minor systemic symptoms like rhinitis,or
minor asthmatic symptoms (3.2)
non-life-threatening systemic symptoms
like urticaria, angioedema,severe
asthmatic symptoms (3.3)
severe systemic symptoms like
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anaphylactic shock [extended
documentation as SAE] (3.4)
other (4)
Please specify any other symptoms that occured
within 30 min after injection of fourth
desensitization
Have severe local, gastrointestinal or systemic
symptoms occured during fourth desensitization?
If yes, the SAE sheet has to be filled in and sent
to the sponsor within 24 hours.
Yes
No
What measures have been taken in response to
the SAE?
termination of study -> please fill in study
completion form (1)
adjustment of dose during next course of
desensitization (2)
Adverse Events
Did any Adverse Events occur?
Yes
No
Have these been serious adverse events?
Yes
No
Please describe the AE
Adverse Event Start Date
Adverse Event End Date
How often did the event occur?
once (1)
regularly (2)
continuing (3)
Please give your opinion to the severity of the AE
minor (1)
moderate (2)
severe (3)
Adverse Event Outcome
Recovered (1)
Subsiding (2)
Continuing (3)
resolved with sequelae (4)
increased symptoms (5)
fatal (6)
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What actions have been taken regarding the trial
substance?
not applicable (1)
no adjustment in dose (2)
adjustment of dose (3)
suspension of treatment (4)
discontinuation of treatment (5)
other (6)
What other actions have been taken in response
to the AE?
none (1)
change of concomitant medication (2)
hospitalization/prolonged stay in hospital
(3)
further therapeutic and diagnostic
measures (4)
Is the AE related to the trial substance?
undecided/incomplete (1)
inconclusive (2)
without context to trial substance (3)
unlikely (4)
possible (5)
probable (6)
confirmed (7)
Please agree to a date for follow up V3 within
next month
Date of completion of this form
Signature
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Prospective,multicentric,double blind and placebo-
controlled Phase III clinical trial to determine efficacy and
tolerability of subcutaneous hyposensitization with
CLUSTOID in patients with allergic rhinoconjunctivits
caused by grass or rye pollen. EudraCT-Nr. 2008-000513-
29 Study-code:CLU-2008-001 Sponsor: ROXALL Medizin
GmbH Carl-Petersen-Straße 4 20535 Hamburg Phone:040-
8972520 Fax:040-89725223 Project coordinator: Dr.Jenny
Uhlig ROXALL Medizin GmbH Head of clinical
investigation: Prof.Dr.med.Ludger Klimek An den Quellen
10 65183 Wiesbaden Phone:0611-8904381 Fax:0611-
3082360 Monitoring,data management and statistical
evaluation: IMSIE- Institut for medical statistics,computer
sciences and epidemiology University hospital Cologne
Lindenburger Allee 42 50931 Cologne Phone:0221-
4783456 Fax:0221-4783465
All rights reserved. Please visit https://medical-data-
models.org/forms/13155
Case report form Visit 3
Visit 3: Maintenance Visit
Please give Patient ID composed of Study site Nr
and Patient Nr
Date of visit 3
Is the patient still participating in this trial? If no,
please fill in study completion form
Yes
No
Female of childbearing potential, using safe
contraceptive measures? If no please fill in study
completion form
Yes
No
Peak flow best value during visit 1
l/min
Please take 3 consecutive peak flow
measurements
l/min
Second peak flow measurement
l/min
Third peak flow measurement
l/min
Peak flow best value during visit 3
l/min
If peak flow measurement is > 80% of expected
best value, continue with allergen exposure, if no
suspend next exposure to allergen and repeat
peak flow measurement
Yes
No
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First peak flow measurement after suspension
l/min
Second peak flow measurement after suspension
l/min
Third peak flow measurement after suspension
l/min
Blood pressure measurement
mm/Hg
Heart rate count
bpm
Body height
cm
Body weight
kg
Rhinoscopic evaluation:Edema
none (0)
little (1)
severe (2)
Rhinoscopic evaluation: secretion
none (0)
clear fluid (1)
thick mucous (2)
Rhinoscopic evaluation:redness
none (0)
little (1)
severe (2)
Has concomitant medication been subject to
change?
Yes
No
Please specify any changes of therapy and
review for exclusion criteria
Have comorbidities changed?
Yes
No
If comorbidities have changed,please specify and
review for exclusion criteria
Subcutaneous desensitization
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Has the fifth dose of desensitization been
administered?
Yes
No
Please give the date and time, the fifth dose has
been administered
If the fifth dose has not been administered,
please specify the reason why
How much of the trial substance has been
titrated?
ml
0,5ml (1)
adjusted dose (2)
If the dose of trial substance has been adjusted,
please specify the reason why and how much
has actually been administered
Please specify which arm has been used for
injection
right arm (1)
left arm (2)
30 min after injection, has the patient
experienced any local, gastrointestinal, systemic
or other symptoms
Yes
No
Have any of the following symptoms occured?If
yes please do not forget to fill in AE report
local reaction of the
skin:swelling,itching,rash,or burning
sensation (1)
gastrointestinal
symptoms:nausea,vomiting,dyspepsia,fla
tulence,diarrhea (2)
systemic reactions (3)
unspecified symptoms like headache,
discomfort (3.1)
minor systemic symptoms like rhinitis,or
minor asthmatic symptoms (3.2)
non-life-threatening systemic symptoms
like urticaria, angioedema,severe
asthmatic symptoms (3.3)
severe systemic symptoms like
anaphylactic shock [extended
documentation as SAE] (3.4)
other (4)
Please specify any other symptoms that occured
within 30 min after injection of fifth desensitization
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Have severe local, gastrointestinal or systemic
symptoms occured during fifth desensitization? If
yes, the SAE sheet has to be filled in and sent to
the sponsor within 24 hours.
Yes
No
What measures have been taken in response to
the SAE?
termination of study -> please fill in study
completion form  (1)
adjustment of dose during next course of
desensitization (2)
Adverse Events
Did any Adverse Events occur?
Yes
No
Have these been serious adverse events?
Yes
No
Please describe the AE
Adverse Event Start Date
Adverse event end date
How often did the event occur?
once (1)
regularly (2)
continuing (3)
Please give your opinion to the severity of the AE
minor (1)
moderate (2)
severe (3)
Adverse Event Outcome
Recovered (1)
Subsiding (2)
Continuing (3)
resolved with sequelae (4)
increased symptoms (5)
fatal (6)
What actions have been taken regarding the trial
substance?
not applicable (1)
no adjustment in dose (2)
adjustment of dose (3)
suspension of treatment (4)
discontinuation of treatment (5)
other (6)
4 / 5
Efficacy and tolerability of subcutaneous hyposensitization with
CLUSTOID in Patients with allergic rhinoconjunctivitis Visit 3
What other actions have been taken in response
to the AE?
none (1)
change of concomitant medication (2)
hospitalization/prolonged stay in hospital
(3)
further therapeutic and diagnostic
measures (4)
Is the AE related to the trial substance?
undecided/incomplete (1)
inconclusive (2)
without context to trial substance (3)
unlikely (4)
possible (5)
probable (6)
confirmed (7)
Please agree to a date for follow up V4 within
next month
Date of completion of this form
Signature
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Prospective,multicentric,double blind and placebo-
controlled Phase III clinical trial to determine efficacy and
tolerability of subcutaneous hyposensitization with
CLUSTOID in patients with allergic rhinoconjunctivits
caused by grass or rye pollen. EudraCT-Nr. 2008-000513-
29 Study-code:CLU-2008-001 Sponsor: ROXALL Medizin
GmbH Carl-Petersen-Straße 4 20535 Hamburg Phone:040-
8972520 Fax:040-89725223 Project coordinator: Dr.Jenny
Uhlig ROXALL Medizin GmbH Head of clinical
investigation: Prof.Dr.med.Ludger Klimek An den Quellen
10 65183 Wiesbaden Phone:0611-8904381 Fax:0611-
3082360 Monitoring,data management and statistical
evaluation: IMSIE- Institut for medical statistics,computer
sciences and epidemiology University hospital Cologne
Lindenburger Allee 42 50931 Cologne Phone:0221-
4783456 Fax:0221-4783465
All rights reserved. Please visit https://medical-data-
models.org/forms/13157
Case report form Visit 4
Visit 4: Maintenance Visit
Please give Patient ID composed of Study site Nr
and Patient Nr
Date of visit 4
Is the patient still participating in this trial? If no,
please fill in study completion form
Yes
No
Female of childbearing potential, using safe
contraceptive measures? If no please fill in study
completion form
Yes
No
Peak flow best value during visit 1
l/min
Please take 3 consecutive peak flow
measurements
l/min
Second peak flow measurement
l/min
Third peak flow measurement
l/min
Peak flow best value during visit 4
l/min
If peak flow measurement is > 80 percent of best
value during visit 1, continue with allergen
exposure, if no suspend next exposure to
allergen and repeat peak flow measurement
Yes
No
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First peak flow measurement after suspension
l/min
Second peak flow measurement after suspension
l/min
Third peak flow measurement after suspension
l/min
Blood pressure measurement
mm/Hg
Heart rate count
bpm
Body height
Body weight
Rhinoscopic evaluation:Edema
none (0)
little (1)
severe (2)
Rhinoscopic evaluation: secretion
none (0)
clear fluid (1)
thick mucous (2)
Rhinoscopic evaluation:redness
none (0)
little (1)
severe (2)
Has concomitant medication been subject to
change?
Yes
No
Please specify any changes of therapy and
review for exclusion criteria
Have comorbidities changed?
Yes
No
If comorbidities have changed,please specify and
review for exclusion criteria
Subcutaneous desensitization
Has the sixth dose of desensitization been
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administered?
Yes
No
Please give the date and time, the sixth dose has
been administered
If the sixth dose has not been administered,
please specify the reason why
How much of the trial substance has been
injected?
ml
0,5ml (1)
adjusted dose (2)
If the dose of trial substance has been adjusted,
please specify the reason why and how much
has actually been administered
Please specify which arm has been used for
injection
right arm (1)
left arm (2)
30 min after injection, has the patient
experienced any local, gastrointestinal, systemic
or other symptoms?
Yes
No
Have any of the following symptoms occured?If
yes please do not forget to fill in AE report
local reaction of the
skin:swelling,itching,rash,or burning
sensation (1)
gastrointestinal
symptoms:nausea,vomiting,dyspepsia,fla
tulence,diarrhea (2)
systemic reactions (3)
unspecified symptoms like headache,
discomfort (3.1)
minor systemic symptoms like rhinitis,or
minor asthmatic symptoms (3.2)
non-life-threatening systemic symptoms
like urticaria, angioedema,severe
asthmatic symptoms (3.3)
severe systemic symptoms like
anaphylactic shock [extended
documentation as SAE] (3.4)
other (4)
Please specify any other symptoms that occured
within 30 min after injection of sixth
desensitization
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Have severe local, gastrointestinal or systemic
symptoms occured during sixth desensitization?
If yes, the SAE sheet has to be filled in and sent
to the sponsor within 24 hours.
Yes
No
What measures have been taken in response to
the SAE?
termination of study -> please fill in study
completion form 2=adjustment of dose
during next course of desensitization (1)
Adverse Events
Did any Adverse Events occur?
Yes
No
Have these been serious adverse events?
Yes
No
Please describe the AE
Adverse Event Start Date
Adverse Event End Date
How often did the event occur?
once (1)
regularly (2)
continuing (3)
Please give your opinion to the severity of the AE
minor (1)
moderate (2)
severe (3)
Adverse Event Outcome
Recovered (1)
Subsiding (2)
Continuing (3)
resolved with sequelae (4)
increased symptoms (5)
fatal (6)
What actions have been taken regarding the trial
substance?
not applicable (1)
no adjustment in dose (2)
adjustment of dose (3)
suspension of treatment (4)
discontinuation of treatment (5)
other (6)
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What other actions have been taken in response
to the AE?
none (1)
change of concomitant medication (2)
hospitalization/prolonged stay in hospital
(3)
further therapeutic and diagnostic
measures (4)
Is the AE related to the trial substance?
undecided/incomplete (1)
inconclusive (2)
without context to trial substance (3)
unlikely (4)
possible (5)
probable (6)
confirmed (7)
Please agree to a date for follow up V5 within
next month
Date of completion of this form
Signature
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Efficacy and tolerability of subcutaneous hyposensitization with
CLUSTOID in Patients with allergic rhinoconjunctivitis Visit 4
Efficacy and tolerability of subcutaneous hyposensitization with
CLUSTOID in Patients with allergic rhinoconjunctivitis Visit 5
Prospective,multicentric,double blind and placebo-
controlled Phase III clinical trial to determine efficacy and
tolerability of subcutaneous hyposensitization with
CLUSTOID in patients with allergic rhinoconjunctivits
caused by grass or rye pollen. EudraCT-Nr. 2008-000513-
29 Study-code:CLU-2008-001 Sponsor: ROXALL Medizin
GmbH Carl-Petersen-Straße 4 20535 Hamburg Phone:040-
8972520 Fax:040-89725223 Project coordinator: Dr.Jenny
Uhlig ROXALL Medizin GmbH Head of clinical
investigation: Prof.Dr.med.Ludger Klimek An den Quellen
10 65183 Wiesbaden Phone:0611-8904381 Fax:0611-
3082360 Monitoring,data management and statistical
evaluation: IMSIE- Institut for medical statistics,computer
sciences and epidemiology University hospital Cologne
Lindenburger Allee 42 50931 Cologne Phone:0221-
4783456 Fax:0221-4783465
All rights reserved. Please visit https://medical-data-
models.org/forms/13172
Case Report Form Visit 5
Visit 5:Maintenance Visit
Please give Patient ID composed of Study site Nr
and Patient Nr
Date of visit 5
Is the patient still participating in this trial? If no,
please fill in study completion form
Yes
No
Females of childbearing potential, using safe
contraceptive measures? If no please fill in study
completion form
Yes
No
Peak flow best value during visit 1
l/min
Please take 3 consecutive peak flow
measurements
l/min
Second peak flow measurement
l/min
Third peak flow measurement
l/min
Peak flow best value during visit 5
l/min
If peak flow measurement is > 80 percent of best
value during visit 1, continue with allergen
exposure, if no suspend next exposure to
allergen and repeat peak flow measurement
Yes
No
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First peak flow measurement after suspension
l/min
Second peak flow measurement after suspension
l/min
Third peak flow measurement after suspension
l/min
Blood pressure measurement
mm/Hg
Heart rate count
bpm
Body Height
cm
Body Weight
Rhinoscopic evaluation:Edema
none (0)
little (1)
severe (2)
Rhinoscopic evaluation: secretion
none (0)
clear fluid (1)
thick mucous (2)
Rhinoscopic evaluation:redness
none (0)
little (1)
severe (2)
Has concomitant medication been subject to
change?
Yes
No
Please specify any changes of therapy and
review for exclusion criteria
Have comorbidities changed?
Yes
No
If comorbidities have changed,please specify and
review for exclusion criteria
Subcutaneous desensitization
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Has the seventh dose of desensitization been
administered?
Yes
No
Please give the date and time, the Seventh dose
has been administered
If the seventh dose has not been administered,
please specify the reason why
How much of the trial substance has been
injected?
ml
0,5ml (1)
adjusted dose (2)
If the dose of trial substance has been adjusted,
please specify the reason why and how much
has actually been administered
Please specify which arm has been used for
injection
right arm (1)
left arm (2)
30 min after injection, has the patient
experienced any local, gastrointestinal, systemic
or other symptoms?
Yes
No
Have any of the following symptoms occured?If
yes please do not forget to fill in AE report
local reaction of the
skin:swelling,itching,rash,or burning
sensation (1)
gastrointestinal
symptoms:nausea,vomiting,dyspepsia,fla
tulence,diarrhea (2)
systemic reactions (3)
unspecified symptoms like headache,
discomfort (3.1)
minor systemic symptoms like rhinitis,or
minor asthmatic symptoms (3.2)
non-life-threatening systemic symptoms
like urticaria, angioedema,severe
asthmatic symptoms (3.3)
severe systemic symptoms like
anaphylactic shock [extended
documentation as SAE] (3.4)
other (4)
Please specify any other symptoms that occured
within 30 min after injection of seventh
desensitization
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Have severe local, gastrointestinal or systemic
symptoms occured during seventh
desensitization? If yes, the SAE sheet has to be
filled in and sent to the sponsor within 24 hours.
Yes
No
What measures have been taken in response to
the SAE?
termination of study -> please fill in study
completion form 2=adjustment of dose
during next course of desensitization (1)
Adverse Events
Did any Adverse Events occur?
Yes
No
Have these been serious adverse events?
Yes
No
Please describe the AE
Adverse Event Start Date
Adverse Event End Date
How often did the event occur?
once (1)
regularly (2)
continuing (3)
Please give your opinion to the severity of the AE
minor (1)
moderate (2)
severe (3)
Adverse Event Outcome
Recovered (1)
Subsiding (2)
Continuing (3)
resolved with sequelae (4)
increased symptoms (5)
fatal (6)
What actions have been taken regarding the trial
substance?
not applicable (1)
no adjustment in dose (2)
adjustment of dose (3)
suspension of treatment (4)
discontinuation of treatment (5)
other (6)
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What other actions have been taken in response
to the AE?
none (1)
change of concomitant medication (2)
hospitalization/prolonged stay in hospital
(3)
further therapeutic and diagnostic
measures (4)
Is the AE related to the trial substance?
undecided/incomplete (1)
inconclusive (2)
without context to trial substance (3)
unlikely (4)
possible (5)
probable (6)
confirmed (7)
Please agree to a date for follow up V6 within
next month
Date of completion of this form
Signature
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Eligibility Lymphoma NCT00004228
Combination Chemotx in Treating Children or Adolescents
With Newly Diagnosed Stg III or Stg IV Lymphoblastic
Lymphoma; ODM derived from:
https://clinicaltrials.gov/show/NCT00004228
All rights reserved. Please visit https://medical-data-
models.org/forms/13179
Eligibility Lymphoma NCT00004228
Criteria
newly diagnosed disseminated lymphoblastic
lymphoma or localized lymphoblastic lymphoma*
note: *localized lymphoblastic lymphoma is
closed to accrual as of 10/2005*
Yes
No
less than 25% tumor cells in the bone marrow*
Yes
No
previously untreated (prior intrathecal cytarabine
allowed if protocol therapy begins within 72
hours)*
Yes
No
stage iii or iv disease*
Yes
No
age: 1 to 30*
Yes
No
cardiovascular: adequate cardiac function*
Yes
No
prior concurrent therapy: 
endocrine therapy: emergency steroid therapy (if
required) must be started within 72 hours prior to
protocol therapy*
Yes
No
prior concurrent therapy: 
radiotherapy: emergency radiotherapy (if
required) must be started within 72 hours prior to
protocol therapy*
Yes
No
other: no other prior therapy except for
emergency treatment of airway obstruction and/or
superior vena cava syndrome*
Yes
No
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Eligibility Lymphoma NCT00005601
Combination Chemotherapy Plus Rituximab in Treating
Patients With Relapsed Non-Hodgkin's Lymphoma; ODM
derived from: https://clinicaltrials.gov/show/NCT00005601
All rights reserved. Please visit https://medical-data-
models.org/forms/13180
Eligibility Lymphoma NCT00005601
Criteria
histologically confirmed cd20+ b-cell non-
hodgkin's lymphoma*
Yes
No
relapsed following chemotherapy and eligible for
platinum-containing regimen*
Yes
No
measurable disease*
Yes
No
must be at least 1.5 x 1.5 cm*
Yes
No
age: 18 and over*
Yes
No
performance status: ecog 0-2*
Yes
No
hematopoietic: absolute neutrophil count at least
1,500/mm^3*
Yes
No
hematopoietic: platelet count at least
75,000/mm^3*
Yes
No
hepatic: bilirubin no greater than 2.0 mg/dl*
Yes
No
renal: creatinine no greater than 1.5 times upper
limit of normal*
Yes
No
cardiovascular: no uncontrolled hypertension*
Yes
No
hiv negative*
Yes
No
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no other active malignancy*
Yes
No
no uncontrolled diabetes mellitus*
Yes
No
no uncontrolled peptic ulcer disease*
Yes
No
no uncontrolled infection*
Yes
No
not pregnant or nursing*
Yes
No
negative pregnancy test*
Yes
No
fertile patients must use effective contraception*
Yes
No
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Eligibility Lymphoma NCT00005601
Efficacy and tolerability of subcutaneous hyposensitization with
CLUSTOID in Patients with allergic rhinoconjunctivitis Visit 7
Prospective,multicentric,double blind and placebo-
controlled Phase III clinical trial to determine efficacy and
tolerability of subcutaneous hyposensitization with
CLUSTOID in patients with allergic rhinoconjunctivits
caused by grass or rye pollen. EudraCT-Nr. 2008-000513-
29 Study-code:CLU-2008-001 Sponsor: ROXALL Medizin
GmbH Carl-Petersen-Straße 4 20535 Hamburg Phone:040-
8972520 Fax:040-89725223 Project coordinator: Dr.Jenny
Uhlig ROXALL Medizin GmbH Head of clinical
investigation: Prof.Dr.med.Ludger Klimek An den Quellen
10 65183 Wiesbaden Phone:0611-8904381 Fax:0611-
3082360 Monitoring,data management and statistical
evaluation: IMSIE- Institut for medical statistics,computer
sciences and epidemiology University hospital Cologne
Lindenburger Allee 42 50931 Cologne Phone:0221-
4783456 Fax:0221-4783465
All rights reserved. Please visit https://medical-data-
models.org/forms/13183
Case Report Form Visit 7
Visit 7:Maintenance Visit
Please give Patient ID composed of Study site Nr
and Patient Nr
Date of visit 7
Is the patient still participating in this trial? If no,
please fill in study completion form
Yes
No
Females of childbearing potential, using safe
contraceptive measures? If no please fill in study
completion form
Yes
No
Peak flow best value during visit 1
l/min
Please take 3 consecutive peak flow
measurements
l/min
Second peak flow measurement
l/min
Third peak flow measurement
l/min
Peak flow best value during visit 7
l/min
If peak flow measurement is > 80 percent of best
value during visit 1, continue with allergen
exposure, if no suspend next exposure to
allergen and repeat peak flow measurement
Yes
No
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First peak flow measurement after suspension
l/min
Second peak flow measurement after suspension
l/min
Third peak flow measurement after suspension
l/min
Blood pressure measurement
mm/Hg
Heart rate count
bpm
Body Height
cm
Body weight
Rhinoscopic evaluation:Edema
none (0)
little (1)
severe (2)
Rhinoscopic evaluation: secretion
none (0)
clear fluid (1)
thick mucous (2)
Rhinoscopic evaluation:redness
none (0)
little (1)
severe (2)
Has concomitant medication been subject to
change?
Yes
No
Please specify any changes of therapy and
review for exclusion criteria
Have comorbidities changed?
Yes
No
If comorbidities have changed,please specify and
review for exclusion criteria
Subcutaneous desensitization
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CLUSTOID in Patients with allergic rhinoconjunctivitis Visit 7
Has the ninth dose of desensitization been
administered?
Yes
No
Please give the date and time, the ninth dose has
been administered
If the ninth dose has not been administered,
please specify the reason why
How much of the trial substance has been
injected?
ml
0,5ml (1)
adjusted dose (2)
If the dose of trial substance has been adjusted,
please specify the reason why and how much
has actually been administered
Please specify which arm has been used for
injection
right arm (1)
left arm (2)
30 min after injection, has the patient
experienced any local, gastrointestinal, systemic
or other symptoms?
Yes
No
Have any of the following symptoms occured?If
yes please do not forget to fill in AE report
local reaction of the
skin:swelling,itching,rash,or burning
sensation (1)
gastrointestinal
symptoms:nausea,vomiting,dyspepsia,fla
tulence,diarrhea (2)
systemic reactions (3)
unspecified symptoms like headache,
discomfort (3.1)
minor systemic symptoms like rhinitis,or
minor asthmatic symptoms (3.2)
non-life-threatening systemic symptoms
like urticaria, angioedema,severe
asthmatic symptoms (3.3)
severe systemic symptoms like
anaphylactic shock [extended
documentation as SAE] (3.4)
other (4)
Please specify any other symptoms that occured
within 30 min after injection of ninth
desensitization
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Have severe local, gastrointestinal or systemic
symptoms occured during ninth desensitization?
If yes, the SAE sheet has to be filled in and sent
to the sponsor within 24 hours.
Yes
No
What measures have been taken in response to
the SAE?
termination of study -> please fill in study
completion form 2=adjustment of dose
during next course of desensitization (1)
Adverse Events
Did any Adverse Events occur?
Yes
No
Have these been serious adverse events?
Yes
No
Please describe the AE
Adverse Event Start Date
Adverse Event End Date
How often did the event occur?
once (1)
regularly (2)
continuing (3)
Please give your opinion to the severity of the AE
minor (1)
moderate (2)
severe (3)
Adverse Event Outcome
Recovered (1)
Subsiding (2)
Continuing (3)
resolved with sequelae (4)
increased symptoms (5)
fatal (6)
What actions have been taken regarding the trial
substance?
not applicable (1)
no adjustment in dose (2)
adjustment of dose (3)
suspension of treatment (4)
discontinuation of treatment (5)
other (6)
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What other actions have been taken in response
to the AE?
none (1)
change of concomitant medication (2)
hospitalization/prolonged stay in hospital
(3)
further therapeutic and diagnostic
measures (4)
Is the AE related to the trial substance?
undecided/incomplete (1)
inconclusive (2)
without context to trial substance (3)
unlikely (4)
possible (5)
probable (6)
confirmed (7)
Please agree to a date for follow up V8 within
next month
Date of completion of this form
Signature
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Efficacy and tolerability of subcutaneous hyposensitization with
CLUSTOID in Patients with allergic rhinoconjunctivitis Visit 6
Prospective,multicentric,double blind and placebo-
controlled Phase III clinical trial to determine efficacy and
tolerability of subcutaneous hyposensitization with
CLUSTOID in patients with allergic rhinoconjunctivits
caused by grass or rye pollen. EudraCT-Nr. 2008-000513-
29 Study-code:CLU-2008-001 Sponsor: ROXALL Medizin
GmbH Carl-Petersen-Straße 4 20535 Hamburg Phone:040-
8972520 Fax:040-89725223 Project coordinator: Dr.Jenny
Uhlig ROXALL Medizin GmbH Head of clinical
investigation: Prof.Dr.med.Ludger Klimek An den Quellen
10 65183 Wiesbaden Phone:0611-8904381 Fax:0611-
3082360 Monitoring,data management and statistical
evaluation: IMSIE- Institut for medical statistics,computer
sciences and epidemiology University hospital Cologne
Lindenburger Allee 42 50931 Cologne Phone:0221-
4783456 Fax:0221-4783465
All rights reserved. Please visit https://medical-data-
models.org/forms/13184
Case Report Form Visit 6
Visit 6:Maintenance Visit
Please give Patient ID composed of Study site Nr
and Patient Nr
Date of visit 6
Is the patient still participating in this trial? If no,
please fill in study completion form
Yes
No
Females of childbearing potential, using safe
contraceptive measures? If no please fill in study
completion form
Yes
No
Peak flow best value during visit 1
l/min
Please take 3 consecutive peak flow
measurements
l/min
Second peak flow measurement
l/min
Third peak flow measurement
l/min
Peak flow best value during visit 6
l/min
If peak flow measurement is > 80 percent of best
value during visit 1, continue with allergen
exposure, if no suspend next exposure to
allergen and repeat peak flow measurement
Yes
No
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First peak flow measurement after suspension
l/min
Second peak flow measurement after suspension
l/min
Third peak flow measurement after suspension
l/min
Blood pressure measurement
mm/Hg
Heart rate count
bpm
Body Height
cm
Body Weight
kg
Rhinoscopic evaluation:Edema
none (0)
little (1)
severe (2)
Rhinoscopic evaluation: secretion
none (0)
clear fluid (1)
thick mucous (2)
Rhinoscopic evaluation:redness
none (0)
little (1)
severe (2)
Has concomitant medication been subject to
change?
Yes
No
Please specify any changes of therapy and
review for exclusion criteria
Have comorbidities changed?
Yes
No
If comorbidities have changed,please specify and
review for exclusion criteria
Subcutaneous desensitization
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Has the eighth dose of desensitization been
administered?
Yes
No
Please give the date and time, the eighth dose
has been administered
If the eighth dose has not been administered,
please specify the reason why
How much of the trial substance has been
injected?
ml
0,5ml (1)
adjusted dose (2)
If the dose of trial substance has been adjusted,
please specify the reason why and how much
has actually been administered
Please specify which arm has been used for
injection
right arm (1)
left arm (2)
30 min after injection, has the patient
experienced any local, gastrointestinal, systemic
or other symptoms?
Yes
No
Have any of the following symptoms occured?If
yes please do not forget to fill in AE report
local reaction of the
skin:swelling,itching,rash,or burning
sensation (1)
gastrointestinal
symptoms:nausea,vomiting,dyspepsia,fla
tulence,diarrhea (2)
systemic reactions (3)
unspecified symptoms like headache,
discomfort (3.1)
minor systemic symptoms like rhinitis,or
minor asthmatic symptoms (3.2)
non-life-threatening systemic symptoms
like urticaria, angioedema,severe
asthmatic symptoms (3.3)
severe systemic symptoms like
anaphylactic shock [extended
documentation as SAE] (3.4)
other (4)
Please specify any other symptoms that occured
within 30 min after injection of eighth
desensitization
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Have severe local, gastrointestinal or systemic
symptoms occured during eighth desensitization?
If yes, the SAE sheet has to be filled in and sent
to the sponsor within 24 hours.
Yes
No
What measures have been taken in response to
the SAE?
termination of study -> please fill in study
completion form 2=adjustment of dose
during next course of desensitization (1)
Adverse Events
Did any Adverse Events occur?
Yes
No
Have these been serious adverse events?
Yes
No
Please describe the AE
Adverse Event Start Date
Adverse Event End Date
How often did the event occur?
once (1)
regularly (2)
continuing (3)
Please give your opinion to the severity of the AE
minor (1)
moderate (2)
severe (3)
Adverse Event Outcome
Recovered (1)
Subsiding (2)
Continuing (3)
resolved with sequelae (4)
increased symptoms (5)
fatal (6)
What actions have been taken regarding the trial
substance?
not applicable (1)
no adjustment in dose (2)
adjustment of dose (3)
suspension of treatment (4)
discontinuation of treatment (5)
other (6)
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What other actions have been taken in response
to the AE?
none (1)
change of concomitant medication (2)
hospitalization/prolonged stay in hospital
(3)
further therapeutic and diagnostic
measures (4)
Is the AE related to the trial substance?
undecided/incomplete (1)
inconclusive (2)
without context to trial substance (3)
unlikely (4)
possible (5)
probable (6)
confirmed (7)
Please agree to a date for follow up V7 within
next month
Date of completion of this form
Signature
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Eligibility Hepatitis B NCT00697242
Comparison of Immuno, Reacto and Safety of Recombinant
Hepatitis B Vaccine With or Without MPL in Healthy Older
Adults; ODM derived from:
https://clinicaltrials.gov/show/NCT00697242
All rights reserved. Please visit https://medical-data-
models.org/forms/13192
Eligibility Hepatitis B NCT00697242
Inclusion Criteria
healthy male or female subjects between 50 and
70 years old.*
Yes
No
written informed consent will have been obtained
from the subjects.*
Yes
No
good physical condition as established by
physical examination and history taking at the
time of entry*
Yes
No
Exclusion Criteria
positive titres for anti hepatitis antibodies*
Yes
No
any vaccination against hepatitis b in the past.*
Yes
No
any previous administration of mpl*
Yes
No
elevated serum liver enzymes at two subsequent
determinations 14 days apart.*
Yes
No
history of significant and persisting hematologic,
hepatic, renal, cardiac or respiratory disease.*
Yes
No
axillary temperature > 37.5°c at the time of
injection.*
Yes
No
any acute disease at the moment of entry.*
Yes
No
chronic alcohol consumption.*
Yes
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No
any treatment with immunosuppressive or
immunostimulant therapy.*
Yes
No
any chronic drug treatment, which in the
investigator's opinion, precludes inclusion into the
study.*
Yes
No
history of allergic disease likely to be stimulated
by any component of the vaccine.*
Yes
No
administration of any other vaccine(s) or any
immunoglobulin during the study period.*
Yes
No
simultaneous participation in any other clinical
trial.*
Yes
No
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Eligibility Hepatitis B NCT00697242
Eligibility Leukemia NCT00002700
Chemotherapy With or Without Bone Marrow
Transplantation in Treating Patients With Acute
Lymphoblastic Leukemia; ODM derived from:
https://clinicaltrials.gov/show/NCT00002700
All rights reserved. Please visit https://medical-data-
models.org/forms/13193
Eligibility Leukemia NCT00002700
Criteria
newly diagnosed acute lymphoblastic leukemia or
lymphoblastic lymphoma with more than 30%
blasts in bone marrow*
Yes
No
Age 15 to 60*
Yes
No
bilirubin less than 2 mg/dl (unless elevation due
to leukemic involvement of liver)*
Yes
No
creatinine less than 2 mg/dl (unless elevation due
to leukemic involvement of kidneys)*
Yes
No
no severe cardiac disease*
Yes
No
no severe pulmonary disease*
Yes
No
no severe neurological or metabolic disease*
Yes
No
hiv negative (if tested)*
Yes
No
no other prior malignancy except
nonmelanomatous skin cancer, stage i cervical
carcinoma, or other curatively treated
malignancy*
Yes
No
no prior biologic therapy*
Yes
No
no prior chemotherapy*
Yes
No
no prior endocrine therapy*
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Yes
No
no prior radiotherapy*
Yes
No
no prior surgery*
Yes
No
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Eligibility Leukemia NCT00002700
Eligibility Major Depression NCT00296725
Dichotic Listening as a Predictor of Medication Response in
Depression; ODM derived from:
https://clinicaltrials.gov/show/NCT00296725
All rights reserved. Please visit https://medical-data-
models.org/forms/13194
Eligibility Major Depression
NCT00296725
Inclusion Criteria
ages between 18-65*
Yes
No
meets dsm-iv criteria for current major
depression, dysthymia or depression nos*
Yes
No
Exclusion Criteria
known hearing impairment*
Yes
No
active suicidal ideation (history of suicide
attempts will be evaluated on a case by case
basis)*
Yes
No
hamd > 20*
Yes
No
current (past six months) alcohol and/or drug
abuse or dependence*
Yes
No
medical condition likely to require intervention
contraindicated with study medication (e.g.,
known arrhythmia likely to be exacerbated by
imipramine)*
Yes
No
bipolar i*
Yes
No
psychosis*
Yes
No
if currently taking antidepressants or mood
stabilizers, cannot be off psychotropic medication
for 7 weeks (10 weeks for prozac) or felt to
require other psychiatric medication (other than
occasional sleep or anxiety medication)*
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Yes
No
premenopausal women not using known effective
birth control*
Yes
No
not currently depressed (whether considered due
to current treatment or not)*
Yes
No
nonresponse to adequate trial of both study
medications (i.e., > 4weeks on > escitalopram 30
mg/d, and imipramine 200 mg/d); patients having
an inadequate response to one study medication
could be enrolled and receive the other; patients
having responded to an adequate trial of either
study medication would be offered a retrial; also
excluded will be subjects having non responded
to an adequate trial with citalopram (i.e., > 4
weeks on > citalopram 60 mg/d)*
Yes
No
left-handed*
Yes
No
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Eligibility Major Depressive Disorder
NCT01360190
Neurophysiologic Monitoring of Antidepressant Treatment;
ODM derived from:
https://clinicaltrials.gov/show/NCT01360190
All rights reserved. Please visit https://medical-data-
models.org/forms/13195
Eligibility Major Depressive Disorder
NCT01360190
Inclusion Criteria
all subjects will meet dsm-iv criteria for major
depression based upon the structured clinical
interview for dsm-iv - patient version (scid-p) (first
et al., 1994).  all research personnel have
undergone scid-p training, and soon will extend
this training to the dsm-iv version.*
Yes
No
subjects also will have a score on the 17-item
hamilton depression rating scale of > 18 (with
item #1 > 2).*
Yes
No
all subjects will be under the care of a clinician
not affiliated with the study at the time of entry
into the study, and through the course of the
study.*
Yes
No
Exclusion Criteria
subjects will have no serious medical illness.*
Yes
No
we will exclude patients also meeting criteria for
the following groups of axis i diagnoses:  delirium
or dementia, substance-related disorders,
schizophrenia or other psychotic disorders, or
eating disorders.*
Yes
No
in addition, patients meeting criteria for cluster a
or b axis ii diagnoses will be excluded.*
Yes
No
subjects with a history of current or past active
suicidal ideation, or suicide attempts will be
excluded, as will patients who previously have
failed to respond to an adequate clinical trial of
fluoxetine, or have failed to tolerate the
medication.*
Yes
No
subjects who have had suboptimal trials,
however, may still be considered for the study.*
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Yes
No
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Eligibility Multiple Sclerosis NCT00203021
Copaxone® Study to Follow Patients From the First
Original Study for Safety and Effectiveness.; ODM derived
from: https://clinicaltrials.gov/show/NCT00203021
All rights reserved. Please visit https://medical-data-
models.org/forms/13196
Eligibility Multiple Sclerosis
NCT00203021
Inclusion Criteria
patients must have participated (been
randomized) in the copaxone double-blind
placebo controlled study (protocol 01-9001).*
Yes
No
gender:  patients may be male or female.  women
of childbearing potential must practice an
acceptable method of birth control.*
Yes
No
patients must meet the criteria of clinically
definite ms as defined by poser.5*
Yes
No
the patient's signs and symptoms cannot be
better explained by another disease process.*
Yes
No
patients must sign an approved informed consent
prior to initiating the study.*
Yes
No
patients must be psychologically and physically
stable to participate in the trial as judged by the
investigator.*
Yes
No
Exclusion Criteria
pregnancy or lactation.*
Yes
No
medical or psychiatric conditions that affect the
patient's ability to give informed consent or
complete the study.*
Yes
No
inability to self-administer subcutaneous
medication or lack of another responsible
individual to administer the study preparation
daily.*
Yes
No
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use of interferons, experimental ms therapies, or
previous immunosuppressive therapy with
cytotoxic chemotherapy (azathioprine,
cyclophosphamide, or cyclosporine), or total
lymphoid irradiation within 30 days of study
entry.*
Yes
No
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Eligibility Nasopharyngeal Carcinoma
NCT00201344
A Phase III Study of Radiotherapy With or Without Adjuvant
C/T in Advanced Stage Nasopharyngeal Carcinoma
Patients; ODM derived from:
https://clinicaltrials.gov/show/NCT00201344
All rights reserved. Please visit https://medical-data-
models.org/forms/13197
Eligibility Nasopharyngeal
Carcinoma NCT00201344
Inclusion Criteria
patients must have histologically proven
nasopharyngeal carcinoma who have just
completed curative radiotherapy treatment.*
Yes
No
original stage must be stage iv disease (m0)*
Yes
No
patients must have a complete response, partial
response or stable disease assessed 4 weeks
after radiotherapy.*
Yes
No
performance status scale  ecog  grade 0，1.*
Yes
No
creatinine ≦ 1.5mg/dl and bilirubin ≦ 2.0mg/dl,
wbc ≧ 3,000/mm3 and plt ≧ 100,000/mm3,*
Yes
No
creatinine clearance ＞ 45ml/min if creatinine ＞
1.5mg/dl.*
Yes
No
patients must be younger than 70 year-old.*
Yes
No
patients must give signed informed consent.*
Yes
No
Exclusion Criteria
patients had progressive disease after
radiotherapy*
Yes
No
patients had evidence of distant metastasis.*
Yes
No
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patients had completed radiotherapy for more
than 7 weeks.*
Yes
No
the presence of life-threatening illness*
Yes
No
history of prior malignancy excluding basal cell
carcinoma or squamous carcinoma of the skin or
in-situ cervical cancer within 3 years of the
diagnosis of npc cancer.*
Yes
No
previous chemotherapy.*
Yes
No
pregnancy.*
Yes
No
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Eligibility Lymphoma NCT00154440
Helicobacter – Lymphoma – Radiation Part I: Eradication,
Part II: Radiation; ODM derived from:
https://clinicaltrials.gov/show/NCT00154440
All rights reserved. Please visit https://medical-data-
models.org/forms/13198
Eligibility Lymphoma NCT00154440
Inclusion Criteria
histologically diagnosed, primary gastric low-
grade b-cell malt lymphoma stages ie or ii1e,
helicobacter pylori-positive (in histology, urease
test , and serology) for inclusion into helyx part i*
Yes
No
histologically diagnosed, primary gastric low-
grade b-cell malt lymphoma stages ie or ii1e,
helicobacter pylori-negative (in histology, urease
test, and serology) for inclusion into helyx part ii*
Yes
No
patients who achieved a study end point of helyx
i: partial remission or no change 12 months after
successful antibiotic therapy for inclusion into
helyx part ii,*
Yes
No
age > 18 and < 75 years*
Yes
No
karnofsky-index > 60%*
Yes
No
sufficient liver function, defined as bilirubin <
34µmol/l*
Yes
No
sufficient renal function, defined as creatinine <
133µmol/l*
Yes
No
written informed consent*
Yes
No
complete clinical tumor staging*
Yes
No
Exclusion Criteria
primary gastric low-grade malt lymphoma, stages
>ii1e or gastric high-grade lymphoma or other
lymphoma entities of the stomach e.g.
1 / 2
lymphoblastic lymphoma or burkitt’s lymphoma*
Yes
No
age < 18 and > 75 years*
Yes
No
karnofsky-index < 60%*
Yes
No
insufficient liver and renal function (see above)*
Yes
No
hiv-infection*
Yes
No
pregnancy or nursing*
Yes
No
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Eligibility Lymphoma, AIDS-related
NCT00006436
EPOCH and Rituximab to Treat Non-Hodgkin's Lymphoma
in Patients With HIV Infection; ODM derived from:
https://clinicaltrials.gov/show/NCT00006436
All rights reserved. Please visit https://medical-data-
models.org/forms/13199
Eligibility Lymphoma, AIDS-related
NCT00006436
Criteria
aggressive cd20 positive diffuse large b-cell
lymphoma confirmed by laboratory of pathology,
nci.*
Yes
No
hiv + serology.*
Yes
No
all stages (i-iv) of disease.*
Yes
No
ecog performance status 0-4*
Yes
No
nhl previously untreated with cytotoxic
chemotherapy.*
Yes
No
age greater than or equal to 18 years*
Yes
No
creatinine less than or equal to 1.5 mg/dl or
creatinine clearance greater than or equal to 50
ml/min*
Yes
No
bilirubin less than 2.0 mg/dl, or total bilirubin less
than or equal to 4.5 mg/dl with direct fraction less
than or equal to 0.3 mg/dl in patients for whom
these abnormalities are felt to be due to protease
inhibitor therapy*
Yes
No
ast and alt less than or equal to 3x uln (ast and
alt less than or equal to 6x uln for patients on
hyperalimentation for whom these abnormalities
are felt to be due to the hyperalimentation)*
Yes
No
anc greater than or equal to 1000/mm(3)*
Yes
No
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platelet greater than or equal to 75,000/mm(3)
(unless impairment due to itp)*
Yes
No
ability of patient to provide informed consent.*
Yes
No
Exclusion Criteria
previous rituximab*
Yes
No
pregnancy or nursing.*
Yes
No
doxorubicin, etoposide, vincristine and
cyclophosphamide are teratogenic and may be
excreted in milk.*
Yes
No
antiretroviral therapy is indicated during
pregnancy and nursing.*
Yes
No
current clinical heart failure or symptomatic
ischemic heart disease.*
Yes
No
serious underlying medical condition or infection
other than hiv that would contraindicate sc-
epoch-r.*
Yes
No
severe aids-related wasting*
Yes
No
sever intractable diarrhea*
Yes
No
active inadequately treated opportunistic infection
of the cns*
Yes
No
concurrent anti-retroviral therapy during epoch
therapy.*
Yes
No
primary cns lymphoma.*
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Yes
No
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Eligibility Lymphoma, Non-Hodgkin
NCT01868035
Iodine-131 Anti-B1 Antibody Consolidation for Patients With
Non-Hodgkin's Lymphoma Following First-line CHOP; ODM
derived from: https://clinicaltrials.gov/show/NCT01868035
All rights reserved. Please visit https://medical-data-
models.org/forms/13201
Eligibility Lymphoma, Non-Hodgkin
NCT01868035
Inclusion Criteria
male or female subjects age 18 to 80 years,
inclusive, with any international prognostic index
score; treated with 6 or more cycles of first-line
chop chemotherapy and achieved a pr, cru, or cr*
Yes
No
de novo diffuse large b-cell nhl according to the
real classification; ann arbor stage iii, stage iv, or
bulky stage ii disease (any mass ≥10 cm in
diameter)*
Yes
No
less than an average of 25% of the
intratrabecular marrow space involved by nhl in
bilateral bone marrow biopsy specimens or <10%
involvement with nhl from unilateral bone marrow
biopsy; tumor tissue expressing the cd20
antigen*
Yes
No
≥60% performance status on the karnofsky
performance scale and an anticipated survival of
at least 3 months*
Yes
No
absolute neutrophil count (anc) ≥1500 cells/mm3
and platelet count ≥100,000/mm3*
Yes
No
adequate renal function (serum creatinine <1.5 ×
upper limit of normal [uln]) and hepatic function
(total bilirubin ≤2.0 × uln and aspartate
aminotransferase <5 × uln)*
Yes
No
Exclusion Criteria
prior radiation, prior biological therapy, or prior
chemotherapy other than first-line chop*
Yes
No
active bilateral obstructive hydronephrosis*
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Yes
No
new york heart association class iii or iv heart
disease or other serious illness*
Yes
No
prior malignancy other than lymphoma (except for
adequately treated skin cancer, in situ cervical
cancer, or other cancer for which they had been
disease-free for >5 years)*
Yes
No
human immunodeficiency virus infection*
Yes
No
hama positive*
Yes
No
brain or leptomeningeal metastases at any time
since diagnosis*
Yes
No
active infection requiring intravenous anti-
infectives*
Yes
No
pregnant or breastfeeding*
Yes
No
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Eligibility Major Depressive Disorder
NCT00533832
Pivotal Trial (D02) of Vagus Nerve Stimulation (VNS) for
Treatment-Resistant Depression (TRD); ODM derived from:
https://clinicaltrials.gov/show/NCT00533832
All rights reserved. Please visit https://medical-data-
models.org/forms/13205
Eligibility Major Depressive Disorder
NCT00533832
Inclusion Criteria
1. diagnosed with major depressive episode
(mde)*
Yes
No
2. chronic (>=2 years)or recurrent (>-=4) lifetime
mdes*
Yes
No
3. resistant to >=2 treatments from different
categories*
Yes
No
4. completed >=6 weeks of psychotherapy*
Yes
No
5. score >=20 on 24-item hamilton rating scale of
depression*
Yes
No
6. iq >=70*
Yes
No
7. stable on current antidepressant medication
(no more than 5 antidepressant meds) or taking
no antidepressant meds for >=4 weeks before
visit b1*
Yes
No
8. stable on atypical antipsychotic and
anticonvulsant medications as for item #7*
Yes
No
9. age >=18 amd <=80 years*
Yes
No
10. male or nonpregnant female adequately
protected from conception.*
Yes
No
11. able to comply with testing and follow-up
visits*
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Yes
No
12. voluntarily signed informed consent*
Yes
No
13. patients with bipolar disorder demonstrated a
resistance to lithium treatment or has a medical
contraindication to treatment with lithium or is
known to be intolerant to lithium (not applicable to
patients with mdd)*
Yes
No
Exclusion Criteria
1. atypical depression at study entry or psychotic
symptoms in any mde*
Yes
No
2. history of schizophrenia, schizoaffective
disorder, or delusional disorders*
Yes
No
3. rapid cycling bopolar disorder*
Yes
No
4. secondary diagnosis of, or signs of, delirium,
dementia, amnestic, or other cognitive disorders*
Yes
No
5. failed 7 or more antidepressant treatments*
Yes
No
6. a. suicide attempt requiring medical attention
within previous 12 months b. >=2 suicide
attempts in the past 12 months c. cannot
guarantee that will not implement suicide d. likely
to attempt suicide within next 6 mon in
investigator's opinion*
Yes
No
7. alcohol or substance dependence within
previous 12 months or abuse within previous 6
mon other than nicotine dependence or abuse*
Yes
No
8. history of myocardial infarction or cardiac
arrest*
Yes
No
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9. other progressive neurological disease,
significant central nervous system disease or
injury, or cervical fracture that makes implantation
difficult*
Yes
No
10. received general anesthesia with 390 days
before enrollment.*
Yes
No
11. taken an investigational drug within a
clearance duration of 5 x the half-life of the
investigational drug  or within <=4weeks before
visit b1, whichever time is greater*
Yes
No
12. enrolled in another investigational study*
Yes
No
13. using another investigational device*
Yes
No
14. significant cardiac or pulmonary condition
currently under treatment resulting in an asa
score >=iii*
Yes
No
15. history of, or evidence of, significant brain
malformation or significant head injury or
clinically apparent cerebral vascular events, or
prior brain surgery such as cingulatomy*
Yes
No
16. unilateral or bilateral cervical vagotomy*
Yes
No
17. demand cardiac pacemaker, implantable
defibrillator, or other implantable stimulator*
Yes
No
18. likely to require a whole body mri after ncp
implantation*
Yes
No
19. currently receiving or likely to receive short-
wave diathermy, microwave diathermy, or
therapeutic ultrasound diathermy after
implantation*
Yes
No
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20. plans to relocate or move to a location distant
from the study site within one year of enrollment*
Yes
No
21. previously enrolled in this or any other ncp
system study -*
Yes
No
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Eligibility Mantle Cell Lymphoma
NCT00005780
Chemotherapy Plus Vaccination to Treat Mantle Cell
Lymphoma; ODM derived from:
https://clinicaltrials.gov/show/NCT00005780
All rights reserved. Please visit https://medical-data-
models.org/forms/13206
Eligibility Mantle Cell Lymphoma
NCT00005780
Criteria
tissue diagnosis of mantle cell lymphoma
(confirmed in laboratory of pathology). blastic cell
variant will be eligible.*
Yes
No
age greater than or equal to 18.*
Yes
No
previously untreated with cytotoxic chemotherapy.
patients may have received local radiation or a
short course of steroids for control of symptoms.*
Yes
No
all stages of disease.*
Yes
No
lymph node of greater than or equal to 2 cm
accessible for biopsy/harvest or greater than
1000/microliters of circulating tumor cells in the
blood.*
Yes
No
ecog performance status of less than or equal to
3.*
Yes
No
adequate major organ function (serum creatinine
1.5 mg/dl or creatinine clearance greater than 60
ml/min; bilirubin less than 2 mg/dl (total) except
less than 5 mg/dl in patients with gilbert's
syndrome as defined by greater than 80%
unconjugated; anc greater than 1000 and
platelets greater than 100,000) unless
impairment due to organ involvement by
lymphoma.*
Yes
No
no active symptomatic ischemic heart disease,
myocardial infarction or congestive heart failure
within the past year.  if muga is obtained, the lvef
should exceed 40%.*
Yes
No
ability to give informed consent.*
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Yes
No
Exclusion Criteria
antibodies to hiv or presence of hepatitis b
surface antigen.*
Yes
No
pregnant or lactating.*
Yes
No
prior malignancy in past 5 years except
squamous or basal cell carcinoma or curatively
treated in situ of the cervix.*
Yes
No
involvement of central nervous system by
lymphoma.*
Yes
No
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Eligibility Mantle Cell Lymphoma
NCT00183989
Combination Therapy With Fludarabine, Mitoxantrone and
Rituximab in Mantle Cell Lymphoma; ODM derived from:
https://clinicaltrials.gov/show/NCT00183989
All rights reserved. Please visit https://medical-data-
models.org/forms/13207
Eligibility Mantle Cell Lymphoma
NCT00183989
Inclusion Criteria
pathologic diagnosis of non-hodgkin's lymphoma
of the mantle cell sub-type lymphoma only, as
determined by morphologic assessment and
consistent immunophemotypic markers*
Yes
No
newly diagnosed and patients who have received
prior treatment are eligible*
Yes
No
measurable or evaluable disease*
Yes
No
karnofsky performance status greater or equal to
50%*
Yes
No
men and women, age greater or equal to 18
years old*
Yes
No
agc greater or equal to 1.0; platelets greater or
equal to 75,000; hemoglobin greater or equal to
8.0 (unless because of lymphomatous infiltration
of the marrow)*
Yes
No
creatinine less than 2.0; bilirubin less than 2.0;
sgot less than 3 times upper limit of normal
(unless elevations are due to lymphomatous
involvement)*
Yes
No
women of child bearing potential must have
negative pregnancy test within 14 days of study
entry.*
Yes
No
signed informed consent*
Yes
No
Exclusion Criteria
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history of congestive heart failure or significant
cardiac disease*
Yes
No
prior exposure to either fludarabine or
mitoxantrone. prior exposure to rituximab
allowed*
Yes
No
active infection*
Yes
No
hiv seropositive*
Yes
No
pregnant or lactating females*
Yes
No
second active malignancy, other than squamous
cell skin cancer,in-situ cervical cancer, or history
of other cancer diagnosed within the preceding 5
years*
Yes
No
presence of psychological or emotional disorders
which would make valid informed consent
impossible*
Yes
No
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Eligibility Metastases of Central Nervous
System NCT00831545
Study to Evaluate the Efficacy and Safety of Temozolomide
in Subjects With Brain Metastases of Either Malignant
Melanoma, Breast, or Non-small Cell Lung Cancer
(P02064); ODM derived from:
https://clinicaltrials.gov/show/NCT00831545
All rights reserved. Please visit https://medical-data-
models.org/forms/13208
Eligibility Metastases of Central
Nervous System NCT00831545
Inclusion Criteria
cytological/histological diagnosis of either
melanoma, non-small cell lung cancer and
breast;*
Yes
No
brain metastases >=1 cm presenting or in
progression following >=4 weeks time interval
free from previous malignancy-specific
chemotherapy, hormone therapy, or other medical
therapies;*
Yes
No
magnetic resonance imaging suspected brain
metastases; patients with brain lesion(s) not
univocal as brain metastases must have negative
radiolabeled leukocyte brain scan to rule out
infectious non-malignant disease; all
neuroradiological studies (baseline and treatment
outcome evaluation), except for emergency
exams must be performed after 10 days of
unchanged schedule of dexamethasone, and
obtained in the axial-coronal-sagittal planes in t1
and t2 before and after gadolinium
enhancement.*
Yes
No
presence of al least one bidimensionally
measurable and not previously irradiated
metastasis.*
Yes
No
age <=70 years.*
Yes
No
performance status 0-2 (ecog-who scale).*
Yes
No
blood leukocytes >=3.5 x 10^9/l and platelets
>=100 x 10^9/l.*
Yes
No
bilirubin <=25 m/l.*
1 / 2
Yes
No
seric transaminases <=2 x upper limit of normal
values.*
Yes
No
creatinine <=150 m/l, creatinine clearance >=60
ml/min.*
Yes
No
signed written informed consent.*
Yes
No
Exclusion Criteria
diabetes not allowing administration of adequate
doses of dexamethasone at least during the first
2 months of treatment.*
Yes
No
previous whole brain irradiation.*
Yes
No
brain metastases eligible to neurosurgery or
stereotactic radiation therapy.*
Yes
No
previous or current malignancies at other sites
with the exception of adequately treated in situ
carcinoma of the cervix or basal and squamous
carcinoma of the skin.*
Yes
No
pregnant or nursing women.*
Yes
No
acute infection requiring intravenous antibiotics.*
Yes
No
severe vomiting or medical condition which could
interfere with oral medication intake.*
Yes
No
anticonvulsant chronic therapy.*
Yes
No
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Eligibility Metastatic Colorectal Cancer
NCT00176761
Tumor-Pulsed Dendritic Cells Used as a Tumor Vaccine;
ODM derived from:
https://clinicaltrials.gov/show/NCT00176761
All rights reserved. Please visit https://medical-data-
models.org/forms/13209
Eligibility Metastatic Colorectal
Cancer NCT00176761
Inclusion Criteria
1. patients must have metastatic colorectal
cancer. patients are eligible  whether they are
previously untreated or had received prior
treatment.*
Yes
No
2. patients must have a source of autologous
tumor that can be easily  harvested.  this includes
patients with subcutaneous or cutaneous
metastases, patients with easily excisable lymph
nodes containing metastatic tumor, and patients
with malignant pleural effusions or ascites. in
addition, some patients who undergo a planned
curative operation are found at that time of
surgery to be unresectable and these patients
could have a sample of tumor resected at that
time to be eligible for this study.*
Yes
No
3. karnofsky performance status equal to or
greater than 70%.*
Yes
No
4. life expectancy of at least three months.*
Yes
No
5. patients must have evaluable or measurable
disease in addition to the  disease that will be
surgically removed for the purposes of
formulating the autologous vaccine.*
Yes
No
6.1. platelet count equal to or greater than
100,000/mm3*
Yes
No
6.2. total white blood count equal to or greater
than 3,000/mm3*
Yes
No
7. patients must not have received any
antineoplastic chemotherapy or immunotherapy
for the four weeks preceding entry onto the study
(six weeks for nitrosoureas and mitomycin-c).*
1 / 3
Yes
No
8. patients must not have received irradiation for
the four weeks prior to entry onto the study.*
Yes
No
9. ability to give informed consent.*
Yes
No
Exclusion Criteria
1. patients may not have received prior antitumor
vaccines.*
Yes
No
2. history of any autoimmune diseases (e.g. sle,
rheumatoid arthritis, myasthenia gravis).*
Yes
No
3. active infection (bacterial, fungal, or viral), or
active bleeding (e.g. hemoptysis, gi bleeding).*
Yes
No
4. pregnancy or lactation; women of childbearing
potential and men must use effective
contraception during the course of this clinical
trial.*
Yes
No
5. uncontrolled angina, arrhythmias,
bronchospasm, hypertension, hyperglycemia or
hypercalcemia.*
Yes
No
6. history of corticosteroid use in the four weeks
preceding entry onto the clinical study.*
Yes
No
7. patients who require corticosteroids.*
Yes
No
8. evidence of hiv infection or aids and/or testing
positive for hbsag.*
Yes
No
9. any medical or psychiatric illness which in the
opinion of the clinical investigators would
compromise the patients ability to tolerate this
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treatment.*
Yes
No
10. patients who require anticoagulation.*
Yes
No
11. there is no exclusion for sex or ethnic
background.*
Yes
No
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Eligibility Multiple Myeloma NCT00083538
Study of Tumor Antigen-Pulsed Autologous Dendritic Cell
Vaccination Administrated Subcutaneously or Intranodally;
ODM derived from:
https://clinicaltrials.gov/show/NCT00083538
All rights reserved. Please visit https://medical-data-
models.org/forms/13210
Eligibility Multiple Myeloma
NCT00083538
Inclusion Criteria
patients must have confirmed diagnosis of one of
the following: smoldering or indolent multiple
myeloma, multiple myeloma more than 1 year
after autologous transplant and with stable
disease, or multiple myeloma with cytogenetic
abnormalities*
Yes
No
patients with secretory iga or igg must have
purified idiotype protein available and/or tumor
cells available, and patients with light chain or
non-secretory myeloma must have tumor cells
available*
Yes
No
karnofsky performance score greater than or
equal to 60*
Yes
No
anc greater than or equal to 1,000/microliters,
platelet count greater than or equal to
60,000/microliters, and cd4 count greater than or
equal to 400/microliters.*
Yes
No
expected survival of 3 months or more*
Yes
No
18 years of age and older*
Yes
No
have given a written consent and been informed
about the investigational nature of the study.*
Yes
No
negative serology for hiv, hepatitis c, and
negative for hepatitis b surface antigen*
Yes
No
Exclusion Criteria
patients with cd4 count < 400/microliters, and/or
with severely damaged immune functions*
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Yes
No
chemotherapy or other immunosuppressive
treatment with steroids, cytoxan, methotrexate
within 8 weeks*
Yes
No
fever or active infection*
Yes
No
liver function: total bilirubin greater than or equal
to 2 x uln or ast/alt greater than or equal to 3 x
uln*
Yes
No
renal function: patients on dialysis*
Yes
No
simultaneous treatment with a second
investigational drug or biologic agent*
Yes
No
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Eligibility Multiple Myeloma NCT00344422
Vincristine, DOXIL (Doxorubicin HCl Liposome Injection)
and Dexamethasone vs. Vincristine, Doxorubicin, and
Dexamethasone in Patients With Newly Diagnosed Multiple
Myeloma; ODM derived from:
https://clinicaltrials.gov/show/NCT00344422
All rights reserved. Please visit https://medical-data-
models.org/forms/13211
Eligibility Multiple Myeloma
NCT00344422
Inclusion Criteria
untreated multiple myeloma requiring treatment*
Yes
No
total cumulative dose of prior doxorubicin can not
exceed 240 mg/m2*
Yes
No
must have measurable disease*
Yes
No
left ventricular ejection fraction (lvef) >= 50 %
determined by multiple gated acquisition scan
(muga)*
Yes
No
karnofsky performance status of >= 60%*
Yes
No
adequate bone marrow, liver and renal function*
Yes
No
disease-free from prior malignancies >= 5 years
with the exception of basal cell or squamous cell
carcinoma of the skin or carcinoma in situ of the
cervix*
Yes
No
female participants (if of child bearing potential
and sexually active) and male participants (if
sexually active with a partner of child-bearing
potential) must use medically acceptable
methods of birth control.*
Yes
No
Exclusion Criteria
life expectancy of >= 3 months*
Yes
No
pregnant or breast feeding*
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Yes
No
history of cardiac disease, with new york heart
association class ii or greater, with congestive
heart failure*
Yes
No
or unstable angina, uncontrolled hypertension or
cardiac arrythmias or myocardial infarction within
the last 6 months*
Yes
No
uncontrolled diabetes mellitus or systemic
infection*
Yes
No
nonsecretory myeloma, monoclonal gammopathy
of unknown significance (mgus) or smoldering
myeloma*
Yes
No
confusion, disorientation, or history of psychiatric
illness which may impair patient's ability to give
informed consent*
Yes
No
prior chemotherapy to treat multiple myeloma*
Yes
No
prior radiotherapy to an area greater than 1/3 of
the skeleton*
Yes
No
prior local radiotherapy within 1 week of
treatment*
Yes
No
any investigational agent within 30 days of the
first dose of treatment*
Yes
No
prior single agent dexamethasone (or another
corticosteroid) to treat multiple myeloma.*
Yes
No
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Eligibility Parkinson Disease NCT00004670
Phase II Study of Pallidotomy for Parkinson Disease; ODM
derived from: https://clinicaltrials.gov/show/NCT00004670
All rights reserved. Please visit https://medical-data-
models.org/forms/13212
Eligibility Parkinson Disease
NCT00004670
Criteria
idiopathic parkinson disease hoehn and yahr
stage iii or worse during "off" periods*
Yes
No
responsive to levodopa by history or exam sub-
optimal clinical response to maximal medication
medication optimized for at least 4 weeks prior to
entry*
Yes
No
no atypical or secondary disease, e.g.:*
Yes
No
no history of cerebrovascular accident*
Yes
No
no cerebellar involvement*
Yes
No
no severe brain atrophy on magnetic resonance
imaging*
Yes
No
no mattis dementia rating scale score less than
116*
Yes
No
no dementia meeting diagnostic and statistical
manual of mental disorders-iv criteria*
Yes
No
no hamilton depression rating scale score greater
than 10*
Yes
No
no hamilton anxiety scale score greater than 14*
Yes
No
other: no medical contraindication to surgery,
e.g.: diabetes, cardiopulmonary diseases*
Yes
No
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Eligibility Schizophrenia NCT00169039
Clozapine Versus Chlorpromazine for Treatment-
Unresponsive Schizophrenia; ODM derived from:
https://clinicaltrials.gov/show/NCT00169039
All rights reserved. Please visit https://medical-data-
models.org/forms/13213
Eligibility Schizophrenia
NCT00169039
Inclusion Criteria
19-60 years of age*
Yes
No
diagnosis of schizophrenia*
Yes
No
bprs score > 50*
Yes
No
clinical global impressions rating > 4*
Yes
No
one of the following:  bprs items rated greater
than or equal to 4, conceptual disorganization,
suspiciousness, hallucinations, unusual thought
content.*
Yes
No
at least 2 six-week trials of different neuroleptics
given at a dosage equivalent to at least 600 mg
per day of chlorpromazine or at least 1 eight-
week trial of a neuroleptic given at a dosage
equivalent to at least 800 mg per day of
chlorpromazine.*
Yes
No
the patient (or the patient's authorized legal
representative) must understand the nature of the
study and sign the informed consent.*
Yes
No
Exclusion Criteria
history of substance dependence within the past
2 months*
Yes
No
major medical problems precluding the use of
clozapine*
Yes
No
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pregnancy or lactation*
Yes
No
a serious suicide/homicide risk*
Yes
No
2 / 2
Eligibility Schizophrenia NCT00169039
Eligibility Coronary Disease NCT01422317
Effects of High-dose n-3 Fatty Acids on Clinical Outcome
and Serum Lipids - Omacor Following Acute Myocardial
Infarction; ODM derived from:
https://clinicaltrials.gov/show/NCT01422317
All rights reserved. Please visit https://medical-data-
models.org/forms/13214
Eligibility Coronary Disease
NCT01422317
Inclusion Criteria
verified an acute myocardial infarction (mi) by
world health organization criteria*
Yes
No
age above 18 years*
Yes
No
discontinuation of a regular supplementation of
other fish-oil products*
Yes
No
signed informed consent*
Yes
No
Exclusion Criteria
assumed noncompliance to protocol*
Yes
No
expected survival < 2 y because of severe heart
failure (new york heart association class iv),
malignancy, or other reasons*
Yes
No
ongoing gastrointestinal bleeding or verified
stomach ulcer*
Yes
No
thrombocytopenia or blood platelets < 100 x
10'9/l*
Yes
No
liver insufficiency*
Yes
No
participation in any other study*
Yes
No
residence outside the recruitment area of this
study*
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Yes
No
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Eligibility Dementia NCT00249145
A Study of the Effectiveness and Safety of Risperidone in
the Treatment of Behavioral Disturbances in Patients With
Dementia; ODM derived from:
https://clinicaltrials.gov/show/NCT00249145
All rights reserved. Please visit https://medical-data-
models.org/forms/13215
Eligibility Dementia NCT00249145
Inclusion Criteria
patients with dementia of the alzheimer's type,
mixed dementia, or vascular dementia, (as
classified by the diagnostic and statistical manual
of mental diseases, 4th edition [dsm-iv]) and have
behavioral disturbances*
Yes
No
a score >=4 on the fast*
Yes
No
a score <=23 on the mmse*
Yes
No
a behave-ad total score >=8, and a behave-ad
global rating >=1*
Yes
No
must be institutionalized.*
Yes
No
Exclusion Criteria
patients with other medical or neurological
conditions in which cognition (thinking,
perception, learning, verbal communication,
memory, judgment) is diminished (for example,
drug overdosage, severe liver, heart, lung, and
kidney malfunctions, parkinson's disease)*
Yes
No
other psychiatric disorders, including major
depression, schizophrenia, substance abuse or
dependence*
Yes
No
abnormal electrocardiogram (ecg) findings*
Yes
No
abnormal clinical laboratory test findings.*
Yes
No
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Eligibility Hepatitis B NCT00698087
Comparison of Safety, Immuno- and Reactogenicity of
MPL-Adjuvanted Recombinant Hepatitis B Vaccine to That
of Engerix™-B; ODM derived from:
https://clinicaltrials.gov/show/NCT00698087
All rights reserved. Please visit https://medical-data-
models.org/forms/13216
Eligibility Hepatitis B NCT00698087
Inclusion Criteria
between 18 and 40 years old.*
Yes
No
written informed consent will have been obtained
from the subjects.*
Yes
No
good physical condition as established by
physical examination and history taking at the
time of entry.*
Yes
No
female participants will avoid becoming pregnant
during the study period and they will have been
on a contraceptive program for at least 2 months
before entry*
Yes
No
Exclusion Criteria
pregnancy or lactation.*
Yes
No
positive titres for anti hepatitis b antibodies*
Yes
No
any vaccination against hepatitis b in the past.*
Yes
No
any previous administration of mpl.*
Yes
No
elevated serum liver enzymes.*
Yes
No
history of significant and persisting hematologic,
hepatic, renal, cardiac or respiratory disease.*
Yes
No
axillary temperature > 37.5°c at the time of
injection.*
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Yes
No
any acute disease at the moment of entry.*
Yes
No
chronic alcohol consumption.*
Yes
No
any treatment with immunosuppressive or
immunostimulant therapy.*
Yes
No
any chronic drug treatment, which in the
investigator's opinion, precludes inclusion into the
study.*
Yes
No
history of allergic disease likely to be stimulated
by any component of the vaccine.*
Yes
No
simultaneous administration of any other
vaccine(s).*
Yes
No
administration of any immunoglobulin during the
study period.*
Yes
No
simultaneous participation in any other clinical
trial*
Yes
No
2 / 2
Eligibility Hepatitis B NCT00698087
Eligibility Hypertension NCT00389168
Irbesartan and Atenolol in Hypertensive Heart Disease;
ODM derived from:
https://clinicaltrials.gov/show/NCT00389168
All rights reserved. Please visit https://medical-data-
models.org/forms/13217
Eligibility Hypertension
NCT00389168
Inclusion Criteria
at least 18 ys old*
Yes
No
male or female with no child bearing potential*
Yes
No
seated blood pressure diastolic 90-115 mm hg*
Yes
No
left ventricular mass above 131 g/m2 for men,
above 100 g/m2 for women*
Yes
No
informed consent*
Yes
No
Exclusion Criteria
coronary artery disease, heart failure or other
significant cardiac disorder*
Yes
No
cerebrovascular accident within the past 6
months*
Yes
No
a seated systolic blood pressure above 200 mm
hg*
Yes
No
significant renal disease, collagen or vascular
disease, or gastrointestinal condition*
Yes
No
significant allergy or intolerance to study drug*
Yes
No
alcohol or drug abuse*
Yes
No
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uncontrolled diabetes mellitus*
Yes
No
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Eligibility Hypertension NCT02177331
Lacidipine in Medical Practice in Patients With Mild to
Moderate Essential Hypertension; ODM derived from:
https://clinicaltrials.gov/show/NCT02177331
All rights reserved. Please visit https://medical-data-
models.org/forms/13218
Eligibility Hypertension
NCT02177331
Inclusion Criteria
fulfillment of entry criteria for the preceding yearly
study*
Yes
No
male or female patients aged between 20 and 85
years*
Yes
No
known history of mild to moderate essential
hypertension requiring drug treatment, who grade
i to ii*
Yes
No
controlled blood pressure (rr diastolic ≤ 90 mm hg
or 91 - 95 mm hg and concurrent reduction in
blood pressure of at least 10 mm compared to
baseline level) during treatment with lacidipine at
a dose of 2 - 6 mg once a day*
Yes
No
final visit of the previous yearly study (visit 4)
completed as scheduled*
Yes
No
informed consent to participate in the follow-up
study*
Yes
No
Exclusion Criteria
violation of entry/exclusion criteria on enrolment
in the preceding yearly study*
Yes
No
occurrence of the following exclusion criteria in
the intervening period:*
Yes
No
pregnancy, lactation, possibility of conception
without the use of a scientifically recognised
method of contraception*
Yes
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No
secondary form of hypertension*
Yes
No
consumptive illness*
Yes
No
clinically manifest concomitant cardiovascular
illness, e.g.: aortic or mitral valve stenosis,
hypertrophic obstructive cardiomyopathy or any
other condition hindering left ventricular outflow,
aortic isthmus stenosis, severe (nyha class iii or
higher) or decompensated heart failure, clinically
relevant hypo- or hyperkinetic cardiac arrhythmia*
Yes
No
myocardial infarction or cerebrovascular accident
within the 6 months prior to the start of the follow-
up study*
Yes
No
hypersensitivity to dihydropyridines*
Yes
No
concomitant long-term treatment (> 3 weeks) with
antihypertensive substances not envisaged in the
protocol (exception: short-acting nitrates),
sedatives, tricyclic antidepressants*
Yes
No
suspected alcohol, narcotic or drug abuse*
Yes
No
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Eligibility Multiple Myeloma NCT00367185
Treatment of Newly Diagnosed Elderly Patients With
Multiple Myeloma; ODM derived from:
https://clinicaltrials.gov/show/NCT00367185
All rights reserved. Please visit https://medical-data-
models.org/forms/13219
Eligibility Multiple Myeloma
NCT00367185
Inclusion Criteria
stage ii or iii multiple myeloma according to durie
and salmon criteria.*
Yes
No
patients between 65 and 75 years of age*
Yes
No
previously untreated patients*
Yes
No
Exclusion Criteria
prior history of another neoplasm (except
basocellular cutaneous or cervical epithelioma)*
Yes
No
primary or associated amyloidosis*
Yes
No
world health organisation performance index of at
least 3*
Yes
No
significant renal insufficiency with creatinine
serum levels of 5.0 mg per deciliter or more*
Yes
No
cardiac or hepatic dysfunction*
Yes
No
cerebral circulatory insufficiency*
Yes
No
absolute contraindication to corticosteroids*
Yes
No
peripheral neuropathy*
Yes
No
hiv or hepatitis b or c positivity*
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Yes
No
patients who had geographic, social or
psychological conditions which might prevent
adequate follow-up*
Yes
No
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Eligibility Multiple Myeloma NCT00560053
Pethema Multiple Myeloma 2000; ODM derived from:
https://clinicaltrials.gov/show/NCT00560053
All rights reserved. Please visit https://medical-data-
models.org/forms/13220
Eligibility Multiple Myeloma
NCT00560053
Inclusion Criteria
less 70 years*
Yes
No
ecog 0-2*
Yes
No
symptomatic mm (pain, anemia, infection,
haemorrhage, loss of weight,  hypercalcemia,
extramedulary plasmocytoma, creatinine >2
mg/dl).*
Yes
No
no previous chemotherapy*
Yes
No
Exclusion Criteria
>70 years*
Yes
No
ecog 3-4*
Yes
No
myeloma quiescent*
Yes
No
cardiopathy*
Yes
No
liver disfunction*
Yes
No
hiv+*
Yes
No
hepatitis b-c +*
Yes
No
previous chemotherapy*
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Yes
No
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Eligibility Multiple Myeloma NCT00781170
Dose-Reduced Allogeneic Stem Cell Transplantation After
Autologous High-Dose Chemotherapy in Patients With
Multiple Myeloma; ODM derived from:
https://clinicaltrials.gov/show/NCT00781170
All rights reserved. Please visit https://medical-data-
models.org/forms/13221
Eligibility Multiple Myeloma
NCT00781170
Inclusion Criteria
multiple myeloma stadium ii / iii acc. to salmon
and durie*
Yes
No
signed informed consent*
Yes
No
adequate organ function prior autologous
respectively allogeneic sct*
Yes
No
availability of hla-identical related or unrelated
donor*
Yes
No
availability of at least 2 x 10^6 cd34+ cells per kg
bw of recipient for the autologous sct and at least
3 x 10^6 cd34+ cells for allogeneic sct*
Yes
No
for mrd-sct: 18-66 years; for mud-sct: 18-55
years*
Yes
No
at age <55 years existence of risk factors that
make an myeloablative allogeneic transplantation
to risky*
Yes
No
consent of donor to give dli*
Yes
No
Exclusion Criteria
severe heart insufficiency*
Yes
No
cardiovascular diseases or severe concomitant
diseases*
Yes
No
1 / 2
active infections that need antibiotic therapy*
Yes
No
positive for hiv or hepatitis*
Yes
No
malign secondary disease*
Yes
No
limited liver function with total bilirubin > 1.5 uln*
Yes
No
increased transaminase > 3 uln*
Yes
No
increased serum creatinine > 2 mg/dl*
Yes
No
pregnant or lactating women*
Yes
No
known hypersensitivity to fludarabine or
melphalan*
Yes
No
participation in another trial*
Yes
No
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Eligibility Multiple Myeloma Stage I
NCT00171925
Therapy With Zoledronic Acid in Patients With Multiple
Myeloma Stage I; ODM derived from:
https://clinicaltrials.gov/show/NCT00171925
All rights reserved. Please visit https://medical-data-
models.org/forms/13222
Eligibility Multiple Myeloma Stage I
NCT00171925
Inclusion Criteria
evidence of myeloma according to the criteria of
the british columbia cancer agency (for the
diagnosis, 2 of the 3 criteria must be met):*
Yes
No
evidence of paraprotein in the serum or urine*
Yes
No
bone marrow infiltration with plasma cells which
represent more than 10% of the nucleated cells*
Yes
No
radiologically, at least one osteolytic lesion*
Yes
No
asymptomatic patients with stage i (durie and
salmon) multiple myeloma*
Yes
No
Exclusion Criteria
patients with more than one osteolytic lesion on
conventional skeletal radiography*
Yes
No
previous treatment with bisphosphonates*
Yes
No
bilirubin > 2.5 mg/dl*
Yes
No
abnormal renal function as evidenced by: a
calculated creatinine clearance < 30 ml/minute.
creatinine clearance (crcl) is calculated using the
cockcroft-gault formula:
crcl= [140-age(years)] x
weight(kg)/[72xserumcreatinine(mg/dl)] x {0.85
for female patients}*
Yes
No
patients with other malignant diseases or severe
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concomitant diseases*
Yes
No
potentially fertile patients who are not using a
reliable and appropriate method of contraception*
Yes
No
pregnancy or breast-feeding*
Yes
No
participation in another clinical study with an
investigational drug within 12 weeks of study
entry*
Yes
No
current active dental problems including infection
of the teeth or jawbone (maxilla or mandibular);
dental or fixture trauma, or a current or prior
diagnosis of osteonecrosis of the jaw (onj), of
exposed bone in the mouth, or of slow healing
after dental procedures.*
Yes
No
recent (within 6 weeks) or planned dental or jaw
surgery (e.g.. extraction, implants)*
Yes
No
other protocol-defined inclusion and exclusion
criteria may apply.*
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Efficacy and tolerability of subcutaneous hyposensitization with
CLUSTOID in Patients with allergic rhinoconjunctivitis Visit 8
Prospective,multicentric,double blind and placebo-
controlled Phase III clinical trial to determine efficacy and
tolerability of subcutaneous hyposensitization with
CLUSTOID in patients with allergic rhinoconjunctivits
caused by grass or rye pollen. EudraCT-Nr. 2008-000513-
29 Study-code:CLU-2008-001 Sponsor: ROXALL Medizin
GmbH Carl-Petersen-Straße 4 20535 Hamburg Phone:040-
8972520 Fax:040-89725223 Project coordinator: Dr.Jenny
Uhlig ROXALL Medizin GmbH Head of clinical
investigation: Prof.Dr.med.Ludger Klimek An den Quellen
10 65183 Wiesbaden Phone:0611-8904381 Fax:0611-
3082360 Monitoring,data management and statistical
evaluation: IMSIE- Institut for medical statistics,computer
sciences and epidemiology University hospital Cologne
Lindenburger Allee 42 50931 Cologne Phone:0221-
4783456 Fax:0221-4783465
All rights reserved. Please visit https://medical-data-
models.org/forms/13223
Case Report Form Visit 8
Visit 8:Maintenance Visit
Please give Patient ID composed of Study site Nr
and Patient Nr
Date of visit 8
Is the patient still participating in this trial? If no,
please fill in study completion form
Yes
No
Females of childbearing potential, using safe
contraceptive measures? If no please fill in study
completion form
Yes
No
Peak flow best value during visit 1
l/min
Please take 3 consecutive peak flow
measurements
l/min
Second peak flow measurement
l/min
Third peak flow measurement
l/min
Peak flow best value during visit 8
l/min
If peak flow measurement is > 80 percent of best
value during visit 1, continue with allergen
exposure, if no suspend next exposure to
allergen and repeat peak flow measurement
Yes
No
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First peak flow measurement after suspension
l/min
Second peak flow measurement after suspension
l/min
Third peak flow measurement after suspension
l/min
Blood pressure measurement
mm/Hg
Heart rate count
bpm
Body height
cm
Body weight
Rhinoscopic evaluation:Edema
none (0)
little (1)
severe (2)
Rhinoscopic evaluation: secretion
none (0)
clear fluid (1)
thick mucous (2)
Rhinoscopic evaluation:redness
none (0)
little (1)
severe (2)
Has concomitant medication been subject to
change?
Yes
No
Please specify any changes of therapy and
review for exclusion criteria
Have comorbidities changed?
Yes
No
If comorbidities have changed,please specify and
review for exclusion criteria
Patient diary part 1 has been handed out to the
patient for documentation purposes of daily
symptoms and required rescue medication.
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Yes
No
Dispensation of demand medication
Pruritus-> eye drops Cromone (0)
step 1-> oral antihistamine Loratadine (1)
step 2-> nasal steroid Beclomethasone
(2)
step 3-> Leukotrien-antagonist
Montelukast (In case of severe asthmatic
symptoms with separate prescription) (3)
Subcutaneous desensitization
Has the tenth dose of desensitization been
administered?
Yes
No
Please give the date and time, the tenth dose has
been administered
If the tenth dose has not been administered,
please specify the reason why
How much of the trial substance has been
injected?
ml
0,5ml (1)
adjusted dose (2)
If the dose of trial substance has been adjusted,
please specify the reason why and how much
has actually been administered
Please specify which arm has been used for
injection
right arm (1)
left arm (2)
30 min after injection, has the patient
experienced any local, gastrointestinal, systemic
or other symptoms?
Yes
No
Have any of the following symptoms occured?If
yes please do not forget to fill in AE report
local reaction of the
skin:swelling,itching,rash,or burning
sensation (1)
gastrointestinal
symptoms:nausea,vomiting,dyspepsia,fla
tulence,diarrhea (2)
systemic reactions (3)
unspecified symptoms like headache,
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discomfort (3.1)
minor systemic symptoms like rhinitis,or
minor asthmatic symptoms (3.2)
non-life-threatening systemic symptoms
like urticaria, angioedema,severe
asthmatic symptoms (3.3)
severe systemic symptoms like
anaphylactic shock [extended
documentation as SAE] (3.4)
other (4)
Please specify any other symptoms that occured
within 30 min after injection of tenth
desensitization
Have severe local, gastrointestinal or systemic
symptoms occured during tenth desensitization?
If yes, the SAE sheet has to be filled in and sent
to the sponsor within 24 hours.
Yes
No
What measures have been taken in response to
the SAE?
termination of study -> please fill in study
completion form 2=adjustment of dose
during next course of desensitization (1)
Adverse Events
Did any Adverse Events occur?
Yes
No
Have these been serious adverse events?
Yes
No
Please describe the AE
Adverse Event Start Date
Adverse Event End Date
How often did the event occur?
once (1)
regularly (2)
continuing (3)
Please give your opinion to the severity of the AE
minor (1)
moderate (2)
severe (3)
Adverse Event Outcome
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Recovered (1)
Subsiding (2)
Continuing (3)
resolved with sequelae (4)
increased symptoms (5)
fatal (6)
What actions have been taken regarding the trial
substance?
not applicable (1)
no adjustment in dose (2)
adjustment of dose (3)
suspension of treatment (4)
discontinuation of treatment (5)
other (6)
What other actions have been taken in response
to the AE?
none (1)
change of concomitant medication (2)
hospitalization/prolonged stay in hospital
(3)
further therapeutic and diagnostic
measures (4)
Is the AE related to the trial substance?
undecided/incomplete (1)
inconclusive (2)
without context to trial substance (3)
unlikely (4)
possible (5)
probable (6)
confirmed (7)
Please agree to a date for follow up V9 within
next month
Date of completion of this form
Signature
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Efficacy and tolerability of subcutaneous hyposensitization with
CLUSTOID in Patients with allergic rhinoconjunctivitis Visit 9
Prospective,multicentric,double blind and placebo-
controlled Phase III clinical trial to determine efficacy and
tolerability of subcutaneous hyposensitization with
CLUSTOID in patients with allergic rhinoconjunctivits
caused by grass or rye pollen. EudraCT-Nr. 2008-000513-
29 Study-code:CLU-2008-001 Sponsor: ROXALL Medizin
GmbH Carl-Petersen-Straße 4 20535 Hamburg Phone:040-
8972520 Fax:040-89725223 Project coordinator: Dr.Jenny
Uhlig ROXALL Medizin GmbH Head of clinical
investigation: Prof.Dr.med.Ludger Klimek An den Quellen
10 65183 Wiesbaden Phone:0611-8904381 Fax:0611-
3082360 Monitoring,data management and statistical
evaluation: IMSIE- Institut for medical statistics,computer
sciences and epidemiology University hospital Cologne
Lindenburger Allee 42 50931 Cologne Phone:0221-
4783456 Fax:0221-4783465
All rights reserved. Please visit https://medical-data-
models.org/forms/13224
Case Report Form Visit 9
Visit 9:Maintenance Visit
Please give Patient ID composed of Study site Nr
and Patient Nr
Date of visit 9
Is the patient still participating in this trial? If no,
please fill in study completion form
Yes
No
Females of childbearing potential, using safe
contraceptive measures? If no please fill in study
completion form
Yes
No
Peak flow best value during visit 1
l/min
Please take 3 consecutive peak flow
measurements
l/min
Second peak flow measurement
l/min
Third peak flow measurement
l/min
Peak flow best value during visit 9
l/min
If peak flow measurement is > 80 percent of best
value during visit 1, continue with allergen
exposure, if no suspend next exposure to
allergen and repeat peak flow measurement
Yes
No
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First peak flow measurement after suspension
l/min
Second peak flow measurement after suspension
l/min
Third peak flow measurement after suspension
l/min
Blood pressure measurement
mm/Hg
Heart rate count
bpm
Body height
cm
Body weight
kg
Rhinoscopic evaluation:Edema
none (0)
little (1)
severe (2)
Rhinoscopic evaluation: secretion
none (0)
clear fluid (1)
thick mucous (2)
Rhinoscopic evaluation:redness
none (0)
little (1)
severe (2)
Has concomitant medication been subject to
change?
Yes
No
Please specify any changes of therapy and
review for exclusion criteria
Have comorbidities changed?
Yes
No
If comorbidities have changed,please specify and
review for exclusion criteria
Patient diary part 1 has been retrieved from the
patient. If no, please collect it during next visit
Yes
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No
Patient diary part 2 has been handed out to the
patient for documentation purposes of daily
symptoms and required demand medication.
Yes
No
Dispensation of demand medication
Pruritus-> eye drops Cromone (0)
step 1-> oral antihistamine Loratadine (1)
step 2-> nasal steroid Beclomethasone
(2)
step 3-> Leukotrien-antagonist
Montelukast (In case of severe asthmatic
symptoms with separate prescription) (3)
Subcutaneous desensitization
Has the eleventh dose of desensitization been
administered?
Yes
No
Please give the date and time, the eleventh dose
has been administered
If the eleventh dose has not been administered,
please specify the reason why
How much of the trial substance has been
injected?
ml
0,5ml (1)
adjusted dose (2)
If the dose of trial substance has been adjusted,
please specify the reason why and how much
has actually been administered
Please specify which arm has been used for
injection
right arm (1)
left arm (2)
30 min after injection, has the patient
experienced any local, gastrointestinal, systemic
or other symptoms?
Yes
No
Have any of the following symptoms occured?If
yes please do not forget to fill in AE report
local reaction of the
skin:swelling,itching,rash,or burning
sensation (1)
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gastrointestinal
symptoms:nausea,vomiting,dyspepsia,fla
tulence,diarrhea (2)
systemic reactions (3)
unspecified symptoms like headache,
discomfort (3.1)
minor systemic symptoms like rhinitis,or
minor asthmatic symptoms (3.2)
non-life-threatening systemic symptoms
like urticaria, angioedema,severe
asthmatic symptoms (3.3)
severe systemic symptoms like
anaphylactic shock [extended
documentation as SAE] (3.4)
other (4)
Please specify any other symptoms that occured
within 30 min after injection of eleventh
desensitization
Have severe local, gastrointestinal or systemic
symptoms occured during eleventh
desensitization? If yes, the SAE sheet has to be
filled in and sent to the sponsor within 24 hours.
Yes
No
What measures have been taken in response to
the SAE?
termination of study -> please fill in study
completion form 2=adjustment of dose
during next course of desensitization (1)
Adverse Events
Did any Adverse Events occur?
Yes
No
Have these been serious adverse events?
Yes
No
Please describe the AE
Adverse Event Start Date
Adverse Event End Date
How often did the event occur?
once (1)
regularly (2)
continuing (3)
Please give your opinion to the severity of the AE
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minor (1)
moderate (2)
severe (3)
Adverse Event Outcome
Recovered (1)
Subsiding (2)
Continuing (3)
resolved with sequelae (4)
increased symptoms (5)
fatal (6)
What actions have been taken regarding the trial
substance?
not applicable (1)
no adjustment in dose (2)
adjustment of dose (3)
suspension of treatment (4)
discontinuation of treatment (5)
other (6)
What other actions have been taken in response
to the AE?
none (1)
change of concomitant medication (2)
hospitalization/prolonged stay in hospital
(3)
further therapeutic and diagnostic
measures (4)
Is the AE related to the trial substance?
undecided/incomplete (1)
inconclusive (2)
without context to trial substance (3)
unlikely (4)
possible (5)
probable (6)
confirmed (7)
Please agree to a date for follow up V10 within
next month
Date of completion of this form
Signature
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Moxaverine 200mg p.o. in patients with
central nervous vertigo
Placebo controlled,double blind and randomized parallel
group trial to verify effectivity and tolerability of moxaverine
p.o. in patients with central nervous vertigo.
Sponsor:
URSAPHARM
Industriestrasse
66129 Saarbrücken
Phone 06805-9292-0
Fax 06805- 929288
Head of clinical trial:
Univ.-Prof.Dr.med. Ralph Mösges
Medical Faculty, University of Cologne 
Phone 0221-4783456
Fax 0221-4783465
All rights reserved. Please visit https://medical-data-
models.org/forms/13225
Case report form Visit 1
Demographic Information
Patient number
Study site number
Assessment Date
signed informed consent
Yes
No
Date of informed consent
Patient Initials: first three characters of given and
last name
Patient age
Patient Gender
Female (f)
Male (m)
Body height
>= 0
cm
Body weight
>= 0
kg
What is your current occupation?
Patient Ethnicity
caucasian (1)
negroid (2)
asian (3)
other (4)
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neurological preliminary assessment
Are there any of the following neurological
conditions (as well in patient medical history)
apoplexy (1)
multiple sclerosis (2)
M. Parkinson (3)
cerebellar vertigo (4)
polyneuropathy (5)
traumatic brain injury (6)
cerebellar infarction (7)
otorhinolaryngologic preliminary
assessment
Are there any of the following ENT-conditions (as
well in patient medical history)
sudden hearing loss with asymmetrical
hearing impairment > 20db (1)
vestibular vertigo(caloric vestibular
testing at 44°C >20 percent) (2)
Eligibility
Has the diagnose of central nervous vertigo been
confirmed?
Yes
No
Patient will be included into this trial
Yes
No
Signature Date
Signature
Inclusion criteria
Patient has central nervous vertigo
Yes
No
Patient, male or female, age between 18-75
>= 18
<= 75
Yes
No
Patient hast given written informed consent
Yes
No
Patient is willing and able to comply to study
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protocol
Yes
No
Exclusion criteria
Patient does not meet all required inclusion
criteria
Yes
No
Patient is currently using medication that is not
allowed during the trial
Yes
No
Patient cannot be tested on tetrax platform
because of comorbidities
Yes
No
Hypersensitivity to Moxaverine
Yes
No
Patient has vestibular or cerebellar vertigo
Yes
No
Patient has asymmetric hearing impairment (> 20
db)
Yes
No
Patient shows side difference in vestibular
evaluation with caloric testing
Yes
No
Patient is diagnosed with multiple
sclerosis,parkinsons disease,polyneuropathy,
malignancies or HIV
Yes
No
Patient has a history of myocardial infarction or
apoplexy
Yes
No
Patient has a condition that could influence
gastrointestinal absorption of the tested
substance
Yes
No
Patient is suspected of poor compliance behavior
Yes
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No
Subject Participation Status in Clinical Study
within last four weeks
Yes
No
Women pregnant or breastfeeding or of
childbearing potential not using adequate
contraceptive methods
Yes
No
Patients with a history of substance use disorder
within one year prior to enrollment
Yes
No
Informed consent limited due to comorbidity or
language barrier
Yes
No
Date of signature
Signature
otorhinolaryngologic examination
Otoscopy
normal (1)
findings (2)
Please specify findings of Otoscopy
Rinne test
normal (1)
findings (2)
Please specify findings of Rinne test
Webers test
normal (1)
findings (2)
Please specify findings of Webers test
Nystagmus testing with frenzel-lens eyeglasses
Yes
No
Direction of eye movement with frenzel-lens
eyeglasses
horizontal (1)
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vertical (2)
rotating (3)
Amplitude of eye movement with frenzel-lens
eyeglasses
small (1)
medium (2)
heavy (3)
Frequency of eye movement with frenzel lens
eyeglasses
little (1)
medium (2)
high (3)
Dizziness with frenzel lens eyeglasses
little (1)
distinctly (2)
severe (3)
Posturography
Any significant findings during computerized
dynamic posturography procedure
Yes
No
Please specify findings during computerized
dynamic posturography procedure
Tasks of investigator during this visit
DHI-Questionnaire given to patient
Yes
No
Patient identification card handed to patient
Yes
No
correct amount of trial substance handed to
patient
Yes
No
Any questions the patient might have have been
answered.
Yes
No
Signature Date
Signature
Comorbidities and concomitant Medication
Are there any comorbidities?
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Yes
No
Please specify comorbidities by ICD-Code
Does the patient use any other medication?
Yes
No
Please specify medication name,dose,start and
end date of therapy
additional comments
Signature Date
Signature
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Efficacy and tolerability of subcutaneous hyposensitization with
CLUSTOID in Patients with allergic rhinoconjunctivitis Visit 10
Prospective,multicentric,double blind and placebo-
controlled Phase III clinical trial to determine efficacy and
tolerability of subcutaneous hyposensitization with
CLUSTOID in patients with allergic rhinoconjunctivits
caused by grass or rye pollen. EudraCT-Nr. 2008-000513-
29 Study-code:CLU-2008-001 Sponsor: ROXALL Medizin
GmbH Carl-Petersen-Straße 4 20535 Hamburg Phone:040-
8972520 Fax:040-89725223 Project coordinator: Dr.Jenny
Uhlig ROXALL Medizin GmbH Head of clinical
investigation: Prof.Dr.med.Ludger Klimek An den Quellen
10 65183 Wiesbaden Phone:0611-8904381 Fax:0611-
3082360 Monitoring,data management and statistical
evaluation: IMSIE- Institut for medical statistics,computer
sciences and epidemiology University hospital Cologne
Lindenburger Allee 42 50931 Cologne Phone:0221-
4783456 Fax:0221-4783465
All rights reserved. Please visit https://medical-data-
models.org/forms/13226
Case Report Form Visit 10
Visit 10:Maintenance Visit
Please give Patient ID composed of Study site Nr
and Patient Nr
Date of visit 10
Is the patient still participating in this trial? If no,
please fill in study completion form
Yes
No
Females of childbearing potential, using safe
contraceptive measures? If no please fill in study
completion form
Yes
No
Peak flow best value during visit 1
l/min
Please take 3 consecutive peak flow
measurements
l/min
Second peak flow measurement
l/min
Third peak flow measurement
l/min
Peak flow best value during visit 10
l/min
If peak flow measurement is > 80 percent of best
value during visit 1, continue with allergen
exposure, if no suspend next exposure to
allergen and repeat peak flow measurement
Yes
No
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First peak flow measurement after suspension
l/min
Second peak flow measurement after suspension
l/min
Third peak flow measurement after suspension
l/min
Blood pressure measurement
mm/Hg
Heart rate count
bpm
Body height
cm
Body weight
kg
Rhinoscopic evaluation:Edema
none (0)
little (1)
severe (2)
Rhinoscopic evaluation: secretion
none (0)
clear fluid (1)
thick mucous (2)
Rhinoscopic evaluation:redness
none (0)
little (1)
severe (2)
Has concomitant medication been subject to
change?
Yes
No
Please specify any changes of therapy and
review for exclusion criteria
Have comorbidities changed?
Yes
No
If comorbidities have changed,please specify and
review for exclusion criteria
Has the patient filled in the questionnaire
regarding the quality of life of patients with
rhinoconjunctivitis?
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Yes
No
Patient diary part 2 has been retrieved from the
patient and reviewed. If no, please collect it
during next visit
Yes
No
Patient diary part 3 has been handed out to the
patient for documentation purposes of daily
symptoms and required demand medication.
Yes
No
Dispensation of demand medication
Pruritus-> eye drops Cromone (0)
step 1-> oral antihistamine Loratadine (1)
step 2-> nasal steroid Beclomethasone
(2)
step 3-> Leukotrien-antagonist
Montelukast (In case of severe asthmatic
symptoms with separate prescription) (3)
Subcutaneous desensitization
Has the twelfth dose of desensitization been
administered?
Yes
No
Please give the date and time, the twelfth dose
has been administered
If the twelfth dose has not been administered,
please specify the reason why
How much of the trial substance has been
injected?
ml
0,5ml (1)
adjusted dose (2)
If the dose of trial substance has been adjusted,
please specify the reason why and how much
has actually been administered
Please specify which arm has been used for
injection
right arm (1)
left arm (2)
30 min after injection, has the patient
experienced any local, gastrointestinal, systemic
or other symptoms?
Yes
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No
Have any of the following symptoms occured?If
yes please do not forget to fill in AE report
local reaction of the
skin:swelling,itching,rash,or burning
sensation (1)
gastrointestinal
symptoms:nausea,vomiting,dyspepsia,fla
tulence,diarrhea (2)
systemic reactions (3)
unspecified symptoms like headache,
discomfort (3.1)
minor systemic symptoms like rhinitis,or
minor asthmatic symptoms (3.2)
non-life-threatening systemic symptoms
like urticaria, angioedema,severe
asthmatic symptoms (3.3)
severe systemic symptoms like
anaphylactic shock [extended
documentation as SAE] (3.4)
other (4)
Please specify any other symptoms that occured
within 30 min after injection of twelfth
desensitization
Have severe local, gastrointestinal or systemic
symptoms occured during twelfth
desensitization? If yes, the SAE sheet has to be
filled in and sent to the sponsor within 24 hours.
Yes
No
What measures have been taken in response to
the SAE?
termination of study -> please fill in study
completion form 2=adjustment of dose
during next course of desensitization (1)
Adverse Events
Did any Adverse Events occur?
Yes
No
Have these been serious adverse events?
Yes
No
Please describe the AE
Adverse Event Start Date
Adverse Event End Date
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How often did the event occur?
once (1)
regularly (2)
continuing (3)
Please give your opinion to the severity of the AE
minor (1)
moderate (2)
severe (3)
Adverse Event Outcome
Recovered (1)
Subsiding (2)
Continuing (3)
resolved with sequelae (4)
increased symptoms (5)
fatal (6)
What actions have been taken regarding the trial
substance?
not applicable (1)
no adjustment in dose (2)
adjustment of dose (3)
suspension of treatment (4)
discontinuation of treatment (5)
other (6)
What other actions have been taken in response
to the AE?
none (1)
change of concomitant medication (2)
hospitalization/prolonged stay in hospital
(3)
further therapeutic and diagnostic
measures (4)
Is the AE related to the trial substance?
undecided/incomplete (1)
inconclusive (2)
without context to trial substance (3)
unlikely (4)
possible (5)
probable (6)
confirmed (7)
Please agree to a date for follow up V11 within
next month
Date of completion of this form
Signature
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Efficacy and tolerability of subcutaneous hyposensitization with
CLUSTOID in Patients with allergic rhinoconjunctivitis Visit 11
Prospective,multicentric,double blind and placebo-
controlled Phase III clinical trial to determine efficacy and
tolerability of subcutaneous hyposensitization with
CLUSTOID in patients with allergic rhinoconjunctivits
caused by grass or rye pollen. EudraCT-Nr. 2008-000513-
29 Study-code:CLU-2008-001 Sponsor: ROXALL Medizin
GmbH Carl-Petersen-Straße 4 20535 Hamburg Phone:040-
8972520 Fax:040-89725223 Project coordinator: Dr.Jenny
Uhlig ROXALL Medizin GmbH Head of clinical
investigation: Prof.Dr.med.Ludger Klimek An den Quellen
10 65183 Wiesbaden Phone:0611-8904381 Fax:0611-
3082360 Monitoring,data management and statistical
evaluation: IMSIE- Institut for medical statistics,computer
sciences and epidemiology University hospital Cologne
Lindenburger Allee 42 50931 Cologne Phone:0221-
4783456 Fax:0221-4783465
All rights reserved. Please visit https://medical-data-
models.org/forms/13229
Case Report Form Visit 11
Visit 11:Maintenance Visit
Please give Patient ID composed of Study site Nr
and Patient Nr
Date of visit 11
Is the patient still participating in this trial? If no,
please fill in study completion form
Yes
No
Females of childbearing potential, using safe
contraceptive measures? If no please fill in study
completion form
Yes
No
Peak flow best value during visit 1
l/min
Please take 3 consecutive peak flow
measurements
l/min
Second peak flow measurement
l/min
Third peak flow measurement
l/min
Peak flow best value during visit 11
l/min
If peak flow measurement is > 80 percent of best
value during visit 1, continue with allergen
exposure, if no suspend next exposure to
allergen and repeat peak flow measurement
Yes
No
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First peak flow measurement after suspension
l/min
Second peak flow measurement after suspension
l/min
Third peak flow measurement after suspension
l/min
Blood pressure measurement
mm/Hg
Heart rate count
bpm
Body height
cm
Body weight
kg
Rhinoscopic evaluation:Edema
none (0)
little (1)
severe (2)
Rhinoscopic evaluation: secretion
none (0)
clear fluid (1)
thick mucous (2)
Rhinoscopic evaluation:redness
none (0)
little (1)
severe (2)
Has concomitant medication been subject to
change?
Yes
No
Please specify any changes of therapy and
review for exclusion criteria
Have comorbidities changed?
Yes
No
If comorbidities have changed,please specify and
review for exclusion criteria
Patient diary part 3 has been retrieved from the
patient and reviewed. If no, please collect it
during next visit
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Yes
No
Patient diary part 4 has been handed out to the
patient for documentation purposes of daily
symptoms and required demand medication.
Yes
No
Dispensation of demand medication
Pruritus-> eye drops Cromone (0)
step 1-> oral antihistamine Loratadine (1)
step 2-> nasal steroid Beclomethasone
(2)
step 3-> Leukotrien-antagonist
Montelukast (In case of severe asthmatic
symptoms with separate prescription) (3)
Subcutaneous desensitization
Has the thirteenth dose of desensitization been
administered?
Yes
No
Please give the date and time, the thirteenth
dose has been administered
If the thirteenth dose has not been administered,
please specify the reason why
How much of the trial substance has been
injected?
ml
0,5ml (1)
adjusted dose (2)
If the dose of trial substance has been adjusted,
please specify the reason why and how much
has actually been administered
Please specify which arm has been used for
injection
right arm (1)
left arm (2)
30 min after injection, has the patient
experienced any local, gastrointestinal, systemic
or other symptoms?
Yes
No
Have any of the following symptoms occured?If
yes please do not forget to fill in AE report
local reaction of the
skin:swelling,itching,rash,or burning
3 / 5
Efficacy and tolerability of subcutaneous hyposensitization with
CLUSTOID in Patients with allergic rhinoconjunctivitis Visit 11
sensation (1)
gastrointestinal
symptoms:nausea,vomiting,dyspepsia,fla
tulence,diarrhea (2)
systemic reactions (3)
unspecified symptoms like headache,
discomfort (3.1)
minor systemic symptoms like rhinitis,or
minor asthmatic symptoms (3.2)
non-life-threatening systemic symptoms
like urticaria, angioedema,severe
asthmatic symptoms (3.3)
severe systemic symptoms like
anaphylactic shock [extended
documentation as SAE] (3.4)
other (4)
Please specify any other symptoms that occured
within 30 min after injection of thirteenth
desensitization
Have severe local, gastrointestinal or systemic
symptoms occured during thirteenth
desensitization? If yes, the SAE sheet has to be
filled in and sent to the sponsor within 24 hours.
Yes
No
What measures have been taken in response to
the SAE?
termination of study -> please fill in study
completion form 2=adjustment of dose
during next course of desensitization (1)
Adverse Events
Did any Adverse Events occur?
Yes
No
Have these been serious adverse events?
Yes
No
Please describe the AE
Adverse Event Start Date
Adverse Event End Date
How often did the event occur?
once (1)
regularly (2)
continuing (3)
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Please give your opinion to the severity of the AE
minor (1)
moderate (2)
severe (3)
Adverse Event Outcome
Recovered (1)
Subsiding (2)
Continuing (3)
resolved with sequelae (4)
increased symptoms (5)
fatal (6)
What actions have been taken regarding the trial
substance?
not applicable (1)
no adjustment in dose (2)
adjustment of dose (3)
suspension of treatment (4)
discontinuation of treatment (5)
other (6)
What other actions have been taken in response
to the AE?
none (1)
change of concomitant medication (2)
hospitalization/prolonged stay in hospital
(3)
further therapeutic and diagnostic
measures (4)
Is the AE related to the trial substance?
undecided/incomplete (1)
inconclusive (2)
without context to trial substance (3)
unlikely (4)
possible (5)
probable (6)
confirmed (7)
Please agree to a date for follow up V12 within
next month
Date of completion of this form
Signature
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Efficacy and tolerability of subcutaneous hyposensitization with
CLUSTOID in Patients with allergic rhinoconjunctivitis Visit 12
Prospective,multicentric,double blind and placebo-
controlled Phase III clinical trial to determine efficacy and
tolerability of subcutaneous hyposensitization with
CLUSTOID in patients with allergic rhinoconjunctivits
caused by grass or rye pollen. EudraCT-Nr. 2008-000513-
29 Study-code:CLU-2008-001 Sponsor: ROXALL Medizin
GmbH Carl-Petersen-Straße 4 20535 Hamburg Phone:040-
8972520 Fax:040-89725223 Project coordinator: Dr.Jenny
Uhlig ROXALL Medizin GmbH Head of clinical
investigation: Prof.Dr.med.Ludger Klimek An den Quellen
10 65183 Wiesbaden Phone:0611-8904381 Fax:0611-
3082360 Monitoring,data management and statistical
evaluation: IMSIE- Institut for medical statistics,computer
sciences and epidemiology University hospital Cologne
Lindenburger Allee 42 50931 Cologne Phone:0221-
4783456 Fax:0221-4783465
All rights reserved. Please visit https://medical-data-
models.org/forms/13231
Case Report Form Visit 12
Visit 12:Maintenance Visit
Please give Patient ID composed of Study site Nr
and Patient Nr
Date of visit 12
Is the patient still participating in this trial? If no,
please fill in study completion form
Yes
No
Females of childbearing potential, using safe
contraceptive measures? If no please fill in study
completion form
Yes
No
Peak flow best value during visit 1
l/min
Please take 3 consecutive peak flow
measurements
l/min
Second peak flow measurement
l/min
Third peak flow measurement
l/min
Peak flow best value during visit 12
l/min
If peak flow measurement is > 80 percent of best
value during visit 1, continue with allergen
exposure, if no suspend next exposure to
allergen and repeat peak flow measurement
Yes
No
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First peak flow measurement after suspension
l/min
Second peak flow measurement after suspension
l/min
Third peak flow measurement after suspension
l/min
Blood pressure measurement
mm/Hg
Heart rate count
bpm
Body Height
cm
Body weight
kg
Rhinoscopic evaluation:Edema
none (0)
little (1)
severe (2)
Rhinoscopic evaluation: secretion
none (0)
clear fluid (1)
thick mucous (2)
Rhinoscopic evaluation:redness
none (0)
little (1)
severe (2)
Has concomitant medication been subject to
change?
Yes
No
Please specify any changes of therapy and
review for exclusion criteria
Have comorbidities changed?
Yes
No
If comorbidities have changed,please specify and
review for exclusion criteria
Patient diary part 4 has been retrieved from the
patient and reviewed. If no, please collect it
during next visit
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Yes
No
Patient diary part 5 has been handed out to the
patient for documentation purposes of daily
symptoms and required demand medication.
Yes
No
Dispensation of demand medication
Pruritus-> eye drops Cromone (0)
step 1-> oral antihistamine Loratadine (1)
step 2-> nasal steroid Beclomethasone
(2)
step 3-> Leukotrien-antagonist
Montelukast (In case of severe asthmatic
symptoms with separate prescription) (3)
Subcutaneous desensitization
Has the fourteenth dose of desensitization been
administered?
Yes
No
Please give the date and time, the fourteenth
dose has been administered
If the fourteenth dose has not been administered,
please specify the reason why
How much of the trial substance has been
injected?
ml
0,5ml (1)
adjusted dose (2)
If the dose of trial substance has been adjusted,
please specify the reason why and how much
has actually been administered
Please specify which arm has been used for
injection
right arm (1)
left arm (2)
30 min after injection, has the patient
experienced any local, gastrointestinal, systemic
or other symptoms?
Yes
No
Have any of the following symptoms occured?If
yes please do not forget to fill in AE report
local reaction of the
skin:swelling,itching,rash,or burning
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sensation (1)
gastrointestinal
symptoms:nausea,vomiting,dyspepsia,fla
tulence,diarrhea (2)
systemic reactions (3)
unspecified symptoms like headache,
discomfort (3.1)
minor systemic symptoms like rhinitis,or
minor asthmatic symptoms (3.2)
non-life-threatening systemic symptoms
like urticaria, angioedema,severe
asthmatic symptoms (3.3)
severe systemic symptoms like
anaphylactic shock [extended
documentation as SAE] (3.4)
other (4)
Have severe local, gastrointestinal or systemic
symptoms occured during fourteenth
desensitization? If yes, the SAE sheet has to be
filled in and sent to the sponsor within 24 hours.
Yes
No
What measures have been taken in response to
the SAE?
termination of study -> please fill in study
completion form 2=adjustment of dose
during next course of desensitization (1)
Adverse Events
Did any Adverse Events occur?
Yes
No
Have these been serious adverse events?
Yes
No
Please describe the AE
Adverse Event Start Date
Adverse Event End Date
How often did the event occur?
once (1)
regularly (2)
continuing (3)
Please give your opinion to the severity of the AE
minor (1)
moderate (2)
severe (3)
Adverse Event Outcome
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Recovered (1)
Subsiding (2)
Continuing (3)
resolved with sequelae (4)
increased symptoms (5)
fatal (6)
What actions have been taken regarding the trial
substance?
not applicable (1)
no adjustment in dose (2)
adjustment of dose (3)
suspension of treatment (4)
discontinuation of treatment (5)
other (6)
What other actions have been taken in response
to the AE?
none (1)
change of concomitant medication (2)
hospitalization/prolonged stay in hospital
(3)
further therapeutic and diagnostic
measures (4)
Is the AE related to the trial substance?
undecided/incomplete (1)
inconclusive (2)
without context to trial substance (3)
unlikely (4)
possible (5)
probable (6)
confirmed (7)
Please agree to a date for follow up V13 within
next month
Date of completion of this form
Signature
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Eligibility Multiple Sclerosis NCT00262314
Prospective, Open-label Tolerability and Safety Monitoring
Study of Novantrone in a Selected Cohort of Multiple
Sclerosis Patients; ODM derived from:
https://clinicaltrials.gov/show/NCT00262314
All rights reserved. Please visit https://medical-data-
models.org/forms/13239
Eligibility Multiple Sclerosis
NCT00262314
Inclusion Criteria
platelet count >100,000 cells/µl*
Yes
No
granulocyte count > 2000 cells/µl*
Yes
No
age 18-65 years*
Yes
No
negative pregnancy test for female patients who
are biologically capable of becoming pregnant,
even if they are taking birth control*
Yes
No
for patients of reproductive age, agreement to
practice effective contraception throughout the
study and for 6 months following the last
administration of novantrone®*
Yes
No
signed inform consent.*
Yes
No
Exclusion Criteria
presence of cardiac risk factors:*
Yes
No
history of congestive heart failure*
Yes
No
lvef < 50% determined by echocardiography or
muga*
Yes
No
previous treatment with novantrone®, other
anthracenediones, or anthracyclines*
Yes
No
prior mediastinal radiotherapy or total lymphoidal
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irradiation*
Yes
No
ast, alt, bilirubin > 2x upper limits of normal*
Yes
No
severe untreated infection (including current
urinary tract infection)*
Yes
No
nursing or pregnant women)*
Yes
No
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Eligibility Non-Hodgkin's Lymphoma
NCT00061425
Treatment of Non-Hodgkin's Lymphoma With 90Y-hLL2
IgG; ODM derived from:
https://clinicaltrials.gov/show/NCT00061425
All rights reserved. Please visit https://medical-data-
models.org/forms/13240
Eligibility Non-Hodgkin's Lymphoma
NCT00061425
Criteria
histological or cytological diagnosis of b-cell
lymphoma, and has failed at least one regimen of
standard chemotherapy.  (all histological grades
of nhl will be eligible for this trial.)*
Yes
No
measureable via ct, with at least one lesion > or =
1.5cm in one or both dimensions. (splenic tumors
in absence of other tumors will not qualify.)*
Yes
No
radiological studies (ie - ct) must be performed
within 4 weeks prior to study start.*
Yes
No
acceptable tumor burden that will allow adequate
follow-up and evaluation.*
Yes
No
less that 25% bone marrow involvement,
determined by bone marrow biopsy.*
Yes
No
at least 4 weeks beyond any major surgery. at
least 4 weeks beyond any radiation therapy to the
index lesion, and has recovered from radiation-
induced toxicity.*
Yes
No
at least 4 weeks beyond chemotherapy and/or
immunotherapy. at least 2 weeks beyond
corticosteriod(s) use and blood counts are with
laboratory criteria.*
Yes
No
must have karnofsky score >70% (or equivalent,
ecog 0-2) with expected survival of at least 6
months.*
Yes
No
serum creatinine < or = 1.5mg/dl or creatinine
clearance > or = 50ml/min.*
Yes
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No
serum bilirubin < or = 2mg/dl.*
Yes
No
hemoglobin > or = 10 g/dl; wbc > or = 3000/mm3;
granulocyte count > or = 150/mm3; platelet count
> or = 100,000/mm3 with out transfusions or
cytokines for at least 30 days prior to study.*
Yes
No
immunomedics elisa assay of hahll2 < 100ng/ml
for those with prior history of monoclonal
antibody infusions.*
Yes
No
cognizant informed consent.*
Yes
No
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Eligibility Non-Hodgkins Lymphoma
NCT00091676
Study of the BiovaxId Tumor Derived Idiotype Vaccine in
Patients With Follicular Lymphoma; ODM derived from:
https://clinicaltrials.gov/show/NCT00091676
All rights reserved. Please visit https://medical-data-
models.org/forms/13241
Eligibility Non-Hodgkins Lymphoma
NCT00091676
Criteria
diagnosis of indolent follicular lymphoma(follicular
small-cleaved cell, follicular mixed or follicular
large cell with centrocytes) with surface igm or
igg phenotype.*
Yes
No
stage iii-iv with lymph node > 2cm or stage ii with
lymph node > 5 cm*
Yes
No
no prior chemotherapy other than local radiation
(not greater than 2 sites)*
Yes
No
ecog < 2*
Yes
No
survival > 1 yr*
Yes
No
serum creatinine < 1.5 mg/dl*
Yes
No
bilirubin <1.5 mg/dl*
Yes
No
sgot/sgpt < 3.5 uln*
Yes
No
no hiv antibodies or hbv antigen*
Yes
No
negative pregnancy screen (females)*
Yes
No
no unrelated neoplasm in the previous 10 years*
Yes
No
no evidence of primary or secondary cns
lymphoma*
Yes
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Eligibility Osteoarthritis NCT00306930
Clinical Study Evaluating an Acetabular Cup System After
Total Hip Replacement; ODM derived from:
https://clinicaltrials.gov/show/NCT00306930
All rights reserved. Please visit https://medical-data-
models.org/forms/13242
Eligibility Osteoarthritis
NCT00306930
Inclusion Criteria
primary hip replacement*
Yes
No
sufficient bone stock to support implant*
Yes
No
signed informed patient consent form*
Yes
No
Exclusion Criteria
prior renal transplant*
Yes
No
history of active joint sepsis*
Yes
No
recent high dose of corticosteroids*
Yes
No
primary or secondary carcinoma in the last 5
years*
Yes
No
neurological disease*
Yes
No
psychosocial disease that would limit
rehabilitation*
Yes
No
use of structural bone graft*
Yes
No
simultaneous participation in another hip study*
Yes
No
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Prospective,multicentric,double blind and placebo-
controlled Phase III clinical trial to determine efficacy and
tolerability of subcutaneous hyposensitization with
CLUSTOID in patients with allergic rhinoconjunctivits
caused by grass or rye pollen. EudraCT-Nr. 2008-000513-
29 Study-code:CLU-2008-001 Sponsor: ROXALL Medizin
GmbH Carl-Petersen-Straße 4 20535 Hamburg Phone:040-
8972520 Fax:040-89725223 Project coordinator: Dr.Jenny
Uhlig ROXALL Medizin GmbH Head of clinical
investigation: Prof.Dr.med.Ludger Klimek An den Quellen
10 65183 Wiesbaden Phone:0611-8904381 Fax:0611-
3082360 Monitoring,data management and statistical
evaluation: IMSIE- Institut for medical statistics,computer
sciences and epidemiology University hospital Cologne
Lindenburger Allee 42 50931 Cologne Phone:0221-
4783456 Fax:0221-4783465
All rights reserved. Please visit https://medical-data-
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Case Report Form Visit 13
Visit 13:Maintenance Visit
Please give Patient ID composed of Study site Nr
and Patient Nr
Date of visit 13
Is the patient still participating in this trial? If no,
please fill in study completion form
Yes
No
Females of childbearing potential, using safe
contraceptive measures? If no please fill in study
completion form
Yes
No
Peak flow best value during visit 1
l/min
Please take 3 consecutive peak flow
measurements
l/min
Second peak flow measurement
l/min
Third peak flow measurement
l/min
Peak flow best value during visit 13
l/min
If peak flow measurement is > 80 percent of best
value during visit 1, continue with allergen
exposure, if no suspend next exposure to
allergen and repeat peak flow measurement
Yes
No
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First peak flow measurement after suspension
l/min
Second peak flow measurement after suspension
l/min
Third peak flow measurement after suspension
l/min
Blood pressure measurement
mm/Hg
Heart rate count
bpm
Body Height
cm
Body weight
kg
Rhinoscopic evaluation:Edema
none (0)
little (1)
severe (2)
Rhinoscopic evaluation: secretion
none (0)
clear fluid (1)
thick mucous (2)
Rhinoscopic evaluation:redness
none (0)
little (1)
severe (2)
Has concomitant medication been subject to
change?
Yes
No
Please specify any changes of therapy and
review for exclusion criteria
Have comorbidities changed?
Yes
No
If comorbidities have changed,please specify and
review for exclusion criteria
Patient diary part 5 has been retrieved from the
patient and reviewed. If no, please collect it
during next visit
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Yes
No
Dispensation of demand medication
Pruritus-> eye drops Cromone (0)
step 1-> oral antihistamine Loratadine (1)
step 2-> nasal steroid Beclomethasone
(2)
step 3-> Leukotrien-antagonist
Montelukast (In case of severe asthmatic
symptoms with separate prescription) (3)
Subcutaneous desensitization
Has the fifteenth dose of desensitization been
administered?
Yes
No
Please give the date and time, the fifteenth dose
has been administered
If the fifteenth dose has not been administered,
please specify the reason why
How much of the trial substance has been
injected?
ml
0,5ml (1)
adjusted dose (2)
If the dose of trial substance has been adjusted,
please specify the reason why and how much
has actually been administered
Please specify which arm has been used for
injection
right arm (1)
left arm (2)
30 min after injection, has the patient
experienced any local, gastrointestinal, systemic
or other symptoms?
Yes
No
Have any of the following symptoms occured?If
yes please do not forget to fill in AE report
local reaction of the
skin:swelling,itching,rash,or burning
sensation (1)
gastrointestinal
symptoms:nausea,vomiting,dyspepsia,fla
tulence,diarrhea (2)
systemic reactions (3)
unspecified symptoms like headache,
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discomfort (3.1)
minor systemic symptoms like rhinitis,or
minor asthmatic symptoms (3.2)
non-life-threatening systemic symptoms
like urticaria, angioedema,severe
asthmatic symptoms (3.3)
severe systemic symptoms like
anaphylactic shock [extended
documentation as SAE] (3.4)
other (4)
Have severe local, gastrointestinal or systemic
symptoms occured during fifteenth
desensitization? If yes, the SAE sheet has to be
filled in and sent to the sponsor within 24 hours.
Yes
No
What measures have been taken in response to
the SAE?
termination of study -> please fill in study
completion form 2=adjustment of dose
during next course of desensitization (1)
Adverse Events
Did any Adverse Events occur?
Yes
No
Have these been serious adverse events?
Yes
No
Please describe the AE
Adverse Event Start Date
Adverse Event End Date
How often did the event occur?
once (1)
regularly (2)
continuing (3)
Please give your opinion to the severity of the AE
minor (1)
moderate (2)
severe (3)
Adverse Event Outcome
Recovered (1)
Subsiding (2)
Continuing (3)
resolved with sequelae (4)
increased symptoms (5)
fatal (6)
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What actions have been taken regarding the trial
substance?
not applicable (1)
no adjustment in dose (2)
adjustment of dose (3)
suspension of treatment (4)
discontinuation of treatment (5)
other (6)
What other actions have been taken in response
to the AE?
none (1)
change of concomitant medication (2)
hospitalization/prolonged stay in hospital
(3)
further therapeutic and diagnostic
measures (4)
Is the AE related to the trial substance?
undecided/incomplete (1)
inconclusive (2)
without context to trial substance (3)
unlikely (4)
possible (5)
probable (6)
confirmed (7)
Please agree to a date for follow up V14 within
next month
Date of completion of this form
Signature
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Efficacy and tolerability of subcutaneous hyposensitization with
CLUSTOID in Patients with allergic rhinoconjunctivitis Visit 14
Prospective,multicentric,double blind and placebo-
controlled Phase III clinical trial to determine efficacy and
tolerability of subcutaneous hyposensitization with
CLUSTOID in patients with allergic rhinoconjunctivits
caused by grass or rye pollen. EudraCT-Nr. 2008-000513-
29 Study-code:CLU-2008-001 Sponsor: ROXALL Medizin
GmbH Carl-Petersen-Straße 4 20535 Hamburg Phone:040-
8972520 Fax:040-89725223 Project coordinator: Dr.Jenny
Uhlig ROXALL Medizin GmbH Head of clinical
investigation: Prof.Dr.med.Ludger Klimek An den Quellen
10 65183 Wiesbaden Phone:0611-8904381 Fax:0611-
3082360 Monitoring,data management and statistical
evaluation: IMSIE- Institut for medical statistics,computer
sciences and epidemiology University hospital Cologne
Lindenburger Allee 42 50931 Cologne Phone:0221-
4783456 Fax:0221-4783465
All rights reserved. Please visit https://medical-data-
models.org/forms/13244
Case Report Form Visit 14
Visit 14:Study Completion Visit
Please give Patient ID composed of Study site Nr
and Patient Nr
Date of visit 14
Is the patient still participating in this trial? If no,
please fill in study completion form
Yes
No
Females of childbearing potential, using safe
contraceptive measures? If no please fill in study
completion form
Yes
No
Peak flow best value during visit 1
l/min
Please take 3 consecutive peak flow
measurements
l/min
Second peak flow measurement
l/min
Third peak flow measurement
l/min
Peak flow best value during visit 14
l/min
If peak flow measurement is > 80 percent of best
value during visit 1, continue with allergen
exposure, if no suspend next exposure to
allergen and repeat peak flow measurement
Yes
No
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First peak flow measurement after suspension
l/min
Second peak flow measurement after suspension
l/min
Third peak flow measurement after suspension
l/min
Blood pressure measurement
mm/Hg
Heart rate count
bpm
Body Height
cm
Body weight
kg
Rhinoscopic evaluation:Edema
none (0)
little (1)
severe (2)
Rhinoscopic evaluation: secretion
none (0)
clear fluid (1)
thick mucous (2)
Rhinoscopic evaluation:redness
none (0)
little (1)
severe (2)
Has concomitant medication been subject to
change?
Yes
No
Please specify any changes of therapy and
review for exclusion criteria
Have comorbidities changed?
Yes
No
If comorbidities have changed,please specify and
review for exclusion criteria
Has the patient filled in the questionnaire
regarding the quality of life of patients with
rhinoconjunctivitis?
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Yes
No
Baseline value of nasal irritation
0 sneezing 0-2 times (0)
1 sneezing 3-5 times (1)
2 >5 times (2)
blank value of nasal irritation
0 sneezing 0-2 times (0)
1 sneezing 3-5 times (1)
2 sneezing >5 times (2)
First provocation value of nasal irritation
0 sneezing 0-2 times (0)
1 sneezing 3-5 times (1)
2 sneezing >5 times (2)
second provocation value of nasal irritation
0 sneezing 0-2 times (0)
1 sneezing 3-5 times (1)
2 sneezing >5 times (2)
Baseline value of nasal secretion provocation
0 no secretion (0)
1 little secretion (1)
2 heavy secretion (2)
Blank value of nasal secretion provocation
0 no secretion (0)
1 little secretion (1)
2 heavy secretion (2)
First provocation value of nasal secretion
0 no secretion (0)
1 little secretion (1)
2 heavy secretion (2)
Second provocation value of nasal secretion
0 no secretion (0)
1 little secretion (1)
2 heavy secretion (2)
Baseline value of remote symptom provocation
0 none (0)
1 lacrimation and/or itching of
palate/ears (1)
2 conjunctivitis and/or urticaria and/or
coughing and/or shortness of breath (2)
Blank value of remote symptom provocation
0 none (0)
1 lacrimation and/or itching of
palate/ears (1)
2 conjunctivitis and/or urticaria and/or
coughing and/or shortness of breath (2)
First provocation value of remote symptoms
0 none  (0)
1 lacrimation and/or itching of
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palate/ears  (1)
2 conjunctivitis and/or urticaria and/or
coughing and/or shortness of breath (2)
Second provocation value of remote symptoms
0 none  (0)
1 lacrimation and/or itching of
palate/ears  (1)
2 conjunctivitis and/or urticaria and/or
coughing and/or shortness of breath (2)
Sum of nasal provocation test symptom scores:
baseline value
<= 6
Sum of nasal provocation test symptom scores:
blank value
<= 6
Sum of nasal provocation test symptom
scores:first provocation value
<= 6
Sum of nasal provocation test symptom
scores:second provocation value
<= 6
Flow volume in cm3/sec baseline value
cm3
Flow volume in cm3/sec blank value
cm3
Flow volume in cm3/sec first provocation value
cm3
Flow volume in cm3/sec second provocation
value
cm3
Percentage of flow reduction:blank value
%
Percentage of flow reduction:first provocation
value
%
Percentage of flow reduction:second provocation
value
%
Rhinoscopic evaluation after provocation
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tests:Edema
none (0)
little (1)
severe (2)
Rhinoscopic evaluation after provocation test:
secretion
none (0)
clear fluid (1)
thick mucous (2)
Rhinoscopic evaluation after provocation
tests:redness
none (0)
little (1)
severe (2)
Determination of specific IgE and Safety
Laboratory parameter
Radioallergosorbent test categories for timothy
grass
<0,35 (0)
0,35-069 (I)
0,70-3,49 (II)
3,50-17,49 (III)
17,5-49,99 (IV)
50-100 (V)
>100 (VI)
Please specify RAST-Category [kU/L] for Timothy
grass
kU/L
Radioallergosorbent test categories for rye
<0,35 I= 0,35-069 II= 0,70-3,49 III= 3,50-
17,49 IV= 17,5-49,99 V= 50-100 VI=
>100 (0)
Please specify RAST-Category [kU/L] for rye
pollen
kU/L
Total IgE [kU/L]
kU/L
Verification of RAST categories: timothy grass,
specific IgG4
<0,35 I= 0,35-069 II= 0,70-3,49 III= 3,50-
17,49 IV= 17,5-49,99 V= 50-100 VI=
>100 (0)
Please specify RAST-Category [kU/L] for Timothy
grass, specific IgG4
kU/L
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Verification of RAST categories for rye ,specific
IgG4
<0,35 I= 0,35-069 II= 0,70-3,49 III= 3,50-
17,49 IV= 17,5-49,99 V= 50-100 VI=
>100 (0)
Please specify RAST-Category [kU/L] for rye
pollen, specific IgG4
kU/L
Please specify measured hemoglobine and units
used
Please specify measured amount of erythrocytes
and units used
Please specify measured amount of leucocytes
and units used
Please specify measured amount of neutrophils
and units used
Please specify measured amount of eosinophils
and units used
Please specify measured amount of basophils
and units used
Please specify measured amount of monocytes
and units used
Please specify measured amount of lymphocytes
and units used
Please specify measured hematocrit and units
used
Please specify measured amount of
thrombocytes and units used
Please specify measured amount of total bilirubin
and units used
Please specify the measured SGPT and units
used
Please specify the measurement of LDH and
units used
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Please specify the measurement of creatinine
and units used
Please specify the measurement of serum
glutamate-oxaloacetate transaminase and units
used
Please specify the measurement of CRP and
units used
Subcutaneous desensitization
Has the sixteenth dose of desensitization been
administered?
Yes
No
Please give the date and time, the sixteenth dose
has been administered
If the sixteenth dose has not been administered,
please specify the reason why
How much of the trial substance has been
injected?
ml
0,5ml (1)
adjusted dose (2)
If the dose of trial substance has been adjusted,
please specify the reason why and how much
has actually been administered
Please specify which arm has been used for
injection
right arm (1)
left arm (2)
30 min after injection, has the patient
experienced any local, gastrointestinal, systemic
or other symptoms?
Yes
No
Have any of the following symptoms occured?If
yes please do not forget to fill in AE report
local reaction of the
skin:swelling,itching,rash,or burning
sensation (1)
gastrointestinal
symptoms:nausea,vomiting,dyspepsia,fla
tulence,diarrhea (2)
systemic reactions (3)
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unspecified symptoms like headache,
discomfort (3.1)
minor systemic symptoms like rhinitis,or
minor asthmatic symptoms (3.2)
non-life-threatening systemic symptoms
like urticaria, angioedema,severe
asthmatic symptoms (3.3)
severe systemic symptoms like
anaphylactic shock [extended
documentation as SAE] (3.4)
other (4)
Have severe local, gastrointestinal or systemic
symptoms occured during fifteenth
desensitization? If yes, the SAE sheet has to be
filled in and sent to the sponsor within 24 hours.
Yes
No
What measures have been taken in response to
the SAE?
termination of study -> please fill in study
completion form 2=adjustment of dose
during next course of desensitization (1)
Adverse Events
Did any Adverse Events occur?
Yes
No
Have these been serious adverse events?
Yes
No
Please describe the AE
Adverse Event Start Date
Adverse Event End Date
How often did the event occur?
once (1)
regularly (2)
continuing (3)
Please give your opinion to the severity of the AE
minor (1)
moderate (2)
severe (3)
Adverse Event Outcome
Recovered (1)
Subsiding (2)
Continuing (3)
resolved with sequelae (4)
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increased symptoms (5)
fatal (6)
What actions have been taken regarding the trial
substance?
not applicable (1)
no adjustment in dose (2)
adjustment of dose (3)
suspension of treatment (4)
discontinuation of treatment (5)
other (6)
What other actions have been taken in response
to the AE?
none (1)
change of concomitant medication (2)
hospitalization/prolonged stay in hospital
(3)
further therapeutic and diagnostic
measures (4)
Is the AE related to the trial substance?
undecided/incomplete (1)
inconclusive (2)
without context to trial substance (3)
unlikely (4)
possible (5)
probable (6)
confirmed (7)
Date of completion of this form
Signature
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Efficacy and tolerability of subcutaneous hyposensitization with CLUSTOID
in Patients with allergic rhinoconjunctivitis overall appraisal of treatment
Prospective,multicentric,double blind and placebo-
controlled Phase III clinical trial to determine efficacy and
tolerability of subcutaneous hyposensitization with
CLUSTOID in patients with allergic rhinoconjunctivits
caused by grass or rye pollen. EudraCT-Nr. 2008-000513-
29 Study-code:CLU-2008-001 Sponsor: ROXALL Medizin
GmbH Carl-Petersen-Straße 4 20535 Hamburg Phone:040-
8972520 Fax:040-89725223 Project coordinator: Dr.Jenny
Uhlig ROXALL Medizin GmbH Head of clinical
investigation: Prof.Dr.med.Ludger Klimek An den Quellen
10 65183 Wiesbaden Phone:0611-8904381 Fax:0611-
3082360 Monitoring,data management and statistical
evaluation: IMSIE- Institut for medical statistics,computer
sciences and epidemiology University hospital Cologne
Lindenburger Allee 42 50931 Cologne Phone:0221-
4783456 Fax:0221-4783465
All rights reserved. Please visit https://medical-data-
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Case Report Form: overall appraisal
of treatment
Appraisal by Investigator
Effectiveness of treatment in comparison to last
years pollen season
deteriorated condition (0)
no change in condition (1)
little to moderate improvement (2)
distinct to very pronounced improvement
(3)
General tolerance of trial substance
poor (0)
moderate (1)
good (2)
very good (3)
Appraisal by patient
Please rate your satisfaction with the resulting
desensitization by the investigational agent
not at all satisfied (0)
less satisfied (1)
satisfied (2)
very satisfied (3)
Would you recommend this treatment of specific
desensitization to other patients?
I certainly wouldn´t recommend this
treatment (0)
I probably wouldn´t recommend this
treatment (1)
I probably would recommend this
treatment (2)
I certainly would recommend this
treatment (3)
Date and Signature
Study completion form has been filled in
Yes
No
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Date of completion of this form
Signature
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Efficacy and tolerability of subcutaneous hyposensitization with
CLUSTOID in Patients with allergic rhinoconjunctivitis Study completion
Prospective,multicentric,double blind and placebo-
controlled Phase III clinical trial to determine efficacy and
tolerability of subcutaneous hyposensitization with
CLUSTOID in patients with allergic rhinoconjunctivits
caused by grass or rye pollen. EudraCT-Nr. 2008-000513-
29 Study-code:CLU-2008-001 Sponsor: ROXALL Medizin
GmbH Carl-Petersen-Straße 4 20535 Hamburg Phone:040-
8972520 Fax:040-89725223 Project coordinator: Dr.Jenny
Uhlig ROXALL Medizin GmbH Head of clinical
investigation: Prof.Dr.med.Ludger Klimek An den Quellen
10 65183 Wiesbaden Phone:0611-8904381 Fax:0611-
3082360 Monitoring,data management and statistical
evaluation: IMSIE- Institut for medical statistics,computer
sciences and epidemiology University hospital Cologne
Lindenburger Allee 42 50931 Cologne Phone:0221-
4783456 Fax:0221-4783465
All rights reserved. Please visit https://medical-data-
models.org/forms/13257
Case report form Study completion
Study completion form
Please give Patient ID composed of Study site Nr
and Patient Nr
This clinical trail has been completed according
to protocol
Yes
No
If the trial has not been completed according to
protocol please specify the reason why
adverse effect  during dose titration (1)
adverse/serious adverse event (2)
withdrawal of informed consent (3)
comorbidities (4)
protocol violation (i.e lack of compliance)
(5)
pregnancy (6)
private considerations of patient (7)
other reason (8)
lost to follow up (9)
Please specify any other reason that caused
discontinuation
If the patient was lost to follow up, please specify
date the patient was last seen
Participation discontinued by
Patient (1)
Investigator (2)
Patient diary part 1-5 has been retrieved from the
patient.
Yes
No
Further comments
Confirmatin of investigator: The treatment of this
patient during this investigation was under my
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supervision and according to study protocol. All
data and statements in this CRF are complete
and correct
Yes
No
Date of completion of this form
Signature of investigator
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Efficacy and tolerability of subcutaneous hyposensitization with
CLUSTOID in Patients with allergic rhinoconjunctivitis Telephone Visit 1
Prospective,multicentric,double blind and placebo-
controlled Phase III clinical trial to determine efficacy and
tolerability of subcutaneous hyposensitization with
CLUSTOID in patients with allergic rhinoconjunctivits
caused by grass or rye pollen. EudraCT-Nr. 2008-000513-
29 Study-code:CLU-2008-001 Sponsor: ROXALL Medizin
GmbH Carl-Petersen-Straße 4 20535 Hamburg Phone:040-
8972520 Fax:040-89725223 Project coordinator: Dr.Jenny
Uhlig ROXALL Medizin GmbH Head of clinical
investigation: Prof.Dr.med.Ludger Klimek An den Quellen
10 65183 Wiesbaden Phone:0611-8904381 Fax:0611-
3082360 Monitoring,data management and statistical
evaluation: IMSIE- Institut for medical statistics,computer
sciences and epidemiology University hospital Cologne
Lindenburger Allee 42 50931 Cologne Phone:0221-
4783456 Fax:0221-4783465
All rights reserved. Please visit https://medical-data-
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Case report form: Telephone Visit 1
Telephone Visit
Please give Patient ID composed of Study site Nr
and Patient Nr
Date of phone contact
Safety laboratory results of visit 14 have been
completed. If yes, please inform your patient of
the results.
Yes
No
Laboratory results are without findings, no
additional visit required
Yes
No
One or more laboratory results are abnormal: this
is an AE, please arrange for an additional visit,
note the date of appointment below and complete
the AE report form.
Yes
No
Please fill in the date of the additional
appointment
Date of completion of this form
Signature
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Prospective,multicentric,double blind and placebo-
controlled Phase III clinical trial to determine efficacy and
tolerability of subcutaneous hyposensitization with
CLUSTOID in patients with allergic rhinoconjunctivits
caused by grass or rye pollen. EudraCT-Nr. 2008-000513-
29 Study-code:CLU-2008-001 Sponsor: ROXALL Medizin
GmbH Carl-Petersen-Straße 4 20535 Hamburg Phone:040-
8972520 Fax:040-89725223 Project coordinator: Dr.Jenny
Uhlig ROXALL Medizin GmbH Head of clinical
investigation: Prof.Dr.med.Ludger Klimek An den Quellen
10 65183 Wiesbaden Phone:0611-8904381 Fax:0611-
3082360 Monitoring,data management and statistical
evaluation: IMSIE- Institut for medical statistics,computer
sciences and epidemiology University hospital Cologne
Lindenburger Allee 42 50931 Cologne Phone:0221-
4783456 Fax:0221-4783465
All rights reserved. Please visit https://medical-data-
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Adverse Event report form
Adverse Events
Please give Patient ID composed of Study site Nr
and Patient Nr
Did any Adverse Events occur?
Yes
No
Please describe the AE
Adverse Event Start Date
Adverse Event End Date
How often did the event occur?
once (1)
regularly (2)
continuing (3)
Please give your opinion to the severity of the AE
minor (1)
moderate (2)
severe (3)
Adverse Event Outcome
Recovered (1)
Subsiding (2)
Continuing (3)
resolved with sequelae (4)
increased symptoms (5)
fatal (6)
unknown (7)
What actions have been taken regarding the trial
substance?
not applicable (1)
no adjustment in dose (2)
adjustment of dose (3)
suspension of treatment (4)
discontinuation of treatment (5)
other (6)
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What other actions have been taken in response
to the AE?
none (1)
change of concomitant medication (2)
hospitalization/prolonged stay in hospital
(3)
further therapeutic and diagnostic
measures (4)
Is the AE related to the trial substance?
undecided/incomplete (1)
inconclusive (2)
without context to trial substance (3)
unlikely (4)
possible (5)
probable (6)
confirmed (7)
Date of completion of this form
Signature
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Efficacy and tolerability of subcutaneous hyposensitization with
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Prospective,multicentric,double blind and placebo-
controlled Phase III clinical trial to determine efficacy and
tolerability of subcutaneous hyposensitization with
CLUSTOID in patients with allergic rhinoconjunctivits
caused by grass or rye pollen. EudraCT-Nr. 2008-000513-
29 Study-code:CLU-2008-001 Sponsor: ROXALL Medizin
GmbH Carl-Petersen-Straße 4 20535 Hamburg Phone:040-
8972520 Fax:040-89725223 Project coordinator: Dr.Jenny
Uhlig ROXALL Medizin GmbH Head of clinical
investigation: Prof.Dr.med.Ludger Klimek An den Quellen
10 65183 Wiesbaden Phone:0611-8904381 Fax:0611-
3082360 Monitoring,data management and statistical
evaluation: IMSIE- Institut for medical statistics,computer
sciences and epidemiology University hospital Cologne
Lindenburger Allee 42 50931 Cologne Phone:0221-
4783456 Fax:0221-4783465
All rights reserved. Please visit https://medical-data-
models.org/forms/13260
Case report form: Additional Visit
Additional Visit
Please give Patient ID composed of Study site Nr
and Patient Nr
Blood pressure measurement
mm/Hg
Heart rate count
bpm
Body Height
cm
Body Weight
kg
Rhinoscopic evaluation: Edema
none (0)
little (1)
severe (2)
Rhinoscopic evaluation: Secretion
none (0)
clear fluid (1)
thick mucous (2)
Rhinoscopic evaluation: Redness
none (0)
little (1)
severe (2)
Has concomitant medication been subject to
change?
Yes
No
Please specify any changes of therapy since last
visit
Have comorbidities changed?
Yes
1 / 4
No
If comorbidities have changed,please specify any
change since last visit
Safety Laboratory parameter
Please specify measured hemoglobine and units
used
Please specify measured amount of erythrocytes
and units used
Please specify measured amount of leucocytes
and units used
Please specify measured amount of neutrophils
and units used
Please specify measured amount of eosinophils
and units used
Please specify measured amount of basophils
and units used
Please specify measured amount of monocytes
and units used
Please specify measured amount of lymphocytes
and units used
Please specify measured hematocrit and units
used
Please specify measured amount of
thrombocytes and units used
Please specify measured amount of total bilirubin
and units used
Please specify the measured SGPT and units
used
Please specify the measurement of LDH and
units used
Please specify the measurement of creatinine
and units used
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Please specify the measurement of serum
glutamate-oxaloacetate transaminase and units
used
Please specify the measurement of CRP and
units used
Diagnosis based on latest laboratory findings and
or current physical examination (please note also
as AE)
Please specify further treatment of your patient
Adverse Events
Please describe the AE
Adverse Event Start Date
Adverse Event End Date
How often did the event occur?
once (1)
regularly (2)
continuing (3)
Please give your opinion to the severity of the AE
minor (1)
moderate (2)
severe (3)
Adverse Event Outcome
Recovered (1)
Subsiding (2)
Continuing (3)
resolved with sequelae (4)
increased symptoms (5)
fatal (6)
unknown (7)
What actions have been taken regarding the trial
substance?
not applicable (1)
no adjustment in dose (2)
adjustment of dose (3)
suspension of treatment (4)
discontinuation of treatment (5)
other (6)
What other actions have been taken in response
to the AE?
none (1)
change of concomitant medication (2)
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hospitalization/prolonged stay in hospital
(3)
further therapeutic and diagnostic
measures (4)
Is the AE related to the trial substance?
undecided/incomplete (1)
inconclusive (2)
without context to trial substance (3)
unlikely (4)
possible (5)
probable (6)
confirmed (7)
Date of completion of this form
Signature
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Efficacy and tolerability of subcutaneous hyposensitization with
CLUSTOID in Patients with allergic rhinoconjunctivitis SAE report form
Prospective,multicentric,double blind and placebo-
controlled Phase III clinical trial to determine efficacy and
tolerability of subcutaneous hyposensitization with
CLUSTOID in patients with allergic rhinoconjunctivits
caused by grass or rye pollen. EudraCT-Nr. 2008-000513-
29 Study-code:CLU-2008-001 Sponsor: ROXALL Medizin
GmbH Carl-Petersen-Straße 4 20535 Hamburg Phone:040-
8972520 Fax:040-89725223 Project coordinator: Dr.Jenny
Uhlig ROXALL Medizin GmbH Head of clinical
investigation: Prof.Dr.med.Ludger Klimek An den Quellen
10 65183 Wiesbaden Phone:0611-8904381 Fax:0611-
3082360 Monitoring,data management and statistical
evaluation: IMSIE- Institut for medical statistics,computer
sciences and epidemiology University hospital Cologne
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Serious Adverse Event report form
SAE report form
Please give Patient ID composed of Study site Nr
and Patient Nr
Patient date of birth
At which visit has the SAE occurred?
Patient Gender
Female (1)
Male (2)
Body Height
cm
Body Weight
kg
Observed SAE
When did the SAE occur? Please note
day/month/year
Please describe anything relevant to this specific
event: clinically relevant findings,laboratory
results, medical history and comorbidities
Opinion of investigator
Applied medication with lot number, please
include also the investigational product.
Daily dose of medication
Drug application route (i.e: i.v, s.c, i.m,oral,...)
1 / 2
Medication use start date
Medication use end date
Is the SAE related to the pharmaceutical
product?
no correlation (1)
unlikely  (2)
possible (3)
confirmed (4)
inconclusive/insufficent data (5)
Outcome and treatment
Lifethreatening adverse event
Yes
No
Event resulted in a hospitalization
Yes
No
Date of hospital admission
Please describe treatment (i.e chronological
sequence, determining factors, discontinuation of
medication, clinical condition of the patient at this
point)
Please describe any attached documents
(hospital report, lab results or other tests
contributing to the diagnosis)
What ist the result of the reported SAE?
Recovered (1)
Recovered with persisting sequelae (2)
Continuing  (3)
Unknown (4)
Lethal (5)
Death related to Serious Adverse Event
Yes
No
Death of the patient is not related to the trial
substance
Yes
No
Date of completion of this form
Signature
2 / 2
Efficacy and tolerability of subcutaneous hyposensitization with
CLUSTOID in Patients with allergic rhinoconjunctivitis SAE report form
Visit V4_LAIS grass tablets by allergic
rhinoconjunctivitis_EudraCT-Nr.2012-004916-79
Study part: Visit V4 (Day 84 + - 7). Effectiveness and
tolerance of sublingual desensitization with LAIS grass
tablets in Patients with an allergic rhinoconjunctivitis caused
by grass pollen.  A prospective, multi-center, doubleblind,
randomized, placebo-controlled Phase III study. Principal
Investigator Prof. Dr. med. Ralph Mösges.
All rights reserved. Please visit https://medical-data-
models.org/forms/13264
Visit V4 (Day 84 + - 7)
Visit 4
Date of visit
Does the patient still take part in the study?
yes (1)
no, please then fill up the form "Study
completion" (2)
Did the patient take the medication according to
the protocol?
always (1)
mostly yes (2)
mostly no (3)
no (4)
If the compliance was not always, please mention
in detail
Comorbidity? Please fill up the form
"Documentation adverse event"
Yes
No
Concomitant medication? Please use the form
"Documentation Concomitant medication"
Yes
No
Date for next visit 5 (Day 140 + - 7 days)
Did an adverse event occur during the treatment?
(If yes, please use the form "Documentation
adverse event")
Yes
No
Did a serious adverse event occur during the
treatment? (If yes, please use the form
"Documentation serious adverse events")
Yes
No
Are there any undocumented adverse events,
which were not recorded during the previous
visit?  (If yes, please use the form
"Documentation adverse event")
Yes
No
1 / 3
Physical examination
Weight
kg
Systolic blood pressure
mmHg
Diastolic blood pressure
mmHg
Heart rate
1/ min
Examination (Rhinoscope)
Edema
no (1)
slight (2)
medium (3)
strong (4)
Secretion
no (1)
slight (2)
medium (3)
strong (4)
Redness
no (1)
slight (2)
medium (3)
strong (4)
Spirometry or Peak expiratory flow
measurement (For asthmatics)
FEV1 (age-appropriate standard value)
FEV1
FEV1/ Standard value (If FEV1 < 70% of age
appropriate standard value, exclusion)
%
PEF 1
l/min
PEF 2
l/ min
2 / 3
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Nr.2012-004916-79
PEF 3
l/ min
Best PEF
l/ min
Optimum individual value PEF (If FEV1 < 70% of
optimum individual value, exclusion)
l/ min
Study medication and Concomitant
medication (Taking back of the second
study medication box with 7 blister pack)
Number of tablets left (study medication)
Number of tablets left (Loratadin)
Mention, if incomplete
Handing out of third study medication box with 8
blister pack and 1 blister pack of concomitant
medication (if necessary)
Yes
No
Conjunctival provocation testing
Conjunctival provocation test result 1
positive (1)
negative (2)
Conjunctival provocation test result 2 (to be
carried out only when test 1 outcome is negative)
positive (1)
negative (2)
Conjunctival provocation test result 3 (to be
carried out only when test 2 outcome is negative)
positive (1)
negative (2)
Allergen concentration at which the test outcome
is positive
100 SQ- E/ ml (1)
1000 SQ-E/ ml (2)
10000 SQ-E/ ml (3)
The outcome for all tests is negative
Yes
No
3 / 3
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Visit V2_LAIS grass tablets by allergic
rhinoconjunctivitis_EudraCT-Nr.2012-004916-79
Study part: Visit V2 (Day 7+ - 2). Effectiveness and
tolerance of sublingual desensitization with LAIS grass
tablets in Patients with an allergic rhinoconjunctivitis caused
by grass pollen.  A prospective, multi-center, doubleblind,
randomized, placebo-controlled Phase III study. Principal
Investigator Prof. Dr. med. Ralph Mösges.
All rights reserved. Please visit https://medical-data-
models.org/forms/13265
Visit V2 (Day 7+ - 2)
Visit 2
Date of visit
Does the patient still take part in the study?
yes (1)
no, please then fill up the form "Study
completion" (2)
Did the patient take the medication according to
the protocol?
always (1)
mostly yes (2)
mostly no (3)
no (4)
If the compliance was not always, please mention
in detail
Comorbidity? Please fill up the form
"Documentation adverse event"
Yes
No
Concomitant medication? Please use the form
"Documentation Concomitant medication"
Yes
No
Date for next visit 3 (Day 28 + - 7 days)
Did an adverse event occur during the treatment?
(If yes, please use the form "Documentation
adverse event")
Yes
No
Did a serious adverse event occur during the
treatment? (If yes, please use the form
"Documentation serious adverse events")
Yes
No
Are there any undocumented adverse events,
which were not recorded during the previous
visit?  (If yes, please use the form
"Documentation adverse event")
Yes
No
1 / 3
Physical examination
Weight
kg
Systolic blood pressure
mmHg
Diastolic blood pressure
mmHg
Heart rate
1/ min
Examination (Rhinoscope)
Edema
no (1)
slight (2)
medium (3)
strong (4)
Secretion
no (1)
slight (2)
medium (3)
strong (4)
Redness
no (1)
slight (2)
medium (3)
strong (4)
Spirometry or Peak expiratory flow
measurement (For asthmatics)
FEV1 (age-appropriate standard value)
FEV1
FEV1/ Standard value (If FEV1 < 70% of age
appropriate standard value, exclusion)
%
PEF 1
l/min
PEF 2
l/ min
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PEF 3
l/ min
Best PEF
l/ min
Optimum individual value PEF (If FEV1 < 70% of
optimum individual value, exclusion)
l/ min
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Visit V3_LAIS grass tablets by allergic
rhinoconjunctivitis_EudraCT-Nr.2012-004916-79
Study part: Visit V3 (Day 28 + - 7). Effectiveness and
tolerance of sublingual desensitization with LAIS grass
tablets in Patients with an allergic rhinoconjunctivitis caused
by grass pollen.  A prospective, multi-center, doubleblind,
randomized, placebo-controlled Phase III study. Principal
Investigator Prof. Dr. med. Ralph Mösges.
All rights reserved. Please visit https://medical-data-
models.org/forms/13266
Visit V3 (Day 28 + - 7)
Visit 3
Date of visit
Does the patient still take part in the study?
yes (1)
no, please then fill up the form "Study
completion" (2)
Did the patient take the medication according to
the protocol?
always (1)
mostly yes (2)
mostly no (3)
no (4)
If the compliance was not always, please mention
in detail
Comorbidity? Please fill up the form
"Documentation adverse event"
Yes
No
Concomitant medication? Please use the form
"Documentation Concomitant medication"
Yes
No
Date for next visit 4 (Day 84 + - 7 days)
Did an adverse event occur during the treatment?
(If yes, please use the form "Documentation
adverse event")
Yes
No
Did a serious adverse event occur during the
treatment? (If yes, please use the form
"Documentation serious adverse events")
Yes
No
Are there any undocumented adverse events,
which were not recorded during the previous
visit?  (If yes, please use the form
"Documentation adverse event")
Yes
No
1 / 3
Physical examination
Weight
kg
Systolic blood pressure
mmHg
Diastolic blood pressure
mmHg
Heart rate
1/ min
Examination (Rhinoscope)
Edema
no (1)
slight (2)
medium (3)
strong (4)
Secretion
no (1)
slight (2)
medium (3)
strong (4)
Redness
no (1)
slight (2)
medium (3)
strong (4)
Spirometry or Peak expiratory flow
measurement (For asthmatics)
FEV1 (age-appropriate standard value)
FEV1
FEV1/ Standard value (If FEV1 < 70% of age
appropriate standard value, exclusion)
%
PEF 1
l/min
PEF 2
l/ min
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PEF 3
l/ min
Best PEF
l/ min
Optimum individual value PEF (If FEV1 < 70% of
optimum individual value, exclusion)
l/ min
Study medication and Concomitant
medication (Taking back of the first study
medication box with 4 blister pack)
Number of tablets left (study medication)
Number of tablets left (Loratadin)
Mention, if incomplete
Handing out of second study medication box with
7 blister pack and 1 blister pack of concomitant
medication (if necessary)
Yes
No
Conjunctival provocation testing
Conjunctival provocation test result 1
positive (1)
negative (2)
Conjunctival provocation test result 2 (to be
carried out only when test 1 outcome is negative)
positive (1)
negative (2)
Conjunctival provocation test result 3 (to be
carried out only when test 2 outcome is negative)
positive (1)
negative (2)
Allergen concentration at which the test outcome
is positive
100 SQ- E/ ml (1)
1000 SQ-E/ ml (2)
10000 SQ-E/ ml (3)
The outcome for all tests is negative
Yes
No
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Visit V3_LAIS grass tablets by allergic rhinoconjunctivitis_EudraCT-
Nr.2012-004916-79
Visit V5_LAIS grass tablets by allergic
rhinoconjunctivitis_EudraCT-Nr.2012-004916-79
Study part: Visit V5 (Day 140 + - 14). Effectiveness and
tolerance of sublingual desensitization with LAIS grass
tablets in Patients with an allergic rhinoconjunctivitis caused
by grass pollen.  A prospective, multi-center, doubleblind,
randomized, placebo-controlled Phase III study. Principal
Investigator Prof. Dr. med. Ralph Mösges.
All rights reserved. Please visit https://medical-data-
models.org/forms/13267
Visit V5 (Day 140 + - 14)
Visit 5
Date of visit
Does the patient still take part in the study?
yes (1)
no, please then fill up the form "Study
completion" (2)
Did the patient take the medication according to
the protocol?
always (1)
mostly yes (2)
mostly no (3)
no (4)
If the compliance was not always, please mention
in detail
Comorbidity? Please fill up the form
"Documentation adverse event"
Yes
No
Concomitant medication? Please use the form
"Documentation Concomitant medication"
Yes
No
Date for next visit 6 (Day 196 + - 14 days)
Did an adverse event occur during the treatment?
(If yes, please use the form "Documentation
adverse event")
Yes
No
Did a serious adverse event occur during the
treatment? (If yes, please use the form
"Documentation serious adverse events")
Yes
No
Are there any undocumented adverse events,
which were not recorded during the previous
visit?  (If yes, please use the form
"Documentation adverse event")
Yes
No
1 / 4
Patient diary (part 1) handed out?
Yes
No
Did the patient fill up the documentation form on
quality of life of rhinoconjunctivitis patients?
Physical examination
Weight
kg
Systolic blood pressure
mmHg
Diastolic blood pressure
mmHg
Heart rate
1/ min
Examination (Rhinoscope)
Edema
no (1)
slight (2)
medium (3)
strong (4)
Secretion
no (1)
slight (2)
medium (3)
strong (4)
Redness
no (1)
slight (2)
medium (3)
strong (4)
Spirometry or Peak expiratory flow
measurement (For asthmatics)
FEV1 (age-appropriate standard value)
FEV1
FEV1/ Standard value (If FEV1 < 70% of age
appropriate standard value, exclusion)
%
2 / 4
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PEF 1
l/min
PEF 2
l/ min
PEF 3
l/ min
Best PEF
l/ min
Optimum individual value PEF (If FEV1 < 70% of
optimum individual value, exclusion)
l/ min
Study medication and Concomitant
medication (Taking back of the third study
medication box with 8 blister pack)
Number of tablets left (study medication)
Number of tablets left (Loratadin)
Mention, if incomplete
Hematology
Blood collection on
Ig G4 Gräser
mg/l
Hemoglobin
mmol/l
Hematocrit
l/l
Erythrocyte
/pl
Thrombocyte
/nl
Leucocyte (total)
/nl
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Biochemistry
Bilirubin (total)
μmol/l
SGPT- Serum Glutamate pyruvate transaminase
U/l
Alkaline phosphatase
U/l
Glucose
mmol/l
Creatinine
μmol/l
SGOT- Aspartate aminotransferase
measurement
U/l
CRP C reactive protein
mg/l
Gamma-glutamyl transpeptidase
U/l
Demand medication
Number of antihistamines (oral) handed out
Number of Levocabastin eye drops given out
Number of Beclometason nasal sprays given out
Number of combination of inhaled cortisone +
long acting β2-receptor-agonist handed out
4 / 4
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Visit V6_LAIS grass tablets by allergic
rhinoconjunctivitis_EudraCT-Nr.2012-004916-79
Study part: Visit V6 (Day 196 + - 14). Effectiveness and
tolerance of sublingual desensitization with LAIS grass
tablets in Patients with an allergic rhinoconjunctivitis caused
by grass pollen.  A prospective, multi-center, doubleblind,
randomized, placebo-controlled Phase III study. Principal
Investigator Prof. Dr. med. Ralph Mösges.
All rights reserved. Please visit https://medical-data-
models.org/forms/13268
Visit V6 (Day 196 + - 14)
Visit 6
Date of visit
Does the patient still take part in the study?
yes (1)
no, please then fill up the form "Study
completion" (2)
Did the patient take the medication according to
the protocol?
always (1)
mostly yes (2)
mostly no (3)
no (4)
If the compliance was not always, please mention
in detail
Comorbidity? Please fill up the form
"Documentation adverse event"
Yes
No
Concomitant medication? Please use the form
"Documentation Concomitant medication"
Yes
No
Date for next visit 7 (Day 238 + - 14 days)
Did an adverse event occur during the treatment?
(If yes, please use the form "Documentation
adverse event")
Yes
No
Did a serious adverse event occur during the
treatment? (If yes, please use the form
"Documentation serious adverse events")
Yes
No
Are there any undocumented adverse events,
which were not recorded during the previous
visit?  (If yes, please use the form
"Documentation adverse event")
Yes
No
1 / 3
Patient diary part 1 collected and part 2 handed
out?
Yes
No
Did the patient fill up the documentation forms on
quality of life of rhinoconjunctivitis patients and
Rhinitis control assessment test?
Physical examination
Weight
kg
Systolic blood pressure
mmHg
Diastolic blood pressure
mmHg
Heart rate
1/ min
Examination (Rhinoscope)
Edema
no (1)
slight (2)
medium (3)
strong (4)
Secretion
no (1)
slight (2)
medium (3)
strong (4)
Redness
no (1)
slight (2)
medium (3)
strong (4)
Spirometry or Peak expiratory flow
measurement (For asthmatics)
FEV1 (age-appropriate standard value)
FEV1
FEV1/ Standard value (If FEV1 < 70% of age
appropriate standard value, exclusion)
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%PEF 1
l/min
PEF 2
l/ min
PEF 3
l/ min
Best PEF
l/ min
Optimum individual value PEF (If FEV1 < 70% of
optimum individual value, exclusion)
l/ min
Demand medication
Number of used antihistamines (oral), please
specify if incomplete
Return of unused medications
Yes
No
Number of opened eyedrops (Levocabastin),
please specify if incomplete
Return of unused medications
Yes
No
Number of nasal spray bottles opened
(Beclometason), please specify if incomplete
Return of unused medications
Yes
No
Number of opened packets of combination of
inhaled cortisone + long acting β2-receptor-
agonist, please specify if incomplete
Return of unused medications
Yes
No
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Visit V7_LAIS grass tablets by allergic
rhinoconjunctivitis_EudraCT-Nr.2012-004916-79
Study part: Visit V7 (Day 238 + - 14) Final examination.
Effectiveness and tolerance of sublingual desensitization
with LAIS grass tablets in Patients with an allergic
rhinoconjunctivitis caused by grass pollen.  A prospective,
multi-center, doubleblind, randomized, placebo-controlled
Phase III study. Principal Investigator Prof. Dr. med. Ralph
Mösges.
All rights reserved. Please visit https://medical-data-
models.org/forms/13269
Visit V7 (Day 238 + - 14) Final
examination
Visit 7
Date of visit
Does the patient still take part in the study?
yes (1)
no, please then fill up the form "Study
completion" (2)
Did the patient take the medication according to
the protocol?
always (1)
mostly yes (2)
mostly no (3)
no (4)
If the compliance was not always, please mention
in detail
Comorbidity? Please fill up the form
"Documentation adverse event"
Yes
No
Concomitant medication? Please use the form
"Documentation Concomitant medication"
Yes
No
Patient diary (part 2) collected and controlled?
Yes
No
Did the patient fill up the documentation form on
quality of life of rhinoconjunctivitis patients?
Yes
No
Documentation of study completion done?
(Please use the form "Study completion")
Yes
No
Physical examination
Weight
kg
1 / 3
Systolic blood pressure
mmHg
Diastolic blood pressure
mmHg
Heart rate
1/ min
Examination (Rhinoscope)
Edema
no (1)
slight (2)
medium (3)
strong (4)
Secretion
no (1)
slight (2)
medium (3)
strong (4)
Redness
no (1)
slight (2)
medium (3)
strong (4)
Spirometry or Peak expiratory flow
measurement (For asthmatics)
FEV1 (age-appropriate standard value)
FEV1
FEV1/ Standard value (If FEV1 < 70% of age
appropriate standard value, exclusion)
%
PEF 1
l/min
PEF 2
l/ min
PEF 3
l/ min
Best PEF
l/ min
2 / 3
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Optimum individual value PEF (If FEV1 < 70% of
optimum individual value, exclusion)
l/ min
Pregnancy test
Pregnancy test carried out on
Pregnancy test result
positive (1)
negative (2)
3 / 3
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Study completion_LAIS grass tablets by allergic
rhinoconjunctivitis_EudraCT-Nr.2012-004916-79
Study part: Study completion form.Effectiveness and
tolerance of sublingual desensitization with LAIS grass
tablets in Patients with an allergic rhinoconjunctivitis caused
by grass pollen.  A prospective, multi-center, doubleblind,
randomized, placebo-controlled Phase III study. Principal
Investigator Prof. Dr. med. Ralph Mösges.
All rights reserved. Please visit https://medical-data-
models.org/forms/13270
Study completion form
Study completion
study completion
Yes
No
The study was terminated on
The study was terminated by
Investigator  (1)
Patient (2)
The study was terminated due to
adverse event (1)
withdrawal of consent (2)
comorbidity (3)
protocol violation (e.g. bad compliance)
(4)
pregnancy (5)
other (6)
Patient no longer reachable (7)
If other, please specify
Date of last contact
Hematology
Hemoglobin
mmol/l
Hematocrit
l/l
Erythrocyte
/pl
Thrombocyte
/nl
Leucocyte (total)
/nl
Biochemistry
1 / 3
Bilirubin (total)
μmol/l
SGPT- Serum Glutamate pyruvate transaminase
U/l
Alkaline phosphatase
U/l
Glucose
mmol/l
Creatinine
μmol/l
SGOT- Aspartate aminotransferase
measurement
U/l
CRP C reactive protein
mg/l
Gamma-glutamyl transpeptidase
U/l
Pregnancy test
positive (1)
negative (2)
Date of pregnancy test
Withdrawal of demand medication
Patient compliance
always (1)
mostly yes (2)
mostly no (3)
no (4)
Number of used antihistamines (oral), please
specify if incomplete
Number of opened eyedrops (Levocabastin),
please specify if incomplete
Number of nasal spray bottles opened
(Beclometason), please specify if incomplete
Number of opened packets of combination of
inhaled cortisone  + long acting β2-receptor-
2 / 3
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agonist, please specify if incomplete
Assessment
Physician's assessment about the efficiency of
the treatment
deteriorated condition (1)
no change in the state (2)
mild to moderate improvement in the
state (3)
pronounced to very pronounced
improvement in the state (4)
Physician's assessment about the tolerance of
the treatment
bad (1)
satisfactory (2)
good (3)
very good (4)
Patient's assessment about the satisfaction of the
treatment
unsatisfactory (1)
little satisfactory (2)
satisfactory (3)
absolutely satisfied (4)
Recommendation
I would never recommend this therapy
(1)
May be I won't recommend this therapy
(2)
May be I will further recommend this
therapy (3)
I will absolutely recommend this therapy
(4)
3 / 3
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Adverse events_LAIS grass tablets by allergic
rhinoconjunctivitis_EudraCT-Nr.2012-004916-79Test Study
Study part: Documentation adverse events. Effectiveness
and tolerance of sublingual desensitization with LAIS grass
tablets in Patients with an allergic rhinoconjunctivitis caused
by grass pollen.  A prospective, multi-center, doubleblind,
randomized, placebo-controlled Phase III study. Principal
Investigator Prof. Dr. med. Ralph Mösges.
All rights reserved. Please visit https://medical-data-
models.org/forms/13271
Documentation adverse events
Register form adverse event
Adverse event
Date on which adverse event began
Is it a systemic reaction? (based on SLIT)
nonspecific symptoms (e.g. headache,
apprehension) (1)
slight specific symptoms (local urticaria,
rhinitis or slight asthma (PEF<20%)) (2)
medium specific symptoms (slow onset
of (> 15 min) of urticaria and/ or medium
asthma (PEF < 40%)) (3)
serious (not life threatening) systemic
symptoms (rapid onset (< 15min) of
urticaria, Angioedema or serious asthma
(PEF > 40%)) (4)
anaphylactic shock (please document
additionally as SAE) (5)
not applicable (6)
Relation to medication
not related (1)
may be related (2)
related (3)
Frequency of adverse event
once only (1)
regular (2)
continuous (3)
Seriousness of adverse event
slight (1)
medium (2)
serious (3)
Course of adverse event
finished (1)
subsided (2)
continuous (3)
finished/ resulting in additional symptoms
(4)
increased (5)
deadly (6)
unknown (7)
Measures related to study medication
no (1)
dose adjustment (2)
second interruption of therapy (3)
1 / 2
discontinuation of therapy (4)
other (5)
Other taken measures
no (1)
change of concomitant medication (2)
hospitalization/ extension of a hospital
stay (3)
additional therapeutic or diagnostic
measure (4)
Date on which adverse event ended
Ongoing of adverse event (beyond V7)?
Yes
No
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Concomitant medication_LAIS grass tablets by allergic
rhinoconjunctivitis_EudraCT-Nr.2012-004916-79
Study part: Documentation concomitant medication.
Effectiveness and tolerance of sublingual desensitization
with LAIS grass tablets in Patients with an allergic
rhinoconjunctivitis caused by grass pollen.  A prospective,
multi-center, doubleblind, randomized, placebo-controlled
Phase III study. Principal Investigator Prof. Dr. med. Ralph
Mösges.
All rights reserved. Please visit https://medical-data-
models.org/forms/13272
Documentation concomitant
medication
Concomitant medication
Name of concomitant medication
Active substance
Medication dose
daily (1)
if necessary (2)
Indication of medication
Contraindicated drugs
Yes
No
Medication intake began on
Medication intake ended on
1 / 1
Serious adverse events_LAIS grass tablets by allergic
rhinoconjunctivitis EudraCT-Nr. 2012-004916-79
Study part: Documentation serious adverse events.
Effectiveness and tolerance of sublingual desensitization
with LAIS grass tablets in Patients with an allergic
rhinoconjunctivitis caused by grass pollen.  A prospective,
multi-center, doubleblind, randomized, placebo-controlled
Phase III study. Principal Investigator Prof. Dr. med. Ralph
Mösges.
All rights reserved. Please visit https://medical-data-
models.org/forms/13273
Documentation serious adverse
events
Patient information
Patient ID
Date of birth
Visit number
Gender
male (1)
female (2)
Height
cm
Weight
kg
Serious adverse events
Date of serious adverse event appearance
Symptoms of serious adverse event
Laboratory test
Medical history
Comorbidity
Medication
Medication name
Medication dose
Drug administration route
Drug intake begin
1 / 2
Drug intake ended
Relation between study drug and serious adverse
event
no relation (1)
implausible (2)
possible (3)
plausible (4)
certain (5)
undecidable, insufficient data (6)
2 / 2
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EudraCT-Nr. 2012-004916-79
Eligibility Acute Promyelocytic Leukemia
NCT00465933
Treatment of Acute Promyelocytic Leukemia With All-Trans
Retinoic Acid (ATRA) and Idarubicin (AIDA); ODM derived
from: https://clinicaltrials.gov/show/NCT00465933
All rights reserved. Please visit https://medical-data-
models.org/forms/13276
Eligibility Acute Promyelocytic
Leukemia NCT00465933
Inclusion Criteria
age <= 75 years*
Yes
No
ecog = 3.*
Yes
No
morphological diagnosis of m3 or m3v. those
cases without typical morphology but with pml-
rara rearrangement may also be included.*
Yes
No
genetic diagnosis: t(15;17), pml-rara
rearrangement, monoclonal anti-pml positive.
obviously, the result of these tests may become
available after having initiated the treatment
based on a tentative morphological diagnosis. the
presence of secondary cytogenetic changes
associated with t(15;17) is not a reason for
exclusion nor do they require a different
therapeutic approach.*
Yes
No
Exclusion Criteria
age > 75 years (the treatment with this protocol
can be considered on an individual basis but
these patients will be analysed separately)*
Yes
No
absence of pml-rara rearrangement.*
Yes
No
prior antileukemic chemotherapy.*
Yes
No
presence of an associated neoplasm.*
Yes
No
presence of a severe psychiatric disease.*
Yes
No
hiv seropositivity.*
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Yes
No
contraindication for intensive chemotherapy,
especially to anthracyclines.*
Yes
No
serum creatinine = 2.5 mg/dl.*
Yes
No
bilirubin, alkaline phosphatase, or sgot > 3 times
the upper normal limit*
Yes
No
positive pregnancy test.*
Yes
No
2 / 2
Eligibility Acute Promyelocytic Leukemia NCT00465933
Eligibility Adult Acute Myeloid Leukemia in
Remission NCT00005940
Radiolabeled BC8 Antibody, Busulfan, Cyclophosphamide
Followed by Donor Stem Cell Transplant in Treating
Patients With Acute Myelogenous Leukemia in First
Remission; ODM derived from:
https://clinicaltrials.gov/show/NCT00005940
All rights reserved. Please visit https://medical-data-
models.org/forms/13277
Eligibility Adult Acute Myeloid
Leukemia in Remission
NCT00005940
Inclusion Criteria
patients with aml in first remission*
Yes
No
creatinine < 2.0 mg/dl*
Yes
No
bilirubin < 1.5 mg/dl which is expected to exclude
patients at high risk of developing veno-occlusive
disease of the liver*
Yes
No
aspartate aminotransferase (ast) < 1.5 times the
upper limit of normal which is expected to
exclude patients at high risk of developing veno-
occlusive disease of the liver*
Yes
No
patients must have an expected survival of > 60
days and must be free of major infection*
Yes
No
donor: genotypic or phenotypic hla-matched
family members; related donors should be
matched by molecular methods at the
intermediate resolution level at hla-a, b, c, and dr
beta 1 (drb1) according to fred hutchinson cancer
research center (fhcrc) standard practice
guidelines and to the allele level at dq beta 1
(dqb1)*
Yes
No
Exclusion Criteria
patients with history of or current leukemic
involvement of the central nervous system (cns)*
Yes
No
prior radiation to maximally tolerated levels to any
normal organ*
Yes
No
1 / 2
inability to understand or give an informed
consent*
Yes
No
patients who are seropositive for human
immunodeficiency virus (hiv)*
Yes
No
perceived inability to tolerate diagnostic or
therapeutic procedures, particularly treatment in
radiation isolation*
Yes
No
circulating antibody against mouse
immunoglobulin*
Yes
No
donor: unrelated donors and donors mismatched
for 1 or more hla antigens*
Yes
No
donor: donors who for psychologic, physiologic or
medical reasons are unable to undergo filgrastim
(g-csf)- mobilized pbsc collection or marrow
harvesting*
Yes
No
donor: donors who are seropositive for hiv*
Yes
No
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Eligibility Adult Acute Myeloid Leukemia in Remission NCT00005940
Eligibility Alzheimer Disease NCT00006399
Effects of Estrogen on Memory in Post-Menopausal
Women and Patients With Alzheimer's Disease; ODM
derived from: https://clinicaltrials.gov/show/NCT00006399
All rights reserved. Please visit https://medical-data-
models.org/forms/13278
Eligibility Alzheimer Disease
NCT00006399
Inclusion Criteria
normal volunteers and women with mild
alzheimer's disease:*
Yes
No
non-smoker*
Yes
No
no use of hormone replacement therapy for at
least one year*
Yes
No
no menses for at least one year*
Yes
No
normal mammogram within the last year*
Yes
No
minimum age is 45 for patients with alzheimer's
disease; 50 for normal volunteers*
Yes
No
maximum age is 85 for patients with alzheimer's
disease; there is no maximum age for normal
volunteers.*
Yes
No
Exclusion Criteria
women who are currently taking estrogen
therapy.*
Yes
No
women who are smokers.*
Yes
No
women who have had breast cancer.*
Yes
No
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Eligibility Alzheimer Disease NCT00432081
Effect of Indomethacin on the Progression of Alzheimer's
Disease; ODM derived from:
https://clinicaltrials.gov/show/NCT00432081
All rights reserved. Please visit https://medical-data-
models.org/forms/13279
Eligibility Alzheimer Disease
NCT00432081
Inclusion Criteria
the patient will satisfy the dsm-iv criteria for
dementia of the alzheimer’s type.*
Yes
No
the patient will satisfy the nincds/adrda criteria for
the clinical diagnosis of probable alzheimer’s
disease (appendix i).*
Yes
No
the severity of dementia for each patient will be
quantified by a mini-mental state examination
(mmse) score between 10 and 26 (both
inclusive).*
Yes
No
the patient is living at home or in a home for the
elderly.*
Yes
No
the patient has a responsible caregiver who is
able to provide information about the patient’s
functional status.*
Yes
No
written informed consent is obtained from the
patient or the legally accepted representative.*
Yes
No
Exclusion Criteria
the patient satisfies the ninds-airen criteria for
probable vascular dementia.*
Yes
No
a known exaggerated pharmacological sensitivity
or allergy to nsaid’s.*
Yes
No
history of peptic ulceration, gastric surgery or
gastrointestinal bleeding.*
Yes
No
1 / 2
current diagnosis of active peptic ulceration.*
Yes
No
current diagnosis of severe and unstable
cardiovascular disease.*
Yes
No
current diagnosis of renal failure.*
Yes
No
advanced, severe and unstable disease of any
type, other than alzheimer’s disease, that may
interfere with primary and secondary variable
evaluations, including a medical condition which
should be expected to progress, recur, or change
to such an extent that it may bias the assessment
of the clinical or mental status of the patient to a
significant degree or put the patient at special
risk.*
Yes
No
intake of any of the following concomitant
medications: salicylates, coumarin derivatives,
ace-inhibitors, loop diuretics.*
Yes
No
intake of any of the following concomitant
medications more than two months immediately
prior or during the study: nsaid’s, systemic
corticosteroids.*
Yes
No
intake of any of the following concomitant
medications with a possible effect on cognition:
estrogen, deprenyl, vitamin e, neuroleptics,
anticholinergics. patients using stable doses of
cholinesterase inhibitors were eligible, with the
provision that the dose should not be changed
during the study. cholinesterase inhibitors could
not be initiated during the study.*
Yes
No
excessive use of alcohol (more than 5 units per
day)*
Yes
No
the patient is, either alone or with the aid of a
caregiver, not able to reliably take the
medication.*
Yes
No
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Eligibility Alzheimer Disease NCT00432081
Eligibility Alzheimer's Disease
NCT00009217
Treatment of Behavioral Symptoms in Alzheimer's Disease;
ODM derived from:
https://clinicaltrials.gov/show/NCT00009217
All rights reserved. Please visit https://medical-data-
models.org/forms/13280
Eligibility Alzheimer's Disease
NCT00009217
Inclusion Criteria
meets dsm-iv criteria for dementia either sex, age
50-95 years*
Yes
No
meets nincds-adrda criteria for probable
alzheimer's disease*
Yes
No
meets folstein mini-mental state exam score of 5-
26, inclusive*
Yes
No
intellectual impairment reported for at least six
months*
Yes
No
availability of family member who has had direct
contact with the patient for an average of at least
once every week during the three months prior to
study entry*
Yes
No
has current symptoms of psychosis or agitation.
criteria for "psychosis" requires the presence of
delusions and/or hallucinations identified by the
columbia university scale for psychopathology in
alzheimer's disease (cuspad) and a minimum
brief psychiatric rating scale (bprs) psychosis
factor score of at least 4 (moderate severity) on
one of the following two items:  these two items
comprise the psychosis factor, excluding the item
for conceptual disorganization.  agitation is
defined as a score of greater than 3 (present at
least 10 days per month) on one or more of the
cerad behavioral rating scale for dementia items
for agitation, purposeless wandering, verbal
aggression or physical aggression.*
Yes
No
free of psychotropic medication for at least two
weeks prior to study entry, or able to tolerate
medication washout for this period.*
Yes
No
informed consent by patient and family member,
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as per irb procedures at new york state
psychiatric institute.*
Yes
No
Exclusion Criteria
acute unstable medical condition, delirium,
alcohol or substance abuse or dependence within
the past 1*
Yes
No
clinical evidence of stroke, other dementias
including vascular or lewy body or frontotemporal
dementia, multiple sclerosis, parkinson's disease,
huntington's disease, tardive dyskinesia*
Yes
No
diagnosis of a psychotic disorder antedating the
onset of dementia*
Yes
No
antipsychotic medication usage during 4 weeks
prior to study entry*
Yes
No
contraindication to the use of haloperidol*
Yes
No
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Eligibility Alzheimer's Disease NCT00009217
Eligibility Alzheimer's Disease
NCT01594346
Multicenter Vitamin E Trial in Aging Persons With Down
Syndrome; ODM derived from:
https://clinicaltrials.gov/show/NCT01594346
All rights reserved. Please visit https://medical-data-
models.org/forms/13281
Eligibility Alzheimer's Disease
NCT01594346
Inclusion Criteria
presence of clinically determined down syndrome
(karyotypes optional)*
Yes
No
appropriately signed and witnessed consent
form*
Yes
No
age of 50 years or older at the start of the
protocol*
Yes
No
medically stable*
Yes
No
medications stable more than 1 month*
Yes
No
involvement/cooperation of informant/caregiver*
Yes
No
Exclusion Criteria
medical/neurological condition (other than
alzheimer disease) associated with dementia*
Yes
No
inability to adequately perform the brief praxis
test, as demonstrated by a score <20*
Yes
No
in the presence of dementia, modified hachinski
score > 4 at screening visit*
Yes
No
major depression within 3 months*
Yes
No
history of coagulopathy (inherited or acquired)*
Yes
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No
current use of anticoagulants*
Yes
No
use of experimental medications within 2 months*
Yes
No
regular use of vitamin e greater than 50 units per
day during the previous 6 months*
Yes
No
allergy to vitamin e*
Yes
No
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Eligibility Alzheimer's Disease NCT01594346
Administrative Data SIMPLIFy TAVI Transcatheter Aortic
Valve Implantation Without Predilation NCT01539746
Use of the Self-Expanding CoreValve Prosthesis without
Predilation in Patients with
Significantly IMPaired Left-VentrIcular Ejection Fraction for
Transcatheter Aortic Valve
Implantation Study.
Form is used in following visits: 
- Baseline
Projektleiter (LKP):
Prof. Dr. med. Georg Nickenig
Medizinische Klinik und Poliklinik II
Sigmund-Freud-Str. 25, 53125 Bonn
Tel. 0228-287-15217, Fax 0228-287-16423
Email: georg.nickenig@ukb.uni-bonn.de
All rights reserved. Please visit https://medical-data-
models.org/forms/13282
Administrative Data NCT01539746
Administrative Data
Study site number
Screening number
Randomization number
Treatment group
Gender
Female (F)
Male (M)
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Patient information and informed consent SIMPLIFy TAVI Transcatheter
Aortic Valve Implantation Without Predilation NCT01539746
Use of the Self-Expanding CoreValve Prosthesis without
Predilation in Patients with
Significantly IMPaired Left-VentrIcular Ejection Fraction for
Transcatheter Aortic Valve
Implantation Study.
Form is used in following visits: 
- Baseline
Projektleiter (LKP):
Prof. Dr. med. Georg Nickenig
Medizinische Klinik und Poliklinik II
Sigmund-Freud-Str. 25, 53125 Bonn
Tel. 0228-287-15217, Fax 0228-287-16423
Email: georg.nickenig@ukb.uni-bonn.de
All rights reserved. Please visit https://medical-data-
models.org/forms/13283
Patient information and informed
consent NCT01539746
Patient information
The patient was informed and gave his consent:
Yes
No
Informed consent
A copy of the signed informed consent was
handed over to the patient?
Yes
No
Date of informed consent:
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Eligibility Anemia NCT00211133
A Study to Evaluate the Impact of Maintaining Hemoglobin
Levels Using Epoetin Alfa in Patients With Metastatic
Breast Cancer Receiving Chemotherapy; ODM derived
from: https://clinicaltrials.gov/show/NCT00211133
All rights reserved. Please visit https://medical-data-
models.org/forms/13285
Eligibility Anemia NCT00211133
Inclusion Criteria
female patients >= 18 years of age with
confirmed diagnosis of metastatic breast cancer
who are predicted to start chemotherapy for the
first time*
Yes
No
weight > = 40 kg (88 lbs)*
Yes
No
postmenopausal for at least 1 year, surgically
sterile or practicing an effective method of birth
control and have a negative serum pregnancy
test at the start of the study*
Yes
No
must have signed an informed consent*
Yes
No
Exclusion Criteria
clinically significant lung, heart, hormone,
neurological, gastrointestinal, urinary tract or
reproductive system disease*
Yes
No
receiving dose intensification chemotherapy for
bone marrow or stem cell transplantation*
Yes
No
cancer of the brain or brain/spinal cord disease*
Yes
No
locally advanced or inflammatory breast cancer
as the only symptom of breast cancer*
Yes
No
active second primary cancer or documented
history of other cancer within the last 3 years*
Yes
No
anemia from a cause other than cancer or
radiotherapy/chemotherapy*
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Yes
No
history of stoke, clots in the lungs or legs or any
other blood clotting disorders*
Yes
No
uncontrolled high blood pressure*
Yes
No
untreated folate or vitamin b12 deficiency*
Yes
No
treatment with epoetin alfa or other forms of
erythropoietin within the last 4 weeks*
Yes
No
known hypersensitivity to epoetin alfa or any of its
components*
Yes
No
pregnant or breast-feeding*
Yes
No
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Eligibility Anemia NCT00211133
Eligibility Anemia NCT00211133
A Study to Evaluate the Impact of Maintaining Hemoglobin
Levels Using Epoetin Alfa in Patients With Metastatic
Breast Cancer Receiving Chemotherapy; ODM derived
from: https://clinicaltrials.gov/show/NCT00211133
All rights reserved. Please visit https://medical-data-
models.org/forms/13286
Eligibility Anemia NCT00211133
Inclusion Criteria
female patients >= 18 years of age with
confirmed diagnosis of metastatic breast cancer
who are predicted to start chemotherapy for the
first time*
Yes
No
weight > = 40 kg (88 lbs)*
Yes
No
postmenopausal for at least 1 year, surgically
sterile or practicing an effective method of birth
control and have a negative serum pregnancy
test at the start of the study*
Yes
No
must have signed an informed consent*
Yes
No
Exclusion Criteria
clinically significant lung, heart, hormone,
neurological, gastrointestinal, urinary tract or
reproductive system disease*
Yes
No
receiving dose intensification chemotherapy for
bone marrow or stem cell transplantation*
Yes
No
cancer of the brain or brain/spinal cord disease*
Yes
No
locally advanced or inflammatory breast cancer
as the only symptom of breast cancer*
Yes
No
active second primary cancer or documented
history of other cancer within the last 3 years*
Yes
No
anemia from a cause other than cancer or
radiotherapy/chemotherapy*
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Yes
No
history of stoke, clots in the lungs or legs or any
other blood clotting disorders*
Yes
No
uncontrolled high blood pressure*
Yes
No
untreated folate or vitamin b12 deficiency*
Yes
No
treatment with epoetin alfa or other forms of
erythropoietin within the last 4 weeks*
Yes
No
known hypersensitivity to epoetin alfa or any of its
components*
Yes
No
pregnant or breast-feeding*
Yes
No
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Eligibility Anemia NCT00211133
Eligibility Asthma NCT00017693
Recombinant Human IL-4 Receptor Used in Treatment of
Asthma; ODM derived from:
https://clinicaltrials.gov/show/NCT00017693
All rights reserved. Please visit https://medical-data-
models.org/forms/13287
Eligibility Asthma NCT00017693
Inclusion Criteria
patients may be eligible for this study if they:*
Yes
No
are 12 to 85 years of age (consent of parent or
guardian required if under 18 years).*
Yes
No
have continuous asthma and are being treated
with albuterol mdi only.*
Yes
No
have reduced lung functions.*
Yes
No
have a positive reaction to 2 substances as
demonstrated with a skin test.*
Yes
No
have been a nonsmoker for at least 2 years and
have not smoked more than 1 pack a day for 5
years or less.*
Yes
No
agree to use contraception throughout the study.*
Yes
No
agree not to donate blood throughout the study.*
Yes
No
are able to use correctly an aerosol drug delivery
device.*
Yes
No
have had an asthma attack on at least 3 of the
last 7 days.*
Yes
No
Exclusion Criteria
patients will not be eligible for this study if they:*
Yes
No
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had asthma requiring hospitalization within 6
weeks of beginning study treatment.*
Yes
No
had asthma requiring emergency room treatment
within 12 months of beginning study treatment.*
Yes
No
had a respiratory infection that affected asthma
within 2 weeks of beginning study treatment.*
Yes
No
had a breathing tube inserted for asthma
treatment within 15 years of beginning study
treatment.*
Yes
No
were previously enrolled in a study of soluble il-4
receptor.*
Yes
No
have drug abuse, alcohol abuse, or a mental
illness that may interfere with the study.*
Yes
No
have serious medical problems (such as heart or
lung problems, uncontrolled high blood pressure,
are overweight to the extent that ability to breathe
is affected, or have cancer other than skin
cancer), diabetes, autoimmune diseases, or hiv.*
Yes
No
are pregnant or breast-feeding.*
Yes
No
have used certain drugs.*
Yes
No
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Eligibility Asthma NCT00017693
Eligibility Asthma NCT00029679
Borage Oil and Ginkgo Biloba (EGb 761) in Asthma; ODM
derived from: https://clinicaltrials.gov/show/NCT00029679
All rights reserved. Please visit https://medical-data-
models.org/forms/13288
Eligibility Asthma NCT00029679
Inclusion Criteria
symptoms (cough, wheeze, chest tightness)
consistent with the national asthma education
program (naep) guidelines for mild persistent to
moderate asthma*
Yes
No
Exclusion Criteria
severe asthma or mild intermittent asthma by
naep revised guidelines*
Yes
No
history of vasovagal reactions (nausea, dizziness,
flushed/warm) upon having blood drawn*
Yes
No
pregnancy or lactation*
Yes
No
history of emergency room care in the last 6
months*
Yes
No
history of hospitalization*
Yes
No
use of prednisone in the past 3 months*
Yes
No
concurrent pulmonary disease: pulmonary
hypertension, cystic fibrosis, sarcoidosis,
bronchiectasis, hypersensitivity pneumonitis,
restrictive lung disease*
Yes
No
cigarette smoking within the past 1 year; over 10-
pack year history of cigarette smoking in ex-
smokers*
Yes
No
recent (within one month) upper or lower
respiratory tract infection*
Yes
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No
the following concurrent medical diagnoses:
alcoholism, coronary artery disease, diabetes, hiv
infection, chronic hepatitis, uncontrolled
hypertension, or a psychiatric disorder that is
judged to make full participation difficult*
Yes
No
use of prednisone in the past 3 months; current
use of zileuton (leukotriene receptor antagonists
are allowed) or theophylline*
Yes
No
use of dietary supplements (except for standard
dose multiple vitamins such as one-a-day or
centrum) including herbal supplements, mega
dose of multiple vitamins/antioxidants,
magnesium, fish oil, borage oil, evening primrose
oil, black currant oil, fungal oil, g. biloba,
quercetin, or mega intake of garlic or onion
(subjects will be asked to stop such therapies as
a requirement of enrollment)*
Yes
No
ongoing use of homeopathic remedies or
acupuncture, acupressure, therapeutic massage
(subjects will be asked to stop such therapies as
a requirement of enrollment)*
Yes
No
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Eligibility Asthma NCT00029679
Eligibility Asthma NCT00667407
Efficacy and Safety of Levalbuterol Versus Racemic
Albuterol in Asthma; ODM derived from:
https://clinicaltrials.gov/show/NCT00667407
All rights reserved. Please visit https://medical-data-
models.org/forms/13289
Eligibility Asthma NCT00667407
Inclusion Criteria
male and female subjects must be at least
greater than or equal to 18 years of age at the
time of consent.*
Yes
No
subjects must have history of asthma for at least
6 months.*
Yes
No
subjects must present to the emergency
department (ed) or clinic with forced expiratory
volume in one second (fev1) of 20 to 55%
(inclusive) predicted at baseline*
Yes
No
subjects must have o2 saturation greater than or
equal to 90% at room air or with no more than 6
liters/minute supplemental oxygen and no other
cause of wheezing or shortness of breath other
than asthma as determined by the physician.*
Yes
No
prior use of a beta-agonist (e.g., primatine mist,
albuterol, salmeterol, etc.) within 24 hours of
presentation to the ed or clinic.*
Yes
No
smoked ≤ 10 pack-years or non-smoker.*
Yes
No
be in good health with the exception of asthma
and not suffering from any chronic condition
which might affect their lung function, such as
copd or emphysema.*
Yes
No
near-normal activity level between
exacerbations.*
Yes
No
subjects who are taking inhaled or systemic
corticosteroids must be on a stable dose for at
least 21 days prior to study entry.*
Yes
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No
Exclusion Criteria
subjects who have received treatment for asthma
in an ed, clinic, or urgent care center within 2
weeks prior to study entry.*
Yes
No
based upon history or physical exam in the ed or
clinic, subjects with known or suspected cause of
pulmonary symptoms other than asthma, such as
copd, chf, pneumonia, pulmonary embolism, or
angioedema.*
Yes
No
subjects with a history of asthma episodes
associated with hypercapnia, respiratory arrest,
hypoxic seizures, or requiring intubation within 12
months prior to entry.*
Yes
No
hospitalization for asthma within two months prior
to entry.*
Yes
No
female subjects who are pregnant or lactating.*
Yes
No
subjects who have a history of a clinically
significant psychiatric disorder within the last 3
months, with the exception of mild depression.*
Yes
No
subjects who have participated in an
investigational drug study within 30 days of study
entry or have previously participated in the
current trial.*
Yes
No
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Eligibility Asthma NCT00667407
Eligibility Atrial Fibrillation NCT00410020
Arrhythmia Prevention With an Alpha-Linolenic Enriched
Diet; ODM derived from:
https://clinicaltrials.gov/show/NCT00410020
All rights reserved. Please visit https://medical-data-
models.org/forms/13290
Eligibility Atrial Fibrillation
NCT00410020
Inclusion Criteria
patients hospitalized in one of the three centers in
the bordeaux region*
Yes
No
clinical diagnosis of atrial fibrillation*
Yes
No
who subsequently underwent successful
electrical cardioversion*
Yes
No
Exclusion Criteria
unable to receive electrical cardioversion*
Yes
No
already enrolled in another trial*
Yes
No
unable or unwilling to comply with the diet
recommendations (experimental or control) or
follow-up requirements*
Yes
No
clinically significant cardiac disease, advanced
heart failure, cardiac cachexia*
Yes
No
thyroid disease, treated or untreated,*
Yes
No
clinically significant hepatic or renal disease*
Yes
No
history of malignant disease*
Yes
No
alcohol abuse*
Yes
No
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taking ala rich foods or recording intakes of ala
>2g/d on the control diet or reporting using <1g/d
on the ala diet was considered a major deviation
from the protocol*
Yes
No
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Eligibility Atrial Fibrillation NCT00410020
Eligiblity Criteria SIMPLIFy TAVI Transcatheter Aortic
Valve Implantation Without Predilation NCT01539746
Use of the Self-Expanding CoreValve Prosthesis without
Predilation in Patients with
Significantly IMPaired Left-VentrIcular Ejection Fraction for
Transcatheter Aortic Valve
Implantation Study.
Form is used in following visits: 
- Baseline
Projektleiter (LKP):
Prof. Dr. med. Georg Nickenig
Medizinische Klinik und Poliklinik II
Sigmund-Freud-Str. 25, 53125 Bonn
Tel. 0228-287-15217, Fax 0228-287-16423
Email: georg.nickenig@ukb.uni-bonn.de
All rights reserved. Please visit https://medical-data-
models.org/forms/13294
Eligiblity Criteria NCT01539746
Date of visit
Date of visit
Inclusion Criteria
LVEF ≤35%
Yes
No
Aortic valve stenosis with an aortic valve area <1
cm2 (<0,6 cm3/m2)
Yes
No
Males or females at least 18 years of age
Yes
No
Logistic EuroSCORE ≥15% and age ≥75 years or
if age <75 years: logistic EuroSCORE ≥20%
and/or a significant contraindication for open
heart surgery (e.g., porcelain aorta or severe
COPD)
Yes
No
Signed informed consent
Yes
No
Exclusion Criteria
Patients with a device regulating the heart rhythm
by pacing (e.g. pacemaker, resynchronization
device, implanted defibrillator) with
atrioventricular block >= 1. degree and ventricular
pacing rate > 10%
Yes
No
Patients with implanted pacemaker because of
AV block >= Degree II or Cardiac
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Resynchronization Therapy (CRT)
Yes
No
Lack of written informed consent, severe mental
disorder, drug/alcohol addiction
Yes
No
Life expectancy < 1 year
Yes
No
Hypersensitivity or contraindication to acetyl
salicyl acid, heparin, ticlopidine, clopidogrel,
nitinol or sensitivity to contrast media that cannot
be adequately premedicated
Yes
No
Recent myocardial infarction (STEMI within the
last 3 months)
Yes
No
Left ventricular or atrial thrombus
Yes
No
Uncontrolled atrial fibrillation (heart rate >
140/Min)
Yes
No
Mitral or tricuspidal valvular insufficiency (> grade
II)
Yes
No
Previous aortic valve replacement with
mechanical valve
Yes
No
Evolutive or recent cerebrovascular event (within
the last 3 months)
Yes
No
Vascular conditions that make insertion and
endovascular access to the aortic valve
impossible
Yes
No
Symptomatic carotid or vertebral arterial
narrowing (>70%) disease
Yes
No
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Eligiblity Criteria SIMPLIFy TAVI Transcatheter Aortic Valve Implantation
Without Predilation NCT01539746
Abdominal or thoracic aortic aneurysm in the
path of the delivery system
Yes
No
Bleeding diathesis or contraindication to blood
transfusion
Yes
No
Active gastritis or peptic ulcer disease
Yes
No
Severely impaired renal function, GFR < 30
ml/min
Yes
No
Sepsis including acute endocarditis
Yes
No
Partition in another clinical trial
Yes
No
High probability of non-compliant study
participation
Yes
No
Pregnancy
Yes
No
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Eligiblity Criteria SIMPLIFy TAVI Transcatheter Aortic Valve Implantation
Without Predilation NCT01539746
Anamnesis SIMPLIFy TAVI Transcatheter Aortic
Valve Implantation Without Predilation NCT01539746
Use of the Self-Expanding CoreValve Prosthesis without
Predilation in Patients with
Significantly IMPaired Left-VentrIcular Ejection Fraction for
Transcatheter Aortic Valve
Implantation Study.
Form is used in following visits: 
- Baseline
Projektleiter (LKP):
Prof. Dr. med. Georg Nickenig
Medizinische Klinik und Poliklinik II
Sigmund-Freud-Str. 25, 53125 Bonn
Tel. 0228-287-15217, Fax 0228-287-16423
Email: georg.nickenig@ukb.uni-bonn.de
All rights reserved. Please visit https://medical-data-
models.org/forms/13296
Anamnesis NCT01539746
Date of visit
Date of visit
Anamnesis and comorbidities
Arterial hypertension
Yes
No
Aortic aneurysm
Yes
No
Porcelain aorta
Yes
No
Atrial fibrillation
Yes
No
Coronary artery disease (CAD)
Yes
No
Involved coronary arteries
One-vessel disease (1)
Two-vessel disease (2)
Three-vessel disease (3)
Myocardial infarction
Yes
No
Date of myocardial infarction
PCI
Yes
No
Date of PCI
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Pacemaker
Yes
No
ICD
Yes
No
Carotid stenosis
Yes
No
Stroke
Yes
No
Date of stroke
Yes
No
Peripheral arterial disease
Yes
No
COPD
Yes
No
FEV1 < 1 l
Yes
No
Diabetes mellitus
Yes
No
Type of diabetes mellitus
non insulin-dependent diabetes mellitus
(1)
insulin-dependent diabetes mellitus (2)
Immunosuppressive therapy
Yes
No
Dementia
Yes
No
Malignancy
Yes
No
Pulmonary hypertension (PAP > 60mmHg)
Yes
No
Renal Insufficiency with GFR < 60mL/Min
Yes
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Anamnesis SIMPLIFy TAVI Transcatheter Aortic Valve Implantation
Without Predilation NCT01539746
No
Liver cirrhosis
Yes
No
Cachexia
Yes
No
Surgical Anamnesis
Coronary artery bypass surgery (CABG-Op)
Yes
No
Heart valve surgery
Yes
No
Balloon valvuloplasty
Yes
No
Further comorbidities
Comorbidity
Onset of comorbidity
End of comorbidity
Currently present
Yes
No
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Anamnesis SIMPLIFy TAVI Transcatheter Aortic Valve Implantation
Without Predilation NCT01539746
Procedure (day 0) SIMPLIFy TAVI Transcatheter Aortic
Valve Implantation Without Predilation NCT01539746
Use of the Self-Expanding CoreValve Prosthesis without
Predilation in Patients with
Significantly IMPaired Left-VentrIcular Ejection Fraction for
Transcatheter Aortic Valve
Implantation Study.
Form is used in following visits: 
- Procedure day 0
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Tel. 0228-287-15217, Fax 0228-287-16423
Email: georg.nickenig@ukb.uni-bonn.de
All rights reserved. Please visit https://medical-data-
models.org/forms/13297
Procedure (day 0) NCT01539746
Date of visit
Date of visit
Procedure
Date
Time of first puncture
Time of suture of the vessel
Duration of the procedure
Min
Anaesthesia
local (1)
sedation (2)
general anaesthetic (3)
Hemodynamic method
None (1)
Heart-lung machine (2)
ECMO (3)
LV assist device (4)
Amount of contrast agent
ml
Access type
percutaneous (1)
surgical preparation (2)
Access localization
transfemoral (1)
trans-subclavicular (2)
transaortal (3)
Closure path
closure device (1)
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surgical (2)
stent (3)
Additional PCI: due to complications
Yes
No
Additional PCI: as part of the procedure
Yes
No
Hemodynamics before implantation: blood
pressure aorta systolic value
mmHg
Hemodynamics before implantation: blood
pressure aorta diastolic value
mmHg
Hemodynamics before implantation: systolic
blood pressure left ventricular
mmHg
Hemodynamics before implantation: end-diastolic
blood pressure left ventricular
mmHg
Randomisation
Treatment group after randomisation
TAVI with balloon dilatation (Group A)
TAVI without balloon dilatation (Group B)
Pre-dilation of valve
Pre-dilation of valve carried out
Yes
No
Balloon type
Nucleus (1)
Z-Med (2)
Tyshak (3)
Osypka (4)
other (5)
Dimension of the balloon - max. diameter
mm
Dimension of the balloon - length
cm
Number of balloons
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Procedure (day 0) SIMPLIFy TAVI Transcatheter Aortic Valve
Implantation Without Predilation NCT01539746
Number of dilatations
Overstimulation time
sec
Heart valve
Number CoreValves used
Product
CoreValve (1)
Core Valve Evolut R (2)
Product name - Size
23 mm (1)
26 mm (2)
29 mm (3)
31 mm (4)
Post-dilatation of valve
Post-dilatation of valve carried out
Yes
No
Balloon type
Nucleus (1)
Z-Med (2)
Tyshak (3)
Osypka (4)
other (5)
Dimension of the balloon - max. diameter
mm
Dimension of the balloon - length
cm
Number of balloons
Number of dilatations
Overstimulation time
sec
Angiography after implantation - n.d.
Yes
No
Implantant depth
mm
3 / 6
Procedure (day 0) SIMPLIFy TAVI Transcatheter Aortic Valve
Implantation Without Predilation NCT01539746
Paravalvular aortic insuffiency
none (0)
slight (1)
medium (2)
severe (3)
Hemodynamics after implantation: blood pressure
aorta systolic value
mmHg
Hemodynamics after implantation: blood pressure
aorta diastolic value
mmHg
Hemodynamics after implantation: systolic blood
pressure left ventricular
mmHg
Hemodynamics after implantation: end-diastolic
blood pressure left ventricular
mmHg
Complications
Success of procedure
Yes
No
Complications during procedure
Yes
No
Conversion to open heart surgery
Yes
No
Repositioning with "snare"
Yes
No
Second heart valve ("valve-in-valve")
Yes
No
Dislocation heart valve
Yes
No
Ventricular perforation
Yes
No
Cardiac tamponade
Yes
No
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Procedure (day 0) SIMPLIFy TAVI Transcatheter Aortic Valve
Implantation Without Predilation NCT01539746
Reanimation
Yes
No
Ventricular fibrillation
Yes
No
Defibrillation
Yes
No
Allergic reaction
Yes
No
Death
Yes
No
Stroke / TIA
Yes
No
Myocardial infarction
Yes
No
Vascular complications
Yes
No
Vascular complication due to closure device
Yes
No
Implantation of covered stent
Yes
No
Surgical closure
Yes
No
Bleeding
Yes
No
RBC transfusion in catheter laboratory
Yes
No
Number of RBC transfusions
Other complication
Yes
No
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Procedure (day 0) SIMPLIFy TAVI Transcatheter Aortic Valve
Implantation Without Predilation NCT01539746
Other
6 / 6
Procedure (day 0) SIMPLIFy TAVI Transcatheter Aortic Valve
Implantation Without Predilation NCT01539746
ECG SIMPLIFy TAVI Transcatheter Aortic Valve
Implantation Without Predilation NCT01539746
Use of the Self-Expanding CoreValve Prosthesis without
Predilation in Patients with
Significantly IMPaired Left-VentrIcular Ejection Fraction for
Transcatheter Aortic Valve
Implantation Study.
Form is used in following visits: 
- Baseline
- Procedure day 0
- Visit 1 (6h +-2h)
- Visit 2 (24h +-8h)
- Visit 3 (72h +-12h)
- Visit 4 (7 days +1d)
- Visit 5 (30 days +15d)
- Visit 6 (180 day +-30d)
- Visit 7 (1 year +1m)
Projektleiter (LKP):
Prof. Dr. med. Georg Nickenig
Medizinische Klinik und Poliklinik II
Sigmund-Freud-Str. 25, 53125 Bonn
Tel. 0228-287-15217, Fax 0228-287-16423
Email: georg.nickenig@ukb.uni-bonn.de
All rights reserved. Please visit https://medical-data-
models.org/forms/13298
ECG NCT01539746
Date of visit
Date of visit
ECG
Date ECG
Rhythm
sinus rhythm (1)
atrial fibrillation (2)
pacemaker (3)
other (4)
Heart frequency
/Min
Left bundle-branch block
Yes
No
Right bundle-branch block
Yes
No
AV block
Grade I (1)
Grade II Type 1 (2)
Grade II Type 2 (3)
Grade III (4)
1 / 1
Eligibility Breast Cancer NCT00200174
Combined Estrogen Blockade of the Breast With
Exemestane and Raloxifene in Postmenopausal Women
With a History of Breast Cancer Who Have No Clinical
Evidence of Disease; ODM derived from:
https://clinicaltrials.gov/show/NCT00200174
All rights reserved. Please visit https://medical-data-
models.org/forms/13299
Eligibility Breast Cancer
NCT00200174
Inclusion Criteria
postmenopausal women with a history of ajcc
stage 0, i, ii or iii breast cancer, with no clinical
evidence of disease, after completion of all
planned adjuvant therapy. patients must not have
received anti-estrogen therapy as part of their
adjuvant treatment. patients with a history of
invasive er- and/or pr-positive breast cancer are
eligible only if they have not received an anti-
estrogen as part of adjuvant therapy, and they are
at least 2 years from the time of their primary
surgery.*
Yes
No
patients must have completed all planned
adjuvant therapy, including surgery,
chemotherapy, and radiation therapy, at least 4
weeks prior to treatment.  there is no limit as to
the amount of time that may have passed since
completion of adjuvant therapy and initiation of
treatment.*
Yes
No
patients must be postmenopausal, as defined by
either:*
Yes
No
1. no spontaneous menses for at least 5 years;
women who have had a hysterectomy in this
group, but have intact ovaries must have
luteinizing hormone (lh) and follicle-stimulating
hormone (fsh) levels within the postmenopausal
range*
Yes
No
2. spontaneous menses within the past 5 years,
but amenorrheic (e.g. spontaneous or secondary
to chemotherapy, radiation therapy or
hysterectomy) for at least 12 months, and
luteinizing hormone (lh) and follicle-stimulating
hormone (fsh) levels within the postmenopausal
range*
Yes
No
3. bilateral oophorectomy*
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Yes
No
patients must have a history of breast cancer
confirmed by the department of pathology at
memorial sloan-kettering cancer center.*
Yes
No
patients must be at least 18 years old, and must
be able to give written informed consent.*
Yes
No
karnofsky performance status > 80%.*
Yes
No
laboratory parameters:*
Yes
No
wbc =>3.0 x 106 cells/ml serum bilirubin <= 1.5
mg/dl serum creatinine <= 1.5 mg/dl serum ast
(sgot) <= 2x upper institutional normal cea and
ca15-3 within institutional normal limits*
Yes
No
Exclusion Criteria
prior history of bilateral mastectomy.*
Yes
No
prior history of ovarian or endometrial cancer.*
Yes
No
prior or current history of osteoporosis, as
defined by a lumbar-spine bone mineral density <
2.5 sd below the mean value for normal
premenopausal women.*
Yes
No
use of bisphosphonates or calcitonin within the
past 3 months.*
Yes
No
prior history of venous thrombosis or pulmonary
embolism.*
Yes
No
patients with unstable angina or new york heart
association class iii or iv heart disease.*
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Eligibility Breast Cancer NCT00200174
Yes
No
prior hormonal therapy within the past 3 months.*
Yes
No
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Eligibility Parkinson Disease NCT00036205
Open Label Sumanirole Study of Safety, Tolerability, and
Therapeutic Response In Patients With Parkinson's
Disease; ODM derived from:
https://clinicaltrials.gov/show/NCT00036205
All rights reserved. Please visit https://medical-data-
models.org/forms/13300
Eligibility Parkinson Disease
NCT00036205
Inclusion Criteria
idiopathic parkinson's disease*
Yes
No
modified hoehn and yahr scale stages 1-4*
Yes
No
age over 30 years*
Yes
No
previous participation in prior sumanirole studies*
Yes
No
Exclusion Criteria
use of dopamine agonist medications and other
medications in defined timeframe*
Yes
No
unstable dose of cns active therapies (eg,
hypnotics, antidepressants, anxiolytics) within the
last 30 days*
Yes
No
atypical parkinson's syndromes due to drugs,
metabolic disorders, encephalitis, or degenerative
diseases*
Yes
No
dementia*
Yes
No
history of active epilepsy within the past year*
Yes
No
significant liver disease with defined laboratory
criteria*
Yes
No
significant renal disease with defined laboratory
criteria*
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Yes
No
certain cardiac conditions*
Yes
No
electroconvulsive therapy in the previous 90
days*
Yes
No
subjects participating in other drug studies or
receiving other investigational drugs within
previous 30 days*
Yes
No
positive pregnancy test at screen*
Yes
No
unwillingness to use adequate contraceptive
methods*
Yes
No
lactating women*
Yes
No
history of stereotaxic brain surgery*
Yes
No
malignant melanoma or history of treated
melanoma*
Yes
No
2 / 2
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Eligibility Breast Cancer NCT00392184
Partial Breast Irradiation With Multi-Catheter Brachytherapy
for pT1-2pN0 Breast Cancer After Breast Conserving
Surgery; ODM derived from:
https://clinicaltrials.gov/show/NCT00392184
All rights reserved. Please visit https://medical-data-
models.org/forms/13301
Eligibility Breast Cancer
NCT00392184
Inclusion Criteria
pt1/2 (≤ 3 cm)*
Yes
No
pn0 or pn1 mi*
Yes
No
m0 and no contralateral bc*
Yes
No
clear margins (≥ 2 mm)*
Yes
No
age ≥ 35 years*
Yes
No
er and/or pr positive*
Yes
No
Exclusion Criteria
multifocality or multicentricity*
Yes
No
eic*
Yes
No
lymphovascular invasion*
Yes
No
poorly differentiated tumors*
Yes
No
diffuse microcalcifications*
Yes
No
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Eligibility Breast Cancer NCT00392184
Partial Breast Irradiation With Multi-Catheter Brachytherapy
for pT1-2pN0 Breast Cancer After Breast Conserving
Surgery; ODM derived from:
https://clinicaltrials.gov/show/NCT00392184
All rights reserved. Please visit https://medical-data-
models.org/forms/13302
Eligibility Breast Cancer
NCT00392184
Inclusion Criteria
pt1/2 (≤ 3 cm)*
Yes
No
pn0 or pn1 mi*
Yes
No
m0 and no contralateral bc*
Yes
No
clear margins (≥ 2 mm)*
Yes
No
age ≥ 35 years*
Yes
No
er and/or pr positive*
Yes
No
Exclusion Criteria
multifocality or multicentricity*
Yes
No
eic*
Yes
No
lymphovascular invasion*
Yes
No
poorly differentiated tumors*
Yes
No
diffuse microcalcifications*
Yes
No
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Eligibility Parkinson's Disease
NCT00006077
Effects of Monoamine Reuptake Inhibitor NS2330 in
Parkinson's Disease; ODM derived from:
https://clinicaltrials.gov/show/NCT00006077
All rights reserved. Please visit https://medical-data-
models.org/forms/13303
Eligibility Parkinson's Disease
NCT00006077
Inclusion Criteria
male and females are eligible for this study.*
Yes
No
ages 18-75.*
Yes
No
women must be at least one year post-
menopausal or using an adequate contraceptive
method for at least one month prior to and during
participation in the study.*
Yes
No
all will carry the diagnosis of idiopathic
parkinson's disease based on the presence of a
characteristic clinical history and neurologic
findings.*
Yes
No
all will have relatively advanced disease with
levodopa-associated motor response
complications, including wearing-off fluctuations
and peak-dose dyskinesias.*
Yes
No
Exclusion Criteria
the  presence or history of any medical condition
that can reasonably be expected to subject the
patient to unwarranted risk.*
Yes
No
any clinically significant laboratory abnormalities
including liver enzyme elevations more than twice
the upper limit of normal, or neutropenia (wbc
less than 4000).*
Yes
No
patients with diphasic or end-of dose dyskinesias
or disabling dystonia.*
Yes
No
patients who are unable to be treated with
levodopa/carbidopa alone or a single, relatively
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short-acting dopamine agonist.*
Yes
No
patients with any form of parkinsonism other than
idiopathic pd or with a diagnosis of dementia or
major psychiatric disorder.  individuals with mild
to moderate depression will be sought for this
study, unless their depressive disorder currently
requires regular medical therapy.*
Yes
No
patients who are on unacceptable
prior/concomitant medications.*
Yes
No
pregnant women*
Yes
No
those who are not practicing effective birth
control.*
Yes
No
patients with prior bilateral neurosurgical
intervention for the treatment of parkinsonian
symptoms, i.e. deep brain stimulation,
pallidotomy, fetal tissue transplantation as well as
patients at risk for symptomatic hypotension,
cardiac arrhythmia, and/or myocardial ischemia
secondary to intravenous levodopa challenge or
ns2330 therapy.*
Yes
No
patients who have taken an investigational drug
within the last two months prior to
randomization.*
Yes
No
previous participation in any ns 2330 study.*
Yes
No
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Eligibility Parkinson's Disease
NCT00203034
Multicenter Study of Rasagiline in Parkinson's Disease
Patients Using Levodopa and Experiencing Motor
Fluctuations; ODM derived from:
https://clinicaltrials.gov/show/NCT00203034
All rights reserved. Please visit https://medical-data-
models.org/forms/13304
Eligibility Parkinson's Disease
NCT00203034
Inclusion Criteria
men and women with idiopathic parkinson's
disease whose diagnosis is confirmed by at least
two of the cardinal signs (resting tremor,
bradykinesia, rigidity) being present, without any
other known or suspected cause of
parkinsonism.*
Yes
No
subjects must experience levodopa related motor
fluctuations averaging at least 2.5 hours daily in
the off state.*
Yes
No
subjects must be taking optimized
levodopa/carbidopa or levodopa /benserazide
carbidopa/levodopa therapy (based on
investigator's judgment), stable for at least 14
days prior to baseline.  subjects must be
receiving at least 3 daily doses of levodopa, not
including a bedtime dose.*
Yes
No
selegiline must be discontinued for at least 90
days prior to baseline.*
Yes
No
subject must be age 30 or older.*
Yes
No
subjects must be willing and able to give informed
consent.*
Yes
No
Exclusion Criteria
subjects with a clinically significant or unstable
medical or surgical condition which would
preclude safe and complete study participation.
such conditions may include cardiovascular,
pulmonary, hepatic, renal, or metabolic diseases
or malignancies as determined by medical
history, physical exam, laboratory tests, chest x-
ray, or ecg for parkinson's disease [e.g.,
pallidotomy, thalamotomy, and deep brain
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stimulation (dbs)] within the 12 months preceding
the baseline visit.*
Yes
No
subjects who have undergone neurosurgical
transplantation are excluded regardless of when
the procedure(s) was performed.  no
programming changes are permitted in subjects
who have undergone dbs.*
Yes
No
participation in a previous clinical trial of
rasagiline. concomitant therapy with mao
inhibitors, reserpine, methyldopa within the past
three months, or treatment with an anti-emetic or
neuroleptic medication with central dopamine
antagonist activity with the past six months.*
Yes
No
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Eligibility Persistent Atrial Fibrillation
NCT00845780
Withdrawal Versus Continuation of Amiodarone in
Successfully Treated Patients With Persistent Atrial
Fibrillation; ODM derived from:
https://clinicaltrials.gov/show/NCT00845780
All rights reserved. Please visit https://medical-data-
models.org/forms/13305
Eligibility Persistent Atrial Fibrillation
NCT00845780
Inclusion Criteria
history of persistent atrial fibrillation,
necessitating at least one electrical
cardioversion*
Yes
No
presence of sinus rhythm during the last 6
months, while on amiodarone treatment without
adverse events related to amiodarone*
Yes
No
clinically stable*
Yes
No
age > 18 years*
Yes
No
written informed consent*
Yes
No
Exclusion Criteria
sinus rhythm maintenance is preferable (because
of atrial fibrillation related morbidity or any other
reason)*
Yes
No
symptomatic heart failure nyha iii or iv*
Yes
No
unstable angina pectoris*
Yes
No
hemodynamically significant valvular disease*
Yes
No
concomitant treatment with other class i or iii
antiarrhythmic drug*
Yes
No
pci,cabg, other cardiac surgery or major non-
1 / 2
cardiac surgery within the last three months*
Yes
No
recent myocardial infarction (< 3 months)*
Yes
No
presence of any disease that is likely to shorten
life expectancy to < 1 year*
Yes
No
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Eligibility Pre-dialysis NCT00527137
NESP Pediatric Study; ODM derived from:
https://clinicaltrials.gov/show/NCT00527137
All rights reserved. Please visit https://medical-data-
models.org/forms/13306
Eligibility Pre-dialysis NCT00527137
Inclusion Criteria
1 to 18 years of age*
Yes
No
esrd receiving dialysis or cri with egfr less than
30 ml/min*
Yes
No
baseline hemoglobin 9.5 - 12.5 g/dl and iron
replete*
Yes
No
stable rhuepo therapy for 8 weeks*
Yes
No
Exclusion Criteria
scheduled for a living-related kidney transplant*
Yes
No
uncontrolled blood pressure*
Yes
No
seizure activity*
Yes
No
hyperparathyroidism*
Yes
No
major surgery within 12 weeks or active
inflammatory disease*
Yes
No
currently receiving antibiotics*
Yes
No
clinical evidence of malignancy*
Yes
No
pregnant or breast-feeding*
Yes
No
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Eligibility Breast Cancer NCT00588029
Collection of Tissue, Blood, and Cells to Be Used For
Studying the Causes, Prevention, Diagnosis, and Treatment
of Breast Cancer; ODM derived from:
https://clinicaltrials.gov/show/NCT00588029
All rights reserved. Please visit https://medical-data-
models.org/forms/13307
Eligibility Breast Cancer
NCT00588029
Inclusion Criteria
for acquisition of existing breast cancer tissue
specimens from the mskcc tissue procurement
service, the only criteria are a pathologically-
confirmed diagnosis of invasive breast cancer
and the availability of corresponding
nonmalignant tissue from each case.*
Yes
No
for the prospective acquisition of blood or saliva
from control subjects without breast cancer,
eligibility criteria include:*
Yes
No
any patient with a previous diagnosis of invasive
breast cancer who undergoes a palliative
procedure related to the presence of a pleural
effusion is eligible for the pleural fluid collection
aspect of this protocol.*
Yes
No
any female patient, or any female over the age of
18 accompanying a patient under the care of a
physician in the department of urology,
department of surgery, or department of
medicine.*
Yes
No
subjects will have no history of preinvasive
(carcinoma in situ) or invasive breast cancer.*
Yes
No
subjects will be eligible without regard to racial, or
ethnic status. attending physicians authorized to
obtain informed consent may exercise discretion
in excluding individuals for appropriate medical or
other (e.g., mentally impaired) reasons.*
Yes
No
for the prospective acquisition of blood, saliva,
pleural fluid or cerebrospinal fluid from patients
who have or are suspected of having breast
cancer or carcinoma in-situ, eligibility criteria
include:*
Yes
No
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any patient at mskcc with a previously confirmed
or suspected diagnosis of malignant or
premalignant (e.g., carcinoma in situ) breast
disease is eligible for inclusion in the blood
acquisition aspect of this protocol.*
Yes
No
any patient with a previous diagnosis of invasive
breast cancer who undergoes a palliative
procedure related to the presence of a pleural
effusion is eligible for the pleural fluid collection
aspect of this protocol.*
Yes
No
any patient with a previous diagnosis of invasive
breast cancer with leptomeningeal metastasis
who undergoes a routine procedure associated
with the collection of cerebrospinal fluid is eligible
for the cerebrospinal fluid collection aspect of this
protocol.*
Yes
No
all subjects must be under the care of one or
more members of the mskcc breast disease
management team at the time of enrollment.*
Yes
No
subjects may have received prior hormonal
therapy, cytotoxic chemotherapy, radiation
therapy, or surgical therapy at mskcc or another
institution.*
Yes
No
all subjects must be 18 years or older*
Yes
No
subjects will be eligible without regard to sex,
racial, or ethnic status.   it is anticipated that
approximately 99% of the patients will be female.
attending physicians authorized to obtain
informed consent may exercise discretion in
excluding individuals for appropriate medical or
other (e.g., mentally impaired) reasons.*
Yes
No
if, after pathologic diagnosis, preinvasive or
invasive breast disease is not found, patients
previously consented for the blood collection
aspect of this protocol will not be included.*
Yes
No
2 / 3
Eligibility Breast Cancer NCT00588029
Exclusion Criteria
for the prospective acquisition of blood or saliva
from control subjects without breast cancer,
ineligibility criteria include:*
Yes
No
a first degree relative (mother, daughter, sister,
father, brother or son) who has been diagnosed
with breast cancer.*
Yes
No
a personal history of breast cancer, lobular
carcinoma in situ or atypia.*
Yes
No
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Eligibility Breast Cancer NCT00668616
Adjuvant Treatment of Breast Cancer With 1-3 Aflicted
Lymph Nodes; ODM derived from:
https://clinicaltrials.gov/show/NCT00668616
All rights reserved. Please visit https://medical-data-
models.org/forms/13308
Eligibility Breast Cancer
NCT00668616
Inclusion Criteria
women with histologically proven breast cancer
(pt1/pt2/pt3, pn1, n0)*
Yes
No
ecog performance status 0-1*
Yes
No
start of adjuvant therapy not later than 4 weeks
after surgery*
Yes
No
hematology: platelets at least 100xgpt/l,
neutrophiles  at least 2xgpt/l*
Yes
No
normal liver function as defined by: bilirubine till
1.5 x normal value, sgot/sgpt till 1.25 x normal
value*
Yes
No
normal kidney function as defined by: creatine till
1.5 x normal value*
Yes
No
negative pregnancy test for patients before
menopause and effective contraception*
Yes
No
written informed consent*
Yes
No
Exclusion Criteria
prior radiation, chemotherapy, hormontherapy
and immunotherapy*
Yes
No
patients with more than 3 afflicted lymph nodes*
Yes
No
afflicted lymph nodes on the cantralateal side
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and/or afflicted supraclavicular or intraclavicular
lymph nodes*
Yes
No
bilateral breast cancer or second carcinoma of
the breast*
Yes
No
inflammatory breast cancer and/or distant
metastases*
Yes
No
existing clinically relevant peripheral neuropathie*
Yes
No
heart infection during the last 6 months or
therapeutically not compensated heart failure or
cardiac arrhythmias of at least lown ii*
Yes
No
patients with active infections and/or not
controlled hypercalcemia*
Yes
No
pregnant or breastfeeding women or women of
child-bearing age who do not use effictive
contrazeptiva*
Yes
No
2 / 2
Eligibility Breast Cancer NCT00668616
Eligibility Breast Cancer NCT00724386
Concomitant Chemoradiotherapy With Weekly Paclitaxel
and Vinorelbine and Granulocyte Colony Stimulating Factor
(GCSF) Support in Patients With Advanced Breast Cancer;
ODM derived from:
https://clinicaltrials.gov/show/NCT00724386
All rights reserved. Please visit https://medical-data-
models.org/forms/13309
Eligibility Breast Cancer
NCT00724386
Inclusion Criteria
histologically or cytologically confirmed
adenocarcinoma of the male or female breast
(male or female) with gross, uncontrolled,
unresectable breast and/or chest wall disease
including:*
Yes
No
1. patients with locally advanced unresectable
stage iiia or iiib;*
Yes
No
2. patients with locally recurrent (including
locoregional lymph nodes) disease for which
curative surgery is not thought possible*
Yes
No
3. patients with metastatic disease and
uncontrolled locoregional disease are eligible.*
Yes
No
prior chemotherapy allowed, except for
nitrosoureas and mitomycin chemotherapy or
high dose chemotherapy with marrow or stem cell
rescue.*
Yes
No
prior palliative radiation to sites of metastases
allowed (i.e. bone, brain, lung)*
Yes
No
4 weeks since any prior treatments (excluding
hormonal therapy).  concurrent hormonal therapy
is not allowed.*
Yes
No
aged 18 years or older*
Yes
No
calgb performance status of 0 - 2*
Yes
No
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life expectance of at least 12 weeks*
Yes
No
initial laboratory data:*
Yes
No
anc count > 1500/mm3*
Yes
No
platelet count > 100,000/mm3*
Yes
No
creatine ≤ 2.0 mg/dl*
Yes
No
bilirubin ≤ 1.5 mg/dl*
Yes
No
alt (sgpt) ≤ 3 times the upper limit of normal*
Yes
No
signed informed consent*
Yes
No
Exclusion Criteria
prior breast or chest wall radiation is not allowed
unless the proposed site radiation port does not
overlap with prior ports*
Yes
No
subjects must not be pregnant (females able to
have children must have negative pregnancy test
and agree to use adequate contraception)*
Yes
No
patients with a documented hypersensitivity to
e.coli derived proteins are excluded.*
Yes
No
no other serious medical condition such as
uncontrolled infection that in the opinion of the
investigators places patient at undue risk for
study treatment*
Yes
No
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Eligibility Breast Neoplasm NCT00001806
Methods in Education for Breast Cancer Genetics; ODM
derived from: https://clinicaltrials.gov/show/NCT00001806
All rights reserved. Please visit https://medical-data-
models.org/forms/13310
Eligibility Breast Neoplasm
NCT00001806
Criteria
at least one of the following:*
Yes
No
diagnosis of breast cancer, or dcis prior to or at
45, or ovarian cancer prior to or at age 50;*
Yes
No
diagnosis of breast cancer with bilateral disease
or multiple primaries or breast cancer and
ovarian cancer in the same individual;*
Yes
No
diagnosis of breast or ovarian cancer and one
first or second degree relative with breast cancer
diagnosed prior to or at age 45, or ovarian cancer
prior to or at age 50;*
Yes
No
diagnosis of breast or ovarian cancer and three
relatives in the same lineage with breast or
ovarian cancer; each affected individual must be
a first- or second-degree relative to another of the
affected individuals;*
Yes
No
diagnosis of breast or ovarian cancer and a first
or second degree male relative with breast
cancer;*
Yes
No
a woman of ashkenazi jewish descent who meets
any of the above criteria, with specified ages of
onset of 50 for breast cancer and any age for
ovarian cancer;*
Yes
No
a male with breast cancer diagnosed at any age;*
Yes
No
documented brca mutation in the family.*
Yes
No
all individuals must be able to give informed
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consent.*
Yes
No
Exclusion Criteria
patients will be considered ineligible for any of the
following reasons:*
Yes
No
any psychological disorder which may hinder the
participant's ability to understand and process the
material, based on a psychiatric consultation.*
Yes
No
inable to return for 2 visits.*
Yes
No
age under 18 years old.*
Yes
No
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Echocardiography SIMPLIFy TAVI Transcatheter Aortic
Valve Implantation Without Predilation NCT01539746
Use of the Self-Expanding CoreValve Prosthesis without
Predilation in Patients with
Significantly IMPaired Left-VentrIcular Ejection Fraction for
Transcatheter Aortic Valve
Implantation Study.
Form is used in following visits: 
- Baseline
- Visit 4 (7 days +1d)
- Visit 5 (30 days +15d)
- Visit 6 (180 day +-30d)
- Visit 7 (1 year +1m)
Projektleiter (LKP):
Prof. Dr. med. Georg Nickenig
Medizinische Klinik und Poliklinik II
Sigmund-Freud-Str. 25, 53125 Bonn
Tel. 0228-287-15217, Fax 0228-287-16423
Email: georg.nickenig@ukb.uni-bonn.de
All rights reserved. Please visit https://medical-data-
models.org/forms/13311
Echocardiography NCT01539746
Date of visit
Date of visit
Transthoracal echocardiography
Date of transthoracal echocardiography
Velocity
m/s
Peak gradient
mmHg
Mean gradient
mmHg
Aortic valve area
cm^2
LVEF
%
sPAP
mmHg
Diameter of aortic valve anulus
mm
TEE 3D used
Yes
No
Degree of aortic valve insuffiency
none (0)
mild (1)
moderate (2)
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severe (3)
Degree of mitral valve insufficiency
none (0)
mild (1)
moderate (2)
severe (3)
Tricuspid valve insufficiency
none (0)
mild (1)
moderate (2)
severe (3)
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Echocardiography SIMPLIFy TAVI Transcatheter Aortic Valve
Implantation Without Predilation NCT01539746
Laboratory Tests SIMPLIFy TAVI Transcatheter Aortic
Valve Implantation Without Predilation NCT01539746
Use of the Self-Expanding CoreValve Prosthesis without
Predilation in Patients with
Significantly IMPaired Left-VentrIcular Ejection Fraction for
Transcatheter Aortic Valve
Implantation Study.
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- Baseline
- Visit 1 (6h +-2h)
- Visit 2 (24h +-8h)
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Laboratory Tests NCT01539746
Date of visit
Date of visit
Laboratory parameters
Date of laboratory tests
Haemoglobin
g/dL
Haemoglobin unit (if divergent)
Pathological value
Yes
No
Clinically relevant
Yes
No
Not done
Yes
No
Hematocrit
%
Hematocrit unit (if divergent)
Pathological value
Yes
No
Clinically relevant
Yes
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No
Not done
Yes
No
Platelets (G/l)
G/L
Platelets unit (if divergent)
Pathological value
Yes
No
Clinically relevant
Yes
No
Not done
Yes
No
Leucocytes
G/L
Leucocytes unit (if divergent)
Pathological value
Yes
No
Clinically relevant
Yes
No
Not done
Yes
No
Creatinine, Serum
mg/dL
Creatinine unit (if divergent)
Pathological value
Yes
No
Clinically relevant
Yes
No
Not done
Yes
No
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Laboratory Tests SIMPLIFy TAVI Transcatheter Aortic Valve Implantation
Without Predilation NCT01539746
CK-MB
ng/mL
CK-MB unit (if divergent)
Pathological value
Yes
No
Clinically relevant
Yes
No
Not done
Yes
No
Troponin
ng/mL
Troponin type
Type I (I)
Type T (T)
Troponin unit (if divergent)
Pathological value
Yes
No
Clinically relevant
Yes
No
Not done
Yes
No
BNP or NT-proBNP
BNP (1)
NT-proBNP (2)
BNP unit (if divergent)
Pathological value
Yes
No
Clinically relevant
Yes
No
Not done
Yes
No
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Laboratory Tests SIMPLIFy TAVI Transcatheter Aortic Valve Implantation
Without Predilation NCT01539746
Pacemaker Check SIMPLIFy TAVI Transcatheter Aortic
Valve Implantation Without Predilation NCT01539746
Use of the Self-Expanding CoreValve Prosthesis without
Predilation in Patients with
Significantly IMPaired Left-VentrIcular Ejection Fraction for
Transcatheter Aortic Valve
Implantation Study.
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- Visit 7 (1 year +1m)
Projektleiter (LKP):
Prof. Dr. med. Georg Nickenig
Medizinische Klinik und Poliklinik II
Sigmund-Freud-Str. 25, 53125 Bonn
Tel. 0228-287-15217, Fax 0228-287-16423
Email: georg.nickenig@ukb.uni-bonn.de
All rights reserved. Please visit https://medical-data-
models.org/forms/13314
Pacemaker Check NCT01539746
Date of visit
Date of visit
Check of pacemaker
Ventricular pacing > 10%?
Yes
No
Date
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Scores SIMPLIFy TAVI Transcatheter Aortic Valve
Implantation Without Predilation NCT01539746
Use of the Self-Expanding CoreValve Prosthesis without
Predilation in Patients with
Significantly IMPaired Left-VentrIcular Ejection Fraction for
Transcatheter Aortic Valve
Implantation Study.
Form is used in following visits: 
- Baseline
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Scores NCT01539746
Date of visit
Date of visit
Logist. EuroScore
Logist. EuroScore
%
Not done
Yes
No
STS mortality score
STS mortality score
%
Not done
Yes
No
ASA classification
ASA classification
I (I)
II (II)
III (III)
IV (IV)
not done (n.d.)
V (V)
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Neurological assessment SIMPLIFy TAVI Transcatheter
Aortic Valve Implantation Without Predilation NCT01539746
Use of the Self-Expanding CoreValve Prosthesis without
Predilation in Patients with
Significantly IMPaired Left-VentrIcular Ejection Fraction for
Transcatheter Aortic Valve
Implantation Study.
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Neurological assessment
NCT01539746
Date of visit
Date of visit
Neurological assessment
NIH stroke scale score
Points
Not done
Yes
No
Modified rankin scale score
0 (0)
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
not done (99)
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Adverse Events SIMPLIFy TAVI Transcatheter Aortic
Valve Implantation Without Predilation NCT01539746
Use of the Self-Expanding CoreValve Prosthesis without
Predilation in Patients with
Significantly IMPaired Left-VentrIcular Ejection Fraction for
Transcatheter Aortic Valve
Implantation Study.
Form is used in following visits: 
- Visit 1 (6h +-2h)
- Visit 2 (24h +-8h)
- Visit 3 (72h +-12h)
- Visit 4 (7 days +1d)
- Visit 5 (30 days +15d)
- Visit 6 (180 day +-30d)
- Visit 7 (1 year +1m)
Projektleiter (LKP):
Prof. Dr. med. Georg Nickenig
Medizinische Klinik und Poliklinik II
Sigmund-Freud-Str. 25, 53125 Bonn
Tel. 0228-287-15217, Fax 0228-287-16423
Email: georg.nickenig@ukb.uni-bonn.de
All rights reserved. Please visit https://medical-data-
models.org/forms/13317
Adverse Events NCT01539746
Date of visit
Date of visit
AE
Sepsis
Yes
No
Date
Pneumonia
Yes
No
Date
Re-Intubation
Yes
No
Date
Number of RBC transfusions
Did further AEs occur since the last visit?
Yes
No
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Endpoints SIMPLIFy TAVI Transcatheter Aortic Valve
Implantation Without Predilation NCT01539746
Use of the Self-Expanding CoreValve Prosthesis without
Predilation in Patients with
Significantly IMPaired Left-VentrIcular Ejection Fraction for
Transcatheter Aortic Valve
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Endpoints NCT01539746
Date of visit
Date of visit
Endpoints
Death
No (0)
Yes (1)
due to cardiovascular issue (2)
Date
Myocardial infarction
Yes
No
Date
TIA
Yes
No
Date
Acute kidney failure
Yes
No
Grading
Grade I (1)
Grad II (2)
Grade III (3)
Date
Implantation of pacemaker (or if already
implanted pacemaker - ventricular pacing < 10%)
Yes
No
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Date
Abnormal cardiac conduction
Yes
No
Date
Bleeding
Yes
No
Bleeding evaluation
mild (1)
severe (2)
life-threatening (3)
Date
Complications due to site of access
Yes
No
Date
Paravalvular aortic insuffiency
Yes
No
Paravalvular aortic insuffiency evaluation
mild (1)
moderate (2)
severe (3)
Another aortic valve intervention
Yes
No
Intervention type
TAVI (1)
OP (2)
Date
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Endpoints SIMPLIFy TAVI Transcatheter Aortic Valve Implantation
Without Predilation NCT01539746
Medication SIMPLIFy TAVI Transcatheter Aortic
Valve Implantation Without Predilation NCT01539746
Use of the Self-Expanding CoreValve Prosthesis without
Predilation in Patients with
Significantly IMPaired Left-VentrIcular Ejection Fraction for
Transcatheter Aortic Valve
Implantation Study.
Form is used in following visits: 
- Visit 4 (7 days +1d)
- Visit 5 (30 days +15d)
- Visit 6 (180 day +-30d)
- Visit 7 (1 year +1m)
Projektleiter (LKP):
Prof. Dr. med. Georg Nickenig
Medizinische Klinik und Poliklinik II
Sigmund-Freud-Str. 25, 53125 Bonn
Tel. 0228-287-15217, Fax 0228-287-16423
Email: georg.nickenig@ukb.uni-bonn.de
All rights reserved. Please visit https://medical-data-
models.org/forms/13326
Medication NCT01539746
Medication
ASS
Yes
No
Clopidogrel
Yes
No
Beta-blocker
Yes
No
ACE inhibitor or angiotensin-receptor-antagonist
Yes
No
Diuretics
Yes
No
Aldosteron-antagonist
Yes
No
Calcium antagonist
Yes
No
Digoxin/ Digitoxin
Yes
No
Statins
Yes
No
Oral anticoagulation therapy
Yes
No
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Final Exam SIMPLIFy TAVI Transcatheter Aortic
Valve Implantation Without Predilation NCT01539746
Use of the Self-Expanding CoreValve Prosthesis without
Predilation in Patients with
Significantly IMPaired Left-VentrIcular Ejection Fraction for
Transcatheter Aortic Valve
Implantation Study.
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- Completion of the study
- Study termination/ Drop-out
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Final Exam NCT01539746
Date of visit
Date of visit
Study completion
Was the study completion according the protocol
in regular way?
Yes
No
Termination of study participation
Date of study termination (in case of early
termination of study participation)
Reason for early study termination
death (1)
withdrawal of informed consent (2)
other reason (3)
Date of death
If applicable,  please specify: Death due to
primary disease (1)
(S)AE (2)
Date of last regular study visit?
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Eligibility Acute Myelogenous Leukemia (AML) - Relapsed,
Primary Refractory Disease or Poor Risk Factors NCT00185679
Haploid Allogeneic Transplant Using the CliniMACS
System; ODM derived from:
https://clinicaltrials.gov/show/NCT00185679
All rights reserved. Please visit https://medical-data-
models.org/forms/13335
Eligibility Acute Myelogenous
Leukemia (AML) - Relapsed, Primary
Refractory Disease or Poor Risk
Factors NCT00185679
Inclusion Criteria Recipient
Histopathologically-confirmed diagnosis of
hematological or lymphatic malignancy, defined
as one of the following:*
Yes
No
Acute myeloid leukemia (aml) as primary
refractory disease, or in relapse*
Yes
No
acute leukemia in first remission with poor risk
factors and molecular prognosis*
Yes
No
aml with -5,-7, t(6;9), tri8, -11*
Yes
No
acute lymphocytic / lymphoblastic leukemia (all)
with phil+ t(9;22),(q34;q11.2), and
t(4:11)(q21;23)*
Yes
No
Chronic myelogenous leukemia (cml in
accelerated, second chronic phase)*
Yes
No
Myelodysplastic syndrome with high intermediate
to high risk categories*
Yes
No
Non-hodgkin's lymphoma (nhl)*
Yes
No
Chronic lymphocytic leukemia (cll), refractory*
Yes
No
Creatinine clearance > 50 ml/min for those above
serum creatinine of 1.5  mg/dl,  serum bilirubin <
2.0 mg/dl, alt < 2x uln (unless secondary to
disease)*
Yes
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No
< 50 years old at time of registration
Yes
No
Donor is related, Donor is genotypically-matched
and haploidentical for HLA-A, B,C and DRB1, DQ
loci Donor differs for 2 or 3 HLA alleles on the
unshared haplotype in the GvHD direction
Yes
No
No HLA-matched sibling or matched unrelated
donor is identified
Yes
No
ECOG performance status not more than 2
Yes
No
LVEF
Yes
No
DLCO > 50%
Yes
No
Corrected for hemoglobin Serum creatinine < 1.5
mg/dL
Yes
No
Females of childbearing potential must have a
negative serum or urine beta-HCG test within 3
weeks of registration
Yes
No
No prior cancer within 5 years with the exception
of surgically-cured, non-melanoma skin cancer or
in situ cancer of the cervix
No prior myeloablative therapy or transplant
Yes
No
Duly-executed informed consent
Yes
No
Exclusion Criteria Recipient
Suitable candidate for autologous transplantation
Yes
No
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Eligibility Acute Myelogenous Leukemia (AML) - Relapsed, Primary
Refractory Disease or Poor Risk Factors NCT00185679
Participation in other investigational drugs or
devices trials that might influence the study
endpoints
Yes
No
Evidence of active hepatitis
Yes
No
Evidence of active cirrhosis
Yes
No
HIV-positive
Yes
No
History of invasive aspergillosis
Yes
No
Presence of any other uncontrolled, active
infection, ie, bacterial, viral or fungal
Yes
No
Uncontrolled CNS involvement
Yes
No
Documented allergy to murine proteins
Yes
No
Documented allergy to iron dextran
Yes
No
Female of child-bearing potential unwilling to
implement adequate birth control
Yes
No
Medical problem / neurologic/psychiatric
dysfunction which would impair his/her ability to
be compliant with the medical regimen and/or to
tolerate transplantation, in the opinion of the
principal investigator
Yes
No
Medical problem / neurologic/psychiatric
dysfunction which would prolong hematologic
recovery and place the recipient at unacceptable
risk, in the opinion of the principal investigator
would
Yes
No
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Eligibility Acute Myelogenous Leukemia (AML) - Relapsed, Primary
Refractory Disease or Poor Risk Factors NCT00185679
Inclusion Criteria Donor
Age < 60 years
Yes
No
Weight > 25 kg
Yes
No
Medical history and physical examination confirm
good health status as defined by institutional
standards
Yes
No
Within 30 days of apheresis collection,
seronegative for HIV assessed as HIV Ag; HIV
1+2 Ab; or HTLV I/II Ab
Yes
No
Within 30 days of apheresis collection,
seronegative for hepatitis assessed as HBsAg;
HBcAb (IgM and IgG); or HCV Ab
Yes
No
Within 30 days of apheresis collection,
seronegative for syphilis assessed as RPR
Yes
No
Genotypically haploidentical as determined by
HLA typing
Yes
No
Female donors of child-bearing potential must
have a negative serum or urine beta-HCG test
within 3 weeks of mobilization
Yes
No
Capable of undergoing leukapheresis, Has
adequate venous access
Yes
No
Willing to undergo insertion of a central catheter
should leukapheresis via peripheral vein be
inadequate
Yes
No
Agreeable to second donation of PBPC (or a
bone marrow harvest) should the recipient fail to
demonstrate sustained engraftment following the
transplant
Yes
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Eligibility Acute Myelogenous Leukemia (AML) - Relapsed, Primary
Refractory Disease or Poor Risk Factors NCT00185679
No
Duly-executed informed consent
Yes
No
Screened for CMV seroreactivity
Yes
No
Exclusion Criteria Donor
Evidence of active infection (including urinary
tract infection, or upper respiratory tract infection)
Yes
No
Evidence of hepatitis (on screening)
Yes
No
Medical, physical or psychological reason which
makes the donor unlikely to tolerate or cooperate
with growth factor therapy and leukapheresis
Yes
No
Factors placing donor at increased risk for
leukapheresis or G-CSF-related complications
Yes
No
Lactating female, Female of child-bearing
potential unwilling to implement adequate birth
control
Yes
No
HIV-positive
Yes
No
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Eligibility Acute Myelogenous Leukemia (AML) - Relapsed, Primary
Refractory Disease or Poor Risk Factors NCT00185679
Eligibility Acute Myocardial Infarction
NCT00187460
Study of the Effectiveness of Report Cards on the Quality
of Care for Heart Attack and Heart Failure Patients; ODM
derived from: https://clinicaltrials.gov/show/NCT00187460
All rights reserved. Please visit https://medical-data-
models.org/forms/13336
Eligibility Acute Myocardial Infarction
NCT00187460
Inclusion Criteria
Hospital: treat > 30 ami/chf cases/patients per
year in ontario*
Yes
No
AMI most responsible diagnosis of acute
myocardial infarction(icd-9 code 410)*
Yes
No
CHF most responsible diagnosis of heart
failure(icd-9 code 428)*
Yes
No
Exclusion Criteria
AMI not admitted to an acute care hospital*
Yes
No
AMI age < 20 or > 105 years*
Yes
No
AMI invalid health card number*
Yes
No
AMI admitted to non-cardiac surgical service*
Yes
No
AMI transferred from another acute care facility*
Yes
No
AMI coded as an in-hospital complication*
Yes
No
AMI admission within the past year*
Yes
No
CHF not admitted to an acute care hospital*
Yes
No
CHF age < 20 or > 105 years*
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Yes
No
CHF invalid health card number*
Yes
No
CHF admitted to surgical service*
Yes
No
CHF transferred from another acute care facility*
Yes
No
CHF coded as an in-hospital complication*
Yes
No
CHF admission within the past three years*
Yes
No
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Eligibility Acute Myocardial Infarction NCT00187460
Eligibility Leukemia, Myelocytic, Acute
NCT00251368
Multicenter Study of 9-Aminocamptothecin (9-AC) in
Patients With Refractory Leukemia; ODM derived from:
https://clinicaltrials.gov/show/NCT00251368
All rights reserved. Please visit https://medical-data-
models.org/forms/13337
Eligibility Leukemia, Myelocytic,
Acute NCT00251368
Inclusion Criteria
18 years of age or older*
Yes
No
aml or all in first or subsequent relapse,
secondary aml, or cml in blastic phase*
Yes
No
central venous access*
Yes
No
ecog performance status of less than or equal to
2*
Yes
No
bilirubin < 1.3*
Yes
No
sgot < 2 x uln*
Yes
No
alkaline phosphatase < 2 x uln*
Yes
No
creatinine < 1.5*
Yes
No
Exclusion Criteria
undergone bone marrow transplantation*
Yes
No
uncontrolled infection*
Yes
No
other active malignancy*
Yes
No
hiv positivity*
Yes
No
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serious medical or psychiatric illness*
Yes
No
pregnancy*
Yes
No
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Eligibility Leukemia, Myelocytic, Acute NCT00251368
Eligibility Leukemia, Myeloid, Chronic
NCT00167167
Donor Lymphocyte Infusion (DLI) for Relapsed (Post
Transplant) Leukemia; ODM derived from:
https://clinicaltrials.gov/show/NCT00167167
All rights reserved. Please visit https://medical-data-
models.org/forms/13338
Eligibility Leukemia, Myeloid, Chronic
NCT00167167
Inclusion Criteria
patients with cml, aml, mds or all relapsed after
related or unrelated donor allogeneic marrow
transplantation.*
Yes
No
patients must be within one year of identification
of relapse or if beyond that time period, must
have some evidence of donor dna by rflp or
cytogenetics.*
Yes
No
patients may have evidence of relapse based on
molecular, cytogenetic or morphologic criteria.*
Yes
No
cml patients must have cytogenetic evidence of
relapse or if ph negative to start, obvious
evidence of relapse other than minimal residual
disease.*
Yes
No
patients must have <30% marrow blasts on a
marrow biopsy performed within two weeks of the
first donor lymphocyte infusion.*
Yes
No
patients with >30% blasts can become eligible for
donor lymphocytes after reinduction with any
standard therapy regimen.*
Yes
No
patients with aml, mds or all achieving a cr with
standard therapy regimens are eligible for this
protocol.*
Yes
No
patients who relapse with their initial disease or
develop a second malignancy after related or
unrelated donor allogeneic marrow
transplantation with other initial diagnoses (such
as but not limited to cll, lymphoma, myeloma,
juvenile cml, sarcoma, breast cancer) may also
be included in this protocol.  patients will be
eligible with or without other adjunct
chemotherapy or radiation therapy.  post-
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transplant lymphomas (often referred to as ebv-
associated lymphomas) will be eligible for donor
leukocyte infusions on this protocol.  treatment
with donor leukocytes under this protocol is
restricted to malignant diseases only.  graft failure
or relapse of non-malignant disorders is excluded
from receiving donor leukocyte infusions on this
protocol.  autologous transplant patients who
relapse are not eligible for this protocol.  patients
with malignant diseases amenable to other
curative therapy are not eligible (i.e. skin
cancers).*
Yes
No
Exclusion Criteria
patients with concurrent signs of acute or chronic
graft-versus-host disease requiring ongoing
treatment at the time of relapse will be ineligible.*
Yes
No
patients with >30% marrow blasts at the time of
therapy will be ineligible.*
Yes
No
patients on prednisone, cyclosporine, imuran or
other immunosuppressive medications are not
eligible until these medications are discontinued
for at least  2 weeks without a flare of gvhd.*
Yes
No
cml patients in complete cytogenetic remission
who are bcr/abl positive by pcr only are not
eligible.*
Yes
No
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Eligibility Leukemia, Myeloid, Chronic NCT00167167
CT Scan SIMPLIFy TAVI Transcatheter Aortic Valve
Implantation Without Predilation NCT01539746
Use of the Self-Expanding CoreValve Prosthesis without
Predilation in Patients with
Significantly IMPaired Left-VentrIcular Ejection Fraction for
Transcatheter Aortic Valve
Implantation Study.
Form is used in following visits: 
- Baseline
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CT Scan NCT01539746
Date of visit
Date of visit
CT scan
CT scan not done
Yes
No
Aortic valve anulus: max. diameter
mm
Aortic valve anulus: min. diameter
mm
Aortic valve anulus: perimeter
mm
Aortic valve anulus: area
mm^2
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Eligibility LOCALLY ADVANCED UNDIFFERENTIATED
CARCINOMA NASOPHARYNGEAL TYPE UCNT NCT00180973
PHASE III TRIAL COMPARING, NEOADJUVANT
CHEMOTHERAPY FOLLOWED BY STANDARD
RADIOTHERAPY VERSUS THE SAME NEOADJUVANT
CHEMOTHERAPY FOLLOWED BY STANDARD
RADIOTHERAPY ASSOCIATED WITH DAILY
HYDROXYUREA IN THE TREATMENT OF LOCALLY
ADVANCED UNDIFFERENTIATED CARCINOMA
NASOPHARYNGEAL TYPE.; ODM derived from:
https://clinicaltrials.gov/show/NCT00180973
All rights reserved. Please visit https://medical-data-
models.org/forms/13342
Eligibility LOCALLY ADVANCED
UNDIFFERENTIATED CARCINOMA
NASOPHARYNGEAL TYPE UCNT
NCT00180973
Inclusion Criteria
of either sex*
Yes
No
aged 15 to 70 years*
Yes
No
never previously treated with radiotherapy,
chemotherapy or surgery for malignant disease
(except neck adenectomy/diagnosis)*
Yes
No
with awho performance status * 2.*
Yes
No
amenable to regular follow-up*
Yes
No
capable of receiving chemotherapy and
radiotherapy : in particular, with no
contraindications to the use of anthracyclines,
bleomycin or cisplatinum.*
Yes
No
with informed consent at entry time, in writing or
witnessed oral informed consent, in accordance
with local legislation requirements.*
Yes
No
neutrophil count * 2000 /mm3 
platelet count * 150,000 /mm3 
hemoglobin * 10 g / dl*
Yes
No
Exclusion Criteria
histologic types other than type ii - iii of the who
1 / 2
classification*
Yes
No
t1 - t2 n0 - n1 or patients with metastatic*
Yes
No
aged < 15 or > 70.*
Yes
No
patients in whom chemotherapy is
contraindicated: history of myocardial infarction
over the last 6 months before inclusion, or
clinically present cardiac pathology.*
Yes
No
who performance status >2*
Yes
No
history of prior malignancies (other than non
melanoma skin cancer or excised cervical
carcinoma in situ).*
Yes
No
uncontrolled infection,*
Yes
No
patients refusing participation.*
Yes
No
patients who, for social, familial or geographic
reasons are unlikely to comply with a long term
follow-up.*
Yes
No
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Eligibility LOCALLY ADVANCED UNDIFFERENTIATED CARCINOMA
NASOPHARYNGEAL TYPE UCNT NCT00180973
Eligibility Major Depression NCT00427128
Prozac Treatment of Major Depression: Discontinuation
Study; ODM derived from:
https://clinicaltrials.gov/show/NCT00427128
All rights reserved. Please visit https://medical-data-
models.org/forms/13343
Eligibility Major Depression
NCT00427128
Inclusion Criteria
1. men and women ages 18-65*
Yes
No
2. meets criteria for dsm iv major depression*
Yes
No
3. signs informed consent and able to comply
with study*
Yes
No
Exclusion Criteria
1. pregnant women and women of child-bearing
potential who are not using a medically accepted
means of contraception.*
Yes
No
2. women taking oral contraceptives, the initiation
of which was temporally associated with the
onset of depression; women who are breast-
feeding.*
Yes
No
3. patients with serious suicidal risk, including
any patient who became suicidal with previous
discontinuation of an antidepressant.*
Yes
No
4. patients with a history of seizure disorder.*
Yes
No
5. patients with unstable physical disorders
(cardiovascular, hepatic, renal, respiratory,
endocrine, neurologic, or hematologic) or any
physical disorder judged to significantly affect cns
function.*
Yes
No
6. patients meeting criteria for the following dsm-
iv diagnoses: organic mental disorders;
substance use disorders, including alcohol, active
within the last 6 months; schizophrenia;
delusional disorder; psychotic disorders; bipolar
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disorder; antisocial personality disorder; or
presence of psychotic features*
Yes
No
7. patients with a history of non-response to an
adequate trial of a selective serotonin reuptake
inhibitor in a past or current depressive episode,
defined as a four-week trial of a minimum of
40mg/day of fluoxetine or paroxetine, or
100mg/day of sertraline.*
Yes
No
8. concurrent use of exclusionary drugs*
Yes
No
9. clinical or laboratory evidence of
hypothyroidism without adequate stable
replacement (eg, low total t4 or elevated tsh by a
high sensitivity method).*
Yes
No
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Eligibility Major Depression NCT00427128
Eligibility Non-Hodgkin's Lymphoma
NCT00262210
A Comparative Study for Non-Hodgkin's Lymphoma in
Hepatitis B Virus Carriers; ODM derived from:
https://clinicaltrials.gov/show/NCT00262210
All rights reserved. Please visit https://medical-data-
models.org/forms/13344
Eligibility Non-Hodgkin's Lymphoma
NCT00262210
Criteria
1. histologically proven nhl, and for which
intensive chemotherapy is  considered treatment-
of-choice.*
Yes
No
2. hbsag-positive.*
Yes
No
3. no previous chemotherapy and radiotherapy.*
Yes
No
4. no concurrent radiotherapy. agc ≧ 2,000/mm3,
platelet ≧ 100,000/mm3 of peripheral blood.*
Yes
No
5. total bilirubin ≦ 2.5 mg/dl. alanine
aminotransferase (sgpt) ＜ 200 i.u/l*
Yes
No
6. serum creatinine ≦1.5 mg/dl blood urea
nitrogen (bun) ≦ 25 mg/dl*
Yes
No
7. objectively measurable or evaluable disease*
Yes
No
8. signed informed consent*
Yes
No
Exclusion criteria
age ＞ 75 years, or age ＜ 15 years
Yes
No
Pregnant or breast-feeding women.
Yes
No
brain metastasis or cns involvement
Yes
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No
child's class b or c, liver cirrhosis
Yes
No
impaired cardiac function with nyha classification
≧ grii.
Yes
No
concurrent glucocorticoids use
Yes
No
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Eligibility Non-Hodgkin's Lymphoma NCT00262210
Eligibility Non-Small Cell Lung Cancer
NCT00176137
Preoperative Twice Daily Chemoradiation in Addition to
Chemotherapy Prior to Surgery in Stage III Non-Small Cell
Lung Cancer (NSCLC); ODM derived from:
https://clinicaltrials.gov/show/NCT00176137
All rights reserved. Please visit https://medical-data-
models.org/forms/13345
Eligibility Non-Small Cell Lung
Cancer NCT00176137
Inclusion Criteria
non-small cell lung cancer proven by histology*
Yes
No
stage iiia / stage iiib*
Yes
No
mediastinoscopy*
Yes
No
performance score ecog 0,1*
Yes
No
predicted postoperative fev 1 > 1.0 l*
Yes
No
Exclusion Criteria
small cell lung cancer*
Yes
No
cardiac disability (nyha iii/iv)*
Yes
No
prior radio- or chemotherapy*
Yes
No
pregnancy*
Yes
No
other malignancy*
Yes
No
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Eligibility Parkinson Disease NCT00038116
Embryonic Dopamine Cell Implants for Parkinson's
Disease; ODM derived from:
https://clinicaltrials.gov/show/NCT00038116
All rights reserved. Please visit https://medical-data-
models.org/forms/13347
Eligibility Parkinson Disease
NCT00038116
Inclusion Criteria
idiopathic parkinson's disease of at least 7 years
duration and responsive to levodopa.  other
parkinson syndromes excluded.*
Yes
No
patients previously tried on other available forms
of medical treatment.*
Yes
No
age between 20 and 75 years.*
Yes
No
presence of an intractable problem, such as "off"
periods, dyskinesias, or "freezing," not controlled
by dopamine agonists such as levodopa or
pergolide.*
Yes
No
no serious depression and no cognitive
impairment.*
Yes
No
successful completion of home diary by patient or
responsible party.*
Yes
No
successful videotape recordings at home of "on"
and "off" status.*
Yes
No
normal mri of brain within the last 18 months.*
Yes
No
fluorodopa pet scan compatible with idiopathic
parkinson's disease.*
Yes
No
medically fit to undergo implant surgery with
certification by the patient's physician.*
Yes
No
able to financially cover expenses not paid for by
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nih grant (between $1,000 and*
Yes
No
$2,000 for unreimbursed travel, video camera,
and blood screening as specified in the consent
form.*
Yes
No
Exclusion Criteria
severe or moderately severe depression or
cognitive impairment.*
Yes
No
previous brain surgery.*
Yes
No
presence of diabetes mellitus, severe
cardiopulmonary disease or other severe medical
disease, or mri evidence of cerebrovascular
disease.*
Yes
No
not medically cleared to undergo a surgical
procedure.*
Yes
No
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Eligibility Parkinson Disease NCT00038116
Eligibility Prostate Cancer NCT00116220
Study of External Beam Radiation Therapy With and
Without Hormonal Therapy to Treat Prostate Cancer; ODM
derived from: https://clinicaltrials.gov/show/NCT00116220
All rights reserved. Please visit https://medical-data-
models.org/forms/13348
Eligibility Prostate Cancer
NCT00116220
Inclusion Criteria
biopsy proven prostate cancer*
Yes
No
negative bone scan*
Yes
No
lymph nodes by ct or mri*
Yes
No
adequate blood work*
Yes
No
performance status - ecog 0-1*
Yes
No
life expectancy of at least 10 years*
Yes
No
>40 years of age*
Yes
No
Exclusion Criteria
prior history of malignancy*
Yes
No
prior hormonal therapy or chemotherapy*
Yes
No
prior pelvic radiation therapy*
Yes
No
unable to tolerate lying still 5-10 minutes/day*
Yes
No
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Eligibility Therapy-related Acute Myeloid Leukemia
and Myelodysplastic Syndrome NCT02438761
PF-05212384 (PKI-587) for t-AML/MDS or de Novo
Relapsed or Refractory Acute Myeloid Leukemia (AML);
ODM derived from:
https://clinicaltrials.gov/show/NCT02438761
All rights reserved. Please visit https://medical-data-
models.org/forms/13349
Eligibility Therapy-related Acute
Myeloid Leukemia and
Myelodysplastic Syndrome
NCT02438761
Inclusion Criteria
Patients belong to one of three categories:*
Yes
No
Myeloid neoplasm secondary to chemo-
radiotherapy (t-aml/mds) aged 60 and over with
unfavorable cytogenetics (european leukemia
network definition 2010), the first cancer must
have been in remission for more than two years,
except in situ carcinoma, basal cell carcinoma
and squamous cell carcinoma*
Yes
No
relapsed or refractory de novo aml aged 18 and
over (multiple relapses allowed), regardless of the
risk group, provided not being eligible for
allogeneic bone marrow transplantation*
Yes
No
De novo aml at diagnosis, aged 60 and over and
considered unfit to benefit from induction
chemotherapy associated with aplasia (at the
discretion of the investigator)*
Yes
No
Adequate glycemic control defined by glycated
hemoglobin ≤ 8%*
%
Yes
No
Female of childbearing potential (fcbp) should
receive effective contraception: a negative
pregnancy blood test is required within 2 weeks
before starting experimental treatment.*
Yes
No
Eastern cooperative oncology group (ecog)
performance status (ps) ≤ 2*
Yes
No
Absence of severe or active infection*
Yes
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No
Adequate systolic cardiac function : left
ventricular ejection fraction (lvef) ≥ 50%*
Yes
No
Adequate hepatic function: aspartate
aminotransferase test (ast) and alanine
aminotransferase test (alt) ≤ 3 times the upper
limit of normal (uln), bilirubin ≤ 1,5 * upper limit of
normall*
Yes
No
Adequate renal function: serum creatinine ≤ 1.5 x
uln or calculated creatinine clearance > 60
ml/min.*
Yes
No
Signed informed consent*
Yes
No
Exclusion Criteria
Glucose intolerance or diabetes mellitus, treated
or untreated*
Yes
No
First cancer in evolution (solid tumor or
lymphoma) or in remission for less than two
years, except in situ carcinoma, basal cell
carcinoma and squamous cell carcinoma*
Yes
No
Aml secondary to mds or myeloproliferative
syndrome (who 2008 definitions)*
Yes
No
Acute promyelocytic leukaemia (apl or aml french
american british (fab) classification 3) de novo or
secondary to treatment (t-apl)*
Yes
No
De novo or secondary core binding factor
(cbf)/aml*
Yes
No
De novo or secondary philadelphia chromosome
(ph) 1 positive aml defined by the presence of a
t(9.22) or a breakpoint cluster region-abelson
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Eligibility Therapy-related Acute Myeloid Leukemia and Myelodysplastic
Syndrome NCT02438761
murine leukemia viral oncogene homolog (bcr-
abl) transcript*
Yes
No
Leukocytes above 30.000/mm3 (30 g/l) at
enrollment*
mm3
Yes
No
Antileukemic treatment within 15 days before
enrollment, with the exception of hydroxyurea*
Yes
No
Central nervous system leukemic involvement*
Yes
No
Pregnant or lactating women, or women of
childbearing potential without effective
contraception*
Yes
No
Prior history of allogeneic bone marrow
transplantation*
Yes
No
Prior history of organ transplantation or other
cause of severe or chronic immunodeficiency
human*
Yes
No
Seropositivity for human immunodeficiency virus
(hiv) or human t-lymphotropic virus-1 (htlv-1)
viruses, active b or c hepatitis*
Yes
No
Inclusion in another experimental anti-cancer
clinical trial*
Yes
No
Patients unable to undergo medical monitoring for
geographical, social or psychological issues*
Yes
No
Person under a legal protection measure*
Yes
No
No social security*
Yes
No
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Eligibility Therapy-related Acute Myeloid Leukemia and Myelodysplastic
Syndrome NCT02438761
For ethical reasons, the exclusion period before
considering the possibility of participating in
another clinical study with a new experimental
molecule cannot be determined, yet each case
will be discussed on an individual basis with the
study coordinator.*
Yes
No
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Eligibility Therapy-related Acute Myeloid Leukemia and Myelodysplastic
Syndrome NCT02438761
Eligibility Persistent Fetal Circulation
Syndrome NCT01891500
Early iNO for Oxidative Stress, Vascular Tone and
Inflammation in Babies With Hypoxic Respiratory Failure;
ODM derived from:
https://clinicaltrials.gov/show/NCT01891500
All rights reserved. Please visit https://medical-data-
models.org/forms/13350
Eligibility Persistent Fetal Circulation
Syndrome NCT01891500
Inclusion Criteria
Gestational age ≥ 35 weeks gestation*
Yes
No
Age ≤ 48 hours*
Yes
No
Diagnosis of hypoxic respiratory failure (hrf)*
Yes
No
Exclusion Criteria
Gestational age < 35 weeks gestation.*
Yes
No
Post-natal age > 48 hours.*
Yes
No
Previous treatment with 100% oxygen for more
than 4 hours.*
Yes
No
Confirmed congenital diaphragmatic hernia.*
Yes
No
Suspected or confirmed congenital airway or
pulmonary anomaly.*
Yes
No
Suspected or confirmed chromosomal anomaly
or genetic aberration, with the exception of
patients with trisomy 21 who do not have complex
congenital heart disease.*
Yes
No
Infants with pneumothorax as the primary cause
of their hrf.*
Yes
No
Infants with confirmed complex congenital heart
disease.*
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Yes
No
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Eligibility Persistent Fetal Circulation Syndrome NCT01891500
Eligibility Alzheimer Disease NCT00066157
Alzheimer's Disease: Therapeutic Potential of Estrogen;
ODM derived from:
https://clinicaltrials.gov/show/NCT00066157
All rights reserved. Please visit https://medical-data-
models.org/forms/13354
Eligibility Alzheimer Disease
NCT00066157
Inclusion Criteria
Postmenopausal women with alzheimer's disease
and without other dementias (diagnosed by study
staff or from an outside clinic)*
Yes
No
Mini mental state examination score greater than
15/30*
Yes
No
Exclusion Criteria
History of cancer of reproductive tissues*
Yes
No
History of deep vein thrombosis or blot clots*
Yes
No
Diabetes*
Yes
No
Heart disease or stroke*
Yes
No
Liver problems including hepatitis*
Yes
No
Severe vision or hearing problems*
Yes
No
Tobacco use*
Yes
No
Lack of an adequate caregiver*
Yes
No
Inability to perform psychometric testing*
Yes
No
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Eligibility Alzheimer Disease NCT00161473
Alzheimer's in Long-Term Care--Treatment for Agitation;
ODM derived from:
https://clinicaltrials.gov/show/NCT00161473
All rights reserved. Please visit https://medical-data-
models.org/forms/13355
Eligibility Alzheimer Disease
NCT00161473
Inclusion Criteria
No age limit*
Yes
No
Probable/possible alzheimer's disease diagnosis*
Yes
No
Disruptive agitated behaviors (e.g., irritability,
aggression, uncooperativeness, pacing)*
Yes
No
No hypotension*
Yes
No
No concurrent use of alpha-1-blockers*
Yes
No
No delirium, schizophrenia, mania, psychotic
symptoms*
Yes
No
Exclusion Criteria
Cardiovascular: unstable angina, recent
myocardial infarction, second or third degree
atrioventricular (av) block, preexisting
hypotension (systolic blood pressure less than
110) or orthostatic hypotension*
Yes
No
Other medical exclusions: chronic renal or
hepatic failure, or any unstable medical condition*
Yes
No
Exclusionary medications: current treatment with
prazosin, other alpha-1-blockers*
Yes
No
Current enrollment in a separate investigational
drug trial*
Yes
No
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Psychoactive medications: subjects may be
psychoactive medication-free or be partial
responders (by subjective assessment of
referring health care professional) to one
psychoactive medication from any of the following
classes: antipsychotics, anticonvulsants, mood
stabilizers, antidepressants, benzodiazepines, or
buspirone. partial response is defined as some
improvement in agitated behavior but persistence
of agitated behaviors severe enough to cause
patient distress and/or difficulty with caregiving.
although not formally rated, this improvement is
equivalent to a clinical global impression of
change (cgic) rating of no more than minimal
improvement (improvement is noticed by not
enough to improve patient function or caregiver's
practical management of the patient).*
Yes
No
Psychiatric/behavioral: lifetime schizophrenia;
current delirium, mania, depression, or
uncontrolled persistent distressing psychotic
symptoms (hallucinations, delusions), substance
abuse, panic disorder, or any behavior which
poses an immediate danger to patient or others
or which results in the patient being too
uncooperative to meet the requirements of study
participation.*
Yes
No
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Eligibility Alzheimer Disease NCT00161473
SacBo PZ: Case Report Form Hospitalization
Documentation Diarrhea - AAD - CDAD
Test Study
All rights reserved. Please visit https://medical-data-
models.org/forms/13358
SacBo PZ: Case Report Form
Hospitalization Documentation
Diarrhea - AAD - CDAD
Default Itemgroup
What date did the diarrhea/AAD/CDAD occur?
What is the number of the episode?
What date was the stool sample acquired to be
passedn on to the BNI?
Was there antibiotic-assoiated diarrhea as a
clinical diagnosis?
Yes
No
Did antibiotic-associated diarrhea occur and were
microbes found?
Yes
No
What kind of microbes were found?
Did clostridium difficile associated diarrhea occur
and was the diagnosis confirmed by stool
culture?
Yes
No
Did CDAD occur and was the diagnosis
confirmed by finding Toxin A and/or Toxin B?
Yes
No
Did CDAD occur that was confirmed by
endoscopy?
Yes
No
Did CDAD occur and was the diagnosis
confirmed by methods of molecular biology?
Yes
No
Did diarrhea occur that was exclusively diarrhea
other than AAD or CDAD?
Yes
No
Clinical diagnosis
Was there blood in the stool?
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yes (1)
no (2)
not known (3)
Was there abdominal pain or cramps?
yes (1)
no (2)
not known (3)
Was there dehydration?
yes (1)
no (2)
not known (3)
Was there fever?
yes (1)
no (2)
not known (3)
Did the patient receive any medication?
Yes
No
Conservative or surgical therapy for
AAD/CDAD
Was there any further conservative or surgical
therapy necessary for AAD/CDAD?
Yes
No
If there was further treatment necessary please
specify:
Further episode of diarrhea/AAD/CDAD
Was there any further episode of
diarrhea/AAD/CDAD or was another stool sample
acquired?
Yes
No
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SacBo PZ: Case Report Form Hospitalization Documentation Diarrhea -
AAD - CDAD
Eligibility Arthritis NCT00524160
A Study of the Effect on Pain Control of Treatment With
Fentanyl, Administered Through the Skin, in Patients With
Rheumatoid Arthritis or Osteoarthritis; ODM derived from:
https://clinicaltrials.gov/show/NCT00524160
All rights reserved. Please visit https://medical-data-
models.org/forms/13360
Eligibility Arthritis NCT00524160
Inclusion Criteria
Patients must meet the american college of
rheumatology criteria for rheumatoid arthritis (ra)
or osteoarthritis (oa) of the hip or knee and have
moderate or severe pain that is not adequately
controlled by other medications (paracetamol
(acetaminophen), nsaids, cox-2 inhibitors, weak
opioids)*
Yes
No
OA patients must be in need of and waiting for
hip or knee replacement*
Yes
No
RA patients using disease modifying
antirheumatic drugs (dmards) must have been on
stable dose of medication for >=3 months.*
Yes
No
Exclusion Criteria
Patients who have received regular treatment
with strong opioids during the month prior to
study*
Yes
No
Another continuous pain that stands out
compared to RA or OA pain*
Yes
No
Skin disease or known allergy or hypersensitivity
to fentanyl or to the adhesives*
Yes
No
History of liver disease*
Yes
No
New physical therapy or change in that therapy
within one month of study*
Yes
No
Pregnant or nursing females, or those without
adequate contraception.*
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Yes
No
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Eligibility Arthritis NCT00524160
Start-up Resource - NINDS Stroke CDE
Recommendations
Modified Form
Summary of Core/Supplemental - Highly Recommended or
Supplemental Recommendations: Stroke CDEs 
Updated: October 13, 2015
This modified form used the National Institute of
Neurological Disorders and Stroke Common Data Elements
(http://www.commondataelements.ninds.nih.gov/)
The National Institute of Neurological Disorders and Stroke
(NINDS) and other Federal agencies and international
organizations have the common mission of developing data
standards for clinical research. Through the efforts of
subject-specific working groups, topic-driven data elements
have been created.
References section:  
Grinnon ST, Miller K, Marler JR, Lu Y, Stout A, Odenkirchen
J, Kunitz S. National Institute of Neurological Disorders and
Stroke Common Data Element Project - approach and
methods. Clin Trials. 2012;9(3):322-9. 
All rights reserved. Please visit https://medical-data-
models.org/forms/13361
ODM-UMLS: Summary of Stroke
CDE Recommendations
Core CDEs for all NINDs Studies
Patient date of birth (dd.mm.yyyy)*
Ethnic group*
Hispanic or Latino (1)
Not Hispanic or Latino (2)
Unknown (3)
Not reported (4)
Racial group*
American Indian or Alaska Native (1)
Asian (2)
Black or African-American (3)
Native Hawaiian or other Pacific Islander
(4)
White (5)
Unknown (6)
Not reported (7)
Gender*
Female (1)
Male (2)
Unknown (3)
Unspecified (4)
Not reported (5)
Educational Status*
years
Medical History
Core CDEs for Stroke Studies
Systolic blood pressure measurement*
mmHg
Diastolic blood pressure measurement*
1 / 5
mmHg
Vital signs date and time*
Ambulatory Status*
Able to ambulate independently (no help
from another person) w/ or w/o device
(1)
With assistance (from person) (2)
Unable to ambulate (3)
Unknown (4)
Supplemental/Highly Recommended
CDEs for Types of Stroke Studies
heart rate*
/min
Body Height*
Unit of Measure*
Inches (1)
Centimeters (2)
meters (3)
feet (4)
Respiratory rate*
Body temperature*
Unit of Measure*
degrees Fahrenheit (1)
degrees Celsius (2)
Body weight*
Unit of Measure*
Pounds (1)
Kilograms (2)
Oxygen saturation measurement*
percent
Tobacco smoking status*
yes (1)
no (2)
unknown (3)
Former smoker*
yes (1)
no (2)
unknown (3)
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Drug abuse*
Sedatives (e.g., sleeping pills,
barbiturates, Seconal, Quaaludes, or
Chloral Hydrate) (1)
Other, specify (e.g., Methadone, Elavil,
steroids, Thorazine, or Haldol) (10)
Tranquilizers or anti-anxiety drugs (e.g.,
Valium, Librium, muscle relaxants, or
Zanax) (2)
Painkillers (e.g., Codeine, Darvon,
Percodan, Dilaudid, or Demerol) (3)
Stimulants (e.g., Preludin, Benzedrine,
Methadrine, uppers, or Speed) (4)
Marijuana, hash, THC, or grass (5)
Cocaine or crack (6)
Hallucinogens (e.g., Ecstasy, LSD,
mescaline, psilocybin, PCP, angel dust,
or peyote) (7)
Inhalants or Solvents (e.g., Amyl nitrate,
nitrous oxide, glue, tolune, or gasoline)
(8)
Heroin (9)
Drug or substance illicitly used other text*
Substance Abuse Detection*
Yes (1)
No (2)
Unknown (3)
Behavioral history*
Alcohol consumption*
Monthly or less (1)
2 to 4 times a month (2)
2 to 3 times a week (3)
4 or more times a week (4)
unknown (5)
never (6)
Hospital admission date (DD.MM.YYYY)*
Psychological Well Being*
admission to hospital arrival date and time*
Clinical stroke time-based definition indicator*
Yes (1)
No (2)
Unknown (3)
Clinical stroke tissue-based definition indicator*
Yes (1)
No (2)
Unknown (3)
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Clinical stroke time-based definition type*
Ischemic Stroke (1)
Transient Ischemic Attack (TIA) (2)
Intracerebral hemorrhage (ICH) (3)
Intraventricular hemorrhage (IVH) (4)
Subarachnoid hemorrhage (SAH) (5)
Clinical Stroke of Uncertain Type (6)
Silent Stroke (Clinically Asymptomatic)
(7)
Clinical stroke tissue-based definition type*
Ischemic Stroke (1)
Transient Ischemic Attack (TIA) (2)
Intracerebral hemorrhage (ICH) (3)
Intraventricular hemorrhage (IVH) (4)
Subarachnoid hemorrhage (SAH) (5)
Clinical Stroke of Uncertain Type (6)
Silent Stroke (Clinically Asymptomatic)
(7)
Hospital discharge date  (DD.MM.YYYY)*
Principal diagnosis*
Treatment-subsequent & other section*
Initial residence (1)
Discharge destination (2)
Thrombolysis, cerebral, by intravenous infusion*
Yes - within 0-3 hour window (1)
Yes - within 3-4.5 hour window (2)
No (3)
IV tPA initiated date and time (Date & Time;
alteplase)*
Intra-arterial infusion of thrombolytic Agent
(Indicator; Intra-arterial infusion of thrombolytic
Agent)*
Yes (1)
No (2)
Unknown (3)
Intra-arterial (IA) procedure type (Procedure
Code)*
Pharmacological (1)
Mechanical (2)
Both (3)
Anticoagulant in hospital indicator (Indicator
Anticoagulants)*
Yes (1)
No (2)
Unknown (3)
Anticoagulants*
Unfractionated heparin IV (1)
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Full dose LMW heparin (Enoxaparin ,
Others) (2)
Warfarin (Coumadin) (3)
Fondaparinux (Arixtra) (4)
Other (5)
specify (6)
Anticoagulant other text*
Antiplatelet in hospital indicator (Indicator;
Antiplatelet Agents)*
Yes (1)
No (2)
Unknown (3)
Antiplatelet Agents*
Aspirin (1)
Aspirin/Dipyridamole (in separate
formulations or as Aggrenox) (2)
Clopidogrel (Plavix) (3)
Ticlopidine (Ticlid) (4)
Other (5)
specify (6)
Antiplatelet other text*
Stroke discharge medication category
(Medication.discharge:Cmplx:Pt:^Patient:Set)*
Anticoagulants (1)
Antiplatelets (2)
Antihypertensives (3)
Anti-diabetic agents (4)
Lipid lowering agents (5)
Description of plan for follow-up care*
Yes (1)
No (2)
Unknown (3)
Primary Health Care*
Yes (1)
No (2)
Unknown (3)
Laterality:Type:Pt:Anatomic part.*:Nom*
Walking time Duration (Walking (activity))*
Walking speed*
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Eligibility Prostate Cancer NCT00005072
Leuvectin in Treating Patients With Locally Recurrent
Prostate Cancer; ODM derived from:
https://clinicaltrials.gov/show/NCT00005072
All rights reserved. Please visit https://medical-data-
models.org/forms/13364
Eligibility Prostate Cancer
NCT00005072
Criteria
patient characteristics: age: 18 and over.
performance status: karnofsky 80-100% or
eastern cooperative oncology group (ecog) 0 or
1. life expectancy: not specified. hematopoietic:
white blood cell count (wbc) greater than
3,000/mm3. platelet count greater than
100,000/mm3. hemoglobin greater than 9.0 g/dl.
hepatic: bilirubin normal. serum glutamic
oxaloacetic transaminase (sgot) or serum
glutamic-pyruvic transaminase (sgpt) less than 3
times upper limit of normal. albumin greater than
3 g/dl. prothrombin time (pt) and partial
thromboplastin time (ptt) normal. hepatitis b
surface antigen negative. renal: creatinine
normal. cardiovascular: no uncontrolled
hypertension. no significant cardiovascular
disease, e.g.: history of ventricular dysfunction;
congestive heart failure; symptoms of coronary
artery disease; history of any ventricular
arrhythmia; prior myocardial infarction. other: hiv
negative. fertile patients must use effective
double-barrier contraception during and for 3
months after study participation. no active
autoimmune disease. no active infection requiring
iv antibiotics. no uncontrolled diabetes mellitus.
no significant psychiatric disorder that would
preclude study. no other malignancy within the
past 5 years except adequately treated basal cell
or squamous cell skin cancer.*
Yes
No
prior concurrent therapy: biologic therapy: no
prior leuvectin. chemotherapy: at least 3 weeks
since prior chemotherapy (6 weeks for mitomycin
or hydroxyurea). endocrine therapy: no prior
hormonal therapy for prostate cancer.
radiotherapy: see disease characteristics. at least
3 weeks since prior radiotherapy. surgery: at least
1 month since prior intrathoracic or intra-
abdominal surgery. at least 2 weeks since other
prior major surgery. other: at least 10 days since
prior anticoagulants or non-steroidal anti-
inflammatory agents. no neoadjuvant or other
concurrent anticancer drug therapy. no
concurrent immunosuppressive drugs. no other
concurrent experimental therapy.*
Yes
No
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Eligibility Prostate Cancer NCT00038181
Preoperative Thalidomide Followed By Radical Retropubic
Prostatectomy In Select Patients With Locally Advanced
Prostate Cancer; ODM derived from:
https://clinicaltrials.gov/show/NCT00038181
All rights reserved. Please visit https://medical-data-
models.org/forms/13365
Eligibility Prostate Cancer
NCT00038181
Inclusion Criteria
prostatic adenocarcinoma without evidence of
regional or distant metastases, clinical stage t1c-
t2c with gleason score > 7 on initial biopsy and
psa > 10 ng/dl  or clinical stage t3.*
Yes
No
negative bone scan and ct abd/pelvis.*
Yes
No
life expectancy of at least 10 years.*
Yes
No
surgical candidate for radical prostatectomy and
ecog performance status of < 2.*
Yes
No
patients must have no other concurrent
malignancies (or within the past 5 years, with the
exception of non-melanoma skin cancer or
treated superficial transitional cell carcinoma of
the bladder).*
Yes
No
peripheral granulocyte count > 1,500/mm3,
platelet count of > 100,000/mm3 and hb> 10.0
gm/dl, adequate hepatic function with a bilirubin <
1.5 mg % and sgpt < 2.5x the upper limits of
normal, and adequate renal function defined as
serum creatinine < 1.5 mg% or creatinine
clearance > 40 ml/min.*
Yes
No
patients with biochemical hypothyroidism will
have their thyroid hormone replaced concurrent
with starting the study.  patients with clinical
hypothyroidism should have their thyroid replaced
prior to starting this study.*
Yes
No
informed consent indicating that patients are
aware of the investigational nature of the study, in
keeping with the policies of the institution.  the
only approved consent form is appended to this
protocol.*
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Yes
No
patients must be willing and able to travel to ut-
mdacc for re-evaluation as necessary per
protocol.*
Yes
No
patients should be counseled about the
possibility that thalidomide may be present in the
semen and must use a latex condom every time
they have sexual intercourse with a woman
during therapy and for 4 weeks after
discontinuing thalidomide, even if they had a
successful vasectomy.*
Yes
No
Exclusion Criteria
patients who have received any prior hormonal-,
immuno-, radiation or chemo-therapy for prostate
carcinoma are excluded from the trial.  prior
herbal and/or homeopathic medication is allowed
if discontinued at least 2 weeks prior to study
entry.  pc-spes is considered hormonal therapy.*
Yes
No
patients with history of substantial non-iatrogenic
bleeding diathesis and patients with macroscopic
hematuria or active gi bleeding are not eligible.*
Yes
No
patients with uncontrolled cardiac, respiratory,
hepatic, renal, neurologic or psychiatric disorder
are excluded from the trial.*
Yes
No
patients with nci grade 2 or greater peripheral
neuropathy of any cause (clinically detectable), or
receiving anti-convulsive medications are not
eligible for this trial.*
Yes
No
patients who are receiving sedative/hypnotic
agents which cannot be discontinued (if
necessary) are not eligible for this study.*
Yes
No
patients positive for hiv are excluded from this
trial.*
Yes
No
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Eligibility Prostate Cancer NCT00684905
Leuprolide, Bicalutamide, and Implant Radiation Therapy in
Treating Patients With Locally Recurrent Prostate Cancer
After External-Beam Radiation Therapy; ODM derived
from: https://clinicaltrials.gov/show/NCT00684905
All rights reserved. Please visit https://medical-data-
models.org/forms/13366
Eligibility Prostate Cancer
NCT00684905
Criteria
biopsy-proven adenocarcinoma of the prostate*
Yes
No
locally recurrent disease, defined by digital rectal
examination and/or rising prostate-specific
antigen (psa)*
Yes
No
no evidence of nodal or distant metastasis (i.e.,
n0, m0) on physical examination, bone scan, or ct
scan of the pelvis*
Yes
No
clinical stage t1c-t3a disease at the time of
recurrence*
Yes
No
psa < 10 ng/ml*
Yes
No
prostate volume by transrectal ultrasonography <
60 cc*
Yes
No
received prior external beam radiotherapy*
Yes
No
ecog performance status 0-2*
Yes
No
wbc ≥ 3,000/μl*
Yes
No
platelet count ≥ 90,000/μl*
Yes
No
hemoglobin ≥ 10 g/dl*
Yes
No
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alkaline phosphatase < 2 times normal*
Yes
No
ast < 2 times normal*
Yes
No
normal prothrombin time and partial
thromboplastin time*
Yes
No
no significant obstructive urinary symptoms (aua
score ≤ 16)*
Yes
No
no contraindication for general anesthesia*
Yes
No
prior concurrent therapy: no prior transurethral
resection of the prostate*
Yes
No
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Eligibility Prostatic Neoplasms, Locally
Advanced NCT01122121
Leuprorelin Associated With Radiotherapy Versus
Leuprorelin Alone in T3 - T4 or pT3 (on Biopsy) N0, M0
Prostate Cancer; ODM derived from:
https://clinicaltrials.gov/show/NCT01122121
All rights reserved. Please visit https://medical-data-
models.org/forms/13367
Eligibility Prostatic Neoplasms,
Locally Advanced NCT01122121
Inclusion Criteria
histologically confirmed locally advanced
adenocarcinoma of the prostate, graded: t3 or t4
or pt3 on biopsies (presence  of  tumour tissue in
periprostatic fat observed on biopsies), n0
(absence  of  metastatic), m0 (no distant
metastases detectable on the following
examinations: bone scan, chest x-ray, abdominal
and pelvic ultrasound).*
Yes
No
patient in whom the prostatic adenocarcinoma
has received no prior treatment of any type, with
the possible exception of  transurethral resection
due to obstructive symptoms.*
Yes
No
patient with a karnofsky index greater than or
equal to (≥) 70.*
Yes
No
patient aged under 80 years on the
randomization date.*
Yes
No
patient with a life expectancy of at least 7 years.*
Yes
No
patient  who,  after  having  received  clear
information, gave his written consent to
participate and cooperate in the study.*
Yes
No
patient  for  whom  a  recent  blood  test  (less
than [<] 2  months)  has  not revealed elevated
transaminases ≥ 3 times the normal laboratory
range.*
Yes
No
Exclusion Criteria
patient incapable of understanding the
information supplied concerning the study or of
giving his consent, or having refused to sign the
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informed consent form,*
Yes
No
patient  for  whom  there  is  a  risk  that  follow-
up  in compliance with the conditions stipulated
by the protocol will not be possible,*
Yes
No
patient  having  already  received  prior  treatment
for  prostate  cancer, excluding transurethral
resection of the prostate to relieve obstruction,*
Yes
No
patient having undergone surgical castration, or
with a   history of bilateral adrenalectomy or
hypophysectomy,*
Yes
No
patient having had another cancer within the
previous 5 years (including carcinoma in situ  of
the  bladder) excluding  basocellular epithelioma
or carcinoma in situ (other than in the bladder),*
Yes
No
patient with lymph node or metastatic spread of
the prostatic  adenocarcinoma suspected on
imaging,*
Yes
No
patient with a non-controlled severe active
disease,*
Yes
No
patient with a contraindication to external
prostatic radiotherapy,*
Yes
No
patient receiving or having received another
experimental treatment within 3 months prior to
inclusion in the study,*
Yes
No
patient with impaired liver function or elevated
transaminases ≥3 times the normal laboratory
range.*
Yes
No
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Eligibility Recurrent or Metastatic Colorectal
Cancer NCT00155558
A Phase I Trial of HDFL48 in Recurrent or Metastatic
Colorectal Cancers; ODM derived from:
https://clinicaltrials.gov/show/NCT00155558
All rights reserved. Please visit https://medical-data-
models.org/forms/13368
Eligibility Recurrent or Metastatic
Colorectal Cancer NCT00155558
Inclusion Criteria
pathologically confirmed recurrent or metastatic
colorectal adenocarcinoma*
Yes
No
patients are indicated for 5-fu (1st-line after
recurrence/metastasis), or have failed 5-fu
,treatment with other schedules*
Yes
No
at least one bi-dimensionally measurable
lesion(s)*
Yes
No
previous c/t, r/t >= 4 weeks*
Yes
No
kps > 50%*
Yes
No
age >= 18 years*
Yes
No
fasting tg > 70 mg/dl (within 7 days)*
Yes
No
wbc >= 3,000/ul or anc >= 1,500/ul*
Yes
No
plt >= 75,000/ul*
Yes
No
cre<= 1.5 mg/dl*
Yes
No
proteinuria < 1+*
Yes
No
normal t-bil*
Yes
No
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ast/ alt <= 3.5-fold of uln*
Yes
No
Exclusion Criteria
concomitant anticancer therapy or radiotherapy*
Yes
No
cns metastasis*
Yes
No
pregnant women*
Yes
No
patients who have second malignancy*
Yes
No
symptomatic heart disease (significant
arrhythmia, chf or mi within 3 months of entry)*
Yes
No
active infection exists*
Yes
No
extensive liver disease or liver cirrhosis*
Yes
No
patients who refuse port-a catheter implantation*
Yes
No
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Visit 1 LAIS grass tablets by allergic
rhinoconjunctivitis EudraCT-Nr.2012-004916-79
Study part: Visit V1 (Day 0). Effectiveness and tolerance of
sublingual desensitization with LAIS grass tablets in
Patients with an allergic rhinoconjunctivitis caused by grass
pollen.  A prospective, multi-center, doubleblind,
randomized, placebo-controlled Phase III study. Principal
Investigator Prof. Dr. med. Ralph Mösges.
All rights reserved. Please visit https://medical-data-
models.org/forms/13369
Visit V1 (Day 0)
Visit 1
Date of visit
Does the patient still take part in the study?
yes (1)
no, please then fill up the form "Study
completion" (2)
Did new comorbidities occur during the study? (If
yes, please fill the form ''Adverse event")
Yes
No
Concomitant medication? If yes, please use the
form "Documentation Concomitant medication"
Yes
No
Inclusion criteria
Date for next visit 2 (Day 7 + - 2 days)
Questionnaire on quality of life of
rhinoconjunctivitis patients handed out and filled?
Yes
No
Physical examination
Weight
kg
Systolic blood pressure
mmHg
Diastolic blood pressure
mmHg
Heart rate
1/ min
Examination (Rhinoscope)
Edema
1 / 4
no (1)
slight (2)
medium (3)
strong (4)
Secretion
no (1)
slight (2)
medium (3)
strong (4)
Redness
no (1)
slight (2)
medium (3)
strong (4)
Spirometry or Peak expiratory flow
measurement (For asthmatics)
FEV1 (age-appropriate standard value)
FEV1
FEV1/ Standard value (If FEV1 < 70% of age
appropriate standard value, exclusion)
%
PEF 1
l/min
PEF 2
l/ min
PEF 3
l/ min
Best PEF
l/ min
Optimum individual value PEF (If FEV1 < 70% of
optimum individual value, exclusion)
l/ min
Conjunctival provocation testing
Conjunctival provocation test result 1
positive (1)
negative (2)
Conjunctival provocation test result 2 (to be
carried out only when test 1 outcome is negative)
positive (1)
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negative (2)
Conjunctival provocation test result 3 (to be
carried out only when test 2 outcome is negative)
positive (1)
negative (2)
Allergen concentration at which the test outcome
is positive
100 SQ- E/ ml (1)
1000 SQ-E/ ml (2)
10000 SQ-E/ ml (3)
The outcome for all tests is negative
Yes
No
Sublingual immunotherapy
Did the Patient receive study medication and the
medications on demand?
Yes
No
When was the study drug administered?
Did adverse events occur within 30 minutes of
drug intake?
Yes
No
Local reaction
Oral allergy syndrome
Yes
No
Gastrointestinal symptom (e.g. nausea, vomiting,
bloating, dyspepsia, diarrhea)
Yes
No
Systemic reactions
nonspecific symptoms e.g.  headache,
discomfort (1)
slight systemic symptoms (local urticaria,
rhinitis or slight asthma (PEF< 20%)) (2)
medium systemic symptoms (slow onset
(> 15 min) of urticaria and/ or medium
asthma (PEF< 40%)) (3)
anaphylactic shock (4)
other (5)
When other, please mention
Is this a serious adverse event? If yes, please fill
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the documentation part "serious adverse event"
Yes
No
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Visit V0 LAIS grass tablets by allergic
rhinoconjunctivitis EudraCT-Nr.2012-004916-79
Study part: Visit V0 Screening visit. Effectiveness and
tolerance of sublingual desensitization with LAIS grass
tablets in Patients with an allergic rhinoconjunctivitis caused
by grass pollen. A prospective, multi-center, doubleblind,
randomized, placebo-controlled Phase III study. Principal
Investigator Prof. Dr. med. Ralph Mösges.
All rights reserved. Please visit https://medical-data-
models.org/forms/13374
Visit V0 Screening visit
Inclusion Criteria
Female or male patients between 18 and 75
years with at least 2 years known, induced by
grass pollen allergic rhinitis and / or allergic
rhinoconjunctivitis with or without controlled
allergic asthma
Yes
No
Clinical sensitization to grass pollen. Patients with
sensitization to perennial allergens such as dust
mites, cats, dogs may be included where such
sensitization during the analysis period are not
clinically relevant.
Yes
No
Reliability and ability of the patient to fill out the
patient diary for self-assessment of symptoms
and taking the anti symptomatic medication
selbsständig
Yes
No
Signed and dated informed consent of the patient
Yes
No
Exclusion Criteria
Simultaneous participation in other clinical trials
Yes
No
Previous immunotherapy with grass pollen
allergen or cross-reacting allergen in the last 5
years
Yes
No
Continuing immunotherapy for allergens
Yes
No
Patients who are in any sort of relationship or
dependence on the sponsor and / or investigator
Yes
No
Other reasons that according to the opinion of the
investigator contraindicate an inclusion in the
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clinical trial (e.g, low reliability, inability of the
patient to understand the study documents and
instructions)
Yes
No
An existing or planned pregnancy, lactation and /
or lack of adequate contraception
Yes
No
Mostly perennial allergic rhinitis
Yes
No
Only partially controlled or non-controlled or
predominantly perenniales Asthma
Yes
No
Chronic asthma or emphysema, in particular with
an FEV1 <70% of the expected value
Yes
No
Chronic asthma or emphysema, in particular with
an FEV1 <70% of the individual value
Yes
No
Infections in the oral cavity with severe symptoms
Yes
No
Patients with hereditary problems of galactose
intolerance, lactase deficiency, glucose galactose
malabsorption
Yes
No
Patients with deformities of the nose and / or
adenoids
Yes
No
Active tuberculosis
Yes
No
General inflammatory / febrile and severe acute
or chronic inflammatory diseases
Yes
No
Immunodeficiencies (for example, also induced
by immunosuppressants)
Yes
No
Autoimmune diseases
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Yes
No
By a doctor diagnosed internal diseases (for
example, the liver, spleen, nervous system, the
thyroid gland and rheumatic disorders), which are
due to an autoimmune mechanism.
Yes
No
Malignant tumors
Yes
No
Alcohol abuse, drugs or medication abuse
Yes
No
Contraindication to epinephrine (e.g. in acute or
chronic myocardial ischemia symptomatology,
severe hypertension)
Yes
No
Completed or ongoing long-term treatment with
sedatives, or psychoactive drugs
Yes
No
Patients being treated with contraindicated Drug
Yes
No
Demographics
Date of screening visit (= Day -28/ -3 of the
study)
Date on which informed consent is signed
Birth year
Gender
male (1)
female (2)
Ethnicity
caucasian (1)
asian (2)
negroid (3)
other (4)
If other, please mention
Date of next Visit V1 (3 to 28 days after V0)
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Laboratory
Date of venipuncture  for total and specific IgE
Date of venipuncture for safety laboratory
Does the patient have a safe contraception?
no, then exclusion (1)
yes, according to Supplement
"Recognised methods of reliable
contraception" (2)
yes, other reasons for a safe
contraception (3)
Pregnancy test date
Pregnancy test result
positive, exclusion (1)
negative (2)
Physical examination
Weight
kg
Systolic blood pressure
mmHg
Diastolic blood pressure
mmHg
Heart rate
1/ min
Examination (Rhinoscope)
Edema
no (1)
slight (2)
medium (3)
strong (4)
Secretion
no (1)
slight (2)
medium (3)
strong (4)
Redness
no (1)
slight (2)
medium (3)
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strong (4)
History of allergies
Grass pollen
Yes
No
Tree pollen
Yes
No
Atopic dermatitis
Yes
No
Weed pollen
Yes
No
Food allergies
Yes
No
If yes, which?
Other allergies
Clinical symptoms
Allergic rhinitis/ allergic rhinoconjunctivitis
Yes
No
Allergic rhinitis/ allergic rhinoconjunctivitis
seasonal (1)
predominantly perennial, then exclusion
(2)
Allergic rhinoconjunctivitis or allergic rhinitis since
Retrospective Rhinoconjunctivitis Total
Symptom Score
Sneezing
no symptoms 0 (1)
slight symptoms 1 (2)
moderate symptoms 2 (3)
strong symptoms 3 (4)
Runny nose
no symptoms 0 (1)
slight symptoms 1 (2)
moderate symptoms 2 (3)
strong symptoms 3 (4)
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Itching in the nose
no symptoms 0 (1)
slight symptoms 1 (2)
moderate symptoms 2 (3)
strong symptoms 3 (4)
Stuffy nose
no symptoms 0 (1)
slight symptoms 1 (2)
moderate symptoms 2 (3)
strong symptoms 3 (4)
Watery eyes
no symptoms 0 (1)
slight symptoms 1 (2)
moderate symptoms 2 (3)
strong symptoms 3 (4)
Itching of eye
no symptoms 0 (1)
slight symptoms 1 (2)
moderate symptoms 2 (3)
strong symptoms 3 (4)
Summation (when total RTSS score is < 8,
exclusion of patient)
Concomitant medication
Concomitant medication
Yes
No
Type of concomitant medication
contraindicated drugs (1)
other medicines (2)
If other, please mention
Medical history
Cardiovascular system
Yes
No
Respiratory
Yes
No
Gastrointestinal Tract
Yes
No
Eye
Yes
No
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Nose
Yes
No
Ears
Yes
No
Neck
Yes
No
Skin
Yes
No
Skin
Yes
No
Endocrine / lymphatic system
Yes
No
Muscle/ Skeleton
Yes
No
Nervous system
Yes
No
Genitourinary
Yes
No
Metabolic System
Yes
No
Comorbidity
no (1)
yes, please match with exclusion criteria
and specify (2)
Specification of comorbidity
Retrospective registration of disease or surgical
procedures on other organs within the last 10
years
If diagnosis, please describe
Skin prick test
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Size of wheal for grass pollen mixture (> = 3 mm)
mm
Size of wheal for histamine dihydrochloride
(positive control 10 mg/ml) (>=3 mm)
mm
Size of wheal for saline solution (< 2 mm)
mm
Size of wheal for rye pollen
mm
Size of wheal for hazel pollen
mm
Size of wheal for ambrosia pollen
mm
Size of wheal for birch pollen
mm
Size of wheal for mugwort pollen
mm
Size of wheal for house dust mite
mm
Size of wheal for cat hair
mm
Size of wheal for dog hair
mm
Size of wheal for alternaria
mm
Spirometry or Peak expiratory flow
measurement (For asthmatics)
FEV1 (age-appropriate standard value)
FEV1
FEV1/ Standard value (If FEV1 < 70% of age
appropriate standard value, exclusion)
%
PEF 1
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l/min
PEF 2
l/ min
PEF 3
l/ min
Best PEF
l/ min
Optimum individual value PEF (If FEV1 < 70% of
optimum individual value, exclusion)
l/ min
Conjunctival provocation testing
Conjunctival provocation test result 1
positive (1)
negative (2)
Conjunctival provocation test result 2 (to be
carried out only when test 1 outcome is negative)
positive (1)
negative (2)
Conjunctival provocation test result 3 (to be
carried out only when test 2 outcome is negative)
positive (1)
negative (2)
Allergen concentration at which the test outcome
is positive
100 SQ- E/ ml (1)
1000 SQ-E/ ml (2)
10000 SQ-E/ ml (3)
The outcome for all tests is negative
Yes
No
Allergy diagnostics
Total Immunoglobulin E
kU/l
Immunoglobulin IgG4
kU/l
Grass (Phleum pratense) Phl p 1
kU/l
RAST class for grass Phl p 1
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Class 0 (< 0.35) (1)
Class 1 (0.35- 0.69) (2)
Class 2 (0.70-3.49) (3)
Class 3 (3.50-17.49) (4)
Class 4 (17.50-49.99) (5)
Class 5 (50-100) (6)
Class 6 (> 100) (7)
Grass (Phleum pratense) Phl p5b
kU/l
RAST class for grass Phl p5b
Class 0 (< 0.35) (1)
Class 1 (0.35- 0.69) (2)
Class 2 (0.70-3.49) (3)
Class 3 (3.50-17.49) (4)
Class 4 (17.50-49.99) (5)
Class 5 (50-100) (6)
Class 6 (> 100) (7)
Grass (Phleum pratense) Phl p 7
kU/l
RAST class for grass Phl p7
Class 0 (< 0.35) (1)
Class 1 (0.35- 0.69) (2)
Class 2 (0.70-3.49) (3)
Class 3 (3.50-17.49) (4)
Class 4 (17.50-49.99) (5)
Class 5 (50-100) (6)
Class 6 (> 100) (7)
Grass (Phleum pratense) Phl p 12
kU/l
RAST class for grass Phl p 12
Class 0 (< 0.35) (1)
Class 1 (0.35- 0.69) (2)
Class 2 (0.70-3.49) (3)
Class 3 (3.50-17.49) (4)
Class 4 (17.50-49.99) (5)
Class 5 (50-100) (6)
Class 6 (> 100) (7)
Birch Bet v 1
kU/l
RAST class for birch Bet v1
Class 0 (< 0.35) (1)
Class 1 (0.35- 0.69) (2)
Class 2 (0.70-3.49) (3)
Class 3 (3.50-17.49) (4)
Class 4 (17.50-49.99) (5)
Class 5 (50-100) (6)
Class 6 (> 100) (7)
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Mugwort Art v1
kU/l
RAST class for mugwort Art v1
Class 0 (< 0.35) (1)
Class 1 (0.35- 0.69) (2)
Class 2 (0.70-3.49) (3)
Class 3 (3.50-17.49) (4)
Class 4 (17.50-49.99) (5)
Class 5 (50-100) (6)
Class 6 (> 100) (7)
Ambrosia Amb a1
kU/l
RAST class for ambrosia Amb a1
Class 0 (< 0.35) (1)
Class 1 (0.35- 0.69) (2)
Class 2 (0.70-3.49) (3)
Class 3 (3.50-17.49) (4)
Class 4 (17.50-49.99) (5)
Class 5 (50-100) (6)
Class 6 (> 100) (7)
D. pteronyssinus Der p1
kU/l
RAST class for D. pteronyssinus Der p1
Class 0 (< 0.35) (1)
Class 1 (0.35- 0.69) (2)
Class 2 (0.70-3.49) (3)
Class 3 (3.50-17.49) (4)
Class 4 (17.50-49.99) (5)
Class 5 (50-100) (6)
Class 6 (> 100) (7)
D. farinae Der p2
kU/l
RAST class for D. farinae
Class 0 (< 0.35) (1)
Class 1 (0.35- 0.69) (2)
Class 2 (0.70-3.49) (3)
Class 3 (3.50-17.49) (4)
Class 4 (17.50-49.99) (5)
Class 5 (50-100) (6)
Class 6 (> 100) (7)
Dog Can f1
kU/l
RAST class for dog Can f1
Class 0 (< 0.35) (1)
Class 1 (0.35- 0.69) (2)
Class 2 (0.70-3.49) (3)
Class 3 (3.50-17.49) (4)
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Class 4 (17.50-49.99) (5)
Class 5 (50-100) (6)
Class 6 (> 100) (7)
Cat Fel d1
kU/l
RAST class for cat Fel d1
Class 0 (< 0.35) (1)
Class 1 (0.35- 0.69) (2)
Class 2 (0.70-3.49) (3)
Class 3 (3.50-17.49) (4)
Class 4 (17.50-49.99) (5)
Class 5 (50-100) (6)
Class 6 (> 100) (7)
Alternaria Alt a1
kU/l
RAST class for Alternaria Alt a1
Class 0 (< 0.35) (1)
Class 1 (0.35- 0.69) (2)
Class 2 (0.70-3.49) (3)
Class 3 (3.50-17.49) (4)
Class 4 (17.50-49.99) (5)
Class 5 (50-100) (6)
Class 6 (> 100) (7)
Hematology
Hemoglobin
mmol/l
Erythrocyte
/pl
Thrombocyte
/nl
Leucocyte (total)
/nl
Hematocrit
l/l
Biochemistry
Bilirubin (total)
μmol/l
SGPT- Serum Glutamate pyruvate transaminase
U/l
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Alkaline phosphatase
U/l
Glucose
mmol/l
Creatinine
μmol/l
SGOT- Aspartate aminotransferase
measurement
U/l
CRP C reactive protein
mg/l
Gamma-glutamyl transpeptidase
U/l
Inclusion Criteria (Part 2)
the occurrence of the majority of the
corresponding clinical symptoms during the grass
pollen season
Yes
No
Patients should not suffer from typical symptoms
caused by co-allergens during the grass pollen
season (for example, patients with sensitization to
animal fur / - dandruff are not be exposed)
Yes
No
the positive skin prick test (wheal size> = 3 mm,
negative control <2 mm)
Yes
No
The results in the skin prick test for co-seasonal
and most of the perennial co-allergenic are
smaller than the skin prick test result for Grass
pollen
Yes
No
a positive reaction in the conjunctival Provocation
test (CPT) with one of the three dilutions of grass
allergy solution
Yes
No
Retrospective Total symptom score (RRTSS)
during the previous grass pollen season is
greater than or equal to 8
13 / 14
Visit V0 LAIS grass tablets by allergic rhinoconjunctivitis EudraCT-
Nr.2012-004916-79
Yes
No
Planned antiallergic or antiasthmatic treatment
with the following medicines: local treatment with
levocabastine (eye), loratadine (oral),
beclomethasone (nasal) or inhaled corticosteroid
with a long-acting beta-2 agonists
Yes
No
Specific IgE reactivity to grass pollen: CAP RAST
results for Phl p 1 or Phl p5b> = class 2 (0.70 kU
/ l) and CAP-RAST results for Phl p 1 or Phl p5b>
CAP-RAST results for Phl p 7 or Phl p 12
Yes
No
The specific IgE values for predominantly
perennial co- allergy (animal hair / - dandruff,
dust mites) or for the predominantly co-seasonal
allergen Alternaria must be less than the sIgE
results for grass pollen allergens (Phl p 1 or Phl
p5b). The difference must be at least a CAP
RAAST class (> = 1).
Yes
No
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Eligibility Asthma NCT00046748
Efficacy and Safety of Omalizumab in Patients With Severe
Persistent Asthma; ODM derived from:
https://clinicaltrials.gov/show/NCT00046748
All rights reserved. Please visit https://medical-data-
models.org/forms/13381
Eligibility Asthma NCT00046748
Criteria
With a positive prick skin test (diameter of wheal
> 3 mm) to at least one perennial allergen (e.g.
dust mite, animal dander, cockroaches), within
the past 5 years or at visit 1, to which the patient
will be exposed on a regular basis (most days) for
the duration of the study. a rast test may be
performed for patients with a borderline skin prick
test result.*
Yes
No
With total serum ige level 30 to 700 iu/ml.*
Yes
No
Demonstrating 12% increase in fev1 over
baseline value within 30 minutes of taking up to 4
puffs  salbutamol (albuterol) or nebulized
salbutamol up to 5mg (or equivalent of alternative
b-2 agonist) documented within the past year, at
screening, during the run-in period or at baseline
prior to randomization.*
Yes
No
With fev1 40-80% of predicted normal value for
the patient (demonstrable at least 6 hours after
short acting b-2 agonist use or 12 hours after
long acting b-2 agonist use) at baseline.*
Yes
No
Who have either experienced at least two
independent asthma exacerbations requiring
unscheduled clinical intervention with a systemic
corticosteroid in the past year.*
Yes
No
Been admitted to hospital (including intensive
care unit) or received emergency room (including
urgent care centers) treatment in the past 12
months for an asthma exacerbation, which in
accordance with the gina guidelines met all of the
following criteria for a severe exacerbation:*
Yes
No
1. pef or fev1< 60% of predicted/personal best, or
patient is too breathless to provide pef.*
Yes
No
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2. no improvement after initial treatment and
therefore requiring repeated treatment with
inhaled b-2 agonist (high dose, spacer or
nebulized).*
Yes
No
3. requiring treatment with systemic
corticosteroids*
Yes
No
Receiving high dose inhaled corticosteroid (at
least 1000ug beclomethasone dipropionate or
equivalent) and a regular inhaled long acting b-2
agonist for at least 3 months prior to screening
and prior to at least two independent asthma
exacerbations requiring unscheduled clinical
intervention with a systemic corticosteroid in the
past year or the severe asthma exacerbation
requiring the hospitalization/er visit.*
Yes
No
Who are receiving an ics dosage > 1000ug
beclomethasone dipropionate or  equivalent and
a regular inhaled long acting b-2 agonist for the
last 4 weeks of the run-in period and at
randomization (to be maintained throughout the
study).*
Yes
No
Whose asthma medication remains unchanged in
the final 4 weeks of the run-in period (to be
maintained throughout the study).*
Yes
No
With evidence of poor asthma symptom control at
screening (based on patient history) and during
the 4 weeks immediately prior to baseline.*
Yes
No
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Eligibility Asthma NCT00046748
Efficacy and Safety of Omalizumab in Patients With Severe
Persistent Asthma; ODM derived from:
https://clinicaltrials.gov/show/NCT00046748
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Eligibility Asthma NCT00046748
Criteria
With a positive prick skin test (diameter of wheal
> 3 mm) to at least one perennial allergen (e.g.
dust mite, animal dander, cockroaches), within
the past 5 years or at visit 1, to which the patient
will be exposed on a regular basis (most days) for
the duration of the study. a rast test may be
performed for patients with a borderline skin prick
test result.*
Yes
No
With total serum ige level 30 to 700 iu/ml.*
Yes
No
Demonstrating 12% increase in fev1 over
baseline value within 30 minutes of taking up to 4
puffs  salbutamol (albuterol) or nebulized
salbutamol up to 5mg (or equivalent of alternative
b-2 agonist) documented within the past year, at
screening, during the run-in period or at baseline
prior to randomization.*
Yes
No
With fev1 40-80% of predicted normal value for
the patient (demonstrable at least 6 hours after
short acting b-2 agonist use or 12 hours after
long acting b-2 agonist use) at baseline.*
Yes
No
Who have either experienced at least two
independent asthma exacerbations requiring
unscheduled clinical intervention with a systemic
corticosteroid in the past year.*
Yes
No
Been admitted to hospital (including intensive
care unit) or received emergency room (including
urgent care centers) treatment in the past 12
months for an asthma exacerbation, which in
accordance with the gina guidelines met all of the
following criteria for a severe exacerbation:*
Yes
No
1. pef or fev1< 60% of predicted/personal best, or
patient is too breathless to provide pef.*
Yes
No
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2. no improvement after initial treatment and
therefore requiring repeated treatment with
inhaled b-2 agonist (high dose, spacer or
nebulized).*
Yes
No
3. requiring treatment with systemic
corticosteroids*
Yes
No
Receiving high dose inhaled corticosteroid (at
least 1000ug beclomethasone dipropionate or
equivalent) and a regular inhaled long acting b-2
agonist for at least 3 months prior to screening
and prior to at least two independent asthma
exacerbations requiring unscheduled clinical
intervention with a systemic corticosteroid in the
past year or the severe asthma exacerbation
requiring the hospitalization/er visit.*
Yes
No
Who are receiving an ics dosage > 1000ug
beclomethasone dipropionate or  equivalent and
a regular inhaled long acting b-2 agonist for the
last 4 weeks of the run-in period and at
randomization (to be maintained throughout the
study).*
Yes
No
Whose asthma medication remains unchanged in
the final 4 weeks of the run-in period (to be
maintained throughout the study).*
Yes
No
With evidence of poor asthma symptom control at
screening (based on patient history) and during
the 4 weeks immediately prior to baseline.*
Yes
No
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Eligibility Asthma NCT01141439
Real-world Effectiveness and Cost-effectiveness of Leading
Inhaled Corticosteroids in Asthma Management; ODM
derived from: https://clinicaltrials.gov/show/NCT01141439
All rights reserved. Please visit https://medical-data-
models.org/forms/13383
Eligibility Asthma NCT01141439
Inclusion Criteria
aged 5-60 years*
Yes
No
Evidence of asthma: a diagnostic code of asthma
or ≥2 prescriptions for asthma in baseline year at
different points in time including one of ics*
Yes
No
On current therapy at the ipd, defined as ≥1 ics
script and ≥1 other asthma prescriptions in the 12
months prior to first change in therapy*
Yes
No
Had definite dosing instructions*
Yes
No
Have at least 1 year of up-to-standard (uts)
baseline data before ipd*
Yes
No
Have at least 1 year of uts outcome data after
ipd.*
Yes
No
Exclusion Criteria
Had a diagnostic read code for chronic
obstructive pulmonary disease (copd) at any
time*
Yes
No
Had a diagnostic read code for chronic
respiratory disease at any time*
Yes
No
For the therapy increase patient cohort, any
patients receiving a combination inhaler in
addition to their separate ics inhaler in the year
prior to ipd were also excluded.*
Yes
No
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Eligibility Atrial Fibrillation NCT00130975
Candesartan in the Prevention of Relapsing Atrial
Fibrillation; ODM derived from:
https://clinicaltrials.gov/show/NCT00130975
All rights reserved. Please visit https://medical-data-
models.org/forms/13384
Eligibility Atrial Fibrillation
NCT00130975
Inclusion Criteria
Patients with atrial fibrillation, diagnosed
electrocardiographically, of more than 48 hours
duration in whom direct current (dc) cardioversion
is planned.*
Yes
No
Exclusion Criteria
Patients with a history of known hypersensitivity
or contraindication to any angiotensin ii receptor
blocker or any angiotensin-converting enzyme
(ace) inhibitor.*
Yes
No
Patients currently receiving an ace inhibitor or
angiotensin ii antagonist because of heart failure
or other strong indication.*
Yes
No
Patients currently receiving any antiarrhythmic
medication including sotalol. other beta-blockers
will not be regarded as specific antiarrhythmic
agents.*
Yes
No
Significant renal artery stenosis and any medical
condition in which administration of a vasodilator
is contraindicated; serum creatinine > 225
micromol/l; or serum potassium > 5.5 mmol/l; or
serum sodium < 128 mmol/l.*
Yes
No
Patients with severe hepatic dysfunction*
Yes
No
life-limiting disease or substance abuse which
may affect participation.*
Yes
No
Patients unwilling to participate*
Yes
No
Patients who have previously undergone dc
cardioversion for atrial fibrillation within the last
1 / 2
month.*
Yes
No
Thyrotoxicosis*
Yes
No
Patients with a systolic blood pressure of < 100
mm hg.*
Yes
No
Hypertensive patients requiring intensified
treatment prior to dc cardioversion*
Yes
No
Pregnancy or lactation*
Yes
No
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Eligibility Atrial Fibrillation NCT00130975
Eligibility Atrial Fibrillation NCT00597077
Atrial Fibrillation and Congestive Heart Failure Trial; ODM
derived from: https://clinicaltrials.gov/show/NCT00597077
All rights reserved. Please visit https://medical-data-
models.org/forms/13385
Eligibility Atrial Fibrillation
NCT00597077
Inclusion Criteria
1. left ventricular ejection fraction </=35% as
measured by nuclear imaging, echocardiography,
or cardiac angiography within 6 months
preceding enrollment.  if the patient has had a
myocardial infarction or heart surgery during this
period, the ejection fraction must be
remeasured.*
Yes
No
2. symptomatic CHF (nyha class ii-iv) at some
time during the 6 months before randomization,
despite therapy with an ace inhibitor (however,
patients who do not tolerate an ace inhibitor are
eligible). asymptomatic patients (nyha class i)
with either a prior hospitalization for chf during
the 6 months before randomization or with a left
ventricular ejection fraction of </=25% are also
eligible.*
Yes
No
3. history of significant AF, defined as either:
1. one episode lasting >/=6 hours (duration of af
will be determined by history), within the past 6
months with electrocardiographic confirmation; or
2. an episode lasting >/=10 minutes (by history)
within the past 6 months with
electrocardiographic confirmation in a patient with
a prior electrical cardioversion for af.*
Yes
No
4. in the opinion of the clinical investigator, the
patient must be eligible for long-term treatment
with either treatment strategy of af.*
Yes
No
Exclusion Criteria
1. af is known to be present and uninterrupted for
more than 12 months prior to randomization.
however, if such a patient is cardioverted and
maintained in sinus rhythm for >/=24 hours, he or
she becomes eligible.*
Yes
No
2. reversible cause of af such as acute
pericarditis, pulmonary embolism,
1 / 3
hyperthyroidism, alcohol intoxication.*
Yes
No
3. af occurring and not persisting beyond 10 days
of surgery or myocardial infarction.*
Yes
No
4. reversible cause of chf such as severe aortic or
mitral stenosis and tachycardia-induced
cardiomyopathy.*
Yes
No
5. decompensated chf within 48 hours of
randomization.*
Yes
No
6. antiarrhythmic drugs other than calcium
channel blockers, beta-blockers or digoxin
required for other arrhythmias or other
indications.*
Yes
No
7. more than 7 days of amiodarone therapy within
the last month prior to randomization.*
Yes
No
8. second or third degree av block, sinus pause
>3 seconds, resting heart rate <50 bpm without a
permanent pacemaker.*
Yes
No
9. history of drug-induced torsades de pointes or
congenital long qt syndrome.*
Yes
No
10. prior av nodal ablation or maze surgery.*
Yes
No
11. probable cardiac transplantation in the next 6
months.*
Yes
No
12. chronic renal failure requiring dialysis.*
Yes
No
13. women of child-bearing potential and not on a
reliable method of birth control.*
Yes
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No
14. geographic or social factors, drug or alcohol
abuse making follow-up or compliance difficult.*
Yes
No
15. other noncardiovascular medical condition
(such as cancer) making 1 year survival unlikely.*
Yes
No
16. less than 18 years of age.*
Yes
No
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Eligibility Atrial Fibrillation NCT00597077
Eligibility Autoimmune Hepatitis
NCT00838214
Budesonide 3x3mg/d Versus Prednisone in Active
Autoimmune Hepatitis; ODM derived from:
https://clinicaltrials.gov/show/NCT00838214
All rights reserved. Please visit https://medical-data-
models.org/forms/13386
Eligibility Autoimmune Hepatitis
NCT00838214
Inclusion Criteria
age 10 to 70 years*
Yes
No
diagnosis of acute aih according to alvarez score*
Yes
No
normal range of tpmt activity*
Yes
No
normal acth test*
Yes
No
Negative pregnancy test at screening for females
of childbearing potential*
Yes
No
Written informed consent*
Yes
No
Exclusion Criteria
Presence of hepatitis a, b, c, e or g virus
infection*
Yes
No
Liver cirrhosis or clinical signs of portal
hypertension*
Yes
No
PBC*
Yes
No
PSC*
Yes
No
History of hypersensitivity to the study
medication*
Yes
No
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Eligibility Breast Cancer NCT00038402
Evaluation of the Addition of Herceptin to Standard
Chemotherapy in the Neoadjuvant Setting for Operable
Breast Cancer; ODM derived from:
https://clinicaltrials.gov/show/NCT00038402
All rights reserved. Please visit https://medical-data-
models.org/forms/13387
Eligibility Breast Cancer
NCT00038402
Inclusion Criteria
1. all patients with histologic confirmation of
invasive, but non-inflammatory carcinoma of the
breast with t2-3 (greater than 2 cm), n0-1, m0 will
be eligible. patients with t1n1 (after histological
confirmation of nodal disease) will be eligible for
the study.*
Yes
No
2. histologic confirmation of invasive tumor will be
done by core needle biopsy. on the tissue
obtained, estrogen and progesterone receptors
(er/pr) as well as her-2/neu (will be determined by
immunohistochemistry (ih) and/or fluorescence in
situ hybridization (fish)) and p53 will be done (for
research evaluation). tumor proliferation rate will
be evaluable by immunohistochemistry using
paraffin-embedded sections and monoclonal
antibody for ki-67. residual tumor tissue will be
saved in the tissue bank for further future
studies.*
Yes
No
3. all patients who are her-2/neu positive will be
eligible for the study. her-2/neu positivity for
protocol purposes will be determined by ihc and
patients with tumors that are 3+ or fish + will be
eligible.*
Yes
No
4. patients must sign an informed consent
indicating that they are aware of the
investigational nature of the study, in keeping with
institutional policy.*
Yes
No
5. all patients should have adequate bone
marrow function, as defined by peripheral
granulocyte count of >1,500/mm3, and platelet
count > 100,000 mm3. patients must have
adequate liver function, with a bilirubin within
normal laboratory values. in addition, patients
should have adequate renal function, defined as
serum creatinine <2.0 mg%.*
Yes
No
6. patients must have a normal cardiac ejection
1 / 2
fraction as determined by baseline
echocardiogram. tape must be saved for review
by central cardiologist.*
Yes
No
7. patients who underwent biopsy outside will be
eligible if they had a measurable residual tumor.*
Yes
No
8. patients with multicentric disease and
extensive  ductal carcinoma in situ (dcis) will be
eligible for study.*
Yes
No
9. patients with a history of cardiac arrhythmia
will be eligible for study after being cleared by
cardiology.*
Yes
No
Exclusion Criteria
1. patients with t1n0 disease are not eligible for
the study.*
Yes
No
2. those patients with history of other invasive
malignancies will be excluded except non-
melanoma skin cancer and non-invasive cervical
cancer.*
Yes
No
3. patients with a history of congestive heart
failure will be excluded.*
Yes
No
4. patients who had surgical therapy prior to
referral will be ineligible.*
Yes
No
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Eligibility Breast Cancer NCT00041470
Navelbine, Taxol, Herceptin and Neupogen in Stage IV
Breast Cancer: A Phase I - II Trial; ODM derived from:
https://clinicaltrials.gov/show/NCT00041470
All rights reserved. Please visit https://medical-data-
models.org/forms/13388
Eligibility Breast Cancer
NCT00041470
Inclusion Criteria
Have stage iv carcinoma of the breast that has
been microscopically confirmed*
Yes
No
Be age > 18*
Yes
No
Be fully active or ambulatory with symptoms but
able to do light work*
Yes
No
Have a life expectancy of > 16 weeks*
Yes
No
Be > 2 weeks from prior surgery; > 3 weeks from
radiation therapy to the pelvis, spine or long
bones; > 3 weeks from prior chemotherapy (> 6
weeks for mitomycin c or nitrosureas) and > 2
weeks from prior hormonal therapy*
Yes
No
Have had one or less prior regimens for
metastatic disease*
Yes
No
Have measurable (bidimensionally) or evaluable
disease that is in an area that has not been
radiated*
Yes
No
Exclusion Criteria
Have rapidly progressing liver or lung metastases
or uncontrolled central nervous system
metastases
Yes
No
Are medically unstable
Yes
No
Are pregnant, nursing or unwilling to employ
adequate contraception
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Yes
No
Have pre-existing clinically significant peripheral
neuropathy except for abnormalities due to
cancer
Yes
No
Have psychological, familial, sociological or
geographical conditions that do not permit weekly
medical follow-up and compliance with the study
protocol
Yes
No
Have hypersensitivity to e. coli-derived proteins,
filgrastim, or any of its components
Yes
No
Have had prior therapy with navelbine
Yes
No
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Eligibility Breast Cancer NCT00133796
Neoadjuvant Herceptin in Patients With Breast Cancer;
ODM derived from:
https://clinicaltrials.gov/show/NCT00133796
All rights reserved. Please visit https://medical-data-
models.org/forms/13389
Eligibility Breast Cancer
NCT00133796
Inclusion Criteria
All patients must be female.*
Yes
No
Informed consent must be signed.*
Yes
No
Women with locally advanced breast cancers or
primary breast cancers with concomitant gross
metastatic disease are eligible. locally advanced
cancers must be of clinical and/or radiologic size
> 4 cm, and/or are deemed surgically
inoperable.*
Yes
No
Her2/neu overexpressing tumors defined as
herceptest score of 3+, or >/= one-third of
invasive tumor showing membranous staining, or
fluorescence in situ hybridization (fish) positive.*
Yes
No
Negative serum pregnancy test (bhcg) within 7
days of starting study, if of child-bearing
potential.*
Yes
No
kidney and liver function tests - all within 1.5
times of the institution's upper limit of normal.*
Yes
No
Performance status (world health organization
[who] scale) < 2 and life expectancy > 6 months.*
Yes
No
Age > 18.*
Yes
No
No metastatic disease without concomitant
primary breast cancer.*
Yes
No
No previous or current malignancies at other sites
within the last 5 years, with exception of
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adequately treated cone-biopsied in situ
carcinoma of the cervix uteri and basal or
squamous cell carcinoma of the skin.*
Yes
No
Exclusion Criteria
Pregnancy or unwillingness to use a reliable
contraceptive method in women of child-bearing
potential.*
Yes
No
Severe underlying chronic illness or disease.*
Yes
No
Cardiomyopathy or baseline left ventricular
ejection fraction (lvef) < 50%.*
Yes
No
Patients on other investigational drugs while on
study.*
Yes
No
Severe or uncontrolled hypertension defined as
blood pressure (bp) > 180/100 on three separate
occasions.*
Yes
No
History of congestive heart failure.*
Yes
No
History of coronary arterial disease.*
Yes
No
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Eligibility Renal Cell Carcinoma
NCT00026663
Collection of Blood, Bone Marrow, Tumor, or Tissue
Samples From Patients With Cancer to Study Drug
Resistance; ODM derived from:
https://clinicaltrials.gov/show/NCT00026663
All rights reserved. Please visit https://medical-data-
models.org/forms/13390
Eligibility Renal Cell Carcinoma
NCT00026663
Criteria
1. patients 18 years of age and older are eligible.*
Yes
No
2. patients must have a performance status of
ecog 0, 1, 2, or 3 for admission to this protocol.*
Yes
No
3. patients with malignancy are eligible.*
Yes
No
4. patients requiring a surgical procedure for any
medical indication can be included on study.*
Yes
No
5. patients requiring biopsy or any procedure for
any medical indication can be included on study.*
Yes
No
6. patients not requiring biopsy for a medical
indication can be included on the study solely for
the purpose of obtaining research samples,
including blood, pleural fluid, or peritoneal fluid, or
biopsy samples, providing the biopsy or
aspiration procedure is of minimal risk, i.e. fine
needle aspirate, bone marrow aspirate, or
excisional biopsy. no radiology tests will be used
in the procedure to collect a sample that would
not be otherwise used for an appropriate medical
indication.*
Yes
No
7. normal volunteers 18 years of age and older
are eligible to enroll. normal volunteers must be
willing to sign informed consent and must be
willing to provide samples to be used for
research.*
Yes
No
Exclusion Criteria
1. pregnant individuals will not be eligible due to
potential risks to the fetus associated with
radiologic procedures required for biopsy.*
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Yes
No
2. children will not be eligible because of potential
risks from complications due to procedures
involved in obtaining the biopsies.*
Yes
No
3. normal volunteers with a history of a clotting
disorder may not enroll.*
Yes
No
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Eligibility Schizophrenia NCT00159120
Maintenance Treatment vs. Stepwise Drug Discontinuation
in First-Episode Schizophrenia; ODM derived from:
https://clinicaltrials.gov/show/NCT00159120
All rights reserved. Please visit https://medical-data-
models.org/forms/13391
Eligibility Schizophrenia
NCT00159120
Inclusion Criteria
patients after 1 year of maintenance treatment
after their first-episode in schizophrenia
(according icd-10 f20)*
Yes
No
age between 18 and 55*
Yes
No
informed consent*
Yes
No
one year neuroleptic maintenance treatment*
Yes
No
reaching stable course*
Yes
No
Exclusion Criteria
residence outside of the catchment area*
Yes
No
legal reasons*
Yes
No
insufficient knowledge of the german language*
Yes
No
substance abuse or addiction*
Yes
No
pregnancy*
Yes
No
serious physical illness*
Yes
No
organic brain disease*
Yes
No
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contraindication to neuroleptic treatment*
Yes
No
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Eligibility Schizophrenia NCT00205725
Pfizer/IVGTT/Ziprasidone/Olanzapine; ODM derived from:
https://clinicaltrials.gov/show/NCT00205725
All rights reserved. Please visit https://medical-data-
models.org/forms/13392
Eligibility Schizophrenia
NCT00205725
Inclusion Criteria
patients: meets dsm-iv criteria for schizophrenia,
any type, or schizoaffective disorder;*
Yes
No
aged 18 to 60 years;*
Yes
No
able to give informed consent;*
Yes
No
no medication changes for 2 weeks prior to and
during the period of study;*
Yes
No
patients: currently taking an antipsychotic.*
Yes
No
Exclusion Criteria
controls: axis i psychiatric disorder criteria met
except for substance use disorders as below;*
Yes
No
meets dsm-iv criteria for the diagnoses of
substance abuse or dependence within the past
six months;*
Yes
No
involuntary legal status (as per missouri law);*
Yes
No
the presence of any serious medical disorder that
may (as confirmed by peer-reviewed literature)
confound the assessment of symptoms, relevant
biologic measures or diagnosis;*
Yes
No
insulin- or non-insulin-dependent diabetes
mellitus;*
Yes
No
any intra-abdominal or intrathoracic surgery or
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limb amputation within the prior 6 months;*
Yes
No
any diagnosed cardiac condition causing
documented hemodynamic compromise;*
Yes
No
any diagnosed respiratory condition causing
documented or clinically recognized hypoxia;*
Yes
No
pregnancy or high dose estrogens, fever, narcotic
therapy, acute sedative hypnotic withdrawal,
corticosteroid or spironolactone therapy,
dehydration, epilepsy, endocrine disease, high-
dose benzodiazepine therapy (> 25 mg/day of
diazepam), or any medical condition known to
interfere with glucose utilization;*
Yes
No
meets dsm-iv criteria for mental retardation (mild
or worse).*
Yes
No
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Eligibility Schizophrenia NCT00205738
Janssen - Glucose Regulation/Risp/Olanz; ODM derived
from: https://clinicaltrials.gov/show/NCT00205738
All rights reserved. Please visit https://medical-data-
models.org/forms/13393
Eligibility Schizophrenia
NCT00205738
Inclusion Criteria
1. patients: meets dsm-iv criteria for
schizophrenia, any type, or schizoaffective
disorder;*
Yes
No
2. aged 18 to 60 years;*
Yes
No
3. able to give informed consent;*
Yes
No
4. no medication changes for 2 weeks prior to
and during the period of study; 5. patients:
currently taking olanzapine, risperidone,
haloperidol or another typical antipsychotic.*
Yes
No
Exclusion Criteria
1. controls: axis i psychiatric disorder criteria met
except for substance use disorders as below;*
Yes
No
2. meets dsm-iv criteria for the diagnoses of
substance abuse or dependence within the past
six months;*
Yes
No
3. involuntary legal status (as per missouri law);*
Yes
No
4. the presence of any serious medical disorder
that may (as confirmed by peer-reviewed
literature) confound the assessment of
symptoms, relevant biologic measures or
diagnosis; the following conditions are currently
identified: insulin- or non-insulin-dependent
diabetes mellitus; any intra-abdominal or
intrathoracic surgery or limb amputation within
the prior 6 months; any diagnosed cardiac
condition causing documented hemodynamic
compromise; any diagnosed respiratory condition
causing documented or clinically recognized
hypoxia; pregnancy or high dose estrogens, fever,
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narcotic therapy, acute sedative hypnotic
withdrawal, corticosteroid or spironolactone
therapy, dehydration, epilepsy, endocrine
disease, high-dose benzodiazepine therapy (> 25
mg/day of diazepam), or any medical condition
known to interfere with glucose utilization;*
Yes
No
5. meets dsm-iv criteria for mental retardation
(mild or worse).*
Yes
No
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Eligibility Schizophrenia NCT00712686
Comparative Study of Aripiprazole and Olanzapine in the
Treatment of Patients With Acute Schizophrenia; ODM
derived from: https://clinicaltrials.gov/show/NCT00712686
All rights reserved. Please visit https://medical-data-
models.org/forms/13394
Eligibility Schizophrenia
NCT00712686
Inclusion Criteria
patients with dsm-iv diagnosis of schizophrenia
patients in acute relapse*
Yes
No
treated as outpatients for at least one continuous
3-month period during the past 12 months*
Yes
No
panss total score ≥60*
Yes
No
previously responsive to neuroleptics (other than
clozapine)*
Yes
No
able to give informed consent and comprehend
and satisfactorily comply with the protocol
requirements*
Yes
No
Exclusion Criteria
an axis i (dsm-iv) diagnosis of schizoaffective
disorder*
Yes
No
a clinical picture and/or history that was
consistent with: (a) delirium, dementia, amnestic
or other cognitive disorders; (b) bipolar disorder;
(c)personality disorder*
Yes
No
nonresponsive to prior olanzapine therapy*
Yes
No
likely to require prohibited concomitant therapy*
Yes
No
dsm-iv criteria for any significant substance
abuse within the past three months, including
addiction to cocaine or alcohol*
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Yes
No
known to be allergic or hypersensitive to study
drugs*
Yes
No
represented a significant risk of committing
suicide based on history or mental status exam*
Yes
No
unstable thyroid pathology and treatment within
the past six months*
Yes
No
a history or evidence of a medical condition that
would expose the patient to an undue risk*
Yes
No
clinically significant abnormal laboratory test
results (including urine drug screen), vital sign, or
ecg findings*
Yes
No
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Evaluation Sheet Acute Graft vs. Host
Disease Akute myeloische Leukämie (AML)
Klinische Routinedokumentation Hämatologie
Knappschaftskrankenhaus Bochum-Langendreer
All rights reserved. Please visit https://medical-data-
models.org/forms/13395
Evaluation Sheet Acute Graft vs.
Host Disease Akute myeloische
Leukämie (AML)
Default Itemgroup
Patient Name
Date of Transplantation
Day after Transplantation
days
Skin
Grade of Skin Lesion
Maculopapulöses Exanthem <25% der
KO (+)
Maculopapulöses Exanthem 25-50% der
KO (++)
Generalisierte Erythrodermie (+++)
Desquamation, Bullae (++++)
Liver
Bilirubin
Bilirubin 2-3 mg/dl (+)
Bilirubin 3-6 mg/dl (++)
Bilirubin 6-15 mg/dl (+++)
Bilirubin >15 mg/dl (++++)
Intestines
Diarrhea
500-1000ml or persisting Nausea (+)
1000-1500ml (++)
>1500ml (+++)
Pain, Ileus (++++)
Patient findings
Acute Graft vs. Host Disease Grade
Skin +/++ Liver 0 Intestines 0 (I)
Skin +/++/+++ Liver + Intestines + (II)
Skin ++/+++ Liver ++/+++ Intestines
++/+++ (III)
Skin ++/+++/++++ Liver ++/+++/++++
Intestines ++/+++/++++ (IV)
Signature
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Date
Name of Investigator
Signature of investigator
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Evaluation Sheet Acute Graft vs. Host Disease Akute myeloische
Leukämie (AML)
Medical History - Department of Internal Medicine
Knappschaftskrankenhaus Bochum-Langendreer
Medical History - Department of Internal Medicine
Knappschaftskrankenhaus Bochum-Langendreer
With friendly permission of Prof. Schmiegel and Prof.
Schroers
All rights reserved. Please visit https://medical-data-
models.org/forms/13397
Medical History - Department of
Internal Medicine
Knappschaftskrankenhaus Bochum-
Langendreer
Default Itemgroup
Diagnosis
ICD-Codes
Date
Department
Treating physician
Signs and Symptoms
Medical history
Review of systems
Medication
Self-medication (prescribed)
C0599401 (C0599401)
Self-medication (nonprescribed)
Stimulants/Drugs
Stimulants
Illicit drugs
Social life
Social and personal history
Familiy history
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Physical examination
Age
years
Weight
kg
Height
BMI
kg/sqm
Nutritional status (if no BMI calculated)
Skin
Hair
Icterus
Cyanosis
Edema
Head and Mouth/Tooth
Neck
Describe entire Thorax: shape, mammae, heart
and lung auscultation
Abdomen
Musculokeletal system
Peripheral pulse
Blood pressure
Varicosity
Lymph nodes
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Medical History - Department of Internal Medicine
Knappschaftskrankenhaus Bochum-Langendreer
Neurologic symptoms
Date and Signature
Date
Signature
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Medical History - Department of Internal Medicine
Knappschaftskrankenhaus Bochum-Langendreer
Analysis of chimerism after SCT AML - Department of Internal
Medicine Knappschaftskrankenhaus Bochum-Langendreer
Data derived from electronic file of the Department of
Internal Medicine. With friendly permission of Prof. Dr. med.
Schmiegel http://www.medunikkh.de
All rights reserved. Please visit https://medical-data-
models.org/forms/13401
Analysis of Chimerism after SCT
AML
Default Itemgroup
Patient name
Date of birth
Patient Address
Patient ID
Donor
Findings
Specimen
Date of examination
Number of examination
Sender of material
Question
Correlation coefficient
Recipient signal
%
Diagnosis
Diagnosis
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Stem cell transplant documentation - Department of Internal
Medicine Knappschaftskrankenhaus Bochum-Langendreer
Data derived from paper-based form of the Department of
Internal Medicine. With friendly permission of Prof. Dr. med.
Schmiegel http://www.medunikkh.de/
All rights reserved. Please visit https://medical-data-
models.org/forms/13402
Patient medical record
Default Itemgroup
Patient Name
Date of birth
Date
Date of Transplantation
Day after Transplantation
Diagnosis
Nurse
Blood group for transfusion of pRBC
Blood group for emergency transfusion of pRBC
Blood group for platelet concentrates
Laboratory
Differential blood count
Creatinine
Magnesium
Sodium
Potassium
Chlorid
Lactatdehydrogenase
GOT/Aspartat Transaminase
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Bilirubin
Ciclosporine level
CRP
GPT/Alanine Transaminase
Gamma-GT
Alkaline phosphatase
Urea
Platelet count
Infectiological Marker
Cytomegalovirus
Yes
No
Epstein-Barr Virus
Yes
No
Galactomannan/Apergillus
Yes
No
Examination
Planned examinations
Oral medication
Oral medication
Acute medication
Vital signs
Pulse
Blood pressure
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Stem cell transplant documentation - Department of Internal Medicine
Knappschaftskrankenhaus Bochum-Langendreer
Body temperature
Central venous pressure
Weight
Oxygen saturation
%
Blood glucose concentration
Intravenous medication
Intravenous medication
Infusion pump
Antibiotics
Subcutaneous medication
Fluid balance
Fluid intake
Excretions
Fluid summary after 24hrs (Fluid balance)
Vomiting
Stool frequency
Signature
Signature
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Knappschaftskrankenhaus Bochum-Langendreer
Infectiological Report after HSCT - Department of Internal
Medicine Knappschaftskrankenhaus Bochum-Langendreer
Data derived from paper-based form of the Department of
Internal Medicine. With friendly permission of Prof. Dr. med.
Schmiegel http://www.medunikkh.de/
All rights reserved. Please visit https://medical-data-
models.org/forms/13403
Infectiological Report 2 KKH Bochum
SCT AML
Patient data
Patient name
Date of birth
Request
Specimen
Serologic test for Aspergillus (Galactomannan)
positive
Yes
No
Signature
Signature
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Lab Report HSCT - Department of Internal Medicine
Knappschaftskrankenhaus Bochum-Langendreer
Data derived from paper-based form of the Department of
Internal Medicine. With friendly permission of Prof. Dr. med.
Schmiegel http://www.medunikkh.de/
All rights reserved. Please visit https://medical-data-
models.org/forms/13404
Lab Report KKH Bochum SCT AML
Patient data
Patient name
Date of birth
Patient ID
Department
Date
Time
Molecular diagnostics
CMV-Ag
Yes
No
EBV-PCR
Copies/ml
Drug monitoring
Cyclosporine A level
ng/ml
Hematology
WBC(Leukocytes)
1000/ul
RBC(Erythrocytes)
100^6/ul
HGB (Hb)
g/dl
HK (Hematocrit)
%
MCV(Mean corpuscular volume)
fl
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MCH(Mean corpuscular hemoglobin)
pg
MCHC(Mean corpuscular hemoglobin
concentration)
g/dl
RDW(Red cell distribution width)
%
Platelets
10^3/ul
Normoblasts
10^3/ul
Neutrophiles
%
Lymphocytes
%
Monocytes
%
Eosinophiles
%
undefined item
Basophiles
%
Neutrophiles absolute
10^3/ul
Lymphocytes absolute
10^3/ul
Monocytes absolute
10^3/ul
Basophiles absolute
10^3/ul
Immunoglobulins
%
Immunoglobulins absolute
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Knappschaftskrankenhaus Bochum-Langendreer
Peroxidase stain
Yes
No
Esterase stain
Yes
No
Iron stain
Yes
No
Eosinophiles absolute
10^3/ul
Manual diffential blood count
Polychromasia
Yes
No
Clinical Chemistry
Sodium
mmol/l
Potassium
mmol/l
Chlorid
mmol/l
Calcium
mmol/l
Phosphate
mmol/l
Magnesium
mg/dl
Urea
mg/dl
Creatinine
mg/dl
MDRD
ml/min
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Knappschaftskrankenhaus Bochum-Langendreer
Protein
g/dl
Iron
ug/dl
Uric acid
mg/dl
Bilirubin
mg/dl
GOT
U/l
GPT/Alanine Transaminase
U/l
Alkaline phosphatase
U/l
Gamma-GT
U/l
Choline esterase
kU/l
LDH
U/l
Creatinine Kinase
U/l
Amylase
U/l
Lipase
U/l
Glucose
mg/dl
CRP
mg/dl
Coagulation
Quick
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Lab Report HSCT - Department of Internal Medicine
Knappschaftskrankenhaus Bochum-Langendreer
%INR
PTT
sec
Endocrinology
TSH
uU/ml
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Knappschaftskrankenhaus Bochum-Langendreer
HSCT Donor selection form - Department of Internal
Medicine Knappschaftskrankenhaus Bochum-Langendreer
Data derived from paper-based form of the Department of
Internal Medicine. With friendly permission of Prof. Dr. med.
Schmiegel http://www.medunikkh.de/
All rights reserved. Please visit https://medical-data-
models.org/forms/13405
Donor selection SCT AML KKH
Bochum
Patient data
Patient name
Date of birth
Blood group
CMV
Yes
No
Weight
Age
Gender
male (1)
female (2)
Pregnancy/Pregnancies
Donor data
Patient name
Date of birth
HLA-Constellation/HLA-matches
Blood group
CMV
Yes
No
Weight
Age
Gender
male (1)
female (2)
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Pregnancy/Pregnancies
Choice/Reason for exclusion
Signature
Signature of investigator
Date
2 / 2
HSCT Donor selection form - Department of Internal Medicine
Knappschaftskrankenhaus Bochum-Langendreer
Visit 2 Phase 1 clinical trial for intrasurgical hyperthermic intraperitoneal
chemoperfusion with cisplatin (HIPEC) in patients with ovarian cancer recidiv
Phase 1 clinical trial for intrasurgical hyperthermic
intraperitoneal chemoperfusion with cisplatin (HIPEC) in
patients with ovarian cancer recidiv EudraCT Nr.: 2010-
024352-28 Principal investigator und authorized
representative of Sponsor: PD Dr. med. Oliver Zivanovic
Center for Obstetrics and Gynaecology University Hospital
Bonn Sigmund-Freud-Str. 25 53105 Bonn Sponsor:
Rheinische Friedrich-Wilhelms-Universität Bonn
represented by the Dean of Medical Faculty
All rights reserved. Please visit https://medical-data-
models.org/forms/13407
Case report form (HIPEC) Visit 2
Patient Identification
Patient number
CRF number
Date of visit
Debulking surgery
Date of surgery
Please give the time the surgery procedure
started
Please give the time the surgical procedure was
completed
Time from incision to suture
Minutes
Type of surgery:Hysterectomy
Yes
No
Type of surgery:unilateral salpingo-oophorectomy
Yes
No
Type of surgery:bilateral salpingectomy with
oophorectomy
Yes
No
Type of surgery: Right hemicolectomy
Yes
No
Type of surgery:Transverse colectomy
Yes
No
Type of surgery: left colectomy
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Yes
No
Type of surgery: Stripping of pelvic peritoneum
Yes
No
Type of surgery: Excision of periaortic lymph
nodes
Yes
No
Type of surgery: Appendectomy
Yes
No
Type of surgery:Splenectomy
Yes
No
Type of surgery: Rectosigmoidectomy
Yes
No
Type of surgery: Colostomy Procedure
Yes
No
Type of surgery: Resection of small intestines
Yes
No
Type of surgery: Diaphragm stripping
Yes
No
Type of surgery: supracolic omentectomy
Yes
No
Type of surgery:infracolic omentectomy
Yes
No
Type of surgery:Complete pelvic lymph node
excision
Yes
No
Type of surgery:Sampling of lymph node
Yes
No
Please specifiy any other type of surgery
performed
Was there a residue after surgery?
makroscopic no residue (0)
<1cm residual tumor  (1)
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Visit 2 Phase 1 clinical trial for intrasurgical hyperthermic intraperitoneal
chemoperfusion with cisplatin (HIPEC) in patients with ovarian cancer recidiv
≥1cm residual tumor (2)
Outcome of surgery and HIPEC
without complications (1)
with complications (Please fill in AE-
Form and specify complications below)
(2)
Please specify any complications during surgery
and HIPEC such as: i.e adhesions
Biopsy sample of tumor tissue collected
(separate consent required)
Yes
No
HIPEC
Has the HIPEC Procedure been performed? If
"No", please specify the reason why below.
Yes
No
Please specify the reason why the HIPEC-
Procedure has not been performed
Date the HIPEC-Procedure has been performed
Time procedure was started
Time procedure was completed
Used dose in planned escalation scheme
I/I 60mg/sqm (1)
II/II 80mg/sqm (2)
III/III 100mg/sqm (3)
Total dose applied (calculated from dose in mg
multiplicated with body surface in square meter)
mg
Was there a reaction during application? If "yes",
please fill in AE form
Yes
No
Please give the total volume applied during
perfusion
ml
Please specify any particularities occurred during
HIPEC Procedure
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Visit 2 Phase 1 clinical trial for intrasurgical hyperthermic intraperitoneal
chemoperfusion with cisplatin (HIPEC) in patients with ovarian cancer recidiv
Pharmacokinetics
Blood sampling to validate concentration of
cisplatin (ng/ml)
Yes
No
Measuring point (from start of perfusion)
0min (before application of chemo) (1)
12h (10)
18h (11)
24h (12)
15min (2)
30min (3)
45min (4)
60min (5)
75min (6)
90min (7)
3h (8)
6h (9)
Measuring point valid?
Yes
No
Concentration of Cisplatin
ng/ml
Comments on any particularities during blood
sampling and testing. Please specify measuring
point
Sample of perfusate taken?
Yes
No
Measuring point (from start of perfusion)
0min (before application of chemo) (1)
15min (2)
30min (3)
45min (4)
60min (5)
75min (6)
90min (7)
Measuring point valid?
Yes
No
Concentration of Cisplatin
ng/ml
Comments on any particularities during perfusate
sampling and testing. Please specify measuring
point
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chemoperfusion with cisplatin (HIPEC) in patients with ovarian cancer recidiv
Recording of CTCAE: Have any AE occurred
perioperative or since the last Visit? If "Yes"
please fill in AE-Form
Yes
No
Has concomitant medication been subject to
change? If "Yes" please fill in Concomitant
medication form.
Yes
No
Confirmation of correctness
Confirmatin of investigator: I hereby confirm that I
personally checked this CRF for completeness
and correctness. All data and statements in this
CRF are ,according to best knowlwdge ,complete
and correct.
Yes
No
Name of Investigator
Signature of investigator
Date of completion of this form
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Visit 2 Phase 1 clinical trial for intrasurgical hyperthermic intraperitoneal
chemoperfusion with cisplatin (HIPEC) in patients with ovarian cancer recidiv
CDASH Vital Signs
modified from http://www.cdisc.org
All rights reserved. Please visit https://medical-data-
models.org/forms/13414
CDASH Vital Signs
Generelle Information
Wurden Vitalzeichen erhoben?*
Ja
Nein
Vitalzeichen
Datum der Messung der Vitalzeichen*
Körpergröße*
>= 0
cm
Körpergewicht*
>= 0
kg
Diastolischer Blutdruck*
>= 0
mmHg
Systolischer Blutdruck*
>= 0
mmHg
Ort der Blutdruckmessung*
Fußknöchel (ANKLE)
A. brachialis (BRACHIAL ARTERY)
Position der Blutdruckmessung*
in Bauchlage (PRONE)
sitzend (SITTING)
stehend (STANDING)
in Rückenlage (SUPINE)
Puls*
>= 0
BEATS/MIN
Ort der Pulsmessung*
A. brachialis (BRACHIAL ARTERY)
A. carotis (CAROTID ARTERY)
A. radialis (RADIAL ARTERY)
Position bei der Pulsmessung*
in Bauchlage (PRONE)
sitzend (SITTING)
stehend (STANDING)
in Rückenlage (SUPINE)
Körpertemperatur*
1 / 2
°C
Ort der Temperaturmessung*
Axilla (AXILLA)
Ohr (EAR)
Körperbau*
groß (LARGE)
mittel (MEDIUM)
klein (SMALL)
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SacBo TI: Case Report Form End Of Study
Code Box NCT01143272
Antibiotic-associated diarrhoea (AAD) is a frequent
condition in hospitalised patients receiving antibiotic
treatment. The same is true for Clostridium difficile-
associated diarrhoea (CDAD) with even more grave
consequences of increased morbidity and mortality. The
development and evaluation of preventive strategies is one
key public health challenge. In the absence of clinically
evaluated alternatives, probiotics have been suggested to
be beneficial for the prevention of AAD and CDAD.
However, data have so far been inconclusive and recently
published meta-analyses strongly recommended large
state-of-the-art clinical trials on probiotic substances for the
prevention of AAD and CDAD. Since the efficacy, side-
effects and modes of action of different probiotic bacteria
and yeast are strain specific, benefits and risks cannot be
generalised. The non-pathogenic yeast Saccharomyces
cerevisiae var. boulardii (Sac. boulardii) is considered the
most promising probiotic substance for the prevention of
AAD and CDAD. We carry out a randomised, placebo
controlled, double blind multicentre clinical trial to evaluate
Sac. boulardii for the indication of prevention of AAD and
CDAD in 1520 adult, hospitalised patients.
All rights reserved. Please visit https://medical-data-
models.org/forms/13418
SacBo TI: Case Report Form End Of
Study Code Box NCT01143272
Baseline and follow-up boxes
What is the code of the box?
How many capsules are left?
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SacBo TI Basic Information Registration
NCT01143272
Antibiotic-associated diarrhoea (AAD) is a frequent
condition in hospitalised patients receiving antibiotic
treatment. The same is true for Clostridium difficile-
associated diarrhoea (CDAD) with even more grave
consequences of increased morbidity and mortality. The
development and evaluation of preventive strategies is one
key public health challenge. In the absence of clinically
evaluated alternatives, probiotics have been suggested to
be beneficial for the prevention of AAD and CDAD.
However, data have so far been inconclusive and recently
published meta-analyses strongly recommended large
state-of-the-art clinical trials on probiotic substances for the
prevention of AAD and CDAD. Since the efficacy, side-
effects and modes of action of different probiotic bacteria
and yeast are strain specific, benefits and risks cannot be
generalised. The non-pathogenic yeast Saccharomyces
cerevisiae var. boulardii (Sac. boulardii) is considered the
most promising probiotic substance for the prevention of
AAD and CDAD. We carry out a randomised, placebo
controlled, double blind multicentre clinical trial to evaluate
Sac. boulardii for the indication of prevention of AAD and
CDAD in 1520 adult, hospitalised patients.
All rights reserved. Please visit https://medical-data-
models.org/forms/13419
SacBo TI Basic Information
Registration NCT01143272
SacBo Registration
Randomization number
Enter randomization number
randomization number control
Patient discharge or transfer*
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SacBo TI Phone Interview Investigational
Drug NCT01143272
Antibiotic-associated diarrhoea (AAD) is a frequent
condition in hospitalised patients receiving antibiotic
treatment. The same is true for Clostridium difficile-
associated diarrhoea (CDAD) with even more grave
consequences of increased morbidity and mortality. The
development and evaluation of preventive strategies is one
key public health challenge. In the absence of clinically
evaluated alternatives, probiotics have been suggested to
be beneficial for the prevention of AAD and CDAD.
However, data have so far been inconclusive and recently
published meta-analyses strongly recommended large
state-of-the-art clinical trials on probiotic substances for the
prevention of AAD and CDAD. Since the efficacy, side-
effects and modes of action of different probiotic bacteria
and yeast are strain specific, benefits and risks cannot be
generalised. The non-pathogenic yeast Saccharomyces
cerevisiae var. boulardii (Sac. boulardii) is considered the
most promising probiotic substance for the prevention of
AAD and CDAD. We carry out a randomised, placebo
controlled, double blind multicentre clinical trial to evaluate
Sac. boulardii for the indication of prevention of AAD and
CDAD in 1520 adult, hospitalised patients.
All rights reserved. Please visit https://medical-data-
models.org/forms/13421
SacBo TI Phone Interview
Investigational Drug NCT01143272
Last dose of investigational drug
When did the patient receive the last dose of the
investigational agent?
When did the patient receive the last dose of the
investigational agent?
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SacBo TI: Case Report Form Phone
Interview Diary TI NCT01143272
Antibiotic-associated diarrhoea (AAD) is a frequent
condition in hospitalised patients receiving antibiotic
treatment. The same is true for Clostridium difficile-
associated diarrhoea (CDAD) with even more grave
consequences of increased morbidity and mortality. The
development and evaluation of preventive strategies is one
key public health challenge. In the absence of clinically
evaluated alternatives, probiotics have been suggested to
be beneficial for the prevention of AAD and CDAD.
However, data have so far been inconclusive and recently
published meta-analyses strongly recommended large
state-of-the-art clinical trials on probiotic substances for the
prevention of AAD and CDAD. Since the efficacy, side-
effects and modes of action of different probiotic bacteria
and yeast are strain specific, benefits and risks cannot be
generalised. The non-pathogenic yeast Saccharomyces
cerevisiae var. boulardii (Sac. boulardii) is considered the
most promising probiotic substance for the prevention of
AAD and CDAD. We carry out a randomised, placebo
controlled, double blind multicentre clinical trial to evaluate
Sac. boulardii for the indication of prevention of AAD and
CDAD in 1520 adult, hospitalised patients.
All rights reserved. Please visit https://medical-data-
models.org/forms/13422
SacBo TI: Case Report Form Phone
Interview Diary TI NCT01143272
Current contact
Was the current contact a phone call?
Yes
No
Was the current contact performed at an
alternative date?
Until what date was the documentation on the
current eForm performed?
When is the maximum end of documentation
What date did the current contact take place?
Stool frequency and consistency
What date do the following items concern?
Was the patient rehospitalized in the study
hospital?
Yes
No
How many hard stools?
How many soft stools?
How many mushy or watery stools?
Was there no stool on this date or is the amount
1 / 2
not known?
no stool (1)
not known (2)
Intake of investigational agent
Did the patient take the investigational agent in
the morning?
yes (1)
no (2)
not known (3)
Did the patient take the investigational agent in
the evening?
yes (1)
no (2)
not known (3)
Did the patient use any laxatives?
yes (1)
no (2)
not known (3)
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SacBo TI: Case Report Form Phone Interview Medication
Obligatory For Documentation NCT01143272
Antibiotic-associated diarrhoea (AAD) is a frequent
condition in hospitalised patients receiving antibiotic
treatment. The same is true for Clostridium difficile-
associated diarrhoea (CDAD) with even more grave
consequences of increased morbidity and mortality. The
development and evaluation of preventive strategies is one
key public health challenge. In the absence of clinically
evaluated alternatives, probiotics have been suggested to
be beneficial for the prevention of AAD and CDAD.
However, data have so far been inconclusive and recently
published meta-analyses strongly recommended large
state-of-the-art clinical trials on probiotic substances for the
prevention of AAD and CDAD. Since the efficacy, side-
effects and modes of action of different probiotic bacteria
and yeast are strain specific, benefits and risks cannot be
generalised. The non-pathogenic yeast Saccharomyces
cerevisiae var. boulardii (Sac. boulardii) is considered the
most promising probiotic substance for the prevention of
AAD and CDAD. We carry out a randomised, placebo
controlled, double blind multicentre clinical trial to evaluate
Sac. boulardii for the indication of prevention of AAD and
CDAD in 1520 adult, hospitalised patients.
All rights reserved. Please visit https://medical-data-
models.org/forms/13423
SacBo TI: Case Report Form Phone
Interview Medication Obligatory For
Documentation NCT01143272
Antibiotic treatment
What is the number of this line?
Whats is the name of the antibiotic used?
What class does the antibiotic used belong to?
beta-lactam (1)
Nitroimidazol derivate (10)
unknown (11)
Tetracycline (2)
Aminoglycoside (3)
Macrolide (4)
Lincosamid (5)
Gyrase-Inhibitor (6)
Sulfonamide/Trimethoprim (7)
Glycopeptide (8)
Polypeptide (9)
What date was the first dose applied?
Was an entire day dose given at first dose?
Yes
No
What date was the last dose given?
How many days was the patient treated with the
antibiotic?
days
When did the antibiotic treatment end?
1 / 2
Treatment with drugs/opiates causing
constipation
What is the number of this line?
What is the name of the medication?
When did the treatment with this medication
start?
Is the date the medication was first applied not
known?
Yes
No
When was the last dose of this medication
applied?
Is the date of the last dose not known?
Yes
No
Treatment with systemic antifungal agents;
note that the use of systemic antifungal
agents makes the patient retrospectively
ineligible for this study as of exclusion
criterion 06; please record ear...
What is the number of this line?
What is the name of the medication used?
When did the treatment with this medication
start?
Is the date the medication was first applied not
known?
Yes
No
When was the last dose of this medication
applied?
Is the date of the last dose not known?
Yes
No
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SacBo TI: Case Report Form End Of Study
Study Discontinuation NCT01143272
Antibiotic-associated diarrhoea (AAD) is a frequent
condition in hospitalised patients receiving antibiotic
treatment. The same is true for Clostridium difficile-
associated diarrhoea (CDAD) with even more grave
consequences of increased morbidity and mortality. The
development and evaluation of preventive strategies is one
key public health challenge. In the absence of clinically
evaluated alternatives, probiotics have been suggested to
be beneficial for the prevention of AAD and CDAD.
However, data have so far been inconclusive and recently
published meta-analyses strongly recommended large
state-of-the-art clinical trials on probiotic substances for the
prevention of AAD and CDAD. Since the efficacy, side-
effects and modes of action of different probiotic bacteria
and yeast are strain specific, benefits and risks cannot be
generalised. The non-pathogenic yeast Saccharomyces
cerevisiae var. boulardii (Sac. boulardii) is considered the
most promising probiotic substance for the prevention of
AAD and CDAD. We carry out a randomised, placebo
controlled, double blind multicentre clinical trial to evaluate
Sac. boulardii for the indication of prevention of AAD and
CDAD in 1520 adult, hospitalised patients.
All rights reserved. Please visit https://medical-data-
models.org/forms/13424
SacBo TI: Case Report Form End Of
Study Study Discontinuation
NCT01143272
End of study / study discontinuation
Did the study end regularly?
Yes
No
Did the patient leave the study early?
Yes
No
What date was the end of study or the study
termination
If study discontinuation
Did the patient revoke written consent?
Yes
No
Was the patient lost to follow up?
Yes
No
Did the patient become retrospectively ineligible
for this study and if so what criterion was the
reason for becoming ineligible?
Hypersensitivity to yeast and/or
perenterol (Exclusion1 )
currently participating in another trial
(Exclusion10 )
Central venous catheterization
(Exclusion2 )
Immunosuppression (Exclusion3 )
Currently having diarrhea and/or
frequent diarrhea (Exclusion4 )
Frequent use of perenterol or yomogi (7
days before start of study) (Exclusion5 )
systemic antifungal treatment
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(Exclusion6 )
systemic antibiotic treatment (6 weeks
before start of study) (Exclusion7 )
for women: pregnancy (Exclusion8 )
for women: lactation (Exclusion9 )
Adult (Inclusion1 )
Patient hospitalized in study hospital
(Inclusion2 )
systemic antiobiotic treatment planned
(>= 3 days) (Inclusion3 )
Patient contractually capable (Inclusion4
)
Patient physically and mentally fit
(Inclusion5 )
For women of child-bearing age:
contraception (Inclusion6 )
Informed consent obtained (Inclusion7 )
Was there any other reason for early study
termination?
Yes
No
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SacBo TI: Case Report Form End Of Study Study Discontinuation
NCT01143272
SacBo TI: Case Report Form End Of Study
Signature NCT01143272
Antibiotic-associated diarrhoea (AAD) is a frequent
condition in hospitalised patients receiving antibiotic
treatment. The same is true for Clostridium difficile-
associated diarrhoea (CDAD) with even more grave
consequences of increased morbidity and mortality. The
development and evaluation of preventive strategies is one
key public health challenge. In the absence of clinically
evaluated alternatives, probiotics have been suggested to
be beneficial for the prevention of AAD and CDAD.
However, data have so far been inconclusive and recently
published meta-analyses strongly recommended large
state-of-the-art clinical trials on probiotic substances for the
prevention of AAD and CDAD. Since the efficacy, side-
effects and modes of action of different probiotic bacteria
and yeast are strain specific, benefits and risks cannot be
generalised. The non-pathogenic yeast Saccharomyces
cerevisiae var. boulardii (Sac. boulardii) is considered the
most promising probiotic substance for the prevention of
AAD and CDAD. We carry out a randomised, placebo
controlled, double blind multicentre clinical trial to evaluate
Sac. boulardii for the indication of prevention of AAD and
CDAD in 1520 adult, hospitalised patients.
All rights reserved. Please visit https://medical-data-
models.org/forms/13425
SacBo TI: Case Report Form End Of
Study Signature NCT01143272
electronic signature
Is the integrity and the accuracy of the data
confirmed?
Yes
No
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SacBo TI: Case Report Form End Of Study
Comment Log NCT01143272
Antibiotic-associated diarrhoea (AAD) is a frequent
condition in hospitalised patients receiving antibiotic
treatment. The same is true for Clostridium difficile-
associated diarrhoea (CDAD) with even more grave
consequences of increased morbidity and mortality. The
development and evaluation of preventive strategies is one
key public health challenge. In the absence of clinically
evaluated alternatives, probiotics have been suggested to
be beneficial for the prevention of AAD and CDAD.
However, data have so far been inconclusive and recently
published meta-analyses strongly recommended large
state-of-the-art clinical trials on probiotic substances for the
prevention of AAD and CDAD. Since the efficacy, side-
effects and modes of action of different probiotic bacteria
and yeast are strain specific, benefits and risks cannot be
generalised. The non-pathogenic yeast Saccharomyces
cerevisiae var. boulardii (Sac. boulardii) is considered the
most promising probiotic substance for the prevention of
AAD and CDAD. We carry out a randomised, placebo
controlled, double blind multicentre clinical trial to evaluate
Sac. boulardii for the indication of prevention of AAD and
CDAD in 1520 adult, hospitalised patients.
All rights reserved. Please visit https://medical-data-
models.org/forms/13426
SacBo TI: Case Report Form End Of
Study Comment Log NCT01143272
Comment Log
What is the number of this line?
Comment
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SacBo PZ: Case Report Form First Visit
Randomization NCT01143272
Antibiotic-associated diarrhoea (AAD) is a frequent
condition in hospitalised patients receiving antibiotic
treatment. The same is true for Clostridium difficile-
associated diarrhoea (CDAD) with even more grave
consequences of increased morbidity and mortality. The
development and evaluation of preventive strategies is one
key public health challenge. In the absence of clinically
evaluated alternatives, probiotics have been suggested to
be beneficial for the prevention of AAD and CDAD.
However, data have so far been inconclusive and recently
published meta-analyses strongly recommended large
state-of-the-art clinical trials on probiotic substances for the
prevention of AAD and CDAD. Since the efficacy, side-
effects and modes of action of different probiotic bacteria
and yeast are strain specific, benefits and risks cannot be
generalised. The non-pathogenic yeast Saccharomyces
cerevisiae var. boulardii (Sac. boulardii) is considered the
most promising probiotic substance for the prevention of
AAD and CDAD. We carry out a randomised, placebo
controlled, double blind multicentre clinical trial to evaluate
Sac. boulardii for the indication of prevention of AAD and
CDAD in 1520 adult, hospitalised patients.
All rights reserved. Please visit https://medical-data-
models.org/forms/13427
SacBo PZ: Case Report Form First
Visit Randomization NCT01143272
Default Itemgroup
Is the patient eligible for this study according to
inclusion and exclusion criteria?
Yes
No
When was the informed consent form signed?
What is the randomization number?
Entry of randomization number
Control entry of randomization number
What date did the randomization take place?
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SacBo PZ: Case Report Form First Visit
Patient Data NCT01143272
Antibiotic-associated diarrhoea (AAD) is a frequent
condition in hospitalised patients receiving antibiotic
treatment. The same is true for Clostridium difficile-
associated diarrhoea (CDAD) with even more grave
consequences of increased morbidity and mortality. The
development and evaluation of preventive strategies is one
key public health challenge. In the absence of clinically
evaluated alternatives, probiotics have been suggested to
be beneficial for the prevention of AAD and CDAD.
However, data have so far been inconclusive and recently
published meta-analyses strongly recommended large
state-of-the-art clinical trials on probiotic substances for the
prevention of AAD and CDAD. Since the efficacy, side-
effects and modes of action of different probiotic bacteria
and yeast are strain specific, benefits and risks cannot be
generalised. The non-pathogenic yeast Saccharomyces
cerevisiae var. boulardii (Sac. boulardii) is considered the
most promising probiotic substance for the prevention of
AAD and CDAD. We carry out a randomised, placebo
controlled, double blind multicentre clinical trial to evaluate
Sac. boulardii for the indication of prevention of AAD and
CDAD in 1520 adult, hospitalised patients.
All rights reserved. Please visit https://medical-data-
models.org/forms/13428
SacBo PZ: Case Report Form First
Visit Patient Data NCT01143272
Patient Data
Whats is the patient's date of birth?
Whats is the patient's gender?
male (1)
female (2)
What is the patient's body height?
cm
What is the patient's body weight?
kg
Antibiotic initially used
When was the first dose applied?
First dose of investigational drug
When was the first dose of the investigational
drug applied?
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SacBo PZ: Case Report Form First Visit
CRP, Leukocytes NCT01143272
Antibiotic-associated diarrhoea (AAD) is a frequent
condition in hospitalised patients receiving antibiotic
treatment. The same is true for Clostridium difficile-
associated diarrhoea (CDAD) with even more grave
consequences of increased morbidity and mortality. The
development and evaluation of preventive strategies is one
key public health challenge. In the absence of clinically
evaluated alternatives, probiotics have been suggested to
be beneficial for the prevention of AAD and CDAD.
However, data have so far been inconclusive and recently
published meta-analyses strongly recommended large
state-of-the-art clinical trials on probiotic substances for the
prevention of AAD and CDAD. Since the efficacy, side-
effects and modes of action of different probiotic bacteria
and yeast are strain specific, benefits and risks cannot be
generalised. The non-pathogenic yeast Saccharomyces
cerevisiae var. boulardii (Sac. boulardii) is considered the
most promising probiotic substance for the prevention of
AAD and CDAD. We carry out a randomised, placebo
controlled, double blind multicentre clinical trial to evaluate
Sac. boulardii for the indication of prevention of AAD and
CDAD in 1520 adult, hospitalised patients.
All rights reserved. Please visit https://medical-data-
models.org/forms/13429
SacBo PZ: Case Report Form First
Visit CRP, Leukocytes NCT01143272
Examination date
What date did the examination take place?
CRP
What was the CRP value?
Was the CRP measurement not performed?
Yes
No
Is the unit mg/L?
Yes
No
Is the unit mg/dl?
Yes
No
Was a different unit used?
Yes
No
What was the unit that was used?
Leukocytes
What was the measured leukocyte value?
Was the leukocyte measurement not performed?
Yes
No
Is the unit 10**9/L?
1 / 2
10**9/L equals: 1000/mcL, 10*3/mcL, /nL, G/L,
Gpt/L, Giga/L
Yes
No
Is the unit /mcL = /mm3?
Yes
No
Was a different unit used?
Yes
No
What was the unit that was used?
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SacBo PZ: Case Report Form
Hospitalization Readmission NCT01143272
Antibiotic-associated diarrhoea (AAD) is a frequent
condition in hospitalised patients receiving antibiotic
treatment. The same is true for Clostridium difficile-
associated diarrhoea (CDAD) with even more grave
consequences of increased morbidity and mortality. The
development and evaluation of preventive strategies is one
key public health challenge. In the absence of clinically
evaluated alternatives, probiotics have been suggested to
be beneficial for the prevention of AAD and CDAD.
However, data have so far been inconclusive and recently
published meta-analyses strongly recommended large
state-of-the-art clinical trials on probiotic substances for the
prevention of AAD and CDAD. Since the efficacy, side-
effects and modes of action of different probiotic bacteria
and yeast are strain specific, benefits and risks cannot be
generalised. The non-pathogenic yeast Saccharomyces
cerevisiae var. boulardii (Sac. boulardii) is considered the
most promising probiotic substance for the prevention of
AAD and CDAD. We carry out a randomised, placebo
controlled, double blind multicentre clinical trial to evaluate
Sac. boulardii for the indication of prevention of AAD and
CDAD in 1520 adult, hospitalised patients.
All rights reserved. Please visit https://medical-data-
models.org/forms/13430
SacBo PZ: Case Report Form
Hospitalization Readmission
NCT01143272
Readmission
When was the patient readmitted to the hospital?
Was the patient readmitted as an out-patient or
as an in-patient?
out-patient (1)
in-patient (2)
What was the reason for the return/readmission
to the hospital?
Diarrhea/AAD/CDAD (1)
Aggravation of underlying disease (2)
Known and listed side effect of the
antibiotic used (3)
Adverse event (4)
other reason (5)
What phase of the study is the patient currently
in?
Treatment 1 (1)
Treatment 2 (2)
Follow Up (3)
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Medication subject to documentation NCT01143272
Antibiotic-associated diarrhoea (AAD) is a frequent
condition in hospitalised patients receiving antibiotic
treatment. The same is true for Clostridium difficile-
associated diarrhoea (CDAD) with even more grave
consequences of increased morbidity and mortality. The
development and evaluation of preventive strategies is one
key public health challenge. In the absence of clinically
evaluated alternatives, probiotics have been suggested to
be beneficial for the prevention of AAD and CDAD.
However, data have so far been inconclusive and recently
published meta-analyses strongly recommended large
state-of-the-art clinical trials on probiotic substances for the
prevention of AAD and CDAD. Since the efficacy, side-
effects and modes of action of different probiotic bacteria
and yeast are strain specific, benefits and risks cannot be
generalised. The non-pathogenic yeast Saccharomyces
cerevisiae var. boulardii (Sac. boulardii) is considered the
most promising probiotic substance for the prevention of
AAD and CDAD. We carry out a randomised, placebo
controlled, double blind multicentre clinical trial to evaluate
Sac. boulardii for the indication of prevention of AAD and
CDAD in 1520 adult, hospitalised patients.
Please note:
1) At first hospitalization please enter the antibiotic initially
used in the first line!
2) Please enter the medication in chronological order!
3) Obligatory documentation starts with the date the (re-)
hospitalization begins!
If there is preexisting medication the starting date is
determined as follows:
a) First hospitalization = Date of first dose of antibiotic!
b) Rehospitalization = Date of Rehospitalization!
4) Documentation of the last dose of any of the medication
subject for documentation is only necessary until the
regular end of the study.
All rights reserved. Please visit https://medical-data-
models.org/forms/13431
SacBo PZ: Case Report Form
Hospitalization Medication subject to
documentation NCT01143272
Antibiotics
Number
Antibiotic group
Beta-Lactam (1)
Nitroimidazole Derivative (10)
Tetracycline (2)
Aminoglycoside (3)
Macrolide (4)
Lincosamide (5)
Gyrase inhibitor (6)
Sulfonamide (7)
Glykopeptide (8)
Polypeptide (9)
What was the indication for the treatment?
Antibiotic-associated diarrhea (1)
Clostridium difficile associated diarrhea
(2)
What is the ICD-10 code of the indication?
How was the antibiotic applied?
oral (1)
1 / 2
intravenous (2)
intramuscular (3)
When was the first dose applied?
When was the last dose applied?
If antibiotic was used: was the treatment
terminated because of AAD/CDAD?
Yes
No
When did treatment phase 1 end?
Further medication subject to
documentation
Whats is the number of the medication?
What kind of medication was used?
Laxatives (1)
Opiates causing obstipation / other
medication causing obstipation (2)
systemic antifungal agents (3)
When was the first dose of the medication used?
When was the last dose of the medication used?
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SacBo: Case Report Form Hospitalization
Patient Diary NCT01143272
Antibiotic-associated diarrhoea (AAD) is a frequent
condition in hospitalised patients receiving antibiotic
treatment. The same is true for Clostridium difficile-
associated diarrhoea (CDAD) with even more grave
consequences of increased morbidity and mortality. The
development and evaluation of preventive strategies is one
key public health challenge. In the absence of clinically
evaluated alternatives, probiotics have been suggested to
be beneficial for the prevention of AAD and CDAD.
However, data have so far been inconclusive and recently
published meta-analyses strongly recommended large
state-of-the-art clinical trials on probiotic substances for the
prevention of AAD and CDAD. Since the efficacy, side-
effects and modes of action of different probiotic bacteria
and yeast are strain specific, benefits and risks cannot be
generalised. The non-pathogenic yeast Saccharomyces
cerevisiae var. boulardii (Sac. boulardii) is considered the
most promising probiotic substance for the prevention of
AAD and CDAD. We carry out a randomised, placebo
controlled, double blind multicentre clinical trial to evaluate
Sac. boulardii for the indication of prevention of AAD and
CDAD in 1520 adult, hospitalised patients.
All rights reserved. Please visit https://medical-data-
models.org/forms/13432
SacBo: Case Report Form
Hospitalization Patient Diary
NCT01143272
Starting date of documentation
When did documentation start?
Stool frequency and consistency
What day do the following items concern?
What date is it?
How many hard stools on this day?
Soft Stool
How many mushy or watery stools on this day?
Was there no stool on this day or is the number of
stools not known?
no stool (1)
unknown (2)
Until what date is there documentation in the
diary?
New page
Do you want to start a new page in order to
continue the patient diary?
Yes
No
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Diarrhea or AAD or CDAD NCT01143272
Antibiotic-associated diarrhoea (AAD) is a frequent
condition in hospitalised patients receiving antibiotic
treatment. The same is true for Clostridium difficile-
associated diarrhoea (CDAD) with even more grave
consequences of increased morbidity and mortality. The
development and evaluation of preventive strategies is one
key public health challenge. In the absence of clinically
evaluated alternatives, probiotics have been suggested to
be beneficial for the prevention of AAD and CDAD.
However, data have so far been inconclusive and recently
published meta-analyses strongly recommended large
state-of-the-art clinical trials on probiotic substances for the
prevention of AAD and CDAD. Since the efficacy, side-
effects and modes of action of different probiotic bacteria
and yeast are strain specific, benefits and risks cannot be
generalised. The non-pathogenic yeast Saccharomyces
cerevisiae var. boulardii (Sac. boulardii) is considered the
most promising probiotic substance for the prevention of
AAD and CDAD. We carry out a randomised, placebo
controlled, double blind multicentre clinical trial to evaluate
Sac. boulardii for the indication of prevention of AAD and
CDAD in 1520 adult, hospitalised patients.
All rights reserved. Please visit https://medical-data-
models.org/forms/13433
SacBo PZ: Case Report Form
Hospitalization Diarrhea or AAD or
CDAD NCT01143272
Current hospitalization
Was there diarrhea/AAD/CDAD at current
hospitalization?
Yes
No
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Documentation Diarrhea - AAD - CDAD NCT01143272
Antibiotic-associated diarrhoea (AAD) is a frequent
condition in hospitalised patients receiving antibiotic
treatment. The same is true for Clostridium difficile-
associated diarrhoea (CDAD) with even more grave
consequences of increased morbidity and mortality. The
development and evaluation of preventive strategies is one
key public health challenge. In the absence of clinically
evaluated alternatives, probiotics have been suggested to
be beneficial for the prevention of AAD and CDAD.
However, data have so far been inconclusive and recently
published meta-analyses strongly recommended large
state-of-the-art clinical trials on probiotic substances for the
prevention of AAD and CDAD. Since the efficacy, side-
effects and modes of action of different probiotic bacteria
and yeast are strain specific, benefits and risks cannot be
generalised. The non-pathogenic yeast Saccharomyces
cerevisiae var. boulardii (Sac. boulardii) is considered the
most promising probiotic substance for the prevention of
AAD and CDAD. We carry out a randomised, placebo
controlled, double blind multicentre clinical trial to evaluate
Sac. boulardii for the indication of prevention of AAD and
CDAD in 1520 adult, hospitalised patients.
All rights reserved. Please visit https://medical-data-
models.org/forms/13434
SacBo PZ: Case Report Form
Hospitalization Documentation
Diarrhea - AAD - CDAD
NCT01143272
Default Itemgroup
What date did the diarrhea/AAD/CDAD occur?
What is the number of the episode?
What date was the stool sample acquired to be
passed on to the BNI?
Was there antibiotic-assoiated diarrhea as a
clinical diagnosis?
Yes
No
Did antibiotic-associated diarrhea occur and were
microbes found?
Yes
No
What kind of microbes were found?
Did clostridium difficile associated diarrhea occur
and was the diagnosis confirmed by stool
culture?
Yes
No
Did CDAD occur and was the diagnosis
confirmed by finding Toxin A and/or Toxin B?
Yes
No
Did CDAD occur that was confirmed by
endoscopy?
1 / 2
Yes
No
Did CDAD occur and was the diagnosis
confirmed by methods of molecular biology?
Yes
No
Did diarrhea occur that was exclusively diarrhea
other than AAD or CDAD?
Yes
No
Clinical diagnosis
Was there blood in the stool?
yes (1)
no (2)
not known (3)
Was there abdominal pain or cramps?
yes (1)
no (2)
not known (3)
Was there dehydration?
yes (1)
no (2)
not known (3)
Was there fever?
yes (1)
no (2)
not known (3)
Did the patient receive any medication?
Yes
No
Conservative or surgical therapy for
AAD/CDAD
Was there any further conservative or surgical
therapy necessary for AAD/CDAD?
Yes
No
If there was further treatment necessary please
specify:
Further episode of diarrhea/AAD/CDAD
Was there any further episode of
diarrhea/AAD/CDAD or was another stool sample
acquired?
Yes
No
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SacBo PZ: Case Report Form Hospitalization
Completion Of Current Visit NCT01143272
Antibiotic-associated diarrhoea (AAD) is a frequent
condition in hospitalised patients receiving antibiotic
treatment. The same is true for Clostridium difficile-
associated diarrhoea (CDAD) with even more grave
consequences of increased morbidity and mortality. The
development and evaluation of preventive strategies is one
key public health challenge. In the absence of clinically
evaluated alternatives, probiotics have been suggested to
be beneficial for the prevention of AAD and CDAD.
However, data have so far been inconclusive and recently
published meta-analyses strongly recommended large
state-of-the-art clinical trials on probiotic substances for the
prevention of AAD and CDAD. Since the efficacy, side-
effects and modes of action of different probiotic bacteria
and yeast are strain specific, benefits and risks cannot be
generalised. The non-pathogenic yeast Saccharomyces
cerevisiae var. boulardii (Sac. boulardii) is considered the
most promising probiotic substance for the prevention of
AAD and CDAD. We carry out a randomised, placebo
controlled, double blind multicentre clinical trial to evaluate
Sac. boulardii for the indication of prevention of AAD and
CDAD in 1520 adult, hospitalised patients.
All rights reserved. Please visit https://medical-data-
models.org/forms/13435
SacBo PZ: Case Report Form
Hospitalization Completion Of
Current Visit NCT01143272
Discharge/Transfer/End of study/Early
study termination
What date did the discharge/transferal/end of
study/early study termination take place?
Was the patient discharges as an in-patient or did
the patient revisit as an out-patient?
Yes
No
Was the patient transferred to another ward or
hospital?
Yes
No
Did the study end regularly?
Yes
No
Was the study early terminated?
Yes
No
Investigational Drug Starting Box
Does the patient take the starting box home?
Yes
No
Investigational Drug Following Boxes
How many days of antibiotic treatment in
treatment phase 1 are there according to the data
obtained?
days
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How many following boxes does the patient
therefore need?
The following following boxes were already given
to the patient during prior hospitalizations:
What is the number of the following box?
Does the patient take the following box home?
Yes
No
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SacBo PZ: Case Report Form
Hospitalization Transferal NCT01143272
Antibiotic-associated diarrhoea (AAD) is a frequent
condition in hospitalised patients receiving antibiotic
treatment. The same is true for Clostridium difficile-
associated diarrhoea (CDAD) with even more grave
consequences of increased morbidity and mortality. The
development and evaluation of preventive strategies is one
key public health challenge. In the absence of clinically
evaluated alternatives, probiotics have been suggested to
be beneficial for the prevention of AAD and CDAD.
However, data have so far been inconclusive and recently
published meta-analyses strongly recommended large
state-of-the-art clinical trials on probiotic substances for the
prevention of AAD and CDAD. Since the efficacy, side-
effects and modes of action of different probiotic bacteria
and yeast are strain specific, benefits and risks cannot be
generalised. The non-pathogenic yeast Saccharomyces
cerevisiae var. boulardii (Sac. boulardii) is considered the
most promising probiotic substance for the prevention of
AAD and CDAD. We carry out a randomised, placebo
controlled, double blind multicentre clinical trial to evaluate
Sac. boulardii for the indication of prevention of AAD and
CDAD in 1520 adult, hospitalised patients.
All rights reserved. Please visit https://medical-data-
models.org/forms/13436
SacBo PZ: Case Report Form
Hospitalization Transferal
NCT01143272
Doctor's letter received after transferal
Was the discharge document received after
transferal?
Yes
No
What date was the patient discharged from the
ward/hospital where the treatment was
continued?
Was there a new episode of AAD after the
transferal to a different ward/hospital?
Yes
No
Was there a new episode of clostridium difficile
associated diarrhea after transferal to a different
ward/hospital?
Yes
No
Was the study terminated early?
Yes
No
Medication subject to documentation
What is the number of the medication?
What kind of medication was used?
Beta-Lactam Antibiotic  (1)
Nitroimidazole Derivative  (10)
Laxatives  (11)
Opiates causing obstipation / other
medication causing obstipation  (12)
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Systemic antifungal agents (13)
Tetracycline  (2)
Aminoglycoside  (3)
Macrolide Antibiotic  (4)
Lincosamide  (5)
Gyrase inhibitor  (6)
Sulfonamide/Trimethoprim  (7)
Glykopeptide Antibiotic  (8)
Polypeptide Antibiotic  (9)
What date was the first dose used?
What date was the last dose used?
Doctor's letter after transferal not received
despite request
Was the doctor's letter after transferal not
received despite request?
Yes
No
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SacBo PZ: Case Report Form Hospitalization
Information On Current Visit NCT01143272
Antibiotic-associated diarrhoea (AAD) is a frequent
condition in hospitalised patients receiving antibiotic
treatment. The same is true for Clostridium difficile-
associated diarrhoea (CDAD) with even more grave
consequences of increased morbidity and mortality. The
development and evaluation of preventive strategies is one
key public health challenge. In the absence of clinically
evaluated alternatives, probiotics have been suggested to
be beneficial for the prevention of AAD and CDAD.
However, data have so far been inconclusive and recently
published meta-analyses strongly recommended large
state-of-the-art clinical trials on probiotic substances for the
prevention of AAD and CDAD. Since the efficacy, side-
effects and modes of action of different probiotic bacteria
and yeast are strain specific, benefits and risks cannot be
generalised. The non-pathogenic yeast Saccharomyces
cerevisiae var. boulardii (Sac. boulardii) is considered the
most promising probiotic substance for the prevention of
AAD and CDAD. We carry out a randomised, placebo
controlled, double blind multicentre clinical trial to evaluate
Sac. boulardii for the indication of prevention of AAD and
CDAD in 1520 adult, hospitalised patients.
All rights reserved. Please visit https://medical-data-
models.org/forms/13437
SacBo PZ: Case Report Form
Hospitalization Information On
Current Visit NCT01143272
Information according to the data obtained
What date was the patient
discharged/transferred?
What phase of the study is the patient currently
in?
Treatment Phase 1 (1)
Treatment Phase 2 (2)
Follow Up (3)
What date was the first dose of the initially used
antibiotic applied?
What date did the first treatment phase end?
How many days of antibiotic treatment were
there?
days
When did treatment phase 2 end?
When did the follow-up end?
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Revisit/Rehospitalization Necessary? NCT01143272
Antibiotic-associated diarrhoea (AAD) is a frequent
condition in hospitalised patients receiving antibiotic
treatment. The same is true for Clostridium difficile-
associated diarrhoea (CDAD) with even more grave
consequences of increased morbidity and mortality. The
development and evaluation of preventive strategies is one
key public health challenge. In the absence of clinically
evaluated alternatives, probiotics have been suggested to
be beneficial for the prevention of AAD and CDAD.
However, data have so far been inconclusive and recently
published meta-analyses strongly recommended large
state-of-the-art clinical trials on probiotic substances for the
prevention of AAD and CDAD. Since the efficacy, side-
effects and modes of action of different probiotic bacteria
and yeast are strain specific, benefits and risks cannot be
generalised. The non-pathogenic yeast Saccharomyces
cerevisiae var. boulardii (Sac. boulardii) is considered the
most promising probiotic substance for the prevention of
AAD and CDAD. We carry out a randomised, placebo
controlled, double blind multicentre clinical trial to evaluate
Sac. boulardii for the indication of prevention of AAD and
CDAD in 1520 adult, hospitalised patients.
All rights reserved. Please visit https://medical-data-
models.org/forms/13438
SacBo PZ: Case Report Form
Hospitalization
Revisit/Rehospitalization Necessary?
NCT01143272
Revisit/Rehospitalization Necessary?
Is documentation of any further visit or
rehospitalization necessary?
Yes
No
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SacBo PZ: Case Report Form AE Termination
Signature Early Study Termination NCT01143272
Antibiotic-associated diarrhoea (AAD) is a frequent
condition in hospitalised patients receiving antibiotic
treatment. The same is true for Clostridium difficile-
associated diarrhoea (CDAD) with even more grave
consequences of increased morbidity and mortality. The
development and evaluation of preventive strategies is one
key public health challenge. In the absence of clinically
evaluated alternatives, probiotics have been suggested to
be beneficial for the prevention of AAD and CDAD.
However, data have so far been inconclusive and recently
published meta-analyses strongly recommended large
state-of-the-art clinical trials on probiotic substances for the
prevention of AAD and CDAD. Since the efficacy, side-
effects and modes of action of different probiotic bacteria
and yeast are strain specific, benefits and risks cannot be
generalised. The non-pathogenic yeast Saccharomyces
cerevisiae var. boulardii (Sac. boulardii) is considered the
most promising probiotic substance for the prevention of
AAD and CDAD. We carry out a randomised, placebo
controlled, double blind multicentre clinical trial to evaluate
Sac. boulardii for the indication of prevention of AAD and
CDAD in 1520 adult, hospitalised patients.
All rights reserved. Please visit https://medical-data-
models.org/forms/13439
SacBo PZ: Case Report Form AE
Termination Signature Early Study
Termination NCT01143272
Early study termination
When was the study terminated?
Was the reason for early study termination the
repeal of consent?
Yes
No
Did the patient become retrospectively ineligible
by failing to meet the inclusion/exclusion criteria
and if so what criterion was the reason for
becoming ineligible?
Hypersensitivity to yeast and/or
perenterol (Exclusion1 )
currently participating in another trial
(Exclusion10 )
Central venous catheterization
(Exclusion2 )
Immunosuppression (Exclusion3 )
Currently having diarrhea and/or
frequent diarrhea (Exclusion4 )
Frequent use of perenterol or yomogi (7
days before start of study) (Exclusion5 )
systemic antifungal treatment
(Exclusion6 )
systemic antibiotic treatment (6 weeks
before start of study) (Exclusion7 )
for women: pregnancy (Exclusion8 )
for women: lactation (Exclusion9 )
Adult (Inclusion1 )
Patient hospitalized in study hospital
(Inclusion2 )
systemic antiobiotic treatment planned
(>= 3 days) (Inclusion3 )
Patient contractually capable (Inclusion4
)
Patient physically and mentally fit
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(Inclusion5 )
For women of child-bearing age:
contraception (Inclusion6 )
Informed consent obtained (Inclusion7 )
Does the patient receive a central venous
catheter?
Yes
No
Did any kind of immunosuppression occur?
Yes
No
Was the study early terminated by the doctor due
to hypersensitivity reaction or any other severe
complications?
Yes
No
Comment:
Is there any other reason for early study
termination?
Yes
No
Comment:
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SacBo PZ: Case Report Form AE Termination Signature Early Study
Termination NCT01143272
Test Study
Test Study
All rights reserved. Please visit https://medical-data-
models.org/forms/13442
ODM-Form
vital signs
test1
test2
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Acute Leukaemia AML EBMT HSCT
Registry MED-B Follow Up Form
The European Society for Blood and Marrow
Transplantation maintains a huge registry and delivers data
collection forms. The original forms for submitting data to
the EBMT can be found under:
http://www.ebmt.org/Contents/Data-
Management/Registrystructure/MED-
ABdatacollectionforms/Pages/MED-AB-data-collection-
forms.aspx#HSCTMedB This ODM form is derived from the
AML-disease specific form of the section MED-B.
http://www.ebmt.org/Contents/Data-
Management/Registrystructure/MED-
ABdatacollectionforms/Documents/05AL.pdf
All rights reserved. Please visit https://medical-data-
models.org/forms/13445
Acute Leukaemia AML EBMT HSCT
Registry MED-B Follow Up Form
Default Itemgroup
Unique Identification Code (UIC)
Date of this report
yyyy/mm/dd
Patient following national / international study /
trial:
No (1)
Yes (2)
Not evaluated (3)
Name of study / trial
Hospital Unique Patient Number
Initials
Date of birth
yyyy/mm/dd
Date of last HSCT for this patient
yyyy/mm/dd
Patient last seen
Date of last contact or death
yyyy/mm/dd
Graft versus Host Disease (GvHD) since
last report
Acute Graft versus Host Disease (aGvHD) -
Grade
grade 0 (Absent) (1)
grade I (2)
grade II (3)
grade III (4)
1 / 10
grade IV (5)
Not evaluated (6)
aGvHD
New onset (1)
Recurrent (2)
Persistent (3)
aGvHD Reason
Tapering (1)
DLI (2)
Unexplained (3)
Date onset of this episode (if new or recurrent)
yyyy/mm/dd
Date onset of this episode:
Not applicable (Not applicable)
Stage skin
0 (1)
1 (2)
2 (3)
3 (4)
4 (5)
Not evaluated (6)
unknown (7)
Stage liver
0 (1)
1 (2)
2 (3)
3 (4)
4 (5)
Not evaluated (6)
unknown (7)
Stage gut
0 (1)
1 (2)
2 (3)
3 (4)
4 (5)
Not evaluated (6)
unknown (7)
Resolution
No  (1)
Yes (2)
Date of resolution
yyyy/mm/dd
Chronic Graft versus Host Disease
Presence of cGVHD
No (1)
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Yes, First Episode (2)
Yes, Recurrence (3)
Date of onset
yyyy/mm/dd
Present continuously since last reported episode
Yes
No
cGvHD grade
limited (1)
Extensive (2)
Organs affected
Skin (1)
Gut (2)
Liver (3)
Mouth (4)
Eyes (5)
Lung (6)
Other, specify (7)
Unknown (8)
Specify
Resolved: Date of resolution
yyyy/mm/dd
Other complications since last report
Infection related complications
Yes
No
Systemic symptoms of infection
Septic shock (1)
ARDS (2)
Multiorgan failure due to infection (3)
Endorgan disease
Pneumonia (1)
Hepatitis (2)
CNS infection (3)
Gut infection (4)
Skin infection (5)
Cystitis (6)
Retinitis (7)
Other (8)
Infectious Disease Date
yyyy/mm/dd
AML Pathogens of interest
Adenovirus (Adenovirus Fungi)
Aspergillus sp (Aspergillus sp)
Candida sp (Candida sp)
CMV (CMV)
3 / 10
Acute Leukaemia AML EBMT HSCT Registry MED-B Follow Up Form
EBV (EBV)
Haemophilus influenzae (Haemophilus
influenzae)
HBV (HBV)
HCV (HCV)
HHV-6 (HHV-6)
HIV (HIV)
HSV (HSV)
Legionella sp (Legionella sp)
Mycobacteria sp (Mycobacteria sp)
Other (Other)
Other gram negative (i.e.: E. coli
klebsiella, proteus, serratia,
pseudomonas …) (Other gram negative
(i.e.: E. coli klebsiella, proteus, serratia,
pseudomonas …))
Other gram positive (i.e.: other
streptococci, staphylococci, listeria …)
(Other gram positive (i.e.: other
streptococci, staphylococci, listeria …))
Other respiratory virus (influenza,
parainfluenza, rhinovirus) (Other
respiratory virus (influenza,
parainfluenza, rhinovirus))
Papovavirus (Papovavirus)
Parvovirus (Parvovirus Parasites)
Pneumocystis carinii (Pneumocystis
carinii)
RSV (RSV)
S. pneumoniae (S. pneumoniae)
Toxoplasma gondii (Toxoplasma gondii)
VZV (VZV)
Non infection related complications
Yes
No
Idiopathic pneumonia syndrome
Yes (1)
No (2)
Unknown (3)
VOD
Yes (1)
No (2)
Unknown (3)
Cataract
Yes (1)
No (2)
Unknown (3)
Haemorrhagic cystitis, non infectious
Yes (1)
No (2)
Unknown (3)
ARDS, non infectious
Yes (1)
No (2)
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Unknown (3)
Multiorgan failure
Yes (1)
No (2)
Unknown (3)
HSCT-associated microangiopathy
Yes (1)
No (2)
Unknown (3)
Renal failure requiring dialysis
Yes (1)
No (2)
Unknown (3)
Haemolytic anaemia due to blood group
Yes (1)
No (2)
Unknown (3)
Aseptic bone necrosis
Yes (1)
No (2)
Unknown (3)
Other
Dates of non infection related complications
yyyy/mm/dd
Graft assessment and chimaerism
Graft loss
No (1)
Yes (2)
Not evaluated (3)
Overall chimaerism
Full (donor >95 %) (1)
Mixed (partial) (2)
Autologous reconstitution (recipient >95
%) (3)
Aplasia (4)
Not evaluated (5)
Chimerism test
Date of test
yyyy/mm/dd
Identification of donor or Cord Blood Unit given
by the centre
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Number in the infusion order (if applicable)
......... (1)
N/A (2)
Cell type on which test was performed
BM  (1)
Other, specify: (10)
PB mononuclear cells (PBMC)  (2)
T-cell (3)
B-cells (4)
Red blood cells (5)
Monocytes (6)
PMNs (neutrophils) (7)
Lymphocytes, NOS (8)
Myeloid cells, NOS (9)
Percent Donor cells
%
Test used
FISH (1)
Molecular (2)
Cytogenetic (3)
AB0 group (4)
Other (5)
Unknown (6)
Other, specify
Secondary malignancy, lymphoproliferative or
myeloproliferative disorder diagnosed
Previously reported (1)
Yes, date of diagnosis: (2)
Diagnosis: AML  (3)
Diagnosis: MDS  (4)
Diagnosis: Lymphoproliferative disorder
(5)
Diagnosis: Other (6)
No at date of this follow-up (7)
Date of diagnosis
yyyy/mm/dd
Diagnosis, other:
Date of diagnosis
yyyy/mm/dd
Additional therapies since last follow up
Treatment given since last report
No (1)
Yes (2)
Unknown (3)
Treatment start date
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yyyy/mm/dd
If yes: Cellular therapy (One cell therapy regimen
is defined as any number of infusions given within
10 weeks for the same indication. If more than
one regimen of cell therapy has been given since
last report, copy this section and complete it as
many times as necessary.)
No  (1)
Yes (Mark disease status before this
cellular therapy) (2)
Unknown (3)
Disease status before cellular therapy
CR (1)
Not in CR (2)
Not evaluated (3)
If yes: Type of cells
Donor lymphocyte infusion (DLI) (1)
Mesenchymal cells (2)
Other (3)
Unknown (4)
Number of Nucleated cells infused (DLI only)
10^8/kg
Number (1)
Not evaluated (2)
Unknown (3)
Number of CD34+ cells infused (DLI only)
x10^6/kg
Number (1)
Not evaluated (2)
Unknown (3)
Number of CD3+ cells infused (DLI only)
x10^6/kg
Number (1)
Not evaluated (2)
Unknown (3)
Total number of cells infused (non DLI only)
x10^6/kg
Number (1)
Not evaluated (2)
Unknown (3)
Chronological number of this cell therapy for this
patient
Indication
Planned/protocol  (1)
Treatment for disease (2)
Prophylactic (3)
Mixed chimaerism (4)
Treatment of GvHD  (5)
Treatment viral infection (6)
Loss/decreased chimaerism  (7)
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Treatment PTLD, EBV lymphoma (8)
Other, specify (9)
Indication: specify
Number of infusions within 10 weeks (count only
infusions that are part of same regimen and given
for the same indication)
Acute Graft Versus Host Disease (after this
infusion but before any further infusion /
transplant)
Grade 0 (absent) (1)
Grade 1 (2)
Grade 2 (3)
Grade 3 (4)
Grade 4 (5)
present, grade unknown (6)
Disease treatment (apart from donor cell infusion
or other type of cell therapy)
No (1)
Yes: Planned (planned before HSCT took
place) (2)
Yes: Not planned (for
relapse/progression or persistent
disease) (3)
First evidence of relapse or progression
since last HSCT
Relapse or progression
Previously reported (1)
No (2)
yes (3)
Continuous progression since transplant
(4)
Unknown (5)
Relapse or Progression: Date diagnosed
yyyy/mm/dd
Cinical/haematological relapse or progression
No (1)
Yes (2)
Not evaluated (3)
Cytogenetic relapse or progression
No (1)
Yes (2)
Not evaluated (3)
Molecular relapse or progression
No (1)
Yes (2)
Not evaluated (3)
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Date of the assessment/Date first seen
yyyy/mm/dd
Relapse or progression site
marrow - blood (1)
extramedullary (2)
Last disease and patient status
Last disease and patient status
CR (1)
Stable Disease (2)
Relapse (3)
Progression (4)
Clinical/haematological
No (1)
Yes (2)
Not evaluated (3)
Cytogenetic/FISH
No (1)
Yes: Considered disease
relapse/progression No (2)
Yes: Considered disease
relapse/progression Yes (3)
Yes: Considered disease
relapse/progression Not evaluated (4)
Last date evaluated/Last date assessed
yyyy/mm/dd
Conception - Has patient or partner become
pregnant after this HSCT?
Yes  (1)
No (2)
Unknown (3)
Survival status
Alive (1)
Dead (2)
Performance score (if alive)
Karnofsky (1)
Lansky (2)
Score
100 (Normal, NED) (1)
10 (Moribund) (10)
Not evaluated (11)
Unknown (12)
90 (Normal activity)  (2)
80 (Normal with effort) (3)
70 (Cares for self) (4)
60 (Requires occasional assistance) (5)
50 (Requires assistance) (6)
40 (Disabled) (7)
30 (Severely disabled) (8)
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20 (Very sick) (9)
Cause of death (if dead)
Relapse or progression (1)
Secondary malignancy (including
lymphoproliferative disease) (2)
HSCT related cause  (3)
Unknown (4)
Other (5)
HSCT related cause
GvHD (1)
Veno-occlusive disease (VOD) (10)
Haemorrhage (11)
Cardiac toxicity (12)
Central nervous system toxicity (13)
Gastro intestinal toxicity (14)
Skin toxicity (15)
Renal failure (16)
Multiple organ failure (17)
Other (18)
Interstitial pneumonitis (2)
Pulmonary toxicity (3)
Infection bacterial (4)
Infection viral (5)
Infection fungal (6)
Infection parasitic (7)
Infection unknown (8)
Rejection / poor graft function (9)
Comments
Comments
Identification and Signature
Identification and Signature
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AML- Register_Registration
form_SAL_University hospital dresden
Items used as routine documentation for the SAL
(Studienallianz Leukämie) study centre of university
hospital dresden. ODM derived from original form "AML-
Register Meldebogen - A", converted to ODM format.
All rights reserved. Please visit https://medical-data-
models.org/forms/13446
AML- Register_Registration
form_SAL_University hospital
dresden
Clinic information
Name of the hospital:
Clinic code:
Hospital address:
Telephone number:
Fax number:
Patient information
Patient's surname:
Patient's first name:
Patient ID:
Date of birth:
Gender:
Male (1)
Female (2)
Patient's address:
Address of the family doctor:
Is the signed informed consent available?
Yes
No
Does the patient agree to the transfer of
ownership of the collected tissue sample?
Yes
No
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diagnosis_SAL_University hospital dresden
Items used as routine documentation for the SAL
(Studienallianz Leukmie) study centre of university hospital
dresden. ODM derived from original form "AML-Register
Erstdiagnose-B1 und Komorbidität-B2", converted to ODM
format.
All rights reserved. Please visit https://medical-data-
models.org/forms/13447
First diagnosis
Patient information
Patient name:
Patient ID:
Clinic code:
Date of birth:
Height:
cm
Weight:
kg
Date anamnesis carried out:
Gender
male (1)
female (2)
Anamnesis status
Date of the first diagnosis:
de novo?
Yes
No
Previous tumor disease in history?
Yes
No
When yes, what type of tumor?
Year of the first tumor diagnosis:
After chemotherapy in anamnesis?
Yes
No
Year of Chemotherapy?
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Chemoschema:
After radiotherapy in anamnesis?
Yes
No
Year of radiotherapy?
Dose of radiotherapy:
Gy
Myelodysplastic syndrome history?
Yes
No
Myeloproliferative neoplasm/ Myelofibrosis
history?
Yes
No
WHO classification:
FAB classification:
Extramedullary manifestation?
Yes
No
If yes, please mention the site of extramedullary
manifestation.
ECOG-Status:
Laboratory
leukocyte number:
/nl
Hemoglobin:
g/dl
Platelets number:
/nl
LDH:
U/l
PB blast cells:
%
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Bone marrow blasts:
%
CD34 (preferred from bone marrow):
%
Mutations
FLT3-ITD:
negative (1)
not applicable (2)
positive (3)
When yes, FLT3-ITD ratio:
NPM1:
wild type (1)
mutated (2)
not applicable (3)
CEBPA:
wild type (1)
mutated (2)
not applicable (3)
PML-RARA:
wild type (1)
mutated (2)
not applicable (3)
Other mutations:
Karyotype:
Comorbidity
Comorbidity
Migraine/ Headache:
yes (1)
no (2)
unknown (3)
Osteoporosis:
yes (1)
no (2)
unknown (3)
Arthopathy:
yes (1)
no (2)
unknown (3)
Hypertension:
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yes (1)
no (2)
unknown (3)
Gastrointestinal disease (incl. inflammatory bowel
disease):
yes (1)
no (2)
unknown (3)
mild pulmonary disease (DLco and / or FEV1>
80% or dyspnea by moderate activities):
yes (1)
no (2)
unknown (3)
Mild kidney disease (Blood serum creatinine 1.2-
2 mg / dl):
yes (1)
no (2)
unknown (3)
Metabolic disease:
yes (1)
no (2)
unknown (3)
Hemorrhage:
yes (1)
no (2)
unknown (3)
Coagulopathy (deep vein thrombosis or
pulmonary embolism):
yes (1)
no (2)
unknown (3)
Asthma:
yes (1)
no (2)
unknown (3)
Cardiac Arrhythmia (Atrial flutter, atrial fibrillation,
sick sinus syndrome, ventricular arrhythmias):
yes (1)
no (2)
unknown (3)
Cardiac disease (CHD, congestive heart
failure,Myocardial Infarction, EF ≤50%):
yes (1)
no (2)
unknown (3)
Mild liver disease (chronic hepatitis, bilirubin>
ULN - 1.5x ULN or AST / ALT> ULN - 2.5x ULN):
yes (1)
no (2)
unknown (3)
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Cerebrovascular disease (Patient with TIA, stroke
or cerebral hemorrhage):
yes (1)
no (2)
unknown (3)
Obesity (BMI >35 kg/m²):
yes (1)
no (2)
unknown (3)
Diabetes (therapy need):
yes (1)
no (2)
unknown (3)
Mental disorders (Depression or anxiety,
psychiatric counseling or treatment require):
yes (1)
no (2)
unknown (3)
Infection (Need antibiotic treatment):
yes (1)
no (2)
unknown (3)
Rheumatic disease (SLE, RA, polymyositis,
mixed CTD, polymyalgia rheumatica):
yes (1)
no (2)
unknown (3)
Moderate pulmonary disease (DLco and / or
FEV1> 65% -80% or Dyspnea by light activity):
yes (1)
no (2)
unknown (3)
Gastrointestinal ulcer (Therapy need):
yes (1)
no (2)
unknown (3)
Moderately-severe kidney Disease (Blood serum
creatinine> 2 mg / dl, dialysis dependent, state
after Kidney transplantation):
yes (1)
no (2)
unknown (3)
Heart valve disease (except mitral valve
prolapse):
yes (1)
no (2)
unknown (3)
Preexisting solid tumor (chemotherapy required):
yes (1)
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no (2)
unknown (3)
Moderately-severe liver disease (Liver Cirrhosis,
bilirubin> 1.5x ULN or AST / ALT> 2.5x ULN):
yes (1)
no (2)
unknown (3)
Severe pulmonary disease (DLco and / or FEV1
≤65% or resting dyspnea or oxygen need):
yes (1)
no (2)
unknown (3)
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AML- Register_Progress
sheet_SAL_University hospital dresden
Items used as routine documentation for the SAL
(Studienallianz Leukämie) study centre of university
hospital dresden. ODM derived from original form "AML-
Register Verlaufsbogen - C", converted to ODM format.
All rights reserved. Please visit https://medical-data-
models.org/forms/13448
AML- Register_Progress
sheet_SAL_University hospital
dresden
Patient information
Patient name:
Patient ID:
Clinic code:
Date of birth:
Gender:
male (1)
female (2)
Date of last Progress sheet:
Date of previous contact:
Number of therapies since the last visit
(Chemotherapy, immunotherapies, small
molecules, transplants):
Patient alive
CR by  acute promyelocytic leukemia (leukocytes
>=1,0 GPt/l ; platelets >=100 GPt/l):
hematological (1)
molecular (2)
CRi (Leukocytes <1,0 GPt/l):
Yes
No
CRp (Leukocytes >=1,0 GPt/l ; Platelets <100
GPt/l):
Yes
No
No CR by  by  acute promyelocytic leukemia :
primary refractory; hematological (1)
primary refractory; molecular (2)
recurrence; hematological (3)
recurrence; molecular (4)
Patient dead (Please fill only when the
1 / 2
patient is dead)
Date of death:
Cause of death:
due to tumor (1)
unknown (2)
other (3)
For other, please mention:
Recurrence
Recurrence since last documentation?
Yes
No
Date of recurrence:
Recurrence number:
Localization:
bone marrow/ blood (1)
extramedullary (2)
Tumor site:
Therapy and delayed effect:
secondary malignancy (1)
chronic GvHD (2)
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AML- Register_Therapy
form_SAL_University hospital dresden
Items used as routine documentation for the SAL
(Studienallianz Leukämie) study centre of university
hospital dresden. ODM derived from original form "AML-
Register Therapiebogen-D", converted to ODM format.
All rights reserved. Please visit https://medical-data-
models.org/forms/13459
AML- Register_Therapy
form_SAL_University hospital
dresden
Patient information
Patient name:
Patient ID:
Clinic code:
Date of birth:
Gender:
male  (1)
female (2)
Cancer remission by therapy beginning (to
be completed from 2nd therapy)
Date of cancer remission:
Through bone marrow puncture secured?
Yes
No
Remission status:
good response (blasts under 10%) (1)
moderate response (min. halving the
number of Blast auf >=10%) (2)
no response (no decrease in the blasts,
decrease of <50%) (3)
CR by acute promyelocytic leukemia:
hematological (1)
molecular (2)
Recurrence by acute promyelocytic leukemia:
hematological (1)
molecular (2)
CRi/ CRp:
Yes
No
Partial remission:
Yes
No
1 / 3
Progression / refractory:
Yes
No
Can not be assessed:
Yes
No
Chemotherapy
Date of chemotherapy:
Chemotherapy:
during a study; curative  (1)
during a study; palliative (2)
outside of a study; curative  (3)
outside of a study; palliative (4)
Therapy schema:
Medication (chemotherapy)
Medication:
Chemotherapy start date:
Days:
Total dose:
mg
Transplantation
Date of transplantation:
Stem cell transplantation centre:
Stem cell transplantation type:
Autologous (1)
Allogeneic (related) (2)
Allogeneic (unrelated) (3)
Donor:
identical (1)
haploidentical  (2)
Mismatch (3)
Conditioning regimens:
Toxicity grade III-IV
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Creatinine:
Yes
No
Hemorrhage:
Yes
No
Bilirubin:
Yes
No
Infection:
Yes
No
Heart:
Yes
No
GvHD:
Yes
No
ALAT/ASAT:
Yes
No
Other:
Therapy outcome
Date of therapy response:
Through bone marrow puncture secured?
Yes
No
Therapy outcome:
good response (blasts under 10%) (1)
Partial remission (10)
Patient dead (11)
Progression / refractory (12)
can not be assessed (13)
moderate response (min. halving the
number of Blast auf >=10%) (2)
no response (no decrease in the blasts,
decrease of <50%) (3)
CR by acute promyelocytic leukemia,
hematological (4)
CR by acute promyelocytic leukemia,
molecular (5)
Recurrence by acute promyelocytic
leukemia, hematological (6)
Recurrence by acute promyelocytic
leukemia, molecular (7)
CRi (8)
CRp (9)
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AML- Register_Accompanying Material
Form_SAL_University hospital dresden
Items used as routine documentation for the SAL
(Studienallianz Leukmie) study centre of university hospital
dresden. ODM derived from original form "AML-Register
Materialbegleitbogen
für Biomaterialbank", converted to ODM format.
All rights reserved. Please visit https://medical-data-
models.org/forms/13460
AML- Register_Accompanying
Material Form_SAL_University
hospital dresden
Patient information
Patient name:
Patient ID:
Clinic code:
Date of birth:
Gender:
female (1)
male (2)
Collected material
Date of collection:
Specimen collected during:
first diagnosis (1)
progress (2)
recurrence (3)
after end of treatment (4)
3rd month (5)
6th month (6)
9th month (7)
12th month (8)
x month (9)
Please state the month, if you chose "x month":
Specimen sent to study centre:
10 ml of heparinized bone marrow (1)
50 ml of heparinized peripheral blood (2)
min. 4 unstained bone marrow smears (if
cytomorphology desired) (3)
min. 3 unstained peripheral blood smear
(if cytomorphology desired) (4)
Patient agrees with the transfer of ownership
(transfer of ownership) of the tissue samples to
the SAL biomaterial storage and use for scientific
purposes?
Yes
No
The following diagnostic desired:
1 / 2
cytomorphology (1)
Molecular Biology (2)
immunophenotyping (3)
cytogenetics (4)
Sender information
Physician:
Clinic:
Telephone:
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Acute Leukaemia AML EBMT HSCT
Registry MED-B Disease Specific Form
The European Society for Blood and Marrow
Transplantation maintains a huge registry and delivers data
collection forms.
The original forms for submitting data to the EBMT can be
found under:
http://www.ebmt.org/Contents/Data-
Management/Registrystructure/MED-
ABdatacollectionforms/Pages/MED-AB-data-collection-
forms.aspx#HSCTMedB
This ODM form is derived from the AML-disease specific
form of the section MED-B.
http://www.ebmt.org/Contents/Data-
Management/Registrystructure/MED-
ABdatacollectionforms/Documents/05AL.pdf
All rights reserved. Please visit https://medical-data-
models.org/forms/13461
Acute Leukaemia AML EBMT HSCT
Registry MED-B Disease Specific
Form
Team
EBMT Centre Identification Code (CIC)
Hospital
Unit
Contact Person
Telephone
Fax
E-mail
Report date
yyyy/mm/dd
Patient following national / international study /
trial
No (1)
Yes (2)
Not evaluated (3)
Unknown (4)
Name of study / trial
Patient
Unique Identification Code (UIC)
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Hospital Unique Patient Number or Code
Initials (first name(s) - surname(s))
Patient date of birth
yyyy/mm/dd
Sex
Female (Female)
Male (Male)
AB0 Group
Rh factor
Absent (Absent)
Not evaluated (Not evaluated)
Present (Present)
Disease
Date of diagnosis
yyyy/mm/dd
Primary disease diagnosis
Acute Leukaemia (1)
Hodgkin's Disease (10)
Myeloma /Plasma cell disorder (11)
Solid Tumour (12)
Myelodysplastic syndromes (13)
MDS (14)
MD/MPN (15)
Myeloproliferative neoplasm (16)
Bone marrow failure including Aplastic
anaemia (17)
Inherited disorders (18)
Primary immune deficiencies (19)
Myelogenous (AML) (2)
Metabolic disorders (20)
Histiocytic disorders (21)
Autoimmune disease (22)
Juvenile Idiopathic Arthritis (23)
Multiple Sclerosis (24)
Systemic Lupus (25)
Systemic Sclerosis (26)
Haemoglobinopathy (27)
Other diagnosis (28)
Lymphoblastic (ALL) (3)
Secondary Acute Leukaemia(do not use
if transformed from MDS/MPN) (4)
Chronic Leukaemia (5)
Chronic Myeloid Leukaemia (CML) (6)
Chronic Lymphocytic Leukaemia (7)
Lymphoma (8)
Non Hodgkin (9)
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Other diagnosis, specify:
Initial Diagnosis
Has the information requested in this section
been submitted with a previous HSCT registration
for this patient?
Yes: go to page 5, Type of HSCT (1)
No: proceed with this section (2)
Diagnosis
Acute Myelogenous Leukaemia
(AML)(non-lymphoblastic) → Fill in
subclassification below (1)
Precursor lymphoid neoplasm (old ALL)
→ Fill in subclassification in next page
(2)
Acute Undifferentiated Leukaemia (3)
Mixed phenotype leukaemia NOS (4)
Mixed phenotype B/myeloid, NOS (5)
Mixed phenotype T/myeloid, NOS (6)
Natural killer (NK)- cell lymphoblastic
leukaemia/lymphoma (7)
Other, specify: (8)
Other, specify:
WHO Classification at Diagnosis of de novo AML 
Acute myeloid leukaemia with recurrent genetic
abnormalities:
AML with t(8;21)(q22;q22); RUNX1-
RUNX1T1 (1)
AML with inv(16)(p13.1;q22) or
t(16;16)(p13.1;q22); CBFB-MYH11 (2)
Acute promyelocytic leukaemia with
t(15;17)(q22;q12); PML/RARA (3)
AML with t(9;11) (p22;q23); MLLT 3-MLL
(4)
AML with myelodysplasia related
changes (with multilineage dysplasia;
w/o MDS or MDS/MPN antecedents) (5)
AML with t(6;9) (p23;q24); DEK-NUP214
(6)
AML with inv(3) (q21;q26.2) or t(3;3)
(q21;q26.2); RPN1-EVI1 (7)
AML (megakaryoblastic) with t(1;22)
(p13;q13); RBM15-MKL1 (8)
Acute myeloid leukaemia, not otherwise
categorized, classify as
AML with minimal differentiation (FAB
M0) (1)
Myeloid sarcoma (Granulocytic sarcoma)
(10)
Myeloid proliferations related to Down
syndrome (11)
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Blastic plasmacytoid dendritic cell
neoplasm (BPDCN) (12)
Acute myeloid leukaemia not otherwise
specified or other (13)
AML without maturation (FAB M1) (2)
AML with maturation (FAB M2) (3)
Acute myelomonocytic leukaemia (FAB
M4) (4)
Acute monoblastic and monocytic
leukaemia (FAB M5) (5)
Acute erythroid leukaemia (FAB M6) (6)
Acute megakaryoblastic leukaemia (FAB
M7) (7)
Acute basophilic leukaemia (8)
Acute panmyelosis with myelofibrosis (9)
Specify
WHO Classification at diagnosis of de novo
Precursor Lymphoid Neoplasms (old ALL)
B lymphoblastic leukaemia/lymphoma
NOS (old Precursor B-cell ALL) (1)
lymphoblastic leukaemia/lymphoma not
otherwise specifed or other (10)
with t(9;22)(q34;q11.2); BCR-ABL1 (2)
with t(v;11q23); MLL rearranged (3)
with t(12;21)(p13;q22); TEL-AML1 (ETV-
RUNX1) (4)
with hyperdiploidy (5)
with hypodiploidy (6)
with t(5;14)(q31;q32); IL3-IGH (7)
with t(1;19)(q23;p13.3); E2A-PBX1 (8)
T lymphoblastic leukaemia/lymphoma
(old Precursor T-cell ALL) (9)
Specify
Secondary origin (If the answer to this question is
“Yes” for any reason, do not complete this form;
instead complete the MYELODYSPLASTIC
SYNDROME or MDS+MPS or SECONDARY
ACUTE LEUKAEMIA form)
No (1)
Yes, evolution of MDS  (2)
Yes, disease related to prior exposure to
therapeutic drugs or radiation (treatment
for previous malignancies) (3)
Cytgenetics
Chromosome analysis
Not done or failed (1)
Done: normal  (2)
Done: abnormal  (3)
Unknown (4)
If abnormal: Are there 3 or more abnormalities
4 / 9
Acute Leukaemia AML EBMT HSCT Registry MED-B Disease Specific
Form
(complex kariotype)?
No (1)
Yes (2)
Not evaluated (3)
Unknown (4)
If done: number of metaphases with abnormalites
number of metaphases examined
Indicate which abnormalities found
hypodiploid (<46) absent (1)
t(4;11) present (10)
inv (16) absent (11)
inv (16) present (12)
t(15;17) absent (13)
t(15;17) present (14)
t(8;21) absent (15)
t(8;21) present (16)
abn 5 absent (17)
abn 5 present (18)
other abn 11q absent (19)
hypodiploid (<46) present (2)
other abn 11q present (20)
t(12;21) absent (21)
t(12;21) present (22)
t(1;19) absent (23)
t(1;19) present (24)
trisomy 8 absent (25)
trisomy 8 present (26)
monosomy 7 absent (27)
monosomy 7 present (28)
other abn 7 absent (29)
hyperdiploid (>46 ) absent (3)
other abn 7 present (30)
Other or associated abnormalities
(specify, including whether absent or
present) (31)
hyperdiploid (>46 ) present (4)
pseudodiploid absent (5)
pseudodiploid present (6)
t(9;22) absent (7)
t(9;22) present (8)
t(4;11) absent (9)
If hypodiploid/hyperdiploid: number of
chromosomes
Other or associated abnormalities (specify,
including whether absent or present)
Molecular Biology
Molecular markers
Evaluated: Absent  (1)
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Evaluated: Present (2)
Not evaluated (3)
unknown (4)
BCR-ABL
Absent (1)
Present (2)
Not evaluated (3)
unknown (4)
PML-RAR
Absent (1)
Present (2)
Not evaluated (3)
unknown (4)
AML1-ETO
Absent (1)
Present (2)
Not evaluated (3)
unknown (4)
FLT3-ITD
Absent (1)
Present (2)
Not evaluated (3)
unknown (4)
CEBPA mutation
Absent (1)
Present (2)
Not evaluated (3)
unknown (4)
NPM1 mutation
Absent (1)
Present (2)
Not evaluated (3)
unknown (4)
MLL-PTD
Absent (1)
Present (2)
Not evaluated (3)
unknown (4)
Other
Absent (1)
Present (2)
Not evaluated (3)
unknown (4)
Specify
White blood cell count at diagnosis
10^9/l
WBC not available/unknown
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not available (1)
unknown (2)
Involvement at Diagnosis
Bone marrow
No (1)
Yes (2)
Not evaluated (3)
Unknown (4)
Metastases CNS
No (1)
Yes (2)
Not evaluated (3)
Unknown (4)
Testis/ovary
No (1)
Yes (2)
Not evaluated (3)
Unknown (4)
Chloroma
No (1)
Yes (2)
Not evaluated (3)
Unknown (4)
Other
No (1)
Yes (2)
Not evaluated (3)
Unknown (4)
Type of HSCT
HSCT
Allogeneic: Proceed to Status of disease
at HSCT (1)
Autologous (2)
Treatment and Status of Disease at Stem
Cell Collection
Date of Collection
yyyy/mm/dd
Number of chemotherapy course(s) from last CR
to stem cell collection (fill in only if patient had a
CR prior to this HSCT )
Number of chemotherapy course(s) from
collection to HSCT
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Acute Leukaemia AML EBMT HSCT Registry MED-B Disease Specific
Form
Disease Hematological Status
Initial diagnosis / Untreated (1)
Primary induction failure (2)
Complete Remission Number of this
remission 1st  (3)
Complete Remission Number of this
remission 2nd (4)
Complete Remission Number of this
remission 3rd or higher (5)
Relapse Number of this relapse 1st  (6)
Relapse Number of this relapse 2nd (7)
Relapse Number of this relapse 3rd or
higher (8)
Complete cytogenetic remission (fill in only if
cytogenetic abnormality/ies detected at
diagnosis)
No: Persistence of previously detected
abnormality/ies (1)
Yes: Absence of previously detected
abnormality/ies (2)
Not Done / Not available (3)
Complete molecular remission (fill in only if
molecular abnormality/ies detected at diagnosis)
No: Persistence of previously detected
abnormality/ies (1)
Yes: Absence of previously detected
abnormality/ies (2)
Not Done / Not available (3)
Status of Disease at HSCT
Hematological status (considering number of
blasts in bone marrow)
Initial diagnosis / Untreated (1)
Primary induction failure (2)
Complete Remission Number of this
remission 1st  (3)
Complete Remission Number of this
remission 2nd (4)
Complete Remission Number of this
remission 3rd or higher (5)
Relapse Number of this relapse 1st  (6)
Relapse Number of this relapse 2nd (7)
Relapse Number of this relapse 3rd or
higher (8)
Complete cytogenetic remission (fill in only if
cytogenetic abnormality/ies detected at
diagnosis)
No: Persistence of previously detected
abnormality/ies (1)
Yes: Absence of previously detected
abnormality/ies (2)
Not Done / Not available (3)
Complete molecular remission (fill in only if
8 / 9
Acute Leukaemia AML EBMT HSCT Registry MED-B Disease Specific
Form
molecular abnormality/ies detected at diagnosis)
No: Persistence of previously detected
abnormality/ies (1)
Yes: Absence of previously detected
abnormality/ies (2)
Not Done / Not available (3)
Additional Treatment Post-HSCT
Additional disease treatment
No (1)
Yes, Planned (planned before HSCT took
place) (2)
Yes, Not planned (for
relapse/progression or persistant
disease) (3)
Best disease response at 100 days post-
HSCT
Best response at 100 days after HSCT
CR (maintained or achieved) (1)
Relapse / progression (2)
Death (3)
Not evaluable (4)
Unknown (5)
If complete response: date of CR
yyyy/mm/dd
Forms to be filled in
AUTOgraft, proceed to Autograft form
ALLOgraft or Syngeneic graft, proceed to
Allograft form
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Form
Data elements in routine documentation of AML patients after stem cell
transplantation (HSCT), EHR, University Hospital Knappschaftskrankenhaus
Bochum-Langendreer
Data elements in routine documentation of AML Patients
after stem cell transplantation (HSCT) at the University
Hospital Knappschaftskrankenhaus Bochum-Langendreer.
Data derived from anonymized hospital discharge letters of
patients after HSCT and diagnosis of Acute Myeolocytic
Leukemia (AML).
The documents contain data of the years 2014/2015.
All rights reserved. Please visit https://medical-data-
models.org/forms/13462
Data elements in routine
documentation of AML patients after
stem cell transplantation (HSCT),
EHR, University Hospital
Knappschaftskrankenhaus Bochum-
Langendreer
Patient data
Patient name
Date of birth
dd/mm/yyyy
Inpatient stay dates
Comorbidities
Concomitant Disease
Gender
male (1)
female (2)
Height
Weight
Laboratory results
Sodium
Potassium
Calcium
Phosphate
Glucose
1 / 6
Uric acid
Urea
Creatinine
Bilirubin
AST
ALT
gamma GT
AP
LDH
Lipase
CRP
Albumin
Magnesium
Blood count
Leukocytes
Erythrocytes
Hb
Hematocrit
MCV
Platelets
MCH
MCHC
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Data elements in routine documentation of AML patients after stem cell
transplantation (HSCT), EHR, University Hospital Knappschaftskrankenhaus
Bochum-Langendreer
Coagulation
TPZ
Quick
INR
PTT
Fibrinogen
Differential blood count
Neutrophil band form
Segmented neutrophil
Lymphocytes
Monocyte
Eosinophil
Basophils
Blasts
Ciclosporin A level
Chloride
Immunoglobulins
TSH
Diagnosis
Diagnosis
Date of first diagnosis
dd/mm/yyyy
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Data elements in routine documentation of AML patients after stem cell
transplantation (HSCT), EHR, University Hospital Knappschaftskrankenhaus
Bochum-Langendreer
FAB type of AML
Cytogenetics
Karyotype
Molecular genetics
Immunophenotyping
Medical history
Comorbidities
Heart
Thorax
Blood pressure
Heart rate
Abdomen
Nervous system
Bone Marrow
Cytology
Extramedullary disease
ECG
Physical examination
Disease response
Transplant
AML status before transplantation
Hematological remission (1)
Cytogenetical remission (2)
4 / 6
Data elements in routine documentation of AML patients after stem cell
transplantation (HSCT), EHR, University Hospital Knappschaftskrankenhaus
Bochum-Langendreer
Current therapy
Chemotherapy regimen
HSCT type
Autologous (1)
Allogeneic (2)
Number of CD34 cells infused
10^6/kg KG
HLA-Typing
Donor histocompatibility crossmatch
Transplantation-related complications
GvHD
Immunosuppression
Blood group
CMV
HLA Antigens
HLA Class II
HLA Class I
HLA-A
HLA-B
HLA-C
HLA-DRB1
HLA-DQB1
Rhesus factor
Kell system
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Data elements in routine documentation of AML patients after stem cell
transplantation (HSCT), EHR, University Hospital Knappschaftskrankenhaus
Bochum-Langendreer
Number of CD3 cells infused
Engraftment neutrophil
Engraftment platelets
Toxicity
Fever
Chimerism analysis post transplantation
Engraftment leukocytes
Therapy regimen
Disease remission
Microbiology
Infections
CMV
Toxoplasmose
EBV
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Data elements in routine documentation of AML patients after stem cell
transplantation (HSCT), EHR, University Hospital Knappschaftskrankenhaus
Bochum-Langendreer
Elements in Routine Documentation of AML Patients after Stem
Cell Transplantation (HSCT), EHR, University Hospital Münster
Elements in Routine Documentation of AML Patients after
Stem Cell Transplantation (HSCT) at the University Hospital
Münster, Centre for Stem Cell Transplanation.
Data derived from a collection of anonymized Hospital
discharge letters of Patients after HSCT and Diagnosis of
Acute Myeolocytic Leukemia (AML).
The Hospital discharge letters contain data of the Years
2014/2015.
All rights reserved. Please visit https://medical-data-
models.org/forms/13466
Elements in Routine Documentation
of AML Patients after Stem Cell
Transplantation (HSCT), EHR,
University Hospital Münster
Patient data
Patient name
Date of birth
dd/mm/yyyy
Inpatient stay dates
Comorbidities
Concomitant Disease
Allergies
Gender
male (1)
female (2)
Height
Weight
Laboratory results
Sodium
Potassium
Calcium
Phosphate
Glucose
1 / 7
Uric acid
Urea
Creatinine
Bilirubin
AST
ALT
gamma GT
AP
LDH
Lipase
CRP
Albumin
Magnesium
Blood count
Leukocytes
Erythrocytes
Hb
Hematocrit
MCV
Platelets
MCH
MCHC
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Elements in Routine Documentation of AML Patients after Stem Cell
Transplantation (HSCT), EHR, University Hospital Münster
Coagulation
TPZ
Quick
INR
INR
PTT
Fibrinogen
Thrombin time
Antithrombin
D-Dimer
Differential blood count
Neutrophil band form
Segmented neutrophil
Lymphocytes
Monocyte
Eosinophil
Basophils
Myelocyte
Metamyelocyte
Promyelocyte
Ciclosporin A level
Blasts
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Elements in Routine Documentation of AML Patients after Stem Cell
Transplantation (HSCT), EHR, University Hospital Münster
Diagnosis
Diagnosis
Date of first diagnosis
dd/mm/yyyy
FAB type of AML
Cytogenetics
Karyotype
Molecular genetics
Immunophenotyping
Medical history
Comorbidities
ECOG
Heart
Thorax
Blood pressure
Heart rate
Abdomen
Nervous system
Bone Marrow
Cytology
Extramedullary disease
ECG
Echocardiography
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Elements in Routine Documentation of AML Patients after Stem Cell
Transplantation (HSCT), EHR, University Hospital Münster
EF
Left ventricular function
Pulmonary function
VC
FEV1
TLCO
Blood gas analysis
HCT-CI Score
Therapy regimen
Physical examination
Disease response
Transplant
AML status before transplantation
Hematological remission (1)
Cytogenetical remission (2)
Current therapy
Chemotherapy regimen
HSCT type
Autologous (1)
Allogeneic (2)
Number of CD34 cells infused
10^6/kg KG
HLA-Typing
Donor histocompatibility crossmatch
Transplantation-related complications
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Elements in Routine Documentation of AML Patients after Stem Cell
Transplantation (HSCT), EHR, University Hospital Münster
GvHD
Immunosuppression
Blood group
CMV
HLA Antigens
HLA Class II
HLA Class I
HLA-A
HLA-B
HLA-C
HLA-DRB1
HLA-DQB1
Donor age
Rhesus factor
Kell system
Number of CD3 cells infused
Engraftment neutrophil
Engraftment platelets
Toxicity
Fever
Donor ID
Number of mononuclear cells infused
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Elements in Routine Documentation of AML Patients after Stem Cell
Transplantation (HSCT), EHR, University Hospital Münster
Microbiology
Infections
Hepatitis A
Hepatitis B
Hepatitis C
CMV
HHV-8
HIV
HTLV
Lues
Parvovirus
Toxoplasmose
Aspergillus
EBV
VZV
HSV
MRSA
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Elements in Routine Documentation of AML Patients after Stem Cell
Transplantation (HSCT), EHR, University Hospital Münster
Hematology / Clinical Chemistry AMLSG 21-13
NCT02013648 Akute myeloische Leukämie (AML)
Randomized Phase III Study of Intensive Chemotherapy
with or without Dasatinib (Sprycel) in Adult Patients
with Newly Diagnosed Core-Binding Factor
Acute Myeloid Leukemia (CBF-AML)
All rights reserved. Please visit https://medical-data-
models.org/forms/13468
Hematology / Clinical Chemistry
AMLSG 21-13 NCT02013648 Akute
myeloische Leukämie (AML)
Point in time
Point in time
Diagnostic (0)
Induction (1)
Induction II (optional) (2)
Consolidation I (3)
Consolidation II (4)
Consolidation III (5)
Consolidation IV (6)
Maintenance (7)
Maintenance Month
Month
Hematology
Date
Hemoglobin
[g/dl]
Erythrocytes
[Tera/l]
Leukocytes
[Giga/l]
Platelets
[Giga/l]
Clinical Chemistry
Date
Creatinine
[umol/l]
Creatinine
[mg/dl]
Sodium
[mmol/l]
1 / 3
Potassium
[mmol/l]
Calcium
[mmol/l]
AST/SGOT
[U/l]
ALT/SGPT
[U/l]
Alkaline Phosphatase
[U/l]
Bilirubin
[umol/l]
Bilirubin
[mg/dl]
Blood urea nitrogen
[mmol/l]
LDH
[U/l]
Phosphate
[mmol/l]
Uric acid
[umol/l]
Albumin
[g/l]
Coagulation
Date
PT/Quick
%
aPTT
Seconds
Signature
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Hematology / Clinical Chemistry AMLSG 21-13 NCT02013648 Akute
myeloische Leukämie (AML)
Date
Name of Investigator
Signature of investigator
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Hematology / Clinical Chemistry AMLSG 21-13 NCT02013648 Akute
myeloische Leukämie (AML)
Evaluation AMLSG 21-13 NCT02013648
Akute myeloische Leukämie (AML)
Randomized Phase III Study of Intensive Chemotherapy
with or without Dasatinib (Sprycel(TM)) in Adult Patients
with Newly Diagnosed Core-Binding Factor
Acute Myeloid Leukemia (CBF-AML)
All rights reserved. Please visit https://medical-data-
models.org/forms/13469
Evaluation AMLSG 21-13
NCT02013648 Akute myeloische
Leukämie (AML)
Evaluation
Point in time
Induction I (1)
Induction II (optional) (2)
Consolidation I (3)
Consolidation II (4)
Consolidation III (5)
Consolidation IV (6)
Maintenance (7)
Follow-up (8)
If in Maintenance: Month
after 12 Months (12)
after 3 Months (3)
after 6 Months (6)
after 9 Months (9)
If Follow-up: consecutive Follow-up number
Status
Is the patient alive?
Yes
No
Date of last information/death
Cause of death
Leukemia (1)
Infection (2)
Bleeding (3)
Secondary illness (4)
Other (5)
Unknown (6)
Specifiy if Cause of death = 2,4,5
Response after Induction Cycles or
Consolidation or Maintenance or during
Follow-up
Date of evaluation
Response
CR (1)
1 / 2
CRi (2)
PR (3)
RD (4)
PD (5)
ED (6)
HD (7)
Extramedullary Manifestatation
Yes
No
Please specify Extramedullary Manifestation
Evaluation based on on following
examinations
Bone marrow evaluation done (If yes specify on
CRF "Bone marrow Evaluation"
Yes
No
Blood count evaluation done? (If yes specify on
CRF "Blood Count Evaluation"
Yes
No
Signature
Date
Name of Investigator
Signature of investigator
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Evaluation AMLSG 21-13 NCT02013648 Akute myeloische Leukämie
(AML)
Concomitant Medication AMLSG 21-13
NCT02013648 Akute myeloische Leukämie (AML)
Randomized Phase III Study of Intensive Chemotherapy
with or without Dasatinib (Sprycel(TM)) in Adult Patients
with Newly Diagnosed Core-Binding Factor
Acute Myeloid Leukemia (CBF-AML)
All rights reserved. Please visit https://medical-data-
models.org/forms/13470
Concomitant Medication AMLSG 21-
13 NCT02013648 Akute myeloische
Leukämie (AML)
Concomitant Medication
Point in time
Diagnostic (0)
Induction I (1)
Induction II (optional) (2)
Consolid. I (3)
Consolid. II (4)
Consolid. III (5)
Consolid. IV (6)
Maintenance (7)
If Maintenance: Month
Month
after 1 Month (1)
after 10 Month (10)
after 11 Month (11)
after 12 Month (12)
after 2 Month (2)
after 3 Month (3)
after 4 Month (4)
after 5 Month (5)
after 6 Month (6)
after 7 Month (7)
after 8 Month (8)
after 9 Month (9)
Pharmalogical Substance
Dose
Unit
Application
oral (1)
intravenous (2)
intramuscular (3)
subcutaneous (4)
sublingual (5)
rectal (6)
Inhalation (7)
topical (8)
other (9)
Frequency
Medical indication
1 / 2
Start Date of Medication
Stop Date Medication
Signature
Date
Name of Investigator
Signature of investigator
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Concomitant Medication AMLSG 21-13 NCT02013648 Akute myeloische
Leukämie (AML)
Newly diagnosed Malignancy AMLSG 21-13
NCT02013648 Akute myeloische Leukämie (AML)
Randomized Phase III Study of Intensive Chemotherapy
with or without Dasatinib (Sprycel(TM)) in Adult Patients
with Newly Diagnosed Core-Binding Factor
Acute Myeloid Leukemia (CBF-AML)
All rights reserved. Please visit https://medical-data-
models.org/forms/13471
Newly diagnosed Malignancy
AMLSG 21-13 NCT02013648 Akute
myeloische Leukämie (AML)
Newly diagnosed Malignancy
Point in time
Diagnostic (0)
Induction I (1)
Induction II (optional) (2)
Consolid. I (3)
Consolid. II (4)
Consolid III (5)
consolid IV (6)
Maintenance (7)
Maintenance Month
after 1 Month (1)
after 10 Months (10)
after 11 Months (11)
after 12 Months (12)
after 2 Months (2)
after 3 Months (3)
after 4 Months (4)
after 5 Months (5)
after 6 Month (6)
after 7 Months (7)
after 8 Months (8)
after 9 Months (9)
Date of Diagnosis
Diagnosis
Therapy
Comment
Signature
Date
Name of Investigator
Signature of investigator
1 / 1
Maintenance AMLSG 21-13 NCT02013648
Akute myeloische Leukämie (AML)
Randomized Phase III Study of Intensive Chemotherapy
with or without Dasatinib (Sprycel(TM)) in Adult Patients
with Newly Diagnosed Core-Binding Factor
Acute Myeloid Leukemia (CBF-AML)
All rights reserved. Please visit https://medical-data-
models.org/forms/13472
Maintenance AMLSG 21-13
NCT02013648 Akute myeloische
Leukämie (AML)
Maintenance
Point in time
after 1 Month (1)
after 10 Month (10)
after 11 Month (11)
after 12 Month (12)
after 2 Month (2)
after 3 Month (3)
after 4 Month (4)
after 5 Month (5)
after 6 Month (6)
after 7 Month (7)
after 8 Month (8)
after 9 Month (9)
Date of evaluation
Weight
kg
Body surface area
sqm
Body temperature
Degree Celcius
Blood pressure
mmHg
Pulse
bpm
General Condition (WHO / ECOG)
<= 4
>= 0
Dasatinib intake during last month (since
last visit)
Start Date Desatinib intake
End Date of Dasatinib intake
Daily dose
1 / 3
Reason for change of dose
Date of last administration of Desatinib
Urinalysis
Urinalysis done
Yes
No
Urinalysis date
Urine pH
pH
Urine protein
normal (0)
+ (1)
++ (2)
+++ (3)
++++ (4)
Urinalysis glucose
normal (0)
+ (1)
++ (2)
+++ (3)
++++ (4)
Pregnancy test done? (Female patients of
childbearing age only)
Yes
No
Pregnancy test result
negative (0)
positive (End of Study) (1)
Adverse Event
Did any Adverse Event occur last month?
Yes
No
Concomitant Medication
Did the Patient take any Concomitant
Medication?
Yes
No
Signature
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Maintenance AMLSG 21-13 NCT02013648 Akute myeloische Leukämie
(AML)
Date
Name of Investigator
Signature of investigator
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Maintenance AMLSG 21-13 NCT02013648 Akute myeloische Leukämie
(AML)
Cycle AMLSG 21-13 NCT02013648 Akute
myeloische Leukämie (AML)
Randomized Phase III Study of Intensive Chemotherapy
with or without Dasatinib (Sprycel™) in Adult Patients
with Newly Diagnosed Core-Binding Factor
Acute Myeloid Leukemia (CBF-AML)
All rights reserved. Please visit https://medical-data-
models.org/forms/13473
Cycle AMLSG 21-13 NCT02013648
Akute myeloische Leukämie (AML)
At start of cycle
Point in time
Induction I (1)
Induction II (optional) (2)
Consolid. I (3)
Consolid. II (4)
Consolid. III (5)
Consolid. IV (6)
Weight [kg]
kg
Body surface area
squaremeter
Temperature
Degree Celcius
Blood pressure
mmHg
Pulse
bpm
General Condition (WHO / ECOG)
>= 0
<= 4
For Induction I only
Administration of Hydroxyurea before start of
Induction I?
Yes
No
If yes, how many days before start of Induction I?
Date of last administration
Cycle
Start of Cycle
Cytarabine
1 / 6
Total Dose[mg]
mg
Dose
complete scheduled Dose (1 )
Withdrawal of consent (2 )
Dose reduced >10% (3 )
Dose reduced and delayed (4 )
not administered (5 )
discontinued and administered again (6 )
completed prematurely (7 )
Other (please specify) (8 )
Reasons (if dose <1)
Toxicity (please specify) (1)
Withdrawal of consent (2)
Other (please specify) (3)
Daunorubicin
Total Dose [mg]
mg
Dose
complete scheduled Dose (1 )
Withdrawal of consent (2 )
Dose reduced >10% (3 )
Dose reduced and delayed (4 )
not administered (5 )
discontinued and administered again (6 )
completed prematurely (7 )
Other (please specify) (8 )
Reason
Toxicity (please specify) (1)
Withdrawal of consent (2)
Other (please specify) (3)
Dasatinib
Total Dose [mg]
mg
Dose
complete scheduled Dose (1 )
Withdrawal of consent (2 )
Dose reduced >10% (3 )
Dose reduced and delayed (4 )
not administered (5 )
discontinued and administered again (6 )
completed prematurely (7 )
Other (please specify) (8 )
Reason
Toxicity (please specify) (1)
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Cycle AMLSG 21-13 NCT02013648 Akute myeloische Leukämie (AML)
Withdrawal of consent (2)
Other (please specify) (3)
Events
Did any Adverse Events occur? If Yes, please
document on CRF Adverse Event (7)
Yes
No
Number of Days with Fever higher than 38.5°C
Number of Nights in Hospital (until discharge or
start of next Cycle)
nights
Inpatient Hospitalisation during Cycle
Was the Patient hospitalised again after
discharge in this Cycle?
Yes
No
Number of Hospitalisations
Date of first Hospitalisation
Duration of all Hospitalsations in this Cycle
Nights
Reason(s) for Hospitalisation(s)
MUGA/Echo Scan
Echocardiography
Yes
No
Echocardiography date
Ejection fraction
%
Abnormalities
Concomitant Medication
Intake of Medication? (If Yes, specify on CRF
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Cycle AMLSG 21-13 NCT02013648 Akute myeloische Leukämie (AML)
"Concomitant Medication"
Yes
No
Buccal Swab (For Induction I only)
Buccal Swab
Yes
No
Date of Buccal Swab
Pregnancy test (female Patients of child-
bearing age only)
Pregnancy test date
Pregnancy test result
negative (0)
positive (1)
Supportive Care (Period: Start Cycle –
Start next Cycle / End of Study)
Number of platelet concentrates Single Donor
(HLA-ident)
Number of platelet concentrates Random / Pool
Date of first Transfusion platelet concentrates
Date of last Transfusion Platelet concentrate
Number of Erythrocyte concentrates/Packed red
blood cells
Date of first Transfusion Erythrocyte concentrate
Date of last Transfusion Erythrocyte concentrate
Hematological Regeneration
Neutrophiles > 0.5 Giga/l
never reduced (1)
regenerated on this day (2)
not yet regenerated (3)
not regenerated until next Cycle (4)
not regenerated until Death (5)
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Cycle AMLSG 21-13 NCT02013648 Akute myeloische Leukämie (AML)
Neutrophiles > 0.5 Giga/l Date
Neutrophiles > 1.5 Giga/l
never reduced (1)
regenerated on this day (2)
not yet regenerated (3)
not regenerated until next Cycle (4)
not regenerated until Death (5)
Neutrophiles > 1.5 Giga/l Date
Leukocytes > 1.0 Giga/l
never reduced (1)
regenerated on this day (2)
not yet regenerated (3)
not regenerated until next Cycle (4)
not regenerated until Death (5)
Leukocytes > 1.0 Giga/l Date
Platelets > 20 Giga/l
never reduced (1)
regenerated on this day (2)
not yet regenerated (3)
not regenerated until next Cycle (4)
not regenerated until Death (5)
Platelets > 20 Giga/l Date
Platelets > 50 Giga/l
never reduced (1)
regenerated on this day (2)
not yet regenerated (3)
not regenerated until next Cycle (4)
not regenerated until Death (5)
Platelets > 50 Giga/l Date
Platelets > 100 Giga/l
never reduced (1)
regenerated on this day (2)
not yet regenerated (3)
not regenerated until next Cycle (4)
not regenerated until Death (5)
Platelets > 100 Giga/l Date
Further Therapy planned
Yes
No
Signature
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Cycle AMLSG 21-13 NCT02013648 Akute myeloische Leukämie (AML)
Date
Name  of Investigator
Signature of investigator
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Cycle AMLSG 21-13 NCT02013648 Akute myeloische Leukämie (AML)
End of Study AMLSG 21-13 NCT02013648
Akute myeloische Leukämie (AML)
Randomized Phase III Study of Intensive Chemotherapy
with or without Dasatinib (Sprycel(TM)) in Adult Patients
with Newly Diagnosed Core-Binding Factor
Acute Myeloid Leukemia (CBF-AML)
All rights reserved. Please visit https://medical-data-
models.org/forms/13475
End of Study AMLSG 21-13
NCT02013648 Akute myeloische
Leukämie (AML)
End of Study
End of Study Date
Reason for End of Study
regular End of Study (0)
no CR after Induction (Progressive
Disease) (1)
exzessive extramedullary medical toxicity
(2)
death (3)
relapse after CR (4)
Withdrawal of informed consent (5)
Protocol deviation (6)
other (7)
Specify if Reason for End of Study = 6 or 7
Induction therapy I administered
Yes
No
Induction therapy II administered
Yes
No
Consolidation therapy I administered
Yes
No
Consolidation therapy II administered
Yes
No
Consolidation therapy III administered
Yes
No
Consolidation therapy IV administered
Yes
No
Maintenance therapy administered
Yes
No
Signature
Date
1 / 2
Name of Investigator
Signature of investigator
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End of Study AMLSG 21-13 NCT02013648 Akute myeloische Leukämie
(AML)
Internal Follow-up Akute myeloische Leukämie (AML) Department of
Internal Medicine Knappschaftskrankenhaus Bochum-Langendreer
Data derived from paper-based form of the Department of
Internal Medicine. With friendly permission of Prof. Dr. med.
Schmiegel and Prof. Dr. med. Schroers
http://www.medunikkh.de/
All rights reserved. Please visit https://medical-data-
models.org/forms/13477
Internal Follow-up KKH Akute
myeloische Leukämie (AML)
Patient data
Patient Name
Patient Forname
Number
Number this year
Date of birth
Age at stem cell transplant
years
Type of Disease
Specific Disease
Karnofsky Index
State of Disease before Transplantation
CR(Complete Remission) (1)
PR(Partial Remission) (2)
SD(Stable Disease) (3)
PD(Progressive Disease) (4)
Chemotherapy Regimen
Graft versus host disease prophylaxis
Start of Induction Therapy
Comments (incl. former High dose
chemotherapy/Stem cell transplantation
Reduction of dose
Date of stem cell transplant
1 / 3
Donor relation to patient
MRD (1)
MUD (2)
Amount of transplanted CD34
Mill. cells/kg
ANC >500 - Day after Transplant
U/l
ANC > 500 u/l date
ANC > 500 u/l after 21 days
Yes
No
Platelets self-sustaining at day
Platelets self-sustaining at date
Platelets self-sustaining after 21 days
Yes
No
Fever
Yes
No
Antibiotic therapy
Yes
No
Antibiotic substance
Pathogen-detection
Pathogenic organism
Resistogram
Infectious Mononucleosis
Yes
No
Death
Death Day after Transplantation
Death before 100 days after Transplantation
Yes
No
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Internal Follow-up Akute myeloische Leukämie (AML) Department of
Internal Medicine Knappschaftskrankenhaus Bochum-Langendreer
Cause of death
State of Disease after Transplantation -
Remission
CR (1)
PR (2)
SD (3)
PD (4)
Relapse day after Transplantation
Relapse date
Date last contact
State of Disease at last contact
CR (1)
PR (2)
SD (3)
PD (4)
Count of days since Transplant at last contact
Day of Transplantation +100
3 / 3
Internal Follow-up Akute myeloische Leukämie (AML) Department of
Internal Medicine Knappschaftskrankenhaus Bochum-Langendreer
Registration and Randomization Form (HOVON
132 AML/SAKK 30/13 EudraCT 2013-002843-26)
Randomized study with a run-in dose-selection phase to
assess the added value of Lenalidomide in combination
with standard remission-induction chemotherapy and post-
remission treatment in patients aged 18-65 years with
previously untreated acute myeloid leukemia (AML) or high
risk myelodysplasia (MDS) (IPSS-R risk score> 4.5)
With friendly permission of HOVON-Group - Prof. G.
Ossenkoppele
All rights reserved. Please visit https://medical-data-
models.org/forms/13478
Registration and Randomization
Form (HOVON 132 AML/SAKK
30/13 EudraCT 2013-002843-26)
Patient data
Caller
Responsible physician
Date of birth
Sex
Male (1)
Female (2)
Date of written Informed Consent
Date of diagnosis of AML or MDS
Patient consent
Approach for future research
Yes
No
Keeping body material up to 15 years after trial
for additional future research
Yes
No
Taking extra bone marrow, blood and saliva for
additional research
Yes
No
Eligibility
AML or MDS diagnosis (see protocol appendix
A1-3)
AML (1)
RAEB (2)
Leukemia with ambiguous lineage (3)
IPSS-R risk score
WHO performance status
0 (0)
1 / 4
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
Sampled BM/PB samples for analysis and MRD
evaluation
no (0)
yes (1)
dry tap (2)
Blood sampling
Serum creatinine
mg/dL
GFR
mL/min
Bilirubin
mg/dL
Bilirubin ULN
mg/dL
AST (SGOT)
U/L
AST (SGOT) ULN
U/L
ALT (SGPT)
U/L
ALT (SGPT) ULN
U/L
Alkaline Phosphatase
U/L
Alkaline Phosphatase ULN
U/L
Ability and willingness to adhere to lenalidomide
pregnancy prevention program
Yes
No
Previous therapy with lenalidomide
Yes
No
2 / 4
Registration and Randomization Form (HOVON 132 AML/SAKK 30/13
EudraCT 2013-002843-26)
Acute promyelocytic leukemia
Yes
No
Myeloproliferative neoplasia
Yes
No
Previous treatment for AML or high risk MDS,
except hydroxyurea
Yes
No
Concurrent history of active malignancy in two
past years prior to diagnosis (except for basal
and squamous cell carcinoma of the skin and in
situ carcinoma of the cervix)
Yes
No
Concurrent severe and/or uncontrolled medical
condition (e.g. uncontrolled diabetes, infection,
hypertension, pulmonary disease etcetera)
Yes
No
Cardiac dysfunction (see protocol section 8.1.2)
Yes
No
Hypersensitivity to the active substance or to any
of the excipients of the drug product
Yes
No
Pregnant or lactating females
Yes
No
Unwilling or not capable to use effective means of
birth control
Yes
No
Any psychological, familial, sociological and
geographical condition potentially hampering
compliance with the study protocol and follow-up
schedule
Yes
No
Data from HOVON data center
Date of Randomization
Patient study number
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Lenalidomide treatment arm allocated
Arm A: induction chemotherapy without
Lenalidomide (1)
Arm B: induction chemotherapy with
Lenalidomide 20mg (2)
Arm B: induction chemotherapy with
Lenalidomide 15mg (5)
Arm B: induction chemotherapy with
Lenalidomide 10mg (6)
4 / 4
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Baseline Concomitant Diseases Form HOVON
132 AML/SAKK 30/13 EudraCT 2013-002843-26
Randomized study with a run-in dose-selection phase to
assess the added value of Lenalidomide in combination
with standard remission-induction chemotherapy and post-
remission treatment in patients aged 18-65 years with
previously untreated acute myeloid leukemia (AML) or high
risk myelodysplasia (MDS) (IPSS-R risk score> 4.5)
Description of Form: Baseline Concomitant Diseases Form
All rights reserved. Please visit https://medical-data-
models.org/forms/13480
Baseline Concomitant Diseases
Form
Baseline Concomitant Diseases
Disease nr
System Organ Class
Blood and lymphatic system disorders
(1)
Immune system disorders  (10)
Infections and infestations  (11)
Injury, poisoning and procedural
complications  (12)
Investigations  (13)
Metabolism and nutrition disorders  (14)
Musculoskeletal and connective tissue
disorders  (15)
Neoplasms benign, malignant and
unspecified (incl cysts and polyps)  (16)
Nervous system disorders  (17)
Pregnancy, puerperium and perinatal
conditions  (18)
Psychiatric disorders  (19)
Heart failure (2)
Renal and urinary disorders  (20)
Reproductive system and breast
disorders  (21)
Respiratory, thoracic and mediastinal
disorders  (22)
Skin and subcutaneous tissue disorders
(23)
Social circumstances  (24)
Surgical and medical procedures  (25)
Vascular disorders (26)
Congenital, familial and genetic
disorders  (3)
Ear and labyrinth disorders  (4)
Endocrine disorders  (5)
Eye disorders  (6)
Gastrointestinal disorders  (7)
General disorders and administration site
conditions  (8)
Hepatobiliary disorders  (9)
Adverse event term (please use CTCAE short
name plus select term if applicable)
Active at baseline
Yes
No
1 / 2
CTCAE grade
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Adverse Event Form HOVON 132
AML/SAKK 30/13 EudraCT 2013-002843-26
Randomized study with a run-in dose-selection phase to
assess the added value of Lenalidomide in combination
with standard remission-induction chemotherapy and post-
remission treatment in patients aged 18-65 years with
previously untreated acute myeloid leukemia (AML) or high
risk myelodysplasia (MDS) (IPSS-R risk score> 4.5)
Description of Form: Adverse Event Form
All rights reserved. Please visit https://medical-data-
models.org/forms/13481
Adverse Event Form
Adverse Event
AE nr
System Organ Class
Blood and lymphatic system disorders
(1)
Immune system disorders  (10)
Infections and infestations  (11)
Injury, poisoning and procedural
complications  (12)
Investigations  (13)
Metabolism and nutrition disorders  (14)
Musculoskeletal and connective tissue
disorders  (15)
Neoplasms benign, malignant and
unspecified (incl cysts and polyps)  (16)
Nervous system disorders  (17)
Pregnancy, puerperium and perinatal
conditions  (18)
Psychiatric disorders  (19)
Cardiac disorders  (2)
Renal and urinary disorders  (20)
Reproductive system and breast
disorders  (21)
Respiratory, thoracic and mediastinal
disorders  (22)
Skin and subcutaneous tissue disorders
(23)
Social circumstances  (24)
Surgical and medical procedures  (25)
Vascular disorders (26)
Congenital, familial and genetic
disorders  (3)
Ear and labyrinth disorders  (4)
Endocrine disorders  (5)
Eye disorders  (6)
Gastrointestinal disorders  (7)
General disorders and administration site
conditions  (8)
Hepatobiliary disorders  (9)
Adverse Event Term (please use CTCAE Short
Name plus Select term if applicable)
CTCAE grade
Serious adverse event
1 / 2
Yes
No
Relationship to protocol treatment
unrelated  (0)
unlikely  (1)
possibly  (2)
probably  (3)
definitely  (4)
unknown (5)
Related to
Lenalidomide  (1)
other trial medication/SCT  (2)
Lenalidomide + other trial
medication/SCT  (3)
unknown (9)
Treatment changed
Yes
No
AE date start
dd/mm/yyyy
AE Outcome
resolved completely  (1)
resolved to baseline  (2)
resolved with sequelae  (3)
ongoing (pending)  (4)
ongoing with higher CTCAE grade  (5)
ongoing (closed)  (6)
death (7)
Date end
dd/mm/yyyy
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Hematological Evaluation Form HOVON 132
AML/SAKK 30/13 EudraCT 2013-002843-26
Randomized study with a run-in dose-selection phase to
assess the added value of Lenalidomide in combination
with standard remission-induction chemotherapy and post-
remission treatment in patients aged 18-65 years with
previously untreated acute myeloid leukemia (AML) or high
risk myelodysplasia (MDS) (IPSS-R risk score> 4.5)
Description of Form: Hematological Evaluation Form
All rights reserved. Please visit https://medical-data-
models.org/forms/13482
Hematological Evaluation Form
Form Relation
Form related to
induction cycle I  (1)
observation/maintenance (1-6) (11-16)
induction cycle II (2)
post induction cycle III  (3)
autoHSCT (4)
alloHSCT (5)
Supportive Care
Number of platelet transfusions
Date last platelet transfusion
dd/mm/yyyy
Number of RBC transfusions
Date of last RBC transfusion
dd/mm/yyyy
Hematological Evaluations
Hematological Evaluation at
Start of treatment  (1)
If not ≥ 100 x 109/L, last platelets before
next treatment  (10)
If not ≥ 100 x 109/L, last platelets before
end of protocol (11)
First evaluation ANC < 0.5 x 109/L  (2)
First evaluation ANC ≥ 0,5 x 109/L  (3)
First evaluation ANC ≥ 1,0 x 109/L  (4)
If not ≥ 1,0 x 109/L, last ANC before next
treatment  (5)
If not ≥ 1,0 x 109/L, last ANC before end
of protocol  (6)
First evaluation platelets < 50 x 109/L
(7)
First evaluation platelets ≥ 50 x 109/L
(8)
First evaluation platelets ≥ 100 x 109/L
(9)
Date
dd/mm/yyyy
1 / 2
Blasts
%
ANC
10^9/L
Platelets
10^9/l
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M6 Bone Marrow Evaluation Form HOVON 132
AML/SAKK 30/13 EudraCT 2013-002843-26
Randomized study with a run-in dose-selection phase to
assess the added value of Lenalidomide in combination
with standard remission-induction chemotherapy and post-
remission treatment in patients aged 18-65 years with
previously untreated acute myeloid leukemia (AML) or high
risk myelodysplasia (MDS) (IPSS-R risk score> 4.5)
Description of Form: M6 Bone Marrow Evaluation Form
All rights reserved. Please visit https://medical-data-
models.org/forms/13483
M6 Bone Marrow Evaluation Form
Bone Marrow Evaluation
Bone marrow evaluation related to period
remission induction treatment cycle I (1)
observation/maintenance (1-6) (11-16)
follow up (17)
remission induction treatment cycle II (2)
post induction treatment cycle III (3)
autoHSCT (4)
alloHSCT (5)
BM sampling date
dd/mm/yyyy
BM Aspirate evaluable
Yes
No
Cellularity
low  (1)
medium  (2)
high (3)
Blasts (i.e. leukemic blasts)
%
Promyelocytes
%
Myelocytes
%
Metamyelocytes
%
Neutrophils
%
Monocytes
%
Eosinophils
%
Basophils
1 / 2
%Erythroblasts
%
Lymphocytes & Plasma cells
%
Other
%
Auer rods
absent (0)
present (1)
Dyserythropoiesis
no  (0)
yes (1)
Dysmegakaryopoiesis
no  (0)
yes (1)
Dysgranulopoiesis
no  (0)
yes (1)
Comment
Comment
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Pregnancy Form HOVON 132 AML/SAKK
30/13 EudraCT 2013-002843-26
Randomized study with a run-in dose-selection phase to
assess the added value of Lenalidomide in combination
with standard remission-induction chemotherapy and post-
remission treatment in patients aged 18-65 years with
previously untreated acute myeloid leukemia (AML) or high
risk myelodysplasia (MDS) (IPSS-R risk score> 4.5)
Description of Form: Pregnancy Form
All rights reserved. Please visit https://medical-data-
models.org/forms/13484
Pregnancy Form
Site Information
Form completed by
Telephone Number
Date of initial report (within 24 hours)
dd/mm/yyyy
Date of follow up report (in case of new data).
dd/mm/yyyy
Subject Information
Who has become pregnant?
female patient  (1)
partner of male patient (2)
Date of Birth
dd/mm/yyyy
Start date of last menses
dd/mm/yyyy
Date pregnancy confirmed
dd/mm/yyyy
Anticipated date of childbirth
dd/mm/yyyy
Trial Medication and Outcome
Period of treatment/last given treatment at time of
conception
before start protocol treatment  (0)
induction cycle I (1)
maintenance (1-6)  (11-16)
follow up  (17)
other* (18)
induction cycle II  (2)
post induction cycle III (3)
autoHSCT  (4)
alloHSCT (5)
1 / 2
Pregnancy outcome
not known at this date (please send in
follow up report when new data are
known) (1)
uneventful (normal/healthy baby) (2)
induced abortion (3)
spontaneous abortion (4)
still birth (5)
neonatal death (6)
birth defects (7)
other* (8)
Specify
Comments
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Second Randomization Form HOVON 132
AML/SAKK 30/13 EudraCT 2013-002843-26
Randomized study with a run-in dose-selection phase to
assess the added value of Lenalidomide in combination
with standard remission-induction chemotherapy and post-
remission treatment in patients aged 18-65 years with
previously untreated acute myeloid leukemia (AML) or high
risk myelodysplasia (MDS) (IPSS-R risk score> 4.5)
Form Description: Second Randomization Form
All rights reserved. Please visit https://medical-data-
models.org/forms/13485
Second Randomization Form
Default Itemgroup
Caller
Last treatment
post induction cycle III (3)
autoHSCT (4)
Date start last treatment
dd/mm/yyyy
Eligibility (See Protocol Section 8)
Patient in CR(i)
no CR(i) (0)
CR  (1)
CRi (2)
ANC
10^9/L
Platelets
10^9/L
Serum Creatinine Clearance
mL/min
Total bilirubin
mg/dL
Bilirubin ULN
mg/dL
AST
U/L
AST (SGOT) ULN
U/L
ALT
U/L
ALT ULN
U/L
1 / 2
Severe cardiac dysfunction (see appendix G)
Yes
No
Severe pulmonary dysfunction (see appendix F)
Yes
No
Severe neurological or psychiatric disease
Yes
No
Serious active infections
Yes
No
Previous serious toxicities related to the use of
lenalidomide
no  (0)
yes  (1)
NA (2)
CMV reactivation, which is not responsive to first
line valganciclovir
Yes
No
Data from HOVON data center
Date of Randomization
dd/mm/yyyy
Treatment arm allocated
Arm A: Observation only (1)
Arm B: Maintenance with Lenalidomide
(2)
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Lenalidomide Maintenance Treatment Form HOVON
132 AML/SAKK 30/13 EudraCT 2013-002843-26
Randomized study with a run-in dose-selection phase to
assess the added value of Lenalidomide in combination
with standard remission-induction chemotherapy and post-
remission treatment in patients aged 18-65 years with
previously untreated acute myeloid leukemia (AML) or high
risk myelodysplasia (MDS) (IPSS-R risk score> 4.5)
Description of Form: Lenalidomide Maintenance Treatment
Form
All rights reserved. Please visit https://medical-data-
models.org/forms/13486
Lenalidomide Maintenance
Treatment Form
Form Relation
Form related to administration
maintenance 1 (11)
maintenance 2  (12)
maintenance 3  (13)
maintenance 4 (14)
maintenance 5 (15)
maintenance 6 (16)
Treatment Administration
Date start Lenalidomide
dd/mm/yyyy
Lenalidomide Total dose actually given
mg
Lenalidomide Dosage
full dose according to schedule (1)
full dose given but start of treatment
delayed (2)
daily dose reduced >10% (3)
daily dose reduced and start delayed (4)
not given (5)
interrupted during the cycle and resumed
(6)
stopped early (7)
other (specify) (8)
Reason
hematological toxicity (1)
non-hematological toxicity (specify) (2)
other (specify) (8)
Comments
Comments
1 / 1
Lenalidomide Maintenance and Observation Evaluation Form
HOVON 132 AML/SAKK 30/13 EudraCT 2013-002843-26
Randomized study with a run-in dose-selection phase to
assess the added value of Lenalidomide in combination
with standard remission-induction chemotherapy and post-
remission treatment in patients aged 18-65 years with
previously untreated acute myeloid leukemia (AML) or high
risk myelodysplasia (MDS) (IPSS-R risk score> 4.5)
Form Description: Lenalidomide Maintenance and
Observation Evaluation Form
All rights reserved. Please visit https://medical-data-
models.org/forms/13487
Lenalidomide Maintenance and
Observation Evaluation Form
Default Itemgroup
Form related to
observation 1/maintenance 1 (11)
observation 2/maintenance 2 (12)
observation 3/maintenance 3 (13)
observation 4/maintenance 4 (14)
observation 5/maintenance 5 (15)
observation 6/maintenance 6 (16)
Nights in hospital
Remission Status
Date of Evaluation
dd/mm/yyyy
Remission status
no CR(i)  (0)
CR  (1)
CRi (2)
undefined item
Date of relapse
dd/mm/yyyy
Survival status
alive (1)
death (2)
Comments
Comments
1 / 1
Lenalidomide Maintenance and Observation Bone Marrow Evaluation
Form HOVON 132 AML/SAKK 30/13 EudraCT 2013-002843-26
Randomized study with a run-in dose-selection phase to
assess the added value of Lenalidomide in combination
with standard remission-induction chemotherapy and post-
remission treatment in patients aged 18-65 years with
previously untreated acute myeloid leukemia (AML) or high
risk myelodysplasia (MDS) (IPSS-R risk score> 4.5)
Form Description: Lenalidomide Maintenance and
Observation Bone Marrow Evaluation Form
All rights reserved. Please visit https://medical-data-
models.org/forms/13488
Lenalidomide Maintenance and
Observation Bone Marrow
Evaluation Form
Bone Marrow Evaluation (6 Months after
second randomization
BM sampling date
dd/mm/yyyy
BM aspirate done
Yes
No
BM Aspirate evaluable
Yes
No
*Blasts
%
*Auer rods
Yes
No
BM biopsy done
Yes
No
Clusters of blasts present
Yes
No
Comments
Comments
1 / 1
End of Protocol Form HOVON 132
AML/SAKK 30/13 EudraCT 2013-002843-26
Randomized study with a run-in dose-selection phase to
assess the added value of Lenalidomide in combination
with standard remission-induction chemotherapy and post-
remission treatment in patients aged 18-65 years with
previously untreated acute myeloid leukemia (AML) or high
risk myelodysplasia (MDS) (IPSS-R risk score> 4.5)
Description of Form: End of Protocol Form
All rights reserved. Please visit https://medical-data-
models.org/forms/13489
End of Protocol Form
Default Itemgroup
Date when taken off protocol
dd/mm/yyyy
Reason for going off protocol
no CR(i) after cycle II (1)
excessive drug toxicity* (2)
hypoplastic bone marrow abnormalities
(3)
death (4)
relapse after initial CR (5)
no compliance of the patient / refusal of
treatment (6)
patient not eligible for 2nd
randomization* (7)
pregnancy (8)
other* (88)
*Specify
Comments
Comments
1 / 1
Autologous Stem Cell Harvest Form HOVON
132 AML/SAKK 30/13 EudraCT 2013-002843-26
Randomized study with a run-in dose-selection phase to
assess the added value of Lenalidomide in combination
with standard remission-induction chemotherapy and post-
remission treatment in patients aged 18-65 years with
previously untreated acute myeloid leukemia (AML) or high
risk myelodysplasia (MDS) (IPSS-R risk score> 4.5)
Desription of Form: Autologous Stem Cell Harvest Form
All rights reserved. Please visit https://medical-data-
models.org/forms/13493
Autologous Stem Cell Harvest Form
Harvesting
Harvesting attempted
Yes
No
If yes, date harvest
dd/mm/yyyy
Harvesting successful
Yes
No
If yes, number of CD34+ cells
x10^6 cell/kg
If no, specify reason
Comments
Comments
1 / 1
Autologous Transplant Form HOVON 132
AML/SAKK 30/13 EudraCT 2013-002843-26
Randomized study with a run-in dose-selection phase to
assess the added value of Lenalidomide in combination
with standard remission-induction chemotherapy and post-
remission treatment in patients aged 18-65 years with
previously untreated acute myeloid leukemia (AML) or high
risk myelodysplasia (MDS) (IPSS-R risk score> 4.5)
Form Description: Autologous Transplant Form
All rights reserved. Please visit https://medical-data-
models.org/forms/13494
Autologous Transplant Form
Conditioning
Date Start
dd/mm/yyyy
Remission status
no CR(i)  (0)
CR  (1)
CRi (2)
Patient weight
kg
Drug
Busulfan total dose
mg
Busilvex total dose
mg
Cyclophosphamide total dose
mg
Phenytoin total dose
mg
Other chemotherapy
Yes
No
Other chemotherapy, specify
Transplant
Source of stem cells (actually infused)
bone marrow  (1)
peripheral blood (2)
BM + PB (3)
Transplant date
dd/mm/yyyy
1 / 2
Number of nucleated cells infused
10^8/kg
Number of CD34+ cells infused
10^6/kg
Comments
Comments
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Allogeneic Transplant Form HOVON 132
AML/SAKK 30/13 EudraCT 2013-002843-26
Randomized study with a run-in dose-selection phase to
assess the added value of Lenalidomide in combination
with standard remission-induction chemotherapy and post-
remission treatment in patients aged 18-65 years with
previously untreated acute myeloid leukemia (AML) or high
risk myelodysplasia (MDS) (IPSS-R risk score> 4.5)
Form Description: Allogeneic Transplant Form
All rights reserved. Please visit https://medical-data-
models.org/forms/13495
Allogeneic Transplant Form
Donor and Patient Characteristic at Entry
Donor date of birth
dd/mm/yyyy
Relation with patient
monozygotic twin (1)
HLA identical sibling (2)
HLA identical parent (3)
1-antigen-mismatched related donor (4)
2-or more-antigen mismatched related
donor (haplo-identical) (5)
matched unrelated donor# (6)
mismatched unrelated donor## (7)
cord blood unit identified (8)
unknown (9)
*number of cord blood donors
EBMT Risk Score
EBMT risk score calculated (Appendix K)
Yes
No
EBMT risk score
Comorbidity Index
Comorbidity index calculated (Appendix J)
Yes
No
Date of evaluation
dd/mm/yyyy
Comorbidity score
Conditioning
Conditioning
non-myelo ablative  (1)
myelo ablative (2)
1 / 3
Date start
dd/mm/yyyy
Remission status
no CR(i)  (0)
CR  (1)
CRi (2)
Patient weight
>= 0
kg
Drug
Cyclophosphamide total dose
mg
Busulfan total dose
mg
Busilvex total dose
mg
ATG total dose
mg
Fludarabine total dose
mg
Other chemotherapy
Yes
No
*Specify
Total body irradiation
Yes
No
Total dose
Gy
Transplant
Transplant date
dd/mm/yyyy
Source of stem cells (actually infused)
bone marrow  (1)
peripheral blood (2)
BM + PB (3)
cord blood (4)
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Number of nucleated cells infused
10^8/kg
Number of CD34+ cells infused
10^6/kg
T-cell depletion
Yes
No
*Specify
Number of T-cells infused
10^4/kg
GvHD Prevention
MTX given
Yes
No
Cyclosporin given
Yes
No
Mycophenolate (Myfortic) given
Yes
No
Other*
Yes
No
Specify
Comments
Comments
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On Study Form HOVON 132 AML/SAKK
30/13 EudraCT  2013-002843-26
Randomized study with a run-in dose-selection phase to
assess the added value of Lenalidomide in combination
with standard remission-induction chemotherapy and post-
remission treatment in patients aged 18-65 years with
previously untreated acute myeloid leukemia (AML) or high
risk myelodysplasia (MDS) (IPSS-R risk score> 4.5)
All rights reserved. Please visit https://medical-data-
models.org/forms/13496
On Study Form
Patient Characteristics At Entry
Height
>= 0
cm
Diagnosis
WHO-AML classification (Appendix A.1, A.2. and
A.3)
FAB type (Appendix A.4)
M0  (0)
M1  (1)
AML, not M3 (10)
M2  (2)
M4  (4)
M5  (5)
M6  (6)
M7  (7)
RAEB  (8)
RAEB-t  (9)
History Of Disease And Clincial Status
Prior MDS
no  (0)
yes  (1)
unknown (9)
MDS Date of Diagnosis
MDS Subtype
RCUD  (1)
MDS unclassified (10)
MDS associated with isolated del(5q)
(11)
RA  (2)
RN (3)
RT  (4)
RARS  (5)
RCMD (6)
RAEB1  (7)
RAEB2 (8)
unknown (9)
Other hematological disease(> 3 months duration
prior to
1 / 6
diagnosis disease under study).
no  (0)
yes  (1)
unknown (9)
Hematological disease Date of diagnosis
Hematological Disease Specification
Other oncological disease
no  (0)
yes  (1)
unknown (9)
Oncological disease Date of diagnosis
Oncological disease Specification
Chemotherapy/Radiotherapy
Yes
No
Chemotherapy/Radiotherapy Date or year start
Chemotherapy/Radiotherapy Specification
Exposure to toxic agents (e.g. insecticide)
no  (0)
yes  (1)
unknown (9)
Exposure to Toxic agents since year
Toxic agents Specification
Existence of one (or more) relatives having
previously suffered from AML
no  (0)
yes  (1)
unknown (9)
*Specify family relation
*specify diagnosis
*specify age of relative at diagnosis
Extramedullary disease
no (go to box 31)  (0)
skin*  (1)
CNS*  (2)
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26
liver*  (3)
spleen*  (4)
lymphadenopathy*  (5)
other* (8)
*Specify site
Level of evidence - Physical examination
no  (0)
yes  (1)
unknown (9)
Level of evidence - Radiologically confirmed
no  (0)
yes  (1)
unknown (9)
Level of evidence - Pathologically confirmed
no  (0)
yes  (1)
unknown (9)
Lactate dehydrogenase (LDH) (U/L)
Lactate dehydrogenase ULN
Bone Marrow Aspirate
BM aspirate done
not done (go to box 33)  (0)
done (1)
Evaluable
no (go to box 33)  (0)
yes (1)
BM sampling date
Cellularity
low  (1)
medium  (2)
high (3)
Blasts
%
Promyelocytes
%
Myelocytes
%
Metamyelocytes
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26
%Neutrophils (segments & bands)
%
Monocytes
%
Eosinophils
%
Basophils
%
Erythroblasts
%
Lymphocytes
%
Other*
%
*Specify
Auer rods
absent (0)
present (1)
Dyserythropoiesis
no  (0)
yes (1)
Dysmegakaryopoiesis
no  (0)
yes (1)
Dysgranulopoiesis
no  (0)
yes (1)
Bone Marrow Biopsy
BM biopsy done
not done (go to box 60)  (0)
done (1)
Evaluable
no (go to box 60)  (0)
yes (1)
Date of BM biopsy
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On Study Form HOVON 132 AML/SAKK 30/13 EudraCT  2013-002843-
26
Cellularity
low  (1)
medium  (2)
high (3)
Clusters of blasts present
Yes
No
Blasts (i.e.leukemic blasts) estimated
%
Peripheral blood evaluation
Peripheral blood evaluation
not done  (0)
done (1)
Blood sampling date
Hemoglobin
mmol/l
Platelets
x10^9/l
WBC
x10^9/l
Blasts
%
Promyelocytes
%
Myelocytes
%
Metamyelocytes
Neutrophils
%
Basophils
%
Lymphocytes
%
Monocytes
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26
%Other*
%
*Specify
Erythroblasts
Auer rods
absent (0)
present (1)
Did patient start protocol treatment
Yes
No
Comments
6 / 6
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26
AutoHSCT Evaluation Form HOVON 132
AML/SAKK 30/13 EudraCT 2013-002843-26
Randomized study with a run-in dose-selection phase to
assess the added value of Lenalidomide in combination
with standard remission-induction chemotherapy and post-
remission treatment in patients aged 18-65 years with
previously untreated acute myeloid leukemia (AML) or high
risk myelodysplasia (MDS) (IPSS-R risk score> 4.5)
Decription of Form: AutoHSCT Evaluation Form
All rights reserved. Please visit https://medical-data-
models.org/forms/13497
AutoHSCT Evaluation Form
Form Relation
Form Relation
autoHSCT (4)
Nights in hospital
Bone Marrow Evaluation
BM sampling date
BM aspirate done
Yes
No
BM Aspirate evaluable
Yes
No
*Blasts
%
Auer rods
Yes
No
BM biopsy done
Yes
No
Clusters of blasts present
Yes
No
Response Evaluation
Date of evaluation (preferably date of BM)
dd/mm/yyyy
Extramedullary disease
no  (0)
skin*  (1)
CNS*  (2)
liver*  (3)
spleen*  (4)
lymphadenopathy*  (5)
1 / 2
other* (8)
*Specify
Response / remission status
CR  (1)
CRi  (2)
Relapse (7)
Survival Status
alive (0)
dead (1)
Comments
Comments
2 / 2
AutoHSCT Evaluation Form HOVON 132 AML/SAKK 30/13 EudraCT
2013-002843-26
AlloHSCT Evaluation Form HOVON 132
AML/SAKK 30/13 EudraCT 2013-002843-26
Randomized study with a run-in dose-selection phase to
assess the added value of Lenalidomide in combination
with standard remission-induction chemotherapy and post-
remission treatment in patients aged 18-65 years with
previously untreated acute myeloid leukemia (AML) or high
risk myelodysplasia (MDS) (IPSS-R risk score> 4.5)
Form Description: AlloHSCT Evaluation Form
All rights reserved. Please visit https://medical-data-
models.org/forms/13498
AlloHSCT Evaluation Form
Form Relation
Form related to
alloHSCT (5)
Nights in hospital
GVHD
Acute GvHD
none  (0)
Grade I  (1)
Grade II (2)
Grade III  (3)
Grade IV (4)
Chronic GvHD
none  (0)
limited  (1)
extensive  (2)
too early (3)
Bone Marrow Evaluation
BM sampling date
dd/mm/yyyy
BM aspirate done
Yes
No
BM Aspirate evaluable
Yes
No
*Blasts
%
*Auer rods
Yes
No
BM biopsy done
Yes
No
1 / 2
Clusters of blasts present
Yes
No
Response Evaluation
Date of evaluation (preferably date of BM)
dd/mm/yyyy
Extramedullary disease
no  (0)
skin*  (1)
CNS*  (2)
liver*  (3)
spleen*  (4)
lymphadenopathy*  (5)
other* (8)
Response / remission status
CR  (1)
CRi  (2)
Relapse (7)
Survival Status
alive (0)
dead (1)
Comments
Comments
2 / 2
AlloHSCT Evaluation Form HOVON 132 AML/SAKK 30/13 EudraCT
2013-002843-26
Dose Limiting Toxicity (DLT) Form HOVON 132
AML/SAKK 30/13 EudraCT 2013-002843-26
Randomized study with a run-in dose-selection phase to
assess the added value of Lenalidomide in combination
with standard remission-induction chemotherapy and post-
remission treatment in patients aged 18-65 years with
previously untreated acute myeloid leukemia (AML) or high
risk myelodysplasia (MDS) (IPSS-R risk score> 4.5)
Form Description: Dose Limiting Toxicity (DLT) Form
All rights reserved. Please visit https://medical-data-
models.org/forms/13499
Dose Limiting Toxicity (DLT) Form
Form Relation
DLT form related to induction cycle
induction cycle I  (1)
induction cycle II (2)
Date DLT evaluation was done
dd/mm/yyyy
Treatment
Has Induction cycle been given (either partially or
completely)
Yes
No
Dose level Lenalidomide (fill out 20 mg, 15 mg,
10 mg)
mg
Date start of this induction cycle
dd/mm/yyyy
Planned start date next treatment
dd/mm/yyyy
Planned next treatment
cycle II (2)
cycle III  (3)
autoHSCT  (4)
alloHSCT  (5)
treatment off protocol (6)
Date off protocoll
dd/mm/yyyy
Survival Status
Date last known to be alive or death
dd/mm/yyyy
Survival Status
alive (0)
dead (1)
Cause of death
1 / 2
leukemia  (1)
pneumonia  (2)
other infection  (3)
hemorrhage (4)
veno-occlusive disease*  (5)
other* (8)
*Specify
Toxicity
CTCAE grade ≥ 4 non hematological toxicity
no (0)
yes, fill out items 15 and 16 (1)
CTCAE grade ≥ 4 non hematological toxicity Date
onset
dd/mm/yyyy
CTCAE grade ≥ 4 non hematological toxicity
Specification
Recovery
Was ANC recovered to > 0.5x109/L
no, give last date ANC was measured
box 18 (0)
yes, fill out date of recovery box 19
and/or 20 (1)
never below (2)
Last date ANC was measured
dd/mm/yyyy
First date ANC >0.5 x 109/L
dd/mm/yyyy
First date ANC >1.0 x 109/L
dd/mm/yyyy
Platelets recovered to > 50x109/L
no  (0)
yes, fill out date of recovery  (1)
never below (2)
First date platelets >50 x 109/L
dd/mm/yyyy
2 / 2
Dose Limiting Toxicity (DLT) Form HOVON 132 AML/SAKK 30/13
EudraCT 2013-002843-26
Rapid Reporting Form HOVON 132
AML/SAKK 30/13 EudraCT 2013-002843-26
Randomized study with a run-in dose-selection phase to
assess the added value of Lenalidomide in combination
with standard remission-induction chemotherapy and post-
remission treatment in patients aged 18-65 years with
previously untreated acute myeloid leukemia (AML) or high
risk myelodysplasia (MDS) (IPSS-R risk score> 4.5)
Form Description: Rapid Reporting Form
All rights reserved. Please visit https://medical-data-
models.org/forms/13500
Rapid Reporting Form
Form Relation
Form related to induction cycle
induction cycle I  (1)
induction cycle II (2)
Date evaluation was done
dd/mm/yyyy
Treatment
Has Induction cycle been given (either partially or
completely)
Yes
No
Dose level Lenalidomide (fill out 20 mg, 15 mg,
10 mg)
mg
Date start of this induction cycle
dd/mm/yyyy
Planned start date next treatment
dd/mm/yyyy
Planned next treatment
cycle II  (2)
cycle III  (3)
autoHSCT  (4)
alloHSCT  (5)
treatment off protocol (6)
Date off protocoll
dd/mm/yyyy
Survival Status
Date last known to be alive or death
dd/mm/yyyy
Survival Status
alive (0)
dead (1)
Cause of death
1 / 2
leukemia  (1)
pneumonia  (2)
other infection  (3)
hemorrhage (4)
veno-occlusive disease*  (5)
other* (8)
*Specify
Toxicity
CTCAE grade ≥ 4 non hematological toxicity
dd/mm/yyyy
no (0)
yes, fill out items 15 and 16 (1)
CTCAE grade ≥ 4 non hematological toxicity Date
onset
dd/mm/yyyy
CTCAE grade ≥ 4 non hematological toxicity
specification
Recovery
Was ANC recovered to > 0.5x109/L
no, give last date ANC was measured
box 18 (0)
yes, fill out date of recovery box 19
and/or 20 (1)
never below (2)
Last date ANC was measured
dd/mm/yyyy
First date ANC >0.5 x 109/L
dd/mm/yyyy
First date ANC >1.0 x 109/L
dd/mm/yyyy
Platelets recovered to > 50x109/L
no  (0)
yes, fill out date of recovery  (1)
never below (2)
First date platelets >50 x 109/L
dd/mm/yyyy
2 / 2
Rapid Reporting Form HOVON 132 AML/SAKK 30/13 EudraCT 2013-
002843-26
Tissue Typing Form HOVON 132 AML/SAKK
30/13 EudraCT 2013-002843-26
Randomized study with a run-in dose-selection phase to
assess the added value of Lenalidomide in combination
with standard remission-induction chemotherapy and post-
remission treatment in patients aged 18-65 years with
previously untreated acute myeloid leukemia (AML) or high
risk myelodysplasia (MDS) (IPSS-R risk score> 4.5)
Form Description: Tissue Typing Form
All rights reserved. Please visit https://medical-data-
models.org/forms/13501
Tissue Typing Form
Tissue Typing Form
Was tissue typing of siblings/other relative done
no# (0)
yes## (1)
unknown (9)
#If no, reason why not
no siblings  (1)
early relapse/progression/death (2)
patient’s condition  (3)
good risk (4)
intermediate risk  (5)
other*  (8)
unknown (9)
*Specify
##Date first sibling typed
dd/mm/yyyy
##Result of typing related donor
monozygotic twin (1)
HLA identical sibling (2)
HLA identical parent (3)
1-antigen-mismatched related donor (4)
2-or more-antigen mismatched related
donor (haplo- identical related donor) (5)
unknown (9)
Was searched for an unrelated donor/cord blood
no# (0)
yes## (1)
unknown (9)
#If no, reason why not
no siblings  (1)
early relapse/progression/death (2)
patient’s condition  (3)
good risk (4)
intermediate risk  (5)
other*  (8)
unknown (9)
*Specify
##Date start search for unrelated donor/cord
blood
dd/mm/yyyy
1 / 3
##Result of typing unrelated donor/cord blood
no donor (0)
matched unrelated donor+ (6)
mismatched unrelated donor++ (7)
cord blood unit identified (8)
unknown (9)
Allo HSCT
Allo HSCT given?
Yes
No
AB0 Patient
O  (0)
A  (1)
B  (2)
AB (3)
AB0 blood type Donor a
O  (0)
A  (1)
B  (2)
AB (3)
AB0 Blood type Donor b
O  (0)
A  (1)
B  (2)
AB (3)
Rh factor Patient
Yes
No
Rh factor Donor a
Yes
No
Rh factor Donor b
Yes
No
CMV Status Patient
Yes
No
CMV Status Donor a
Yes
No
CMV Status Donor b
Yes
No
HLA Patient
HLA-A
2 / 3
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002843-26
HLA-B
HLA-C
HLA-DR
HLA-DQ
HLA Donor
HLA-A
HLA-B
HLA-C
HLA-DR
HLA-DQ
Donor Sex
male (1)
female (2)
If a donor was available, but no allo-SCT was
done give reason
patient’s condition  (1)
early relapse/progression/death  (2)
patient refused  (3)
donor refused (4)
other*  (8)
unknown (9)
*Specify
Comments
Comments
3 / 3
Tissue Typing Form HOVON 132 AML/SAKK 30/13 EudraCT 2013-
002843-26
Chemotherapy Evaluation Form HOVON 132
AML/SAKK 30/13 EudraCT 2013-002843-26
Randomized study with a run-in dose-selection phase to
assess the added value of Lenalidomide in combination
with standard remission-induction chemotherapy and post-
remission treatment in patients aged 18-65 years with
previously untreated acute myeloid leukemia (AML) or high
risk myelodysplasia (MDS) (IPSS-R risk score> 4.5)
All rights reserved. Please visit https://medical-data-
models.org/forms/13502
Chemotherapy Evaluation Form
Cycle
Form related to
induction cycle I  (1)
induction cycle II (2)
post induction cycle III (3)
Nights in hospital
Bone Marrow Evaluation
BM sampling date
dd/mm/yyyy
BM aspirate done
Yes
No
BM aspirate evaluable
no  (0)
yes* (1)
*Blasts
%
Auer rods
Yes
No
BM biopsy done
Yes
No
Clusters of blasts present
Yes
No
Response Evaluation
Date of evaluation (preferably date of BM)
dd/mm/yyyy
Extramedullary disease
no  (0)
skin*  (1)
CNS*  (2)
liver*  (3)
1 / 2
spleen*  (4)
lymphadenopathy*  (5)
other* (8)
*specify
Response / remission status
CR  (1)
CRi  (2)
PR  (3)
RD (4)
Death in aplasia  (5)
Death from indeterminate cause (6)
Relapse (7)
Survival status
alive  (0)
dead (1)
Next treatment given
no further treatment (0)
induction cycle II (2)
post induction cycle III (3)
autoHSCT (4)
alloHSCT (5)
Comments
Comments
2 / 2
Chemotherapy Evaluation Form HOVON 132 AML/SAKK 30/13 EudraCT
2013-002843-26
Chemotherapy Treatment Form HOVON 132
AML/SAKK 30/13 EudraCT 2013-002843-26
Randomized study with a run-in dose-selection phase to
assess the added value of Lenalidomide in combination
with standard remission-induction chemotherapy and post-
remission treatment in patients aged 18-65 years with
previously untreated acute myeloid leukemia (AML) or high
risk myelodysplasia (MDS) (IPSS-R risk score> 4.5)
All rights reserved. Please visit https://medical-data-
models.org/forms/13503
Chemotherapy Treatment Form
Cycle
Form related to
induction cycle I  (1)
induction cycle II  (2)
post induction cycle III (3)
Patient Characteristics At Start Cylce
Weight
>= 0
kg
Administration Of Treatment
Date start treatment
dd/mm/yyyy
Drug
Drug
Idarubicin (1)
Cytarabin (2)
Lenalidomide (3)
Daunorubicin (4)
Mitoxantrone (5)
Etoposide (6)
Total dose actually given
mg
Dosage
full dose according to schedule (1 )
full dose given but start of treatment
delayed (2 )
daily dose reduced >10% (3 )
daily dose reduced and start delayed (4 )
not given (5 )
interrupted during the cycle and resumed
(6 )
stopped early (7 )
other (specify) (8 )
Reason (if dosage >1)
hematological toxicity (1)
non-hematological toxicity (specify) (2)
other (specify) (8)
Comments
1 / 1
Cytogenetic and FISH Form HOVON 132
AML/SAKK 30/13 EudraCT 2013-002843-26
Randomized study with a run-in dose-selection phase to
assess the added value of Lenalidomide in combination
with standard remission-induction chemotherapy and post-
remission treatment in patients aged 18-65 years with
previously untreated acute myeloid leukemia (AML) or high
risk myelodysplasia (MDS) (IPSS-R risk score> 4.5)
All rights reserved. Please visit https://medical-data-
models.org/forms/13504
Cytogenetic and FISH Form
Cytogenetic and FISH Form
Patient date of birth
DD.MM.YYYY
Cytogenetic study
not done 1=done successfully 2=failure
(0)
Date of sample for cytogenetic study
dd/mm/yyyy
Type of examination
BM  (1)
PB  (2)
both  (3)
other (8)
Number of mitoses examined
Number of banded cells fully analysed
General classification
NN 2=AN 3=AA (1)
Number of cells with normal karyotype
Number of cells with clonal abnormality
Nr of cells with complex (>=3) abnormalities
Abnormalities present in
not present  (0)
in one or in related cell clones (1)
in non-related cell clones (2)
Constitutional chromosome abnormality
no  (0)
yes*  (1)
unknown (9)
*Specify
Karyotype (according to ISCN 2005) for complex
karyotypes you can refer to included copy of
original report
1 / 3
FISH done
no  (0)
yes, fill out next items and page 2 (1)
Did FISH confirm cytogenetic results
no*  (0)
yes (1)
*Specify
Comment Of The Reviewer
Comment of the Reviewer
Date reviewed
dd/mm/yyyy
Signature reviewer
Interphase FISH
Target code
5q (1)
chr 5 (11)
chr 7 (12)
chr 8 (13)
20q12 (14)
21q22/AML1 (15)
7q (2)
3q26/EVI-1 (3)
11q23/MLL (4)
16q22/CBFB (5)
t(8;21)(q22;q22) (6)
t(9;22)(q34;q11) (7)
t(15;17)(q22;q21) (8)
Probe
No. analysed
loss %
%
Normal [%]
%
gain [%]
%
transloc [%]
2 / 3
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2013-002843-26
%Metaphase FISH
Metaphase FISH Describe results only if different
from interphase FISH, e.g. elucidation of marker
chromosomes etc. Also include a picture if this is
more informative and results are not
straightforward
Comment Of The Reviewer
Comment of the Reviewer
Date reviewed
dd/mm/yyyy
Signature reviewer
3 / 3
Cytogenetic and FISH Form HOVON 132 AML/SAKK 30/13 EudraCT
2013-002843-26
Last Pazopanib AML Pazopanib
NCT01361334
Pilot Clinical Trial of Pazopanib in Patients With Relapsed
or Refractory Acute Myeloid Leukemia (AML) or at Initial
Diagnosis When no Intensive Treatment is Possible
(PAZOPANIB-AML)
https://clinicaltrials.gov/ct2/show/NCT01361334
Principal Investigator: PD Dr. Torsten Kessler, University
Hospital Muenster, Germany
All rights reserved. Please visit https://medical-data-
models.org/forms/13505
Last Pazopanib AML Pazopanib
NCT01361334
Letzte Gabe Pazopanib
Patientennummer (derived)
Letzte Pazopanib-Gabe: Datum
dd/mm/yyyy
Letzte Pazopanib-Gabe: Datum Status
T (1)
TM (2)
M (3)
Pazopanib wird nach Monat 12 weiter verabreicht
Pazopanib wird nach Monat 12 weiter
verabreicht (1)
Pazopanib abgesetzt: Reguläres Ende der
Einnahme
reguläres Ende der Pazopanib-
Einnahme (Monat 12) (1)
Pazopanib abgesetzt: Studienabbruch
Studienabbruch (1)
Pazopanib abgesetzt: Unerwünschte(s)
Ereignis(se)
unerwünschte(s) Ereignis(se) (1)
Pazopanib abgesetzt: Ermessen des Prüfers
Ermessen des Prüfers (1)
Pazopanib abgesetzt: Ermessen des Prüfers -
Grund
Pazopanib abgesetzt: Widerruf der Einwilligung
Widerruf der Einwilligungserklärung
durch den Patienten (1)
Pazopanib abgesetzt: Dauerth. unerlaubte
Begleitm.
Dauertherapie mit unerlaubter
Begleitmedikation zwingend notwendig
(1)
Pazopanib abgesetzt: Anderer Grund
anderer Grund (9)
Pazopanib abgesetzt: Anderer Grund - Text
1 / 2
Letzte Pazopanib-Gabe: Signatur - Datum
Letzte Pazopanib-Gabe: Signatur - Datum Status
T (1)
TM (2)
M (3)
Letzte Pazopanib-Gabe: Signatur - Prüfer
nein (0)
ja (1)
Kommentar Letzte Gabe Pazopanib
Pazopanib abgesetzt: RQG
Pazopanib abgesetzt: Unerwünschtes Ereignis
AE-Nr
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Follow Up AML Pazopanib NCT01361334
Pilot Clinical Trial of Pazopanib in Patients With Relapsed
or Refractory Acute Myeloid Leukemia (AML) or at Initial
Diagnosis When no Intensive Treatment is Possible
(PAZOPANIB-AML)
https://clinicaltrials.gov/ct2/show/NCT01361334
Principal Investigator: PD Dr. Torsten Kessler, University
Hospital Muenster, Germany
All rights reserved. Please visit https://medical-data-
models.org/forms/13506
Follow Up AML Pazopanib
NCT01361334
Krankheitsstatus
Patientennummer (derived)
Visitenname
Baseline (1)
Monat 6 (10)
Monat 9 (11)
Monat 12 (12)
Progression - Rezidiv (13)
Follow Up - Blatt Nr. 1 (14)
Follow Up - Blatt Nr. 2 (15)
Follow Up - Blatt Nr. 3 (16)
Follow Up - Blatt Nr. 4 (17)
Tag 1 (2)
Tag 2 (3)
Tag 7 (4)
Tag 10 (5)
Tag 14 (6)
Tag 28 (7)
Monat 2 (8)
Monat 3 (9)
Krankheitsstatus: Patient verstorben
Ja
Nein
Letztes Follow Up
ja (1)
Follow Up: Signatur Prüfer
nein (0)
ja (1)
Remissionsstatus
Komplette Remission (CR) (1)
Komplette Remission mit unvollständiger
Erholung der Thrombozyten (CRp) (2)
Komplette Remission mit unvollständiger
Erholung der Granulozyten (CRi) (3)
Partielle Remission (PR) (4)
Stabile Erkrankung (5)
Progression (Studienabbruch, falls schon
mehr als 7 Tage Pazopanib
eingenommen wurde) (6)
Rezidiv (7)
unbekannt (8)
sonstiges (9)
Kommentar Krankheitsstatus
1 / 2
Krankheitsstatus: Patient verstorben Datum
Krankheitsstatus: Patient verstorben Datum
Status
T (1)
TM (2)
M (3)
Follow Up: Signatur - Datum
Follow Up: Signatur - Datum Status
T (1)
TM (2)
M (3)
Follow Up: Datum
2 / 2
Follow Up AML Pazopanib NCT01361334
Agent AML Pazopanib NCT01361334
Pilot Clinical Trial of Pazopanib in Patients With Relapsed
or Refractory Acute Myeloid Leukemia (AML) or at Initial
Diagnosis When no Intensive Treatment is Possible
(PAZOPANIB-AML)
https://clinicaltrials.gov/ct2/show/NCT01361334
Principal Investigator: PD Dr. Torsten Kessler, University
Hospital Muenster, Germany
All rights reserved. Please visit https://medical-data-
models.org/forms/13507
Agent AML Pazopanib
NCT01361334
Gabe Pazopanib
Patientennummer (derived)
Gabe von Pazopanib: Blatt-Nummer
Gabe von Pazopanib: Neue Seite anlegen*
ja (1)
Gabe von Pazopanib: Signatur - Datum
Gabe von Pazopanib: Signatur - Datum Status
T (1)
TM (2)
M (3)
Gabe von Pazopanib: Signatur - Prüfer
nein (0)
ja (1)
Kommentar Gabe Pazopanib
Gabe von Pazopanib: RQG
Gabe von Pazopanib: Nummer
Gabe von Pazopanib: Start - Datum
Gabe von Pazopanib: Start - Datum Status
T (1)
TM (2)
M (3)
Gabe von Pazopanib: Ende - Datum
Gabe von Pazopanib: Ende - Datum Status
T (1)
TM (2)
M (3)
Gabe von Pazopanib: Dosis pro Tag
mg
1 / 2
Gabe von Pazopanib: Grund für Dosisanpassung
Adverse Event (1)
Cyp3A4-Inhibitor (2)
Entscheidung Patient (3)
anderer Grund (4)
2 / 2
Agent AML Pazopanib NCT01361334
End of study AML Pazopanib
NCT01361334
Pilot Clinical Trial of Pazopanib in Patients With Relapsed
or Refractory Acute Myeloid Leukemia (AML) or at Initial
Diagnosis When no Intensive Treatment is Possible
(PAZOPANIB-AML)
https://clinicaltrials.gov/ct2/show/NCT01361334
Principal Investigator: PD Dr. Torsten Kessler, University
Hospital Muenster, Germany
All rights reserved. Please visit https://medical-data-
models.org/forms/13508
End of study AML Pazopanib
NCT01361334
Studienabbruch
Patientennummer (derived)
Studienabbruch: Datum
Studienabbruch: Datum Status
T (1)
TM (2)
M (3)
Studienabbruch: Widerruf der Einwilligung
Widerruf der Einwilligungserklärung
durch den Patienten oder gesetzlichen
Vertreter (1)
Studienabbruch: Verletzte Ein-Ausschlusskrit.
nachträgliche Feststellung durch den
Prüfarzt, dass Einschlusskriterien nicht
erfüllt sind ... (1)
Studienabbruch: Unerwünschte(s) Ereignis(se)
unerwünschte(s) Ereignis(se) (1)
Studienabbruch: Tod
Tod (1)
Studienabbruch: Lost to follow up
lost to follow up (1)
Studienabbruch: Progression
Progression (1)
Studienabbruch: Rezidiv
Rezidiv (1)
Studienabbruch: Neue anti-leuk Ther - Datum
Studienabbruch: Neue anti-leuk Ther - Datum
Status
T (1)
TM (2)
M (3)
Studienabbruch: Neue anti-leukäm. Therapie -
Text
1 / 3
Studienabbruch: Anderer Gund
anderer Grund (9)
Studienabbruch: Anderer Gund - Text
Studienabbruch: Komplette Remission (CR)
Komplette Remission (CR) (1)
Studienabbruch: Komplette Remission (CRp)
Komplette Remission mit unvollständiger
Erholung der Thrombozyten (CRp) (1)
Studienabbruch: Komplette Remission (CRi)
Komplette Remission mit unvollständiger
Erholung der Granulozyten (CRi) (1)
Studienabbruch: Partielle Remission (PR)
Partielle Remission (PR) (1)
Studienabbruch: Stabile Erkrankung
Stabile Erkrankung (1)
Studienabbruch: Progression
Progression (1)
Studienabbruch: Rezidiv
Rezidiv (1)
Studienabbruch: Unbekannt
unbekannt (9)
Studienabbruch: Sonstiges
sonstiges (9)
Studienabbruch: Sonstiges - Text
Studienabbruch: Signatur - Datum
Studienabbruch: Signatur - Datum Status
T (1)
TM (2)
M (3)
Studienabbruch: Signatur - Prüfer
nein (0)
ja (1)
Kommentar Studienabbruch
Studienabbruch: verletzte Ein-
Ausschlusskrit. RQG
Studienabbruch: Verletzte Ein-Ausschlusskrit.
Code
EIN01 (1)
2 / 3
End of study AML Pazopanib NCT01361334
AUS01 (10)
AUS02 (11)
AUS03 (12)
AUS04 (13)
AUS05 (14)
AUS06 (15)
AUS07 (16)
AUS08 (17)
AUS09 (18)
AUS10 (19)
EIN02 (2)
AUS11 (20)
AUS12 (21)
AUS13 (22)
AUS14 (23)
AUS15 (24)
EIN03 (3)
EIN04 (4)
EIN05 (5)
EIN06 (6)
EIN07 (7)
EIN08 (8)
EIN09 (9)
Studienabbruch: Unerwünschte(s)
Ereignis(se) RQG
Studienabbruch: Unerwünschte(s) Ereignis(se)-
AE-Nr
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End of study AML Pazopanib NCT01361334
Death AML Pazopanib NCT01361334
Pilot Clinical Trial of Pazopanib in Patients With Relapsed
or Refractory Acute Myeloid Leukemia (AML) or at Initial
Diagnosis When no Intensive Treatment is Possible
(PAZOPANIB-AML)
https://clinicaltrials.gov/ct2/show/NCT01361334
Principal Investigator: PD Dr. Torsten Kessler, University
Hospital Muenster, Germany
All rights reserved. Please visit https://medical-data-
models.org/forms/13509
Death AML Pazopanib
NCT01361334
Tod
Patientennummer (derived)
Tod: Datum
Tod: Datum Status
T (1)
TM (2)
M (3)
Tod: Ursache
zugrundeliegende Leukämie (1)
andere Ursache (9)
Tod: Ursache - Text
Tod: Komplette Remission (CR)
Komplette Remission (CR) (1)
Tod: Komplette Remission (CRp)
Komplette Remission mit unvollständiger
Erholung der Thrombozyten (CRp) (1)
Tod: Komplette Remission (CRi)
Komplette Remission mit unvollständiger
Erholung der Granulozyten (CRi) (1)
Tod: Partielle Remission (PR)
Partielle Remission (PR) (1)
Tod: Stabile Erkrankung
Stabile Erkrankung (1)
Tod: Progression
Progression (1)
Tod: Rezidiv
Rezidiv (1)
Tod: Tod in Aplasie
Tod in Aplasie (1)
Tod: Tod, Leukämiestatus unbekannt
Tod, Leukämiestatus unbekannt (1)
Tod: Unbekannt
unbekannt (9)
1 / 2
Tod: Sonstiges
sonstiges (9)
Tod: Sonstiges - Text
Tod: Signatur- Datum
Tod: Signatur- Datum Status
T (1)
TM (2)
M (3)
Tod: Signatur - Prüfer
nein (0)
ja (1)
Kommentar Tod
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Patient data AML Pazopanib NCT01361334
Pilot Clinical Trial of Pazopanib in Patients With Relapsed
or Refractory Acute Myeloid Leukemia (AML) or at Initial
Diagnosis When no Intensive Treatment is Possible
(PAZOPANIB-AML)
https://clinicaltrials.gov/ct2/show/NCT01361334
Principal Investigator: PD Dr. Torsten Kessler, University
Hospital Muenster, Germany
All rights reserved. Please visit https://medical-data-
models.org/forms/13510
Patient data AML Pazopanib
NCT01361334
Patientendaten
Patientennummer (derived)
Visitenname
Baseline (1)
Monat 6 (10)
Monat 9 (11)
Monat 12 (12)
Progression - Rezidiv (13)
Follow Up - Blatt Nr. 1 (14)
Follow Up - Blatt Nr. 2 (15)
Follow Up - Blatt Nr. 3 (16)
Follow Up - Blatt Nr. 4 (17)
Tag 1 (2)
Tag 2 (3)
Tag 7 (4)
Tag 10 (5)
Tag 14 (6)
Tag 28 (7)
Monat 2 (8)
Monat 3 (9)
Geburtsdatum: Monat
Geburtsdatum: Jahr
Einverständnis: Datum
Einverständnis: Datum Status
T (1)
TM (2)
M (3)
Geschlecht
maennlich (m)
weiblich (w)
Zustimmung: Analyse Gewebeproben
Ja
Nein
Anamnesestatus: De novo AML
De novo AML (1)
Anamnesestatus: Sekundäre AML
Sekundäre AML (1)
1 / 2
Anamnesestatus: Extramedullärer Befall
Ja
Nein
Anamnesestatus: Stadium
Erstdiagnose (1)
Refraktär (2)
Rezidiv (3)
Kommentar Patientendaten
Bisherige Behandlung AML: RQG
Bisherige Behandlung AML
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Comorbidity AML Pazopanib NCT01361334
Pilot Clinical Trial of Pazopanib in Patients With Relapsed
or Refractory Acute Myeloid Leukemia (AML) or at Initial
Diagnosis When no Intensive Treatment is Possible
(PAZOPANIB-AML)
https://clinicaltrials.gov/ct2/show/NCT01361334
Principal Investigator: PD Dr. Torsten Kessler, University
Hospital Muenster, Germany
All rights reserved. Please visit https://medical-data-
models.org/forms/13511
Comorbidity AML Pazopanib
NCT01361334
Vor- Begleiterkrankungen
Patientennummer (derived)
Visitenname
Baseline (1)
Monat 6 (10)
Monat 9 (11)
Monat 12 (12)
Progression - Rezidiv (13)
Follow Up - Blatt Nr. 1 (14)
Follow Up - Blatt Nr. 2 (15)
Follow Up - Blatt Nr. 3 (16)
Follow Up - Blatt Nr. 4 (17)
Tag 1 (2)
Tag 2 (3)
Tag 7 (4)
Tag 10 (5)
Tag 14 (6)
Tag 28 (7)
Monat 2 (8)
Monat 3 (9)
Vor- Begleiterkrankung: Vorhanden
Ja
Nein
Kommentar Vor- Begleiterkrankungen
Vor- Begleiterkrankung: RQG
Vor- Begleiterkrankung: Nummer
Vor- Begleiterkrankung: Erkrankung
Vor- Begleiterkrankung: Andauernd
Ja
Nein
1 / 1
Bone Marrow AML Pazopanib
NCT01361334
Pilot Clinical Trial of Pazopanib in Patients With Relapsed
or Refractory Acute Myeloid Leukemia (AML) or at Initial
Diagnosis When no Intensive Treatment is Possible
(PAZOPANIB-AML)
https://clinicaltrials.gov/ct2/show/NCT01361334
Principal Investigator: PD Dr. Torsten Kessler, University
Hospital Muenster, Germany
All rights reserved. Please visit https://medical-data-
models.org/forms/13512
Bone Marrow AML Pazopanib
NCT01361334
Knochenmarkuntersuchung
Patientennummer (derived)
Visitenname
Baseline (1)
Monat 6 (10)
Monat 9 (11)
Monat 12 (12)
Progression - Rezidiv (13)
Follow Up - Blatt Nr. 1 (14)
Follow Up - Blatt Nr. 2 (15)
Follow Up - Blatt Nr. 3 (16)
Follow Up - Blatt Nr. 4 (17)
Tag 1 (2)
Tag 2 (3)
Tag 7 (4)
Tag 10 (5)
Tag 14 (6)
Tag 28 (7)
Monat 2 (8)
Monat 3 (9)
Knochenmarkuntersuchung: Datum
Knochenmarkuntersuchung: Datum Status
T (1)
TM (2)
M (3)
Knochenmarkuntersuchung: nd
nd (9)
Zytologie: nd
nd (9)
Zytologie: Zellularität
stark hyperzellulär (1)
mässig hyperzellulär (2)
normozellulär (3)
mässig hypozellulär (4)
stark hypozellulär (5)
nicht beurteilbar (8)
Zytologie: Blastenanteil Kategorien
< 5% (1)
>= 5% (2)
nicht beurteilbar (8)
1 / 3
Zytologie: Blastenanteil Blasten
%
Zytologie: Dysplasiezeichen
keine (0)
in einer Linie (1)
Mehrliniendysplasie (2)
nicht beurteilbar (8)
nicht untersucht (9)
FAB_Klassifikation: M0
M0 (1)
FAB_Klassifikation: M1
M1 (1)
FAB_Klassifikation: M2
M2 (1)
FAB_Klassifikation: M4
M4 (1)
FAB_Klassifikation: M4eo
M4eo (1)
FAB_Klassifikation: M5
M5 (1)
FAB_Klassifikation: M6
M6 (1)
FAB_Klassifikation: M7
M7 (1)
FAB_Klassifikation: unbekannt
unbekannt (9)
FACS: Blastenanteil nd
nd (9)
FACS: Blastenanteil Kategorien
< 5% (1)
>= 5% (2)
nicht beurteilbar (8)
FACS: Blastenanteil Blasten
%
Finale Beurteilung: Blastenanteil Kategorien
< 5% (1)
>= 5% (2)
Finale Beurteilung: Blastenanteil Blasten
%
Target-Rez-Phosph. Knochenm.: Western Blot nd
nd (9)
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Bone Marrow AML Pazopanib NCT01361334
Target-Rez-Phosph. Knochenm.: Western Blot
PDGFR
Target-Rez-Phosph. Knochenm.: Western Blot
VEGFR
Target-Rez-Phosph. Knochenm.: Western Blot c-
Kit
Target-Rez-Phosph. Knochenm.:
Immunphänonotypisierung nd
nd (9)
Target-Rez-Phosph. Knochenm.:
Immunphänotypisierung PDGFR
Target-Rez-Phosph. Knochenm.:
Immunphänotypisierng VEGFR
Target-Rez-Phosph. Knochenm.:
Immunphänotypisierung c-Kit
Target-Rez-Phosph. Knochenm.:
Immunhistochemie nd
nd (9)
Target-Rez-Phosph. Blasten: Western Blot nd
nd (9)
Target-Rez-Phosph. Blasten: Western Blot
PDGFR
Target-Rez-Phosph. Blasten: Western Blot
VEGFR
Target-Rez-Phosph. Blasten: Western Blot c-Kit
Target-Rez-Phosph. Blasten:
Immunphänotypisierung nd
nd (9)
Target-Rez-Phosph. Blasten: Immunphäno
PDGFR
Target-Rez-Phosph. Blasten:
Immunphänotypisierung VEGFR
Target-Rez-Phosph. Blasten:
Immunphänotypisierung c-Kit
Kommentar Knochenmarkuntersuchung
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Genetics AML Pazopanib NCT01361334
Pilot Clinical Trial of Pazopanib in Patients With Relapsed
or Refractory Acute Myeloid Leukemia (AML) or at Initial
Diagnosis When no Intensive Treatment is Possible
(PAZOPANIB-AML)
https://clinicaltrials.gov/ct2/show/NCT01361334
Principal Investigator: PD Dr. Torsten Kessler, University
Hospital Muenster, Germany
All rights reserved. Please visit https://medical-data-
models.org/forms/13513
Genetics AML Pazopanib
NCT01361334
Genetik
Patientennummer (derived)
Visitenname
Baseline (1)
Monat 6 (10)
Monat 9 (11)
Monat 12 (12)
Progression - Rezidiv (13)
Follow Up - Blatt Nr. 1 (14)
Follow Up - Blatt Nr. 2 (15)
Follow Up - Blatt Nr. 3 (16)
Follow Up - Blatt Nr. 4 (17)
Tag 1 (2)
Tag 2 (3)
Tag 7 (4)
Tag 10 (5)
Tag 14 (6)
Tag 28 (7)
Monat 2 (8)
Monat 3 (9)
Mikrogefässzahl: Bestimmung nd
nd (9)
Mikrogefässzahl: Bestimmung 1
/1,5 mm2
Mikrogefässzahl: Bestimmung 2
Mikrogefässzahl: Bestimmung 3
Mikrogefässzahl: Bestimmung 4
Zytogenetik: Datum
Zytogenetik: Datum Status
T (1)
TM (2)
M (3)
Zytogenetik: nd
nd (9)
Zytogenetik: normaler Karyotyp
1 / 3
normaler Karyotyp (1)
Zytogenetik: t(8;21)
t(8;21) (1)
Zytogenetik: t(6;9)
t(6;9) (1)
Zytogenetik: t(16;16)
t(16;16) (1)
Zytogenetik: inv(16)
inv(16) (1)
Zytogenetik: -7/7q-
-7/7q- (1)
Zytogenetik: -5/5q-
-5/5q- (1)
Zytogenetik: +8 als Einzelaberration
+8 als Einzelaberration (1)
Zytogenetik: t(3;3)
t(3;3) (1)
Zytogenetik: +8 mit einer weiteren Aberration
+8 mit einer weiteren Aberration (ausser
t(9;11)) (1)
Zytogenetik: 11q23 - aberrations
11q23 - aberrations (1)
Zytogenetik: komplexer Karyotyp (>= 3 Läsionen)
komplexer Karyotyp (>= 3 Läsionen) (1)
Zytogenetik: sonstige Aberrationen
sonstige Aberrationen (9)
Zytogenetik: sonstige Aberrationen Text
Molekulargenetik: Datum
Molekulargenetik: Datum Status
T (1)
TM (2)
M (3)
Molekulargenetik: nd
nd (9)
Molekulargenetik: AML1 / ETO
nein (0)
ja (1)
nicht untersucht (9)
Molekulargenetik: CBFbeta / MYH11
nein (0)
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ja (1)
nicht untersucht (9)
Molekulargenetik: NPM1-Mut
nein (0)
ja (1)
nicht untersucht (9)
Molekulargenetik: Flt3-ITD
nein (0)
ja (1)
nicht untersucht (9)
Molekulargenetik: Bcr-Abl
nein (0)
ja (1)
nicht untersucht (9)
Molekulargenetik: sonstige
sonstige (9)
Molekulargenetik: sonstige Text
Prog/Rez: Signatur - Datum
Prog/Rez: Signatur - Datum Status
T (1)
TM (2)
M (3)
Prog/Rez: Signatur - Prüfer
nein (0)
ja (1)
Kommentar Genetik
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Remission status AML Pazopanib
NCT01361334
Pilot Clinical Trial of Pazopanib in Patients With Relapsed
or Refractory Acute Myeloid Leukemia (AML) or at Initial
Diagnosis When no Intensive Treatment is Possible
(PAZOPANIB-AML)
https://clinicaltrials.gov/ct2/show/NCT01361334
Principal Investigator: PD Dr. Torsten Kessler, University
Hospital Muenster, Germany
All rights reserved. Please visit https://medical-data-
models.org/forms/13514
Remission status AML Pazopanib
NCT01361334
Remissionsstatus
Patientennummer (derived)
Visitenname
Baseline (1)
Monat 6 (10)
Monat 9 (11)
Monat 12 (12)
Progression - Rezidiv (13)
Follow Up - Blatt Nr. 1 (14)
Follow Up - Blatt Nr. 2 (15)
Follow Up - Blatt Nr. 3 (16)
Follow Up - Blatt Nr. 4 (17)
Tag 1 (2)
Tag 2 (3)
Tag 7 (4)
Tag 10 (5)
Tag 14 (6)
Tag 28 (7)
Monat 2 (8)
Monat 3 (9)
Komplette Remission (CR)
Komplette Remission (CR) (1)
Komplette Remission: unvollständige Erholung
(CRp)
Komplette Remission mit unvollständiger
Erholung der Thrombozyten (CRp) (1)
Komplette Remission: unvollständige Erholung
(CRi)
Komplette Remission mit unvollständiger
Erholung der Granulozyten (CRi) (1)
Partielle Remission (PR)
Partielle Remission (PR) (1)
Stabile Erkrankung
Stabile Erkrankung (1)
Progression
Progression (1)
Rezidiv
Rezidiv (1)
Rem.status: Unbekannt
unbekannt (9)
1 / 2
Rem.status: Sonstiges
sonstiges (9)
Rem.status Sonstiges: Text
Kommentar Remissionsstatus
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Urine analysis AML Pazopanib
NCT01361334
Pilot Clinical Trial of Pazopanib in Patients With Relapsed
or Refractory Acute Myeloid Leukemia (AML) or at Initial
Diagnosis When no Intensive Treatment is Possible
(PAZOPANIB-AML)
https://clinicaltrials.gov/ct2/show/NCT01361334
Principal Investigator: PD Dr. Torsten Kessler, University
Hospital Muenster, Germany
All rights reserved. Please visit https://medical-data-
models.org/forms/13515
Urine analysis AML Pazopanib
NCT01361334
Urinanalyse
Patientennummer (derived)
Visitenname
Baseline (1)
Monat 6 (10)
Monat 9 (11)
Monat 12 (12)
Progression - Rezidiv (13)
Follow Up - Blatt Nr. 1 (14)
Follow Up - Blatt Nr. 2 (15)
Follow Up - Blatt Nr. 3 (16)
Follow Up - Blatt Nr. 4 (17)
Tag 1 (2)
Tag 2 (3)
Tag 7 (4)
Tag 10 (5)
Tag 14 (6)
Tag 28 (7)
Monat 2 (8)
Monat 3 (9)
Urinanalyse: Datum
Urinanalyse: Datum Status
T (1)
TM (2)
M (3)
Urin-Protein-Verhältnis
Gesamtprotein im 24-h Urin
Gesamtprotein im 24-h Urin: nd
nd (9)
Kommentar Urinanalyse
HarnproteineQG
Harnprotein Wert
Harnprotein Einheit
1 / 2
1=mg/dl (1)
2=g/l (2)
3=mg/l (3)
9=and. (9)
Harnprotein andere Einheit
Harnprotein Status
1=ok (1)
2=< (2)
3=> (3)
7=nd (7)
8=na (8)
9=nk (9)
Harnprotein anderes Datum
Harnprotein Faktor
Harnprotein stand. Wert
Harnprotein Gruppe
KreatininQG
Urin Kreatinin
Kreatinin Einheit
1=mg/dl (1)
2=µmol/l (2)
9=and. (9)
Kreatinin andere Einheit
Kreatinin Status
1=ok (1)
2=< (2)
3=> (3)
7=nd (7)
8=na (8)
9=nk (9)
Kreatinin anderes Datum
Kreatinin Faktor
Kreatinin stand. Wert
Kreatinin Gruppe
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Adverse Event AML Pazopanib
NCT01361334
Pilot Clinical Trial of Pazopanib in Patients With Relapsed
or Refractory Acute Myeloid Leukemia (AML) or at Initial
Diagnosis When no Intensive Treatment is Possible
(PAZOPANIB-AML)
https://clinicaltrials.gov/ct2/show/NCT01361334
Principal Investigator: PD Dr. Torsten Kessler, University
Hospital Muenster, Germany
All rights reserved. Please visit https://medical-data-
models.org/forms/13516
Adverse Event AML Pazopanib
NCT01361334
Adverse Event
Patientennummer (derived)
AE: Blatt Nummer
AE: Datum Unterschrift
AE: Unterschrift Datum Status
T (1)
TM (2)
M (3)
AE: Unterschrift
nein (0)
ja (1)
AE: Neue eForm*
ja (1)
Kommentar Adverse Event
AERQG
AE: Nummer
AE: Begrifflichkeit
AE: Start Datum
AE: Start Datum Status
T (1)
TM (2)
M (3)
AE: Schwerwiegendes Ereignis
Ja
Nein
AE: Toxizität (CTCAE) Grad
0 (0)
1 (1)
2 (2)
1 / 3
3 (3)
4 (4)
5 (5)
AE: Zusammenhang mit Studienmedikation XXX
0 (0)
1 (1)
AE: Veränderung der Studientmedikation XXX
0 (0)
1 (1)
2 (2)
3 (3)
AE: AE führte zum Studienabbruch
nein (0)
ja (1)
AE: Enddatum
AE: Enddatum Status
T (1)
TM (2)
M (3)
AE: anhaltend
ja (1)
AE: Ausgang des AE
0 (0)
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
AE: CTCAE Grading
fehlend (0)
leicht (1)
mittel (2)
schwer (3)
lebensbedrohlich (4)
Tod (5)
AE: Zusammenhang mit Prüfmedikation
keine vernünftige Möglichkeit eines
Zus.hangs (0)
vernünftige Möglichkeit eines Zus.hangs
(1)
AE: Maßnahmen bzgl. Prüfmedikation
keine (0)
Dosis geändert (1)
Medikament vorübergehend abgesetzt
(2)
Medikament endgültig abgesetzt (3)
AE: Ausgang des AE
wiederhergestellt (0)
2 / 3
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gebessert (1)
noch nicht gebessert (2)
wiederhergestellt mit bleibendem
Schaden (3)
Tod (4)
unbekannt (5)
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Clinical Chemistry AML Pazopanib
NCT01361334
Pilot Clinical Trial of Pazopanib in Patients With Relapsed
or Refractory Acute Myeloid Leukemia (AML) or at Initial
Diagnosis When no Intensive Treatment is Possible
(PAZOPANIB-AML)
https://clinicaltrials.gov/ct2/show/NCT01361334
Principal Investigator: PD Dr. Torsten Kessler, University
Hospital Muenster, Germany
All rights reserved. Please visit https://medical-data-
models.org/forms/13517
Clinical Chemistry AML Pazopanib
NCT01361334
Klinische Chemie
Patientennummer (derived)
Visitenname
Baseline (1)
Monat 6 (10)
Monat 9 (11)
Monat 12 (12)
Progression - Rezidiv (13)
Follow Up - Blatt Nr. 1 (14)
Follow Up - Blatt Nr. 2 (15)
Follow Up - Blatt Nr. 3 (16)
Follow Up - Blatt Nr. 4 (17)
Tag 1 (2)
Tag 2 (3)
Tag 7 (4)
Tag 10 (5)
Tag 14 (6)
Tag 28 (7)
Monat 2 (8)
Monat 3 (9)
Klinische Chemie: Datum
Kommentar Klinische Chemie
Harnsäure
md/dl
Glukose
mg/dl
Kreatinin
mg/dl
Bilirubin (gesamt)
mg/dl
Direktes Bilirubin
mg/dl
AP
U/L
1 / 2
ASAT (SGOT) (U/L)
U/L
ALAT (SGPT) (U/L)
U/L
Gamma-GT
U/L
Laktat Dehydrogenase (LDH)
U/L
Lipase
U/L
PTT
sek
Fibrinogen
mg/dl
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Clinical examination AML Pazopanib
NCT01361334
Pilot Clinical Trial of Pazopanib in Patients With Relapsed
or Refractory Acute Myeloid Leukemia (AML) or at Initial
Diagnosis When no Intensive Treatment is Possible
(PAZOPANIB-AML)
https://clinicaltrials.gov/ct2/show/NCT01361334
Principal Investigator: PD Dr. Torsten Kessler, University
Hospital Muenster, Germany
All rights reserved. Please visit https://medical-data-
models.org/forms/13518
Clinical examination AML Pazopanib
NCT01361334
Klinischer Befund
Patientennummer (derived)
Visitenname
Baseline (1)
Monat 6 (10)
Monat 9 (11)
Monat 12 (12)
Progression - Rezidiv (13)
Follow Up - Blatt Nr. 1 (14)
Follow Up - Blatt Nr. 2 (15)
Follow Up - Blatt Nr. 3 (16)
Follow Up - Blatt Nr. 4 (17)
Tag 1 (2)
Tag 2 (3)
Tag 7 (4)
Tag 10 (5)
Tag 14 (6)
Tag 28 (7)
Monat 2 (8)
Monat 3 (9)
Durchführung der Visite: Ja
ja (1)
Visitendatum ab Visite 2
Visitendatum ab Visite 2 Status
T (1)
TM (2)
M (3)
Durchführung der Visite: Nein
nein, Patient verbleibt aber in der Studie
(0)
Durchführung der Visite: Studienabbruch
Studienabbruch (9)
Klinischer Befund: Datum
Klinischer Befund: Datum Status
T (1)
TM (2)
M (3)
ECOG-Status
1 / 2
ECOG-Status 0 (0)
ECOG-Status 1 (1)
ECOG-Status 2 (2)
ECOG-Status 3 (3)
ECOG-Status 4 (4)
ECOG-Status: nd
nd (9)
Gewicht
kg
Gewicht: nd
nd (9)
Grösse
cm
Puls
/min
Puls: nd
nd (9)
Systolischer Blutdruck
mmHg
Diastolischer Blutdruck
mmHg
Blutdruck: nd
nd (9)
EKG (QT-Zeit)
<= 480
ms
EKG (QT-Zeit): nd
nd (9)
Untersuchungsbefund
unauffällig (1)
auffällig, bitte spezifizieren (2)
Untersuchungsbefunde
Untersuchungsbefund
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Concomitant Medication AML Pazopanib
NCT01361334
Pilot Clinical Trial of Pazopanib in Patients With Relapsed
or Refractory Acute Myeloid Leukemia (AML) or at Initial
Diagnosis When no Intensive Treatment is Possible
(PAZOPANIB-AML)
https://clinicaltrials.gov/ct2/show/NCT01361334
Principal Investigator: PD Dr. Torsten Kessler, University
Hospital Muenster, Germany
All rights reserved. Please visit https://medical-data-
models.org/forms/13519
Concomitant Medication AML
Pazopanib NCT01361334
Begleitmedikation
Patientennummer (derived)
Visitenname
Baseline (1)
Monat 6 (10)
Monat 9 (11)
Monat 12 (12)
Progression - Rezidiv (13)
Follow Up - Blatt Nr. 1 (14)
Follow Up - Blatt Nr. 2 (15)
Follow Up - Blatt Nr. 3 (16)
Follow Up - Blatt Nr. 4 (17)
Tag 1 (2)
Tag 2 (3)
Tag 7 (4)
Tag 10 (5)
Tag 14 (6)
Tag 28 (7)
Monat 2 (8)
Monat 3 (9)
Antibiotika 1: Clarithromycin
Clarithromycin (1)
Antibiotika 1: Telithromycin
Telithromycin (1)
Antibiotika 1: Troleandomycin
Troleandomycin (1)
Antimycotika: Itraconazol
Itraconazol (1)
Antimycotika: Ketoconazol
Ketoconazol (1)
Antimycotika: Voriconazol
Voriconazol (1)
Antimycotika: Fluconazol
Fluconazol (1)
HIV-Protease-Inhibitoren: Ritonavir
Ritonavir (1)
HIV-Protease-Inhibitoren: Indinavir
Indinavir (1)
1 / 3
HIV-Protease-Inhibitoren: Saquinavir
Saquinavir (1)
HIV-Protease-Inhibitoren: Nelfinavir
Nelfinavir (1)
HIV-Protease-Inhibitoren: Amprenavir
Amprenavir (1)
HIV-Protease-Inhibitoren: Lopinavir
Lopinavir (1)
Antidepressiva: Nefazodon
Nefazodon (1)
Sonstige 1: Grapefruitsaft
Grapefruitsaft (1)
Sonstige 1: Weitere
weitere (9)
Sonstige 1: Weitere - Text
Anticoagulantien: Phenprocoumon (Marcumar)
Phenprocoumon (Marcumar) (1)
Anticoagulantien: Heparin (NMH/UFH)
Heparin (NMH/UFH) (1)
Anticoagulantien: Ticagrelor
Ticagrelor (1)
Anticoagulantien: ASS
ASS (1)
Anticoagulantien: Andere
andere (1)
Antihypertensiva: Betablocker
Betablocker (1)
Antihypertensiva: Kalziumantagonisten
Kalziumantagonisten (1)
Antihypertensiva: ACE-Hemmer
ACE-Hemmer (1)
Antihypertensiva: Angiotensin-II-Antagonisten
Angiotensin-II-Antagonisten (1)
Antihypertensiva: Diuretika
Diuretika (1)
Antihypertensiva: Andere
andere (9)
Antibiotika 2: Penicilline
Penicilline (1)
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Antibiotika 2: Cephalosporine
Cephalosporine (1)
Antibiotika 2: Carbapeneme
Carbapeneme (1)
Antibiotika 2: Aminogylcoside
Aminogylcoside (1)
Antibiotika 2: Tetracycline
Tetracycline (1)
Antibiotika 2: Lincosamine
Lincosamine (1)
Antibiotika 2: Andere
andere (9)
Antiarrhythmika: Klasse I-Natriumkanalblocker
Klasse I - Natriumkanalblocker (1)
Antiarrhythmika: Klasse II-Betablocker
Klasse II - Betablocker (1)
Antiarrhythmika: Klasse III-Kaliumkanalblocker
Klasse III - Kaliumkanalblocker (1)
Antiarrhythmika: Klasse IV-Calciumantagonisten
Klasse IV-Calciumantagonisten (1)
Antiarrhythmika: Andere
andere (9)
Sonstige 2: Glucocorticoide
Glucocorticoide (1)
Sonstige 2: Protonenpumpeninhibitoren
Protonenpumpeninhibitoren (1)
Sonstige 2: Weitere
weitere (9)
Sonstige 2: Weitere - Text
Begleitmedikation: Signatur - Datum
Begleitmedikation: Signatur - Datum Status
T (1)
TM (2)
M (3)
Begleitmedikation: Signatur - Prüfer
nein (0)
ja (1)
Kommentar Begleitmedikation
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Differential blood count AML Pazopanib
NCT01361334
Pilot Clinical Trial of Pazopanib in Patients With Relapsed
or Refractory Acute Myeloid Leukemia (AML) or at Initial
Diagnosis When no Intensive Treatment is Possible
(PAZOPANIB-AML)
https://clinicaltrials.gov/ct2/show/NCT01361334
Principal Investigator: PD Dr. Torsten Kessler, University
Hospital Muenster, Germany
All rights reserved. Please visit https://medical-data-
models.org/forms/13520
Differential blood count AML
Pazopanib NCT01361334
Differentialblutbild
Patienten ID (derived)
Visitenname
Baseline (1)
Monat 6 (10)
Monat 9 (11)
Monat 12 (12)
Progression - Rezidiv (13)
Follow Up - Blatt Nr. 1 (14)
Follow Up - Blatt Nr. 2 (15)
Follow Up - Blatt Nr. 3 (16)
Follow Up - Blatt Nr. 4 (17)
Tag 1 (2)
Tag 2 (3)
Tag 7 (4)
Tag 10 (5)
Tag 14 (6)
Tag 28 (7)
Monat 2 (8)
Monat 3 (9)
Rezidiv-Diagnose: Datum
Rezidiv-Diagnose: Datum Status
T (1)
TM (2)
M (3)
Differentialblutbild: Datum
Differentialblutbild: Datum Status
T (1)
TM (2)
M (3)
Differentialblutbild: Summe
Periphere Blasten: Progredienz der AML
nein (0)
ja (1)
nicht beurteilbar (9)
Kommentar Differentialblutbild
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Leukozyten
Leukozyten Wert
Leukozyten Einheit
1=Tsd/µl (1)
2=/nl (2)
3=G/l=gpt/l=Giga/l (3)
4=1E9/l (4)
5=/cmm=/µl (5)
9=and. (9)
Leukozyten andere Einheit
Leukozyten Status
1=ok (1)
2=< (2)
3=> (3)
7=nd (7)
8=na (8)
9=nk (9)
Leukozyten anderes Datum
Leukozyten Faktor
Leukozyten stand. Wert
Leukozyten Gruppe
Hämoglobin
Hämoglobin Wert
Hämoglobin Einheit
1=g/dl (1)
2=g/l (2)
3=mmol/l (3)
9=and. (9)
Hämoglobin andere Einheit
Hämoglobin Status
1=ok (1)
2=< (2)
3=> (3)
7=nd (7)
8=na (8)
9=nk (9)
Hämoglobin anderes Datum
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Hämoglobin Faktor
Hämoglobin stand. Wert
Hämoglobin Gruppe
Thrombozyten
Thrombozyten Wert
Thrombozyten Einheit
1=Tsd/µl (1)
2=/nl (2)
3=G/l=gpt/l=Giga/l (3)
4=1E9/l (4)
5=/cmm=/µl (5)
9=and. (9)
Thrombozyten andere Einheit
Thrombozyten Status
1=ok (1)
2=< (2)
3=> (3)
7=nd (7)
8=na (8)
9=nk (9)
Thrombozyten anderes Datum
Thrombozyten Faktor
Thrombozyten stand. Wert
Thrombozyten Gruppe
Blasten
Blasten Wert
Blasten Einheit
1=Tsd/µl (1)
2=/cmm = /µl (2)
3=% (3)
9=and. (9)
Blasten andere Einheit
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Blasten Status
1=ok (1)
2=< (2)
3=> (3)
7=nd (7)
8=na (8)
9=nk (9)
Blasten anderes Datum
Blasten Gruppe
Stabkernige
Stabkernige Wert
Stabkernige Einheit
1=Tsd/µl (1)
2=/cmm = /µl (2)
3=% (3)
9=and. (9)
Stabkernige andere Einheit
Stabkernige Status
1=ok (1)
2=< (2)
3=> (3)
7=nd (7)
8=na (8)
9=nk (9)
Stabkernige anderes Datum
Stabkernige Gruppe
SegmentkernigQG
Segmentkernige  Wert
Segmentkernige Einheit
1=Tsd/µl (1)
2=/cmm = /µl (2)
3=% (3)
9=and. (9)
Segmentkernige andere Einheit
Segmentkernige Status
1=ok (1)
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2=< (2)
3=> (3)
7=nd (7)
8=na (8)
9=nk (9)
Segmentkernige anderes Datum
Segmentkernige Gruppe
EosinophileQG
Eosinophile Wert
Eosinophile Einheit
1=Tsd/µl (1)
2=/cmm=/µl (2)
3=% (3)
4=1E9/l (4)
9=and. (9)
Eosinophile andere Einheit
Eosinophile Status
1=ok (1)
2=< (2)
3=> (3)
7=nd (7)
8=na (8)
9=nk (9)
Eosinophile anderes Datum
Eosinophile Faktor
Eosinophile stand. Wert
Eosinophile Gruppe
BasophileQG
Basophile Wert
Basophile Einheit
1=Tsd/µl (1)
2=/cmm=/µl (2)
3=% (3)
4=1E9/l (4)
9=and. (9)
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Basophile andere Einheit
Basophile Status
1=ok (1)
2=< (2)
3=> (3)
7=nd (7)
8=na (8)
9=nk (9)
Basophile anderes Datum
Basophile Faktor
Basophile stand. Wert
Basophile Gruppe
MonozytenQG
Monozyten Wert
Monozyten Einheit
1=Tsd/µl (1)
2=/cmm=/µl (2)
3=% (3)
4=1E9/l (4)
9=and. (9)
Monozyten andere Einheit
Monozyten Status
1=ok (1)
2=< (2)
3=> (3)
7=nd (7)
8=na (8)
9=nk (9)
Monozyten anderes Datum
Monozyten Faktor
Monozyten stand. Wert
Monozyten Gruppe
LymphozytenQG
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Lymphozyten Wert
Lymphozyten Einheit
1=Tsd/µl (1)
2=/cmm=/µl (2)
3=% (3)
4=1E9/l (4)
9=and. (9)
Lymphozyten andere Einheit
Lymphozyten Status
1=ok (1)
2=< (2)
3=> (3)
7=nd (7)
8=na (8)
9=nk (9)
Lymphozyten anderes Datum
Lymphozyten Faktor
Lymphozyten stand. Wert
Lymphozyten Gruppe
PromyelozytenQG
Promyelozyten Wert
Promyelozyten Einheit
1=Tsd/µl (1)
2=/cmm = /µl (2)
3=% (3)
9=and. (9)
Promyelozyten andere Einheit
Promyelozyten Status
1=ok (1)
2=< (2)
3=> (3)
7=nd (7)
8=na (8)
9=nk (9)
Promyelozyten anderes Datum
Promyelozyten Gruppe
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MyelozytenQG
Myelozyten Wert
Myelozyten Einheit
1=Tsd/µl (1)
2=/cmm = /µl (2)
3=% (3)
9=and. (9)
Myelozyten andere Einheit
Myelozyten Status
1=ok (1)
2=< (2)
3=> (3)
7=nd (7)
8=na (8)
9=nk (9)
Myelozyten anderes Datum
Myelozyten Gruppe
MetamyelozytenQG
Metamyelozyten Wert
Metamyelozyten Einheit
1=Tsd/µl (1)
2=/cmm = /µl (2)
3=% (3)
9=and. (9)
Metamyelozyten andere Einheit
Metamyelozyten Status
1=ok (1)
2=< (2)
3=> (3)
7=nd (7)
8=na (8)
9=nk (9)
Metamyelozyten anderes Datum
Metamyelozyten Gruppe
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Eligibility Acute Myeloid Leukemia
NCT01361334
Pilot Clinical Trial of Pazopanib in Patients With Relapsed
or Refractory Acute Myeloid Leukemia (AML) or at Initial
Diagnosis When no Intensive Treatment is Possible; ODM
derived from: https://clinicaltrials.gov/show/NCT01361334
Principal Investigator: PD Dr. Torsten Kessler, University
Hospital Muenster, Germany
All rights reserved. Please visit https://medical-data-
models.org/forms/13521
Eligibility Acute Myeloid Leukemia
NCT01361334
Inclusion Criteria
1. subjects must provide written informed consent
prior to performance of study-specific procedures
or assessments which are not routinely
performed for diagnosis or monitoring of acute
myeloid leukemia (aml), and the subjects must be
willing to comply with treatment and to follow up
assessments and procedures*
Yes
No
2. histologically or cytologically confirmed
diagnosis of aml relapsed after or refractory to at
least one induction regimen, or patients with aml
at initial diagnosis who are not eligible for
allogeneic transplant or intensive induction
chemotherapy, except for aml m3 (acute
promyelocytic leukemia)*
Yes
No
3. age at least 18 years*
Yes
No
4. eastern cooperative oncology group (ecog)
performance status of ≤3*
<= 3
Yes
No
5. measurable disease burden (blasts in bm
and/or pb, extramedullary blasts [chloroma])*
Yes
No
6. able to swallow and retain oral medication*
Yes
No
7. a life expectancy of at least 4 weeks*
>= 4
weeks
Yes
No
8. adequate contraception methods*
Yes
No
9. adequate organ function as defined in the
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study protocol*
Yes
No
Exclusion Criteria
1. patients with a valid option for intensive
chemotherapy and/or stem cell transplantation
(patients after allogeneic stem cell transplant
must be off immunosuppressive agents for at
least 2 weeks prior to study entry and graft-
versus host disease must have resolved to grade
≤2)*
Yes
No
2. history of cancer that according to the
investigator might confound the assessment of
the endpoints of the study*
Yes
No
3. uncontrolled peptic ulcer disease or clinically
significant gastrointestinal abnormalities which
interfere with oral dosing or any unstable or
serious concurrent condition (e.g., active
uncontrolled infection)*
Yes
No
4. poorly controlled hypertension [defined as
systolic blood pressure (sbp) of ≥140 mmhg or
diastolic blood pressure (dbp) of ≥90 mmhg].
note: initiation or adjustment of antihypertensive
medication(s) is permitted prior to study entry.  bp
must be re-assessed on two occasions that are
separated by a minimum of 1 hour; on each of
these occasions, the mean (of 3 readings) sbp /
dbp values from each bp assessment must be
<140/90 mmhg in order for a subject to be eligible
for the study*
Yes
No
5. prolongation of corrected qt interval (qtc) >480
milliseconds*
>= 480
ms
Yes
No
6. history of any one of more of the following
cardiovascular conditions within the past 6
months: cardiac angioplasty or stenting,
myocardial infarction, unstable angina,
symptomatic peripheral vascular disease, class iii
or iv congestive heart failure, as defined by the
new york heart association (nyha)*
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Yes
No
7. history of cerebrovascular infarction or
bleeding, pulmonary embolism, or untreated
deep venous thrombosis (dvt) within the past 6
months. note: subjects with recent dvt who have
been treated with therapeutic anti-coagulant
agents for at least 6 weeks are eligible*
Yes
No
8. evidence of serious active bleeding or bleeding
diathesis (except for bleeding or petechiae due to
aml-related thrombocytopenia which will be
treated using platelet transfusions). also, patients
with known endobronchial lesions and/or lesions
infiltrating major pulmonary vessels will be
excluded from the study due to excess risk of
bleeding.*
Yes
No
9. prior major surgery or trauma within 28 days
prior to first dose of study drug*
Yes
No
10. treatment with an investigational agent within
28 days or 5 half-lives, whichever is longer prior
to the first dose of study drug (for bevacizumab
60 days).*
Yes
No
11. concurrent cytoreductive chemotherapy
(hydroxyurea must be discontinued at least one
day before start of study medication)*
Yes
No
12. known immediate or delayed hypersensitivity
reaction or idiosyncrasy to pazopanib*
Yes
No
13. patients with psychological, familial,
sociological, or geographical conditions that do
not permit compliance with the protocol*
Yes
No
14. pregnant or lactating and actively
breastfeeding patients*
Yes
No
15. patients taking any of the following prohibited
medication: clarithromycin, telithromycin,
troleandomycin (antibiotics)*
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Yes
No
ritonavir, indinavir, saquinavir, nelfinavir,
amprenavir, lopinavir (hiv protease inhibitors)*
Yes
No
itraconazole, ketoconazole, voriconazole,
fluconazole (antifungals)*
Yes
No
nefazodone (antidepressant)*
Yes
No
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Physical examination SIMPLIFy TAVI Transcatheter Aortic
Valve Implantation Without Predilation NCT01539746
Use of the Self-Expanding CoreValve Prosthesis without
Predilation in Patients with
Significantly IMPaired Left-VentrIcular Ejection Fraction for
Transcatheter Aortic Valve
Implantation Study.
Form is used in following visits: 
- Baseline
- Visit 5 (30 days +15d)
- Visit 6 (180 days +-30d)
- Visit 7 (1 year + 1m)
Projektleiter (LKP):
Prof. Dr. med. Georg Nickenig
Medizinische Klinik und Poliklinik II
Sigmund-Freud-Str. 25, 53125 Bonn
Tel. 0228-287-15217, Fax 0228-287-16423
Email: georg.nickenig@ukb.uni-bonn.de
All rights reserved. Please visit https://medical-data-
models.org/forms/13522
Physical examination NCT01539746
Date of visit
Date of visit
Physical Examination
Height
cm
Weight
kg
General condition
Normal (1)
Path. (2)
Not examined (3)
Further comments
Head, Eyes, Neck, Nose, Throat, Ears
Normal (1)
Path. (2)
Not examined (3)
Further comments
Lung
Normal (1)
Path. (2)
Not examined (3)
Further comments
Heart/ cardiovascular system
Normal (1)
Path. (2)
Not examined (3)
Further comments
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Abdomen
Normal (1)
Path. (2)
Not examined (3)
Further comments
Musculoskeletal system
Normal (1)
Path. (2)
Not examined (3)
Further comments
Lymph nodes
Normal (1)
Path. (2)
Not examined (3)
Further comments
Neurological examination
Normal (1)
Path. (2)
Not examined (3)
Further comments
Skin/ Mucous membrane
Normal (1)
Path. (2)
Not examined (3)
Other
Normal (1)
Path. (2)
Not examined (3)
Further comments
6-MWT
6-MWT: Distance
m
6-MWT not possible
Yes
No
NYHA class
NYHA class
I (1)
II (2)
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III (3)
IV (4)
not done (99)
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Case Report Form Phase 1 clinical trial for intrasurgical hyperthermic
intraperitoneal chemoperfusion with cisplatin (HIPEC) in patients with ovarian
cancer recidiv
Phase 1 clinical trial for intrasurgical hyperthermic
intraperitoneal chemoperfusion with cisplatin (HIPEC) in
patients with ovarian cancer recidiv
EudraCT Nr.: 2010-024352-28
Principal investigator und authorized representative of
Sponsor:
PD Dr. med. Oliver Zivanovic
Center for Obstetrics and Gynaecology
University Hospital Bonn
Sigmund-Freud-Str. 25
53105 Bonn
Sponsor:
Rheinische Friedrich-Wilhelms-Universität Bonn
represented by the Dean of Medical Faculty
All rights reserved. Please visit https://medical-data-
models.org/forms/13523
Case Report Form (HIPEC)
Visit 1: Screening visit and informed
consent
Patient number
CRF number
Date of visit
Date of informed consent
Patient received a copy of written and signed
informed consent
Yes
No
Informed Consent for biobanking obtained
Yes
No
Date of informed consent for biobanking
Year of birth
Medical history of first cancer diagnosis
Date ovarian cancer was first diagnosed
FIGO Staging at the point of first diagnosis
I (0)
I-A (1)
III-A1i (10)
III-A1ii (11)
III-A2 (12)
III-B (13)
III-C (14)
IV (15)
IV-A (16)
IV-B (17)
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I-B (2)
I-C (3)
II (4)
II-A (5)
II-B (6)
III (7)
III-A (8)
III-A1 (9)
Surgery
Has a debulking surgical procedure been
performed?
Yes
No
Please give the date the debulking procedure has
been performed
Was there a residue after surgery?
no residue (microscopic) (0)
<1cm residual tumor  (1)
≥1cm residual tumor (2)
Prior treatment
Did the patient already receive chemotherapy? If
yes, please specify below
Yes
No
Chemotherapy regimen number
Which chemotherapeutic agents have been
used?
How has the chemotherapy been adminstered?
intravenous (1)
intraperitoneally (2)
other (3)
Chemotherapy Start Date
Chemotherapy End Date
Chemotherapy currently ongoing
Yes
No
Did the patient receive any other treatment for the
ovarian cancer? If yes please specify below
Yes
No
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What kind of treatment did the patient receive?
hormone/biological (1)
antineoplastic immunotherapy (2)
radiotherapy (3)
other (4)
Please specify any other treatment, not listed
above
Date of relapse diagnosis
Medical history
Which Body system are you referring to?
eyes,nose,ears,throat (1)
skin (10)
allergies/hypersensitivities (11)
urinary tract (12)
other (13)
cardiovascular system (2)
respiratory tract (3)
gastrointestinal system, liver (4)
gynaecological incl breasts (5)
neurological disorder (6)
hematology (7)
endocrine system (8)
musculoskeletal system (9)
Diagnosis or ICD-Code
Please give the date, the condition was first
diagnosed
Please give the date the condition was cured
Persistent illness
Yes
No
Vital signs and physical examination
Heart rate count
bpm
Blood pressure measurement
mm/Hg
Body Weight
kg
Body Height
cm
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Body Mass Index
kg/m2
Body Temperature
°C
Performance status (ECOG):
0 (0)
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
Karnofsky performance status
%
General physical condition
normal (1)
pathological (2)
not assessed (3)
General physical condition:further comment
Skin assessment
normal (1)
pathological (2)
not assessed (3)
Skin assessment:further comment
Cardiovascular system assessment
normal (1)
pathological (2)
not assessed (3)
Cardiovascular system:further comment
Respiratory system assessment
normal (1)
pathological (2)
not assessed (3)
Respiratory System:further comment
Otorhinolaryngologic diseases
none (1)
yes (2)
not assessed (3)
Otorhinolaryngologic diseases:further comment
Abdominal examination
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normal (1)
pathological (2)
not assessed (3)
Abdominal examination:further comment
Lymphatic system
normal (1)
pathological (2)
not assessed (3)
Lymphatic system:further comment
Mucous Membranes
normal (1)
pathological (2)
not assessed (3)
Mucous Membranes:further comment
Neurological examination
Normal (1)
Pathological (2)
not assessed (3)
Neurological examination:further comment
Gynecological Examination
normal (1)
pathological (2)
not assessed (3)
Gynecological Examination:further comment
Urinary Tract and Kidney Examination
normal (1)
pathological (2)
not assessed (3)
Urinary Tract and Kidneys:further comment
Please specify any other clinically significant
findings
Does the patient currently use any other
medication?If yes please specify on the enclosed
concomitant medication form
Yes
No
Date ECG was performed
ECG findings
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normal (1)
pathological, clinically not significant
(please specify below) (2)
pathological, clinically significant (please
specify below) (3)
Please specify any ECG findings
Laboratory results
Date of venous blood sampling
Time of laboratory procedure (according to
laboratory sheet)
Quick test result
%
Quick test value at normal range?
Yes
No
Are Quick test findings clinically significant?
Yes
No
Prothrombin time ratio
sec
Prothrombin time ratio within normal range?
Yes
No
Are PTT findings clinically significant?
Yes
No
INR test result
INR test within normal range?
Yes
No
Are INR test findings clinically significant?
Yes
No
Creatinine measurement value
mg/dl
Creatinine value within normal range?
Yes
No
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Are Creatinine measurement findings clinically
significant?
Yes
No
Urea measurement value
mg/dl
Urea measurement value within normal range?
Yes
No
Are Urea measurement findings clinically
significant?
Yes
No
Bilirubin measurement value
mg/dl
Is Bilirubin measurement value within normal
range?
Yes
No
Are Bilirubin measurement findings clinically
significant?
Yes
No
GPT measurement value
U/l
Is GPT value within normal range?
Yes
No
Are GPT measurement findings clinically
significant?
Yes
No
GOT measurement value
U/l
Is GOT value within normal range?
Yes
No
Are GOT measurement findings clinically
significant?
Yes
No
GGT measurement value
U/l
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Is GGT measurement within normal range?
Yes
No
Are GGT measurement findings clinically
significant?
Yes
No
Albumin measurement value
g/l
Is Albumin measurement within normal range?
Yes
No
Are Albumin measurement findings clinically
significant?
Yes
No
Serum potassium measurement value
mmol/l
Is serum potassium measurement value within
normal range?
Yes
No
Are serum potassium measurement findings
clinically significant?
Yes
No
Serum sodium measurement value
mmol/l
Is serum sodium measurement value within
normal range?
Yes
No
Are serum sodium measurement findings
clinically significant?
Yes
No
Serum calcium measurement value
mmol/l
Is serum calcium measurement value within
normal range?
Yes
No
Are serum calcium measurement findings
clinically significant?
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Yes
No
Serum chloride measurement value
mmol/l
Is serum chloride measurement value within
normal range?
Yes
No
Are serum chloride measurement findings
clinically significant?
Yes
No
Tumor marker CA125 measurement value
Is measurement value of tumor marker CA 125
within normal range?
Yes
No
Are tumor marker CA 125 findings clinically
significant?
Yes
No
Urine sample date and time
Urine Sample test results
normal (1)
abnormal, clinically not  significant (2)
abnormal, clinically significant (3)
If urine sample test results are abnormal, please
specify
Blood cell count
Hemoglobin measurement value
g/dl
Is the hemoglobin measurement value within
normal range?
Yes
No
Are hemoglobin measurement findings clinically
significant?
Yes
No
Hematocrit level
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%Is the hematocrit level within normal range?
Yes
No
Are findings in hematocrit level clinically
significant?
Yes
No
Erythrocyte measurement value
mg/dl
Is the erythrocyte measurement value within
normal range?
Yes
No
Are findings in erythrocyte measurement clinically
significant?
Yes
No
Leukocyte measurement value
U/l
Is the leukocyte measurement value within
normal range?
Yes
No
Are findings in Leukocyte measurement clinically
significant?
Yes
No
Absolute neutrophils count measurement value
U/l
Is the count of neutrophils within normal range?
Yes
No
Are findings in neutrophils count clinically
significant?
Yes
No
Lymphocyte count measurement value
U/l
Is the count of lymphocytes within normal range?
Yes
No
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Are findings in lymphocyte count clinically
significant?
Yes
No
Monocyte measurement value
g/l
Is the monocyte measurement value within
normal range?
Yes
No
Are findings in monocyte count clinically
significant?
Yes
No
Eosinophils measurement value
g/l
Is the eosinophils count within normal range?
Yes
No
Are findings in eosinophils count clinically
significant?
Yes
No
Basophil measurement value
g/l
Is the basophil count within normal range?
Yes
No
Are findings in basophil count clinically
significant?
Yes
No
Platelets count measurement value
g/l
Is the platelets count within normal range?
Yes
No
Are findings in platelets count clinically
significant?
Yes
No
CTCAE Staging/Preexisting symptoms
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Are there pre-existing symptoms?
Yes
No
Pre-existing constipation
mild (1)
moderate (2)
severe (3)
lifethreatening (4)
not applicable (5)
When did the constipation occur for the first time?
Pre-existing Dyspnea
mild  (1)
moderate (2)
severe (3)
lifethreatening (4)
not applicable (5)
When did the Dyspnea occur for the first time?
Pre-existing fatigue
mild (1)
moderate (2)
severe (3)
lifethreatening (4)
not applicable (5)
When did the fatigue occur for the first time?
Pre-existing Edema
mild (1)
moderate (2)
severe (3)
lifethreatening (4)
not applicable (5)
When did the edema occur for the first time?
Pre-existing Lymphedema
mild (1)
moderate (2)
severe (3)
lifethreatening (4)
not applicable (5)
When did the lymphedema occur for the first
time?
Pre-existing lymphocele
mild (1)
moderate (2)
severe (3)
lifethreatening (4)
not applicable (5)
12 / 18
Case Report Form Phase 1 clinical trial for intrasurgical hyperthermic
intraperitoneal chemoperfusion with cisplatin (HIPEC) in patients with ovarian
cancer recidiv
When did the lymphocele occur for the first time?
Pre-existing sensory neuropathy
mild (1)
moderate (2)
severe (3)
lifethreatening (4)
not applicable (5)
When did the sensory neuropathy occur for the
first time?
Pre-existing motor neuropathy
mild (1)
moderate (2)
severe (3)
lifethreatening (4)
not applicable (5)
When did the motor neuropathy occur for the first
time?
Pre-existing ascites
mild (1)
moderate (2)
severe (3)
lifethreatening (4)
not applicable (5)
When did the ascites occur for the first time?
Pre-existing pleural effusion
mild (1)
moderate (2)
severe (3)
lifethreatening (4)
not applicable (5)
When did the pleural effusion occur for the first
time?
Pre-existing pain
mild (1)
moderate (2)
severe (3)
lifethreatening (4)
not applicable (5)
When did the pain occur for the first time?
Pre-existing diarrhea
mild (1)
moderate (2)
severe (3)
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lifethreatening (4)
not applicable (5)
When did the diarrhea occur for the first time?
Pre-existing infection
mild (1)
moderate (2)
severe (3)
lifethreatening (4)
not applicable (5)
Please specify the kind of pre-existing infection
When did the infection occur for the first time?
Pre-existing vomiting
mild (1)
moderate (2)
severe (3)
lifethreatening (4)
not applicable (5)
When did the vomiting occur for the first time?
Pre-existing oliguria and anuria
mild (1)
moderate (2)
severe (3)
lifethreatening (4)
not applicable (5)
When did the oliguria / anuria occur for the first
time?
Pre-existing other symptoms
mild (1)
moderate (2)
severe (3)
lifethreatening (4)
not applicable (5)
Please specify other pre-existing symptoms
When did the symptom occur for the first time?
Inclusion criteria
Patients must be ≥18 Years to ≤70 Years
Yes
No
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Written informed consent given
Yes
No
Patient is willing and able to comply to study
protocol
Yes
No
Patients with histologically confirmed or strong
suspicion of ovarian carcinoma relapse
Yes
No
Treatment free interval after completion of
primary treatment with platinum antineoplastic
compounds ≥ 6 months
Yes
No
Known history and histologically confirmed
diagnosis of ovarian carcinoma. (Initial diagnosis)
Yes
No
Histologic differentiations qualifying for inclusion
are:serous papillary adenocarcinoma,
endometrioid adenocarcinoma, undifferentiated
carcinoma, clear cell carcinoma
Yes
No
Karnofsky performance status must be greater
than 70 percent.
Yes
No
Patient must be classified "operable"
Yes
No
Neutrophils must be ≥ 1,500/μl (equivalent of
CTC grade 1)
/μL
Yes
No
Platelets must be ≥ 100,000/μl (CTC grade 0-1)
/μl
Yes
No
Creatinine must be ≤ 1.2 mg/dl
mg/dl
Yes
No
Bilirubin ≤ 1.5 x upper level of normal (CTC
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Grade 1)
Yes
No
AST ≤ 2.5 x upper level of normal (CTC Grade 1)
Yes
No
Sensory neuropathy ≤ CTC Grad 2
Yes
No
PT (INR) ≤ 1.5 (Exception: therapeutic
antikoagulation- INR 2-3)
Yes
No
Exclusion criteria
Age younger than 18 years or  older than 70
years
Yes
No
Informed Consent denied
Yes
No
Patient is unable to understand extent,
significance or consequences of this trial
Yes
No
Patient is unable to follow protocol requirements
Yes
No
Allergy or hypersensitivity against trial substance
or chemically similar substances like Cisplatin or
Carboplatin
Yes
No
Patient is currently or up to 30 days prior to
enrollment participating in another clinical trial
that includes the use of a trial substance
Yes
No
Known or current alcohol, prescription or illegal
drug abuse
Yes
No
Current or planned pregnancy or breast feeding
mothers
Yes
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No
Women of childbearing potential
Yes
No
Fails to meet eligibility criteria in laboratory
results
Yes
No
Patient has been judged "inoperable"
Yes
No
Diagnose of mucinous ovarian carcinoma
Yes
No
New diagnose or relapse of a non-invasive
borderline tumor
Yes
No
Therapeutic radiology procedure of abdomen or
pelvis
Yes
No
Therapeutic radiology procedure of Chest,Skin or
Neck/Head for any malignancy less than 3 years
ago
Yes
No
Any other acute malignancy or recurrent disease
than the investigated indication
Yes
No
Acute infection
Yes
No
Patients with
cardiac,pulmonary,renal,hepatic,metabolic,gastro
intestinal,chronic or latent infectious or
immunocompromising diseases that pose, at the
discretion of the investigator, an intolerable risk to
the patient
Yes
No
Any other circumstances that pose,at the
descretion of the investigator, an unacceptable
risk to the patient.
Yes
No
Patients with severely impaired renal function
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Yes
No
Patients with hearing impairment
Yes
No
Patients with a seizure disorder
Yes
No
Patients with preexisting neuropathy or
motoric/sensory neurotoxicity (>CTC grade 2)
Yes
No
Patients with preexisting bone marrow depression
Yes
No
Patients with dehydration
Yes
No
Inclusion of Patient
Patient will be included into this trial
Yes
No
Patient is excluded because
informed consent has been withdrawn
(1)
In-/Exclusion criteria have not been met
(2)
other (3)
If patient is excluded for other reasons, please
specify below
Name of Investigator
Signature by investigator: I personally controlled
all entries into this form for this patient. All data
and statements in this CRF are complete and
correct
Date of completion of this form
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Visit 3 Phase 1 clinical trial for intrasurgical hyperthermic intraperitoneal
chemoperfusion with cisplatin (HIPEC) in patients with ovarian cancer recidiv
Phase 1 clinical trial for intrasurgical hyperthermic
intraperitoneal chemoperfusion with cisplatin (HIPEC) in
patients with ovarian cancer recidiv EudraCT Nr.: 2010-
024352-28 Principal investigator und authorized
representative of Sponsor: PD Dr. med. Oliver Zivanovic
Center for Obstetrics and Gynaecology University Hospital
Bonn Sigmund-Freud-Str. 25 53105 Bonn Sponsor:
Rheinische Friedrich-Wilhelms-Universität Bonn
represented by the Dean of Medical Faculty
All rights reserved. Please visit https://medical-data-
models.org/forms/13524
Case Report Form (HIPEC) Visit 3
Visit 3:Day 1 post-surgery
Patient ID
CRF number
Date of visit
Vital signs, concomitant medication and
CTCAE
Heart rate
bpm
Blood pressure
mm/Hg
Body Temperature
°C
Has concomitant medication been subject to
change? If `Yes` please fill in Concomitant
medication form.
Yes
No
Recording of CTCAE: Have any AE occurred
since the last Visit? If `Yes` please fill in AE-Form
Yes
No
Laboratory results
Date of venous blood sampling
Time of laboratory procedure (according to
laboratory sheet)
Quick test result
%
Quick test value at normal range?
Yes
1 / 7
No
Are Quick test findings clinically significant? If
"Yes", please fill in AE form.
Yes
No
Prothrombin time ratio
sec
Prothrombin time ratio within normal range?
Yes
No
Are PTT findings clinically significant? If "Yes",
please fill in AE form.
Yes
No
INR test result
INR test within normal range?
Yes
No
Are INR test findings clinically significant? If
"Yes", please fill in AE form.
Yes
No
Creatinine measurement value
mg/dl
Creatinine value within normal range?
Yes
No
Are Creatinine measurement findings clinically
significant? If "Yes", please fill in AE- form.
Yes
No
Urea measurement value
mg/dl
Urea measurement value within normal range?
Yes
No
Are Urea measurement findings clinically
significant? If "Yes", please fill in AE-Form.
Yes
No
Bilirubin measurement value
mg/dl
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Is Bilirubin measurement value within normal
range?
Yes
No
Are Bilirubin measurement findings clinically
significant? If "Yes", please fill in AE form.
Yes
No
GPT measurement value
U/l
Is GPT value within normal range?
Yes
No
Are GPT measurement findings clinically
significant? If "Yes", please fill in AE form.
Yes
No
GOT measurement value
U/l
Is GOT value within normal range?
Yes
No
Are GOT measurement findings clinically
significant? If "Yes", please fill in AE form.
Yes
No
GGT measurement value
U/l
Is GGT measurement within normal range?
Yes
No
Are GGT measurement findings clinically
significant? If "Yes", please fill in AE form.
Yes
No
Albumin measurement value
g/l
Is Albumin measurement within normal range?
Yes
No
Are Albumin measurement findings clinically
significant? If "Yes", please fill in AE form.
Yes
No
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Serum potassium measurement value
mmol/l
Is serum potassium measurement value within
normal range?
Yes
No
Are serum potassium measurement findings
clinically significant? If "Yes", please fill in AE
form.
Yes
No
Serum sodium measurement value
mmol/l
Is serum sodium measurement value within
normal range?
Yes
No
Are serum sodium measurement findings
clinically significant? If "Yes", please fill in AE
form.
Yes
No
Serum calcium measurement value
mmol/l
Is serum calcium measurement value within
normal range?
Yes
No
Are serum calcium measurement findings
clinically significant? If "Yes", please fill in AE
form.
Yes
No
Serum chloride measurement value
mmol/l
Is serum chloride measurement value within
normal range?
Yes
No
Are serum chloride measurement findings
clinically significant? If "Yes" , please fill in AE
form.
Yes
No
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Hemoglobin measurement value
g/dl
Is the hemoglobin measurement value within
normal range?
Yes
No
Are hemoglobin measurement findings clinically
significant? If "Yes", please fill in AE form.
Yes
No
Hematocrit level
%
Is the hematocrit level within normal range?
Yes
No
Are findings in hematocrit level clinically
significant? If "Yes", please fill in AE form.
Yes
No
Erythrocyte measurement value
mg/dl
Is the erythrocyte measurement value within
normal range?
Yes
No
Are findings in erythrocyte measurement clinically
significant? If "Yes", please fill in AE form.
Yes
No
Leukocyte measurement value
U/l
Is the leukocyte measurement value within
normal range?
Yes
No
Are findings in Leukocyte measurement clinically
significant? If "Yes", please fill in AE form.
Yes
No
Absolute neutrophils count measurement value
U/l
Is the count of neutrophils within normal range?
Yes
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No
Are findings in neutrophils count clinically
significant? If "Yes", please fill in AE form.
Yes
No
Lymphocyte count measurement value
U/l
Is the count of lymphocytes within normal range?
Yes
No
Are findings in lymphocyte count clinically
significant? If "Yes", please fill in AE form.
Yes
No
Monocyte measurement value
g/l
Is the monocyte measurement value within
normal range?
Yes
No
Are findings in monocyte count clinically
significant? If "Yes", please fill in AE form.
Yes
No
Eosinophils measurement value
g/l
Is the count of eosinophils within normal range?
Yes
No
Are findings in eosinophils count clinically
significant? If "Yes", please fill in AE form.
Yes
No
Basophil measurement value
g/l
Is the count of basophils within normal range?
Yes
No
Are findings in basophil count clinically
significant? If "Yes", please fill in AE form.
Yes
No
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Platelets count measurement value
g/l
Is the platelets count within normal range?
Yes
No
Are findings in platelets count clinically
significant? If "Yes", please fill in AE form.
Yes
No
Urine sample date and time
Urine Sample test results, if results are clinically
significantly abnormal please fill in AE form.
normal (1)
abnormal, clinically not  significant (2)
abnormal, clinically significant (3)
If urine sample test results are abnormal, please
specify
Confirmation of correctness
Name of Investigator
Signature by investigator: I personally controlled
all entries into this form for this patient. All data
and statements in this CRF are complete and
correct
Date of completion of this form
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Phase 1 clinical trial for intrasurgical hyperthermic
intraperitoneal chemoperfusion with cisplatin (HIPEC) in
patients with ovarian cancer recidiv EudraCT Nr.: 2010-
024352-28 Principal investigator und authorized
representative of Sponsor: PD Dr. med. Oliver Zivanovic
Center for Obstetrics and Gynaecology University Hospital
Bonn Sigmund-Freud-Str. 25 53105 Bonn Sponsor:
Rheinische Friedrich-Wilhelms-Universität Bonn
represented by the Dean of Medical Faculty
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Visit 4:Day 3 post-surgery
Patient ID
CRF number
Date of visit
Vital signs, concomitant medication and
CTCAE
Heart rate count
bpm
Blood pressure measurement
mm/Hg
Body Temperature
°C
Has concomitant medication been subject to
change? If `Yes` please fill in Concomitant
medication form.
Yes
No
Recording of CTCAE: Have any AE occurred
since the last Visit? If `Yes` please fill in AE-Form
Yes
No
Laboratory results
Date of venous blood sampling
Time of laboratory procedure (according to
laboratory sheet)
Quick test result
%
Quick test value at normal range?
Yes
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No
Are Quick test findings clinically significant? If
`Yes`, please fill in AE form.
Yes
No
Prothrombin time ratio
sec
Prothrombin time ratio within normal range?
Yes
No
Are PTT findings clinically significant? If `Yes`,
please fill in AE form.
Yes
No
INR test result
INR test within normal range?
Yes
No
Are INR test findings clinically significant? If
`Yes`, please fill in AE form.
Yes
No
Creatinine measurement value
mg/dl
Creatinine value within normal range?
Yes
No
Are Creatinine measurement findings clinically
significant? If `Yes`, please fill in AE- form.
Yes
No
Urea measurement value
mg/dl
Urea measurement value within normal range?
Yes
No
Are Urea measurement findings clinically
significant? If `Yes`, please fill in AE-Form.
Yes
No
Bilirubin measurement value
mg/dl
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Is Bilirubin measurement value within normal
range?
Yes
No
Are Bilirubin measurement findings clinically
significant? If `Yes`, please fill in AE form.
Yes
No
GPT measurement value
U/l
Is GPT value within normal range?
Yes
No
Are GPT measurement findings clinically
significant? If `Yes`, please fill in AE form.
Yes
No
GOT measurement value
U/l
Is GOT value within normal range?
Yes
No
Are GOT measurement findings clinically
significant? If `Yes`, please fill in AE form.
Yes
No
GGT measurement value
U/l
Is GGT measurement within normal range?
Yes
No
Are GGT measurement findings clinically
significant? If `Yes`, please fill in AE form.
Yes
No
Albumin measurement value
g/l
Is Albumin measurement within normal range?
Yes
No
Are Albumin measurement findings clinically
significant? If `Yes`, please fill in AE form.
Yes
No
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Serum potassium measurement value
mmol/l
Is serum potassium measurement value within
normal range?
Yes
No
Are serum potassium measurement findings
clinically significant? If `Yes`, please fill in AE
form.
Yes
No
Serum sodium measurement value
mmol/l
Is serum sodium measurement value within
normal range?
Yes
No
Are serum sodium measurement findings
clinically significant? If `Yes`, please fill in AE
form.
Yes
No
Serum calcium measurement value
mmol/l
Is serum calcium measurement value within
normal range?
Yes
No
Are serum calcium measurement findings
clinically significant? If `Yes`, please fill in AE
form.
Yes
No
Serum chloride measurement value
mmol/l
Is serum chloride measurement value within
normal range?
Yes
No
Are serum chloride measurement findings
clinically significant? If `Yes` , please fill in AE
form.
Yes
No
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Hemoglobin measurement value
g/dl
Is the hemoglobin measurement value within
normal range?
Yes
No
Are hemoglobin measurement findings clinically
significant? If `Yes`, please fill in AE form.
Yes
No
Hematocrit level
%
Is the hematocrit level within normal range?
Yes
No
Are findings in hematocrit level clinically
significant? If `Yes`, please fill in AE form.
Yes
No
Erythrocyte measurement value
mg/dl
Is the erythrocyte measurement value within
normal range?
Yes
No
Are findings in erythrocyte measurement clinically
significant? If `Yes`, please fill in AE form.
Yes
No
Leukocyte measurement value
U/l
Is the leukocyte measurement value within
normal range?
Yes
No
Are findings in Leukocyte measurement clinically
significant? If `Yes`, please fill in AE form.
Yes
No
Absolute neutrophils count measurement value
U/l
Is the count of neutrophils within normal range?
Yes
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No
Are findings in neutrophils count clinically
significant? If `Yes`, please fill in AE form.
Yes
No
Lymphocyte count measurement value
U/l
Is the count of lymphocytes within normal range?
Yes
No
Are findings in lymphocyte count clinically
significant? If `Yes`, please fill in AE form.
Yes
No
Monocyte measurement value
g/l
Is the monocyte measurement value within
normal range?
Yes
No
Are findings in monocyte count clinically
significant? If `Yes`, please fill in AE form.
Yes
No
Eosinophils measurement value
g/l
Is the count of eosinophils within normal range?
Yes
No
Are findings in eosinophils count clinically
significant? If `Yes`, please fill in AE form.
Yes
No
Basophil measurement value
g/l
Is the count of basophils within normal range?
Yes
No
Are findings in basophil count clinically
significant? If `Yes`, please fill in AE form.
Yes
No
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Platelets count measurement value
g/l
Is the platelets count within normal range?
Yes
No
Are findings in platelets count clinically
significant? If `Yes`, please fill in AE form.
Yes
No
Urine sample date and time
Urine Sample test results, if results are clinically
significantly abnormal please fill in AE form.
normal (1)
abnormal, clinically not  significant (2)
abnormal, clinically significant (3)
If urine sample test results are abnormal, please
specify
Confirmation of correctness
Name of Investigator
Signature by investigator: I personally controlled
all entries into this form for this patient. All data
and statements in this CRF are complete and
correct
Date of completion of this form
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Eligibility Type 2 Diabetes Mellitus
NCT01824264
Dose-finding Study of LIK066 Compared With Placebo or
Sitagliptin to Evaluate Change in HbA1c in Patients With
Diabetes; ODM derived from:
https://clinicaltrials.gov/show/NCT01824264
All rights reserved. Please visit https://medical-data-
models.org/forms/13526
Eligibility Type 2 Diabetes Mellitus
NCT01824264
Inclusion Criteria
Confirmed diagnosis of t2dm by standard criteria*
Yes
No
Drug-naïve patients, defined as patients not
having received any anti-diabetic medication
previously,*
Yes
No
Currently untreated patients , who, after the
diagnosis of t2dm, have received anti-diabetic
medication for not more than 12 consecutive
weeks, and have not received any anti-diabetic
treatment within 12 weeks prior to visit 1*
Yes
No
Patients being treated with mono-therapy for at
least 8 consecutive weeks prior to visit 1 with the
following oads: metformin, dipeptidyl peptidase-4
inhibitors (dpp-4i), su, glinide, alpha-glucosidase
inhibitor (agi)*
Yes
No
Hba1c ≥ 7 to ≤ 10.5% at visit 1 for drug-
naïve/currently untreated patients*
Yes
No
Hba1c ≥ 7 to ≤ 9.5% at visit 1 for patients treated
with oad monotherapy*
Yes
No
Hba1c ≥ 7 to ≤ 10.5% at visit 199 for all patients*
Yes
No
Age: ≥18 and ≤ 75 years old at visit 1*
Yes
No
Bmi ≥22 to ≤45 kg/m2 at visit 1*
Yes
No
Exclusion Criteria
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Fpg ≥270 mg/dl (15 mmol/l) for drug-
naïve/currently untreated patients or ≥240 mg/dl
(13.3 mmol/l) for patients on oad monotherapy at
visit 1*
Yes
No
Insulin treatment > 4 consecutive weeks in the
last 6 months, corticosteroid use >7 days in the
last 8 weeks, use of growth hormones in the last
6 months, or use of weight control products > 4
weeks in the last 6 months*
Yes
No
History of acute metabolic complications, cv
disease, type 1 diabetes mellitus, hepatic
disorders, pancreatitis, chronic diarrhea*
Yes
No
Significant lab abnormalities such as tsh outside
of normal range, uacr>300 mg/g creatinine, egfr
<60 ml/min/1.73m2, hemoglobin <12 g/l in men
and <11 g/l in women, hematuria*
Yes
No
Ecg abnormalities including av block, long qt
syndrome or qtc>450 msec for men and >470
msec for women*
Yes
No
History of malignancy*
Yes
No
Women of child-bearing potential not using
effective methods of contraception other protocol-
defined inclusion/exclusion criteria may apply*
Yes
No
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Eligibility Type 2 Diabetes NCT02148250
PK/PD STUDY OF U-500 REGULAR INSULIN; ODM
derived from: https://clinicaltrials.gov/show/NCT02148250
All rights reserved. Please visit https://medical-data-
models.org/forms/13527
Eligibility Type 2 Diabetes
NCT02148250
Inclusion Criteria
Diabetes Mellitus Type 2*
Yes
No
Age 30-65 years*
Yes
No
A1c between 7-9.5% within the past month*
Yes
No
On >200 units of insulin per day (>150 units if
also on oral/glp-1 agents)*
Yes
No
willing to discontinue oral/injectable non-insulin
hypoglycemic agents for minimum of 1 week prior
to study*
Yes
No
Willing to avoid exercise 48 hours prior to study*
Yes
No
Willing to be fasting for up to 24 hours*
Yes
No
Bmi between 25 and 38 kg/m2*
Yes
No
Exclusion Criteria
Systemic corticosteroids in preceding 3 months*
Yes
No
heavy alcohol consumption (>21 drinks/week
men, >14 drinks/week women)*
Yes
No
Unwillingness to stop alcohol consumption for 24
hours before each study visit*
Yes
No
Pregnant or actively trying to conceive*
1 / 2
Yes
No
Current diagnosis of active infection, cancer
(other than basal cell carcinoma), vascular
disease, organ failure*
Yes
No
Current transplant recipient*
Yes
No
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Eligibility Arthropathy of Knee Joint
NCT00967161
Motion Analysis of EMP Knee Versus Posterior Stabilized
Knee Arthroplasty for Osteoarthritis; ODM derived from:
https://clinicaltrials.gov/show/NCT00967161
All rights reserved. Please visit https://medical-data-
models.org/forms/13528
Eligibility Arthropathy of Knee Joint
NCT00967161
Inclusion Criteria
40 patients between the ages of 50 and 75 yrs
undergoing unilateral total knee replacement for
non-inflammatory degenerative osteoarthritis will
participate, as well as 10 control participants will
be recruited from the general population for the
present study matching to experimental groups
for age, gender and bmi.patients who do not
meet any exclusion criteria.*
Yes
No
Exclusion Criteria
potential participants for the control group will be
asked if they have had degenerative
osteoarthritis of lower-limb joints (hip, knee and
ankle) and if they have they will be excluded.*
Yes
No
exclusion for patient group*
Yes
No
1. patients suffering from any other lower-limb
joint disorders other than the one for which total
knee arthroplasty.*
Yes
No
2. patients with any other joint replacement in the
ipsilateral and contralateral limb.*
Yes
No
3. patients with evidence of active infection.*
Yes
No
4. patients with neurologic or musculoskeletal
disease that may adversely affect gait, weight-
bearing or quadriceps function.*
Yes
No
5. patients with neuropathic joints.*
Yes
No
6. patients requiring structural bone grafts.*
Yes
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No
7. patients with a documented allergy to cobalt
chromium molybdenum.*
Yes
No
8. patient with a bmi larger than 30 kg/m2.*
Yes
No
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Eligibility Asthma NCT01026870
Efficacy and Safety of Mometasone Furoate for Persistent
Asthma Previously Treated With Low-Dose Inhaled
Glucocorticosteroids (ICS) (Study P06115); ODM derived
from: https://clinicaltrials.gov/show/NCT01026870
All rights reserved. Please visit https://medical-data-
models.org/forms/13529
Eligibility Asthma NCT01026870
Inclusion Criteria
an adult or adolescent subject with a diagnosis of
persistent asthma of >=6 months duration may be
selected for this study.*
Yes
No
both subject (and/or parent/guardian, if
appropriate) and investigator must agree that
changing therapy is acceptable and poses no
inherent risk.*
Yes
No
subject must have been using a low daily
maintenance dose of inhaled corticosteroids (ics),
with or without added long-acting β2-agonist
(laba), for >=12 weeks prior to screening, and
must have been on a stable regimen (daily dose
unchanged) for at least the last 2 weeks of that
period.*
Yes
No
at screening, the subject must have a
prebronchodilator fev1 between 60% and 90% of
the predicted value when restricted medications
have been withheld.*
Yes
No
to be randomized, the subjects must be
symptomatic with fev1 at baseline must be
between 50% and 85% of predicted.*
Yes
No
Exclusion Criteria
a subject must not have been admitted to the
hospital for management of airway obstruction
within the last 3 months prior to screening, and
must not have experienced an occurrence of any
clinical deterioration of asthma that resulted in
emergency treatment, hospitalization due to
asthma, or treatment with additional, excluded
asthma medication, as judged by the clinical
investigator at any time from screening to
baseline/randomization.*
Yes
No
in addition, a subject must not have
1 / 2
demonstrated a decrease in absolute fev1 of
>20% at any time from screening to baseline, or
a decrease in am peak expiratory flow (pef)
below the pef stability limit on any 2 consecutive
days prior to baseline/randomization.*
Yes
No
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Eligibility Asthma NCT01202084
A Study Comparative of Formoterol/Fluticasone Foraseq®
and Fluticasone in Asthma Patients; ODM derived from:
https://clinicaltrials.gov/show/NCT01202084
All rights reserved. Please visit https://medical-data-
models.org/forms/13530
Eligibility Asthma NCT01202084
Inclusion Criteria
sign the icf*
Yes
No
age ≥ 12 years*
Yes
No
persistent asthma diagnosis, as per the gina
classification (www.ginasthma.com),18 with
symptoms for at least 6 months and clinically
stable for at least 1 month, with the acq-745 test
(see appendix c) ≤ 3.0*
Yes
No
current use of inhaled corticosteroid
(beclomethasone dipropionate dose of up to
1000*
Yes
No
µg), associated or not with long-term β2-
adrenergic agents and breakthrough medication
(salbutamol or equivalent)*
Yes
No
initial fev1 of at least 40% of the predicted normal
value*
Yes
No
serum cortisol assessment within normal values.*
Yes
No
Exclusion Criteria
use of oral or parenteral corticosteroid within the
3 months prior to study beginning*
Yes
No
requirement of admission due to asthma within
the 3 months prior to study beginning*
Yes
No
presence of active smoking, defined as the use of
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cigarette, pipe, cigar or any form of smoking at
any amount within the last 3 months*
Yes
No
presence of severe co-morbidities, such as
cardiovascular, renal, liver, neurological,
neoplastic, hematological, infectious,
dermatological, neurological, psychiatric or
chronic respiratory disease other than asthma*
Yes
No
recent (< 6 months) or predicted participation
during this study in other clinical studies involving
drugs of any nature or in studies of any form of
intervention for treating asthma*
Yes
No
intolerance or allergy to any of the components of
the drugs assessed in the study*
Yes
No
pregnancy or lactation*
Yes
No
chronic use of β-blocker medications, per routine
oral or intravenous route, or also as ophthalmic
solutions*
Yes
No
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Eligibility Type 2 Diabetes NCT02171351
Effect of Neuromuscular Electrostimulation on Sympathetic
Nerve Activity in Patients With Type 2 Diabetes
(ELECTROSYMP2); ODM derived from:
https://clinicaltrials.gov/show/NCT02171351
All rights reserved. Please visit https://medical-data-
models.org/forms/13533
Eligibility Type 2 Diabetes
NCT02171351
Inclusion Criteria
Type 2 diabetes for at least 12 month*
Yes
No
Treatment by oral hypoglycemic agents and/or
glp1 agonists*
Yes
No
hba1c : 6-10%*
%
Suspected insulin-resistance (at least one criteria
below):*
Yes
No
Waist circumference > 80cm (female); > 94cm
(male)*
Yes
No
Triglycerides > 150 mg/dl*
Yes
No
Hdl-cholesterol < 50 mg/dl (female); < 40 mg/dl
(male)*
Yes
No
Low background physical activity (ricci-gagnon
score < 27)*
Yes
No
Exclusion Criteria
Type 1 diabetes*
Yes
No
Treatment with insulin*
Yes
No
Seizure*
Yes
No
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Pace maker*
Yes
No
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Eligibility Type 2 Diabetic Patients
NCT02164578
Microvascular and Antiinflammatory Effects of Rivaroxaban
Compared to Aspirin in Type-2 Diabetic Patients With
Cardiovascular Disease; ODM derived from:
https://clinicaltrials.gov/show/NCT02164578
All rights reserved. Please visit https://medical-data-
models.org/forms/13534
Eligibility Type 2 Diabetic Patients
NCT02164578
Inclusion Criteria
Type 2 diabetes duration between 2 and 20
years*
Yes
No
Documented atherosclerotic cvd:*
Yes
No
Major cardiovascular event in medical history*
Yes
No
Coronary angiography showing a coronary artery
stenosis of > 50 % or*
Yes
No
Carotid ultrasound showing an imt > 1 mm and
plaque of carotid artery*
Yes
No
Left ventricular hypertrophy*
Yes
No
Macroalbuminuria in the absence of other renal
diseases*
Yes
No
Increased hscrp (> 2 mg/l but < 10 mg/l) and/or
increased pai 1 (> 15 ng/ml)*
Yes
No
Stable treatment with statins (if tolerated)*
Yes
No
Age 40 - 75 years*
Yes
No
Exclusion Criteria
CV event with need for oral anticoagulation or
dual platelet inhibitor therapy or acute coronary
syndrome < 12 month before study entry*
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Yes
No
Sustained uncontrolled hypertension: systolic bp
> 180 mmhg or diastolic bp > 100 mmhg*
Yes
No
Hypersensitivity to the active substance*
Yes
No
Active clinically significant bleeding*
Yes
No
Significant risks for major bleeding*
Yes
No
Concomitant treatment of acs with antiplatelet
therapy in patients with a prior stroke or a
transient ischaemic attack (tia)*
Yes
No
Hepatic disease associated with coagulopathy
and clinically relevant bleeding risk*
Yes
No
Chronic renal failure with egfr < 15 ml/min (mdrd
formula)*
Yes
No
Pregnant or breast-feeding woman and woman
without adequate method of contraception.*
Yes
No
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Eligibility Schizophrenic Disorders
NCT00161408
Psychological Intervention for Relapse Prevention in First
Episode Schizophrenia; ODM derived from:
https://clinicaltrials.gov/show/NCT00161408
All rights reserved. Please visit https://medical-data-
models.org/forms/13535
Eligibility Schizophrenic Disorders
NCT00161408
Inclusion Criteria
diagnosis of schizophrenic disorder according to
icd 10: f20*
Yes
No
first episode*
Yes
No
age between 18 and 55*
Yes
No
willingness to give informed consent also to a
double blind pharmacological treatment study*
Yes
No
Exclusion Criteria
residence outside of the catchment area*
Yes
No
insufficient knowledge of the german language*
Yes
No
substance abuse or addiction as primary clinical
problem*
Yes
No
serious physical illness*
Yes
No
organic brain disease*
Yes
No
pregnancy*
Yes
No
contraindications to neuroleptic treatment*
Yes
No
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Eligibility Sick Sinus Syndrome
NCT00161538
Pacing of the Atria in Sick Sinus Syndrome Trial Preventive
Strategies for Atrial Fibrillation; ODM derived from:
https://clinicaltrials.gov/show/NCT00161538
All rights reserved. Please visit https://medical-data-
models.org/forms/13536
Eligibility Sick Sinus Syndrome
NCT00161538
Inclusion Criteria
sick sinus syndrome*
Yes
No
symptomatic sinus bradycardia*
Yes
No
symptomatic sa block*
Yes
No
bradycardia-tachycardia-syndrom*
Yes
No
binodal diseases, sinus node syndrome and high
degree av-block*
Yes
No
in case of antiarrhythmic drug therapy: patient
must be on a stable dose for at least 3 months
before enrollment*
Yes
No
Exclusion Criteria
permanent atrial tachycardia that cannot be
transferred into sinus rhythm by drugs or electric
cardioversion*
Yes
No
decompensated heart failure*
Yes
No
dilatative cardiomyopathy with an ejection fraction
< 35%*
Yes
No
hypertrophic obstructive cardiomyopathy*
Yes
No
symptomatic hypo- or hyperthyreosis*
Yes
No
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myocardial infarction less than 6 months ago*
Yes
No
planned cardiac surgery intervention*
Yes
No
pregnant woman*
Yes
No
patients under 18 years of age*
Yes
No
patients involved in other studies*
Yes
No
patients, already implanted with other (cardiac)
leads*
Yes
No
patients with reduced expectancy of life due to
other diseases*
Yes
No
patients who are not able to agree in participation
of the study*
Yes
No
patients, who cannot attend follow-up visits due
to their place of residence*
Yes
No
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Eligibility Sick Sinus Syndrome NCT00161538
Eligibility Type 2 Diabetes Mellitus
NCT00194896
Preferred Treatment of Type 1.5 Diabetes; ODM derived
from: https://clinicaltrials.gov/show/NCT00194896
All rights reserved. Please visit https://medical-data-
models.org/forms/13537
Eligibility Type 2 Diabetes Mellitus
NCT00194896
Inclusion Criteria
age at onset of diabetes - 35-69 years old.*
Yes
No
no history of ketonuria or ketoacidosis.*
Yes
No
not requiring insulin to achieve glycemic control.*
Yes
No
not receiving more than two oral hypoglycemic
agents.*
Yes
No
not taking a thiazolidinedione agent.*
Yes
No
hba1c in established patients (on an oral
hypoglycemia agent for over 4  months) of
greater than 6% and under 10%.*
Yes
No
fasting c-peptide greater than or equal to 0.8
ng/ml.*
Yes
No
women must be either post-menopausal or on
adequate birth control (i.e. oral contraceptives,
tubal ligation, hysterectomy, condoms, or
diaphragm) or use abstinence.*
Yes
No
Exclusion Criteria
patients with history of chronic pancreatitis or
other secondary causes of diabetes.*
Yes
No
patients receiving systemic corticosteroids.*
Yes
No
patients with severe systemic illness (e.g. recent
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mi, chf or cerebral vascular disease).*
Yes
No
creatinine greater than 1.4 or liver enzymes
greater than 2 times the upper limits of normal.*
Yes
No
not able to adhere to the protocol.*
Yes
No
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Eligibility Type 2 Diabetes NCT00627783
Do You Need to Assess Myocardial Ischemia in Type 2
Diabetes; ODM derived from:
https://clinicaltrials.gov/show/NCT00627783
All rights reserved. Please visit https://medical-data-
models.org/forms/13538
Eligibility Type 2 Diabetes
NCT00627783
Inclusion Criteria
patients 55 to 75 years old had type-2 diabetes
and at least two of the following cardiovascular
risk factors:*
Yes
No
urinary albumin excretion > 30 mg/l or > 30
mg/24 hours,*
Yes
No
treated or untreated hypertension,*
Yes
No
treated or untreated lipid abnormality,*
Yes
No
peripheral arterial disease,*
Yes
No
history of transient ischemic accident,*
Yes
No
tobacco consumption*
Yes
No
familial history of premature cardiovascular
disease.*
Yes
No
Exclusion Criteria
history of myocardial infarction, coronary artery
disease, or stroke,*
Yes
No
previous positive stress test or myocardial
perfusion imaging,*
Yes
No
negative stress test or myocardial perfusion
imaging within the last three years*
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Yes
No
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Eligibility Wobenzym NCT02088411
The Safety and Efficacy of an Enzyme Combination in
Managing Knee Osteoarthritis Pain in Adults; ODM derived
from: https://clinicaltrials.gov/show/NCT02088411
All rights reserved. Please visit https://medical-data-
models.org/forms/13539
Eligibility Wobenzym NCT02088411
Inclusion Criteria
knee osteoarthritis confirmed by radiography or
tomography*
Yes
No
lequesne functional index score of 10-14*
Yes
No
womac-a pain subscale score greater than or
equal to 25*
Yes
No
Exclusion Criteria
history of knee trauma*
Yes
No
history of joint infection*
Yes
No
history of joint surgery*
Yes
No
history of intra-articular injection (viscotherapy)*
Yes
No
history of gastrointestinal diseases*
Yes
No
use of corticosteroids*
Yes
No
use of cox-ii inhibitors*
Yes
No
use of glucosamine/chondroitin*
Yes
No
known sensitivity to paracetamol*
Yes
No
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known sensitivity to non-steroidal anti-
inflammatory drugs (nsaids)*
Yes
No
known sensitivity to oral enzymes*
Yes
No
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Eligibility Wobenzym NCT02088411
Visit 5 Phase 1 clinical trial for intrasurgical hyperthermic intraperitoneal
chemoperfusion with cisplatin (HIPEC) in patients with ovarian cancer recidiv
Phase 1 clinical trial for intrasurgical hyperthermic
intraperitoneal chemoperfusion with cisplatin (HIPEC) in
patients with ovarian cancer recidiv EudraCT Nr.: 2010-
024352-28 Principal investigator und authorized
representative of Sponsor: PD Dr. med. Oliver Zivanovic
Center for Obstetrics and Gynaecology University Hospital
Bonn Sigmund-Freud-Str. 25 53105 Bonn Sponsor:
Rheinische Friedrich-Wilhelms-Universität Bonn
represented by the Dean of Medical Faculty
All rights reserved. Please visit https://medical-data-
models.org/forms/13540
Case Report Form (HIPEC) Visit 5
Visit 5:Day 5 post-surgery
Patient ID
CRF number
Date of visit
Vital signs, concomitant medication and
CTCAE
Heart rate count
bpm
Blood pressure measurement
mm/Hg
Body Temperature
°C
Has concomitant medication been subject to
change? If `Yes` please fill in Concomitant
medication form.
Yes
No
Recording of CTCAE: Have any AE occurred
since the last Visit? If `Yes` please fill in AE-Form
Yes
No
Laboratory results
Date of venous blood sampling
Time of laboratory procedure (according to
laboratory sheet)
Quick test result
%
Quick test value at normal range?
Yes
1 / 7
No
Are Quick test findings clinically significant? If
`Yes`, please fill in AE form.
Yes
No
Prothrombin time ratio
sec
Prothrombin time ratio within normal range?
Yes
No
Are PTT findings clinically significant? If `Yes`,
please fill in AE form.
Yes
No
INR test result
INR test within normal range?
Yes
No
Are INR test findings clinically significant? If
`Yes`, please fill in AE form.
Yes
No
Creatinine measurement value
mg/dl
Creatinine value within normal range?
Yes
No
Are Creatinine measurement findings clinically
significant? If `Yes`, please fill in AE- form.
Yes
No
Urea measurement value
mg/dl
Is Urea measurement value within normal range?
Yes
No
Are Urea measurement findings clinically
significant? If `Yes`, please fill in AE-Form.
Yes
No
Bilirubin measurement value
mg/dl
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Is Bilirubin measurement value within normal
range?
Yes
No
Are Bilirubin measurement findings clinically
significant? If `Yes`, please fill in AE form.
Yes
No
GPT measurement value
U/l
Is GPT value within normal range?
Yes
No
Are GPT measurement findings clinically
significant? If `Yes`, please fill in AE form.
Yes
No
GOT measurement value
U/l
Is GOT value within normal range?
Yes
No
Are GOT measurement findings clinically
significant? If `Yes`, please fill in AE form.
Yes
No
GGT measurement value
U/l
Is GGT measurement within normal range?
Yes
No
Are GGT measurement findings clinically
significant? If `Yes`, please fill in AE form.
Yes
No
Albumin measurement value
g/l
Is Albumin measurement within normal range?
Yes
No
Are Albumin measurement findings clinically
significant? If `Yes`, please fill in AE form.
Yes
No
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Serum potassium measurement value
mmol/l
Is serum potassium measurement value within
normal range?
Yes
No
Are serum potassium measurement findings
clinically significant? If `Yes`, please fill in AE
form.
Yes
No
Serum sodium measurement value
mmol/l
Is serum sodium measurement value within
normal range?
Yes
No
Are serum sodium measurement findings
clinically significant? If `Yes`, please fill in AE
form.
Yes
No
Serum calcium measurement value
mmol/l
Is serum calcium measurement value within
normal range?
Yes
No
Are serum calcium measurement findings
clinically significant? If `Yes`, please fill in AE
form.
Yes
No
Serum chloride measurement value
mmol/l
Is serum chloride measurement value within
normal range?
Yes
No
Are serum chloride measurement findings
clinically significant? If `Yes` , please fill in AE
form.
Yes
No
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Hemoglobin measurement value
g/dl
Is the hemoglobin measurement value within
normal range?
Yes
No
Are hemoglobin measurement findings clinically
significant? If `Yes`, please fill in AE form.
Yes
No
Hematocrit level
%
Is the hematocrit level within normal range?
Yes
No
Are findings in hematocrit level clinically
significant? If `Yes`, please fill in AE form.
Yes
No
Erythrocyte measurement value
mg/dl
Is the erythrocyte measurement value within
normal range?
Yes
No
Are findings in erythrocyte measurement clinically
significant? If `Yes`, please fill in AE form.
Yes
No
Leukocyte measurement value
U/l
Is the leukocyte measurement value within
normal range?
Yes
No
Are findings in Leukocyte measurement clinically
significant? If `Yes`, please fill in AE form.
Yes
No
Absolute neutrophils count measurement value
U/l
Is the count of neutrophils within normal range?
Yes
5 / 7
Visit 5 Phase 1 clinical trial for intrasurgical hyperthermic intraperitoneal
chemoperfusion with cisplatin (HIPEC) in patients with ovarian cancer recidiv
No
Are findings in neutrophils count clinically
significant? If `Yes`, please fill in AE form.
Yes
No
Lymphocyte count measurement value
U/l
Is the count of lymphocytes within normal range?
Yes
No
Are findings in lymphocyte count clinically
significant? If `Yes`, please fill in AE form.
Yes
No
Monocyte measurement value
g/l
Is the monocyte measurement value within
normal range?
Yes
No
Are findings in monocyte count clinically
significant? If `Yes`, please fill in AE form.
Yes
No
Eosinophils measurement value
g/l
Is the count of eosinophils within normal range?
Yes
No
Are findings in eosinophils count clinically
significant? If `Yes`, please fill in AE form.
Yes
No
Basophil measurement value
g/l
Is the count of basophils within normal range?
Yes
No
Are findings in basophil count clinically
significant? If `Yes`, please fill in AE form.
Yes
No
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Platelets count measurement value
g/l
Is the platelets count within normal range?
Yes
No
Are findings in platelets count clinically
significant? If `Yes`, please fill in AE form.
Yes
No
Urine sample date and time
Urine Sample test results, if results are clinically
significantly abnormal please fill in AE form.
normal (1)
abnormal, clinically not  significant (2)
abnormal, clinically significant (3)
If urine sample test results are abnormal, please
specify
Confirmation of correctness
Name of Investigator
Signature by investigator: I personally controlled
all entries into this form for this patient. All data
and statements in this CRF are complete and
correct
Date of completion of this form
7 / 7
Visit 5 Phase 1 clinical trial for intrasurgical hyperthermic intraperitoneal
chemoperfusion with cisplatin (HIPEC) in patients with ovarian cancer recidiv
Visit 6 Phase 1 clinical trial for intrasurgical hyperthermic intraperitoneal
chemoperfusion with cisplatin (HIPEC) in patients with ovarian cancer recidiv
Phase 1 clinical trial for intrasurgical hyperthermic
intraperitoneal chemoperfusion with cisplatin (HIPEC) in
patients with ovarian cancer recidiv EudraCT Nr.: 2010-
024352-28 Principal investigator und authorized
representative of Sponsor: PD Dr. med. Oliver Zivanovic
Center for Obstetrics and Gynaecology University Hospital
Bonn Sigmund-Freud-Str. 25 53105 Bonn Sponsor:
Rheinische Friedrich-Wilhelms-Universität Bonn
represented by the Dean of Medical Faculty
All rights reserved. Please visit https://medical-data-
models.org/forms/13541
Case Report Form (HIPEC) Visit 6
Visit 6:Day 7 post-surgery
Patient ID
CRF number
Date of visit
Vital signs, concomitant medication and
CTCAE
Heart rate count
bpm
Blood pressure measurement
mm/Hg
Body Temperature
°C
Has concomitant medication been subject to
change? If `Yes` please fill in Concomitant
medication form.
Yes
No
Recording of CTCAE: Have any AE occurred
since the last Visit? If `Yes` please fill in AE-Form
Yes
No
Laboratory results
Date of venous blood sampling
Time of laboratory procedure (according to
laboratory sheet)
Creatinine measurement value
mg/dl
Is Creatinine value within normal range?
Yes
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No
Are Creatinine measurement findings clinically
significant? If `Yes`, please fill in AE- form.
Yes
No
Urea measurement value
mg/dl
Is Urea measurement value within normal range?
Yes
No
Are Urea measurement findings clinically
significant? If `Yes`, please fill in AE-Form.
Yes
No
Bilirubin measurement value
mg/dl
Is Bilirubin measurement value within normal
range?
Yes
No
Are Bilirubin measurement findings clinically
significant? If `Yes`, please fill in AE form.
Yes
No
GPT measurement value
U/l
Is GPT value within normal range?
Yes
No
Are GPT measurement findings clinically
significant? If `Yes`, please fill in AE form.
Yes
No
GOT measurement value
U/l
Is GOT value within normal range?
Yes
No
Are GOT measurement findings clinically
significant? If `Yes`, please fill in AE form.
Yes
No
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GGT measurement value
U/l
Is GGT measurement within normal range?
Yes
No
Are GGT measurement findings clinically
significant? If `Yes`, please fill in AE form.
Yes
No
Albumin measurement value
g/l
Is Albumin measurement within normal range?
Yes
No
Are Albumin measurement findings clinically
significant? If `Yes`, please fill in AE form.
Yes
No
Serum potassium measurement value
mmol/l
Is serum potassium measurement value within
normal range?
Yes
No
Are serum potassium measurement findings
clinically significant? If `Yes`, please fill in AE
form.
Yes
No
Serum sodium measurement value
mmol/l
Is serum sodium measurement value within
normal range?
Yes
No
Are serum sodium measurement findings
clinically significant? If `Yes`, please fill in AE
form.
Yes
No
Serum calcium measurement value
mmol/l
Is serum calcium measurement value within
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normal range?
Yes
No
Are serum calcium measurement findings
clinically significant? If `Yes`, please fill in AE
form.
Yes
No
Serum chloride measurement value
mmol/l
Is serum chloride measurement value within
normal range?
Yes
No
Are serum chloride measurement findings
clinically significant? If `Yes` , please fill in AE
form.
Yes
No
Hemoglobin measurement value
g/dl
Is the hemoglobin measurement value within
normal range?
Yes
No
Are hemoglobin measurement findings clinically
significant? If `Yes`, please fill in AE form.
Yes
No
Hematocrit level
%
Is the hematocrit level within normal range?
Yes
No
Are findings in hematocrit level clinically
significant? If `Yes`, please fill in AE form.
Yes
No
Erythrocyte measurement value
mg/dl
Is the erythrocyte measurement value within
normal range?
Yes
No
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Are findings in erythrocyte measurement clinically
significant? If `Yes`, please fill in AE form.
Yes
No
Leukocyte measurement value
U/l
Is the leukocyte measurement value within
normal range?
Yes
No
Are findings in Leukocyte measurement clinically
significant? If `Yes`, please fill in AE form.
Yes
No
Absolute neutrophils count measurement value
U/l
Is the count of neutrophils within normal range?
Yes
No
Are findings in neutrophils count clinically
significant? If `Yes`, please fill in AE form.
Yes
No
Lymphocyte count measurement value
U/l
Is the count of lymphocytes within normal range?
Yes
No
Are findings in lymphocyte count clinically
significant? If `Yes`, please fill in AE form.
Yes
No
Monocyte measurement value
g/l
Is the monocyte measurement value within
normal range?
Yes
No
Are findings in monocyte count clinically
significant? If `Yes`, please fill in AE form.
Yes
No
Eosinophils measurement value
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g/l
Is the count of eosinophils within normal range?
Yes
No
Are findings in eosinophils count clinically
significant? If `Yes`, please fill in AE form.
Yes
No
Basophil measurement value
g/l
Is the count of basophils within normal range?
Yes
No
Are findings in basophil count clinically
significant? If `Yes`, please fill in AE form.
Yes
No
Platelets count measurement value
g/l
Is the platelets count within normal range?
Yes
No
Are findings in platelets count clinically
significant? If `Yes`, please fill in AE form.
Yes
No
Urine sample date and time
Urine Sample test results, if results are clinically
significantly abnormal please fill in AE form.
normal (1)
abnormal, clinically not  significant (2)
abnormal, clinically significant (3)
If urine sample test results are abnormal, please
specify
Confirmation of correctness
Name of Investigator
Signature by investigator: I personally controlled
all entries into this form for this patient. All data
and statements in this CRF are complete and
correct
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Date of completion of this form
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Visit 7 Phase 1 clinical trial for intrasurgical hyperthermic intraperitoneal
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Phase 1 clinical trial for intrasurgical hyperthermic
intraperitoneal chemoperfusion with cisplatin (HIPEC) in
patients with ovarian cancer recidiv EudraCT Nr.: 2010-
024352-28 Principal investigator und authorized
representative of Sponsor: PD Dr. med. Oliver Zivanovic
Center for Obstetrics and Gynaecology University Hospital
Bonn Sigmund-Freud-Str. 25 53105 Bonn Sponsor:
Rheinische Friedrich-Wilhelms-Universität Bonn
represented by the Dean of Medical Faculty
All rights reserved. Please visit https://medical-data-
models.org/forms/13545
Case Report Form (HIPEC) Visit 7
Visit 7:Day 14 post-surgery
Patient ID
CRF number
Date of visit
Vital signs, concomitant medication and
CTCAE
Heart rate count
bpm
Blood pressure measurement
mm/Hg
Body Temperature
°C
Has concomitant medication been subject to
change? If `Yes` please fill in Concomitant
medication form.
Yes
No
Recording of CTCAE: Have any AE occurred
since the last Visit? If `Yes` please fill in AE-Form
Yes
No
Laboratory results
Date of venous blood sampling
Time of laboratory procedure (according to
laboratory sheet)
Creatinine measurement value
mg/dl
Is Creatinine value within normal range?
Yes
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No
Are Creatinine measurement findings clinically
significant? If `Yes`, please fill in AE- form.
Yes
No
Urea measurement value
mg/dl
Is Urea measurement value within normal range?
Yes
No
Are Urea measurement findings clinically
significant? If `Yes`, please fill in AE-Form.
Yes
No
Bilirubin measurement value
mg/dl
Is Bilirubin measurement value within normal
range?
Yes
No
Are Bilirubin measurement findings clinically
significant? If `Yes`, please fill in AE form.
Yes
No
GPT measurement value
U/l
Is GPT value within normal range?
Yes
No
Are GPT measurement findings clinically
significant? If `Yes`, please fill in AE form.
Yes
No
GOT measurement value
U/l
Is GOT value within normal range?
Yes
No
Are GOT measurement findings clinically
significant? If `Yes`, please fill in AE form.
Yes
No
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GGT measurement value
U/l
Is GGT measurement within normal range?
Yes
No
Are GGT measurement findings clinically
significant? If `Yes`, please fill in AE form.
Yes
No
Albumin measurement value
g/l
Is Albumin measurement within normal range?
Yes
No
Are Albumin measurement findings clinically
significant? If `Yes`, please fill in AE form.
Yes
No
Serum potassium measurement value
mmol/l
Is serum potassium measurement value within
normal range?
Yes
No
Are serum potassium measurement findings
clinically significant? If `Yes`, please fill in AE
form.
Yes
No
Serum sodium measurement value
mmol/l
Is serum sodium measurement value within
normal range?
Yes
No
Are serum sodium measurement findings
clinically significant? If `Yes`, please fill in AE
form.
Yes
No
Serum calcium measurement value
mmol/l
Is serum calcium measurement value within
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normal range?
Yes
No
Are serum calcium measurement findings
clinically significant? If `Yes`, please fill in AE
form.
Yes
No
Serum chloride measurement value
mmol/l
Is serum chloride measurement value within
normal range?
Yes
No
Are serum chloride measurement findings
clinically significant? If `Yes` , please fill in AE
form.
Yes
No
Hemoglobin measurement value
g/dl
Is the hemoglobin measurement value within
normal range?
Yes
No
Are hemoglobin measurement findings clinically
significant? If `Yes`, please fill in AE form.
Yes
No
Hematocrit level
%
Is the hematocrit level within normal range?
Yes
No
Are findings in hematocrit level clinically
significant? If `Yes`, please fill in AE form.
Yes
No
Erythrocyte measurement value
mg/dl
Is the erythrocyte measurement value within
normal range?
Yes
No
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Are findings in erythrocyte measurement clinically
significant? If `Yes`, please fill in AE form.
Yes
No
Leukocyte measurement value
U/l
Is the leukocyte measurement value within
normal range?
Yes
No
Are findings in Leukocyte measurement clinically
significant? If `Yes`, please fill in AE form.
Yes
No
Absolute neutrophils count measurement value
U/l
Is the count of neutrophils within normal range?
Yes
No
Are findings in neutrophils count clinically
significant? If `Yes`, please fill in AE form.
Yes
No
Lymphocyte count measurement value
U/l
Is the count of lymphocytes within normal range?
Yes
No
Are findings in lymphocyte count clinically
significant? If `Yes`, please fill in AE form.
Yes
No
Monocyte measurement value
g/l
Is the monocyte measurement value within
normal range?
Yes
No
Are findings in monocyte count clinically
significant? If `Yes`, please fill in AE form.
Yes
No
Eosinophils measurement value
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g/l
Is the count of eosinophils within normal range?
Yes
No
Are findings in eosinophils count clinically
significant? If `Yes`, please fill in AE form.
Yes
No
Basophil measurement value
g/l
Is the count of basophils within normal range?
Yes
No
Are findings in basophil count clinically
significant? If `Yes`, please fill in AE form.
Yes
No
Platelets count measurement value
g/l
Is the platelets count within normal range?
Yes
No
Are findings in platelets count clinically
significant? If `Yes`, please fill in AE form.
Yes
No
Urine sample date and time
Urine Sample test results, if results are clinically
significantly abnormal please fill in AE form.
normal (1)
abnormal, clinically not  significant (2)
abnormal, clinically significant (3)
If urine sample test results are abnormal, please
specify
Confirmation of correctness
Name of Investigator
Signature by investigator: I personally controlled
all entries into this form for this patient. All data
and statements in this CRF are complete and
correct
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Date of completion of this form
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Eligibility Mobil-c1 Cardiac Innervation In Genetic Models Of
Arrhythmia In Humans And Mice EudraCT 2006-002767-41
The primary purpose is to investigate the autonomic
nervous system using positron emission tomography (PET)
in genotyped longQT syndrome patients and corresponding
mouse model and compare the results with the genetic
subtype, the phenotype and the role of the autonomic
nervous system in the onset of tachyarrhythmias. 
See https://www.clinicaltrialsregister.eu/ctr-
search/trial/2006-002767-41/DE#E
All rights reserved. Please visit https://medical-data-
models.org/forms/13548
Eligibility Mobil-c1 Cardiac
Innervation In Genetic Models Of
Arrhythmia In Humans And Mice
EudraCT 2006-002767-41
Inclusion Criteria
Date
Age
Yes
No
Female of childbearing age with adequate
contraceptive methods
Yes
No
Females: negative pregnancy test
Yes
No
patients: genetic defect for long-QT-Syndrom
Yes
No
Cardiac medication can be paused
Yes
No
written informed consent
Yes
No
Exclusion criteria
Controls: Coronary heart disease
Yes
No
Participation in another clinical trial within the last
8 weeks
Yes
No
Participation in another clinical trial with
radioactive agents
Yes
No
Use of caffeine on the day of examination
1 / 2
Yes
No
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Assessment Tracer Injection Mobil-c1 Items Cardiac Innervation In Genetic
Models Of Arrhythmia In Humans And Mice EudraCT 2006-002767-41
The primary purpose is to investigate the autonomic
nervous system using positron emission tomography (PET)
in genotyped longQT syndrome patients and corresponding
mouse model and compare the results with the genetic
subtype, the phenotype and the role of the autonomic
nervous system in the onset of tachyarrhythmias. 
See https://www.clinicaltrialsregister.eu/ctr-
search/trial/2006-002767-41/DE#E
All rights reserved. Please visit https://medical-data-
models.org/forms/13550
Assessment Tracer Injection Mobil-
c1 Items Cardiac Innervation In
Genetic Models Of Arrhythmia In
Humans And Mice EudraCT 2006-
002767-41
General information for Assessment
injection site
right arm (1)
left arm (2)
right hand (3)
left hand (4)
BP measurement site
right arm (1)
left arm (2)
Oxygen measurement site
right arm (1)
left arm (2)
Tracer H215O
Name of physician
Name of physician assistant
Application time
Application dose
MBQ
Baseline blood pressure
mmHg
BP Baseline not performed, because
cuff defect (1)
other reason (2)
Baseline Heart rate
b/min
Baseline heart rate not performed, because
ECG defect (1)
other reason (2)
1 / 2
Baseline oxygen saturation
%
Baseline Oxygen saturation not performed,
because
Clip defect  (1)
other reason (2)
Tracer C-11 MQNB / mHED
Name of physician
Name of physician assistant
Application time
Application dose
MBQ
Baseline blood pressure
mmHg
BP Baseline not performed, because
cuff defect (1)
other reason (2)
Baseline Heart rate
b/min
Baseline heart rate not performed, because
ECG defect (1)
other reason (2)
Baseline oxygen saturation
%
Baseline Oxygen saturation not performed,
because
Clip defect  (1)
other reason (2)
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Vital Signs post Tracer Injection Mobil-c1 Items Cardiac Innervation In Genetic
Models Of Arrhythmia In Humans And Mice EudraCT 2006-002767-41
The primary purpose is to investigate the autonomic
nervous system using positron emission tomography (PET)
in genotyped longQT syndrome patients and corresponding
mouse model and compare the results with the genetic
subtype, the phenotype and the role of the autonomic
nervous system in the onset of tachyarrhythmias. 
See https://www.clinicaltrialsregister.eu/ctr-
search/trial/2006-002767-41/DE#E
All rights reserved. Please visit https://medical-data-
models.org/forms/13551
Vital Signs post Tracer Injection
Mobil-c1 Items Cardiac Innervation
In Genetic Models Of Arrhythmia In
Humans And Mice EudraCT 2006-
002767-41
Vital signs 15 min p.i.
Name of physician
Name of physician assistant
Blood pressure acquisition time p.i.
Blood pressure
mmHg
Blood pressure not performed, because
cuff defect (1)
other reason (2)
Heart rate acquisition time p.i.
Heart rate
b/min
Heart rate not performed, because
ECG defect (1)
other reason (2)
Oxygen saturation acquisition time p.i.
Oxygen saturation
%
Oxygen saturation not performed, because
Clip defect  (1)
other reason (2)
Vital signs 30 min p.i.
Blood pressure acquisition time p.i.
Blood pressure
1 / 5
mmHg
Blood pressure not performed, because
cuff defect (1)
other reason (2)
Heart rate acquisition time p.i.
Heart rate
b/min
Heart rate not performed, because
ECG defect (1)
other reason (2)
Oxygen saturation acquisition time p.i.
Oxygen saturation
%
Oxygen saturation not performed, because
Clip defect  (1)
other reason (2)
Vital signs 45 min p.i.
Blood pressure acquisition time p.i.
Blood pressure
mmHg
Blood pressure not performed, because
cuff defect (1)
other reason (2)
Heart rate acquisition time p.i.
Heart rate
b/min
Heart rate not performed, because
ECG defect (1)
other reason (2)
Oxygen saturation acquisition time p.i.
Oxygen saturation
%
Oxygen saturation not performed, because
Clip defect  (1)
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other reason (2)
Vital signs 60 min p.i.
Blood pressure acquisition time p.i.
Blood pressure
mmHg
Blood pressure not performed, because
cuff defect (1)
other reason (2)
Heart rate acquisition time p.i.
Heart rate
b/min
Heart rate not performed, because
ECG defect (1)
other reason (2)
Oxygen saturation acquisition time p.i.
Oxygen saturation
%
Oxygen saturation not performed, because
Clip defect  (1)
other reason (2)
Vital signs 75 min p.i.
Blood pressure acquisition time p.i.
Blood pressure
mmHg
Blood pressure not performed, because
cuff defect (1)
other reason (2)
Heart rate acquisition time p.i.
Heart rate
b/min
Heart rate not performed, because
ECG defect (1)
other reason (2)
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Oxygen saturation acquisition time p.i.
Oxygen saturation
%
Oxygen saturation not performed, because
Clip defect  (1)
other reason (2)
Vital signs 90 min p.i.
Blood pressure acquisition time p.i.
Blood pressure
mmHg
Blood pressure not performed, because
cuff defect (1)
other reason (2)
Heart rate acquisition time p.i.
Heart rate
b/min
Heart rate not performed, because
ECG defect (1)
other reason (2)
Oxygen saturation acquisition time p.i.
Oxygen saturation
%
Oxygen saturation not performed, because
Clip defect  (1)
other reason (2)
additional assessment of vital signs
Blood pressure acquisition time p.i.
Blood pressure
mmHg
Heart rate acquisition time p.i.
Heart rate
b/min
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Oxygen saturation acquisition time p.i.
Oxygen saturation
%
additional assessment of vital signs
Blood pressure acquisition time p.i.
Blood pressure
mmHg
Heart rate acquisition time p.i.
Heart rate
b/min
Oxygen saturation acquisition time p.i.
Oxygen saturation
%
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Blood sampling Mobil-c1 Items Cardiac Innervation In Genetic Models
Of Arrhythmia In Humans And Mice EudraCT 2006-002767-41
The primary purpose is to investigate the autonomic
nervous system using positron emission tomography (PET)
in genotyped longQT syndrome patients and corresponding
mouse model and compare the results with the genetic
subtype, the phenotype and the role of the autonomic
nervous system in the onset of tachyarrhythmias. 
See https://www.clinicaltrialsregister.eu/ctr-
search/trial/2006-002767-41/DE#E
All rights reserved. Please visit https://medical-data-
models.org/forms/13552
Blood sampling Mobil-c1 Items
Cardiac Innervation In Genetic
Models Of Arrhythmia In Humans
And Mice EudraCT 2006-002767-41
General information
Date of Assessment
Name of physician
Name of physician assistant
Time of Injection of 2nd Tracer
Time of start of counting
MW Background
cpm
MW standard sample QC
cpm
Acquisition time of MW standard sample QC
Blood sampling site
right hand (1)
left hand (2)
right elle bow  (3)
left elle bow (4)
Blood sampling
Time of blood sample (minutes after injection)
minutes
MW cpm Plasma (1ml)
cpm
MW cpm Blood
cpm
1 / 2
Clinical chemistry
Prescan sample acquisition time
Sodium measurement prescan
mmol/l
Potassium measurement prescan
mmol/l
Postscan sample acquisition time
Sodium measurement postscan
mmol/l
Potassium measurement postscan
mmol/l
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Adverse Events and Study Termination Mobil-c1 Items Cardiac Innervation In
Genetic Models Of Arrhythmia In Humans And Mice EudraCT 2006-002767-41
The primary purpose is to investigate the autonomic
nervous system using positron emission tomography (PET)
in genotyped longQT syndrome patients and corresponding
mouse model and compare the results with the genetic
subtype, the phenotype and the role of the autonomic
nervous system in the onset of tachyarrhythmias. 
See https://www.clinicaltrialsregister.eu/ctr-
search/trial/2006-002767-41/DE#E
All rights reserved. Please visit https://medical-data-
models.org/forms/13553
Adverse Events and Study
Termination Mobil-c1 Items Cardiac
Innervation In Genetic Models Of
Arrhythmia In Humans And Mice
EudraCT 2006-002767-41
Adverse Events
Did Adverse Events occur
No (1)
yes (2)
Study termination
No (1)
yes (2)
If study was terminated, please specify reason
Adverse events (1)
Wish of patient prescan (2)
Wish of patient postscan (3)
other reason, specifiy: (4)
List of Adverse Events
Adverse event
Start date of Adverse Event
Was the AE serious
No  (1)
yes (2)
AE leads to termination of study
No (1)
Yes (2)
AE Correlation to Protocol Agent
no correlation (0)
reasonable correlation to protocol agent
(1)
CTCAE-Grading of Adverse Event
<= 5
>= 1
AE End date, if ended
AE ongoing
No (1)
1 / 2
Yes (2)
Final consequence of AE
recovered (0)
improved (1)
not yet improved (2)
recovered with defect (3)
unknown (4)
death (5)
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Eligibility Patients Undergoing Open Resection
of Colorectal Tumours NCT02136277
Vascular Changes During Colorectal Surgery; ODM derived
from: https://clinicaltrials.gov/show/NCT02136277
All rights reserved. Please visit https://medical-data-
models.org/forms/13554
Eligibility Patients Undergoing Open
Resection of Colorectal Tumours
NCT02136277
Inclusion Criteria
Age 18 - 80 years*
Yes
No
Confirmed colorectal cancer*
Yes
No
Surgery offered by derbyshire colorectal
multidisciplinary team*
Yes
No
No metastatic disease*
Yes
No
Able to consent in english by themselves*
Yes
No
Exclusion Criteria
Metastatic disease*
Yes
No
Esophageal Varices*
Yes
No
Patients with recent acute coronary syndrome
(symptoms involving the heart) or unstable
ischaemic cardiac disease (reduced blood supply
to the heart)*
Yes
No
Hypertension (high blood pressure in the
pulmonary artery, the blood vessel that leads
from the heart to the lungs), uncontrolled
hypertension (high blood pressure) for adult
respiratory distress syndrome (severe fluid build-
up in both lungs)*
Yes
No
Pregnant or breast-feeding patient*
Yes
No
1 / 2
Sensitivity to SonoVue*
Yes
No
Prolonged qt syndrome*
Yes
No
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DESCRIBE CRF Medical History of
Diagnostics
DESCRIBE (DZNE – Clinical Register Study of
neurodegenerative Disorders)
Background and Purpose:
The purpose of the DESCRIBE study is to document the
natural course of diseases in context of medical care of
neurodegenerative disorders as well as cerebrovascular
diseases and to perform phenotyping of the test persons.
Disease-spanning analyses of the measured clincial data,
the results of the imaging processes, results of the analysis
of the biometerials including genetic analysis are planed.
Principal Investigator: Prof. Klockgether, Dr. Spottke DZNE,
Bonn.
Source: DESCRIBE-Studie
http://www.dzne.de/forschung/forschungsbereiche/klinische
-forschung/studien/describe-bn006.html 
Participating Study Sites:
Berlin, Bonn, Göttingen, Dresden, Köln, Magdeburg,
München, Rostock/Greifswald, Tübingen
All rights reserved. Please visit https://medical-data-
models.org/forms/13557
Medical History of Diagnostics
Date of Visit
Study-ID:
Visit
Date of visit
Imaging Techniques - Anamnesis and
Documentation
CCT or MRI performed
No (0)
Yes (1)
Unknown (99)
Date of test
Done by institution
Method/ type of examination
CCT (1)
MRT (2)
Field strength
1,5 T (1)
3 T (2 )
Performed according to DZNE SOPs
No (0)
Yes (1)
N.A. (88)
Unknown (99)
Upload to database of imaging results done
Yes
1 / 11
No
Imaging Techniques - Radiologic results
Signs of another neurological disorder (e.g.
hydrocephalus, neoplasms, multiple sclerosis)
not present (0)
present (1)
unknown (99)
Evidence of cerebral lesions after e.g. seizure,
bleeding or head trauma?
not present (0)
present (1)
unknown (99)
Athrophy beyond normal age scale
No (0)
Yes (1)
Unknown (99)
Cortical - prefrontal
Yes
No
Cortical - prefrontal side
right (1)
left (2)
symmetrical (3)
Cortical - central region
Yes
No
Cortical - central region side
right (1)
left (2)
symmetrical (3)
Cortical - parietal
Yes
No
Cortical - parietal side
right (1)
left (2)
symmetrical (3)
Cortical - temporal
Yes
No
Cortical - temporal side
right (1)
left (2)
symmetrical (3)
Cortical - occipital
Yes
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No
Cortical - occipital side
right (1)
left (2)
symmetrical (3)
Other cortical region
Other cortical region - side
right (1)
left (2)
symmetrical (3)
Subcortical - striatum
Yes
No
Subcortical - striatum side
right (1)
left (2)
symmetrical (3)
Subcortical - thalamus
Yes
No
Subcortical - thalamus side
right (1)
left (2)
symmetrical (3)
Subcortical - cerebellum
Yes
No
Subcortical - cerebellum side
right (1)
left (2)
symmetrical (3)
Subcortical - pons
Yes
No
Subcortical - pons side
right (1)
left (2)
symmetrical (3)
Subcortical - midbrain
Yes
No
Subcortical - midbrain side
right (1)
left (2)
symmetrical (3)
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Subcortical - brain stem
Yes
No
Subcortical - brain stem side
right (1)
left (2)
symmetrical (3)
Other subcortical region
Other subcortical region side
right (1)
left (2)
symmetrical (3)
SPECT examination (FP-CIT / IBZM) of basal
ganglia performed?
No (0)
Yes (1)
Unknown (99)
1. pre-synaptic: examination date
Done by (institution)
Performed according to DZNE SOPs
No (0)
Yes (1)
N.A. (88)
Unknown (99)
Upload to database of imaging results done
Yes
No
Finding pre-synaptic
normal finding (1)
reduced absorption of ligands (2)
other finding (3)
Other pre-synaptic finding
2. post-synaptic: Examination date
Done by (institution)
Performed according to DZNE SOPs
No (0)
Yes (1)
N.A. (88)
Unknown (99)
Upload to database of imaging results done
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Yes
No
Finding post-synaptic
normal finding (1)
reduced absorption of ligands (2)
other finding (3)
Other post-synaptic finding
Tau PET imaging performed
No (0)
Yes (1)
Unknown (99)
Amyloid PET imaging performed
No (0)
Yes (1)
Unknown (99)
Date of examination (Amyloid PET/ Tau PET)
Done by institution
Performed according to DZNE SOPs
No (0)
Yes (1)
N.A. (88)
Unknown (99)
Upload to database of imaging results done
Yes
No
Used tracer (Tau-PET)
F-18 T807 (1)
C-11 PBB3 (2)
F-18 FDDNP (3)
F-18 THK-5117 (4)
F-18 THK-523 (5)
F-18 T808 (6)
other tracer (7)
unknown (99)
Used tracer (amyloid PET)
PIB (1)
flutemetamol (2)
florbetaben (3)
florbetapir (4)
other tracer (5)
unknown (99)
Other tracer
Other tracer
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Nuclide accumulation
not present (0)
present (1)
unknown (99)
Cortical - prefrontal
Yes
No
Cortical - prefrontal side
right (1)
left (2)
symmetrical (3)
Cortical - central region
Yes
No
Cortical - central region side
right (1)
left (2)
symmetrical (3)
Cortical - parietal
Yes
No
Cortical - parietal side
right (1)
left (2)
symmetrical (3)
Cortical - temporal
Yes
No
Cortical - temporal side
right (1)
left (2)
symmetrical (3)
Cortical - occipital
Yes
No
Cortical - occipital side
right (1)
left (2)
symmetrical (3)
Other cortical region
Other cortical region - side
right (1)
left (2)
symmetrical (3)
Subcortical - striatum
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Yes
No
Subcortical - striatum side
right (1)
left (2)
symmetrical (3)
Subcortical - thalamus
Yes
No
Subcortical - thalamus side
right (1)
left (2)
symmetrical (3)
Subcortical - cerebellum
Yes
No
Subcortical - cerebellum side
right (1)
left (2)
symmetrical (3)
Subcortical - pons
Yes
No
Subcortical - pons side
right (1)
left (2)
symmetrical (3)
Subcortical - midbrain
Yes
No
Subcortical - midbrain side
right (1)
left (2)
symmetrical (3)
Subcortical - brain stem
Yes
No
Subcortical - brain stem side
right (1)
left (2)
symmetrical (3)
Other subcortical region
Other subcortical region side
right (1)
left (2)
symmetrical (3)
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EEG
EEG performed
No (0)
Yes (1)
Unknown (99)
Date of examination
Done by institution
1. Quality
good or not significant (artefacts making
interpretation difficult e.g. slight artefacts
of muscles, ECG artefacts) (1)
moderate (interpretation obviously more
difficult due to artefacts) (2)
bad (interpretation not valid) (3)
Particularities taking EEG (e.g. not cooperative
participant)
2. General assessment
normal finding (alpha rhythm occipital
accented, blockage when eyes opening,
no side difference, no focal finding, no
epilepsy typical potentials) (1)
variation (pathological finding, uncertain,
e.g. beta rhythm) (2)
abnormal finding (3)
In case of abnormal finding
slow-down (1)
potentials typical for epilepsy (2)
special patterns (3)
4. Slow-down: Occurrence
continuous (1)
intermittent (2)
4. Slow-down: Spread
focal (1)
generalized (2)
4. Slow-down: Side
right (1)
left (2)
bilateral (3)
4. Slow-down: Region
frontal (1)
temporal (2)
parietal (3)
occipital (4)
not clear (5)
5. Patterns typical for epilepsy: Potential
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Spikes (1)
Sharp Waves (2)
Polysharps (3)
Spike-Waves (4 )
5. Patterns typical for epilepsy: Spread
focal (1)
generalized (2)
5. Patterns typical for epilepsy: Side
right (1)
left (2)
bilateral (3)
5. Patterns typical for epilepsy: Region
frontal (1)
temporal (2)
parietal (3)
occipital (4)
not clear (5)
6. Special patterns
triphasic waves (1)
periodic pattern (2)
PLEDs, BiPLEDs (3)
asymmetries (due to a pathological
raising) (4)
other (5)
7. Comments
Scintigraphy
Myocard scintigraphy performed
No (0)
Yes (1)
Unknown (99)
Date of examination
Done by institution:
Laboratory parameters - Liquor
Date of liquor collection
Done by institution:
Cell count/ leukocytes:
Unit
Reference region: from
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Reference region: up tp
Glucose
Unit
Reference region: from
Reference region: up to
Total protein
Unit
Reference region: from
Reference region: up to
Total tau-protein
Unit
Reference region: from
Reference region: up to
pTau protein
Unit
Reference region: from
Reference region: up to
Aβ1-42
Unit
Reference region: from
Reference region: up to
Aβ1-40
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Unit
Reference region: from
Reference region: up to
α-synuclein
Unit
Reference region: from
Reference region: up to
Aβ42/40 ratio
Laboratory parameters - Serum
Date of blood sampling
Done by (institution):
1. Glucose
Unit
Reference region: from
Reference region: up to
2. Total protein
Unit
Reference region: from
Reference region: up to
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Eligibility Asthma NCT01404013
Effects of Leukotriene Modulator Montelukast on Cough
Variant Asthma; ODM derived from:
https://clinicaltrials.gov/show/NCT01404013
All rights reserved. Please visit https://medical-data-
models.org/forms/13559
Eligibility Asthma NCT01404013
Inclusion Criteria
1. patients who have a history of cough as sole or
main symptom lasting more than 8 weeks, often
irritating cough more cough at night.*
Yes
No
2. patients who were diagnosed with positive
result in bronchial provocation test by
methacholine inhalation challenge.*
Yes
No
3. there is evidence that bronchodilator
treatment* is efficient for cough symptom
(symptom score improved 1 at least).*
Yes
No
4. patients whose chest x-ray outcome was
normal or without any active focus.*
Yes
No
5. patients who was aged from 18 years old (≥ 18
years old ) to 75 years old (≤ 75 years old).*
Yes
No
Exclusion Criteria
1. patients demonstrate fev1/fvc ＜70% in lung
function test. fev1 stands for forced expiratory
volume in 1 second, fvc stands for forced vital
capacity.*
Yes
No
2. patients who is a smoker or ex-smoker and has
smoked within the previous year or has a
cumulative smoking history ＞10 pack-years or
equivalence.*
Yes
No
3. patients with concomitance of gerc
(gastroesophageal reflux-related chronic cough),
chronic bronchitis , bronchiectasis, bronchial
tuberculosis, acei induced cough, bronchogenic
carcinoma, psychologic cough, pulmonary
fibrosis, bronchus foreign body, microlithiasis,
tracheobroncheopathia osteochondroplastica,
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mediastinal tumor, left ventricular dysfunction.*
Yes
No
4. female subjects who are pregnant, breast-
feeding or risk of becoming pregnant during the
study.*
Yes
No
5. subjects who are known or suspected to be
hypersensitive to any component of the study
medication or relief medications.*
Yes
No
6. subjects who have received any therapy in the
previous seven days, e.g. oral/*
Yes
No
inhaled/systematic corticosteroid, long-acting β2
agonist, theophylline sustained release.*
Yes
No
7. subjects who are diagnosed with past or
present disease, which as judged by the
investigator, may affect the outcome of this study.
these diseases include, but are not limited to,
cardiovascular disease, malignancy, hepatic
disease, renal disease, haematological disease,
neurological disease, endocrine disease or
pulmonary disease. e.g.nasal-sinus infection,
lower respiratory tract infection, chronic
bronchitis, emphysema, bronchiectasis, cystic
fibrosis or bronchopulmonary dysplasia.*
Yes
No
8. subjects who demonstrate significant
abnormality on biochemistry, hematology, ecg.*
Yes
No
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Eligibility Asthma NCT01435902
A Study of a New Asthma Medicine in Asthmatics Whose
Asthma Worsens With Exercise; ODM derived from:
https://clinicaltrials.gov/show/NCT01435902
All rights reserved. Please visit https://medical-data-
models.org/forms/13560
Eligibility Asthma NCT01435902
Inclusion Criteria
outpatient male or female 12 to 50 years of age*
Yes
No
females of child-bearing potential must be willing
to use birth control or commit to abstinence
during the study*
Yes
No
diagnosis of persistent asthma for at least 6
months*
Yes
No
best pre-bronchodilator fev1 of at least 70%.*
Yes
No
current use of a low- to moderate-dose inhaled
corticosteroid*
Yes
No
ability to withhold albuterol 6 hours prior to visits.*
Yes
No
physically able to perform exercise testing on a
treadmill when albuterol has been withheld*
Yes
No
Exclusion Criteria
intermittent asthma, seasonal asthma, or
exercise-induced asthma only*
Yes
No
symptomatic allergic rhinitis and/or thrush*
Yes
No
abnormal, clinically significant electrocardigraph*
Yes
No
respiratory infection within 4 weeks of first visit
leading to asthma medication change or could
affect subjects's asthma status or participation*
Yes
No
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asthma exacerbation within 12 weeks of first visit*
Yes
No
respiratory diseases or other concurrent disease
that would put subject at risk or confound results
interpretation*
Yes
No
investigational medicines within 30 days of first
visit or less than five half-lives of medication in
prior study*
Yes
No
allergy to study drugs or study drug excipients*
Yes
No
concomitant medications that could interact with
study medications or affect the course of asthma*
Yes
No
tobacco use within last year and/or a 10 pack-
years history*
Yes
No
inability to comply with requirements of the study*
Yes
No
affiliation with investigator's site (example: family
member)*
Yes
No
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Eligibility Asthma NCT01471340
A Serious Asthma Outcome Study With Mometasone
Furoate/Formoterol Versus Mometasone Furoate in
Asthmatics 12 Years and Over (P06241 AM3); ODM
derived from: https://clinicaltrials.gov/show/NCT01471340
All rights reserved. Please visit https://medical-data-
models.org/forms/13561
Eligibility Asthma NCT01471340
Inclusion Criteria
persistent asthma for at least 1-year*
Yes
No
must use a daily asthma controller medication for
at least 4 weeks prior to randomization, including
an inhaled corticosteroid (ics) with or without a
long-acting beta agonist (laba) or other adjunctive
asthma therapy or be using a leukotriene
receptor antagonist (ltra), xanthine or short acting
beta agonist (saba) as a monotherapy.*
Yes
No
must be able to discontinue current asthma
medication*
Yes
No
must have a history of at least one asthma
exacerbation in previous 4 to 52 weeks*
Yes
No
Exclusion Criteria
unstable asthma*
Yes
No
taking high dose ics with or without other
adjunctive therapy who have an asthma control
questionnaire 6 (acq6) total score ≥ 1.5*
Yes
No
taking ltra, xanthine or saba monotherapy with an
acq-6 total score < 1.5 (controlled)*
Yes
No
chronic obstructive pulmonary disease (copd),
cystic fibrosis (cf), or other significant, non-
asthmatic, lung disease*
Yes
No
clinically significant abnormality, illness or
disorder of any body or organ system*
Yes
No
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significant underlying cardiovascular condition
which may contraindicate use of a beta-agonist.*
Yes
No
history of smoking greater than 10-pack years*
Yes
No
had an asthma exacerbation within 4 weeks of
the baseline visit*
Yes
No
had more than 4 asthma exacerbations or 2
hospitalizations within 52 weeks of the
randomization visit*
Yes
No
known or suspected hypersensitivity or
intolerance to corticosteroids, beta-2 agonists, or
any of the (inactive ingredients) excipients
present in the medications used in this study*
Yes
No
require the use of chronic systemic steroids,
omalizumab, or other monoclonal or polyclonal
antibodies*
Yes
No
requires the use of beta-blockers*
Yes
No
history of life-threatening asthma, including an
asthma episode that required intubation and/or
was associated with hypercapnia requiring
noninvasive ventilatory support*
Yes
No
lactating, pregnant, or plans to become pregnant
during the course of the trial*
Yes
No
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Visit 8 Phase 1 clinical trial for intrasurgical hyperthermic intraperitoneal
chemoperfusion with cisplatin (HIPEC) in patients with ovarian cancer recidiv
Phase 1 clinical trial for intrasurgical hyperthermic
intraperitoneal chemoperfusion with cisplatin (HIPEC) in
patients with ovarian cancer recidiv EudraCT Nr.: 2010-
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Case Report Form (HIPEC) Visit  8
Visit 8: Day 21 post-OP
Patient ID
CRF number
Date of visit
Vital signs and physical examination
Heart rate count
bpm
Blood pressure measurement
mm/Hg
Body Temperature
°C
Performance status (ECOG):
0 (0)
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
General physical condition
normal (1)
pathological (2)
not assessed (3)
General physical condition:further comment
Skin assessment
normal (1)
pathological (2)
not assessed (3)
Skin assessment:further comment
Cardiovascular system assessment
normal (1)
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pathological (2)
not assessed (3)
Cardiovascular system:further comment
Respiratory system assessment
normal (1)
pathological (2)
not assessed (3)
Respiratory System:further comment
Otorhinolaryngologic diseases
none (1)
yes (2)
not assessed (3)
Otorhinolaryngologic diseases:further comment
Abdominal examination
normal (1)
pathological (2)
not assessed (3)
Abdominal examination:further comment
Lymphatic system
normal (1)
pathological (2)
not assessed (3)
Lymphatic system:further comment
Mucous Membranes
normal (1)
pathological (2)
not assessed (3)
Mucous Membranes:further comment
Neurological examination
Normal (1)
Pathological (2)
not assessed (3)
Neurological examination:further comment
Gynecological Examination
normal (1)
pathological (2)
not assessed (3)
Gynecological Examination:further comment
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Urinary Tract and Kidney Examination
normal (1)
pathological (2)
not assessed (3)
Urinary Tract and Kidneys:further comment
Please specify any other clinically significant
findings
Has concomitant medication been subject to
change? If "Yes", please fill in concomitant
medication form.
Yes
No
Recording of CTCAE: Have any AE occurred
since the last Visit? If `Yes` please fill in AE-Form
Yes
No
Laboratory results
Date of venous blood sampling
Time of laboratory procedure (according to
laboratory sheet)
Creatinine measurement value
mg/dl
Is Creatinine value within normal range?
Yes
No
Are Creatinine measurement findings clinically
significant? If `Yes`, please fill in AE- form.
Yes
No
Urea measurement value
mg/dl
Is Urea measurement value within normal range?
Yes
No
Are Urea measurement findings clinically
significant? If `Yes`, please fill in AE-Form.
Yes
No
Bilirubin measurement value
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mg/dl
Is Bilirubin measurement value within normal
range?
Yes
No
Are Bilirubin measurement findings clinically
significant? If `Yes`, please fill in AE form.
Yes
No
GPT measurement value
U/l
Is GPT value within normal range?
Yes
No
Are GPT measurement findings clinically
significant? If `Yes`, please fill in AE form.
Yes
No
GOT measurement value
U/l
Is GOT value within normal range?
Yes
No
Are GOT measurement findings clinically
significant? If `Yes`, please fill in AE form.
Yes
No
GGT measurement value
U/l
Is GGT measurement within normal range?
Yes
No
Are GGT measurement findings clinically
significant? If `Yes`, please fill in AE form.
Yes
No
Albumin measurement value
g/l
Is Albumin measurement within normal range?
Yes
No
Are Albumin measurement findings clinically
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significant? If `Yes`, please fill in AE form.
Yes
No
Serum potassium measurement value
mmol/l
Is serum potassium measurement value within
normal range?
Yes
No
Are serum potassium measurement findings
clinically significant? If `Yes`, please fill in AE
form.
Yes
No
Serum sodium measurement value
mmol/l
Is serum sodium measurement value within
normal range?
Yes
No
Are serum sodium measurement findings
clinically significant? If `Yes`, please fill in AE
form.
Yes
No
Serum calcium measurement value
mmol/l
Is serum calcium measurement value within
normal range?
Yes
No
Are serum calcium measurement findings
clinically significant? If `Yes`, please fill in AE
form.
Yes
No
Serum chloride measurement value
mmol/l
Is serum chloride measurement value within
normal range?
Yes
No
Are serum chloride measurement findings
clinically significant? If `Yes` , please fill in AE
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form.
Yes
No
Hemoglobin measurement value
g/dl
Is the hemoglobin measurement value within
normal range?
Yes
No
Are hemoglobin measurement findings clinically
significant? If `Yes`, please fill in AE form.
Yes
No
Hematocrit level
%
Is the hematocrit level within normal range?
Yes
No
Are findings in hematocrit level clinically
significant? If `Yes`, please fill in AE form.
Yes
No
Erythrocyte measurement value
mg/dl
Is the erythrocyte measurement value within
normal range?
Yes
No
Are findings in erythrocyte measurement clinically
significant? If `Yes`, please fill in AE form.
Yes
No
Leukocyte measurement value
U/l
Is the leukocyte measurement value within
normal range?
Yes
No
Are findings in Leukocyte measurement clinically
significant? If `Yes`, please fill in AE form.
Yes
No
Absolute neutrophils count measurement value
U/l
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Is the count of neutrophils within normal range?
Yes
No
Are findings in neutrophils count clinically
significant? If `Yes`, please fill in AE form.
Yes
No
Lymphocyte count measurement value
U/l
Is the count of lymphocytes within normal range?
Yes
No
Are findings in lymphocyte count clinically
significant? If `Yes`, please fill in AE form.
Yes
No
Monocyte measurement value
g/l
Is the monocyte measurement value within
normal range?
Yes
No
Are findings in monocyte count clinically
significant? If `Yes`, please fill in AE form.
Yes
No
Eosinophils measurement value
g/l
Is the count of eosinophils within normal range?
Yes
No
Are findings in eosinophils count clinically
significant? If `Yes`, please fill in AE form.
Yes
No
Basophil measurement value
g/l
Is the count of basophils within normal range?
Yes
No
Are findings in basophil count clinically
significant? If `Yes`, please fill in AE form.
Yes
No
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Platelets count measurement value
g/l
Is the platelets count within normal range?
Yes
No
Are findings in platelets count clinically
significant? If `Yes`, please fill in AE form.
Yes
No
Tumor marker CA125 measurement value
Is measurement value of tumor marker CA 125
within normal range?
Yes
No
Are findings in tumor marker CA 125 clinically
significant?
Yes
No
Urine sample date and time
Urine Sample test results
normal (1)
abnormal, clinically not  significant (2)
abnormal, clinically significant (3)
If urine sample test results are abnormal, please
specify
Inquiry of dose limiting toxicity
Has a dose limiting toxicity been reached?
Yes
No
If dose limiting toxicity has been reached, please
specify the date it occurred
Please specify the toxicities that have occurred
and give the corresponding AE number
Has maximum tolerated dose been reached?
Yes
No
Confirmation of correctness
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Name of Investigator
Signature by investigator: I personally controlled
all entries into this form for this patient. All data
and statements in this CRF are complete and
correct
Date of completion of this form
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Case Report Form (HIPEC) Visit 9
Visit 9: First cycle of post-OP
Chemotherapy
Patient ID
CRF number
Date of visit
Status of Patient and recording of CTCAE
Has patient appeared for the planned visit?
Yes
No
If patient didn´t come for the scheduled visit,
please call the patient and try to verify the reason
why.
Has the Patient deceased?
Yes
No
Please specify the date the patient died
Has a progressive disease been diagnosed?
Yes
No
Please give the date, the progression was
diagnosed
Recurrent Disease
Yes
No
Please give the date, the relapse was diagnosed
Yes
No
Recording of CTCAE: Have any AE occurred
since the last Visit? If `Yes` please fill in AE-Form
Yes
No
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Postoperative chemotherapy
Postoperative chemotherapy will be administered
Yes
No
Please specify the reason why, if chemotherapy
will not be administered
If chemotherapy will be administered, please
specify the nature of the planned regimen
monotherapy (1)
combination therapy (2)
Please specify the agent used for chemotherapy
Carboplatin (1)
Paclitaxel (2)
Gemcitabine (used on first or eighth day
of cycle) (3)
Doxorubicin liposome (4)
other (5)
Please specify other chemotherapeutic agent
used
Dose of Carboplatin administerd
AUC
Dose of Paclitaxel administered
mg/m2
Dose of Gemcitabine administered
mg/m2
Dose of Doxorubicin liposome administered
mg/m2
Dose of other antineoplastic agent administered
mg/m2
Course of chemotherapy cycle
Date of first chemotherapy
Total dose of Carboplatin administered
mg
Has the dose been modified?
Yes
No
Please specify what kind of dose modification
was used
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Dose reduction (1)
Delay/Deceleration (2)
Discontinuation (3)
Please specify the reason for the dose
modification
hematologic toxicitiy (1)
hypersensitivity (2)
other (3)
Total dose of Paclitaxel administered
mg
Has the dose been modified?
Yes
No
Please specify what kind of dose modification
was used
Dose reduction (1)
Delay/Deceleration (2)
Discontinuation (3)
Please specify the reason for the dose
modification
hematologic toxicity (1)
hypersensitivity (2)
other (3)
Total dose of Gemcitabine administered
mg
Has the dose been modified?
Yes
No
Please specify what kind of dose modification
was used
Dose reduction  (1)
Delay/Deceleration  (2)
Discontinuation (3)
Please specify the reason for the dose
modification
hematologic toxicity  (1)
hypersensitivity  (2)
other (3)
Total dose of doxorubicin liposome administered
mg
Has the dose been modified?
Yes
No
Please specify what kind of dose modification
has been used
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Dose reduction (1)
Delay/Deceleration (2)
Discontinuation (3)
Please specify the reason for the dose
modification
hematologic toxicity  (1)
hypersensitivity  (2)
other (3)
Total dose of other chemotherapeutic agent
administered
mg
Has the dose been modified?
Yes
No
Please specify what kind of dose modification
has been used
Dose reduction  (1)
Delay/Deceleration  (2)
Discontinuation (3)
Please specify the reason for the dose
modification
hematologic toxicity  (1)
hypersensitivity  (2)
other (3)
Any further oncologic treatments?
Yes
No
Please specify any further antineoplastic
treatments that have been carried out.
Confirmation of correctness
Name of Investigator
Signature by investigator: I personally controlled
all entries into this form for this patient. All data
and statements in this CRF are complete and
correct
Date of completion of this form
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Rheinische Friedrich-Wilhelms-Universität Bonn
represented by the Dean of Medical Faculty
All rights reserved. Please visit https://medical-data-
models.org/forms/13569
Case Report Form (HIPEC) Visit 10
Visit 10: Second cycle of post-OP
Chemotherapy
Patient ID
CRF number
Date of visit
Status of Patient and recording of CTCAE
Has patient appeared for the planned visit?
Yes
No
If patient didn´t come for the scheduled visit,
please call the patient and try to verify the reason
why.
Is the Patient deceased?
Yes
No
Please specify the date the patient died
Has a progressive disease been diagnosed?
Yes
No
Please give the date, the progression was
diagnosed
Recurrent Disease
Yes
No
Please give the date, the relapse was diagnosed
Yes
No
Recording of CTCAE: Have any AE occurred
since the last Visit? If `Yes` please fill in AE-Form
Yes
No
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Postoperative intravenous chemotherapy
Postoperative chemotherapy will be continued
Yes
No
Please specify the reason why, if chemotherapy
will be discontinued
If chemotherapy will be continued, please specify
the nature of the regimen used
monotherapy (1)
combination therapy (2)
Please specify the agent used for chemotherapy
Carboplatin (1)
Paclitaxel (2)
Gemcitabine (used on first or eighth day
of cycle) (3)
Doxorubicin liposome (4)
other (5)
Please specify other chemotherapeutic agent
used
Dose of Carboplatin administerd
AUC
Dose of Paclitaxel administered
mg/m2
Dose of Gemcitabine administered
mg/m2
Dose of Doxorubicin liposome administered
mg/m2
Dose of other antineoplastic agent administered
mg/m2
Course of chemotherapy cycle
Date of second chemotherapy cycle
Total dose of Carboplatin administered
mg
Has the dose been modified?
Yes
No
Please specify what kind of dose modification
was used
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Dose reduction (1)
Delay/Deceleration (2)
Discontinuation (3)
Please specify the reason for the dose
modification
hematologic toxicity  (1)
hypersensitivity  (2)
other (3)
Total dose of Paclitaxel administered
mg
Has the dose been modified?
Yes
No
Please specify what kind of dose modification
was used
Dose reduction (1)
Delay/Deceleration (2)
Discontinuation (3)
Please specify the reason for the dose
modification
hematologic toxicity  (1)
hypersensitivity  (2)
other (3)
Total dose of Gemcitabine administered
mg
Has the dose been modified?
Yes
No
Please specify what kind of dose modification
was used
Dose reduction (1)
Delay/Deceleration (2)
Discontinuation (3)
Please specify the reason for the dose
modification
hematologic toxicity  (1)
hypersensitivity  (2)
other (3)
Total dose of doxorubicin liposome administered
mg
Has the dose been modified?
Yes
No
Please specify what kind of dose modification
has been used
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Dose reduction (1)
Delay/Deceleration (2)
Discontinuation (3)
Please specify the reason for the dose
modification
hematologic toxicity  (1)
hypersensitivity  (2)
other (3)
Total dose of other chemotherapeutic agent
administered
mg
Has the dose been modified?
Yes
No
Please specify what kind of dose modification
has been used
Dose reduction (1)
Delay/Deceleration (2)
Discontinuation (3)
Please specify the reason for the dose
modification
hematologic toxicity  (1)
hypersensitivity  (2)
other (3)
Any further oncologic treatments?
Yes
No
Please specify any further antineoplastic
treatments that have been carried out.
Confirmation of correctness
Name of Investigator
Signature by investigator: I personally controlled
all entries into this form for this patient. All data
and statements in this CRF are complete and
correct
Date of completion of this form
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Case Report Form (HIPEC) Visit 11
Visit 11: Third cycle of post-OP
Chemotherapy
Patient ID
CRF number
Date of visit
Status of Patient and recording of CTCAE
Has patient appeared for the planned visit?
Yes
No
If patient didn´t come for the scheduled visit,
please call the patient and try to verify the reason
why.
Is the Patient deceased?
Yes
No
Please specify the date the patient died
Has a progressive disease been diagnosed?
Yes
No
Please give the date, the progression was
diagnosed
Recurrent Disease
Yes
No
Please give the date, the relapse was diagnosed
Yes
No
Recording of CTCAE: Have any AE occurred
since the last Visit? If `Yes` please fill in AE-Form
Yes
No
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Postoperative intravenous chemotherapy
Postoperative chemotherapy will be continued
Yes
No
Please specify the reason why, if chemotherapy
will be discontinued
If chemotherapy will be continued, please specify
the nature of the regimen used
monotherapy (1)
combination therapy (2)
Please specify the agent used for chemotherapy
Carboplatin (1)
Paclitaxel (2)
Gemcitabine (used on first or eighth day
of cycle) (3)
Doxorubicin liposome (4)
other (5)
Please specify other chemotherapeutic agent
used
Dose of Carboplatin administered
AUC
Dose of Paclitaxel administered
mg/m2
Dose of Gemcitabine administered
mg/m2
Dose of Doxorubicin liposome administered
mg/m2
Dose of other antineoplastic agent administered
mg/m2
Course of chemotherapy cycle
Date of third chemotherapy cycle
Total dose of Carboplatin administered
mg
Has the dose been modified?
Yes
No
Please specify what kind of dose modification
was used
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Dose reduction (1)
Delay/Deceleration (2)
Discontinuation (3)
Please specify the reason for the dose
modification
hematologic toxicity  (1)
hypersensitivity  (2)
other (3)
Total dose of Paclitaxel administered
mg
Has the dose been modified?
Yes
No
Please specify what kind of dose modification
was used
Dose reduction (1)
Delay/Deceleration (2)
Discontinuation (3)
Please specify the reason for the dose
modification
hematologic toxicity  (1)
hypersensitivity  (2)
other (3)
Total dose of Gemcitabine administered
mg
Has the dose been modified?
Yes
No
Please specify what kind of dose modification
was used
Dose reduction (1)
Delay/Deceleration (2)
Discontinuation (3)
Please specify the reason for the dose
modification
hematologic toxicity  (1)
hypersensitivity  (2)
other (3)
Total dose of doxorubicin liposome administered
mg
Has the dose been modified?
Yes
No
Please specify what kind of dose modification
has been used
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Dose reduction (1)
Delay/Deceleration (2)
Discontinuation (3)
Please specify the reason for the dose
modification
hematologic toxicity  (1)
hypersensitivity  (2)
other (3)
Total dose of other chemotherapeutic agent
administered
mg
Has the dose been modified?
Yes
No
Please specify what kind of dose modification
has been used
Dose reduction (1)
Delay/Deceleration (2)
Discontinuation (3)
Please specify the reason for the dose
modification
hematologic toxicity  (1)
hypersensitivity  (2)
other (3)
Any further oncologic treatments?
Yes
No
Please specify any further antineoplastic
treatments that have been carried out.
Confirmation of correctness
Name of Investigator
Signature by investigator: I personally controlled
all entries into this form for this patient. All data
and statements in this CRF are complete and
correct
Date of completion of this form
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Bonn Sigmund-Freud-Str. 25 53105 Bonn Sponsor:
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Case Report Form (HIPEC) Visit 12
Visit 12: Fourth cycle of post-OP
Chemotherapy
Patient ID
CRF number
Date of visit
Status of Patient and recording of CTCAE
Has patient appeared for the planned visit?
Yes
No
If patient didn´t come for the scheduled visit,
please call the patient and try to verify the reason
why.
Is the Patient deceased?
Yes
No
Please specify the date the patient died
Has a progressive disease been diagnosed?
Yes
No
Please give the date, the progression was
diagnosed
Recurrent Disease
Yes
No
Please give the date, the relapse was diagnosed
Yes
No
Recording of CTCAE: Have any AE occurred
since the last Visit? If `Yes` please fill in AE-Form
Yes
No
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Postoperative intravenous chemotherapy
Postoperative chemotherapy will be continued
Yes
No
Please specify the reason why, if chemotherapy
will be discontinued
If chemotherapy will be continued, please specify
the nature of the regimen used
monotherapy (1)
combination therapy (2)
Please specify the agent used for chemotherapy
Carboplatin (1)
Paclitaxel (2)
Gemcitabine (used on first or eighth day
of cycle) (3)
Doxorubicin liposome (4)
other (5)
Please specify other chemotherapeutic agent
used
Dose of Carboplatin administered
AUC
Dose of Paclitaxel administered
mg/m2
Dose of Gemcitabine administered
mg/m2
Dose of Doxorubicin liposome administered
mg/m2
Dose of other antineoplastic agent administered
mg/m2
Course of chemotherapy cycle
Date of third chemotherapy cycle
Total dose of Carboplatin administered
mg
Has the dose been modified?
Yes
No
Please specify what kind of dose modification
was used
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Dose reduction (1)
Delay/Deceleration (2)
Discontinuation (3)
Please specify the reason for the dose
modification
hematologic toxicity  (1)
hypersensitivity  (2)
other (3)
Total dose of Paclitaxel administered
mg
Has the dose been modified?
Yes
No
Please specify what kind of dose modification
was used
Dose reduction (1)
Delay/Deceleration (2)
Discontinuation (3)
Please specify the reason for the dose
modification
hematologic toxicity  (1)
hypersensitivity  (2)
other (3)
Total dose of Gemcitabine administered
mg
Has the dose been modified?
Yes
No
Please specify what kind of dose modification
was used
Dose reduction (1)
Delay/Deceleration (2)
Discontinuation (3)
Please specify the reason for the dose
modification
hematologic toxicity  (1)
hypersensitivity  (2)
other (3)
Total dose of doxorubicin liposome administered
mg
Has the dose been modified?
Yes
No
Please specify what kind of dose modification
has been used
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Dose reduction (1)
Delay/Deceleration (2)
Discontinuation (3)
Please specify the reason for the dose
modification
hematologic toxicity  (1)
hypersensitivity  (2)
other (3)
Total dose of other chemotherapeutic agent
administered
mg
Has the dose been modified?
Yes
No
Please specify what kind of dose modification
has been used
Dose reduction (1)
Delay/Deceleration (2)
Discontinuation (3)
Please specify the reason for the dose
modification
hematologic toxicity  (1)
hypersensitivity  (2)
other (3)
Any further oncologic treatments?
Yes
No
Please specify any further antineoplastic
treatments that have been carried out.
Confirmation of correctness
Name of Investigator
Signature by investigator: I personally controlled
all entries into this form for this patient. All data
and statements in this CRF are complete and
correct
Date of completion of this form
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Case Report Form (HIPEC) Visit 13
Visit 13: Fifth cycle of post-OP
Chemotherapy
Patient ID
CRF number
Date of visit
Status of Patient and recording of CTCAE
Has patient appeared for the planned visit?
Yes
No
If patient didn´t come for the scheduled visit,
please call the patient and try to verify the reason
why.
Is the Patient deceased?
Yes
No
Please specify the date the patient died
Has a progressive disease been diagnosed?
Yes
No
Please give the date, the progression was
diagnosed
Recurrent Disease
Yes
No
Please give the date, the relapse was diagnosed
Yes
No
Recording of CTCAE: Have any AE occurred
since the last Visit? If `Yes` please fill in AE-Form
Yes
No
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Postoperative intravenous chemotherapy
Postoperative chemotherapy will be continued
Yes
No
Please specify the reason why, if chemotherapy
will be discontinued
If chemotherapy will be continued, please specify
the nature of the regimen used
monotherapy (1)
combination therapy (2)
Please specify the agent used for chemotherapy
Carboplatin (1)
Paclitaxel (2)
Gemcitabine (used on first or eighth day
of cycle) (3)
Doxorubicin liposome (4)
other (5)
Please specify other chemotherapeutic agent
used
Dose of Carboplatin administered
AUC
Dose of Paclitaxel administered
mg/m2
Dose of Gemcitabine administered
mg/m2
Dose of Doxorubicin liposome administered
mg/m2
Dose of other antineoplastic agent administered
mg/m2
Course of chemotherapy cycle
Date of third chemotherapy cycle
Total dose of Carboplatin administered
mg
Has the dose been modified?
Yes
No
Please specify what kind of dose modification
was used
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Dose reduction (1)
Delay/Deceleration (2)
Discontinuation (3)
Please specify the reason for the dose
modification
hematologic toxicity  (1)
hypersensitivity  (2)
other (3)
Total dose of Paclitaxel administered
mg
Has the dose been modified?
Yes
No
Please specify what kind of dose modification
was used
Dose reduction (1)
Delay/Deceleration (2)
Discontinuation (3)
Please specify the reason for the dose
modification
hematologic toxicity  (1)
hypersensitivity  (2)
other (3)
Total dose of Gemcitabine administered
mg
Has the dose been modified?
Yes
No
Please specify what kind of dose modification
was used
Dose reduction (1)
Delay/Deceleration (2)
Discontinuation (3)
Please specify the reason for the dose
modification
hematologic toxicity  (1)
hypersensitivity  (2)
other (3)
Total dose of doxorubicin liposome administered
mg
Has the dose been modified?
Yes
No
Please specify what kind of dose modification
has been used
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Dose reduction (1)
Delay/Deceleration (2)
Discontinuation (3)
Please specify the reason for the dose
modification
hematologic toxicity  (1)
hypersensitivity  (2)
other (3)
Total dose of other chemotherapeutic agent
administered
mg
Has the dose been modified?
Yes
No
Please specify what kind of dose modification
has been used
Dose reduction (1)
Delay/Deceleration (2)
Discontinuation (3)
Please specify the reason for the dose
modification
hematologic toxicity  (1)
hypersensitivity  (2)
other (3)
Any further oncologic treatments?
Yes
No
Please specify any further antineoplastic
treatments that have been carried out.
Confirmation of correctness
Name of Investigator
Signature by investigator: I personally controlled
all entries into this form for this patient. All data
and statements in this CRF are complete and
correct
Date of completion of this form
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Visit 13 Phase 1 clinical trial for intrasurgical hyperthermic intraperitoneal
chemoperfusion with cisplatin (HIPEC) in patients with ovarian cancer recidiv
Visit 14 Phase 1 clinical trial for intrasurgical hyperthermic intraperitoneal
chemoperfusion with cisplatin (HIPEC) in patients with ovarian cancer recidiv
Phase 1 clinical trial for intrasurgical hyperthermic
intraperitoneal chemoperfusion with cisplatin (HIPEC) in
patients with ovarian cancer recidiv EudraCT Nr.: 2010-
024352-28 Principal investigator und authorized
representative of Sponsor: PD Dr. med. Oliver Zivanovic
Center for Obstetrics and Gynaecology University Hospital
Bonn Sigmund-Freud-Str. 25 53105 Bonn Sponsor:
Rheinische Friedrich-Wilhelms-Universität Bonn
represented by the Dean of Medical Faculty
All rights reserved. Please visit https://medical-data-
models.org/forms/13573
Case Report Form (HIPEC) Visit 14
Visit 14: Sixth cycle of post-OP
Chemotherapy
Patient ID
CRF number
Date of visit
Status of Patient and recording of CTCAE
Has patient appeared for the planned visit?
Yes
No
If patient didn´t come for the scheduled visit,
please call the patient and try to verify the reason
why.
Is the Patient deceased?
Yes
No
Please specify the date the patient died
Has a progressive disease been diagnosed?
Yes
No
Please give the date, the progression was
diagnosed
Recurrent Disease
Yes
No
Please give the date, the relapse was diagnosed
Yes
No
Recording of CTCAE: Have any AE occurred
since the last Visit? If `Yes` please fill in AE-Form
Yes
No
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Postoperative intravenous chemotherapy
Postoperative chemotherapy will be continued
Yes
No
Please specify the reason why, if chemotherapy
will be discontinued
If chemotherapy will be continued, please specify
the nature of the regimen used
monotherapy (1)
combination therapy (2)
Please specify the agent used for chemotherapy
Carboplatin (1)
Paclitaxel (2)
Gemcitabine (used on first or eighth day
of cycle) (3)
Doxorubicin liposome (4)
other (5)
Please specify other chemotherapeutic agent
used
Dose of Carboplatin administered
AUC
Dose of Paclitaxel administered
mg/m2
Dose of Gemcitabine administered
mg/m2
Dose of Doxorubicin liposome administered
mg/m2
Dose of other antineoplastic agent administered
mg/m2
Course of chemotherapy cycle
Date of third chemotherapy cycle
Total dose of Carboplatin administered
mg
Has the dose been modified?
Yes
No
Please specify what kind of dose modification
was used
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Visit 14 Phase 1 clinical trial for intrasurgical hyperthermic intraperitoneal
chemoperfusion with cisplatin (HIPEC) in patients with ovarian cancer recidiv
Dose reduction (1)
Delay/Deceleration (2)
Discontinuation (3)
Please specify the reason for the dose
modification
hematologic toxicity  (1)
hypersensitivity  (2)
other (3)
Total dose of Paclitaxel administered
mg
Has the dose been modified?
Yes
No
Please specify what kind of dose modification
was used
Dose reduction (1)
Delay/Deceleration (2)
Discontinuation (3)
Please specify the reason for the dose
modification
hematologic toxicity  (1)
hypersensitivity  (2)
other (3)
Total dose of Gemcitabine administered
mg
Has the dose been modified?
Yes
No
Please specify what kind of dose modification
was used
Dose reduction (1)
Delay/Deceleration (2)
Discontinuation (3)
Please specify the reason for the dose
modification
hematologic toxicity  (1)
hypersensitivity  (2)
other (3)
Total dose of doxorubicin liposome administered
mg
Has the dose been modified?
Yes
No
Please specify what kind of dose modification
has been used
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Visit 14 Phase 1 clinical trial for intrasurgical hyperthermic intraperitoneal
chemoperfusion with cisplatin (HIPEC) in patients with ovarian cancer recidiv
Dose reduction (1)
Delay/Deceleration (2)
Discontinuation (3)
Please specify the reason for the dose
modification
hematologic toxicity  (1)
hypersensitivity  (2)
other (3)
Total dose of other chemotherapeutic agent
administered
mg
Has the dose been modified?
Yes
No
Please specify what kind of dose modification
has been used
Dose reduction (1)
Delay/Deceleration (2)
Discontinuation (3)
Please specify the reason for the dose
modification
hematologic toxicity  (1)
hypersensitivity  (2)
other (3)
Any further oncologic treatments?
Yes
No
Please specify any further antineoplastic
treatments that have been carried out.
Confirmation of correctness
Name of Investigator
Signature by investigator: I personally controlled
all entries into this form for this patient. All data
and statements in this CRF are complete and
correct
Date of completion of this form
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Visit 14 Phase 1 clinical trial for intrasurgical hyperthermic intraperitoneal
chemoperfusion with cisplatin (HIPEC) in patients with ovarian cancer recidiv
Adverse Events Phase 1 clinical trial for intrasurgical hyperthermic intraperitoneal
chemoperfusion with cisplatin (HIPEC) in patients with ovarian cancer recidiv
Phase 1 clinical trial for intrasurgical hyperthermic
intraperitoneal chemoperfusion with cisplatin (HIPEC) in
patients with ovarian cancer recidiv EudraCT Nr.: 2010-
024352-28 Principal investigator und authorized
representative of Sponsor: PD Dr. med. Oliver Zivanovic
Center for Obstetrics and Gynaecology University Hospital
Bonn Sigmund-Freud-Str. 25 53105 Bonn Sponsor:
Rheinische Friedrich-Wilhelms-Universität Bonn
represented by the Dean of Medical Faculty
All rights reserved. Please visit https://medical-data-
models.org/forms/13575
Case Report Form (HIPEC) Adverse
Events
Adverse Events Form
Patient ID
CRF number
Serial number of the Adverse Event
Please describe the Adverse Event, using
CTCAE designations
Adverse Event Start Date
Adverse Event End Date
Is the Adverse Event Ongoing?
Yes
No
CTCAE Grade
0 (0)
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
Was the Adverse Event serious (SAE)?
Yes
No
Criteria for serious adverse events, please
specify
fatal (1)
life threatening (2)
hospitalization/prolonged stay at hospital
(3)
permanent or severe disability (4)
congenital abberation/birth defect (5)
Please give the date, the adverse event turned
out to be serious
Adverse Event Outcome
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Recovered (1)
Subsiding (2)
Continuing (3)
resolved with sequelae (4)
increased symptoms (5)
fatal (6)
unknown (7)
Causality with trial substance
confirmed (1)
probable (2)
possible (3)
unlikely (4)
Adverse event treatment
Yes
No
Please specify treatment given for this adverse
event
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Adverse Events Phase 1 clinical trial for intrasurgical hyperthermic intraperitoneal
chemoperfusion with cisplatin (HIPEC) in patients with ovarian cancer recidiv
Concomitant medication Phase 1 clinical trial for intrasurgical hyperthermic
intraperitoneal chemoperfusion with cisplatin (HIPEC) in patients with ovarian
cancer recidiv
Phase 1 clinical trial for intrasurgical hyperthermic
intraperitoneal chemoperfusion with cisplatin (HIPEC) in
patients with ovarian cancer recidiv EudraCT Nr.: 2010-
024352-28 Principal investigator und authorized
representative of Sponsor: PD Dr. med. Oliver Zivanovic
Center for Obstetrics and Gynaecology University Hospital
Bonn Sigmund-Freud-Str. 25 53105 Bonn Sponsor:
Rheinische Friedrich-Wilhelms-Universität Bonn
represented by the Dean of Medical Faculty
All rights reserved. Please visit https://medical-data-
models.org/forms/13576
Case Report Form (HIPEC)
Concomitant medication
Concomitant Medication Form
Patient ID
CRF number
Concomitant agent name or generic substance
Please specify the daily dose of given medication
Please specify the unit of the daily dose
Dosage form
Tablet (1)
creme (2)
spray (3)
injection (4)
suppository (5)
oral drops/solution (6)
infusion (7)
Drug administration route
intramuscular (1)
intravenous (2)
per os (3)
subcutaneous (4)
transdermal (5)
inhalative (6)
rectally (7)
Indication for concomitant medication
Concomitant agent start date
Concomitant agent end date
Continuing treatment with concomitant
medication
Yes
No
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Initial Assessments Mobil-c1 Items Cardiac Innervation In Genetic
Models Of Arrhythmia In Humans And Mice EudraCT 2006-002767-41
The primary purpose is to investigate the autonomic
nervous system using positron emission tomography (PET)
in genotyped longQT syndrome patients and corresponding
mouse model and compare the results with the genetic
subtype, the phenotype and the role of the autonomic
nervous system in the onset of tachyarrhythmias. 
See https://www.clinicaltrialsregister.eu/ctr-
search/trial/2006-002767-41/DE#E
All rights reserved. Please visit https://medical-data-
models.org/forms/13584
Initial Assessments Mobil-c1 Items
Cardiac Innervation In Genetic
Models Of Arrhythmia In Humans
And Mice EudraCT 2006-002767-41
Prescan Checklist
Body Height
cm
Body weight
kg
Date of birth
Gender
female (female)
male (male)
written informed consent obtained on
LQT Genotype determination
LQT1 (1)
LQT2 (2)
LQT3 (3)
Control (4)
Tracer
C11MQNB (1)
C11mHED (2)
Pregnancy test
Date
Time
Pregnancy test not obtained, because
If a test was performed, please specify result
Negative (1)
Positive (2)
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SPE-Scale
Tool to evaluate a subjective prognosis of ability to work
Source:
Mittag O, Glaser-Möller N, Ekkernkamp M, Matthis C,
Héon-Klin V, Raspe A, Raspe H (2003). 
Predictive validity of a short scale for a subjective prognosis
of a persons ability to work (SPE-Scale) in a cohort of LVA-
insured patients with severe back pain or functional
complaints in internal medicine. Social and preventive
medicine 48:361-369
All rights reserved. Please visit https://medical-data-
models.org/forms/13586
SPE-Scale
Evaluation of general health and
vocational ability
Wenn Sie an Ihren derzeitigen
Gesundheitszustand und Ihre berufliche
Leistungsfähigkeit denken: Glauben Sie, dass Sie
bis zum Erreichen des Rentenalters berufstätig
sein können?
sicher (1)
eher (2)
unsicher (3)
eher auf (4)
keinen Fall (5)
Sehen Sie durch Ihren derzeitigen
Gesundheitszustand Ihre Erwerbsfähigkeit
dauerhaft gefährdet?
<= 1
>= 1
Ja
Nein
Tragen Sie sich zur Zeit mit dem Gedanken,
einen Rentenantrag (Frührente aus
Gesundheitsgründen) zu stellen?
>= 1
<= 1
Ja
Nein
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Eligibility Acute Lymphoblastic Leukemia
NCT02336282
Treatment for Executive Dysfunction in Adult Survivors of
Childhood Acute Lymphoblastic Leukemia; ODM derived
from: https://clinicaltrials.gov/show/NCT02336282
All rights reserved. Please visit https://medical-data-
models.org/forms/13587
Eligibility Acute Lymphoblastic
Leukemia NCT02336282
Inclusion Criteria
current st. jude life (sjlife) protocol participant*
Yes
No
long term survivor of acute lymphoblastic
leukemia (all)*
Yes
No
currently ≥ 18 years of age*
Yes
No
wi-fi internet access at home*
Yes
No
history of executive dysfunction, documented by
neurocognitive testing, and defined as having an
age-adjusted standard score <10th percentile on
trail making test part b, verbal fluency, or digit
span backward.*
Yes
No
history of self-reported executive dysfunction in
daily life, defined as having a standardized score
<10th percentile on brief initiate, shift, or working
memory domains or having scored <10th
percentile on the childhood cancer survivor study
neurocognitive questionnaire task efficiency of
memory domains.*
Yes
No
participant is able to speak and understand the
english language.*
Yes
No
Exclusion Criteria
any survivor with full scale intelligence quotient
(iq) <80*
Yes
No
currently on stimulants or other medications
intended to treat cognitive impairment*
Yes
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No
history of seizures*
Yes
No
no implanted medical devices or implanted metal
in the head*
Yes
No
currently pregnant or planning to become
pregnant.*
Yes
No
inability or unwillingness of research participant
or legal guardian/representative to give written
informed consent.*
Yes
No
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Eligibility Acute Lymphoblastic Leukemia NCT02336282
Eligibility Acute Lymphoblastic Leukemia
NCT02451774
Pentoxifylline In Pediatric Acute Lymphoblastic Leukemia
During Induction; ODM derived from:
https://clinicaltrials.gov/show/NCT02451774
All rights reserved. Please visit https://medical-data-
models.org/forms/13588
Eligibility Acute Lymphoblastic
Leukemia NCT02451774
Inclusion Criteria
pediatric and teenaged patients of both genders
≤18 years of age with newly diagnosed acute
lymphoblastic leukemia in accordance with
french-american-british criteria and under
immunophenotypical classification and paired
within the risk-classification group.*
Yes
No
patients with ≥20 kg of weight at the time of
treatment assignment.*
Yes
No
patients who are able to swallow the medicine*
Yes
No
patients agreeing to enter the protocol by the
signing of informed consent by the parent*
Yes
No
patients who could give their assent to enter the
protocol*
Yes
No
the parent or guardian must be able to read.*
Yes
No
Exclusion Criteria
patients with treatment adherence of ≥80
percent*
Yes
No
patients or their parents who decide to abandon
the study or who withdraw consent for
participation*
Yes
No
patients who present grade iii or higher adverse
event.*
Yes
No
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patients previously treated with chemotherapy
and/or radiotherapy*
Yes
No
history of peptic acid disease or gastrointestinal
bleeding*
Yes
No
known pentoxifylline intolerance and general
intolerance to xanthine, caffeine or theophylline*
Yes
No
patients in treatment with anticoagulants,
cimetidine, ciprofloxacin, or theophylline*
Yes
No
patients with down syndrome*
Yes
No
patients with several bleeding or extensive retinal
hemorrhage, several cardiac arrhythmias
(paroxysmal supraventricular tachycardia,
congenital atrioventricular block, arrhythmias
associated with congenital heart disease, digital
poisoning,  and patients after cardiac surgery,
hypoxia, hypercapnia, and electrolyte
disturbances)*
Yes
No
patients with hypotension*
Yes
No
several liver failures*
Yes
No
bleeding diathesis (for bleeding disorders or
anticoagulant medication)*
Yes
No
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Eligibility Acute Lymphoblastic Leukemia NCT02451774
Eligibility Peripheral T Cell Lymphoma
NCT00970385
Study About Treatment of Newly Diagnosed Non
Cutaneous Peripheral T Cell Lymphoma; ODM derived
from: https://clinicaltrials.gov/show/NCT00970385
All rights reserved. Please visit https://medical-data-
models.org/forms/13594
Eligibility Peripheral T Cell
Lymphoma NCT00970385
Inclusion Criteria
newly diagnosed untreated ptcl*
Yes
No
age 18 and 70 years*
Yes
No
performance status ≤ 2*
Yes
No
ann arbor stage i to iv*
Yes
No
normal cardiac ventricular ejection fraction over
50%*
Yes
No
normal hepatic function (asat, alat, pal < 2.5 uln)*
Yes
No
Exclusion Criteria
cutaneous form of ptcl*
Yes
No
previous treatment*
Yes
No
age < 18 and > 70*
Yes
No
performance status > 2*
Yes
No
abnormal cardiac or hepatic functions*
Yes
No
hiv-, hcv- or hbv- positivity*
Yes
No
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Eligibility Prostate Cancer NCT00201916
Shorter Radiation Schedule for the Treatment of Prostate
Cancer; ODM derived from:
https://clinicaltrials.gov/show/NCT00201916
All rights reserved. Please visit https://medical-data-
models.org/forms/13595
Eligibility Prostate Cancer
NCT00201916
Inclusion Criteria
histologic diagnosis of adenocarcinoma of the
prostate with no evidence of metastatic disease
to the nodes, bone or lung*
Yes
No
stage t1a moderately or poorly differentiated, t1b,
t1c or t2 by the current uicc-tnm classification*
Yes
No
Exclusion Criteria
psa > 40 mcg/l*
Yes
No
previous therapy for carcinoma of the prostate
other than biopsy or turp, including patients
previously on hormone therapy for treatment of
their prostate cancer*
Yes
No
prior or active malignancy other than non-
melanoma skin cancer; or colon or thyroid cancer
treated a minimum of five years prior to study
entry and presumed cured*
Yes
No
simulated volume exceeds 1000 cm3*
Yes
No
previous pelvic radiotherapy*
Yes
No
inflammatory bowel disease*
Yes
No
serious non-malignant disease which would
preclude radiotherapy or surgical biopsy*
Yes
No
geographic inaccessibility for follow-up*
Yes
No
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psychiatric or addictive disorder which would
preclude obtaining informed consent or
adherence to protocol*
Yes
No
unable to commence radiation therapy within 26
weeks of the date of last prostatic biopsy*
Yes
No
failure to give informed consent to participate in
the study*
Yes
No
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Eligibility Prostate Cancer NCT00201916
Eligibility Dementia NCT00009204
Serotonergic Pharmacotherapy for Agitation of Dementia;
ODM derived from:
https://clinicaltrials.gov/show/NCT00009204
All rights reserved. Please visit https://medical-data-
models.org/forms/13596
Eligibility Dementia NCT00009204
Inclusion Criteria
meets dsm-iv criteria for diagnosis of dementia of
the alzheimer's type (ad), vascular dementia (vd),
mixed (ad and vd) or dementia nos (not otherwise
specified)*
Yes
No
presents with psychosis or behavioral problems
severe enough to endanger the patient's health,
well-being or safety, as evidenced by a score     of
at least 3 (moderate) on one of the
neurobehavioral rating scale (nbrs) agitation
items (8,11,14) or psychosis items (16,18,20) and
are not secondary to physical illness nor
amenable to environmental optimization*
Yes
No
able to participate in study evaluations and ingest
oral medication*
Yes
No
has next of kin or a guardian available to consent
to patient's participation.*
Yes
No
Exclusion Criteria
has an unstable medical illness including
significant cardiac (specifically bradycardia with
ventricular rate below 50), renal, hepatic, or
neurological illness (especially parkinson's
disease) other than dementia*
Yes
No
meets dsm-iv criteria for delirium upon
admission to western psychiatric institute and
clinic*
Yes
No
has been medicated within 4 weeks of protocol
admission with fluoxetine or 2 weeks with a
monoamine oxidase inhibitor (patients will
undergo a monitored psychotropic drug washout
prior to entering the protocol)*
Yes
No
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is currently being treated with cognitive
enhancing drugs (tacrine or aricept) or any
experimental drug*
Yes
No
has a concurrent diagnosis of schizophrenia,
bipolar disorder, or major depression*
Yes
No
has preexisting orthostatic hypotension (with > 20
mmhg change from sitting to standing pressure)*
Yes
No
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Eligibility Dementia NCT00009204
Eligibility Hepatitis B NCT00697840
Safety, Immunogenicity and Reactogenicity of Recombinant
Hepatitis B Vaccine (Adjuvanted & New Formulation) and
Engerix™-B; ODM derived from:
https://clinicaltrials.gov/show/NCT00697840
All rights reserved. Please visit https://medical-data-
models.org/forms/13597
Eligibility Hepatitis B NCT00697840
Inclusion Criteria
between 18 and 40 years old.*
Yes
No
written informed consent will have been obtained
from the subjects.*
Yes
No
good physical condition as established by
physical examination and history taking at the
time of entry.*
Yes
No
female participants will avoid becoming pregnant
during the study period and they will have been
on a contraceptive program for at least 2 months
before entry*
Yes
No
Exclusion Criteria
pregnancy or lactation.*
Yes
No
positive titres for anti hbs antibody.*
Yes
No
any vaccination against hepatitis b in the past.*
Yes
No
any previous administration of mpl.*
Yes
No
elevated serum liver enzymes.*
Yes
No
history of significant and persisting hematologic,
hepatic, renal, cardiac or respiratory disease.*
Yes
No
axillary temperature > 37.5°c at the time of
injection.*
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Yes
No
any acute disease at the moment of entry.*
Yes
No
chronic alcohol consumption.*
Yes
No
any treatment with immunosuppressive or
immunostimulant therapy.*
Yes
No
any chronic drug treatment, which in the
investigator's opinion, precludes inclusion into the
study.*
Yes
No
history of allergic disease likely to be stimulated
by any component of the vaccine.*
Yes
No
simultaneous administration of any other
vaccine(s).*
Yes
No
administration of any immunoglobulin during the
study period.*
Yes
No
simultaneous participation in any other clinical
trial.*
Yes
No
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Eligibility Hepatitis B NCT00697840
NINDS CDE Diagnosis Criteria Summary
Amyotrophic Lateral Sclerosis
NINDS Common Data Elements (Diagnosis Criteria
Summary Amyotrophic Lateral Sclerosis) Used from the
National Institute of Neurological Disorders and Stroke
Common Data Elements
(https://www.commondataelements.ninds.nih.gov/)
References: Grinnon ST, Miller K, Marler JR, Lu Y, Stout A,
Odenkirchen J, Kunitz S. National Institute of Neurological
Disorders and Stroke Common Data Element Project -
approach and methods. Clin Trials. 2012;9(3):322-9.
All rights reserved. Please visit https://medical-data-
models.org/forms/13602
Diagnosis Criteria Summary
Symptom/Sign/Diagnosis Criteria
Summary Information
Study-ID
Study site name
Subject ID
Symptom onset date
Date of diagnosis
What is the patients classification?
ALS (1)
Upper motor neuron predominant (2)
Lower motor neuron predominant (3)
PLS (4)
Site of onset of progressive weakness (select
one):
Bulbar (1)
Truncal (2)
Generalized (3)
Respiratory (4)
Upper Limb (5)
Lower Limb (6)
Bulbar UMN-Clinical
Yes (1)
No (2)
Not Assessed (3)
Truncal UMN-Clinical
Yes (1)
No (2)
Not assessed (3)
Generalized UMN - Clinical
Yes (1)
No (2)
Not assessed (3)
Respiratory UMN-Clinical
Yes (1)
No (2)
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Not assessed (3)
Upper Limb UMN-Clinical
Yes (1)
No (2)
Not assessed (3)
Lower Limb UMN-Clinical
Yes (1)
No (2)
Not assessed (3)
Bulbar LMN-Clinical
Yes (1)
No (2)
Not assessed (2)
Truncal LMN-Clinical
Yes (1)
No (2)
Not assessed (3)
Generalized LMN-Clinical
Yes (1)
No (2)
Not assessed (3)
Upper Limb LMN-Clinical
Yes (1)
No (2)
Not assessed (3)
Lower Limb LMN-Clinical
Yes (1)
No (2)
Not assessed (3)
Revised El Escorial Criteria
Definite (1)
Probable (2)
Lab-supported probable (3)
Possible (4)
Familial (5)
Awaji criteria
definite (1)
probable (2)
possible (3)
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NINDS CDE Diagnosis Criteria Summary Amyotrophic Lateral Sclerosis
NINDS CDE Genetics Amyotrophic Lateral
Sclerosis
NINDS Common Data Elements (Genetics Amyotrophic
Lateral Sclerosis) Used from the National Institute of
Neurological Disorders and Stroke Common Data Elements
(https://www.commondataelements.ninds.nih.gov/)
References: Grinnon ST, Miller K, Marler JR, Lu Y, Stout A,
Odenkirchen J, Kunitz S. National Institute of Neurological
Disorders and Stroke Common Data Element Project -
approach and methods. Clin Trials. 2012;9(3):322-9.
All rights reserved. Please visit https://medical-data-
models.org/forms/13606
NINDS CDE Genetics
Genetics
Has the SOP1 Gene been screened?
Yes
No
Was the SOP1 gene positive?
Yes
No
Has the FUS gene been screened?
Yes
No
Was the screening of FUS gene positive?
Yes
No
Has the TDP43 gene been screened?
Yes
No
Was the sceening of TDP43 gene positive?
Yes
No
Hast the VCP gene been screened?
Yes
No
Was the screening of VCP gene positive?
Yes
No
Has the C9ORF72 gene been screened?
Yes
No
Was the screening of C9ORF72 gene positive?
Yes
No
Please specify the mutation
Have you given a blood sample to a repository?
Yes
No
If you have given a blood sample to a repository,
please give the name of the repository
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Eligibility Leukemia NCT00002705
Topotecan in Treating Children With Refractory Leukemia;
ODM derived from:
https://clinicaltrials.gov/show/NCT00002705
All rights reserved. Please visit https://medical-data-
models.org/forms/13611
Eligibility Leukemia NCT00002705
Criteria
histologically or cytologically confirmed leukemia
refractory to conventional therapy or for which no
effective curative therapy exists*
Yes
No
age: under 21*
Yes
No
performance status: ecog 0-2*
Yes
No
life expectancy: at least 8 weeks*
Yes
No
adequate platelet count and hemoglobin required
(transfusion allowed)*
Yes
No
bilirubin no greater than 1.5 mg/dl*
Yes
No
ast or alt no greater than 2 times normal*
Yes
No
creatinine less than 1.5 mg/dl*
Yes
No
adequate nutritional status, e.g. higher than third
percentile weight for height*
Yes
No
albumin at least 3 g/dl*
Yes
No
no severe uncontrolled infection*
Yes
No
no pregnant women*
Yes
No
effective contraception required of fertile women*
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Yes
No
at least 3 weeks since systemic chemotherapy (6
weeks since nitrosoureas)*
Yes
No
recovered at least 3 months since bone marrow
transplant (at least 6 months since total-body
irradiation)*
Yes
No
no concurrent anticancer therapy*
Yes
No
no concurrent treatment studies*
Yes
No
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Eligibility Leukemia NCT00002705
Eligibility Low-Grade or Follicular B-Cell
Non-Hodgkin's Lymphoma NCT00168740
Treatment of Relapsed Low-Grade or Follicular Lymphoma
With Rituximab (Also Known as Rituxan, IDEC-C2B8,
IDEC-102); ODM derived from:
https://clinicaltrials.gov/show/NCT00168740
All rights reserved. Please visit https://medical-data-
models.org/forms/13612
Eligibility Low-Grade or Follicular B-
Cell Non-Hodgkin's Lymphoma
NCT00168740
Inclusion Criteria
diagnosis of relapsed, low-grade or follicular b-
cell lymphoma*
Yes
No
cd20-positive lymphoma*
Yes
No
progressive, measurable disease*
Yes
No
sign informed consent*
Yes
No
3 weeks beyond standard therapy*
Yes
No
good performance status*
Yes
No
adequate hematologic, renal, and hepatic
function*
Yes
No
Exclusion Criteria
chronic lymphocytic leukemia*
Yes
No
lesions greater than or equal to 10 cm in
diameter*
Yes
No
cns lymphoma*
Yes
No
aids-related lymphoma*
Yes
No
pleural effusions or ascites secondary to
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lymphoma*
Yes
No
active, opportunistic infection*
Yes
No
serious nonmalignant disease*
Yes
No
prior investigational therapies, including prior anti-
cd20 therapy*
Yes
No
recent major surgery*
Yes
No
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Eligibility Low-Grade or Follicular B-Cell Non-Hodgkin's Lymphoma
NCT00168740
Eligibility Major Depression NCT00208702
Thyroid Medication and Antidepressants for Treating Major
Depression; ODM derived from:
https://clinicaltrials.gov/show/NCT00208702
All rights reserved. Please visit https://medical-data-
models.org/forms/13613
Eligibility Major Depression
NCT00208702
Inclusion Criteria
male or female between the ages of 18 and 60.
(the upper age is limited to 60 because thyroid
changes, including blunting of the tsh response to
trh occurs with age and can potentially confound
the relationship between the hpt axis and mdd.)*
Yes
No
primary diagnosis of unipolar major depressive
disorder*
Yes
No
ham-d (21 item) score >18*
Yes
No
Exclusion Criteria
alcohol abuse or alcohol dependence within the
past year.*
Yes
No
psychoactive substance abuse or dependence
within the past year.*
Yes
No
clinical evidence of severe personality disorder
that would make study participation and
completion unlikely.*
Yes
No
ect within the past 6 months.*
Yes
No
grade i hypothyroidism defined as low thyroid
hormone levels with an associated elevated tsh;
hyperthyroidism defined as elevated thyroid
hormone concentrations with a low tsh.*
Yes
No
serious and unstable medical illnesses.*
Yes
No
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Eligibility Multiple Sclerosis NCT00004816
A Maintenance Extension of Phase I Pilot Study of
Chimeric Anti-CD4 Antibody M-T412 in Patients With
Multiple Sclerosis; ODM derived from:
https://clinicaltrials.gov/show/NCT00004816
All rights reserved. Please visit https://medical-data-
models.org/forms/13614
Eligibility Multiple Sclerosis
NCT00004816
Criteria
diagnosis of chronic, advanced, progressive
multiple sclerosis (ms)*
Yes
No
biologic therapy: no sensitivity to murine proteins
no prior treatment at any time with anti-cd4
antibodies, other murine antibodies, or other anti-
t cell antibodies (e.g., xenologous or human) at
least 4 weeks since use of other biological
agents*
Yes
No
chemotherapy: no concomitant chemotherapy at
least 3 months since prior chemotherapy*
Yes
No
endocrine therapy: no concomitant steroidal
therapy at least 3 months since prior steroidal
therapy*
Yes
No
radiotherapy: no total lymphoid irradiation prior to
study no concomitant radiotherapy at least 3
months since prior radiotherapy*
Yes
No
other: no use of investigational drugs within 30
days prior to study*
Yes
No
age: 21 to 75*
Yes
No
hematopoietic: hemoglobin at least 10 g/dl wbc at
least 4000/mm3 granulocyte count at least
1500/mm3 platelet count at least 100,000/mm3
cd4+ lymphocyte count at least 300 cells/mm3*
Yes
No
other: not pregnant or lactating effective
contraception required of fertile patients for 3
months prior to and during study no substance
abuse (e.g., drug or alcohol) not hiv positive no
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aids-related complex (arc) no serum antibodies to
hiv negative serum antibody test for hiv within 1
month prior to study no underlying medical or
psychiatric condition*
Yes
No
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Eligibility Non-small Cell Lung Cancer
NCT00997724
Assisted-VATS Sleeve Lobectomy for Non-small Cell Lung
Cancer; ODM derived from:
https://clinicaltrials.gov/show/NCT00997724
All rights reserved. Please visit https://medical-data-
models.org/forms/13617
Eligibility Non-small Cell Lung
Cancer NCT00997724
Inclusion Criteria
histologically confirmed non-small cell lung
cancer (squamous, adenosquamous, large cell,
or poorly differentiated)*
Yes
No
patients with central tumors located at the origin
of a lobar bronchus.*
Yes
No
ecog performance status 0-1*
Yes
No
hematopoietic: wbc at least 4,000/mm^3; platelet
count at least 100,000/mm^3*
Yes
No
hepatic: bilirubin normal; ast/alt no greater than
1.5 times upper limit of normal (uln); alkaline
phosphatase no greater than 2.5 times uln*
Yes
No
renal: creatinine clearance greater than 60
ml/min*
Yes
No
cardiovascular: cardiac function normal*
Yes
No
Exclusion Criteria
severe complications or infections*
Yes
No
pregnant or breast-feeding women*
Yes
No
clinically significant heart disease*
Yes
No
uncontrolled hepatitis, chronic liver disease, or
diabetes mellitus*
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Yes
No
another active cancer except properly treated
carcinoma in situ of the cervix or basal/squamous
cell skin carcinoma*
Yes
No
2 / 2
Eligibility Non-small Cell Lung Cancer NCT00997724
Eligibility Prostatic Neoplasms
NCT00817739
Intermittent Hormonal Therapy With Leuprorelin and
Flutamide in the Treatment of Stage D2 or TxNxM1b,c;
ODM derived from:
https://clinicaltrials.gov/show/NCT00817739
All rights reserved. Please visit https://medical-data-
models.org/forms/13618
Eligibility Prostatic Neoplasms
NCT00817739
Inclusion Criteria
histologically confirmed metastatic cancer of the
prostate (stage d2 or tx nx m1 ≠ m1a)*
Yes
No
with measurable bone or visceral (lung, liver, etc.)
metastases (radiographic conformation was
necessary in the event of a questionable bone
scan detection in conjunction with only slightly
elevated psa levels [at least 20 ng/ml or less than
or equal to 50 ng/ml]). the prostatic carcinoma
could have been diagnosed at an earlier stage
and treated without castration.*
Yes
No
pre-assessment psa 5-fold or higher than the
standard level set by the central laboratory, that
is, psa greater than or equal to (≥) 20 ng/ml as
quantitated by the hybritech radioimmunoassay
(normal is less than [<] 4 ng/ml).*
Yes
No
ecog performance status of no more than 2.*
Yes
No
normal testosterone levels according to the
central laboratory standards.*
Yes
No
aspartate transaminase (ast) and alanine
transaminase (alt) < 2.25-fold higher than the
standard levels set by the central laboratory
(except when liver metastases were present).*
Yes
No
anticipated life expectancy greater than 9
months.*
Yes
No
written informed consent given to participate and
collaborate in the study. inclusion criteria for
continuous or intermittent treatment phase*
Yes
No
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subjects who meet the pre-assessment criteria
and who has psa < 4 ng/ml after 6 months of
induction therapy.*
Yes
No
Exclusion Criteria
subject refuse to sign the informed consent form
or is likely to be uncooperative or not to comply
with the obligations set out in the study protocol.*
Yes
No
subject has received prior hormonal (and
neoadjuvant) treatment prompting medical
castration (estrogens, hormone-releasing
hormone agonists, androgens) or has undergone
surgical castration.*
Yes
No
subject has undergone bilateral
suprarenalectomy or hypophysectomy.*
Yes
No
subject had another cancer (except basiloma)
with the past 5 years.*
Yes
No
subject has serious unstable progressive disease
(renal, hepatic, cardiovascular, psychological,
etc).*
Yes
No
subject is receiving or has received another
experimental treatment within 3 months prior to
inclusion.*
Yes
No
exclusion criteria for continuous or intermittent
treatment phase*
Yes
No
subjects who met the pre-assessment criteria
and who, after 6 months of induction therapy, had
psa ≥ 4 ng/ml and/or on-treatment signs of
disease progression.*
Yes
No
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Eligibility Type 1 Diabetes Mellitus
NCT00570102
Nutritional Prevention Pilot Trial for Type 1 Diabetes; ODM
derived from: https://clinicaltrials.gov/show/NCT00570102
All rights reserved. Please visit https://medical-data-
models.org/forms/13619
Eligibility Type 1 Diabetes Mellitus
NCT00570102
Inclusion Criteria
the participant must have a mother, biological
father or sibling with type 1 diabetes*
Yes
No
the participant must carry a susceptible hla
genotype(hla-dqb1*02 and/or dqb1*0302 without
protective alleles (dqb1*0301, *0602 and *0603)*
Yes
No
Exclusion Criteria
no telephone*
Yes
No
no accessibility to any of the research centers*
Yes
No
inability of parents to understand the study and
instructions*
Yes
No
unwillingness/inability to feed the infant cm-
containing food for any reason (e.g. religious,
cultural reasons)*
Yes
No
gestational age less than 36 weeks*
Yes
No
any severe illness such as chromosomal
abnormalities, congenital malformations,
respiratory failure, enzyme deficiencies of the
newborn.*
Yes
No
the newborn infant has received any cow's milk-
based product prior to randomization*
Yes
No
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Eligibility Coronary Artery Disease
NCT00475449
The Stent or Surgery (SoS) Trial; ODM derived from:
https://clinicaltrials.gov/show/NCT00475449
All rights reserved. Please visit https://medical-data-
models.org/forms/13620
Eligibility Coronary Artery Disease
NCT00475449
Inclusion Criteria
written informed consent.*
Yes
No
patient has typical angina pectoris - stable or
unstable symptoms.*
Yes
No
atherosclerotic coronary artery disease
demonstrated with selective coronary
angiography with a significant lesion present in at
least two of the principal epicardial vessel
systems.*
Yes
No
revascularisation procedure clinically indicated.*
Yes
No
nominated trial surgeon accepts the patient for
cabg.*
Yes
No
nominated trial interventionist accepts the patient
for ptca and stent.*
Yes
No
at least one identified lesion suitable and targeted
for primary stent implantation.*
Yes
No
a procedure for the completion of either
revascularisation strategy can be performed
within 6 weeks of randomisation.*
Yes
No
Exclusion Criteria
previous cabg procedure or other thoracotomy.*
Yes
No
previous coronary interventional procedure (of
any type).*
Yes
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No
intervention on any cardiac valve scheduled for
the index revascularisation procedure.*
Yes
No
excision or other intervention on the myocardium
scheduled for the index revascularisation
procedure.*
Yes
No
intervention on the great vessels, carotid arteries
or aorta scheduled for the index revascularisation
procedure.*
Yes
No
absent autologous graft material.*
Yes
No
non-cardiac disease influencing survival.*
Yes
No
acute myocardial infarction in the 48 hours
preceding the proposed revascularisation
procedure.*
Yes
No
participation in any other study that would involve
deviation from the routine local management of a
revascularisation procedure.*
Yes
No
allergy to anti-platelet agents in local use.*
Yes
No
language or other communication barrier.*
Yes
No
follow-up for two years not possible / patient
unreliable.*
Yes
No
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Eligibility Dementia NCT00178165
Coordinating Center for Enhancing ADRD Caregiving;
ODM derived from:
https://clinicaltrials.gov/show/NCT00178165
All rights reserved. Please visit https://medical-data-
models.org/forms/13621
Eligibility Dementia NCT00178165
Criteria
Inclusion Criteria
1. nincds -adrda criteria for alzheimer’s disease
and/or dsm iv criteria for alzheimer’s disease or
other dementia or mmse score < 23.*
Yes
No
2. functional impairment:  presence of two iadl or
one adl impairments.*
Yes
No
Exclusion Criteria
1. any terminal illness with life expectancy < 6
months*
2. active treatment (chemotherapy, radiation
therapy) for cancer*
Yes
No
3. more than three acute medical hospitalizations
in past year (not for psychiatric or alzheimer’s
disease related admission)*
Yes
No
4. schizophrenia (onset of delusions before age
45)*
Yes
No
5. dementia secondary to head trauma
(probable)*
Yes
No
6. blindness or deafness if either disability
prohibits them from completion of data collection
or participation in the interventions*
Yes
No
7. mmse = 0 and bedbound (confined to a bed or
chair for > 22 hours per day, for at least 4 of the
past 7 days)*
Yes
No
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8. planned nursing home admission in 6 months*
Yes
No
Inclusion Criteria for core caregiver
1. age:  21 years and older*
Yes
No
2. language:  site specific, must be competent
either orally or written*
Yes
No
3. lives with care recipient*
Yes
No
4. family member*
Yes
No
5. gender:  palo alto/los angeles will only enroll
women.  all other sites will enroll men and
women*
Yes
No
6. must have a telephone*
Yes
No
7. at enrollment, plan to remain in area for the
duration of the intervention and follow-up*
Yes
No
8. caregiver role of at least 6 months*
Yes
No
9. provides > 4 hours of supervision or direct
assistance per day for the care recipient*
Yes
No
Exclusion Criteria for core caregiver
1. any terminal illness with life expectancy < 6
months*
Yes
No
2. active treatment (chemotherapy, radiation
therapy) for cancer*
Yes
No
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3. more than three acute medical hospitalizations
in past year*
Yes
No
4. involved in another clinical trial of interventions
for caregivers (non drug study)*
Yes
No
second level review if the caregiver has been
inconsistent with answers or repeated answers,
then the interviewer will administer the spmsq.
the interviewer will then discuss with the pi and
coordinate another phone call with the caregiver.*
Yes
No
if in the course of the telephone screen the
research assistant believes that there may be
difficulties for the caregiver regarding travel
arrangements, hesitancy to answer questions, or
other specific items (site-specific indications), the
research assistant will refer to the pi for review.*
Yes
No
all potential caregivers will receive a follow-up
phone call for second level exclusion from the
trial when appropriate.*
Yes
No
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Eligibility Heart Failure, Congestive
NCT00288730
A Study of Two Doses of Intravenous NATRECOR hBNP
(Nesiritide) in Patients With Worsening Congestive Heart
Failure Who Have Difficulty Breathing at Rest; ODM
derived from: https://clinicaltrials.gov/show/NCT00288730
All rights reserved. Please visit https://medical-data-
models.org/forms/13622
Eligibility Heart Failure, Congestive
NCT00288730
Inclusion Criteria
history of chronic congestive heart failure (chf)*
Yes
No
symptomatic, decompensated chf for which
intravenous therapy is deemed appropriate for
the hospitalized patient*
Yes
No
documentation of pulmonary capillary wedge
pressure (pcwp) >= 18 mm hg, cl <= 2.7
ml/min/m² and systolic blood pressure >= 90 mm
hg with consistent baseline hemodynamic
measurements.*
Yes
No
Exclusion Criteria
had a myocardial infarction within the previous 48
hours or unstable angina*
Yes
No
stroke within the previous 3 months or other
evidence of significantly compromised central
nervous system perfusion*
Yes
No
has significant valvular stenosis hypertrophic,
restrictive or obstructive cardiomyopathy,
constrictive pericarditis, primary pulmonary
hypertension, biopsy-proven active myocarditis,
or complex congenital heart disease*
Yes
No
receiving ongoing treatment with an intravenous
vasostrictive agent for this episode of
decompressed chf that could not be discontinued
for an appropriate washout period to permit the
reassessment of baseline hemodynamic and
clinical status prior to initiating drug study*
Yes
No
clinical status so unstable that the subject can not
tolerate placement of a swan-ganz catheter.*
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Yes
No
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Eligibility High Risk NCT00590785
Phase III Comparison of Adjuvant Chemotherapy W/High-
Dose Cyclophosphamide Plus Doxorubicin (AC) vs
Sequential Doxorubicin Fol by Cyclophosphamide (A-C) in
High Risk Breast Cancer Patients With 0-3 Positive Nodes
(Intergroup, CALGB 9394); ODM derived from:
https://clinicaltrials.gov/show/NCT00590785
All rights reserved. Please visit https://medical-data-
models.org/forms/13623
Eligibility High Risk NCT00590785
Criteria
patients must have undergone an axillary
dissection, and at least 6 nodes must have een
removed and examined. nodal involvement by
tumor must be negative or must not xceed three
positive nodes.*
Yes
No
disease must be considered sufficiently high-risk
by the investigator to justify the use of
chemotherapy. to be eligible, disease must satisfy
one of the following requirements:*
Yes
No
1. tumor is both er negative and pgr negative and
greater than 1.0 cm in greatest diameter.
negative is defined as c 10 fmollmg cytosol
protein if measured in these units; othennrise
negative is defined according to institutional
standards.*
Yes
No
2. tumor that is greater than 2.0 cm in greatest
diameter irrespective of hormone receptor status
(including unknown).*
Yes
No
3. tumor involves one to three axillary lymph
nodes.*
Yes
No
breast cancer was not locally advanced at
diagnosis. this is left to investigator judgement,
but generally should exclude patients with fixed
tumors, fixed nodes, peau d'orange skin changes,
skin ulcerations or inflammatory changes (t4
disease).*
Yes
No
patient is currently free of breast cancer (no
evidence of disease). this is also left to
investigator judgement, but generally should
include no evidence of distant disease on chest
x-ray or mgmmogram of the opposite breast prior
to registration, within 3 months prior to surgery;
and no gross or microscopically positive surgical
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margins noted in the final surgery or pathology
reports. patients with synchronous bilateral
breast cancer may be considered, provided both
breasts are treated with curative intent and that
eligibility is based on the side with the most
adverse prognostic features.*
Yes
No
registration must be within 84 days of
mastectomy, or within 84 days of axillary
dissection if the patient's most extensive breast
surgery was a breast sparing procedure. patients
not having mastectomy or breast sparing surgery
are ineligible. patients must not have had prior
chemotherapy for this breast cancer. patients
must not have had systemic therapy of any type
for a previous breast cancer.*
Yes
No
patients must not have had external beam
radiotherapy for this breast cancer prior to
registration. brachytherapy (interstitial radiation
therapy) at the time of breast sparing procedure
is acceptable and would not render the patient
ineligible. (if external beam radiotherapy is
planned to be given with brachytherapy, it must
be delayed until after chemotherapy is complete.)
patients whose most extensive breast surgery
was a breast sparing procedure must be planning
to receive radiotherapy after chemotherapy is
complete.*
Yes
No
patients must have adequate hematologic,
hepatic, renal and cardiac function for high dose
chemotherapy and adequate health for long-term
follow-up. this must include normal wbc (2
4,0001pl). neutrophll count (2 1,50o/pl), platelet
count (2 institutional lower limit of normal), and
lvef (left ventricular ejection fraction by
institutional criteria); bilirubin within 1.5 times
institutional upper limit of normal; creatinine
within 1.5 times institutional upper limit of normal;
and no serious disease other than breast
cancer.*
Yes
No
pregnant or nursing women may not participate.
men are ineligible. women of childbearing
potential must be planning to use effective
contraception.*
Yes
No
all patients must be informed of the
investigational nature of this study and give
2 / 3
Eligibility High Risk NCT00590785
written informed consent in accordance with
institution and federal guidelines.*
Yes
No
at the time of registration, the date of institutional
review board approval for this study must be
provided to the statistical center.*
Yes
No
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Eligibility Juvenile Idiopathic Arthritis
NCT00420251
Efficacy and Safety of Growth Hormone Treatment in
Juvenile Idiopathic Arthritis; ODM derived from:
https://clinicaltrials.gov/show/NCT00420251
All rights reserved. Please visit https://medical-data-
models.org/forms/13624
Eligibility Juvenile Idiopathic Arthritis
NCT00420251
Inclusion Criteria
polyarticular or systemic juvenile idiopathic
arthritis,*
Yes
No
growth velocity below the 25th percentile and or
short stature ,*
Yes
No
treatment with glucocorticoids for at least the
previous 6 months before inclusion,*
Yes
No
prepubertal stage,*
Yes
No
bone age below 10 in girls and 12 in boys,*
Yes
No
growth hormone levels after stimulation with
clonidine or arginine above 10 ng/ml*
Yes
No
Exclusion Criteria
previous treatment with growth hormone,*
Yes
No
endocrinopathy,*
Yes
No
additional chronic disease beside juvenile
idiopathic arthritis,*
Yes
No
malignant disase,*
Yes
No
chromosomal aberration or othe syndromal
disease,*
Yes
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No
previous treatment with oxandrolone,*
Yes
No
small for gestational age,*
Yes
No
elevated fasting glucose level*
Yes
No
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Eligibility Leukemia, Nonlymphoblastic,
Acute NCT00180115
AML96 - Risk-Adapted and Randomized Postremission-
Therapy for Adult Acute Myeloid Leukemia Patients; ODM
derived from: https://clinicaltrials.gov/show/NCT00180115
All rights reserved. Please visit https://medical-data-
models.org/forms/13625
Eligibility Leukemia,
Nonlymphoblastic, Acute
NCT00180115
Inclusion Criteria
de novo or secondary acute myeloid leukemia of
the fab subtypes m0-m2 and m4-m7*
Yes
No
de novo or secondary myelodysplastic syndrome
fab subtypes raeb and raeb-t*
Yes
No
written informed consent*
Yes
No
Exclusion Criteria
severe comorbidities*
Yes
No
severe uncontrolled complications of the
leukemia*
Yes
No
previous therapy of leukemia/mds*
Yes
No
hiv-infection*
Yes
No
known relevant allergy against study medication*
Yes
No
pregnancy*
Yes
No
missing written informed consent*
Yes
No
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Eligibility Lymphoma NCT00002946
Penclomedine in Treating Patients With Solid Tumors or
Lymphoma; ODM derived from:
https://clinicaltrials.gov/show/NCT00002946
All rights reserved. Please visit https://medical-data-
models.org/forms/13626
Eligibility Lymphoma NCT00002946
Criteria
histologically confirmed malignancy (solid tumor
or lymphoma)*
Yes
No
no history of brain metastases*
Yes
No
age: 18 and over*
Yes
No
life expectancy: at least 12 weeks*
Yes
No
performance status: ecog 0-2*
Yes
No
wbc at least 4,000/mm3*
Yes
No
absolute neutrophil count at least 1,500/mm3*
Yes
No
platelet count at least 100,000/mm3*
Yes
No
bilirubin less than 1.5 mg/dl*
Yes
No
creatinine normal*
Yes
No
no history of seizure disorder not pregnant or
nursing*
Yes
No
at least 4 weeks since prior chemotherapy (6
weeks since nitrosoureas and mitomycin) and
recovered*
Yes
No
at least 4 weeks since prior radiotherapy and
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recovered*
Yes
No
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Eligibility Lymphoma, Non-Hodgkin
NCT00989664
Pivotal Study of Iodine I 131 Tositumomab for
Chemotherapy-refractory Low-grade or Transformed Low-
grade B-cell Non-Hodgkin's Lymphoma; ODM derived from:
https://clinicaltrials.gov/show/NCT00989664
All rights reserved. Please visit https://medical-data-
models.org/forms/13627
Eligibility Lymphoma, Non-Hodgkin
NCT00989664
Inclusion Criteria
male and female subjects ≥18 years of age with
histologically confirmed at initial diagnosis,
previously treated (at least 2 prior chemotherapy
regimens), low-grade nhl or low-grade lymphoma
that had transformed to intermediate- or high-
grade histology.*
Yes
No
Exclusion Criteria
subjects with more than an average of 25% of the
intratrabecular marrow space involved by
lymphoma in bone marrow biopsy specimens as
assessed microscopically within 42 days of study
entry. bilateral posterior iliac crest core biopsies
are required if the percentage of intratrebecular
space involved exceeds 10% in a unilateral
biopsy. the mean of bilateral biopsies must be no
more than 25%.*
Yes
No
cytotoxic chemotherapy, radiation therapy,
immunosuppressants, or cytokine treatment
within 4 weeks prior to study entry or persistent
clinical evidence of toxicity.*
Yes
No
prior stem cell transplant.*
Yes
No
active obstructive hydronephrosis.*
Yes
No
evidence of active infection requiring intravenous
(iv) antibiotics at the time of study entry.*
Yes
No
new york heart association class iii or iv heart
disease or other serious illness that would
preclude evaluation.*
Yes
No
prior malignancy other than lymphoma, except for
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adequately treated skin cancer, in situ cervical
cancer, or other cancer for which the subject has
been disease-free for 5 years.*
Yes
No
known hiv infection.*
Yes
No
known brain or leptomeningeal metastases.*
Yes
No
subjects who are pregnant or nursing.*
Yes
No
previous allergic reactions to iodine. this does not
include reactions to intravenous iodine-containing
contrast materials.*
Yes
No
prior exposure to monoclonal or polyclonal
antibodies of any non-human species for either
diagnostic or therapeutic purposes, including
engineered chimeric and humanized antibodies.*
Yes
No
prior radioimmunotherapy.*
Yes
No
progressive disease within 1 year of irradiation
arising in a field that has been previously
irradiated with >3500 cgy.*
Yes
No
current use of either approved or non-approved
(through another protocol) anti-cancer drugs or
biologics*
Yes
No
de novo intermediate- or high-grade lymphoma.*
Yes
No
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CABACS Case Report Form
Screening
Study site number
Patient ID
Date of screening for trial
Inclusion criteria
Elective coronary artery bypass grafting planned
Yes
No
Extracranial carotid stenosis ≥80 percent
(ECST),asymptomatic for at least 180 days
Yes
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No
Eligible for carotid endarterectomy for treatment
of carotid stenosis
Yes
No
Gender
Male (1)
Female (2)
18 Years and older
Yes
No
Patient is legally competent and has signed
informed consent
Yes
No
Patient is willing to come back for follow up
Yes
No
Negative pregnancy test in females of
childbearing potential.
Yes
No
Exclusion criteria
Carotid stenosis other than atherosclerotic
Yes
No
Modified Rankin Scale score of >3 or severe
aphasia
Yes
No
Carotid artery occlusion
Yes
No
Prior vascular stent in current stenosis
Yes
No
Stenosis due to prior radiation therapy
Yes
No
Ipsilateral carotid stenosis with higher grade
inoperable stenosis (intracranial or intrathoracic)
Yes
No
Other known indication for carotid
revascularization
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Yes
No
Myocardial infarction NSTEMI<48h or STEMI<7d
or hemodynamic instability
Yes
No
Intracranial hemorrhage within 90 days prior to
enrollment
Yes
No
Life expectancy less than one year due to
comorbidities
Yes
No
Simultaneously planned heart valve surgery  or
other cardiac surgery except CABG/CEA
Yes
No
Any other elective surgery planned during 8
weeks after randomization into this study
Yes
No
Inclusion into any other clinical trial
Yes
No
Date of completion of this form
Signature Investigator
Name of Investigator
3 / 3
Case Report Form Coronary Artery Bypass graft surgery in patients with
Asymptomatic Carotid Stenosis
Medical History Coronary Artery Bypass graft surgery
in patients with Asymptomatic Carotid Stenosis
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CABACS Case Report Form
[Medical History]
Medical history
Date of screening for trial
Patient ID
Month of birth
Year of birth
Gender
male (1)
female (2)
Body Height
cm
Body Weight
kg
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Hypertensive disease
Yes
No
Hyperlipidemia
Yes
No
Smoking status
Never (1)
Quit smoking (2)
smoker (3)
If you are a former smoker, when did you quit
smoking?
≥ 5 years (1)
< 5 years (2)
Anatomical position of carotid stenosis
ACC right (1)
ACC left (2)
ACI right (3)
ACI left (4)
Prior carotid TEA
No (1)
right side (2)
left side (3)
Prior carotid TEA:please give the year of the
procedure
Are there any other relevant comorbidities?
Please specify below
Yes
No
Please specify comorbidities by ICD-Code or
Diagnosis
Please give the year, the comorbidity was first
diagnosed
Is the symptom/comorbidity persistent?
Yes
No
Date of completion of this form
Signature by Investigator
Name of Investigator
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Eligibility Lymphoma NCT00003113
Oral Combination Chemotherapy in Treating Elderly
Patients With Intermediate or High-Grade Non-Hodgkin's
Lymphomas; ODM derived from:
https://clinicaltrials.gov/show/NCT00003113
All rights reserved. Please visit https://medical-data-
models.org/forms/13635
Eligibility Lymphoma NCT00003113
Criteria
biopsy proven stage i through iv intermediate to
high grade non-hodgkin's lymphoma of b-cell, t-
cell, or indeterminate immunologic phenotype*
Yes
No
measurable or evaluable*
Yes
No
no cytologic or radiographic evidence of cns
lymphoma*
Yes
No
60 and over*
Yes
No
performance status: ecog 0-3*
Yes
No
life expectancy: at least 6 weeks*
Yes
No
wbc at least 1500/mm3*
Yes
No
platelet count at least 50,000/mm3*
Yes
No
bilirubin no greater than 3.0 mg/dl*
Yes
No
creatinine no greater than 3.0 mg/dl*
Yes
No
no prior chemotherapy*
Yes
No
prior radiotherapy allowed for localized stage i or
ii disease that has progressed beyond initial
radiotherapy ports*
Yes
No
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Eligibility Lymphoma NCT00003261
Chemotherapy and Radiation Therapy in Treating Patients
With HIV-Related Primary Central Nervous System
Lymphoma; ODM derived from:
https://clinicaltrials.gov/show/NCT00003261
All rights reserved. Please visit https://medical-data-
models.org/forms/13636
Eligibility Lymphoma NCT00003261
Criteria
histologically proven hiv-related non-hodgkin's
lymphoma of the cns*
Yes
No
no systemic lymphoma*
Yes
No
Age: 18 and over*
Yes
No
performance status: who 0-3*
Yes
No
wbc at least 3000/mm^3*
Yes
No
platelet count at least 80,000/mm^3*
Yes
No
no serious impairment of liver function*
Yes
No
no serious impairment of renal function*
Yes
No
creatinine clearance at least 40 ml/min*
Yes
No
no serious impairment of cardiac function*
Yes
No
neurological functional status 0-3*
Yes
No
no prior or active cns-opportunistic infections*
Yes
No
no aids dementia complex*
Yes
No
1 / 2
no active systemic infections*
Yes
No
prior concurrent therapy:*
Yes
No
no prior chemotherapy or radiotherapy*
Yes
No
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Eligibility Multiple Myeloma and Plasma Cell
Neoplasm NCT00006232
Combination Chemotherapy in Treating Patients With Stage
II or Stage III Multiple Myeloma; ODM derived from:
https://clinicaltrials.gov/show/NCT00006232
All rights reserved. Please visit https://medical-data-
models.org/forms/13637
Eligibility Multiple Myeloma and
Plasma Cell Neoplasm
NCT00006232
Criteria
diagnosis of stage ii or iii multiple myeloma*
Yes
No
no prior therapy except local radiotherapy to bone
lesions*
Yes
No
no indolent multiple myeloma*
Yes
No
no monoclonal gammopathy of unknown
significance*
Yes
No
Age: 75 and under*
Yes
No
bilirubin no greater than 2.34 mg/dl*
Yes
No
no end stage renal failure (creatinine greater than
5.65 mg/dl after rehydration)*
Yes
No
no requirement for dialysis*
Yes
No
no other medical condition that would preclude
intensive treatment*
Yes
No
not pregnant or nursing*
Yes
No
fertile patients must use effective contraception*
Yes
No
no other prior malignancy*
Yes
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No
prior biologic therapy: see disease
characteristics*
Yes
No
prior chemotherapy: see disease characteristics*
Yes
No
prior endocrine therapy: see disease
characteristics*
Yes
No
prior radiotherapy: concurrent local radiotherapy
allowed for painful lesions or lesions that appear
likely to lead to an imminent fracture*
Yes
No
prior surgery: see disease characteristics*
Yes
No
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Eligibility Schizophrenia NCT00169091
Clozapine Versus Haloperidol for Treating the First Episode
of Schizophrenia; ODM derived from:
https://clinicaltrials.gov/show/NCT00169091
All rights reserved. Please visit https://medical-data-
models.org/forms/13638
Eligibility Schizophrenia
NCT00169091
Inclusion Criteria
rdc diagnosis of schizophrenia*
Yes
No
men and women, without regard to
race/ethnicity,*
Yes
No
aged 18-45*
Yes
No
acutely psychotic with a score of at least 3 on
one of the psychotic scale items of the brief
psychiatric rating scale (bprs) (hallucinations,
delusions, conceptual disorganization) and a total
bprs of > 21 (on a 0 - 6 scale);*
Yes
No
require treatment with neuroleptic drugs on a
clinical basis;*
Yes
No
the patient (or the patient's authorized legal
representative) must understand the nature of the
study and sign the informed consent;*
Yes
No
be within the first episode of a psychotic
disorder;*
Yes
No
have a history of neuroleptic treatment of < 12
weeks;*
Yes
No
likely to remain in the study for 2 years.*
Yes
No
Exclusion Criteria
substance dependence in the last six months*
Yes
No
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history of seizure or blood dyscrasia*
Yes
No
major medical illness*
Yes
No
pregnancy or lactation*
Yes
No
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Eligibility T-cell Lymphoma NCT00001582
Investigation of the Human Immune Response in Normal
Subjects and Patients With Disorders of the Immune
System and Cancer; ODM derived from:
https://clinicaltrials.gov/show/NCT00001582
All rights reserved. Please visit https://medical-data-
models.org/forms/13639
Eligibility T-cell Lymphoma
NCT00001582
Criteria
patient must meet at least one of these criteria:*
Yes
No
have suspected or known disorder of the immune
system or malignancy*
Yes
No
be a known or potential carrier of genetically
determined autoimmune disorder or
immunodeficiency disease.*
Yes
No
specific i disorders may include but are not
limited to:  x-linked (severe combined
immunodeficiency) scid (c gamma deficiency),
autosomal recessive scid, x-linked cd40 ligand
deficiency, common variable immunodeficiency,
ataxia-telangiectasia, wiskott aldrich syndrome,
digeorge syndrome and infection with htlv-1*
Yes
No
age of birth and above for patients with
suspected or known disorders of the immune
system.*
Yes
No
patient (or parent/guardian of a minor child) must
be able to understand and sign informed
consent.*
Yes
No
hematocrit greater than 28%, and platelet count
greater than 50,000 necessary for apheresis.*
subjects for whom apheresis is desired but
whose counts are lower than those above must
be evaluated and approved by a department of
transfusion medicine consult physician.*
Yes
No
weight greater than 25 kg is necessary for
apheresis.*
Yes
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No
Exclusion Criteria
overall exclusion criteria:*
Yes
No
pregnant or breast feeding women will not be
eligible for any aspect of this protocol except
phlebotomy*
Yes
No
children less than 18 years old are not eligible for
lymph node or bone marrow biopsy*
Yes
No
exclusion criteria for skin/parenteral antigen
tests:*
Yes
No
any history of severe reaction or allergy to a
particular skin test antigen or other ingredients in
the formulation (e.g. thimerosal, eggs or avian
protein) will exclude a subject from receiving that
particular skin test.*
Yes
No
children under the age of 2 years are not eligible
to receive the pneumococcal polyvalent vaccine.*
Yes
No
subjects under the age of 18 years are not
eligible to receive the candida or mumps skin test
antigens.*
Yes
No
exclusion criteria for apheresis alone:*
Yes
No
any diagnosed medical condition which may be
worsened by the apheresis procedure.
specifically the patient should not have any of the
following:*
Yes
No
1. congestive heart failure*
Yes
No
2. history of angina*
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Yes
No
3. severe hypotension (at the discretion of the
patient's physician, the apheresis staff and the
attending physician from the department of
transfusion medicine (dtm) per dtm standard
operating policies.)*
Yes
No
4. poorly controlled hypertension (average
baseline blood pressure greater than 160/90)*
Yes
No
5. history of a coagulation protein disorder.*
Yes
No
pediatric normal volunteers (less than 18 years)
will not undergo apheresis.*
Yes
No
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Eligibility Colorectal Neoplasm
NCT00001568
Phase II Study of the Role of Anti-CEA Antibody
Immunoscintigraphy & Positron Emission Tomography in
the Localization of Recurrent Colorectal Carcinoma in
Patients With Rising Serum CEA Levels in the Absence of
Imageable Disease by Conventional Modalities; ODM
derived from: https://clinicaltrials.gov/show/NCT00001568
All rights reserved. Please visit https://medical-data-
models.org/forms/13640
Eligibility Colorectal Neoplasm
NCT00001568
Criteria
rising serum cea levels greater than 6 on two
successive tests.*
Yes
No
resectable residual or recurrent disease.  patients
in the occult arm (arm 1) must have no visible
residual disease in the abdomen at the time of
the last surgical exploration.  in addition, there
must be no imageable definitive site of recurrent
disease using conventional imaging modalities
including; ct scan of chest/ abdomen/ pelvis with
contrast, mri scan, and chest x-ray.  patients in
arm 2 may have a single site of recurrent or
metastatic disease which is resectable but in
whom additional sites of disease are not known
and no imageable disease other than a solitary
site of potentially resectable disease is identified.*
Yes
No
patients must have an ecog performance status
of 0-1.*
Yes
No
patients must be willing to return to nih for follow-
up.*
Yes
No
patients must be able to provide informed
consent as demonstrated by the signed consent.*
Yes
No
patients must be 2 or more months from
abdominal or thoracic surgery.*
Yes
No
no patients with medical contraindication to
abdominal exploration.*
Yes
No
no patients with recurrent disease detected by
conventional imaging studies as outlined above.
metastatic disease localized outside of the
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abdominal cavity by conventional imaging studies
as outlined above.  patients must weigh less than
136 kgs.  which is the weight limit for the scanner
tables.*
Yes
No
no patients with previous injection of murine
monoclonal antibodies: human anti-mouse assay
(hama) will be performed in patients with prior
history of receiving murine monoclonal
antibodies.*
Yes
No
no patients that are pregnant or breast feeding.*
Yes
No
patients who are hiv + will be excluded.*
Yes
No
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Eligibility Atrial Fibrillation NCT00442494
Corticosteroids for the Prevention of Atrial Fibrillation After
Cardiac Surgery; ODM derived from:
https://clinicaltrials.gov/show/NCT00442494
All rights reserved. Please visit https://medical-data-
models.org/forms/13641
Eligibility Atrial Fibrillation
NCT00442494
Inclusion Criteria
patients scheduled to undergo their first on-pump
cabg, aortic valve replacement or combined
aortic valve replacement and cabg were
enrolled.*
Yes
No
Exclusion Criteria
previous episodes of af or flutter*
Yes
No
uncontrolled diabetes mellitus*
Yes
No
systemic mycotic infection*
Yes
No
active tuberculosis*
Yes
No
cushing's syndrome*
Yes
No
psychotic mental disorder*
Yes
No
herpes simplex keratitis*
Yes
No
serum creatinine exceeding 200 µg/ml*
Yes
No
patients were also excluded if they had a history
of previous peptic ulcer or thrombophlebitis.*
Yes
No
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Eligibility Atrial Fibrillation NCT01349491
Ranolazine for the Prevention of Atrial Fibrillation After
Electrical Cardioversion; ODM derived from:
https://clinicaltrials.gov/show/NCT01349491
All rights reserved. Please visit https://medical-data-
models.org/forms/13642
Eligibility Atrial Fibrillation
NCT01349491
Inclusion Criteria
male or female with persistent atrial fibrillation,
aged 21 or older*
Yes
No
duration of atrial fibrillation less than one year*
Yes
No
the patient does not have any contraindications
for anticoagulation*
Yes
No
the patient is willing to participate in the study for
a total of 6 months with 3 outpatient office visits*
Yes
No
the patient has provided written informed consent
during the screening visit to any test or procedure
being performed, or medication being changed,
for this study.*
Yes
No
the patient has no clinically significant abnormal
clinical laboratory values, which in the
investigator's opinion precludes the patient from
safely participating in the study.*
Yes
No
Exclusion Criteria
any contraindication for anticoagulation*
Yes
No
new york heart association class iv heart failure*
Yes
No
currently taking anti-arrhythmic drugs*
Yes
No
chronic kidney disease (serum creatinine less
than 2.5mg/dl) or severe liver dysfunction*
Yes
No
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pregnancy/nursing*
Yes
No
prolonged qt interval (>500ms)*
Yes
No
taking other medications known to prolong the qt
interval*
Yes
No
taking other medications known to affect the
metabolism of ranolazine*
Yes
No
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Eligibility Breast Cancer NCT00896324
Intellectual Impairment in Women With Breast Cancer;
ODM derived from:
https://clinicaltrials.gov/show/NCT00896324
All rights reserved. Please visit https://medical-data-
models.org/forms/13643
Eligibility Breast Cancer
NCT00896324
Inclusion Criteria
3.1.1 primary, non-metastatic breast cancer*
Yes
No
3.1.2 newly diagnosed patients who have not yet
begun treatment.*
Yes
No
3.1.4 female participants age 40-65 years of all
ethnicities who speak fluent english will be
recruited.*
Yes
No
3.1.5 there are no life expectancy restrictions.*
Yes
No
3.1.6 karnofsky performance status 70%
minimum. ecog will not be employed.*
Yes
No
3.1.7 there are no requirements for marrow
function. the brain must be free from gross
neuropathology and metastases in order to
participate.*
Yes
No
3.1.8 ability to understand and the willingness to
sign a written informed consent document.*
Yes
No
Exclusion Criteria
3.2.1 history of cognitive, psychiatric or medical
conditions prior or unrelated to cancer diagnosis
and/or known to significantly impact assessments
(e.g. premature birth, developmental delays,
learning disabilities, severe psychiatric
conditions, brain injury, stroke). non-english
speaking. major sensory impairment (e.g.
hearing loss, blindness) that would render
assessments invalid. mri contraindications (e.g.
metallic implants or devices). distant metastases.
see also section 4.2.1.*
Yes
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No
3.2.2 participants currently involved in studies
specifically aimed at improving cognitive
symptoms will be excluded.*
Yes
No
3.2.3 participants with significant co-morbid
diseases known to significant impact
neuropsychological function such as alzheimer's
or parkinson's will be excluded.*
Yes
No
3.2.4 there are no known risks for allergic
reactions to any of the study procedures.*
Yes
No
3.2.5 participants taking certain medications that
affect neuropsychological and/or brain function
including haldol, aricept, ritalin, etc. will be
excluded. most anti-depressants are acceptable.
some anti-anxiety medications may not be. each
case will be individually reviewed.*
Yes
No
3.2.6 there are no other agent-specific exclusion
criteria.*
Yes
No
3.2.7 pregnant individuals will be excluded as this
is a contraindication for the 3 tesla research mri
scanner employed by this study but not because
of the treatment programs per se. nursing
individuals can enroll.*
Yes
No
3.2.8 patients who are hiv positive will be
excluded given the known effects of this condition
on cognitive function which would confound the
effects of anti-cancer treatments on cognitive
outcome.*
Yes
No
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Eligibility Breast Cancer NCT01365845
Proton Therapy for Lymph Nodes in Breast Cancer; ODM
derived from: https://clinicaltrials.gov/show/NCT01365845
All rights reserved. Please visit https://medical-data-
models.org/forms/13644
Eligibility Breast Cancer
NCT01365845
Inclusion Criteria
pathologically confirmed invasive
adenocarcinoma of the breast stage i-iii (tx, t0-4,
n0-3) with medially located tumor and/or axillary
node invasion.*
Yes
No
patients must have undergone either mastectomy
or breast conservation surgery.*
Yes
No
patients are required to have axillary staging
which can include sentinel node biopsy alone if
sentinel node is negative.*
Yes
No
patient must require peripheral lymph node
radiation per physician discretion.*
Yes
No
Exclusion Criteria
evidence of distant metastasis (m1).*
Yes
No
prior radiotherapy to the area of interest.*
Yes
No
prior history of cardiovascular disease per
physician discretion.*
Yes
No
prior or concurrent cancer other than non-
melanomatous skin cancer unless disease free
for at least 5 years.*
Yes
No
collagen vascular disease, specifically
dermatomyositis with a cpk level above normal or
with an active skin rash, systemic lupus
erythematosis or scleroderma.*
Yes
No
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Eligibility Breast Cancer NCT01388777
Cryoablation for Invasive Breast Carcinoma Following
Neoadjuvant Therapy; ODM derived from:
https://clinicaltrials.gov/show/NCT01388777
All rights reserved. Please visit https://medical-data-
models.org/forms/13645
Eligibility Breast Cancer
NCT01388777
Inclusion Criteria
1. unifocal primary invasive ductal breast
carcinoma diagnosed by core needle biopsy.
note: patients with lobular carcinoma, multifocal
and/or multicentric ipsilateral breast cancer,
multifocal calcifications, or dcis with
microinvasion are not eligible. patients with
contralateral disease will remain eligible.*
Yes
No
2. neoadjuvant chemotherapy or hormonal
therapy for the index tumor is required.*
Yes
No
3. residual tumor size </= 2.0 cm in greatest
diameter. specifically, the tumor must measure
</= 2.0 cm in the axis parallel to the treatment
probe and </= 1.5 cm in the axis anti-parallel to
the treatment probe. largest size measured by
mammogram, ultrasound or mri will be used to
determine eligibility.*
Yes
No
4. tumor enhancement on pre-registration mri.*
Yes
No
5. tumor with <25% intraductal components in the
aggregate.*
Yes
No
6. adequate breast size for safe cryoablation.
male breast cancer patients and female breast
cancer patients with breasts too small to allow
safe cryoablation are not eligible as the minimal
thickness of the breast tissue does not lend itself
to cryoablation.*
Yes
No
7. patients with prior in-situ or invasive breast
carcinomas are eligible if the prior carcinomas
occurred in the contralateral breast. patients with
prior in-situ or invasive carcinomas of the
ipsilateral breast are not eligible.*
Yes
No
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Exclusion Criteria
1. history of open surgical biopsy and/or
lumpectomy for diagnosis/treatment of the index
breast cancer. note: prior rotational and/or
vacuum-assisted core biopsies are permitted if
no significant distortion is seen on imaging that
could obscure visualization and detection of
residual disease on mri, or visualization of cancer
on ultrasound for cryoablation procedure.*
Yes
No
2. pregnant and/or lactating. patients of
childbearing potential must have a negative
serum or urine pregnancy test. note: peri-
menopausal women must be amenorrheic for >
12 months to be considered not of childbearing
potential.*
Yes
No
3. patient has contra-indication to an mri
examination, such as clips/prostheses/implants
that are not mri compatible, or compromised
renal function, with a measured or calculated
glomerular filtration rate of 60ml/min/1.73m^2*
Yes
No
4. patients less than 18 years of age will not be
included in this study.*
Yes
No
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Eligibility Breast Cancer NCT01423890
A Prospective Cohort Study to Evaluate the Oncotype DX®
Test in Early Stage Breast Cancer; ODM derived from:
https://clinicaltrials.gov/show/NCT01423890
All rights reserved. Please visit https://medical-data-
models.org/forms/13646
Eligibility Breast Cancer
NCT01423890
Inclusion Criteria
women or men with histologic evidence of
invasive breast cancer (ductal, lobular or mixed
disease).*
Yes
No
surgical resection including breast conserving
surgery or modified radical mastectomy or simple
mastectomy, within the last four months.*
Yes
No
axillary lymph nodes assessed for tumor by:*
Yes
No
(i)  sentinel node biopsy, or (ii) axillary node
dissection, or (iii) both*
Yes
No
axillary lymph node assessment negative for
cancer, or positive only for micrometastases (i.e.,
cancer <2mm by h&e stain).*
Yes
No
tumor is estrogen receptor (er) positive.*
Yes
No
receiving or to receive adjuvant endocrine
therapy (i.e., tamoxifen or aromatase inhibitor).*
Yes
No
being considered for adjuvant chemotherapy.*
Yes
No
Exclusion Criteria
axillary lymph node positive for cancer.*
Yes
No
patients with inoperable locally advanced breast
cancer.*
Yes
No
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metastatic breast cancer, including local
ipsilateral recurrence.*
Yes
No
her2 neu positive.*
Yes
No
physician/patient unwilling to comply with study
protocol.*
Yes
No
inability to provide informed consent (e.g.
dementia or severe cognitive impairment).*
Yes
No
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Eligibility Cancer Survivor NCT01347970
Pharmacologic Reversal of Ventricular Remodeling in
Childhood Cancer Survivors at Risk for Congestive Heart
Failure (PREVENT-CHF): A Phase IIB Randomized
Placebo-Controlled Trial; ODM derived from:
https://clinicaltrials.gov/show/NCT01347970
All rights reserved. Please visit https://medical-data-
models.org/forms/13647
Eligibility Cancer Survivor
NCT01347970
Inclusion Criteria
cancer diagnosis prior to 22 years of age,
irrespective of current age*
Yes
No
lifetime cumulative anthracycline dose: >= 300
mg/m^2 without the protection of dexrazoxane
(zinecard) therapy*
Yes
No
time from completion of cancer treatment to study
entry: >= 2 years*
Yes
No
Exclusion Criteria
receiving treatment for cardiomyopathy or
congestive heart failure*
Yes
No
resting ejection fraction < 50% or fractional
shortening < 25%*
Yes
No
uncorrected primary obstructive or severe
regurgitative valvular disease, nondilated
(restrictive) or hypertrophic cardiomyopathy, or
significant systemic ventricular outflow
obstruction*
Yes
No
low resting systolic blood pressure: < 90 mm
hemoglobin (hg)*
Yes
No
bradycardia: heart rate < 50 beats per minute
(bpm)*
Yes
No
sustained or symptomatic ventricular
dysrhythmias uncontrolled with drug therapy or
implantable device; significant conduction defects
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(i.e.: second or third degree atrio-ventricular block
or sick sinus syndrome)*
Yes
No
history or current clinical evidence of moderate
-to-severe obstructive pulmonary disease or
reactive airway diseases (i.e.: asthma) requiring
therapy*
Yes
No
significant hepatic (serum aspartate
aminotransferase [ast] and/or alanine
aminotransferase [alt] > 3 time upper limit of
normal institutional normal), gastrointestinal, or
biliary disorders that could impair absorption,
metabolism, or excretion of orally administered
medications*
Yes
No
endocrine disorders such as primary
aldosteronism, pheochromocytoma, hyper- or
hypothyroidism not controlled with medication, or
insulin dependent diabetes mellitus*
Yes
No
females of child bearing potential who are
pregnant, lactating, or sexually active and not
taking adequate contraceptive precautions (i.e.:
intrauterine device [iud] or oral contraceptives for
3 months prior to entry into the study)*
Yes
No
history of drug sensitivity or allergic reaction to
alpha- or beta-blockers*
Yes
No
anemia (hematocrit < 28%)*
Yes
No
use of an investigational drug or beta adrenergic
blockers, including metoprolol, sotalol, within 30
days of randomization*
Yes
No
use of select cytochrome p450 2d6 (cyp2d6)
inhibitor medications*
Yes
No
inability to swallow pills*
Yes
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No
unwillingness or inability to cooperate, or, for the
parents or guardians of minors, to give consent,
or for the child to give assent, or any condition of
sufficient severity to impair cooperation with the
study*
Yes
No
use of any other blood pressure lowering
medication for treatment of hypertension, within
30 days of randomization*
Yes
No
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Table II- Core Asthma Outcomes NIH AHRQ
for adults and adolescents >= 12 years of age
Documentation part: Table II [Recommendations for core
asthma outcomes for NIH- initiated clinical research for
adults and adolescents (>= 12 years of age)]. 
ODM derived from:
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4259286/
Background:
Asthma clinical research will highly benefit from
standardization of major outcomes in terms of definition
and assessment methodology. This will permit useful
comparisons across interventional or observational studies
and will allow more effective data sharing.
Objective:
National Institutes of Health (NIH) institutes and the Agency
for Healthcare Research and Quality (AHRQ) convened a
workshop involving 7 expert subcommittees to propose
which asthma outcomes should be assessed with
standardized methodology in future asthma clinical
research studies.
Permission granted by: Michelle Freemer.
All rights reserved. Please visit https://medical-data-
models.org/forms/13648
Table II- Core Asthma Outcomes NIH
AHRQ for adults and adolescents >=
12 years of age
Characterization of study
population for prospective clinical trials
Serologic multiallergen screen
(IgE) to define atopic status (also
for observational studies)
Composite scores: Either ACQ or ACT
ACQ  (1)
ACT (2)
Events in the 12 months prior to study entry:
Systemic corticosteroids for asthma (1)
Asthma-specific hospital admissions (2)
Asthma-specific ED visits
(separate UC visits when these can
be differentiated) (3)
History of:
Asthma-specific hospital admissions (1)
Asthma-specific ED visits (2)
Asthma-specific outpatient visits (3)
Asthma-specific medication use (4)
Pulmonary physiology: Spirometry (pre-
 and post bronchodilator)
Prospective clinical trial efficacy/
effectiveness outcomes
Composite Scores: Either ACQ or ACT
ACQ  (1)
ACT (2)
Events in the 12 months prior to study entry:
Systemic corticosteroids for
asthma, for at least 3 days (1)
Asthma-specific hospital admissions (2)
 Asthma-specific ED visits
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(separate UC visits when these
can be differentiated) (3)
Asthma-specific ICU
admissions/intubations (4)
 Death (all cause and asthma related) (5)
History of:
Asthma-specific hospital admissions  (1)
Asthma-specific ED visits  (2)
Asthma-specific outpatient visits  (3)
Asthma-specific detailed medication use
(name, dose, duration) (4)
Resource use related to the
intervention (eg, personnel time,
mite eradication, equipment) (5)
If option 4 chosen above, please mention the
name, dose and duration of the asthma
medication used
Physiology Pulmonary: Spirometry (without
bronchodilator)
Observational study outcomes
Composite Scores: Either ACQ or ACT
ACQ  (1)
ACT (2)
Events in the 12 months prior to study entry:
Systemic corticosteroids for asthma (1)
Asthma-specific hospital admissions (2)
Asthma-specific ED visits
(separate UC visits when these can
be differentiated) (3)
History of:
Asthma-specific hospital admissions  (1)
Asthma-specific ED visits  (2)
Asthma-specific outpatient visits  (3)
Asthma-specific detailed medication use
(name, dose, duration) (4)
Resource use related to the
intervention (eg, personnel time,
mite eradication, equipment) (5)
If option 4 chosen above, please mention the
name, dose and duration of the asthma
medication used
Physiology Pulmonary: Spirometry (pre and
post bronchodilator)
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Table III- Core Asthma Outcomes NIH
AHRQ for children (511 years of age)
Documentation part: Table III [Recommendations for core
asthma outcomes for NIH- initiated clinical research for
children (5-11 years of age)]. 
ODM derived from:
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4259286/
Background:
Asthma clinical research will highly benefit from
standardization of major outcomes in terms of definition
and assessment methodology. This will permit useful
comparisons across interventional or observational studies
and will allow more effective data sharing.
Objective:
National Institutes of Health (NIH) institutes and the Agency
for Healthcare Research and Quality (AHRQ) convened a
workshop involving 7 expert subcommittees to propose
which asthma outcomes should be assessed with
standardized methodology in future asthma clinical
research studies.
Permission granted by: Michelle Freemer.
All rights reserved. Please visit https://medical-data-
models.org/forms/13650
Table III- Core Asthma Outcomes
NIH AHRQ for children (5-
11 years of age)
Characterization of study
population for prospective clinical trials
Serologic multiallergen screen
(IgE) to define atopic status (also
for observational studies)
Composite Scores: cACT
(childhood Asthma Control Test)
Events in the 12 months prior to study entry:
Systemic corticosteroids for asthma (1)
Asthma-specific hospital admissions (2)
Asthma-specific ED visits
(separate UC visits when these can
be differentiated) (3)
History of:
Asthma-specific hospital admissions (1)
Asthma-specific ED visits (2)
Asthma-specific outpatient visits (3)
Asthma-specific medication use (4)
Physiology Pulmonary: Spirometry (pre-
 and post bronchodilator)
Prospective clinical trial efficacy/
effectiveness outcomes
Events in the 12 months prior to study entry:
 Systemic corticosteroids for asthma (1)
Asthma-specific hospital admissions (2)
 Asthma-specific ED visits
(separate UC visits when these
can be differentiated) (3)
Asthma-specific ICU
admissions/intubations (4)
 Death (all cause and asthma related) (5)
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History of:
Asthma-specific hospital admissions  (1)
Asthma-specific ED visits  (2)
Asthma-specific outpatient visits  (3)
Asthma-specific detailed medication use
(name, dose, duration) (4)
Resource use related to the
intervention (eg, personnel time,
mite eradication, equipment) (5)
If option 4 chosen above, please mention the
name, dose and duration of the asthma
medication used
Physiology Pulmonary: Spirometry (without
bronchodilator)
Observational study outcomes
Composite Scores: cACT
(childhood Asthma Control Test)
Events in the 12 months prior to study entry:
Systemic corticosteroids for asthma (1)
Asthma-specific hospital admissions (2)
Asthma-specific ED visits
(separate UC visits when these can
be differentiated) (3)
History of:
Asthma-specific hospital admissions  (1)
Asthma-specific ED visits  (2)
Asthma-specific outpatient visits  (3)
Asthma-specific detailed medication use
(name, dose, duration) (4)
Resource use related to the
intervention (eg, personnel time,
mite eradication, equipment) (5)
If option 4 chosen above, please mention the
name, dose and duration of the asthma
medication used
Physiology Pulmonary: Spirometry (pre and
post bronchodilator)
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Table III- Core Asthma Outcomes NIH AHRQ for children (5-
11 years of age)
Table IV- Supplemental Asthma Outcomes
NIH AHRQ for adults
Documentation part: Table IV (Recommendations for
supplemental asthma outcomes for NIH- initiated clinical
research for adults). 
ODM derived from:
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4259286/
Background:
Asthma clinical research will highly benefit from
standardization of major outcomes in terms of definition
and assessment methodology. This will permit useful
comparisons across interventional or observational studies
and will allow more effective data sharing.
Objective:
National Institutes of Health (NIH) institutes and the Agency
for Healthcare Research and Quality (AHRQ) convened a
workshop involving 7 expert subcommittees to propose
which asthma outcomes should be assessed with
standardized methodology in future asthma clinical
research studies.
Permission granted by: Michelle Freemer.
All rights reserved. Please visit https://medical-data-
models.org/forms/13651
Table IV- Supplemental Asthma
Outcomes NIH AHRQ for adults
Characterization of study
population for prospective clinical trials
Biomarkers
FeNO (1)
 Sputum eosinophils (2)
 CBC (total eosinophils) (3)
 Total IgE (4)
 Allergenspecific IgE (5)
Urinary LTE4 (6)
Composite Scores: ATAQ
 in studies of healthcare utilization
Exacerbation of asthma
For trials in the acute management of
exacerbations (ED setting): FEV1 (1)
 Any prior exacerbation (2)
 Any prior ICU admission/intubation (3)
SES of the study population (4)
Healthcare Utilization and Costs
 Categorization of asthmaspecific
outpatient visits: Scheduled primary care
(1)
Categorization of asthmaspecific
outpatient visits: Unscheduled primary
care (2)
Categorization of asthmaspecific
outpatient visits: Scheduled
Specialty care (3)
Categorization of asthmaspecific
outpatient visits: Unscheduled
Specialty care (4)
 Respiratory healthcare use
(pneumonia, bronchitis, etc) (5)
Asthma school absences (6)
Asthma work absences (7)
Physiology Pulmonary
PEF monitoring (1)
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Airway responsiveness (2)
 Lung volumes (3)
Gas exchange (4)
Quality of Life
ABP  (1)
AIS6  (2)
AQLQS  (3)
MiniAQLQ  (4)
LWAQ  (5)
Modified AQLQMarks  (6)
SGRQ  (7)
AQ20 (8)
Symptoms
ASUI (retrospective questionnaire) (1)
Daytime Symptom Diary Scale and
Nocturnal Diary Scale (daily diary) (2)
Prospective clinical trial efficacy/
effectiveness outcomes
Biomarkers
FeNO (1)
 Sputum eosinophils (2)
 CBC (total eosinophils) (3)
 Total IgE (4)
 Allergenspecific IgE (5)
Urinary LTE4 (6)
Exacerbation of asthma
For trials in the acute management of
exacerbations (ED setting): FEV1 (1)
Healthcare Utilization and Costs
 Categorization of asthmaspecific
outpatient visits: Scheduled primary care
(1)
Categorization of asthmaspecific
outpatient visits: Unscheduled primary
care (2)
Categorization of asthmaspecific
outpatient visits: Scheduled
Specialty care (3)
Categorization of asthmaspecific
outpatient visits: Unscheduled
Specialty care (4)
 Respiratory healthcare use  (5)
Asthma school absences (6)
Asthma work presenteeism
and absenteeism (WPAI instrument) (7)
Cost analysis and cost-
effectiveness analysis (8)
Physiology Pulmonary
PEF monitoring (1)
Airway responsiveness (2)
 Lung volumes (3)
Gas exchange (4)
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Spirometry (pre and post bronchodilator)
(5)
Quality of Life
ABP  (1)
AIS6  (2)
AQLQS  (3)
MiniAQLQ  (4)
LWAQ  (5)
Modified AQLQMarks  (6)
SGRQ  (7)
AQ20 (8)
Symptoms
ASUI (retrospective questionnaire) (1)
Daytime Symptom Diary Scale and
Nocturnal Diary Scale (daily diary) (2)
Observational study outcomes
Biomarkers
FeNO (1)
 Sputum eosinophils (2)
 CBC (total eosinophils) (3)
 Total IgE (4)
 Allergenspecific IgE (5)
Urinary LTE4 (6)
ATAQ  in studies of healthcare utilization
Healthcare Utilization and Costs
 Categorization of asthmaspecific
outpatient visits: Scheduled primary care
(1)
Categorization of asthmaspecific
outpatient visits: Unscheduled primary
care (2)
Categorization of asthmaspecific
outpatient visits: Scheduled
Specialty care (3)
Categorization of asthmaspecific
outpatient visits: Unscheduled
Specialty care (4)
 Respiratory healthcare use  (5)
Asthma school absences (6)
Asthma work presenteeism
and absenteeism (WPAI instrument) (7)
Cost analysis and cost-
effectiveness analysis (8)
Physiology Pulmonary
PEF monitoring (1)
Airway responsiveness (2)
 Lung volumes (3)
Gas exchange (4)
Quality of Life
ABP  (1)
AIS6  (2)
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AQLQS  (3)
MiniAQLQ  (4)
LWAQ  (5)
Modified AQLQMarks  (6)
SGRQ  (7)
AQ20 (8)
Symptoms
ASUI (retrospective questionnaire) (1)
Daytime Symptom Diary Scale and
Nocturnal Diary Scale (daily diary) (2)
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Table IV- Supplemental Asthma Outcomes NIH AHRQ for adults
Eligibility Cardiovascular Disease
NCT01313702
Single Pill to Avert Cardiovascular Events; ODM derived
from: https://clinicaltrials.gov/show/NCT01313702
All rights reserved. Please visit https://medical-data-
models.org/forms/13653
Eligibility Cardiovascular Disease
NCT01313702
Inclusion Criteria
adults age ≥ 18 years old;*
Yes
No
patient that could written informed consent;*
Yes
No
patient with current atherothrombotic
cardiovascular disease or at high cardiovascular
risk, defined as:*
Yes
No
patients with previous coronary artery disease
(miocardial infarction, estable or instable angina
pectoris or coronary revascularization
procedures);*
Yes
No
patients with previous myocardial infarction,
defined as medical registry (with documentation
of at least 2 criterias: clinical
symptoms,pathological electrocardiogram and
elevation of cardiac enzymes- ck-mb and/or
troponin);*
Yes
No
patients with previous brain ischemia (stroke or
transient ischemic attack)*
Yes
No
patients with confirmed previous peripheral
arterial disease (coronary artery bypass
procedures or angioplasty or amputation due
peripheral arterial disease)*
Yes
No
patients with no established cardiovascular
disease but at high cardiovascular risk, defined
as 15% or more in 5 years (using the anderson
framingham scale, 1991)*
Yes
No
Exclusion Criteria
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contraindication for any of the polipill*
Yes
No
if the physician opinion is that therapeutical
change could harm the patient (for example,
heart failure, need of high beta blocker dose for
treatment angina symptons and for the atrial
fibrillation rhythm,severe hypertension [degree 3],
malignant hypertension or renal insufficiency*
Yes
No
acute clinical conditions/ surgeries*
Yes
No
psychiatry  clinical conditions(for example,
schizophrenia, serious depression)*
Yes
No
pregnant or lactation women*
Yes
No
women at fertile period  mulheres not using
effective contraceptive methods (oral
contraceptive, condom, intrauterine device)*
Yes
No
liver diseases (ast/alt/fa upon 3 x normal superior
limits / bilirrubin upon 1,5 x normal superior limits
/ diagnosed liver cirrhosis*
Yes
No
renal dysfunction (any laboratorial exams upon 3
x normal superior limits)*
Yes
No
previous participation on other clinical trial*
Yes
No
the participant is unable or refuse to give
informed consent.*
Yes
No
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Eligibility Cardiovascular Disease
NCT01427855
Dietary Protein Sources and Atherogenic Dyslipidemia;
ODM derived from:
https://clinicaltrials.gov/show/NCT01427855
All rights reserved. Please visit https://medical-data-
models.org/forms/13654
Eligibility Cardiovascular Disease
NCT01427855
Inclusion Criteria
30-65 years old*
Yes
No
non-smoking*
Yes
No
agrees to abstain from alcohol and dietary
supplements during the study*
Yes
No
willing to consume all study foods as instructed*
Yes
No
Exclusion Criteria
history of heart disease, cerebrovascular
disease, peripheral vascular disease, bleeding
disorder, liver or renal disease, lung disease,
diabetes, human immunodeficiency virus (hiv), or
cancer (other than skin cancer) in the last 5
years*
Yes
No
body mass index (bmi) > 35 kg/m2 or < 20
kg/m2*
Yes
No
not weight stable*
Yes
No
abnormal thyroid stimulating hormone*
Yes
No
blood pressure > 150/90*
Yes
No
fasting blood sugar >126 mg/dl*
Yes
No
fasting triglyceride levels >500 mg/dl*
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Yes
No
total- and ldl cholesterol >95th percentile for age
and sex*
Yes
No
pregnant or breastfeeding*
Yes
No
taking hormones or drugs known to affect lipid
metabolism*
Yes
No
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Eligibility Chronic Heart Failure
NCT01251406
Efficacy and Safety of Human Neuregulin-1 to Treat Stable
Chronic Heart Failure; ODM derived from:
https://clinicaltrials.gov/show/NCT01251406
All rights reserved. Please visit https://medical-data-
models.org/forms/13655
Eligibility Chronic Heart Failure
NCT01251406
Inclusion Criteria
age > 18 years.*
Yes
No
male or female subjects.*
Yes
No
have chronic heart failure defined as nyha
classification of ii or iii.*
Yes
No
be on a stable regimen of acei/arb and/or beta-
blocker 3 months prior to receiving study
medication and are expected to remain on a
stable hf medication regime throughout the
duration of the trial.*
Yes
No
left ventricular ejection fraction (lvef) of < 35% as
determined at screening by 2-d
echocardiography.*
Yes
No
is able to understand and provide informed
consent.*
Yes
No
if subject has dilated cardiomyopathy, ischemic
heart disease or corrected valvular heart disease,
and had surgery to repair or replace value, the
surgery must have been performed 3 months
prior to receiving study medication and the
surgical area is functioning normally.*
Yes
No
proper birth control must be used at least 3
weeks prior to the study (women only), during the
infusion period of study drug (men and women),
4-weeks after study drug administration (men and
women) and the remaining 11 months in the
study follow-up (women).  women must have a
negative pregnancy test at screening.*
Yes
No
no greater than mild pericardial effusion < 0.5 cm
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on echocardiography (roughly corresponds to <
100 ml).*
Yes
No
have an implantable cardioverter-defibrillator
(icd). the icd should have been implanted at least
3 months prior to receiving study medication.
patients should undergo interrogation of their icds
between 1 and 7 days before randomization to
drug for the previous thirty (30) days. this
interrogation would include surveillance for
ventricular arrhythmias as well as assessment of
icd discharge(s) and/or anti-tachycardia pacing.*
Yes
No
Exclusion Criteria
has chronic heart failure classified as nyha class i
or iv.*
Yes
No
has a history of any malignancy or positive test
as specified in the pre-cancer screening.*
Yes
No
have other conditions which in the opinion of the
investigator preclude participation in the study,
e.g. serious co-morbidity, known or suspected
substance abuse or non-compliance.*
Yes
No
has a body weight >350lbs.*
Yes
No
has had any cause hospitalization 30 days prior
to screening.*
Yes
No
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Eligibility Chronic Kidney Disease
NCT01250405
Acute Effects of Cinacalcet on Arterial Stiffness and
Ventricular Function in Hemodialysis Patients; ODM derived
from: https://clinicaltrials.gov/show/NCT01250405
All rights reserved. Please visit https://medical-data-
models.org/forms/13656
Eligibility Chronic Kidney Disease
NCT01250405
Inclusion Criteria
chronic (> 3 months) hemodialysis population of
> 18 years old*
Yes
No
pth > 300 ng/l*
Yes
No
corrected ca > 2.10 mmol/l*
Yes
No
stable hypertensive drugs (> 1 month)*
Yes
No
stable doses of phosphate binders and dialysis
calcium concentration*
Yes
No
palpable femoral pulse*
Yes
No
systolic bp of 90-180 mmhg*
Yes
No
expected survival of > 6 months*
Yes
No
Exclusion Criteria
hemodialysis > 3 years*
Yes
No
acute infection*
Yes
No
history of myocardial infarction or stroke within
the past 3 months*
Yes
No
inability to consent*
Yes
1 / 2
No
intolerance to cinacalcet*
Yes
No
inadequate birth control*
Yes
No
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Eligibility Chronic Kidney Disease
NCT01462097
Exercise Trial in Chronic Kidney Disease; ODM derived
from: https://clinicaltrials.gov/show/NCT01462097
All rights reserved. Please visit https://medical-data-
models.org/forms/13657
Eligibility Chronic Kidney Disease
NCT01462097
Inclusion Criteria
stage 3-4 chronic kidney disease (estimated gfr
15-45)*
Yes
No
age 60 to 85*
Yes
No
english speaking*
Yes
No
Exclusion Criteria
dementia or cognitive impairment*
Yes
No
renal transplant*
Yes
No
ny heart association class 3-4 heart failure*
Yes
No
severe chronic lung disease*
Yes
No
unstable angina or coronary revascularization
within the last 3 months*
Yes
No
orthopedic problems that would preclude aerobic
exercise training*
Yes
No
known, untreated infection*
Yes
No
disabling arthritis*
Yes
No
uncontrolled arrhythmia*
Yes
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No
more than 14 alcoholic drinks per week*
Yes
No
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Eligibility Chronic Kidney Disease NCT01462097
Table V- Supplemental Asthma Outcomes
NIH AHRQ for children
Documentation part: Table V (Recommendations for
supplemental asthma outcomes for NIH- initiated clinical
research for children). 
ODM derived from:
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4259286/
Background:
Asthma clinical research will highly benefit from
standardization of major outcomes in terms of definition
and assessment methodology. This will permit useful
comparisons across interventional or observational studies
and will allow more effective data sharing.
Objective:
National Institutes of Health (NIH) institutes and the Agency
for Healthcare Research and Quality (AHRQ) convened a
workshop involving 7 expert subcommittees to propose
which asthma outcomes should be assessed with
standardized methodology in future asthma clinical
research studies.
Permission granted by: Michelle Freemer.
All rights reserved. Please visit https://medical-data-
models.org/forms/13659
Table V- Supplemental Asthma
Outcomes NIH AHRQ for children
Characterization of study
population for prospective clinical trials
Biomarkers
FeNO (1)
 Sputum eosinophils (2)
 CBC (total eosinophils) (3)
 Total IgE (4)
 Allergenspecific IgE (5)
Urinary LTE4 (6)
Exacerbation of asthma
For trials in the acute management of
exacerbations (ED setting):  Validated as
sessment tools, such as
PASS, PS, PRAM, CAS, PI, ASS=PASS,
 PS, PRAM, CAS, PI, ASS (1)
For trials in the acute management of
exacerbations (ED setting): FEV1
(ages 511 years, as feasible) (2)
 Any prior exacerbation (3)
 Any prior ICU admission/intubation (4)
SES of the study population (5)
Healthcare Utilization and Costs
 Categorization of asthma-specific
outpatient visits: Scheduled primary care
(1)
Categorization of asthma-specific
outpatient visits: Unscheduled primary
care (2)
Categorization of asthma-specific
outpatient visits: Scheduled
Specialty care (3)
Categorization of asthma-specific
outpatient visits: Unscheduled
Specialty care (4)
 Respiratory healthcare use
(pneumonia, bronchitis, etc) (5)
Asthma school absences (6)
Asthma work absences (7)
1 / 4
Physiology Pulmonary
PEF monitoring (1)
Airway responsiveness (2)
 Lung volumes (3)
Gas exchange (4)
Quality of Life
 CHSA  (1)
 PAQLQ  (2)
Pediatric Caregiver AQLQ  (3)
PedsQL 3.0, Asthma Module (4)
Symptoms: PACD (daily diary)
Prospective clinical trial efficacy/
effectiveness outcomes
Biomarkers
FeNO (1)
 Sputum eosinophils (2)
 CBC (total eosinophils) (3)
 Total IgE (4)
 Allergenspecific IgE (5)
Urinary LTE4 (6)
cACT
Exacerbation of asthma
For trials in the acute management of
exacerbations (ED setting):  Validated as
sessment tools, such as
PASS, PS, PRAM, CAS, PI, ASS=PASS,
 PS, PRAM, CAS, PI, ASS (1)
For trials in the acute management of
exacerbations (ED setting): FEV1
(ages 511 years, as feasible) (2)
Healthcare Utilization and Costs
 Categorization of asthmaspecific
outpatient visits: Scheduled primary care
(1)
Categorization of asthmaspecific
outpatient visits: Unscheduled primary
care (2)
Categorization of asthmaspecific
outpatient visits: Scheduled
Specialty care (3)
Categorization of asthmaspecific
outpatient visits: Unscheduled
Specialty care (4)
 Respiratory healthcare use  (5)
Asthma school absences (6)
Asthma work presenteeism
and absenteeism (WPAI instrument) (7)
Cost analysis and cost-
effectiveness analysis (8)
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Physiology Pulmonary
PEF monitoring (1)
Airway responsiveness (2)
 Lung volumes (3)
Gas exchange (4)
Spirometry (pre and post-
bronchodilator) (5)
Quality of Life
 CHSA  (1)
 PAQLQ  (2)
Pediatric Caregiver AQLQ  (3)
PedsQL 3.0, Asthma Module (4)
PACD (daily diary)
Observational study outcomes
Biomarkers
FeNO (1)
 Sputum eosinophils (2)
 CBC (total eosinophils) (3)
 Total IgE (4)
 Allergenspecific IgE (5)
Urinary LTE4 (6)
Healthcare Utilization and Costs
 Categorization of asthmaspecific
outpatient visits: Scheduled primary care
(1)
Categorization of asthmaspecific
outpatient visits: Unscheduled primary
care (2)
Categorization of asthmaspecific
outpatient visits: Scheduled
Specialty care (3)
Categorization of asthmaspecific
outpatient visits: Unscheduled
Specialty care (4)
 Respiratory healthcare use  (5)
Asthma school absences (6)
Asthma work presenteeism
and absenteeism (WPAI instrument) (7)
Cost analysis and cost-
effectiveness analysis (8)
Physiology Pulmonary
PEF monitoring (1)
Airway responsiveness (2)
 Lung volumes (3)
Gas exchange (4)
Quality of Life
 CHSA  (1)
 PAQLQ  (2)
Pediatric Caregiver AQLQ  (3)
PedsQL 3.0, Asthma Module (4)
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PACD (daily diary)
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ZUF-8 Fragebogen zur
Patientenzufriedenheit
Lizenz: CC-BY-NC-ND
Quellenangabe:
http://www.gfqg.de/downloads.html?file=files/content/downl
oads/Assessment/ZUF-8%20Fragebogen.pdf
Beim Abstract bitte einfügen:
„Eine Bitte, bevor Sie den ZUF-8 downloaden: anders als
die meisten anderen gebräuchlichen psychometrischen
Verfahren stellen wir Ihnen den ZUF-8 hier kostenlos zur
Verfügung. Das Instrument wurde mit privaten und
öffentlichen Forschungsgeldern entwickelt und soll jedem
öffentlich zur Verfügung stehen, der es für seine eigenen
Forschungsarbeiten benötigt (kommerzielle Nutzungen
ausgeschlossen).
Weil wir das Instrument ständig weiterentwickeln haben wir
die Bitte an Sie: stellen Sie uns Ihre – anonymisierten –
ZUF-8-Daten zur Verfügung, inkl. einer kurzen
Beschreibung, in welchem Rahmen sie erhoben wurden.
Wir sammeln die Daten hierzu fortlaufend, aktuell liegt eine
Stichprobe von über 100.000 Rehapatienten aller wichtigen
Hauptindikationen vor. Helfen Sie bitte mit, diese
Datenbasis zu erweitern. Damit können wir Ihnen künftig
noch bessere Referenzdaten anbieten.
All rights reserved. Please visit https://medical-data-
models.org/forms/13660
ZUF-8 Fragebogen zur
Patientenzufriedenheit
ZUF-8 Fragebogen zur
Patientenzufriedenheit
Wie würden Sie die Qualität der Behandlung,
welche Sie erhalten haben, beurteilen?
ausgezeichnet (1)
gut (2)
weniger gut (3)
schlecht (4)
Haben Sie die Art von Behandlung erhalten, die
Sie wollten?
eindeutig nicht (1)
eigentlich nicht (2)
im Allgemeinen ja (3)
eindeutig ja (4)
In welchem Maße hat unsere Klinik Ihren
Bedürfnissen entsprochen?
sie hat fast allen meinen Bedürfnissen
entsprochen (1)
sie hat den meisten meiner Bedürfnisse
entsprochen (2)
sie hat nur wenigen meiner Bedürfnisse
entsprochen (3)
sie hat meinen Bedürfnissen nicht
entsprochen (4)
Würden Sie einem Freund / einer Freundin
unsere Klinik empfehlen, wenn er / sie eine
ähnliche Hilfe benötigen würde?
eindeutig nicht (1)
Ich glaube nicht (2)
Ich glaube ja (3)
eindeutig ja (4)
Wie zufrieden sind Sie mit dem Ausmaß der
Hilfe, welche Sie hier erhalten haben?
ziemlich unzufrieden (1)
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leidlich oder leicht unzufrieden (2)
weitgehend zufrieden (3)
sehr zufrieden (4)
Hat die Behandlung, die Sie hier erhielten, Ihnen
dabei geholfen, angemessener mit
Ihren Problemen umzugehen?
ja, sie half eine ganze Menge (1)
ja, sie half etwas (2)
nein, sie half eigentlich nicht (3)
nein, sie hat mir die Dinge schwerer
gemacht (4)
Wie zufrieden sind Sie mit der Behandlung, die
Sie erhalten haben, im Großen und
Ganzen?
sehr zufrieden (1)
weitgehend zufrieden (2)
leidlich oder leicht unzufrieden (3)
ziemlich unzufrieden (4)
Würden Sie wieder in unsere Klinik kommen,
wenn Sie eine Hilfe bräuchten?
eindeutig nicht (1)
ich glaube nicht (2)
ich glaube ja (3)
eindeutig ja (4)
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SIMBO Screening-Instrument zur Erkennung des Bedarfs
an Medizinisch-beruflich orientierter Rehabilitation
Quelle:
http://www.medizinisch-berufliche-
orientierung.de/bausteine/diagnostische_instrumente/#sim
bo
German Federal Pension Insurance
Department of Rehabilitation
Coordination and Development of Medical and Vocational
Rehabilitation Hohenzollerndamm 47
D-10704 Berlin
( +49(0)30 865-81591 (phone)
7 +49(0)30 865-82122 (fax)
mailto: dr.marco.streibelt@drv-bund.de
All rights reserved. Please visit https://medical-data-
models.org/forms/13661
SIMBO-C Fragebogen
SIMBO-C Questionnaire
Please enter your social security number
Age
Jahre
Gender
male (1)
female (2)
What is your current employment situation?
fulltime employment (1)
halftime employment (2)
part time employment (3)
homemaker (4)
unemployed (5)
on disability pension (6)
retiree (7)
not working due to other reasons (8)
Did your physician declare you currently unfit for
work?
Yes
No
Have you been declared unfit for work within the
last 12 month?
Yes
No
If you have been declared unfit to work within the
last 12 month, how long was that in total?
less than a week (1)
1-6 weeks (2)
7-12 weeks (3)
13-26 weeks (4)
longer than 26 weeks (5)
How severe would you rate your impairment at
work through your health issues?
0 (0)
1 (1)
10 (10)
2 (2)
3 (3)
4 (4)
1 / 2
5 (5)
6 (6)
7 (7)
8 (8)
9 (9)
How would you see your occupational future? I
think I
can work in my profession in the future
(1)
cannot work in my profession in the
future (2)
will search for another employment (3)
will be unable to work at all (4)
will apply for a pension/will receive a
pension (5)
will be unemployed (6)
will be declared unfit for work (7)
don´t know it yet (8)
What do you expect from your medical-vocational
rehabilitation? I hope that finally somebody will
have time for me
not at all (1)
a little (2)
moderately (3)
pretty much (4)
very much (5)
What do you expect from your medical-vocational
rehabilitation? I hope that I will find relief of strain
through psychological counseling
not at all (1)
a little (2)
moderately (3)
pretty much (4)
very much (5)
What do you expect from your medical-vocational
rehabilitation? I hope that the rehabilitation will
help to settle or to improve my occupational
situation
not at all (1)
a little (2)
moderately (3)
pretty much (4)
very much (5)
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Medizinisch-beruflich orientierter Rehabilitation
Eligibility Hairy Cell Leukemia
NCT00001567
A Phase II Efficacy Study of Roferon-A in Hairy Cell
Leukemia; ODM derived from:
https://clinicaltrials.gov/show/NCT00001567
All rights reserved. Please visit https://medical-data-
models.org/forms/13663
Eligibility Hairy Cell Leukemia
NCT00001567
Criteria
patients must have morphologically identifiable
hairy cells in peripheral blood and bone marrow,
or tissue biopsies with at least one of the
following:  1) positive stain for the tartrate-
resistant acid phosphatase  2) electron
microscopy compatible with hairy cells.*
Yes
No
patients must be ambulatory with an expected
survival greater than 16 weeks and be willing and
able to give written informed consent.*
Yes
No
patients must have a disease that is assessable,
defined by:  1) pancytopenia 2) bone marrow
leukemic infiltrate 3) lymphadenopathy,
splenomegaly, or hepatomegaly.*
Yes
No
patients must not require palliative chemotherapy,
immunotherapy or hormonal therapy other than
the treatment prescribed in this protocol.*
Yes
No
patients must be tested for hepatitis b surface
antigen within one week of entry into this study.*
Yes
No
no pregnant or lactating women.  no fertile men
and women, unless using effective
contraception.*
Yes
No
no patients with unstable angina.  patients with
class iii or iv cardiovascular disease may be
entered only after medical clearance by a
cardiology consultant.*
Yes
No
no patients with severe intercurrent infection or
patients having had surgery within the past four
weeks unless fully recovered.*
Yes
No
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no patients with impaired renal function (serum
creatinine greater than 1.8).*
Yes
No
no patients with impaired hepatic function (total
bilirubin greater than 1.4).*
Yes
No
no patients with serum calcium greater than 12
mg/dl.*
Yes
No
no patients with a performance status less than
or equal to 60% on the karnofsky scale.*
Yes
No
no patients who have had any prior (leukocyte or
fibroblast) interferon therapy.*
Yes
No
no patients unable to carry out the treatment
program.*
Yes
No
no patients less than 20,000 per cu mm platelets
and clinical bleeding disorder; both must be
present for patient to be excluded.*
Yes
No
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Eligibility Hepatocellular Carcinoma
NCT00149565
Phase _ Randomized Trial in Postoperative Hepatocellular
Carcinoma; ODM derived from:
https://clinicaltrials.gov/show/NCT00149565
All rights reserved. Please visit https://medical-data-
models.org/forms/13665
Eligibility Hepatocellular Carcinoma
NCT00149565
Inclusion Criteria
1. histologically proven hepatocellular
carcinoma.*
Yes
No
2. hcc underwent curative resection within 6
weeks before registration.*
Yes
No
3. grossly, the resection margin should be > 1
cm.*
Yes
No
4. patients must be younger than 70 year-old.*
Yes
No
5. patients must have a performance status of
ecog score < 2.*
Yes
No
6. patients must have adequate liver reservation
and adequate hemogram.*
Yes
No
7. pugh-child‘s score < 7.*
Yes
No
8. the serum total bilirubin level are < 2 mg/dl.*
Yes
No
9. the prothrombin times are < 3 sec above
normal control.*
Yes
No
10. the platelet are > 10 x 104 / mm3.*
Yes
No
11. the wbc are > 3,000 / mm3.*
Yes
No
12. patient must have serum creatinine < 1.5
1 / 3
mg/dl*
Yes
No
13. cardiac function with nyha classification <
grade ii*
Yes
No
14. known hbv or hcv status.*
Yes
No
15. signed informed consent.*
Yes
No
exclusion criteria:*
Yes
No
1. patients who have non-curative resection are
not eligible.*
Yes
No
2. resected hccs with histologically positive
margins are not eligible.*
Yes
No
3. hccs with radiological evidence of portal vein
thrombus are not eligible.*
Yes
No
4. patients with other systemic diseases which
required concurrent usage of glucocorticosteroid
or immunosuppressant agent(s) are not eligible.*
Yes
No
5. patients with advanced second primary
malignancy are not eligible.*
Yes
No
6. patients with pregnacy or breast-feeding are
not eligible.*
Yes
No
7. patients with severe cardiopulmonary diseases
are not eligible.*
Yes
No
8. patients with clinically significant psychiatric
disorder are not eligible.*
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Yes
No
9. patients who had antineoplastic
chemotherapeutic or immuno-therapeutic drugs
or corticosteroids within 6 weeks of commencing
the protocol are not eligible.*
Yes
No
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Eligibility Leukemia NCT00262782
Fludarabine or Observation in Treating Patients With Stage
0, Stage I, or Stage II Chronic Lymphocytic Leukemia;
ODM derived from:
https://clinicaltrials.gov/show/NCT00262782
All rights reserved. Please visit https://medical-data-
models.org/forms/13666
Eligibility Leukemia NCT00262782
Criteria
confirmed diagnosis of b-cell chronic lymphocytic
leukemia*
Yes
No
rai stage 0-ii (binet stage a) disease*
Yes
No
meets 1 of the following criteria:*
Yes
No
high-risk disease, as defined by the following:*
Yes
No
serum thymidine kinase level > 7.0 u/l*
Yes
No
elevated β2-microglobulin level*
Yes
No
presence of non-nodular bone marrow infiltration*
Yes
No
short lymphocyte doubling time*
Yes
No
low-risk disease*
Yes
No
meets none of the criteria (as listed above) for
high-risk disease*
Yes
No
life expectancy: more than 6 months*
Yes
No
no autoimmune hemolytic anemia*
Yes
No
no thrombocytopenia*
Yes
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No
no severe organ dysfunction*
Yes
No
no other prior or concurrent malignancy*
Yes
No
no prior chemotherapy*
Yes
No
no other concurrent chemotherapy*
Yes
No
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Eligibility Lung Cancer NCT00003006
Detection of Early Metastases in Patients With Stage I Non-
small Cell Lung Cancer; ODM derived from:
https://clinicaltrials.gov/show/NCT00003006
All rights reserved. Please visit https://medical-data-
models.org/forms/13667
Eligibility Lung Cancer
NCT00003006
Criteria
suspected or histologically confirmed previously
untreated non-small cell lung cancer*
Yes
No
clinical stage i disease*
Yes
No
t1 or t2 primary*
Yes
No
n1 or n2 lymph nodes less than 1 cm on ct scan
or negative mediastinoscopy*
Yes
No
planned thoracotomy for lobectomy or
pneumonectomy*
Yes
No
video-assisted lobectomy is acceptable if no
preliminary wedge resection of tumor is
performed*
Yes
No
no history of prior lung cancer*
Yes
No
Age: 18 and over*
Yes
No
no other prior or concurrent malignancy within the
past 5 years except inactive non-melanoma skin
cancer or carcinoma in situ of the cervix*
Yes
No
at least 5 years since prior chemotherapy*
Yes
No
radiotherapy:*
Yes
No
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at least 5 years since prior radiotherapy*
Yes
No
no prior mediastinal or chest radiotherapy*
Yes
No
see disease characteristics*
Yes
No
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Modified Rankin scale,structured interview and ultrasound examination Coronary
Artery Bypass graft surgery in patients with Asymptomatic Carotid Stenosis
Coronary Artery Bypass graft surgery in patients with
Asymptomatic Carotid Stenosis. A randomized controlled
clinical trial. Short title: "CABACS" DRKS
Number:DRKS00000521 IRSCTN
Number:ISRCTN13486906 Phase:Therapeutic
confirmatory(Phase III) Head of clinical trial: Prof. Dr. med.
Christian Weimar University Duisburg-Essen Phone:
0201/723-6503 Fax: 0201/723-6948 e-mail:
christian.weimar@uk-essen.de University Hospital Essen
Hospital for Neurology Hufelandstr. 55 45122 Essen Trial
coordinator: Dr. med. Stephan Knipp Phone: 0201/723-
4915 Fax: 0201/723-5451 e-mail: stephan.knipp@uk-
essen.de University Duisburg-Essen University Hospital
Essen Hospital for thoracic- and cardiovascular surgery
Hufelandstr. 55 45122 Essen Data Management: Anja Marr
Phone: 0201/92239-257 Fax: 0201/92239-333 o. 0201/723-
5933 e-mail: anja.marr@uk-essen.de University Hospital
Essen Center for clinical trials Essen c/o IMIBE
Hufelandstr. 55 45122 Essen Monitoring: Dipl.-Biol.
Konstantinos Bilbilis Phone: 0201/92239-252 Fax:
0201/92239-310 e-mail: konstantinos.bilbilis@uk-essen.de
University Hospital Essen Center for clinical trials Essen c/o
IMIBE Hufelandstr. 55 45122 Essen
All rights reserved. Please visit https://medical-data-
models.org/forms/13668
CABACS Case Report Form
[Modified Rankin scale,structured
interview and ultrasound
examination]
Modified Rankin Scale,structured
interview
Date of screening for trial
Patient ID
Do you (your family member) need constant
nursing care?
yes (severe
disability,bedridden,incontinence,constan
t nursing care in almost every aspect of
daily life) 5 (1)
No (2)
Do you (your family member)need assistance
with eating,toileting,personal hygiene or walking?
Yes (moderately severe disability, walking
without help impossible,assistance with
ADL´s needed) 4 (1)
No (2)
Do you (your family member) need assistance to
prepare a simple meal, for house keeping tasks,
deal with money, do the groceries or to get along
in your home town?
Yes (Moderate disability, assistance
needed but can walk with or without
walking aid) 3 (1)
No (2)
Have there been changes in your (your family
members) ability to work or care for others if
that´s what you did? Have there been changes in
your (your family members) ability to participate
in social and leisure activities?
Have you (your family member) experienced
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problems with personal relationships or did you
(your family member) seclude yourself?
Yes (mild disability, not all former
activities can be performed but
independend life without help is still
possible) 2 (1)
No (2)
Do you (your family member) have problems with
reading or writing or to find the right words durin
conversation?
Have you (your family member) experienced
problems with balance, coordination, vision,
numbness of diverse skin spots or problems to
swallow?
Yes (no significant disability, despite
symptoms all daily activities can be
performed independently) 1 (1)
No (2)
No disability at all
Yes
No
Patient age
years
Did you perform the DemTect test with the
patient?
Yes
No
Count of correctly repeated words of wordlist:
plate,dog,lamp,letter,apple,pants,table,lawn,glass
,tree.
<= 20
Converting numbers: Count of correctly
converted numbers 209= ;4054= ;
sixhundredeightyone= ;
twothousandeightyseven=
<= 4
Please count the number of items to buy in a
grocery store your patient can think of within one
minute
<= 30
Please note the longest line of numbers (max. 6
numbers in a row) your patient was able to repeat
backwards. Two attempts allowed.
<= 6
Please ask your patient to repeat again the ten
words of the first question and count the correctly
repeated words.
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<= 10
Please note any particularities regarding the
testing situation (i.e patient with hearing
impairment, any interruption during testing...)
Date of completion of this form
Signature by investigator/neurologist
Name of Investigator/neurologist
Ultrasound examination
Date of ultrasound examination
Percentage of stenosis (ECST) in right common
carotid artery structure
%
Intima media thickness of right common artery
structure (1 cm proximal of bulb)
mm
Percentage of stenosis of internal carotid artery
structure (ECST)
%
Structure of right vertebral artery:
normal (1)
hypoplasia (2)
circulation disorder (3)
occlusion (4)
Structure of right supratrochlear artery
orthograde (1)
retrograde (2)
Echo pattern of the stenosis to be treated
homogeneous (1)
inhomogeneous (2)
inconclusive (3)
Echogenicity of the stenosis to be treated
mostly hyperechoic (1)
mostly hypoechoic (2)
inconclusive (3)
Surface of the stenosis to be treated
smooth (1)
irregular (2)
ulcerated (3)
inconclusive (4)
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Method of measurement
CO2-Breathing (5%) (1)
Diamox (15mg/kgKG) (2)
not assessed (3)
Measured acceleration of flow in middle cerebral
artery
%
Deceleration of flow in middle cerebral artery
Yes
No
Doppler ultrasound of basilar artery
normal (1)
stenosis signal (2)
Deceleration (3)
reversal of direction of flow (4)
Date of completion of this form
Signature by investigator/neurologist
Name of Investigator
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Patient randomization form Coronary Artery Bypass graft
surgery in patients with Asymptomatic Carotid Stenosis
Coronary Artery Bypass graft surgery in patients with
Asymptomatic Carotid Stenosis. A randomized controlled
clinical trial. Short title: "CABACS" DRKS
Number:DRKS00000521 IRSCTN
Number:ISRCTN13486906 Phase:Therapeutic
confirmatory(Phase III) Head of clinical trial: Prof. Dr. med.
Christian Weimar University Duisburg-Essen Phone:
0201/723-6503 Fax: 0201/723-6948 e-mail:
christian.weimar@uk-essen.de University Hospital Essen
Hospital for Neurology Hufelandstr. 55 45122 Essen Trial
coordinator: Dr. med. Stephan Knipp Phone: 0201/723-
4915 Fax: 0201/723-5451 e-mail: stephan.knipp@uk-
essen.de University Duisburg-Essen University Hospital
Essen Hospital for thoracic- and cardiovascular surgery
Hufelandstr. 55 45122 Essen Data Management: Anja Marr
Phone: 0201/92239-257 Fax: 0201/92239-333 o. 0201/723-
5933 e-mail: anja.marr@uk-essen.de University Hospital
Essen Center for clinical trials Essen c/o IMIBE
Hufelandstr. 55 45122 Essen Monitoring: Dipl.-Biol.
Konstantinos Bilbilis Phone: 0201/92239-252 Fax:
0201/92239-310 e-mail: konstantinos.bilbilis@uk-essen.de
University Hospital Essen Center for clinical trials Essen c/o
IMIBE Hufelandstr. 55 45122 Essen
All rights reserved. Please visit https://medical-data-
models.org/forms/13669
CABACS Case Report Form [Patient
randomization form]
Patient randomization form
Patient ID
Are all inclusion criteria met?
Yes
No
Have any exclusion criteria been answered with
yes?
Yes
No
Informed consent signed
Yes
No
Date of informed consent
Study site number
Age
<60years (1)
≥ 60 Jahre (2)
Gender
male (1)
female (2)
Modified rankin scale score
0-1 (1)
2-3 (2)
Please enter a phone number for further
questions that might occur
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Please enter a valid fax number
Date of Randomization
Signature by investigator
Name of Investigator
Patient has been randomized into following group
CABG with CEA (1)
CABG without CEA (2)
Date of Randomization
Signature by randomizing Person
Name of randomizing person
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Baseline visit Coronary Artery Bypass graft surgery
in patients with Asymptomatic Carotid Stenosis
Coronary Artery Bypass graft surgery in patients with
Asymptomatic Carotid Stenosis. A randomized controlled
clinical trial. Short title: "CABACS" DRKS
Number:DRKS00000521 IRSCTN
Number:ISRCTN13486906 Phase:Therapeutic
confirmatory(Phase III) Head of clinical trial: Prof. Dr. med.
Christian Weimar University Duisburg-Essen Phone:
0201/723-6503 Fax: 0201/723-6948 e-mail:
christian.weimar@uk-essen.de University Hospital Essen
Hospital for Neurology Hufelandstr. 55 45122 Essen Trial
coordinator: Dr. med. Stephan Knipp Phone: 0201/723-
4915 Fax: 0201/723-5451 e-mail: stephan.knipp@uk-
essen.de University Duisburg-Essen University Hospital
Essen Hospital for thoracic- and cardiovascular surgery
Hufelandstr. 55 45122 Essen Data Management: Anja Marr
Phone: 0201/92239-257 Fax: 0201/92239-333 o. 0201/723-
5933 e-mail: anja.marr@uk-essen.de University Hospital
Essen Center for clinical trials Essen c/o IMIBE
Hufelandstr. 55 45122 Essen Monitoring: Dipl.-Biol.
Konstantinos Bilbilis Phone: 0201/92239-252 Fax:
0201/92239-310 e-mail: konstantinos.bilbilis@uk-essen.de
University Hospital Essen Center for clinical trials Essen c/o
IMIBE Hufelandstr. 55 45122 Essen
All rights reserved. Please visit https://medical-data-
models.org/forms/13670
CABACS Case Report Form
[Baseline visit]
Baseline Examination
Date of visit
Patient ID
ECG done?
Yes
No
Date of ECG
Any pathologic findings in ECG?
Yes
No
Please specify any pathologic ECG findings
Did any of the events listed below happen after
randomization but before CABG surgery? If yes,
please fill in the outcome event form.
Stroke (1)
Myocardial infarction (2)
Death (3)
Not applicable (4)
Did the patient take antiplatelet agents the day
before surgery?
Yes
No
Please choose from the list below, which
antiplatelet drug the patient took
Acetyl salicylic acid (1)
Clopidogrel (2)
Acetyl salicylic acid plus Dipyridamole
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(3)
More than one of the list (4)
Other (5)
Please specify which antiplatelet drugs the
patient took, if you chose "other" or "more than
one"
Did the patient take any anticoagulants the day
before surgery?
Yes
No
Please choose which one of the anticoagulants
listed below the patient took.
Unfractionated heparin IV (1)
Full dose LMW heparin (Enoxaparin ,
Others) (2)
Vitamin K Antagonists like Warfarin
(Coumadin) (3)
Dabigatran (4)
Other (5)
More than one of the list (6)
Please specify which anticoagulant the patient
took, if you chose "other" or "more than one".
Did the patient take any antihypertensive drugs
the day before surgery?
Yes
No
Please choose which one of the antihypertensive
drugs listed below the patient took.
ACE inhibitor (1)
angiotensin receptor blocker (2)
Diuretics (3)
Calcium Antagonist (4)
Beta blocker (5)
Other (6)
More than one of the list (7)
Please specify which antihypertensive agent the
patient took, if you chose "other" or "more than
one".
Did the patient take any lipid lowering agents the
day before surgery?
Yes
No
Please choose which one of the antilipemic
agents listed below the patient took
Statine (1)
Other (2)
More than one (3)
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Please specify which antilipemic agent the
patient took, if you chose "other" or "more than
one".
Any other relevant concomitant medication the
patient took the day before surgery?
Yes
No
Please specify what other concomitant
medication the patient took
Date of completion of this form
Signature by investigator
Name of Investigator
3 / 3
Baseline visit Coronary Artery Bypass graft surgery in patients with
Asymptomatic Carotid Stenosis
Eligibility Multiple Sclerosis NCT00001669
A 48-Week (24-Week Baseline Followed by a 24-Week
Treatment) Phase II Pilot Study of the Tolerability and
Effect/Efficacy of Subcutaneously Administered Insulin-Like
Growth Factor-1 (rhIGF) (CEP-151) in Multiple Sclerosis
(MS) Patients; ODM derived from:
https://clinicaltrials.gov/show/NCT00001669
All rights reserved. Please visit https://medical-data-
models.org/forms/13676
Eligibility Multiple Sclerosis
NCT00001669
Criteria
stage i - known by history to have a mean
enhancing lesion frequency of 0.3 per month or
greater;*
Yes
No
stage ii - known by history to have a mean
enhancing lesion frequency of 0.5 per month or
greater;*
Yes
No
ability to comply with protocol requirements;*
Yes
No
provide written informed consent;*
Yes
No
if a female patient, not of child bearing potential
(surgically sterilized or post-menopausal) or if of
child bearing potential, documented to be
nonpregnant by urine pregnancy test and not
lactating with adequate contraception and
counseling.*
Yes
No
male patients should also receive adequate
counseling and exercise adequate
contraception.*
Yes
No
no clinically significant abnormalities on the
prestudy laboratory evaluations, physical
examination, electrocardiogram (ecg), chest x-
ray, mammogram or ophthalmologic exam.*
Yes
No
no connective tissue or rheumatic disorder
(systemic lupus erythematosus [sle] ; rheumatoid
arthritis [ra]; progressive systemic sclerosis [pss];
sjogren's syndrome [ss]).*
Yes
No
patient may not be hiv (human immunodeficiency
1 / 3
virus), htlv-1 (human t cell leukemia virus), or
hb/c ag (hepatitis b or c surface antigen)
positive.*
Yes
No
no history of insulin-producing tumors or reactive
hypoglycemia.*
Yes
No
no clinically significant medical condition (e.g.,
within 6 months of screen had myocardial
infarction, angina pectoris, untreated
hypertension, and/or congestive heart failure [chf]
that, in the opinion of the investigator would
compromise the safety of the patient.*
Yes
No
ability to tolerate mri examinations due to
claustrophobia, or have contraindications to mri
scanning, such as pacemakers, aneurysm clips,
or shrapnel fragments.  welders and metal
workers must have radiographic evidence to
document lack of foreign bodies in the eyes or
they will be excluded, due to the risk of eye injury
while in the mri machine.*
Yes
No
no history of substance use disorder (dsm-iv
criteria) within the past two years.*
Yes
No
no type i or type ii diabetes treated with
hypoglycemic agents (diet-controlled type ii
diabetes may be included.)*
Yes
No
no history of cancer (with the exception of
localized skin cancers with no evidence of
metastasis, significant invasion, or recurrence)
within three years of screening.*
Yes
No
no first or second degree relatives with breast
cancer.*
Yes
No
have not used an investigational drug within 30
days of the screen visit.*
Yes
No
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have previously received interferon-alpha,
interferon-beta, copolymer 1, cyclophosphamide,
intravenous immunoglobulin, oral myelin, or other
immunosuppressive drugs within 6 months of
screen.*
Yes
No
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Eligibility Non-Hodgkin's Lymphoma
NCT00225212
Rituximab After Autologous Stem Cell Transplant for
Relapsed B-cell Non-Hodgkin's Lymphoma; ODM derived
from: https://clinicaltrials.gov/show/NCT00225212
All rights reserved. Please visit https://medical-data-
models.org/forms/13677
Eligibility Non-Hodgkin's Lymphoma
NCT00225212
Inclusion Criteria
b-cell, cd20+ nhl*
Yes
No
evidence of engraftment post-autologous
peripheral blood stem cell transplant (pbsc-t), aka
autologous stem cell transplant (asct)*
Yes
No
eastern cooperative oncology group (ecog)
performance status 0 to 1*
Yes
No
creatinine < 2 mg/dl*
Yes
No
bilirubin < 2.0 mg/dl*
Yes
No
liver function tests (lfts) < 5 x upper limit of
normal (uln)*
Yes
No
Exclusion Criteria
graft source from bone marrow*
Yes
No
non-responders [progressive disease (pd) or
stable disease (sd)] to prior anti-cd20 therapy*
Yes
No
progressive disease after asct*
Yes
No
post-asct radiotherapy*
Yes
No
concomitant treatment with radiotherapy,
chemotherapy or immunotherapy including
rituximab*
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Yes
No
evidence of active pneumonitis*
Yes
No
evidence of active infection*
Yes
No
concurrent prednisone or other systemic steroid
medication*
Yes
No
nitrosourea therapy within 6 weeks of the first
treatment with rituximab*
Yes
No
presence of anti-murine antibody (hama)
reactivity*
Yes
No
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Eligibility Prostate Cancer NCT00002848
Group Therapy Compared With Educational Materials in
Patients With Prostate Cancer; ODM derived from:
https://clinicaltrials.gov/show/NCT00002848
All rights reserved. Please visit https://medical-data-
models.org/forms/13678
Eligibility Prostate Cancer
NCT00002848
Criteria
biopsy-proven prostate cancer diagnosed within 1
year prior to entry*
Yes
No
clinical stage i/ii (t1b-c or t2, n0 or nx, m0)
disease*
Yes
No
pathologic local upstaging (e.g., to t3) allowed*
Yes
No
no nx disease if pathologic or partial pathologic
(e.g., lymph node biopsy or dissection) staging
performed*
Yes
No
no major psychiatric illness requiring
hospitalization or medication other than
depression or anxiety for less than 1 year*
Yes
No
no second malignancy within 10 years except
nonmelanomatous skin cancer*
Yes
No
clinical follow-up by a urologist, medical
oncologist, or radiation therapist required at least
semi-annually*
Yes
No
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NCT00412815
Exercise Training, Insulin Resistance and Coronary Artery
Disease; ODM derived from:
https://clinicaltrials.gov/show/NCT00412815
All rights reserved. Please visit https://medical-data-
models.org/forms/13679
Eligibility Coronary Artery Disease
NCT00412815
Inclusion Criteria
men and women over 18 years of age*
Yes
No
fasting plasma glucose concentration 5.4-7.7
mmol/l*
Yes
No
confirmed coronary artery disease (diagnosed on
the basis of a previous myocardial perfusion
study or cardiac catheterization, or a history of a
myocardial infarction or coronary artery
angioplasty or coronary artery bypass surgery).*
Yes
No
Exclusion Criteria
known type 1 or 2 diabetes*
Yes
No
clinical heart failure*
Yes
No
uncorrected significant valvular or congenital
heart disease*
Yes
No
significant obstructive pulmonary disease (forced
expiratory volume in 1 sec / forced vital capacity
< 0.5)*
Yes
No
uncontrolled hypertension (blood pressure > 220
/ 120 mm hg)*
Yes
No
participation in a regular exercise program within
the preceding three months*
Yes
No
inability to perform exercise training, atrial
fibrillation*
Yes
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No
a permanent pacemaker*
Yes
No
regularly used corticosteroid*
Yes
No
recent (< 3 months) myocardial infarction,
unstable angina, coronary artery bypass graft
surgery, or coronary artery angioplasty*
Yes
No
run-in phase fasting blood glucose was < 5.4
mmol/l or > 11.1 mmol/l at 2 hours following the
75 gram oral glucose load.*
Yes
No
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Eligibility Chronic Lymphocytic Leukemia
(CLL) NCT01463852
A Study of the Effect of Vinca Alkaloids on c-Jun N-terminal
Kinase (JNK) Phosphorylation in Patients With Chronic
Lymphocytic Leukemia (CLL); ODM derived from:
https://clinicaltrials.gov/show/NCT01463852
All rights reserved. Please visit https://medical-data-
models.org/forms/13680
Eligibility Chronic Lymphocytic
Leukemia (CLL) NCT01463852
Inclusion Criteria
1. male or female, 18 years old or older.*
Yes
No
2. a diagnosis of chronic lymphocytic
leukemia(cll) which is cd5/cd19/cd23 positive,
confirmed by peripheral blood
immunophenotyping and/or lymph node biopsy
and immunophenotyping and/or bone marrow
biopsy and immunophenotyping. cd23-negative
cll cases are eligible, however additional
diagnostic confirmation should include absence
of cyclin d1 rearrangement [t(11;14)] as
determined by standard laboratory methods
(such as fluorescent in situ hybridization).*
Yes
No
3. patients are planning to start chemotherapy for
cll recommended and prescribed by their primary
oncologist.*
Yes
No
4. peripheral blood lymphocyte count above
20,000/mm3*
Yes
No
5. be able to provide written informed consent*
Yes
No
Exclusion Criteria
1. patients who have had chemotherapy or
radiotherapy within 4 weeks (6 weeks for
nitrosoureas or mitomycin c) prior to entering the
study or those who have not recovered from
adverse events due to agents administered more
than 4 weeks earlier.*
Yes
No
2. patients who are receiving any other
investigational agents.*
Yes
No
3. history of allergic reactions attributed to
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compounds of similar chemical or biologic
composition to vincristine.*
Yes
No
4. uncontrolled concurrent illness including, but
not limited to, ongoing or active infection,
symptomatic congestive heart failure, unstable
angina pectoris, cardiac arrhythmia, or psychiatric
illness/social situations that would limit
compliance with study requirements.*
Yes
No
5. liver function test abnormalities of ≥ grade 3
(total bilirubin >3 uln (upper limit of normal), ast>
5 uln, alt> 5 uln) as per ctcae 4.0 criteria, or
direct bilirubin ≥ 3.0 mg/dl*
Yes
No
6. pre-existing neuropathy grade 2 or greater as
per ctcae 4.0 criteria (moderate symptoms
limiting instrumental activities of daily living -
adls)*
Yes
No
7. patients who are pregnant or planning to
become pregnant during their participation in the
study.*
Yes
No
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Genereral information EBMT MDS
ODM derived from HSCT forms on http://www.ebmt.org/
All rights reserved. Please visit https://medical-data-
models.org/forms/13681
Genereral information EBMT MDS
Team
EBMT Centre Identification Code (CIC)
Name of the hospital
Unit
Name of contact person
Telephone number of contact person
Fax number of contact number
E-mail address of contact number
Date of this report
Patient following national/ international study/ trial
if yes specify name of study/ trial
No (No)
Unknown (Unknown)
Yes (Yes)
Name of study trial
Patient
Unique identification code
(to be entered if patient previously reported)
Hospital Unique Patient number or code
First name(s) - surname(s)
(Registrations will not be accepted if this item is
left blank)
Patient Firstname
(Registrations will not be accepted if this item is
left blank)
Patient Surname
(Registrations will not be accepted if this item is
left blank)
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Date of birth
Gender of patient
Female (Female)
Male (Male)
Patient's blood group (AB0)
0 (0)
A (A)
AB (AB)
B (B)
Specification of blood group (Rhesus factor)
absent (absent)
not evaluated (not evaluated)
present (present)
Disease
Date of diagnosis
Check the disease for which this transplant was
performed
(if other diagnosis, specify)
Acute Leukaemia (Acute Leukaemia)
Autoimmune Disease (Autoimmune
Disease)
Bone marrow failure including Aplastic
Anaemia (Bone marrow failure including
Aplastic Anaemia)
Chronic Leukaemia (Chronic Leukaemia)
Chronic Lymphocytic Leukaemia (CLL)
(Chronic Lymphocytic Leukaemia (CLL))
Chronic Myeloid Leukaemia (CML)
(Chronic Myeloid Leukaemia (CML))
Haemoglobinopathy
(Haemoglobinopathy)
Histocytic Disorders (Histocytic
Disorders)
Hodgkin's Disease (Hodgkin's Disease)
Inherited disorders (Inherited disorders)
Juvenile Idiopathic Arthritis (Juvenile
Idiopathic Arthritis)
Lymphoblastic (ALL) (Lymphoblastic
(ALL))
Lymphoma (Lymphoma)
MD/ MPN (MD/ MPN)
MDS (MDS)
Metabolic disorders (Metabolic
disorders)
Multiple Sclerosis (Multiple Sclerosis)
Myelodysplastic Syndromes
(Myelodysplastic Syndromes)
Myelogenous (AML) (Myelogenous
(AML))
Myeloma/ Plasma Cell Disorder
(Myeloma/ Plasma Cell Disorder)
2 / 3
Genereral information EBMT MDS
Myeloproliferative neoplasm
(Myeloproliferative neoplasm)
Non Hodgkin (Non Hodgkin)
Other diagnosis (Other diagnosis)
Primary immune deficiencies (Primary
immune deficiencies)
Secondary Acute Leukaemia (Do not
use if transformed from MDS/ MPN)
(Secondary Acute Leukaemia (Do not
use if transformed from MDS/ MPN))
Solid Tumor (Solid Tumor)
Systemic Lupus (Systemic Lupus)
Systemic Sclerosis (Systemic Sclerosis)
If use other diagnosis, specification
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Genereral information EBMT MDS
Eligibility Chronic Lymphocytic Leukemia
NCT01400685
Lenalidomide Plus Bendamustine and Rituximab for
Untreated CLL/SLL; ODM derived from:
https://clinicaltrials.gov/show/NCT01400685
All rights reserved. Please visit https://medical-data-
models.org/forms/13682
Eligibility Chronic Lymphocytic
Leukemia NCT01400685
Inclusion Criteria
diagnosed with b-cell cll or sll (chronic
lymphocytic leukemia or small lymphocytic
leukemia)*
Yes
No
life expectancy > 3 months*
Yes
No
organ and marrow function with protocol
parameters*
Yes
No
able to take aspirin daily*
Yes
No
Exclusion Criteria
age >80 years*
Yes
No
prior systemic therapy for cll/sll including
chemotherapy or antibody therapy*
Yes
No
pregnant or breast-feeding*
Yes
No
serious medical condition, laboratory abnormality,
or psychiatric illness that would prevent the
subject from signing informed consent*
Yes
No
known hypersensitivity to thalidomide or
lenalidomide*
Yes
No
prior use of lenalidomide*
Yes
No
concurrent use of other anti-cancer agents or
treatments*
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Yes
No
hiv positive*
Yes
No
prior history of another malignancy unless
disease free for at least 2 years*
Yes
No
uncontrolled intercurrent illness*
Yes
No
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Eligibility Chronic Lymphocytic Leukemia NCT01400685
Eligibility Chronic Lymphocytic Leukemia
NCT01465230
Maintenance Therapy: Lenalidomide Following
Bendamustine and Rituximab Induction Therapy for
Chronic Lymphocytic Leukemia; ODM derived from:
https://clinicaltrials.gov/show/NCT01465230
All rights reserved. Please visit https://medical-data-
models.org/forms/13683
Eligibility Chronic Lymphocytic
Leukemia NCT01465230
Inclusion Criteria
previous induction treatment with bendamustine
and rituximab*
Yes
No
18 or more years of age*
Yes
No
chronic lymphocytic leukemia*
Yes
No
ecog performance status less than or equal to 2*
Yes
No
absolute neutrophile count more than 1,000*
Yes
No
platelet count more than 70,000*
Yes
No
Exclusion Criteria
serious medical condition that would prevent
treatment with lenalidomide*
Yes
No
evidence of tumor lysis syndrome*
Yes
No
any prior treatment with lenalidomide*
Yes
No
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Eligibility Contrast Induced Nephropathy
NCT01456013
Evaluation of RenalGuard® System to Reduce the
Incidence of Contrast Induced Nephropathy in At-Risk
Patients; ODM derived from:
https://clinicaltrials.gov/show/NCT01456013
All rights reserved. Please visit https://medical-data-
models.org/forms/13684
Eligibility Contrast Induced
Nephropathy NCT01456013
Inclusion Criteria
male or non-pregnant female equal or greater
than the age of 18 years old and is able to
provide informed consent.*
Yes
No
subject is scheduled to undergo an elective
catheterization procedure*
Yes
No
hemodynamically stable*
Yes
No
at increased risk of developing cin*
Yes
No
subject has agreed to all follow-up testing.*
Yes
No
Exclusion Criteria
class 3 or 4 congestive heart failure (chf)*
Yes
No
is anuric or has undergone renal replacement
therapy within the past month, or has a known
inability to have a foley catheter placed.*
Yes
No
subject has been hospitalized or treated
medically for any change in renal function over
the past week (i.e. dialysis, etc.), or a significant
change in renal function is noted at time of
screening.*
Yes
No
has documented severe aortic stenosis.(note:
subjects who have undergone successful
replacement or repair of their aortic valve are not
excluded.)*
Yes
No
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currently has a known clinically significant
electrolyte imbalance or clinically significant
arrhythmias which compromise subject's
hemodynamic state.*
Yes
No
patient has moderate to severe anemia
(hematocrit < 27%) at screening*
Yes
No
has received contrast within 10 days of procedure
or has a planned additional cardiac or renal or
other major surgical procedure within the7 day
follow-up period.*
Yes
No
has ruled in for an serious heart attack within 48
hours of the planned procedure*
Yes
No
has documented respiratory insufficiency as
evidenced by an oxygen saturation of < 90% on
room air assessed on day of procedure.*
Yes
No
planned addition, discontinuation or dose
adjustment of the nephrotoxic drugs*
Yes
No
subject has a known hypersensitivity to
furosemide and/or the contrast agent being
used.*
Yes
No
subject is currently, plans, or has been enrolled in
another clinical study involving use of an
investigational drug or device within the prior 30
days.*
Yes
No
subject is pregnant or breastfeeding.*
Yes
No
subject is unable to provide informed consent.*
Yes
No
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Eligibility Contrast Induced Nephropathy NCT01456013
Specification of the disease EBMT MDS
ODM derived from HSCT forms on http://www.ebmt.org/
All rights reserved. Please visit https://medical-data-
models.org/forms/13685
Specification of the disease
Initial Diagnosis
Myelodysplastic Syndrome 
(WHO)-Subclassification
(Please use the WHO subclassification if
possible)
Childhood myelodysplastic syndrome
(Refractory cytopenia of childhood
(RCC)) (Childhood myelodysplastic
syndrome (Refractory cytopenia of
childhood (RCC)))
MDS associated with isolated del(5q)
(MDS associated with isolated del(5q))
RA with excess of blasts (RAEB-1) (RA
with excess of blasts (RAEB-1))
RA with excess of blasts (RAEB-2) (RA
with excess of blasts (RAEB-2))
RA with ring sideroblasts (RARS) (RA
with ring sideroblasts (RARS))
Refractory Anaemia (without ring
sideroblasts) RA (Refractory Anaemia
(without ring sideroblasts) RA)
Refractory cytopenia with multilineage
dysplasia (RCMD) (Refractory cytopenia
with multilineage dysplasia (RCMD))
Refractory cytopenia with multilineage
dysplasia and ringed sideroblasts
(RCMD-RS) (Refractory cytopenia with
multilineage dysplasia and ringed
sideroblasts (RCMD-RS))
Unclassified (MDS-U) (Unclassified
(MDS-U))
Myelodysplastic Syndrome
(FAB)-Subclassification
RA with excess of blasts (RAEB) (RA
with excess of blasts (RAEB))
RA with ring siderodblasts (RARS) (RA
with ring siderodblasts (RARS))
RA without ring siderboblasts (RA) (RA
without ring siderboblasts (RA))
RAEB in transformation (RAEB-t) (RAEB
in transformation (RAEB-t))
Unclassified (Unclassified)
Myelodysplastic/ Myeloproliferative Neoplasm
Specification
Atpyical Chronic Myeloid Leukaemia
(Atypical CML, t(9;22)negative and
BCR/ABL negative) (Atpyical Chronic
Myeloid Leukaemia (Atypical CML,
t(9;22)negative and BCR/ABL negative))
Chronic Myelomonocytic Leukaemia
(CMMoL, CMML) (Chronic
Myelomonocytic Leukaemia (CMMoL,
CMML))
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Juvenile Myelomonocytic Leukaemia
(JCMMoL, JMML, JCML, JCMML)
(Juvenile Myelomonocytic Leukaemia
(JCMMoL, JMML, JCML, JCMML))
Type I (Type I)
Type II (Type II)
Secondary Acute Leukaemia
Related to prior treatment and not after a
previous diagnosis of MDS or MPS).
Acute Myelogenous Leukaemia (AML)
(ProMiSe users: Please use code 1 for
main diagnosis) (Acute Myelogenous
Leukaemia (AML) (ProMiSe users:
Please use code 1 for main diagnosis))
Secondary Origin of Disease
If yes, specify cause
If yes, specify primary disease
No (No)
Unknown (Unknown)
Yes (If Secondary Acute Leukaemia, it
must always be Yes) (Yes (If Secondary
Acute Leukaemia, it must always be
Yes))
Secondary Origin 
If yes, specify cause
After stem cell HSCT (After stem cell
HSCT)
Alkylating agent/radiation-related
(Alkylating agent/radiation-related)
Chemoth./ Radiationth. treated disease
(tick all that apply): (Chemoth./
Radiationth. treated disease (tick all that
apply):)
Immune suppression (Immune
suppression)
Other (Other)
Radiation (Radiation)
Topoisomerase II inhibitor-related
(Topoisomerase II inhibitor-related)
Unknown (Unknown)
Unknown (Unknown)
Secondary Origin 
If yes, specify cause
If cause other, specify
Secondary origin 
If yes, specify Primary Disease
Date of diagnosis of Primary Disease
Secondary Origin
If yes, specify Primary Disease
If other, Specify
ALL (ALL)
AML (AML)
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Specification of the disease EBMT MDS
Aplastic anamia (Aplastic anamia)
Autoimmune (Autoimmune)
CML (CML)
Hodgkin's disease (Hodgkin's disease)
Inherited disorder (Inherited disorder)
Multiple myeloma (Multiple myeloma)
NHL (NHL)
Other (Other)
Other chronic leukaemia (Other chronic
leukaemia)
Other plasma cell disorder (Other
plasma cell disorder)
PNH (PNH)
Solid tumour (Solid tumour)
unknown (unknown)
Secondary Origin
If yes, specify Primary Disease
If other, specify
Include all analysis before treatment; describe
results of most recent complete analysis
Chromosome analysis
Done: abnormal (Done: abnormal)
Done: normal (Done: normal)
Not Done or failed (Not Done or failed)
Unknown (Unknown)
Chromosome analysis
If abnormal: are there 3 or more abnormalities
(complex kariotype)=
No (No)
unknown (unknown)
Yes (Yes)
Chromosome analysis
If done: number of metaphases with
abnormalities
Chromosome analysis
If done: number of metaphases examined
Chromosome Analysis
Indicate which abnormalities found:
del 20q (20q-) (del 20q (20q-))
del 5q (5q-) (del 5q (5q-))
del 7q (7q-) (del 7q (7q-))
del Y (-Y) (del Y (-Y))
Other abn 5 (Other abn 5)
Other abn 7 (Other abn 7)
Other abnormalities (Other
abnormalities)
Indicate which abnormalities found:
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Specification of the disease EBMT MDS
Absent (Absent)
Present (Present)
Indicate which abnormalities foud:
If other, specify
Haematological values (at diagnosis)
Peripheral blood analysis
evaluated (evaluated)
not evaluated (not evaluated)
Peripheral Blood Analysis
If evaluated:
Hb (g/dL)
g/dL
Peripheral Blood Analysis 
If evaluated: 
Platelets (10^9/L)
10^9/L
Peripheral Blood Analysis 
If evaluated: 
White Blood Cells (10^9/L)
10^9/L
Peripheral Blood Analysis 
If evaluated: 
% blasts
%
Peripheral Blood Analysis 
If evaluated: 
% monocytes
%
Peripheral Blood Analysis 
If evaluated: 
% neutrophils
%
Bone marrow analysis
Evaluated  (Evaluated )
Not evaluated (Not evaluated)
Bone marrow analysis: 
If evaluated:
% blasts
%
Bone marrow analysis
Auer rods present
No (No)
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Not Evaluated (Not Evaluated)
Unknown (Unknown)
Yes (Yes)
Fill only for MDS and CMML; do not fill for
treatment related secondary Acute leukaemia, or
jMML)
High (> 2.5) (High (> 2.5))
Intermediate-1 (0.5 - 1.0) (Intermediate-1
(0.5 - 1.0))
Intermediate-2 (1.5 - 2) (Intermediate-2
(1.5 - 2))
Low (0) (Low (0))
Unknown (Unknown)
BM Investigation
Cytology (Cytology)
Histology (Histology)
Not available (Not available)
Results
(at diagnosis; check one in each column)
Cellularity on BM Aspirate/ BM biopsy
Acellular (Acellular)
Focal cellularity (Focal cellularity)
Hypercellular (Hypercellular)
Hypocellular (Hypocellular)
Normocellular (Normocellular)
Unknown (Unknown)
Results 
(at diagnosis; check one in each column) 
Fibrosis on BM biopsy
Mild (Mild)
Moderate (Moderate)
No (No)
Not evaluable (Not evaluable)
Severe (Severe)
Unknown (Unknown)
First Line Therapy
First Line Therapy given
(If No, proceed to "Subclassification & Status of
Disease at HSCT"
If Yes, specify start date)
Yes
No
Start Date of First Line Therapy
Myelodysplastic Syndrome 
(WHO)-Subclassification
(Please use the WHO subclassification if
possible)
(If patient had Secondary Acute Leukaemia
related to prior treatment, skip this
Subclassification section and proceed to
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Specification of the disease EBMT MDS
Treatment section)
Childhood myelodysplastic syndrome
(Refractory cytopenia of childhood
(RCC)) (Childhood myelodysplastic
syndrome (Refractory cytopenia of
childhood (RCC)))
MDS associated with isolated del(5q)
(MDS associated with isolated del(5q))
RA with excess of blasts (RAEB-1) (RA
with excess of blasts (RAEB-1))
RA with excess of blasts (RAEB-2) (RA
with excess of blasts (RAEB-2))
RA with ring sideroblasts (RARS) (RA
with ring sideroblasts (RARS))
Refractory Anaemia (without ring
sideroblasts) RA (Refractory Anaemia
(without ring sideroblasts) RA)
Refractory cytopenia with multilineage
dysplasia (RCMD) (Refractory cytopenia
with multilineage dysplasia (RCMD))
Refractory cytopenia with multilineage
dysplasia and ringed sideroblasts
(RCMD-RS) (Refractory cytopenia with
multilineage dysplasia and ringed
sideroblasts (RCMD-RS))
Unclassified (MDS-U) (Unclassified
(MDS-U))
Myelodysplastic Syndrome
(FAB)-Subclassification
RA with excess of blasts (RAEB) (RA
with excess of blasts (RAEB))
RA with ring siderodblasts (RARS) (RA
with ring siderodblasts (RARS))
RA without ring siderboblasts (RA) (RA
without ring siderboblasts (RA))
RAEB in transformation (RAEB-t) (RAEB
in transformation (RAEB-t))
Unclassified (Unclassified)
Myelodysplastic/ Myeloproliferative Neoplasm
Specification
Atpyical Chronic Myeloid Leukaemia
(Atypical CML, t(9;22)negative and
BCR/ABL negative) (Atpyical Chronic
Myeloid Leukaemia (Atypical CML,
t(9;22)negative and BCR/ABL negative))
Chronic Myelomonocytic Leukaemia
(CMMoL, CMML) (Chronic
Myelomonocytic Leukaemia (CMMoL,
CMML))
Juvenile Myelomonocytic Leukaemia
(JCMMoL, JMML, JCML, JCMML)
(Juvenile Myelomonocytic Leukaemia
(JCMMoL, JMML, JCML, JCMML))
Type I (Type I)
Type II (Type II)
If transformed into Secondary Acute Leukaemia,
specify date of transformation
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Specification of the disease EBMT MDS
Chemo/drug/agent
Yes
No
If yes, specify
AML like therapy (AML like therapy)
Ara-C (Ara-C)
Histondeacetlyase inhibitor
(Histondeacetlyase inhibitor)
Hydroxyurea (Hydroxyurea)
Hypomethylating agents
(Hypomethylating agents)
Other (Other)
Retinoic acid (Retinoic acid)
If other, specify
Response to treatment
Complete remission (Complete
remission)
Never in CR (Never in CR)
If complete remission, date of first CR
(If subsequent HSCT, indicate the date of the 1st
CR after this treatment)
Subclassification & Status of Disease at
HSCT (to be evaluated just before starting
conditioning)
Date of HSCT
jMML only: fill in splenectomy details
Yes
No
jMML only: fill in splenectomy details
if yes, date of splenectomy
Transfusion of red blood cells
No (No)
Unknown (Unknown)
Yes (Yes)
Transfusion of red blood cells
If yes, specify the amount
< 20 units (< 20 units)
> 50 units (> 50 units)
20 - 50 units (20 - 50 units)
Transfusion of platelets
No (No)
Unknown (Unknown)
Yes (Yes)
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Myelodysplastic Syndrome 
(WHO)-Subclassification
(Please use the WHO subclassification if
possible)
(if patient had Secondary Acute Leukaemia
related to prior treatment, skip this section and
proceed to "Disease status at HSCT")
Childhood myelodysplastic syndrome
(Refractory cytopenia of childhood
(RCC)) (Childhood myelodysplastic
syndrome (Refractory cytopenia of
childhood (RCC)))
MDS associated with isolated del(5q)
(MDS associated with isolated del(5q))
RA with excess of blasts (RAEB-1) (RA
with excess of blasts (RAEB-1))
RA with excess of blasts (RAEB-2) (RA
with excess of blasts (RAEB-2))
RA with ring sideroblasts (RARS) (RA
with ring sideroblasts (RARS))
Refractory Anaemia (without ring
sideroblasts) RA (Refractory Anaemia
(without ring sideroblasts) RA)
Refractory cytopenia with multilineage
dysplasia (RCMD) (Refractory cytopenia
with multilineage dysplasia (RCMD))
Refractory cytopenia with multilineage
dysplasia and ringed sideroblasts
(RCMD-RS) (Refractory cytopenia with
multilineage dysplasia and ringed
sideroblasts (RCMD-RS))
Unclassified (MDS-U) (Unclassified
(MDS-U))
Myelodysplastic Syndrome (FAB)-
Subclassification
RA with excess of blasts (RAEB) (RA
with excess of blasts (RAEB))
RA with ring siderodblasts (RARS) (RA
with ring siderodblasts (RARS))
RA without ring siderboblasts (RA) (RA
without ring siderboblasts (RA))
RAEB in transformation (RAEB-t) (RAEB
in transformation (RAEB-t))
Unclassified (Unclassified)
Myelodysplastic/ Myeloproliferative Neoplasm
Specification
Atpyical Chronic Myeloid Leukaemia
(Atypical CML, t(9;22)negative and
BCR/ABL negative) (Atpyical Chronic
Myeloid Leukaemia (Atypical CML,
t(9;22)negative and BCR/ABL negative))
Chronic Myelomonocytic Leukaemia
(CMMoL, CMML) (Chronic
Myelomonocytic Leukaemia (CMMoL,
CMML))
Juvenile Myelomonocytic Leukaemia
(JCMMoL, JMML, JCML, JCMML)
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(Juvenile Myelomonocytic Leukaemia
(JCMMoL, JMML, JCML, JCMML))
Type I (Type I)
Type II (Type II)
If transformed into Secondary Acute Leukaemia,
specify date of transformation
Disease Status at HSCT
Treated with intention to achieve remission:
(For all diagnosis except jMML (see below for
jMML))
Complete remission (CR) (Complete
remission (CR))
Improvement but no CR (Improvement
but no CR)
Primary refractory phase (no change)
(Primary refractory phase (no change))
Progression/ worse (Progression/ worse)
Relapse (after CR) (Relapse (after CR))
Untreated (Supportive care or treatment
without intetion to achieve remission)
(Untreated (Supportive care or treatment
without intetion to achieve remission))
If CR or relapse, specify number:
1st (1st)
2nd (2nd)
3rd or higher (3rd or higher)
For jMML only:
Complete remission (Complete
remission)
Minor response (Minor response)
Partial remission (Partial remission)
Progressive disease (Progressive
disease)
Stable disease (Stable disease)
Cytogenetics Data (Within 2 months of the
preparative -conditioning- regimen)
Chromosome analysis
Done: abnormal (Done: abnormal)
Done: normal (Done: normal)
Not Done or failed (Not Done or failed)
Unknown (Unknown)
if abnormal: are there 3 or more abnormalities
(complex kariotype)
No (No)
Unknown (Unknown)
Yes (Yes)
Indicate which abnormalties found:
del 20q (20q-) (del 20q (20q-))
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del 5q (5q-) (del 5q (5q-))
del 7q (7q-) (del 7q (7q-))
del Y (-Y) (del Y (-Y))
Other abn 5 (Other abn 5)
Other abn 7 (Other abn 7)
Other abnormalities (Other
abnormalities)
Indicate which abnormalities found:
absent (absent)
present (present)
If other, specify:
Haematological values at HSCT (to be
evaluated just before starting the
preparative -conditioning- regimen)
Peripheral blood analysis
evaluated (evaluated)
not evaluated (not evaluated)
Peripheral Blood Analysis
If evaluated:
Hb (g/dL)
g/dL
Peripheral Blood Analysis
If evaluated:
Platelets (10^9/L)
10^9/L
Peripheral Blood Analysis
If evaluated:
White Blood Cells (10^9/L)
10^9/L
Peripheral blood analysis
If evaluated:
% blasts
%
Peripheral blood analysis:
If evaluated:
% monocytes
%
Peripheral blood analysis:
If evaluated:
% neutrophils
%
Bone marrow analysis
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Evaluated (Evaluated)
Not evaluated (Not evaluated)
Bone marrow analysis: 
If evaluated:
% blasts
%
Bone marrow analysis
Auer rods present
No (No)
Not Evaluated (Not Evaluated)
Unknown (Unknown)
Yes (Yes)
Fill only for MDS and CMML:
High (> 2.5) (High (> 2.5))
Intermediate-1 (0.5 - 1.0) (Intermediate-1
(0.5 - 1.0))
Intermediate-2 (1.5 - 2) (Intermediate-2
(1.5 - 2))
Low (0) (Low (0))
Unknown (Unknown)
Within 2 months of the preparative -conditoning-
regimen:
Cytology (Cytology)
Histology (Histology)
Not available (Not available)
Results
(at diagnosis; check one in each column)
Cellularity on BM Aspirate/ BM biopsy
Acellular (Acellular)
Focal cellularity (Focal cellularity)
Hypercellular (Hypercellular)
Hypocellular (Hypocellular)
Normocellular (Normocellular)
Unknown (Unknown)
Results 
(at diagnosis; check one in each column) 
Fibrosis on BM biopsy
Mild (Mild)
Moderate (Moderate)
No (No)
Not evaluable (Not evaluable)
Severe (Severe)
Unknown (Unknown)
Additional Treatment Post-HSCT
Additional Treatment Post-HSCT
No (No)
Unknown (Unknown)
Yes (Yes)
If yes, planned or not planned
Not planned (for relapse/ progression or
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persistent disease) (Not planned (for
relapse/ progression or persistent
disease))
Planned (planned before HSCT took
place) (Planned (planned before HSCT
took place))
If yes, specify start date:
If yes: Chemo/ drug/agent therapy (including
MoAB, etc.)
No  (No )
Unknown (Unknown)
Yes (Yes)
If additional chemo/drug/agent treatment, specify:
If yes: Other treatment
No (No)
Unknown (Unknown)
Yes (Yes)
If other treatment, specify:
Best Disease Response at 100 days post-
HSCT
Best Disease Response at 100 days post-HSCT
CR (maintained or achieved) (CR
(maintained or achieved))
Not evaluable (Not evaluable)
Relapse/ Progression (Relapse/
Progression)
Unknown (Unknown)
Forms to be filled in
Type of HSCT (Check all that apply):
ALLOgraft or Synergenic graft, proceed
to Allograft form (ALLOgraft or
Synergenic graft, proceed to Allograft
form)
AUTOgraft, proceed to Autograft form
(AUTOgraft, proceed to Autograft form)
Other, contact the EBMT Central
Registry Office for instructions (Other,
contact the EBMT Central Registry
Office for instructions)
If other, specify, and contact the EBMT Central
Registry Office for instructions
12 / 12
Specification of the disease EBMT MDS
Eligibility COPD NCT00730067
Sildenafil for Chronic Obstructive Pulmonary Disease
(COPD) Associated Pulmonary Hypertension; ODM
derived from: https://clinicaltrials.gov/show/NCT00730067
All rights reserved. Please visit https://medical-data-
models.org/forms/13686
Eligibility COPD NCT00730067
Inclusion Criteria
a mean pulmonary arterial pressure of 25 mmhg
measured by right heart catheterization.*
Yes
No
a diagnosis of copd-associated pulmonary
hypertension, implicating that no other potential
cause of pulmonary hypertension is present.*
Yes
No
stable copd, defined by no subjective alterations
of symptoms or use of short acting beta-
antagonists for minimally six weeks. any
exacerbation resulting in admission to hospital or
other contacts to a physician must have ceased
for at least 6 weeks before entering the study.*
Yes
No
age > 18*
Yes
No
informed written consent.*
Yes
No
reliable anticonception for fertile women.*
Yes
No
Exclusion Criteria
rheumatic disease limiting walking capacity.*
Yes
No
exacerbation in copd during the study.*
Yes
No
age>80 years*
Yes
No
fev1 < 25 % of predicted.*
Yes
No
allergy towards contents of sildenafil or placebo
tablets.*
Yes
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No
fall in blood pressure of > 30 mmhg systolic or
>20 mmhg diastolic after intake of the first dose
of trial medication.*
Yes
No
fall in peripheral saturation of > 5% after intake of
the first dose of trial medication.*
Yes
No
treatment with nitrous vasodilators or
aminophyllamines.*
Yes
No
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Eligibility COPD NCT00730067
Eligibility Coronary Artery Disease
NCT01482169
Intravenous Regadenoson Versus Intravenous
Adenoscan® for Fractional Flow Reserve (FFR); ODM
derived from: https://clinicaltrials.gov/show/NCT01482169
All rights reserved. Please visit https://medical-data-
models.org/forms/13687
Eligibility Coronary Artery Disease
NCT01482169
Inclusion Criteria
patients undergoing elective left heart
catheterization*
Yes
No
age ≥ 18 years (female not of child bearing
potential)*
Yes
No
able to provide written informed consent*
Yes
No
Exclusion Criteria
contraindications to administration of either
adenoscan® or regadenoson*
Yes
No
high degree av block, sick sinus syndrome
without a functioning pacemaker*
Yes
No
symptomatic bradycardia*
Yes
No
recent stemi (< 5 days)*
Yes
No
recent nstemi (<5 days) if the peak ck is > 1000
iu*
Yes
No
dipyridamole use within 24 hours*
Yes
No
adenoscan® is contraindicated (hypersensitivity
to adenoscan®, regadenoson, or aminophylline*
Yes
No
known severe bronchoconstrictive lung disease*
Yes
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No
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Eligibility Depression NCT01141426
Halifax Treatment Refractory Depression Trial; ODM
derived from: https://clinicaltrials.gov/show/NCT01141426
All rights reserved. Please visit https://medical-data-
models.org/forms/13688
Eligibility Depression NCT01141426
Inclusion Criteria
patients aged 18 - 65 years.*
Yes
No
patients must identify depression as their primary
problem (rather than being secondary to other
mental health diagnosis).*
Yes
No
any dsm-iv diagnosis of major depression as
assessed by the mini neuropsychiatric interview
plus (m.i.n.i. plus) at time of research intake
interview.*
Yes
No
patients will have had at least one treatment trial
of antidepressants at an acceptable therapeutic
dose (length ≥ 6 weeks) for the current
depressive episode without adequate response
(score on the hamilton rating scale for depression
≥ 16 ) at time of screening interview.*
Yes
No
patients will not have started new medications in
the previous ≥ 6 weeks, or have received
psychotherapy treatment in the 12 months prior
to being invited to participate in the study.*
Yes
No
participants will agree to video-taped sessions
and will consent to the investigator accessing
their information in clinical files and hospital
database (e.g., medications, number of visits to
health care professionals).*
Yes
No
Exclusion Criteria
psychotic depression, bipolar depression,
substance dependence, severe cluster a or b
personality disorders, active suicidality, or
cognitive impairment: such that patients require
an intervention other than psychotherapy (as per
the current protocol for the experimental
treatment arm) or patients unable to give consent
to treatment.*
Yes
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No
patients with depression due to a general medical
condition or secondary to a comorbid mental
health or psychosocial condition will be
excluded.*
Yes
No
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Eligibility Depression NCT01192685
Transcranial Magnetic Stimulation in Major Depression With
EEG and Near Infrared Spectroscopy (NIRS) Monitoring;
ODM derived from:
https://clinicaltrials.gov/show/NCT01192685
All rights reserved. Please visit https://medical-data-
models.org/forms/13689
Eligibility Depression NCT01192685
Inclusion Criteria
1. depressive disorder diagnostic statistical
manual of mental disorders, fourth edition, text
revision (dsm-iv-tr).*
Yes
No
2. madras score of 26 or above and history of
depression, as defined by meeting dsm-iv criteria
for major depression, dysthymic disorder, or
substance-induced mood disorder.*
Yes
No
3. male or female aged 18 to 65.*
Yes
No
4. females who are not pregnant or nursing.*
Yes
No
5. individuals able to provide informed written
consent and are able to comply with study
procedures.*
Yes
No
6. subjects who have received or are receiving
anti-depressant medication.*
Yes
No
7. patients who are depressed as assessed by
the above criteria and have not had optimum
response to their antidepressant medication in
their current episode.*
Yes
No
exclusion criteria list*
Yes
No
1. any axis i diagnosis that, in the opinion of the
investigators, may interfere with the course of the
trial.*
Yes
No
2. any current diagnoses of alcohol abuse or
dependence.*
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Yes
No
3. any current substance use disorder.*
Yes
No
4. medical or neurological illness that in the
investigators judgment would make study
compliance difficult or would be a contraindication
for use with tms.*
Yes
No
5. currently receiving any medication that
markedly increases the risks for seizures, for
example: tricyclic antidepressants, inh,
meperidine, lidocaine, and clozapine.*
Yes
No
6. subjects who have implanted metallic devices
or non-removable metallic objects in or around
the head that can be magnetized, however metal
fillings, braces, and dental implants are
acceptable.*
Yes
No
7. subjects who have implanted devices that emit
physiological signals including cardioverter
defibrillators (icds), and vagus nerve stimulators.*
Yes
No
8. subjects who have received any investigational
drug during the prior 30 days.*
Yes
No
9. clinically significant abnormal lab values as
assesses by the investigator.*
Yes
No
10. risk for suicidal behavior based on clinician
assessment and a score of greater than 5 on the
suicidal thought item of the madrs or a score of 4
on the suicide item of the hamilton depression
rating scale.*
Yes
No
11. subjects who have had a serious suicide
attempt in the past year as assessed by the
investigator.*
Yes
No
12. current other somatic antidepressant therapy,
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i.e. vagus nerve stimulation, electroconvulsive
therapy, or phototherapy.*
Yes
No
13. started psychotherapy in the past 30 days.*
Yes
No
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Eligibility Depression NCT01443234
OxIGen: Oxford Imagery Generation: Investigating the
Effects of an Internet Based Computer Program in
Depression; ODM derived from:
https://clinicaltrials.gov/show/NCT01443234
All rights reserved. Please visit https://medical-data-
models.org/forms/13690
Eligibility Depression NCT01443234
Inclusion Criteria
willing and able to give consent to the study*
Yes
No
male or female, aged between 18 and 65 years*
Yes
No
current major depressive episode (assessed by
semi-structured clinical interview)*
Yes
No
access to internet in order to complete the online
program*
Yes
No
able to travel to research centre for assessment
appointments*
Yes
No
fluent in written and spoken english*
Yes
No
Exclusion Criteria
meets criteria for current psychotic disorder*
Yes
No
history of mania or hypomania as assessed by
semi-structured clinical interview, or has
elsewhere received a diagnosis of bipolar
disorder*
Yes
No
antidepressant medication begun or changed in
dosage during last month*
Yes
No
meets criteria for current substance abuse
disorder*
Yes
No
involved in other current treatment trials*
Yes
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No
currently receiving psychological therapy*
Yes
No
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Eligibility Depressive Disorder, Treatment-
Resistant NCT01179009
Treatment Resistant Depression (Pilot); ODM derived from:
https://clinicaltrials.gov/show/NCT01179009
All rights reserved. Please visit https://medical-data-
models.org/forms/13692
Eligibility Depressive Disorder,
Treatment-Resistant NCT01179009
Inclusion Criteria
1. males and females aged 18-65 years;*
Yes
No
2. diagnostic and statistical manual (dsm) iv
diagnosis of major depressive disorder, recurrent,
severe;*
Yes
No
3. depression must be considered treatment
refractory as defined by montgomery asberg
depression rating scale (madrs) score of 22 or
above which is consistent with other studies;*
Yes
No
4. on a stable dose of permitted antidepressant
medication or no medication pre-infusion;*
Yes
No
5. not currently psychotic and no history of
psychosis within the previous 12 months;
psychosis reported in the distant past may not be
exclusionary if brief, per pi's judgment;*
Yes
No
6. no history of significant clinical or intolerable
side effects or complications from clonidine;*
Yes
No
7. if a female of child-bearing potential: not
pregnant or breast feeding and agrees to use
birth control during the time of pre-dosing and
infusions; and*
Yes
No
8. able to give informed consent.*
Yes
No
Exclusion Criteria
1. confirmed bipolar disorder, schizophrenia, or
schizoaffective disorder;*
Yes
No
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2. current or recent substance
abuse/dependence (or any lifetime recreational
ketamine or pcp use);*
Yes
No
3. any severe axis ii personality disorder or
schizophrenia spectrum disorder that, in the pi's
judgment, could confound diagnosis or
adherence to treatment;*
Yes
No
4. the presence of any abnormal laboratory
findings or serious medical disorder or condition
that may, in the judgment of the pi, confound the
assessment of relevant biologic measures or
diagnoses including: clinically significant organ
system dysfunction; significant and uncontrolled
endocrine disease, including diabetes mellitus;
hypothyroidism; cardiovascular disease;
coagulopathy; significant anemia; significant
acute infection; glaucoma; dehydration; epilepsy;
any diagnosed cardiac condition causing
documented hemodynamic compromise or
dysfunction of the sa or av node; any diagnosed
respiratory condition causing documented or
clinically recognized hypoxia (e.g., chronic
obstructive or restrictive pulmonary disease);
after evaluation, anyone determined to have a
potentially compromised airway that could be
difficult to intubate; fever; bmi less than 14.5; or
any medical condition known to interfere with
cognitive performance; medication-related
exclusions include memantine, or any medication
that could be considered contraindicated
ketamine;*
Yes
No
5. current treatment with any medication
contraindicated with ketamine or clonidine;*
Yes
No
6. lifetime illegal use of pcp or ketamine; no
clinical use of ketamine for past 3 months*
Yes
No
7. meets dsm-iv criteria for mental retardation;*
Yes
No
8. currently hospitalized;*
Yes
No
9. acutely suicidal or homicidal (i.e., in imminent
danger with plan, urges and intent to harm
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oneself or others) including any prior serious
attempts (e.g., those requiring hospitalization) at
the pi's discretion;*
Yes
No
10. is pregnant or breast-feeding; unwilling to use
birth control if female of child bearing potential*
Yes
No
11. unable to provide informed consent.*
Yes
No
12. for participants in the neuroimaging subset:
history of claustrophobia, serious head injuries,
seizures disorder, developmental delays,
pacemaker, metal implants, permanent metal
piercings or anything else that would preclude
having an mri.*
Yes
No
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Eligibility Diabetes Mellitus, Type 1
NCT01461616
Effect of NPH Insulin, Insulin Detemir and Insulin Glargine
on GH-IGF-IGFBP Axis; ODM derived from:
https://clinicaltrials.gov/show/NCT01461616
All rights reserved. Please visit https://medical-data-
models.org/forms/13693
Eligibility Diabetes Mellitus, Type 1
NCT01461616
Inclusion Criteria
1. informed consent obtained before any trial-
related activities.*
Yes
No
2. diagnosis of diabetes mellitus according to
who criteria; history and clinical course consistent
with type 1 diabetes mellitus.*
Yes
No
3. diagnosed with diabetes for more than 6 years
and using continuous subcutaneous insulin
infusion (csii) at least 6 months at time of
inclusion.*
Yes
No
4. total daily insulin dose between 0.4 and 1.4
units/kg (both values included)*
Yes
No
5. hba1c between 6% and 9% (both values
included).*
Yes
No
6. age ≥ 18 years.*
Yes
No
7. bmi between 18.5 and 28 kg /m2 (including
both values).*
Yes
No
Exclusion Criteria
1. known or suspected allergy to trial product(s)
or related products.*
Yes
No
2. recurrent major hypoglycaemic episodes.*
Yes
No
3. heart: unstable angina pectoris, ami < 12
months or heart insufficiency classified according
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to nyha iii-iv*
Yes
No
4. blood pressure: severe uncontrolled
hypertension with bp > 180/110 mmhg, sitting*
Yes
No
5. liver: impaired hepatic function corresponding
to serum-alat or basic phosphatase > 2 x upper
reference limit of the local laboratory.*
Yes
No
6. kidneys: impaired renal function corresponding
to serum-creatinin > 150 μmol/l according to the
local laboratory.*
Yes
No
7. any disease judged by the investigator to affect
the trial.*
Yes
No
8. pregnancy, breast-feeding or the intention of
becoming pregnant or fertile women not using
adequate contraceptive measures - adequate
contraceptive method is sterilisation,
hysterectomy or current use of contraceptive pills
or intra uterine device.*
Yes
No
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Eligibility Diabetes NCT01219400
Vildagliptin and the Glucagon Response to Hypoglycemia
in Insulin-Treated Patients With Type 2 Diabetes; ODM
derived from: https://clinicaltrials.gov/show/NCT01219400
All rights reserved. Please visit https://medical-data-
models.org/forms/13694
Eligibility Diabetes NCT01219400
Inclusion Criteria
type 2 diabetes*
Yes
No
insulin treatment*
Yes
No
age >18 years*
Yes
No
hba1c <=8.5%*
Yes
No
Exclusion Criteria
pregnancy*
Yes
No
lactation*
Yes
No
acute infection*
Yes
No
liver disease*
Yes
No
treatment with cortisol*
Yes
No
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Eligibility Diabetes, Type 1 NCT01350102
The Relationship of Hemoglobin A1c and Diabetic Wound
Healing; ODM derived from:
https://clinicaltrials.gov/show/NCT01350102
All rights reserved. Please visit https://medical-data-
models.org/forms/13695
Eligibility Diabetes, Type 1
NCT01350102
Inclusion Criteria
>18 years of age*
Yes
No
diabetic (type i and type ii)*
Yes
No
ulceration of the foot at least one centimeter in
width/length*
Yes
No
ulceration at least 0.2 centimeters in depth*
Yes
No
Exclusion Criteria
ulceration width/length  > 7.5 centimeters*
Yes
No
wound depth > 1.25 centimeters*
Yes
No
purulent, excessive drainage and/or other signs
of infection (i.e. erythema, edema, warmth)*
Yes
No
inability to provide informed consent*
Yes
No
inability to swallow pills (vitamin c supplement)*
Yes
No
patients with concurrent renal problems*
Yes
No
patients with medication contraindications to
vitamin c and/or topical wound dressings*
Yes
No
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NCT01439516
Providing Resources to Enhance African American
Patients' Readiness to Make Decisions About Kidney
Disease (PREPARED) Study; ODM derived from:
https://clinicaltrials.gov/show/NCT01439516
All rights reserved. Please visit https://medical-data-
models.org/forms/13696
Eligibility End Stage Renal Disease
(ESRD) NCT01439516
Inclusion Criteria
age 18 or older*
Yes
No
end-stage renal disease (esrd) receiving
hemodialysis for less than 2 years*
Yes
No
self-reported as african-american*
Yes
No
english speaking*
Yes
No
Exclusion Criteria
dementia*
Yes
No
prior kidney transplant*
Yes
No
non-english speaking*
Yes
No
cancer within 2 years prior to recruitment date*
Yes
No
stage 4 congestive heart failure*
Yes
No
end stage liver disease*
Yes
No
unstable coronary artery disease*
Yes
No
pulmonary hypertension*
Yes
No
1 / 2
severe peripheral vascular disease*
Yes
No
chronic debilitating infections*
Yes
No
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Eligibility Estrogen Receptor-positive Breast
Cancer NCT01409811
Biomarkers in Tissue Samples From Patients With Newly
Diagnosed Breast Cancer Treated With Zoledronic Acid;
ODM derived from:
https://clinicaltrials.gov/show/NCT01409811
All rights reserved. Please visit https://medical-data-
models.org/forms/13697
Eligibility Estrogen Receptor-positive
Breast Cancer NCT01409811
Inclusion Criteria
postmenopausal women*
Yes
No
diagnosis of early stage, invasive ductal
carcinoma (for which a lumpectomy or
mastectomy is planned prior to systemic
therapy)*
Yes
No
estrogen receptor (er)/progesterone receptor (pr)
positive tumor (as confirmed by city of hope
pathology department if done on the outside) or*
Yes
No
biopsy proven er/pr positive tumor*
Yes
No
ability to provide informed consent*
Yes
No
Exclusion Criteria
tumor that lacks both estrogen and progesterone
receptors*
Yes
No
patients who will receive neoadjuvant therapy
prior to definitive surgery*
Yes
No
bisphosphonate therapy currently or within the
past 12 months*
Yes
No
regular use of anti-inflammatory agents, with the
exception of a baby aspirin regimen per principal
investigator's (pi's) discretion*
Yes
No
renal impairment as determined by a creatinine
clearance < 60 ml/min as calculated by the
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cockcroft-gault formula using the patient's actual
weight*
Yes
No
current active dental problems including infection
of the teeth or jawbone (maxilla or mandibular);
dental or fixture trauma, or a current or prior
diagnosis of osteonecrosis of the jaw (onj), of
exposed bone in the mouth, or of slow healing
after dental procedures*
Yes
No
recent (within 6 weeks) or planned dental or jaw
surgery (e.g. extraction, implants)*
Yes
No
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Eligibility Heart Failure NCT00610051
Alprostadil Continuous Intravenous Infusion in Bridging
Cardiac Transplant in Severe Heart Failure Patients; ODM
derived from: https://clinicaltrials.gov/show/NCT00610051
All rights reserved. Please visit https://medical-data-
models.org/forms/13698
Eligibility Heart Failure
NCT00610051
Inclusion Criteria
1. patients of either gender and of any
race/ethnicity who are between 18 and 70 years
of age inclusive*
Yes
No
2. patients in advanced cardiac heart failure in
new york heart association (nyha) functional
class iiib or iv*
Yes
No
3. eligible for heart transplant according to the
ishlt guidelines ; it is not necessary that the
patient already be listed at time of screening*
Yes
No
4. patients with secondary pulmonary
hypertension (pulmonary artery pressure [pap] >
50 mmhg on echocardiography or pulmonary
resistance on right heart catheterization), who
are usually excluded from transplantation under
conventional conditions, are eligible for inclusion
in this study*
Yes
No
5. patients with left ventricular ejection fraction
(lvef) ≤ 35% by any acceptable method (e.g.,
echocardiography, radionuclideventriculography,
or ventriculography) assessed within the 3
months prior to randomization*
Yes
No
6. nt-probnp > 2000 pg/ml*
Yes
No
7. women of childbearing potential (i.e., who have
not undergone a hysterectomy or who have not
been postmenopausal for at least 24 consecutive
months) must commit either to abstain
continuously from heterosexual sexual contact or
to use at least one "highly effective" method of
birth control (e.g., intrauterine device [iud],
hormonal contraception, tubal ligation, or
partner's vasectomy) or two "effective" methods
(e.g., latex condom, diaphragm, or cervical cap),
beginning 4 weeks prior to screening and
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throughout study participation*
Yes
No
8. patients must be willing and able to give written
informed consent.  where required, a hipaa
and/or state privacy consent must also be
signed*
Yes
No
Exclusion Criteria
1. patients urgently requiring transplantation (in
the united states, united network for organ
sharing [unos] status 1a; in the e.u., urgent
request mode at eurotransplant)*
Yes
No
2. patients or their relatives/caregivers who are
determined by the training nurse not to be
capable of correctly using the pump delivery
system and handling the study drug*
Yes
No
3. patients presenting with unstable angina, aortic
stenosis, pulmonary edema, severe chronic
obstructive pulmonary disease, or acute gastric
or duodenal ulcers*
Yes
No
4. patients with a history of myocardial infarction
or stroke within 6 months of screening*
Yes
No
5. patients with systolic blood pressure < 90
mmhg under euvolemic or hypervolemic
conditions*
Yes
No
6. patients with significant chronic renal
dysfunction (serum creatinine ≥2.5 mg/dl)*
Yes
No
7. female patients who are pregnant or nursing*
Yes
No
8. patients who have any concomitant illness or
other finding that, in the opinion of the
investigator, would confound the interpretation of
the study results or place the patient at
unacceptable risk if the patient were to participate
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in the study*
Yes
No
9. patients with a known hypersensitivity to study
drug or any component of the formulation of
study drug (denatured ethanol)*
Yes
No
10. patients with prior participation in a study of
alprostadil*
Yes
No
11. patients participating in another research
study within 30 days prior to screening (i.e., the
day the informed consent is signed) or
anticipated to enroll in such during the 24 weeks
after screening*
Yes
No
12. patients for whom informed consent cannot
be obtained*
Yes
No
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Eligibility Heart Failure NCT01480401
Study of Dietary Intervention Under 100 MMOL in Heart
Failure; ODM derived from:
https://clinicaltrials.gov/show/NCT01480401
All rights reserved. Please visit https://medical-data-
models.org/forms/13699
Eligibility Heart Failure
NCT01480401
Inclusion Criteria
patients will be recruited from each research
center if they are 18 years or older, with
confirmed diagnosis of heart failure (including
both those with a reduced and preserved systolic
function), nyha ii-iv, and willing to sign informed
consent.*
Yes
No
Exclusion Criteria
subjects will be excluded if they have severe
hyponatremia (serum sodium <130 mmol/l)*
Yes
No
renal failure (a glomerular filtration rate < 30
ml/min)*
Yes
No
uncontrolled thyroid disorders*
Yes
No
hepatic failure*
Yes
No
implantable cardiac device (icd or crt) or
myocardial revascularization procedures
(coronary angioplasty and/or surgical
revascularization) in the previous 3 months*
Yes
No
uncontrolled atrial fibrillation or recurrent
ventricular arrhythmias*
Yes
No
malignancy, or with moderate-severe dementia.*
Yes
No
patients will be excluded if, in the opinion of the
investigator, another condition exists that would
preclude dietary compliance or compliance with
the protocol.*
Yes
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Eligibility Hepatitis C NCT01413490
Hepatitis C Rimantadine and Antiviral Combination
Therapy; ODM derived from:
https://clinicaltrials.gov/show/NCT01413490
All rights reserved. Please visit https://medical-data-
models.org/forms/13700
Eligibility Hepatitis C NCT01413490
Inclusion Criteria
have a diagnosis of hcv infection, genotype 1 or
genotype 3*
Yes
No
be eligible for standard combination therapy with
pegylated ifn and ribavirin*
Yes
No
be at least 18 but no more than 65 years of age*
Yes
No
have signed an informed consent indicating that
the patient is aware of the infectious nature of
their disease and have been informed of the
procedures of the protocol, the experimental
nature of the therapy, alternatives, potential
benefits, side effects, risks, and discomforts*
Yes
No
be willing and able to comply with scheduled
visits, the treatment plan, and laboratory tests*
Yes
No
have no contraindications to receiving
rimantadine therapy*
Yes
No
have blood results within defined acceptable
haematological and biochemical parameters
(haemoglobin >10 g/dl, platelet count >150 x
109/l,  bilirubin <25 umol/l, albumin >35 g/l,
creatinine <150 umol/l*
Yes
No
Exclusion Criteria
have dementia or altered mental status that
would prohibit informed consent*
Yes
No
have previously received treatment for hcv
infection (i.e. are currently treatment naïve)*
Yes
No
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have any condition which would deem the patient
ineligible for combination therapy with pegylated
ifn or ribavirin. this includes pregnancy, significant
cardiac, renal or autoimmune disease, severe
depression or psychosis, and previous organ
transplantation*
Yes
No
cirrhosis or liver failure as evidenced by clinical
(cutaneous stigmata of chronic liver disease,
ascites, encephalopathy), ultrasonic (cirrhotic
appearance of liver, ascites) or biochemical
(platelet count >150 x 109/l, bilirubin <25 umol/l,
albumin >35 g/l) evidence, routinely collated in all
patients diagnosed with hcv*
Yes
No
any condition which would preclude the use of
rimantadine. this comprises significant renal
impairment (creatinine >150), pregnancy,
epilepsy or history of unexplained seizures*
Yes
No
have any other severe, acute, or chronic medical
or psychiatric condition or laboratory abnormality
that may increase the risk associated with study
participation or study drug administration or may
interfere with the interpretation of study results
and, in the judgment of the chief investigators,
would make the patient inappropriate for this
study. this includes the presence of end stage
liver disease (cirrhosis), and hiv infection*
Yes
No
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Eligibility Hepatitis C NCT01433133
Safety and Biological Activity of InfraDure Biopump
Secreting Sustained Interferon in HCV Patients; ODM
derived from: https://clinicaltrials.gov/show/NCT01433133
All rights reserved. Please visit https://medical-data-
models.org/forms/13701
Eligibility Hepatitis C NCT01433133
Inclusion Criteria
signed patient consent form*
Yes
No
genotype 3 chronic hcv with detectable hcv rna*
Yes
No
no previous treatment for hcv infection*
Yes
No
hepatitis b and human immunodeficiency virus
negative at screening visit*
Yes
No
able and willing to follow contraception
requirements*
Yes
No
screening laboratory values, test, and physical
exam within acceptable ranges*
Yes
No
Exclusion Criteria
current enrollment in another investigational
device or drug study*
Yes
No
anticipated inability to complete all clinic visits
and comply with study procedures*
Yes
No
history of, or any current medical condition, which
could impact the safety of the subject during the
study*
Yes
No
autoimmune hepatitis, suspected hepatocellular
carcinoma, decompensated liver disease, or
other known liver disease other than hcv*
Yes
No
alcoholism or substance abuse with <6
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documented months of sobriety*
Yes
No
known allergy or sensitivity to interferons or
ribavirin*
Yes
No
any other condition that, in the opinion of the
investigator, would make the subject unsuitable
for enrollment or could interfere with the subject
participating in and completing the study*
Yes
No
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Coronary Artery Bypass graft surgery in
patients with Asymptomatic Carotid Stenosis
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CABACS Case Report Form
[surgery documentation]
Surgery documentation
Patient ID
Date of hospital admission
Pseudonymized copy enclosed?
Yes
No
Medical history and findings
Yes
No
Clinical severity of heart failure (NYHA-
Classification)
I Normal physical capacity, asymptomatic
(1)
II symptoms under physical exertion (2)
III symptoms under mild physical
exertion (3)
IV symptoms at rest (4)
Angina pectoris
I. Ordinary physical activity does not
cause angina (1)
II. Slight limitation of ordinary activity (2)
III. Marked limitation of ordinary activity
(3)
IV. Inability to carry out any physical
activity without discomfort - angina
syndrome may be present at rest (4)
Myocardial infarction
No (0)
Yes, within last 48 hours (1)
Yes,within past 21 days (2)
Yes, longer than 21 but no longer than 91
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days ago (3)
Yes, more than 91 days ago (4)
Yes but date of event unknown  (8)
unknown (9)
Cardiogenic shock
No (0)
Yes, within last 48 hours (1)
Yes, within past 21 days (2)
Yes, longer than 21 days ago (3)
Yes, but date of event unknown (8)
unknown (9)
Resuscitation
No (0)
Yes, within last 48 hours (1)
Yes, within past 21 days (2)
Yes, longer than 21 days ago (3)
Yes, date of event unknown (8)
unknown (9)
Patient is on artificial respiration
Yes
No
Pulmonary Hypertension
Yes (1)
No (2)
unknown (9)
Cardiac rhythm
Normal sinus rhythm (1)
Atrial fibrillation (2)
Other (8)
Patient wears an artificial cardiac
pacemaker/defibrillator
No (0)
Yes,Pacemaker (1)
Yes,Defibrillator (2)
ASA Classification
A normal healthy patient (1)
A patient with mild systemic disease (2)
A patient with severe systemic disease
(3)
A patient with very severe systemic
disease that is a constant threat to life
(4)
A moribund patient (5)
LVEF
bad or less than 30% (1)
average or 30-50% (2)
good or more than 50% (3)
coronary angiography findings
no coronary heart disease (0)
1-vessel disease (1)
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2-vessel disease (2)
3-vessel disease (3)
Significant left main stem disease?
No (0)
Yes equal to or more than 50% (1)
unknown (9)
Previous percutaneous coronary intervention?
Yes
No
Previous heart surgery or aortic surgery
number of interventions unknown, but at
least one (8)
unknown (9)
Other current infection
none (0)
Mediastinitis (1)
UTI (10)
wound infection of lower extremities (11)
HIV infection (12)
Hepatitis b or C (13)
other wound infection (18)
Bacteremia (2)
broncho-pulmonary infection (3)
oto-laryngologic infection (4)
florid endocarditis (5)
Peritonitis (6)
thoracic wound infection (7)
pleural empyema (8)
other general infection (88)
infection of venous puncture site (9)
Diabetes mellitus
no (0)
yes, only set dietary (1)
yes, medical controlled (2)
yes, insulin dependent (3)
yes, untreated (4)
unknown (9)
Arterial vascular disease
no (0)
Yes (1)
unknown (9)
peripheral arterial disease
no (0)
yes (1)
unknown (9)
Carotid artery disease
No (0)
Yes (1)
unknown (9)
Aortic aneurysm
no (0)
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Yes (1)
unknown (9)
Other arterial diseases
No (0)
Yes (1)
unknown (9)
Lung diseases
No (0)
Yes COPD with chronic medication (1)
Yes COPD without chronic medication
(2)
Yes, other lung disease (8)
unknown (9)
Neurologic diseases
No (0)
Yes,CNS cerebrovascular
(hemorrhage,ischemia) (1)
Yes,CNS other (2)
Yes, peripheral (3)
Yes, combination (4)
unknown (9)
Modified Rankin Stroke Scale score if you
answered the previous question with CNS-1
No symptoms at all (0)
No significant disability despite
symptoms; able to carry out all usual
duties and activities (1)
Slight disability; unable to carry out all
previous activities but able to look after
own affairs without assistance (2)
Moderate disability; requiring some help
but able to walk without assistance (3)
Moderately severe disability; unable to
walk without assistance and unable to
attend to own bodily needs without
assistance (4)
Severe disability; bedridden, incontinent,
and requiring constant nursing care and
attention (5)
Preoperative dialysis
No (0)
Acute (1)
Chronic (2)
Serum creatinine preoperative
mg/dL
Serum creatinine preoperative
μmol/l
Date of completion of this form
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Signature by investigator
Name of Investigator
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CABACS Case Report Form
[surgery:basic data]
Surgery documentation
Date
Patient ID
Number of surgical procedures, which number is
this current procedure?
Date of surgery
Category of surgical procedure: coronary surgery
Yes
No
Category of surgical procedure: aortic valve
surgery
no (0)
yes, conventional surgical procedure (1)
yes, catheter supported endovascular (2)
yes,catheter supported transapically (3)
Category of surgical procedure: other surgical
procedure
Yes
No
Surgical procedure:OPS-Code
Urgency of procedure
elective (1)
urgent (2)
emergency (3)
resuscitation/ultima ratio (4)
Nitrates preoperative
Yes
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No
Elevated troponin levels
Yes
No
Inotropic agent preoperative
Yes
No
Mechanical circulatory support
No (0)
yes, intra-aortic balloon pump (iabp) (1)
yes, other device (2)
Wound contamination classifcation (according to
definition by CDC)
aseptic procedure (1)
partially aseptic procedure (2)
procedure with contamination (3)
septic procedure (4)
Type of surgical procedure
with life support machine (1)
without life support machine (2)
change from procedure without life
support machine to procedure with life
support machine (3)
Surgical approach
conventional sternotomy (1)
other procedure (2)
Operative time: from first incision to suture
Bypass time
Aortic clamp time in minutes from placement to
removal of aortic cross clamp
Minutes
Number of grafts
Type of Graft(s)
Vein  (1)
Right internal thoracic artery  (2)
Left internal thoracic artery  (3)
Radial artery (4)
Other grafts (5)
Count of central anastomoses
Number of peripheral arterial anastomoses
Number of peripheral venous anastomoses
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Coronary Artery Bypass graft surgery in patients with Asymptomatic
Carotid Stenosis
Endarterectomy with thrombectomy
no (0)
yes, left side (1)
yes, right side (2)
yes, bilateral (3)
Coronary arteries surgically treated
LAD and/or branches (1)
RCA and or branches (2)
RCX and/or branches (3)
Other surgical procedure on coronary arteries
Yes
No
Hypothermia
Yes
No
If hypothermia was induced, please specify body
temperature during hypothermia
°C
Manipulation of arteria ascendens
Yes
No
If "yes" please specify number of central
anastomoses
Application of clamp
no (0)
cross clamp (1)
partial clamping (2)
If no manipulation of arteria ascendens, bypass
graft:T-Graft
T-Graft (1)
other graft (2)
Intraoperative epiaortic ultrasonography, if "yes"
please fill in optional form
Yes
No
Date of completion of this form
Signature by investigator
Name of Investigator
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Carotid Stenosis
General Information EBMT CML
ODM derived from HSCT forms on http://www.ebmt.org/
All rights reserved. Please visit https://medical-data-
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General Information EBMT CML
Team
EBMT Centre Identification Code (CIC)
Hospital
Department within the Hospital
Name of a Contact Person
Telephone number
Fax number
E-Mail Address
Date of this report
Patient follwing national/ international study/ trial
No (No)
Unknown (Unknown)
Yes (Yes)
Patient following national/ international study/
trial:
If yes, specify:
Patient
To be entered only if patient previously reported
Hospital Unique Patient Number or Code
First name(s) - surname(s)
(Registration will not be accepted if this item is
left blank)
Date of birth
(Registration will not be accepted if this item is
left blank)
Patient's sex
(Registration will not be accepted if this item is
left blank)
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Female (Female)
Male (Male)
AB0 Blood Group
0 (0)
A (A)
AB (AB)
B (B)
Rhesus factor
Absent (Absent)
Not evaluated (Not evaluated)
Present (Present)
Disease
Date of Diagnosis
Check the disease for which this transplant was
performed
Acute Leukaemia (Acute Leukaemia)
Acute Lymphoblastic Leukaemia (ALL)
(Acute Lymphoblastic Leukaemia (ALL))
Acute Myelogenous Leukaemia (AML)
(Acute Myelogenous Leukaemia (AML))
Autoimmune disease (Autoimmune
disease)
Bone marrow failure including Aplastic
anaemia (Bone marrow failure including
Aplastic anaemia)
Chronic Leukaemia (Chronic Leukaemia)
Chronic Lymphocytic Leukaemia
(Chronic Lymphocytic Leukaemia)
Chronic Myeloid Leukaemia (CML)
(Chronic Myeloid Leukaemia (CML))
Haemoglobinopathiy
(Haemoglobinopathiy)
Histiocytic disorders (Histiocytic
disorders)
Hodgkin's Disease (Hodgkin's Disease)
Inherited disorders (Inherited disorders)
Juvenile Idiopathic Arthritis (Juvenile
Idiopathic Arthritis)
Lymphoma (Lymphoma)
MD/ MPN (MD/ MPN)
MDS (MDS)
Metabolic disorders (Metabolic
disorders)
Multiple Sclerosis (Multiple Sclerosis)
Myelodysplastic syndromes
(Myelodysplastic syndromes)
Myeloma/ Plasma cell disorder
(Myeloma/ Plasma cell disorder)
Myeloproliferative neoplasm
(Myeloproliferative neoplasm)
Non Hodgkin (Non Hodgkin)
Other diagnosis (Other diagnosis)
Primary immune deficiencies (Primary
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immune deficiencies)
Secondary Acute Leukaemia (do not use
if transformed from MDS/MPN)
(Secondary Acute Leukaemia (do not
use if transformed from MDS/MPN))
Solid Tumour (Solid Tumour)
Systemic Lupus (Systemic Lupus)
Systemic Sclerosis (Systemic Sclerosis)
If other, specify:
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Eligibility Hepatitis C NCT01466790
A Study of TMC435 in Combination With PSI-7977
(GS7977) in Chronic Hepatitis C Genotype 1-Infected Prior
Null Responders To Peginterferon/Ribavirin Therapy or
HCV Treatment-Naive Patients; ODM derived from:
https://clinicaltrials.gov/show/NCT01466790
All rights reserved. Please visit https://medical-data-
models.org/forms/13711
Eligibility Hepatitis C NCT01466790
Inclusion Criteria
chronic genotype 1 hepatitis c virus (hcv)
infection*
Yes
No
plasma hcv rna of more than 10,000 iu/ml at
screening*
Yes
No
patients in cohort 1 must be null responders to
pegifn/ribavirin with at least 1 documented
previous course of pegifn/ribavirin therapy for at
least 12 consecutive weeks*
Yes
No
patients in cohort 2 must be null responders to
pegifn/ribavirin with at least 1 documented
previous course of pegifn/ribavirin therapy for at
least 12 consecutive weeks and could also be
hcv treatment-naive, meaning never received
treatment with any approved or investigational
drug for the treatment of hcv*
Yes
No
null responders patients in cohort 1 and cohort 2
must meet the defined criterion for a null
responder, defined as on-treatment less than 2
log10 iu/ml reduction in hcv rna from baseline at
week 12 of the most recent pegifn/ribavirin
therapy*
Yes
No
patient must have had a liver biopsy within 3
years before screening (or between screening
and baseline visit) or patient must have had a
liver biopsy at any time in the past which showed
metavir f3 or f4 fibrosis*
Yes
No
must agree to use 2 forms of effective
contraception throughout the study (male and
female)*
Yes
No
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Exclusion Criteria
has evidence of hepatic decompensation*
Yes
No
has any liver disease of non-hcv etiology*
Yes
No
has an infection/co-infection with non-genotype 1
hcv*
Yes
No
has a co-infection with human immunodeficiency
virus (hiv) type 1 or type 2 (hiv-1 or hiv-2)
(positive hiv-1 or hiv-2 antibody test at
screening)*
Yes
No
has a co-infection with hepatitis b virus (hepatitis
b surface antigen [hbsag] positive)*
Yes
No
has a history of malignancy within 5 years of the
screening visit*
Yes
No
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Eligibility Hepatitis C NCT01467492
Telaprevir, Peg-IFN-alfa-2a, and RBV in Treatment-
Experienced Black/African American and Non-
Black/African American Subjects With Genotype 1 Chronic
Hepatitis C; ODM derived from:
https://clinicaltrials.gov/show/NCT01467492
All rights reserved. Please visit https://medical-data-
models.org/forms/13712
Eligibility Hepatitis C NCT01467492
Inclusion Criteria
participants self-identify as black/african
american (group a) or did not self-identify as
black/african american (group b)*
Yes
No
participants have genotype 1 chc and laboratory
evidence of hepatitis c virus (hcv) infection for at
least 6 months*
Yes
No
participants did not achieve sustained viral
response 24 weeks after last dose of study drug
(svr24), after at least 1 prior course of peg-ifn-
alfa-2a/rbv therapy of standard duration*
Yes
No
Exclusion Criteria
participants have received previous treatment
with telaprevir or any other protease inhibitor(s)
for chc*
Yes
No
participants who have evidence of hepatic
decompensation*
Yes
No
participants have diagnosed or suspected
hepatocellular carcinoma*
Yes
No
participants have any other cause of significant
liver disease in addition to hcv*
Yes
No
participants are currently abusing illicit drugs or
alcohol, or have history of illicit substance or
alcohol abuse within 2 years before the screening
visit*
Yes
No
participants who participated in any
investigational drug study within 90 days before
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dosing*
Yes
No
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Eligibility Hepatitis C Virus (HCV)
NCT01447394
Safety and Efficacy Study of Pegylated Interferon Lambda
Versus Pegylated Interferon Alfa, Plus Ribavirin in Subjects
With Hepatitis C; ODM derived from:
https://clinicaltrials.gov/show/NCT01447394
All rights reserved. Please visit https://medical-data-
models.org/forms/13713
Eligibility Hepatitis C Virus (HCV)
NCT01447394
Inclusion Criteria
chronic hepatitis c, genotype 1 or 4*
Yes
No
hcv ribonucleic acid (rna) ≥ 100,000 iu/ml at
screening*
Yes
No
liver biopsy documenting no cirrhosis (within prior
2 years) or cirrhosis (from any time prior to
randomization).  where approved for staging of
liver disease, non-invasive imaging may be used
to assess the extent of liver disease. subjects
with compensated cirrhosis can enroll and will be
capped at 10%*
Yes
No
naive to prior anti-hcv therapy*
Yes
No
Exclusion Criteria
infected with hcv other than genotype 1 or 4*
Yes
No
positive hepatitis b surface antigen (hbsag), or
human immunodeficiency virus-1 (hiv-1)/hiv-2
antibody or hepatitis d virus (hdv) at screening*
Yes
No
evidence of liver disease other than hcv*
Yes
No
active substance abuse*
Yes
No
use of hematologic growth factors within 90 days
prior to study randomization*
Yes
No
evidence of decompensated cirrhosis based on
radiologic criteria or biopsy results and clinical
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criteria*
Yes
No
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Specifications of the disease EBMT CML
ODM derived from HSCT forms on http://www.ebmt.org/
All rights reserved. Please visit https://medical-data-
models.org/forms/13714
Specifications of the disease EBMT
CML
Initial Diagnosis
has the information requested in this section
been submitted with a previous HSCT
registration?
No: Proceed with this section (No:
Proceed with this section)
Yes: go to "Pre-HSCT treatment" (Yes:
go to "Pre-HSCT treatment")
At least one investigation must be positive:
Translocation (9;22)
Absent (Absent)
Not evaluated (Not evaluated)
Present (Present)
At least one investigation must be positive:
bcr-abl
Absent (Absent)
Not evaluated (Not evaluated)
Present (Present)
Status of disease at diagnosis
Accelerated phase (Accelerated phase)
Blast crisis (Blast crisis)
Chronic phase (Chronic phase)
Initial  Diagnosis - Cytogenetics
Cytogenetics other than for translocation (9;22) at
diagnosis
Abnormal (Abnormal)
Normal (Normal)
Not done or failed (Not done or failed)
Unknown (Unknown)
Cytogenetics other than for translocation (9;22) at
diagnosis: 
If abnormal, indicate type of abnormalitiy:
Translocation
Yes
No
Cytogenetics other than for translocation (9;22) at
diagnosis:
If abnormal, indicate type of abnormalitiy: 
Translocation
If yes, write chromosomes involved
Cytogenetics other than for translocation (9;22) at
diagnosis: 
If abnormal, indicate type of abnormalitiy: 
Deletion
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Yes
No
Cytogenetics other than for translocation (9;22) at
diagnosis: 
If abnormal, indicate type of abnormalitiy: 
Deletion
If yes, write chromosomes involved
Cytogenetics other than for translocation (9;22) at
diagnosis: 
If abnormal, indicate type of abnormalitiy: 
Inversion
Yes
No
Cytogenetics other than for translocation (9;22) at
diagnosis: 
If abnormal, indicate type of abnormalitiy:
Inversion
If yes, write chromosomes involved
Cytogenetics other than for translocation (9;22) at
diagnosis: 
If abnormal, indicate type of abnormalitiy:
Isochromosome
Yes
No
Cytogenetics other than for translocation (9;22) at
diagnosis: 
If abnormal, indicate type of abnormalitiy:
Isochromosome
If yes, write chromosomes involved
Cytogenetics other than for translocation (9;22) at
diagnosis: 
If abnormal, indicate type of abnormalitiy:
Multiple (=>3)
Yes
No
Cytogenetics other than for translocation (9;22) at
diagnosis: 
If abnormal, indicate type of abnormalitiy:
Multiple (=>3)
If yes, write chromosomes involved
Cytogenetics other than for translocation (9;22) at
diagnosis: 
If abnormal, indicate type of abnormalitiy:
Hypodiploid
Yes
No
Cytogenetics other than for translocation (9;22) at
diagnosis: 
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If abnormal, indicate type of abnormalitiy:
Hypodiploid
If yes, write chromosomes involved
Cytogenetics other than for translocation (9;22) at
diagnosis: 
If abnormal, indicate type of abnormalitiy:
Hyperdiploid
Yes
No
Cytogenetics other than for translocation (9;22) at
diagnosis: 
If abnormal, indicate type of abnormalitiy:
Hyperdiploid
If yes, write chromosomes involved
Cytogenetics other than for translocation (9;22) at
diagnosis: 
If abnormal, indicate type of abnormalitiy:
Monosomy (include loss of arms)
Yes
No
Cytogenetics other than for translocation (9;22) at
diagnosis: 
If abnormal, indicate type of abnormalitiy:
Monosomy (include loss of arms)
If yes, write chromosomes involved
Cytogenetics other than for translocation (9;22) at
diagnosis: 
If abnormal, indicate type of abnormalitiy:
Trisomy
Yes
No
Cytogenetics other than for translocation (9;22) at
diagnosis: 
If abnormal, indicate type of abnormalitiy:
Trisomy
If yes, write chromosomes involved
Cytogenetics other than for translocation (9;22) at
diagnosis: 
If abnormal, indicate type of abnormalitiy: 
Other
Number of metaphases with anomalies:
Number of metaphases examined
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Initial Diagnosis - Haematological values
Evaluated?:
Hb (g/dL)
Yes
No
If evaluated, specify:
Hb (g/dL)
g/dL
Evaluated?:
Platelets (10^9/ L)
Yes
No
If evaluated, specify:
Platelets (10^9/ L)
10^9/L
Evaluated?:
White Blood Count (10^9/L)
Yes
No
If evaluated, specify:
White Blood Count (10^9/ L)
10^9/L
Evaluated?:
% basophils
Yes
No
If evaluated, specify:
% basophils
%
Evaluated?:
% blasts
Yes
No
If evaluated, specify:
% blasts
%
Evaluated?:
% blasts
Yes
No
If evaluated, specify:
% blasts
%
Palpable Splenomegaly
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Absent (Absent)
Not evaluated (Not evaluated)
Present (Present)
Unknown (Unknown)
Palpable Splenomegaly:
Physical examination: evaluated?
Yes
No
Palpable Splenomegaly: 
Physical examination: 
If evaluated, specify: cm (below costal margin)
cm
Palpable Splenomegaly:
Spleen span in ultrasound or CT scan:
evaluated?
Yes
No
Palpable Splenomegaly:
Spleen span in ultrasound or CT scan: 
If evaluated, specify: cm (maximum diameter)
cm
Pre-HSCT Treatment
Primary Treamtent
No (Proceed to Date of HSCT) (No
(Proceed to Date of HSCT))
Yes (continue and specify) (Yes (continue
and specify))
Start Date of Primary Treatment
Chemotherapy/ Drugts used for primary
treatment
No  (No )
Unknown (Unknown)
Yes (continue and specify) (Yes)
Chemotherapy/ Drugs:
Imatinib
Yes
No
Chemotherapy/ Drugs:
Imatinib
If yes, specify duration
Chemotherapy/ Drugs:
Dasatinib
Yes
No
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Chemotherapy/ Drugs:
Dasatinib
If yes, specify duration
Chemotherapy/ Drugs:
Nilotinib
Yes
No
Chemotherapy/ Drugs:
Nilotinib
If yes, specify duration
Chemotherapy/ Drugs:
Interferon alpha
Yes
No
Chemotherapy/ Drugs:
Interferon alpha
If yes, specify duration
Chemotherapy/ Drugs:
Hydroxyurea
Yes
No
Chemotherapy/ Drugs:
Hydroxyurea
If yes, specify duration
Chemotherapy/ Drugs:
Busulfan
Yes
No
Chemotherapy/ Drugs:
Busulfan
If yes, specify duration
Chemotherapy/ Drugs:
Cytosine arabinoside (ARAC)
Yes
No
Chemotherapy/ Drugs:
Cytosine arabinoside (ARAC)
If yes, specify duration
Chemotherapy/ Drugs:
Other Chemotherapy
Yes
No
6 / 15
Specifications of the disease EBMT CML
Chemotherapy/ Drugs
Other Chemotherapy
If yes, specify duration
Other treatment
No (No)
Unknown (Unknown)
Yes (Yes)
Other treatment
If yes, specify:
HSCT Date and Type
Date of HSCT
Splenectomy performed?
Yes
No
If Splenectomy performed, specify the date:
HSCT Type
Allogenic (Allogenic)
Autologuos (Autologuos)
Main reason for HSCT
(tick one main reason only)
Abl mutation (Abl mutation)
Advanced phase (Advanced phase)
Clinical study (Clinical study)
Clonal evolution (Clonal evolution)
Dasatinib resistance (Dasatinib
resistance)
Imatinib resistance (Imatinib resistance)
Nilotinib resistance (Nilotinib resistance)
No engraftment after allo BMT (No
engraftment after allo BMT)
other (other)
Poor risk patient or high risk CML (e.g.
Sokal > 1.2) (Poor risk patient or high
risk CML (e.g. Sokal > 1.2))
Standard indication at diagnosis
(Standard indication at diagnosis)
Main reason for HSCT 
(tick one main reason only)
If other, specify:
Secondary reason for HSCT 
(tick as many secondary as applicable)
Abl mutation (Abl mutation)
Advanced phase (Advanced phase)
Clinical study (Clinical study)
Clonal evolution (Clonal evolution)
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Dasatinib resistance (Dasatinib
resistance)
Imatinib resistance (Imatinib resistance)
Nilotinib resistance (Nilotinib resistance)
No engraftment after allo BMT (No
engraftment after allo BMT)
other (other)
Poor risk patient or high risk CML (e.g.
Sokal > 1.2) (Poor risk patient or high
risk CML (e.g. Sokal > 1.2))
Standard indication at diagnosis
(Standard indication at diagnosis)
Secondary reason for HSCT 
(tick as many secondary as applicable)
If other, specify:
Only if autograft (For autograft only. If
allograft proceed to "Status at HSCT")
Date of Collection
Disease Status
Chronic Phase (Chronic Phase)
Number of Chronic phase
1st (1st)
2nd (2nd)
3rd or higher (3rd or higher)
Unknown (Unknown)
Remission Status
(complete only if chronic phase, check all that
apply):
Haematological remission
No (No)
Not evaluated (Not evaluated)
Yes (Yes)
Remission Status 
(complete only if chronic phase, check all that
apply): 
Cytogenetic remission
No (No)
Not evaluated (Not evaluated)
Yes (Yes)
Remission Status 
(complete only if chronic phase, check all that
apply): 
Molecular remission
No (No)
Not evaluated (Not evaluated)
Yes (Yes)
Translocation (9;22)
(to be completed only if disease status is not
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cytogenetic remission)
Absent (Absent)
Not evaluated (Not evaluated)
Present (Present)
Unknown (Unknown)
Translocation (9;22) 
(to be completed only if disease status is not
cytogenetic remission) 
If yes, specify percentage of Translocation (9;22)
metaphases:
%
Translocation (9;22) 
(to be completed only if disease status is not
cytogenetic remission)
If yes, specify number of examined metaphases:
FISH analysis
t(9;22)
Negative (Negative)
Not evaluated (Not evaluated)
Positive (Positive)
Unknown (Unknown)
FISH analysis 
t(9;22)
If positive, specify percentage of positive cells:
%
FISH analysis 
t(9;22) 
If positive, specify number of examined cells:
Additional cytogenetic analysis?
Abnormal (Abnormal)
Normal (Normal)
Not done or failed (Not done or failed)
Unknown (Unknown)
Molecular status of mobilised product
(to be completed only if disease status is not
molecular remission)
Molecular marker BCR-ABL
Absent (Absent)
Not evaluated (Not evaluated)
Present (Present)
Unknown (Unknown)
Status of disease at HSCT
Phase of Disease
Acceleraed phase (Acceleraed phase)
Blast Crisis (Blast Crisis)
Chronic phase (Chronic phase)
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If Chronic phase, specify number of chronic
phase
1st (1st)
2nd (2nd)
3rd or higer (3rd or higer)
Unknown (Unknown)
Remission Status 
(complete only if chronic phase, check all that
apply): 
Haematological remission
No (No)
Not evaluated (Not evaluated)
Yes  (Yes)
Remission Status 
(complete only if chronic phase, check all that
apply): 
Cytogenetic remission
No  (No)
Not evaluated (Not evaluated)
Yes  (Yes)
Remission Status 
(complete only if chronic phase, check all that
apply): 
Molecular remission
No  (No)
Not evaluated (Not evaluated)
Yes  (Yes)
If accelerated phase, specify number of
accelerated phase
If blast crisis, specify number of blast crisis
1st (1st)
2nd (2nd)
3rd or higer (3rd or higer)
If blast crisis, specify:
Lymphoid (Lymphoid)
Myeloid (Myeloid)
Other (Erythrhoblastic or
megakaryoblastic or mixed) (Other
(Erythrhoblastic or megakaryoblastic or
mixed))
Cytogenetics at HSCT
Translocation (9;22) 
(to be completed only if disease status is not
cytogenetic remission)
Absent  (Absent)
Not evaluated  (Not evaluated)
Present  (Present)
Unknown (Unknown)
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Translocation (9;22) 
(to be completed only if disease status is not
cytogenetic remission) 
If yes, specify percentage of Translocation (9;22)
metaphases:
%
Translocation (9;22) 
(to be completed only if disease status is not
cytogenetic remission) 
If yes, specify number of examined metaphases:
FISH analysis 
t(9;22)
FISH analysis 
t(9;22) 
If positive, specify percentage of positive cells:
%
FISH analysis 
t(9;22) 
If positive, specify number of examined cells:
Additional cytogenetic analysis?
Abnormal  (Abnormal)
Normal  (Normal)
Not done or failed  (Not done or failed)
Unknown (Unknown)
Molecular Status at HSCT (to be
completed only if disease status is not
molecular remission)
Molecular Marker BCR-ABL
Absent  (Absent)
Not evaluated  (Not evaluated)
Present (Present)
Unknown (Unknown)
If BCR-ABL pesent and disease status is not
cytogenetic remission fill in the results:
Evaluated?:
BCR-ABL result (number of copies/ μg of RNA)
Yes
No
If BCR-ABL pesent and disease status is not
cytogenetic remission fill in the results: 
If evaluated, specify BCR-ABL result (number of
copies/ μg of RNA)
number of copies/ μg of RNA
If BCR-ABL pesent and disease status is not
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cytogenetic remission fill in the results:
Evaluated?:
Control gene result (number of copies/ μg of
RNA)
Yes
No
If BCR-ABL pesent and disease status is not
cytogenetic remission fill in the results: 
If evaluated, specify control gene result (number
of copies/ μg of RNA)
number of copies/ μg of RNA
BCR-ABL/ control gene ratio: (%)
%
Haematological values at HSCT
Evaluated?:
Hb (g/dL)
Yes
No
If evaluated, specify:
Hb (g/dL)
g/dL
Evaluated?:
Platelets (10^9/ L)
Yes
No
If evaluated, specify:
Platelets (10^9/ L)
10^9/L
Evaluated?:
White Blood Count (10^9/L)
Yes
No
If evaluated, specify:
White Blood Count (10^9/ L)
10^9/L
Evaluated?:
% basophils
Yes
No
If evaluated, specify:
% basophils
%
Evaluated?:
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% blasts
Yes
No
If evaluated, specify:
% blasts
%
Evaluated?:
% blasts
Yes
No
If evaluated, specify: 
% blasts
%
Large foci or clusters in BM
No (No)
Not evaluated (Not evaluated)
Unknown (Unknown)
Yes (Yes)
Extramedullary blast proliferation
No (No)
Not evaluated (Not evaluated)
Unknown (Unknown)
Yes (Yes)
Palpable Splenomegaly
Absent  (Absent)
Not evaluated  (Not evaluated)
Present  (Present)
Unknown (Unknown)
Palpable Splenomegaly: 
Physical examination: evaluated?
Yes
No
Palpable Splenomegaly: 
Physical examination: 
If evaluated, specify: cm (below costal margin)
cm
Palpable Splenomegaly: 
Spleen span in ultrasound or CT scan:
evaluated?
Yes
No
Palpable Splenomegaly: 
Spleen span in ultrasound or CT scan: 
If evaluated, specify: cm (maximum diameter)
cm
13 / 15
Specifications of the disease EBMT CML
Additional Treatment Post-HSCT
Additional Treatment
No (No)
Unknown (Unknown)
Yes (Yes)
Additional Treatment:
If yes, specify:
Not planned (for relapse/ progression or
persistent disease) (Not planned (for
relapse/ progression or persistent
disease))
Planned (planned before HSCT took
place) (Planned (planned before HSCT
took place))
If Additional Treatment, specify:
Imatinib
Yes
No
If Additional Treatment: 
Imatinib 
If yes, specify duration
If Additional Treatment, specify:
Dasatinib
Yes
No
If Additional Treatment: 
Dasatinib 
If yes, specify duration
If Additional Treatment, specify:
Nilotinib
Yes
No
If Additional Treatment: 
Nilotinib
If yes, specify duration
If Additional Treatment, specify: 
Interferon alpha
Yes
No
If Additional Treatment: 
Interferon alpha
If yes, specify duration
If Additional Treatment, specify: 
Other chemo/ drug
Yes
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No
If Additional Treatment:
Other chemo/ drug
If yes, specify duration
If additional treatment:
Other treatment
No (No)
Unknown (Unknown)
Yes (Yes)
If Other additinal treatment, specify
Disease Status at Day +100 post HSCT
Molecular remission
No (No)
Not evaluated (Not evaluated)
Yes (Yes)
Cytogenetic remission
No (No)
Not evaluated (Not evaluated)
Yes (Yes)
Haematological remission
No (No)
Not evaluated (Not evaluated)
Yes (Yes)
Forms to be filled in
Type of Transplant
ALLOgraft or Syngeneic graft (proceed to
Allograft form) (ALLOgraft or Syngeneic
graft (proceed to Allograft form))
AUTOgraft (proceed to Autograft form)
(AUTOgraft (proceed to Autograft form))
Other (contact the EBMT Central
Registry for instructions) (Other (contact
the EBMT Central Registry for
instructions))
If other, specify:
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Eligibility Hepatitis C, Chronic
NCT01425190
Pharmacokinetics of Boceprevir in Pediatric Subjects With
Chronic Hepatitis C Genotype 1 (P07614); ODM derived
from: https://clinicaltrials.gov/show/NCT01425190
All rights reserved. Please visit https://medical-data-
models.org/forms/13715
Eligibility Hepatitis C, Chronic
NCT01425190
Inclusion Criteria
documented chronic hepatitis c (chc) genotype 1
infection*
Yes
No
treatment naïve or failed previous
interferon/ribavirin therapy (≥12 uninterrupted
weeks)*
Yes
No
weigh between 10 kg to 90 kg inclusive at
screening and baseline (day -1).*
Yes
No
body mass index (bmi) from the 5th to the 95th
percentile for the participant's age and gender,
inclusive, per tables from the center for disease
control and prevention, usa*
Yes
No
use of acceptable methods of contraception for at
least 3 months prior to baseline and continue on
study*
Yes
No
Exclusion Criteria
co-infection with the human immunodeficiency
virus (hiv) or hepatitis b virus (hbsag positive).*
Yes
No
treatment with ribavirin within 90 days, or any
interferon-alfa within 30 days*
Yes
No
discontinued from interferon treatment due to
adverse events*
Yes
No
currently receiving antiviral/immunomodulating
therapy for hepatitis c*
Yes
No
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prior treatment with an hcv protease inhibitor*
Yes
No
prior treatment with any known hepatotoxic agent
(including herbal remedies)*
Yes
No
use of investigational drugs within 30 days of
enrollment into study*
Yes
No
evidence of de-compensated liver disease
including, but not limited to, a history or presence
of clinical ascites, bleeding varices, or hepatic
encephalopathy.*
Yes
No
substance abuse (including but not limited to
alcohol abuse, illicit drugs,*
Yes
No
inhalational drugs, marijuana use, etc) any time
prior to entry into the study*
Yes
No
any surgical or medical condition which might
significantly alter the absorption, distribution,
metabolism or excretion of any drug.*
Yes
No
pregnant or breastfeeding female*
Yes
No
meeting any of the laboratory exclusion criteria*
Yes
No
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Eligibility Hypertension, Pulmonary
NCT01469169
Inhaled Iloprost (Ventavis): Efficacy, Safety, and
Pharmacokinetics (PK) Confirmation Study; ODM derived
from: https://clinicaltrials.gov/show/NCT01469169
All rights reserved. Please visit https://medical-data-
models.org/forms/13716
Eligibility Hypertension, Pulmonary
NCT01469169
Inclusion Criteria
male or female subjects aged 18 to 75 years*
Yes
No
symptomatic pulmonary artery hypertension
(pah) classified (dana point classification 1)*
Yes
No
new york heart association (nyha)/world health
organization (who) functional class iii or iv*
Yes
No
papmean at rest > 25 mm hg, pulmonary
capillary wedge pressure (pcwp) or left
ventricular end-diastolic pressure </= 15 mm hg
and pulmonary vascular resistance (pvr) >/= 240
dyn･sec･cm-5 (>/= 400 dyn・sec・cm-5 for
patients treated with both endothelin receptor
antagonist (era) and phosphodiesterase-5
inhibitor (pde5i) ) as measured by right heart
catheter test*
Yes
No
women of childbearing potential and men must
agree to use adequate contraception when
sexually active*
Yes
No
Exclusion Criteria
baseline 6-minute walk distance of less than 100
meters or more than 500 meters*
Yes
No
subjects with critical severe pah*
Yes
No
forced expiratory volume in 1 second
(fev1)/forced vital capacity (fvc) ratio < 60%
and/or total lung capacity (tlc) < 70% predicted
(especially at interstitial lung disease, tlc < 60%
predicted)*
Yes
No
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clinically relevant obstructive lung disease (e.g.
asthma or chronic obstructive pulmonary disease
)*
Yes
No
more than mild patchy interstitial lung disease on
high resolution computerized tomography (hrct)*
Yes
No
history of left-sided heart disease*
Yes
No
uncontrolled systemic hypertension as evidenced
by systolic blood pressure >/= 160 mm hg or
diastolic blood pressure >/= 100 mm hg on
repeated measurement*
Yes
No
systemic hypotension with systolic blood
pressure < 85 mm hg*
Yes
No
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CABACS Case Report Form [carotid
reconstruction]
Surgery documentation "CABG with CEA"
Patient ID
Outcome event "technical failure":Did the carotid
stenosis prove to be inoperable or could be
reduced inadequately (less than 70 percent
according to ECST)
Yes
No
Sequence of surgical procedures
First CEA, then CABG (1)
First CABG, then CEA (2)
Surgical procedures,OPS codes
General anaesthesia
Yes
No
Regional anesthesia
Yes
No
Creation of shunt
Yes
No
Endarterectomy with thrombectomy
no (0)
venous patch (1)
PTFE-Patch (2)
polyurethane patch (3)
dacron patch (4)
direct suture (5)
other (6)
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Endarterectomy of internal carotid artery with
eversion and end-to-end anastomosis
Yes
No
Carotid interposition
no (0)
vein (1)
PTFE (2)
Dacron (3)
other (9)
Other surgical procedures
no (0)
Externa plastic (1)
carotid-carotid bypass (2)
other (9)
Additional intraoperative procedures/actions
Yes
No
Time vessels have been clamped
Minutes
Neurological monitoring
Yes
No
Neurological monitoring:please specify
SEP (1)
EEG (2)
Oxymetry (3)
other (9)
Intraprocedural control
Yes
No
Intraprocedural control:Please specify
Ultrasound (1)
Angiography (2)
Doppler-Flowmetry (3)
other (9)
Operative time from first incision to suture
Minutes
Recurrent procedure
Yes
No
Hypothermia,induced
Yes
No
Hypothermia,induced: please specify body
temperature
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°C
Date of completion of this form
Signature by investigator
Name of Investigator
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ODM Example Study
Test of ODM
All rights reserved. Please visit https://medical-data-
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ODM Example
ODM Beispiel Merkmalsgruppe
Bereitschaft zur Teilnahme*
Ja
Nein
Alter
>= 0
<= 120
Jahre
Geschlecht
weiblich (f)
maennlich (m)
unbekannt (u)
Geburtsdatum
Diagnosetext
Diagnosekode
ICD10-GM
Kreatinin
>= 0
<= 20
mg/dl
Zeitpunkt des Laborwerts
hh:mm
Datum des Laborwerts
DD.MM.YYYY
Kommentar
Kalium
mmol/l
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CABACS Case Report Form
[Neurological examination]
Neurological examination
Date of screening for trial
Patient ID
Consciousness
awake 0 (1)
dazed,reaction to small stimuli 1 (2)
stuporous,reaction only to repeated or
strong stimuli 2 (3)
comatose 3 (4)
Orientation to age and month
both answers correct  (1)
one answer correct  (2)
no answer correct (3)
Request patient to close eyes and to squeeze
hand
followed both requests correctly 0 (1)
followed one request correctly 1 (2)
followed no request correctly 2 (3)
Eye movement
normal 0 (1)
partial gaze palsy 1 (2)
forced deviation (total gaze paresis) 2 (3)
Peripheral vision
normal 0 (1)
partial visual field loss 1 (2)
total hemianopsia 2 (3)
bilateral hemianopsia or blindness 3 (4)
Facial expression
normal 0 (1)
little asymmetry 1 (2)
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partial paresis of lower half of the face 2
(3)
total facial paresis 3 (4)
Motor function of arms ( one arm at a time)
right: no dropping 0 (1)
left:no active raise against gravity 3 (10)
left:no movement at all 4 (11)
left:amputation or joint immobility 9 (12)
right: dropping of arm within 10 sec 1 (2)
right:drops arm onto the pad,raise
possible against gravity 2 (3)
right:no active raise against gravity 3 (4)
right:no movement at all 4 (5)
right:amputation or joint immobility 9 (6)
left: no dropping 0 (7)
left: dropping of arm within 10 sec 1 (8)
left:drops arm onto the pad,raise
possible against gravity 2 (9)
Motor function of legs (One leg at a time)
right: no dropping 0 (1)
left:no active raise against gravity 3 (10)
left:no movement at all 4 (11)
left:amputation or joint immobility 9 (12)
right: dropping of leg within 10 sec 1 (2)
right:drops leg onto the pad,raise
possible against gravity 2 (3)
right:no active raise against gravity 3 (4)
right:no movement at all 4 (5)
right:amputation or joint immobility 9 (6)
left: no dropping 0 (7)
left: dropping of leg within 10 sec 1 (8)
left:drops leg onto the pad,raise possible
against gravity 2 (9)
Ataxia
no ataxia or only related to paresis 0 (1)
ataxia of one extremity 1 (2)
ataxia of two or more extremities 2 (3)
Sensibility
normal 0 (1)
partial loss of sensibility 1 (2)
severe or total loss of sensibility 2 (3)
Verbal expression
no aphasia 0 (1)
reduced verbal fluency or reduced
speech understanding 1 (2)
severe aphasia or fragmented verbal
expression 2 (3)
global aphasia/Muteness 3 (4)
Speech
normal 0 (1)
slurred speech, but still understandable 1
(2)
mute or unintelligible/ anarthria 2 (3)
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Neglect
no neglect 0 (1)
partial hemi-neglect of one quality 1 (2)
severe hemi-neglect of more than one
quality 2 (3)
Other neurologic deficits
Yes 1 (1)
No 0 (2)
Please specify other neurologic deficits
Modified Rankin Stroke Scale score
No symptoms at all 0 (1)
No significant disability despite
symptoms; able to carry out all usual
duties and activities 1 (2)
Slight disability; unable to carry out all
previous activities but able to look after
own affairs without assistance 2 (3)
Moderate disability; requiring some help
but able to walk without assistance 3 (4)
Moderately severe disability; unable to
walk without assistance and unable to
attend to own bodily needs without
assistance 4 (5)
Severe disability; bedridden, incontinent,
and requiring constant nursing care and
attention 5 (6)
Date of completion of this form
Signature by investigator
Name of Investigator
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CABACS Case Report Form
[Neurological examination-NIH
stroke scale]
NIH Stroke scale
Date of visit
Patient ID
Consciousness
awake  (1)
dazed,reaction to small stimuli  (2)
stuporous,reaction only to repeated or
strong stimuli  (3)
comatose (4)
Orientation to age and month
both answers correct  (1)
one answer correct  (2)
no answer correct (3)
Request patient to close eyes and to squeeze
hand
followed both requests correctly  (1)
followed one request correctly  (2)
followed no request correctly (3)
Eye movement
normal  (1)
partial gaze palsy  (2)
forced deviation (total gaze paresis) (3)
Peripheral vision
normal  (1)
partial visual field loss  (2)
total hemianopsia  (3)
bilateral hemianopsia or blindness (4)
Facial expression
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normal  (1)
little asymmetry  (2)
partial paresis of lower half of the face
(3)
total facial paresis (4)
Motor function of arms ( one arm at a time)
right: no dropping  (1)
left:no active raise against gravity  (10)
left:no movement at all  (11)
left:amputation or joint immobility (12)
right: dropping of arm within 10 sec  (2)
right:drops arm onto the pad,raise
possible against gravity  (3)
right:no active raise against gravity  (4)
right:no movement at all  (5)
right:amputation or joint immobility  (6)
left: no dropping  (7)
left: dropping of arm within 10 sec  (8)
left:drops arm onto the pad,raise
possible against gravity  (9)
Motor function of legs (One leg at a time)
right: no dropping  (1)
left:no active raise against gravity  (10)
left:no movement at all  (11)
left:amputation or joint immobility (12)
right: dropping of leg within 10 sec  (2)
right:drops leg onto the pad,raise
possible against gravity  (3)
right:no active raise against gravity  (4)
right:no movement at all  (5)
right:amputation or joint immobility  (6)
left: no dropping  (7)
left: dropping of leg within 10 sec  (8)
left:drops leg onto the pad,raise possible
against gravity  (9)
Ataxia
no ataxia or only related to paresis  (1)
ataxia of one extremity  (2)
ataxia of two or more extremities (3)
Sensibility
normal  (1)
partial loss of sensibility  (2)
severe or total loss of sensibility (3)
Verbal expression
no aphasia  (1)
reduced verbal fluency or reduced
speech understanding  (2)
severe aphasia or fragmented verbal
expression  (3)
global aphasia/Muteness (4)
Speech
normal  (1)
slurred speech, but still understandable
(2)
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mute or unintelligible/ anarthria (3)
Neglect
no neglect  (1)
partial hemi-neglect of one quality  (2)
severe hemi-neglect of more than one
quality (3)
Other neurologic deficits
Yes  (1)
No (2)
Please specify other neurologic deficits
Date of completion of this form
Signature by investigator
Name of Investigator
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CABACS Case Report Form [Day 7
post-Op]
Day 7 post surgery
Date of visit
Patient ID
ECG
Date ECG was performed
Any pathologic findings in ECG?
Yes
No
Please specify any pathologic ECG findings
Screening: Outcome events
Did the patient experience any (transient) visual
impairment (since surgery)?
Yes
No
Did the patient experience paresthesia or
weakness on one side of the body (since
surgery)?
Yes
No
Did the patient experience speech disorder (since
surgery)?
Yes
No
Did the patient experience any new signs or
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symptoms (since surgery)?
Yes
No
Is at least one of the following adverse events
present: cerebrovascular stroke, myocardial
infaction,technical failure, death? If "yes" please
fill in Adverse event form and send to study
coordinator within 7 days.
Yes
No
Complications
Deep wound infection
Yes
No
Sepsis
Yes
No
Deep vein thrombosis
Yes
No
Pulmonary Embolism
Yes
No
Pneumonia
Yes
No
Injury of cervical nerves
Yes
No
Severe hemodynamic instability longer than 24h
Yes
No
Carotid dilatation
Yes
No
Carotid bleeding requiring revision
Yes
No
Deterioration of comorbidity (possibly) because of
surgical procedure
Yes
No
Deterioration of comorbidity:If "yes" please
specify
Other relevant complications
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Yes
No
Other relevant complications:Please specify
Serious adverse events
Re-CEA/unplanned CEA
Yes
No
Resuscitation
Yes
No
Did any serious adverse events occur?
Yes
No
Date of completion of this form
Signature by investigator
Name of Investigator
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CABACS Case Report Form [Day 30
post-Op NIH Stroke scale]
NIH Stroke scale
Date of visit
Patient ID
Consciousness
awake  (1)
dazed,reaction to small stimuli  (2)
stuporous,reaction only to repeated or
strong stimuli  (3)
comatose (4)
Orientation to age and month
both answers correct  (1)
one answer correct  (2)
no answer correct (3)
Request patient to close eyes and to squeeze
hand
followed both requests correctly  (1)
followed one request correctly  (2)
followed no request correctly (3)
Eye movement
normal  (1)
partial gaze palsy  (2)
forced deviation (total gaze paresis) (3)
Peripheral vision
normal  (1)
partial visual field loss  (2)
total hemianopsia  (3)
bilateral hemianopsia or blindness (4)
Facial expression
normal  (1)
little asymmetry  (2)
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partial paresis of lower half of the face
(3)
total facial paresis (4)
Motor function of arms ( one arm at a time)
right: no dropping  (1)
left:no active raise against gravity  (10)
left:no movement at all  (11)
left:amputation or joint immobility (12)
right: dropping of arm within 10 sec  (2)
right:drops arm onto the pad,raise
possible against gravity  (3)
right:no active raise against gravity  (4)
right:no movement at all  (5)
right:amputation or joint immobility  (6)
left: no dropping  (7)
left: dropping of arm within 10 sec  (8)
left:drops arm onto the pad,raise
possible against gravity  (9)
Motor function of legs (One leg at a time)
right: no dropping  (1)
left:no active raise against gravity  (10)
left:no movement at all  (11)
left:amputation or joint immobility (12)
right: dropping of leg within 10 sec  (2)
right:drops leg onto the pad,raise
possible against gravity  (3)
right:no active raise against gravity  (4)
right:no movement at all  (5)
right:amputation or joint immobility  (6)
left: no dropping  (7)
left: dropping of leg within 10 sec  (8)
left:drops leg onto the pad,raise possible
against gravity  (9)
Ataxia
no ataxia or only related to paresis  (1)
ataxia of one extremity  (2)
ataxia of two or more extremities (3)
Sensibility
normal  (1)
partial loss of sensibility  (2)
severe or total loss of sensibility (3)
Verbal expression
no aphasia  (1)
reduced verbal fluency or reduced
speech understanding  (2)
severe aphasia or fragmented verbal
expression  (3)
global aphasia/Muteness (4)
Speech
normal  (1)
slurred speech, but still understandable
(2)
mute or unintelligible/ anarthria (3)
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Neglect
no neglect  (1)
partial hemi-neglect of one quality  (2)
severe hemi-neglect of more than one
quality (3)
Other neurologic deficits
Yes
No
Please specify other neurologic deficits
Modified Rankin Stroke Scale score
No symptoms at all (0)
No significant disability despite
symptoms; able to carry out all usual
duties and activities (1)
Slight disability; unable to carry out all
previous activities but able to look after
own affairs without assistance (2)
Moderate disability; requiring some help
but able to walk without assistance (3)
Moderately severe disability; unable to
walk without assistance and unable to
attend to own bodily needs without
assistance (4)
Severe disability; bedridden, incontinent,
and requiring constant nursing care and
attention (5)
Death (6)
Date of completion of this form
Signature by investigator
Name of Investigator
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CABACS Case Report Form [Day 30
post-Op]
Doppler Ultrasonography
Right common carotid artery % stenosis
according to ECST
%
Left common carotid artery % stenosis according
to ECST
%
Right internal Carotid Artery % stenosis
according to ECST
%
Left internal Carotid Artery % stenosis according
to ECST
%
ECG
Date ECG was performed
Any pathologic findings in ECG?
Yes
No
Please specify any pathologic ECG findings
Screening: Outcome events
Did the patient experience any (transient) visual
impairment (since surgery)?
Yes
No
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Did the patient experience paresthesia or
weakness on one side of the body (since
surgery)?
Yes
No
Did the patient experience speech disorder (since
surgery)?
Yes
No
Did the patient experience any new signs or
symptoms (since surgery)?
Yes
No
Is at least one of the following adverse events
present: cerebrovascular stroke, myocardial
infaction,carotid occlusion, recurrent carotid
stenosis or death? If `yes` please fill in Adverse
event form and send to study coordinator within 7
days.
Yes
No
Complications
Deep wound infection
Yes
No
Sepsis
Yes
No
Deep vein thrombosis
Yes
No
Pulmonary Embolism
Yes
No
Pneumonia
Yes
No
Severe hemodynamic instability longer than 24h
Yes
No
Carotid dilatation
Yes
No
Carotid bleeding requiring revision
Yes
No
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Deterioration of comorbidity (possibly) because of
surgical procedure
Yes
No
Deterioration of comorbidity:If `yes` please
specify
Other relevant complications
Yes
No
Other relevant complications:Please specify
Serious adverse events
Re-CEA/unplanned CEA
Yes
No
Resuscitation
Yes
No
Did any serious adverse events occur?
Yes
No
Patient is on artificial respiration longer than 30
days after surgery
Yes
No
Concomitant medication
Does the patient take antiplatelet agents?
Yes
No
Please choose from the list below, which
antiplatelet drug the patient takes
Acetyl salicylic acid (1)
Clopidogrel (2)
Acetyl salicylic acid plus Dipyridamole
(3)
More than one of the list (4)
Other (5)
Please specify which antiplatelet drugs the
patient took, if you chose `other`
Does the patient take any anticoagulants?
Yes
No
Please choose which one of the anticoagulants
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listed below the patient takes.
Unfractionated heparin IV (1)
Full dose LMW heparin (Enoxaparin ,
Others) (2)
Vitamin K Antagonists like Warfarin
(Coumadin) (3)
Dabigatran (4)
Other (5)
More than one of the list (6)
Please specify which anticoagulant the patient
takes, if you chose `other`.
Does the patient take any antihypertensive
drugs?
Yes
No
Please choose which one of the antihypertensive
drugs listed below the patient takes.
ACE inhibitor (1)
angiotensin receptor blocker (2)
Diuretics (3)
Calcium Antagonist (4)
Beta blocker (5)
Other (6)
More than one of the list (7)
Please specify which antihypertensive agent the
patient takes, if you chose `other`.
Does the patient take any lipid lowering agents?
Yes
No
Please choose which one of the antilipemic
agents listed below the patient takes
Statine (1)
Other (2)
More than one (3)
Please specify which antilipemic agent the
patient takes, if you chose `other`.
Any other relevant concomitant medication the
patient takes?
Yes
No
Please specify what other concomitant
medication the patient takes
Has Subject undergone any other relevant
surgical procedures other than recorded on this
form
Yes
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No
Please specify the nature of the other surgical
procedure
Date of completion of this form
Signature by investigator
Name of Investigator
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CABACS Case Report Form
[neurological examination:day 30]
Modified Rankin Scale,structured
interview
Patient ID
Do you (your family member) need constant
nursing care?
yes (severe
disability,bedridden,incontinence,constan
t nursing care in almost every aspect of
daily life)  (1)
No (2)
Do you (your family member)need assistance
with eating,toileting,personal hygiene or walking?
Yes (moderately severe disability, walking
without help impossible,assistance with
ADL´s needed)  (1)
No (2)
Do you (your family member) need assistance to
prepare a simple meal, for house keeping tasks,
deal with money, do the groceries or to get along
in your home town?
Yes (Moderate disability, assistance
needed but can walk with or without
walking aid)  (1)
No (2)
Have there been changes in your (your family
members) ability to work or care for others if
that´s what you did? Have there been changes in
your (your family members) ability to participate
in social and leisure activities?
Have you (your family member) experienced
problems with personal relationships or did you
(your family member) seclude yourself?
Yes (mild disability, not all former
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activities can be performed but
independend life without help is still
possible)  (1)
No (2)
Do you (your family member) have problems with
reading or writing or to find the right words during
conversation?
Have you (your family member) experienced
problems with balance, coordination, vision,
numbness of diverse skin spots or problems to
swallow?
Yes (no significant disability, despite
symptoms all daily activities can be
performed independently)  (1)
No (2)
No disability at all
Yes
No
DemTect B
Date of visit
Patient ID
Patient age
Did you perform the DemTect test with the
patient?
Yes
No
Count of correctly repeated words of
wordlist:grass,butter,stone,child,shack,whistle,pla
nk,horse,earth,nail
<= 20
Converting numbers: Count of correctly
converted numbers 308= ;6032= ;
fourhundredtwentythree= ;
eightthousandfiftyseven=
<= 4
Please count the number of animals your patient
can think of within one minute
<= 30
Please note the longest line of numbers (max. 6
numbers in a row) your patient was able to repeat
backwards. Two attempts allowed.
<= 6
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Please ask your patient to repeat again the ten
words of the first question and count the correctly
repeated words.
<= 10
Please note any particularities regarding the
testing situation (i.e patient with hearing
impairment, any interruption during testing...)
Date of completion of this form
Signature by investigator
Name of Investigator
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[Hospital discharge]
Postoperative progress
Days patient was in intensive care
days
Patient mobilization after surgery
not mobilized (0)
mobilized the first day after surgery (1)
mobilized the second day after surgery
(2)
mobilized the third day after surgery (3)
can not be assessed (4)
Mediastinitis
Yes
No
Resuscitation
Yes
No
Myocardial infarction
Yes
No
Low Cardiac Output
no (0)
yes, treated conservatively (1)
yes,IABP (2)
yes,other mechanical circulatory support
(3)
Reason for revision thoracotomy
no revision thoracotomy/no further
reason (0)
hemorrhage/hematoma (1)
other reason (10)
low cardiac output (2)
tamponade (3)
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complications with the graft/ischemia (4)
wound infection/mediastinitis (5)
dissection (6)
prosthetic dysfunction (7)
unstable sternum (8)
chylothorax (9)
Respiratory insufficiency
no (0)
yes, with forced respiration therapy (1)
yes, reintubation or prolonged artificial
respiration (2)
yes,tracheotomy (3)
Cerebrovascular accident until hospital
discharge?
Yes
No
Duration of cerebrovascular accident
up to 24 hours (1)
longer than 24 hours up to 72 hours (2)
longer than 72 hours (3)
Rankin severity score of neurological deficit after
cerebrovascular accident (duration longer than 24
hours)
No symptoms at all (0)
No significant disability despite
symptoms; able to carry out all usual
duties and activities (1)
Slight disability; unable to carry out all
previous activities but able to look after
own affairs without assistance (2)
Moderate disability; requiring some help
but able to walk without assistance (3)
Moderately severe disability; unable to
walk without assistance and unable to
attend to own bodily needs without
assistance (4)
Severe disability; bedridden, incontinent,
and requiring constant nursing care and
attention (5)
Death (6)
Psychosyndrome
no (0)
yes, transitory without treatment (1)
yes, relevant with treatment (2)
Gastrointestinal complications that required
treatment
No (0)
Yes,conservatively (1)
Yes,with intervention (2)
Yes,laparotomy (3)
Serum creatinine after surgery
mg/dL
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Serum Creatinine
μmol/l
Postoperative dialysis
No (0)
acute (1)
chronic (2)
Did the patient receive RBC transfusions
Yes
No
Number of RBC transfusions
Red blood cell transfusion
exact number of transfusions unknown,
but at least one (1)
unknown (2)
Number of FFP transfusions
Platelet concentrate administered
Yes
No
Cardiac rhythm upon discharge
Sinus rhythm (1)
Atrial fibrillation (2)
patient deceased/no cardiac rhythm (3)
other cardiac rhythm (4)
Patient wears a cardiac pacemaker/defibrillator
No (0)
Yes, pacemaker (1)
Yes, defibrillator (2)
Hospital discharge diagnosis: Please give ICD-
Codes of all relevant diagnoses at discharge
Date of hospital discharge
Reason for Discharge
Date of completion of this form
Signature by investigator
Name of Investigator
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CABACS Case Report Form [1 year
follow up]
Doppler Ultrasonography
Right common carotid artery % stenosis
according to ECST
%
Left common carotid artery % stenosis according
to ECST
%
Right internal Carotid Artery % stenosis
according to ECST
%
Left internal Carotid Artery % stenosis according
to ECST
%
Doppler ultrasonography of right vertebral arteria
normal (1)
Hypoplasia (2)
circulatory disruption (3)
occlusion (4)
Doppler ultrasonography of left vertebral artery
normal (1)
Hypoplasia (2)
circulatory disruption (3)
occlusion (4)
Doppler Ultrasonography of basilar artery
normal (1)
stenosis signal (2)
deceleration of flow (3)
reversal of flow (4)
Screening: Outcome events
1 / 9
Did the patient experience any (transient) visual
impairment (since last visit)?
Yes
No
Did the patient experience paresthesia or
weakness on one side of the body (since last
visit)?
Yes
No
Did the patient experience speech disorder (since
last visit)?
Yes
No
Did the patient experience any new signs or
symptoms (since last visit)?
Yes
No
If at least one of the above has been answered
"yes", has cerebral imaging been performed?
Yes
No
Is at least one of the following adverse events
present: cerebrovascular stroke, myocardial
infaction,carotid occlusion, recurrent carotid
stenosis or death? If `yes` please fill in Adverse
event form and send to study coordinator within 7
days.
Yes
No
Concomitant medication
Does the patient take antiplatelet agents?
Yes
No
Please choose from the list below, which
antiplatelet drug the patient takes
Acetyl salicylic acid (1)
Clopidogrel (2)
Acetyl salicylic acid plus Dipyridamole
(3)
Other (4)
Please specify which antiplatelet drugs the
patient took, if you chose `other`
Does the patient take any anticoagulants?
Yes
No
Please choose which one of the anticoagulants
listed below the patient takes.
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Full dose LMW heparin (Enoxaparin ,
Others) (1)
Vitamin K Antagonists like Warfarin
(Coumadin) (2)
Dabigatran (3)
Other (4)
Please specify which anticoagulant the patient
takes, if you chose `other`.
Does the patient take any antihypertensive
drugs?
Yes
No
Please choose which one of the antihypertensive
drugs listed below the patient takes.
ACE inhibitor (1)
angiotensin receptor blocker (2)
Diuretics (3)
Calcium Antagonist (4)
Beta blocker (5)
Other (6)
Please specify which antihypertensive agent the
patient takes, if you chose `other`.
Does the patient take any lipid lowering agents?
Yes
No
Please choose which one of the antilipemic
agents listed below the patient takes
Statine (1)
Other (2)
Please specify which antilipemic agent the
patient takes, if you chose `other`.
Any other relevant concomitant medication the
patient takes?
Yes
No
Please specify what other concomitant
medication the patient takes
Has the patient undergone any other relevant
surgical procedures other than recorded on this
form
Yes
No
Please specify the nature of the other surgical
procedure
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NIH Stroke scale
Patient ID
Consciousness
awake  (1)
dazed,reaction to small stimuli  (2)
stuporous,reaction only to repeated or
strong stimuli  (3)
comatose (4)
Orientation to age and month
both answers correct  (1)
one answer correct  (2)
no answer correct (3)
Request patient to close eyes and to squeeze
hand
followed both requests correctly  (1)
followed one request correctly  (2)
followed no request correctly (3)
Eye movement
normal  (1)
partial gaze palsy  (2)
forced deviation (total gaze paresis) (3)
Peripheral vision
normal  (1)
partial visual field loss  (2)
total hemianopsia  (3)
bilateral hemianopsia or blindness (4)
Facial expression
normal  (1)
little asymmetry  (2)
partial paresis of lower half of the face
(3)
total facial paresis (4)
Motor function of arms ( one arm at a time)
right: no dropping  (1)
left:no active raise against gravity  (10)
left:no movement at all  (11)
left:amputation or joint immobility (12)
right: dropping of arm within 10 sec  (2)
right:drops arm onto the pad,raise
possible against gravity  (3)
right:no active raise against gravity  (4)
right:no movement at all  (5)
right:amputation or joint immobility  (6)
left: no dropping  (7)
left: dropping of arm within 10 sec  (8)
left:drops arm onto the pad,raise
possible against gravity  (9)
Motor function of legs (One leg at a time)
right: no dropping  (1)
left:no active raise against gravity  (10)
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left:no movement at all  (11)
left:amputation or joint immobility (12)
right: dropping of leg within 10 sec  (2)
right:drops leg onto the pad,raise
possible against gravity  (3)
right:no active raise against gravity  (4)
right:no movement at all  (5)
right:amputation or joint immobility  (6)
left: no dropping  (7)
left: dropping of leg within 10 sec  (8)
left:drops leg onto the pad,raise possible
against gravity  (9)
Ataxia
no ataxia or only related to paresis  (1)
ataxia of one extremity  (2)
ataxia of two or more extremities (3)
Sensibility
normal  (1)
partial loss of sensibility  (2)
severe or total loss of sensibility (3)
Verbal expression
no aphasia  (1)
reduced verbal fluency or reduced
speech understanding  (2)
severe aphasia or fragmented verbal
expression  (3)
global aphasia/Muteness (4)
Speech
normal  (1)
slurred speech, but still understandable
(2)
mute or unintelligible/ anarthria (3)
Neglect
no neglect  (1)
partial hemi-neglect of one quality  (2)
severe hemi-neglect of more than one
quality (3)
Other neurologic deficits
Yes
No
Please specify other neurologic deficits
Modified Rankin Stroke Scale score
No symptoms at all (0)
No significant disability despite
symptoms; able to carry out all usual
duties and activities (1)
Slight disability; unable to carry out all
previous activities but able to look after
own affairs without assistance (2)
Moderate disability; requiring some help
but able to walk without assistance (3)
Moderately severe disability; unable to
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walk without assistance and unable to
attend to own bodily needs without
assistance (4)
Severe disability; bedridden, incontinent,
and requiring constant nursing care and
attention (5)
Death (6)
Date of completion of this form
Signature by investigator/neurologist
Name of Investigator/neurologist
Modified Rankin Scale,structured
interview
Patient ID
Do you (your family member) need constant
nursing care?
yes (severe
disability,bedridden,incontinence,constan
t nursing care in almost every aspect of
daily life)  (1)
No (2)
Do you (your family member)need assistance
with eating,toileting,personal hygiene or walking?
Yes (moderately severe disability, walking
without help impossible,assistance with
ADL´s needed)  (1)
No (2)
Do you (your family member) need assistance to
prepare a simple meal, for house keeping tasks,
deal with money, do the groceries or to get along
in your home town?
Yes (Moderate disability, assistance
needed but can walk with or without
walking aid)  (1)
No (2)
Have there been changes in your (your family
members) ability to work or care for others if
that´s what you did? Have there been changes in
your (your family members) ability to participate
in social and leisure activities?
Have you (your family member) experienced
problems with personal relationships or did you
(your family member) seclude yourself?
Yes (mild disability, not all former
activities can be performed but
independend life without help is still
possible)  (1)
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No (2)
Do you (your family member) have problems with
reading or writing or to find the right words durin
conversation?
Have you (your family member) experienced
problems with balance, coordination, vision,
numbness of diverse skin spots or problems to
swallow?
Yes (no significant disability, despite
symptoms all daily activities can be
performed independently)  (1)
No (2)
No disability at all
Yes
No
DemTect A
Date of visit
Patient ID
Patient age
Did you perform the DemTect test with the
patient?
Yes
No
Count of correctly repeated words of wordlist:
plate,dog,lamp,letter,apple,pants,table,lawn,glass
,tree.
<= 20
Converting numbers: Count of correctly
converted numbers 209= ;4054= ;
sixhundredeightyone= ;
twothousandeightyseven=
<= 4
Please count the number of items to buy in a
grocery store your patient can think of within one
minute
<= 30
Please note the longest line of numbers (max. 6
numbers in a row) your patient was able to repeat
backwards. Two attempts allowed.
<= 6
Please ask your patient to repeat again the ten
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words of the first question and count the correctly
repeated words.
<= 10
Please note any particularities regarding the
testing situation (i.e patient with hearing
impairment, any interruption during testing...)
Date of completion of this form
Signature by investigator/neurologist
Name of Investigator/neurologist
Completion Form Hospital
Date of visit
Patient ID
Completion Status
Appointment at year 1 was taken (1)
premature end of study (2)
Consent and permission for follow-up phone
contact once a year
permission for follow-up contact once a
year (1)
permission for follow up refused (2)
Date early termination of clinical trial
Reason for early termination
informed consent withdrawn (1)
patient safety at risk (at investigators
discretion) (2)
poor protocol compliance with impact on
validity of trial data (specify) (3)
Occurence of exclusion criteria before
CABG +/- CEA (4)
Occurence of endpoint events before
CABG +/- CEA (specify) (5)
Patient is unable to come for follow up
visits (6)
death (fill in outcome event form) (7)
other reason (specify) (8)
Reason for early termination:please specify
Date of completion of this form
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Signature by investigator
Name of Investigator
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DESCRIBE (DZNE – Clinical Register Study of
neurodegenerative Disorders) CRF Follow Up
Background and Purpose:
The purpose of the DESCRIBE study is to document the
natural course of diseases in context of medical care of
neurodegenerative disorders as well as cerebrovascular
diseases and to perform phenotyping of the test persons.
Disease-spanning analyses of the measured clincial data,
the results of the imaging processes, results of the analysis
of the biometerials including genetic analysis are planed.
Principal Investigator: Prof. Klockgether, Dr. Spottke DZNE,
Bonn.
Source: DESCRIBE-Studie
http://www.dzne.de/forschung/forschungsbereiche/klinische
-forschung/studien/describe-bn006.html 
Participating Study Sites:
Berlin, Bonn, Göttingen, Dresden, Köln, Magdeburg,
München, Rostock/Greifswald, Tübingen
All rights reserved. Please visit https://medical-data-
models.org/forms/13762
DESCRIBE CRF Follow Up
Date of visit
Date of visit
Study-ID:
Follow up:
Clinical diagnosis
Did one or several diagnoses change since the
baseline visit?
Yes
No
Subjective cognitive decline (SCD)
Principle diagnosis (1)
Differential diagnosis 1 (2)
Differential diagnosis 2 (3)
Differential diagnosis 3 (4)
Amnestic mild cognitive impairment (MCI)
Principle diagnosis (1)
Differential diagnosis 1 (2)
Differential diagnosis 2 (3)
Differential diagnosis 3 (4)
Non-anamnestic mild cognitive impairment
Principle diagnosis (1)
Differential diagnosis 1 (2)
Differential diagnosis 2 (3)
Differential diagnosis 3 (4)
Probable dementia along with Alzheimer's
disease
Principle diagnosis (1)
Differential diagnosis 1 (2)
Differential diagnosis 2 (3)
Differential diagnosis 3 (4)
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Possible dementia along with Alzheimer's
disease
Principle diagnosis (1)
Differential diagnosis 1 (2)
Differential diagnosis 2 (3)
Differential diagnosis 3 (4)
Posterior cortical atrophy
Principle diagnosis (1)
Differential diagnosis 1 (2)
Differential diagnosis 2 (3)
Differential diagnosis 3 (4)
Mixed dementia
Principle diagnosis (1)
Differential diagnosis 1 (2)
Differential diagnosis 2 (3)
Differential diagnosis 3 (4)
Vascular dementia (VD)
Principle diagnosis (1)
Differential diagnosis 1 (2)
Differential diagnosis 2 (3)
Differential diagnosis 3 (4)
Frototemperal dementia (FTD) - behavioral
variant
Principle diagnosis (1)
Differential diagnosis 1 (2)
Differential diagnosis 2 (3)
Differential diagnosis 3 (4)
Primary progressive aphasia (PPA)
Principle diagnosis (1)
Differential diagnosis 1 (2)
Differential diagnosis 2 (3)
Differential diagnosis 3 (4)
Progressive nonfluent aphasia (PNFA)
Principle diagnosis (1)
Differential diagnosis 1 (2)
Differential diagnosis 2 (3)
Differential diagnosis 3 (4)
Logopenic progressive Aphasia (LPA)
Principle diagnosis (1)
Differential diagnosis 1 (2)
Differential diagnosis 2 (3)
Differential diagnosis 3 (4)
Semantic dementia
Principle diagnosis (1)
Differential diagnosis 1 (2)
Differential diagnosis 2 (3)
Differential diagnosis 3 (4)
bvFTD + ALS
Principle diagnosis (1)
Differential diagnosis 1 (2)
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Differential diagnosis 2 (3)
Differential diagnosis 3 (4)
PPA + ALS
Principle diagnosis (1)
Differential diagnosis 1 (2)
Differential diagnosis 2 (3)
Differential diagnosis 3 (4)
Idiopathic Parkinson's disease (IPS)
Principle diagnosis (1)
Differential diagnosis 1 (2)
Differential diagnosis 2 (3)
Differential diagnosis 3 (4)
Morbus parkinson along with MCI (PD-MCI)
Principle diagnosis (1)
Differential diagnosis 1 (2)
Differential diagnosis 2 (3)
Differential diagnosis 3 (4)
Dementia due to morbus parkinson (PPD)
Principle diagnosis (1)
Differential diagnosis 1 (2)
Differential diagnosis 2 (3)
Differential diagnosis 3 (4)
Dementia with Lewy bodies (DLB)
Principle diagnosis (1)
Differential diagnosis 1 (2)
Differential diagnosis 2 (3)
Differential diagnosis 3 (4)
Atypical Parkinson syndroms - progressive
supranuclear palsy
Principle diagnosis (1)
Differential diagnosis 1 (2)
Differential diagnosis 2 (3)
Differential diagnosis 3 (4)
Possible progressive supranuclear palsy
Principle diagnosis (1)
Differential diagnosis 1 (2)
Differential diagnosis 2 (3)
Differential diagnosis 3 (4)
Corticobasal degeneration (CBD)
Principle diagnosis (1)
Differential diagnosis 1 (2)
Differential diagnosis 2 (3)
Differential diagnosis 3 (4)
Multiple system atrophy
Principle diagnosis (1)
Differential diagnosis 1 (2)
Differential diagnosis 2 (3)
Differential diagnosis 3 (4)
MSA-p (Parkinson)
Principle diagnosis (1)
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Differential diagnosis 1 (2)
Differential diagnosis 2 (3)
Differential diagnosis 3 (4)
MSA-c (cerebellar)
Principle diagnosis (1)
Differential diagnosis 1 (2)
Differential diagnosis 2 (3)
Differential diagnosis 3 (4)
Essential tremor
Principle diagnosis (1)
Differential diagnosis 1 (2)
Differential diagnosis 2 (3)
Differential diagnosis 3 (4)
Ataxia
Principle diagnosis (1)
Differential diagnosis 1 (2)
Differential diagnosis 2 (3)
Differential diagnosis 3 (4)
Amyotrophic lateral sclerosis
Principle diagnosis (1)
Differential diagnosis 1 (2)
Differential diagnosis 2 (3)
Differential diagnosis 3 (4)
Huntington disease
Principle diagnosis (1)
Differential diagnosis 1 (2)
Differential diagnosis 2 (3)
Differential diagnosis 3 (4)
Creutzfeldt-Jakob-Disease
Principle diagnosis (1)
Differential diagnosis 1 (2)
Differential diagnosis 2 (3)
Differential diagnosis 3 (4)
Depression (primary disease)
Principle diagnosis (1)
Differential diagnosis 1 (2)
Differential diagnosis 2 (3)
Differential diagnosis 3 (4)
Cumulative documentation
Did apects of the comorbidities change since the
last visit?
Yes
No
Did the aspects of the medication change since
the last visit?
Yes
No
Did apects of the procedures change since the
4 / 21
DESCRIBE (DZNE – Clinical Register Study of neurodegenerative
Disorders) CRF Follow Up
last visit?
Yes
No
Did apects of the medical history of the family
change since the last visit?
Yes
No
Living situation
Did apects of the living situation change since the
last visit?
Yes
No
1. Marital status
Single (1)
Married (2)
Separated (3)
Widowed (4)
Divorced (5)
Civil partnership (6)
N.A. (7)
2. What is the current housing situation of the
participant ?
private household, alone (1)
two-person household (2)
multi-person household (3)
retirement home/ (residential) care home
for the elderly (4 )
N.A. (5)
Professional status
Did aspects of the occupation status change
since last visit?
Yes
No
1. Current occupation
worker (1)
employee (2)
civil servant (3)
self-employed (4)
unemployed (5)
not working (6)
retired (7)
1.1. Retirement
old-age pension (1)
early retirement due to occupational
disability (2)
early retirement due to unemployability
(3)
1.2. Retirement since: (month, year)
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Number of years since start of retirement
2. Number of years of occupation (so far)
yrs
3. Professional group (Code)
Consumption of semiluxury food - nicotine
Did your nicotine comsumption change since the
last visit?
Yes
No
1. Are you currently a smoker?
Yes
No
1.1. Since when do you smoke?
yrs
1.2. How many cigarettes do you usually smoke
during a day?
no. cigarettes a day
Pack years
Consumption of semiluxury food - alcohol
Did your alcohol comsumption change since the
last visit?
Yes
No
1. Do you drink alcohol?
Yes
No
1.1. How many alcoholic beverages do you drink
on average during the week?
< 1 per week (1)
1-7 (2)
8-14 (3)
15-21 (4)
22-28 (5)
29-35 (6)
36-42 (7)
Vital signs
1. Height
cm
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2. Weight
kg
Body mass index
kg/m2
Clinical phenotype
Are there new aspects of the clinical phenotype
since the baseline visit?
Yes
No
Clinical phenotype -  Anamnesis and
inspection
Motor activity
hypokinetic-rigid phenotype (hypokinetic-
rigid phenotype)
muscle tonus and strength pathological
(muscle tonus and strength pathological)
not examined (not examined)
tremor and involuntary motor activity
(tremor and involuntary motor activity)
without pathological finding (without
pathological finding)
Gait and standing
without pathological findings (1)
pathological finding (2)
not examined (3)
Behavior
without pathological findings (1)
pathological finding (2)
not examined (3)
Praxia / visual respectively spatial
without pathological findings (1)
pathological finding (2)
not examined (3)
Speech and language
without pathological findings (1)
pathological finding (2)
not examined (3)
Autonomic nervous system
without pathological findings (1)
pathological finding (2)
not examined (3)
Clinical phenotype - Further examination
I. Examination of muscle tonus and strength
performed
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Yes
No
1. Change in muscle tonus
present (1)
not present (2)
not examined (3)
1.1. Rigor
present (1)
not present (2)
not examined (3)
1.2. Spastic
present (1)
not present (2)
not examined (3)
2. Peripheral nerve paresis, which cannot be
assigned to a peripheral nerve or a nerve root.
present (1)
not present (2)
not examined (3)
2.1. Atrophy
present (1)
not present (2)
not examined (3)
2.2. Fasciculation
present (1)
not present (2)
not examined (3)
2. Central pareses
present (1)
not present (2)
not examined (3)
3.1. Central right arm paresis
latent (1)
manifest (2)
mild (3)
severe (4)
not present  (5)
not examined (6)
3.2. Central left arm paresis
latent (1)
manifest (2)
mild (3)
severe (4)
not present  (5)
not examined (6)
3.3. Central right leg paresis
latent (1)
manifest (2)
mild (3)
severe (4)
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not present  (5)
not examined (6)
3.4. Central left leg paresis
latent (1)
manifest (2)
mild (3)
severe (4)
not present  (5)
not examined (6)
4.1. Biceps reflex
diminution of reflex (1)
augmentation of reflex (2)
no pathological finding (3)
not examined (4)
4.2. Patellar reflex
diminution of reflex (1)
augmentation of reflex (2)
no pathological finding (3)
not examined (4)
4.3. Achilles' tendon reflex
diminution of reflex (1)
augmentation of reflex (2)
no pathological finding (3)
not examined (4)
4.4. Babinski sign
negative (0)
positive (1)
not examined (2)
Babinski sign positive side
right (1)
left (2)
bilateral (3)
5. Tremor
present (1)
not present (2)
not examined (3)
Tremor type
resting tremor (1)
action tremor (2)
6. Dyskinetic signs / dystonic signs
present (1)
not present (2)
not examined (3)
6.1. Dyskinetic signs type
oromandibular (1)
axial dystonia (2)
dystonia of extremities (3)
stratial toe (4)
stratial hand (5)
chorea (6)
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tardive dyskinesia (7)
Dystonia of extremities side
right (1)
left (2)
bilateral (3)
Striatal toe
right (1)
left (2)
bilateral (3)
Striatal hand side
right (1)
left (2)
bilateral (3)
7. Myoclonus
pathological (1)
no pathological finding (2)
not examined (3)
7.1. Myoclonus - resting
right (1)
left (2)
bilateral (3)
7.1. Myoclonus - in action
right (1)
left (2)
bilateral (3)
7.1. Stimulus responding myoclonus
right (1)
left (2)
bilateral (3)
8. Hypermetria or hypometria
present (1)
not present (2)
not examined (3)
9. Brady- or Dysdiadochokinesia
present (1)
not present (2)
not examined (3)
Other disorders - alien limb
present (1)
not present (2)
not examined (3)
Alien limb side
right (1)
left (2)
bilateral (3)
11. Cortical somatosensory disorder
present (1)
not present (2)
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not examined (3)
12. Micrographia
present (1)
not present (2)
not examined (3)
13. Camptocormia
present (1)
not present (2)
not examined (3)
14. Clinical characteristics of gait abnormality
hypokinetic rigid (1)
frontal-apractic (2)
spastic (3)
other (myopathic, atrogen, psychogen)
(4)
15. Freezing of gait
present (1)
not present (2)
not examined (3)
16. Clinical frontal lobe symptoms
present (1)
not present (2)
not examined (3)
16.1. Frontal lobe symptoms
apathy (1)
pathological laughing or crying (10)
other signs of disinhibition (hyperactivity,
logorrhea) (11)
impulse decline (2)
language deterioration (3)
bulimia (4)
disinhibition (5)
aggressiveness (6)
tool use behaviour (7)
imitative behaviour (8)
stereotyped behaviour (9)
16.2. Glabella reflex
negative (0)
positive (1)
not examined (2)
16.3. Snout reflex
negative (0)
positive (1)
not examined (2)
16.4. Palm-chin reflex
negative (0)
positive (1)
not examined (2)
17. Apraxia signs
present (1)
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not present (2)
not examined (3)
17.1. Apraxia signs type
buccofacial (1)
apraxia of extremeties (2)
Apraxia of extremities side
right (1)
left (2)
bilateral (3)
17.2. Is there a one-sided ideomotoric apraxia
present?
present (1)
not present (2)
not examined (3)
17.3. Is there a constructual apraxia present?
present (1)
not present (2)
not examined (3)
18. Is there a visual or sensorial hemineglect
present?
present (1)
not present (2)
not examined (3)
19. Are pseudohallucinations or hallucinations
reported or are these in the examination situation
apparent?
present (1)
not present (2)
not examined (3)
20. Speech disorder
present (1)
not present (2)
not examined (3)
20.1. Clinical Characterization of the speech
disorder
bulbar dysarthria (bulbar dysarthria)
cerebellar dysarthria (cerebellar
dysarthria)
freezing of speech (freezing of speech)
hypokinetic (-rigid)/hypophonia
(hypokinetic (-rigid)/hypophonia)
inspiratory stridor (inspiratory stridor)
other (other)
spastic dysarthria (spastic dysarthria)
20.2 Speech apraxia
present (1)
not present (2)
not examined (3)
21.1. disfluent aphasia
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Yes
No
Semantic aphasia
Yes
No
22. Dysphagia
present (1)
not present (2)
not examined (3)
23. Oculomotoric disorder
present (1)
not present (2)
not examined (3)
23.1. Accadic horizontal eye movement
abortion  (abortion )
abortion of eye movement (abortion of
eye movement)
not examined (not examined)
not present (not present)
present (present)
23.2. Slowed saccades
present (1)
not present (2)
not examined (3)
23.3. Hypometric saccades
present (1)
not present (2)
not examined (3)
23.4. Supranuclear facial paresis
present (1)
not present (2)
not examined (3)
23.4.1. If present, please specify:
horizontal left (horizontal left)
horizontal right (horizontal right)
vertical left (vertical left)
vertical right (vertical right)
23.4.2. Occurrence of vertical gazevpalsy after
first motoric symptoms
< 1 Year (< 1 Year)
>1 Year (>1 Year)
23.5. Gaze nystagmus
horizontal (horizontal)
not examined (not examined)
not present (not present)
vertical (vertical)
23.6 Other oculomotoric disorder and unspecific
ocular symptoms
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Umsars I: Questions 9-12
UMSARS I not done
Yes
No
Anamnesis motor skills
1. Progressive course of the motor deficits
no (no)
other (in phases) (other (in phases))
rapidly progressive (rapidly progressive)
slowly progressive (slowly progressive)
unknown (unknown)
2. Unilateral course of motor deficits
>3 Years (>3 Years)
no  (no )
unknown (unknown)
3. Intake of Levodopa
No (No)
Unknown (Unknown)
Yes (Yes)
3.1. How long was Levodopa taken?
5 Years (<)
> 10 Years (> 10 Years)
> 5-10 Years (> 5-10 Years)
unknown (unknown)
3.2. Response to Levodopa
moderately good (31-69%) (moderately
good (31-69%))
poor (0-30%) (poor (0-30%))
unknown (unknown)
very good (70-100%) (very good (70-
100%))
4. Does the participant fall?
No (No)
Unknown (Unknown)
Yes (Yes)
4.1. Occurrence of falling after first motor
symptoms:
< 1 Year (< 1 Year)
> 3 Years (> 3 Years)
1-3 Years (1-3 Years)
5. Elevated sensibility to neuroleptics present
No (No)
Unknown (Unknown)
Yes (Yes)
6. Restless leg syndrome diagnosed?
No (No)
Unknown (Unknown)
Yes (Yes)
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Montreal Cognitive Assessment (MoCA)
Visuospatial/ Executive
no. of points
Naming
no. of points
Attention
no. of points
Language
no. of points
Abstraction
no. of points
Memory
no. of points
Orientation
no. of points
Total score
Geriatric depression scale (GDS)
1. Are you basically satisfied with your life?
Yes
No
2. Have you dropped many of your activities and
interests?
Yes
No
3. Do you feel that your life is empty?
Yes
No
4. Do you often get bored?
Yes
No
5. Are you in good spirits most of the time?
Yes
No
6. Are you afraid that something bad is going to
happen to you?
Yes
No
7. Do you feel happy most of the time?
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Yes
No
8. Do you often feel helpless?
Yes
No
9. Do you prefer to stay at home, rather than
going out and doing new things?
Yes
No
10.  Do you feel you have more problems with
memory than most?
Yes
No
11. Do you think it is wonderful to be alive now?
Yes
No
12. Do you feel pretty worthless the way you are
now?
Yes
No
13. Do you feel full of energy?
Yes
No
14.  Do you feel that your situation is hopeless?
Yes
No
15.  Do you think that most people are better off
than you are?
Yes
No
Score GDS
Sampling - Blood collection
Blood collection done?
Yes
No
Date of blood collection
Was the blood collection successful finished?
Yes
No
If "not successful" please give reasons:
Empty-stomached (during last 12 hrs)?
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Yes
No
Last meal:
Last beverage:
Last beverage with coffeine:
Tabacco smoke (during the last 12 hrs)
Yes
No
Last tabacco smoke:
Sampling according to SOP
1. Sampling performed according to SOP-BM-
01?
Yes
No
1.1. SOP version (No.)
2. Any deviations from SOP-BM-01
Yes
No
2.1. Other vacutainer used for blood collection
and not those at disposal.
Yes
No
2.1.1. other vacutainer, please specify:
2.2. Any deviation from SOP-KA-03, Version X?
Yes
No
Registration of samples
Tube-Type: Serum with coagulation activator 
Volume: 9 ml
Unit: ml
NOT DONE
Yes
No
Tube-Type: Serum with coagulation activator 
Volume: 9 ml
Unit: ml
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Tube: Serum without coagulation activator
Volume: 9 
Unit: ml
NOT DONE
Yes
No
Tube: Serum without coagulation activator
Volume: 9 
Unit: ml
Tube: EDTA plasma
Volume: 9
Unit: ml
Yes
No
Tube: EDTA plasma 
Volume: 9 
Unit: ml
Tube: Citrate plasma 1
Volume: 4,3
Unit: ml
NOT DONE
Yes
No
Tube: Citrate plasma 1 
Volume: 4,3 
Unit: ml
Tube: Citrate plasma 2
Volume: 4,3
Unit: ml
NOT DONE
Yes
No
Tube: Citrate plasma 2
Volume: 4,3 
Unit: ml
Tube: PAXgene RNA 1
Volume: 2,7
Unit: ml
NOT DONE
Yes
No
Tube: PAXgene RNA 1 
Volume: 2,7 
Unit: ml
Tube: PAXgene RNA2
18 / 21
DESCRIBE (DZNE – Clinical Register Study of neurodegenerative
Disorders) CRF Follow Up
Volume: 2,7 
Unit: ml
NOT DONE
Yes
No
Tube: PAXgene RNA 2
Volume: 2,7 
Unit: ml
Tube: CPT full blood
Volume: 8
Unit: ml
NOT DONE
Yes
No
Tube: CPT full blood
Volume: 8 
Unit: ml
Tube: CPT full blood
Volume: 8
Unit: ml
NOT DONE
Yes
No
Tube: CPT full blood
Volume: 8 
Unit: ml
Sampling - Urine sample
Was a collection of urine done?
Yes
No
date of urine sample
Empty-stomached (during the last 12hrs)?
Yes
No
Last meal:
Last beverage:
Last beverage with coffeine:
Consumption of tabacco (during last 12hrs)?
Yes
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No
Last tabacco consumption
Sampling according to SOP (Urine)
1. Sampling performed according to SOP-BM-
01?
Yes
No
1.1. SOP version (No.):
2. Any deviations from SOP-BM-01?
Yes
No
2.1. Other container used for urine collection and
not those at disposal.
Yes
No
2.1.1. If other container used for urine sample,
please specify:
2.2. Urine strips used
Yes
No
Results of urine strips
Glucose
0 (0)
+ (1)
++ (2)
Leucocytes
0 (0)
+ (1)
++ (2)
Nitrite urine
0 (0)
+ (1)
++ (2)
Albumin
0 (0)
+ (1)
++ (2)
Erythrocytes
0 (0)
+ (1)
++ (2)
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Hemoglobin
0 (0)
+ (1)
++ (2)
Registration of samples (Urine)
Container: Urine 1
Volume: 10
Unit: ml
NOT DONE
Yes
No
Container: Urine 1 
Volume: 10 
Unit: ml
Container: Urine 2
Volume: 10 
Unit: ml 
NOT DONE
Yes
No
Container: Urine 2 
Volume: 10 
Unit: ml
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DESCRIBE (DZNE – Clinical Register Study of
neurodegenerative Disorders) CRF Baseline Basis Module
Background and Purpose:
The purpose of the DESCRIBE study is to document the
natural course of diseases in context of medical care of
neurodegenerative disorders as well as cerebrovascular
diseases and to perform phenotyping of the test persons.
Disease-spanning analyses of the measured clincial data,
the results of the imaging processes, results of the analysis
of the biometerials including genetic analysis are planed.
Principal Investigator: Prof. Klockgether, Dr. Spottke DZNE,
Bonn.
Source: DESCRIBE-Studie
http://www.dzne.de/forschung/forschungsbereiche/klinische
-forschung/studien/describe-bn006.html 
Participating Study Sites:
Berlin, Bonn, Göttingen, Dresden, Köln, Magdeburg,
München, Rostock/Greifswald, Tübingen
All rights reserved. Please visit https://medical-data-
models.org/forms/13764
DESCRIBE CRF Baseline Basis
Module
Date of visit
Study-ID:
Date of baseline visit
Demographics
Gender
female (1)
male (2)
Birthdate
National origin
1. Country of birth of test person
Unknown
Yes
No
2. Country of birth of grandparents: grandfather
(paternal)
Unknown
Yes
No
2. Country of birth of grandparents: grandmother
(paternal)
Unknown
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Yes
No
2. Country of birth of grandparents: grandfather
(maternal)
Unknown
Yes
No
2. Country of birth of grandparents: grandmother
(maternal)
Unknown
Yes
No
Mother tongue
1. Is German the mother tongue of the
participant?
Yes
No
1.1. How would you access his/her knowledge of
the German language?
very good (1)
good (2)
moderate (3)
low (4)
2. Since when does the participant live mainly in
Germany?
since birth (1)
since certain year (specified in next item)
(2)
n.a. (3)
Since year:
Clinical diagnosis
Date of initial diagnosis
Age at onset on symptoms
Subjective cognitive decline (SCD)
Principle diagnosis (1)
Differential diagnosis 1 (2)
Differential diagnosis 2 (3)
Differential diagnosis 3 (4)
Mild cognitive impairment (MCI)
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Principle diagnosis (1)
Differential diagnosis 1 (2)
Differential diagnosis 2 (3)
Differential diagnosis 3 (4)
Not anamnestic mild cognitive impairment
Principle diagnosis (1)
Differential diagnosis 1 (2)
Differential diagnosis 2 (3)
Differential diagnosis 3 (4)
Probable dementia along with Alzheimer's
disease
Principle diagnosis (1)
Differential diagnosis 1 (2)
Differential diagnosis 2 (3)
Differential diagnosis 3 (4)
Posterior cortical atrophy
Principle diagnosis (1)
Differential diagnosis 1 (2)
Differential diagnosis 2 (3)
Differential diagnosis 3 (4)
Mixed dementia
Principle diagnosis (1)
Differential diagnosis 1 (2)
Differential diagnosis 2 (3)
Differential diagnosis 3 (4)
Vascular dementia (VD)
Principle diagnosis (1)
Differential diagnosis 1 (2)
Differential diagnosis 2 (3)
Differential diagnosis 3 (4)
Frototemperal dementia (FTD) - behavioral
variant
Principle diagnosis (1)
Differential diagnosis 1 (2)
Differential diagnosis 2 (3)
Differential diagnosis 3 (4)
Primary progressive aphasia (PPA)
Principle diagnosis (1)
Differential diagnosis 1 (2)
Differential diagnosis 2 (3)
Differential diagnosis 3 (4)
Progressive nonfluent aphasia (PNFA)
Principle diagnosis (1)
Differential diagnosis 1 (2)
Differential diagnosis 2 (3)
Differential diagnosis 3 (4)
Logopenic progressive Aphasia (LPA)
Principle diagnosis (1)
Differential diagnosis 1 (2)
Differential diagnosis 2 (3)
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Differential diagnosis 3 (4)
Semantic dementia
Principle diagnosis (1)
Differential diagnosis 1 (2)
Differential diagnosis 2 (3)
Differential diagnosis 3 (4)
bvFTD + ALS
Principle diagnosis (1)
Differential diagnosis 1 (2)
Differential diagnosis 2 (3)
Differential diagnosis 3 (4)
PPA + ALS
Principle diagnosis (1)
Differential diagnosis 1 (2)
Differential diagnosis 2 (3)
Differential diagnosis 3 (4)
Idiopathic Parkinson's disease (IPS)
Principle diagnosis (1)
Differential diagnosis 1 (2)
Differential diagnosis 2 (3)
Differential diagnosis 3 (4)
Morbus parkinson along with MCI (PD-MCI)
Principle diagnosis (1)
Differential diagnosis 1 (2)
Differential diagnosis 2 (3)
Differential diagnosis 3 (4)
Dementia due to morbus parkinson (PPD)
Principle diagnosis (1)
Differential diagnosis 1 (2)
Differential diagnosis 2 (3)
Differential diagnosis 3 (4)
Dementia with Lewy bodies (DLB)
Principle diagnosis (1)
Differential diagnosis 1 (2)
Differential diagnosis 2 (3)
Differential diagnosis 3 (4)
Atypical Parkinson syndroms - progressive
supranuclear palsy
Principle diagnosis (1)
Differential diagnosis 1 (2)
Differential diagnosis 2 (3)
Differential diagnosis 3 (4)
Possible progressive supranuclear palsy
Principle diagnosis (1)
Differential diagnosis 1 (2)
Differential diagnosis 2 (3)
Differential diagnosis 3 (4)
Corticobasal degeneration (CBD)
Principle diagnosis (1)
Differential diagnosis 1 (2)
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Differential diagnosis 2 (3)
Differential diagnosis 3 (4)
Multiple system atrophy
Principle diagnosis (1)
Differential diagnosis 1 (2)
Differential diagnosis 2 (3)
Differential diagnosis 3 (4)
MSA-p (Parkinson)
Principle diagnosis (1)
Differential diagnosis 1 (2)
Differential diagnosis 2 (3)
Differential diagnosis 3 (4)
MSA-c (cerebellar)
Principle diagnosis (1)
Differential diagnosis 1 (2)
Differential diagnosis 2 (3)
Differential diagnosis 3 (4)
Essential tremor
Principle diagnosis (1)
Differential diagnosis 1 (2)
Differential diagnosis 2 (3)
Differential diagnosis 3 (4)
Ataxia
Principle diagnosis (1)
Differential diagnosis 1 (2)
Differential diagnosis 2 (3)
Differential diagnosis 3 (4)
Amyotrophic lateral sclerosis
Principle diagnosis (1)
Differential diagnosis 1 (2)
Differential diagnosis 2 (3)
Differential diagnosis 3 (4)
Huntington disease
Principle diagnosis (1)
Differential diagnosis 1 (2)
Differential diagnosis 2 (3)
Differential diagnosis 3 (4)
Creutzfeldt-Jakob-Disease
Principle diagnosis (1)
Differential diagnosis 1 (2)
Differential diagnosis 2 (3)
Differential diagnosis 3 (4)
Depression (primary disease)
Principle diagnosis (1)
Differential diagnosis 1 (2)
Differential diagnosis 2 (3)
Differential diagnosis 3 (4)
Living situation
5 / 24
DESCRIBE (DZNE – Clinical Register Study of neurodegenerative
Disorders) CRF Baseline Basis Module
Marital status
Single (1)
Married (2)
Separated (3)
Widowed (4)
Divorced (5)
Civil partnership (6)
N.A. (7)
2. What is the current housing situation of the
participant ?
private household, alone (1)
two-person household (2)
multi-person household (3)
retirement home/ (residential) care home
for the elderly (4 )
N.A. (5)
Education and profession
1. Qualification - graduation
unknown (1)
no school-leaving qualifications (max. 7
years) (2)
board school graduation
(Volksschulabschluss) (3)
certificate of secondary education
(Hauptschulabschluss) (4)
secondary school leaving certificate
(mittlere Reife) (5)
extended secondary school leaving
certificate (erweiteter
Sekundarabschluss 1) (6)
vocational baccalaureate diploma
(Fachabitur) (7)
higher education entrance qualification
(Abitur) (8)
other school leaving certificate (9)
Years of education (no leaving certificate)
yrs
Years of education (graduation)
yrs
2. Professional education
unknown (1)
none (2)
apprenticeship (3)
University of Applied Sciences degree
(4)
university degree (5)
additional qualification (postgraduate
course, doctor's degree, habilitation) (6)
other course of studies (7)
Years of education (apprenticeship)
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yrs
Years of education (standard period of study -
university of applied siences)
yrs
Years of education (standard period of study -
university)
yrs
Years of education (additional studies)
yrs
Years of education (other course of studies)
yrs
Total years of education
yrs
1. Current occupation
worker (1)
employee (2)
civil servant (3)
self-employed (4)
unemployed (5)
not working (6)
retired (7)
1.1. Retirement
old-age pension (1)
early retirement due to occupational
disability (2)
early retirement due to unemployability
(3)
1.2. Retirement since: (month, year)
Number of years since start of retirement
2. Professional situation the participant spent
most time in.
worker (1)
employee (2)
civil servant (3)
self-employed (4)
not working (5)
3. Number of years of occupation (so far)
yrs
4. Professional group (Code)
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Consumption of semiluxury food - nicotine
1. Are you currently a smoker?
Yes
No
1.1. Since when do you smoke?
yrs
1.2. How many cigarettes do you usually smoke
during a day?
no. cigarettes a day
Pack years
Consumption of semiluxury food - alcohol
1. Do you drink alcohol?
Yes
No
1.1. How many alcoholic beverages do you drink
on average during the week?
< 1 per week (1)
1-7 (2)
8-14 (3)
15-21 (4)
22-28 (5)
29-35 (6)
36-42 (7)
2. Did you sometime in the past consume more
than 15-21 alcoholic beverages per week?
Yes
No
2.1. Number of years
yrs
Vital signs
1. Height
cm
2. Weight
kg
Body mass index
kg/m2
Clinical phenotype -  Anamnesis and
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inspection
Praxia / visual respectively spatial
without pathological findings (1)
pathological finding (2)
not examined (3)
Speech and language
without pathological findings (1)
pathological finding (2)
not examined (3)
Autonomic nervous system
without pathological findings (1)
pathological finding (2)
not examined (3)
Clinical phenotype - Further examination
I. Examination of muscle tonus and strength
performed
Yes
No
1. Change in muscle tonus
present (1)
not present (2)
not examined (3)
1.1. Rigor
present (1)
not present (2)
not examined (3)
1.2. Spastic
present (1)
not present (2)
not examined (3)
2. Peripheral nerve paresis, which cannot be
assigned to a peripheral nerve or a nerve root.
present (1)
not present (2)
not examined (3)
2.1. Atrophy
present (1)
not present (2)
not examined (3)
2.2. Fasciculation
present (1)
not present (2)
not examined (3)
2. Central pareses
present (1)
not present (2)
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not examined (3)
3.1. Central right arm paresis
latent (1)
manifest (2)
mild (3)
severe (4)
not present  (5)
not examined (6)
3.2. Central left arm paresis
latent (1)
manifest (2)
mild (3)
severe (4)
not present  (5)
not examined (6)
3.3. Central right leg paresis
latent (1)
manifest (2)
mild (3)
severe (4)
not present  (5)
not examined (6)
3.4. Central left leg paresis
latent (1)
manifest (2)
mild (3)
severe (4)
not present  (5)
not examined (6)
4.1. Biceps reflex
diminution of reflex (1)
augmentation of reflex (2)
no pathological finding (3)
not examined (4)
4.2. Patellar reflex
diminution of reflex (1)
augmentation of reflex (2)
no pathological finding (3)
not examined (4)
4.3. Achilles' tendon reflex
diminution of reflex (1)
augmentation of reflex (2)
no pathological finding (3)
not examined (4)
4.4. Babinski sign
negative (0)
positive (1)
not examined (2)
Babinski sign positive side
right (1)
left (2)
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bilateral (3)
5. Tremor
present (1)
not present (2)
not examined (3)
Tremor type
resting tremor (1)
action tremor (2)
6. Dyskinetic signs / dystonic signs
present (1)
not present (2)
not examined (3)
6.1. Dyskinetic signs type
oromandibular (1)
axial dystonia (2)
dystonia of extremities (3)
stratial toe (4)
stratial hand (5)
chorea (6)
tardive dyskinesia (7)
Dystonia of extremities side
right (1)
left (2)
bilateral (3)
Striatal toe
right (1)
left (2)
bilateral (3)
Striatal hand side
right (1)
left (2)
bilateral (3)
7. Myoclonus
pathological (1)
no pathological finding (2)
not examined (3)
7.1. Myoclonus - resting
right (1)
left (2)
bilateral (3)
7.1. Myoclonus - in action
right (1)
left (2)
bilateral (3)
7.1. Stimulus responding myoclonus
right (1)
left (2)
bilateral (3)
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8. Hypermetria or hypometria
present (1)
not present (2)
not examined (3)
9. Brady- or Dysdiadochokinesia
present (1)
not present (2)
not examined (3)
Other disorders - alien limb
present (1)
not present (2)
not examined (3)
Alien limb side
right (1)
left (2)
bilateral (3)
11. Cortical somatosensory disorder
present (1)
not present (2)
not examined (3)
12. Micrographia
present (1)
not present (2)
not examined (3)
13. Camptocormia
present (1)
not present (2)
not examined (3)
14. Clinical characteristics of gait abnormality
hypokinetic rigid (1)
frontal-apractic (2)
spastic (3)
other (myopathic, atrogen, psychogen)
(4)
15. Freezing of gait
present (1)
not present (2)
not examined (3)
16. Clinical frontal lobe symptoms
present (1)
not present (2)
not examined (3)
16.1. Frontal lobe symptoms
apathy (1)
pathological laughing or crying (10)
other signs of disinhibition (hyperactivity,
logorrhea) (11)
impulse decline (2)
language deterioration (3)
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bulimia (4)
disinhibition (5)
aggressiveness (6)
tool use behaviour (7)
imitative behaviour (8)
stereotyped behaviour (9)
16.2. Glabella reflex
negative (0)
positive (1)
not examined (2)
16.3. Snout reflex
negative (0)
positive (1)
not examined (2)
16.4. Palm-chin reflex
negative (0)
positive (1)
not examined (2)
17. Apraxia signs
present (1)
not present (2)
not examined (3)
17.1. Apraxia signs type
buccofacial (1)
apraxia of extremeties (2)
Apraxia of extremities side
right (1)
left (2)
bilateral (3)
17.2. Is there a one-sided ideomotoric apraxia
present?
present (1)
not present (2)
not examined (3)
17.3. Is there a constructual apraxia present?
present (1)
not present (2)
not examined (3)
18. Is there a visual or sensorial hemineglect
present?
present (1)
not present (2)
not examined (3)
19. Are pseudohallucinations or hallucinations
reported or are these in the examination situation
apparent?
present (1)
not present (2)
not examined (3)
20. Speech disorder
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present (1)
not present (2)
not examined (3)
20.1. Clinical Characterization of the speech
disorder
bulbar dysarthria (bulbar dysarthria)
cerebellar dysarthria (cerebellar
dysarthria)
freezing of speech (freezing of speech)
hypokinetic (-rigid)/hypophonia
(hypokinetic (-rigid)/hypophonia)
inspiratory stridor (inspiratory stridor)
other (other)
spastic dysarthria (spastic dysarthria)
20.2 Speech apraxia
present (1)
not present (2)
not examined (3)
21.1. disfluent aphasia
Yes
No
Semantic aphasia
Yes
No
22. Dysphagia
present (1)
not present (2)
not examined (3)
23. Oculomotoric disorder
present (1)
not present (2)
not examined (3)
23.1. Accadic horizontal eye movement
abortion  (abortion )
abortion of eye movement (abortion of
eye movement)
not examined (not examined)
not present (not present)
present (present)
23.2. Slowed saccades
present (1)
not present (2)
not examined (3)
23.3. Hypometric saccades
present (1)
not present (2)
not examined (3)
23.4. Supranuclear facial paresis
present (1)
not present (2)
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not examined (3)
23.4.1. If present, please specify:
horizontal left (horizontal left)
horizontal right (horizontal right)
vertical left (vertical left)
vertical right (vertical right)
23.4.2. Occurrence of vertical gazevpalsy after
first motoric symptoms
< 1 Year (< 1 Year)
>1 Year (>1 Year)
23.5. Gaze nystagmus
horizontal (horizontal)
not examined (not examined)
not present (not present)
vertical (vertical)
23.6 Other oculomotoric disorder and unspecific
ocular symptoms
Umsars I: Questions 9-12
UMSARS I not done
Yes
No
Anamnesis motor skills
1. Date of first manifestation of motor disorder
(month, year)
2. Date of first diagnosis of motor disorder
(month, year)
3. Progressive course of the motor deficits
no (no)
other (in phases) (other (in phases))
rapidly progressive (rapidly progressive)
slowly progressive (slowly progressive)
unknown (unknown)
4. Duration of disorder
3 Years (<)
> 10 Years (> 10 Years)
> 3-5 Years (> 3-5 Years)
>5-10 Years (>5-10 Years)
unknown (unknown)
5. Onset of motor deficits
acute (acute)
insidiously (insidiously)
unknown (unknown)
6. Unilateral onset of motor disorder
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No (No)
Unknown (Unknown)
Yes (Yes)
7. Unilateral course of motor deficits
>3 Years (>3 Years)
no  (no )
unknown (unknown)
8. Intake of Levodopa
No (No)
Unknown (Unknown)
Yes (Yes)
8.1. How long was Levodopa taken?
5 Years (<)
> 10 Years (> 10 Years)
> 5-10 Years (> 5-10 Years)
unknown (unknown)
8.2. Response to Levodopa
moderately good (31-69%) (moderately
good (31-69%))
poor (0-30%) (poor (0-30%))
unknown (unknown)
very good (70-100%) (very good (70-
100%))
9. Does the participant fall?
No (No)
Unknown (Unknown)
Yes (Yes)
9.1. Occurrence of falling after first motor
symptoms:
< 1 Year (< 1 Year)
> 3 Years (> 3 Years)
1-3 Years (1-3 Years)
10. Elevated sensibility to neuroleptics present
No (No)
Unknown (Unknown)
Yes (Yes)
11. Does the participant suffer from another brain
disease, which could explain deficits, e.g. stroke,
craniocerebral trauma, encephalitis, tumor,
multiple sclerosis, epilepsy?
No (No)
Unknown (Unknown)
Yes (Yes)
12. Did the motor deficits occur immediately as
consequence of an existing brain disease (e.g. 3
months later)?
No (No)
Unknown (Unknown)
Yes (Yes)
13. Is the participant in  a state of acute
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psychosis or delirium?
No (No)
Unknown (Unknown)
Yes (Yes)
14. Is there any evidence of current or previous
alcohol or drug abuse or does the participant
suffer from symptoms of withdrawal?
No (No)
Unknown (Unknown)
Yes (Yes)
15. Did the participant take neuroleptics at onset
of illness?
No (No)
Unknown (Unknown)
Yes (Yes)
16. Are there other medical reasons that can fully
explain the motor disorder, e.g. hip prothesis,
morbus whipple?
No (No)
Unknown (Unknown)
Yes (Yes)
17. Restless leg syndrome diagnosed?
No (No)
Unknown (Unknown)
Yes (Yes)
Montreal Cognitive Assessment (MoCA)
Visuospatial/ Executive
no. of points
Naming
no. of points
Attention
no. of points
Language
no. of points
Abstraction
no. of points
Memory
no. of points
Orientation
no. of points
Total score
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Geriatric depression scale (GDS)
1. Are you basically satisfied with your life?
Yes
No
2. Have you dropped many of your activities and
interests?
Yes
No
3. Do you feel that your life is empty?
Yes
No
4. Do you often get bored?
Yes
No
5. Are you in good spirits most of the time?
Yes
No
6. Are you afraid that something bad is going to
happen to you?
Yes
No
7. Do you feel happy most of the time?
Yes
No
8. Do you often feel helpless?
Yes
No
9. Do you prefer to stay at home, rather than
going out and doing new things?
Yes
No
10.  Do you feel you have more problems with
memory than most?
Yes
No
11. Do you think it is wonderful to be alive now?
Yes
No
12. Do you feel pretty worthless the way you are
now?
Yes
No
13. Do you feel full of energy?
Yes
No
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14.  Do you feel that your situation is hopeless?
Yes
No
15.  Do you think that most people are better off
than you are?
Yes
No
Score GDS
Sampling - Blood collection
Blood collection done?
Yes
No
Date of blood collection
Was the blood collection successful finished?
Yes
No
If "not successful" please give reasons:
Empty-stomached (during last 12 hrs)?
Yes
No
Last meal:
Last beverage:
Last beverage with coffeine:
Tabacco smoke (during the last 12 hrs)
Yes
No
Last tabacco smoke:
Sampling according to SOP
1. Sampling performed according to SOP-BM-
01?
Yes
No
1.1. SOP version (No.)
2. Any deviations from SOP-BM-01
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Yes
No
2.1. Other vacutainer used for blood collection
and not those at disposal.
Yes
No
2.1.1. other vacutainer, please specify:
2.2. Any deviation from SOP-KA-03, Version X?
Yes
No
Registration of samples
Tube-Type: Serum with coagulation activator 
Volume: 9 ml
Unit: ml
NOT DONE
Yes
No
Tube-Type: Serum with coagulation activator 
Volume: 9 ml
Unit: ml
Tube: Serum without coagulation activator
Volume: 9 
Unit: ml
NOT DONE
Yes
No
Tube: Serum without coagulation activator
Volume: 9 
Unit: ml
Tube: EDTA plasma
Volume: 9
Unit: ml
Yes
No
Tube: EDTA plasma 
Volume: 9 
Unit: ml
Tube: Citrate plasma 1
Volume: 4,3
Unit: ml
NOT DONE
Yes
No
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Tube: Citrate plasma 1 
Volume: 4,3 
Unit: ml
Tube: Citrate plasma 2
Volume: 4,3
Unit: ml
NOT DONE
Yes
No
Tube: Citrate plasma 2
Volume: 4,3 
Unit: ml
Tube: EDTA blood for DNA 1
Volume: 4
Unit: ml
NOT DONE
Yes
No
Tube: EDTA blood for DNA 1
Volume: 4 
Unit: ml
Tube: EDTA blood for DNA 2
Volume: 4 
Unit: ml
NOT DONE
Yes
No
Tube: EDTA blood for DNA 2 
Volume: 4 
Unit: ml
Tube: PAX gene DNA
Volume: 8,5
Unit: ml
NOT DONE
Yes
No
Tube: PAX gene DNA
Volume: 8,5
Unit: ml
Tube: PAXgene RNA 1
Volume: 2,7
Unit: ml
NOT DONE
Yes
No
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Tube: PAXgene RNA 1 
Volume: 2,7 
Unit: ml
Tube: PAXgene RNA2
Volume: 2,7 
Unit: ml
NOT DONE
Yes
No
Tube: PAXgene RNA 2
Volume: 2,7 
Unit: ml
Tube: CPT full blood
Volume: 8
Unit: ml
NOT DONE
Yes
No
Tube: CPT full blood
Volume: 8 
Unit: ml
Tube: CPT full blood
Volume: 8
Unit: ml
NOT DONE
Yes
No
Tube: CPT full blood
Volume: 8 
Unit: ml
Sampling - Urine sample
Was a collection of urine done?
Yes
No
date of urine sample
Empty-stomached (during the last 12hrs)?
Yes
No
Last meal:
Last beverage:
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Last beverage with coffeine:
Consumption of tabacco (during last 12hrs)?
Yes
No
Last tabacco consumption
Sampling according to SOP (Urine)
1. Sampling performed according to SOP-BM-
01?
Yes
No
1.1. SOP version (No.):
2. Any deviations from SOP-BM-01?
Yes
No
2.1. Other container used for urine collection and
not those at disposal.
Yes
No
2.1.1. If other container used for urine sample,
please specify:
2.2. Urine strips used
Yes
No
Results of urine strips
Glucose
0 (0)
+ (1)
++ (2)
Leucocytes
0 (0)
+ (1)
++ (2)
Nitrite urine
0 (0)
+ (1)
++ (2)
Albumin
0 (0)
+ (1)
++ (2)
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Erythrocytes
0 (0)
+ (1)
++ (2)
Hemoglobin
0 (0)
+ (1)
++ (2)
Registration of samples (Urine)
Container: Urine 1
Volume: 10
Unit: ml
NOT DONE
Yes
No
Container: Urine 1 
Volume: 10 
Unit: ml
Container: Urine 2
Volume: 10 
Unit: ml 
NOT DONE
Yes
No
Container: Urine 2 
Volume: 10 
Unit: ml
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Eligibility Multiple Myeloma NCT01269203
Efficacy of NF-kB Inhibition for Reducing Symptoms During
Maintenance Therapy in Multiple Myeloma Patients; ODM
derived from: https://clinicaltrials.gov/show/NCT01269203
All rights reserved. Please visit https://medical-data-
models.org/forms/13766
Eligibility Multiple Myeloma
NCT01269203
Inclusion Criteria
1. must have a histologically confirmed diagnosis
of multiple myeloma.*
Yes
No
2. must be >/= 18 years of age.*
Yes
No
3. must have a performance status (ecog ps) of
0-2.*
Yes
No
4. must be qualified and have signed consent to
receive lenalidomide for maintenance therapy for
mm.*
Yes
No
5. must have signed informed consent indicating
that they are aware of the investigational nature
of the study, and are aware that participation is
voluntary.*
Yes
No
6. must also agree to refrain from use of self
prescribed curcumin during the course of the
study.*
Yes
No
7. must have negative pregnancy test before
signing consent for mm therapy.*
Yes
No
Exclusion Criteria
1. unable to understand the symptom
assessment or not willing to participate in the
study.*
Yes
No
2. treatment for other carcinomas within the last 5
years, except for cured non-melanoma skin and
treated in-situ cervical cancer.*
Yes
No
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3. uncontrolled intercurrent illness including, but
not limited to, ongoing or requiring iv antibiotics,
cardiac disease (nyha class iii or iv heart failure),
unstable angina pectoris, unstable cardiac
arrhythmia or tachycardia, or psychiatric illness/
social situations that would limit compliance with
the study requirements are excluded.*
Yes
No
4. concurrent use of coumadin other than low
dose (1 mg) coumadin used for line patency.*
Yes
No
5. concurrent use of cimetidine, allopurinol, or
aluminium hydroxide and magnesium hydroxide-
containing antacids such as maalox.*
Yes
No
6. sorivudine and brivudine use within 4 weeks of
the start of study treatment.*
Yes
No
7. gastric or duodenal ulcers, or gastric
hyperacidity disorders.*
Yes
No
8. currently receiving anticoagulants (heparin) or
antiplatelets (clopidogrel, ticlopidine,
aspirin/dipyridamole)*
Yes
No
9. inr > 1.5 (upper limit of normal = 1.5).*
Yes
No
10. history of deep vein thrombosis.*
Yes
No
11. received allogeneic transplant.*
Yes
No
12. allergy to turmeric, curcumin, or yellow dye.*
Yes
No
13. bowel or bile duct obstruction.*
Yes
No
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Eligibility Multiple Sclerosis NCT01371760
BRAVE-DREAMS (BRAin VEnous DRainage Exploited
Against Multiple Sclerosis); ODM derived from:
https://clinicaltrials.gov/show/NCT01371760
All rights reserved. Please visit https://medical-data-
models.org/forms/13767
Eligibility Multiple Sclerosis
NCT01371760
Inclusion Criteria
patients affected by ccsvi associated with ms*
Yes
No
relapsing-remitting and\or secondary
progressive*
Yes
No
18-65 years old*
Yes
No
edss 2-5*
Yes
No
disease duration < 10y*
Yes
No
no relapse in the 30 days preceding the
procedure*
Yes
No
clinical stability in the last 6 months with disease
mod. treatments*
Yes
No
patients under the best available therapy*
Yes
No
Exclusion Criteria
patients previously treated for ccsvi or inserted in
other clinical trials in the last 3 months*
Yes
No
under treatment with natalizumab*
Yes
No
pregnant or refusing to adopt contraception*
Yes
No
presence of significant comorbidities*
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Yes
No
alcool-drug abuse*
Yes
No
thrombophilia*
Yes
No
contraindication to mr*
Yes
No
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Eligibility Multiple Sclerosis NCT01433250
A Study to Evaluate the Safety, Tolerability and Efficacy of
AIN457 in Patients With Relapsing-remitting Multiple
Sclerosis; ODM derived from:
https://clinicaltrials.gov/show/NCT01433250
All rights reserved. Please visit https://medical-data-
models.org/forms/13768
Eligibility Multiple Sclerosis
NCT01433250
Inclusion Criteria
1. was exposed to ain457 or placebo in study
cain457b2201 and completed the cain457b2201
study, up to at and including visit 10 (week 24).*
Yes
No
Exclusion Criteria
1. have been treated with:*
Yes
No
immunosuppressive medications such as
azathioprine or methotrexate within 1 month prior
to enrollment, if lymphocyte count normal.*
Yes
No
immunoglobulins and/or monoclonal antibodies
(with the exception of ain457) within 2 month
prior to enrollment, or if the immunosuppressive
effects are likely to persist at enrollment (such as
presence of b cell depletion after rituximab
treatment).*
Yes
No
2. have received total lymphoid irradiation, bone
marrow transplantation, alemtuzumab, cladribine,
cyclophosphamide, mitoxantrone or other
immunosuppressive treatments with long-lasting
(over 6 months) or permanent effects.*
Yes
No
3. have received any live or live attenuated
vaccines (including live vaccines for varicella-
zoster virus or measles) within 2 months prior to
enrollment.*
Yes
No
4. a diagnosis of chronic disease of the immune
system other than ms, or of an immunodeficiency
syndrome.*
Yes
No
5. current severe depression.*
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Yes
No
6. pregnant or nursing (lactating) women.*
Yes
No
7. malignancy diagnosed since enrollment in the
core study (except for successfully-treated basal
or squamous cell carcinoma of skin).*
Yes
No
8. a new diagnosis of diabetes*
Yes
No
9. positive testing for tuberculosis (quantiferon or
chest x-ray).*
Yes
No
10. subjects with clinically significant cardiac
abnormalities*
Yes
No
11. unable or unwilling to undergo multiple
venipunctures*
Yes
No
12. unable to undergo mri scans due to newly
acquired claustrophobia or metallic implants
incompatible with mri.*
Yes
No
other protocol-defined inclusion/exclusion criteria
may apply*
Yes
No
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Eligibility Negative Symptoms of
Schizophrenia NCT01234298
SPD489 as Adjunctive Treatment in Adults With Negative
Symptoms of Schizophrenia; ODM derived from:
https://clinicaltrials.gov/show/NCT01234298
All rights reserved. Please visit https://medical-data-
models.org/forms/13769
Eligibility Negative Symptoms of
Schizophrenia NCT01234298
Inclusion Criteria
subject has diagnosis of schizophrenia for at
least 2 years*
Yes
No
subject has persistent predominant negative
symptoms*
Yes
No
subject has 2 or more persistent predominant
negative symptoms (affective flattening, alogia,
avolition apathy, and anhedonia-asociality)
determined to have been present for at least 6
months*
Yes
No
subject is maintained on antipsychotic
monotherapy or polytherapy with no more than 2
antipsychotic medications*
Yes
No
subject has been clinically stable and is in the
non-acute phase of illness*
Yes
No
Exclusion Criteria
subject has clinically notable positive symptoms*
Yes
No
subject is considered to be treatment refractory*
Yes
No
subject has current history of substance
abuse/dependance*
Yes
No
subject is considered a suicide risk or risk to
harm others*
Yes
No
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Eligibility Non Small-cell Lung Cancer
NCT01402089
Cytochrom p450 3A4 and 1A2 Phenotyping for the
Individualization of Treatment With Sunitinib or Erlotinib in
Cancer Patients; ODM derived from:
https://clinicaltrials.gov/show/NCT01402089
All rights reserved. Please visit https://medical-data-
models.org/forms/13770
Eligibility Non Small-cell Lung
Cancer NCT01402089
Inclusion Criteria
histologically or cytologically confirmed renal-cell
cancer or  gastrointestinal stromal tumor (for
sunitinib) or non small-cell lung cancer (for
erlotinib)*
Yes
No
both early or advanced tumor stage*
Yes
No
indication for the therapeutic use of either
sunitinib or erlotinib*
Yes
No
written informed consent and willing to undergo
pk-sampling*
Yes
No
patients > 18 years of age*
Yes
No
ecog performance status or ≤2*
Yes
No
adequate laboratory parameters:*
Yes
No
i.   serum creatinine and serum bilirubin ≤ 1.5 x
uln ii.  serum alt and ast ≤ 2.5 x uln (or ≤ 5 in
case of liver metastases) iii. serum calcium ≤
11,6 mg/dl (2.9 mmol/l)*
Yes
No
Exclusion Criteria
previous treatment with sunitinib or erlotinib*
Yes
No
known hypersensitivity to trial drug or any
compounds of the drug*
Yes
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No
concurrent radiotherapy*
Yes
No
concurrent systemic anticancer treatment with
the exception of bisphosphonates and
bevacizumab in patients with non small-cell lung
cancer*
Yes
No
2 / 2
Eligibility Non Small-cell Lung Cancer NCT01402089
Eligibility Non-small Cell Lung Cancer
NCT01398124
Cyclin B1 Peptide-Pulsed Autologous Dendritic Cell
Vaccine for Resectable Non-Small Cell Lung Cancer; ODM
derived from: https://clinicaltrials.gov/show/NCT01398124
All rights reserved. Please visit https://medical-data-
models.org/forms/13771
Eligibility Non-small Cell Lung
Cancer NCT01398124
Inclusion Criteria
patients must have histologically or cytologically
confirmed non-small cell lung cancer*
Yes
No
all patients must have one of the following stages:
stage ia(t1no), and ib t2no), ii & iiia (n2 negative)*
Yes
No
no prior chemotherapy or radiation therapy for
non-small cell lung cancer*
Yes
No
age >18 years*
Yes
No
ecog performance status <2*
Yes
No
patients must have acceptable organ and
marrow*
Yes
No
patient must be deemed surgically and medically
resectable*
Yes
No
men and women of childbearing potential must
be willing to use effective contraception while on
treatment and for at least 3 months thereafter.*
Yes
No
ability to understand and the willingness to sign a
written informed consent document.*
Yes
No
Exclusion Criteria
patients may not be receiving any other
investigational agents.*
Yes
No
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patients should not have received chemotherapy
or radiotherapy within 3 months prior to entry to
study.*
Yes
No
patients with tumors involving the superior sulcus
are not eligible.*
Yes
No
patients must not have post-obstructive
pneumonia or other serious infection at the time
of registration or other serious underlying medical
condition that would impair the ability of the
patient to receive protocol treatment.*
Yes
No
prior resection of lung cancer is allowed, if at
least five years have elapsed between previous
resection and registration.*
Yes
No
uncontrolled intercurrent illness including, but not
limited to, ongoing or active infection,
symptomatic congestive heart failure, unstable
angina pectoris, cardiac arrhythmia, or psychiatric
illness/social situations that would limit
compliance with study requirements.*
Yes
No
pregnant women are excluded from this study.
women of childbearing potential must have a
negative pregnancy test.*
Yes
No
known hiv-positive patients are excluded from the
study.*
Yes
No
patients with a history of known autoimmune
disease are excluded from this study.*
Yes
No
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Eligibility Non-Small Cell Lung Cancer
NCT01423760
Collect Long-term Data on Subjects Following Participation
in Previous EMD 531444 (L-BLP25 or BLP25 Liposome
Vaccine) Clinical Trials; ODM derived from:
https://clinicaltrials.gov/show/NCT01423760
All rights reserved. Please visit https://medical-data-
models.org/forms/13772
Eligibility Non-Small Cell Lung
Cancer NCT01423760
Inclusion Criteria
signed written informed consent.*
Yes
No
registration and treatment in a clinical trial with
tecemotide (l blp25) under sponsorship of merck
kgaa / emd serono / merck serono japan (feeder
trial). [note, subjects who have been allocated to
treatments not containing tecemotide (l blp25) in
the feeder trial are eligible for this trial and will be
followed-up for pd (if applicable) and survival.]*
Yes
No
end of treatment procedures have been
performed in the feeder trial.*
Yes
No
additional inclusion criteria also apply.*
Yes
No
Exclusion Criteria
pregnancy and lactation period; women of
childbearing potential, unless using effective
contraception as determined by the investigator.
subjects whom the investigator considers may be
at risk of pregnancy will have a pregnancy test
performed per institutional standard.*
Yes
No
known hypersensitivity to any of the trial
treatment ingredients (if applicable).*
Yes
No
legal incapacity or limited legal capacity.*
Yes
No
any other reason that, in the opinion of the
investigator, precludes the subject from
participating in the trial.*
Yes
No
additional exclusion criteria also apply.*
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Yes
No
2 / 2
Eligibility Non-Small Cell Lung Cancer NCT01423760
Eligibility Non-small Cell Lung Cancer
NCT01459497
Hypofractionated Image-Guided Radiation Therapy (IGRT)
in Patients With Stage II-III Non-Small Cell Lung Cancer;
ODM derived from:
https://clinicaltrials.gov/show/NCT01459497
All rights reserved. Please visit https://medical-data-
models.org/forms/13773
Eligibility Non-small Cell Lung
Cancer NCT01459497
Inclusion Criteria
all patients must be willing and capable to provide
informed consent to participate in the protocol.*
Yes
No
patients must have appropriate staging studies
identifying them as ajcc stage ii or iii non small
cell lung cancer, (according to ajcc staging, 6th
edition; see appendix iii), or recurrent non small
cell lung cancer.  histologic confirmation of
cancer will be required by biopsy or cytology
within 6 months of study entry.*
Yes
No
patients must have the potential for benefit from
local therapy (at the discretion of the
investigator).*
Yes
No
the patient's zubrod performance status must be
2 or greater or patients with zubrod performance
status 0-1 and weight loss >10% are considered
eligible.  in addition, patients determined to be
medically unfit or refusing combined modality
therapy are eligible.*
Yes
No
age ≥ 18.*
Yes
No
patients must have measurable or evaluable
disease.*
Yes
No
women of childbearing potential and male
participants must agree to use an effective
method of contraception.*
Yes
No
patients must sign study specific informed
consent prior to study entry.*
Yes
No
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patients must not have plans for concurrent
chemoradiation therapy.*
Yes
No
patients must complete all required pretreatment
evaluations*
Yes
No
Exclusion Criteria
total (aggregate) gross tumor volume > 500 cm3
(500 cc's or 0.5 liters)*
Yes
No
prior radiotherapy to the region of the study
cancer that would result in direct overlap of
radiation therapy fields.*
Yes
No
chemotherapy given within one week of study
registration.*
Yes
No
pregnant or lactating women, as treatment
involves unforeseeable risks to the embryo or
fetus.*
Yes
No
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Eligibility Non-small Cell Lung Cancer
Stage II NCT01470716
Neoadjuvant Erlotinib for Operable Stage II or IIIA NSCLC
With EGFR Mutations; ODM derived from:
https://clinicaltrials.gov/show/NCT01470716
All rights reserved. Please visit https://medical-data-
models.org/forms/13775
Eligibility Non-small Cell Lung
Cancer Stage II NCT01470716
Inclusion Criteria
pathologically confirmed stage ii & iiia non-small
cell lung cancer*
Yes
No
egfr exon 19 or 21 mutations*
Yes
No
age ≥ 18 years and ecog performance 0~1*
Yes
No
has measurable lesion by recist 1.1*
Yes
No
no previous chemotherapy or radiation therapy*
Yes
No
adequate organ function by following; anc
≥1,500/ul, hemoglobin ≥9.0g/dl, platelet
≥100,000/ul, pao2 ≥ 60 mmhg, serum cr < 1 x unl
or creatinine clearance > 60 ml/min, serum
bilirubin < 1 x unl, ast (sgot) and alt (sgpt) < 2.5 x
unl, alkaline phosphatase < 5 x unl*
Yes
No
written informed consent form*
Yes
No
Exclusion Criteria
previous chemotherapy or radiation therapy*
Yes
No
previous history of malignancy within 5 years
from study entry except treated non-
melanomatous skin cancer or uterine cervical
cancer in situ*
Yes
No
known allergic history of erlotinib*
Yes
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No
interstitial lung disease or fibrosis on chest
radiogram*
Yes
No
active infection, uncontrolled systemic disease
(cardiopulmonary insufficiency, fatal arrhythmias,
hepatitis)*
Yes
No
pregnant or nursing women*
Yes
No
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Eligibility Non-Squamous Non-Small Cell
Lung Cancer NCT01372384
A Study of Tarceva (Erlotinib) in Patients With Locally
Advanced, Metastatic or Recurrent Non-Small Cell Cancer
Who Present Epidermal Growth Factor Receptor Mutations;
ODM derived from:
https://clinicaltrials.gov/show/NCT01372384
All rights reserved. Please visit https://medical-data-
models.org/forms/13776
Eligibility Non-Squamous Non-Small
Cell Lung Cancer NCT01372384
Inclusion Criteria
adult patients, >/= 18 years of age*
Yes
No
locally advanced (stage iiib), metastatic (stage iv)
or recurrent non-small cell lung cancer with
mutations in the tyrosine kinase domain of the
epidermal growth factor receptor (egfr)*
Yes
No
at least one measurable lesion according to recist
criteria*
Yes
No
european cooperative oncology group (ecog)
performance status 0-2*
Yes
No
adequate hematological, liver and renal function*
Yes
No
patients with stable cerebral metastases who
have received surgical or radiotherapy will be
eligible*
Yes
No
Exclusion Criteria
previous chemotherapy or therapy against egfr for
metastatic disease (neoadjuvant or adjuvant
therapy after radical surgery is allowed if finalized
>/= 6 months before entering the study)*
Yes
No
history of another neoplasm except for carcinoma
in situ of the cervix, adequately treated basal cell
skin carcinoma, radically treated prostate
carcinoma with good prognosis (gleason </= 6),
or another curatively treated neoplasm without
evidence of disease in the last 5 years*
Yes
No
symptomatic cerebral metastases*
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Yes
No
any significant ophthalmologic abnormality*
Yes
No
use of coumarins*
Yes
No
pregnant or breast-feeding women*
Yes
No
pre-existing parenchymal lung disease such as
pulmonary fibrosis, lymphangiosis and
carcinomatosis (if this is the only presence of the
disease)*
Yes
No
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Eligibility Osteoarthritis NCT01463566
Gender Solutions Natural Knee Post-Market Study; ODM
derived from: https://clinicaltrials.gov/show/NCT01463566
All rights reserved. Please visit https://medical-data-
models.org/forms/13777
Eligibility Osteoarthritis
NCT01463566
Inclusion Criteria
patient 18-75 years of age, inclusive;*
Yes
No
patient qualifies for a total knee arthroplasty
based on physical exam and medical history
including at least one of the following:
osteoarthritis, inflammatory arthritis, post-
traumatic arthritis, rheumatoid arthritis, or valgus,
varus, or flexion deformities;*
Yes
No
patient has undergone a study related informed
consent process;*
Yes
No
patient is willing and able to provide written
consent;*
Yes
No
patient is willing and able to cooperate in the
required post-operative therapy;*
Yes
No
patient is willing and able to complete scheduled
follow-up evaluations.*
Yes
No
Exclusion Criteria
patient has previous history of infection in the
affected joint and/or a local or systemic infection
that could affect the prosthetic joint;*
Yes
No
insufficient bone stock on femoral or tibial
surfaces;*
Yes
No
skeletal immaturity*
Yes
No
neuropathic arthropathy*
Yes
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No
osteoporosis or any loss of musculature or
neuromuscular disease that compromises the
affected limb;*
Yes
No
stable, painless arthrodesis in a satisfactory
functional position;*
Yes
No
severe instability secondary to the absence of
collateral ligament integrity;*
Yes
No
patient has rheumatoid arthritis and an ulcer of
the skin or a history of recurrent breakdown of
the skin because of their risk of postoperative
infection is greater;*
Yes
No
patient has known sensitivity or allergy to one or
more of the implanted materials;*
Yes
No
patients pregnant or considered a member of a
protected population (e.g., prisoner, mental
incompetence, unable to understand what clinical
trial participation entails, etc.)*
Yes
No
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Eligibility Osteoarthritis, Knee
NCT01280903
Staying Active With Arthritis; ODM derived from:
https://clinicaltrials.gov/show/NCT01280903
All rights reserved. Please visit https://medical-data-
models.org/forms/13778
Eligibility Osteoarthritis, Knee
NCT01280903
Inclusion Criteria
age 50 years or older.*
Yes
No
is community dwelling.*
Yes
No
has osteoarthritis of the knee.*
Yes
No
has hypertension for which monotherapy or
combination pharmacological treatment is
prescribed.*
Yes
No
able to complete a behavioral run-in consisting of
completing questionnaires, using a 7-day
electronic-diary, and wearing an actigraph
accelerometer at the waist for 7 days.*
Yes
No
has written permission to participate from the
physician.*
Yes
No
Exclusion Criteria
reports currently doing lower extremity exercise
=> 2 times/week.*
Yes
No
reports currently fitness walking => 90
minutes/week.*
Yes
No
incapable of managing their own treatment
regimen.*
Yes
No
does not have, or cannot use, a telephone or is
unwilling to provide a telephone number.*
Yes
No
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has received cortisone or synvisc injections in the
knee, angioplasty, stents, or a pacemaker in the
past 6 months.*
Yes
No
reports unstable cardiovascular, pulmonary, or
metabolic disease or signs and symptoms
suggestive of cardiovascular, pulmonary, or
metabolic disease that restrict activity.*
Yes
No
has resting systolic blood pressure => 160 mm
hg or diastolic blood pressure => 100 mm hg.*
Yes
No
reports other conditions, such as osteoarthritis of
the hip, spinal stenosis, inflammatory arthritis,
foot drop, diabetes treated with insulin, or diabetic
complications that may affect performance of
lower extremity exercise and participation in
fitness walking.*
Yes
No
reports current knee conditions, such as
meniscus tears and knee ligament ruptures.*
Yes
No
reports major depression that may impact the
ability to fully participate in this study.*
Yes
No
is scheduled to undergo a major surgical
procedure in the next 13 months.*
Yes
No
is concurrently participating in a drug or
psychoeducational trial that may confound, or be
confounded by, participation in this study.*
Yes
No
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Eligibility Overweight NCT01345500
UCSD Take Charge Study; ODM derived from:
https://clinicaltrials.gov/show/NCT01345500
All rights reserved. Please visit https://medical-data-
models.org/forms/13779
Eligibility Overweight NCT01345500
Inclusion Criteria
aged 18 years or older*
Yes
No
type 2 diabetes*
Yes
No
bmi 25-45 kg/m2*
Yes
No
willing to participate in any of the study diet arms
(higher or lower carbohydrate diet or usual care)
over a one-year period*
Yes
No
able to comply with all required study procedures
and schedule*
Yes
No
must live within the san diego or minneapolis
area*
Yes
No
Exclusion Criteria
pregnant, breastfeeding or planning to become
pregnant in the next year*
Yes
No
serious medical condition or psychiatric illness*
Yes
No
history of having an eating disorder, food allergy
or food intolerance*
Yes
No
have food restrictions or requires a special diet*
Yes
No
objects to frozen, processed or prepackaged
foods*
Yes
No
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inability to be moderately physically active*
Yes
No
currently enrolled in a weight loss program or
another diet intervention*
Yes
No
current use of weight loss medication or
supplements*
Yes
No
planned surgical procedure that can impact the
conduct of the study*
Yes
No
previous surgical procedures for weight
reduction*
Yes
No
does not have own transportation*
Yes
No
have plans to relocate from area within 1 year*
Yes
No
hba1c >11%, fasting triglycerides >600 mg/dl,
serum creatinine >1.4 mg/dl (women) or 1.5
mg/dl (men) -- to be screened at baseline visit*
Yes
No
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Eligibility Parkinson Disease NCT01470027
N-Acetylcysteine for Neuroprotection in Parkinson's
Disease; ODM derived from:
https://clinicaltrials.gov/show/NCT01470027
All rights reserved. Please visit https://medical-data-
models.org/forms/13780
Eligibility Parkinson Disease
NCT01470027
Inclusion Criteria
diagnosis of idiopathic pd according to the united
kingdom parkinson's disease society brain bank
criteria (ukpdsbb) criteria (only for pd group*
Yes
No
age 50 to 75 years*
Yes
No
able to give informed consent for study
participation*
Yes
No
not on any medication for pd (anticholinergic
agents allowed)*
Yes
No
Exclusion Criteria
unable to give informed consent*
Yes
No
unable to undergo a brain mri*
Yes
No
pd duration ≥15 years*
Yes
No
receiving dopamine receptor blocking agents,
including typical neuroleptics, prochlorperazine,
and metoclopramide*
Yes
No
diagnosis of major depression or other axis i
psychopathology*
Yes
No
modified mini-mental status exam (mmse) ≤
24/30*
Yes
No
diagnosis of chronic or persistent illnesses that
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could affect oxidative stress status, such as
diabetes or congestive heart failure*
Yes
No
significant concomitant medical disease limiting
life expectancy to less than 12 months from study
inclusion*
Yes
No
diagnosis of primary mitochondrial disorder,
epilepsy, stroke, multiple sclerosis or other
neurodegenerative diseases such as alzheimer's
disease or als*
Yes
No
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Eligibility Parkinson's Disease (PD)
NCT01398748
Intranasal Glutathione in Parkinson's Disease; ODM
derived from: https://clinicaltrials.gov/show/NCT01398748
All rights reserved. Please visit https://medical-data-
models.org/forms/13781
Eligibility Parkinson's Disease (PD)
NCT01398748
Inclusion Criteria
1. diagnosis of parkinson's disease made by
neurologist within previous 10 years*
Yes
No
2. modified hoehn and yahr stage <3*
Yes
No
3. age >20*
Yes
No
4. subjects must be able to attend study visits at
screening, baseline, weeks 4, 8, 12, 16*
Yes
No
5. subjects must be able to demonstrate self-
administration of study medication or have active
caregiver who can administer daily.*
Yes
No
6. dose and frequency of all pharmaceutical
medications must be stable for one month prior to
enrollment.*
Yes
No
7. diet, exercise and supplementation must be
kept constant throughout participation in study*
Yes
No
8. ability to read and speak english*
Yes
No
Exclusion Criteria
1. dementia as evidenced by montreal cognitive
assessment (moca) <24*
Yes
No
2. diseases with features common to parkinson's
disease (eg. essential tremor, multiple system
atrophy, progressive supranuclear palsy)*
Yes
No
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3. epilepsy*
Yes
No
4. history of stroke, cva*
Yes
No
5. elevated levels of alt, ast, bun or creatinine*
Yes
No
6. chronic sinusitis as defined by snot-20 score
>1.0 on items 1-10.*
Yes
No
7. presence of other serious illness*
Yes
No
8. history of brain surgery*
Yes
No
9. history of structural brain damage*
Yes
No
10. history of intranasal telangiectasia*
Yes
No
11. supplementation with glutathione and agents
shown to increase glutathione will not be
permitted and will require a 90 day washout
period.*
Yes
No
12. pregnant or at risk of becoming pregnant.*
Yes
No
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Eligibility Parkinson's Disease
NCT01428648
Impact of Dance Therapy on Parkinson's Disease; ODM
derived from: https://clinicaltrials.gov/show/NCT01428648
All rights reserved. Please visit https://medical-data-
models.org/forms/13782
Eligibility Parkinson's Disease
NCT01428648
Inclusion Criteria
18 years and older, both males and females, all
races and all ethnicities*
Yes
No
idiopathic parkinson's disease diagnosed using
united kingdom parkinson's disease society brain
bank diagnostic criteria*
Yes
No
mild to moderate disease severity (stage 2 to 3
on the modified hoehn and yahr scale)*
Yes
No
stable medication regimen for a minimum of 1
month before testing*
Yes
No
ability to ambulate independently without using a
walking aid*
Yes
No
ability to give informed consent*
Yes
No
Exclusion Criteria
prior enrollment in a dancing class during the last
6 months*
Yes
No
presence of another neurological or medical
disorder likely to affect gait or causing frequent
falls (rheumatologic/orthopedic disease, stroke,
myelopathy, severe neuropathy)*
Yes
No
significant cognitive decline (mmse ≤ 24)*
Yes
No
visual deficit*
Yes
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No
hearing deficit that impairs music perception*
Yes
No
psychotic symptoms*
Yes
No
symptomatic heart disease*
Yes
No
depression associated with suicidal ideation*
Yes
No
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Eligibility Paroxysmal Atrial Fibrillation
(PAF) NCT01456949
Sustained Treatment of Paroxysmal Atrial Fibrillation Post-
Approval Study (STOP AF PAS); ODM derived from:
https://clinicaltrials.gov/show/NCT01456949
All rights reserved. Please visit https://medical-data-
models.org/forms/13783
Eligibility Paroxysmal Atrial
Fibrillation (PAF) NCT01456949
Inclusion Criteria
1. documented paf:*
Yes
No
diagnosis of paroxysmal atrial fibrillation (paf),
and*
Yes
No
2 or more episodes of af during the 3 months
preceding the consent date, and*
Yes
No
at least 1 episode of af documented with a
tracing within 12 months preceding the consent
date.*
Yes
No
2. age 18 years or older*
Yes
No
3. failure for the treatment of af (effectiveness or
intolerance) of at least one membrane active aad
for rhythm control.*
Yes
No
Exclusion Criteria
1. any previous left atrial (la) ablation (except
permissible retreatment subjects)*
Yes
No
2. any previous la surgery*
Yes
No
3. current intracardiac thrombus (can be treated
after thrombus is resolved)*
Yes
No
4. presence of any pulmonary vein stents*
Yes
No
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5. presence of any pre-existing pulmonary vein
stenosis*
Yes
No
6. pre-existing hemidiaphragmatic paralysis*
Yes
No
7. anteroposterior la diameter > 5.5 cm by tte*
Yes
No
8. presence of any cardiac valve prosthesis*
Yes
No
9. clinically significant mitral valve regurgitation or
stenosis*
Yes
No
10. myocardial infarction, pci / ptca or coronary
artery stenting which occurred during the 3
month interval preceding the consent date*
Yes
No
11. unstable angina*
Yes
No
12. any cardiac surgery which occurred during
the 3 month interval preceding the consent date*
Yes
No
13. any significant congenital heart defect
corrected or not (including atrial septal defects or
pulmonary vein abnormalities but not including
minor pfo)*
Yes
No
14. nyha class iii or iv congestive heart failure*
Yes
No
15. left ventricular ejection fraction (lvef) < 40%*
Yes
No
16. 2º (type ii) or 3º atrioventricular block*
Yes
No
17. presence of a permanent pacemaker,
biventricular pacemaker, atrial defibrillator or any
type of implantable cardiac defibrillator (with or
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without biventricular pacing function)*
Yes
No
18. brugada syndrome*
Yes
No
19. long qt syndrome*
Yes
No
20. arrhythmogenic right ventricular dysplasia*
Yes
No
21. sarcoidosis*
Yes
No
22. hypertrophic cardiomyopathy*
Yes
No
23. known cryoglobulinemia*
Yes
No
24. uncontrolled hyperthyroidism*
Yes
No
25. any cerebral ischemic event (strokes or tias)
which occurred during the 6 month interval
preceding the consent date.*
Yes
No
26. any woman known to be pregnant*
Yes
No
27. life expectancy less than one (1) year*
Yes
No
28. current or anticipated participation in any
other clinical trial of a drug, device or biologic
during the duration of this study not pre-approved
by medtronic*
Yes
No
29. unwilling or unable to comply fully with study
procedures and followup*
Yes
No
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Eligibility Perimenopausal Depression
NCT01368068
Investigation of Tibolone and Escitalopram in
Perimenopausal Depression; ODM derived from:
https://clinicaltrials.gov/show/NCT01368068
All rights reserved. Please visit https://medical-data-
models.org/forms/13784
Eligibility Perimenopausal
Depression NCT01368068
Inclusion Criteria
females who are currently physically well and
between 45 and 55 years of age*
Yes
No
current dsm-iv diagnosis of depression disorder*
Yes
No
able to give informed consent*
Yes
No
perimenopausal as determined by symptom
profile on the stages of reproductive aging
workshop and gonadal hormonal profile*
Yes
No
Exclusion Criteria
known abnormalities in the hypothalamic-pituitary
gonadal axis, thyroid dysfunction, central nervous
system tumours, active or past history of a
venous thromboembolic event, breast pathology,
undiagnosed vaginal bleeding or abnormal pap
smear results in the previous 2 years.*
Yes
No
patients with any significant unstable medical
illness such as epilepsy and diabetes or known
active cardiac, renal or liver disease; or the
presence of illness causing immobilisation.*
Yes
No
patients receiving treatment for depression
including antidepressant medications,
electroconvulsive therapy (ect) / transcranial
magnetic stimulation (tms), formal psychotherapy
or counselling, within the past 6 months*
Yes
No
patients experiencing severe melancholia,
neurovegetative symptoms or current suicidality
necessitating acute hospitalisation or intensive
psychiatric treatment.*
Yes
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No
patients with psychotic symptoms or past history
of severe mental illness including schizophrenia,
and bipolar disorder.*
Yes
No
use of any form of estrogen, progestin or
androgen as hormonal therapy, or antiandrogen
including tibolone or use of phytoestrogen
supplements as powder or tablet*
Yes
No
pregnancy / lactation*
Yes
No
smoking cigarettes and other nicotine products.*
Yes
No
illicit drug use and more than 3 standard drinks
per day*
Yes
No
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Eligibility Pre-diabetes NCT01364675
Primary Prevention of Cardiovascular Disease (CVD) in
Pre-diabetic & Pre-hypertensive Subjects; ODM derived
from: https://clinicaltrials.gov/show/NCT01364675
All rights reserved. Please visit https://medical-data-
models.org/forms/13785
Eligibility Pre-diabetes
NCT01364675
Inclusion Criteria
pre-diabetes*
Yes
No
pre-hypertensives*
Yes
No
ldl-cholesterol >= 100 < 190 mg/dl*
Yes
No
bmi >= 23*
Yes
No
estimated gfr >= 60 ml/min/1.73 m2 (mdrd
equation)*
Yes
No
willing to participate and provide written inform
consent*
Yes
No
Exclusion Criteria
current involved in other studied medications*
Yes
No
regular use of corticosteroids*
Yes
No
current use of weight loss medication*
Yes
No
history of renal disease*
Yes
No
active liver disease including jaundice, chronic
hepatitis with alt >= 2.5 the upper normal limit*
Yes
No
active malignancy*
Yes
1 / 2
No
major psychiatric disorder*
Yes
No
diseases and medications that affect glucose
tolerance (e.g. pheochromocytoma, cushing's
syndrome, acromegaly, steroid-dependent
asthma, protease inhibitors, antipsychotics)*
Yes
No
nursing women, pregnant women, or those that
plan to become pregnant in the study period*
Yes
No
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Follow up EBMT CML
ODM derived from HSCT forms on http://www.ebmt.org/
All rights reserved. Please visit https://medical-data-
models.org/forms/13786
Follow up EBMT CML
Follow Up
Unique Identification Code (UIC)
(if known)
Date of this report
Patient following national/ international study/ trial
No (No)
Unknown (Unknown)
Yes (Yes)
If yes, specify Name of study/ trial
Hospital Unique Patient Number
First name(s)_surname(s)
Date of birth
Date of last HSCT for this patient
Patient last seen
Date of last contact or death
Acute Graft versus Host Disease (aGvHD)
since last report
Acute Graft versus Host Disease
Maximum grade
grade 0 (Absent) (grade 0 (Absent))
grade I (grade I)
grade II (grade II)
grade III (grade III)
grade IV (grade IV)
Not evaluated (Not evaluated)
If present, specify:
New onset (New onset)
Persistent (Persistent)
Recurrent (Recurrent)
Reason for aGvHD
DLI (DLI)
Tapering (Tapering)
Unexplained (Unexplained)
Date of onset of this episode 
(if new or recurrent)
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(if applicable)
aGvHD:
Stage skin
Evaluated (Evaluated)
Not evaluated (Not evaluated)
Unknown (Unknown)
aGvHD:
Stage skin
If evaluatd, specify:
1 (1)
2 (2)
3 (3)
4 (4)
aGvHD
Stage liver
Evaluated (Evaluated)
Not evaluated (Not evaluated)
Unknown (Unknown)
aGvHD
Stage liver
If evaluated, specify:
1 (1)
2 (2)
3 (3)
4 (4)
aGvHD
Stage gut
Evaluated (Evaluated)
Not evaluated (Not evaluated)
Unknown (Unknown)
aGvHD
Stage gut
If evaluated, specify:
1 (1)
2 (2)
3 (3)
4 (4)
aGvHD
Resolution
Yes
No
If yes, specify the date of resolution
Chronic Graft versus Host Disease
(cGvHD) since last report
Presence of cGvHD
No (No)
Present continously since last reported
episode (Present continously since last
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reported episode)
Resolved (Resolved)
Yes (Yes)
If yes, specify:
First episode (First episode)
Recurrence (Recurrence)
If yes, specify Date of onset:
If present continously since last report, specify
cGvHD gade:
Extensive (Extensive)
Limited (Limited)
If present continously since last reported episode,
speicfy affected organs:
Eyes (Eyes)
Gut (Gut)
Liver (Liver)
Lung (Lung)
Mouth (Mouth)
Other (Other)
Skin  (Skin )
Unknown (Unknown)
If present continously since last reported episode,
speicfy affected organs:
If other, specify:
If resolved, specify the date of resolution:
Other Complications since last report
(please use the document "Definitions of
infectious diseases and complications
after stem cell transplantation" to fill these
items.)
Infection related complications
Yes
No
If yes, specify the type (bacteriaemia/ fungemia/
viremia/ parasites)
(General)
Adenovirus (Adenovirus)
Aspergillus sp (Aspergillus sp)
Bacteria: (Bacteria:)
Candida sp (Candida sp)
CMV (CMV)
EBV (EBV)
Fungi: (Fungi:)
Haemophilus influenza (Haemophilus
influenza)
HBV (HBV)
HCV (HCV)
HHV-6 (HHV-6)
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HIV (HIV)
HSV (HSV)
Legionella sp (Legionella sp)
Mycobacteria sp (Mycobacteria sp)
Other (Other)
Other (Other)
Other (Other)
Other (Other)
Other gram negative (i.e. E.coli,
klebsiella, proteus, serratia,
pseudomonas,...) (Other gram negative
(i.e. E.coli, klebsiella, proteus, serratia,
pseudomonas,...))
Other gram positive (i.e. other
streptococci, staphylococci, listeria,...)
(Other gram positive (i.e. other
streptococci, staphylococci, listeria,...))
Other respiratory virus (influenza,
parainfluezna, rhinovirus) (Other
respiratory virus (influenza,
parainfluezna, rhinovirus))
Papovirus (Papovirus)
Parasites: (Parasites:)
Parovirus (Parovirus)
Pneumocystis carinii (Pneumocystis
carinii)
RSV (RSV)
S. pneumoniae (S. pneumoniae)
Toxoplasma gondii (Toxoplasma gondii)
Viruses: (Viruses:)
VZV (VZV)
If other, specify (general):
Specify the date of the episode (General)
Systemic Symptoms of Infections
ARDS (ARDS)
Multiorgan failure due to infection
(Multiorgan failure due to infection)
Septic shock (Septic shock)
Systemic Symptoms of Infections: specify the
type (bacteriaemia/ fungemia/ viremia/ parasites)
Adenovirus (Adenovirus)
Aspergillus sp (Aspergillus sp)
Bacteria: (Bacteria:)
Candida sp (Candida sp)
CMV (CMV)
EBV (EBV)
Fungi: (Fungi:)
Haemophilus influenza (Haemophilus
influenza)
HBV (HBV)
HCV (HCV)
HHV-6 (HHV-6)
HIV (HIV)
HSV (HSV)
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Legionella sp (Legionella sp)
Mycobacteria sp (Mycobacteria sp)
Other (Other)
Other (Other)
Other (Other)
Other (Other)
Other gram negative (i.e. E.coli,
klebsiella, proteus, serratia,
pseudomonas,...) (Other gram negative
(i.e. E.coli, klebsiella, proteus, serratia,
pseudomonas,...))
Other gram positive (i.e. other
streptococci, staphylococci, listeria,...)
(Other gram positive (i.e. other
streptococci, staphylococci, listeria,...))
Other respiratory virus (influenza,
parainfluezna, rhinovirus) (Other
respiratory virus (influenza,
parainfluezna, rhinovirus))
Papovirus (Papovirus)
Parasites: (Parasites:)
Parovirus (Parovirus)
Pneumocystis carinii (Pneumocystis
carinii)
RSV (RSV)
S. pneumoniae (S. pneumoniae)
Toxoplasma gondii (Toxoplasma gondii)
Viruses: (Viruses:)
VZV (VZV)
Systemic symptoms of infection: if other, specify:
Systemic symptoms of infection: Specify the date
of the episode
Endorgan diseases
CNS infection (CNS infection)
Cystitis (Cystitis)
Gut infection (Gut infection)
Hepatits (Hepatits)
Other (Other)
Pneumonia (Pneumonia)
Retinitis (Retinitis)
Skin infection (Skin infection)
Endorgan disease: specify the type
(bacteriaemia/ fungemia/ viremia/ parasites)
Adenovirus (Adenovirus)
Aspergillus sp (Aspergillus sp)
Bacteria: (Bacteria:)
Candida sp (Candida sp)
CMV (CMV)
EBV (EBV)
Fungi: (Fungi:)
Haemophilus influenza (Haemophilus
influenza)
HBV (HBV)
HCV (HCV)
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HHV-6 (HHV-6)
HIV (HIV)
HSV (HSV)
Legionella sp (Legionella sp)
Mycobacteria sp (Mycobacteria sp)
Other (Other)
Other (Other)
Other (Other)
Other (Other)
Other gram negative (i.e. E.coli,
klebsiella, proteus, serratia,
pseudomonas,...) (Other gram negative
(i.e. E.coli, klebsiella, proteus, serratia,
pseudomonas,...))
Other gram positive (i.e. other
streptococci, staphylococci, listeria,...)
(Other gram positive (i.e. other
streptococci, staphylococci, listeria,...))
Other respiratory virus (influenza,
parainfluezna, rhinovirus) (Other
respiratory virus (influenza,
parainfluezna, rhinovirus))
Papovirus (Papovirus)
Parasites: (Parasites:)
Parovirus (Parovirus)
Pneumocystis carinii (Pneumocystis
carinii)
RSV (RSV)
S. pneumoniae (S. pneumoniae)
Toxoplasma gondii (Toxoplasma gondii)
Viruses: (Viruses:)
VZV (VZV)
Endorgan diseases: If other, specify:
Endorgan diseases: Specify the date of the
episode
Non infection related complications
Yes
No
Specify: Idiopathic pneumonia syndrome
No  (No )
Unknown (Unknown)
Yes (Yes)
If yes, specify: 
Idiopathic pneumonia syndrome
Date of onset
Specify: 
VOD
No  (No )
Unknown (Unknown)
Yes (Yes)
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If yes, specify: 
VOD
Date of onset
Specify:
Cataract
No (No)
Unknown (Unknown)
Yes (Yes)
If yes, specify:
Cataract
Date of onset
Specify:
Haemorrhagic cystitis, non infectious
No  (No )
Unknown (Unknown)
Yes  (Yes )
If yes, specify:
Haemorrhagic cystitis, non infectious
Date of onset
Specify:
ARDS, non infectious
No (No)
Unknown (Unknown)
Yes (Yes)
If yes, specify:
ARDS, non infectious
Date of onset
Specify:
Multiorgan-failre, non infectious
No  (No )
Unknown (Unknown)
Yes (Yes)
If yes, specify: 
Multiorgan-failre, non infectious
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Date of onset
Specify:
HSCT-associated microangiopathy
No (No)
Unknown (Unknown)
Yes (Yes)
If yes, specify:
HSCT-associated microangiopathy
Date of onset
Specify:
Renal failure requiring dialysis
No (No)
Unknown (Unknown)
Yes (Yes)
If yes, specify:
Renal failure requiring dialysis
Date of onset
Specify:
Haemolytic anaemia due to blood group
No (No)
Unknown (Unknown)
Yes (Yes)
If yes, specify:
Haemolytic anaemia due to blood group
Date of onset
Specify:
Aseptic bone necrosis
No (No)
Unknown (Unknown)
Yes (Yes)
If yes, specify:
Aseptic bone necrosis
Date of onset
If other, specify:
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If other:
Date of onset
Graft Assessment and Haemopoietic
chimaerism
Graft loss
No (No)
Not evaluated (Not evaluated)
Yes (Yes)
Overall chimaerism
Aplasia (Aplasia)
95%) (Autologuos reconstitution
(recipient >)
95%) (Full (donor >)
Mixed (partial) (Mixed (partial))
Not evaluated (Not evaluated)
Indicate the date(s) and results of all tests
done for all donors. Split the results by
donor and by the cell type on which the
test was performed if applicable. Copy this
table as many times as nec...
Date of test
Identification of donor or Cord Blood Unit given
by the centre
Number in the infusion order (if applicable)
Cell type on which test was performed (% Donor
Cells):
BM
%
Cell type on which test was performed (% Donor
cells):
PB mononuclear cells (PBMC)
%
Cell type on which test was performed (% Donor
cells):
T-Cells
%
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Cell type on which test was performed (% Donor
cells):
B-Cells
%
Cell type on which test was performed (% Donor
cells):
Red blood cells
%
Cell type on which test was performed (% Donor
cells):
Monocytes
%
Cell type on which test was performed (% Donor
cells):
PMNs (neutrophils)
%
Cell type on which test was performed (% Donor
cells):
Lymphocytes, NOS
%
Cell type on which test was performed (% Donor
cells):
Myeloid cells, NOS
%
Cell type on which test was performed:
Other, specify:
Cell type on which test was performed (% Donor
cells):
Other
%
Test used:
ABO group (ABO group)
Cytogenetic (Cytogenetic)
FISH (FISH)
Molecular (Molecular)
Other (Other)
unknown (unknown)
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Test used:
If other, specify:
Other complications since last report -
secondary malignancy, lymphoproliferative
or myeloproliferative disorder diagnosed
Secondary Malignancy, Lymphoproliferative or
Myeloproliferative disorder diagnosed
No at date of this follow up (No at date of
this follow up)
Previously reported (Previously reported)
Yes (Yes)
If yes, specify date of diagnosis
If yes, specify the diagnosis
AML (AML)
Lymphoproliferative disorder
(Lymphoproliferative disorder)
MDS (MDS)
Other (Other)
If other, specify:
Additional therapies since last follow up
Treatment given since last report
No (No)
Unknown (Unknown)
Yes (Yes)
If yes, specify the start date
One cell therapy regimen is defined as
any number of insufiosn given within 10
weeks for the same indication. If more
than one regimen of cell therapy has been
given since last report, copy this sec...
If additional treatment is given, specify for cellular
therapy:
No  (No)
Unknown (Unknown)
Yes  (Yes)
If yes, specify the disease status before this
cellular therapy
CR (CR)
Not evaluated (Not evaluated)
Not in CR (Not in CR)
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If yes, specify the cell type
Donor lymphocyte infusion (DLI) (Donor
lymphocyte infusion (DLI))
Mesenchymal cells (Mesenchymal cells)
Other (Other)
Unknown (Unknown)
If yes, specify the cell type:
If cell type other, specify:
If DLI, specify the number of cells infused by
type:
Nucleated cells
Evaluated (Evaluated)
Not evaluated (Not evaluated)
unknown (unknown)
If DLI, specify the number of cells infused by
type:
Nucleated cells (10^8/kg)
10^8/kg
If DLI, specify the number of cells infused by
type:
CD 34+
Evaluated (Evaluated)
Not Evaluated (Not Evaluated)
Unknown (Unknown)
Number of infused CD34+ cells
If DLI, specify the number of cells infused by
type: 
CD 3+
Evaluated  (Evaluated )
Not evaluated (Not evaluated)
Unknown (Unknown)
Number of infused CD3+ cells
If non DLI, specify total number of cells infused:
Evaluated (Evaluated)
Not Evaluated (Not Evaluated)
Unknown (Unknown)
If non DLI, specify the total number of cells
infused (10^6/kg)
(10^6/kg)
Chronological number of this cell therapy for this
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patient
Indication 
(check all that apply)
Loss/decreased chimaerism
(Loss/decreased chimaerism)
Mixed chimaerism (Mixed chimaerism)
Other (Other)
Planned/ protocol (Planned/ protocol)
Prophylactic (Prophylactic)
Treatment for disease (Treatment for
disease)
Treatment of GvHD (Treatment of GvHD)
Treatment PTLD, EBV, lymphoma
(Treatment PTLD, EBV, lymphoma)
Treatment viral infection (Treatment viral
infection)
Indication:
If other, specify:
Number of Infusions (within 10 weeks)
(count only infusions that are part of same
regimen and given for the same indication)
Acute Graft versus Host Disease 
(after this infusion but before any further infusion/
transplant)
Maximum grade:
grade 0 (absent) (grade 0 (absent))
grade 1 (grade 1)
grade 2 (grade 2)
grade 3 (grade 3)
grade 4 (grade 4)
present, grade unknown (present, grade
unknown)
Apart from donor cell infusion or other
type of cell therapy
Disease treatment
No (No)
Unknown (Unknown)
Yes (Yes)
If yes, specify:
Not planned (for relapse/ progression or
persistent disease) (Not planned (for
relapse/ progression or persistent
disease))
Planned (planned before HSCT took
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place) (Planned (planned before HSCT
took place))
Imatinib
(Please report every treatment given - please
replicate these items as often as necessary in
order to provide the history of all assessments
since last report)
No (No)
Ongoing (Ongoing)
Yes (Yes)
Imatinib:
If yes, specify duration:
(Please report every treatment given - please
replicate these items as often as necessary in
order to provide the history of all assessments
since last report)
Dasatinib
(Please report every treatment given - please
replicate these items as often as necessary in
order to provide the history of all assessments
since last report)
No (No)
Ongoing (Ongoing)
Yes (Yes)
Dasatinib,
If yes, specify duration:
(Please report every treatment given - please
replicate these items as often as necessary in
order to provide the history of all assessments
since last report)
Nilotinib
(Please report every treatment given - please
replicate these items as often as necessary in
order to provide the history of all assessments
since last report)
No (No)
Ongoing (Ongoing)
Yes (Yes)
Nilotinib
If yes, specify duration:
(Please report every treatment given - please
replicate these items as often as necessary in
order to provide the history of all assessments
since last report)
Interferon alpha
(Please report every treatment given - please
replicate these items as often as necessary in
order to provide the history of all assessments
since last report)
No (No)
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Ongoing (Ongoing)
Yes (Yes)
Interferon alpha
If yes, specify duration:
(Please report every treatment given - please
replicate these items as often as necessary in
order to provide the history of all assessments
since last report)
Other chemo/ drug
(Please report every treatment given - please
replicate these items as often as necessary in
order to provide the history of all assessments
since last report)
Other chemo/ drug
If yes, specify duration:
(Please report every treatment given - please
replicate these items as often as necessary in
order to provide the history of all assessments
since last report)
Immunosuppressive therapy
(Please report every treatment given - please
replicate these items as often as necessary in
order to provide the history of all assessments
since last report)
No (therapy stopped) (No (therapy
stopped))
Unknown (Unknown)
Yes (with tapering) (Yes (with tapering))
Yes, tapering off (Yes, tapering off)
Other treatment
(Please report every treatment given - please
replicate these items as often as necessary in
order to provide the history of all assessments
since last report)
No (No)
Unknown (Unknown)
Yes (Yes)
Other treatment
If yes, specify:
(Please report every treatment given - please
replicate these items as often as necessary in
order to provide the history of all assessments
since last report)
First evidence of relapse or progression
since last HSCT
Relapse or Progression
Continous progression since transplant
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(Continous progression since transplant)
No (No)
Previously reported (Previously reported)
Unknown (Unknown)
Yes (Yes)
If yes, specify date of diagnosis
First evidence of relapse or progression
since last HSCT - Clinical/ haematological
relapse or progression
Clinical/ haematological relapse or progression
No (No)
Not evaluated (Not evaluated)
Yes (Yes)
If No, specify Date of assessment:
If Yes, specify date first seen:
If Yes, specify affected site:
blood (blood)
extramedullary (extramedullary)
marrow (marrow)
If Haematological relapse yes, specify:
Accelerated phase (Accelerated phase)
Blast crisis (Blast crisis)
Chronic phase (Chronic phase)
First evidence of relapse or progression
since last HSCT - Cytogenetic relapse or
progression
Cytogenetic relapse or progression
No (No)
Not evaluated (Not evaluated)
Yes (Yes)
If No, specify Date of assessment:
If Yes, specify date first seen:
If Yes, specify affected site:
blood  (blood)
extramedullary (extramedullary)
marrow  (marrow)
First evidence of relapse or progression
since last HSCT - Molecular relapse or
progression
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Molecular relapse or progression
No (No)
Not evaluated (Not evaluated)
Yes (Yes)
If No, specify Date of assessment:
If Yes, specify date first seen:
If Yes, specify affected site:
blood  (blood)
extramedullary (extramedullary)
marrow  (marrow)
Last Disease status - Clinical/
haematological
Clinical/ haematological disease stage:
(record the ost recent status and date for each
method)
No (No)
Not evaluated (Not evaluated)
Yes (Yes)
If Yes, specify last date of evaluation:
If Disease detected by Clinical/ Haematological
Method "yes", specify:
Accelerated phase (Accelerated phase)
Blast crisis (Blast crisis)
Chronic phase (Chronic phase)
Last Disease status - Cytogenetic/ FISH
Cytogenetic/ FISH
No (No)
Not evaluated (Not evaluated)
Yes (Yes)
If Yes, considered disease relapse/ progression
Yes
No
If Yes, specify t(p;22) + metaphases (%)
%
If Yes, specify t(9;22) + cells by FISH (%)
%
If Yes, specify last date of evaluation:
Last Disease status - Molecular
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Molecular
No (No)
Not Evaluated (Not Evaluated)
Yes (Yes)
If Yes, considered disease relapse/ progression
Yes
No
If Yes, specify last date of evaluation:
Last Disease status - Conception
Has patient or partner become  pregnant after
this HSCT?
No (No)
Unknown (Unknown)
Yes (Yes)
Last Disease status - Survival status
Survival status
Alive (Alive)
Dead (Dead)
If alive: Type of score used:
Karnofsky (Karnofsky)
Lansky (Lansky)
Not evaluated (Not evaluated)
Unknown (Unknown)
If alive and performance score evaluated, specify:
10 (Moribund) (10 (Moribund))
100 (Normal, NED) (100 (Normal, NED))
20 (Very sick) (20 (Very sick))
30 (Severely disabled) (30 (Severely
disabled))
40 (Disabled) (40 (Disabled))
50 (Requires assistance) (50 (Requires
assistance))
60 (Requires occasional assistance) (60
(Requires occasional assistance))
70 (Cares for self) (70 (Cares for self))
80 (Normal with effort) (80 (Normal with
effort))
90 (Normal activity) (90 (Normal activity))
Last Disease status - Cause of death (if
dead)
If dead, specify cause of death:
HSCT related cause  (HSCT related
cause )
Other (Other)
Relapse or progression (Relapse or
progression)
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Secondary malignancy (including
lymphoproliferative disease) (Secondary
malignancy (including lymphoproliferative
disease))
Unknown  (Unknown )
If dead and HSCT related cause of death, specify
(check as many as apppropriate):
GvHD
No  (No )
Unknown (Unknown)
Yes (Yes)
If dead and HSCT related cause of death, specify
(check as many as apppropriate):
Interstitial Pneumonitis
No  (No )
Unknown (Unknown)
Yes (Yes)
If dead and HSCT related cause of death, specify
(check as many as apppropriate): 
Pulmonary toxicity
No  (No )
Unknown (Unknown)
Yes (Yes)
If dead and HSCT related cause of death, specify
(check as many as apppropriate): 
Infection
No  (No )
Unknown (Unknown)
Yes (Yes)
If dead and HSCT related cause of death, specify
(check as many as apppropriate): 
If Infection, specify:
Bacterial (Bacterial)
Fungal (Fungal)
Parasitic (Parasitic)
Unknown (Unknown)
Viral (Viral)
If dead and HSCT related cause of death, specify
(check as many as apppropriate): 
Rejection/ Poor graft function
No  (No )
Unknown (Unknown)
Yes (Yes)
If dead and HSCT related cause of death, specify
(check as many as apppropriate): 
Veno-Occlusive disease (VOD)
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No  (No )
Unknown (Unknown)
Yes (Yes)
If dead and HSCT related cause of death, specify
(check as many as apppropriate): 
Haemorrhage
No  (No )
Unknown (Unknown)
Yes (Yes)
If dead and HSCT related cause of death, specify
(check as many as apppropriate): 
Cardiac toxicity
No  (No )
Unknown (Unknown)
Yes (Yes)
If dead and HSCT related cause of death, specify
(check as many as apppropriate): 
Central nervous system toxicity
No  (No )
Unknown (Unknown)
Yes (Yes)
If dead and HSCT related cause of death, specify
(check as many as apppropriate): 
Gastro intestinal toxicity
No  (No )
Unknown (Unknown)
Yes (Yes)
If dead and HSCT related cause of death, specify
(check as many as apppropriate): 
Skin toxicity
No  (No )
Unknown (Unknown)
Yes (Yes)
If dead and HSCT related cause of death, specify
(check as many as apppropriate): 
Renal failure
No  (No )
Unknown (Unknown)
Yes (Yes)
If dead and HSCT related cause of death, specify
(check as many as apppropriate): 
Multiple organ failure
No  (No )
Unknown (Unknown)
Yes (Yes)
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If dead and HSCT related cause of death, specify
(check as many as apppropriate): 
Other
No  (No )
Unknown (Unknown)
Yes (Yes)
If dead and HSCT related cause of death, specify
(check as many as apppropriate): 
If other, specify:
If other, specify:
Additional notes if applicable
Comments:
Identification and Signature
Identification
Signature
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Eligibility Prostate Cancer NCT01262664
Prohibitin Targeting Peptide 1 (Fat Zapper); ODM derived
from: https://clinicaltrials.gov/show/NCT01262664
All rights reserved. Please visit https://medical-data-
models.org/forms/13787
Eligibility Prostate Cancer
NCT01262664
Inclusion Criteria
1. have histologically confirmed carcinoma of the
prostate that is metastatic or otherwise incurable,
and a bmi defined as obese (i.e. >30 kg/m2). any
histologic variant is acceptable other than small
cell carcinoma.*
Yes
No
2. have been on androgen deprivation therapy for
a minimum of 6 months, and continue that
therapy or an equivalent therapy to suppress
testosterone during this trial.*
Yes
No
3. patients with castrate resistant prostate cancer
(crpc) must have no standard options for therapy.
prior to registration on the study, patients with
crpc must be at least 3 weeks from their last
treatment, such as ketoconazole, abiraterone,
low-dose dexamethasone, anti-androgens, or
cytotoxic therapy, (excluding ongoing therapy to
suppress testosterone, which must also be
continued during this trial).*
Yes
No
4. have an ecog performance status 0, 1 or 2*
Yes
No
5. have adequate bone marrow function defined
as an absolute peripheral granulocyte count of
>/= 1,000/mm^3 and platelet count of >/=
100,000/mm^3; hemoglobin >/= 8.0 g/dl (without
transfusion or growth factor support)*
Yes
No
6. have adequate hepatic function defined as a
total bilirubin of </= 1.5 mg/dl and ast </= 2x the
upper limits of normal*
Yes
No
7. have adequate renal function defined as serum
creatinine </= 1.5x the upper limit of normal or
creatinine clearance >/= 60 ml/min (measured or
calculated). in addition, patients must have a 24
hr urine collection showing less than 2000 mg of
protein. exception: patients with hematuria will be
eligible with up to 3000 mg protein per 24 hours
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provided they do not have casts, eosinophiluria or
electrolyte wasting.*
Yes
No
8. have adequate cardiovascular function as
defined by: i) a normal b-type natruetic peptide
(bnp) with ii) no signs or symptoms suggestive of
cardiac disease and iii) a normal ecg. if these
criteria are not met, patients must have an
echocardiogram or multigated cardiac scan
(muga) showing an ef of 45% or greater with no
more than "mild" diastolic dysfunction and a bnp
of < 200 pg/ml to be eligible.*
Yes
No
9. sign the current irb approved informed consent
indicating that they are aware of the
investigational nature of this study, in keeping
with the policies of the institution*
Yes
No
Exclusion Criteria
1. small cell prostate cancer*
Yes
No
2. infectious process, which, in the opinion of the
investigator, could worsen or its outcome be
affected, as a result of the investigational
therapy*
Yes
No
3. any of the following in previous 6 months: nyha
class iii/iv congestive heart failure, unstable
angina, cerebrovascular accident (including
transient ischemic attack), pulmonary embolism
or myocardial infarction (by ecg or serologic
criteria)*
Yes
No
4. significant co-morbidity that could affect the
safety or evaluability of participants, specifically
including: i) chronically uncontrolled
hypertension, defined conventionally as
consistent systolic pressures above 140 or
diastolic pressures above 90 despite therapy.
note that this may be better established with
home bp readings than with clinic visit results.
note further that this is not a criterion related to
particular bp results at the time of assessment for
eligibility, nor does it apply to acute bp excursions
that are related to iatrogenic causes, acute pain
or other transient, reversible causes. the intent is
to exclude patients that may have unrecognized
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renal damage from chronic, uncontrolled
hypertension, not to exclude patients who may be
hypertensive acutely. there are no absolute
criteria for bp readings with respect to eligibility
(as determined by treating physician).*
Yes
No
5. ( # 9 cont'd) (ii) uncontrolled diabetes mellitus,
defined as: hgb a1c >8.5%; or symptomatic
hypoglycemic episodes > 1 per week during the
two months prior to eligibility evaluation; or more
than 1 glucose excursion to >300 mg/dl in prior
two months--unless clearly iatrogenic and the
cause has been eliminated iii) lung disease
requiring supplemental oxygen iv) known chronic
liver disease causing either fibrosis or synthetic
dysfunction v) known hiv infection vi) overt
psychosis, mental disability or being otherwise
incompetent to grant informed consent or a
history of non-compliance with medical care.*
Yes
No
6. hydronephrosis (either bilateral or involving a
solitary kidney) that has not been addressed by
means of a nephrostomy or indwelling stent.
exception: non-obstructive hydronephrosis in
setting of prior urinary diversion is consistent with
eligibility.*
Yes
No
7. patients require ongoing therapy with non-
steroidal anti-inflammatory drugs (nsaids), i.v.
vancomycin, aminoglycosides, or other potently
nephrotoxic drugs, and must agree to abstain
from nsaids from the time the consent is signed
up until 30 days after the last dose of study drug
is received, other than low-dose aspirin (81
mg/day or less).*
Yes
No
8. any other medical condition that in the opinion
of the principal investigator would compromise
the ability to deliver or evaluate study drug.*
Yes
No
9. unwillingness to maintain adequate
contraception measures for the entire course of
the study*
Yes
No
10. age < 18 years.*
Yes
No
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Eligibility Individuals at Risk for Depression
NCT01080105
Internet Intervention for the Prevention of Depression -
Approaches to Improving Mood; ODM derived from:
https://clinicaltrials.gov/show/NCT01080105
All rights reserved. Please visit https://medical-data-
models.org/forms/13788
Eligibility Individuals at Risk for
Depression NCT01080105
Inclusion Criteria
predictd risk score of .130*
Yes
No
has a telephone, e-mail account, computer, and
broadband access to the     internet.*
Yes
No
is able to speak and read english.*
Yes
No
is at least 19 years of age.*
Yes
No
is able to give informed consent.*
Yes
No
Exclusion Criteria
has dsm-iv diagnosis of major depressive
episode assessed using the mini*
Yes
No
has hearing or voice impairment that would
prevent participation in psychotherapy.*
Yes
No
has visual impairment that would prevent use of
the workbook and completion of assessment
materials.*
Yes
No
meets criteria for dementia by scoring < 25 on the
telephone interview for cognitive status (tics).*
Yes
No
is diagnosed with a psychotic disorder, bipolar
disorder, dissociative disorder, current post-
traumatic stress disorder (ptsd), current
substance abuse, or other diagnosis for which
participation in a clinical trial of psychotherapy
may be either inappropriate or dangerous.
patients with substance abuse diagnoses who
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have been clean and sober for 3 months will be
admitted if otherwise eligible.*
Yes
No
is currently receiving individual psychotherapy or
planning to receive psychotherapy during the 12-
week treatment phase of the study.*
Yes
No
is planning to be out of town or unavailable for
treatment for 4 weeks or more during the
scheduled treatment time.*
Yes
No
exhibits severe suicidality, including ideation,
plan, and intent.*
Yes
No
has initiated treatment with an antidepressant in
past 10 days.  once patients have been on a
stable dose for 10 days and do not have an
appointment with a physician or psychiatrist to
change this dose, the patient will be eligible
based on this criterion.*
Yes
No
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Eligibility Ischemic Stroke NCT01422616
Enhanced Control of Hypertension and Thrombolysis
Stroke Study (ENCHANTED); ODM derived from:
https://clinicaltrials.gov/show/NCT01422616
All rights reserved. Please visit https://medical-data-
models.org/forms/13789
Eligibility Ischemic Stroke
NCT01422616
Inclusion Criteria
adult (age ≥18 years)*
Yes
No
a clinical diagnosis of acute ischaemic stroke
confirmed by brain imaging*
Yes
No
able to receive treatment within 4.5 hours after
the definite time of onset of symptoms*
Yes
No
have a systolic bp ≤185 mmhg*
Yes
No
provide informed consent (or via an appropriate
proxy, according to local requirements)*
Yes
No
specific criteria for arm [a] of low-dose vs
standard-dose rtpa:*
Yes
No
able to receive either low-dose or standard-dose
rtpa*
Yes
No
specific criteria for arm [b] of intensive bp
lowering vs guideline recommended bp control*
Yes
No
patient will or has received thrombolysis
treatment with rtpa, either randomised dose
within the trial or physician decided dose rtpa
outside of the trial*
Yes
No
sustained elevated systolic bp level, defined as 2
readings 150 mmhg*
Yes
No
able to commence intensive bp lowering
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treatment within 6 hours of stroke onset*
Yes
No
able to receive either immediate intensive bp
lowering or conservative bp management*
Yes
No
Exclusion Criteria
unlikely to potentially benefit from the therapy
(e.g. advanced dementia), or a very high
likelihood of death within 24 hours of stroke
onset.*
Yes
No
other medical illness that interferes with outcome
assessments and follow-up [known significant
pre-stroke disability (mrs scores 2-5)].*
Yes
No
specific contraindications to rtpa (actilyse) or any
of the blood pressure agents to be used.*
Yes
No
participation in another clinical trial involving
evaluation of pharmacological agents.*
Yes
No
need for following concomitant medication,
including phosphodiesterase inhibitors and
monoamine oxidase inhibitors.*
Yes
No
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Eligibility Knee Osteoarthritis
NCT01427153
A Comparison of Manual Physical Therapy and
Corticosteroid Injections for Knee Osteoarthritis; ODM
derived from: https://clinicaltrials.gov/show/NCT01427153
All rights reserved. Please visit https://medical-data-
models.org/forms/13790
Eligibility Knee Osteoarthritis
NCT01427153
Inclusion Criteria
all subjects must be eligible for care in the military
health system*
Yes
No
meet altman's clinical criteria for knee oa*
Yes
No
have english language skills sufficient to
complete the womac and groc outcome
instruments*
Yes
No
be 38 years of age or older*
Yes
No
Exclusion Criteria
steroid injections or physical therapy treatment for
their knee in the past 12 months*
Yes
No
current or past history of rheumatoid arthritis or
similar rheumatic condition*
Yes
No
current or past history of gout or pseudogout of
the knee*
Yes
No
active infection in the knee within the past 12
months*
Yes
No
other physical ailment or condition that is typically
more limiting or painful than their knee oa during
activities such as sitting, standing, walking, or
stair climbing*
Yes
No
history of allergy or adverse effect to
corticosteroids*
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Yes
No
cannot speak/read english adequately to
understand and provide consent to participate in
the study*
Yes
No
pregnant or intending to become pregnant*
Yes
No
military service members pending a medical
evaluation board, physical evaluation board,
equivalent discharge process, or on medical hold
to determine long-term disposition.  for non-
military personnel, anyone that is pending or
undergoing any litigation for this condition.*
Yes
No
contraindication to receiving a corticosteroid
injection (history of allergic or adverse reaction to
steroid injection, history of multiple corticosteroid
injections in that area even if not within last year,
etc)*
Yes
No
unable to give informed consent to participate in
the study.*
Yes
No
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Genereral information EBMT CLL
ODM derived from HSCT forms on http://www.ebmt.org/
All rights reserved. Please visit https://medical-data-
models.org/forms/13791
Genereral information EBMT CLL
Team
EBMT Centre Identification Code (CIC)
Name of the hospital
Unit
Name of contact person
Telephone number
Fax number
E-Mail Address
Date of this report
Patient following national/ international study/ trial
No (No)
Unknown (Unknown)
Yes (Yes)
If yes, specify Name of study/ trial
Patient
To be entered only if patient previously reported
Hospital Unique Patient Number or Code
First name(s)_surname(s)
(Registrations will not be accepted if this item is
left blank)
Date of birth
(Registrations will not be accepted if this item is
left blank)
Patient Gender
Female (Female)
Male (Male)
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AB0 Blood Group
0 (0)
A (A)
AB (AB)
B (B)
Specification of blood group (Rhesus factor)
absent (absent)
not evaluated (not evaluated)
present (present)
Disease
Date of Diagnosis
Check the disease for which this transplant was
performed
Acute Leukaemia (Acute Leukaemia)
Acute Lymphoblastic Leukaemia (ALL)
(Acute Lymphoblastic Leukaemia (ALL))
Acute Myelogenous Leukaemia (AML)
(Acute Myelogenous Leukaemia (AML))
Autoimmune disease (Autoimmune
disease)
Bone marrow failure including Aplastic
anaemia (Bone marrow failure including
Aplastic anaemia)
Chronic Leukaemia (Chronic Leukaemia)
Chronic Lymphocytic Leukaemia
(Chronic Lymphocytic Leukaemia)
Chronic Myeloid Leukaemia (CML)
(Chronic Myeloid Leukaemia (CML))
Haemoglobinopathiy
(Haemoglobinopathiy)
Histiocytic disorders (Histiocytic
disorders)
Hodgkin´s Disease (Hodgkin´s Disease)
Inherited disorders (Inherited disorders)
Juvenile Idiopathic Arthritis (Juvenile
Idiopathic Arthritis)
Lymphoma (Lymphoma)
MD/ MPN (MD/ MPN)
MDS (MDS)
Metabolic disorders (Metabolic
disorders)
Multiple Sclerosis (Multiple Sclerosis)
Myelodysplastic syndromes
(Myelodysplastic syndromes)
Myeloma/ Plasma cell disorder
(Myeloma/ Plasma cell disorder)
Myeloproliferative neoplasm
(Myeloproliferative neoplasm)
Non Hodgkin (Non Hodgkin)
Other diagnosis (Other diagnosis)
Primary immune deficiencies (Primary
immune deficiencies)
Secondary Acute Leukaemia (do not use
if transformed from MDS/MPN)
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Genereral information EBMT CLL
(Secondary Acute Leukaemia (do not
use if transformed from MDS/MPN))
Solid Tumour (Solid Tumour)
Systemic Lupus (Systemic Lupus)
Systemic Sclerosis (Systemic Sclerosis)
If other diagnosis, specify:
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Genereral information EBMT CLL
Contact data for annual phone contact Coronary Artery Bypass
graft surgery in patients with Asymptomatic Carotid Stenosis
Coronary Artery Bypass graft surgery in patients with
Asymptomatic Carotid Stenosis. A randomized controlled
clinical trial. Short title: "CABACS" DRKS
Number:DRKS00000521 IRSCTN
Number:ISRCTN13486906 Phase:Therapeutic
confirmatory(Phase III) Head of clinical trial: Prof. Dr. med.
Christian Weimar University Duisburg-Essen Phone:
0201/723-6503 Fax: 0201/723-6948 e-mail:
christian.weimar@uk-essen.de University Hospital Essen
Hospital for Neurology Hufelandstr. 55 45122 Essen Trial
coordinator: Dr. med. Stephan Knipp Phone: 0201/723-
4915 Fax: 0201/723-5451 e-mail: stephan.knipp@uk-
essen.de University Duisburg-Essen University Hospital
Essen Hospital for thoracic- and cardiovascular surgery
Hufelandstr. 55 45122 Essen Data Management: Anja Marr
Phone: 0201/92239-257 Fax: 0201/92239-333 o. 0201/723-
5933 e-mail: anja.marr@uk-essen.de University Hospital
Essen Center for clinical trials Essen c/o IMIBE
Hufelandstr. 55 45122 Essen Monitoring: Dipl.-Biol.
Konstantinos Bilbilis Phone: 0201/92239-252 Fax:
0201/92239-310 e-mail: konstantinos.bilbilis@uk-essen.de
University Hospital Essen Center for clinical trials Essen c/o
IMIBE Hufelandstr. 55 45122 Essen
All rights reserved. Please visit https://medical-data-
models.org/forms/13792
CABACS Case Report Form
[Contact data for annual phone
contact]
Patient contact data
Patient given name
Patient surname
Patient date of birth
Gender
male (1)
female (2)
Street name, house or appartement number, zip
code and city of residence
Please enter a phone number for the annual
interview
Please enter a cell phone number if applicable
Relative contact data
Given name of patient´s relative
Last name of patient´s relative
Date of birth of patient´s relative
Gender
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male (1)
female (2)
Home Address of patient´s relative
Please enter a phone number to contact the
patient´s relative
Please enter a cell phone number, if applicable
Relationship to patient
spouse/cohabitee (1)
child (2)
father or mother (3)
friend (4)
other (specify) (5)
Please specify other relationship to patient
Family physician or residential care facility
contact person
Name and Surname
Function of contact person
Facility name
Department
Address:street name, house number,zip code
and city of residence.
Please enter a phone number for contact
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Outcome event stroke Coronary Artery Bypass graft
surgery in patients with Asymptomatic Carotid Stenosis
Coronary Artery Bypass graft surgery in patients with
Asymptomatic Carotid Stenosis. A randomized controlled
clinical trial. Short title: "CABACS" DRKS
Number:DRKS00000521 IRSCTN
Number:ISRCTN13486906 Phase:Therapeutic
confirmatory(Phase III) Head of clinical trial: Prof. Dr. med.
Christian Weimar University Duisburg-Essen Phone:
0201/723-6503 Fax: 0201/723-6948 e-mail:
christian.weimar@uk-essen.de University Hospital Essen
Hospital for Neurology Hufelandstr. 55 45122 Essen Trial
coordinator: Dr. med. Stephan Knipp Phone: 0201/723-
4915 Fax: 0201/723-5451 e-mail: stephan.knipp@uk-
essen.de University Duisburg-Essen University Hospital
Essen Hospital for thoracic- and cardiovascular surgery
Hufelandstr. 55 45122 Essen Data Management: Anja Marr
Phone: 0201/92239-257 Fax: 0201/92239-333 o. 0201/723-
5933 e-mail: anja.marr@uk-essen.de University Hospital
Essen Center for clinical trials Essen c/o IMIBE
Hufelandstr. 55 45122 Essen Monitoring: Dipl.-Biol.
Konstantinos Bilbilis Phone: 0201/92239-252 Fax:
0201/92239-310 e-mail: konstantinos.bilbilis@uk-essen.de
University Hospital Essen Center for clinical trials Essen c/o
IMIBE Hufelandstr. 55 45122 Essen
All rights reserved. Please visit https://medical-data-
models.org/forms/13793
CABACS Case Report Form
[Outcome event stroke]
Endpoint event "stroke"
Patient ID
Date of stroke
Affected cerebral hemisphere
right (1)
left (2)
indefinite (3)
Duration of symptoms (until complete remission)
<24 hrs (1)
≥24 hrs (2)
Persistent (3)
Region of cerebrovascular accident
anterior cerebral artery (1)
middle cerebral artery (2)
posterior cerebral artery (3)
vertebrobasilar (4)
Infarction at supply area of trial relevant carotid
stenosis
Yes
No
Type of cerebrovascular infarction
ischemic (1)
hemorrhagic (2)
unknown (3)
Correlation with trial procedure CABG +/- CEA
definite (1)
probable (2)
possible (3)
not likely (4)
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no correlation (5)
can not be assessed (6)
Additional medical examination
none (0)
CCT (1)
angiography (2)
cerebral MRI (3)
Doppler Ultrasonography (4)
Verification in diagnostic imaging
Yes
No
Please give a detailed description of the event
Date of completion of this form
Signature by investigator
Name of Investigator
Stroke follow-up
Date of stroke
Date of follow-up contact
Type of Contact (Select how the information was
obtained:)
personal (1)
phone contact (2)
through another person (i.e health care
provider,relative,...) (3)
Modified Rankin Stroke Scale score
No symptoms at all (0)
No significant disability despite
symptoms; able to carry out all usual
duties and activities (1)
Slight disability; unable to carry out all
previous activities but able to look after
own affairs without assistance (2)
Moderate disability; requiring some help
but able to walk without assistance (3)
Moderately severe disability; unable to
walk without assistance and unable to
attend to own bodily needs without
assistance (4)
Severe disability; bedridden, incontinent,
and requiring constant nursing care and
attention (5)
Death (6)
Date of completion of this form
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Signature by investigator
Name of Investigator
Modified Rankin Scale,structured
interview
Patient ID
Do you (your family member) need constant
nursing care?
yes (severe
disability,bedridden,incontinence,constan
t nursing care in almost every aspect of
daily life) 5 (1)
No (2)
Do you (your family member)need assistance
with eating,toileting,personal hygiene or walking?
Yes (moderately severe disability, walking
without help impossible,assistance with
ADL´s needed)  (1)
No (2)
Do you (your family member) need assistance to
prepare a simple meal, for house keeping tasks,
deal with money, do the groceries or to get along
in your home town?
Yes (Moderate disability, assistance
needed but can walk with or without
walking aid)  (1)
No (2)
Have there been changes in your (your family
members) ability to work or care for others if
that´s what you did? Have there been changes in
your (your family members) ability to participate
in social and leisure activities?
Have you (your family member) experienced
problems with personal relationships or did you
(your family member) seclude yourself?
Yes (mild disability, not all former
activities can be performed but
independend life without help is still
possible)  (1)
No (2)
Do you (your family member) have problems with
reading or writing or to find the right words durin
conversation?
Have you (your family member) experienced
problems with balance, coordination, vision,
numbness of diverse skin spots or problems to
swallow?
Yes (no significant disability, despite
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symptoms all daily activities can be
performed independently)  (1)
No (2)
No disability at all
Yes
No
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Outcome event myocardial infarction Coronary Artery Bypass
graft surgery in patients with Asymptomatic Carotid Stenosis
Coronary Artery Bypass graft surgery in patients with
Asymptomatic Carotid Stenosis. A randomized controlled
clinical trial. Short title: "CABACS" DRKS
Number:DRKS00000521 IRSCTN
Number:ISRCTN13486906 Phase:Therapeutic
confirmatory(Phase III) Head of clinical trial: Prof. Dr. med.
Christian Weimar University Duisburg-Essen Phone:
0201/723-6503 Fax: 0201/723-6948 e-mail:
christian.weimar@uk-essen.de University Hospital Essen
Hospital for Neurology Hufelandstr. 55 45122 Essen Trial
coordinator: Dr. med. Stephan Knipp Phone: 0201/723-
4915 Fax: 0201/723-5451 e-mail: stephan.knipp@uk-
essen.de University Duisburg-Essen University Hospital
Essen Hospital for thoracic- and cardiovascular surgery
Hufelandstr. 55 45122 Essen Data Management: Anja Marr
Phone: 0201/92239-257 Fax: 0201/92239-333 o. 0201/723-
5933 e-mail: anja.marr@uk-essen.de University Hospital
Essen Center for clinical trials Essen c/o IMIBE
Hufelandstr. 55 45122 Essen Monitoring: Dipl.-Biol.
Konstantinos Bilbilis Phone: 0201/92239-252 Fax:
0201/92239-310 e-mail: konstantinos.bilbilis@uk-essen.de
University Hospital Essen Center for clinical trials Essen c/o
IMIBE Hufelandstr. 55 45122 Essen
All rights reserved. Please visit https://medical-data-
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CABACS Case Report Form
[Outcome event myocardial
infarction]
Endpoint event "myocardial infarction"
Date of myocardial infarction
Cardiac marker enzymes used for laboratory
verification
Troponin T (1)
Troponin I (2)
Creatine Kinase (3)
Creatine Kinase MB (4)
Highest level of cardiac marker enzyme
Units used for measurement of cardiac marker
enzymes
Upper Limit of Normal for this marker enzyme
Unit of measure for ULN
Clinical symptoms of cardiac ischemia
Yes (1)
No (2)
unknown (3)
ST elevation in ECG
Yes (1)
No (2)
unknown (3)
Development of pathological Q waves in the ECG
Yes (1)
No (2)
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unknown (3)
Cardiac dyskinesia or ventricular asynergy
Yes (1)
No (2)
unknown (3)
Other relevant information,please specify
Correlation with trial procedure CABG +/- CEA
definite (1)
probable (2)
possible (3)
not likely (4)
no correlation (5)
can not be assessed (6)
Outcome
recovered (1)
not yet recovered (2)
improvement (3)
recovered with sequelae (4)
fatal (5)
unknown (6)
If myocardial infarction was fatal,please specify
the date of death
Date of completion of this form
Signature by investigator
Name of Investigator
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Outcome event technical failure/restenosis Coronary Artery Bypass
graft surgery in patients with Asymptomatic Carotid Stenosis
Coronary Artery Bypass graft surgery in patients with
Asymptomatic Carotid Stenosis. A randomized controlled
clinical trial. Short title: "CABACS" DRKS
Number:DRKS00000521 IRSCTN
Number:ISRCTN13486906 Phase:Therapeutic
confirmatory(Phase III) Head of clinical trial: Prof. Dr. med.
Christian Weimar University Duisburg-Essen Phone:
0201/723-6503 Fax: 0201/723-6948 e-mail:
christian.weimar@uk-essen.de University Hospital Essen
Hospital for Neurology Hufelandstr. 55 45122 Essen Trial
coordinator: Dr. med. Stephan Knipp Phone: 0201/723-
4915 Fax: 0201/723-5451 e-mail: stephan.knipp@uk-
essen.de University Duisburg-Essen University Hospital
Essen Hospital for thoracic- and cardiovascular surgery
Hufelandstr. 55 45122 Essen Data Management: Anja Marr
Phone: 0201/92239-257 Fax: 0201/92239-333 o. 0201/723-
5933 e-mail: anja.marr@uk-essen.de University Hospital
Essen Center for clinical trials Essen c/o IMIBE
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University Hospital Essen Center for clinical trials Essen c/o
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All rights reserved. Please visit https://medical-data-
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CABACS Case Report Form
[Outcome event technical
failure/restenosis]
Endpoint event "technical
failure/restenosis"
Patient ID
Date of diagnosis
Extent of restenosis
%
Localization
right (1)
left (2)
Reason for restenosis
hyperplasia of tunica intima (1)
atherosclerotic plaque (2)
dissection of vessel (3)
thrombotic event (4)
hematoma (5)
intervention termination (6)
unknown (7)
Additional medical examination
CTA-computed angiography (1)
MRA- magnetic resonance angiography
(2)
DSA-digital subtraction angiography (3)
Other (specify) (4)
Additional medical examination, please specify
other method used
Extent of disease confirmed?
Yes
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No
Symptomatic technical failure
No (0)
TIA/Amaurosis (1)
cerebrovascular accident (please fill in
outcome event form "Stroke") (2)
Treatment
No (0)
Yes (please fill in SAE form) (1)
Treatment
Percutaneous Transluminal
Angioplasty/Stent (1)
Repeated surgical procedure (2)
Date of repeated surgery or Percutaneous
Transluminal Angioplasty/Stent
Correlation with trial procedure CABG +/- CEA
definite (1)
probable (2)
possible (3)
not likely (4)
no correlation (5)
can not be assessed (6)
Outcome
recovered (1)
not yet recovered (2)
improvement (3)
recovered with sequelae (4)
fatal (5)
unknown (6)
Other relevant information,please specify
Date of completion of this form
Signature by investigator
Name of Investigator
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Outcome event death/SAE Coronary Artery Bypass graft
surgery in patients with Asymptomatic Carotid Stenosis
Coronary Artery Bypass graft surgery in patients with
Asymptomatic Carotid Stenosis. A randomized controlled
clinical trial. Short title: "CABACS" DRKS
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Number:ISRCTN13486906 Phase:Therapeutic
confirmatory(Phase III) Head of clinical trial: Prof. Dr. med.
Christian Weimar University Duisburg-Essen Phone:
0201/723-6503 Fax: 0201/723-6948 e-mail:
christian.weimar@uk-essen.de University Hospital Essen
Hospital for Neurology Hufelandstr. 55 45122 Essen Trial
coordinator: Dr. med. Stephan Knipp Phone: 0201/723-
4915 Fax: 0201/723-5451 e-mail: stephan.knipp@uk-
essen.de University Duisburg-Essen University Hospital
Essen Hospital for thoracic- and cardiovascular surgery
Hufelandstr. 55 45122 Essen Data Management: Anja Marr
Phone: 0201/92239-257 Fax: 0201/92239-333 o. 0201/723-
5933 e-mail: anja.marr@uk-essen.de University Hospital
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CABACS Case Report Form
[Outcome event death/SAE]
Endpoint event "death/SAE"
Patient ID
Gender
male (1)
female (2)
Patient date of birth
Study site number
SAE number
Date of first notification about the SAE
Date of follow up notification about previously
documented SAE (please specify number of
SAE)
If you chose "Follow-up notification" please
specify previously documented SAE number
Hospital Name/medical department
Phone number of hospital or medical department
Diagnostic criteria for SAE
fatal outcome (1)
life threatening event (2)
lead to hospitalization or prolonged
hospitalization (3)
lead to permanent or significant
disability/invalidity (4)
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congenital abnormality or birth defect (5)
longterm artificial respiration 30 days
after CABG/CAE (6)
Correlation with trial procedure CABG +/- CEA
definite (1)
probable (2)
possible (3)
not likely (4)
no correlation (5)
can not be assessed (6)
SAE diagnosis: please specify including
symptoms if possible.
SAE Start date
SAE End Date
Date of death if applicable
Outcome of SAE
recovered (1)
not yet recovered (2)
improvement (3)
recovered with sequelae (4)
fatal (5)
unknown (6)
Cause of death if SAE was fatal
Date of completion of this form
Signature by investigator
Name of Investigator
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Second year follow up Coronary Artery Bypass graft
surgery in patients with Asymptomatic Carotid Stenosis
Coronary Artery Bypass graft surgery in patients with
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Number:DRKS00000521 IRSCTN
Number:ISRCTN13486906 Phase:Therapeutic
confirmatory(Phase III) Head of clinical trial: Prof. Dr. med.
Christian Weimar University Duisburg-Essen Phone:
0201/723-6503 Fax: 0201/723-6948 e-mail:
christian.weimar@uk-essen.de University Hospital Essen
Hospital for Neurology Hufelandstr. 55 45122 Essen Trial
coordinator: Dr. med. Stephan Knipp Phone: 0201/723-
4915 Fax: 0201/723-5451 e-mail: stephan.knipp@uk-
essen.de University Duisburg-Essen University Hospital
Essen Hospital for thoracic- and cardiovascular surgery
Hufelandstr. 55 45122 Essen Data Management: Anja Marr
Phone: 0201/92239-257 Fax: 0201/92239-333 o. 0201/723-
5933 e-mail: anja.marr@uk-essen.de University Hospital
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CABACS Case Report Form [second
year follow up]
Screening: Outcome events
Patient ID
Date of interview
Did the patient experience any (transient) visual
impairment (since last visit)?
Yes
No
Did the patient experience paresthesia or
weakness on one side of the body (since last
visit)?
Yes
No
Did the patient experience speech disorder (since
last visit)?
Yes
No
Did the patient experience any new signs or
symptoms (since last visit)?
Yes
No
If at least one of the above has been answered
`yes`, has cerebral imaging been performed?
Yes
No
Did the patient suffer a stroke or myocardial
infarction since last visit?
Yes
No
1 / 4
Modified Rankin Scale,structured
interview
Do you (your family member) need constant
nursing care?
yes (severe
disability,bedridden,incontinence,constan
t nursing care in almost every aspect of
daily life)  (1)
No (2)
Do you (your family member)need assistance
with eating,toileting,personal hygiene or walking?
Yes (moderately severe disability, walking
without help impossible,assistance with
ADL´s needed)  (1)
No (2)
Do you (your family member) need assistance to
prepare a simple meal, for house keeping tasks,
deal with money, do the groceries or to get along
in your home town?
Yes (Moderate disability, assistance
needed but can walk with or without
walking aid)  (1)
No (2)
Have there been changes in your (your family
members) ability to work or care for others if
that´s what you did? Have there been changes in
your (your family members) ability to participate
in social and leisure activities?
Have you (your family member) experienced
problems with personal relationships or did you
(your family member) seclude yourself?
Yes (mild disability, not all former
activities can be performed but
independend life without help is still
possible)  (1)
No (2)
Do you (your family member) have problems with
reading or writing or to find the right words durin
conversation?
Have you (your family member) experienced
problems with balance, coordination, vision,
numbness of diverse skin spots or problems to
swallow?
Yes (no significant disability, despite
symptoms all daily activities can be
performed independently)  (1)
No (2)
No disability at all
Yes
No
Risk factors
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Smoking Status
non-smoker (1)
ex-smoker (2)
current smoker (3)
Body weight
kg
Concomitant medication
Does the patient take antiplatelet agents?
Yes
No
Please choose from the list below, which
antiplatelet drug the patient takes
Acetyl salicylic acid (1)
Clopidogrel (2)
Acetyl salicylic acid plus Dipyridamole
(3)
Other (4)
Please specify which antiplatelet drugs the
patient took, if you chose `other`
Does the patient take any anticoagulants?
Yes
No
Please choose which one of the anticoagulants
listed below the patient takes.
Full dose LMW heparin (Enoxaparin ,
Others) (1)
Vitamin K Antagonists like Warfarin
(Coumadin) (2)
Dabigatran (3)
Other (4)
Please specify which anticoagulant the patient
takes, if you chose `other`.
Does the patient take any antihypertensive
drugs?
Yes
No
Please choose which one of the antihypertensive
drugs listed below the patient takes.
ACE inhibitor (1)
angiotensin receptor blocker (2)
Diuretics (3)
Calcium Antagonist (4)
Beta blocker (5)
other (6)
More than one of the list (7)
3 / 4
Second year follow up Coronary Artery Bypass graft surgery in patients
with Asymptomatic Carotid Stenosis
Please specify which antihypertensive agent the
patient takes, if you chose `other`.
Does the patient take any lipid lowering agents?
Yes
No
Please choose which one of the antilipemic
agents listed below the patient takes
Statine (1)
Other (2)
Please specify which antilipemic agent the
patient takes, if you chose `other`.
Does the patient take any antidiabetic agents?
No (0)
oral antidiabetics (1)
insulin (2)
Any other relevant concomitant medication the
patient takes?
Yes
No
Please specify what other concomitant
medication the patient takes
Has the patient undergone any other relevant
surgical procedures other than recorded on this
form since last visit?
Yes
No
Please specify the nature of the other surgical
procedure
Interview answered by:
Patient (1)
Relative (2)
residential care professional (3)
Date of completion of this form
Signature by interviewer
Name of interviewer
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Third year follow up Coronary Artery Bypass graft
surgery in patients with Asymptomatic Carotid Stenosis
Coronary Artery Bypass graft surgery in patients with
Asymptomatic Carotid Stenosis. A randomized controlled
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Christian Weimar University Duisburg-Essen Phone:
0201/723-6503 Fax: 0201/723-6948 e-mail:
christian.weimar@uk-essen.de University Hospital Essen
Hospital for Neurology Hufelandstr. 55 45122 Essen Trial
coordinator: Dr. med. Stephan Knipp Phone: 0201/723-
4915 Fax: 0201/723-5451 e-mail: stephan.knipp@uk-
essen.de University Duisburg-Essen University Hospital
Essen Hospital for thoracic- and cardiovascular surgery
Hufelandstr. 55 45122 Essen Data Management: Anja Marr
Phone: 0201/92239-257 Fax: 0201/92239-333 o. 0201/723-
5933 e-mail: anja.marr@uk-essen.de University Hospital
Essen Center for clinical trials Essen c/o IMIBE
Hufelandstr. 55 45122 Essen Monitoring: Dipl.-Biol.
Konstantinos Bilbilis Phone: 0201/92239-252 Fax:
0201/92239-310 e-mail: konstantinos.bilbilis@uk-essen.de
University Hospital Essen Center for clinical trials Essen c/o
IMIBE Hufelandstr. 55 45122 Essen
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CABACS Case Report Form [third
year follow up]
Screening: Outcome events
Patient ID
Date of interview
Did the patient experience any (transient) visual
impairment (since last visit)?
Yes
No
Did the patient experience paresthesia or
weakness on one side of the body (since last
visit)?
Yes
No
Did the patient experience speech disorder (since
last visit)?
Yes
No
Did the patient experience any new signs or
symptoms (since last visit)?
Yes
No
If at least one of the above has been answered
`yes`, has cerebral imaging been performed?
Yes
No
Did the patient suffer a stroke or myocardial
infarction since last visit?
Yes
No
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Modified Rankin Scale,structured
interview
Do you (your family member) need constant
nursing care?
yes (severe
disability,bedridden,incontinence,constan
t nursing care in almost every aspect of
daily life)  (1)
No (2)
Do you (your family member)need assistance
with eating,toileting,personal hygiene or walking?
Yes (moderately severe disability, walking
without help impossible,assistance with
ADL´s needed)  (1)
No (2)
Do you (your family member) need assistance to
prepare a simple meal, for house keeping tasks,
deal with money, do the groceries or to get along
in your home town?
Yes (Moderate disability, assistance
needed but can walk with or without
walking aid)  (1)
No (2)
Have there been changes in your (your family
members) ability to work or care for others if
that´s what you did? Have there been changes in
your (your family members) ability to participate
in social and leisure activities?
Have you (your family member) experienced
problems with personal relationships or did you
(your family member) seclude yourself?
Yes (mild disability, not all former
activities can be performed but
independend life without help is still
possible)  (1)
No (2)
Do you (your family member) have problems with
reading or writing or to find the right words durin
conversation?
Have you (your family member) experienced
problems with balance, coordination, vision,
numbness of diverse skin spots or problems to
swallow?
Yes (no significant disability, despite
symptoms all daily activities can be
performed independently)  (1)
No (2)
No disability at all
Yes
No
Risk factors
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Smoking Status
non-smoker (1)
ex-smoker (2)
current smoker (3)
Body weight
kg
Concomitant medication
Does the patient take antiplatelet agents?
Yes
No
Please choose from the list below, which
antiplatelet drug the patient takes
Acetyl salicylic acid (1)
Clopidogrel (2)
Acetyl salicylic acid plus Dipyridamole
(3)
Other (4)
Please specify which antiplatelet drugs the
patient took, if you chose `other`
Does the patient take any anticoagulants?
Yes
No
Please choose which one of the anticoagulants
listed below the patient takes.
Full dose LMW heparin (Enoxaparin ,
Others) (1)
Vitamin K Antagonists like Warfarin
(Coumadin) (2)
Dabigatran (3)
Other (4)
Please specify which anticoagulant the patient
takes, if you chose `other`.
Does the patient take any antihypertensive
drugs?
Yes
No
Please choose which one of the antihypertensive
drugs listed below the patient takes.
ACE inhibitor (1)
angiotensin receptor blocker (2)
Diuretics (3)
Calcium Antagonist (4)
Beta blocker (5)
other (6)
More than one of the list (7)
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Please specify which antihypertensive agent the
patient takes, if you chose `other`.
Does the patient take any lipid lowering agents?
Yes
No
Please choose which one of the antilipemic
agents listed below the patient takes
Statine (1)
Other (2)
Please specify which antilipemic agent the
patient takes, if you chose `other`.
Does the patient take any antidiabetic agents?
No (0)
oral antidiabetics (1)
insulin (2)
Any other relevant concomitant medication the
patient takes?
Yes
No
Please specify what other concomitant
medication the patient takes
Has the patient undergone any other relevant
surgical procedures other than recorded on this
form since last visit?
Yes
No
Please specify the nature of the other surgical
procedure
Interview answered by:
Patient (1)
Relative (2)
residential care professional (3)
Date of completion of this form
Signature by interviewer
Name of interviewer
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Fourth year follow up Coronary Artery Bypass graft
surgery in patients with Asymptomatic Carotid Stenosis
Coronary Artery Bypass graft surgery in patients with
Asymptomatic Carotid Stenosis. A randomized controlled
clinical trial. Short title: "CABACS" DRKS
Number:DRKS00000521 IRSCTN
Number:ISRCTN13486906 Phase:Therapeutic
confirmatory(Phase III) Head of clinical trial: Prof. Dr. med.
Christian Weimar University Duisburg-Essen Phone:
0201/723-6503 Fax: 0201/723-6948 e-mail:
christian.weimar@uk-essen.de University Hospital Essen
Hospital for Neurology Hufelandstr. 55 45122 Essen Trial
coordinator: Dr. med. Stephan Knipp Phone: 0201/723-
4915 Fax: 0201/723-5451 e-mail: stephan.knipp@uk-
essen.de University Duisburg-Essen University Hospital
Essen Hospital for thoracic- and cardiovascular surgery
Hufelandstr. 55 45122 Essen Data Management: Anja Marr
Phone: 0201/92239-257 Fax: 0201/92239-333 o. 0201/723-
5933 e-mail: anja.marr@uk-essen.de University Hospital
Essen Center for clinical trials Essen c/o IMIBE
Hufelandstr. 55 45122 Essen Monitoring: Dipl.-Biol.
Konstantinos Bilbilis Phone: 0201/92239-252 Fax:
0201/92239-310 e-mail: konstantinos.bilbilis@uk-essen.de
University Hospital Essen Center for clinical trials Essen c/o
IMIBE Hufelandstr. 55 45122 Essen
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CABACS Case Report Form [fourth
year follow up]
Screening: Outcome events
Patient ID
Date of interview
Did the patient experience any (transient) visual
impairment (since last visit)?
Yes
No
Did the patient experience paresthesia or
weakness on one side of the body (since last
visit)?
Yes
No
Did the patient experience speech disorder (since
last visit)?
Yes
No
Did the patient experience any new signs or
symptoms (since last visit)?
Yes
No
If at least one of the above has been answered
`yes`, has cerebral imaging been performed?
Yes
No
Did the patient suffer a stroke or myocardial
infarction since last visit?
Yes
No
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Modified Rankin Scale,structured
interview
Do you (your family member) need constant
nursing care?
yes (severe
disability,bedridden,incontinence,constan
t nursing care in almost every aspect of
daily life)  (1)
No (2)
Do you (your family member)need assistance
with eating,toileting,personal hygiene or walking?
Yes (moderately severe disability, walking
without help impossible,assistance with
ADL´s needed)  (1)
No (2)
Do you (your family member) need assistance to
prepare a simple meal, for house keeping tasks,
deal with money, do the groceries or to get along
in your home town?
Yes (Moderate disability, assistance
needed but can walk with or without
walking aid)  (1)
No (2)
Have there been changes in your (your family
members) ability to work or care for others if
that´s what you did? Have there been changes in
your (your family members) ability to participate
in social and leisure activities?
Have you (your family member) experienced
problems with personal relationships or did you
(your family member) seclude yourself?
Yes (mild disability, not all former
activities can be performed but
independend life without help is still
possible)  (1)
No (2)
Do you (your family member) have problems with
reading or writing or to find the right words durin
conversation?
Have you (your family member) experienced
problems with balance, coordination, vision,
numbness of diverse skin spots or problems to
swallow?
Yes (no significant disability, despite
symptoms all daily activities can be
performed independently)  (1)
No (2)
No disability at all
Yes
No
Risk factors
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Smoking Status
non-smoker (1)
ex-smoker (2)
current smoker (3)
Body weight
kg
Concomitant medication
Does the patient take antiplatelet agents?
Yes
No
Please choose from the list below, which
antiplatelet drug the patient takes
Acetyl salicylic acid (1)
Clopidogrel (2)
Acetyl salicylic acid plus Dipyridamole
(3)
Other (4)
Please specify which antiplatelet drugs the
patient took, if you chose `other`
Does the patient take any anticoagulants?
Yes
No
Please choose which one of the anticoagulants
listed below the patient takes.
Full dose LMW heparin (Enoxaparin ,
Others) (1)
Vitamin K Antagonists like Warfarin
(Coumadin) (2)
Dabigatran (3)
Other (4)
Please specify which anticoagulant the patient
takes, if you chose `other`.
Does the patient take any antihypertensive
drugs?
Yes
No
Please choose which one of the antihypertensive
drugs listed below the patient takes.
ACE inhibitor (1)
angiotensin receptor blocker (2)
Diuretics (3)
Calcium Antagonist (4)
Beta blocker (5)
other (6)
More than one of the list (7)
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Please specify which antihypertensive agent the
patient takes, if you chose `other`.
Does the patient take any lipid lowering agents?
Yes
No
Please choose which one of the antilipemic
agents listed below the patient takes
Statine (1)
Other (2)
Please specify which antilipemic agent the
patient takes, if you chose `other`.
Does the patient take any antidiabetic agents?
No (0)
oral antidiabetics (1)
insulin (2)
Any other relevant concomitant medication the
patient takes?
Yes
No
Please specify what other concomitant
medication the patient takes
Has the patient undergone any other relevant
surgical procedures other than recorded on this
form since last visit?
Yes
No
Please specify the nature of the other surgical
procedure
Interview answered by:
Patient (1)
Relative (2)
residential care professional (3)
Date of completion of this form
Signature by interviewer
Name of interviewer
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Fifth year follow up Coronary Artery Bypass graft
surgery in patients with Asymptomatic Carotid Stenosis
Coronary Artery Bypass graft surgery in patients with
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Christian Weimar University Duisburg-Essen Phone:
0201/723-6503 Fax: 0201/723-6948 e-mail:
christian.weimar@uk-essen.de University Hospital Essen
Hospital for Neurology Hufelandstr. 55 45122 Essen Trial
coordinator: Dr. med. Stephan Knipp Phone: 0201/723-
4915 Fax: 0201/723-5451 e-mail: stephan.knipp@uk-
essen.de University Duisburg-Essen University Hospital
Essen Hospital for thoracic- and cardiovascular surgery
Hufelandstr. 55 45122 Essen Data Management: Anja Marr
Phone: 0201/92239-257 Fax: 0201/92239-333 o. 0201/723-
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Hufelandstr. 55 45122 Essen Monitoring: Dipl.-Biol.
Konstantinos Bilbilis Phone: 0201/92239-252 Fax:
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CABACS Case Report Form [fifth
year follow up]
Screening: Outcome events
Patient ID
Date of interview
Did the patient experience any (transient) visual
impairment (since last visit)?
Yes
No
Did the patient experience paresthesia or
weakness on one side of the body (since last
visit)?
Yes
No
Did the patient experience speech disorder (since
last visit)?
Yes
No
Did the patient experience any new signs or
symptoms (since last visit)?
Yes
No
If at least one of the above has been answered
`yes`, has cerebral imaging been performed?
Yes
No
Did the patient suffer a stroke or myocardial
infarction since last visit?
Yes
No
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Modified Rankin Scale,structured
interview
Do you (your family member) need constant
nursing care?
yes (severe
disability,bedridden,incontinence,constan
t nursing care in almost every aspect of
daily life)  (1)
No (2)
Do you (your family member)need assistance
with eating,toileting,personal hygiene or walking?
Yes (moderately severe disability, walking
without help impossible,assistance with
ADL´s needed)  (1)
No (2)
Do you (your family member) need assistance to
prepare a simple meal, for house keeping tasks,
deal with money, do the groceries or to get along
in your home town?
Yes (Moderate disability, assistance
needed but can walk with or without
walking aid)  (1)
No (2)
Have there been changes in your (your family
members) ability to work or care for others if
that´s what you did? Have there been changes in
your (your family members) ability to participate
in social and leisure activities?
Have you (your family member) experienced
problems with personal relationships or did you
(your family member) seclude yourself?
Yes (mild disability, not all former
activities can be performed but
independend life without help is still
possible)  (1)
No (2)
Do you (your family member) have problems with
reading or writing or to find the right words durin
conversation?
Have you (your family member) experienced
problems with balance, coordination, vision,
numbness of diverse skin spots or problems to
swallow?
Yes (no significant disability, despite
symptoms all daily activities can be
performed independently)  (1)
No (2)
No disability at all
Yes
No
Risk factors
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Smoking Status
non-smoker (1)
ex-smoker (2)
current smoker (3)
Body weight
kg
Concomitant medication
Does the patient take antiplatelet agents?
Yes
No
Please choose from the list below, which
antiplatelet drug the patient takes
Acetyl salicylic acid (1)
Clopidogrel (2)
Acetyl salicylic acid plus Dipyridamole
(3)
Other (4)
Please specify which antiplatelet drugs the
patient took, if you chose `other`
Does the patient take any anticoagulants?
Yes
No
Please choose which one of the anticoagulants
listed below the patient takes.
Full dose LMW heparin (Enoxaparin ,
Others) (1)
Vitamin K Antagonists like Warfarin
(Coumadin) (2)
Dabigatran (3)
Other (4)
Please specify which anticoagulant the patient
takes, if you chose `other`.
Does the patient take any antihypertensive
drugs?
Yes
No
Please choose which one of the antihypertensive
drugs listed below the patient takes.
ACE inhibitor (1)
angiotensin receptor blocker (2)
Diuretics (3)
Calcium Antagonist (4)
Beta blocker (5)
other (6)
More than one of the list (7)
3 / 4
Fifth year follow up Coronary Artery Bypass graft surgery in patients with
Asymptomatic Carotid Stenosis
Please specify which antihypertensive agent the
patient takes, if you chose `other`.
Does the patient take any lipid lowering agents?
Yes
No
Please choose which one of the antilipemic
agents listed below the patient takes
Statine (1)
Other (2)
Please specify which antilipemic agent the
patient takes, if you chose `other`.
Does the patient take any antidiabetic agents?
No (0)
oral antidiabetics (1)
insulin (2)
Any other relevant concomitant medication the
patient takes?
Yes
No
Please specify what other concomitant
medication the patient takes
Has the patient undergone any other relevant
surgical procedures other than recorded on this
form since last visit?
Yes
No
Please specify the nature of the other surgical
procedure
Interview answered by:
Patient (1)
Relative (2)
residential care professional (3)
Date of completion of this form
Signature by interviewer
Name of interviewer
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Follow up completion form Coronary Artery Bypass graft
surgery in patients with Asymptomatic Carotid Stenosis
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coordinator: Dr. med. Stephan Knipp Phone: 0201/723-
4915 Fax: 0201/723-5451 e-mail: stephan.knipp@uk-
essen.de University Duisburg-Essen University Hospital
Essen Hospital for thoracic- and cardiovascular surgery
Hufelandstr. 55 45122 Essen Data Management: Anja Marr
Phone: 0201/92239-257 Fax: 0201/92239-333 o. 0201/723-
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Hufelandstr. 55 45122 Essen Monitoring: Dipl.-Biol.
Konstantinos Bilbilis Phone: 0201/92239-252 Fax:
0201/92239-310 e-mail: konstantinos.bilbilis@uk-essen.de
University Hospital Essen Center for clinical trials Essen c/o
IMIBE Hufelandstr. 55 45122 Essen
All rights reserved. Please visit https://medical-data-
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CABACS Case Report Form [follow
up completion form]
Follow up completion
Patient ID
Study end date
Type of trial completion
no follow-up, see completion clinical trial
section (0)
normal end of study (1)
premature end of study (specify) (2)
If premature end of study, specify reason
informed consent withdrawn (1)
Patient unable to participate any more
due to comorbidity, no legal
representative  (2)
lost to follow up (3)
Death (Investigate further,fill in outcome
event form) (4)
other reason (5)
Please specify withdrawn IC, kind of
comorbidity,death and other reasons for
premature end of study
Date of completion of this form
Signature by investigator
Name of Investigator
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Eligibility Acute Myeloid Leukemia
NCT01440920
A Phase I Study of OCV-501 in Acute Myeloid Leukemia
Patients; ODM derived from:
https://clinicaltrials.gov/show/NCT01440920
All rights reserved. Please visit https://medical-data-
models.org/forms/13812
Eligibility Acute Myeloid Leukemia
NCT01440920
Criteria
patients with acute myeloid leukemia including
patients with secondary leukemia. however, the
patients with mds apparently evolved itno aml
and patients with aml accompanied by
t(15;17)(q22;q12),(pml/raralpha) ,  should be
excluded.*
Yes
No
patients who achieved the first complete
remission after the induction regimen and
finished a standard consolidation therapy.*
Yes
No
age: ≥ 60years of age(at the time of signature of
the informed consent form)*
Yes
No
sex: male and female*
Yes
No
patients who are capable of giving informed
consent*
Yes
No
patient's blasts cells show expression of
wt1mrna, detected by quantitative rt-pcr.*
Yes
No
patients must be one of the following hla drb1
types: hla-drb1*01:01, *04:05, *15:01, *15:02,
*08:03 and *09:01.*
Yes
No
Exclusion criteria
patients who are scheduled for a bone marrow
transplantation
Yes
No
patients who were administered exceeded
acceptable therapeutic dose of
immunosuppressants and adrenal cortical
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steroids.
Yes
No
patients with uncontrollable active infectious
diseases
Yes
No
patients with autoimmune diseases (including
hashimoto's disease, idiopathic thrombocytopenic
purpura, and autoimmune hepatitis) or with a
medical history of active autoimmune diseases
Yes
No
immunocompetent patients
Yes
No
patients with a complication of interstitial
pneumonia or with a medical history of interstitial
pneumonia
Yes
No
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Visit 1 - Baseline Form Clinical Trial on the Efficacy and Safety BID
Mometasone Furoate Nasal Spray (MFNS) in the Treatment of Chronic Sinusitis
This study evaluates the effectiveness and safety of MFNS
in improving the Treatment of Chronic Sinusitis.
ODM derived from:"Randomized Double-blind Clinical Trial
on the Efficacy and Safety of 200 mcg BID Mometasone
Furoate Nasal Spray (MFNS) or Placebo in the Treatment
of Chronic Sinusitis". 
Leader of the clinical trial: 
Prof. Dr. med. Karl Hörmann 
Direktor der Hals-Nasen-Ohren-Klinik / Clinic Director Ear,
Nose and Throat Clinic
Medical Faculty Mannheim Heidelberg University at the
University Medical Centre Mannheim
Theodor-Kutzer-Ufer 1-3
68167 Mannheim
All rights reserved. Please visit https://medical-data-
models.org/forms/13815
Visit 1 - Baseline Form
Header module
Visit number
Patient Name
Center #
Date
Patient demographics
Date of birth
Height
>= 0
cm
Weight
kg
Temperatur
°C
Blood pressure
mmHg
Systolic (1)
Diastolic (2)
Heart rate
1/sec
Gender
male (1)
female (2)
Ethnicity
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Caucasian (1)
Black (2)
Oriental/Asian (3)
Other (4)
Medical history of serious illness, accidents,
surgeries
Yes
No
Does the patient suffer from allergies?
Yes (1)
No (2)
If yes, please specify (3)
Chronic sinusitis
Symptoms persit for more than 8 weeks
(1)
Patient has had at east 4 episodes with
more than 10 symptom days/ year (2)
What kind of pretreatment has been
applied? (3)
Inclusion criteria
Initial examination including Ear, Nose and Throat
Examination
Yes
No
Patient age between 18-65
Yes
No
Patient with chronic sinusitis
Yes
No
Sinusitis symptom score
Yes
No
Sinusitis diagnostics through coronary CT
Yes
No
Patient in good general condition
Yes
No
Patient with stable intermittent asthma
Yes
No
Patient on prior medication
Yes
No
Written informed consent
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Yes
No
Footer module
no participation
Yes
No
Date and signature
Exclusion criteria
Patient who do not fulfill all inclusion criteria
Yes
No
Patient without contraception, pregnant/ breast-
feeding
Yes
No
Patient has undergone nasal operation within the
last 6 months
Yes
No
Patient with significant ECG changes
Yes
No
Patient with clinically relevant changes of vital
bodily function
Yes
No
Patient with Wegener's granulomatosis and/ or
several other diseases
Yes
No
Patient on systemic steroid therapy < 4 weeks
prior to begin of study
Yes
No
Patient on inhalable or intranasal steroid therapy
< 2 weeks prior to begin of study
Yes
No
Drug intolerance
Yes
No
Acute exacerbation of sinusitis
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Yes
No
Body Temperature
°C
Yes
No
White blood cell count
Acute Upper Respiratory Infection
Yes
No
Patient on antibiotic therapy
Yes
No
Person participating in trial
Yes
No
Exclusion Criteria
Yes
No
Physical Examination
Physical Examination
Done (1)
Not done (2)
Findings (3)
Examination of nose
Done (1)
Note done (2)
Findings (3)
Anatomic, Congenital , Surgery-induced changes
Yes
No
Nasal Polyps
Yes
No
Endoscopy
Done (1)
Note done (2)
Findings (3)
Endoscopy findings
Edema (1)
Post-nasal drip (2)
Irritation (3)
Ulceration (4)
Lund-MacKay (LM) CT scoring scale
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Maxillary Sinus (1)
Frontal Sinus  (2)
Sphenoidal sinus  (3)
Ethmoidal sinus  (4)
osteo-meatal complex (5)
Medication
Concomitant medications
Drug, please put generic name (1)
Dosage (2)
Start of medication (3)
End of medication (4)
Indication (5)
PRN Medicines
Drug (1)
Dosage (2)
Date (3)
Indication (4)
Non-drug therapy
Typ of treatment (1)
Start (2)
End (3)
Indication (4)
Signature
Laboratory
Blood test
Sodium (1)
Chorionic Gonadotropin (bHCG) (10)
Erythrocyte sedimentation rate (11)
Urea (12)
Potassium (2)
Glucose  (3)
Alanine transaminase (4)
Aspartate transaminase  (5)
Bilirubin (6)
Creatinine (7)
Phosphate  (HPO42−) (8)
CRP (9)
Rhinosinusitis Disability Index (RSBI)
Rhinosinusitis Disability Index (RSBI)
Physical (11 items) (1)
9.	Because of my problem I don’t sleep
well (10)
10.	I have difficulty with exertion due to
my nasal obstruction (11)
11.	My sexual activity is affected by my
problem (12)
Functional (9 items) (13)
1.	Because of my problem I feel
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handicapped (14)
2.	Because of my problem I feel restricted
in performance of my routine daily
activities (15)
3.	Because of my problem I restrict my
recreational activities (16)
4.	Because of my problem I feel frustrated
(17)
5.	Because of my problem I feel fatigued
(18)
6.	Because of my problem I avoid
traveling (19)
1.	The pain or pressure in my face makes
it difficult for me to concentrate (2)
7.	Because of my problem I miss work or
social activities (20)
8.	My outlook on the world is affected by
my problem (21)
9.	Because of my problem I find it difficult
to focus my attention away from my
problem and on other things (22)
Emotional (10 items) (23)
1.	Because of my problem I feel stressed
in relationships with friends and family
(24)
2.	Because of my problem I feel confused
(25)
3.	Because of my problem I have difficulty
paying attention (26)
4.	Because of my problem I avoid being
around people (27)
5.	Because of my problem I am frequently
angry (28)
6.	Because of my problem I do not like to
socialize (29)
2.	The pain in my eyes makes it difficult
for me to read (3)
7.	Because of my problem I frequently
feel tense (30)
8.	Because of my problem I frequently
feel irritable (31)
9.	Because of my problem I am
depressed (32)
10.	My problem places stress on my
relationships with members of my family
or friends (33)
3.	I have difficulty stooping over to lift
objects because of face pressure (4)
4.	Because of my problem I have difficulty
with strenuous yard work and housework
(5)
5.	Straining increases or worsens my
problem (6)
6.	I am inconvenienced by my chronic
runny nose (7)
7.	Food does not taste good because of
my change in smell (8)
8.	My frequent sniffing is irritating to my
friends and family (9)
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Study schedule - Clinical Trial on the Efficacy and Safety BID Mometasone
Furoate Nasal Spray (MFNS) in the Treatment of Chronic Sinusitis
This study evaluates the effectiveness and safety of MFNS
in improving the Treatment of Chronic Sinusitis.
ODM derived from:"Randomized Double-blind Clinical Trial
on the Efficacy and Safety of 200 mcg BID Mometasone
Furoate Nasal Spray (MFNS) or Placebo in the Treatment
of Chronic Sinusitis". 
Leader of the clinical trial: 
Prof. Dr. med. Karl Hörmann 
Direktor der Hals-Nasen-Ohren-Klinik / Clinic Director Ear,
Nose and Throat Clinic
Medical Faculty Mannheim Heidelberg University at the
University Medical Centre Mannheim
Theodor-Kutzer-Ufer 1-3
68167 Mannheim
All rights reserved. Please visit https://medical-data-
models.org/forms/13816
Study schedule
Study scheudle
examination / treatment day 1
Patient informed consent (1)
Body temperature (10)
Laboratory: Blood count, Clinical
Chemistry, Urine (11)
Serum Pregnancy Tests (all female
patients of reproductive age) (12)
Sinusitis-Symptom-Score (13)
Assessment of patient’s individual
symptoms and general examination by
treating physician  (14)
CodelistItem 802793 (15)
Assessment, if in the past or since the
last appointment an exacerbation of
sinusitis has taken place that requires an
antibiotic treatment (16)
Handing out of dairy to patient (17)
CodelistItem 802796 (18)
Rapid shallow breathing Index (RSBI)
questionnaire (Appendix 4) (19)
Evaluation inclusion/ exclusion criteria
(2)
Employability and activity impairment
questionnaire (20)
CodelistItem 802799 (21)
Collecting and weighing of study
medication (22)
Review of the patient's general medical
history, ENT specific history and allergy
history (3)
Review of simultaneously administered
medication (4)
General physical examination (5)
Assessment of coronary CT of facial
bones according to “Lund scale” (6)
Nasal examination and endoscopy (7)
Height, Weight (8)
Vital signs  (blood pressure, heart rate)
(9)
examination 2  / treatment day 8
Review of the patient's general medical
1 / 5
history, ENT specific history and
hypertensivity history (1)
Assessment, if in the past or since the
last appointment an exacerbation of
sinusitis has taken place that requires an
antibiotic treatment (10)
Handing out of diary to patient (11)
Collecting and reviewing of diary (12)
Nasal examination and endoscopy (2)
Vital signs (blood pressure, heart rate)
(3)
Body temperature (4)
Urine Pregnancy Tests (all female
patients of reproductive age) (5)
Sinusitis-Symptom-Score (6)
Assessment of patient’s individual
symptoms and general examination by
treating physician  (7)
Assessment of therapeutic effects by
patient (8)
Evaluation of adverse events (9)
examination 3 / treatment day 28
Review of the patient's general medical
history, ENT specific history and
hypertensivity history (1)
Assessment, if in the past or since the
last appointment an exacerbation of
sinusitis has taken place that requires an
antibiotic treatment (10)
Handing out of diary to patient (11)
Collecting and reviewing of diary (12)
Nasal examination and endoscopy (2)
Vital signs (blood pressure, heart rate)
(3)
Body temperature (4)
Urine Pregnancy Tests (all female
patients of reproductive age) (5)
Sinusitis-Symptom-Score (6)
Assessment of patient’s individual
symptoms and general examination by
treating physician  (7)
Assessment of therapeutic effects by
patient (8)
Evaluation of adverse events (9)
examination 4  / treatment day 56
Review of the patient's general medical
history, ENT specific history and
hypertensivity history (1)
Assessment, if in the past or since the
last appointment an exacerbation of
sinusitis has taken place that requires an
antibiotic treatment (10)
Handing out of dairy to patient (11)
Collecting and reviewing of diary (12)
RSBI questionnaire (Appendix 4) (13)
Collecting and weighing of study
medication  (14)
Handing out study medication to patient
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(15)
Employability and activity impairment
questionnaire (16)
Nasal examination and endoscopy (2)
Vital signs (blood pressure, heart rate)
(3)
Body temperature (4)
Urine Pregnancy Tests (all female
patients of reproductive age) (5)
Sinusitis-Symptom-Score (6)
Assessment of patient’s individual
symptoms and general examination by
treating physician  (7)
Assessment of therapeutic effects by
patient (8)
Evaluation of adverse events (9)
examination 5 / treatment day 84
Review of the patient's general medical
history, ENT specific history and
hypertensivity history (1)
Assessment, if in the past or since the
last appointment an exacerbation of
sinusitis has taken place that requires an
antibiotic treatment (10)
Handing out of dairy to patient (11)
Collecting and reviewing of diary (12)
RSBI questionnaire (Appendix 4) (13)
Collecting and weighing of study
medication  (14)
Handing out study medication to patient
(15)
Employability and activity impairment
questionnaire (16)
Nasal examination and endoscopy (2)
Vital signs (blood pressure, heart rate)
(3)
Body temperature (4)
Urine Pregnancy Tests (all female
patients of reproductive age) (5)
Sinusitis-Symptom-Score (6)
Assessment of patient’s individual
symptoms and general examination by
treating physician  (7)
Assessment of therapeutic effects by
patient (8)
Evaluation of adverse events (9)
examination 6 / treatment day 112
Review of the patient's general medical
history, ENT specific history and
hypertensivity history (1)
Assessment, if in the past or since the
last appointment an exacerbation of
sinusitis has taken place that requires an
antibiotic treatment (10)
Handing out of dairy to patient (11)
Collecting and reviewing of diary (12)
RSBI questionnaire (Appendix 4) (13)
Collecting and weighing of study
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medication  (14)
Handing out study medication to patient
(15)
Employability and activity impairment
questionnaire (16)
Satisfaction questionnaire (17)
Laboratory: Blood count, Clinical
Chemistry, Urine (18)
Nasal examination and endoscopy (2)
Vital signs (blood pressure, heart rate)
(3)
Body temperature (4)
Serume Pregnancy Tests (all female
patients of reproductive age) (5)
Sinusitis-Symptom-Score (6)
Assessment of patient’s individual
symptoms and general examination by
treating physician  (7)
Assessment of therapeutic effects by
patient (8)
Evaluation of adverse events (9)
Concomitant medication
Concomitant medication
low dose aspirin for cardiac prevention,
up to 325 mg daily (1)
oral or inhalative beta antagonists
(against asthma) (10)
CodelistItem 802885 (11)
Other drugs may be used during the trial
unless they are excluded by the protocol,
e.g. Central nervous system agents,
hormones, diabetes medication,
nonsteroidal ophthalmic drugs (12)
Paracetamol if needed (Paracetamol is
the recommended analgesic. If this is no
sufficient, NSAID may be used
restrictedly; NSAID treatment may not
exceed 5 consecutive days) (2)
Contraceptive, Norplant (3)
Low to medium potency (group 4-7)
topical steroids (Stoughton-Cornell-
Scale) for dermatological purposes (4)
topical vaginal therapeutics against
candidiasis (5)
CodelistItem 802880 (6)
The following medication have to, if
needed, be taken according to a rigid
treatment plan (7)
oral or inhalative cromolyn or
necrodormil (against asthma) (8)
oral or inhalative theophylline (against
asthma) (9)
Prohibited Medication
corticosteroids: oral, IV, rectal (1)
Cetrizin, Fexofenadin (10)
Astemizol (11)
4 / 5
Study schedule - Clinical Trial on the Efficacy and Safety BID Mometasone
Furoate Nasal Spray (MFNS) in the Treatment of Chronic Sinusitis
Accolate, Singulair, Zileuton (12)
decongestion drug/ vasoconstrictor:
short-acting versions of
pseudoephedrine: oral, topical, nasal,
intranasal (13)
topical nasal, oral or ocular anti-
inflammatory drugs (14)
nasal Cromolyn (15)
nasal atropine or ipratropiumbromid (16)
nonsteroidal antiinflammatory drugs (17)
topical nasal or oral antifungal agents
(18)
Guaifenesin (19)
corticosteroids: Intra-articular /
Intramuscular (2)
corticosteroids: intranasal (3)
corticosteroids: inhalable (4)
potent to super potent corticosteroids
(Stoughton-Cornell-Scale )for
dermatological purposes (5)
antihistamines, Short-acting (e.g.
Chlorphenamine) (6)
Clemastine, long-acting (7)
long-acting antihistamines (e.g.
Loratadin, Terfenadin, Hydroxyzin) (8)
long-acting antihistamines (e.g.
Azelastin) (9)
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Visit 5 - Clinical Trial on the Efficacy and Safety BID Mometasone
Furoate Nasal Spray (MFNS) in the Treatment of Chronic Sinusitis
This study evaluates the effectiveness and safety of MFNS
in improving the Treatment of Chronic Sinusitis.
ODM derived from:"Randomized Double-blind Clinical Trial
on the Efficacy and Safety of 200 mcg BID Mometasone
Furoate Nasal Spray (MFNS) or Placebo in the Treatment
of Chronic Sinusitis". 
Leader of the clinical trial: 
Prof. Dr. med. Karl Hörmann 
Direktor der Hals-Nasen-Ohren-Klinik / Clinic Director Ear,
Nose and Throat Clinic
Medical Faculty Mannheim Heidelberg University at the
University Medical Centre Mannheim
Theodor-Kutzer-Ufer 1-3
68167 Mannheim
All rights reserved. Please visit https://medical-data-
models.org/forms/13817
Visit 5
Header module
Visit Number
Patient Name
Center #
Date
Examination
Temperature
°C
Blood pressure
Diastolic ( 2)
Systolic (1)
Heart rate
1/sec
Examination of nose
Done (1)
Note done (2)
Finding (3)
Change of sinusitis since last visit
Were Antibiotics administered?
Endoscopy
Done, please state date (1)
Not done (2)
Findings (3)
Endoscopy findings
1 / 2
edema (1)
flow of secretion (2)
irritation  (3)
ulceration (4)
Urine pregnancy test
Result (1)
Not done (2)
Medication checked and weighed?
Dairy checked?
Yes
No
Medication
Concomitant drug
Drug name (1)
Dosage (2)
Start of medication (3)
End of medication (4)
Indication (5)
PRN medicine
Drug (1)
Dosage (2)
Date (3)
Indication (4)
Non-drug therapy
Typ of treatment (1)
Start (2)
End (3)
Indication (4)
Adverse event
Did an adverse event occur?
Is this a serious adverse event ?
Adverse event form
Description of adverse event icd (1)
Date and time of adverse event (2)
Previously in CRF documted (3)
Progress (4)
Related to study drug? (5)
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Visit 6 - Clinical Trial on the Efficacy and Safety BID Mometasone
Furoate Nasal Spray (MFNS) in the Treatment of Chronic Sinusitis
This study evaluates the effectiveness and safety of MFNS
in improving the Treatment of Chronic Sinusitis.
ODM derived from:"Randomized Double-blind Clinical Trial
on the Efficacy and Safety of 200 mcg BID Mometasone
Furoate Nasal Spray (MFNS) or Placebo in the Treatment
of Chronic Sinusitis". 
Leader of the clinical trial: 
Prof. Dr. med. Karl Hörmann 
Direktor der Hals-Nasen-Ohren-Klinik / Clinic Director Ear,
Nose and Throat Clinic
Medical Faculty Mannheim Heidelberg University at the
University Medical Centre Mannheim
Theodor-Kutzer-Ufer 1-3
68167 Mannheim
All rights reserved. Please visit https://medical-data-
models.org/forms/13818
Visit 6
Header module
Visit Number
Patient Name
Center #
Date
Examination
Temperature
°C
Blood pressure
Diastolic ( 2)
Systolic (1)
Heart rate
1/sec
Examination of nose
Done (1)
Note done (2)
Finding (3)
Anatomical / congenital/ operation induced
changes?
Were Antibiotics administered?
Endoscopy
Done, please state date (1)
Not done (2)
Findings (3)
1 / 5
Endoscopy findings
edema (1)
flow of secretion (2)
irritation  (3)
ulceration (4)
Urine pregnancy test
Result (1)
Not done (2)
Medication collected?
Diary collected?
Yes
No
Medication
Concomitant drug
Drug name (1)
Dosage (2)
Start of medication (3)
End of medication (4)
Indication (5)
PRN medicine
Drug (1)
Dosage (2)
Date (3)
Indication (4)
Non-drug therapy
Typ of treatment (1)
Start (2)
End (3)
Indication (4)
Adverse event
Did an adverse event occur?
Is this a serious adverse event ?
Adverse event form
Description of adverse event icd (1)
Date and time of adverse event (2)
Previously in CRF documted (3)
Progress (4)
Related to study drug? (5)
Rhinosinusitis Disability Index (RSBI)
(RSBI) Rhinosinusitis Disability Index (RSBI)
Physical (11 items) (1)
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9.	Because of my problem I don’t sleep
well (10)
10.	I have difficulty with exertion due to
my nasal obstruction (11)
11.	My sexual activity is affected by my
problem (12)
Functional (9 items) (13)
1.	Because of my problem I feel
handicapped (14)
2.	Because of my problem I feel restricted
in performance of my routine daily
activities (15)
3.	Because of my problem I restrict my
recreational activities (16)
4.	Because of my problem I feel frustrated
(17)
5.	Because of my problem I feel fatigued
(18)
6.	Because of my problem I avoid
traveling (19)
1.	The pain or pressure in my face makes
it difficult for me to concentrate (2)
7.	Because of my problem I miss work or
social activities (20)
8.	My outlook on the world is affected by
my problem (21)
9.	Because of my problem I find it difficult
to focus my attention away from my
problem and on other things (22)
Emotional (10 items) (23)
1.	Because of my problem I feel stressed
in relationships with friends and family
(24)
2.	Because of my problem I feel confused
(25)
3.	Because of my problem I have difficulty
paying attention (26)
4.	Because of my problem I avoid being
around people (27)
5.	Because of my problem I am frequently
angry (28)
6.	Because of my problem I do not like to
socialize (29)
2.	The pain in my eyes makes it difficult
for me to read (3)
7.	Because of my problem I frequently
feel tense (30)
8.	Because of my problem I frequently
feel irritable (31)
9.	Because of my problem I am
depressed (32)
10.	My problem places stress on my
relationships with members of my family
or friends (33)
3.	I have difficulty stooping over to lift
objects because of face pressure (4)
4.	Because of my problem I have difficulty
with strenuous yard work and housework
(5)
5.	Straining increases or worsens my
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problem (6)
6.	I am inconvenienced by my chronic
runny nose (7)
7.	Food does not taste good because of
my change in smell (8)
8.	My frequent sniffing is irritating to my
friends and family (9)
Impairment due to chronic sinusitis
Laboratory
Blood test
Sodium (1)
Chorionic Gonadotropin (bHCG) (10)
Erythrocyte sedimentation rate (11)
Urea (12)
Potassium (2)
Glucose  (3)
Alanine transaminase (4)
Aspartate transaminase  (5)
Bilirubin (6)
Creatinine (7)
Phosphate  (HPO42−) (8)
CRP (9)
Urinalysis
Urine screening for blood  (1)
Urine leukocytes finding  (2)
Urine pregnancy test  (3)
Microscopic urinalysis  (4)
Overall assessment of the treatment
Overall therapy evaluation
Efficacy  (1)
Adverse events (2)
Assessment of treatment satisfaction
Treatment satisfaction
extremely satisfied (1)
very satisfied (2)
somewhat satisfied (3)
somewhat unsatisfied (4)
very unsatisfied (5)
extremely unsatisfied (6)
Would you be willing to take this medication for
the treatment of chronic sinusitis again?
Yes
No
Would you recommend this treatment of the
chronic sinusitis to other patients?
I would definitely recommend it (1)
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I would likely recommend it (2)
I am not sure (3)
I would likely not recommend it (4)
I would definitely not recommend it (5)
Final report
Reason for discontinuation of trial
study terminated as scheduled (1)
adverse event (2)
serious study protocol deviation (3)
lack of efficacy (4)
reasons that are not linked to the study
(5)
loss of contact (6)
other, please specify (7)
End of study date and time
Study terminated by
Patient (1)
Sponsor (2)
Study director (3)
Confirmation of study results
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Visit 4 - Clinical Trial on the Efficacy and Safety BID Mometasone
Furoate Nasal Spray (MFNS) in the Treatment of Chronic Sinusitis
This study evaluates the effectiveness and safety of MFNS
in improving the Treatment of Chronic Sinusitis.
ODM derived from:"Randomized Double-blind Clinical Trial
on the Efficacy and Safety of 200 mcg BID Mometasone
Furoate Nasal Spray (MFNS) or Placebo in the Treatment
of Chronic Sinusitis". 
Leader of the clinical trial: 
Prof. Dr. med. Karl Hörmann 
Direktor der Hals-Nasen-Ohren-Klinik / Clinic Director Ear,
Nose and Throat Clinic
Medical Faculty Mannheim Heidelberg University at the
University Medical Centre Mannheim
Theodor-Kutzer-Ufer 1-3
68167 Mannheim
All rights reserved. Please visit https://medical-data-
models.org/forms/13819
Visit 4
Header module
Visit Number
Patient Name
Center #
Date
Examination
Temperature
°C
Blood pressure
Diastolic ( 2)
Systolic (1)
Heart rate
1/sec
Examination of nose
Done (1)
Note done (2)
Finding (3)
Change of sinusitis since last visit
Were Antibiotics administered?
Endoscopy
Done, please state date (1)
Not done (2)
Findings (3)
Endoscopy findings
1 / 4
edema (1)
flow of secretion (2)
irritation  (3)
ulceration (4)
Urine pregnancy test
Result (1)
Medication checked and weighed?
Dairy checked?
Yes
No
Rhinosinusitis Disability Index (RSBI)
Rhinosinusitis Disability Index (RSBI)
Physical (11 items) (1)
9.	Because of my problem I don’t sleep
well (10)
10.	I have difficulty with exertion due to
my nasal obstruction (11)
11.	My sexual activity is affected by my
problem (12)
Functional (9 items) (13)
1.	Because of my problem I feel
handicapped (14)
2.	Because of my problem I feel restricted
in performance of my routine daily
activities (15)
3.	Because of my problem I restrict my
recreational activities (16)
4.	Because of my problem I feel frustrated
(17)
5.	Because of my problem I feel fatigued
(18)
6. Because of my problem I avoid
traveling (19)
1.	The pain or pressure in my face makes
it difficult for me to concentrate (2)
7.	Because of my problem I miss work or
social activities (20)
8.	My outlook on the world is affected by
my problem (21)
9.	Because of my problem I find it difficult
to focus my attention away from my
problem and on other things (22)
Emotional (10 items) (23)
1.	Because of my problem I feel stressed
in relationships with friends and family
(24)
2.	Because of my problem I feel confused
(25)
3.	Because of my problem I have difficulty
paying attention (26)
4.	Because of my problem I avoid being
around people (27)
5.	Because of my problem I am frequently
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angry (28)
6.	Because of my problem I do not like to
socialize (29)
2.	The pain in my eyes makes it difficult
for me to read (3)
7.	Because of my problem I frequently
feel tense (30)
38.	Because of my problem I frequently
feel irritable (31)
9.	Because of my problem I am
depressed (32)
10.My problem places stress on my
relationships with members of my family
or friends (33)
3.	I have difficulty stooping over to lift
objects because of face pressure (4)
4.	Because of my problem I have difficulty
with strenuous yard work and housework
(5)
5.	Straining increases or worsens my
problem (6)
6.	I am inconvenienced by my chronic
runny nose (7)
7.	Food does not taste good because of
my change in smell (8)
8.	My frequent sniffing is irritating to my
friends and family (9)
Impairment due to chronic sinusitis
Medication
Concomitant drug
Drug name (1)
Dosage (2)
Start of medication (3)
End of medication (4)
Indication (5)
PRN medicine
Drug (1)
Dosage (2)
Date (3)
Indication (4)
Non-drug therapy
Typ of treatment (1)
Start (2)
End (3)
Indication (4)
Adverse event
Did an adverse event occur?
Is this a serious adverse event ?
3 / 4
Visit 4 - Clinical Trial on the Efficacy and Safety BID Mometasone
Furoate Nasal Spray (MFNS) in the Treatment of Chronic Sinusitis
Adverse event form
Description of adverse event icd (1)
Date and time of adverse event (2)
Previously in CRF documted (3)
Progress (4)
Related to study drug? (5)
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Visit 3 - Clinical Trial on the Efficacy and Safety BID Mometasone
Furoate Nasal Spray (MFNS) in the Treatment of Chronic Sinusitis
This study evaluates the effectiveness and safety of MFNS
in improving the Treatment of Chronic Sinusitis.
ODM derived from:"Randomized Double-blind Clinical Trial
on the Efficacy and Safety of 200 mcg BID Mometasone
Furoate Nasal Spray (MFNS) or Placebo in the Treatment
of Chronic Sinusitis". 
Leader of the clinical trial: 
Prof. Dr. med. Karl Hörmann 
Direktor der Hals-Nasen-Ohren-Klinik / Clinic Director Ear,
Nose and Throat Clinic
Medical Faculty Mannheim Heidelberg University at the
University Medical Centre Mannheim
Theodor-Kutzer-Ufer 1-3
68167 Mannheim
All rights reserved. Please visit https://medical-data-
models.org/forms/13820
Visit 3
Header module
Visit Number
Patient Name
Center #
Date
Examination
Temperature
°C
Blood pressure
Diastolic ( 2)
Systolic (1)
Heart rate
1/sec
Examination of nose
Done (1)
Note done (2)
Finding (3)
Change of sinusitis since last visit
Were Antibiotics administered?
Endoscopy
Done, please state date (1)
Not done (2)
Findings (3)
Endoscopy findings
1 / 2
edema (1)
flow of secretion (2)
irritation  (3)
ulceration (4)
Urine pregnancy test
Result (1)
Medication checked and weighed?
Dairy checked?
Yes
No
Medication
Concomitant drug
Drug name (1)
Dosage (2)
Start of medication (3)
End of medication (4)
Indication (5)
PRN medicine
Drug (1)
Dosage (2)
Date (3)
Indication (4)
Non-drug therapy
Typ of treatment (1)
Start (2)
End (3)
Indication (4)
Adverse event
Did an adverse event occur?
Is this a serious adverse event ?
Adverse event form
Description of adverse event icd (1)
Date and time of adverse event (2)
Previously in CRF documted (3)
Progress (4)
Related to study drug? (5)
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Visit 2 - Clinical Trial on the Efficacy and Safety BID Mometasone
Furoate Nasal Spray (MFNS) in the Treatment of Chronic Sinusitis
This study evaluates the effectiveness and safety of MFNS
in improving the Treatment of Chronic Sinusitis.
ODM derived from:"Randomized Double-blind Clinical Trial
on the Efficacy and Safety of 200 mcg BID Mometasone
Furoate Nasal Spray (MFNS) or Placebo in the Treatment
of Chronic Sinusitis". 
Leader of the clinical trial: 
Prof. Dr. med. Karl Hörmann 
Direktor der Hals-Nasen-Ohren-Klinik / Clinic Director Ear,
Nose and Throat Clinic
Medical Faculty Mannheim Heidelberg University at the
University Medical Centre Mannheim
Theodor-Kutzer-Ufer 1-3
68167 Mannheim
All rights reserved. Please visit https://medical-data-
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Visit 2
Header module
Visit Number
Patient Name
Center #
Date
Examination
Temperature
°C
Blood pressure
Systolic (1)
Diastolic (2)
Heart rate
1/sec
Examination of nose
Done (1)
Note done (2)
Finding (3)
Change of sinusitis since last visit
Yes (1)
No (2)
If yes, please specify (3)
Were Antibiotics administered?
Yes
No
Endoscopy
Done (1)
1 / 3
Note done (2)
Findings (3)
Endoscopy findings
edema (1)
flow of secretion (2)
irritation  (3)
ulceration (4)
Urine pregnancy test
Result (1)
Dairy
Yes
No
Concomitant drug
Concomitant drug
Drug name (1)
Dosage (2)
Start of medication (3)
End of medication (4)
Indication (5)
PRN Medicine
PRN medicine
Drug (1)
Dosage (2)
Date (3)
Indication (4)
Non-drug therapy
Typ of treatment (1)
Start (2)
End (3)
Indication (4)
Adverse event
Did an adverse event occur?
Yes
No
Is this a serious adverse event
Yes
No
Adverse event form
Description of adverse event icd (1)
Date and time of adverse event (2)
Previously in CRF documted (3)
Progress (4)
Related to study drug? (5)
Countermeasures, progress,assessment and
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outcome of AE
Did a serious adverse event occur during the
treatment?
Yes
No
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Visit 1 - Clinical Trial on the Efficacy and Safety BID Mometasone
Furoate Nasal Spray (MFNS) in the Treatment of Chronic Sinusitis
This study evaluates the effectiveness and safety of MFNS
in improving the Treatment of Chronic Sinusitis.
ODM derived from:"Randomized Double-blind Clinical Trial
on the Efficacy and Safety of 200 mcg BID Mometasone
Furoate Nasal Spray (MFNS) or Placebo in the Treatment
of Chronic Sinusitis". 
Leader of the clinical trial: 
Prof. Dr. med. Karl Hörmann 
Direktor der Hals-Nasen-Ohren-Klinik / Clinic Director Ear,
Nose and Throat Clinic
Medical Faculty Mannheim Heidelberg University at the
University Medical Centre Mannheim
Theodor-Kutzer-Ufer 1-3
68167 Mannheim
All rights reserved. Please visit https://medical-data-
models.org/forms/13822
Visit 1 - Baseline Form
Header module
Visit number
Patient Name
Center #
Date
Patient demographics
Date of birth
Height
>= 0
cm
Weight
kg
Temperatur
°C
Blood pressure
mmHg
Systolic (1)
Diastolic (2)
Heart rate
1/sec
Gender
male (1)
female (2)
Ethnicity
1 / 7
Caucasian (1)
Black (2)
Oriental/Asian (3)
Other (4)
Medical history of serious illness, accidents,
surgeries
Yes
No
Does the patient suffer from allergies?
Yes (1)
No (2)
If yes, please specify (3)
Chronic sinusitis
Symptoms persit for more than 8 weeks
(1)
Patient has had at least 4 episodes with
more than 10 symptom days per year (2)
What kind of pre-treatment has been
applied? (3)
Inclusion criteria
Initial examination including Ear, Nose and Throat
Examination
Yes
No
Patient age between 18-65
Yes
No
Patient with chronic sinusitis
Yes
No
Sinusitis symptom score
Yes
No
Sinusitis diagnostics through coronary CT
Yes
No
Patient in good general condition
Yes
No
Patient with stable intermittent asthma
Yes
No
Patient on prior medication
Yes
No
Written informed consent
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Yes
No
Exclusion criteria
Patient who do not fulfill all inclusion criteria
Yes
No
Patient without contraception, pregnant/ breast-
feeding
Yes
No
Patient has undergone nasal operation within the
last 6 months
Yes
No
Patient with significant ECG changes
Yes
No
Patient with clinically relevant changes of vital
bodily function
Yes
No
Patient with Wegener's granulomatosis and/ or
several other diseases
Yes
No
Patient on systemic steroid therapy < 4 weeks
prior to begin of study
Yes
No
Patient on inhalable or intranasal steroid therapy
< 2 weeks prior to begin of study
Yes
No
Drug intolerance
Yes
No
Acute exacerbation of sinusitis
Yes
No
Body Temperature
°C
Yes
No
White blood cell count
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Acute Upper Respiratory Infection
Yes
No
Patient on antibiotic therapy
Yes
No
Person participating in trial
Yes
No
Exclusion Criteria
Yes
No
Physical Examination
Physical Examination
Done (1)
Not done (2)
Findings (3)
Examination of nose
Done (1)
Note done (2)
Findings (3)
Anatomic, Congenital , Surgery-induced changes
Yes
No
Nasal Polyps
Yes
No
Endoscopy
Done (1)
Note done (2)
Findings (3)
Endoscopy findings
Edema (1)
Post-nasal drip (2)
Irritation (3)
Ulceration (4)
Lund-MacKay (LM) CT scoring scale
Maxillary Sinus (1)
Frontal Sinus  (2)
Sphenoidal sinus  (3)
Ethmoidal sinus  (4)
osteo-meatal complex (5)
Medication
Concomitant medications
Drug, please put generic name (1)
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Dosage (2)
Start of medication (3)
End of medication (4)
Indication (5)
PRN Medicines
Drug (1)
Dosage (2)
Date (3)
Indication (4)
Non-drug therapy
Typ of treatment (1)
Start (2)
End (3)
Indication (4)
Signature
Laboratory
Blood test
Sodium (1)
Chorionic Gonadotropin (bHCG) (10)
Erythrocyte sedimentation rate (11)
Urea (12)
Potassium (2)
Glucose  (3)
Alanine transaminase (4)
Aspartate transaminase  (5)
Bilirubin (6)
Creatinine (7)
Phosphate  (HPO42−) (8)
CRP (9)
Rhinosinusitis Disability Index (RSBI)
Rhinosinusitis Disability Index (RSBI)
Physical (11 items) (1)
9.	Because of my problem I don’t sleep
well (10)
10.	I have difficulty with exertion due to
my nasal obstruction (11)
11.	My sexual activity is affected by my
problem (12)
Functional (9 items) (13)
1.	Because of my problem I feel
handicapped (14)
2.	Because of my problem I feel restricted
in performance of my routine daily
activities (15)
3.	Because of my problem I restrict my
recreational activities (16)
4.	Because of my problem I feel frustrated
(17)
5.	Because of my problem I feel fatigued
(18)
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6.	Because of my problem I avoid
traveling (19)
1.	The pain or pressure in my face makes
it difficult for me to concentrate (2)
7.	Because of my problem I miss work or
social activities (20)
8.	My outlook on the world is affected by
my problem (21)
9.	Because of my problem I find it difficult
to focus my attention away from my
problem and on other things (22)
Emotional (10 items) (23)
1.	Because of my problem I feel stressed
in relationships with friends and family
(24)
2.	Because of my problem I feel confused
(25)
3.	Because of my problem I have difficulty
paying attention (26)
4.	Because of my problem I avoid being
around people (27)
5.	Because of my problem I am frequently
angry (28)
6.	Because of my problem I do not like to
socialize (29)
2.	The pain in my eyes makes it difficult
for me to read (3)
7.	Because of my problem I frequently
feel tense (30)
8.	Because of my problem I frequently
feel irritable (31)
9.	Because of my problem I am
depressed (32)
10.	My problem places stress on my
relationships with members of my family
or friends (33)
3.	I have difficulty stooping over to lift
objects because of face pressure (4)
4.	Because of my problem I have difficulty
with strenuous yard work and housework
(5)
5.	Straining increases or worsens my
problem (6)
6.	I am inconvenienced by my chronic
runny nose (7)
7.	Food does not taste good because of
my change in smell (8)
8.	My frequent sniffing is irritating to my
friends and family (9)
Impairment due to chronic sinusitis
Footer module
no participation
Yes
No
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Date and signature
7 / 7
Visit 1 - Clinical Trial on the Efficacy and Safety BID Mometasone
Furoate Nasal Spray (MFNS) in the Treatment of Chronic Sinusitis
Follow up EBMT MDS
ODM derived from HSCT forms on http://www.ebmt.org/
All rights reserved. Please visit https://medical-data-
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Follow up EBMT MDS
Follow up - Please use this form for
annual follow up only and not data at 100
days, which is already included in the first
report
Unique Identification Code (UIC)
(if known)
Date of this report
Patient following national/ international study/trial
No (No)
Unknown (Unknown)
Yes (Yes)
If yes, specify:
Hospital Unique Patient Number
First name(s)_surname(s)
Date of birth
Date of last HSCT for this patient
Patient last seen
Date of last contact or death
Graft versus Host Disease (GvHD) since
last report
Acute Graft versus Host Disease (aGvHD) -
Maximum grade
grade 0 (absent) (grade 0 (absent))
grade I (grade I)
grade II (grade II)
grade III (grade III)
grade IV (grade IV)
not evaluated (not evaluated)
If present, specify:
New onset (New onset)
Persistent (Persistent)
Recurrent (Recurrent)
If present, specify reason:
DLI (DLI)
Tapering (Tapering)
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Unexplained (Unexplained)
If yes, specify date of onset of this episode
(if new or recurrent and applicable)
If yes, specify stage skin:
0 (0)
1 (1)
2 (2)
3 (3)
4 (4)
Not evaluated (Not evaluated)
unknown (unknown)
If yes, specify stage liver:
0 (0)
1 (1)
2 (2)
3 (3)
4 (4)
Not evaluated (Not evaluated)
unknown (unknown)
If yes, specify stage gut:
0 (0)
1 (1)
2 (2)
3 (3)
4 (4)
Not evaluated (Not evaluated)
unknown (unknown)
Resolution
Yes
No
If resolution, specify date:
Presence of cGvHD
No (No)
Present continuously since last reported
episode (Present continuously since last
reported episode)
Resolved (Resolved)
Yes (Yes)
If yes, specify:
First episode (First episode)
Recurrence (Recurrence)
If yes, specify date of onset:
If present continuously since last reported
episode, specify cGvHD grade:
Extensive (Extensive)
Limited (Limited)
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If present continuously since last reported
episode, specify which organs are affected:
Eyes (Eyes)
Gut (Gut)
Liver (Liver)
Lung (Lung)
Mouth (Mouth)
Other (Other)
Skin (Skin)
Unknown (Unknown)
If present continuously since last reported
episode, specify others:
If resolved, specify date of resolution:
Other Complications since last report
(please use the document "Definitions of
infectious diseases and complications
after stem cell transplantation" to fill these
items.)
Infection related complications
Yes
No
If yes, specify the type (bacteriaemia/ fungemia/
viremia/ parasites)
(General)
Adenovirus (Adenovirus)
Aspergillus sp (Aspergillus sp)
Bacteria: (Bacteria:)
Candida sp (Candida sp)
CMV (CMV)
EBV (EBV)
Fungi: (Fungi:)
Haemophilus influenza (Haemophilus
influenza)
HBV (HBV)
HCV (HCV)
HHV-6 (HHV-6)
HIV (HIV)
HSV (HSV)
Legionella sp (Legionella sp)
Mycobacteria sp (Mycobacteria sp)
Other (Other)
Other (Other)
Other (Other)
Other (Other)
Other gram negative (i.e. E.coli,
klebsiella, proteus, serratia,
pseudomonas,...) (Other gram negative
(i.e. E.coli, klebsiella, proteus, serratia,
pseudomonas,...))
Other gram positive (i.e. other
streptococci, staphylococci, listeria,...)
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(Other gram positive (i.e. other
streptococci, staphylococci, listeria,...))
Other respiratory virus (influenza,
parainfluezna, rhinovirus) (Other
respiratory virus (influenza,
parainfluezna, rhinovirus))
Papovirus (Papovirus)
Parasites: (Parasites:)
Parovirus (Parovirus)
Pneumocystis carinii (Pneumocystis
carinii)
RSV (RSV)
S. pneumoniae (S. pneumoniae)
Toxoplasma gondii (Toxoplasma gondii)
Viruses: (Viruses:)
VZV (VZV)
If other, specify (general):
Specify the date of the episode
(General)
Systemic Symptoms of Infections
ARDS (ARDS)
Multiorgan failure due to infection
(Multiorgan failure due to infection)
Septic shock (Septic shock)
Systemic Symptoms of Infections:
specify the type (bacteriaemia/ fungemia/
viremia/ parasites)
Adenovirus (Adenovirus)
Aspergillus sp (Aspergillus sp)
Bacteria: (Bacteria:)
Candida sp (Candida sp)
CMV (CMV)
EBV (EBV)
Fungi: (Fungi:)
Haemophilus influenza (Haemophilus
influenza)
HBV (HBV)
HCV (HCV)
HHV-6 (HHV-6)
HIV (HIV)
HSV (HSV)
Legionella sp (Legionella sp)
Mycobacteria sp (Mycobacteria sp)
Other (Other)
Other (Other)
Other (Other)
Other (Other)
Other gram negative (i.e. E.coli,
klebsiella, proteus, serratia,
pseudomonas,...) (Other gram negative
(i.e. E.coli, klebsiella, proteus, serratia,
pseudomonas,...))
Other gram positive (i.e. other
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streptococci, staphylococci, listeria,...)
(Other gram positive (i.e. other
streptococci, staphylococci, listeria,...))
Other respiratory virus (influenza,
parainfluezna, rhinovirus) (Other
respiratory virus (influenza,
parainfluezna, rhinovirus))
Papovirus (Papovirus)
Parasites: (Parasites:)
Parovirus (Parovirus)
Pneumocystis carinii (Pneumocystis
carinii)
RSV (RSV)
S. pneumoniae (S. pneumoniae)
Toxoplasma gondii (Toxoplasma gondii)
Viruses: (Viruses:)
VZV (VZV)
Systemic symptoms of infection:
if other, specify:
Systemic symptoms of infection:
Specify the date of the episode
Endorgan diseases
CNS infection (CNS infection)
Cystitis (Cystitis)
Gut infection (Gut infection)
Hepatits (Hepatits)
Other (Other)
Pneumonia (Pneumonia)
Retinitis (Retinitis)
Skin infection (Skin infection)
Endorgan disease:
specify the type (bacteriaemia/ fungemia/
viremia/ parasites)
Adenovirus (Adenovirus)
Aspergillus sp (Aspergillus sp)
Bacteria: (Bacteria:)
Candida sp (Candida sp)
CMV (CMV)
EBV (EBV)
Fungi: (Fungi:)
Haemophilus influenza (Haemophilus
influenza)
HBV (HBV)
HCV (HCV)
HHV-6 (HHV-6)
HIV (HIV)
HSV (HSV)
Legionella sp (Legionella sp)
Mycobacteria sp (Mycobacteria sp)
Other (Other)
Other (Other)
Other (Other)
Other (Other)
Other gram negative (i.e. E.coli,
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klebsiella, proteus, serratia,
pseudomonas,...) (Other gram negative
(i.e. E.coli, klebsiella, proteus, serratia,
pseudomonas,...))
Other gram positive (i.e. other
streptococci, staphylococci, listeria,...)
(Other gram positive (i.e. other
streptococci, staphylococci, listeria,...))
Other respiratory virus (influenza,
parainfluezna, rhinovirus) (Other
respiratory virus (influenza,
parainfluezna, rhinovirus))
Papovirus (Papovirus)
Parasites: (Parasites:)
Parovirus (Parovirus)
Pneumocystis carinii (Pneumocystis
carinii)
RSV (RSV)
S. pneumoniae (S. pneumoniae)
Toxoplasma gondii (Toxoplasma gondii)
Viruses: (Viruses:)
VZV (VZV)
Endorgan diseases:
If other, specify:
Endorgan diseases: 
Specify the date of the episode
Non infection related complications
Yes
No
If yes, specify:
Idiopathic pneumonia syndrome
No (No)
Unknown (Unknown)
Yes (Yes)
If yes, specify: 
Idiopathic pneumonia syndrome
Date of onset
Specify: 
VOD
No  (No )
Unknown (Unknown)
Yes (Yes)
If yes, specify: 
VOD
Date of onset
Specify:
Cataract
No (No)
Unknown (Unknown)
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Yes (Yes)
If yes, specify:
Cataract
Date of onset
Specify:
Haemorrhagic cystitis, non infectious
No  (No )
Unknown (Unknown)
Yes  (Yes )
If yes, specify:
Haemorrhagic cystitis, non infectious
Date of onset
Specify:
ARDS, non infectious
No (No)
Unknown (Unknown)
Yes (Yes)
If yes, specify:
ARDS, non infectious
Date of onset
Specify:
Multiorgan-failre, non infectious
No  (No )
Unknown (Unknown)
Yes (Yes)
If yes, specify: 
Multiorgan-failre, non infectious
Date of onset
Specify:
HSCT-associated microangiopathy
No (No)
Unknown (Unknown)
Yes (Yes)
If yes, specify:
HSCT-associated microangiopathy
Date of onset
Specify:
Renal failure requiring dialysis
No (No)
Unknown (Unknown)
Yes (Yes)
If yes, specify:
Renal failure requiring dialysis
Date of onset
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Specify:
Haemolytic anaemia due to blood group
No (No)
Unknown (Unknown)
Yes (Yes)
If yes, specify:
Haemolytic anaemia due to blood group
Date of onset
Specify:
Aseptic bone necrosis
No (No)
Unknown (Unknown)
Yes (Yes)
If yes, specify:
Aseptic bone necrosis
Date of onset
Specify:
Other
If other:
Date of onset
Graft loss
No (No)
Not evaluated (Not evaluated)
Yes (Yes)
Overall chimaerism
Aplasia (Aplasia)
95%) (Autologuos reconstitution
(recipient >)
95%) (Full (donor >)
Mixed (partial) (Mixed (partial))
Not evaluated (Not evaluated)
Graft assessment and Haemopoietic
chimaerism
Date of test
(Indicate the date(s) and results of all tests done
for all donors. Split the results by donor and by
the cell type on which the test was performed if
applicable. Copy this table as many times as
necessary.)
Identification of donor or Cord Blood Unit given
by the centre
(Indicate the date(s) and results of all tests done
for all donors. Split the results by donor and by
the cell type on which the test was performed if
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applicable. Copy this table as many times as
necessary.)
Number in the infusion order (if applicable)
(Indicate the date(s) and results of all tests done
for all donors. Split the results by donor and by
the cell type on which the test was performed if
applicable. Copy this table as many times as
necessary.)
Cell type on which test was performed (% Donor
Cells):
BM
(Indicate the date(s) and results of all tests done
for all donors. Split the results by donor and by
the cell type on which the test was performed if
applicable. Copy this table as many times as
necessary.)
%
Cell type on which test was performed (% Donor
cells):
PB mononuclear cells (PBMC)
(Indicate the date(s) and results of all tests done
for all donors. Split the results by donor and by
the cell type on which the test was performed if
applicable. Copy this table as many times as
necessary.)
%
Cell type on which test was performed (% Donor
cells):
T-Cells
(Indicate the date(s) and results of all tests done
for all donors. Split the results by donor and by
the cell type on which the test was performed if
applicable. Copy this table as many times as
necessary.)
%
Cell type on which test was performed (% Donor
cells):
B-Cells
(Indicate the date(s) and results of all tests done
for all donors. Split the results by donor and by
the cell type on which the test was performed if
applicable. Copy this table as many times as
necessary.)
%
Cell type on which test was performed (% Donor
cells):
Red blood cells
(Indicate the date(s) and results of all tests done
for all donors. Split the results by donor and by
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the cell type on which the test was performed if
applicable. Copy this table as many times as
necessary.)
%
Cell type on which test was performed (% Donor
cells):
Monocytes
(Indicate the date(s) and results of all tests done
for all donors. Split the results by donor and by
the cell type on which the test was performed if
applicable. Copy this table as many times as
necessary.)
%
Cell type on which test was performed (% Donor
cells):
PMNs (neutrophils)
(Indicate the date(s) and results of all tests done
for all donors. Split the results by donor and by
the cell type on which the test was performed if
applicable. Copy this table as many times as
necessary.)
%
Cell type on which test was performed (% Donor
cells):
Lymphocytes, NOS
(Indicate the date(s) and results of all tests done
for all donors. Split the results by donor and by
the cell type on which the test was performed if
applicable. Copy this table as many times as
necessary.)
%
Cell type on which test was performed (% Donor
cells):
Myeloid cells, NOS
(Indicate the date(s) and results of all tests done
for all donors. Split the results by donor and by
the cell type on which the test was performed if
applicable. Copy this table as many times as
necessary.)
%
Cell type on which test was performed:
Other, specify:
(Indicate the date(s) and results of all tests done
for all donors. Split the results by donor and by
the cell type on which the test was performed if
applicable. Copy this table as many times as
necessary.)
Cell type on which test was performed (% Donor
cells):
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Other
(Indicate the date(s) and results of all tests done
for all donors. Split the results by donor and by
the cell type on which the test was performed if
applicable. Copy this table as many times as
necessary.)
%
Test used
(Indicate the date(s) and results of all tests done
for all donors. Split the results by donor and by
the cell type on which the test was performed if
applicable. Copy this table as many times as
necessary.)
ABO group (ABO group)
Cytogenetic (Cytogenetic)
FISH (FISH)
Molecular (Molecular)
Other (Other)
unknown (unknown)
Test used:
If other, specify:
(Indicate the date(s) and results of all tests done
for all donors. Split the results by donor and by
the cell type on which the test was performed if
applicable. Copy this table as many times as
necessary.)
Secondary Malignancy,
Lymphoproliferative or Myeloproliferative
disorder
Secondary Malignancy, Lymphoproliferative or
Myeloproliferative disorder diagnosed
No at date of this follow up (No at date of
this follow up)
Previously reported (Previously reported)
Yes (Yes)
If yes, specify date of diagnosis
If yes, specify the diagnosis
AML (AML)
Lymphoproliferative disorder
(Lymphoproliferative disorder)
MDS (MDS)
Other (Other)
If other, specify:
Additional therapies since last follow up
Treatment given since last report
No (No)
Unknown (Unknown)
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Yes (Yes)
If yes, specify the start date
If yes: One cell therapy regimen is defined as any
number of infusions given wihtin 10 weeks for the
same indication. If more than one regimen of cell
therapy has been given since last report, copy
this section and complete it as many times as
necessary.
No  (No )
Unknown (Unknown)
Yes (Yes)
If yes, specify the disease status before this
cellular therapy
CR (CR)
Not evaluated (Not evaluated)
Not in CR (Not in CR)
If yes, specify the cell type
Donor lymphocyte infusion (DLI) (Donor
lymphocyte infusion (DLI))
Mesenchymal cells (Mesenchymal cells)
Other (Other)
Unknown (Unknown)
If yes, specify the cell type:
If cell type other, specify:
If DLI, specify the number of cells infused by
type:
Nucleated cells
Evaluated (Evaluated)
Not evaluated (Not evaluated)
unknown (unknown)
If DLI, specify the number of cells infused by
type:
Nucleated cells (10^8/kg)
10^8/kg
If DLI, specify the number of cells infused by
type:
CD 34+
Evaluated (Evaluated)
Not Evaluated (Not Evaluated)
Unknown (Unknown)
If DLI, specify the number of cells infused by
type:
CD 34+ (10^6/kg)
(10^6/kg)
If DLI, specify the number of cells infused by
type: 
CD 3+
Evaluated  (Evaluated )
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Not evaluated (Not evaluated)
Unknown (Unknown)
If DLI, specify the number of cells infused by
type: 
CD 3+ (10^6/kg)
(10^6/kg)
If non DLI, specify total number of cells infused:
Evaluated (Evaluated)
Not Evaluated (Not Evaluated)
Unknown (Unknown)
If non DLI, specify the total number of cells
infused (10^6/kg)
(10^6/kg)
Chronological number of this cell therapy for this
patient
Indication 
(check all that apply)
Loss/decreased chimaerism
(Loss/decreased chimaerism)
Mixed chimaerism (Mixed chimaerism)
Other (Other)
Planned/ protocol (Planned/ protocol)
Prophylactic (Prophylactic)
Treatment for disease (Treatment for
disease)
Treatment of GvHD (Treatment of GvHD)
Treatment PTLD, EBV, lymphoma
(Treatment PTLD, EBV, lymphoma)
Treatment viral infection (Treatment viral
infection)
Indication:
If other, specify:
Number of Infusions (within 10 weeks)
(count only infusions that are part of same
regimen and given for the same indication)
Acute Graft versus Host Disease 
(after this infusion but before any further infusion/
transplant)
Maximum grade:
grade 0 (absent) (grade 0 (absent))
grade 1 (grade 1)
grade 2 (grade 2)
grade 3 (grade 3)
grade 4 (grade 4)
present, grade unknown (present, grade
unknown)
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apart from donor cell infusion or other type of cell
therapy:
Yes
No
If yes, specify:
Not planned (for relapse/ progression or
persistent disease) (Not planned (for
relapse/ progression or persistent
disease))
Planned (planned before HSCT took
place) (Planned (planned before HSCT
took place))
First evidence of relapse or progression
since last HSCT
Relapse or Progression
Continous progression since transplant
(Continous progression since transplant)
No (No)
Previously reported (Previously reported)
Unknown (Unknown)
Yes (Yes)
If yes, specify the date of diagnosis:
Last disease and pateint status
last disease status
Complete Remission (Complete
Remission)
Relapse (Relapse)
Treatment failure/ progression (Treatment
failure/ progression)
Has patient or partner become  pregnant after
this HSCT?
No (No)
Unknown (Unknown)
Yes (Yes)
Survival status
Alive (Alive)
Dead (Dead)
If alive: Type of score used:
Karnofsky (Karnofsky)
Lansky (Lansky)
Not evaluated (Not evaluated)
Unknown (Unknown)
If alive and performance score evaluated, specify:
10 (Moribund) (10 (Moribund))
100 (Normal, NED) (100 (Normal, NED))
20 (Very sick) (20 (Very sick))
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30 (Severely disabled) (30 (Severely
disabled))
40 (Disabled) (40 (Disabled))
50 (Requires assistance) (50 (Requires
assistance))
60 (Requires occasional assistance) (60
(Requires occasional assistance))
70 (Cares for self) (70 (Cares for self))
80 (Normal with effort) (80 (Normal with
effort))
90 (Normal activity) (90 (Normal activity))
If dead, specify cause of death:
HSCT related cause  (HSCT related
cause )
Other (Other)
Relapse or progression (Relapse or
progression)
Secondary malignancy (including
lymphoproliferative disease) (Secondary
malignancy (including lymphoproliferative
disease))
Unknown  (Unknown )
If dead and HSCT related cause of death, specify
(check as many as apppropriate):
GvHD
No  (No )
Unknown (Unknown)
Yes (Yes)
If dead and HSCT related cause of death, specify
(check as many as apppropriate):
Interstitial Pneumonitis
No  (No )
Unknown (Unknown)
Yes (Yes)
If dead and HSCT related cause of death, specify
(check as many as apppropriate): 
Pulmonary toxicity
No  (No )
Unknown (Unknown)
Yes (Yes)
If dead and HSCT related cause of death, specify
(check as many as apppropriate): 
Infection
No  (No )
Unknown (Unknown)
Yes (Yes)
If dead and HSCT related cause of death, specify
(check as many as apppropriate): 
If Infection, specify:
Bacterial (Bacterial)
Fungal (Fungal)
Parasitic (Parasitic)
Unknown (Unknown)
Viral (Viral)
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If dead and HSCT related cause of death, specify
(check as many as apppropriate): 
Rejection/ Poor graft function
No  (No )
Unknown (Unknown)
Yes (Yes)
If dead and HSCT related cause of death, specify
(check as many as apppropriate): 
Veno-Occlusive disease (VOD)
No  (No )
Unknown (Unknown)
Yes (Yes)
If dead and HSCT related cause of death, specify
(check as many as apppropriate): 
Haemorrhage
No  (No )
Unknown (Unknown)
Yes (Yes)
If dead and HSCT related cause of death, specify
(check as many as apppropriate): 
Cardiac toxicity
No  (No )
Unknown (Unknown)
Yes (Yes)
If dead and HSCT related cause of death, specify
(check as many as apppropriate): 
Central nervous system toxicity
No  (No )
Unknown (Unknown)
Yes (Yes)
If dead and HSCT related cause of death, specify
(check as many as apppropriate): 
Gastro intestinal toxicity
No  (No )
Unknown (Unknown)
Yes (Yes)
If dead and HSCT related cause of death, specify
(check as many as apppropriate): 
Skin toxicity
No  (No )
Unknown (Unknown)
Yes (Yes)
If dead and HSCT related cause of death, specify
(check as many as apppropriate): 
Renal failure
No  (No )
Unknown (Unknown)
Yes (Yes)
If dead and HSCT related cause of death, specify
(check as many as apppropriate): 
Multiple organ failure
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No  (No )
Unknown (Unknown)
Yes (Yes)
If dead and HSCT related cause of death, specify
(check as many as apppropriate): 
Other
No  (No )
Unknown (Unknown)
Yes (Yes)
If dead and HSCT related cause of death, specify
(check as many as apppropriate): 
If other, specify:
If other, specify:
Additional notes if applicable
Comments:
Identification and Signature
Identification
Signature
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VX-950HPC3006 NCT01571583 Liver
Disease History
This is an open-label (all people know the identity of the
intervention), multicenter study in genotype 1 chronic HCV
infected liver transplant patients who will be treated for 12
weeks with telaprevir 750 mg every 8 hours given in
combination with Peg-IFN-alfa-2a and ribavirin followed by
36 weeks of treatment with Peg-IFN-alfa-2a and ribavirin
alone. The total treatment duration will be 48 weeks. Safety
will be evaluated throughout the study and will include
evaluations of adverse events, clinical laboratory tests,
electrocardiogram, vital signs, and physical examination.
NCT01571583
All rights reserved. Please visit https://medical-data-
models.org/forms/13836
VX-950HPC3006 Liver Disease
History
Liver Disease History
Date of HCV Infection*
Date of diagnosis*
Date of liver transplant*
Liver Graft Biopsy Result
Date of biopsy*
Did the subject show a stable stage of hepatic
fibrosis over the past 3 years prior to the
screening visit, as assessed by serial liver graft
biopsies during this peior?
Yes
No
liver fibrosis score (metavir)*
F0 (1)
F1 (2)
F2 (3)
F3 (4)
F4 (5)
Inflammation score (metavir)*
A0 (1)
A1 (2)
A2 (3)
A3 (4)
Is there steatosis?*
Yes
No
Hepatic steatosis grade
less than 30% (1)
30% to 60% (2)
more than 60% (3)
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DESCRIBE (DZNE – Clinical Register Study of
neurodegenerative Disorders) CRF Diagnostic Criteria
Background and Purpose:
The purpose of the DESCRIBE study is to document the
natural course of diseases in context of medical care of
neurodegenerative disorders as well as cerebrovascular
diseases and to perform phenotyping of the test persons.
Disease-spanning analyses of the measured clincial data,
the results of the imaging processes, results of the analysis
of the biometerials including genetic analysis are planed.
Principal Investigator: Prof. Klockgether, Dr. Spottke DZNE,
Bonn.
Source: DESCRIBE-Studie
http://www.dzne.de/forschung/forschungsbereiche/klinische
-forschung/studien/describe-bn006.html 
Participating Study Sites:
Berlin, Bonn, Göttingen, Dresden, Köln, Magdeburg,
München, Rostock/Greifswald, Tübingen
All rights reserved. Please visit https://medical-data-
models.org/forms/13841
CRF Diagnostic Criteria
Date of visit
Date of visit
Study-ID:
Visit:
Mild cognitive impairment (MCI)
Is the patient currently diagnosed with a MCI
according to Winblad & Petersen 2004?
Yes
No
Cognitive Impairment
1. Subjective deterioration of cognition observed
by the patient or an informant and/or...
Yes
No
2. Evidence of degradation of cognition in time
due to psychometric tests
Yes
No
3. Ability to perform activities of everyday living/
minimal impairment of complex instrumental
everyday functions
Yes
No
4. No signs of disturbed consciousness, of a
delirium, of a dementia or  of an amnesic aphasia
that cannot be explained better by other
psychotic illnesses (e.g. a disorder in connection
with psychotropic substances or major
depression).
Yes
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No
Operationalization
1. Wordlist - delayed word retrieval
Yes
No
2. Visuospatial ability - Drawing
Yes
No
3. Visuospatial ability - Delayed retrieval
Yes
No
4. Trial making test A or B
Yes
No
5. Semantic or phonetic fluency
Yes
No
6. Object naming
Yes
No
7. No abnormal finding FAQ
Yes
No
Classification
a. Amnesic MCI single domain (only memory)
Yes
No
b. Amnesic MCI multi domain (memory and one
additional area)
Yes
No
c. Non-amnesic MCI single domain (one area,
except memory)
Yes
No
d. Non-amnesic MCI multi domain (several areas,
except memory)
Yes
No
Dementia in Alzheimer's Disease (AD)
Is the patient currently diagnosed with AD
according to NINCDS/ADRDA-Criteria (McKhann
et al. 1984)?
Yes
No
I. Necessary requirements
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Evidence of dementia in a clinical examination
including neuropsychological tests
Yes
No
Deficits in at least two cognitive areas
Yes
No
Progressive disturbance of memory and other
cognitive functions
Yes
No
No consciousness disturbance
Yes
No
Onset between age of 40 and 90, mostly 65 and
older
Yes
No
No evidence of other system- or brain diseases
as cause
Yes
No
II. Subsidiary Findings
Progressive deterioration of specific cognitive
functions, e.g. of speech (aphasia), motor activity
(apraxia) and perception (agnosia)
Yes
No
Impairment of everyday activities and emerging
of behavior modifications
Yes
No
Family history of similar disorders (especially if
neurologically proven)
Yes
No
Results of additional examinations:
Evidence of - progressively evolving in follow ups-
cerebral atrophy due to imaging diagnostics
Yes
No
Normal finding or unspecific changes in EEG
Yes
No
Normal finding of cerebrospinal fluid
Yes
No
III. Matching with a probable diagnosis of
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Alzheimer's disease
Temporal stagnation in course of disease
Yes
No
Attendant symptoms like depression, insomnia,
incontinence,  illusion, hallucination, delusion,
sudden aggressive outbreaks, sexual dysfunction
and weight loss
Yes
No
Neurological distinctive feature (particularly in
case of advanced disease) like elevated muscle
tonus, myoclonus or gait disturbance
Yes
No
Epileptic seizure (in case of advanced disease)
Yes
No
CT commensurate with age
Yes
No
IV. Exclusion Criteria
Sudden, apoplectic onset
Yes
No
Focal neurological signs like hemiparesis,
sensorial failures,  visual field defects or problems
with coordination in early stage of disease
Yes
No
Epileptic seizures or gait disturbance at onset or
in early stage of disease
Yes
No
V. Clinical possible AD
Dementia syndrome with atypical symptomatic
with regard to onset, course and deficit profile, in
absence of other neurological, psychiatric or
internal disease that could cause the dementia
syndrome
Yes
No
Second systemic or brain disease that could
cause dementia, but is commonly not regarded
as a substantial cause
Yes
No
Progressive severe cognitive deficit without
notable different cause
4 / 36
DESCRIBE (DZNE – Clinical Register Study of neurodegenerative
Disorders) CRF Diagnostic Criteria
Yes
No
Posterior cortical atrophy (PCA)
Is the patient currently diagnosed with PCA
according to the criteria of Mendez et.al. 2002?
Yes
No
Main symptoms (all symptoms have to be
present)
A. Insidious onset and gradual progression
Yes
No
B. Presentation with visual disorders while visual
function intact
Yes
No
C. Evidence of prominent complex visual deficits
Yes
No
Elements of Balint syndrome
Yes
No
Visual agnosia
Yes
No
Dressing apraxis
Yes
No
Topographic disorientation
Yes
No
D. Relatively small memory deficits and word
fluency deficits
Yes
No
E. Relatively good awareness of disability with or
without depression
Yes
No
Subsidiary diagnosis
A. Presenile onset
Yes
No
B. Alexia
Yes
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No
C. Elements of Gerstmann syndrome
Yes
No
D. Ideomotor apraxia
Yes
No
E. Physical examination within the norms
Yes
No
F. Neuropsychiatric: Prominent impairment of
perceptual functions
Yes
No
Imaging:
Prominent occipitoparietal abnormality (especially
in functional imaging) with relative recess of
frontal and mesiotemporal regions
Yes
No
Vascular dementia
Is the patient currently diagnosed with VD
according to the criteria of NINDS/AIREN
(Roman et al. 1993?)
Yes
No
I. Dementia
Cognitive impairment regarding previous higher
functional status manifested by disturbance of
memory
Yes
No
Orientation
Yes
No
Attention
Yes
No
Speech
Yes
No
Spatial visualization ability
Yes
No
Ability to judge
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Yes
No
Action ability
Yes
No
Abstraction ability
Yes
No
Motor control
Yes
No
Praxia
Yes
No
Activities of daily living
Yes
No
Exclusion criteria
Disturbed consciousness
Yes
No
Delirium
Yes
No
Psychosis
Yes
No
Severe aphasia
Yes
No
Prominent sensomotoric disorder, which makes
testing impossible
Yes
No
Systemic or other brain diseases, that can cause
cognitive disorders for their part
Yes
No
II. Cerebrovascular disease
Central focal neurological signs with or without
anamnestic stroke and signs of relevant
cerebrovascular disease in CT/MRT
Yes
No
A. cerebri anterior, bilateral
Yes
No
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A. cerebri anterior
Yes
No
Parietotemporal or temporoparietal association
complex
Yes
No
Superiore frontale and parietal watershed zone
Yes
No
Disease of small vessels:
Basal ganglia and frontal lacuna of white matter
Yes
No
Broad periventricular white matter lesions
Yes
No
Bilateral thalamus lesions
Yes
No
Severity:
great vessel lesions in dominant hemisphere
Yes
No
Bilateral lesions of great vessel in hemisphere
Yes
No
Leukoencephalopathy => 25% of white matter
Yes
No
III. Combination of I. and II.
Onset of dementia within three months after
stroke
Yes
No
Abrupt degeneration of cognitive functions
Yes
No
Fluctuating or gradual progression of cognitive
deficits
Yes
No
Supporting Symptoms:
Early occuring gait disturbance
Yes
No
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Motoric instability and frequent support
Yes
No
Bladder problem (frequent urge to urinate, not
urological explainable)
Yes
No
Pseudobulbar paralysis
Yes
No
Personality disorder or mood alteration
Yes
No
Abulia
Yes
No
Depression
Yes
No
Emotional incontinence
Yes
No
Other subcortical deficits
Yes
No
Frontotemporal dementia, behavioral
variant
Is the patient currently diagnosed with bvFTD
according to the criteria of Raskovsky et. al.
2011?
Yes
No
I. Signs of neurodegenerative disease:
Slowly progressing disturbance of behavior or of
cognition in order to distinguish it from acute
beginning or stable disturbance for a long time,
which is typical for psychiatric disease
Yes
No
II. "Possible" bvFTD
Three of the symptoms listed in A to F have to be
fulfilled. It should be ensured that these
symptoms are prominent and persistent and are
not rare or even nonrecurring clinical pictures.
A. Early onset of behavior disturbance with the
symptom "disinhibition"  A.1.Socially
inappropriate behavior
Yes
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No
A.2. Loss of manners and decency
Yes
No
A.3. Impulsive, unreflected or reckless behavior
Yes
No
B. Early onset of symptoms of apathy or inactivity
B.1. Apathy
Yes
No
B.2. Inactivity
Yes
No
C. Early loss of sympathy or empathy (one
symptom has to be present)
C.1. Reduced sympathy for needs and feelings or
other human beings
Yes
No
C.2. Reduced interest in social contacts or
human affection
Yes
No
D. Early onset of perservative, stereotypic or
compulsive, ritualized behaviour patterns (one of
the symptoms has to be present)
D.1. Simple repetitive movements
Yes
No
D.2. Complex, compulsive executed or ritualized
behaviour patterns
Yes
No
D.3. Stereotypes in language
Yes
No
E. Hyperorality or changes in eating behavior
(one of the symptoms has to be present)
E.1. Disturbed preference in choice of food
Yes
No
E.2. Eating orgy, increased consumption of
alcohol or cigarettes
Yes
No
E.3. Oral exposure behavior or even oral
consumption of uneatable objects
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Yes
No
F. Typical neuropsychological profile: Disturbance
of executive functions along with relatively intact
memory and intact visuoconstructive skills (all
symptoms must be present)
F.1. Disturbance in executive functions, including
complex cognitive functions like working memory,
planing, generalization of rules and abstracting of
rules, problem solution and mental flexibility
Yes
No
F.2. Relatively intact performance of episodic
memory
Yes
No
F.3. Relatively intact performance testing
visuocontructive functions
Yes
No
III. "Probable" bvFTD
All of the following criteria(A-C) have to be
fulfilled for a diagnosis of a probable bvFTD
A. Diagnosis criteria of a probable FTD have to
be fulfilled
Yes
No
B. The amount of disturbance causes disturbance
in everyday functioning
Yes
No
C. Imaging is compatible with the behavioral
variant of FTD (one of the two attributes has to be
present)
C.1. CT or MRI imaging show a frontal and/or
anterior temporal atrophy
Yes
No
C.2. PET or SPECT examinations showing frontal
and/or temporal hypo-perfusion/hypo-metabolism
Yes
No
IV. bvFTD with ensured FTD-pathology (criterion
A  and one additional criterion (B or C) have to be
fulfilled)
A. Criteria of possible or probable FTD fulfilled
Yes
No
B. Histopathological evidence for the disease (by
biopsy or post mortem)
Yes
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No
C. Presence of a known mutation which causes
the behavioural variant of FTD
Yes
No
V. Exclusion criteria for bvFTD
A. The pattern of disturbance can be better
explained by another (neurodegenerative)
disease
Yes
No
B. The behavioral disturbances can be better
explained by a psychiatric disease
Yes
No
C. Biomarkers emphasize Alzheimer's disease or
another neurodegenarative disease
Yes
No
Primary progressive aphasia (PPA)
Is the patient currently diagnosed with PPA
according to the criteria of Mesulam et. al. 2001?
Yes
No
1. Gradually starting and slowly progressing
impairment in word formation, object naming,
syntax or word comprehension in conversation or
applying a well-established neuropsychologic
speech tests.
Yes
No
2. All restrictions in everyday life in the first two
years after onset of symptoms can be attributed
to impairment of speech.
Yes
No
3. The premobid function of speech is intact (a
dyslexia during development is possible).
Yes
No
4. A prominent apathy, disinhibition, disturbance
of short-term memory, visuo-spatial disturbances,
disability of visual recognition and sensomotoric
deficits are missing in the first two years of
disease in consideration of anamnesis, everyday
activities or neuropsychologic results, so that the
participant fulfills no diagnostic criteria of another
dementia.
Yes
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No
5. Dyscalculia, ideomotoric apraxia and problems
tracing can be present in the first two years of
disease. However these are not developed so
that everyday activities are influenced.
Yes
No
6. Other cognitive functions can be affected after
the first two years after disease, but speech
remains the strongest impaired function during
the whole course of disease and declines faster
than every other function.
Yes
No
7. Other reasons for aphasia like stroke or tumor
are excluded by imaging.
Yes
No
Progressive nonfluent aphasia (PNFA)
Is the patient currently diagnosed with PNFA
according to the criteria of Gorno-Tempini et. al.
2011?
Yes
No
I. Clinical diagnosis of PNFA
At least one of the diagnostic main criteria has to
be fulfilled:
1. Speech with agrammatism
Yes
No
2. Labored, haltingly speech with inconsistent
prosody and speech attitudes (speech apraxia)
Yes
No
At least  two of the following features have to be
fulfilled:
1. Speech intelligibility disturbances formulating
sentences with complex syntax
Yes
No
2. Maintained speech intelligibility of single words
Yes
No
3. Maintained object knowledge
Yes
No
II. Imaging results supporting diagnosis of PNFA
Both criteria have to be fulfilled
1. Clinical diagnosis of PNFA
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Yes
No
2. Imaging diagnostics have to show one of the
following findings:
2a. MRI: Emphasized atrophy in posterior part of
frontal lobe/island region of left hemisphere
Yes
No
2b. SPECT/PET: Emphasized hypoperfusion and
hypometabolism in posterior part of frontal
lobe/insular region of left hemisphere
Yes
No
III. Diagnostic criteria for PNFA and clear
histopathologic finding
The clinical diagnosis (criterion 1) an criterion 2
or criterion 3 have to be fulfilled:
1. Clinical diagnosis of PNFA
Yes
No
2. Histopathological evidence of a specific
neurodegenerative pathology 
(e.g. FTD-tau, FTD-TDP, AD or another specific
pathology)
Yes
No
3. Evidence of a common mutation
Yes
No
Logopenic progressive aphasia (LPA)
Is the patient currently diagnosed with LPA
according to the criteria of Gorno-Tempini et. al.
2011 and Raskovsky et. al. 2011?
Yes
No
I. Clinical diagnosis of LPA:
Both diagnostic main criteria have to be fulfilled:
1. Disturbed ability to fetch words in sponteneous
speech and in naming
Yes
No
2. Repeating of sentences and sentence
elements disturbed
Yes
No
At least 3 of the following characteristics have to
be fulfilled:
1. Phonologic paraphrasia in spontaneous
speech and naming
Yes
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No
2. Maintained speech intelligibility of single words
and object knowledge
Yes
No
3. Maintained motor speech (no speech apraxia)
Yes
No
4. No distinctive agrammatism
Yes
No
I. Diagnosis of LPA supported by imaging
Both of the following criteria have to be fulfilled
1. Clinical diagnosis of LPA
Yes
No
2. Imaging diagnostics have to show one or
several of the following findings:
2a. MRI: Emphasized atrophy in posterior
sections of perisylvian area or parietal atrophy
Yes
No
2b. SPECT/PET: Emphasized hypoperfusion and
hypometabolism in a section of perisylvian area
or parietal lobe
Yes
No
II. Diagnostic criteria for LPA and clear
histopathologic finding
The clinical diagnosis (criterion 1) and criterion 2
or criterion 3 have to be fulfilled:
1. Clinical diagnosis of LPA
Yes
No
2. Histopathological evidence of a specific
neurodegenerative pathology (e.g. FTD-tau, FTD-
TDP, AD or another specific pathology)
Yes
No
3. Evidence of a common mutation
Yes
No
Semantic dementia (SemD)
Is the patient currently diagnosed with SemD
according to the criteria of Gorno-Tempini et. al.
2011?
Yes
No
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I. Clinical diagnosis of SemD:
Both diagnostic main criteria have to be fulfilled:
1. Disturbed behavior (anomia)
Yes
No
2. Disturbed speech intelligibility of single words
Yes
No
At least three of the following characteristics have
to be fulfilled:
1. Disturbed object knowledge, especially of
words which are rarely used or have a lower
familiarity
Yes
No
2. Dyslexia or agraphia
Yes
No
3. Undisturbed repetition
Yes
No
4. Maintained fluent production of speech
(grammatically correct and without apraxic
disorders)
Yes
No
II. Imaging results supporting diagnosis of SemD:
Both of the following criteria have to be fulfilled
1. Clinical diagnosis of SemD
Yes
No
2. Imaging diagnostics have to show one of the
following findings:
2a. MRI: Emphasized atrophy in anterior part of
frontal lobe
Yes
No
2b. SPECT/PET: Emphasized hypoperfusion and
hypometabolism in anterior part of frontal lope
Yes
No
III. Diagnostic criteria for SemD and clear
histopathologic finding
1. Clinical diagnosis of SemD
Yes
No
2. Histopathological evidence of a specific
neurodegenerative pathology (e.g. FTD-tau, FTD-
TDP, AD or another specific pathology)
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Yes
No
3. Evidence of a common mutation
Yes
No
Idiopathic Parkinson's disease (IPS)
Is the patient currently diagnosed with IPS
according to the UKBB criteria (Litvan et. al.
2003)?
Yes
No
Hypo-bradykinesia
Yes
No
Resting tremor
Yes
No
Rigor
Yes
No
Postural instability
Yes
No
Unilateral onset
Yes
No
Resting tremor manifest
Yes
No
Progressive course of disease
Yes
No
Laterality
Yes
No
Excellent response to L-Dopa (70-100%)
Yes
No
L-Dopa induced chorea
Yes
No
Response to L-Dopa over 5 years
Yes
No
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Response to L-Dopa over 10 years
Yes
No
Medical history of brain damage (e.g. stroke,
craniocerebral trauma)
Yes
No
Medical history of encephalitis
Yes
No
Oculogyric crisis
Yes
No
Therapy using neuroleptic drugs at onset of
disease
Yes
No
Remission of disease
Yes
No
Unilateral motor impairment after 3 years of
disease
Yes
No
Supranuclear palsy
Yes
No
Cerebellar signs
Yes
No
Severe autonomous dysfunction (e.g. urinary
incontinence, cardiovascular system problem)
Yes
No
Early development of dementia (within first year
of disease) with special impairment of memory,
speech and in practice
Yes
No
Babinski sign
Yes
No
Poor response to L-Dopa
Yes
No
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
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(MTPT) exposition
Yes
No
Morbus parkinson along with MCI (PD-
MCI)
Is the patient currently diagnosed with PD-MCI
according to the criteria Litvan et. al. 2012?
Yes
No
Diagnosis of Parkinson disease according to
UKPD BB criteria
Yes
No
Insidious onset and progressive course of
disease of cognitive dysfunction under PD
disease reported by participant, relatives and
treating physician
Yes
No
Loss of power (<=1.5 times standard deviation
below the mean value of reference group) in 
(A) two assessments of a domain or (B) in each
assessment of two different domains.
Following domains can be affected:
-attention & working memory
-executive functions
-visuo-constructive/visuospatial performance
-memory
-speech
Yes
No
Cognitive deficits do not interfere with lost of
independence regarding everyday activities,
although mild impairment may occur performing
complex tasks
Yes
No
Parkinson disease with dementia according to
criteria of Movement Disorder Society Task Force
Yes
No
Diseases that can explain cognitive impairment
primarily (e.g. delir, stroke, traumatic brain injury,
metabolic disorder, side effects of medication,
severe depressive episode)
Yes
No
Other PD associated comorbidities like severe
motor impairment, high anxiety,
depression,increasing daytime sleepiness,
19 / 36
DESCRIBE (DZNE – Clinical Register Study of neurodegenerative
Disorders) CRF Diagnostic Criteria
psychosis, which have a significant influence on
test performance according to a clinician's
opinion.
Yes
No
Dementia in Parkinsons disease
Is the patient currently diagnosed with PDD
according to the criteria Emre et. al. 2007?
Yes
No
I. Main criteria of PDD
Diagnosis of Parkonson disease according to
UKPD BB criteria
Yes
No
Dementia syndrome with insidious onset and
progressive course of disease with respect to
Parkinson's disease (onset of dementia > 1 year
after diagnosis of Parkinson's disease
Yes
No
Loss of power (<=1.5 times standard deviation
below mean of reference group/normal
population) affecting more than one cognitive
domain and represent an impairment in contrast
to the premobid level of performance
Yes
No
Cognitive deficits interfer with loss of
independence in everyday activities (concerning
social, occupational or personal aspects of life).
These limitations of activities in everyday living
should be primarily caused by cognitive factors
and not by motor impairment or an autonomous
functional disorder.
Yes
No
II. Additional criteria
a) Following domains can be affected:
-attention & working memory
-executive functions
-visuo-constructive/visuospatial performance
-memory
-speech
Yes
No
b) The following behavior changes can occur:
-apathy (reduced spontaneity, loss of motivation,
interest and performance)
-change of personality like depressive or anxious
symptomatic
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-hallucinations (at most visual, complex visions of
humans, animals or objects)
-delusions (at most of paranoid nature like
cheating of the partner or foreign persons living in
the household)
-increased sleepiness at daytime or doziness at
daytime
Yes
No
III. Findings, which make PDD diagnosis less
probable
Diseases that can also cause cognitive
impairment as a result (e.g. vascular distinctive
feature in MRI), but cannot be considered
primary cause of dementia
Yes
No
Time interval between onset of cognitive and
motor symptoms unknown
Yes
No
IV. Exclusion criteria of PDD
Cognitive symptomes or behavioral disorders
occor exclusively as part of another disease or
concomitants, like e.g. delir caused by a systemic
disease or as consequence of a certain
medication or a severe depressive episode
Yes
No
Prevalence of a probable vascular dementia
according to NINDS-AIREN-criteria
Yes
No
Probable PDD
-All criteria in section I have to be fulfilled
-Typical profile of cognitive impairment along with
distinctive features in more than one cognitive
domain (IIa), especially deficits of attention, a
dysexecutive syndrome, an impaired visuospatial
perception, limitations regarding direct recall of
memory performance with improvement after
provided assistance in recall.
-presence of at least one behavior disorder (IIb)
-no criteria mentioned in section III and IV must
be present
Yes
No
Possible PDD
-atypical profile of cognitive impairment with
abnormalities in more than one cognitive domain
(IIa) like fluent aphasia or memory impairment or
attention deficit
-behavior disorders (IIb) can be present but do
not have to be present
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-one or more criteria in III may be present
-no criterion mentioned in section IV must be
present
Yes
No
Dementia with Lewy bodies (DLB)
Is the patient currently diagnosed with DLB
according to the criteria Mc Keith et. al. 2005?
Yes
No
Central Criterion
1. Dementia, defined as progressive loss, which
causes loss of independence in everyday living
activities (concerning social, occupational or
personal life aspects)
Yes
No
Main criteria
2. Fluctuations in cognition, especially attention
performance
Yes
No
3. Recurrent visual hallucinations, that typically
consists of figures and are detailed.
Yes
No
Spontaneous Parkinson symptomatic
Yes
No
Additional criteria
5. REM sleep behavior disorder
Yes
No
6. Severe side effects due to neuroleptic
medication
Yes
No
Reduced dopamine transporter ligand storage in
basal ganglia (SPECT/PET)
Yes
No
8. Dementia occurred before or at the same time
(resp.  within first year) symptoms of Parkinson's
disease did?
Yes
No
Probable DLB (item 1 and at least one feature in
2-4 and at least one feature 5-7 applies, item 8 is
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fulfilled)
Yes
No
Possible DLB (item 1 and at least one feature in
5-7 apply; item 8 is fulfilled)
Yes
No
Supportive Symptoms without diagnostic specifity
Frequent falls or syncopes
Yes
No
Transient loss of consciousness
Yes
No
Severe autonomous dysfunction
Yes
No
Hallucinations in other modalities
Yes
No
Delusions
Yes
No
Depression
Yes
No
Medial temporal lobe slightly changed in MRI
Yes
No
Light take in SPECT/PET perfusion scan at
reduced occipital activity
Yes
No
Abnormally light take in MIBG myocardial
scintiscan
Yes
No
Prominent slow-wave-activity in EEG with
temporal transient shape waves
Yes
No
Findings making diagnosis less probable
medical history of brain injury (e.g. stroke,
traumatic brain injury)
Yes
No
Presence of another medical or neurological
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condition explaining deficits
Yes
No
Symptoms of Parkinson's disease occur in a
severe stadium of dementia for the first time
Yes
No
Progressive supranuclear palsy
Is the patient currently diagnosed with PSP
according to the criteria NINDS-PSP-criteria
(Litvan et. al. 1996)?
Yes
No
Conditions
Gradual progressive disease with onset of
disease at age of at least 40
Yes
No
Main criteria
1. Vertical palsy (up or down)
Yes
No
2. Slowing of vertical saccades
Yes
No
3. Postural instability with falls < 1 year after
onset of disease
Yes
No
Probable PSP (item 1 and item 3 have to be
answered with 'Yes'
Yes
No
Possible PSP (item 1 or 2 und item 3 have to be
answered with 'Yes')
Yes
No
Supportive symptoms
Symmetric akinesia or rigor, proximal more than
distal
Yes
No
Abnormal head posture especially retrocollis
Yes
No
Poor or low response to L-Dopa
Yes
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No
Earlier dysphagia or dysarthria
Yes
No
Earlier onset of a cognitive impairment along with
presence at least two of the following symptoms:
Apathy, impairment of abstract thinking, reduced
verbal fluency, tool use behavior, imitation and
frontal lobe syndrome
Yes
No
Exclusion criteria
Medical history of brain injury (e.g. encephalitis)
Yes
No
Presence of another medical or neurological
condition explaining deficits
Yes
No
Presence of alien limb syndrome
Yes
No
Presence of a cortical perception disorder
Yes
No
Evidence of focal frontal or temporal-parietal
atrophy
Yes
No
Occurrence of hallucinations and delusions
independently of a dopaminergic  therapy
Yes
No
Prominent early signs of cerebellar diseases
Yes
No
Evidence of severe autonomous functional
disorder with unknown cause
Yes
No
Severe asymmetric signs of Parkinson's
syndrome
Yes
No
Neuroradiological evidence of relevant structural
abnormalities
Yes
No
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Evidence of Morbus Whipple
Yes
No
Corticobasal degeneration (CBD)
Is the patient currently diagnosed with CBD
according to the criteria of Boeve et. al. 1996?
Yes
No
Main criteria
1. Insidious onset and progressive course of
disease
Yes
No
2. No other medical or neurological disease can
explain the deficits
Yes
No
3. Cortical dysfunction with at least one of the
following symptoms:
3a. Focal or asymmetric ideomotor apraxia
Yes
No
3b. Alien limb syndrome
Yes
No
3c. Cortical sensibility loss
Yes
No
3d. Visual or sensorial hemineglect
Yes
No
3e. Constructional apraxia
Yes
No
3e. Focal or asymmetric myoclonus
Yes
No
3g. Speech apraxia/ non-fluent aphasia
Yes
No
4. Extrapyramidal dysfunction with at least one of
the following symptomes:
4a. Focal or asymmetrical rigor of extremities
without clear reponse to L-Dopa
Yes
No
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4b. Focal or asymmetrical dystonia of extremity
muscles
Yes
No
Diagnosis of CBD 
If item 1,2 and at least one item in 3a-3g and at
least one in item 4a, item 4b is fulfilled
Yes
No
Supportive symptoms
Neuropsychological testing: Evidenz of focal or
lateralised cognitive impairment with relatively
maintained learning and memory function
Yes
No
Evidence in MRI/ CT of focal or asymmetric
atrophy, typically manifesting in frontoparietal
cortex
Yes
No
Evidence in SPECT or PET of focal or
asymmetrical hypoperfusion, typically manifested
in frontoparietal cortex at maximum, with or
without involvement of basal ganglia resp. the
thalamus
Yes
No
Multiple system atrophy (MSA)
Is the patient currently diagnosed with MSA
according to the criteria of Gilman et. al. 2008?
Yes
No
Conditions
Episodic, progressive disease with onset of
symptoms after age of 30
Yes
No
Conditions
Episodic, progressive disease with onset of
symptoms after age of 30
Yes
No
1. Parkinson's disease (bradykinesia with rigor,
tremor or postural instability)
Yes
No
Or a cerebellar syndrome (gait ataxia with
cerebellar dysarthria, limb ataxia or cerebellar
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oculomotor disturbance)
Yes
No
2. At least one sign suggesting autonomous
dysfunction:
-bladder incontinence that cannot be explained by
another disease
-incomplete urination
-erectile dysfunction
-significant  decrease of orthostatic blood
pressure without fulfilling criteria of a probable
MSA
Yes
No
3. At least one additional sign have to be fulfilled
Yes
No
Possible MSA (items 1-3 apply)
Yes
No
Signs of a probable multiple system atrophy
4. Autonomous disorder
-with bladder incontinence (inability to control
urination along with erectile dysfunction among
men)
-orthostatic decrease of blood pressure standing
for 3 minutes of >30mmHg systolic or >15mmHg
Yes
No
5. Parkinson's syndrome (bradykinesia with rigor,
tremor or postural instability) with poor response
to Levodopa
Yes
No
Or a cerebellar syndrome (gait ataxia with
cerebellar dysarthria, limb ataxia or cerebellar
oculomotor disturbance)
Yes
No
Probable MSA (item 4-5 apply)
Yes
No
additional signs of MSA-P or MSA-C
Yes
No
Babinski sign with increased reflex
Yes
No
Stridor
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Yes
No
Rapid progression of Parkinson's syndrome
Yes
No
Poor response to L-Dopa
Yes
No
Postural instability within three years after first
motor symptomes
Yes
No
Gait ataxia, cerebellar dysarthria, ataxia of
extremities or cerebellar occulomotor disorder
Yes
No
Dysphagia within 5 years after onset of motor
disease
Yes
No
Atrophy of putamen, cerebellar peduncle, pons or
cerebellum proven in MRI
Yes
No
Hypometabolism in putamen, brain stem or
cerebellum proven in FDG-PET
Yes
No
Parkinson's syndrome (bradykinesia and rigor)
Yes
No
Putamen atrophy, middling cerebellar peduncle
atrophy or pons atrophy proven in MRI
Yes
No
Presynaptic striatonigral dopaminergic
denervation
Yes
No
Orofacial dystonia
Yes
No
Unproportional antecollis
Yes
No
Camptocormia
Yes
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No
Contractions of hands and feet
Yes
No
Inspiratory sighs
Yes
No
Severe dysphonia
Yes
No
Severe dysarthria
Yes
No
Incipient snoring
Yes
No
Cold hand or feet
Yes
No
Pathological laughter or crying
Yes
No
Jerky, myoclonic resting or action tremor
Yes
No
Classic pill rolling tremor
Yes
No
Clinically significant neuropathy
Yes
No
Hallucinations which are not induced by
medication
Yes
No
Onset of disease after age of 75
Yes
No
Positive family history of ataxia or parkinsonism
Yes
No
Dementia diagnosis
Yes
No
Lesions of white substance in MRI hinting for
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diagnosis of multiple sclerosis
Yes
No
Essential tremor (ET)
Is the patient currently diagnosed with ET
according to the criteria of Deutschi et. al. 1998?
Yes
No
Known family genesis of tremor?
Yes
No
I. Signs of a definite essential tremor
1. Bilateral , at most symmetric resting or action
tremor, concerning hands and forearms, that is
persistent and visible (Persistent tremor in other
body regions can occur in addition; bilateral
tremor can have different severity grades; tremor
is described by participant as permanent
continuous, but amplitude of the tremor can vary;
tremor can cause disabilities in everyday living,
but do not have to.
Yes
No
2. Duration of illness > 5 years
Yes
No
II. Exclusion criteria of definite essential tremor
3. Presence of other abnormal neurological
symptoms
Yes
No
4. Presence of indications or known reasons for
occurrence of physiologic tremor
Yes
No
5. Current or earlier intake of psychogenic
substances that can cause tremor or the current
withdrawal symptoms
Yes
No
6. Other medical or neurological diseases, that
can explain the tremor (especially brain injury,
peripheral injury or trauma, 3 months before
onset of tremor.
Yes
No
7. Anamnestic indication or clinical evidence for
psychosomatic tremor
Yes
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No
8. Indication for acute onset or stepped course of
disease
Yes
No
III. Signs of probable essential tremor
III1. Bilateral, mainly symmetric resting or action
tremor, which concerns hands and forearms but
other body parts as well like head or legs, visible
and persistent (bilateral tremor can be
asymmetric; tremor is described by participant as
permanent continuous, but amplitude of the
tremor can vary; tremor can cause disabilities in
everyday living, but do not have to)
Yes
No
III2. Duration of disease > 3 years
Yes
No
III Exclusion criteria for possible essential tremor
III.3 At least one exclusion criterion mentioned in
I3-I8 is true.
Yes
No
III4. Presence of primary orthostatic tremor
Yes
No
III5. Presence of isolated tremor of the voice
Yes
No
III6. Presence of isolated tremor specific to
position and tasks, including action-specific
tremor or a primary writing tremor
Yes
No
III7. Presence of isolated tongue or chin tremor
Yes
No
III. Signs of possible tremor
Type I: Persons fulfilling criteria of definite or
probable essential tremor but suffering from
another neurological disease like parkinsonism, a
dystonia, a peripheral neuropathology or restless
leg syndrome. 
Persons fulfilling criteria of definite or probable
essential tremor but suffering from other
neurological symptoms that are not sufficient
enough to make the diagnosis of another
neurological illness. These symptoms concern for
example minimal extra pyramidal signs like
hypomimia, reduced arm drive or mild
32 / 36
DESCRIBE (DZNE – Clinical Register Study of neurodegenerative
Disorders) CRF Diagnostic Criteria
bradykinesia.
Yes
No
Mono-symptomatic and isolated tremor with
uncertain relation to essential tremor, like for
example isolated tremor specific to position and
task, including action-specific tremor or a primary
writing tremor, a primary orthostatic tremor, an
isolated voice tremor, an isolated leg tremor or a
unilateral resting tremor of the hand.
Yes
No
III. Exclusion criteria for possible essential tremor
At least one exclusion criterion mentioning in I4-
I6 is true
Yes
No
Amyotrophic lateral sclerosis (ALS)
Is the patient currently diagnosed with ALS
according to the criteria of El-Escorial (revised
1998)?
Yes
No
Symptoms that have to be present:
Signs of lesion of 1. motor neuron
Yes
No
Signs of lesion of 2. motor neuron (including
EMG changes in clinically not affected muscles)
Yes
No
Progression
Yes
No
Symptoms, excluding a diagnosis of ALS
emotional disorder
Yes
No
sphincter disturbance
Yes
No
Vision disorder
Yes
No
Autonomous dysfunctions (e.g. urinary
incontinence, cerebrovascular circulation)
Yes
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No
Alzheimer's disease
Yes
No
Syndromes similar to ALS
Yes
No
Supportive symptoms
Fasciculations in one or several region
Yes
No
Neurogenic change in EMG
Yes
No
Normal motor and sensory nerve conduction
study
Yes
No
Missing nerve conduction block
Yes
No
Definite ALS
Signs of damage of 1. and 2. motor neuron in 3
of 4 regions (bulbar, cervical, thoracic,
lumbosacral)
Yes
No
Probable ALS
Signs of damage of 1. and 2. motor neuron in 2
of 4 regions, where the damage signs of 2. motor
neuron has to be in position rostral of the
damage of the 2. motor neuron
Yes
No
Probable, laboratory supported symptoms
Signs of damage of 1. and 2. motor neuron in 1
of 4 regions (or only one region of 1. motor
neuron) and signs of degeneration in EMG in at
least two extremities
Yes
No
Possible ALS
Signs of damage of 1. and 2. motor neuron in
one of 4 regions
Yes
No
Depression
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Is the patient currently diagnosed with an episode
of major depression according to the criteria of
DSM-IV?
Yes
No
Key syndrome: Episode of major depression
Five (or more) of the following symptoms have
been present during the same 2-week period and
represent a change from previous functioning;
at least one of the symptoms is either (1)
depressed mood or (2) loss of interest or
pleasure.
1 depressed mood most of the day, nearly every
day, as indicated by either subjective report (e.g.,
feels sad or empty) or observation made by
others (e.g., appears tearful). 
2 markedly diminished interest or pleasure in all,
or almost all, activities most of the day, nearly
every day (as indicated by either subjective
account or observation made by others)
3 significant weight loss when not dieting or
weight gain (e.g., a change of more than 5% of
body weight in a month), or decrease or increase
in appetite nearly every day. 
4 insomnia or hypersomnia nearly every day
5 psychomotor agitation or retardation nearly
every day (observable by others, not merely
subjective feelings of restlessness or being
slowed down)
6 fatigue or loss of energy nearly every day
7 feelings of worthlessness or excessive or
inappropriate guilt (which may be delusional)
nearly every day (not merely self-reproach or guilt
about being sick)
8 diminished ability to think or concentrate, or
indecisiveness, nearly every day (either by
subjective account or as observed by others)
9 recurrent thoughts of death (not just fear of
dying), recurrent suicidal ideation without a
specific plan, or a suicide attempt or a specific
plan for committing suicide
Yes
No
B The symptoms do not meet criteria for a Mixed
Episode
Yes
No
C. The symptoms cause clinically significant
distress or impairment in social, occupational, or
other important areas of functioning
Yes
No
D. The symptoms are not due to the direct
physiological effects of a substance (e.g., a drug
of abuse, a medication) or a general medical
condition (e.g., hypothyroidism).
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Yes
No
E. The symptoms are not better accounted for by
bereavement, i.e., after the loss of a loved one,
the symptoms persist for longer than 2 months or
are characterized by marked functional
impairment, morbid preoc-cupation with
worthlessness, suicidal ideation, psychotic
symptoms, or psychomotor retardation.
Yes
No
A. Presence of a single Major Depressive
Episode
Yes
No
B. The Major Depressive Episode is not better
accounted for by Schizoaffective Disorder and is
not superimposed on Schizophrenia,
Schizophreniform Disorder, Delusional Disorder,
or Psychotic disorder not otherwise specified.
Yes
No
C. There has never been a Manic Episode, a
Mixed Episode, or a Hypomanic Episode.
Yes
No
Major depression, recurrent
A. Presence of two or more Major Depressive
Episodes. (To be considered separate episodes,
there must be an interval of at least 2 consecutive
months in which criteria are not met for a Major
Depressive Episode)
Yes
No
B. The Major Depressive Episodes are not better
accounted for by Schizoaffective Disorder and
are not superimposed on Schizophrenia,
Schizophreniform Disorder, Delusional Disorder,
or Psychotic Disorder Not Otherwise Specified.
Yes
No
There has never been a Manic Episode, a Mixed
Episode, or a Hypomanic Episode. (This
exclusion does not apply if all of the manic-like,
mixed-like, or hypomanic-like episodes are
substance or treatment induced or are due to the
direct physiological effects of a general medical
condition.)
Yes
No
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Common Data Elements Myeloid Leukemia
Lab: Cytology/Cytogenetics/Cytochemistry
Common Data Element for Myeloid Leukemia (MDS, AML,
CML) for use
in clinical routine and clinical trial documentation.
All rights reserved. Please visit https://medical-data-
models.org/forms/13848
Lab:
Cytology/Cytogenetics/Cytochemistr
y
Lab: Cytology/Cytogenetics/Cytochemistry
IPSS-R risk score
Bone marrow examination/Aspirate/Biopsy
Aspirate (Aspirate)
Biopsy (Biopsy)
Bone marrow examination date
Location of bone marrow puncture
Punctio sicca
Yes
No
Bone marrow cellularity
%
Bone marrow Blasts
%
Bone marrow Basophils
%
Bone marrow Promyelocytes
%
Auer rods
Yes
No
Karyotype Fish finding according to ISCN
Monosomal karyotype-
Yes
No
Complex Karyotype-
Yes
No
FAB Type
AML (not M3) (AML (not M3))
CMML (CMML)
M0 (M0)
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M1 (M1)
M2 (M2)
M3 (M3)
M4 (M4)
M4eo (M4eo)
M5 (M5)
M5a (M5a)
M5b (M5b)
M6 (M6)
M7 (M7)
RA (RA)
RAEBRAEB-t (RAEBRAEB-t)
RARS (RARS)
Unknown (Unknown)
Cytoplasmic Myeloperoxidase (cMPO)
Yes
No
Nonspecific esterase (NSE)
Yes
No
Lysozyme
µg/l
t(8;21)(q22;q22)
Yes
No
inv(16)(p13.1q22)
Yes
No
t(16;16)(p13.1;q22)
Yes
No
t(9;11)(p22;q23)
Yes
No
inv(3)(q21q26.2)
Yes
No
t(3;3)(q21;q26.2)
Yes
No
t(6;9)(p23;q34)
Yes
No
t(v;11)(v;q23)
Yes
No
t(9;22)(q34;q11)
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Yes
No
ASXL1 mutation
Yes
No
Major Route ACA
Isochromosom 17 (Isochromosom 17)
Trisomy 19 (Trisomy 19)
Trisomy 22 (Trisomy 22)
Trisomy 8 (Trisomy 8)
Correlation of cytogenetic and molecular genetic
data in AML (Doehner et al, 2010)
Adverse (Adverse)
Favorable (Favorable)
Intermediate-1 (Intermediate-1)
Intermediate-2 (Intermediate-2)
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Common Data Elements Myeloid Leukemia
Lab: Urinalysis
Common Data Element for Myeloid Leukemia (MDS, AML,
CML) for use
in clinical routine and clinical trial documentation.
All rights reserved. Please visit https://medical-data-
models.org/forms/13849
Lab: Urinalysis
Lab: Urinalysis
Urine pH
Urine glucose
mg/dl
Urine erythrocytes
/hpf
Urine leukocytes
/hpf
Urine protein
mg/dl
Urine nitrite positivity
Yes
No
Urine Total protein
mg/dl
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Lab: Immunophenotyping
Lab: Immunophenotyping
CD38+
Yes
No
CD117+
Yes
No
CD133+
Yes
No
CD15+
Yes
No
CD16+
Yes
No
CD33+
Yes
No
CD65+
Yes
No
CD11c
Yes
No
CD14
Yes
No
CD64
Yes
No
CD4
Yes
No
CD11b
Yes
No
CD36
Yes
No
CD41
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Yes
No
CD61
Yes
No
CD42
Yes
No
CD235a
Yes
No
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Bone Marrow Transplant
Common Data Element for Myeloid Leukemia (MDS, AML,
CML) for use
in clinical routine and clinical trial documentation.
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Bone Marrow Transplant
Bone Marrow Transplant
HSCT eligibility
Yes
No
HSCT date
Type of transplant
Allogeneic (Allogeneic)
Autologous (Autologous)
Reason for no allo-SCT
Source of Stem cells
Bone Marrow (Bone Marrow)
Peripheral blood (Peripheral blood)
Umbilical cord with number units
(Umbilical cord with number units)
Number of CD34+ infused (HSCT)
10^6kg  / Patient Body Weight
Graft loss
Yes
No
Overall chimerism
Aplasia (Aplasia)
Autologous reconstitution
(recepient>95%) (Autologous
reconstitution (recepient>95%))
Full (donor>95%) (Full (donor>95%))
Mixed (partial) (Mixed (partial))
Not evaluated (Not evaluated)
Number of siblings
Number of HLA-typed siblings
Ratio HLA matched loci / HLA loci tested
%
CMV positivity donor
Yes
No
CMV positivity patient
Yes
No
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in clinical routine and clinical trial documentation.
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GVHD
GVHD
Acute GvHD
Yes
No
aGVHD
Affected organ (aGVHD)
Gut (Gut)
Liver (Liver)
Skin (Skin)
aGVHD stage
1 (1)
2 (2)
3 (3)
4 (4)
Not evaluated (Not evaluated)
Unknown (Unknown)
aGVHD reason
aGVHD resolution
Yes
No
aGVHD prevention applied
Antihuman T-lymphocyte immune
globulin (ATG) given (Antihuman T-
lymphocyte immune globulin (ATG)
given)
MTX given (MTX given)
Mycophenolate given (Mycophenolate
given)
No (No)
Other[text] (Other[text])
Unknown (Unknown)
cGVHD
Chronic GvHD
Yes
No
Affected organ (cGVHD)
Eyes (Eyes)
Gut (Gut)
Liver (Liver)
Lung (Lung)
Mouth (Mouth)
Other[text] (Other[text])
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Skin (Skin)
cGVHD stage
Extensive (Extensive)
Limited (Limited)
Unknown (Unknown)
cGVHD reason
cGVHD resolution
Yes
No
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Lab: Molecular Genetics
Common Data Element for Myeloid Leukemia (MDS, AML,
CML) for use
in clinical routine and clinical trial documentation.
All rights reserved. Please visit https://medical-data-
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Lab: Molecular Genetics
Lab: Molecular Genetics
Molecular Genetic Analysis
RUNX1/RUNX1T1 Fusion
Yes
No
HLA-Typing
HLA-A (HLA-A)
HLA-B (HLA-B)
HLA-C (HLA-C)
HLA-DQ (HLA-DQ)
HLA-DR (HLA-DR)
CEBPA Mutation
double mutation (double mutation)
none (none)
single mutation (single mutation)
BCR-ABL International Scale Percent Ratio of
Fusion Transcripts
KIT Mutation
Yes
No
RAS Mutation
Yes
No
TP 53 Mutation
Yes
No
TET2 Mutation
Yes
No
IDH1 Mutation
Yes
No
ERG Mutation
Yes
No
MN1 Mutation
Yes
No
EVI1 overexpression
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Yes
No
BAALC overexpression
Yes
No
CBFB-MYH11 Fusion
Yes
No
PML - RARA Fusion
Yes
No
MLL  - MLLT3 Fusion
Yes
No
GATA2 - EVI1 Fusion
Yes
No
DEK - NUP214 Fusion
Yes
No
MLL rearranged
Yes
No
del(5q)
Yes
No
Loss of Chromosome 7
Yes
No
abnl(17p)
Yes
No
NPM1 Mutation
Yes
No
FLT Internal Tandem Duplication (ITD)
Yes
No
FLT3 point mutation
Yes
No
Other mutations
[Dynamic codelist] ([Dynamic codelist])
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Treatment Details
Common Data Element for Myeloid Leukemia (MDS, AML,
CML) for use
in clinical routine and clinical trial documentation.
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Treatment Details
Treatment Details
Chemotherapy regimen
Chemotherapy cycle Number
Drug Name
Medication Start Date
Medication End Date
Medication Route of Administration
[codelist] ([codelist])
Unit of Drug Administration
Drug Dose
Total Drug Dose within therapy block
Therapeutic Procedure
[codelist] ([codelist])
Conditioning therapy
Myelo ablative (Myelo ablative)
No conditioning (No conditioning)
Non-myelo ablative (Non-myelo ablative)
Other[text] (Other[text])
Cellular therapy: Type of cells
Donor lymphocyte infusion (DLI)
Mesenchymal cells (Donor lymphocyte
infusion (DLI) Mesenchymal cells)
Other[text] (Other[text])
Unknown (Unknown)
Treatment Error
Yes
No
Donor Relation
1-antigen-mismatched related Donor (1-
antigen-mismatched related Donor)
2-or-more antigen mismatched related
donor (haplo-identical) (2-or-more
antigen mismatched related donor
(haplo-identical))
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Cord blood unit identified (Cord blood
unit identified)
HLA-identical parent (HLA-identical
parent)
HLA-identical sibling (HLA-identical
sibling)
Matched unrelated donor (Matched
unrelated donor)
Mismatched unrelated donor
(Mismatched unrelated donor)
Monocygotic twin (Monocygotic twin)
Unknown (Unknown)
EBMT Risk Score
T-cell depletion
Yes
No
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Administrative/Demographic Details
Common Data Element for Myeloid Leukemia (MDS, AML,
CML) for use in clinical routine and clinical trial
documentation.
All rights reserved. Please visit https://medical-data-
models.org/forms/13856
Administrative/Demographic Details
Administrative/Demographic Details
Patient Birth Date
Patient Sex
Female (Female)
Male (Male)
Patient/ Study Subject Identification(s)
Hospital Identifier
Admission Date
Discharge Date
Which protocol treatment arm is the patient
assigned to?
Ethnicity
Afro-Carribean (Afro-Carribean)
Caucasian (Caucasian)
Chinese (Chinese)
Filipino (Filipino)
Kurd (Kurd)
Latin American (Latin American)
North African (North African)
Not Known (Not Known)
Other  (Other )
Roma (Roma)
South Asian (South Asian)
Sub-Saharan African (Sub-Saharan
African)
Turk (Turk)
Informed Consent
No (No)
Withdrawn (Withdrawn)
Yes (Yes)
Patient unable to understand or sign informed
consent
Yes
No
Date patient last known to be alive/seen
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Medical History
Diagnosis
Previous/Current Diagnosis (diagnosis code)
Date of Diagnosis
Medical History
Record of malignant neoplasms
Medical History/Concomitant Diseases
Lens opacities ( 10)
Macular degeneration ( 11)
Other ophtalmic Disease (please specify)
( 12)
Hearing Impairment ( 13)
Diabetes mellitus ( 14)
Thyroid disease ( 15)
Pituitary dysfunction ( 16)
Gonadal dysfunction ( 17)
Adrenal dysfunction ( 18)
Renal disease ( 19)
Angina pectoris ( 2)
Hepatic disease ( 20)
Malignant disease ( 21)
Inflammatory Bowel disease ( 22)
Cerebro-vascular disease ( 23)
Rheumatological disease ( 24)
Peptic ulcer ( 25)
Auto-immune disease ( 26)
Organ Transplant ( 27)
Alcohol abuse ( 28)
Positive HIV Status ( 29)
Cardiac arrhythmia ( 3)
Enlargement of lymph-nodes ( 30)
Splenomegaly ( 31)
Other (please specify)[text] ( 32)
Heart failure requiring drug treatment ( 4)
Dyspnea on moderate activity ( 5)
Psychiatric disturbance ( 6)
Infection (see "Infection" below) ( 9)
Myocardial infarction (1)
Hematopoietic Cell Transplantation-Comorbidity
Index
Exposure to toxic agents
Benzene (Benzene)
Insecticides (Insecticides)
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Family History
Family History:Family member
Brother (Brother)
Father (Father)
Grandparent (Grandparent)
Mother (Mother)
Other (Other)
Sister (Sister)
Family History:Diseases of family member
Leukemic diseases (Leukemic diseases)
Malignant neoplasms (Malignant
neoplasms)
Tobacco consumption
Pack/years
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Physical Examination/Follow up
Common Data Element for Myeloid Leukemia (MDS, AML,
CML) for use
in clinical routine and clinical trial documentation.
All rights reserved. Please visit https://medical-data-
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Physical Examination/Follow up
Physical Examination/Follow up
Body Height
cm
Body Weight
kg
Body Surface Area
m2
Pregnancy
Yes
No
Leukemic Extramedullary Manifestation
Liver (Liver)
Lymph Node (Lymph Node)
Other [text] (Other [text])
Skin (Skin)
Spleen (Spleen)
ECOG performance status finding
0 (0)
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
Non-hematological toxicity
Yes
No
Survival Status
Alive (Alive)
Dead (Dead)
Cause of Death
ICD Codes and/or others (ICD Codes
and/or others)
Vitals
Heart Rate
beats/min
Systolic Blood Pressure
mmHg
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Diastolic Blood Pressure
mmHg
CTCAE
CTCAE Adverse Event Name
CTCAE Grade
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
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Global Disease Course
Common Data Element for Myeloid Leukemia (MDS, AML,
CML) for use
in clinical routine and clinical trial documentation.
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Global Disease Course
Global Disease Course
Minimal Residual Disease
Yes
No
Disease Response/Remission Status
CR with incomplete recovery (CRi) [with
date] (CR with incomplete recovery (CRi)
[with date])
Cytogenic CR (CRc) [with date]
(Cytogenic CR (CRc) [with date])
Death [with date] (Death [with date])
Molecular CR (CRm) [with date]
(Molecular CR (CRm) [with date])
Morphologic leukemia- free state [with
date] (Morphologic leukemia- free state
[with date])
Partial Remission [with date] (Partial
Remission [with date])
Progression [with date] (Progression
[with date])
Relapse [with date] (Relapse [with date])
Resistant disease (RD) [with date]
(Resistant disease (RD) [with date])
Suggested Minimum Value Set:
Complete remission (CR) [with date]
(Suggested Minimum Value Set:
Complete remission (CR) [with date])
WHO - AML Classification
AML with t(8;21)(q22;q22);RUNX1-
RUNX1T1 (1)
AML with inv(16)(p13.1;q22) or
t(16;16)(p13.1;q22);CBFB - MYH11 (2)
Acute promyelocytic leukaemia with
t(15;17)(q22;q12);PML/RARA (3)
AML with t(9;11)(p22;q23);MLLT 3-MLL
(4)
AML with myelodysplasia related
changes (with multilineage dysplasia;w/o
MDS or MDS/MPN antecedents (5)
AML with t(6;9)(p23;q24);DEK - NUP214
(6)
AML with inv(3)(q21;q26.2) or
t(3;3)(q21;q26.2);RPN1 - EVI1 (7)
AML (megakaryoblastic) with
t(1;22)(p13;q13)RBM15 - MKL1 (8)
Molecular Remission BCR-ABL
<0.001% (MR5) (<0.001% (MR5))
bcr-abl<0,0032% (MR4,5) (bcr-
abl<0,0032% (MR4,5))
bcr-abl<0,1%(MMR) (bcr-
abl<0,1%(MMR))
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bcr-abl<0,1%(MR4) (bcr-
abl<0,1%(MR4))
bcr-abl<10% (bcr-abl<10%)
bcr-abl>10% (bcr-abl>10%)
Active Infection
No (No)
Unknown (Unknown)
Yes:controlled (Yes:controlled)
Yes:uncontrolled (Yes:uncontrolled)
AML pathogens of interest
Adenovirus (Adenovirus)
Aspergillus (Aspergillus)
Candida sp (Candida sp)
CMV (CMV)
EBV (EBV)
Haemophilus influenzae (Haemophilus
influenzae)
HBV (HBV)
HCV (HCV)
HHV-6 (HHV-6)
HIV (HIV)
HSV (HSV)
Legionella sp (Legionella sp)
Mycobacteria sp (Mycobacteria sp)
other gram-negative (i.e.: E.Coli
klebsiella,proteus,serratia,pseudomonas,
...) (other gram-negative (i.e.: E.Coli
klebsiella,proteus,serratia,pseudomonas,
...))
other gram-positive (i.e.: other
streptococci,listeria,...) (other gram-
positive (i.e.: other
streptococci,listeria,...))
Other respiratory virus (influenza,
parainfluenza, rhinovirus) (Other
respiratory virus (influenza,
parainfluenza, rhinovirus))
other[text] (other[text])
Papovavirus (Papovavirus)
Pneumocystis carinii (Pneumocystis
carinii)
RSV (RSV)
S.pneumoniae (S.pneumoniae)
Toxoplasma gondii (Toxoplasma gondii)
VZV (VZV)
Complications
ARDS non infectious [Yes, No,unknown]
(ARDS non infectious [Yes,
No,unknown])
Aseptic bone necrosis [Yes, No,
unknown] (Aseptic bone necrosis [Yes,
No, unknown])
Cataract [Yes, No, unknown] (Cataract
[Yes, No, unknown])
Endorgan disease [Pneumonia,
Hepatitis,CNS infection, Gut infection,
skin infection,Cystitis, Retinitis, Other]
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(Endorgan disease [Pneumonia,
Hepatitis,CNS infection, Gut infection,
skin infection,Cystitis, Retinitis, Other])
Haemolytic anemia due to blood group
[Yes, No, unknown] (Haemolytic anemia
due to blood group [Yes, No, unknown])
Haemorrhagic cystitis non infectious
[Yes, No, unknown] (Haemorrhagic
cystitis non infectious [Yes, No,
unknown])
HSCT-associated microangiopathy [Yes,
No, unknown] (HSCT-associated
microangiopathy [Yes, No, unknown])
Idiopathic pneumonia syndrome [Yes,
No, unknown]  (Idiopathic pneumonia
syndrome [Yes, No, unknown] )
Infection (Infection)
Multiorgan failure [Yes, No, unknown]
(Multiorgan failure [Yes, No, unknown])
Non infection related complications [Yes,
No] (Non infection related complications
[Yes, No])
Other[text] (Other[text])
Renal failure requiring dialysis [Yes, No,
unknown] (Renal failure requiring dialysis
[Yes, No, unknown])
Systemic symptoms of infection [Septic
shock, ARDS,Multiorgan failure due to
infection]  (Systemic symptoms of
infection [Septic shock, ARDS,Multiorgan
failure due to infection] )
VOD [ Yes, No, unknown] (VOD [ Yes,
No, unknown])
Red Cell Transfusion
Date of red cell transfusion
Number of units in red cell transfusion
Platelet Cell Transfusion
Date of platelet transfusion
Number of units in platelet transfusion
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Common Data Elements Myeloid Leukemia
Apparatus-based Diagnostics
Common Data Element for Myeloid Leukemia (MDS, AML,
CML) for use
in clinical routine and clinical trial documentation.
All rights reserved. Please visit https://medical-data-
models.org/forms/13860
Apparatus-based Diagnostics
Apparatus-based Diagnostics
Splenic volume by ultrasound
cm3
Chest X-Ray report
[add further text] ([add further text])
abnormal  (abnormal )
normal (normal)
ECG report
[add further text] ([add further text])
abnormal  (abnormal )
normal (normal)
Echocardiography report
[add further text] ([add further text])
abnormal  (abnormal )
normal (normal)
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Eligibility Leukemia NCT01390402
Alloreactive Haploidentical Natural Killer (NK) Cells With
Busulfan and Fludarabine/ATG; ODM derived from:
https://clinicaltrials.gov/show/NCT01390402
All rights reserved. Please visit https://medical-data-
models.org/forms/13862
Eligibility Leukemia NCT01390402
Inclusion Criteria
1. patients who meet the following eligibility
criteria are eligible for inclusion in this study.
pediatric team to assess eligibility appropriate for
patient age.*
Yes
No
2. age </= 70 years of age.*
Yes
No
3. patients with diagnosis of cml in first chronic
phase or accelerated phase with less than 15%
blast in the blood and bone marrow at study entry
which has failed to respond adequately to
imatinib by the consensus criteria of baccarani et
al: a) no hematologic remission at 3 months, b)
no cytogenetic response at 6 months, c) no major
cytogenetic response at 12 months, d) no
complete cytogenetic response or major
molecular response at >18 months, or e) loss of a
response with increasing cytogenetic or
molecular evidence of disease. or are intolerant
to tyrosine kinase inhibitor therapy. or with
second or greater chronic phase (with prior
transformation who respond to treatment and
have <15% blasts at study entry).*
Yes
No
4. histocompatible stem cell donor: patients must
have an hla matched related or unrelated donor
(hla a, b, c and dr) willing to donate for allogeneic
hematopoietic transplantation.*
Yes
No
5. haploidentical nk cell donor: patients must
have a haploidentical relative with the absence of
a kir-ligand (hla molecule).*
Yes
No
6. performance status: zubrod </= 2 or lansky ps
greater or equal to 70%.*
Yes
No
7. cardiac function: left ventricular ejection
fraction >/= 40%. no uncontrolled arrhythmias or
uncontrolled symptomatic cardiac disease.*
Yes
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No
8. pulmonary function: no symptomatic
pulmonary disease. forced expiratory volume at
one second (fev1), forced vital capacity (fvc) and
diffusion capacity of lung for carbon monoxide
(dlco) >/= 50% of expected, corrected for
hemoglobin. for pediatric patients, if unable to
perform pulmonary function tests (most children
< 7 years of age), pulse oximetry >/= 92% on
room air by pulse oximetry.*
Yes
No
9. renal function: serum creatinine </= 1.8mg/dl
or creatinine clearance greater or equal than 40
cc/min. creatinine for pediatric patients </= 1.5
mg/dl or </= 2 times upper limit of normal for age
(whichever is less).*
Yes
No
10. liver function: bilirubin </= 1.5 mg/dl (unless
gilbert's syndrome), alt or ast </= 200 iu/ml for
adults unless related to underline disease. for
pediatric patients conjugated (direct) bilirubin <2x
upper limit of normal, alt or ast <5 times upper
limit of normal.no evidence of chronic active
hepatitis or cirrhosis. if positive hepatitis serology,
discuss with study chairman and consider liver
biopsy.*
Yes
No
11. patient or patient's legal representative,
parent(s) or guardian able to provide written
informed consent. assent as is age appropriate.*
Yes
No
Exclusion Criteria
1. uncontrolled infection, not responding to
appropriate antimicrobial agents after seven days
of therapy. the protocol pi is the final arbiter of
eligibility.*
Yes
No
2. pleural/pericardial effusion or ascites estimated
to be >1l*
Yes
No
3. hiv-positive.*
Yes
No
4. breast feeding or pregnancy. pregnancy means
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a positive beta human chorionic gonadotropin
(hcg) test in a woman with child bearing potential
defined as not post-menopausal for 12 months or
no previous surgical sterilization.*
Yes
No
5. known allergy to mouse proteins*
Yes
No
6. active hepatitis b or c infection.*
Yes
No
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Eligibility Leukemia NCT01428635
Eltrombopag for Management of Thrombocytopenia; ODM
derived from: https://clinicaltrials.gov/show/NCT01428635
All rights reserved. Please visit https://medical-data-
models.org/forms/13863
Eligibility Leukemia NCT01428635
Inclusion Criteria
1. cml patients in chronic phase receiving
treatment with any fda approved tki; or cml
patients in accelerated or blastic phase who are
considered to be in this phase because of
thrombocytopenia or because of clonal evolution
and with no other criteria for accelerated/blastic
phase or patients with myelofibrosis receiving
treatment with fda approved tki and with
peripheral blood and/or bone marrow blasts </=
10%.*
Yes
No
2. grade >/= 3 thrombocytopenia (platelets < 50 x
10^9/l) after the first 3 months of therapy with the
tki for patients with cml and platelets <100 x
10^9/l for patients with mf after the first 3 months
of therapy. thrombocytopenia must be either
recurrent (i.e., second or greater episode of
thrombocytopenia) or having required dose
reductions of the tki.*
Yes
No
3. subject is anticipated to have therapy with tki
continued for >/= 3 months*
Yes
No
4. adequate organ function: total bilirubin (except
for gilbert's syndrome) </= 1.5 x uln; alt and ast <
3 x uln; creatinine </= 2 x uln*
Yes
No
Exclusion Criteria
1. cml patients in accelerated or blastic phase
except for those who are considered to be in this
phase because of thrombocytopenia or because
of clonal evolution and with no other criteria for
accelerated/blastic phase; or myelofibrosis
patients who have transformed to acute leukemia
or have >/= 10% blasts in peripheral  blood
and/or in bone marrow.*
Yes
No
2. thrombocytopenia that is considered to be
unrelated to treatment with tki or accelerated
phase as defined above;*
Yes
No
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3. age < 18 years;*
Yes
No
4. stem cell transplantation within preceding 60
days prior to registration;*
Yes
No
5. patients with documented active hepatitis b or
c infection;*
Yes
No
6. patients with known bone marrow reticulin
fibrosis (only applicable to patients with cml);*
Yes
No
7. patients with palpable splenomegaly >/= 16cm
below coastal margin (only applicable to patients
with cml).*
Yes
No
8. female subjects who are pregnant or
breastfeeding. women of childbearing potential
are required to have a bhcg serum or urine
pregnancy test performed within 7 days prior to
first study drug dose. a female of childbearing
potential is a sexually mature woman who: 1) has
not undergone a hysterectomy or bilateral
oophorectomy; or 2) has not been naturally
postmenopausal for at least 12 consecutive
months (i.e., has had menses at any time in the
preceding 12 consecutive months). women of
child-bearing potential and men must agree to
use contraception prior to study entry and for the
duration of study participation.*
Yes
No
9. patients with known risk factors for
thromboembolism (e.g. factor v leiden mutation,
atiii deficiency, protein c and s deficiency,
antiphospholipid syndrome, portal hypertension,
etc.)*
Yes
No
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Eligibility Leukemia, Myeloid, Acute,
NCT01468467
A Study of AC220 Given After Transplant in Subjects With
Acute Myeloid Leukemia (AML); ODM derived from:
https://clinicaltrials.gov/show/NCT01468467
All rights reserved. Please visit https://medical-data-
models.org/forms/13864
Eligibility Leukemia, Myeloid, Acute,
NCT01468467
Inclusion Criteria
subject has a diagnosis of acute myeloid
leukemia (aml) according to who classification
(2008) and has received a high dose or a
reduced intensity conditioning allogeneic
hematopoietic stem cell transplant (hsct) during
first or second remission and within 30 to 60 days
prior to first dose of ac220. donors may be
human leukocyte antigen (hla)-matched for hla-a,
b, c, drb1, and dqb1 by high resolution typing,
related or unrelated (only a single allele disparity
will be allowed for hla-a, b, or c as defined by
high resolution typing) note:  more than one hsct
is allowed*
Yes
No
subject must be in morphologic remission (< 5%
marrow blasts) and without active central nervous
system (cns) aml within 14 days prior to first dose
of ac220*
Yes
No
subject must have cd3 donor chimerism > 50 %
at screening*
Yes
No
subject has a karnofsky performance status (kps)
of ≥ 60*
Yes
No
subject must have absolute neutrophil count
(anc) > 1000/mm3 and platelet count >
50,000/mm3 without platelet transfusion support
within 2 weeks prior to first dose*
Yes
No
subject must have adequate renal, hepatic, and
coagulation parameters*
Yes
No
female subjects must not be lactating and must
not be breastfeeding at screening or during the
study period and for 28 days [or five half lives of
the study drug whichever is longer] after final
study drug administration.*
Yes
1 / 3
No
subject is able to comply with study procedures
and follow-up examinations*
Yes
No
Exclusion Criteria
subject received ac220 and relapsed during
treatment with ac220*
Yes
No
subject has active ≥ grade 2 graft versus host
disease (gvhd)*
Yes
No
subject has received concurrent chemotherapy,
immunotherapy, or radio-therapy within 21 days
prior to the first dose of ac220, or any
antineoplastic therapy that is considered to be
investigational (i.e., used for non-approved
indications(s) and in the context of a research
investigation) within 30 days or 5 half-lives
(whichever is longer) prior to the first dose of
study drug*
Yes
No
subject requires treatment with concomitant
drugs that prolong qt/qtc interval or strong
cytochrome p-3a4 (cyp3a4) inhibitors or inducers
with the exception of immunosuppressants,
antibiotics, antifungals, and antivirals that are
used as standard of care post-transplant or to
prevent or treat infections and other such drugs
that are considered absolutely essential for the
care of the subject*
Yes
No
subject requires treatment with anticoagulant
therapy*
Yes
No
subject has a known positive test for human
immunodeficiency virus, hepatitis c, or hepatitis b
surface antigen*
Yes
No
subject had major surgery within 4 weeks prior to
first dose of ac220*
Yes
No
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subject has uncontrolled or significant
cardiovascular disease*
Yes
No
subject has an active acute fungal, bacterial, or
other infection that is unresponsive to therapy*
Yes
No
subject has participated in any interventional
clinical study or has been treated with any
investigational drugs within 30 days or 5 half lives
whichever is longer, prior to the initiation of
screening.*
Yes
No
subject has any medical, psychiatric, addictive or
other kind of disorder which compromises the
ability of the subject to give written informed
consent and/or to comply with procedures*
Yes
No
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Eligibility Major Depressive Disorder
NCT01421342
VA Augmentation and Switching Treatments for Improving
Depression Outcomes; ODM derived from:
https://clinicaltrials.gov/show/NCT01421342
All rights reserved. Please visit https://medical-data-
models.org/forms/13865
Eligibility Major Depressive Disorder
NCT01421342
Inclusion Criteria
dsm-iv diagnosis of single or recurrent, non-
psychotic, major depressive disorder*
Yes
No
currently taking a selective serotonin reuptake
inhibitor (ssri) or serotonin-norepinephrine
reuptake inhibitor (snri) or mirtazapine for major
depressive disorder*
Yes
No
need for "next-step" treatment based on
documented suboptimal outcome from current
antidepressant treatment for major depressive
episode (at least 6 weeks treatment with a qids-
c16 >= 16 or at least 8 weeks with a qids-c16 >=
11; and at least 3 weeks at a stable "optimal"
dose*
Yes
No
age: 18 years of age or older*
Yes
No
Exclusion Criteria
prior inadequate response after an adequate
treatment trial or clear cut intolerance to either of
the study medications (aripiprazole or
bupropion)*
Yes
No
current treatment with bupropion, aripiprazole or
any other antipsychotic agent*
Yes
No
lifetime history of bipolar disorder, schizophrenia,
schizoaffective disorder, or psychosis not
otherwise specified*
Yes
No
current diagnosis of dementia*
Yes
No
current diagnosis of an eating disorder or a
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seizure disorder*
Yes
No
high suicide risk currently requiring acute
intervention (other than outpatient treatment of
depression)*
Yes
No
unstable, serious medical condition or one
requiring acute medical treatment, or anticipation
of hospitalization for extended care*
Yes
No
requiring immediate hospitalization for psychiatric
disorders*
Yes
No
physiologic substance dependence requiring
detoxification (excluding nicotine) in the past 30
days (substance abuse is not an exclusion
criteria)*
Yes
No
taking  any concomitant medication that
contraindicates any of treatment options or
augmenting agents known to have an
antidepressant effect*
Yes
No
concurrent or recent participation (within the last
30 days) in another conflicting clinical trial with a
mental health, investigational drug, or medical
device intervention*
Yes
No
female - pregnant or lactating or planning to
become pregnant*
Yes
No
patient was not able or willing to provide informed
consent; or changed mind about participating
prior to randomization*
Yes
No
patient was not referred to the study*
Yes
No
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Eligibility Major Depressive Disorder
NCT01423240
Major Depressive Disorder With Mixed Features; ODM
derived from: https://clinicaltrials.gov/show/NCT01423240
All rights reserved. Please visit https://medical-data-
models.org/forms/13866
Eligibility Major Depressive Disorder
NCT01423240
Inclusion Criteria
subject provides written informed consent and is
willing and able to comply with the protocol in the
opinion of the investigator.*
Yes
No
subject is 18 to 75 years of age, inclusive. subject
has mdd (diagnosed by dsm-iv-tr, and confirmed
by the structured clinical interview for dsm-iv
disorders - clinical trial version [scid-ct]).*
Yes
No
subject is currently experiencing a major
depressive episode (diagnosed by dsm-iv-tr; at
least 2 weeks in duration) and two or three of the
following manic symptoms occurring on most
days over at least the last 2 weeks (confirmed by
the scid-ct modified for study d1050305):*
Yes
No
elevated, expansive mood*
Yes
No
inflated self-esteem or grandiosity*
Yes
No
more talkative than usual or pressure to keep
talking*
Yes
No
flight of ideas or subjective experience that
thoughts are racing*
Yes
No
increase in energy or goal-directed activity (either
socially, at work or school, or sexually)*
Yes
No
increased or excessive involvement in activities
that have a high potential for painful
consequences (e.g., engaging in unrestrained
buying sprees, sexual indiscretions, or foolish
business investments)*
Yes
1 / 2
No
decreased need for sleep (feeling rested despite
sleeping less than usual; to be contrasted from
insomnia) subject has a rater-administered
montgomery-asberg depression rating scale
(madrs) total score of ≥ 26 at screening and both
a rater-administered and self-rated (administered
by computer) madrs total score ≥ 26 at baseline.*
Yes
No
Exclusion Criteria
subject has axis i or axis ii diagnosis other than
mdd that has been the primary focus of treatment
within the 3 months prior to screening subject
answers "yes" to "suicidal ideation" item 4 or 5 on
the c-ssrs (at time of evaluation) at screening or
baseline visit.*
Yes
No
subject has attempted suicide within the past 3
months. subject has a lifetime history of any
bipolar i manic or mixed manic episode. subject
has any abnormal laboratory parameter at
screening that indicates a clinically significant
medical condition as determined by the
investigator.*
Yes
No
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Eligibility Major Depressive Disorder
NCT01464229
Iloperidone Augmentation of SSRIs for Patients With Major
Depressive Disorder With Residual Anger and Irritability;
ODM derived from:
https://clinicaltrials.gov/show/NCT01464229
All rights reserved. Please visit https://medical-data-
models.org/forms/13867
Eligibility Major Depressive Disorder
NCT01464229
Inclusion Criteria
written informed consent.*
Yes
No
men or women ages 18-65 years old.*
Yes
No
current major depressive episode in partial
remission based on the structured clinical
interview for dsm iv-axis i disorders (scid i/p) and
a ham-d-17 score between 9 and 15.*
Yes
No
current treatment with a selective serotonin
reuptake inhibitor (ssri) other than paroxetine or
fluoxetine for at least three months, at a stable
dose for the past 4 weeks, and more than 50%
but less than 75% improvement on the current
antidepressant, as determined by the mgh
antidepressant treatment response questionnaire
(atrq).*
Yes
No
score > 8 on the anger/hostility scale of the
symptom questionnaire both at screen and
baseline.*
Yes
No
Exclusion Criteria
the following dsm-iv diagnoses: 1) organic mental
disorders; 2) substance use disorders, including
alcohol, active within the last 3 months; 3)
schizophrenia; 4) delusional disorder; 5)
psychotic disorders not elsewhere classified; 6)
bipolar disorder; and 9) antisocial personality
disorder; 10) dementia.*
Yes
No
current, serious suicidal or homicidal risk.*
Yes
No
pregnancy or breast-feeding.*
Yes
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No
serious, unstable medical illness including
cardiovascular, kidney, liver, neurological and
endocrine disorders.*
Yes
No
congenital long qt syndrome or a qtc > 450 ms.*
Yes
No
history of cardiac arrhythmias.*
Yes
No
electroconvulsive therapy (ect) within the 6
months preceding baseline.*
Yes
No
concomitant use of buspirone, fluoxetine,
paroxetine, any psychostimulant, modafinil, other
antipsychotic drugs, or anticonvulsants (although
stable doses of benzodiazepines and hypnotics
are allowed) (see concomitant therapy).*
Yes
No
2 / 2
Eligibility Major Depressive Disorder NCT01464229
Eligibility Male Breast Cancer
NCT01463072
Paclitaxel Albumin-Stabilized Nanoparticle Formulation in
Treating Older Patients With Locally Advanced or
Metastatic Breast Cancer; ODM derived from:
https://clinicaltrials.gov/show/NCT01463072
All rights reserved. Please visit https://medical-data-
models.org/forms/13868
Eligibility Male Breast Cancer
NCT01463072
Inclusion Criteria
locally advanced or metastatic breast cancer*
Yes
No
any estrogen receptor (er), progesterone receptor
(pr), or human epidermal growth factor receptor 2
(her2neu) status as long as the patient will
receive nab-paclitaxel alone*
Yes
No
first or second line chemotherapy treatment for
metastatic disease*
Yes
No
karnofsky performance scale (kps) >= 70%*
Yes
No
resolution of grade >= 2 toxicity from prior therapy
(other than alopecia)*
Yes
No
peripheral neuropathy =< grade 1*
Yes
No
absolute neutrophil count >= 1,500/mm^3*
Yes
No
platelets >= 100,000 cells/mm^3*
Yes
No
hemoglobin (hb) >= 9.0 g/dl*
Yes
No
aspartate aminotransferase (ast) and alanine
aminotransferase (alt) =< 2.5 x institutional upper
limit of normal*
Yes
No
alkaline phosphatase =< 2.5 x upper limit of
normal unless bone metastasis are present in the
absence of liver metastases*
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Yes
No
bilirubin =< 1.5 mg/dl*
Yes
No
creatinine clearance (calculated or 24 hour) >=
30 ml/min*
Yes
No
ability to understand and the willingness to sign a
written informed consent document*
Yes
No
Exclusion Criteria
patients may not be receiving any other
investigational agents*
Yes
No
untreated central nervous system (cns)
metastases or symptomatic cns metastases
requiring escalating doses of corticosteroids*
Yes
No
known history of allergic reactions to paclitaxel*
Yes
No
presence of any serious or uncontrolled infection*
Yes
No
receipt of a taxane for adjuvant therapy or
metastatic disease in the last 12 months*
Yes
No
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Eligibility Mantle Cell Lymphoma
NCT01439750
Bortezomib (VELCADE), Cladribine and Rituximab (VCR)
in Mantle Cell Lymphoma (PSHCI 10-011); ODM derived
from: https://clinicaltrials.gov/show/NCT01439750
All rights reserved. Please visit https://medical-data-
models.org/forms/13869
Eligibility Mantle Cell Lymphoma
NCT01439750
Inclusion Criteria
females that are postmenopausal for at least 1
year before the screening visit, surgically
sterilized or if they are of childbearing potential
agree to practice 2 effective methods of
contraception from the time of signing the
informed consent form through 30 days after the
last dose.*
Yes
No
male subjects must agree to practice effective
barrier contraception during the entire study
treatment period and through a minimum of 30
days after the last dose of study drug, or
completely abstain from heterosexual
intercourse.*
Yes
No
patients with newly diagnosed and relapsed
mantle cell lymphoma.*
Yes
No
ecog performance status grade 3 or higher.*
Yes
No
Exclusion Criteria
patient has a platelet count of <50x10 9/l within
14 days before enrollment if not related to
disease.*
Yes
No
patient has an absolute neutrophil count less
than 100 within 14 days before enrollment if not
related to disease.*
Yes
No
patient has a calculated or measured creatinine
clearance of <20 ml/minute within 14 days before
enrollment.*
Yes
No
patient has > grade 2 peripheral neuropathy
within 14 days before enrollment.*
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Yes
No
patient has > 1.5 x uln total bilirubin.*
Yes
No
myocardial infarction within 6 months prior to
enrollment or has new york heart association
class ii or iv heart failure, uncontrolled angina,
severe uncontrolled ventricular arrhythmias, or
electrocardiographic evidence of acute ischemia
or active conduction system abnormalities.*
Yes
No
patient has hypersensitivity to bortezomib, boron
or mannitol.*
Yes
No
female subject is pregnant or breast-feeding.*
Yes
No
patient has received other investigational drugs
within 14 days before enrollment.*
Yes
No
serious medical or psychiatric illness likely to
interfere with participation in this clinical study.*
Yes
No
diagnosed or treated for another malignancy
within 3 years of enrollment, with the exception of
complete resection of basal cell carcinoma or
squamous cell carcinoma of the skin, an in situ
malignancy, or low-risk prostate cancer after
curative therapy.*
Yes
No
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Eligibility Metastatic Breast Cancer
NCT00907959
A Clinical Trial Assessing Safety and Efficacy of BZL101 for
Metastatic Breast Cancer; ODM derived from:
https://clinicaltrials.gov/show/NCT00907959
All rights reserved. Please visit https://medical-data-
models.org/forms/13870
Eligibility Metastatic Breast Cancer
NCT00907959
Inclusion Criteria
1. women 18 years or older.*
Yes
No
2. histologically confirmed diagnosis of breast
cancer based on pathology report of primary,
regional or metastatic breast cancer.*
Yes
No
3. clinical evidence of metastatic (stage iv)
involvement other than bone only metastasis
based on the investigator's clinical and/or
radiographic findings.*
Yes
No
4. availability of estrogen receptor and
progesterone receptor status measured on
biopsy tissue. (status on the most recent biopsy
where er/pr status was documented will be used
to determine hormone receptor status for
stratification).*
Yes
No
5. at least one measurable disease site defined
by recist criteria, with measurement made within
30 days of beginning study therapy. (non-
measurable disease includes bone lesions,
leptomeningeal disease, ascites,
pleural/pericardial effusion, inflammatory breast
disease, lymphangitis cutis/pulmonis, abdominal
masses that are not confirmed and followed by
imaging techniques, and cystic lesions. for
lesions in a previously irradiated field, the
radiated lesion cannot be assessed as a
measurable lesion unless growth of that lesion
has been documented after radiation).*
Yes
No
6. no more than 2 prior cytotoxic regimens
administered for metastatic breast cancer.
(participants may have received any number of
exogenous hormone therapies for stage iv
disease and/or adjuvant therapy).*
Yes
No
7. life expectancy of >12 weeks.*
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Yes
No
8. eastern cooperative oncology group
performance status <2.*
Yes
No
9. women of child bearing potential must agree to
use two adequate methods of contraception or
abstain from sexual intercourse during study
treatment. acceptable methods of contraception
are as follows:*
Yes
No
1. intrauterine device (iud)*
Yes
No
2. hormonal birth control*
Yes
No
3. tubal ligation*
Yes
No
4. partner's vasectomy*
Yes
No
5. latex condom*
Yes
No
6. diaphragm*
Yes
No
7. cervical cap*
Yes
No
10. adequate organ and marrow function
measured within 14 days of study treatment as
defined below:*
Yes
No
absolute neutrophil count >1,500 cells/mm3
platelets >100,000 cells/mm3 hemoglobin >10
g/dl total bilirubin <1.5 mg/dl ast(sgot)/alt(sgpt)
<2.5 x institutional upper limit of normal or <5 x
normal with documented liver metastasis alkaline
phosphatase <3 x institutional upper limit of
normal or <5 x normal with documented liver or
bone metastasis serum creatinine <1.5 mg/dl or
creatinine clearance >60 ml/min/1.73 m2 for
participants with serum creatinine levels above
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institutional normal.*
Yes
No
Exclusion Criteria
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Eligibility Metastatic Breast Cancer
NCT01288092
BEZ235 Trial in Patients With HER2-(Human Epidermal
Growth Factor Receptor 2 Negative) /HR+ (Hormonal
Receptor Positive) Metastatic Breast Cancer; ODM derived
from: https://clinicaltrials.gov/show/NCT01288092
All rights reserved. Please visit https://medical-data-
models.org/forms/13871
Eligibility Metastatic Breast Cancer
NCT01288092
Inclusion Criteria
female ≥ 18 years*
Yes
No
ecog performance status ≤ 2*
Yes
No
histologically and/or cytologically confirmed
diagnosis of  breast cancer presenting with
metastatic disease (hormone receptor positive
and her2 negative)*
Yes
No
known pi3k activation status (defined by pik3ca
(phosphoinositide-3-kinase, catalytic, alpha
polypeptide) mutation and pten pten
(phosphatase and tensin homolog)
mutation/expression)*
Yes
No
prior treatment with at least one prior line of
endocrine therapy and at least two and no more
than three prior lines of chemotherapy for
metastatic breast cancer*
Yes
No
objective and radiologically confirmed
progression of disease after prior treatment and
at least one measurable lesion as per recist*
Yes
No
adequate bone marrow and organ function*
Yes
No
Exclusion Criteria
previous treatment with pi3k and/or mtor
inhibitors*
Yes
No
symptomatic central nervous system (cns)
metastases*
Yes
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No
concurrent malignancy or malignancy in the last 5
years prior to start of study treatment*
Yes
No
wide field radiotherapy ≤ 28 days or limited field
radiation for palliation ≤ 14 days prior to starting
study drug*
Yes
No
active cardiac disease (e.g. left ventricular
ejection fraction (lvef) < 50%, qtcf > 480 msec on
screening ecgelectrocardiogram (ecg), unstable
angina pectoris, ventricular, supraventricular or
nodal arrhythmias)*
Yes
No
inadequately controlled hypertension*
Yes
No
impairment of gastrointestinal (gi) function or gi
disease that may significantly alter the absorption
of bez235*
Yes
No
treatment at start of study treatment with drugs
with a known risk to induce torsades de pointes,
moderate and strong inhibitors or inducers of
isoenzyme cyp3a4, warfarin and coumadin
analogues, lhrh agonists*
Yes
No
history of photosensitivity reactions to other
drugs*
Yes
No
pregnant or nursing (lactating) woman*
Yes
No
other protocol-defined inclusion/exclusion criteria
may apply*
Yes
No
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Eligibility Metastatic Breast Cancer
NCT01392586
Systemic Therapy With or Without Upfront Surgery in
Metastatic Breast Cancer; ODM derived from:
https://clinicaltrials.gov/show/NCT01392586
All rights reserved. Please visit https://medical-data-
models.org/forms/13872
Eligibility Metastatic Breast Cancer
NCT01392586
Inclusion Criteria
newly diagnosed primary distant metastatic
breast cancer (m1)*
Yes
No
anticipated survival of at least 6 months*
Yes
No
histologically proven breast cancer*
Yes
No
hormonal and her2neu status should be known*
Yes
No
t1-t3, resectable t4 status, n0-n3*
Yes
No
performance status of the patient should allow
surgery / systemic therapy*
Yes
No
co-morbidity of the patient should allow surgery /
systemic therapy*
Yes
No
age > 18 years*
Yes
No
written informed consent*
Yes
No
Exclusion Criteria
primary invasive breast cancer in medical history*
Yes
No
other malignancy within the last 10 years,
besides basal cell carcinoma of the  skin or early
stage cervical cancer*
Yes
No
1 / 2
surgical treatment / radiotherapy of this breast
tumor before randomization*
Yes
No
irresectable t4 breast tumor*
Yes
No
synchronous bilateral breast cancer*
Yes
No
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Eligibility Prostate Cancer NCT01313273
Study of Lanreotide in Non Metastatic Castration-resistant
Prostate Cancer Patients; ODM derived from:
https://clinicaltrials.gov/show/NCT01313273
All rights reserved. Please visit https://medical-data-
models.org/forms/13873
Eligibility Prostate Cancer
NCT01313273
Inclusion Criteria
histologically proven diagnosis of prostate
cancer*
Yes
No
evidence of psa progression despite castrate
levels of testosterone (<50 ng/dl) following
orchiectomy or during therapy with luteinizing
hormone releasing hormone agonists (lhrh-a)*
Yes
No
patients with non-metastatic or stable metastatic
disease*
Yes
No
chromogranin a elevation above normal range
(confirmed by a second evaluation at least 1
week later) [cut off levels will be > 20 u/l for
enzyme linked immunosorbent (elisa) assay and
> 100 ng/ml for immunoradiometric (irma) assay]*
Yes
No
Exclusion Criteria
patients who according to the investigator opinion
are candidates to be treated immediately with
chemotherapy (e.g. docetaxel)*
Yes
No
first line treatment with antiandrogen in
monotherapy*
Yes
No
visceral metastasis*
Yes
No
previous or concomitant treatment with a
somatostatin analogue*
Yes
No
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Feasibility and Toxicity of Degarelix for Prostate Downsizing
Prior to Permanent Seed Prostate Brachytherapy; ODM
derived from: https://clinicaltrials.gov/show/NCT01446991
All rights reserved. Please visit https://medical-data-
models.org/forms/13874
Eligibility Prostate Cancer
NCT01446991
Inclusion Criteria
histologic diagnosis of prostate cancer*
Yes
No
favorable risk disease (ct1 or t2a, gleason score
(gs) 6, and prostate specific antigen (psa) < 10
ng/ml)*
Yes
No
low-tier intermediate risk disease (ct2c,gs=6,and
psa 10-15 ng/ml, or gs=7 and psa < 10 ng/ml)*
Yes
No
intermediate risk disease and androgen
deprivation therapy recommended by the treating
physician for oncologic reasons such as (≥ 50%
positive biopsy cores,ct2c,psa 15-20 ng/ml,gs=7)*
Yes
No
patient requires baseline planning trans-rectal
ultrasound for the purposes of prostate
brachytherapy, showing prostate volume > 40 ml
and pubic arch interference (not required for
those requiring androgen ablation for oncologic
reasons)*
Yes
No
Exclusion Criteria
castrate serum testosterone level*
Yes
No
previous or concurrent pelvic radiotherapy*
Yes
No
unable to give written informed consent*
Yes
No
contraindications to permanent seed prostate
brachytherapy or to androgen deprivation
therapy*
Yes
No
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prior treatment for prostate cancer*
Yes
No
prior trans-urethral resection of the prostate*
Yes
No
previous therapy with a 5-α reductase inhibitor,
anti-androgen agent, or lhrh agonist*
Yes
No
previous therapy with degarelix*
Yes
No
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Eligibility Prostate Cancer NCT01478828
Pre-Prostatectomy Lovastatin on Prostate Cancer; ODM
derived from: https://clinicaltrials.gov/show/NCT01478828
All rights reserved. Please visit https://medical-data-
models.org/forms/13875
Eligibility Prostate Cancer
NCT01478828
Inclusion Criteria
1. adenocarcinoma of the prostate, without
evidence of spread beyond to lymph nodes,
bone, or visceral organs, stage t1c or higher.*
Yes
No
2. tumor gleason sum of 7 (4+3 and 3+4 allowed)
in at least one core, after central review of
prostate biopsy at johns hopkins. however, in
accordance with standard clinical practices,
adenocarcinoma must be present in at least two
discrete biopsy sections ( may vary in gleason
score).*
Yes
No
3. age ≥18 years of age.*
Yes
No
4. radical prostatectomy scheduled at johns
hopkins.*
Yes
No
5. willingness to sign and ability to understand
informed consent.*
Yes
No
6. no history of treatment with any statin-class
medication within 6 months of entry into the trial.*
Yes
No
7. ecog (eastern cooperative oncology group)
performance status 0-1.*
Yes
No
8. adequate bone marrow, hepatic, and renal
function as determined by:*
Yes
No
wbc (white blood cells) >3,500 cells/mm3 anc
(absolute neutrophil count) >1,500 cells/mm3
hemoglobin >9 g/dl platelet count >100,000
cells/mm3 serum creatinine < 2.6 mg/dl serum
bilirubin <2 mg/dl alt (alanine aminotransferase),
ast (aspartate aminotransferase), and alkaline
phosphatase <2 times the upper limit of  normal
1 / 3
triglycerides and total cholesterol <3 times the
upper limit of normal*
Yes
No
Exclusion Criteria
1. patients with evidence of metastatic prostate
cancer, including bone, visceral, brain, and lymph
node metastases.*
Yes
No
2. other histologic prostate cancers, including
ductal, sarcomatous, lymphoma, small cell, and
neuroendocrine tumors.*
Yes
No
3. uncontrolled medical conditions that could
potentially increase the risk of toxicities or
complications of this therapy including active liver
disease, unexplained persistent elevation of
serum transaminases, or medications that
interfere with the metabolism of lovastatin, or
gastrointestinal disease that would limit the ability
to swallow or take oral medications or absorb
them.*
Yes
No
4. concurrent malignancy other than prostate
cancer.*
Yes
No
5. inability to provide informed consent.*
Yes
No
6. concomitant use of azole antifungals,
cyclosporine, clarithromycin, erythromycin, fibric
acid derivatives, lopinavir/ritonavir, niacin,
ritonavir/saquinavir*
Yes
No
7. prior chemotherapy, radiation therapy, biologic
therapy, or immunotherapy for prostate cancer.*
Yes
No
8. poor performance status (ecog >1).*
Yes
No
9. prostatectomy at other hospital other than
johns hopkins.*
Yes
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No
10. prior history of allergy or severe reaction to
statins or statin derivatives.*
Yes
No
3 / 3
Eligibility Prostate Cancer NCT01478828
Eligibility Prostatic Neoplasms
NCT01423474
Prostate Accurately Targeted Radiotherapy Investigation of
Overall Treatment Time; ODM derived from:
https://clinicaltrials.gov/show/NCT01423474
All rights reserved. Please visit https://medical-data-
models.org/forms/13876
Eligibility Prostatic Neoplasms
NCT01423474
Inclusion Criteria
low or intermediate risk prostate cancer patients
as defined by:*
Yes
No
clinical stage t1-2b, gleason score <=7, and psa
<=20 ng/ml*
Yes
No
age >= 18 years*
Yes
No
Exclusion Criteria
androgen deprivation therapy (lhrh-agonists or
antiandrogens) >6 months*
Yes
No
prior pelvic radiotherapy*
Yes
No
anticoagulation medication (if unsafe to
discontinue for gold seed insertion)*
Yes
No
diagnosis of bleeding diathesis*
Yes
No
large prostate (>90cm3) on imaging*
Yes
No
immunosuppressive medications*
Yes
No
inflammatory bowel disease*
Yes
No
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Eligibility Pulmonary Arterial Hypertension
NCT01433328
Lidocaine Subcutaneous Infusion for Control of Treprostinil
Related Site Pain; ODM derived from:
https://clinicaltrials.gov/show/NCT01433328
All rights reserved. Please visit https://medical-data-
models.org/forms/13877
Eligibility Pulmonary Arterial
Hypertension NCT01433328
Inclusion Criteria
pah*
Yes
No
treprostinil treatment for at least 3 months*
Yes
No
severe infusion site pain*
Yes
No
Exclusion Criteria
pregnancy/breastfeeding*
Yes
No
decompensated heart failure*
Yes
No
chronic liver disease*
Yes
No
abnormal electrolytes*
Yes
No
heart block (2/3 degree), sino-atrial block,
idioventricular rhythm*
Yes
No
systolic systemic bp <90mmhg*
Yes
No
bradycardia hr <55*
Yes
No
adverse reaction to lidocaine or other amide local
anesthestic*
Yes
No
interacting medications (anti-arrhythmics, cyp1a2
inhibitors)*
Yes
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No
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Eligibility Retinopathy NCT00969956
Time To Complications Occurs in Diabetes; ODM derived
from: https://clinicaltrials.gov/show/NCT00969956
All rights reserved. Please visit https://medical-data-
models.org/forms/13878
Eligibility Retinopathy NCT00969956
Inclusion Criteria
diabetes type 1, 2 or lada: 18-75 years of age.*
Yes
No
group a: 150 type 1 diabetes, duration 15 years
(+/-2 years) and 150 type 2*
Yes
No
diabetes 2 years (+/-2 years) (50% f/m)*
Yes
No
group b: 150 type 1 diabetes, duration 20 years
(+/-2 years) and 150 type 2*
Yes
No
diabetes 7 years (+/-2 years) (50% f/m)*
Yes
No
group c: 150 type 1 diabetes, duration 25 years
(+/-2 years) and 150 type 2*
Yes
No
diabetes 12 years (+/-2 years) (50% f/m)*
Yes
No
group d: 50 lada, onset after 35 years of age,
duration of 5-10 years (50% f/m)*
Yes
No
type 1 diabetes: positive ica antibodies and/or
gad-antibodies and/or neg c-peptide. debut <30
years of age.*
Yes
No
type 2 diabetes: negative ica-antibodies and gad-
antibodies and pos c-peptide (>0.35 mmol/l).*
Yes
No
lada: positive ica-antibodies and/or gad-
antibodies. debut >35 years of age.*
Yes
No
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Eligibility Schizophrenia NCT01422902
Evaluation of a Cognitive Adaptive E-treatment in
Schizophrenia-diagnosed Adults; ODM derived from:
https://clinicaltrials.gov/show/NCT01422902
All rights reserved. Please visit https://medical-data-
models.org/forms/13879
Eligibility Schizophrenia
NCT01422902
Inclusion Criteria
18 years of older with confirmed diagnosis of
schizophrenia*
Yes
No
adequate decisional and reading capacity*
Yes
No
clinical stable*
Yes
No
moderate or less severity on positive and
negative symptoms scale*
Yes
No
english speaker*
Yes
No
capable of completing clinical and cognitive
assessment battery*
Yes
No
lack of visual, auditory or motor capacity to
participate in the study*
Yes
No
minimal level of extrapyramidal symptoms*
Yes
No
minimal level of depressive symptoms*
Yes
No
Exclusion Criteria
failure to meet suicidality rating criteria*
Yes
No
prescribed greater than 2 anti-psychotics*
Yes
No
significant alcohol and illicit drug use*
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Yes
No
history of mental retardation or pervasive
developmental disorder or other neurological
disorder*
Yes
No
prior specified computer-based cognitive
remediation training*
Yes
No
participation in a concurrent study that could
affect the outcome of this one*
Yes
No
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Eligibility Schizophrenia NCT01458379
Brain Myelination Effects of Paliperidone Palmitate Versus
Oral Risperidone in First Episode Schizophrenia; ODM
derived from: https://clinicaltrials.gov/show/NCT01458379
All rights reserved. Please visit https://medical-data-
models.org/forms/13880
Eligibility Schizophrenia
NCT01458379
Criteria
a first episode of a psychotic illness is occurring
or did occur within the last 2 years;*
Yes
No
a diagnosis by dsm-iv of schizophrenia,
schizoaffective disorder, depressed type, or
schizophreniform disorder; and*
Yes
No
between 18 and 45 years of age.*
Yes
No
exclusion criteria (identical to clinical trial "parent
study"):*
Yes
No
neurological disorder (e.g., epilepsy) or significant
head injury;*
Yes
No
significant alcohol or substance use disorder
within the six months prior to the first episode and
evidence that substance abuse triggered the
psychotic episode or makes the schizophrenia
diagnosis ambiguous;*
Yes
No
mental retardation, i.e. premorbid iq less than
70;*
Yes
No
insufficient acculturation and fluency in the
english language to avoid invalidating research
measures of thought, language, and speech
disorder or of verbal abilities;*
Yes
No
residence likely to be outside of commuting
distance of the ucla aftercare research program;
or*
Yes
No
patient has shown an inadequate response to an
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adequate previous trial of oral or long-acting
injectable risperidone, paliperidone, or
paliperidone palmitate.*
Yes
No
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Eligibility Skin Neoplasms NCT01482104
New Versus Approved Methyl-aminolevulinate
Photodynamic Therapy (MAL-PDT) Regime in Basal Cell
Carcinoma (BCC); ODM derived from:
https://clinicaltrials.gov/show/NCT01482104
All rights reserved. Please visit https://medical-data-
models.org/forms/13881
Eligibility Skin Neoplasms
NCT01482104
Inclusion Criteria
male/female above 18 years of age*
Yes
No
written informed consent*
Yes
No
1 or more primary histologically verified bcc,
clinically assessed as of either superficial of
nodular type*
Yes
No
Exclusion Criteria
pregnancy*
Yes
No
breastfeeding*
Yes
No
gorlin's syndrome*
Yes
No
porphyria*
Yes
No
xeroderma pigmentosum*
Yes
No
history of arsenic exposure*
Yes
No
known allergy to mal*
Yes
No
concomitant treatment with immunosuppressive
medication*
Yes
No
physical or mental conditions that most likely will
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prevent patients attending follow-up sessions*
Yes
No
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Eligibility Spasticity NCT01457352
Efficacy and Safety of Baclofen ER Capsules (GRS) in
Subjects With Spasticity Due to Multiple Sclerosis; ODM
derived from: https://clinicaltrials.gov/show/NCT01457352
All rights reserved. Please visit https://medical-data-
models.org/forms/13882
Eligibility Spasticity NCT01457352
Inclusion Criteria
men and women age 18 years and older*
Yes
No
women of child bearing potential practicing an
acceptable method of birth control for the
duration of the study as judged by the
investigator(s) [such as condoms, foams, jellies,
diaphragm, intrauterine device (iud), oral or long
acting injected contraceptives, bilateral tubal
ligation or vasectomized partner] for at least 3
months prior to study entry or postmenopausal
for at least 1 year or surgically sterile (bilateral
oophorectomy or hysterectomy)*
Yes
No
if female, negative pregnancy test*
Yes
No
known history of spasticity due to ms prior to
starting baclofen*
Yes
No
a stable daily dose of baclofen ir, ranging from 30
to 60 mg/day (i.e., same dose given in the same
schedule for last 30 days)*
Yes
No
able and willing to comply with the protocol,
including availability for a scheduled clinic visits*
Yes
No
willingness and giving of written informed
consent*
Yes
No
Exclusion Criteria
history of hypersensitivity to baclofen*
Yes
No
in relapse or history of unstable course over the
prior 30 days prior to the screening visit*
Yes
No
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concomitant neurologic conditions causing
spasticity*
Yes
No
has received an investigational drug or device
within 30 days that would interfere with the study
goals prior to the screening visit*
Yes
No
unable to comply with study procedures in the
opinion of the investigator*
Yes
No
has had major surgery within 3 months prior to
screening visit that may affect spasticity
assessments such as abdominal surgery, back
surgery, or lower leg or knee surgeries*
Yes
No
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Eligibility Stage I Breast Cancer
NCT01140282
Exercise Program for Early Breast Cancer Survivors; ODM
derived from: https://clinicaltrials.gov/show/NCT01140282
All rights reserved. Please visit https://medical-data-
models.org/forms/13883
Eligibility Stage I Breast Cancer
NCT01140282
Inclusion Criteria
newly diagnosed (i-iii) with a first primary invasive
breast cancer*
Yes
No
have undergone a lumpectomy or mastectomy*
Yes
No
have completed neoadjuvant/adjuvant
chemotherapy and able to initiate exercise
program (if randomized to that arm) within 12
weeks of therapy completion*
Yes
No
body mass index (bmi) > 25 kg/m^2 or body fat >
30% (determined by dr. dieli-conwright at
baseline visit)*
Yes
No
currently participate in less than 60 minutes of
physical activity per week may use adjuvant
endocrine therapy if use will be continued for
duration of study period*
Yes
No
nonsmokers (i.e., not smoking during previous 12
months)*
Yes
No
willing to travel to the exercise facility and usc*
Yes
No
able to provide physician clearance to participate
in exercise program*
Yes
No
women of all racial and ethnic backgrounds will
be included in the study enrollment process*
Yes
No
Exclusion Criteria
history of chronic disease including diabetes,
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uncontrolled hypertension or thyroid disease*
Yes
No
weight reduction >= 10% within past 6 months*
Yes
No
diagnosed with human epidermal growth factor
receptor 2 (her2)-positive tumor (exclusion due to
patient use of herceptin medication for 1 year
following chemotherapy)*
Yes
No
metastatic disease*
Yes
No
planned reconstructive surgery with flap repair
during trial and follow-up period*
Yes
No
cardiovascular, respiratory or musculoskeletal
disease or joint problems that preclude moderate
physical activity*
Yes
No
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Specification of the disease EBMT CLL
ODM derived from HSCT forms on http://www.ebmt.org/
All rights reserved. Please visit https://medical-data-
models.org/forms/13884
Specification of the disease EBMT
CLL
Initial Diagnosis
Has the information requested in this section
been submittedwith a previous HSCT
registration?
No: proceed with this section (No:
proceed with this section)
Yes: go to "Pre-HSCT treatment" (Yes:
go to "Pre-HSCT treatment")
Subclassification
Atypical Hairy Cell Leukaemia (Atypical
Hairy Cell Leukaemia)
Chronic Lymphocytic Leukaemia (CLL)/
Small Lymphocytic Lymphoma (SLL)
(Chronic Lymphocytic Leukaemia (CLL)/
Small Lymphocytic Lymphoma (SLL))
CLL previously known (CLL previously
known)
Hairy Cell Leukaemia (HCL) (Hairy Cell
Leukaemia (HCL))
Other (Other)
PLL, B type (PLL, B type)
PLL, T type (PLL, T type)
Primary Richter (wihtout previous known
diagnosis of CLL) (Primary Richter
(wihtout previous known diagnosis of
CLL))
Prolymphocytic Leukaemia (PLL)
(Prolymphocytic Leukaemia (PLL))
Richter's syndrome: (Richter's
syndrome:)
If Richter's syndrome and CLL previously known,
specify date of CLL diagnosis
If other, specify:
Biological Risk Factor Assessment:
Cytogenetics
Abnormal (Abnormal)
Normal (Normal)
Not done or failed (Not done or failed)
Unknown (Unknown)
Biological Risk Factor Assessment:
Technique:
Both (Both)
Conventional (Conventional)
FISH (FISH)
Unknown (Unknown)
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Biological Risk Factor Assessment:
Abnormalities (if present)
Del 11q22-23 (Del 11q22-23)
Del 13q14 (Del 13q14)
Del 17p13 (Del 17p13)
Other (Other)
t(11;14) (t(11;14))
Trisomy 12 (Trisomy 12)
Biological Risk Factor Assessment:
Abnormalities (if present)
If other, specify:
VH gene status
Mutated (Mutated)
Not evaluated (Not evaluated)
Not mutated (Not mutated)
Unknown (Unknown)
VH gene status:
If evaluated, specify VH3-21 status:
Not used (Not used)
Used (Used)
Biological Risk Factor Assessment:
Markers:
Molecular or other type of markers:
Absent (Absent)
Not evaluated (Not evaluated)
Present (Present)
Unknown (Unknown)
Biological Risk Factor Assessment:
Markers:
Molecular or other type of markers:
If present, specify:
Other (Other)
ZAP-70: Expression cut off used (ZAP-
70: Expression cut off used)
Biological Risk Factor Assessment:
Markers
Molecular or other type of markers:
If present and ZAP-70 (Expression cut-off used),
specify: (%)
%
Biological Risk Factor Assessment: 
Markers: Molecular or other type of markers: 
If present and other, specify:
Clinical status at diagnosis:
Lymphocyte doubling time
< 12 months (< 12 months)
> 12 months (> 12 months)
Unknown (Unknown)
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Clinical Status at diagnosis:
Binet stage
A (A)
B (B)
C (C)
Not evaluated (Not evaluated)
If this registration pertains to a second or
subsequent HSCT the therapy number
should be counted since last reported
HSCT
Was the patient treated before the HSCT
procedure?
No (proceed to "Date of HSCT") (No
(proceed to "Date of HSCT"))
Unknown (Unknown)
Yes (Yes)
If previous treatment, specify Start Date:
If previous treatment, specify sequential number
of this treatment 
(Counted from diagnosis, or last HSCT if
applicable)
If previous treatment, specify the modality:
Chemo/ drug/ agent (including MoAB,
vaccination, etc.)
Yes
No
If Chemotherapy, specify the regimen:
If Chemotherapy, specify the number of cycles:
If previous treatment, specify the modality: 
Radiotherapy
Yes
No
If previous treatment, specify response:
CR (CR)
No change (No change)
Other (Other)
PR (PR)
Progression (Progression)
Unknown (Unknown)
If previous treatment, specify response:
If other, specify:
If this registration pertains to a second or
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subsequent HSCT the therapy number
should be counted since last reported
HSCT
Additional Pre-HSCT treatment
No (No)
Unknown (Unknown)
Yes (Yes)
If additional Pre-HSCT treatment performed,
specify start date:
If additional Pre-HSCT treatment performed,
specify sequential number of this treatment:
(counted from diagnosis, or last HSCT if
applicable)
If additional Pre-HSCT treatment performed,
specify modality:
Chemo/ drug/ agent
(including MoAB, vaccination, etc.)
Yes
No
If additional chemo/ drug/ agent treatment
performed, specify chemotherapy regimen:
If additional chemo/ drug/ agent treatment
performed, specify chemotherapy cycle:
If additional Pre-HSCT treatment performed,
specify modality:
Radiotherapy
Yes
No
If additional Pre-HSCT treatment performed,
specify disease response:
CR (CR)
No change (No change)
Other (Other)
PR (PR)
Progression (Progression)
Unknown (Unknown)
If additional Pre-HSCT treatment performed,
specify disease response
If other, specify:
To be evaluated just before starting
conditioning
Date of HSCT
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Splenectomy
Yes
No
If Splenectomy performed, specify date:
Disease Status:
CR (CR)
Never treated (Never treated)
No response (No response)
Nodular PR (nPR) (Nodular PR (nPR))
PR (PR)
Progression: (Progression:)
Resistant to last regimen (Resistant to
last regimen)
Sensitive to last regimen (Sensitive to
last regimen)
Unknown (Unknown)
Residual disease status (only to be completed
when patient in Haematological CR):
Minimal residual disease investigated by:
Immunophenotyping
Negative (Negative)
Not evaluated (Not evaluated)
Positive (Positive)
Unknown (Unknown)
Residual disease status (only to be completed
when patient in Haematological CR):
Minimal residual disease investigated by:
Molecular Biology
Negative (Negative)
Not evaluated (Not evaluated)
Positive (Positive)
Unknown (Unknown)
Residual disease status (only to be completed
when patient in Haematological CR):
Sensitivity of minimal residual disease (MRD)
assay:
Known?
Yes
No
Residual disease status (only to be completed
when patient in Haematological CR):
Sensitivity of minimal residual disease (MRD)
assay
If known, specify:
Worst Binet stage up to and including this date:
A (A)
B (B)
C (C)
Not evaluated (Not evaluated)
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Disease Status at HSCT - Biological Risk
Factor Assessment
Cytogenetics
Abnomal (Abnomal)
Normal (Normal)
Not done or failed (Not done or failed)
Unknown (Unknown)
Laboratory Technique
Both (Both)
Convential (Convential)
FISH (FISH)
Unknown (Unknown)
Chromosomal Abnormalities
Del 11q22-23 (Del 11q22-23)
Del 13q14 (Del 13q14)
DEL 17p13 (Del 17p13)
Other (Other)
t(11;14) (t(11;14))
Trisomy 12 (Trisomy 12)
Chromosomal Abnormalities:
If other, specify:
VH gene status
Mutated (Mutated)
Not evaluated (Not evaluated)
Not mutated (Not mutated)
Unknown (Unknown)
If evaluated: VH3-21 status:
Not used (Not used)
Used (Used)
Disease Status at HSCT - Haematological
values
Hb
Evaluated?
Yes
No
If Hb evaluated, specify:
g/dL
Platelets
Evaluated?
Yes
No
If platelets evaluated, specify:
10^9/L
White Blood Count
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Evaluated?
Yes
No
If White Blood Count evaluated, specify:
10^9/L
Lymphocytes
Evaluated?
Yes
No
If Lymphocytes evaluated, specify:
%
BM aspirate: lymphocytes
Evaluated?
Yes
No
If BM aspirate: lymphocytes evaluated, specify:
%
BM trephine: lymphocytes
Evaluated?
Yes
No
If BM trephine: lymphocytes evaluated, specify:
%
Disease Status at HSCT - Clinical data
Lymphadenopathy
No (No)
Not evaluated (Not evaluated)
Unknown (Unknown)
Yes (Yes)
If yes, number of lymph node sites
< 3 (< 3)
> 5  (> 5 )
3- 5 (3- 5)
Not evaluated (Not evaluated)
Unknown (Unknown)
Thoraco abdominal CT scan
Abnormal (Abnormal)
Normal (Normal)
Not done (Not done)
Unknown (Unknown)
Palpable Splenomegaly
Absent  (Absent)
Not evaluated  (Not evaluated)
Present  (Present)
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Unknown (Unknown)
Palpable Splenomegaly:
Physical examination: evaluated?
Yes
No
Palpable Splenomegaly: 
Physical examination: 
If evaluated, specify: cm (below costal margin)
cm
Palpable Splenomegaly:
Spleen span in ultrasound or CT scan:
evaluated?
Yes
No
Palpable Splenomegaly:
Spleen span in ultrasound or CT scan: 
If evaluated, specify: cm (maximum diameter)
cm
Palpable Hepatomegaly
Absent  (Absent)
Not evaluated  (Not evaluated)
Present  (Present)
Unknown (Unknown)
Palpable Hepatomegaly:
Physical examination: evaluated?
Yes
No
Palpable Hepatomegaly:
Physical examination: 
If evaluated, specify: cm (below costal margin)
cm
Palpable Hepatomegaly:
Liver span in ultrasound or CT scan: evaluated?
Yes
No
Palpable Hepatomegaly:
Liver span in ultrasound or CT scan: 
If evaluated, specify: cm (maximum diameter)
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cm
If patient has not been treated before skip this
section and go to additional treatment Post-
HSCT.
Purine analogue-refractory?
(non response or relapse within 6 months after
completion of purine analogue- containing
chemotherapy)
No (No)
Unknown (Unknown)
Yes (Yes)
If patient has not been treated before skip this
section and go to additional treatment Post-
HSCT.
Early relapse after intensive therapy?
(within 24 months after completion of purine
analogue-containing combination therapy or
autologous SCT)
No (No)
Unknown (Unknown)
Yes (Yes)
Additional-Treatment Post-HSCT
Additional Disease Treatment
No (No)
Unknown (Unknown)
Yes (Yes)
If Additional Disease Treatment performed,
specify:
Not planned (for relapse/ progression or
persistent disease) (Not planned (for
relapse/ progression or persistent
disease))
Planned (planned before HSCT took
place) (Planned (planned before HSCT
took place))
If Additional Disease Treatment performed,
specify start date:
If Additonal Disease Treatment performed,
specify:
Chemo/drug/agent
(including MoAB, vaccination, etc.)
Known?
Yes
No
If Additonal Disease Treatment performed,
specify: 
Chemo/drug/agent (including MoAB, vaccination,
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etc.)
If performed, specify:
If Additional Disease Treatment performed,
specify:
Radiotherapy
No (No)
Unknown (Unknown)
Yes (Yes)
If Additional Disease Treatment performed,
specify:
Other treatment
No (No)
Unknown (Unknown)
Yes (Yes)
If Additional Disease Treatment performed,
specify:
Other treatment
If Yes, specify:
BM trephine: lymphocytes percentage
Best Disease Response at 100 days post-
HSCT
Best Disease Response at 100 days post-HSCT
CR  (CR )
No response (No response)
PR (PR)
Progression (Progression)
Unknown (Unknown)
Date of evaluation
Residual Disease Status (Only to be completed
when patient in Haematological Complete
Remission)
Minimal residual disease investigated by:
Immunophenotyping
Negative (Negative)
Not evaluated (Not evaluated)
Positive (Positive)
Unknown (Unknown)
Residual Disease Status (Only to be completed
when patient in Haematological Complete
Remission)
Minimal residual disease investigated by:
Molecular Biology
Negative (Negative)
Not evaluated (Not evaluated)
Positive (Positive)
10 / 12
Specification of the disease EBMT CLL
Unknown (Unknown)
Residual disease status (only to be completed
when patient in Haematological CR):
Sensitivity of minimal residual disease (MRD)
assay:
Known?
Yes
No
Residual disease status (only to be completed
when patient in Haematological CR):
Sensitivity of minimal residual disease (MRD)
assay
If known, specify:
Best Disease Response at 100 days post-
HSCT - Haematological values
Hb
Evaluated?
Yes
No
If Hb evaluated, specify:
g/dL
Platelets
Evaluated?
Yes
No
If platelets evaluated, specify:
10^9/L
White Blood Count 
Evaluated?
Yes
No
If White Blood Count evaluated, specify:
10^9/L
Lymphocyts
Evaluated?
Yes
No
If Lymphocyte evaluated, specify:
%
BM aspirate: lymphocytes 
Evaluated?
Yes
No
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If BM aspirate: lymphocytes evaluated, specify:
%
BM trephine: lymphocytes 
Evaluated?
Yes
No
If BM trephine: lymphocytes evaluated, specify:
%
Forms to be filled in
Type of Transplant
ALLOgraft or Syngeneic graft (proceed to
Allograft form) (ALLOgraft or Syngeneic
graft (proceed to Allograft form))
AUTOgraft (proceed to Autograft form)
(AUTOgraft (proceed to Autograft form))
Other (contact the EBMT Central
Registry for instructions) (Other (contact
the EBMT Central Registry for
instructions))
If Other, specify:
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Eligibility Tourniquet-induced Pain
NCT01441531
Efficacy of Gabapentin in Prevention of Tourniquet Pain and
Hypertension; ODM derived from:
https://clinicaltrials.gov/show/NCT01441531
All rights reserved. Please visit https://medical-data-
models.org/forms/13885
Eligibility Tourniquet-induced Pain
NCT01441531
Inclusion Criteria
patient ages 18-64*
Yes
No
asa physical status 1-3*
Yes
No
schedule for orif tibia fracture with use of
pneumatic tourniquet*
Yes
No
Exclusion Criteria
allergy to study medications*
Yes
No
polytrauma*
Yes
No
lower extremity crush injury*
Yes
No
chronic opioid use*
Yes
No
sickle cell disease or trait*
Yes
No
peripheral vascular disease*
Yes
No
poorly controlled hypertension*
Yes
No
history of dvt/pe*
Yes
No
morbid obesity (bmi > 35)*
Yes
No
1 / 2
patient or surgeon refusal*
Yes
No
patient inability to properly describe postoperative
pain to investigators*
Yes
No
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Eligibility Type 1 Diabetes NCT01351857
Diabetes Care Management Compared to Standard
Diabetes Care in Adolescents and Young Adults With Type
1 Diabetes; ODM derived from:
https://clinicaltrials.gov/show/NCT01351857
All rights reserved. Please visit https://medical-data-
models.org/forms/13886
Eligibility Type 1 Diabetes
NCT01351857
Inclusion Criteria
established t1d diagnosis for a minimum of one
year (chosen to allow time for adjustment to a
new diagnosis and more stable disease control).*
Yes
No
between the ages of 17 and 20 years. it is left to
the clinical judgment of the pediatric
endocrinologist to determine individually the
appropriate age of the transition for each subject*
Yes
No
at least 1 visit during the previous year with the
pediatric endocrinologist at a diabetes clinic (aim
is to minimize the non-adherence with the
intervention).*
Yes
No
ability to participate in all aspects of this clinical
trial.*
Yes
No
written informed consent/assent must be
obtained and documented.*
Yes
No
resident of ontario.*
Yes
No
Exclusion Criteria
pregnant or lactating females or intent to become
pregnant during the next 3 years.*
Yes
No
conditions which in the opinion of the investigator
may interfere with the subject's ability to
participate in the study.*
Yes
No
prior enrollment in the current study.*
Yes
No
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current participation in another clinical trial or
participation in another clinical trial in the 6
months prior to enrollment.*
Yes
No
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Eligibility Type 2 Diabetes Mellitus
NCT01240252
Insulin Receptor Substrate 1 (IRS-1) Regulation in Insulin
Resistance; ODM derived from:
https://clinicaltrials.gov/show/NCT01240252
All rights reserved. Please visit https://medical-data-
models.org/forms/13887
Eligibility Type 2 Diabetes Mellitus
NCT01240252
Inclusion Criteria
age 30-65 y*
Yes
No
healthy lean, obese, or known type 2 diabetic*
Yes
No
body mass index (bmi) less than 36*
Yes
No
all nondiabetic subjects must have normal oral
glucose tolerance*
Yes
No
subjects must have the following laboratory
values:*
Yes
No
1. hematocrit ≥ 35 vol%*
Yes
No
2. serum creatinine ≤ 1.6 mg/dl*
Yes
No
3. aspartate aminotransferase (ast) (sgot)< 2
times upper limit of normal*
Yes
No
4. alanine aminotransferase (alt) (sgpt)< 2 times
upper limit of normal*
Yes
No
5. alkaline phosphatase < 2 times upper limit of
normal*
Yes
No
6. triglycerides < 150 mg/dl*
Yes
No
7. prothrombin time (pt)  11.7 -14.3 seconds*
Yes
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No
8. partial thromboplastin time 23.0-37.0 seconds*
Yes
No
Exclusion Criteria
no diseases known to affect glucose metabolism
other than healthy type 2 diabetes*
Yes
No
subjects must not be receiving any of the
following medications: thiazide or furosemide
diuretics, beta-blockers, or other chronic
medications with known adverse effects on
glucose tolerance levels unless the patient has
been on stable dose of such agents for the past
three months before entry into the study. subjects
may be taking a stable dose of estrogens or other
hormonal replacement therapy, if the subject has
been on these agents for the prior three months.
subjects taking systemic glucocorticoids are
excluded.*
Yes
No
subjects with a history of clinically significant
heart disease (new york heart classification
greater than grade ii; more than non-specific st-t
wave changes on the ekg), peripheral vascular
disease (history of claudication), or pulmonary
disease (dyspnea on exertion of one flight or less;
abnormal breath sounds on auscultation) will not
be studied.*
Yes
No
recent systemic or pulmonary embolus, untreated
high-risk proliferative retinopathy, recent retinal
hemorrhage, uncontrolled hypertension, systolic
bp>180, diastolic bp>105, autonomic neuropathy,
resting heart rate >100, electrolyte
abnormalities.*
Yes
No
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Eligibility Type 2 Diabetes Mellitus
NCT01275235
Exposure to Type II Diabetes for Two Siblings With the
Same Parents; ODM derived from:
https://clinicaltrials.gov/show/NCT01275235
All rights reserved. Please visit https://medical-data-
models.org/forms/13888
Eligibility Type 2 Diabetes Mellitus
NCT01275235
Inclusion Criteria
you are one of a sibling pair with the same
mother and father, and your mother had diabetes
(gestational or type 2) while she was pregnant
with the younger sibling but not the older sibling.*
Yes
No
your sibling is willing to participate in the study.*
Yes
No
you are between the ages of 20 and 34 years
(inclusive)*
Yes
No
your body mass index is between 20 and 29
kg/m2  inclusive (this is a number calculated for
your height and weight and indicates that you are
either normal weight or overweight, but not
obese).*
Yes
No
you are healthy as assessed by medical history
and standard physical examination*
Yes
No
you are weight stable (your body weight has not
changed .6.5 lbs over the last 3 months).*
Yes
No
you do not smoke*
Yes
No
you provide written informed consent to
participate in the study.*
Yes
No
you are willing to stay overnight one time at the
pennington center.*
Yes
No
you have low physical activity (< 100 min of
exercise per week).*
Yes
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No
Exclusion Criteria
you were born prematurely (<37 weeks of
pregnancy)*
Yes
No
you are currently taking medication that may
influence your body weight or metabolism.*
Yes
No
you have heart disease, lung disease, liver
disease, blood disease, kidney disease, type 1 or
2 diabetes, or any other disease that in the
opinion of the doctor might make you ineligible.*
Yes
No
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Follow up EBMT CLL
ODM derived from HSCT forms on http://www.ebmt.org/
All rights reserved. Please visit https://medical-data-
models.org/forms/13889
Follow up EBMT CLL
Follow Up
Unique Identification Code (UIC)
(if known)
Date of this report
Patient following national/ international study/ trial
No (No)
Unknown (Unknown)
Yes (Yes)
If yes, specify Name of study/ trial
Hospital Unique Patient Number
First name(s)_surname(s)
Date of birth
Date of last HSCT for this patient
Patient last seen
Date of last contact or death
Acute Graft versus Host Disease (aGvHD)
since last report
Acute Graft versus Host Disease
Maximum grade
grade 0 (Absent) (grade 0 (Absent))
grade I (grade I)
grade II (grade II)
grade III (grade III)
grade IV (grade IV)
Not evaluated (Not evaluated)
If present, specify:
New onset (New onset)
Persistent (Persistent)
Recurrent (Recurrent)
Reason for aGvHD
DLI (DLI)
Tapering (Tapering)
Unexplained (Unexplained)
Date of onset of this episode 
(if new or recurrent)
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(if applicable)
aGvHD:
Stage skin
Evaluated (Evaluated)
Not evaluated (Not evaluated)
Unknown (Unknown)
aGvHD:
Stage skin
If evaluatd, specify:
1 (1)
2 (2)
3 (3)
4 (4)
aGvHD
Stage liver
Evaluated (Evaluated)
Not evaluated (Not evaluated)
Unknown (Unknown)
aGvHD
Stage liver
If evaluated, specify:
1 (1)
2 (2)
3 (3)
4 (4)
aGvHD
Stage gut
Evaluated (Evaluated)
Not evaluated (Not evaluated)
Unknown (Unknown)
aGvHD
Stage gut
If evaluated, specify:
1 (1)
2 (2)
3 (3)
4 (4)
aGvHD
Resolution
Yes
No
If yes, specify the date of resolution
Chronic Graft versus Host Disease
(cGvHD) since last report
Presence of cGvHD
No (No)
Present continously since last reported
episode (Present continously since last
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reported episode)
Resolved (Resolved)
Yes (Yes)
If yes, specify:
First episode (First episode)
Recurrence (Recurrence)
If yes, specify Date of onset:
If present continously since last report, specify
cGvHD gade:
Extensive (Extensive)
Limited (Limited)
If present continously since last reported episode,
speicfy affected organs:
Eyes (Eyes)
Gut (Gut)
Liver (Liver)
Lung (Lung)
Mouth (Mouth)
Other (Other)
Skin  (Skin )
Unknown (Unknown)
If present continously since last reported episode,
speicfy affected organs:
If other, specify:
If resolved, specify the date of resolution:
Other Complications since last report
(please use the document "Definitions of
infectious diseases and complications
after stem cell transplantation" to fill these
items.)
Infection related complications
Yes
No
If yes, specify the type (bacteriaemia/ fungemia/
viremia/ parasites)
(General)
Adenovirus (Adenovirus)
Aspergillus sp (Aspergillus sp)
Bacteria: (Bacteria:)
Candida sp (Candida sp)
CMV (CMV)
EBV (EBV)
Fungi: (Fungi:)
Haemophilus influenza (Haemophilus
influenza)
HBV (HBV)
HCV (HCV)
HHV-6 (HHV-6)
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HIV (HIV)
HSV (HSV)
Legionella sp (Legionella sp)
Mycobacteria sp (Mycobacteria sp)
Other (Other)
Other (Other)
Other (Other)
Other (Other)
Other gram negative (i.e. E.coli,
klebsiella, proteus, serratia,
pseudomonas,...) (Other gram negative
(i.e. E.coli, klebsiella, proteus, serratia,
pseudomonas,...))
Other gram positive (i.e. other
streptococci, staphylococci, listeria,...)
(Other gram positive (i.e. other
streptococci, staphylococci, listeria,...))
Other respiratory virus (influenza,
parainfluezna, rhinovirus) (Other
respiratory virus (influenza,
parainfluezna, rhinovirus))
Papovirus (Papovirus)
Parasites: (Parasites:)
Parovirus (Parovirus)
Pneumocystis carinii (Pneumocystis
carinii)
RSV (RSV)
S. pneumoniae (S. pneumoniae)
Toxoplasma gondii (Toxoplasma gondii)
Viruses: (Viruses:)
VZV (VZV)
If other, specify (general):
Specify the date of the episode (General)
Systemic Symptoms of Infections
ARDS (ARDS)
Multiorgan failure due to infection
(Multiorgan failure due to infection)
Septic shock (Septic shock)
Systemic Symptoms of Infections: specify the
type (bacteriaemia/ fungemia/ viremia/ parasites)
Adenovirus (Adenovirus)
Aspergillus sp (Aspergillus sp)
Bacteria: (Bacteria:)
Candida sp (Candida sp)
CMV (CMV)
EBV (EBV)
Fungi: (Fungi:)
Haemophilus influenza (Haemophilus
influenza)
HBV (HBV)
HCV (HCV)
HHV-6 (HHV-6)
HIV (HIV)
HSV (HSV)
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Legionella sp (Legionella sp)
Mycobacteria sp (Mycobacteria sp)
Other (Other)
Other (Other)
Other (Other)
Other (Other)
Other gram negative (i.e. E.coli,
klebsiella, proteus, serratia,
pseudomonas,...) (Other gram negative
(i.e. E.coli, klebsiella, proteus, serratia,
pseudomonas,...))
Other gram positive (i.e. other
streptococci, staphylococci, listeria,...)
(Other gram positive (i.e. other
streptococci, staphylococci, listeria,...))
Other respiratory virus (influenza,
parainfluezna, rhinovirus) (Other
respiratory virus (influenza,
parainfluezna, rhinovirus))
Papovirus (Papovirus)
Parasites: (Parasites:)
Parovirus (Parovirus)
Pneumocystis carinii (Pneumocystis
carinii)
RSV (RSV)
S. pneumoniae (S. pneumoniae)
Toxoplasma gondii (Toxoplasma gondii)
Viruses: (Viruses:)
VZV (VZV)
Systemic symptoms of infection: if other, specify:
Systemic symptoms of infection: Specify the date
of the episode
Endorgan diseases
CNS infection (CNS infection)
Cystitis (Cystitis)
Gut infection (Gut infection)
Hepatits (Hepatits)
Other (Other)
Pneumonia (Pneumonia)
Retinitis (Retinitis)
Skin infection (Skin infection)
Endorgan disease: specify the type
(bacteriaemia/ fungemia/ viremia/ parasites)
Adenovirus (Adenovirus)
Aspergillus sp (Aspergillus sp)
Bacteria: (Bacteria:)
Candida sp (Candida sp)
CMV (CMV)
EBV (EBV)
Fungi: (Fungi:)
Haemophilus influenza (Haemophilus
influenza)
HBV (HBV)
HCV (HCV)
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HHV-6 (HHV-6)
HIV (HIV)
HSV (HSV)
Legionella sp (Legionella sp)
Mycobacteria sp (Mycobacteria sp)
Other (Other)
Other (Other)
Other (Other)
Other (Other)
Other gram negative (i.e. E.coli,
klebsiella, proteus, serratia,
pseudomonas,...) (Other gram negative
(i.e. E.coli, klebsiella, proteus, serratia,
pseudomonas,...))
Other gram positive (i.e. other
streptococci, staphylococci, listeria,...)
(Other gram positive (i.e. other
streptococci, staphylococci, listeria,...))
Other respiratory virus (influenza,
parainfluezna, rhinovirus) (Other
respiratory virus (influenza,
parainfluezna, rhinovirus))
Papovirus (Papovirus)
Parasites: (Parasites:)
Parovirus (Parovirus)
Pneumocystis carinii (Pneumocystis
carinii)
RSV (RSV)
S. pneumoniae (S. pneumoniae)
Toxoplasma gondii (Toxoplasma gondii)
Viruses: (Viruses:)
VZV (VZV)
Endorgan diseases: If other, specify:
Endorgan diseases: Specify the date of the
episode
Non infection related complications
Yes
No
Specify: Idiopathic pneumonia syndrome
No  (No )
Unknown (Unknown)
Yes (Yes)
If yes, specify: 
Idiopathic pneumonia syndrome
Date of onset
Specify: 
VOD
No  (No )
Unknown (Unknown)
Yes (Yes)
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If yes, specify: 
VOD
Date of onset
Specify:
Cataract
No (No)
Unknown (Unknown)
Yes (Yes)
If yes, specify:
Cataract
Date of onset
Specify:
Haemorrhagic cystitis, non infectious
No  (No )
Unknown (Unknown)
Yes  (Yes )
If yes, specify:
Haemorrhagic cystitis, non infectious
Date of onset
Specify:
ARDS, non infectious
No (No)
Unknown (Unknown)
Yes (Yes)
If yes, specify:
ARDS, non infectious
Date of onset
Specify:
Multiorgan-failure, non infectious
No  (No )
Unknown (Unknown)
Yes (Yes)
If yes, specify: 
Multiorgan-failure, non infectious
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Date of onset
Specify:
HSCT-associated microangiopathy
No (No)
Unknown (Unknown)
Yes (Yes)
If yes, specify:
HSCT-associated microangiopathy
Date of onset
Specify:
Renal failure requiring dialysis
No (No)
Unknown (Unknown)
Yes (Yes)
If yes, specify:
Renal failure requiring dialysis
Date of onset
Specify:
Haemolytic anaemia due to blood group
No (No)
Unknown (Unknown)
Yes (Yes)
If yes, specify:
Haemolytic anaemia due to blood group
Date of onset
Specify:
Aseptic bone necrosis
No (No)
Unknown (Unknown)
Yes (Yes)
If yes, specify:
Aseptic bone necrosis
Date of onset
If other, specify:
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If other:
Date of onset
Graft Assessment and Haemopoietic
chimaerism
Graft loss
No (No)
Not evaluated (Not evaluated)
Yes (Yes)
Overall chimaerism
Aplasia (Aplasia)
95%) (Autologuos reconstitution
(recipient >)
95%) (Full (donor >)
Mixed (partial) (Mixed (partial))
Not evaluated (Not evaluated)
Indicate the date(s) and results of all tests
done for all donors. Split the results by
donor and by the cell type on which the
test was performed if applicable. Copy this
table as many times as nec...
Date of test
Identification of donor or Cord Blood Unit given
by the centre
Number in the infusion order (if applicable)
Cell type on which test was performed (% Donor
Cells):
BM
%
Cell type on which test was performed (% Donor
cells):
PB mononuclear cells (PBMC)
%
Cell type on which test was performed (% Donor
cells):
T-Cells
%
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Cell type on which test was performed (% Donor
cells):
B-Cells
%
Cell type on which test was performed (% Donor
cells):
Red blood cells
%
Cell type on which test was performed (% Donor
cells):
Monocytes
%
Cell type on which test was performed (% Donor
cells):
PMNs (neutrophils)
%
Cell type on which test was performed (% Donor
cells):
Lymphocytes, NOS
%
Cell type on which test was performed (% Donor
cells):
Myeloid cells, NOS
%
Cell type on which test was performed:
Other, specify:
Cell type on which test was performed (% Donor
cells):
Other
%
Test used:
ABO group (ABO group)
Cytogenetic (Cytogenetic)
FISH (FISH)
Molecular (Molecular)
Other (Other)
unknown (unknown)
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Test used:
If other, specify:
Other complications since last report -
secondary malignancy, lymphoproliferative
or myeloproliferative disorder diagnosed
Secondary Malignancy, Lymphoproliferative or
Myeloproliferative disorder diagnosed
No at date of this follow up (No at date of
this follow up)
Previously reported (Previously reported)
Yes (Yes)
If yes, specify date of diagnosis
If yes, specify the diagnosis
AML (AML)
Lymphoproliferative disorder
(Lymphoproliferative disorder)
MDS (MDS)
Other (Other)
If other, specify:
Additional therapies since last follow up
Treatment given since last report
No (No)
Unknown (Unknown)
Yes (Yes)
If yes, specify the start date
One cell therapy regimen is defined as
any number of insufiosn given within 10
weeks for the same indication. If more
than one regimen of cell therapy has been
given since last report, copy this sec...
If additional treatment is given, specify for cellular
therapy:
No  (No)
Unknown (Unknown)
Yes  (Yes)
If yes, specify the disease status before this
cellular therapy
CR (CR)
Not evaluated (Not evaluated)
Not in CR (Not in CR)
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If yes, specify the cell type
Donor lymphocyte infusion (DLI) (Donor
lymphocyte infusion (DLI))
Mesenchymal cells (Mesenchymal cells)
Other (Other)
Unknown (Unknown)
If yes, specify the cell type:
If cell type other, specify:
If DLI, specify the number of cells infused by
type:
Nucleated cells
Evaluated (Evaluated)
Not evaluated (Not evaluated)
unknown (unknown)
If DLI, specify the number of cells infused by
type:
Nucleated cells (10^8/kg)
10^8/kg
If DLI, specify the number of cells infused by
type:
CD 34+
Evaluated (Evaluated)
Not Evaluated (Not Evaluated)
Unknown (Unknown)
Number of infused CD34+ cells
If DLI, specify the number of cells infused by
type: 
CD 3+
Evaluated  (Evaluated )
Not evaluated (Not evaluated)
Unknown (Unknown)
Number of infused CD3+ cells
If non DLI, specify total number of cells infused:
Evaluated (Evaluated)
Not Evaluated (Not Evaluated)
Unknown (Unknown)
If non DLI, specify the total number of cells
infused (10^6/kg)
(10^6/kg)
Chronological number of this cell therapy for this
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patient
Indication 
(check all that apply)
Loss/decreased chimaerism
(Loss/decreased chimaerism)
Mixed chimaerism (Mixed chimaerism)
Other (Other)
Planned/ protocol (Planned/ protocol)
Prophylactic (Prophylactic)
Treatment for disease (Treatment for
disease)
Treatment of GvHD (Treatment of GvHD)
Treatment PTLD, EBV, lymphoma
(Treatment PTLD, EBV, lymphoma)
Treatment viral infection (Treatment viral
infection)
Indication:
If other, specify:
Number of Infusions (within 10 weeks)
(count only infusions that are part of same
regimen and given for the same indication)
Acute Graft versus Host Disease 
(after this infusion but before any further infusion/
transplant)
Maximum grade:
grade 0 (absent) (grade 0 (absent))
grade 1 (grade 1)
grade 2 (grade 2)
grade 3 (grade 3)
grade 4 (grade 4)
present, grade unknown (present, grade
unknown)
Apart from donor cell infusion or other
type of cell therapy
Disease treatment
Yes
No
If yes, specify:
Not planned (for relapse/ progression or
persistent disease) (Not planned (for
relapse/ progression or persistent
disease))
Planned (planned before HSCT took
place) (Planned (planned before HSCT
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took place))
First evidence of relapse or progression
since last HSCT
Relapse or Progression
Continous progression since HSCT
(Continous progression since HSCT)
No (No)
Previously reported (Previously reported)
Unknown (Unknown)
Yes (Yes)
If yes, specify date of diagnosis
Clinical/ haematological relapse or progression
No (No)
Not evaluated (Not evaluated)
Yes (Yes)
If Clinical/ haematological relapse or progression
"No", specify Date of assessment:
If Clinical/ haematological relapse or progression
"Yes", specify date first seen:
If Clinical/ haematological relapse or progression
"Yes", specify affected site:
blood (blood)
extramedullary (extramedullary)
marrow (marrow)
Clinical/ haematological relapse or progression
No (No)
Not evaluated (Not evaluated)
Yes (Yes)
If MRD relapse or progression "No", specify Date
of assessment:
If MRD relapse or progression "Yes", specify date
first seen:
If MRD relapse or progression "Yes", specify
affected site:
blood  (blood)
extramedullary (extramedullary)
marrow  (marrow)
If MRD relapse or progression "Yes", specify
sensitivity of MRD assay:
Known?
Yes
No
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If MRD relapse or progression "Yes", specify
sensitivity of MRD assay:
If known, specify:
Last Disease status
Last Disease Status
Complete Remission (Complete
Remission)
Progression (Progression)
Relapse (Relapse)
Stable disease (Stable disease)
Only to be completed when patient is in
Haematological Complete Remission
Residual Disease Status
Minimal residual disease investigated by:
Immunophenotyping
Negative (Negative)
Not evaluated (Not evaluated)
Positive (Positive)
Unknown (Unknown)
Residual Disease Status 
Minimal residual disease investigated by:
Molecular Biology
Negative (Negative)
Not evaluated (Not evaluated)
Positive (Positive)
Unknown (Unknown)
Please indicate sensitivity of MRD assay:
Known?
Yes
No
Please indicate the sensitivity of MRD assay:
If known, specify:
Last Disease status - Conception
Has patient or partner become  pregnant after
this HSCT?
No (No)
Unknown (Unknown)
Yes (Yes)
Last Disease status - Survival status
Survival status
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Alive (Alive)
Dead (Dead)
If alive: Type of score used:
Karnofsky (Karnofsky)
Lansky (Lansky)
Not evaluated (Not evaluated)
Unknown (Unknown)
If alive and performance score evaluated, specify:
10 (Moribund) (10 (Moribund))
100 (Normal, NED) (100 (Normal, NED))
20 (Very sick) (20 (Very sick))
30 (Severely disabled) (30 (Severely
disabled))
40 (Disabled) (40 (Disabled))
50 (Requires assistance) (50 (Requires
assistance))
60 (Requires occasional assistance) (60
(Requires occasional assistance))
70 (Cares for self) (70 (Cares for self))
80 (Normal with effort) (80 (Normal with
effort))
90 (Normal activity) (90 (Normal activity))
Last Disease status - Cause of death (if
dead)
If dead, specify cause of death:
HSCT related cause  (HSCT related
cause )
Other (Other)
Relapse or progression (Relapse or
progression)
Secondary malignancy (including
lymphoproliferative disease) (Secondary
malignancy (including lymphoproliferative
disease))
Unknown  (Unknown )
If dead and HSCT related cause of death, specify
(check as many as apppropriate):
GvHD
No  (No )
Unknown (Unknown)
Yes (Yes)
If dead and HSCT related cause of death, specify
(check as many as apppropriate):
Interstitial Pneumonitis
No  (No )
Unknown (Unknown)
Yes (Yes)
If dead and HSCT related cause of death, specify
(check as many as apppropriate): 
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Pulmonary toxicity
No  (No )
Unknown (Unknown)
Yes (Yes)
If dead and HSCT related cause of death, specify
(check as many as apppropriate): 
Infection
No  (No )
Unknown (Unknown)
Yes (Yes)
If dead and HSCT related cause of death, specify
(check as many as apppropriate): 
If Infection, specify:
Bacterial (Bacterial)
Fungal (Fungal)
Parasitic (Parasitic)
Unknown (Unknown)
Viral (Viral)
If dead and HSCT related cause of death, specify
(check as many as apppropriate): 
Rejection/ Poor graft function
No  (No )
Unknown (Unknown)
Yes (Yes)
If dead and HSCT related cause of death, specify
(check as many as apppropriate): 
Veno-Occlusive disease (VOD)
No  (No )
Unknown (Unknown)
Yes (Yes)
If dead and HSCT related cause of death, specify
(check as many as apppropriate): 
Haemorrhage
No  (No )
Unknown (Unknown)
Yes (Yes)
If dead and HSCT related cause of death, specify
(check as many as apppropriate): 
Cardiac toxicity
No  (No )
Unknown (Unknown)
Yes (Yes)
If dead and HSCT related cause of death, specify
(check as many as apppropriate): 
Central nervous system toxicity
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No  (No )
Unknown (Unknown)
Yes (Yes)
If dead and HSCT related cause of death, specify
(check as many as apppropriate): 
Gastro intestinal toxicity
No  (No )
Unknown (Unknown)
Yes (Yes)
If dead and HSCT related cause of death, specify
(check as many as apppropriate): 
Skin toxicity
No  (No )
Unknown (Unknown)
Yes (Yes)
If dead and HSCT related cause of death, specify
(check as many as apppropriate): 
Renal failure
No  (No )
Unknown (Unknown)
Yes (Yes)
If dead and HSCT related cause of death, specify
(check as many as apppropriate): 
Multiple organ failure
No  (No )
Unknown (Unknown)
Yes (Yes)
If dead and HSCT related cause of death, specify
(check as many as apppropriate): 
Other
No  (No )
Unknown (Unknown)
Yes (Yes)
If dead and HSCT related cause of death, specify
(check as many as apppropriate): 
If other, specify:
If other, specify:
Additional notes if applicable
Comments:
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Identification and Signature
Identification
Signature
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Eligibility Type 2 Diabetes Mellitus
NCT01392898
Liraglutide and Insulin Therapy in Patients With Type 2
Diabetes; ODM derived from:
https://clinicaltrials.gov/show/NCT01392898
All rights reserved. Please visit https://medical-data-
models.org/forms/13890
Eligibility Type 2 Diabetes Mellitus
NCT01392898
Inclusion Criteria
patients with type 2 diabetes mellitus on short-
term insulin therapy     (≤ 12 months); all types of
insulin allowed*
Yes
No
documented insulin-associated weight gain ≥ 3.0
kg from the start of insulin therapy until inclusion*
Yes
No
age 18-75 years*
Yes
No
bmi ≥ 25 kg/m2*
Yes
No
stable glycaemic control mirrored by hba1c ≥ 6.5
and ≤ 8.5 %*
Yes
No
Exclusion Criteria
inability to provide informed consent*
Yes
No
type 1 diabetes mellitus, mody diabetes, or lada
diabetes (presence of anti-gad)*
Yes
No
presence of any medical condition that might
interfere with the current study protocol.*
Yes
No
inflammatory bowel disease (e.g. m. crohn,
ulcerative colitis)*
Yes
No
recurrent hypoglycaemic events*
Yes
No
diabetic gastroparesis*
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Yes
No
heart failure (lvef ≤ 30%)*
Yes
No
use of tzds (glitazones), ddp-iv
(dipeptidylpeptidase-inhibitor)*
Yes
No
use of medication associated with impaired
glucose metabolism including corticosteroids*
Yes
No
pregnancy or breast-feeding (contraception of at
least 3 months before inclusion is required for
fertile women)*
Yes
No
pre-existing thyroid disease*
Yes
No
liver disease (aspartate aminotransferase or
alanine aminotransferase level of more than three
times the upper limit of normal range)*
Yes
No
renal disease (creatinine > 130 µmol/l or mdrd-gfr
<30 ml/min/1.73m2)*
Yes
No
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Eligibility Type 2 Diabetes NCT01475201
Step Monitoring to Improve ARTERial Health; ODM derived
from: https://clinicaltrials.gov/show/NCT01475201
All rights reserved. Please visit https://medical-data-
models.org/forms/13891
Eligibility Type 2 Diabetes
NCT01475201
Inclusion Criteria
followed by a smarter collaborating doctor*
Yes
No
bmi ≥ 25 kg/m2 but < 40 kg/m2 (i.e. overweight to
class ii obese)*
Yes
No
type 2 diabetes and/or hypertension*
Yes
No
conversant in either english or french*
Yes
No
Exclusion Criteria
≥ 150 minutes of leisure time physical activity per
week be self- report*
Yes
No
acute or chronic co-morbid conditions that may
affect the ability or likelihood to adhere to trial
procedures (e.g. inflammatory arthritis, active
malignancy, major depression or other significant
psychiatric disorders, and/or significant visual
impairment)*
Yes
No
pregnancy/planning a pregnancy*
Yes
No
baseline step count averaging ≥ 10,000 steps/day
at baseline assessment*
Yes
No
arrhythmia that prevents accurate assessment of
carotid-femoral pulse wave velocity (e.g., atrial
fibrillation)*
Yes
No
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Eligibility Type I Diabetes NCT01477476
Anti-IL-1 Treatment in Children DKA at Diagnosis of Type 1
Diabetes; ODM derived from:
https://clinicaltrials.gov/show/NCT01477476
All rights reserved. Please visit https://medical-data-
models.org/forms/13892
Eligibility Type I Diabetes
NCT01477476
Inclusion Criteria
age 8-18 years at diagnosis of type 1 diabetes*
Yes
No
diabetic ketoacidosis: plasma glucose
concentration >300 mg/dl, venous ph< 7.30 or
serum bicarbonate concentration <15 mmol/l, and
ketones in urine or serum*
Yes
No
hematology: wbc> 3000 x 109/l; platelets >
100,000 x 109/l; hemoglobin > 10.0 g/dl*
Yes
No
negative blood pregnancy test in females.*
Yes
No
Exclusion Criteria
children with underlying disorders, including:
active autoimmune or immune deficiency disorder
other than type 1 diabetes, malignancy, organ
transplant, any condition requiring chronic
corticosteroid use*
Yes
No
previous immunotherapy to prevent type 1
diabetes*
Yes
No
current or prior infection with hiv, hepatitis b or
hepatitis c assessed by history*
Yes
No
patients who present with dka concomitant with
alcohol or drug use, head trauma, meningitis or
other conditions which might affect neurological
function*
Yes
No
renal failure*
Yes
No
any condition, medical or otherwise that would, in
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the opinion of the investigator, prevent complete
participation in the study, or that would pose a
significant hazard to the subject's participation*
Yes
No
patients with a history of known hypersensitivity
to e coli-derived proteins, anakinra, or any
components of the investigational drug product*
Yes
No
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Eligibility Unipolar Depression
NCT00964054
Depression Outcomes Study of Exercise; ODM derived
from: https://clinicaltrials.gov/show/NCT00964054
All rights reserved. Please visit https://medical-data-
models.org/forms/13893
Eligibility Unipolar Depression
NCT00964054
Inclusion Criteria
primary diagnosis of dsm-iv major depression
disorder (mdd)*
Yes
No
child depression rating scale revised > or = 40 at
final screen*
Yes
No
12 to 21 years of age*
Yes
No
on a stable dose of antidepressants or adhd
medication only*
Yes
No
physically capable of exercise according to aha
and acsm standards*
Yes
No
able to pass illicit drug screen*
Yes
No
perform < 20 minutes per day of moderate to
vigorous physical activity*
Yes
No
parental consent and participant assent*
Yes
No
denver metropolitan area including jefferson
county*
Yes
No
Exclusion Criteria
chronic disease that would limit exercise*
Yes
No
other psychiatric illness*
Yes
No
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suicidal or homicidal*
Yes
No
concurrent psychotherapy*
Yes
No
two previous failed ssri trials or a failed trial of
cbt*
Yes
No
current pregnancy or breastfeeding*
Yes
No
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Eligibility Recurrent and Second Primary Squamous Cell Carcinoma of the Oral
Cavity in the Previously Irradiated Territory in Case of Primary Unresectable Tumor.
NCT01427010
A Feasibility Study on Adaptive 18F-FDG-guided
Radiotherapy for Recurrent and Second Primary Head and
Neck Cancer in the Previously Irradiated Territory.; ODM
derived from: https://clinicaltrials.gov/show/NCT01427010
All rights reserved. Please visit https://medical-data-
models.org/forms/13894
Eligibility Recurrent and Second
Primary Squamous Cell Carcinoma
of the Oral Cavity in the Previously
Irradiated Territory in Case of
Primary Unresectable Tumor.
NCT01427010
Inclusion Criteria
histologically confirmed recurrences and second
primary squamous cell carcinoma of the oral
cavity, oropharynx, hypopharynx or larynx in the
previously irradiated territory.*
Yes
No
primary unresectable tumor and/or patients
refused surgery.*
Yes
No
no grade 3 or more late toxicity (except
xerostomia) after the initial radio(chemo)therapy
for primary head and neck cancer.*
Yes
No
minimal interval 12 months after the initial
radio(chemo)therapy for primary head and neck
cancer.*
Yes
No
decision of a multidisciplinary tumor board on
curative radiotherapy (in combination or not with
targeted therapy with cetuximab)*
Yes
No
karnofsky performance status ≥70%.*
Yes
No
age ≥ 18 years old.*
Yes
No
informed consent obtained, signed and dated
before specific protocol procedures.*
Yes
No
Exclusion Criteria
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previous radiotherapy for ct1-2 cn0 m0 glottic
cancer.*
Yes
No
brachytherapy as treatment for second primary /
recurrence.*
Yes
No
distant metastases.*
Yes
No
other second primary tumors that are not under
control.*
Yes
No
pregnant or lactating women.*
Yes
No
elevated blood creatinine level.*
Yes
No
allergy to the ct-contrast agents.*
Yes
No
mental condition rendering the patient unable to
understand the nature, scope, and possible
consequences of the study.*
Yes
No
patient unlikely to comply with protocol, i.e.
uncooperative attitude, inability to return for
follow-up visits, and unlikely to complete the
study.*
Yes
No
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Eligibility Recurrent and Second Primary Squamous Cell Carcinoma of the Oral
Cavity in the Previously Irradiated Territory in Case of Primary Unresectable Tumor.
NCT01427010
DESCRIBE (DZNE – Clinical Register Study of
neurodegenerative Disorders) CRF Skin Biopsy Baseline
Background and Purpose:
The purpose of the DESCRIBE study is to document the
natural course of diseases in context of medical care of
neurodegenerative disorders as well as cerebrovascular
diseases and to perform phenotyping of the test persons.
Disease-spanning analyses of the measured clincial data,
the results of the imaging processes, results of the analysis
of the biometerials including genetic analysis are planed.
Principal Investigator: Prof. Klockgether, Dr. Spottke DZNE,
Bonn.
Source: DESCRIBE-Studie
http://www.dzne.de/forschung/forschungsbereiche/klinische
-forschung/studien/describe-bn006.html 
Participating Study Sites:
Berlin, Bonn, Göttingen, Dresden, Köln, Magdeburg,
München, Rostock/Greifswald, Tübingen
All rights reserved. Please visit https://medical-data-
models.org/forms/13896
CRF Skin Biopsy Baseline
Date of visit
Date of visit
Study-ID:
Skin Biopsy
Date of information about skin biopsy
Was a control of coagulation performed?
Yes
No
Coagulation control performed:
PPT (Partial Thromboplastin Time)
sec
International Normalization Ratio (INR)
Count platelets:
µl
Was skin biopsy performed?
Yes
No
Date of skin biopsy:
Localization
Thigh (Thigh)
Upper arm (Upper arm)
Size of punch (diameter)
mm
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Was the skin biopsy successfully completed?
Yes
No
If 'successfully completed' any complications?
Yes
No
If complications, which one?
If 'not successfully completed' please give
reasons:
Other comments
Sampling
Date of skin biopsy
1. Sampling performed according to SOP-BM-
01?
Yes
No
1.1. SOP version (No.)
2. Any deviations from SOP-BM-01?
Yes
No
Other devices used for skin tissue than the ones
available.
Yes
No
If 'other device used' please specify:
Another solution than 0.9% NaCl-solution was
used
Yes
No
Please name other solution:
Samples:
Tuble sort (Greiner)
Skin tissue
Skin biopsy not done
Yes
No
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DESCRIBE (DZNE – Clinical Register Study of neurodegenerative
Disorders) CRF Skin Biopsy Baseline
DESCRIBE (DZNE – Clinical Register Study of
neurodegenerative Disorders) CRF Skin Biopsy Follow Up
Background and Purpose:
The purpose of the DESCRIBE study is to document the
natural course of diseases in context of medical care of
neurodegenerative disorders as well as cerebrovascular
diseases and to perform phenotyping of the test persons.
Disease-spanning analyses of the measured clincial data,
the results of the imaging processes, results of the analysis
of the biometerials including genetic analysis are planed.
Principal Investigator: Prof. Klockgether, Dr. Spottke DZNE,
Bonn.
Source: DESCRIBE-Studie
http://www.dzne.de/forschung/forschungsbereiche/klinische
-forschung/studien/describe-bn006.html 
Participating Study Sites:
Berlin, Bonn, Göttingen, Dresden, Köln, Magdeburg,
München, Rostock/Greifswald, Tübingen
All rights reserved. Please visit https://medical-data-
models.org/forms/13897
CRF Skin Biopsy Follow Up
Date of visit
Date of visit
Study-ID:
Visit:
Skin Biopsy
Date of information about skin biopsy
Was a control of coagulation performed?
Yes
No
Coagulation control performed:
PPT (Partial Thromboplastin Time)
sec
International Normalization Ratio (INR)
Count platelets:
µl
Was skin biopsy performed?
Yes
No
Date of skin biopsy:
Localization
Thigh (Thigh)
Upper arm (Upper arm)
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Size of punch (diameter)
mm
Was the skin biopsy successfully completed?
Yes
No
If 'successfully completed' any complications?
Yes
No
If complications, which one?
If 'not successfully completed' please give
reasons:
Other comments
Sampling
Date of skin biopsy
1. Sampling performed according to SOP-BM-
01?
Yes
No
1.1. SOP version (No.)
2. Any deviations from SOP-BM-01?
Yes
No
Other devices used for skin tissue than the ones
available.
Yes
No
If 'other device used' please specify:
Another solution than 0.9% NaCl-solution was
used
Yes
No
Please name other solution:
Samples:
Tuble sort (Greiner)
Skin tissue
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Disorders) CRF Skin Biopsy Follow Up
Skin biopsy not done
Yes
No
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DESCRIBE (DZNE – Clinical Register Study of neurodegenerative
Disorders) CRF Skin Biopsy Follow Up
Screening Visit LenaMain-Study
A randomised comparison of daily 25 mg versus 5 mg
lenalidomide as maintenance therapy after high-dose
therapy and autologous stem cell transplantation in patients
with multiple myeloma.
Protocol-Code: RV-MM-PI-280
EudraCT-Number: 2007-003945-33
Author: Claus Schreiber
Review: Gerd Felder
Approval of CRF: Prof. Dr. med. G. Kobbe (LKP)
Release for MDM: Prof. Gattermann, Düsseldorf
(26.1.2016)
Principal Investigator „LenaMain“-Studie: Prof. Roland
Fenk, Düsseldorf
Coordinating center for clinical trial
Medical faculty of University Hospital
Heinrich-Heine-University
Scientific Director: Herr Dr. J. Grebe
Moorenstrasse 5                                          
40225 Düsseldorf  
Tel.: +49 (0) 211-81-19701
Fax: +49 (0) 211-81-19702 
All rights reserved. Please visit https://medical-data-
models.org/forms/13901
Screening visit
Medical history
Date of screening visit
Date of Informed Consent
Gender
male (1)
female (2)
Date of initial diagnosis
Monoclonal gammopathy of undetermined
significance (MGUS-Preliminary phase)
Yes
No
Date of initial diagnosis: MGUS
Multiple Myeloma,not eligible for treatment
Yes
No
Date of initial diagnosis: MM,not eligible for
treatment
Multiple myeloma, eligible for treatment
Yes
No
Date of initial diagnosis:MM,eligible for treatment
Previous treatment:please specify
Number of induction cycles
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1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
Response to induction
sCR (0)
CR (1)
vgPR (2)
PR (3)
SD (5)
PD (6)
Date of response to induction
Number of mobilization cycles
1 (1)
2 (2)
Response to mobilization
sCR (0)
CR (1)
vgPR (2)
PR (3)
SD (5)
PD (6)
Date of response:mobilization
Radiation therapy:please specify
Date of first stem cell transplant
Conditioning
M100 (1)
M140 (2)
M200 (3)
other (4)
If other conditioning,please specify
Response after first transplant
sCR (0)
CR (1)
vgPR (2)
PR (3)
SD (5)
PD (6)
Date of Evaluation
Date of second transplant
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Conditioning
M100 (1)
M140 (2)
M200 (3)
other (4)
If other conditioning,please specify
Response after second transplant
sCR (0)
CR (1)
vgPR (2)
PR (3)
SD (5)
PD (6)
Date of evaluation
Initial diagnosis: Multiple myeloma
Subtype
IgG (1)
IgA (2)
IgM (3)
IgD (4)
Light chain (5)
Light chain
Kappa (k)
Lambda (l)
Salmon-Durie Stage
I (1)
II (2)
III (3)
Salmon-Durie Stage codicil
A (a)
B (b)
ISS Stage
1 (1)
2 (2)
3 (3)
beta2-Microglobulin
mg/l
Albumin
g/dL
Cytogenetic examination done?
Yes
No
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Cytogenetics:please specify
Cytogenetic examination date
Contrast infiltration
%
Contrast examination date
Extramedullary lesion
Yes
No
Lytic lesion of bones
None (1)
Osteopenia (2)
1-5 lytic lesions of bone (3)
>6 lytic lesions of bone (4)
Complications:please specify
Vital signs
Heart rate
bpm
Systolic blood pressure
mmHg
Diastolic blood pressure
mmHg
Body weight
kg
Body Height
cm
ECOG Performance status
Score 0 (0)
Score 1 (1)
Score 2 (2)
Score 3 (3)
Score 4 (4)
Score 5 (5)
ECG normal?
Yes
No
Please specify any pathologic ECG findings
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DESCRIBE (DZNE – Clinical Register Study of
neurodegenerative Disorders) CRF Lumbar Puncture Baseline
Background and Purpose:
The purpose of the DESCRIBE study is to document the
natural course of diseases in context of medical care of
neurodegenerative disorders as well as cerebrovascular
diseases and to perform phenotyping of the test persons.
Disease-spanning analyses of the measured clincial data,
the results of the imaging processes, results of the analysis
of the biometerials including genetic analysis are planed.
Principal Investigator: Prof. Klockgether, Dr. Spottke DZNE,
Bonn.
Source: DESCRIBE-Studie
http://www.dzne.de/forschung/forschungsbereiche/klinische
-forschung/studien/describe-bn006.html 
Participating Study Sites:
Berlin, Bonn, Göttingen, Dresden, Köln, Magdeburg,
München, Rostock/Greifswald, Tübingen
All rights reserved. Please visit https://medical-data-
models.org/forms/13902
CRF Lumbar Puncture Baseline
Date of visit
Date of visit
Study-ID:
Lumbar puncture
Date of information about lumbar puncture
Was a control of coagulation performed?
Yes
No
Coagulation control performed:
PPT (Partial Thromboplastin Time)
sec
International Normalization Ratio (INR)
Count platelets:
µl
Was lumbar puncture performed?
Yes
No
Date of lumbar puncture
Was the lumbar puncture successfully
completed?
Yes
No
If 'successfully completed' any complications?
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Yes
No
If complications, which one?
If 'not successfully completed' please give
reasons:
Other comments
Date of lumbar puncture
Sampling
Empty-stomached (during last 12 hrs)?
Yes
No
Last meal:
Last beverage:
Last beverage with coffeine:
Tabacco smoke (during the last 12 hrs)
Yes
No
Last tabacco smoke:
1. Sampling performed according to SOP-BM-
01?
Yes
No
1.1. SOP version (No.)
2. Any deviations from SOP-BM-01
Yes
No
2.1. Other container used for CSF sampling and
not those at disposal.
Yes
No
2.1.1. other container, please specify:
2.2. Any deviation from SOP-KA-02, Version X?
Yes
No
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DESCRIBE (DZNE – Clinical Register Study of neurodegenerative
Disorders) CRF Lumbar Puncture Baseline
CSF tube volume
ml
CSF tube barcode
CSF sampling NOT DONE
Yes
No
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DESCRIBE (DZNE – Clinical Register Study of neurodegenerative
Disorders) CRF Lumbar Puncture Baseline
DESCRIBE (DZNE – Clinical Register Study of
neurodegenerative Disorders) CRF Lumbar Puncture Follow Up
Background and Purpose:
The purpose of the DESCRIBE study is to document the
natural course of diseases in context of medical care of
neurodegenerative disorders as well as cerebrovascular
diseases and to perform phenotyping of the test persons.
Disease-spanning analyses of the measured clincial data,
the results of the imaging processes, results of the analysis
of the biometerials including genetic analysis are planed.
Principal Investigator: Prof. Klockgether, Dr. Spottke DZNE,
Bonn.
Source: DESCRIBE-Studie
http://www.dzne.de/forschung/forschungsbereiche/klinische
-forschung/studien/describe-bn006.html 
Participating Study Sites:
Berlin, Bonn, Göttingen, Dresden, Köln, Magdeburg,
München, Rostock/Greifswald, Tübingen
All rights reserved. Please visit https://medical-data-
models.org/forms/13903
CRF Lumbar Puncture Follow Up
Date of visit
Date of visit
Study-ID:
Follow-Up:
Lumbar puncture
Date of information about lumbar puncture
Was a control of coagulation performed?
Yes
No
Coagulation control performed:
PPT (Partial Thromboplastin Time)
sec
International Normalization Ratio (INR)
Count platelets:
µl
Was lumbar puncture performed?
Yes
No
Date of lumbar puncture
Was the lumbar puncture successfully
completed?
Yes
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No
If 'successfully completed' any complications?
Yes
No
If complications, which one?
If 'not successfully completed' please give
reasons:
Other comments
Date of lumbar puncture
Sampling
Empty-stomached (during last 12 hrs)?
Yes
No
Last meal:
Last beverage:
Last beverage with coffeine:
Tabacco smoke (during the last 12 hrs)
Yes
No
Last tabacco smoke:
1. Sampling performed according to SOP-BM-
01?
Yes
No
1.1. SOP version (No.)
2. Any deviations from SOP-BM-01
Yes
No
2.1. Other container used for CSF sampling and
not those at disposal.
Yes
No
2.1.1. other container, please specify:
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Disorders) CRF Lumbar Puncture Follow Up
2.2. Any deviation from SOP-KA-02, Version X?
Yes
No
CSF tube volume
ml
CSF tube barcode
CSF sampling NOT DONE
Yes
No
3 / 3
DESCRIBE (DZNE – Clinical Register Study of neurodegenerative
Disorders) CRF Lumbar Puncture Follow Up
DESCRIBE (DZNE – Clinical Register Study of
neurodegenerative Disorders) CRF Endpoints
Background and Purpose:
The purpose of the DESCRIBE study is to document the
natural course of diseases in context of medical care of
neurodegenerative disorders as well as cerebrovascular
diseases and to perform phenotyping of the test persons.
Disease-spanning analyses of the measured clincial data,
the results of the imaging processes, results of the analysis
of the biometerials including genetic analysis are planed.
Principal Investigator: Prof. Klockgether, Dr. Spottke DZNE,
Bonn.
Source: DESCRIBE-Studie
http://www.dzne.de/forschung/forschungsbereiche/klinische
-forschung/studien/describe-bn006.html 
Participating Study Sites:
Berlin, Bonn, Göttingen, Dresden, Köln, Magdeburg,
München, Rostock/Greifswald, Tübingen
All rights reserved. Please visit https://medical-data-
models.org/forms/13904
CRF Endpoints
End of study participation
Study-ID:
Date of survey:
End of participation in clinical register because of:
Another disease than the diagnosis
concerning register, which inhibits further
study participation (Please add
comorbidity in follow-up documentation)
(1)
Decision of responsible physician or
investigator (2)
Request of participant or a family
member (withdrawal of consent) (3)
reasons concerning study site (4)
Loss of contact (5)
Participant bedridden (6)
Participant in nursing home (7)
Participant moved away from study site
(8)
other reason (9)
Other reason
Mortality
Date of death
Place of death
At home (At home)
Clinic (Clinic)
Hospice (Hospice)
Nursing home (Nursing home)
Unknown (Unknown)
Cause of death
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Medical certificate of cause of death confirms
cause of death
Yes
No
Autopsy performed
Yes
No
Main information source of cause of death
Death notice in newspapers (Death
notice in newspapers)
Friend (Friend)
Life partner/family (Life partner/family)
Medical certificate of cause of death
(Medical certificate of cause of death)
Other (Other)
Physician/Nurse (Physician/Nurse)
Registration office (Registration office)
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Laboratory results
Protein electrophoresis
Albumin
g/dL
Total Protein in 24h urine
mg/24h
Total Serum Protein
g/dl
Beta-globulin
g/dL
Gamma-Globulin measurement
g/dL
Beta and gamma globulin total
g/dL
Serum immunofixation
positive (1)
negative (2)
Comment on serum immunofixation
Urine immunofixation
positive (1)
negative (2)
Comment on urine immunofixation
IgA measurement
mg/dl
IgD measurement
mg/dl
IgG measurement
mg/dl
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Immunoglobulin M measurement
mg/dl
FLC kappa measurement
mg/l
Kappa
FLC lambda measurement
mg/l
Lambda
Kappa/lambda quotient
Hematology
Erythrocytes
Mio/μl
Hemoglobin
g/dl
Hematocrit
%
Mean Corpuscular Volume
fl
MCH
pg
Mean corpuscular hemoglobin concentration
g Hb/dL Ery
Leukocytes
1000/μl
Leukocytes (total)
Platelet count
1000/μl
Neutrophils percentage
%
Neutrophils
2 / 4
Laboratory results LenaMain-Study
abs.
Eosinophils percentage
%
Basophils percentage
%
Monocytes percentage
%
Lymphocytes percentage
%
Neutrophils
1000/μl
Serum chemistry
Sodium
mmol/L
Potassium
mmol/l
Calcium
mmol/l
Glucose
mg/dl
Alkaline Phosphatase
U/l
Bilirubin
mg/dL
AST (SGOT)
U/L
ALT
U/L
Gamma GT
U/l
Lactate Dehydrogenase (LDH) (U/l)
Urea
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mg/dl
CRP
md/dl
Serum Creatinine
mg/dl
Creatinine Clearance
mL/min
Pregnancy test
Is the subject of childbearing potential?
Yes
No
Pregnancy test result
positive (1)
negative (2)
Has the patient experienced irregularities with her
menstrual period since her last pregnancy test?
No menstruation (0)
Yes (1)
No (2)
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Quality of Life EORTC QLQ-C30
EORTC QLQ-C30 (version 3) Quality of
life questionnaire
Do you have any trouble doing strenuous
activities, like carrying a heavy shopping bag or a
suitcase
Not at all (1)
A little (2)
Quite a bit (3)
Very much (4)
Do you have any trouble taking a long walk
Not at all (1)
A little (2)
Quite a bit (3)
Very much (4)
Do you have any trouble taking a short walk
outside of the house
Not at all (1)
A little (2)
Quite a bit (3)
Very much (4)
Do you need to stay in bed or a chair during the
day
Not at all (1)
A little (2)
Quite a bit (3)
Very much (4)
Do you need help with eating, dressing, washing
yourself or using the toilet
Not at all (1)
A little (2)
Quite a bit (3)
Very much (4)
EORTC1 Past Week
Were you limited in doing either your work or
other daily activities?
Not at all (1)
A little (2)
Quite a bit (3)
Very much (4)
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Were you limited in pursuing your hobbies or
other leisure time activities?
Not at all (1)
A little (2)
Quite a bit (3)
Very much (4)
Were you short of breath
Not at all (1)
A little (2)
Quite a bit (3)
Very much (4)
Have you had pain
Not at all (1)
A little (2)
Quite a bit (3)
Very much (4)
Did you need to rest
Not at all (1)
A little (2)
Quite a bit (3)
Very much (4)
Eortc2 past week
Have you had trouble sleeping
Not at all (1)
A little (2)
Quite a bit (3)
Very much (4)
Have you felt weak
Not at all (1)
A little (2)
Quite a bit (3)
Very much (4)
Have you lacked appetite
Not at all (1)
A little (2)
Quite a bit (3)
Very much (4)
Have you felt nauseated
Not at all (1)
A little (2)
Quite a bit (3)
Very much (4)
Have you vomited
Not at all (1)
A little (2)
Quite a bit (3)
Very much (4)
Eortc3 past week
2 / 4
Quality of Life LenaMain-Study
Have you been constipated
Not at all (1)
A little (2)
Quite a bit (3)
Very much (4)
Have you had diarrhea
Not at all (1)
A little (2)
Quite a bit (3)
Very much (4)
Were you tired
Not at all (1)
A little (2)
Quite a bit (3)
Very much (4)
Did pain interfere with your daily activities
Not at all (1)
A little (2)
Quite a bit (3)
Very much (4)
Have you had difficulty in concentrating on things,
like reading a newspaper or watching television
Not at all (1)
A little (2)
Quite a bit (3)
Very much (4)
Eortc4 past week
Did you feel tense
Not at all (1)
A little (2)
Quite a bit (3)
Very much (4)
Did you worry
Not at all (1)
A little (2)
Quite a bit (3)
Very much (4)
Did you feel irritable
Not at all (1)
A little (2)
Quite a bit (3)
Very much (4)
Did you feel depressed
Not at all (1)
A little (2)
Quite a bit (3)
Very much (4)
Have you had difficulty remembering things
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Not at all (1)
A little (2)
Quite a bit (3)
Very much (4)
Eortc5 past week
Has your physical condition or medical treatment
interfered with your family life
Not at all (1)
A little (2)
Quite a bit (3)
Very much (4)
Has your physical condition or medical treatment
interfered with your social activities
Not at all (1)
A little (2)
Quite a bit (3)
Very much (4)
Has your physical condition or medical treatment
caused you financial difficulties
Not at all (1)
A little (2)
Quite a bit (3)
Very much (4)
How would you rate your overall health during the
past week?
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
7 (7)
How would you rate your overall quality of life
during the past week?
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
7 (7)
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Baseline Visit
Inclusion of Patient
Date of baseline visit
Date of informed consent
Screening Date
Date of Inclusion
Patient Birth Date
Patient age
Remission status at baseline
sCR (0)
CR (1)
vgPR (2)
PR (3)
SD (5)
PD (6)
ISS Score
1 (1)
2 (2)
3 (3)
Randomization
Branch A (1)
Branch B (2)
Inclusion criteria
Informed consent obtained according to
ICH/EU/GCP
Yes
No
Age at enrollment
>= 18
<= 75
years
Yes
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No
Patient is willing and able to comply to study
protocol
Yes
No
Patients with multiple myeloma, who received
high-dose therapy and autologous stem cell
therapy as initial therapy within the last 90-120
days and didn´t show any disease progression.
Patients may have received a second high-dose
therapy if not at least VGPR has been achieved
or patients who received an intermediate dose of
Melphalan due to age greater than 65 years.
Yes
No
Patients may have received 6 cycles of Induction
therapy (E. G. Idarubicine, Dexamethasone) and
up to 2 cycles of a mobilization chemotherapy (E.
G. Cyclophosphamide). Induction therapy with
Bortezomib or Thalidomide is allowed as well as
an accompanying Radiotherapy. The use of
Lenalidomide as a single agent or Combination
therapy is not allowed.
Yes
No
Measurable paraprotein in serum (> 0.5 g / dL) or
in urine (> 0.2 g / 24h) or measurable free Light
chains (FLC) in serum (> 50 mg / l) with an
abnormal FLC part must be documented at the
time of diagnosis
Yes
No
ECOG performance status ≤2 at the time of
enrollment
Yes
No
Laboratory values within the following
Limits: ANC ≥ 1,000 / uL,
Platelets ≥ 100,000 / uL, total
Bilirubin ≤ 2.5 mg / dL, AST (SGOT)
and ALT (SGPT) ≤ 3 x ULN
Yes
No
Patient must be willing and able to use safe
contraceptive measures.
Yes
No
Women of childbearing potential must agree to
the concurrent use of two medically approved,
secure contraceptive methods or continuous
abstinence from heterosexual intercourse. Men
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must consent to use condoms during the study
until at least 28 days after conclusion of study,
even after having a successful vasectomy, if their
partner is of childbearing potential.
Yes
No
Patients should not have suffered an active
malignancy during the last 5 years with the
exception of a currently treated Basalioma, a
squamous cell carcinoma of the skin or a
carcinoma "in situ" of the cervix or breast
Yes
No
Exclusion criteria
Patient is unable to understand and sign informed
consent due to any medical condition, change in
laboratory parameter or mental illness
Yes
No
Pregnancy or breastfeeding mothers
Yes
No
All blood chemistry changes that would place an
unacceptable risk to the patient in case of study
participation or that could influence study
evaluation
Yes
No
Known hypersensitivity to thalidomide or
lenalidomide
Yes
No
Any unexpected skin reaction with a CTC-grade
equal to or higher than 3 (i.e: desquamating rash)
during application of thalidomid or similar agents
Yes
No
Prior use of lenalidomide
Yes
No
Active infection with HIV or Hepatitis A,B or C
Yes
No
Parameter of multiple myeloma at
enrollment
ISS Stage
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1 (1)
2 (2)
3 (3)
Cytogenetic examination done?
Yes
No
Cytogenetics:please specify
Cytogenetics date
beta2-Microglobulin
mg/l
Contrast infiltration
%
Extramedullary lesion
Yes
No
Lytic lesion of bones
None (1)
Osteopenia (2)
1-5 lytic lesions of bone (3)
>6 lytic lesions of bone (4)
Paraprotein
g/dl
Vital signs
Heart rate
bpm
Blood pressure, systolic
mmHg
Blood pressure, diastolic
mmHg
Body weight
kg
Body Height
cm
Ecog performance status
Score 0 (0)
Score 1 (1)
Score 2 (2)
Score 3 (3)
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Score 4 (4)
Score 5 (5)
Comorbidities
Consecutive number
Comorbidity:please specify
Initial Diagnosis
Is the comorbidity persistent?
Yes
No
Does the comorbidity require treatment
Yes
No
Laboratory:Protein electrophoresis
Albumin
g/dL
Total Protein in 24h urine
mg/24h
Total Serum Protein
g/dl
Beta-globulin measurement
g/dL
Gamma-Globulin measurement
g/dL
Beta and gamma globulin total
g/dL
Serum immunofixation
positive (1)
negative (2)
Comment on serum immunofixation
Urine immunofixation
positive (1)
negative (2)
Comment on urine immunofixation
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IgA measurement
mg/dl
IgD measurement
mg/dl
IgG measurement
mg/dl
Immunoglobulin M measurement
mg/dl
FLC kappa measurement
mg/l
Kappa
FLC lambda measurement
mg/l
Lambda
Kappa/lambda quotient
Laboratory:Hematology
Erythrocytes
Mio/μl
Hemoglobin
g/dL
Hematocrit
%
Mean Corpuscular Volume
fl
MCH
pg
Mean corpuscular hemoglobin concentration
g Hb/dL Ery
Leukocytes
1000/μl
Leukocytes (total)
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Platelet count
1000/uL
Neutrophils percentage
%
Neutrophils
abs.
Eosinophils percentage
%
Basophils percentage
%
Monocytes percentage
%
Lymphocytes percentage
%
Neutrophils
1000/μl
Laboratory:serum chemistry
Sodium
mmol/L
Potassium
mmol/l
Calcium
mmol/l
Glucose
mg/dl
Alkaline Phosphatase
U/L
Bilirubin
mg/dL
AST (SGOT)
U/L
ALT
U/L
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Gamma GT
U/l
Lactate Dehydrogenase (LDH)
U/L
Urea
mg/dl
CRP
md/dl
Serum creatinine
mg/dL
Creatinine Clearance
mL/min
Laboratory:pregnancy test
Is the subject of childbearing potential?
Yes
No
Pregnancy test result
positive (1)
negative (2)
Has the patient experienced irregularities with her
menstrual period since her last pregnancy test?
No menstruation (0)
Yes (1)
No (2)
Quality of life
Total Score QoL
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First Consolidation Cycle
Weekly control visit (large)
Date of visit
Medication dosage of last cycle
mg
Prior trial substance dosage
mg
25 mg (1)
15 mg (2)
10 mg (3)
5 mg (4)
20 mg (5)
New trial substance dosage
25 mg (1)
15 mg (2)
10 mg (3)
5 mg (4)
20 mg (5)
Please specify reason for dose reduction
Did any Adverse Events occur?
Yes
No
Vital signs
Heart rate
bpm
Blood pressure, systolic
mmHg
Blood pressure, diastolic
mmHg
Body weight
kg
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Body Height
cm
Ecog performance status
Score 0 (0)
Score 1 (1)
Score 2 (2)
Score 3 (3)
Score 4 (4)
Score 5 (5)
Laboratory:Hematology
Erythrocytes
Mio/μl
Hemoglobin
g/dL
Hematocrit
%
Mean Corpuscular Volume
fl
MCH
pg
Mean corpuscular hemoglobin concentration
g Hb/dL Ery
Leukocytes
1000/μl
Leukocytes (total)
Platelet count
1000/uL
Neutrophils percentage
%
Neutrophils
abs.
Eosinophils percentage
%
Basophils percentage
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%Monocytes percentage
%
Lymphocytes percentage
%
Neutrophils
1000/μl
Laboratory:serum chemistry
Sodium
mmol/L
Potassium
mmol/l
Calcium
mmol/l
Glucose
mg/dl
Alkaline Phosphatase
U/L
Bilirubin
mg/dL
AST (SGOT)
U/L
ALT
U/L
Gamma GT
U/l
Lactate Dehydrogenase (LDH)
U/L
Urea
mg/dl
CRP
md/dl
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Serum creatinine
mg/dL
Creatinine Clearance
mL/min
Laboratory:pregnancy test
Is the subject of childbearing potential?
Yes
No
Pregnancy test result
positive (1)
negative (2)
Has the patient experienced irregularities with her
menstrual period since her last pregnancy test?
No menstruation (0)
Yes (1)
No (2)
Quality of life
Total Score QoL
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First Consolidation Cycle
2. Weekly control visit (large)
Date of visit
Medication dosage of last cycle
mg
Prior trial substance dosage
mg
25 mg (1)
15 mg (2)
10 mg (3)
5 mg (4)
20 mg (5)
New trial substance dosage
25 mg (1)
15 mg (2)
10 mg (3)
5 mg (4)
20 mg (5)
Please specify reason for dose reduction
Did any Adverse Events occur?
Yes
No
Laboratory:Hematology
Erythrocytes
Mio/μl
Hemoglobin
g/dL
Hematocrit
%
Mean Corpuscular Volume
fl
1 / 3
MCH
pg
Mean corpuscular hemoglobin concentration
g Hb/dL Ery
Leukocytes
1000/μl
Leukocytes (total)
Platelet count
1000/uL
Neutrophils percentage
%
Neutrophils
abs.
Eosinophils percentage
%
Basophils percentage
%
Monocytes percentage
%
Lymphocytes percentage
%
Neutrophils
1000/μl
Laboratory:serum chemistry
Sodium
mmol/L
Potassium
mmol/l
Calcium
mmol/l
Glucose
mg/dl
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Alkaline Phosphatase
U/L
Bilirubin
mg/dL
AST (SGOT)
U/L
ALT
U/L
Gamma GT
U/l
Lactate Dehydrogenase (LDH)
U/L
Urea
mg/dl
CRP
md/dl
Serum creatinine
mg/dL
Creatinine Clearance
mL/min
Laboratory:pregnancy test
Is the subject of childbearing potential?
Yes
No
Pregnancy test result
positive (1)
negative (2)
Has the patient experienced irregularities with her
menstrual period since her last pregnancy test?
No menstruation (0)
Yes (1)
No (2)
3 / 3
First Consolidation Cycle 2.week LenaMain-Study
DESCRIBE (DZNE – Clinical Register Study of
neurodegenerative Disorders) CRF Continuous Documentation
Background and Purpose:
The purpose of the DESCRIBE study is to document the
natural course of diseases in context of medical care of
neurodegenerative disorders as well as cerebrovascular
diseases and to perform phenotyping of the test persons.
Disease-spanning analyses of the measured clincial data,
the results of the imaging processes, results of the analysis
of the biometerials including genetic analysis are planed.
Principal Investigator: Prof. Klockgether, Dr. Spottke DZNE,
Bonn.
Source: DESCRIBE-Studie
http://www.dzne.de/forschung/forschungsbereiche/klinische
-forschung/studien/describe-bn006.html 
Participating Study Sites:
Berlin, Bonn, Göttingen, Dresden, Köln, Magdeburg,
München, Rostock/Greifswald, Tübingen
All rights reserved. Please visit https://medical-data-
models.org/forms/13914
CRF Continuous Documentation
Diseases
Study-ID:
Does the participant have any pre-existing
conditions or comorbidities?
Yes
No
Documentation of diseases
No.
Diagnosis
Onset of disease
End of disease
Disease enduring
Yes
No
Checklist pre-existing conditions
No. 1 Hypertension
No  (No )
Not specified (Not specified)
Unknown (Unknown)
Yes  (Yes )
Initial diagnosis
No.2  Hypercholesterolemia
No  (No )
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Not specified (Not specified)
Unknown (Unknown)
Yes  (Yes )
Initial diagnosis
No.3 Hypertriglyceridemia
No  (No )
Not specified (Not specified)
Unknown (Unknown)
Yes  (Yes )
Initial diagnosis
No.4 Other hyperlipedimia or dyslipidemia
No  (No )
Not specified (Not specified)
Unknown (Unknown)
Yes  (Yes )
Initial diagnosis
No. 5 Diabetes mellitus type 1
No  (No )
Not specified (Not specified)
Unknown (Unknown)
Yes  (Yes )
Initial diagnosis
No. 6 Diabetes mellitus type 2
No  (No )
Not specified (Not specified)
Unknown (Unknown)
Yes  (Yes )
Initial diagnosis
No. 7 Diabetic polyneuropathy
No  (No )
Not specified (Not specified)
Unknown (Unknown)
Yes  (Yes )
Initial diagnosis
No. 8 Cardiac infarction
No  (No )
Not specified (Not specified)
Unknown (Unknown)
Yes  (Yes )
Initial diagnosis
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No.9 Transient ischemic attack (TIA)
No  (No )
Not specified (Not specified)
Unknown (Unknown)
Yes  (Yes )
Initial diagnosis
No. 10 Coronary heart disease
No  (No )
Not specified (Not specified)
Unknown (Unknown)
Yes  (Yes )
Initial diagnosis
No. 11 Stroke (ischemic)
No  (No )
Not specified (Not specified)
Unknown (Unknown)
Yes  (Yes )
Initial diagnosis
No. 12 Cerebral venous sinus thrombosis or
cerebral thrombosis
No  (No )
Not specified (Not specified)
Unknown (Unknown)
Yes  (Yes )
Initial date
No. 13  Subarachnoid hemorrhage
No  (No )
Not specified (Not specified)
Unknown (Unknown)
Yes  (Yes )
Initial diagnosis
No. 14 Intracerebral hemorrhage (ICH)
No  (No )
Not specified (Not specified)
Unknown (Unknown)
Yes  (Yes )
Initial diagnosis
No. 15 Subdural hematoma
No  (No )
Not specified (Not specified)
Unknown (Unknown)
Yes  (Yes )
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Initial diagnosis
No. 16 Concussion
No  (No )
Not specified (Not specified)
Unknown (Unknown)
Yes  (Yes )
Initial diagnosis
No. 17 Other pre-existing brain condition
No  (No )
Not specified (Not specified)
Unknown (Unknown)
Yes  (Yes )
Initial diagnosis
No. 18 Peripheral arterial disease
No  (No )
Not specified (Not specified)
Unknown (Unknown)
Yes  (Yes )
Initial diagnosis
No. 19 Atrial fibrillation
No  (No )
Not specified (Not specified)
Unknown (Unknown)
Yes  (Yes )
Initial diagnosis
No. 20 Hemophilia
No  (No )
Not specified (Not specified)
Unknown (Unknown)
Yes  (Yes )
Initial diagnosis
No. 21 Parkinson's disease
No  (No )
Not specified (Not specified)
Unknown (Unknown)
Yes  (Yes )
Initial diagnosis
No. 22 Rheumatism or arthritis
No  (No )
Not specified (Not specified)
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Unknown (Unknown)
Yes  (Yes )
Initial diagnosis
No. 23 Hypersensitivity
No  (No )
Not specified (Not specified)
Unknown (Unknown)
Yes  (Yes )
Initial diagnosis
Procedures
Did the participant receive one or several
treatments in the past?
No  (No )
Unknown (Unknown)
Yes (Yes)
Documentation of procedures
No.
Procedure
Indication
Date of procedure
Medication
Does the participant take any medication at the
moment?
No  (No )
Unknown (Unknown)
Yes (Yes)
Documentation of medication
No.
Medical drug/active agents
Daily dose
Unit
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Type of application
tablet (1)
cream (2)
spray (3)
syringe (4)
suppository (5)
drops (6)
infusion (7)
transdermal (8)
other (9)
Route of application
per os (1)
intravenous (2)
intramuscular (3)
subcutaneous (4)
rectal (5)
local (6)
per inhalation (7)
transdermal (8)
other (9)
Indication
Duration - Start of procedure
Duration - End of procedure
Procedure enduring
Yes
No
Family history - family tree
Here you have the opportunity to draw a sketch of
the family tree.
Family history - parents
Mother: Year of birth
Screened diseases
Yes
No
Alive?
No  (No )
Unknown (Unknown)
Yes (Yes)
Mother - Year of death
Unknown
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Yes
No
Father - Year of birth
Screened diseases?
Yes
No
Alive?
No  (No )
Unknown (Unknown)
Yes (Yes)
Father - Year of death
Unknown
Family history - siblings
Sibling
brother (brother)
sister (sister)
Sibling - Year of birth
Screened diseases?
Yes
No
Alive?
No  (No )
Unknown (Unknown)
Yes (Yes)
Sibling - Year of death
year of death sibling unknown
Yes
No
Family history - children
Child
daughter (daughter)
son (son)
Child - Year of birth
Screened diseases?
Yes
No
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Alive?
No  (No )
Unknown (Unknown)
Yes (Yes)
Child - Year of death
Unknown
Family history - further relatives
Degree of affinity
Great-Grandfather/Great-Grandmother
(1)
Nephew/Niece (10)
Grandchild (11)
Grandfather/Grandmother (2)
Granduncle/Grand-aunt (3)
Father/Mother (4)
Uncle/Aunt (5)
Brother/Sister (6)
Son/Daughter (7)
Cousin (8)
Cousin (2. degree) (9)
Side
maternal (M)
paternal (P)
unknown (U)
Gender
Female (Female)
Male (Male)
Relative - Year of birth
Screened diseases?
Yes
No
Alive?
No  (No )
Unknown (Unknown)
Yes (Yes)
Relative - Year of death
Unknown
Yes
No
Family history - relatives with screened
diseases
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Degree of affinity
Great-Grandfather/Great-Grandmother
(1)
Nephew/Niece (10)
Grandchild (11)
Grandfather/Grandmother (2)
Granduncle/Grand-aunt (3)
Father/Mother (4)
Uncle/Aunt (5)
Brother/Sister (6)
Son/Daughter (7)
Cousin (8)
Cousin (2. degree) (9)
Side
maternal (M)
paternal (P)
unknown (U)
Gender
Female (Female)
Male (Male)
Year of birth
Diagnosis
Dementia, not further specified (1)
Mixed dementia (10)
Vascular dementia (VD) (11)
Frototemperal dementia (FTD) -
behavioral variant (12)
Primary progressive aphasia (PPA) (13)
Progressive nonfluent aphasia (PNFA)
(14)
Logopenic progressive Aphasia (LPA)
(15)
Semantic dementia (SemD) (16)
bvFTD + ALS (17)
PPA + ALS (18)
Idiopathic Parkinson's disease (IPS) (19)
Motor disturbances, not further specified
(2)
Morbus parkinson along with MCI (PD-
MCI) (20)
Dementia due to morbus parkinson
(PPD) (21)
Dementia with Lewy bodies (DLB) (22)
Progressive supranuclear palsy (PSP)
(23)
Corticobasal degeneration (CBD) (24)
Multiple system atrophy (MSA) (25)
MSA-p (Parkinson) (26)
MSA-c (cerebral) (27)
Essential tremor (ET) (28)
Ataxia (29)
Psychiatric disease, not further specified
(3)
Amyotrophic lateral sclerosis (ALS) (30)
Huntington disease (HD) (31)
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Creutzfeldt-Jakob-Disease (32)
Depression (primary disease) (33)
Subjective cognitive decline (SCD) (4)
Amnestic mild cognitive disorder (5)
Non-amnestic mild cognitive disorder (6)
Probable dementia in Alzheimer's
disease (AD) (7)
Possible dementia in Alzheimer's
disease (AD) (8)
Posterior cortical atrophy (PCA) (9)
Verified?
specialist (neurologist/psychiatrist) (1)
DZNE center (2)
no verfication (3)
Age at onset on symptoms
Register?
Yes
No
Participant-ID
Handedness
Which hand do you use to write a legible letter?
always left (-2) (always left (-2))
always right (+2) (always right (+2))
no preference (0) (no preference (0))
usually left (-1) (usually left (-1))
usually right (+1) (usually right (+1))
Which hand do you use to throw a ball?
always left (-2) (always left (-2))
always right (+2) (always right (+2))
no preference (0) (no preference (0))
usually left (-1) (usually left (-1))
usually right (+1) (usually right (+1))
Which hand do you use to play with a racket in a
game?
always left (-2) (always left (-2))
always right (+2) (always right (+2))
no preference (0) (no preference (0))
usually left (-1) (usually left (-1))
usually right (+1) (usually right (+1))
Which hand do you use as upper hand using a
broom?
always left (-2) (always left (-2))
always right (+2) (always right (+2))
no preference (0) (no preference (0))
usually left (-1) (usually left (-1))
usually right (+1) (usually right (+1))
Which hand do you use as upper hand to use a
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spade snow shoveling?
Which hand do you use to strike a match?
always left (-2) (always left (-2))
always right (+2) (always right (+2))
no preference (0) (no preference (0))
usually left (-1) (usually left (-1))
usually right (+1) (usually right (+1))
Which hand do you use to hold the scissors
cutting?
always left (-2) (always left (-2))
always right (+2) (always right (+2))
no preference (0) (no preference (0))
usually left (-1) (usually left (-1))
usually right (+1) (usually right (+1))
Which do you use to thread a needle?
always left (-2) (always left (-2))
always right (+2) (always right (+2))
no preference (0) (no preference (0))
usually left (-1) (usually left (-1))
usually right (+1) (usually right (+1))
Which hand do you use to deal cards?
always left (-2) (always left (-2))
always right (+2) (always right (+2))
no preference (0) (no preference (0))
usually left (-1) (usually left (-1))
usually right (+1) (usually right (+1))
Which hand do you use to hold a hammer
nailing?
always left (-2) (always left (-2))
always right (+2) (always right (+2))
no preference (0) (no preference (0))
usually left (-1) (usually left (-1))
usually right (+1) (usually right (+1))
Which hand do you use to hold a toothbrush?
always left (-2) (always left (-2))
always right (+2) (always right (+2))
no preference (0) (no preference (0))
usually left (-1) (usually left (-1))
usually right (+1) (usually right (+1))
Which hand do you use to open a bottle?
always left (-2) (always left (-2))
always right (+2) (always right (+2))
no preference (0) (no preference (0))
usually left (-1) (usually left (-1))
usually right (+1) (usually right (+1))
Which eye do you use, if you can only use one
eye (e.g. keyhole)?
left eye (left eye)
right eye (right eye)
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Overview - Study participation
Study abbreviation (Study number)
Date of consent
Date end of study
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Disorders) CRF Continuous Documentation
DESCRIBE (DZNE – Clinical Register Study of
neurodegenerative Disorders) CRF MRI Contraindications
Background and Purpose:
The purpose of the DESCRIBE study is to document the
natural course of diseases in context of medical care of
neurodegenerative disorders as well as cerebrovascular
diseases and to perform phenotyping of the test persons.
Disease-spanning analyses of the measured clincial data,
the results of the imaging processes, results of the analysis
of the biometerials including genetic analysis are planed.
Principal Investigator: Prof. Klockgether, Dr. Spottke DZNE,
Bonn.
Source: DESCRIBE-Studie
http://www.dzne.de/forschung/forschungsbereiche/klinische
-forschung/studien/describe-bn006.html 
Participating Study Sites:
Berlin, Bonn, Göttingen, Dresden, Köln, Magdeburg,
München, Rostock/Greifswald, Tübingen
All rights reserved. Please visit https://medical-data-
models.org/forms/13915
CRF MRI Contraindications
Questionaire - MRI contraindications
Study-ID:
Body weight
>= 0
kg
Height
>= 0
cm
1. Were heart or head surgeries performed?
? (?)
No  (No )
Yes (Yes)
2. Do you have implants?
? (?)
No  (No )
Yes (Yes)
3. Are there any metal pieces or foreign bodies in
or on your body?
? (?)
No  (No )
Yes (Yes)
4. Did you work in a metalworking industry?
? (?)
No  (No )
Yes (Yes)
5. Do you suffer from tinnitus?
? (?)
No  (No )
Yes (Yes)
6. Do you have an anxiety of confined space (e.g.
riding in an elevator)?
? (?)
1 / 2
No  (No )
Yes (Yes)
7. Do you wear body jewellery that you cannot
get off?
? (?)
No  (No )
Yes (Yes)
8. Do you have a family history of epilepsy?
? (?)
No  (No )
Yes (Yes)
9. Are you under the influence of drinks or drugs
(e.g. alcohol)?
? (?)
No  (No )
Yes (Yes)
10. Does a pregnancy exist?
? (?)
No  (No )
Yes (Yes)
11. Do you suffer from pain, circulatory problems
or respiratory problems, if you lie down on your
back for a while?
? (?)
No  (No )
Yes (Yes)
12. Do you have fever?
? (?)
No  (No )
Yes (Yes)
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DESCRIBE (DZNE – Clinical Register Study of neurodegenerative
Disorders) CRF MRI Contraindications
Second Consolidation Cycle 1.week
LenaMain-Study
A randomised comparison of daily 25 mg versus 5 mg
lenalidomide as maintenance therapy after high-dose
therapy and autologous stem cell transplantation in patients
with multiple myeloma. Protocol-Code: RV-MM-PI-280
EudraCT-Number: 2007-003945-33 Author: Claus
Schreiber Review: Gerd Felder Approval of CRF: Prof. Dr.
med. G. Kobbe (LKP) Release for MDM: Prof. Gattermann,
Düsseldorf (26.1.2016) Principal Investigator „LenaMain“-
Studie: Prof. Roland Fenk, Düsseldorf Coordinating center
for clinical trial Medical faculty of University Hospital
Heinrich-Heine-University Scientific Director: Herr Dr. J.
Grebe Moorenstrasse 5 40225 Düsseldorf Tel.: +49 (0)
211-81-19701 Fax: +49 (0) 211-81-19702
All rights reserved. Please visit https://medical-data-
models.org/forms/13917
Second Consolidation Cycle
Weekly control visit (small)
Date of visit
Medication dosage of last cycle
mg
Prior trial substance dosage
mg
25 mg (1)
15 mg (2)
10 mg (3)
5 mg (4)
20 mg (5)
New trial substance dosage
25 mg (1)
15 mg (2)
10 mg (3)
5 mg (4)
20 mg (5)
Please specify reason for dose reduction
Response after first consolidation cycle
sCR (0)
CR (1)
vgPR (2)
PR (3)
SD (5)
PD (6)
External assessment of response
Yes
No
Did any Adverse Events occur?
Yes
No
Vital signs
Heart rate
bpm
1 / 6
Blood pressure, systolic
mmHg
Blood pressure, diastolic
mmHg
Body weight
kg
Body Height
cm
Ecog performance status
Score 0 (0)
Score 1 (1)
Score 2 (2)
Score 3 (3)
Score 4 (4)
Score 5 (5)
Laboratory:Protein electrophoresis
Albumin
g/dL
Total Protein in 24h urine
mg/24h
Total Serum Protein
g/dl
Beta-globulin measurement
g/dL
Gamma-Globulin measurement
g/dL
Beta and gamma globulin total
g/dL
Serum immunofixation
positive (1)
negative (2)
Comment on serum immunofixation
Urine immunofixation
positive (1)
negative (2)
Comment on urine immunofixation
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Second Consolidation Cycle 1.week LenaMain-Study
IgA measurement
mg/dl
IgD measurement
mg/dl
IgG measurement
mg/dl
Immunoglobulin M measurement
mg/dl
FLC kappa measurement
mg/l
Kappa
FLC lambda measurement
mg/l
Lambda
Kappa/lambda quotient
Laboratory:Hematology
Erythrocytes
Mio/μl
Hemoglobin
g/dL
Hematocrit
%
Mean Corpuscular Volume
fl
MCH
pg
Mean corpuscular hemoglobin concentration
g Hb/dL Ery
Leukocytes
1000/μl
Leukocytes (total)
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Second Consolidation Cycle 1.week LenaMain-Study
Platelet count
1000/uL
Neutrophils percentage
%
Neutrophils
abs.
Eosinophils percentage
%
Basophils percentage
%
Monocytes percentage
%
Lymphocytes percentage
%
Neutrophils
1000/μl
Laboratory:serum chemistry
Sodium
mmol/L
Potassium
mmol/l
Calcium
mmol/l
Glucose
mg/dl
Alkaline Phosphatase
U/L
Bilirubin
mg/dL
AST (SGOT)
U/L
ALT
U/L
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Gamma GT
U/l
Lactate Dehydrogenase (LDH)
U/L
Urea
mg/dl
CRP
md/dl
Serum creatinine
mg/dL
Creatinine Clearance
mL/min
Laboratory:pregnancy test
Is the subject of childbearing potential?
Yes
No
Pregnancy test result
positive (1)
negative (2)
Has the patient experienced irregularities with her
menstrual period since her last pregnancy test?
No menstruation (0)
Yes (1)
No (2)
Quality of life
Total Score QoL
Hematotoxicity CTC
Hemoglobin CTC
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
Date of lowest hemoglobin value
Hemoglobin: actions taken with study medication
No change required (0)
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Interruption/ prolongation without dose
reduction (1)
Interruption/ prolongation with dose
reduction (2)
Leukocytes CTC
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
Date of lowest leukocytes value
Actions taken with study medication:leukocytes
No change required (0)
Interruption/ prolongation without dose
reduction (1)
Interruption/ prolongation with dose
reduction (2)
Platelets CTC
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
Date of lowest platelets value
Actions taken with study medication:platelets
No change required (0)
Interruption/ prolongation without dose
reduction (1)
Interruption/ prolongation with dose
reduction (2)
Neutrophils CTC
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
Date of lowest neutrophils value
Actions taken with study medication:neutrophils
No change required (0)
Interruption/ prolongation without dose
reduction (1)
Interruption/ prolongation with dose
reduction (2)
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Second Consolidation Cycle 1.week LenaMain-Study
First Consolidation Cycle 3.week LenaMain-
Study
A randomised comparison of daily 25 mg versus 5 mg
lenalidomide as maintenance therapy after high-dose
therapy and autologous stem cell transplantation in patients
with multiple myeloma. Protocol-Code: RV-MM-PI-280
EudraCT-Number: 2007-003945-33 Author: Claus
Schreiber Review: Gerd Felder Approval of CRF: Prof. Dr.
med. G. Kobbe (LKP) Release for MDM: Prof. Gattermann,
Düsseldorf (26.1.2016) Principal Investigator „LenaMain“-
Studie: Prof. Roland Fenk, Düsseldorf Coordinating center
for clinical trial Medical faculty of University Hospital
Heinrich-Heine-University Scientific Director: Herr Dr. J.
Grebe Moorenstrasse 5 40225 Düsseldorf Tel.: +49 (0)
211-81-19701 Fax: +49 (0) 211-81-19702
All rights reserved. Please visit https://medical-data-
models.org/forms/13918
First Consolidation Cycle
3. Weekly control visit (large)
Date of visit
Medication dosage of last cycle
mg
Prior trial substance dosage
mg
25 mg (1)
15 mg (2)
10 mg (3)
5 mg (4)
20 mg (5)
New trial substance dosage
25 mg (1)
15 mg (2)
10 mg (3)
5 mg (4)
20 mg (5)
Please specify reason for dose reduction
Did any Adverse Events occur?
Yes
No
Laboratory:Hematology
Erythrocytes
Mio/μl
Hemoglobin
g/dL
Hematocrit
%
Mean Corpuscular Volume
fl
1 / 3
MCH
pg
Mean corpuscular hemoglobin concentration
g Hb/dL Ery
Leukocytes
1000/μl
Leukocytes (total)
Platelet count
1000/uL
Neutrophils percentage
%
Neutrophils
abs.
Eosinophils percentage
%
Basophils percentage
%
Monocytes percentage
%
Lymphocytes percentage
%
Neutrophils
1000/μl
Laboratory:serum chemistry
Sodium
mmol/L
Potassium
mmol/l
Calcium
mmol/l
Glucose
mg/dl
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Alkaline Phosphatase
U/L
Bilirubin
mg/dL
AST (SGOT)
U/L
ALT
U/L
Gamma GT
U/l
Lactate Dehydrogenase (LDH)
U/L
Urea
mg/dl
CRP
md/dl
Serum creatinine
mg/dL
Creatinine Clearance
mL/min
Laboratory:pregnancy test
Is the subject of childbearing potential?
Yes
No
Pregnancy test result
positive (1)
negative (2)
Has the patient experienced irregularities with her
menstrual period since her last pregnancy test?
No menstruation (0)
Yes (1)
No (2)
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First Consolidation Cycle 4.week LenaMain-
Study
A randomised comparison of daily 25 mg versus 5 mg
lenalidomide as maintenance therapy after high-dose
therapy and autologous stem cell transplantation in patients
with multiple myeloma. Protocol-Code: RV-MM-PI-280
EudraCT-Number: 2007-003945-33 Author: Claus
Schreiber Review: Gerd Felder Approval of CRF: Prof. Dr.
med. G. Kobbe (LKP) Release for MDM: Prof. Gattermann,
Düsseldorf (26.1.2016) Principal Investigator „LenaMain“-
Studie: Prof. Roland Fenk, Düsseldorf Coordinating center
for clinical trial Medical faculty of University Hospital
Heinrich-Heine-University Scientific Director: Herr Dr. J.
Grebe Moorenstrasse 5 40225 Düsseldorf Tel.: +49 (0)
211-81-19701 Fax: +49 (0) 211-81-19702
All rights reserved. Please visit https://medical-data-
models.org/forms/13919
First Consolidation Cycle
4. Weekly control visit (large)
Date of visit
Medication dosage of last cycle
mg
Prior trial substance dosage
mg
25 mg (1)
15 mg (2)
10 mg (3)
5 mg (4)
20 mg (5)
New trial substance dosage
25 mg (1)
15 mg (2)
10 mg (3)
5 mg (4)
20 mg (5)
Please specify reason for dose reduction
Did any Adverse Events occur?
Yes
No
Laboratory:Hematology
Erythrocytes
Mio/μl
Hemoglobin
g/dL
Hematocrit
%
Mean Corpuscular Volume
fl
1 / 3
MCH
pg
Mean corpuscular hemoglobin concentration
g Hb/dL Ery
Leukocytes
1000/μl
Leukocytes (total)
Platelet count
1000/uL
Neutrophils percentage
%
Neutrophils
abs.
Eosinophils percentage
%
Basophils percentage
%
Monocytes percentage
%
Lymphocytes percentage
%
Neutrophils
1000/μl
Laboratory:serum chemistry
Sodium
mmol/L
Potassium
mmol/l
Calcium
mmol/l
Glucose
mg/dl
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Alkaline Phosphatase
U/L
Bilirubin
mg/dL
AST (SGOT)
U/L
ALT
U/L
Gamma GT
U/l
Lactate Dehydrogenase (LDH)
U/L
Urea
mg/dl
CRP
md/dl
Serum creatinine
mg/dL
Creatinine Clearance
mL/min
Laboratory:pregnancy test
Is the subject of childbearing potential?
Yes
No
Pregnancy test result
positive (1)
negative (2)
Has the patient experienced irregularities with her
menstrual period since her last pregnancy test?
No menstruation (0)
Yes (1)
No (2)
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Second Consolidation Cycle 2.week
LenaMain-Study
A randomised comparison of daily 25 mg versus 5 mg
lenalidomide as maintenance therapy after high-dose
therapy and autologous stem cell transplantation in patients
with multiple myeloma. Protocol-Code: RV-MM-PI-280
EudraCT-Number: 2007-003945-33 Author: Claus
Schreiber Review: Gerd Felder Approval of CRF: Prof. Dr.
med. G. Kobbe (LKP) Release for MDM: Prof. Gattermann,
Düsseldorf (26.1.2016) Principal Investigator „LenaMain“-
Studie: Prof. Roland Fenk, Düsseldorf Coordinating center
for clinical trial Medical faculty of University Hospital
Heinrich-Heine-University Scientific Director: Herr Dr. J.
Grebe Moorenstrasse 5 40225 Düsseldorf Tel.: +49 (0)
211-81-19701 Fax: +49 (0) 211-81-19702
All rights reserved. Please visit https://medical-data-
models.org/forms/13920
Second Consolidation Cycle
2. Weekly control visit (large)
Date of visit
Medication dosage of last cycle
mg
Prior trial substance dosage
mg
25 mg (1)
15 mg (2)
10 mg (3)
5 mg (4)
20 mg (5)
New trial substance dosage
25 mg (1)
15 mg (2)
10 mg (3)
5 mg (4)
20 mg (5)
Please specify reason for dose reduction
Did any Adverse Events occur?
Yes
No
Laboratory:Hematology
Erythrocytes
Mio/μl
Hemoglobin
g/dL
Hematocrit
%
Mean Corpuscular Volume
fl
1 / 3
MCH
pg
Mean corpuscular hemoglobin concentration
g Hb/dL Ery
Leukocytes
1000/μl
Leukocytes (total)
Platelet count
1000/uL
Neutrophils percentage
%
Neutrophils
abs.
Eosinophils percentage
%
Basophils percentage
%
Monocytes percentage
%
Lymphocytes percentage
%
Neutrophils
1000/μl
Laboratory:serum chemistry
Sodium
mmol/L
Potassium
mmol/l
Calcium
mmol/l
Glucose
mg/dl
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Alkaline Phosphatase
U/L
Bilirubin
mg/dL
AST (SGOT)
U/L
ALT
U/L
Gamma GT
U/l
Lactate Dehydrogenase (LDH)
U/L
Urea
mg/dl
CRP
md/dl
Serum creatinine
mg/dL
Creatinine Clearance
mL/min
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Second Consolidation Cycle 3.week
LenaMain-Study
A randomised comparison of daily 25 mg versus 5 mg
lenalidomide as maintenance therapy after high-dose
therapy and autologous stem cell transplantation in patients
with multiple myeloma. Protocol-Code: RV-MM-PI-280
EudraCT-Number: 2007-003945-33 Author: Claus
Schreiber Review: Gerd Felder Approval of CRF: Prof. Dr.
med. G. Kobbe (LKP) Release for MDM: Prof. Gattermann,
Düsseldorf (26.1.2016) Principal Investigator „LenaMain“-
Studie: Prof. Roland Fenk, Düsseldorf Coordinating center
for clinical trial Medical faculty of University Hospital
Heinrich-Heine-University Scientific Director: Herr Dr. J.
Grebe Moorenstrasse 5 40225 Düsseldorf Tel.: +49 (0)
211-81-19701 Fax: +49 (0) 211-81-19702
All rights reserved. Please visit https://medical-data-
models.org/forms/13921
Second Consolidation Cycle
3. Weekly control visit (large)
Date of visit
Prior trial substance dosage
mg
25 mg (1)
15 mg (2)
10 mg (3)
5 mg (4)
20 mg (5)
New trial substance dosage
25 mg (1)
15 mg (2)
10 mg (3)
5 mg (4)
20 mg (5)
Please specify reason for dose reduction
Did any Adverse Events occur?
Yes
No
Laboratory:Hematology
Erythrocytes
Mio/μl
Hemoglobin
g/dL
Hematocrit
%
Mean Corpuscular Volume
fl
MCH
pg
1 / 3
Mean corpuscular hemoglobin concentration
g Hb/dL Ery
Leukocytes
1000/μl
Leukocytes (total)
Platelet count
1000/uL
Neutrophils percentage
%
Neutrophils
abs.
Eosinophils percentage
%
Basophils percentage
%
Monocytes percentage
%
Lymphocytes percentage
%
Neutrophils
1000/μl
Laboratory:serum chemistry
Sodium
mmol/L
Potassium
mmol/l
Calcium
mmol/l
Glucose
mg/dl
Alkaline Phosphatase
U/L
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Bilirubin
mg/dL
AST (SGOT)
U/L
ALT
U/L
Gamma GT
U/l
Lactate Dehydrogenase (LDH)
U/L
Urea
mg/dl
CRP
md/dl
Serum creatinine
mg/dL
Creatinine Clearance
mL/min
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Second Consolidation Cycle 3.week LenaMain-Study
Second Consolidation Cycle 4.week
LenaMain-Study
A randomised comparison of daily 25 mg versus 5 mg
lenalidomide as maintenance therapy after high-dose
therapy and autologous stem cell transplantation in patients
with multiple myeloma. Protocol-Code: RV-MM-PI-280
EudraCT-Number: 2007-003945-33 Author: Claus
Schreiber Review: Gerd Felder Approval of CRF: Prof. Dr.
med. G. Kobbe (LKP) Release for MDM: Prof. Gattermann,
Düsseldorf (26.1.2016) Principal Investigator „LenaMain“-
Studie: Prof. Roland Fenk, Düsseldorf Coordinating center
for clinical trial Medical faculty of University Hospital
Heinrich-Heine-University Scientific Director: Herr Dr. J.
Grebe Moorenstrasse 5 40225 Düsseldorf Tel.: +49 (0)
211-81-19701 Fax: +49 (0) 211-81-19702
All rights reserved. Please visit https://medical-data-
models.org/forms/13922
Second Consolidation Cycle
4. Weekly control visit (large)
Date of visit
Prior trial substance dosage
mg
25 mg (1)
15 mg (2)
10 mg (3)
5 mg (4)
20 mg (5)
New trial substance dosage
25 mg (1)
15 mg (2)
10 mg (3)
5 mg (4)
20 mg (5)
Please specify reason for dose reduction
Did any Adverse Events occur?
Yes
No
Laboratory:Hematology
Erythrocytes
Mio/μl
Hemoglobin
g/dL
Hematocrit
%
Mean Corpuscular Volume
fl
MCH
pg
1 / 3
Mean corpuscular hemoglobin concentration
g Hb/dL Ery
Leukocytes
1000/μl
Leukocytes (total)
Platelet count
1000/uL
Neutrophils percentage
%
Neutrophils
abs.
Eosinophils percentage
%
Basophils percentage
%
Monocytes percentage
%
Lymphocytes percentage
%
Neutrophils
1000/μl
Laboratory:serum chemistry
Sodium
mmol/L
Potassium
mmol/l
Calcium
mmol/l
Glucose
mg/dl
Alkaline Phosphatase
U/L
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Bilirubin
mg/dL
AST (SGOT)
U/L
ALT
U/L
Gamma GT
U/l
Lactate Dehydrogenase (LDH)
U/L
Urea
mg/dl
CRP
md/dl
Serum creatinine
mg/dL
Creatinine Clearance
mL/min
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Third Consolidation Cycle 1.week
LenaMain-Study
A randomised comparison of daily 25 mg versus 5 mg
lenalidomide as maintenance therapy after high-dose
therapy and autologous stem cell transplantation in patients
with multiple myeloma. Protocol-Code: RV-MM-PI-280
EudraCT-Number: 2007-003945-33 Author: Claus
Schreiber Review: Gerd Felder Approval of CRF: Prof. Dr.
med. G. Kobbe (LKP) Release for MDM: Prof. Gattermann,
Düsseldorf (26.1.2016) Principal Investigator „LenaMain“-
Studie: Prof. Roland Fenk, Düsseldorf Coordinating center
for clinical trial Medical faculty of University Hospital
Heinrich-Heine-University Scientific Director: Herr Dr. J.
Grebe Moorenstrasse 5 40225 Düsseldorf Tel.: +49 (0)
211-81-19701 Fax: +49 (0) 211-81-19702
All rights reserved. Please visit https://medical-data-
models.org/forms/13923
Third Consolidation Cycle
Weekly control visit (small)
Date of visit
Medication dosage of last cycle
mg
Prior trial substance dosage
mg
25 mg (1)
15 mg (2)
10 mg (3)
5 mg (4)
20 mg (5)
New trial substance dosage
25 mg (1)
15 mg (2)
10 mg (3)
5 mg (4)
20 mg (5)
Please specify reason for dose reduction
Response after first consolidation cycle
sCR (0)
CR (1)
vgPR (2)
PR (3)
SD (5)
PD (6)
External assessment of response
Yes
No
Did any Adverse Events occur?
Yes
No
Vital signs
Heart rate
bpm
1 / 6
Blood pressure, systolic
mmHg
Blood pressure, diastolic
mmHg
Body weight
kg
Body Height
cm
Ecog performance status
Score 0 (0)
Score 1 (1)
Score 2 (2)
Score 3 (3)
Score 4 (4)
Score 5 (5)
Laboratory:Protein electrophoresis
Albumin
g/dL
Total Protein in 24h urine
mg/24h
Total Serum Protein
g/dl
Beta-globulin measurement
g/dL
Gamma-Globulin measurement
g/dL
Beta and gamma globulin total
g/dL
Serum immunofixation
positive (1)
negative (2)
Comment on serum immunofixation
Urine immunofixation
positive (1)
negative (2)
Comment on urine immunofixation
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IgA measurement
mg/dl
IgD measurement
mg/dl
IgG measurement
mg/dl
Immunoglobulin M measurement
mg/dl
FLC kappa measurement
mg/l
Kappa
FLC lambda measurement
mg/l
Lambda
Kappa/lambda quotient
Laboratory:Hematology
Erythrocytes
Mio/μl
Hemoglobin
g/dL
Hematocrit
%
Mean Corpuscular Volume
fl
MCH
pg
Mean corpuscular hemoglobin concentration
g Hb/dL Ery
Leukocytes
1000/μl
Leukocytes (total)
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Platelet count
1000/uL
Neutrophils percentage
%
Neutrophils
abs.
Eosinophils percentage
%
Basophils percentage
%
Monocytes percentage
%
Lymphocytes percentage
%
Neutrophils
1000/μl
Laboratory:serum chemistry
Sodium
mmol/L
Potassium
mmol/l
Calcium
mmol/l
Glucose
mg/dl
Alkaline Phosphatase
U/L
Bilirubin
mg/dL
AST (SGOT)
U/L
ALT
U/L
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Gamma GT
U/l
Lactate Dehydrogenase (LDH)
U/L
Urea
mg/dl
CRP
md/dl
Serum creatinine
mg/dL
Creatinine Clearance
mL/min
Laboratory:pregnancy test
Is the subject of childbearing potential?
Yes
No
Pregnancy test result
positive (1)
negative (2)
Has the patient experienced irregularities with her
menstrual period since her last pregnancy test?
No menstruation (0)
Yes (1)
No (2)
Quality of life
Total Score QoL
Hematotoxicity CTC
Hemoglobin CTC
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
Date of lowest hemoglobin value
Hemoglobin: actions taken with study medication
No change required (0)
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Interruption/ prolongation without dose
reduction (1)
Interruption/ prolongation with dose
reduction (2)
Leukocytes CTC
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
Date of lowest leukocytes value
Actions taken with study medication:leukocytes
No change required (0)
Interruption/ prolongation without dose
reduction (1)
Interruption/ prolongation with dose
reduction (2)
Platelets CTC
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
Date of lowest platelets value
Actions taken with study medication:platelets
No change required (0)
Interruption/ prolongation without dose
reduction (1)
Interruption/ prolongation with dose
reduction (2)
Neutrophils CTC
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
Date of lowest neutrophils value
Actions taken with study medication:neutrophils
No change required (0)
Interruption/ prolongation without dose
reduction (1)
Interruption/ prolongation with dose
reduction (2)
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Third Consolidation Cycle 2.week
LenaMain-Study
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therapy and autologous stem cell transplantation in patients
with multiple myeloma. Protocol-Code: RV-MM-PI-280
EudraCT-Number: 2007-003945-33 Author: Claus
Schreiber Review: Gerd Felder Approval of CRF: Prof. Dr.
med. G. Kobbe (LKP) Release for MDM: Prof. Gattermann,
Düsseldorf (26.1.2016) Principal Investigator „LenaMain“-
Studie: Prof. Roland Fenk, Düsseldorf Coordinating center
for clinical trial Medical faculty of University Hospital
Heinrich-Heine-University Scientific Director: Herr Dr. J.
Grebe Moorenstrasse 5 40225 Düsseldorf Tel.: +49 (0)
211-81-19701 Fax: +49 (0) 211-81-19702
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2. Weekly control visit (large)
Date of visit
Prior trial substance dosage
mg
25 mg (1)
15 mg (2)
10 mg (3)
5 mg (4)
20 mg (5)
New trial substance dosage
25 mg (1)
15 mg (2)
10 mg (3)
5 mg (4)
20 mg (5)
Please specify reason for dose reduction
Did any Adverse Events occur?
Yes
No
Laboratory:Hematology
Erythrocytes
Mio/μl
Hemoglobin
g/dL
Hematocrit
%
Mean Corpuscular Volume
fl
MCH
pg
1 / 3
Mean corpuscular hemoglobin concentration
g Hb/dL Ery
Leukocytes
1000/μl
Leukocytes (total)
Platelet count
1000/uL
Neutrophils percentage
%
Neutrophils
abs.
Eosinophils percentage
%
Basophils percentage
%
Monocytes percentage
%
Lymphocytes percentage
%
Neutrophils
1000/μl
Laboratory:serum chemistry
Sodium
mmol/L
Potassium
mmol/l
Calcium
mmol/l
Glucose
mg/dl
Alkaline Phosphatase
U/L
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Bilirubin
mg/dL
AST (SGOT)
U/L
ALT
U/L
Gamma GT
U/l
Lactate Dehydrogenase (LDH)
U/L
Urea
mg/dl
CRP
md/dl
Serum creatinine
mg/dL
Creatinine Clearance
mL/min
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Third Consolidation Cycle 3.week
LenaMain-Study
A randomised comparison of daily 25 mg versus 5 mg
lenalidomide as maintenance therapy after high-dose
therapy and autologous stem cell transplantation in patients
with multiple myeloma. Protocol-Code: RV-MM-PI-280
EudraCT-Number: 2007-003945-33 Author: Claus
Schreiber Review: Gerd Felder Approval of CRF: Prof. Dr.
med. G. Kobbe (LKP) Release for MDM: Prof. Gattermann,
Düsseldorf (26.1.2016) Principal Investigator „LenaMain“-
Studie: Prof. Roland Fenk, Düsseldorf Coordinating center
for clinical trial Medical faculty of University Hospital
Heinrich-Heine-University Scientific Director: Herr Dr. J.
Grebe Moorenstrasse 5 40225 Düsseldorf Tel.: +49 (0)
211-81-19701 Fax: +49 (0) 211-81-19702
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3. Weekly control visit (large)
Date of visit
Prior trial substance dosage
mg
25 mg (1)
15 mg (2)
10 mg (3)
5 mg (4)
20 mg (5)
New trial substance dosage
25 mg (1)
15 mg (2)
10 mg (3)
5 mg (4)
20 mg (5)
Please specify reason for dose reduction
Did any Adverse Events occur?
Yes
No
Laboratory:Hematology
Erythrocytes
Mio/μl
Hemoglobin
g/dL
Hematocrit
%
Mean Corpuscular Volume
fl
MCH
pg
1 / 3
Mean corpuscular hemoglobin concentration
g Hb/dL Ery
Leukocytes
1000/μl
Leukocytes (total)
Platelet count
1000/uL
Neutrophils percentage
%
Neutrophils
abs.
Eosinophils percentage
%
Basophils percentage
%
Monocytes percentage
%
Lymphocytes percentage
%
Neutrophils
1000/μl
Laboratory:serum chemistry
Sodium
mmol/L
Potassium
mmol/l
Calcium
mmol/l
Glucose
mg/dl
Alkaline Phosphatase
U/L
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Bilirubin
mg/dL
AST (SGOT)
U/L
ALT
U/L
Gamma GT
U/l
Lactate Dehydrogenase (LDH)
U/L
Urea
mg/dl
CRP
md/dl
Serum creatinine
mg/dL
Creatinine Clearance
mL/min
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Quality assurance Heart Transplant Heart Assist
Devices Artificial Heart - Transplant (AQUA)
Documentation form for quality assurance in German
Health Care by the Institute for Applied Quality
Improvement and Research in Health Care (Aqua),
https://www.aqua-institut.de/en/home. Internal Aqua form
version: HTXM-T Specification 2015 V02
All rights reserved. Please visit https://medical-data-
models.org/forms/13926
Quality assurance Heart Transplant
Heart Assist Devices Artificial Heart -
Transplant (AQUA)
Heart Transplant Heart Assist Devices
Artificial Heart - Transplant
Number of transplantations during this stay?*
Recipient details
PRA (Penal reactive Antibodies in %)*
>= 0
<= 100
%
Risk profile
Urgency*
high urgency (1)
elective (2)
Current mechanically assisted circulation device*
no (0)
LVAD (1)
BVAD (2)
TAH (3)
ECMO (4)
IABP (5)
Beginning of current mechanical cardiac
assistance (TT.MM.JJJJ)
Pulmonary vascular resistance (in dyn*s*cm-5)
>= 0
dyn*s*cm-5
Patient received ventilatory assistance*
Yes
No
Serum Creatinine  (in mg/dl)
>= 0
mg/dl
Serum Creatinine  (in µmol/l)
>= 0
µmol/l
1 / 6
Initiale immunosuppression
First-Line therapy*
no (0)
ATG (1)
OKT3 (2)
IL2-receptor antagonist (3)
other (9)
Cyclosporine*
Yes
No
Tacrolimus*
Yes
No
Azathioprine*
Yes
No
Mycophenolat*
Yes
No
Steroids*
Yes
No
m-ToR-Inhibitor*
Yes
No
other*
Yes
No
Donor's details
Donor ID (ET-Number)*
Donor age (in years)
Gender*
male (1)
female (2)
Body Height (in cm)
>= 0
cm
Body weight (in kg)
>= 0
kg
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Transplant (AQUA)
Donor's findings
Blood group*
A (1)
B (2)
0 (3)
AB (4)
not determined (9)
Date of organ harvesting (TT.MM.JJJJ)
Category of donor organ
a (1)
b (2)
c (3)
not categorized (9)
Use of Organ Care System (OCS)
Yes
No
Quality of transplanted organ at time of
harvesting*
well (1)
medium (2)
bad (3)
Hypotensive periode*
Yes
No
Cardiac arrest*
Yes
No
Creatine kinase MB (in U/l)
>= 0
U/l
Creatine kinase (in U/l)
>= 0
U/l
Catecholamine therapy*
Yes
No
Cause of death - Donor*
T_CAPI: trauma: cranium  (216)
T_OTH: trauma: not classifiable
otherwise (217)
CVA: cerebrovascular accident, not
classifiable otherwise (218)
CIRC: bloodstream, not classifiable
otherwise (219)
RESP: breathing, not classifiable
otherwise (220)
BRAIN: brain neoplasms, not classifiable
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otherwise (221)
ANENC: anencephaly (222)
NAO: nontraumatic cause of death, not
classifiable otherwise (223)
S_HEAD: suicide: craniocerebral injury
(224)
S_DRUG: suicide: medication / drugs
(225)
OTH: suicide: not classifiable otherwise
(226)
MAL: malignant diseases (228)
CBL: intracerebral haemorrhage (229)
CID: ischemic stroke (230)
BRA12: brain neoplasms, astrocytoma
grade 1 or 2 (231)
BRA3: brain neoplasms, astrocytoma
grade 3 (232)
BRAM: brain neoplasms, malignant
(233)
SAB: subarachnoid hemorrhage (234)
SDH: hematoma, subdural (235)
EDH: hematoma, epidural (236)
RSA: breathing: status asthmaticus (237)
REP: breathing: epiglotitis / laryngitis
(238)
CIAM: bloodstream: acute myocardial
infarction (239)
CIRM: bloodstream: acute myocardial
infarction, recurrence (240)
CICA: bloodstream: cardiac arrest (241)
BRBE: brain neoplasms, benign (242)
CSE: status epilepticus (243)
CMB: meningitis: bacterial (244)
CMV: meningitis: viral (245)
CMU: meningitis: not classifiable
otherwise (246)
TLA: trauma: travel accident on land
(247)
TWA: trauma: travel Accident to water
(248)
TFA: trauma: falling (249)
TDR: trauma: drowning (250)
TSU: trauma: suffocate (251)
TGS: trauma: exposition to gases /
fumes / vapor (252)
TME: trauma: mechanically (253)
SRE: suicide : respiratory tract (254)
SJU: suicide : falling (255)
MME: medical complications :
medication (256)
MSU: medical complications : surgical /
medical treatment (257)
MDI: medical complications : diagnostic
intervention (258)
Rhesus phenotype*
positive (1)
negative (2)
not determined (9)
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Transplant (AQUA)
Hematokrit (Hk)(in %)
>= 0
<= 100
%
Operation
OP-Datum*
Operation date (DD.MM.YY)*
Transplantation stopped*
Yes
No
Quality Measure of transplanted organ at time of
transplantation*
well (1)
medium (2)
bad (3)
Cold ischemia time*
>= 30
<= 720
minutes
Postoperative course
Cyclosporin*
Yes
No
Tacrolimus*
Yes
No
Azathioprine*
Yes
No
Mycophenolate*
Yes
No
Steroids*
Yes
No
m-ToR-Inhibitor*
Yes
No
other*
Yes
No
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Transplant (AQUA)
Number of treated rejection episodes (0 = none))
Number of treated rejection episodes unknown
Yes
No
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Third Consolidation Cycle 4.week
LenaMain-Study
A randomised comparison of daily 25 mg versus 5 mg
lenalidomide as maintenance therapy after high-dose
therapy and autologous stem cell transplantation in patients
with multiple myeloma. Protocol-Code: RV-MM-PI-280
EudraCT-Number: 2007-003945-33 Author: Claus
Schreiber Review: Gerd Felder Approval of CRF: Prof. Dr.
med. G. Kobbe (LKP) Release for MDM: Prof. Gattermann,
Düsseldorf (26.1.2016) Principal Investigator „LenaMain“-
Studie: Prof. Roland Fenk, Düsseldorf Coordinating center
for clinical trial Medical faculty of University Hospital
Heinrich-Heine-University Scientific Director: Herr Dr. J.
Grebe Moorenstrasse 5 40225 Düsseldorf Tel.: +49 (0)
211-81-19701 Fax: +49 (0) 211-81-19702
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Third Consolidation Cycle
4. Weekly control visit (large)
Date of visit
Prior trial substance dosage
mg
25 mg (1)
15 mg (2)
10 mg (3)
5 mg (4)
20 mg (5)
New trial substance dosage
25 mg (1)
15 mg (2)
10 mg (3)
5 mg (4)
20 mg (5)
Please specify reason for dose reduction
Did any Adverse Events occur?
Yes
No
Laboratory:Hematology
Erythrocytes
Mio/μl
Hemoglobin
g/dL
Hematocrit
%
Mean Corpuscular Volume
fl
MCH
pg
1 / 3
Mean corpuscular hemoglobin concentration
g Hb/dL Ery
Leukocytes
1000/μl
Leukocytes (total)
Platelet count
1000/uL
Neutrophils percentage
%
Neutrophils
abs.
Eosinophils percentage
%
Basophils percentage
%
Monocytes percentage
%
Lymphocytes percentage
%
Neutrophils
1000/μl
Laboratory:serum chemistry
Sodium
mmol/L
Potassium
mmol/l
Calcium
mmol/l
Glucose
mg/dl
Alkaline Phosphatase
U/L
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Bilirubin
mg/dL
AST (SGOT)
U/L
ALT
U/L
Gamma GT
U/l
Lactate Dehydrogenase (LDH)
U/L
Urea
mg/dl
CRP
md/dl
Serum creatinine
mg/dL
Creatinine Clearance
mL/min
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Fourth Consolidation Cycle LenaMain-
Study
A randomised comparison of daily 25 mg versus 5 mg
lenalidomide as maintenance therapy after high-dose
therapy and autologous stem cell transplantation in patients
with multiple myeloma. Protocol-Code: RV-MM-PI-280
EudraCT-Number: 2007-003945-33 Author: Claus
Schreiber Review: Gerd Felder Approval of CRF: Prof. Dr.
med. G. Kobbe (LKP) Release for MDM: Prof. Gattermann,
Düsseldorf (26.1.2016) Principal Investigator „LenaMain“-
Studie: Prof. Roland Fenk, Düsseldorf Coordinating center
for clinical trial Medical faculty of University Hospital
Heinrich-Heine-University Scientific Director: Herr Dr. J.
Grebe Moorenstrasse 5 40225 Düsseldorf Tel.: +49 (0)
211-81-19701 Fax: +49 (0) 211-81-19702
All rights reserved. Please visit https://medical-data-
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Fourth Consolidation Cycle
Monthly control visit with response
evaluation
Date of visit
Medication dosage of last cycle
mg
Prior trial substance dosage
mg
25 mg (1)
15 mg (2)
10 mg (3)
5 mg (4)
20 mg (5)
New trial substance dosage
25 mg (1)
15 mg (2)
10 mg (3)
5 mg (4)
20 mg (5)
Please specify reason for dose reduction
Response after first consolidation cycle
sCR (0)
CR (1)
vgPR (2)
PR (3)
SD (5)
PD (6)
External assessment of response
Yes
No
Did any Adverse Events occur?
Yes
No
Vital signs
Heart rate
1 / 7
bpm
Blood pressure, systolic
mmHg
Blood pressure, diastolic
mmHg
Body weight
kg
Body Height
cm
Ecog performance status
Score 0 (0)
Score 1 (1)
Score 2 (2)
Score 3 (3)
Score 4 (4)
Score 5 (5)
Laboratory:Protein electrophoresis
Albumin
g/dL
Total Protein in 24h urine
mg/24h
Total Serum Protein
g/dl
Beta-globulin measurement
g/dL
Gamma-Globulin measurement
g/dL
Beta and gamma globulin total
g/dL
Serum immunofixation
positive (1)
negative (2)
Comment on serum immunofixation
Urine immunofixation
positive (1)
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negative (2)
Comment on urine immunofixation
IgA measurement
mg/dl
IgD measurement
mg/dl
IgG measurement
mg/dl
Immunoglobulin M measurement
mg/dl
FLC kappa measurement
mg/l
Kappa
FLC lambda measurement
mg/l
Lambda
Kappa/lambda quotient
Laboratory:Hematology
Erythrocytes
Mio/μl
Hemoglobin
g/dL
Hematocrit
%
Mean Corpuscular Volume
fl
MCH
pg
Mean corpuscular hemoglobin concentration
g Hb/dL Ery
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Leukocytes
1000/μl
Leukocytes (total)
Platelet count
1000/uL
Neutrophils percentage
%
Neutrophils
abs.
Eosinophils percentage
%
Basophils percentage
%
Monocytes percentage
%
Lymphocytes percentage
%
Neutrophils
1000/μl
Laboratory:serum chemistry
Sodium
mmol/L
Potassium
mmol/l
Calcium
mmol/l
Glucose
mg/dl
Alkaline Phosphatase
U/L
Bilirubin
mg/dL
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AST (SGOT)
U/L
ALT
U/L
Gamma GT
U/l
Lactate Dehydrogenase (LDH)
U/L
Urea
mg/dl
CRP
md/dl
Serum creatinine
mg/dL
Creatinine Clearance
mL/min
Laboratory:pregnancy test
Is the subject of childbearing potential?
Yes
No
Pregnancy test result
positive (1)
negative (2)
Has the patient experienced irregularities with her
menstrual period since her last pregnancy test?
No menstruation (0)
Yes (1)
No (2)
Quality of life
Total Score QoL
Hematotoxicity CTC
Hemoglobin CTC
1 (1)
2 (2)
3 (3)
4 (4)
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5 (5)
Date of lowest hemoglobin value
Hemoglobin: actions taken with study medication
No change required (0)
Interruption/ prolongation without dose
reduction (1)
Interruption/ prolongation with dose
reduction (2)
Leukocytes CTC
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
Date of lowest leukocytes value
Actions taken with study medication:leukocytes
No change required (0)
Interruption/ prolongation without dose
reduction (1)
Interruption/ prolongation with dose
reduction (2)
Platelets CTC
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
Date of lowest platelets value
Actions taken with study medication:platelets
No change required (0)
Interruption/ prolongation without dose
reduction (1)
Interruption/ prolongation with dose
reduction (2)
Neutrophils CTC
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
Date of lowest neutrophils value
Actions taken with study medication:neutrophils
No change required (0)
Interruption/ prolongation without dose
reduction (1)
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Interruption/ prolongation with dose
reduction (2)
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Fifth Consolidation Cycle LenaMain-Study
A randomised comparison of daily 25 mg versus 5 mg
lenalidomide as maintenance therapy after high-dose
therapy and autologous stem cell transplantation in patients
with multiple myeloma. Protocol-Code: RV-MM-PI-280
EudraCT-Number: 2007-003945-33 Author: Claus
Schreiber Review: Gerd Felder Approval of CRF: Prof. Dr.
med. G. Kobbe (LKP) Release for MDM: Prof. Gattermann,
Düsseldorf (26.1.2016) Principal Investigator „LenaMain“-
Studie: Prof. Roland Fenk, Düsseldorf Coordinating center
for clinical trial Medical faculty of University Hospital
Heinrich-Heine-University Scientific Director: Herr Dr. J.
Grebe Moorenstrasse 5 40225 Düsseldorf Tel.: +49 (0)
211-81-19701 Fax: +49 (0) 211-81-19702
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Fifth Consolidation Cycle
Monthly control visit with response
evaluation
Date of visit
Medication dosage of last cycle
mg
Prior trial substance dosage
mg
25 mg (1)
15 mg (2)
10 mg (3)
5 mg (4)
20 mg (5)
New trial substance dosage
25 mg (1)
15 mg (2)
10 mg (3)
5 mg (4)
20 mg (5)
Please specify reason for dose reduction
Response after first consolidation cycle
sCR (0)
CR (1)
vgPR (2)
PR (3)
SD (5)
PD (6)
External assessment of response
Yes
No
Did any Adverse Events occur?
Yes
No
Vital signs
Heart rate
1 / 7
bpm
Blood pressure, systolic
mmHg
Blood pressure, diastolic
mmHg
Body weight
kg
Body Height
cm
Ecog performance status
Score 0 (0)
Score 1 (1)
Score 2 (2)
Score 3 (3)
Score 4 (4)
Score 5 (5)
Laboratory:Protein electrophoresis
Albumin
g/dL
Total Protein in 24h urine
mg/24h
Total Serum Protein
g/dl
Beta-globulin measurement
g/dL
Gamma-Globulin measurement
g/dL
Beta and gamma globulin total
g/dL
Serum immunofixation
positive (1)
negative (2)
Comment on serum immunofixation
Urine immunofixation
positive (1)
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negative (2)
Comment on urine immunofixation
IgA measurement
mg/dl
IgD measurement
mg/dl
IgG measurement
mg/dl
Immunoglobulin M measurement
mg/dl
FLC kappa measurement
mg/l
Kappa
FLC lambda measurement
mg/l
Lambda
Kappa/lambda quotient
Laboratory:Hematology
Erythrocytes
Mio/μl
Hemoglobin
g/dL
Hematocrit
%
Mean Corpuscular Volume
fl
MCH
pg
Mean corpuscular hemoglobin concentration
g Hb/dL Ery
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Leukocytes
1000/μl
Leukocytes (total)
Platelet count
1000/uL
Neutrophils percentage
%
Neutrophils
abs.
Eosinophils percentage
%
Basophils percentage
%
Monocytes percentage
%
Lymphocytes percentage
%
Neutrophils
1000/μl
Laboratory:serum chemistry
Sodium
mmol/L
Potassium
mmol/l
Calcium
mmol/l
Glucose
mg/dl
Alkaline Phosphatase
U/L
Bilirubin
mg/dL
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AST (SGOT)
U/L
ALT
U/L
Gamma GT
U/l
Lactate Dehydrogenase (LDH)
U/L
Urea
mg/dl
CRP
md/dl
Serum creatinine
mg/dL
Creatinine Clearance
mL/min
Laboratory:pregnancy test
Is the subject of childbearing potential?
Yes
No
Pregnancy test result
positive (1)
negative (2)
Has the patient experienced irregularities with her
menstrual period since her last pregnancy test?
No menstruation (0)
Yes (1)
No (2)
Quality of life
Total Score QoL
Hematotoxicity CTC
Hemoglobin CTC
1 (1)
2 (2)
3 (3)
4 (4)
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5 (5)
Date of lowest hemoglobin value
Hemoglobin: actions taken with study medication
No change required (0)
Interruption/ prolongation without dose
reduction (1)
Interruption/ prolongation with dose
reduction (2)
Leukocytes CTC
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
Date of lowest leukocytes value
Actions taken with study medication:leukocytes
No change required (0)
Interruption/ prolongation without dose
reduction (1)
Interruption/ prolongation with dose
reduction (2)
Platelets CTC
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
Date of lowest platelets value
Actions taken with study medication:platelets
No change required (0)
Interruption/ prolongation without dose
reduction (1)
Interruption/ prolongation with dose
reduction (2)
Neutrophils CTC
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
Date of lowest neutrophils value
Actions taken with study medication:neutrophils
No change required (0)
Interruption/ prolongation without dose
reduction (1)
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Interruption/ prolongation with dose
reduction (2)
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Sixth Consolidation Cycle
Monthly control visit with response
evaluation
Date of visit
Medication dosage of last cycle
mg
Prior trial substance dosage
mg
25 mg (1)
15 mg (2)
10 mg (3)
5 mg (4)
20 mg (5)
New trial substance dosage
25 mg (1)
15 mg (2)
10 mg (3)
5 mg (4)
20 mg (5)
Please specify reason for dose reduction
Response after first consolidation cycle
sCR (0)
CR (1)
vgPR (2)
PR (3)
SD (5)
PD (6)
External assessment of response
Yes
No
Did any Adverse Events occur?
Yes
No
Vital signs
Heart rate
1 / 7
bpm
Blood pressure, systolic
mmHg
Blood pressure, diastolic
mmHg
Body weight
kg
Body Height
cm
Ecog performance status
Score 0 (0)
Score 1 (1)
Score 2 (2)
Score 3 (3)
Score 4 (4)
Score 5 (5)
Laboratory:Protein electrophoresis
Albumin
g/dL
Total Protein in 24h urine
mg/24h
Total Serum Protein
g/dl
Beta-globulin measurement
g/dL
Gamma-Globulin measurement
g/dL
Beta and gamma globulin total
g/dL
Serum immunofixation
positive (1)
negative (2)
Comment on serum immunofixation
Urine immunofixation
positive (1)
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negative (2)
Comment on urine immunofixation
IgA measurement
mg/dl
IgD measurement
mg/dl
IgG measurement
mg/dl
Immunoglobulin M measurement
mg/dl
FLC kappa measurement
mg/l
Kappa
FLC lambda measurement
mg/l
Lambda
Kappa/lambda quotient
Laboratory:Hematology
Erythrocytes
Mio/μl
Hemoglobin
g/dL
Hematocrit
%
Mean Corpuscular Volume
fl
MCH
pg
Mean corpuscular hemoglobin concentration
g Hb/dL Ery
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Leukocytes
1000/μl
Leukocytes (total)
Platelet count
1000/uL
Neutrophils percentage
%
Neutrophils
abs.
Eosinophils percentage
%
Basophils percentage
%
Monocytes percentage
%
Lymphocytes percentage
%
Neutrophils
1000/μl
Laboratory:serum chemistry
Sodium
mmol/L
Potassium
mmol/l
Calcium
mmol/l
Glucose
mg/dl
Alkaline Phosphatase
U/L
Bilirubin
mg/dL
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AST (SGOT)
U/L
ALT
U/L
Gamma GT
U/l
Lactate Dehydrogenase (LDH)
U/L
Urea
mg/dl
CRP
md/dl
Serum creatinine
mg/dL
Creatinine Clearance
mL/min
Laboratory:pregnancy test
Is the subject of childbearing potential?
Yes
No
Pregnancy test result
positive (1)
negative (2)
Has the patient experienced irregularities with her
menstrual period since her last pregnancy test?
No menstruation (0)
Yes (1)
No (2)
Quality of life
Total Score QoL
Hematotoxicity CTC
Hemoglobin CTC
1 (1)
2 (2)
3 (3)
4 (4)
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5 (5)
Date of lowest hemoglobin value
Hemoglobin: actions taken with study medication
No change required (0)
Interruption/ prolongation without dose
reduction (1)
Interruption/ prolongation with dose
reduction (2)
Leukocytes CTC
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
Date of lowest leukocytes value
Actions taken with study medication:leukocytes
No change required (0)
Interruption/ prolongation without dose
reduction (1)
Interruption/ prolongation with dose
reduction (2)
Platelets CTC
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
Date of lowest platelets value
Actions taken with study medication:platelets
No change required (0)
Interruption/ prolongation without dose
reduction (1)
Interruption/ prolongation with dose
reduction (2)
Neutrophils CTC
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
Date of lowest neutrophils value
Actions taken with study medication:neutrophils
No change required (0)
Interruption/ prolongation without dose
reduction (1)
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Interruption/ prolongation with dose
reduction (2)
7 / 7
Sixth Consolidation Cycle LenaMain-Study
Staging after Consolidation LenaMain-
Study
A randomised comparison of daily 25 mg versus 5 mg
lenalidomide as maintenance therapy after high-dose
therapy and autologous stem cell transplantation in patients
with multiple myeloma. Protocol-Code: RV-MM-PI-280
EudraCT-Number: 2007-003945-33 Author: Claus
Schreiber Review: Gerd Felder Approval of CRF: Prof. Dr.
med. G. Kobbe (LKP) Release for MDM: Prof. Gattermann,
Düsseldorf (26.1.2016) Principal Investigator „LenaMain“-
Studie: Prof. Roland Fenk, Düsseldorf Coordinating center
for clinical trial Medical faculty of University Hospital
Heinrich-Heine-University Scientific Director: Herr Dr. J.
Grebe Moorenstrasse 5 40225 Düsseldorf Tel.: +49 (0)
211-81-19701 Fax: +49 (0) 211-81-19702
All rights reserved. Please visit https://medical-data-
models.org/forms/13931
Staging after Consolidation
Monthly control visit with response
evaluation
Date of visit
Medication dosage of last cycle
mg
Prior trial substance dosage
mg
25 mg (1)
15 mg (2)
10 mg (3)
5 mg (4)
20 mg (5)
New trial substance dosage
25 mg (1)
15 mg (2)
10 mg (3)
5 mg (4)
20 mg (5)
Please specify reason for dose reduction
Response after first consolidation cycle
sCR (0)
CR (1)
vgPR (2)
PR (3)
SD (5)
PD (6)
External assessment of response
Yes
No
Did any Adverse Events occur?
Yes
No
Parameter of multiple myeloma
Cytogenetic examination done?
1 / 6
Yes
No
Cytogenetics:please specify
Cytogenetics date
Contrast infiltration
%
Contrast examination date
Extramedullary lesion
Yes
No
Lytic lesion of bones
None (1)
Osteopenia (2)
1-5 lytic lesions of bone (3)
>6 lytic lesions of bone (4)
Progressive disease reason
Vital signs
Heart rate
bpm
Blood pressure, systolic
mmHg
Blood pressure, diastolic
mmHg
Body weight
kg
Body Height
cm
Ecog performance status
Score 0 (0)
Score 1 (1)
Score 2 (2)
Score 3 (3)
Score 4 (4)
Score 5 (5)
Laboratory:Protein electrophoresis
2 / 6
Staging after Consolidation LenaMain-Study
Albumin
g/dL
Total Protein in 24h urine
mg/24h
Total Serum Protein
g/dl
Beta-globulin measurement
g/dL
Gamma-Globulin measurement
g/dL
Beta and gamma globulin total
g/dL
Serum immunofixation
positive (1)
negative (2)
Comment on serum immunofixation
Urine immunofixation
positive (1)
negative (2)
Comment on urine immunofixation
IgA measurement
mg/dl
IgD measurement
mg/dl
IgG measurement
mg/dl
Immunoglobulin M measurement
mg/dl
FLC kappa measurement
mg/l
Kappa
FLC lambda measurement
mg/l
3 / 6
Staging after Consolidation LenaMain-Study
Lambda
Kappa/lambda quotient
Laboratory:Hematology
Erythrocytes
Mio/μl
Hemoglobin
g/dL
Hematocrit
%
Mean Corpuscular Volume
fl
MCH
pg
Mean corpuscular hemoglobin concentration
g Hb/dL Ery
Leukocytes
1000/μl
Leukocytes (total)
Platelet count
1000/uL
Neutrophils percentage
%
Neutrophils
abs.
Eosinophils percentage
%
Basophils percentage
%
Monocytes percentage
%
Lymphocytes percentage
4 / 6
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%Neutrophils
1000/μl
Laboratory:serum chemistry
Sodium
mmol/L
Potassium
mmol/l
Calcium
mmol/l
Glucose
mg/dl
Alkaline Phosphatase
U/L
Bilirubin
mg/dL
AST (SGOT)
U/L
ALT
U/L
Gamma GT
U/l
Lactate Dehydrogenase (LDH)
U/L
Urea
mg/dl
CRP
md/dl
Serum creatinine
mg/dL
Creatinine Clearance
mL/min
5 / 6
Staging after Consolidation LenaMain-Study
Laboratory:pregnancy test
Is the subject of childbearing potential?
Yes
No
Pregnancy test result
positive (1)
negative (2)
Has the patient experienced irregularities with her
menstrual period since her last pregnancy test?
No menstruation (0)
Yes (1)
No (2)
Quality of life
Total Score QoL
6 / 6
Staging after Consolidation LenaMain-Study
First Maintenance Cycle LenaMain-Study
A randomised comparison of daily 25 mg versus 5 mg
lenalidomide as maintenance therapy after high-dose
therapy and autologous stem cell transplantation in patients
with multiple myeloma. Protocol-Code: RV-MM-PI-280
EudraCT-Number: 2007-003945-33 Author: Claus
Schreiber Review: Gerd Felder Approval of CRF: Prof. Dr.
med. G. Kobbe (LKP) Release for MDM: Prof. Gattermann,
Düsseldorf (26.1.2016) Principal Investigator „LenaMain“-
Studie: Prof. Roland Fenk, Düsseldorf Coordinating center
for clinical trial Medical faculty of University Hospital
Heinrich-Heine-University Scientific Director: Herr Dr. J.
Grebe Moorenstrasse 5 40225 Düsseldorf Tel.: +49 (0)
211-81-19701 Fax: +49 (0) 211-81-19702
All rights reserved. Please visit https://medical-data-
models.org/forms/13932
First Maintenance Cycle
Monthly control visit with response
evaluation
Date of visit
Medication dosage of last cycle
mg
Prior trial substance dosage
mg
25 mg (1)
15 mg (2)
10 mg (3)
5 mg (4)
20 mg (5)
New trial substance dosage
25 mg (1)
15 mg (2)
10 mg (3)
5 mg (4)
20 mg (5)
Please specify reason for dose reduction
Response after first consolidation cycle
sCR (0)
CR (1)
vgPR (2)
PR (3)
SD (5)
PD (6)
External assessment of response
Yes
No
Did any Adverse Events occur?
Yes
No
Vital signs
Heart rate
1 / 7
bpm
Blood pressure, systolic
mmHg
Blood pressure, diastolic
mmHg
Body weight
kg
Body Height
cm
Ecog performance status
Score 0 (0)
Score 1 (1)
Score 2 (2)
Score 3 (3)
Score 4 (4)
Score 5 (5)
Laboratory:Protein electrophoresis
Albumin
g/dL
Total Protein in 24h urine
mg/24h
Total Serum Protein
g/dl
Beta-globulin measurement
g/dL
Gamma-Globulin measurement
g/dL
Beta and gamma globulin total
g/dL
Serum immunofixation
positive (1)
negative (2)
Comment on serum immunofixation
Urine immunofixation
positive (1)
2 / 7
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negative (2)
Comment on urine immunofixation
IgA measurement
mg/dl
IgD measurement
mg/dl
IgG measurement
mg/dl
Immunoglobulin M measurement
mg/dl
FLC kappa measurement
mg/l
Kappa
FLC lambda measurement
mg/l
Lambda
Kappa/lambda quotient
Laboratory:Hematology
Erythrocytes
Mio/μl
Hemoglobin
g/dL
Hematocrit
%
Mean Corpuscular Volume
fl
MCH
pg
Mean corpuscular hemoglobin concentration
g Hb/dL Ery
3 / 7
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Leukocytes
1000/μl
Leukocytes (total)
Platelet count
1000/uL
Neutrophils percentage
%
Neutrophils
abs.
Eosinophils percentage
%
Basophils percentage
%
Monocytes percentage
%
Lymphocytes percentage
%
Neutrophils
1000/μl
Laboratory:serum chemistry
Sodium
mmol/L
Potassium
mmol/l
Calcium
mmol/l
Glucose
mg/dl
Alkaline Phosphatase
U/L
Bilirubin
mg/dL
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AST (SGOT)
U/L
ALT
U/L
Gamma GT
U/l
Lactate Dehydrogenase (LDH)
U/L
Urea
mg/dl
CRP
md/dl
Serum creatinine
mg/dL
Creatinine Clearance
mL/min
Laboratory:pregnancy test
Is the subject of childbearing potential?
Yes
No
Pregnancy test result
positive (1)
negative (2)
Has the patient experienced irregularities with her
menstrual period since her last pregnancy test?
No menstruation (0)
Yes (1)
No (2)
Quality of life
Total Score QoL
Hematotoxicity CTC
Hemoglobin CTC
1 (1)
2 (2)
3 (3)
4 (4)
5 / 7
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5 (5)
Date of lowest hemoglobin value
Hemoglobin: actions taken with study medication
No change required (0)
Interruption/ prolongation without dose
reduction (1)
Interruption/ prolongation with dose
reduction (2)
Leukocytes CTC
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
Date of lowest leukocytes value
Actions taken with study medication:leukocytes
No change required (0)
Interruption/ prolongation without dose
reduction (1)
Interruption/ prolongation with dose
reduction (2)
Platelets CTC
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
Date of lowest platelets value
Actions taken with study medication:platelets
No change required (0)
Interruption/ prolongation without dose
reduction (1)
Interruption/ prolongation with dose
reduction (2)
Neutrophils CTC
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
Date of lowest neutrophils value
Actions taken with study medication:neutrophils
No change required (0)
Interruption/ prolongation without dose
reduction (1)
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First Maintenance Cycle LenaMain-Study
Interruption/ prolongation with dose
reduction (2)
7 / 7
First Maintenance Cycle LenaMain-Study
Second Maintenance Cycle LenaMain-
Study
A randomised comparison of daily 25 mg versus 5 mg
lenalidomide as maintenance therapy after high-dose
therapy and autologous stem cell transplantation in patients
with multiple myeloma. Protocol-Code: RV-MM-PI-280
EudraCT-Number: 2007-003945-33 Author: Claus
Schreiber Review: Gerd Felder Approval of CRF: Prof. Dr.
med. G. Kobbe (LKP) Release for MDM: Prof. Gattermann,
Düsseldorf (26.1.2016) Principal Investigator „LenaMain“-
Studie: Prof. Roland Fenk, Düsseldorf Coordinating center
for clinical trial Medical faculty of University Hospital
Heinrich-Heine-University Scientific Director: Herr Dr. J.
Grebe Moorenstrasse 5 40225 Düsseldorf Tel.: +49 (0)
211-81-19701 Fax: +49 (0) 211-81-19702
All rights reserved. Please visit https://medical-data-
models.org/forms/13933
Second Maintenance Cycle
Monthly control visit with response
evaluation
Date of visit
Medication dosage of last cycle
mg
Prior trial substance dosage
mg
25 mg (1)
15 mg (2)
10 mg (3)
5 mg (4)
20 mg (5)
New trial substance dosage
25 mg (1)
15 mg (2)
10 mg (3)
5 mg (4)
20 mg (5)
Please specify reason for dose reduction
Response after first consolidation cycle
sCR (0)
CR (1)
vgPR (2)
PR (3)
SD (5)
PD (6)
External assessment of response
Yes
No
Did any Adverse Events occur?
Yes
No
Vital signs
Heart rate
1 / 7
bpm
Blood pressure, systolic
mmHg
Blood pressure, diastolic
mmHg
Body weight
kg
Body Height
cm
Ecog performance status
Score 0 (0)
Score 1 (1)
Score 2 (2)
Score 3 (3)
Score 4 (4)
Score 5 (5)
Laboratory:Protein electrophoresis
Albumin
g/dL
Total Protein in 24h urine
mg/24h
Total Serum Protein
g/dl
Beta-globulin measurement
g/dL
Gamma-Globulin measurement
g/dL
Beta and gamma globulin total
g/dL
Serum immunofixation
positive (1)
negative (2)
Comment on serum immunofixation
Urine immunofixation
positive (1)
2 / 7
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negative (2)
Comment on urine immunofixation
IgA measurement
mg/dl
IgD measurement
mg/dl
IgG measurement
mg/dl
Immunoglobulin M measurement
mg/dl
FLC kappa measurement
mg/l
Kappa
FLC lambda measurement
mg/l
Lambda
Kappa/lambda quotient
Laboratory:Hematology
Erythrocytes
Mio/μl
Hemoglobin
g/dL
Hematocrit
%
Mean Corpuscular Volume
fl
MCH
pg
Mean corpuscular hemoglobin concentration
g Hb/dL Ery
3 / 7
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Leukocytes
1000/μl
Leukocytes (total)
Platelet count
1000/uL
Neutrophils percentage
%
Neutrophils
abs.
Eosinophils percentage
%
Basophils percentage
%
Monocytes percentage
%
Lymphocytes percentage
%
Neutrophils
1000/μl
Laboratory:serum chemistry
Sodium
mmol/L
Potassium
mmol/l
Calcium
mmol/l
Glucose
mg/dl
Alkaline Phosphatase
U/L
Bilirubin
mg/dL
4 / 7
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AST (SGOT)
U/L
ALT
U/L
Gamma GT
U/l
Lactate Dehydrogenase (LDH)
U/L
Urea
mg/dl
CRP
md/dl
Serum creatinine
mg/dL
Creatinine Clearance
mL/min
Laboratory:pregnancy test
Is the subject of childbearing potential?
Yes
No
Pregnancy test result
positive (1)
negative (2)
Has the patient experienced irregularities with her
menstrual period since her last pregnancy test?
No menstruation (0)
Yes (1)
No (2)
Quality of life
Total Score QoL
Hematotoxicity CTC
Hemoglobin CTC
1 (1)
2 (2)
3 (3)
4 (4)
5 / 7
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5 (5)
Date of lowest hemoglobin value
Hemoglobin: actions taken with study medication
No change required (0)
Interruption/ prolongation without dose
reduction (1)
Interruption/ prolongation with dose
reduction (2)
Leukocytes CTC
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
Date of lowest leukocytes value
Actions taken with study medication:leukocytes
No change required (0)
Interruption/ prolongation without dose
reduction (1)
Interruption/ prolongation with dose
reduction (2)
Platelets CTC
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
Date of lowest platelets value
Actions taken with study medication:platelets
No change required (0)
Interruption/ prolongation without dose
reduction (1)
Interruption/ prolongation with dose
reduction (2)
Neutrophils CTC
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
Date of lowest neutrophils value
Actions taken with study medication:neutrophils
No change required (0)
Interruption/ prolongation without dose
reduction (1)
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Interruption/ prolongation with dose
reduction (2)
7 / 7
Second Maintenance Cycle LenaMain-Study
Third Maintenance Cycle LenaMain-Study
A randomised comparison of daily 25 mg versus 5 mg
lenalidomide as maintenance therapy after high-dose
therapy and autologous stem cell transplantation in patients
with multiple myeloma. Protocol-Code: RV-MM-PI-280
EudraCT-Number: 2007-003945-33 Author: Claus
Schreiber Review: Gerd Felder Approval of CRF: Prof. Dr.
med. G. Kobbe (LKP) Release for MDM: Prof. Gattermann,
Düsseldorf (26.1.2016) Principal Investigator „LenaMain“-
Studie: Prof. Roland Fenk, Düsseldorf Coordinating center
for clinical trial Medical faculty of University Hospital
Heinrich-Heine-University Scientific Director: Herr Dr. J.
Grebe Moorenstrasse 5 40225 Düsseldorf Tel.: +49 (0)
211-81-19701 Fax: +49 (0) 211-81-19702
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Third Maintenance Cycle
Monthly control visit with response
evaluation
Date of visit
Medication dosage of last cycle
mg
Prior trial substance dosage
mg
25 mg (1)
15 mg (2)
10 mg (3)
5 mg (4)
20 mg (5)
New trial substance dosage
25 mg (1)
15 mg (2)
10 mg (3)
5 mg (4)
20 mg (5)
Please specify reason for dose reduction
Response after first consolidation cycle
sCR (0)
CR (1)
vgPR (2)
PR (3)
SD (5)
PD (6)
External assessment of response
Yes
No
Did any Adverse Events occur?
Yes
No
Vital signs
Heart rate
1 / 7
bpm
Blood pressure, systolic
mmHg
Blood pressure, diastolic
mmHg
Body weight
kg
Body Height
cm
Ecog performance status
Score 0 (0)
Score 1 (1)
Score 2 (2)
Score 3 (3)
Score 4 (4)
Score 5 (5)
Laboratory:Protein electrophoresis
Albumin
g/dL
Total Protein in 24h urine
mg/24h
Total Serum Protein
g/dl
Beta-globulin measurement
g/dL
Gamma-Globulin measurement
g/dL
Beta and gamma globulin total
g/dL
Serum immunofixation
positive (1)
negative (2)
Comment on serum immunofixation
Urine immunofixation
positive (1)
2 / 7
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negative (2)
Comment on urine immunofixation
IgA measurement
mg/dl
IgD measurement
mg/dl
IgG measurement
mg/dl
Immunoglobulin M measurement
mg/dl
FLC kappa measurement
mg/l
Kappa
FLC lambda measurement
mg/l
Lambda
Kappa/lambda quotient
Laboratory:Hematology
Erythrocytes
Mio/μl
Hemoglobin
g/dL
Hematocrit
%
Mean Corpuscular Volume
fl
MCH
pg
Mean corpuscular hemoglobin concentration
g Hb/dL Ery
3 / 7
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Leukocytes
1000/μl
Leukocytes (total)
Platelet count
1000/uL
Neutrophils percentage
%
Neutrophils
abs.
Eosinophils percentage
%
Basophils percentage
%
Monocytes percentage
%
Lymphocytes percentage
%
Neutrophils
1000/μl
Laboratory:serum chemistry
Sodium
mmol/L
Potassium
mmol/l
Calcium
mmol/l
Glucose
mg/dl
Alkaline Phosphatase
U/L
Bilirubin
mg/dL
4 / 7
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AST (SGOT)
U/L
ALT
U/L
Gamma GT
U/l
Lactate Dehydrogenase (LDH)
U/L
Urea
mg/dl
CRP
md/dl
Serum creatinine
mg/dL
Creatinine Clearance
mL/min
Laboratory:pregnancy test
Is the subject of childbearing potential?
Yes
No
Pregnancy test result
positive (1)
negative (2)
Has the patient experienced irregularities with her
menstrual period since her last pregnancy test?
No menstruation (0)
Yes (1)
No (2)
Quality of life
Total Score QoL
Hematotoxicity CTC
Hemoglobin CTC
1 (1)
2 (2)
3 (3)
4 (4)
5 / 7
Third Maintenance Cycle LenaMain-Study
5 (5)
Date of lowest hemoglobin value
Hemoglobin: actions taken with study medication
No change required (0)
Interruption/ prolongation without dose
reduction (1)
Interruption/ prolongation with dose
reduction (2)
Leukocytes CTC
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
Date of lowest leukocytes value
Actions taken with study medication:leukocytes
No change required (0)
Interruption/ prolongation without dose
reduction (1)
Interruption/ prolongation with dose
reduction (2)
Platelets CTC
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
Date of lowest platelets value
Actions taken with study medication:platelets
No change required (0)
Interruption/ prolongation without dose
reduction (1)
Interruption/ prolongation with dose
reduction (2)
Neutrophils CTC
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
Date of lowest neutrophils value
Actions taken with study medication:neutrophils
No change required (0)
Interruption/ prolongation without dose
reduction (1)
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Interruption/ prolongation with dose
reduction (2)
7 / 7
Third Maintenance Cycle LenaMain-Study
Fourth Maintenance Cycle LenaMain-Study
A randomised comparison of daily 25 mg versus 5 mg
lenalidomide as maintenance therapy after high-dose
therapy and autologous stem cell transplantation in patients
with multiple myeloma. Protocol-Code: RV-MM-PI-280
EudraCT-Number: 2007-003945-33 Author: Claus
Schreiber Review: Gerd Felder Approval of CRF: Prof. Dr.
med. G. Kobbe (LKP) Release for MDM: Prof. Gattermann,
Düsseldorf (26.1.2016) Principal Investigator „LenaMain“-
Studie: Prof. Roland Fenk, Düsseldorf Coordinating center
for clinical trial Medical faculty of University Hospital
Heinrich-Heine-University Scientific Director: Herr Dr. J.
Grebe Moorenstrasse 5 40225 Düsseldorf Tel.: +49 (0)
211-81-19701 Fax: +49 (0) 211-81-19702
All rights reserved. Please visit https://medical-data-
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Fourth Maintenance Cycle
Monthly control visit with response
evaluation
Date of visit
Medication dosage of last cycle
mg
Prior trial substance dosage
mg
25 mg (1)
15 mg (2)
10 mg (3)
5 mg (4)
20 mg (5)
New trial substance dosage
25 mg (1)
15 mg (2)
10 mg (3)
5 mg (4)
20 mg (5)
Please specify reason for dose reduction
Response after first consolidation cycle
sCR (0)
CR (1)
vgPR (2)
PR (3)
SD (5)
PD (6)
External assessment of response
Yes
No
Did any Adverse Events occur?
Yes
No
Vital signs
Heart rate
1 / 7
bpm
Blood pressure, systolic
mmHg
Blood pressure, diastolic
mmHg
Body weight
kg
Body Height
cm
Ecog performance status
Score 0 (0)
Score 1 (1)
Score 2 (2)
Score 3 (3)
Score 4 (4)
Score 5 (5)
Laboratory:Protein electrophoresis
Albumin
g/dL
Total Protein in 24h urine
mg/24h
Total Serum Protein
g/dl
Beta-globulin measurement
g/dL
Gamma-Globulin measurement
g/dL
Beta and gamma globulin total
g/dL
Serum immunofixation
positive (1)
negative (2)
Comment on serum immunofixation
Urine immunofixation
positive (1)
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negative (2)
Comment on urine immunofixation
IgA measurement
mg/dl
IgD measurement
mg/dl
IgG measurement
mg/dl
Immunoglobulin M measurement
mg/dl
FLC kappa measurement
mg/l
Kappa
FLC lambda measurement
mg/l
Lambda
Kappa/lambda quotient
Laboratory:Hematology
Erythrocytes
Mio/μl
Hemoglobin
g/dL
Hematocrit
%
Mean Corpuscular Volume
fl
MCH
pg
Mean corpuscular hemoglobin concentration
g Hb/dL Ery
3 / 7
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Leukocytes
1000/μl
Leukocytes (total)
Platelet count
1000/uL
Neutrophils percentage
%
Neutrophils
abs.
Eosinophils percentage
%
Basophils percentage
%
Monocytes percentage
%
Lymphocytes percentage
%
Neutrophils
1000/μl
Laboratory:serum chemistry
Sodium
mmol/L
Potassium
mmol/l
Calcium
mmol/l
Glucose
mg/dl
Alkaline Phosphatase
U/L
Bilirubin
mg/dL
4 / 7
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AST (SGOT)
U/L
ALT
U/L
Gamma GT
U/l
Lactate Dehydrogenase (LDH)
U/L
Urea
mg/dl
CRP
md/dl
Serum creatinine
mg/dL
Creatinine Clearance
mL/min
Laboratory:pregnancy test
Is the subject of childbearing potential?
Yes
No
Pregnancy test result
positive (1)
negative (2)
Has the patient experienced irregularities with her
menstrual period since her last pregnancy test?
No menstruation (0)
Yes (1)
No (2)
Quality of life
Total Score QoL
Hematotoxicity CTC
Hemoglobin CTC
1 (1)
2 (2)
3 (3)
4 (4)
5 / 7
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5 (5)
Date of lowest hemoglobin value
Hemoglobin: actions taken with study medication
No change required (0)
Interruption/ prolongation without dose
reduction (1)
Interruption/ prolongation with dose
reduction (2)
Leukocytes CTC
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
Date of lowest leukocytes value
Actions taken with study medication:leukocytes
No change required (0)
Interruption/ prolongation without dose
reduction (1)
Interruption/ prolongation with dose
reduction (2)
Platelets CTC
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
Date of lowest platelets value
Actions taken with study medication:platelets
No change required (0)
Interruption/ prolongation without dose
reduction (1)
Interruption/ prolongation with dose
reduction (2)
Neutrophils CTC
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
Date of lowest neutrophils value
Actions taken with study medication:neutrophils
No change required (0)
Interruption/ prolongation without dose
reduction (1)
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Interruption/ prolongation with dose
reduction (2)
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Fourth Maintenance Cycle LenaMain-Study
Fifth Maintenance Cycle LenaMain-Study
A randomised comparison of daily 25 mg versus 5 mg
lenalidomide as maintenance therapy after high-dose
therapy and autologous stem cell transplantation in patients
with multiple myeloma. Protocol-Code: RV-MM-PI-280
EudraCT-Number: 2007-003945-33 Author: Claus
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Heinrich-Heine-University Scientific Director: Herr Dr. J.
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Fifth Maintenance Cycle
Monthly control visit with response
evaluation
Date of visit
Medication dosage of last cycle
mg
Prior trial substance dosage
mg
25 mg (1)
15 mg (2)
10 mg (3)
5 mg (4)
20 mg (5)
New trial substance dosage
25 mg (1)
15 mg (2)
10 mg (3)
5 mg (4)
20 mg (5)
Please specify reason for dose reduction
Response after first consolidation cycle
sCR (0)
CR (1)
vgPR (2)
PR (3)
SD (5)
PD (6)
External assessment of response
Yes
No
Did any Adverse Events occur?
Yes
No
Vital signs
Heart rate
1 / 7
bpm
Blood pressure, systolic
mmHg
Blood pressure, diastolic
mmHg
Body weight
kg
Body Height
cm
Ecog performance status
Score 0 (0)
Score 1 (1)
Score 2 (2)
Score 3 (3)
Score 4 (4)
Score 5 (5)
Laboratory:Protein electrophoresis
Albumin
g/dL
Total Protein in 24h urine
mg/24h
Total Serum Protein
g/dl
Beta-globulin measurement
g/dL
Gamma-Globulin measurement
g/dL
Beta and gamma globulin total
g/dL
Serum immunofixation
positive (1)
negative (2)
Comment on serum immunofixation
Urine immunofixation
positive (1)
2 / 7
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negative (2)
Comment on urine immunofixation
IgA measurement
mg/dl
IgD measurement
mg/dl
IgG measurement
mg/dl
Immunoglobulin M measurement
mg/dl
FLC kappa measurement
mg/l
Kappa
FLC lambda measurement
mg/l
Lambda
Kappa/lambda quotient
Laboratory:Hematology
Erythrocytes
Mio/μl
Hemoglobin
g/dL
Hematocrit
%
Mean Corpuscular Volume
fl
MCH
pg
Mean corpuscular hemoglobin concentration
g Hb/dL Ery
3 / 7
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Leukocytes
1000/μl
Leukocytes (total)
Platelet count
1000/uL
Neutrophils percentage
%
Neutrophils
abs.
Eosinophils percentage
%
Basophils percentage
%
Monocytes percentage
%
Lymphocytes percentage
%
Neutrophils
1000/μl
Laboratory:serum chemistry
Sodium
mmol/L
Potassium
mmol/l
Calcium
mmol/l
Glucose
mg/dl
Alkaline Phosphatase
U/L
Bilirubin
mg/dL
4 / 7
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AST (SGOT)
U/L
ALT
U/L
Gamma GT
U/l
Lactate Dehydrogenase (LDH)
U/L
Urea
mg/dl
CRP
md/dl
Serum creatinine
mg/dL
Creatinine Clearance
mL/min
Laboratory:pregnancy test
Is the subject of childbearing potential?
Yes
No
Pregnancy test result
positive (1)
negative (2)
Has the patient experienced irregularities with her
menstrual period since her last pregnancy test?
No menstruation (0)
Yes (1)
No (2)
Quality of life
Total Score QoL
Hematotoxicity CTC
Hemoglobin CTC
1 (1)
2 (2)
3 (3)
4 (4)
5 / 7
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5 (5)
Date of lowest hemoglobin value
Hemoglobin: actions taken with study medication
No change required (0)
Interruption/ prolongation without dose
reduction (1)
Interruption/ prolongation with dose
reduction (2)
Leukocytes CTC
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
Date of lowest leukocytes value
Actions taken with study medication:leukocytes
No change required (0)
Interruption/ prolongation without dose
reduction (1)
Interruption/ prolongation with dose
reduction (2)
Platelets CTC
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
Date of lowest platelets value
Actions taken with study medication:platelets
No change required (0)
Interruption/ prolongation without dose
reduction (1)
Interruption/ prolongation with dose
reduction (2)
Neutrophils CTC
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
Date of lowest neutrophils value
Actions taken with study medication:neutrophils
No change required (0)
Interruption/ prolongation without dose
reduction (1)
6 / 7
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Interruption/ prolongation with dose
reduction (2)
7 / 7
Fifth Maintenance Cycle LenaMain-Study
Sixth Maintenance Cycle LenaMain-Study
A randomised comparison of daily 25 mg versus 5 mg
lenalidomide as maintenance therapy after high-dose
therapy and autologous stem cell transplantation in patients
with multiple myeloma. Protocol-Code: RV-MM-PI-280
EudraCT-Number: 2007-003945-33 Author: Claus
Schreiber Review: Gerd Felder Approval of CRF: Prof. Dr.
med. G. Kobbe (LKP) Release for MDM: Prof. Gattermann,
Düsseldorf (26.1.2016) Principal Investigator „LenaMain“-
Studie: Prof. Roland Fenk, Düsseldorf Coordinating center
for clinical trial Medical faculty of University Hospital
Heinrich-Heine-University Scientific Director: Herr Dr. J.
Grebe Moorenstrasse 5 40225 Düsseldorf Tel.: +49 (0)
211-81-19701 Fax: +49 (0) 211-81-19702
All rights reserved. Please visit https://medical-data-
models.org/forms/13937
Sixth Maintenance Cycle
Monthly control visit with response
evaluation
Date of visit
Medication dosage of last cycle
mg
Prior trial substance dosage
mg
25 mg (1)
15 mg (2)
10 mg (3)
5 mg (4)
20 mg (5)
New trial substance dosage
25 mg (1)
15 mg (2)
10 mg (3)
5 mg (4)
20 mg (5)
Please specify reason for dose reduction
Response after first consolidation cycle
sCR (0)
CR (1)
vgPR (2)
PR (3)
SD (5)
PD (6)
External assessment of response
Yes
No
Did any Adverse Events occur?
Yes
No
Vital signs
Heart rate
1 / 7
bpm
Blood pressure, systolic
mmHg
Blood pressure, diastolic
mmHg
Body weight
kg
Body Height
cm
Ecog performance status
Score 0 (0)
Score 1 (1)
Score 2 (2)
Score 3 (3)
Score 4 (4)
Score 5 (5)
Laboratory:Protein electrophoresis
Albumin
g/dL
Total Protein in 24h urine
mg/24h
Total Serum Protein
g/dl
Beta-globulin measurement
g/dL
Gamma-Globulin measurement
g/dL
Beta and gamma globulin total
g/dL
Serum immunofixation
positive (1)
negative (2)
Comment on serum immunofixation
Urine immunofixation
positive (1)
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negative (2)
Comment on urine immunofixation
IgA measurement
mg/dl
IgD measurement
mg/dl
IgG measurement
mg/dl
Immunoglobulin M measurement
mg/dl
FLC kappa measurement
mg/l
Kappa
FLC lambda measurement
mg/l
Lambda
Kappa/lambda quotient
Laboratory:Hematology
Erythrocytes
Mio/μl
Hemoglobin
g/dL
Hematocrit
%
Mean Corpuscular Volume
fl
MCH
pg
Mean corpuscular hemoglobin concentration
g Hb/dL Ery
3 / 7
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Leukocytes
1000/μl
Leukocytes (total)
Platelet count
1000/uL
Neutrophils percentage
%
Neutrophils
abs.
Eosinophils percentage
%
Basophils percentage
%
Monocytes percentage
%
Lymphocytes percentage
%
Neutrophils
1000/μl
Laboratory:serum chemistry
Sodium
mmol/L
Potassium
mmol/l
Calcium
mmol/l
Glucose
mg/dl
Alkaline Phosphatase
U/L
Bilirubin
mg/dL
4 / 7
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AST (SGOT)
U/L
ALT
U/L
Gamma GT
U/l
Lactate Dehydrogenase (LDH)
U/L
Urea
mg/dl
CRP
md/dl
Serum creatinine
mg/dL
Creatinine Clearance
mL/min
Laboratory:pregnancy test
Is the subject of childbearing potential?
Yes
No
Pregnancy test result
positive (1)
negative (2)
Has the patient experienced irregularities with her
menstrual period since her last pregnancy test?
No menstruation (0)
Yes (1)
No (2)
Quality of life
Total Score QoL
Hematotoxicity CTC
Hemoglobin CTC
1 (1)
2 (2)
3 (3)
4 (4)
5 / 7
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5 (5)
Date of lowest hemoglobin value
Hemoglobin: actions taken with study medication
No change required (0)
Interruption/ prolongation without dose
reduction (1)
Interruption/ prolongation with dose
reduction (2)
Leukocytes CTC
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
Date of lowest leukocytes value
Actions taken with study medication:leukocytes
No change required (0)
Interruption/ prolongation without dose
reduction (1)
Interruption/ prolongation with dose
reduction (2)
Platelets CTC
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
Date of lowest platelets value
Actions taken with study medication:platelets
No change required (0)
Interruption/ prolongation without dose
reduction (1)
Interruption/ prolongation with dose
reduction (2)
Neutrophils CTC
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
Date of lowest neutrophils value
Actions taken with study medication:neutrophils
No change required (0)
Interruption/ prolongation without dose
reduction (1)
6 / 7
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Interruption/ prolongation with dose
reduction (2)
7 / 7
Sixth Maintenance Cycle LenaMain-Study
Seventh Maintenance Cycle LenaMain-
Study
A randomised comparison of daily 25 mg versus 5 mg
lenalidomide as maintenance therapy after high-dose
therapy and autologous stem cell transplantation in patients
with multiple myeloma. Protocol-Code: RV-MM-PI-280
EudraCT-Number: 2007-003945-33 Author: Claus
Schreiber Review: Gerd Felder Approval of CRF: Prof. Dr.
med. G. Kobbe (LKP) Release for MDM: Prof. Gattermann,
Düsseldorf (26.1.2016) Principal Investigator „LenaMain“-
Studie: Prof. Roland Fenk, Düsseldorf Coordinating center
for clinical trial Medical faculty of University Hospital
Heinrich-Heine-University Scientific Director: Herr Dr. J.
Grebe Moorenstrasse 5 40225 Düsseldorf Tel.: +49 (0)
211-81-19701 Fax: +49 (0) 211-81-19702
All rights reserved. Please visit https://medical-data-
models.org/forms/13938
Seventh Maintenance Cycle
Monthly control visit with response
evaluation
Date of visit
Medication dosage of last cycle
mg
Prior trial substance dosage
mg
25 mg (1)
15 mg (2)
10 mg (3)
5 mg (4)
20 mg (5)
New trial substance dosage
25 mg (1)
15 mg (2)
10 mg (3)
5 mg (4)
20 mg (5)
Please specify reason for dose reduction
Response after first consolidation cycle
sCR (0)
CR (1)
vgPR (2)
PR (3)
SD (5)
PD (6)
External assessment of response
Yes
No
Did any Adverse Events occur?
Yes
No
Vital signs
Heart rate
1 / 7
bpm
Blood pressure, systolic
mmHg
Blood pressure, diastolic
mmHg
Body weight
kg
Body Height
cm
Ecog performance status
Score 0 (0)
Score 1 (1)
Score 2 (2)
Score 3 (3)
Score 4 (4)
Score 5 (5)
Laboratory:Protein electrophoresis
Albumin
g/dL
Total Protein in 24h urine
mg/24h
Total Serum Protein
g/dl
Beta-globulin measurement
g/dL
Gamma-Globulin measurement
g/dL
Beta and gamma globulin total
g/dL
Serum immunofixation
positive (1)
negative (2)
Comment on serum immunofixation
Urine immunofixation
positive (1)
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negative (2)
Comment on urine immunofixation
IgA measurement
mg/dl
IgD measurement
mg/dl
IgG measurement
mg/dl
Immunoglobulin M measurement
mg/dl
FLC kappa measurement
mg/l
Kappa
FLC lambda measurement
mg/l
Lambda
Kappa/lambda quotient
Laboratory:Hematology
Erythrocytes
Mio/μl
Hemoglobin
g/dL
Hematocrit
%
Mean Corpuscular Volume
fl
MCH
pg
Mean corpuscular hemoglobin concentration
g Hb/dL Ery
3 / 7
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Leukocytes
1000/μl
Leukocytes (total)
Platelet count
1000/uL
Neutrophils percentage
%
Neutrophils
abs.
Eosinophils percentage
%
Basophils percentage
%
Monocytes percentage
%
Lymphocytes percentage
%
Neutrophils
1000/μl
Laboratory:serum chemistry
Sodium
mmol/L
Potassium
mmol/l
Calcium
mmol/l
Glucose
mg/dl
Alkaline Phosphatase
U/L
Bilirubin
mg/dL
4 / 7
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AST (SGOT)
U/L
ALT
U/L
Gamma GT
U/l
Lactate Dehydrogenase (LDH)
U/L
Urea
mg/dl
CRP
md/dl
Serum creatinine
mg/dL
Creatinine Clearance
mL/min
Laboratory:pregnancy test
Is the subject of childbearing potential?
Yes
No
Pregnancy test result
positive (1)
negative (2)
Has the patient experienced irregularities with her
menstrual period since her last pregnancy test?
No menstruation (0)
Yes (1)
No (2)
Quality of life
Total Score QoL
Hematotoxicity CTC
Hemoglobin CTC
1 (1)
2 (2)
3 (3)
4 (4)
5 / 7
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5 (5)
Date of lowest hemoglobin value
Hemoglobin: actions taken with study medication
No change required (0)
Interruption/ prolongation without dose
reduction (1)
Interruption/ prolongation with dose
reduction (2)
Leukocytes CTC
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
Date of lowest leukocytes value
Actions taken with study medication:leukocytes
No change required (0)
Interruption/ prolongation without dose
reduction (1)
Interruption/ prolongation with dose
reduction (2)
Platelets CTC
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
Date of lowest platelets value
Actions taken with study medication:platelets
No change required (0)
Interruption/ prolongation without dose
reduction (1)
Interruption/ prolongation with dose
reduction (2)
Neutrophils CTC
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
Date of lowest neutrophils value
Actions taken with study medication:neutrophils
No change required (0)
Interruption/ prolongation without dose
reduction (1)
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Interruption/ prolongation with dose
reduction (2)
7 / 7
Seventh Maintenance Cycle LenaMain-Study
Eighth Maintenance Cycle LenaMain-Study
A randomised comparison of daily 25 mg versus 5 mg
lenalidomide as maintenance therapy after high-dose
therapy and autologous stem cell transplantation in patients
with multiple myeloma. Protocol-Code: RV-MM-PI-280
EudraCT-Number: 2007-003945-33 Author: Claus
Schreiber Review: Gerd Felder Approval of CRF: Prof. Dr.
med. G. Kobbe (LKP) Release for MDM: Prof. Gattermann,
Düsseldorf (26.1.2016) Principal Investigator „LenaMain“-
Studie: Prof. Roland Fenk, Düsseldorf Coordinating center
for clinical trial Medical faculty of University Hospital
Heinrich-Heine-University Scientific Director: Herr Dr. J.
Grebe Moorenstrasse 5 40225 Düsseldorf Tel.: +49 (0)
211-81-19701 Fax: +49 (0) 211-81-19702
All rights reserved. Please visit https://medical-data-
models.org/forms/13939
Eighth Maintenance Cycle
Monthly control visit with response
evaluation
Date of visit
Medication dosage of last cycle
mg
Prior trial substance dosage
mg
25 mg (1)
15 mg (2)
10 mg (3)
5 mg (4)
20 mg (5)
New trial substance dosage
25 mg (1)
15 mg (2)
10 mg (3)
5 mg (4)
20 mg (5)
Please specify reason for dose reduction
Response after first consolidation cycle
sCR (0)
CR (1)
vgPR (2)
PR (3)
SD (5)
PD (6)
External assessment of response
Yes
No
Did any Adverse Events occur?
Yes
No
Vital signs
Heart rate
1 / 7
bpm
Blood pressure, systolic
mmHg
Blood pressure, diastolic
mmHg
Body weight
kg
Body Height
cm
Ecog performance status
Score 0 (0)
Score 1 (1)
Score 2 (2)
Score 3 (3)
Score 4 (4)
Score 5 (5)
Laboratory:Protein electrophoresis
Albumin
g/dL
Total Protein in 24h urine
mg/24h
Total Serum Protein
g/dl
Beta-globulin measurement
g/dL
Gamma-Globulin measurement
g/dL
Beta and gamma globulin total
g/dL
Serum immunofixation
positive (1)
negative (2)
Comment on serum immunofixation
Urine immunofixation
positive (1)
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negative (2)
Comment on urine immunofixation
IgA measurement
mg/dl
IgD measurement
mg/dl
IgG measurement
mg/dl
Immunoglobulin M measurement
mg/dl
FLC kappa measurement
mg/l
Kappa
FLC lambda measurement
mg/l
Lambda
Kappa/lambda quotient
Laboratory:Hematology
Erythrocytes
Mio/μl
Hemoglobin
g/dL
Hematocrit
%
Mean Corpuscular Volume
fl
MCH
pg
Mean corpuscular hemoglobin concentration
g Hb/dL Ery
3 / 7
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Leukocytes
1000/μl
Leukocytes (total)
Platelet count
1000/uL
Neutrophils percentage
%
Neutrophils
abs.
Eosinophils percentage
%
Basophils percentage
%
Monocytes percentage
%
Lymphocytes percentage
%
Neutrophils
1000/μl
Laboratory:serum chemistry
Sodium
mmol/L
Potassium
mmol/l
Calcium
mmol/l
Glucose
mg/dl
Alkaline Phosphatase
U/L
Bilirubin
mg/dL
4 / 7
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AST (SGOT)
U/L
ALT
U/L
Gamma GT
U/l
Lactate Dehydrogenase (LDH)
U/L
Urea
mg/dl
CRP
md/dl
Serum creatinine
mg/dL
Creatinine Clearance
mL/min
Laboratory:pregnancy test
Is the subject of childbearing potential?
Yes
No
Pregnancy test result
positive (1)
negative (2)
Has the patient experienced irregularities with her
menstrual period since her last pregnancy test?
No menstruation (0)
Yes (1)
No (2)
Quality of life
Total Score QoL
Hematotoxicity CTC
Hemoglobin CTC
1 (1)
2 (2)
3 (3)
4 (4)
5 / 7
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5 (5)
Date of lowest hemoglobin value
Hemoglobin: actions taken with study medication
No change required (0)
Interruption/ prolongation without dose
reduction (1)
Interruption/ prolongation with dose
reduction (2)
Leukocytes CTC
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
Date of lowest leukocytes value
Actions taken with study medication:leukocytes
No change required (0)
Interruption/ prolongation without dose
reduction (1)
Interruption/ prolongation with dose
reduction (2)
Platelets CTC
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
Date of lowest platelets value
Actions taken with study medication:platelets
No change required (0)
Interruption/ prolongation without dose
reduction (1)
Interruption/ prolongation with dose
reduction (2)
Neutrophils CTC
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
Date of lowest neutrophils value
Actions taken with study medication:neutrophils
No change required (0)
Interruption/ prolongation without dose
reduction (1)
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Interruption/ prolongation with dose
reduction (2)
7 / 7
Eighth Maintenance Cycle LenaMain-Study
Ninth Maintenance Cycle LenaMain-Study
A randomised comparison of daily 25 mg versus 5 mg
lenalidomide as maintenance therapy after high-dose
therapy and autologous stem cell transplantation in patients
with multiple myeloma. Protocol-Code: RV-MM-PI-280
EudraCT-Number: 2007-003945-33 Author: Claus
Schreiber Review: Gerd Felder Approval of CRF: Prof. Dr.
med. G. Kobbe (LKP) Release for MDM: Prof. Gattermann,
Düsseldorf (26.1.2016) Principal Investigator „LenaMain“-
Studie: Prof. Roland Fenk, Düsseldorf Coordinating center
for clinical trial Medical faculty of University Hospital
Heinrich-Heine-University Scientific Director: Herr Dr. J.
Grebe Moorenstrasse 5 40225 Düsseldorf Tel.: +49 (0)
211-81-19701 Fax: +49 (0) 211-81-19702
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Ninth Maintenance Cycle
Monthly control visit with response
evaluation
Date of visit
Medication dosage of last cycle
mg
Prior trial substance dosage
mg
25 mg (1)
15 mg (2)
10 mg (3)
5 mg (4)
20 mg (5)
New trial substance dosage
25 mg (1)
15 mg (2)
10 mg (3)
5 mg (4)
20 mg (5)
Please specify reason for dose reduction
Response after first consolidation cycle
sCR (0)
CR (1)
vgPR (2)
PR (3)
SD (5)
PD (6)
External assessment of response
Yes
No
Did any Adverse Events occur?
Yes
No
Vital signs
Heart rate
1 / 7
bpm
Blood pressure, systolic
mmHg
Blood pressure, diastolic
mmHg
Body weight
kg
Body Height
cm
Ecog performance status
Score 0 (0)
Score 1 (1)
Score 2 (2)
Score 3 (3)
Score 4 (4)
Score 5 (5)
Laboratory:Protein electrophoresis
Albumin
g/dL
Total Protein in 24h urine
mg/24h
Total Serum Protein
g/dl
Beta-globulin measurement
g/dL
Gamma-Globulin measurement
g/dL
Beta and gamma globulin total
g/dL
Serum immunofixation
positive (1)
negative (2)
Comment on serum immunofixation
Urine immunofixation
positive (1)
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negative (2)
Comment on urine immunofixation
IgA measurement
mg/dl
IgD measurement
mg/dl
IgG measurement
mg/dl
Immunoglobulin M measurement
mg/dl
FLC kappa measurement
mg/l
Kappa
FLC lambda measurement
mg/l
Lambda
Kappa/lambda quotient
Laboratory:Hematology
Erythrocytes
Mio/μl
Hemoglobin
g/dL
Hematocrit
%
Mean Corpuscular Volume
fl
MCH
pg
Mean corpuscular hemoglobin concentration
g Hb/dL Ery
3 / 7
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Leukocytes
1000/μl
Leukocytes (total)
Platelet count
1000/uL
Neutrophils percentage
%
Neutrophils
abs.
Eosinophils percentage
%
Basophils percentage
%
Monocytes percentage
%
Lymphocytes percentage
%
Neutrophils
1000/μl
Laboratory:serum chemistry
Sodium
mmol/L
Potassium
mmol/l
Calcium
mmol/l
Glucose
mg/dl
Alkaline Phosphatase
U/L
Bilirubin
mg/dL
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AST (SGOT)
U/L
ALT
U/L
Gamma GT
U/l
Lactate Dehydrogenase (LDH)
U/L
Urea
mg/dl
CRP
md/dl
Serum creatinine
mg/dL
Creatinine Clearance
mL/min
Laboratory:pregnancy test
Is the subject of childbearing potential?
Yes
No
Pregnancy test result
positive (1)
negative (2)
Has the patient experienced irregularities with her
menstrual period since her last pregnancy test?
No menstruation (0)
Yes (1)
No (2)
Quality of life
Total Score QoL
Hematotoxicity CTC
Hemoglobin CTC
1 (1)
2 (2)
3 (3)
4 (4)
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5 (5)
Date of lowest hemoglobin value
Hemoglobin: actions taken with study medication
No change required (0)
Interruption/ prolongation without dose
reduction (1)
Interruption/ prolongation with dose
reduction (2)
Leukocytes CTC
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
Date of lowest leukocytes value
Actions taken with study medication:leukocytes
No change required (0)
Interruption/ prolongation without dose
reduction (1)
Interruption/ prolongation with dose
reduction (2)
Platelets CTC
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
Date of lowest platelets value
Actions taken with study medication:platelets
No change required (0)
Interruption/ prolongation without dose
reduction (1)
Interruption/ prolongation with dose
reduction (2)
Neutrophils CTC
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
Date of lowest neutrophils value
Actions taken with study medication:neutrophils
No change required (0)
Interruption/ prolongation without dose
reduction (1)
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Interruption/ prolongation with dose
reduction (2)
7 / 7
Ninth Maintenance Cycle LenaMain-Study
Tenth Maintenance Cycle LenaMain-Study
A randomised comparison of daily 25 mg versus 5 mg
lenalidomide as maintenance therapy after high-dose
therapy and autologous stem cell transplantation in patients
with multiple myeloma. Protocol-Code: RV-MM-PI-280
EudraCT-Number: 2007-003945-33 Author: Claus
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med. G. Kobbe (LKP) Release for MDM: Prof. Gattermann,
Düsseldorf (26.1.2016) Principal Investigator „LenaMain“-
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211-81-19701 Fax: +49 (0) 211-81-19702
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Tenth Maintenance Cycle
Monthly control visit with response
evaluation
Date of visit
Medication dosage of last cycle
mg
Prior trial substance dosage
mg
25 mg (1)
15 mg (2)
10 mg (3)
5 mg (4)
20 mg (5)
New trial substance dosage
25 mg (1)
15 mg (2)
10 mg (3)
5 mg (4)
20 mg (5)
Please specify reason for dose reduction
Response after first consolidation cycle
sCR (0)
CR (1)
vgPR (2)
PR (3)
SD (5)
PD (6)
External assessment of response
Yes
No
Did any Adverse Events occur?
Yes
No
Vital signs
Heart rate
1 / 7
bpm
Blood pressure, systolic
mmHg
Blood pressure, diastolic
mmHg
Body weight
kg
Body Height
cm
Ecog performance status
Score 0 (0)
Score 1 (1)
Score 2 (2)
Score 3 (3)
Score 4 (4)
Score 5 (5)
Laboratory:Protein electrophoresis
Albumin
g/dL
Total Protein in 24h urine
mg/24h
Total Serum Protein
g/dl
Beta-globulin measurement
g/dL
Gamma-Globulin measurement
g/dL
Beta and gamma globulin total
g/dL
Serum immunofixation
positive (1)
negative (2)
Comment on serum immunofixation
Urine immunofixation
positive (1)
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negative (2)
Comment on urine immunofixation
IgA measurement
mg/dl
IgD measurement
mg/dl
IgG measurement
mg/dl
Immunoglobulin M measurement
mg/dl
FLC kappa measurement
mg/l
Kappa
FLC lambda measurement
mg/l
Lambda
Kappa/lambda quotient
Laboratory:Hematology
Erythrocytes
Mio/μl
Hemoglobin
g/dL
Hematocrit
%
Mean Corpuscular Volume
fl
MCH
pg
Mean corpuscular hemoglobin concentration
g Hb/dL Ery
3 / 7
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Leukocytes
1000/μl
Leukocytes (total)
Platelet count
1000/uL
Neutrophils percentage
%
Neutrophils
abs.
Eosinophils percentage
%
Basophils percentage
%
Monocytes percentage
%
Lymphocytes percentage
%
Neutrophils
1000/μl
Laboratory:serum chemistry
Sodium
mmol/L
Potassium
mmol/l
Calcium
mmol/l
Glucose
mg/dl
Alkaline Phosphatase
U/L
Bilirubin
mg/dL
4 / 7
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AST (SGOT)
U/L
ALT
U/L
Gamma GT
U/l
Lactate Dehydrogenase (LDH)
U/L
Urea
mg/dl
CRP
md/dl
Serum creatinine
mg/dL
Creatinine Clearance
mL/min
Laboratory:pregnancy test
Is the subject of childbearing potential?
Yes
No
Pregnancy test result
positive (1)
negative (2)
Has the patient experienced irregularities with her
menstrual period since her last pregnancy test?
No menstruation (0)
Yes (1)
No (2)
Quality of life
Total Score QoL
Hematotoxicity CTC
Hemoglobin CTC
1 (1)
2 (2)
3 (3)
4 (4)
5 / 7
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5 (5)
Date of lowest hemoglobin value
Hemoglobin: actions taken with study medication
No change required (0)
Interruption/ prolongation without dose
reduction (1)
Interruption/ prolongation with dose
reduction (2)
Leukocytes CTC
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
Date of lowest leukocytes value
Actions taken with study medication:leukocytes
No change required (0)
Interruption/ prolongation without dose
reduction (1)
Interruption/ prolongation with dose
reduction (2)
Platelets CTC
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
Date of lowest platelets value
Actions taken with study medication:platelets
No change required (0)
Interruption/ prolongation without dose
reduction (1)
Interruption/ prolongation with dose
reduction (2)
Neutrophils CTC
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
Date of lowest neutrophils value
Actions taken with study medication:neutrophils
No change required (0)
Interruption/ prolongation without dose
reduction (1)
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Tenth Maintenance Cycle LenaMain-Study
Interruption/ prolongation with dose
reduction (2)
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Tenth Maintenance Cycle LenaMain-Study
First Follow-up LenaMain-Study
A randomised comparison of daily 25 mg versus 5 mg
lenalidomide as maintenance therapy after high-dose
therapy and autologous stem cell transplantation in patients
with multiple myeloma. Protocol-Code: RV-MM-PI-280
EudraCT-Number: 2007-003945-33 Author: Claus
Schreiber Review: Gerd Felder Approval of CRF: Prof. Dr.
med. G. Kobbe (LKP) Release for MDM: Prof. Gattermann,
Düsseldorf (26.1.2016) Principal Investigator „LenaMain“-
Studie: Prof. Roland Fenk, Düsseldorf Coordinating center
for clinical trial Medical faculty of University Hospital
Heinrich-Heine-University Scientific Director: Herr Dr. J.
Grebe Moorenstrasse 5 40225 Düsseldorf Tel.: +49 (0)
211-81-19701 Fax: +49 (0) 211-81-19702
All rights reserved. Please visit https://medical-data-
models.org/forms/13942
First Follow-Up
Follow-Up
Date of visit
Date
Patient Vital Status
Alive (0)
Dead (1)
Myeloma: lines of treatment
Secondary disease occurred?
Yes
No
Secondary disease: please specify
Has a progressive disease been diagnosed?
Yes
No
Response
sCR (0)
CR (1)
vgPR (2)
PR (3)
SD (5)
PD (6)
Laboratory:pregnancy test
Is the subject of childbearing potential?
Yes
No
Pregnancy test result
positive (1)
negative (2)
Has the patient experienced irregularities with her
menstrual period since her last pregnancy test?
No menstruation (0)
Yes (1)
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No (2)
Survival Status
Survival Status
alive (0)
dead (1)
Date of death
Death certificate available?
Yes
No
Autopsy performed?
Yes
No
Cause of death
malignant disease (1)
side effect (2)
infection (3)
second neoplasm (4)
cardiovascular disease (5)
other chronic comorbidity (6)
other comorbidity (7)
unknown (8)
progressive disease (9)
Other cause of death:please specify
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First Follow-up LenaMain-Study
Second Follow-up LenaMain-Study
A randomised comparison of daily 25 mg versus 5 mg
lenalidomide as maintenance therapy after high-dose
therapy and autologous stem cell transplantation in patients
with multiple myeloma. Protocol-Code: RV-MM-PI-280
EudraCT-Number: 2007-003945-33 Author: Claus
Schreiber Review: Gerd Felder Approval of CRF: Prof. Dr.
med. G. Kobbe (LKP) Release for MDM: Prof. Gattermann,
Düsseldorf (26.1.2016) Principal Investigator „LenaMain“-
Studie: Prof. Roland Fenk, Düsseldorf Coordinating center
for clinical trial Medical faculty of University Hospital
Heinrich-Heine-University Scientific Director: Herr Dr. J.
Grebe Moorenstrasse 5 40225 Düsseldorf Tel.: +49 (0)
211-81-19701 Fax: +49 (0) 211-81-19702
All rights reserved. Please visit https://medical-data-
models.org/forms/13943
Second Follow-Up
Follow-Up
Date of visit
Date
Patient Vital Status
Alive (0)
Dead (1)
Myeloma: lines of treatment
Secondary disease occurred?
Yes
No
Secondary disease: please specify
Has a progressive disease been diagnosed?
Yes
No
Response
sCR (0)
CR (1)
vgPR (2)
PR (3)
SD (5)
PD (6)
Survival Status
Survival Status
alive (0)
dead (1)
Date of death
Death certificate available?
Yes
No
Autopsy performed?
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Yes
No
Cause of death
malignant disease (1)
side effect (2)
infection (3)
second neoplasm (4)
cardiovascular disease (5)
other chronic comorbidity (6)
other comorbidity (7)
unknown (8)
progressive disease (9)
Other cause of death:please specify
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Third Follow-up LenaMain-Study
A randomised comparison of daily 25 mg versus 5 mg
lenalidomide as maintenance therapy after high-dose
therapy and autologous stem cell transplantation in patients
with multiple myeloma. Protocol-Code: RV-MM-PI-280
EudraCT-Number: 2007-003945-33 Author: Claus
Schreiber Review: Gerd Felder Approval of CRF: Prof. Dr.
med. G. Kobbe (LKP) Release for MDM: Prof. Gattermann,
Düsseldorf (26.1.2016) Principal Investigator „LenaMain“-
Studie: Prof. Roland Fenk, Düsseldorf Coordinating center
for clinical trial Medical faculty of University Hospital
Heinrich-Heine-University Scientific Director: Herr Dr. J.
Grebe Moorenstrasse 5 40225 Düsseldorf Tel.: +49 (0)
211-81-19701 Fax: +49 (0) 211-81-19702
All rights reserved. Please visit https://medical-data-
models.org/forms/13944
Third Follow-Up
Follow-Up
Date of visit
Date
Patient Vital Status
Alive (0)
Dead (1)
Myeloma: lines of treatment
Secondary disease occurred?
Yes
No
Secondary disease: please specify
Has a progressive disease been diagnosed?
Yes
No
Response
sCR (0)
CR (1)
vgPR (2)
PR (3)
SD (5)
PD (6)
Survival Status
Survival Status
alive (0)
dead (1)
Date of death
Death certificate available?
Yes
No
Autopsy performed?
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Yes
No
Cause of death
malignant disease (1)
side effect (2)
infection (3)
second neoplasm (4)
cardiovascular disease (5)
other chronic comorbidity (6)
other comorbidity (7)
unknown (8)
progressive disease (9)
Other cause of death:please specify
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Third Follow-up LenaMain-Study
Fourth Follow-up LenaMain-Study
A randomised comparison of daily 25 mg versus 5 mg
lenalidomide as maintenance therapy after high-dose
therapy and autologous stem cell transplantation in patients
with multiple myeloma. Protocol-Code: RV-MM-PI-280
EudraCT-Number: 2007-003945-33 Author: Claus
Schreiber Review: Gerd Felder Approval of CRF: Prof. Dr.
med. G. Kobbe (LKP) Release for MDM: Prof. Gattermann,
Düsseldorf (26.1.2016) Principal Investigator „LenaMain“-
Studie: Prof. Roland Fenk, Düsseldorf Coordinating center
for clinical trial Medical faculty of University Hospital
Heinrich-Heine-University Scientific Director: Herr Dr. J.
Grebe Moorenstrasse 5 40225 Düsseldorf Tel.: +49 (0)
211-81-19701 Fax: +49 (0) 211-81-19702
All rights reserved. Please visit https://medical-data-
models.org/forms/13945
Fourth Follow-Up
Follow-Up
Date of visit
Date
Patient Vital Status
Alive (0)
Dead (1)
Myeloma: lines of treatment
Secondary disease occurred?
Yes
No
Secondary disease: please specify
Has a progressive disease been diagnosed?
Yes
No
Response
sCR (0)
CR (1)
vgPR (2)
PR (3)
SD (5)
PD (6)
Survival Status
Survival Status
alive (0)
dead (1)
Date of death
Death certificate available?
Yes
No
Autopsy performed?
1 / 2
Yes
No
Cause of death
malignant disease (1)
side effect (2)
infection (3)
second neoplasm (4)
cardiovascular disease (5)
other chronic comorbidity (6)
other comorbidity (7)
unknown (8)
progressive disease (9)
Other cause of death:please specify
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Fourth Follow-up LenaMain-Study
Progressive disease LenaMain-Study
A randomised comparison of daily 25 mg versus 5 mg
lenalidomide as maintenance therapy after high-dose
therapy and autologous stem cell transplantation in patients
with multiple myeloma. Protocol-Code: RV-MM-PI-280
EudraCT-Number: 2007-003945-33 Author: Claus
Schreiber Review: Gerd Felder Approval of CRF: Prof. Dr.
med. G. Kobbe (LKP) Release for MDM: Prof. Gattermann,
Düsseldorf (26.1.2016) Principal Investigator „LenaMain“-
Studie: Prof. Roland Fenk, Düsseldorf Coordinating center
for clinical trial Medical faculty of University Hospital
Heinrich-Heine-University Scientific Director: Herr Dr. J.
Grebe Moorenstrasse 5 40225 Düsseldorf Tel.: +49 (0)
211-81-19701 Fax: +49 (0) 211-81-19702
All rights reserved. Please visit https://medical-data-
models.org/forms/13947
Progressive disease
Monthly control visit with response
evaluation
Date of visit
Medication dosage of last cycle
mg
Prior trial substance dosage
mg
25 mg (1)
15 mg (2)
10 mg (3)
5 mg (4)
20 mg (5)
New trial substance dosage
25 mg (1)
15 mg (2)
10 mg (3)
5 mg (4)
20 mg (5)
Please specify reason for dose reduction
Response after first consolidation cycle
sCR (0)
CR (1)
vgPR (2)
PR (3)
SD (5)
PD (6)
External assessment of response
Yes
No
Did any Adverse Events occur?
Yes
No
Parameter of multiple myeloma
Cytogenetic examination done?
1 / 7
Yes
No
Cytogenetics:please specify
Cytogenetics date
Contrast infiltration
%
Contrast examination date
Extramedullary lesion
Yes
No
Lytic lesion of bones
None (1)
Osteopenia (2)
1-5 lytic lesions of bone (3)
>6 lytic lesions of bone (4)
Progressive disease reason
Vital signs
Heart rate
bpm
Blood pressure, systolic
mmHg
Blood pressure, diastolic
mmHg
Body weight
kg
Body Height
cm
Ecog performance status
Score 0 (0)
Score 1 (1)
Score 2 (2)
Score 3 (3)
Score 4 (4)
Score 5 (5)
Laboratory:Protein electrophoresis
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Progressive disease LenaMain-Study
Albumin
g/dL
Total Protein in 24h urine
mg/24h
Total Serum Protein
g/dl
Beta-globulin measurement
g/dL
Gamma-Globulin measurement
g/dL
Beta and gamma globulin total
g/dL
Serum immunofixation
positive (1)
negative (2)
Comment on serum immunofixation
Urine immunofixation
positive (1)
negative (2)
Comment on urine immunofixation
IgA measurement
mg/dl
IgD measurement
mg/dl
IgG measurement
mg/dl
Immunoglobulin M measurement
mg/dl
FLC kappa measurement
mg/l
Kappa
FLC lambda measurement
mg/l
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Progressive disease LenaMain-Study
Lambda
Kappa/lambda quotient
Laboratory:Hematology
Erythrocytes
Mio/μl
Hemoglobin
g/dL
Hematocrit
%
Mean Corpuscular Volume
fl
MCH
pg
Mean corpuscular hemoglobin concentration
g Hb/dL Ery
Leukocytes
1000/μl
Leukocytes (total)
Platelet count
1000/uL
Neutrophils percentage
%
Neutrophils
abs.
Eosinophils percentage
%
Basophils percentage
%
Monocytes percentage
%
Lymphocytes percentage
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%Neutrophils
1000/μl
Laboratory:serum chemistry
Sodium
mmol/L
Potassium
mmol/l
Calcium
mmol/l
Glucose
mg/dl
Alkaline Phosphatase
U/L
Bilirubin
mg/dL
AST (SGOT)
U/L
ALT
U/L
Gamma GT
U/l
Lactate Dehydrogenase (LDH)
U/L
Urea
mg/dl
CRP
md/dl
Serum creatinine
mg/dL
Creatinine Clearance
mL/min
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Progressive disease LenaMain-Study
Quality of life
Total Score QoL
Hematotoxicity CTC
Hemoglobin CTC
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
Date of lowest hemoglobin value
Hemoglobin: actions taken with study medication
No change required (0)
Interruption/ prolongation without dose
reduction (1)
Interruption/ prolongation with dose
reduction (2)
Leukocytes CTC
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
Date of lowest leukocytes value
Actions taken with study medication:leukocytes
No change required (0)
Interruption/ prolongation without dose
reduction (1)
Interruption/ prolongation with dose
reduction (2)
Platelets CTC
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
Date of lowest platelets value
Actions taken with study medication:platelets
No change required (0)
Interruption/ prolongation without dose
reduction (1)
Interruption/ prolongation with dose
reduction (2)
Neutrophils CTC
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Progressive disease LenaMain-Study
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
Date of lowest neutrophils value
Actions taken with study medication:neutrophils
No change required (0)
Interruption/ prolongation without dose
reduction (1)
Interruption/ prolongation with dose
reduction (2)
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Progressive disease LenaMain-Study
Concomitant medication LenaMain-Study
A randomised comparison of daily 25 mg versus 5 mg
lenalidomide as maintenance therapy after high-dose
therapy and autologous stem cell transplantation in patients
with multiple myeloma. Protocol-Code: RV-MM-PI-280
EudraCT-Number: 2007-003945-33 Author: Claus
Schreiber Review: Gerd Felder Approval of CRF: Prof. Dr.
med. G. Kobbe (LKP) Release for MDM: Prof. Gattermann,
Düsseldorf (26.1.2016) Principal Investigator „LenaMain“-
Studie: Prof. Roland Fenk, Düsseldorf Coordinating center
for clinical trial Medical faculty of University Hospital
Heinrich-Heine-University Scientific Director: Herr Dr. J.
Grebe Moorenstrasse 5 40225 Düsseldorf Tel.: +49 (0)
211-81-19701 Fax: +49 (0) 211-81-19702
All rights reserved. Please visit https://medical-data-
models.org/forms/13949
Concomitant Medication
Concomitant medication
Consecutive number
Concomitant medication use indication
Concomitant agent name or generic substance
Please specify medication dose per day
or
Therapy
Frequency of intake
Application route
1 oral (1)
nasal (2)
iv (3)
sc (4)
transdermally (5)
rectal (6)
inhalatively (7)
Concomitant Medication Start Date
Concomitant medication end date
1 / 2
Has concomitant medication been subject to
change?
No change in medication dose (1)
Dose reduction (2)
Dose increased (3)
Please specify reason for changes of
concomitant medication
Concomitant Medication ongoing after end of trial
Yes
No
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Concomitant medication LenaMain-Study
Pregnancy tests LenaMain-Study
A randomised comparison of daily 25 mg versus 5 mg
lenalidomide as maintenance therapy after high-dose
therapy and autologous stem cell transplantation in patients
with multiple myeloma. Protocol-Code: RV-MM-PI-280
EudraCT-Number: 2007-003945-33 Author: Claus
Schreiber Review: Gerd Felder Approval of CRF: Prof. Dr.
med. G. Kobbe (LKP) Release for MDM: Prof. Gattermann,
Düsseldorf (26.1.2016) Principal Investigator „LenaMain“-
Studie: Prof. Roland Fenk, Düsseldorf Coordinating center
for clinical trial Medical faculty of University Hospital
Heinrich-Heine-University Scientific Director: Herr Dr. J.
Grebe Moorenstrasse 5 40225 Düsseldorf Tel.: +49 (0)
211-81-19701 Fax: +49 (0) 211-81-19702
All rights reserved. Please visit https://medical-data-
models.org/forms/13950
Additional Pregnancy Test
Pregnancy test
Consecutive number
Trial Phase
Consolidation (C)
Follow-up (F)
Maintainance (M)
Cycle number
Trial week number
Date
Pregnancy test result
positive (1)
negative (2)
1 / 1
DESCRIBE (DZNE – Clinical Register Study of neurodegenerative Disorders)
CRF Amyotrophic lateral sclerosis functional rating scale (ALSFRS-R)
Background and Purpose:
The purpose of the DESCRIBE study is to document the
natural course of diseases in context of medical care of
neurodegenerative disorders as well as cerebrovascular
diseases and to perform phenotyping of the test persons.
Disease-spanning analyses of the measured clincial data,
the results of the imaging processes, results of the analysis
of the biometerials including genetic analysis are planed.
Principal Investigator: Prof. Klockgether, Dr. Spottke DZNE,
Bonn.
Source: DESCRIBE-Studie
http://www.dzne.de/forschung/forschungsbereiche/klinische
-forschung/studien/describe-bn006.html 
Participating Study Sites:
Berlin, Bonn, Göttingen, Dresden, Köln, Magdeburg,
München, Rostock/Greifswald, Tübingen
All rights reserved. Please visit https://medical-data-
models.org/forms/13951
CRF Amyotrophic lateral sclerosis
functional rating scale (ALSFRS-R)
Date of visit
Study-ID:
Date of visit
Visit:
ALS Functional Rating Scale
1. Speech
Loss of useful speech (0)
Speech combined with nonvocal
communication (1)
Intelligible with repeating (2)
Detectable speech disturbance (3)
Normal speech processes (4)
2. Salivation
Marked drooling; requires constant
tissue or handkerchief (0)
Marked excess of saliva with some
drooling (1)
Moderately excessive saliva; may have
minimal drooling (2)
Slight but definite excess of saliva in
mouth; may have nighttime drooling (3)
Normal (4)
3. Swallowing
NPO (exclusively parenteral or enteral
feeding) (0)
Needs supplemental tube feeding (1)
Dietary consistency changes (2)
Early eating problems-occasional
choking (3)
Normal eating habits (4)
1 / 3
4. Handwriting
Unable to grip pen (0)
Able to grip pen but unable to write (1)
Not all words are legible (2)
Slow or sloppy; all words are legible (3)
Normal (4)
5. a.Cutting food without gastrostomy/PEG
Needs to be fed (0)
Food must be cut by someone, but can
still feed slowly (1)
Can cut most foods, although clumsy
and slow; some help needed (2)
Somewhat slow and clumsy, but no help
needed (3)
Normal (4)
5. b.Cutting food with gastrostomy/PEG
Unable to perform any aspect of task (0)
Provides minimal assistance to caregiver
(1)
Some help needed with closures and
fasteners (2)
Clumsy but able to perform all
manipulations independently (3)
Normal (4)
6. Dressing and hygiene
Total dependence (0)
Needs attendant for self-care (1)
Intermittent assistance or substitute
methods (2)
Independent and complete self-care with
effort or decreased efficiency (3)
Normal function (4)
7. Turning in bed
Helpless (0)
Can initiate, but not turn or adjust sheets
alone (1)
Can turn alone or adjust sheets, but with
great difficulty (2)
Somewhat slow and clumsy, but no help
needed (3)
Normal (4)
8. Walking
No purposeful leg movement (0)
Non-ambulatory functional movement
only (1)
Walks with assistance (2)
Early ambulation difficulties (3)
Normal (4)
9. Climbing stairs
Cannot do (0)
Needs assistance (1)
Mild unsteadiness or fatigue (2)
Slow (3)
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DESCRIBE (DZNE – Clinical Register Study of neurodegenerative Disorders)
CRF Amyotrophic lateral sclerosis functional rating scale (ALSFRS-R)
Normal (4)
10. Dyspnea
Significant difficulty, considering using
mechanical respiratory support (0)
Occurs at rest, difficulty breathing when
either sitting or lying (1)
Occurs with one or more of the following:
eating, bathing, dressing (ADL) (2)
Occurs when walking (3)
None (4)
11. Orthopnea
Unable to sleep (0)
Can only sleep sitting up (1)
Needs extra pillow in order to sleep
(more than two) (2)
Some difficulty sleeping at night due to
shortness of breath. Does not routinely
use more than two pillows (3)
None (4)
12. Respiratory insufficiency
Invasive mechanical ventilation by
intubation or tracheostomy (0)
Continuous use of BiPAP during the
night and day (1)
Continuous use of BiPAP (2)
Intermittent use of BiPAP (3)
None (4)
Total score
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DESCRIBE (DZNE – Clinical Register Study of neurodegenerative Disorders)
CRF Amyotrophic lateral sclerosis functional rating scale (ALSFRS-R)
Adverse events LenaMain-Study
A randomised comparison of daily 25 mg versus 5 mg
lenalidomide as maintenance therapy after high-dose
therapy and autologous stem cell transplantation in patients
with multiple myeloma. Protocol-Code: RV-MM-PI-280
EudraCT-Number: 2007-003945-33 Author: Claus
Schreiber Review: Gerd Felder Approval of CRF: Prof. Dr.
med. G. Kobbe (LKP) Release for MDM: Prof. Gattermann,
Düsseldorf (26.1.2016) Principal Investigator „LenaMain“-
Studie: Prof. Roland Fenk, Düsseldorf Coordinating center
for clinical trial Medical faculty of University Hospital
Heinrich-Heine-University Scientific Director: Herr Dr. J.
Grebe Moorenstrasse 5 40225 Düsseldorf Tel.: +49 (0)
211-81-19701 Fax: +49 (0) 211-81-19702
All rights reserved. Please visit https://medical-data-
models.org/forms/13952
Adverse Events CTC
Adverse Events
Consecutive number of adverse event
CTC classification?
Yes
No
Version CTC
CTCAE category
Category ID
Adverse event CTC term (superordinate)
Adverse event CTC subordinate term
Meddra Low Level Term
MedDRA Low Level Term Code
MedDRA Low Level Term ID
Common Toxicity Criteria Adverse Event Grade
Please describe the AE
Adverse event severity
minor (1)
moderate (2)
severe (3)
Adverse Event Start Date
Adverse event start time
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Adverse Event End Date
Adverse event end time
Adverse event ongoing?
Yes
No
Was the AE serious?
Yes
No
Causality with trial substance
confirmed (1)
probable (2)
possible (3)
unlikely (4)
no causality (5)
cannot be assessed (6)
Actions taken with study medication
dose increased (1)
dose unchanged (2)
dose decreased (3)
medication paused (4)
medication discontinued (5)
not applicable (6)
unknown (7)
Adverse Event Outcome
Recovered (1)
Subsiding (2)
Alive With Sequelae (3)
Ongoing (4)
Death (5)
Unknown (6)
Adverse event treatment
none (0)
with medication (1)
transfusion (2)
hospitalized (3)
other(please specify) (4)
Please specify treatment given for this adverse
event
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Adverse events LenaMain-Study
End of study LenaMain-Study
A randomised comparison of daily 25 mg versus 5 mg
lenalidomide as maintenance therapy after high-dose
therapy and autologous stem cell transplantation in patients
with multiple myeloma. Protocol-Code: RV-MM-PI-280
EudraCT-Number: 2007-003945-33 Author: Claus
Schreiber Review: Gerd Felder Approval of CRF: Prof. Dr.
med. G. Kobbe (LKP) Release for MDM: Prof. Gattermann,
Düsseldorf (26.1.2016) Principal Investigator „LenaMain“-
Studie: Prof. Roland Fenk, Düsseldorf Coordinating center
for clinical trial Medical faculty of University Hospital
Heinrich-Heine-University Scientific Director: Herr Dr. J.
Grebe Moorenstrasse 5 40225 Düsseldorf Tel.: +49 (0)
211-81-19701 Fax: +49 (0) 211-81-19702
All rights reserved. Please visit https://medical-data-
models.org/forms/13953
Trial End
End of study
Study end date
Was the treatment completed?
Yes
No
Reason trial was concluded
Progress of disease (1)
Toxicity of study medication (2)
other (3)
Please specify other reason for end of trial
Survival Status
Survival Status
alive (0)
dead (1)
Date of death
Death certificate available?
Yes
No
Autopsy performed?
Yes
No
Cause of death
malignant disease (1)
side effect (2)
infection (3)
second neoplasm (4)
cardiovascular disease (5)
other chronic comorbidity (6)
other comorbidity (7)
unknown (8)
progressive disease (9)
Other cause of death:please specify
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Monthly control visit with response
evaluation
Date of visit
Medication dosage of last cycle
mg
Prior trial substance dosage
mg
25 mg (1)
15 mg (2)
10 mg (3)
5 mg (4)
20 mg (5)
New trial substance dosage
25 mg (1)
15 mg (2)
10 mg (3)
5 mg (4)
20 mg (5)
Please specify reason for dose reduction
Response after first consolidation cycle
sCR (0)
CR (1)
vgPR (2)
PR (3)
SD (5)
PD (6)
External assessment of response
Yes
No
Did any Adverse Events occur?
Yes
No
Parameter of multiple myeloma
Cytogenetic examination done?
Yes
No
Cytogenetics:please specify
Cytogenetics date
Contrast infiltration
%
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End of study LenaMain-Study
Contrast examination date
Extramedullary lesion
Yes
No
Lytic lesion of bones
None (1)
Osteopenia (2)
1-5 lytic lesions of bone (3)
>6 lytic lesions of bone (4)
Progressive disease reason
Vital signs
Heart rate
bpm
Blood pressure, systolic
mmHg
Blood pressure, diastolic
mmHg
Body weight
kg
Body Height
cm
Ecog performance status
Score 0 (0)
Score 1 (1)
Score 2 (2)
Score 3 (3)
Score 4 (4)
Score 5 (5)
Laboratory:Protein electrophoresis
Albumin
g/dL
Total Protein in 24h urine
mg/24h
Total Serum Protein
g/dl
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Beta-globulin measurement
g/dL
Gamma-Globulin measurement
g/dL
Beta and gamma globulin total
g/dL
Serum immunofixation
positive (1)
negative (2)
Comment on serum immunofixation
Urine immunofixation
positive (1)
negative (2)
Comment on urine immunofixation
IgA measurement
mg/dl
IgD measurement
mg/dl
IgG measurement
mg/dl
Immunoglobulin M measurement
mg/dl
FLC kappa measurement
mg/l
Kappa
FLC lambda measurement
mg/l
Lambda
Kappa/lambda quotient
Laboratory:Hematology
Erythrocytes
4 / 8
End of study LenaMain-Study
Mio/μl
Hemoglobin
g/dL
Hematocrit
%
Mean Corpuscular Volume
fl
MCH
pg
Mean corpuscular hemoglobin concentration
g Hb/dL Ery
Leukocytes
1000/μl
Leukocytes (total)
Platelet count
1000/uL
Neutrophils percentage
%
Neutrophils
abs.
Eosinophils percentage
%
Basophils percentage
%
Monocytes percentage
%
Lymphocytes percentage
%
Neutrophils
1000/μl
Laboratory:serum chemistry
Sodium
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mmol/L
Potassium
mmol/l
Calcium
mmol/l
Glucose
mg/dl
Alkaline Phosphatase
U/L
Bilirubin
mg/dL
AST (SGOT)
U/L
ALT
U/L
Gamma GT
U/l
Lactate Dehydrogenase (LDH)
U/L
Urea
mg/dl
CRP
md/dl
Serum creatinine
mg/dL
Creatinine Clearance
mL/min
Quality of life
Total Score QoL
Hematotoxicity CTC
Hemoglobin CTC
1 (1)
2 (2)
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End of study LenaMain-Study
3 (3)
4 (4)
5 (5)
Date of lowest hemoglobin value
Hemoglobin: actions taken with study medication
No change required (0)
Interruption/ prolongation without dose
reduction (1)
Interruption/ prolongation with dose
reduction (2)
Leukocytes CTC
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
Date of lowest leukocytes value
Actions taken with study medication:leukocytes
No change required (0)
Interruption/ prolongation without dose
reduction (1)
Interruption/ prolongation with dose
reduction (2)
Platelets CTC
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
Date of lowest platelets value
Actions taken with study medication:platelets
No change required (0)
Interruption/ prolongation without dose
reduction (1)
Interruption/ prolongation with dose
reduction (2)
Neutrophils CTC
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
Date of lowest neutrophils value
Actions taken with study medication:neutrophils
No change required (0)
Interruption/ prolongation without dose
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End of study LenaMain-Study
reduction (1)
Interruption/ prolongation with dose
reduction (2)
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End of study LenaMain-Study
DESCRIBE (DZNE – Clinical Register Study of
neurodegenerative Disorders) CRF Cognition Module Baseline
Background and Purpose:
The purpose of the DESCRIBE study is to document the
natural course of diseases in context of medical care of
neurodegenerative disorders as well as cerebrovascular
diseases and to perform phenotyping of the test persons.
Disease-spanning analyses of the measured clincial data,
the results of the imaging processes, results of the analysis
of the biometerials including genetic analysis are planed.
Principal Investigator: Prof. Klockgether, Dr. Spottke DZNE,
Bonn.
Source: DESCRIBE-Studie
http://www.dzne.de/forschung/forschungsbereiche/klinische
-forschung/studien/describe-bn006.html 
Participating Study Sites:
Berlin, Bonn, Göttingen, Dresden, Köln, Magdeburg,
München, Rostock/Greifswald, Tübingen
All rights reserved. Please visit https://medical-data-
models.org/forms/13956
CRF Cognition Module Baseline
Date of visit
Study-ID:
Date of visit
Anamnesis cognition 1: Subjective
cognitive decline
1. Did your memory changed for the worse?
Yes
No
A. If 'yes', does this make you worry?
Yes
No
B. If 'yes', when did deterioration start?
within the last six month (1)
from six month ago on to two years ago
(2)
from two to five years ago (3)
more than five years ago (4)
not specified (5)
C. If 'yes', is your ability in this section worse than
of other persons your age?
Yes
No
D. If 'yes', have you ever consulted or talked to
your doctor about these problems?
Yes
No
E. If 'yes', when for the first time?
months
2. Do you have to grope for words more often
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than before?
Yes
No
A. If 'yes', does this make you worry?
Yes
No
B. If 'yes', when did deterioration start?
within the last six month (1)
from six month ago on to two years ago
(2)
from two to five years ago (3)
more than five years ago (4)
not specified (5)
C. If 'yes', is your ability in this section worse than
of other persons your age?
Yes
No
D. If 'yes', have you ever consulted or talked to
your doctor about these problems?
Yes
No
E. If 'yes', when for the first time?
months
3. Do you have more often problems planning
forward-thinking or keeping order?
Yes
No
A. If 'yes', does this make you worry?
Yes
No
B. If 'yes', when did deterioration start?
within the last six month (1)
from six month ago on to two years ago
(2)
from two to five years ago (3)
more than five years ago (4)
not specified (5)
C. If 'yes', is your ability in this section worse than
of other persons your age?
Yes
No
D. If 'yes', have you ever consulted or talked to
your doctor about these problems?
Yes
No
E. If 'yes', when for the first time?
months
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4. Do you make mistakes more frequently, if you
not fully concentrate on one thing?
Yes
No
A. If 'yes', does this make you worry?
Yes
No
B. If 'yes', when did deterioration start?
within the last six month (1)
from six month ago on to two years ago
(2)
from two to five years ago (3)
more than five years ago (4)
not specified (5)
C. If 'yes', is your ability in this section worse than
of other persons your age?
Yes
No
D. If 'yes', have you ever consulted or talked to
your doctor about these problems?
Yes
No
E. If 'yes', when for the first time?
months
5. Did you notice any other mental deterioration?
In which sections?
Yes
No
Other mental deterioation:
A. If 'yes', does this make you worry?
Yes
No
B. If 'yes', when did deterioration start?
within the last six month (1)
from six month ago on to two years ago
(2)
from two to five years ago (3)
more than five years ago (4)
not specified (5)
C. If 'yes', is your ability in this section worse than
of other persons your age?
Yes
No
D. If 'yes', have you ever consulted or talked to
your doctor about these problems?
Yes
No
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E. If 'yes', when for the first time?
months
Anamnesis cognition 2: Observed
cognitive decline
Presence of informant (Questions may be asked
while participant is present)
no informant present (no informant
present)
participant refuses interview with relative
(participant refuses interview with
relative)
Informations are reported by: (only one answer)
Brother/Sister (Brother/Sister)
Child (Child)
Friend (Friend)
Other attendant (Other attendant)
Spouse (Spouse)
1. Did the memory of the participant change for
the worse?
Yes
No
Start of deterioation:
within the last six month (1)
from six month ago on to two years ago
(2)
from two to five years ago (3)
more than five years ago (4)
not specified (5)
2. Does the participant have frequently problems
finding words?
Yes
No
Start of deterioation:
within the last six month (1)
from six month ago on to two years ago
(2)
from two to five years ago (3)
more than five years ago (4)
not specified (5)
3.  Does the participant have more often
problems planning forward-thinking or keeping
order?
Yes
No
Start of deterioation:
within the last six month (1)
from six month ago on to two years ago
(2)
from two to five years ago (3)
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more than five years ago (4)
not specified (5)
4. Does the participant make mistakes more
frequently, if he not fully concentrates on one
thing?
Yes
No
Start of deterioation:
within the last six month (1)
from six month ago on to two years ago
(2)
from two to five years ago (3)
more than five years ago (4)
not specified (5)
5. Did you notice any other mental deterioration?
In which sections?
Yes
No
Other mental deterioation:
Start of deterioation:
within the last six month (1)
from six month ago on to two years ago
(2)
from two to five years ago (3)
more than five years ago (4)
not specified (5)
6. Did you notice a change of behavior or
personality of the participant?
Yes
No
Start of change:
within the last six month (1)
from six month ago on to two years ago
(2)
from two to five years ago (3)
more than five years ago (4)
not specified (5)
Mini mental state examination (MMSE)
1. Orientation
1.1. Orientation in time
<= 5
>= 0
1.2. Orientation to place
<= 5
>= 0
2. Retention in memory
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>= 0
<= 3
3. Attention
>= 0
<= 5
4. Powers of recollection
>= 0
<= 3
5. Speech
<= 8
>= 0
6. Drawing
<= 1
>= 0
total score MMSE
>= 0
<= 30
Neuropsychologic testing
1. Do you have difficulties hearing?
Extreme impairment/ loss of hearing
(almost nothing/nothing can be
understood) (Extreme impairment/ loss
of hearing (almost nothing/nothing can
be understood))
Mild impairment (only load speech can
be understood, hearing aid device
necessary) (Mild impairment (only load
speech can be understood, hearing aid
device necessary))
No impairment (speech in normal sound
level is understandable, no hearing
device) (No impairment (speech in
normal sound level is understandable, no
hearing device))
Severe impairment (only if spoken out
very loudly speech can be understood,
communication very difficult) (Severe
impairment (only if spoken out very
loudly speech can be understood,
communication very difficult))
2. Do you have difficulties seeing?
Compounded seeing (reading only
possible with effort;  fatiguing fast; only
large type like headlines can be read
without effort) (Compounded seeing
(reading only possible with effort;
fatiguing fast; only large type like
headlines can be read without effort))
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No impairment (can see well with
glasses on, fine print can be read without
any problems) (No impairment (can see
well with glasses on, fine print can be
read without any problems))
Severe visual impairment (only seeing
shadows, only differing between light-
and dark contrasts; blindness or almost
blindness) (Severe visual impairment
(only seeing shadows, only differing
between light- and dark contrasts;
blindness or almost blindness))
Significant (severe impairment, e.g.
cataract, recognize persons and objects,
reading only with magnifier) (Significant
(severe impairment, e.g. cataract,
recognize persons and objects, reading
only with magnifier))
3. Visus measurement
Start of testing (time):
Initials of head of test
Verbal fluency: Category animals
Total score
>= 0
<= 80
Sum of correct words
Boston naming test
Total score
>= 0
<= 15
Sum of correct words
Please name version of word list:
Version 1 (Version 1)
Version 2 (Version 2)
Version 3 (Version 3)
1. Round: No. of correct answers
<= 10
>= 0
2. Round: No. of correct answers
<= 10
>= 0
3. Round: No. of correct answers
>= 0
<= 10
1. Round: No. intrusions
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>= 0
<= 10
2. Round: No. intrusions
>= 0
<= 10
3. Round: No. of intrusions
<= 10
>= 0
Total score
>= 0
<= 30
Drawing figures: Circle
>= 0
<= 2
no. of points
Drawing figures: Rhombus
>= 0
<= 3
no. of points
Drawing figures: Rectangle
>= 0
<= 2
no. of points
Drawing figures: Cube
>= 0
<= 4
no. of points
Wordlist recall: Total number of correct answers
>= 0
<= 10
Recalling wordlist: Total number of intrusions
>= 0
<= 10
Intrusions total
>= 0
<= 40
Savings
>= 0
<= 100
%
Recognizing wordlist: No. recognized as old
>= 0
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<= 10
Recognizing wordlist: No. recognized as new
>= 0
<= 10
Discriminability
>= 0
<= 100
%
Recalling figures: Circle
>= 0
<= 2
no. of points
Recalling figures: Rhombus
>= 0
<= 3
no. of points
Recalling figures: Rectangle
>= 0
<= 2
no. of points
Recalling figures: Cube
>= 0
<= 4
no. of points
Total
>= 0
<= 11
no. of points
Savings
%
Total
>= 0
<= 80
Sum of correct words
TMT A time needed
>= 0
<= 180
sec
TMT B time needed
>= 0
<= 300
sec
TMT B/A
9 / 12
DESCRIBE (DZNE – Clinical Register Study of neurodegenerative
Disorders) CRF Cognition Module Baseline
Range of numbers
Correct rows forward
>= 0
<= 12
Correct rows backwards
>= 0
<= 12
MWT-B Test: No. correct words
>= 0
<= 37
BTA- Form N (Numbers)
>= 0
<= 10
BTA- Form L (letters)
>= 0
<= 10
BTA total
z-value
Total raw value
>= 0
<= 20
Percentile
>= 0
<= 100
%
Total raw value
>= 0
<= 33
z-value
>= -3
<= 3
The test person was not motivated enough
Yes
No
The test person refused to perform the tasks.
Yes
No
The test person had physical problems like e.g.
sensorial or motor impairment or pain obviously
reducing test performance
Yes
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No
The test person was cognitively over-challenged
performing single task
Yes
No
The test person did not have adequate language
knowledge
Yes
No
If one question was answered 'Yes', please
specify your answer:
The examination was disturbed or interrupted
Yes
No
There were deviations from standard instruction
Yes
No
Tasks have not been performed.
Yes
No
The examination was not compliant to rules for
other reasons.
Yes
No
If one question was answered with 'Yes', please
specify, which subtest the given details address
and how to assess these.
Pill questionnaire
not done
Yes
No
Participant knows name of his pills?
Yes
No
The participant knows in which doses to take the
pills and the color of his pills.
Yes
No
The participant knows the time table of his
medication?
Yes
No
Is the participant able to state medication name,
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doses or color of the pills and time of intake (3
times 'Yes') correctly?
Yes
No
Is the participant able to correctly state time of
intake and at least one of the following features
name, dosis, pill color?
Yes
No
Does your relative take his medication totally
independent and without control?
Yes
No
Does your relative have to be reminded to take
his pills?
Yes
No
Were there ever any incidence when you had to
consult a physician because your relative took his
pills in a wrong way?
Was question 1 in section B2 answered 'Yes' and
question 2 and 3 answered 'No'?
Yes
No
War section B1 answered 'Yes'?
Yes
No
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Visit 2 (3 Months) Ponderosa CML
ZKSJ0083
Study part: Visit 2 (3 Months).Observational study on CML
patients in any phase treated with ponatinib (Iclusig®) at
any dose. Principal Investigator Prof. Dr. A. Hochhaus.
All rights reserved. Please visit https://medical-data-
models.org/forms/13958
Visit 2 (3 Months)
Patient status
Date of visit
Patient died?
Yes
No
Blood pressure
Blood pressure measurement carried out?
Yes
No
Systolic Blood Pressure
mmHg
Diastolic Blood Pressure
mmHg
Laboratory parameters
Urea
Normal (1)
Grade of deviation 1 according to
CTCAE (2)
Grade of deviation 2 according to
CTCAE (3)
Grade of deviation 3 according to
CTCAE (4)
Grade of deviation 4 according to
CTCAE (5)
not analyzed (5)
Creatinine
Normal (1)
Grade of deviation 1 according to
CTCAE (2)
Grade of deviation 2 according to
CTCAE (3)
Grade of deviation 3 according to
CTCAE (4)
Grade of deviation 4 according to
CTCAE (5)
not analyzed (5)
Uric acid
Normal (1)
Grade of deviation 1 according to
CTCAE (2)
Grade of deviation 2 according to
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CTCAE (3)
Grade of deviation 3 according to
CTCAE (4)
Grade of deviation 4 according to
CTCAE (5)
not analyzed (5)
Total Bilirubin
Normal (1)
Grade of deviation 1 according to
CTCAE (2)
Grade of deviation 2 according to
CTCAE (3)
Grade of deviation 3 according to
CTCAE (4)
Grade of deviation 4 according to
CTCAE (5)
not analyzed (5)
Bilirubin, direct
Normal (1)
Grade of deviation 1 according to
CTCAE (2)
Grade of deviation 2 according to
CTCAE (3)
Grade of deviation 3 according to
CTCAE (4)
Grade of deviation 4 according to
CTCAE (5)
not analyzed (5)
Glucose
Normal (1)
Grade of deviation 1 according to
CTCAE (2)
Grade of deviation 2 according to
CTCAE (3)
Grade of deviation 3 according to
CTCAE (4)
Grade of deviation 4 according to
CTCAE (5)
not analyzed (5)
Total protein
Normal (1)
Grade of deviation 1 according to
CTCAE (2)
Grade of deviation 2 according to
CTCAE (3)
Grade of deviation 3 according to
CTCAE (4)
Grade of deviation 4 according to
CTCAE (5)
not analyzed (5)
Albumin
Normal (1)
Grade of deviation 1 according to
CTCAE (2)
Grade of deviation 2 according to
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CTCAE (3)
Grade of deviation 3 according to
CTCAE (4)
Grade of deviation 4 according to
CTCAE (5)
not analyzed (5)
ASAT (AST, GOT)
Normal (1)
Grade of deviation 1 according to
CTCAE (2)
Grade of deviation 2 according to
CTCAE (3)
Grade of deviation 3 according to
CTCAE (4)
Grade of deviation 4 according to
CTCAE (5)
not analyzed (5)
ALAT (ALT, GPT)
Normal (1)
Grade of deviation 1 according to
CTCAE (2)
Grade of deviation 2 according to
CTCAE (3)
Grade of deviation 3 according to
CTCAE (4)
Grade of deviation 4 according to
CTCAE (5)
not analyzed (5)
Gamma-GT
Normal (1)
Grade of deviation 1 according to
CTCAE (2)
Grade of deviation 2 according to
CTCAE (3)
Grade of deviation 3 according to
CTCAE (4)
Grade of deviation 4 according to
CTCAE (5)
not analyzed (5)
Alkaline phosphatase
Normal (1)
Grade of deviation 1 according to
CTCAE (2)
Grade of deviation 2 according to
CTCAE (3)
Grade of deviation 3 according to
CTCAE (4)
Grade of deviation 4 according to
CTCAE (5)
not analyzed (5)
Cholesterol
Normal (1)
Grade of deviation 1 according to
CTCAE (2)
Grade of deviation 2 according to
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CTCAE (3)
Grade of deviation 3 according to
CTCAE (4)
Grade of deviation 4 according to
CTCAE (5)
not analyzed (5)
Triglycerides
Normal (1)
Grade of deviation 1 according to
CTCAE (2)
Grade of deviation 2 according to
CTCAE (3)
Grade of deviation 3 according to
CTCAE (4)
Grade of deviation 4 according to
CTCAE (5)
not analyzed (5)
Amylase
Normal (1)
Grade of deviation 1 according to
CTCAE (2)
Grade of deviation 2 according to
CTCAE (3)
Grade of deviation 3 according to
CTCAE (4)
Grade of deviation 4 according to
CTCAE (5)
not analyzed (5)
Lipase
Normal (1)
Grade of deviation 1 according to
CTCAE (2)
Grade of deviation 2 according to
CTCAE (3)
Grade of deviation 3 according to
CTCAE (4)
Grade of deviation 4 according to
CTCAE (5)
not analyzed (5)
Leukocytes
x10^3 /µl
Erythrocytes
x10^6 /µl
Hemoglobin
g/dl
Hematocrit
%
Erythrocyte Mean Corpuscular Volume, MCV
fl
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Mean Corpuscular Hemoglobin, MCH
pg
Mean corpuscular hemoglobin concentration
MCHC
g/dl
Platelets
x10^3 /µl
Ponatinib treatment
Was the treatment interrupted or ended?
yes (1)
no (2)
interrupted (3)
ended (4)
Treatment Begin Date
Treatment End Date
Reason
Were there any dosage changes?
Yes
No
Start date of dosage change
Dosage
Reason of dosage change
Response
Hematologic findings known?
Yes
No
Date of hematologic test
Hematologic test
CHR (1)
no CHR (2)
BCR-ABL Mutation
T315I  (1)
Other (2)
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Please mention if other:
Cytogenetic Analysis carried out?
Yes
No
Date of Cytogenetic Analysis
Laboratory of Cytogenetic Analysis
Evaluated mitosis
Normal karyotype
Philadelphia negative, with additional aberrations
Philadelphia Chromosome t(9;22)
Philadelphia Chromosome with additional
aberrations
Not evaluable mitoses
Cytogenetic response
no response (1)
CyR (2)
partial (PCyR)  (3)
complete (CcyR) (4)
complete (CcyR) (4)
not determined (5)
Bone marrow biopsy performed?
yes (1)
no (2)
unknown (3)
Date of bone marrow biopsy
Bone marrow biopsy findings
Chronic phase (1)
Accelerated phase (2)
Blast crisis (3)
Other (4)
If other, please mention:
Molecular Analysis known?
Yes
No
Date of Molecular Analysis
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Laboratory of Molecular Analysis
BCR-ABL International Scale
%
Polymerase Chain Reaction, PCR
no MMR (1)
MMR (2)
MR4 (3)
MR4.5 (4)
MR5 (5)
CMR (6)
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Eligibility Acute Myeloid Leukemia
NCT01478074
ALT-801-activated Natural Killer Cells After FLAG Induction
for Acute Myeloid Leukemia; ODM derived from:
https://clinicaltrials.gov/show/NCT01478074
All rights reserved. Please visit https://medical-data-
models.org/forms/13959
Eligibility Acute Myeloid Leukemia
NCT01478074
Recipient inclusion criteria
Patients with relapsed aml, including those with
cns disease or previous hematopoietic stem cell
transplantation, or primary refractory aml
(primary aml that has failed remission to at least
two cycles of induction therapy)*
Yes
No
For patients of cohorts 2 to 4, availability of a
haploidentical family peripheral blood stem cell
donor selected for best possible kir reactivity*
Yes
No
Patient is between 2 and 59 years of age,
inclusive
Yes
No
Patient must have recovered from the treatment-
related toxicities of prior cytotoxic agents received
in the 4 weeks prior to beginning treatment on
this protocol, with the exception of cytopenias
resulting from persistent disease, and alopecia*
Yes
No
Zubrod performance scale (refer to appendix c) ≤
2 or lansky (refer to appendix d) > 60*
Yes
No
Adequate renal function for adults and children*
Yes
No
Adequate liver function, defined as: total bilirubin
≤ 2 mg/dl and sgpt (alt) ≤ 2.5 x uln for age
(unless gilbert's disease or abnormal liver
function due to primary disease)*
Yes
No
Pulmonary symptoms controlled by medication
and pulse oximetry> 92% room air*
Yes
No
New york heart association classification < iii*
Yes
No
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Negative serum test to rule out pregnancy within
2 weeks prior to registration in females of
childbearing potential (non childbearing potential
defined as premenarchal, greater than one year
post-menopausal, or surgically sterilized)*
Yes
No
Sexually active males and females of
childbearing potential must agree to use a form of
contraception considered effective and medically
acceptable by the investigator*
Yes
No
Negative serology for human immunodeficiency
virus (hiv)*
Yes
No
Recipient exclusion criteria
Investigational therapies in the 4 weeks prior to
beginning treatment on this protocol
Yes
No
Congestive heart failure < 6 months prior to
screening
Yes
No
Unstable angina pectoris < 6 months prior to
screening
Yes
No
Myocardial infarction < 6 months prior to
screening
Yes
No
Donor inclusion criteria
Related to recipient (sibling, parent, offspring,
offspring of a sibling)
Yes
No
Hla-haploidentical to recipient (need not be re-
tested if already performed previously, provided
copies of the original results are available)
Yes
No
Able and willing to undergo apheresis
Yes
No
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Willing to donate blood for baseline chimerism
assessment
Yes
No
Negative serum test to rule out pregnancy within
two weeks prior to registration in females of
childbearing potential (non childbearing potential
defined as premenarchal, greater than one year
post-menopausal, or surgically sterilized)
Yes
No
Donor must meet institutional eligibility criteria for
allogeneic blood stem cell donation including
infectious disease screening panel (hepatitis b,
hepatitis c, hiv, cmv, and west nile virus) and cbc,
differential and platelet studies
Yes
No
Donor must meet stem cell donor eligibility
criteria as set forth in 21 cfr 1271 subpart c
Yes
No
8. the preferred donor will be selected as the
most alloreactive of the available haploidentical
related donors on the basis of predicted nk cell
alloreactivity using recipient and donor hla type.
if necessary, the best of equally alloreactive
donors will be determined by donor kir type.  nk
alloreactivity is defined as o a kir gene is present
on the donor nk cells for which
Yes
No
the hla haplotype (kir ligand) for the kir receptor in
question is absent in the recipient
Yes
No
The hla haplotype (kir ligand) for the kir receptor
in question is present in the donor
Yes
No
Donor exclusion criteria
Active infection (defined as on antimicrobial
therapy and/or febrile)
Yes
No
Pregnant females
Yes
No
Breast-feeding females
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Yes
No
4 / 4
Eligibility Acute Myeloid Leukemia NCT01478074
Eligibility Carcinoma, Non-Small-Cell Lung
NCT02204059
Biodistribution Study With 186 Re-labelled Humanised
Monoclonal Antibody BIWA 4 in Patients With Non-small
Cell Lung Cancer; ODM derived from:
https://clinicaltrials.gov/show/NCT02204059
All rights reserved. Please visit https://medical-data-
models.org/forms/13960
Eligibility Carcinoma, Non-Small-Cell
Lung NCT02204059
Inclusion Criteria
patients must have histological or cytological
confirmation of non small cell lung cancer (nsclc)
stage i, ii or iiia according to the staging system
of the american joint committee on cancer (ajcc)*
Yes
No
patients destined for resection of the tumour*
Yes
No
patients over 18 years of age*
Yes
No
patients younger than 80 years of age*
Yes
No
patients who had given 'written informed
consent'*
Yes
No
patients with a life expectancy of at least 3
months*
Yes
No
patients with a good performance status:
karnofsky > 60*
Yes
No
Exclusion Criteria
life-threatening infection, allergic diathesis, organ
failure (bilirubin > 30µmol/l and/or creatinine >
150 µmol/l) or evidence of a recent myocardial
infarction on electrocardiogram (ecg) or unstable
angina pectoris*
Yes
No
pre-menopausal women (last menstruation <= 1
year prior to study start)*
Yes
No
not surgically sterile (hysterectomy, tubal ligation)
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and*
Yes
No
not practicing acceptable means of birth control,
(or not planned to be continued throughout the
study). acceptable methods of birth control
include oral, implantable or injectable
contraceptives*
Yes
No
women with a positive serum pregnancy test at
baseline*
Yes
No
white blood cell count < 3000/mm³, granulocyte
count < 1500/mm³ or platelet count <
100000/mm³. details of prior chemotherapy and
radiotherapy had to be known.*
Yes
No
hematological disorders, congestive heart failure,
bronchial asthma, alimentary or contact allergy,
severe atopy or allergy*
Yes
No
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Eligibility Cardiovascular Disease
NCT00106886
HOPE-2 Study (Heart Outcomes Prevention Evaluation-2
Study); ODM derived from:
https://clinicaltrials.gov/show/NCT00106886
All rights reserved. Please visit https://medical-data-
models.org/forms/13961
Eligibility Cardiovascular Disease
NCT00106886
Inclusion Criteria
women and men 55 years of age or over with
established cvd and at high risk for future fatal
and nonfatal cv events, defined as:*
Yes
No
1. documented coronary artery disease (cad);*
Yes
No
2. documented peripheral vascular disease
(pvd);*
Yes
No
3. documented cerebrovascular disease;*
Yes
No
4. diabetes with one of the following; additional
cardiovascular risk factors:*
Yes
No
i) hypertension (bp >160 mmhg systolic or >90
mmhg diastolic or on treatment); ii) total
cholesterol >5.2 mmol/l (>200 mg/dl); iii) hdl
cholesterol <0.9 mmol/l (3.5 mg/dl); iv) current
cigarette smoker; v) any evidence of previous
vascular disease*
Yes
No
provision of informed consent*
Yes
No
Exclusion Criteria
current use of any vitamin supplements
containing folic acid >200 micrograms/day. the
patients taking such vitamin supplements can be
asked if they agree to discontinue these
supplements. if they agree, they can be
randomized to the study following a one month
wash-out period.*
Yes
No
known previous adverse reactions to folic acid
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and/or vitamin b6 and/or b12.*
Yes
No
planned cardiac, peripheral or cerebrovascular
revascularization, defined as a decision taken by
the patient and his or her physician(s) to perform
surgical or percutaneous transluminal
revascularization within the next 6 months.*
Yes
No
hemodynamically significant primary valvular
outflow tract obstruction (e.g. mitral stenosis,
asymmetric septal hypertrophy, malfunctioning
prosthetic valve).*
Yes
No
constrictive pericarditis.*
Yes
No
complex congenital heart disease.*
Yes
No
syncopal episodes presumed to be due to
uncontrolled life-threatening arrhythmias
(asymptomatic arrhythmias including ventricular
tachycardia are not exclusion criteria.*
Yes
No
uncontrolled hypertension.*
Yes
No
cor pulmonale.*
Yes
No
heart transplant recipient.*
Yes
No
other important non-cardiovascular disease(s)
expected to limit compliance and/or impact on
patient's ability to complete the study, such as:
*history of alcohol or drug abuse, *psychiatric
disorders, *senility, *severe physical disability,*
Yes
No
*illnesses including terminal stage of cancer and
other major systemic illnesses expected to limit
the patient's ability to comply with the study
protocol and to complete the study.*
Yes
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No
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Eligibility CD20-Positive Large B-Cell
Lymphoma NCT00169169
Efficacy Study of Rituximab After ASCT in High-Risk
Diffuse Large B-Cell Lymphoma; ODM derived from:
https://clinicaltrials.gov/show/NCT00169169
All rights reserved. Please visit https://medical-data-
models.org/forms/13962
Eligibility CD20-Positive Large B-Cell
Lymphoma NCT00169169
Inclusion Criteria
patient with histologically proven cd20+ diffuse
large b cell lymphoma (who classification).*
Yes
No
aged from 18 to 59 years, eligible for transplant.*
Yes
No
patient not previously treated.*
Yes
No
age adjusted international prognostic index equal
to 2 or 3.*
Yes
No
having previously signed a written informed
consent.*
Yes
No
women of childbearing potential currently
practicing an adequate method of contraception.*
Yes
No
Exclusion Criteria
any other histological type of lymphoma.*
Yes
No
any history of treated or non-treated indolent
lymphoma.*
Yes
No
central nervous system or meningeal involvement
by lymphoma.*
Yes
No
contra-indication to any drug contained in the
chemotherapy regimens.*
Yes
No
poor renal function (creatinin level>150mmol/l),
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poor hepatic function (total bilirubin
level>30mmol/l, transaminases>2.5 maximum
normal level) unless these abnormalities are
related to the lymphoma.*
Yes
No
poor bone marrow reserve as defined by
neutrophils < 1.5 g/l or platelets < 100 g/l, unless
related to bone marrow infiltration.*
Yes
No
any history of cancer during the last 5 years, with
the exception of non-melanoma skin tumors or
stage 0 (in situ) cervical carcinoma.*
Yes
No
any serious active disease (according to the
investigator’s decision).*
Yes
No
hiv, htlv1 or hbv related disease.*
Yes
No
any organ transplantation before inclusion.*
Yes
No
pregnant women.*
Yes
No
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Eligibility CD20-Positive Large B-Cell Lymphoma NCT00169169
Eligibility Central Nervous System
Lymphoma NCT00153530
Whole Brain Irradiation in Primary Central Nervous System
(CNS) Lymphoma (PCNSL); ODM derived from:
https://clinicaltrials.gov/show/NCT00153530
All rights reserved. Please visit https://medical-data-
models.org/forms/13963
Eligibility Central Nervous System
Lymphoma NCT00153530
Inclusion Criteria
histologically or cytologically/immunocytologically
confirmed primary non-hodgkin's lymphoma of
the cns. a central reference pathological report
will be made on inclusion into the study (prof. dr.
pietsch, reference center for brain tumors of the
german society for neuropathology and
neuroanatomy, institute of neuropathology of the
bonn university hospital). histological diagnosis is
usually performed by preferential stereotactic
biopsy of suspicious lesions in the brain or spinal
cord. the diagnosis from cerebrospinal fluid (csf)
requires the detection of malignant lymphocytes
according to cytological and immunocytological
criteria. there should be no more than 2 weeks
between establishing the diagnosis and inclusion
in the study. the availability of the reference
pathological report is not absolutely necessary for
inclusion in the study and beginning therapy.*
Yes
No
aged > 18 years*
Yes
No
life expectancy of at least 2 months*
Yes
No
adequate bone marrow reserve with a peripheral
granulocyte count of > 1,500/µl and thrombocyte
count of > 100,000/µl; bilirubin in the normal
range; got of < three times the upper normal limit
and adequate renal function with a creatinine
clearance of > 50 ml/min and serum creatinine in
the normal range.*
Yes
No
written informed consent*
Yes
No
in women of child-bearing age, pregnancy is
excluded, effective contraception is necessary,
and women should not be breast feeding.*
Yes
No
Exclusion Criteria
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manifestation of lymphoma outside of the cns*
Yes
No
severe diseases in other organs which would
make performing intensive chemotherapy
impossible; karnofsky index > 50% due to
previous diseases other than pcnsl. karnofsky >
30 will be accepted only due to the pcnsl.*
Yes
No
active infection*
Yes
No
HIV positivity*
Yes
No
previous treatment of pcnsl other than with
corticosteroids, antiepileptics or diuretics*
Yes
No
previous radiotherapy of the brain*
Yes
No
concomitant or previous malignant diseases in
the last 5 years except for an adequately treated
basal cell carcinoma or cervical carcinoma in
situ*
Yes
No
immunosuppression, concomitant
immunosuppressive therapy, or organ
transplantation*
Yes
No
ongoing chemotherapy for another disease*
Yes
No
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Eligibility Central Nervous System Lymphoma NCT00153530
Eligibility Chronic Heart Failure
NCT00151619
Effects of Amlodipine in the Management of Chronic Heart
Failure; ODM derived from:
https://clinicaltrials.gov/show/NCT00151619
All rights reserved. Please visit https://medical-data-
models.org/forms/13964
Eligibility Chronic Heart Failure
NCT00151619
Inclusion Criteria
patients over 18 years*
Yes
No
chronic heart failure with new york heart
association class iii or iv.*
Yes
No
ischemic or dilated cardiopathy known for at least
3 months*
Yes
No
systolic arterial pressure > 110 mmhg under
treatment*
Yes
No
stroke volume between 20 and 40% under
treatment*
Yes
No
informed written consent*
Yes
No
Exclusion Criteria
history of allergy to one of the studied
pharmaceutical classes*
Yes
No
history of  troubles in ventricular rythm
(tachycardia, fibrillation) or acute heart failure*
Yes
No
chronic renal, hepatic or respiratory failure*
Yes
No
diabetes*
Yes
No
valvulopathy*
Yes
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No
myocarditis,constrictive pericarditis*
Yes
No
life prognosis < 6 months due to a non cardiac
pathology*
Yes
No
absence of woman contraception, pregnancy,
breast-feeding*
Yes
No
treatment with calcium channel blockers or
antiarrythmics class ic*
Yes
No
unstable patient under standardized treatment*
Yes
No
unable to do a stress test*
Yes
No
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Eligibility Chronic Heart Failure NCT00151619
Eligibility Chronic Hepatitis C
NCT00146016
Study on Chronic Hepatitis C Treatment With Interferon
Alpha, Ribavirin and Amantadine in Naive Patients; ODM
derived from: https://clinicaltrials.gov/show/NCT00146016
All rights reserved. Please visit https://medical-data-
models.org/forms/13965
Eligibility Chronic Hepatitis C
NCT00146016
Inclusion Criteria
anti-hcv positivity >6 months*
Yes
No
alt and/or ast elevation on at least once in the
previous 6 months*
Yes
No
positive hcv-rna*
Yes
No
liver biopsy within one year before the start of
therapy in non-   cirrhosis. in the case of known
cirrhosis, liver biopsy is not necessary*
Yes
No
intention to be treated and participate treatment*
Yes
No
obtained written informed consent*
Yes
No
Exclusion Criteria
age < 18 years*
Yes
No
pregnancy or intention to get pregnant within the
12 months period of    treatment and up to 6
months after discontinuation of therapy, no
adequate contraception, lactation*
Yes
No
men not practicing or willing to practice
acceptable methods of contraception during the
treatment period and up to 6 months after
discontinuation of therapy*
Yes
No
life expectancy < 1 year*
Yes
No
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child pugh b or c (appendix iii)*
Yes
No
creatinine > 150 μmol/l or > 1.70 mg/dl*
Yes
No
haemoglobulin < 6.5 mmol/l or < 10.5 g/dl*
Yes
No
white blood cell count < 2,5 x 109/l, neutrophil <
1,5 x 109/l*
Yes
No
platelet count < 70 x 109/l*
Yes
No
hiv positivity*
Yes
No
chemotherapy, systematical antiviral treatment
during the 6 months prior to study entry*
Yes
No
other serious disease (e.g. malignancy,
uncontrolled myocardial disease or severe
arrhythmias)*
Yes
No
active uncontrolled psychiatric disorders and
suicidal leanings*
Yes
No
patients with a history of uncontrolled seizure or
other significant cns dysfunction*
Yes
No
any condition which in the opinion of the (co-
)investigator might interfere with the evaluation of
the study objectives*
Yes
No
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Eligibility Chronic Hepatitis C NCT00146016
Eligibility Chronic Lymphocytic Leukemia
NCT00022880
Safety and Efficacy Study of Iodine-131 Anti-B1 Antibody
for Chronic Lymphocytic Leukemia; ODM derived from:
https://clinicaltrials.gov/show/NCT00022880
All rights reserved. Please visit https://medical-data-
models.org/forms/13966
Eligibility Chronic Lymphocytic
Leukemia NCT00022880
Inclusion Criteria
patients must fulfill the criteria for the diagnosis of
intermediate-risk b-cell cll or high-risk b-cell cll*
Yes
No
the bone marrow aspirate must demonstrate that
greater than or equal to 30% of all nucleated cells
are lymphoid.*
Yes
No
patients must have evidence that their leukemic
lymphocytes express the cd20 antigen.*
Yes
No
patients must have been previously treated with
chemotherapy or biologic therapy and have
progressed on, failed to achieve an objective
response (cr or partial response [pr]) on, or
progressed after completion of last therapy.
patients must have received at least one therapy
containing a purine nucleoside analogue. patients
must not have received more than 4 prior
therapies.  this includes both chemotherapy and
biologic therapy.*
Yes
No
patients must have an absolute granulocyte count
>500 cells/mm3 and a platelet count of either
>100,000 cells/mm3 (cohort a) or a platelet count
of 75,000-100,000 cells/mm3 deemed to be
secondary to cll by the investigator, (cohort b)
within 14 days of study entry.  these blood counts
must be sustained for 4 weeks without support of
hematopoietic cytokines or transfusion of blood
products.*
Yes
No
patients must have a karnofsky performance
status of at least 60% and an anticipated survival
of at least 3 months.*
Yes
No
patients must have adequate renal function
(defined as serum creatinine <1.5 x upper limit of
normal [uln]) and hepatic function (defined as
total bilirubin <1.5 x uln and ast <3 x uln) within
14 days of study entry.  for patients with
1 / 3
autoimmune hemolytic anemia, the bilirubin must
be less than or equal to 8 x uln.*
Yes
No
Exclusion Criteria
patients who have received prior therapy with
cytotoxic chemotherapy or immunosuppressants
(with the exception of maintenance prednisone
therapy not to exceed a dose of 20 mg/day for
autoimmune hemolysis only) within four weeks
prior to study entry (6 weeks for nitrosourea
compounds) or who exhibit persistent clinical
evidence of toxicity.  the prednisone must have
been started more than 4 weeks prior to study
entry.*
Yes
No
patients with progressive disease within 1 year of
irradiation arising in a field that has been
previously irradiated with >3500 cgy.*
Yes
No
patients with new york heart association class iii
or iv heart disease or other serious illness that
would preclude evaluation.*
Yes
No
patients with active obstructive hydronephrosis.*
Yes
No
patients with prior malignancy other than cll,
except for adequately treated skin cancer, in situ
cervical cancer, or other cancer for which the
patient has been disease-free for 5 years.
patients who have been disease-free of another
cancer for greater than 5 years must be carefully
assessed at the time of study entry to rule out
recurrent disease.*
Yes
No
patients with known hiv infection.*
Yes
No
patients who are pregnant or nursing.  patients of
childbearing potential must undergo a serum
pregnancy test within 7 days prior to study entry.
males and females must agree to use a
contraceptive method from enrollment to 6
months after receiving iodine-131 anti-b1
antibody.*
Yes
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No
patients who are concurrently receiving either
approved or non-approved (through another
protocol) anti-cancer drugs or biologics.*
Yes
No
patients with evidence of active infection requiring
intravenous treatment with anti-infectives.*
Yes
No
patients known to be hama positive.*
Yes
No
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Eligibility Chronic Lymphocytic Leukemia NCT00022880
Eligibility Congestive Heart Failure (CHF)
NCT00211874
Improving Heart Failure Care in Minority Communities;
ODM derived from:
https://clinicaltrials.gov/show/NCT00211874
All rights reserved. Please visit https://medical-data-
models.org/forms/13967
Eligibility Congestive Heart Failure
(CHF) NCT00211874
Inclusion Criteria
• adults >18 years,*
Yes
No
systolic dysfunction documented on a cardiac
test (echocardiography, radionuclide
ventriculography, myocardial stress
sestamibi/thallium testing, or left-heart
catherization),*
Yes
No
english- or spanish-speaking,*
Yes
No
community-dwelling at enrollment, and*
Yes
No
current patient in a general medicine, geriatrics,
or cardiology clinic or office at a participating
site.*
Yes
No
Exclusion Criteria
• medical conditions that prevented a patient’s
interacting with the nurse, including blindness,
deafness, and cognitive impairment;*
Yes
No
medical conditions that required individualized
management that might differ from standard
protocol, namely pregnancy, renal dialysis, and
terminal illness; and*
Yes
No
procedures that corrected systolic dysfunction,
such as heart transplantation.*
Yes
No
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Eligibility ALK-Rearranged Non-Small Cell
Lung Cancer NCT01588028
A Clinical Study Testing The Safety and Efficacy of
CH5424802/RO5424802 in Patients With ALK Positive
Non-Small Cell Lung Cancer; ODM derived from:
https://clinicaltrials.gov/show/NCT01588028
All rights reserved. Please visit https://medical-data-
models.org/forms/13968
Eligibility ALK-Rearranged Non-
Small Cell Lung Cancer
NCT01588028
Inclusion Criteria
performance status: ecog 0-2*
Yes
No
non-small cell lung cancer proven by histology*
Yes
No
non-small cell lung cancer proven by histology*
Yes
No
measurable disease*
Yes
No
Hepatic function*
Exclusion Criteria
Therapy*
Brain metastases*
History of cardiac disease: congestive heart
failure >NYHA class 2. Active CAD (MI more than
6 mo prior to study entry is allowed). Cardiac
arrythmias requiring anti-arrythmic therapy (beta
blockers or digoxin are permitted) or uncontrolled
hypertension*
Yes
No
16. gastrointestinal disorders or abnormalities
that would interfere with absorption of the study
drug*
Yes
No
pregnancy*
Yes
No
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Eligibility All Multiple Sclerosis Patients
NCT00220506
Fatigue Treatment Using Provigil; ODM derived from:
https://clinicaltrials.gov/show/NCT00220506
All rights reserved. Please visit https://medical-data-
models.org/forms/13969
Eligibility All Multiple Sclerosis
Patients NCT00220506
Inclusion Criteria
Multiple Sclerosis*
EDSS score from 0 to 5.5, inclusive*
Yes
No
positive fatigue impact scale 40 points or more.*
Yes
No
Age*
>= 18
<= 55
years
Patient is willing and able to comply to study
protocol*
Yes
No
Written informed consent*
Yes
No
Women of childbearing potential*
Yes
No
Exclusion Criteria
Patient is willing and able to comply to study
protocol*
Yes
No
Recurrent Disease*
systemic steroid therapy within 30 days*
Yes
No
known hypersensitivity or intolerance, to provigil
or related substances or to any component of the
formulation.*
Yes
No
patients, who have a risk professional with
symptomatic sleep apnea*
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Yes
No
known to suffer from narcolepsy or another
significant sleep disorder.*
Yes
No
Subject Participation Status in Clinical Study*
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Eligibility All Multiple Sclerosis Patients NCT00220506
Visit 3 (6 Months) Ponderosa CML
ZKSJ0083
Study part: Visit 3 (6 Months).Observational study on CML
patients in any phase treated with ponatinib (Iclusig®) at
any dose. Principal Investigator Prof. Dr. A. Hochhaus.
All rights reserved. Please visit https://medical-data-
models.org/forms/13970
Visit 3 (6 Months)
Patient status
Date of visit
Patient died?
Yes
No
Blood pressure
Blood pressure measurement carried out?
Yes
No
Systolic Blood Pressure
mmHg
Diastolic Blood Pressure
mmHg
Laboratory parameters
Urea
Normal (1)
Grade of deviation 1 according to
CTCAE (2)
Grade of deviation 2 according to
CTCAE (3)
Grade of deviation 3 according to
CTCAE (4)
Grade of deviation 4 according to
CTCAE (5)
not analyzed (5)
Creatinine
Normal (1)
Grade of deviation 1 according to
CTCAE (2)
Grade of deviation 2 according to
CTCAE (3)
Grade of deviation 3 according to
CTCAE (4)
Grade of deviation 4 according to
CTCAE (5)
not analyzed (5)
Uric acid
Normal (1)
Grade of deviation 1 according to
CTCAE (2)
Grade of deviation 2 according to
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CTCAE (3)
Grade of deviation 3 according to
CTCAE (4)
Grade of deviation 4 according to
CTCAE (5)
not analyzed (5)
Total Bilirubin
Normal (1)
Grade of deviation 1 according to
CTCAE (2)
Grade of deviation 2 according to
CTCAE (3)
Grade of deviation 3 according to
CTCAE (4)
Grade of deviation 4 according to
CTCAE (5)
not analyzed (5)
Bilirubin, direct
Normal (1)
Grade of deviation 1 according to
CTCAE (2)
Grade of deviation 2 according to
CTCAE (3)
Grade of deviation 3 according to
CTCAE (4)
Grade of deviation 4 according to
CTCAE (5)
not analyzed (5)
Glucose
Normal (1)
Grade of deviation 1 according to
CTCAE (2)
Grade of deviation 2 according to
CTCAE (3)
Grade of deviation 3 according to
CTCAE (4)
Grade of deviation 4 according to
CTCAE (5)
not analyzed (5)
Total protein
Normal (1)
Grade of deviation 1 according to
CTCAE (2)
Grade of deviation 2 according to
CTCAE (3)
Grade of deviation 3 according to
CTCAE (4)
Grade of deviation 4 according to
CTCAE (5)
not analyzed (5)
Albumin
Normal (1)
Grade of deviation 1 according to
CTCAE (2)
Grade of deviation 2 according to
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Visit 3 (6 Months) Ponderosa CML ZKSJ0083
CTCAE (3)
Grade of deviation 3 according to
CTCAE (4)
Grade of deviation 4 according to
CTCAE (5)
not analyzed (5)
ASAT (AST, GOT)
Normal (1)
Grade of deviation 1 according to
CTCAE (2)
Grade of deviation 2 according to
CTCAE (3)
Grade of deviation 3 according to
CTCAE (4)
Grade of deviation 4 according to
CTCAE (5)
not analyzed (5)
ALAT (ALT, GPT)
Normal (1)
Grade of deviation 1 according to
CTCAE (2)
Grade of deviation 2 according to
CTCAE (3)
Grade of deviation 3 according to
CTCAE (4)
Grade of deviation 4 according to
CTCAE (5)
not analyzed (5)
Gamma-GT
Normal (1)
Grade of deviation 1 according to
CTCAE (2)
Grade of deviation 2 according to
CTCAE (3)
Grade of deviation 3 according to
CTCAE (4)
Grade of deviation 4 according to
CTCAE (5)
not analyzed (5)
Alkaline phosphatase
Normal (1)
Grade of deviation 1 according to
CTCAE (2)
Grade of deviation 2 according to
CTCAE (3)
Grade of deviation 3 according to
CTCAE (4)
Grade of deviation 4 according to
CTCAE (5)
not analyzed (5)
Cholesterol
Normal (1)
Grade of deviation 1 according to
CTCAE (2)
Grade of deviation 2 according to
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Visit 3 (6 Months) Ponderosa CML ZKSJ0083
CTCAE (3)
Grade of deviation 3 according to
CTCAE (4)
Grade of deviation 4 according to
CTCAE (5)
not analyzed (5)
Triglycerides
Normal (1)
Grade of deviation 1 according to
CTCAE (2)
Grade of deviation 2 according to
CTCAE (3)
Grade of deviation 3 according to
CTCAE (4)
Grade of deviation 4 according to
CTCAE (5)
not analyzed (5)
Amylase
Normal (1)
Grade of deviation 1 according to
CTCAE (2)
Grade of deviation 2 according to
CTCAE (3)
Grade of deviation 3 according to
CTCAE (4)
Grade of deviation 4 according to
CTCAE (5)
not analyzed (5)
Lipase
Normal (1)
Grade of deviation 1 according to
CTCAE (2)
Grade of deviation 2 according to
CTCAE (3)
Grade of deviation 3 according to
CTCAE (4)
Grade of deviation 4 according to
CTCAE (5)
not analyzed (5)
Leukocytes
x10^3 /µl
Erythrocytes
x10^6 /µl
Hemoglobin
g/dl
Hematocrit
%
Erythrocyte Mean Corpuscular Volume, MCV
fl
4 / 7
Visit 3 (6 Months) Ponderosa CML ZKSJ0083
Mean Corpuscular Hemoglobin, MCH
pg
Mean corpuscular hemoglobin concentration
MCHC
g/dl
Platelets
x10^3 /µl
Ponatinib treatment
Was the treatment interrupted or ended?
yes (1)
no (2)
interrupted (3)
ended (4)
Treatment Begin Date
Treatment End Date
Reason
Were there any dosage changes?
Yes
No
Start date of dosage change
Dosage
Reason of dosage change
Response
Hematologic findings known?
Yes
No
Date of hematologic test
Hematologic test
CHR (1)
no CHR (2)
BCR-ABL Mutation
T315I  (1)
Other (2)
5 / 7
Visit 3 (6 Months) Ponderosa CML ZKSJ0083
Please mention if other:
Cytogenetic Analysis carried out?
Yes
No
Date of Cytogenetic Analysis
Laboratory of Cytogenetic Analysis
Evaluated mitosis
Normal karyotype
Philadelphia negative, with additional aberrations
Philadelphia Chromosome t(9;22)
Philadelphia Chromosome with additional
aberrations
Not evaluable mitoses
Cytogenetic response
no response (1)
CyR (2)
partial (PCyR)  (3)
complete (CcyR) (4)
complete (CcyR) (4)
not determined (5)
Bone marrow biopsy performed?
yes (1)
no (2)
unknown (3)
Date of bone marrow biopsy
Bone marrow biopsy findings
Chronic phase (1)
Accelerated phase (2)
Blast crisis (3)
Other (4)
If other, please mention:
Molecular Analysis known?
Yes
No
Date of Molecular Analysis
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Visit 3 (6 Months) Ponderosa CML ZKSJ0083
Laboratory of Molecular Analysis
BCR-ABL International Scale
%
Polymerase Chain Reaction, PCR
no MMR (1)
MMR (2)
MR4 (3)
MR4.5 (4)
MR5 (5)
CMR (6)
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Visit 3 (6 Months) Ponderosa CML ZKSJ0083
Visit 4 (9 Months) Ponderosa CML
ZKSJ0083
Study part: Visit 4 (9 Months).Observational study on CML
patients in any phase treated with ponatinib (Iclusig®) at
any dose. Principal Investigator Prof. Dr. A. Hochhaus.
All rights reserved. Please visit https://medical-data-
models.org/forms/13971
Visit 4 (9 Months)
Patient status
Date of visit
Patient died?
Yes
No
Blood pressure
Blood pressure measurement carried out?
Yes
No
Systolic Blood Pressure
mmHg
Diastolic Blood Pressure
mmHg
Laboratory parameters
Urea
Normal (1)
Grade of deviation 1 according to
CTCAE (2)
Grade of deviation 2 according to
CTCAE (3)
Grade of deviation 3 according to
CTCAE (4)
Grade of deviation 4 according to
CTCAE (5)
not analyzed (5)
Creatinine
Normal (1)
Grade of deviation 1 according to
CTCAE (2)
Grade of deviation 2 according to
CTCAE (3)
Grade of deviation 3 according to
CTCAE (4)
Grade of deviation 4 according to
CTCAE (5)
not analyzed (5)
Uric acid
Normal (1)
Grade of deviation 1 according to
CTCAE (2)
Grade of deviation 2 according to
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CTCAE (3)
Grade of deviation 3 according to
CTCAE (4)
Grade of deviation 4 according to
CTCAE (5)
not analyzed (5)
Total Bilirubin
Normal (1)
Grade of deviation 1 according to
CTCAE (2)
Grade of deviation 2 according to
CTCAE (3)
Grade of deviation 3 according to
CTCAE (4)
Grade of deviation 4 according to
CTCAE (5)
not analyzed (5)
Bilirubin, direct
Normal (1)
Grade of deviation 1 according to
CTCAE (2)
Grade of deviation 2 according to
CTCAE (3)
Grade of deviation 3 according to
CTCAE (4)
Grade of deviation 4 according to
CTCAE (5)
not analyzed (5)
Glucose
Normal (1)
Grade of deviation 1 according to
CTCAE (2)
Grade of deviation 2 according to
CTCAE (3)
Grade of deviation 3 according to
CTCAE (4)
Grade of deviation 4 according to
CTCAE (5)
not analyzed (5)
Total protein
Normal (1)
Grade of deviation 1 according to
CTCAE (2)
Grade of deviation 2 according to
CTCAE (3)
Grade of deviation 3 according to
CTCAE (4)
Grade of deviation 4 according to
CTCAE (5)
not analyzed (5)
Albumin
Normal (1)
Grade of deviation 1 according to
CTCAE (2)
Grade of deviation 2 according to
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CTCAE (3)
Grade of deviation 3 according to
CTCAE (4)
Grade of deviation 4 according to
CTCAE (5)
not analyzed (5)
ASAT (AST, GOT)
Normal (1)
Grade of deviation 1 according to
CTCAE (2)
Grade of deviation 2 according to
CTCAE (3)
Grade of deviation 3 according to
CTCAE (4)
Grade of deviation 4 according to
CTCAE (5)
not analyzed (5)
ALAT (ALT, GPT)
Normal (1)
Grade of deviation 1 according to
CTCAE (2)
Grade of deviation 2 according to
CTCAE (3)
Grade of deviation 3 according to
CTCAE (4)
Grade of deviation 4 according to
CTCAE (5)
not analyzed (5)
Gamma-GT
Normal (1)
Grade of deviation 1 according to
CTCAE (2)
Grade of deviation 2 according to
CTCAE (3)
Grade of deviation 3 according to
CTCAE (4)
Grade of deviation 4 according to
CTCAE (5)
not analyzed (5)
Alkaline phosphatase
Normal (1)
Grade of deviation 1 according to
CTCAE (2)
Grade of deviation 2 according to
CTCAE (3)
Grade of deviation 3 according to
CTCAE (4)
Grade of deviation 4 according to
CTCAE (5)
not analyzed (5)
Cholesterol
Normal (1)
Grade of deviation 1 according to
CTCAE (2)
Grade of deviation 2 according to
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Visit 4 (9 Months) Ponderosa CML ZKSJ0083
CTCAE (3)
Grade of deviation 3 according to
CTCAE (4)
Grade of deviation 4 according to
CTCAE (5)
not analyzed (5)
Triglycerides
Normal (1)
Grade of deviation 1 according to
CTCAE (2)
Grade of deviation 2 according to
CTCAE (3)
Grade of deviation 3 according to
CTCAE (4)
Grade of deviation 4 according to
CTCAE (5)
not analyzed (5)
Amylase
Normal (1)
Grade of deviation 1 according to
CTCAE (2)
Grade of deviation 2 according to
CTCAE (3)
Grade of deviation 3 according to
CTCAE (4)
Grade of deviation 4 according to
CTCAE (5)
not analyzed (5)
Lipase
Normal (1)
Grade of deviation 1 according to
CTCAE (2)
Grade of deviation 2 according to
CTCAE (3)
Grade of deviation 3 according to
CTCAE (4)
Grade of deviation 4 according to
CTCAE (5)
not analyzed (5)
Leukocytes
x10^3 /µl
Erythrocytes
x10^6 /µl
Hemoglobin
g/dl
Hematocrit
%
Erythrocyte Mean Corpuscular Volume, MCV
fl
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Visit 4 (9 Months) Ponderosa CML ZKSJ0083
Mean Corpuscular Hemoglobin, MCH
pg
Mean corpuscular hemoglobin concentration
MCHC
g/dl
Platelets
x10^3 /µl
Ponatinib treatment
Was the treatment interrupted or ended?
yes (1)
no (2)
interrupted (3)
ended (4)
Treatment Begin Date
Treatment End Date
Reason
Were there any dosage changes?
Yes
No
Start date of dosage change
Dosage
Reason of dosage change
Response
Hematologic findings known?
Yes
No
Date of hematologic test
Hematologic test
CHR (1)
no CHR (2)
BCR-ABL Mutation
T315I  (1)
Other (2)
5 / 7
Visit 4 (9 Months) Ponderosa CML ZKSJ0083
Please mention if other:
Cytogenetic Analysis carried out?
Yes
No
Date of Cytogenetic Analysis
Laboratory of Cytogenetic Analysis
Evaluated mitosis
Normal karyotype
Philadelphia negative, with additional aberrations
Philadelphia Chromosome t(9;22)
Philadelphia Chromosome with additional
aberrations
Not evaluable mitoses
Cytogenetic response
no response (1)
CyR (2)
partial (PCyR)  (3)
complete (CcyR) (4)
complete (CcyR) (4)
not determined (5)
Bone marrow biopsy performed?
yes (1)
no (2)
unknown (3)
Date of bone marrow biopsy
Bone marrow biopsy findings
Chronic phase (1)
Accelerated phase (2)
Blast crisis (3)
Other (4)
If other, please mention:
Molecular Analysis known?
Yes
No
Date of Molecular Analysis
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Visit 4 (9 Months) Ponderosa CML ZKSJ0083
Laboratory of Molecular Analysis
BCR-ABL International Scale
%
Polymerase Chain Reaction, PCR
no MMR (1)
MMR (2)
MR4 (3)
MR4.5 (4)
MR5 (5)
CMR (6)
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Visit 4 (9 Months) Ponderosa CML ZKSJ0083
Visit 5 (12 Months) Ponderosa CML
ZKSJ0083
Study part: Visit 5 (12 Months).Observational study on CML
patients in any phase treated with ponatinib (Iclusig®) at
any dose. Principal Investigator Prof. Dr. A. Hochhaus.
All rights reserved. Please visit https://medical-data-
models.org/forms/13972
Visit 5 (12 Months)
Patient status
Date of visit
Patient died?
Yes
No
Blood pressure
Blood pressure measurement carried out?
Yes
No
Systolic Blood Pressure
mmHg
Diastolic Blood Pressure
mmHg
Laboratory parameters
Urea
Normal (1)
Grade of deviation 1 according to
CTCAE (2)
Grade of deviation 2 according to
CTCAE (3)
Grade of deviation 3 according to
CTCAE (4)
Grade of deviation 4 according to
CTCAE (5)
not analyzed (5)
Creatinine
Normal (1)
Grade of deviation 1 according to
CTCAE (2)
Grade of deviation 2 according to
CTCAE (3)
Grade of deviation 3 according to
CTCAE (4)
Grade of deviation 4 according to
CTCAE (5)
not analyzed (5)
Uric acid
Normal (1)
Grade of deviation 1 according to
CTCAE (2)
Grade of deviation 2 according to
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CTCAE (3)
Grade of deviation 3 according to
CTCAE (4)
Grade of deviation 4 according to
CTCAE (5)
not analyzed (5)
Total Bilirubin
Normal (1)
Grade of deviation 1 according to
CTCAE (2)
Grade of deviation 2 according to
CTCAE (3)
Grade of deviation 3 according to
CTCAE (4)
Grade of deviation 4 according to
CTCAE (5)
not analyzed (5)
Bilirubin, direct
Normal (1)
Grade of deviation 1 according to
CTCAE (2)
Grade of deviation 2 according to
CTCAE (3)
Grade of deviation 3 according to
CTCAE (4)
Grade of deviation 4 according to
CTCAE (5)
not analyzed (5)
Glucose
Normal (1)
Grade of deviation 1 according to
CTCAE (2)
Grade of deviation 2 according to
CTCAE (3)
Grade of deviation 3 according to
CTCAE (4)
Grade of deviation 4 according to
CTCAE (5)
not analyzed (5)
Total protein
Normal (1)
Grade of deviation 1 according to
CTCAE (2)
Grade of deviation 2 according to
CTCAE (3)
Grade of deviation 3 according to
CTCAE (4)
Grade of deviation 4 according to
CTCAE (5)
not analyzed (5)
Albumin
Normal (1)
Grade of deviation 1 according to
CTCAE (2)
Grade of deviation 2 according to
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Visit 5 (12 Months) Ponderosa CML ZKSJ0083
CTCAE (3)
Grade of deviation 3 according to
CTCAE (4)
Grade of deviation 4 according to
CTCAE (5)
not analyzed (5)
ASAT (AST, GOT)
Normal (1)
Grade of deviation 1 according to
CTCAE (2)
Grade of deviation 2 according to
CTCAE (3)
Grade of deviation 3 according to
CTCAE (4)
Grade of deviation 4 according to
CTCAE (5)
not analyzed (5)
ALAT (ALT, GPT)
Normal (1)
Grade of deviation 1 according to
CTCAE (2)
Grade of deviation 2 according to
CTCAE (3)
Grade of deviation 3 according to
CTCAE (4)
Grade of deviation 4 according to
CTCAE (5)
not analyzed (5)
Gamma-GT
Normal (1)
Grade of deviation 1 according to
CTCAE (2)
Grade of deviation 2 according to
CTCAE (3)
Grade of deviation 3 according to
CTCAE (4)
Grade of deviation 4 according to
CTCAE (5)
not analyzed (5)
Alkaline phosphatase
Normal (1)
Grade of deviation 1 according to
CTCAE (2)
Grade of deviation 2 according to
CTCAE (3)
Grade of deviation 3 according to
CTCAE (4)
Grade of deviation 4 according to
CTCAE (5)
not analyzed (5)
Cholesterol
Normal (1)
Grade of deviation 1 according to
CTCAE (2)
Grade of deviation 2 according to
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Visit 5 (12 Months) Ponderosa CML ZKSJ0083
CTCAE (3)
Grade of deviation 3 according to
CTCAE (4)
Grade of deviation 4 according to
CTCAE (5)
not analyzed (5)
Triglycerides
Normal (1)
Grade of deviation 1 according to
CTCAE (2)
Grade of deviation 2 according to
CTCAE (3)
Grade of deviation 3 according to
CTCAE (4)
Grade of deviation 4 according to
CTCAE (5)
not analyzed (5)
Amylase
Normal (1)
Grade of deviation 1 according to
CTCAE (2)
Grade of deviation 2 according to
CTCAE (3)
Grade of deviation 3 according to
CTCAE (4)
Grade of deviation 4 according to
CTCAE (5)
not analyzed (5)
Lipase
Normal (1)
Grade of deviation 1 according to
CTCAE (2)
Grade of deviation 2 according to
CTCAE (3)
Grade of deviation 3 according to
CTCAE (4)
Grade of deviation 4 according to
CTCAE (5)
not analyzed (5)
Leukocytes
x10^3 /µl
Erythrocytes
x10^6 /µl
Hemoglobin
g/dl
Hematocrit
%
Erythrocyte Mean Corpuscular Volume, MCV
fl
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Visit 5 (12 Months) Ponderosa CML ZKSJ0083
Mean Corpuscular Hemoglobin, MCH
pg
Mean corpuscular hemoglobin concentration
MCHC
g/dl
Platelets
x10^3 /µl
Ponatinib treatment
Was the treatment interrupted or ended?
yes (1)
no (2)
interrupted (3)
ended (4)
Treatment Begin Date
Treatment End Date
Reason
Were there any dosage changes?
Yes
No
Start date of dosage change
Dosage
Reason of dosage change
Response
Hematologic findings known?
Yes
No
Date of hematologic test
Hematologic test
CHR (1)
no CHR (2)
BCR-ABL Mutation
T315I  (1)
Other (2)
5 / 7
Visit 5 (12 Months) Ponderosa CML ZKSJ0083
Please mention if other:
Cytogenetic Analysis carried out?
Yes
No
Date of Cytogenetic Analysis
Laboratory of Cytogenetic Analysis
Evaluated mitosis
Normal karyotype
Philadelphia negative, with additional aberrations
Philadelphia Chromosome t(9;22)
Philadelphia Chromosome with additional
aberrations
Not evaluable mitoses
Cytogenetic response
no response (1)
CyR (2)
partial (PCyR)  (3)
complete (CcyR) (4)
complete (CcyR) (4)
not determined (5)
Bone marrow biopsy performed?
yes (1)
no (2)
unknown (3)
Date of bone marrow biopsy
Bone marrow biopsy findings
Chronic phase (1)
Accelerated phase (2)
Blast crisis (3)
Other (4)
If other, please mention:
Molecular Analysis known?
Yes
No
Date of Molecular Analysis
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Visit 5 (12 Months) Ponderosa CML ZKSJ0083
Laboratory of Molecular Analysis
BCR-ABL International Scale
%
Polymerase Chain Reaction, PCR
no MMR (1)
MMR (2)
MR4 (3)
MR4.5 (4)
MR5 (5)
CMR (6)
7 / 7
Visit 5 (12 Months) Ponderosa CML ZKSJ0083
Visit 6 (15 Months) Ponderosa CML
ZKSJ0083
Study part: Visit 6 (15 Months).Observational study on CML
patients in any phase treated with ponatinib (Iclusig®) at
any dose. Principal Investigator Prof. Dr. A. Hochhaus.
All rights reserved. Please visit https://medical-data-
models.org/forms/13973
Visit 6 (15 Months)
Patient status
Date of visit
Patient died?
Yes
No
Blood pressure
Blood pressure measurement carried out?
Yes
No
Systolic Blood Pressure
mmHg
Diastolic Blood Pressure
mmHg
Laboratory parameters
Urea
Normal (1)
Grade of deviation 1 according to
CTCAE (2)
Grade of deviation 2 according to
CTCAE (3)
Grade of deviation 3 according to
CTCAE (4)
Grade of deviation 4 according to
CTCAE (5)
not analyzed (5)
Creatinine
Normal (1)
Grade of deviation 1 according to
CTCAE (2)
Grade of deviation 2 according to
CTCAE (3)
Grade of deviation 3 according to
CTCAE (4)
Grade of deviation 4 according to
CTCAE (5)
not analyzed (5)
Uric acid
Normal (1)
Grade of deviation 1 according to
CTCAE (2)
Grade of deviation 2 according to
1 / 7
CTCAE (3)
Grade of deviation 3 according to
CTCAE (4)
Grade of deviation 4 according to
CTCAE (5)
not analyzed (5)
Total Bilirubin
Normal (1)
Grade of deviation 1 according to
CTCAE (2)
Grade of deviation 2 according to
CTCAE (3)
Grade of deviation 3 according to
CTCAE (4)
Grade of deviation 4 according to
CTCAE (5)
not analyzed (5)
Bilirubin, direct
Normal (1)
Grade of deviation 1 according to
CTCAE (2)
Grade of deviation 2 according to
CTCAE (3)
Grade of deviation 3 according to
CTCAE (4)
Grade of deviation 4 according to
CTCAE (5)
not analyzed (5)
Glucose
Normal (1)
Grade of deviation 1 according to
CTCAE (2)
Grade of deviation 2 according to
CTCAE (3)
Grade of deviation 3 according to
CTCAE (4)
Grade of deviation 4 according to
CTCAE (5)
not analyzed (5)
Total protein
Normal (1)
Grade of deviation 1 according to
CTCAE (2)
Grade of deviation 2 according to
CTCAE (3)
Grade of deviation 3 according to
CTCAE (4)
Grade of deviation 4 according to
CTCAE (5)
not analyzed (5)
Albumin
Normal (1)
Grade of deviation 1 according to
CTCAE (2)
Grade of deviation 2 according to
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Visit 6 (15 Months) Ponderosa CML ZKSJ0083
CTCAE (3)
Grade of deviation 3 according to
CTCAE (4)
Grade of deviation 4 according to
CTCAE (5)
not analyzed (5)
ASAT (AST, GOT)
Normal (1)
Grade of deviation 1 according to
CTCAE (2)
Grade of deviation 2 according to
CTCAE (3)
Grade of deviation 3 according to
CTCAE (4)
Grade of deviation 4 according to
CTCAE (5)
not analyzed (5)
ALAT (ALT, GPT)
Normal (1)
Grade of deviation 1 according to
CTCAE (2)
Grade of deviation 2 according to
CTCAE (3)
Grade of deviation 3 according to
CTCAE (4)
Grade of deviation 4 according to
CTCAE (5)
not analyzed (5)
Gamma-GT
Normal (1)
Grade of deviation 1 according to
CTCAE (2)
Grade of deviation 2 according to
CTCAE (3)
Grade of deviation 3 according to
CTCAE (4)
Grade of deviation 4 according to
CTCAE (5)
not analyzed (5)
Alkaline phosphatase
Normal (1)
Grade of deviation 1 according to
CTCAE (2)
Grade of deviation 2 according to
CTCAE (3)
Grade of deviation 3 according to
CTCAE (4)
Grade of deviation 4 according to
CTCAE (5)
not analyzed (5)
Cholesterol
Normal (1)
Grade of deviation 1 according to
CTCAE (2)
Grade of deviation 2 according to
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Visit 6 (15 Months) Ponderosa CML ZKSJ0083
CTCAE (3)
Grade of deviation 3 according to
CTCAE (4)
Grade of deviation 4 according to
CTCAE (5)
not analyzed (5)
Triglycerides
Normal (1)
Grade of deviation 1 according to
CTCAE (2)
Grade of deviation 2 according to
CTCAE (3)
Grade of deviation 3 according to
CTCAE (4)
Grade of deviation 4 according to
CTCAE (5)
not analyzed (5)
Amylase
Normal (1)
Grade of deviation 1 according to
CTCAE (2)
Grade of deviation 2 according to
CTCAE (3)
Grade of deviation 3 according to
CTCAE (4)
Grade of deviation 4 according to
CTCAE (5)
not analyzed (5)
Lipase
Normal (1)
Grade of deviation 1 according to
CTCAE (2)
Grade of deviation 2 according to
CTCAE (3)
Grade of deviation 3 according to
CTCAE (4)
Grade of deviation 4 according to
CTCAE (5)
not analyzed (5)
Leukocytes
x10^3 /µl
Erythrocytes
x10^6 /µl
Hemoglobin
g/dl
Hematocrit
%
Erythrocyte Mean Corpuscular Volume, MCV
fl
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Visit 6 (15 Months) Ponderosa CML ZKSJ0083
Mean Corpuscular Hemoglobin, MCH
pg
Mean corpuscular hemoglobin concentration
MCHC
g/dl
Platelets
x10^3 /µl
Ponatinib treatment
Was the treatment interrupted or ended?
yes (1)
no (2)
interrupted (3)
ended (4)
Treatment Begin Date
Treatment End Date
Reason
Were there any dosage changes?
Yes
No
Start date of dosage change
Dosage
Reason of dosage change
Response
Hematologic findings known?
Yes
No
Date of hematologic test
Hematologic test
CHR (1)
no CHR (2)
BCR-ABL Mutation
T315I  (1)
Other (2)
5 / 7
Visit 6 (15 Months) Ponderosa CML ZKSJ0083
Please mention if other:
Cytogenetic Analysis carried out?
Yes
No
Date of Cytogenetic Analysis
Laboratory of Cytogenetic Analysis
Evaluated mitosis
Normal karyotype
Philadelphia negative, with additional aberrations
Philadelphia Chromosome t(9;22)
Philadelphia Chromosome with additional
aberrations
Not evaluable mitoses
Cytogenetic response
no response (1)
CyR (2)
partial (PCyR)  (3)
complete (CcyR) (4)
complete (CcyR) (4)
not determined (5)
Bone marrow biopsy performed?
yes (1)
no (2)
unknown (3)
Date of bone marrow biopsy
Bone marrow biopsy findings
Chronic phase (1)
Accelerated phase (2)
Blast crisis (3)
Other (4)
If other, please mention:
Molecular Analysis known?
Yes
No
Date of Molecular Analysis
6 / 7
Visit 6 (15 Months) Ponderosa CML ZKSJ0083
Laboratory of Molecular Analysis
BCR-ABL International Scale
%
Polymerase Chain Reaction, PCR
no MMR (1)
MMR (2)
MR4 (3)
MR4.5 (4)
MR5 (5)
CMR (6)
7 / 7
Visit 6 (15 Months) Ponderosa CML ZKSJ0083
Visit 7 (18 Months) Ponderosa CML
ZKSJ0083
Study part: Visit 7 (18 Months).Observational study on CML
patients in any phase treated with ponatinib (Iclusig®) at
any dose. Principal Investigator Prof. Dr. A. Hochhaus.
All rights reserved. Please visit https://medical-data-
models.org/forms/13974
Visit 7 (18 Months)
Patient status
Date of visit
Patient died?
Yes
No
Blood pressure
Blood pressure measurement carried out?
Yes
No
Systolic Blood Pressure
mmHg
Diastolic Blood Pressure
mmHg
Laboratory parameters
Urea
Normal (1)
Grade of deviation 1 according to
CTCAE (2)
Grade of deviation 2 according to
CTCAE (3)
Grade of deviation 3 according to
CTCAE (4)
Grade of deviation 4 according to
CTCAE (5)
not analyzed (5)
Creatinine
Normal (1)
Grade of deviation 1 according to
CTCAE (2)
Grade of deviation 2 according to
CTCAE (3)
Grade of deviation 3 according to
CTCAE (4)
Grade of deviation 4 according to
CTCAE (5)
not analyzed (5)
Uric acid
Normal (1)
Grade of deviation 1 according to
CTCAE (2)
Grade of deviation 2 according to
1 / 7
CTCAE (3)
Grade of deviation 3 according to
CTCAE (4)
Grade of deviation 4 according to
CTCAE (5)
not analyzed (5)
Total Bilirubin
Normal (1)
Grade of deviation 1 according to
CTCAE (2)
Grade of deviation 2 according to
CTCAE (3)
Grade of deviation 3 according to
CTCAE (4)
Grade of deviation 4 according to
CTCAE (5)
not analyzed (5)
Bilirubin, direct
Normal (1)
Grade of deviation 1 according to
CTCAE (2)
Grade of deviation 2 according to
CTCAE (3)
Grade of deviation 3 according to
CTCAE (4)
Grade of deviation 4 according to
CTCAE (5)
not analyzed (5)
Glucose
Normal (1)
Grade of deviation 1 according to
CTCAE (2)
Grade of deviation 2 according to
CTCAE (3)
Grade of deviation 3 according to
CTCAE (4)
Grade of deviation 4 according to
CTCAE (5)
not analyzed (5)
Total protein
Normal (1)
Grade of deviation 1 according to
CTCAE (2)
Grade of deviation 2 according to
CTCAE (3)
Grade of deviation 3 according to
CTCAE (4)
Grade of deviation 4 according to
CTCAE (5)
not analyzed (5)
Albumin
Normal (1)
Grade of deviation 1 according to
CTCAE (2)
Grade of deviation 2 according to
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Visit 7 (18 Months) Ponderosa CML ZKSJ0083
CTCAE (3)
Grade of deviation 3 according to
CTCAE (4)
Grade of deviation 4 according to
CTCAE (5)
not analyzed (5)
ASAT (AST, GOT)
Normal (1)
Grade of deviation 1 according to
CTCAE (2)
Grade of deviation 2 according to
CTCAE (3)
Grade of deviation 3 according to
CTCAE (4)
Grade of deviation 4 according to
CTCAE (5)
not analyzed (5)
ALAT (ALT, GPT)
Normal (1)
Grade of deviation 1 according to
CTCAE (2)
Grade of deviation 2 according to
CTCAE (3)
Grade of deviation 3 according to
CTCAE (4)
Grade of deviation 4 according to
CTCAE (5)
not analyzed (5)
Gamma-GT
Normal (1)
Grade of deviation 1 according to
CTCAE (2)
Grade of deviation 2 according to
CTCAE (3)
Grade of deviation 3 according to
CTCAE (4)
Grade of deviation 4 according to
CTCAE (5)
not analyzed (5)
Alkaline phosphatase
Normal (1)
Grade of deviation 1 according to
CTCAE (2)
Grade of deviation 2 according to
CTCAE (3)
Grade of deviation 3 according to
CTCAE (4)
Grade of deviation 4 according to
CTCAE (5)
not analyzed (5)
Cholesterol
Normal (1)
Grade of deviation 1 according to
CTCAE (2)
Grade of deviation 2 according to
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Visit 7 (18 Months) Ponderosa CML ZKSJ0083
CTCAE (3)
Grade of deviation 3 according to
CTCAE (4)
Grade of deviation 4 according to
CTCAE (5)
not analyzed (5)
Triglycerides
Normal (1)
Grade of deviation 1 according to
CTCAE (2)
Grade of deviation 2 according to
CTCAE (3)
Grade of deviation 3 according to
CTCAE (4)
Grade of deviation 4 according to
CTCAE (5)
not analyzed (5)
Amylase
Normal (1)
Grade of deviation 1 according to
CTCAE (2)
Grade of deviation 2 according to
CTCAE (3)
Grade of deviation 3 according to
CTCAE (4)
Grade of deviation 4 according to
CTCAE (5)
not analyzed (5)
Lipase
Normal (1)
Grade of deviation 1 according to
CTCAE (2)
Grade of deviation 2 according to
CTCAE (3)
Grade of deviation 3 according to
CTCAE (4)
Grade of deviation 4 according to
CTCAE (5)
not analyzed (5)
Leukocytes
x10^3 /µl
Erythrocytes
x10^6 /µl
Hemoglobin
g/dl
Hematocrit
%
Erythrocyte Mean Corpuscular Volume, MCV
fl
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Visit 7 (18 Months) Ponderosa CML ZKSJ0083
Mean Corpuscular Hemoglobin, MCH
pg
Mean corpuscular hemoglobin concentration
MCHC
g/dl
Platelets
x10^3 /µl
Ponatinib treatment
Was the treatment interrupted or ended?
yes (1)
no (2)
interrupted (3)
ended (4)
Treatment Begin Date
Treatment End Date
Reason
Were there any dosage changes?
Yes
No
Start date of dosage change
Dosage
Reason of dosage change
Response
Hematologic findings known?
Yes
No
Date of hematologic test
Hematologic test
CHR (1)
no CHR (2)
BCR-ABL Mutation
T315I  (1)
Other (2)
5 / 7
Visit 7 (18 Months) Ponderosa CML ZKSJ0083
Please mention if other:
Cytogenetic Analysis carried out?
Yes
No
Date of Cytogenetic Analysis
Laboratory of Cytogenetic Analysis
Evaluated mitosis
Normal karyotype
Philadelphia negative, with additional aberrations
Philadelphia Chromosome t(9;22)
Philadelphia Chromosome with additional
aberrations
Not evaluable mitoses
Cytogenetic response
no response (1)
CyR (2)
partial (PCyR)  (3)
complete (CcyR) (4)
complete (CcyR) (4)
not determined (5)
Bone marrow biopsy performed?
yes (1)
no (2)
unknown (3)
Date of bone marrow biopsy
Bone marrow biopsy findings
Chronic phase (1)
Accelerated phase (2)
Blast crisis (3)
Other (4)
If other, please mention:
Molecular Analysis known?
Yes
No
Date of Molecular Analysis
6 / 7
Visit 7 (18 Months) Ponderosa CML ZKSJ0083
Laboratory of Molecular Analysis
BCR-ABL International Scale
%
Polymerase Chain Reaction, PCR
no MMR (1)
MMR (2)
MR4 (3)
MR4.5 (4)
MR5 (5)
CMR (6)
7 / 7
Visit 7 (18 Months) Ponderosa CML ZKSJ0083
Visit 8 (21 Months) Ponderosa CML
ZKSJ0083
Study part: Visit 8 (21 Months).Observational study on CML
patients in any phase treated with ponatinib (Iclusig®) at
any dose. Principal Investigator Prof. Dr. A. Hochhaus.
All rights reserved. Please visit https://medical-data-
models.org/forms/13975
Visit 8 (21 Months)
Patient status
Date of visit
Patient died?
Yes
No
Blood pressure
Blood pressure measurement carried out?
Yes
No
Systolic Blood Pressure
mmHg
Diastolic Blood Pressure
mmHg
Laboratory parameters
Urea
Normal (1)
Grade of deviation 1 according to
CTCAE (2)
Grade of deviation 2 according to
CTCAE (3)
Grade of deviation 3 according to
CTCAE (4)
Grade of deviation 4 according to
CTCAE (5)
not analyzed (5)
Creatinine
Normal (1)
Grade of deviation 1 according to
CTCAE (2)
Grade of deviation 2 according to
CTCAE (3)
Grade of deviation 3 according to
CTCAE (4)
Grade of deviation 4 according to
CTCAE (5)
not analyzed (5)
Uric acid
Normal (1)
Grade of deviation 1 according to
CTCAE (2)
Grade of deviation 2 according to
1 / 7
CTCAE (3)
Grade of deviation 3 according to
CTCAE (4)
Grade of deviation 4 according to
CTCAE (5)
not analyzed (5)
Total Bilirubin
Normal (1)
Grade of deviation 1 according to
CTCAE (2)
Grade of deviation 2 according to
CTCAE (3)
Grade of deviation 3 according to
CTCAE (4)
Grade of deviation 4 according to
CTCAE (5)
not analyzed (5)
Bilirubin, direct
Normal (1)
Grade of deviation 1 according to
CTCAE (2)
Grade of deviation 2 according to
CTCAE (3)
Grade of deviation 3 according to
CTCAE (4)
Grade of deviation 4 according to
CTCAE (5)
not analyzed (5)
Glucose
Normal (1)
Grade of deviation 1 according to
CTCAE (2)
Grade of deviation 2 according to
CTCAE (3)
Grade of deviation 3 according to
CTCAE (4)
Grade of deviation 4 according to
CTCAE (5)
not analyzed (5)
Total protein
Normal (1)
Grade of deviation 1 according to
CTCAE (2)
Grade of deviation 2 according to
CTCAE (3)
Grade of deviation 3 according to
CTCAE (4)
Grade of deviation 4 according to
CTCAE (5)
not analyzed (5)
Albumin
Normal (1)
Grade of deviation 1 according to
CTCAE (2)
Grade of deviation 2 according to
2 / 7
Visit 8 (21 Months) Ponderosa CML ZKSJ0083
CTCAE (3)
Grade of deviation 3 according to
CTCAE (4)
Grade of deviation 4 according to
CTCAE (5)
not analyzed (5)
ASAT (AST, GOT)
Normal (1)
Grade of deviation 1 according to
CTCAE (2)
Grade of deviation 2 according to
CTCAE (3)
Grade of deviation 3 according to
CTCAE (4)
Grade of deviation 4 according to
CTCAE (5)
not analyzed (5)
ALAT (ALT, GPT)
Normal (1)
Grade of deviation 1 according to
CTCAE (2)
Grade of deviation 2 according to
CTCAE (3)
Grade of deviation 3 according to
CTCAE (4)
Grade of deviation 4 according to
CTCAE (5)
not analyzed (5)
Gamma-GT
Normal (1)
Grade of deviation 1 according to
CTCAE (2)
Grade of deviation 2 according to
CTCAE (3)
Grade of deviation 3 according to
CTCAE (4)
Grade of deviation 4 according to
CTCAE (5)
not analyzed (5)
Alkaline phosphatase
Normal (1)
Grade of deviation 1 according to
CTCAE (2)
Grade of deviation 2 according to
CTCAE (3)
Grade of deviation 3 according to
CTCAE (4)
Grade of deviation 4 according to
CTCAE (5)
not analyzed (5)
Cholesterol
Normal (1)
Grade of deviation 1 according to
CTCAE (2)
Grade of deviation 2 according to
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Visit 8 (21 Months) Ponderosa CML ZKSJ0083
CTCAE (3)
Grade of deviation 3 according to
CTCAE (4)
Grade of deviation 4 according to
CTCAE (5)
not analyzed (5)
Triglycerides
Normal (1)
Grade of deviation 1 according to
CTCAE (2)
Grade of deviation 2 according to
CTCAE (3)
Grade of deviation 3 according to
CTCAE (4)
Grade of deviation 4 according to
CTCAE (5)
not analyzed (5)
Amylase
Normal (1)
Grade of deviation 1 according to
CTCAE (2)
Grade of deviation 2 according to
CTCAE (3)
Grade of deviation 3 according to
CTCAE (4)
Grade of deviation 4 according to
CTCAE (5)
not analyzed (5)
Lipase
Normal (1)
Grade of deviation 1 according to
CTCAE (2)
Grade of deviation 2 according to
CTCAE (3)
Grade of deviation 3 according to
CTCAE (4)
Grade of deviation 4 according to
CTCAE (5)
not analyzed (5)
Leukocytes
x10^3 /µl
Erythrocytes
x10^6 /µl
Hemoglobin
g/dl
Hematocrit
%
Erythrocyte Mean Corpuscular Volume, MCV
fl
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Visit 8 (21 Months) Ponderosa CML ZKSJ0083
Mean Corpuscular Hemoglobin, MCH
pg
Mean corpuscular hemoglobin concentration
MCHC
g/dl
Platelets
x10^3 /µl
Ponatinib treatment
Was the treatment interrupted or ended?
yes (1)
no (2)
interrupted (3)
ended (4)
Treatment Begin Date
Treatment End Date
Reason
Were there any dosage changes?
Yes
No
Start date of dosage change
Dosage
Reason of dosage change
Response
Hematologic findings known?
Yes
No
Date of hematologic test
Hematologic test
CHR (1)
no CHR (2)
BCR-ABL Mutation
T315I  (1)
Other (2)
5 / 7
Visit 8 (21 Months) Ponderosa CML ZKSJ0083
Please mention if other:
Cytogenetic Analysis carried out?
Yes
No
Date of Cytogenetic Analysis
Laboratory of Cytogenetic Analysis
Evaluated mitosis
Normal karyotype
Philadelphia negative, with additional aberrations
Philadelphia Chromosome t(9;22)
Philadelphia Chromosome with additional
aberrations
Not evaluable mitoses
Cytogenetic response
no response (1)
CyR (2)
partial (PCyR)  (3)
complete (CcyR) (4)
complete (CcyR) (4)
not determined (5)
Bone marrow biopsy performed?
yes (1)
no (2)
unknown (3)
Date of bone marrow biopsy
Bone marrow biopsy findings
Chronic phase (1)
Accelerated phase (2)
Blast crisis (3)
Other (4)
If other, please mention:
Molecular Analysis known?
Yes
No
Date of Molecular Analysis
6 / 7
Visit 8 (21 Months) Ponderosa CML ZKSJ0083
Laboratory of Molecular Analysis
BCR-ABL International Scale
%
Polymerase Chain Reaction, PCR
no MMR (1)
MMR (2)
MR4 (3)
MR4.5 (4)
MR5 (5)
CMR (6)
7 / 7
Visit 8 (21 Months) Ponderosa CML ZKSJ0083
Visit 9 (24 Months) Ponderosa CML
ZKSJ0083
Study part: Visit 9 (24 Months).Observational study on CML
patients in any phase treated with ponatinib (Iclusig®) at
any dose. Principal Investigator Prof. Dr. A. Hochhaus.
All rights reserved. Please visit https://medical-data-
models.org/forms/13976
Visit 9 (24 Months)
Patient status
Date of visit
Patient died?
Yes
No
Blood pressure
Blood pressure measurement carried out?
Yes
No
Systolic Blood Pressure
mmHg
Diastolic Blood Pressure
mmHg
Laboratory parameters
Urea
Normal (1)
Grade of deviation 1 according to
CTCAE (2)
Grade of deviation 2 according to
CTCAE (3)
Grade of deviation 3 according to
CTCAE (4)
Grade of deviation 4 according to
CTCAE (5)
not analyzed (5)
Creatinine
Normal (1)
Grade of deviation 1 according to
CTCAE (2)
Grade of deviation 2 according to
CTCAE (3)
Grade of deviation 3 according to
CTCAE (4)
Grade of deviation 4 according to
CTCAE (5)
not analyzed (5)
Uric acid
Normal (1)
Grade of deviation 1 according to
CTCAE (2)
Grade of deviation 2 according to
1 / 7
CTCAE (3)
Grade of deviation 3 according to
CTCAE (4)
Grade of deviation 4 according to
CTCAE (5)
not analyzed (5)
Total Bilirubin
Normal (1)
Grade of deviation 1 according to
CTCAE (2)
Grade of deviation 2 according to
CTCAE (3)
Grade of deviation 3 according to
CTCAE (4)
Grade of deviation 4 according to
CTCAE (5)
not analyzed (5)
Bilirubin, direct
Normal (1)
Grade of deviation 1 according to
CTCAE (2)
Grade of deviation 2 according to
CTCAE (3)
Grade of deviation 3 according to
CTCAE (4)
Grade of deviation 4 according to
CTCAE (5)
not analyzed (5)
Glucose
Normal (1)
Grade of deviation 1 according to
CTCAE (2)
Grade of deviation 2 according to
CTCAE (3)
Grade of deviation 3 according to
CTCAE (4)
Grade of deviation 4 according to
CTCAE (5)
not analyzed (5)
Total protein
Normal (1)
Grade of deviation 1 according to
CTCAE (2)
Grade of deviation 2 according to
CTCAE (3)
Grade of deviation 3 according to
CTCAE (4)
Grade of deviation 4 according to
CTCAE (5)
not analyzed (5)
Albumin
Normal (1)
Grade of deviation 1 according to
CTCAE (2)
Grade of deviation 2 according to
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CTCAE (3)
Grade of deviation 3 according to
CTCAE (4)
Grade of deviation 4 according to
CTCAE (5)
not analyzed (5)
ASAT (AST, GOT)
Normal (1)
Grade of deviation 1 according to
CTCAE (2)
Grade of deviation 2 according to
CTCAE (3)
Grade of deviation 3 according to
CTCAE (4)
Grade of deviation 4 according to
CTCAE (5)
not analyzed (5)
ALAT (ALT, GPT)
Normal (1)
Grade of deviation 1 according to
CTCAE (2)
Grade of deviation 2 according to
CTCAE (3)
Grade of deviation 3 according to
CTCAE (4)
Grade of deviation 4 according to
CTCAE (5)
not analyzed (5)
Gamma-GT
Normal (1)
Grade of deviation 1 according to
CTCAE (2)
Grade of deviation 2 according to
CTCAE (3)
Grade of deviation 3 according to
CTCAE (4)
Grade of deviation 4 according to
CTCAE (5)
not analyzed (5)
Alkaline phosphatase
Normal (1)
Grade of deviation 1 according to
CTCAE (2)
Grade of deviation 2 according to
CTCAE (3)
Grade of deviation 3 according to
CTCAE (4)
Grade of deviation 4 according to
CTCAE (5)
not analyzed (5)
Cholesterol
Normal (1)
Grade of deviation 1 according to
CTCAE (2)
Grade of deviation 2 according to
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CTCAE (3)
Grade of deviation 3 according to
CTCAE (4)
Grade of deviation 4 according to
CTCAE (5)
not analyzed (5)
Triglycerides
Normal (1)
Grade of deviation 1 according to
CTCAE (2)
Grade of deviation 2 according to
CTCAE (3)
Grade of deviation 3 according to
CTCAE (4)
Grade of deviation 4 according to
CTCAE (5)
not analyzed (5)
Amylase
Normal (1)
Grade of deviation 1 according to
CTCAE (2)
Grade of deviation 2 according to
CTCAE (3)
Grade of deviation 3 according to
CTCAE (4)
Grade of deviation 4 according to
CTCAE (5)
not analyzed (5)
Lipase
Normal (1)
Grade of deviation 1 according to
CTCAE (2)
Grade of deviation 2 according to
CTCAE (3)
Grade of deviation 3 according to
CTCAE (4)
Grade of deviation 4 according to
CTCAE (5)
not analyzed (5)
Leukocytes
x10^3 /µl
Erythrocytes
x10^6 /µl
Hemoglobin
g/dl
Hematocrit
%
Erythrocyte Mean Corpuscular Volume, MCV
fl
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Mean Corpuscular Hemoglobin, MCH
pg
Mean corpuscular hemoglobin concentration
MCHC
g/dl
Platelets
x10^3 /µl
Ponatinib treatment
Was the treatment interrupted or ended?
yes (1)
no (2)
interrupted (3)
ended (4)
Treatment Begin Date
Treatment End Date
Reason
Were there any dosage changes?
Yes
No
Start date of dosage change
Dosage
Reason of dosage change
Response
Hematologic findings known?
Yes
No
Date of hematologic test
Hematologic test
CHR (1)
no CHR (2)
BCR-ABL Mutation
T315I  (1)
Other (2)
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Please mention if other:
Cytogenetic Analysis carried out?
Yes
No
Date of Cytogenetic Analysis
Laboratory of Cytogenetic Analysis
Evaluated mitosis
Normal karyotype
Philadelphia negative, with additional aberrations
Philadelphia Chromosome t(9;22)
Philadelphia Chromosome with additional
aberrations
Not evaluable mitoses
Cytogenetic response
no response (1)
CyR (2)
partial (PCyR)  (3)
complete (CcyR) (4)
complete (CcyR) (4)
not determined (5)
Bone marrow biopsy performed?
yes (1)
no (2)
unknown (3)
Date of bone marrow biopsy
Bone marrow biopsy findings
Chronic phase (1)
Accelerated phase (2)
Blast crisis (3)
Other (4)
If other, please mention:
Molecular Analysis known?
Yes
No
Date of Molecular Analysis
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Laboratory of Molecular Analysis
BCR-ABL International Scale
%
Polymerase Chain Reaction, PCR
no MMR (1)
MMR (2)
MR4 (3)
MR4.5 (4)
MR5 (5)
CMR (6)
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Cancellation Visits Ponderosa CML
ZKSJ0083
Study part: Cancellation Visits.Observational study on CML
patients in any phase treated with ponatinib (Iclusig®) at
any dose. Principal Investigator Prof. Dr. A. Hochhaus.
All rights reserved. Please visit https://medical-data-
models.org/forms/13977
Cancellation Visits
Patient status
Date of visit
Patient died?
Yes
No
Blood pressure
Blood pressure measurement carried out?
Yes
No
Systolic Blood Pressure
mmHg
Diastolic Blood Pressure
mmHg
Laboratory parameters
Urea
Normal (1)
Grade of deviation 1 according to
CTCAE (2)
Grade of deviation 2 according to
CTCAE (3)
Grade of deviation 3 according to
CTCAE (4)
Grade of deviation 4 according to
CTCAE (5)
not analyzed (5)
Creatinine
Normal (1)
Grade of deviation 1 according to
CTCAE (2)
Grade of deviation 2 according to
CTCAE (3)
Grade of deviation 3 according to
CTCAE (4)
Grade of deviation 4 according to
CTCAE (5)
not analyzed (5)
Uric acid
Normal (1)
Grade of deviation 1 according to
CTCAE (2)
Grade of deviation 2 according to
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CTCAE (3)
Grade of deviation 3 according to
CTCAE (4)
Grade of deviation 4 according to
CTCAE (5)
not analyzed (5)
Total Bilirubin
Normal (1)
Grade of deviation 1 according to
CTCAE (2)
Grade of deviation 2 according to
CTCAE (3)
Grade of deviation 3 according to
CTCAE (4)
Grade of deviation 4 according to
CTCAE (5)
not analyzed (5)
Bilirubin, direct
Normal (1)
Grade of deviation 1 according to
CTCAE (2)
Grade of deviation 2 according to
CTCAE (3)
Grade of deviation 3 according to
CTCAE (4)
Grade of deviation 4 according to
CTCAE (5)
not analyzed (5)
Glucose
Normal (1)
Grade of deviation 1 according to
CTCAE (2)
Grade of deviation 2 according to
CTCAE (3)
Grade of deviation 3 according to
CTCAE (4)
Grade of deviation 4 according to
CTCAE (5)
not analyzed (5)
Total protein
Normal (1)
Grade of deviation 1 according to
CTCAE (2)
Grade of deviation 2 according to
CTCAE (3)
Grade of deviation 3 according to
CTCAE (4)
Grade of deviation 4 according to
CTCAE (5)
not analyzed (5)
Albumin
Normal (1)
Grade of deviation 1 according to
CTCAE (2)
Grade of deviation 2 according to
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CTCAE (3)
Grade of deviation 3 according to
CTCAE (4)
Grade of deviation 4 according to
CTCAE (5)
not analyzed (5)
ASAT (AST, GOT)
Normal (1)
Grade of deviation 1 according to
CTCAE (2)
Grade of deviation 2 according to
CTCAE (3)
Grade of deviation 3 according to
CTCAE (4)
Grade of deviation 4 according to
CTCAE (5)
not analyzed (5)
ALAT (ALT, GPT)
Normal (1)
Grade of deviation 1 according to
CTCAE (2)
Grade of deviation 2 according to
CTCAE (3)
Grade of deviation 3 according to
CTCAE (4)
Grade of deviation 4 according to
CTCAE (5)
not analyzed (5)
Gamma-GT
Normal (1)
Grade of deviation 1 according to
CTCAE (2)
Grade of deviation 2 according to
CTCAE (3)
Grade of deviation 3 according to
CTCAE (4)
Grade of deviation 4 according to
CTCAE (5)
not analyzed (5)
Alkaline phosphatase
Normal (1)
Grade of deviation 1 according to
CTCAE (2)
Grade of deviation 2 according to
CTCAE (3)
Grade of deviation 3 according to
CTCAE (4)
Grade of deviation 4 according to
CTCAE (5)
not analyzed (5)
Cholesterol
Normal (1)
Grade of deviation 1 according to
CTCAE (2)
Grade of deviation 2 according to
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CTCAE (3)
Grade of deviation 3 according to
CTCAE (4)
Grade of deviation 4 according to
CTCAE (5)
not analyzed (5)
Triglycerides
Normal (1)
Grade of deviation 1 according to
CTCAE (2)
Grade of deviation 2 according to
CTCAE (3)
Grade of deviation 3 according to
CTCAE (4)
Grade of deviation 4 according to
CTCAE (5)
not analyzed (5)
Amylase
Normal (1)
Grade of deviation 1 according to
CTCAE (2)
Grade of deviation 2 according to
CTCAE (3)
Grade of deviation 3 according to
CTCAE (4)
Grade of deviation 4 according to
CTCAE (5)
not analyzed (5)
Lipase
Normal (1)
Grade of deviation 1 according to
CTCAE (2)
Grade of deviation 2 according to
CTCAE (3)
Grade of deviation 3 according to
CTCAE (4)
Grade of deviation 4 according to
CTCAE (5)
not analyzed (5)
Leukocytes
x10^3 /µl
Erythrocytes
x10^6 /µl
Hemoglobin
g/dl
Hematocrit
%
Erythrocyte Mean Corpuscular Volume, MCV
fl
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Mean Corpuscular Hemoglobin, MCH
pg
Mean corpuscular hemoglobin concentration
MCHC
g/dl
Platelets
x10^3 /µl
Ponatinib treatment
Was the treatment interrupted or ended?
yes (1)
no (2)
interrupted (3)
ended (4)
Treatment Begin Date
Treatment End Date
Reason
Were there any dosage changes?
Yes
No
Start date of dosage change
Dosage
Reason of dosage change
Response
Hematologic findings known?
Yes
No
Date of hematologic test
Hematologic test
CHR (1)
no CHR (2)
BCR-ABL Mutation
T315I  (1)
Other (2)
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Please mention if other:
Cytogenetic Analysis carried out?
Yes
No
Date of Cytogenetic Analysis
Laboratory of Cytogenetic Analysis
Evaluated mitosis
Normal karyotype
Philadelphia negative, with additional aberrations
Philadelphia Chromosome t(9;22)
Philadelphia Chromosome with additional
aberrations
Not evaluable mitoses
Cytogenetic response
no response (1)
CyR (2)
partial (PCyR)  (3)
complete (CcyR) (4)
complete (CcyR) (4)
not determined (5)
Bone marrow biopsy performed?
yes (1)
no (2)
unknown (3)
Date of bone marrow biopsy
Bone marrow biopsy findings
Chronic phase (1)
Accelerated phase (2)
Blast crisis (3)
Other (4)
If other, please mention:
Molecular Analysis known?
Yes
No
Date of Molecular Analysis
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Laboratory of Molecular Analysis
BCR-ABL International Scale
%
Polymerase Chain Reaction, PCR
no MMR (1)
MMR (2)
MR4 (3)
MR4.5 (4)
MR5 (5)
CMR (6)
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Study end Ponderosa CML ZKSJ0083
Study part: Study end.Observational study on CML patients
in any phase treated with ponatinib (Iclusig®) at any dose.
Principal Investigator Prof. Dr. A. Hochhaus.
All rights reserved. Please visit https://medical-data-
models.org/forms/13978
Study end
Patient status
Date of contact with patients
Patient status
Patient lives on the day of the Follow-Up
(1)
Patient status at the time of follow-up
unknown (Establishment of contact is
further attempted) (2)
Lost to follow-up  (3)
Informed consent withdrawn (4)
Dead (5)
Completed study period (6)
Discontinuation of Sponsor (7)
Other status (8)
If other status, please mention:
Date of death
Cause of death
1 / 1
Adverse Events Ponderosa CML ZKSJ0083
Study part: Adverse Events.Observational study on CML
patients in any phase treated with ponatinib (Iclusig®) at
any dose. Principal Investigator Prof. Dr. A. Hochhaus.
All rights reserved. Please visit https://medical-data-
models.org/forms/13979
Adverse Events
Adverse Events
Did  Adverse Events occur?
Yes
No
Adverse Event:
Adverse Event Start Date Time
Adverse Event End Date Time
Serious adverse event, SAE
Connection with intervention
no connection (1)
connection exists (2)
unknown (3)
Degree of severity
mild (1 )
moderate (2 )
severe (3 )
life-threatening (4 )
fatal (death) (5 )
Measures taken regarding adverse event
no (1 )
dose reduction (2 )
dose increase (3 )
drug interrupted (4 )
drug discontinued (5 )
adjunctive therapy (6 )
unknown (9 )
Adverse Event outcome
recovered (1 )
recovered with consequential damages
(2 )
unchanged (3 )
fatal (4 )
unknown (9 )
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Concomitant medication Ponderosa CML
ZKSJ0083
Study part: Concomitant medication.Observational study on
CML patients in any phase treated with ponatinib (Iclusig®)
at any dose. Principal Investigator Prof. Dr. A. Hochhaus.
All rights reserved. Please visit https://medical-data-
models.org/forms/13980
Concomitant medication
Concomitant medication
Patient ID
Was concomitant medication administered?
Yes
No
Concomitant medication
Concomitant medication use indication
Concomitant therapy start date
Concomitant therapy start unknown?
Yes
No
Concomitant therapy end date
Concomitant therapy end
continuous (1)
unknown (2)
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Visit 1 Ponderosa CML ZKSJ0083
Study part: Visit 1.Observational study on CML patients in
any phase treated with ponatinib (Iclusig®) at any dose.
Principal Investigator Prof. Dr. A. Hochhaus.
All rights reserved. Please visit https://medical-data-
models.org/forms/13981
Visit 1
Inclusion Criteria
Adult patients (age ≥18 years) with CML
Yes
No
Written patient informed consent
Yes
No
Exclusion Criteria
Patient was treated with ponatinib already (in a
clinical trial)
Yes
No
Patient receives a study drug
Yes
No
Patient is pregnant and / or breastfeeding
Yes
No
Patient unable to sign the consent
Yes
No
Informed consent
Was the patient informed about the study and is
the informed consent available?
Yes
No
Date Informed Consent signed
Cohort Studies
prospective (1)
retrospective (2)
Demographics
Patient ID
Date of visit
Date of birth
1 / 17
Gender
male (1)
female (2)
If female, patient of childbearing potential?
yes (1)
no (2)
no menopause (3)
no medical history (4)
Height
cm
Weight
kg
Ethnicity
Caucasian (1 )
Black (2 )
Latin (3 )
Oriental / Asian (4 )
Other (5 )
If other, please mention
Smoking status
Non smoking (1 )
ex-smoker (2 )
Smoker (3 )
unknown (4 )
CML diagnosis
CML diagnosis confirmed?
Yes
No
Date of  first CML- diagnosis
CML in
Chronic phase, CP (1)
Accelerated phase, AP (2)
Blast crisis, BC (3)
If BC, choose one if the following
myeloid (1 )
lymphatic (2 )
other (3 )
If other, please mention
BCR-ABL Mutation
T315I  (1)
Other (2)
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Please mention if other:
Molecular Analysis known?
Yes
No
Date of Molecular Analysis
Laboratory of Molecular Analysis
BCR-ABL International Scale
%
Cytogenetic Analysis carried out?
Yes
No
Date of Cytogenetic Analysis
Laboratory of Cytogenetic Analysis
Evaluated mitosis
Normal karyotype
Philadelphia negative, with additional aberrations
Philadelphia Chromosome t(9;22)
Philadelphia Chromosome with additional
aberrations
Not evaluable mitoses
CML treatment course
Did the patient previously receive a CML-specific
therapy?
Yes
No
Therapy (incl. All TKIs, other neoplastica and
steroids)
imatinib (1)
dasatinib (2)
Nilotinib (3)
Bosutinib (4)
Interferon (5)
Hydroxyurea (6)
Prednisone (7)
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Other (8)
If other, please mention
Therapy Start Date
Therapy end date
Medication dose
mg
Previous TKI therapies?
yes (1)
no (2)
unknown (3)
Best response to TKI pretreatment known?
Yes
No
Date of best response to TKI pretreatment
Hematologic test
CHR  (1)
no CHR (2)
Date of hematologic test
Cytogenetic response
no response  (1)
CyR  (2)
partial (PCyR)  (3)
complete (CcyR)  (4)
not determined (5)
Date of Cytogenetic response
Polymerase Chain Reaction, PCR
no MMR  (1)
MMR  (2)
MR4  (3)
MR4.5  (4)
MR5  (5)
CMR (6)
Last response to TKI pretreatment known?
Yes
No
Date of last response to TKI pretreatment
Hematologic test
CHR  (1)
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no CHR (2)
Date of hematologic test
Cytogenetic response
no response  (1)
CyR  (2)
partial (PCyR)  (3)
complete (CcyR)  (4)
not determined (5)
Date of Cytogenetic response
Polymerase Chain Reaction, PCR
no MMR  (1)
MMR  (2)
MR4  (3)
MR4.5  (4)
MR5  (5)
CMR (6)
Patient medical history
Myocardial Infarction
yes (1)
no (2)
unknown (3)
Diagnosis year
Diagnosis status
completed  (1)
persistent (2)
unknown (3)
Angina Pectoris
yes  (1)
no  (2)
unknown (3)
Diagnosis year
Diagnosis status
completed  (1)
persistent  (2)
unknown (3)
coronary heart disease
yes  (1)
no  (2)
unknown (3)
Diagnosis year
Diagnosis status
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completed  (1)
persistent  (2)
unknown (3)
Peripheral arterial disease
yes  (1)
no  (2)
unknown (3)
Diagnosis year
Diagnosis status
completed  (1)
persistent  (2)
unknown (3)
Heart failure
yes  (1)
no  (2)
unknown (3)
Diagnosis year
Diagnosis status
completed  (1)
persistent  (2)
unknown (3)
Arrhythmias
yes  (1)
no  (2)
unknown (3)
Diagnosis year
Diagnosis status
completed  (1)
persistent  (2)
unknown (3)
Stroke, TIA
yes  (1)
no  (2)
unknown (3)
Diagnosis year
Diagnosis status
completed  (1)
persistent  (2)
unknown (3)
Peripheral atherosclerotic vascular disease
yes  (1)
no  (2)
unknown (3)
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Diagnosis year
Diagnosis status
completed  (1)
persistent  (2)
unknown (3)
Retinal artery occlusion
yes  (1)
no  (2)
unknown (3)
Diagnosis year
Diagnosis status
completed  (1)
persistent  (2)
unknown (3)
Revascularization procedures
yes  (1)
no  (2)
unknown (3)
Diagnosis year
Diagnosis status
completed  (1)
persistent  (2)
unknown (3)
Embolism
yes  (1)
no  (2)
unknown (3)
Diagnosis year
Diagnosis status
completed  (1)
persistent  (2)
unknown (3)
Thrombophilia
yes  (1)
no  (2)
unknown (3)
Diagnosis year
Diagnosis status
completed  (1)
persistent  (2)
unknown (3)
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Prolonged immobilization
yes  (1)
no  (2)
unknown (3)
Diagnosis year
Diagnosis status
completed  (1)
persistent  (2)
unknown (3)
Recent surgery
yes  (1)
no  (2)
unknown (3)
Diagnosis year
Diagnosis status
completed  (1)
persistent  (2)
unknown (3)
Diabetes mellitus
yes  (1)
no  (2)
unknown (3)
Diagnosis year
Diagnosis status
completed  (1)
persistent  (2)
unknown (3)
Arterial hypertension
yes  (1)
no  (2)
unknown (3)
Diagnosis year
Diagnosis status
completed  (1)
persistent  (2)
unknown (3)
Hypercholesterolemia
yes  (1)
no  (2)
unknown (3)
Diagnosis year
Diagnosis status
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completed  (1)
persistent  (2)
unknown (3)
Hyperlipidemia
yes  (1)
no  (2)
unknown (3)
Diagnosis year
Diagnosis status
completed  (1)
persistent  (2)
unknown (3)
Pancreatitis
yes  (1)
no  (2)
unknown (3)
Diagnosis year
Diagnosis status
completed  (1)
persistent  (2)
unknown (3)
Other cardiovascular events
yes  (1)
no  (2)
unknown (3)
Cardiovascular events
Diagnosis year
Diagnosis status
completed  (1)
persistent  (2)
unknown (3)
Family medical history
Myocardial infarction
yes  (1)
no  (2)
unknown (3)
Relationship to patient
Parents (1)
Siblings (2)
Children (3)
Angina Pectoris
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yes  (1)
no  (2)
unknown (3)
Relationship to patient
Parents (1)
Siblings (2)
Children (3)
Coronary heart disease
yes  (1)
no  (2)
unknown (3)
Relationship to patient
Parents (1)
Siblings (2)
Children (3)
Peripheral arterial disease
yes  (1)
no  (2)
unknown (3)
Relationship to patient
Parents (1)
Siblings (2)
Children (3)
Heart failure
yes  (1)
no  (2)
unknown (3)
Relationship to patient
Parents (1)
Siblings (2)
Children (3)
Arrhythmias
yes  (1)
no  (2)
unknown (3)
Relationship to patient
Parents (1)
Siblings (2)
Children (3)
Stroke, TIA
yes  (1)
no  (2)
unknown (3)
Relationship to patient
Parents (1)
Siblings (2)
Children (3)
Peripheral atherosclerotic vascular disease
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yes  (1)
no  (2)
unknown (3)
Relationship to patient
Parents (1)
Siblings (2)
Children (3)
Retinal artery occlusion
yes  (1)
no  (2)
unknown (3)
Relationship to patient
Parents (1)
Siblings (2)
Children (3)
Revascularization procedures
yes  (1)
no  (2)
unknown (3)
Relationship to patient
Parents (1)
Siblings (2)
Children (3)
Embolism
yes  (1)
no  (2)
unknown (3)
Relationship to patient
Parents (1)
Siblings (2)
Children (3)
Thrombophilia
yes  (1)
no  (2)
unknown (3)
Relationship to patient
Parents (1)
Siblings (2)
Children (3)
Prolonged immobilization
yes  (1)
no  (2)
unknown (3)
Relationship to patient
Parents (1)
Siblings (2)
Children (3)
Diabetes mellitus
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yes  (1)
no  (2)
unknown (3)
Relationship to patient
Parents (1)
Siblings (2)
Children (3)
Arterial hypertension
yes  (1)
no  (2)
unknown (3)
Relationship to patient
Parents (1)
Siblings (2)
Children (3)
Hypercholesterolemia
yes  (1)
no  (2)
unknown (3)
Relationship to patient
Parents (1)
Siblings (2)
Children (3)
Hyperlipidemia
yes  (1)
no  (2)
unknown (3)
Relationship to patient
Parents (1)
Siblings (2)
Children (3)
Pancreatitis
yes  (1)
no  (2)
unknown (3)
Relationship to patient
Parents (1)
Siblings (2)
Children (3)
Other cardiovascular events
yes  (1)
no  (2)
unknown (3)
Cardiovascular events
Relationship to patient
Parents (1)
Siblings (2)
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Children (3)
Blood pressure
Blood pressure measurement carried out?
Yes
No
Systolic Blood Pressure
mmHg
Diastolic Blood Pressure
mmHg
Laboratory parameters
Urea
Normal (1)
Grade of deviation 1 according to
CTCAE (2)
Grade of deviation 2 according to
CTCAE (3)
Grade of deviation 3 according to
CTCAE (4)
Grade of deviation 4 according to
CTCAE (5)
not analyzed (5)
Creatinine
Normal (1)
Grade of deviation 1 according to
CTCAE (2)
Grade of deviation 2 according to
CTCAE (3)
Grade of deviation 3 according to
CTCAE (4)
Grade of deviation 4 according to
CTCAE (5)
not analyzed (5)
Uric acid
Normal (1)
Grade of deviation 1 according to
CTCAE (2)
Grade of deviation 2 according to
CTCAE (3)
Grade of deviation 3 according to
CTCAE (4)
Grade of deviation 4 according to
CTCAE (5)
not analyzed (5)
Total Bilirubin
Normal (1)
Grade of deviation 1 according to
CTCAE (2)
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Grade of deviation 2 according to
CTCAE (3)
Grade of deviation 3 according to
CTCAE (4)
Grade of deviation 4 according to
CTCAE (5)
not analyzed (5)
Bilirubin, direct
Normal (1)
Grade of deviation 1 according to
CTCAE (2)
Grade of deviation 2 according to
CTCAE (3)
Grade of deviation 3 according to
CTCAE (4)
Grade of deviation 4 according to
CTCAE (5)
not analyzed (5)
Glucose
Normal (1)
Grade of deviation 1 according to
CTCAE (2)
Grade of deviation 2 according to
CTCAE (3)
Grade of deviation 3 according to
CTCAE (4)
Grade of deviation 4 according to
CTCAE (5)
not analyzed (5)
Total protein
Normal (1)
Grade of deviation 1 according to
CTCAE (2)
Grade of deviation 2 according to
CTCAE (3)
Grade of deviation 3 according to
CTCAE (4)
Grade of deviation 4 according to
CTCAE (5)
not analyzed (5)
Albumin
Normal (1)
Grade of deviation 1 according to
CTCAE (2)
Grade of deviation 2 according to
CTCAE (3)
Grade of deviation 3 according to
CTCAE (4)
Grade of deviation 4 according to
CTCAE (5)
not analyzed (5)
ASAT (AST, GOT)
Normal (1)
Grade of deviation 1 according to
CTCAE (2)
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Grade of deviation 2 according to
CTCAE (3)
Grade of deviation 3 according to
CTCAE (4)
Grade of deviation 4 according to
CTCAE (5)
not analyzed (5)
ALAT (ALT, GPT)
Normal (1)
Grade of deviation 1 according to
CTCAE (2)
Grade of deviation 2 according to
CTCAE (3)
Grade of deviation 3 according to
CTCAE (4)
Grade of deviation 4 according to
CTCAE (5)
not analyzed (5)
Gamma-GT
Normal (1)
Grade of deviation 1 according to
CTCAE (2)
Grade of deviation 2 according to
CTCAE (3)
Grade of deviation 3 according to
CTCAE (4)
Grade of deviation 4 according to
CTCAE (5)
not analyzed (5)
Alkaline phosphatase
Normal (1)
Grade of deviation 1 according to
CTCAE (2)
Grade of deviation 2 according to
CTCAE (3)
Grade of deviation 3 according to
CTCAE (4)
Grade of deviation 4 according to
CTCAE (5)
not analyzed (5)
Cholesterol
Normal (1)
Grade of deviation 1 according to
CTCAE (2)
Grade of deviation 2 according to
CTCAE (3)
Grade of deviation 3 according to
CTCAE (4)
Grade of deviation 4 according to
CTCAE (5)
not analyzed (5)
Triglycerides
Normal (1)
Grade of deviation 1 according to
CTCAE (2)
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Grade of deviation 2 according to
CTCAE (3)
Grade of deviation 3 according to
CTCAE (4)
Grade of deviation 4 according to
CTCAE (5)
not analyzed (5)
Amylase
Normal (1)
Grade of deviation 1 according to
CTCAE (2)
Grade of deviation 2 according to
CTCAE (3)
Grade of deviation 3 according to
CTCAE (4)
Grade of deviation 4 according to
CTCAE (5)
not analyzed (5)
Amylase
Normal (1)
Grade of deviation 1 according to
CTCAE (2)
Grade of deviation 2 according to
CTCAE (3)
Grade of deviation 3 according to
CTCAE (4)
Grade of deviation 4 according to
CTCAE (5)
not analyzed (5)
Lipase
Normal (1)
Grade of deviation 1 according to
CTCAE (2)
Grade of deviation 2 according to
CTCAE (3)
Grade of deviation 3 according to
CTCAE (4)
Grade of deviation 4 according to
CTCAE (5)
not analyzed (5)
Leukocytes
x10^3 /µl
Erythrocytes
x10^6 /µl
Hemoglobin
g/dl
Hematocrit
%
Erythrocyte Mean Corpuscular Volume, MCV
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fl
Mean Corpuscular Hemoglobin, MCH
pg
Mean corpuscular hemoglobin concentration
MCHC
g/dl
Platelets
x10^3 /µl
Ponatinib treatment
Did treatment with ponatinib begin?
Yes
No
Therapy Start Date
Start dose
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NINDS CDE Neuromuscular Examination
Amyotrophic Lateral Sclerosis
NINDS Common Data Elements Neuromuscular
Examination Amyotrophic Lateral Sclerosis) Used from the
National Institute of Neurological Disorders and Stroke
Common Data Elements
(https://www.commondataelements.ninds.nih.gov/)
References: Grinnon ST, Miller K, Marler JR, Lu Y, Stout A,
Odenkirchen J, Kunitz S. National Institute of Neurological
Disorders and Stroke Common Data Element Project -
approach and methods. Clin Trials. 2012;9(3):322-9.
All rights reserved. Please visit https://medical-data-
models.org/forms/13982
Neuromuscular Examination
Neuromuscular Exam:cranial segment
Study-ID
Study site name
Subject ID
Fasciculations of upper face?
Yes (1)
No (2)
Not assessed (3)
Fasciculations of lower face?
Yes (1)
No (2)
Not assessed (3)
Upper facial weakness
Yes (1)
No (2)
Not assessed (3)
Lower facial weakness
Yes (1)
No (2)
Not assessed (3)
Tongue atrophy
Yes (1)
No (2)
Not assessed (3)
Tongue fasciculations
Yes (1)
No (2)
Not assessed (3)
Tongue weakness
Yes (1)
No (2)
Not assessed (3)
Tongue movement
Normal (1)
Slow (2)
No movement (3)
1 / 9
Not assessed (4)
Dysarthria
None (1)
Dysarthria (2)
Anarthria (3)
Not assessed (4)
Jaw Jerk
Absent (1)
Present (2)
Brisk (3)
Clonus (4)
Not assessed (5)
Neck strength on flexion
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
Neck strength on extension
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
Neck muscles
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
Neuromuscular Exam:Arm muscle
condition
Right arm: atrophy
Yes (1)
No (2)
Not assessed (3)
Right arm: fasciculations
Yes (1)
No (2)
Not assessed (3)
Right arm: Hoffman´s reflex
Yes (1)
No (2)
Not assessed (3)
Right arm: Muscle tone
Yes (1)
No (2)
Not assessed (3)
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Right arm: Normal Reflexes
Yes (1)
No (Please specify below) (2)
Not assessed (3)
Right arm: Reflex of elbow flexors
Absent (1)
Diminished (2)
Normal (3)
Brisk (4)
Right arm: Brachioradialis reflex
Absent (1)
Diminished (2)
Normal (3)
Brisk (4)
Right arm: Elbow extensor reflex
Absent (1)
Diminished (2)
Normal (3)
Brisk (4)
Right arm: strength
Normal (1)
Abnormal (please specify below:Muscle
strength abnormalities) (2)
Not assessed (3)
Left arm: atrophy
Yes (1)
No (2)
Not assessed (3)
Left arm: fasciculations
Yes (1)
No (2)
Not assessed (3)
Left arm: Hoffman´s reflex
Yes (1)
No (2)
Not assessed (3)
Left arm: Muscle tone
Yes (1)
No (2)
Not assessed (3)
Left arm: Normal reflexes
Yes (1)
No (2)
Not assessed (3)
Left arm: Elbow flexor reflexes
Absent (1)
Diminished (2)
Normal (3)
Brisk (4)
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Left arm: Brachioradialis reflexes
Absent (1)
Diminished (2)
Normal (3)
Brisk (4)
Left arm: Elbow extensor reflexes
Absent (1)
Diminished (2)
Normal (3)
Brisk (4)
Left arm: strength
Normal (1)
Abnormal (please specify below:Muscle
strength abnormalities) (2)
Not assessed (3)
Neuromuscular Exam:Arm muscle
strength abnormalities
Right arm: Shoulder abduction strength
1 (1)
2 (2)
3 (3)
4 (4)
Right arm: Elbow flexor strength
1 (1)
2 (2)
3 (3)
4 (4)
Right arm: Elbow extensor strength
1 (1)
2 (2)
3 (3)
4 (4)
Right arm: Wrist flexor strength
1 (1)
2 (2)
3 (3)
4 (4)
Right arm: Wrist extensor strength
1 (1)
2 (2)
3 (3)
4 (4)
Right arm: Finger flexor strength
1 (1)
2 (2)
3 (3)
4 (4)
Right arm: Finger extensor strength
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1 (1)
2 (2)
3 (3)
4 (4)
Right arm: First dorsal interosseus strength
1 (1)
2 (2)
3 (3)
4 (4)
Right arm: Abductor digiti minimi strength
1 (1)
2 (2)
3 (3)
4 (4)
Right arm: Abductor pollicis brevis strength
1 (1)
2 (2)
3 (3)
4 (4)
Left arm: Shoulder abduction strength
1 (1)
2 (2)
3 (3)
4 (4)
Left arm: Elbow flexor strength
1 (1)
2 (2)
3 (3)
4 (4)
Left arm: Elbow extensor strength
1 (1)
2 (2)
3 (3)
4 (4)
Left arm: Wrist flexor strength
1 (1)
2 (2)
3 (3)
4 (4)
Left arm: Wrist extensor strength
1 (1)
2 (2)
3 (3)
4 (4)
Left arm: Finger flexor strength
1 (1)
2 (2)
3 (3)
4 (4)
Left arm: Finger extensor strength
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1 (1)
2 (2)
3 (3)
4 (4)
Left arm: First dorsal interosseous stength
1 (1)
2 (2)
3 (3)
4 (4)
Left arm: Abductor digiti minimi strength
1 (1)
2 (2)
3 (3)
4 (4)
Left arm: Abductor pollicis brevis strength
1 (1)
2 (2)
3 (3)
4 (4)
Arm muscle strength: additional comments
Thoracic paraspinal fasciculations
Present (1)
Absent (2)
Not assessed (3)
Abdominal wall fasciculations
Present (1)
Absent (2)
Not assessed (3)
Superficial abdominal reflexes
Present (1)
Absent (2)
Not assessed (3)
Thoracic segment: additional comments
Neuromuscular Exam:Leg muscle
condition
Right leg: Atrophy
Yes (1)
No (2)
Not Assessed (3)
Right leg:Fasciculations
Yes (1)
No (2)
Not Assessed (3)
Right leg: Plantar
Normal (1)
Extensor (2)
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Indeterminate (3)
Right leg: Muscle tone
Normal (1)
Flaccid (2)
Spastic (3)
Right leg: Normal reflexes
Yes (1)
No (complete "Reflex questions") (2)
Not Assessed (3)
Right leg: Patellar reflex
Absent (1)
Diminished (2)
Normal (3)
Brisk (4)
Right leg: Ankle reflex
Absent (1)
Diminished (2)
Normal (3)
Brisk (4)
Right leg: Strength
Normal (1)
Abnormal (please complete strength
questions) (2)
Not Assessed (3)
Left leg: Atrophy
Yes (1)
No (2)
Not Assessed (3)
Left leg: fasciculations
Yes (1)
No (2)
Not Assessed (3)
Left leg: Plantar
Normal (1)
Extensor (2)
Indeterminate (3)
Left leg: Muscle tone
Normal (1)
Flaccid (2)
Spastic (3)
Left leg: Normal reflexes
Yes (1)
No (please complete reflex questions)
(2)
Not Assessed (3)
Left leg: Patellar reflex
Absent  (1)
Diminished  (2)
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Normal  (3)
Brisk (4)
Left leg: Ankle reflex
Absent  (1)
Diminished  (2)
Normal  (3)
Brisk (4)
Left leg: Strength
Normal  (1)
Abnormal (Please complete strength
questions )  (2)
Not Assessed (3)
Neuromuscular Exam:Leg muscle
strength
Muscle strength: right hip flexion
0 (0)
1 (1)
2 (2)
3 (3)
4 (4)
Muscle strength: right hip extension
0 (0)
1 (1)
2 (2)
3 (3)
4 (4)
Muscle strength: right hip abduction
0 (0)
1 (1)
2 (2)
3 (3)
4 (4)
Muscle strength: right hip adduction
0 (0)
1 (1)
2 (2)
3 (3)
4 (4)
Muscle strength: right knee flexion
0 (0)
1 (1)
2 (2)
3 (3)
4 (4)
Muscle strength: right knee extension
0 (0)
1 (1)
2 (2)
3 (3)
4 (4)
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Muscle strength: right ankle dorsiflexion
0 (0)
1 (1)
2 (2)
3 (3)
4 (4)
Muscle strength: right ankle plantar flexion
0 (0)
1 (1)
2 (2)
3 (3)
4 (4)
Muscle strength: right ankle inversion
0 (0)
1 (1)
2 (2)
3 (3)
4 (4)
Muscle strength: right ankle eversion
0 (0)
1 (1)
2 (2)
3 (3)
4 (4)
Muscle strength: right toe extensors
0 (0)
1 (1)
2 (2)
3 (3)
4 (4)
Muscle strength: right toe flexors
0 (0)
1 (1)
2 (2)
3 (3)
4 (4)
Muscle strength: additional comments
Gait assessment
Normal (1)
Abnormal (2)
Not assessed (3)
Gait on heels
Normal  (1)
Abnormal  (2)
Not assessed (3)
Gait on toes
Normal  (1)
Abnormal  (2)
Not assessed (3)
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NINDS CDE Physical Examination
Amyotrophic Lateral Sclerosis
NINDS Common Data Elements (Physical Examination
Amyotrophic Lateral Sclerosis) Used from the National
Institute of Neurological Disorders and Stroke Common
Data Elements
(https://www.commondataelements.ninds.nih.gov/)
References: Grinnon ST, Miller K, Marler JR, Lu Y, Stout A,
Odenkirchen J, Kunitz S. National Institute of Neurological
Disorders and Stroke Common Data Element Project -
approach and methods. Clin Trials. 2012;9(3):322-9.
All rights reserved. Please visit https://medical-data-
models.org/forms/13984
Physical Examination
Physical Exam
Study-ID:
Study site name
Subject ID
Date of examination
Was a physical exam performed on the
participant/subject?
Yes
No
Allergic/Immunologic
Normal (1)
Abnormal (2)
Not examined (3)
Allergic/Immunologic: please specify abnormality
or if not examined
Cardiovascular
Normal (1)
Abnormal (2)
Not examined (3)
Cardiovascular:Please specify any abnormality or
if not examined
Constitutional symptoms (e.g., fever, weight loss)
Normal (1)
Abnormal (2)
Not examined (3)
Constitutional symptoms (e.g., fever, weight loss):
Please specify any abnormality or if not examined
Ears, Nose, Mouth, and Throat
Normal (1)
Abnormal (2)
Not examined (3)
1 / 3
Ears, Nose, Mouth, and Throat: please specify
any abnormality or if not examined
Endocrine system
Normal  (1)
Abnormal  (2)
Not examined (3)
Endocrine system: please specify any
abnormality or if not examined
Eyes
Normal (1)
Abnormal (2)
Not examined (3)
Eyes: please specify any abnormality or if not
examined
Gastrointestinal
Normal (1)
Abnormal (2)
Not examined (3)
Gastrointestinal: please specify any abnormality
or if not examined
Genitourinary
Normal- (1)
Abnormal (2)
Not examined (3)
Genitourinary:please specify any abnormality or if
not examined
Hematologic/Lymphatic
Normal (1)
Abnormal (2)
Not examined (3)
Hematologic/Lymphatic:Please specify any
abnormality or if not examined
Integumentary (skin and/or breast)
Normal (1)
Abnormal (2)
Not examined (3)
Integumentary (skin and/or breast):Please
specify any abnormality or if not examined
Musculoskeletal (separate from ALS exam)
Normal (1)
Abnormal (2)
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Not examined (3)
Musculoskeletal (separate from ALS
exam):Please specify any abnormality or if not
examined
Neurological (separate from ALS exam)
Normal (1)
Abnormal (2)
Not examined (3)
Neurological (separate from ALS exam):Please
specify any abnormality or if not examined
Psychiatric
Normal (1)
Abnormal (2)
Not examined (3)
Psychiatric:Please specify any abnormality or if
not examined
Respiratory
Normal (1)
Abnormal (2)
Not examined (3)
Respiratory:Please specify any abnormality or if
not examined
Hand preference
Left hand  (1)
Right hand  (2)
Both hands  (3)
Unknown (4)
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Eligibility Allergic Asthma NCT00396409
Efficacy/ Safety of Omalizumab in Patients With Seasonal
Allergic Asthma and Seasonal Allergic Rhinoconjunctivitis;
ODM derived from:
https://clinicaltrials.gov/show/NCT00396409
All rights reserved. Please visit https://medical-data-
models.org/forms/13986
Eligibility Allergic Asthma
NCT00396409
Inclusion Criteria
Gender*
Female (F)
Male (M)
Asthma symptoms are mainly*
patients with a positive rast (>cap2) result for
grass pollen (and/or rye pollen) specific ige at
screening (visit 1 (v1) or within the previous 12
months.*
Yes
No
FEV1*
>= 80
%
Exclusion Criteria
pregnancy*
Yes
No
any coexisting major illness or organ failure*
Yes
No
History of allergy/hypersensitivity (including
medication allergy) that is deemed relevant to the
trial by the investigator. Relevance in this context
refers to any increased risk of hypersensitivity
reaction to trial medication. (Specific concerns
currently identified with respect to the use of
inhaled glutathione in allergic patients per se are
not existing)*
Yes
No
2. patients with a history of food or drug related
severe anaphylactoid or anaphylactic
reaction(s).*
Yes
No
Hypersensitivity*
Hypersensitivity*
1 / 2
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DESCRIBE (DZNE – Clinical Register Study of
neurodegenerative Disorders) CRF Cognition Module Follow-Up
Background and Purpose:
The purpose of the DESCRIBE study is to document the
natural course of diseases in context of medical care of
neurodegenerative disorders as well as cerebrovascular
diseases and to perform phenotyping of the test persons.
Disease-spanning analyses of the measured clincial data,
the results of the imaging processes, results of the analysis
of the biometerials including genetic analysis are planed.
Principal Investigator: Prof. Klockgether, Dr. Spottke DZNE,
Bonn.
Source: DESCRIBE-Studie
http://www.dzne.de/forschung/forschungsbereiche/klinische
-forschung/studien/describe-bn006.html 
Participating Study Sites:
Berlin, Bonn, Göttingen, Dresden, Köln, Magdeburg,
München, Rostock/Greifswald, Tübingen
All rights reserved. Please visit https://medical-data-
models.org/forms/13987
CRF Cognition Module Follow Up
Date of visit
Study-ID:
Date of visit
Follow-Up:
Anamnesis cognition 1: Subjective
cognitive decline
1. Did your memory changed for the worse?
Yes
No
A. If 'yes', does this make you worry?
Yes
No
B. If 'yes', when did deterioration start?
within the last six month (1)
from six month ago on to two years ago
(2)
from two to five years ago (3)
more than five years ago (4)
not specified (5)
C. If 'yes', is your ability in this section worse than
of other persons your age?
Yes
No
D. If 'yes', have you ever consulted or talked to
your doctor about these problems?
Yes
No
E. If 'yes', when for the first time?
1 / 12
months
2. Do you have to grope for words more often
than before?
Yes
No
A. If 'yes', does this make you worry?
Yes
No
B. If 'yes', when did deterioration start?
within the last six month (1)
from six month ago on to two years ago
(2)
from two to five years ago (3)
more than five years ago (4)
not specified (5)
C. If 'yes', is your ability in this section worse than
of other persons your age?
Yes
No
D. If 'yes', have you ever consulted or talked to
your doctor about these problems?
Yes
No
E. If 'yes', when for the first time?
months
3. Do you have more often problems planning
forward-thinking or keeping order?
Yes
No
A. If 'yes', does this make you worry?
Yes
No
B. If 'yes', when did deterioration start?
within the last six month (1)
from six month ago on to two years ago
(2)
from two to five years ago (3)
more than five years ago (4)
not specified (5)
C. If 'yes', is your ability in this section worse than
of other persons your age?
Yes
No
D. If 'yes', have you ever consulted or talked to
your doctor about these problems?
Yes
No
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E. If 'yes', when for the first time?
months
4. Do you make mistakes more frequently, if you
not fully concentrate on one thing?
Yes
No
A. If 'yes', does this make you worry?
Yes
No
B. If 'yes', when did deterioration start?
within the last six month (1)
from six month ago on to two years ago
(2)
from two to five years ago (3)
more than five years ago (4)
not specified (5)
C. If 'yes', is your ability in this section worse than
of other persons your age?
Yes
No
D. If 'yes', have you ever consulted or talked to
your doctor about these problems?
Yes
No
E. If 'yes', when for the first time?
months
5. Did you notice any other mental deterioration?
In which sections?
Yes
No
Other mental deterioation:
A. If 'yes', does this make you worry?
Yes
No
B. If 'yes', when did deterioration start?
within the last six month (1)
from six month ago on to two years ago
(2)
from two to five years ago (3)
more than five years ago (4)
not specified (5)
C. If 'yes', is your ability in this section worse than
of other persons your age?
Yes
No
D. If 'yes', have you ever consulted or talked to
3 / 12
DESCRIBE (DZNE – Clinical Register Study of neurodegenerative
Disorders) CRF Cognition Module Follow-Up
your doctor about these problems?
Yes
No
E. If 'yes', when for the first time?
months
Anamnesis cognition 2: Observed
cognitive decline
Presence of informant (Questions may be asked
while participant is present)
no informant present (no informant
present)
participant refuses interview with relative
(participant refuses interview with
relative)
Informations are reported by: (only one answer)
Brother/Sister (Brother/Sister)
Child (Child)
Friend (Friend)
Other attendant (Other attendant)
Spouse (Spouse)
1. Did the memory of the participant change for
the worse?
Yes
No
Start of deterioation:
within the last six month (1)
from six month ago on to two years ago
(2)
from two to five years ago (3)
more than five years ago (4)
not specified (5)
2. Does the participant have frequently problems
finding words?
Yes
No
Start of deterioation:
within the last six month (1)
from six month ago on to two years ago
(2)
from two to five years ago (3)
more than five years ago (4)
not specified (5)
3.  Does the participant have more often
problems planning forward-thinking or keeping
order?
Yes
No
Start of deterioation:
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within the last six month (1)
from six month ago on to two years ago
(2)
from two to five years ago (3)
more than five years ago (4)
not specified (5)
4. Does the participant make mistakes more
frequently, if he not fully concentrates on one
thing?
Yes
No
Start of deterioation:
within the last six month (1)
from six month ago on to two years ago
(2)
from two to five years ago (3)
more than five years ago (4)
not specified (5)
5. Did you notice any other mental deterioration?
In which sections?
Yes
No
Other mental deterioation:
Start of deterioation:
within the last six month (1)
from six month ago on to two years ago
(2)
from two to five years ago (3)
more than five years ago (4)
not specified (5)
6. Did you notice a change of behavior or
personality of the participant?
Yes
No
Start of change:
within the last six month (1)
from six month ago on to two years ago
(2)
from two to five years ago (3)
more than five years ago (4)
not specified (5)
Mini mental state examination (MMSE)
1. Orientation
1.1. Orientation in time
<= 5
>= 0
1.2. Orientation to place
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<= 5
>= 0
2. Retention in memory
>= 0
<= 3
3. Attention
>= 0
<= 5
4. Powers of recollection
>= 0
<= 3
5. Speech
<= 8
>= 0
6. Drawing
<= 1
>= 0
total score MMSE
>= 0
<= 30
Neuropsychologic testing
1. Do you have difficulties hearing?
Extreme impairment/ loss of hearing
(almost nothing/nothing can be
understood) (Extreme impairment/ loss
of hearing (almost nothing/nothing can
be understood))
Mild impairment (only load speech can
be understood, hearing aid device
necessary) (Mild impairment (only load
speech can be understood, hearing aid
device necessary))
No impairment (speech in normal sound
level is understandable, no hearing
device) (No impairment (speech in
normal sound level is understandable, no
hearing device))
Severe impairment (only if spoken out
very loudly speech can be understood,
communication very difficult) (Severe
impairment (only if spoken out very
loudly speech can be understood,
communication very difficult))
2. Do you have difficulties seeing?
Compounded seeing (reading only
possible with effort;  fatiguing fast; only
large type like headlines can be read
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without effort) (Compounded seeing
(reading only possible with effort;
fatiguing fast; only large type like
headlines can be read without effort))
No impairment (can see well with
glasses on, fine print can be read without
any problems) (No impairment (can see
well with glasses on, fine print can be
read without any problems))
Severe visual impairment (only seeing
shadows, only differing between light-
and dark contrasts; blindness or almost
blindness) (Severe visual impairment
(only seeing shadows, only differing
between light- and dark contrasts;
blindness or almost blindness))
Significant (severe impairment, e.g.
cataract, recognize persons and objects,
reading only with magnifier) (Significant
(severe impairment, e.g. cataract,
recognize persons and objects, reading
only with magnifier))
3. Visus measurement
Start of testing (time):
Initials of head of test
Verbal fluency: Category animals
Total score
>= 0
<= 80
Sum of correct words
Boston naming test
Total score
>= 0
<= 15
Sum of correct words
Please name version of word list:
Version 1 (Version 1)
Version 2 (Version 2)
Version 3 (Version 3)
1. Round: No. of correct answers
<= 10
>= 0
2. Round: No. of correct answers
<= 10
>= 0
3. Round: No. of correct answers
>= 0
<= 10
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1. Round: No. intrusions
>= 0
<= 10
2. Round: No. intrusions
>= 0
<= 10
3. Round: No. of intrusions
<= 10
>= 0
Total score
>= 0
<= 30
Drawing figures: Circle
>= 0
<= 2
no. of points
Drawing figures: Rhombus
>= 0
<= 3
no. of points
Drawing figures: Rectangle
>= 0
<= 2
no. of points
Drawing figures: Cube
>= 0
<= 4
no. of points
Wordlist recall: Total number of correct answers
>= 0
<= 10
Recalling wordlist: Total number of intrusions
>= 0
<= 10
Intrusions total
>= 0
<= 40
Savings
>= 0
<= 100
%
Recognizing wordlist: No. recognized as old
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>= 0
<= 10
Recognizing wordlist: No. recognized as new
>= 0
<= 10
Discriminability
>= 0
<= 100
%
Recalling figures: Circle
>= 0
<= 2
no. of points
Recalling figures: Rhombus
>= 0
<= 3
no. of points
Recalling figures: Rectangle
>= 0
<= 2
no. of points
Recalling figures: Cube
>= 0
<= 4
no. of points
Total
>= 0
<= 11
no. of points
Savings
%
Total
>= 0
<= 80
Sum of correct words
TMT A time needed
>= 0
<= 180
sec
TMT B time needed
>= 0
<= 300
sec
TMT B/A
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Range of numbers
Correct rows forward
>= 0
<= 12
Correct rows backwards
>= 0
<= 12
MWT-B Test: No. correct words
>= 0
<= 37
BTA- Form N (Numbers)
>= 0
<= 10
BTA- Form L (letters)
>= 0
<= 10
BTA total
z-value
Total raw value
>= 0
<= 20
Percentile
>= 0
<= 100
%
Total raw value
>= 0
<= 33
z-value
>= -3
<= 3
The test person was not motivated enough
Yes
No
The test person refused to perform the tasks.
Yes
No
The test person had physical problems like e.g.
sensorial or motor impairment or pain obviously
reducing test performance
Yes
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No
The test person was cognitively over-challenged
performing single task
Yes
No
The test person did not have adequate language
knowledge
Yes
No
If one question was answered 'Yes', please
specify your answer:
The examination was disturbed or interrupted
Yes
No
There were deviations from standard instruction
Yes
No
Tasks have not been performed.
Yes
No
The examination was not compliant to rules for
other reasons.
Yes
No
If one question was answered with 'Yes', please
specify, which subtest the given details address
and how to assess these.
Pill questionnaire
not done
Yes
No
Participant knows name of his pills?
Yes
No
The participant knows in which doses to take the
pills and the color of his pills.
Yes
No
The participant knows the time table of his
medication?
Yes
No
Is the participant able to state medication name,
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doses or color of the pills and time of intake (3
times 'Yes') correctly?
Yes
No
Is the participant able to correctly state time of
intake and at least one of the following features
name, dosis, pill color?
Yes
No
Does your relative take his medication totally
independent and without control?
Yes
No
Does your relative have to be reminded to take
his pills?
Yes
No
Were there ever any incidence when you had to
consult a physician because your relative took his
pills in a wrong way?
Was question 1 in section B2 answered 'Yes' and
question 2 and 3 answered 'No'?
Yes
No
War section B1 answered 'Yes'?
Yes
No
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NINDS CDE Vital Signs Amyotrophic
Lateral Sclerosis
NINDS Common Data Elements (Vital Signs Amyotrophic
Lateral Sclerosis) Used from the National Institute of
Neurological Disorders and Stroke Common Data Elements
(https://www.commondataelements.ninds.nih.gov/)
References: Grinnon ST, Miller K, Marler JR, Lu Y, Stout A,
Odenkirchen J, Kunitz S. National Institute of Neurological
Disorders and Stroke Common Data Element Project -
approach and methods. Clin Trials. 2012;9(3):322-9.
All rights reserved. Please visit https://medical-data-
models.org/forms/13989
Vital Signs
Vital Signs
Study-ID:
Study site name
Subject ID
Date and time
Heart rate
bpm
Respiratory Rate
/min
Blood pressure measurement systolic and
diastolic
mm/Hg
Patient position for blood pressure measurement
Sitting  (1)
Standing  (2)
Supine (3)
Body Temperature
Please specify body temperature measurement
unit
Degrees Fahrenheit (1)
Degrees Celsius (2)
Please specify measurement method
oral (1)
rectal (2)
axillary (3)
tympanic (4)
Body weight
Please specify units used for body weight
measurement
kg (1)
pounds (2)
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Body Height
Body Height: Please specify units used for
measurement
inches (1)
centimeters (2)
Body Mass Index
kg/m2
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Eligibility Allergic Asthma NCT00421018
Optimization of Asthma Treatment Through Exhaled NO for
Increased Asthma-Related Quality of Life (NOAK); ODM
derived from: https://clinicaltrials.gov/show/NCT00421018
All rights reserved. Please visit https://medical-data-
models.org/forms/13991
Eligibility Allergic Asthma
NCT00421018
Inclusion Criteria
Age*
>= 18
<= 64
years
Asthma*
glucocorticoid treatment > 6 months.*
>= 7
months
Yes
No
Hypersensitivity*
read and speak swedish*
Yes
No
Exclusion Criteria
Smoking*
Yes
No
Current therapy*
treatment with singulair only or in combination
with glucocorticoids*
Yes
No
Subject Participation Status in Clinical Study*
pregnancy*
Yes
No
unstable asthma*
Yes
No
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Eligibility Acute Myeloid Leukemia
NCT01489722
Safety, Tolerability, Pharmacokinetics and Efficacy of
AZD1208 in Acute Myelogenous Leukemia (AML) Patients;
ODM derived from:
https://clinicaltrials.gov/show/NCT01489722
All rights reserved. Please visit https://medical-data-
models.org/forms/13996
Eligibility Acute Myeloid Leukemia
NCT01489722
Inclusion Criteria
males or females at least 18 years of age*
Yes
No
Patients with relapsed or refractory acute
myelogenous leukemia (aml) or aml secondary to
myelodysplastic syndromes, myeloproliferative
neoplasm, or chronic myelogenous leukemia*
Yes
No
Eastern oncology cooperative group (ecog)
performance status 0-2 and considered likely to
complete at least 4 weeks of therapy*
Yes
No
Exclusion Criteria
With the exception of alopecia, any unresolved
toxicities from prior therapy greater than ctcae
grade 1 at the time of starting study treatment.*
Yes
No
As judged by the investigator, any evidence of
severe or uncontrolled systemic diseases,
including uncontrolled hypertension, active
bleeding diatheses, or active infection including
hepatitis b, hepatitis c and hiv.*
Yes
No
Active heart disease including myocardial
infarction within the last 3 months, symptomatic
coronary artery disease, clinically significant
arrhythmias not controlled by medication or
uncontrolled congestive heart failure*
Yes
No
Prior allogeneic transplant requiring
immunosuppressive therapy  (patients with prior
allogeneic transplants who remain clinically
stable for ≥ 2 weeks or more off
immunosuppressive therapy, are eligible)*
Yes
No
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White blood cell count ≥ 100,000/mm3
(100x10*9/l)*
Yes
No
type 1 diabetes or uncontrolled type ii diabetes*
Yes
No
hba1c ≥8% or fasting blood glucose >160 mg/dl
(>8.9 mmol/l)*
Yes
No
Baseline fasting total cholesterol >300 mg/dl
(>7.75 mmol/l)*
Yes
No
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Eligibility Acute Myeloid Leukemia
NCT01546038
A Study To Evaluate PF-04449913 With Chemotherapy In
Patients With Acute Myeloid Leukemia or Myelodysplastic
Syndrome; ODM derived from:
https://clinicaltrials.gov/show/NCT01546038
All rights reserved. Please visit https://medical-data-
models.org/forms/13997
Eligibility Acute Myeloid Leukemia
NCT01546038
Inclusion Criteria
Patients with aml or raeb 2 high risk mds who are
newly diagnosed according to the who 2008
classification and previously untreated.*
Yes
No
Patients with aml (arising from an antecedent
hematologic disease [ahd]) or mds who may have
had one prior regimen with commercially
available agents for the treatment of their prior
hematologic disease.  the patients may not have
had a prior therapy for their aml.*
Yes
No
aml patients include de novo aml, aml evolving
from mds or other ahd and aml after previous
cytotoxic therapy or radiation (secondary aml)*
Yes
No
For a diagnosis of aml, a bone marrow blast
count of 20% or more is required.*
Yes
No
For a diagnosis of high-risk myelodysplastic
syndrome raeb 2 the patient must have 10-19%
bone marrow blasts*
Yes
No
Adequate organ function*
Yes
No
ecog performance status 0, 1, or 2*
Yes
No
Exclusion Criteria
aml m3 acute promyelocytic leukemia (apl) or
patients with a t(9:22) cytogenetic translocation.*
Yes
No
patients with known active uncontrolled central
nervous system (cns) leukemia.*
Yes
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No
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Eligibility Acute Myeloid Leukemia
NCT01683123
Study With Intravenous Busulfan And Fludarabine
Myeloablative Conditioning Regimen For HLA Identical
Sibling Donor HSCT; ODM derived from:
https://clinicaltrials.gov/show/NCT01683123
All rights reserved. Please visit https://medical-data-
models.org/forms/13998
Eligibility Acute Myeloid Leukemia
NCT01683123
Inclusion Criteria
Acute myeloid leukemia (AML)*
Yes
No
Myelodysplastic syndrome*
Yes
No
Myeloproliferative disease*
Yes
No
Chronic myeloid leukemia*
Yes
No
Exclusion Criteria
performance status ecog>2*
Yes
No
cardiomyopathy (lvef <39%)*
Yes
No
Pulmonary dysfunction (dlco<39%)*
Yes
No
Hepatic dysfunction grade >1*
Yes
No
Renal dysfunction grade >1 (creatinine > 1.6
mg/dl)*
Yes
No
hiv-infection*
Yes
No
Other active neoplasm*
Yes
No
1 / 1
Eligibility Acute Myeloid Leukemia
NCT01702155
Phase I/II Study of DFP-10917 in Patients With Acute
Leukemia; ODM derived from:
https://clinicaltrials.gov/show/NCT01702155
All rights reserved. Please visit https://medical-data-
models.org/forms/13999
Eligibility Acute Myeloid Leukemia
NCT01702155
Inclusion Criteria
Patients must have pathologically-confirmed
acute leukemia, refractory or relapsed after
standard therapy for the disease or for which
conventional systemic chemotherapy is not
reliably effective or no effective therapy is
available phase ii only: patient must have
histologically or pathologically confirmed
diagnosis of aml based on who classification that
is refractory after standard therapy, or for which
conventional systemic chemotherapy is not
reliably effective, or no effective therapy is
available.  patients aged 60 years or older with
newly diagnosed aml who are not eligible for, or
who refuse, standard care are also eligible.*
Yes
No
Aged ≥ 18 years*
Yes
No
Ecog performance status of 0, 1 or 2*
Yes
No
Adequate clinical laboratory values (i.e., plasma
creatinine <= 1.5 x upper limit of normal (uln) for
the institution, bilirubin <=1.5 x uln, alanine
transaminase (alt) and aspartate transaminase
(ast) <= 2.5 x uln).*
Yes
No
Absence of cns involvement by leukemia.*
Yes
No
Absence of uncontrolled intercurrent illnesses,
including uncontrolled infections, cardiac
conditions, or other organ dysfunctions.*
Yes
No
Signed informed consent prior to the start of any
study specific procedures.*
Yes
No
Women of child-bearing potential must have a
negative serum or urine pregnancy test. male
and female patients must agree to use
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acceptable contraceptive methods for the
duration of the study and for at least one month
after the last drug administration.*
Yes
No
Exclusion Criteria
The interval from prior treatment to time of study
drug administration is < 2 weeks for cytotoxic
agents or < 5 half-lives for noncytotoxic agents.
exceptions: use of hydroxyurea is allowed before
the start of study  and may be administered up to
day 5 of the first cycle.*
Yes
No
Any >grade 1 persistent clinically significant
toxicities from prior chemotherapy.*
Yes
No
Extensive prior radiotherapy to more than 30% of
bone marrow reserves, or prior bone
marrow/stem cell transplantation.*
Yes
No
Any concomitant condition that in the opinion of
the investigator could compromise the objectives
of this study and the patient's compliance.*
Yes
No
A pregnant or lactating woman*
Yes
No
Current malignancies of another type.
exceptions: patients may participate if they have
previously treated and currently controlled
prostate cancer, adequately treated in situ
cervical cancer and basal cell skin cancer or
other malignancies with no evidence of disease
for 2 years or more.*
Yes
No
Patient has acute promyelocytic leukemia (apl).*
Yes
No
Patients with known hiv, hbv or hcv infection
(note: testing for these infections is not
required).*
Yes
No
Documented or known clinically significant
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bleeding disorder*
Yes
No
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Eligibility ALK-positive Advanced NSCLC
NCT02511184
Crizotinib Plus Pembrolizumab In Alk-positive Advanced
Non Small Cell Lung Cancer Patients; ODM derived from:
https://clinicaltrials.gov/show/NCT02511184
All rights reserved. Please visit https://medical-data-
models.org/forms/14000
Eligibility ALK-positive Advanced
NSCLC NCT02511184
Inclusion Criteria
histologically or cytologically proved diagnosis of
locally advanced recurrent or metastatic non-
squamous nsclc that is not suitable  for local
curative treatment.*
Yes
No
alk-positive nsclc as determined by a test that is
approved or validated for use as a companion
diagnostic test.*
Yes
No
no prior systemic therapy for metastatic disease.*
Yes
No
adjuvant chemotherapy more than 12 months
prior to study enrollment.*
Yes
No
Measurable disease as per recist 1.1*
Yes
No
Ecog ps 0 or 1.*
Exclusion Criteria
prior exposure to alk receptor tyrosine kinase
inhibitor, anti-pd1, anti-pdl1 or any drug targeting
t-cell checkpoint pathways.*
Yes
No
Known diagnosis of immunodeficiency or is
receiving systemic steroid therapy or other form
of immunosuppressive therapy within 7 days of
clinical trial treatment.*
Yes
No
Active autoimmune disease that has required
systemic treatment in the past 3 months.*
Yes
No
history of extensive disseminated interstitial
fibrosis or any grade of interstitial lung disease.*
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Yes
No
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Eligibility Acute Myeloid Leukemia
NCT01766375
the Effects and Safety of Idarubicin-strengthened
Pretreatment Program and Conventional Busulfan
Cyclophosphamide Pretreatment Program on High-risk
Acute Myeloid Leukemia Patient; ODM derived from:
https://clinicaltrials.gov/show/NCT01766375
All rights reserved. Please visit https://medical-data-
models.org/forms/14001
Eligibility Acute Myeloid Leukemia
NCT01766375
Inclusion Criteria
Age: 18～50*
Yes
No
Received peripheral blood hematopoietic stem
cell transplantation from siblings or unrelated
allogeneic donors with identical matching of hla
or 1 alleles mismatched.*
Yes
No
Diagnosis: refer to 2011 edition of aml china
guideline for the diagnosis and treatment and
diagnosis standards of high-risk acute myeloid
leukemia developed through literatures (see
appendix b);*
Yes
No
Under general condition, ecog score ≤ 1;*
Yes
No
Normal cardiac functions*
Yes
No
Normal liver and renal function: blood bilirubin≤35
μ mol\/l, ast/alt lower than twice in the upper limit
of normal value, serum creatinine≤ 150 μ mol\/l;*
Yes
No
Subjects have signed the informed consent
form.*
Yes
No
Exclusion Criteria
Severe uncontrolled infection before
transplantation;*
Yes
No
With contraindications of idarubicin*
Yes
No
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Reached the maximum cumulative dose of
anthracyclines, for instance, dnr≥ 450mg/m2,
mitoxantrone≥140mg/m2, the total cumulative
dose of idarubicin≥ 300mg/m2;*
Yes
No
The other conditions that do not meet the
inclusion criteria.*
Yes
No
Withdrawal criteria:*
Those do not meet the inclusion criteria
or meet the exclusion criteria after
reviewing (1)
Patient withdraws the informed consent
form (2)
Patient violates the clinical study protocol
(3)
Patient experiences severe adverse
events that treatment has to be
terminated (4)
Patient that considered no longer fit to
complete clinical trials by researchers.
(5)
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Eligibility Acute Myeloid Leukemia
NCT01810705
GRASPA Treatment for Patients With Acute Myeloblastic
Leukemia; ODM derived from:
https://clinicaltrials.gov/show/NCT01810705
All rights reserved. Please visit https://medical-data-
models.org/forms/14002
Eligibility Acute Myeloid Leukemia
NCT01810705
Inclusion Criteria
Patient over 65 years old and less than 85 years
old*
Yes
No
Newly diagnosed acute myeloid leukemia or post
myelodysplastic syndrome diagnosed in the 6
months prior study enrollment*
Yes
No
unfit for intensive chemotherapy (at risk to suffer
treatment related pejorative toxicities /early
death) or patient unwilling to receive intensive
chemotherapy*
Yes
No
who performance status ≤2 and estimated life
expectancy ≥ 3 months*
Yes
No
eligible to receive low-dose cytarabine treatment*
Yes
No
Evidence of post-menopausal status for female
(absence of menstruation for 12 months)*
Yes
No
Exclusion Criteria
Patients with m3 aml of french american british
classification ( acute promyelocytic leukemia)*
Yes
No
Patients with aml involving chromosome 16
abnormalities or translocation (8:21)*
Yes
No
history of grade 3-4 pancreatitis or grade 3-4
thromboembolic event*
Yes
No
presenting with a general or visceral
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contraindication (uncontrolled or severe
cardiovascular disease ; plasma creatinine
concentration 2 times greater than the upper limit
of laboratory ranges ; aspartate aminotransferase
(ast) or alanine aminotransferase (alt) levels, 3.5
times greater than the upper limit of laboratory
ranges ; patient presenting evolutive cancer other
than aml, except in situ basal-cell carcinoma or in
situ cervix cancer ; severe evolutive infection, or,
hiv seropositive or, active hepatitis related to b or
c viral infection)*
Yes
No
History of grade 3 transfusional incident*
Yes
No
Has known or suspected hypersensitivity or
intolerance to mannitol*
Yes
No
Patient presenting contraindication to cytarabine
treatment*
Yes
No
Participation in an investigational drug study
within the 30 days prior to entry*
Yes
No
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Eligibility Acute Myeloid Leukemia
NCT01819558
Phase I/II Study of Immune Therapy After Allograft in
Patients With Myeloid Hemopathy; ODM derived from:
https://clinicaltrials.gov/show/NCT01819558
All rights reserved. Please visit https://medical-data-
models.org/forms/14003
Eligibility Acute Myeloid Leukemia
NCT01819558
Inclusion Criteria
Patients older than 18 and younger than 65
years.*
Yes
No
Karnofsky Performance Status ≥ 70 %*
Yes
No
Patients with acute or chronic myeloid leukemia,
or myelodysplastic syndrome, who underwent
allogeneic stem cell transplantation from hla-
identical donor (related or unrelated) after
reduced-intensity conditioning regimen.*
Yes
No
Patients in morphologic complete remission at
the time of transplantation.*
Yes
No
Wt1 expression detectable on tumor cells.*
Yes
No
Expected life duration more than 6 months.*
Yes
No
Creatinine clearance ≥ 50 ml/min*
Yes
No
Bilirubinemia < 1.5n and asat < 2.5n*
Yes
No
Women of childbearing age: negative pregnancy
test and effective contraception for at least 30
days before vaccinal immunotherapy (the same
contraceptive method must be continued at least
2 months after the last vaccine infusion).*
Yes
No
Membership of a social security scheme or
beneficiary of such a regime.*
Yes
No
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Signed inform consent*
Yes
No
Exclusion Criteria
Patients with severe and uncontrolled affections,
especially active graft-versus-host disease
requiring steroid treatment (>0.3 mg/kg/j) and/or
mycophenolate mofetil.*
Yes
No
Pregnant or lactating women*
Yes
No
HIV Seropositivity*
Yes
No
Autoimmune disease (lupus, multiple sclerosis,
chrone disease)*
Yes
No
Previous history of allergic state which could be
potentially compound by a component of the
vaccinal immunotherapy.*
Yes
No
Patients who received (or are planned to receive)
another experimental treatment within 30 days
following the first infusion of the experimental
drug of this protocol.*
Yes
No
Previous history of another cancer, except if
considered as probably cured by the
investigator.*
Yes
No
Patients deprived of liberty, or under
guardianship.*
Yes
No
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Eligibility Acute Myeloid Leukemia
NCT01889407
Idarubicin Overcomes MDR1 Induced Chemoresistance
With Higher Induction Remission Rate and Quality Than
Daunorubicin in Acute Myeloid Leukemia Patients; ODM
derived from: https://clinicaltrials.gov/show/NCT01889407
All rights reserved. Please visit https://medical-data-
models.org/forms/14004
Eligibility Acute Myeloid Leukemia
NCT01889407
Inclusion Criteria
Diagnosis of aml (who classification definition of
>/= 20% blasts).*
Yes
No
Patients aged 16 to 60 years are eligible. patients
must be chemo-naïve, i.e. not have received any
prior chemotherapy (except hydrea) for aml. they
could have received transfusion, hematopoietic
growth factors or vitamins. temporary measures
such as pheresis or hydrea (0.5 to 5g daily or
more for up to 3 days) are allowed.*
Yes
No
the relative expression level of mdr1 mrna
(mdr1/gapdh ratio using the quantitative real-time
pcr) in pre-treated bone marrow samples should
over 0.016 (cut-off point from our results of
preliminary experiment data)*
Yes
No
ECOG performance status of 0, 1, 2 at
screening*
Yes
No
Serum biochemical values with the following
limits: - creatinine </= 2.0 mg/dl -*
Yes
No
Total bilirubin </= 2.0 mg/dl, unless increase is
due to hemolysis -*
mg/dl
Yes
No
Transaminases (sg pt) </= 3x uln*
Yes
No
Ability to understand and provide signed informed
consent.*
Yes
No
Exclusion Criteria
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Subjects with acute promyelocytic leukemia (apl)*
Yes
No
Presence of active systemic infection*
Yes
No
Any coexisting medical condition that in the
judgment of the treating physician is likely to
interfere with study procedures or results.*
Yes
No
Nursing women, women of childbearing potential
with positive urine pregnancy test, or women of
childbearing potential who are not willing to
maintain adequate contraception (such as birth
control pills, iud, diaphragm, abstinence, or
condoms by their partner) over the entire course
of the study.*
Yes
No
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VX-950HPC3006 NCT01571583
Administration of Ribavirin
This is an open-label (all people know the identity of the
intervention), multicenter study in genotype 1 chronic HCV
infected liver transplant patients who will be treated for 12
weeks with telaprevir 750 mg every 8 hours given in
combination with Peg-IFN-alfa-2a and ribavirin followed by
36 weeks of treatment with Peg-IFN-alfa-2a and ribavirin
alone. The total treatment duration will be 48 weeks. Safety
will be evaluated throughout the study and will include
evaluations of adverse events, clinical laboratory tests,
electrocardiogram, vital signs, and physical examination.
NCT01571583
All rights reserved. Please visit https://medical-data-
models.org/forms/14013
VX-950HPC3006 NCT01571583
Administration of Ribavirin
Administration of Ribavirin
start date*
end date*
total daily dose*
mg
frequency*
b.i.d. - twice daily (1)
other, please specify (2)
reason for change
AE (1)
weight change (2)
other specify (3)
row number
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Eligibility Acute Myeloid Leukemia
NCT01961882
A Phase 2 Trial to Evaluate the Efficacy and Safety of OCV-
501 in Elderly Patients With Acute Myeloid Leukemia; ODM
derived from: https://clinicaltrials.gov/show/NCT01961882
All rights reserved. Please visit https://medical-data-
models.org/forms/14020
Eligibility Acute Myeloid Leukemia
NCT01961882
Inclusion Criteria
Patients with aml who achieved first complete
remission within one or two courses of standard
induction therapy, and completed standard
consolidation therapy (more than one course).*
Yes
No
Patients who are 60 years or older.*
Yes
No
Patients who have provided written informed
consent within 90 days from the last dose of
consolidation therapy on an informed consent
form that has been approved by an institutional
review board or independent ethics committee.*
Yes
No
Exclusion Criteria
Patients who have acute promyelocytic leukemia
(apl) with t(15;17) (q22;q12), (pml/rara) karyotype
abnormalities, and other variant types.*
Yes
No
Patients who are scheduled for hematopoietic
stem cell transplantation*
Yes
No
Patients who have received drugs potentially
affecting the immune system within 4 weeks
before starting imp administration or who may
receive such drugs after start of the trial.*
Yes
No
Patients who have a severe concurrent disease
or psychiatric illness likely to interfere with
participation in this trial.*
Yes
No
Patients who are hiv antibody positive, hbv-dna
positive or  have unrecovered chronic hepatitis c
with positive hcv antibody.*
Yes
No
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Patients who have cirrhosis.*
Yes
No
Patients judged to be ineligible by the investigator
(or subinvestigator) for any other reasons.*
Yes
No
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Eligibility Acute Myeloid Leukemia
NCT02188290
Transplant-Related Mortality in Patients Undergoing a
Peripheral Blood Stem Cell Transplantation or an Umbilical
Cord Blood Transplantation; ODM derived from:
https://clinicaltrials.gov/show/NCT02188290
All rights reserved. Please visit https://medical-data-
models.org/forms/14022
Eligibility Acute Myeloid Leukemia
NCT02188290
Inclusion Criteria
Acute myeloid leukemia (aml) in remission at the
time of the transplantation*
Yes
No
Acute lymphoblastic leukemia (all) in remission at
the time of the transplantation*
Yes
No
Myelodysplastic syndrome*
Yes
No
Allogeneic t-cell depleted hsct without atir
administration from a haploidentical donor
between 1 january 2006 and 30 june 2013 (haplo
group)*
Yes
No
allogeneic hsct from a fully matched or 1-locus
mismatched unrelated donor between 1 january
2010 and 31 december 2012 (mud/mmud
groups)*
Yes
No
Double umbilical cord blood transplantation
between 1 january 2010 and 31 december 2012
with no more than 2 human leukocyte antigen
(hla)-mismatches at hla-a,  b, and/or -dr between
each of the units and the recipient (ucb group)*
Yes
No
Male or female, age ≥ 18, ≤ 65 years.*
Yes
No
Exclusion Criteria
allogeneic stem cell transplantation prior to the
transplantation qualifying for the study.*
Yes
No
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Eligibility Acute Myeloid Leukemia
NCT02190695
A Safety and Efficacy Study Using Decitabine,
Decitabine/Carboplatin, Decitabine/Arsenic for the
Treatment of Relapsed, Refractory, and Elderly Acute
Myeloid Leukemia , Myelodysplastic Syndrome and Chronic
Myelomonocytic Leukemia; ODM derived from:
https://clinicaltrials.gov/show/NCT02190695
All rights reserved. Please visit https://medical-data-
models.org/forms/14023
Eligibility Acute Myeloid Leukemia
NCT02190695
Inclusion Criteria
acute myeloid leukemia, relapsed or refractory
and elderly(over 65)*
Yes
No
acute myeloid leukemia under 65 but who are
unfit for conventional therapy*
Yes
No
de novo or treated myelodysplastic syndrome,
chronic myelomonocytic leukemia who are int-1or
above*
Yes
No
Patients may have prior exposure to azacitidine
but no decitabine*
Yes
No
Must be off all chemotherapy for 2 weeks and
recovered from any toxicities unless rapidly
progressive disease.*
Yes
No
Hydrea is permitted for first 4 cycles*
Yes
No
Performance 0-2 (ecog)*
Yes
No
Adequate cardiac functions assessed by 2d echo
(nyha cardiac iii-iv excluded)*
Yes
No
Pretreatment Electrocardiogram*
Yes
No
Lab results*
Creatinine (1)
Total billirubine (2)
Absence of significant intercurrent illness such as
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uncontrolled heart failure, unstable angina or
cardiac arrhythmia*
Yes
No
Psychiatric illness which precludes the giving of
informed consent*
Yes
No
Informed Consent*
Yes
No
Exclusion Criteria
Nursing and pregnant females*
Yes
No
Current uncontrolled infections*
Yes
No
Uncontrolled intercurrent illness including , but
not limited to the above list*
Yes
No
Chronic kidney disease> stage 3*
Yes
No
Hiv infection*
Yes
No
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Eligibility Coronary Artery Disease
NCT00225654
The ELUTES Clinical Trial; ODM derived from:
https://clinicaltrials.gov/show/NCT00225654
All rights reserved. Please visit https://medical-data-
models.org/forms/14024
Eligibility Coronary Artery Disease
NCT00225654
Inclusion Criteria
patient must be eligible to undergo planned
treatment of a single de novo lesion in a native
coronary artery.*
Yes
No
patient must be an acceptable candidate for
coronary artery bypass surgery.*
Yes
No
patient or legal guardian must have signed
informed consent.*
Yes
No
patient agrees to return at one month for an office
visit to assess cardiovascular status and at 6
months for an office visit to assess cardiovascular
status and for a diagnostic angiogram.*
Yes
No
Exclusion Criteria
patient must be less than 18 years old.*
Yes
No
patient has history of bleeding diathesis or
coagulopathy or will refuse blood transfusions.*
Yes
No
patient is simultaneously participating in another
investigative interventional cardiovascular device
or drug study.*
Yes
No
patient has known hypersensitivity or
contraindication to aspirin, clopidogrel, or
stainless steel, or a sensitivity to contrast dye
that.*
Yes
No
women of child bearing potential.*
Yes
No
patient has other medical condition that may
cause non-compliance with the protocol,
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confound the results, or is associated with limited
life expectancy.*
Yes
No
patient has been diagnosed with a myocardial
infarction within 72 hours prior to procedure.*
Yes
No
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Eligibility Acute Myeloid Leukemia
NCT02250937
Allogeneic Transplantation Using Timed Sequential
Busulfan, Cladribine, and Fludarabine Conditioning in
Patients With Acute Myelogenous Leukemia (AML) and
Myelodysplastic Syndrome (MDS); ODM derived from:
https://clinicaltrials.gov/show/NCT02250937
All rights reserved. Please visit https://medical-data-
models.org/forms/14026
Eligibility Acute Myeloid Leukemia
NCT02250937
Inclusion Criteria
Patients with acute myeloid leukemia or
myelodysplastic syndrome not in complete
remission (patients with disease detectable only
by flow cytometry, cytogenetics, or molecular
studies are eligible).*
Yes
No
Hla-identical sibling or 8/8 matched unrelated
donor transplant.*
Yes
No
Patients age 18 to 70 years old. Eligibility for
pediatric patients will be determined in
conjunction with an mdacc pediatrician. patients
age 2-17 years old may be enrolled after at least
10 adults (ages 18-70 years old) have been
assessed for safety at day 30, as defined in the
statistical considerations section.*
Yes
No
Direct bilirubin < 1 mg/dl and alt < 3 times upper
limit of normal.*
mg/dl
Yes
No
Creatinine clearance > 50 ml/min (calculated
creatinine clearance is permitted).*
Yes
No
Adequate pulmonary function with fev1, fvc and
dlco >/=50% of expected corrected for
hemoglobin and/or volume. children unable to
perform pulmonary function tests (e.g., less than
7 years old) pulse oximetry of >/= 92% on room
air.*
Yes
No
Lvef >/= 40%.*
Yes
No
Able to sign informed consent.*
Yes
No
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Negative beta hcg test in a woman with child
bearing potential, defined as not post-
menopausal for 12 months or no previous
surgical sterilization. women of child bearing
potential must be willing to use an effective
contraceptive measure while on study.*
Yes
No
Performance score of >/= 70 by karnofsky/lansky
or ps 0 to 1 (ecog </=1).*
Yes
No
Exclusion Criteria
Prior allogeneic or autologous transplantation.*
Yes
No
Uncontrolled infections.*
Yes
No
HIV Seropositivity*
Yes
No
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Eligibility Acute Myeloid Leukemia
NCT02277847
Idarubicin at Different Dosages as Induction Therapy for
Newly Diagnosed Acute Myeloid Leukaemia; ODM derived
from: https://clinicaltrials.gov/show/NCT02277847
All rights reserved. Please visit https://medical-data-
models.org/forms/14027
Eligibility Acute Myeloid Leukemia
NCT02277847
Inclusion Criteria
age: 14~60 years old;no gender limit.*
Yes
No
diagnosis: according to the diagnosis standards
of aml( with the exception of m3 ) ( according to
2008 who diagnosis criteria of aml)*
Yes
No
performance status is not bad with eastern
cooperative oncology group (ecog) score*
Yes
No
Written informed consent obtained prior to the
initiation of any study related procedures*
Yes
No
Exclusion Criteria
chronic myelogenous leukemia (cml) in crisis
phase.*
Yes
No
aml transformed from other myeloproliferative
diseases.*
Yes
No
Patient is accompanied with other progressing
neoplasms.*
Yes
No
With severe malfunction of liver, lungs, kidneys or
heart: the plasma levels of direct bilirubin, indirect
bilirubin, alanine transaminase, aspartate
transaminase and serum creatinine all are 2
times higher than normal, cardiac function is
above grade ii.*
Yes
No
Infection*
Yes
No
1 / 1
Eligibility Acute Myeloid Leukemia
NCT02293993
Phase 1 Study of SGI-110 in Patients With Acute Myeloid
Leukemia; ODM derived from:
https://clinicaltrials.gov/show/NCT02293993
All rights reserved. Please visit https://medical-data-
models.org/forms/14029
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Inclusion Criteria
Male or female patients with a diagnosis of aml
(who classification 2008).*
Yes
No
patients, 20 years of age or older, who are
unresponsive to standard chemotherapy or have
relapsed following standard chemotherapy*
Yes
No
patients, 65 years of age or older, who are not
eligible for standard intensive chemotherapy*
Yes
No
Patients with ecog performance status (ps) of 0 to
2*
Yes
No
Patients with adequate organ function*
Yes
No
women of child-bearing potential must not be
pregnant or breast feeding (pregnancy test will be
performed at screening).  women of child bearing
potential and all men with female partners of child
bearing potential must practice two medically
acceptable methods of birth control and must not
become pregnant or father a child while receiving
treatment with sgi-110 and for 3 months following
last dosing.*
Yes
No
Patients who have undergone prior allogeneic
hematopoietic stem cell transplantation must
have no evidence of active graft-versus host
disease (gvhd) and must be off
immunosuppressive therapy by ≥2 weeks prior to
imp administration.*
Yes
No
Exclusion Criteria
patients with acute promyelocytic leukemia
accompanied by t(15;17)(q22;q12) or (pml/rara)
karyotype abnormalities (include other variant
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types of apl)*
Yes
No
patients with multiple cancers (except for
adequately treated basal cell or squamous cell
skin cancer, in situ cervical cancer, or other
cancer from which the subject has been disease
free for at least 3 years)*
Yes
No
subjects with life-threatening illnesses other than
aml or mds, uncontrolled medical conditions or
organ system dysfunction which, in the
investigator's opinion, could compromise the
subject's safety, or put the study outcomes at
risk.*
Yes
No
patients with poorly controlled arrhythmias, or any
class 3 or 4 cardiac disease as defined by the
new york heart association functional
classification*
Yes
No
patients with symptomatic central nervous
system involvement.*
Yes
No
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Eligibility Acute Myeloid Leukemia
NCT02298166
Study of Crenolanib in Combination Combination With
Chemotherapy in Patients With Relapsed or Refractory
Acute Myeloid Leukemia and Activating FLT3 Mutations;
ODM derived from:
https://clinicaltrials.gov/show/NCT02298166
All rights reserved. Please visit https://medical-data-
models.org/forms/14030
Eligibility Acute Myeloid Leukemia
NCT02298166
Inclusion Criteria
Patients with confirmed diagnosis of aml either
refractory to induction therapy or relapsed after
first line treatment including chemotherapy,
autologous and allogeneic hsct*
Yes
No
Refractory to induction therapy is defined as no
cr, cri, pr (according to standard criteria, 28) after
one intensive induction therapy including at least
7 days of cytarabine 100-200mg/m² continuously
and 3 days of an anthracycline (e.g.
daunorubicin, idarubucin )*
Yes
No
Relapsed after first line therapy is defined as
relapsed aml (according to standard criteria, 28)
after a first line therapy including at least one
intensive induction and consolidation therapy*
Yes
No
Presence of flt3-activating mutation at the time of
refractory disease or relapse assessed in the
central amlsg reference laboratories; positivity
positivity of flt3-itd and flt3-tkd is defined based
on genescan analysis with a mutant to wild-type
ratio equal or above 5%*
Yes
No
Patients considered eligible for intensive
chemotherapy*
Yes
No
Ecog performance status of ≤ 2*
Yes
No
Age ≥ 18 years with the capacity to give written
informed consent*
Yes
No
Non-pregnant and non-nursing women of
childbearing potential (wocbp) must have a
negative serum or urine pregnancy test within a
1 / 4
sensitivity of at least 25 miu/ml within 72 hours
prior to registration ("women of childbearing
potential" is defined as a sexually active mature
woman who has not undergone a hysterectomy
or who has had menses at any time in the
preceding 24 consecutive months)*
Yes
No
Female patients of reproductive age and male
patients must agree to avoid getting pregnant or
to father a child while on therapy and for 3
months after the last dose of crenolanib*
Yes
No
Women of child-bearing potential must either
commit to continued abstinence from
heterosexual intercourse or begin one acceptable
method of birth control (iud, tubal ligation, or
partner's vasectomy). hormonal contraception is
an inadequate method of birth control*
Yes
No
men must use a latex condom during any sexual
contact with women of childbearing potential,
even if they have undergone a successful
vasectomy (while on therapy and for 3 month
after the last dose of crenolanib)*
Yes
No
Willing to adhere to protocol specific
requirements*
Yes
No
Following receipt of verbal and written information
about the study, the patient must provide signed
informed consent before any study related activity
is carried out*
Yes
No
Exclusion Criteria
ecog performance status >2 3
Yes
No
Known or suspected hypersensitivity to the study
drugs and/or any excipients*
Yes
No
inadequate cardiac function defined as: ejection
fraction < 45% confirmed by echocardiography*
Yes
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No
inadequat renal function at the screening visit
defined as: creatinine >1.5x upper normal serum
level*
Yes
No
inadequat liver function at the screening visit
defined as: total bilirubin, ast or alt  >2.5 upper
normal serum level*
Yes
No
Any clinically significant, advanced or unstable
disease or history of that may interfere with
primary or secondary variable evaluations or put
the patient at special risk*
Yes
No
myocardial infarction, unstable angina within 3
months before screening*
Yes
No
heart failure nyha iii/iv*
Yes
No
severe obstructive or restrictive ventilation
disorder*
Yes
No
uncontrolled infection 6. severe neurological or
psychiatric disorder interfering with ability of
giving an informed consent 7. currently receiving
a therapy not permitted during the study, as
defined in section 10.6.5 8. active graft-versus-
host disease (gvhd) under immunosuppressive
therapy different from steroids 9. patients with a
"currently active" second malignancy other than
non-melanoma skin cancers. patients are not
considered to have a "currently active"
malignancy if they have completed therapy and
are considered by their physician to be at less
than 30% risk of relapse within one year 10.
known history of positive test for hepatitis b
surface antigen (hsbag) or hepatitis c antibody or
history of positive test for human
immunodeficiency virus (hiv) 11. hematological
disorder independent of leukemia 12. no consent
for registration, storage and processing of the
individual disease characteristics and course as
well as information of the family physician and/or
other physicians involved in the treatment of the
patient about study participation 13. no consent
for biobanking 14. current participation in any
other interventional clinical study within 30 days
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before the first administration of the
investigational product or at any time during the
study 15. patients known or suspected of not
being able to comply with this trial protocol 16.
breast feeding women or women with a positive
pregnancy test at screening visit 17. patients of
childbearing potential not willing to use adequate
contraception during study and 3 months after
last dose of crenolanib*
Yes
No
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Eligibility Acute Myeloid Leukemia
NCT02319135
Azacytidine (Vidaza®) Versus Fludarabine and Cytarabine
(Fluga Scheme) in Elderly Patients With Newly Diagnosed
Acute Myeloid Leukemia; ODM derived from:
https://clinicaltrials.gov/show/NCT02319135
All rights reserved. Please visit https://medical-data-
models.org/forms/14031
Eligibility Acute Myeloid Leukemia
NCT02319135
Inclusion Criteria
Having voluntarily given informed consent before
performing any test that is not part of*
Yes
No
Routine care of patients.*
Yes
No
Age greater than or equal to 65.*
Yes
No
Morphological diagnosis of non-promyelocytic
aml according to the who criteria.*
Yes
No
Ecog performance status <4.*
Yes
No
Ability and willingness to comply with the
schedule of study visits.*
Yes
No
Exclusion Criteria
Genetic diagnosis of acute promyelocytic
leukemia.*
Yes
No
Patients with aml secondary to myelodysplastic
syndrome (mds) or chronic myeloproloferative
syndrome who have been previously treated with
antileukemic agents*
Yes
No
hypomethylating or standard chemotherapy.*
Yes
No
serum creatinine ≥ 250 mmol / l (≥ 2.5 mg/dl)
(unless attributed to aml).*
Yes
No
1 / 2
bilirubin, alkaline phosphatase or alt > 5 times the
value of the upper limit of normal (unless
attributed to aml) .*
Yes
No
presence of an active and/or non controlled
pathology different to aml which is severe and
life-threatening, that in the investigator's opinion,
prevents the subject participation in the study.*
Yes
No
other active concomitant malignancy or whose
remission is less than one year from the
screening day (except carcinoma in situ).*
Yes
No
presence of any psychiatric illness or medical
condition that, in the investigator's opinion,
prevents the subject participation in the study.*
Yes
No
life expectancy less than x months.*
Yes
No
inability of the patient or his legal representative
to understand and voluntarily sign the informed
consent form.*
Yes
No
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Eligibility ALK Positive Non Small Cell Lung
Cancer NCT01970865
A Study Of PF-06463922 An ALK/ROS1 Inhibitor In
Patients With Advanced Non Small Cell Lung Cancer With
Specific Molecular Alterations; ODM derived from:
https://clinicaltrials.gov/show/NCT01970865
All rights reserved. Please visit https://medical-data-
models.org/forms/14032
Eligibility ALK Positive Non Small
Cell Lung Cancer NCT01970865
Inclusion Criteria
evidence of histologically or cytologically
confirmed diagnosis of locally advanced or
metastatic nsclc (stage iv, ajcc v7.0) that carries
an alk rearrangement, as determined by the food
and drug administration (fda) approved fish assay
(abbott molecular inc) or by
immunohistochemistry (ihc) (ventana inc), or a
ros1 rearrangement as determined by fish or rt
pcr or next generation sequencing (ngs) via a
local diagnostic test (ldt).*
Yes
No
alk+ nsclc patients must either be treatment
naïve in the advanced setting or have had
disease progression after 1or 2 previous alk
inhibitor therapy(ies), as the last therapy given
(phase 1 allows for intervening chemotherapy
and more than 2 prior alk inhibitors).*
Yes
No
ros1+ nsclc patients must either be treatment
naïve in the advanced setting or have had
disease progression after 1or 2 previous ros1
inhibitor therapy(ies), as the last therapy given
(phase 1 allows for intervening chemotherapy
and more than 2 prior ros inhibitors).*
Yes
No
archival tissue sample available collected prior to
enrollment.*
Yes
No
all patients must have at least one measurable
target extracranial lesion according to recist v1.1.
in addition patients with asymptomatic cns
metastases (including patients asymptomatic by
means of stable or decreasing doses of steroids
within the last 2 weeks prior to study entry) are
eligible.*
Yes
No
adequate bone marrow, pancreatic, renal, liver
function.*
Yes
No
pregnancy test (for females of childbearing
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potential) negative at screening and at the
baseline visit . male and female patients of
childbearing potential must agree to use two
highly effective methods of contraception from
the time of the first negative pregnancy test at
screening, throughout the study and for 90 days
after the last dose of assigned treatment.*
Yes
No
Exclusion Criteria
radiation therapy (except palliative to relieve bone
pain) within 2 weeks of study entry.  stereotactic
or small field brain irradiation must have
completed at least 2 weeks prior to study entry.
whole brain radiation must have completed at
least 4 weeks prior to study entry.*
Yes
No
systemic anticancer therapy completed within a
minimum of 5 half-lives of study entry.*
Yes
No
any one of the following currently or in the
previous 3 months: myocardial infarction,
congenital long qt syndrome, torsades de
pointes, arrhythmias (including sustained
ventricular tachyarrhythmia and ventricular
fibrillation), right bundle branch block and left
anterior hemiblock (bifascicular block), unstable
angina, coronary/peripheral artery bypass graft,
symptomatic congestive heart failure (chf ny
heart association class iii or iv), cerebrovascular
accident, transient ischemic attack or
symptomatic pulmonary embolism not adequately
medically managed with anticoagulants; as well
as bradycardia defined as <50 bpms.  ongoing
cardiac dysrhythmias of nci ctcae grade ≥ 2,
symptomatic atrial fibrillation of any grade, or qtc
interval >=481 msec at screening.  right bundle
branch block.*
Yes
No
history of extensive, disseminated, bilateral or
presence of grade 3 or 4 interstitial fibrosis or
interstitial lung disease.*
Yes
No
current use or anticipated need for food or drugs
that are known strong or moderate cyp3a4
inhibitors, inducers and cyp3a4 substrates with
narrow therapeutic indices.*
Yes
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No
concurrent use of drugs that are cyp2c9
substrates with narrow therapeutic indices or
those that are sensitive cyp2b6 substrates.*
Yes
No
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Eligibility Alcoholism NCT00338962
Naltrexone & SSRI in Alcoholics With Depression/PTSD;
ODM derived from:
https://clinicaltrials.gov/show/NCT00338962
All rights reserved. Please visit https://medical-data-
models.org/forms/14034
Eligibility Alcoholism NCT00338962
Inclusion Criteria
dsm-iv diagnosis of alcohol dependence and
current dsm-iv depressive disorder or ptsd*
Yes
No
a recent episode of heavy drinking*
Yes
No
outpatient, sober from alcohol and other abused
substance for at least 2 days before
randomization*
Yes
No
stable medication regiment for at least 2 weeks*
Yes
No
women on adequate methods of contraception*
Yes
No
Exclusion Criteria
current opioid dependence or abuse*
Yes
No
history (within the last 3 months) of opioid
dependence or abuse*
Yes
No
pregnant*
Yes
No
history of psychotic disorders or current treatment
with antipsychotic medications*
Yes
No
medication thought to influence drinking
including: acamprosate, disulfiram, naltrexone,
ondansetron, valproic acid or tegretol*
Yes
No
current (within the lst 6 months) use of mao
inhibitors*
Yes
1 / 2
No
suicidal active ideation or intent*
Yes
No
significant underlying medical condition*
Yes
No
history of cardiac condition abnormalities*
Yes
No
2 / 2
Eligibility Alcoholism NCT00338962
Eligibility Alcoholic Hepatitis NCT02473341
Comparison of Combination Therapy of Corticosteroids and
Bovine Colostrum Versus Corticosteroids and Placebo:
Randomized Double Blind Placebo Controlled Trial in
Treatment of Severe Alcoholic Hepatitis; ODM derived from:
https://clinicaltrials.gov/show/NCT02473341
All rights reserved. Please visit https://medical-data-
models.org/forms/14035
Eligibility Alcoholic Hepatitis
NCT02473341
Inclusion Criteria
alcoholic hepatitis*
Yes
No
jaundice < 3 months*
Yes
No
first liver decompensating event*
Yes
No
bilirubin > 5 mg/dl*
mg/dl
Yes
No
pti (inr) increased*
Yes
No
neutrophilia*
Yes
No
ast< 300 iu/l ; ast/alt >2*
Yes
No
hepatic encephalopathy*
Yes
No
men and women age > 18 years and above*
Yes
No
df≥32 or meld≥20*
Yes
No
actively consuming alcohol within 6 weeks of
entry into the study*
Yes
No
patient with controlled upper gi bleed, resolved
sepsis and acute kidney injury can be enrolled*
Yes
No
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liver biopsy (as many as possible)*
Yes
No
Exclusion Criteria
failure to obtain informed consent*
Yes
No
jaundice more then 3 months*
Yes
No
ast>300 iu/l*
Yes
No
active infection or sepsis*
Yes
No
other concomitant causes of liver disease: viral
hepatitis, autoimmune liver disease, metabolic
liver disease, vascular liver disease*
Yes
No
hiv positive*
Yes
No
cow milk allergy or severe lactose intolerance*
Yes
No
active gastrointestinal bleeding.*
Yes
No
acute kidney injury at time of randomization with
creatinine > 1.5 mg/dl*
Yes
No
evidence of acute pancreatitis or biliary
obstruction*
Yes
No
subjects who are pregnant or lactating*
Yes
No
Significant systemic cardio-pulmonary illness*
Yes
No
patients requiring the use of vasopressors or
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inotropic support in 12 hours prior to
randomization*
Yes
No
treatment for alcoholic hepatitis within 1 month of
study entry with corticosteroids use>1 week.*
Yes
No
any patient who has received any investigational
drug or device within 30 days entering into the
study.*
Yes
No
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Eligibility Alcoholic Hepatitis NCT02442180
Efficacy and Safety of G-CSF in Patients With Severe
Alcoholic Hepatitis With Null or Partial Response to Steroid;
ODM derived from:
https://clinicaltrials.gov/show/NCT02442180
All rights reserved. Please visit https://medical-data-
models.org/forms/14037
Eligibility Alcoholic Hepatitis
NCT02442180
Inclusion criteria
clinical significant alcohol intake history (men
over 50g within 3 months, women over 40g within
3 months)*
Yes
No
modified df score greater than or equal to 32*
Yes
No
transjugular liver biopsy shows typical feature of
alcoholic hepatitis or meet the clinical diagnosis
(total serum bilirubin level over 5 mg/dl, aspartate
aminotransferase/alanine aminotransferase ratio
>2, aspartate aminotransferase < 300 iu/l)*
Yes
No
included patients should meet the all above
criteria and lille score > 0.16  at the day 7 of
prednisolone 40mg (or 32 mg of
methylprednisolone) daily treatment.*
Yes
No
Exclusion criteria
hepatitis b surface antigen (hbsag), anti-hepatitis
c virus (anti-hcv), or anti-human
immunodeficiency virus (hiv) (+)
Yes
No
hepatocellular carcinoma
Yes
No
portal vein thrombosis, hemochromatosis,
autoimmune hepatitis, wilson's disease, alpha-1-
antitrypsin deficiency
Yes
No
pregnancy, breast feeding, or who refuses
contraception, or who cannot do contraception
Yes
No
history of adverse event including allergic
response, hypersensitivity to g-csf
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Yes
No
hypovolemic shock due to gastrointestinal
hemorrhage or who need packed red blood cell
(rbc) transfusion more than 3 units or increased
modified discriminant factor (df) score greater or
equal to 32 from below 32 due to gastrointestinal
hemorrhage
Yes
No
sepsis or uncontrolled acute infection
Yes
No
hepatic encephalopathy grade 3-4
Yes
No
history of steroid or pentoxifylline treatment within
3 months
Yes
No
myeloblast on peripheral blood smear test
Yes
No
critical comorbidities (type i hepatorenal
syndrome, serum creatinine >2.5mg/dl, heart
failure, pulmonary disease, psychiatric disease,
acute pancreatitis etc.)
Yes
No
patient who refuses to participate in clinical trial
Yes
No
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DESCRIBE (DZNE – Clinical Register Study of
neurodegenerative Disorders) CRF Optional assessment motion
Background and Purpose:
The purpose of the DESCRIBE study is to document the
natural course of diseases in context of medical care of
neurodegenerative disorders as well as cerebrovascular
diseases and to perform phenotyping of the test persons.
Disease-spanning analyses of the measured clincial data,
the results of the imaging processes, results of the analysis
of the biometerials including genetic analysis are planed.
Principal Investigator: Prof. Klockgether, Dr. Spottke DZNE,
Bonn.
Source: DESCRIBE-Studie
http://www.dzne.de/forschung/forschungsbereiche/klinische
-forschung/studien/describe-bn006.html 
Participating Study Sites:
Berlin, Bonn, Göttingen, Dresden, Köln, Magdeburg,
München, Rostock/Greifswald, Tübingen
All rights reserved. Please visit https://medical-data-
models.org/forms/14041
CRF Optional assessment motion
Date of visit
Study-ID:
Visit:
Date of visit
PD-NMS-Questionnaire
Have you experienced any of the following in the
last month?
1. Dribbling of saliva during the daytime
Yes
No
2. Loss or change in your ability to taste or smell
Yes
No
3. Difficulty swallowing food or drink or problems
with choking.
Yes
No
4. Vomiting or feelings of sickness (nausea)
Yes
No
5. Constipation (less than 3 bowel movements a
week) or having to strain to pass a stool (faeces)
Yes
No
6. Bowel (fecal) incontinence
Yes
No
7. Feeling that your bowel emptying is incomplete
after having been to the toilet .
1 / 20
7. Feeling that your bowel emptying is incomplete
after having been to the toilet .
Yes
No
8. A sense of urgency to pass urine makes you
rush to the toilet .
Yes
No
9. Getting up regularly at night to pass urine
Yes
No
10. Unexplained pains (not due to known
conditions
such as arthritis)
Yes
No
11. Unexplained change in weight (not due to
change in diet)
Yes
No
12. Problems remembering things that have
happened recently or for getting to do things
Yes
No
13. Loss of interest in what is happening around
you or doing things
Yes
No
14. Seeing or hearing things that you know or are
told are not there
Yes
No
15. Difficulty concentrating or staying focussed
Yes
No
16. Feeling sad, ‘low’ or ‘blue’
Yes
No
17. Feeling anxious, frightened or panicky
Yes
No
18. Feeling less interested in sex or more
interested in sex
Yes
No
19. Finding it difficult to have sex when you try
Yes
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No
20. Feeling light headed, dizzy or weak standing
from sitting or lying
Yes
No
21. Falling
Yes
No
22. Finding it difficult to stay awake during
activities such as working, driving or eating
Yes
No
23. Difficulty getting to sleep at night or staying
asleep at night
Yes
No
24. Intense, vivid dreams or frightening dreams
Yes
No
25. Talking or moving about in your sleep as if
you are ‘acting’ out a dream
Yes
No
26. Unpleasant sensations in your legs at night or
while resting, and a feeling that you need to move
Yes
No
27. Swelling of your legs
Yes
No
28. Excessive sweating
Yes
No
29. Double vision
Yes
No
30. Believing things are happening to you that
other people say are not true
Yes
No
NMS-Scale (section 1-5)
Domain 1: Cardiovascular including falls
1. Does the patient experience light-headedness,
dizziness, weakness on standing from sitting or
lying position? SEVERITY
None (0)
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Mild (1)
Moderate (2)
Severe (3)
1. Does the patient experience light-headedness,
dizziness, weakness on standing from sitting or
lying position? FREQUENCY
Rarely (<1/wk) (1)
Often (1/wk) (2)
Frequent (several times per week) (3)
Very Frequent (daily or all the time) (4)
1. Does the patient experience light-headedness,
dizziness, weakness on standing from sitting or
lying position? SCORE
2. Does the patient fall because of fainting or
blacking out? SEVERITY
None (0)
Mild (1)
Moderate (2)
Severe (3)
2. Does the patient fall because of fainting or
blacking out? FREQUENCY
Rarely (<1/wk) (1)
Often (1/wk) (2)
Frequent (several times per week) (3)
Very Frequent (daily or all the time) (4)
2. Does the patient fall because of fainting or
blacking out? SCORE
Total score (SEVERITY x FREQUENCY)
Domain 2: Sleep/fatigue
3. Does the patient doze off or fall asleep
unintentionally during daytime activities? (For
example, during conversation, during mealtimes,
or while watching television or reading).
SEVERITY
None (0)
Mild (1)
Moderate (2)
Severe (3)
3. Does the patient doze off or fall asleep
unintentionally during daytime activities? (For
example, during conversation, during mealtimes,
or while watching television or reading).
FREQUENCY
Rarely (<1/wk) (1)
Often (1/wk) (2)
Frequent (several times per week) (3)
Very Frequent (daily or all the time) (4)
3. Does the patient doze off or fall asleep
unintentionally during daytime activities? (For
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example, during conversation, during mealtimes,
or while watching television or reading). SCORE
4. Does fatigue (tiredness) or lack of energy (not
slowness) limit the patient’s daytime activities?
SEVERITY
None (0)
Mild (1)
Moderate (2)
Severe (3)
4. Does fatigue (tiredness) or lack of energy (not
slowness) limit the patient<80><99>s daytime
activities? FREQUENCY
Rarely (<1/wk) (1)
Often (1/wk) (2)
Frequent (several times per week) (3)
Very Frequent (daily or all the time) (4)
4. Does fatigue (tiredness) or lack of energy (not
slowness) limit the patient<80><99>s daytime
activities? SCORE
5. Does the patient have difficulties falling or
staying asleep? SEVERITY
None (0)
Mild (1)
Moderate (2)
Severe (3)
5. Does the patient have difficulties falling or
staying asleep? FREQUENCY
Rarely (<1/wk) (1)
Often (1/wk) (2)
Frequent (several times per week) (3)
Very Frequent (daily or all the time) (4)
5. Does the patient have difficulties falling or
staying asleep? SCORE
6. Does the patient experience an urge to move
the legs or restlessness in legs that improves with
movement when he/she is sitting or lying down
inactive? SEVERITY
None (0)
Mild (1)
Moderate (2)
Severe (3)
6. Does the patient experience an urge to move
the legs or restlessness in legs that improves with
movement when he/she is sitting or lying down
inactive? FREQUENCY
Rarely (<1/wk) (1)
Often (1/wk) (2)
Frequent (several times per week) (3)
Very Frequent (daily or all the time) (4)
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6. Does the patient experience an urge to move
the legs or restlessness in legs that improves with
movement when he/she is sitting or lying down
inactive? SCORE
Total score (SEVERITY x FREQUENCY)
Domain 3: Mood/cognition
7. Has the patient lost interest in his/her
surroundings? SEVERITY
None (0)
Mild (1)
Moderate (2)
Severe (3)
7. Has the patient lost interest in his/her
surroundings? FREQUENCY
Rarely (<1/wk) (1)
Often (1/wk) (2)
Frequent (several times per week) (3)
Very Frequent (daily or all the time) (4)
7. Has the patient lost interest in his/her
surroundings? SCORE
8. Has the patient lost interest in doing things or
lack motivation to start new activities? SEVERITY
None (0)
Mild (1)
Moderate (2)
Severe (3)
8. Has the patient lost interest in doing things or
lack motivation to start new activities?
FREQUENCY
Rarely (<1/wk) (1)
Often (1/wk) (2)
Frequent (several times per week) (3)
Very Frequent (daily or all the time) (4)
8. Has the patient lost interest in doing things or
lack motivation to start new activities? SCORE
9.  Does the patient feel nervous, worried or
frightened for no apparent reason? SEVERITY
None (0)
Mild (1)
Moderate (2)
Severe (3)
9. Does the patient feel nervous, worried or
frightened for no apparent reason? FREQUENCY
None (0)
Mild (1)
Moderate (2)
Severe (3)
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9. Does the patient feel nervous, worried or
frightened for no apparent reason? SCORE
10. Does the patient seem sad or depressed or
has he/she reported such feelings? SEVERITY
None (0)
Mild (1)
Moderate (2)
Severe (3)
10. Does the patient seem sad or depressed or
has he/she reported such feelings?
FREQUENCY
Rarely (<1/wk) (1)
Often (1/wk) (2)
Frequent (several times per week) (3)
Very Frequent (daily or all the time) (4)
10. Does the patient seem sad or depressed or
has he/she reported such feelings? SCORE
11. Does the patient have flat moods without the
normal “highs” and “ lows” ? SEVERITY
None (0)
Mild (1)
Moderate (2)
Severe (3)
11. Does the patient have flat moods without the
normal <80><9c>highs<80><9d> and <80><9c>
lows<80><9d> ? FREQUENCY
Rarely (<1/wk) (1)
Often (1/wk) (2)
Frequent (several times per week) (3)
Very Frequent (daily or all the time) (4)
11. Does the patient have flat moods without the
normal <80><9c>highs<80><9d> and <80><9c>
lows<80><9d> ? SCORE
12. Does the patient have difficulty in
experiencing pleasure from their usual activities
or report that they lack pleasure? SEVERITY
None (0)
Mild (1)
Moderate (2)
Severe (3)
12. Does the patient have difficulty in
experiencing pleasure from their usual activities
or report that they lack pleasure? FREQUENCY
Rarely (<1/wk) (1)
Often (1/wk) (2)
Frequent (several times per week) (3)
Very Frequent (daily or all the time) (4)
12. Does the patient have difficulty in
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experiencing pleasure from their usual activities
or report that they lack pleasure? SCORE
Total score (SEVERITY x FREQUENCY)
Domain 4: Perceptual problems/hallucinations
13. Does the patient indicate that he/she sees
things that are not there? SEVERITY
None (0)
Mild (1)
Moderate (2)
Severe (3)
13. Does the patient indicate that he/she sees
things that are not there? FREQUENCY
Rarely (<1/wk) (1)
Often (1/wk) (2)
Frequent (several times per week) (3)
Very Frequent (daily or all the time) (4)
13. Does the patient indicate that he/she sees
things that are not there? SCORE
14. Does the patient have beliefs that you know
are not true? (For example, about being harmed,
being robbed or being unfaithful) SEVERITY
None (0)
Mild (1)
Moderate (2)
Severe (3)
14. Does the patient have beliefs that you know
are not true? (For example, about being harmed,
being robbed or being unfaithful) FREQUENCY
Rarely (<1/wk) (1)
Often (1/wk) (2)
Frequent (several times per week) (3)
Very Frequent (daily or all the time) (4)
14. Does the patient have beliefs that you know
are not true? (For example, about being harmed,
being robbed or being unfaithful) SCORE
15. Does the patient experience double vision? (2
separate real objects and not blurred vision)
SEVERITY
None (0)
Mild (1)
Moderate (2)
Severe (3)
15. Does the patient experience double vision? (2
separate real objects and not blurred vision)
FREQUENCY
Rarely (<1/wk) (1)
Often (1/wk) (2)
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Frequent (several times per week) (3)
Very Frequent (daily or all the time) (4)
15. Does the patient experience double vision? (2
separate real objects and not blurred vision)
SCORE
Total score (SEVERITY x FREQUENCY)
Domain 5: Attention/memory
16. Does the patient have problems sustaining
concentration during activities? (For example,
reading or having a conversation) SEVERITY
None (0)
Mild (1)
Moderate (2)
Severe (3)
16. Does the patient have problems sustaining
concentration during activities? (For example,
reading or having a conversation) FREQUENCY
Rarely (<1/wk) (1)
Often (1/wk) (2)
Frequent (several times per week) (3)
Very Frequent (daily or all the time) (4)
16. Does the patient have problems sustaining
concentration during activities? (For example,
reading or having a conversation) SCORE
17. Does the patient forget things that he/she has
been told a short time ago or events that
appened in the last few days? SEVERITY
None (0)
Mild (1)
Moderate (2)
Severe (3)
17. Does the patient forget things that he/she has
been told a short time ago or events that
appened in the last few days? FREQUENCY
Rarely (<1/wk) (1)
Often (1/wk) (2)
Frequent (several times per week) (3)
Very Frequent (daily or all the time) (4)
17. Does the patient forget things that he/she has
been told a short time ago or events that
appened in the last few days? SCORE
Total score (SEVERITY x FREQUENCY)
Functional Activities Questionnaire (FAQ)
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Informations are reported by: (only one answer
possible)
Brother/Sister (Brother/Sister)
Child (Child)
Friend (Friend)
other informant (other informant)
participant (no informant available)
(participant (no informant available))
Spouse (Spouse)
Other informant:
1. Writing checks, paying bills, balancing
checkbook
Never did the activity but could do now
(0)
Has difficulty but does by self or never
did and would have difficulty now (1)
Requires assistance (2)
Dependent (3)
2. Assembling tax records, business affairs, or
papers
Never did the activity but could do now
(0)
Has difficulty but does by self or never
did and would have difficulty now (1)
Requires assistance (2)
Dependent (3)
3. Shopping alone for clothes, household
necessities, or groceries
Never did the activity but could do now
(0)
Has difficulty but does by self or never
did and would have difficulty now (1)
Requires assistance (2)
Dependent (3)
4. Playing a game of skill, working on a hobby
Never did the activity but could do now
(0)
Has difficulty but does by self or never
did and would have difficulty now (1)
Requires assistance (2)
Dependent (3)
5. Heating water, making a cup of coffee, turning
off stove after use
Never did the activity but could do now
(0)
Has difficulty but does by self or never
did and would have difficulty now (1)
Requires assistance (2)
Dependent (3)
6. Preparing a balanced meal
Never did the activity but could do now
(0)
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Has difficulty but does by self or never
did and would have difficulty now (1)
Requires assistance (2)
Dependent (3)
7. Keeping track of current events
Never did the activity but could do now
(0)
Has difficulty but does by self or never
did and would have difficulty now (1)
Requires assistance (2)
Dependent (3)
8. Paying attention to, understanding, discussing
TV, book, magazin
Never did the activity but could do now
(0)
Has difficulty but does by self or never
did and would have difficulty now (1)
Requires assistance (2)
Dependent (3)
9. Remembering appointments, family occasions,
holidays, medications
Never did the activity but could do now
(0)
Has difficulty but does by self or never
did and would have difficulty now (1)
Requires assistance (2)
Dependent (3)
10. Traveling out of neighborhood, driving,
arranging to take buses
Never did the activity but could do now
(0)
Has difficulty but does by self or never
did and would have difficulty now (1)
Requires assistance (2)
Dependent (3)
FAQ - Total Score
>= 0
<= 30
Specific Famlily History - Parkinson's
disease
Does your relative suffer from Parkinson's
disease? 
Referring to tremor of the hand occurring at most
resting, slowness of gait, bent posture and
shuffling gait?
No  (No )
Unknown (Unknown)
Yes (Yes)
Relative:
Aunt (Aunt)
Brother (Brother)
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Cousin, female (Cousin, female)
Cousin, male (Cousin, male)
Daughter (Daughter)
Father (Father)
Grandfather (Grandfather)
Grandmother (Grandmother)
Mother (Mother)
other relative (other relative)
Sister (Sister)
Son  (Son )
Uncle (Uncle)
unknown (unknown)
Family side:
maternal (maternal)
paternal (paternal)
unknown (unknown)
Remarks
1.1. Resting tremor
No  (No )
Unknown (Unknown)
Yes (Yes)
1.2. Shuffling gait
No  (No )
Unknown (Unknown)
Yes (Yes)
1.3. Bent posture
1.4. Muscle rigidity
No  (No )
Unknown (Unknown)
Yes (Yes)
2.1. Neurologist
No  (No )
Unknown (Unknown)
Yes (Yes)
2.2. Non-neurologist:
No  (No )
Unknown (Unknown)
Yes (Yes)
3.1. Intake of Levodopa
No  (No )
Unknown (Unknown)
Yes (Yes)
Certainty of diagnosis, please stage:
definite Parkinson's disease (at least two
symptoms under point 1 AND criterion
2.1. apply) (definite Parkinson's disease
(at least two symptoms under point 1
AND criterion 2.1. apply))
possible Parkinson's disease (either
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three symptoms under point 1 OR one
symptom in 1 and one criterion in 2-3
apply) (possible Parkinson's disease
(either three symptoms under point 1 OR
one symptom in 1 and one criterion in 2-
3 apply))
probable Parkinson's disease (at least
two symptoms under point 1 AND one
criterion in 2-3 apply) (probable
Parkinson's disease (at least two
symptoms under point 1 AND one
criterion in 2-3 apply))
questionable Parkinson's disease (at
least one symptoms under point 1
applies) (questionable Parkinson's
disease (at least one symptoms under
point 1 applies))
uncertain Parkinson's disease (at least
two symptoms under point 1 apply)
(uncertain Parkinson's disease (at least
two symptoms under point 1 apply))
Test of ability to smell (12 Sniffin' Sticks)
Do you have currently problems smelling?
Yes
No
Sniffin stick 1:
Blackberry (Blackberry)
Orange (Orange)
Pineapple (Pineapple)
Strawberry (Strawberry)
Sniffin stick 2:
Fume (Fume)
Glue (Glue)
Grass (Grass)
Shoeleather (Shoeleather)
Sniffin stick 3:
Chocolate (Chocolate)
Cinnamon (Cinnamon)
Honey (Honey)
Vanilla (Vanilla)
Sniffin stick 4:
Chives (Chives)
Onion (Onion)
Peppermint (Peppermint)
Spruce (Spruce)
Sniffin stick 5:
Banana (Banana)
Cherry (Cherry)
Coconut (Coconut)
Walnut (Walnut)
Sniffin stick 6:
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Apple (Apple)
Citron (Citron)
Grapefruit (Grapefruit)
Peach (Peach)
Sniffin stick 7:
Chewing gum (Chewing gum)
Cookies (Cookies)
Licorice (Licorice)
Rubber (Rubber)
Sniffin stick 8:
Cigarette (Cigarette)
Coffee (Coffee)
Smoke of candle (Smoke of candle)
Wine  (Wine )
Sniffin stick 9:
Cinnamon (Cinnamon)
Clove (Clove)
Mustard (Mustard)
Pepper (Pepper)
Sniffin stick 10:
Peach (Peach)
Pear (Pear)
Pinapple (Pinapple)
Plum (Plum)
Sniffin stick 11:
Chamomile (Chamomile)
Cherry (Cherry)
Raspberry (Raspberry)
Rose (Rose)
Sniffin stick 12:
Bread (Bread)
Cheese (Cheese)
Fish (Fish)
Ham (Ham)
1, Sum of correctly identificated scents
>= 0
<= 12
2. Sum of correctly identified scents %
%
Anamnesis of smelling ability
Do you suffer currently from a severe cold or
inflammation of nose, resp. paranasal sinuses,
with significant impairment of smelling ability?
Yes
No
Do you suffer currently from allergies like hay
fever, that impair your smelling ability?
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Yes
No
Do you suffer from chronic asthma or another
chronic inflammatory disease of nose, paranasal
sinus, that significantly impairs your smelling
ability.
Yes
No
Did you have regular contact with following
substances in the past, for example in context of
your occupation?
Solvent
Yes
No
Wood, metal dust or fume
Yes
No
Did you have surgery on your nose as an adult,
child or teenager, e.g. nasal polypectomy ?
Yes
No
Was a tying of internal nose artery performed in
the past because of severe nose bleeding?
Yes
No
Did you have an accident with head injury
causing significant impairment of smelling ability?
Yes
No
Do you suffer from another condition concerning
nose or pharynx which significantly impairs your
smelling ability?
Yes
No
Do you suffer from another condition concerning
nose or pharynx which significantly impairs your
smelling ability? Which one?
Gait time measurement: 8-meter-walking-
test (8MWT)
1. Gait time test performed?
Yes
No
1.1.
Other reason (Other reason)
Participant was not able to walk because
of physical impairment (Participant was
not able to walk because of physical
impairment)
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2. Does the participant need gait aid?
None (None)
One walking aid (One walking aid)
Prosthesis (Prosthesis)
Two walking aids (Two walking aids)
Wheeled walker (Wheeled walker)
3. Time measurement of walking:
3.1. First try:
sec
3.2. Second try:
sec
4. Was a repetition of the walking test necessary?
Yes
No
4.1. Repetition because of:
Distraction of participant (Distraction of
participant)
Falling of participant (Falling of
participant)
Other reason (Other reason)
Other reason:
Examination of gait (GaitRite®)
1. Instrument-based gait analysis performed?
Yes
No
1.1.
Cognitive impairment (Cognitive
impairment)
other reasons (other reasons)
Participant cannot walk/can only walk
with walking aid because of physical
impairment (Participant cannot walk/can
only walk with walking aid because of
physical impairment)
Risk of falling (Risk of falling)
Technical problems (Technical problems)
Reason for physical impairment:
Other reason:
2.1. Gait single task
2.1.1. Preferred speed NOT DONE
Yes
No
Reason:
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Number of runs
>= 1
<= 8
2.1.2 Walking slowly NOT DONE
Yes
No
Reason:
Number of runs
<= 8
>= 1
2.1.3 Walking fast NOT DONE
Yes
No
Reason:
Number of runs
<= 8
>= 1
2.2. Gait dual task
2.2.1. Single serial subtraction NOT DONE
Yes
No
Reason:
Time:
sec
Number of mistakes:
Subtraction chosen:
-3 (-3)
-7 (-7)
2.2.2 Serial subtraction + walking fast NOT
DONE
Yes
No
Reason:
Number of runs
Subtraction chosen:
-3 (-3)
-7 (-7)
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Number of subtractions
Number of mistakes:
3. Tandem/Turn
3.1. Tandem gait
1x (1x)
not done (not done)
3.2. 180° turn
1x (1x)
not done (not done)
Please only comment if one or several
examinations not done
Examination of human resting and activity
profiles (Somno-Module)
1. Examinations of somno module performed?
Yes
No
1.1.
Other reason (Other reason)
Participant could not perform test
because of physical impairment
(Participant could not perform test
because of physical impairment)
Other reason:
2. Test performance and duration of somno
module
Start of examination:
End of examination:
Dominant hand
Right (1)
Left (2)
Assembly:
Activity
Yes
No
Actigraph applied?
left hand (left hand)
right hand (right hand)
Tremor
Yes
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No
Actigraph applied?
left hand (left hand)
right hand (right hand)
PLM
Yes
No
Actigraph applied?
right leg (right leg)
Storage of data on file server?
Yes
No
Comment
Examination of eye movements
(oculography)
1. Examination of eye movements performed?
Yes
No
1.1.
Other reason (Other reason)
Participant could not perform test
because of physical impairment
(Participant could not perform test
because of physical impairment)
Other Reason:
dominant eye
left eye (left eye)
right eye (right eye)
Visus, close, uncorrected
visus test monitor
Visual impairment known?
Yes
No
Diopter right (+/-)
Diopter left (+/-)
Test using visual aid?
Yes
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No
Optical aid
contact lenses (contact lenses)
glasses (glasses)
Test protocol used
NPT  (NPT )
other (other)
Other:
Testing successfully performed?
Yes
No
Not successful performed?
dependent on participant (dependent on
participant)
technical reasons (technical reasons)
Storage of data on file server?
Yes
No
Comment:
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DESCRIBE (DZNE – Clinical Register Study of
neurodegenerative Disorders) CRF Optional assessment motion
Background and Purpose:
The purpose of the DESCRIBE study is to document the
natural course of diseases in context of medical care of
neurodegenerative disorders as well as cerebrovascular
diseases and to perform phenotyping of the test persons.
Disease-spanning analyses of the measured clincial data,
the results of the imaging processes, results of the analysis
of the biometerials including genetic analysis are planed.
Principal Investigator: Prof. Klockgether, Dr. Spottke DZNE,
Bonn.
Source: DESCRIBE-Studie
http://www.dzne.de/forschung/forschungsbereiche/klinische
-forschung/studien/describe-bn006.html 
Participating Study Sites:
Berlin, Bonn, Göttingen, Dresden, Köln, Magdeburg,
München, Rostock/Greifswald, Tübingen
All rights reserved. Please visit https://medical-data-
models.org/forms/14042
CRF Optional assessment motion
Date of visit
Study-ID:
Visit:
Date of visit
PD-NMS-Questionnaire
Have you experienced any of the following in the
last month?
1. Dribbling of saliva during the daytime
Yes
No
2. Loss or change in your ability to taste or smell
Yes
No
3. Difficulty swallowing food or drink or problems
with choking.
Yes
No
4. Vomiting or feelings of sickness (nausea)
Yes
No
5. Constipation (less than 3 bowel movements a
week) or having to strain to pass a stool (faeces)
Yes
No
6. Bowel (fecal) incontinence
Yes
No
7. Feeling that your bowel emptying is incomplete
after having been to the toilet .
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7. Feeling that your bowel emptying is incomplete
after having been to the toilet .
Yes
No
8. A sense of urgency to pass urine makes you
rush to the toilet .
Yes
No
9. Getting up regularly at night to pass urine
Yes
No
10. Unexplained pains (not due to known
conditions
such as arthritis)
Yes
No
11. Unexplained change in weight (not due to
change in diet)
Yes
No
12. Problems remembering things that have
happened recently or for getting to do things
Yes
No
13. Loss of interest in what is happening around
you or doing things
Yes
No
14. Seeing or hearing things that you know or are
told are not there
Yes
No
15. Difficulty concentrating or staying focussed
Yes
No
16. Feeling sad, ‘low’ or ‘blue’
Yes
No
17. Feeling anxious, frightened or panicky
Yes
No
18. Feeling less interested in sex or more
interested in sex
Yes
No
19. Finding it difficult to have sex when you try
Yes
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No
20. Feeling light headed, dizzy or weak standing
from sitting or lying
Yes
No
21. Falling
Yes
No
22. Finding it difficult to stay awake during
activities such as working, driving or eating
Yes
No
23. Difficulty getting to sleep at night or staying
asleep at night
Yes
No
24. Intense, vivid dreams or frightening dreams
Yes
No
25. Talking or moving about in your sleep as if
you are ‘acting’ out a dream
Yes
No
26. Unpleasant sensations in your legs at night or
while resting, and a feeling that you need to move
Yes
No
27. Swelling of your legs
Yes
No
28. Excessive sweating
Yes
No
29. Double vision
Yes
No
30. Believing things are happening to you that
other people say are not true
Yes
No
NMS-Scale (section 1-5)
Domain 1: Cardiovascular including falls
1. Does the patient experience light-headedness,
dizziness, weakness on standing from sitting or
lying position? SEVERITY
None (0)
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Mild (1)
Moderate (2)
Severe (3)
1. Does the patient experience light-headedness,
dizziness, weakness on standing from sitting or
lying position? FREQUENCY
Rarely (<1/wk) (1)
Often (1/wk) (2)
Frequent (several times per week) (3)
Very Frequent (daily or all the time) (4)
1. Does the patient experience light-headedness,
dizziness, weakness on standing from sitting or
lying position? SCORE
2. Does the patient fall because of fainting or
blacking out? SEVERITY
None (0)
Mild (1)
Moderate (2)
Severe (3)
2. Does the patient fall because of fainting or
blacking out? FREQUENCY
Rarely (<1/wk) (1)
Often (1/wk) (2)
Frequent (several times per week) (3)
Very Frequent (daily or all the time) (4)
2. Does the patient fall because of fainting or
blacking out? SCORE
Total score (SEVERITY x FREQUENCY)
Domain 2: Sleep/fatigue
3. Does the patient doze off or fall asleep
unintentionally during daytime activities? (For
example, during conversation, during mealtimes,
or while watching television or reading).
SEVERITY
None (0)
Mild (1)
Moderate (2)
Severe (3)
3. Does the patient doze off or fall asleep
unintentionally during daytime activities? (For
example, during conversation, during mealtimes,
or while watching television or reading).
FREQUENCY
Rarely (<1/wk) (1)
Often (1/wk) (2)
Frequent (several times per week) (3)
Very Frequent (daily or all the time) (4)
3. Does the patient doze off or fall asleep
unintentionally during daytime activities? (For
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example, during conversation, during mealtimes,
or while watching television or reading). SCORE
4. Does fatigue (tiredness) or lack of energy (not
slowness) limit the patient’s daytime activities?
SEVERITY
None (0)
Mild (1)
Moderate (2)
Severe (3)
4. Does fatigue (tiredness) or lack of energy (not
slowness) limit the patient<80><99>s daytime
activities? FREQUENCY
Rarely (<1/wk) (1)
Often (1/wk) (2)
Frequent (several times per week) (3)
Very Frequent (daily or all the time) (4)
4. Does fatigue (tiredness) or lack of energy (not
slowness) limit the patient<80><99>s daytime
activities? SCORE
5. Does the patient have difficulties falling or
staying asleep? SEVERITY
None (0)
Mild (1)
Moderate (2)
Severe (3)
5. Does the patient have difficulties falling or
staying asleep? FREQUENCY
Rarely (<1/wk) (1)
Often (1/wk) (2)
Frequent (several times per week) (3)
Very Frequent (daily or all the time) (4)
5. Does the patient have difficulties falling or
staying asleep? SCORE
6. Does the patient experience an urge to move
the legs or restlessness in legs that improves with
movement when he/she is sitting or lying down
inactive? SEVERITY
None (0)
Mild (1)
Moderate (2)
Severe (3)
6. Does the patient experience an urge to move
the legs or restlessness in legs that improves with
movement when he/she is sitting or lying down
inactive? FREQUENCY
Rarely (<1/wk) (1)
Often (1/wk) (2)
Frequent (several times per week) (3)
Very Frequent (daily or all the time) (4)
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6. Does the patient experience an urge to move
the legs or restlessness in legs that improves with
movement when he/she is sitting or lying down
inactive? SCORE
Total score (SEVERITY x FREQUENCY)
Domain 3: Mood/cognition
7. Has the patient lost interest in his/her
surroundings? SEVERITY
None (0)
Mild (1)
Moderate (2)
Severe (3)
7. Has the patient lost interest in his/her
surroundings? FREQUENCY
Rarely (<1/wk) (1)
Often (1/wk) (2)
Frequent (several times per week) (3)
Very Frequent (daily or all the time) (4)
7. Has the patient lost interest in his/her
surroundings? SCORE
8. Has the patient lost interest in doing things or
lack motivation to start new activities? SEVERITY
None (0)
Mild (1)
Moderate (2)
Severe (3)
8. Has the patient lost interest in doing things or
lack motivation to start new activities?
FREQUENCY
Rarely (<1/wk) (1)
Often (1/wk) (2)
Frequent (several times per week) (3)
Very Frequent (daily or all the time) (4)
8. Has the patient lost interest in doing things or
lack motivation to start new activities? SCORE
9.  Does the patient feel nervous, worried or
frightened for no apparent reason? SEVERITY
None (0)
Mild (1)
Moderate (2)
Severe (3)
9. Does the patient feel nervous, worried or
frightened for no apparent reason? FREQUENCY
None (0)
Mild (1)
Moderate (2)
Severe (3)
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9. Does the patient feel nervous, worried or
frightened for no apparent reason? SCORE
10. Does the patient seem sad or depressed or
has he/she reported such feelings? SEVERITY
None (0)
Mild (1)
Moderate (2)
Severe (3)
10. Does the patient seem sad or depressed or
has he/she reported such feelings?
FREQUENCY
Rarely (<1/wk) (1)
Often (1/wk) (2)
Frequent (several times per week) (3)
Very Frequent (daily or all the time) (4)
10. Does the patient seem sad or depressed or
has he/she reported such feelings? SCORE
11. Does the patient have flat moods without the
normal “highs” and “ lows” ? SEVERITY
None (0)
Mild (1)
Moderate (2)
Severe (3)
11. Does the patient have flat moods without the
normal <80><9c>highs<80><9d> and <80><9c>
lows<80><9d> ? FREQUENCY
Rarely (<1/wk) (1)
Often (1/wk) (2)
Frequent (several times per week) (3)
Very Frequent (daily or all the time) (4)
11. Does the patient have flat moods without the
normal <80><9c>highs<80><9d> and <80><9c>
lows<80><9d> ? SCORE
12. Does the patient have difficulty in
experiencing pleasure from their usual activities
or report that they lack pleasure? SEVERITY
None (0)
Mild (1)
Moderate (2)
Severe (3)
12. Does the patient have difficulty in
experiencing pleasure from their usual activities
or report that they lack pleasure? FREQUENCY
Rarely (<1/wk) (1)
Often (1/wk) (2)
Frequent (several times per week) (3)
Very Frequent (daily or all the time) (4)
12. Does the patient have difficulty in
7 / 20
DESCRIBE (DZNE – Clinical Register Study of neurodegenerative
Disorders) CRF Optional assessment motion
experiencing pleasure from their usual activities
or report that they lack pleasure? SCORE
Total score (SEVERITY x FREQUENCY)
Domain 4: Perceptual problems/hallucinations
13. Does the patient indicate that he/she sees
things that are not there? SEVERITY
None (0)
Mild (1)
Moderate (2)
Severe (3)
13. Does the patient indicate that he/she sees
things that are not there? FREQUENCY
Rarely (<1/wk) (1)
Often (1/wk) (2)
Frequent (several times per week) (3)
Very Frequent (daily or all the time) (4)
13. Does the patient indicate that he/she sees
things that are not there? SCORE
14. Does the patient have beliefs that you know
are not true? (For example, about being harmed,
being robbed or being unfaithful) SEVERITY
None (0)
Mild (1)
Moderate (2)
Severe (3)
14. Does the patient have beliefs that you know
are not true? (For example, about being harmed,
being robbed or being unfaithful) FREQUENCY
Rarely (<1/wk) (1)
Often (1/wk) (2)
Frequent (several times per week) (3)
Very Frequent (daily or all the time) (4)
14. Does the patient have beliefs that you know
are not true? (For example, about being harmed,
being robbed or being unfaithful) SCORE
15. Does the patient experience double vision? (2
separate real objects and not blurred vision)
SEVERITY
None (0)
Mild (1)
Moderate (2)
Severe (3)
15. Does the patient experience double vision? (2
separate real objects and not blurred vision)
FREQUENCY
Rarely (<1/wk) (1)
Often (1/wk) (2)
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Frequent (several times per week) (3)
Very Frequent (daily or all the time) (4)
15. Does the patient experience double vision? (2
separate real objects and not blurred vision)
SCORE
Total score (SEVERITY x FREQUENCY)
Domain 5: Attention/memory
16. Does the patient have problems sustaining
concentration during activities? (For example,
reading or having a conversation) SEVERITY
None (0)
Mild (1)
Moderate (2)
Severe (3)
16. Does the patient have problems sustaining
concentration during activities? (For example,
reading or having a conversation) FREQUENCY
Rarely (<1/wk) (1)
Often (1/wk) (2)
Frequent (several times per week) (3)
Very Frequent (daily or all the time) (4)
16. Does the patient have problems sustaining
concentration during activities? (For example,
reading or having a conversation) SCORE
17. Does the patient forget things that he/she has
been told a short time ago or events that
appened in the last few days? SEVERITY
None (0)
Mild (1)
Moderate (2)
Severe (3)
17. Does the patient forget things that he/she has
been told a short time ago or events that
appened in the last few days? FREQUENCY
Rarely (<1/wk) (1)
Often (1/wk) (2)
Frequent (several times per week) (3)
Very Frequent (daily or all the time) (4)
17. Does the patient forget things that he/she has
been told a short time ago or events that
appened in the last few days? SCORE
Total score (SEVERITY x FREQUENCY)
Functional Activities Questionnaire (FAQ)
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Informations are reported by: (only one answer
possible)
Brother/Sister (Brother/Sister)
Child (Child)
Friend (Friend)
other informant (other informant)
participant (no informant available)
(participant (no informant available))
Spouse (Spouse)
Other informant:
1. Writing checks, paying bills, balancing
checkbook
Never did the activity but could do now
(0)
Has difficulty but does by self or never
did and would have difficulty now (1)
Requires assistance (2)
Dependent (3)
2. Assembling tax records, business affairs, or
papers
Never did the activity but could do now
(0)
Has difficulty but does by self or never
did and would have difficulty now (1)
Requires assistance (2)
Dependent (3)
3. Shopping alone for clothes, household
necessities, or groceries
Never did the activity but could do now
(0)
Has difficulty but does by self or never
did and would have difficulty now (1)
Requires assistance (2)
Dependent (3)
4. Playing a game of skill, working on a hobby
Never did the activity but could do now
(0)
Has difficulty but does by self or never
did and would have difficulty now (1)
Requires assistance (2)
Dependent (3)
5. Heating water, making a cup of coffee, turning
off stove after use
Never did the activity but could do now
(0)
Has difficulty but does by self or never
did and would have difficulty now (1)
Requires assistance (2)
Dependent (3)
6. Preparing a balanced meal
Never did the activity but could do now
(0)
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Has difficulty but does by self or never
did and would have difficulty now (1)
Requires assistance (2)
Dependent (3)
7. Keeping track of current events
Never did the activity but could do now
(0)
Has difficulty but does by self or never
did and would have difficulty now (1)
Requires assistance (2)
Dependent (3)
8. Paying attention to, understanding, discussing
TV, book, magazin
Never did the activity but could do now
(0)
Has difficulty but does by self or never
did and would have difficulty now (1)
Requires assistance (2)
Dependent (3)
9. Remembering appointments, family occasions,
holidays, medications
Never did the activity but could do now
(0)
Has difficulty but does by self or never
did and would have difficulty now (1)
Requires assistance (2)
Dependent (3)
10. Traveling out of neighborhood, driving,
arranging to take buses
Never did the activity but could do now
(0)
Has difficulty but does by self or never
did and would have difficulty now (1)
Requires assistance (2)
Dependent (3)
FAQ - Total Score
>= 0
<= 30
Specific Famlily History - Parkinson's
disease
Does your relative suffer from Parkinson's
disease? 
Referring to tremor of the hand occurring at most
resting, slowness of gait, bent posture and
shuffling gait?
No  (No )
Unknown (Unknown)
Yes (Yes)
Relative:
Aunt (Aunt)
Brother (Brother)
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Cousin, female (Cousin, female)
Cousin, male (Cousin, male)
Daughter (Daughter)
Father (Father)
Grandfather (Grandfather)
Grandmother (Grandmother)
Mother (Mother)
other relative (other relative)
Sister (Sister)
Son  (Son )
Uncle (Uncle)
unknown (unknown)
Family side:
maternal (maternal)
paternal (paternal)
unknown (unknown)
Remarks
1.1. Resting tremor
No  (No )
Unknown (Unknown)
Yes (Yes)
1.2. Shuffling gait
No  (No )
Unknown (Unknown)
Yes (Yes)
1.3. Bent posture
1.4. Muscle rigidity
No  (No )
Unknown (Unknown)
Yes (Yes)
2.1. Neurologist
No  (No )
Unknown (Unknown)
Yes (Yes)
2.2. Non-neurologist:
No  (No )
Unknown (Unknown)
Yes (Yes)
3.1. Intake of Levodopa
No  (No )
Unknown (Unknown)
Yes (Yes)
Certainty of diagnosis, please stage:
definite Parkinson's disease (at least two
symptoms under point 1 AND criterion
2.1. apply) (definite Parkinson's disease
(at least two symptoms under point 1
AND criterion 2.1. apply))
possible Parkinson's disease (either
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three symptoms under point 1 OR one
symptom in 1 and one criterion in 2-3
apply) (possible Parkinson's disease
(either three symptoms under point 1 OR
one symptom in 1 and one criterion in 2-
3 apply))
probable Parkinson's disease (at least
two symptoms under point 1 AND one
criterion in 2-3 apply) (probable
Parkinson's disease (at least two
symptoms under point 1 AND one
criterion in 2-3 apply))
questionable Parkinson's disease (at
least one symptoms under point 1
applies) (questionable Parkinson's
disease (at least one symptoms under
point 1 applies))
uncertain Parkinson's disease (at least
two symptoms under point 1 apply)
(uncertain Parkinson's disease (at least
two symptoms under point 1 apply))
Test of ability to smell (12 Sniffin' Sticks)
Do you have currently problems smelling?
Yes
No
Sniffin stick 1:
Blackberry (Blackberry)
Orange (Orange)
Pineapple (Pineapple)
Strawberry (Strawberry)
Sniffin stick 2:
Fume (Fume)
Glue (Glue)
Grass (Grass)
Shoeleather (Shoeleather)
Sniffin stick 3:
Chocolate (Chocolate)
Cinnamon (Cinnamon)
Honey (Honey)
Vanilla (Vanilla)
Sniffin stick 4:
Chives (Chives)
Onion (Onion)
Peppermint (Peppermint)
Spruce (Spruce)
Sniffin stick 5:
Banana (Banana)
Cherry (Cherry)
Coconut (Coconut)
Walnut (Walnut)
Sniffin stick 6:
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Apple (Apple)
Citron (Citron)
Grapefruit (Grapefruit)
Peach (Peach)
Sniffin stick 7:
Chewing gum (Chewing gum)
Cookies (Cookies)
Licorice (Licorice)
Rubber (Rubber)
Sniffin stick 8:
Cigarette (Cigarette)
Coffee (Coffee)
Smoke of candle (Smoke of candle)
Wine  (Wine )
Sniffin stick 9:
Cinnamon (Cinnamon)
Clove (Clove)
Mustard (Mustard)
Pepper (Pepper)
Sniffin stick 10:
Peach (Peach)
Pear (Pear)
Pinapple (Pinapple)
Plum (Plum)
Sniffin stick 11:
Chamomile (Chamomile)
Cherry (Cherry)
Raspberry (Raspberry)
Rose (Rose)
Sniffin stick 12:
Bread (Bread)
Cheese (Cheese)
Fish (Fish)
Ham (Ham)
1, Sum of correctly identificated scents
>= 0
<= 12
2. Sum of correctly identified scents %
%
Anamnesis of smelling ability
Do you suffer currently from a severe cold or
inflammation of nose, resp. paranasal sinuses,
with significant impairment of smelling ability?
Yes
No
Do you suffer currently from allergies like hay
fever, that impair your smelling ability?
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Yes
No
Do you suffer from chronic asthma or another
chronic inflammatory disease of nose, paranasal
sinus, that significantly impairs your smelling
ability.
Yes
No
Did you have regular contact with following
substances in the past, for example in context of
your occupation?
Solvent
Yes
No
Wood, metal dust or fume
Yes
No
Did you have surgery on your nose as an adult,
child or teenager, e.g. nasal polypectomy ?
Yes
No
Was a tying of internal nose artery performed in
the past because of severe nose bleeding?
Yes
No
Did you have an accident with head injury
causing significant impairment of smelling ability?
Yes
No
Do you suffer from another condition concerning
nose or pharynx which significantly impairs your
smelling ability?
Yes
No
Do you suffer from another condition concerning
nose or pharynx which significantly impairs your
smelling ability? Which one?
Gait time measurement: 8-meter-walking-
test (8MWT)
1. Gait time test performed?
Yes
No
1.1.
Other reason (Other reason)
Participant was not able to walk because
of physical impairment (Participant was
not able to walk because of physical
impairment)
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2. Does the participant need gait aid?
None (None)
One walking aid (One walking aid)
Prosthesis (Prosthesis)
Two walking aids (Two walking aids)
Wheeled walker (Wheeled walker)
3. Time measurement of walking:
3.1. First try:
sec
3.2. Second try:
sec
4. Was a repetition of the walking test necessary?
Yes
No
4.1. Repetition because of:
Distraction of participant (Distraction of
participant)
Falling of participant (Falling of
participant)
Other reason (Other reason)
Other reason:
Examination of gait (GaitRite®)
1. Instrument-based gait analysis performed?
Yes
No
1.1.
Cognitive impairment (Cognitive
impairment)
other reasons (other reasons)
Participant cannot walk/can only walk
with walking aid because of physical
impairment (Participant cannot walk/can
only walk with walking aid because of
physical impairment)
Risk of falling (Risk of falling)
Technical problems (Technical problems)
Reason for physical impairment:
Other reason:
2.1. Gait single task
2.1.1. Preferred speed NOT DONE
Yes
No
Reason:
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Number of runs
>= 1
<= 8
2.1.2 Walking slowly NOT DONE
Yes
No
Reason:
Number of runs
<= 8
>= 1
2.1.3 Walking fast NOT DONE
Yes
No
Reason:
Number of runs
<= 8
>= 1
2.2. Gait dual task
2.2.1. Single serial subtraction NOT DONE
Yes
No
Reason:
Time:
sec
Number of mistakes:
Subtraction chosen:
-3 (-3)
-7 (-7)
2.2.2 Serial subtraction + walking fast NOT
DONE
Yes
No
Reason:
Number of runs
Subtraction chosen:
-3 (-3)
-7 (-7)
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Number of subtractions
Number of mistakes:
3. Tandem/Turn
3.1. Tandem gait
1x (1x)
not done (not done)
3.2. 180° turn
1x (1x)
not done (not done)
Please only comment if one or several
examinations not done
Examination of human resting and activity
profiles (Somno-Module)
1. Examinations of somno module performed?
Yes
No
1.1.
Other reason (Other reason)
Participant could not perform test
because of physical impairment
(Participant could not perform test
because of physical impairment)
Other reason:
2. Test performance and duration of somno
module
Start of examination:
End of examination:
Dominant hand
Right (1)
Left (2)
Assembly:
Activity
Yes
No
Actigraph applied?
left hand (left hand)
right hand (right hand)
Tremor
Yes
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No
Actigraph applied?
left hand (left hand)
right hand (right hand)
PLM
Yes
No
Actigraph applied?
right leg (right leg)
Storage of data on file server?
Yes
No
Comment
Examination of eye movements
(oculography)
1. Examination of eye movements performed?
Yes
No
1.1.
Other reason (Other reason)
Participant could not perform test
because of physical impairment
(Participant could not perform test
because of physical impairment)
Other Reason:
dominant eye
left eye (left eye)
right eye (right eye)
Visus, close, uncorrected
visus test monitor
Visual impairment known?
Yes
No
Diopter right (+/-)
Diopter left (+/-)
Test using visual aid?
Yes
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No
Optical aid
contact lenses (contact lenses)
glasses (glasses)
Test protocol used
NPT  (NPT )
other (other)
Other:
Testing successfully performed?
Yes
No
Not successful performed?
dependent on participant (dependent on
participant)
technical reasons (technical reasons)
Storage of data on file server?
Yes
No
Comment:
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DESCRIBE (DZNE – Clinical Register Study of
neurodegenerative Disorders) CRF Optional Questionnaire
Background and Purpose:
The purpose of the DESCRIBE study is to document the
natural course of diseases in context of medical care of
neurodegenerative disorders as well as cerebrovascular
diseases and to perform phenotyping of the test persons.
Disease-spanning analyses of the measured clincial data,
the results of the imaging processes, results of the analysis
of the biometerials including genetic analysis are planed.
Principal Investigator: Prof. Klockgether, Dr. Spottke DZNE,
Bonn.
Source: DESCRIBE-Studie
http://www.dzne.de/forschung/forschungsbereiche/klinische
-forschung/studien/describe-bn006.html 
Participating Study Sites:
Berlin, Bonn, Göttingen, Dresden, Köln, Magdeburg,
München, Rostock/Greifswald, Tübingen
All rights reserved. Please visit https://medical-data-
models.org/forms/14043
CRF Optional Questionnaire
Date of visit
Study-ID:
Visit:
Date of visit
RBDSQ - Questionnaire REM Sleep
Behavior Disorder
1. I sometimes have very vivid dreams.
Yes
No
2. My dreams have frequently an aggressive or
action-packed contents.
Yes
No
3. The dream contents mostly match my
nocturnal behavior.
Yes
No
4. I know that my arms or legs move when I
sleep.
Yes
No
5. It thereby happened that I almost hurt my bed
partner or myself.
Yes
No
6. I have or had the following phenomena during
my dreams:
6.1. Speaking, screaming, offending, laughing
loudly
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Yes
No
6.2. Sudden limb movements, 'fights'
Yes
No
6.3. Gestures, complex movements, that are
useless during sleep, e.g. to wave, to salute, to
frighten mosquitoes, to fall out of bed
Yes
No
7. It happens that my movements awake me.
Yes
No
8. After awakening I mostly remember the
content of my dreams well.
Yes
No
9. My sleep is frequently disturbed.
Yes
No
10. I have/had a disease of the nervous system
(e.g. stroke, head trauma, parkinsonism, RLS,
narcolepsy, depression, epilepsy, inflammatory
disease of the brain).
Yes
No
Total Score RBDSQ
<= 13
>= 0
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VX-950HPC3006 NCT01571583 Physical
Examination
This is an open-label (all people know the identity of the
intervention), multicenter study in genotype 1 chronic HCV
infected liver transplant patients who will be treated for 12
weeks with telaprevir 750 mg every 8 hours given in
combination with Peg-IFN-alfa-2a and ribavirin followed by
36 weeks of treatment with Peg-IFN-alfa-2a and ribavirin
alone. The total treatment duration will be 48 weeks. Safety
will be evaluated throughout the study and will include
evaluations of adverse events, clinical laboratory tests,
electrocardiogram, vital signs, and physical examination.
NCT01571583
All rights reserved. Please visit https://medical-data-
models.org/forms/14051
VX-950HPC3006 NCT01571583
Physical Examination
Date of examination
Same date as visit date
Yes
No
Other date, please specify
General Appearance
Not done
Yes
No
Normal
Yes
No
Abnormal, is the abnormality a new finding?
no (1)
yes, please specify (2)
Is the abnormality clinically significant?
Yes
No
Skin and mucous membranes
not done
Yes
No
normal
Yes
No
abnormal, is the abnormality a new finding?
no (1)
yes, please specify: (2)
Is the abnormality clinically significant?
Yes
No
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Eyes
not done
Yes
No
normal
Yes
No
abnormal, is the abnormality a new finding?
no (1)
yes, specify (2)
Is the abnormality clinically significant?
Yes
No
Ears, nose, throat
not done
Yes
No
normal
Yes
No
abnormal, is the abnormality a new finding?
no (1)
yes, specify (2)
is the abnormality clinically significant?
Yes
No
Cardiovascular system
not done
Yes
No
normal
Yes
No
abnormal, is the abnormality a new finding?
no (1)
yes, please specify (2)
is the abnormality clinically significant?
Yes
No
Respiratory system
not done
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Yes
No
normal
Yes
No
abnormal, is the abnormality a new finding?
no (1)
yes please specify (2)
is the abnormality clinically significant?
Yes
No
Gastrointestinal system
not done
Yes
No
normal
Yes
No
abnormal, is the abnormality a new finding?
no (1)
yes please specify (2)
is the abnormality clinically significant?
Yes
No
Genito-urinary system
not done
Yes
No
normal
Yes
No
abnormal, is the abnormality a new finding?
no (1)
yes please specify (2)
is the abnormality clinically significant?
Yes
No
neurological system
not done
Yes
No
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normal
Yes
No
abnormal, is the abnormality a new finding?
no (1)
yes specify (2)
is the abnormality clinically significant?
Yes
No
musculo-skeletal system
not done
Yes
No
normal
Yes
No
abnormal, is the abnormality a new finding?
no (1)
yes specify (2)
is the abnormality clinically significant?
Yes
No
lymph nodes
not done
Yes
No
normal
Yes
No
abnormal, is the abnormality a new finding?
no (1)
yes please specify (2)
is the abnormality clinically significant?
Yes
No
anorectal
not done
Yes
No
normal
Yes
No
abnormal, is the abnormality a new finding?
4 / 5
VX-950HPC3006 NCT01571583 Physical Examination
no (1)
yes please specify (2)
is the abnormality clinically significant?
Yes
No
other abnormality
other abnormality
is the abnormality clinically significant?
Yes
No
row number
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Eligibility Allergic Asthma NCT00581048
Study on the Role of Treatment With Vitamin E on
Asthmatic Responses in Allergic Asthmatics; ODM derived
from: https://clinicaltrials.gov/show/NCT00581048
All rights reserved. Please visit https://medical-data-
models.org/forms/14054
Eligibility Allergic Asthma
NCT00581048
Inclusion Criteria
normal health status except for allergic asthma*
Yes
No
physician diagnosis of mild allergic asthma*
Yes
No
positive allergen skin tests to common
aeroallergens*
Yes
No
Exclusion Criteria
use of systemic or high doses of inhaled
corticosteroids, >840 mcg of inhaled
beclomethasone of its equivalent (as defined in
the consensus report (6))*
Yes
No
past history of severe asthma (as defined in the
consensus report (6))*
Yes
No
history of asthma exacerbation within the past
month*
Yes
No
history of recent upper respiratory infection within
the past month*
Yes
No
active immunotherapy for allergic diseases*
Yes
No
significant disease other than allergic asthma and
allergic rhinitis, such as coronary disease,
hypertension, renal failure, anemia,
immunodeficiency, cancer, diabetes*
Yes
No
present or remote tobacco smoking*
Yes
No
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use of otc drugs including acetaminophen and
pseudoephedrine, herbs, or vitamins*
Yes
No
psychiatric illness that would make adherence to
protocol difficult*
Yes
No
inability to give informed consent*
Yes
No
nursing or pregnant women*
Yes
No
woman planning to become pregnant during the
study or not using adequate birth control methods
(barrier or hormonal methods)*
Yes
No
h/o sensitivity to tocopherol-derivatives or
medications used during bronchoscopy*
Yes
No
inability to comply with the research protocol*
Yes
No
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DESCRIBE (DZNE – Clinical Register Study
of neurodegenerative Disorders) CRF Scores
Background and Purpose:
The purpose of the DESCRIBE study is to document the
natural course of diseases in context of medical care of
neurodegenerative disorders as well as cerebrovascular
diseases and to perform phenotyping of the test persons.
Disease-spanning analyses of the measured clincial data,
the results of the imaging processes, results of the analysis
of the biometerials including genetic analysis are planed.
Principal Investigator: Prof. Klockgether, Dr. Spottke DZNE,
Bonn.
Source: DESCRIBE-Studie
http://www.dzne.de/forschung/forschungsbereiche/klinische
-forschung/studien/describe-bn006.html 
Participating Study Sites:
Berlin, Bonn, Göttingen, Dresden, Köln, Magdeburg,
München, Rostock/Greifswald, Tübingen
All rights reserved. Please visit https://medical-data-
models.org/forms/14057
CRF Scores
Scores
Unified Parkinson's Disease Rating Scale
Questionnaire-UPDRS
Beck depression inventory - BDI-II
Neuropsychiatric Inventory Questionnaire  - NPI-
Q
Epworth Sleepiness Scale Questionnaire - ESS
Parkinson’s Disease Questionnaire (PDQ-39)
Unified Multiple System Atrophy Rating Scale -
UMSARS
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Subcutaneous-Sublingual Immunotherapy With
Depigmented and Polymerized Dermatophagoides
Pteronyssinus Allergen Extract; ODM derived from:
https://clinicaltrials.gov/show/NCT00622362
All rights reserved. Please visit https://medical-data-
models.org/forms/14063
Eligibility Allergic Asthma
NCT00622362
Inclusion Criteria
written informed consent signed by the patient
and guardian.*
Yes
No
positive clinical history of allergy to dust mites.*
Yes
No
fev1 greater than or equal to 80 percent of the
expected value and improvement in fev1 greater
than 12 percent after bronchodilation.*
>= 80
%
Yes
No
age-between 5 and 14 years.*
>= 5
<= 14
years
Yes
No
sensitization to dust mites, diagnosed by positive
skin tests to dermatophagoides pteronyssinus:
wheal size > 3 mm diameter and / or rast (> 0.7
ku / l).*
Yes
No
Exclusion Criteria
patients out of  the age range.*
Yes
No
use of immunotherapy during the last four years.*
>= 1
<= 4
years
Yes
No
any contraindication for the use of
immunotherapy in accordance with european
allergy and clinical immunology immunotherapy
subcommittee criteria:*
Yes
No
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treatment with ß-blockers*
Yes
No
patients who have a condition in which adrenaline
is contraindicated (hyperthyroidism, hypertension,
heart disease, etc..).*
Yes
No
coexistence of immunopathological diseases
(e.g. of the liver, kidney, the nervous system,
thyroid gland, rheumatic diseases) in which
autoimmune mechanisms play a role*
Yes
No
patients suffering from immune deficiencies*
Yes
No
patients with serious psychiatric / psychological
disturbances*
Yes
No
patients aspirin intolerance*
Yes
No
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Eligibility Coronary Artery Disease
NCT00196079
The ASPECT Study - Asian Paclitaxel-Eluting Stent Clinical
Trial; ODM derived from:
https://clinicaltrials.gov/show/NCT00196079
All rights reserved. Please visit https://medical-data-
models.org/forms/14064
Eligibility Coronary Artery Disease
NCT00196079
Inclusion Criteria
patient must be eligible to undergo planned
treatment of a single de novo lesion in a native
coronary artery.*
Yes
No
patient must be an acceptable candidate for
coronary artery bypass surgery.*
Yes
No
patient must have given signed informed
consent.*
Yes
No
patient agrees to return at one month for an office
visit to assess cardiovascular status and at 4-6
months for an office visit to assess cardiovascular
status and for a diagnostic angiogram.*
Yes
No
Exclusion Criteria
patient is less than 18 years old.*
Yes
No
patient has history of bleeding diathesis or
coagulopathy or will refuse blood transfusions.*
Yes
No
the patient is simultaneously participating in
another investigative interventional
cardiovascular device or drug study.*
Yes
No
patient has known hypersensitivity or
contraindication to aspirin, clopidogrel, or
stainless steel, or a sensitivity to contrast dye
that.*
Yes
No
patient is pregnant.*
Yes
No
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patient has other medical condition that may
cause the patient to be non-compliant with the
protocol, confound the results or is associated
with limited life expectancy.*
Yes
No
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Eligibility Allergic Asthma NCT00670930
Efficacy of Omalizumab in Adults (18-60 Years of Age) With
Moderate-Severe, Persistent Allergic Asthma, Despite
Receiving Inhaled Corticosteroids and Long Acting Beta-
agonists; ODM derived from:
https://clinicaltrials.gov/show/NCT00670930
All rights reserved. Please visit https://medical-data-
models.org/forms/14069
Eligibility Allergic Asthma
NCT00670930
Inclusion Criteria
patients 18-75 years of age with moderate to
severe persistent allergic asthma receiving a high
dose inhaled corticosteroid (≥800µg per day bdp
or equivalent) and a regular long acting beta-
agonist for at least 3 months prior to screening*
>= 18
<= 75
years
Yes
No
with a body weight between 20 and 150kg and a
serum total ige level of 30 to 700 iu/ml*
>= 20
<= 150
kg
Yes
No
with ≥2 percent eosinophilia in induced sputum at
screening*
>= 2
%
Yes
No
with post-bronchodilator forced expiratory volume
in 1 second (fev1) ≥60 percent predicted*
>= 60
%
Yes
No
with a positive skin prick test (diameter of wheal ≥
3 mm) or rast test to at least one perennial aero-
allergen (eg. dust mite, cat/dog dander,
cockroaches), documented within the past 2
years or demonstrated at visit 1, to which the
patient will be exposed on a regular basis (most
days) for the duration of the study.*
Yes
No
Exclusion Criteria
patients who've had an asthma exacerbation
during the 4 weeks prior to randomization*
Yes
No
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current smokers, stopped smoking within the last
12 months or have a smoking history of >10 pack
years*
Yes
No
history of severe allergy to food or drugs*
Yes
No
previous treatment with omalizumab*
Yes
No
any patient considered to be unsuitable to
bronchoscopy, according to the judgment of the
investigator*
Yes
No
other protocol-defined inclusion/exclusion criteria
applied.*
Yes
No
2 / 2
Eligibility Allergic Asthma NCT00670930
Eligibility Allergic Asthma NCT00829179
Role of RhuMab-E25 in Reducing Exhaled Nitric Oxide
(NO) in Allergic Asthma; ODM derived from:
https://clinicaltrials.gov/show/NCT00829179
All rights reserved. Please visit https://medical-data-
models.org/forms/14070
Eligibility Allergic Asthma
NCT00829179
Inclusion Criteria
subjects must be at least 18 years of age,*
>= 18
years
Yes
No
must have an fev1 of > 70 percent of predicted,*
>= 71
%
Yes
No
must have evidence of bronchial hyperreactivity
to methacholine as      defined by a methacholine
provocation causing a 20% or greater fall in fev1
(pc20) < 8 mg/ml*
Yes
No
use of inhaled steroid is permitted; however, no
change in inhaled steroid dosage will be
permitted over the duration of study*
Yes
No
must have a normal platelet count,*
Yes
No
must be willing to and competent to sign the
consent form*
Yes
No
Exclusion Criteria
subjects that do not have allergic asthma will be
excluded.*
Yes
No
subjects with er visits or upper respiratory
infections within the last six weeks will be
excluded.*
Yes
No
subjects with tobacco use within the past year or
> 10 pack year history of tobacco use will be
excluded.*
Yes
1 / 2
No
subjects with serum ige levels of less than 30 or
greater than 700 iu/ml will be excluded.*
Yes
No
subjects that require oral steroid use will be
excluded.*
Yes
No
subjects who weigh < 30 kg or > 150 kg are
excluded, and subjects with baseline ige levels
greater than 300 may be excluded, depending on
weight*
>= 30
<= 150
kg
Yes
No
pregnant or nursing females will be excluded.*
Yes
No
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Eligibility Allergic Asthma NCT01155700
Pharmacokinetics and Pharmacodynamics, Efficacy and
Safety of Omalizumab in Japanese Children (6 - 15 Years);
ODM derived from:
https://clinicaltrials.gov/show/NCT01155700
All rights reserved. Please visit https://medical-data-
models.org/forms/14071
Eligibility Allergic Asthma
NCT01155700
Inclusion Criteria
body weight and serum total ige level within the
dosing table range; body weight of 20 to 150 kg
and serum total ige levels of 30 to 1300 iu/ml*
>= 20
<= 150
kg
Yes
No
receiving asthma long-term control medications
of high dose ics (>200 µg/day fp or equivalent)
and two or more controller medications out of ltra,
theophylline, sodium cromoglycate, laba, or ocss
12 weeks prior to the run-in period. these
medications should be kept stable for 4 weeks
prior to the run-in period and during the run-in
period (except for management of asthma
attacks/exacerbations)*
Yes
No
having 2 or more asthma exacerbations requiring
treatment with a doubling of the maintenance ics
dose for at least 3 days and/or systemic (oral or
iv) corticosteroids in the past; one of these
exacerbations must have occurred in the previous
12 months, which is documented in the medical
record*
Yes
No
demonstrating inadequately controlled asthma
symptoms during the last 14 day run-in period
based on the patient diary which meet any of the
following:*
Yes
No
asthma symptoms every day; night-time
symptoms in ≥2 out of the last 14 days (missing
data to be treated as a day with no symptoms);
limitation of daily activities in ≥2 out of the last 14
days (missing data to be treated as a day with no
limitations)*
Yes
No
Exclusion Criteria
1 / 2
with a history of food or drug related severe
anaphylactoid or anaphylactic reaction(s)*
Yes
No
with positive skin reaction to the study drug at the
run-in period*
Yes
No
with known hypersensitivity to any ingredients,
including excipients (sucrose, histidine,
polysorbate 20) of the study drug or drug related
to omalizumab (e.g., monoclonal antibodies,
polyclonal gamma globulin)*
Yes
No
with platelet level ≤ 100,000/µl (100 x 109/l) at the
run-in period*
Yes
No
who are taking intra-muscular depo-steroids
within 4 weeks of the run-in period*
Yes
No
who are taking systemic (oral or iv)
corticosteroids for reasons other than asthma
within 4 weeks of the run-in period (patients with
chronic ocss use for asthma are allowed)*
Yes
No
other protocol-defined inclusion/exclusion criteria
may apply*
Yes
No
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Eligibility Asthma NCT01869543
Asthma and Indoor-air: Reducing Exposures; ODM derived
from: https://clinicaltrials.gov/show/NCT01869543
All rights reserved. Please visit https://medical-data-
models.org/forms/14074
Eligibility Asthma NCT01869543
Inclusion Criteria
6-12 years of age*
>= 6
<= 12
years
Yes
No
living in fresno, san bernardino or riverside
counties.*
Yes
No
physician diagnosed asthma, as stated by the
participant's caregiver.*
Yes
No
in the last six months, the child must have had
asthma symptoms at least twice a week for
several weeks in a row.*
Yes
No
Exclusion Criteria
children living in homes where more than 2
cigarettes are smoked per week in the home.*
Yes
No
children that spend 2 or more nights per week in
another home.*
Yes
No
children living in homes that are planning on
moving in the next 2 years.*
Yes
No
children living in homes that keep their windows
open most of the time.*
Yes
No
children living in homes that have existing high
efficiency filtration.*
Yes
No
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Eligibility Alcoholic Hepatitis NCT02039219
Trial of Obeticholic Acid in Patients With Moderately Severe
Alcoholic Hepatitis (AH); ODM derived from:
https://clinicaltrials.gov/show/NCT02039219
All rights reserved. Please visit https://medical-data-
models.org/forms/14077
Eligibility Alcoholic Hepatitis
NCT02039219
Inclusion Criteria
individuals ≥ 21 years with a diagnosis of acute
ah. the diagnosis of acute alcoholic hepatitis will
be based on clinical features and testing
including hepatomegaly, jaundice, fever,
leukocytosis, compatible liver biochemistries in
the context of heavy alcohol consumption. a liver
biopsy is not mandatory, but will be required to
confirm the diagnosis if a firm diagnosis of ah
cannot be made on clinical and laboratory
criteria*
Yes
No
moderate severity defined as meld score > 11
and < 19*
Yes
No
heavy alcohol consumption (defined as > 40
grams per day on average in women and > 60
grams per day on average in men for a minimum
of 6 months and within the 6 weeks prior to study
enrollment)*
Yes
No
Written informed consent*
Yes
No
negative urine pregnancy test where appropriate*
Yes
No
women of child bearing potential should be willing
to practice contraception throughout the
treatment period*
Yes
No
Exclusion Criteria
significant active infection (e.g., sepsis, or
spontaneous bacterial peritonitis; sbp). subjects
can be reconsidered after the infection is under
control.*
Yes
No
serum creatinine > 2.5 mg/dl*
1 / 2
mg/dl
Yes
No
must not be receiving systemic steroids > 1 week
at the time of screening or any experimental
medicines for ah*
Yes
No
presence of any other disease or condition that is
interfering with the absorption, distribution,
metabolism, or excretion of drugs including bile
salt metabolism in the intestine.  patients who
have undergone gastric bypass procedures will
be excluded (gastric lap band is acceptable).*
Yes
No
participation in another investigational drug,
biologic, or medical device trial within 30 days
prior to screening*
Yes
No
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Eligibility Alcoholic Hepatitis NCT02075918
Integrated Approaches for Identifying Molecular Targets in
Alcoholic Hepatitis; ODM derived from:
https://clinicaltrials.gov/show/NCT02075918
All rights reserved. Please visit https://medical-data-
models.org/forms/14078
Eligibility Alcoholic Hepatitis
NCT02075918
Inclusion Criteria
patients ≥18 and <70 years of age.*
Yes
No
active alcohol abuse defined according to the
diagnostic and statistical manual of mental
disorders iv (dsm iv) and excessive alcohol
consumption prior to admission (> 60 g per day
for men and> 40 g per day for women).*
Yes
No
moderate elevation of aminotransferases (usually
less than 300 u / l) with a characteristic pattern of
ast/ alt ratio of 2:1.*
Yes
No
elevated serum ggt and bilirubin levels.*
Yes
No
absence of prior autoimmune liver disease
(ana<1/80, sma<1/80, lkm1 neg, ama neg).*
Yes
No
absence of hepatitis b and c and hiv infection
(anti-hcv, surface hbv antigen and anti-hiv neg).*
Yes
No
patients with decompensated alcoholic cirrhosis
will be suitable for inclusion (eg, acute
gastrointestinal bleeding, acute renal failure,
hepatic encephalopathy and bacterial
infections).*
Yes
No
because there are no non-diagnostic tools to
diagnose alcoholic hepatitis, histological
confirmation is required in all patients (preferably
through a transjugular biopsy): alcoholic hepatitis
will be diagnosed on the presence of the
following histologic features:*
steatosis (either macro or
microvesicular). (1)
hepatocellular damage (eg, hepatocyte
ballooning and presence of mallory-denk
bodies). (2)
1 / 2
inflammatory infiltrate (predominantly
polymorphonuclear cells). (3)
pericellular or sinusoidal fibrosis. (4)
Exclusion Criteria
hepatocellular carcinoma.*
Yes
No
complete portal vein thrombosis.*
Yes
No
advanced or terminal extrahepatic diseases (eg
heart failure, advanced lung diseases, advanced
oncologic diseases).*
Yes
No
lack of consent to participate in the study.*
Yes
No
pregnancy*
Yes
No
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Eligibility Alcoholic Hepatitis NCT02281929
Efficacy of Antibiotic Therapy in Severe Alcoholic Hepatitis
Treated With Prednisolone; ODM derived from:
https://clinicaltrials.gov/show/NCT02281929
All rights reserved. Please visit https://medical-data-
models.org/forms/14079
Eligibility Alcoholic Hepatitis
NCT02281929
Inclusion Criteria
patients aged 18-75*
Yes
No
recent onset of jaundice (<3 months)*
Yes
No
biopsy proven alcoholic hepatitis (transjugular
liver biopsy)*
Yes
No
maddrey's discriminant function ≥  32, defining
severe alcoholic hepatitis*
Yes
No
meld score ≥21*
Yes
No
alcohol consumption ≥  40g/day (women) and ≥
50g/day (men)*
Yes
No
Written informed consent*
Yes
No
Exclusion Criteria
previous severe allergy or hypersensitivity to
amoxicillin or clavulanic acid (anaphylactic shock,
quincke edema, severe urticaria)*
Yes
No
hypersensitivity to any component of the
medication*
Yes
No
history of liver injury*
Yes
No
phenylketonuria, because of the presence of
aspartame in the powder for the oral suspension*
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Yes
No
type 1 hepatorenal syndrome before the initiation
of treatment*
Yes
No
severe extrahepatic disease*
Yes
No
any malignant tumor < 2 years*
Yes
No
uncontrolled gastrointestinal bleeding*
Yes
No
ongoing viral or parasitic infection*
Yes
No
untreated bacterial infection.*
Yes
No
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Eligibility Alcoholic Hepatitis NCT01918462
Protective Immune Mechanisms in Alcoholic Hepatitis;
ODM derived from:
https://clinicaltrials.gov/show/NCT01918462
All rights reserved. Please visit https://medical-data-
models.org/forms/14080
Eligibility Alcoholic Hepatitis
NCT01918462
Inclusion Criteria
diagnosis of alcoholic hepatitis:*
Yes
No
relevant history of alcohol consumption (>40g/day
for a minimum of 6 months with cessation      of
consumption no earlier than 3 months prior to
admission)*
Yes
No
bilirubin > 80 mol/l*
Yes
No
neutrophil granulocytes > 10x10^9/l*
Yes
No
exclusion of other liver pathology including biliary
disease*
Yes
No
histological verification on liver biopsy*
Yes
No
written, informed consent*
Yes
No
Exclusion Criteria
other chronic inflammatory or autoimmune
diseases*
Yes
No
severe, acute bacterial infection (peritonitis,
sepsis, pneumonia, urinary tract infection etc.)*
Yes
No
cancer*
Yes
No
prednisolon or pentoxifylline treatment within the
past 8 weeks*
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Yes
No
pregnancy*
Yes
No
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Eligibility Alcoholic Hepatitis NCT01918462
Eligibility Alcoholic Hepatitis NCT01912404
Study of IDN-6556 in Patients With Severe AH and
Contradictions to Steroid Therapy; ODM derived from:
https://clinicaltrials.gov/show/NCT01912404
All rights reserved. Please visit https://medical-data-
models.org/forms/14081
Eligibility Alcoholic Hepatitis
NCT01912404
Inclusion Criteria
male or female patients 21 years of age or older*
Yes
No
patients with alcoholic hepatitis defined as:*
Yes
No
history of heavy alcohol abuse use: >40 g/day in
females and >60 g/day in males for a minimum
period of 6 months*
Yes
No
consumed alcohol within 6 weeks of entry into
the study*
Yes
No
biochemical parameters of severe disease as
evidenced by meld score >20 but <35, or meld
score 35-40 if the sofa score is <10*
Yes
No
patients with established contraindications to
steroid use including but not limited to the
following:*
Yes
No
gi bleed*
Yes
No
active infection, including spontaneous bacterial
peritonitis, based on positive blood culture, urine
culture, or chest x-ray (if positive, must have been
on antibiotics for at least 24 hours prior to study
entry)*
Yes
No
acute pancreatitis (increased lipase > 3x uln or
radiologic evidence)*
Yes
No
positivity for hepatitis b (hbsag+) or c virus
(hcv+), and*
Yes
No
1 / 3
renal failure*
Yes
No
Exclusion Criteria
other or concomitant cause of liver disease as a
result of:*
Yes
No
autoimmune liver disease (positive anti-
mitochondrial antibody and smooth muscle
antibody, positive reading on anti-nuclear
antibody titer >1:160)*
Yes
No
metabolic liver disease (abnormal ceruloplasmin
levels)*
Yes
No
vascular liver disease*
Yes
No
drug induced liver disease*
Yes
No
sepsis as evidenced by positive blood or urine
culture, pneumonia as confirmed by x-ray*
Yes
No
history of renal transplant and/or on dialysis at
time of entry into study*
Yes
No
diagnosed or suspected systemic lupus
erythematosus (sle) and/or rheumatoid arthritis
(ra)*
Yes
No
hepatocellular carcinoma (hcc) at entry into the
study*
Yes
No
active non-liver malignancies other than
curatively treated skin cancer (basal cell or
squamous cell carcinomas)*
Yes
No
liver biopsy, if carried out, showing findings not
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compatible with alcoholic hepatitis*
Yes
No
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Eligibility Alcoholic Hepatitis NCT01768715
Liver Transplantation in Alcoholic Hepatitis; ODM derived
from: https://clinicaltrials.gov/show/NCT01768715
All rights reserved. Please visit https://medical-data-
models.org/forms/14082
Eligibility Alcoholic Hepatitis
NCT01768715
Inclusion Criteria
diagnosis of alcoholic hepatitis (liver biopsy will
be advisable).*
Yes
No
first episode of clinical decompensation of
alcoholic liver disease (defined as jaundice,
variceal bleeding, ascites or portal-systemic
encephalopathy).*
Yes
No
absence of a high risk of alcoholic recidivism
(according to de gottardi, et al).*
Yes
No
severe alcoholic hepatitis (abic score > 6.71)*
Yes
No
informed consent*
Yes
No
Exclusion Criteria
age over 65 years*
Yes
No
hepatitis b or c or hiv infections.*
Yes
No
uncontrolled bacterial infection*
Yes
No
other liver diseases, such as alpha-1-antitrypsin
deficiency, primary biliary cirrhosis, ...*
Yes
No
morbid obesity (bmi > 35 kg/m2)*
Yes
No
major uncontrolled psychiatric disease*
Yes
No
1 / 2
drug addiction (excluding tobacco) in the last two
years.*
Yes
No
absence of informed consent.*
Yes
No
acute-on-chronic liver disease.*
Yes
No
paracetamol consumption over 10 grams in the
last week.*
Yes
No
criteria for liver transplantation*
Yes
No
absence of response to steroid therapy  (lille
score ≥ 0.45 7 days after initiation of steroid
therapy).*
Yes
No
adequate social and familiar environment*
Yes
No
complete agreement in the medical staff about
the candidate to transplantation.*
Yes
No
absence of bacterial or fungal infection*
Yes
No
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Eligibility Coronary Artery Disease
NCT00233805
The Initial Double-Blind Drug-Eluting Stent vs Bare-Metal
Stent Study.; ODM derived from:
https://clinicaltrials.gov/show/NCT00233805
All rights reserved. Please visit https://medical-data-
models.org/forms/14084
Eligibility Coronary Artery Disease
NCT00233805
Inclusion Criteria
1. diagnosis of angina pectoris as defined by
canadian cardiovascular society classification
(ccs i, ii, iii, iv) or unstable angina pectoris
(braunwald classification b&c, i-ii-iii) or patients
with documented silent ischemia;*
Yes
No
2. single treatment of de novo lesion in a
coronary artery which can be appropriately
covered by a study stent of 18mm in length in
patients with single or multivessel disease;
patients with multiple lesions can be included
only if the other lesions do not require treatment;*
Yes
No
3. target lesion is >= 2.5 and <= 3.5mm in
diameter (visual estimate);*
Yes
No
4. target lesion is located in a native coronary
artery which can be covered by one stent (single
lesion);*
Yes
No
5. target lesion stenosis is >50% and <100% (timi
i) (visual estimate).*
Yes
No
Exclusion Criteria
1. a q-wave or non-q-wave myocardial infarction
within the preceding 72 hours unless the ck and
ck-mb enzymes are back to normal;*
Yes
No
2. unprotected left main coronary disease with
>=50% stenosis;*
Yes
No
3. have an ostial target lesion;*
Yes
No
4. angiographic evidence of thrombus within
1 / 2
target lesion;*
Yes
No
5. calcified lesions which cannot be successfully
predilated;*
Yes
No
6. ejection fraction <=30%;*
Yes
No
7. totally occluded vessel (timi 0 level);*
Yes
No
8. target lesion involves bifurcation including a
side branch >=2.5mm in diameter (either stenosis
of both main vessel and major branch or stenosis
of just major branch) that would require side
branch stenting which is likely to occur if side
branch is diseased and intended to be stented;*
Yes
No
9. planned direct stenting.*
Yes
No
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Eligibility Asthma NCT01890148
Distribution of Neutrophils in Bronchial Mucosal Tissue in
Asthma Patients Before and After 4 Weeks Treatment With
AZD 5069; ODM derived from:
https://clinicaltrials.gov/show/NCT01890148
All rights reserved. Please visit https://medical-data-
models.org/forms/14087
Eligibility Asthma NCT01890148
Inclusion Criteria
1. male or female patients of caucasian origin,
aged between 18 to 65 years, inclusive, at the
time informed consent is obtained.*
>= 18
<= 65
years
Yes
No
2. physician based (according to gina 2011)
diagnosis of asthma for at least 6 months prior to
the date informed consent is obtained and
confirmed by 1 of the detailed respiratory criteria
stated in the csp*
Yes
No
3. morning prebronchodilator (ie, after abstinence
from short-acting and long-acting*
Yes
No
ß-agonist treatment for ≥ 6 and ≥ 12 hours,
respectively) fev1 of ≥70 percent of predicted
normal (pn) for age, sex and height at enrolment*
Yes
No
4. increased number of neutrophils in induced
sputum samples at baseline, with a relative
neutrophil count of  ≥ 50 percent of total sputum
cell count*
Yes
No
5. physician prescribed daily use of medium or
high dose ics (≥ fluticasone 250 μg to ≤*
Yes
No
1.000 µg or the equivalent daily, as defined in
gina 2011; see csp appendix e) plus laba.*
Yes
No
Exclusion Criteria
1. history of clinically relevant allergies or
idiosyncrasies to azd5069 or other investigational
cxcr2 antagonists, or any inactive ingredient(s) of
1 / 2
the imp, or tool-substances (eg, salbutamol, local
anaesthetics) used for the purpose of this study*
Yes
No
2. history of severe asthma exacerbation
requiring hospitalization within the last 12 months
before screening.*
Yes
No
3. asthma exacerbation requiring a treatment
course of systemic (ie, oral or parenteral)
corticosteroids within the 3 months before
screening or ≥ 3 courses within the last 12
months before screening.*
Yes
No
4. moderate to severe airflow limitation (fev1
<70% pn)*
<= 69
%
Yes
No
5. any chronic lower respiratory disease other
than asthma (see csp for details) that, as judged
by the investigator or medical monitor, would
interfere with the evaluation of the imp or
interpretation of patient safety or study results.*
Yes
No
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Eligibility Asthma NCT01891630
Observational Assessment of Baseline Asthma Control in
African-American Children; ODM derived from:
https://clinicaltrials.gov/show/NCT01891630
All rights reserved. Please visit https://medical-data-
models.org/forms/14088
Eligibility Asthma NCT01891630
Criteria
1. self-identified as african-american*
Yes
No
2. ages 12-17 years*
>= 12
<= 17
years
Yes
No
3. live within convenient driving distance of the
unc rex clinic in raleigh, nc.*
Yes
No
4. physician-diagnosis of moderate-to-severe
persistent asthma*
Yes
No
5. current treatment with appropriate therapy for
moderate-to-severe persistent asthma symptoms
as per the nhlbi guidelines including:  daily
controller medication use for asthma requiring at
least a medium-dose inhaled corticosteroids (ics)
or a low dose ics + long-acting beta2 agonist
(laba) combination.  subjects may use daily or
every other day oral corticosteroids for control of
asthma symptoms*
Yes
No
inclusion criteria for well-controlled asthmatics
(from nhlbi guidelines):*
Yes
No
1. nighttime awakening with asthma symptoms ≤
2x/month over the past 6 months*
Yes
No
2. use of short-acting beta2 agonist for symptom
control ≤ 2 days /week over the past 6 months*
Yes
No
3. asthma control test score >19.  the asthma
control test is a standardized clinical tool to
assess asthma control over the previous 4 week
period (attached).*
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>= 20
Yes
No
4. baseline fev1(pre-albuterol) > 80 percent of
that predicted for gender, ethnicity, age and
height (nhanes iii predicted set)*
>= 81
%
Yes
No
inclusion criteria for poorly-controlled asthmatics
(from nhlbi guidelines):*
Yes
No
1. nighttime awakening with asthma symptoms >
2x/month over the past 6 months*
Yes
No
2. use of short-acting beta2 agonist for symptom
control > 2 days /week over the past 6 months*
Yes
No
3. asthma control test score <19. the asthma
control test is a standardized clinical tool to
assess asthma control over the previous 4 week
period (attached).*
<= 18
Yes
No
4. baseline fev1 (pre-albuterol) < 80 percent of
that predicted for gender, ethnicity, age and
height (nhanes iii predicted set)*
<= 79
%
Yes
No
exclusion criteria for all subjects:*
Yes
No
1. children younger than age 12 and older than
17*
Yes
No
2. children unable to perform spirometry*
Yes
No
3. medical history or underlying health problems
that may preclude participation in the protocol per
the study physician (including but not limited to
cystic fibrosis, chronic bronchitis, recurrent
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pneumonia, immunodeficiency, hematologic
disorders)*
Yes
No
4. history of bleeding disorder or anemia*
Yes
No
5. subjects and families unwilling to travel to the
clinic for the required 6 visits*
Yes
No
6. unwilling or unable to refrain from the following
medications for the week prior to the study as
well as the week of the study including fish oil;
anti-inflammatory agents such as ibuprofen
(advil, motrin), naproxen (aleve) or aspirin as
needed**. acetaminophen (tylenol) is allowed.**if
the child requires anti-inflammatory medications
for a fever or joint/muscle pain, in the week prior
to the study visit, all subsequent visits may be
rescheduled.*
Yes
No
7. other uncontrolled health problems*
Yes
No
8. non-english speaking subjects*
Yes
No
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Eligibility Coronary Artery Disease
NCT00233818
FIM-NL - First-in-Man Study (Netherlands Part) With
Sirolimus Coated Modified BX Velocity Stent; ODM derived
from: https://clinicaltrials.gov/show/NCT00233818
All rights reserved. Please visit https://medical-data-
models.org/forms/14091
Eligibility Coronary Artery Disease
NCT00233818
Inclusion Criteria
1. diagnosis of angina pectoris as defined by
canadian cardiovascular society classification
(ccs) or a positive ischemia study;*
Yes
No
2. single de novo lesion requiring treatment in a
major native coronary artery;*
Yes
No
3. target lesion is <=18mm in length (visual
estimate);*
Yes
No
4. target lesion is  >=3.0mm and <=3.5mm in
diameter (visual estimate);*
Yes
No
5. target lesion stenosis is >50% and <100%
(visual estimate);*
Yes
No
Exclusion Criteria
1. a q-wave or non-q-wave myocardial infarction
within the preceding 72 hours unless the ck and
ck-mb enzymes are back to normal;*
Yes
No
2. unprotected left main coronary disease with
>=50% stenosis;*
Yes
No
3. have an ostial target lesion;*
Yes
No
4. angiographic evidence of thrombus within
target lesion;*
Yes
No
5. calcified lesions which cannot be successfully
predilated;*
Yes
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No
6. ejection fraction <=30%;*
Yes
No
7. target lesion involves bifurcation (either
stenosis of both main vessel and major branch or
stenosis of just major branch);*
Yes
No
8. totally occluded vessel;*
Yes
No
2 / 2
Eligibility Coronary Artery Disease NCT00233818
Eligibility Coronary Artery Disease
NCT00287690
Isoflavones and the Coronary Circulation in Men and
Women With Coronary Artery Disease; ODM derived from:
https://clinicaltrials.gov/show/NCT00287690
All rights reserved. Please visit https://medical-data-
models.org/forms/14094
Eligibility Coronary Artery Disease
NCT00287690
Inclusion Criteria
aged 30-75 years*
Yes
No
patients requiring diagnostic coronary
angiography*
Yes
No
presence of coronary artery disease on
angiogram but with at least one non-obstructed
(lesions <70% narrowed compared with the
adjacent normal part of the vessel) atheromatous
vessel (confirmed at diagnostic cardiac
catheterisation)*
Yes
No
female patients must be postmenopausal (fsh>40
iu/l)*
Yes
No
willing to give informed, written consent*
Yes
No
Exclusion Criteria
age <30 or >75 years*
Yes
No
allergy to radiographic contrast media*
Yes
No
sino-atrial disease or significant bradycardia*
Yes
No
concomitant medication with persantin
(dipyridamole) or theophyllines*
Yes
No
asthma*
Yes
No
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hypertension*
Yes
No
left ventricular hypertrophy or dysfunction
(clinical/ecg/echo/cxr)*
Yes
No
female patients with fsh<40 iu/l
(postmenopausal)*
Yes
No
female patients currently taking hormone therapy,
or who have taken hormone therapy in previous 6
months*
Yes
No
unwilling to give written informed consent*
Yes
No
participation in another study within previous 60
days*
Yes
No
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Eligibility Asthma NCT01894048
Targeted Small Airways Therapy in Persistent Asthma;
ODM derived from:
https://clinicaltrials.gov/show/NCT01894048
All rights reserved. Please visit https://medical-data-
models.org/forms/14095
Eligibility Asthma NCT01894048
Inclusion Criteria
male and female volunteers aged 18-65, with
persistent asthma*
>= 18
<= 65
years
Yes
No
asthma control questionnaire score >1.0 (at end
of run-in)*
>= 2
Yes
No
fev1 >60 percent predicted*
>= 61
%
Yes
No
r5>130% predicted and r5-r20>0.03kpa/l/s*
>= 131
%
Yes
No
ability to perform spirometry, impulse
oscillometry, bronchial challenge and all
domiciliary measurements*
Yes
No
ability to give informed consent*
Yes
No
asthmatic patients receiving treatment at step 2,
3, or 4 of british thoracic society asthma
guidelines*
Yes
No
ability to withhold long-acting beta-agonists for
the duration of the study*
Yes
No
Exclusion Criteria
patients already receiving extra-fine particle
inhaled corticosteroids (qvar, fostair, alvesco)*
Yes
No
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pregnancy or lactation*
Yes
No
known or suspected sensitivity to the
investigational medicinal product*
Yes
No
inability to comply with protocol*
Yes
No
any clinically significant medical conditions that
may either endanger the health or safety of the
participant, or jeopardise the protocol*
Yes
No
an asthma exacerbation requiring systemic
steroid therapy or lower respiratory tract infection
requiring antibiotics within 3 months prior to study
commencement*
Yes
No
participation in previous trial within 30 days*
Yes
No
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Eligibility Coronary Artery Disease
NCT00317265
Coronary Bypass Surgery Trial: Complete Arterial
Revascularization and Conventional Coronary Artery
Surgery; ODM derived from:
https://clinicaltrials.gov/show/NCT00317265
All rights reserved. Please visit https://medical-data-
models.org/forms/14096
Eligibility Coronary Artery Disease
NCT00317265
Inclusion Criteria
1. patient eligible for surgical myocardial
revascularization*
Yes
No
2. age 70 years or less*
Yes
No
3. triple vessel coronary disease with significant
coronary artery stenosis defined as a stenosis of
at least 50% in luminal diameter*
Yes
No
4. patients with stable angina pectoris (canadian
cardiovascular society 1, 2, 3, or 4) or unstable
angina pectoris (braunwald classification 1b, 2b,
3b)  or proven silent myocardial ischemia.*
Yes
No
Exclusion Criteria
1. no informed consent*
Yes
No
2. age > 65 years*
Yes
No
3. participation in another study with any
investigational drug or coronary revascularization
procedure*
Yes
No
4. when follow up over a period of five years is
difficult or unlikely*
Yes
No
5. concomitant non-cardiac disease likely to limit
long-term prognosis (e.g. cancer)*
Yes
No
6. one or two vessel coronary disease and
isolated left main stenosis*
Yes
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No
7. estimated left ventricular ejection fraction <
25%*
Yes
No
8. myocardial infarction within seven days*
Yes
No
9. need for concomitant major cardiac or non-
cardiac surgery (e.g. valve surgery, left
ventricular aneurysm, aortic aneurysm, carotid
artery desobliteration, etc.)*
Yes
No
10. redo-cardiac surgery*
Yes
No
11. presence of the combination of insulin
dependent diabetes mellitus and chronic
obstructive pulmonary disease requiring therapy*
Yes
No
12. renal insufficiency requiring dialysis*
Yes
No
13. presence of the combination of severe
adiposity and insulin dependent diabetes
mellitus*
Yes
No
14. presence of the combination of  severe
adiposity and chronic obstructive pulmonary
disease requiring therapy*
Yes
No
15. severe hepatic disease*
Yes
No
16. emergent operation for coronary artery
disease with signs of ischemia (e.g. failed ptca,
ongoing myocardial infarction)*
Yes
No
17. unstable angina pectoris class a and c
according to braunwald classification (i.e.
secondary unstable angina and postinfarction
unstable angina within one week after acute mi)*
Yes
No
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18. inadequate quality of saphenous vein
material*
Yes
No
19. inadequate quality or number of arterial
conduits to achieve complete revascularization
likely (e.g. chest irradiation, major abdominal
surgery)*
Yes
No
20. recent (< 2weeks) cerebrovascular event (tia,
rind, stroke)*
Yes
No
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Eligibility Coronary Heart Disease
NCT00010738
Effects of Meditation on Mechanism of Coronary Heart
Disease; ODM derived from:
https://clinicaltrials.gov/show/NCT00010738
All rights reserved. Please visit https://medical-data-
models.org/forms/14098
Eligibility Coronary Heart Disease
NCT00010738
Inclusion Criteria
able to attend training sessions and meetings*
Yes
No
local residence*
Yes
No
Exclusion Criteria
comorbid disease precluding survival in group*
Yes
No
mi, unstable angina, cabg or ptca within last three
months.*
Yes
No
cognitive/psychological/substance abuse
impairment*
Yes
No
atrial fibrillation, predominant pacemaker rhythm
or significant conduction system disease*
Yes
No
significant valvular heart disease*
Yes
No
class iii or iv heart failure*
Yes
No
renal failure*
Yes
No
participating in a formal stress management
program*
Yes
No
participation in another trial*
Yes
No
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Eligibility Depression NCT00177528
Safety and Efficacy of Venlafaxine XR in Elderly Patients
With Major Depression; ODM derived from:
https://clinicaltrials.gov/show/NCT00177528
All rights reserved. Please visit https://medical-data-
models.org/forms/14099
Eligibility Depression NCT00177528
Inclusion Criteria
men and women of all races who are 60 years
old or older;*
Yes
No
a dsm-iv diagnosis of major depressive episode
without psychotic features;*
Yes
No
17-item ham-d score of >15 for potential subjects
who have not received any antidepressant
treatment during this illness episode or ham-d >
11 for potential subjects who have received
treatment with an antidepressant (other than
venlafaxine-xr) during this illness episode;*
Yes
No
a mmse score of >15.*
Yes
No
Exclusion Criteria
history of meeting dsm-iv criteria for mania,
schizophrenia or other psychotic disorder;*
Yes
No
history of substance abuse or dependence,
including alcohol, within the last three months;*
Yes
No
current hyponatremia (as defined as a serum
sodium level < 130 meq/l);*
Yes
No
untreated or uncontrolled hypertension;*
Yes
No
a history of being unable to tolerate venlafaxine-
xr or venlafaxine immediate release formulation;*
Yes
No
history of receiving venlafaxine-xr or venlafaxine
immediate release formulation of 6 or more
weeks at 300mg/d during index depressive
episode; (7) ekg revealing qtc > 480 msec;*
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Yes
No
myocardial infarction, unstable angina, palpitation
or cardiogenic syncope within 3 months prior to
entering this study;*
Yes
No
the presence of active suicidal ideation with
intent.*
Yes
No
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Eligibility Depression NCT00331305
Exercise Training Versus Drug Therapy for Treating
Depression in Older Adults; ODM derived from:
https://clinicaltrials.gov/show/NCT00331305
All rights reserved. Please visit https://medical-data-
models.org/forms/14100
Eligibility Depression NCT00331305
Inclusion Criteria
dsm-iv diagnosis of major depressive disorder
(mdd)*
Yes
No
score of greater than 11 on the beck depression
inventory (bdi)*
Yes
No
Exclusion Criteria
primary psychiatric diagnosis other than major
depressive disorder (e.g., bipolar disorder)*
Yes
No
any of the following dsm-iv diagnoses: dementia
or delirium; obsessive compulsive disorder (ocd);
schizophrenia, schizoaffective, or other psychotic
disorder; psychotic features, including any
delusions or hallucinations during the current
depressive episode; current alcohol or other
substance abuse disorder; acute risk for suicide
(e.g., score of greater than 2 on the suicide item
on the ham-d) or acute risk for homicide*
Yes
No
may require treatment with additional
psychotherapeutic agents (other than chloral
hydrate for sleep) during the course of the study*
Yes
No
significant medical conditions that may cause an
increased risk for a significant adverse
experience during the course of the trial (e.g.,
unstable angina, myocardial infarction within 3
months of study entry, etc.)*
Yes
No
unable to be randomly assigned to the study drug
due to a risk for adverse cardiac events, such as
prolonged qt interval, use of other medications
that would be counterindicated for use with
sertraline, or other conditions that may make
study participation unsafe*
Yes
No
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unable to be randomly assigned to an exercise
condition due to medical conditions such as
musculoskeletal problems or abnormal cardiac
response to exercise (e.g., exercise-induced
ventricular tachycardia, abnormal blood pressure
response, etc.)*
Yes
No
currently receiving antidepressant medication or
actively engaged in psychotherapy*
Yes
No
currently exercising regularly*
Yes
No
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Eligibility Diabetes Mellitus NCT01511042
Vascular Dysfunction in Diabetes: Genes and Hormones;
ODM derived from:
https://clinicaltrials.gov/show/NCT01511042
All rights reserved. Please visit https://medical-data-
models.org/forms/14101
Eligibility Diabetes Mellitus
NCT01511042
Inclusion Criteria
type ii diabetes mellitus*
Yes
No
age between 18-65 years*
Yes
No
bmi < 40*
Yes
No
in overall good health*
Yes
No
Exclusion Criteria
history of coronary atherosclerotic disease, mi,
cva, or significant peripheral vascular disease*
Yes
No
bmi > 40*
Yes
No
subjects with diastolic blood pressures greater
than 100 mm hg while on anti-hypertensive
medications, or systolic blood pressures greater
than 160 mm hg while on anti-hypertensive
medications will be excluded.*
Yes
No
current alcohol or drug abuse*
Yes
No
subjects taking other medications (except thyroid
supplements, oral hyperglycemic agents and
insulin) will be excluded*
Yes
No
subjects who are on medications that cannot be
discontinued such as anti-depressants, anti-
seizure medications, etc that may interfere with
salt and water handling will not be studied.*
Yes
No
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Eligibility Asthma NCT01902290
Study of Efficacy and Safety of Brodalumab Compared
With Placebo in Inadequately Controlled Asthma Subjects
With High Bronchodilator Reversibility; ODM derived from:
https://clinicaltrials.gov/show/NCT01902290
All rights reserved. Please visit https://medical-data-
models.org/forms/14102
Eligibility Asthma NCT01902290
Inclusion Criteria
diagnosis of asthma, and presently has
reversibility over pre-bronchodilator fev1 of*
Yes
No
≥ 20 percent at screening*
>= 20
%
Yes
No
percent of predicted fev1 ≥ 40% and ≤ 80% at
screening*
>= 40
<= 80
%
Yes
No
ics ≥ 200 and ≤ 1000/μg/day fluticasone powder
or equivalent*
Yes
No
ongoing asthma symptoms with acq composite
score at screening and baseline ≥ 1.5 points*
>= 1.5
points
Yes
No
Exclusion Criteria
history of chronic obstructive pulmonary disease
or other chronic pulmonary condition other than
asthma*
Yes
No
history of allergic bronchopulmonary
aspergillosis*
Yes
No
respiratory infection within 4 weeks of screening
or 1 week of baseline visit*
Yes
No
subject has known history of crohn's disease
subject has any other significant concurrent
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medical condition of laboratory abnormalities, as
defined in the study protocol*
Yes
No
subject has previously used any anti-il17  biologic
therapy*
Yes
No
subject is pregnant or breastfeeding, or planning
to become pregnant while enrolled in the study*
Yes
No
female subject is unwilling to use highly effective
methods of birth control unless 2 years post-
menopausal or surgically sterile*
Yes
No
subject has severe depression measured by
personal health questionnaire depression scale
(phq-8) or suicidal ideation/behavior as measured
by and columbia suicide severity rating scale (e-
cssrs)*
Yes
No
subject has a history or evidence of psychiatric
disorder or substance abuse considered by the
investigator to pose a risk to subject safety*
Yes
No
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Eligibility Diabetes Mellitus, Type 2
NCT00195884
Diabetes Aerobic and Resistance Exercise (DARE) Study;
ODM derived from:
https://clinicaltrials.gov/show/NCT00195884
All rights reserved. Please visit https://medical-data-
models.org/forms/14103
Eligibility Diabetes Mellitus, Type 2
NCT00195884
Inclusion Criteria
type 2 diabetes mellitus as defined by the 1998
cda guidelines*
Yes
No
male or female*
Yes
No
treated with diet and/or oral agents (no insulin)*
Yes
No
age 40-70*
Yes
No
hba1c 0.066-0.099*
Yes
No
Exclusion Criteria
participation during the previous 6 months in a
regular program of exercise or aerobic sports
greater than 2 times per week for at least 20
minutes per session, or in any resistance training
during the previous 6 months*
Yes
No
insulin therapy, or uncontrolled hyperglycemia
(hba1c>0.099).  insulin therapy is an exclusion
criterion because it would render homa insulin
sensitivity calculation invalid.*
Yes
No
changes in medications for diabetes, bp or lipids
in the 2 months prior to enrollment.*
Yes
No
significant weight change (increase or decrease
of greater than 5% of body weight during the two
months before enrollment).*
Yes
No
significant renal disease: serum creatinine
greater than 200 meq/l. or proteinuria >1 g/24
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hours.*
Yes
No
uncontrolled hypertension: bp >160 mm hg
systolic or >95 mm hg diastolic bp in a sitting
position.*
Yes
No
restrictions in physical activity due to disease:
intermittent claudication, severe peripheral
neuropathy or active proliferative retinopathy,
unstable cardiac or pulmonary disease, disabling
stroke, severe arthritis.*
Yes
No
other illness, judged by the patient or study
physician to make participation in this study
inadvisable.*
Yes
No
significant cognitive deficit resulting in inability to
understand or comply with instructions.*
Yes
No
pregnancy at the start of the study, or intention to
become pregnant in the next year.*
Yes
No
inability to communicate in english or french.*
Yes
No
unwillingness to sign informed consent.*
Yes
No
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Eligibility Diabetes NCT00832182
Examining the Long-term Safety of Insulin Aspart When
Used as a Part of the Treatment for Type 1 Diabetes; ODM
derived from: https://clinicaltrials.gov/show/NCT00832182
All rights reserved. Please visit https://medical-data-
models.org/forms/14104
Eligibility Diabetes NCT00832182
Inclusion Criteria
signed informed consent obtained before any
trial-related activities. (trial-related activities are
any procedure that would not have been
performed during normal management of the
subject)*
Yes
No
the subject must have completed the
ana/dcd/065 trial*
Yes
No
Exclusion Criteria
impaired hepatic function*
Yes
No
impaired renal function*
Yes
No
total daily insulin requirements of more than 1.4
u/kg*
Yes
No
cardiac problems*
Yes
No
uncontrolled hypertension*
Yes
No
known or suspected allergy to trial product or
related products*
Yes
No
current hypoglycaemic unawareness as judged
by the investigator*
Yes
No
known or suspect abuse of alcohol or narcotics*
Yes
No
women breastfeeding or having the intention of
becoming pregnant, or if judged not to be using
adequate contraceptive measures (adequate
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measures are intrauterine device (iud), oral
contraception and barrier methods)*
Yes
No
any condition that the investigator and/or sponsor
feels would interfere with trial participation or
evaluation of results*
Yes
No
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Eligibility Diabetes NCT01507311
Effect of Liraglutide on Pulsatile Insulin Secretion in
Subjects With Type 2 Diabetes; ODM derived from:
https://clinicaltrials.gov/show/NCT01507311
All rights reserved. Please visit https://medical-data-
models.org/forms/14105
Eligibility Diabetes NCT01507311
Inclusion Criteria
diagnosed with type 2 diabetes, either newly
diagnosed with at least two months of diet
treatment, or in current oha (oral hypoglycaemic
agent) treatment with stable dose for at least six
months*
Yes
No
bmi (body mass index) between 24 and 35
kg/m^2 (both inclusive)*
Yes
No
fasting plasma glucose between 6 and 15 mmol/l
(both inclusive)*
Yes
No
anti-gad (glutamic acid decarboxylase) negative*
Yes
No
Exclusion Criteria
known or suspected allergy to trial product or
related products*
Yes
No
receipt of any investigational drug within three
months prior to this trial*
Yes
No
recurrent severe hypoglycaemia as judged by the
investigator*
Yes
No
cardiac disease or any clinically significant
abnormal ecg (electrocardiogram)*
Yes
No
use of any drug (except oral hypoglycaemic
agents (ohas)) which in the investigator's opinion
could interfere*
Yes
No
with the blood glucose level (i.e., insulin, systemic
corticosteroids, thiazides)*
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Yes
No
liver or renal disease*
Yes
No
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Eligibility Asthma NCT01907763
Study Phase III Study to Assess the Efficacy and Safety of
SOTB07 in Asthma Patients; ODM derived from:
https://clinicaltrials.gov/show/NCT01907763
All rights reserved. Please visit https://medical-data-
models.org/forms/14110
Eligibility Asthma NCT01907763
Inclusion Criteria
1. male or eligible female subjects aged 15 years
or more*
>= 15
years
Yes
No
2. a female is eligible if she is of:*
Yes
No
non-child bearing potential (i.e., physiologically
incapable of becoming pregnant), including any
female who is at least 2 year after post-
menopausal*
Yes
No
child bearing potential and agrees to the
acceptable contraceptive methods used
consistently and correctly*
Yes
No
negative pregnancy test at screening*
Yes
No
3. non-smoker for at least 1 year, a pack history
of ≤ 10 pack years*
>= 1
years
Yes
No
4. symptom of persistent asthma, as defined by
the national institute of health (nih) 5.50 percent ≤
fev1 ≤ 80 percent predicted at screening visit
(withholding inhaled, short acting*
Yes
No
ß-agonist for 6 hours)*
Yes
No
6.fev1 reversibility ≥ 12 percent and 200 ml at 20-
30 minutes after inhalation of a short acting*
Yes
No
ß-agonist (salbutamol 2 puffs; 200㎍) at visit 1 or
within 6 months before visit 1 7.capable of
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withholding salbutamol use for ≥ 6 hours prior to
clinic visits 8.appropriately signed and dated
informed consent has been obtained*
Yes
No
Exclusion Criteria
1. active upper or lower respiratory tract infection
within 3 weeks before visit 1*
Yes
No
2. emergency room treatment for asthma within 1
month or hospitalization for asthma within 3
months before visit 1*
Yes
No
3. any evidence of infectious, oncologic, or other
active pulmonary disease obtained by chest
radiography within 12 months before visit 1*
Yes
No
4. clinically significant, in the opinion of the
investigator, hematological, liver, renal, heart,
neurological disease, or other serious disease*
Yes
No
5. hypersensitivity to any β2-agonist,
sympathomimetic drug, leukotriene receptor
antagonist or sophora tonkinensis radix rhizoma*
Yes
No
6. clinically significant and uncontrolled
psychiatric disease*
Yes
No
7. history of drug or alcohol abuse*
Yes
No
8. inhaled, oral or parenteral corticosteroids
within 4 weeks before visit 1*
Yes
No
9. change of immunotherapy within 6 months
before visit 1*
Yes
No
10. administration of the antiasthma agent within
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1 week of visit 1*
Yes
No
11. administration of any other medication which
may affect the course of asthma, or interact with
sympathomimetic amines*
Yes
No
12. participation in study using an experimental
medication within 1 month before visit 1*
Yes
No
13. other ineligible subject in the opinion of the
investigator*
Yes
No
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Eligibility Asthma NCT01908075
Real-world Effectiveness of Combination Therapies in
Primary Care Asthma Management; ODM derived from:
https://clinicaltrials.gov/show/NCT01908075
All rights reserved. Please visit https://medical-data-
models.org/forms/14118
Eligibility Asthma NCT01908075
Inclusion Criteria
aged: 18-80 years 61-80 years to be non-
smokers only*
>= 18
<= 80
years
Yes
No
evidence of asthma: a diagnostic code for asthma
or two scripts for asthma..*
Yes
No
baseline fp/sal therapy: ≥2 prescription for
ics/laba therapy as fp/sal*
Yes
No
evidence of continuing therapy: include only
patients who receive ≥2 prescriptions for the
therapy under study during the outcome year (i.e.
≥1 prescription at the index date and ≥1 other).
uk average is 3-4 prescriptions refilled per year,
so ≥2 ensures capture of "real-life" data.*
Yes
No
evidence of switching for economic reasons:
fp/sal patients from practices with ≥5 switches to
fostair in a 3 month period to minimise data taken
from switching of anomalous patients; optimal
practices for inclusion are those switching
"wholesale" for economic reasons.*
Yes
No
Exclusion Criteria
any chronic respiratory disease other than
asthma*
Yes
No
are receiving maintenance oral steroid therapy
during baseline period*
Yes
No
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Eligibility Asthma NCT01920529
Aerobic Exercise in Children With Moderate and Severe
Asthma; ODM derived from:
https://clinicaltrials.gov/show/NCT01920529
All rights reserved. Please visit https://medical-data-
models.org/forms/14123
Eligibility Asthma NCT01920529
Inclusion Criteria
age greater than eight and less than nineteen
years*
>= 9
<= 18
years
Yes
No
diagnosis of moderate to severe persistent
asthma according to criteria of gina*
Yes
No
forced expiratory volume in one minute (fev1)
below 80 percent of predicts*
<= 79
%
Yes
No
initiation of treatment with inhaled corticosteroids
for at least eight weeks before the start of
collection.*
Yes
No
Exclusion Criteria
associated disease that limits physical activity,
such as neuromuscular disease, congenital or
acquired, severe cor pulmonate, severe
congenital malformation*
Yes
No
associated with chronic lung disease (cystic
fibrosis, bronchiectasis, bronchopulmonary
dysplasia, interstitial lung diseases*
Yes
No
significant cognitive deficit, which makes the
participant to respond adequately to the
questionnaire and / or failure to meet the
commands*
Yes
No
exacerbation of crisis (this will be a temporary
exclusion criterion, as having taken action as
directed by medical routine, the participant can
return to training)*
Yes
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No
mental deficit.*
Yes
No
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Eligibility Acute Myeloid Leukemia
NCT02328755
Peginterferon Alfa-2a to Enhance Anti-leukemic Responses
After Allogeneic Transplantation in Acute Myeloid
Leukemia; ODM derived from:
https://clinicaltrials.gov/show/NCT02328755
All rights reserved. Please visit https://medical-data-
models.org/forms/14127
Eligibility Acute Myeloid Leukemia
NCT02328755
Inclusion Criteria
patient must have aml not in remission or at very
high risk for hct (hematopoietic cell
transplantation) relapse.*
Yes
No
for newly diagnosed aml, patients must have
achieved two consecutive induction attempts
without achieving complete remission*
Yes
No
for patients initially in complete remission whose
aml relapses > 6 months after preceding
remission, one re-induction must be attempted to
be eligible*
Yes
No
for aml patients with early relapse, in whom the
preceding remission is shorter than 6 months
duration, no re-induction regimen is necessary to
be eligible*
Yes
No
patients with antecedent mds (myelodysplastic
syndrome) who progress to aml may have
therapies rendered during both phases counted
towards these requirements.*
Yes
No
availability of an 8/8 matched donor at a, b, c, and
dr loci. mismatch at hla dq are permissible.
matched related or unrelated donors are
acceptable peripheral blood or bone marrow stem
cells are acceptable*
Yes
No
patients must be ≥ 18 years of age and
considered a candidate for hct*
Yes
No
karnofsky ≥ 70%*
Yes
No
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patients must meet acceptable organ function
criteria:  total bilirubin ≤2.5 mg, ast (aspartate
transaminase) and alt (alanine transaminase)
<5.0 x institutional upper limit of normal; gfr
(glomerular filtration rate) >40 ml/min/1.73 m2 for
patients with creatinine levels above institutional
normal; lung function tests (dlco, fev1, fvc) >
50%; ejection fraction > 50%*
total bilirubin ≤2.5 mg (1)
ast/alt 5.0 x institutional upper limit of
normal (2)
gfr (glomerular filtration rate) >40  (3)
lung function tests (dlco, fev1, fvc) (4)
written informed consent*
Yes
No
women and men of child-bearing potential must
agree to use adequate contraception*
Yes
No
Exclusion Criteria
prior chemotherapy treatment for aml within 21
days from the initiation of hct conditioning*
Yes
No
patients may not have evidence or symptoms of
cns disease at the time of enrollment*
Yes
No
hiv or htlv1 / htlv2 (human t-lymphotrophic virus)
(seropositivity and/or pcr positivity)*
Yes
No
patients less than 18 years of age*
Yes
No
pregnant and nursing mothers are excluded from
this study*
Yes
No
patients with untreated or uncontrolled
neuropsychiatric illness*
Yes
No
any physical or psychological condition that, in
the opinion of the investigator, would pose
unacceptable risk to the patient*
Yes
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No
uncontrolled infections*
Yes
No
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Eligibility Acute Myeloid Leukemia
NCT02400255
Crenolanib Maintenance Following Allogeneic Stem Cell
Transplantation in FLT3-positive Acute Myeloid Leukemia
Patients; ODM derived from:
https://clinicaltrials.gov/show/NCT02400255
All rights reserved. Please visit https://medical-data-
models.org/forms/14128
Eligibility Acute Myeloid Leukemia
NCT02400255
Inclusion Criteria
history of aml according to world health
organization (who) classification*
Yes
No
first allogeneic hematopoietic stem cell
transplantation (hsct) using myeloablative
conditioning (mac), non-myeloablative (nma), or
reduced-intensity conditioning (ric) preparative
regimens.*
Yes
No
flt3-itd or flt3-d835 positive disease at any time
during disease course.*
Yes
No
hematopoietic stem cell source is either with
peripheral blood, bone marrow or cord blood.*
Yes
No
donor source is matched related, unrelated,
haploidentical donor or cord blood.*
Yes
No
at the time of allogeneic hsct*
Yes
No
no more than 1 antigen mismatch at hla-a, -b, -c,
-drb1 or -dqb1 locus for unrelated donor with
peripheral blood and bone marrow as the
hematopoietic stem cell source; and*
Yes
No
bone marrow blast ≤ 10%*
Yes
No
no sooner than 45 days but no later than 90 days
after allogeneic hsct.*
Yes
No
post-transplant bone marrow blast count ≤ 5%
confirmed within 21 days prior to starting study
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therapy*
Yes
No
evidence of donor engraftment as defined by
institutional standard t cell chimerism > 50%.*
Yes
No
adequate engraftment within 7 days prior to
starting study therapy: anc ≥ 1.0 x 109/l without
daily use of myeloid growth factor; and platelet ≥
25 x 109/l without platelet transfusion within 1
week*
Yes
No
non-hematological toxicities ≤  grade 2*
Yes
No
serum creatinine ≤ 1.5 × uln or creatinine
clearance ≥ 50ml/min/1.73 m2 for subjects with
creatinine levels above institutional normal*
Yes
No
adequate liver function with serum ast, alt and
bilirubin within the normal range at the time of
crenolanib commencement*
Yes
No
acute graft-versus-host disease (gvhd) ≤ grade 1,
either no signs of chronic gvhd or mild chronic
gvhd graded as limited disease*
Yes
No
eastern cooperative oncology group (ecog)
performance status of  0-2*
Yes
No
age ≥ 18 years with the capacity to give written
informed consent*
Yes
No
non-pregnant and non-nursing women of
childbearing potential must have a negative
serum or urine pregnancy test*
Yes
No
women of childbearing potential and men must
agree to use adequate contraception prior to
study entry, for the duration of study participation
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and for 90 days following completion of therapy*
Yes
No
Exclusion Criteria
uncontrolled infection
Yes
No
bone marrow blast > 5% within 21 days of start of
study drug*
Yes
No
active gvhd grade ≥ 2*
Yes
No
concurrent use of corticosteroids equivalent of
prednisone at a dose > 0.5 mg/kg*
Yes
No
active and/or untreated central nervous system
(cns) leukemia*
Yes
No
concomitant therapies for treatment or control of
leukemia.*
Yes
No
use of any of the following after transplantation
and prior to starting study therapy:*
chemotherapeutic agents for therapy of
aml (note that prophylactic use of these
agents is allowed in this study, e.g.,
methotrexate for gvhd) (1)
investigational agents/therapies (2)
azacitidine, decitabine or other
demethylating agents (3)
lenalidomide, thalidomide and
pomalidomide (4)
known positive for human immunodeficiency virus
(hiv); active hepatitis b (hbv) or hepatitis c (hcv)
infection*
Yes
No
significant cardiac disease (new york heart
association classes iii or iv) or unstable angina
despite medication*
Yes
No
pregnant or breast-feeding*
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Yes
No
receipt of investigational agents within 5 half-lives
of last dose of investigational agent*
Yes
No
prior treatment with crenolanib with progression
on treatment*
Yes
No
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Eligibility Asthma NCT01921894
Vitamin D and Severe Asthma Exacerbations; ODM derived
from: https://clinicaltrials.gov/show/NCT01921894
All rights reserved. Please visit https://medical-data-
models.org/forms/14129
Eligibility Asthma NCT01921894
Inclusion Criteria
be at least 6 years of age and younger than 15
years of age*
>= 6
<= 14
years
Yes
No
have physician-diagnosed asthma*
Yes
No
taking a medium dose of ics (e.g. fluticasone
220mcg bid) for daily asthma control for at least 6
months in the prior year.*
Yes
No
have had a severe asthma exacerbation in the
previous year, defined as an emergency
department (ed) visit, hospitalization, or
unscheduled clinic visit for asthma resulting in
intramuscular, intravenous, or oral steroids.*
Yes
No
have bronchodilator responsiveness (bdr, an
increase in fev1 ≥12 percent from baseline after
administration of inhaled albuterol) or (if no bdr)
increased airway responsiveness to methacholine
challenge*
Yes
No
have vitamin d insufficiency (a serum vitamin d
(25(oh)d) level <30 ng/ml)*
Yes
No
have his/her parents give voluntary written
consent to participate in the study*
Yes
No
Exclusion Criteria
chronic respiratory disorder other than asthma
(e.g., bronchiectasis).*
Yes
No
severe asthma, as evidenced by any of the
following: a) chronic need for medication other
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than single controller therapy and inhaled  β2-
agonist, b) intubation for asthma at any time, and
c) ≥2 hospitalizations or ≥6 severe asthma
exacerbations in the previous year*
Yes
No
history of cigarette smoking in the prior year or
former smoking if ≥5 pack-years*
Yes
No
hepatic or renal disease, metabolic rickets,
malabsorptive disorders, or other chronic
diseases that would affect vitamin d metabolism*
Yes
No
immune deficiency, cleft palate or down's
syndrome, which might increase the child's
likelihood of respiratory infections*
Yes
No
treatment with anticonvulsants or
pharmacological doses of vitamin d (≥1,000
iu/day of vitamin d2 or d3)*
Yes
No
chronic oral corticosteroid therapy*
Yes
No
inability to perform acceptable spirometry*
Yes
No
use of investigational therapies or participation in
clinical trials 30 days before or during the
duration of the study*
Yes
No
serum calcium >10.8 mg/dl*
Yes
No
serum 25(oh) d <10 ng/ml (severe vitamin d
deficiency)*
Yes
No
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Eligibility Asthma NCT01928368
A First-in-Human, Double Blind, Single Dose Study in
Healthy Subjects and Subjects With Mild Atopic Asthma.;
ODM derived from:
https://clinicaltrials.gov/show/NCT01928368
All rights reserved. Please visit https://medical-data-
models.org/forms/14132
Eligibility Asthma NCT01928368
Criteria
is a current non-smoker, has not used any
nicotine or tobacco containing products (including
but not limited to:  snuff, chewing tobacco, cigars,
cigarettes, pipes, or nicotine patches) within the
last 6 months, and cumulative smoking history is
≤10 pack years.*
Yes
No
females must be of documented non-reproductive
potential (ie, postmenopausal [see definition
below]; or history of hysterectomy; or history of
bilateral salpingectomy; or history of bilateral
oophorectomy).*
Yes
No
body mass index (bmi) between ≥ 18.0 and ≤
32.0 kg/m2 at screening. (subjects with mild
atopic asthma only)*
Yes
No
documented history of mild, stable atopic asthma
within 2 years of screening.*
Yes
No
has used only inhaled short-acting β2-agonists
(less than twice weekly) to treat asthma.*
Yes
No
pre-bronchodilator forced expiratory volume in 1
second (fev1) > 70 percent predicted at
screening.*
>= 71
%
Yes
No
Exclusion Criteria
(all subjects)*
Yes
No
history or evidence of a clinically significant
disorder, condition or disease that, in the opinion
of the principal investigator or amgen medical
monitor would pose a risk to subject safety or
interfere with the study evaluation, procedures, or
1 / 2
completion.*
Yes
No
subject has a history of residential exposure to
tuberculosis without a documented history of
prophylactic treatment of tuberculosis or subject
has a positive purified protein derivative (ppd) or
quantiferon test at screening. subjects with a
documented negative ppd or quantiferon test
within 4 weeks prior to screening who have no
known tuberculosis exposure and have not
traveled to an area with tuberculosis do not need
to have a test performed at screening.*
Yes
No
has donated or lost ≥ 500 ml of blood or plasma
within 8 weeks of administration of the first dose
of ip.*
Yes
No
other criteria may apply.*
Yes
No
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Eligibility Asthma NCT01928771
Efficacy and Safety Study of Benralizumab Added to High-
dose Inhaled Corticosteroid Plus LABA in Patients With
Uncontrolled Asthma; ODM derived from:
https://clinicaltrials.gov/show/NCT01928771
All rights reserved. Please visit https://medical-data-
models.org/forms/14134
Eligibility Asthma NCT01928771
Inclusion Criteria
1. written informed consent for study participation
must be obtained prior to any study related
procedures being performed (local regulations
are to be followed in determining the
assent/consent requirements for children and
parent[s]/guardian[s]) and according to
international guidelines and/or applicable
european union guidelines.*
Yes
No
2. female and male aged 12 to 75 years
inclusively, at the time of visit 1. for those
patients, who are 17 on the day of visit 1 but will
turn 18 after this day, will be considered an
adolescent for the purposes of this trial.*
>= 12
<= 75
years
Yes
No
3. history of physician-diagnosed asthma
requiring treatment with medium-to-high dose ics
(>250μg fluticasone dry powder formulation
equivalents total daily dose) and a laba, for at
least 12 months prior to visit 1*
Yes
No
4. documented treatment with ics and laba for at
least 3 months prior to visit 1 with or without oral
corticosteroids and additional asthma
controllers.*
Yes
No
for subjects 18 years of age and older, the ics
dose must be >500 mcg/day fluticasone
propionate dry powder formulation or equivalent
daily.*
>= 18
years
Yes
No
for subjects ages 12-17, the ics dose must be
≥500 mcg /day fluticasone propionate dry powder
formulation or equivalent daily.*
>= 12
<= 17
years
Yes
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No
Exclusion Criteria
1. clinically important pulmonary disease other
than asthma (e.g. active lung infection, copd,
bronchiectasis, pulmonary fibrosis, cystic fibrosis,
hypoventilation syndrome associated with
obesity, lung cancer, alpha 1 anti-trypsin
deficiency, and primary ciliary dyskinesia) or ever
been diagnosed with pulmonary or systemic
disease, other than asthma, that are associated
with elevated peripheral eosinophil counts (e.g.
allergic bronchopulmonary aspergillosis/mycosis,
churg- strauss syndrome, hypereosinophilic
syndrome)*
Yes
No
2. any disorder, including, but not limited to,
cardiovascular, gastrointestinal, hepatic, renal,
neurological, musculoskeletal, infectious,
endocrine, metabolic, haematological,
psychiatric, or major physical impairment that is
not stable in the opinion of the investigator and
could:*
Yes
No
affect the safety of the patient throughout the
study*
Yes
No
influence the findings of the studies or their
interpretations*
Yes
No
impede the patient's ability to complete the entire
duration of study*
Yes
No
3. acute upper or lower respiratory infections
requiring antibiotics or antiviral medication within
30 days prior to the date informed consent is
obtained or during the screening/run-in period*
Yes
No
4. any clinically significant abnormal findings in
physical examination, vital signs, haematology,
clinical chemistry, or urinalysis during
screening/run-in period, which in the opinion of
the investigator, may put the patient at risk
because of his/her participation in the study, or
may influence the results of the study, or the
patient's ability to complete entire duration of the
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Eligibility Asthma NCT01928771
study*
Yes
No
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Eligibility Asthma NCT01930461
Dose Ranging Study of SLIT Tablets of House Dust Mite
Allergen Extracts (HDM) in Adults With HDM-associated
Allergic Asthma; ODM derived from:
https://clinicaltrials.gov/show/NCT01930461
All rights reserved. Please visit https://medical-data-
models.org/forms/14135
Eligibility Asthma NCT01930461
Inclusion Criteria
written informed consent.*
Yes
No
male or female from 18 to 50 years of age.*
>= 18
<= 50
years
Yes
No
diagnosed asthma and rhinitis with medical
history consistent with hdm-induced allergic
asthma and rhinitis.*
Yes
No
positive spt to hdm and and hdm-specific ige
serum value ≥ 0.7 ku/l.*
Yes
No
stable asthma therapies.*
Yes
No
spirometry (pre-bronchodilator) with best fev1 ≥
70 percent of the predicted value.*
>= 70
%
Yes
No
spirometry with reversibility in fev1 of ≥ 12
percent and ≥ 200 ml.*
Yes
No
asthma control test™ (act) score ≤ 19.*
<= 19
Yes
No
Exclusion Criteria
former smoker with > 10 pack year history or
current smoker.*
Yes
No
patient with a urine level of cotinine ≥ 500 ng/ml.*
Yes
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No
co-sensitisation to any allergen possibly leading
to clinically relevant symptoms likely to
significantly change the asthma symptoms of the
subject during the study.*
Yes
No
patient who received allergen immunotherapy for
hdm within the past 10 years.*
Yes
No
ongoing immunotherapy for an aeroallergen other
than house dust mite.*
Yes
No
patient with any oral condition that could
confound the safety assessments or planning to
have a dental extraction during the study.*
Yes
No
patient treated with beta-blockers, tricyclic
antidepressants or monoamine oxidase inhibitors
(maois).*
Yes
No
pregnant women or breast-feeding/lactating.*
Yes
No
women with childbearing potential who are not
using a medically accepted birth control method.*
Yes
No
patient with a past or current disease, which as
judged by the investigator, may affect the
patient's participation in, or the outcome of this
study.*
Yes
No
2 / 2
Eligibility Asthma NCT01930461
Eligibility Asthma NCT01931696
Clinical Assessment of Acupuncture for the Treatment of
Chronic Asthma; ODM derived from:
https://clinicaltrials.gov/show/NCT01931696
All rights reserved. Please visit https://medical-data-
models.org/forms/14139
Eligibility Asthma NCT01931696
Inclusion Criteria
patients diagnosed with mild-to-moderate
persistent asthma*
Yes
No
forced expiratory volume in one second (fev1)
reversibility of greater than or equal to 12%
following bronchodilator administration (2 puffs)*
>= 12
%
Yes
No
patients who have given written informed
consent*
Yes
No
Exclusion Criteria
participation in another clinical trial 1 month prior
to study entry*
Yes
No
use of systemic corticosteroids 2 weeks prior to
study entry*
Yes
No
patients with general infection, lower respiratory
infection, pulmonary tuberculosis and fungal
infection 1 month prior to study entry*
Yes
No
hospitalization due to acute exacerbation 3
months prior to study entry*
Yes
No
patients cannot stop using forbidden drugs which
include inhaled corticosteroid, theophylline, long-
term β2 agonist, sodium cromoglicate,
leukotrienes antagonist and anticholinergic drug*
Yes
No
patients who are allergic to albuterol and
corticosteroid*
Yes
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No
patients with severe primary diseases such as
cancer, cardiovascular system, liver, kidney and
hematopoietic system diseases*
Yes
No
wheeze caused by pulmonary tuberculosis,
bronchiectasia and cardiac insufficiency*
Yes
No
patients with hyperthyroidism*
Yes
No
patients with mental illness, acrasia*
Yes
No
female patients in pregnancy, lactation period and
planning to get pregnant during the trial*
Yes
No
any significant disorder that in the investigator's
opinion, might put the patients at risk or influence
the study outcomes*
Yes
No
acupuncture contraindications: serious allergic or
infectious dermatitis and hemorrhagic diseases
such as thrombocytopenic purpura and
hemophilia*
Yes
No
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Eligibility Diabetes NCT01509755
Comparison of Liraglutide and Glimepiride on Blood Sugar
Control in Subjects With Type 2 Diabetes; ODM derived
from: https://clinicaltrials.gov/show/NCT01509755
All rights reserved. Please visit https://medical-data-
models.org/forms/14140
Eligibility Diabetes NCT01509755
Inclusion Criteria
subjects with type 2 diabetes*
Yes
No
duration of diabetes at least 3 months*
Yes
No
both diet treated and patients in therapy with oha
(oral hypoglycemic agents)*
Yes
No
body mass index maximum 40 kg/m^2*
Yes
No
hba1c based on analysis from central laboratory:
between 7.5-10.0%, both inclusive, for diet
treated, or maximum 9.0% for oha treated*
Yes
No
Exclusion Criteria
liver or renal disease*
Yes
No
cardiac problems*
Yes
No
uncontrolled treated/untreated hypertension*
Yes
No
proliferative retinopathy*
Yes
No
recurrent severe hypoglycaemia as judged by the
investigator*
Yes
No
known or suspected allergy to trial product or
related products*
Yes
No
use of any drug (except for ohas) which in the
investigator's opinion could interfere with the
1 / 2
blood glucose level*
Yes
No
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Eligibility Diabetes NCT01520753
Comparison of Two Biphasic Insulin Aspart Treatments in
Subjects With Type 2 Diabetes; ODM derived from:
https://clinicaltrials.gov/show/NCT01520753
All rights reserved. Please visit https://medical-data-
models.org/forms/14141
Eligibility Diabetes NCT01520753
Inclusion Criteria
type 2 diabetes*
Yes
No
duration of diabetes for longer than 12 months*
Yes
No
body mass index (bmi) below 35.0 kg/m^2*
Yes
No
hba1c below 11.0 %*
Yes
No
treatment with bhi (biphasic human insulin) 20 or
30 twice daily for at least three months and in the
last month as sole anti-diabetic treatment (i.e., no
additional oral hypoglycaemic medication or daily
use of short-acting insulin supplement)*
Yes
No
Exclusion Criteria
current treatment with agents affecting glucose
metabolism*
Yes
No
history of drug or alcohol dependence*
Yes
No
impaired hepatic function*
Yes
No
impaired renal function*
Yes
No
cardiac disease*
Yes
No
proliferative retinopathy*
Yes
No
recurrent severe hypoglycaemia or advanced
neuropathy*
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Yes
No
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Eligibility Diabetes NCT01520818
Comparison of Biphasic Human Insulin 30 With Biphasic
Insulin Aspart in Subjects With Diabetes; ODM derived
from: https://clinicaltrials.gov/show/NCT01520818
All rights reserved. Please visit https://medical-data-
models.org/forms/14142
Eligibility Diabetes NCT01520818
Inclusion Criteria
type 1 or type 2 diabetes*
Yes
No
current treatment with bhi 30 twice daily as the
only insulin therapy for at least 3 months, with or
without combination with oral hypoglycaemic
agents*
Yes
No
body mass index (bmi) maximum 40.0 kg/m^2*
Yes
No
Exclusion Criteria
history of drug or alcohol dependence*
Yes
No
impaired hepatic function*
Yes
No
impaired renal function*
Yes
No
cardiac disease*
Yes
No
proliferative retinopathy*
Yes
No
total daily insulin dose at least 1.80 iu/kg*
Yes
No
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Eligibility Diabetes NCT01650129
Safety and Efficacy of Biphasic Insulin Aspart 50 in
Subjects With Type 2 Diabetes; ODM derived from:
https://clinicaltrials.gov/show/NCT01650129
All rights reserved. Please visit https://medical-data-
models.org/forms/14143
Eligibility Diabetes NCT01650129
Inclusion Criteria
subjects with type 2 diabetes*
Yes
No
subjects with insulin treated for at least 24
weeks*
Yes
No
hba1c maximum 11.0%*
Yes
No
body mass index (bmi) below 30.0 kg/m^2*
Yes
No
patients who have the skill of self-injection of
insulin, and are able and willing to perform self-
monitoring blood glucose (smbg) and are able to
take measures against hypoglycaemic episodes*
Yes
No
Exclusion Criteria
recurrent severe hypoglycaemia*
Yes
No
subjects with proliferative retinopathy or
preproliferative retinopathy diagnosed within the
last 12 weeks, or receiving photocoagulation
therapy within the last one year*
Yes
No
impaired hepatic function*
Yes
No
impaired renal function*
Yes
No
cardiac diseases*
Yes
No
uncontrolled hypertension*
Yes
No
subjects with history of severe allergic or severe
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hypersensitive reactions*
Yes
No
total daily insulin dose at least 100 iu*
Yes
No
treatment with oral hypoglycaemic agents within
the last 4 weeks*
Yes
No
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Eligibility Asthma NCT01951222
Bronchodilator Properties and Safety in Asthma; ODM
derived from: https://clinicaltrials.gov/show/NCT01951222
All rights reserved. Please visit https://medical-data-
models.org/forms/14144
Eligibility Asthma NCT01951222
Inclusion Criteria
aged 18 to 65 years-old.*
>= 18
<= 65
years
Yes
No
18 ≤ bmi <30 kg/m².*
Yes
No
clinical history consistent asthma, in the
judgement of the investigator.*
Yes
No
asthma controlled or partly controlled according
to gina 2012 criteria:*
Yes
No
asthma treated by ics and laba (fixed-dose
combination or free combination) at stable dose
for at least 3 months.*
Yes
No
able to replace the usual ics and laba therapy by
ics at the usual dose regimen and salbutamol as
needed.*
Yes
No
able to stop salbutamol at least 6 hours before a
study visit.*
Yes
No
able to perform at least 3 acceptable and
reproducible fev1 and fvc measurements
according to ers/ats 2005 recommendations.*
Yes
No
Exclusion Criteria
clinically significant respiratory conditions other
than asthma (e.g. pneumonia, pneumothorax,
atelectasis, bronchiectasis, chronic bronchitis,
copd, emphysema, pulmonary arterial
hypertension, pulmonary fibrosis,etc.).*
Yes
No
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upper or lower respiratory tract infection within 4
weeks.*
Yes
No
exacerbation (requiring oral corticosteroids or
hospitalization) within 3 months.*
Yes
No
current smoker or former smoker less than 6
months or total lifetime smoking history greater
than 10 pack-years.*
Yes
No
intolerance to salbutamol.*
Yes
No
intolerance to tiotropium (or any other atropine-
derived compound).*
Yes
No
intolerance to one of the ingredients of the study
product*
Yes
No
severe hepatic impairment, moderate to severe
renal impairment, epilepsy, narrow angle
glaucoma, gastrointestinal obstruction, moderate
to severe prostatic hypertrophy, bladder neck
obstruction.*
Yes
No
any acute or chronic disease that will not allow
the participation in the study, in the judgement of
the investigator.*
Yes
No
clinically relevant physical examination
abnormality.*
Yes
No
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Eligibility Hepatitis B NCT00383227
Comparison of Adjuvanted Hepatitis B Vaccine to Double
Dose of Engerix™-B in Pre- /Haemodialysis Patients Aged
_15 Years; ODM derived from:
https://clinicaltrials.gov/show/NCT00383227
All rights reserved. Please visit https://medical-data-
models.org/forms/14145
Eligibility Hepatitis B NCT00383227
Inclusion Criteria
a male or female > = 15 years of age at the time
of the first vaccination.*
Yes
No
written informed consent obtained from the
subject/ from the parents or guardians of the
subject.*
Yes
No
seronegative for anti-hbs antibodies, anti-hbc
antibodies & hepatitis b surface antigen (hbsag).*
Yes
No
if the subject was a female, she was of non-
childbearing potential or, if of childbearing
potential, she had to be abstinent or use
adequate contraceptive precautions for one
month prior to enrollment and up to two months
after the last vaccination.*
Yes
No
pre-haemodialysis patient* or a patient on
haemodialysis.*
Yes
No
Exclusion Criteria
use of any investigational or non-registered drug
or vaccine other than the study vaccine during
the study period or within 30 days preceding the
first dose of study vaccine.*
Yes
No
previous vaccination against hepatitis b.*
Yes
No
history of hepatitis b infection.*
Yes
No
known exposure to hepatitis b virus within 6
weeks. pregnant or lactating female*
Yes
No
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clinically abnormal alt/ast values (> 3 times
normal values)*
Yes
No
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Eligibility Hepatitis B NCT00383383
Comparison of Adjuvanted Hepatitis B Vaccine to Double
Dose of Engerix™-B in Pre- /Haemodialysis Patients Aged
_15 Years; ODM derived from:
https://clinicaltrials.gov/show/NCT00383383
All rights reserved. Please visit https://medical-data-
models.org/forms/14146
Eligibility Hepatitis B NCT00383383
Inclusion Criteria
a male or female > = 15 years of age at the time
of the first vaccination.*
Yes
No
written informed consent obtained from the
subject/ from the parents or guardians of the
subject.*
Yes
No
seronegative for anti-hbs antibodies, anti-hbc
antibodies & hepatitis b surface antigen (hbsag).*
Yes
No
if the subject was a female, she was of non-
childbearing potential or, if of childbearing
potential, she had to be abstinent or use
adequate contraceptive precautions for one
month prior to enrollment and up to two months
after the last vaccination.*
Yes
No
pre-haemodialysis patient* or a patient on
haemodialysis.*
Yes
No
Exclusion Criteria
use of any investigational or non-registered drug
or vaccine other than the study vaccine during
the study period or within 30 days preceding the
first dose of study vaccine.*
Yes
No
previous vaccination against hepatitis b.*
Yes
No
history of hepatitis b infection.*
Yes
No
known exposure to hepatitis b virus within 6
weeks. pregnant or lactating female*
Yes
No
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clinically abnormal alt/ast values (> 3 times
normal values)*
Yes
No
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Eligibility Hepatitis B NCT00696917
Safety and Immunogenicity of 3 Lots of GSK Biologicals'
HBV-MPL Vaccine and Engerix™-B in Healthy Volunteers _
15y; ODM derived from:
https://clinicaltrials.gov/show/NCT00696917
All rights reserved. Please visit https://medical-data-
models.org/forms/14147
Eligibility Hepatitis B NCT00696917
Inclusion Criteria
a male or female aged ≥ 15 years at the time of
the first vaccination. in centre 103 (germany) and
centre 1 (netherlands), only subjects ≥ 18 years
will be enrolled.*
Yes
No
free of obvious health problems as established by
medical history and clinical examination before
entering into the study.*
Yes
No
written informed consent obtained from the
subject and/or from the parent or guardian of the
subject.*
Yes
No
if the subject was a female, she was of non-
childbearing potential, if of childbearing potential,
she was abstinent or used adequate
contraceptive precautions for one month prior to
enrollment and up to two months after the last
vaccination*
Yes
No
Exclusion Criteria
use of any investigational or non-registered drug
or vaccine other than the study vaccine (s) during
the study period or within 30 days preceding the
first dose of study vaccine.*
Yes
No
planned administration/ administration of a
vaccine not foreseen by the study protocol during
the period starting from 30 days before each
dose of vaccine and ending 30 days after.*
Yes
No
previous vaccination against hepatitis b.*
Yes
No
history of non-response to previous hepatitis b
vaccination.*
Yes
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No
known exposure to hepatitis b virus within 6
weeks.*
Yes
No
history of hepatitis b infection.*
Yes
No
confirmed human immunodeficiency virus (hiv)
infection.*
Yes
No
a family history of congenital or hereditary
immunodeficiency.*
Yes
No
history of allergic disease or reactions likely to be
exacerbated by any component of the vaccine.*
Yes
No
acute disease at the time of enrollment.*
Yes
No
hepatomegaly, right upper quadrant abdominal
pain or tenderness.*
Yes
No
administration of immunoglobulins and/or any
blood products within the three months preceding
the first dose of study vaccine or planned
administration/ administration during the study
period.*
Yes
No
pregnant or lactating female*
Yes
No
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Eligibility Asthma NCT01961154
Stepping Down of Asthma Medication in Controlled
Asthma; ODM derived from:
https://clinicaltrials.gov/show/NCT01961154
All rights reserved. Please visit https://medical-data-
models.org/forms/14148
Eligibility Asthma NCT01961154
Criteria
doctor's diagnosis of asthma and right to special
reimbursement from anti-asthma medication
expenses according to finnish social insurance
institute criteria  (code 203 in the social insurance
card)*
Yes
No
asthma diagnosis confirmed at least two years
previously*
Yes
No
regular treatment with inhaled corticosteroids and
long-acting beta-agonists for at least 6 months*
Yes
No
no changes in regular anti-asthma medication
within 6 months*
Yes
No
asthma is well controlled (all conditions must be
fulfilled):*
Yes
No
no courses of oral corticosteroids due to asthma
within one year*
Yes
No
no hospital admissions due to asthma within one
year*
Yes
No
juniper's asthma control questionnaire score
equal or less than 0.75*
<= 0.75
Yes
No
Exclusion Criteria
the presence of another chronic respiratory
disease in addition to asthma. such diseases
include moderate to severe polypotic chronic
rhinosinusitis, chronic obstructive pulmonary
disease, sarcoidosis, and cystic fibrosis*
Yes
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No
presence of severe co-morbidity*
Yes
No
history of smoking more than 10 pack-years*
>= 11
pack-years
Yes
No
pregnancy*
Yes
No
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Eligibility Asthma NCT01973751
Asthma Biomarkers for Predicting Response to Therapy;
ODM derived from:
https://clinicaltrials.gov/show/NCT01973751
All rights reserved. Please visit https://medical-data-
models.org/forms/14149
Eligibility Asthma NCT01973751
Criteria
Inclusion Criteria
male and female subjects between the ages of 18
and 70 years*
>= 18
<= 70
years
Yes
No
no respiratory symptoms*
Yes
No
normal spirometric value and methacholine pd20
>2.5mg*
Yes
No
group b:*
Yes
No
Inclusion Criteria
male and female subjects between the ages of 18
and 70 years*
>= 18
<= 70
years
Yes
No
history of asthma*
Yes
No
no use of oral or inhaled corticosteroids for the
treatment of asthma*
Yes
No
no use of leukotriene antagonist for the treatment
of asthma*
Yes
No
hyperreactivity to methacholine (pd20 fev1
methacholine < 2.5 mg) and/or ≥12% increase in
fev1 following inhalation of 200μg salbutamol*
Yes
No
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asthma symptoms of episodic cough, wheeze
and/or breathlessness*
Yes
No
Exclusion Criteria
current or former smokers*
Yes
No
pregnant women*
Yes
No
subjects with a history of lung disease other than
asthma*
Yes
No
subjects with a history of a medical disease,
which in the opinion of the investigator may put
the subject at extra risk from study-related
procedures or because the disease may
influence the results of the study*
Yes
No
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Eligibility Asthma NCT01974921
Study of Physiopathological Mechanisms and Results of
Treatment With Bronchial Thermoplasty in Severe Asthma;
ODM derived from:
https://clinicaltrials.gov/show/NCT01974921
All rights reserved. Please visit https://medical-data-
models.org/forms/14150
Eligibility Asthma NCT01974921
Inclusion Criteria
patients under 18 years old.*
<= 17
years
Yes
No
severe persistent asthma according to gina.*
Yes
No
inhaled corticosteroids and long-acting ß2
agonist (laba).*
Yes
No
other medications for asthma, as oral
corticosteroids, anti-ige, theofiline, etc. are also
acceptable.*
Yes
No
asthma quality of life questionnaire (aqlq) < 7*
<= 6
Yes
No
asthma control test (act) < 19*
<= 18
Yes
No
≥ 2 exacerbations in last year*
Yes
No
Exclusion Criteria
history of cigarette smoking with > 15
pack/years.*
>= 16
pack-years
Yes
No
other respiratory diseases.*
Yes
No
comorbidity that can justify the symptoms of the
patients.*
Yes
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No
life-threating unstable asthma.*
Yes
No
any contraindication to perform a bronchoscopy
(respiratory insufficiency, coagulation
abnormalities, allergy to sedative drugs, etc.)*
Yes
No
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Eligibility Asthma NCT01976767
Longitudinal Assessment of Adults With Severe Asthma;
ODM derived from:
https://clinicaltrials.gov/show/NCT01976767
All rights reserved. Please visit https://medical-data-
models.org/forms/14151
Eligibility Asthma NCT01976767
Criteria
1. able to give written informed consent prior to
participation in the study, which includes ability to
comply with the requirements and restrictions
listed in the consent form. informed consent must
be obtained prior to undertaking any study
procedures.*
Yes
No
2. male or female subject aged 18 years or older
at screening.*
>= 18
years
Yes
No
3. able to complete the study and all
measurements.*
Yes
No
4. able to read, comprehend, and write at a
sufficient level to complete study related
materials.*
Yes
No
5. subjects will be allowed to enrol in other
studies while taking part on this study. however,
permission from the scientific board must be
obtained to enrol or allow the continued
participation of a subject enrolled in another
study.*
Yes
No
general exclusion criteria:*
Yes
No
1. as a result of medical interview, physical
examination or screening investigation the
physician responsible considers the subject unfit
for the study either because of the risk to the
subject due to the study or the influence this may
have on the study results.*
Yes
No
2. the subject has a history of recreational drug
use or other allergy, which, in the opinion of the
responsible physician, contra-indicates their
participation.*
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Yes
No
3. subject is female who is pregnant or lactating
or up to 6 weeks post partum or 6 weeks
cessation of breast feeding. if a woman is
subsequently found to have been pregnant at the
time of an assessment data from that
assessment will not be included in the analyses.*
Yes
No
4. the subject has participated within 3 months of
the first dose in a study using a new molecular
entity, or the first dose in any other study
investigating drugs or having participated within
three months in a study with invasive procedures.
any u-biopred assessments should be deferred
until 3 months after the first dose or invasive
procedure. permission from the scientific board
must be obtained to enroll or allow the continued
participation of a subject enrolled in another
study.*
Yes
No
5. those who, in the opinion of the investigator,
have a risk of non-compliance with study
procedures.*
Yes
No
6. the subject has a recent history of
incapacitating psychiatric disorders*
Yes
No
7. history or current evidence of an upper or
lower respiratory infection or symptoms (including
common cold) within 2 weeks of baseline
assessments (assessments should be deferred).*
Yes
No
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Eligibility Asthma NCT01976767
Eligibility Asthma NCT01979224
Efficacy of Educational Intervention for Parents of Children
With Asthma; ODM derived from:
https://clinicaltrials.gov/show/NCT01979224
All rights reserved. Please visit https://medical-data-
models.org/forms/14152
Eligibility Asthma NCT01979224
Eligibility Criteria
children 4-11 years with diagnosed asthma with
parents attending the outpatient pediatric
pneumology and pediatric emergency because of
acute asthma in general hospital de soledad.*
>= 4
<= 11
years
Yes
No
patients with a baseline score less than 27 points
in childhood act*
<= 26
points
Yes
No
patients with government health insurance. (to
ensure access to medication and medical care)*
Yes
No
parents who can read and write*
Yes
No
parents willing and able to participate*
Yes
No
parents who do not belong or have been part of
an educational program on asthma by asthma
clinic.*
Yes
No
Exclusion Criteria
parents with children having other comorbidities
that prevent or hinder proper control of asthma,
such as cerebral palsy, (pci) psychomotor
retardation, psychiatric sd. down, congenital
malformations, which alter the chest wall, obesity,
nasal polyp.*
Yes
No
elimination criteria*
Yes
No
parents who fail to attend 50% of the sessions
given (since it does not allow parents to acquire
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sufficient knowledge to significantly improve the
control of asthma as gema educational
guidance)*
>= 50
%
Yes
No
patients and parents who decide not to continue
in the project.*
Yes
No
patients who develop pulmonary comorbidities
over a month of evolution and lung tissue
affecting significantly, as syncytial respiratory
virus, pneumonia, tuberculosis, and asthma
control difficulties.*
Yes
No
patients who leave or do not take the prescribed
treatment by physician for a month.*
Yes
No
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Eligibility Asthma NCT01979224
Eligibility Acute Myeloid Leukemia
NCT02462265
Oshadi D & Oshadi R Combined With Salvage
Chemotherapy for Relapsed Acute Myeloid Leukemia or
Lymphoid Leukemia Patients; ODM derived from:
https://clinicaltrials.gov/show/NCT02462265
All rights reserved. Please visit https://medical-data-
models.org/forms/14153
Eligibility Acute Myeloid Leukemia
NCT02462265
Inclusion Criteria
patients is diagnosed as aml or all*
Yes
No
relapse defined as the presence of disease after
the achievement of complete remission(cr).
refractory disease is defined as progression from
or no response while treated with a previous line
chemotherapy regimen, or progression within 30
days of last bone marrow assessment.*
Yes
No
male or female ≥ 18 years of age*
Yes
No
minimal performance status (ecog 0, ≤2)*
Yes
No
patients must have a measurable disease by
bone marrow blast counts of > 5 % of nucleated
cells.*
Yes
No
written informed consent*
Yes
No
adequate hepatic function (lfts up to x4 the
normal limits), renal function calculated creatinine
clearance (crcl) for adverse effects of >30)*
Yes
No
ability to swallow the medications.*
Yes
No
females of childbearing potential and males must
be willing to use an effective method of
contraception (hormonal or barrier method of
birth control; abstinence) from the time consent is
signed until 6 weeks after treatment
discontinuation.*
Yes
No
females of childbearing potential must have a
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negative pregnancy test within 7 days prior to
being registered for protocol therapy.*
Yes
No
Exclusion Criteria
active infectious disease uncontrolled by
antibiotics.*
Yes
No
partially treated induction patients (i.e. day 14
non responding patients).*
Yes
No
Inability to receive high dose salvage
chemotherapy.*
Yes
No
patient with known positive hiv serology at
screening.*
Yes
No
female patient who are breastfeeding or have a
positive pregnancy test at screening or at any
time during the study.*
Yes
No
evidence of ongoing cardiac dysrhythmias of nci
common toxicity criteria for adverse effects (ctcae
) version 3.0 grade 2.*
Yes
No
pre-existing malabsorption syndrome, irritable
bowel syndrome or other clinical situation which
could affect oral absorption.*
Yes
No
mental disorders*
Yes
No
inability to give written informed consent*
Yes
No
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Eligibility Acute Myeloid Leukemia NCT02462265
Eligibility Acute Myeloid Leukemia
NCT02483312
A Study of IL-12 in Patients With Acute Myelogenous
Leukemia (AML); ODM derived from:
https://clinicaltrials.gov/show/NCT02483312
All rights reserved. Please visit https://medical-data-
models.org/forms/14155
Eligibility Acute Myeloid Leukemia
NCT02483312
Inclusion Criteria
patient with aml and >=18 years of age.*
Yes
No
Patient agrees to participate in the study and
signs the informed consent*
Yes
No
viably frozen cells from the time of diagnosis or
relapse are available*
Yes
No
first complete remission and have high risk
features of relapse.*
Yes
No
less than 10% blast cells in the bone marrow
following induction or re-induction therapy and not
desiring further intensive treatment.*
Yes
No
acceptable creatinine, ast, alp, bilirubin*
Yes
No
agree to use contraception*
Yes
No
not pregnant*
Yes
No
able to comply with study procedures*
Yes
No
Exclusion Criteria
ecog performance status <2*
Yes
No
known persistent infection*
Yes
No
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known cns disease*
Yes
No
greater than 10% blasts in the bone marrow or
circulating blast cells*
Yes
No
life expectancy < 2 months*
Yes
No
receiving any chemotherapy, corticosteroids,
cox2 inhibitors or any non-drug therapies with the
intent of altering the immune response or kill
leukemic cells within one week prior to infusion of
il-12 -infected cells.*
Yes
No
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Eligibility Acute Myeloid Leukemia NCT02483312
Eligibility Acute Myeloid Leukemia
NCT02508324
IPA Targeted Adoptive Immunotherapy vs Adult Haplo-
identical Cell Infusion During Induction of High Risk
Leukemia; ODM derived from:
https://clinicaltrials.gov/show/NCT02508324
All rights reserved. Please visit https://medical-data-
models.org/forms/14157
Eligibility Acute Myeloid Leukemia
NCT02508324
Inclusion Criteria
Patients must be 18 years of age or older*
Yes
No
Patients with a confirmed diagnosis of aml or
mds, according to who classification (excluding
acute promyelocytic leukaemia) who have
received two or three previous induction/re-
induction regimens. one of the (re-)induction
regimens could be stem cell transplantation (sct)
for achievement of remission. maintenance and
consolidation (including sct) may have been
given, but are not counted as previous regimens.*
Yes
No
have never attained cr or cri (primary refractory)*
Yes
No
Patients have failed initial induction therapy, and
have attained cr or cri after salvage therapy(ies),
and then relapsed within < 6 months*
Yes
No
Patients have attained cr or cri after initial
induction therapy and relapsed within <12
months, and failed to respond to salvage
therapy(ies); or have relapsed after the latest cr
or cri within < 6 months*
Yes
No
Patients younger than 60 years should have
received previous treatment with cytarabine*
Yes
No
Patients must have ecog performance status (ps)
of 0 - 2*
Yes
No
Women of child-bearing potential must have a
negative serum or urine pregnancy test within 2
weeks prior to treatment start*
Yes
No
Patients must be capable of understanding and
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complying with protocol requirements, and must
be able and willing to sign a written informed
consent form*
Yes
No
Exclusion Criteria
Persistent clinically significant toxicities from
previous chemotherapy*
Yes
No
Known positive status for human
immunodeficiency virus (hiv)*
Yes
No
pregnant and nursing patients*
Yes
No
Uncontrolled intercurrent illness including, but not
limited to, uncontrolled infection, or psychiatric
illness/social situations that would limit
compliance with study requirements*
Yes
No
Iimpairment of hepatic or renal function to such
an extent that the patient, in the opinion of the
investigator, will be exposed to an excessive risk
if entered into this clinical study*
Yes
No
active heart disease including myocardial
infarction within previous 3 months, symptomatic
coronary artery disease, arrhythmias not
controlled by medication, or uncontrolled
congestive heart failure. any nyha grade 3 or 4.*
Yes
No
Any medical condition which in the opinion of the
investigator places the patient at an unacceptably
high risk for toxicities*
Yes
No
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Eligibility Acute Myeloid Leukemia NCT02508324
Eligibility Asthma NCT01982162
Longitudinal Assessment of Children With Severe Asthma
and Severe Pre-school Wheeze; ODM derived from:
https://clinicaltrials.gov/show/NCT01982162
All rights reserved. Please visit https://medical-data-
models.org/forms/14164
Eligibility Asthma NCT01982162
Inclusion Criteria
1. parent / guardian must be able to give written
informed consent prior to participation in the
study, which includes ability to comply with the
requirements and restrictions listed in the
consent form. informed consent must be obtained
prior to undertaking any study procedures.*
Yes
No
2. assent should be obtained from all children in
the study where appropriate.*
Yes
No
3. male or female subject aged between 1 - 17
years inclusive at screening.*
>= 1
<= 17
years
Yes
No
4. the parent / guardian, or where appropriate the
child must be able to read, comprehend, and
write at a sufficient level to complete study
related materials.*
Yes
No
5. subjects will be allowed to enrol in other
studies while taking part on this study. however,
permission from the scientific board must be
obtained to enrol or allow the continued
participation of a subject enrolled in another
study.*
Yes
No
Exclusion Criteria
1. as a result of medical interview, physical
examination or screening investigation the
physician responsible considers the child unfit for
the study.*
Yes
No
2. the subject has a history of drug or other
allergy, which, in the opinion of the responsable
physician, contra-indicates their participation.*
Yes
No
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3. subject is female who is pregnant or lactating
or up to 6 weeks post partum or 6 weeks
cessation of breast feeding. if a woman is
subsequently found to have been pregnant at the
time of an assessment data from that
assessment will not be included in the analyses*
Yes
No
4. the child has participated within 3 months of
the first dose in a study using a new molecular
entity, or the first dose in any other study
investigating drugs or having participated within
three months in a study with invasive procedures.
any u-biopred assessments should be deferred
until 3 months after the first dose or invasive
procedure. permission from the scientific board
must be obtained to enroll or allow the continued
participation of a child enrolled in another study.*
Yes
No
5. those who, in the opinion of the investigator,
have a risk of non-compliance with study
procedures.*
Yes
No
6. prematurity ≤35 weeks gestation*
<= 35
weeks
Yes
No
7. the child had changed asthma medication
within 4 weeks of the screening
assessment(except those using the symbicort
maintenance and reliever therapy (smart)
regime)(assessment should be deferred)*
Yes
No
8. history or current evidence of an upper or
lower respiratory infection or symptoms (including
common cold) within 2 weeks of baseline
assessment (assessment should be deferred).*
Yes
No
9. the child has had a severe exacerbation
(requiring er attendance or hospital admission
and/or a course of high dose ocs for at least 3
days duration) within 4 weeks of the baseline
assessment (assessment should be deferred).*
Yes
No
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Eligibility Asthma NCT01982162
Eligibility Asthma NCT01993329
A Study to Evaluate the Effect of AF-219 on Methacholine
Hyper-reactivity in Subjects With Asthma; ODM derived
from: https://clinicaltrials.gov/show/NCT01993329
All rights reserved. Please visit https://medical-data-
models.org/forms/14165
Eligibility Asthma NCT01993329
Inclusion Criteria
non-smokers or former smokers, who stopped
smoking 6 months prior to screening. former
smokers should not have a smoking history of
more than 5 pack years (1 pack of 20 cigarettes
per day over 5 years).*
Yes
No
pre-bronchodilator (after abstaining from short
acting β2-agonist for ≥8 hrs) forced expiratory
volume (fev1) ≥70 percent of the predicted
normal value at the screening visit.*
>= 71
%
Yes
No
pre-bronchodilator (after abstaining from short
acting β2-agonist for ≥8 hrs) forced expiratory
volume (fev1) ≥70% of the predicted normal value
or if less than 70% must be within +/- 12 % of
screening fev1 prior to randomization.*
>= 71
%
Yes
No
history or diagnosis of asthma for at least 6
months prior to screening according to the global
initiative in asthma guidelines (gina, 2012).*
Yes
No
use of short acting β2-agonist therapy only (≤ 8
puffs per day) for at least 4 weeks prior to
screening and prior to randomisation.*
Yes
No
positive response to methacholine challenge
(pc20 ≤ 8 mg/ml) at screening.*
Yes
No
positive response to atp challenge (pc20 ≤ 200
µmol/ml) at screening.*
Yes
No
Exclusion Criteria
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hospitalized or attended the emergency
department for an asthma attack in the 12
months prior to screening.*
Yes
No
exacerbation of asthma or lower respiratory tract
infection during the 4 weeks before screening.*
Yes
No
upper respiratory tract infection during the 4
weeks before screening or prior to randomization
requiring treatment with antibiotics.*
Yes
No
inhaled or systemic corticosteroids (oral,
intravenous, intramuscular) within 4 weeks prior
to screening.*
Yes
No
short-acting or long-acting antihistamines within
48hrs or 7 days, respectively, prior to screening.*
Yes
No
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Eligibility Asthma NCT01993329
Eligibility Asthma NCT01996891
Asthma (and Dietary) Inflammation Reduction; ODM
derived from: https://clinicaltrials.gov/show/NCT01996891
All rights reserved. Please visit https://medical-data-
models.org/forms/14167
Eligibility Asthma NCT01996891
Inclusion Criteria
age 10-21 years*
>= 10
<= 21
years
Yes
No
clinical diagnosis of moderate or severe
persistent asthma*
Yes
No
currently prescribed inhaled corticosteroids for
asthma with anticipated stable dosing regimen for
the duration of the study*
Yes
No
admission to boston children's hospital for clinical
asthma exacerbation*
Yes
No
medical clearance from primary care provider*
Yes
No
willingness to comply with study diet*
Yes
No
Exclusion Criteria
body mass index (bmi) < 3rd centile (age- and
gender- adjusted normative range from center for
disease control)*
Yes
No
known eating disorder*
Yes
No
celiac disease*
Yes
No
any food allergy*
Yes
No
any other major illness as assessed by medical
history or the following screening tests:*
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Yes
No
alanine aminotransferase (alt) > twice upper limit
of normal for age*
Yes
No
creatinine > 1.0  mg/dl  for age 10-18 years; > 1.2
mg/dl for females > 18 years; or > 1.4 mg/dl for
males > 18 years)*
Yes
No
random glucose > 200 mg/dl*
Yes
No
hemoglobin < 11 g/dl for males age 10-18 years;
< 11. g/dl for females age 10-18 years; <11.4 g/dl
for males >18 years; or <10.9 g/dl for females
age > 18 years*
Yes
No
use of systemic steroids for indication other than
asthma*
Yes
No
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Eligibility Asthma NCT01996891
Eligibility Acute Myeloid Leukemia With Multilineage Dysplasia
Following Myelodysplastic Syndrome NCT01567059
Tosedostat in Combination With Cytarabine or Decitabine in
Treating Patients With Newly Diagnosed Acute Myeloid
Leukemia or High-Risk Myelodysplastic Syndrome; ODM
derived from: https://clinicaltrials.gov/show/NCT01567059
All rights reserved. Please visit https://medical-data-
models.org/forms/14170
Eligibility Acute Myeloid Leukemia
With Multilineage Dysplasia
Following Myelodysplastic Syndrome
NCT01567059
Inclusion Criteria
capable of understanding the investigational
nature, potential risks and benefits of the study,
and able to provide valid informed consent*
Yes
No
all adults >= 60 years of age with untreated aml
or high-risk mds (10-19% marrow blasts)
including those with prior myelodysplasia
(mds)/aml, therapy-related aml, aml with
trilineage dysplasia (aml-tld), and aml with
adverse cytogenetics; patients may be enrolled if
they received prior treatment with hydroxyurea to
control blood counts or demethylating agents
specifically for the purpose of treating mds*
Yes
No
adults age 18 to 59 with untreated aml or high-
risk mds and a transplant-related mortality (trm)
score of >= 9.2; previous data suggests these
people would have a 25% mortality with standard
therapy, making this treatment a reasonable
alternative*
Yes
No
eastern cooperative oncology group (ecog)
performance status of 0 - 2*
Yes
No
serum creatinine =< 2.0 mg/dl; if serum creatinine
> 2.0 mg/dl, then the estimated glomerular
filtration rate (gfr) must be > 50 ml/min/1.73 m^2
as calculated by the modification of diet in renal
disease equation*
mg/dL
Yes
No
serum bilirubin*
Yes
No
aspartate transaminase (ast)/alanine
transaminase (alt) =< 3.0 × uln*
Yes
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No
alkaline phosphatase =< 2.5 × uln*
U/L
Yes
No
male subjects, even if surgically sterilized (i.e.,
status postvasectomy) must agree to 1 of the
following: practice effective barrier contraception
during the entire study treatment period and
through a minimum of 30 days after the last dose
of study drug, or completely abstain from
heterosexual intercourse*
Yes
No
female subject is either postmenopausal for at
least 1 year before the screening visit, is
surgically sterilized or if they are of childbearing
potential, agree to practice 2 effective methods of
contraception from the time of signing the
informed consent form through 30 days after the
last dose of study drug, or agree to completely
abstain from heterosexual intercourse*
Yes
No
Exclusion Criteria
current concomitant chemotherapy, radiation
therapy, or immunotherapy other than as
specified in the protocol*
Yes
No
active uncontrolled infection*
Yes
No
known infection with human immunodeficiency
virus (hiv)*
Yes
No
medical condition, serious concurrent illness, or
other extenuating circumstance that, in the
judgment of the principal investigator, could
jeopardize patient safety or interfere with the
objectives of the study*
Yes
No
uncontrolled angina or myocardial infarction
within 6 months; patients with recent myocardial
infarction apparently due to medical causes
unrelated to underlying cardiac abnormalities
must have a cardiac consult, and be cleared to
participate in the research by the cardiologist
prior to initiation of treatment and may be enrolled
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Eligibility Acute Myeloid Leukemia With Multilineage Dysplasia Following
Myelodysplastic Syndrome NCT01567059
at the discretion of the primary investigator (pi)
and treating physician*
Yes
No
current or history of congestive heart failure new
york heart association (nyha) class 3 or 4, unless
a screening echocardiogram (echo) or multiple
gate acquisition scan (muga) performed within 1
month prior to study screening results in a left
ventricular ejection fraction (lvef) that is >= 45%
(or institutional lower limit of normal value)*
Yes
No
diagnosed or treated for another malignancy
within 1 year of enrollment, with the exception of
complete resection of basal cell carcinoma or
squamous cell carcinoma of the skin, an in situ
malignancy, or low-risk prostate cancer after
curative therapy*
Yes
No
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Eligibility Acute Myeloid Leukemia With Multilineage Dysplasia Following
Myelodysplastic Syndrome NCT01567059
Eligibility Acute Myeloid Leukemia With Multilineage Dysplasia
Following Myelodysplastic Syndrome NCT02029417
Omacetaxine Mepesuccinate, Cytarabine, and Decitabine
in Treating Older Patients With Newly Diagnosed Acute
Myeloid Leukemia; ODM derived from:
https://clinicaltrials.gov/show/NCT02029417
All rights reserved. Please visit https://medical-data-
models.org/forms/14171
Eligibility Acute Myeloid Leukemia
With Multilineage Dysplasia
Following Myelodysplastic Syndrome
NCT02029417
Inclusion Criteria
patients who are not eligible for standard
induction chemotherapy (or any standard therapy
known to be life prolonging) because of poor
performance status, significant tissue
comorbidities, or unfavorable risk of disease*
Yes
No
have an unequivocal histologic diagnosis of acute
myeloid leukemia (aml) (including secondary
aml)*
Yes
No
no prior therapy for aml except hydroxyurea to
control counts*
Yes
No
must agree to use adequate contraceptive
methods (e.g., hormonal or barrier method of
birth control; abstinence) prior to study entry and
for the duration of study participation*
Yes
No
subject or legal representative must understand
the investigational nature of this study and sign
an independent ethics committee/institutional
review board approved written informed consent
form prior to receiving any study related
procedure*
Yes
No
Exclusion Criteria
subjects with the diagnosis of acute
promyelocytic leukemia (t[15;17])*
Yes
No
unwilling or unable to follow protocol
requirements*
Yes
No
any condition which in the investigator's opinion
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deems the subject an unsuitable candidate to
receive study drug*
Yes
No
patients with sickle cell disease and sickle cell
crisis*
Yes
No
received an investigational agent for another
disease within 30 days prior to enrollment*
Yes
No
the patient has an uncontrolled and active
infection that would preclude study conduct and
assessment*
Yes
No
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Eligibility Acute Myeloid Leukemia With Multilineage Dysplasia Following
Myelodysplastic Syndrome NCT02029417
Eligibility Acute Myocardial Infarction
NCT00669227
Intracoronary Stem Cell Therapy in Patients With Acute
Myocardial Infarction (SCAMI); ODM derived from:
https://clinicaltrials.gov/show/NCT00669227
All rights reserved. Please visit https://medical-data-
models.org/forms/14173
Eligibility Acute Myocardial Infarction
NCT00669227
Inclusion Criteria
acute myocardial infarction with time to
revascularization >6 hours from symptom start*
Yes
No
clear target vessel*
Yes
No
large myocardial infarction defined as: proximal
vessel occlusion, ck > 1000 u/l, myocardial scar
in magnetic resonance imaging > 10% of left
ventricular muscle mass*
Yes
No
potential prior thrombolysis*
Yes
No
Written informed consent*
Yes
No
Exclusion Criteria
acute myocardial infarction with revascularization
within 6 hours after symptom start*
Yes
No
prior myocardial infarction*
Yes
No
no clear target vessel*
Yes
No
contraindication for magnetic resonance imaging
(e.g. pacemaker, icd)*
Yes
No
severely depressed left ventricular ejection
fraction (less than 20% in magnetic resonance
imaging)*
Yes
No
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prior hematologic disease*
Yes
No
prior chemotherapy*
Yes
No
prior stem cell transplantation*
Yes
No
prior treatment with g-csf*
Yes
No
known alteration of the bone marrow by alcohol
or drugs, e.g. agranulocytosis*
Yes
No
local infection of puncture sites*
Yes
No
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Eligibility Acute Myocardial Infarction NCT00669227
Eligibility Asthma NCT01999907
Vitamin D to Reduce Colds and Asthma Attacks in Young
Children; ODM derived from:
https://clinicaltrials.gov/show/NCT01999907
All rights reserved. Please visit https://medical-data-
models.org/forms/14174
Eligibility Asthma NCT01999907
Inclusion Criteria
children aged 1-5 years*
>= 1
<= 5
years
Yes
No
physician-diagnosed asthma as per gina
guidelines*
Yes
No
upper respiratory tract infections as the main
asthma exacerbation trigger*
Yes
No
≥4 respiratory infections in the past 12 months*
>= 4
respiratory infections
Yes
No
≥1 exacerbation requiring rescue oral steroids in
the past 6 months or ≥2 in the previous 12
months.*
Yes
No
Exclusion Criteria
extreme prematurity (<28 weeks gestation)*
<= 27
weeks
Yes
No
infants <12 months of age*
<= 11
months
Yes
No
breastfed infants with no vitamin d
supplementation*
Yes
No
recent (<1 year) immigrants from countries where
rickets and malnutrition prevalent*
Yes
No
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other chronic respiratory disease (broncho-
pulmonary dysplasia; cystic fibrosis)*
Yes
No
endocrine disorder of calcium/ vitamin d
metabolism*
Yes
No
disorder/ disease with associated malabsorption
(inflammatory bowel disease)*
Yes
No
kidney/ liver disease*
Yes
No
sickle cell anemia*
Yes
No
medications known to interfere with bone
metabolism/ vitamin d levels*
Yes
No
vitamin d supplementation >1000 iu/ day in past 3
months*
Yes
No
unable to attend medical visit in 3-4 months*
Yes
No
plan to leave the province during the next 6
months.*
Yes
No
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Eligibility Asthma NCT01999907
Eligibility Asthma NCT02003911
Azithromycin for Children Hospitalized With Asthma; ODM
derived from: https://clinicaltrials.gov/show/NCT02003911
All rights reserved. Please visit https://medical-data-
models.org/forms/14175
Eligibility Asthma NCT02003911
Inclusion Criteria
4-12 years of age*
>= 4
<= 12
years
Yes
No
admission diagnosis of asthma at the children's
hospital at montefiore*
Yes
No
history of persistent asthma (as defined by
national heart, lung, and blood institute)*
Yes
No
Exclusion Criteria
concurrent bacterial infection requiring
antibiotics*
Yes
No
antibiotics received within previous 2 weeks*
Yes
No
contraindication to azithromycin (including allergy
to macrolides)*
Yes
No
chronic lung disease other than asthma
(including bronchopulmonary dysplasia, cystic
fibrosis, bronchiectasis) or home oxygen
requirement*
Yes
No
immunodeficiency (primary or acquired)*
Yes
No
chronic systemic steroid use*
Yes
No
invasive or non-invasive mechanical ventilation
required acutely as result of current asthma
admission*
Yes
No
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significant cardiac co-morbidity (including
hemodynamically significant cardiac disease or
arrhythmia)*
Yes
No
liver disease (hepatitis)*
Yes
No
pregnancy*
Yes
No
seizure disorder, currently on anti-epileptic
medication)*
Yes
No
receiving albuterol every 4 hours (q4h) at the time
of enrollment*
Yes
No
previous enrollment in study*
Yes
No
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Eligibility Asthma NCT02003911
Eligibility Asthma NCT02012400
Effects of Regular Exercise on Adult Asthma; ODM derived
from: https://clinicaltrials.gov/show/NCT02012400
All rights reserved. Please visit https://medical-data-
models.org/forms/14176
Eligibility Asthma NCT02012400
Inclusion Criteria
diagnosis of asthma made by physician, or
reimbursement for asthma medication from the
national social insurance institution of finland
(code 203), or patient fulfills the diagnostic
criteria for asthma as outlined in the finnish
guidelines for asthma management (käypä hoito
-suositus 2006 and 2012)*
Yes
No
Exclusion Criteria
fev1 < 60 percent of predicted in spirometry*
<= 59
%
Yes
No
pef variability > 30 % at least 2 times during a 1-
week monitoring period*
Yes
No
use of bronchodilating medication at least 4 times
daily*
Yes
No
permanent, daily steroid tablet treatment*
Yes
No
patients who exercise regularly already at
baseline at least 3 times a week at least 30 min
at a time*
Yes
No
serious coronary heart disease*
Yes
No
severe hypotension*
Yes
No
severe heart failure*
Yes
No
severe musculoskeletal disorder*
Yes
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No
dementia*
Yes
No
physician-diagnosed chronic obstructive lung
disease*
Yes
No
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Eligibility Asthma NCT02012400
Eligibility Asthma NCT02017795
Asthma Self-management Via Application of Telehealth;
ODM derived from:
https://clinicaltrials.gov/show/NCT02017795
All rights reserved. Please visit https://medical-data-
models.org/forms/14177
Eligibility Asthma NCT02017795
Inclusion Criteria
1. physician diagnosed asthma.*
Yes
No
2. a history of an asthma exacerbation requiring
oral corticosteroids or admission to emergency
department/hospital in the previous year.*
Yes
No
3. ability to understand english and follow the
material included in the two different
interventions.*
Yes
No
4. ownership of a mobile phone with the capacity
to support text messaging.*
Yes
No
5. patients on maintenance inhaled
corticosteroids alone or with a combination
inhaler. subjects on other controller therapies will
not be excluded as long as they fulfill these
inclusion criteria.*
Yes
No
Exclusion Criteria
1. inability to provide written informed consent.*
Yes
No
2. a history of smoking cigarettes for greater than
ten pack years.*
>= 11
pack-years
Yes
No
3. not owning a mobile cell phone.*
Yes
No
4. subjects only taking a reliever medication and
on no controller medication.*
Yes
No
5. a history of significant co morbid disease
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judged by the investigator to preclude enrolment.*
Yes
No
6. a history of an asthma exacerbation requiring
oral corticosteroids in the previous six weeks.*
Yes
No
7. plans to move out of the study area in the next
year. -*
Yes
No
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Eligibility Allergic Asthma NCT01976208
Safety and Efficacy Study of Omalizumab to Treat Allergic
Asthma; ODM derived from:
https://clinicaltrials.gov/show/NCT01976208
All rights reserved. Please visit https://medical-data-
models.org/forms/14178
Eligibility Allergic Asthma
NCT01976208
Inclusion Criteria
male or female aged 15~65 years*
Yes
No
written informed consent provided*
Yes
No
total serum ige >=60iu/ml*
Yes
No
duration of allergic asthma >= 1 year according to
gina(2008)*
Yes
No
poor response to moderate to high dose inhaled
corticosteroid (400ug/day~800ug/day) >= 4
weeks*
Yes
No
agreed to be not pregnant, contraception during
study and later 6 months.*
Yes
No
Exclusion Criteria
patients who met the below criteria were
excluded:*
Yes
No
be regular smokers(>10 cigarettes per day and
for at least 2 years)*
Yes
No
patients who are currently pregnant or nursing or
intend to become pregnant over the course of the
study or later 6 months*
Yes
No
copd, according to the guideline of chinese
society of respiratory diseases*
Yes
No
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an active lung disease other than allergic
asthma*
Yes
No
patients with significant underlying medical
conditions*
Yes
No
allergic to immunoglobin or any formulation
ingredient of the product*
Yes
No
patients with diabetes or uncontrolled
hypertension(systolic blood pressure>160mmhg
or diastolic blood pressure>95mmhg)*
Yes
No
hiv positivity or cancer patient*
Yes
No
prior exposure to xolair*
Yes
No
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Eligibility Allergic Bronchial Asthma
NCT01026506
c9,t11-CLA in Children and Adolescents With Allergic
Asthma; ODM derived from:
https://clinicaltrials.gov/show/NCT01026506
All rights reserved. Please visit https://medical-data-
models.org/forms/14179
Eligibility Allergic Bronchial Asthma
NCT01026506
Inclusion Criteria
age 6-18 years*
Yes
No
doctor-diagnosed bronchial asthma*
Yes
No
allergic sensitization (house dust mite, grass
pollen)*
Yes
No
willingness to use only the recommended drugs*
Yes
No
competence regarding the daily documentation of
peak-flow data and symptoms*
Yes
No
Exclusion Criteria
sit within the last 2 years*
Yes
No
primary and secondary immune deficiency*
Yes
No
usage of systemic corticoids*
Yes
No
intolerance against milk protein*
Yes
No
alcohol and drug abuse*
Yes
No
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Eligibility Allergic NCT00836368
In Vitro Basophil Responsiveness to Allergen Challenge
After Gamma-tocopherol Supplementation in Allergic
Asthmatics; ODM derived from:
https://clinicaltrials.gov/show/NCT00836368
All rights reserved. Please visit https://medical-data-
models.org/forms/14180
Eligibility Allergic NCT00836368
Inclusion Criteria
1. specific allergy to house dust mite farinae
confirmed by positive immediate skin test
response.*
Yes
No
2. oxygen saturation of > 94 % at baseline 3.
blood pressure within the following parameters
(systolic between 140 - 90, diastolic between 90-
60 mm hg) 4. moderate or severe persistent
asthma according to nhlbi definitions including
history of one of the following:*
Yes
No
1. episodic wheezing, chest tightness or
shortness of breath consistent with asthma
occurring at least once a week that may affect
activity*
Yes
No
2. asthma symptoms occurring at night or during
sleep at least 1 time per week*
Yes
No
3. measured fev1 or fvc is <80% of predicted or*
Yes
No
4. physician diagnosed moderate or severe
persistent asthma which is currently treated or
controlled with maintenance medication including
moderate or high dose inhaled corticosteroid, or
any dose of inhaled corticosteroid and a long-
acting inhaled b2-agonist*
Yes
No
Exclusion Criteria
1. any chronic medical condition considered by
the pi as a contraindication to receiving gamma-t,
including significant cardiovascular disease,
diabetes requiring medication, chronic renal
disease, chronic thyroid disease, kidney disease
or coagulation defects.*
Yes
No
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2. use of inhaled steroids, cromolyn or
leukotriene inhibitors (montelukast or zafirlukast)
which have been used for at least one month are
allowed. patients must be on a stable regimen of
maintenance asthma therapy which has not
changed in the past month prior to entrance into
the study.*
Yes
No
3. non-steroidal anti-inflammatory drugs (nsaids)
or aspirin (asa) use within 48 hours of beginning
the study, and inability to suspended use of these
medications during the length of the study.*
Yes
No
5. diagnosis of anemia or abnormal blood counts
at screening.   abnormal pt or ptt values at
screening (pt that is prolonged more than 1-2 sec
and ptt prolonged more than 3-5 sec of normal.
the normal values used will be those defined by
mclendon lab.)
Yes
No
6. pregnancy or nursing a baby.  as this is a
phase i study, the potential risk to a fetus cannot
be justified.
Yes
No
4. use of anticoagulants including warfarin,
heparin, or clopidogrel.*
Yes
No
7. children will not be included in this study as the
potential risk to a growing child cannot be
justified.*
Yes
No
8. adults age 51 and older are excluded as the
potential for concomitant illness in this population
increases the risk for confounding the data.*
Yes
No
9. known vagal response to venipuncture*
Yes
No
10. use of any tobacco product within the past 6
months
Yes
No
11. hypertension, classified as a systolic blood
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pressure of equal to or greater than 140, and a
diastolic blood pressure equal to or greater than
90.
Yes
No
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Eligibility Allergic Rhinitis NCT02033252
Acupuncture for Rhinitis Complicated With Asthma; ODM
derived from: https://clinicaltrials.gov/show/NCT02033252
All rights reserved. Please visit https://medical-data-
models.org/forms/14181
Eligibility Allergic Rhinitis
NCT02033252
Inclusion Criteria
1. suffering from persistent allergic rhinitis (par;
nasal obstruction, rhinorrhoea, sneezing and
nasal itching) symptoms for more than 4
days/week, and greater than 4 consecutive
weeks.*
Yes
No
2. moderate-severe symptoms according to
allergic rhinitis and its impact on asthma (aria)
criteria.*
Yes
No
3. positive reaction for more than or equal to one
respiratory allergen (spt or mast)*
Yes
No
4. stable asthma symptoms with diagnosis of
asthma by respiratory or allergic disease
specialist.*
Yes
No
5. no changes in asthma or allergic rhinitis drugs
for the past month*
Yes
No
6. aged greater than or equal to 18 years, either
sex.*
Yes
No
7. no problem with expression of opinion*
Yes
No
8. provided with written consent*
Yes
No
9. no other disease except allergic rhinitis or
asthma which could affect the disease.*
Yes
No
Exclusion Criteria
1. having experience using ventilator due to
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exacerbation of asthma symptoms within six
months.*
Yes
No
2. experience of acute respiratory tract infection
treated with antibiotics within 14 days*
Yes
No
3. having anatomical occlusion or deformation in
nasal cavity.*
Yes
No
4. signs of infection in chest x-ray or having active
respiratory disease except asthma*
Yes
No
5. below or equal to 4 on total nasal symptom
score (tnss) in the latest week.*
Yes
No
6. received drugs affecting directly to allergic
rhinitis such as h1-antihistamines, decongestants
(nasal, oral or ocular), corticosteroids within 14
days.*
Yes
No
7. received following treatments for allergic
rhinitis or asthma within six months ; traditional
korean medicine interventions such as
acupuncture, moxibustion, cupping therapy and
herbal medication inhalation or cam including
homeopathy.*
Yes
No
8. received herbal medication for allergic rhinitis
or asthma within 14 days.*
Yes
No
9. pregnant, planning the pregnancy or breast-
feeding*
Yes
No
10. tuberculosis, hepatitis or more than 2 x
normal limit of serum creatinine, ast/alt.*
Yes
No
11. skin lesion on acupoint or other systemic
disease insufficient for acupuncture.*
Yes
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No
12. night-shift workers staying up all night*
Yes
No
13. who cannot participate clinical trial properly.*
Yes
No
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Eligibility Alport Syndrome NCT01705132
Urinary Biomarkers of the Progression of Alport Kidney
Disease; ODM derived from:
https://clinicaltrials.gov/show/NCT01705132
All rights reserved. Please visit https://medical-data-
models.org/forms/14182
Eligibility Alport Syndrome
NCT01705132
Inclusion Criteria
subjects eligible for inclusion in this study have to
fulfill all of the following criteria:*
Yes
No
1. able to understand and comply with the
requirements of the study and able to provide
written informed consent.*
Yes
No
2. male and female subjects ≥ 5 years of age.*
Yes
No
3. physically able to provide a single first-morning
urine sample of at least 30 ml (one ounce).*
Yes
No
4. alport syndrome diagnosis: clinical and/or
histopathologic and/or genetic diagnosis of alport
syndrome, as per the subject's physician and/or
genotyping.*
Yes
No
Exclusion Criteria
subjects fulfilling any of the following criteria are
not eligible for inclusion in this study:*
Yes
No
1. use of investigational drugs at the time of
enrollment, or within 30 days or 5 half-lives of
enrollment, whichever is longer; or longer if
required by local regulations, and for any other
limitation of participation in an investigational trial
based on local regulations.*
Yes
No
2. chronic kidney disease, defined as a known
diagnosis of ckd, and/or receiving chronic
phosphate-lowering therapy or erythropoietin
therapy.*
Yes
No
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3. ongoing chronic hemodialysis therapy and/or
renal transplant recipient.*
Yes
No
4. nephrotic-range proteinuria: spot urine protein-
to-creatinine ratio ≥ 3 on at least 2 of the last 3
clinical assessments.*
Yes
No
2 / 2
Eligibility Alport Syndrome NCT01705132
Eligibility Alzheimer Disease NCT00007189
Alzheimer's Disease Anti-Inflammatory Prevention Trial
(ADAPT); ODM derived from:
https://clinicaltrials.gov/show/NCT00007189
All rights reserved. Please visit https://medical-data-
models.org/forms/14183
Eligibility Alzheimer Disease
NCT00007189
Inclusion Criteria
aged 70 years or older.*
Yes
No
family history of parent, brother, or sister who
has, or had, serious age-related memory loss,
senility, dementia, or alzheimer's disease.*
Yes
No
study partner available to provide information on
the cognitive status of the participant and to
assist with monitoring of trial medications, if
needed.*
Yes
No
sufficient fluency in written and spoken english to
participate in study visits and neuropsychological
testing.*
Yes
No
willingness to limit use of the following for the
duration of the study: vitamin e (at doses greater
than 400 iu per day), non-aspirin nsaids,
histamine h2 receptor antagonists (tagamet, for
example), corticosteroids, anti-inflammatory or
analgesic doses of aspirin (greater than 81 mg
per day), ginkgo biloba extracts*
Yes
No
ability and intention to participate in regular study
visits, in the opinion of the study physician.*
Yes
No
provision of informed consent.*
Yes
No
Exclusion Criteria
history of peptic ulcer disease with bleeding or
obstruction.*
Yes
No
clinically significant liver or kidney disease.*
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Yes
No
history of hypersensitivity to aspirin, ibuprofen,
celecoxib, naproxen, or other nsaids.*
Yes
No
use of anti-coagulant medication.*
Yes
No
cognitive impairment or dementia.*
Yes
No
current alcohol abuse or dependence*
Yes
No
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Eligibility Alzheimer Disease NCT00009191
The Depression in Alzheimer's Disease Study (DIADS);
ODM derived from:
https://clinicaltrials.gov/show/NCT00009191
All rights reserved. Please visit https://medical-data-
models.org/forms/14184
Eligibility Alzheimer Disease
NCT00009191
Criteria
diagnosis of probable alzheimer's disease (ad) by
nincds/adrda criteria (mckann et al., 1984), with a
mmse score greater than 10*
Yes
No
diagnosis of current major depressive episode
(md), by dsm-iv, based on the scid-iv
examination*
Yes
No
patients will be included even if they have a pre-
ad history of unipolar depression*
Yes
No
patients who currently are being treated with
antidepressants but continue to meet criteria for
md (i.e., have not responded to the medications)
and who are willing to discontinue the other
medication and enter the study also will be
included*
Yes
No
currently residing in the community (own
home,family member's home, or small group
home) and agreeing to 13 weeks of followup in
the study*
Yes
No
stable medical history and general health, in the
opinion of the study psychiatrist*
Yes
No
a caregiver who knows the patient well (spends
at least 10 hours per week with him or her), and
who is in reasonably good health, agrees to
participate as well*
Yes
No
participant and his/her legal representative
provide informed consent*
Yes
No
exclusion:*
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Yes
No
use of sertraline is contraindicated, based on the
food and drug administration package insert for
sertraline*
Yes
No
patient has a lifetime diagnosis of schizophrenia,
bipolar disorder, or pre-ad anxiety disorder, as
determined by the scid*
Yes
No
patient has a current substance use disorder, as
determined by the scid*
Yes
No
patient is acutely suicidal or requires inpatient
psychiatric hospitalization, as determined by the
study psychiatrist*
Yes
No
no psychotropic medicine dose changes,
including cholinesterase inhibitors, after study
entry*
Yes
No
may enter with any drug except another
antidepressant.*
Yes
No
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Eligibility Alzheimer Disease NCT00040378
Prevention of Alzheimer's Disease by Vitamin E and
Selenium (PREADVISE); ODM derived from:
https://clinicaltrials.gov/show/NCT00040378
All rights reserved. Please visit https://medical-data-
models.org/forms/14189
Eligibility Alzheimer Disease
NCT00040378
Inclusion Criteria
participating in select prevention study;*
Yes
No
62 years or older if other ethnic origin, or 60
years or older if african-american or hispanic;*
Yes
No
general good health with no neurological or
psychiatric illness.*
Yes
No
Exclusion Criteria
the select doctors or staff will review the
preadvise applicants' medical history and drugs
to verify that they have no condition(s) that would
exclude them from this study. the participant must
not have any of the following neurological
conditions based on self report (were told by a
physician):*
Yes
No
alzheimer's disease, or any other form of
dementia such as pick's disease, dementia with
lewy bodies, frontotemporal dementia, vascular
dementia, significant cognitive and motor
impairment from a stroke or corticobasal
degeneration;*
Yes
No
huntington's disease, epilepsy, parkinson's
disease, brain tumor, multiple sclerosis, manic-
depressive disorder, or schizophrenia;*
Yes
No
the participant must not have had a head injury
with prolonged loss of consciousness (over 30
minutes) within the past five years;*
Yes
No
the participant must not have a current alcohol or
substance abuse diagnosis, or must have been
treatment free for the past 24 months;*
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Yes
No
the participant must not have had a diagnosis of
depression or anxiety disorder in the past 4
months and must not currently be under
treatment for depression or anxiety disorder.  [a
participant who was previously diagnosed with
depression or anxiety disorder but completed
treatment more than four months ago is
eligible.];*
Yes
No
the participant must not currently use of any of
the following medications: aricept, cognex,
exelon, reminyl, or hydergine;*
Yes
No
the participant must not have blindness,
deafness, language difficulties or any other
disability that may prevent completion of the
memory screen.*
Yes
No
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Eligibility Alzheimer Disease NCT00062569
Bathing Persons With Alzheimer's Disease aT Home (The
BATH Study); ODM derived from:
https://clinicaltrials.gov/show/NCT00062569
All rights reserved. Please visit https://medical-data-
models.org/forms/14190
Eligibility Alzheimer Disease
NCT00062569
Criteria
have a diagnosis of probable alzheimer's disease
or a related disorder according to standard
criteria.*
Yes
No
have functional dependence in bathing;*
Yes
No
demonstrate resistiveness to care during
bathing;*
Yes
No
live in the community in a home setting (house,
apartment, condominium);*
Yes
No
have a primary caregiver spouse or partner who
lives with the care recipient and agrees to be in
the study; and*
Yes
No
have no anticipated admission for long term care
within 3 months.*
Yes
No
must be married couples or life partners living
with alzheimer's disease or related disorder living
within a 15-mile radius of boston college.*
Yes
No
spouse or caregiver partner is the primary
caregiver, including assistance with bathing.*
Yes
No
women and minorities are encouraged to
participate.*
Yes
No
exclusion:*
Yes
No
severe concomitant medical conditions of patient
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or spouse.*
Yes
No
not fluent in english.*
Yes
No
couple resides in an institutional setting.*
Yes
No
couple anticipates a significant change of living
situation within three months.*
Yes
No
couple does not meet the above inclusion
criteria.*
Yes
No
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Eligibility Alzheimer Disease NCT00066157
Alzheimer's Disease: Therapeutic Potential of Estrogen;
ODM derived from:
https://clinicaltrials.gov/show/NCT00066157
All rights reserved. Please visit https://medical-data-
models.org/forms/14191
Eligibility Alzheimer Disease
NCT00066157
Inclusion Criteria
postmenopausal women with alzheimer's disease
and without other dementias (diagnosed by study
staff or from an outside clinic)*
Yes
No
mini mental state examination score greater than
15/30*
Yes
No
Exclusion Criteria
history of cancer of reproductive tissues*
Yes
No
history of deep vein thrombosis or blot clots*
Yes
No
diabetes*
Yes
No
heart disease or stroke*
Yes
No
liver problems including hepatitis*
Yes
No
severe vision or hearing problems*
Yes
No
tobacco use*
Yes
No
lack of an adequate caregiver*
Yes
No
inability to perform psychometric testing*
Yes
No
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Eligibility Alzheimer Disease NCT00088673
Evaluation of 3APS in Patients With Mild to Moderate
Alzheimer’s Disease; ODM derived from:
https://clinicaltrials.gov/show/NCT00088673
All rights reserved. Please visit https://medical-data-
models.org/forms/14192
Eligibility Alzheimer Disease
NCT00088673
Inclusion Criteria
patients may be included in this study if they
meet all of the following criteria:*
Yes
No
male or female (age 50 years and older):  female
must be of non-childbearing potential (i.e.
surgically sterilized or at least 2 years post-
menopausal).*
Yes
No
diagnosis of probable alzheimer’s disease based
on the national institute of neurological and
communicative disorders and stroke/alzheimer’s
disease and related disorders association
(nincds-adrda criteria).*
Yes
No
severity of dementia of mild to moderate degree
as assessed by the mini mental state
examination (mmse) performed at the screening
visit.*
Yes
No
patient must be living in the community with a
reliable caregiver. participant living in an assisted
living facility may be included if study medication
intake is supervised and participant has a reliable
caregiver.*
Yes
No
potential participant must be treated with
conventional alzheimer’s disease therapies and
must be on stable dose for at least 4 months prior
to the screening visit and during the entire study
period.*
Yes
No
fluency in english, french or spanish (oral and
written).*
Yes
No
signed informed consent from potential
participant or legal representative and caregiver.*
Yes
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No
Exclusion Criteria
patients will not be eligible to participate in the
study if they meet any of the following criteria:*
Yes
No
potential participant with any other cause of
dementia.*
Yes
No
life expectancy less than 2 years.*
Yes
No
potential participant with a clinically significant
and/or uncontrolled condition or other significant
medical disease.*
Yes
No
use of an investigational drug within 30 days prior
to the screening visit or during the entire study.*
Yes
No
previous use of 3aps.*
Yes
No
patient recruitment is done by participating
centers.*
Yes
No
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Eligibility Alzheimer Disease NCT00094913
PET Changes in Alzheimer's Disease (AD); ODM derived
from: https://clinicaltrials.gov/show/NCT00094913
All rights reserved. Please visit https://medical-data-
models.org/forms/14193
Eligibility Alzheimer Disease
NCT00094913
Inclusion Criteria
males and females with a minimum high school
education and between the ages of 50 and 90 will
be selected for groups 1 and 2. for group 3,
normal subjects between the ages of 20 and 49
years of age will be selected. the groups 1 and 2
will be balanced for age, and all three groups
balanced for gender and apoe genotype.*
Yes
No
discontinuance of all psychotropic and/or
cognitively active medication at least four weeks
prior to evaluation.*
Yes
No
Exclusion Criteria
past history or mri evidence of brain damage
including significant trauma, stroke,
hydrocephalus, lacunar infarcts, seizures, mental
retardation or serious neurological disorder.*
Yes
No
significant history of alcoholism or drug abuse.*
Yes
No
any history of psychiatric illness (e.g.,
schizophrenia, mania or depression).*
Yes
No
any focal signs or significant neuropathology.*
Yes
No
a score of 4 or greater on the modified hachinski
ischemia scale, indicative of cerebrovascular
disease.*
Yes
No
a total score of 16 or more on the hamilton
depression scale to exclude possible cases of
primary depression.*
Yes
No
evidence of clinically relevant hypertensive,
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cardiac, pulmonary, vascular, metabolic or
hematologic conditions. specific exclusion will be
made for individuals with fasting glucose levels
>110 mg/dl.*
Yes
No
physical impairment of such severity as to
adversely affect the validity of psychological
testing.*
Yes
No
hostility or refusal to cooperate.*
Yes
No
any prosthetic devices (e.g., pacemaker or
surgical clips) that could be affected by the
magnetic field employed during mri imaging.*
Yes
No
evidence of cognitive or memory impairment
reaching early ad levels at the initial evaluation. at
baseline, delayed paragraph recall z-scores > 2
below the reference group.*
Yes
No
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Eligibility Alzheimer Disease NCT00094939
Predictors of Cognitive Decline in Normal Aging; ODM
derived from: https://clinicaltrials.gov/show/NCT00094939
All rights reserved. Please visit https://medical-data-
models.org/forms/14194
Eligibility Alzheimer Disease
NCT00094939
Inclusion Criteria
males and females, from all racial and ethnic
categories between the ages of 60-80 years of
age, with english as their first language.*
Yes
No
residents of the new york city metropolitan area.*
Yes
No
minimum of 12 years of education.*
Yes
No
participants will be grouped according to the
following classifications: normal aging, mild
cognitive impairment (mci), alzheimer's disease
(ad), or frontotemporal dementia (ftd).*
Yes
No
participants will agree to apoe genotyping and
dna banking.*
Yes
No
Exclusion Criteria
past history or mri evidence of brain damage
including significant trauma, stroke,
hydrocephalus, lacunar infarcts, seizures, mental
retardation or serious neurological disorder.*
Yes
No
significant history of alcoholism or drug abuse.*
Yes
No
history of psychiatric illness (e.g., schizophrenia,
mania or depression).*
Yes
No
any focal signs or significant neuropathology.*
Yes
No
a score of 4 or greater on the modified hachinski
ischemia scale suggesting cerebrovascular
disease.*
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Yes
No
a total score of 16 or more on the hamilton
depression scale to exclude possible cases of
primary depression.*
Yes
No
evidence of clinically relevant and uncontrolled
hypertensive, cardiac, pulmonary, vascular,
metabolic or hematologic conditions.*
Yes
No
physical impairment of such severity as to
adversely affect the validity of psychological
testing.*
Yes
No
hostility or refusal to cooperate.*
Yes
No
any prosthetic devices (e.g., pacemaker or
surgical clips) that could be affected by the
magnetic field employed during mri imaging.*
Yes
No
history of familial early onset dementia.*
Yes
No
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Eligibility Alzheimer Disease NCT00105547
Efficacy Study of MPC-7869 to Treat Patients With
Alzheimer's; ODM derived from:
https://clinicaltrials.gov/show/NCT00105547
All rights reserved. Please visit https://medical-data-
models.org/forms/14195
Eligibility Alzheimer Disease
NCT00105547
Inclusion Criteria
have had a diagnosis of probable alzheimer's
disease.*
Yes
No
men or women ages 55 years or greater and
living in the community at the time of enrollment
(i.e., not living in a rest home or nursing care
facility).*
Yes
No
signed the subject informed consent form and is
willing and able to participate for the duration of
the study.*
Yes
No
ability to read and understand english or spanish
to ensure compliance with cognitive testing and
study visit procedures.*
Yes
No
female subjects must be surgically sterile or
postmenopausal for > 1 year.*
Yes
No
subjects currently taking approved medication for
alzheimer's disease for at  least six months prior
to day 1 may be enrolled.*
Yes
No
subjects must have a reliable caregiver who can
read, understand and speak english or spanish.*
Yes
No
Exclusion Criteria
current evidence of other causes of dementia.*
Yes
No
history or evidence of, active malignancy, except
for basal cell carcinoma or squamous cell
carcinoma of the skin, within the 24 months prior
to entry. men with prostate cancer may be
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enrolled at the discretion of the sponsor.*
Yes
No
chronic or acute renal, hepatic or metabolic
disorder.*
Yes
No
use of any investigational therapy within 30 days,
or 5 half-lives, whichever is longer, and/or use of
ad immunotherapy prior to screening.*
Yes
No
major surgery and related complications not
resolved within 12 weeks prior to day 1.*
Yes
No
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Eligibility Alzheimer Disease NCT00161473
Alzheimer's in Long-Term Care--Treatment for Agitation;
ODM derived from:
https://clinicaltrials.gov/show/NCT00161473
All rights reserved. Please visit https://medical-data-
models.org/forms/14196
Eligibility Alzheimer Disease
NCT00161473
Inclusion Criteria
no age limit*
Yes
No
probable/possible alzheimer's disease diagnosis*
Yes
No
disruptive agitated behaviors (e.g., irritability,
aggression, uncooperativeness, pacing)*
Yes
No
no hypotension*
Yes
No
no concurrent use of alpha-1-blockers*
Yes
No
no delirium, schizophrenia, mania, psychotic
symptoms.*
Yes
No
Exclusion Criteria
cardiovascular: unstable angina, recent
myocardial infarction, second or third degree
atrioventricular (av) block, preexisting
hypotension (systolic blood pressure less than
110) or orthostatic hypotension*
Yes
No
other medical exclusions: chronic renal or hepatic
failure, or any unstable medical condition*
Yes
No
exclusionary medications: current treatment with
prazosin, other alpha-1-blockers*
Yes
No
current enrollment in a separate investigational
drug trial*
Yes
No
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psychoactive medications: subjects may be
psychoactive medication-free or be partial
responders (by subjective assessment of
referring health care professional) to one
psychoactive medication from any of the following
classes: antipsychotics, anticonvulsants, mood
stabilizers, antidepressants, benzodiazepines, or
buspirone. partial response is defined as some
improvement in agitated behavior but persistence
of agitated behaviors severe enough to cause
patient distress and/or difficulty with caregiving.
although not formally rated, this improvement is
equivalent to a clinical global impression of
change (cgic) rating of no more than minimal
improvement (improvement is noticed by not
enough to improve patient function or caregiver's
practical management of the patient).*
Yes
No
psychiatric/behavioral: lifetime schizophrenia;
current delirium, mania, depression, or
uncontrolled persistent distressing psychotic
symptoms (hallucinations, delusions), substance
abuse, panic disorder, or any behavior which
poses an immediate danger to patient or others
or which results in the patient being too
uncooperative to meet the requirements of study
participation.*
Yes
No
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Eligibility Asthma NCT02022761
Safety, Tolerability and Pharmacokinetics of Inhaled
Laninamivir Octanoate TwinCaps® DPI in Adults With
Chronic Asthma; ODM derived from:
https://clinicaltrials.gov/show/NCT02022761
All rights reserved. Please visit https://medical-data-
models.org/forms/14197
Eligibility Asthma NCT02022761
Inclusion Criteria
1. healthy male or female subjects 18 to 65 years
of age, inclusive*
Yes
No
2. body mass index (bmi) within the range of 19.0
to 33.0 kg/m2, inclusive at screening*
>= 19.0
<= 33.0
kg/m2
Yes
No
3. minimum weight of 55.0 kg at screening and
pre-dose day 1*
>= 55.0
kg
Yes
No
4. clinical diagnosis of asthma by a physician for
≥12 months prior to screening confirmed in
writing and/or by medical records*
Yes
No
5. mild asthmatics currently requiring treatment
with low dose inhaled corticosteroids or other low
intensity treatment or moderate asthmatics,
requiring treatment with low dose inhaled
corticosteroids and long-acting beta agonists,
medium- high dose inhaled corticosteroids alone
or low dose inhaled corticosteroids and other low
intensity treatment8*
Yes
No
6. well controlled asthma for 1 month prior to
dosing defined by the following:*
Yes
No
1. daytime symptoms occur ≤8 times/ 4 weeks*
Yes
No
2. daily activity is not limited by asthma*
Yes
No
3. no nocturnal symptoms resulting in nighttime
awakenings*
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Yes
No
4. use of short-acting beta-agonist (saba) ≤8
times/4 weeks for the treatment of symptoms*
Yes
No
7. there has been no change in asthma
medication (dose or regimen) within 4 weeks
prior to dosing*
Yes
No
8. pre-short-acting β2 agonist (saba) forced
expiratory volume in 1 second (fev1) of*
Yes
No
≥80 percent of predicted normal values at
screening*
>= 80
%
Yes
No
9. non-smokers for at least 6 months prior to
screening and agrees not to smoke during the
study*
Yes
No
10. negative test results for smoking status at
screening (urine cotinine) and pre-dose day 1
(smokerlyser)*
Yes
No
11. female subjects of childbearing potential must
be practising true abstinence when this is in line
with the preferred and usual lifestyle of the
subject (periodic abstinence, e.g. calendar,
ovulation, symptothermal, post-ovulation
methods and withdrawal are not acceptable
methods of contraception), or be using and
willing to continue using a medically acceptable
form of birth control for at least 1 month prior to
screening (at least 3 months for hormonal
contraceptives) and for at least 1 month after the
last study drug administration*
Yes
No
12. male subjects of reproductive potential who
are not truly abstinent must be using and willing
to continue using medically acceptable
contraceptive precautions from screening and for
at least 1 month after the last study drug
administration*
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Yes
No
13. female subjects must have a negative serum
pregnancy test at screening and a negative urine
pregnancy test pre-dose day 1*
Yes
No
14. able to speak, read, and understand english
sufficiently to understand the nature of the study,
to provide informed consent, and to allow
completion of all study assessments*
Yes
No
15. must provide written informed consent prior to
the initiation of any protocol-specific procedures*
Yes
No
Exclusion Criteria
1. a history of a life-threatening asthma
exacerbation that required intubation and
mechanical ventilation*
Yes
No
2. history of severe asthma exacerbation in the
last year that required the use of systemic
corticosteroids (tablets, suspension or injection)*
Yes
No
3. hospitalization or a visit to er because of
asthma in the last year*
Yes
No
4. intensive care admission for asthma in the
previous 5 years*
Yes
No
5. any clinically significant abnormalities on
clinical chemistry, haematology, or urinalysis, as
judged by the investigator (at screening and/or
day -1)*
Yes
No
6. clinically significant abnormalities on physical
examination, medical history, 12-lead ecg, or vital
signs, as judged by the investigator (at screening
or pre-dose day 1)*
Yes
No
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7. a qtcf >430 msec for male subjects and >450
msec for female subjects on ecg at screening or
pre-dose day 1*
Yes
No
8. history or presence of any clinically significant
illness (e.g., cardiovascular, hepatic, renal,
hematologic, gastrointestinal, endocrine,
immunologic, dermatologic, neurologic,
oncologic, musculoskeletal, or psychiatric) or any
other condition, which in the opinion of the
investigator would jeopardize the safety of the
subject or the validity of the study results*
Yes
No
9. history or clinical evidence of other respiratory
disease (e.g., copd, cystic fibrosis)*
Yes
No
10. recent (within 2 weeks) or current signs or
symptoms of a respiratory infection at screening
or pre-dose day 1*
Yes
No
11. currently taking theophylline or has taken
theophylline in the 3 months prior to screening*
Yes
No
12. use of non-prescription drugs within 3 days
prior to day 1*
Yes
No
13. use of prescription medications (except
acceptable asthma medications, acceptable
forms of birth control, and hormone replacement)
and recreational drugs within 14 days prior to day
1*
Yes
No
14. positive urine drug screen or breath alcohol
test at screening or pre-dose day 1*
Yes
No
15. female subjects who are pregnant or lactating
or who are planning to become pregnant within
30 days of study drug administration*
Yes
No
16. history of allergy, hypersensitivity, or serious
adverse reaction to lactose or neuraminidase
inhibitors*
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Yes
No
17. previous exposure to laninamivir octanoate*
Yes
No
18. positive for hepatitis b surface antigen,
hepatitis c virus antibody, or human
immunodeficiency virus (hiv) p24
antigen/antibodies at screening*
Yes
No
19. donation or loss of ≥500 ml whole blood
within 2 months prior to day 1*
>= 500
ml
Yes
No
20. current or pending legal charges or currently
on probation, based on subject report*
Yes
No
21. receipt of an investigational product in a
clinical trial within 30 days or 5 half-lives,
whichever is longer, prior to day 1*
Yes
No
22. concurrent enrolment in any other type of
medical research, judged by the investigator not
to be scientifically or medically compatible with
this study*
Yes
No
23. an employee of the sponsor or research site
personnel directly affiliated with this study or their
immediate family members defined as a spouse,
parent, sibling, or child, whether biological or
legally adopted*
Yes
No
24. a subject who, in the opinion of the
investigator, is not considered to be suitable and
is unlikely to comply with the study protocol for
any reason*
Yes
No
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NINDS CDE Fasting information and
Laboratory tests Amyotrophic Lateral Sclerosis
NINDS Common Data Elements (Fasting information and
Laboratory tests Amyotrophic Lateral Sclerosis) Used from
the National Institute of Neurological Disorders and Stroke
Common Data Elements
(https://www.commondataelements.ninds.nih.gov/)
References: Grinnon ST, Miller K, Marler JR, Lu Y, Stout A,
Odenkirchen J, Kunitz S. National Institute of Neurological
Disorders and Stroke Common Data Element Project -
approach and methods. Clin Trials. 2012;9(3):322-9.
All rights reserved. Please visit https://medical-data-
models.org/forms/14201
Fasting information and Laboratory
tests
Fasting Information
Study ID
Study site name
Subject ID
Was the participant fasting prior to sample
collection?
Yes
No
Date and time participant last ate
Date and time participant last ate is unknown
Yes
No
Date and time participant last drank caffeine
Date and time participant last drank caffeine is
unknown
Yes
No
Date and time participant last drank alcohol
Date and time participant last drank alcohol is
unknown
Yes
No
Were medications withheld prior to sample
collection
Yes (1)
No (2)
Unknown (3)
If yes, what medication was withheld prior to
sample collection?
Length of time medication withheld
1 / 39
hrs/24h
Laboratory Tests Information
Where were the Lab Tests done?
Site Lab (1)
Central Lab (2)
Which lab panel was done, please select one
CHEMISTRY (1)
HEMATOLOGY (2)
URINALYSIS (3)
Other, specify (4)
If you selected "other", please specify what
laboratory tests have been done
Date and time of specimen collection
Please specify the time for specimen collection
AM (1)
PM (2)
24hr clock (3)
Complete Blood Count Laboratory Tests
White blood cell count result
White blood cell count:Please specify units used
for measurement
White blood cell count not performed?
Yes
No
White blood cell count:please specify why
procedure was not performed
White blood cell count
Abnormal (1)
Normal (2)
Unknown (3)
White blood cell count
Clinically significant (1)
Not clinically significant (2)
Red blood cell count result
Red blood cell count: Please specify units used
for measurement
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Red blood cell count not performed
Yes
No
Red blood cell count:please specify why
procedure was not performed
Red blood cell count
Abnormal (1)
Normal (2)
Unknown (3)
Red blood cell count
Clinically significant (1)
Not clinically significant (2)
Mean Corpuscular Volume (MCV) result
Mean Corpuscular Volume: Please specify unit
used for measurement
Mean Corpuscular Volume measurement not
performed
Yes
No
Mean Corpuscular Volume:please specify why
procedure was not performed
Mean Corpuscular Volume (MCV)
Abnormal  (1)
Normal (2)
Unknown (3)
Mean Corpuscular Volume
Clinically significant (1)
Not clinically significant (2)
Lymphocytes absolut result
Lymphocytes absolut: please specify unit used
for measurement
Lymphocytes absolut:measurement not
performed
Yes
No
Lymphocytes absolut:please specify why
procedure was not performed
Lymphocytes absolut
Normal (1)
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Abnormal (2)
Unknown (3)
Lymphocytes absolut
Clinically significant (1)
Not clinically significant (2)
Lymphocytes result
Lymphocytes:please specify unit used for
measurement
Lymphocytes:Measurement not performed
Yes
No
Lymphocytes:please specify why procedure was
not performed
Lymphocytes
Abnormal (1)
Normal (2)
Unknown (3)
Lymphocytes
Clinically significant (1)
Not clinically significant (2)
Absolute Neutrophil Count result
Absolute Neutrophil Count:please specify unit
used for measurement
Absolute Neutrophil Count:Measurement not
performed
Yes
No
Absolute Neutrophil Count:please specify why
procedure was not performed
Absolute Neutrophil Count
Abnormal (1)
Normal (2)
Unknown (3)
Absolute Neutrophil Count
Clinically significant (1)
Not clinically significant (2)
Neutrophil count result
Neutrophil count: Please specify unit used for
measurement
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Neutrophil count:measurement not performed
Yes
No
Neutrophil count:please specify why procedure
was not performed
Neutrophil count
Abnormal (1)
Normal (2)
Unknown (3)
Neutrophil count
Clinically significant (1)
Not clinically significant (2)
Monocytes absolut result
Monocytes absolut:please specify unit used for
measurement
Monocytes absolut:measurement not performed
Yes
No
Monocytes absolut:please specify why procedure
was not performed
Monocytes absolut
Abnormal (1)
Normal (2)
Unknown (3)
Monocytes absolute
Clinically significant (1)
Not clinically significant (2)
Monocytes count result
Monocytes count:Please specify unit used for
measurement
Monocytes count: Measurement not performed
Yes
No
Monocytes count:please specify why procedure
was not performed
Monocytes Count
Abnormal (1)
Normal (2)
Unknown (3)
Monocytes count
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Clinically significant (1)
Not clinically significant (2)
Eosinophils absolut result
Eosinophils absolut:please specify unit used for
measurement
Eosinophils absolut:measurement not performed
Yes
No
Eosinophils absolut:please specify why
procedure was not performed
Eosinophils absolut
Abnormal (1)
Normal (2)
Unknown (3)
Eosinophils absolut
Clinically significant (1)
Not clinically significant (2)
Eosinophil count result
Eosinophil count:please specify unit used for
measurement
Eosinophil count:measurement not performed
Yes
No
Eosinophil count:please specify why procedure
was not performed
Eosinophil count
Abnormal  (1)
Normal  (2)
Unknown (3)
Eosinophil count
Clinically significant (1)
Not clinically significant (2)
Hematocrit result
Hematocrit:please specify unit used for
measurement
Hematocrit:measurement not performed
Yes
6 / 39
NINDS CDE Fasting information and Laboratory tests Amyotrophic
Lateral Sclerosis
No
Hematocrit:please specify why procedure was not
performed
Hematocrit
Abnormal (1)
Normal (2)
Unknown (3)
Hematocrit
Clinically significant (1)
Not clinically significant (2)
Hemoglobin result
Hemoglobin:please specify unit used for
measurement
Hemoglobin:measurement not performed
Yes
No
Hemoglobin:please specify why procedure was
not performed
Hemoglobin
Abnormal (1)
Normal (2)
Unknown (3)
Hemoglobin
Clinically significant (1)
Not clinically significant (2)
Platelet count result
Platelet count:please specify unit used for
measurement
Platelet count:measurement not performed
Yes
No
Platelet count:please specify why procedure was
not performed
Platelet count
Abnormal (1)
Normal (2)
Unknown (3)
Platelet count
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Clinically significant (1)
Not clinically significant (2)
Basophils absolut result
Basophils absolut:please specify unit used for
measurement
Basophils absolut:measurement not performed
Yes
No
Basophils absolut:please specify why procedure
was not performed
Basophils absolut
Abnormal (1)
Normal (2)
Unknown (3)
Basophils absolut
Clinically significant (1)
Not clinically significant (2)
Basophil count result
Basophil count:please specify unit used for
measurement
Basophil count:measurement not performed
Yes
No
Basophil count:please specify why procedure
was not performed
Basophil count
Abnormal (1)
Normal (2)
Unknown (3)
Basophil count
Clinically significant (1)
Not clinically significant (2)
Chemistry Laboratory Tests
Blood urea nitrogen (BUN) result
Blood urea nitrogen (BUN):please specify unit
used for measurement
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Blood urea nitrogen (BUN):measurement not
performed
Yes
No
Blood urea nitrogen (BUN):please specify why
procedure was not performed
Blood urea nitrogen (BUN):
Abnormal (1)
Normal (2)
Unknown (3)
Blood urea nitrogen (BUN):
Clinically significant (1)
Not clinically significant (2)
Creatinine result
Creatinine:please specify unit used for
measurement
Creatinine:measurement not performed
Yes
No
Creatinine:please specify why procedure was not
performed
Creatinine
Abnormal (1)
Normal (2)
Unknown (3)
Creatinine
Clinically significant (1)
Not clinically significant (2)
Glucose result
Glucose:please specify unit used for
measurement
Glucose:measurement not performed
Yes
No
Glucose:please specify why procedure was not
performed
Glucose
Abnormal (1)
Normal (2)
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Unknown (3)
Glucose
Clinically significant (1)
Not clinically significant (2)
Phosphate result
Phosphate:please specify unit used for
measurement
Phosphate:measurement not performed
Yes
No
Phosphate:please specify why procedure was not
performed
Phosphate
Abnormal (1)
Normal (2)
Unknown (3)
Phosphate
Clinically significant (1)
Not clinically significant (2)
Calcium result
Calcium:please specify unit used for
measurement
Calcium:measurement not performed
Yes
No
Calcium:please specify why procedure was not
performed
Calcium
Abnormal (1)
Normal (2)
Unknown (3)
Calcium
Clinically significant (1)
Not clinically significant (2)
Creatine Kinase result
Creatine Kinase:please specify unit used for
measurement
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Creatine Kinase:measurement not performed
Yes
No
Creatine Kinase:please specify why procedure
was not performed
Creatine Kinase
Abnormal (1)
Normal (2)
Unknown (3)
Creatine Kinase
Clinically significant (1)
Not clinically significant (2)
Uric acid result
Uric acid:please specify unit used for
measurement
Uric acid:measurement not performed
Yes
No
Uric acid:please specify why procedure was not
performed
Uric acid
Abnormal (1)
Normal (2)
Unknown (3)
Uric acid
Clinically significant (1)
Not clinically significant (2)
Electrolyte Laboratory Tests
Sodium result
Sodium:please specify unit used for
measurement
Sodium:measurement not performed
Yes
No
Sodium:please specify why procedure was not
performed
Sodium
Abnormal (1)
Normal (2)
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Unknown (3)
Sodium
Clinically significant (1)
Not clinically significant (2)
Potassium result
Potassium:please specify unit used for
measurement
Potassium:measurement not performed
Yes
No
Potassium:please specify why procedure was not
performed
Potassium
Abnormal (1)
Normal (2)
Unknown (3)
Potassium
Clinically significant (1)
Not clinically significant (2)
Chloride result
Chloride:please specify unit used for
measurement
Chloride:measurement not performed
Yes
No
Chloride:please specify why procedure was not
performed
Chloride
Abnormal (1)
Normal (2)
Unknown (3)
Chloride
Clinically significant (1)
Not clinically significant (2)
Bicarbonate result
Bicarbonate: please specify unit used for
measurement
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Bicarbonate:measurement not performed
Yes
No
Bicarbonate:please specify why procedure was
not performed
Bicarbonate
Abnormal (1)
Normal (2)
Unknown (3)
Bicarbonate
Clinically significant (1)
Not clinically significant (2)
Blood Gasses
pH result
pH:please specify unit used for measurement
pH:measurement not performed
Yes
No
pH:please specify why procedure was not
performed
pH
Abnormal (1)
Normal (2)
Unknown (3)
pH
Clinically significant (1)
Not clinically significant (2)
PCO2 result
PCO2:please specify unit used for measurement
PCO2:measurement not performed
Yes
No
PCO2:please specify why procedure was not
performed
PCO2
Abnormal (1)
Normal (2)
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Unknown (3)
PCO2
Clinically significant (1)
Not clinically significant (2)
PO2 result
PO2:please specify unit used for measurement
PO2:measurement not performed
Yes
No
PO2:please specify why procedure was not
performed
PO2
Abnormal (1)
Normal (2)
Unknown (3)
PO2
Clinically significant (1)
Not clinically significant (2)
Liver Function Laboratory Tests
Prealbumin result
Prealbumin:please specify unit used for
measurement
Prealbumin:measurement not performed
Yes
No
Prealbumin:please specify why procedure was
not performed
Prealbumin
Abnormal (1)
Normal (2)
Unknown (3)
Prealbumin
Clinically significant (1)
Not clinically significant (2)
Albumin result
Albumin:please specify unit used for
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measurement
Albumin:measurement not performed
Yes
No
Albumin:please specify why procedure was not
performed
Albumin
Abnormal (1)
Normal (2)
Unknown (3)
Albumin
Clinically significant (1)
Not clinically significant (2)
Total Serum Protein result
Total Serum Protein:please specify unit used for
measurement
Total Serum Protein:measurement not performed
Yes
No
Total Serum Protein:please specify why
procedure was not performed
Total Serum Protein
Abnormal (1)
Normal (2)
Unknown (3)
Total Serum Protein
Clinically significant (1)
Not clinically significant (2)
AST result
AST:please specify unit used for measurement
AST:measurement not performed
Yes
No
AST:please specify why procedure was not
performed
AST
Abnormal (1)
Normal (2)
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Unknown (3)
AST
Clinically significant (1)
Not clinically significant (2)
ALT result
ALT:please specify unit used for measurement
ALT:measurement not performed
Yes
No
ALT:please specify why procedure was not
performed
ALT
Abnormal (1)
Normal (2)
Unknown (3)
ALT
Clinically significant (1)
Not clinically significant (2)
Total Bilirubin result
Total Bilirubin:please specify unit used for
measurement
Total Bilirubin:measurement not performed
Yes
No
Total Bilirubin:please specify why procedure was
not performed
Total Bilirubin
Abnormal (1)
Normal (2)
Unknown (3)
Total Bilirubin
Clinically significant (1)
Not clinically significant (2)
GGT result
GGT:please specify unit used for measurement
GGT:measurement not performed
Yes
No
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GGT:please specify why procedure was not
performed
GGT
Abnormal (1)
Normal (2)
Unknown (3)
GGT
Clinically significant (1)
Not clinically significant (2)
Alkaline Phosphatase result
Alkaline Phosphatase:please specify unit used for
measurement
Alkaline Phosphatase:measurement not
performed
Yes
No
Alkaline Phosphatase:please specify why
procedure was not performed
Alkaline Phosphatase
Abnormal (1)
Normal (2)
Unknown (3)
Alkaline Phosphatase
Clinically significant (1)
Not clinically significant (2)
Lipid Laboratory Tests
Was this test done while the participant was
fasting?
Yes (1)
No (2)
Unknown (3)
Total cholesterol result
Total Cholesterol:please specify unit used for
measurment
Total Cholesterol:measurement not performed
Yes
No
Total Cholesterol:please specify why procedure
was not performed
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Total Cholesterol
Abnormal (1)
Normal (2)
Unknown (3)
Total Cholesterol
Clinically significant (1)
Not clinically significant (2)
LDL result
LDL:please specify unit used for measurement
LDL:measurement not performed
Yes
No
LDL:please specify why procedure was not
performed
LDL
Abnormal (1)
Normal (2)
Unknown (3)
LDL
Clinically significant (1)
Not clinically significant (2)
HDL result
HDL:please specify unit used for measurement
HDL:measurement not performed
Yes
No
HDL:please specify why procedure was not
performed
HDL
Abnormal (1)
Normal (2)
Unknown (3)
HDL
Clinically significant (1)
Not clinically significant (2)
Triglycerides result
Triglycerides: please specify unit used for
measurement
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Triglycerides:measurement not performed
Yes
No
Triglycerides:please specify why procedure was
not performed
Triglycerides
Abnormal (1)
Normal (2)
Unknown (3)
Triglycerides
Clinically significant (1)
Not clinically significant (2)
Autoimmune Laboratory Tests
Antinuclear Antibodies (ANA) result
Antinuclear Antibodies (ANA):please specify unit
used for measurement
Antinuclear Antibodies:measurement not
performed
Yes
No
Antinuclear Antibodies:please specify why
procedure was not performed
Antinuclear Antibodies
Abnormal (1)
Normal (2)
Unknown (3)
Antinuclear Antibodies
Clinically significant (1)
Not clinically significant (2)
Rheumatoid Factor result
Rheumatoid Factor:please specify unit used for
measurement
Rheumatoid Factor:measurement not performed
Yes
No
Rheumatoid Factor:please specify why procedure
was not performed
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Rheumatoid Factor
Abnormal (1)
Normal (2)
Unknown (3)
Rheumatoid Factor
Clinically significant (1)
Not clinically significant (2)
Immunoglobulin G result
Immunoglobulin G:please specify unit used for
measurement
Immunoglobulin G:measurement not performed
Yes
No
Immunoglobulin G:please specify why procedure
was not performed
Immunoglobulin G
Abnormal (1)
Normal (2)
Unknown (3)
Immunoglobulin G
Clinically significant (1)
Not clinically significant (2)
Immunoglobulin A result
Immunoglobulin A:please specify unit used for
measurement
Immunoglobulin A:measurement not performed
Yes
No
Immunoglobulin A:please specify why procedure
was not performed
Immunoglobulin A
Abnormal (1)
Normal (2)
Unknown (3)
Immunoglobulin A
Clinically significant (1)
Not clinically significant (2)
Immunoglobulin M result
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Immunoglobulin M:please specify unit used for
measurement
Immunoglobulin M:measurement not performed
Yes
No
Immunoglobulin M:please specify why procedure
was not performed
Immunoglobulin M
Abnormal (1)
Normal (2)
Unknown (3)
Immunoglobulin M
Clinically significant (1)
Not clinically significant (2)
Serum Protein EP result
Serum Protein EP:please specify unit used for
measurement
Serum Protein EP:measurement not performed
Yes
No
Serum Protein EP:please specify why procedure
was not performed
Serum Protein EP
Abnormal (1)
Normal (2)
Unknown (3)
Serum Protein EP
Clinically significant (1)
Not clinically significant (2)
GM1 Antibody result
Negative (1)
Positive (2)
GM1 Antibody:if positive please specify Titer
GM1 Antibody:please specify unit used for
measurement
GM1 Antibody:measurement not performed
Yes
No
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GM1 Antibody:please specify why procedure was
not performed
GM1 Antibody
Abnormal (1)
Normal (2)
Unknown (3)
GM1 Antibody
Clinically significant (1)
Not clinically significant (2)
GQ1b Antibody result
Negative (1)
Positive (2)
GQ1b Antibody:if positive please specify Titer
GQ1b Antibody:please specify unit used for
measurement
GQ1b Antibody:measurement not performed
Yes
No
GQ1b Antibody:please specify why procedure
was not performed
GQ1b Antibody
Abnormal (1)
Normal (2)
Unknown (3)
GQ1b Antibody
Clinically significant (1)
Not clinically significant (2)
GT1a Antibody result
Negative (1)
Positive (2)
GT1a Antibody:if positive please specify Titer
GT1a Antibody:please specify unit used for
measurement
GT1a Antibody:measurement not performed
Yes
No
GT1a Antibody:please specify why procedure
was not performed
GT1a Antibody
Abnormal (1)
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Normal (2)
Unknown (3)
GT1a Antibody
Clinically significant (1)
Not clinically significant (2)
GD1b Antibody result
Negative (1)
Positive (2)
GD1b Antibody:if positive please specify Titer
GD1b Antibody:please specify unit used for
measurement
GD1b Antibody:measurement not performed
Yes
No
GD1b Antibody:please specify why procedure
was not performed
GD1b Antibody
Abnormal (1)
Normal (2)
Unknown (3)
GD1b Antibody
Clinically significant (1)
Not clinically significant (2)
GD1a Antibody result
Negative (1)
Positive (2)
GD1a Antibody:if positive please specify Titer
GD1a Antibody:please specify unit used for
measurement
GD1a Antibody:measurement not performed
Yes
No
GD1a Antibody:please specify why procedure
was not performed
GD1a Antibody
Abnormal (1)
Normal (2)
Unknown (3)
GD1a Antibody
Clinically significant (1)
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Not clinically significant (2)
GalNAc-GD1a Antibody result
Negative (1)
Positive (2)
GalNAc-GD1a Antibody: Please specify unit used
for measurement
GalNAc-GD1a Antibody: if positive, please
specify Titer
GalNAc-GD1a Antibody:measurement not
performed
Yes
No
GalNAc-GD1a Antibody:please specify why
procedure was not performed
GalNAc-GD1a Antibody
Abnormal (1)
Normal (2)
Unknown (3)
GalNAc-GD1a Antibody
Clinically significant (1)
Not clinically significant (2)
Lysoganglioside-GM1 Antibody result
Negative (1)
Positive (2)
Lysoganglioside-GM1 Antibody:if positive please
specify Titer
Lysoganglioside-GM1 Antibody:please specify
unit used for measurement
Lysoganglioside-GM1 Antibody:measurement not
performed
Yes
No
Lysoganglioside-GM1 Antibody:please specify
why procedure was not performed
Lysoganglioside-GM1 Antibody
Abnormal (1)
Normal (2)
Unknown (3)
Lysoganglioside-GM1 Antibody
Clinically significant (1)
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Not clinically significant (2)
Sulfatide Antibody result
Negative (1)
Positive (2)
Sulfatide Antibody:if positive please specify Titer
Sulfatide Antibody:please specify unit used for
measurement
Sulfatide Antibody:measurement not performed
Yes
No
Sulfatide Antibody:please specify why procedure
was not performed
Sulfatide Antibody
Abnormal (1)
Normal (2)
Unknown (3)
Sulfatide Antibody
Clinically significant (1)
Not clinically significant (2)
C-Reactive Protein (CRP) result
C-Reactive Protein (CRP):please specify unit
used for measurement
C-Reactive Protein (CRP):measurement not
performed
Yes
No
C-Reactive Protein (CRP):please specify why
procedure was not performed
C-Reactive Protein (CRP)
Abnormal (1)
Normal (2)
Unknown (3)
C-Reactive Protein (CRP)
Clinically significant (1)
Not clinically significant (2)
Erythrocyte Sedimentation Rate result
Erythrocyte Sedimentation Rate:please specify
unit used for measurement
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Erythrocyte Sedimentation Rate:measurement
not performed
Yes
No
Erythrocyte Sedimentation Rate:please specify
why procedure was not performed
Erythrocyte Sedimentation Rate
Abnormal (1)
Normal (2)
Unknown (3)
Erythrocyte Sedimentation Rate
Clinically significant (1)
Not clinically significant (2)
Clotting Laboratory Tests
Prothrombin Time (PT) result
Prothrombin Time (PT):please specify unit used
for measurement
Prothrombin Time (PT):measurement not
performed
Yes
No
Prothrombin Time (PT):please specify why
procedure was not performed
Prothrombin Time (PT)
Abnormal (1)
Normal (2)
Unknown (3)
Prothrombin Time (PT)
Clinically significant (1)
Not clinically significant (2)
Activated Partial Thromboplastin Time (aPTT)
result
Activated Partial Thromboplastin Time
(aPTT):please specify unit used for measurement
Activated Partial Thromboplastin Time (aPTT):
measurement not performed
Yes
No
Activated Partial Thromboplastin Time
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(aPTT):please specify why procedure was not
performed
Activated Partial Thromboplastin Time (aPTT)
Abnormal (1)
Normal (2)
Unknown (3)
Activated Partial Thromboplastin Time (aPTT)
Clinically significant (1)
Not clinically significant (2)
International Normalized Ratio (INR) result
International Normalized Ratio (INR):please
specify unit used for measurement
International Normalized Ratio
(INR):measurement not performed
Yes
No
International Normalized Ratio (INR):please
specify why procedure was not performed
International Normalized Ratio (INR)
Abnormal (1)
Normal (2)
Unknown (3)
International Normalized Ratio (INR)
Clinically significant (1)
Not clinically significant (2)
Endocrine Laboratory Tests
Free T4 result
Free T4:please specify unit used for
measurement
Free T4:measurement not performed
Yes
No
Free T4:please specify why procedure was not
performed
Free T4
Abnormal (1)
Normal (2)
Unknown (3)
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Free T4
Clinically significant (1)
Not clinically significant (2)
Thyroid-Stimulating Hormone (TSH) result
Thyroid-Stimulating Hormone (TSH):please
specify unit used for measurement
Thyroid-Stimulating Hormone
(TSH):measurement not performed
Yes
No
Thyroid-Stimulating Hormone (TSH):please
specify why procedure was not performed
Thyroid-Stimulating Hormone (TSH)
Abnormal (1)
Normal (2)
Unknown (3)
Thyroid-Stimulating Hormone (TSH)
Clinically significant (1)
Not clinically significant (2)
Insulin-like Growth Factor-1 (IGF-1) result
Insulin-like Growth Factor-1 (IGF-1):please
specify unit used for measurement
Insulin-like Growth Factor-1 (IGF-
1):measurement not performed
Yes
No
Insulin-like Growth Factor-1 (IGF-1):please
specify why procedure was not performed
Insulin-like Growth Factor-1 (IGF-1)
Abnormal (1)
Normal (2)
Unknown (3)
Insulin-like Growth Factor-1 (IGF-1)
Clinically significant (1)
Not clinically significant (2)
Glycosylated Hemoglobin (HgbA1C) result
Glycosylated Hemoglobin (HgbA1C):please
specify unit used for measurement
Glycosylated Hemoglobin
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(HgbA1C):measurement not performed
Yes
No
Glycosylated Hemoglobin (HgbA1C):please
specify why procedure was not performed
Glycosylated Hemoglobin (HgbA1C)
Abnormal (1)
Normal (2)
Unknown (3)
Glycosylated Hemoglobin (HgbA1C)
Clinically significant (1)
Not clinically significant (2)
Cerebrospinal Fluid (CSF) Laboratory
Tests
Was CSF testing done?
Yes (1)
No (2)
Not applicable (3)
RBC result
RBC:please specify unit used for measurement
RBC:measurement not performed
Yes
No
RBC:please specify why procedure was not
performed
RBC
Abnormal (1)
Normal (2)
Unknown (3)
RBC
Clinically significant (1)
Not clinically significant (2)
WBC CSF result
WBC CSF:Please specify unit used for
measurement
WBC CSF:measurement not performed
Yes
No
WBC CSF:please specify why procedure was not
performed
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WBC CSF
Abnormal (1)
Normal (2)
Unknown (3)
WBC CSF
Clinically significant (1)
Not clinically significant (2)
Glucose CSF result
Glucose CSF:please specify unit used for
measurement
Glucose CSF:measurement not performed
Yes
No
Glucose CSF:please specify why procedure was
not performed
Glucose CSF
Abnormal (1)
Normal (2)
Unknown (3)
Glucose CSF
Clinically significant (1)
Not clinically significant (2)
Protein CSF result
Protein CSF:please specify unit used for
measurement
Protein CSF:measurement not performed
Yes
No
Protein CSF:please specify why procedure was
not performed
Protein CSF
Abnormal (1)
Normal (2)
Unknown (3)
Protein CSF
Clinically significant (1)
Not clinically significant (2)
Albumin clinical bands result
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Albumin clinical bands:please specify unit used
for measurement
Albumin clinical bands:measurement not
performed
Yes
No
Albumin clinical bands:please specify why
procedure was not performed
Albumin clinical bands
Abnormal (1)
Normal (2)
Unknown (3)
Albumin clinical bands
Clinically significant (1)
Not clinically significant (2)
Pregnancy Tests
Was a pregnancy test performed?
Yes (1)
No (2)
Not applicable (3)
Date of pregnancy test
Pregnancy test method
Blood (1)
Urine (2)
Pregnancy Test Result
positive (1)
negative (2)
not applicable (3)
Pregnancy Test not applicable,please specify
reason why
Post-Menopausal  (1)
Surgically sterile  (2)
Non-surgically sterile  (3)
Male (4)
Urinalysis Tests
Urinalysis clincally normal?
Yes
No
Albumin Urine result
Albumin Urine: please specify unit used for
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measurement
Albumin Urine:measurement not performed
Yes
No
Albumin Urine:please specify why procedure was
not performed
Albumin Urine
Abnormal (1)
Normal (2)
Unknown (3)
Albumin Urine
Clinically significant (1)
Not clinically significant (2)
Bacteria in urine result
Bacteria in urine:please specify unit used for
measurement
Bacteria in urine:measurement not performed
Yes
No
Bacteria in urine:please specify why procedure
was not performed
Bacteria in urine
Abnormal (1)
Normal (2)
Unknown (3)
Bacteria in urine
Clinically significant (1)
Not clinically significant (2)
Bilirubin in urine result
Bilirubin in urine:please specify unit used for
measurement
Bilirubin in urine:measurement not performed
Yes
No
Bilirubin in urine:please specify why procedure
was not performed
Bilirubin in urine
Abnormal (1)
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Normal (2)
Unknown (3)
Bilirubin in urine
Clinically significant (1)
Not clinically significant (2)
Blood in urine result
Blood in urine:please specify unit used for
measurement
Blood in urine:measurement not performed
Yes
No
Blood in urine:please specify why procedure was
not performed
Blood in urine
Abnormal (1)
Normal (2)
Unknown (3)
Blood in urine
Clinically significant (1)
Not clinically significant (2)
Calcium Oxalate Crystals result
Calcium Oxalate Crystals:please specify unit
used for measurement
Calcium Oxalate Crystals:measurement not
performed
Yes
No
Calcium Oxalate Crystals:please specify why
procedure was not performed
Calcium Oxalate Crystals
Abnormal (1)
Normal (2)
Unknown (3)
Calcium Oxalate Crystals
Clinically significant (1)
Not clinically significant (2)
Casts result
Casts:please specify unit used for measurement
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Casts:measurement not performed
Yes
No
Casts:please specify why procedure was not
performed
Casts
Abnormal (1)
Normal (2)
Unknown (3)
Casts
Clinically significant (1)
Not clinically significant (2)
Glucose Urine result
Glucose Urine:please specify unit used for
measurement
Glucose Urine:measurement not performed
Yes
No
Glucose Urine:please specify why procedure was
not performed
Glucose Urine
Abnormal (1)
Normal (2)
Unknown (3)
Glucose Urine
Clinically significant (1)
Not clinically significant (2)
Ketones Urine result
Ketones Urine:please specify unit used for
measurement
Ketones Urine:measurement not performed
Yes
No
Ketones Urine:please specify why procedure was
not performed
Ketones Urine
Abnormal (1)
Normal (2)
Unknown (3)
Ketones Urine
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Clinically significant (1)
Not clinically significant (2)
Leukocyte Esterase result
Leukocyte Esterase:please specify unit used for
measurement
Leukocyte Esterase:measurement not performed
Yes
No
Leukocyte Esterase:please specify why
procedure was not performed
Leukocyte Esterase
Abnormal (1)
Normal (2)
Unknown (3)
Leukocyte Esterase
Clinically significant (1)
Not clinically significant (2)
Nitrites result
Nitrite:please specify unit used for measurement
Nitrite:measurement not performed
Yes
No
Nitrite:please specify why procedure was not
performed
Nitrite
Abnormal (1)
Normal (2)
Unknown (3)
Nitrite
Clinically significant (1)
Not clinically significant (2)
pH Urine result
pH Urine:please specify unit used for
measurement
pH Urine:measurement not performed
Yes
No
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pH Urine:please specify why procedure was not
performed
pH Urine
Abnormal (1)
Normal (2)
Unknown (3)
pH Urine
Clinically significant (1)
Not clinically significant (2)
Protein Urine result
Protein Urine:please specify unit used for
measurement
Protein Urine:measurement not performed
Yes
No
Protein Urine:please specify why procedure was
not performed
Protein Urine
Abnormal (1)
Normal (2)
Unknown (3)
Protein Urine
Clinically significant (1)
Not clinically significant (2)
RBC Urine result
RBC Urine:please specify unit used for
measurement
RBC Urine:measurement not performed
Yes
No
RBC Urine:please specify why procedure was not
performed
RBC Urine
Abnormal (1)
Normal (2)
Unknown (3)
RBC Urine
Clinically significant (1)
Not clinically significant (2)
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Culture Urine result
Culture Urine:please specify unit used for
measurement
Culture Urine:measurement not performed
Yes
No
Culture Urine:please specify why procedure was
not performed
Culture Urine
Abnormal (1)
Normal (2)
Unknown (3)
Culture Urine
Clinically significant (1)
Not clinically significant (2)
Specific Gravity result
Specific Gravity:please specify unit used for
measurement
Specific Gravity:measurement not performed
Yes
No
Specific Gravity:please specify why procedure
was not performed
Specific Gravity
Abnormal (1)
Normal (2)
Unknown (3)
Specific Gravity
Clinically significant (1)
Not clinically significant (2)
Urobilinogen result
Urobilinogen:please specify unit used for
measurement
Urobilinogen:measurement not performed
Yes
No
Urobilinogen:please specify why procedure was
not performed
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Urobilinogen
Abnormal (1)
Normal (2)
Unknown (3)
Urobilinogen
Clinically significant (1)
Not clinically significant (2)
WBC Urine result
WBC Urine:please specify unit used for
measurement
WBC Urine:measurement not performed
Yes
No
WBC Urine:please specify why procedure was
not performed
WBC Urine
Abnormal (1)
Normal (2)
Unknown (3)
WBC Urine
Clinically significant (1)
Not clinically significant (2)
Urine Chemistry Tests
Creatinine Random Urine result
Creatinine Random Urine:please specify unit
used for measurement
Creatinine Random Urine:measurement not
performed
Yes
No
Creatinine Random Urine:please specify why
procedure was not performed
Creatinine Random Urine
Abnormal (1)
Normal (2)
Unknown (3)
Creatinine Random Urine
Clinically significant (1)
Not clinically significant (2)
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Estimated Glomerular Filtration Rate result
Estimated Glomerular Filtration Rate:please
specify unit used for measurement
Estimated Glomerular Filtration
Rate:measurement not performed
Yes
No
Estimated Glomerular Filtration Rate :please
specify why procedure was not performed
Estimated Glomerular Filtration Rate
Abnormal (1)
Normal (2)
Unknown (3)
Estimated Glomerular Filtration Rate
Clinically significant (1)
Not clinically significant (2)
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Eligibility Asthma NCT02031640
A Safety and Efficacy Study of Beclomethasone
Dipropionate Delivered Via Breath-Actuated Inhaler (BAI)
or Metered-Dose Inhaler (MDI) in Participants >=12 Years
Old With Persistent Asthma; ODM derived from:
https://clinicaltrials.gov/show/NCT02031640
All rights reserved. Please visit https://medical-data-
models.org/forms/14205
Eligibility Asthma NCT02031640
Inclusion Criteria
severity of disease: the patient has persistent
asthma, with a forced expiratory volume in 1
second (fev1) 40 percent - 85 percent of the
value predicted for age, height, sex, and race as
per the national health and nutrition examination
survey (nhanes iii) (hankinson et al 1999)
reference values at screening visit.*
Yes
No
current asthma therapy: the patient must be on a
stable dose of an inhaled corticosteroid (ics) of at
least 440 mcg/day of fluticasone propionate or
equivalent for a minimum of 4 weeks before
screening visit, or any inhaled corticosteroid/long-
acting beta2-agonist (ics/laba) combination for a
minimum of 4 weeks before the prescreening
visit.*
Yes
No
reversibility of disease: the patient has
demonstrated at least 12% reversibility of fev1
and at least 200 ml increase from baseline fev1
(patients age 18 and older) within 30 minutes
after 2-4 inhalations of albuterol/salbutamol
hydrofluoroalkane (hfa) mdi (90 mcg ex-actuator)
or equivalent at the screening visit*
>= 18
years
Yes
No
if female, the patient is currently not pregnant,
breast feeding, or attempting to become
pregnant.  if of childbearing potential, has a
negative serum pregnancy test and is willing to
commit to using a consistent and acceptable
method of birth control.*
Yes
No
other criteria apply, please contact the
investigator for more information*
Yes
No
Exclusion Criteria
the patient has a history of life-threatening
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asthma, defined for this protocol as an asthma
episode that required intubation and/or was
associated with hypercapnea, respiratory arrest,
or hypoxic seizures.*
Yes
No
the patient is pregnant or lactating, or plans to
become pregnant during the study period or for
30 days after the patient's last study-related visit
(for eligible patients only, if applicable). eligible
female patients unwilling to employ appropriate
contraceptive measures to ensure that pregnancy
will not occur during the study will be excluded.
any patient becoming pregnant during the study
will be withdrawn from the study.*
Yes
No
the patient has a known hypersensitivity to any
corticosteroid or any of the excipients in the study
drug or rescue medication formulation.*
Yes
No
the patient currently smokes or has a smoking
history of 10 pack-years or more (a pack-year is
defined as smoking 1 pack of cigarettes/day for 1
year).*
Yes
No
the patient has had an asthma exacerbation
requiring oral corticosteroids within 30 days
before the screening visit, or has had any
hospitalization for asthma within 2 months before
the screening visit.*
Yes
No
the patient has historical or current evidence of a
clinically significant disease. significant disease is
defined as any disease that in the medical
judgment of the investigator would put the safety
of the patient at risk through participation or that
could affect the efficacy or safety analysis if the
disease/condition worsened during the study.*
Yes
No
other criteria apply, please contact the
investigator for more information*
Yes
No
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Eligibility Acute Myocardial Infarction
NCT00669227
Intracoronary Stem Cell Therapy in Patients With Acute
Myocardial Infarction (SCAMI); ODM derived from:
https://clinicaltrials.gov/show/NCT00669227
All rights reserved. Please visit https://medical-data-
models.org/forms/14210
Eligibility Acute Myocardial Infarction
NCT00669227
Inclusion Criteria
acute myocardial infarction with time to
revascularization >6 hours from symptom start*
Yes
No
clear target vessel*
Yes
No
large myocardial infarction defined as: proximal
vessel occlusion, ck > 1000 u/l, myocardial scar
in magnetic resonance imaging > 10% of left
ventricular muscle mass*
Yes
No
potential prior thrombolysis*
Yes
No
written informed consent*
Yes
No
Exclusion Criteria
acute myocardial infarction with revascularization
within 6 hours after symptom start*
Yes
No
prior myocardial infarction*
Yes
No
no clear target vessel*
Yes
No
contraindication for magnetic resonance imaging
(e.g. pacemaker, icd)*
Yes
No
severely depressed left ventricular ejection
fraction (less than 20% in magnetic resonance
imaging)*
Yes
No
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prior hematologic disease*
Yes
No
prior chemotherapy*
Yes
No
prior stem cell transplantation*
Yes
No
prior treatment with g-csf*
Yes
No
known alteration of the bone marrow by alcohol
or drugs, e.g. agranulocytosis*
Yes
No
local infection of puncture sites*
Yes
No
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Eligibility Acute Myocardial Infarction
NCT01175018
Anakinra to Prevent Adverse Post-infarction Remodeling
(2); ODM derived from:
https://clinicaltrials.gov/show/NCT01175018
All rights reserved. Please visit https://medical-data-
models.org/forms/14211
Eligibility Acute Myocardial Infarction
NCT01175018
Inclusion Criteria
patients with stemi will be asked to enroll
according to the following   inclusion criteria:*
Yes
No
age > 18 years*
>= 0
<= 120
years
Yes
No
acute (<12 h) onset of chest pain associated with
st segment elevation (>2 mm) in 2 or more
anatomically contiguous leads at ecg,*
Yes
No
successful primary percutaneous coronary
intervention*
Yes
No
Exclusion Criteria
inability to give informed consent*
Yes
No
unsuccessful revascularization procedure*
Yes
No
hemodynamic instability including hypotension*
Yes
No
prior q-wave ami*
Yes
No
end-stage congestive heart failure (aha/acc class
c-d, new york heart association iv), severe left
ventricular dysfunction (ef<20%)*
Yes
No
severe valvular heart disease*
Yes
No
pregnancy, dye allergy or contraindications to
cardiac angiography and/or magnetic resonance
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imaging, coagulopathy (inr>1.5 or platelet
count<50000/mm3),*
Yes
No
recent (<14 days) use of anti-inflammatory drugs
(not including nsaids)*
Yes
No
chronic inflammatory disease (including but not
limited to rheumatoid arthritis, systemic lupus
erythematosus), and malignancy or any
comorbidity limiting survival or conditions
predicting inability to complete the study.*
Yes
No
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Eligibility Acute on Chronic Hepatic Failure
NCT01698723
A Trial of Ribavirin in Patients With ACLF Due to Hepatitis E
Virus; ODM derived from:
https://clinicaltrials.gov/show/NCT01698723
All rights reserved. Please visit https://medical-data-
models.org/forms/14212
Eligibility Acute on Chronic Hepatic
Failure NCT01698723
Inclusion Criteria
all aclf due to hev*
Yes
No
consent to participate in trial and collection of
blood*
Yes
No
Exclusion Criteria
pregnant and nursing mothers*
Yes
No
severe anemia*
Yes
No
other etiologies of aclf (eg. alcohol, drugs,
reactivation of hepatitis b and hepatitis c, variceal
bleeding, surgical intervention and sepsis)*
Yes
No
hepatocellular carcinoma (hcc)*
Yes
No
hepatorenal syndrome (hrs) at admission*
Yes
No
presence of life threatening cardiovascular,
respiratory and neurological disease*
Yes
No
acquired immunodeficiency syndrome*
Yes
No
patients with hemoglobinopathies (e.g.,
thalassemia major, sickle-cell anemia)*
Yes
No
refusal to provide consent to participate in the
study*
Yes
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No
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Eligibility Acute Promyelocytic Leukemia
NCT00408278
Treatment of Newly Diagnosed Patients With Acute
Promyelocytic Leukemia (PETHEMA LPA 2005); ODM
derived from: https://clinicaltrials.gov/show/NCT00408278
All rights reserved. Please visit https://medical-data-
models.org/forms/14213
Eligibility Acute Promyelocytic
Leukemia NCT00408278
Inclusion Criteria
age ≤ 75 years*
Yes
No
ecog ≤ 3*
Yes
No
morphologic diagnosis of lpa (fab m3 or variant
m3). those cases without typical morphology but
with pml-rarα reordering also must be including.*
Yes
No
genetic diagnosis: t (15; 17) demonstrated by
cariotipo conventional, fish, pml-rarα*
Yes
No
reordering detected by rt-pcr or a pattern
microspeckled demonstrated with antibody anti-
pml (positive pgm3). obvious, it will be had the
result of these tests once initiated the treatment
on the basis of a suspicion diagnoses
morphologic*
Yes
No
Exclusion Criteria
age >75 years (the treatment with this protocol
can be considered individually)*
Yes
No
absence of pml-rare reordering*
Yes
No
to have received previously some type of
treatment for lpa, including chemotherapy or
retinoides. the previous treatment with corticoids,
hidroxiurea or leucoaféresis is not reason for
exclusion.*
Yes
No
to have received chemotherapy or x-ray for the
treatment of a disease vitiates previous*
Yes
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No
associate neoplasia*
Yes
No
serious psychiatric disease*
Yes
No
HIV+*
Yes
No
contraindication to receive intensive
chemotherapy, specially antraciclinas.*
Yes
No
Serum creatinine ≥ 2,5 mg/dl (≥ 250 μmol/l).*
Yes
No
Bilirubin, fosfatasa alkaline, or got > 3 times the
normal limit*
Yes
No
Positive pregnancy test*
Yes
No
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Eligibility Acute Promyelocytic Leukemia
NCT00504764
Treatment of Relapsed Promyelocytic Leukemia With
Arsenic Trioxide (ATO); ODM derived from:
https://clinicaltrials.gov/show/NCT00504764
All rights reserved. Please visit https://medical-data-
models.org/forms/14214
Eligibility Acute Promyelocytic
Leukemia NCT00504764
Inclusion Criteria
ecog ≤ 3*
Yes
No
patients in first or subsequent hematological or
molecular relapse of apl*
Yes
No
persistence of a positive pcr (positive pcr after 3
consolidation cycles of first line therapy).*
Yes
No
diagnostic measures confirmation of relapse by
rt-pcr of pml/rara, cytogenetics, fish or positive
pgm3.*
Yes
No
age over 18 years (no upper age limit)*
Yes
No
informed consent of the patient*
Yes
No
Exclusion Criteria
ecog 4status (ECOG):*
Yes
No
heart failure nyha grade iii and iv*
Yes
No
renal or hepatic failure who grade ³iii*
Yes
No
HIV+*
Yes
No
psychological dysfunction*
Yes
No
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associated active neoplasia*
Yes
No
pregnancy*
Yes
No
arsenic hypersensibility*
Yes
No
qtc-interval prolonged over 460 msec before
therapy (normal electrolytes, no other drugs
prolonging the qt-interval)*
Yes
No
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Eligibility Alcoholic Hepatitis NCT01768715
Liver Transplantation in Alcoholic Hepatitis; ODM derived
from: https://clinicaltrials.gov/show/NCT01768715
All rights reserved. Please visit https://medical-data-
models.org/forms/14215
Eligibility Alcoholic Hepatitis
NCT01768715
Inclusion Criteria
diagnosis of alcoholic hepatitis (liver biopsy will
be advisable).*
Yes
No
first episode of clinical decompensation of
alcoholic liver disease (defined as jaundice,
variceal bleeding, ascites or portal-systemic
encephalopathy).*
Yes
No
absence of a high risk of alcoholic recidivism
(according to de gottardi, et al).*
Yes
No
severe alcoholic hepatitis (abic score > 6.71)*
Yes
No
Informed Consent*
Yes
No
Exclusion Criteria
age over 65 years*
Yes
No
hepatitis b or c or hiv infections*
Yes
No
uncontrolled bacterial infection*
Yes
No
other liver diseases, such as alpha-1-antitrypsin
deficiency, primary biliary cirrhosis, ...*
Yes
No
morbid obesity (bmi > 35 kg/m2)*
Yes
No
major uncontrolled psychiatric disease*
Yes
No
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drug addiction (excluding tobacco) in the last two
years.*
Yes
No
absence of informed consent*
Yes
No
acute-on-chronic liver disease*
Yes
No
paracetamol consumption over 10 grams in the
last week.*
Yes
No
criteria for liver transplantation*
Yes
No
absence of response to steroid therapy  (lille
score ≥ 0.45 7 days after initiation of steroid
therapy).*
Yes
No
adequate social and familiar environment*
Yes
No
complete agreement in the medical staff about
the candidate to transplantation*
Yes
No
absence of bacterial or fungal infection*
Yes
No
2 / 2
Eligibility Alcoholic Hepatitis NCT01768715
Eligibility Asthma NCT02040766
A Safety and Efficacy Study of Beclomethasone
Dipropionate Delivered Via Breath-Actuated Inhaler (BAI)
or Metered-Dose Inhaler (MDI) in Participants Ages 5-11
Years Old With Persistent Asthma; ODM derived from:
https://clinicaltrials.gov/show/NCT02040766
All rights reserved. Please visit https://medical-data-
models.org/forms/14216
Eligibility Asthma NCT02040766
Inclusion Criteria
written informed consent*
Yes
No
asthma diagnosis: the patient has a diagnosis of
asthma as defined by the national institute of
health (nih). the asthma diagnosis has been
present for a minimum of 3 months and has been
stable (defined as no exacerbations and no
changes in medication) for at least 30 days
before screening visit*
Yes
No
severity of disease: the patient has persistent
asthma, with a forced expiratory volume in 1
second (fev1) 40 percent to 90 percent of the
value predicted for age, height, and sex at
screening visit (sv)*
Yes
No
current asthma therapy: the patient is currently
being treated with 1 of the following:  1) a stable
daily dosage of an inhaled corticosteroid (ics) in
the range of 88-176 mcg/day of fluticasone
propionate (or equivalent) for a minimum of 4
weeks (28 days) before screening visit  2) a
stable daily dosage of non-corticosteroid therapy
3) a daily dose of ics plus a long-acting beta2-
agonist (laba) (at a dose less than or equivalent
to fluticasone propionate 100 mcg/salmeterol 50
mcg twice daily)*
Yes
No
reversibility of disease: the patient has
demonstrated at least 12% reversibility of fev1
within 30 minutes after 2-4 inhalations of
albuterol/salbutamol hydrofluoroalkane (hfa) mdi
(90 mcg ex-actuator) or equivalent at screening
visit or on retesting.*
Yes
No
other criteria apply, please contact the
investigator for more information*
Yes
No
Exclusion Criteria
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the patient has a history of life-threatening
asthma, defined for this protocol as an asthma
episode that required intubation and/or was
associated with hypercapnia, respiratory arrest,
or hypoxic seizures.*
Yes
No
the patient is pregnant or lactating, or plans to
become pregnant during the study period or for
30 days after the patient's last study-related visit
(for eligible patients only, if applicable). any
patient becoming pregnant during the study will
be withdrawn from the study.*
Yes
No
the patient has a known hypersensitivity to any
corticosteroid or any of the excipients in the study
drug or rescue medication formulation.*
Yes
No
the patient has used tobacco products within the
past year (eg, cigarettes, cigars, chewing
tobacco, or pipe tobacco, as applicable).*
Yes
No
the patient has had an asthma exacerbation
requiring oral corticosteroids within 30 days
before screening visit, or has had any
hospitalization for asthma within 2 months before
screening visit.*
Yes
No
the patient has historical or current evidence of a
clinically significant disease. significant disease is
defined as any disease that in the medical
judgment of the investigator would put the safety
of the patient at risk through participation or that
could affect the efficacy or safety analysis if the
disease/condition worsened during the study.*
Yes
No
other criteria apply, please contact the
investigator for more information*
Yes
No
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Eligibility Hepatitis C, Chronic
NCT00122629
Triple Therapy With Peg-Interferon Alfa-2b/Ribavirin Plus
Amantadine Compared to Standard Peg-Interferon Alfa-
2b/Ribavirin for Previous Hepatitis C Virus (HCV) Non
Responders; ODM derived from:
https://clinicaltrials.gov/show/NCT00122629
All rights reserved. Please visit https://medical-data-
models.org/forms/14217
Eligibility Hepatitis C, Chronic
NCT00122629
Inclusion Criteria
positive anti-hcv antibody test*
Yes
No
patients who did not respond to treatment with
standard interferon + ribavirin (hcv rna+ by pcr in
the last month of treatment)*
Yes
No
compensated liver disease*
Yes
No
neutrophil count over or equal to1000/mm3*
Yes
No
platelet count over or equal to 100 giga/l*
Yes
No
haemoglobin over or equal to 10g/dl*
Yes
No
patients had to have undergone a post-treatment
liver biopsy within a year, showing a metavir
histological score over or equal to a1f1, without
cirrhosis (fibrosis score below f4)*
Yes
No
alt over n and hcv rna+ at screening*
Yes
No
Exclusion Criteria
co-infection with hepatitis b or human
immunodeficiency virus*
Yes
No
any other cause of liver disease*
Yes
No
active drug abuse, active alcohol consumption
1 / 2
above 40g/day*
Yes
No
organ grafts*
Yes
No
presence of hepatocellular carcinoma*
Yes
No
cardiovascular, metabolic, renal, haematological,
neurological or psychiatric disease*
Yes
No
patients with previous amantadine use*
Yes
No
systemic immunosuppressive or antiviral
treatment during the last 24 weeks and those
with a history of interferon and/or ribavirin
intolerance*
Yes
No
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Eligibility HER-2 Positive Metastatic Breast
Cancer NCT00146042
UMCC 9901: Phase II Study of Tailored-Dose Docetaxel +
Trastuzumab in Her-2 Positive Metastatic Breast Cancer;
ODM derived from:
https://clinicaltrials.gov/show/NCT00146042
All rights reserved. Please visit https://medical-data-
models.org/forms/14218
Eligibility HER-2 Positive Metastatic
Breast Cancer NCT00146042
Inclusion Criteria
patients with biopsy proven, measurable
metastatic breast cancer.  patients with bone-
only, and/or effusion-only disease are excluded.*
Yes
No
her-2 neu positive by standard
immunohistochemical criteria (2+ positivity).*
Yes
No
no prior chemotherapy for distant metastatic
disease.*
Yes
No
prior paclitaxel in the adjuvant setting is allowed.*
Yes
No
karnofsky performance status equal to 70 or
greater.*
Yes
No
anc > 1500, hgb > 10, plt > 100.*
Yes
No
patients with some degree of hepatic dysfunction
and renal dysfunction are encouraged, in order to
evaluate the ability of the ermbt in tailoring dose
in these patient populations.*
Yes
No
Exclusion Criteria
age less than 18 years.*
Yes
No
allergy to erythromycin.*
Yes
No
previous treatment with docetaxel.  prior
paclitaxel is allowed.*
Yes
No
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grade > 2 peripheral neuropathy.*
Yes
No
no confounding factors present to provide
misinterpretation of data (i.e., concurrent
malignancy).*
Yes
No
patients who are pregnant or nursing will not be
eligible for this protocol.  women of childbearing
age who are not practicing reliable birth control
must have a documented negative serum hcg.*
Yes
No
patients who require concurrent treatment with
drugs which are known to induce or inhibit cyp3a
activity will be ineligible for the trial.  this list
includes the drugs midazolam, anti-mycotic
agents (ketoconazole and related compounds),
macrolide antibiotics (erythromycin and related
compounds), nifedipine, anti-seizure drugs, and
rifampin (induction).*
Yes
No
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Eligibility HER-2 Positive Metastatic Breast Cancer NCT00146042
Eligibility Asthma NCT02054130
Study to Evaluate the Efficacy and Safety of MEDI9929
(AMG 157) in Adult Subjects With Inadequately Controlled,
Severe Asthma; ODM derived from:
https://clinicaltrials.gov/show/NCT02054130
All rights reserved. Please visit https://medical-data-
models.org/forms/14225
Eligibility Asthma NCT02054130
Inclusion Criteria
age 18 through 75*
>= 18
<= 75
years
Yes
No
bmi between 18-40 kg/m2 and weight greater
than or equal 40 kg*
>= 18
<= 40
kg/m2
Yes
No
documented physician-diagnosed asthma  -
subjects must have received a physician-
prescribed asthma controller regimen with
medium- or high-dose ics plus laba -if on asthma
controller medications in addition to ics plus laba,
the dose of the other asthma controller
medications (leukotriene receptor inhibitors,
theophylline, secondary ics, lama, cromones, or
maintenance oral prednisone or equivalent up to
a maximum of 10 mg daily or 20 mg every other
day for the maintenance treatment of asthma)
must be stable. -subjects must have a
documented history of at least 2 asthma
exacerbation events or at least 1 severe asthma
exacerbation resulting in hospitalization within the
12 months prior to first study visit.*
Yes
No
Exclusion Criteria
diagnosis of vocal cord dysfunction, reactive
airways dysfunction syndrome, hyperventilation
and panic attacks, or other mimics of asthma.*
Yes
No
current smokers or subjects with a smoking
history of ≥ 10 pack years*
Yes
No
former smokers with < 10 pack years must have
stopped for at least 1 year to be eligible.*
Yes
No
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any concomitant respiratory disease that in the
opinion of the investigator and/or medical monitor
will interfere with the evaluation of the
investigational product or interpretation of subject
safety or study results (eg, chronic obstructive
pulmonary disease, cystic fibrosis, pulmonary
fibrosis, bronchiectasis, allergic
bronchopulmonary aspergillosis, churg-strauss
syndrome).*
Yes
No
evidence of active liver disease.*
Yes
No
history of cancer, except for basal cell carcinoma
or insitu carcinoma of the cervix treated with
apparent success with curative therapy or other
malignancies are eligible provided that curative
therapy was completed -known history of active
tuberculosis (tb)*
Yes
No
history of anaphylaxis to any biologic therapy*
Yes
No
positive medical history for hepatitis b or c*
Yes
No
subject with hiv or subject taking antiretroviral
medications, as determined by medical history
and/or subject's verbal report.*
Yes
No
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Eligibility Asthma NCT02054130
Eligibility Alzheimer Disease NCT00253214
Placebo-Controlled Evaluation of Galantamine in the
Treatment of Alzheimer's Disease: Safety and Efficacy of a
Controlled-Release Formulation; ODM derived from:
https://clinicaltrials.gov/show/NCT00253214
All rights reserved. Please visit https://medical-data-
models.org/forms/14226
Eligibility Alzheimer Disease
NCT00253214
Inclusion Criteria
outpatients with a diagnosis of mild-to-moderate
alzheimer's disease according to the national
institute of neurological and communicative
disorders and the alzheimer's disease and
related disorders association (nincds-adrda)
criteria (including patients living in residential
homes for the elderly or day patients)*
Yes
No
have a mini-mental status examination (mmse)
score of 10 - 24, and a score of at least 18 on the
cognitive portion of the alzheimer's disease
assessment scale (adas-cog-11) with an onset
between ages 40 and 90*
Yes
No
history of at least a 6 months of gradual and
progressive cognitive decline*
Yes
No
have a consistent informant to accompany the
patient on scheduled visits*
Yes
No
Exclusion Criteria
neurogenerative disorders such as parkinson's
disease*
Yes
No
cognitive impairment resulting from acute
cerebral trauma, cerebral damage due to a lack
of oxygen, vitamin deficiency, infections such as
meningitis or aids, significant endocrine or
metabolic disease, mental retardation or a brain
tumor*
Yes
No
dementia caused by small strokes or
cerebrovascular disease*
Yes
No
having epilepsy, significant psychiatric disease,
1 / 2
active peptic ulcer, clinically significant liver,
kidney or lung disorders, or heart disease*
Yes
No
females of child bearing potential without
adequate contraception*
Yes
No
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Eligibility Alzheimer Disease NCT00253214
Eligibility Alzheimer Disease NCT00255086
The Effect of Memantine on Brain Structure and Chemistry
in Alzheimer's Disease Patients; ODM derived from:
https://clinicaltrials.gov/show/NCT00255086
All rights reserved. Please visit https://medical-data-
models.org/forms/14227
Eligibility Alzheimer Disease
NCT00255086
Criteria
2. 50-95 years of age inclusive.*
Yes
No
3. mmse at screen and baseline 7-28 inclusive.*
Yes
No
4. conversant in english.*
Yes
No
5. caregiver/study partner willing to participate,
supervise the patient and be available for
administration of study medication.*
Yes
No
6. able to ingest oral medication.*
Yes
No
exclusion criteria:1. history of clinically significant
stroke without substantial recovery.*
Yes
No
2. neurological or medical conditions causing
significant disability independent of dementia.*
Yes
No
3. parkinson's disease.*
Yes
No
4. history in past two years of focal brain lesion,
head injury with loss of consciousness or dsm-iv
criteria for any major psychiatric disorder
including psychosis, major depression, bipolar
disorder, alcohol or substance abuse.*
Yes
No
5. dementia due to korsakoff's syndrome or
infectious diseases such as creutzfeldt-jakob
disease, herpes, encephalitis, or human
immunodeficiency virus.*
Yes
No
6. sensory impairment that would prevent subject
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from participating in or cooperating with the
protocol.*
Yes
No
7. significant clinical disorder or laboratory finding
that renders the subject unsuitable for receiving
an investigational drug including: clinically
significant or unstable hematologic, hepatic,
cardiovascular, pulmonary, gastrointestinal,
endocrine, metabolic, renal, or other systemic
disease or laboratory abnormality.*
Yes
No
8. clinical contraindication to the use of
memantine (e.g., hypersensitivity).*
Yes
No
9. history of seizure within past 5 years prior to
screening.*
Yes
No
10. platelet count < 100,000/mm3.*
Yes
No
11. history of claustrophobia*
Yes
No
12. presence of metallic implants such as
pacemakers, surgical aneurysm clips, or known
metal fragments embedded in the body*
Yes
No
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Eligibility Alzheimer Disease NCT00255086
Eligibility Alzheimer Disease NCT00285025
Study of the Effect of SR57667B in Patients With
Alzheimer's Disease; ODM derived from:
https://clinicaltrials.gov/show/NCT00285025
All rights reserved. Please visit https://medical-data-
models.org/forms/14228
Eligibility Alzheimer Disease
NCT00285025
Inclusion Criteria
male / female outpatients.*
Yes
No
age > 50 years at screening.*
Yes
No
dementia of alzheimer’s type (dsm-iv 290.0)
according to dsm-iv  criteria, probable ad
according to nincds-adrda  criteria, mini-mental
state examination  score > 12 and < 26.*
Yes
No
untreated or treated for a minimum of 6 months
before randomization with a stable dose of the
cholinesterase inhibitors*
Yes
No
generally healthy and ambulatory or ambulatory-
aided (i.e., walker or cane).*
Yes
No
presence of a reliable caregiver.*
Yes
No
patient, identified caregiver and, if applicable,
patient surrogate (primary relative, legal
guardian, medical proxy) have given their
informed written consent and are capable of
following study procedures*
Yes
No
Exclusion Criteria
any cause of dementia not due to alzheimer’s
disease, delusions, delirium, psychosis,
depression, or other significant psychiatric
disorder.*
Yes
No
treatment with any registered or putative
cognitive enhancer or disease modifier other than
donepezil, rivastigmine or galantamine.*
Yes
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No
females who are pregnant or breast-feeding.
females of child bearing potential
(premenopausal female biologically capable of
becoming pregnant) must have a confirmed
negative serum b–hcg pregnancy test at the
screening visit, and must use an acceptable
method of birth control.*
Yes
No
severe or unstable cardiovascular, respiratory,
renal, hematological, endocrinological,
neurological or other somatic disease.*
Yes
No
use of cyp3a4 strong  inhibitors*
Yes
No
evidence (detected by history, physical
examination and / or laboratory / ecg tests) of any
clinically significant or unstable medical disorder
that could interfere with the subject's participation
in the clinical trial; interfere with the absorption,
metabolism or excretion of the study medication;
or interfere with the evaluation of the study drug.
alterations of laboratory tests or ecg findings of
potential clinical significance.*
Yes
No
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Eligibility Alzheimer Disease NCT00285025
Eligibility Asthma NCT02054975
Vitamin D in Pediatric Asthma: a Randomized Controlled
Open-label Pilot Trial; ODM derived from:
https://clinicaltrials.gov/show/NCT02054975
All rights reserved. Please visit https://medical-data-
models.org/forms/14229
Eligibility Asthma NCT02054975
Inclusion Criteria
1. informed consent and assent signed and dated
before participation.*
Yes
No
2. male or female, ages 8 through 17 at baseline;
all races and ethnicities*
>= 8
<= 17
years
Yes
No
3. asthma and currently taking a prescribed daily
inhaled steroid asthma medication*
Yes
No
4. english-speaking with at least one english-
speaking parent*
Yes
No
5. vitamin d deficiency (<20 ng/ml)*
<= 19
ng/ml
Yes
No
6. compliant with attending at least 2/4 of their
last asthma-related scheduled clinic visits*
Yes
No
Exclusion Criteria
1. if female, pregnant, planning to become
pregnant, and/or sexually active and not using
reliable contraception*
Yes
No
2. unable to provide informed consent (mental
retardation, etc)*
Yes
No
3. current substance dependence (within the past
2 months)*
Yes
No
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4. known metabolic bone disease, including
rickets*
Yes
No
5. known malabsorption disease: crohn's,
ulcerative colitis, celiac sprue*
Yes
No
6. bmi>40*
>= 41
Yes
No
7. has begun new treatment with vitamin d (>600
iu/day) within the past month*
Yes
No
8. treatment with prednisone or other oral or iv
steroid within the past 4 weeks*
Yes
No
9. taking mineral oil or thiazide diuretics on a
daily basis*
Yes
No
10. acute or chronic liver, renal, endocrine,
neurologic, infectious, autoimmune, cardiac,
pulmonary, gastrointestinal, hematologic,
metabolic disorder or any other disorder, per
study physician judgment.*
Yes
No
11. severe treatment noncompliance documented
in medical record or by managing provider
report.*
Yes
No
our definition of a highly effective method of birth
control is consistent with ich guidance for industry
m3 nonclinical safety studies for the conduct of
human clinical trials for pharmaceuticals (april
1997) when used consistently and correctly, such
as implants, injectables, oral contraceptives,
some intrauterine devices (iuds), sexual
abstinence, or a vasectomized partner. subjects
will also be reminded to use condoms to prevent
sexually transmitted diseases and as a second
method toward birth control.*
Yes
No
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Eligibility Asthma NCT02054975
Eligibility Alzheimer Disease NCT00287248
Assess 123-I IMPY and SPECT Imaging as a Tool to
Detect _-Amyloid in the Brain; ODM derived from:
https://clinicaltrials.gov/show/NCT00287248
All rights reserved. Please visit https://medical-data-
models.org/forms/14231
Eligibility Alzheimer Disease
NCT00287248
Inclusion Criteria
the participant is 50 years or older.*
Yes
No
written informed consent is obtained.*
Yes
No
participants have a clinical diagnosis of
alzheimer's disease based on national institute of
neurological and communicative disorders and
stroke/alzheimer's disease and related disorders
association (nincds/adra) criteria.*
Yes
No
mini-mental status exam score > 16 and < 25.*
Yes
No
patients have a diagnosis of probable ad for < 3
years prior to screening.*
Yes
No
Exclusion Criteria
the subject has signs or symptoms of another
neurodegenerative disease including parkinson's
disease, diffuse lewy body dementia, or history of
significant cerebrovascular disease.*
Yes
No
subjects with an iodine allergy.*
Yes
No
the subject has a clinically significant clinical
laboratory value and/or medical or psychiatric
illness.*
Yes
No
the subject has any disorder that may interfere
with drug absorption distribution, metabolism, or
excretion (including gastrointestinal surgery).*
Yes
No
the subject has evidence of clinically significant
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thyroid disease, gastrointestinal, cardiovascular,
hepatic, renal, hematologic, neoplastic,
endocrine, neurologic, immunodeficiency,
pulmonary, or other medical or psychiatric
disorder.*
Yes
No
the subject has received an investigational drug
within 60 days before the screening visit.*
Yes
No
pregnancy*
Yes
No
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Eligibility Alzheimer Disease NCT00287248
Eligibility Alzheimer Disease NCT00322036
Global Efficacy Study of MPC-7869 to Treat Patients With
Alzheimer's; ODM derived from:
https://clinicaltrials.gov/show/NCT00322036
All rights reserved. Please visit https://medical-data-
models.org/forms/14233
Eligibility Alzheimer Disease
NCT00322036
Inclusion Criteria
1. have had a diagnosis of probable alzheimer's
disease*
Yes
No
2. men or women ages greater than or equal to
55 years and living in the community at the time
of enrollment (ie, not living in a rest home or
nursing care facility).*
Yes
No
3. signed the subject informed consent form (icf)
and is willing and able to participate for the
duration of the study.*
Yes
No
4. ability to read and understand english, dutch,
danish, flemish, french, german, italian, spanish
or swedish to ensure compliance with cognitive
testing and study visit procedures.*
Yes
No
5. at least 6 years of education, or sufficient work
history to exclude mental retardation.*
Yes
No
6. female subjects must be surgically sterile or
postmenopausal for > 1 year.*
Yes
No
7. adequate vision and hearing to participate in
study assessments.*
Yes
No
8. subjects must have a reliable caregiver who
can read, understand and speak same
language.*
Yes
No
Exclusion Criteria
1. current evidence of other causes of dementia..
.*
Yes
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No
2. history of, or evidence of, active malignancy,
except for basal cell carcinoma or squamous cell
carcinoma of the skin, within the 24 months prior
to entry.  men with prostate cancer may be
enrolled at the discretion of the sponsor.*
Yes
No
3. use of any investigational therapy within 30
days, or 5 half-lives, whichever is longer, and/or
use of ad immunotherapy prior to screening.*
Yes
No
4. major surgery and related complications not
resolved within 12 weeks prior to day 1.*
Yes
No
5. previous participation in an mpc-7869 clinical
study.*
Yes
No
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Eligibility Alzheimer Disease NCT00322036
NINDS CDE Tissue Based Marker
Amyotrophic Lateral Sclerosis
NINDS Common Data Elements (Tissue Based Marker
Amyotrophic Lateral Sclerosis) Used from the National
Institute of Neurological Disorders and Stroke Common
Data Elements
(https://www.commondataelements.ninds.nih.gov/)
References: Grinnon ST, Miller K, Marler JR, Lu Y, Stout A,
Odenkirchen J, Kunitz S. National Institute of Neurological
Disorders and Stroke Common Data Element Project -
approach and methods. Clin Trials. 2012;9(3):322-9.
All rights reserved. Please visit https://medical-data-
models.org/forms/14234
Tissue Based Marker
Tissue Based Marker
Study-ID
Study site name
Subject ID
Was a muscle biopsy done?
Yes (1)
No (2)
Unknown (3)
If muscle biopsy was done, was the limb which
the biopsy was taken from, affected clinically?
Yes
No
If yes, specify how the limb was clinically affected
Indicate the results of the electromyography
(EMG)
Normal (1)
Abnormal (2)
Was skin biopsy performed?
Yes (1)
No (2)
Unknown (3)
If skin biopsy was done what site was it collected
from
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Eligibility Alzheimer Disease NCT00385684
Low-Dose Opiate Therapy for Discomfort in Dementia (L-
DOT); ODM derived from:
https://clinicaltrials.gov/show/NCT00385684
All rights reserved. Please visit https://medical-data-
models.org/forms/14235
Eligibility Alzheimer Disease
NCT00385684
Inclusion Criteria
55 years of age or older;*
Yes
No
must have a diagnosis of dementia;*
Yes
No
advanced stage of dementia demonstrated by a
score of 6 or greater on the functional
assessment staging (fast) scale;*
Yes
No
unable to report pain in a reliable and consistent
manner;*
Yes
No
have a painad score of at least 2 on two
consecutive assessments (separated by at least
two days) or an average painad score of at least
2 on three consecutive assessments each
separated by at least two days;*
Yes
No
the patient must have at least one medical
condition associated with pain recorded on the
cprs problem list.*
Yes
No
Exclusion Criteria
the existence of an effective analgesia treatment
regimen;*
Yes
No
pain treatment related to angina or pain judged to
be related to angina;*
Yes
No
current pain treatment with opiates that cannot, in
the opinion of the attending physician, be
discontinued without placing the patient at risk for
increased pain or opiate withdrawal;*
Yes
No
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current pain treatment with tramadol that cannot,
in the opinion of the attending physician, be
discontinued;*
Yes
No
presence of necessary drug therapy that is
incompatible with or has potential for clinically
significant drug interaction with either
hydrocodone or acetaminophen;*
Yes
No
a history of allergy, hypersensitivity, or intolerance
to either hydrocodone or acetaminophen;*
Yes
No
constipation refractory to current treatment
measures or a condition that would make
constipation dangerous for the patient in the
opinion of the attending physician;*
Yes
No
the presence of liver disease, hepatic
encephalopathy, or clinically significant elevation
of liver function tests (lfts), as determined by the
attending physician;*
Yes
No
the presence of renal failure, clinically significant
renal insufficiency, or clinically significant
elevations of serum bun or creatinine levels, as
determined by the attending physician; or*
Yes
No
evidence, based on assessment by a geriatrician,
that the apparent behavioral manifestations of
discomfort are better explained by another
problem (e.g., fever, infection, dehydration,
delirium, psychosis)*
Yes
No
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Eligibility Alzheimer Disease NCT00385684
Eligibility Alzheimer Disease NCT00480467
Study Evaluating the Safety, Tolerability, Pharmacokinetics,
and Pharmacodynamics of SAM-315 in Healthy Japanese
Males; ODM derived from:
https://clinicaltrials.gov/show/NCT00480467
All rights reserved. Please visit https://medical-data-
models.org/forms/14236
Eligibility Alzheimer Disease
NCT00480467
Inclusion Criteria
men aged 20 to 45 years (inclusive) at the time of
getting informed consent.*
Yes
No
body mass index (bmi) in the range of 18.5 to
25.0 kg/m2 and body weight≥50 kg (bmi =
[weight (kg)]/[height (m)]2).*
Yes
No
healthy as determined by the investigator on the
basis of medical history, physical examination,
clinical laboratory test results, vital signs, and
digital 12-lead electrocardiogram (ecg). alanine
aminotransferase (alt), aspartate
aminotransferase (ast) and creatinine levels must
be within the upper limit of normal for eligibility.*
Yes
No
Exclusion Criteria
any significant cardiovascular, hepatic, renal,
respiratory, gastrointestinal, endocrine,
immunologic, dermatologic, hematologic,
neurologic, or psychiatric disease.*
Yes
No
any clinically important deviation from normal
limits in physical examination, vital signs, digital
12-lead ecgs, or clinical laboratory test results.*
Yes
No
consumption of any caffeine-containing products
(eg, coffee, tea, chocolate, or cola) or alcoholic
beverages is prohibited from 48 hours and
consumption of grapefruit or a grapefruit-
containing products is prohibited from 72 hours
before study day 1.*
Yes
No
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Eligibility Alzheimer Disease NCT00481520
Study Evaluating the Safety,Tolerability, PK and PD of
SAM-531 in the Subjects With Mild to Moderate
Alzheimer's Disease; ODM derived from:
https://clinicaltrials.gov/show/NCT00481520
All rights reserved. Please visit https://medical-data-
models.org/forms/14237
Eligibility Alzheimer Disease
NCT00481520
Inclusion Criteria
1. signed and dated written informed consent
obtained from the subject or the subject`s legally
authorized representative (lar) or next of kin (if
applicable), in accordance with the local
regulations.  the subject`s caregiver must also
consent to participate in the study.*
Yes
No
2. diagnosis of probable alzheimer's disease
according to national institute of neurological and
communicative disorders and stroke-alzheimer's
disease and related disorders association
(nincds-adrda) criteria.*
Yes
No
3. men and postmenopausal or surgically sterile
women aged from 50 to 90 inclusive.
postmenopausal women must have had 12
months of spontaneous amenorrhea.  surgically
sterile women are defined as having a
hysterectomy, bilateral ovariectomy
[oophorectomy], or bilateral tubal ligation.  men
who are sexually active will need to agree to use
a form of contraception that is satisfactory as per
the investigator.*
Yes
No
4. able to participate in all scheduled evaluations
with a high probability of completing all required
procedures and neuropsychological tests.*
Yes
No
Exclusion Criteria
1. significant neurological disease other than
alzheimer's disease, which may affect cognition
(eg, epilepsy, parkinson disease).*
Yes
No
2. current diagnosis of a major depressive
disorder or other major psychiatric symptom
according to the criteria of diagnostic and
statistical manual of mental disorders, fourth
edition text version (dsm-iv-tr).*
Yes
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No
3. current clinically significant systemic illness,
which is likely to deteriorate or affect the subject's
safety, influence cognitive assessment or ability
to complete the study.*
Yes
No
4. any clinically important deviation from normal
limits in physical and neurological examination,
vital signs, on electrocardiogram (ecg) or clinical
laboratory test results that could compromise the
study or be detrimental to the subject.*
Yes
No
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Eligibility Alzheimer Disease NCT00481520
Eligibility Asthma NCT02061280
Use of Mobile Devices and the Internet to Streamline an
Asthma Clinical Trial; ODM derived from:
https://clinicaltrials.gov/show/NCT02061280
All rights reserved. Please visit https://medical-data-
models.org/forms/14239
Eligibility Asthma NCT02061280
Inclusion Criteria
age 12-17 years*
>= 12
<= 17
years
Yes
No
physician diagnosed asthma (without any other
co-morbid pulmonary disease) that is well-
controlled on medium dose inhaled corticosteroid
and long-acting β2-agonist given twice daily
[advair diskus (fluticasone propionate/salmeterol)
250/50mcg; advair hfa (hydrofluoroalkane)
(fluticasone propionate/salmeterol
hydrofluoroalkane) 115/21mcg; symbicort
(budesonide/formoterol) 160/4.5mcg; dulera
(mometasone/formoterol) 100/4.5mcg] based on
an act score > 20, and the absence of
unscheduled visits or use of rescue prednisone
for 4 weeks prior to enrollment*
Yes
No
pre-bronchodilator forced expiratory volume in the
first second > 70 percent predicted*
>= 71
%
Yes
No
< 10 pack/year history of tobacco use and
abstinence for at least 1 year*
<= 9
pack/years
Yes
No
Exclusion Criteria
chronic oral steroid therapy*
Yes
No
hospitalization or urgent care visit within 4 weeks
of the screening visit*
Yes
No
near fatal asthma within 2 years of enrollment or
high risk of near fatal or fatal asthma 125-127*
Yes
No
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women who are pregnant or lactating*
Yes
No
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Eligibility Asthma NCT02061280
Eligibility Asthma NCT00163319
Efficacy of Ciclesonide and Fluticasone Propionate in Adult
Patients With Moderate and Severe Persistent Asthma (18
to 75 y) (BY9010/IT-101); ODM derived from:
https://clinicaltrials.gov/show/NCT00163319
All rights reserved. Please visit https://medical-data-
models.org/forms/14241
Eligibility Asthma NCT00163319
Criteria
written informed consent*
Yes
No
history of bronchial asthma for at least 6 months*
Yes
No
pre-treatment with cfc-beclomethasone
dipropionate (cfc-bdp) ≥ 1000 mcg/day or
equivalent and a long-acting beta agonist (laba)
either in free or fixed combination*
Yes
No
fev1 ≥ 80% of predicted*
Yes
No
Exclusion criteria
concomitant severe diseases or diseases which
are contraindications for the use of inhaled
steroids or contraindications for the use of labas*
Yes
No
copd*
Yes
No
smoking with ≥10 pack-years*
Yes
No
pregnancy*
Yes
No
intention to become pregnant during the course
of the study*
Yes
No
breast feeding*
Yes
No
lack of safe contraception*
Yes
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No
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Eligibility Asthma NCT00163319
Eligibility Asthma NCT00163345
Efficacy of Ciclesonide on Small Airways in Patients With
Stable Asthma (18 to 60 y) (BY9010/M1-131); ODM
derived from: https://clinicaltrials.gov/show/NCT00163345
All rights reserved. Please visit https://medical-data-
models.org/forms/14242
Eligibility Asthma NCT00163345
Criteria
written informed consent*
Yes
No
history of bronchial asthma*
Yes
No
fev1 more than or equal to 60% of predicted*
Yes
No
stable asthma*
Yes
No
patients who are in good health with the
exception of asthma*
Yes
No
Exclusion criteria
concomitant severe diseases, diseases expected
to interfere with the outcome of the study, or
diseases which are contraindications for the use
of ics*
Yes
No
copd (i.e. chronic bronchitis or emphysema)
and/or other relevant lung diseases causing
alternating impairment in lung function*
Yes
No
use of ics 4 weeks before entry into the baseline
period*
Yes
No
pregnancy*
Yes
No
intention to become pregnant during the course
of the study*
Yes
No
breast feeding*
Yes
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No
lack of safe contraception*
Yes
No
use of other drugs not allowed*
Yes
No
current smokers and ex-smokers with more than
or equal to 10 pack-years*
Yes
No
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Eligibility Asthma NCT00163345
Eligibility Asthma NCT00163358
Efficacy of Ciclesonide vs Fixed Combination of
Fluticasone Propionate/Salmeterol vs Placebo in Patients
With Mild Persistent Asthma (12 to 75 y) (BY9010/M1-132);
ODM derived from:
https://clinicaltrials.gov/show/NCT00163358
All rights reserved. Please visit https://medical-data-
models.org/forms/14244
Eligibility Asthma NCT00163358
Criteria
clinical diagnosis of mild persistent asthma*
Yes
No
pre-treatment with sabas only*
Yes
No
fev1 ≥80% predicted*
Yes
No
good health with the exception of asthma*
Yes
No
Exclusion criteria
concomitant severe diseases or diseases which
are contraindications for the use of inhaled
steroids*
Yes
No
copd (chronic bronchitis or emphysema) and/or
other relevant lung diseases causing alternating
impairment in pulmonary function*
Yes
No
pregnancy*
Yes
No
intention to become pregnant during the course
of the study*
Yes
No
breast feeding*
Yes
No
lack of safe contraception*
Yes
No
current smokers ≥10 pack-years and ex-smokers
with ≥10 pack-years*
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Yes
No
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Eligibility Asthma NCT00163358
Eligibility Asthma NCT00163436
Efficacy and Safety of Ciclesonide Administered With or
Without Different Spacers in Patients With Asthma (12 to
75 y) (BY9010/M1-145); ODM derived from:
https://clinicaltrials.gov/show/NCT00163436
All rights reserved. Please visit https://medical-data-
models.org/forms/14245
Eligibility Asthma NCT00163436
Criteria
written informed consent*
Yes
No
history of persistent bronchial asthma for at least
6 months*
Yes
No
good health with the exception of asthma*
Yes
No
Exclusion criteria
concomitant severe diseases or diseases which
are contraindications for the use of inhaled
steroids*
Yes
No
smoking history with ≥10 cigarette pack years*
Yes
No
pregnancy*
Yes
No
intention to become pregnant*
Yes
No
breast feeding*
Yes
No
lack of safe contraception*
Yes
No
previous enrolment into the current study*
Yes
No
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Eligibility Asthma NCT00163371
Effects of Inhaled Ciclesonide Versus Fluticasone
Propionate Versus Placebo on Lower Leg Growth in
Prepubertal Children With Mild Persistent Asthma (6 to 12
y) (BY9010/M1-208); ODM derived from:
https://clinicaltrials.gov/show/NCT00163371
All rights reserved. Please visit https://medical-data-
models.org/forms/14247
Eligibility Asthma NCT00163371
Criteria
written informed consent by the patient's
parent(s) or legal guardian(s) and by the patient,
if capable*
Yes
No
prepubertal stage*
Yes
No
good health with the exception of asthma*
Yes
No
history of asthma for at least 6 months*
Yes
No
currently using rescue medication only*
Yes
No
Exclusion criteria
childbearing potential (beyond menarche)*
Yes
No
concurrent diseases or conditions which may
subsequently affect growth*
Yes
No
copd or relevant lung diseases causing
alternating impairment in lung function*
Yes
No
concomitant severe diseases or diseases which
are contraindications for the use of inhaled
steroids*
Yes
No
history of life-threatening asthma*
Yes
No
current smoking*
Yes
No
1 / 1
Eligibility Asthma NCT00163423
Efficacy of Ciclesonide Versus Fluticasone Propionate in
Patients With Mild to Moderate Asthma (12 to 75 y)
(BY9010/M1-142); ODM derived from:
https://clinicaltrials.gov/show/NCT00163423
All rights reserved. Please visit https://medical-data-
models.org/forms/14248
Eligibility Asthma NCT00163423
Criteria
outpatients*
Yes
No
written informed consent*
Yes
No
history of bronchial asthma for at least 6 months*
Yes
No
good health with the exception of asthma*
Yes
No
treated with inhaled steroids with a maximum
daily constant dosage of 250 mcg fluticasone
propionate or equivalent*
Yes
No
fev1 80 - 105% of predicted*
Yes
No
Exclusion criteria
concomitant severe diseases or diseases which
are contraindications for the use of inhaled
steroids*
Yes
No
copd (i.e. chronic bronchitis or emphysema)
and/or other relevant lung diseases causing
alternating impairment in lung function*
Yes
No
current smoking with more than 10 pack-years*
Yes
No
previous smoking with more than 10 pack-years*
Yes
No
use of systemic steroids 4 weeks (injectable
depot steroids 6 weeks) before entry into the
baseline period, or more than 2 times*
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Yes
No
pregnancy*
Yes
No
intention to become pregnant during the course
of the study*
Yes
No
breast feeding*
Yes
No
lack of safe contraception*
Yes
No
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Eligibility Asthma NCT00163410
Efficacy of Ciclesonide Inhaled Once Daily Versus
Fluticasone Propionate Inhaled Twice Daily in Children With
Asthma (4 to 15 y) (BY9010/M1-205); ODM derived from:
https://clinicaltrials.gov/show/NCT00163410
All rights reserved. Please visit https://medical-data-
models.org/forms/14249
Eligibility Asthma NCT00163410
Criteria
history of persistent bronchial asthma for at least
6 months*
Yes
No
fev1 50-90% of predicted*
Yes
No
Exclusion criteria
concomitant severe diseases or diseases which
are contraindications for the use of inhaled
steroids*
Yes
No
copd (chronic bronchitis or emphysema) and/or
other relevant lung diseases causing alternating
impairment in lung function*
Yes
No
respiratory tract infection or asthma exacerbation
within the last 30 days prior to entry into the
study*
Yes
No
history of life-threatening asthma*
Yes
No
premature birth*
Yes
No
current smoking*
Yes
No
smoking history with either equal or more than 10
pack-years*
Yes
No
pregnancy*
Yes
No
intention to become pregnant during the course
1 / 2
of the study*
Yes
No
breast feeding*
Yes
No
lack of safe contraception*
Yes
No
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Eligibility Asthma NCT00163410
Eligibility High Blood Pressure
NCT00140907
ALLOGRAFT, A Study to Evaluate the Renal Protective
Effects of Losartan (0954-222)(COMPLETED); ODM
derived from: https://clinicaltrials.gov/show/NCT00140907
All rights reserved. Please visit https://medical-data-
models.org/forms/14250
Eligibility High Blood Pressure
NCT00140907
Inclusion Criteria
patients with end stage chronic renal failure, four
to eight week after receiving  a first or a second
renal transplant from a dead donor. in the case of
a second transplant the survival of the first graft
must has been 6 month or more*
Yes
No
patients must have a serum creatinine * 2 at visit
1 and 2.  results must be within 25% of each
other. the baseline period may be extended until
four  more weeks to obtain an additional serum
creatinine if one of the first two serum creatinine
results do not qualify*
Yes
No
patients with hypertension must have a sitting
blood pressure  < 200/110 mmhg at the time of
randomization*
Yes
No
normotensive patients must have a sitting systolic
blood pressure >100 mmhg at  the time of
randomization*
Yes
No
Exclusion Criteria
hyperimmunized patients at the transplant time or
in the previous 6 month, with a pra of 50 %*
Yes
No
patients with evidence of advanced liver disease*
Yes
No
serum potassium <3.5 or >5.5 meq/l*
Yes
No
history of allergy to losartan*
Yes
No
other factors which may affect participation (e.g.,
significant concurrent or life limiting disease such
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as cancer in the last five year except skin
neoplasias, mental or legal incapacitation, drug
or alcohol abuse within the last 2 years, extensive
travel planned in the next 3 years, investigative
drug trial within the last 4 weeks)*
Yes
No
patients with disseminated or localized active
infectious disease, at the time of transplant*
Yes
No
acute graft rejection in the grade iii of banff
classification*
Yes
No
patients with double-transplant (reno-pancreatic)*
Yes
No
patients with heart failure or history of myocardial
infarction requiring ace inhibitor or aiia therapies.
presence or known history of hemodynamically
significant obstructive valvular disease or
hypertrophic cardiomyopathy*
Yes
No
renal graft artery stenosis. an eco-doppler test
must be performed in order to exclude a graft
artery stenosis*
Yes
No
pregnant or nursing women*
Yes
No
chronic use of nsaids*
Yes
No
major psychotropic agents such as
phenothiazines are not permitted, use of lithium
is not permitted*
Yes
No
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Eligibility Asthma NCT02062463
Study to Evaluate the Mastery of Inhaler Technique for
Budesonide Formoterol (BF) SPIROMAX® as Compared to
SYMBICORT® TURBOHALER® as Treatment for Adult
Patients With Asthma; ODM derived from:
https://clinicaltrials.gov/show/NCT02062463
All rights reserved. Please visit https://medical-data-
models.org/forms/14253
Eligibility Asthma NCT02062463
Inclusion Criteria
written informed consent signed and dated by the
adult patient before conducting any study related
procedures.*
Yes
No
the patient is a man or woman 18 through 75
years of age as of the screening visit.*
>= 18
<= 75
years
Yes
No
the patient has a diagnosis of asthma in
accordance with global initiative for asthma (gina)
criteria as evidenced by a united kingdom (uk)
quality outcome framework approved read code
(uk diagnostic coding system).*
Yes
No
the patient is receiving step 3 or 4 therapy for
asthma as defined by the british thoracic society
(bts) guidelines (daily doses of bdp-equivalent
inhaled corticosteroid (ics) ≥800 mcg to 2000
mcg as part of fixed or free combinations with
long-acting beta-agonists (laba).*
Yes
No
if patient is a female of childbearing potential
(postmenarche or less than 2 years post-
menopausal or not surgically sterile) the patient
must be willing to commit to using a medically
accepted method of contraception for the
duration of study and 30 days after discontinuing
study drug.*
Yes
No
the patient, as judged by the investigator, must be
willing and able to understand risks and benefits
of study participation to give informed consent
and to comply with all study requirements as
specified in this protocol for the entire duration of
their study participation.*
Yes
No
the patient is spiromax and turbohaler naïve (no
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use of a turbohaler device in the last 6 months,
minimizing carryover from prior device use).*
Yes
No
if female, the patient must have a negative urine
pregnancy test. o other criteria apply, please
contact the investigator for additional information*
Yes
No
Exclusion Criteria
the patient has any clinically significant
uncontrolled medical condition (treated or
untreated) that, in the judgment of the
investigator, will cause participation in the study
to be detrimental to the patient.*
Yes
No
the patient has participated in a teva sponsored
clinical study with bf spiromax in the last 6
months.*
Yes
No
the patient is a pregnant, attempting to become
pregnant, or breast feeding. (any woman
becoming pregnant during the study will be
withdrawn from the study.)*
Yes
No
the patient has used a clinical trial investigational
drug within 1 month before the screening visit.*
Yes
No
the patient has an ongoing asthma exacerbation
or has received ocs and/or antibiotics for a lower
respiratory condition (proxy measure for
identifying an asthma exacerbation and/or lower
respiratory infection, suggestive of altered
inspiratory capabilities) in the 2 weeks preceding
visit*
Yes
No
the patient is currently receiving any ocs
(including long or short courses).*
Yes
No
the patient has a significant chronic lower
respiratory tract disease other than asthma eg
chronic obstructive pulmonary disease (copd),
cystic fibrosis or interstitial lung disease.
conditions that are not predominant, such as
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minor degrees of bronchiectasis, are not a reason
for exclusion.*
Yes
No
the patient has a known allergy or severe
sensitivity to the constituents of the study drugs
(spiromax or turbohaler) eg, to lactose or to milk
protein.*
Yes
No
other criteria apply, please contact the
investigator for additional information*
Yes
No
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Eligibility Asthma NCT00163384
Effectiveness of Ciclesonide Versus Budesonide in Patients
With Asthma (18 to 75 y) (BY9010/M1-136); ODM derived
from: https://clinicaltrials.gov/show/NCT00163384
All rights reserved. Please visit https://medical-data-
models.org/forms/14257
Eligibility Asthma NCT00163384
Criteria
during the last 4 weeks prior to baseline,
treatment with an inhaled steroid (dosage: up to
250 mcg fluticasone propionate or equivalent)*
Yes
No
fev1 80 - 105% of predicted*
Yes
No
healthy with the exception of asthma*
Yes
No
written informed consent has been obtained*
Yes
No
outpatients*
Yes
No
patients who have a history of persistent
bronchial asthma for at least 6 months*
Yes
No
Exclusion criteria
concomitant severe diseases or diseases which
are contraindications for the use of inhaled
steroids*
Yes
No
concomitant copd (chronic bronchitis or
emphysema) and/or other relevant lung diseases
causing alternating impairment in lung function*
Yes
No
an asthma exacerbation or an infection of the
lower airways prior to entry into the baseline
period*
Yes
No
pregnancy*
Yes
No
intention to become pregnant during the course
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of the study*
Yes
No
breast feeding*
Yes
No
lack of safe contraception*
Yes
No
patient is current smoker with 10 or more pack-
years*
Yes
No
patient is ex-smoker with 10 or more pack-years*
Yes
No
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Eligibility Asthma NCT00163384
Eligibility Asthma NCT00163397
Efficacy of Ciclesonide Versus Budesonide in Patients With
Asthma (18 to 75 y) (BY9010/M1-137); ODM derived from:
https://clinicaltrials.gov/show/NCT00163397
All rights reserved. Please visit https://medical-data-
models.org/forms/14258
Eligibility Asthma NCT00163397
Criteria
during the last 4 weeks prior to baseline,
treatment with an inhaled steroid (dosage: up to
250 mcg fluticasone propionate or equivalent)*
Yes
No
fev1 80 - 105% of predicted*
Yes
No
healthy with the exception of asthma*
Yes
No
written informed consent has been obtained*
Yes
No
outpatients*
Yes
No
patients who have a history of persistent
bronchial asthma for at least 6 months*
Yes
No
Exclusion criteria
concomitant severe diseases or diseases which
are contraindications for the use of inhaled
steroids*
Yes
No
concomitant copd (i.e. chronic bronchitis or
emphysema) and/or other relevant lung diseases
causing alternating impairment in lung function*
Yes
No
an asthma exacerbation or an infection of the
lower airways prior to entry into the baseline
period*
Yes
No
pregnancy*
Yes
No
intention to become pregnant during the course
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of the study*
Yes
No
breast feeding*
Yes
No
lack of safe contraception*
Yes
No
patient is current smoker with 10 or more pack-
years*
Yes
No
patient is ex-smoker with 10 or more pack-years*
Yes
No
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Eligibility Asthma NCT02065258
Breathing Versus Aerobic Exercises on Asthma Control;
ODM derived from:
https://clinicaltrials.gov/show/NCT02065258
All rights reserved. Please visit https://medical-data-
models.org/forms/14259
Eligibility Asthma NCT02065258
Inclusion Criteria
asthma moderate and severe*
Yes
No
asthma will diagnosed (global initiative for asthma
-gina)*
Yes
No
body mass index <35 kg/ m2*
<= 34
kg/m2
Yes
No
sedentary*
Yes
No
medical treatment, for at least 6 months*
Yes
No
clinically stable*
Yes
No
Exclusion Criteria
smokers*
Yes
No
cardiac disease*
Yes
No
chronic obstructive pulmonary disease*
Yes
No
active cancer*
Yes
No
pregnant*
Yes
No
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Eligibility Asthma NCT02075255
Efficacy and Safety Study of Benralizumab to Reduce OCS
Use in Patients With Uncontrolled Asthma on High Dose
Inhaled Corticosteroid Plus LABA and Chronic OCS
Therapy; ODM derived from:
https://clinicaltrials.gov/show/NCT02075255
All rights reserved. Please visit https://medical-data-
models.org/forms/14266
Eligibility Asthma NCT02075255
Inclusion Criteria
1. provision of informed consent prior to any
study specific procedures*
Yes
No
2. female and male aged from 18 to 75 years,
inclusively*
>= 18
<= 75
years
Yes
No
3. history of physician-diagnosed asthma
requiring treatment with medium dose ics  and a
laba*
Yes
No
4. elevated level of peripheral blood eosinophil*
Yes
No
5. documented treatment with high-dose ics and
laba for at least 6 months prior to visit 1*
Yes
No
6. chronic oral prednisone or prednisolone
therapy for at least 6 continuous months directly
preceding visit 1, and on a stable dose for at least
one month prior to visit 1*
Yes
No
7. patients with documented failures of ocs
reduction within 6 months prior to visit 1 will not
be required to proceed through the dose
optimization phase during run-in.*
Yes
No
8. morning pre-bronchodilator (pre-bd) fev1 of
<80 percent predicted*
<= 79
%
Yes
No
9. either documented post bronchodilator (post-
bd) reversibility of ≥ 12% and ≥ 200 ml in fev1 or
pc20 fev1*
Yes
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No
10. at least 1 documented asthma exacerbation
in the previous 12 months prior to the date
informed consent is obtained*
Yes
No
11. optimized ocs dose reached at least 2 weeks
prior to randomization*
Yes
No
12. additional asthma controller medication must
not have been initiated during run-in period*
Yes
No
13. at least 70 percent compliance with ocs use*
>= 70
%
Yes
No
14. at least 70 percent compliance with usual
asthma controller ics-laba*
>= 70
%
Yes
No
15. minimum 70 percent (i.e. 10 of 14 days)
compliance with asthma daily diary (morning and
evening diary)*
>= 70
%
Yes
No
16. no documented asthma exacerbations during
the screening/dose optimization period*
Yes
No
Exclusion Criteria
1. clinically important pulmonary disease other
than asthma or ever been diagnosed with
pulmonary or systemic disease, other than
asthma, that are associated with elevated
peripheral eosinophil counts.*
Yes
No
2. any disorder, including, but not limited to,
cardiovascular, gastrointestinal, hepatic, renal,
neurological, musculoskeletal, infectious,
endocrine, metabolic, haematological,
psychiatric, or major physical impairment that is
not stable in the opinion of the investigator and
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could:*
Yes
No
affect the safety of the patient throughout the
study*
Yes
No
influence the findings of the studies or their
interpretations*
Yes
No
impede the patient's ability to complete the entire
duration of study*
Yes
No
3. acute upper or lower respiratory infections
requiring antibiotics or antiviral medication within
30 days prior to the date informed consent is
obtained or during the screening/run-in period*
Yes
No
4. any clinically significant abnormal findings in
physical examination, vital signs, haematology,
clinical chemistry, or urinalysis during
screening/run-in period, which in the opinion of
the investigator, may put the patient at risk
because of his/her participation in the study, or
may influence the results of the study, or the
patient's ability to complete entire duration of the
study*
Yes
No
5. history of life-threatening asthma*
Yes
No
6. asthma control reached at an ocs dose of
≤5mg during run-in/ocs optimization phase*
Yes
No
7. qualifies for 3 consecutive dose reductions at
visits 2-4 and continues to meet ocs dose
reduction criteria at visit 5*
Yes
No
8. receipt of oral dexamethasone as the
maintenance oral steroid controller for asthma
symptoms*
Yes
No
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Eligibility Asthma NCT02075151
Bronchial Thermoplasty: Mechanism of Action and Defining
Asthma Phenotype; ODM derived from:
https://clinicaltrials.gov/show/NCT02075151
All rights reserved. Please visit https://medical-data-
models.org/forms/14267
Eligibility Asthma NCT02075151
Inclusion Criteria
males and females between 21-65 years of age*
>= 21
<= 65
years
Yes
No
poorly controlled severe persistent asthma (act
score < 20) despite high-dose inhaled steroids
(>500 mcg fluticasone/day or >800 mcg
budesonide/day) in combination with inhaled
long-acting beta-2 agonist and/or anticholinergic
agent. other drugs include leukotriene modifiers,
omalizumab (if used for at least 1 year prior), and
oral corticosteroids 10mg/day or less*
Yes
No
stopped smoking for > 1 year and <10 pack-
years*
>= 2
years
Yes
No
stable maintenance asthma medications for 4
weeks*
Yes
No
pre-bronchodilator fev1 >60 percent predicted*
>= 61
%
Yes
No
Exclusion Criteria
males and females <21 and >65 years of age*
Yes
No
presence of pacemaker, internal defibrillator, or
other implantable electronic devices*
Yes
No
patients previously treated with bronchial
thermoplasty (bt)*
Yes
No
use of immunosuppressant (excluding oral
steroids)*
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Yes
No
increased risk of adverse events associated with
bronchoscopy or anesthesia (including
pregnancy, uncontrolled coronary artery disease,
acute or chronic renal failure, and uncontrolled
hypertension)*
Yes
No
inability to cease antiplatelet or anticoagulant
therapy prior to procedure*
Yes
No
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Eligibility Asthma NCT02075151
Eligibility Asthma NCT02083029
Vagal Nerve Stimulation Assessed by the Diving Reflex: An
Investigation Into Mechanisms of Asthma Death; ODM
derived from: https://clinicaltrials.gov/show/NCT02083029
All rights reserved. Please visit https://medical-data-
models.org/forms/14269
Eligibility Asthma NCT02083029
Inclusion Criteria
syncopal asthmatics: asthmatic patients with a
history of syncope during asthma exacerbations*
Yes
No
normal asthmatics: asthmatic patients on bts step
3 treatment (laba/ics) with no history of syncope
during exacerbations*
Yes
No
normal volunteers: no history of airways disease
or syncope*
Yes
No
Exclusion Criteria
• subjects who are pregnant, or have pacemakers
in situ are excluded from this study.*
Yes
No
subjects with significant cardiovascular disease
are excluded from this study.*
Yes
No
those who are non-english speakers and special
groups (i.e. mentally ill, children under 16 years
of age, and those suffering from dementia) will be
excluded.*
Yes
No
no test will be performed on any subject during
an acute worsening of asthma or upper airway
infection. if the subject has had an upper airway
infection in the last three weeks.  another
appointment should be made unless the subject
is unwilling to come back, in which case testing
should continue. the number of days elapsed
since the end of the airway infection should be
recorded.*
Yes
No
if the subject smokes: citric acid or capsaicin
challenges must be performed at least one hour
after the last cigarette has been smoked.*
Yes
No
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subjects taking beta-blockers and calcium
antagonists will be excluded from this study. no
beta agonists should be taken within 6 hours of
starting this study.*
Yes
No
if the subject has taken any over the counter (otc)
cough mixture within the last twelve hours: if the
subject is willing to come back another time for
challenge testing, another appointment should be
made. if the subject is unwilling to return another
time, testing should proceed and the medication
used recorded.*
Yes
No
if the subject has had any food or drink products
containing caffeine or menthol within the last
hour. if the subject is unwilling to wait for 1 hour
before starting the test, the subject should return
another time. if the subject is unwilling to return
another time, testing should proceed and the
medication used recorded.*
Yes
No
if the participant is currently involved in research,
or within 3 months of participation in any type of
research, they will be excluded from this study.*
Yes
No
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Eligibility Asthma NCT02086799
Thyroid Hormones Treatment in Asthma Exacerbation;
ODM derived from:
https://clinicaltrials.gov/show/NCT02086799
All rights reserved. Please visit https://medical-data-
models.org/forms/14271
Eligibility Asthma NCT02086799
Inclusion Criteria
18 years of age or older*
Yes
No
known asthma*
Yes
No
the exacerbation is defined as moderate or
severe.*
Yes
No
not currently enrolled as an active participant in
another clinical trial of a medical therapy or
device.*
Yes
No
the patient or first degree family relative (in cases
where the patient is intubated) has authorized
his/her consent to participate in this trial. the
patient will be asked to give his consent only after
initial bronchodilator therapy*
Yes
No
Exclusion Criteria
60 years of age or older*
Yes
No
known thyroid disorders*
Yes
No
subject where thyrotoxicosis is suspected*
Yes
No
known heart disease*
Yes
No
heart rate > 140*
Yes
No
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Eligibility Asthma NCT02087644
CYT003 in Patients With Mild to Moderate Allergic Asthma
Not Sufficiently Controlled on Inhaled Glucocorticosteroids;
ODM derived from:
https://clinicaltrials.gov/show/NCT02087644
All rights reserved. Please visit https://medical-data-
models.org/forms/14279
Eligibility Asthma NCT02087644
Inclusion Criteria
1. provide written informed consent.*
Yes
No
2. complete all protocol requirements.*
Yes
No
3. between 18 to 65 years of age.*
Yes
No
4. persistent allergic asthma patients*
Yes
No
5. forced expiratory volume in one second (fev1)
≥60 percent to ≤ 90 percent of predicted value*
Yes
No
6. reversibility of airway obstruction*
Yes
No
7. patients meeting the contraception
requirements*
Yes
No
8. at baseline: patients treated with ics and
insufficiently controlled*
Yes
No
9. blood eosinophil count above a certain level*
Yes
No
Exclusion Criteria
1. failure to meet at least 80 percent compliance
of use of the patient e-diary/ peak expiratory flow
(pef) meter (am3 device) at the baseline visit*
Yes
No
2. treatment or hospitalization for asthma
exacerbation within past 2 months*
Yes
No
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3. current use or use of systemic corticosteroids
within past 2 months*
Yes
No
4. current smokers.*
Yes
No
5. ex-smokers for less than 1 year, with a tobacco
smoking history of >10 pack years*
Yes
No
6. major surgery within 3 months prior to signing
the icf or anticipated during study*
Yes
No
7. presence or history of clinically relevant
cardiovascular, renal, pulmonary (e.g. copd),
endocrine, autoimmune, dermatological,
neurological, psychiatric, or ocular disease as
judged by the investigator.*
Yes
No
8. any malignancy within the previous 5 years*
Yes
No
9. presence of suspicious lymphadenopathy or
splenomegaly on physical examination.*
Yes
No
10. confirmed or suspected current infection with
human immunodeficiency virus (hiv), hepatitis b
virus (hbv), or hepatitis c virus (hcv).*
Yes
No
11. presence of active infectious disease as
judged by the investigator*
Yes
No
12. active autoimmune diseases or prior
diagnosis of autoimmune disease including but
not limited to rheumatoid arthritis, lupus and
ulcerative colitis.*
Yes
No
13. pregnancy (based on positive urine test at
screening visit) or lactation.*
Yes
No
2 / 3
Eligibility Asthma NCT02087644
14. female planning to become pregnant during
the study period.*
Yes
No
15. patients with any history of abuse of alcohol
or other recreational drugs.*
Yes
No
16. ongoing or planned specific immunotherapy
(sit) during the whole study period or sit
completed within the last 3 years.*
Yes
No
17. bmi >40*
Yes
No
18. use of investigational or approved
biologics/immune-modulators within the last 6
months.*
Yes
No
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Eligibility Asthma NCT02091648
A Pilot Stress Management Intervention Study for High
Risk Children With Asthma; ODM derived from:
https://clinicaltrials.gov/show/NCT02091648
All rights reserved. Please visit https://medical-data-
models.org/forms/14280
Eligibility Asthma NCT02091648
Inclusion Criteria
in grades 3 through 6 and attending one of the 5
participating public schools*
Yes
No
age 8 through 12 years*
Yes
No
qualify for the free or reduced cost school lunch
program in pennsylvania (families that receive
food stamps or have an annual income of <
$40,900).*
Yes
No
meets national heart lung and blood institute
(nhlbi, 2007) criteria for any asthma diagnosis
except mild, intermittent  asthma, as confirmed
by the study physician using nhlbi guidelines for
the diagnosis and management of asthma
(http://www.nhlbi.nih.gov/guidelines/asthma/asths
umm.pdf, page 40).*
Yes
No
has a parent or legal guardian who is willing to
participate in the study*
Yes
No
fluent in english (i.e., have commonly used
english in everyday speaking and reading for at
least 10 years)*
Yes
No
Exclusion Criteria
history of a chronic illness in addition to asthma
(determined by parent or guardian report)*
Yes
No
prescribed medications other than for asthma*
Yes
No
mental retardation or significant developmental
delay*
Yes
No
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inability to speak or understand english*
Yes
No
a diagnosis of mild, intermittent asthma as
determined using nhlbi (2007) criteria (see
above)*
Yes
No
age less then 8 years or greater than 12 years*
Yes
No
not in grades 3 through 6*
Yes
No
not qualifying for free or reduced cost school
lunches in pennsylvania*
Yes
No
no parent or legal guardian who is willing to
participate*
Yes
No
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Eligibility Asthma NCT02134028
Long-Term Safety Evaluation of Dupilumab in Patients With
Asthma (LIBERTY ASTHMA TRAVERSE); ODM derived
from: https://clinicaltrials.gov/show/NCT02134028
All rights reserved. Please visit https://medical-data-
models.org/forms/14281
Eligibility Asthma NCT02134028
Inclusion Criteria
eligible patients who have completed the entire
study duration of dri12544, or who completed the
treatment period in the other previous asthma
studies.*
Yes
No
Exclusion Criteria
patients who did not complete the dri12544 study
or the treatment period in other previous asthma
studies.*
Yes
No
patients who have experienced hypersensitivity
reactions to dupilumab which, in the opinion of
the investigator, could indicate that continued
treatment with dupilumab may present an
unreasonable risk for the patient.*
Yes
No
patients diagnosed with active parasitic infection;
suspected or at high risk of parasitic infection,
unless clinical and/or laboratory assessments
before enrollment have ruled out an active
infection.*
Yes
No
medical history of human immunodeficiency virus
(hiv) infection.*
Yes
No
known or suspected medical history of
immunosuppression, including history of invasive
opportunistic infections (eg, tuberculosis,
histoplasmosis, listeriosis, coccidioidomycosis,
pneumocystosis, aspergillosis) despite infection
resolution; or unusually frequent, recurrent or
prolonged infections, as per investigator
judgment.*
Yes
No
evidence of acute or chronic infection requiring
treatment with antibacterials, antivirals,
antifungals, antiparasitics or antiprotozoals within
4 weeks before visit 1; significant viral infections
within 4 weeks before visit 1 that may not have
received antiviral treatment (eg, influenza
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receiving only symptomatic treatment).*
Yes
No
patients with any event or laboratory abnormality
that, as per investigator judgment, would
adversely affect participation of the patient in this
study.*
Yes
No
patients who have traveled to parasitic endemic
area within 6 months prior to screening.*
Yes
No
for patients from dri12544 study, drug induced
liver injury related criteria at screening:*
Yes
No
underlying clinically significant hepatobiliary
disease or*
Yes
No
alanine aminotransferase (alt) >3 upper limit of
normal (uln).*
Yes
No
for patients from dri12544 study, abnormal lab
values at screening:*
Yes
No
creatine phosphokinase (cpk) >10 uln or*
Yes
No
platelets <100.000 cells/mm^3 or*
Yes
No
eosinophils >1500 cells/mm^3*
Yes
No
the above information is not intended to contain
all considerations relevant to a patient's potential
participation in a clinical trial.*
Yes
No
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Eligibility Asthma NCT02170883
EmPhAsIS: Empowering Pharmacists in Asthma
Management Through Interactive SMS; ODM derived from:
https://clinicaltrials.gov/show/NCT02170883
All rights reserved. Please visit https://medical-data-
models.org/forms/14297
Eligibility Asthma NCT02170883
Inclusion Criteria
individuals who fill a (incident or prevalent)
prescription for inhaled corticosteroids (either
monotherapy or in combination inhaler with long-
acting beta-agonists) who have been diagnosed
by a doctor as having asthma*
Yes
No
possessing a cell-phone with ability to
send/receive text messages*
Yes
No
residing in british columbia (bc), canada and
planning to reside in bc for the next 12 months*
Yes
No
registered with the medical services plan (msp,
the provincial insure of medically-required
services) in the past 12 months, and planning to
remain registered for the next 12 months*
Yes
No
designated pharmacy being the main drugstore
for patient*
Yes
No
not participating in another interventional study*
Yes
No
consent to participate in the study.*
Yes
No
Exclusion Criteria
unable to communicate in english*
Yes
No
under 14 years of age*
Yes
No
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Eligibility Asthma NCT02189616
Efficacy of Mobile Phone Short Message Service (SMS)
Reminder and Consultation on Asthma Control; ODM
derived from: https://clinicaltrials.gov/show/NCT02189616
All rights reserved. Please visit https://medical-data-
models.org/forms/14298
Eligibility Asthma NCT02189616
Inclusion Criteria
1. physician diagnosed uncontrolled or partly-
controlled asthma by global initiative for
asthma(gina) standard.*
Yes
No
2. at least 6 months asthma history.*
Yes
No
3. ownership of a mobile phone and currently
using the text messaging service.*
Yes
No
4. age between 18 and 65 years old.*
Yes
No
5. willingness to participate in this study.*
Yes
No
6. willing to sign the written informed consent to
take part in the study.*
Yes
No
Exclusion Criteria
1. inability to provide written informed consent or
to fill in the paper asthma diary.*
Yes
No
2. a history of smoking cigarettes for greater than
ten pack years.*
Yes
No
3. other current or a history of severe
comorbidity.*
Yes
No
4. being in other clinical trials.*
Yes
No
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Eligibility Asthma NCT02195284
To Study Device Attributes by Investigating Errors Made in
Use, Ease of Use and Preference Among Different Inhalers
in Subjects With Asthma; ODM derived from:
https://clinicaltrials.gov/show/NCT02195284
All rights reserved. Please visit https://medical-data-
models.org/forms/14299
Eligibility Asthma NCT02195284
Inclusion Criteria
informed consent: subject must give their signed
and dated written informed consent to participate;
subject understands and is willing, able, and
likely to comply with study procedures and
restrictions; subject must be able to read,
comprehend, and record information in dutch
and/or english*
Yes
No
age: >=18 years of age*
Yes
No
gender: male or female subjects.*
Yes
No
asthma diagnosis: a diagnosis of asthma as
defined by the national institutes of health.
comorbidities (rheumatoid arthritis or other
locomotor problems, visual impairment, and
depression or anxiety) will be documented as
relevant to inhaler use.*
Yes
No
asthma treatment: all subjects should be
currently receiving treatment for asthma.*
Yes
No
must be naive to using ellipta inhaler and at least
one other inhaler device.*
Yes
No
Exclusion Criteria
chronic obstructive pulmonary disease (copd):
subjects with a current diagnosis of copd only.*
Yes
No
contraindications: a history of allergy or
hypersensitivity to lactose/milk protein or
magnesium stearate or to any other excipient.*
Yes
No
subjects who are currently participating in
1 / 2
another randomised pharmacological
interventional trial.*
Yes
No
inability to read: in the opinion of the investigator,
any subject who is unable to read and/or would
not be able to complete a questionnaire and
understand verbal instructions*
Yes
No
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Eligibility Asthma NCT02197702
Vitamin D in Preschoolers With Viral-induced Asthma;
ODM derived from:
https://clinicaltrials.gov/show/NCT02197702
All rights reserved. Please visit https://medical-data-
models.org/forms/14302
Eligibility Asthma NCT02197702
Inclusion Criteria
age 1-5 years*
Yes
No
physician-diagnosed asthma as per the global
initiative for asthma (gina) guidelines*
Yes
No
urtis as the main asthma trigger (parental report)*
Yes
No
≥4 urtis in the past 12 months (parental report)*
Yes
No
≥1 asthma exacerbation requiring rescue oral
corticosteroids (ocs) in the past 6 months or ≥2 in
the past 12 months*
Yes
No
Exclusion Criteria
intake or intention to use more than 400 iu/day of
vitamin d supplement*
Yes
No
extreme prematurity (<28 weeks gestation)*
Yes
No
infants <12 months of age*
Yes
No
no vitamin d supplementation when breast-fed*
Yes
No
recent (<1 year) immigrants from a region at high
risk of rickets*
Yes
No
children with vitamin d restrictive diets e.g.
vegans*
Yes
No
other chronic respiratory disease (broncho-
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pulmonary dysplasia; cystic fibrosis)*
Yes
No
condition(s) that alter calcium or vitamin d
metabolism/absorption
(hypo/hyperparathyroidism, kidney/liver disease,
inflammatory bowel disease)*
Yes
No
medications that interfere with vitamin d
metabolism (anti-epileptics, diuretics, antacids,
anti-fungal drug)*
Yes
No
vitamin d supplementation >1000 iu/ day in last 3
months*
Yes
No
anticipated difficult follow-up (unable to attend
clinic visits; plan to leave the province).*
Yes
No
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Eligibility Asthma NCT02210806
Albuterol DPI (A006) Clinical Study-B3:Efficacy, Dose-
ranging and Safety Evaluation; ODM derived from:
https://clinicaltrials.gov/show/NCT02210806
All rights reserved. Please visit https://medical-data-
models.org/forms/14303
Eligibility Asthma NCT02210806
Inclusion Criteria
generally healthy, male and female adults, 18-55
years of age at screening*
Yes
No
with mild-to-moderate persistent asthma for at
least 6 months prior to screening, and having
used inhaled β-agonist(s) for asthma control*
Yes
No
demonstrating a screening baseline fev1 at 50.0 -
85.0 percent of predicted normal*
Yes
No
demonstrating a ≥ 15.0% airway reversibility in
fev1 within 30 min after inhaling 2 actuations of
proventil® mdi (180 mcg) at screening*
Yes
No
demonstrating peak inspiratory flow rate (pif)
within 80-150 l/min (after training), for at least 2
times consecutively with a maximum of 5
attempts*
Yes
No
demonstrating proficiency in the use of a dpi and
an mdi after training*
Yes
No
females of child-bearing potential must be non-
pregnant, non-lactating; both males and females
enrolled into the study must agree to practice a
clinically acceptable form of birth control
(including but not limited to, abstinence, double
barrier, etc)*
Yes
No
having properly consented to participate in the
trial*
Yes
No
Exclusion Criteria
a smoking history of ≥ 5 pack-years, or having
1 / 3
smoked within 6 months prior to screening*
Yes
No
upper respiratory tract infections or lower
respiratory tract infection within 6 weeks, prior to
screening*
Yes
No
asthma exacerbations that required emergency
care or hospitalized treatment, within 4 weeks
prior to screening*
Yes
No
any current or recent respiratory conditions that,
per investigator discretion, might significantly
affect pharmacodynamic response to the study
drugs, including cystic fibrosis, bronchiectasis,
tuberculosis, emphysema, and other significant
respiratory diseases besides asthma*
Yes
No
concurrent clinically significant cardiovascular
(e.g. hypertension and tachyarrhythmia and
bradyarrhythmia), hematological, renal,
neurologic, hepatic, endocrine, psychiatric,
malignant, or other illnesses that in the opinion of
the investigator could impact on the conduct,
safety and evaluation of the study*
Yes
No
known intolerance or hypersensitivity to any of
the ingredients of the study drug dpi or proventil®
hfa mdi (i.e., albuterol, sulfate, lactose, milk
protein, hfa-134a, oleic acid, and ethanol)*
Yes
No
baseline ecg at screening or visit 1 showing any
single or multiple premature ventricular
contractions (pvc)*
Yes
No
baseline ecg at screening or visit 1 with a
confirmed (through performing a second ecg) qtc
reading greater than 450ms*
Yes
No
use of prohibited drugs or failure to observe the
drug washout restrictions*
Yes
No
having been on other clinical drug/device studies
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in the last 30 days prior to screening.*
Yes
No
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Eligibility Asthma NCT02210806
Eligibility Asthma NCT02212483
Clinical Effectiveness and Economical Impact of Medical
Indoor Environment Counselors Visiting Homes of Asthma
Patients; ODM derived from:
https://clinicaltrials.gov/show/NCT02212483
All rights reserved. Please visit https://medical-data-
models.org/forms/14308
Eligibility Asthma NCT02212483
Inclusion Criteria
age greater than or equal to 6 years and less
than 45 (<45 years),*
Yes
No
patients with an eligible control level of asthma,*
Yes
No
sensitization to one or more allergens
demonstrated during the last 24 months with
prick tests (papules with a diameter > 3 mm
compared to a negative control or > 50 percent of
positive control) and/or specific ige detection (>
0.35 u/ml),*
Yes
No
patients > 15 years presenting with a reversibility
to ß2-agonists > 200 ml and/or > 12 percent
compared to the initial fev1 value (test performed
during the last 24 months) or patients ≥ 6 years
and  ≤ 15 years presenting with a reversibility to
ß2-agonists > 200 ml and/or > 12% compared to
the initial fev1 value (at least once in the life)
and/or a positive metacholine challenge (at least
once in the life),*
Yes
No
patients sleeping > 6 nights per week in the same
house*
Yes
No
individuals affiliated to 1 of the 3 french social
security (for matching data from french social
security via sniiram system),*
Yes
No
only one patient per dwelling,*
Yes
No
patient oral consent (written attestation by
investigator)*
Yes
No
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Exclusion Criteria
chronic obstructive pulmonary disease (copd),*
Yes
No
identified occupational asthma,*
Yes
No
move within the 6 months before home
intervention or predicted during the first year of
inclusion,*
Yes
No
advices provided during the year before inclusion
during a home intervention of a miec*
Yes
No
smokers with a consumption of more than 10
years of 20 cigarettes/day,*
Yes
No
patients < 18 years for whom the parents (or legal
guardian) are opposed to the inclusion in ecenvir
study,*
Yes
No
major people being the object of a legal
protection (protection(saving) of justice,
guardianship, supervision(guardianship)) and
private persons of freedom*
Yes
No
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Eligibility Asthma NCT02227394
Study to Compare the Effects of Z7200 And Symbicort®
Turbohaler on Respiratory Imaging Parameters in
Asthmatic Patients; ODM derived from:
https://clinicaltrials.gov/show/NCT02227394
All rights reserved. Please visit https://medical-data-
models.org/forms/14309
Eligibility Asthma NCT02227394
Inclusion Criteria
1. male or female patient ≥ 18 years old.*
Yes
No
2. written informed consent obtained.*
Yes
No
3. patient with a documented diagnosis of asthma
according to the global initiative for asthma (gina)
guidelines*
Yes
No
4. patient with a co-operative attitude and ability
to correctly use the dpi.*
Yes
No
5. female patient of childbearing potential who
confirm that a reliable method of contraception
was used at least 14 days before visit 1 and will
continue to use a reliable method of
contraception during the study, or post-
menopausal women (at least 12 months of
amenorrhea)*
Yes
No
6. patient must be stable and treated in
accordance with the gina guidelines.*
Yes
No
7. patient must be a non-smoker or ex-smoker
who have stopped smoking at least 1 month prior
to visit 1 and has a smoking history of < 10 pack
years.*
Yes
No
8. patient must be able to understand and
complete the protocol requirements, instructions,
questionnaires and protocol-stated restrictions.*
Yes
No
Exclusion Criteria
1. pregnant or lactating female.*
Yes
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No
2. unstable patient who developed an asthma
exacerbation in the 4 weeks before screening.*
Yes
No
3. patient with upper or lower airways infection in
the 4 weeks before screening.*
Yes
No
4. patient unable to perform pulmonary function
testing.*
Yes
No
5. patients unable to withdraw fixed combination
or long acting bronchodilator inhalation products*
Yes
No
6. patient with an uncontrolled disease or any
condition that might, in the judgement of the
investigator, place the patient at undue risk or
potentially compromise the results or
interpretation of the study.*
Yes
No
7. patient with active lung cancer or any other
chronic disease with poor prognosis and*
Yes
No
/or affecting patient status.*
Yes
No
8. patient with allergy, sensitivity or intolerance to
study drugs and/ or study drug formulation
ingredients.*
Yes
No
9. patient unlikely to comply with the protocol or
unable to understand the nature, scope and
possible consequences of the study.*
Yes
No
10. patient who received systemic corticosteroids
within the last 4 weeks prior to visit*
Yes
No
11. patient who received any investigational new
drug within the last 4 weeks prior to visit 1 and is
participating in any clinical trial.*
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Yes
No
12. patient with a history of alcohol or substance
abuse that in the opinion of the investigator may
be of clinical significance*
Yes
No
13. patient with diagnosis of chronic obstructive
pulmonary disease (copd).*
Yes
No
14. patients who has a lactose intolerance or
history of allergy to milk proteins.*
Yes
No
15. patients treated with medications or herbal
medicines that are strong cytochrome p450 3a4
(cyp3a4) inhibitors (e.g., ritonavir, indinavir,
nelfinavir, saquinavir, atazanavir, ketoconazole,
itraconazole, voriconazole, fluconazole,
cyclosporine, mibefradil, nefazodone,
clarithromycin, telithromycin, troleandromycin,
norfloxacin, ciprofloxacin) or inducers (e.g.
phenobarbital, phenytoin, barbiturates,
carbamazepine, oxcarbazepine, rifabutin,
rifampin, st john's wort) within 2 weeks prior to
screening visit and during the study.*
Yes
No
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Eligibility Asthma NCT02230332
Alendronate to Prevent Loss of Bronchoprotection in
Asthma; ODM derived from:
https://clinicaltrials.gov/show/NCT02230332
All rights reserved. Please visit https://medical-data-
models.org/forms/14312
Eligibility Asthma NCT02230332
Inclusion Criteria
clinical history consistent with moderate asthma
for >1 year*
Yes
No
asthma is controlled with ics, with an fp dose ≤
1000mcg/day and >100mcg/day (or equivalent)*
Yes
No
able to perform reproducible spirometry
according to ats criteria*
Yes
No
baseline fev1 ≥ 50% of predicted and ≥1l.*
Yes
No
if fev1 <80%, a minimum 12% increase in fev1
post-bronchodilator or a mch pc20 ≤ 8 mg/ml*
Yes
No
if fev1 ≥80%, a mch pc20 ≤ 8 mg/ml*
Yes
No
salmeterol protected mch ≤ 16 mg/ml*
Yes
No
Exclusion Criteria
uncontrolled asthma, as suggested by an act
score <18 while on high-dose ics (fp daily dose
>500mcg or equivalent)*
Yes
No
non-ics controller medication or laba use within 4
weeks of study entry.*
Yes
No
contraindications to use of bisphosphonates:
history of intolerance to bisphosphonates, history
of esophageal ulcers, history of hematemesis,
uncontrolled gastro-esophageal reflux disease,
inability to stay erect for 30 minutes after oral
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drug, history of osteonecrosis of the jaw, dental
extraction or root canal in prior 8 weeks, or
anticipated during the study*
Yes
No
calculated gfr of less than 35 ml/min*
Yes
No
history of smoking (cigarettes, cigars, pipes,
marijuana or any other substances) within the
past 1 year, or > 10 pack-years total if ≥ 18 years
of age*
Yes
No
systemic corticosteroid treatment for any
condition within 4 weeks of enrollment at visit 1,
history of significant asthma exacerbation
requiring systemic corticosteroids within 4 weeks
of visit 1 or more than five courses of systemic
corticosteroids in the past year, history of a life-
threatening asthma exacerbation requiring
intubation, mechanical ventilation, or resulting in
a hypoxic seizure within the last 2 years*
Yes
No
history of a respiratory tract infection within 4
weeks of visit 1*
Yes
No
receiving hyposensitization therapy other than an
established maintenance regimen defined as a
continuous regimen for ≥ 3 months prior to
enrollment*
Yes
No
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Eligibility Juvenile Myelomonocytic
Leukemia NCT00167219
Stem Cell Transplant for Juvenile Myelomonocytic
Leukemia (JMML); ODM derived from:
https://clinicaltrials.gov/show/NCT00167219
All rights reserved. Please visit https://medical-data-
models.org/forms/14313
Eligibility Juvenile Myelomonocytic
Leukemia NCT00167219
Inclusion Criteria
patients must have a diagnosis of jmml and fulfill
these minimal criteria (international diagnostic
criteria for jmml):*
Yes
No
leukocytosis (> 13,000) with absolute
monocytosis (> 1,000)*
Yes
No
the presence of immature myeloid cells in the
peripheral blood*
Yes
No
less than 30% marrow blasts*
Yes
No
absence of t(9:22) or bcr-abl transcript*
Yes
No
adequate major organ function including:*
Yes
No
cardiac: ejection fraction > 45%*
Yes
No
hepatic: no clinical evidence of hepatic failure
(e.g. coagulopathy, ascites)*
Yes
No
karnofsky performance status > 70% or lansky
score > 50%*
Yes
No
creatinine must be < 2 x normal for age*
Yes
No
written informed consent.*
Yes
No
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Exclusion Criteria
active uncontrolled infection within one week of
hct.*
Yes
No
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Eligibility Kidney Disease NCT00001835
Oxaliplatin in Cancer Patients With Impaired Kidney
Function; ODM derived from:
https://clinicaltrials.gov/show/NCT00001835
All rights reserved. Please visit https://medical-data-
models.org/forms/14314
Eligibility Kidney Disease
NCT00001835
Criteria
patients with prior chemotherapy, radiation
therapy, hormonal therapy and immunotherapy
are allowed with the exception that patients
cannot have had prior treatment with oxaliplatin.*
Yes
No
patients greater than or equal to 18 years of age.*
Yes
No
patients must have an ecog performance status
less than or equal to 2 (karnofsky greater than or
equal to 60 percent) and a life expectancy of at
least 3 months.*
Yes
No
patients must have adequate organ and marrow
function which includes:*
Yes
No
leukocytes must be greater than or equal to
3,000/microliter.*
Yes
No
absolute neutrophil count  must be greater than
or equal to 1,500/microliter.*
Yes
No
platelet count must be greater than or equal to
100,000/microliter.*
Yes
No
total bilirubin within normal institutional limits.*
Yes
No
ast (sgot)/alt(sgpt) less than or equal to 1.5 times
the upper limit of normal.*
Yes
No
patients with no evidence of clinically significant
neuropathy.*
Yes
No
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women of child-bearing potential and men must
agree to use adequate contraception.*
Yes
No
patients must have the ability to understand and
the willingness to sign a written informed consent
document.*
Yes
No
patients who have had chemotherapy or
radiotherapy within 4 weeks prior to entering the
study, or within 6 weeks of prior platinum therapy
will be excluded.*
Yes
No
patients undergoing therapy with other
investigational agents will be excluded.*
Yes
No
patients with known brain metastases will be
excluded.*
Yes
No
patients with a history of an allergy to platinum
compounds will be excluded.*
Yes
No
patients with uncontrolled intercurrent illness
including but not limited to ongoing or active
infection, symptomatic congestive heart failure, or
unstable angina pectoris, or cardiac arrhythmia
will be excluded.*
Yes
No
women must not be pregnant or nursing.*
Yes
No
patients must not be hiv-positive or receiving anti-
retroviral therapy (haart).*
Yes
No
patients actively receiving renal dialysis
treatments while on the study will be excluded.*
Yes
No
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Eligibility Kidney Diseases NCT00309218
Steroid Withdrawal in Pediatric Renal Transplant Recipients
Under Cyclosporine (CyA) and Mycophenolate Mofetil
(MMF); ODM derived from:
https://clinicaltrials.gov/show/NCT00309218
All rights reserved. Please visit https://medical-data-
models.org/forms/14315
Eligibility Kidney Diseases
NCT00309218
Inclusion Criteria
age < 18.0 years*
Yes
No
bone age of boys < 15 years, of girls < 13 years*
Yes
No
patients 12-24 months after renal transplantation
with stable transplant function*
Yes
No
first or second kidney transplant, living or cadaver
kidney donation*
Yes
No
triple immunosuppression with cyclosporine
(cya), mmf, and daily steroids at study entry*
Yes
No
patients and parents, respectively, have given
their written consent after enlightenment
(informed consent)*
Yes
No
Exclusion Criteria
irreversible rejection of former transplant within 6
months*
Yes
No
highly reactive (> 80%) lymphocytotoxic
antibodies within 12 months prior to
transplantation*
Yes
No
anamnestically steroid-resistant rejection of
current transplant*
Yes
No
more than 2 acute rejection reactions prior to
study entry (i.e., in the first 12-24 months after
kidney transplantation) or 1 acute rejection
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reaction during the last 6 months before study
entry*
Yes
No
glomerular filtration rate (gfr) < 40 ml/min/1.73 m²
(schwartz formula) at study entry*
Yes
No
acute rejection reaction or unstable transplant
function (increase of serum creatinine > 20%)
during the last 6 months before study entry or
histologically confirmed chronic rejection
reaction*
Yes
No
suspected insufficient medication compliance*
Yes
No
patients receiving a basic immunosuppression
other than that prescribed in this protocol*
Yes
No
simultaneous therapy with growth hormone after
renal transplantation*
Yes
No
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Eligibility Knee Osteoarthritis
NCT01303666
Tidal Irrigation Versus Intra-articular Steroid Injection in the
Treatment of Knee Osteoarthritis; ODM derived from:
https://clinicaltrials.gov/show/NCT01303666
All rights reserved. Please visit https://medical-data-
models.org/forms/14316
Eligibility Knee Osteoarthritis
NCT01303666
Inclusion Criteria
clinical diagnosis of knee oa*
Yes
No
knee pain for most days of the prior month*
Yes
No
radiographic evidence consistent with knee oa*
Yes
No
aged between 40 and 90 years old*
Yes
No
Exclusion Criteria
symptomatic hip oa*
Yes
No
co-existent inflammatory or crystal arthritis*
Yes
No
prior knee surgery*
Yes
No
injury to the knee in the preceding 6 months*
Yes
No
any intra-articular injection in the preceding 3
months*
Yes
No
inability to provide informed consent*
Yes
No
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Eligibility Leukemia NCT00003700
Combination Chemotherapy in Treating Patients With
Untreated Acute Lymphoblastic Leukemia; ODM derived
from: https://clinicaltrials.gov/show/NCT00003700
All rights reserved. Please visit https://medical-data-
models.org/forms/14317
Eligibility Leukemia NCT00003700
Criteria
2. uncontrolled or severe cardiovascular
disease.*
Yes
No
3. history of pancreatitis or overt coagulopathy
(prior cerebrovascular accident or hemorrhage,
transient ischemic attack or deep venous
thrombosis).*
Yes
No
4. elevations in bilirubin, creatinine, or amylase
that may suggest impaired hepatic, renal, or
pancreatic function must be considered as
potentially serious obstacles for safe tolerance of
the therapy prescribed in this protocol.*
Yes
No
5. prior use of the agents administered in this
protocol for other non-malignant disease may
reduce the likelihood of beneficial outcome, and
should also be considered prior to enrolling
patients.*
Yes
No
6. treatment under this protocol would expose an
unborn child to significant risks.*
Yes
No
women and men of reproductive potential should
agree to use an effective means of birth control.*
Yes
No
7. unequivocal histologic diagnosis of acute
lymphoblastic leukemia (all), fab l1-or l2 or acute
undifferentiated leukemia (aul).*
Yes
No
8. age ≥ 15 years*
Yes
No
9. prior treatment: no prior treatment for
leukemia, with three permissible exceptions:*
Yes
No
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i. emergency leukapheresis; ii. emergency
treatment for hyperleukocytosis with hydroxyurea;
iii. cranial rt for cns leukostasis (one dose only).*
Yes
No
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Eligibility Leukemia NCT00003861
Diagnostic Study of Patients With Acute Lymphoblastic
Leukemia or Acute Promyelocytic Leukemia; ODM derived
from: https://clinicaltrials.gov/show/NCT00003861
All rights reserved. Please visit https://medical-data-
models.org/forms/14318
Eligibility Leukemia NCT00003861
Criteria
diagnosis of 1 of the following diseases:*
Yes
No
acute lymphoblastic leukemia (all)*
Yes
No
patients enrolled on calgb-19802 or any calgb
treatment trials for previously untreated all, must
be enrolled on this trial*
Yes
No
acute promyelocytic leukemia (apl)*
Yes
No
patients enrolled on swog-s0521 or swog-s0535
for previously untreated apl must be enrolled on
this trial*
Yes
No
patient characteristics:*
Yes
No
age:*
Yes
No
adult*
Yes
No
performance status:*
Yes
No
see disease characteristics*
Yes
No
life expectancy:*
Yes
No
see disease characteristics*
Yes
No
hematopoietic:*
1 / 2
Yes
No
see disease characteristics*
Yes
No
hepatic:*
Yes
No
see disease characteristics*
Yes
No
renal:*
Yes
No
see disease characteristics*
Yes
No
prior concurrent therapy:*
Yes
No
see disease characteristics*
Yes
No
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Eligibility Leukemia NCT00003910
Methotrexate With or Without Cyclophosphamide in
Treating Patients With Lymphocytic Leukemia; ODM
derived from: https://clinicaltrials.gov/show/NCT00003910
All rights reserved. Please visit https://medical-data-
models.org/forms/14319
Eligibility Leukemia NCT00003910
Criteria
phenotypic studies from peripheral blood showing
cd3+, cd57+ cells greater than 400/mm3 or cd8+
cells greater than 650/mm3 within eight weeks
prior to registration*
Yes
No
evidence for clonal t-cell receptor gene
rearrangement within one year prior to
registration*
Yes
No
at least one of the following: severe neutropenia
less than 500/mm3, neutropenia associated with
recurrent infections, symptomatic anemia, or
transfusion-dependent anemia*
Yes
No
bilirubin ≤ 2.0 mg/dl, sgot(ast) ≤ 1.5 times normal,
and creatinine ≤ 2.0 mg/dl within 4 weeks prior to
registration*
Yes
No
ecog performance status of 0-2*
Yes
No
at least 18 years of age*
Yes
No
written informed consent*
Yes
No
exclusion:*
Yes
No
prior therapy with oral mtx or oral cy*
Yes
No
previous or concurrent malignancies except
inactive non-melanoma skin cancer, in situ
carcinoma of the cervix, or other cancer if the
patient has been disease free for over 5 years*
Yes
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No
pregnant or breast-feeding for female patients*
Yes
No
serious medical illness, other than that treated by
the study, which would limit survival to less than 2
years, or psychiatric condition which would
prevent informed consent*
Yes
No
note: to be eligible for step 2 of this study,
patients were required to have no response after
at least 4 months of methotrexate treatment.*
Yes
No
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Eligibility Asthma NCT00382889
As Needed Beclomethasone/Salbutamol Combination in
Single Inhaler for Mild Persistent Asthma; ODM derived
from: https://clinicaltrials.gov/show/NCT00382889
All rights reserved. Please visit https://medical-data-
models.org/forms/14320
Eligibility Asthma NCT00382889
Inclusion Criteria
clinical diagnosis of mild persistent asthma as
defined by nhlbi/who 97; for at least 6 months;*
Yes
No
fev1 ³ 75% of predicted normal value;*
Yes
No
positive response to the reversibility test to b2
agonist, defined as an increase > 12% in the fev1
measured 30 minutes following 2 puffs
(2x100mg) of inhaled salbutamol spray, or
positive methacholine challenge (pc20<8mg/ml or
pd20<1 mg) within the previous 6 months;*
Yes
No
stable asthma. asthma is defined stable if none of
the following occurred during the last 14 days of
the run-in period: diurnal variation of more than
20% in pef on 2 consecutive days; use of four or
more inhalations of b2 agonist per day on two
consecutive days; need the use of oral
corticosteroids;*
Yes
No
Exclusion Criteria
copd as defined by the ers – consensus
statement;*
Yes
No
patients with more than 10 packs/year of
cigarettes history and current smokers;*
Yes
No
history of near fatal asthma and/or admission in
intensive care unit because of asthma;*
Yes
No
one severe exacerbation during the run-in
period;*
Yes
No
three or more courses of oral corticosteroids or
hospitalisation for asthma during the previous 1
1 / 2
year;*
Yes
No
patients treated with more than 500 mcg/day of
beclomethasone or equivalent for more than 6
months in the previous last year;*
Yes
No
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Eligibility Asthma NCT00386737
Development of a Breath Analyzer for Asthma Screening;
ODM derived from:
https://clinicaltrials.gov/show/NCT00386737
All rights reserved. Please visit https://medical-data-
models.org/forms/14325
Eligibility Asthma NCT00386737
Inclusion Criteria
healthy subjects   (n=120)*
Yes
No
asthma (total n=450) [diagnosed according to
nhlbi/ naepp guidelines (1998)]*
Yes
No
non-treated or b2-agonist treated asthmatics
(n=150),*
Yes
No
glucocorticoid treated asthmatics, (n=150),*
Yes
No
leukotriene antagonist treated asthmatics,
(n=75),*
Yes
No
glucocorticoid and leukotriene antagonists
treated asthmatics, (n= 75).*
Yes
No
acute respiratory illnesses (n=65*
Yes
No
sinusitis (acute and chronic),*
Yes
No
influenza,*
Yes
No
common cold,*
Yes
No
pneumonia,*
Yes
No
related symptoms, but no diagnosis.*
Yes
No
allergies   (n=65)*
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Yes
No
atopic dermatitis,*
Yes
No
allergic rhinitis,*
Yes
No
seasonal allergies.*
Yes
No
Exclusion Criteria
younger than 4*
Yes
No
older than 65*
Yes
No
pregnant*
Yes
No
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Eligibility Leukemia NCT00015873
Comparison of Different Combination Chemotherapy
Regimens in Treating Infants With Acute Lymphoblastic
Leukemia; ODM derived from:
https://clinicaltrials.gov/show/NCT00015873
All rights reserved. Please visit https://medical-data-
models.org/forms/14327
Eligibility Leukemia NCT00015873
Criteria
diagnosis of acute lymphoblastic leukemia (all)*
Yes
No
newly diagnosed*
Yes
No
morphological verification by cytochemistry and
immunophenotyping*
Yes
No
cns or testicular leukemia at diagnosis allowed*
Yes
No
trisomy 21 allowed*
Yes
No
patient characteristics:*
Yes
No
age:*
Yes
No
365 days or less*
Yes
No
performance status:*
Yes
No
not specified*
Yes
No
life expectancy:*
Yes
No
not specified*
Yes
No
hematopoietic:*
Yes
No
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not specified*
Yes
No
hepatic:*
Yes
No
not specified*
Yes
No
renal:*
Yes
No
not specified*
Yes
No
prior concurrent therapy:*
Yes
No
biologic therapy:*
Yes
No
not specified*
Yes
No
chemotherapy:*
Yes
No
no prior chemotherapy for leukemia*
Yes
No
endocrine therapy:*
Yes
No
at least 4 weeks since prior systemic
corticosteroids*
Yes
No
prior inhaled steroids allowed*
Yes
No
radiotherapy:*
Yes
No
no prior radiotherapy for leukemia*
Yes
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No
surgery:*
Yes
No
not specified*
Yes
No
3 / 3
Eligibility Leukemia NCT00015873
Eligibility Leukemia NCT00058799
Treating High Risk Leukemia With CD40 Ligand & IL-2
Gene Modified Tumor Vaccine; ODM derived from:
https://clinicaltrials.gov/show/NCT00058799
All rights reserved. Please visit https://medical-data-
models.org/forms/14328
Eligibility Leukemia NCT00058799
Inclusion Criteria
1. patients less than or equal to 75 years old with
lymphoid (pre-b, b, t, non b-, non t, or burkitt if
bone marrow blasts > 20%) or acute myeloid
leukemia (m0 to m7) or myelodysplastic
syndrome and with: disease that has entered
remission with chemotherapy and/or bone
marrow transplantation, but is considered to be at
high risk of relapse. or primary, or relapsed
treatment-refractory disease who, at the time of
reinjection of the tumor vaccine, are at a state of
complete or partial cytological remission disease
(<20% blasts infiltrating the bone marrow) after a
second/higher line of conventional and/or high
dose chemotherapy.*
Yes
No
2. patients must have a life expectancy of at least
10 weeks.*
Yes
No
3. patients must have ecog performance status of
0-2 as below:*
Yes
No
4. patients must have recovered from the toxic
effects of all prior chemotherapy before entering
this study, and have an absolute neutrophil count
>500/mm3, absolute lymphocyte count
>200/mm3, and platelet count >50,000/mm3.*
Yes
No
5. patients must not have active gvhd at the time
of protocol entry.*
Yes
No
6. patient has not received high dose steroids
within the last week or other immunosuppressive
drugs within a week (or longer as indicated by the
half life of the agent)*
Yes
No
7. patients must not be infected at time of
protocol entry, and should not be receiving
antibiotics (other than prophylactic septra.)*
Yes
No
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8. patients must not be hiv-positive.*
Yes
No
9. patients must have adequate liver function
(bilirubin<1.5 mg% sgot<2x normal, normal
prothrombin time).*
Yes
No
10. patients must have transduced cells available
that are demonstrably >20% cd40l expressing
fibroblasts and producing>150 pg il-2/10 6 cell/24
hr.*
Yes
No
11. patients or legal guardians must sign an
informed consent indicating that they are aware
this is a research study and have been told of its
possible benefits and toxic side effects. patients
or their guardians will be given a copy of the
consent form.*
Yes
No
12. patient must not have received treatment with
other investigational agents within the last 4
weeks.*
Yes
No
13. patients must be willing to utilize one of the
more effective birth control methods during the
study and for 3 months after the study is
concluded. the male partner should use a
condom.*
Yes
No
Exclusion Criteria
1. rapidly progressive/refractory disease (>20%
blasts infiltrating the bone marrow)*
Yes
No
2. life expectancy < 10 weeks*
Yes
No
3. active infection*
Yes
No
4. need for concomitant drugs except analgesics*
Yes
No
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5. pregnancy or lactation*
Yes
No
6. seropositive for hiv*
Yes
No
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Eligibility Asthma NCT02245672
MGR001 / Advair Diskus Local Equivalence Study in
Asthma; ODM derived from:
https://clinicaltrials.gov/show/NCT02245672
All rights reserved. Please visit https://medical-data-
models.org/forms/14329
Eligibility Asthma NCT02245672
Criteria
male or female subjects aged ≥18 years.  females
may be of either childbearing or non-childbearing
potential*
Yes
No
physician diagnosed history of asthma for at least
12 weeks prior to screening*
Yes
No
pre-bronchodilator fev1 60-85% at screening and
other specified visits*
Yes
No
post-bronchodilator reversibility >/=12%*
Yes
No
non-smokers and prior smokers with no history of
smoking within the past 12 months prior to
screening and a total smoking history of ≤10
pack-years*
Yes
No
subjects able to discontinue asthma medications
for the duration of the study and be maintained
using albuterol as required*
Yes
No
body mass index between 18-40 kg/m2 inclusive*
Yes
No
key exclusion criteria include:*
Yes
No
presence or recent history of any other active,
severe, progressive, and/or uncontrolled clinical
disease, eg, poorly controlled type 1 or 2
diabetes, seizure disorder or epilepsy,
cerebrovascular accident, significant cardiac
conduction abnormalities*
Yes
No
respiratory conditions other than asthma and
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allergic rhinitis, including but not limited to: severe
nasal polyposis or chronic rhinosinusitis, chronic
obstructive pulmonary disease, bronchiectasis,
churg-strauss disease, lung resection, pulmonary
fibrosis (primary or secondary), pulmonary
hypertension, cystic fibrosis, sarcoidosis*
Yes
No
history of life-threatening asthma, defined as a
history of asthma episode(s) requiring intubation,
and/or associated with hypercapnia; respiratory
arrest or hypoxic seizures, asthma related
syncopal episode(s)*
Yes
No
in patient hospitalization (not including er visits)
for an asthma exacerbation within the past year
or during the run in period*
Yes
No
an asthma exacerbation requiring change in
asthma therapy or oral/iv corticosteroids in the 3
months prior to screening*
Yes
No
history of seasonally unstable asthma where the
season will coincide with the subject's
participation in the study*
Yes
No
use of prescription or non-prescription drugs,
including beta blockers, tricyclic antidepressants,
oral decongestants, benzodiazepines, digitalis,
phenothiazines, monoamine oxidase inhibitors,
etc*
Yes
No
suspected hypersensitivity to the study drugs
(including lactose) or severe milk protein allergy*
Yes
No
clinically significant abnormalities in the
screening ecg*
Yes
No
evidence of alcohol or drug abuse or dependency
within 6 months prior to screening*
Yes
No
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Eligibility Asthma NCT02251379
Environmental Control as Add-on Therapy in Childhood
Asthma; ODM derived from:
https://clinicaltrials.gov/show/NCT02251379
All rights reserved. Please visit https://medical-data-
models.org/forms/14335
Eligibility Asthma NCT02251379
Inclusion Criteria
have physician-diagnosed asthma at least 1 year
prior to the baseline visit, or asthma symptoms
for at least 1 year*
Yes
No
meet criteria for current persistent asthma
defined as either:*
Yes
No
1. on a long-term controller medication for
asthma, or*
Yes
No
2. meet naepp guideline requirements for
persistent disease:(46)*
Yes
No
asthma symptoms 3 or more days per week over
the past 2 weeks or*
Yes
No
nocturnal asthma symptoms at least 3 times in
the past month*
Yes
No
have evidence of uncontrolled disease as defined
by at least one of the following:*
Yes
No
1. one asthma-related unscheduled visit to an
emergency department (ed), clinic or urgent care
facility in the previous 12 mo*
Yes
No
2. one asthma-related overnight hospitalization in
the previous 12 mo*
Yes
No
3. one or more bursts of oral corticosteroids in
the previous 12 mo*
Yes
No
reside within a geographic area of the study site
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so that home visits are feasible.*
Yes
No
have no plans to move within the upcoming 6
months*
Yes
No
have insurance to cover prescription
medications.*
Yes
No
have a positive skin test (net wheal ≥2mm) to cat,
dog, mouse, cockroach, or dust mites or have a
positive cat, dog, mouse, german cockroach, or
d. farinae-specific ige test, as quantified using the
immunocap system (≥0.35 ku/l)*
Yes
No
Exclusion Criteria
lung disease, other than asthma, that requires
daily medication*
Yes
No
cardiovascular disease that requires daily
medication, excluding hypertension*
Yes
No
taking a beta-blocker*
Yes
No
allergy to dairy*
Yes
No
on xolair < 5 months*
Yes
No
on immunotherapy and has not reached
maintenance dose*
Yes
No
sleeping in another home 4 or more nights/week*
Yes
No
active smoker defined as a positive urine screen
for high levels of urine cotinine*
Yes
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No
unable to access areas of home necessary to
conduct extermination*
Yes
No
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Eligibility Asthma NCT02258308
CDC Medicaid Asthma Home Visit Project; ODM derived
from: https://clinicaltrials.gov/show/NCT02258308
All rights reserved. Please visit https://medical-data-
models.org/forms/14337
Eligibility Asthma NCT02258308
Inclusion Criteria
caretaker is age 18 or older and child is age 3-
17*
Yes
No
have not controlled as thma*
Yes
No
residence in king county*
Yes
No
spoken language is english or spanish*
Yes
No
child is enrolled in a medicaid managed care
health plan offered by community health plan of
washington (chpw) or molina health plan of
washington, inc (molina).*
Yes
No
Exclusion Criteria
parent/guardian plans to move out of king county
within the next year or lacks permanent housing.*
Yes
No
parent/guardian has a mental or physical
disability making it impossible to participate in the
protocols.*
Yes
No
the household appears to be unsafe for visitation
by the chw.*
Yes
No
the child has other serious chronic medical
conditions (e.g.  poorly controlled sickle cell
disease, cystic fibrosis) that cause sufficient
limitation in functional status so that that asthma
control is not a priority.*
Yes
No
the family is enrolled in another asthma research
study within the past three years. this is to avoid
the potential confounding effect from other
studies.*
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Yes
No
the child is in foster care or group care settings.*
Yes
No
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Eligibility Asthma NCT02258893
Indoor Air Pollution and Children With Asthma: An
Intervention Trial; ODM derived from:
https://clinicaltrials.gov/show/NCT02258893
All rights reserved. Please visit https://medical-data-
models.org/forms/14338
Eligibility Asthma NCT02258893
Inclusion Criteria
5-11 years of age, enrolled in grades k-5 and
living in one of 16 selected towns*
Yes
No
[the screening questionnaire will determine
asthma symptoms in the past 12 months
(wheeze, persistent cough, shortness of breath,
chest tightness); and asthma medication use in
the past 12 months (short-acting β2-agonists,
long-acting*
Yes
No
β2-agonists, inhaled steroids, oral steroids,
theophylline, cromones, and/or leukotriene
inhibitors). based on symptoms and medication,
asthma severity will be categorized with a score
adapted from the global initiative for asthma
guidelines (1=mild transient, 2=mild persistent,
3=moderate, 4=severe). only children in
categories 2 (mild persistent, 3 (moderate) or 4
(severe) will be eligible.]*
Yes
No
for potential subjects satisfying these inclusion
criteria, a passive no2 monitor will be sent to the
home for placement in the main living space for
one week. families will be called after one week
and instructed to cap and return the no2 monitor
in a pre-paid mailer. families of children living in
homes where the one-week integrated average
no2 concentration is > 20 ppb will be invited to
participate. we will permit the enrollment of more
than one eligible child per family.*
Yes
No
Exclusion Criteria
not using steroid medication for a condition other
than asthma*
Yes
No
no chronic respiratory condition other than
asthma*
Yes
No
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no intention to move or relocate within 6 months*
Yes
No
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Eligibility Asthma NCT02263794
Hyperpolarized Magnetic Resonance Imaging in Asthma
Pre- and Post-Bronchial Thermoplasty; ODM derived from:
https://clinicaltrials.gov/show/NCT02263794
All rights reserved. Please visit https://medical-data-
models.org/forms/14342
Eligibility Asthma NCT02263794
Inclusion Criteria
subject understands the study procedures and is
willing to participate in the study as indicated by
signature on the informed consent*
Yes
No
male and female aged 18-60 years of age with a
clinical diagnosis of asthma, as per:*
Yes
No
beta-agonist reversibility of fev1>12%, or*
Yes
No
methacholine fev1 pc20 ≤ 8 mg/ml if not receiving
ics or ≤ 16mg/ml if receiving an ics.*
Yes
No
subject has asthma and is taking regular
maintenance medication for the past 12 months
that includes:*
Yes
No
inhaled corticosteroid (ics)*
Yes
No
long-acting beta agonist (laba)*
Yes
No
other asthma medication such as leukotriene
modifier, or anti-ige, are acceptable*
Yes
No
fev1 > 50%pred pre-bronchodilator*
Yes
No
subject assigned by the clinical team to receive
bronchial thermoplasty as part of their asthma
treatment plan*
Yes
No
subject is a non-smoker for 1 year or greater (if
former smoker less than 10 pack years total
smoking history).*
Yes
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No
subject able to perform reproducible pulmonary
function testing (i.e., the 3 best acceptable
spirograms have fev1 values that do not vary
more than 5% of the largest value or more than
100 ml, whichever is greater.)*
Yes
No
subject is judged to be in otherwise stable health
on the basis of medical history*
Yes
No
Exclusion Criteria
subject is, in the opinion of the investigator,
mentally or legally incapacitated, preventing
informed consent from being obtained, or cannot
read or understand the written material*
Yes
No
subject is unable to perform spirometry or
plethysmography maneuvers*
Yes
No
subject is pregnant*
Yes
No
recent (within 4 weeks of bl visit 1) or current
asthma exacerbation and/or respiratory tract
infection*
Yes
No
subject has an implanted mechanically,
electrically or magnetically activated device or
any metal in their body which cannot be removed,
including but not limited to pacemakers,
neurostimulators, biostimulators, implanted
insulin pumps, aneurysm clips, bioprosthesis,
artificial limb, metallic fragment or foreign body,
shunt, surgical staples (including clips or metallic
sutures and/or ear implants.)  (at the discretion of
the mri technologist/3t manager)*
Yes
No
in the investigator's opinion, subject suffers from
any physical, psychological or other condition(s)
that might prevent performance of the mri, such
as severe claustrophobia.*
Yes
No
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Eligibility Asthma NCT02264691
UTMB Research on Severe Asthma (UROSA) Study; ODM
derived from: https://clinicaltrials.gov/show/NCT02264691
All rights reserved. Please visit https://medical-data-
models.org/forms/14351
Eligibility Asthma NCT02264691
Inclusion Criteria
all participants must be in good general health
(with exception to asthma). • normal controls /
healthy volunteers (nc) subjects with no past
history of asthma or other lung disease.  to
determine this, subjects must have an fev1 equal
to or greater than 80% of predicted value and
have a normal fev1/fvc ratio.*
Yes
No
asthma subjects eligible asthmatic participants
must have a physician diagnosis of asthma for at
least 1 year.  participants must either have
historical evidence of reversibility of fev1 of at
least 12%, or demonstrate such a change during
the study visits, or must have historical evidence
of a pc20 for methacholine < 8mg/ml.*
Yes
No
mild asthma with no corticosteroids (manc) will
be defined as control of asthma with short acting
β2-agonists or leukotrine antagonist or both, but
not requiring inhaled corticosteroids.*
Yes
No
mild to moderate asthma (mma) will be defined
as control of asthma with an inhaled
corticosteroid (less than or equal to 250 mcg
daily inhaled fluticasone equivalent) in addition to
the medications listed in the manc group or long
acting β2-agonists.*
Yes
No
severe asthma  (sa) will be defined according to
the ats criteria for refractory asthma (10)*
Yes
No
Exclusion Criteria
exclusion criteria apply for all subjects:*
Yes
No
current smoker, or former smoker with >10 pack
years history or having quit within the past year*
Yes
No
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asthma exacerbation, requiring a new or
increased dose of oral corticosteroids, within the
past 30 days*
Yes
No
pregnant or lactating female*
Yes
No
significant/uncontrolled medical condition
(uncontrolled diabetes, coronary artery disease,
uncontrolled hypertension)*
Yes
No
diagnosis of emphysema or other significant
pulmonary disease*
Yes
No
if, in the opinion of the pi (wjc) the subject has co-
morbid conditions that make them unsafe to
undergo bronchoscopy, subjects will be given the
choice to withdraw from the study or allowed to
complete visits 1-3 only.*
Yes
No
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Eligibility Acute Promyelocytic Leukemia
NCT00670150
New Retinoid Agent Combined With Arsenic Trioxide for
Untreated Acute Promyelocytic Leukemia; ODM derived
from: https://clinicaltrials.gov/show/NCT00670150
All rights reserved. Please visit https://medical-data-
models.org/forms/14352
Eligibility Acute Promyelocytic
Leukemia NCT00670150
Inclusion Criteria
diagnosis patients must have a clinical diagnosis
of acute promyelocytic leukemia (apl) morphology
or fab m3 variant confirmed by rt-pcr assay for
pml-rarα or chromosome analysis/fish showing
t(15:17) translocation. a patient may be entered
prior to confirmatory studies, but a patient who is
subsequently found to be pml-rarα*
Yes
No
prior treatment the patient must not have
received any systemic definitive treatment for apl,
including cytotoxic chemotherapy, retinoids or
arsenic trioxide. prior therapy with corticosteroids,
hydroxyurea or leukapheresis will not exclude the
patient.*
Yes
No
Patients must be of age eighteen (18) or above.*
Yes
No
Bilirubin equal or less than 1.5 times the upper
limit of normal.*
mg/dL
Yes
No
Creatinine equal or less than 1.5 times the upper
limit of normal*
mg/dL
Yes
No
Pregnancy / nursing status*
Yes
No
Patients entered into this study should be non-
pregnant and non-nursing and should not plan on
becoming pregnant while on treatment. treatment
under this protocol would expose an unborn child
to significant risks. treatment. women and men of
reproductive potential should agree to use an
effective means of birth control. there is an
extremely high risk of fetal malformation if
pregnancy occurs while on treatment in any
amount with retinoid drugs even for short
periods.*
Yes
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No
Exclusion Criteria
non-apl, aml patients should be excluded from
the study.*
Yes
No
Other serious illnesses which would limit survival
to 1 year.*
Yes
No
psychiatric conditions which would prevent
compliance with treatment or informed consent.*
Yes
No
uncontrolled or severe cardiovascular disease.
this would include history of a recent acute
myocardial infarction, uncontrolled congestive
heart failure, or active angina.*
Yes
No
aids or hiv positive patients, although hiv test is
not required for accrual.*
Yes
No
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Eligibility Acute Promyelocytic Leukemia
NCT00675870
Study of NRX 195183 Therapy for Patients With Relapsed
or Refractory Acute Promyelocytic Leukemia; ODM derived
from: https://clinicaltrials.gov/show/NCT00675870
All rights reserved. Please visit https://medical-data-
models.org/forms/14353
Eligibility Acute Promyelocytic
Leukemia NCT00675870
Inclusion Criteria
clinical diagnosis of apl morphology or fab m3
variant confirmed by rt-pcr assay or chromosome
analysis/fish showing t(15:17) translocation.
patients must also have relapse from, resistance
to or intolerance of any one or more of the
following therapies:*
Yes
No
ATRA - Tretinoin*
Yes
No
Cytotoxic chemotherapy*
Yes
No
arsenic trioxide*
Yes
No
patients must be 18 or older*
Yes
No
bilirubin equal or less than 1.5 times the upper
limit of normal.*
mg/dL
Yes
No
creatinine equal or less than 1.5 times the upper
limit of normal.*
mg/dL
Yes
No
patients entered into this study should be non-
pregnant and non-nursing and should not plan on
becoming pregnant while on treatment.
treatment under this protocol would expose an
unborn child to significant risks. women and men
of reproductive potential should agree to use an
effective means of birth control. there is an
extremely high risk that a severely deformed
infant will result if nrx 195183 is administered
during pregnancy.*
Yes
No
Exclusion Criteria
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non-apl, aml patients should be excluded from
the study.*
Yes
No
other serious illnesses which would limit survival
to 6 months.*
Yes
No
psychiatric conditions which would prevent
compliance with treatment or informed consent.*
Yes
No
uncontrolled or severe cardiovascular disease.
this would include history of a recent acute
myocardial infarction, uncontrolled congestive
heart failure, or active angina.*
Yes
No
aids or hiv positive patients, although hiv test is
not required for accrual.*
Yes
No
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Eligibility Acute Promyelocytic Leukemia
NCT01226303
Treatment Study for Children and Adolescents With Acute
Promyelocitic Leukemia; ODM derived from:
https://clinicaltrials.gov/show/NCT01226303
All rights reserved. Please visit https://medical-data-
models.org/forms/14354
Eligibility Acute Promyelocytic
Leukemia NCT01226303
Inclusion Criteria
patients with a clinical diagnosis of initial apl and
subsequently confirmed to have pml-rarα, npm1-
rarα or numa-rarα fusion. whilst this study is only
for atra-sensitive apl, apl is a hematological
emergency and atra should be commenced as
soon as the diagnosis is suspected. study entry
should not wait until the diagnosis of apl has
been confirmed molecularly or cytogenetically*
Yes
No
less than 21 years of age at initial diagnosis (for
aieop, see appendix a)*
Yes
No
considered suitable for anthracycline-based
chemotherapy*
Yes
No
Informed Consent*
Yes
No
Negative serum test to rule out pregnancy within
2 weeks prior to registration in females of
childbearing potential (non childbearing potential
defined as premenarchal, greater than one year
post-menopausal, or surgically sterilized)*
Yes
No
Exclusion Criteria
patients with a clinical diagnosis of apl but
subsequently found to have plzf-rarα*
Yes
No
fusion or lacking pml-rarα, npm-rarα or numa-
rarα rearrangement should be withdrawn from the
study and treated on an alternative protocol.*
Yes
No
refractory/relapsed apl (the guidelines in this
protocol for that subgroup are intended for
patients treated from initial diagnosis according to
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this protocol)*
Yes
No
concurrent active malignancy*
Yes
No
Pregnant or lactating*
Yes
No
physician and patient/guardian think that
intensive chemotherapy is not an appropriate
treatment option*
Yes
No
patients who have received alternative
chemotherapy for 7 days or longer without atra for
any reason (either apl not initially suspected or
atra not available).*
Yes
No
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Eligibility Acute Promyelocytic Leukemia
NCT01404949
Combined Tretinoin and Arsenic Trioxide for Patients With
Newly Diagnosed Acute Promyelocytic Leukemia Followed
by Risk-Adapted Postremission Therapy; ODM derived
from: https://clinicaltrials.gov/show/NCT01404949
All rights reserved. Please visit https://medical-data-
models.org/forms/14355
Eligibility Acute Promyelocytic
Leukemia NCT01404949
Inclusion Criteria
previously untreated patients with a morphologic
diagnosis of apl, confirmed by demonstration of
t(15;17) using conventional cytogenetics or
florescence in situ hybridization (fish), or a
positive rt-pcr assay for pml-rar at the subject's
local institution.*
Yes
No
age ≥18 years. karnofsky performance status of ≥
60%.*
Yes
No
adequate renal function as demonstrated by a
serum creatinine ≤ 2.0 mg/dl or a creatinine
clearance of > 60 ml/min.*
Yes
No
adequate hepatic function as demonstrated by a
bilirubin < 2.0 mg/dl (unless attributable to
gilbert's disease) and an alkaline phosphatase,
ast, and alt ≤ 2.5 times the upper limit of normal.*
Yes
No
normal cardiac function as demonstrated by a left
ventricular ejection fraction ≥ 50% on
echocardiogram or muga scan.*
Yes
No
qtc ≤ 500 msec on baseline ecg.*
Yes
No
negative serum pregnancy test in women of
childbearing potential.*
Yes
No
ability to swallow oral medication.*
Yes
No
men and women of child-bearing potential must
be willing to practice an effective method of birth
control during treatment and at least 4 months
after treatment is finished.*
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Yes
No
patients with central nervous system involvement
by apl are eligible and may receive concomitant
treatment with radiation therapy and/or intrathecal
chemotherapy in accordance with standard
medical practice.*
Yes
No
Exclusion Criteria
previous treatment for apl, except tretinoin, which
may be given for up to 7 days prior to study
entry.*
Yes
No
active serious infections not controlled by
antibiotics.*
Yes
No
pregnant women or women who are breast-
feeding.*
Yes
No
concurrent active malignancy requiring immediate
therapy.*
Yes
No
clinically significant cardiac disease (ny heart
association class iii or iv), including chronic
arrhythmias, or pulmonary disease.*
Yes
No
other serious or life-threatening conditions
deemed unacceptable by the principal
investigator.*
Yes
No
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Eligibility Acute Schizophrenia
NCT00350467
A Randomized, Active-controlled, Double-blind, Parallel-
Goup Study of the Efficacy and Safety of Extended
Release(ER) Paliperidone in the Treatment of
Schizophrenia; ODM derived from:
https://clinicaltrials.gov/show/NCT00350467
All rights reserved. Please visit https://medical-data-
models.org/forms/14357
Eligibility Acute Schizophrenia
NCT00350467
Inclusion Criteria
patients (or their legally acceptable
representatives) must have signed an informed
consent document indicating that they
understand the purpose of and procedures
required for the study and are willing to
participate in the study*
Yes
No
dsm-iv diagnosis of schizophrenia (295.10,
295.20, 295.30, 295.60, 295.90) at entry*
Yes
No
total panss score at screening and baseline
between 60 and 120, inclusive*
Yes
No
female patients must be postmenopausal for at
least 1 year, surgically sterile, or practicing an
effective method of birth control (e.g., prescription
oral contraceptives, contraceptive injections,
intrauterine device, double-barrier method,
contraceptive patch) before entry (and agree to
continue that method throughout the study) -
abstinence is not an acceptable method*
Yes
No
have a negative urine b hcg pregnancy test at
screening*
Yes
No
capable of self-administering study drug, or has
consistent help and support available throughout
the study to do this*
Yes
No
Exclusion Criteria
a dsm-iv (diagnostic and statistical manual of
mental disorders) axis i diagnosis other than
schizophrenia*
Yes
No
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inability to swallow the study drug whole with the
aid of water (participants may not chew, divide,
dissolve, or crush the study drug, as this may
affect the release profile)*
Yes
No
previous history of a lack of response to any
antipsychotic (lack of response defined as subject
having had least twice a documented medical
history of no clinical response despite adequate
doses and durations of treatment, or the inability
to tolerate effective doses)*
Yes
No
significant risk of suicidal or violent behavior*
Yes
No
injection of a depot antipsychotic within 120 days
before screening, or use of paliperidone palmitate
within 10 months before screening*
Yes
No
use of monoamine oxidase inhibitors within 4
weeks before screening*
Yes
No
use of antidepressants other than monoamine
oxidase inhibitors or mood stabilizers (e.g.,
antiepileptics, lithium) within 2 weeks before
screening*
Yes
No
received electroconvulsive therapy within 3
months before screening*
Yes
No
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Eligibility Asthma NCT00455923
SERETIDE Vs FLIXOTIDE In Mild Persistent Asthma
(GINAII); ODM derived from:
https://clinicaltrials.gov/show/NCT00455923
All rights reserved. Please visit https://medical-data-
models.org/forms/14358
Eligibility Asthma NCT00455923
Inclusion Criteria
willing to give informed consent.*
Yes
No
males or females aged 18-70.*
Yes
No
able to understand and complete dairy cards.*
Yes
No
mild persistent asthma according to gina.
in addition, at randomisation subjects were
required to have:           1. day time symptoms
more than once a week but not every day. 2.
night-time symptoms not more than once a week.
3. fev1 >80% predicted 4. pc20 <8mg/ml*
Yes
No
Exclusion Criteria
change to regular asthma medication in 4-weeks
prior to visit 1.*
Yes
No
use of oral, depot or parenteral corticosteroids
within 8 weeks of visit 1.*
Yes
No
lower respiratory tract within 4 weeks of visit 1*
Yes
No
received investigational study drug within 4
weeks of visit*
Yes
No
smoking history of >10 pack years of more.*
Yes
No
serious uncontrolled disease.*
Yes
No
medical conditions or medications known to affect
the assessments or endpoints.*
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Yes
No
evidence of alcohol or drug abuse.*
Yes
No
known pregnancy or planned pregnancy.*
Yes
No
known or suspected hypersensitivity to inhaled
corticosteroids, beta-agonists or lactose.*
Yes
No
previous enrollment in the study*
Yes
No
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Eligibility Asthma NCT02275559
Asthma Symptom Management Through Mindfulness
Training; ODM derived from:
https://clinicaltrials.gov/show/NCT02275559
All rights reserved. Please visit https://medical-data-
models.org/forms/14362
Eligibility Asthma NCT02275559
Inclusion Criteria
age 18 and older*
Yes
No
documented diagnosis of asthma from a
physician for greater than 12 months that
includes an objective indicator of bronchial
hyperresponsiveness (positive methacholine
challenge test or > 12% improvement in forced
expiratory volume in 1 second (fev1) or forced
vital capacity (fvc) in response to
bronchodilator);*
Yes
No
meets criteria for mild, moderate or severe
asthma*
Yes
No
treatment with inhaled corticosteroids for at least
12 weeks with stable dosing for greater than 4
weeks;*
Yes
No
able to read and understand english, and
complete informed consent process and study
data collection procedures.*
Yes
No
Exclusion Criteria
current smoker or greater than 10 pack-year
smoking history*
Yes
No
diagnosis of asthma of intermittent severity*
Yes
No
other lung diseases besides asthma*
Yes
No
cancer, except non-melanoma skin cancer;*
Yes
No
currently receiving treatment for symptomatic
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cardiovascular disease within  past 6 months*
Yes
No
current or recent (within the past 3 months)
severe exacerbation of asthma requiring
hospitalization or oral glucocorticoids;*
Yes
No
currently pregnant*
Yes
No
major psychiatric disorders or psychiatric
hospitalization in the last 2 years;*
Yes
No
has taken the mbsr program in the past, and/or
currently practicing meditation or yoga on a
regular basis.*
Yes
No
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Eligibility Asthma NCT02293499
Peer Led Asthma Self Management for Adolescents:
PLASMA; ODM derived from:
https://clinicaltrials.gov/show/NCT02293499
All rights reserved. Please visit https://medical-data-
models.org/forms/14366
Eligibility Asthma NCT02293499
Inclusion Criteria
eligibility criteria for adolescent (camp)
participants include:*
Yes
No
1. age between 12-17 years;*
Yes
No
2. physician-diagnosed asthma that has required
health service use (preventive or acute) within 12
months prior to recruitment;*
Yes
No
3. persistent asthma determined by current use
of a control medication or presenting at least one
of the following four symptom levels in the past 4
weeks, as defined by the naepp guidelines91:*
Yes
No
> 2 days/week of daytime symptoms,*
Yes
No
>3-4 times of nighttime awakening,*
Yes
No
>2 days/week of saba use, or*
Yes
No
any interference with normal activities due to
asthma 91 (4) no other chronic conditions
requiring daily medication (e.g., diabetes, cancer,
arthritis, etc.) and no severe mental illness (e.g.,
bipolar disorder, schizophrenia) or behavioral
issues (e.g., criminal history) reported by parents
or guardians; (5) primary residence located in the
participating inner cities based on zip codes; and
(6) ability to understand spoken and written
english.*
Yes
No
eligibility criteria for peer leaders include:*
Yes
No
1. age between 16-20 years;*
Yes
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No
2. nomination from school teachers/nurses or
healthcare providers for candidates'*
Yes
No
exemplary asthma self-management, leadership,
and emotional intelligence; and*
Yes
No
3. fulfillment of eligibility criteria (2)-(6) prescribed
for adolescent participants.*
Yes
No
Exclusion Criteria
1. adolescents who are pregnant*
Yes
No
2. have learning disabilities based on reports
from teachers or clinicians will be excluded from
the study because such conditions can confound
the interpretation of findings.*
Yes
No
3. adolescents who become pregnant or
incarcerated after enrollment will be withdrawn
because these conditions can impact the study
outcomes (e.g., quality of life) and limit the
investigators' capacity to follow up.*
Yes
No
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Eligibility Asthma NCT02296411
Efficacy of LAMA Added to ICS in Treatment of Asthma;
ODM derived from:
https://clinicaltrials.gov/show/NCT02296411
All rights reserved. Please visit https://medical-data-
models.org/forms/14369
Eligibility Asthma NCT02296411
Inclusion Criteria
history of asthma ≥ 5 years and diagnosed before
40 years old*
Yes
No
uncontrolled asthma on low-medium doses of
inhaled corticosteroid (ics) with acq (asthma
control questionnaire) ≥1.5*
Yes
No
pre-bronchodilator fev1 ≥40% and <90% of their
predicted normal value*
Yes
No
positive reversibility test*
Yes
No
Exclusion Criteria
pregnant or lactating women*
Yes
No
diagnosis of chronic obstructive pulmonary
disease (copd)*
Yes
No
patients treated for asthma exacerbation in the 4
weeks prior to study entry*
Yes
No
patients who are in therapy for gastroesophageal
reflux disease*
Yes
No
patients who have a clinically significant
cardiovascular condition*
Yes
No
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Eligibility Asthma NCT02303561
The Childhood Health and Asthma Management Program;
ODM derived from:
https://clinicaltrials.gov/show/NCT02303561
All rights reserved. Please visit https://medical-data-
models.org/forms/14370
Eligibility Asthma NCT02303561
Inclusion Criteria
speaks english;*
Yes
No
has a physician-verified persistent asthma
diagnosis or by indicating on a screening
questionnaire that they*
Yes
No
1. having a current prescription for a controller
medication (e.g. fluticasone), or*
Yes
No
2. demonstrating any of the following symptom
frequency in the previous month: (i) daytime
asthma symptoms more than two days a week,
(ii) nighttime awakenings due to asthma more
than times a month, (iii) short-acting beta agonist
use 2 days a week, (iv) normal activity limitation,
(v) oral steroid use 2 times a year, (vi) emergency
department visit due to asthma in past year;*
Yes
No
has a bmi at or above the 85th percentile for age
and gender norms as published by the cdc.*
Yes
No
participating parents of legal guardians must:*
Yes
No
live in the same home with the child;*
Yes
No
speak english;*
Yes
No
be aged 75 or younger. there is no bmi
requirement for participating parents/legal
guardians.*
Yes
No
Exclusion Criteria
child or parent has dietary restriction or a medical
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condition that contraindicates mild energy
restriction or physical activity (history of musculo-
skeletal condition that limits walking, heart
condition, chronic lung diseases limiting physical
activity, current participation in commercial weight
loss program);*
Yes
No
use of antipsychotic agents, monoamine oxidase
inhibitors, systemic corticosteroids within 3
months, or prescription weight loss drugs within 6
months.*
Yes
No
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Eligibility Asthma NCT02307669
Inhaler Adherence in Poorly Controlled Asthma; ODM
derived from: https://clinicaltrials.gov/show/NCT02307669
All rights reserved. Please visit https://medical-data-
models.org/forms/14381
Eligibility Asthma NCT02307669
Inclusion Criteria
must be willing to give voluntary informed
consent*
Yes
No
must have a clinical diagnosis of asthma-*
Yes
No
must have a bronchodilator fev1 > 40% and
<80% in the past 1 year*
Yes
No
current unstable asthma i.e. act score is less than
19 at enrolment.*
Yes
No
two or more courses of oral corticosteroids in the
prior year, or a hospitalization or ed attendance
with an asthma exacerbation in the  last year*
Yes
No
age 18 years or older at time of consent.*
Yes
No
capable of understanding and complying with the
requirements of the protocol, including ability to
attend for all required visits.*
Yes
No
able and willing to take inhaled medication via a
diskus.*
Yes
No
in the opinion of the investigator suitable for use
of a salmeterol/fluticasone diskus    inhaler or
already using a salmeterol/fluticasone inhaler.*
Yes
No
Exclusion Criteria
have used any investigational product or device
within 3 months of the enrolment visit.*
Yes
No
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have known previous sensitivity to seretide.*
Yes
No
have a known significant (in the opinion of the
investigator) concurrent medical disease that
might mean that the participant cannot complete
the year long observation study.*
Yes
No
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Eligibility Leukemia NCT00609739
Cytosine Arabinoside and Mitoxantrone for Patients With
Juvenile Myelomonocytic Leukemia Receiving Repeat
Stem Cell Transplantation; ODM derived from:
https://clinicaltrials.gov/show/NCT00609739
All rights reserved. Please visit https://medical-data-
models.org/forms/14382
Eligibility Leukemia NCT00609739
Inclusion Criteria
patients age 0-18 with juvenile myelomonocytic
leukemia (jmml) who have relapsed or have
residual disease after allogeneic hct. residual
disease is defined as failure to eradicate original
disease without prior documentation of remission.
relapse is defined as reappearance of i)
leukocytosis with absolute monocytosis >1 x
10^8/l, ii) presence of immature myeloid cells in
the peripheral circulation in two consecutive bone
marrow specimens taken at least one month
apart, or iii) presence of clonal cytogenetic
abnormality. the diagnosis of relapse will be
supported by the return of an abnormal
cytogenetic marker (if present at diagnosis) or the
presence of host cells by rflp or other method.*
Yes
No
patients should be at least 6 months from first
hematopoietic cell transplant (hct) if clinically
stable. (if jmml is rapidly progressive, second hct
may be performed earlier).*
Yes
No
adequate major organ function including:*
Yes
No
cardiac: ejection fraction ≥45%*
Yes
No
pulmonary: fev >50%, dlco >50%*
Yes
No
renal: creatinine clearance ≥40 ml/min*
Yes
No
hepatic: no clinical evidence of hepatic failure
(e.g. coagulopathy, ascites)*
Yes
No
karnofsky performance status ≥70% or lansky
score ≥50%*
Yes
No
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written informed consent.*
Yes
No
Exclusion Criteria
active uncontrolled infection within one week of
hct.*
Yes
No
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Eligibility Acute Schizophrenia
NCT01668797
Efficacy, Safety, and Tolerability of Brexpiprazole (OPC-
34712) as Maintenance Treatment in Adults With
Schizophrenia; ODM derived from:
https://clinicaltrials.gov/show/NCT01668797
All rights reserved. Please visit https://medical-data-
models.org/forms/14384
Eligibility Acute Schizophrenia
NCT01668797
Inclusion Criteria
patients age 18 years or older to less than 65
years, inclusive (at time of informed consent)*
Yes
No
subjects with a current diagnosis of
schizophrenia, as defined by dsm-iv-tr criteria
and a history of the illness for at least three years
prior to screening (as per subject, family,
healthcare provider, or by previous medical
records).*
Yes
No
subjects with a stable living environment, as
demonstrated by the ability to provide contact
information for themselves and/or
family/friend(s)/caregiver(s).*
Yes
No
subjects who showed previous response to
antipsychotic treatment in the past year.*
Yes
No
subjects who are currently treated with oral or
depot antipsychotics other than clozapine or who
have had a recent lapse in antipsychotic
treatment requiring chronic treatment with
antipsychotic medication for stabilization.*
Yes
No
subjects who are experiencing a current acute
exacerbation of psychotic symptoms requiring
stabilization*
Yes
No
subjects with a history of relapse and/or
exacerbation of symptoms when they are not
receiving antipsychotic treatment.*
Yes
No
Exclusion Criteria
female patients who are breastfeeding or who
have a positive pregnancy test (urine) result prior
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to receiving investigational medicinal product*
Yes
No
patients presenting a first episode of
schizophrenia based on the clinical judgment of
the investigator*
Yes
No
patients who are diagnosed with a disease other
than schizophrenia (schizoaffective disorder,
major depressive disorder, bipolar disorder,
posttraumatic stress disorder, anxiety disorder,
delirium, dementia, amnesia, or other cognitive
disorder) based on current dsm-iv-tr axis ι
criteria, or who are diagnosed with a personality
disorder (borderline, paranoid, histrionic,
schizotypal, schizoid, or antisocial)*
Yes
No
subjects experiencing acute depressive
symptoms within the past 30 days*
Yes
No
subjects with schizophrenia who are considered
resistant/refractory to antipsychotic treatment by
history*
Yes
No
subjects with a significant risk of violent behavior;
who represent a risk of committing suicide*
Yes
No
subjects with clinically significant tardive
dyskinesia*
Yes
No
subjects currently treated with insulin for
diabetes.*
Yes
No
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Eligibility Acute Viral Hepatitis
NCT00689546
Acute Viral Hepatitis and Diabetes Mellitus; ODM derived
from: https://clinicaltrials.gov/show/NCT00689546
All rights reserved. Please visit https://medical-data-
models.org/forms/14385
Eligibility Acute Viral Hepatitis
NCT00689546
Inclusion Criteria
all patients between the ages of 18 to 70 years*
Yes
No
Exclusion Criteria
recent intake of drugs known to cause acute
hepatitis*
Yes
No
history of alcohol ingestion >40mg/day*
Yes
No
suspected ischemic hepatitis*
Yes
No
illness causing acute hepatitis such as malaria
hepatits, enteric  hepatitis, leptospirosis,
septecemia*
Yes
No
hiv*
Yes
No
associated co morbidities, which can affect
survival such as cardiovascular disease and
diabetic nephropathy.*
Yes
No
recent intake of drugs known to cause acute
hepatitis*
Yes
No
history of alcohol ingestion >40mg/day*
Yes
No
suspected ischemic hepatitis*
Yes
No
malaria hepatits, enteric hepatitis, leptospirosis,
septecemia*
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Yes
No
Coinfection with hiv*
Yes
No
comorbidities which affect survival such as cad
and diabetic nephropathy.*
Yes
No
gestational diabetes*
Yes
No
pregnant female*
Yes
No
cirrhosis*
Yes
No
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Eligibility Leukemia NCT01225874
Biomarkers to Classify Young Patients With Acute
Lymphoblastic Leukemia (ALL) and Remission Induction
Therapy in Young Patients With B-Precursor ALL; ODM
derived from: https://clinicaltrials.gov/show/NCT01225874
All rights reserved. Please visit https://medical-data-
models.org/forms/14386
Eligibility Leukemia NCT01225874
Criteria
meets one of the following sets of criteria:*
Yes
No
classification study:*
Yes
No
newly diagnosed all**
Yes
No
must have one of the following:*
Yes
No
≥ 25% blasts in bone marrow*
Yes
No
≥ 100,000/μl peripheral blood wbc with ≥ 75%
blasts, if bone marrow aspiration is omitted for
any reason other than medical contraindication*
Yes
No
≥ 30,000/μl wbc with ≥ 75% blasts, if bone
marrow aspiration is omitted because of medical
contraindication*
Yes
No
immunophenotype and wright's stain morphology
of blast cells consistent with acute lymphocytic
leukemia*
Yes
No
≤ 21 years of age at the time of diagnosis*
Yes
No
no previous registration on 9900*
Yes
No
samples must be sent for local institution and cog
reference laboratory studies note: *it is urged that
a bone marrow aspiration be performed for every
patient with suspected all. however, a marrow is
not required for patients with ≥ 100,000/μl
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peripheral blood wbc and ≥ 75% blasts or for
those patients whose clinical condition precludes
performing the procedure safely. patients with a
medical contraindication to the procedure must
be discussed with one of the study coordinators
and must have a peripheral blood wbc of ≥
30,000/μl with ≥ 75% blasts.*
Yes
No
induction therapy study:*
Yes
No
patients must have a confirmed diagnosis of b-
precursor acute lymphoblastic leukemia*
Yes
No
patients must be 1.001 to 21.999 years at
diagnosis note: patients meeting all of the above
eligibility criteria are eligible for registration on
9900 whether or not they are to be entered on a
cog frontline protocol for treatment of newly
diagnosed all. registration on 9900 is required for
all legacy pog institution patients in order to be
eligible for entry on the following cog all studies,
which are either currently open or only
temporarily closed: p9407, 9904, 9905, 9907,
aall0031 and aall00p2.*
Yes
No
patient characteristics:*
Yes
No
see disease characteristics*
Yes
No
prior concurrent therapy:*
Yes
No
previously untreated, with the following
exception:*
Yes
No
steroid treatment* in the 48-hour period just prior
to study entry will be allowed provided that a
physical examination and cbc with differential
were performed immediately prior to beginning
steroids and results of both are known note:
*patients on chronic steroid treatment for another
disease are not eligible for a cog new all
protocol.*
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Yes
No
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Eligibility Acute-on-chronic Hepatitis B Liver
Failure NCT01826760
Study of the Model to Predict 3-month Mortality Risk of
Acute-on-chronic Hepatitis B Liver Failure; ODM derived
from: https://clinicaltrials.gov/show/NCT01826760
All rights reserved. Please visit https://medical-data-
models.org/forms/14387
Eligibility Acute-on-chronic Hepatitis
B Liver Failure NCT01826760
Inclusion Criteria
acute hepatic insult manifesting as jaundice and
coagulopathy*
Yes
No
complicated within 4 weeks by ascites*
Yes
No
encephalopathy in a patient with chronic hbv
infection*
Yes
No
Exclusion Criteria
patients with evidence of non-b hepatitis virus*
Yes
No
alcohol abuse leads to liver failure*
Yes
No
autoimmune leads to liver failure*
Yes
No
toxic or other causes that might lead to liver
failure*
Yes
No
past or current hepatocellular carcinoma*
Yes
No
liver transplantation*
Yes
No
serious diseases in other organ systems*
Yes
No
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Eligibility Asthma NCT00526357
Effect of Dietary Supplements With Fish Oil on Mannitol-
induced Airway Sensitivity & Inflammation in Persons With
Asthma; ODM derived from:
https://clinicaltrials.gov/show/NCT00526357
All rights reserved. Please visit https://medical-data-
models.org/forms/14391
Eligibility Asthma NCT00526357
Inclusion Criteria
male or female (medically or surgically
postmenopausal or practicing an accepted form
of barrier or hormonal contraception) subjects
age 18-55.*
Yes
No
stable, mild atopic asthma with forced expiratory
volume in one second (fev1) greater than 70% of
predicted for age and height, and not requiring
any medical treatment other than short acting
inhaled beta2-agonists as required or for those
on steroids, taking < 1000 mcg of inhaled
corticosteroid per day.*
Yes
No
no recent or significant history of cigarette
smoking (no smoking within six months prior to
entry into the study; less than 10 pack-years
cumulative history of cigarette smoking).*
Yes
No
signed written informed consent to participate in
the study; ability to return to the clinic for
repeated visits.*
Yes
No
no history of asthma exacerbations or acute
intercurrent respiratory illness (viral respiratory
syndrome, bronchitis, pneumonia) for a four week
period preceding entry into the screening phase
of the study.*
Yes
No
subjects who take inhales steroids regularly must
demonstrate reproducibility to inhaled mannitol
(pd15<1.0 doubling doses) during a 2 week run-
in period.*
Yes
No
a pd15 to the mannitol challenge < 315mg*
Yes
No
Exclusion Criteria
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significant gastrointestinal (including hepatic),
hematological, cardiovascular, cerebrovascular,
metabolic such as including type ii diabetes or
other body system disorder.*
Yes
No
regular consumption of fish consisting more than
1 meal of fish per week or regular fish oil
supplements during the trial and for at least 2
weeks prior to the first study visit.*
Yes
No
subjects who have taken oral corticosteroids or a
leukotriene receptor antagonist in 4 weeks prior
to entry into the study.*
Yes
No
psychosis, alcoholism, active substance abuse,
or any personality disorder, which would make
compliance with this protocol problematic.*
Yes
No
pregnant or nursing females.*
Yes
No
any other medical or social condition which, in the
opinion of the investigator, could confound the
interpretation of the data derived from this study.*
Yes
No
subjects taking >1000 mcg of inhaled steroids
daily in those subjects taking inhaled steroids.*
Yes
No
subjects requiring regular anti-histamines for
allergies.*
Yes
No
subjects who have allergy to fish or any other
ingredient in the study products.*
Yes
No
subjects using anti-coagulants  (warfarin,
heparin)*
Yes
No
subjects who have surgery planned over the
course of the trial.*
Yes
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No
subjects who use medications to lower ldl
cholesterol levels*
Yes
No
subjects using non-steroidal anti-inflammatory
medications (e.g., aspirin, ibuprofen)*
Yes
No
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Eligibility Asthma NCT02319967
Coordinated Healthcare Interventions for Childhood
Asthma Gaps in Outcomes; ODM derived from:
https://clinicaltrials.gov/show/NCT02319967
All rights reserved. Please visit https://medical-data-
models.org/forms/14396
Eligibility Asthma NCT02319967
Inclusion Criteria
age: 5-11 years at date of ed visit*
Yes
No
seen at participating ed*
Yes
No
attending physician clinical diagnosis of asthma
exacerbation*
Yes
No
treatment with at least 1 dose short acting
bronchodilator (beta2 agonist or anticholinergic)*
Yes
No
treatment with at least 1 dose systemic
corticosteroids (oral, iv or im)*
Yes
No
receiving treatment for asthma in ed and/or
observation unit for at least 1 hour*
Yes
No
attending physician indicates that patient is likely
(>75% chance) to be discharged to home directly
from ed or observation unit.**
Yes
No
primary language: english or spanish*
Yes
No
Exclusion Criteria
patient admitted to the hospital*
Yes
No
discharge location other than home (e.g., other
hospital)*
Yes
No
caregiver unable or declines to provide written
permission or informed consent prior to discharge
to home*
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Yes
No
child or other member of household is
current/previous participant in the chicago trial*
Yes
No
concurrent enrollment in other asthma research
or enrolled in a different community health worker
(chw) home visit program.*
Yes
No
plan to move away from study site in next 12
months.*
Yes
No
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ODM Example Study
Test of ODM
All rights reserved. Please visit https://medical-data-
models.org/forms/14398
ODM Example
ODM Beispiel Merkmalsgruppe
Bereitschaft zur Teilnahme*
Ja
Nein
Alter
>= 0
<= 120
Jahre
Geschlecht
weiblich (f)
maennlich (m)
unbekannt (u)
Geburtsdatum
Diagnosetext
Diagnosekode
ICD10-GM
Kreatinin
>= 0
<= 20
mg/dl
Zeitpunkt des Laborwerts
hh:mm
Datum des Laborwerts
DD.MM.YYYY
Kommentar
Kalium
mmol/l
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Eligibility Asthma NCT02322775
Study to Evaluate the Efficacy and Safety of Benralizumab
in Adult Patients With Mild to Moderate Persistent Asthma;
ODM derived from:
https://clinicaltrials.gov/show/NCT02322775
All rights reserved. Please visit https://medical-data-
models.org/forms/14408
Eligibility Asthma NCT02322775
Inclusion Criteria
written informed consent for study participation
must be obtained prior to any study related
procedures being performed and according to
international guidelines and/or applicable
european union (eu) guidelines.*
Yes
No
female and male aged 18 to 75 years, inclusively,
at the time of visit 1.*
Yes
No
weight of ≥40 kg.*
Yes
No
evidence of asthma as documented by post-
bronchodilator (post-bd) reversibility in fev1 of ≥
12% demonstrated at visit 2.*
Yes
No
documented use of 1 of the following types of
asthma therapy at time of informed consent: low-
to medium-dose ics (ie, 100 to 500 μg fluticasone
dry powder formulation equivalents total daily
dose) with or without other controller medications,
eg, an ltra and/or theophylline or low-dose
ics/laba fixed combination therapy (eg, the lowest
regular maintenance dose approved in the local
country will meet this criterion)*
Yes
No
morning pre-bronchodilator (pre-bd) fev1 of >
50% to ≤ 90% predicted at visit 2.*
Yes
No
Exclusion Criteria
clinically important pulmonary disease other than
asthma (eg, active lung infection, copd,
bronchiectasis, pulmonary fibrosis, cystic fibrosis,
hypoventilation syndrome associated with
obesity, lung cancer, alpha 1 anti-trypsin
deficiency, and primary ciliary dyskinesia) or ever
been diagnosed with pulmonary or systemic
disease, other than asthma, that are associated
with elevated peripheral eosinophil counts (eg,
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allergic bronchopulmonary aspergillosis/mycosis,
churg-strauss syndrome, hypereosinophilic
syndrome).*
Yes
No
any disorder, including, but not limited to,
cardiovascular, gastrointestinal, hepatic, renal,
neurological, musculoskeletal, infectious,
endocrine, metabolic, hematological, psychiatric,
or major physical impairment that is not stable in
the opinion of the investigator and could:*
Yes
No
affect the safety of the patient throughout the
study*
Yes
No
nfluence the findings of the studies or their
interpretations,- impede the patient's ability to
complete the entire duration of study.*
Yes
No
known history of allergy or reaction to the
investigational product formulation.*
Yes
No
history of anaphylaxis to any biologic therapy.-
history of guillain-barré syndrome.*
Yes
No
a helminth parasitic infection diagnosed within 24
weeks prior to the date informed consent is
obtained that has not been treated with, or has
failed to respond to standard of care therapy.-
acute upper or lower respiratory infections
requiring antibiotics or antiviral medication within
30 days prior to the date informed consent is
obtained or during the screening/run-in period.*
Yes
No
any clinically significant abnormal findings in
physical examination, vital signs, hematology,
clinical chemistry, or urinalysis during screening
period, which in the opinion of the investigator,
may put the patient at risk because of his/her
participation in the study, or may influence the
results of the study, or the patient's ability to
complete entire duration of the study.*
Yes
No
positive hepatitis b surface antigen, or hepatitis c
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virus antibody serology, or a positive medical
history for hepatitis b or c. patients with a history
of hepatitis b vaccination without history of
hepatitis b are allowed to enroll.*
Yes
No
a history of known immunodeficiency disorder
including a positive human immunodeficiency
virus (hiv) test.*
Yes
No
history of cancer:*
Yes
No
patients who have had basal cell carcinoma,
localized squamous cell carcinoma of the skin or
in situ carcinoma of the cervix are eligible
provided that the patient is in remission and
curative therapy was completed at least 12
months prior to the date informed consent was
obtained.*
Yes
No
patients who have had other malignancies are
eligible provided that the patient is in remission
and curative therapy was completed at least 5
years prior to the date informed consent was
obtained*
Yes
No
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Eligibility Adenoid Cystic Carcinoma
NCT01586767
Intensity-Modulated or Proton Radiation Therapy for
Sinonasal Malignancy; ODM derived from:
https://clinicaltrials.gov/show/NCT01586767
All rights reserved. Please visit https://medical-data-
models.org/forms/14412
Eligibility Adenoid Cystic Carcinoma
NCT01586767
Inclusion Criteria
biopsy proven head and neck adenoid cystic
carcinoma with skull base or intracranial
extension or stage iii - ivb sinonasal squamous
cell carcinoma, adenoid cystic carcinoma,
adenocarcinoma, mucoepidermoid carcinoma,
sinonasal undifferentiated carcinoma,
schneiderian carcinoma, or undifferentiated
carcinoma.*
Yes
No
locally advanced sinus, nasal cavity, palate, major
or minor salivary gland tumors, or lacrimal
apparatus are eligible.*
Yes
No
nutritional and general physical condition must be
considered compatible with the proposed
radiation +/- chemotherapy treatment*
Yes
No
normal organ and marrow function*
Yes
No
Exclusion Criteria
active alcohol addiction*
Yes
No
pregnant or breastfeeding*
Yes
No
Study drug*
Yes
No
history of allergic reactions attributed to
compounds of similar chemical or biologic
composition to cisplatin for subjects who will
receive chemotherapy*
Yes
No
evidence of distant metastases or distant
leptomeningeal metastases*
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Yes
No
previous irradiation for head and neck tumor, skull
base, or brain tumors*
Yes
No
uncontrolled intercurrent illness*
Yes
No
history of a different malignancy unless disease-
free for at least 2 years and are deemed by the
investigator to be at low-risk for recurrence.
individuals with the following cancers are eligible
if diagnosed and treated for cure within the past 2
years: cervical cancer in situ, carcinoma in situ of
the breast, and basal cell or squamous ceel
carcinoma of the skin*
Yes
No
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Eligibility Adolescent Depression
NCT01170520
Repetitive Transcranial Stimulation (rTMS) for Resistant
Depression in Adolescents; ODM derived from:
https://clinicaltrials.gov/show/NCT01170520
All rights reserved. Please visit https://medical-data-
models.org/forms/14413
Eligibility Adolescent Depression
NCT01170520
Inclusion Criteria
age 15-18 years old*
Yes
No
Right handed*
Yes
No
suffering from major depression*
Yes
No
cdrs > 60*
Yes
No
at least 3 months of current depressive episode*
Yes
No
failed 2 drug trials (or 3 drug trials if trial
terminated prematurely due to side effects) and
at least 1 course of psychotherapy*
Yes
No
no contraindication for rtms (safety
questionnaire)*
Yes
No
no change in pharmacotherapy in the last month*
Yes
No
Exclusion Criteria
schizophrenia or psychotic symptoms*
Yes
No
hypertension*
Yes
No
Epilepsia*
Yes
No
history of major head trauma*
Yes
1 / 2
No
metal implements in the head*
Yes
No
history of neurosurgery*
Yes
No
history of severe head migraine*
Yes
No
history of hearing loss or sp cochlear
transplantation*
Yes
No
pregnancy*
Yes
No
current drug abuse*
Yes
No
unstable medical condition*
Yes
No
history of manic episode*
Yes
No
current treatment with lithium or tricyclic or
tetracyclic antidepressants*
Yes
No
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Eligibility Adolescent Depression
NCT01857518
Depression in Adolescents. A Cerebral Structural,
Diffusion, and Functional Magnetic Resonance Imaging
Study; ODM derived from:
https://clinicaltrials.gov/show/NCT01857518
All rights reserved. Please visit https://medical-data-
models.org/forms/14414
Eligibility Adolescent Depression
NCT01857518
Inclusion Criteria
depressed adolescents*
Yes
No
teenagers of both sexes, from 15 to 18 years old,
without contreindications in magnetic fields*
affiliation to a social insurance*
Yes
No
informed consent signed by the holders of the
parental rights (a specific information note to the
teenager)*
Yes
No
diagnosis dsm-iv-tr ( 2000 ) of depressive
disorder of the humor without psychotic
characteristics. the symptoms will have to be
persistent for 3 weeks, in spite of a coverage of
support ( 2 consultations).*
Yes
No
Exclusion Criteria
ferromagnetical material in the body*
Yes
No
claustrophobia, syndrom of post-traumatic stress,
obsessive-compulsive disorder, disturb tricks,
disturbs abuse of substances*
Yes
No
intrusive disorder of the development, disturbs
hyperactivity deficit of the attention, disorders of
the conducts, schizophrenia*
Yes
No
current antidepressant or antipsychotic
psychotropic treatment for more than 15 days in
effective doses*
Yes
No
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current somatic pathology, or pregnancy (urinary
test of pregnancy in case of doubt)*
Yes
No
histories of cranial trauma or neurological
pathology, or of lower born weight in 800g*
Yes
No
history of electroconvulsivotherapy in the
previous 6 months*
Yes
No
refusal to give his (her) consent or to be revised
on one year after inclusion*
Yes
No
healthy adolescents: will be screened to be
matched to the patients according to age and
sex. they will have no psychiatric diagnosis, and
no family history of psychiatric conditions.*
Yes
No
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Eligibility Adolescents Surviving Childhood
Leukemia LEA NCT01741662
Prevalence of Psychocognitive Impairments in Adolescents
Surviving Childhood Leukemia : LEA-PsyCog; ODM
derived from: https://clinicaltrials.gov/show/NCT01741662
All rights reserved. Please visit https://medical-data-
models.org/forms/14415
Eligibility Adolescents Surviving
Childhood Leukemia LEA
NCT01741662
Inclusion Criteria
age 18-year-old subordinate at the time of the
diagnosis;*
Yes
No
diagnosis of acute(sharp) leukaemia*
Yes
No
treatment (processing) of the acute (sharp)
leukaemia introduced in one of the inquiring
centers (services(departments) specialized
hematology and clermont ferrand's pediatric
oncology, grenoble, lyon, marseille, nancy, nancy,
nice, paris -*
Yes
No
living in France*
Yes
No
possessing a national insurance scheme*
Yes
No
24-month-old survivor of recoil(drop) with regard
to(compared with) the diagnosis for the
leukaemia aiguës myéloblastiques (lam) and
leukaemia aiguës lymphoblastiques ( lal)
transplanted in 1st complete forgiveness; or in 48
months of recoil(drop) with regard to(compared
with) the diagnosis for the lal not transplanted in
first complete forgiveness;*
Yes
No
Exclusion Criteria
failure to respect the criteria of inclusion
beforehand quoted*
Yes
No
initial treatment (processing) realized except 2
participating centers (marseille, nice), even in
case of moving in in the geographical zones
covered by these centers during the phase of
treatment (processing) or in the course of follow-
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up*
Yes
No
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Eligibility Alcoholic Hepatitis NCT01756794
Validation of the Procedure of Early Liver Transplantation in
Alcoholic Hepatitis Resisting to Medical Treatment; ODM
derived from: https://clinicaltrials.gov/show/NCT01756794
All rights reserved. Please visit https://medical-data-
models.org/forms/14416
Eligibility Alcoholic Hepatitis
NCT01756794
Inclusion criteria
age > 18 years*
Yes
No
maddrey score > 32*
Yes
No
liver biopsy confirming the diagnosis of alcoholic
hepatitis*
Yes
No
non-response to medical treatment: lille score ≥
0.45 at day 7, or early worsening of liver function
(meld score > 25) despite a low lille score (<
0.45)*
Yes
No
hospitalization stay < 1 month*
Yes
No
algorithm score ≥ 220/250.*
Yes
No
inclusion criteria (group b):*
Yes
No
inclusion criteria (group b)
age >18 years
Yes
No
diagnosis of alcoholic cirrhosis
Yes
No
alcoholic withdrawal of 6 months minimum before
inscription on the transplant list
Yes
No
meld score ≥ 15 for patients with hepatocellular
carcinoma responding to milan criteria (1 node <
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5 cm or 3 nodes < 3 cm)
Yes
No
no recommendation of meld score for patients
having obtained an "expert" component
Yes
No
Exclusion criteria
bacterial or viral infection uncontrolled by medical
treatment
Yes
No
fungal or aspergillosis uncontrolled infection
Yes
No
hepatocellular carcinoma or invasive cancer
Yes
No
positive test for hbsag, positive test for
hiv,positive pcr for hcv
Yes
No
portal thrombosis
Yes
No
pregnancy or breast-feeding
Yes
No
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Eligibility Asthma NCT02327897
NHALES (Natural History of Asthma With Longitudinal
Environmental Sampling); ODM derived from:
https://clinicaltrials.gov/show/NCT02327897
All rights reserved. Please visit https://medical-data-
models.org/forms/14422
Eligibility Asthma NCT02327897
Criteria
participants must meet all of the following criteria
for enrollment:*
Yes
No
1. male or female, 18 to 60 years of age*
Yes
No
2. must have clinical evidence of moderate-
severe atopic asthma:*
Yes
No
self-reported symptoms suggestive of asthma
(such as wheezing, chest tightness, shortness of
breath, cough nocturnal symptoms) for at least
one year, and*
Yes
No
a positive methacholine test confirming diagnosis
[provocative concentration causing a 20% fall in
forced expiratory volume in 1 second (pc20 fev1)
< 16 mg/ml for participants on inhaled
corticosteroids and < 8 mg/ml for participants not
on inhaled corticosteroids] or postbronchodilator
fev1 with at least 12% or 200 ml increase in fev1
or forced volume vital capacity (fvc) on
bronchodilator challenge, and*
Yes
No
no other diagnosis that could explain symptoms.*
Yes
No
3. able to travel to the niehs cru, in research
triangle park, north carolina, for required study
visits*
Yes
No
4. able to present a valid government issued form
of identification for entry to the niehs campus*
Yes
No
5. able to receive asthma treatment medication(s)
via mail*
Yes
No
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6. willingness to comply with instructions
regarding medication regimen, diet, and life style
as directed by the investigator that are required
per protocol*
Yes
No
7. access to a vacuum cleaner with a detachable
hose component*
Yes
No
bronchoscopy sub-study inclusion criterion*
Yes
No
in addition to the above inclusion criteria,
participants must be able to fast for 6 hours (no
food or drink, except a small amount of water if
needed to take approved medications) prior to
the bronchoscopy visit in order to be eligible for
enrollment in the bronchoscopy sub-study.*
Yes
No
Exclusion Criteria
participants meeting any of the following criteria
at screening will not be eligible for enrollment or
to continue with study visits:*
Yes
No
1. women who are pregnant or lactating at the
time of screening (this exclusion is in place
because certain enrollment procedures, may
pose an undue risk on the unborn fetus; women
may rescreen at a later date once no longer
pregnant or breastfeeding; women who are
pregnant or lactating at the time of the baseline
visit and are scheduled to complete the
methacholine challenge will be withdrawn due to
the potential risk to the fetus; women who
become pregnant after completing the baseline
visit will not be excluded from further participation
but will also not be eligible for participation in the
bronchoscopy sub-study)*
Yes
No
2. current smoker, significant second-hand smoke
exposure (defined by urine cotinine > 100 ng/ml
at screening), or a history of smoking greater
than 5 pack years. smoking encompasses all
inhaled products, including e-cigarettes.*
Yes
No
3. pico smokealyzer   value of > 11ppm*
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Yes
No
4. history of the following comorbidities: chronic
obstructive pulmonary disease, cystic fibrosis
(cf), emphysema, non-cf bronchiectasis,
pulmonary fibrosis, sarcoidosis, unstable angina,
pulmonary hypertension*
Yes
No
5. allergy or history of adverse reactions to
methacholine*
Yes
No
6. any condition that, in the investigator's opinion,
places the participant at undue risk for
complications associated with required study
procedures*
Yes
No
7. comorbid diseases that affect global health or
survival- such as dvt, pulmonary embolism, class
iii - iv congestive heart failure, or a malignancy
under treatment*
Yes
No
bronchoscopy sub-study exclusion criteria*
Yes
No
in addition to the above exclusion criteria,
participants meeting any of the following criteria
will not be eligible for enrollment into the
bronchoscopy sub-study:*
Yes
No
1. pregnant, as indicated by urine pregnancy
test*
Yes
No
2. any condition that, in the investigator's opinion,
places the participant at undue risk for
complications associated with bronchoscopy*
Yes
No
3. bleeding disorders*
Yes
No
4. facial deformity, major facial surgery*
Yes
No
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5. asthma exacerbation or respiratory infection
less than or equal to 4 weeks prior to study visit*
Yes
No
6. severe persistent asthma, defined as by ats-
ers criteria.*
Yes
No
7. allergy or history of adverse reactions to
lidocaine*
Yes
No
8. temperature > 37.6 (infinite)c; blood pressure <
90/50 mm hg or > 160/100 mm hg; pulse rate <
50 or > 100 beats/minute*
Yes
No
9. body weight < 50 kg (< 110 lbs)*
Yes
No
10. the following abnormal lab values (values
obtained during clinical assessment):*
Yes
No
platelet count < 150,000 per   l*
Yes
No
white blood cells count < 3000 per   l*
Yes
No
absolute neutrophil count < 1000 per   l*
Yes
No
hematocrit < 35% for both female and male*
Yes
No
prothrombin time (pt) / abnormal international
normalized ratio (inr) and partial
prothromboplastin time (ptt) based on reference
laboratory established reference ranges*
Yes
No
serum creatinine > 1.4 mg/dl*
Yes
No
participants with active bronchospasm on the day
of the bronchoscopy will not undergo
bronchoscopy.*
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Yes
No
5 / 5
Eligibility Asthma NCT02327897
Eligibility Asthma NCT02345928
A Single Ascending Dose Study in Healthy Participants and
Multiple Ascending Dose Study of CNTO 7160 in
Participants With Asthma and Participants With Atopic
Dermatitis; ODM derived from:
https://clinicaltrials.gov/show/NCT02345928
All rights reserved. Please visit https://medical-data-
models.org/forms/14424
Eligibility Asthma NCT02345928
Inclusion Criteria
part 1 (healthy participants): participant must
have a body weight in the range of 50 to 100
kilogram (kg) inclusive and have a body mass
index (bmi) of 19 to 30 kilogram per meter square
(kg/m^2) inclusive*
Yes
No
part 1 (healthy participants): participant must be
healthy on the basis of physical examination,
medical history, vital signs and 12-lead ecg
performed at screening*
Yes
No
part 2 (asthma participants): participant must
have a body weight in the range of 50 to 125 kg
inclusive and have a bmi of 19 to 32 kg/m^2
inclusive*
Yes
No
part 2 (asthma participants): participant must
have a physician documented diagnosis of
asthma for at least 12 months before screening*
Yes
No
part 2 (atopic dermatitis participants): participant
must have a body weight in the range of 50 to
100 kg inclusive and have a bmi of 19 to 30
kg/m^2 inclusive*
Yes
No
part 2 (atopic dermatitis participants): participant
has physician documented diagnosis of atopic
dermatitis for at least 12 months before screening
based on uk refinements of the rajka and hanifin
criteria*
Yes
No
Exclusion Criteria
part 1 (healthy participants): participant has any
known malignancy or history of malignancy, with
the exception of basal cell carcinoma or
squamous cell carcinoma in situ of the skin that
has been treated with no evidence of recurrence
within 6 months prior to the screening visit*
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Yes
No
part 1 (healthy participants):  participant currently
has or has a history of any clinically significant
cardiovascular disease, including but not limited
to a history of angina or myocardial infarction,
congestive heart failure, symptomatic
atherosclerotic vascular disease, or arrhythmia.*
Yes
No
part 2 (asthma participants): participant has any
known malignancy or history of malignancy, with
the exception of basal cell carcinoma or
squamous cell carcinoma in situ of the skin that
has been treated with no evidence of recurrence
within 6 months prior to the screening visit*
Yes
No
part 2 (asthma participants): participant has or
have had a serious infection (eg, sepsis,
pneumonia or pyelonephritis), or have been
hospitalized or received iv antibiotics for a serious
infection during the 4 months prior to the
screening visit*
Yes
No
part 2 (atopic dermatitis participants):  participant
has any known malignancy or history of
malignancy, with the exception of basal cell
carcinoma or squamous cell carcinoma in situ of
the skin that has been treated with no evidence of
recurrence within 6 months prior to the screening
visit.*
Yes
No
part 2 (atopic dermatitis participants): participant
has or have had a serious infection (eg, sepsis,
pneumonia or pyelonephritis), or have been
hospitalized or received iv antibiotics for a serious
infection during the 4 months prior to the
screening visit*
Yes
No
2 / 2
Eligibility Asthma NCT02345928
NINDS CDE Magnetic Resonance Imaging
Amyotrophic Lateral Sclerosis
NINDS Common Data Elements (Magnetic Resonance
Imaging Amyotrophic Lateral Sclerosis) Used from the
National Institute of Neurological Disorders and Stroke
Common Data Elements
(https://www.commondataelements.ninds.nih.gov/)
References: Grinnon ST, Miller K, Marler JR, Lu Y, Stout A,
Odenkirchen J, Kunitz S. National Institute of Neurological
Disorders and Stroke Common Data Element Project -
approach and methods. Clin Trials. 2012;9(3):322-9.
All rights reserved. Please visit https://medical-data-
models.org/forms/14425
Magnetic Resonance Imaging
Brain Perfusion Magnetic Resonance
Imaging
Study ID
Study site name
Subject ID
Magnetic Field Strength of Scanner Used
1.5 T  (1)
3.0 T  (2)
4.0 T  (3)
7.0 T  (4)
Other, specify below (5)
Magnetic Field Strength:if other,please specify
T
RF receiver coil(s) and number of channels:head
coil
Yes
No
RF receiver coil(s) and number of channels: Body
coil
Yes
No
Perfusion Imaging Method
Dynamic Susceptibility Contrast (DSC)
(1)
Arterial Spin Labeling (ASL) (2)
Contrast agent used?
Yes
No
If Yes, name of the contrast
Contrast dosage
Injection rate of contrast
mL/min
For Axial DSC T2- MRI Sequence
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parameters:Sequence
Gradient-echo  (1)
Other, specify (2)
For Axial DSC T2- MRI Sequence parameter: if
other sequence, please specify
For Axial DSC T2- MRI Sequence
parameter:Field of view
x mm²
For Axial DSC T2- MRI Sequence parameter: In-
plane resolution
x mm²
For Axial DSC T2- MRI Sequence parameter:
Slice thickness
mm
For Axial DSC T2- MRI Sequence parameter:
number of slices
For Axial DSC T2- MRI Sequence parameter:
Repetition time (TR)
msec
For Axial DSC T2- MRI Sequence parameter:
Echo time (TE)
msec
For Axial DSC T2- MRI Sequence parameter:
Number of signal averages
For Axial DSC T2- MRI Sequence parameter:
Acquisition time
Minutes
For Axial DSC T2- MRI Sequence parameter:
Base resolution
points
For Axial DSC T2- MRI Sequence parameter:
Phase resolution Partial Fourier
%
For Axial DSC T2- MRI Sequence parameter:
Band width
Hz
For Axial DSC T2- MRI Sequence parameter:
Echo spacing
msec
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For Axial DSC T2- MRI Sequence parameter:
Echo train length
EPI factor
For Axial DSC T2- MRI Sequence parameter: No.
of shots
For Axial DSC T2- MRI Sequence parameter:
Interpolation
Yes
No
For Axial DSC T2- MRI Sequence parameter:
Phase-encode direction
For Axial DSC T2- MRI Sequence parameter:
Flow compensation
Yes
No
For Axial DSC T2- MRI Sequence parameter: Fat
signal suppressed
Yes
No
For Axial DSC T2- MRI Sequence parameter:
Parallel acquisition used
Yes
No
Parallel acquisition used:if yes, please specify
method
GRAPPA  (1)
SENSE  (2)
Other, specify (3)
Parallel acquisition method:if other please specify
For Axial ASL Aquisition Sequence
Parameter:Sequence
Pulsed-ASL  (1)
Continuous-ASL  (2)
Pseudocontinuous-ASL (3)
For Axial ASL Aquisition Sequence Parameter:
Field of view
x mm²
For Axial ASL Aquisition Sequence Parameter:
In-plane resolution
x mm²
For Axial ASL Aquisition Sequence Parameter:
Slice thickness
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mm
For Axial ASL Aquisition Sequence Parameter:
Number of slices
For Axial ASL Aquisition Sequence Parameter:
Repetition time (TR)
msec
For Axial ASL Aquisition Sequence Parameter:
Echo time (TE)
msec
For Axial ASL Aquisition Sequence Parameter:
Number of signal averages
For Axial ASL Aquisition Sequence Parameter:
Labeling pulse duration
msec
For Axial ASL Aquisition Sequence Parameter:
Post-labeling delay
msec
For Axial ASL Aquisition Sequence Parameter:
Distance of the labeling plane from the center
slice
mm
For Axial ASL Aquisition Sequence Parameter:
Number of pairs (control and tag) of
measurements
For Axial ASL Aquisition Sequence Parameter:
Aquisition time
Minutes
For Axial ASL Aquisition Sequence Parameter:
Base resolution
points
For Axial ASL Aquisition Sequence Parameter:
Phase resolution
%
For Axial ASL Aquisition Sequence Parameter:
Phase resolution Partial Fourier
Yes, please specify below (1)
No (2)
Phase resolution Partial Fourier:if yes please
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specify
For Axial ASL Aquisition Sequence Parameter:
Band width
Hz
For Axial ASL Aquisition Sequence Parameter:
Echo spacing
msec
For Axial ASL Aquisition Sequence Parameter:
Echo train length
EPI factor
For Axial ASL Aquisition Sequence Parameter:
No. of shots
For Axial ASL Aquisition Sequence Parameter:
Interpolation
Yes
No
For Axial ASL Aquisition Sequence Parameter:
Phase-encode direction
For Axial ASL Aquisition Sequence Parameter:
Flow compensation
Yes
No
For Axial ASL Aquisition Sequence Parameter:
Fat signal suppressed
Yes
No
For Axial ASL Aquisition Sequence Parameter:
Parallel acquisition used
Yes
No
Parallel acquisition used:If yes, please specify
method
GRAPPA  (1)
SENSE  (2)
Other,please specify below (3)
Parallel acquisition method:If other please specify
Post processing and analysis: Software used
Scanner provided  (1)
FSL (2)
DtiStudio (3)
Other, specify (4)
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Post processing and analysis: Software Version
Number
Post processing and analysis: Parameter maps
calculated
Time to Peak (TTP) (1)
Relative cerebral blood volume (relCBV)
(2)
Relative cerebral flow (relCBF) (3)
Relative mean transit time (relMTT) (4)
Name of the scanner manufacturer
GE  (1)
Siemens  (2)
Philips  (3)
Other, specify (4)
Name of manufacturer:If other, please specify
Name of the scanner software
Version number of scanner software
Diffusion Tensor Imaging
Magnetic Field Strength of Scanner Used
1.5 T  (1)
3.0 T  (2)
4.0 T  (3)
7.0 T  (4)
Other, specify below (5)
Magnetic Field Strength:if other,please specify
T
Body part scanned
Brain  (1)
Cervical spine  (2)
Thoracic spine  (3)
Lumbar spine (4)
RF receiver coil(s) and number of channels:
Head coil
Yes
No
RF receiver coil(s) and number of channels: Neck
coil
Yes
No
RF receiver coil(s) and number of channels:
Spine Array
Yes
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No
RF receiver coil(s) and number of channels: Body
coil (transmit)
Yes
No
T2-weighted spin-echo acquired (for B0-
susceptibility distortion correction):
Yes
No
Contrast agent used
Yes
No
If Yes, name of the contrast
Contrast dosage
DTI sequence parameters: Sequence
Spin-echo  (1)
STEAM (2)
DTI sequence parameters: Slice orientation
Axial  (1)
Coronal  (2)
Sagittal (3)
Oblique (4)
Other,please specify below (5)
DTI sequence parameters: Field of view (mm x
mm): by
DTI sequence parameters: In-plane resolution
(mm x mm): by
DTI sequence parameters: Slice thickness
mm
DTI sequence parameters: number of slices
DTI sequence parameters: Repetition time (TR)
msec
DTI sequence parameters: Echo time (TE)
msec
DTI sequence parameters: Number of signal
averages
DTI sequence parameters: Number of diffusion-
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weighting gradient directions
DTI sequence parameters: 1st b-values (square
mm per second):
mm²/sec
DTI sequence parameters: 2nd b-values (square
mm per second):
mm²/sec
DTI sequence parameters: 3rd b-values (square
mm per second):
mm²/sec
DTI sequence parameters: 4th b-values (square
mm per second):
mm²/sec
DTI sequence parameters: 5th b-values (square
mm per second):
mm²/sec
DTI sequence parameters: 6th b-values (square
mm per second):
mm²/sec
DTI sequence parameters: Acquisition time
Minutes
DTI sequence parameters: Base resolution
points
DTI sequence parameters: Phase resolution
Partial Fourier
%
Yes, please specify below (1)
No (2)
Phase resolution Partial Fourier: if Yes please
specify
DTI sequence parameters: Band width
Hz per Pixel
DTI sequence parameters: Echo spacing
msec
DTI sequence parameters: Echo train length
EPI factor
DTI sequence parameter: No of shots
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DTI sequence parameter: Interpolation
Yes
No
DTI sequence parameter: Phase-encode
direction
DTI sequence parameter: Flow compensation
Yes
No
DTI sequence parameter: Fat signal suppressed
Yes
No
DTI sequence parameter: Parallel acquisition
used
Yes
No
Parallel acquisition used:If yes, please specify
method
GRAPPA  (1)
SENSE  (2)
Other,please specify below (3)
Parallel acquisition method:If other, please
specify method
Post processing and analysis: Software used
Scanner provided  (1)
FSL (2)
DtiStudio (3)
Other, specify (4)
DWI co-registered to b = 0 image and corrected
for subject motion and eddy current induced
distortion (affine transformation)?
Yes
No
DWI co-registered to T2 image for B0-
susceptibility distortion correction?
Yes
No
Spatially registered to a template for data
analysis?
Yes
No
Name of the scanner manufacturer
GE  (1)
Siemens  (2)
Philips  (3)
Other, specify (4)
Name of manufacturer:If other, please specify
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Name of the scanner software
Version number of scanner software
Functional Magnetic Resonance Imaging
Magnetic Field Strength of Scanner Used
1.5 T  (1)
3.0 T  (2)
4.0 T  (3)
7.0 T  (4)
Other, specify below (5)
Magnetic Field Strength:if other,please specify
T
RF receiver coil(s) and number of channels:
Head coil
Yes
No
RF receiver coil(s) and number of channels: Body
coil (transmit)
Yes
No
Sequences used
fMRI  (1)
T1-weighted  (2)
Other, specify (3)
Sequences used:if other,please specify
fMRI sequence:Resting state with eyes
Closed-awake  (1)
Closed-sleep  (2)
Open-fixated  (3)
Open-random (4)
fMRI Sequence:Functional with tasks as
Block designed  (1)
Event related (2)
fMRI Sequence:Slice orientation
Axial  (1)
Coronal  (2)
Sagittal (3)
Oblique (4)
Other,please specify below (5)
fMRI Sequence: Field of view (mm x mm):	by
fMRI Sequence: In-plane resolution (mm x mm):
by
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fMRI Sequence: Slice thickness
mm
fMRI Sequence: Number of slices
fMRI Sequence: Gap between slices
mm
fMRI Sequence: Number of volumes or frames
fMRI Sequence: Repetition time (TR)
msec
fMRI Sequence: Echo time (TE)
msec
fMRI Sequence: Phase-encode direction
fMRI Sequence: Acquisition time
Minutes
fMRI Sequence: Flip angle (FA)
degrees °
fMRI Sequence: Base resolution
points
fMRI Sequence: Phase resolution Partial Fourier
%
Yes, please specify below (1)
No (2)
fMRI sequence parameters: Phase resolution
Partial Fourier
%
fMRI Sequence: Band width
Hz/Pixel
fMRI Sequence: flow compensation used
Yes
No
fMRI Sequence:Fat signal suppressed
Yes
No
fMRI Sequence:parallel acquisition used
Yes
No
Parallel acquisition used:if yes, please specify
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method
GRAPPA  (1)
SENSE  (2)
Other, specify (3)
Parallel acquisition used:if other,please specify
method
T1-fMRI sequence parameters:Slice orientation
Axial  (1)
Coronal  (2)
Sagittal (3)
Oblique (4)
Other,please specify below (5)
T1-fMRI sequence parameters:Field of view (mm
x mm):	by
T1-fMRI sequence parameters: In-plane
resolution: (mm x mm):	by
T1-fMRI sequence parameters: Slice thickness
mm
T1-fMRI sequence parameters: Number of slices
T1-fMRI sequence parameters: Repetition time
(TR)
msec
T1-fMRI sequence parameters: Echo time (TE)
msec
T1-fMRI sequence parameters:Acquisition time
Minutes
T1-fMRI sequence parameter: Inversion time (TI)
msec
T1-fMRI sequence parameters: Flip angle (FA)
degrees °
T1-fMRI sequence parameters: Base resolution
points
T1-fMRI sequence parameters: Phase resolution
Partial Fourier
%
Yes, please specify below (1)
No (2)
T1-fMRI sequence parameters: Phase resolution
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Partial Fourier
%
T1-fMRI sequence parameters: Band width
Hz/Pixel
T1-fMRI sequence parameters: Echo spacing
msec
T1-fMRI sequence parameters: Echo train length
T1-fMRI sequence parameters: slice over
sampling
%
T1-fMRI sequence parameters: Phase-encode
direction
T1-fMRI sequence parameters: Flow
compensation used
Yes
No
Flow compensation used:if yes, please specify
method
GRAPPA  (1)
SENSE  (2)
Other,please specify below (3)
Flow compensation used:if other, please specify
method
fMRI data processing software used
SPM (1)
AFNI (2)
FSL (3)
Other (please specify below) (4)
Software used for quantitative analysis of T1-MRI
SPM (1)
FSL (2)
FreeSurfer (3)
Other (please specify below) (4)
fMRI data processing software used:if other
please specify
Software used for quantitative analysis of T1-
MRI:if other,please specify
Software version number
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Name of scanner manufacturer
GE  (1)
Siemens  (2)
Philips  (3)
Other, specify (4)
Name of the scanner software
Version number of scanner software
Name of scanner manufacturer: if other,please
specify
Magnetic Resonance Imaging
Magnetic Field Strength of Scanner Used
1.5 T  (1)
3.0 T  (2)
4.0 T  (3)
7.0 T  (4)
Other, specify below (5)
Body part scanned
Brain (1)
Cervical spine (2)
Thoracic spine (3)
Lumbar spine  (4)
Other, specify: (5)
RF receiver coil(s) and number of channels:
Head coil
Yes
No
RF receiver coil(s) and number of channels: Neck
coil
Yes
No
RF receiver coil(s) and number of channels:
Spine Array
Yes
No
RF receiver coil(s) and number of channels: Body
coil (transmit)
Yes
No
RF receiver coil(s) and number of channels:
Other,please specify
Sequences used
T1-weighted (1)
T2-weighted (2)
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FLAIR (3)
Other,please specify below (4)
Sequence used:if other please specify
Contrast agent used
Yes
No
Please specify the name of the contrast agent
used
Please specify dosage of contrast agent used
T1-MRI sequence parameters: Slice orientation
Axial  (1)
Coronal  (2)
Sagittal (3)
Oblique (4)
Other,please specify below (5)
T1-MRI sequence parameters: Field of view mm
x mm
mm²
T1-MRI sequence parameters: In-Plane
resolution mm x mm
mm²
T1-MRI sequence parameters: Slice thickness
mm
T1-MRI sequence parameters: Gap between
slices
mm
T1-MRI sequence parameters: Number of slices
T1-MRI sequence parameters: Repetition time
(TR)
msec
T1-MRI sequence parameters: Echo Time (TE)
msec
T1-MRI sequence parameters: Acquisition time
Minutes
T1-MRI sequence parameters: Inversion time (TI)
msec
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T1-MRI sequence parameters: Flip Angle (FA)
degrees °
T1-MRI sequence parameters: Base resolution
points
T1-MRI sequence parameters: Phase resolution
Partial Fourrier
%
Yes, please specify below (1)
No (2)
T1-MRI sequence parameters: Phase resolution
Partial Fourrier if yes, please specify
%
T1-MRI sequence parameters: Band width
Hz/Pixel
T1-MRI sequence parameters: Echo spacing
msec
T1-MRI Sequence parameter: Echo train length
T1-MRI Sequence parameter: Slice over
sampling
%
T1-MRI Sequence parameter: Phase encode
direction
T1-MRI Sequence parameter: Flow
compensation used
Yes
No
T1-MRI Sequence parameter: Fat signal
suppressed
Yes
No
T1-MRI Sequence parameter: Parallel acquisition
used
Yes
No
Parallel acquisition used; if yes, please specify
method
GRAPPA  (1)
SENSE  (2)
Other, specify (3)
Parallel acquisition used; if other, please specify
method
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T2-MRI sequence parameters: Slice orientation
Axial  (1)
Coronal  (2)
Sagittal (3)
Oblique (4)
Other,please specify below (5)
T2-MRI sequence parameters: Field of view mm
x mm
mm²
T2-MRI sequence parameters: In-Plane
resolution mm x mm
mm²
T2-MRI sequence parameters: Slice thickness
mm
T2-MRI sequence parameters: Gap between
slices
mm
T2-MRI sequence parameters: Number of slices
T2-MRI sequence parameters: Repetition time
(TR)
msec
T2-MRI sequence parameters: Echo Time (TE)
msec
T2-MRI sequence parameters: Acquisition time
Minutes
T2-MRI sequence parameters: Flip Angle (FA)
degrees °
T2-MRI sequence parameters: Base resolution
points
T2-MRI sequence parameters: Phase resolution
Partial Fourrier
%
Yes, please specify below (1)
No (2)
T2-MRI sequence parameters: Phase resolution
Partial Fourrier if yes please specify
%
T2-MRI sequence parameters: Band width
Hz/Pixel
17 / 25
NINDS CDE Magnetic Resonance Imaging Amyotrophic Lateral Sclerosis
T2-MRI sequence parameters: Echo spacing
msec
T2-MRI Sequence parameter: Echo train length
T2-MRI Sequence parameter: Slice over
sampling
%
T2-MRI Sequence parameter: Phase encode
direction
T2-MRI Sequence parameter: Flow
compensation used
Yes
No
T2-MRI Sequence parameter: Fat signal
suppressed
Yes
No
T2-MRI Sequence parameter: Parallel acquisition
used
Yes
No
Parallel acquisition used; if yes, please specify
method
GRAPPA  (1)
SENSE  (2)
Other, specify (3)
Parallel acquisition used; if other, please specify
method
FLAIR sequence parameters:Slice orientation
Axial  (1)
Coronal  (2)
Sagittal (3)
Oblique (4)
Other,please specify below (5)
FLAIR sequence parameters: Field of view mm x
mm
mm²
FLAIR sequence parameters: In-Plane resolution
mm x mm
mm²
FLAIR sequence parameters: Slice thickness
mm
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FLAIR sequence parameters: Gap between
slices
mm
FLAIR sequence parameters: Number of slices
FLAIR sequence parameters: Repetition time
(TR)
msec
FLAIR sequence parameters: Echo Time (TE)
msec
FLAIR sequence parameters: Acquisition time
Minutes
FLAIR sequence parameters: Flip Angle (FA)
degrees °
FLAIR sequence parameters: Base resolution
points
FLAIR sequence parameters: Phase resolution
Partial Fourrier
%
Yes, please specify below (1)
No (2)
FLAIR sequence parameters: Phase resolution
Partial Fourrier if yes, please specify
%
FLAIR sequence parameters: Band width
Hz/Pixel
FLAIR sequence parameters: Echo spacing
msec
FLAIR Sequence parameter: Echo train length
FLAIR Sequence parameter: Slice over sampling
%
FLAIR Sequence parameter: Phase encode
direction
FLAIR Sequence parameter: Flow compensation
used
Yes
No
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FLAIR Sequence parameter: Fat signal
suppressed
Yes
No
FLAIR Sequence parameter: Parallel acquisition
used
Yes
No
Parallel acquisition used; if yes, please specify
method
GRAPPA  (1)
SENSE  (2)
Other, specify (3)
Parallel acquisition used; if other, please specify
method
Clinical read of MRI:Read type
Local (1)
Central (2)
Other, specify (3)
Clinical read of MRI: read type, if other please
specify
Clinical read of MRI:Reader blinded to clincial
data?
Yes
No
Clinical read of MRI: Quality of images technically
satisfactory?
Yes
No
Lesions found
Yes
No
Type of lesion: if yes please specify
WM hyperintensity (1)
Infarct (2)
Spondylosis (3)
Other, specify (4)
Type of lesion:if other please specify
Location of lesion: if lesion found, please specify
site
Software used for quantitative analysis of T1-MRI
SPM (1)
FSL (2)
FreeSurfer (3)
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Other (please specify below) (4)
Software used for quantitative analysis of T1-
MRI:if other,please specify
Software version number
Name of scanner manufacturer
GE  (1)
Siemens  (2)
Philips  (3)
Other, specify (4)
Name of scanner manufacturer:if other please
specify
Name of the scanner software
Version number of scanner software
Magnetic Resonance Spectroscopy
Magnetic Field Strength of Scanner Used
1.5 T  (1)
3.0 T  (2)
4.0 T  (3)
7.0 T  (4)
Other, specify below (5)
Body part scanned
Brain  (1)
Cervical spine  (2)
Thoracic spine  (3)
Lumbar spine (4)
RF receiver coil(s) and number of channels:
Head coil
Yes
No
RF receiver coil(s) and number of channels: Neck
coil
Yes
No
RF receiver coil(s) and number of channels:
Spine Array
Yes
No
RF receiver coil(s) and number of channels: Body
coil (transmit)
Yes
No
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Sequences used
Single voxel (SVS)	 (1)
Spectroscopic Imaging (SI)-2D  (2)
SI-3D (3)
PRESS  (4)
STEAM (5)
Spin-echo (6)
T1 (for segmenting to obtain CSF and
tissue-type (GM and WM) composition of
MRS voxels used) (7)
Other, specify: (8)
Sequence used:if other please specify
Spectroscopy sequence parameters:for
metabolite data acquisition Repetition time (TR)
msec
Spectroscopy sequence parameters:for
metabolite data acquisition TE: ms; For STEAM,
TM= ms
msec
Spectroscopy sequence parameters:for
metabolite data acquisition Number of averages:
Acquisition time: minutes
Minutes
Spectroscopy sequence parameters: SVS
Anatomical location of voxel
Spectroscopy sequence parameters: Voxel size
left to right
mm
Spectroscopy sequence parameters:Voxel size
anterior to posterior
mm
Spectroscopy sequence parameters:Voxel size
inferior to superior
mm
Spectroscopy sequence parameters:Voxel
volume
mm³
Spectroscopy sequence parameters:SI
Anatomical coverage of CSI-slice or slab FOV: In-
plane: x mm2
mm²
Spectroscopy sequence parameters SI
Anatomical coverage of CSI-slice or slab z-
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direction (3D): mm
mm
Spectroscopy sequence parameters SI
Anatomical coverage of CSI-slice or slab
slice/slab thickness: mm
mm
Spectroscopy sequence parameters:SI
Anatomical coverage of CSI-slice or slab Matrix
size: In-plane: x
Spectroscopy sequence parameters:SI
Anatomical coverage of CSI-slice or slab z-
direction (3D): points
points
Spectroscopy sequence parameters water
suppression scheme
CHESS  (1)
Other (2)
Spectroscopy sequence parameters:Water signal
suppression bandwidth
Hz
Spectroscopy sequence parameters for water
reference data acquisition TR = ms (if different
from the metabolite data acquisition)
msec
Spectroscopy sequence parameters for water
reference data acquisition TE = ms (if different
from the metabolite data acquisition)
msec
Spectroscopy sequence parameters Number of
averages
Spectroscopy sequence parameters Acquisition
time: minutes
Minutes
Spectroscopy sequence parameters spectral
points (data size): Points
points
Spectroscopy sequence parameters spectral
bandwidth: Hz
Hz
Spectroscopy sequence parameters for PRESS,
23 / 25
NINDS CDE Magnetic Resonance Imaging Amyotrophic Lateral Sclerosis
is it symmetric (TE = TE1 + TE2; TE1 = TE2) or
asymmetric (TE1 ≠ TE2)?
Symmetric (1)
Asymmetric (2)
Spectroscopy sequence parameters if
asymmetric TE1
msec
Spectroscopy sequence parameters if
asymmetric TE2
msec
Post processing applied:B0-shift correction
Yes
No
Post processing applied: Eddy-current-induced
spectral distortion correction?
Yes
No
Post processing applied: Residual water signal
removed?
Yes
No
Residual water signal removed? If yes,water
signal removal filter used
Post processing applied:Metabolite concentration
reported in
Absolute value (1)
Institutional unit (2)
Ratio (3)
Post processing applied: Quantitation takes into
account CSF partial volume?
Yes
No
Post processing applied:spectral fit software used
LCM (1)
jMRUI (2)
Other (3)
Name of scanner manufacturer
GE  (1)
Siemens  (2)
Philips  (3)
Other, specify (4)
Name of scanner manufacturer:if other please
specify
Name of the scanner software
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Version number of scanner software
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Eligibility Asthma NCT02351141
Structure and Function MRI of Asthma; ODM derived from:
https://clinicaltrials.gov/show/NCT02351141
All rights reserved. Please visit https://medical-data-
models.org/forms/14426
Eligibility Asthma NCT02351141
Inclusion Criteria
subjects male and female aged 18-60 with a
clinical diagnosis of asthma*
Yes
No
smoking history ≤ 1 pack/year*
Yes
No
subject understands the study procedures and is
willing to participate in the study as indicated by
signature on the informed consent*
Yes
No
subject is judged to be in otherwise stable health
on the basis of medical history*
Yes
No
subject able to perform reproducible pulmonary
function testing (i.e., the 3 best acceptable
spirograms have fev1 values that do not vary
more than 5% of the largest value or more than
100 ml, whichever is greater.)*
Yes
No
fev1 >60% predicted*
Yes
No
Exclusion Criteria
patient is, in the opinion of the investigator,
mentally or legally incapacitated, preventing
informed consent from being obtained, or cannot
read or understand the written material*
Yes
No
patient is unable to perform spirometry or
plethysmography maneuvers*
Yes
No
subject has an implanted mechanically,
electrically or magnetically activated device or
any metal in their body which cannot be removed,
including but not limited to pacemakers,
neurostimulators, biostimulators, implanted
insulin pumps, aneurysm clips, bioprosthesis,
1 / 2
artificial limb, metallic fragment or foreign body,
shunt, surgical staples (including clips or metallic
sutures and/or ear implants.)  (at the discretion of
the mri technologist/3t manager)*
Yes
No
in the investigator's opinion, subject suffers from
any physical, psychological or other condition(s)
that might prevent performance of the mri, such
as severe claustrophobia.*
Yes
No
patient is pregnant*
Yes
No
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Eligibility Asthma NCT02363192
Effectiveness of Pharmacist Interventions in Difficult
Asthma; ODM derived from:
https://clinicaltrials.gov/show/NCT02363192
All rights reserved. Please visit https://medical-data-
models.org/forms/14427
Eligibility Asthma NCT02363192
Inclusion Criteria
clinical diagnosis of asthma*
Yes
No
fulfil the criteria for difficult asthma (defined as
persistent symptoms and/or frequent
exacerbations despite treatment at step 4 or step
5 of the british tyhoracic society / sign asthma
guidelines 2011)*
Yes
No
adult patients age between 18 and 70 years*
Yes
No
able to speak, read and write in english*
Yes
No
all patients must have received their regular
medication from the same community pharmacy
for at least 3 months prior to their baseline visit*
Yes
No
their community pharmacy must be registered
with leeds primary care trust(pct) to undertake
targeted medicines use reviews (tmurs).*
Yes
No
Exclusion Criteria
failure to meet the inclusion criteria*
Yes
No
patient is not responsible for administering their
own medications*
Yes
No
patient is unlikely to be available for the 6-month
follow-up period*
Yes
No
failure to provide written informed consent*
Yes
No
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patient has had an mur within the 12 months
preceding the study period.*
Yes
No
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Eligibility Asthma NCT02407262
Potential Benefits of Black Seed Oil Supplementation on
Asthma Inflammation and Outcomes; ODM derived from:
https://clinicaltrials.gov/show/NCT02407262
All rights reserved. Please visit https://medical-data-
models.org/forms/14428
Eligibility Asthma NCT02407262
Inclusion Criteria
adult male/female (age 18-65 years),*
Yes
No
partial and uncontrolled asthmatic patient based
on gina guidelines (act score 5-20)*
Yes
No
no severe asthma exacerbation in the last 4
weeks*
Yes
No
able to obtain consent*
Yes
No
Exclusion Criteria
patients with serious co-morbid conditions such
as; cancer, renal, hepatic, cardio-vascular,
gastrointestinal diseases, mental health
conditions and respiratory disorder such as tb
and copd.*
Yes
No
smoking history*
Yes
No
pregnant women*
Yes
No
currently taking any form of black seed.*
Yes
No
known history of hypersensitivity to black seed.*
Yes
No
taking medications that may interact with black
seed supplement: anticoagulant/antiplatelet,
antidiabetic, antihypertensive, cns depressants,
and immunosuppressant drugs*
Yes
No
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Eligibility Asthma NCT02391090
FeNO After Hypoxia in Asthma Patients; ODM derived
from: https://clinicaltrials.gov/show/NCT02391090
All rights reserved. Please visit https://medical-data-
models.org/forms/14431
Eligibility Asthma NCT02391090
Inclusion Criteria
stable asthma (gina 1-2)*
Yes
No
Exclusion Criteria
autoimmune disease*
Yes
No
unstable asthma (gina 3-4)*
Yes
No
history of pneumonia/fever within 3 months*
Yes
No
place of residence >1000m above sea level*
Yes
No
trip/vacation above >2500m within 4 weeks*
Yes
No
cystic fibrosis*
Yes
No
diabetes mellitus*
Yes
No
immunodeficiency*
Yes
No
atopic dermatitis*
Yes
No
ciliary dyskinesia*
Yes
No
pregnancy*
Yes
No
chronic obstructive pulmonary disease*
Yes
No
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history of smoking (>1py)*
Yes
No
immunosuppression / systemic corticosteroids
within 3 months*
Yes
No
cardiovascular diseases*
Yes
No
interstitial lung disease*
Yes
No
bronchopulmonary dysplasia*
Yes
No
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Eligibility Alcoholic Hepatitis NCT01214226
Double-blind Randomized Controlled Trial in Severe
Alcoholic Hepatitis; ODM derived from:
https://clinicaltrials.gov/show/NCT01214226
All rights reserved. Please visit https://medical-data-
models.org/forms/14432
Eligibility Alcoholic Hepatitis
NCT01214226
Inclusion Criteria
alcohol consumption more than 40 gram/day for
women and 50 gram/day for men*
Yes
No
maddrey discriminant function higher than 32*
Yes
No
onset of jaundice within the 3 previous months*
Yes
No
biopsy-proven alcoholic hepatitis*
Yes
No
Exclusion Criteria
hypersensitivity to pentoxifylline*
Yes
No
any severe disease that may potential affect
survival such as cardiac failure, ischemic
cardiopathy, respiratory failure*
Yes
No
any neoplasm that occurred within the 2 previous
years*
Yes
No
hepatocellular carcinoma or any previous
diagnosis of hepatocellular carcinoma*
Yes
No
portal thrombosis*
Yes
No
severe gastrointestinal bleeding*
Yes
No
uncontrolled sepsis within the 7 previous days*
Yes
No
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hepatorenal syndrome type i*
Yes
No
viral and fungal infection*
Yes
No
acute pancreatitis*
Yes
No
any tuberculosis that occurred within the 5
previous years*
Yes
No
psychiatric disorders that contraindicate the use
of corticosteroids*
Yes
No
infection related to virus of the hepatites b or c*
Yes
No
Human immunodeficiency virus infection*
Yes
No
any treatment with corticosteroids,
immunosuppressive agents, budesonide,
thalidomide or pentoxifylline that was given within
the previous year*
Yes
No
pregnancy or breast feeding*
Yes
No
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Eligibility Asthma NCT02414854
Evaluation of Dupilumab in Patients With Persistent
Asthma; ODM derived from:
https://clinicaltrials.gov/show/NCT02414854
All rights reserved. Please visit https://medical-data-
models.org/forms/14433
Eligibility Asthma NCT02414854
Inclusion Criteria
adults and adolescent patients with a physician
diagnosis of asthma for ≥12 months, based on
the global initiative for asthma (gina) 2014
guidelines and the following criteria:*
Yes
No
existing treatment with medium to high dose ics
(≥250 mcg of fluticasone propionate twice daily or
equipotent ics daily dosage to a maximum of
2000 mcg/day of fluticasone propionate or
equivalent) in combination with a second
controller (eg, long-acting beta agonist,
leukotriene receptor antagonist) for at least 3
months with a stable dose ≥1 month prior to visit
1.*
Yes
No
note for japan: for subjects aged 18 years and
older, ics must be on ≥200 mcg of fluticasone
propionate twice daily or equivalent; for subjects
aged 12 to 17 years, ics must be ≥100 mcg of
fluticasone propionate twice daily or equivalent).*
Yes
No
patients requiring a third controller for their
asthma will be considered eligible for this study,
and it should also be used for at least 3 months
with a stable dose*
Yes
No
≥1 month prior to visit 1.*
Yes
No
Exclusion Criteria
patients <12 years of age or the minimum legal
age for adolescents in the country of the
investigative site, whichever is higher (for those
countries where local regulations permit
enrollment of adults only, subject recruitment will
be restricted to those who are ≥18 years of age).*
Yes
No
weight is less than 30 kilograms.*
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Yes
No
chronic obstructive pulmonary disease or other
lung diseases (eg, idiopathic pulmonary fibrosis,
churg-strauss syndrome, etc) which may impair
lung function.*
Yes
No
a subject who experiences a severe asthma
exacerbation (defined as a deterioration of
asthma that results in emergency treatment,
hospitalization due to asthma, or treatment with
systemic steroids at any time from 1 month prior
to the screening visit up to and including the
baseline visit).*
Yes
No
clinical evidence or imaging (eg, chest x-ray,
computed tomography) within 12 months of visit 1
consistent with lung disease(s) other than
asthma.*
Yes
No
current smoker or cessation of smoking within 6
months prior to visit 1.*
Yes
No
previous smoker with a smoking history >10
pack-years.*
Yes
No
comorbid disease that might interfere with the
evaluation of investigational medicinal product.*
Yes
No
the above information is not intended to contain
all considerations relevant to a patient's potential
participation in a clinical trial.*
Yes
No
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Eligibility Alcoholic Hepatitis NCT00863785
Treatment of Severe Alcoholic Hepatitis With Corticoids
Plus N Acetyl Cysteine Versus Corticoids Alone; ODM
derived from: https://clinicaltrials.gov/show/NCT00863785
All rights reserved. Please visit https://medical-data-
models.org/forms/14434
Eligibility Alcoholic Hepatitis
NCT00863785
Inclusion Criteria
patient consent*
Yes
No
chronic alcohol intake in the last 3 to 6 months*
Yes
No
maddrey score ≥ 32*
Yes
No
liver histology compatible*
Yes
No
Exclusion Criteria
hepato renal syndrome*
Yes
No
hepatocarcinoma*
Yes
No
recent variceal haemorrhage*
Yes
No
recent bacterial infections*
Yes
No
other liver diseases associated (hcv, hbv,
hemochromatosis, aih)*
Yes
No
cancers or cardiac and respiratory disease, hiv
infection*
Yes
No
nac allergy*
Yes
No
no patient consent*
Yes
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No
acetaminophen intoxication*
Yes
No
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Eligibility Asthma NCT02424552
Effect of Vitamin D as add-on Therapy for Vitamin D
Insufficient Patients With Severe Asthma; ODM derived
from: https://clinicaltrials.gov/show/NCT02424552
All rights reserved. Please visit https://medical-data-
models.org/forms/14435
Eligibility Asthma NCT02424552
Inclusion Criteria
male or female patients, age ≥ 18 years*
Yes
No
a pulmonary specialist documented diagnosis of
severe asthma according to the global initiative
for asthma and the german asthma network (gan,
www.german-asthma-net.de)*
Yes
No
treatment with long-acting β2-agonists (laba) and
inhaled corticosteroids (ics) at a dose of at least
1000 µg beclomethasone (or equivalent) per day,
- chronic oral corticosteroid (ocs) use is allowed
stable asthma medication for ≥1 month prior to
screening (≥4 months for omalizumab)*
Yes
No
asthma control questionnaire (acq-5) score ≥ 1.5*
Yes
No
vitamin d insufficiency as defined by a serum
vitamin d concentration of < 30 ng/ml but ≥ 10
ng/ml at screening*
Yes
No
Exclusion Criteria
patients on vitamin d substitution*
Yes
No
current smokers or ex-smokers with a smoking
history of more than 10 pack-years*
Yes
No
pregnant or nursing women or women who intend
to become pregnant during the study*
Yes
No
known impaired renal function (gfr < 30 ml/min)
and history of physician-diagnosed
nephrolithiasis*
Yes
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No
use of other investigational drugs during the
study or within 30 days of screening*
Yes
No
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NINDS CDE Electrophysiology Amyotrophic
Lateral Sclerosis
NINDS Common Data Elements (Electrophysiology
Amyotrophic Lateral Sclerosis) Used from the National
Institute of Neurological Disorders and Stroke Common
Data Elements
(https://www.commondataelements.ninds.nih.gov/)
References: Grinnon ST, Miller K, Marler JR, Lu Y, Stout A,
Odenkirchen J, Kunitz S. National Institute of Neurological
Disorders and Stroke Common Data Element Project -
approach and methods. Clin Trials. 2012;9(3):322-9.
All rights reserved. Please visit https://medical-data-
models.org/forms/14436
Electrophysiology
Core Table EMG/NCS
Study-ID
Study site name
Subject ID
Weakness of right arm
Yes
No
Weakness of left arm
Yes
No
Weakness of right leg
Yes
No
Weakness of left leg
Yes
No
Weakness of facial muscles
Yes
No
Evidence of conduction block right arm
Yes (1)
No (2)
Unknown (3)
Evidence of Conduction Block left arm
Yes (1)
No (2)
Unknown (3)
Evidence of Conduction Block right leg
Yes (1)
No (2)
Unknown (3)
Evidence of Conduction Block left leg
Yes (1)
No (2)
Unknown (3)
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Presence of Fasciculations right arm
Yes
No
Presence of Fasciculations left arm
Yes
No
Presence of Fasciculations right leg
Yes
No
Presence of Fasciculations left leg
Yes
No
Presence of Fasciculations facial muscles
Yes
No
Presence of Fasciculations thoracic muscles
Yes
No
Presence of Fibrillation/ Positive Waves right arm
Yes
No
Presence of Fibrillation/ Positive Waves left arm
Yes
No
Presence of Fibrillation/ Positive Waves right leg
Yes
No
Presence of Fibrillation/ Positive Waves left leg
Yes
No
Presence of Fibrillation/ Positive Waves facial
muscles
Yes
No
Presence of Fibrillation/ Positive Waves thoracic
muscles
Yes
No
Evidence of Neurogenic Motor Units right arm
Yes
No
Evidence of Neurogenic Motor Units left arm
Yes
No
Evidence of Neurogenic Motor Units right leg
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Yes
No
Evidence of Neurogenic Motor Units left leg
Yes
No
Evidence of Neurogenic Motor Units facial
muscles
Yes
No
Evidence of Neurogenic Motor Units thoracic
muscles
Yes
No
Cranial Supplemental Table for EMG
Tongue, right side
Fascics	 (1)
Fibs/PSWs	 (2)
Neurogenic motor units	 (3)
Normal	 (4)
Not Assessed (5)
Tongue, right side: further comments
Tongue, left side
Fascics	 (1)
Fibs/PSWs	 (2)
Neurogenic motor units	 (3)
Normal	 (4)
Not Assessed (5)
Tongue, left side:further comments
Right masseter
Fascics	 (1)
Fibs/PSWs	 (2)
Neurogenic motor units	 (3)
Normal	 (4)
Not Assessed (5)
Left masseter
Fascics	 (1)
Fibs/PSWs	 (2)
Neurogenic motor units	 (3)
Normal	 (4)
Not Assessed (5)
Right masseter, further comments
Left masseter,further comments
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Other cranial muscle,right side
Fascics	 (1)
Fibs/PSWs	 (2)
Neurogenic motor units	 (3)
Normal	 (4)
Not Assessed (5)
Other cranial muscle, right side:further comments
Other cranial muscle, left side
Fascics	 (1)
Fibs/PSWs	 (2)
Neurogenic motor units	 (3)
Normal	 (4)
Not Assessed (5)
Other cranial muscle,further comments
Cervical Supplemental Table for EMG
Right biceps
Fascics	 (1)
Fibs/PSWs	 (2)
Neurogenic motor units	 (3)
Normal	 (4)
Not Assessed (5)
Right biceps,further comments
Left biceps
Fascics	 (1)
Fibs/PSWs	 (2)
Neurogenic motor units	 (3)
Normal	 (4)
Not Assessed (5)
Left biceps,further comments
Right triceps
Fascics	 (1)
Fibs/PSWs	 (2)
Neurogenic motor units	 (3)
Normal	 (4)
Not Assessed (5)
Right triceps, further comments
Left triceps
Fascics	 (1)
Fibs/PSWs	 (2)
Neurogenic motor units	 (3)
Normal	 (4)
Not Assessed (5)
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Left triceps, further comments
Right EDC
Fascics	 (1)
Fibs/PSWs	 (2)
Neurogenic motor units	 (3)
Normal	 (4)
Not Assessed (5)
Right EDC, further comments
Left EDC
Fascics	 (1)
Fibs/PSWs	 (2)
Neurogenic motor units	 (3)
Normal	 (4)
Not Assessed (5)
Left EDC, further comments
Right APB
Fascics	 (1)
Fibs/PSWs	 (2)
Neurogenic motor units	 (3)
Normal	 (4)
Not Assessed (5)
Right APB,further comments
Left APB
Fascics	 (1)
Fibs/PSWs	 (2)
Neurogenic motor units	 (3)
Normal	 (4)
Not Assessed (5)
Left APB,further comments
Right ADM
Fascics	 (1)
Fibs/PSWs	 (2)
Neurogenic motor units	 (3)
Normal	 (4)
Not Assessed (5)
Right ADM, further comments
Left ADM
Fascics	 (1)
Fibs/PSWs	 (2)
Neurogenic motor units	 (3)
Normal	 (4)
Not Assessed (5)
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Left ADM, further comments
Right FDI
Fascics	 (1)
Fibs/PSWs	 (2)
Neurogenic motor units	 (3)
Normal	 (4)
Not Assessed (5)
Right FDI, further comments
Left FDI
Fascics	 (1)
Fibs/PSWs	 (2)
Neurogenic motor units	 (3)
Normal	 (4)
Not Assessed (5)
Left FDI,further comments
Other cervical muscles, right side
Fascics	 (1)
Fibs/PSWs	 (2)
Neurogenic motor units	 (3)
Normal	 (4)
Not Assessed (5)
Other cervical muscles, right side: further
comments
Other cervical muscles, left side
Fascics	 (1)
Fibs/PSWs	 (2)
Neurogenic motor units	 (3)
Normal	 (4)
Not Assessed (5)
Other cervical muscles,left side:further comments
Thoracic Supplemental Table for EMG
Right paraspinal muscle
Fascics	 (1)
Fibs/PSWs	 (2)
Neurogenic motor units	 (3)
Normal	 (4)
Not Assessed (5)
Right paraspinal muscle,further comments
Left paraspinal muscle
Fascics	 (1)
Fibs/PSWs	 (2)
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Neurogenic motor units	 (3)
Normal	 (4)
Not Assessed (5)
Left paraspinal muscle,further comments
Lumbosacral Supplemental Table for EMG
Right vastus lateralis
Fascics	 (1)
Fibs/PSWs	 (2)
Neurogenic motor units	 (3)
Normal	 (4)
Not Assessed (5)
Right vastus lateralis,further comments
Left vastus lateralis
Fascics	 (1)
Fibs/PSWs	 (2)
Neurogenic motor units	 (3)
Normal	 (4)
Not Assessed (5)
Left vastus lateralis,further comments
Right tibialis anterior
Fascics	 (1)
Fibs/PSWs	 (2)
Neurogenic motor units	 (3)
Normal	 (4)
Not Assessed (5)
Right tibialis anterior,further comments
Left tibialis anterior
Fascics	 (1)
Fibs/PSWs	 (2)
Neurogenic motor units	 (3)
Normal	 (4)
Not Assessed (5)
Left tibialis anterior,further comments
Right tibialis posterior
Fascics	 (1)
Fibs/PSWs	 (2)
Neurogenic motor units	 (3)
Normal	 (4)
Not Assessed (5)
Right tibialis posterior,further comments
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Left tibialis posterior
Fascics	 (1)
Fibs/PSWs	 (2)
Neurogenic motor units	 (3)
Normal	 (4)
Not Assessed (5)
Left tibialis posterior,further comments
Right gastrocnemius
Fascics	 (1)
Fibs/PSWs	 (2)
Neurogenic motor units	 (3)
Normal	 (4)
Not Assessed (5)
Right gastrocnemius,further comments
Left gastrocnemius
Fascics	 (1)
Fibs/PSWs	 (2)
Neurogenic motor units	 (3)
Normal	 (4)
Not Assessed (5)
Left gastrocnemius,further comments
Other lumbosacral muscle, right side
Fascics	 (1)
Fibs/PSWs	 (2)
Neurogenic motor units	 (3)
Normal	 (4)
Not Assessed (5)
Other lumbosacral muscle, right side:further
comments
Other lumbosacral muscle, left side
Fascics	 (1)
Fibs/PSWs	 (2)
Neurogenic motor units	 (3)
Normal	 (4)
Not Assessed (5)
Other lumbosacral muscle, left side:further
comments
Core Table for MUNE
Please specify which muscle was examined
Weakness in examined muscle area?
Yes
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No
Method used
Incremental (1)
Multipoint (2)
Statistical (3)
Other, specify (4)
If other, please specify method used
Compound Motor Action Potential Amplitude
(mV)
Single Motor Unit Potential Amplitude Estimate
(µV)
Motor Unit Number Estimate
Supplemental Table for MUNE
CMAP (mV) right ulnar
CMAP (mV) left ulnar
CMAP (mV) median right
CMAP (mV) median Left
CMAP (mV) peroneal right
CMAP (mV) peroneal left
1st amplitude (μV) ulnar right
2nd amplitude (μV) ulnar right
3rd amplitude (μV) ulnar right
SMUP (= 3rdamplitude / 3) ulnar right
1st amplitude (μV) ulnar left
2nd amplitude (μV) ulnar left
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3rd amplitude (μV) ulnar left
SMUP (= 3rdamplitude / 3) ulnar left
1st amplitude (μV) median right
2nd amplitude (μV) median right
3rd amplitude (μV) median right
SMUP (= 3rdamplitude / 3) median right
1st amplitude (μV) median left
2nd amplitude (μV) median left
3rd amplitude (μV) median left
SMUP (= 3rdamplitude / 3) median left
1st amplitude (μV) Peroneal Right
2nd amplitude (μV) Peroneal Right
3rd amplitude (μV) Peroneal Right
SMUP (= 3rdamplitude / 3) Peroneal Right
1st amplitude (μV) Peroneal Left
2nd amplitude (μV) Peroneal Left
3rd amplitude (μV) Peroneal Left
SMUP (= 3rdamplitude / 3) Peroneal Left
Average SMUP ulnar right
Average SMUP ulnar left
Average SMUP median right
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Average SMUP median left
Average SMUP peroneal right
Average SMUP peroneal left
MUNE ulnar right
MUNE ulnar left
MUNE median right
MUNE median left
MUNE peroneal right
MUNE peroneal left
Core Table for Transcranial Magnetic
Stimulation
Please specify muscle recorded from
Muscle weakness
Yes
No
Additional comments
Core Table for Electrical Impedance
Myography
Muscle Studied
Side of body
right (1)
left (2)
Muscle weakness
Yes
No
Method used
Single frequency (1)
Multi-frequency (2)
Other, specify: (3)
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If other,please specify method used
Comments (Free Text)
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NINDS CDE Prior and Concomitant
Medications Amyotrophic Lateral Sclerosis
NINDS Common Data Elements (Prior and concomitant
medications Amyotrophic Lateral Sclerosis) Used from the
National Institute of Neurological Disorders and Stroke
Common Data Elements
(https://www.commondataelements.ninds.nih.gov/)
References: Grinnon ST, Miller K, Marler JR, Lu Y, Stout A,
Odenkirchen J, Kunitz S. National Institute of Neurological
Disorders and Stroke Common Data Element Project -
approach and methods. Clin Trials. 2012;9(3):322-9.
All rights reserved. Please visit https://medical-data-
models.org/forms/14437
Prior and Concomitant Medications
Prior and Concomitant Medications
Study-ID
Study site name
Subject ID
Did the participant/subject take any medications
before or during the study?
Yes
No
Medication name
Indication
Dose
Units
Medication frequency
Route of administration
Buccal (1)
Subcutaneous (10)
Sublingual (11)
Transdermal (12)
Unknown (13)
Other specify (14)
Inhaled (2)
Intramuscular (3)
Intravenous (4)
Nasal (5)
Oral (6)
Rectal (7)
By ear (8)
Topical (9)
If other route of administration, please specify
Agent Start Date (yyyy-mm-dd)
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Agent End Date (yyyy-mm-dd)
Medication ongoing
Yes
No
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Eligibility Asthma NCT02443298
Efficacy and Safety of BI 655066 in Patients With Severe
Persistent Asthma.; ODM derived from:
https://clinicaltrials.gov/show/NCT02443298
All rights reserved. Please visit https://medical-data-
models.org/forms/14438
Eligibility Asthma NCT02443298
Inclusion Criteria
1. pre-bronchodilator clinic measured fev1 of
=40% and =85% of predicted normal.*
Yes
No
2. one year history of asthma diagnosed by a
physician, and have fev1 reversibility of = 12%
and an absolute change of at least 200 ml after
administration of 400 µg salbutamol.*
Yes
No
3. must be on at least medium dose inhaled
corticosteroids and at least one other asthma
controller medication for at least one year.*
Yes
No
4. must have documented history of two or more
severe asthma exacerbations in the last 12
months.*
Yes
No
Exclusion Criteria
1. patients with a significant disease other than
asthma.*
Yes
No
2. patients who are not able to produce sputum or
sputum samples of sufficient quality.*
Yes
No
3. patients who had clinically relevant history of
intubation for asthma exacerbation in the past
year.*
Yes
No
4. patients diagnosed with any concurrent
respiratory disease.*
Yes
No
5. recent history (within 6 months) of myocardial
infarction or hospitalized for cardiac failure in the
past year.*
Yes
No
6. patients who have undergone thoracotomy with
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pulmonary resection.*
Yes
No
7. patients who have undergone bronchial
thermoplasty or radiotherapy procedure in the
past year or have planned procedures during the
study.*
Yes
No
8. patients taking oral corticosteroids with a total
daily dose of more than 20 mg prednisone (or
equivalent) in the past 6 weeks.*
Yes
No
9. pregnant or nursing women.*
Yes
No
10. women of childbearing potential that, if
sexually active, is unwilling to use a highly
effective method of birth control.*
Yes
No
11. clinically relevant acute infections or chronic
infections.*
Yes
No
12. have received any live bacterial or live viral
vaccination in the last12 weeks.*
Yes
No
13. have received bacille calmette-guerin (bcg)
vaccination in the last 12 months.*
Yes
No
14. have received treatment with ustekinumab
(stelara®).*
Yes
No
15. have received treatment with any other
biologics in the last 3 months or within 6 times
the half-life of the compound.*
Yes
No
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NINDS CDE Clinical Milestones and Events
Amyotrophic Lateral Sclerosis
NINDS Common Data Elements (Clinical milestones and
events Amyotrophic Lateral Sclerosis) Used from the
National Institute of Neurological Disorders and Stroke
Common Data Elements
(https://www.commondataelements.ninds.nih.gov/)
References: Grinnon ST, Miller K, Marler JR, Lu Y, Stout A,
Odenkirchen J, Kunitz S. National Institute of Neurological
Disorders and Stroke Common Data Element Project -
approach and methods. Clin Trials. 2012;9(3):322-9.
All rights reserved. Please visit https://medical-data-
models.org/forms/14441
Clinical Milestones and Events
Clinical Milestones and Events Data
Collection Table
Noninvasive ventilation (NIV) utilized
Yes (1)
No (2)
Unknown (3)
Date of event
Loss of speech
Yes (1)
No (2)
Unknown (3)
Date of event
Loss of ambulation
Yes (1)
No (2)
Unknown (3)
Date of event
Percutaneous endoscopic gastrostomy /Feeding
tube placement
Yes (1)
No (2)
Unknown (3)
Date of event
Tracheostomy performed
Yes (1)
No (2)
Unknown (3)
Date of event
Death
Yes (1)
No (2)
Unknown (3)
Clinical Events and Falls Data Collection
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Grid
Day of week
Monday (1)
Tuesday (2)
Wednesday (3)
Thursday (4)
Friday (5)
Saturday (6)
Sunday (7)
Date
Falls,near falling
No Falls (1)
Near Falls (2)
Falls (3)
Near falling: if occurred, how many times?
Falls:if occured, how many times?
Clinical Events Cramps Data Collection
Grid
Day of week
Monday (1)
Tuesday (2)
Wednesday (3)
Thursday (4)
Friday (5)
Saturday (6)
Sunday (7)
Date
Cramps
Yes
No
If cramps occured, how many times (each day of
occurence)
Global rating of cramp severity over the period
None (0 )
Rare cramps, related to voluntary muscle
activity (1 )
Spontaneous cramps one to seven times
weekly (2 )
More than one cramp per day, or seven
per week (3 )
Activity interrupted by severe cramps (4 )
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Eligibility Asthma NCT02449473
Study to Evaluate Efficacy & Safety of Tralokinumab in
Subjects With Asthma Inadequately Controlled on
Corticosteroids (ICS) With or Without Other Controllers;
ODM derived from:
https://clinicaltrials.gov/show/NCT02449473
All rights reserved. Please visit https://medical-data-
models.org/forms/14448
Eligibility Asthma NCT02449473
Inclusion Criteria
1. age 18 to 75 years*
Yes
No
2. documented physician-diagnosed asthma for
at least 12 months prior to enrolment (v1)*
Yes
No
3. documented treatment with an asthma
controller regimen requiring treatment with ics
(minimum dose of ≥ 250 ug fluticasone
propionate via dry powder inhaler equivalents
total daily dose) alone or in combination ≥ 6
months and that has been taken at a stable dose
for at least 1 month prior to enrolment (v1)*
Yes
No
4. additional maintenance asthma controller
medications must be given at a stable dose for at
least 1 month prior to v1.*
Yes
No
5. at enrolment (v1) the subject must have a
predicted normal value (pnv) for the morning pre-
bronchodilator (bd) fev1>50% and more than 1l.*
Yes
No
6. post-bd reversibility in fev1 of ≥12% and ≥200
ml at enrolment (v1).*
Yes
No
Exclusion Criteria
1. history of interstitial lung disease, chronic
obstructive pulmonary disease (copd), or other
clinically significant lung disease other than
asthma.*
Yes
No
2. history of anaphylaxis following any biologic
therapy.*
Yes
No
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3. hepatitis b, c or hiv*
Yes
No
4. pregnant or breastfeeding*
Yes
No
5. history of cancer*
Yes
No
6. current tobacco smoking or a history of
tobacco smoking for ≥10 pack-years.*
Yes
No
7. previous receipt of tralokinumab*
Yes
No
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Eligibility Leukemia, Lymphocytic, Chronic,
B-Cell NCT00220311
A Study to Confirm the Efficacy and Safety of Fludarabine
Phosphate Administered in Untreated Chronic Lymphocytic
Leukemia Patients With Anemia and/or Thrombocytopenia;
ODM derived from:
https://clinicaltrials.gov/show/NCT00220311
All rights reserved. Please visit https://medical-data-
models.org/forms/14451
Eligibility Leukemia, Lymphocytic,
Chronic, B-Cell NCT00220311
Inclusion Criteria
patients with histologically or cytologically
confirmed cll*
Yes
No
patients with hemoglobin concentration and/or
platelet count below the institution's lower limit of
normal*
Yes
No
patients who have not received cancer
chemotherapy or radiotherapy*
Yes
No
Exclusion Criteria
patients with apparent infections (including viral
infections)*
Yes
No
patients with serious complications (heart, liver,
or kidney disease, etc.)*
Yes
No
patients with a serious bleeding tendency (e.g.,
dic)*
Yes
No
patients with serious cns symptoms*
Yes
No
patients with fever >= 38°c (excluding tumor
fever)*
Yes
No
patients with interstitial pneumonia or pulmonary
fibrosis*
Yes
No
patients with active multiple cancers*
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Yes
No
patients receiving other investigational products
within 6 months before registration in this study*
Yes
No
patients with prior allergies to medications that
are similar to the investigational product (purine
nucleoside derivatives)*
Yes
No
women who are pregnant, of childbearing
potential, or lactating*
Yes
No
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Eligibility Lung Cancer NCT00193245
Oral Topotecan Versus Docetaxel in Second-Line
Treatment of Non-Small Cell Lung Cancer; ODM derived
from: https://clinicaltrials.gov/show/NCT00193245
All rights reserved. Please visit https://medical-data-
models.org/forms/14453
Eligibility Lung Cancer
NCT00193245
Inclusion Criteria
to be included in this study, you must meet the
following criteria:*
Yes
No
relapsed or progressive disease*
Yes
No
stage iiib (not candidate for combined modality)
or iv*
Yes
No
no more than one prior chemotherapy regimen*
Yes
No
able to perform activities of daily living without
assistance*
Yes
No
measurable disease outside of radiation port*
Yes
No
adequate bone marrow, liver and kidney function*
Yes
No
must understand study and sign informed
consent prior to enrollment*
Yes
No
Exclusion Criteria
you cannot participate in this study if any of the
following apply to you:*
Yes
No
prior treatment with topotecan or docetaxel*
Yes
No
uncontrolled brain metastases*
Yes
No
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moderate peripheral neuropathy*
Yes
No
please note:  there are additional
inclusion/exclusion criteria.  the study center will
determine if you meet all of the criteria.  if you do
not qualify for the trial, study personnel will
explain the reasons.  if you do qualify, study
personnel will explain the trial in detail and
answer any questions you may have.*
Yes
No
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Eligibility Lung Neoplasms NCT00157209
Phase IIb Randomized Controlled Study of BLP25
Liposome Vaccine for Immunotherapy of Non-Small Cell
Lung Cancer; ODM derived from:
https://clinicaltrials.gov/show/NCT00157209
All rights reserved. Please visit https://medical-data-
models.org/forms/14455
Eligibility Lung Neoplasms
NCT00157209
Inclusion Criteria
stage iiib or stage iv nsclc*
Yes
No
stable disease or a clinical response following
first-line treatment, consisting of either
chemotherapy alone or chemotherapy and
radiotherapy.  patients must have completed the
first-line treatment at least 3 weeks prior to study
entry*
Yes
No
ecog performance status of ≤2*
Yes
No
ability to understand and willingness to sign a
written informed consent*
Yes
No
Exclusion Criteria
received immunotherapy within 4 weeks prior to
study entry*
Yes
No
received immunosuppressive drugs within 3
weeks prior to study entry*
Yes
No
patients with known brain metastases*
Yes
No
past or current history of neoplasm other than
lung carcinoma, except for curatively treated non-
melanoma skin cancer, in situ carcinoma of the
cervix or other cancer curatively treated and with
no evidence of disease for at least 5 years*
Yes
No
autoimmune disease or immunodeficiency*
Yes
No
clinically significant hepatic, renal or cardiac
dysfunction*
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Yes
No
patients with clinically significant active infection*
Yes
No
pregnant or breast feeding women, women of
childbearing potential, unless using effective
contraception as determined by the investigator*
Yes
No
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Eligibility Adult Acute Lymphoblastic
Leukemia in Remission NCT00039377
Chemotherapy, Imatinib Mesylate, and Peripheral Stem Cell
Transplantation in Treating Patients With Newly Diagnosed
Acute Lymphoblastic Leukemia; ODM derived from:
https://clinicaltrials.gov/show/NCT00039377
All rights reserved. Please visit https://medical-data-
models.org/forms/14457
Eligibility Adult Acute Lymphoblastic
Leukemia in Remission
NCT00039377
Inclusion Criteria
unequivocal histologic diagnosis of all*
Yes
No
detection of the t(9;22)(q34;q11) or 3-way variant
by metaphase cytogenetics or bcr-abl positive by
molecular analysis (rt-pcr or fluorescence in situ
hybridization [fish})*
Yes
No
complete or partial remission following one
course of induction chemotherapy with an
intensive 4 or 5 drug regimen (with or without
imatinib mesylate) on a calgb or swog all protocol
for previously untreated all patients*
Yes
No
the double induction regimen of swog s0333 is
considered to be one course of induction
chemotherapy for the purpose of this eligibility
criterion; therefore, patients from s0333 may be
eligible for this study only after completing the
entire double induction regimen*
Yes
No
complete or partial remission following one
course of therapy on any standard induction
regimen (with or without imatinib mesylate)
without prior enrollment on a cooperative group
frontline protocol; in these instances,
documentation of philadelphia chromosome (ph)+
positivity may occur outside a calgb or swog
laboratory*
Yes
No
calgb institutions must enroll patients on calgb
9862 and submission of an initial sample for the
companion trial must occur at time of enrollment
on calgb c10001; enrollment on companion
studies calgb 8461 and 9665 is not required*
Yes
No
no more than six weeks of prior imatinib mesylate
during induction therapy before study enrollment*
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Yes
No
non-pregnant and non-nursing; treatment under
this protocol would expose an unborn child to
significant risks; women and men of reproductive
potential should agree to use an effective means
of birth control and contraception should continue
for three months after the last dose of imatinib
mesylate (gleevec) to allow complete clearance
of drug and its principle metabolites from the
body; in women of childbearing potential, a
pregnancy test will be required at study entry*
Yes
No
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NCT00039377
Eligibility Adult Acute Lymphocytic
Leukemia NCT00198978
German Multicenter Trial for Treatment of Elderly Patients
With Newly Diagnosed Acute Lymphoblastic Leukemia;
ODM derived from:
https://clinicaltrials.gov/show/NCT00198978
All rights reserved. Please visit https://medical-data-
models.org/forms/14458
Eligibility Adult Acute Lymphocytic
Leukemia NCT00198978
Inclusion Criteria
diagnosis of acute lymphoblastic leukemia (pro b,
pre b, c-all or t-all), proved by morphology and
immunophenotyping*
Yes
No
age > 55 yrs (no upper age limit)*
Yes
No
written informed consent*
Yes
No
Exclusion Criteria
severe leukemia associated complications, not
controllable before therapy onset e.g.*
Yes
No
life threatening infections as sepsis, pneumonia,
hypoxia, shock, life threatening bleeding)*
Yes
No
decompensated renal failure if not caused by
leukemia  with creatinine > 2x uln*
Yes
No
heart failure (nyha ii/iv), instable angina,
significant coronary stenosis*
Yes
No
hepatic insufficiency e.g. liver cirrhosis or chronic
active hepatitis with bilirubin > 1,5 x uln and/or
asa, ala, ap > 2,5 uln*
Yes
No
decompensated metabolic disturbances (e.g. not
controllable diabetes)*
Yes
No
severe obstructive or restrictive pulmonary
disease with hypoxaemia*
Yes
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No
severe psychiatric illness or other circumstances
which may compromise cooperation of the
patient*
Yes
No
active second neoplasia*
Yes
No
hiv infection*
Yes
No
severely reduced general condition*
Yes
No
cytostatic pre-treatment of all*
Yes
No
chemotherapy treatment of any other malignancy
during the last 5 years*
Yes
No
participation in other clinical trials interfering with
the study therapy*
Yes
No
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Eligibility Adult Acute Lymphocytic
Leukemia NCT00199004
Trial for Treatment of Adult Patients With Standard Risk
Acute Lymphoblastic Leukemia With Chemotherapy and
Rituximab; ODM derived from:
https://clinicaltrials.gov/show/NCT00199004
All rights reserved. Please visit https://medical-data-
models.org/forms/14459
Eligibility Adult Acute Lymphocytic
Leukemia NCT00199004
Inclusion Criteria
b-precursor all (common / pre b-all)*
Yes
No
standard risk*
Yes
No
cd20 expression >20%*
Yes
No
ph/bcr-abl negative*
Yes
No
age 15-65 years (55-65 if biologically younger)*
Yes
No
written informed consent*
Yes
No
Exclusion Criteria
severe complications due to leukemia or
secondary illnesses*
Yes
No
late relapse of childhood all*
Yes
No
cytostatic pretreatment*
Yes
No
pregnancy*
Yes
No
severe psychiatric illness or other circumstances
which may compromise cooperation of the patient
or informed consent*
Yes
No
known severe allergy to foreign proteins*
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Yes
No
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Eligibility Adult Acute Lymphocytic
Leukemia NCT00199108
Treatment of Acute Lymphoblastic Leukemia or Aggressive
Lymphoma With Relapse in Central Nervous System With
Depocyt; ODM derived from:
https://clinicaltrials.gov/show/NCT00199108
All rights reserved. Please visit https://medical-data-
models.org/forms/14460
Eligibility Adult Acute Lymphocytic
Leukemia NCT00199108
Inclusion Criteria
proven diagnosis of all or very aggressive non-
hodgkin-lymphoma (burkitt/burkitt-like) and cns
relapse*
Yes
No
cns involvement demonstrated by a positive
ventricular or lumbar csf cytology or characteristic
signs and symptoms of neoplastic meningitis plus
an mri or ct scan indicating the presence of
meningeal involvement*
Yes
No
in combined relapse in cns and other locations:
systemic therapy with cns active drugs can be
postponed for at least 2 weeks*
Yes
No
karnofsky performance score is > or = 60%*
Yes
No
18 years of age or older*
Yes
No
free of uncontrolled infection*
Yes
No
recovered from any grade iii / iv toxicities
attributable to prior treatment with the exception
of hematotoxicity*
Yes
No
patient not pregnant or breast feeding and
effective methods to prevent pregnancy*
Yes
No
free from severe heart, lung, liver or kidney
dysfunction*
Yes
No
written informed consent*
Yes
No
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Exclusion Criteria
failed to respond (as defined by no clearance of
the csf) to > 1 dose of prior i.th. mtx or arac or
triple therapy*
Yes
No
history of neurotoxicity (grade iii - iv) attributed to
i.th. or systemic hd therapy with mtx or arac*
Yes
No
prior cns relapse < 1 month before*
Yes
No
2 / 2
Eligibility Adult Acute Lymphocytic Leukemia NCT00199108
Eligibility Asthma NCT02450461
Breath Analysis in Asthma; ODM derived from:
https://clinicaltrials.gov/show/NCT02450461
All rights reserved. Please visit https://medical-data-
models.org/forms/14461
Eligibility Asthma NCT02450461
Inclusion Criteria
1. confirmed asthma. diagnosis of asthma is
made with episodic chest symptoms and a
documented reversibility of at least 12% and/or
200 ml in fev1 after 200 ug of inhaled salbutamol
or airway hyperresponsiveness in the case of
normal lung function testing (pc20 methacholine
< 4mg/ml) at the time of diagnosis.*
Yes
No
2. age between 18 and 80 years at study entry.*
Yes
No
3. healthy controls: never-smokers, normal
spirometry (baseline fev1 > 85% predicted and
fev1/fvc greater than 0.7).*
Yes
No
Exclusion Criteria
1. asthma exacerbation within the last 6 weeks,
defined as worsening of asthma symptoms
requiring a change in therapy by a physician or a
change in regular asthma therapy (including short
course of oral corticosteroids)*
Yes
No
2. any lung disease other than asthma.*
Yes
No
3. acute inflammatory disease (e.g. common
cold) within the last 4 weeks.*
Yes
No
4. regular intake of oral steroids.*
Yes
No
5. active smoking habits / positive history of
smoking.*
Yes
No
6. acute or chronic hepatic disease.*
Yes
No
7. renal failure or renal replacement therapy.*
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Yes
No
8. pregnancy.*
Yes
No
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Eligibility Asthma NCT02458482
Trial of AccuPAP Device Versus Standard Nebulizer
Therapy in Acute Asthma Exacerbation in Children; ODM
derived from: https://clinicaltrials.gov/show/NCT02458482
All rights reserved. Please visit https://medical-data-
models.org/forms/14462
Eligibility Asthma NCT02458482
Inclusion Criteria
investigators will enroll children ages 6 - 17 years
(inclusive) with a previous diagnosis of asthma
who present in an acute exacerbation to the
pediatric emergency department.*
Yes
No
patients will be evaluated using the acute asthma
intensity research score (aairs) which has been
validated at vanderbilt university medical center
and is currently the standard of care when
triaging patients with asthma.*
Yes
No
an included patient's severity of current
exacerbation must be qualified using the aairs
and fall in the moderate category of 7 to 11
points.*
Yes
No
patients who have received nebulized
bronchodilator medications at either a referring
facility or at home will be included.*
Yes
No
patients who present from a referring facility or
primary care physician (pcp) and have received
systemic corticosteroids (scs) within one hour of
initial aairs scoring will also be included.*
Yes
No
Exclusion Criteria
exclusion criteria will include the following: other
medical conditions contributing to respiratory
distress (e.g., pneumonia, cystic fibrosis,
anaphylaxis),*
Yes
No
developmental delay or any impedance to
following basic accupap use instructions,*
Yes
No
any condition precluding a patient from receiving
beta-agonist therapy (ie-*
Yes
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No
predisposition to supraventricular tachycardia).*
Yes
No
patients with a history of spontaneous
pneumothorax, recent facial, oral or skull
surgery/trauma, history of esophageal surgery,
known or suspected tympanic membrane rupture
or other middle ear pathology, acute sinusitis,
epistaxis, active hemoptysis or nausea will be
excluded as these are contraindications for
accupap use.*
Yes
No
patients who have received additional adjunctive
therapies beyond repeated saba and atrovent
nebulizers or those who have received scs
greater than 1 hour prior to initial ed evaluation,
those who have received intravenous magnesium
sulfate infusion, or subcutaneous terbutaline or
epinephrine will be excluded.*
Yes
No
those patients whose parents are require a
translator for consent will also be excluded (ie,
exclusively spanish speaking or other non-english
speaking families/patients). the justification for
this exclusion is that patients with respiratory
distress often need rapid initiation of treatment
and the delay that may be caused by coordination
efforts required in order to obtain a translator for
study consent and explanation may delay care for
these patients and result in adverse outcomes
that may potentially result in harm.*
Yes
No
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Eligibility Asthma NCT02464995
Bronchial Thermoplasty in Severe Asthma With Frequent
Exacerbations; ODM derived from:
https://clinicaltrials.gov/show/NCT02464995
All rights reserved. Please visit https://medical-data-
models.org/forms/14463
Eligibility Asthma NCT02464995
Inclusion Criteria
age 18-65 years*
Yes
No
asthma which requires treatment with guidelines
suggested medications for gina steps 4-5*
Yes
No
four or more bursts of systemic corticosteroids >3
days each in the previous year*
Yes
No
willingness and ability to give written informed
consent*
Yes
No
Exclusion Criteria
current smoker and former smoker > 10 pack
years total smoking history*
Yes
No
participation in another clinical trial within the
prior 4 months*
Yes
No
omalizumab therapy within the prior 4 months*
Yes
No
allergic bronchopulmonary aspergillosis*
Yes
No
patient having had severe exacerbation of their
asthma requiring high doses of oral
corticosteroids (> 60 mg equivalent prednisolone)
more than one month in the previous year*
Yes
No
post-bronchodilator fev1 of less than 30%*
Yes
No
past diagnosis of copd and chronic respiratory
insufficiency*
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Yes
No
known coagulopathy or platelet dysfunction*
Yes
No
use of anticoagulants*
Yes
No
use of an internal or external pacemaker or
internal cardiac defibrillator*
Yes
No
contraindication to perform bronchoscopy*
Yes
No
contraindication to perform general anesthesia*
Yes
No
significant cardiovascular disease*
Yes
No
current or recent respiratory tract infection
resolved less than 4 weeks*
Yes
No
known cancer or cancer history less than 12
months*
Yes
No
pregnancy and nursing mother*
Yes
No
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Eligibility Asthma NCT02494076
Positive Expiratory Pressure for the Treatment of Acute
Asthma in Children; ODM derived from:
https://clinicaltrials.gov/show/NCT02494076
All rights reserved. Please visit https://medical-data-
models.org/forms/14464
Eligibility Asthma NCT02494076
Inclusion Criteria
age >= 2 and < 18 years of age*
Yes
No
established diagnosis of asthma, defined as at
least two prior episodes of treatment with
bronchodilators in their lifetime*
Yes
No
initial ed presentation with a moderate to severe
asthma exacerbation, as defined by a pulmonary
asthma score (pas) >7*
Yes
No
pas score >7 and <12 after completion of first line
therapies (three doses albuterol/ipratropium
bromide and oral corticosteroids)*
Yes
No
Exclusion Criteria
do not receive complete first line therapies*
Yes
No
immediately receive a disposition (admission or
discharge) as determined by the treating clinician
after completion of first line therapies*
Yes
No
receive prednisone or more than two doses of
inhaled bronchodilators prior to main ed
evaluation (e.g. during ems transport or primary
care visit)*
Yes
No
co-morbid illnesses interfering with or
contraindicated to usual asthma therapy (e.g.
facial or airway abnormalities, pneumonia,
chronic lung disease, congenital heart disease,
cystic fibrosis, or pneumothorax)*
Yes
No
critically ill at presentation*
Yes
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No
pregnant women (women known to be pregnant
at the time of enrollment)*
Yes
No
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Eligibility Asthma NCT02496468
Kinder-Register Asthma Clinical Cohort; ODM derived
from: https://clinicaltrials.gov/show/NCT02496468
All rights reserved. Please visit https://medical-data-
models.org/forms/14465
Eligibility Asthma NCT02496468
Inclusion Criteria
informed consent by parents (and by children if
age > 8 years)*
Yes
No
age 6 months to 18 years*
Yes
No
term delivery (≥ 37 weeks)*
Yes
No
active/passive understanding of german*
Yes
No
age 6 months - < 6 years: preschool wheeze
(more than two episodes of wheeze during 12
months prior to inclusion)*
Yes
No
age at least 6 years: doctor diagnosed asthma
(according to current guidelines)*
Yes
No
Exclusion Criteria
known inborn or perinatal pulmonary disease*
Yes
No
airway malformation*
Yes
No
oxygen therapy after birth with a duration of more
than 24 hours*
Yes
No
ventilator support or mechanical ventilation after
birth*
Yes
No
diagnoses of cystic fibrosis; primary ciliary
dyskinesia*
Yes
No
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heart failure diagnosed after birth affecting
pulmonary circulation*
Yes
No
major respiratory diseases such as e.g. interstitial
lung disease*
Yes
No
any current non-atopic comorbidity*
Yes
No
fever of at least 38.5°c during the last two weeks
prior to the planned first visit*
Yes
No
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Eligibility Asthma NCT02499887
Repeat Emergency Department Visits Among Patients With
Asthma and COPD; ODM derived from:
https://clinicaltrials.gov/show/NCT02499887
All rights reserved. Please visit https://medical-data-
models.org/forms/14466
Eligibility Asthma NCT02499887
Inclusion Criteria
treated in the ed at the erie county medical center
(ecmc) for         acute symptoms of asthma or
copd during the study period*
Yes
No
patient age ≥ 18 years*
Yes
No
resident of the city of buffalo or erie county*
Yes
No
discharged to home*
Yes
No
patient expresses willingness to return to ecmc or
own primary care provider for follow-up visits*
Yes
No
able to provide informed consent*
Yes
No
able to comprehend english language*
Yes
No
Exclusion Criteria
received oral or inhaled corticosteroids in the
week before ed presentation*
Yes
No
presented to the ed primarily for prescription
refills*
Yes
No
complicated comorbid conditions (e.g. renal
disease, cardiovascular disease, chf, hiv)*
Yes
No
admitted to ecmc or discharged to another
facility*
Yes
No
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previously enrolled during a prior visit to the ed
during the study period*
Yes
No
for female patients--pregnant or pregnancy status
indeterminate*
Yes
No
antibiotics are prescribed to treat current
asthma/copd exacerbation.*
Yes
No
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Eligibility Lymphoma NCT00003963
Chemotherapy and Monoclonal Antibody Therapy in
Treating Patients With B-cell Non-Hodgkin's Lymphoma
That Has Relapsed Following Peripheral Stem Cell
Transplantation; ODM derived from:
https://clinicaltrials.gov/show/NCT00003963
All rights reserved. Please visit https://medical-data-
models.org/forms/14467
Eligibility Lymphoma NCT00003963
Inclusion Criteria
patients with b-cell lymphoma, relapsing after
high dose chemotherapy and autologous stem
cell transplantation or allogeneneic stem cell or
bone marrow transplant*
Yes
No
age > 18 years old*
Yes
No
adequate hematologic function, as manifested by
anc > 1000/mm3 and platelet count >
40,000/mm3*
Yes
No
ps who: < 3*
Yes
No
Exclusion Criteria
patients with serum creatinine > 2 mg%,
transaminases (alt, ast) > 3 times upper normal
value, direct bilirubin > 2 mg%, unless they result
from tumor involvement*
Yes
No
pregnant or lactating females*
Yes
No
history of myelodysplastic syndrome*
Yes
No
uncontrolled cns disease*
Yes
No
active serious infection*
Yes
No
history of refractoriness to vinorelbine.  however,
prior treatment with rituxan is not an exclusion
(synergy may still occur)*
Yes
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No
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Eligibility Lymphoma NCT01939730
Rituximab + GM-CSF in Patients With Follicular B-Cell
Lymphoma; ODM derived from:
https://clinicaltrials.gov/show/NCT01939730
All rights reserved. Please visit https://medical-data-
models.org/forms/14468
Eligibility Lymphoma NCT01939730
Inclusion Criteria
1. histologically confirmed follicular b-cell
lymphoma.  this can include relapsed patients,
who have had no prior rituximab therapy, or
previously untreated patients. previously
untreated patients should be made aware of
higher priority protocols such as combination
chemo-immunotherapy protocols, but if they
decline that, they can be entered on this
protocol.*
Yes
No
2. males or females, 18 years or older; expected
survival of =/> 4 months; performance status of 0,
1 or 2.*
Yes
No
3. demonstrable monoclonal cluster of
differentiation antigen 20 (cd20)-positive b-cell
population.*
Yes
No
4. acceptable hematologic status including:*
Yes
No
i. hemoglobin (hgb) =/> 8.0 gm/dl*
Yes
No
ii. white blood count (wbc) =/> 3.0 x 10^3/mm^3(x
10^9/l)*
Yes
No
iii. absolute granulocyte count =/> 1.5 x
10^3/mm^3*
Yes
No
iv. platelet count =/>75 x 10^3/mm^3*
Yes
No
e. adequate renal function (serum creatinine ≤
2mg/dl)*
Yes
No
Exclusion Criteria
1 / 2
1. presence of central nervous system (cns)
lymphoma*
Yes
No
2. chronic lymphocytic leukemia (cll)*
Yes
No
3. small lymphocytic lymphoma*
Yes
No
4. therapy in prior 3 weeks (6 weeks for
nitrosourea; 6 months for bone marrow
transplantation (bmt))*
Yes
No
5. patients who received prior rituximab or other
anti-cd20 therapy*
Yes
No
6. serious non-malignant disease, or other
malignancy*
Yes
No
7. active infection*
Yes
No
8. history of hiv infection*
Yes
No
i pregnancy*
Yes
No
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Eligibility Lymphoma, Large-Cell, Diffuse
NCT00169130
ACVBP Followed by ASCT in Patients With BCL-2 Positive
Diffuse Large B-Cell Lymphoma; ODM derived from:
https://clinicaltrials.gov/show/NCT00169130
All rights reserved. Please visit https://medical-data-
models.org/forms/14469
Eligibility Lymphoma, Large-Cell,
Diffuse NCT00169130
Inclusion Criteria
patient with diffuse large b-cell lymphoma
according to the who classification (anti cd20
labeling)*
Yes
No
aged 18 to 60 years*
Yes
No
non previously treated*
Yes
No
with one and only one of the following adverse
characteristics: ecog performance status 2 or
more, or ann arbor stage iii or iv, or elevated ldh
level*
Yes
No
negative hiv, hbv and hcv serologies (except
vaccination)*
Yes
No
with a minimum life expectancy of 3 months*
Yes
No
having previously signed a written informed
consent*
Yes
No
Exclusion Criteria
any history of treated or non-treated indolent
lymphoma.*
Yes
No
t-cell lymphoma.*
Yes
No
central nervous system or meningeal involvement
by lymphoma.*
Yes
No
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any contra-indication to any drug contained in the
chemotherapy regimens.*
Yes
No
poor renal  function (creatinin level>150µmol/l),
poor hepatic function (total bilirubin
level>30mmol/l, transaminases>2.5 maximum
normal level) unless these abnormalities are
related to the lymphoma.*
Yes
No
serious active disease (according to the
investigator’s decision).*
Yes
No
poor bone marrow reserve as defined by
neutrophils <1.5g/l or platelets<100g/l, unless
related to bone marrow infiltration.*
Yes
No
any history of cancer during the last 5 years with
the exception of non-melanoma skin tumors or
stage 0 (in situ) cervical carcinoma.*
Yes
No
treatment with any investigational drug within 30
days before planned first cycle of chemotherapy
and during the study.*
Yes
No
childbearing woman.*
Yes
No
patients previously treated with an organ
transplantation.*
Yes
No
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Eligibility Alzheimer Disease NCT00486044
Evaluating Simvastatin's Potential Role in Therapy; ODM
derived from: https://clinicaltrials.gov/show/NCT00486044
All rights reserved. Please visit https://medical-data-
models.org/forms/14470
Eligibility Alzheimer Disease
NCT00486044
Inclusion Criteria
age 35 to 69*
Yes
No
parent with alzheimer's disease*
Yes
No
Exclusion Criteria
current use of cholesterol lowering medication*
Yes
No
history of liver disease*
Yes
No
history of adverse reaction to statin medications*
Yes
No
history of previous lumbar spine surgery*
Yes
No
elevated lab values (creatine kinase and
creatinine)*
Yes
No
use of prohibited medications: simvastatin,
pravastatin, cholestyramine, lovastatin, colestipol,
gemfibrozil, niacin, atorvastatin, fluvastatin,
fenofibrate, rosuvastatin, clarithromycin,
cyclosporine, digoxin, erythromycin, itraconazole,
ketaconazole, fluconazole, nefazodone, warfarin,
saquinavir, ritonavir, indinavir, nelfinavir,
amprenavir, amiodarone, verapamil*
Yes
No
history of dementia*
Yes
No
currently pregnant*
Yes
No
use of large quantities of grapefruit juice (more
than 1 quart per day)*
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Yes
No
current involvement in another investigational
drug study*
Yes
No
contraindications to mri*
Yes
No
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Eligibility Alzheimer Disease NCT00500500
Effect of EGb 761® on Patients With Mild to Moderate
Alzheimer's Disease; ODM derived from:
https://clinicaltrials.gov/show/NCT00500500
All rights reserved. Please visit https://medical-data-
models.org/forms/14471
Eligibility Alzheimer Disease
NCT00500500
Inclusion Criteria
female or male of 50 to 85 years old with a care
giver*
Yes
No
mini mental status (mms) test between 16 to 26
inclusive*
Yes
No
clinical dementia rating (cdr) test inferior or equal
to 1*
Yes
No
national institute of neurological and
communicative disorders and stroke /*
Yes
No
alzheimer's disease and related disorders
association (nincds/adrda) test positive for an
alzheimer's disease*
Yes
No
diagnostic and statistical manual of mental
disorders, 4th edition (dsm iv) test positive for
dementia*
Yes
No
Exclusion Criteria
patient already treated by medicines which could
interfere with the study*
Yes
No
low level of vitamin b12 and folate which are
considered as clinically relevant*
Yes
No
clinically relevant pathologies (eg: pulmonary
illness, cardiovascular illness; evolutive cancer,
neurological illness, blood illness….)*
Yes
No
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Eligibility Alzheimer Disease NCT00506415
Comparative Efficacy, Safety, and Tolerability of
Rivastigmine 10 and 15 cm^2 Patch in Patients With
Alzheimer's Disease (AD) Showing Cognitive Decline; ODM
derived from: https://clinicaltrials.gov/show/NCT00506415
All rights reserved. Please visit https://medical-data-
models.org/forms/14472
Eligibility Alzheimer Disease
NCT00506415
Inclusion Criteria
male or female patients between 50 and 85 years
of age with a diagnosis of probable alzheimers
disease,*
Yes
No
baseline mini-mental state examination (mmse)
score 10-24 inclusive,*
Yes
No
a primary caregiver willing to accept responsibility
for supervising treatment, assessing the patient's
condition throughout the study, and for providing
input into efficacy assessments.*
Yes
No
for double blind only: meet the decline criteria of
functional (as assessed by the investigator) and
cognitive (assessed by a 1 point reduction in
mini-mental state examination) score between
visits or a 3 point reduction from baseline) decline
at weeks 23, 36 or 48.*
Yes
No
Exclusion Criteria
presence of an advanced, severe, progressive, or
unstable disease of any type that could interfere
with efficacy and safety assessments or put the
patient at particular risk,*
Yes
No
any medical or neurological condition other than
alzheimers disease that could explain the
patient's dementia,*
Yes
No
a diagnosis of probable or possible vascular
dementia,*
Yes
No
a current diagnosis of unsuccessfully-treated
depression, or any other mental disorder that
may interfere with the evaluation of the patient's
1 / 2
response to study medication,*
Yes
No
a history or current diagnosis of cerebrovascular
disease (e.g. stroke),*
Yes
No
a current diagnosis of severe or unstable
cardiovascular disease (e.g. unstable coronary
artery disease).*
Yes
No
other protocol-defined inclusion/exclusion criteria
may apply.*
Yes
No
2 / 2
Eligibility Alzheimer Disease NCT00506415
Eligibility Alzheimer Disease NCT00548145
The Clinical Study of Pitavastatin Treatment for Group of
Mild to Moderate Alzheimer's Disease; ODM derived from:
https://clinicaltrials.gov/show/NCT00548145
All rights reserved. Please visit https://medical-data-
models.org/forms/14473
Eligibility Alzheimer Disease
NCT00548145
Inclusion Criteria
alzheimer's disease patients (15 ≤ mmse total
score ≤ 23, cdr "1" or "2")*
Yes
No
patients with hypercholesterolemia*
Yes
No
patients who have taken donepezil more than 3
months stably*
Yes
No
both patients and care-givers must be more than
20 years old*
Yes
No
Exclusion Criteria
women with pregnancy or breast-feeding*
Yes
No
malignant tumor*
Yes
No
cerebrovascular disorder or myocardial infarction
prior to 12 weeks*
Yes
No
heart failure [new york heart association (nyha)
class iii or iv]*
Yes
No
hepatic or renal dysfunction*
Yes
No
severe hypertension*
Yes
No
hypothyroidism, hereditary muscular disease,
history of drug-induced myopathy*
Yes
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No
current involvement in another investigational
drug study*
Yes
No
alcoholism, drug abuse*
Yes
No
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Eligibility Alzheimer Disease NCT00556660
Evaluation of [123I] AV51 and SPECT as a Marker of Beta-
Amyloid Protein Deposition in Subjects With Alzheimer
Disease in Comparison to Healthy Subjects; ODM derived
from: https://clinicaltrials.gov/show/NCT00556660
All rights reserved. Please visit https://medical-data-
models.org/forms/14474
Eligibility Alzheimer Disease
NCT00556660
Inclusion Criteria
healthy control subject selection. healthy control
subjects who have no neurological disease will
be recruited for this study. the following criteria
will be met for inclusion of healthy control
subjects in this study:*
Yes
No
the participant is 50 years or older.*
Yes
No
written informed consent is obtained.*
Yes
No
negative history of neurological or psychiatric
illness based on evaluation by a research
physician.*
Yes
No
mini-mental status exam score ≥28.*
Yes
No
for females, non-child bearing potential or
negative urine or blood pregnancy test on day of
123-i av51 injection.*
Yes
No
alzheimer's subject selection. subjects who have
a clinical diagnosis of mild to moderate
alzheimer's disease will be recruited for this
study. the following criteria will be met for
inclusion of ad subjects in this study:*
Yes
No
the participant is 50 years or older.*
Yes
No
written informed consent is obtained.*
Yes
No
participants have a clinical diagnosis of
alzheimer's disease based on national institute of
neurological and communicative disorders and
1 / 3
stroke/alzheimer's disease and related disorders
association (nincds/adrda) criteria.*
Yes
No
mini-mental status exam score < 25.*
Yes
No
modified hachinski ischemia scale score of ≤ 4.*
Yes
No
geriatric depression scales (gds) ≤ 10.*
Yes
No
for females, non-child bearing potential or
negative urine or blood pregnancy test on day of
123-i av51 injection.*
Yes
No
Exclusion Criteria
healthy control subjects will be excluded from
participation for the following reasons:*
Yes
No
the subject has a clinically significant abnormal
laboratory value and/or clinically significant
unstable medical or psychiatric illness.*
Yes
No
the subject has any disorder that may interfere
with drug absorption distribution, metabolism, or
excretion (including gastrointestinal surgery).*
Yes
No
the subject has evidence of clinically significant
gastrointestinal, cardiovascular, hepatic, renal,
hematological, neoplastic, endocrine,
neurological, immunodeficiency, pulmonary, or
other disorder or disease.*
Yes
No
pregnancy*
Yes
No
alzheimer's subjects will be excluded from
participation for the following reasons:*
Yes
No
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Eligibility Alzheimer Disease NCT00556660
the subject has signs or symptoms of another
neurodegenerative disease including parkinson's
disease, diffuse lewy body dementia, or history of
significant cerebrovascular disease.*
Yes
No
the subject has a clinically significant abnormal
laboratory value and/or clinically significant
unstable medical or psychiatric illness*
Yes
No
the subject has any disorder that may interfere
with drug absorption distribution, metabolism, or
excretion (including gastrointestinal surgery)*
Yes
No
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Eligibility Alzheimer Disease NCT00568776
ELND005 in Patients With Mild to Moderate Alzheimer's
Disease; ODM derived from:
https://clinicaltrials.gov/show/NCT00568776
All rights reserved. Please visit https://medical-data-
models.org/forms/14475
Eligibility Alzheimer Disease
NCT00568776
Inclusion Criteria
diagnosis of probable ad*
Yes
No
age 50 to 85 years, inclusive*
Yes
No
mini-mental status exam (mmse) score of 16-26,
inclusive*
Yes
No
brain magnetic resonance imaging (mri) scan
consistent with the diagnosis of ad*
Yes
No
fluency in english, french, or spanish*
Yes
No
stable doses of medications (cholinesterase
inhibitors and memantine allowed)*
Yes
No
caregiver is able to attend all study visits*
Yes
No
Exclusion Criteria
significant neurological disease other than ad*
Yes
No
major psychiatric disorder*
Yes
No
significant medical illness*
Yes
No
history of stroke or seizure*
Yes
No
history of a heart attack within the last 2 years*
Yes
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No
prior treatment with certain experimental
medicines*
Yes
No
presence of pacemakers or foreign metal objects
in the eyes, skin, or body that would prevent
patient from having mri scan*
Yes
No
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Eligibility Alzheimer' Disease NCT00627848
Rivastigmine in Mild Alzheimer's Disease, FMRI Study;
ODM derived from:
https://clinicaltrials.gov/show/NCT00627848
All rights reserved. Please visit https://medical-data-
models.org/forms/14476
Eligibility Alzheimer' Disease
NCT00627848
Inclusion Criteria
probable alzheimer's disease according to the
nincds-adrda criteria*
Yes
No
mild disease, cdr 1*
Yes
No
the clinician is planning to start anticholinesterase
treatment*
Yes
No
Exclusion Criteria
cognitive impairment for other reason than
alzheimer's disease*
Yes
No
severe depression*
Yes
No
other unstable physical disease*
Yes
No
medal in body prevention mri examination,
claustrophobia*
Yes
No
cardiac pacemaker*
Yes
No
other significant neurologic or psychiatric
disease*
Yes
No
contraindication for anticholinesterase treatment*
Yes
No
1 / 1
Eligibility Alzheimer Disease NCT00677885
P-glycoprotein Function in Brain Diseases; ODM derived
from: https://clinicaltrials.gov/show/NCT00677885
All rights reserved. Please visit https://medical-data-
models.org/forms/14477
Eligibility Alzheimer Disease
NCT00677885
Criteria
patients with the diagnosis of probable alzheimer
disease, parkinson disease, or frontotemporal
dementia.  all patients must either meet capacity
criteria to consent to research, or be able to
assign a surrogate decision-maker who is able to
consent to research on the subject   s behalf.*
Yes
No
healthy volunteers.*
Yes
No
Exclusion Criteria
current psychiatric disease, substance abuse or
severe systemic disease based on history and
physical exam.*
Yes
No
laboratory tests with clinically significant
abnormalities.*
Yes
No
subjects on blood-thinning medications, having
coagulation disorders, or clinically significant
abnormal blood clotting test (pt/ptt).*
Yes
No
prior participation in other research protocols or
clinical care in the last year such that radiation
exposure, including that from this protocol, would
exceed the guidelines set by the radiation safety
committee (rsc).*
Yes
No
pregnancy or breast feeding.*
Yes
No
positive result on urine screen for illicit drugs.*
Yes
No
subjects who cannot lie on their back for
extended periods of time.*
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Yes
No
history of neurological disease other than
alzheimer disease, parkinson disease, or
frontotemporal dementia.*
Yes
No
subjects who have a cardiac pacemaker or metal
in their body.*
Yes
No
subjects taking cyclosporine a.*
Yes
No
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Eligibility Alzheimer Disease NCT00765115
A Study of Healthy Subjects to Assess the Effect of
LY450139 on Amyloid Beta Peptide Production Rate and or
Dose Response.; ODM derived from:
https://clinicaltrials.gov/show/NCT00765115
All rights reserved. Please visit https://medical-data-
models.org/forms/14478
Eligibility Alzheimer Disease
NCT00765115
Inclusion Criteria
healthy volunteers: men within the ages of 21 and
50*
Yes
No
Exclusion Criteria
have serious or unstable medical conditions*
Yes
No
have a history of serious infections affecting the
brain or head trauma resulting in protracted loss
of consciousness within the last 5 years or
multiple episodes of head trauma*
Yes
No
have a history of primary or recurrent malignant
disease*
Yes
No
have a recent laboratory result indicating a
clinically significant laboratory abnormality as
determined by the investigator*
Yes
No
have a history of chronic alcohol or drug abuse
within the past 5 years*
Yes
No
have a known history of human
immunodeficiency virus (hiv), afebrile seizures, or
clinically significant multiple drug allergies*
Yes
No
are judged clinically by the investigator to be at
serious risk for suicide*
Yes
No
have electrocardiogram abnormalities obtained at
visit 1 that in the opinion of the investigator are
clinically significant*
Yes
No
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use of prescription or over the counter
medications that cannot safely be discontinued
within 14 days prior to visit 2*
Yes
No
have criteria that would preclude a lp such as
allergy to all local anesthetics; have a local
infection at the site of the lp or have any medical
condition requiring treatment with warfarin or
heparin.*
Yes
No
have received treatment within the last 30 days
with a drug that has not received regulatory
approval for any indication at the time of study
entry.*
Yes
No
are investigator site personnel directly affiliated
with this study and or immediate families.*
Yes
No
are lilly employees*
Yes
No
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Eligibility Alzheimer Disease NCT00880555
Semantic Memory, Financial Capacity, and Brain Perfusion
in Mild Cognitive Impairment (MCI) (CASL); ODM derived
from: https://clinicaltrials.gov/show/NCT00880555
All rights reserved. Please visit https://medical-data-
models.org/forms/14479
Eligibility Alzheimer Disease
NCT00880555
Inclusion Criteria
veteran or non-veteran*
Yes
No
age 50-89*
Yes
No
with normal cognition or memory impairment (mci
or mild ad)*
Yes
No
english speaking*
Yes
No
right handed*
Yes
No
adequate vision and hearing to take part in tests*
Yes
No
able and willing to undergo mri scan*
Yes
No
medically and psychiatrically stable*
Yes
No
no other brain disease (such as tumor,
parkinson's disease, major stroke)*
Yes
No
Exclusion Criteria
pregnancy*
Yes
No
inability to tolerate mri (due to metal in body or
claustrophobia)*
Yes
No
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Eligibility Alzheimer Disease NCT00884507
A Study of RO5313534 as Add-on to Donepezil Treatment
in Patients With Mild to Moderate Alzheimer's Disease;
ODM derived from:
https://clinicaltrials.gov/show/NCT00884507
All rights reserved. Please visit https://medical-data-
models.org/forms/14480
Eligibility Alzheimer Disease
NCT00884507
Inclusion Criteria
adult patients, >/=50 years of age;*
Yes
No
probable alzheimer's disease;*
Yes
No
mmse score at screening of 13-22;*
Yes
No
under stable donepezil treatment given at a fixed
dose of 5 or 10mg daily for >=4 months prior to
baseline;*
Yes
No
not requiring nursing home care, but looked after
by a caregiver/carer.*
Yes
No
Exclusion Criteria
dementia due to condition other than alzheimer's
disease;*
Yes
No
other significant neurological disorder;*
Yes
No
untreated/non-stabilized major depressive
disorder;*
Yes
No
bipolar disorder, schizophrenia, or any other
serious psychiatric condition.*
Yes
No
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Eligibility Alzheimer Disease NCT00895895
Study Comparing 3 Dosage Levels Of SAM-531 In
Outpatients With Mild To Moderate Alzheimer Disease;
ODM derived from:
https://clinicaltrials.gov/show/NCT00895895
All rights reserved. Please visit https://medical-data-
models.org/forms/14481
Eligibility Alzheimer Disease
NCT00895895
Inclusion Criteria
diagnosis of probable alzheimer disease
according to the  national institute of neurological
and communicative disorders and stroke-
alzheimer's diseases and related disorders
association (nincds-adrda) criteria.*
Yes
No
mini-mental state examination (mmse) score of
12 to 24 at screening*
Yes
No
rosen modified hachinski ischemic score < or
equal to 4 at screening.*
Yes
No
Exclusion Criteria
relevant neurologic disease other than alzheimer
disease  that may affect cognition or ability to
complete the study.*
Yes
No
current major depressive disorder or other current
major psychiatric disorder.*
Yes
No
history of clinically evident stroke or clinically
important carotid or vertebrobasilar stenosis or
plaque.*
Yes
No
use of prescription or nonprescription
medications for cognitive enhancement (including
memantine, ginkgo biloba, huperzine a,  and
cholinesterase inhibitors) within 3 months before
the baseline visit.*
Yes
No
1 / 1
NINDS CDE Grip Strength Amyotrophic
Lateral Sclerosis
NINDS Common Data Elements (Grip Strength
Amyotrophic Lateral Sclerosis) Used from the National
Institute of Neurological Disorders and Stroke Common
Data Elements
(https://www.commondataelements.ninds.nih.gov/)
References: Grinnon ST, Miller K, Marler JR, Lu Y, Stout A,
Odenkirchen J, Kunitz S. National Institute of Neurological
Disorders and Stroke Common Data Element Project -
approach and methods. Clin Trials. 2012;9(3):322-9.
All rights reserved. Please visit https://medical-data-
models.org/forms/14486
Grip Strength
Grip Strength
Study-ID
Study site name
Subject ID
Was the grip strength testing done?
Yes
No
Date Performed
Time performed
Time
am (1)
pm (2)
24-hour clock (3)
Handedness
Left hand (1)
Right hand (2)
Both (3)
Unknown (4)
Left Grip Strength Max-Grip Test 1
Left Grip Strength Max-Grip Test 1
kilograms (kg)
pounds (lb)
newtons (N)
Left Grip Strength Max-Grip Test 2
Left Grip Strength Max-Grip Test 2
kilograms (kg)
pounds (lb)
newtons (N)
Right Grip Strength Max-Grip Test 1
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Right Grip Strength Max-Grip Test 1
kilograms (kg)
pounds (lb)
newtons (N)
Right Grip Strength Max-Grip Test 2
Right Grip Strength Max-Grip Test 2
kilograms (kg)
pounds (lb)
newtons (N)
Grip Strength Fatigue
Was the grip strength fatigue testing done?
Yes
No
Date Performed
Handedness
Left hand (1)
Right hand (2)
Both (3)
Unknown (4)
Left Grip Strength Max-Grip Test 1
Left Grip Strength Max-Grip Test 1
kilograms (kg)
pounds (lb)
newtons (N)
Left Grip Strength Max-Grip Test 2
Left Grip Strength Max-Grip Test 2
kilograms (kg)
pounds (lb)
newtons (N)
Left Grip Strength:Target
Left Grip Strength:Target
kilograms (kg)
pounds (lb)
newtons (N)
Left Grip Strength: 100 % of Target reached
(seconds)
Left Grip Strength: 90% of Target reached
(seconds)
Left Grip Strength: 80% of Target reached
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(seconds)
Left Grip Strength: 70% of Target reached
(seconds)
Left Grip Strength: 60% of Target reached
(seconds)
Left Grip Strength:% of Target not reached
not reached  (100% of Target)
not reached (60% of Target)
not reached  	 (70% of Target)
not reached   (80% of Target)
not reached   (90% of Target)
Right Grip Strength Max-Grip Test 1
Right Grip Strength Max-Grip Test 1
kilograms (kg)
pounds (lb)
newtons (N)
Right Grip Strength Max-Grip Test 2
Right Grip Strength Max-Grip Test 2
kilograms (kg)
pounds (lb)
newtons (N)
Right Grip Strength:Target
Right Grip Strength:Target
kilograms (kg)
pounds (lb)
newtons (N)
Right Grip Strength:100% of Target reached
(seconds)
Right Grip Strength:90% of Target reached
(seconds)
Right Grip Strength:80% of Target reached
(seconds)
Right Grip Strength:70% of Target reached
(seconds)
Right Grip Strength:60% of Target reached
(seconds)
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Right Grip Strength:% of Target not reached
not reached  (100% of Target)
not reached (60% of Target)
not reached  	 (70% of Target)
not reached   (80% of Target)
not reached   (90% of Target)
Hand Held Dynamometry
Was the muscle testing done?
Yes
No
Please specify the date the test was performed
(yyyy-mm-dd)
Please specify the time the test was performed
Left shoulder flexion:Result (including units)
Left shoulder flexion: Break technique- able to
break?
Yes
No
Left shoulder flexion: reason no result
Unable to test (1)
Not done (2)
Right shoulder flexion:Result  (include units)
Right shoulder flexion: Break technique- Able to
Break?
Yes
No
Right shoulder flexion: Reason No Result
Unable to test (1)
Not done (2)
Left elbow flexion: Result (include units)
Left elbow flexion: Break technique- Able to
Break?
Yes
No
Left elbow flexion: Reason No Result
Unable to test (1)
Not done (2)
Right elbow flexion: Result (include units)
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Right elbow flexion: Break technique- Able to
Break?
Yes
No
Right elbow flexion: Reason No Result
Unable to test (1)
Not done (2)
Left elbow extension: Result (include units)
Left elbow extension: Break technique- Able to
Break?
Yes
No
Left elbow extension: Reason No Result
Unable to test (1)
Not done (2)
Right elbow extension: Result (include units)
Right elbow extension: Break technique- Able to
Break?
Yes
No
Right elbow extension: Reason No Result
Unable to test (1)
Not done (2)
Left wrist extension: Result (include units)
Left wrist extension: Break technique- Able to
Break?
Yes
No
Left wrist extension: Reason no result
Unable to test (1)
Not done (2)
Right wrist extension: Result (include units)
Right wrist extension: Break technique- Able to
Break?
Yes
No
Right wrist extension: Reason no result
Unable to test (1)
Not done (2)
Left hip flexion: Result (include units)
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Left hip flexion: Break technique-able to break
Yes
No
Left hip flexion: Reason no result
Unable to test (1)
Not done (2)
Right hip flexion: Result (include units)
Right hip flexion: Break technique-able to break
Yes
No
Right hip flexion: Reason no result
Unable to test (1)
Not done (2)
Left knee flexion: Result (include units)
Left knee flexion: Break technique-able to break
Yes
No
Left knee flexion:Reason no result
Unable to test (1)
Not done (2)
Right knee flexion: Result (include units)
Right knee flexion: Break technique-able to break
Yes
No
Right knee flexion: Reason no result
Unable to test (1)
Not done (2)
Left knee extension:Result (include units)
Left knee extension: Break technique- able to
break
Yes
No
Left knee extension: Reason no result
Unable to test (1)
Not done (2)
Right knee extension: Result (include units)
Right knee extension: Break technique- able to
break
Yes
No
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Right knee extension: Reason no result
Unable to test (1)
Not done (2)
Left ankle dorsiflexion: Result (include units)
Left ankle dorsiflexion: Break technique-able to
break
Yes
No
Left ankle dorsiflexion: Reason no result
Unable to test (1)
Not done (2)
Right ankle dorsiflexion: Result (include units)
Right ankle dorsiflexion: Break technique-able to
break
Yes
No
Right ankle dorsiflexion: Reason no result
Unable to test (1)
Not done (2)
Left first dorsal interosseous: Result (include
units)
Left first dorsal interosseous: Break technique-
able to break
Yes
No
Left first dorsal interosseous: Reason no result
Unable to test (1)
Not done (2)
Right first dorsal interosseous: Result (include
units)
Right first dorsal interosseous: Break technique-
able to break
Yes
No
Right first dorsal interosseous: Reason no result
Unable to test (1)
Not done (2)
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NINDS CDE Myocardial Oxygen Consumption, Gas Exchange ,Nocturnal
Oximetry and pulmonary function Amyotrophic Lateral Sclerosis]
NINDS Common Data Elements (Myocardial Oxygen
Consumption, Gas Exchange ,Nocturnal Oximetry and
pulmonary function Amyotrophic Lateral Sclerosis) Used
from the National Institute of Neurological Disorders and
Stroke Common Data Elements
(https://www.commondataelements.ninds.nih.gov/)
References: Grinnon ST, Miller K, Marler JR, Lu Y, Stout A,
Odenkirchen J, Kunitz S. National Institute of Neurological
Disorders and Stroke Common Data Element Project -
approach and methods. Clin Trials. 2012;9(3):322-9.
All rights reserved. Please visit https://medical-data-
models.org/forms/14487
Myocardial Oxygen Consumption,
Gas Exchange ,Nocturnal Oximetry
and pulmonary function
Myocardial Oxygen Consumption
Study ID
Study site name
Subject ID
Left ventricular (LV) systolic pressure
mmHg
End-diastolic volume
ml
Left ventricular (LV) wall thickness
cm
Contractility
mmHg/ml
Heart rate
bpm
Systolic blood pressure
mmHg
Myocardial oxygen consumption (Mo2):
[derived/calculated value] ml/100g/min
Myocardial oxygen consumption calculation
method
Intramyocardial wall tension, contractility,
and heart rate (1)
Estimated by heart rate and systolic
blood pressure (2)
Gas Exchange
Mean pCO2
1 / 5
%Maximum pCO2
mmHg
Range of pCO2 over a 4 hour period: Minimum
value
mmHg
Range of pCO2 over a 4 hour period: Maximum
value
mmHg
Is there an increase > 15mmHg in pCO2?
Yes
No
Mean transcutaneous pCO2
%
Maximum transcutaneous pCO2
mmHg
Range of transcutaneous pCO2 over a 4 hour
period: Minimum value
mmHg
Range of transcutaneous pCO2 over a 4 hour
period: Maximum value
mmHg
Is there an increase > 15mmHg in
transcutaneous pCO2?
Yes
No
Nocturnal Oximetry
Start date and time
End date and time
Oxymetry recording time
Net time
Baseline SpO2
%
Mean SpO2
%
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Total number of desaturations
Total time SpO2 below 89%
Pulmonary function
Date of Pulmonary Function Testing
What type of pulmonary function testing is being
performed?*
Slow Vital Capacity (sVC) (1)
Maximum Inspiratory Pressure (MIP) –
specify type below: (2)
Sniff Nasal Inspiratory Pressure (SNIP)
(3)
Maximal Voluntary Ventilation (MVV) (4)
Maximum Expiratory Pressure (MEP) (5)
Peak Expiratory Flow (PEF) (6)
Forced Vital Capacity (FVC) (7)
Forced Expiratory Volume in 1 second
(FEV1) (8)
Position for the assessment
Sitting  (1)
Supine (FVC only)  (2)
Sitting and Supine (3)
What type of mouthpiece was used
Scuba  (1)
Tube  (2)
Mask  (3)
Other (4)
sVC Results: Test performed
Yes
No
sVC Results: Trial number
1 (1)
2 (2)
3 (3)
sVC Results
liter
sVC Results: percent of predicted
%
MIP Results:Test performed
Yes
No
MIP Results:Trial number
1 (1)
2 (2)
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3 (3)
MIP Results
cm H20
MEP Results: Test performed
Yes
No
MEP Results:Trial number
1 (1)
2 (2)
3 (3)
MEP Results
cm H20
PEF Results: Test performed
Yes
No
PEF Results:Trial number
1 (1)
2 (2)
3 (3)
PEF Results
l/min
FEV1 Results:Test performed
Yes
No
FEV1 Results:Trial number
1 (1)
2 (2)
3 (3)
FEV1 Results
liter
FVC Results: Test performed
Yes
No
FVC Results:Trial number
FVC Results: Flow volume crossed x-axis
Yes
No
FVC Results
liter
FVC Results: percent of predicted normal-
TBD
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SNIP Results: Test performed
Yes
No
SNIP Results: Trial number
1 (1)
2 (2)
3 (3)
SNIP Results
cm H20
SNIP Results: Peak Pressure Value
cm H2O
SNIP Results: Nare
left (1)
right (2)
SNIP Results:Nasal congestion
Yes
No
MVV Results:Test performed
Yes
No
MVV Results:Trial number
1 (1)
2 (2)
3 (3)
MVV Results
l/min
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Eligibility Asthma NCT02491684
A Study in Asthma Patients to Evaluate Efficacy, Safety and
Tolerability of 14 Days Once Daily Inhaled Interferon Beta-
1a After the Onset of Symptoms of an Upper Respiratory
Tract Infection; ODM derived from:
https://clinicaltrials.gov/show/NCT02491684
All rights reserved. Please visit https://medical-data-
models.org/forms/14496
Eligibility Asthma NCT02491684
Inclusion Criteria
for inclusion in the study patients should fulfil the
following criteria:*
Yes
No
1. provision of signed and dated written informed
consent prior to any study specific procedures*
Yes
No
2. male or female aged 18 and above at the time
of enrolment*
Yes
No
3. history of physician-diagnosed asthma
requiring treatment with medium-to-high dose ics
(>250 μg fluticasone dry powder formulation
equivalents total daily dose, as defined in gina
2014; see appendix chapter 5) and a second
controller medication (eg, laba or leukotriene
receptor antagonist). the medium or high dose ics
plus laba can be any combination inhaler or 2
separate inhalers. patients must have taken ics
(>250*
Yes
No
μg fluticasone or the equivalent daily) plus
second controller medication for at least 12
months prior to the date the informed consent is
obtained, with or without another controller such
as oral corticosteroids (ocs), theophylline,
tiotropium, or leukotriene receptor antagonists*
Yes
No
4. proof of post-bronchodilator reversibility in fev1
of ≥12% and ≥200 ml (pellegrino et al 2005)
documented within 5 years prior to visit 1, or
proof of a positive response to a methacholine or
histamine challenge (a decrease in fev1 by 20%
[pc20] at ≤8 mg/ml) performed according to
ats/ers guidelines (american thoracic society
2000) documented within 5 years prior to visit 1.
if historical documentation is not available,
reversibility or proof of a positive response to a
methacholine challenge must be demonstrated
and documented at visit 1*
Yes
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No
5. must answer "yes" to the question "does a cold
or flu make your asthma worse?"*
Yes
No
6. to have had at least two documented severe
asthma exacerbations within the last 24 months
that were suspected by the patient to have been
caused by a common cold or flu and to have had
at least one documented severe asthma
exacerbation within the last 12 months that was
suspected by the patient to have been caused by
a common cold or flu*
Yes
No
7. female patients must be 1 year post-
menopausal, surgically sterile, or using an
acceptable method of contraception.*
Yes
No
8. negative pregnancy test (urine) for female
patients of childbearing potential*
Yes
No
9. motivation (in the investigator's opinion) to
complete all study visits, the ability to
communicate well with the investigator and be
capable of understanding the nature of the
research and its treatment including its risks and
benefits*
Yes
No
10. ability to read and write and use the
electronic devices*
Yes
No
Exclusion Criteria
patients should not enter the study if any of the
following exclusion criteria are fulfilled:*
Yes
No
1. involvement in the planning and/or conduct of
the study (applies to both astrazeneca staff and
staff at third party vendors or staff at the study
sites)*
Yes
No
2. previous randomization to treatment in the
present study*
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Yes
No
3. any condition, including findings in the medical
history or in the pre-study assessments that, in
the opinion of the investigator, constitutes a risk
or a contraindication for the participation of the
patient in the study or that could interfere with the
study objectives, conduct or evaluation*
Yes
No
4. lung disease other than asthma (eg, chronic
obstructive pulmonary disease, cystic fibrosis,
allergic bronchopulmonary aspergillosis)*
Yes
No
5. patients with ≥4 severe exacerbations during
the last 12 months that the patient suspected
were triggered by something else than an upper
respiratory tract infection*
Yes
No
6. current participation in another clinical trial or
participation in a clinical trial where the patient
has received a dose of a test product (imp) within
12 weeks prior to entry into the study for small
molecules and within 12 months prior to entry
into the study for biologicals*
Yes
No
7. patients who currently have, or have had within
the past 3 months, any significant underlying
medical condition(s) that could impact
interpretation of results eg, infections,
haematological disease, malignancy, renal,
hepatic, coronary heart disease or other
cardiovascular disease, including arrhythmias,
endocrinological or gastrointestinal disease*
Yes
No
8. abnormal vital signs, after at least 10 minutes
supine rest, defined as any of the following:*
Yes
No
in patients < 60 years old, systolic blood pressure
<90 mmhg or ≥150 mmhg*
Yes
No
in patients > 60 years old, systolic blood pressure
<90 mmhg or ≥160 mmhg*
Yes
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No
diastolic blood pressure <50 mmhg or ≥100
mmhg*
Yes
No
hr <45 or >95 beats per minute*
Yes
No
9. any clinically important abnormalities in
rhythm, conduction or morphology of the resting
ecg and any abnormalities in the 12-lead ecg
that, as considered by the investigator, may
interfere with the interpretation of qtc interval
changes, including abnormal st-t-wave
morphology (particularly in the protocol defined
primary lead) or left ventricular hypertrophy*
Yes
No
10. prolonged qtcf >450 ms (for both gender) or
shortened qtcf <340 ms or family history of long
qt syndrome*
Yes
No
11. pr(pq) interval shortening <120ms (pr<120
ms but >110 ms is acceptable if there is no
evidence of ventricular pre-excitation).*
Yes
No
12. pr(pq) interval prolongation (>240ms),
intermittent second or third degree av block, or av
dissociation*
Yes
No
13. qrs duration >120ms including persistent or
intermittent bundle branch block*
Yes
No
14. patients with implantable cardiac defibrillator
(icd) or a permanent pacemaker and patients
with symptomatic ventricular and / or atrial
tachyarrhythmias*
Yes
No
15. patients with unstable angina pectoris or
stable angina pectoris classified higher than
canadian cardiovascular society (css) class ii or a
myocardial infarction or stroke within 6 months*
Yes
No
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16. history of hospitalization within 12 months
caused by heart failure or a diagnosis of heart
failure higher than new york heart association
(nyha) class ii*
Yes
No
17. history of hypersensitivity to natural or
recombinant interferon beta-1a or to any of the
drug preparation excipients*
Yes
No
18. received any marketed biologic agent (eg,
omalizumab) within 12 months or 5 times the
half-life (whichever is the longer) of the agent
prior to enrolment*
Yes
No
19. significant history of depressive disorder or
suicidal ideation. specifically; individuals with
current severe depression (ie, a low mood, which
pervades all aspects of life and an inability to
experience pleasure in activities that formerly
were enjoyed); individuals with a past history of
depression that required hospitalization or referral
to psychiatric services in the past 5 years;
individuals who currently feel suicidal or have
attempted suicide in the past*
Yes
No
20. history of epilepsy or seizures after the age of
5 years, other than febrile childhood seizure(s)*
Yes
No
21. history of drug or alcohol abuse within 12
months prior to enrolment*
Yes
No
22. patients who have hepatic serum enzyme
levels ≥2.5 times the normal range*
Yes
No
23. positive test for serum hepatitis b surface
antigen, hepatitis c antibody, or hiv*
Yes
No
24. patients with a smoking history of ≥20 pack-
years (1 pack year = 20 cigarettes smoked per
day for one year)*
Yes
No
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25. female who is breast-feeding, pregnant
(verified by urine dipstick pregnancy test) or
intends to become pregnant during the study*
Yes
No
26. patients who are unable to demonstrate an
acceptable spirometry technique*
Yes
No
27. patients that have previously been included in
studies evaluating the investigational medicinal
product*
Yes
No
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Eligibility Asthma NCT02264691
UTMB Research on Severe Asthma (UROSA) Study; ODM
derived from: https://clinicaltrials.gov/show/NCT02264691
All rights reserved. Please visit https://medical-data-
models.org/forms/14497
Eligibility Asthma NCT02264691
Inclusion Criteria
all participants must be in good general health
(with exception to asthma). • normal controls /
healthy volunteers (nc) subjects with no past
history of asthma or other lung disease.  to
determine this, subjects must have an fev1 equal
to or greater than 80% of predicted value and
have a normal fev1/fvc ratio.*
Yes
No
asthma subjects eligible asthmatic participants
must have a physician diagnosis of asthma for at
least 1 year.  participants must either have
historical evidence of reversibility of fev1 of at
least 12%, or demonstrate such a change during
the study visits, or must have historical evidence
of a pc20 for methacholine < 8mg/ml.*
Yes
No
mild asthma with no corticosteroids (manc) will
be defined as control of asthma with short acting
β2-agonists or leukotrine antagonist or both, but
not requiring inhaled corticosteroids.*
Yes
No
mild to moderate asthma (mma) will be defined
as control of asthma with an inhaled
corticosteroid (less than or equal to 250 mcg
daily inhaled fluticasone equivalent) in addition to
the medications listed in the manc group or long
acting β2-agonists.*
Yes
No
severe asthma  (sa) will be defined according to
the ats criteria for refractory asthma (10)*
Yes
No
Exclusion Criteria
exclusion criteria apply for all subjects:*
Yes
No
current smoker, or former smoker with >10 pack
years history or having quit within the past year*
Yes
No
1 / 2
asthma exacerbation, requiring a new or
increased dose of oral corticosteroids, within the
past 30 days*
Yes
No
pregnant or lactating female*
Yes
No
significant/uncontrolled medical condition
(uncontrolled diabetes, coronary artery disease,
uncontrolled hypertension)*
Yes
No
diagnosis of emphysema or other significant
pulmonary disease*
Yes
No
if, in the opinion of the pi (wjc) the subject has co-
morbid conditions that make them unsafe to
undergo bronchoscopy, subjects will be given the
choice to withdraw from the study or allowed to
complete visits 1-3 only.*
Yes
No
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Eligibility Adult Acute Megakaryoblastic
Leukemia (M7) NCT00112853
Tipifarnib and Etoposide in Treating Older Patients With
Newly Diagnosed Acute Myeloid Leukemia; ODM derived
from: https://clinicaltrials.gov/show/NCT00112853
All rights reserved. Please visit https://medical-data-
models.org/forms/14498
Eligibility Adult Acute
Megakaryoblastic Leukemia (M7)
NCT00112853
Inclusion Criteria
adults age with established, pathologically
confirmed diagnoses of newly diagnosed aml,
including de novo and secondary amls but
excluding newly diagnosed acute progranulocytic
leukemia (apl, m3), will be considered eligible for
study*
Yes
No
ecog performance status 0-2*
Yes
No
patient must be able to give informed consent*
Yes
No
serum creatinine =< 2.0 mg/dl*
mg/dl
Yes
No
sgot and sgpt =< 5 x upper limit normal (uln)*
Yes
No
bilirubin =< 2 mg/dl*
mg/dl
Yes
No
newly diagnosed aml, subtypes m0,1,2,4-7 but
excluding m3 (apl), including myelodysplasia
(mds)-related aml (mds/aml) and treatment-
related aml*
Yes
No
patients who have received hydroxyurea alone or
have received non-cytotoxic therapies previously
for mds (e.g., thalidomide, interferon, cytokines,
5-azacytidine) will be eligible for this trial*
Yes
No
Exclusion Criteria
any previous treatment with r115777 or vp-16*
Yes
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No
patients receiving concomitant chemotherapy,
radiation therapy or immunotherapy*
Yes
No
hyperleukocytosis with >= 30,000 blasts/ul or
rapidly rising blast count with projected doubling
time of =< 2 days*
Yes
No
acute progranulocytic leukemia (apl,m3)*
Yes
No
active cns leukemia*
Yes
No
active, uncontrolled infection; patients with
infection under active treatment and controlled
with antibiotics are eligible*
Yes
No
presence of other life-threatening illness*
Yes
No
patients with mental deficits and/or psychiatric
history that preclude them from giving informed
consent or from following protocol*
Yes
No
patients on enzyme-inducing anti-convulsants
(e.g., phenytoin, fosphenytoin, phenobarbital,
primidone, carbamazepine, oxcarbazepine);
patients may be changed to non-enzyme
inducing anti-convulsants and stabilized before
starting study treatment*
Yes
No
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Eligibility Asthma NCT02491970
Study to Evaluate Small Airway Parameters of
Fluticasone/Formoterol (Flutiform®) Compared to
Fluticasone/Salmeterol in Asthma Patients; ODM derived
from: https://clinicaltrials.gov/show/NCT02491970
All rights reserved. Please visit https://medical-data-
models.org/forms/14507
Eligibility Asthma NCT02491970
Inclusion Criteria
1. adult (over 19 years) asthma patients*
Yes
No
2. patients who have a history of mild-to-
moderate-severe, persistent asthma for at least 6
months prior to screening.*
Yes
No
3. patients who were required to demonstrate a
fev1 of ≥ 40 % and ≤ 85% of predicted normal
values during screening period following
appropriate withholding of asthma medications (if
applicable).*
Yes
No
4. patients who were required to show
reversibility of ≥15% fev1 after salbutamol
inhalation (2 actuations, 100µg per actuation)
from the pre- salbutamol value at screening*
Yes
No
5. patients who have uncontrolled asthma by
seretide® 250/50 defined as act less than 20*
Yes
No
6. patients who showed r5-20 more than 0.1
kpa/l/s*
Yes
No
7. blood eosinophil count > 300/µl on screening
visit*
Yes
No
8. female patients of childbearing potential must
have a negative urine pregnancy test at
screening.*
Yes
No
9. patients who are able to use the inhaler*
Yes
No
10. patients who is willing to voluntarily sign the
study consent form*
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Yes
No
Exclusion Criteria
1. patients who have experienced life-threatening
asthma within 12 months prior to screening or
respiratory infection within 4 weeks prior to
screening, or patients who have experienced any
emergency visit or hospitalization due to acute
asthma symptoms within 4 weeks prior to
screening*
Yes
No
2. patients who have diagnosed as clinically
significant disease or non- reversible pulmonary
disease or patients who currently have active
pulmonary disease (eg. copd, cystic fibrosis,
bronchiectasis, active tuberculosis)*
Yes
No
3. patients who have diagnosed as laryngitis,
chronic sinusitis, infectious rhinitis or allergic
rhinitis within 4 weeks prior to screening, or
patients who have had any symptoms of acute
exacerbation or purulent discharge by the
disease above within 2 weeks prior to screening*
Yes
No
4. current smoker or past smoker defined as
below:*
Yes
No
current smoker: smoking history within 12 months
prior to screening*
Yes
No
past smoker: smoking amount ≥10 pack year**
Yes
No
pack year (py) calculation: average amount of
smoking per day (pack) x duration of smoking
(year)*
Yes
No
5. patients who currently are pregnant or
lactating*
Yes
No
6. patient who had taken systemic corticosteroid
within 4 weeks prior to screening*
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Yes
No
7. patients who had taken omalizumab within 24
weeks prior to screening*
Yes
No
8. patients who had taken the following
medications within 1 week prior to screening:*
Yes
No
potent cyp3a inhibitors*
Yes
No
β-blockers*
Yes
No
monoamine oxidase inhibitor*
Yes
No
tca (tricyclic antidepressants)*
Yes
No
quinidine-type anti arrhythmic*
Yes
No
leukotriene anatagonist*
Yes
No
astemizole*
Yes
No
9. patients who are participating or going to
participate in any interventional clinical trials*
Yes
No
10. qt interval prolongation in ecg result at
screening*
Yes
No
11. patients with hypersensitive to investigational
products or to any component of the drug*
Yes
No
12. patients who are judged difficult to participate
in this investigation by the investigator*
Yes
No
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NINDS CDE Classification of Etiology,Seizures
and syndromes by age of onset Epilepsy
NINDS Common Data Elements Used from the National
Institute of Neurological Disorders and Stroke Common
Data Elements
(https://www.commondataelements.ninds.nih.gov/)
References: Grinnon ST, Miller K, Marler JR, Lu Y, Stout A,
Odenkirchen J, Kunitz S. National Institute of Neurological
Disorders and Stroke Common Data Element Project -
approach and methods. Clin Trials. 2012;9(3):322-9.
All rights reserved. Please visit https://medical-data-
models.org/forms/14509
Classification of Etiology,Seizures
and syndromes by age of onset
Classification of Etiology
Genetic or presumed genetic OR epilepsy of
unknown cause
No (1)
Possible (2)
Probable (3)
Definite (4)
Unknown (5)
N/A (6)
Structural or metabolic
No (1)
Possible (2)
Probable (3)
Definite (4)
Unknown (5)
N/A (6)
Specific Etiology
Viral, bacterial and parasitic infections
No (1)
Possible (2)
Probable (3)
Definite (4)
Unknown (5)
N/A (6)
Viral, bacterial and parasitic infections
Primary cause (1)
Secondary cause (2)
Viral, bacterial and parasitic infections: If more
than one specific etiology, please specify
Traumatic brain injury
No (1)
Possible (2)
Probable (3)
Definite (4)
Unknown (5)
N/A (6)
Traumatic brain injury
Primary cause (1)
Secondary cause (2)
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Traumatic brain injury: If more than one specific
etiology is selected, specify
Stroke
No (1)
Possible (2)
Probable (3)
Definite (4)
Unknown (5)
N/A (6)
Stroke
Primary cause (1)
Secondary cause (2)
Stroke: If more than one specific etiology is
selected, specify:
Intraventricular hemorrhage
No (1)
Possible (2)
Probable (3)
Definite (4)
Unknown (5)
N/A (6)
Intraventricular hemorrhage
Primary cause (1)
Secondary cause (2)
Intraventricular hemorrhage: If more than one
specific etiology is selected, specify:
Hypoxic-ischemic encephalopathy
No (1)
Possible (2)
Probable (3)
Definite (4)
Unknown (5)
N/A (6)
Hypoxic-ischemic encephalopathy
Primary cause (1)
Secondary cause (2)
Hypoxic-ischemic encephalopathy: If more than
one specific etiology is selected, specify:
Other metabolic or toxic insults
No (1)
Possible (2)
Probable (3)
Definite (4)
Unknown (5)
N/A (6)
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Other metabolic or toxic insults
Primary cause (1)
Secondary cause (2)
Other metabolic or toxic insults:If more than one
specific etiology is selected, specify:
Neurocutaneous syndromes
No (1)
Possible (2)
Probable (3)
Definite (4)
Unknown (5)
N/A (6)
Neurocutaneous syndromes
No (1)
Possible (2)
Probable (3)
Definite (4)
Unknown (5)
N/A (6)
Neurocutaneous syndromes: If more than one
specific etiology is selected, specify:
Inborn errors of metabolism
No (1)
Possible (2)
Probable (3)
Definite (4)
Unknown (5)
N/A (6)
Inborn errors of metabolism
Primary cause (1)
Secondary cause (2)
Inborn errors of metabolism:If more than one
specific etiology is selected, specify:
Genetic and chromosomal development
encephalopathies
No (1)
Possible (2)
Probable (3)
Definite (4)
Unknown (5)
N/A (6)
Genetic and chromosomal development
encephalopathies
Primary cause (1)
Secondary cause (2)
Genetic and chromosomal development
encephalopathies: If more than one specific
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etiology is selected, specify
Developmental encephalopathy of unknown
cause as evidenced by the presence of mental
retardation, cerebral palsy, or autism with no
evidence of a specific insult of disorder to which
cause can be attributed preceding the onset of
epilepsy
No (1)
Possible (2)
Probable (3)
Definite (4)
Unknown (5)
N/A (6)
Developmental encephalopathy of unknown
cause as evidenced by the presence of mental
retardation, cerebral palsy, or autism with no
evidence of a specific insult of disorder to which
cause can be attributed preceding the onset of
epilepsy
Primary cause (1)
Secondary cause (2)
Developmental encephalopathy of unknown
cause as evidenced by the presence of mental
retardation, cerebral palsy, or autism with no
evidence of a specific insult of disorder to which
cause can be attributed preceding the onset of
epilepsy: If more than one specific etiology is
selected, specify
Malformations of cortical or other brain
development with or without known  genetic
determinants
No (1)
Possible (2)
Probable (3)
Definite (4)
Unknown (5)
N/A (6)
Malformations of cortical or other brain
development with or without known  genetic
determinants
Primary cause (1)
Secondary cause (2)
Malformations of cortical or other brain
development with or without known  genetic
determinants: If more than one specific etiology is
selected, specify
Neoplasia
No (1)
Possible (2)
Probable (3)
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Definite (4)
Unknown (5)
N/A (6)
Neoplasia
Primary cause (1)
Secondary cause (2)
Neoplasia: If more than one specific etiology is
selected, specify
Mesial temporal sclerosis
No (1)
Possible (2)
Probable (3)
Definite (4)
Unknown (5)
N/A (6)
Mesial temporal sclerosis
Primary cause (1)
Secondary cause (2)
Mesial temporal sclerosis: If more than one
specific etiology is selected, specify
Dementia
No (1)
Possible (2)
Probable (3)
Definite (4)
Unknown (5)
N/A (6)
Dementia
Primary cause (1)
Secondary cause (2)
Dementia: If more than one specific etiology is
selected, specify
Other degenerative neurologic diseases
No (1)
Possible (2)
Probable (3)
Definite (4)
Unknown (5)
N/A (6)
Other degenerative neurologic diseases
Primary cause (1)
Secondary cause (2)
Genetic or presumed genetic, if known specify:
Genetic or presumed genetic
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No (1)
Possible (2)
Probable (3)
Definite (4)
Unknown (5)
N/A (6)
Genetic or presumed genetic
Primary cause (1)
Secondary cause (2)
Genetic or presumed genetic, if more than one
specific etiology is selected, specify:
Epilepsy of unknown cause, without relevant
abnormalities on examination, cognition, history,
or imaging
No (1)
Possible (2)
Probable (3)
Definite (4)
Unknown (5)
N/A (6)
Epilepsy of unknown cause, without relevant
abnormalities on examination, cognition, history,
or imaging
Primary cause (1)
Secondary cause (2)
Epilepsy of unknown cause without relevant
abnormalities on examination, cognition, history,
or imaging:If more than one specific etiology is
selected, specify
Other Etiology, specify:
Other etiology
No (1)
Possible (2)
Probable (3)
Definite (4)
Unknown (5)
N/A (6)
Other etiology
Primary cause (1)
Secondary cause (2)
Other etiology,If more than one specific etiology
is selected, specify:
Classification of Seizures
Generalized seizures
Yes
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No
Tonic clonic seizures (in any combination)
No (1)
Possible (2)
Probable (3)
Definite (4)
Unknown (5)
N/A (6)
Absence
No (1)
Possible (2)
Probable (3)
Definite (4)
Unknown (5)
N/A (6)
Generalized Seizure Typical
No (1)
Possible (2)
Probable (3)
Definite (4)
Unknown (5)
N/A (6)
Generalized Seizure Atypical
No (1)
Possible (2)
Probable (3)
Definite (4)
Unknown (5)
N/A (6)
Generalized Seizure Myoclonic absence
No (1)
Possible (2)
Probable (3)
Definite (4)
Unknown (5)
N/A (6)
Generalized Seizure Eyelid myoclonia
No (1)
Possible (2)
Probable (3)
Definite (4)
Unknown (5)
N/A (6)
Generalized Seizure Myoclonic
No (1)
Possible (2)
Probable (3)
Definite (4)
Unknown (5)
N/A (6)
Generalized Seizure Myoclonic atonic
No (1)
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Possible (2)
Probable (3)
Definite (4)
Unknown (5)
N/A (6)
Generalized Seizure Myoclonic tonic
No (1)
Possible (2)
Probable (3)
Definite (4)
Unknown (5)
N/A (6)
Generalized Seizure Clonic
No (1)
Possible (2)
Probable (3)
Definite (4)
Unknown (5)
N/A (6)
Generalized seizures tonic
No (1)
Possible (2)
Probable (3)
Definite (4)
Unknown (5)
N/A (6)
Generalized seizures atonic
No (1)
Possible (2)
Probable (3)
Definite (4)
Unknown (5)
N/A (6)
Focal seizures
Yes
No
Focal Seizure without impairment of
consciousness or responsiveness
No (1)
Possible (2)
Probable (3)
Definite (4)
Unknown (5)
N/A (6)
Focal Seizure with observable motor or
autonomic components (roughly corresponds to
the concept of “simple partial seizure”)
No (1)
Possible (2)
Probable (3)
Definite (4)
Unknown (5)
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N/A (6)
Focal Seizure involving subjective sensory or
psychic phenomena only (corresponds to the
concept of “aura”)
No (1)
Possible (2)
Probable (3)
Definite (4)
Unknown (5)
N/A (6)
Focal Seizure with impairment of consciousness
or responsiveness (roughly corresponds to the
concept of “complex partial seizure”)
No (1)
Possible (2)
Probable (3)
Definite (4)
Unknown (5)
N/A (6)
Focal Seizure evolving to a bilateral, convulsive
seizure (involving tonic, clonic, or tonic and clonic
components; replaces the term “secondarily
generalized seizure”)
No (1)
Possible (2)
Probable (3)
Definite (4)
Unknown (5)
N/A (6)
Unclassified Seizure
Yes
No
Unclassified Seizure Epileptic spasms – focal or
generalized
No (1)
Possible (2)
Probable (3)
Definite (4)
Unknown (5)
N/A (6)
Unclassified Seizure
No (1)
Possible (2)
Probable (3)
Definite (4)
Unknown (5)
N/A (6)
If two or more seizure types were selected as
present, rate the confidence level that these are
distinct seizure types
0 No Confidence (1)
Possible (2)
Probable (3)
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Definite (4)
Unknown (5)
N/A (6)
Date of completion of this form
Information complete up to (mm/dd/yyyy)
Syndromes by Age of Onset
Benign familial neonatal epilepsy (BFNE)
No (1)
Possible (2)
Probable (3)
Definite (4)
Unknown (5)
N/A (6)
Early myoclonic encephalopathy (EME)
No (1)
Possible (2)
Probable (3)
Definite (4)
Unknown (5)
N/A (6)
Ohtahara syndrome
No (1)
Possible (2)
Probable (3)
Definite (4)
Unknown (5)
N/A (6)
Epilepsy of infancy with migrating focal seizures
No (1)
Possible (2)
Probable (3)
Definite (4)
Unknown (5)
N/A (6)
West syndromes
No (1)
Possible (2)
Probable (3)
Definite (4)
Unknown (5)
N/A (6)
Myoclonic epilepsy in infancy (MEI)
No (1)
Possible (2)
Probable (3)
Definite (4)
Unknown (5)
N/A (6)
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Benign infantile epilepsy
No (1)
Possible (2)
Probable (3)
Definite (4)
Unknown (5)
N/A (6)
Benign familial infantile epilepsy
No (1)
Possible (2)
Probable (3)
Definite (4)
Unknown (5)
N/A (6)
Dravet syndrome
No (1)
Possible (2)
Probable (3)
Definite (4)
Unknown (5)
N/A (6)
Myoclonic encephalopathy in nonprogressive
disorders
No (1)
Possible (2)
Probable (3)
Definite (4)
Unknown (5)
N/A (6)
Childhood Febrile seizures plus
No (1)
Possible (2)
Probable (3)
Definite (4)
Unknown (5)
N/A (6)
Early onset benign childhood occipital epilepsy
(Panayiotopoulos type)
No (1)
Possible (2)
Probable (3)
Definite (4)
Unknown (5)
N/A (6)
Childhood Epilepsy with myoclonic atonic
seizures
No (1)
Possible (2)
Probable (3)
Definite (4)
Unknown (5)
N/A (6)
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Benign childhood epilepsy with centrotemporal
spikes (BCECTS)
No (1)
Possible (2)
Probable (3)
Definite (4)
Unknown (5)
N/A (6)
Autosomal-dominant nocturnal frontal lobe
epilepsy (ADNFLE)
No (1)
Possible (2)
Probable (3)
Definite (4)
Unknown (5)
N/A (6)
Late onset childhood occipital epilepsy (Gastaut
type)
No (1)
Possible (2)
Probable (3)
Definite (4)
Unknown (5)
N/A (6)
Epilepsy with myoclonic absences
No (1)
Possible (2)
Probable (3)
Definite (4)
Unknown (5)
N/A (6)
Lennox-Gastaut syndrome
No (1)
Possible (2)
Probable (3)
Definite (4)
Unknown (5)
N/A (6)
Epileptic encephalopathy with continuous spike-
and-wave during sleep (CSWS)
No (1)
Possible (2)
Probable (3)
Definite (4)
Unknown (5)
N/A (6)
Landau-Kleffner syndrome (LKS)
No (1)
Possible (2)
Probable (3)
Definite (4)
Unknown (5)
N/A (6)
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Childhood absence epilepsy (CAE)
No (1)
Possible (2)
Probable (3)
Definite (4)
Unknown (5)
N/A (6)
Juvenile absence epilepsy (JAE)
No (1)
Possible (2)
Probable (3)
Definite (4)
Unknown (5)
N/A (6)
Other familial temporal lobe epilepsies
No (1)
Possible (2)
Probable (3)
Definite (4)
Unknown (5)
N/A (6)
Juvenile myoclonic epilepsy
No (1)
Possible (2)
Probable (3)
Definite (4)
Unknown (5)
N/A (6)
Progressive myoclonus epilepsies
No (1)
Possible (2)
Probable (3)
Definite (4)
Unknown (5)
N/A (6)
Autosomal Dominant Epilepsy with Auditory
Features (ADEAF)
No (1)
Possible (2)
Probable (3)
Definite (4)
Unknown (5)
N/A (6)
Epilepsy with generalized tonic-clonic seizures
alone
No (1)
Possible (2)
Probable (3)
Definite (4)
Unknown (5)
N/A (6)
Familial focal epilepsy with variable foci
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(childhood to adult)
No (1)
Possible (2)
Probable (3)
Definite (4)
Unknown (5)
N/A (6)
Reflex epilepsies
No (1)
Possible (2)
Probable (3)
Definite (4)
Unknown (5)
N/A (6)
Mesial temporal lobe epilepsy
No (1)
Possible (2)
Probable (3)
Definite (4)
Unknown (5)
N/A (6)
Rasmussen syndrome
No (1)
Possible (2)
Probable (3)
Definite (4)
Unknown (5)
N/A (6)
Gelastic seizures with hypothalamic hamartoma
No (1)
Possible (2)
Probable (3)
Definite (4)
Unknown (5)
N/A (6)
Temporal lobe epilepsy
No (1)
Possible (2)
Probable (3)
Definite (4)
Unknown (5)
N/A (6)
Frontal lobe epilepsy
No (1)
Possible (2)
Probable (3)
Definite (4)
Unknown (5)
N/A (6)
Occipital lobe epilepsy
No (1)
Possible (2)
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Probable (3)
Definite (4)
Unknown (5)
N/A (6)
Parietal lobe epilepsy
No (1)
Possible (2)
Probable (3)
Definite (4)
Unknown (5)
N/A (6)
Focal epilepsy (specific localization unknown)
No (1)
Possible (2)
Probable (3)
Definite (4)
Unknown (5)
N/A (6)
The epilepsy does not fit into one of these
specific electro-clinical or distinctive
constellations categories
No (1)
Possible (2)
Probable (3)
Definite (4)
Unknown (5)
N/A (6)
If two or more epilepsy syndromes were selected
as present, rate the confidence level that these
are distinct syndromes
0 No Confidence (1)
Possible (2)
Probable (3)
Definite (4)
Unknown (5)
N/A (6)
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Eligibility Asthma NCT02501824
Effectiveness of Anthroposophic Speech Therapy in
Patients With Asthma; ODM derived from:
https://clinicaltrials.gov/show/NCT02501824
All rights reserved. Please visit https://medical-data-
models.org/forms/14510
Eligibility Asthma NCT02501824
Inclusion Criteria
signed informed consent*
Yes
No
age ≥ 12 years*
Yes
No
asthma ≥ 1 year*
Yes
No
inhaling β2 agonist ≥ once weekly*
Yes
No
Exclusion Criteria
not willing to perform therapy actively*
Yes
No
insufficient general condition for active therapy*
Yes
No
copd*
Yes
No
coronary heart disease*
Yes
No
oral corticosteroids*
Yes
No
pregnancy*
Yes
No
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Eligibility Asthma NCT02509130
MISSION Severe Asthma Modern Innovative Solutions to
Improve Outcomes in Severe Asthma.; ODM derived from:
https://clinicaltrials.gov/show/NCT02509130
All rights reserved. Please visit https://medical-data-
models.org/forms/14511
Eligibility Asthma NCT02509130
Inclusion Criteria
male or female, aged 18 years or above.*
Yes
No
is in one of the following population groups:*
Yes
No
attended the mission raac or*
Yes
No
attended the mission saac or*
Yes
No
identified as uncontrolled asthma by record
searches and invited to mission raac but did not
attend - 'primary care patients' or*
Yes
No
has been referred to the specialist asthma clinic
at queen alexandra hospital -*
Yes
No
'outpatient severe asthma patients' or*
Yes
No
attended the mission raac or saac as a health
care professional*
Yes
No
participant is willing and able to give informed
consent for participation in the study.*
Yes
No
Exclusion Criteria
the patient is unable or unwilling to give consent*
Yes
No
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Eligibility Asthma, Bronchial NCT00213252
Use of Montelukast to Treat Children With Mild to Moderate
Acute Asthma; ODM derived from:
https://clinicaltrials.gov/show/NCT00213252
All rights reserved. Please visit https://medical-data-
models.org/forms/14514
Eligibility Asthma, Bronchial
NCT00213252
Inclusion Criteria
age 2-17 years*
Yes
No
clinical diagnosis of mild to moderate asthma as
a second wheezing episode associated with
signs of respiratory distress suggesting lower
airway obstruction such as tachypnea and/or use
of accessory muscles of respiration.*
Yes
No
baseline pulmonary index clinical score
(appendix b) ≤ 11 out of 15 possible points as
well as pram ≤ 8 out of 12 points.*
Yes
No
presenting to the sick kids emergency
department*
Yes
No
children capable of fev1 measurement will have
fev1 more than 60% of the predicted value*
Yes
No
male or female*
Yes
No
willing and able to provide informed consent (or
informed consent by parents)*
Yes
No
Exclusion Criteria
no previous history of wheezing or bronchodilator
therapy.  this population may eventually have
diagnoses other than asthma or viral induced
wheezing*
Yes
No
patients who received more than a single dose of
oral corticosteroids within 72 hours prior to
arrival*
Yes
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No
patients receiving more than 500 mcg per day of
fluticasone for more than 1 month or more than
250 mcg of fluticasone for more than 7 days prior
to arrival*
Yes
No
patients who have had more than 2 previous
visits to the asthma clinic at sickkids*
Yes
No
patients who received montelukast within one
week of arrival*
Yes
No
critically ill patients requiring airway stabilization*
Yes
No
patients with severe asthma, defined as pi 12 to
15 or pram 9 to 12.*
Yes
No
co-existent co-morbidities such as chronic
pulmonary disease and cardiac disease requiring
pharmacotherapy, neurologic disease and
immune disorders.*
Yes
No
previous admission to icu for asthma.*
Yes
No
more than 3 hospitalizations for asthma during
the past 12 months.*
Yes
No
contact with varicella within the previous 21
days.*
Yes
No
insufficient command of the english language*
Yes
No
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ePflegebericht (electronic nursing report)
ePflegebericht
Prof. Dr. Ursula Hübner
Forschungsgruppe Informatik im Gesundheitswesen
Hochschule Osnabrück
Fakultät Wirtschafts- und Sozialwissenschaften
http://wiki.hl7.de/index.php?title=IG:Pflegebericht
All rights reserved. Please visit https://medical-data-
models.org/forms/14515
Header
Pflegefachkraft
Name
Unterschrift
Datum
Patient
Nachname
Vorname
Geschlecht
Weiblich (F)
Männlich (M)
Geburtsdatum
Geburtsort
Addresse
Religionszugehörigkeit
Kirchliche Gemeinde
Sprache
Staatsbürgerschaft
Nation
Personen
Absender
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Empfänger
Weiterer Empfänger
Beteiligter
Body
Pflegeproblem
Pflegeproblem
Ja
Nein
Titel
Code des Pflegeproblems
Ätiologie/Ursache
Symptome
Ressource
hat Pflegemaßnahme
Ja
Nein
hat Hilfsmittel
Ja
Nein
Score
Score
Ja
Nein
Titel
Gesamtpunktzahl
Ätiologie
Symptome
Ressource
2 / 5
ePflegebericht (electronic nursing report)
hat Pflegemaßnahme
Ja
Nein
hat Hilfsmittel
Ja
Nein
Pflegeziel
Pflegeziel
Ja
Nein
Titel
Code
Ätiologie
Symptome
Ressource
hat Pflegemaßnahme
Ja
Nein
hat Hilfsmittel
Ja
Nein
Pflegemaßnahme
Pflegemaßnahme
Ja
Nein
Name
Code
Ergebnis
Ja
Nein
Name
Code
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Hilfsmittel
Ja
Nein
Hilfsmittel
Hersteller
AEDL / ATL
AEDL / ATL
Homecare Status
Hilfsmittel
Ja
Nein
Hilfsmittel Titel
Hilfsmittel Status
Lieferant
Hersteller
Wohnform
Barrierefreier Zugang zur Wohnung
Barrierefreiheit in der Wohnung
Wohnraumanpassung
Wohnumfeldberatung
Soziale Informationen
Biographische Informationen
Berufstätigkeit
Sozialrechtliche Informationen
Bestellung Betreuer
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Hilfe zur Pflege nach SGBXII, BSHG
Pflegestufe
Patientenverfügung
Medizinische Informationen
Medikation
Medizinische Diagnose
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Eligibility Asthma, Bronchial NCT00385593
Symbicort Single Inhaler Therapy vs Conventional Best
Practice for the Treatment of Persistent Asthma in Adults;
ODM derived from:
https://clinicaltrials.gov/show/NCT00385593
All rights reserved. Please visit https://medical-data-
models.org/forms/14527
Eligibility Asthma, Bronchial
NCT00385593
Inclusion Criteria
minimum of 3 months history of asthma,
diagnosed according to the american thoracic
society (ats) definition (9).*
Yes
No
prescribed inhaled gcs at a dose of 400μg/day of
budesonide (or equivalents)and within the
approved label for the relevant drug during the
last 3 months prior to visit 1.*
Yes
No
either daily maintenance treatment with both
inhaled gcs and laba or daily treatment with
inhaled gcs alone (i.e. without laba)*
Yes
No
a history of suboptimal asthma control the month
prior to enrolment as judged by the investigator*
Yes
No
use of  ≥3 inhalations of as needed medication
for symptom relief during the last 7 days before
enrolment*
Yes
No
Exclusion Criteria
previous treatment with symbicort single inhaler;*
Yes
No
use of any b-blocking agent, including eye-drops
and oral gcs as maintenance treatment.*
Yes
No
known or suspected hypersensitivity to study
therapy or excipients.*
Yes
No
a history of smoking ≥ 10 pack years.*
Yes
No
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asthma exacerbation requiring change in asthma
treatment during the last 14 days prior to or at
visit 1.*
Yes
No
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Eligibility Metastatic Breast Cancer
NCT00148070
Phase II Study of Tailored-Dose Docetaxel in Metastatic
Breast Cancer; ODM derived from:
https://clinicaltrials.gov/show/NCT00148070
All rights reserved. Please visit https://medical-data-
models.org/forms/14531
Eligibility Metastatic Breast Cancer
NCT00148070
Inclusion Criteria
patients with biopsy proven, measurable
metastatic breast cancer.  patients with bone-
only, and/or effusion-only disease are excluded.*
Yes
No
karnofsky performance status equal to 70 or
greater.*
Yes
No
anc > 1500, hgb > 10, plt > 100.*
Yes
No
patients with some degree of hepatic dysfunction
and renal dysfunction are encouraged, in order to
evaluate the ability of the ermbt in tailoring dose
in these patient populations.*
Yes
No
Exclusion Criteria
age less than 18 years.*
Yes
No
allergy to erythromycin.*
Yes
No
previous treatment with docetaxel.  prior
paclitaxel is allowed.*
Yes
No
grade > 2 peripheral neuropathy.*
Yes
No
no confounding factors present to provide
misinterpretation of data (i.e., concurrent
malignancy).*
Yes
No
patients who are pregnant or nursing will not be
eligible for this protocol.  women of childbearing
age who are not practicing reliable birth control
must have a documented negative serum hcg.*
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Yes
No
patients who require concurrent treatment with
drugs which are known to induce or inhibit cyp3a
activity will be ineligible for the trial.  this list
includes the drugs midazolam, anti-mycotic
agents (ketoconazole and related compounds),
macrolide antibiotics (erythromycin and related
compounds), nifedipine, anti-seizure drugs, and
rifampin (induction).*
Yes
No
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Eligibility Multiple Myeloma NCT00222053
IFM 99-02 Thalidomide in Myeloma; ODM derived from:
https://clinicaltrials.gov/show/NCT00222053
All rights reserved. Please visit https://medical-data-
models.org/forms/14533
Eligibility Multiple Myeloma
NCT00222053
Inclusion Criteria
de novo myeloma*
Yes
No
according to durie and salmon classification
stage ii, iii and stage i with a lytic bone lesion*
Yes
No
patients from 18 to 65 years old*
Yes
No
beta2microglobulin < 3 mg/l or del13 absent*
Yes
No
signed informed consent*
Yes
No
eligible for transplantation*
Yes
No
Exclusion Criteria
peripheral neurological toxicities*
Yes
No
uncontrolled or severe cardiovascular disease*
Yes
No
other malignancy except basocellular carcinoma
or figo  stage i carcinoma of the cervix*
Yes
No
patient who received biphosphonate during the
last 60 days*
Yes
No
renal failure definited as creatinine > 150 µmol/l*
Yes
No
patient with obvious vascular cerebral medical
history*
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Yes
No
liver dysfunction definited as bilirubin > 35 µmol/l
or asat, alat, pal > 4n*
Yes
No
respiratory dysfunction*
Yes
No
hiv +*
Yes
No
patient who refused to use an acceptable barrier
method for contraception*
Yes
No
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Eligibility Asthma, Bronchial NCT00644462
Wheeze Detection in Adults During Dynamic Bronchial
Situations Measured by PulmoTrack® 2010 With WIM-
PC™ Technologies Recording; ODM derived from:
https://clinicaltrials.gov/show/NCT00644462
All rights reserved. Please visit https://medical-data-
models.org/forms/14534
Eligibility Asthma, Bronchial
NCT00644462
Inclusion Criteria
asthmatic or healthy subjects;*
Yes
No
age 18 and up;*
Yes
No
not smoking for at the last two years;*
Yes
No
subject or subject's parents/guardian is able to
comprehend and give informed consent for
participation in the study.*
Yes
No
Exclusion Criteria
chest burns;*
Yes
No
copd;*
Yes
No
pregnant or lactating;*
Yes
No
mechanically ventilatory;*
Yes
No
homodynamic instability;*
Yes
No
unstable angina and/or congestive heart failure
requiring hospitalization  within the last 6 months
prior to screening;*
Yes
No
acute infection requiring intravenous antibiotics at
the time of screening;*
Yes
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No
uncontrolled bleeding and coagulation disorders;*
Yes
No
uncontrolled diabetes mellitus: iddm or niddm;*
Yes
No
hiv positive or any other immunosuppressive
disorder;*
Yes
No
subject objects to the study protocol;*
Yes
No
concurrent participation in any other clinical
study;*
Yes
No
physician objection.*
Yes
No
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Eligibility Asthma, Bronchial NCT00644462
Eligibility Multiple Myeloma NCT00702247
Tandem Autologous- Nonmyeloablative Allogeneic
Transplant for Newly Diagnosed Multiple Myeloma
(Trapianto Tandem Autologo-Allogenico Non Mieloablativo
Nel Mieloma Alla Diagnosi); ODM derived from:
https://clinicaltrials.gov/show/NCT00702247
All rights reserved. Please visit https://medical-data-
models.org/forms/14536
Eligibility Multiple Myeloma
NCT00702247
Inclusion Criteria
durie-salmon stage iia-iiib multiple myeloma*
Yes
No
age > 18 and ≤ 65 years*
Yes
No
previously untreated myeloma*
Yes
No
presence of a sibling (potential donor)*
Yes
No
bilirubins < twice normal;alat and asat < four
times normal*
Yes
No
left ventricular ejection fraction > 40%*
Yes
No
creatinine clearances > 40 ml/min*
Yes
No
pulmonary dysfunction with diffusing capacity for
carbon monoxide (dlco) > 40% and/or need for
continuous oxygen supplementation*
Yes
No
karnofsky performance status > 60%*
Yes
No
patients must give written informed consent*
Yes
No
Exclusion Criteria
age > 65 years*
Yes
No
previously treated myeloma*
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Yes
No
absence of a sibling (genetic randomisation
cannot be applied)*
Yes
No
karnofsky performance status score < 60%*
Yes
No
hiv-infection*
Yes
No
pregnancy*
Yes
No
refusal to use contraceptive techniques during
and for 12 months following treatment*
Yes
No
patients unable to give written informed consent*
Yes
No
ps. informed consent is obtained from each
patient according to the institutional review
boards of the participating centers. the study is
conducted according to the declaration of
helsinki.*
Yes
No
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Eligibility Multiple Sclerosis NCT00006060
Diagnostic Study of Quantitative Imaging and Spectroscopy
in Patients With Multiple Sclerosis; ODM derived from:
https://clinicaltrials.gov/show/NCT00006060
All rights reserved. Please visit https://medical-data-
models.org/forms/14537
Eligibility Multiple Sclerosis
NCT00006060
Criteria
-disease characteristics--*
Yes
No
diagnosis of multiple sclerosis relapsing-remitting
defined as 2 exacerbations and a worsening of
neurologic function over 1 day followed by at least
30 days of no progression or secondary-
progressive defined as increase of at least 1.0
unit on expanded disability status scale (edss) in
past 2 years with or without exacerbations*
Yes
No
-prior/concurrent therapy--*
Yes
No
biologic therapy: prior interferon beta 1a, 1b, or
glatiramer acetate no concurrent interferon beta
1a, 1b, or glatiramer acetate*
Yes
No
endocrine therapy: concurrent oral and iv
corticosteroids allowed*
Yes
No
-patient characteristics--*
Yes
No
performance status: edss no greater than 7.0*
Yes
No
hematopoietic: no hematologic dysfunction
including hemolytic anemia*
Yes
No
hepatic: no hepatic dysfunction*
Yes
No
renal: no renal dysfunction*
Yes
No
cardiovascular: no cardiac pacemaker*
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Yes
No
other: not pregnant or nursing negative
pregnancy test no intracranial clips, metal
implants, or external clips within 10 mm of head
no metal in eyes no known gadolinium texaphyrin
allergy no known claustrophobia*
Yes
No
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Eligibility Multiple Sclerosis NCT00062972
Improving Memory in Patients With Multiple Sclerosis;
ODM derived from:
https://clinicaltrials.gov/show/NCT00062972
All rights reserved. Please visit https://medical-data-
models.org/forms/14538
Eligibility Multiple Sclerosis
NCT00062972
Inclusion Criteria
ms as defined by the poser criteria*
Yes
No
expanded disability status scale (edss) score of 0
to 6.5*
Yes
No
stable neurologic function for at least 30 days
prior to study entry*
Yes
No
agree to continue all current medications for
study duration*
Yes
No
rey auditory verbal learning test score in low
normal range or below*
Yes
No
mini-mental status exam score of 26 or higher*
Yes
No
montgomery-asberg depression scale scaled
score of 14 or lower*
Yes
No
fluent in english*
Yes
No
Exclusion Criteria
use of anticholinergic or benzodiazepine
medication*
Yes
No
change in dosage of medications judged to have
the potential to impact cognitive function (e.g.,
antispasticity medications) within 2 weeks of
study entry*
Yes
No
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current alcohol or substance abuse*
Yes
No
history of neurological or major medical problem
that has a known effect on cognitive functioning*
Yes
No
history of noncompliance*
Yes
No
visual or upper extremity impairment which
precludes ability to participate in cognitive
assessment*
Yes
No
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Eligibility Multiple Sclerosis NCT00473213
Optimizing IFN Beta - 1B Dose; ODM derived from:
https://clinicaltrials.gov/show/NCT00473213
All rights reserved. Please visit https://medical-data-
models.org/forms/14539
Eligibility Multiple Sclerosis
NCT00473213
Inclusion Criteria
1. written informed consent obtained.*
Yes
No
2. age between 18 and 50 years inclusive.*
Yes
No
3. male and female patients.*
Yes
No
4. clinically definite or laboratory supported
definite rr ms (poser et al, 1983) for not less than
2 year.*
Yes
No
5. two clinically documented relapses during the
preceding 24 months.*
Yes
No
6. no relapse or relapse related neurological
deterioration for at least 30 days prior to entry in
the study.*
Yes
No
7. patients edss score from 1 to 3.5 (probably to
be extended to 5.5).*
Yes
No
8. mri activity. at least one  enhancing lesion
during the baseline mri run-in study .*
Yes
No
9. women capable of having children must agree
to use adequate con-traceptive methods
(condoms with spermicides, iucd, oral
contraceptives or other adequate barrier
contraception).*
Yes
No
10. caregivers agreement to assist the patient to
comply with study requirements, if neces-sary
(e.g. study drug administration, visits to center).*
Yes
No
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Exclusion Criteria
1. any form of multiple sclerosis other than
relapsing-remitting.*
Yes
No
2. any other disease which could better explain
the patient's signs and symptoms.*
Yes
No
3. any other disabling condition, which could
interfere with the clinical evaluation.*
Yes
No
4. pregnancy or lactation.*
Yes
No
5. medical psychiatric, or other conditions that
compromise patient's ability to give informed
consent, to comply with the trial protocol, or to
complete the study.*
Yes
No
6. alcohol or drug abuse in the 90 days preceding
screening visit.*
Yes
No
7. uncontrolled clinically significant heart
diseases, i.e., cardiac arrhythmias, uncon-trolled
angina pectoris, uncompensated congestive
heart failure*
Yes
No
8. clinically significant liver, renal and bone
marrow dysfunction as defined by the ranges of
laboratory evaluations. the following ranges (see
table 1) for key laboratory evaluations will be
considered as adequate for inclusion:*
Yes
No
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Eligibility Multiple Sclerosis NCT00473213
Eligibility Asthma, NCT01274507
A Study for Disease Profiling of Asthma and Chronic
Obstructive Pulmonary Disease; ODM derived from:
https://clinicaltrials.gov/show/NCT01274507
All rights reserved. Please visit https://medical-data-
models.org/forms/14546
Eligibility Asthma, NCT01274507
Inclusion Criteria
age: for part 1, healthy: 18 and 55 years; for part
1, asthma: 18 and 70 years; for part 2,
nonsmokers: 40 and 65 years; for part 2,
smokers: 40 and 65 years; for part 2, chronic
obstructive pulmonary disease (copd): 40 and 65
years*
Yes
No
having mild, moderate, or severe asthma (for part
1, asthma)*
Yes
No
clinically stable asthma and have been on their
current asthma controller therapy for at least 6
weeks prior to screening (for part 1, asthma)*
Yes
No
no history of chronic respiratory disease including
asthma (for part 2, nonsmokers)*
Yes
No
be a nonsmoker for 1 year or more at initial
screening visit and have 10 packs or less per
year history of smoking (for all part 1 and pat 2,
nonsmokers)*
Yes
No
be a current smoker with a current history of at
least 20 pack years (for part 2, smokers)*
Yes
No
stable copd in the 3 months prior to screening (for
part 2, copd)*
Yes
No
treating with beta-adrenergic receptor agonist,
anticholinergic bronchodilators, inhaled
corticosteroid at stable doses for at least 4 weeks
prior to screening (for part 2, copd)*
Yes
No
Exclusion Criteria
history of sleep apnea requiring medical
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intervention and positive urine pregnancy
screening result (for all part 1 and part 2)*
Yes
No
positive urine screen for nicotine; positive
serology test for human immunodeficiency virus
(hiv) antibodies, hepatitis b surface antigen, or
hepatitis c virus antibody at screening (for all part
1 and part 2)*
Yes
No
allergic bronchopulmonary aspergillosis, allergic
bronchopulmonary mycosis, or occupational
asthma (for part 1, asthma)*
Yes
No
requires long term oxygen therapy on a daily
basis for chronic hypoxemia at screening visit
except when used for exercise only (for part 2,
copd)*
Yes
No
pneumonia, copd exacerbation that required
systemic steroids, upper or lower respiratory tract
infection, lung cancer surgery, lung volume
reduction, or a lung transplant (for part 2, copd)*
Yes
No
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Eligibility Asthmatic NCT01738087
Lung Bioavailability and Total Systemic Exposure to
Beclomethasone17MonoPropionate and Formoterol Across
Two Strengths of NEXThaler Inhalation Powder; ODM
derived from: https://clinicaltrials.gov/show/NCT01738087
All rights reserved. Please visit https://medical-data-
models.org/forms/14548
Eligibility Asthmatic NCT01738087
Inclusion Criteria
diagnosis of asthma as defined by global initiative
for asthma (gina) 2011*
Yes
No
asthmatic patients already treated with low daily
doses of inhaled corticosteroids (ics) (eg
budesonide or equivalent lower than 400
mcg/day) or low dose of ics/long acting beta2
agonists (laba) fixed combinations.*
Yes
No
patients with forced expiratory volume in 1 sec
(fev1) >= 70 % of predicted values*
Yes
No
non or ex-smokers*
Yes
No
body mass index (bmi) >= 18.5 and <= 32 kg/m2*
Yes
No
Exclusion Criteria
pregnant or lactating women unless using
acceptable methods of contraception*
Yes
No
diagnosis of chronic obstructive pulmonary
disease (copd)*
Yes
No
history of near fatal asthma*
Yes
No
patients with abnormal qtcf at screening visit*
Yes
No
hospitalization due to asthma exacerbation within
4 weeks prior to the screening visit or during the
run-in period.*
Yes
No
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lower respiratory tract infection within 4 weeks
prior to the screening visit or during the run-in
period.*
Yes
No
history of drug addiction or excessive use of
alcohol ;*
Yes
No
diagnosis of restrictive lung disease.*
Yes
No
patients treated with oral or parenteral
corticosteroids in the previous 2 months before
the screening visit (3 months for parenteral depot
corticosteroids)*
Yes
No
significant medical history or any laboratory
abnormality indicative of a significant underlying
condition*
Yes
No
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Eligibility Asthmatic NCT01738087
Eligibility Asymmetric Parkinson's Disease
NCT01367782
A Double Blind Sham-controled Study to Evaluate the
Influence of Low Frequency Repetitive Transcranial
Stimulation (r-TMS) on Motor and Cognitive Measurements
in Patients With Asymmetric Parkinson's Disease; ODM
derived from: https://clinicaltrials.gov/show/NCT01367782
All rights reserved. Please visit https://medical-data-
models.org/forms/14553
Eligibility Asymmetric Parkinson's
Disease NCT01367782
Inclusion Criteria
pd patients with asymmetric disease aged 40
years or older, diagnosed as idiopathic pd
according to the uk brain bank criteria, with
hoehn & yahr stages ii - iv while "off".*
Yes
No
participants on antidepressants should be at least
2 months on stable therapy.*
Yes
No
Exclusion Criteria
1. patients who have concomitant epilepsy, a
history of seizure or heat convulsion or history of
epilepsy in first degree relative.*
Yes
No
2. patients  on neuroleptics.*
Yes
No
3. patients with unstable medical disorder.*
Yes
No
4. history or current unstable hypertension.*
Yes
No
5. history of head injury or neurosurgical
interventions.*
Yes
No
6. history of any metal in the head (outside the
mouth).*
Yes
No
7. known history of any metallic particles in the
eye, implanted cardiac pacemaker, implanted
neurostimulators, surgical clips (above the
shoulder line) or any medical pumps.*
Yes
No
8. history of migraine or frequent or severe
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headaches.*
Yes
No
9. current hearing loss.*
Yes
No
10. the presence of cochlear implants*
Yes
No
11. current drug abuse or alcoholism.*
Yes
No
12. pregnancy or not using a reliable method of
birth control.*
Yes
No
13. participation in current clinical study or clinical
study within 30 days prior to this study.*
Yes
No
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Header
Pflegefachkraft
Name
Unterschrift
Datum
Patient
Nachname
Vorname
Geschlecht
Weiblich (F)
Männlich (M)
Geburtsdatum
Geburtsort
Addresse
Religionszugehörigkeit
Kirchliche Gemeinde
Sprache
Staatsbürgerschaft
Nation
Personen
Absender
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Empfänger
Weiterer Empfänger
Beteiligter
Body - Anamnese (medical history)
Wundbeurteilung
Wundgröße
cm2
Wundumgebung
trocken-rissig (1)
Schmerzen (10)
feucht (2)
mazeriert (3)
atroph (4)
livide (5)
Rötung (6)
Schwellung (7)
Blasenbildung (8)
Juckreiz (9)
Wundfläche
Muskel (1)
Knochen (2)
Sehne (3)
Granulation (4)
Fibrin (5)
feuchtes oder trockenes avitales Gewebe
(6)
Wundrand
flach (1)
wulstig (2)
unterminiert (3)
vital (4)
livide (5)
mazeriert (6)
hyperkeratös (7)
ausgetrocknet (8)
Wundexsudat
serös (1)
serös-eitrig (2)
fibrinös (3)
hämorrhagisch (4)
jauchig (5)
von der Wunde ausgehende Schmerzen
Wundgeruch
unauffällig (1)
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auffällig (2)
beeinträchtigend (3)
Lokalisation der Wunde
Hinweise auf infektionsbedingte Erkrankung
PEDIS Grad 1 (1)
PEDIS Grad 2 (2)
PEDIS Grad 3 (3)
PEDIS Grad 4 (4)
Infektionsrisiko
Ödem
Wunddauer
Darüber hinaus gehende Beschreibung des
Erscheinungsbildes
Aktueller Status Patient
Diagnostik zugrunde liegender Erkrankungen
Ernährungsstatus, Ernährungsdefizite
Immunstatus
Psychsoziale Faktoren
Bewusstseinslevel
Soziale Faktoren
Individuelle Risikofaktoren
Individuelle Risikofaktoren
Typ-1-Diabetes (1)
männliches Geschlecht (2)
chronischer Nikotin-Abusus (3)
Risikoassessmentskala
Name der Risikoassessmentskala
Score/Ergebnis
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Interpretation
Hygieneassessment
Körperhygiene
Hautassessment
Hautsituation
Hautverfärbung (1)
feucht (10)
mazeriert (11)
atroph (12)
livide (13)
trophische Störungen (2)
Rötung (3)
Schwellung (4)
Blasenbildung (5)
Juckreiz (6)
Schmerzen (7)
Hauterkrankungen (8)
trocken-rissig (9)
Hautbarrierefunktion
Details über geheilte Wunden
Heilungsdauer
Frühere Behandlungen
Verwendete Produkte/Maßnahmen
Gesundheitsrelevantes
Patientenverhalten, Adhärenz
Therapieakzeptanz, Therapieeinhaltung
Lebensstil und Fähigkeiten, Selbstpflegefähigkeit
Körperliche Beeinträchtigungen
Mobilitäts-/Aktivitätseinschränkungen
Schmerzen
Empfindungsbeeinträchtigungen
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Wundgeruch: subjektive Beeinträchtigung
unauffällig (1)
auffällig (2)
beeinträchtigend (3)
Psychosoziale Beeinträchtigungen
Beeinträchtigung der Lebensqualität, soziale und
berufliche Teilhabe
Leiden unter den Symptomen
Body - Diagnose (diagnosis)
Wundbezogene Diagnose
Wundart
Ulcus cruris venosum (1)
Ulcus cruris arteriosum (2)
Ulcus cruris mixtum (3)
Ulcera im Rahmen des Diabetischen
Fußes (4)
Grunderkrankung
vaskuläre und metabolische Ursachen
(1)
Infektionen (2)
Neuropathien (3)
Erkrankungen des blutbildenden
Systems und der Blutgerinnung (4)
Autoimmunerkrankungen (5)
genetische Defekte (6)
exogene Reize (7)
Medikamente (8)
benigne und maligne Neoplasien (9)
Wundstadium
Exsudation (1)
Granulation (2)
Epithelisierung (3)
Relevante medizinische Daten und
Testergebnisse
Name des Tests
Score/Ergebnis
Interpretation des Tests
Body - Therapie (therapy)
Behandlungsziele
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Behandlungsziel
Optimierung der Kausaltherapie (1)
möglichst schnelles Abheilen (2)
stabiles Narbenergebnis (3)
Schaffung von Wundverhältnissen, die
einen operativen Wundverschluss
ermöglichen (4)
Linderung von Faktoren, die die
Lebensqualität beeinflussen (5)
Förderung und Erhalt von
Alltagskompetenzen (6)
Behandlungsplan
Wundreinigung
Debridement
Primärverband
Schaumstoff (1)
Hydrokolloid (2)
Mikrofaser/Hydrofaser (3)
Polyacrylat (4)
Alginat (5)
Folien (6)
Gaze (7)
Mull-und Vlieskompressen (8)
wirkstoffhaltige Produkte (9)
Sekundärverband
Abwehrreaktionen auf Wundprodukte, Allergien
Physikalische Interventionen
Vakuumtherapie (1)
Reizstrom (2)
Stoßwellentherapie (3)
Softlasertherapie (4)
Magnetfeldtherapie (5)
wIRA (6)
hyperbare Sauerstofftherapie (7)
Ultraschall (8)
Benötigte Ausrüstung, Ressourcen
Matratze/Bett zur Druckminderung
Stuhl/Sitz
Personelle Unterstützung
Spezielle Patientenbedürfnisse
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Transferausrüstung
Mobilitätsausrüstung
Ernährungsbedarf
Heilungs- und Therapieverlauf
Assessmentskala
Assessment-Score
Interpretation des Tests
Beschreibung
Schmerzmanagement
Hygienemaßnahmen
spezifische Hygieneanforderungen
Versorgungsdetails potenziell infektiöser
Patienten
Wundrand-/Wundumgebungsschutz
Wundrand-/Wundumgebungsschutz
Acrylate film (1 )
Zinc oxide products (2 )
Hydrofibres (3 )
Polyacrylate containing absorbent
dressings (4 )
Hydrocolloids / films (5 )
Steroids (6 )
Oils (7 )
Prophylaxis against dehydration (8 )
Kausaltherapie
Kausaltherapie
Schulung und Anleitung von Patient und
Angehörigen
Inhalte
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Durchführung
Bisherige Ergebnisse der Behandlung
Bisherige Ergebnisse der Behandlung
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NINDS CDE Assessments and
Examinations Epilepsy
NINDS Common Data Elements Used from the National
Institute of Neurological Disorders and Stroke Common
Data Elements
(https://www.commondataelements.ninds.nih.gov/)
References: Grinnon ST, Miller K, Marler JR, Lu Y, Stout A,
Odenkirchen J, Kunitz S. National Institute of Neurological
Disorders and Stroke Common Data Element Project -
approach and methods. Clin Trials. 2012;9(3):322-9.
All rights reserved. Please visit https://medical-data-
models.org/forms/14558
Assessments and Examinations
Neurological examination
Study ID
Study site name
Subject ID
Date of examination:
If follow-up exam, change from prior exam
No change (1)
Improved (2)
Worse (3)
Unknown (4)
Other, specify (5)
If other change from prior exam, please specify
Mental Status
Mental assessments:Attention Abnormality
Present
Yes  (1)
No (2)
Unknown (3)
Attention Abnormality Present: please specify
Working memory Abnormality Present
Yes  (1)
No (2)
Unknown (3)
Working memory Abnormality Present:please
specify
Recent (Episodic) Memory Abnormality Present
Yes  (1)
No (2)
Unknown (3)
Recent (Episodic) Memory Abnormality Present:
please specify
Remote (Semantic) Memory Abnormality Present
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Yes  (1)
No (2)
Unknown (3)
Remote (Semantic) Memory Abnormality
Present:please specify
Language Spontaneous speech Abnormality
Present
Yes  (1)
No (2)
Unknown (3)
Language Spontaneous speech Abnormality
Present:please specify
Language comprehension Abnormality Present
Yes  (1)
No (2)
Unknown (3)
Language comprehension Abnormality
Present:please specify
Naming Abnormality Present
Yes  (1)
No (2)
Unknown (3)
Naming Abnormality Present:please specify
Repetition Abnormality Present
Yes  (1)
No (2)
Unknown (3)
Repetition Abnormality Present:please specify
Reading Abnormality Present
Yes  (1)
No (2)
Unknown (3)
Reading Abnormality Present:please specify
Affect Abnormality Present
Yes  (1)
No (2)
Unknown (3)
Affect Abnormality Present:please specify
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Cranial Nerves
Cranial Nerves global assessment
Normal (1)
Abnormal (explain further in questions
5a through 5k below) (2)
Cannot Assess, explain (3)
Other, specify (4)
Cranial Nerves global assessment:please specify
CN II Abnormality
Left  (1)
Right  (2)
Bilateral (3)
CN II Abnormality:please specify
CN III Abnormality
Left  (1)
Right  (2)
Bilateral (3)
CN III Abnormality:please specify
CN IV Abnormality
Left  (1)
Right  (2)
Bilateral (3)
CN IV Abnormality:please specify
CN V Abnormality
Left  (1)
Right  (2)
Bilateral (3)
CN V Abnormality:please specify
CN VI Abnormality
Left  (1)
Right  (2)
Bilateral (3)
CN VI Abnormality:please specify
CN VII Abnormality
Left  (1)
Right  (2)
Bilateral (3)
CN VII Abnormality:please specify
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CN VIII Abnormality
Left  (1)
Right  (2)
Bilateral (3)
CN VIII Abnormality:please specify
CN IX Abnormality
Left  (1)
Right  (2)
Bilateral (3)
CN IX Abnormality:please specify
CN X Abnormality
Left  (1)
Right  (2)
Bilateral (3)
CN X Abnormality:please specify
CN XI Abnormality
Left  (1)
Right  (2)
Bilateral (3)
CN XI Abnormality:please specify
CN XII Abnormality
Left  (1)
Right  (2)
Bilateral (3)
CN XII Abnormality:please specify
Nystagmus
Yes (Specify type below)  (1)
No  (2)
Cannot Assess, explain (3)
Nystagmus:please specify if cannot be assessed
Type of Nystagmus
Physiologic  (1)
Abnormal  (2)
Other, specify (3)
Type of Nystagmus:if other type, please specify
Motor Assessments
Muscle Bulk global assessment
Yes  (1)
No (2)
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Cannot assess, explain (3)
Muscle Bulk global assessment: if cannot be
assessed, please specify
Muscle Bulk global assessment: if abnormal,
please specify type
Abnormal and symmetric (1)
Abnormal and asymmetric (2)
Right upper extremity Abnormality
Yes  (1)
No (2)
Cannot assess, explain (3)
Right upper extremity if abnormal,please specify
type
Abnormal–Decreased (1)
Other, specify (2)
Right upper extremity Abnormality if cannot be
assessed, please specify
Right upper extremity Abnormality:if other please
specify
Left upper extremity Abnormality
Yes  (1)
No (2)
Cannot assess, explain (3)
Left upper extremity Abnormality:if cannot be
assessed please specify
Left upper extremity if abnormal, please specify
type
Abnormal–Decreased (1)
Other, specify (2)
Left upper extremity Abnormality:if other please
specify
Right lower extremity Abnormality
Yes  (1)
No (2)
Cannot assess, explain (3)
Right lower extremity Abnormality:if cannot be
assessed please specify
Right lower extremity if abnormal, please specify
type
Abnormal–Decreased (1)
Other, specify (2)
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Right lower extremity Abnormality:if other,please
specify
Left lower extremity Abnormality
Yes  (1)
No (2)
Cannot assess, explain (3)
Left lower extremity Abnormality:if cannot be
assessed, please specify
Left lower extremity if abnormal, please specify
type
Abnormal–Decreased (1)
Other, specify (2)
Left lower extremity Abnormality: if other,please
specify
Muscle Tone global assessment
Yes  (1)
No (2)
Cannot assess, explain (3)
Muscle Tone global assessment: if cannot be
assessed, please specify
Muscle Tone global assessment if abnormal,
please specify type
Abnormal and symmetric (1)
Abnormal and asymmetric (2)
Right upper extremity muscle tone abnormality
Yes  (1)
No (2)
Cannot assess, explain (3)
Right upper extremity muscle tone abnormality:if
cannot be assessed, please specify
Right upper extremity muscle tone if abnormal,
please specify type
Abnormal–Increased (1)
Other, specify (2)
Right upper extremity muscle tone abnormality: if
other, please specify
Left upper extremity muscle tone abnormality
Yes  (1)
No (2)
Cannot assess, explain (3)
Left upper extremity muscle tone abnormality:if
cannot be assessed, please specify
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Left upper extremity muscle tone if abnormal,
please specify type
Abnormal–Increased (1)
Other, specify (2)
Left upper extremity muscle tone abnormality:if
other,please specify
Right lower extremity muscle tone abnormality
Yes  (1)
No (2)
Cannot assess, explain (3)
Right lower extremity muscle tone abnormality: if
cannot be assessed, please specify
Right lower extremity muscle tone if abnormal,
please specify type
Abnormal–Increased (1)
Other, specify (2)
Right lower extremity muscle tone abnormality:if
other, please specify
Left lower extremity muscle tone abnormality
Yes  (1)
No (2)
Cannot assess, explain (3)
Left lower extremity muscle tone abnormality:if
cannot be assessed, please specify
Left lower extremity muscle tone if abnormal,
please specify type
Abnormal–Increased (1)
Other, specify (2)
Left lower extremity muscle tone abnormality: if
other, please specify
Truncal tone abnormality
Yes  (1)
No (2)
Cannot assess, explain (3)
Truncal tone abnormality:if cannot be assessed,
please specify
Truncal tone if abnormal, please specify type
Abnormal–Increased (1)
Abnormal–Decreased (2)
Other, specify (3)
Truncal tone abnormality: if other, please specify
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Muscle Strength global assessment
Yes  (1)
No (2)
Cannot assess, explain (3)
Muscle Strength global assessment:if cannot be
assessed, please specify
Muscle Strength global assessment: if
abnormal,please specify type
Abnormal and symmetric (1)
Abnormal and asymmetric (2)
Right upper extremity muscle strength
abnormality
Yes  (1)
No (2)
Cannot assess, explain (3)
Right upper extremity muscle strength
abnormality:if cannot be assessed, please
specify
Right upper extremity muscle strength if
abnormal,please specify type
Abnormal–Decreased (1)
Other, specify (2)
Right upper extremity muscle strength
abnormality:if other, please specify
Left upper extremity muscle strength abnormality
Yes  (1)
No (2)
Cannot assess, explain (3)
Left upper extremity muscle strength
abnormality:if cannot be assessed, please
specify
Left upper extremity muscle strength if abnormal,
please specify type
Abnormal–Decreased (1)
Other, specify (2)
Left upper extremity muscle strength
abnormality:if other, please specify
Right lower extremity muscle strength
abnormality
Yes  (1)
No (2)
Cannot assess, explain (3)
Right lower extremity muscle strength
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abnormality:if cannot be assessed, please
specify
Right lower extremity muscle strength if
abnormal, please specify type
Abnormal–Decreased (1)
Other, specify (2)
Right lower extremity muscle strength
abnormality:if other,please specify
Left lower extremity muscle strength abnormality
Yes  (1)
No (2)
Cannot assess, explain (3)
Left lower extremity muscle strength
abnormality:if cannot be assessed, please
specify
Left lower extremity muscle strength if abnormal,
please specify type
Abnormal–Decreased (1)
Other, specify (2)
Left lower extremity muscle strength
abnormality:if other, please specify
Weakness
Yes
No
Does the weakness suggest one of the following
patterns?
Right Hemiparesis (1)
Left Hemiparesis  (2)
Diplegia/Paraparesis (3)
Quadriplegia/Quadraparesis (4)
Peripheral Nerve Lesion(s), describe (5)
Neuropathic Weakness, describe (6)
Myopathic Weakness, describe (7)
Other, specify (8)
Weakness,if applicable please describe further
Specify the neurological location of the weakness
Brain (1)
Spinal Cord (2)
Peripheral Nervous System (3)
Other, specify (4)
If other neurological location, please specify
Tremor
Yes (1)
No  (2)
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Cannot Assess, explain (3)
Other, specify (4)
Tremor, if applicable please specify or explain
further
Type of tremor
Postural (1)
Rest (2)
Intention (3)
Other, specify (4)
(5)
  (6)
If other type of tremor,please specify
Cerebellar/Coordination
Finger-to-Nose Abnormality
Yes  (1)
No (2)
Cannot Assess (3)
Other specify (4)
Finger-to-nose abnormality:if other, please
specify
Finger-to-nose if abnormal please explain
RUE  (1)
LUE (2)
Dysmetria  (3)
Slowness (4)
Cannot Assess due to Weakness (5)
Other, specify (6)
Finger-to-nose abnormality:if other, please
specify
Rapid Alternating Movements abnormality
Yes  (1)
No (2)
Cannot Assess (3)
Other specify (4)
Rapid Alternating Movements abnormality: if
other,please specify
Rapid Alternating Movements if abnormal, please
explain
RUE  (1)
LUE (2)
Dysmetria  (3)
Slowness (4)
Cannot Assess due to Weakness (5)
Other, specify (6)
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Rapid Alternating Movements abnormality: if
other,please specify
Heel-to-shin abnormality
Yes  (1)
No (2)
Cannot Assess (3)
Other specify (4)
Heel-to-shin abnormality:if other,please specify
Heel-to-shin if abnormal,please explain
RUE  (1)
LUE (2)
Dysmetria  (3)
Slowness (4)
Cannot Assess due to Weakness (5)
Other, specify (6)
Heel-to-shin abnormality:if other,please specify
Reflexes
Reflexes global assessment
Normal (1)
Abnormal (specify below) (2)
Cannot Assess (3)
Other, specify (4)
Reflexes of right arm
Increased with clonus (1)
Increased without clonus (2)
Hypoactive (3)
Absent (4)
Reflexes of left arm
Increased with clonus (1)
Increased without clonus (2)
Hypoactive (3)
Absent (4)
Reflexes of right leg
Increased with clonus (1)
Increased without clonus (2)
Hypoactive (3)
Absent (4)
Reflexes of left leg
Increased with clonus (1)
Increased without clonus (2)
Hypoactive (3)
Absent (4)
Plantar response right
Flexor (1)
Extensor (2)
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Equivocal (3)
Cannot Assess (4)
Other, specify (5)
Plantar response left
Flexor (1)
Extensor (2)
Equivocal (3)
Cannot Assess (4)
Other, specify (5)
Plantar response right: if other,please specify
Plantar response left: if other,please specify
Gait
Gait global assessment
Normal  (1)
Abnormal (Indicate type below)  (2)
Cannot Assess  (3)
Other, specify (4)
Gait global assessment,if other please specify
Type of abnormal gait
Ataxic Gait (1)
Hemiparetic Gait–Left side (2)
Hemiparetic Gait–Right side (3)
Diplegic Gait (4)
Parkinsonian Gait (5)
Other Gait Abnormalities, specify (6)
If other abnormal type of gait, please specify
Sensory/Sensation
Sensory System global assessment
Normal (1)
Abnormal (specify below) (2)
Cannot Assess (3)
Other, specify (4)
Sensory system global assessment symmetry of
abnormality
Symmetric  (1)
Asymmetric (2)
Sensory system location of abnormality
Stocking, explain (1)
Stocking/Glove, explain (2)
Dermatome, explain (3)
Sensory Nerve, explain (4)
Other, specify (5)
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Sensory system location of abnormality: if
applicable,please explain/specify further
Sensory system, patient description of abnormal
symptoms
Sensory modalities affected
Light Touch (1)
Pain and Temperature (2)
Vibration (3)
Proprioception (4)
Other, specify (5)
If other sensory modality is affected, please
specify
Physical Exam
Date of examination:
If follow-up exam, change from prior exam
No change (1)
Improved (2)
Worse (3)
Unknown (4)
Other, specify (5)
If other change from prior exam, please specify
Tanner Stage
I (1)
II (2)
III (3)
IV (4)
V (5)
Handedness
Left hand (1)
Right hand (2)
Both (3)
Unknown (4)
Constitutional symptoms (e.g., fever, weight loss)
Normal (1)
Abnormal (2)
Not examined (3)
Eyes
Normal (1)
Abnormal (2)
Not examined (3)
Ears, Nose, Mouth, and Throat
Normal (1)
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Abnormal (2)
Not examined (3)
Cardiovascular
Normal (1)
Abnormal (2)
Not examined (3)
Respiratory
Normal (1)
Abnormal (2)
Not examined (3)
Gastrointestinal
Normal (1)
Abnormal (2)
Not examined (3)
Genitourinary
Normal- (1)
Abnormal (2)
Not examined (3)
Musculoskeletal
Normal (1)
Abnormal (2)
Not examined (3)
Integumentary (skin and/or breast)
Normal (1)
Abnormal (2)
Not examined (3)
Neurological
Normal (1)
Abnormal (2)
Not examined (3)
Psychiatric
Normal (1)
Abnormal (2)
Not examined (3)
Endocrine system
Normal  (1)
Abnormal  (2)
Not examined (3)
Hematologic/Lymphatic
Normal (1)
Abnormal (2)
Not examined (3)
Allergic/Immunologic
Normal (1)
Abnormal (2)
Not examined (3)
Constitutional symptoms (e.g., fever, weight loss):
Please specify any abnormality or if not examined
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Eyes: please specify any abnormality or if not
examined
Ears, Nose, Mouth, and Throat: please specify
any abnormality or if not examined
Cardiovascular:Please specify any abnormality or
if not examined
Respiratory:Please specify any abnormality or if
not examined
Gastrointestinal: please specify any abnormality
or if not examined
Genitourinary:please specify any abnormality or if
not examined
Musculoskeletal: Please specify any abnormality
or if not examined
Integumentary (skin and/or breast):Please
specify any abnormality or if not examined
Neurological: Please specify any abnormality or if
not examined
Psychiatric:Please specify any abnormality or if
not examined
Endocrine system: please specify any
abnormality or if not examined
Hematologic/Lymphatic:Please specify any
abnormality or if not examined
Allergic/Immunologic: please specify abnormality
or if not examined
Vital Signs
Date of exam
Time of exam
Time
am (1)
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pm (2)
24-hour clock (3)
Heart rate
bpm
Respiratory Rate
breath/min
Blood pressure measurement (syst/dia)
mm/Hg
Participants position during blood pressure
measurement
Sitting (1)
Standing (2)
Supine (3)
Temperature
Unit for temperature measurement
°F (1)
°C (2)
Method of temperature measurement
Oral (1)
Rectal (2)
Axillary (3)
Tympanic  (4)
Bladder (5)
Esophageal (6)
Brain (7)
Other, specify (8)
If other method of measurement, please specify
Body weight
Unit for body weight
pounds (1)
kilograms (2)
Body Height
Unit for body height
inches (1)
centimeters (2)
Head circumference
Unit for Head circumference
inches (1)
centimeters (2)
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Eligibility Asymptomatic Multiple Myeloma
NCT01884688
A Study of Autologous Expanded Natural Killer Cell
Therapy for Asymptomatic Multiple Myeloma; ODM derived
from: https://clinicaltrials.gov/show/NCT01884688
All rights reserved. Please visit https://medical-data-
models.org/forms/14560
Eligibility Asymptomatic Multiple
Myeloma NCT01884688
Inclusion Criteria
the study population will be participants with amm
being seen at myeloma institute for research and
therapy (mirt), and under continuing followup with
standard clinical care testing .*
Yes
No
participants must have a diagnosis of amm as
defined in staging criteria (section 3.0) and gep-
70 score >-0.26.*
Yes
No
participant (male or female) from any race or
ethnicity must be at least 18 years of age and not
older than 75 years of age at the time of
registration.*
Yes
No
participants must have a performance status of 0
- 2 by zubrod criteria*
Yes
No
participants must have signed an institutional
review board (irb)-approved informed consent
and health insurance portability and
accountability act (hipaa) authorization form.*
Yes
No
must be fit to undergo leukapheresis for enk cell
generation as determined by pi.*
Yes
No
must be a suitable candidate for insertion of
apheresis catheter. participants with unusual
anatomy or vascular anomalies preventing
insertion of apheresis catheter will not qualify.*
Yes
No
patients must have previous test results indicating
adequate pulmonary function studies (pft) > 50%
of predicted on mechanical aspects (fev1, forced
vital capacity(fvc), etc) and diffusion capacity
(dlco) > 50% of predicted.*
Yes
No
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Exclusion Criteria
participants must not have received prior
treatment for their disease. prior use of
bisphosphonates is permitted.*
Yes
No
no other prior malignancy is allowed except for
the following: adequately treated basal cell or
squamous cell skin cancer, in situ cervical
cancer, adequately treated stage i or ii cancer
from which the patient is currently in complete
remission, or any other cancer from which the
patient has been disease-free for 2 years.*
Yes
No
may not have history of poorly-controlled
hypertension, diabetes mellitus, or any other
serious medical illness or psychiatric illness that
could potentially interfere with the completion of
treatment according to this protocol or could be
considered to be an exclusion criterion deemed
by the pi.*
Yes
No
pregnant or nursing women may not participate.
women of childbearing potential must have a
negative pregnancy test documented within 10 to
14 days of enrollment. women/men of
reproductive potential may not participate unless
they have either agreed to practice true
abstinence, when this is in line with the preferred
and usual lifestyle of the participant. (periodic
abstinence [eg,calendar, ovulation,
symptothermal, post-ovulation methods] and
withdrawal are not acceptable methods of
contraception.) or begin two reliable methods of
birth control: 1 highly effective method and 1
additional effective method at the same time, at
least 28 days before starting study treatment
through 30 days after the last dose of study
treatment.*
Yes
No
serologic evaluation will be used to assess
exposure to syphilis, west nile virus, chagas,
cytomegalovirus (cmv), immunoglobulin g (igg),
hepatitis b, and c, hiv i and ii,  and human t cell
lymphoma virus (htlv) i/ii.  participants may not be
hepatitis b or c (+) unless positive due to previous
vaccination or positive but has received therapy
and is negative for hepatitis b or c by rapid test
polymerase chain reaction (rt-pcr). an hiv-i/ii(+)
and htlv-1/ii (+) participant will be rejected on
medical grounds.  participants serologically
positive for syphilis, west nile virus, chagas, cmv,
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are only excluded if they are being treated for
active infection.*
Yes
No
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Eligibility Atherosclerotic Coronary Artery
Disease NCT01202058
An Observational Safety Evaluation of Patients Treated
With the NEVO™ Sirolimus-eluting Coronary Stent. (NEVO
II); ODM derived from:
https://clinicaltrials.gov/show/NCT01202058
All rights reserved. Please visit https://medical-data-
models.org/forms/14561
Eligibility Atherosclerotic Coronary
Artery Disease NCT01202058
Inclusion Criteria
subject has atherosclerotic coronary artery
disease with an indication for stent implantation;*
Yes
No
target lesion(s) with a diameter stenosis of
minimally 50% (visual estimate) or a functional
study documenting the hemodynamic relevance
of the target lesion(s);*
Yes
No
all target lesion(s) require treatment with stents
having diameters from 2.5mm to 3.5mm (visual
estimate);*
Yes
No
subject is ≥18 years of age;*
Yes
No
subject must sign ethics committee approved
informed consent prior to undergoing any study
specific procedure;*
Yes
No
subject must be willing and able to comply with
specified follow-up schedule.*
Yes
No
Exclusion Criteria
planned medical procedures or concomitant
disease requiring modification of dapt regimen
within 6 months of enrollment into this study;*
Yes
No
women of childbearing potential without negative
pregnancy test within 7 days before enrollment or
women who do not agree to remain on birth
control until angiographic follow-up at 13 months
if applicable or lactating women. for women of
childbearing potential, requiring an acute, non-
elective procedure, a verbal confirmation of non-
pregnancy and birth control is sufficient;*
Yes
No
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currently participating in an investigational study
that has not completed the primary endpoint or
that clinically interferes with the study endpoints.*
Yes
No
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Eligibility Atopic Asthma NCT00644514
Genetics of Asthma - Bronchoscopy Studies; ODM derived
from: https://clinicaltrials.gov/show/NCT00644514
All rights reserved. Please visit https://medical-data-
models.org/forms/14562
Eligibility Atopic Asthma
NCT00644514
Inclusion Criteria
allergic asthmatic, allergic non-asthmatic, or
nonallergic nonasthmatic*
Yes
No
willing/able to give informed consent & adhere to
visit/protocol schedules.*
Yes
No
screening visit laboratory, c-xray, ekg, results
within normal limits*
Yes
No
women of childbearing potential must have a
negative serum pregnancy test*
Yes
No
screening pulmonary function testing above study
criteria parameters*
Yes
No
Exclusion Criteria
systemic corticosteroid administration for asthma
within the previous 90days*
Yes
No
antibiotic administration within the previous 30
days.*
Yes
No
viral respiratory infection within the previous 14
days.*
Yes
No
history of severe asthma requiring intubation.*
Yes
No
occupational exposure to hay or grain dust.*
Yes
No
significant exposure history to cigarette smoke*
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Yes
No
past or present history of allergen immunotherapy
to within the last 10 yrs*
Yes
No
underlying illnesses that may result in altered
lung function*
Yes
No
students or employees under direct supervision
by protocol investigators  are ineligible*
Yes
No
subjects allergic to medications used (or
potentially used) in the study will be excluded.*
Yes
No
subjects using aspirin will be excluded*
Yes
No
subjects who abuse alcohol or illicit substances
will be excluded*
Yes
No
medication use other than for asthma, allergies or
contraception*
Yes
No
other medical or psychological conditions which,
in the opinion of the investigator, might create
undue risk to the subject or interfere with the
subject's ability to comply with the protocol
requirements*
Yes
No
nursing mothers*
Yes
No
other investigational medication within the last 30
days*
Yes
No
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Eligibility Atopic Dermatitis NCT01234909
Asthma, Missed Immunizations, and Vitamin D Deficiency
in Atopic Dermatitis; ODM derived from:
https://clinicaltrials.gov/show/NCT01234909
All rights reserved. Please visit https://medical-data-
models.org/forms/14564
Eligibility Atopic Dermatitis
NCT01234909
Inclusion Criteria
diagnosed with atopic dermatitis by a children's
hospital of wisconsin (chw) pediatric
dermatologist*
Yes
No
age 1- 18 years old*
Yes
No
primary residence in milwaukee county*
Yes
No
Exclusion Criteria
other chronic, systemic diseases other than
asthma or environmental allergies*
Yes
No
hyperimmunoglobulin e or job syndrome*
Yes
No
ichthyosis disorder other than ichthyosis vulgaris*
Yes
No
prior systemic therapy or phototherapy for atopic
dermatitis*
Yes
No
ongoing or prior treatment for known vitamin d
deficiency*
Yes
No
on chronic systemic corticosteroids for asthma*
Yes
No
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Eligibility Adult Acute Megakaryoblastic
Leukemia (M7) NCT01031368
Clofarabine, Cytarabine, and Filgrastim Followed by
Infusion of Non-HLA Matched Ex Vivo Expanded Cord
Blood Progenitors in Treating Patients With Acute Myeloid
Leukemia; ODM derived from:
https://clinicaltrials.gov/show/NCT01031368
All rights reserved. Please visit https://medical-data-
models.org/forms/14565
Eligibility Adult Acute
Megakaryoblastic Leukemia (M7)
NCT01031368
Inclusion Criteria
cohort a: diagnosis of aml by world health
organization (who) criteria, either relapsed or
refractory; acute promyelocytic leukemia [acute
promyelocytic leukemia with t(15;17)(q22;q12)
and variants] will be eligible only after failure of a
regimen containing arsenic trioxide; patients in
this cohort must have had an initial remission
duration of < 1 year and cannot have received
any prior salvage chemotherapy*
Yes
No
cohort b: untreated aml patients, excluding those
with favorable cytogenetic or molecular
abnormalities per the european leukemianet
recommendations*
Yes
No
cohort c: untreated aml patients, including those
with favorable cytogenetic or molecular
abnormalities per the european leukemianet
recommendations*
Yes
No
the first three patients enrolled in cohorts a and b
must be less than 60 years old; thereafter,
patients aged >= 18 and =< 70 are eligible*
Yes
No
the first three patients enrolled in cohorts a and b
must have an eastern cooperative oncology
group (ecog) performance status of 0 -1;
thereafter, ecog performance status of 0-2 is
required*
Yes
No
serum creatinine =< 1.0 mg/dl; if serum creatinine
> 1.0 mg/dl, then the estimated glomerular
filtration rate (gfr) must be > 60 ml/min/1.73 m^2
as calculated by the modification of diet in renal
disease equation where predicted gfr
(ml/min/1.73 m^2) = 186 x (serum creatinine)^-
1.154 x (age in years)^-0.203 x (0.742 if patient is
female) x (1.212 if patient is black)*
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Yes
No
serum total bilirubin =< 1.5 x upper limit of normal
(uln) unless elevation is thought to be due to
gilbert's syndrome, hemolysis, or hepatic
infiltration by the hematologic malignancy*
Yes
No
aspartate aminotransferase (ast)/alanine
aminotransferase (alt) =< 2.5 x uln, unless
elevation is thought to be due to hepatic
infiltration by the hematologic malignancy*
Yes
No
alkaline phosphatase =< 2.5 x uln*
Yes
No
capable of understanding the investigational
nature, potential risks and benefits of the study,
and able to provide valid informed consent*
Yes
No
female patients of childbearing potential must
have a negative serum pregnancy test within 2
weeks prior to enrollment*
Yes
No
male and female patients must be willing to use
an effective contraceptive method during the
study and for a minimum of 90 days after study
treatment*
Yes
No
Exclusion Criteria
allogeneic transplant recipients*
Yes
No
cytotoxic chemotherapy, radiation therapy,
immunosuppressants, or cytokine treatment
within 4 weeks prior to study entry or persistent
clinical evidence of toxicity.*
Yes
No
have any other severe concurrent disease, or
have a history of serious organ dysfunction or
disease involving the heart, kidney, liver
(including symptomatic hepatitis, veno-occlusive
disease), or other organ system dysfunction*
Yes
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No
patients with a systemic fungal, bacterial, viral, or
other infection not controlled (defined as
exhibiting ongoing signs/symptoms related to the
infection and without improvement, despite
appropriate antibiotics or other treatment)*
Yes
No
pregnant or lactating patients*
Yes
No
any significant concurrent disease, illness, or
psychiatric disorder that would compromise
patient safety or compliance, interfere with
consent, study participation, follow up, or
interpretation of study results*
Yes
No
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Eligibility Adult Acute Megakaryoblastic
Leukemia (M7) NCT01835288
Arsenic Trioxide in Treating Patients With Relapsed or
Refractory Acute Myeloid Leukemia; ODM derived from:
https://clinicaltrials.gov/show/NCT01835288
All rights reserved. Please visit https://medical-data-
models.org/forms/14566
Eligibility Adult Acute
Megakaryoblastic Leukemia (M7)
NCT01835288
Inclusion Criteria
aml, any french- american- british (fab) subtype
except m3, with confirmed mutation in the npm1
gene*
Yes
No
relapsed and/or refractory aml from any duration
of complete remission (cr); any number of prior
therapies allowed*
Yes
No
eastern cooperative oncology group (ecog)
performance status 0-2, life expectancy > 3
months*
Yes
No
serum creatinine =< 2.0 mg/dl*
mg/dl
Yes
No
bilirubin =< 2.0 mg/dl*
mg/dl
Yes
No
alanine aminotransferase (alt)/aspartate
aminotransferase (ast) =< 3 x upper limit of
normal (uln)*
Yes
No
ability to understand and the willingness to sign a
written informed consent document*
Yes
No
Exclusion Criteria
pregnant or breast-feeding women will not be
entered on this study due to risks of fetal and
teratogenic adverse events as seen in
animal/human studies; pregnancy tests must be
obtained in women; sexually active males or
females may not participate unless they have
agreed to use an effective contraceptive method*
Yes
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No
patients who are currently receiving another
investigational drug*
Yes
No
patients who are currently receiving other anti-
cancer agents*
Yes
No
uncontrolled systemic fungal, bacterial, viral, or
other infection (defined as exhibiting ongoing
signs/symptoms related to the infection and
without improvement, despite appropriate
antibiotics or other treatment)*
Yes
No
known hypersensitivity to arsenic trioxide*
Yes
No
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Eligibility Adult Acute Megakaryoblastic
Leukemia (M7) NCT01904643
Lenalidomide and Combination Chemotherapy in Treating
Patients With Relapsed or Refractory Acute Myeloid
Leukemia; ODM derived from:
https://clinicaltrials.gov/show/NCT01904643
All rights reserved. Please visit https://medical-data-
models.org/forms/14567
Eligibility Adult Acute
Megakaryoblastic Leukemia (M7)
NCT01904643
Inclusion Criteria
patients eligible include those with diagnosis of
aml other than acute promyelocytic leukemia by
world health organization (who) criteria with
relapsed disease after induction therapy or
refractory to induction chemotherapy, as
determined by morphology on bone marrow
biopsy; also eligible are patients unwilling to
receive standard induction chemotherapy*
Yes
No
eastern cooperative oncology group (ecog)
performance status 0-2*
Yes
No
serum creatinine =< 1.5 mg/dl; if serum creatinine
> 1.5 mg/dl, then the estimated glomerular filtrate
rate (gfr) must be > 60ml/min/1.73m^2 as
calculated by the modification of diet in renal
disease equation*
mg/dl
Yes
No
serum bilirubin =< 1.5 x upper limit of normal
(uln) unless elevation is considered to be
secondary to gilbert's syndrome, hemolysis, or
hepatic infiltration by aml*
Yes
No
aspartate transaminase (ast)/alanine
transaminase (alt) =< 2.5 x uln*
Yes
No
alkaline phosphatase =< 2.5 x uln*
Yes
No
all study participants must be registered into the
mandatory revlimid assistance (revassist)
program, and be willing and able to comply with
the requirements of revassist*
Yes
No
females of childbearing potential (fcbp) must have
a negative serum or urine pregnancy test with a
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sensitivity of at least 50 miu/ml within 10 - 14
days and again within 24 hours prior to
prescribing lenalidomide for cycle 1 (prescriptions
must be filled within 7 days as required by
revassist) and must either commit to continued
abstinence from heterosexual intercourse or
begin two acceptable methods of birth control,
one highly effective method and one additional
effective method at the same time, at least 28
days before she starts taking lenalidomide; fcbp
must also agree to ongoing pregnancy testing;
men must agree to use a latex condom during
sexual contact with a fcbp even if they have had a
successful vasectomy*
Yes
No
Exclusion Criteria
patient must not undergo concomitant
radiotherapy, chemotherapy or immunotherapy;
patient must not be in concurrent study with other
investigational agents*
Yes
No
patients who have received prior lenalidomide
therapy are not eligible for this study; further
there should be at least a 14-day window from
the patient's last prior therapy before initiation of
treatment on clinical trial*
Yes
No
have other severe concurrent disease or serious
organ dysfunction involving the heart, kidney, liver
or other organ system that may place the patient
at undue risk to undergo treatment*
Yes
No
have significant, uncontrolled active infection*
Yes
No
pregnant or nursing patients will be excluded
from the study*
Yes
No
known human immunodeficiency virus (hiv)
infection*
Yes
No
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Eligibility Adult Acute Megakaryoblastic
Leukemia (M7) NCT02144675
Choline Magnesium Trisalicylate and Combination
Chemotherapy in Treating Patients With Acute Myeloid
Leukemia; ODM derived from:
https://clinicaltrials.gov/show/NCT02144675
All rights reserved. Please visit https://medical-data-
models.org/forms/14568
Eligibility Adult Acute
Megakaryoblastic Leukemia (M7)
NCT02144675
Inclusion Criteria
patients must have a diagnosis of non-m3 aml
(patients with m3 subtype are excluded);
determination of the presence of cytogenetic
abnormalities will be by standard cytogenetics +/-
fluorescent-in-situ (fish) studies; additional
molecular analyses for nucleophosmin (npm)
mutation and fms-related tyrosine kinase 3 (flt3)
internal tandem duplication will be obtained as a
part of standard care by institutional procedures*
Yes
No
leukemic blast count > 1500/mm^3 of peripheral
blood*
Yes
No
patients must have an eastern cooperative
oncology group (ecog) performance status =< 3*
Yes
No
total bilirubin < 2 times the institutional upper limit
of normal (uln)*
Yes
No
aspartate aminotransferase (ast) (serum glutamic
oxaloacetic transaminase [sgot]) < 3 times the
institutional uln*
Yes
No
serum creatinine < 1.5 times the institutional uln*
Yes
No
multi gated acquisition scan (muga) or
echocardiogram with left ventricular ejection
fraction (lvef) > 50%*
Yes
No
women of childbearing potential must have a
negative pregnancy test*
Yes
No
no uncontrolled psychiatric illness that the
principal investigator feels will compromise
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obtaining informed consent from a patient*
Yes
No
patient must be informed of the investigational
nature of this study and must give written
informed consent in accordance with institutional
and federal guidelines; patients who do not
provide informed consent will not be eligible for
the study*
Yes
No
Exclusion Criteria
any coexisting medical condition or medications
precluding full compliance with any of the arms of
the study*
Yes
No
allergies to any investigational drugs and/or to the
chemotherapeutic agents*
Yes
No
allergies to any non-steroidal anti-inflammatory
drugs (nsaids)/salicylates (e.g., aspirin)*
Yes
No
endoscopically documented upper or lower
gastrointestinal (gi) related hemorrhage within
last 6 months; also, patients with a clinical
diagnosis of gi bleeding requiring blood
transfusions will be excluded*
Yes
No
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Eligibility Adult Acute Megakaryoblastic
Leukemia NCT01361464
Tipifarnib in Treating Older Patients With Acute Myeloid
Leukemia; ODM derived from:
https://clinicaltrials.gov/show/NCT01361464
All rights reserved. Please visit https://medical-data-
models.org/forms/14569
Eligibility Adult Acute
Megakaryoblastic Leukemia
NCT01361464
Inclusion Criteria
previously untreated acute myeloid leukemia
(aml) (de novo or secondary)*
Yes
No
no diagnosis of acute promyelocytic leukemia
(apl)*
Yes
No
deemed unsuitable for or refuses standard
induction chemotherapy*
Yes
No
rasgrp1:aptx ratio >= 5, through bone marrow
screening*
Yes
No
no patients with known leukemic involvement of
the central nervous system*
Yes
No
ecog performance status =< 2*
Yes
No
no wbc >= 30,000/ul (hydroxyurea permitted up
to 24 hours prior to initiation of therapy)*
Yes
No
serum creatinine less than 1.5 times the upper
limit of the normal range (uln) (national cancer
institute [nci] common toxicity criteria [ctc] grade
1)*
Yes
No
total bilirubin less than 1.5 times uln (unless the
increase is unequivocally due to hemolysis or
gilbert syndrome)*
Yes
No
alt and ast less than 2.5 times uln (nci ctc grade
1)*
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Yes
No
men must agree to use adequate contraception
(hormonal or barrier method of birth control;
abstinence) prior to study entry and for the
duration of study participation*
Yes
No
no symptomatic neuropathy of grade 2 or worse*
Yes
No
no uncompensated disseminated intravascular
coagulation (dic) or uncontrolled bleeding*
Yes
No
no history of allergic reactions attributed to
compounds of similar chemical or biologic
composition to tipifarnib (r115777), such as the
imidazole drugs, including clotrimazole,
ketoconazole, miconazole, econazole,
fenticonazole, isoconazole, sulconazole,
ticonazole, or terconazole*
Yes
No
no uncontrolled intercurrent illness including, but
not limited to, ongoing or active infection,
symptomatic congestive heart failure, unstable
angina pectoris, cardiac arrhythmia, or psychiatric
illness/social situations that would limit
compliance with study requirements*
Yes
No
known hiv-positive patients on combination
antiretroviral therapy are ineligible because of the
potential for pharmacokinetic interactions with
r115777; in addition, these patients are at
increased risk of lethal infections when treated
with marrow-suppressive therapy; known hiv-
positive patients not on antiretroviral therapy and
with a cd4 cell count >= 400/mm^3 are eligible*
Yes
No
no other concurrent cytotoxic or biologic
antileukemic therapy*
Yes
No
no patients who are receiving any other
investigational agents*
Yes
No
use of enzyme-inducing anticonvulsants (e.g.,
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phenytoin, fosphenytoin, phenobarbital,
primidone, carbamazepine, oxcarbazepine) while
taking tipifarnib (r115777) is contraindicated*
Yes
No
if clinically indicated, subjects may use non-
enzyme-inducing anticonvulsants during
treatment with r115777*
Yes
No
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Eligibility Adult Acute Myeloid Leukemia in
Remission NCT01519596
Symptom-Adapted Physical Activity Intervention in
Minimizing Physical Function Decline in Older Patients With
Acute Myeloid Leukemia Undergoing Chemotherapy; ODM
derived from: https://clinicaltrials.gov/show/NCT01519596
All rights reserved. Please visit https://medical-data-
models.org/forms/14570
Eligibility Adult Acute Myeloid
Leukemia in Remission
NCT01519596
Inclusion Criteria
diagnosis of aml with pathologic confirmation by
world health organization (who) criteria*
Yes
No
planned induction chemotherapy*
Yes
No
absence of active medical problems that preclude
participation in exercise (including, but not limited
to: bleeding, acute thrombosis, ischemia,
hemodynamic instability, uncontrolled pain)*
Yes
No
patient must be ambulatory or able to walk with a
cane*
Yes
No
patients must have limited cognitive deficits (< 3
incorrect responses on the pfeiffer mental status
scale)*
Yes
No
adequate english skills to understand and
complete questionnaires*
Yes
No
ability to understand and the willingness to sign a
written informed consent document*
Yes
No
Exclusion Criteria
presence of active medical conditions precluding
participation to exercise (e.g., ischemia, bleeding,
thrombosis, uncontrolled pain, hemodynamic
instability)*
Yes
No
inability to ambulate*
Yes
No
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Eligibility Adult Acute Myeloid Leukemia With
11q23 (MLL) Abnormalities NCT01083706
Azacitidine in Treating Patients With Relapsed
Myelodysplastic Syndrome, Chronic Myelomonocytic
Leukemia, or Acute Myeloid Leukemia Who Have
Undergone Stem Cell Transplant; ODM derived from:
https://clinicaltrials.gov/show/NCT01083706
All rights reserved. Please visit https://medical-data-
models.org/forms/14571
Eligibility Adult Acute Myeloid
Leukemia With 11q23 (MLL)
Abnormalities NCT01083706
Inclusion Criteria
mds, cmml or aml patients (as diagnosed by
world health organization [who] criteria) with
evidence of relapse or progression at >= day 28
and < day 100 post-transplant*
Yes
No
recurrent or increased cytogenetic abnormalities
by standard karyotype or fluorescence in situ
hybridization (fish) (the cytogenetic abnormalities
must have been previously documented at some
time point between diagnosis and date of stem
cell transplant)*
Yes
No
morphologic evidence of recurrence or increased
abnormal myeloblasts in peripheral blood or
marrow*
Yes
No
flow cytometric evidence of disease as
determined by recurrent or increased abnormal
myeloblasts in peripheral blood or marrow*
Yes
No
extramedullary relapse (local radiotherapy will be
allowed)*
Yes
No
mds, cmml, or aml patients with persistent stable
disease or persistent disease with regression at
>= day 28 and < day 100 post-transplant; the
inclusion of patients with persistent stable or
persistent regressing disease in this protocol is
not meant to advocate treatment; however, if the
attending physician is inclined to offer treatment
then these patients would be eligible for this
study*
Yes
No
persistence of cytogenetic abnormalities by
standard karyotype or fish*
Yes
No
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persistent morphologic evidence of abnormal
myeloblasts (in patients with cmml the
monoblastoid population is included) in peripheral
blood or marrow*
Yes
No
extramedullary persistence or regression*
Yes
No
Exclusion Criteria
refractory disease at time of stem cell transplant;
patients who received chemotherapy prior to
transplant with no evidence of response by
international working group (iwg) criteria*
Yes
No
>= 10% bone marrow myeloblasts as measured
by morphology*
Yes
No
evidence of central nervous system (cns) disease
at time of relapse by morphology or flow (a
diagnostic lumbar puncture [lp] is not required at
time of relapse)*
Yes
No
serum creatinine > 2 x uln (upper limit of normal)*
Yes
No
aspartate aminotransferase (ast)/ alanine
aminotransferase (alt) > 2x uln*
Yes
No
performance status > 2 (eastern cooperative
oncology group [ecog] scale)*
Yes
No
patients with severe disease other than mds,
cmml or aml which would be expected to prevent
compliance with treatment*
Yes
No
patients with severe infections (pneumonia,
sepsis, etc) within the 2 weeks prior to the
anticipated start of protocol treatment*
Yes
No
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Eligibility Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
NCT01083706
Eligibility Adult Acute Myeloid Leukemia With
11q23 (MLL) Abnormalities NCT01869803
Gemtuzumab Ozogamicin in Treating Patients With
Relapsed or Refractory Acute Myeloid Leukemia or Acute
Promyelocytic Leukemia; ODM derived from:
https://clinicaltrials.gov/show/NCT01869803
All rights reserved. Please visit https://medical-data-
models.org/forms/14572
Eligibility Adult Acute Myeloid
Leukemia With 11q23 (MLL)
Abnormalities NCT01869803
Inclusion Criteria
diagnosis of relapsed or refractory aml and not
candidate for standard consolidation treatment
after daunorubicin and cytosine arabinoside or
diagnosis of apl relapsed after tretinoin (atra) and
arsenic trioxide therapy or apl with persisting or
rising blasts, and no other comparable or
satisfactory alternative therapy available
(including patients not eligible for, or who have
access to, investigational therapies via a clinical
trial)*
Yes
No
patients must have an initial diagnosis of aml,
biphenotypic acute leukemia, or apl*
Yes
No
patients must have cluster of differentiation
(cd)33 positivity of > 30%*
Yes
No
eastern cooperative oncology group (ecog)
performance status =< 3 / karnofsky > 60%*
Yes
No
total bilirubin within normal institutional limits*
Yes
No
aspartate aminotransferase (ast) (serum glutamic
oxaloacetic transaminase [sgot])/alanine
aminotransferase (alt) (serum glutamate pyruvate
transaminase [sgpt]) =< 2 x institutional upper
limit of normal*
Yes
No
it is deemed ethical to provide an experimental
drug (e.g., mylotarg) that is associated with
hepatotoxicity (veno-occlusive disease [vod]) and
myelosuppression*
Yes
No
women of child-bearing potential and men must
agree to use adequate contraception (hormonal
or barrier method of birth control; abstinence)
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prior to receiving mylotarg and for the duration of
treatment; should a woman become pregnant or
suspect she is pregnant while receiving treatment
with mylotarg, she should inform her treating
physician immediately*
Yes
No
ability to understand and the willingness to sign a
written institutional review board (irb)-approved
informed consent document*
Yes
No
Exclusion Criteria
patients may not currently be receiving any other
investigational agents for leukemia*
Yes
No
patients with known untreated hepatitis c*
Yes
No
uncontrolled intercurrent illness including, but not
limited to active liver disease, or psychiatric
illness/social situations that would limit
compliance with study requirements*
Yes
No
pregnant women are excluded from this study;
breastfeeding should be discontinued if the
mother is treated with mylotarg*
Yes
No
human immunodeficiency virus (hiv)-positive
patients on combination antiretroviral therapy are
ineligible; appropriate studies will be undertaken
in patients receiving combination antiretroviral
therapy when indicated*
Yes
No
patients with a known hypersensitivity to
gemtuzumab ozogamicin or its parts:
recombinant humanized anti-cd33 monoclonal
(hp67.6) antibody, calicheamicin derivatives or
other ingredients*
Yes
No
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Eligibility Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
NCT01869803
NINDS CDE Imaging Diagnostics Epilepsy
NINDS Common Data Elements Used from the National
Institute of Neurological Disorders and Stroke Common
Data Elements
(https://www.commondataelements.ninds.nih.gov/)
References: Grinnon ST, Miller K, Marler JR, Lu Y, Stout A,
Odenkirchen J, Kunitz S. National Institute of Neurological
Disorders and Stroke Common Data Element Project -
approach and methods. Clin Trials. 2012;9(3):322-9.
All rights reserved. Please visit https://medical-data-
models.org/forms/14578
Imaging Diagnostics
Functional Magnetic Resonance Imaging
Study ID
Study site name
Subject ID
Date of exam
Last seizure occurrence in relation to study
Time of seizure
am (1)
pm (2)
24-hour clock (3)
Magnetic Field Strength of Scanner Used
1.5 T  (1)
3.0 T  (2)
Other, specify below (3)
Magnetic Field Strength:if other,please specify
T
Technique fMRI
BOLD  (1)
ASL  (2)
Other (3)
Technique fMRI:if other,please specify
Complicating factor: postictal
Yes
No
Complicating factor: Mass
Yes
No
Complicating factor:vascular malformation
Yes
No
Complicating factor: carotid stenosis
1 / 13
Yes
No
Paradigm Task Design:Block Design
Yes
No
Paradigm Task Design:Event related
Yes
No
Behavioral Monitoring
Yes
No
Domain tested:Motor
Yes
No
Domain tested:Somatosensory
Yes
No
Domain tested:Visual
Yes
No
Domain tested:Language
Expressive  (1)
Receptive  (2)
Both (3)
Domain tested:Memory
Explicit (1)
Implicit (2)
Recall (3)
Encoding (4)
Verbal (5)
Visual spatial (6)
Both (7)
Analysis
Native space (1)
Standard space (Talairach, MNI, other)
(2)
If standard space analysis, please specify
Analysis software: SPM
Yes
No
Analysis software:AFNI
Yes
No
Analysis software:FSL
Yes
No
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Analysis software:MEDX
Yes
No
Analysis software:other
Yes
No
Analysis
Visual blinded (1)
Visual unblinded (2)
Analysis
ROI  (1)
Mask (2)
VBM (3)
Analysis: if ROI, specify hemisphere,region and
activation mean
Language
Frontal Laterality (1)
Temporal Laterality (2)
Hemisphere Laterality (3)
Laterality
Left (1)
Right (2)
Bilateral (3)
Not lateralized (4)
Memory Hemisphere Laterality
Left (1)
Right (2)
Bilateral (3)
Not lateralized (4)
Description of language and memory paradigms
Ictal SPECT Localization
Date of exam
Last seizure occurrence in relation to study
Time
am (1)
pm (2)
24-hour clock (3)
Ligand
ECD (1)
HMPAO (2)
Other, specify (3)
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Ligand:if other please specify
Ligand Dose
Processing
None- ictal and interictal scans not
registered and no intensity correction (1)
Ictal – interictal SPECT subtraction (2)
Ictal – interictal SPECT analyzed by
SPM (3)
EEG during uptake to assure
interictal/ictal study (4)
Co-registered to MRI (5)
Processing: Condition of study
Inter-Ictal	 (1)
Ictal	 (2)
Peri-Ictal (3)
Rating
Visual (1)
Semi quantitative (ROI AI) (2)
Voxel based (SPM) (3)
Subtraction based (4)
Uptake
Increased (1)
Decreased (2)
Distribution
Global (1)
Hemisphere (2)
Multifocal (3)
Lobar (4)
Regional (5)
Lateralization
Left (1)
Right (2)
Bilateral (3)
Not lateralized (4)
Frontal Polar (FP)
Left (1)
Right (2)
Mesial frontal (MF):
Left (1)
Right (2)
Dorsal lateral frontal (DLF):
Left (1)
Right (2)
Orbital frontal (OF):
Left (1)
Right (2)
Mesial parietal (MP):
4 / 13
NINDS CDE Imaging Diagnostics Epilepsy
Left (1)
Right (2)
Insula (INS):
Left (1)
Right (2)
Dorsal lateral parietal (DLP):
Left (1)
Right (2)
Basal ganglia
Left (1)
Right (2)
Mesial occipital (MO)
Left (1)
Right (2)
Lateral occipital (LO)
Left (1)
Right (2)
Basal occipital (BO)
Left (1)
Right (2)
Temporal polar (TP)
Left (1)
Right (2)
Mesial temporal (MT):
Left (1)
Right (2)
Lateral temporal (LT):
Left (1)
Right (2)
Thalamus:
Left (1)
Right (2)
Cerebellum
Left (1)
Right (2)
Study conclusion
Positive (e.g. definite abnormality or
change(s) and localizes to a single
predominant region) (1)
Negative (e.g. normal, no change) (2)
Inconclusive (e.g. some abnormality or
change, but indeterminate or not definite)
(3)
Magnetic Resonance Imaging
Epilepsy-specific Protocol
Yes
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No
Sequences Obtained
Date of scan
Imaging Normality
Normal (1)
Abnormal (2)
Incidental (not relevant for epilepsy
evaluation) (3)
Imaging normality:if abnormal, please specify
number of abnormality types
Imaging normality: if abnormal,please describe
types
Lateralization
Left (1)
Right (2)
Bilateral (3)
Distribution
Diffuse / generalized (Diffuse /
generalized)
Hemispheric (Hemispheric)
Multifocal	 (Multifocal	)
Multilobar	 (Multilobar	)
Unifocal	 (Unifocal	)
Cortical location of recording
Basal occipital (BO) (1)
0 Mesial parietal (MP) (10)
0 Mesial temporal (MT) (11)
0 Orbital frontal (OF) (12)
0 Temporal polar (TP) (13)
Dorsal lateral frontal (DLF) (2)
Dorsal lateral parietal (DLP) (3)
Frontal Polar (FP) (4)
Insula (INS) (5)
Lateral occipital (LO) (6)
0 Lateral temporal (LT) (7)
0 Mesial frontal (MF) (8)
0 Mesial occipital (MO) (9)
Side of recording
Left (1)
Right (2)
Subcortical location of recording
Basal ganglia (1)
Callosum (2)
Grey-white matter junction (3)
Periventricular (4)
Thalamus (5)
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White matter-other (6)
Side of recording
Left (1)
Right (2)
Agenesis
Yes
No
Atrophy
Yes
No
Cortical thinning
Yes
No
Cystic (including multicystic)
Yes
No
Decreased grey-white matter distinction
Yes
No
Dysgenesis (includes dysmorphology of cortical
mantle)
Yes
No
Heterotopic tissue versus migration abnormality
Yes
No
Hypertrophy
Yes
No
Hyperplasia (grey or white matter)
Yes
No
Hypoplasia (grey or white matter)
Yes
No
Loss of architecture (specific to hippocampus)
Yes
No
Malformation related white matter signal
abnormality
Yes
No
Contrast agent used
Yes
No
Impression of Specific Abnormalities: Mesial
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Temporal Sclerosis
Yes
No
Mesial Temporal Sclerosis: if applicable, please
specify
Hippocampal sclerosis (1)
Hippocampal sclerosis plus inter-lateral
temporal dysplasia/atrophy (2)
Hippocampal sclerosis with remote dual
pathology (i.e., remote lesion) (3)
Impression of specific abnormalities:
Malformation of cortical development (MCD)
Yes
No
Malformation of cortical development (MCD): if
applicable, please specify
Band heterotopias (1)
Partial Hemimegalencephaly (10)
Periventricular nodular heterotopias (11)
Polymicrogyria (12)
Schizencephaly (malformation related
only) (13)
Transmantle focal cortical dysplasia (14)
Tuberous sclerosis Comments (15)
Development tumor-like lesion (2)
Focal cortical dysplasia (3)
Hemimegalencephaly (4)
Heterotopia / heterotopion (other) (5)
Hypothalamic hamartoma (6)
Lissencephaly (7)
Microcephaly (8)
Pachygyria (9)
Malformation of cortical development (MCD):
Comments
Impression of specific abnormalities: Vascular
Yes
No
Vascular abnormalities: if applicable, please
specify
Arterial stroke (1)
Arterial vascular malformation (2)
Cavernoma (3)
Hemorrhage (including post hemorrhage
evidence, e.g. periventricular) (4)
Venous stroke (5)
Vascular malformation (other) (6)
Impression of specific abnormalities: Neoplasm
Yes
No
Neoplasm:if applicable, please specify
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Primary (1)
Secondary (2)
Impression of specific abnormalities:
Inflamatory/infectious
Yes
No
Inflammatory/infectious:if applicable, please
specify
Abcess (1)
Cysticercosis (2)
Encephalitis (other) (3)
Limbic encephalitis (4)
Sarcoidosis (5)
Vasculitis (6)
Impression of specific abnormalities: Atrophy or
tissue loss
Yes
No
Atrophy or tissue loss: if applicable, please
specify
Encephalomalacia (related to surgery,
abscess, radiation, trauma) (1)
Focal or lobar atrophy (other) (2)
Trauma related (3)
Vascular related (If caused by Stroke,
see Vascular to classify) (4)
MEG Acquisition
Date of exam
MEG Acquisition Methods: Spontaneous
Yes
No
MEG Acquisition Methods Spontaneous:
Duration
MEG Acquisition Methods spontaneous:
Sedation
Yes
No
MEG Acquisition Methods spontaneous:
sampling frequency
MEG Acquisition Methods Spontaneous:
Bandwidth
MEG Acquisition Methods: Evoked field
Yes
No
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MEG Acquisition Method evoked fields: Epoch
number
MEG Acquisition Method evoked field:Sedation
Yes
No
MEG Acquisition Methods Sedation: if applicable,
please specify type
MEG Acquisition Method evoked field: Sampling
frequency
MEG Acquisition Method evoked field: Bandwidth
MEG / EEG Source Analysis Methods: Volume
conductor
One shell sphere (1)
Two shell sphere (2)
Three shell sphere (3)
Four shell sphere (4)
Boundary element model (BEM) (5)
Finite element model (FEM) (6)
MEG / EEG Source Analysis Method: Dipole
Moving (1)
Rotating (2)
Regional (3)
Fixed coherent (4)
Fixed MUSIC (5)
MEG / EEG Source Analysis Method: Distributed
source models
Minimum norm least squares (MNLS, L2
Norm) (1)
Standardized low resolution
electromagnetic tomography (sLORETA)
(2)
L1 Norm (3)
Lp Norm (4)
Low resolution electromagnetic
tomography (LORETA) (5)
Dynamic statistical parametric mapping
(dSPM) (6)
MEG / EEG Source Analysis Method:
Beamformer
Vector	 (1)
SAM	 (2)
LCMV (3)
PET Localization
Date of exam
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Last seizure occurrence in relation to study
Time
am (1)
pm (2)
24-hour clock (3)
Ligand
FDG (1)
FMZ (2)
AMT (3)
FCWAY (4)
Other, specify (5)
Ligand:if other please specify
Ligand dose
Processing
None-routine visual analysis (1)
Co-registered to MRI (2)
Co-registered CT (3)
3D stereotactic surface projection (SSP)
(4)
SPM analysis (5)
EEG during uptake to assure interictal
study (6)
Condition of study: specify below (7)
Processing: Condition of study
Inter-Ictal	 (1)
Ictal	 (2)
Peri-Ictal (3)
Rating
Visual (1)
Semi quantitative (ROI AI) (2)
Quantitative (ROI) (3)
Voxel based (SPM) (4)
Uptake
Increased (1)
Decreased (2)
Distribution
Global (1)
Hemisphere (2)
Multifocal (3)
Lobar (4)
Regional (5)
Lateralization
Left (1)
Right (2)
Bilateral (3)
Not lateralized (4)
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Frontal Polar (FP)
Left (1)
Right (2)
Mesial frontal (MF):
Left (1)
Right (2)
Dorsal lateral frontal (DLF):
Left (1)
Right (2)
Orbital frontal (OF):
Left (1)
Right (2)
Mesial parietal (MP):
Left (1)
Right (2)
Insula (INS):
Left (1)
Right (2)
Dorsal lateral parietal (DLP):
Left (1)
Right (2)
Basal ganglia
Left (1)
Right (2)
Mesial occipital (MO)
Left (1)
Right (2)
Lateral occipital (LO)
Left (1)
Right (2)
Basal occipital (BO)
Left (1)
Right (2)
Temporal polar (TP)
Left (1)
Right (2)
Mesial temporal (MT):
Left (1)
Right (2)
Lateral temporal (LT):
Left (1)
Right (2)
Thalamus:
Left (1)
Right (2)
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Cerebellum
Left (1)
Right (2)
Study conclusion
Positive (e.g. definite abnormality or
change(s) and localizes to a single
predominant region) (1)
Negative (e.g. normal, no change) (2)
Inconclusive (e.g. some abnormality or
change, but indeterminate or not definite)
(3)
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Eligibility Atrial Fibrillation (Prevention of
Stroke) NCT02485873
Real-Life Evidence on Stroke Prevention in SPAF; ODM
derived from: https://clinicaltrials.gov/show/NCT02485873
All rights reserved. Please visit https://medical-data-
models.org/forms/14580
Eligibility Atrial Fibrillation
(Prevention of Stroke) NCT02485873
Inclusion Criteria
age ≥18 years on the day of the first prescription
of the study drug (= index date) during study
selection window*
Yes
No
diagnosis of nvaf on start date of study or
anytime during 365 days before this date*
Yes
No
availability of follow-up at least 180 days after the
date of the first prescription of study drug within
selection window of study (exposure start date)*
Yes
No
evidence of patient activity in the database during
90 days before the date of the first prescription of
target drug within selection window.*
Yes
No
Exclusion Criteria
patients with valvular af*
Yes
No
prescriptions of oral anticoagulants (oacs: vka,
dabigatran, rivaroxaban) before index date*
Yes
No
prescription of more than one oac on the index
date or switch to another oac during the follow-up
period*
Yes
No
prescriptions of < 15mg rivaroxaban at index date
or during the follow-up period for patients in
rivaroxaban cohort*
Yes
No
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Eligibility Atrial Fibrillation NCT00032591
The Home INR Study; ODM derived from:
https://clinicaltrials.gov/show/NCT00032591
All rights reserved. Please visit https://medical-data-
models.org/forms/14581
Eligibility Atrial Fibrillation
NCT00032591
Inclusion Criteria
1. have af and/or a mhv;*
Yes
No
2. be scheduled to receive warfarin indefinitely
(operationally defined as 2 years);*
Yes
No
3. be using warfarin according to the criteria
described in the coumadin package insert (no off-
label uses);*
Yes
No
4. be expected to survive for the duration of the
study;*
Yes
No
5. not be suffering from intracranial bleeding
(intracranial hemorrhage, subarachnoid
hemorrhage, hemorrhagic stroke) or any other
contraindication described in the coumadin
package insert;*
Yes
No
6. be willing to perform pst;*
Yes
No
7. be willing to be randomized;*
Yes
No
8. possess adequate cognitive and language
skills to follow the protocol and all related
instructions;*
Yes
No
9. be willing to participate for the full duration of
the study;*
Yes
No
10. sign the informed consent form;  and*
Yes
No
11. not be enrolled in another randomized clinical
1 / 2
trial that involves a drug or device intervention.*
Yes
No
Exclusion Criteria
1. subject has had intracranial hemorrhage,
subarachnoid hemorrhage, hemorrhagic stroke,
or any other absolute/major contraindication
described in the warfarin package insert within
the last month*
Yes
No
2. subject enrolled in another randomized clinical
trial that involves a drug or device intervention*
Yes
No
3. subject is not able to follow the protocol and all
related instructions, and does not have a
caregiver with these skills*
Yes
No
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Eligibility Atrial Fibrillation NCT00111488
Guidant Microwave Ablation System for the Treatment of
Atrial Fibrillation; ODM derived from:
https://clinicaltrials.gov/show/NCT00111488
All rights reserved. Please visit https://medical-data-
models.org/forms/14587
Eligibility Atrial Fibrillation
NCT00111488
Inclusion Criteria
patient age >= 18 years*
Yes
No
documented permanent af (for at least three
months)*
Yes
No
scheduled for an open chest cardiac surgery for
the primary indication of mitral valve repair or
replacement*
Yes
No
has been informed of the nature of the study,
agrees to its provisions, and provided written
informed consent, which was approved by the
appropriate institutional review board/ethics
committee of the respective clinical site*
Yes
No
Exclusion Criteria
cerebral vascular accident (cva, stroke) or
transient ischemic attack (tia) within the previous
6 months*
Yes
No
myocardial infarction within the previous 6 weeks*
Yes
No
documented history of pulmonary vein stenosis*
Yes
No
previous ablation attempt for af*
Yes
No
previous thoracic procedures*
Yes
No
left atrial size > 7.0 cm*
Yes
No
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left ventricular ejection fraction < 30%*
Yes
No
presence of left atrial or left atrial appendage
thrombi*
Yes
No
esophageal fistula or other stricture, untreated
esophagitis, varices, dysphagia or odynophagia
contraindicating transesophageal
echocardiography*
Yes
No
known allergy or contraindication to warfarin
therapy*
Yes
No
known allergy or contraindication to
antiarrhythmic (classes ia, ic, iii) therapy*
Yes
No
other comorbidity with reduced life expectancy of
less than 1 year or protocol noncompliance that
would limit follow-up*
Yes
No
geographically remote or unable to return for
follow-up examinations*
Yes
No
pregnant or planning to become pregnant during
the study*
Yes
No
enrolled in any concurrent study, without guidant
written approval, that may confound the results of
the study*
Yes
No
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Eligibility Atrial Fibrillation NCT00126022
Intravenous Tedisamil in the Rapid Conversion of Atrial
Fibrillation or Flutter to Normal Sinus Rhythm in Female
Subjects; ODM derived from:
https://clinicaltrials.gov/show/NCT00126022
All rights reserved. Please visit https://medical-data-
models.org/forms/14588
Eligibility Atrial Fibrillation
NCT00126022
Inclusion Criteria
willing to sign informed consent before screening
examinations are performed and before the study
drug is administered*
Yes
No
females > 18 years of age*
Yes
No
subjects with documented (60 second rhythm
strip) symptomatic atrial fibrillation or flutter
(duration > 3 hours and < 45 days) at the time of
randomization*
Yes
No
subjects who are in no distress and
hemodynamically stable (supine systolic blood
pressure > 90 mmhg and diastolic blood pressure
< 105 mmhg)*
Yes
No
Exclusion Criteria
pregnancy and lactation*
Yes
No
acute myocardial infarction and cerebrovascular
accidents*
Yes
No
coronary syndromes and congestive heart failure
(chf) new york heart association (nyha) iv*
Yes
No
life-threatening ventricular arrhythmias and
electrocardiogram (ecg) abnormalities*
Yes
No
concurrent antiarrhythmic treatments*
Yes
No
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Eligibility Adult Acute Promyelocytic Leukemia With
t(15;17)(q22;q12); PML-RARA NCT02339740
Tretinoin and Arsenic Trioxide in Treating Patients With
Untreated Acute Promyelocytic Leukemia; ODM derived
from: https://clinicaltrials.gov/show/NCT02339740
All rights reserved. Please visit https://medical-data-
models.org/forms/14589
Eligibility Adult Acute Promyelocytic
Leukemia With t(15;17)(q22;q12);
PML-RARA NCT02339740
Inclusion Criteria
patients must be newly diagnosed with a clinical
diagnosis of apl (initially by morphology of bone
marrow or peripheral blood)*
Yes
No
bone marrow is highly preferred but in cases
where marrow cannot be obtained at diagnosis,
peripheral blood will be accepted*
Yes
No
if the rq-pcr results are known at the time of study
enrollment, the patient must demonstrate the
pml-raralpha transcript by rq-pcr to be eligible*
Yes
No
note: a lumbar puncture is not required in order to
be enrolled on study nor are lumbar punctures
recommended at the time of diagnosis; if the
diagnosis of apl is known or suspected,
diagnostic lumbar punctures in patients with
neurologic symptoms should be deferred until
any coagulopathy is corrected; if central nervous
system (cns) disease is suspected or proven, a
computed tomography (ct) or magnetic
resonance imaging (mri) should be considered to
rule out the possibility of an associated chloroma;
if cns disease is documented, patients are still
eligible and will receive protocol directed
intrathecal treatments*
Yes
No
patients may receive up to a maximum of 5 days
of pre-treatment with atra prior to administration
of protocol therapy*
Yes
No
treatment with hydroxyurea, corticosteroids (any
route) and intrathecal cytarabine prior to
beginning protocol directed therapy is allowed;
however, it should be noted that lumbar puncture
and intrathecal therapy at initial diagnosis of apl
is not recommended*
Yes
No
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all patients and/or their parents or legal guardians
must sign a written informed consent*
Yes
No
all institutional, food and drug administration
(fda), and national cancer institute (nci)
requirements for human studies must be met*
Yes
No
Exclusion Criteria
patients with secondary apl are excluded; this
includes all patients with apl that may have
resulted from prior treatment (chemotherapy or
radiation)*
Yes
No
patients with isolated myeloid sarcoma
(myeloblastoma, chloroma, including leukemia
cutis) but without evidence of apl by bone marrow
or peripheral blood morphology are excluded*
Yes
No
patients with a pre-existing diagnosis of a
prolonged qt syndrome (even if corrected qt
interval [qtc] is normal at the time of apl
diagnosis) are excluded*
Yes
No
patients with a baseline qtc of > 450 msec are
excluded; bazett's formula is to be used for
measurement of the corrected qt interval: the qt
interval (msec) divided by the square root of the
rr interval (msec)*
msec
Yes
No
patients with a history or presence of significant
ventricular or atrial tachyarrhythmia are excluded*
Yes
No
patients with right bundle branch block plus left
anterior hemiblock, bifascicular block are
excluded*
Yes
No
patients with serum creatinine > 3.0 mg/dl and
patients on active dialysis for renal dysfunction
are excluded*
mg/dl
Yes
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No
patients who have received treatment with any
other cytotoxic chemotherapy prior to beginning
protocol therapy (other than allowed in above
criteria) are excluded*
Yes
No
female patients who are pregnant are exclude;
patients should not be pregnant or plan to
become pregnant while on treatment; a
pregnancy test prior to enrollment is required for
female patients of childbearing potential*
Yes
No
lactating females who plan to breastfeed their
infants are excluded*
Yes
No
sexually active patients of reproductive potential
who have not agreed to be abstinent or use 2
forms of effective contraception during treatment
through 1 month off therapy are excluded*
Yes
No
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Eligibility Adult Hepatocellular Carcinoma
NCT02072486
Sorafenib Tosylate in Treating Patients With Liver Cancer
That Cannot Be Removed by Surgery; ODM derived from:
https://clinicaltrials.gov/show/NCT02072486
All rights reserved. Please visit https://medical-data-
models.org/forms/14590
Eligibility Adult Hepatocellular
Carcinoma NCT02072486
Inclusion Criteria
subject or legal representative must understand
the investigational nature of this study and sign
an independent ethics committee/institutional
review board approved written informed consent
form prior to receiving any study related
procedure*
Yes
No
outpatients with histologically/cytologically
documented or radiographically diagnosed
unresectable hepatocellular carcinoma (hcc) who
are candidates for systemic therapy and for
whom a decision to treat with sorafenib has been
made; radiographic diagnosis needs typical
findings of hcc by a radiographic method, i.e. on
multi-dimensional dynamic computed tomography
(ct), ct hepatic arteriography (ctha)/ct arterial
portography (ctap) or magnetic resonance
imaging (mri)*
Yes
No
patients must have a life expectancy of at least 8
weeks*
Yes
No
patients must not have any evidence of bleeding
diathesis or active gastrointestinal bleeding*
Yes
No
Exclusion Criteria
uncontrolled intercurrent illness including, but not
limited to, ongoing or active infection,
symptomatic congestive heart failure, unstable
angina pectoris, cardiac arrhythmia, or psychiatric
illness/social situations that would limit
compliance with study requirements*
Yes
No
pregnant or nursing female subjects*
Yes
No
unwilling or unable to follow protocol
requirements*
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Yes
No
any condition which in the investigator's opinion
deems the subject an unsuitable candidate to
receive study drug*
Yes
No
patients who have had prior anti-angiogenic
therapy, including but not limited to sorafenib,
brivanib, bevacizumab, or sunitinib; prior
treatment with liver directed, ablative or surgical
therapies will be permitted as long as there is
documented progression justifying the need for
starting sorafenib therapy*
Yes
No
no known contraindications to anti-angiogenics
such as severe coronary artery disease, recent
myocardial infarction or stroke within 6 months,
bleeding peptic ulcer or varices within last 3
months, and any other major illness that may
jeopardize study treatment or follow up*
Yes
No
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Attention-Deficit/Hyperactivity Disorder
Symptoms - Child PhenX Toolkit
The Strengths and Weaknesses of Attention-
Deficit/Hyperactivity Disorder Symptoms and Normal
Behavior Scale (SWAN) is an 18-question parent or teacher
rating scale to assess for the indication of attention-deficit
hyperactivity disorder in children.
"Weaknesses" are scored as positive and the "strengths"
are scored as negative because the usual ratings (i.e., in
the Swanson, Nolan and Pelham (SNAP)) are ratings of
"symptom severity". This keeps the average rating-per-item
of the SWAN aligned with the average rating-per-item of the
SNAP if the negative item ratings of the SWAN are set to 0
before averaging the items.
ODM derived from: https://cde.nlm.nih.gov
Primary source: https://www.phenxtoolkit.org/
Recent publication: Hendershot, T., Pan, H., Haines, J.,
Harlan, W.R., Marazita, M.L., McCarty, C.A., Ramos, E.M.,
and Hamilton, C.M. (2015) Using the PhenX toolkit to add
standard measures to a study. Curr. Protoc. Hum. Genet.
86:1.21.1-1.21.17. doi: 10.1002/0471142905.hg0121s86
Permission to publish granted by
Carol M. Hamilton.
All rights reserved. Please visit https://medical-data-
models.org/forms/14591
Attention-Deficit/Hyperactivity
Disorder Symptoms - Child PhenX
Toolkit
PhenX - attention-deficit - hyperactivity
disorder symptoms protocol - child
Give close attention to detail and avoid careless
mistakes
Above     (Above    )
Average     (Average    )
Below     (Below    )
Far above (Far above)
Slightly above    (Slightly above   )
Slightly below (Slightly below)
Sustain attention on tasks or play activitie
Above     (Above    )
Average     (Average    )
Below     (Below    )
Far above (Far above)
Slightly above    (Slightly above   )
Slightly below (Slightly below)
Listen when spoken to directly
Above     (Above    )
Average     (Average    )
Below     (Below    )
Far above (Far above)
Slightly above    (Slightly above   )
Slightly below (Slightly below)
Follow through on instructions & finish school
work/chores
Above     (Above    )
Average     (Average    )
Below     (Below    )
Far above (Far above)
Slightly above    (Slightly above   )
Slightly below (Slightly below)
Organize tasks and activities
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Above     (Above    )
Average     (Average    )
Below     (Below    )
Far above (Far above)
Slightly above    (Slightly above   )
Slightly below (Slightly below)
Engage in tasks that require sustained mental
effort
Above     (Above    )
Average     (Average    )
Below     (Below    )
Far above (Far above)
Slightly above    (Slightly above   )
Slightly below (Slightly below)
Keep track of things necessary for activities
Above     (Above    )
Average     (Average    )
Below     (Below    )
Far above (Far above)
Slightly above    (Slightly above   )
Slightly below (Slightly below)
Ignore extraneous stimuli
Above     (Above    )
Average     (Average    )
Below     (Below    )
Far above (Far above)
Slightly above    (Slightly above   )
Slightly below (Slightly below)
Remember daily activities
Above     (Above    )
Average     (Average    )
Below     (Below    )
Far above (Far above)
Slightly above    (Slightly above   )
Slightly below (Slightly below)
Sit still (control movement of hands/feet or control
squirming)
Above     (Above    )
Average     (Average    )
Below     (Below    )
Far above (Far above)
Slightly above    (Slightly above   )
Slightly below (Slightly below)
Stay seated (when required by class rules/social
conventions)
Above     (Above    )
Average     (Average    )
Below     (Below    )
Far above (Far above)
Slightly above    (Slightly above   )
Slightly below (Slightly below)
Modulate motor activity (inhibit inappropriate
running/climbing)
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Above     (Above    )
Average     (Average    )
Below     (Below    )
Far above (Far above)
Slightly above    (Slightly above   )
Slightly below (Slightly below)
Play quietly (keep noise level reasonable)
Above     (Above    )
Average     (Average    )
Below     (Below    )
Far above (Far above)
Slightly above    (Slightly above   )
Slightly below (Slightly below)
Settle down and rest (control constant activity)
Above     (Above    )
Average     (Average    )
Below     (Below    )
Far above (Far above)
Slightly above    (Slightly above   )
Slightly below (Slightly below)
Modulate verbal activity (control excess talking)
Above     (Above    )
Average     (Average    )
Below     (Below    )
Far above (Far above)
Slightly above    (Slightly above   )
Slightly below (Slightly below)
Reflect on questions (control blurting out
answers)
Above     (Above    )
Average     (Average    )
Below     (Below    )
Far above (Far above)
Slightly above    (Slightly above   )
Slightly below (Slightly below)
Await turn (stand in line and take turns)
Above     (Above    )
Average     (Average    )
Below     (Below    )
Far above (Far above)
Slightly above    (Slightly above   )
Slightly below (Slightly below)
Enter into conversation and games (control
interrupting/intruding)
Above     (Above    )
Average     (Average    )
Below     (Below    )
Far above (Far above)
Slightly above    (Slightly above   )
Slightly below (Slightly below)
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Eligibility Adult Hepatocellular Carcinoma
NCT02379377
18F-FSPG PET in Imaging Patients With Liver Cancer
Before Undergoing Surgery or Transplant; ODM derived
from: https://clinicaltrials.gov/show/NCT02379377
All rights reserved. Please visit https://medical-data-
models.org/forms/14592
Eligibility Adult Hepatocellular
Carcinoma NCT02379377
Inclusion Criteria
diagnosis of hcc with clinically documented
cirrhosis and one or more of the following:*
Yes
No
liver mass (>= 1 cm) with arterial phase contrast
enhancement and early washout on subsequent
phases by ct; or*
cm
Yes
No
suggestive imaging findings plus alpha-feto
protein (afp) > 200 mg/dl; or*
Yes
No
tumor confirmed by arteriography*
Yes
No
patients with a diagnosis or suspicion of hcc who
are candidates for resection surgery but do not
meet milan criteria for liver transplant*
Yes
No
each patient must provide written informed
consent and have completed conventional
imaging and staging and ct (multiphase) before
initiation of the investigational pet studies*
Yes
No
Exclusion Criteria
patients with a known prior malignancy within five
years, except basal cell carcinoma of the skin,
carcinoma in situ of the cervix, and prior hcc, are
excluded*
Yes
No
pregnant and breastfeeding patients*
Yes
No
patients with poorly controlled diabetes mellitus
(fasting blood glucose level > 200 mg/dl)*
Yes
No
1 / 2
patients with a known infiltrative variant of hcc*
Yes
No
prior treatment within 1 year for hcc*
Yes
No
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Eligibility Adult Primary Hepatocellular
Carcinoma NCT02072356
Radiolabeled Glass Beads in Treating Patients With Liver
Cancer That Cannot be Removed by Surgery; ODM
derived from: https://clinicaltrials.gov/show/NCT02072356
All rights reserved. Please visit https://medical-data-
models.org/forms/14593
Eligibility Adult Primary
Hepatocellular Carcinoma
NCT02072356
Inclusion Criteria
diagnosis of intrahepatic malignancy including but
not limited to hcc; the histopathology confirmation
criterion may be waived in patients with a
radiographically identifiable liver mass, known
laboratory or clinical risk factors for cancer or
elevated tumor markers such as alpha-fetoprotein
(afp) and clinical findings*
Yes
No
eastern cooperative oncology group (ecog)
performance status score 0 - 2*
Yes
No
life expectancy >= 3 months*
Yes
No
> 4 weeks since prior radiation, surgery or
chemotherapy*
Yes
No
able to comprehend and provide written informed
consent in accordance with institutional and
federal guidelines*
Yes
No
ineligible for surgical resection*
Yes
No
Exclusion Criteria
aspartate aminotransferase (ast) or alanine
aminotransferase (alt) > 5 times upper limit of
normal (unl)*
Yes
No
serum bilirubin > 2.0 mg/dl (unless segmental
infusion is planned)*
mg/dl
Yes
No
history of severe allergy or intolerance to any
1 / 2
contrast media, narcotics, sedatives, or atropine
that cannot be corrected or premedicated*
Yes
No
bleeding diathesis, not correctable by usual forms
of therapy*
Yes
No
severe peripheral vascular disease that would
preclude catheterization*
Yes
No
evidence of potential delivery of greater than 16.5
mci (30 gy absorbed dose) of radiation to the
lungs in a single treatment*
Yes
No
evidence of pulmonary insufficiency*
Yes
No
evidence of any detectable technetium-99m
macroaggregated serum albumin (tc-99m maa)
flow to the stomach or duodenum, not correctable
by using established angiographic techniques to
stop or mitigate such flow*
Yes
No
significant extrahepatic disease representing an
imminent life-threatening outcome*
Yes
No
active uncontrolled infection*
Yes
No
significant underlying medical or psychiatric
illness*
Yes
No
co-morbid disease of condition that would
preclude safe delivery of therasphere treatment
or, in the judgment of the physician, place the
patient at undue risk*
Yes
No
pregnancy*
Yes
No
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Eligibility Adult Survivors of Childhood
Leukemia NCT02244411
Exercise and QUality Diet After Leukemia: The EQUAL
Study; ODM derived from:
https://clinicaltrials.gov/show/NCT02244411
All rights reserved. Please visit https://medical-data-
models.org/forms/14594
Eligibility Adult Survivors of
Childhood Leukemia NCT02244411
Inclusion Criteria
eligibility will be confirmed via the ccss-based
medical record and by a series of questions on
the equal website, prior to consent.*
Yes
No
diagnosed with acute lymphoblastic leukemia <
18 years of age*
Yes
No
cancer free at time of study enrollment*
Yes
No
current age ≥ 18 years*
Yes
No
a body mass index (bmi) ≥ 30 kg/m2 (obese), as
determined by self-reported height and weight on
the most recent ccss questionnaire*
kg/m2
Yes
No
access to internet and usual use, possession of
an email address*
Yes
No
able to read and comprehend informed consent*
Yes
No
Exclusion Criteria
prior history of congestive heart failure, coronary
artery disease, myocardial infarction, stroke, or
unstable angina;*
Yes
No
medical condition for which weight loss might be
contraindicated or which would cause weight
loss, such as pregnancy, anorexia or bulimia;*
Yes
No
use of prescription weight loss medication within
1 / 2
the previous 6 months*
Yes
No
history of total body irradiation (tbi)*
Yes
No
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Eligibility Adult T Acute Lymphoblastic
Leukemia NCT00408005
Combination Chemotherapy in Treating Young Patients
With Newly Diagnosed T-Cell Acute Lymphoblastic
Leukemia or T-cell Lymphoblastic Lymphoma; ODM
derived from: https://clinicaltrials.gov/show/NCT00408005
All rights reserved. Please visit https://medical-data-
models.org/forms/14595
Eligibility Adult T Acute
Lymphoblastic Leukemia
NCT00408005
Inclusion Criteria
t-all patients must be enrolled on aall08b1 prior to
treatment and enrollment on aall0434*
Yes
No
patients must have newly diagnosed t-all or t-
lineage lymphoblastic lymphoma (t-nhl) stage ii-
iv; b-lineage lymphoblastic lymphoma will not be
eligible for this study; a diagnosis of t-all is
established when leukemic blasts lack
myeloperoxidase or evidence of b-lineage
derivation (cluster of differentiation
[cd]19/cd22/cd20), and express either surface or
cytoplasmic cd3 or two or more of the antigens
cd8, cd7, cd5, cd4, cd2 or cd1a; if surface cd3 is
expressed on all leukemic cells, additional
markers of immaturity, including transmission
disequilibrium test (tdt), cd34 or cd99 will be
assessed for expression; cases with uncertain
expression will receive additional review within
the appropriate children's oncology group (cog)
reference laboratory*
Yes
No
for t-nhl patients with tissue available for flow
cytometry, the criterion for diagnosis should be
analogous to t-all; for tissue processed by other
means (i.e. paraffin blocks), the methodology and
criteria for immunophenotypic analysis to
establish the diagnosis of t-nhl defined by the
submitting institution will be accepted*
Yes
No
prior therapy restrictions*
Yes
No
patients shall have had no prior cytotoxic
chemotherapy with the exception of steroids
and/or it cytarabine*
Yes
No
if chemotherapy with cytarabine is allowed prior
to registration for patient convenience; this is
usually done at the time of the diagnostic bone
marrow or venous line placement to avoid a
second lumbar puncture; (note: the cns status
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must be determined based on a sample obtained
prior to administration of any systemic or
intrathecal chemotherapy, except for steroid
pretreatment); systemic chemotherapy must
begin within 72 hours of this it therapy*
Yes
No
patients diagnosed as having t-nhl or t-all with
respiratory distress or hyperleukocytosis may
require steroids prior to the initiation of additional
systemic therapy; they are eligible for aall0434
and will be stratified, based on the initial
complete blood count (cbc); steroid pretreatment
may alter the risk group assessment; if the t-all
patient's clinical status precludes a lumbar
puncture within 48 hours of the initiation of
steroid therapy, t-all patients cannot be classified
as low risk and will be intermediate or high risk
based on the results of the day 29 marrow as
above; patients with t-nhl who receive steroid pre-
treatment will be classified as high risk; the dose
and duration of previous steroid therapy should
be carefully documented*
Yes
No
for the management of airway compromise,
patients who have received emergent chest
irradiation up to 600 cgy will be eligible for this
study*
Yes
No
patients with a prior seizure disorder requiring
anti-convulsant therapy are not eligible to receive
nelarabine; in addition, patients with pre-existing
grade 2 (or greater) peripheral neurotoxicity, as
determined prior to induction treatment by the
treating physician or a neurologist, are not eligible
to receive nelarabine; these restrictions in
eligibility are designed to prevent excessive
nelarabine-induced central and peripheral
neurotoxicity in at-risk patients; for the purposes
of this study, this includes any patient that has
received anticonvulsant therapy to prevent/treat
seizures in the prior two years*
Yes
No
Exclusion Criteria
pregnant or lactating females*
Yes
No
patients with down syndrome*
Yes
No
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b-precursor lymphoblastic lymphoma*
Yes
No
morphologically unclassifiable lymphoma*
Yes
No
absence of both b-cell and t-cell phenotype
markers in a case submitted as lymphoblastic
lymphoma*
Yes
No
cns-positive or testicular involvement*
Yes
No
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Eligibility Adults With Uncontrolled
Hypertension NCT01632943
Single-arm Study of Symplicity™ Renal Denervation
System in Patients With Uncontrolled HyperTensioN in
India; ODM derived from:
https://clinicaltrials.gov/show/NCT01632943
All rights reserved. Please visit https://medical-data-
models.org/forms/14596
Eligibility Adults With Uncontrolled
Hypertension NCT01632943
Inclusion Criteria
individual is 18 and 80 years old at time of
treatment.*
Yes
No
individual is receiving a stable medication
regimen including 3 or more anti-hypertensive
medications of different classes, of which one
must be a diuretic that is expected to be
maintained without changes for at least 6
months.*
Yes
No
individual has an office systolic blood pressure of
160 mm hg based on an average of 3 blood
pressure readings measured at screening visits*
mm hg
Yes
No
individual or legally authorized representative
agrees to have all study procedures performed,
and is competent and willing to provide written,
informed consent to participate in this clinical
study.*
Yes
No
Exclusion Criteria
main renal arteries with less than 4 mm diameter
or with less than 20 mm treatable length*
mm
Yes
No
multiple renal arteries where the main renal
artery is estimated to supply less than 75 percent
of the kidney.*
Yes
No
renal artery stenosis more than 50 percent or
renal artery aneurysm in either renal artery.*
Yes
No
a history of prior renal artery intervention
including balloon angioplasty or stenting.*
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Yes
No
individual has an estimated glomerular filtration
rate of less than 45ml per min per 1.73m2, using
the mdrd calculation.*
min
Yes
No
individual has had more than 1 in-patient
hospitalization for a hypertensive crisis within the
past year.*
Yes
No
individual has type 1 diabetes mellitus.*
Yes
No
individual has had 1 or more episodes of
symptomatic orthostatic hypotension within the
past year or during the screening process.*
Yes
No
individual requires chronic oxygen support or
mechanical ventilation other than nocturnal
respiratory support for sleep apnea.*
Yes
No
individual has primary pulmonary hypertension.*
Yes
No
individual has known secondary causes of
hypertension, such as untreated
pheochromocytoma, cushing's disease,
coarctation of the aorta, hyperthyroidism, or
hyperparathyroidism.*
Yes
No
individual has experienced a myocardial
infarction, unstable angina pectoris, syncope, or a
cerebrovascular accident within 6 months of the
screening period, or has widespread
atherosclerosis, with documented intravascular
thrombosis or unstable plaques.*
Yes
No
individual has a scheduled or planned surgery or
cardiovascular intervention in the next 6 months.*
Yes
No
individual has a condition that would prohibit or
interfere with ability to obtain an accurate blood
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pressure measurement using the protocol
specified automatic blood pressure monitor*
Yes
No
individual has severe cardiac valve stenosis for
which, in the opinion of the investigator, a
significant reduction of blood pressure is
contraindicated.*
Yes
No
individual has any serious medical condition,
which in the opinion of the investigator, may
adversely affect the safety and/or effectiveness of
the participant or the study*
Yes
No
individual is pregnant, nursing or planning to be
pregnant.*
Yes
No
individual has a known, unresolved history of
drug use or alcohol dependency, lacks the ability
to comprehend or follow instructions, or would be
unlikely or unable to comply with study follow-up
requirements.*
Yes
No
individual is currently enrolled in another
investigational drug or device trial. for the
purposes of this protocol, participants involved in
extended follow-up trials for products that were
investigational but are currently commercially
available are not considered enrolled in an
investigational trial.*
Yes
No
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Eligibility Uterine Fibroids NCT00067249
Women's Use of Alternative Medicine: A Multiethnic Study;
ODM derived from:
https://clinicaltrials.gov/show/NCT00067249
All rights reserved. Please visit https://medical-data-
models.org/forms/14597
Eligibility Uterine Fibroids
NCT00067249
Inclusion Criteria
pregnancy related symptoms*
Yes
No
menopausal related symptoms*
Yes
No
Headaches*
Yes
No
Back pain*
Yes
No
osteoporosis*
Yes
No
cancer*
Yes
No
high blood pressure*
Yes
No
high cholesterol*
Yes
No
heart disease*
Yes
No
joint pain/arthritis*
Yes
No
arthritis*
Yes
No
uterine fibroids*
Yes
No
urinary tract infection*
Yes
No
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vaginal tract infection*
Yes
No
medically diagnosed depression*
Yes
No
menstrual symptoms*
Yes
No
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Eligibility Uterine Fibroids NCT00067249
Eligibility Advanced Breast Cancer
NCT02499146
Palbociclib Pharmacokinetics Study In Postmenopausal
Chinese Women With ER (+), HER2 (-) Advanced Breast
Cancer; ODM derived from:
https://clinicaltrials.gov/show/NCT02499146
All rights reserved. Please visit https://medical-data-
models.org/forms/14598
Eligibility Advanced Breast Cancer
NCT02499146
Inclusion Criteria
er(+), her2(-), postmenopausal adult (ages 18-65
years, inclusive) chinese women with proven
diagnosis of adenocarcinoma of the breast with
evidence locoregionally recurrent or metastatic
disease not amenable to resection or radiation
therapy with curative intent and for whom
chemotherapy is not clinically indicated.*
Yes
No
postmenopausal women: i. prior bilateral surgical
oophorectomy; or ii. medically confirmed post-
menopausal status defined as spontaneous
cessation of regular menses for at least 12
consecutive months with no alternative
pathological or physiological cause b.
documentation of histologically or cytologically
confirmed diagnosis of: i. er(+) breast cancer. c.
documentation of her2(-) breast cancer. d.
previously untreated with any systemic anti
cancer therapy for their locoregionally recurrent
or metastatic er+ disease.*
Yes
No
measurable disease as defined per recist v.1.1 or
bone-only disease.    - tumor lesions previously
irradiated or subjected to other locoregional
therapy will only be deemed measurable if
disease progression at the treated site after
completion of therapy is clearly documented.*
Yes
No
Exclusion Criteria
her2-positive tumor as defined by documentation
of erbb-2 gene amplification by fish (as defined
by a her2/cep17 ratio ≥2) or chromogenic in situ
hybridization (cish, as defined by the
manufacturer's kit instruction) or documentation
of her2 overexpression by ihc (defined as ihc3+,
or ihc2+ with fish or cish confirmation) based on
local laboratory results*
Yes
No
patients with advanced, symptomatic, visceral
spread, that are at risk of life-threatening
complications in the short term (including patients
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with massive uncontrolled effusions [pleural,
pericardial, peritoneal], pulmonary lymphangitis,
and over 50% liver involvement).*
Yes
No
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Eligibility Advanced Renal Cell Carcinoma
NCT00494091
Study Evaluating The Safety, Efficacy & Pharmacokinetics
Of Temsirolimus(CCI-779) In Subjects With Advanced
Renal Cell Carcinoma; ODM derived from:
https://clinicaltrials.gov/show/NCT00494091
All rights reserved. Please visit https://medical-data-
models.org/forms/14599
Eligibility Advanced Renal Cell
Carcinoma NCT00494091
Inclusion Criteria
subjects with histologically confirmed, advanced
(stage iv or recurrent disease) rcc. the american
joint committee on cancer (ajcc) staging and
classification criteria will be used.*
Yes
No
ecog performance status of 0-1.*
Yes
No
at least one measurable lesion per recist.*
Yes
No
age greater than or equal to 20 years.*
Yes
No
japanese, chinese, or korean ethnicity.*
Yes
No
Exclusion Criteria
cns metastases at screening or history or cns
metastases.*
Yes
No
prior targeted, chemotherapeutic, cytokine-based,
or other investigational agents for the treatment of
rcc within 4 weeks before first dose of test article.
subjects must have documented objective
progressive disease after any prior systemic rcc
treatment and have recovered to grade 1 or lower
toxicities from effects of prior systemic therapy for
rcc.*
Yes
No
in past 5 years, other prior malignancy (except
basal cell carcinoma, squamous cell carcinoma
of the skin, or cervical carcinoma in situ).*
Yes
No
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Eligibility Multiple Sclerosis NCT00915460
Open-Label Safety Extension Study of Avonex; ODM
derived from: https://clinicaltrials.gov/show/NCT00915460
All rights reserved. Please visit https://medical-data-
models.org/forms/14600
Eligibility Multiple Sclerosis
NCT00915460
Inclusion Criteria
must have completed (as defined below) one of
the following biogen avonex® clinical studies and
meet the other criteria indicated.*
Yes
No
subjects enrolled from studies c95-812 and c97-
830 must have completed their respective study
within 12 months prior to enrollment in c98-838.
subjects enrolled from study c96-823 must have
completed the study within 24 months prior to
enrollment in c98-838.*
Yes
No
have not been diagnosed with any other disease
that accounts for their neurologic symptoms.*
Yes
No
Exclusion Criteria
history of any significant cardiac, hepatic,
pulmonary, or renal disease; immune deficiency;
or other medical conditions that would preclude
therapy with interferon beta.*
Yes
No
history of severe allergic or anaphylactic
reactions or history of hypersensitivity to human
albumin.*
Yes
No
history of seizure within the 3 months prior to
enrollment.*
Yes
No
abnormal laboratory results at the screening
visit:*
Yes
No
history of suicidal ideation or an episode of
severe depression within the 3 months prior to
enrollment into this study.*
Yes
No
other inclusion and exclusion criteria apply as per
1 / 2
biogen idec protocol*
Yes
No
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Eligibility Multiple Sclerosis NCT00915460
Eligibility Nasopharyngeal Neoplasms
NCT00563862
Benefit of Adding Chemotherapy And/Or Modification of
Radiotherapy Schedule for Advance Nasopharyngeal
Carcinoma (T3-4N0-1M0); ODM derived from:
https://clinicaltrials.gov/show/NCT00563862
All rights reserved. Please visit https://medical-data-
models.org/forms/14601
Eligibility Nasopharyngeal
Neoplasms NCT00563862
Inclusion Criteria
undifferentiated or non-keratinizing carcinoma*
Yes
No
tumor staged as t3-4 and n0-1*
Yes
No
no evidence of distant metastasis (m0)*
Yes
No
performance status: 0-2*
Yes
No
marrow: wbc >= 4 and platelet = 100*
Yes
No
renal: creatinine clearance = 60*
Yes
No
informed consent*
Yes
No
Exclusion Criteria
who type i squamous cell carcinoma or
adenocarcinoma*
Yes
No
age >= 70*
Yes
No
palliative intent or tumor extent mandating ap
opposing facio-cervical fields*
Yes
No
prior malignancy except adequately treated basal
cell or squamous cell skin cancer, in situ cervical
cancer, or other cancer for which the patient has
been disease-free for 5 years*
Yes
No
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previous radiotherapy (except non-melanomatous
skin cancers outside the intended rt treatment
volume*
Yes
No
previous chemotherapy*
Yes
No
patient is pregnant or lactating*
Yes
No
2 / 2
Eligibility Nasopharyngeal Neoplasms NCT00563862
Eligibility Atrial Fibrillation NCT00126061
Intravenous Tedisamil in the Rapid Conversion of Atrial
Fibrillation or Flutter to Normal Sinus Rhythm in Male
Subjects; ODM derived from:
https://clinicaltrials.gov/show/NCT00126061
All rights reserved. Please visit https://medical-data-
models.org/forms/14602
Eligibility Atrial Fibrillation
NCT00126061
Inclusion Criteria
willing to sign informed consent before screening
examinations are performed and before the study
drug is administered*
Yes
No
males > 18 years of age*
Yes
No
subjects with documented (60 second rhythm
strip) symptomatic atrial fibrillation or flutter
(duration > 3 hours and < 45 days) at the time of
randomization*
Yes
No
subjects who are in no distress and
hemodynamically stable (supine systolic blood
pressure > 90 mmhg and diastolic blood pressure
< 105 mmhg)*
Yes
No
Exclusion Criteria
acute myocardial infarction and cerebrovascular
accidents*
Yes
No
coronary and heart failure symptoms*
Yes
No
life-threatening ventricular arrhythmias and
electrocardiogram (ecg) abnormalities*
Yes
No
electrolyte abnormalities*
Yes
No
concurrent antiarrhythmic treatments*
Yes
No
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Eligibility Nasopharyngeal Neoplasms
NCT00563927
Benefit of Adding Chemotherapy for Advance
Nasopharyngeal Carcinoma (T1-4N2-3M0); ODM derived
from: https://clinicaltrials.gov/show/NCT00563927
All rights reserved. Please visit https://medical-data-
models.org/forms/14603
Eligibility Nasopharyngeal
Neoplasms NCT00563927
Inclusion Criteria
undifferentiated or non-keratinizing carcinoma*
Yes
No
tumor staged as n2-3*
Yes
No
no evidence of distant metastasis (m0)*
Yes
No
performance status:0-2*
Yes
No
marrow: wbc >= 4 and platelet >= 100*
Yes
No
renal: creatinine clearance >= 60*
Yes
No
informed consent*
Yes
No
Exclusion Criteria
who type i squamous cell carcinoma or
adenocarcinoma*
Yes
No
age >= 70*
Yes
No
palliative intent or tumor extent mandating ap
opposing facio-cervical fields*
Yes
No
prior malignancy except adequately treated basal
cell or squamous cell skin cancer, in situ cervical
cancer, or other cancer for which the patient has
been disease-free for 5 years*
Yes
No
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previous radiotherapy (except non-melanomatous
skin cancers outside the intended rt treatment
volume*
Yes
No
previous chemotherapy*
Yes
No
patient is pregnant or lactating*
Yes
No
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Eligibility Nasopharyngeal Neoplasms NCT00563927
Eligibility Atrial Fibrillation NCT00126074
Intravenous Tedisamil in the Rapid Conversion of Atrial
Fibrillation or Flutter to Normal Sinus Rhythm in Female
Subjects; ODM derived from:
https://clinicaltrials.gov/show/NCT00126074
All rights reserved. Please visit https://medical-data-
models.org/forms/14604
Eligibility Atrial Fibrillation
NCT00126074
Inclusion Criteria
willing to sign informed consent before screening
examinations are performed and before the study
drug is administered*
Yes
No
females > 18 years of age*
Yes
No
subjects with documented (60 second rhythm
strip) symptomatic atrial fibrillation or flutter
(duration > 3 hours and < 45 days) at the time of
randomization*
Yes
No
subjects who are in no distress and
hemodynamically stable (supine systolic blood
pressure > 90 mmhg and diastolic blood pressure
< 105 mmhg)*
Yes
No
Exclusion Criteria
pregnancy and lactation*
Yes
No
acute myocardial infarction and cerebrovascular
accidents*
Yes
No
coronary syndromes and congestive heart failure
(chf) new york heart association (nyha) iv*
Yes
No
life-threatening ventricular arrhythmias and
electrocardiogram (ecg) abnormalities*
Yes
No
concurrent antiarrhythmic treatments*
Yes
No
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Eligibility Atopy NCT00295737
Effect of an Immunotoxin on Activated Human
Macrophages in Those With Allergic Rhinitis or Mild
Intermittent Asthma; ODM derived from:
https://clinicaltrials.gov/show/NCT00295737
All rights reserved. Please visit https://medical-data-
models.org/forms/14605
Eligibility Atopy NCT00295737
Inclusion Criteria
physician diagnosis of atopy (allergic rhinitis or
mild intermittent asthma)*
Yes
No
age 18-55 years*
Yes
No
nonsmoker (> 5 years)*
Yes
No
forced expiratory volume in 1 second (fev1) >
70% of the predicted value*
Yes
No
a positive skin prick test for grass mix or d.
pteronyssinus at or within 12 months prior to the
screening visit*
Yes
No
informed consent*
Yes
No
females with negative pregnancy test*
Yes
No
Exclusion Criteria
infections of the respiratory tract within the last
month*
Yes
No
past or present disease, which as judged by the
investigator, may affect the outcome of this study.
these diseases include, but are not limited to,
cardiovascular disease, malignancy, hepatic
disease, renal disease, hematological disease,
neurological disease, endocrine disease or
pulmonary disease (including but not confined to
chronic bronchitis, emphysema, tuberculosis,
bronchiectasis or cystic fibrosis).*
Yes
No
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pathological findings in blood tests (differential
blood count, blood clotting, electrolytes, liver
enzymes, retention parameters)*
Yes
No
subject is undergoing allergen desensitization
therapy*
Yes
No
permanent medication*
Yes
No
systemic or inhaled corticosteroid use within the
last month*
Yes
No
anti-inflammatory medication within the last
month*
Yes
No
pregnancy*
Yes
No
neurological or psychiatric disease or history of
drug or alcohol abuse which would interfere with
the subject's proper completion of the protocol
assignment*
Yes
No
there is a risk of non-compliance with study
procedures*
Yes
No
participation in a clinical trial 30 days prior to
enrolment*
Yes
No
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Eligibility Atopy NCT00295737
Eligibility Non Small Cell Lung Cancer
NCT00212043
Phase I/II Trial of Infusional Gemcitabine in Combination
With Carboplatin in Chemonaive Non-small Cell
Carcinoma; ODM derived from:
https://clinicaltrials.gov/show/NCT00212043
All rights reserved. Please visit https://medical-data-
models.org/forms/14606
Eligibility Non Small Cell Lung
Cancer NCT00212043
Inclusion Criteria
• histologically or cytologically confirmed nsclc.*
Yes
No
stage iiib unsuitable for radical radiation (eg. with
cytologically proven malignant effusion) or stage
iv disease as defined by the ajcc criteria (see
appendix 1).*
Yes
No
karnofsky performance status 70% or higher (see
appendix 2).*
Yes
No
presence of at least one bidimensionally or
unidimensionally measurable, non-cns, indicator
lesion defined by radiologic study or physical
examination.*
Yes
No
no previous chemotherapy for advanced disease.
prior neoadjuvant or adjuvant chemotherapy, or
chemotherapy given concurrently with
radiotherapy for non-metastatic disease, is
allowed if the last dose was given 6 months or
more before study entry.*
Yes
No
patients with recurrent disease after primary
surgery and/or radiotherapy will be eligible.*
Yes
No
for patients with previous radiotherapy, the
indicator lesion(s) must not be within previous
radiation field. the last dose of radiotherapy
should be at least 3 weeks prior to study entry.
the total radiotherapy received should not be
more than 30% of the bone marrow.*
Yes
No
screening laboratory criteria:*
Yes
No
wbc count  > 3500/microl neutrophils  >
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2000/microl platelet count  > 100,000/microl
hemoglobin  > 9 g/dl (transfusion allowed)*
Yes
No
serum creatinine  < 133 micromol/l, or creatinine
clearance  > 30 ml/min, based on the cockcroft
formula (see section 5.1.1)*
Yes
No
bilirubin  < 1.5 x upper limit of normal alt/ast  < 2
x upper limit of normal if liver metastases are
absent < 5 x upper limit of normal if liver
metastases are present*
Yes
No
aged 18 years and above.*
Yes
No
life expectancy > 3 months.*
Yes
No
written informed consent.*
Yes
No
Exclusion Criteria
• patients with only evaluable disease.*
Yes
No
active uncontrolled infection.*
Yes
No
pregnant or lactating women.*
Yes
No
females of childbearing potential who are
unwilling to avoid pregnancy, for the duration of
the study.*
Yes
No
presence of any underlying medical conditions
which in the investigators opinion would make the
patient unsuitable for treatment.*
Yes
No
concomitant malignancies or previous
malignancies other than nsclc within the last 5
years, with the exception of adequately treated
basal or squamous cell carcinoma of the skin,
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Eligibility Non Small Cell Lung Cancer NCT00212043
carcinoma-in-situ of the cervix, or stage a low
grade prostate cancer.*
Yes
No
patients with cns and/or leptomeningeal
metastases; unless asymptomatic and not
receiving corticosteriod therapy.*
Yes
No
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Eligibility Non-Hodgkin's Lymphoma
NCT00133302
Study of Standard CHOP Versus Biweekly CHOP in
Aggressive Non-Hodgkin's Lymphoma (JCOG9809); ODM
derived from: https://clinicaltrials.gov/show/NCT00133302
All rights reserved. Please visit https://medical-data-
models.org/forms/14607
Eligibility Non-Hodgkin's Lymphoma
NCT00133302
Inclusion Criteria
intermediate- or high-grade non-hodgkin's
lymphoma, excluding cutaneous t-cell lymphoma
(ctcl), adult t-cell leukemia-lymphoma (atl) and t-
cell lymphoblastic lymphoma (t-lbl) (working
formulation)*
Yes
No
ann arbor stage: ii, iii, iv*
Yes
No
no prior chemotherapy or radiotherapy*
Yes
No
age: 15 to 69*
Yes
No
performance status (ps): 0, 1, 2*
Yes
No
wbc >= 3,000 /mm3, anc >= 1,200 /mm3, platelet
>= 75,000 /mm3*
Yes
No
got/gpt <= 5 x normal upper limit, t-bil <= 2.0
mg/dl*
Yes
No
creatinine <= 2.0 mg/dl*
Yes
No
normal ecg, ejection fraction >= 50%*
Yes
No
pao2 >= 65 mmhg*
Yes
No
written informed consent*
Yes
No
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Exclusion Criteria
uncontrollable diabetes mellitus*
Yes
No
severe complication (infection, heart failure, renal
failure, liver failure, etc)*
Yes
No
anamnesis of heart disease*
Yes
No
acute or chronic hepatitis,  liver cirrhosis and
portal hypertension*
Yes
No
synchronous or metachronous malignancy*
Yes
No
severe pulmonary dysfunction*
Yes
No
central nervous system (cns) invasion*
Yes
No
hiv positive*
Yes
No
hepatitis b surface antigen (hbs-ag) positive*
Yes
No
hepatitis c virus antibody (hcv-ab) positive*
Yes
No
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Eligibility Non-Hodgkin's Lymphoma NCT00133302
Eligibility Non-small Cell Lung Cancer
NCT00246181
Phase I and II Study Of Stereotactic Body Radiotherapy in
Medically Unresectable Patients With Stage 1 NSCLC;
ODM derived from:
https://clinicaltrials.gov/show/NCT00246181
All rights reserved. Please visit https://medical-data-
models.org/forms/14608
Eligibility Non-small Cell Lung
Cancer NCT00246181
Inclusion Criteria
consistent with most therapeutic oncology trials,
patients are not actively "recruited," but are
screened by their physician for appropriate
clinical trial(s) at the time of their routine clinic
visit.*
Yes
No
all patients must be willing and capable to provide
informed consent to participate in the protocol.*
Yes
No
eligible patients must have appropriate staging
studies identifying them as ajcc stage i (t1 or t2,
n0, m0) primary lung carcinoma. the patient
should not have direct evidence of regional or
distant metastases after appropriate staging
studies.  histologic confirmation will be required
by either biopsy or cytology.  the following primary
cancer types are eligible: squamous cell
carcinoma, adenocarcinoma, large cell
carcinoma, bronchioloalveolar cell carcinoma or
non-small cell; not otherwise specified.*
Yes
No
the primary tumor must be deemed technically
resectable by an experienced thoracic cancer
clinician, with a reasonable possibility of obtaining
a gross total resection with negative margins
(defined as a potentially curative resection, pcr);
however, the patient should have underlying
physiological medical problems that would
prohibit a pcr due to a low probability of tolerating
general anesthesia, the operation, the post-
operative recovery period, or the removal of
adjacent functioning lung.  standard "cut-off "
guidelines regarding surgical resection of nsclc
include the following: baseline fev1 <40%, post-
operative predicted fev1 <30%, severely reduced
diffusion capacity, baseline hypoxemia and/or
hypercapnia and exercise oxygen consumption
<50% predicted.*
Yes
No
patients who refuse a pcr due to preference,
ideology, emotional or psychological issues,
mental illness, or inability to give consent for the
pcr and who have no specific accepted medical
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contraindications for the pcr are not eligible.*
Yes
No
eligible patients should not have had previous
lung or mediastinal radiotherapy.*
Yes
No
there must be no plans for the patient to receive
other concomitant antineoplastic therapy while on
this protocol.  patients who have received
chemotherapy within 8 weeks of the start date of
study are ineligible.*
Yes
No
patients must be able to fit inside the stereotactic
body frame and able to undergo a ct or mri scan
in the frame.*
Yes
No
the patient's primary tumor must not be larger
than 7.0 cm in greatest dimension.*
Yes
No
patients with active systemic, pulmonary, or
pericardial infection are ineligible.*
Yes
No
pregnant or lactating women are ineligible.
women/men of reproductive potential may not
participate unless they agreed to use an effective
contraceptive method such as
condom/diaphragm and spermicidal foam,
intrauterine device (iud), or prescription birth
control pills.*
Yes
No
patients must be past their 18th birthday at time
of registration. karnofsky performance status >
60.*
Yes
No
Exclusion Criteria
see inclusion criteria.*
Yes
No
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Eligibility Non-Small-Cell Lung Cancer
NCT00913705
Neoadjuvant or Adjuvant Chemotherapy in Patients With
Operable Non-small-cell Lung Cancer; ODM derived from:
https://clinicaltrials.gov/show/NCT00913705
All rights reserved. Please visit https://medical-data-
models.org/forms/14609
Eligibility Non-Small-Cell Lung
Cancer NCT00913705
Inclusion Criteria
the patients eligible for the study are those with a
diagnosis, histologically or cytologically proven, of
nsclc without metastases at stages ib, iia, iib and
iiia (not n2) of the disease. patients with stage ia
and tumor size >2cm will be eligible as well.*
Yes
No
patients aged > 18 years.*
Yes
No
tumor considered resectable by the attending
surgeon.*
Yes
No
the patient must have an ecog *2 or karnofsky
>60%.*
Yes
No
the patients need to have adequate
hematological, renal and hepatic function defined
as:*
Yes
No
absolute neutrophil counts (anc*) *1.5 x 109/l
platelet counts *100 x 109/l total bilirubin *1.25 x
upper limit of normal distribution serum creatinine
<120 umol/l (<1.5 mg/dl) creatinine clearance
>60 ml/min*
Yes
No
anc = segmented neutrophils + banded
neutrophils*
Yes
No
the patients should have recovered from any
serious surgical sequellae.*
Yes
No
informed consent must be obtained from the
patient in accordance with the requirements of
the irb/ec.*
Yes
No
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if female, the patient must not be pregnant or
breast-feeding. women of child bearing potential
need to have a pregnancy test performed and to
take appropriate contraceptive action during the
period of the study.*
Yes
No
operability criteria: lung function test will be
performed so as to confirm a predictive
postoperative value of fev-1 >-800 ml, i.e. correct
homeostasis. a carbon monoxide diffusion test is
to be conducted and, when applicable, repeated
following the induction treatment while taking into
account the sensitivity of post-chemotherapy
pulmonary toxicity detection.*
Yes
No
Exclusion Criteria
patients who have previously been treated with
chemotherapy and/or radiotherapy.*
Yes
No
history of significant cardiovascular disease such
as non-controlled hypertension, unstable angina
or congestive heart failure even if these are
controlled by medication. documented history of
acute myocardial infarction in the previous year,
ventricular arrhythmias that required medication
or 2nd or 3rd atrial-ventricular blocks.*
Yes
No
pre-existing sensory or motor neurotoxicity grade
>2 based on the who criteria.*
Yes
No
active infection or other clinical state that could
seriously reduce the patient's capacity to tolerate
the treatment protocol, including previous allergic
reactions to products containing cremophor (e.g.
cyclosporin or vitamin k).*
Yes
No
previous or concomitant malignant tumor (with
the exception of in situ cervical carcinoma, baso-
cellular carcinoma, squamous cell skin carcinoma
or urothelial superficial carcinoma) which are
considered potentially curable with oncological
treatment and have a disease free survival (dfs)
greater than 5 years excepting breast cancer,
melanoma and hypernephroma*
Yes
2 / 3
Eligibility Non-Small-Cell Lung Cancer NCT00913705
No
marked psychoses or senility*
Yes
No
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Eligibility Non-Small-Cell Lung Cancer NCT00913705
Eligibility Obesity NCT00231660
A Study of the Efficacy and Safety of Topiramate in the
Treatment fo Obese, Type 2 Diabetic Patients Treated With
Metformin; ODM derived from:
https://clinicaltrials.gov/show/NCT00231660
All rights reserved. Please visit https://medical-data-
models.org/forms/14610
Eligibility Obesity NCT00231660
Inclusion Criteria
diagnosis of type 2 diabetes and receiving
metformin monotherapy for at least the previous 4
months and on a stable daily dose for at least 2
months prior to enrollment*
Yes
No
metformin total daily dose not to exceed 2.1
grams/day*
Yes
No
body mass index >= 27 and < 50*
Yes
No
hba1c < 11%*
Yes
No
fasting plasma glucose >= 126 and < 240*
Yes
No
stable weight*
Yes
No
female patients must be postmenopausal for at
least 1 year, surgically incapable of childbearing,
or practicing an acceptable method of
contraception (requires negative pregnancy test)*
Yes
No
Exclusion Criteria
known contraindication, or hypersensitivity to
topiramate*
Yes
No
use of other antidiabetic medications within the
last 4 months*
Yes
No
excessive weight loss*
Yes
No
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diagnosis of type 1 diabetes*
Yes
No
history of severe or recurrent hypoglycemic
episodes*
Yes
No
severe pulmonary disease*
Yes
No
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Eligibility Obesity NCT00231660
Eligibility Oral Cavity NCT00201279
Chemoprevention Study of Oral Cavity Squamous Cell
Carcinoma; ODM derived from:
https://clinicaltrials.gov/show/NCT00201279
All rights reserved. Please visit https://medical-data-
models.org/forms/14611
Eligibility Oral Cavity NCT00201279
Inclusion Criteria
clinically free of disease after having undergone
surgery for histologically confirmed primary scc of
the oral cavity(buccal mucosa +oral tongue )*
Yes
No
without any risk factor of recurrence listed below:*
Yes
No
nodal extracapsular spread of disease (ecs)*
Yes
No
number of positive node > 2*
Yes
No
perineural involvement*
Yes
No
lymphovascular emboli/permeation in resected
surgical specimen*
Yes
No
histologically positive surgical margins, but no
gross residual disease*
Yes
No
Exclusion Criteria
a kps of less than 50 percent*
Yes
No
serum creatinine and/or got/gpt greater than 2
times upper normal limit*
Yes
No
distant metastasis*
Yes
No
has previously received chemotherapy*
Yes
No
has received within the two years diagnosis of
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any cancer*
Yes
No
women of reproductive capacity*
Yes
No
cases beyond the age range of 20-65 years.*
Yes
No
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Eligibility Oral Cavity NCT00201279
Eligibility Osteoarthritis of the Knee
NCT00568295
A Four-Week Study Comparing Acetaminophen Extended
Release and Rofecoxib in the Treatment of Osteoarthritis of
the Knee; ODM derived from:
https://clinicaltrials.gov/show/NCT00568295
All rights reserved. Please visit https://medical-data-
models.org/forms/14612
Eligibility Osteoarthritis of the Knee
NCT00568295
Inclusion Criteria
symptomatic idiopathic osteoarthritis of the knee
for a minimum of six months duration requiring
treatment with either an analgesic or anti-
inflammatory agent on a regular basis (greater
than or equal to three days/week) for at least
three months.*
Yes
No
a history of osteoarthritis of the knee
characterized by pain of at least a moderate
intensity.*
Yes
No
demonstrated radiographic evidence of mild to
moderate osteoarthritis based on the kellgren
and lawrence radiographic entry criteria of grade
2 or 3 osteoarthritis.*
Yes
No
subjects' physical ability was to be either
american college of rheumatology (acr) function
class i or ii*
Yes
No
at the baseline visit, subjects must have reported
a maximum pain intensity experienced over the
previous 24 hours of at least moderate on a five-
point scale of none(0), mild(1), moderate(2),
moderately severe(3), or severe(4) in order to be
enrolled in the study.*
Yes
No
Exclusion Criteria
medical history, physical examinations, or
radiographs suggestive of other types of arthritis,
pseudogout, collagen vascular disease or
fibromyalgia.*
Yes
No
medical or psychiatric conditions that may
influence absorption, metabolism, or excretion of
the study medications or interfere with
interpretation of adverse reactions to the study
drug.*
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Yes
No
history of allergy, sensitivity, contraindication or
non-response to acetaminophen, rofecoxib, or
drugs classified as nsaids including aspirin.*
Yes
No
use of concomitant medications that might
interfere with study drug assessments, including
intra-articular corticosteroids.*
Yes
No
signs of active knee inflammation, morning
stiffness of greater than 30 minutes duration.*
Yes
No
rheumatoid factor quantitative value greater than
or equal to 40 iu/ml or a westergren erythrocyte
sedimentation rate greater than or equal to 40
mm/hour.*
Yes
No
acr functional class iii or iv, or unable to walk
without assistive devices.*
Yes
No
pregnancy, lactation, or expect to become
pregnant within one month of study completion.*
Yes
No
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Eligibility Osteoarthritis of the Knee NCT00568295
Eligibility Osteoarthritis, Knee
NCT00144820
Hyaluronan Versus NaCl 20 Ml Versus Placebo in Knee
Osteoarthritis; ODM derived from:
https://clinicaltrials.gov/show/NCT00144820
All rights reserved. Please visit https://medical-data-
models.org/forms/14613
Eligibility Osteoarthritis, Knee
NCT00144820
Inclusion Criteria
patients, men/women age > 60 years with
clinical,*
Yes
No
radiological and possible arthroscopical verified
knee osteoarthritis.*
Yes
No
knee pain on the day of examination scoring
more than 20 mm on a visual analogue scale
(vas) at baseline.*
Yes
No
Exclusion Criteria
age below 60*
Yes
No
unconsciousness*
Yes
No
psychosis*
Yes
No
demens*
Yes
No
ingestion of drugs that may influence the results
of the clinical examinations*
Yes
No
inflammatory diseases of the joints*
Yes
No
rheumatoid arthritis or other inflammatory arthritis
as diagnosed by american college of
rheumatology criteria*
Yes
No
contraindication to hyalgan treatment*
Yes
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No
previous intraarticular fracture of a knee joint*
Yes
No
infection or skin disease located at the place of
injection and invasive procedures done to the
knee joint within previous two months inclusive
intra-articular injections of steroids.*
Yes
No
any other condition that might interfere with the
efficacy assessment or completion of the trial.*
Yes
No
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Eligibility Osteoarthritis, Knee NCT00144820
Eligibility Parkinson Disease NCT00200512
Continued Efficacy of Apomorphine After Previous
Exposure of at Least Three Months; ODM derived from:
https://clinicaltrials.gov/show/NCT00200512
All rights reserved. Please visit https://medical-data-
models.org/forms/14614
Eligibility Parkinson Disease
NCT00200512
Inclusion Criteria
patients diagnosed with idiopathic parkinson's
disease and classified as stage ii-iv of the hoehn
and yahr scale for staging the severity of
parkinson's disease*
Yes
No
patients must have been on an optimally
maximized oral therapy regimen including
levodopa/decarboxylase inhibitors in either
immediate or delayed release forms, plus at least
one direct acting oral dopamine agonist for at
least 30 days prior to randomization*
Yes
No
patients must have been receiving apomorphine
subcutaneous injections for rescue therapy for
"off" events for at least three months with an
average dosing requirement of at least 2 doses
per day over the week prior to enrollment with a
dose of less than 11 mg*
Yes
No
Exclusion Criteria
patients under medical therapy for clinically
significant psychoses or dementia not related to
ingestion of antiparkinson medications.  (patients
with hallucinations or other central adverse
reactions associated solely with antiparkinson
medications were not excluded.)*
Yes
No
patients with a history of drug or alcohol
dependency within one year prior to study
enrollment*
Yes
No
patients with unstable and clinically significant
disease of cardiovascular (including orthostatic
hypotension), hematologic (including coombs'
positive hemolytic anemia), hepatic, renal,
metabolic, respiratory, gastrointestinal or
endocrinological systems or neoplasm within the
threemonths before the start of the study.*
Yes
No
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patients with a history of allergy or intolerance to
morphine or its derivatives, sulfur, sulfur
containing medication, sulfites, domperidone,
trimethobenzamide or other anticholinergics.*
Yes
No
patients treated with experimental agents (other
than apomorphine intermittent subcutaneous
injections) within 3 months before study entry,
experimental agents were defined on the basis of
the regulatory status in the country of patient
observation, or with other disallowed
medications*
Yes
No
patients whose apomorphine regimen was
characterized by continuous infusion or by
administration methods other than intermittent
subcutaneous injection.*
Yes
No
patients who could not or would not sign an
informed consent form.*
Yes
No
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Eligibility Parkinson Disease NCT00200512
Eligibility Parkinson Disease NCT00200512
Continued Efficacy of Apomorphine After Previous
Exposure of at Least Three Months; ODM derived from:
https://clinicaltrials.gov/show/NCT00200512
All rights reserved. Please visit https://medical-data-
models.org/forms/14615
Eligibility Parkinson Disease
NCT00200512
Inclusion Criteria
patients diagnosed with idiopathic parkinson's
disease and classified as stage ii-iv of the hoehn
and yahr scale for staging the severity of
parkinson's disease*
Yes
No
patients must have been on an optimally
maximized oral therapy regimen including
levodopa/decarboxylase inhibitors in either
immediate or delayed release forms, plus at least
one direct acting oral dopamine agonist for at
least 30 days prior to randomization*
Yes
No
patients must have been receiving apomorphine
subcutaneous injections for rescue therapy for
"off" events for at least three months with an
average dosing requirement of at least 2 doses
per day over the week prior to enrollment with a
dose of less than 11 mg*
Yes
No
Exclusion Criteria
patients under medical therapy for clinically
significant psychoses or dementia not related to
ingestion of antiparkinson medications.  (patients
with hallucinations or other central adverse
reactions associated solely with antiparkinson
medications were not excluded.)*
Yes
No
patients with a history of drug or alcohol
dependency within one year prior to study
enrollment*
Yes
No
patients with unstable and clinically significant
disease of cardiovascular (including orthostatic
hypotension), hematologic (including coombs'
positive hemolytic anemia), hepatic, renal,
metabolic, respiratory, gastrointestinal or
endocrinological systems or neoplasm within the
threemonths before the start of the study.*
Yes
No
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patients with a history of allergy or intolerance to
morphine or its derivatives, sulfur, sulfur
containing medication, sulfites, domperidone,
trimethobenzamide or other anticholinergics.*
Yes
No
patients treated with experimental agents (other
than apomorphine intermittent subcutaneous
injections) within 3 months before study entry,
experimental agents were defined on the basis of
the regulatory status in the country of patient
observation, or with other disallowed
medications*
Yes
No
patients whose apomorphine regimen was
characterized by continuous infusion or by
administration methods other than intermittent
subcutaneous injection.*
Yes
No
patients who could not or would not sign an
informed consent form.*
Yes
No
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Eligibility Parkinson's Disease
NCT00053625
Deep Brain Stimulation for Parkinson's Disease Trial; ODM
derived from: https://clinicaltrials.gov/show/NCT00053625
All rights reserved. Please visit https://medical-data-
models.org/forms/14616
Eligibility Parkinson's Disease
NCT00053625
Criteria
clinical diagnosis of idiopathic parkinson's
disease based on the presence of at least 2 of
the cardinal motor signs (akinesia/bradykinesia,
rigidity, tremor, and gait/balance disorder) and a
clear response to levodopa therapy.*
Yes
No
hoehn & yahr staging iii or worse "off " medication
periods.*
Yes
No
intractable, disabling motor fluctuations,
dyskinesias, or freezing episodes.*
Yes
No
unsatisfactory clinical response to maximal
medical management or previous surgical
treatment.*
Yes
No
stable on parkinson's medications for at least 30
days with total l-dopa equivalence varying no
more than +/- twenty percent during the 30 day
period.*
Yes
No
absence of cognitive, or psychiatric or other co-
morbidities that might interfere with the patient's
ability to understand and sign the informed
consent form.*
Yes
No
exclusion:*
Yes
No
clinically significant medical history that increases
pre- / post operative complications (cardiac or
pulmonary disease, uncontrolled hypertension,
diabetes…).*
Yes
No
secondary or atypical parkinsonism as suggested
by: i. history of stroke, encephalitis, exposure to
toxins or neuroleptics. ii. neurologic signs of
1 / 2
upper motor neuron or cerebella involvement,
supranuclear gaze palsy, or significant autonomic
dysfunction. iii. mri scan with evidence of
significant brain atrophy, lacunar infracts, or iron
deposits in the putamen.*
Yes
No
dementia as indicated by a mattis dementia rating
scale (drs) less than 116 or dsm-iv criterion for
dementia.*
Yes
No
clinically significant psychiatric disorder meeting
structured clinical interview for the dsm-iv criteria
for an active anxiety, depressive, or psychotic
disorder.*
Yes
No
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Eligibility Prostate Cancer NCT00005947
Vaccine Therapy in Treating Patients With Metastatic
Prostate Cancer That Has Not Responded to Hormone
Therapy; ODM derived from:
https://clinicaltrials.gov/show/NCT00005947
All rights reserved. Please visit https://medical-data-
models.org/forms/14617
Eligibility Prostate Cancer
NCT00005947
Criteria
metastatic disease as evidenced by soft tissue
and/or bony metastases.*
Yes
No
baseline psa value of at least 5 ng/ml.  all
subjects must have stable or rising psa.*
Yes
No
tumor progression after hormonal therapy.*
Yes
No
hormonal therapy consisting of castration by
orchiectomy or lhrh agonists for treatment of
prostate cancer.  castration levels of testosterone
(< 50 ng/dl) must be documented for all subjects
including subjects who underwent orchiectomy as
therapy for cancer of the prostate.*
Yes
No
a subject is eligible if he initially responded to
antiandrogen withdrawal (> 25% decrease in psa)
but at the time of registration demonstrated tumor
progression.  a subject is eligible if he failed to
respond to antiandrogen withdrawal.*
Yes
No
subjects have no cancer-related pain and do not
regularly require analgesics for cancer-related
pain.*
Yes
No
ecog performance status of 0 or 1.*
Yes
No
life expectancy of at least 16 weeks.*
Yes
No
adequate hematologic, renal, and liver function.*
Yes
No
exclusion criteria include:*
Yes
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No
visceral organ metastases (e.g., liver, lung, brain)
or cytologically positive effusions (e.g., pleural
effusions or ascites).*
Yes
No
metastatic disease expected to be in need of
radiation therapy within 4 months.*
Yes
No
concurrent therapy with experimental agents.*
Yes
No
systemic corticosteroids at doses greater than 40
mg hydrocortisone per day for any reason other
than treatment of prostate cancer within the
previous 6 months without prior approval.*
Yes
No
please note that there are additional eligibility
criteria. the study center will determine if you
meet all of the criteria.*
Yes
No
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Eligibility Prostate Cancer NCT00193193
Weekly Paclitaxel, Low-Dose Estramustine, and
Carboplatin in the Treatment of Hormone Refractory
Prostate Carcinoma; ODM derived from:
https://clinicaltrials.gov/show/NCT00193193
All rights reserved. Please visit https://medical-data-
models.org/forms/14618
Eligibility Prostate Cancer
NCT00193193
Inclusion Criteria
adenocarcinoma of the prostate not curable with
local treatment*
Yes
No
disease progression while receiving hormonal
therapy*
Yes
No
measurable or evaluable disease*
Yes
No
previous treatment with a maximum of one prior
chemotherapy regimen*
Yes
No
ecog performance status 0, 1, or 2.*
Yes
No
adequate bone marrow, liver and kidney function*
Yes
No
able to comprehend the nature of this study and
give written informed consent*
Yes
No
Exclusion Criteria
you cannot participate in this study if any of the
following apply to you:*
Yes
No
age < 18 years*
Yes
No
history of treatment for an invasive malignancy
within five years*
Yes
No
significant heart disease*
Yes
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No
please note:  there are additional
inclusion/exclusion criteria.  the study center will
determine if you meet all of the criteria.  if you do
not qualify for the trial, study personnel will
explain the reasons.  if you do qualify, study
personnel will explain the trial in detail and
answer any questions you may have.*
Yes
No
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Eligibility Stage I Adult Soft Tissue Sarcoma
NCT00896961
EF5 to Evaluate Tumor Hypoxia in Patients With High-
Grade Soft Tissue Sarcoma or Mouth Cancer; ODM
derived from: https://clinicaltrials.gov/show/NCT00896961
All rights reserved. Please visit https://medical-data-
models.org/forms/14619
Eligibility Stage I Adult Soft Tissue
Sarcoma NCT00896961
Inclusion Criteria
histologically confirmed high-grade soft tissue
sarcoma (sts) of the trunk or extremity or
squamous cell carcinoma of the oral cavity for
which surgical biopsy or resection is standard
initial therapy*
Yes
No
clinical imaging of mass that is likely to be sts or
squamous cell carcinoma of the head and neck
allowed if surgery is indicated prior to definitive
diagnosis*
Yes
No
planned resection and standard oncologic
treatment*
Yes
No
no known distant metastatic disease*
Yes
No
ecog 0-2*
Yes
No
wbc at least 2,000/mm^3*
Yes
No
platelet count at least 100,000/mm^3*
Yes
No
bilirubin less than 2.0 mg/dl*
Yes
No
creatinine less than 2.0 mg/dl or creatinine
clearance at least 50 ml/min*
Yes
No
no significant cardiac condition that would
preclude study compliance*
Yes
No
weight no greater than 130 kg*
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Yes
No
no grade iii or iv peripheral neuropathy*
Yes
No
no other medical condition that would preclude
study compliance*
Yes
No
not pregnant or nursing*
Yes
No
fertile patients must use effective contraception*
Yes
No
no chemotherapy within 3 months before planned
surgery*
Yes
No
preoperative radiotherapy allowed for sts*
Yes
No
no radiotherapy within 3 months before planned
surgery*
Yes
No
no other concurrent investigational agents*
Yes
No
2 / 2
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Eligibility Schizophrenia NCT00167362
Cognitive Enhancement Therapy for Early-Stage
Schizophrenia; ODM derived from:
https://clinicaltrials.gov/show/NCT00167362
All rights reserved. Please visit https://medical-data-
models.org/forms/14620
Eligibility Schizophrenia
NCT00167362
Inclusion Criteria
DSM-IV diagnosis of schizophrenia,
schizoaffective or schizophreniform disorder at
the time of initial assessment*
Yes
No
pre-treatment illness duration an average of 5
years, not to exceed 8 years*
Yes
No
stable positive symptoms (e.g., if present do not
grossly interfere with behavior such as command
hallucinations or delusions)*
Yes
No
currently maintained and compliant with
prescribed antipsychotic medication*
Yes
No
socially and cognitively disabled, e.g., meet
criteria on a cognitive style scale (score greater
than or equal to 7), and social cognition disability
scale (score greater than or equal to 12).*
Yes
No
Exclusion Criteria
alcohol/drug abuse or dependence that has
significantly interfered with adjustment in the past
two months (e.g., patients currently undergoing d
and a treatment must successfully complete their
recovery program prior to referral)*
Yes
No
organic brain syndrome, including hiv illness (due
to its effect on cns function)*
Yes
No
IQ below 80 or language skills below the sixth
grade level*
Yes
No
medical contraindications that preclude an
appropriate antipsychotic medication*
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Yes
No
persistent suicidality*
Yes
No
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Eligibility Schizophrenia NCT00159133
Prodrome-Based Early Intervention With Antipsychotics vs.
Benzodiazepines in First-Episode Schizophrenia; ODM
derived from: https://clinicaltrials.gov/show/NCT00159133
All rights reserved. Please visit https://medical-data-
models.org/forms/14621
Eligibility Schizophrenia
NCT00159133
Inclusion Criteria
first-episode in schizophrenia (according icd-10
f20)*
Yes
No
age between 18 and 55*
Yes
No
informed consent*
Yes
No
one year neuroleptic maintenance treatment*
Yes
No
Exclusion Criteria
residence outside of the catchment area*
Yes
No
legal reasons*
Yes
No
insufficient knowledge of the german language*
Yes
No
substance abuse or addiction*
Yes
No
pregnancy*
Yes
No
serious physical illness*
Yes
No
organic brain disease*
Yes
No
contraindication to neuroleptic treatment*
Yes
No
1 / 1
Eligibility Schizophrenia NCT00069433
Enhancing the Outcome of Skills Training for People With
Schizophrenia; ODM derived from:
https://clinicaltrials.gov/show/NCT00069433
All rights reserved. Please visit https://medical-data-
models.org/forms/14622
Eligibility Schizophrenia
NCT00069433
Inclusion Criteria
diagnosis of schizophrenia or schizoaffective
disorder for > 5 years*
Yes
No
use of stable dose risperidone, olanzapine, or
quetiapine for at least 1 month with no planned
medication changes*
Yes
No
social behavior scale (sbs) score > 45*
Yes
No
willing and able to provide informed consent*
Yes
No
Exclusion Criteria
intelligence quotient < 70*
Yes
No
use of more than one antipsychotic medication*
Yes
No
use of benzodiazepines, tricyclic antidepressants,
or anticholinergic medication commonly used to
treat extrapyramidal symptoms*
Yes
No
diagnostic and statistical manual (dsm)-iv criteria
for alcohol or other substance dependence*
Yes
No
history of any traumatic brain injury leading to
loss of consciousness for > 30 minutes*
Yes
No
diagnosis of a comorbid medical condition that
could interfere with antipsychotic medication
treatment or the ability to complete the study*
Yes
No
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Eligibility Schizophrenia NCT00056498
Risperidone Treatment in Schizophrenia Patients Who Are
Currently Taking Clozapine; ODM derived from:
https://clinicaltrials.gov/show/NCT00056498
All rights reserved. Please visit https://medical-data-
models.org/forms/14623
Eligibility Schizophrenia
NCT00056498
Inclusion Criteria
dsm-iv criteria for schizophrenia or
schizoaffective disorder*
Yes
No
current clozapine treatment*
Yes
No
moderate illness severity and inadequate positive
symptom response to clozapine treatment*
Yes
No
6 month period of clozapine treatment with
documented clozapine blood level greater than or
equal to 350 ng/ml or clozapine and norclozapine
blood level greater than or equal to 450 ng/ml*
Yes
No
Exclusion Criteria
organic brain disorder*
Yes
No
mental retardation*
Yes
No
medical condition whose pathology or treatment
could alter the presentation or treatment of
schizophrenia or significantly increase the risk
associated with the proposed treatment protocol*
Yes
No
pregnancy*
Yes
No
dsm-iv criteria for current alcohol or substance
dependence within the last 6 months or dsm-iv
criteria for alcohol or substance abuse within the
last month*
Yes
No
previously received adjunctive risperidone (at
doses greater than or equal to 8 mg/day) with
1 / 2
their clozapine treatment for greater than or equal
to 6 weeks*
Yes
No
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Eligibility Schizophrenia NCT00044655
Switching Medication to Treat Schizophrenia; ODM derived
from: https://clinicaltrials.gov/show/NCT00044655
All rights reserved. Please visit https://medical-data-
models.org/forms/14624
Eligibility Schizophrenia
NCT00044655
Inclusion Criteria
scid diagnosis of schizophrenia or schizoaffective
disorder*
Yes
No
partially remitted outpatients, defined as persons
who have received clear symptomatic benefit
from antipsychotic medication but remain
symptomatic (due to lack of efficacy or inability to
tolerate an efficacious dose) or suffer significant
side effects*
Yes
No
treatment with antipsychotic medications for at
least 2 months*
Yes
No
received at least 1 outpatient mental health
service every 3 months for the past 6 months*
Yes
No
Exclusion Criteria
severe symptoms or side effects that indicate the
necessity for a medication change*
Yes
No
currently taking 3 or more antipsychotic
medications for ongoing daily administration (prn
medications and mood stabilizers are allowable)*
Yes
No
treatment with clozapine*
Yes
No
one or more nights spent in a psychiatric
hospitalization within the past 3 months*
Yes
No
received services from a crisis intervention
program within the past 3 months*
Yes
No
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require placement in a skilled nursing facility as a
result of a physical condition or disability*
Yes
No
criminal charges pending  (once charges clear,
the person will be considered)*
Yes
No
pregnant or breast feeding*
Yes
No
contraindication to any of the medications to
which the patient might be assigned*
Yes
No
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Eligibility Psychosis, Schizophrenia
NCT00272584
CARE Study: Improving Treatment for the Most Severely Ill
With Schizophrenia; ODM derived from:
https://clinicaltrials.gov/show/NCT00272584
All rights reserved. Please visit https://medical-data-
models.org/forms/14625
Eligibility Psychosis, Schizophrenia
NCT00272584
Inclusion Criteria
subjects treated with clozapine for the indication
of poor response to other antipsychotic
medications.*
Yes
No
treatment with clozapine is at a stable dose for at
least 12 weeks. dose must be 400 mg/day or
more, unless side effects limited increase of
dose.*
Yes
No
Exclusion Criteria
subjects with significant alcohol or substance
abuse in the past 3 months.*
Yes
No
subjects with a previous trial of risperidone
augmentation of clozapine*
Yes
No
subjects who are pregnant, breast-feeding, or
women of child-bearing potential not using
adequate contraception*
Yes
No
subjects requiring treatment with
anticonvulsants.*
Yes
No
subjects with known hypersensitivity or allergy to
risperidone.*
Yes
No
subjects with hematological or other
contraindications to continued clozapine
treatment.*
Yes
No
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Eligibility Advanced Breast Cancer
NCT00387907
Study of Larotaxel in Combination With Weekly Herceptin®
in Patients With HER2 Positive Metastatic Breast Cancer;
ODM derived from:
https://clinicaltrials.gov/show/NCT00387907
All rights reserved. Please visit https://medical-data-
models.org/forms/14626
Eligibility Advanced Breast Cancer
NCT00387907
Inclusion Criteria
diagnosis of breast cancer*
Yes
No
evidence that cancer has spread beyond its
original location or has come back and cannot be
removed by surgery*
Yes
No
no more than one prior treatment for advanced
disease*
Yes
No
her2 positive status*
Yes
No
adequate liver and kidney function*
Yes
No
no remaining severe harmful effects to prior
treatments*
Yes
No
Exclusion Criteria
certain heart condition*
Yes
No
pregnant women*
Yes
No
history of another cancer except some skin
cancers and cervical cancer*
Yes
No
taking other treatments for your cancer at the
time you enter the trial*
Yes
No
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Eligibility Advanced Breast Cancer
NCT01927081
Self-management Interventions for Advanced Breast
Cancer; ODM derived from:
https://clinicaltrials.gov/show/NCT01927081
All rights reserved. Please visit https://medical-data-
models.org/forms/14627
Eligibility Advanced Breast Cancer
NCT01927081
Inclusion Criteria
diagnosis of stage iv breast cancer or recurrent
metatastic breast cancer*
Yes
No
receiving care at duke cancer institute*
Yes
No
life expectancy ≥9 months as estimated by the
treating oncologist*
Yes
No
speak and read english*
Yes
No
be at least age 18*
Yes
No
be able to travel to the duke cancer institute*
Yes
No
Exclusion Criteria
cognitive impairment as assessed by the 6-item
mini-mental status exam,*
Yes
No
karnofsky performance rating of <60 as rated by
the oncology provider,  an ecog rating of 0-2*
Yes
No
treatment for serious psychiatric illness (e.g.,
schizophrenia, severe depression) in the past 6
months*
Yes
No
currently engaged in yoga practice ≥ 1 day per
week*
Yes
No
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Eligibility Advanced Solid Malignancies
NCT01588548
Global Phase1 Study to Assess the Safety and Tolerability
of AZD1208 in Advanced Solid Tumors and Malignant
Lymphoma; ODM derived from:
https://clinicaltrials.gov/show/NCT01588548
All rights reserved. Please visit https://medical-data-
models.org/forms/14628
Eligibility Advanced Solid
Malignancies NCT01588548
Inclusion Criteria
patients who have signed this written informed
consent form after a full explanation about the
participation in this study*
Yes
No
patients aged 18 years or older patients
diagnosed with a solid malignant tumour or
malignant lymphoma that is refractory to standard
therapies or for which no standard therapies
exist*
Yes
No
patients with good physical conditions (you can
walk and can look after yourself) within the last 2
weeks.*
Yes
No
patients who have at least one lesion that can be
accurately assessed*
Yes
No
Exclusion Criteria
patients who have recently received or are
receiving prohibited medications or treatments*
Yes
No
patients who have any unresolved side effects of
previous treatments*
Yes
No
patients who have spinal cord compression or
brain metastases*
Yes
No
patients who have severe systemic diseases
(e.g., uncontrolled hypertension, hepatitis b,
hepatitis c and human immunodeficiency virus
[hiv] infection)*
Yes
No
patients with significant abnormal ecg findings*
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Yes
No
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Eligibility Advanced Non Small Cell Lung
Cancer NCT00072631
Erlotinib (Tarceva (Trademark), OSI-774) in Treating
Patients With Advanced Non-Small Cell Lung Cancer;
ODM derived from:
https://clinicaltrials.gov/show/NCT00072631
All rights reserved. Please visit https://medical-data-
models.org/forms/14629
Eligibility Advanced Non Small Cell
Lung Cancer NCT00072631
Inclusion Criteria
confirmed diagnosis of stage iiib or iv non-small
cell lung cancer (histological or cytological).*
Yes
No
received prior chemotherapy treatment for
advanced, metastatic non-small cell lung cancer.*
Yes
No
measurable disease per recist criteria.*
Yes
No
adequate bone marrow, hepatic and renal
function.*
Yes
No
Exclusion Criteria
breast cancer or skin cancer at any time in the
past or any other cancer in the past 5 years.*
Yes
No
brain metastases that are unstable, require
steroids, are life-threatening or required radiation
in the last 28 days.*
Yes
No
known hypersensitivity to minocycline*
Yes
No
history of serious cardiac disease that is not
controlled*
Yes
No
serious eye conditions*
Yes
No
prior treatment with inhibitors of egfr of any kind.*
Yes
No
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Eligibility Advanced EGFRm (Del 19 or
L858R +/- T790M) NSCLC NCT02297425
A Study For Patients With EGFRm (Epidermal Growth
Factor Receptor Mutant) Lung Cancer; ODM derived from:
https://clinicaltrials.gov/show/NCT02297425
All rights reserved. Please visit https://medical-data-
models.org/forms/14630
Eligibility Advanced EGFRm (Del 19
or L858R +/- T790M) NSCLC
NCT02297425
Inclusion Criteria
evidence of histological or cytologically confirmed
diagnosis of locally advanced or metastatic egfrm
(del19 or l858r) nsclc that is resistant to standard
therapy. patients must have progressed on
treatment with an egfr tki, and may have also
received other line of therapy.*
Yes
No
tissue available (formalin fixed paraffin embedded
(ffpe) block or 10 unstained sections (5 micron)*
Yes
No
patients must be willing to participate in additional
pk studies as required (cohort dependent);
patients will be informed of which pk studies are
required prior to consenting for study
participation*
Yes
No
adequate bone marrow function (complete blood
count laboratory test results)*
Yes
No
adequate liver function (laboratory test)*
Yes
No
Exclusion Criteria
previously diagnosed brain metastases, unless
the patient has completed their treatment and
has recovered from the acute effects of radiation
therapy or surgery prior to the study registration,
have discontinued corticosteroid treatment for
these metastases for at least 2 weeks and are
neurologically stable*
Yes
No
systemic anti-cancer therapy within 4 weeks of
starting study treatment excluding egfr tkis.
patients on egfr tkis must discontinue the agent
for a minimum of 5 days prior to starting study
drug*
Yes
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No
hypertension that cannot be controlled by
medication (150/100 mmhg despite optimal
medical therapy).*
Yes
No
2 / 2
Eligibility Advanced EGFRm (Del 19 or L858R +/- T790M) NSCLC
NCT02297425
Checklist Kidney Transplant Urology Department
Transplant Center Clinic Bremen-Mitte
Item used as routine documentation by Clinic Bremen-
Mitte, Urology Department, Kidney transplant.  ODM
derived from form “C H E C K L I S T E - Untersuchungen
zur Transplantationsanmeldung” Number TPLF006, Version
3, Transplant Center Bremen, Clinic Bremen-Mitte gGmbH
28177 Bremen, Germany.
All rights reserved. Please visit https://medical-data-
models.org/forms/14632
Checklist- Examinations for the
registration of transplant
Untersuchungen zur
Transplantationsanmeldung
Datum Rö.-Thorax
Beurteilung Rö.-Thorax
o.B.  (1)
patholog. (2)
Datum Rö.-Beckenübersicht
Beurteilung Rö.-Beckenübersicht
o.B.  (1)
patholog. (2)
Datum Nierenblasenübersicht
Beurteilung Nierenblasenübersicht
o.B.  (1)
patholog. (2)
Datum Miktionszystogramm (MCU)
Beurteilung Miktionszystogramm (MCU)
o.B.  (1)
patholog. (2)
Datum CT
Beurteilung CT
o.B.  (1)
patholog. (2)
Datum arterielle Angiographie
Beurteilung arterielle Angiographie
o.B.  (1)
patholog. (2)
Datum USG Abdomen
Beurteilung USG Abdomen
o.B.  (1)
patholog. (2)
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Datum Laboruntersuchungen
Beurteilung Laboruntersuchungen
o.B.  (1)
patholog. (2)
Datum Virologie
Beurteilung Virologie
o.B.  (1)
patholog. (2)
Datum Hepatitis-B-Impfung
Beurteilung Hepatitis-B-Impfung
o.B.  (1)
patholog. (2)
Datum EKG
Beurteilung EKG
o.B.  (1)
patholog. (2)
Datum Echokardiographie
Beurteilung Echokardiographie
o.B.  (1)
patholog. (2)
Datum Belastungs-EKG
Beurteilung Belastungs-EKG
o.B.  (1)
patholog. (2)
Datum Coronarangiographie
Beurteilung Coronarangiographie
o.B.  (1)
patholog. (2)
Datum Urologe
Beurteilung Urologe
o.B.  (1)
patholog. (2)
Datum Urethro-Zystoskopie
Beurteilung Urethro-Zystoskopie
o.B.  (1)
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patholog. (2)
Datum retrograde Ureterographien li./re.
Beurteilung retrograde Ureterographien li./re.
o.B.  (1)
patholog. (2)
Datum Spülzytologien li./re.
Beurteilung Spülzytologien li./re.
o.B.  (1)
patholog. (2)
Datum Augenarzt
Beurteilung Augenarzt
o.B.  (1)
patholog. (2)
Datum Gynäkologe
Beurteilung Gynäkologe
o.B.  (1)
patholog. (2)
Datum Dermatologe
Beurteilung Dermatologe
o.B.  (1)
patholog. (2)
Datum HNO-Arzt
Beurteilung HNO-Arzt
o.B.  (1)
patholog. (2)
Datum Zahnarzt
Beurteilung Zahnarzt
o.B.  (1)
patholog. (2)
Datum Carotisdoppler
Beurteilung Carotisdoppler
o.B.  (1)
patholog. (2)
Datum Lungenfunktionsprüfung
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Beurteilung Lungenfunktionsprüfung
o.B.  (1)
patholog. (2)
Datum Gastroskopie
Beurteilung Gastroskopie
o.B.  (1)
patholog. (2)
Datum Coloskopie/Colon-Kontrasteinlauf
Beurteilung Coloskopie/Colon-Kontrasteinlauf
o.B.  (1)
patholog. (2)
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Registration Form Kidney Transplant Urology
Department Transplant Center Clinic Bremen-Mitte
Item used as routine documentation by Clinic Bremen-
Mitte, Urology Department, Kidney transplant.  ODM
derived from form “Anmdeldebogen- NTx” Number
TPLF006, Version 3, Transplant Center Bremen, Clinic
Bremen-Mitte gGmbH 28177 Bremen, Germany.
Investigations before registering for kidney transplant
(Application with medical report and Epicrisis)
1. Obligatory examinations
1.1. Imaging techniques
- Chest X-ray in two planes
(Finding and image)
- X- ray pelvis overview (without gonad protection in
females)
(Finding and image)
- Abdominal ultrasonography (liver, gall bladder, kidney
own, aorta)
1.2. Consultation and additional examinations
- Ophthalmologist
- Gynecologist
- Dermatologist
- Otolaryngologist
- Dentist
- Urologist: Uroflow (rest precipitation> 500 mL / d),
residual urine, sediment, urine culture, Prostate palpation
and PSA determination aged 30 and older
- Cardiologist: ECG (Original / Copy)
1.3. Laboratory tests
Blood count, electrolytes, urea, creatinine, uric acid, iPTH,
inorg. Phosphate, alkaline phosphatase, GGT, ALT, AST,
LDH, total Bilirubin, total Protein, fasting blood sugar level,
basal C-peptide and HbA1c  (In all diabetics), triglycerides,
cholesterol, BSG, BM-Test Colon albumin (3x), 55 years
and older colonoscopy (according to current guideline)
1.4. Virology
- Hepatitis (HBsAg, HBcAK, HBsAK, HCV antibodies)
- HIV (1 and 2), CMV, EBV, VZV
1.5. Hepatitis B vaccination (with antibody detection)
2. Selective indicated examinations
2.1. Imaging tests
- Abdominal CT by cystic kidneys, tumors in the History,
Analgesic nephropathy       
- Coronary angiography by cardiac risk, by diabetics
- Arterial angiography by PAD, pelvic vascular sclerosis in
pelvic x- ray
- Colonoscopy / Colon contrast enema with diverticulosis
- CT abdomen on spec diverticulitis
- Voiding cystourethrogram  (VCUG) at Pyelonephritis-,
urinary tract infection or stone in the urinary tract , unclear
etiology of renal insufficiency
- Urethro cystoscopy, retrograde Urethrography left/ right
and
Bladder irrigation left/ right Analgesic nephropathy or
hematuria
- Kidney bladder overview by medical history of kidney
stone
2.2. Other examinations
- Echocardiography, exercise ECG by aged 50 and older
and by all diabetics
- Gastroscopy at ulcer anamnesis
- Lung function tests only if indicated (all smokers)
- Carotid Doppler by flow noise or cerebral circulatory
disorder
All rights reserved. Please visit https://medical-data-
models.org/forms/14633
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PERSÖNLICHE ANGABEN
Anschrift:
Beruf:
Arbeitgeber:
Telefon (tags/nachts/sonstige):
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Krankenkasse:
Status:
M (1)
F (2)
R (3)
Mitgliedsnummer:
Dialysezentrum:
Tel.:
betreuender Arzt:
Tel.:
Nierentransplantation
Verstorbenennieren-TX_ (1)
Lebend-TX (2)
Nierentransplantation
1. Tx (1)
2. Tx (2)
Datum  Anmeldung
Diagnose
renale Grundkrankheit:
histologische Sicherung:
Ja
Nein
histologische Sicherung durchgeführt am:
weitere Diagnosen:
Therapie
Datum der ersten Dialyse:
Dialyseart:
Acetat-HD (1)
Bicarb.-HD (2)
HF (3)
CAPD (4)
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Dialysedauer:
Dialysetage:
Shunt:
Shuntkomplikationen:
Restdiurese:
ml/24 h
Trockengewicht:
kg
Größe:
cm
Dialysespezifische Probleme:
Medikamente:
Anamnestische Angaben
Med. Anamnese:  (FA, EA, Nierenerkrankungen,
Hochdruck-, kardiopulmonale, gastrointestinale,
endokrinologische, vaskulär-cerebrale
Komplikationen, Infektionskrankheiten, OPs, etc.)
Allergien:
Soziale und psychologische Anamnese (geistige
Gesamtsituation, Kooperationsbereitschaft,
Familienstand, Kinder, beruflich-soziale Situation,
etc.)
Nikotinkonsum:
/d
Alkohol-/Medikamentenabusus:
Klinische Beurteilung
Allgemeinzustand
RR:
mmHg
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Herzfrequenz:
/min
Herzrhythmus
Perkussions- und Auskultationsbefund von Lunge
und Thorax
Perkussions- und Auskultationsbefund des
Abdomens
1. BM-Test-Colon:
positiv (1)
negativ (2)
2. BM-Test-Colon:
positiv (1)
negativ (2)
3. BM-Test-Colon:   (ab 55 Jahre stattdessen
Koloskopie, gemäß akt.Leitlinie)
positiv (1)
negativ (2)
Palpations- und Auskultationsbefund A. carotis
re.:
positiv (1)
negativ (2)
Palpations- und Auskultationsbefund A. carotis li.:
positiv (1)
negativ (2)
Palpations- und Auskultationsbefund A. femoralis
re.:
positiv (1)
negativ (2)
Palpations- und Auskultationsbefund A. femoralis
li.:
positiv (1)
negativ (2)
Palpations- und Auskultationsbefund A. poplitea
re.:
positiv (1)
negativ (2)
Palpations- und Auskultationsbefund A. poplitea
li.:
positiv (1)
negativ (2)
Palpations- und Auskultationsbefund A. tibialis
re.:
positiv (1)
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negativ (2)
Palpations- und Auskultationsbefund A. tibialis  li.:
positiv (1)
negativ (2)
Palpations- und Auskultationsbefund A. dorsalis
pedis   re.:
positiv (1)
negativ (2)
Palpations- und Auskultationsbefund A. dorsalis
pedis  li.:
positiv (1)
negativ (2)
Immunologische Angaben
Blutgruppe (bitte den Blutgruppenschein
beifügen)
Bluttransfusionen
Zeitraum:
Anzahl:
Erykonzentrat:
Ja
Nein
Vollblut:
Ja
Nein
FFP:
Ja
Nein
Organtransplantationen:
Ja
Nein
Zentrum
Jahr
ET-Nummer
Antikörper bekannt:
Ja
Nein
welche:
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Schwangerschaften:
Ja
Nein
wann:
Hinweise für das Vorliegen einer
Autoimmunerkrankung:
Ja
Nein
welche:
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Eligibility Atrial Fibrillation NCT02071680
Autonomic Innervation and MIBG Imaging; ODM derived
from: https://clinicaltrials.gov/show/NCT02071680
All rights reserved. Please visit https://medical-data-
models.org/forms/14634
Eligibility Atrial Fibrillation
NCT02071680
Inclusion Criteria
age 18-80 years.*
Yes
No
symptoms including one or more of the following:
palpitations, shortness of breath, dizziness,
presyncope or syncope, chest pain, tiredness or
lack of energy.*
Yes
No
failure of beta-blockers or at least one
antiarrhythmic agent other than amiodarone to
prevent af.  in those patients who are not eligible
to antiarrhythmic agents other than amiodarone,
patients may choose to undergo catheter ablation
rather than starting amiodarone.*
Yes
No
paroxysmal (self-terminating af within 7 days) or
persistent af (requiring an intervention to
terminate or lasting more than 7 days).*
Yes
No
Exclusion Criteria
intracardiac thrombus as determined by
transesophageal echocardiography*
Yes
No
class iii or iv congestive heart failure*
Yes
No
persistent af duration of more than 3 years*
Yes
No
myocardial infarction within the last 6 months*
Yes
No
left atrial size of greater than 55 mm determined
by 2d echocardiogram*
Yes
No
inability to undergo a transesophageal
1 / 2
echocardiogram or cardiac ct*
Yes
No
inability to undergo d-spect™ imaging*
Yes
No
inability to take warfarin or the new oral
anticoagulants*
Yes
No
previously received 123i-mibg or 131i-mibg*
Yes
No
history or suspicion of significant allergic reaction
or anaphylaxis to iodine or iodinated imaging
agents*
Yes
No
use of medications for non-cardiac medical
conditions that are known to interfere with 123i-
mibg uptake and these medications cannot be
safely withheld for at least 24 hours before study
procedures*
Yes
No
diagnosis of or signs or symptoms of a neurologic
disease such as parkinson's disease, multiple
systems atrophy or parkinsonian syndromes, or
other diseases known to affect the sympathetic
nervous system*
Yes
No
pregnancy as determined by a pre-procedure
pregnancy tests*
Yes
No
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Eligibility Atrial Fibrillation NCT02168829
Optimal Anticoagulation for Higher Risk Patients Post-
Catheter Ablation for Atrial Fibrillation Trial; ODM derived
from: https://clinicaltrials.gov/show/NCT02168829
All rights reserved. Please visit https://medical-data-
models.org/forms/14635
Eligibility Atrial Fibrillation
NCT02168829
Inclusion Criteria
at  least  one  year  post-successful  catheter
ablation  for  af  or  left  atrial arrhythmia.
successful af ablation is defined as no af/afl/at
>30 seconds on any pre-enrolment monitoring*
Yes
No
chads2 risk score of 1 or more. patients with
chads2 score of 0, but who are >65 years old, or
who are female with vascular disease will also be
included*
Yes
No
> 18 years of age*
Yes
No
Exclusion Criteria
does not meet all of the above listed inclusion
criteria.*
Yes
No
unable or unwilling to provide informed consent.*
Yes
No
included in another clinical trial*
Yes
No
gfr < 30 ml/min*
Yes
No
contraindication to oral anticoagulation (oac)*
Yes
No
metallic prosthetic heart valve*
Yes
No
non-arrhythmic condition necessitating long-term
oac*
Yes
No
stroke within one year prior to enrolment*
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Yes
No
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Eligibility Atrial Fibrillation NCT02251509
Rate Control in Atrial Fibrillation: A Randomized, Double-
Blind, Crossover Comparison of Carvedilol and Metoprolol
Tartrate; ODM derived from:
https://clinicaltrials.gov/show/NCT02251509
All rights reserved. Please visit https://medical-data-
models.org/forms/14637
Eligibility Atrial Fibrillation
NCT02251509
Inclusion Criteria
permanent atrial fibrillation*
Yes
No
baseline ventricular rate (prior to treatment) > 110
bpm*
Yes
No
Exclusion Criteria
history of accessory tract re-entry tachycardia*
Yes
No
ejection fraction < 35% or history of nyha class
iii/iv stage c/d heart failure*
Yes
No
acute coronary syndrome, percutaneous
coronary intervention, or cardiac surgery in the
past 2 months*
Yes
No
child-pugh class b or c hepatic dysfunction*
Yes
No
uncontrolled hypertension*
Yes
No
thyroid disease*
Yes
No
intolerance to beta-blockers*
Yes
No
history of lung disease resulting in hospitalization
in the past year*
Yes
No
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Eligibility Atrial Fibrillation NCT02271152
FAST Mapping During Atrial Fibrillation; ODM derived from:
https://clinicaltrials.gov/show/NCT02271152
All rights reserved. Please visit https://medical-data-
models.org/forms/14638
Eligibility Atrial Fibrillation
NCT02271152
Inclusion Criteria
all patients must be over the age 18 and have a
clinical indication for their first catheter ablation of
af because of symptomatic af.*
Yes
No
this will include patients with either high burden
paroxysmal (>4 self-terminating episodes of af
within the last 6 months with two episodes lasting
at least 6 hours within the last year) or persistent
af (lasting ≥7 days, but which can still be
converted to sinus rhythm).*
Yes
No
Exclusion Criteria
long-standing persistent af (ie. af which cannot be
converted to sinus rhythm, or where multiple
attempts at restoring sinus rhythm have failed)*
Yes
No
rheumatic valvular disease*
Yes
No
hypertrophic cardiomyopathy*
Yes
No
uncorrected cardiac shunts (eg. secundum asd)*
Yes
No
severe mitral regurgitation or mechanical mitral
valve*
Yes
No
left atrial size >55 mm (echo derived parasternal
long axis view).*
Yes
No
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Early Childhood Speech and Language Assessment -
Speech and Language Assessment Scale PhenX Toolkit
The Speech and Language Assessment Scale (SLAS) is a
19-item, parent-report questionnaire designed to identify
children with delayed speech and language skills. The
SLAS uses seven-point Likert-style questions to assess six
subscales: assertiveness, responsiveness, semantics,
syntax, articulation, and talkativeness. The protocol
includes instructions to generate composite scale scores.
ODM derived from: https://cde.nlm.nih.gov
Primary source: https://www.phenxtoolkit.org/
Recent publication: Hendershot, T., Pan, H., Haines, J.,
Harlan, W.R., Marazita, M.L., McCarty, C.A., Ramos, E.M.,
and Hamilton, C.M. (2015) Using the PhenX toolkit to add
standard measures to a study. Curr. Protoc. Hum. Genet.
86:1.21.1-1.21.17. doi: 10.1002/0471142905.hg0121s86
Permission to publish granted by
Carol M. Hamilton.
All rights reserved. Please visit https://medical-data-
models.org/forms/14640
Early Childhood Speech and
Language Assessment - Speech and
Language Assessment Scale PhenX
Toolkit
PhenX - early childhood speech and
language assessment protocol - speech
and language assessment scale
My child's ability to ask questions properly is:
Very low (1)
2 (2)
3 (3)
Normal for age (4)
5 (5)
6 (6)
Very high (7)
My child's ability to answer questions properly is:
Very low (1)
2 (2)
3 (3)
Normal for age (4)
5 (5)
6 (6)
Very high (7)
My child's ability to understand what others say to
him/her is:
Very low (1)
2 (2)
3 (3)
Normal for age (4)
5 (5)
6 (6)
Very high (7)
My child's ability to say sentences clearly enough
to be understood by strangers is:
Very low (1)
2 (2)
3 (3)
Normal for age (4)
5 (5)
6 (6)
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Very high (7)
The number of words my child knows is:
Very low (1)
2 (2)
3 (3)
Normal for age (4)
5 (5)
6 (6)
Very high (7)
My child's ability to use his/her words correctly is:
Very low (1)
2 (2)
3 (3)
Normal for age (4)
5 (5)
6 (6)
Very high (7)
My child's ability to get his/her messages across
to others when talking is:
Very low (1)
2 (2)
3 (3)
Normal for age (4)
5 (5)
6 (6)
Very high (7)
My child's ability to understand directions spoken
to him/her is:
Very low (1)
2 (2)
3 (3)
Normal for age (4)
5 (5)
6 (6)
Very high (7)
My child's ability to follow directions spoken to
him/her is:
Very low (1)
2 (2)
3 (3)
Normal for age (4)
5 (5)
6 (6)
Very high (7)
My child's ability to use the proper words when
talking to others is:
Very low (1)
2 (2)
3 (3)
Normal for age (4)
5 (5)
6 (6)
Very high (7)
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My child's ability to get what he/she wants by
talking is:
Very low (1)
2 (2)
3 (3)
Normal for age (4)
5 (5)
6 (6)
Very high (7)
My child's ability to start a conversation, or start
talking with other children is:
Very low (1)
2 (2)
3 (3)
Normal for age (4)
5 (5)
6 (6)
Very high (7)
My child's ability to keep a conversation going
with other children is:
Very low (1)
2 (2)
3 (3)
Normal for age (4)
5 (5)
6 (6)
Very high (7)
The length of this child's sentences is:
Very low (1)
2 (2)
3 (3)
Normal for age (4)
5 (5)
6 (6)
Very high (7)
My child's ability to make "grown up" sentences
is:
Very low (1)
2 (2)
3 (3)
Normal for age (4)
5 (5)
6 (6)
Very high (7)
My child's ability to correctly say the sounds in
individual words is:
Very low (1)
2 (2)
3 (3)
Normal for age (4)
5 (5)
6 (6)
Very high (7)
My child's awareness of differences in the way
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people act, speak, dress, etc. is:
Very low (1)
2 (2)
3 (3)
Normal for age (4)
5 (5)
6 (6)
Very high (7)
My child usually speaks:
Too soft     (1)
2 (2)
3 (3)
About loud enough     (4)
5 (5)
6 (6)
Too loud (7)
My child usually speaks:
Not often     (1)
2 (2)
3 (3)
About often enough    (4)
5 (5)
6 (6)
Too often (7)
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Assay for Hepatitis B Protocol PhenX
Toolkit
This protocol provides instructions for drawing, processing,
and storing blood for hepatitis B (HBV) from the National
Health and Nutrition Examination Survey (NHANES). As
multiple tests must be performed to make the most
accurate diagnosis of HBV, the protocol also provides basic
guidelines to aid comparability among different studies.
Toolkit users are referred to the U.S. Food and Drug
Administration’s (FDA’s) approved laboratory assays.
ODM derived from: https://cde.nlm.nih.gov
Primary source: https://www.phenxtoolkit.org/
Recent publication: Hendershot, T., Pan, H., Haines, J.,
Harlan, W.R., Marazita, M.L., McCarty, C.A., Ramos, E.M.,
and Hamilton, C.M. (2015) Using the PhenX toolkit to add
standard measures to a study. Curr. Protoc. Hum. Genet.
86:1.21.1-1.21.17. doi: 10.1002/0471142905.hg0121s86
Permission to publish granted by
Carol M. Hamilton.
All rights reserved. Please visit https://medical-data-
models.org/forms/14641
Assay for Hepatitis B Protocol PhenX
Toolkit
Exclusion criteria - assays PhenX
Do you have hemophilia?*
Yes (1)
No (2)
Refused (3)
Don´t know (4)
Have you received cancer chemotherapy in the
past four weeks or do you anticipate such therapy
in the next four weeks?*
Yes (1)
No (2)
Refused (3)
Don´t know (4)
Process variables for assays PhenX
Exclusion Criteria*
Hemophilia (1)
Received cancer chemotherapy in the
last 3 weeks (2)
None – proceed with blood draw (3)
Was blood drawn?*
Yes
No
Was full sample obtained?*
Yes
No
Service comment*
Service comment*
Repeatability of the assay*
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Coefficient of variation for the assay*
Manufacturer variables for assays PhenX
Make of the equipment used to perform...*
Manufacturer of the equipment used to
perform...*
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Perceived Social Support/Conflict Protocol
PhenX Toolkit
The respondent completes three groups of questions about
interactions with spouse/partner, family, and friends. Each
group includes social support questions about how much
they care about you, how much they understand the way
you feel, if you can rely on them, and if you can talk to them
about your worries. Each group also includes social conflict
questions such as if the family members or friends make
too many demands on you, criticize you, let you down when
you are counting on them, or get on your nerves.
ODM derived from: https://cde.nlm.nih.gov
Primary source: https://www.phenxtoolkit.org/
Recent publication: Hendershot, T., Pan, H., Haines, J.,
Harlan, W.R., Marazita, M.L., McCarty, C.A., Ramos, E.M.,
and Hamilton, C.M. (2015) Using the PhenX toolkit to add
standard measures to a study. Curr. Protoc. Hum. Genet.
86:1.21.1-1.21.17. doi: 10.1002/0471142905.hg0121s86
Permission to publish granted by
Carol M. Hamilton.
All rights reserved. Please visit https://medical-data-
models.org/forms/14642
Perceived Social Support/Conflict
Protocol PhenX Toolkit
PhenX - perceived social support - conflict
protocol
The next several questions are about your
spouse/partner. How much does your spouse or
partner really care about you?
A lot     (1)
Some (2)
A little (3)
Not at all (4)
The next several questions are about your
spouse/partner. How much does he or she
understand the way you feel about things?
A lot     (1)
Some (2)
A little (3)
Not at all (4)
The next several questions are about your
spouse/partner. How much does he or she
appreciate you?
A lot     (1)
Some (2)
A little (3)
Not at all (4)
The next several questions are about your
spouse/partner. How much can you rely on him
or her for help if you have a serious problem?
A lot     (1)
Some (2)
A little (3)
Not at all (4)
The next several questions are about your
spouse/partner. How much can you open up to
him or her if you need to talk about your worries?
A lot     (1)
Some (2)
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A little (3)
Not at all (4)
The next several questions are about your
spouse/partner. Please circle the appropriate
number for each item. How much can you relax
and be yourself around him or her?
A lot     (1)
Some (2)
A little (3)
Not at all (4)
The next several questions are about your
spouse/partner. How often does your spouse or
partner make too many demands on you?
Often (1)
Sometimes (2)
Rarely (3)
Never (4)
The next several questions are about your
spouse/partner. How often does he or she make
you feel tense?
Often (1)
Sometimes (2)
Rarely (3)
Never (4)
The next several questions are about your
spouse/partner. How often does he or she argue
with you?
Often (1)
Sometimes (2)
Rarely (3)
Never (4)
The next several questions are about your
spouse/partner. How often does he or she
criticize you?
Often (1)
Sometimes (2)
Rarely (3)
Never (4)
The next several questions are about your
spouse/partner. How often does he or she let you
down when you are counting on him or her?
Often (1)
Sometimes (2)
Rarely (3)
Never (4)
The next several questions are about your
spouse/partner. How often does he or she get on
your nerves?
Often (1)
Sometimes (2)
Rarely (3)
Never (4)
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Not including your spouse or partner, how much
do members of your family really care about you?
A lot     (1)
Some (2)
A little (3)
Not at all (4)
How much do they understand the way you feel
about things?
A lot     (1)
Some (2)
A little (3)
Not at all (4)
How much can you rely on them for help if you
have a serious problem?
A lot     (1)
Some (2)
A little (3)
Not at all (4)
How much can you open up to them if you need
to talk about your worries?
A lot     (1)
Some (2)
A little (3)
Not at all (4)
How much do you really care about the members
of your family, not including your partner or
spouse?
A lot     (1)
Some (2)
A little (3)
Not at all (4)
How much do you understand the way they feel
about things?
A lot     (1)
Some (2)
A little (3)
Not at all (4)
Not including your spouse or partner, how often
do members of your family make too many
demands on you?
A lot     (1)
Some (2)
A little (3)
Not at all (4)
How often do they criticize you?
A lot     (1)
Some (2)
A little (3)
Not at all (4)
How often do they let you down when you are
counting on them?
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A lot     (1)
Some (2)
A little (3)
Not at all (4)
How often do they get on your nerves?
A lot     (1)
Some (2)
A little (3)
Not at all (4)
How much do your friends really care about you?
A lot     (1)
Some (2)
A little (3)
Not at all (4)
How much do they understand the way you feel
about things?
A lot     (1)
Some (2)
A little (3)
Not at all (4)
How much can you rely on them for help if you
have a serious problem?
A lot     (1)
Some (2)
A little (3)
Not at all (4)
How much can you open up to them if you need
to talk about your worries?
A lot     (1)
Some (2)
A little (3)
Not at all (4)
How often do your friends make too many
demands on you?
Often (1)
Sometimes (2)
Rarely (3)
Never (4)
How often do they criticize you?
A lot     (1)
Some (2)
A little (3)
Not at all (4)
How often do they let you down when you are
counting on them?
A lot     (1)
Some (2)
A little (3)
Not at all (4)
How often do they get on your nerves?
A lot     (1)
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Some (2)
A little (3)
Not at all (4)
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NINDS CDE Non Imaging Diagnostics
Epilepsy
NINDS Common Data Elements Used from the National
Institute of Neurological Disorders and Stroke Common
Data Elements
(https://www.commondataelements.ninds.nih.gov/)
References: Grinnon ST, Miller K, Marler JR, Lu Y, Stout A,
Odenkirchen J, Kunitz S. National Institute of Neurological
Disorders and Stroke Common Data Element Project -
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Non Imaging Diagnostics
Scalp Electroencephalogram (EEG)
Study ID
Study site name
Subject ID
For what purpose(s) were the EEG data originally
obtained: Research purposes-prospective
Yes
No
For what purpose(s) were the EEG data originally
obtained: Research purposes-retrospective
Yes
No
For what purpose(s) were the EEG data originally
obtained: Clinical purposes
Yes
No
For what purpose(s) were the EEG data originally
obtained: Other,please specify
EEG Type: Routine or prolonged?
Routine (1)
Prolonged (2)
EEG Type: If prolonged, please specify duration
Less than 24 hours (1)
Greater than or equal to 24 hours (2)
N/A (3)
Other, specify (4)
Prolonged EEG:if other time interval, please
specify
EEG location
Outpatient EEG lab (1)
Inpatient Epilepsy Monitoring Unit (EMU)
(2)
Intensive Care Unit (ICU) (3)
Ambulatory (4)
Other, specify (5)
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EEG location:if other,please specify
Video EEG
No	 (1)
Yes (2)
Unknown	 (3)
Other, specify (4)
Video EEG:if other,please specify
EEG; behavioral states recorded: Awake
Yes
No
EEG; behavioral states recorded: asleep
Yes
No
EEG; behavioral states recorded: Unresponsive
state
Yes
No
EEG; behavioral states recorded: Indeterminate
Yes
No
EEG; behavioral states recorded: Other, specify
EEG activation procedures: Sleep
Yes
No
EEG activation procedures: Hyperventilation
Yes
No
EEG activation procedures: Photic stimulation
Yes
No
EEG activation procedures: Unknown
Yes
No
EEG activation procedures:other,please specify
Posterior dominant rhythm present
Yes
No
Frequency of the posterior dominant rhythm
during relaxed wakefulness Hz
Hz
Total number of seizures recorded with EEG and
Video
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Total number of seizures recorded with EEG only
Total number of seizures recorded on video only
Date of EEG recorded
Inter Ictal Abnormalities
Date of record
Time(s) of Interictal Abnormality
Time
am (1)
pm (2)
24-hour clock (3)
Time
am (1)
pm (2)
24-hour clock (3)
N/A (4)
Interictal Epileptiform Location: Localized focal
Yes
No
Interictal Epileptiform Location: area of origin of
the interictal abnormality
FP1 (1)
FT9 (10)
T3 (11)
C3 (12)
CZ (13)
C4 (14)
T4 (15)
FT10 (16)
T5 (17)
P3 (18)
PZ (19)
FP2 (2)
P4 (20)
T6 (21)
O1 (22)
O2 (23)
T1 (3)
F7 (4)
F3 (5)
FZ (6)
F4 (7)
F8 (8)
T2 (9)
Interictal Epileptiform Location: full extent of
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abnormal electrical field
FP1 (1)
FT9 (10)
T3 (11)
C3 (12)
CZ (13)
C4 (14)
T4 (15)
FT10 (16)
T5 (17)
P3 (18)
PZ (19)
FP2 (2)
P4 (20)
T6 (21)
O1 (22)
O2 (23)
T1 (3)
F7 (4)
F3 (5)
FZ (6)
F4 (7)
F8 (8)
T2 (9)
Interictal Epileptiform Location:
Localized regional lobar or multilobar (1)
Hemispheric Left (10)
Hemispheric Right (11)
Generalized (12)
No localized onset (13)
Other, specify (14)
Left Frontal (2)
Left Parietal (3)
Left Occipital (4)
Left Temporal (5)
Right Frontal (6)
Right Parietal (7)
Right Occipital (8)
Right Temporal (9)
Interictal Epileptiform Location: if "No localized
onset" or "other" ,please specify
Interictal Type of Discharge
Generalized Epileptiform Discharge (1)
Diffuse Fast Rhythms (2)
Diffuse Attenuation (3)
Rhythmic (frequency) Hz (4)
Periodic discharges (5)
Other, specify (6)
Interictal Type of Discharge: Rhythmic
(frequency) Hz(round to the closest 0.5 Hz)
Hz
Interictal Type of Discharge: Periodic discharges
4 / 17
NINDS CDE Non Imaging Diagnostics Epilepsy
Sharp waves (1)
Spikes (2)
Single Spike-Wave (3)
Polyspike-Wave (4)
Other, specify (5)
Interictal Type of Discharge: if other,please
specify
Interictal Type of Discharge Periodic discharges:
if other,please specify
Interictal Circumstances
Awake (1)
Drowsy (2)
Sleep (3)
Hyperventilation (4)
Photic stimulation (5)
Indeterminate (6)
Other, specify (7)
Interictal circumstances:if other, please specify
Focal and generalized slowing
Focus
Start time
hh:mm:ss
Slowing type
Persistent (i.e., continuous)	 (1)
Transient	 (2)
Post-Ictal (3)
Slowing location
Localized regional lobar or multilobar (1)
Hemispheric Left (10)
Hemispheric Right (11)
Generalized (12)
No localized onset (13)
Other, specify (14)
Left Frontal (2)
Left Parietal (3)
Left Occipital (4)
Left Temporal (5)
Right Frontal (6)
Right Parietal (7)
Right Occipital (8)
Right Temporal (9)
Slowing Location: if "No localized onset" or
"other" ,please specify
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Ictal EEG Evaluation
Seizure number
Total number of seizures
Date of seizure
Start time
hh:mm:ss
End time
hh:mm:ss
Ictal Onset: Location on EEG
Localized focal (1)
T2 (10)
FT9 (11)
T3 (12)
C3 (13)
CZ (14)
C4 (15)
T4 (16)
FT10 (17)
T5 (18)
P3 (19)
FP1 (2)
PZ (20)
P4 (21)
T6 (22)
O1 (23)
O (24)
FP2 (3)
T1 (4)
F7 (5)
F3 (6)
FZ (7)
F4 (8)
F8 (9)
Ictal onset time
Full Ictal Propagation: Location on EEG
Localized focal (1)
T2 (10)
FT9 (11)
T3 (12)
C3 (13)
CZ (14)
C4 (15)
T4 (16)
FT10 (17)
T5 (18)
P3 (19)
FP1 (2)
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PZ (20)
P4 (21)
T6 (22)
O1 (23)
O (24)
FP2 (3)
T1 (4)
F7 (5)
F3 (6)
FZ (7)
F4 (8)
F8 (9)
Ictal Onset Location on EEG: Localized focal
Yes
No
Full Ictal Propagation Location on EEG: Localized
focal
Yes
No
Ictal Onset Location on EEG
Localized regional lobar or multilobar (1)
Right Temporal Mesial (10)
Right Temporal Neocortical (11)
Hemispheric Left  (12)
Hemispheric Right (13)
Generalized  (14)
No localized onset (15)
Other, specify (16)
Left Frontal (2)
Left Parietal (3)
Left Occipital (4)
Left Temporal Mesial (5)
Left Temporal Neocortical (6)
Right Frontal (7)
Right Parietal (8)
Right Occipital (9)
Full Ictal Propagation Location on EEG
Localized regional lobar or multilobar (1)
Right Temporal Mesial (10)
Right Temporal Neocortical (11)
Hemispheric Left  (12)
Hemispheric Right (13)
Generalized  (14)
No localized onset (15)
Other, specify (16)
Left Frontal (2)
Left Parietal (3)
Left Occipital (4)
Left Temporal Mesial (5)
Left Temporal Neocortical (6)
Right Frontal (7)
Right Parietal (8)
Right Occipital (9)
Ictal onset Pattern on EEG
Generalized tonic-clonic pattern (1)
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Diffuse Fast Rhythms (2)
Diffuse Attenuation (3)
Rhythmic (frequency) Hz (4)
Periodic discharges Sharp waves (5)
Periodic discharges Spikes (6)
Periodic discharges Single Spike-Wave
(7)
Periodic discharges Polyspike-Wave (8)
Periodic discharges Other, specify (9)
Ictal Onset Pattern on EEG: Rhythmic
(frequency) Hz(round to the closest 0.5 Hz)
Hz
Ictal Onset Circumstances
Awake (1)
Drowsy (2)
Sleep (3)
Hyperventilation (4)
Photic stimulation (5)
Indeterminate (6)
Other, specify (7)
Ictal Onset Circumstances: if other,please specify
Video EEG Ictal Evaluation
Video Seizure Number
Total number of seizures on video
Ictal EEG available
Yes
No
Date EEG recorded
Start time
hh:mm:ss
Patient able to push alarm (onset, during, after
seizure)
Yes
No
Behavioral state at onset of seizure
Awake  (1)
Asleep  (2)
Unknown  (3)
Other, specify (4)
Behavioral state at onset of seizure:if
other,please specify
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Image Quality
Good  (1)
Fair  (2)
Poor (3)
View of patient
Full  (1)
Face  (2)
Trunk  (3)
Side  (4)
Back  (5)
None (6)
Responsiveness
Arousal from sleep (1)
Behavior Arrest (2)
Hypermotor (3)
Other Specify (4)
Responsiveness:if other,please specify
Vocalization
Laugh (1)
Song (2)
Incoherent Speech (3)
Groan/Cry (4)
Other Specify: (5)
Coherent Speech Spontaneous (6)
Coherent Speech Response to Question
(7)
Testing of Responsiveness
Follow Command(s) (1)
Repeat Memory Item(s) (2)
Other, Specify (3)
Testing of Responsiveness: if other,please
specify
Subjective Symptoms Reported by the Patient
Somatosensory (1)
Autonomic (10)
Gustatory (2)
Psychic (3)
Visual (4)
Epigastric (5)
Other, Specify: (6)
Auditory (7)
Cephalic (8)
Olfactory (9)
Eye signs: Eyes opening/widening
Right (1)
Left (2)
Other (3)
Eyes opening/widening:Sequence
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Eye signs: Version
Right (1)
Left (2)
Other (3)
Eye version:Sequence
Eye signs: Blinking
Right (1)
Left (2)
Other (3)
Eye blinking: Sequence
Eye signs: Nystagmus
Right (1)
Left (2)
Other (3)
Nystagmus:Sequence
Eye signs:other
Right (1)
Left (2)
Other (3)
Eye signs other:Sequence
Face signs:Head Version
Right (1)
Left (2)
Other (3)
Head version:Sequence
Face signs:Head + Eye Version
Right (1)
Left (2)
Other (3)
Face signs Head + Eye Version:Sequence
Face signs:Mouth Deviation/Twisting
Right (1)
Left (2)
Other (3)
Face signs Mouth Deviation/Twisting: Sequence
Face signs:Automatism
Right (1)
Left (2)
Other (3)
Face Automatism: Sequence
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Lip Smacking
Right (1)
Left (2)
Other (3)
Lip Smacking:Sequence
Other facial automatism
Right (1)
Left (2)
Other (3)
Other facial automatism,if other than left or right
side, please specify
Face signs: Other
Right (1)
Left (2)
Other (3)
Other face signs: if other than right or left side,
please specify
Arrest of Movement
Trunk right (1)
Arm L>R	 (10)
Leg L>R	 (11)
Trunk L>R	 (12)
Unsure (13)
Trunk left	 (2)
Arm	right (3)
Leg	Right (4)
Arm left (5)
Leg left	 (6)
Arm R>L (7)
Leg R>L (8)
Trunk R>L	 (9)
Arrest of movement:Sequence
Version
Trunk right (1)
Arm L>R	 (10)
Leg L>R	 (11)
Trunk L>R	 (12)
Unsure (13)
Trunk left	 (2)
Arm	right (3)
Leg	Right (4)
Arm left (5)
Leg left	 (6)
Arm R>L (7)
Leg R>L (8)
Trunk R>L	 (9)
Version:Sequence
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Tonic extension
Trunk right (1)
Arm L>R	 (10)
Leg L>R	 (11)
Trunk L>R	 (12)
Unsure (13)
Trunk left	 (2)
Arm	right (3)
Leg	Right (4)
Arm left (5)
Leg left	 (6)
Arm R>L (7)
Leg R>L (8)
Trunk R>L	 (9)
Tonic extension:Sequence
Trunk or limb signs: Tonic flexion
Trunk right (1)
Arm L>R	 (10)
Leg L>R	 (11)
Trunk L>R	 (12)
Unsure (13)
Trunk left	 (2)
Arm	right (3)
Leg	Right (4)
Arm left (5)
Leg left	 (6)
Arm R>L (7)
Leg R>L (8)
Trunk R>L	 (9)
Tonic flexion:Sequence
Trunk or limb signs: Clonic-early
Trunk right (1)
Arm L>R	 (10)
Leg L>R	 (11)
Trunk L>R	 (12)
Unsure (13)
Trunk left	 (2)
Arm	right (3)
Leg	Right (4)
Arm left (5)
Leg left	 (6)
Arm R>L (7)
Leg R>L (8)
Trunk R>L	 (9)
Clonic-early:Sequence
Trunk or limb signs: Clonic-later
Trunk right (1)
Arm L>R	 (10)
Leg L>R	 (11)
Trunk L>R	 (12)
Unsure (13)
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Trunk left	 (2)
Arm	right (3)
Leg	Right (4)
Arm left (5)
Leg left	 (6)
Arm R>L (7)
Leg R>L (8)
Trunk R>L	 (9)
Clonic later:Sequence
Trunk or limb signs: dystonic posture
Trunk right (1)
Arm L>R	 (10)
Leg L>R	 (11)
Trunk L>R	 (12)
Unsure (13)
Trunk left	 (2)
Arm	right (3)
Leg	Right (4)
Arm left (5)
Leg left	 (6)
Arm R>L (7)
Leg R>L (8)
Trunk R>L	 (9)
Dystonic posture: Sequence
Trunk or limb signs: Sign-of-4 arm Ext
Trunk right (1)
Arm L>R	 (10)
Leg L>R	 (11)
Trunk L>R	 (12)
Unsure (13)
Trunk left	 (2)
Arm	right (3)
Leg	Right (4)
Arm left (5)
Leg left	 (6)
Arm R>L (7)
Leg R>L (8)
Trunk R>L	 (9)
Sign-of-4 arm Ext: Sequence
Trunk or limb signs: Myoclonic Jerk
Trunk right (1)
Arm L>R	 (10)
Leg L>R	 (11)
Trunk L>R	 (12)
Unsure (13)
Trunk left	 (2)
Arm	right (3)
Leg	Right (4)
Arm left (5)
Leg left	 (6)
Arm R>L (7)
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Leg R>L (8)
Trunk R>L	 (9)
Myoclonic jerk: Sequence
Lower Extremity Complex Movements
R	 (1)
L	 (2)
R>L	 (3)
L>R	 (4)
Unsure (5)
Lower Extremity Complex Movements:Sequence
Automatism: Face/nose wiping or rubbing
R	 (1)
L	 (2)
R>L	 (3)
L>R	 (4)
Unsure (5)
Face/nose wiping or rubbing:Sequence
Automatism: Clothes/sheet picking
R	 (1)
L	 (2)
R>L	 (3)
L>R	 (4)
Unsure (5)
Clothes/sheet picking: Sequence
Automatism: Rocking
Trunk (1)
R	 (2)
L	 (3)
R>L	 (4)
L>R	 (5)
Unsure (6)
Rocking: Sequence
Automatism: Spinning/Turning (direction)
R (1)
L (2)
Unsure (3)
Spinning/Turning: Sequence
Automatism: Other,please specify
Automatism:Other
Trunk right (1)
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Arm L>R	 (10)
Leg L>R	 (11)
Trunk L>R	 (12)
Unsure (13)
Trunk left	 (2)
Arm	right (3)
Leg	Right (4)
Arm left (5)
Leg left	 (6)
Arm R>L (7)
Leg R>L (8)
Trunk R>L	 (9)
Automatism:Other Sequence
Other signs
Vomiting (1)
Spitting (2)
Coughing (3)
Tongue biting (4)
Other,Specify (5)
Other signs, please specify
Other signs: Sequence
Benign EEG Variants
Benign EEG variants
Yes
No
If yes, please select all EEG variants that are
present
Small sharp spikes (1)
Wicket spikes (2)
14- and 6-Hz Positive Bursts (3)
6-Hz Spike and Wave (4)
Rhythmic Temporal Theta Bursts of
Drowsiness (5)
Subclinical Rhythmic EEG Discharges in
Adults (6)
Midline Theta Rhythm (7)
Scalp EEG Short Form
EEG Category
Initial inclusion study protocol EEG (1)
Clinical EEG used for study inclusion (2)
Supplemental EEG (3)
EEG Category: if supplemental, please specify
reason
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EEG Type:Duration
1 hour or less  (1)
1-2 hours (2)
2 hours (3)
Greater than 2 hours (4)
N/A (5)
Other, specify (6)
EEG duration, if other, please specify
Video EEG
No (1)
Yes (2)
Unknown (3)
Other, specify (4)
Video EEG, if other please specify
EEG Sampling rate unknown
Yes
No
EEG Sampling rate,please specify
EEG data type
Digital EEG (1)
Screen shots or paper EEG (2)
EEG report only (3)
EEG report including screen shots or
paper EEG (4)
Other specify (5)
EEG data type: if other, please specify
Behavioral states recorded
Awake (1)
Asleep (2)
Indeterminate (3)
Other, specify (4)
Activating procedures used
Sleep deprivation (1)
Hyperventilation (2)
Photic stimulation (3)
Unknown (4)
Other, specify (5)
If other activating procedure, please specify
EEG background and posterior dominant rhythm
(PDR) normal for age
Yes (1)
No - PDR slow, disorganized or absent,
or background slow (2)
EEG data not adequate to assess
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background and PDR (3)
Frequency of the posterior dominant rhythm
during relaxed wakefulness Hz (round to the
closed 0.5 Hz):
Hz
EEG abnormal
Yes
No
Seizures recorded
Yes
No
Focal sharp waves
Yes
No
Focal slowing
Yes
No
Generalized epileptiform abnormalities
Yes: ≥ 3 Hz (1)
Yes: < 3 Hz (2)
No (3)
Other abnormalities
Yes
No
Other abnormalities: if yes, please specify
Date of examination
Age of participant when EEG obtained
Did the patient receive any medication? Please
specify
Further comments/notes to EEG reviewers
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NINDS CDE Drugs Epilepsy
NINDS Common Data Elements Used from the National
Institute of Neurological Disorders and Stroke Common
Data Elements
(https://www.commondataelements.ninds.nih.gov/)
References: Grinnon ST, Miller K, Marler JR, Lu Y, Stout A,
Odenkirchen J, Kunitz S. National Institute of Neurological
Disorders and Stroke Common Data Element Project -
approach and methods. Clin Trials. 2012;9(3):322-9.
All rights reserved. Please visit https://medical-data-
models.org/forms/14646
Drugs
Anti Epileptic Drug (AED) Plasma
Concentration Log
Study ID
Study site name
Subject ID
Line Number
Generic Name of AED
Number of line on AED Log
Date and Time of Blood Draw (mm/dd/yyyy
hh:mm)
Amount of Last Dose Before Blood Draw
(Specify Units)
Please specify unit of medication dosage
Date and Time of Last Dose Before Blood Draw
Plasma Concentration Result
Plasma concentration please specify unit
Plasma concentration:Not Done
Yes
No
Clinically Significant Non Adherence Expected/
Confirmed?
Yes
No
Further comments
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Anti Epileptic Drug (AED) Resistance Log
Line number
Antiepileptic drug name
Antiepileptic drug formulation known?
Yes
No
Antiepileptic drug: if formulation is known, please
specify
AED Schedule Known?
Yes
No
Antiepileptic drug schedule is known, please
specify
Reason for discontinuation known?
Idiosyncratic Side Effect(s), specify (1)
Dose Related Side Effect(s), specify (2)
Chronic Side Effects (3)
Inadequate Seizure Control (4)
Other, specify (5)
Reason for discontinuation: please specify
Was antiepileptic drug appropriate for the
epilepsy syndrome?
Yes
No
Was 3 months of therapy achieved without
discontinuation due to adverse events?
Yes  (1)
No (2)
Unknown (3)
Were attempts made to adjust dose? (not
titration)
Yes  (1)
No (2)
Unknown (3)
Did the subject continue to have seizures on this
AED despite dose adjustment?
Yes
No
Are the answers to all the previous questions
known?
Yes
No
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Are the answers to all the previous questions
“Yes”?
Yes
No
Anti Epileptic Drug (AED) Log
Did the subject take any non-study antiepileptic
drugs during the study?
Yes
No
Name of Antiepileptic Drug
Generic or Brand used?
Generic (1)
Brand (2)
Unknown (3)
Formulation
Dosing Schedule -Times of Administration
Dosing Schedule -Times of Administration: N/A -
taken PRN
Yes
No
Dosing Schedule -Times of Administration:
Average frequency = times per month
Dose
Unit of dosage
gram (g )
grain (gr )
drop (gtt )
microgram (mcg )
microliter (mcL )
milligram (mg )
milliliter (mL )
other, specify (OTH )
ounce (oz )
teaspoon (Sp )
spray/squirt (SPY )
suppository (supp )
tablespoon (TBSP )
Unknown (UNK)
Route of administration
Start Date
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End Date
ongoing
Yes
No
If Applicable, Reason for Discontinuation
Idiosyncratic Side Effect(s), specify (1)
Dose Related Side Effect(s), specify (2)
Chronic Side Effects (3)
Inadequate Seizure Control (4)
Other, specify (5)
Reason for Discontinuation:please specify
Further comments
Non Anti Epileptic Medication Log
Did the participant/subject take any medications
days before or during the study?
Yes
No
Line number
Generic Name of Medication
Dose Frequency
Dose frequency N/A-taken PRN
Yes
No
Dose frequency Average frequency= times per
month
Total Daily Dose or PRN Dose
Dosage unit
gram (g )
grain (gr )
drop (gtt )
microgram (mcg )
microliter (mcL )
milligram (mg )
milliliter (mL )
other, specify (OTH )
ounce (oz )
teaspoon (Sp )
spray/squirt (SPY )
suppository (supp )
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tablespoon (TBSP )
Unknown (UNK)
Dosage unit: if other please specify
Start date
dd/mm/yy
Concomitant Medication: End Date
Ongoing
Yes
No
Indication
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Eligibility Atrial Fibrillation NCT02347111
Pilot Pharmacogenetic Study of Antiarrhythmic Drugs for
Atrial Fibrillation; ODM derived from:
https://clinicaltrials.gov/show/NCT02347111
All rights reserved. Please visit https://medical-data-
models.org/forms/14647
Eligibility Atrial Fibrillation
NCT02347111
Inclusion Criteria
caucasians ≥ 18 years of age*
Yes
No
history of typical or lone symptomatic af*
Yes
No
af symptoms present at least once per month*
Yes
No
ecg that was recorded within 12 months of
randomization showing af*
Yes
No
starting a class i or class iii aad*
Yes
No
in sinus rhythm at enrollment*
Yes
No
able to give informed consent*
Yes
No
Exclusion Criteria
permanent af or isolated atrial flutter.*
Yes
No
cardiac or thoracic surgery within the previous 6
months*
Yes
No
previous use of amiodarone other than short-term
use (e.g. for an acute arrhythmia in hospital)*
Yes
No
medical condition that is likely to be fatal in less
than one year*
Yes
No
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received 2 or more aads in past*
Yes
No
creatinine clearance <40 ml/min*
Yes
No
contra-indication to a class i aad e.g., structural
heart disease, or history of mi*
Yes
No
contra-indication to a class iii aad, e.g.,
congenital or acquired long qt syndrome with
qtc>450 ms at baseline*
Yes
No
a reversible cause of af (e.g., thyrotoxicosis)*
Yes
No
previously treated with class i and class iii
antiarrhythmic drugs*
Yes
No
females who are pregnant or nursing.*
Yes
No
history of severe av node dysfunction unless an
electronic pacemaker is present*
Yes
No
any race other than caucasian*
Yes
No
first- or second-degree relative has already
participated in the study.*
Yes
No
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Eligibility Atrial Fibrillation NCT02273700
Plasma Modifications Associated With Rivaroxaban®
Treatment for Stroke Prevention; ODM derived from:
https://clinicaltrials.gov/show/NCT02273700
All rights reserved. Please visit https://medical-data-
models.org/forms/14649
Eligibility Atrial Fibrillation
NCT02273700
Inclusion Criteria
the patient was correctly informed about the
study, its implementation, objectives, associated
restrictions and patient rights*
Yes
No
the patient must have given his/her informed and
signed consent*
Yes
No
the patient must be insured or beneficiary of a
health insurance plan*
Yes
No
the patient is available for 1 month of follow-up*
Yes
No
the patient has non-valvular atrial fibrillation that
was diagnosed within the last 3 months.
documentation of atrial fibrillation by a 12-lead
ecg, an ecg rhythm strip, atrial fibrillation episode
lasting at least 30 seconds.*
Yes
No
the patient has a cha2-ds2-vasc score = 1, that is
to say the presence of at least one of the
following risk factors: (1) congestive heart failure
or moderate to severe systolic dysfunction of the
left ventricle;  (2) history of systolic blood
pressure> 160 mmhg;  (3) diabetes;  (4) history
of ischemic stroke or systemic embolism;  (5)
vascular disease (myocardial infarction, arterial
disease);  (6) age > 65 years;  (7) female.*
Yes
No
the patient will start rivaroxaban (xarelto®) at the
nîmes university hospital*
Yes
No
Exclusion Criteria
the patient is participating in another
interventional study*
Yes
No
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the patient has participated in another
interventional study within the past three months*
Yes
No
the patient is in an exclusion period determined
by a previous study*
Yes
No
the patient is under judicial protection, under
tutorship or curatorship*
Yes
No
the patient refuses to sign the consent*
Yes
No
it is impossible to correctly inform the patient*
Yes
No
the patient is pregnant, parturient, or
breastfeeding*
Yes
No
presence of a mechanical heart valve or valve
disease*
Yes
No
patient who recieved another new direct oral
anticoagulant other than xarelto® in the previous
three months*
Yes
No
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Eligibility Atrial Fibrillation NCT02364401
Impedance vs. Contact Force Guided Atrial Fibrillation
Ablation Using Automated Annotation System; ODM
derived from: https://clinicaltrials.gov/show/NCT02364401
All rights reserved. Please visit https://medical-data-
models.org/forms/14650
Eligibility Atrial Fibrillation
NCT02364401
Inclusion Criteria
patients with non-valvular atrial fibrillation*
Yes
No
patients having atrial fibrillation even after
receiving continued treatment with at least 1
antiarrhythmic drug for more than 6 weeks*
Yes
No
patients with tachycardia-bradycardia syndrome
associated with atrial fibrillation.*
Yes
No
patients who can understand the information
sheet and consent form on the need and
procedure of catheter ablation and submitted
them*
Yes
No
patients who are available of follow-up at least for
more than three months after catheter ablation*
Yes
No
Exclusion Criteria
patients unsuitable for catheter ablation because
the size of left atrium is over 5.5cm*
Yes
No
patients unsuitable for catheter ablation due to
previous history of pulmonary surgery or
structural heat disease.*
Yes
No
patients who cannot receive standard treatments
such as anticoagulation therapy which need to be
continuously performed prior to radiofrequency
catheter ablation*
Yes
No
patients in the subject group vulnerable to clinical
study*
Yes
No
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patients who had undergone a prior catheter
ablation for atrial fibrillation*
Yes
No
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Eligibility Atrial Fibrillation NCT02421900
Analysis of the Role of T-cell Response in Patients With
Atrial Fibrillation for Clinical Application; ODM derived from:
https://clinicaltrials.gov/show/NCT02421900
All rights reserved. Please visit https://medical-data-
models.org/forms/14651
Eligibility Atrial Fibrillation
NCT02421900
Inclusion Criteria
patients who consent with study*
Yes
No
patients with age more than19*
Yes
No
patients who undergoing catheter ablation of
atrial fibrillation due to symptomatic, drug
refractory atrial fibrillation*
Yes
No
Exclusion Criteria
patients who do not agree with study inclusion*
Yes
No
permanent af refractory to electrical
cardioversion*
Yes
No
af with rheumatic valvular disease*
Yes
No
patients with left atrial diameter greater than
60mm*
Yes
No
patients with age less than 19*
Yes
No
patient with malignant tumor and chronic infection
disease*
Yes
No
patient are given immune inhibitor and steroidal
anti-inflammatory drug within 2weeks*
Yes
No
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Eligibility Prostate Cancer NCT00223171
Duration of Androgen Blockade Combined With Pelvic
Irradiation in Prostate Cancers; ODM derived from:
https://clinicaltrials.gov/show/NCT00223171
All rights reserved. Please visit https://medical-data-
models.org/forms/14652
Eligibility Prostate Cancer
NCT00223171
Inclusion Criteria
to have at least one of the following three risk
factors:*
Yes
No
tumour classified t3 or t4*
Yes
No
gleason score 8-10*
Yes
No
prostate-specific antigen (psa) level > 20*
Yes
No
performance status score of 0-1.*
Yes
No
patients must sign a consent form before the start
of the study.*
Yes
No
no evidence of regional disease: clinically
negative regional adenopathies are revealed by
imaging (computed axial tomography [cat] scan,
magnetic resonance imaging [mri],
lymphography) or surgical staging or negative
pelvic node dissection.*
Yes
No
no distant metastasis. these patients must all
have a negative bone scan 12 weeks prior to
randomization.*
Yes
No
hormonal therapy is allowed up to a maximum of
two months before the consent form is signed, as
long as the initial work-up was done, including
having the requested deadlines respected.*
Yes
No
patients with a previous history of cancer are
eligible on the condition that they have not had
any disease progression for more than five
years.*
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Yes
No
the patient must be available for treatments and
follow-up visits.*
Yes
No
treatments must start in the three weeks following
randomization.*
Yes
No
Exclusion Criteria
severe medical or psychiatric problems that could
compromise study compliance.*
Yes
No
chronic hepatic disease, abnormal hepatic
functions, i.e. aspartate aminotransferase,
alanine aminotransferase > 1.5 times the upper
normal limit.*
Yes
No
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Eligibility Prostate Cancer NCT00841113
Abarelix Versus Goserelin Plus Bicalutamide in Patients
With Advanced or Metastatic Prostate Cancer; ODM
derived from: https://clinicaltrials.gov/show/NCT00841113
All rights reserved. Please visit https://medical-data-
models.org/forms/14653
Eligibility Prostate Cancer
NCT00841113
Inclusion Criteria
histologically proven prostate cancer and not
previously treated with hormones*
Yes
No
evidance of advanced disease or metastases*
Yes
No
life expectancy of at least 3 months*
Yes
No
normal serum testosterone levels*
Yes
No
written informed consent*
Yes
No
Exclusion Criteria
previous endocrine or cytoxic theapy for prostate
cancer*
Yes
No
known tumour complication of prostate cancer
which owuld require immediate treatment*
Yes
No
another malignancy other than basal cell cancer*
Yes
No
history of significant drug hypersensitivity to
either lhrh agonists or gnrh antagonists.*
Yes
No
congenital or acquired coagulation disorders
contraindicating intramuscular injections*
Yes
No
pagets disease of the bone*
Yes
No
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qtcb > 450 msec at day - 14*
Yes
No
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Eligibility Relapsing Remitting Multiple
Sclerosis NCT00534261
Does Quality of Life Improve in Multiple Sclerosis Patients
Treated With Interferon Beta-1a?; ODM derived from:
https://clinicaltrials.gov/show/NCT00534261
All rights reserved. Please visit https://medical-data-
models.org/forms/14654
Eligibility Relapsing Remitting
Multiple Sclerosis NCT00534261
Inclusion Criteria
relapsing remitting multiple sclerosis*
Yes
No
interferon naïve*
Yes
No
eligible for interferon beta-1a (avonex®) therapy
as per summary of product characteristics:*
Yes
No
subject has had relapsing ms for > 1 year*
Yes
No
subject has had experienced 2 exacerbations in
the last 2 years*
Yes
No
subject had an edss [5] score of < 5.5*
Yes
No
subject was ambulant*
Yes
No
Exclusion Criteria
diagnosis of ms defined as progressive*
Yes
No
history of any significant cardiac, hepatic,
pulmonary, or renal disease; immune deficiency;
or other medical conditions that would preclude
therapy with interferon beta*
Yes
No
history of severe allergic or anaphylactic
reactions or history of hypersensitivity to human
albumin*
Yes
No
history of seizures within the 3 months prior to
starting this study*
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Yes
No
history of intolerance to acetaminophen
(paracetamol), ibuprofen, naproxen or other
nsaids, that would preclude use of at least one of
these during the study*
Yes
No
history of intolerance to interferons*
Yes
No
previous use of interferon beta*
Yes
No
female subjects who were pregnant or breast-
feeding*
Yes
No
for female subjects, unless postmenopausal or
surgically sterile, unwillingness to practice
effective contraception*
Yes
No
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Eligibility Relapsing-Remitting Multiple
Sclerosis NCT00219908
Evaluation of a New Therapeutic Strategy in Early and
Active Relapsing-Remitting Multiple Sclerosis; ODM
derived from: https://clinicaltrials.gov/show/NCT00219908
All rights reserved. Please visit https://medical-data-
models.org/forms/14655
Eligibility Relapsing-Remitting
Multiple Sclerosis NCT00219908
Inclusion Criteria
age : 18-45 years,*
Yes
No
clinical disease satisfying the poser criteria
(amdmt n°4)*
Yes
No
relapsing-remitting disease (amdmt n°4)*
Yes
No
at least 2 exacerbations within the preceding 12
months, having left sequelae,*
Yes
No
mri activity at inclusion expressed by at least one
gadolinium-enhanced lesion (cranial mri with
0.1mmol/kg gadolinium),*
Yes
No
a significant disability at inclusion: edss score
between 2.5 and 5.5 (amdt n° 4)*
Yes
No
written informed consent*
Yes
No
Exclusion Criteria
pregnancy and breast-feeding*
Yes
No
use of an insufficiency effective contraceptive
method,*
Yes
No
general immunosuppressive therapy using
cyclophosphamide, mitoxantrone,or total
lymphoid irradiation*
Yes
No
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treatment with azathioprine during the 3 months
preceding the study*
Yes
No
clinical relapse or intensive corticosteroid
treatment within the 30 days preceding inclusion,*
Yes
No
associated disease (psychiatric disorder,
depressive statenot controlled by appropriate
drug therapy, history of heart disease at inclusion
examination*
Yes
No
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Liebe Patientin, lieber Patient, 
wenn  die  Funktion  der  eigenen  Nieren  nicht  mehr
ausreicht  die    harnpflichtigen  Giftstoffe auszuscheiden,
wird  ein  Nierenersatzverfahren  erforderlich.  Dies  ist
entweder  die Hämodialyse, die Peritonealdialyse
(Bauchfelldialyse) oder die Nierentransplantation. Dabei 
kann  im  Laufe  der  Zeit  immer  wieder  von  einem
Nierenersatzverfahren  zu  einem  anderen
Nierenersatzverfahren gewechselt werden. Nun haben Sie
sich für die Nierentransplantation interessiert. Dies ist in
der Regel eine gute Entscheidung. Eine
Nierentransplantation hat viele Vorteile, ist aber keinesfalls
unbedingt notwendig. Sicher haben Sie mit Ihrem
Nephrologen (Dialysearzt)  die  wichtigsten  Vorteile  und
möglichen  Nachteile  einer  Nierentransplantation schon
einmal besprochen. Wie überall in der Medizin gibt es keine
Garantie für den Erfolg einer  Nierentransplantation  und
es  ist  immer  möglich,  dass  Nebenwirkungen  oder  gar
Komplikationen auftreten. Trotzdem funktionieren die
meisten Nierentransplantate nach der Transplantation und
Komplikationen sind selten. In besonderen Fällen kann es
sinnvoll sein, gleichzeitig mit der Nierentransplantation die
Bauchspeicheldrüse (Pankreas) oder die Leber zu
transplantieren. In einem solchen Fall erhalten Sie von uns
zusätzliche Informationen. Der nachfolgende Text bezieht
sich auf die alleinige Nierentransplantation. 
Für eine Nierentransplantation müssen Sie bei
Eurotransplant(siehe unten) gemeldet werden. 
Wir,  die  Nephrologen  der  Klinik  für  Nephrologie  und
die  Transplantationschirurgen  der 
Klinik  für  Allgemein-  und  Transplantationschirurgie
möchten  noch  einmal  die  wichtigsten Punkte
ansprechen, die Sie vor einer Meldung zur Transplantation
wissen sollten.  
Auch  die  Nierentransplantation  ist,  wie  die  Dialyse,
keine  Heilung  Ihrer  Nierenkrankheit, sondern stellt
lediglich ein modernes, alternatives Behandlungsverfahren
dar. Dies bedeutet, 
dass Sie auch nach einer Nierentransplantation regelmäßig
unter ärztlicher Kontrolle stehen 
müssen. Diese Nachbetreuung wird in der Regel durch die
Nephrologen der hiesigen Klinik 
für Nephrologie gemeinsam mit Ihrem Nephrologen
(Dialysearzt) vorgenommen. Sie müssen 
auch  weiterhin  ganz  regelmäßig  und  gewissenhaft
Medikamente  einnehmen,  auf  deren 
Wirkungen und Nebenwirkungen wir später noch eingehen
werden. 
Organisation: 
Wenn wir nach dem Nierentransplantationsgespräch
gemeinsam zu der Auffassung kommen, 
dass eine Nierentransplantation für Sie ein geeignetes
Behandlungsverfahren darstellt, werden 
wir Ihnen Blut zur Feststellung Ihrer Gewebemerkmale
entnehmen. Die erhobenen Befunde 
werden  anschließend  an    Eurotransplant  per  Internet
übermittelt  und  dort  gespeichert. 
Eurotransplant  ist  die  europäische
Transplantationszentrale,  welche  von  der 
Bundesärztekammer mit der Organverteilung betraut
wurde. Hierher werden auch die Daten 
der  Organspender  gemeldet.  Mit  Ihrem  Einverständnis
zur  Anmeldung  für  eine 
Transplantation erklären Sie sich einverstanden, dass Ihre
persönlichen Daten zum Zweck der 
Vermittlung des Transplantats bei Eurotransplant in Leiden,
Niederlande, gespeichert werden. 
Zusätzlich werden zur Qualitätssicherung der
Transplantationen Daten an das Aqua-Institut 
für Qualitätssicherung und die Deutsche Stiftung
Organtransplantation anonymisierter Form 
weitergegeben.  Bestimmte  Gewebemerkmale  von
Spender  und  Empfänger  müssen 
zusammenpassen,  damit  das  Organ  angenommen  wird.
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Über  ein    Computerprogramm  bei 
Eurotransplant in Leiden wird nach Ausmaß der
Gewebeübereinstimmung unter zusätzlicher 
Berücksichtigung  der  Wartezeit  und  geographischen
Gesichtspunkten  derjenige/diejenige 
Patient/in herausgesucht, für den/die die Niere am
geeignetsten erscheint. Transplantatnieren 
von Spendern mit einer fraglichen oder einer
nachgewiesenen Hepatitis B oder Hepatitis C 
werden nur an Empfänger vermittelt, die bereits eine
Hepatitis B oder Hepatitis C haben. 
Wenn Sie als der geeignetste Patient/die geeignetste
Patientin herausgesucht wurden, werden 
wir als Transplantationszentrum bei dem Sie gemeldet sind
unverzüglich informiert. Das kann 
von Beginn der Dialyse mehrere Jahre dauern, passiert
aber immer dann, wenn man es am wenigsten erwartet.
Wir nehmen Rücksprache mit Ihrem Nephrologen
(Dialysearzt), der dann 
Kontakt  mit  Ihnen  aufnimmt.  Insgesamt  stehen  für
diesen  Vorgang  60  Minuten  zur 
Verfügung. Um Tag und Nacht die für Ihre
Nierentransplantation notwendigen persönlichen 
und medizinischen Informationen verfügbar zu haben,
speichern wir diese Daten in unserer 
Datenbank,  die  allen  Mitarbeitern  unseres
Transplantationszentrums  zum  Zwecke  einer 
organisatorisch  optimalen  Nierentransplantation
zugänglich  ist.  Zur  schnellen 
Informationsübermittlung  an  die  Direktoren  der  Klinik
für  Allgemein-  und 
Transplantationschirurgie, Herrn Prof. Dr. Paul und der
Klinik für Nephrologie, Herrn Prof. 
Dr. Kribben, und deren Mitarbeiter werden die Daten
innerhalb des Transplantationszentrums 
im  Einzelfall  Passwort-geschützt  und  verschlüsselt  auch
über  Internet  verfügbar  gemacht (Verschlüsselung,
Passwort-geschützt).  Der  Sinn  dieses  Vorgehens  ist,  im
Falle  eines Organangebotes, welches häufig nachts
erfolgt, möglichst schnell Ihre medizinischen Daten 
einsehen zu können, um zu entscheiden, ob Sie
transplantabel sind und welche eventuellen 
medizinischen  Probleme  beachtet  werden  müssen.
Dadurch  erreichen  wir  eine  kürzere 
Konservierungszeit für das zu transplantierende Organ,
was für die Funktion der neuen Niere 
wichtig ist. Mit dem Einverständnis zur Anmeldung für eine
Nierentransplantation erklären 
Sie sich mit diesem Vorgehen einverstanden.  
Damit  Sie  innerhalb  von  60  Minuten  auch  sicher
gefunden  werden  können,  sollten  Sie  in Ihrem
Dialysezentrum  alle  Telefonnummern  angeben,  unter
denen  Sie  zu  erreichen  sind (Handy,  Arbeitsstelle,
Eltern,  Freund  oder  Freundin,  Campingplatz  usw.).  Sie
sollten  sich dabei nicht völlig auf das Handy verlassen, da
im entscheidenden Augenblick der Akku leer sein  kann
oder  Sie  sich  gerade  in  einem  „Funkloch“  befinden
könnten.  Nach  dieser  ersten Kontaktaufnahme stehen in
der Regel noch 3-5 Stunden zur Verfügung, bis Sie
spätestens im Transplantationszentrum  eintreffen  sollten.
Wenn  Sie  nicht  erreichbar  sind,  wird  die Spenderniere
von Eurotransplant an einen anderen Patienten vergeben.  
Natürlich können Sie auch nach der Meldung zur
Nierentransplantation Urlaub machen.  In 
der  Regel  ist  ein  Urlaub  in  Deutschland,  den
Niederlanden,  Belgien  oder  Luxemburg 
problemlos  möglich, da  Sie ausreichend schnell bei  uns
sein  können. Wichtig ist, dass  Sie 
Ihrem Nephrologen (Dialysearzt) Ort und Telefonnummer
Ihres Aufenthaltsortes (Hotel usw.) 
mitteilen.  Damit  Sie  möglichst  schnell  in  unsere  Klinik
kommen  können,  gibt  es  spezielle Rückholdienste,  für
die  Sie  sich  versichern  lassen  können.  Diese  Dienste
werden  zum Beispiel  von  der  Deutschen
Rettungsflugwacht  angeboten.  Im  Falle  einer  Reise  an
einen fernen  Urlaubsort  sollten  Sie  sich  vorübergehend
für  die  Zeit  Ihres  Urlaubes  im Transplantationszentrum
"stumm"  melden,  wenn  Sie  uns  innerhalb  der
vorgegebenen  Zeit 
nicht erreichen können. Sie erhalten in dieser Zeit kein
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Transplantationsangebot, sondern das 
Angebot geht automatisch an den nächsten geeigneten
Patienten. Die Wartezeit läuft in dieser 
Zeit des „Stumm-meldens“ unverändert weiter.  
Zur  Zeit  werden  in  der  Bundesrepublik  Deutschland
pro  Jahr  ca.  3.500  
Nierentransplantationen  durchgeführt. Auf der  Warteliste
von Eurotransplant stehen 10.000 
Patienten. Die derzeitige Wartezeit beträgt ca. 4-6  Jahre
im Durchschnitt. Das heißt natürlich 
nicht, dass alle Patienten genau 5 Jahre warten. Es gibt
Patienten, für die findet sich wenige 
Wochen nach Anmeldung eine passende Niere. Dafür
warten andere Patienten 6 oder 7, selten 
sogar noch mehr Jahre. Dies hängt damit zusammen, dass
so viele Übereinstimmungen Ihrer 
Gewebemerkmale mit dem jeweiligen Spender wie möglich
vorhanden sein sollten. 
Transplantate von Spendern über 65 Jahren werden
bevorzugt an Patienten, die ebenfalls über 
65  Jahre  alt  sind,  vermittelt.  Damit  verkürzt  sich  die
Wartezeit  für  diese  Patienten    . 
Allerdings  haben  die  Nieren  eines  älteren  Spenders
bereits  einen  Alterungsprozess 
durchlaufen. 
Zunehmend  wird  auch  von  der  Möglichkeit  der
Transplantation  einer  Niere  von  einem 
lebenden Organspender Gebrauch gemacht. Dies kommt
für Verwandte, und für Personen, die 
dem Empfänger in besonderer emotioneller Verbundenheit
nahe stehen, in Betracht. Vorteile 
dabei sind die kurze Wartezeit, die  Planbarkeit der
Operation und die sehr kurze Zeit, die die 
Transplantatniere außerhalb des Körpers sein muß. Wir
informieren Sie gerne über weitere 
Einzelheiten dieser Form der Transplantation. 
Erfolgsaussichten und Risiken: 
Mit einer Nierentransplantation kann die Funktion der
erkrankten Nieren ersetzt werden. Die 
Nierenkrankheit  bleibt allerdings  auch nach der
Transplantation unverändert bestehen.. Ob 
und  wie  lange  ein  Transplantat  funktioniert,  ist  nicht
vorherzusagen.  Im  Durchschnitt 
funktionieren  die  Hälfte  aller  Nierentransplantate  länger
als  10  Jahre,  80%  -  90%  aller Nierentransplantate
länger als 1 Jahr und nur 5 - 10% der Nierentransplantate
funktionieren nie. Der Grund für den Verlust der
Transplantatfunktion sind die schleichende Abstoßung und
selten  das  Widerauftreten  der  ursprünglichen
Nierenerkrankung  im  Transplantat.    Für  den Erfolg der
Transplantation spielt es keine Rolle, ob Sie vorher mit der
Hämodialyse oder der Peritonealdialyse  behandelt
wurden.  In  den  letzten  Jahren  sind  die  Erfolge  einer
Nierentransplantation  aufgrund  moderner  Medikamente
und  der  zunehmenden  Erfahrung immer  besser
geworden.  Nachdem  ein  Transplantat  versagt  hat,  kann
sofort  wieder  die Hämodialyse oder die Peritonealdialyse
fortgesetzt werden. Danach ist es auch möglich, Sie für
eine weitere Nierentransplantation vorzubereiten.  
Wie jede Operation ist auch eine Nierentransplantation
nicht ohne Risiko. Dieses Risiko wird 
größer, wenn der zu transplantierende Patient
Risikofaktoren aufweist, d. h. wenn er neben 
seiner  Nierenerkrankung  noch  andere  Krankheiten,  wie
z.B.  eine  Herzerkrankung,  einen 
schweren  Bluthochdruck  oder  eine  starke
Gefäßverkalkung  aufweist.  Auch  das 
Zigarettenrauchen ist ein Risikofaktor. Insgesamt
versterben innerhalb des ersten Jahres nach 
einer Nierentransplantation  2 – 4 % aller Patienten. Bei
Empfängern, die über 65 Jahre alt 
sind liegt das Risiko der Sterblichkeit bei 5 – 10 %. Im
Vergleich zu den letzten Jahren hat 
dieses  Risiko  deutlich  abgenommen.  Wenn  Sie
Raucher  sind,  sollten  Sie  unbedingt    das Rauchen
einstellen,  sobald  Sie  für  eine  Transplantation  gemeldet
sind.  Denn  diesen Risikofaktor  können  Sie  ausschalten.
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Wenn  Sie  stark  übergewichtig  sind,  senkt  eine
Reduktion des Körpergewichts ebenfalls das
Operationsrisiko. 
Für die Ärzte, die operiert haben, sowie die in Zukunft
transplantierten Patienten, ist es im 
Falle  eines  Todes  wichtig,  die  genaue  Todesursache  zu
erfahren.  Sollte  dies  aufgrund  der Umstände  nicht  klar
sein,  gehen  wir  davon  aus,  dass  Sie  mit  der
Anmeldung  zur 
Transplantation mit der Durchführung einer Leichenöffnung
einverstanden sind. Sinn dieser 
Maßnahme  ist  es,  die  Behandlung  der  transplantierten
Patienten  zu  verbessern.  Wenn  Sie bedenken,  dass
auch  Ihr  Nierenspender  mit  einer  Leichenöffnung  und
Organentnahme 
einverstanden war, um Ihnen zu helfen, so fällt Ihnen diese
Entscheidung sicher nicht schwer. 
Operation, Krankenhausaufenthalt: 
Wenn Sie zur Transplantation ins Universitätsklinikum
Essen einbestellt werden, gehen Sie 
bitte auf die Station AC 2 in der Etage B 3 des Operativen
Zentrums II (OPZ II). Zuerst muss 
untersucht werden, ob Sie narkosefähig sind und ob Sie vor
der Transplantation noch einmal 
dialysiert  werden  müssen.  Auch    wird  Blut  für  eine
Verträglichkeitsüberprüfung  (sog. 
Kreuzprobe, Crossmatch) abgenommen. Hierbei wird Blut
von Ihnen mit Blut vom Spender 
in Kontakt gebracht. Man sieht dann, ob eine schwerste
Unverträglichkeitsreaktion vorliegt 
oder nicht. Wenn dies der Fall ist (d.h.  Die Kreuzprobe ist
positiv), darf die Transplantation 
nicht  durchgeführt  werden,  da  dann  das  Organ  noch
während  der  Operation  abgestoßen 
werden  würde.  Dann  müssen  Sie  wieder  nach  Hause
gehen  und  auf  das  nächste Nierentransplantat, das
Ihnen von Eurotransplant zugeteilt wird warten. Ihre
Wartezeit bleibt 
dabei unverändert bestehen. Leider fällt die Kreuzprobe in
10% der Fälle positiv aus. Häufig 
ist das bei den Patienten, die viele Schwangerschaften,
viele Bluttransfusionen oder die schon 
einmal  transplantiert  waren.  Die  Verträglichkeitsprobe
nimmt  leider  4  -  6  Stunden  in 
Anspruch.  Solange  müssen  Sie  und  auch  wir  geduldig
abwarten.  Wenn  die  Kreuzprobe 
negativ  ist,  wird  zügig  transplantiert.  Die
Transplantationsoperation  wird  in  Vollnarkose 
durchführt und dauert im allgemeinen zwischen 2 - 4
Stunden. Die Niere wird in den rechten 
oder  linken  Unterbauch  unterhalb  der  Haut,  des
Fettgewebes  und  der  Muskulatur  aber 
außerhalb des Bauchraumes eingepflanzt.  Das Bauchfell
selbst wird nicht eröffnet. Die Niere 
wird  an  die  Beckengefäße  (Arterie  und  Vene)  und  der
Harnleiter  an  die  Harnblase 
angeschlossen. Es wird eine Wunddrainage ausgeleitet,
die nach ca 2-3 Tagen entfernt wird. 
Der Dauerkatheter wird in der Regel 7 Tage belassen. Der
Harnleiter wird über einen Doppel-
J-Katheter geschient, der nach 4-6 Wochen entfernt wird.
Nach der Operation kommen Sie 
entweder auf die Intensivstation AC 1 oder aber auf die
Transplantationsstation AC 2, die auf 
die Versorgung von frisch transplantierten Patienten
besonders eingerichtet ist. Nach einigen 
Tagen (meist 4. postoperativer Tag) werden Sie auf die
nephrologische Station verlegt. Der 
Krankenhausaufenthalt  dauert  in  der  Regel  14  Tage,
kann  sich  aber  bei  Komplikationen 
verlängern. 
Komplikationen: 
Insgesamt  handelt  es  sich  bei  der  Nierentransplantation
um  ein  etabliertes  und  sicheres Standardverfahren.
Trotzdem können auch bei fachgerechter Durchführung der
Narkose und 
der Operation Komplikationen auftreten. 
Das Risiko einer Vollnarkose ist gering. Bei einer
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Vollnarkose mit Beatmungsschlauch und 
zentral-venösem  Katheter  sind  als  Intubations-  und
Narkoserisiken  jedoch  Heiserkeit, 
Halssschmerzen,  Zahn-,  Brücken-  und  Kronenschäden,
Kehlkopf-,  Zungen-  und 
Speiseröhrenriss,  Stimmbandschäden,  Allergien,
Erbrechen,  Herz-,  Kreislauf-,  Gefäß-  und 
Atemkomplikationen,  Thrombosen  einschließlich
Shuntverschluss,  Aspiration, 
Nachbeatmung, Schlaganfall, Herzinfarkt sowie Nerven-
und Lagerungsschäden möglich. 
Von  chirurgischer  Seite  kann  es  neben  allgemeinen
Komplikationen  wie  nicht  heilende 
Wunde,  Blutung/Nachblutung,  Narbenschäden,
Thrombose  und  Embolie  auch  zu 
Heilungsstörungen  im  Bereich  des  Harnleiters  mit
Urinleck  oder  zu  Verschlüssen  der 
angeschlossenen  Gefäße  kommen.  Dies  kann  eine
oder  mehrere  erneute  Operationen erforderlich machen
und im Einzelfall die Entfernung der transplantierten Niere
bedingen. Im 
Rahmen der Operation können, wie bei jeder Operation,
auch Verschlüsse oder Thrombosen 
des Shunts auftreten. 
In  etwa  der  Hälfte  der  Fälle  nimmt  die  Niere  ihre
Funktion  nicht  unmittelbar  nach  der Transplantation auf.
Das hängt damit zusammen, dass das Organ trotz aller
Bemühungen nach 
der Organentnahme nicht so optimal versorgt ist, wie im
menschlichen Körper. Man spricht 
von einem akuten Nierenversagen, das sich in der Regel
zurückbildet. Nach einigen Tagen bis 
(seltener)  Wochen  wird  die  Niere  ihre  Funktion
aufnehmen.  Für  diese  Zeit  müssen  Sie 
weiterhin dialysiert werden. Auch wenn die
Gewebeeigenschaften des Nierenspenders gut mit 
Ihren  Gewebeeigenschaften  übereinstimmen,  kann  es
zu  einer  Organabstoßung  nach  der 
Transplantation kommen, die dann behandelt wird und den
stationären Aufenthalt verlängern 
kann. 
Obwohl der Nierenspender und das Transplantat intensiv
untersucht werden, kann nicht völlig 
ausgeschlossen  werden,  dass  Infektionserreger  mit  dem
Transplantat  transplantiert  werden. 
Neben der sehr seltenen Übertragung von
schwerwiegenden Infektionserkrankungen kommt 
es sehr häufig zu einer Infektion mit dem sogenannten
Cytomegalie - Virus (CMV) oder dem 
Ebstein-Barr  Virus  (EBV).  Bei  der  Nierentransplantation
oder  danach  kann  es  erforderlich werden, dass Ihnen
Blut oder Blutprodukte transfundiert werden müssen.
Obwohl das Blut in der Blutbank eingehend  untersucht
wird, ist in  seltensten Fällen nicht auszuschließen, dass
durch das Blut Infektionen wie eine Hepatitis oder das HIV-
Virus mit transfundiert werden. 
Da Ihre Immunabwehr nach einer Nierentransplantation
durch die erforderliche Behandlung 
geschwächt  ist,  können  Sie  sich  Infekte,  wie  z.  B.  eine
Lungenentzündung  oder 
Harnwegsinfektionen zuziehen. 
Nachsorge – Biopsie, Blut, Verletzungen, Infektionen: 
Wenn Sie aus der Klinik entlassen worden sind, müssen
Sie sich zunächst für 1 - 2  Monate 
2mal  pro  Woche  in  der  Nierentransplantationsambulanz
vorstellen.  Sie  finden  die 
Nierentransplantationsambulanz im Medizinischen Zentrum
im Erdgeschoss. Eine Abstoßung 
tritt  meist  in  dieser  Phase  nach  der  Transplantation
auf.  Ein  frühzeitiges  Erkennen  und Behandeln  einer
Abstoßung  sichert  den  Langzeiterfolg  der
Transplantation,  da  eine  nicht behandelte Abstoßung zu
einem Verlust der Transplantatfunktion führt. . Zum
Nachweis einer Abstoßung  ist  es  häufig  erforderlich,
dass  eine  kleine  Probe  aus  dem  Transplantat
(Transplantatbiopsie) entnommen wird. Dazu müssen Sie
stationär aufgenommen werden und nach der Punktion bis
zum nächsten Morgen im Bett liegen bleiben. Die Probe
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wird zu einem 
spezialisierten  Pathologen  geschickt,  der  nach
mikroskopischer  Untersuchung  feststellen 
kann,  ob  es  sich  um  eine  akute  Abstoßung  handelt,
oder  ob  eine  andere  Ursache  für  eine 
Verschlechterung  der  Transplantatfunktion  verantwortlich
ist.  Als  häufigste  Komplikation 
kommt es nach einer Transplantatbiopsie mit 10% zu einer
Blutung. Diese ist meist harmlos. 
Es  wird  dann  erforderlich,  dass  Sie  viel  trinken  und
möglicherweise  ist  ein  spezieller 
Blasenkatheter zur Spülung der Harnblase erforderlich.
Schwerwiegende Verletzungen sind 
sehr selten. Extrem selten muss nach einer Verletzung
einer Nierenbiopsie operiert werden; 
ebenso  extrem  selten  ist  ein  Verlust  des
Transplantates.  Nach  Ablauf  der  ersten  3  Monate 
verlängern sich die Vorstellungsintervalle und Ihr
Nephrologe (Dialysearzt) wird zunehmend 
in die Betreuung mit eingeschaltet. Nach Ablauf eines
Jahres ist eine Vorstellung nur noch in 
6 – 12 wöchigen Abständen erforderlich. In der Praxis
bedeutet dies, dass Sie nach dem ersten 
Jahr  alle  3  Monate  einmal  in  Essen  sind  und  in  der
Zwischenzeit  von  Ihrem  Nephrologen 
(Dialysearzt) betreut werden. 
Medikamente und Nebenwirkungen: 
Die Behandlung nach der Nierentransplantation soll eine
Abstoßung des Organs verhindern. 
Es stehen hierzu Medikamente zur Verfügung, die in den
Immunmechanismus des Körpers 
eingreifen.  Diese  Medikamente  müssen  regelmäßig
eingenommen  werden.  Es  darf  keinen 
einzigen  Tag geben, an dem Sie die Medikamente nicht
einnehmen. Im Gegenteil: Sollten Sie 
aufgrund  von  Durchfall  oder  Erbrechen  einmal  die
Befürchtung  haben,  Sie  könnten  das 
Medikament  nicht  bei  sich  halten,  müssen  Sie  sich
sofort  in  der  Transplantationsambulanz 
melden,  damit  wir  Ihnen  Ihre  Medikamente  notfalls
intravenös  direkt  ins  Blut  spritzen können.  Um
einerseits  die  Nebenwirkungen  der  Medikamente  zu
mildern,  aber  auch andererseits  an  verschiedenen
Stellen  des  Immunsystems  anzugreifen,  kombiniert  man
üblicherweise  mehrere  Medikamente,  sogenannte
Immunsuppressiva,  miteinander.  Im 
Wesentlichen sind es 3 – 4 Medikamente, die die Basis der
Behandlung darstellen. 
Die  Basisbehandlung  von  nierentransplantierten
Patienten  wird  z.  Zt.  vornehmlich  mit 
Sandimmun Optoral_ oder Prograf_ durchgeführt. Diese
Therapie wird durch die Gabe von 
Prednison_  ergänzt.  Dieses  wird  in  der  täglichen
Dosierung  anfänglich  höher  dosiert,  bei stabiler
Nierenfunktion  in  der  weiteren  ambulanten  Nachsorge
reduziert.  Als  viertes Medikament  kommt
Mycophenolatmofetil  (CellCept_  bzw.  Myfortic_),  zur
Anwendung, 
welches  zusätzliche  Angriffsmöglichkeiten  am
Immunsystem  besitzt,  die  den  anderen 
Medikamenten fehlen.
Die  längste  Erfahrung  hinsichtlich  der  medikamentösen
Behandlung  nierentransplantierter 
Patienten  besteht  mit  einem  Hormon  der
Nebennierenrinden,  dem  so  genannten  Cortison 
(Prednison_).  Als  Nebenwirkungen  kann  Cortison  zu
einer  Zuckerkrankheit  (Diabetes 
mellitus) führen. Zudem sind Fettstoffwechselstörungen
beobachtet worden. Bei Patienten mit 
bekannten Magen-Darmbeschwerden in der Vorgeschichte,
wie z. B. Magengeschwüren oder 
Zwölffingerdarmgeschwüren  (Ulcera),  können  erneute
Geschwüre  und  eventuell  auch 
Blutungen aus der Magenschleimhaut hervorgerufen
werden. Auch Thrombosen wurden unter 
einer  Cortisonmedikation  häufiger  beobachtet  als  bei
gesunden  Patienten,  weshalb  die 
Patienten so früh wie möglich nach einer Transplantation
aufstehen sollten.  
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Hinsichtlich  des  Knochensystems  verursacht  Cortison  in
der  Langzeiteinnahme  eine 
Knochenerweichung  (Osteoporose),  die  insbesondere
bei  hohen  Dosierungen  zu  spontanen 
Knochenbrüchen im Hüftkopfbereich führen kann. Ein
grauer oder grüner Star (Katarakt bzw. 
Glaukom) kann sich unter einer Cortisonmedikation
verschlechtern oder auch neu auftreten. 
Gelegentlich  kann  es,  insbesondere  im  Gesichts-  und
Dekolleté-Bereich,  zu  Papeln  und 
Pusteln  kommen,  die  jedoch  meistens,  insbesondere
nach  Reduktion  des  Cortisons,  rasch 
abklingen  und  harmlos  sind.  Beachten  Sie  auch,  dass
Cortison  zu  einer  beachtlichen 
Steigerung  des  Appetits  und  damit  zu  deutlichen
Gewichtszunahmen  führen  kann. 
Disziplinierte Essgewohnheiten sind deshalb auch nach der
Nierentransplantation dringend zu 
empfehlen. 
Durch die Kombination mit anderen immunsuppressiven
Medikamenten kann heutzutage die 
Cortisondosis  in  der  Regel  so  gering  gehalten  werden,
dass  die  oben  beschriebenen 
Nebenwirkungen weit seltener und weniger stark
ausgeprägt auftreten als noch vor einigen 
Jahren.  Ebenfalls  lange  Erfahrungen  in  der
Transplantationsmedizin  hat  man  mit  dem 
Medikament  Azathioprin  (Imurek_)  und  dessen
Nachfolger  Mycophenolatmofetil 
(CellCept_,  bzw. Myfortic_). Beide Substanzen  sind
weder leber-  noch nierenschädigend, 
können jedoch häufig Störungen im Magen-Darmbereich
wie Übelkeit, Bauchschmerzen oder 
Durchfälle auslösen. Rasch regenerierende Zellen,
einschließlich der blutbildenden Zellen des 
Knochenmarks,  können  durch  diese  Präparate
gehemmt  werden.  Blutbildveränderungen, 
insbesondere  der  weißen  Blutkörperchen  (Leukozyten),
seltener  der  roten  Blutkörperchen 
(Hb)  und  der  Blutplättchen  (Thrombozyten),  wurden
beobachtet.  Meist  genügt  hier  eine 
Reduktion  der  Dosis  von  CellCept_,  bzw.  Myfortic_,  zur
Normalisierung  des  Blutbildes. 
Unter  Einnahme  von  CellCept_,  bzw.  Myfortic_,    wird
häufiger  eine  CMV-Infektion beobachtet. Hierbei handelt
es sich um eine Virusinfektion aus der Familie der
Herpesviren. 
Bei  einer  Durchseuchung  von  bis  zu  90%  in  der
Bundesbevölkerung  stellt  dieses  Virus 
normalerweise für immungesunde Personen kein Problem
dar. Nach der Transplantation kann 
es jedoch, insbesondere wenn ein CMV-positives Organ in
einen CMV-negativen Empfänger 
transplantiert wurde, zu einer hochfieberhaften Erkrankung
kommen. Diese muss heute für 2 
Wochen stationär intravenös mit Cymeven behandelt
werden.  
Die Langzeitbeobachtungen insbesondere mit Imurek_
haben gezeigt, dass die konsequente 
Durchführung eines Lichtschutzes durch Meiden der Sonne
und konsequentes Anwenden von 
Lichtschutzfaktoren das Entstehen von gutartigen aber
auch bösartigen Hauttumoren deutlich 
senken  kann.  Prinzipiell  muss  davon  ausgegangen
werden,  dass  die  Entstehung  von 
Hauttumoren  wie  auch  anderen  bösartigen
Erkrankungen  auch  unter  allen  anderen 
immunsuppressiven Medikamenten auftreten kann. 
Die  Standardmedikamente,  welche  die
Transplantatüberlebenszeit  in  den  vergangenen  10 
Jahren  deutlich  verlängert  haben,  sind  das  Tacrolimus
(Prograf_)  und  das  Cyclosporin  A 
(Sandimmun Optoral)_ : Beide Medikamente ähneln sich in
der Wirkungsweise und haben 
auch teilweise die gleichen Nebenwirkungen. Tacrolimus
(Prograf_) wird heutzutage in den 
meisten Fällen eingesetzt. 
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Insbesondere bei Frauen kann unter Cyclosporin A ein
vermehrter Haarwuchs am gesamten 
Körper  zu  psychischen  Belastungen  führen.  Stets
gutartige  Zahnfleischwucherungen  treten 
gehäuft  auf,  erfordern  jedoch  eine  regelmäßige
zahnärztliche  Betreuung  und  gewissenhafte 
Zahn- und Zahnfleischpflege. In therapieresistenten Fällen
lassen sich durch einen Wechsel 
der  Immunsuppression  von  Cyclosporin  A  (Sandimmun
Optoral_)  auf  Tacrolimus 
(Prograf_)  sowohl  die  verstärkte  Behaarung  als  auch
die  gutartigen  Wucherungen  des 
Zahnfleisches beheben.  
Zu den klassischen Nebenwirkungen des  Tacrolimus
(Prograf_)  gehört  ein,  zumeist dosis-
abhängiges,  Händezittern  (Tremor).  Insbesondere  direkt
nach  der  Transplantation  wird 
Tacrolimus  (Prograf_)  in  einer  höheren  Dosis  gegeben.
.  Im  weiteren  ambulanten  Verlauf wird die Dosis
reduziert, so dass dann das Zittern der Hände im
Allgemeinen kein Problem darstellt.  Tacrolimus  (Prograf_)
kann  die  Entwicklung  einer  manifesten
Zuckererkrankung (Diabetes mellitus) insbesondere in
Kombination mit Prednison_ unterstützen.
Erhöhungen der Blutfettwerte treten unter Cyclosporin A
(Sandimmun Optoral_) auf und in 
milderer Form auch unter Tacrolimus (Prograf_). Im
Gegensatz zu der häufig Cyclosporin A-
vermittelten Zunahme der Körperbehaarung kann es unter
Tacrolimus (Prograf_) zu einem 
diffusen Haarausfall des Kopfhaares kommen. Bei
Cyclosporin A und bei Tacrolimus ist die 
Infektionsgefahr in etwa gleich hoch ist.  
Sowohl bei Tacrolimus (Prograf_) als auch beim
Cyclosporin A (Sandimmun Optoral_)ist 
eine ganz regelmäßige Einnahme der Kapseln erforderlich.
Es sollte möglichst nicht mehr als 
12  Stunden  zwischen  der  morgendlichen  und  der
abendlichen  Einnahme  liegen,  da  für  die 
Verhinderung  einer  Organabstoßung  wirksame
Blutspiegel  eines  der  Medikamente 
erforderlich sind. Diese Blutspiegel werden sowohl direkt
nach der Transplantation als auch 
in  den  weiteren  ambulanten  Vorstellungen  regelmäßig
kontrolliert.  Hinsichtlich  der 
therapeutischen Breite liegt für beide Substanzen nur ein
schmales Fenster vor. Sowohl ein zu 
geringer als auch ein zu hoher Spiegel können
organschädlich sein. Aufgrund dieser Tatsache 
wird eine regelmäßige Blutspiegelbestimmung zur
Dosisanpassung der beiden Medikamente 
sowohl in der stationären Betreuung als auch durch die
Ambulanzärzte vorgenommen. Diese 
Blutspiegel  werden  vor  der  morgendlichen  Einnahme
von  Tacrolimus  oder  Cyclosporin  A 
abgenommen.  Wir  weisen  ausdrücklich  darauf  hin,
dass  in  Deutschland  nur  wenige 
Medikamente  bzw.  Kombinationen  von  Medikamenten
für  die  Transplantation  offiziell 
zugelassen  sind.  Auch  die  aktuelle  Standardtherapie
(eine  Kombination  verschiedener 
Medikamente),  die  zurzeit  dem  internationalen
Behandlungsstandard  entspricht,  ist  in 
Deutschland offiziell nicht zugelassen (sogenannte off-label
Medikation). Für den Erhalt des 
Transplantates  ist  die  Verordnung  dieser
Medikamentenkombination  aber  dringend 
notwendig. 
Zur  Verbesserung  der  Transplantations-  und  damit  auch
Lebensqualität  werden  auch  in 
Zukunft neuere, hochwirksame Medikamente zur
Immunsuppression entwickelt. Diese neuen 
Immunsuppressiva werden im Rahmen sogenannter
kontrollierter Studien zumeist weltweit in 
Transplantationszentren eingeführt. Wir weisen darauf hin,
dass wir intensiv daran forschen, 
Transport  und  Konservierung  der  gespendeten  Nieren
zu  verbessern,  dazu  sind  dann 
Vergleiche  von  Konservierungslösungen  und  –verfahren
erforderlich.  Um  den 
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Transplantationserfolg und damit den Fortschritt der
Medizin im Hinblick auf die zukünftigen 
Generationen zu fördern, möchten wir Sie deshalb ganz
besonders zu der Teilnahme an diesen 
Studien ermuntern. Damit können Sie schon die
modernsten Medikamente erhalten, bevor sie 
in  der  Apotheke  allgemein  erhältlich  sind.  In  der
Vergangenheit  haben  zahlreiche 
transplantierte  Patienten  durch  Teilnahme  an
kontrollierten  Studien  zu  Cyclosporin  A  oder Tacrolimus
zu deren Marktzulassung und damit zur Verbesserung der
Lebensqualität heutiger 
Transplantationspatienten  beigetragen.  Auch  in
Zusammenhang  mit  diesen  „neueren“ 
Immunsuppressiva  gilt  zu  beachten,  dass  konsequenter
Lichtschutz  durch  Benutzen  von 
hohen  Lichtschutzfaktoren,  Meiden  der  Sonne  etc,
notwendig  ist,  um  die 
Langzeitnebenwirkungen durch UV-Schäden zu
vermeiden.  
Ein  weiterer  wichtiger  Punkt  liegt  uns  noch  am
Herzen:  nicht  alle  Medikamente,  die  Sie 
früher  unter  Umständen  problemlos  vertragen  haben,
sind  unschädlich  für  Ihre 
Transplantatniere.  Um  zu  vermeiden,  dass  es  zu  einer
Verschlechterung  der 
Transplantatfunktion nach Transplantation kommt, möchten
wir Sie ganz eindringlich bitten, 
vor der Verordnung eines Ihnen unbekannten
Medikamentes, das Ihnen nicht durch einen der 
Ärzte  unserer  Transplantationsambulanz  oder  Ihrem
Nephrologen  verordnet  wurde, 
Rücksprache mit unserem Zentrum aufzunehmen. Die dort
arbeitenden Ärzte haben sich mit 
den speziellen Problemen nach der Transplantation
eingehend beschäftigt und können Ihnen 
sagen, ob dieses Medikament nierenschädlich oder neutral
ist. Ihre Ärzte geben Ihnen gerne 
Auskunft oder nennen Ihnen entsprechende
Ausweichpräparate. 
Wir  haben  mit  diesen  schriftlichen  Informationen
sicherlich  nicht  alle  Sie  informierenden 
Punkte  aufgreifen  können.  Deshalb  stehen  wir  Ihnen
gerne  auch  für  ein  persönliches 
Gespräch  zur  Verfügung.  Falls  Ihnen  nach  dem
Transplantationsgespräch  irgendwelche 
Fragen  oder  Probleme  noch  einfallen  sollten,  so
können  Sie  diese  entweder  mit  Ihrem 
Nephrologen oder mit uns (vormittags Tel.: 0201-7233952)
direkt besprechen. Auch Fragen 
während der Wartezeit auf der Transplantationsliste
beantworten wir gerne. 
Essen, den  19.02.2013 
Prof. Dr. A. Kribben        Prof. Dr. A. Paul 
Direktor der                Direktor der 
Klinik für Nephrologie      Klinik für Allgemeinchirurgie und
Viszeral-  
Zentrum für Innere Medizin  und Transplantationschirurgie 
Zentrum für Chirurgie
All rights reserved. Please visit https://medical-data-
models.org/forms/14656
Information leaflet on Kidney
transplantation Transplant centre
Essen
Erklärung des Patienten zur
Nierentransplantation (Eine Kopie Ihrer
Einwilligungserklärung erhalten nach dem
Gespräch in unserer  Sprechstunde)
Ich, Herr /Frau/Frl. (Bei Minderjährigen beide
Erziehungsberechtigte)
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wurde durch Herrn/Frau Dr. med.....  informiert
und  aufgeklärt.
Individuelle Besonderheiten oder Risiken:
Ich fühle mich ausreichend aufgeklärt.
Ja
Nein
Datum
Ort
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Eligibility Rheumatoid Arthritis
NCT00195702
Efficacy and Safety of Adalimumab in Patients With Active
Rheumatoid Arthritis Treated Concomitantly With
Methotrexate.; ODM derived from:
https://clinicaltrials.gov/show/NCT00195702
All rights reserved. Please visit https://medical-data-
models.org/forms/14657
Eligibility Rheumatoid Arthritis
NCT00195702
Inclusion Criteria
age 18 or older and in good health (investigator
discretion) with a recent stable medical history*
Yes
No
met american college of rheumatology (acr)
criteria for diagnosis of active rheumatoid arthritis
(ra) and had at both screening and baseline visits
>=6 swollen joints and >=9 tender joints, despite
a minimum of 3-months treatment with
methotrexate (mtx). (distal interphalangeal joints
[dips] were not to be included in joint count for
inclusion. the screening and baseline visits could
be 3 to 28 days apart for patients not previously
receiving disease-modifying anti-rheumatic drugs
[dmards] other than mtx or 4 to 6 weeks for
patients requiring a dmard washout period.)*
Yes
No
insufficient efficacy with mtx 12.5 to 25 mg per
week (10 mg per week if mtx intolerant).*
Yes
No
if patient on a second-line treatment (dmard)
other than mtx, he/she had to discontinue it for at
least 28 days before the baseline visit (the
washout period).*
Yes
No
treatment with oral folic acid 1-3 mg/day or, if
appropriate, up to 10 mg leucovorin per week.*
Yes
No
both rheumatoid factor positivity and a c-reactive
protein value >=1 mg/dl, or at least one joint
erosion on x-ray.*
Yes
No
Exclusion Criteria
subject considered by the investigator, for any
reason, to be an unsuitable candidate for the
study.*
Yes
No
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female subject who was pregnant or breast-
feeding or considering becoming pregnant.*
Yes
No
preceding treatment with any tumor necrosis
factor (tnf) antagonist, including adalimumab.*
Yes
No
prior exposure to alkylating agents, such as
chlorambucil or cyclophosphamide.*
Yes
No
intra-articular, intramuscular, or intravenous
administration of corticosteroids within 4 weeks
prior to the screening visit.*
Yes
No
subject was wheelchair bound or bedridden.*
Yes
No
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Registration for Kidney transplantation Transplant
centre Essen University Hospital Essen
Item used as routine documentation by the University
hospital Essen, Transplant centre, Information leaflet.  ODM
derived from original form “ANMELDUNG ZUR
NIERENTRANSPLANTATION”
University hospital Essen, Transplant centre, Hufelandstr.
55, 45122 Essen, Germany.
All rights reserved. Please visit https://medical-data-
models.org/forms/14658
Registration for Kidney
transplantation Transplant centre
Essen
Personal Information
Patient surname
Patient first name
Date of birth
First day of dialysis
Primary kidney disease
Blood group
Body height
Body weight
Nephrology centre
Date of registration
Questionnaire for registration for renal
transplantation
Patient name
Date
1. Coronary heart disease
Yes
No
Stents or bypasses
Yes
No
2. Heart failure
Yes
No
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NYHA
I (1)
II (2)
III (3)
IV (4)
3. Heart Valve disease
Yes
No
4. Peripheral arterial disease
Yes
No
Vascular prosthesis or peripheral bypass
Yes
No
5. Hepatitis B
Yes
No
Hepatitis C
Yes
No
6. Prior abdominal surgery or inguinal surgery
Yes
No
7. Recurrent thrombosis
Yes
No
8. Hemorrhage
Yes
No
9. Recurrent urinary tract infection
Yes
No
10. Tuberculosis
Yes
No
11. Psychotic reactions
Yes
No
12. Number of operations for dialysis access
(Shunt, atrial catheter, peritoneal dialysis)
Medical Examination (Checklist)
Urology
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Appointment met?
Yes
No
Dentist optional
Appointment met?
Yes
No
Appointment date gynecology
Appointment met?
Yes
No
Appointment date Sonography Abdomen
Appointment met?
Yes
No
Appointment date Doppler pelvic and leg and
closure pressures
Appointment met?
Yes
No
Appointment date Doppler carotid
Appointment met?
Yes
No
Appointment date Chest x-ray
Appointment met?
Yes
No
Appointment date lung function
Appointment met?
Yes
No
Stress ECG (at least 100 watts) alternatively
Myocardial Scintigraphy or stress echo
Appointment met?
Yes
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Registration for Kidney transplantation Transplant centre Essen
University Hospital Essen
No
Appointment date echocardiography
Appointment met?
Yes
No
Appointment date Coronary angiography (from 60
years and older)
Appointment met?
Yes
No
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Registration for Kidney transplantation Transplant centre Essen
University Hospital Essen
NINDS CDE Devices Epilepsy
NINDS Common Data Elements Used from the National
Institute of Neurological Disorders and Stroke Common
Data Elements
(https://www.commondataelements.ninds.nih.gov/)
References: Grinnon ST, Miller K, Marler JR, Lu Y, Stout A,
Odenkirchen J, Kunitz S. National Institute of Neurological
Disorders and Stroke Common Data Element Project -
approach and methods. Clin Trials. 2012;9(3):322-9.
All rights reserved. Please visit https://medical-data-
models.org/forms/14661
Devices
Device Revision/Replacement Log
Study ID
Study site name
Subject ID
Line number
Device and device number on Devices Log
Date of revision
Implantable Neurostimulator
Explant and replace on same day (1)
Explant only (2)
Replacement only (previously explanted)
(3)
Repositioned (4)
Implantable Neurostimulator:Model Nr. of new
INS
Implantable Neurostimulator: Device registration
Nr of new INS
INS Lead (LEFT)
Explant and replace on same day (1)
Explant only (2)
Replacement only (previously explanted)
(3)
Repositioned (4)
INS Lead (LEFT): Model Nr of new lead
INS Lead (LEFT): Device registration Nr of new
lead
INS Lead (RIGHT) if applicable
Explant and replace on same day (1)
Explant only (2)
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Replacement only (previously explanted)
(3)
Repositioned (4)
INS Lead (RIGHT) if applicable: Model Nr of new
lead
INS Lead (RIGHT) if applicable: Device
registration Nr of new lead
INS Extension (LEFT) if applicable
Explant and replace on same day (1)
Explant only (2)
Replacement only (previously explanted)
(3)
Repositioned (4)
INS Extension (LEFT) if applicable: Model Nr of
new extension
INS Extension (LEFT) if applicable: Device
registration Nr of new extension
INS Extension (RIGHT) if applicable
Explant and replace on same day (1)
Explant only (2)
Replacement only (previously explanted)
(3)
Repositioned (4)
INS Extension (RIGHT) if applicable: Model Nr of
new extension
INS Extension (RIGHT) if applicable: Device
registration Nr of new extension
INS: Other component
Explant and replace on same day (1)
Explant only (2)
Replacement only (previously explanted)
(3)
Repositioned (4)
INS other: Model Nr of other new component
INS Other component: Device registration Nr of
other new component
Clinical Condition if applicable, reason for the
device revision/replacement
Serious Adverse Device Effect, specify
(1)
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NINDS CDE Devices Epilepsy
Intolerable Stimulation Related Adverse
Event, specify (2)
Other Adverse Event, specify (3)
Inadequate Seizure Control (4)
Other, specify (5)
Reason for the device
revision/replacement:please specify
Devices Log
Line number
Device name
VNS (1)
DBS (2)
RNS (3)
Other, specify (4)
Device name,please specify
Date of initial implant
Device Manufacturer
Device Registration Nr or Serial Nr
INS (1)
Lead (2)
Extension (if applicable) (3)
Device Registration Nr or Serial Nr
Stimulation Target
Left Vagus Nerve (1)
Hippocampus (2)
Left side (3)
Right side (4)
AN (5)
Unilateral (6)
Bilateral (7)
Other, specify (8)
Stimulation Target:please specify other target
Type of Lead
VNS (1)
Depth; # Contacts (2)
Strip; # Contacts (3)
Other, specify (4)
Type of Lead: Depth; Nr Contacts
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Type of Lead: Strip; Nr Contacts
Type of Lead: please specify other
Location of Neurostimulator
Right Chest (1)
Left Chest (2)
Other, specify (3)
Location of Neurostimulator:please specify
"other"
Date of Permanent Explant (if applicable)
Is any part of the device left in the body?
Yes
No
Is any part of the device left in the body? If yes,
please specify
If applicable, Reason for Discontinuation
Serious Adverse Device Effect, specify
(1)
Intolerable Stimulation Related Adverse
Event, specify (2)
Other Adverse Event, specify (3)
Inadequate Seizure Control (4)
Other, specify (5)
Reason for Discontinuation: please specify
Implanted Devices Log
Line number and number of device on Devices
Log
Device Type
Start date
mm/dd/yyyy
End date
mm/dd/yyyy
Amperage
mA
Voltage
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Frequency
Hz
Pulse Width
uSec
Stimulation Duration ON
mins
Stimulation Duration OFF
mins
Positive Electrode Count if applicable
Negative electrode count if applicable
If applicable, reason for modifying parameters or
electrode configuration
Serious Adverse Device Effect, specify
(1)
Intolerable Stimulation Related Adverse
Event, specify (2)
Other Adverse Event, specify (3)
Inadequate Seizure Control (4)
Other, specify (5)
Reason for modifying parameters or electrode
configuration, please specify
Further comments
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Eligibility Bone Metastases NCT02226276
Copper Cu 64-DOTA-Trastuzumab PET in Predicting
Response to Treatment With Ado-Trastuzumab Emtansine
in Patients With Metastatic HER2 Positive Breast Cancer;
ODM derived from:
https://clinicaltrials.gov/show/NCT02226276
All rights reserved. Please visit https://medical-data-
models.org/forms/14663
Eligibility Bone Metastases
NCT02226276
Inclusion Criteria
women with metastatic her2-positive breast
cancers whose disease has progressed on first-
line trastuzumab + chemotherapy will be
considered eligible for study participation if they
meet the following criteria:*
Yes
No
participants must be women who have
histological confirmation of metastatic invasive
breast cancer that has metastasized outside the
region of the primary tumor and axilla; biopsy
must be obtained within 28 days prior to
enrollment; patients must have metastatic
disease in lung, liver, soft-tissue or bone to
qualify for the study (more than one site is
permissible)*
Yes
No
at least 1 site of metastasis >= 20 mm in mean
diameter must be identified*
Yes
No
the cancer must over express her2 as determined
by immunohistochemistry (ihc) and/or
fluorescence in situ hybridization (fish)*
Yes
No
patients may not have received trastuzumab
within 6 weeks of projected 64cu-dota-
trastuzumab/pet-ct*
Yes
No
participants must have normal cardiac ejection
fraction*
Yes
No
planned therapy with ado-trastuzumab
emtansine*
Yes
No
ability to provide informed consent*
Yes
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No
patients that may need dose reduction to
commence cycle 1 treatment*
Yes
No
eastern cooperative oncology group (ecog)
performance status of 0-2*
Yes
No
negative serum pregnancy test (female of
childbearing potential only)*
Yes
No
patients must have adequate cardiac function; left
ventricular ejection fraction (lvef) >= 50% as
determined by multi gated acquisition (muga)
scan or echocardiogram*
Yes
No
Exclusion Criteria
participants who have received trastuzumab
within the prior 36 days*
Yes
No
participants who are not considered candidates
for ado-trastuzumab-emtansine*
Yes
No
no metastatic sites >= 20 mm*
Yes
No
concurrent malignancy other than skin cancer*
Yes
No
inability to provide informed consent*
Yes
No
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Eligibility Breast Cancer NCT02204462
FBnTP Imaging of Breast Cancer; ODM derived from:
https://clinicaltrials.gov/show/NCT02204462
All rights reserved. Please visit https://medical-data-
models.org/forms/14665
Eligibility Breast Cancer
NCT02204462
Inclusion Criteria
female patients with newly-diagnosed invasive
and/or intraductal breast cancer detected by core
needle or vacuum-assisted biopsy (i.e., index
cancer)*
Yes
No
age > 25 ability and willingness to sign informed
consent prior to any study procedure.*
Yes
No
positive indication of disease on mammogram or
mri scan.*
Yes
No
candidate for breast cancer surgery on the basis
of recommendation of a breast cancer surgeon.*
Yes
No
ability to undergo up to 90 minutes of pem
imaging.*
Yes
No
Exclusion Criteria
any active or chronic illness that, in the opinion of
the investigators, would make the study unsafe or
limit compliance with study procedures.*
Yes
No
past or present history of active substance abuse
(drug or alcohol).*
Yes
No
inability to tolerate venous access.*
Yes
No
pregnant females are excluded from this study. all
females of child-bearing potential will undergo a
serum pregnancy test within 48 hours prior to
fbntp administration.*
Yes
No
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Eligibility Breast Cancer NCT02236806
Cardiotoxicity Prevention in Breast Cancer Patients Treated
With Anthracyclines and/or Trastuzumab; ODM derived
from: https://clinicaltrials.gov/show/NCT02236806
All rights reserved. Please visit https://medical-data-
models.org/forms/14666
Eligibility Breast Cancer
NCT02236806
Inclusion Criteria
female*
Yes
No
age >18 years*
Yes
No
non-metastatic histologically confirmed primary
invasive breast cancer*
Yes
No
scheduled to receive neoadjuvant and/or adjuvant
anthracyclines with or without anti-her2 therapy*
Yes
No
provided informed consent*
Yes
No
able to swallow capsules*
Yes
No
lvef > 50%*
Yes
No
Exclusion Criteria
pregnant or lactating women*
Yes
No
treatment with ace-inhibitors or beta blockers at
diagnosis*
Yes
No
history of nci common toxicity criteria for adverse
effects (ctcae) (version 4.0) grade >2
symptomatic congestive heart failure (chf),
previous myocardial infarction, significant
symptoms (grade>2) relating to lvef dysfunction,
valvular disease, cardiac arrhythmia (grade>3)*
Yes
No
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Personal Medical History of Allergies, Infectious
Diseases, and Immunizations - Child PhenX Toolkit
This protocol is a proxy-administered personal health
record from the American Health Information Management
Association (AHIMA). The parent or guardian is asked to
provide details on the child in the following categories:
Birth, Health Log, Allergies/Drug Sensitivities, Infectious
Disease, and Immunizations.
ODM derived from: https://cde.nlm.nih.gov
Primary source: https://www.phenxtoolkit.org/
Recent publication: Hendershot, T., Pan, H., Haines, J.,
Harlan, W.R., Marazita, M.L., McCarty, C.A., Ramos, E.M.,
and Hamilton, C.M. (2015) Using the PhenX toolkit to add
standard measures to a study. Curr. Protoc. Hum. Genet.
86:1.21.1-1.21.17. doi: 10.1002/0471142905.hg0121s86
Permission to publish granted by
Carol M. Hamilton.
All rights reserved. Please visit https://medical-data-
models.org/forms/14668
Personal Medical History of
Allergies, Infectious Diseases, and
Immunizations - Child PhenX Toolkit
PhenX - personal medical history of
allergies, infectious diseases, and
immunizations - child protocol
Birth hospital facility ID [Identifier] in Facility
Birth weight GNWCH
Body height --lying
cm
Physician [Identifier]
Prenatal events
5 minute Apgar Score
Health problem sequence [PhenX]
Health problem 1   (1)
Health problem 2 (2)
Health problem 3 (3)
History of Unspecified body region disorders
Illness or injury onset date and time
Service comment
Allergies/Causes of Reaction
Patient Reaction
Anaphylaxis within 24 hours
(Anaphylaxis within 24 hours   )
Encephalopathy, disorder of the brain
(Encephalopathy, disorder of the brain)
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Fever     (Fever    )
Hypotonic (Hypotonic)
Pain     (Pain    )
Redness     (Redness    )
Swelling (Swelling)
Date of last reaction
Treatment information
Infectious disease [PhenX]
Chicken pox (Chicken pox)
Hepatitis     (Hepatitis    )
Measles     (Measles    )
Mumps     (Mumps    )
Other (Other)
Pertussis/whooping cough
(Pertussis/whooping cough  )
Pneumonia     (Pneumonia    )
Polio     (Polio    )
Rubella     (Rubella    )
Scarlet fever (Scarlet fever)
Age
Illness or injury onset date and time
Booster sequence [PhenX]
Booster 1     (Booster 1    )
Booster 2  (Booster 2 )
Booster 3 (Booster 3)
Booster type [PhenX]
Diphtheria     (Diphtheria    )
Hepatitis B (Hepatitis B)
Measles     (Measles    )
Mumps     (Mumps    )
Other     (Other    )
Other booster (Other booster)
Pertussis/whooping cough
(Pertussis/whooping cough)
Polio     (Polio    )
Rubella     (Rubella    )
Smallpox     (Smallpox    )
Tetanus     (Tetanus    )
Tuberculosis     (Tuberculosis    )
Typhoid     (Typhoid    )
Booster 1 Age
Booster 1 Date
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Personal Medical History of Allergies, Infectious Diseases, and
Immunizations - Child PhenX Toolkit
Assay for Cytokine Panel 12 Protocol
PhenX Toolkit
This protocol provides instructions for drawing, processing,
and storing blood according to the National Health and
Nutrition Examination Survey (NHANES) and uses the
multi-analyte fluorescent detection (MAFD) method to
measure 12¿different cytokines: Interferon gamma (IFN-
gamma), Interleukin-1 beta (IL-1 beta), Interleukin-10 (IL-
10), Interleukin-12 (IL-12), Interleukin-13 (IL-13),
Interleukin-2 (IL-2), Interleukin-2 Receptor (IL-2R),
Interleukin-4 (IL-4), Interleukin-5 (IL-5), Interleukin-6 (IL-6),
Interleukin-8 (IL-8), Tumor Necrosis Factor alpha (TNF
alpha).
ODM derived from: https://cde.nlm.nih.gov
Primary source: https://www.phenxtoolkit.org/
Recent publication: Hendershot, T., Pan, H., Haines, J.,
Harlan, W.R., Marazita, M.L., McCarty, C.A., Ramos, E.M.,
and Hamilton, C.M. (2015) Using the PhenX toolkit to add
standard measures to a study. Curr. Protoc. Hum. Genet.
86:1.21.1-1.21.17. doi: 10.1002/0471142905.hg0121s86
Permission to publish granted by
Carol M. Hamilton.
All rights reserved. Please visit https://medical-data-
models.org/forms/14669
Assay for Cytokine Panel 12 Protocol
PhenX Toolkit
Exclusion criteria - assays PhenX
Do you have hemophilia?*
Yes (1)
No (2)
Refused (3)
Don´t know (4)
Have you received cancer chemotherapy in the
past four weeks or do you anticipate such therapy
in the next four weeks?*
Yes (1)
No (2)
Refused (3)
Don´t know (4)
Process variables for assays PhenX
Exclusion Criteria*
Hemophilia (1)
Received cancer chemotherapy in the
last 3 weeks (2)
None – proceed with blood draw (3)
Was blood drawn?*
Yes
No
Was full sample obtained?*
Yes
No
Service comment*
Service comment*
Repeatability of the assay*
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Coefficient of variation for the assay*
Manufacturer variables for assays PhenX
Make of the equipment used to perform...*
Manufacturer of the equipment used to
perform...*
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Assay for Cytokine Panel 12 Protocol PhenX Toolkit
Assay for Hepatitis C Protocol PhenX
Toolkit
This protocol provides instructions for drawing, processing,
and storing blood for hepatitis C (HCV) from the National
Health and Nutrition Examination Survey (NHANES). As
multiple tests must be performed to make the most
accurate diagnosis of hepatitis C, the protocol also provides
basic guidelines to aid comparability among different
studies. Toolkit users are referred to the U.S. Food and
Drug Administration’s (FDA’s) approved laboratory assays.
ODM derived from: https://cde.nlm.nih.gov
Primary source: https://www.phenxtoolkit.org/
Recent publication: Hendershot, T., Pan, H., Haines, J.,
Harlan, W.R., Marazita, M.L., McCarty, C.A., Ramos, E.M.,
and Hamilton, C.M. (2015) Using the PhenX toolkit to add
standard measures to a study. Curr. Protoc. Hum. Genet.
86:1.21.1-1.21.17. doi: 10.1002/0471142905.hg0121s86
Permission to publish granted by
Carol M. Hamilton.
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Assay for Hepatitis C Protocol
PhenX Toolkit
Exclusion criteria - assays PhenX
Do you have hemophilia?*
Yes (1)
No (2)
Refused (3)
Don´t know (4)
Have you received cancer chemotherapy in the
past four weeks or do you anticipate such therapy
in the next four weeks?*
Yes (1)
No (2)
Refused (3)
Don´t know (4)
Process variables for assays PhenX
Exclusion Criteria*
Hemophilia (1)
Received cancer chemotherapy in the
last 3 weeks (2)
None – proceed with blood draw (3)
Was blood drawn?*
Yes
No
Was full sample obtained?*
Yes
No
Service comment*
Service comment*
Repeatability of the assay*
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Coefficient of variation for the assay*
Manufacturer variables for assays PhenX
Make of the equipment used to perform...*
Manufacturer of the equipment used to
perform...*
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Assay for Herpes Simplex Virus Types 1
and 2 Protocol PhenX Toolkit
This protocol provides information for drawing, processing,
and storing blood for the herpes simplex virus type 1 (HSV-
1) and type 2 (HSV-2) assay according to National Health
and Nutrition Examination Survey (NHANES) methods.
HSV-1 and HSV-2 are measured using the Solid-Phase
Enzymatic Immunodot method.
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Primary source: https://www.phenxtoolkit.org/
Recent publication: Hendershot, T., Pan, H., Haines, J.,
Harlan, W.R., Marazita, M.L., McCarty, C.A., Ramos, E.M.,
and Hamilton, C.M. (2015) Using the PhenX toolkit to add
standard measures to a study. Curr. Protoc. Hum. Genet.
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Assay for Herpes Simplex Virus
Types 1 and 2 Protocol PhenX
Toolkit
Exclusion criteria - assays PhenX
Do you have hemophilia?*
Yes (1)
No (2)
Refused (3)
Don´t know (4)
Have you received cancer chemotherapy in the
past four weeks or do you anticipate such therapy
in the next four weeks?*
Yes (1)
No (2)
Refused (3)
Don´t know (4)
Process variables for assays PhenX
Exclusion Criteria*
Hemophilia (1)
Received cancer chemotherapy in the
last 3 weeks (2)
None – proceed with blood draw (3)
Was blood drawn?*
Yes
No
Was full sample obtained?*
Yes
No
Service comment*
Service comment*
Repeatability of the assay*
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Coefficient of variation for the assay*
Manufacturer variables for assays PhenX
Make of the equipment used to perform...*
Manufacturer of the equipment used to
perform...*
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Assay for Herpes Simplex Virus Types 1 and 2 Protocol PhenX Toolkit
Assessment of Gallbladder Disease and
Related Conditions Protocol PhenX Toolkit
This measure is used to assess whether the respondent
has had symptoms as a result of gallstones or gallbladder
problems and to determine whether the respondent
received treatment for the gallbladder problem.
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Assessment of Gallbladder Disease
and Related Conditions Protocol
PhenX Toolkit
PhenX - assessment of gallbladder
disease and related conditions protocol
CHECK ITEM. REFER TO AGE OF SP.
17-74 years    (17-74 years   )
75+ years (75+ years)
Please look at this diagram. During the past 12
months, have you had pain in the area shaded on
the diagram?
Yes (1)
No (2)
Don't know (3)
Area of gallbladder pain [PhenX]
Yes (1)
No (2)
Don't know (3)
Sometimes people have more than one type of
pain. I am going to ask you a few questions about
the pain that has been the most uncomfortable in
the past 12 months. For the pain that was most
uncomfortable, please show me where the pain
was located. MARK ALL AREAS INDICATED.
Yes
No
During the past 12 months, what is the longest
time that one episode of this pain has lasted?
On how many days in the past 12 months have
you had this pain?
When you had this pain, was it continuous, or did
it tend to come and go?
Both (Both)
Come and go    (Come and go   )
Continuous     (Continuous    )
When you had the pain, if you moved around, did
you hurt more, less, or was there no difference?
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More (1)
Less (2)
No difference (3)
Don't know (4)
Have you ever seen a doctor about this pain?
Yes
No
What did the doctor say caused the pain?
Appendicitis or appendix problems
(Appendicitis or appendix problems   )
Diverticulitis or diverticulosis
(Diverticulitis or diverticulosis)
Gallstones/gallbladder problems
(Gallstones/gallbladder problems)
Other (Other)
Spastic colon or irritable bowel
(Spastic colon or irritable bowel   )
Ulcer     (Ulcer    )
What did the doctor say caused the pain? Other,
Specify
Has a doctor ever told you that you had
gallstones?
Yes (1)
No (2)
Don't know (3)
What was the reason you visited the doctor the
time that he told you that you had gallstones?
Other (Other)
Pain (Pain)
What was the reason you visited the doctor the
time that he told you that you had gallstones?
Other, Specify
Have you ever had medical treatment to dissolve
or remove gallstones? Do not include surgery.
Yes (1)
No (2)
Don't know (3)
Have you ever had gallbladder surgery?
Yes (1)
No (2)
Don't know (3)
How old were you when you had your gallbladder
surgery?
Did the pain that caused you to visit the doctor
continue after your gallbladder surgery?
Yes (1)
No (2)
Don't know (3)
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Assessment of Gallbladder Disease and Related Conditions Protocol
PhenX Toolkit
Percent Energy from Fat Protocol PhenX
Toolkit
These self-administered questions for adults can be used
to inquire about the frequency of an individual’s
consumption of foods predictive of percentage energy from
fat. There are eight response categories, ranging from
"Never" to "2 or More Times per Day," arrayed on the
response card for the respondent to use in assessing food
patterns.
ODM derived from: https://cde.nlm.nih.gov
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Percent Energy from Fat Protocol
PhenX Toolkit
PhenX - energy from fat protocol
About how often did you eat Cold cereal?
Never (1)
Less than once a month (2)
1-3 times per month (3)
1-2 times per week   (4)
3-4 times per week   (5)
5-6 times per week   (6)
1 time per day     (7)
2 or more times per day (8)
About how often did you drink Skim milk, on
cereal or to drink?
Never (1)
Less than once a month (2)
1-3 times per month (3)
1-2 times per week   (4)
3-4 times per week   (5)
5-6 times per week   (6)
1 time per day     (7)
2 or more times per day (8)
About how often did you eat Eggs, fried or
scrambled in margarine, butter, or oil?
Never (1)
Less than once a month (2)
1-3 times per month (3)
1-2 times per week   (4)
3-4 times per week   (5)
5-6 times per week   (6)
1 time per day     (7)
2 or more times per day (8)
About how often did you eat Sausage or bacon,
regular-fat?
Never (1)
Less than once a month (2)
1-3 times per month (3)
1-2 times per week   (4)
3-4 times per week   (5)
5-6 times per week   (6)
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1 time per day     (7)
2 or more times per day (8)
About how often did you eat Margarine or butter
on bread, rolls, pancakes?
Never (1)
Less than once a month (2)
1-3 times per month (3)
1-2 times per week   (4)
3-4 times per week   (5)
5-6 times per week   (6)
1 time per day     (7)
2 or more times per day (8)
About how often did you drink Orange juice or
grapefruit juice?
Never (1)
Less than once a month (2)
1-3 times per month (3)
1-2 times per week   (4)
3-4 times per week   (5)
5-6 times per week   (6)
1 time per day     (7)
2 or more times per day (8)
About how often did you eat Fruit (not juices)?
Never (1)
Less than once a month (2)
1-3 times per month (3)
1-2 times per week   (4)
3-4 times per week   (5)
5-6 times per week   (6)
1 time per day     (7)
2 or more times per day (8)
About how often did you eat Beef or pork hot
dogs, regular-fat?
Never (1)
Less than once a month (2)
1-3 times per month (3)
1-2 times per week   (4)
3-4 times per week   (5)
5-6 times per week   (6)
1 time per day     (7)
2 or more times per day (8)
About how often did you eat Cheese or cheese
spread, regular-fat?
Never (1)
Less than once a month (2)
1-3 times per month (3)
1-2 times per week   (4)
3-4 times per week   (5)
5-6 times per week   (6)
1 time per day     (7)
2 or more times per day (8)
About how often did you eat French fries, home
fries, or hash brown potatoes?
Never (1)
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Less than once a month (2)
1-3 times per month (3)
1-2 times per week   (4)
3-4 times per week   (5)
5-6 times per week   (6)
1 time per day     (7)
2 or more times per day (8)
About how often did you eat Margarine or butter
on vegetables, including potatoes?
Never (1)
Less than once a month (2)
1-3 times per month (3)
1-2 times per week   (4)
3-4 times per week   (5)
5-6 times per week   (6)
1 time per day     (7)
2 or more times per day (8)
About how often did you eat Mayonnaise, regular-
fat?
Never (1)
Less than once a month (2)
1-3 times per month (3)
1-2 times per week   (4)
3-4 times per week   (5)
5-6 times per week   (6)
1 time per day     (7)
2 or more times per day (8)
About how often did you eat Salad dressings,
regular-fat?
Never (1)
Less than once a month (2)
1-3 times per month (3)
1-2 times per week   (4)
3-4 times per week   (5)
5-6 times per week   (6)
1 time per day     (7)
2 or more times per day (8)
About how often did you eat Rice?
Never (1)
Less than once a month (2)
1-3 times per month (3)
1-2 times per week   (4)
3-4 times per week   (5)
5-6 times per week   (6)
1 time per day     (7)
2 or more times per day (8)
About how often did you eat Margarine, butter, or
oil on rice or pasta?
Never (1)
Less than once a month (2)
1-3 times per month (3)
1-2 times per week   (4)
3-4 times per week   (5)
5-6 times per week   (6)
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1 time per day     (7)
2 or more times per day (8)
Over the past 12 months, when you prepared
foods with margarine or ate margarine, how often
did you use reduced-fat margarine?
Didn't use margarine     (1)
Almost never     (2)
About 1/4 of the time   (3)
About 1/2 of the time     (4)
About 3/4 of the time (5)
Almost always or always (6)
Overall, when you think about the foods you ate
over the past 12 months, would you say your diet
was high, medium, or low in fat?
High (1)
Medium (2)
Low (3)
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Conditions Relevant to Immune Response -
Screener, Child PhenX Toolkit
This screening protocol includes nine proxy-administered
questions from the Centers for Disease Control and
Prevention (CDC) Screening Questionnaire for Child and
Teen Immunization. Parents or guardians are asked to
respond to yes-or-no questions.
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Conditions Relevant to Immune
Response - Screener, Child PhenX
Toolkit
PhenX - conditions relevant to immune
response - screener - child protocol
Is the child sick today?
No (1)
Yes (2)
Don't know (3)
Does the child have allergies to medications,
food, or any vaccine?
No (1)
Yes (2)
Don't know (3)
Has the child had a serious reaction to a vaccine
in the past?
No (1)
Yes (2)
Don't know (3)
Has the child had a seizure or a brain problem?
No (1)
Yes (2)
Don't know (3)
Does the child have cancer, leukemia, AIDS, or
any other immune system problem?
No (1)
Yes (2)
Don't know (3)
Has the child take cortisone, prednisone, other
steroids, or anticancer drugs or had x-ray
treatments in the past 3 months?
No (1)
Yes (2)
Don't know (3)
Has the child received a transfusion of blood or
blood products or been given a medicine called
immune (gamma) globulin in the past year?
No (1)
Yes (2)
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Don't know (3)
Is the child/teen pregnant, or is there a chance
she could become pregnant during the next
month?
No (1)
Yes (2)
Don't know (3)
Has the child received vaccinations in the past 4
weeks?
No (1)
Yes (2)
Don't know (3)
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Refractive Error - Adult PhenX Toolkit
The refractive error of each eye is measured using the
Humphrey Automated Refractor (Carl Zeiss Meditec,
Dublin, CA). After use of the autorefractor, the
autorefractor-generated refractive error for each eye is
dialed in to the phoropter and the participant’s visual acuity
is checked. If the visual acuity is worse than 20/20, then
subjective refraction is performed.
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Refractive Error - Adult PhenX
Toolkit
PhenX - refractive error - adult protocol
Model of instrument used to measure refractive
error
Spherical power [Inverse Length] Eye - right
diop
Cylindrical power [Inverse Length] Eye - right
deg
Cylinder axis Eye - right
deg
Best corrected visual acuity Eye - right
Spherical power [Inverse Length] Eye - left
diop
Cylindrical power [Inverse Length] Eye - left
diop
Cylinder axis Eye - left
deg
Best corrected visual acuity Eye - left
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Audiogram Hearing Test Protocol PhenX
Toolkit
The National Health and Nutrition Examination Survey
(NHANES) 2008-2009 audiometry protocol tests the
examinee’s hearing threshold (in decibels, dB) at 7
frequencies in a soundproof room. Examinees are asked a
series of exclusionary questions, undergo an outer-ear
examination (otoscopy), and then have the mobility of their
eardrum tested (acoustic immittance). Pure tone signals
are then presented to each ear through earphones and the
intensity of the signals is varied until the level is identified at
which the person is just able to hear the sound.
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Audiogram Hearing Test Protocol
PhenX Toolkit
PhenX - audiogram hearing test protocol
Does the examinee have hearing aids that cannot
be removed?
Yes
No
Do you now have a tube in your right or left ear [if
Yes, indicate affected ear(s)]?
Yes, right ear   (1)
Yes, left ear    (2)
Yes, both ears (3)
No (4)
Refused (5)
Don't know (6)
Have you had a cold, sinus problem or earache in
the last 24 hours?
Yes (1)
No (2)
Refused (3)
Don't know (4)
(If yes) Which have you had (check all that
apply)?
Cold (1)
Sinus problem (2)
Earache, right ear (3)
Earache, left ear (4)
Earache, both ears (5)
Refused (6)
Don't know (7)
Have you been exposed to loud noise or listened
to music with headphone in the past 24 hours?
Yes (1)
No (2)
Refused (3)
Don't know (4)
(If Yes) How many hours ago did the noise or
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music end?
h
Do you hear better in one ear than the other?
Yes, right ear (1)
Yes, left ear (2)
No (3)
Refused (4)
Don't know (5)
Enter a comment to describe the right ear
Abnormality, type unknown
(Abnormality, type unknown   )
Collapsing ear canal (Collapsing ear
canal)
Excessive cerumen  (Excessive cerumen
)
Impacted cerumen     (Impacted
cerumen    )
Normal     (Normal    )
Enter a comment to describe the left ear
Abnormality, type unknown
(Abnormality, type unknown   )
Collapsing ear canal (Collapsing ear
canal)
Excessive cerumen  (Excessive cerumen
)
Impacted cerumen     (Impacted
cerumen    )
Normal     (Normal    )
Right ear acoustic immittance
daPa
Right ear tympanogram ID:
Left ear acoustic Immittance
daPa
Left ear tympanogram ID:
Ear tested first
Left ear (Left ear)
Right ear  (Right ear )
Headphones used (original test):
Right or left ear Ear [PhenX]
right (1)
left (2)
Test mode right ear
Automatically    (Automatically   )
Manually     (Manually    )
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Mixed (Mixed)
If mixed, indicate Hz when switched to manual
mode (Right Ear)
1000 – First     (1)
500     (2)
1000 – Second  (3)
2000 (4)
3000 (5)
4000 (6)
6000 (7)
8000 (8)
Frequencies [PhenX]
1000 Hz (1000 Hz)
2000 Hz  (2000 Hz )
3000 Hz (3000 Hz)
4000 Hz   (4000 Hz  )
500 Hz (500 Hz)
6000 Hz    (6000 Hz   )
8000 Hz (8000 Hz)
Threshold [PhenX]
First threshold  (First threshold )
Second threshold (Second threshold)
Test mode left ear
Automatically    (Automatically   )
Manually     (Manually    )
Mixed (Mixed)
If mixed, indicate Hz when switched to manual
mode (Left Ear)
1000 – First     (1)
500     (2)
1000 – Second  (3)
2000 (4)
3000 (5)
4000 (6)
6000 (7)
8000 (8)
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Glycosylated Hemoglobin Assay Protocol
PhenX Toolkit
This protocol provides instructions for drawing, processing,
and storing blood for the hemoglobin A1c assay according
to the National Health and Nutrition Examination Survey
(NHANES) methods. Toolkit users are referred to the
National Glycohemoglobin Standardization Program
(NGSP) for standardized laboratory assays.
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Glycosylated Hemoglobin Assay
Protocol PhenX Toolkit
PhenX - glycosylated hemoglobin assay
reflecting long-term glucose concentration
protocol
Do you have hemophilia?
Yes (1)
No (2)
Refused (3)
Don´t know (4)
Have you received cancer chemotherapy in the
past four weeks or do you anticipate such therapy
in the next four weeks?
Yes (1)
No (2)
Refused (3)
Don´t know (4)
Exclusion Criteria
Hemophilia     (1)
Received cancer chemotherapy in the
last 3 weeks (2)
None – proceed with blood draw (3)
Was blood drawn?
Yes
No
Service comment
Service comment
Was full sample obtained?
Yes
No
Make of the equipment used to perform...
Manufacturer of the equipment used to perform...
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Repeatability of the assay
Coefficient of variation for the assay
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Physical Functioning - Objective Protocol
PhenX Toolkit
This protocol is a brief series of tests used to evaluate a
person’s balance, gait, strength, and endurance. A
technician provides instructions and demonstrates how to
perform each test. The tests include repeated chair stands,
balance testing, and a measured walk. During each test,
the technician uses a stopwatch to time the person and
enters the result on an ordinal scale.
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Physical Functioning - Objective
Protocol PhenX Toolkit
PhenX - physical functioning - objective
protocol
Balance test [PhenX]
Semi tandem stand  (Semi tandem stand
)
Side by side stand (Side by side stand)
Tandem stand (Tandem stand)
Balance test score [PhenX]
Held for 10 sec - 1 point   (Held for 10
sec - 1 point  )
Not attempted - 0 points (Not attempted -
0 points)
Not held for 10 sec - 0 points     (Not held
for 10 sec - 0 points    )
If participant did not attempt test or failed, mark
why:
Not attempted, participant felt unsafe
(Not attempted, participant felt unsafe   )
Other (specify)  (Other (specify) )
Participant could not hold position
unassisted     (Participant could not hold
position unassisted    )
Participant refused (Participant refused)
Participant unable to understand
instructions     (Participant unable to
understand instructions    )
Tried but unable   (Tried but unable  )
If participant did not attempt test or failed, mark
why:
Number of seconds held if less than 10 sec
sec
Total Balance Tests score (sum points)
Service comment
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Length of walk test course
m
Time for 3 or 4 meters
s
Aids for the first walk
Cane     (Cane    )
None (None)
Other (Other)
Record the shorter of the two times
For 4-Meter Walk
Time is 4.82 to 6.20 sec - 3 points (Time
is 4.82 to 6.20 sec - 3 points)
Time is 6.21 to 8.70 sec - 2 points (Time
is 6.21 to 8.70 sec - 2 points)
Time is less than 4.82 sec - 4 points
(Time is less than 4.82 sec - 4 points)
Time is more than 8.70 sec - 1 point
(Time is more than 8.70 sec - 1 point  )
For 3-Meter Walk
Time is 3.62 to 4.65 sec - 3 points (Time
is 3.62 to 4.65 sec - 3 points)
Time is 4.66 to 6.52 sec - 2 points  (Time
is 4.66 to 6.52 sec - 2 points )
Time is less than 3.62 sec - 4 points
(Time is less than 3.62 sec - 4 points)
Time is more than 6.52 sec - 1 point
(Time is more than 6.52 sec - 1 point    )
Safe to stand without help
Yes
No
Participant stood without using arms
Yes
No
Participant used arms to stand
Yes
No
Test not completed
Yes
No
Safe to stand five times
Yes
No
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Plastic Exposures at Work and Home
Protocol PhenX Toolkit
The respondent answers questions about the interior
surfaces in his/her residence and workplace.
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Plastic Exposures at Work and
Home Protocol PhenX Toolkit
PhenX - environmental exposures - plastic
exposures at work and home protocol
Has there been renovation or repairs in your
workspace because of moisture damage?
No (1)
Yes, during the past 12 months    (2)
Yes, 1-3 years ago (3)
Yes, more than 3 years ago (4)
I don’t know (5)
What is the floor material in your workspace?
Concrete   (Concrete  )
Cork     (Cork    )
I don’t know (I don’t know)
Other     (Other    )
Vinyl     (Vinyl    )
Wall-to-wall carpet     (Wall-to-wall carpet
)
Wood     (Wood    )
What is the floor material in your workspace?
Is the wall material of your work space textile
(cloth, jute, etc.)
No - could not recall     (No - could not
recall    )
Yes, at least half of the wall surfaces
(Yes, at least half of the wall surfaces    )
Yes, less than half of the wall surfaces
(Yes, less than half of the wall surfaces)
Is the wall material of your work space plastic?
No - could not recall     (No - could not
recall    )
Yes, at least half of the wall surfaces
(Yes, at least half of the wall surfaces    )
Yes, less than half of the wall surfaces
(Yes, less than half of the wall surfaces)
Has there been renovation or repairs in your
home due to moisture damage?
Yes
No
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Has there been renovation in your home during
the past 12 months?
Yes
No
Which of the following repairs was done in your
home during the past 12 months?
Lacquering of the floor  (Lacquering of
the floor )
Other (Other)
Painting, at least half of the wall area
(Painting, at least half of the wall area    )
Painting, less than half of the wall area
(Painting, less than half of the wall area)
Use of floor putty (Use of floor putty)
Wall-papering, at least half of the wall
area     (Wall-papering, at least half of
the wall area    )
Wall-papering, less than half of the wall
area     (Wall-papering, less than half of
the wall area    )
Which of the following repairs was done in your
home during the past 12 months? (You may circle
more than one alternative):
Do you have wall-to-wall carpeting in your home?
No  (No )
Yes, at least half of the floor area (Yes, at
least half of the floor area)
Yes, less than half of the floor area
(Yes, less than half of the floor area  )
Is the floor material in your home plastic/vinyl?
No  (No )
Yes, at least half of the floor area (Yes, at
least half of the floor area)
Yes, less than half of the floor area
(Yes, less than half of the floor area  )
Is the wall material in your home textile (cloth,
jute, etc.)?
No - could not recall  (No - could not
recall )
Yes, at least half of the wall surfaces
(Yes, at least half of the wall surfaces   )
Yes, less than half of the wall surfaces
(Yes, less than half of the wall surfaces)
Is the wall material in your home plastic?
No - could not recall  (No - could not
recall )
Yes, at least half of the wall surfaces
(Yes, at least half of the wall surfaces   )
Yes, less than half of the wall surfaces
(Yes, less than half of the wall surfaces)
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Male Reproductive Tract Birth Defects
Protocol PhenX Toolkit
The male participant answers whether he was ever
diagnosed with Cryptorchidism, Hypospadius and/or other
related conditions.
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Male Reproductive Tract Birth
Defects Protocol PhenX Toolkit
PhenX - male reproductive tract birth
defects protocol
Were you born with one or both of your testicles
undescended (not completely down in the
scrotum)?
No (1)
Yes (2)
Don't know (3)
Which testicle was this?
right (1)
left (2)
both (3)
Did the testicle go down to the scrotum by itself?
No (1)
Yes (2)
Don't know (3)
Did you receive treatment?
No (1)
Yes (2)
Don't know (3)
What treatment?
Don't know (Don't know)
Hormones     (Hormones    )
Other (specify)     (Other (specify)    )
Surgery (Surgery)
Specify other treament for undescended testicle
Has your doctor or another health care provider
ever told you that you had other diseases of the
penis, testicles, urinary tract or scrotum
(specify)?
No (1)
Yes (2)
Don't know (3)
Specify disease of the penis, testicles, urinary
tract or scrotum.
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Has your doctor or another health care provider
ever told you that you had hypospadius?
No (1)
Yes (2)
Don't know (3)
What was your most recent treatment or
medication (if any)?
When was your most recent treatment or
medication (if any)?
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Myocardial Infarction Protocol PhenX
Toolkit
This measure assesses if an individual has had a
myocardial infarction (MI) through collection of personal
history of disease, treatment and procedure histories, and
medical record abstraction.
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Myocardial Infarction Protocol PhenX
Toolkit
PhenX - myocardial infarct protocol
Has a doctor ever told you that you had a
myocardial infarction or heart attack?
No (1)
Yes (2)
Don't know (3)
Have you had an outpatient or day surgery
procedure to unblock blocked or narrowed blood
vessels of the heart?
Yes
No
Was there an acute episode of pain, discomfort
or tightness in the chest, left arm or jaw within 72
hours of the hospitalization or within 72 hours of
the hospitalization or in-hospital event
No (1)
Yes (2)
Don't know (3)
Was the discomfort or pain diagnosed as having
a non-cardiac origin?
No (1)
Yes (2)
Don't know (3)
Were electrocardiograms (ECGs or EKGs)
recorded?
No (1)
Yes (2)
Don't know (3)
EKG study
Were any cardiac enzyme measurements
performed during this admission?
Yes
No
Did the participant have any active liver disease
(cirrhosis, hepatitis, liver cancer, etc.)?
Yes
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No
Is there any evidence of hemolytic disease during
this hospitalization?
Yes
No
Is there any mention of the participant having
either trauma, a surgical procedure, or
rhabdomyolysis within one week prior to the
measurement of the
No (1)
Yes (2)
Don't know (3)
Date of trauma or procedure
Type of trauma or procedure
Myocardial infarction
Definite (Definite)
No MI (skip to end) (No MI (skip to end))
Probable (Probable)
Date of myocardial infarction
Chest pain
Absent (Absent)
Present (Present)
Cardiac enzymes
Abnormal     (Abnormal    )
Equivocal     (Equivocal    )
Incomplete     (Incomplete    )
Normal (Normal)
Electrocardiogram serial reading
Absent, Uncodable or Other ECG
(Absent, Uncodable or Other ECG)
Evolution of Major Q-Wave  (Evolution of
Major Q-Wave )
Evolution of Minor Q-Wave alone
(Evolution of Minor Q-Wave alone)
Evolution of ST-Depression/Inversion
alone     (Evolution of ST-
Depression/Inversion alone    )
Evolution of ST-T Elevation with or
without Q-Wave  (Evolution of ST-T
Elevation with or without Q-Wave )
New LBBB  (New LBBB )
Single ECG with LBBB, described as
new   (Single ECG with LBBB, described
as new  )
Single ECG with Major Q-Wave (Single
ECG with Major Q-Wave)
Procedure-related
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Autopsy Only (Autopsy Only)
Death Certificate Only     (Death
Certificate Only    )
Hospital inpatient  (Hospital inpatient )
Hospital outpatient facility or clinic
(Hospital outpatient facility or clinic    )
Nursing/convalescent home/hospice
(Nursing/convalescent home/hospice)
Other (Other)
Physician's office/private medical
practitioner (Physician's office/private
medical practitioner)
Radiology or imaging facility (Radiology
or imaging facility)
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Assay for Human Leukocyte Antigen (HLA)
Genotyping Protocol PhenX Toolkit
This protocol includes instructions for drawing, processing
and storing blood according to the Type 1 Diabetes
Genetics Consortium (T1DGC) Manual of Operations.
Human Leukocyte Antigen is measured by using the linear
array genotyping system method.
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Assay for Human Leukocyte Antigen
(HLA) Genotyping Protocol PhenX
Toolkit
Collection date of Blood
Date of blood collection
Process variables for assays - human
leukocyte antigen - HLA PhenX
Was blood drawn?*
Yes
No
Was full sample obtained?*
Yes
No
Service comment*
Service comment*
Repeatability of the assay*
Coefficient of variation for the assay*
Manufacturer variables for assays PhenX
Make of the equipment used to perform...*
Manufacturer of the equipment used to
perform...*
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Perceived Stress Protocol PhenX Toolkit
This 10-item self-administered scale is used to measure an
individual’s level of perceived stress in the past month. As a
result, it measures only current (not chronic) levels of
perceived stress.
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Perceived Stress Protocol PhenX
Toolkit
PhenX - perceived stress protocol
In the last month, how often have you been upset
because of something that happened
unexpectedly?
Never (1)
Almost never (2)
Sometimes (3)
Fairly often (4)
In the last month, how often have you felt that you
were unable to control the important things in
your life?
Never (1)
Almost never (2)
Sometimes (3)
Fairly often (4)
In the last month, how often have you felt nervous
and "stressed"?
Never (1)
Almost never (2)
Sometimes (3)
Fairly often (4)
In the last month, how often have you felt
confident about your ability to handle your
personal problems?
Never (1)
Almost never (2)
Sometimes (3)
Fairly often (4)
In the last month, how often have you felt that
things were going your way?
Never (1)
Almost never (2)
Sometimes (3)
Fairly often (4)
In the last month, how often have you found that
you could not cope with all the things that you
had to do?
Never (1)
Almost never (2)
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Sometimes (3)
Fairly often (4)
In the last month, how often have you been able
to control irritations in your life?
Never (1)
Almost never (2)
Sometimes (3)
Fairly often (4)
In the last month, how often have you felt that you
were on top of things?
Never (1)
Almost never (2)
Sometimes (3)
Fairly often (4)
In the last month, how often have you been
angered because of things that were outside of
your control?
Never (1)
Almost never (2)
Sometimes (3)
Fairly often (4)
In the last month, how often have you felt
difficulties were piling up so high that you could
not overcome them?
Never (1)
Almost never (2)
Sometimes (3)
Fairly often (4)
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History of Stroke - Ischemic Infarction and
Hemorrhage Protocol PhenX Toolkit
The Stroke Symptoms Form from the Jackson Heart Study
is an interviewer-administered questionnaire that captures
the history of stroke(s) and associated symptoms such as
slurred speech, double vision, loss of vision and paralysis.
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History of Stroke - Ischemic
Infarction and Hemorrhage Protocol
PhenX Toolkit
PhenX - history of stroke protocol
Have you ever been told by a physician that you
had a stroke?
Yes
No
When did the first stroke occur?
Have you ever had any sudden loss or changes
in speech lasting 24 hours or longer?
No (0)
Yes (1)
Don't know (9)
Did the episode come on suddenly?
Yes
No
Do any of the following describe your change in
speech [PhenX]
Yes
No
Most Representative Symptom
Could not think of the right words (Could
not think of the right words)
Slurred speech     (Slurred speech    )
Words would not come out  (Words
would not come out )
Wrong words came out    (Wrong words
came out   )
Things occurring with episode of change in
speech [PhenX]
Numbness or tingling  (1)
Paralysis or weakness (2)
Lightheadedness, dizziness, or loss of
balance     (3)
Blackouts or fainting  (4)
Seizures or convulsions     (5)
Headache     (6)
Visual disturbances (7)
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While you were having your episode of change in
speech, did any of these things occur [PhenX]
Yes
No
Did you have difficulty on
Right side only   (1)
Left side only     (2)
Both sides (3)
Did you have
Double vision     (Double vision    )
Total loss of vision in both eyes     (Total
loss of vision in both eyes    )
Trouble in both eyes seeing to both sides
or straight ahead (Trouble in both eyes
seeing to both sides or straight ahead)
Trouble in both eyes seeing to the left
(Trouble in both eyes seeing to the left   )
Trouble in both eyes seeing to the right
(Trouble in both eyes seeing to the right
)
Vision loss in left eye only     (Vision loss
in left eye only    )
Vision loss in right eye only     (Vision
loss in right eye only    )
Have you ever had any sudden loss of vision, or
blurring, lasting 24 hours or longer?
No (0)
Yes (1)
Don't know (9)
During the episode, which of the following parts
of your vision were affected?
Only right eye     (1)
Only left eye     (2)
Both eyes (3)
Did you have
Trouble seeing both sides or straight
ahead (Trouble seeing both sides or
straight ahead)
Trouble seeing to the left, but not to right
(Trouble seeing to the left, but not to right
)
Trouble seeing to the right, but not to left
(Trouble seeing to the right, but not to left
)
Things occurring with loss of vision [PhenX]
Speech disturbance     (1)
Numbness or tingling    (2)
Paralysis or weakness (3)
Lightheadedness, dizziness, or loss of
balance  (4)
Blackouts or fainting   (5)
Seizures or convulsions   (6)
Headache  (7)
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Flashing lights (8)
While you were having your loss of vision, did any
of these things occur [PhenX]
Yes
No
Have you ever had a sudden spell of double
vision, which lasted 24 hours or longer?
No (0)
Yes (1)
Don't know (9)
If you closed one eye, did the double vision go
away?
No (0)
Yes (1)
Don't know (9)
Things occurring with double vision [PhenX]
Speech disturbance (1)
Numbness or tingling (2)
Paralysis or weakness (3)
Lightheadedness, dizziness, or loss of
balance (4)
Blackouts or fainting   (5)
Seizures or convulsions (6)
Headache (7)
While you were having your double vision, did
any of these things occur [PhenX]
Yes
No
Have you ever had sudden numbness, tingling, or
loss of feeling on one side of your body, including
your face, arm, or leg which lasted 24 hours or
longer?
No (0)
Yes (1)
Don't know (9)
Did the feeling of numbness or tingling occur only
when you kept your arms or legs in a certain
position?
No (0)
Yes (1)
Don't know (9)
Body part [PhenX]
Left arm or hand     (1)
Left leg or foot (2)
Left side of face (3)
Right arm or hand (4)
Right leg or foot   (5)
Right side of face    (6)
Other (7)
Was this part of your body affected [PhenX]
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No (0)
Yes (1)
Don't know (9)
During this episode, did the abnormal sensation
start in one part of your body and spread to
another, or did it stay in the same place?
Don't know (Don't know)
Started in one part and spread to
another     (Started in one part and
spread to another    )
Stayed in one part     (Stayed in one part
)
Things occurring with tingling and loss of
sensation [PhenX]
Speech disturbance     (1)
Paralysis or weakness   (2)
Lightheadedness, dizziness, or loss of
balance  (3)
Blackouts or fainting (4)
Seizures or convulsions (5)
Headache     (6)
Pain     (7)
Visual disturbances (8)
While you were having numbness, tingling and
loss of sensation, did any of these things occur
[PhenX]
Yes
No
Have you ever had any sudden episode of
paralysis or weakness on one side of your body,
including your face, arm, or leg which lasted at
least 24 hours?
No (0)
Yes (1)
Don't know (9)
Things occurring with paralysis or weakness
[PhenX]
Speech disturbance (1)
Numbness or tingling (2)
Lightheadedness, dizziness, or loss of
balance (3)
Blackouts or fainting (4)
Seizures or convulsions (5)
Headache     (6)
Pain     (7)
Visual disturbances (8)
While you were having paralysis or weakness did
any of these things occur [PhenX]
Yes
No
Have you had any sudden spells of dizziness,
loss of balance, or sensation of spinning which
lasted 24 hours or longer?
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No (0)
Yes (1)
Don't know (9)
Did the dizziness, loss of balance or spinning
sensation occur only when changing the position
of your head or body?
No (0)
Yes (1)
Don't know (9)
Things occurring with dizziness, loss of balance
or spinning sensation [PhenX]
Speech disturbance (1)
Paralysis or weakness    (2)
Numbness or tingling   (3)
Blackouts or fainting     (4)
Seizures or convulsions (5)
Headache  (6)
Visual disturbances (7)
While you were having sudden spells of
dizziness, loss of balance or spinning sensation,
did any of these things occur [PhenX]
Yes
No
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Eligibility Breast Cancer NCT02240472
Sentinel Node Biopsy in Breast Cancer: Omission of
Axillary Clearance After Macrometastases. A Randomized
Trial.; ODM derived from:
https://clinicaltrials.gov/show/NCT02240472
All rights reserved. Please visit https://medical-data-
models.org/forms/14687
Eligibility Breast Cancer
NCT02240472
Inclusion Criteria
patients with invasive breast cancer ≤ 5 cm (t1-
t2)*
Yes
No
n0 on palpation*
Yes
No
pathology report shows macrometastasis in 1-2
sentinel lymph nodes*
Yes
No
patients with non-palpable but cytologically and
radiologically demonstrated preoperative axillary
metastasis may undergo sn biopsy and be
included*
Yes
No
patients undergo segmental resection or
mastectomy*
Yes
No
the patient must have provided oral and written
consent*
Yes
No
age ≥ 18 years*
Yes
No
Exclusion Criteria
extranodal growth*
Yes
No
palpable axillary metastases prior to surgery*
Yes
No
metastases outside of the ipsilateral axilla*
Yes
No
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neoadjuvant therapy*
Yes
No
prior history of breast cancer*
Yes
No
pregnancy*
Yes
No
bilateral breast cancer*
Yes
No
medical contraindication for radiotherapy*
Yes
No
> 2 sns with macrometastases*
Yes
No
medical contraindication for systemic treatment*
Yes
No
inability to absorb or understand the meaning of
the study information; for example, through
disability, inadequate language skills or
dementia.*
Yes
No
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Pre-existing Conditions Associated with
Cancer Protocol PhenX Toolkit
This self-administered protocol asks respondents to
indicate the year of diagnosis for clinician-diagnosed
illnesses. The respondent is also asked to provide the year
of first diagnosis.
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Pre-existing Conditions Associated
with Cancer Protocol PhenX Toolkit
PhenX - pre-existing cancer conditions
protocol
Clinician-diagnosed illness [PhenX]
Myocardial infarction     (1)
Basal cell skin cancer  (10)
Squamous cell (epidermoid) carcinoma
(11)
Fibrocystic or other benign breast
disease (12)
Breast cancer     (13)
Other cancer    (14)
Colon or rectal polyp - benign (15)
Ulcerative colitis or Crohn’s  (16)
Gastric or duodenal ulcer   (17)
Barrett’s Esophagus   (18)
Gallstones     (19)
Angina pectoris     (2)
Cholecystectomy     (20)
Diabetes mellitus  (21)
Elevated cholesterol (22)
High blood pressure  (23)
Endometriosis - 1st diagnosis (24)
Uterine fibroids - 1st diagnosis    (25)
Premenstrual syndrome - PMS     (26)
Kidney stones    (27)
Multiple Sclerosis (28)
Asthma, doctor diagnosed     (29)
Coronary bypass  (3)
Emphysema or chronic bronchitis, doctor
diagnosis (30)
Pneumonia, x-ray confirmed    (31)
Graves’ Disease - hyperthyroidism  (32)
Hypothyroidism     (33)
Thyroid nodule (benign) (34)
Gout     (35)
SLE (systemic lupus)    (36)
Rheumatoid arthritis, doctor diagnosis
(37)
Other arthritis   (38)
Depression, clinician diagnosis     (39)
Angioplasty or stent     (4)
Other major illness or surgery (40)
Transient ischemic attack - TIA  (5)
Stroke (CVA) or TIA  (6)
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Deep vein thrombosis (7)
Pulmonary embolism (8)
Melanoma     (9)
Have you had any of these clinician-diagnosed
illnesses? Myocardial infarction (heart attack)?
Yes
No
Year of Diagnosis, Myocardial infarction (heart
attack)?
Confirmed angiography?
Yes
No
Confirmed by breast biopsy?
Yes
No
Confirmed by aspiration?
Yes
No
Specify site of other cancer.
Did you have symptoms?
Yes
No
How diagnosed?
X-Ray or ultrasound   (1)
other (2)
Confirmed by laparoscopy?
Yes
No
Confirmed by pelvic exam?
Yes
No
Confirmed by ultrasound/hysterectomy?
Yes
No
Please specify date.
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Fasting Plasma Glucose - Blood Draw
PhenX Toolkit
Participants are asked to fast for at least 9 hours (generally
overnight) prior to the fasting plasma glucose test.
Participants are asked a series of exclusionary questions
and then have blood drawn. The plasma is separated from
the blood via centrifugation and glucose concentration is
determined via a hexokinase-mediated reaction.
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Fasting Plasma Glucose - Blood
Draw PhenX Toolkit
PhenX - fasting plasma glucose for
diabetes screening - blood draw protocol
Did you eat or drink anything other than plain
water after 11:30 last night?
Yes (1)
No (2)
Refused (3)
Don't know (4)
When did you last eat or drink anything other
than plain water?
Have you had any of the following since {insert
time from 1 here}? Coffee or tea with cream and
sugar? [Include milk or non-dairy creamers.]
Yes
No
If Yes, record date
Have you had any of the following since {insert
time from 1 here}? Alcohol, such as beer, wine,
or liquor?
Yes
No
If Yes, record date
Have you had any of the following since {insert
time from 1 here}? Gum, breath mints, lozenges,
or cough drops, or other cough or cold remedies?
Yes
No
If Yes, record date
Have you had any of the following since {insert
time from 1 here}? Antacids, laxatives, or anti-
diarrheals?
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Yes
No
If Yes, record date:
If Yes, record date
Have you had any of the following since {insert
time from 1 here}? Dietary Supplements such as
vitamins and minerals? [Include multivitamins and
single nutrient supplements.]
Yes
No
Are you currently pregnant?
Yes
No
{Is SP/Are you} now taking insulin?
Yes (1)
No (2)
Refused (3)
Don´t know (4)
{Is SP/Are you} now taking diabetic pills to lower
{his/her}/your} blood sugar?
Yes (1)
No (2)
Refused (3)
Don´t know (4)
Do you have hemophilia?
Yes (1)
No (2)
Refused (3)
Don´t know (4)
Have you received cancer chemotherapy in the
past four weeks or do you anticipate such therapy
in the next four weeks?
Yes (1)
No (2)
Refused (3)
Don´t know (4)
Exclusion Criteria
Taking oral medications for diabetes   (1)
Taking insulin     (2)
Pregnant  (3)
Hemophilia    (4)
Received cancer chemotherapy in the
last 3 weeks  (5)
Has not fasted at least 9 hours   (6)
None – proceed with blood draw (7)
Was blood drawn?
Yes
No
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Was full sample obtained?
Yes
No
Service comment
Service comment
Make of the equipment used to perform...
Manufacturer of the equipment used to perform...
Repeatability of the assay
Coefficient of variation for the assay
Was the participant fasting?
Yes
No
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Substances - Lifetime Abuse and
Dependence Protocol PhenX Toolkit
Measurement of respondent’s signs of substance abuse
and dependence. These responses correspond with criteria
from the Diagnostic and Statistical Manual of Mental
Disorders (4th ed.; DSM-IV). There are two questions
within each of which are multiple parts.
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Substances - Lifetime Abuse and
Dependence Protocol PhenX Toolkit
PhenX - substance - lifetime abuse and
dependence protocol
Have you EVER used any of these medicines or
drugs?
No (1)
Yes (2)
Don't know/refused (3)
Which specific drug of this type did you use?
Did you ever use marijuana at least 21 times in a
single year?
No (1)
Yes (2)
Don't know/refused (3)
Has there ever been a period of a month or more
when a great deal of your time was spent using
marijuana, getting marijuana, or getting over its
effects?
No (1)
Yes (2)
Don't know/refused (3)
Problem, related to marijuana use, that occurred
for more than 24 hours to the point that it
interfered with functioning or relationships
[PhenX]
Decreased contact with friends or family
(Decreased contact with friends or
family)
Feeling depressed or uninterested in
things (Feeling depressed or
uninterested in things)
Feeling paranoid or suspicious of people
(Feeling paranoid or suspicious of
people)
Having trouble concentrating or having
such trouble thinking clearly  (Having
trouble concentrating or having such
trouble thinking clearly )
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Did you continue to use marijuana after you knew
it caused this?
No (1)
Yes (2)
Don't know/refused (3)
Have you often wanted to stop or cut down on
marijuana?
No (1)
Yes (2)
Don't know/refused (3)
Have you ever tried to stop or cut down on
marijuana but found you couldn't?
No (1)
Yes (2)
Don't know/refused (3)
Were you unable to stop or cut down 3 or more
times?
No (1)
Yes (2)
Don't know/refused (3)
Have you often used marijuana more frequently
or in larger amounts than you intended to?
No (1)
Yes (2)
Don't know/refused (3)
Did you ever need larger amounts of marijuana to
get an effect, or did you ever find that you could
no longer get high on the amount you used to
use?
No (1)
Yes (2)
Don't know/refused (3)
Problem when you stopped, cut down or went
without marijuana for 2D or longer [PhenX]
Feel nervous, tense, restless or irritable
(Feel nervous, tense, restless or irritable)
Have a marked increase or decrease in
appetite, that is, have a significant
change from your normal level (Have a
marked increase or decrease in appetite,
that is, have a significant change from
your normal level)
Have diarrhea or stomach aches
(Have diarrhea or stomach aches    )
Have nausea or vomiting     (Have
nausea or vomiting    )
Have trouble sleeping  (Have trouble
sleeping )
Sweat or have a fever   (Sweat or have a
fever  )
Tremble or twitch     (Tremble or twitch    )
When you stopped, cut down, or went without
marijuana, did you ever experience any of these
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problems for most of the day for 2 days or longer
[PhenX]
No (1)
Yes (2)
Don't know/refused (3)
Have you ever used marijuana to keep from
having any of these problems (or to make them
go away)?
No (1)
Yes (2)
Don't know/refused (3)
Did this happen 3 or more times?
No (1)
Yes (2)
Don't know/refused (3)
Did these problems ever occur together?
No (1)
Yes (2)
Don't know/refused (3)
Have you given up or greatly reduced important
activities like sports, work, or associating with
friends or relatives while using marijuana?
No (1)
Yes (2)
Don't know/refused (3)
Has this happened 3 or more times, or did it last
a month or longer?
No (1)
Yes (2)
Don't know/refused (3)
Medicine or drug used to feel good or high, or to
feel more active or alert [PhenX]
Cocaine     (1)
Stimulants    (2)
Sedatives, for example, sleeping pills,
barbiturates, seconal, quaaludes, or
chloral hydrate  (3)
Opiates   (4)
PCP (5)
Hallucinations  (6)
Solvents     (7)
Combination drugs     (8)
Other (9)
How many times in your life have you used
Cocaine?
Was there ever a period of a month or more when
a great deal of your time was spent getting over
this drug or its effects [PhenX]
No (1)
Yes (2)
Don't know/refused (3)
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Have you often wanted to stop or cut down on
Cocaine?
No (1)
Yes (2)
Don't know/refused (3)
Have you ever tried to stop or cut down on this
drug but found that you couldn't [PhenX]
No (1)
Yes (2)
Don't know/refused (3)
Were you unable to stop or cut down 3 or more
times on this drug [PhenX]
No (1)
Yes (2)
Don't know/refused (3)
Did you ever need larger amounts of this drug to
get an effect or find that you could no longer get
high on the amount you used to use [PhenX]
No (1)
Yes (2)
Don't know/refused (3)
Have you ever given up or greatly reduced
important activities like sports, work, or
associating with friends or relatives while using
this drug [PhenX]
No (1)
Yes (2)
Don't know/refused (3)
Has this happened 3 or more times, or did it last
a month or longer?
No (1)
Yes (2)
Don't know/refused (3)
Drug type used steadily, for a month or more
[PhenX]
Cocaine     (1)
Stimulants     (2)
Sedatives, for example, sleeping pills,
barbiturates, seconal, quaaludes, or
chloral hydrate  (3)
Opiates     (4)
Other drugs (5)
Have you often used this drug, used steadily,
more days or in larger amounts than you
intended to [PhenX]
No (1)
Yes (2)
Don't know/refused (3)
Problem when you stopped, cut down, or went
without drugs after using drugs steadily [PhenX]
Feel depressed     (1)
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Have diarrhea  (10)
Have stomach aches or stomach cramps
(11)
Eyes run     (12)
Nose run     (13)
Have muscle pains (14)
Yawn   (15)
Pupils dilated or sensitive to light  (16)
Have gooseflesh, goose bumps, or get
chills     (17)
Heart race     (18)
Sweat     (19)
Feel restless     (2)
Fever (20)
Nausea or vomiting     (21)
Headache     (22)
Nervous, tense, or irritable     (23)
Hands shake    (24)
Tremble or twitch   (25)
Dizziness     (26)
Seizures     (27)
See, hear, or feel things that weren’t
really there   (28)
Think that people were plotting to harm
you (paranoid) (29)
Feel tired, sleepy, or weak    (3)
Have trouble sleeping     (4)
Sleep too much     (5)
Have strong desire or craving for this
drug  (6)
Feel slowed down, like you could hardly
move     (7)
Have an increase in appetite (8)
Have nightmares     (9)
When you stopped, cut down, or went without
drugs after using drugs steadily, did you ever
experience this problem [PhenX]
No (1)
Yes (2)
Don't know/refused (3)
Was there ever a time, because of stopping,
cutting down on, or going without this drug, after
using it steadily, when 2 or more of these
problems occurred together [PhenX]
No (1)
Yes (2)
Don't know/refused (3)
Have you ever used this drug to keep from having
any of these problems or make them go away
[PhenX]
No (1)
Yes (2)
Don't know/refused (3)
Did you have to use this drug to make problems
go away 3 or more times [PhenX]
No (1)
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Yes (2)
Don't know/refused (3)
Did using this drug cause you to have any other
problems, like an overdose that required medical
treatment [PhenX]
No (1)
Yes (2)
Don't know/refused (3)
Did this happen 3 or more times?
No (1)
Yes (2)
Don't know/refused (3)
Did using this drug cause you to have any other
problems, like hepatitis [PhenX]
No (1)
Yes (2)
Don't know/refused (3)
Did you continue to use this drug knowing it
caused hepatitis [PhenX]
No (1)
Yes (2)
Don't know/refused (3)
Did using this drug cause you to have any other
serious health problems [PhenX]
No (1)
Yes (2)
Don't know/refused (3)
Did you continue to use this drug knowing it
caused other serious health problems [PhenX]
No (1)
Yes (2)
Don't know/refused (3)
Emotional or psychological problem related to
drug use [PhenX]
Feeling depressed or uninterested in
things     (Feeling depressed or
uninterested in things    )
Feeling jumpy or easily startled or
nervous  (Feeling jumpy or easily startled
or nervous )
Feeling paranoid or suspicious of people
(Feeling paranoid or suspicious of people
)
Hearing, seeing, or smelling things that
weren’t really there (Hearing, seeing, or
smelling things that weren’t really there)
Has use of this drug ever caused you emotional
or psychological problems for more than 24 hours
to the point that it interfered with your functioning
or relationships [PhenX]
No (1)
Yes (2)
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Don't know/refused (3)
Did you continue to use marijuana after you knew
it caused this?
No (1)
Yes (2)
Don't know/refused (3)
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Disinhibiting Behaviors - Impulsivity -
Adolescent and Adult Protocol PhenX Toolkit
The UPPS Impulsive Behavior Scale contains 59 self-
administered questions that are scored as five subscales
(urgency, premeditation, perseverance, sensation seeking,
and positive urgency). The respondent is asked to
complete the questionnaire by reading each item and
circling the number on a Likert scale, ranging from strongly
agree to strongly disagree, that corresponds to his/her
behavior.
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Disinhibiting Behaviors - Impulsivity -
Adolescent and Adult Protocol
PhenX Toolkit
PhenX - disinhibiting behaviors -
impulsivity - adult protocol UPPS
I have a reserved and cautious attitude toward
life.
Agree strongly     (1)
Agree some     (2)
Disagree some (3)
Disagree strongly (4)
I have trouble controlling my impulses.
Agree strongly     (1)
Agree some     (2)
Disagree some (3)
Disagree strongly (4)
I generally seek new and exciting experiences
and sensations.
Agree strongly     (1)
Agree some     (2)
Disagree some (3)
Disagree strongly (4)
I generally like to see things through to the end.
Agree strongly     (1)
Agree some     (2)
Disagree some (3)
Disagree strongly (4)
When I am very happy, I can't seem to stop
myself from doing things that can have bad
consequences.
Agree strongly     (1)
Agree some     (2)
Disagree some (3)
Disagree strongly (4)
My thinking is usually careful and purposeful.
Agree strongly     (1)
Agree some     (2)
Disagree some (3)
1 / 7
Disagree strongly (4)
I have trouble resisting my cravings (for food,
cigarettes, etc).
Agree strongly     (1)
Agree some     (2)
Disagree some (3)
Disagree strongly (4)
I'll try anything once.
Agree strongly     (1)
Agree some     (2)
Disagree some (3)
Disagree strongly (4)
I tend to give up easily.
Agree strongly     (1)
Agree some     (2)
Disagree some (3)
Disagree strongly (4)
When I am in a great mood, I tend to get into
situations that could cause me problems.
Agree strongly     (1)
Agree some     (2)
Disagree some (3)
Disagree strongly (4)
I am not one of those people who blurt out things
without thinking.
Agree strongly     (1)
Agree some     (2)
Disagree some (3)
Disagree strongly (4)
I often get involved in things I later wish I could
get out of.
Agree strongly     (1)
Agree some     (2)
Disagree some (3)
Disagree strongly (4)
I like sports and games in which you have to
choose your next move very quickly.
Agree strongly     (1)
Agree some     (2)
Disagree some (3)
Disagree strongly (4)
Unfinished tasks really bother me.
Agree strongly     (1)
Agree some     (2)
Disagree some (3)
Disagree strongly (4)
When I am very happy, I tend to do things that
may cause problems in my life.
Agree strongly     (1)
Agree some     (2)
Disagree some (3)
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Disagree strongly (4)
I like to stop and think things over before I do
them.
Agree strongly     (1)
Agree some     (2)
Disagree some (3)
Disagree strongly (4)
When I feel bad, I will often do things I later regret
in order to make myself feel better now.
Agree strongly     (1)
Agree some     (2)
Disagree some (3)
Disagree strongly (4)
I would enjoy water skiing.
Agree strongly     (1)
Agree some     (2)
Disagree some (3)
Disagree strongly (4)
Once I get going on something I hate to stop.
Agree strongly     (1)
Agree some     (2)
Disagree some (3)
Disagree strongly (4)
I tend to lose control when I am in a great mood.
Agree strongly     (1)
Agree some     (2)
Disagree some (3)
Disagree strongly (4)
I don't like to start a project until I know exactly
how to proceed.
Agree strongly     (1)
Agree some     (2)
Disagree some (3)
Disagree strongly (4)
Sometimes when I feel bad, I can't seem to stop
what I am doing even though it is making me feel
worse.
Agree strongly     (1)
Agree some     (2)
Disagree some (3)
Disagree strongly (4)
I quite enjoy taking risks.
Agree strongly     (1)
Agree some     (2)
Disagree some (3)
Disagree strongly (4)
I concentrate easily.
Agree strongly     (1)
Agree some     (2)
Disagree some (3)
Disagree strongly (4)
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When I am really ecstatic, I tend to get out of
control.
Agree strongly     (1)
Agree some     (2)
Disagree some (3)
Disagree strongly (4)
I would enjoy parachute jumping.
Agree strongly     (1)
Agree some     (2)
Disagree some (3)
Disagree strongly (4)
I finish what I start.
Agree strongly     (1)
Agree some     (2)
Disagree some (3)
Disagree strongly (4)
I tend to value and follow a rational, "sensible"
approach to things.
Agree strongly     (1)
Agree some     (2)
Disagree some (3)
Disagree strongly (4)
When I am upset I often act without thinking.
Agree strongly     (1)
Agree some     (2)
Disagree some (3)
Disagree strongly (4)
Others would say I make bad choices when I am
extremely happy about something.
Agree strongly     (1)
Agree some     (2)
Disagree some (3)
Disagree strongly (4)
I welcome new and exciting experiences and
sensations, even if they are a little frightening and
unconventional.
Agree strongly     (1)
Agree some     (2)
Disagree some (3)
Disagree strongly (4)
I am able to pace myself so as to get things done
on time.
Agree strongly     (1)
Agree some     (2)
Disagree some (3)
Disagree strongly (4)
I usually make up my mind through careful
reasoning.
Agree strongly     (1)
Agree some     (2)
Disagree some (3)
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Disagree strongly (4)
When I feel rejected, I will often say things I
regret later.
Agree strongly     (1)
Agree some     (2)
Disagree some (3)
Disagree strongly (4)
Others are shocked or worried about the things I
do when I am feeling very excited.
Agree strongly     (1)
Agree some     (2)
Disagree some (3)
Disagree strongly (4)
I would like to learn to fly an airplane.
Agree strongly     (1)
Agree some     (2)
Disagree some (3)
Disagree strongly (4)
I am a person who always gets the job done.
Agree strongly     (1)
Agree some     (2)
Disagree some (3)
Disagree strongly (4)
I am a cautious person.
Agree strongly     (1)
Agree some     (2)
Disagree some (3)
Disagree strongly (4)
It is hard for me to resist acting on my feelings.
Agree strongly     (1)
Agree some     (2)
Disagree some (3)
Disagree strongly (4)
When I get really happy about something, I tend
to do things that can have bad consequences.
Agree strongly     (1)
Agree some     (2)
Disagree some (3)
Disagree strongly (4)
I sometimes like doing things that are a bit
frightening.
Agree strongly     (1)
Agree some     (2)
Disagree some (3)
Disagree strongly (4)
I almost always finish projects that I start.
Agree strongly     (1)
Agree some     (2)
Disagree some (3)
Disagree strongly (4)
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Before I get into a new situation I like to find out
what to expect from it.
Agree strongly     (1)
Agree some     (2)
Disagree some (3)
Disagree strongly (4)
I often make matters worse because I act without
thinking when I am upset.
Agree strongly     (1)
Agree some     (2)
Disagree some (3)
Disagree strongly (4)
When overjoyed, I feel like I can't stop myself
from going overboard.
Agree strongly     (1)
Agree some     (2)
Disagree some (3)
Disagree strongly (4)
I would enjoy the sensation of skiing very fast
down a high mountain slope.
Agree strongly     (1)
Agree some     (2)
Disagree some (3)
Disagree strongly (4)
Sometimes there are so many little things to be
done that I just ignore them all.
Agree strongly     (1)
Agree some     (2)
Disagree some (3)
Disagree strongly (4)
I usually think carefully before doing anything.
Agree strongly     (1)
Agree some     (2)
Disagree some (3)
Disagree strongly (4)
When I am really excited, I tend not to think of the
consequences of my actions.
Agree strongly     (1)
Agree some     (2)
Disagree some (3)
Disagree strongly (4)
In the heat of an argument, I will often say things
that I later regret.
Agree strongly     (1)
Agree some     (2)
Disagree some (3)
Disagree strongly (4)
I would like to go scuba diving.
Agree strongly     (1)
Agree some     (2)
Disagree some (3)
Disagree strongly (4)
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I tend to act without thinking when I am really
excited.
Agree strongly     (1)
Agree some     (2)
Disagree some (3)
Disagree strongly (4)
I always keep my feelings under control.
Agree strongly     (1)
Agree some     (2)
Disagree some (3)
Disagree strongly (4)
When I am really happy, I often find myself in
situations that I normally wouldn't be comfortable
with.
Agree strongly     (1)
Agree some     (2)
Disagree some (3)
Disagree strongly (4)
Before making up my mind, I consider all the
advantages and disadvantages.
Agree strongly     (1)
Agree some     (2)
Disagree some (3)
Disagree strongly (4)
I would enjoy fast driving.
Agree strongly     (1)
Agree some     (2)
Disagree some (3)
Disagree strongly (4)
When I am very happy, I feel like it is ok to give in
to cravings or overindulge.
Agree strongly     (1)
Agree some     (2)
Disagree some (3)
Disagree strongly (4)
Sometimes I do impulsive things that I later
regret.
Agree strongly     (1)
Agree some     (2)
Disagree some (3)
Disagree strongly (4)
I am surprised at the things I do while in a great
mood.
Agree strongly     (1)
Agree some     (2)
Disagree some (3)
Disagree strongly (4)
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Exposures to Violence - Adult Protocol
PhenX Toolkit
The respondent is asked a comprehensive list of questions
about trauma and victimization experiences over his/her
lifetime. If the respondent answers "yes" to the first
question, the interviewer administers additional follow-up
questions about the event. Follow-up questions collect
information about the person’s age when the event
occurred, whether serious injury or death was involved, if
there was an intense feeling of fear and helplessness, the
frequency of the event, and whether anyone else ever tried
to harm the person in the same way. The questions are
sensitive and cover subjects such as physical violence,
sexual abuse, suicide, and murder.
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Exposures to Violence - Adult
Protocol PhenX Toolkit
PhenX - exposures to violence - adult
protocol
Have you ever been involved in a natural disaster,
such as a tornado, hurricane, flood, or
earthquake?
Yes
No
How old were you the first time it happened?
Were you in danger of death or serious injury?
Yes
No
Did you feel intense fear, helplessness, or horror?
Yes
No
Was there another time this happened [PhenX]
Yes
No
Have you ever been involved in a man-made
disaster, such as a fire, train crash, car accident,
or building collapse?
Yes
No
Have you ever been involved in direct combat
experience in a war?
Yes
No
Have you ever lived in a war zone? (For example,
the Persian Gulf or Bosnia).
Yes
No
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Have you ever had a serious accident at home, at
work, or somewhere else?
Yes
No
Have you ever been exposed to dangerous
chemicals or radioactivity?
Yes
No
Have you ever been shot at, stabbed, struck,
kicked, beaten, punched, slapped around, or
otherwise physically harmed?
Yes
No
How many times did this person do this to you?
How old were you the last time this person did
this to you?
Did anyone else ever do this to you [PhenX]
Yes
No
Have you ever been threatened with any kind of a
weapon, like a knife, gun, baseball bat, frying
pan, scissors, stick, rock or bottle?
Yes
No
Has anyone ever threatened you in a face-to-face
confrontation?
Yes
No
Have you ever been actually assaulted with any
kind of a weapon, like a knife, gun, baseball bat,
frying pan, scissors, stick, rock, or bottle?
Yes
No
When you were a child--that is, when you were in
elementary or middle school, before about age
12--were you ever struck, kicked, beaten,
punched, slapped around, or otherwise physically
harmed?
Yes
No
When you were a child- that is, when you were in
elementary or middle school, before about age
12-were you ever physically abused?
Yes
No
Has anyone--male or female--ever forced or
coerced you to engage in unwanted sexual
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activity?
Yes
No
Other than what we just talked about, did anyone,
male or female ever attempt to--but not actually--
force you to engage in unwanted sexual activity?
Yes
No
Other than what we just talked about, has anyone
ever actually touched private parts of your body
or made you touch theirs against your wishes?
Yes
No
Have you ever had an immediate family member,
romantic partner, or very close friend who was
murdered?
Yes
No
Have you ever seen or been present when
someone was murdered or seriously injured?
Yes
No
Have you ever had an immediate family member,
romantic partner, or very close friend commit
suicide?
Yes
No
Have you ever seen a dead or mutilated body?
Other than at a funeral, in the movies or
newspaper?
Yes
No
Have you ever seen or been present when
another person was shot at, stabbed, struck,
kicked, beaten, slapped around, or otherwise
physically harmed?
Yes
No
Have you ever seen or been present when
another person was raped, sexually attacked, or
made to engage in unwanted sexual activity?
Yes
No
Has anyone ever intentionally damaged or
destroyed property owned by you or by someone
in your household?
Yes
No
Has anyone ever stolen something from you by
using force or the threat of force like in a stick-up,
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mugging, or car-jacking?
Yes
No
Has anyone ever tried to--but not actually--steal
something from you by using force or the threat of
force like in a stick-up, mugging, or car-jacking?
Yes
No
Has anyone ever tried to or actually broken in to
your house, garage, shed, or storage room when
you were not there?
Yes
No
Has anyone ever tried to or actually broken in to
your house, garage, shed, or storage room when
you were there?
Yes
No
Has anyone ever stolen something directly from
you without the threat or use of force (for example
purse-snatching or pick-pocket)?
Yes
No
Have you ever been kidnapped or held captive?
Yes
No
How long were you held or not allowed to leave?
Have you ever been stalked by anyone?
Yes
No
Have you ever been in any other situation in
which you were in danger of death or serious
physical injury, or in which you felt intense fear,
helplessness, or horror?
Yes
No
Have you ever been in any other situation in
which you were in danger of death or serious
physical injury, or in which you felt intense fear,
helplessness, or horror?
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Voice Impairments Protocol PhenX Toolkit
The Voice Handicap Index (VHI) is a 30-item self-
administered questionnaire that asks individuals to
describe their voice and the effects of their voice on their
life. Three subscales cover the areas of functional,
emotional, and physical aspects of voice disorders. Points
from the questions can be combined to assign a total score,
or they can be combined by subscale.
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Voice Impairments Protocol PhenX
Toolkit
PhenX - voice impairments protocol
My voice makes it difficult for people to hear me.
Never (1)
Almost never (2)
Sometimes (3)
Almost always (4)
Always (5)
I run out of air when I talk.
Never (1)
Almost never (2)
Sometimes (3)
Almost always (4)
Always (5)
People have difficulty understanding me in a
noisy room.
Never (1)
Almost never (2)
Sometimes (3)
Almost always (4)
Always (5)
The sound of my voice varies throughout the day.
Never (1)
Almost never (2)
Sometimes (3)
Almost always (4)
Always (5)
My family has difficulty hearing me when I call
them throughout the house.
Never (1)
Almost never (2)
Sometimes (3)
Almost always (4)
Always (5)
I use the phone less often than I would like.
Never (1)
Almost never (2)
Sometimes (3)
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Almost always (4)
Always (5)
I'm tense when talking with others because of my
voice.
Never (1)
Almost never (2)
Sometimes (3)
Almost always (4)
Always (5)
I tend to avoid groups of people because of my
voice.
Never (1)
Almost never (2)
Sometimes (3)
Almost always (4)
Always (5)
People seem irritated with my voice.
Never (1)
Almost never (2)
Sometimes (3)
Almost always (4)
Always (5)
People ask, "What's wrong with your voice?"
Never (1)
Almost never (2)
Sometimes (3)
Almost always (4)
Always (5)
I speak with friends, neighbors, or relatives less
often because of my voice.
Never (1)
Almost never (2)
Sometimes (3)
Almost always (4)
Always (5)
People ask me to repeat myself when speaking
face-to-face.
Never (1)
Almost never (2)
Sometimes (3)
Almost always (4)
Always (5)
My voice sounds creaky and dry.
Never (1)
Almost never (2)
Sometimes (3)
Almost always (4)
Always (5)
I feel as though I have to strain to produce voice.
Never (1)
Almost never (2)
Sometimes (3)
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Almost always (4)
Always (5)
I find other people don't understand my voice
problem.
Never (1)
Almost never (2)
Sometimes (3)
Almost always (4)
Always (5)
My voice difficulties restrict my personal and
social life.
Never (1)
Almost never (2)
Sometimes (3)
Almost always (4)
Always (5)
The clarity of my voice is unpredictable.
Never (1)
Almost never (2)
Sometimes (3)
Almost always (4)
Always (5)
I try to change my voice to sound different.
Never (1)
Almost never (2)
Sometimes (3)
Almost always (4)
Always (5)
I feel left out of conversations because of my
voice.
Never (1)
Almost never (2)
Sometimes (3)
Almost always (4)
Always (5)
I use a great deal of effort to speak.
Never (1)
Almost never (2)
Sometimes (3)
Almost always (4)
Always (5)
My voice is worse in the evening.
Never (1)
Almost never (2)
Sometimes (3)
Almost always (4)
Always (5)
My voice problem causes me to lose income.
Never (1)
Almost never (2)
Sometimes (3)
Almost always (4)
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Always (5)
My voice problem upsets me.
Never (1)
Almost never (2)
Sometimes (3)
Almost always (4)
Always (5)
I am less outgoing because of my voice problem.
Never (1)
Almost never (2)
Sometimes (3)
Almost always (4)
Always (5)
My voice makes me feel handicapped.
Never (1)
Almost never (2)
Sometimes (3)
Almost always (4)
Always (5)
My voice "gives out" on me in the middle of
speaking.
Never (1)
Almost never (2)
Sometimes (3)
Almost always (4)
Always (5)
I feel annoyed when people ask me to repeat.
Never (1)
Almost never (2)
Sometimes (3)
Almost always (4)
Always (5)
I feel embarrassed when people ask me to
repeat.
Never (1)
Almost never (2)
Sometimes (3)
Almost always (4)
Always (5)
My voice makes me feel incompetent.
Never (1)
Almost never (2)
Sometimes (3)
Almost always (4)
Always (5)
I'm ashamed of my voice problem.
Never (1)
Almost never (2)
Sometimes (3)
Almost always (4)
Always (5)
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Contraceptive Methods - Female PhenX
Toolkit
Female participants are asked whether they have had a
tubal ligation and whether they are able to have children.
They are also asked about whether their male partners can
have children. Female participants are then asked about
the type of birth control they have used in the past and the
type they are currently using.
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Contraceptive Methods - Female
PhenX Toolkit
PhenX - contraceptive methods - female
protocol
Have you ever had both of your tubes tied, cut, or
removed? This procedure is often called a tubal
ligation or tubal sterilization.
Yes (1)
If vol: operation failed (2)
No (3)
If vol: operation already reversed (4)
Have you ever had any other operation that
makes it impossible for you to have (a/another)
baby?
Yes
No
Many women who have only one (tube tied/ovary
removed) can still have babies because they are
not completely sterile. As far as you know, are
you completely sterile from this operation, that is,
does it make it impossible for you to have a baby
in the future?
Yes
No
Has (HUSBAND/PARTNER) ever had a
vasectomy or any other operation that would
make it impossible for him to father a baby in the
future?
Yes
No
What type of operation did
(HUSBAND/PARTNER) have?
Vasectomy     (1)
Other operation (2)
If vol: operation failed     (3)
If vol: operation already reversed (4)
As far as you know, is he completely sterile from
this operation, that is, does it make it impossible
for him to father a baby in the future?
Yes
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No
Methods to prevent pregnancy [PhenX]
Birth control pills    (1)
Foam (10)
Cervical cap  (11)
Suppository or an insert  (12)
Today sponge     (13)
IUD - coil, or loop  (14)
Lunelle - a once-a-month injection (15)
Contraceptive patch (16)
Oral contraceptives for >2Mos (2)
Depo-provera or injectables (shots)   (3)
Norplant (implants)     (4)
Rhythm or safe period (5)
Natural family planning or safe period by
temperature or cervical mucus test (6)
Morning after pills or emergency
contraception   (7)
Diaphragm with or without jelly or cream
(8)
Female condoms or vaginal pouches (9)
Have you ever used this method to prevent
pregnancy [PhenX]
Yes
No
Have you ever used oral contraceptives for two
months or more for any reason (contraception,
acne, menstrual irregularity, etc.)?
Yes
No
How old were you when you began using oral
contraceptives?
For how long in total have you used oral
contraceptives?
months
More than one year but less than ten
years (More than one year but less than
ten years)
One year or less (One year or less)
Ten years or more (Ten years or more)
Have you ever had sex with a partner who had a
vasectomy?
Yes
No
Have you ever had sex with a partner who used
withdrawal or "pulling out"?
Yes
No
How many different times have you used
emergency contraception?
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Have you used any other methods of
contraception?
Yes
No
If R used an "OTHER" method of contraception,
Specify.
Are you currently using any method of birth
control?
Yes
No
Mark methods of birth control you are currently
using.
Birth control pills (1)
Vaginal sponge (10)
Withdrawal     (11)
Abstinence     (12)
Rhythm/natural family planning  (13)
Morning after pill (14)
Vasectomy of husband/partner     (15)
Other (16)
Birth control patch (2)
IUD     (3)
Injection  (4)
Condoms     (5)
Diaphragm  (6)
Cervical cap    (7)
Nuvaring®    (8)
Spermicidal foam or jelly   (9)
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Anxiety Disorders Screener - Child PhenX
Toolkit
The revised version of the Screen for Child Anxiety Related
Emotional Disorders (SCARED-R) is a 66 item self report
questionnaire designed to measure symptoms of panic
disorder, generalized anxiety disorder, social phobia,
separation anxiety disorder, obsessive compulsive disorder,
post-traumatic stress disorder and specific phobias in
children age 8 to 17.
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Anxiety Disorders Screener - Child
PhenX Toolkit
PhenX - anxiety disorders screener - child
protocol
When frightened, it is hard to breathe.
Almost never (1)
Sometimes (2)
Often (3)
I am afraid of heights.
Almost never (1)
Sometimes (2)
Often (3)
I get headaches or stomach aches when I am at
school.
Almost never (1)
Sometimes (2)
Often (3)
I don't like to be with people I don't know.
Almost never (1)
Sometimes (2)
Often (3)
When I see blood, I get dizzy.
Almost never (1)
Sometimes (2)
Often (3)
I want that things are in a fixed order.
Almost never (1)
Sometimes (2)
Often (3)
I get scared when I sleep away from home.
Almost never (1)
Sometimes (2)
Often (3)
I worry about others not liking me.
Almost never (1)
Sometimes (2)
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Often (3)
When frightened, I feel like passing out.
Almost never (1)
Sometimes (2)
Often (3)
I think that I will be contaminated with a serious
disease.
Almost never (1)
Sometimes (2)
Often (3)
I am nervous.
Almost never (1)
Sometimes (2)
Often (3)
I follow my parents wherever they go.
Almost never (1)
Sometimes (2)
Often (3)
I have thoughts that frighten me.
Almost never (1)
Sometimes (2)
Often (3)
People tell me that I look nervous.
Almost never (1)
Sometimes (2)
Often (3)
I feel nervous with people I don't know well.
Almost never (1)
Sometimes (2)
Often (3)
I am afraid to visit the doctor.
Almost never (1)
Sometimes (2)
Often (3)
I don't like going to school.
Almost never (1)
Sometimes (2)
Often (3)
When frightened, I feel like going crazy.
Almost never (1)
Sometimes (2)
Often (3)
I worry about sleeping alone.
Almost never (1)
Sometimes (2)
Often (3)
I am afraid to visit the dentist.
Almost never (1)
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Sometimes (2)
Often (3)
I worry about being as good as other kids.
Almost never (1)
Sometimes (2)
Often (3)
I am afraid of an animal that is not really
dangerous.
Almost never (1)
Sometimes (2)
Often (3)
I get scared when there is thunder in the air.
Almost never (1)
Sometimes (2)
Often (3)
I do things more than twice in order to check
whether I did it right.
Almost never (1)
Sometimes (2)
Often (3)
I have frightening dreams about a very aversive
event I once experienced.
Almost never (1)
Sometimes (2)
Often (3)
I want things to be clean and tidy.
Almost never (1)
Sometimes (2)
Often (3)
When frightened, I feel that things are not real.
Almost never (1)
Sometimes (2)
Often (3)
I feel scared when I have to fly in an airplane.
Almost never (1)
Sometimes (2)
Often (3)
I have nightmares about my parents.
Almost never (1)
Sometimes (2)
Often (3)
I worry about going to school.
Almost never (1)
Sometimes (2)
Often (3)
I do things to get less scared of my thoughts.
Almost never (1)
Sometimes (2)
Often (3)
3 / 7
Anxiety Disorders Screener - Child PhenX Toolkit
When frightened, my heart beats fast.
Almost never (1)
Sometimes (2)
Often (3)
I am scared when I get an injection.
Almost never (1)
Sometimes (2)
Often (3)
I am afraid to get a serious disease.
Almost never (1)
Sometimes (2)
Often (3)
I feel weak and shaky.
Almost never (1)
Sometimes (2)
Often (3)
I have nightmares about bad things happening to
me.
Almost never (1)
Sometimes (2)
Often (3)
I am so scared of a harmless animal that I do not
dare to touch it.
Almost never (1)
Sometimes (2)
Often (3)
I worry about things working out for me.
Almost never (1)
Sometimes (2)
Often (3)
I doubt whether I really did something.
Almost never (1)
Sometimes (2)
Often (3)
When frightened, I sweat a lot.
Almost never (1)
Sometimes (2)
Often (3)
I am a worrier.
Almost never (1)
Sometimes (2)
Often (3)
I feel scared when I watch an operation.
Almost never (1)
Sometimes (2)
Often (3)
I try not to think about a very aversive event I
once experienced.
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Almost never (1)
Sometimes (2)
Often (3)
I get really frightened for no reason.
Almost never (1)
Sometimes (2)
Often (3)
I am afraid to be alone at home.
Almost never (1)
Sometimes (2)
Often (3)
I get scared when I think back of a very aversive
event I once experienced.
Almost never (1)
Sometimes (2)
Often (3)
I find it hard to talk with people I don't know.
Almost never (1)
Sometimes (2)
Often (3)
When frightened, I feel like I am choking.
Almost never (1)
Sometimes (2)
Often (3)
People tell me I worry too much.
Almost never (1)
Sometimes (2)
Often (3)
I don't like being away from my family.
Almost never (1)
Sometimes (2)
Often (3)
I am afraid of having anxiety attacks.
Almost never (1)
Sometimes (2)
Often (3)
I worry that bad happens to my parents.
Almost never (1)
Sometimes (2)
Often (3)
I am shy with people I don't know well.
Almost never (1)
Sometimes (2)
Often (3)
I fantasize about hurting other people.
Almost never (1)
Sometimes (2)
Often (3)
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I worry about the future.
Almost never (1)
Sometimes (2)
Often (3)
When frightened, I feel like throwing up.
Almost never (1)
Sometimes (2)
Often (3)
I worry about how well I do things.
Almost never (1)
Sometimes (2)
Often (3)
I am scared to go to school.
Almost never (1)
Sometimes (2)
Often (3)
I worry about things that happened in the past.
Almost never (1)
Sometimes (2)
Often (3)
When frightened, I feel dizzy.
Almost never (1)
Sometimes (2)
Often (3)
I get scared in small, closed places
Almost never (1)
Sometimes (2)
Often (3)
I have thoughts that I prefer not to have.
Almost never (1)
Sometimes (2)
Often (3)
I am afraid of the dark.
Almost never (1)
Sometimes (2)
Often (3)
I have unbidden thoughts about a very aversive
event I once experienced.
Almost never (1)
Sometimes (2)
Often (3)
I am afraid of an animal that most children do not
fear.
Almost never (1)
Sometimes (2)
Often (3)
I don't like being in a hospital.
Almost never (1)
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Sometimes (2)
Often (3)
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Assay for Syphilis Protocol PhenX Toolkit
This protocol provides instructions for drawing, processing,
and storing blood according to the National Health and
Nutrition Examination Survey (NHANES). As multiple tests
must be performed to make the most accurate diagnosis of
syphilis infection, the protocol also provides basic
guidelines to aid comparability among different studies.
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Assay for Syphilis Protocol PhenX
Toolkit
Exclusion criteria - assays PhenX
Do you have hemophilia?
Yes (1)
No (2)
Refused (7)
Don't know (9)
Have you received cancer chemotherapy in the
past four weeks or do you anticipate such therapy
in the next four weeks?
Yes (1)
No (2)
Refused (7)
Don't know (9)
Process variables for assays PhenX
Exclusion Criteria
Hemophilia (1)
Received cancer chemotherapy in the
last 3 weeks (2)
None – proceed with blood draw (3)
Was blood drawn?
Yes
No
Was full sample obtained?
Yes
No
Service comment
Service comment
Repeatability of the assay
Coefficient of variation for the assay
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Manufacturer variables for assays PhenX
Make of the equipment used to perform...
Manufacturer of the equipment used to
perform...*
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Attention-Deficit/Hyperactivity Disorder
Symptoms - Adult PhenX Toolkit
The Adult Attention-Deficit Hyperactivity Disorder Self-
Report Scale (ASRS-v1.1) Symptom Checklist is an 18-
item, two-part questionnaire designed to determine if the
participant exhibits Attention-deficit/hyperactivity disorder
symptoms.
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Attention-Deficit/Hyperactivity
Disorder Symptoms - Adult PhenX
Toolkit
PhenX - attention-deficit - hyperactivity
disorder symptoms protocol - adult
How often do you have trouble wrapping up the
final details of a project, once the challenging
parts have been done?
Never (1)
Rarely (2)
Sometimes (3)
Often (4)
Very often (5)
How often do you have difficulty getting things in
order when you have to do a task that requires
organization?
Never (1)
Rarely (2)
Sometimes (3)
Often (4)
Very often (5)
How often do you have problems remembering
appointments or obligations?
Never (1)
Rarely (2)
Sometimes (3)
Often (4)
Very often (5)
When you have a task that requires a lot of
thought, how often do you avoid or delay getting
started?
Never (1)
Rarely (2)
Sometimes (3)
Often (4)
Very often (5)
How often do you fidget or squirm with your
hands or feet when you have to sit down for a
long time?
Never (1)
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Rarely (2)
Sometimes (3)
Often (4)
Very often (5)
How often do you feel overly active and
compelled to do things, like you were driven by a
motor?
Never (1)
Rarely (2)
Sometimes (3)
Often (4)
Very often (5)
How often do you make careless mistakes when
you have to work on a boring or difficult project?
Never (1)
Rarely (2)
Sometimes (3)
Often (4)
Very often (5)
How often do you have difficulty keeping your
attention when you are doing boring or repetitive
work?
Never (1)
Rarely (2)
Sometimes (3)
Often (4)
Very often (5)
How often do you have difficulty concentrating on
what people say to you, even when they are
speaking to you directly?
Never (1)
Rarely (2)
Sometimes (3)
Often (4)
Very often (5)
How often do you misplace or have difficulty
finding things at home or at work?
Never (1)
Rarely (2)
Sometimes (3)
Often (4)
Very often (5)
How often are you distracted by activity or noise
around you?
Never (1)
Rarely (2)
Sometimes (3)
Often (4)
Very often (5)
How often do you leave your seat in meetings or
other situations in which you are expected to
remain seated?
Never (1)
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Rarely (2)
Sometimes (3)
Often (4)
Very often (5)
How often do you feel restless or fidgety?
Never (1)
Rarely (2)
Sometimes (3)
Often (4)
Very often (5)
How often do you have difficulty unwinding and
relaxing when you have time to yourself?
Never (1)
Rarely (2)
Sometimes (3)
Often (4)
Very often (5)
How often do you find yourself talking too much
when you are in social situations?
Never (1)
Rarely (2)
Sometimes (3)
Often (4)
Very often (5)
When you're in a conversation, how often do you
find yourself finishing the sentences of the people
you are talking to, before they can finish them
themselves?
Never (1)
Rarely (2)
Sometimes (3)
Often (4)
Very often (5)
How often do you have difficulty waiting your turn
in situations when turn taking is required?
Never (1)
Rarely (2)
Sometimes (3)
Often (4)
Very often (5)
How often do you interrupt others when they are
busy?
Never (1)
Rarely (2)
Sometimes (3)
Often (4)
Very often (5)
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Calcium Intake - Children PhenX Toolkit
These self-administered questions are for use with children
of middle school-age (aged 11-14 years). Each question
has a multichoice answer. Pictures help guide the children’s
responses to the questions.
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Calcium Intake - Children PhenX
Toolkit
PhenX - calcium intake - pediatric protocol
How often do you drink 100% orange juice?
1 time per day     (1 time per day    )
1 time per month    (1 time per month   )
1-2 times per week  (1-2 times per week
)
2 or more times per day (2 or more times
per day)
2-3 times per month   (2-3 times per
month  )
3-4 times per week (3-4 times per week)
5-6 times per week     (5-6 times per
week    )
Never or less than 1 time per month
(Never or less than 1 time per month  )
Each time you drink orange juice, how much do
you usually drink?
1 cup (8 ounces) (1 cup (8 ounces))
Less than a cup (Less than a cup)
More than 1 cup (More than 1 cup)
How often is the orange juice you drink calcium
fortified?
Almost always or always (Almost always
or always)
Almost never or never (Almost never or
never)
Don't know (Don't know)
Sometimes (Sometimes)
How often do you drink milk as a beverage (NOT
in cereal)?
1 time per day     (1 time per day    )
1 time per month    (1 time per month   )
1-2 times per week  (1-2 times per week
)
2 or more times per day (2 or more times
per day)
2-3 times per month   (2-3 times per
month  )
3-4 times per week (3-4 times per week)
5-6 times per week     (5-6 times per
week    )
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Never or less than 1 time per month
(Never or less than 1 time per month  )
Each time you drink milk, how much do you
usually drink?
1 cup (8 ounces) (1 cup (8 ounces))
Less than a cup (Less than a cup)
More than 1 cup (More than 1 cup)
What kind of milk do you usually drink?
1% fat milk (1% fat milk)
2% fat milk (2% fat milk)
Chocolate milk (Chocolate milk)
Don't know (Don't know)
Skim or nonfat milk (Skim or nonfat milk)
Soy or rice milk (Soy or rice milk)
Whole milk (Whole milk)
How often do you eat yogurt?
1 time per day     (1 time per day    )
1 time per month    (1 time per month   )
1-2 times per week  (1-2 times per week
)
2 or more times per day (2 or more times
per day)
2-3 times per month   (2-3 times per
month  )
3-4 times per week (3-4 times per week)
5-6 times per week     (5-6 times per
week    )
Never or less than 1 time per month
(Never or less than 1 time per month  )
How often do you eat cold cereal?
1 time per day     (1 time per day    )
1 time per month    (1 time per month   )
1-2 times per week  (1-2 times per week
)
2 or more times per day (2 or more times
per day)
2-3 times per month   (2-3 times per
month  )
3-4 times per week (3-4 times per week)
5-6 times per week     (5-6 times per
week    )
Never or less than 1 time per month
(Never or less than 1 time per month  )
Each time you eat cold cereal, how much do you
usually eat?
2 cups (2 cups)
Less than 2 cups (Less than 2 cups)
More than 2 cups (More than 2 cups)
How often do you eat Mexican foods such as
tacos, tostados, burritos, tamales, fajitas,
enchiladas, quesadillas, or chimichangas?
1 time per day     (1 time per day    )
1 time per month    (1 time per month   )
1-2 times per week  (1-2 times per week
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)
2 or more times per day (2 or more times
per day)
2-3 times per month   (2-3 times per
month  )
3-4 times per week (3-4 times per week)
5-6 times per week     (5-6 times per
week    )
Never or less than 1 time per month
(Never or less than 1 time per month  )
Each time you eat Mexican foods, how much do
you usually eat?
1 taco or burrito (1 taco or burrito)
Less than 1 taco or burrito (Less than 1
taco or burrito)
More than 1 taco or burrito (More than 1
taco or burrito)
How often do you eat pizza?
1 time per day     (1 time per day    )
1 time per month    (1 time per month   )
1-2 times per week  (1-2 times per week
)
2 or more times per day (2 or more times
per day)
2-3 times per month   (2-3 times per
month  )
3-4 times per week (3-4 times per week)
5-6 times per week     (5-6 times per
week    )
Never or less than 1 time per month
(Never or less than 1 time per month  )
Each time you eat pizza, how much do you
usually eat?
1 slice (1 slice)
2 slices or one mini pizza (2 slices or one
mini pizza)
3 or more slices (3 or more slices)
How often do you eat macaroni and cheese?
1 time per day     (1 time per day    )
1 time per month    (1 time per month   )
1-2 times per week  (1-2 times per week
)
2 or more times per day (2 or more times
per day)
2-3 times per month   (2-3 times per
month  )
3-4 times per week (3-4 times per week)
5-6 times per week     (5-6 times per
week    )
Never or less than 1 time per month
(Never or less than 1 time per month  )
Each time you eat macaroni and cheese, how
much do you usually eat?
1 cup (8 ounces) (1 cup (8 ounces))
Less than a cup (Less than a cup)
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More than 1 cup (More than 1 cup)
How often do you eat ice cream, ice cream bars,
milkshakes, or frozen yogurt?
1 time per day     (1 time per day    )
1 time per month    (1 time per month   )
1-2 times per week  (1-2 times per week
)
2 or more times per day (2 or more times
per day)
2-3 times per month   (2-3 times per
month  )
3-4 times per week (3-4 times per week)
5-6 times per week     (5-6 times per
week    )
Never or less than 1 time per month
(Never or less than 1 time per month  )
Each time you eat ice cream, ice cream bars,
milkshakes, or frozen yogurt, how much do you
usually eat?
1 cup (2 scoops) (1 cup (2 scoops))
Less than 1 cup (Less than 1 cup)
More than 1 cup (More than 1 cup)
How often do you eat cheese (including on
salads or in sandwiches or subs)?
1 time per day     (1 time per day    )
1 time per month    (1 time per month   )
1-2 times per week  (1-2 times per week
)
2 or more times per day (2 or more times
per day)
2-3 times per month   (2-3 times per
month  )
3-4 times per week (3-4 times per week)
5-6 times per week     (5-6 times per
week    )
Never or less than 1 time per month
(Never or less than 1 time per month  )
Each time you eat cheese, how much do you
usually eat?
1 slice (1 slice)
Less than 1 slice (Less than 1 slice)
More than 1 slice (More than 1 slice)
How often do you eat bread, toast or dinner rolls,
including bread as part of a sandwich (DO NOT
count buns with hamburgers or hot dogs)?
1 time per day     (1 time per day    )
1 time per month    (1 time per month   )
1-2 times per week  (1-2 times per week
)
2 or more times per day (2 or more times
per day)
2-3 times per month   (2-3 times per
month  )
3-4 times per week (3-4 times per week)
5-6 times per week     (5-6 times per
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week    )
Never or less than 1 time per month
(Never or less than 1 time per month  )
Each time you eat bread, toast or dinner rolls,
how much do you usually eat?
1 slice or 1 dinner roll (1 slice or 1 dinner
roll)
2 slices or 2 dinner rolls (2 slices or 2
dinner rolls)
More than 2 slices or 2 dinner rolls (More
than 2 slices or 2 dinner rolls)
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Tinnitus Protocol PhenX Toolkit
The Tinnitus Handicap Inventory is a 25-item self-
administered questionnaire that assesses the impact of
tinnitus on the respondent’s general well-being. The
Tinnitus Handicap Inventory includes a functional subscale
(11 items) that measures limitations of mental, social, and
physical functioning; an emotional subscale (9 items) that
assesses affective responses such as anger and
frustration; and a catastrophic subscale (5 items) that
measures items such as desperation. The protocol also
includes scoring instructions.
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Tinnitus Protocol PhenX Toolkit
PhenX - tinnitus protocol
Because of your tinnitus is it difficult to
concentrate?
Yes (1)
Sometimes (2)
No (3)
Does the loudness of your tinnitus make it difficult
for you to hear people?
Yes (1)
Sometimes (2)
No (3)
Does your tinnitus make you angry?
Yes (1)
Sometimes (2)
No (3)
Does your tinnitus make you feel confused?
Yes (1)
Sometimes (2)
No (3)
Because of your tinnitus do you feel desperate?
Yes (1)
Sometimes (2)
No (3)
Do you complain a great deal about your tinnitus?
Yes (1)
Sometimes (2)
No (3)
Because of your tinnitus do you have trouble
falling to sleep at night?
Yes (1)
Sometimes (2)
No (3)
Do you feel that you cannot escape your tinnitus?
Yes (1)
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Sometimes (2)
No (3)
Does your tinnitus interfere with your ability to
enjoy social activities (such as going out to
dinner, to the movies)
Yes (1)
Sometimes (2)
No (3)
Because of your tinnitus do you feel frustrated?
Yes (1)
Sometimes (2)
No (3)
Because of your tinnitus do you feel that you have
a terrible disease?
Yes (1)
Sometimes (2)
No (3)
Does your tinnitus make it difficult for you to enjoy
life?
Yes (1)
Sometimes (2)
No (3)
Does your tinnitus interfere with your job or
household duties?
Yes (1)
Sometimes (2)
No (3)
Because of your tinnitus do you find that you are
often irritable?
Yes (1)
Sometimes (2)
No (3)
Because of your tinnitus is it difficult for you to
read?
Yes (1)
Sometimes (2)
No (3)
Does your tinnitus make you upset?
Yes (1)
Sometimes (2)
No (3)
Do you feel that your tinnitus problem has placed
stressed on your relationship with members of
your family and friends?
Yes (1)
Sometimes (2)
No (3)
Do you find it difficult to focus your attention away
from your tinnitus and on other things?
Yes (1)
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Sometimes (2)
No (3)
Do you feel that you have no control over your
tinnitus?
Yes (1)
Sometimes (2)
No (3)
Because of your tinnitus do you often feel tired?
Yes (1)
Sometimes (2)
No (3)
Because of your tinnitus do you feel depressed?
Yes (1)
Sometimes (2)
No (3)
Does your tinnitus make you feel anxious?
Yes (1)
Sometimes (2)
No (3)
Do you feel that you can no longer cope with your
tinnitus?
Yes (1)
Sometimes (2)
No (3)
Does your tinnitus get worse when are you are
under stress?
Yes (1)
Sometimes (2)
No (3)
Does your tinnitus make you feel insecure?
Yes (1)
Sometimes (2)
No (3)
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Liver Function Assay Protocol PhenX
Toolkit
A standard liver panel is comprised of the following
bioassays that are performed on refrigerated serum or
plasma: alanine aminotransferase (ALT), aspartate
aminotransferase (AST), alkaline phosphatase (ALP),
bilirubin, albumin, total protein, and gamma-glutamyl
transferase (GGT).
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Liver Function Assay Protocol PhenX
Toolkit
PhenX - liver function assay protocol
Do you have hemophilia?
Yes (1)
No (2)
Refused (3)
Don't know (4)
Have you received cancer chemotherapy in the
past four weeks or do you anticipate such therapy
in the next four weeks?
Yes (1)
No (2)
Refused (3)
Don't know (4)
Exclusion Criteria
Hemophilia     (1)
Received cancer chemotherapy in the
last 3 weeks (2)
None – proceed with blood draw (3)
Was blood drawn?
Yes
No
Was full sample obtained?
Yes
No
Service comment: Record any comments about
the blood draw, inclu
ding any reasons for the tube not being 
drawn according to the protocol.
Service comment: Record comments to describe
the sample during p
rocessing:
Make of the equipment used to perform...
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Manufacturer of the equipment used to perform...
Repeatability of the assay
Coefficient of variation for the assay
Make of the equipment used to perform...
Manufacturer of the equipment used to perform...
Repeatability of the assay
Coefficient of variation for the assay
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Oral Glucose Tolerance Test Protocol
PhenX Toolkit
Participants are asked to fast for at least 9 hours (generally
overnight) prior to the Oral Glucose Tolerance Test (OGTT).
Participants are asked a series of exclusionary questions
and then have an initial blood draw to determine Fasting
Plasma Glucose levels. Participants are next asked to drink
a calibrated dose (generally 75 grams/10 ounces) of a
dextrose solution (e.g., Trutol®) and have a second
venipuncture 2 hours (plus or minus 15 minutes) after the
first venipuncture. The plasma is separated from the blood
via centrifugation, and glucose concentration is determined
via the hexokinase method.
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Oral Glucose Tolerance Test Protocol
PhenX Toolkit
PhenX - oral glucose tolerance test
protocol
Did you eat or drink anything other than plain
water after 11:30 last night?
Yes (1)
No (2)
Refused (3)
Don't know (4)
When did you last eat or drink anything other
than plain water?
Have you had any of the following since {insert
time from 1 here}? Coffee or tea with cream and
sugar? [Include milk or non-dairy creamers.]
Yes
No
If Yes, record date
Have you had any of the following since {insert
time from 1 here}? Alcohol, such as beer, wine,
or liquor?
Yes
No
If Yes, record date
Have you had any of the following since {insert
time from 1 here}? Gum, breath mints, lozenges,
or cough drops, or other cough or cold remedies?
Yes
No
If Yes, record date
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Have you had any of the following since {insert
time from 1 here}? Antacids, laxatives, or anti-
diarrheals?
Yes
No
If Yes, record date
Have you had any of the following since {insert
time from 1 here}? Dietary Supplements such as
vitamins and minerals? [Include multivitamins and
single nutrient supplements.]
Yes
No
If Yes, record date
Are you currently pregnant?
Yes (1)
No (2)
Don't know (3)
{Is SP/Are you} now taking insulin?
Yes (1)
No (2)
Refused (3)
Don't know (4)
{Is SP/Are you} now taking diabetic pills to lower
{his/her}/your} blood sugar?
Yes (1)
No (2)
Refused (3)
Don't know (4)
Do you have hemophilia?
Yes (1)
No (2)
Refused (3)
Don't know (4)
Have you received cancer chemotherapy in the
past four weeks or do you anticipate such therapy
in the next four weeks?
Yes (1)
No (2)
Refused (3)
Don't know (4)
Exclusion Criteria
Hemophilia (1)
Received cancer chemotherapy in the
last 3 weeks (2)
None – proceed with blood draw (3)
Service comment: Record any comments about
the blood draw, including any reasons for the tube
not being drawn according to the protocol.
2 / 3
Oral Glucose Tolerance Test Protocol PhenX Toolkit
Service comment: Record any comments about
the blood draw, including any reasons for the tube
not being drawn according to the protocol.
Body weight
kg
Record the amount of dextrose solution
administered
ml
Record the amount of dextrose solution the
participant drank
All (1)
Some (2)
None (3)
Record whether all of the solution was consumed
in 10 minutes
Yes – solution consumed in 10 minutes
(1)
No – solution not consumed in 10
minutes (2)
Record the number of minutes elapsed between
consuming dextrose solution and administering
the second blood draw
min
Make of the equipment used to perform...
Manufacturer of the equipment used to perform...
Blood draw [PhenX]
Blood draw 1 (Blood draw 1)
Blood draw 2 (Blood draw 2)
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Total Physical Activity - Comprehensive -
Adolescent Protocol PhenX Toolkit
The child recalls all of the physical activities he/she
engaged in during the previous 3 days. The researcher
utilizes a script and examples to introduce the
questionnaire. An activities scale includes pictures of
typical activities and the intensity of those activities. Using
the activities scale, each child should complete a time
activity log for each day. The child should enter an activity
number (from the activities scale) and a checkmark (for the
intensity) for each 30 minute increment of each day.
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Total Physical Activity -
Comprehensive - Adolescent
Protocol PhenX Toolkit
PhenX - total physical activity -
comprehensive - adolescent protocol
Day name [PhenX]
Sunday (1)
Monday (2)
Tuesday (3)
Wednesday (4)
Thursday (5)
Friday (6)
Saturday (7)
Time period [PhenX]
1:00-1:30pm     (1:00-1:30pm    )
1:30-2:00pm (1:30-2:00pm)
10:00-10:30pm (10:00-10:30pm)
10:30-11:00pm  (10:30-11:00pm )
11:00-11:30am (11:00-11:30am)
11:00-11:30pm    (11:00-11:30pm   )
11:30-12:00am (11:30-12:00am)
11:30-12:00pm   (11:30-12:00pm  )
12:00-12:30pm   (12:00-12:30pm  )
12:30-1:00pm   (12:30-1:00pm  )
2:00-2:30pm   (2:00-2:30pm  )
2:30-3:00pm     (2:30-3:00pm    )
3:30-4:00pm (3:30-4:00pm)
4:00-4:30pm     (4:00-4:30pm    )
4:30-5:00pm  (4:30-5:00pm )
5:00-5:30pm (5:00-5:30pm)
5:30-6:00pm   (5:30-6:00pm  )
6:00-6:30pm     (6:00-6:30pm    )
6:30-7:00pm  (6:30-7:00pm )
7:00-7:30am    (7:00-7:30am   )
7:00-7:30pm   (7:00-7:30pm  )
7:30-8:00am     (7:30-8:00am    )
7:30-8:00pm  (7:30-8:00pm )
8:00-8:30am (8:00-8:30am)
8:00-8:30pm (8:00-8:30pm)
8:30-9:00am (8:30-9:00am)
8:30-9:00pm (8:30-9:00pm)
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9:00-9:30am (9:00-9:30am)
9:00-9:30pm (9:00-9:30pm)
9:30-10:00am (9:30-10:00am)
9:30-10:00pm (9:30-10:00pm)
Adolescent activity [PhenX]
Aerobics - aerobic dancing (Aerobics -
aerobic dancing)
Basketball (Basketball)
Bicycling (Bicycling)
Bowling (Bowling)
Calisthenics - jumping jacks - sit-ups
(Calisthenics - jumping jacks - sit-ups)
Cheerleeding (Cheerleeding)
Church (Church)
Club - student activity (Club - student
activity)
Dancing - ballet, jazz, modern, tap
(Dancing - ballet, jazz, modern, tap)
Dancing - social, recreational   (Dancing
- social, recreational  )
Doing house chores (Doing house
chores)
Eating a meal  (Eating a meal )
Field hockey (Field hockey)
Frisbee (Frisbee)
Getting dressed (Getting dressed)
Getting ready - hair - make-up etc.
(Getting ready - hair - make-up etc.)
Golf (Golf)
Gymnastics - tumbling (Gymnastics -
tumbling)
Hanging around (Hanging around)
Homework (Homework)
Horseback riding (Horseback riding)
Ice - rolling skating (Ice - rolling skating)
Jogging - running (Jogging - running)
Karate - judo, martial arts, self defense
(Karate - judo, martial arts, self defense)
Kick boxing - Tae Bo (Kick boxing - Tae
Bo)
Listening to music (Listening to music)
Lunch - free time - study hall (Lunch -
free time - study hall)
Marching band - flag - drill team
(Marching band - flag - drill team)
Music lesson - playing instrument (Music
lesson - playing instrument)
Other (Other)
Playing video games - surfing internet
(Playing video games - surfing internet  )
Psysical education (P.E.) class (Psysical
education (P.E.) class)
R.O.T.C (R.O.T.C)
Reading (Reading)
Riding in a car - bus (Riding in a car -
bus)
Rollerblading (Rollerblading)
Shopping (Shopping)
Showering - bathing (Showering -
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bathing)
Sitting in class (Sitting in class)
Skateboarding (Skateboarding)
Sleeping (Sleeping)
Snacking     (Snacking    )
Soccer (Soccer)
Softball - baseball (Softball - baseball)
Stationary exercise machines - cycle, ski
machine, stairclimber, treadmill
(Stationary exercise machines - cycle,
ski machine, stairclimber, treadmill    )
Street hockey (Street hockey)
Swimming (Swimming)
Talking on phone (Talking on phone)
Tennis (Tennis)
Track and field (Track and field)
Trampoline (Trampoline)
Travel by bicycling (Travel by bicycling)
Travel by walking (Travel by walking)
Volleyball (Volleyball)
Walking - briskly (Walking - briskly)
Watching TV or movie (Watching TV or
movie)
Weight - circuit training (Weight - circuit
training)
Working (Working)
Yard work (Yard work)
Write in the activity number that corresponds to
the main activity you actually performed during
that particular time period.
Activity intensity [PhenX]
light (1)
moderate (2)
hard (3)
very hard (4)
Name
Social security number
Birth date
Name of participant's school
3 / 3
Total Physical Activity - Comprehensive - Adolescent Protocol PhenX
Toolkit
Epilepsy Screener Protocol PhenX Toolkit
The following protocol is a nine-item interviewer-
administered questionnaire to screen for the presence of
epilepsy.
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Epilepsy Screener Protocol PhenX
Toolkit
PhenX - epilepsy screener protocol
Did anyone ever tell you that you had a seizure or
convulsion caused by a high fever when you were
a child?
Yes (1)
No (2)
Possible (3)
Don't know (4)
Have you ever had, or has anyone ever told you
that you had, a seizure disorder or epilepsy?
Yes (1)
No (2)
Possible (3)
Don't know (4)
A seizure, convulsion, fit or spell under any
circumstances?
Yes (1)
No (2)
Possible (3)
Don't know (4)
Uncontrolled movements of part or all of your
body such as twitching, jerking, shaking or going
limp?
Yes (1)
No (2)
Possible (3)
Don't know (4)
An unexplained change in your mental state or
level of awareness; or an episode of "spacing
out" that you could not control?
Yes (1)
No (2)
Possible (3)
Don't know (4)
Did anyone ever tell you that when you were a
small child, you would daydream or stare into
space more than other children?
Yes (1)
No (2)
Possible (3)
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Don't know (4)
Have you ever noticed any unusual body
movements or feelings when exposed to strobe
lights, video games, flickering lights, or sun glare?
Yes (1)
No (2)
Possible (3)
Don't know (4)
Shortly after waking up, either in the morning or
after a nap, have you ever noticed uncontrollable
jerking or clumsiness, such as dropping things or
things suddenly "flying" from your hands?
Yes (1)
No (2)
Possible (3)
Don't know (4)
Have you ever had any other type of repeated
unusual spells?
Yes (1)
No (2)
Possible (3)
Don't know (4)
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General Distress Screener Protocol PhenX
Toolkit
The K6 is a screening scale consisting of 6 questions to
assess nonspecific psychological distress during the last 30
days. These questions ask about the respondent’s feelings
and how these feelings have affected their normal activities,
and whether or not they have sought professional help.
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General Distress Screener Protocol
PhenX Toolkit
PhenX - general distress screener
protocol
During the past 30 days, about how often did you
feel...nervous?
All of the time (1)
Most of the time (2)
Some of the time (3)
A little of the time (4)
None of the time (5)
During the past 30 days, about how often did you
feel...hopeless ?
All of the time (1)
Most of the time (2)
Some of the time (3)
A little of the time (4)
None of the time (5)
During the past 30 days, about how often did you
feel... restless or fidgety?
All of the time (1)
Most of the time (2)
Some of the time (3)
A little of the time (4)
None of the time (5)
During the past 30 days, about how often did you
feel...so depressed that nothing could cheer you
up?
All of the time (1)
Most of the time (2)
Some of the time (3)
A little of the time (4)
None of the time (5)
Taking them altogether, did these feelings occur
more often in the past 30 days than is usual for
you, about the same as usual, or less often than
usual?
A lot (more often than usual) (1)
Some (more often than usual)  (2)
A little (more often than usual)   (3)
About the same as usual     (4)
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A little (less often than usual)     (5)
Some (less often than usual)     (6)
A lot (less often than usual) (7)
During the past 30 days, how many days out of
30 were you totally unable to work or carry out
your normal activities because of these feelings?
days/30days
Not counting the days you reported in response
to 3, how many days in the past 30 were you able
to do only half or less of what you would normally
have been able to do, because of these feelings?
days/30days
During the past 30 days, about how often did you
feel...that everything was an effort?
All of the time (1)
Most of the time (2)
Some of the time (3)
A little of the time (4)
None of the time (5)
During the past 30 days, how many times did you
see a doctor or other health professional about
these feelings?
/30 days
During the past 30 days, about how often did you
feel...worthless?
All of the time (1)
Most of the time (2)
Some of the time (3)
A little of the time (4)
None of the time (5)
During the past 30 days, how often have physical
health problems been the main cause of these
feelings?
All of the time (1)
Most of the time (2)
Some of the time (3)
A little of the time (4)
None of the time (5)
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Personal and Family History of Psoriasis
Protocol PhenX Toolkit
The Self Evaluation plus Medication Survey is a self-
administered instrument which was developed from the
questionnaires used in the Collaborative Association Study
of Psoriasis (CASP), which is a Genetic Association
Information Network (GAIN) genome-wide association
study (GWAS). The Self Evaluation plus Medication Survey
collects information on individuals with psoriasis and
controls, and their family history of psoriasis and other
autoimmune diseases. Additionally, for individuals with
psoriasis the questionnaire collects information regarding
their symptoms and medication use and its effectiveness.
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Personal and Family History of
Psoriasis Protocol PhenX Toolkit
PhenX - personal and family history of
psoriasis protocol
Age of onset of symptoms
Age at diagnosis?
Is the physician who diagnosed you a
dermatologist:
Yes
No
Name of your current dermatologist
Have you been told by a rheumatologist that you
have psoriatic arthritis?
Yes
No
Have you been diagnosed with Crohn's disease
or another inflammatory bowel disorder?
Yes (1)
No (2)
Explanation (3)
Diagnosis
Date of diagnosis?
Have you been diagnosed with any type of
autoimmune disease (lupus, scleroderma, etc.)?
Yes
No
Do you have any blood relatives affected with
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psoriasis?
Yes
No
Do you have any blood relatives with
inflammatory bowel disease?
Yes
No
Do you have any blood relatives with any type of
autoimmune disease?
Yes (1)
No (2)
Explanation (3)
What color is an average spot of your psoriasis?
0 - no redness  (0)
1 - slight pink  (1)
2 - pink     (2)
3 - red     (3)
4 - dark red (4)
How thick is an average spot of your psoriasis?
0 - no thickness  (1)
1 - feels firm    (2)
2 - raised   (3)
3 - thick (4)
4 - very thick (5)
How scaly is an average spot of your psoriasis?
0 - no scale     (1)
1 - slight scale  (2)
2 - scaly     (3)
3 - flaky   (4)
4 - very flaky (5)
Has a dermatologist told you that you have
pustular psoriasis?
Yes
No
Do you have nail psoriasis?
Yes
No
On the drawings below, mark areas of your body
affected with psoriasis NOW. Face
Service comment
On the drawings below, mark areas of your body
affected with psoriasis WHEN IT WAS THE
WORST IT HAS EVER BEEN. Face
Things to smoke [PhenX]
Cigarettes     (1)
Pipe (2)
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Cigar (3)
How many of the following do you smoke per
day?
Topical Medications (creams, lotions, etc.),
Systemic medications (oral medications),
Biologicals (injected), Phototherapy
Dovonex     (1)
UVB     (10)
Other topicals     (11)
Other systemics (12)
Other biologicals (13)
Methotrexate   (2)
Soriatane     (3)
Cyclosporine     (4)
Humira   (5)
Raptiva (6)
Amevive    (7)
Remicade (8)
PUVA     (9)
Psoriasis treatment duration [PhenX]
Psoriasis treatment effectiveness [PhenX]
0 - not effective   (1)
1 (2)
2 (3)
3 (4)
4 (5)
5 - very effective (6)
Biologicals (injected) Other, please describe
Other systemics [PhenX]
Other topicals [PhenX]
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Physical Functioning - Subjective Protocol
PhenX Toolkit
The interviewer asks the participant (or proxy) a series of
questions about the level of difficulty he/she has performing
everyday activities. These activities may be prohibited by a
long-term (chronic) health problem. A hand card with the
questions and response options is provided to the
participant. Temporary conditions (e.g., broken leg,
pregnancy) that prevent the participant from doing the
activity do not apply.
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Physical Functioning - Subjective
Protocol PhenX Toolkit
PhenX - physical functioning - subjective
protocol
By {yourself/himself/herself} and without using
any special equipment, how much difficulty {do
you/does Sample Person (SP)} have . . managing
{your/his/her} money [such as keeping track of
{your/his/her} expenses or paying bills]?
No difficulty at all     (1)
A little difficulty  (2)
Moderate difficulty   (3)
Extreme difficulty (4)
Stopped doing this because of your
eyesight (5)
Stopped doing this for other reasons or
not interested in doing this (6)
By {yourself/himself/herself} and without using
any special equipment, how much difficulty {do
you/does Sample Person (SP)} have . . Walking
for a quarter of a mile [that is about 2 or 3
blocks]?
No difficulty at all     (1)
A little difficulty  (2)
Moderate difficulty   (3)
Extreme difficulty (4)
Stopped doing this because of your
eyesight (5)
Stopped doing this for other reasons or
not interested in doing this (6)
By {yourself/himself/herself} and without using
any special equipment, how much difficulty {do
you/does Sample Person (SP)} have . . Walking
up 10 steps without resting?
No difficulty at all     (1)
A little difficulty  (2)
Moderate difficulty   (3)
Extreme difficulty (4)
Stopped doing this because of your
eyesight (5)
Stopped doing this for other reasons or
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not interested in doing this (6)
By {yourself/himself/herself} and without using
any special equipment, how much difficulty {do
you/does Sample Person (SP)} have . .stooping,
crouching, or kneeling?
No difficulty at all     (1)
A little difficulty  (2)
Moderate difficulty   (3)
Extreme difficulty (4)
Stopped doing this because of your
eyesight (5)
Stopped doing this for other reasons or
not interested in doing this (6)
By {yourself/himself/herself} and without using
any special equipment, how much difficulty {do
you/does Sample Person (SP)} have . . Lifting or
carrying something as heavy as 10 pounds [like a
sack of potatoes or rice]?
No difficulty at all     (1)
A little difficulty  (2)
Moderate difficulty   (3)
Extreme difficulty (4)
Stopped doing this because of your
eyesight (5)
Stopped doing this for other reasons or
not interested in doing this (6)
By {yourself/himself/herself} and without using
any special equipment, how much difficulty {do
you/does Sample Person (SP)} have . . Doing
chores around the house [like vacuuming,
sweeping, dusting or straightening up]?
No difficulty at all     (1)
A little difficulty  (2)
Moderate difficulty   (3)
Extreme difficulty (4)
Stopped doing this because of your
eyesight (5)
Stopped doing this for other reasons or
not interested in doing this (6)
By {yourself/himself/herself} and without using
any special equipment, how much difficulty {do
you/does Sample Person (SP)} have . .Preparing
{your/his/her} own meals?
No difficulty at all     (1)
A little difficulty  (2)
Moderate difficulty   (3)
Extreme difficulty (4)
Stopped doing this because of your
eyesight (5)
Stopped doing this for other reasons or
not interested in doing this (6)
By {yourself/himself/herself} and without using
any special equipment, how much difficulty {do
you/does Sample Person (SP)} have . .Standing
up from an armless straight chair?
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No difficulty at all     (1)
A little difficulty  (2)
Moderate difficulty   (3)
Extreme difficulty (4)
Stopped doing this because of your
eyesight (5)
Stopped doing this for other reasons or
not interested in doing this (6)
By {yourself/himself/herself} and without using
any special equipment, how much difficulty {do
you/does Sample Person (SP)} have . . Getting in
or out of bed?
No difficulty at all     (1)
A little difficulty  (2)
Moderate difficulty   (3)
Extreme difficulty (4)
Stopped doing this because of your
eyesight (5)
Stopped doing this for other reasons or
not interested in doing this (6)
By {yourself/himself/herself} and without using
any special equipment, how much difficulty {do
you/does Sample Person (SP)} have . Eating, like
holding a fork, cutting food or drinking from a
glass?
No difficulty at all     (1)
A little difficulty  (2)
Moderate difficulty   (3)
Extreme difficulty (4)
Stopped doing this because of your
eyesight (5)
Stopped doing this for other reasons or
not interested in doing this (6)
By {yourself/himself/herself} and without using
any special equipment, how much difficulty {do
you/does Sample Person (SP)} have . Dressing
{yourself/himself/herself}, including tying shoes,
working zippers, and doing buttons?
No difficulty at all     (1)
A little difficulty  (2)
Moderate difficulty   (3)
Extreme difficulty (4)
Stopped doing this because of your
eyesight (5)
Stopped doing this for other reasons or
not interested in doing this (6)
How much difficulty do you have standing or
being on your feet for about 2 hourss [PhenX]
No difficulty   (1)
Some difficulty (2)
Much difficulty (3)
Unable to do     (4)
Do not do this activity     (5)
Refused     (6)
Don't know (7)
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By {yourself/himself/herself} and without using
any special equipment, how much difficulty {do
you/does Sample Person (SP)} have . . Sitting for
about 2 hours?
No difficulty at all     (1)
A little difficulty  (2)
Moderate difficulty   (3)
Extreme difficulty (4)
Stopped doing this because of your
eyesight (5)
Stopped doing this for other reasons or
not interested in doing this (6)
By {yourself/himself/herself} and without using
any special equipment, how much difficulty {do
you/does Sample Person (SP)} have . . Reaching
up over {your/his/her} head?
No difficulty at all     (1)
A little difficulty  (2)
Moderate difficulty   (3)
Extreme difficulty (4)
Stopped doing this because of your
eyesight (5)
Stopped doing this for other reasons or
not interested in doing this (6)
By {yourself/himself/herself} and without using
any special equipment, how much difficulty {do
you/does Sample Person (SP)} have . . Using
{your/his/her} fingers to grasp or handle small
objects?
No difficulty at all     (1)
A little difficulty  (2)
Moderate difficulty   (3)
Extreme difficulty (4)
Stopped doing this because of your
eyesight (5)
Stopped doing this for other reasons or
not interested in doing this (6)
By {yourself/himself/herself} and without using
any special equipment, how much difficulty {do
you/does Sample Person (SP)} have . . . Going
out to things like shopping, movies, or sporting
events?
No difficulty at all     (1)
A little difficulty  (2)
Moderate difficulty   (3)
Extreme difficulty (4)
Stopped doing this because of your
eyesight (5)
Stopped doing this for other reasons or
not interested in doing this (6)
By {yourself/himself/herself} and without using
any special equipment, how much difficulty {do
you/does Sample Person (SP)} have . .
Participating in social activities [visiting friends,
attending clubs or meetings or going to parties]?
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No difficulty at all     (1)
A little difficulty  (2)
Moderate difficulty   (3)
Extreme difficulty (4)
Stopped doing this because of your
eyesight (5)
Stopped doing this for other reasons or
not interested in doing this (6)
By {yourself/himself/herself} and without using
any special equipment, how much difficulty {do
you/does Sample Person (SP)} have . . Doing
things to relax at home or for leisure [reading,
watching TV, sewing, listening to music]?
No difficulty at all     (1)
A little difficulty  (2)
Moderate difficulty   (3)
Extreme difficulty (4)
Stopped doing this because of your
eyesight (5)
Stopped doing this for other reasons or
not interested in doing this (6)
By {yourself/himself/herself} and without using
any special equipment, how much difficulty {do
you/does Sample Person (SP)} have . . Pushing
or pulling large objects like a living room chair?
No difficulty at all     (1)
A little difficulty  (2)
Moderate difficulty   (3)
Extreme difficulty (4)
Stopped doing this because of your
eyesight (5)
Stopped doing this for other reasons or
not interested in doing this (6)
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Eye Patching Protocol PhenX Toolkit
A series of interviewer-administered questions to assess
history of amblyopia and associated treatments including
eye patching.
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Eye Patching Protocol PhenX Toolkit
PhenX - eye patching protocol
Was (name of child) born with any health
problems (either physical or mental)?
Yes (1)
No (2)
Refused (3)
Don't know (4)
Specify the health problem.
During the past 12 months (if child less than 12
months, the child's age in months) has (name of
child) appeared to have any difficulty seeing?
Yes (1)
No (2)
Refused (3)
Don't know (4)
Has (name of child) ever been diagnosed with an
eye problem?
Yes (1)
No (2)
Refused (3)
Don't know (4)
When was (name of child) first diagnosed as
having an eye problem?
Has a doctor ever told you that (name of child)
needs to wear glasses or contact lenses?
Yes (1)
No (2)
Refused (3)
Don't know (4)
Has a doctor ever told you that (name of child)
had amblyopia, that is, poor vision that cannot be
corrected with glasses or contact lenses?
Yes (1)
No (2)
Refused (3)
Don't know (4)
When did (name of child) first begin wearing
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glasses or contact lenses?
When was (name of child) first diagnosed as
having amblyopia?
Does (name of child) have strabismus - that is
one or both eyes are turned in, or turned out, or
up or down, or crossed or wall eyes?
Yes (1)
No (2)
Refused (3)
Don't know (4)
When was (name of child) first diagnosed as
having strabismus?
Did (he/she) ever have an operation to straighten
(his/her) eyes?
Yes (1)
No (2)
Refused (3)
Don't know (4)
When did (name of child) first have this type of
operation?
Did (he/she) ever have to wear an eye patch to
improve his/her vision?
Yes (1)
No (2)
Refused (3)
Don't know (4)
When did (name of child) first start wearing an
eye patch?
In general, is your child's overall health:
Excellent (1)
Very good (2)
Good (3)
Fair (4)
Poor (5)
Refused (6)
Don't know (7)
At the present time, is your child's eyesight using
both eyes:
Excellent (1)
Very good (2)
Good (3)
Fair (4)
Poor (5)
Refused (6)
Don't know (7)
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Serum Creatinine Assay Protocol PhenX
Toolkit
This protocol provides instructions for drawing, processing,
and storing blood for the serum creatinine assay according
to the National Health and Nutrition Examination Survey
(NHANES) methods. Creatinine concentration in a
participant’s serum is measured according to the Jaffe rate
method.
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Serum Creatinine Assay Protocol
PhenX Toolkit
PhenX - serum creatinine assay for kidney
function protocol
Do you have hemophilia?
Yes (1)
No (2)
Refused (3)
Don't know (4)
Have you received cancer chemotherapy in the
past four weeks or do you anticipate such therapy
in the next four weeks?
Yes (1)
No (2)
Refused (3)
Don't know (4)
Exclusion Criteria
Hemophilia     (1)
Received cancer chemotherapy in the
last 3 weeks (2)
None – proceed with blood draw (3)
Was blood drawn?
Yes
No
Was full sample obtained?
Yes
No
Service comment: Record any comments about
the blood draw, including any reasons for the tube
not being drawn according to the protocol.
Service comment: Record any comments about
the sample during processing.
Repeatability of the assay
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Coefficient of variation for the assay
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Conditions Relevant to Immune Response -
Screener, Adult PhenX Toolkit
This screening protocol includes 10 self-administered
questions from the Centers for Disease Control and
Prevention (CDC) Screening Questionnaire for Adult
Immunization. Respondents are asked to respond to yes-
or-no questions.
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Conditions Relevant to Immune
Response - Screener, Adult PhenX
Toolkit
PhenX - conditions relevant to immune
response - screener - adult protocol
Are you sick today?
No (1)
Yes (2)
Don't know (3)
Do you have allergies to medications, food, or
any vaccine?
No (1)
Yes (2)
Don't know (3)
Have you ever had a serious reaction after
receiving a vaccination?
No (1)
Yes (2)
Don't know (3)
Do you have a long-term health problem with
heart disease, lung disease, asthma, kidney
disease, metabolic disease (e.g., diabetes),
anemia, or other blood disorder?
No (1)
Yes (2)
Don't know (3)
Do you have cancer, leukemia, AIDS, or any
other immune system problem?
No (1)
Yes (2)
Don't know (3)
Do you take cortisone, prednisone, other
steroids, or anticancer drugs, or have you had
radiation treatments?
No (1)
Yes (2)
Don't know (3)
Have you had a seizure, brain, or other nervous
system problem?
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No (1)
Yes (2)
Don't know (3)
During the past year, have you received a
transfusion of blood or blood products, or have
you been given immune (gamma) globulin or an
antiviral drug?
No (1)
Yes (2)
Don't know (3)
For women: Are you pregnant, or is there a
chance you could become pregnant during the
next month?
No (1)
Yes (2)
Don't know (3)
Have you received any vaccinations in the past 4
weeks?
No (1)
Yes (2)
Don't know (3)
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Arterial Blood Gas (ABG) Protocol PhenX
Toolkit
This protocol describes the procedures for blood collection
for arterial blood gas (ABG) analysis. It involves puncturing
an artery with a thin needle and syringe and drawing a
small volume of blood. The most common puncture site is
the radial artery at the wrist, but sometimes the femoral
artery in the groin or other sites are used.
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Arterial Blood Gas (ABG) Protocol
PhenX Toolkit
PhenX - respiratory - arterial blood gas -
ABG protocol
Time at blood draw
Body temperature
Celsius
Body position with respect to gravity
Sitting (1)
Lying (2)
Standing (3)
Patient's Activity Level
Respiratory rate
/min
Specimen drawn from
Arterial patency Wrist artery --pre arterial
puncture
negative (negative)
positive (positive)
Inhaled oxygen concentration
Room air (1)
24% mask (2)
28% mask (3)
31% mask (4)
35% mask (5)
40% mask (6)
50% mask (7)
Oxygen gas flow Oxygen delivery system
L/min
Mode of Supported Ventilation
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Carbon dioxide [Partial pressure] in Arterial blood
mmHg
Oxygen [Partial pressure] in Arterial blood
mmHg
pH of Arterial blood
Hemoglobin [Mass/volume] in Blood
g/dL
Fractional oxyhemoglobin in Blood
%
Carboxyhemoglobin/Hemoglobin.total in Blood
%
Methemoglobin/Hemoglobin.total in Blood
%
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Arthritis/Osteoarthritis Protocol PhenX
Toolkit
This protocol is divided into two parts. The first part
contains detailed instructions for obtaining knee, hand, and
pelvic radiographs using the Radiographic Procedure
Manual for Examinations of the Knee, Hand, Pelvis and
Lower Limbs from the Osteoarthritis Initiative: A Knee
Health Study. The second part of the protocol is the
Kellgren-Lawrence Grading Scale©. This scale is a tool
used by radiologists to determine the extent of osteo-
arthritic findings seen via radiographs. Radiologists look at
the amount of spacing between joints, bone formation, and
bone contour when determining the Kellgren-Lawrence
Grade©.
ODM derived from: https://cde.nlm.nih.gov
Primary source: https://www.phenxtoolkit.org/
Recent publication: Hendershot, T., Pan, H., Haines, J.,
Harlan, W.R., Marazita, M.L., McCarty, C.A., Ramos, E.M.,
and Hamilton, C.M. (2015) Using the PhenX toolkit to add
standard measures to a study. Curr. Protoc. Hum. Genet.
86:1.21.1-1.21.17. doi: 10.1002/0471142905.hg0121s86
Permission to publish granted by
Carol M. Hamilton.
All rights reserved. Please visit https://medical-data-
models.org/forms/14712
Arthritis/Osteoarthritis Protocol
PhenX Toolkit
PhenX - arthritis - osteoarthritis protocol
Hand scan image name (ID)
Left or right hand scanned
Left (1)
Right (2)
Kellgren-Lawrence score for hand
Grade 1: doubtful narrowing of joint
space and possible osteophytic lipping
(1)
Grade 2: definite osteophytes, definite
narrowing of joint space (2)
Grade 3: moderate multiple osteophytes,
definite narrowing of joints space, some
sclerosis and possible deformity of bone
contour (3)
Grade 4: large osteophytes, marked
narrowing of joint space, severe sclerosis
and definite deformity of bone contour
(4)
Knee scan image name (ID)
Left or right knee scanned
Left (1)
Right (2)
Kellgren-Lawrence score for knee
Grade 1: doubtful narrowing of joint
space and possible osteophytic lipping
(1)
Grade 2: definite osteophytes, definite
narrowing of joint space (2)
Grade 3: moderate multiple osteophytes,
definite narrowing of joints space, some
sclerosis and possible deformity of bone
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contour (3)
Grade 4: large osteophytes, marked
narrowing of joint space, severe sclerosis
and definite deformity of bone contour
(4)
Hip scan image name (ID)
Left or right hip scanned
Left (1)
Right (2)
Kellgren-Lawrence score for hip
Grade 1: doubtful narrowing of joint
space and possible osteophytic lipping
(1)
Grade 2: definite osteophytes, definite
narrowing of joint space (2)
Grade 3: moderate multiple osteophytes,
definite narrowing of joints space, some
sclerosis and possible deformity of bone
contour (3)
Grade 4: large osteophytes, marked
narrowing of joint space, severe sclerosis
and definite deformity of bone contour
(4)
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Use of Glasses and/or Contact Lenses as a
Child PhenX Toolkit
The respondent is asked a series of 5 questions to assess
their child’s current and past use of glasses and contact
lenses, duration of use, and reason for use.
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Use of Glasses and/or Contact
Lenses as a Child PhenX Toolkit
PhenX - use of glasses - contact lenses
as child protocol
Does your child currently wear glasses or contact
lenses to correct, or partially correct, his/her
eyesight?
No  (1)
Glasses (2)
Contact lenses (3)
How often are the glasses or contact lenses
worn?
All the time (1)
Most of the time (2)
Sometimes (3)
Hardly ever (4)
Only when eyes feel tired (5)
Were the glasses/contact lenses prescribed for
Astigmatism?
No (1)
Yes (2)
Don't know (3)
Were the glasses/contact lenses prescribed for
Short-sightedness/myopia?
No (1)
Yes (2)
Don't know (3)
Were the glasses/contact lenses prescribed for
Long-sightedness/hyperopia?
No (1)
Yes (2)
Don't know (3)
Were the glasses/contact lenses prescribed for
Other?
No (1)
Yes (2)
Don't know (3)
Specify other glasses/contact lenses prescribed.
Has your child worn glasses or contact lenses in
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the past, but no longer needs to wear them?
No (1)
Yes (2)
Uncertain (3)
Please state the date when first prescribed.
Please state the age when first prescribed.
Date stopped?
Reason stopped?
How often did you child wear their
glasses/contact lenses?
All the time (1)
Most of the time (2)
Sometimes (3)
Hardly ever (4)
Only when eyes feel tired (5)
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Use of Glasses and/or Contact Lenses as a Child PhenX Toolkit
Characteristics of Current Residence
Protocol PhenX Toolkit
Questions asked about the type of home, age, time lived in
the residence, garage, pets in the home, and water
damage. The respondent should be an adult who normally
resides in the residence.
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Characteristics of Current Residence
Protocol PhenX Toolkit
PhenX - environmental exposures -
characteristics of current residence
protocol
What is the type of dwelling?
Detached house   (1)
Duplex/triplex   (2)
Row house     (3)
Low rise apartment (1-3 floors)    (4)
High rise apartment (>3 floors)     (5)
Mobile home / trailer  (6)
Other (specify) (7)
What is the type of dwelling?
Other:
Is this property actively used as a farm or ranch?
Yes
No
What is the approximate age of your building?
Age of building __
What is the approximate age of your building?
Year built?
When did you start living there? MO and YR
When did you start living there? MO and YR
When did you start living there? AGE ____
When did you move from there? MO and YR
When did you move from there? MO and YR
When did you move from there? AGE
How many years (have/did) you live(d) there?
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Is there an enclosed garage attached to this
(house/apartment)?
Yes
No
Are automobiles, vans, trucks or other motor
vehicles parked in this attached garage?
Yes
No
Are any gas powered devices stored in any room,
basement, or attached garage in this
(house/apartment)?
No (0)
Yes (1)
Don't know (9)
During the past 12 months, has there been water
or dampness in your home from broken pipes,
leaks, heavy rain, or floods?
No (0)
Yes (1)
Don't know (9)
Does your home frequently have a mildew odor
or musty smell?
No (0)
Yes (1)
Don't know (9)
Is air conditioning (refrigeration) used to cool this
(house/apartment)?
Yes
No
Which types of air conditioning units do you use?
Central unit/units (1)
Window or wall unit/units    (2)
Portable unit/units (3)
During which month (do you usually/would you)
start using air conditioning to cool this
(house/apartment)?
January (1)
October (10)
November (11)
December (12)
February (2)
March (3)
April (4)
May (5)
June (6)
July (7)
August (8)
September (9)
During which month (do you usually/would you)
stop using air conditioning?
January (1)
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October (10)
November (11)
December (12)
February (2)
March (3)
April (4)
May (5)
June (6)
July (7)
August (8)
September (9)
Which fuels are used for heating this
(house/apartment)?
Gas: from underground pipes serving the
neighborhood     (1)
Don't know (10)
Gas: bottled, tank, or LP     (2)
Electricity    (3)
Fuel oil, kerosene, etc   (4)
Coal or coke     (5)
Wood     (6)
Solar energy    (7)
Other fuel     (8)
No fuel used     (9)
Does this (house/apartment) have a central
heating system with ducts that blow air into most
rooms?
Yes
No
During which month (do you usually/would you)
start using heating devices?
January (1)
October (10)
November (11)
December (12)
February (2)
March (3)
April (4)
May (5)
June (6)
July (7)
August (8)
September (9)
During which month (do you usually/would you)
stop using heating devices?
January (1)
October (10)
November (11)
December (12)
February (2)
March (3)
April (4)
May (5)
June (6)
July (7)
August (8)
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September (9)
In the last 12 months, did any dogs, cats or other
small furry animals, such as a rabbit, guinea pig
or hamster, live or spend time inside your home?
Yes (1)
No (2)
Refused (3)
Don't know (4)
What kind of pet was it?
Dog (1)
Cat (2)
Small furry animal  (3)
Refused (4)
Don't know (5)
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Symptoms of Autism Spectrum Disorders -
Adult PhenX Toolkit
The Autism Quotient for Adults is a 50 question self report
instrument designed to screen age 16 and older for
symptoms of autism. A scoring key is also included. This
instrument comes from the UK where age 16 is more
readily considered an adult.
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Symptoms of Autism Spectrum
Disorders - Adult PhenX Toolkit
PhenX - symptoms of autism spectrum
disorders - adult protocol
I prefer to do things with others rather than on my
own.
Definitely agree     (1)
Slightly agree   (2)
Slightly disagree (3)
Definitely disagree (4)
I prefer to do things the same way over and over
again.
Definitely agree     (1)
Slightly agree   (2)
Slightly disagree (3)
Definitely disagree (4)
If I try to imagine something I find it very easy to
create a picture in my mind.
Definitely agree     (1)
Slightly agree   (2)
Slightly disagree (3)
Definitely disagree (4)
I frequently get so strongly absorbed in one thing
that I lose sight of other things.
Definitely agree     (1)
Slightly agree   (2)
Slightly disagree (3)
Definitely disagree (4)
I often notice small sounds when others do not.
Definitely agree     (1)
Slightly agree   (2)
Slightly disagree (3)
Definitely disagree (4)
I usually notice car number plates or similar
strings of information.
Definitely agree     (1)
Slightly agree   (2)
Slightly disagree (3)
Definitely disagree (4)
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Other people frequently tell me that what I've said
is impolite even though I think it is polite.
Definitely agree     (1)
Slightly agree   (2)
Slightly disagree (3)
Definitely disagree (4)
When I'm reading a story I can easily imagine
what the characters might look like.
Definitely agree     (1)
Slightly agree   (2)
Slightly disagree (3)
Definitely disagree (4)
I am fascinated by dates.
Definitely agree     (1)
Slightly agree   (2)
Slightly disagree (3)
Definitely disagree (4)
In a social group can easily keep track of several
different people's conversations.
Definitely agree     (1)
Slightly agree   (2)
Slightly disagree (3)
Definitely disagree (4)
I find social situations easy.
Definitely agree     (1)
Slightly agree   (2)
Slightly disagree (3)
Definitely disagree (4)
I tend to notice details that others do not.
Definitely agree     (1)
Slightly agree   (2)
Slightly disagree (3)
Definitely disagree (4)
I would rather go to a library than a party.
Definitely agree     (1)
Slightly agree   (2)
Slightly disagree (3)
Definitely disagree (4)
I find making up stories easy.
Definitely agree     (1)
Slightly agree   (2)
Slightly disagree (3)
Definitely disagree (4)
I find myself drawn more strongly to people than
to things.
Definitely agree     (1)
Slightly agree   (2)
Slightly disagree (3)
Definitely disagree (4)
I tend to have very strong interests which I get
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upset about if I can't pursue.
Definitely agree     (1)
Slightly agree   (2)
Slightly disagree (3)
Definitely disagree (4)
I enjoy social chit-chat.
Definitely agree     (1)
Slightly agree   (2)
Slightly disagree (3)
Definitely disagree (4)
When I talk, it isn't always easy for others to get a
word in edgeways.
Definitely agree     (1)
Slightly agree   (2)
Slightly disagree (3)
Definitely disagree (4)
I am fascinated by numbers.
Definitely agree     (1)
Slightly agree   (2)
Slightly disagree (3)
Definitely disagree (4)
When I'm reading a story I find it difficult to work
out the characters intentions.
Definitely agree     (1)
Slightly agree   (2)
Slightly disagree (3)
Definitely disagree (4)
I don't particularly enjoy reading fiction.
Definitely agree     (1)
Slightly agree   (2)
Slightly disagree (3)
Definitely disagree (4)
I find it hard to make new friends.
Definitely agree     (1)
Slightly agree   (2)
Slightly disagree (3)
Definitely disagree (4)
I notice patterns in things all the time.
Definitely agree     (1)
Slightly agree   (2)
Slightly disagree (3)
Definitely disagree (4)
I would rather go to the theatre than a museum.
Definitely agree     (1)
Slightly agree   (2)
Slightly disagree (3)
Definitely disagree (4)
It does not upset me if my daily routine is
disturbed.
Definitely agree     (1)
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Slightly agree   (2)
Slightly disagree (3)
Definitely disagree (4)
I frequently find that I don't know how to keep a
conversation going.
Definitely agree     (1)
Slightly agree   (2)
Slightly disagree (3)
Definitely disagree (4)
I find it easy to read between the lines when
someone is talking to me.
Definitely agree     (1)
Slightly agree   (2)
Slightly disagree (3)
Definitely disagree (4)
I usually concentrate more on the whole picture
rather than the small details.
Definitely agree     (1)
Slightly agree   (2)
Slightly disagree (3)
Definitely disagree (4)
I am not very good at remembering phone
numbers.
Definitely agree     (1)
Slightly agree   (2)
Slightly disagree (3)
Definitely disagree (4)
I don't usually notice small changes in a situation
or a person's appearance.
Definitely agree     (1)
Slightly agree   (2)
Slightly disagree (3)
Definitely disagree (4)
I know how to tell if someone listening to me is
getting bored.
Definitely agree     (1)
Slightly agree   (2)
Slightly disagree (3)
Definitely disagree (4)
I find it easy to do more than one thing at once.
Definitely agree     (1)
Slightly agree   (2)
Slightly disagree (3)
Definitely disagree (4)
When I talk on the phone I'm not sure when its
my turn to speak.
Definitely agree     (1)
Slightly agree   (2)
Slightly disagree (3)
Definitely disagree (4)
I enjoy doing things spontaneously.
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Definitely agree     (1)
Slightly agree   (2)
Slightly disagree (3)
Definitely disagree (4)
I am often the last to understand the point of a
joke.
Definitely agree     (1)
Slightly agree   (2)
Slightly disagree (3)
Definitely disagree (4)
I find it easy to work out what someone is
thinking or feeling just by looking at their face.
Definitely agree     (1)
Slightly agree   (2)
Slightly disagree (3)
Definitely disagree (4)
If there is an interruption I can switch back to
what I was doing very quickly.
Definitely agree     (1)
Slightly agree   (2)
Slightly disagree (3)
Definitely disagree (4)
I am good at social chit-chat.
Definitely agree     (1)
Slightly agree   (2)
Slightly disagree (3)
Definitely disagree (4)
People often tell me that I keep going on and on
about the same thing.
Definitely agree     (1)
Slightly agree   (2)
Slightly disagree (3)
Definitely disagree (4)
When I was young I used to enjoy playing games
involving pretending with other children.
Definitely agree     (1)
Slightly agree   (2)
Slightly disagree (3)
Definitely disagree (4)
I like to collect information about categories of
things - types of car, types of bird, types of train,
types of plant, etc.
Definitely agree     (1)
Slightly agree   (2)
Slightly disagree (3)
Definitely disagree (4)
I find it difficult to imagine what it would be like to
be someone else.
Definitely agree     (1)
Slightly agree   (2)
Slightly disagree (3)
Definitely disagree (4)
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I like to plan any activities I participate in
carefully.
Definitely agree     (1)
Slightly agree   (2)
Slightly disagree (3)
Definitely disagree (4)
I enjoy social occasions.
Definitely agree     (1)
Slightly agree   (2)
Slightly disagree (3)
Definitely disagree (4)
I find it difficult to work out peoples intentions.
Definitely agree     (1)
Slightly agree   (2)
Slightly disagree (3)
Definitely disagree (4)
New situations make me anxious.
Definitely agree     (1)
Slightly agree   (2)
Slightly disagree (3)
Definitely disagree (4)
I enjoy meeting new people.
Definitely agree     (1)
Slightly agree   (2)
Slightly disagree (3)
Definitely disagree (4)
I am a good diplomat.
Definitely agree     (1)
Slightly agree   (2)
Slightly disagree (3)
Definitely disagree (4)
I am not very good at remembering peoples date
of birth.
Definitely agree     (1)
Slightly agree   (2)
Slightly disagree (3)
Definitely disagree (4)
I find it very easy to play games with children that
involve pretending.
Definitely agree     (1)
Slightly agree   (2)
Slightly disagree (3)
Definitely disagree (4)
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Air Contaminants in the Home Environment
Protocol PhenX Toolkit
The respondent is asked several questions about interior
home/apartment improvements-such as professional
cleaning, major renovations, new carpeting, and painting in
the last year. The date that the renovation occurred is also
asked. Short-term exposure questions are also included
such as personal activities in and around the home in the
last 48 hours.
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Air Contaminants in the Home
Environment Protocol PhenX Toolkit
PhenX - environmental exposures - air
contaminants in the home environment
protocol
In the past year has there been a major
renovation to this house or apartment, such as
adding a room, putting up or taking down a wall,
replacing wiindows, or refinishing floors?
No (0)
Yes (1)
Don't know (9)
What type of renovation?
When was the last renovation?
Within the last six months were rugs, drapes or
furniture professionally cleaned?
No (0)
Yes (1)
Don't know (9)
Were they cleaned inside the house?
In the house   (1)
Somewhere else (2)
When were they cleaned?
What items were cleaned?
In the past year, was the inside of this house or
apartment painted?
No (0)
Yes (1)
Don't know (9)
When was the last time?
On how many rooms?
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In the past year were new carpets or rugs
installed?
No (0)
Yes (1)
Don't know (9)
When was the installation?
On how many rooms?
Did you go to the dry cleaners during the past
week?
Yes
No
Did you bring home any items from the cleaners
that were dry-cleaned during the past week?
Yes
No
Specify air contaminant in the home [PhenX]
Paints or solvents, paint thinners and
removers, typewriter corrective fluids  (1)
Cleaning solutions, including household
cleaners and chemicals    (10)
Gardening    (11)
Woodworking (12)
Metal working or welding     (13)
Broiling, smoking, grilling or frying inside
the house    (14)
Broiling, smoking, grilling or frying
outside the house (15)
Glues and adhesives   (2)
Gasoline lawn mower    (3)
Chain saw or other gasoline equipment
(4)
Sander and/or saw     (5)
Pesticides sprayed     (6)
Vacuuming     (7)
Sweeping indoors     (8)
Dusting     (9)
Which cleaning solutions [PhenX]
Have you used Paints or solvents (paint thinners
and removers, typewriter corrective fluids) or has
someone used near you in the last 48 hours?
Yes
No
Did you handle Paints or solvents (paint thinners
and removers, typewriter corrective fluids)
yourself? If Yes, for how long?
Yes
No
How long did you handle Paints or solvents (paint
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thinners and removers, typewriter corrective
fluids) yourself?
months
Were you near somebody else who handled
Paints or solvents (paint thinners and removers,
typewriter corrective fluids)? If Yes, for how long?
Yes
No
How long were you near somebody else who
handled Paints or solvents (paint thinners and
removers, typewriter corrective fluids)?
During the last 48 hours , the study period, did
you or anyone else park a car or other motor
vehicle in...
A garage attached to your home (1)
A detached garage (2)
A carport attached to your home (3)
During the last 48 hours , the study period, did
you or anyone else start a car or other motor
vehicle in...
A garage attached to your home (1)
A detached garage (2)
A carport attached to your home (3)
During the last 48 hours , the study period, was
there any diesel vehicles parked around the
house?
No (0)
Yes (1)
Don't know (9)
During the last 48 hours , the study period, have
you operated or been near diesel engines, (e.g.
bus terminal, truck stop)?
No (0)
Yes (1)
Don't know (9)
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Personal and Family History of Respiratory
Symptoms/Diseases - Adult Protocol PhenX Toolkit
This protocol obtains information about the personal history
of respiratory symptoms and illnesses. Duration of disease,
other allergic diseases, occupational history, smoking
status, and family history of selected respiratory diseases
are also assessed. Supplemental questions were added
from other studies in areas judged to be inadequately
covered by this questionnaire.
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Personal and Family History of
Respiratory Symptoms/Diseases -
Adult Protocol PhenX Toolkit
PhenX - respiratory - personal - family hx
of respiratory symptoms - diseases - adult
protocol
Do you usually have a cough?
Yes
No
Do you usually cough as much as 4 to 6 times a
day, 4 or more days out of the week?
Yes
No
Do you usually cough at all on getting up, or first
thing in the morning?
Yes
No
Do you usually cough at all during the rest of the
day or at night?
Yes
No
Do you usually cough like this on most days for 3
consecutive months or more during the year?
Yes (1)
No (2)
Does not apply (3)
For how many years have you had this cough?
Do you usually bring up phlegm from your chest?
Yes
No
Do you usually bring up phlegm like this as much
as twice a day, 4 or more days out of the week?
Yes
No
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Do you usually bring up phlegm at all on getting
up or first thing in the morning?
Yes
No
Do you usually bring up phlegm at all during the
rest of the day or at night?
Yes
No
Do you bring up phlegm like this on most days for
3 consecutive months or more during the year?
Yes (1)
No (2)
Does not apply (3)
For how many years have you had trouble with
phlegm?
Have you had periods or episodes of (increased*)
cough and phlegm lasting for 3 weeks or more
each year?
Yes
No
For how long have you had at least 1 such
episode per year?
Does your chest ever sound wheezy or whistling
when you have a cold?
Yes
No
Does your chest ever sound wheezy or whistling
occasionally apart from colds?
Yes
No
Does your chest ever sound wheezy or whistling
most days or nights?
Yes
No
For how many years has this been present?
Have you ever had an attack of wheezing that
has made you feel short of breath?
Yes
No
How old were you when you had your first such
attack?
Have you had 2 or more such episodes?
Yes (1)
No (2)
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Does not apply (3)
Have you ever required medicine or treatment for
the(se) attack(s)?
Yes (1)
No (2)
Does not apply (3)
If disabled from walking by any condition other
than heart or lung disease, please describe
nature of condition(s).
Are you troubled by shortness of breath when
hurrying on the level or walking up a slight hill?
Yes
No
Do you have to walk slower than people of your
age on the level because of breathlessness?
Yes (1)
No (2)
Does not apply (3)
Do you ever have to stop for breath when walking
at your own pace on the level?
Yes (1)
No (2)
Does not apply (3)
Do you ever have to stop for breath after walking
about 100 yards (or after a few minutes) on the
level?
Yes (1)
No (2)
Does not apply (3)
Are you too breathless to leave the house or
breathless on dressing or undressing?
Yes (1)
No (2)
Does not apply (3)
If you get a cold, does it usually go to your chest?
Yes (1)
No (2)
Does not apply (3)
During the past 3 years, have you had any chest
illnesses that have kept you off work, indoors at
home, or in bed?
Yes
No
Did you produce phlegm with any of these chest
illnesses?
Yes (1)
No (2)
Does not apply (3)
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In the last 3 years, how many such illnesses, with
(increased) phlegm, did you have which lasted a
week or more?
Did you have any lung trouble before the age of
16?
Yes
No
Have you ever had attacks of bronchitis?
Yes
No
Was it confirmed by a doctor?
Yes (1)
No (2)
Does not apply (3)
At what age was your first attack?
Have you ever had pneumonia (include
bronchopneumonia)?
Yes
No
Was it confirmed by a doctor?
Yes (1)
No (2)
Does not apply (3)
At what age did you first have it?
Have you ever had Hay fever?
Yes
No
Was it confirmed by a doctor?
Yes (1)
No (2)
Does not apply (3)
At what age did it start?
Have you ever had chronic bronchitis?
Yes
No
Do you still have it?
Yes (1)
No (2)
Does not apply (3)
Was it confirmed by a doctor?
Yes (1)
No (2)
Does not apply (3)
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At what age did it start?
Have you ever had emphysema?
Yes
No
Do you still have it?
Yes (1)
No (2)
Does not apply (3)
Was it confirmed by a doctor?
Yes (1)
No (2)
Does not apply (3)
At what age did it start?
Have you ever had asthma?
Yes
No
Do you still have it?
Yes (1)
No (2)
Does not apply (3)
Was it confirmed by a doctor?
Yes (1)
No (2)
Does not apply (3)
At what age did it start?
If you no longer have it, at what age did it stop?
Have you ever had any other chest illnesses?
Yes
No
Please specify chest illnesses you had.
Have you ever had any chest operations?
Yes
No
Please specify chest operations you had.
Have you ever had any chest injuries?
Yes
No
Please specify chest injuries you had.
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Has doctor ever told you that you had heart
trouble?
Yes
No
Have you ever had treatment for heart trouble in
the past 10 years?
Yes (1)
No (2)
Does not apply (3)
Has a doctor or nurse ever said that you have
high blood pressure or hypertension?
Yes
No
Have you had any treatment for high blood
pressure (hypertension) in the past 10 years?
Yes (1)
No (2)
Does not apply (3)
Have you ever worked full time (30 hours per
week or more) for 6 months or more?
Yes
No
Have you ever worked for a year or more in any
dusty job?
Yes (1)
No (2)
Does not apply (3)
Dusty job. Specify job/industry.
Dusty job. Total years worked?
Dusty job. Was dust exposure
Mild (1)
Moderate (2)
Severe (3)
Have you ever been exposed to gas or chemical
fumes in your work?
Yes (1)
No (2)
Does not apply (3)
Gas or chemical fumes Specify job/industry.
Gas or chemical fumes total years worked?
Gas or chemical fumes. Was gas or chemical
fumes exposure
Mild (1)
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Moderate (2)
Severe (3)
What kind of business or industry {did you/did
SP} work in for the longest period of time as a
(DISPLAY LONGEST OCCUPATION)?
About how long did {you/SP} work at that job or
business?
What was the job title of the (first/next) job
(you/your___) held at this company?
What kind of business or industry is this?
Have you ever smoked cigarettes?
Yes
No
Do you now smoke cigarettes (as of 1 month
ago)?
Yes (1)
No (2)
Does not apply (3)
How many cigarettes do you smoke per day
now?
On the average of the entire time you smoked,
how many cigarettes did you smoke per day?
Do or did you inhale the cigarette smoke?
Does not apply  (1)
Not at all (2)
Slightly   (3)
Moderately  (4)
Deeply (5)
Have you ever smoked a pipe regularly?
Yes
No
How old were you when you started to smoke a
pipe regularly?
If you have stopped smoking a pipe completely,
how old were you when you stopped?
On the average over the entire time you smoked
a pipe, how much pipe tobacco did you smoke
per week?
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How much pipe tobacco are you smoking now?
Do or did you inhale the pipe smoke?
Does not apply  (1)
Not at all (2)
Slightly   (3)
Moderately  (4)
Deeply (5)
Have you ever smoked cigars regularly?
Yes
No
How old were you when you started smoking
cigars regularly?
If you have stopped smoking cigars completely,
how old were you when you stopped?
On the average over the entire time you smoked
cigars, how many cigars did you smoke per
week?
Do or did you inhale the cigar smoke?
Does not apply  (1)
Not at all (2)
Slightly   (3)
Moderately  (4)
Deeply (5)
How many cigars are you smoking per week
now?
Natural parent [PhenX]
Father (1)
Mother (2)
Were either of your natural parents ever told by a
doctor that they had a chronic lung condition such
as: Chronic bronchitis?
No (0)
Yes (1)
Don't know (2)
Were either of your natural parents ever told by a
doctor that they had a chronic lung condition such
as: Emphysema?
No (0)
Yes (1)
Don't know (2)
Were either of your natural parents ever told by a
doctor that they had a chronic lung condition such
as: Asthma?
No (0)
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Yes (1)
Don't know (2)
Were either of your natural parents ever told by a
doctor that they had a chronic lung condition such
as: Lung cancer?
No (0)
Yes (1)
Don't know (2)
Were either of your natural parents ever told by a
doctor that they had a chronic lung condition such
as: Other chest conditions?
No (0)
Yes (1)
Don't know (2)
Have you ever had wheezing or whistling in your
chest?
Yes
No
About how old were you when you first had
wheezing or whistling in your chest?
In the last 12 months, have you had wheezing or
whistling in your chest at any time?
Yes
No
In the last 12 months, does your chest ever
sound wheezy or whistling: When you have a
cold?
Yes
No
In the last 12 months, does your chest ever
sound wheezy or whistling: More than once a
week?
Yes
No
In the last 12 months, does your chest ever
sound wheezy or whistling: Most days and
nights?
Yes
No
In the last 12 months, have you been awakened
from sleep by coughing, apart from a cough
associated with a cold or chest infection?
Yes
No
In the last 12 months, have you been awakened
from sleep by shortness of breath or a feeling of
tightness in your chest?
Yes
No
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In the past 12 months, have you been bothered
by sneezing or a runny or blocked nose when you
did not have a cold or the flu?
Yes
No
In the past 12 months, have you been bothered
by watery, itchy, or burning eyes when you did not
have a cold or the flu?
Yes
No
In the past 12 months, have you had periods or
episodes of cough with phlegm that lasted 1
week or more?
Yes
No
For how many years have you had at least one
such episode per year?
About how many such episodes have you had in
the past 12 months?
In the past year, have you been to the emergency
room or hospitalized for lung problems?
Yes
No
How many times?
In the past year, have you been treated with
antibiotics for a chest illness?
Yes
No
How many times?
In the past year, have you been treated with
steroid pills or injections, such as prednisone or
solumedrol, for a chest illness?
Yes
No
How many times?
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Personal and Family History of Respiratory
Symptoms/Diseases - Child Protocol PhenX Toolkit
Age-specific questions are asked in this protocol to two
different age ranges of children. For children ages 13 and
14, a set of questions is asked directly to the child. For
children 6 or 7 years old, a set of questions is asked of the
parents.
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PhenX - respiratory - personal - family hx
of respiratory symptoms - diseases - child
protocol
Have you ever had wheezing or whistling in the
chest at any time in the past?
Yes
No
Have you had wheezing or whistling in the chest
in the last 12 months?
Yes
No
How many attacks of wheezing have you had in
the last 12 months?
None (1)
1 to 3 (2)
4 to 12   (3)
More than 12 (4)
In the last 12 months, how often, on average, has
your sleep been disturbed due to wheezing?
In the last 12 months, has wheezing ever been
severe enough to limit your speech to only one or
two words at a time between breaths?
Yes
No
Have you ever had asthma?
Yes
No
In the last 12 months, has your chest sounded
wheezy during or after exercise?
Yes
No
In the last 12 months, have you had a dry cough
at night, apart from a cough associated with a
cold or chest infection?
Yes
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No
Have you ever had a problem with sneezing, or a
runny or blocked nose, when you DID NOT have
a cold or the flu?
Yes
No
In the past 12 months, have you had a problem
with sneezing, or a runny or blocked nose, when
you DID NOT have a cold or the flu?
Yes
No
In the past 12 months, has this nose problem
been accompanied by itchy or watery eyes?
Yes
No
In which of the past 12 months did this nose
problem occur?
January (1)
October (10)
November (11)
December (12)
February (2)
March (3)
April (4)
May (5)
June (6)
July (7)
August (8)
September (9)
In the past 12 months, how much did this nose
problem interfere with your daily activities?
Not at all     (1)
A little  (2)
A moderate amount  (3)
A lot (4)
Have you ever had hay fever?
Yes
No
Have you ever had an itchy rash which was
coming and going for at least six months?
Yes
No
Have you had this itchy rash at any time in the
last 12 months?
Yes
No
Has this itchy rash at any time affected any of the
following places: the folds of the elbows, behind
the knees, in front of the ankles, under the
buttocks, or around the neck, ears, or eyes?
Yes
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No
Has this rash cleared completely at any time
during the last 12 months?
Yes
No
In the last 12 months, how often, on average,
have you been kept awake at night by this itchy
rash?
Never in the last 12 months    (1)
Less than one night per week (2)
One or more nights per week (3)
Have you ever had eczema?
Yes
No
Has your child ever had wheezing or whistling in
the chest at any time in the past?
Yes
No
Has your child had wheezing or whistling in the
chest in the last 12 months?
Yes
No
How many attacks of wheezing has your child
had in the last 12 months?
None (1)
1 to 3 (2)
4 to 12   (3)
More than 12 (4)
In the last 12 months, how often, on average, has
your child's sleep been disturbed due to
wheezing?
In the last 12 months, has wheezing ever been
severe enough to limit your child's speech to only
one or two words at a time between breaths?
Yes
No
Has your child ever had asthma?
Yes
No
In the last 12 months, has your child's chest
sounded wheezy during or after exercise?
Yes
No
In the last 12 months, has your child had a dry
cough at night, apart from a cough associated
with a cold or chest infection?
Yes
No
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Has your child ever had a problem with sneezing,
or a runny or blocked nose, when he/she DID
NOT have a cold or the flu?
Yes
No
In the past 12 months, has your child had a
problem with sneezing, or a runny or blocked
nose, when he/she DID NOT have a cold or the
flu?
Yes
No
In the past 12 months, has this nose problem
been accompanied by itchy, watery eyes?
Yes
No
In which of the past 12 months did this nose
problem occur?
January (1)
October (10)
November (11)
December (12)
February (2)
March (3)
April (4)
May (5)
June (6)
July (7)
August (8)
September (9)
In the past 12 months, how much did this nose
problem interfere with your child's daily activities?
Not at all     (1)
A little  (2)
A moderate amount  (3)
A lot (4)
Has your child ever had hay fever?
Yes
No
Has your child ever had an itchy rash that was
coming and going for at least 6 months?
Yes
No
Has your child had this itchy rash at any time in
the last 12 months?
Yes
No
Has this itchy rash at any time affected any of the
following places: the folds of the elbows, behind
the knees, in front of the ankles, under the
buttocks, or around the neck, ears, or eyes?
Yes
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No
At what age did this itchy rash first occur?
Under 2 years     (1)
2 to 4 years (2)
5 or more years (3)
Has this rash cleared completely at any time
during the last 12 months?
Yes
No
In the last 12 months, how often, on average, has
your child been kept awake at night by this itchy
rash
Never in the last 12 months    (1)
Less than one night per week    (2)
One or more nights per week (3)
Has your child ever had eczema?
Yes
No
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Calcium Intake - Adults PhenX Toolkit
These questions from the Five-Factor Screener were
conducted by an interviewer in-person with the respondent
and may be useful to assess an individual’s approximate
intakes of several foods. These particular questions
address calcium intake. No portion size questions are
asked. This screener does not attempt to assess total diet.
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PhenX - calcium intake - adult protocol
During the past month, how often did you eat
HOT OR COLD CEREALS?
1 time per day     (1 time per day    )
1-2 times per week     (1-2 times per
week    )
1-3 times per month (1-3 times per
month)
2 times per day     (2 times per day    )
3 times per day (3 times per day)
3-4 times per week (3-4 times per week)
4 times per day     (4 times per day    )
5 or more times per day     (5 or more
times per day    )
5-6 times per week      (5-6 times per
week     )
Don't know (Don't know)
Never    (Never   )
Refused     (Refused    )
During the past month . . . When you ate cereal,
which kinds did you usually eat?
All bran cereals (such as All Bran®,
Fiber One®, 100% Bran®, or Bran
Buds®)     (All bran cereals (such as All
Bran®, Fiber One®, 100% Bran®, or
Bran Buds®)    )
Cereals with little bran or fiber (such as
Corn Flakes®, Honey Nut Cheerios®,
Froot Loops®, Rice Krispies®, Kix®,
Frosted Flakes®, Special K®, Cap’n
Crunch®, Blueberry Morning®, Product
19®, etc.) (Cereals with little bran or fiber
(such as Corn Flakes®, Honey Nut
Cheerios®, Froot Loops®, Rice
Krispies®, Kix®, Frosted Flakes®,
Special K®, Cap’n Crunch®, Blueberry
Morning®, Product 19®, etc.)    )
Cereals with some bran or fiber (such as
Cheerios®, Raisin Bran®, Shredded
Wheat®, Total®, Wheaties®, 40% Bran
flakes®, Granola, Grape Nuts®,
Muselix®, etc.)     (Cereals with some
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bran or fiber (such as Cheerios®, Raisin
Bran®, Shredded Wheat®, Total®,
Wheaties®, 40% Bran flakes®, Granola,
Grape Nuts®, Muselix®, etc.)    )
Cooked cereals (such as oatmeal, cream
of wheat, grits)     (Cooked cereals (such
as oatmeal, cream of wheat, grits)    )
Don't know (Don't know)
Other     (Other    )
Refused    (Refused   )
3. During the past month . . . How often did you
have MILK, either to drink or on cereal?
1 time per day     (1 time per day    )
1-2 times per week     (1-2 times per
week    )
1-3 times per month (1-3 times per
month)
2 times per day     (2 times per day    )
3 times per day (3 times per day)
3-4 times per week (3-4 times per week)
4 times per day     (4 times per day    )
5 or more times per day     (5 or more
times per day    )
5-6 times per week      (5-6 times per
week     )
Don't know (Don't know)
Never    (Never   )
Refused     (Refused    )
During the past month, how often did you drink
regular, carbonated SODA OR SOFT DRINKS
that contain sugar?
1 time per day     (1 time per day    )
1-2 times per week     (1-2 times per
week    )
1-3 times per month (1-3 times per
month)
2 times per day     (2 times per day    )
3 times per day (3 times per day)
3-4 times per week (3-4 times per week)
4 times per day     (4 times per day    )
5 or more times per day     (5 or more
times per day    )
5-6 times per week      (5-6 times per
week     )
Don't know (Don't know)
Never    (Never   )
Refused     (Refused    )
During the past month, how often did you drink
100% FRUIT JUICE, such as orange, mango,
apple, and grape juices?
1 time per day     (1 time per day    )
1-2 times per week     (1-2 times per
week    )
1-3 times per month (1-3 times per
month)
2 times per day     (2 times per day    )
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3 times per day (3 times per day)
3-4 times per week (3-4 times per week)
4 times per day     (4 times per day    )
5 or more times per day     (5 or more
times per day    )
5-6 times per week      (5-6 times per
week     )
Don't know (Don't know)
Never    (Never   )
Refused     (Refused    )
How often did you drink FRUIT-FLAVORED
DRINKS with sugar (such as Kool-Aid®, Hi-C®,
lemonade, or cranberry cocktail)?
1 time per day     (1 time per day    )
1-2 times per week     (1-2 times per
week    )
1-3 times per month (1-3 times per
month)
2 times per day     (2 times per day    )
3 times per day (3 times per day)
3-4 times per week (3-4 times per week)
4 times per day     (4 times per day    )
5 or more times per day     (5 or more
times per day    )
5-6 times per week      (5-6 times per
week     )
Don't know (Don't know)
Never    (Never   )
Refused     (Refused    )
During the past month . . . How often did you eat
FRUIT?
1 time per day     (1 time per day    )
1-2 times per week     (1-2 times per
week    )
1-3 times per month (1-3 times per
month)
2 times per day     (2 times per day    )
3 times per day (3 times per day)
3-4 times per week (3-4 times per week)
4 times per day     (4 times per day    )
5 or more times per day     (5 or more
times per day    )
5-6 times per week      (5-6 times per
week     )
Don't know (Don't know)
Never    (Never   )
Refused     (Refused    )
During the past month, how often did you eat a
green leafy or lettuce SALAD, with or without
other vegetables?
1 time per day     (1 time per day    )
1-2 times per week     (1-2 times per
week    )
1-3 times per month (1-3 times per
month)
2 times per day     (2 times per day    )
3 times per day (3 times per day)
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3-4 times per week (3-4 times per week)
4 times per day     (4 times per day    )
5 or more times per day     (5 or more
times per day    )
5-6 times per week      (5-6 times per
week     )
Don't know (Don't know)
Never    (Never   )
Refused     (Refused    )
During the past month . . . How often did you eat
FRENCH FRIES, home fries, or hash brown
potatoes?
1 time per day     (1 time per day    )
1-2 times per week     (1-2 times per
week    )
1-3 times per month (1-3 times per
month)
2 times per day     (2 times per day    )
3 times per day (3 times per day)
3-4 times per week (3-4 times per week)
4 times per day     (4 times per day    )
5 or more times per day     (5 or more
times per day    )
5-6 times per week      (5-6 times per
week     )
Don't know (Don't know)
Never    (Never   )
Refused     (Refused    )
During the past month . . . How often did you eat
other WHITE POTATOES?
1 time per day     (1 time per day    )
1-2 times per week     (1-2 times per
week    )
1-3 times per month (1-3 times per
month)
2 times per day     (2 times per day    )
3 times per day (3 times per day)
3-4 times per week (3-4 times per week)
4 times per day     (4 times per day    )
5 or more times per day     (5 or more
times per day    )
5-6 times per week      (5-6 times per
week     )
Don't know (Don't know)
Never    (Never   )
Refused     (Refused    )
During the past month . . . How often did you eat
COOKED DRIED BEANS, such as refried beans,
baked beans, bean soup, and pork and beans?
1 time per day     (1 time per day    )
1-2 times per week     (1-2 times per
week    )
1-3 times per month (1-3 times per
month)
2 times per day     (2 times per day    )
3 times per day (3 times per day)
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3-4 times per week (3-4 times per week)
4 times per day     (4 times per day    )
5 or more times per day     (5 or more
times per day    )
5-6 times per week      (5-6 times per
week     )
Don't know (Don't know)
Never    (Never   )
Refused     (Refused    )
During the past month . . . Not counting what you
just told me about (lettuce salads, white potatoes,
cooked dried beans), and not counting rice, how
often did you eat OTHER VEGETABLES?
1 time per day     (1 time per day    )
1-2 times per week     (1-2 times per
week    )
1-3 times per month (1-3 times per
month)
2 times per day     (2 times per day    )
3 times per day (3 times per day)
3-4 times per week (3-4 times per week)
4 times per day     (4 times per day    )
5 or more times per day     (5 or more
times per day    )
5-6 times per week      (5-6 times per
week     )
Don't know (Don't know)
Never    (Never   )
Refused     (Refused    )
During the past month . . . How often did you
have TOMATO SAUCES such as spaghetti sauce
or pizza with tomato sauce?
1 time per day     (1 time per day    )
1-2 times per week     (1-2 times per
week    )
1-3 times per month (1-3 times per
month)
2 times per day     (2 times per day    )
3 times per day (3 times per day)
3-4 times per week (3-4 times per week)
4 times per day     (4 times per day    )
5 or more times per day     (5 or more
times per day    )
5-6 times per week      (5-6 times per
week     )
Don't know (Don't know)
Never    (Never   )
Refused     (Refused    )
During the past month . . . How often did you
have SALSA?
1 time per day     (1 time per day    )
1-2 times per week     (1-2 times per
week    )
1-3 times per month (1-3 times per
month)
2 times per day     (2 times per day    )
3 times per day (3 times per day)
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3-4 times per week (3-4 times per week)
4 times per day     (4 times per day    )
5 or more times per day     (5 or more
times per day    )
5-6 times per week      (5-6 times per
week     )
Don't know (Don't know)
Never    (Never   )
Refused     (Refused    )
During the past month . . . How often did you eat
WHOLE GRAIN BREAD including toast, rolls and
in sandwiches?
1 time per day     (1 time per day    )
1-2 times per week     (1-2 times per
week    )
1-3 times per month (1-3 times per
month)
2 times per day     (2 times per day    )
3 times per day (3 times per day)
3-4 times per week (3-4 times per week)
4 times per day     (4 times per day    )
5 or more times per day     (5 or more
times per day    )
5-6 times per week      (5-6 times per
week     )
Don't know (Don't know)
Never    (Never   )
Refused     (Refused    )
During the past month, how often did you eat
DOUGHNUTS, sweet rolls, Danish, muffins, or
Pop-Tarts®?
1 time per day     (1 time per day    )
1-2 times per week     (1-2 times per
week    )
1-3 times per month (1-3 times per
month)
2 times per day     (2 times per day    )
3 times per day (3 times per day)
3-4 times per week (3-4 times per week)
4 times per day     (4 times per day    )
5 or more times per day     (5 or more
times per day    )
5-6 times per week      (5-6 times per
week     )
Don't know (Don't know)
Never    (Never   )
Refused     (Refused    )
During the past month . . . How often did you eat
COOKIES, CAKE, PIE, or BROWNIES?
1 time per day     (1 time per day    )
1-2 times per week     (1-2 times per
week    )
1-3 times per month (1-3 times per
month)
2 times per day     (2 times per day    )
3 times per day (3 times per day)
6 / 7
Calcium Intake - Adults PhenX Toolkit
3-4 times per week (3-4 times per week)
4 times per day     (4 times per day    )
5 or more times per day     (5 or more
times per day    )
5-6 times per week      (5-6 times per
week     )
Don't know (Don't know)
Never    (Never   )
Refused     (Refused    )
During the past month . . . How often did you eat
any kind of CHEESE?
1 time per day     (1 time per day    )
1-2 times per week     (1-2 times per
week    )
1-3 times per month (1-3 times per
month)
2 times per day     (2 times per day    )
3 times per day (3 times per day)
3-4 times per week (3-4 times per week)
4 times per day     (4 times per day    )
5 or more times per day     (5 or more
times per day    )
5-6 times per week      (5-6 times per
week     )
Don't know (Don't know)
Never    (Never   )
Refused     (Refused    )
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Depression - Child  PhenX Toolkit
The Center for Epidemiological Studies Depression Scale
for Children (CES-DC) is a 20 item self report instrument
that measures depressive symptoms in children ages 6
through 17.
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PhenX - depression - child protocol
I was bothered by things that usually don't bother
me.
Not at all (1)
A little   (2)
Some     (3)
A lot (4)
I did not feel like eating, I wasn't very hungry.
Not at all (1)
A little   (2)
Some     (3)
A lot (4)
I wasn't able to feel happy, even when my family
or friends tried to help me feel better.
Not at all (1)
A little   (2)
Some     (3)
A lot (4)
I felt like I was just as good as other kids.
Not at all (1)
A little   (2)
Some     (3)
A lot (4)
I felt like I couldn't pay attention to what I was
doing.
Not at all (1)
A little   (2)
Some     (3)
A lot (4)
I felt down and unhappy.
Not at all (1)
A little   (2)
Some     (3)
A lot (4)
I felt like I was too tired to do things.
Not at all (1)
A little   (2)
Some     (3)
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A lot (4)
I felt like something good was going to happen.
Not at all (1)
A little   (2)
Some     (3)
A lot (4)
I felt like things I did before didn't work out right.
Not at all (1)
A little   (2)
Some     (3)
A lot (4)
I felt scared.
Not at all (1)
A little   (2)
Some     (3)
A lot (4)
I didn't sleep as well as I usually sleep.
Not at all (1)
A little   (2)
Some     (3)
A lot (4)
I was happy.
Not at all (1)
A little   (2)
Some     (3)
A lot (4)
I was more quiet than usual.
Not at all (1)
A little   (2)
Some     (3)
A lot (4)
I felt lonely, like I didn't have any friends.
Not at all (1)
A little   (2)
Some     (3)
A lot (4)
I felt like kids I know were not friendly or that they
didn't want to be with me.
Not at all (1)
A little   (2)
Some     (3)
A lot (4)
I had a good time.
Not at all (1)
A little   (2)
Some     (3)
A lot (4)
I felt like crying.
Not at all (1)
A little   (2)
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Some     (3)
A lot (4)
I felt sad.
Not at all (1)
A little   (2)
Some     (3)
A lot (4)
I felt people didn't like me.
Not at all (1)
A little   (2)
Some     (3)
A lot (4)
It was hard to get started doing things.
Not at all (1)
A little   (2)
Some     (3)
A lot (4)
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Depression - Adult PhenX Toolkit
This protocol is divided into two parts. Part I consists of the
depression section from the Composite International
Diagnostic Interview - Short Form (CIDI-SF), developed for
the World Health Organization, and is a screening tool for
the general population. Part II consists of the Quick
Inventory of Depressive Symptoms (QIDS) that captures
the severity of depressive symptoms in the last seven days.
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PhenX - depression - adult protocol
Have you ever had a time in your life when you
felt sad, blue, or depressed for two weeks or
more in a row?*
A lot     (1)
A little (2)
Not at all (3)
Refused (4)
Not asked (5)
Have you ever had a time in your life lasting two
weeks or more when you lost interest in most
things like hobbies, work, or activities that usually
give you pleasure?*
A lot     (1)
A little (2)
Not at all (3)
Refused (4)
Not asked (5)
How much of the day did these feeling usually
last?*
All day long    (1)
Most of the day   (2)
About half of the day     (3)
Less than half of the day    (4)
Refused (5)
Not asked (6)
Did you feel this way:*
Every day     (1)
Almost every day  (2)
Less often    (3)
Refused (4)
Not asked (5)
Did you feel more tired out or low on energy than
is usual for you?*
A lot     (1)
A little (2)
Not at all (3)
Refused (4)
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Not asked (5)
Did you gain or lose weight without trying, or did
you stay about the same weight?*
Gained (1)
Lost (2)
Both gained and lost weight   (3)
Stayed about the same or on a diet (4)
Refused (5)
Not asked (6)
About how much weight did you gain?*
About how much weight did you lose?*
About how much weight did you gain and lose?*
Did you have more trouble falling asleep than you
usually do?*
A lot     (1)
A little (2)
Not at all (3)
Refused (4)
Not asked (5)
How often did that happen?*
Every night    (1)
Nearly every night (2)
Less often (3)
Refused (4)
Not asked (5)
Did you have a lot more trouble concentrating
than usual?*
A lot     (1)
A little (2)
Not at all (3)
Refused (4)
Not asked (5)
People sometimes feel down on themselves, no
good, or worthless. Did you feel this way?*
A lot     (1)
A little (2)
Not at all (3)
Refused (4)
Not asked (5)
Did you think a lot about death - either your own,
someone else's, or death in general?*
A lot     (1)
A little (2)
Not at all (3)
Refused (4)
Not asked (5)
About how many weeks altogether did you feel
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this way? The total period of depression/loss of
interest was:*
weeks
How many periods like this did you have in your
life, lasting two or more weeks?*
periods
About how old were you the FIRST time you had
a period of two weeks like this? (Whether or not
you received any help for it.)*
About how old were you the LAST time you had a
period of two weeks like this? (Whether or not
you received any help for it.)*
Did you ever tell a professional about these
problems (medical doctor, psychologist, social
worker, counselor, nurse, clergy, or other helping
professional)?*
A lot     (1)
A little (2)
Not at all (3)
Refused (4)
Not asked (5)
Did you take medication or use drugs or alcohol
more than once for these problems?*
A lot     (1)
A little (2)
Not at all (3)
Refused (4)
Not asked (5)
How much did these problems interfere with your
life or activities:*
A lot     (1)
A little (2)
Not at all (3)
Refused (4)
Not asked (5)
Please indicate the one response to each item
that best describes you for the past seven days.
Falling Asleep:*
Never take longer than 30 minutes to fall
asleep     (1)
I take at least 30 minutes to fall asleep,
less than half the time    (2)
I take at least 30 minutes to fall asleep,
more than half the time     (3)
I take more than 60 minutes to fall
asleep, more than half the time (4)
Please indicate the one response to each item
that best describes you for the past seven days.
Sleep During the Night:*
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I do not wake up at night    (1)
I have a restless, light sleep with a few
brief awakenings each night     (2)
I wake up at least once a night, but I go
back to sleep easily     (3)
I awaken more than once a night and
stay awake for 20 minutes or more, more
than half the time (4)
Please indicate the one response to each item
that best describes you for the past seven days.
Waking Up Too Early:*
Most of the time, I awaken no more than
30 minutes before I need to get up     (1)
More than half the time, I awaken no
more than 30 minutes before I need to
get up     (2)
I almost always awaken at least one hour
or so before I need to, but I go back to
sleep eventually     (3)
I awaken at least one hour before I need
to, and can’t go back to sleep (4)
Please indicate the one response to each item
that best describes you for the past seven days.
Sleeping Too Much:*
I sleep no longer than 7-8 hours/night,
without napping during the day     (1)
I sleep no longer than 10 hours in a 24-
hour period including naps     (2)
I sleep no longer than 12 hours in a 24-
hour period including naps     (3)
I sleep longer than 12 hours in a 24-hour
period including naps (4)
Please indicate the one response to each item
that best describes you for the past seven days.
Feeling Sad:*
I do not feel sad (1)
I feel sad less than half the time     (2)
I feel sad more than half the time     (3)
I feel sad nearly all of the time (4)
Please indicate the one response to each item
that best describes you for the past seven days.
Decreased Appetite:*
There is no change in my usual appetite.
(1)
I eat somewhat less often or lesser
amounts of food than usual    (2)
I eat much less than usual and only with
personal effort     (3)
I rarely eat within a 24-hour period, and
only with extreme personal effort or
when others persuade me to eat (4)
Please indicate the one response to each item
that best describes you for the past seven days.
Increased Appetite:*
There is no change in my usual appetite.
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(1)
I feel a need to eat more frequently than
usual     (2)
I regularly eat more often and/or greater
amounts of food than usual    (3)
I feel driven to overeat both at mealtime
and between meals (4)
Please indicate the one response to each item
that best describes you for the past seven days.
Decreased Weight (Within the Last Two Weeks):*
I have not had a change in my weight
(1)
I feel as if I’ve had a slight weight loss
(2)
I have lost 2 pounds or more     (3)
I have lost 5 pounds or more (4)
Please indicate the one response to each item
that best describes you for the past seven days.
Increased Weight (Within the Last Two Weeks):*
I have not had a change in my weight
(1)
I feel as if I’ve had a slight weight gain
(2)
I have gained 2 pounds or more     (3)
I have gained 5 pounds or more (4)
Please indicate the one response to each item
that best describes you for the past seven days.
View of Myself:*
I see myself as equally worthwhile and
deserving as other people     (1)
I am more self-blaming than usual     (2)
I largely believe that I cause problems for
others     (3)
I think almost constantly about major and
minor defects in myself (4)
Please indicate the one response to each item
that best describes you for the past seven days.
Thoughts of Death or Suicide:*
I do not think of suicide or death.    (1)
I feel that life is empty or wonder if it’s
worth living   (2)
I think of suicide or death several times a
week for several minutes     (3)
I think of suicide or death several times a
day in some detail, or I have made
specific plans for suicide or have actually
tried to take my life (4)
Please indicate the one response to each item
that best describes you for the past seven days.
General Interest:*
There is no change from usual in how
interested I am in other people or
activities.  (1)
I notice that I am less interested in
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people or activities   (2)
I find I have interest in only one or two of
my formerly pursued activities   (3)
I have virtually no interest in formerly
pursued activities (4)
Please indicate the one response to each item
that best describes you for the past seven days.
Energy Level:*
There is no change in my usual level of
energy.   (1)
I get tired more easily than usual    (2)
I have to make a big effort to start or
finish my usual daily activities (for
example,shopping, homework, cooking
or going to work)    (3)
I really cannot carry out most of my usual
daily activities because I just don’t have
the energy (4)
Please indicate the one response to each item
that best describes you for the past seven days.
Feeling Slowed Down:*
I think, speak, and move at my usual rate
of speed     (1)
I find that my thinking is slowed down or
my voice sounds dull or flat     (2)
It takes me several seconds to respond
to most questions and I’m sure my
thinking is slowed.  (3)
I am often unable to respond to
questions without extreme effort (4)
Please indicate the one response to each item
that best describes you for the past seven days.
Restless:*
I do not feel restless.     (1)
I’m often fidgety, wringing my hands, or
need to shift how I am sitting   (2)
I have impulses to move about and am
quite restless   (3)
At times, I am unable to stay seated and
need to pace around (4)
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Migraine Protocol PhenX Toolkit
The Self-Administered Questionnaire for Migraine is a 20-
item questionnaire that assesses the frequency of severe
headaches, the level of pain, whether the person is taking
medications, and associated complications such as
nausea.
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PhenX - migraine protocol
Over the past year, have you suffered from
severe headaches?*
Yes
No
Age*
Sex*
male (1)
female (2 )
When you have a severe headache, do you
experience any of the following?*
Nausea     (1)
Numbness of lips, tongue, fingers, or
legs before the headache starts (10)
Vomiting     (2)
One side of head only     (3)
Pulsating/throbbing headaches  (4)
Pain-free intervals of days or weeks
between severe headache attacks  (5)
Sensitivity to light  (6)
Sensitivity to noise    (7)
Blurring of vision   (8)
Seeing shimmering lights, circles, other
shapes, or colors before the eyes, before
the headache starts   (9)
About how often do your severe headaches
occur?*
count
Which statement best describes the pain of your
severe headaches?*
Extremely severe pain  (1)
Severe pain    (2)
Moderately severe pain (3)
Mild pain (4)
Which best describes how you are usually
affected by severe headaches?*
Able to work/function normally     (1)
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Working ability or activity impaired to
some degree    (2)
Working ability or activity severely
impaired     (3)
Bed rest required (4)
Each time you have a severe headache, how long
are you unable to work or undertake normal
activities?*
0 days (no activity restriction)     (1)
Less than 1 day  (2)
1-2 days  (3)
3-5 days    (4)
6 or more days (5)
On how many days in the last 3 months did you
have a headache (if headache lasted more than 1
day, count each day)?*
days
Because of your headaches on how many days in
the last 3 months . . .did you miss work or school*
days
Because of your headaches on how many days in
the last 3 months . . .was your productivity at
work/school reduced by half or more*
days
Because of your headaches on how many days in
the last 3 months . . . did you not do household
work*
days
Because of your headaches on how many days in
the last 3 months . . . was your productivity in
house-hold work reduced by half or more*
days
Because of your headaches on how many days in
the last 3 months . . . did you miss family, social,
or leisure activities*
days
At what age did you BEGIN having severe
headaches?*
Have you ever gone to the hospital emergency
room or to an urgent care clinic because of your
severe headaches?*
Yes
No
Which best describes the way you usually treat
severe headaches?*
Take non-prescription medications     (1)
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Take prescription medications     (2)
Take both prescription and non-
prescription medications (3)
Take no medications (4)
Have you ever taken prescription medication for
headache on a DAILY basis, whether or not you
have a headache, to help prevent a severe
headache from happening in the first place?*
Yes
No
Are you currently taking any other medication on
a DAILY basis?*
Water pill or prescription diuretic for high
blood pressure     (1)
Prescription medicine (other than water
pill) for high blood pressure  (2)
Prescription medicine for seizures,
epilepsy, or fits     (3)
Prescription medicine for diabetes   (4)
Prescription medicine for depression or
anxiety (5)
When did you last take prescription medication
for headache on a DAILY basis to help prevent a
severe headache from happening in the first
place?*
Currently taking    (1)
Last took within the past 3 months  (2)
Last took 3 to 12 months ago     (3)
Last took more than 12 months ago
(4)
Never took (5)
Do you consider your severe headaches to be
migraines?*
Yes
No
Have you ever been diagnosed by a physician or
other health professional as suffering from . . . ?*
Tension headaches (1)
Sinus headaches   (2)
Cluster headaches  (3)
Stress headaches   (4)
'Sick' headaches    (5)
Migraine headaches (6)
If diagnosed with migraines, at what age were
you FIRST DIAGNOSED with migraines?*
Body height --standing*
Body weight*
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Crime and Delinquency - Adolescent
Protocol PhenX Toolkit
Using a list of 40 criminal and delinquent questions, the
respondent indicates if he or she has engaged in each
activity, and if so, how many times in the past year.
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Crime and Delinquency - Adolescent
Protocol PhenX Toolkit
PhenX - crime and delinquency -
adolescent protocol
How many times in the last year have you run
away from home?*
How many times in the last year have you
skipped (classes/school) without an excuse?*
How many times in the last year have you been
suspended or sent home from school for bad
behavior?*
How many times in the last year have you lied
about your age to get into some place or to buy
something (for example, lying about your age to
get into a movie or to buy alcohol)?*
How many times in the last year have you
cheated on school tests?*
How many times in the last year have you
hitchhiked where it was illegal to do so?*
How many times in the last year have you carried
a hidden weapon?*
How many times in the last year have you been
loud, rowdy, or unruly in a public place so that
people complained about it or you got in trouble?*
How many times in the last year have you
begged for money or things from strangers?*
How many times in the last year have you made
obscene telephone calls such as calling someone
and saying dirty things?*
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How many times in the last year have you been
drunk in a public place?*
How many times in the last year have you
purposely damaged or destroyed property that
did not belong to you (for example, breaking,
cutting or marking up something)?*
How many times in the last year have you
purposely set fire to a house, building, car, or
other property or tried to do so?*
How many times in the last year have you broken
city curfew laws (for example, been in a public
place including out in the street without a parent
or other adult during the curfew period)?*
How many times in the last year have you
avoided paying for things such as movies, bus or
subway rides, and food or computer services?*
How many times in the last year have you gone
into or tried to go into a building to steal
something?*
How many times in the last year have you stolen
or tried to steal money or things worth $5 or
less?*
How many times in the last year have you stolen
or tried to steal money or things worth between
$5 and $50?*
How many times in the last year have you stolen
or tried to steal money or things worth more than
$50 but less than $100?*
How many times in the last year have you stolen
or tried to steal money or things worth $100 or
more?*
How many times in the last year have you taken
something from a store without paying for it
(including events you have already told me
about)?*
How many times in the last year have you
snatched someone's purse or wallet or picked
someone's pocket?*
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How many times in the last year have you taken
something from a car that did not belong to you?*
How many times in the last year have you
knowingly bought, sold or held stolen goods or
tried to do any of these things?*
How many times in the last year have you gone
joyriding (that is, taken a motor vehicle such as a
car or motorcycle for a ride or drive without the
owner's permission)?*
How many times in the last year have you stolen
or tried to steal a motor vehicle such as a car or
motorcycle?*
How many times in the last year have you used
checks illegally or used a slug or fake money to
pay for something (including intentional
overdrafts)?*
How many times in the last year have you used
or tried to use a credit or bank cards without the
owner's permission?*
How many times in the last year have you tried to
cheat someone by selling them something that
was worthless or not what you said it was?*
How many times in the last year have you
attacked someone with a weapon or with the idea
of seriously hurting or killing them?*
How many times in the last year have you hit
someone with the idea of hurting them (other
than the events just mentioned)?*
How many times in the last year have you used a
weapon, force, or strong-arm methods to get
money or things from people?*
How many times in the last year have you thrown
objects such as rocks or bottles at people (other
than events you have already mentioned)?*
How many times in the last year have you been
involved in gang fights?*
How many times in the last year have you been
paid for having sexual relations with someone?*
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How many times in the last year have you
physically hurt or threatened to hurt someone to
get them to have sex with you?*
How many times in the last year have you had or
tried to have sexual relations with someone
against their will (other than events you just
mentioned)?*
How many times in the last year have you sold
marijuana or hashish ('pot,' 'grass,' 'hash')?*
How many times in the last year have you sold
hard drugs such as heroin, cocaine, and LSD
(total freq. of all hard drug sales, not limited to
these three drugs)?*
Have you done anything else in the past year that
could have gotten you in trouble with the police?*
What kind of things did you do?*
How many times in the past year?*
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Posttraumatic Stress Disorder (PTSD)
Protocol PhenX Toolkit
The Diagnostic Interview for Genetic Studies (DIGS)
Posttraumatic Stress Disorder (PTSD) Screener is a 20-
question, interviewer-administered questionnaire designed
to screen for symptoms of Posttraumatic Stress Disorder.
This instrument was adapted from the Genetics of
Recurrent Early-Onset Depression (GenRED) research
study.
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Posttraumatic Stress Disorder
(PTSD) Protocol PhenX Toolkit
PhenX - posttraumatic stress disorder
(PTSD) protocol
Have you ever experienced, witnessed, or
otherwise been involved in any events that could
have brought serious harm or even death to you
or someone else? If yes: Specify (in general)*
Yes (1)
No (2)
Unknown (9)
Specify, in general, what you have you ever
experienced, witnessed, or otherwise been
involved in any events that could have brought
serious harm or even death to you or someone
else [PhenX]*
Did this event cause you to have intense feelings
of fear, helplessness, or horror?If yes: Specify (in
general)*
Yes (1)
No (2)
Unknown (9)
If this event caused you to have intense feelings
of fear, helplessness, or horror, specify [PhenX]*
Have you ever been bothered by unwanted
thoughts, or dreams, or images that kept coming
back to you, about a traumatic event that you
experienced or witnessed?*
Yes (1)
No (2)
Unknown (9)
Have you ever felt as if you were reliving some
traumatic event that you experienced or
witnessed?*
Yes (1)
No (2)
Unknown (9)
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Have you ever been intensely distressed or
extremely anxious when you were reminded in
some way about a traumatic event that you
experienced or witnessed?*
Yes (1)
No (2)
Unknown (9)
Have you tried in general to avoid thinking or
talking about the event?*
Yes (1)
No (2)
Unknown (9)
Have you tried in general to avoid activities,
places, or people that remind you of the event?*
Yes (1)
No (2)
Unknown (9)
Are you unable to recall important parts of the
event?*
Yes (1)
No (2)
Unknown (9)
Since the event, do you tend to feel detached
from other people?*
Yes (1)
No (2)
Unknown (9)
Since the event, have you been unable to
experience a full range of feelings?*
Yes (1)
No (2)
Unknown (9)
Since the event, have you found yourself unable
to see a future for yourself?*
Yes (1)
No (2)
Unknown (9)
Since this event happened, have you had
problems with ...difficulty falling asleep or staying
asleep (apart from depression or mania)?*
Yes (1)
No (2)
Unknown (9)
Since this event happened, have you had
problems with...irritability or angry outbursts
(apart from depression or mania)?*
Yes (1)
No (2)
Unknown (9)
Since this event happened, have you had
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problems with ...difficulty concentrating (apart
from depression or mania)?*
Yes (1)
No (2)
Unknown (9)
Since this event happened, have you had
problems with...being too much on alert?*
Yes (1)
No (2)
Unknown (9)
Since this event happened, have you had
problems with...being too easily startled?*
Yes (1)
No (2)
Unknown (9)
Have you been very upset about having these
symptoms?*
Yes (1)
No (2)
Unknown (9)
Have these symptoms interfered with your ability
to work, to be with others, or to function in other
areas of life?*
Yes (1)
No (2)
Unknown (9)
How long did these symptoms (from questions 3-
18) last? Indicate the number of months*
months
When did the traumatic event occur (if several,
ask about the most closely associated with
symptoms)?*
When did you start to experience these
symptoms (from questions 3-18)?*
Age of onset*
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Eating Disorder Diagnostic Scale (DSM-IV)
PhenX Toolkit
The Eating Disorder Diagnostic Scale (EDDS) is a 22 item
self report scale that simultaneously assesses anorexia
nervosa, bulimia nervosa and binge-eating disorder by
asking the respondent about body image, eating habits,
and compensatory behaviors over the last 3 to 6 months.
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Eating Disorder Diagnostic Scale
(DSM-IV) PhenX Toolkit
PhenX - eating disorders screener
protocol
Have you felt fat?*
0 - not at all (1)
1 (2)
2 - slightly     (3)
3 (4)
4 - moderately  (5)
5 (6)
6 - extremely (7)
Have you had a definite fear that you might gain
weight or become fat?*
0 - not at all (1)
1 (2)
2 - slightly     (3)
3 (4)
4 - moderately  (5)
5 (6)
6 - extremely (7)
Has your weight influenced how you think about
(judge) yourself as a person?*
0 - not at all (1)
1 (2)
2 - slightly     (3)
3 (4)
4 - moderately  (5)
5 (6)
6 - extremely (7)
Has you shape influenced how you think about
(judge) yourself as a person?*
0 - not at all (1)
1 (2)
2 - slightly     (3)
3 (4)
4 - moderately  (5)
5 (6)
6 - extremely (7)
During the past 6 months have there been times
when you felt you have eaten what other people
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would regard as an unusually large amount of
food (e.g. a quart of ice cream) given the
circumstances?*
Yes
No
During the times when you ate an unusually large
amount of food, did you experience a loss of
control (feel you couldn't stop eating or control
what or how much you were eating)?*
Yes
No
How many DAYS per week on average over the
past 6 MONTHS have you eaten an unusually
large amount of food and experienced a loss of
control?*
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
7 (7)
How many TIMES per week on average over the
past 3 MONTHS have you eaten an unusually
large amount of food and experienced a loss of
control?*
1 (1)
10 (10)
11 (11)
12 (12)
13 (13)
14 (14)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
7 (7)
8 (8)
9 (9)
Eat much more rapidly than normal?*
Yes
No
Eat until you felt uncomfortably full?*
Yes
No
Eat large amounts of food when you didn't feel
physically hungry?*
Yes
No
Eat alone because you were embarrassed by
how much you were eating?*
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Yes
No
Feel disgusted with yourself, depressed or very
guilty after overeating?*
Yes
No
Feel very upset about your uncontrollable
overeating or resulting weight gain?*
Yes
No
How many times per week on average over the
past 3 months have you made yourself vomit to
prevent weight gain or counteract the effects of
eating?*
1 (1)
10 (10)
11 (11)
12 (12)
13 (13)
14 (14)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
7 (7)
8 (8)
9 (9)
How many times per week on average over the
past 3 months have you used laxatives or
diuretics to prevent weight gain or counteract the
effects of eating?*
1 (1)
10 (10)
11 (11)
12 (12)
13 (13)
14 (14)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
7 (7)
8 (8)
9 (9)
How many times per week on average over the
past 3 months have you fasted (skipped at least 2
meals in a row) to prevent weight gain or
counteract the effects of eating?*
1 (1)
10 (10)
11 (11)
12 (12)
13 (13)
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14 (14)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
7 (7)
8 (8)
9 (9)
How many times per week on average over the
past 3 months have you engaged in excessive
exercise specifically to counteract the effects of
overeating episodes?*
1 (1)
10 (10)
11 (11)
12 (12)
13 (13)
14 (14)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
7 (7)
8 (8)
9 (9)
Body weight*
Body height --standing*
Over the past 3 months, how many menstrual
periods have you missed?*
1 (1)
2 (2)
3 (3)
4 (4)
Not applicable (5)
Have you been taking birth control pills during the
past 3 months?*
Yes
No
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Hypomania/Mania Symptoms - Adult
PhenX Toolkit
The Hypomania Checklist 32 Revised (HCL 32 R1) is a
self-report, 32 item questionnaire that screens for
hypomanic symptoms in major depressive disorder (MDD)
and the presence of bipolar and bipolar spectrum disorders
(including bipolar I and bipolar II Disorders).
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Hypomania/Mania Symptoms - Adult
PhenX Toolkit
PhenX - hypomania - mania symptoms -
adult protocol
First of all, how are you feeling today compared
to your usual state:*
Much worse than usual     (1)
Worse than usual    (2)
A little worse than usual     (3)
Neither better nor worse than usual (4)
A little better than usual   (5)
Better than usual    (6)
Much better than usual (7)
Compared to other people my level of activity,
energy and mood...*
Is always rather stable and even   (1)
Is generally higher   (2)
Is generally lower     (3)
Repeatedly shows periods of ups and
downs (4)
High state behavior or feelings [PhenX]*
Need less sleep     (1)
Physically more active in sport, etc   (10)
Plan more activities or projects   (11)
Have more ideas, I am more creative
(12)
Less shy or inhibited    (13)
Wear more colorful and more
extravagant clothes or make-up   (14)
Want to meet or actually do meet more
people     (15)
More interested in sex, or have
increased sexual desire     (16)
More flirtatious or am more sexually
active     (17)
Talk more     (18)
Think faster     (19)
More energetic and more active    (2)
Make more jokes or puns when I am
talking     (20)
More easily distracted     (21)
Engage in lots of new things  (22)
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Thoughts jump from topic to topic  (23)
Do things more quickly or more easily
(24)
More impatient or get irritable more
easily (25)
Can be exhausting or irritating for others
(26)
Get into more quarrels  (27)
Mood is higher, more optimistic  (28)
Drink more coffee     (29)
More self-confident  (3)
Smoke more cigarettes    (30)
Drink more alcohol     (31)
ake more drugs such as sedatives,
anxiolytics, stimulants (32)
Enjoy my work more   (4)
More sociable, make more phone calls,
go out more  (5)
Want to travel and do travel more  (6)
Tend to drive faster or take more risks
when driving   (7)
Spend more or too much money     (8)
Take more risks in my daily life, my work,
or other activities     (9)
In a high state I have this behavior or feeling
[PhenX]*
Yes
No
Aspects of your life [PhenX]*
Family life     (1)
Social life (2)
Work     (3)
Leisure (4)
Impact of your highs on this aspect of your life
[PhenX]*
Positive and negative  (1)
Positive (2)
Negative (3)
No impact downs (4)
How did people close to you react to or comment
on your "highs"*
Positively (encouraging or supportive)
(1)
Neutral     (2)
Negatively (concerned, annoyed,
irritated, critical)   (3)
Positively and negatively   (4)
No reactions (5)
Length of your "highs" as a rule (on the
average):*
1 day   (1)
2-3 days    (2)
4-7 days   (3)
Longer than 1 week    (4)
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Longer than 1 month (5)
I can't judge/don't know (6)
Have you experienced such "highs" in the past
twelve months?*
Yes
No
If yes, please estimate how many days you spent
in "highs" during the last twelve months:*
days
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Neighborhood Collective Efficacy - Community Cohesion
and Informal Social Control Protocol PhenX Toolkit
This protocol includes 10 Likert-style, interviewer-
administered questions from the Project on Human
Development in Chicago Neighborhoods (PHDCN). The
Social Cohesion and Informal Social Control subscales
include five items each.
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Neighborhood Collective Efficacy -
Community Cohesion and Informal
Social Control Protocol PhenX
Toolkit
PhenX - neighborhood collective efficacy -
community cohesion and informal social
control protocol
This is a close-knit neighborhood.*
Strongly agree     (1)
Agree     (2)
Disagree     (3)
Strongly disagree (4)
People around here are willing to help their
neighbors.*
Strongly agree     (1)
Agree     (2)
Disagree     (3)
Strongly disagree (4)
People in this neighborhood generally don't get
along with each other.*
Strongly agree     (1)
Agree     (2)
Disagree     (3)
Strongly disagree (4)
People in this neighborhood do not share the
same values.*
Strongly agree     (1)
Agree     (2)
Disagree     (3)
Strongly disagree (4)
People in this neighborhood can be trusted.*
Strongly agree     (1)
Agree     (2)
Disagree     (3)
Strongly disagree (4)
If a group of neighborhood children were skipping
school and hanging out on a street corner, how
likely is that your neighbors would do something
about it?*
Very likely     (1)
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Likely     (2)
Unlikely  (3)
Very unlikely (4)
If some children were spray-painting graffiti on a
local building, how likely is it that your neighbors
would do something about it?*
Very likely     (1)
Likely     (2)
Unlikely  (3)
Very unlikely (4)
If a child was showing disrespect to an adult, how
likely is it that people in your neighborhood would
scold that child?*
Very likely     (1)
Likely     (2)
Unlikely  (3)
Very unlikely (4)
If there was a fight in front of your house and
someone was being beaten or threatened, how
likely is it that your neighbors would break it up?*
Very likely     (1)
Likely     (2)
Unlikely  (3)
Very unlikely (4)
Suppose that because of budget cuts the fire
station closest to your home was going to be
closed down by the city. How likely is it that
neighborhood residents would organize to try to
do something to keep the fire station open?*
Very likely     (1)
Likely     (2)
Unlikely  (3)
Very unlikely (4)
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Hand Dominance - 12 Years and Older
PhenX Toolkit
The protocol consists of questions to determine which hand
the participant uses for a series of activities.
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Hand Dominance - 12 Years and
Older PhenX Toolkit
PhenX - hand dominance - 12 years and
older protocol EHI
Hand dominance - write [EHI]*
Right (1)
Left (2)
Both hands (3)
Hand dominance - draw [EHI]*
Right (1)
Left (2)
Both hands (3)
Hand dominance - throw [EHI]*
Right (1)
Left (2)
Both hands (3)
Hand dominance - hold a racquet [EHI]*
Right (1)
Left (2)
Both hands (3)
Hand dominance - clean teeth [EHI]*
Right (1)
Left (2)
Both hands (3)
Hand dominance - hammer [EHI]*
Right (1)
Left (2)
Both hands (3)
Hand dominance - strike a match [EHI]*
Right (1)
Left (2)
Both hands (3)
Hand dominance - use an eraser [EHI]*
Right (1)
Left (2)
Both hands (3)
Hand dominance - deal cards [EHI]*
Right (1)
Left (2)
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Both hands (3)
Hand dominance - thread a needle [EHI]*
Right (1)
Left (2)
Both hands (3)
Hand dominance - cut food with a knife [EHI]*
Right (1)
Left (2)
Both hands (3)
Hand dominance - Total score [EHI]*
Right (1)
Left (2)
Both hands (3)
Hand dominance - 12 years [interpretation] [EHI]*
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History of Head Trauma Protocol PhenX
Toolkit
The Ohio State University Traumatic Brain Injury
Identification Method Short Form (OSU TBI-ID) is an
interviewer-administered questionnaire that captures the
lifetime history of traumatic brain injury. The OSU TBI-ID
gives data for calculating summary indices that reflect the
likelihood that consequences have resulted from lifetime
exposure to traumatic brain injury.
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History of Head Trauma Protocol
PhenX Toolkit
PhenX - head trauma protocol
Have you ever been hospitalized or treated in an
emergency room following an injury to your head
or neck?*
Yes
No
Injury sequence [PhenX]*
Have you ever injured your head or neck in a car
accident or from some other moving vehicle
accident (e.g. motorcycle, ATV)?*
Yes
No
Have you ever injured your head or neck in a fall
or from being hit by something (e.g. falling from a
bike, horse, or rollerblades, falling on ice, being
hit by a rock)? Have you ever injured your head or
neck playing sports or on the playground?*
Yes
No
Have you ever injured your head or neck in a
fight, from being hit by someone, or from being
shaken violently? Have you ever been shot in the
head?*
Yes
No
Have you ever been nearby when an explosion or
a blast occurred?*
Yes
No
If more injuries with LOC: How many more?*
If more injuries with LOC: Longest knocked out*
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If more injuries with LOC: How many > 30
mins.?*
If more injuries with LOC: Youngest age?*
Have you ever lost consciousness from a drug
overdose or being choked?*
Yes
No
Have you ever lost consciousness from a drug
overdose or being choked?*
Yes
No
Injuries
Cause of injury reported
Were you knocked out or did you lose
consciousness (LOC)? If yes, how long?
Yes
No
Were you knocked out or did you lose
consciousness (LOC)? If yes, how long?
No loc   (1)
<30 min    (2)
30 min-24 hrs  (3)
> 24 hrs (4)
If no, were you dazed or did you have a gap in
your memory from the injury?
Yes
No
Age
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Hormonal Therapy Protocol PhenX Toolkit
Female participants are asked whether they have ever used
Evista® or Nolvadex® and then asked length of time they
used it as well as whether they are currently using it. They
are asked whether they are using any over-the-counter
preparations for hormone replacement or post-menopause
symptoms. Lastly, they are asked about their use of
prescription female hormones (number of months taken,
types, dosage).
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Hormonal Therapy Protocol PhenX
Toolkit
PhenX - hormonal therapy protocol
Have you used Evista® (raloxifene) or Nolvadex®
(tamoxifen)?*
Yes
No
How many months have you used Evista®?*
Not used (1)
1-4 months    (2)
5-9    (3)
10-14     (4)
15-19  (5)
20-24 (6)
Used only after 6/09 (7)
How many months have you used Nolvadex®?*
Not used (1)
1-4 months    (2)
5-9    (3)
10-14     (4)
15-19  (5)
20-24 (6)
Used only after 6/09 (7)
Are you currently using Evista® or Nolvadex®?*
No, not currently (1)
Yes, Evista®       (2)
Yes, Nolvadex® (3)
Are you currently using any over-the-counter
(e.g., "herbal," "natural," or soy-based)
preparations for hormone replacement or to treat
post-menopausal symptoms?*
Yes
No
What types?*
Soy estrogen products  (1)
Natural progesterone cream or wild yam
cream     (2)
Dong Quai (e.g. Rejuvex)     (3)
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Black Cohosh (e.g. Remifemin®)   (4)
Other (5)
Have you used prescription female hormones?*
Yes
No
How many months did you use hormones?*
1-4 months (1)
5-9     (2)
10-14  (3)
15-19     (4)
20-25     (5)
26-30 (6)
31-35   (7)
36+ months (8)
Are you currently using them (within the last
month)?*
Yes
No
Mark the type(s) of hormones you are
CURRENTLY using: Combined.*
Prempro® (Beige)    (1)
Prempro® (Gold)     (2)
Prempro® (Peach)    (3)
Prempro® (Light Blue)     (4)
Premphase     (5)
Combipatch     (6)
FemHRT (7)
Mark the type(s) of hormones you are
CURRENTLY using: Estrogen.*
Oral Premarin® or conjugated estrogens
(1)
Patch estrogen   (2)
Vaginal estrogen     (3)
Estrace®     (4)
Estrogen gels, creams, or sprays on skin
(5)
Estratest®  (6)
Ogen®     (7)
Other estrogen (8)
Please specify Other Estrogen you are
CURRENTLY using.*
Mark the type(s) of hormones you are
CURRENTLY using: Progesterone/Progestin.*
Provera®/Cycrin®/MPA   (1)
Vaginal     (2)
Micronized (e.g. Prometrium®)     (3)
Other progresterone (4)
Please specify Other progresterone you are
CURRENTLY using*
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Other hormones CURRENTLY used (e.g., Tri-
est).*
If you used oral conjugated estrogen (e.g.,
Premarin®), what dose did you usually take?*
0.30 mg/day or less   (1)
0.45 mg/day or less   (2)
0.625 mg/day or less  (3)
0.9 mg/day or less    (4)
1.25 mg/day or higher  (5)
Unsure     (6)
Did not take oral conjugated estrogen (7)
What was your pattern of hormone use (Days per
Month)? Estrogen.*
Not used (1)
<1 day/mo. (2)
1-8 days     (3)
9-18  (4)
19-26     (5)
27+ days/mo. (6)
What was your pattern of hormone use (Days per
Month)? Progesterone.*
Not used (1)
<1 day/mo. (2)
1-8 days     (3)
9-18  (4)
19-26     (5)
27+ days/mo. (6)
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Obsessive Compulsive Disorder Screener
Protocol PhenX Toolkit
This screening protocol includes the 15 interviewer-
administered questions from the Obsessive Compulsive
Disorders section (Section I) of the Composite International
Diagnostic Interview - Short Form (CIDI-SF), developed for
the World Health Organization.
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Obsessive Compulsive Disorder
Screener Protocol PhenX Toolkit
PhenX - obsessive compulsive disorder
screener protocol
Have you ever been bothered by having certain
unpleasant thoughts of your own that kept
entering your mind against your wishes?*
Yes (1)
No (2)
Refused (3)
Not asked (4)
Have you ever had any unpleasant and persistent
thoughts like that?*
Yes (1)
No (2)
Refused (3)
Not asked (4)
Did some of these thoughts seem to you to be
unreasonable?*
Yes (1)
No (2)
Refused (3)
Not asked (4)
Did these thoughts keep coming back again and
again into your mind no matter how hard you tried
to resist, ignore, or get rid of them?*
Yes (1)
No (2)
Refused (3)
Not asked (4)
Did you ever tell a doctor about these thoughts?*
Yes (1)
No (2)
Refused (3)
Not asked (4)
Did thinking about these ideas interfere with your
life or work, or cause you difficulty with your
relatives or friends, or upset you a great deal?*
Yes (1)
No (2)
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Refused (3)
Not asked (4)
Have you ever had to do something like that over
and over?*
Yes (1)
No (2)
Refused (3)
Not asked (4)
Did you have a period when you had to say
certain words over and over, either aloud or to
yourself?*
Yes (1)
No (2)
Refused (3)
Not asked (4)
Has there been a period of several weeks when
you felt you had to count something, like the
squares in a tile floor, and couldn't resist doing it
even when you tried to?*
Yes (1)
No (2)
Refused (3)
Not asked (4)
Did you have a period when you had to say
certain words over and over, either aloud or to
yourself?*
Yes (1)
No (2)
Refused (3)
Not asked (4)
Did you think that these actions were
unnecessary or that you overdid it?*
Yes (1)
No (2)
Refused (3)
Not asked (4)
Did you tell a doctor about having to do these
things?*
Yes (1)
No (2)
Refused (3)
Not asked (4)
Did having to do these things interfere with your
life or work, or cause you difficulty with your
relatives or friends, or upset you a great deal?*
Yes (1)
No (2)
Refused (3)
Not asked (4)
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Personal and Family History of Strabismus
Protocol  PhenX Toolkit
A series of self-administered questions to assess family
and personal history of strabismus, including history of
treatments and surgeries.
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Personal and Family History of
Strabismus Protocol  PhenX Toolkit
PhenX - personal - family history of
strabismus protocol
Have you ever had a crossed or wandering eye
(amblyopia)?*
Yes (1)
No (2)
Not sure (3)
Have you ever had double vision?*
Yes (1)
No (2)
Not sure (3)
Do you ever tilt your head when looking straight?*
Yes (1)
No (2)
Not sure (3)
Have you ever undergone eye muscle surgery?*
Yes (1)
No (2)
Not sure (3)
Have you ever worn a patch or used eye drops
(atropine penalization) for eye correction?*
Yes (1)
No (2)
Not sure (3)
Have you ever worn glasses or contacts?*
Yes (1)
No (2)
Not sure (3)
If you answered YES to any of the above
questions (questions 1-6), please provide further
details (i.e. age of onset of eye condition, dates of
surgery, name of procedure if known, reason for
glasses, etc.)*
Do you have a coloboma? (Absence or defect of
ocular tissue ranging from a small pit in the optic
disk to extensive defects in the iris, ciliary body,
choroid, retina, or optic disk)*
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Yes (1)
No (2)
Not sure (3)
Do you have microphthalmia? (Abnormally small
eye)*
Yes (1)
No (2)
Not sure (3)
Do you have epibulbar dermoid? (Eye tumors that
are not recurrent or progressive)*
Yes (1)
No (2)
Not sure (3)
Do you have any abnormal ocular features?*
Yes (1)
No (2)
Not sure (3)
Do you have any retinal defects?*
Yes (1)
No (2)
Not sure (3)
Do you have any visual impairment other than
previously noted?*
Yes (1)
No (2)
Not sure (3)
If you answered YES to any question above
(questions 8-13), please describe.*
Relative
Relative with strabismus [PhenX]
Mother (1)
Paternal Grandfather (10)
Maternal Aunt    (11)
Maternal Uncle   (12)
Paternal Aunt     (13)
Paternal Uncle  (14)
Child 1  (15)
Sibling 1 (16)
Adopted son or daughter   (17)
Half sibling   (18)
Half-sister (19)
Father (2)
Stepson or stepdaughter     (20)
Self (21)
Sister (3)
Brother (4)
Daughter (5)
Son (6)
Maternal Grandmother     (7)
Maternal Grandfather    (8)
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Paternal Grandmother (9)
Treatment related to strabismus [PhenX]
Glasses before age 6    (1)
Patching     (2)
Eye muscle surgery (3)
Did this relative have this strabismus treament
[PhenX]
Yes (1)
No (2)
Not sure (3)
Other relative with strabismus [PhenX]
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Personal History of Gastrointestinal
Conditions Protocol PhenX Toolkit
This self-administered questionnaire asks respondents
about their personal history of several gastrointestinal
conditions including colon or rectal polyps, gallbladder
conditions, gastric ulcers, Barrett’s esophagus, ulcerative
colitis/Crohn’s disease, colon or rectal cancer, pancreatic
cancer, and gastrointestinal bleeding. The questionnaire
also asks about a history of gastrointestinal procedures
such as a colonoscopy, a sigmoidoscopy, and an upper
endoscopy.
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Personal History of Gastrointestinal
Conditions Protocol PhenX Toolkit
PhenX - personal history of
gastrointestinal conditions protocol
In the past 2 years, have you had a...upper
endoscopy (esophagus/stomach)?*
Yes
No
In the past 2 years, have you had a (Virtual) CT
colonoscopy?*
Yes
No
In the past 2 years, have you had a
colonoscopy?*
Yes
No
In the past 2 years, have you had a
sigmoidoscopy?*
Yes
No
Clinician diagnosed gastrointestinal conditions
[PhenX]*
Diverticulitis or diverticulosis     (1)
Colon/rectal cancer     (2)
Gallbladder removal     (3)
Gastric or duodenal ulcer   (4)
Barrett’s Esophagus    (5)
Ulcerative colitis or Crohn’s  (6)
Gastrointestinal bleeding that required
hospitalization or a transfusion (7)
Initial reason(s) you had a colonoscopy/sigmoid
oscopy?
Visible blood  (1)
Family history of colon cancer    (2)
Virtual (CT) colonography   (3)
Occult fecal blood     (4)
Diarrhea/constipation  (5)
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Prior polyps   (6)
Abdominal pain  (7)
Barium enema  (8)
Asymptomatic or routine screening (9)
Have you had any of the following clinician
diagnosed conditions?*
Yes
No
Site of the bleeding [PhenX]*
Esophagus  (1)
Stomach     (2)
Duodenum   (3)
Colon or rectum     (4)
Other (5)
Site unknown (6)
What was the site of the bleeding? (Mark all that
apply.)*
Yes
No
What years did this happen
Before 1993    (1)
Between 1993-1997    (2)
Between 1998-1999 (3)
Between 2000-2001     (4)
Between 2002-2003   (5)
Between 2004-2005     (6)
2006 or later (7)
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Eczema Protocol PhenX Toolkit
The Eczema Area and Severity Index© (EASI) is a tool to
determine the level of severity and extent of atopic eczema.
The EASI© is completed by a physician or trained assistant
observing four regions of the respondent’s body for the
presence of four features of eczema. Each feature is given
a score and the scores are used to determine the severity
of the respondent’s eczema. Full and half scores are
allowed. The EASI© contains detailed scoring instructions.
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Eczema Protocol PhenX Toolkit
PhenX - eczema protocol
Head and neck redness score*
0 - absent     (1)
0.5     (2)
1 - mild (3)
1.5     (4)
2 - moderate (5)
2.5     (6)
3 - severe (7)
Head and neck thickness score*
0 - absent     (1)
0.5     (2)
1 - mild (3)
1.5     (4)
2 - moderate (5)
2.5     (6)
3 - severe (7)
Head and neck scratching score*
0 - absent     (1)
0.5     (2)
1 - mild (3)
1.5     (4)
2 - moderate (5)
2.5     (6)
3 - severe (7)
Head and neck lichenification score*
0 - absent     (1)
0.5     (2)
1 - mild (3)
1.5     (4)
2 - moderate (5)
2.5     (6)
3 - severe (7)
Head and neck percentage area affected by
eczema*
0 - none     (1)
1 - 9%  (2)
10 - 29% (3)
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30 - 49%  (4)
50 - 69%   (5)
70 - 89%   (6)
90 - 100% (7)
Upper limbs redness score*
0 - absent     (1)
0.5     (2)
1 - mild (3)
1.5     (4)
2 - moderate (5)
2.5     (6)
3 - severe (7)
Upper limbs thickness score*
0 - absent     (1)
0.5     (2)
1 - mild (3)
1.5     (4)
2 - moderate (5)
2.5     (6)
3 - severe (7)
Upper limbs scratching score*
0 - absent     (1)
0.5     (2)
1 - mild (3)
1.5     (4)
2 - moderate (5)
2.5     (6)
3 - severe (7)
Upper limbs lichenification score*
0 - absent     (1)
0.5     (2)
1 - mild (3)
1.5     (4)
2 - moderate (5)
2.5     (6)
3 - severe (7)
Upper limbs percentage area affected by
eczema*
0 - none     (1)
1 - 9%  (2)
10 - 29% (3)
30 - 49%  (4)
50 - 69%   (5)
70 - 89%   (6)
90 - 100% (7)
Trunk redness score*
0 - absent     (1)
0.5     (2)
1 - mild (3)
1.5     (4)
2 - moderate (5)
2.5     (6)
3 - severe (7)
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Trunk thickness score*
0 - absent     (1)
0.5     (2)
1 - mild (3)
1.5     (4)
2 - moderate (5)
2.5     (6)
3 - severe (7)
Trunk scratching score*
0 - absent     (1)
0.5     (2)
1 - mild (3)
1.5     (4)
2 - moderate (5)
2.5     (6)
3 - severe (7)
Trunk lichenification score*
0 - absent     (1)
0.5     (2)
1 - mild (3)
1.5     (4)
2 - moderate (5)
2.5     (6)
3 - severe (7)
Trunk percentage area affected by eczema*
0 - none     (1)
1 - 9%  (2)
10 - 29% (3)
30 - 49%  (4)
50 - 69%   (5)
70 - 89%   (6)
90 - 100% (7)
Lower limbs redness score*
0 - absent     (1)
0.5     (2)
1 - mild (3)
1.5     (4)
2 - moderate (5)
2.5     (6)
3 - severe (7)
Lower limbs thickness score*
0 - absent     (1)
0.5     (2)
1 - mild (3)
1.5     (4)
2 - moderate (5)
2.5     (6)
3 - severe (7)
Lower limbs scratching score*
0 - absent     (1)
0.5     (2)
1 - mild (3)
1.5     (4)
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2 - moderate (5)
2.5     (6)
3 - severe (7)
Lower limbs lichenification score*
0 - absent     (1)
0.5     (2)
1 - mild (3)
1.5     (4)
2 - moderate (5)
2.5     (6)
3 - severe (7)
Lower limbs percentage area affected by
eczema*
0 - none     (1)
1 - 9%  (2)
10 - 29% (3)
30 - 49%  (4)
50 - 69%   (5)
70 - 89%   (6)
90 - 100% (7)
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Emotional Distress Protocol PhenX Toolkit
This set of questions from the PROMIS© Version 1.0 item
banks measure self-reported emotional anxiety,
depression, and sleep disturbance. Each question is
measured on a five-point scale asking the respondent to
reflect on the past 7 days.
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Emotional Distress Protocol PhenX
Toolkit
PhenX - emotional distress protocol
In the past 7 days - I felt fearful*
Never (1)
Rarely (2)
Sometimes (3)
Often (4)
Always (5)
In the past 7 days - I felt anxious*
Never (1)
Rarely (2)
Sometimes (3)
Often (4)
Always (5)
In the past 7 days - I felt worried*
Never (1)
Rarely (2)
Sometimes (3)
Often (4)
Always (5)
In the past 7 days - I found it hard to focus on
anything other than my anxiety*
Never (1)
Rarely (2)
Sometimes (3)
Often (4)
Always (5)
In the past 7 days - I felt nervous*
Never (1)
Rarely (2)
Sometimes (3)
Often (4)
Always (5)
In the past 7 days - I felt uneasy*
Never (1)
Rarely (2)
Sometimes (3)
Often (4)
Always (5)
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In the past 7 days - I felt tense*
Never (1)
Rarely (2)
Sometimes (3)
Often (4)
Always (5)
In the past 7 days - I felt worthless*
Never (1)
Rarely (2)
Sometimes (3)
Often (4)
Always (5)
In the past 7 days - I felt that I had nothing to look
forward to*
Never (1)
Rarely (2)
Sometimes (3)
Often (4)
Always (5)
In the past 7 days - I felt helpless*
Never (1)
Rarely (2)
Sometimes (3)
Often (4)
Always (5)
In the past 7 days - I felt sad.*
Never (1)
Rarely (2)
Sometimes (3)
Often (4)
Always (5)
In the past 7 days - I felt like a failure*
Never (1)
Rarely (2)
Sometimes (3)
Often (4)
Always (5)
In the past 7 days - I felt depressed*
Never (1)
Rarely (2)
Sometimes (3)
Often (4)
Always (5)
In the past 7 days - I felt unhappy*
Never (1)
Rarely (2)
Sometimes (3)
Often (4)
Always (5)
In the past 7 days - I felt hopeless*
Never (1)
Rarely (2)
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Sometimes (3)
Often (4)
Always (5)
In the past 7 days - My sleep was restless*
Not at all    (1)
A little bit     (2)
Somewhat     (3)
Quite a bit (4)
Very much (5)
In the past 7 days - I was satisfied with my sleep*
Not at all    (1)
A little bit     (2)
Somewhat     (3)
Quite a bit (4)
Very much (5)
In the past 7 days - My sleep was refreshing*
Not at all    (1)
A little bit     (2)
Somewhat     (3)
Quite a bit (4)
Very much (5)
In the past 7 days - I had difficulty falling asleep*
Not at all    (1)
A little bit     (2)
Somewhat     (3)
Quite a bit (4)
Very much (5)
In the past 7 days - I had trouble staying asleep*
Never (1)
Rarely (2)
Sometimes (3)
Often (4)
Always (5)
In the past 7 days - I had trouble sleeping*
Never (1)
Rarely (2)
Sometimes (3)
Often (4)
Always (5)
In the past 7 days - I got enough sleep*
Never (1)
Rarely (2)
Sometimes (3)
Often (4)
Always (5)
In the past 7 days - My sleep quality was...*
Very poor (1)
Poor (2)
Fair (3)
Good (4)
Very good (5)
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Cancer Treatments Protocol PhenX Toolkit
These questions start by asking if the respondent has had
cancer. For respondents who have had cancer, detailed
follow-up questions ask about the type of cancer treatment,
including surgery, chemotherapy, radiation, and hormone
therapy.
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Cancer Treatments Protocol PhenX
Toolkit
PhenX - cancer treatment protocol
Have you ever had cancer?*
Yes
No
Cancer Site/Type?*
Laterality?*
Left (1)
Right (2)
Both (3)
Not Applicable (4)
Date of diagnosis?*
Age of diagnosis?*
Cancer treatment [PhenX]*
Surgery     (1)
Chemotherapy (2)
Radiation    (3)
Hormonal therapy (4)
Did you have surgery for this cancer?*
Yes (1)
No (2)
Not sure (3)
Name of procedure?*
Surgery Date?*
Treatment hospital?*
Type of chemo?*
Adriamycin®   (1)
Avastin® (10)
Aromasin®   (11)
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Femara®     (12)
Other (13)
Taxol® (Paclitaxel)  (2)
Taxotere® (Docetaxel)    (3)
Cytoxan®  (4)
Xeloda®    (5)
Leucovorin®  (6)
Fluorouracil®   (7)
Methotrexate     (8)
Herceptin®  (9)
Date chemo completed?*
Name of hormone therapy?*
Tamoxifen     (1)
Aromasin®   (2)
Femara®  (3)
Other (4)
Did you receive any other type(s) of therapy?*
Yes (1)
No (2)
Not sure (3)
Name of other therapy?*
Have you had a recurrence with this cancer?*
Yes (1)
No (2)
Not sure (3)
Date of recurrence?*
Where did this cancer recur? (ex. lung, breast,
liver)*
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Cancer: Personal and Family History
Protocol PhenX Toolkit
This protocol is used to assess if the respondent and his or
her biological parents, siblings, and children have had
cancer. This protocol also obtains information about vital
status, age, type of cancer, age at first diagnosis, and any
additional cancer diagnoses.
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Cancer: Personal and Family History
Protocol PhenX Toolkit
PhenX - cancer - personal and family
history protocol
Relative [PhenX]*
Mother (1)
Paternal Grandfather (10)
Maternal Aunt    (11)
Maternal Uncle   (12)
Paternal Aunt     (13)
Paternal Uncle  (14)
Child 1  (15)
Sibling 1 (16)
Adopted son or daughter   (17)
Half sibling   (18)
Half-sister (19)
Father (2)
Stepson or stepdaughter     (20)
Self (21)
Sister (3)
Brother (4)
Daughter (5)
Son (6)
Maternal Grandmother     (7)
Maternal Grandfather    (8)
Paternal Grandmother (9)
Gender*
male (1)
female (2)
Alive?*
Yes
No
Current age or age at death?*
<50  (1)
50-64  (2)
65+ (3)
Never had cancer?*
Yes
No
First cancer diagnosis?*
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Breast cancer (1)
Pancreas cancer    (10)
Other cancer (11)
Ovarian cancer    (2)
Endometrial cancer    (3)
Cervix cancer  (4)
Lymphoma  (5)
Melanoma    (6)
Colon/rectal cancer   (7)
Lung cancer     (8)
Prostate cancer     (9)
Age at first cancer diagnosis*
Second or other cancer diagnoses?*
Breast cancer (1)
Other cancer (11)
Ovarian cancer    (2)
Endometrial cancer    (3)
Melanoma    (6)
Colon/rectal cancer   (7)
Prostate cancer     (9)
Cancer diagnosis if other?*
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Alcohol - Lifetime Abuse and Dependence
Protocol PhenX Toolkit
Measurement of respondent’s symptoms of alcohol abuse
and dependence. These responses correspond with criteria
from the Diagnostic and Statistical Manual of Mental
Disorders (4th ed.; DSM-IV).
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Alcohol - Lifetime Abuse and
Dependence Protocol PhenX Toolkit
PhenX - alcohol - lifetime abuse and
dependence protocol
At what age did you begin to drink regularly; that
is, drinking at least once a month for 6 months or
more?*
How old were you the first time you got drunk,
that is, your speech was slurred or you were
unsteady on your feet?*
In your lifetime, what is the largest number of
drinks you have ever had in a 24 hour period,
including all types of alcohol [PhenX]*
Did you ever become tolerant to alcohol; that is,
you drank a great deal more in order to get an
effect, or found you could no longer get high on
the amount you used to drink?*
No (1)
Yes (2)
Don't know/refused (3)
Was increase 50% or more?*
No (1)
Yes (2)
Don't know/refused (3)
Did you ever find you could drink a lot more
before you got drunk?*
No (1)
Yes (2)
Don't know/refused (3)
Was increase 50% or more?*
No (1)
Yes (2)
Don't know/refused (3)
Have you 3 or more times wanted to stop or cut
down on drinking?*
No (1)
1 / 5
Yes (2)
Don't know/refused (3)
Have you ever tried to stop or cut down on
drinking?*
No (1)
Yes (2)
Don't know/refused (3)
How many times were you unable to stop or cut
down?*
Was it 3 or more times?*
No (1)
Yes (2)
Don't know/refused (3)
Have you ever started drinking at times you
promised yourself that you wouldn't, or have you
ever drunk more than you intended? For
example, when you decided to drink 2 drinks and
ended up drinking 4 or more?*
No (1)
Yes (2)
Don't know/refused (3)
Did this happen 3 or more times?*
No (1)
Yes (2)
Don't know/refused (3)
Have you ever started drinking and become
drunk when you didn't want to?*
No (1)
Yes (2)
Don't know/refused (3)
Did this happen 3 or more times?*
No (1)
Yes (2)
Don't know/refused (3)
Have you ever given up or greatly reduced
important activities while drinking -- like sports,
work, or associating with friends or relatives?*
No (1)
Yes (2)
Don't know/refused (3)
Did this happen 3 or more times?*
No (1)
Yes (2)
Don't know/refused (3)
Has there ever been a period of several days or
more when you spent so much time drinking or
recovering from the effects of alcohol that you
had little time for anything else?*
No (1)
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Yes (2)
Don't know/refused (3)
Has this happened 3 or more times, or did it last
a month or longer?*
No (1)
Yes (2)
Don't know/refused (3)
Health problem resulting from long stretches of
drinking [PhenX]*
Liver disease or yellow jaundice    (1)
Stomach disease or vomiting blood     (2)
Pancreatitis   (3)
Damage to your heart, cardiomyopathy
(4)
Memory problems even when you
weren't drinking (5)
Did long stretches of drinking cause you to have
this health problem [PhenX]*
No (1)
Yes (2)
Don't know/refused (3)
Specify other physical health problems from
drinking*
Shakes, hands trembling     (1)
Fidgety or restless (10)
Unable to sleep (2)
Feel anxious    (3)
Feel depressed or irritable    (4)
Heart beat fast or did you sweat    (5)
Have nausea or vomiting (6)
Feel physically weak    (7)
Have headaches     (8)
See or hear things that weren’t there   (9)
Did drinking ever cause you to have any other
physical health problems? IF YES, SPECIFY*
No (1)
Yes (2)
Don't know/refused (3)
Did you continue to drink knowing that drinking
caused you to have health problems?*
No (1)
Yes (2)
Don't know/refused (3)
Have you ever continued to drink when you knew
you had any (other) serious physical illness or
condition that might be made worse by drinking?*
No (1)
Yes (2)
Don't know/refused (3)
Has drinking ever caused you this emotional or
psychological problem for more than 24 hours to
the point that it interfered with your functioning or
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relationships [PhenX]*
No (1)
Yes (2)
Don't know/refused (3)
Emotional or psychological problem related to
drinking [PhenX]*
Feeling depressed or uninterested in
things     (1)
Feeling jumpy or easily startled or
nervous  (2)
Feeling paranoid or suspicious of people
(3)
Hearing, seeing, or smelling things that
weren’t really there (4)
Did you continue to drink after you knew it
caused you any of these problems?*
No (1)
Yes (2)
Don't know/refused (3)
When you stopped, cut down or went without
drinking, did you ever experience this problem for
most of the day for 2 days or longer [PhenX]*
No (1)
Yes (2)
Don't know/refused (3)
Problem after cutting down or going without
drinking [PhenX]*
Shakes, hands trembling     (1)
Fidgety or restless (10)
Unable to sleep (2)
Feel anxious    (3)
Feel depressed or irritable    (4)
Heart beat fast or did you sweat    (5)
Have nausea or vomiting (6)
Feel physically weak    (7)
Have headaches     (8)
See or hear things that weren’t there   (9)
Was there ever a time when two or more of these
problems occurred together?*
No (1)
Yes (2)
Don't know/refused (3)
Was there ever a time when two or more of these
problems occurred together? Which ones?*
Shakes, hands trembling     (1)
Fidgety or restless (10)
Unable to sleep (2)
Feel anxious    (3)
Feel depressed or irritable    (4)
Heart beat fast or did you sweat    (5)
Have nausea or vomiting (6)
Feel physically weak    (7)
Have headaches     (8)
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See or hear things that weren’t there   (9)
Have you ever taken a drink to keep from having
any of these problems (or to make them go
away)*
No (1)
Yes (2)
Don't know/refused (3)
Did this happen 3 or more times?*
No (1)
Yes (2)
Don't know/refused (3)
When you stopped, cut down, or went without
drinking, did you ever have fits, seizures, or
convulsions, where you lost consciousness, fell to
the floor, and had difficulty remembering what
happened?*
No (1)
Yes (2)
Don't know/refused (3)
On 3 or more different occasions have you taken
a drink to keep from having fits, seizures, or
convulsions or to make them go away*
No (1)
Yes (2)
Don't know/refused (3)
When you stopped, cut down, or went without
drinking, did you ever have the DT's, that is,
where you were very confused, extremely shaky,
felt very frightened or nervous, or saw things that
weren't really there?*
No (1)
Yes (2)
Don't know/refused (3)
On 3 or more different occasions have you taken
a drink to keep from having the DT's or to make
them go away?*
No (1)
Yes (2)
Don't know/refused (3)
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Use of Eye Glasses- Adult PhenX Toolkit
The interviewer asks the respondent if he/she wears
glasses of any kind. If so, additional questions are asked
regarding type of glasses, duration of use, ability to read
newspaper print, and use of a magnifier. If respondent
indicates he/she does not wear glasses, additional
questions are only asked regarding ability to read
newspaper print, and use of a magnifier.
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Toolkit
PhenX - use of eye glasses - adult
protocol
Do you wear glasses of any kind?*
Yes (1)
No (2)
Don't know (3)
Missing (4)
Are they:*
Single vision distance glasses only  (1)
Single vision reading glasses only (2)
Separate reading and distance glasses
(3)
Bifocals     (4)
Multifocals     (5)
Don't know     (6)
Missing (7)
How old were you when you first needed to wear
glasses to see clearly in the distance? ___ years
old*
How old were you when you first needed reading
glasses, bifocals or multifocals? ___ years old*
How long have you had your current glasses?
Glasses are ___years old*
When did you last have the strength of your
glasses checked? ___ years ago*
Can you read the ordinary print in the newspaper
reasonable well, with or without glasses?*
Yes (1)
No (2)
Don't know (3)
Missing (4)
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When were you last able to do this? ___ years
ago*
Do you use a magnifier to read?*
Yes (1)
No (2)
Don't know (3)
Missing (4)
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Sleep Apnea - Adult Protocol PhenX Toolkit
The questionnaire asks about risk factors for sleep apnea,
namely snoring behavior, wake time, sleepiness or fatigue,
and the presence of high blood pressure. The protocol
begins with information that an individual self-reports on
height, weight, age, and sex. The 10 questions address
snoring, fatigue, and high blood pressure. An algorithm is
provided to classify study participants into high or low risk
based on response.
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Sleep Apnea - Adult Protocol PhenX
Toolkit
PhenX - respiratory - sleep apnea - adult
protocol
Body height --standing*
m
Body weight*
kg
Age - Reported*
Sex*
Male (1)
Female (2)
Do you snore?*
Yes (1)
No (2)
Don't know (3)
Your snoring is:*
Slightly louder than breathing  (1)
As loud as talking   (2)
Louder than talking  (3)
Very loud can be heard in adjacent
rooms (4)
How often do you snore?*
Nearly every day    (1)
3-4 times a week   (2)
1-2 times a week  (3)
1-2 times a month   (4)
Never or nearly never (5)
Has your snoring ever bothered other people?*
Yes (1)
No (2)
Don't know (3)
Has anyone noticed that you quit breathing
during your sleep?*
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Nearly every day    (1)
3-4 times a week   (2)
1-2 times a week  (3)
1-2 times a month   (4)
Never or nearly never (5)
How often do you feel tired or fatigued after your
sleep?*
Nearly every day    (1)
3-4 times a week   (2)
1-2 times a week  (3)
1-2 times a month   (4)
Never or nearly never (5)
During your waking time, do you feel tired,
fatigued, or not up to par?*
Nearly every day    (1)
3-4 times a week   (2)
1-2 times a week  (3)
1-2 times a month   (4)
Never or nearly never (5)
Have you ever nodded off or fallen asleep while
driving a vehicle?*
Yes (1)
No (2)
How often does this occur?*
Nearly every day    (1)
3-4 times a week   (2)
1-2 times a week  (3)
1-2 times a month   (4)
Never or nearly never (5)
Do you have high blood pressure?*
Yes (1)
No (2)
Don't know (3)
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Symptoms of Autism Spectrum Disorders -
Child  PhenX Toolkit
The Childhood Autism Spectrum Test (CAST), also known
as the Social and Communication Development
Questionnaire, is a 37 question parent report instrument. It
is based on a variety of behavioral descriptions of the core
features of the autism spectrum (social impairments,
communication impairments and repetitive or stereotyped
behaviors) from the International Statistical Classification of
Diseases and Related Health Problems 10th Revision
(ICD-10) and Diagnostic and Statistical Manual of Mental
Disorders, 4th edition (DSM-IV).
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Symptoms of Autism Spectrum
Disorders - Child  PhenX Toolkit
PhenX - symptoms of autism spectrum
disorders - child protocol
Does your child join in playing games with other
children easily.*
Yes (1)
No (2)
Does s/he come up to you spontaneously for a
chat?*
Yes (1)
No (2)
Was s/he speaking by 2 years old?*
Yes (1)
No (2)
Does your child enjoy sports.*
Yes (1)
No (2)
Is it important to him/her to fit in with the peer
group?*
Yes (1)
No (2)
Does s/he appear to notice unusual details that
others miss?*
Yes (1)
No (2)
Does s/he tend to take things literally?*
Yes (1)
No (2)
When s/he was 3 years old, did s/he spend a lot
of time pretending (e.g., play-acting being a
superhero, or holding teddy's tea parties)?*
Yes (1)
No (2)
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Does s/he like to do things over and over again,
in the same way all the time?*
Yes (1)
No (2)
Does s/he find it easy to interact with other
children?*
Yes (1)
No (2)
Can s/he keep a two-way conversation going?*
Yes (1)
No (2)
Can s/he read appropriately for his/her age?*
Yes (1)
No (2)
Does s/he mostly have the same interests as
his/her peers?*
Yes (1)
No (2)
Does s/he have an interest which takes up so
much time that s/he does little else?*
Yes (1)
No (2)
Does s/he have friends, rather than just
acquaintances?*
Yes (1)
No (2)
Does s/he often bring you things s/he is
interested in to show you?*
Yes (1)
No (2)
Does s/he enjoy joking around?*
Yes (1)
No (2)
Does s/he have difficulty understanding the rules
for polite behavior?*
Yes (1)
No (2)
Does s/he appear to have an unusual memory for
details?*
Yes (1)
No (2)
Is his/her voice unusual (e.g., overly adult, flat, or
very monotonous)?*
Yes (1)
No (2)
Are people important to him/her?*
Yes (1)
No (2)
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Can s/he dress him/herself?*
Yes (1)
No (2)
Is s/he good at turn-taking in conversation?*
Yes (1)
No (2)
Does s/he play imaginatively with other children,
and engage in role-play?*
Yes (1)
No (2)
Does s/he often do or say things that are tactless
or socially inappropriate?*
Yes (1)
No (2)
Can s/he count to 50 without leaving out any
numbers?*
Yes (1)
No (2)
Does s/he make normal eye-contact?*
Yes (1)
No (2)
Does s/he have any unusual and repetitive
movements?*
Yes (1)
No (2)
Is his/her social behavior very one-sided and
always on his/her own terms?*
Yes (1)
No (2)
Does s/he sometimes say "you" or "s/he" when
s/he means "I"?*
Yes (1)
No (2)
Does s/he prefer imaginative activities such as
play-acting or story-telling, rather than numbers
or lists of facts?*
Yes (1)
No (2)
Does s/he sometimes lose the listener because
of not explaining what s/he is talking about?*
Yes (1)
No (2)
Can s/he ride a bicycle (even if with stabilizers)?*
Yes (1)
No (2)
Does s/he try to impose routines on
himself/herself, or on others, in such a way that it
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causes problems?*
Yes (1)
No (2)
Does s/he care how s/he is perceived by the rest
of the group?*
Yes (1)
No (2)
Does s/he often turn conversations to his/her
favorite subject rather than following what the
other person wants to talk about?*
Yes (1)
No (2)
Does s/he have odd or unusual phrases?*
Yes (1)
No (2)
Have teachers/health visitors ever expressed any
concerns about his/her development?*
Yes (1)
No (2)
Have teachers/health visitors ever expressed any
concerns about his/her development? If yes,
please specify*
Has s/he ever been diagnosed with any of the
following?: Language delay*
Yes (1)
No (2)
Has s/he ever been diagnosed with any of the
following?: Hyperactivity/Attention Deficit
Disorder (ADHD)*
Yes (1)
No (2)
Has s/he ever been diagnosed with any of the
following?: Hearing or visual difficulties*
Yes (1)
No (2)
Has s/he ever been diagnosed with any of the
following?: Autism Spectrum Condition, including
Asperger's Syndrome*
Yes (1)
No (2)
Has s/he ever been diagnosed with any of the
following?: A physical disability*
Yes (1)
No (2)
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Visual Function Protocol PhenX Toolkit
Self-reported vision-targeted health status is measured with
the Vision Function Questionnaire (VFQ-25). This
interviewer or self administered questionnaire consists of a
base set of 25 vision-targeted questions representing 11
vision-related constructs, plus an additional single-item
general health rating question. The VFQ-25 also includes
an appendix of additional items from the 51-item National
Eye Institute Vision Function Questionnaire version that
researchers can use to expand the scales up to 39 total
items. Scoring of the VRQ-25 yields 12 sub-scale scores
and an overall composite score.
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Visual Function Protocol PhenX
Toolkit
PhenX - visual function protocol
In general, would you say your overall health is:*
Excellent     (1)
Very Good   (2)
Good (3)
Fair (4)
Poor (5)
At the present time, would you say your eyesight
using both eyes (with glasses or contact lenses, if
you wear them) is excellent, good, fair, poor, or
very poor or are you completely blind?*
Excellent     (1)
Very Good   (2)
Good (3)
Fair (4)
Poor (5)
How much of the time do you worry about your
eyesight?*
None of the time  (1)
A little of the time     (2)
Some of the time    (3)
Most of the time   (4)
All of the time (5)
How much pain or discomfort have you had in
and around your eyes (for example, burning,
itching, or aching)? Would you say it is:*
None (1)
Mild (2)
Moderate (3)
Severe (4)
Very severe (5)
How much difficulty do you have reading ordinary
print in newspapers? Would you say you have:*
No difficulty at all    (1)
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A little difficulty  (2)
Moderate difficulty    (3)
Extreme difficulty (4)
Stopped doing this because of your
eyesight    (5)
Stopped doing this for other reasons or
not interested in doing this (6)
How much difficulty do you have doing work or
hobbies that require you to see well up close,
such as cooking, sewing, fixing things around the
house, or using hand tools? Would you say:*
No difficulty at all    (1)
A little difficulty  (2)
Moderate difficulty    (3)
Extreme difficulty (4)
Stopped doing this because of your
eyesight    (5)
Stopped doing this for other reasons or
not interested in doing this (6)
Because of your eyesight, how much difficulty do
you have finding something on a crowded shelf?*
No difficulty at all    (1)
A little difficulty  (2)
Moderate difficulty    (3)
Extreme difficulty (4)
Stopped doing this because of your
eyesight    (5)
Stopped doing this for other reasons or
not interested in doing this (6)
How much difficulty do you have reading street
signs or the names of stores?*
No difficulty at all    (1)
A little difficulty  (2)
Moderate difficulty    (3)
Extreme difficulty (4)
Stopped doing this because of your
eyesight    (5)
Stopped doing this for other reasons or
not interested in doing this (6)
Because of your eyesight, how much difficulty do
you have going down steps, stairs, or curbs in
dim light or at night?*
No difficulty at all    (1)
A little difficulty  (2)
Moderate difficulty    (3)
Extreme difficulty (4)
Stopped doing this because of your
eyesight    (5)
Stopped doing this for other reasons or
not interested in doing this (6)
Because of your eyesight, how much difficulty do
you have noticing objects off to the side while you
are walking along?*
No difficulty at all    (1)
A little difficulty  (2)
2 / 8
Visual Function Protocol PhenX Toolkit
Moderate difficulty    (3)
Extreme difficulty (4)
Stopped doing this because of your
eyesight    (5)
Stopped doing this for other reasons or
not interested in doing this (6)
Because of your eyesight, how much difficulty do
you have seeing how people react to things you
say?*
No difficulty at all    (1)
A little difficulty  (2)
Moderate difficulty    (3)
Extreme difficulty (4)
Stopped doing this because of your
eyesight    (5)
Stopped doing this for other reasons or
not interested in doing this (6)
Because of your eyesight, how much difficulty do
you have picking out and matching your own
clothes?*
No difficulty at all    (1)
A little difficulty  (2)
Moderate difficulty    (3)
Extreme difficulty (4)
Stopped doing this because of your
eyesight    (5)
Stopped doing this for other reasons or
not interested in doing this (6)
Because of your eyesight, how much difficulty do
you have visiting with people in their homes, at
parties, or in restaurants?*
No difficulty at all    (1)
A little difficulty  (2)
Moderate difficulty    (3)
Extreme difficulty (4)
Stopped doing this because of your
eyesight    (5)
Stopped doing this for other reasons or
not interested in doing this (6)
Because of your eyesight, how much difficulty do
you have going out to see movies, plays, or
sports events?*
No difficulty at all    (1)
A little difficulty  (2)
Moderate difficulty    (3)
Extreme difficulty (4)
Stopped doing this because of your
eyesight    (5)
Stopped doing this for other reasons or
not interested in doing this (6)
Are you currently driving, at least once in a
while?*
No difficulty at all    (1)
A little difficulty  (2)
Moderate difficulty    (3)
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Extreme difficulty (4)
Stopped doing this because of your
eyesight    (5)
Stopped doing this for other reasons or
not interested in doing this (6)
Have you never driven a car or have you given up
driving?*
Never drove (1)
Gave up (2)
Was that mainly because of your eyesight, mainly
for some other reason, or because of both your
eyesight and other reasons?*
Mainly eyesight     (1)
Mainly other reasons (2)
Both eyesight and other reasons (3)
How much difficulty do you have driving during
the daytime in familiar places? Would you say
you have:*
No difficulty at all   (1)
A little difficulty  (2)
Moderate difficulty    (3)
Extreme difficulty (4)
How much difficulty do you have driving at night?
Would you say you have:*
No difficulty at all    (1)
A little difficulty  (2)
Moderate difficulty    (3)
Extreme difficulty (4)
Stopped doing this because of your
eyesight    (5)
Stopped doing this for other reasons or
not interested in doing this (6)
How much difficulty do you have driving in difficult
conditions, such as in bad weather, during rush
hour, on the freeway, or in city traffic? Would you
say you have:*
No difficulty at all    (1)
A little difficulty  (2)
Moderate difficulty    (3)
Extreme difficulty (4)
Stopped doing this because of your
eyesight    (5)
Stopped doing this for other reasons or
not interested in doing this (6)
Do you accomplish less than you would like
because of your vision?*
None of the time  (1)
A little of the time     (2)
Some of the time    (3)
Most of the time   (4)
All of the time (5)
Are you limited in how long you can work or do
other activities because of your vision?*
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None of the time  (1)
A little of the time     (2)
Some of the time    (3)
Most of the time   (4)
All of the time (5)
How much does pain or discomfort in or around
your eyes, for example, burning, itching, or
aching, keep you from doing what you'd like to be
doing? Would you say:*
None of the time  (1)
A little of the time     (2)
Some of the time    (3)
Most of the time   (4)
All of the time (5)
I stay home most of the time because of my
eyesight*
Definitely false   (0)
Definitely true  (1)
Mostly true  (2)
Not sure (3)
Mostly false (4)
I feel frustrated a lot of the time because of my
eyesight*
Definitely false   (0)
Definitely true  (1)
Mostly true  (2)
Not sure (3)
Mostly false (4)
I have much less control over what I do, because
of my eyesight*
Definitely false   (0)
Definitely true  (1)
Mostly true  (2)
Not sure (3)
Mostly false (4)
Because of my eyesight, I have to rely too much
on what other people tell me*
Definitely false   (0)
Definitely true  (1)
Mostly true  (2)
Not sure (3)
Mostly false (4)
I need a lot of help from others because of my
eyesight*
Definitely false   (0)
Definitely true  (1)
Mostly true  (2)
Not sure (3)
Mostly false (4)
I worry about doing things that will embarrass
myself or others, because of my eyesight*
Definitely false   (0)
Definitely true  (1)
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Mostly true  (2)
Not sure (3)
Mostly false (4)
How would you rate your overall health, on a
scale where zero is as bad as death and 10 is
best possible health?*
0 - bad as death     (1)
9 (10)
10 - best possible health (11)
1 (2)
2 (3)
3 (4)
4 (5)
5 (6)
6 (7)
7 (8)
8 (9)
How would you rate your eyesight now (with
glasses or contact lens on, if you wear them), on
a scale of from 1 to 10, where zero means the
worst possible eyesight, as bad or worse than
being blind, and 10 means the best possible
eyesight?*
0 - as bad or worse than being blind   (1)
9 (10)
10 - best possible eyesight (11)
1 (2)
2 (3)
3 (4)
4 (5)
5 (6)
6 (7)
7 (8)
8 (9)
Wearing glasses, how much difficulty do you
have reading the small print in a telephone book,
on a medicine bottle, or on legal forms? Would
you say:*
No difficulty at all    (1)
A little difficulty  (2)
Moderate difficulty    (3)
Extreme difficulty (4)
Stopped doing this because of your
eyesight    (5)
Stopped doing this for other reasons or
not interested in doing this (6)
Because of your eyesight, how much difficulty do
you have figuring out whether bills you receive
are accurate?*
No difficulty at all    (1)
A little difficulty  (2)
Moderate difficulty    (3)
Extreme difficulty (4)
Stopped doing this because of your
eyesight    (5)
Stopped doing this for other reasons or
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not interested in doing this (6)
Because of your eyesight, how much difficulty do
you have doing things like shaving, styling your
hair, or putting on makeup?*
No difficulty at all    (1)
A little difficulty  (2)
Moderate difficulty    (3)
Extreme difficulty (4)
Stopped doing this because of your
eyesight    (5)
Stopped doing this for other reasons or
not interested in doing this (6)
Because of your eyesight, how much difficulty do
you have recognizing people you know from
across a room?*
No difficulty at all    (1)
A little difficulty  (2)
Moderate difficulty    (3)
Extreme difficulty (4)
Stopped doing this because of your
eyesight    (5)
Stopped doing this for other reasons or
not interested in doing this (6)
Because of your eyesight, how much difficulty do
you have taking part in active sports or other
outdoor activities that you enjoy (like golf,
bowling, jogging, or walking)?*
No difficulty at all    (1)
A little difficulty  (2)
Moderate difficulty    (3)
Extreme difficulty (4)
Stopped doing this because of your
eyesight    (5)
Stopped doing this for other reasons or
not interested in doing this (6)
Because of your eyesight, how much difficulty do
you have seeing and enjoying programs on TV?*
No difficulty at all    (1)
A little difficulty  (2)
Moderate difficulty    (3)
Extreme difficulty (4)
Stopped doing this because of your
eyesight    (5)
Stopped doing this for other reasons or
not interested in doing this (6)
Because of your eyesight, how much difficulty do
you have entertaining friends and family in your
home?*
No difficulty at all    (1)
A little difficulty  (2)
Moderate difficulty    (3)
Extreme difficulty (4)
Stopped doing this because of your
eyesight    (5)
Stopped doing this for other reasons or
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not interested in doing this (6)
Do you have more help from others because of
your vision?*
None of the time  (1)
A little of the time     (2)
Some of the time    (3)
Most of the time   (4)
All of the time (5)
Are you limited in how long you can work or do
other activities because of your vision?*
None of the time  (1)
A little of the time     (2)
Some of the time    (3)
Most of the time   (4)
All of the time (5)
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Caffeine Intake Protocol PhenX Toolkit
These self-administered questions can be used to inquire
about the frequency of an individual’s consumption of
beverages containing caffeine. Various time frames,
ranging from once per month to six or more times per day,
are arrayed on the response card for the respondent to use
in assessing caffeine intake. The protocol also includes
scoring procedures to convert an individual’s responses to
an estimate of caffeine intake in milligrams.
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PhenX - caffeine protocol
HOW OFTEN DID YOU DRINK Decaffeinated
coffee (Instant & brewed)?*
Never or less than 1 time per month   (1)
1-3 times per month (2)
1 time per week  (3)
2-4 times per week     (4)
5-6 times per week    (5)
1 time per day  (6)
2-3 times per day (7)
4-5 times per day    (8)
6 or more times per day (9)
HOW OFTEN DID YOU DRINK Instant coffee,
not decaffeinated (Including flavored types)?*
Never or less than 1 time per month   (1)
1-3 times per month (2)
1 time per week  (3)
2-4 times per week     (4)
5-6 times per week    (5)
1 time per day  (6)
2-3 times per day (7)
4-5 times per day    (8)
6 or more times per day (9)
HOW OFTEN DID YOU DRINK Brewed coffee,
not decaffeinated?*
Never or less than 1 time per month   (1)
1-3 times per month (2)
1 time per week  (3)
2-4 times per week     (4)
5-6 times per week    (5)
1 time per day  (6)
2-3 times per day (7)
4-5 times per day    (8)
6 or more times per day (9)
HOW OFTEN DID YOU DRINK Decaffeinated
espresso and espresso drinks (Latte, Mocha,
Americano)?*
Never or less than 1 time per month   (1)
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1-3 times per month (2)
1 time per week  (3)
2-4 times per week     (4)
5-6 times per week    (5)
1 time per day  (6)
2-3 times per day (7)
4-5 times per day    (8)
6 or more times per day (9)
HOW OFTEN DID YOU DRINK Espresso and
espresso drinks, not decaffeinated (Latte, Mocha,
Americano)?*
Never or less than 1 time per month   (1)
1-3 times per month (2)
1 time per week  (3)
2-4 times per week     (4)
5-6 times per week    (5)
1 time per day  (6)
2-3 times per day (7)
4-5 times per day    (8)
6 or more times per day (9)
HOW OFTEN DID YOU DRINK Herbal or
decaffeinated tea (Instant, bottled, and brewed)?*
Never or less than 1 time per month   (1)
1-3 times per month (2)
1 time per week  (3)
2-4 times per week     (4)
5-6 times per week    (5)
1 time per day  (6)
2-3 times per day (7)
4-5 times per day    (8)
6 or more times per day (9)
HOW OFTEN DID YOU DRINK Green tea (Not
decaffeinated-instant, bottled, and brewed)?*
Never or less than 1 time per month   (1)
1-3 times per month (2)
1 time per week  (3)
2-4 times per week     (4)
5-6 times per week    (5)
1 time per day  (6)
2-3 times per day (7)
4-5 times per day    (8)
6 or more times per day (9)
HOW OFTEN DID YOU DRINK Black tea such as
Lipton®, or Earl Grey (Not decaffeinated-instant,
bottled, and brewed)?*
Never or less than 1 time per month   (1)
1-3 times per month (2)
1 time per week  (3)
2-4 times per week     (4)
5-6 times per week    (5)
1 time per day  (6)
2-3 times per day (7)
4-5 times per day    (8)
6 or more times per day (9)
HOW OFTEN DID YOU DRINK Jolt®, Surge®,
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Mountain Dew®, Red Bull® and other highly
caffeinated sodas?*
Never or less than 1 time per month   (1)
1-3 times per month (2)
1 time per week  (3)
2-4 times per week     (4)
5-6 times per week    (5)
1 time per day  (6)
2-3 times per day (7)
4-5 times per day    (8)
6 or more times per day (9)
HOW OFTEN DID YOU DRINK Regular colas
and root beer (With caffeine, not diet)?*
Never or less than 1 time per month   (1)
1-3 times per month (2)
1 time per week  (3)
2-4 times per week     (4)
5-6 times per week    (5)
1 time per day  (6)
2-3 times per day (7)
4-5 times per day    (8)
6 or more times per day (9)
HOW OFTEN DID YOU DRINK Diet colas and
diet root beer (With caffeine)?*
Never or less than 1 time per month   (1)
1-3 times per month (2)
1 time per week  (3)
2-4 times per week     (4)
5-6 times per week    (5)
1 time per day  (6)
2-3 times per day (7)
4-5 times per day    (8)
6 or more times per day (9)
HOW OFTEN DID YOU DRINK Regular colas
and root beer (Caffeine free, not diet)?*
Never or less than 1 time per month   (1)
1-3 times per month (2)
1 time per week  (3)
2-4 times per week     (4)
5-6 times per week    (5)
1 time per day  (6)
2-3 times per day (7)
4-5 times per day    (8)
6 or more times per day (9)
HOW OFTEN DID YOU DRINK Diet colas and
diet root beer (Caffeine free)?*
Never or less than 1 time per month   (1)
1-3 times per month (2)
1 time per week  (3)
2-4 times per week     (4)
5-6 times per week    (5)
1 time per day  (6)
2-3 times per day (7)
4-5 times per day    (8)
6 or more times per day (9)
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What is your serving size for Decaffeinated coffee
(Instant & brewed)?*
small (1)
medium (2)
large (3)
What is your serving size for Instant coffee, not
decaffeinated (Including flavored types)?*
small (1)
medium (2)
large (3)
What is your serving size for Brewed coffee, not
decaffeinated?*
small (1)
medium (2)
large (3)
What is your serving size for Decaffeinated
espresso and espresso drinks (Latte, Mocha,
Americano)?*
small (1)
medium (2)
large (3)
What is your serving size for Espresso and
espresso drinks, not decaffeinated (Latte, Mocha,
Americano)?*
small (1)
medium (2)
large (3)
What is your serving size for Herbal or
decaffeinated tea (Instant, bottled, and brewed)?*
small (1)
medium (2)
large (3)
What is your serving size for Green tea (Not
decaffeinated-instant, bottled, and brewed)?*
small (1)
medium (2)
large (3)
What is your serving size for Black tea such as
Lipton®, or Earl Grey (Not decaffeinated-instant,
bottled, and brewed)?*
small (1)
medium (2)
large (3)
What is your serving size for Jolt®, Surge®,
Mountain Dew®, Red Bull® and other highly
caffeinated sodas?*
small (1)
medium (2)
large (3)
What is your serving size for Regular colas and
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root beer (With caffeine, not diet)?*
small (1)
medium (2)
large (3)
What is your serving size for Diet colas and diet
root beer (With caffeine)?*
small (1)
medium (2)
large (3)
What is your serving size for Regular colas and
root beer (Caffeine free, not diet)?*
small (1)
medium (2)
large (3)
What is your serving size for Diet colas and diet
root beer (Caffeine free)?*
small (1)
medium (2)
large (3)
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Signs of Essential Tremor Protocol PhenX
Toolkit
The Washington Heights-Inwood Genetic Study of
Essential Tremor (WHIGET) Tremor Rating Scale is a 23-
item videotaped examination that assesses rest, postural,
and kinetic tremor severity. Rated tasks include arm
extension, pouring water between cups, drinking from a
spoon, drinking from a cup, drawing Archimedes spirals,
and touching a finger to the nose. The protocol includes
scoring and classification instructions. A teaching videotape
is also available to aid in training raters.
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PhenX Toolkit
PhenX - signs of essential tremor protocol
Dominant hand*
? (0)
Right (1)
Left (2)
Hands resting in lap for 15 s*
No visible tremor   (1)
Low-amplitude/barely perceivable tremor
or intermittent tremor     (2)
Tremor is of moderate amplitude (1-2
cm) and usually present; it is clearly
oscillatory  (3)
Large-amplitude (>2 cm), violent, jerky
tremor resulting in difficulty completing
the task due to spilling or inability to hold
a pen to paper (4)
Arms held at 90? for 15 s (arm sustention)*
No visible tremor   (1)
Low-amplitude/barely perceivable tremor
or intermittent tremor     (2)
Tremor is of moderate amplitude (1-2
cm) and usually present; it is clearly
oscillatory  (3)
Large-amplitude (>2 cm), violent, jerky
tremor resulting in difficulty completing
the task due to spilling or inability to hold
a pen to paper (4)
Arms held in wing position for 15 s*
No visible tremor   (1)
Low-amplitude/barely perceivable tremor
or intermittent tremor     (2)
Tremor is of moderate amplitude (1-2
cm) and usually present; it is clearly
oscillatory  (3)
Large-amplitude (>2 cm), violent, jerky
tremor resulting in difficulty completing
the task due to spilling or inability to hold
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a pen to paper (4)
Pouring water from one cup to another*
No visible tremor   (1)
Low-amplitude/barely perceivable tremor
or intermittent tremor     (2)
Tremor is of moderate amplitude (1-2
cm) and usually present; it is clearly
oscillatory  (3)
Large-amplitude (>2 cm), violent, jerky
tremor resulting in difficulty completing
the task due to spilling or inability to hold
a pen to paper (4)
Bring a spoon of water from lap level up to mouth
and back again; repeat 7 additional times*
No visible tremor   (1)
Low-amplitude/barely perceivable tremor
or intermittent tremor     (2)
Tremor is of moderate amplitude (1-2
cm) and usually present; it is clearly
oscillatory  (3)
Large-amplitude (>2 cm), violent, jerky
tremor resulting in difficulty completing
the task due to spilling or inability to hold
a pen to paper (4)
Drinking water from a full glass; repeat 7 times
with each hand*
No visible tremor   (1)
Low-amplitude/barely perceivable tremor
or intermittent tremor     (2)
Tremor is of moderate amplitude (1-2
cm) and usually present; it is clearly
oscillatory  (3)
Large-amplitude (>2 cm), violent, jerky
tremor resulting in difficulty completing
the task due to spilling or inability to hold
a pen to paper (4)
Finger-nose-finger on right - 8 times*
No visible tremor   (1)
Low-amplitude/barely perceivable tremor
or intermittent tremor     (2)
Tremor is of moderate amplitude (1-2
cm) and usually present; it is clearly
oscillatory  (3)
Large-amplitude (>2 cm), violent, jerky
tremor resulting in difficulty completing
the task due to spilling or inability to hold
a pen to paper (4)
Finger-nose-finger on left 8 times*
No visible tremor   (1)
Low-amplitude/barely perceivable tremor
or intermittent tremor     (2)
Tremor is of moderate amplitude (1-2
cm) and usually present; it is clearly
oscillatory  (3)
Large-amplitude (>2 cm), violent, jerky
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tremor resulting in difficulty completing
the task due to spilling or inability to hold
a pen to paper (4)
Open and close right hand 10 times*
No visible tremor   (1)
Low-amplitude/barely perceivable tremor
or intermittent tremor     (2)
Tremor is of moderate amplitude (1-2
cm) and usually present; it is clearly
oscillatory  (3)
Large-amplitude (>2 cm), violent, jerky
tremor resulting in difficulty completing
the task due to spilling or inability to hold
a pen to paper (4)
Open and close left hand 10 times*
No visible tremor   (1)
Low-amplitude/barely perceivable tremor
or intermittent tremor     (2)
Tremor is of moderate amplitude (1-2
cm) and usually present; it is clearly
oscillatory  (3)
Large-amplitude (>2 cm), violent, jerky
tremor resulting in difficulty completing
the task due to spilling or inability to hold
a pen to paper (4)
Alternatively pronate and supinate right hand 10
times*
No visible tremor   (1)
Low-amplitude/barely perceivable tremor
or intermittent tremor     (2)
Tremor is of moderate amplitude (1-2
cm) and usually present; it is clearly
oscillatory  (3)
Large-amplitude (>2 cm), violent, jerky
tremor resulting in difficulty completing
the task due to spilling or inability to hold
a pen to paper (4)
Alternatively pronate and supinate left hand 10
times*
No visible tremor   (1)
Low-amplitude/barely perceivable tremor
or intermittent tremor     (2)
Tremor is of moderate amplitude (1-2
cm) and usually present; it is clearly
oscillatory  (3)
Large-amplitude (>2 cm), violent, jerky
tremor resulting in difficulty completing
the task due to spilling or inability to hold
a pen to paper (4)
Tap right foot 10 times*
No visible tremor   (1)
Low-amplitude/barely perceivable tremor
or intermittent tremor     (2)
Tremor is of moderate amplitude (1-2
cm) and usually present; it is clearly
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oscillatory  (3)
Large-amplitude (>2 cm), violent, jerky
tremor resulting in difficulty completing
the task due to spilling or inability to hold
a pen to paper (4)
Tap left foot 10 times*
No visible tremor   (1)
Low-amplitude/barely perceivable tremor
or intermittent tremor     (2)
Tremor is of moderate amplitude (1-2
cm) and usually present; it is clearly
oscillatory  (3)
Large-amplitude (>2 cm), violent, jerky
tremor resulting in difficulty completing
the task due to spilling or inability to hold
a pen to paper (4)
Jaw at rest for 5 s*
No visible tremor   (1)
Low-amplitude/barely perceivable tremor
or intermittent tremor     (2)
Tremor is of moderate amplitude (1-2
cm) and usually present; it is clearly
oscillatory  (3)
Large-amplitude (>2 cm), violent, jerky
tremor resulting in difficulty completing
the task due to spilling or inability to hold
a pen to paper (4)
Mouth open for 5 s*
No visible tremor   (1)
Low-amplitude/barely perceivable tremor
or intermittent tremor     (2)
Tremor is of moderate amplitude (1-2
cm) and usually present; it is clearly
oscillatory  (3)
Large-amplitude (>2 cm), violent, jerky
tremor resulting in difficulty completing
the task due to spilling or inability to hold
a pen to paper (4)
Sustained phonation: first "AAA" for 10 s, then
"EEE"*
No visible tremor   (1)
Low-amplitude/barely perceivable tremor
or intermittent tremor     (2)
Tremor is of moderate amplitude (1-2
cm) and usually present; it is clearly
oscillatory  (3)
Large-amplitude (>2 cm), violent, jerky
tremor resulting in difficulty completing
the task due to spilling or inability to hold
a pen to paper (4)
Head while patient is seated for 10 s*
No visible tremor   (1)
Low-amplitude/barely perceivable tremor
or intermittent tremor     (2)
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Tremor is of moderate amplitude (1-2
cm) and usually present; it is clearly
oscillatory  (3)
Large-amplitude (>2 cm), violent, jerky
tremor resulting in difficulty completing
the task due to spilling or inability to hold
a pen to paper (4)
Service comment*
Drawing 2 Archimedes spirals with each hand
(subject should make at least 6 full circular
motions)*
No visible tremor   (1)
Low-amplitude/barely perceivable tremor
or intermittent tremor     (2)
Tremor is of moderate amplitude (1-2
cm) and usually present; it is clearly
oscillatory  (3)
Large-amplitude (>2 cm), violent, jerky
tremor resulting in difficulty completing
the task due to spilling or inability to hold
a pen to paper (4)
Hands hanging at sides for 10 s; videotape legs
too*
Walking 20 ft and turning*
Tandem gait for 10 steps*
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Spine and Femur Bone Density by Dual-Energy
X-ray Absorptiometry Protocol  PhenX Toolkit
The Framingham Osteoporosis Study Generation 3
Musculoskeletal Exam includes instructions for preparing
the sample person for the scan, performing quality
assurance procedures, and performing the scan of the hip
and spine.
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Spine and Femur Bone Density by
Dual-Energy X-ray Absorptiometry
Protocol  PhenX Toolkit
Dual X-ray Absorptometry Femur Bone
Density
Are you currently pregnant?*
Yes (1)
No (2)
Don't know (3)
For women <55 years old: Have you had a
hysterectomy [removal of the uterus] or tubal
ligation [tubes tied]?*
Yes
No
Have you had a hysterectomy (womb removed)?*
Yes
No
Last menstrual period start date*
Pregnancy Test Required?*
Yes
No
If yes, Result:*
positive (1)
negative (2)
Have you had sexual intercourse in the past
seven days?*
Yes
No
Did you use one of the following forms of birth
control each time you had sexual intercourse in
the past seven days?
Oral contraceptives (the pill) Male condom
Female c
ondom Injection (Depo-Provera, 
Lunelle) Diaphragm with spermicide Cervical cap
wit
h spermicide Contraceptive Patch 
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Vaginal contraceptive ring Post-coital contraceptiv
es, taken within 72 hours of 
intercourse (Preven, Plan B) Implant (Norplant)
IUD
(Intrauterine Device) Male surgical 
sterilization*
Yes
No
Make and model name of the dual-energy x-ray
absorptiometry (DXA) instrument*
Femur scan image name (ID)*
Spine scan image name (ID)*
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Discrimination Protocol PhenX Toolkit
The Major Experiences and Everyday Discrimination
Scales include 19 interviewer-administered, yes-or-no
questions. The Major Experiences subscale includes 9
questions about employment, housing, and education; the
Everyday Discrimination subscale includes 10 questions
about interactions with other people, including courtesy,
respect, and harassment. A follow-up question to yes
responses is also administered to probe about the reason
for the discrimination as being related to race, gender, age,
religion, disability, and so forth.
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PhenX - discrimination protocol
At any time in your life, have you ever been
unfairly fired?*
Yes
No
If "yes" follow-up with: What do you think was the
main reason for this experience?*
Your ancestry or national origin     (1)
A physical disability     (10)
Other (11)
Your gender  (2)
Your race   (3)
Your age   (4)
Your religion  (5)
Your height or weight    (6)
Your shade of skin color   (7)
Your sexual orientation   (8)
Your education or income level  (9)
For unfair reasons, have you ever not been hired
for a job?*
Yes
No
Have you ever been unfairly denied a
promotion?*
Yes
No
Have you ever been unfairly stopped, searched,
questioned, physically threatened or abused by
the police?*
Yes
No
Have you ever been unfairly discouraged by a
teacher or advisor from continuing your
education?*
Yes
1 / 3
No
Have you ever been unfairly prevented from
moving into a neighborhood because the landlord
or a realtor refused to sell or rent you a house or
apartment?*
Yes
No
Have you ever moved into a neighborhood where
neighbors made life difficult for you or your
family?*
Yes
No
Have you ever been unfairly denied a bank loan?*
Yes
No
Have you ever received service from someone
such as a plumber or car mechanic that was
worse than what other people get?*
Yes
No
In your day-to-day life, how often have any of the
following things happened to you? You have been
treated with less courtesy than other people*
Four or more times     (1)
Two or more times     (2)
Once (3)
Never (4)
In your day-to-day life, how often have any of the
following things happened to you? You have been
treated with less respect than other people*
Four or more times     (1)
Two or more times     (2)
Once (3)
Never (4)
In your day-to-day life, how often have any of the
following things happened to you? You have
received poorer service than other people at
restaurants or stores*
Four or more times     (1)
Two or more times     (2)
Once (3)
Never (4)
In your day-to-day life, how often have any of the
following things happened to you? People have
acted as if they think you are not smart*
Four or more times     (1)
Two or more times     (2)
Once (3)
Never (4)
In your day-to-day life, how often have any of the
following things happened to you? People have
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acted as if they are afraid of you*
Four or more times     (1)
Two or more times     (2)
Once (3)
Never (4)
In your day-to-day life, how often have any of the
following things happened to you? People have
acted as if they think you are dishonest*
Four or more times     (1)
Two or more times     (2)
Once (3)
Never (4)
In your day-to-day life, how often have any of the
following things happened to you? People have
acted as if they're better than you are*
Four or more times     (1)
Two or more times     (2)
Once (3)
Never (4)
In your day-to-day life, how often have any of the
following things happened to you? You have been
called names or insulted*
Four or more times     (1)
Two or more times     (2)
Once (3)
Never (4)
In your day-to-day life, how often have any of the
following things happened to you? You have been
threatened or harassed*
Four or more times     (1)
Two or more times     (2)
Once (3)
Never (4)
In your day-to-day life, how often have any of the
following things happened to you? You have been
followed around in stores*
Four or more times     (1)
Two or more times     (2)
Once (3)
Never (4)
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Social Isolation Protocol PhenX Toolkit
The UCLA Loneliness Scale includes 20 questions used to
assess how lonely the respondent feels. Each question
begins with the statement "How often do you feel" followed
by a positive or negative description of social interactions
with others. The respondent is asked to indicate the
frequency he/she feels that way (never, rarely, sometimes,
always) for each question.
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PhenX - social isolation protocol
How often do you feel that you are in tune with
the people around you?*
Never (1)
Rarely   (2)
Sometimes  (3)
Always (4)
How often do you feel that you lack
companionship?*
Never (1)
Rarely   (2)
Sometimes  (3)
Always (4)
How often do you feel that there is no one you
can turn to?*
Never (1)
Rarely   (2)
Sometimes  (3)
Always (4)
How often do you feel alone?*
Never (1)
Rarely   (2)
Sometimes  (3)
Always (4)
How often do you feel part of a group of friends?*
Never (1)
Rarely   (2)
Sometimes  (3)
Always (4)
How often do you feel that you have a lot in
common with the people around you?*
Never (1)
Rarely   (2)
Sometimes  (3)
Always (4)
How often do you feel that you are no longer
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close to anyone?*
Never (1)
Rarely   (2)
Sometimes  (3)
Always (4)
How often do you feel that your interests and
ideas are not shared by those around you?*
Never (1)
Rarely   (2)
Sometimes  (3)
Always (4)
How often do you feel outgoing and friendly?*
Never (1)
Rarely   (2)
Sometimes  (3)
Always (4)
How often do you feel close to people?*
Never (1)
Rarely   (2)
Sometimes  (3)
Always (4)
How often do you feel left out?*
Never (1)
Rarely   (2)
Sometimes  (3)
Always (4)
How often do you feel that your relationships with
others are not meaningful?*
Never (1)
Rarely   (2)
Sometimes  (3)
Always (4)
How often do you feel that no one really knows
you well?*
Never (1)
Rarely   (2)
Sometimes  (3)
Always (4)
How often do you feel isolated from others?*
Never (1)
Rarely   (2)
Sometimes  (3)
Always (4)
How often do you feel you can find
companionship when you want it?*
Never (1)
Rarely   (2)
Sometimes  (3)
Always (4)
How often do you feel that there are people who
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really understand you?*
Never (1)
Rarely   (2)
Sometimes  (3)
Always (4)
How often do you feel shy?*
Never (1)
Rarely   (2)
Sometimes  (3)
Always (4)
How often do you feel that people are around you
but not with you?*
Never (1)
Rarely   (2)
Sometimes  (3)
Always (4)
How often do you feel that there are people you
can talk to?*
Never (1)
Rarely   (2)
Sometimes  (3)
Always (4)
How often do you feel that there are people you
can turn to?*
Never (1)
Rarely   (2)
Sometimes  (3)
Always (4)
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General Self-Efficacy - Adult Protocol
PhenX Toolkit
This is a 10-item self-administered set of questions used to
assess self-efficacy.
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General Self-Efficacy - Adult Protocol
PhenX Toolkit
PhenX - general self-efficacy - adult
protocol
I can always manage to solve difficult problems if
I try hard enough.*
Not at all true  (1)
Hardly true (2)
Moderately true  (3)
Exactly true (4)
If someone opposes me, I can find the means
and ways to get what I want.*
Not at all true  (1)
Hardly true (2)
Moderately true  (3)
Exactly true (4)
It is easy for me to stick to my aims and
accomplish my goals.*
Not at all true  (1)
Hardly true (2)
Moderately true  (3)
Exactly true (4)
I am confident that I could deal efficiently with
unexpected events.*
Not at all true  (1)
Hardly true (2)
Moderately true  (3)
Exactly true (4)
Thanks to my resourcefulness, I know how to
handle unforeseen situations.*
Not at all true  (1)
Hardly true (2)
Moderately true  (3)
Exactly true (4)
I can solve most problems if I invest the
necessary effort.*
Not at all true  (1)
Hardly true (2)
Moderately true  (3)
Exactly true (4)
I can remain calm when facing difficulties
because I can rely on my coping abilities.*
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Not at all true  (1)
Hardly true (2)
Moderately true  (3)
Exactly true (4)
When I am confronted with a problem, I can
usually find several solutions.*
Not at all true  (1)
Hardly true (2)
Moderately true  (3)
Exactly true (4)
If I am in trouble, I can usually think of a solution.*
Not at all true  (1)
Hardly true (2)
Moderately true  (3)
Exactly true (4)
I can usually handle whatever comes my way.*
Not at all true  (1)
Hardly true (2)
Moderately true  (3)
Exactly true (4)
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Psychopathy Protocol PhenX Toolkit
The Triarchic Psychopathy Measure (TriPM) is a 58-item
self-report questionnaire designed to measure psychopathy
in terms of three distinct phenotypic constructs (Patrick,
Fowles, & Krueger, 2009): boldness, defined as the nexus
of high dominance, low anxiousness, and
venturesomeness; meanness, reflecting tendencies toward
callousness, cruelty, predatory aggression, and excitement
seeking; and disinhibition, reflecting tendencies toward
impulsiveness, irresponsibility, oppositionality, and
anger/hostility. Each construct is measured by a separate
subscale. Subscale scores are summed to yield a total
psychopathy score.
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Psychopathy Protocol PhenX Toolkit
PhenX - psychopathy protocol
I'm optimistic more often than not.*
True (1)
Somewhat true (2)
Somewhat false (3)
False (4)
How other people feel is important to me.*
True (1)
Somewhat true (2)
Somewhat false (3)
False (4)
I often act on immediate needs.*
True (1)
Somewhat true (2)
Somewhat false (3)
False (4)
I have no strong desire to parachute out of an
airplane.*
True (1)
Somewhat true (2)
Somewhat false (3)
False (4)
I've often missed things I promised to attend.*
True (1)
Somewhat true (2)
Somewhat false (3)
False (4)
I would enjoy being in a high-speed chase.*
True (1)
Somewhat true (2)
Somewhat false (3)
False (4)
I am well-equipped to deal with stress.*
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True (1)
Somewhat true (2)
Somewhat false (3)
False (4)
I don't mind if someone I dislike gets hurt.*
True (1)
Somewhat true (2)
Somewhat false (3)
False (4)
My impulsive decisions have caused problems
with loved ones.*
True (1)
Somewhat true (2)
Somewhat false (3)
False (4)
I get scared easily.*
True (1)
Somewhat true (2)
Somewhat false (3)
False (4)
I sympathize with others problems.*
True (1)
Somewhat true (2)
Somewhat false (3)
False (4)
I have missed work without bothering to call in.*
True (1)
Somewhat true (2)
Somewhat false (3)
False (4)
I'm a born leader.*
True (1)
Somewhat true (2)
Somewhat false (3)
False (4)
I enjoy a good physical fight.*
True (1)
Somewhat true (2)
Somewhat false (3)
False (4)
I jump into things without thinking.*
True (1)
Somewhat true (2)
Somewhat false (3)
False (4)
I have a hard time making things turn out the way
I want.*
True (1)
Somewhat true (2)
Somewhat false (3)
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False (4)
I return insults.*
True (1)
Somewhat true (2)
Somewhat false (3)
False (4)
I've gotten in trouble because I missed too much
school.*
True (1)
Somewhat true (2)
Somewhat false (3)
False (4)
I have a knack for influencing people.*
True (1)
Somewhat true (2)
Somewhat false (3)
False (4)
It doesn't bother me to see someone else in
pain.*
True (1)
Somewhat true (2)
Somewhat false (3)
False (4)
I have good control over myself.*
True (1)
Somewhat true (2)
Somewhat false (3)
False (4)
I function well in new situations, even when
unprepared.*
True (1)
Somewhat true (2)
Somewhat false (3)
False (4)
I enjoy pushing people around sometimes.*
True (1)
Somewhat true (2)
Somewhat false (3)
False (4)
I have taken money from someone's purse or
wallet without asking.*
True (1)
Somewhat true (2)
Somewhat false (3)
False (4)
I don't think of myself as talented*
True (1)
Somewhat true (2)
Somewhat false (3)
False (4)
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I taunt people just to stir things up.*
True (1)
Somewhat true (2)
Somewhat false (3)
False (4)
People often abuse my trust.*
True (1)
Somewhat true (2)
Somewhat false (3)
False (4)
I'm afraid of far fewer things than most people.*
True (1)
Somewhat true (2)
Somewhat false (3)
False (4)
I don't see any point in worrying if what I do hurts
someone else.*
True (1)
Somewhat true (2)
Somewhat false (3)
False (4)
I keep appointments I make.*
True (1)
Somewhat true (2)
Somewhat false (3)
False (4)
I often get bored quickly and lose interest.*
True (1)
Somewhat true (2)
Somewhat false (3)
False (4)
I can get over things that would traumatize
others.*
True (1)
Somewhat true (2)
Somewhat false (3)
False (4)
I am sensitive to the feelings of others.*
True (1)
Somewhat true (2)
Somewhat false (3)
False (4)
I have conned people to get money from them.*
True (1)
Somewhat true (2)
Somewhat false (3)
False (4)
It worries me to go into an unfamiliar situation
without knowing all the details.*
True (1)
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Somewhat true (2)
Somewhat false (3)
False (4)
I don't have much sympathy for people.*
True (1)
Somewhat true (2)
Somewhat false (3)
False (4)
I get in trouble for not considering the
consequences of my actions.*
True (1)
Somewhat true (2)
Somewhat false (3)
False (4)
I can convince people to do what I want.*
True (1)
Somewhat true (2)
Somewhat false (3)
False (4)
For me, honesty really is the best policy.*
True (1)
Somewhat true (2)
Somewhat false (3)
False (4)
I've injured people to see them in pain.*
True (1)
Somewhat true (2)
Somewhat false (3)
False (4)
I don't like to take the lead in groups.*
True (1)
Somewhat true (2)
Somewhat false (3)
False (4)
I sometimes insult people on purpose to get a
reaction from them.*
True (1)
Somewhat true (2)
Somewhat false (3)
False (4)
I have taken items from a store without paying for
them.*
True (1)
Somewhat true (2)
Somewhat false (3)
False (4)
It's easy to embarrass me.*
True (1)
Somewhat true (2)
Somewhat false (3)
False (4)
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Things are more fun if a little danger is involved.*
True (1)
Somewhat true (2)
Somewhat false (3)
False (4)
I have a hard time waiting patiently for things I
want.*
True (1)
Somewhat true (2)
Somewhat false (3)
False (4)
I stay away from physical danger as much as I
can.*
True (1)
Somewhat true (2)
Somewhat false (3)
False (4)
I don't care much if what I do hurts others.*
True (1)
Somewhat true (2)
Somewhat false (3)
False (4)
I have lost a friend because of irresponsible
things I've done.*
True (1)
Somewhat true (2)
Somewhat false (3)
False (4)
I don't stack up well against most others.*
True (1)
Somewhat true (2)
Somewhat false (3)
False (4)
Others have told me they are concerned about
my lack of self-control.*
True (1)
Somewhat true (2)
Somewhat false (3)
False (4)
It's easy for me to relate to other people's
emotions.*
True (1)
Somewhat true (2)
Somewhat false (3)
False (4)
I have robbed someone.*
True (1)
Somewhat true (2)
Somewhat false (3)
False (4)
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I never worry about making a fool of myself with
others.*
True (1)
Somewhat true (2)
Somewhat false (3)
False (4)
It doesn't bother me when people around me are
hurting.*
True (1)
Somewhat true (2)
Somewhat false (3)
False (4)
I have had problems at work because I was
irresponsible.*
True (1)
Somewhat true (2)
Somewhat false (3)
False (4)
I'm not very good at influencing people.*
True (1)
Somewhat true (2)
Somewhat false (3)
False (4)
I have stolen something out of a vehicle.*
True (1)
Somewhat true (2)
Somewhat false (3)
False (4)
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Diabetic Peripheral Neuropathy Protocol
PhenX Toolkit
The Michigan Neuropathy Screening Instrument (MNSI)
consists of 15 yes-or-no questions that assess feelings in
the legs and feet (distal symmetric polyneuropathy). The
MNSI also includes a clinical examination that is not
included here.
ODM derived from: https://cde.nlm.nih.gov
Primary source: https://www.phenxtoolkit.org/
Recent publication: Hendershot, T., Pan, H., Haines, J.,
Harlan, W.R., Marazita, M.L., McCarty, C.A., Ramos, E.M.,
and Hamilton, C.M. (2015) Using the PhenX toolkit to add
standard measures to a study. Curr. Protoc. Hum. Genet.
86:1.21.1-1.21.17. doi: 10.1002/0471142905.hg0121s86
Permission to publish granted by
Carol M. Hamilton.
All rights reserved. Please visit https://medical-data-
models.org/forms/14751
Diabetic Peripheral Neuropathy
Protocol PhenX Toolkit
PhenX - diabetic peripheral neuropathy
protocol
Are your legs and/or feet numb?*
Yes
No
Do you ever have any burning pain in your legs
and/or feet?*
Yes
No
Are your feet too sensitive to touch?*
Yes
No
Do you get muscle cramps in your legs and/or
feet?*
Yes
No
Do you ever have any prickling feelings in your
legs or feet?*
Yes
No
Does it hurt when the bed covers touch your
skin?*
Yes
No
When you get into the tub or shower, are you able
to tell the hot water from the cold water?*
Yes
No
Have you ever had an open sore on your foot?*
Yes
No
Has your doctor ever told you that you have
diabetic neuropathy?*
Yes
No
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Do you feel weak all over most of the time?*
Yes
No
Are your symptoms worse at night?*
Yes
No
Do your legs hurt when you walk?*
Yes
No
Are you able to sense your feet when you walk?*
Yes
No
Is the skin on your feet so dry that it cracks
open?*
Yes
No
Have you ever had an amputation?*
Yes
No
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Dietary Supplements Use Protocol PhenX
Toolkit
These self-administered questions ask how many times per
week a supplement was taken and for how many years.
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Dietary Supplements Use Protocol
PhenX Toolkit
PhenX - dietary supplements protocol
DID YOU TAKE ANY DIETARY SUPPLEMENTS
DURING THE PAST YEAR, AT LEAST ONCE A
WEEK?*
Yes
No
HOW OFTEN did you take Regular One-a-Day
type, Centrum® or Thera-type MULTIPLE
VITAMINS?*
1 to 3 times a week   (1)
4 to 6 times a week (2)
once a day (3)
HOW MANY YEARS did you take Regular One-
a-Day type, Centrum® or Thera-type MULTIPLE
VITAMINS?*
1 year or less    (1)
2 to 4 years  (2)
5 to 9 years (3)
10 years or more (4)
HOW OFTEN did you take B-complex or Stress-
tab type MULTIPLE VITAMINS?*
1 to 3 times a week   (1)
4 to 6 times a week (2)
once a day (3)
HOW MANY YEARS did you take B-complex or
Stress-tab type MULTIPLE VITAMINS?*
1 year or less    (1)
2 to 4 years  (2)
5 to 9 years (3)
10 years or more (4)
HOW OFTEN did you take Vitamin C?*
1 to 3 times a week   (1)
4 to 6 times a week (2)
once a day (3)
HOW MANY YEARS did you take Vitamin C?*
1 year or less    (1)
2 to 4 years  (2)
5 to 9 years (3)
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10 years or more (4)
HOW OFTEN did you take Vitamin E?*
1 to 3 times a week   (1)
4 to 6 times a week (2)
once a day (3)
HOW MANY YEARS did you take Vitamin E?*
1 year or less    (1)
2 to 4 years  (2)
5 to 9 years (3)
10 years or more (4)
HOW OFTEN did you take Folic acid, Folate?*
1 to 3 times a week   (1)
4 to 6 times a week (2)
once a day (3)
HOW MANY YEARS did you take Folic acid,
Folate?*
1 year or less    (1)
2 to 4 years  (2)
5 to 9 years (3)
10 years or more (4)
HOW OFTEN did you take Vitamin B-12?*
1 to 3 times a week   (1)
4 to 6 times a week (2)
once a day (3)
HOW MANY YEARS did you take Vitamin B-12?*
1 year or less    (1)
2 to 4 years  (2)
5 to 9 years (3)
10 years or more (4)
HOW OFTEN did you take Vitamin B-6?*
1 to 3 times a week   (1)
4 to 6 times a week (2)
once a day (3)
HOW MANY YEARS did you take Vitamin B-6?*
1 year or less    (1)
2 to 4 years  (2)
5 to 9 years (3)
10 years or more (4)
HOW OFTEN did you take Calcium, alone or
combined with something else such as in a bone
health supplement OR in an antacid?*
1 to 3 times a week   (1)
4 to 6 times a week (2)
once a day (3)
HOW MANY YEARS did you take Calcium, alone
or combined with something else such as in a
bone health supplement OR in an antacid?*
1 year or less    (1)
2 to 4 years  (2)
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5 to 9 years (3)
10 years or more (4)
HOW OFTEN did you take Vitamin D, alone?*
1 to 3 times a week   (1)
4 to 6 times a week (2)
once a day (3)
HOW MANY YEARS did you take Vitamin D,
alone?*
1 year or less    (1)
2 to 4 years  (2)
5 to 9 years (3)
10 years or more (4)
HOW OFTEN did you take Selenium?*
1 to 3 times a week   (1)
4 to 6 times a week (2)
once a day (3)
HOW MANY YEARS did you take Selenium?*
1 year or less    (1)
2 to 4 years  (2)
5 to 9 years (3)
10 years or more (4)
HOW OFTEN did you take Iron?*
1 to 3 times a week   (1)
4 to 6 times a week (2)
once a day (3)
HOW MANY YEARS did you take Iron?*
1 year or less    (1)
2 to 4 years  (2)
5 to 9 years (3)
10 years or more (4)
HOW OFTEN did you take Zinc?*
1 to 3 times a week   (1)
4 to 6 times a week (2)
once a day (3)
HOW MANY YEARS did you take Zinc?*
1 year or less    (1)
2 to 4 years  (2)
5 to 9 years (3)
10 years or more (4)
HOW OFTEN did you take Fish oil or omega-3
Fatty acids?*
1 to 3 times a week   (1)
4 to 6 times a week (2)
once a day (3)
HOW MANY YEARS did you take Fish oil or
omega-3 Fatty acids?*
1 year or less    (1)
2 to 4 years  (2)
5 to 9 years (3)
10 years or more (4)
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HOW OFTEN did you take Flaxseed?*
1 to 3 times a week   (1)
4 to 6 times a week (2)
once a day (3)
HOW MANY YEARS did you take Flaxseed?*
1 year or less    (1)
2 to 4 years  (2)
5 to 9 years (3)
10 years or more (4)
HOW OFTEN did you take Garlic, as a pill, tablet,
or capsule?*
1 to 3 times a week   (1)
4 to 6 times a week (2)
once a day (3)
HOW MANY YEARS did you take Garlic, as a pill,
tablet, or capsule?*
1 year or less    (1)
2 to 4 years  (2)
5 to 9 years (3)
10 years or more (4)
HOW OFTEN did you take Glucosamine, alone or
combined with something else?*
1 to 3 times a week   (1)
4 to 6 times a week (2)
once a day (3)
HOW MANY YEARS did you take Glucosamine,
alone or combined with something else?*
1 year or less    (1)
2 to 4 years  (2)
5 to 9 years (3)
10 years or more (4)
HOW OFTEN did you take Coenzyme Q-10?*
1 to 3 times a week   (1)
4 to 6 times a week (2)
once a day (3)
HOW MANY YEARS did you take Coenzyme Q-
10?*
1 year or less    (1)
2 to 4 years  (2)
5 to 9 years (3)
10 years or more (4)
HOW OFTEN did you take Saw Palmetto?*
1 to 3 times a week   (1)
4 to 6 times a week (2)
once a day (3)
HOW MANY YEARS did you take Saw
Palmetto?*
1 year or less    (1)
2 to 4 years  (2)
5 to 9 years (3)
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10 years or more (4)
When you took VITAMIN C, how much did you
usually take?*
250 mg or less  (1)
300 to 500 mg  (2)
600 to 1000 mg   (3)
More than 1000 mg (4)
When you took VITAMIN E, how much did you
usually take?*
200 IU or less    (1)
250 to 400 IU  (2)
450 to 1000 IU (3)
More than 1000 IU (4)
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Exogenous Female Hormone Use Protocol
PhenX Toolkit
Female respondents self-report the use of estrogen and
progesterone, including the duration and dose.
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Exogenous Female Hormone Use
Protocol PhenX Toolkit
PhenX - exogenous female hormone use
protocol
Have you ever taken estrogen (female hormones)
for symptoms of menopause (the change of life)
or for other reasons?*
No (1)
Yes, and I am currently taking estrogens
(2)
Yes, but I am no longer taking estrogens
(3)
The most frequently used estrogen is oral
Premarin®. Have you ever taken Premarin® by
mouth (as pills)?*
Yes
No
At what age did you first take Premarin®?*
Before age 45     (1)
45-49    (2)
50-54 (3)
55-59 (4)
60-64   (5)
65-69   (6)
70 or older (7)
At what age did you last take Premarin®?*
currently taking   (1)
Before age 45     (2)
45-49    (3)
50-54 (4)
55-59 (5)
60-64   (6)
65-69   (7)
70 or older (8)
How many years in total did you take Premarin®
(exclude those periods when you temporarily
stopped)?*
Which premarin pill did you use the longest*
Green-0.3 mg     (1)
Brown/Red-0.625 mg (2)
White-0.9 mg    (3)
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Yellow/Orange-1.25 mg   (4)
Purple-2.5 mg (5)
Five commonly used doses of Premarin® can be
distinguished by the color of the pill. Please
indicate any you have ever used and the one you
used for the longest period. Green (0.3 ).*
Yes
No
Five commonly used doses of Premarin® can be
distinguished by the color of the pill. Please
indicate any you have ever used and the one you
used for the longest period. Brown/Red (0.625
mg)
Yes
No
Five commonly used doses of Premarin® can be
distinguished by the color of the pill. Please
indicate any you have ever used and the one you
used for the longest period. White (0.9 mg)
Yes
No
Five commonly used doses of Premarin® can be
distinguished by the color of the pill. Please
indicate any you have ever used and the one you
used for the longest period. Yellow/Orange (1.25
mg)
Yes
No
Five commonly used doses of Premarin® can be
distinguished by the color of the pill. Please
indicate any you have ever used and the one you
used for the longest period. Purple (2.5 mg)
Yes
No
Estrogen administration method
By mouth (1)
By injection  (2)
By patch or implant  (3)
By vaginal cream or suppository (4)
Have you ever used estrogen other than
Premarin® pills? Estrogen by mouth?*
Yes
No
Have you ever used estrogen other than
Premarin® pills? Estrogen injection?
Yes
No
Have you ever used estrogen other than
Premarin® pills? by patch or implant?
Yes
No
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Have you ever used estrogen other than
Premarin® pills? Estrogen vaginal cream or
suppository?
Yes
No
At what age did you first use estrogens other than
Premarin® pills?*
Before age 45     (1)
45-49    (2)
50-54 (3)
55-59 (4)
60-64   (5)
65-69   (6)
70 or older (7)
At what age did you last use estrogens other than
Premarin® pills?*
currently taking   (1)
Before age 45     (2)
45-49    (3)
50-54 (4)
55-59 (5)
60-64   (6)
65-69   (7)
70 or older (8)
How many years in total did you take estrogens
other than Premarin® pills (exclude any time
when you temporarily stopped)?*
less than 1 year (1)
1-2 (2)
3-5 (3)
6-9 (4)
10-14 (5)
15-19 (6)
20 years or more (7)
Sometimes another type of female hormone,
progesterone (or progestin), is given for
symptoms of menopause, either alone or in
combination with estrogen. The most frequently
used progestin is Provera®
(medroxyprogestoerone acetate). Have you ever
used progesterone or a progestin?*
No (1)
Provera only   (2)
Another type only   (3)
Provera and another type only  (4)
Yes, but don't know type (5)
At what age did you first take progesterone or a
progestin?*
Before age 45     (1)
45-49    (2)
50-54 (3)
55-59 (4)
60-64   (5)
65-69   (6)
70 or older (7)
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At what age did you last take progesterone or a
progestin?*
currently taking   (1)
Before age 45     (2)
45-49    (3)
50-54 (4)
55-59 (5)
60-64   (6)
65-69   (7)
70 or older (8)
How many years in total did you take
progesterone or a progestin (excluding any time
when you temporarily stopped)?*
less than 1 year (1)
1-2 (2)
3-5 (3)
6-9 (4)
10-14 (5)
15-19 (6)
20 years or more (7)
If you used Provera®, what was your usual
dose?*
Did not use Provera® (1)
2.5 mg per day (2)
5.0 mg per day (3)
10 mg per day (4)
20 mg per day (5)
Another dose (6)
Don't know (7)
When using progestin or progesterone, for how
many days each month would you usually take
it?*
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Arrhythmia (Atrial and Ventricular) Protocol
PhenX Toolkit
Measure to assess presence of arrhythmias through
collection of personal history, treatments and procedures,
medication usage, and administration of an
electrocardiograph (ECG).
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Arrhythmia (Atrial and Ventricular)
Protocol PhenX Toolkit
Items
Have you been told you have/had a heart rhythm
problem called atrial fibrillation?*
No (0)
Yes (1)
Maybe (2)
Unknown (9)
If yes, Date of first episode*
If yes, ER/hospitalized or saw M.D.?*
No (0)
Hospitalization or ER (1)
Saw MD (2)
Unknown (9)
Hospitalized at*
M.D. seen*
If yes, Permanent pacemaker insertion?*
No (0)
Yes (1)
Maybe (2)
Unknown (9)
If yes, Year done:*
Are you taking any of the cardiovascular
medications of Anticoagulants (Coumadin,
Warfarin, etc.)?*
No (0)
Yes (1)
Maybe (2)
Unknown (9)
Are you taking any of the cardiovascular
medications of Antiarrhythmics (Quinidine,
Procainamide, Norpace,Disopyramide,etc)?*
No (0)
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Yes (1)
Maybe (2)
Unknown (9 )
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Medication Inventory Protocol PhenX
Toolkit
Participants are asked to bring all their current medications
with them at the time of their appointment. For prescription
medications, the interviewer records the name of the
medications, the strength, the number prescribed, and the
actual amount taken during the last 2 weeks. For over-the-
counter medications (including vitamins and supplements),
the interviewer records the name, strength, and actual
amount consumed in the previous 2 weeks.
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Medication Inventory Protocol PhenX
Toolkit
Medication Reception
Have you brought this bag with you? Are these all
the medications that you have taken in the past
two weeks?
Yes (1)
No (2)
Refused (3)
Took no medicines (4)
Prescribed medications
Medications Current medication [PhenX]*
Strength (mg, IU, etc.). Write the decimal one of
the digits.*
Number Prescribed*
PRN Medicine?*
Yes
No
On the average during the last two weeks, how
many of these pills did you take a
day/week/month
Over the counter medications
Medications Current medication [PhenX]*
Strength (mg, IU, etc.). Write the decimal one of
the digits.*
Number Prescribed*
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PRN Medicine?*
On the average during the last two weeks, how
many of these pills did you take a
day/week/month*
2 / 2
Medication Inventory Protocol PhenX Toolkit
Clinical Neuropathy Assessment Protocol
PhenX Toolkit
The Charcot-Marie-Tooth Neuropathy Score is a nine-item
clinical examination that measures sensory symptoms,
motor symptoms, arm and leg strength and nerve
conduction velocities.
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Clinical Neuropathy Assessment
Protocol PhenX Toolkit
PhenX - clinical neuropathy protocol
Sensory symptoms*
None    (1)
Extend up to and may include ankle
(2)
Extend up to and may include knee (3)
Extends above knees (4)
Motor symptoms - legs*
None     (1)
Trips, catches toes, slaps feet   (2)
AFO on at least 1 leg or ankle support
(3)
Cane, walker, ankle surgery (4)
Wheelchair most of the time (5)
Motor symptoms - arms*
None     (1)
Difficulty with buttons/zippers  (2)
Unable to do buttons or zippers but can
write  (3)
Can not write or use keyboard     (4)
Proximal arms (5)
Pin sensibility*
Normal  (1)
Reduced in fingers/toes     (2)
Reduced up to and may include
elbow/knee    (3)
Reduced above elbow/knee (4)
Vibration*
Normal (1)
Reduced in fingers/toes (2)
Reduced up to and may include
elbow/knee    (3)
Reduced above elbow/knee (4)
Strength - legs*
Normal     (1)
4+, 4, or 4- on foot dorsiflexion   (2)
<3 Foot dorsiflexion (3)
<3 Dorsiflexion and plantar flexion (4)
Proximal weakness (5)
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Strength - arms*
Normal     (1)
4+, 4, or 4- on intrinsics or finger
extensors (2)
<3 Intrinsics or finger extensors   (3)
<5 Wrist extensors (4)
Weak above elbow (5)
Ulnar CMAP*
> 6 mV  (1)
4.0-5.9 mV    (2)
2.0-3.9 mV     (3)
0.1-1.9 mV   (4)
Absent (5)
Ulnar CMAP median*
(>4 mV)  (1)
(2.8-3.9) (2)
(1.2-2.7)    (3)
(0.1-1.1)    (4)
Absent (5)
Ulnar SNAP*
> 9 uV     (1)
6.0 - 8.9 uV    (2)
3.0-5.9 uV   (3)
0.1-2.9 uV     (4)
Absent (5)
Ulnar SNAP median*
(>22 uV)  (1)
(14.0-21.9)   (2)
(7.0-13.9)   (3)
(0.1-6.9)   (4)
Absent (5)
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Ocular Exposure to Ultraviolet Light
Protocol PhenX Toolkit
The interviewer-administered questionnaire consists of
three parts: (1) cities and exposure periods, (2) exposure
periods during a typical work week, and (3) leisure/non-
work period sunlight exposure. Answers are recorded on an
answer sheet and UV-B exposure is calculated using a
SAS program.
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Ocular Exposure to Ultraviolet Light
Protocol PhenX Toolkit
PhenX - ocular exposure to ultraviolet light
protocol
In what city or town were you living when you
were 18?*
What year did you turn 18?*
What was your main daytime activity or job when
you turned 18?*
CITIES AND EXPOSURE PERIODS
For subsequent ities/towns... To what city or town
did you move to next?
What year did you move from (CITY/TOWN)?
[For subsequent daytime activities or jobs within
a city/town...] What was your new daytime activity
or job?
When you were living in (CITY/TOWN) did your
exposure to direct sunlight in April through
September stay pretty much the same for all your
daytime activities between the hours of 10 AM
and 4 PM?
Yes
No
What year did your sunlight exposure change?
EXPOSURE DURING TYPICAL WORK
WEEK
When you were living in [CITY/TOWN] as a/an
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[ACTIVITY], how many hours each day during a
typical 5-day work week did you spend outside in
direct sunlight between 10 AM and 4 PM?
Did your main daytime activities during a typical
work week have you on water for a total of three
or more hours a day, for example working on a
boat
Yes
No
During your work time, when you were outside in
direct sunlight, how often did you wear this
sunlight protection [PhenX]
Never   (1)
Less than half the time (2)
More than half the time     (3)
All the time (4)
LEISURE/NON-WORK PERIOD
SUNLIGHT EXPOSURE
How often did you wear this sunlight protection
when you were outside in direct sunlight [PhenX]
Never   (1)
Less than half the time (2)
More than half the time     (3)
All the time (4)
When you were living in [CITY/TOWN] as a/an
[ACTIVITY]. During the months of April through
September, how many hours each day of this
leisure time did you spend outside in direct
sunlight between 10 AM and 4 PM?
Did your main daytime activities during your
leisure time have you over water for a total of
three or more hours a day, for example sailing,
fishing or swimming?
Yes
No
During your leisure time, when you were outside
in direct sunlight, how often did you wear this
sunlight protection [PhenX]
Never   (1)
Less than half the time (2)
More than half the time     (3)
All the time (4)
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Sexual History Protocol PhenX Toolkit
The National Longitudinal Study of Adolescent Health
(AddHealth) questions were conducted via CAPI
(computer-assisted personal interviewing). The participant
answers a question about whether she/he has ever had
vaginal intercourse. If the respondent answers no, the
respondent skips to question 6. If the respondent answers
yes, the respondent proceeds to the next questions (e.g.,
age at first intercourse, number of total partners, number of
different partners, and condom use).
The National STD and Behavior Measurement Experiment
(NSBME) questions were conducted using T-ACASI
(telephone audio computer assisted self-interviewing) and
ask participants about their same-gender sexual history
and experiences.
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Sexual History Protocol PhenX
Toolkit
PhenX - sexual history protocol
Have you ever had vaginal intercourse?*
Yes
No
How old were you the first time you had vaginal
intercourse?*
With how many partners have you ever had
vaginal intercourse, even if only once?*
With how many different partners have you had
vaginal intercourse in the past 12 months?*
How many times have you had vaginal
intercourse in the past 12 months?*
On how many of these occasions did YOU/YOUR
PARTNER use a condom in the past 12 months?*
To whom have you felt sexually attracted, even if
you did not take any action based on feeling
attracted?*
Only to females, never to males  (1)
Mostly to females, and at least once to a
male     (2)
About equally often to females and to
males   (3)
Mostly to males, and at least once to a
female  (4)
Only to males, never to females  (5)
I have never felt sexually attracted to
anyone at all (6)
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Have you ever had any kind of sexual experience
or sexual contact with a female [for women] /
male [for men]?*
Yes
No
[For females] Have you ever had sex with a
woman involving genital area/vaginal contact?
[For males[ Have you ever had sex with a man
involving genital area/penis contact?*
Yes
No
When was the last occasion?*
In the last 7 days  (1)
Between 7 days and 4 weeks ago  (2)
Between 4 weeks and 6 months ago
(3)
Between 6 months and 1 year ago (4)
Between 1 year and 5 years ago   (5)
Longer than 5 years ago (6)
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Sibship/Birth Order Protocol PhenX Toolkit
Questions are asked about the respondent’s siblings,
including the number of full brothers and sisters, if he/she
has twin siblings, and a more detailed description of the
birth order of all siblings including name and vital status.
The protocol uses the adjective, full, to refer to siblings to
whom a subject is related by blood and not by marriage.
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Sibship/Birth Order Protocol PhenX
Toolkit
Sibling Birth Order
How many full brothers do you have?*
How many full sisters do you have?*
Do you have a twin brother or sister?*
Yes (1)
No (2)
NA (9)
Are you and your twin identical or not identical?
Identical (1)
Not identical (2)
NA (9)
Sibling [PhenX]
Who is the oldest?/What is the first name of your
next brother or sister?
What is [NAME'S] sex?
Male (1)
Female (2)
NA (9)
Is [NAME] still living?
Yes (1)
No (2)
Respondent (3)
NA (9)
How old is [NAME] now?/How old was [NAME]
when he/she died?
years
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Consumption of Sweet Beverages Protocol
PhenX Toolkit
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Consumption of Sweet Beverages
Protocol
Consumption of Sweet Beverages
Beverage consumed [PhenX]
Cows’ milk (1)
Water (2)
Flavored water (3)
Sugared beverages made from powder
(4)
Sugar-free beverages made from powder
(5)
Regular pop (6)
Diet pop (7)
Sports drinks (8)
Did your child consume cows' milk during the
past week?
Yes
No
How many servings of cows' milk per day did
your child drink?
The amount of Cows' Milk per serving during the
past week?
If your child drinks cows' milk, what type of cows'
milk does your child usually drink?
Whole milk (1)
2% milk (2)
1% milk (3)
Chocolate milk (4)
Other flavored milk (e.g., strawberry,
vanilla) (5)
Doesn't drink milk (6)
What type of container does your child most often
use for beverages?
Infant bottle (1)
Open cup (2)
Closed cup (sippy cup) (3)
Cup with nonspilling, straw mechanism
(4)
Water bottle (5)
Product container (e.g. juice box, pop
can or bottle) (6)
What beverage does your child most often
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consume at meals?
Cows’ milk (1)
Juice or juice drinks (2)
Water (3)
Regular soda pop or other sugared
beverages (4)
Diet soda pop or other sugar-free
beverages (5)
What beverage does your child most often
consume between meals?
Cows’ milk (1)
Juice or juice drinks (2)
Water (3)
Regular soda pop or other sugared
beverages (4)
Diet soda pop or other sugar-free
beverages[C3843666] (5)
other (6)
Which statement best describes your child's
nighttime feedings?
My child falls asleep with a bottle (1)
My child has a bottle in the middle of the
night (2)
My child has a snack at bedtime (3)
My child has a snack in the middle of the
night (4)
None of the above (5)
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Sleep Disorders Screener Protocol PhenX
Toolkit
The National Institute of Mental Health (NIMH) Sleep
Patterns and Problems instrument is an interviewer-
administered questionnaire which captures routine sleep
schedule, sleep deprivation, morningness-eveningness,
insomnia, narcolepsy, cataplexy and associated distress.
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Sleep Disorders Screener Protocol
PhenX Toolkit
PhenX - sleep disorders screener protocol
Do you normally work (or attend school) during
the day and sleep at night?
No (0)
Yes (1)
Unknown (9)
What is your normal work (or school) and sleep
schedule?
Always works nights, sleeps during the
day     (1)
Schedule rotates/shift work   (2)
Other (3)
What is your normal work (or school) and sleep
schedule? Other, Describe
What shift schedule do you most often work?
Day shift (approx. 7am- 3pm)     (1)
Evening shift (approx. 3pm- 11pm)     (2)
Night shift (approx. 11pm- 7am)     (3)
Other (4)
Day [PhenX]
Work or school day   (1)
Non-work, non-school day or weekend
(2)
At what time do you usually go to bed?
About how many min does it usually take for you
to fall asleep?
min
How long does it take for you to become fully
awake from regular sleep (i.e., after first opening
your eyes in the morning)?
Do you use an alarm clock to wake up in the
morning?
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Never (1)
Sometimes (2)
Always (3)
Do you have great difficulty waking up in the
morning
Never (1)
Sometimes (2)
Always (3)
Do you often have so much trouble waking up
that an alarm clock won't wake you and you have
to use other methods to wake up?
Never (1)
Sometimes (2)
Always (3)
Describe
When you wake up in the morning or from a nap,
do you feel "out of it" and confused?
Never (1)
Sometimes (2)
Always (3)
How long does it take for you to fully awaken?
How much sleep do you usually get on a typical
night?
Do you usually follow the same sleep schedule
(i.e., no more than a 1 hour difference in sleep
and wake times) on both work/school and non-
work/school days? (or school days and
weekends)
Never (1)
Sometimes (2)
Always (3)
How many hours of sleep per night do you think
you need to feel fully rested the next day?
h
When you do not have to maintain a strict
schedule (i.e. not dictated by strict work or school
schedules, as while on vacation or not
working):..are these usual sleep and wake times
always about the same (i.e. each day during a
week of vacation)?
No (0)
Yes (1)
Unknown (9)
Do you feel awake and refreshed after sleeping?
Never (1)
Sometimes (2)
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Always (3)
How often do you take naps?
Never (1)
Rarely (once a month or less) (2)
Sometimes (2-4 times per month) (3)
Often (5-15 times per month)  (4)
Almost always (16-30 times per month)
(5)
Don't know (6)
At what time(s) of the day do you usually take
naps?
How many hours and minutes of sleep do you
usually get when you take a nap?
Do you have great difficulty waking up from
naps?
Never (1)
Sometimes (2)
Always (3)
How often do you dream when you nap?
Never (1)
Rarely (once a month or less) (2)
Sometimes (2-4 times per month) (3)
Often (5-15 times per month)  (4)
Almost always (16-30 times per month)
(5)
Don't know (6)
Are these dreams very intense, detailed and
vivid, like watching a movie?
No (0)
Yes (1)
Unknown (9)
How difficult is it for you to adapt to a sleep loss
of 3 hours or more (i.e. sleeping 3 or more hours
less than you normally do the night before)?
Not at all difficult  (1)
Not very difficult  (2)
Somewhat difficult (3)
Very difficult   (4)
Don't know (5)
Do you feel awake and refreshed after sleeping?
Never (1)
Sometimes (2)
Always (3)
Does this loss of sleep affect you the next day
with respect to ...your mood (being sadder or
happier)?
Yes
No
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Does this loss of sleep affect you the next day
with respect to...your mood (being sadder or
happier)? (If yes, How?)
Improves    (1)
Worsens     (2)
Both (3)
Don't know (4)
Does this loss of sleep affect you the next day
with respect to ...your tendency to be irritable?
Yes
No
Does this loss of sleep affect you the next day
with respect to ...your tendency to be irritable? (If
yes, How?)
Increases     (1)
Decreases (2)
Both (3)
Don't know (4)
Does this loss of sleep affect you the next day
with respect to...your ability to get your work
done?
Yes
No
Does this loss of sleep affect you the next day
with respect to...your ability to get your work
done? (If yes, How?)
Improves    (1)
Worsens     (2)
Both (3)
Don't know (4)
Does this loss of sleep affect you the next day
with respect to...how much you eat?
Yes
No
Does this loss of sleep affect you the next day
with respect to ...how much you eat? (If yes,
How?)
Increases     (1)
Decreases (2)
Both (3)
Don't know (4)
Does this loss of sleep affect you the next day
with respect to...your desire for chocolate or
sweets?
Yes
No
Does this loss of sleep affect you the next day
with respect to ...your desire for chocolate or
sweets? (If yes, How?)
Increases     (1)
Decreases (2)
Both (3)
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Don't know (4)
Does this loss of sleep affect you the next day
with respect to...your mood (being sadder or
happier)? (If yes, How?)
Within 1 day or less (1)
2 to 3 days     (2)
4 or 5 days (3)
Over 5 days  (4)
Don't know (5)
Do you prefer to keep a regular sleep schedule
(i.e. one that does not change much from one
night to the next)?
No (0)
Yes (1)
Unknown (9)
If you do not keep your regular sleep schedule,
how much do you feel ""off"" (i.e. not your regular
self), the next day?
None, feel the same (1)
Yes, somewhat off     (2)
Yes, a great deal off  (3)
Don't know (4)
When you are traveling EAST by air and you
cross over several time zones, how quickly do
you return to your usual sleeping pattern
Within 1 day or less  (1)
2 to 3 days (2)
4 or 5 days (3)
Over 5 days (4)
N/A (5)
Don't know (6)
What about when you are traveling WEST by air
over several time zones?
Within 1 day or less  (1)
2 to 3 days (2)
4 or 5 days (3)
Over 5 days (4)
N/A (5)
Don't know (6)
Do you consider yourself to be a morning person
("early bird"), an evening person ("night owl"), or
neither?
Neither type   (1)
Morning (2)
Evening (3)
How strong is your preference?
None (1)
Some (2)
Strong (3)
INTERVIEWER: Does respondent consistently
fall asleep very late (i.e., 12 a.m. or later) at night
AND characterize him/herself as a "night owl"
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with a "strong preference"?
No (0)
Yes (1)
Unknown (9)
When you do not have to maintain a strict
schedule (i.e. not dictated by strict work or school
schedules, as while on vacation or not working):
...at what time do you usually go to sleep (i.e. feel
sleepy and ready to go to bed)?
At what time do you usually wake up?
When you do not have to maintain a strict
schedule (i.e. not dictated by strict work or school
schedules, as while on vacation or not
working):..are these usual sleep and wake times
always about the same (i.e. each day during a
week of vacation)?
No (0)
Yes (1)
Unknown (9)
When you do not have to maintain a strict
schedule (i.e. not dictated by strict work or school
schedules, as while on vacation or not working):
...do you wake up on your own (i.e., without an
alarm or other assistance)?
No (0)
Yes (1)
Unknown (9)
Have you ever tried to force yourself to fall asleep
at an (earlier) time than your usual bedtime?
No (0)
Yes (1)
Unknown (9)
How often do you remember your dreams? That
is, dreams that occur during your regular sleep
and not while napping
Never (1)
Rarely (once a month or less) (2)
Sometimes (2-4 times per month) (3)
Often (5-15 times per month)  (4)
Almost always (16-30 times per month)
(5)
Don't know (6)
When you tried to shift your sleep schedule to an
earlier bedtime (at least 1 to 2 hours earlier), did
you have difficulty falling asleep
No (0)
Yes (1)
Unknown (9)
Do attempts to change your sleep/wake schedule
tend to make your sleeping difficulties worse?
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During the past year, what was the longest period
of time that you had these sleeping problems on
most nights?
No (0)
Yes (1)
Unknown (9)
How old were you when you first began going to
sleep very late without being able to adjust your
schedule when you tried?
How old were you the last time you experienced
these problems?
Do you currently experience these problems?
No (0)
Yes (1)
Unknown (9)
How much have your late bedtime and inability to
adjust your schedule upset or distressed you?
0 - no distress/impairment    (1)
9 (10)
10 - very severe problems (11)
1 (2)
2 (3)
3 (4)
4 (5)
5 (6)
6 (7)
7 (8)
8 (9)
What number describes how much this
eveningness tendency has affected your social
life and/or relationships with your friends?
0 - no distress/impairment    (1)
9 (10)
10 - very severe problems (11)
1 (2)
2 (3)
3 (4)
4 (5)
5 (6)
6 (7)
7 (8)
8 (9)
What number describes how much this
eveningness tendency has affected your
relationships with family members?
0 - no distress/impairment    (1)
9 (10)
10 - very severe problems (11)
1 (2)
2 (3)
3 (4)
4 (5)
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5 (6)
6 (7)
7 (8)
8 (9)
What number describes how much this
eveningness tendency has affected your
performance in school/work or your relationships
with your co-workers, employers, teachers or
classmates?
0 - no distress/impairment    (1)
9 (10)
10 - very severe problems (11)
1 (2)
2 (3)
3 (4)
4 (5)
5 (6)
6 (7)
7 (8)
8 (9)
Have you ever had frequent problems getting to
sleep at the beginning of the night which has
negatively affected how you function during the
following day?
No (0)
Yes (1)
Unknown (9)
Have you ever had frequent problems staying
asleep at night which has negatively affected how
you function during the following day?
No (0)
Yes (1)
Unknown (9)
Have you ever had frequent problems falling back
to sleep after waking in the middle of the night
which has negatively affected how you function
during the following day?
No (0)
Yes (1)
Unknown (9)
In the past year, have you had difficulty getting to
sleep?
No (0)
Yes (1)
Unknown (9)
In the past year, have you awakened during the
night and had a hard time getting back to sleep?
No (0)
Yes (1)
Unknown (9)
In the past year, have you awakened too early in
the morning and couldn't get back to sleep?
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No (0)
Yes (1)
Unknown (9)
During the past year, what was the longest period
of time that you had these sleeping problems on
most nights?
Things experienced during the daytime due to
difficulties falling asleep or staying asleep at night
[PhenX]
Attention, concentration or memory
problems     (1)
Lack of motivation or energy to do things
(10)
Concerns or worries about sleep (11)
Errors or accidents at work or while
driving  (2)
Social problems or poor work/school
performance    (3)
Fatigue     (4)
Sleepiness     (5)
Feeling tense or muscle tension    (6)
Headache  (7)
Gastrointestinal symptoms (8)
Mood changes-problems or irritability
(9)
Do you experience any of these things during the
daytime due to your difficulties falling asleep or
staying asleep at night [PhenX]
No (0)
Yes (1)
Unknown (9)
Do you do any of the following during the night
when you cannot fall asleep, do you: Experience
frustration, tension and/or anxiety over not being
able to go to sleep?
No (0)
Yes (1)
Unknown (9)
Do you do any of the following during the night
when you cannot fall asleep, do you: Look at the
clock frequently to see how long you have not
been able to fall asleep?
No (0)
Yes (1)
Unknown (9)
When you are NOT sleeping in your usual bed
(e.g. in a hotel room while on vacation, or on your
couch watching television), do you still have
problems initially getting to sleep, staying asleep,
or falling back to sleep after waking up during the
night?
No (0)
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Yes (1)
Unknown (9)
Events or conditions occurring at the same time
as difficulty with insomnia [PhenX]
Changing schedule     (1)
Noisy or uncomfortable surroundings
(2)
Stress or major life event   (3)
Other disturbances - children, pets, etc
(4)
Emotional or mental condition (5)
Other medical condition   (6)
Other drugs or medication (7)
Does your difficulty with insomnia occur at the
same time as any of these events or conditions
[PhenX]
No (0)
Yes (1)
Unknown (9)
Specify
Specify
Specify
Specify
Specify
Specify
Specify
Do you ever have trouble falling asleep or staying
asleep, when there seems to be no cause or
explanation for it?
No (0)
Yes (1)
Unknown (9)
Has your difficulty with sleeping occurred or
worsened during any of the following
conditions...pregnancy?
No (0)
Yes (1)
Unknown (9)
Has your difficulty with sleeping occurred or
worsened during any of the following conditions
...menopause? (ask for women over 35)
No (0)
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Yes (1)
Unknown (9)
Has your difficulty with sleeping occurred or
worsened during any of the following
conditions...just before (a few days)
menstruation?
No (0)
Yes (1)
Unknown (9)
Has your difficulty with sleeping occurred or
worsened during any of the following conditions
...menstruation?
No (0)
Yes (1)
Unknown (9)
How many separate times in your life have you
had difficulty getting to sleep, staying asleep or
falling back to sleep after waking up during the
night (for at least one month)?
How old were you when you first experienced this
kind of difficulty with sleeping (for at least one
month)?
How old were you the last time you experienced
this insomnia (for at least one month)?
Do you currently experience insomnia?
No (0)
Yes (1)
Unknown (9)
How frequently do you experience insomnia?
/weeks
How much does your insomnia (sleep difficulties)
upset or distress you?
0 - no distress/impairment    (1)
9 (10)
10 - very severe problems (11)
1 (2)
2 (3)
3 (4)
4 (5)
5 (6)
6 (7)
7 (8)
8 (9)
What number describes how much your insomnia
has affected your social life or relationships with
your friends?
0 - no distress/impairment    (1)
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9 (10)
10 - very severe problems (11)
1 (2)
2 (3)
3 (4)
4 (5)
5 (6)
6 (7)
7 (8)
8 (9)
What number describes how much your insomnia
has affected your relationships with family
members?
0 - no distress/impairment    (1)
9 (10)
10 - very severe problems (11)
1 (2)
2 (3)
3 (4)
4 (5)
5 (6)
6 (7)
7 (8)
8 (9)
What number describes how much your insomnia
has affected your performance in school/work or
your relationships with your co-workers,
employers, teachers or classmates?
No (0)
Yes (1)
Unknown (9)
Do you feel so sleepy during the day that it
interrupts your normal activities - such as driving,
reading, or concentrating at work or school, even
when you have had enough sleep the night
before?
No (0)
Yes (1)
Unknown (9)
How often do you feel this way?
What is the longest period of time that you have
felt this way (on most days)?
During the daytime, do you experience an
overwhelming desire to go to sleep - so
overwhelming that you cannot resist?
No (0)
Yes (1)
Unknown (9)
How often does this overwhelming desire to go to
sleep occur?
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What is the longest period of time that you have
felt this way (on most days)?
When you do doze off during the day and take a
nap, do you find this sleep refreshing?
No (0)
Yes (1)
Unknown (9)
When you do doze off during the day and take a
nap, do you find this sleep refreshing? Describe:
Do you feel that you are sleepier than other
people your age?
Not at all (1)
Somewhat   (2)
A lot more sleepy     (3)
Don't know (4)
Do you ever experience periods of muscle
weakness, loss of muscle strength or limp
muscles in any part of your body (e.g. in the legs
or face) during the following situations: ...when
you laugh?
No (0)
Yes (1)
Unknown (9)
Do you ever experience periods of muscle
weakness, loss of muscle strength or limp
muscles in any part of your body (e.g. in the legs
or face) during the following situations: ...when
you are angry?
No (0)
Yes (1)
Unknown (9)
Do you ever experience periods of muscle
weakness, loss of muscle strength or limp
muscles in any part of your body (e.g. in the legs
or face) during the following situations: ...when
you hear or tell a joke?
No (0)
Yes (1)
Unknown (9)
Have you ever been told that you "act out" your
dreams?
No (0)
Yes (1)
Unknown (9)
How often does this happen?
Do you ever move so much during your sleep that
you accidentally hit your bed partner (if any) or
hurt yourself?
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No (0)
Yes (1)
Unknown (9)
Do you have any memory of these event(s)?
No (0)
Yes (1)
Unknown (9)
Does moving at night disrupt your sleep? (i.e.
wake you up at night)
No (0)
Yes (1)
Unknown (9)
During what part of the night do these events
most often occur?
First half   (1)
Second half (2)
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Eligibility Breast Cancer NCT02269696
The Effect of Metoprolol on Anaesthesia, the Need for
Analgesics, and Pain in Breast Cancer Patients; ODM
derived from: https://clinicaltrials.gov/show/NCT02269696
All rights reserved. Please visit https://medical-data-
models.org/forms/14763
Eligibility Breast Cancer
NCT02269696
Inclusion Criteria
elective breast surgery due to breast cancer*
Yes
No
voluntary*
Yes
No
bmi ≥ 18 and ≤ 35 kg/m2*
Yes
No
asa 1-3*
Yes
No
no regular use of beta-blockers or during the last
72 hours*
Yes
No
no contraindications to beta-blockers*
Yes
No
Exclusion Criteria
pregnancy or breast feeding*
Yes
No
av-block, degree ii or iii*
Yes
No
untreated cardiac insufficiency*
Yes
No
sinus bradycardia, heart rate < 45 / min or
symptoms*
Yes
No
sick sinus syndrome*
Yes
No
cardiogenic shock*
Yes
1 / 2
No
severe peripheral vascular disorder*
Yes
No
systolic blood pressure < 100 mmhg*
Yes
No
long pq-time, > 0,24 seconds*
Yes
No
known hypersensitivity to beta-blockers or the
ingredients of the drug*
Yes
No
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Eligibility Atrial Fibrillation NCT02426944
Left Atrial Appendage Closure vs. Novel Anticoagulation
Agents in Atrial Fibrillation; ODM derived from:
https://clinicaltrials.gov/show/NCT02426944
All rights reserved. Please visit https://medical-data-
models.org/forms/14764
Eligibility Atrial Fibrillation
NCT02426944
Inclusion Criteria
1. cha2ds2-vasc score > 3 and has-bled > 3; or*
Yes
No
2. significant bleeding during warfarin treatment
in the history (i.e. bleeding which required
intervention or hospitalization); or*
Yes
No
3. cardioembolic event, which occurred on
warfarin treatment*
Yes
No
Exclusion Criteria
1. thrombus in the la or laa;*
Yes
No
2. mechanical valve prosthesis;*
Yes
No
3. mitral stenosis;*
Yes
No
4. previous laa ligation during cardiac surgery;*
Yes
No
5. life expectancy less than 2 years;*
Yes
No
6. comorbidities other than af, which present an
indication for anticoagulation;*
Yes
No
7. patent foramen ovale with atrial septal
aneurysm*
Yes
No
8. mobile plaque in the aorta;*
Yes
No
1 / 2
9. symptomatic atherosclerosis of the carotid
artery;*
Yes
No
10. pericardial effusion greater than 10 mm;*
Yes
No
11. clinically significant bleeding within previous
month;*
Yes
No
12. stroke or other cardioembolic event within
previous month; and 13) acute coronary
syndrome within previous three months*
Yes
No
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Eligibility Atopic Asthma NCT01049178
Randomized Controlled Trial of Silymarin in Asthma; ODM
derived from: https://clinicaltrials.gov/show/NCT01049178
All rights reserved. Please visit https://medical-data-
models.org/forms/14765
Eligibility Atopic Asthma
NCT01049178
Inclusion Criteria
inclusion criteria male or female subject with
confirmed asthma, and*
Yes
No
age ≥ 18 years*
Yes
No
asthma control test (act) score of 15-20, and*
Yes
No
documented atopy by prick skin testing (most
study participants will likely have participated in
one of the investigators prior observational
studies and will have had skin testing, if not, this
will be performed at an in-person screening visit),
and*
Yes
No
for women: not pregnant, as determined by a
negative urinary pregnancy test at the initial
visit(visit 1), and at the start of the cross-over
period (visit 4), and using birth control*
Yes
No
Exclusion Criteria
known allergies to plants in the asteraceae family
(thistles, daisies, artichokes, kiwi)*
Yes
No
non-asthmatic, or inadequate documentation
which includes lack of signs and symptoms of
asthma, or lack of prior confirmatory testing*
Yes
No
pregnant*
Yes
No
age < 18 years*
Yes
No
non-english speaking*
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Yes
No
current smoker (current, or within last year)*
Yes
No
chronic obstructive pulmonary disease(copd)*
Yes
No
unable to swallow capsules*
Yes
No
unable to obtain informed consent*
Yes
No
unable to comply with avoidance of honey and
propolis containing foods (which interfere with the
silybin assays for measurement of plasma
concentrations)*
Yes
No
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NINDS CDE Surgeries and Other
Procedures Epilepsy
NINDS Common Data Elements Used from the National
Institute of Neurological Disorders and Stroke Common
Data Elements
(https://www.commondataelements.ninds.nih.gov/)
References: Grinnon ST, Miller K, Marler JR, Lu Y, Stout A,
Odenkirchen J, Kunitz S. National Institute of Neurological
Disorders and Stroke Common Data Element Project -
approach and methods. Clin Trials. 2012;9(3):322-9.
All rights reserved. Please visit https://medical-data-
models.org/forms/14766
Surgeries and Other Procedures
Surgery and Pathology
Study ID
Study site name
Subject ID
Date of surgery
Diagnostic procedure
Yes
No
Diagnostic Procedure Details: Electrodes
Depth (1)
Subdural (2)
Epidural  (3)
Foramen ovale (4)
Other (5)
Diagnostic Procedure Details: Location
Hippocampus (1)
Frontal (2)
Temporal  (3)
Parietal (4)
Occipital (5)
Other (6)
Anterior Temporal Lobectomy
Yes
No
Anterior Temporal Lobectomy:Estimate of
resection
Anterior Temporal Lobectomy:Superior temporal
gyrus
cm
Anterior Temporal Lobectomy: Middle temporal
gyrus
cm
Anterior Temporal Lobectomy: Inferior temporal
gyrus
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cm
Anterior Temporal Lobectomy: Parahippocampal
gyrus
cm
Anterior Temporal Lobectomy: Amygdala
(Percent of total)
%
Anterior Temporal Lobectomy: Hippocampus
cm
Anterior Temporal Lobectomy plus
Yes
No
Anterior Temporal Lobectomy plus: Adjacent
resection
Yes
No
Anterior Temporal Lobectomy plus:Estimate of
size of resection beyond ATL
Anterior Temporal Lobectomy plus: Largest
Dimension: AP
cm
Anterior Temporal Lobectomy plus:Largest
Dimension: LAT
cm
Anterior Temporal Lobectomy plus: Largest
Dimension: Depth
cm
Anterior Temporal Lobectomy plus:Volume of
resected tissue
cm3
Anterior Temporal Lobectomy plus:Location of
resection beyond ATL
Lateral temporal (1)
Occipital (2)
Parietal  (3)
Orbitofrontal (4)
Dorsolateral frontal (5)
Medial frontal (6)
Central cortex (7)
Amygdalohippocampectomy
Yes
2 / 14
NINDS CDE Surgeries and Other Procedures Epilepsy
No
Amygdalohippocampectomy: Estimate of
resection
Amygdalohippocampectomy: Parahippocampal
gyrus
cm
Amygdalohippocampectomy: Amygdala (percent
of total)
%
Amygdalohippocampectomy:Hippocampus
cm
Amygdalohippocampectomy:approach to
Hippocampus
Sylvian Fissure (1)
Superior temporal gyrus/sulcus (2)
Middle temporal gyrus/sulcus  (3)
Sub-tempora (4)
Other (5)
Lesionectomy
Yes
No
Type of suspected lesion: Neoplasm
Yes
No
Type of suspected lesion:Dysplasia
Yes
No
Type of suspected lesion: Cavernous
malformation
Yes
No
Type of suspected lesion:Arteriovenous
malformation
Yes
No
Type of suspected lesion:Hemorrhage
Yes
No
Type of suspected lesion:Stroke
Yes
No
Type of suspected lesion:Infection
Yes
No
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Type of suspected lesion:Gliosis, cause unknown
Yes
No
Type of suspected lesion:Unknown
Yes
No
Type of suspected lesion:Other, specify
Location of lesion:Temporal
Yes
No
Location of lesion: Frontal
Yes
No
Location of lesion:Parietal
Yes
No
Location of lesion:Occipital
Yes
No
Location of lesion:Hypothalamus
Yes
No
Location of lesion:Thalamus
Yes
No
Location of lesion:Basal Ganglia
Yes
No
Location of lesion:Brainstem
Yes
No
Location of lesion:Cerebellum
Yes
No
Location of lesion:White matter
Yes
No
Location of lesion:Other, specify
Extent of resection
Incomplete lesion removal (1)
Complete lesion removal (2)
Lesion + anatomically abnormal adjacent
brain (3)
Lesion + electrically abnormal adjacent
brain (4)
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Removal of one lesion, others remain (5)
Unknown (6)
Other, specify (7)
Extent of resection:if other,please specify
Lesionectomy plus
Yes
No
Lesionectomy plus:Adjacent resection
Yes
No
Lesionectomy plus:Estimate of size of resection
beyond ATL
Lesionectomy plus:Largest Dimension: AP
cm
Lesionectomy plus:Largest Dimension: LAT
cm
Lesionectomy plus:Largest Dimension:Depth
cm
Lesionectomy plus:Volume of resected tissue
cm3
Lesionectomy plus: Location of resection beyond
ATL
Lateral temporal (1)
Occipital (2)
Parietal  (3)
Orbitofrontal (4)
Dorsolateral frontal (5)
Medial frontal (6)
Central cortex (7)
Extratemporal resection (Topectomy)
Yes
No
Topectomy:Estimate of size
Topectomy:Largest Dimension: AP
cm
Topectomy:Largest Dimension LAT
cm
Topectomy:Largest Dimension Depth
cm
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Topectomy:Volume of resected tissue
cm3
Topectomy location:Lateral temporal
Yes
No
Topectomy location:Occipital
Yes
No
Topectomy location:Parietal
Yes
No
Topectomy location:Orbitofrontal
Yes
No
Topectomy location:Dorsolateral frontal
Yes
No
Topectomy location:Medial frontal
Yes
No
Topectomy location:Central cortex
Yes
No
Topectomy location:Insula
Yes
No
Multi-lobar resection
Yes
No
Multi-lobar resection:Lesion
Yes
No
Multi-lobar resection:Temporal Lobes resected?
Yes
No
Multi-lobar resection: ifTemporal Lobes
resected,estimated percentage of lobe removed
%
0-25 (1)
26-50	 (2)
51-75 (3)
76-100 (4)
Multi-lobar resection:Occipital lobes resected?
Yes
No
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Multi-lobar resection if occipital lobes
resected:Estimated percentage of lobe removed
0-25 (1)
26-50	 (2)
51-75 (3)
76-100 (4)
Multi-lobar resection:Parietal lobes resected?
Yes
No
Multi-lobar resection if parietal lobes
resected:Estimated percentage of lobe removed
0-25 (1)
26-50	 (2)
51-75 (3)
76-100 (4)
Multi-lobar resection:Frontal lobes resected?
Yes
No
Multi-lobar resection if frontal lobes
resected:Estimated percentage of lobe removed
0-25 (1)
26-50	 (2)
51-75 (3)
76-100 (4)
Hemispherectomy
Yes
No
Hemispherectomy
Anatomical hemispherectomy  (1)
Functional hemispherectomy (2)
Hemispherotomy (3)
Other, specify (4)
Hemispherectomy:if other,please specify
Vagus nerve stimulation
Yes
No
Corpus callosotomy
Yes
No
Corpus callosotomy:Location of resection
(opinion of surgeon at time of surgery)
Rostrum (1)
Genu (2)
Part of body (3)
All of body (4)
Splenium (5)
Unknown (6)
Other, specify (7)
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Corpus callosotomy:if other location,please
specify
Corpus callosotomy:Extent of resection
Complete (1st stage) (1)
Anterior two-thirds (2)
Anterior half (3)
Completion of callosotomy (2nd stage)
(4)
Other, specify (5)
Corpus callosotomy: if other extent, please
specify
Multiple subpial transection
Yes
No
Multiple subpial transection:Estimate of size
Multiple subpial transection:Largest dimension
AP
cm
Multiple subpial transection:Largest dimension
LAT
cm
Multiple subpial transection:Location
Lateral temporal (1)
Occipital (2)
Parietal  (3)
Orbitofrontal (4)
Dorsolateral frontal (5)
Medial frontal (6)
Central cortex (7)
Multiple subpial transection: Was resection
performed in conjunction with MST?:
Yes
No
Radiosurgery
Yes
No
Radiosurgery:Location
Radiosurgery:Lesion?
Yes
No
Radiosurgery:Lesion type
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Radiosurgery:Treatment volume
cc
Radiosurgery:Marginal dose
Gy
Radiosurgery:Number of treatment sessions
Therapeutic brain stimulation
Yes
No
Therapeutic brain stimulation:Number of
electrodes placed
Therapeutic brain stimulation:Target of electrodes
Anterior thalamus (1)
Centromedian thalamus  (2)
Hippocampus (3)
Cerebellum (4)
Subthalamic nucleus (5)
Brainstem (6)
Seizure focus (foci) (7)
Other, specify (8)
Therapeutic brain stimulation:if other target,
please specify
Therapeutic brain stimulation stereotactic
coordinates, if available: A-P; LAT; Depth
Therapeutic brain stimulation method of
placement: local anesthesia
Yes
No
Therapeutic brain stimulation method of
placement: general anesthesia
Yes
No
Therapeutic brain stimulation method of
placement:Frameless stereotaxy
Yes
No
Therapeutic brain stimulation method of
placement: Framed stereotaxy
Yes
No
Therapeutic brain stimulation method of
placement:Other,please specify
Therapeutic brain stimulation method of verifying
placement: Neuroimaging
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Yes
No
Therapeutic brain stimulation method of verifying
placement:EEG
Yes
No
Therapeutic brain stimulation method of verifying
placement:Unit recording
Yes
No
Therapeutic brain stimulation method of verifying
placement:None
Yes
No
Therapeutic brain stimulation method of verifying
placement: Other, specify
Therapeutic brain stimulation: Stimulus
parameters
Therapeutic brain stimulation: Frequency
sec
Therapeutic brain stimulation:Voltage
V
Therapeutic brain stimulation: Current
mA
Therapeutic brain stimulation: Polarity
Bipolar (1)
Referential (2)
Other (3)
Therapeutic brain stimulation:Pulse width
microsec
Therapeutic brain stimulation:Stimulus type
Continuous (1)
Intermittent (2)
Responsive stimulation (3)
Therapeutic brain stimulation: On cycle time
sec
Therapeutic brain stimulation:off cycle time
sec
Therapeutic brain stimulation: Post-op MRI-
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verification?
Yes (1)
No (2)
Unknown (3)
Therapeutic brain stimulation:if post-op MRI
verification, please specify TESLA
Tesla
Please specify: other surgical procedure
Additional surgical details
Side
Left (1)
Right (2)
Bilateral (3)
N/A (4)
Language Laterality
Language(dominant) (1)
Language(non-dominant) (2)
Unknown (3)
Intraoperative ECoG
Pre-resection (1)
Post-resection (2)
None (3)
Intraoperative cortical stimulation mapping
Yes
No
Stereotaxis
Frame (1)
Frameless (2)
None (3)
Temporal lobectomy Hippocampus: Classic
hippocampal sclerosis
Yes
No
Temporal lobectomy Hippocampus: End folium
sclerosis
Yes
No
Temporal lobectomy Hippocampus:Dispersion of
dentate granule cell layer
Yes
No
Temporal lobectomy Hippocampus:Other
hippocampal damage Temporal lobe
Yes
No
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Temporal lobectomy Temporal lobe:please
describe
Lesionectomy Vascular:
Cavernous malformation (1)
Sturge Weber malformation (2)
AVM (3)
Stroke(ischemic/hemorrhagic) (4)
Lesionectomy Tumor:
Astrocytoma (include grade) (1)
DNT (2)
Mixed glioma (include grade) (3)
Metastatic (4)
Oligodendroglioma(include grade) (5)
Ganglioglioma (6)
Other, specify (7)
Lesionectomy Tumor Mixed glioma: please
specify grade
Lesionectomy Tumor Oligodendroglioma: please
specify grade
Lesionectomy Tumor Astrocytoma: please specify
grade
Lesionectomy: please specify other Tumor and
grade (if known)
Lesionectomy Tumor: Associated cortical
dysplasia?
Yes
No
Lesionectomy: Infectious/inflammatory
Abscess (1)
Rasmussen’s encephalitis (2)
Other, specify (3)
Lesionectomy other infectious/inflammatory
lesion: please specify
Lesionectomy Developmental:
Focal cortical dysplasia-Palmini IA (1)
Focal cortical dysplasia-Palmini IB (2)
Focal cortical dysplasia-Palmini IIA (3)
Focal cortical dysplasia-Palmini IIB (4)
Polymicrogyria (5)
Tuber (documented TS) (6)
Agyria/pachygyria (7)
Heterotopic gray matter (8)
Hemimegalencephaly (9)
Lesionectomy:Traumatic, please describe
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Hospital stay
days
Postoperative seizures
Yes
No
Postoperative seizures:if yes, how many
Postoperative complications
Postoperative neurological complications
Aphasia – if Yes, specify (1)
Psychiatric – if Yes, specify (10)
Anomia (2)
Visual field deficit (3)
Hemiparesis (4)
Memory deficit – if Yes, specify (5)
Cranial nerve deficit (6)
Altered mental status – if Yes, specify (7)
Herniation syndrome (8)
Stroke (9)
Postoperative neurological complications:please
specify
Postoperative medical complications
Wound infection (1)
Death (10)
Other, specify (11)
Post-operative hematoma (2)
UTI (3)
DVT/PE (4)
Pneumonia (5)
Respiratory, other – if Yes, specify (6)
Nausea/vomiting (7)
GI, other – if Yes, specify (8)
MI (9)
Other: please specify
Re-admissions within 30 days
Yes
No
If re-admitted within 30 days, please specify
reason
Return to operating room?
Yes
No
If returned to operating room, please specify
reason
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Postoperative complication:specify
Largely resolved by date:
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NINDS CDE Adverse Event Tracking Log
Epilepsy
NINDS Common Data Elements Used from the National
Institute of Neurological Disorders and Stroke Common
Data Elements
(https://www.commondataelements.ninds.nih.gov/)
References: Grinnon ST, Miller K, Marler JR, Lu Y, Stout A,
Odenkirchen J, Kunitz S. National Institute of Neurological
Disorders and Stroke Common Data Element Project -
approach and methods. Clin Trials. 2012;9(3):322-9.
All rights reserved. Please visit https://medical-data-
models.org/forms/14767
Adverse Event Tracking Log
Adverse Events
Adverse Event
AE Start date
AE End date
AE ongoing
Yes
No
AE Severity
Mild (1)
Moderate (2)
Severe (3)
Life-threatening/Disabling (4)
Death (5)
Relatedness
Unrelated (1)
Unlikely (2)
Probable (3)
Possible (4)
Definite (5)
Action Taken with Study Intervention
None (1)
Study Intervention Interrupted (2)
Study Intervention Discontinued (3)
Study Intervention Modified (4)
Action Taken with AED
None (1)
AED therapy temporarily interrupted (2)
AED therapy permanently stopped (3)
AED therapy modified (4)
Outcome
Recovered/Resolved (1)
Recovered/Resolved With Sequelae (2)
Recovering/Resolving (3)
Not Recovered/Not Resolved (4)
Fatal (5)
Unknown (6)
Serious Adverse Event
Yes
1 / 2
No
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NINDS CDE Post-Traumatic Epilepsy
Screening Epilepsy
NINDS Common Data Elements Used from the National
Institute of Neurological Disorders and Stroke Common
Data Elements
(https://www.commondataelements.ninds.nih.gov/)
References: Grinnon ST, Miller K, Marler JR, Lu Y, Stout A,
Odenkirchen J, Kunitz S. National Institute of Neurological
Disorders and Stroke Common Data Element Project -
approach and methods. Clin Trials. 2012;9(3):322-9.
All rights reserved. Please visit https://medical-data-
models.org/forms/14768
Post-Traumatic Epilepsy Screening
Post-Traumatic Epilepsy Screening
Study ID
Principal Investigator name
Subject ID
Have you/your family member had or has anyone
ever told you that you/they had any of the
following: Uncontrolled movements of part or all
of the body such as twitching, jerking, shaking or
going limp, lasting about 5 minutes or less?
Yes (1)
No (2)
Unknown (3)
Have you/your family member had or has anyone
ever told you that you/they had any of the
following: An unexplained change in mental state
or level of awareness; or an episode of "spacing
out" which you/your family member could not
control, lasting about 5 minutes or less?
Yes (1)
No (2)
Unknown (3)
Have you/your family member had or has anyone
ever told you that you/they had any of the
following: any other type of repeated unusual
attacks or convulsions lasting about 5 minutes or
less?
Yes (1)
No (2)
Unknown (3)
Has anyone ever told you that you/your family
member/ have seizure(s) or epilepsy?
Yes (1)
No (2)
Unknown (3)
Which of the following sources of information
were queried?
Patient  (1)
Caregiver  (2)
Medical record (3)
Has the participant had seizures or epilepsy prior
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to the traumatic brain injury?
Yes (1)
No (2)
Unknown (3)
Has the participant been diagnosed with epilepsy,
a seizure disorder, or a single seizure after the
date of the traumatic brain injury diagnosis?
Yes (1)
No (2)
Unknown (3)
Did seizure(s) occur later than seven days after
the date of the traumatic brain injury?
Yes (1)
No (2)
Unknown (3)
Date of diagnosis
Who gave this diagnosis?
Neurosurgeon (1)
Neurologist (2)
Pediatric Neurologist (3)
Primary Care Physician (4)
Pediatrician (5)
Psychiatrist (6)
Psychologist  (7)
Nurse Practitioner (8)
Has the patient received medication for seizures
or epilepsy?
Yes (1)
No (2)
Unknown (3)
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Eligibility Breast Cancer NCT02269813
PRospective Study to Measure the Impact of MammaPrint
on Adjuvant Treatment in Hormone Receptor-positive
HER2-negative Breast Cancer Patients (PRIMe); ODM
derived from: https://clinicaltrials.gov/show/NCT02269813
All rights reserved. Please visit https://medical-data-
models.org/forms/14769
Eligibility Breast Cancer
NCT02269813
Inclusion Criteria
women with histologically proven invasive stage 1
and 2 breast cancer*
Yes
No
hormone receptor positive according to local
standards*
Yes
No
her2 negative - i.e. ihc 0-1+, or fish or other ish
non-amplified (locally assessed)*
Yes
No
axillary lymph node status: 0-3 involved (macro
metastases i.e. >2mm or micro metastases i.e.
>0.2-2mm)*
Yes
No
≥ 18 years of age at time of consent*
Yes
No
patients must be eligible to receive adjuvant
chemotherapy and endocrine therapy as defined
by a good karnofsky index, no hematological,
cardiological or hepatic contraindications nor any
impeding comorbidity*
Yes
No
written informed consent*
Yes
No
Exclusion Criteria
≥4 involved axillary nodes*
Yes
No
multi-centric disease with more than 2 clinically
relevant lesions*
Yes
No
hr negative or her2 positive/amplified  (locally
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assessed)*
Yes
No
previous diagnosis of malignancy unless disease
free for 10 years*
Yes
No
metastatic disease*
Yes
No
tumor sample shipped to agendia with ≤ 30%
tumor cells or that fails qa or qc criteria*
Yes
No
women who have started or completed adjuvant
chemotherapy or neo-adjuvant chemotherapy for
current breast cancer*
Yes
No
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NINDS CDE Neuropsychological Testing
Background Information Epilepsy
NINDS Common Data Elements Used from the National
Institute of Neurological Disorders and Stroke Common
Data Elements
(https://www.commondataelements.ninds.nih.gov/)
References: Grinnon ST, Miller K, Marler JR, Lu Y, Stout A,
Odenkirchen J, Kunitz S. National Institute of Neurological
Disorders and Stroke Common Data Element Project -
approach and methods. Clin Trials. 2012;9(3):322-9.
All rights reserved. Please visit https://medical-data-
models.org/forms/14770
Neuropsychological Testing
Background Information
Neuropsychological Testing Background
Information
Study ID
Study site name
Subject ID
Family History of Sinistrality (Do you have any
first degree biological relatives [mother, father,
siblings, children] who write left-handed or with
both hands?):
Yes (1)
No (2)
Unknown (3)
Formal Learning Disability or ADD/ADHD
diagnosis (Were you given formal diagnosis of
any learning disability or diagnosed with
ADD/ADHD?):
Yes (1)
No (2)
Unknown (3)
If you have been diagnosed with learning
disabilities, please specify
ADHD (1)
Dyslexia (2)
Dyscalculia (3)
ADD (4)
Dysgraphia (5)
Other, specify (6)
Please specify other Learning Disability
Did you ever repeat a grade in school?
Yes (1)
No (2)
Unknown (3)
Did you ever receive special accommodations for
coursework?
Yes (1)
No (2)
Unknown (3)
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Disability status
On disability (1)
Applying for disability (2)
Not applicable (3)
Previous psychological/neuropsychological
testing?
Yes (1)
No (2)
Unknown (3)
If you have been tested before, please specify at
what age
Established language laterality (fMRI or Wada):
Yes (1)
No (2)
Unknown (3)
If yes, language:
Left (1)
Right (2)
Bilateral (3)
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NINDS CDE Seizure diary Epilepsy
NINDS Common Data Elements Used from the National
Institute of Neurological Disorders and Stroke Common
Data Elements
(https://www.commondataelements.ninds.nih.gov/)
References: Grinnon ST, Miller K, Marler JR, Lu Y, Stout A,
Odenkirchen J, Kunitz S. National Institute of Neurological
Disorders and Stroke Common Data Element Project -
approach and methods. Clin Trials. 2012;9(3):322-9.
All rights reserved. Please visit https://medical-data-
models.org/forms/14771
Seizure Diary
Seizure Diary
Study ID
Study site name
Subject ID
Date
Day of week
Monday (1)
Tuesday (2)
Wednesday (3)
Thursday (4)
Friday (5)
Saturday (6)
Sunday (7)
Did you have seizures today?
Yes
No
Please specify the Type of seizure. Select all that
apply
Dizzy, double vision (Involving subjective
sensory or psychic phenomena
only)Feeling of déjà vu (Involving
subjective sensory or psychic
phenomena only)**This patient has more
than one seizure of this type (both will be
assigned the same letter) (A)
Dizzy, double vision; shaking of the right
hand  (Focal Seizure with observable
motor or autonomic components) (B)
Dizziness followed by confusion/staring
(Focal Seizure with observable motor or
autonomic components →Focal Seizure
with impairment of consciousness or
responsiveness) (C)
Confusion/staring with no warning (Focal
Seizure with impairment of
consciousness or responsiveness) (D)
Dizziness followed by staring and
convulsion (Focal Seizure with
observable motor or autonomic
components → Evolving to a bilateral,
convulsive seizure (involving tonic,
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clonic, or tonic and clonic components))
(E)
Convulsion with no warning (Evolving to
a bilateral, convulsive seizure involving
tonic, clonic, or tonic and clonic
components) (F)
Please specify the number of seizures you had
today, matching it to the type selected before: i.e.:
A2; C1...
Who is completing the diary?
Participant/Subject (1)
Caregiver (2)
Further comments
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Eligibility Breast Cancer NCT02276443
Molecular Triaging and Diagnostic Imaging to Guide
Neoadjuvant Therapy; ODM derived from:
https://clinicaltrials.gov/show/NCT02276443
All rights reserved. Please visit https://medical-data-
models.org/forms/14772
Eligibility Breast Cancer
NCT02276443
Inclusion Criteria
1. the patient can undergo biopsy or surgery of a
primary tumor site for suspected or proven
invasive breast cancer of clinical stage i to iii*
Yes
No
2. the clinical or radiologic primary tumor size is
at least 1.5 cm diameter*
Yes
No
3. the patient was proven to have tnbc, defined
from standard pathologic assays as negative for
er and pr (<10% tumor staining) and negative for
her2 (ihc score <3, gene copy number not
amplified).*
Yes
No
4. primary tumor sample was collected before
nact began and was evaluated for genomic
testing (integral biomarker). this allows patients
who participate in 2011-0007 to be eligible for
study participation.*
Yes
No
5. patients must be >18 years of age*
Yes
No
6. patients must have lvef > 50% by muga or
echo within 4 weeks prior to registration.*
Yes
No
7. 3.1.7 patients must have adequate organ and
marrow function as defined below: •*
Yes
No
leukocytes >3,000/mcl • absolute neutrophil count
>1,500/mcl • platelets >100,000/mcl*
Yes
No
• total bilirubin within normal institutional limits •
ast(sgot)/alt(sgpt) <2.5 x institutional upper limit
of normal • creatinine within normal institutional
limits or • creatinine clearance >60 ml/min/1.73
m2 for patients with creatinine levels above
institutional normal.*
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Yes
No
Exclusion Criteria
1. the patient has diagnosis of stage iv disease or
is found to have stage iv disease prior to
randomization.*
Yes
No
2. prior history of invasive cancer within 5 years
of study entry or history of metastatic cancer.
exceptions include non-metastatic, curatively
treated basal and squamous cell carcinoma of
the skin.*
Yes
No
3. prior excisional biopsy of the primary invasive
breast cancer.*
Yes
No
4. patients with hematomas or biopsy site
changes that limit response assessment of the
primary tumor by diagnostic imaging.*
Yes
No
5. patients not eligible for chemotherapy with
taxane and/or anthracycline based chemotherapy
regimens.*
Yes
No
6. prior therapy with anthracyclines.*
Yes
No
7. grade ii or higher neuropathy.*
Yes
No
8. patients with zubrod performance status of
>2.*
Yes
No
9. patients with history of serious cardiac events
defined as: • patients with a history of new york
heart association class 3 or 4 heart failure, or
history of myocardial infarction, unstable angina
or cva within 6 months of protocol registration. •*
Yes
No
patients who have history of pr prolongation
(grade 2 or higher) or av block.*
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Yes
No
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Spirometry Protocol PhenX Toolkit
A spirometric test requires that the subject take a full, deep
breath and then exhale as forcefully as possible into a
hand-held portable spirometer. The subject’s effort is called
the forced expiratory maneuver and most commonly
measures the amount and speed of air that is exhaled. The
total amount (volume) of air exhaled is called the forced
vital capacity (FVC). The amount (volume) of air exhaled in
1 second is called the forced expiratory volume in 1 second
(FEV1). While hand-held spirometers are commonly used
in clinical research studies, the same results can be
obtained from more sophisticated floor-mounted devices
that are typically available in a respiratory function testing
laboratory.
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Spirometry Protocol PhenX Toolkit
PhenX - respiratory - spirometry protocol
Data type
Sp E B     (Sp E B    )
Sp E S (Sp E S)
Sp I B (Sp I B)
Sp I S (Sp I S)
Atmospheric pressure
mmHg
Room temperature
Celsius
Relative humidity (%)
%
FVC quality attribute
A (A)
B (B)
C (C)
D (D)
E (E)
F (F)
FEV1 quality attribute
A (A)
B (B)
C (C)
D (D)
E (E)
F (F)
Effort attribute
A (A)
B (B)
C (C)
D (D)
E (E)
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F (F)
Deleted maneuver
Yes
No
Acceptable maneuver
Yes
No
Technician quality control code
Computer quality code
Plateau achieved
Yes
No
Review
N - Needs Review (N - Needs Review)
W - Was reviewed (W - Was reviewed)
BTPS factor
Date of review
Reviewer initials
Manufacturer name
Oxygen saturation device Vendor model code
Oxygen saturation device Vendor serial number
Type of Oxygen saturation device
Testing facility name
City
State, district or territory federal abbreviation
Facility
Zip - post code
Country
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E-mail
Phone number
Date of observation
Calibration result
Date of observation
Technician ID
Maneuver number
Age
Body height Measured
cm
Body weight Measured
kg
Sex
Male (1)
Female (2)
Race, 2-character race code
Birth date
Reference values source
Reference values correction factor
Testing position
Sitting (Sitting)
Standing (Standing)
Supine (Supine)
Test type
Post-bronchodilator (Post-bronchodilator)
Pre-bronchodilator    (Pre-bronchodilator
)
Medication [Mass/volume] Dose
Methacholine [Mass] of Dose
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Forced vital capacity [Volume] Respiratory
system by Spirometry
L
Extrapolated volume
mL
FEV1 (liters)
L
FEV6
L
Maximum expiratory gas flow Respiratory system
airway
L/min
Gas flow FEV 25%-75% airway
L/s
Vital capacity [Volume] Respiratory system by
Spirometry
L
Forced expiratory time
sec
Time to PEF
Forced vital capacity [Volume] Respiratory
system Predicted
L
FEV1 Predicted
L
Predicted FEV6
L
FEV1/FVC Predicted
%
Predicted FEV1/FEV6%
%
Service comment
Original sampling interval
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Gas flow FEV 25%
L/s
Gas flow FEV 50%
L/s
Gas flow FEV 75%
L/s
Gas flow FEV 90%
L/s
Number of data points
Flow data points (mL/s; variable number
contained in number of data points)
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Systemic Lupus Erythematosus Protocol
PhenX Toolkit
The System Lupus International Collaborating Clinics
(SLICC)/American College of Rheumatology (ACR)
Damage Index for Systemic Lupus Erythematosus is a
method that physician investigators use to determine the
extent of permanent damage to various body organs or
organ systems due to lupus or to the treatment thereof.
This method is widely used and allows the physician to
determine if a person has had any nonreversible changes
(i.e., damage) to organ systems. These changes have
occurred since a person is being diagnosed with lupus, are
not related to active inflammation, and are ascertained via
a clinical assessment. Also, unless stated otherwise, these
changes must be present for at least six months prior to the
assessment. The SLICC /ACR Damage Index is a
cumulative index that records damage that occurs in
individuals with lupus, regardless of whether the damage
can be definitively attributed to lupus or is due to another
cause, such as a comorbid condition.
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Systemic Lupus Erythematosus
Protocol PhenX Toolkit
PhenX - systemic lupus erythematosus
protocol
Ocular (either eye, by clinical assessment) Any
cataract ever
Yes
No
Ocular (either eye, by clinical assessment)
Retinal change or optic atrophy
Yes
No
Neuropsychiatric Cognitive impairment (e.g.,
memory deficit, difficulty with calculation, poor
concentration, difficulty in spoken or written
language, impaired performance level) or major
psychosis
Yes
No
Neuropsychiatric Cognitive impairment (e.g.,
memory deficit, difficulty with calculation, poor
concentration, difficulty in spoken or written
language, impaired performance level) or major
psychosis
Yes
No
Neuropsychiatric Cerebrovascular accident ever
(score 2 if > 1)
No (No)
Yes (Yes)
Yes, more than 1 (Yes, more than 1)
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Neuropsychiatric Cranial or peripheral
neuropathy (excluding optic)
Yes
No
Neuropsychiatric Transverse myelitis
Yes
No
Renal Estimated or measured glomerular
filtration rate <50%
Yes
No
Renal Proteinuria > = 3.5 gm/24 hours
Yes
No
Renal End-stage renal disease (regardless of
dialysis or transplantation)
Yes
No
Pulmonary hypertension (right ventricular
prominence, or loud P2)
Yes
No
Pulmonary fibrosis (physical and radiograph)
Yes
No
Pulmonary Shrinking lung (radiograph)
Yes
No
Pulmonary Pleural fibrosis (radiograph)
Yes
No
Pulmonary Pulmonary infarction (radiograph)
Yes
No
Cardiovascular Angina or coronary artery bypass
Yes
No
Cardiovascular Myocardial infarction ever (score
2 if >I)
No (No)
Yes (Yes)
Yes, more than 1 (Yes, more than 1)
Cardiovascular Cardiomyopathy (ventricular
dysfunction)
Yes
No
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Cardiovascular Valvular disease (diastolic,
murmur, or systolic murmur >3/6)
Yes
No
Cardiovascular Pericarditis for 6 months, or
pericardiectomy
Yes
No
Peripheral vascular Claudication for 6 months
Yes
No
Peripheral vascular Minor tissue loss (pulp space)
Yes
No
Peripheral vascular Significant tissue loss ever
(e.g., loss of digit or limb) (score 2 if >1 site)
No (No)
Yes (Yes)
Yes, more than 1 (Yes, more than 1)
Peripheral vascular Venous thrombosis with
swelling, ulceration, or venous stasis
Yes
No
Gastrointestinal Infarction or resection of bowel
below duodenum, spleen, liver, or gall bladder
ever, for cause any (score 2 if > 1)
Yes
No
Gastrointestinal Mesenteric insufficiency
Yes
No
Gastrointestinal Chronic peritonitis
Yes
No
Gastrointestinal Stricture or upper gastrointestinal
tract surgery ever
Yes
No
Musculoskeletal Muscle atrophy or weakness
Yes
No
Musculoskeletal Deforming or erosive arthritis
(including reducible deformities, excluding
avascular necrosis)
Yes
No
Musculoskeletal Osteoporosis with fracture or
vertebral collapse (excluding avascular necrosis)
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Yes
No
Musculoskeletal Avascular necrosis (score 2 if >
1 )
No (No)
Yes (Yes)
Yes, more than 1 (Yes, more than 1)
Musculoskeletal Osteomyelitis
Yes
No
Skin Scarring chronic alopecia
Yes
No
Skin Extensive scarring or panniculum other than
scalp and pulp space
Yes
No
Skin ulceration (excluding thrombosis) for >6
months
Yes
No
Premature gonadal failure
Yes
No
Diabetes (regardless of treatment)
Yes
No
Malignancy (exclude dysplasia) (score 2 if > 1
site)
Yes
No
4 / 4
Systemic Lupus Erythematosus Protocol PhenX Toolkit
Eligibility Breast Cancer NCT02282345
Neoadjuvant BMN673 for Patients With a BRCA
Deleterious Mutation; ODM derived from:
https://clinicaltrials.gov/show/NCT02282345
All rights reserved. Please visit https://medical-data-
models.org/forms/14776
Eligibility Breast Cancer
NCT02282345
Inclusion Criteria
1. signed written informed consent*
Yes
No
2. histologically confirmed primary invasive
adenocarcinoma of the breast with the size of the
primary tumor being at least 1 cm on imaging by
either mammography, ultrasound or breast mri*
Yes
No
3. negative her-2/neu- disease defined as
patients with fish ratio <2.0 or <6.0 her2 gene
copies per nucleus, and ihc staining scores of 0,
1+, or 2+.*
Yes
No
4. no prior treatment for primary invasive
adenocarcinoma of the breast such as irradiation,
chemotherapy, hormonal therapy, immunotherapy,
investigational therapy or surgery. subjects
receiving hormone replacement treatment (hrt)
are eligible if this therapy is discontinued at least
2 weeks before starting study therapy. treatment
for dcis is allowed, such as surgery, hormonal
therapy and radiotherapy.*
Yes
No
5. ecog performance status of 0-1*
Yes
No
6. baseline muga or echocardiogram scans with
lvef of > 50%.*
Yes
No
7. patient must have adequate organ function as
determined by the following laboratory values: a.
anc>/=1,500 /ul b. platelets >/=100,000 / ul c. hgb
>/= 9 g/dl d. creatinine clearance >50 ml/min e.
total bilirubin </= 1.5 x uln f. alt and ast < 2.5 x
uln*
Yes
No
8. men or women 18 years of age or older.*
Yes
No
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9. women of childbearing potential (wocbp) must
be using an adequate method of contraception to
avoid pregnancy throughout the study and for up
to 8 weeks after the last dose of investigational
product in such a manner that the risk of
pregnancy is minimized. for the purposes of this
study, wocbp will be considered 12 months
without menstruation. men on study also must be
using contraception.*
Yes
No
10. negative serum or urine pregnancy test for
women within 72 hours of receiving the first dose
of the study medication for women of childbearing
potential as per institutional guidelines.*
Yes
No
11. identified deleterious mutation in brca 1 or 2
genes ( this does not include variants of
uncertain significance).*
Yes
No
12. eligible to receive standard of care
chemotherapy and/or surgery based upon
standard practices or institutional guidelines.*
Yes
No
Exclusion Criteria
1. women who are pregnant (including positive
pregnancy test at enrollment or prior to study
drug administration) or breast-feeding.*
Yes
No
2. disease free of prior malignancy for < 5 years
with the exception of curatively treated basal
carcinoma of the skin or carcinoma in situ of the
cervix.*
Yes
No
3. any other previous antitumor therapies for the
current cancer event. treatment for dcis is
allowed, such as surgery, hormonal therapy and
radiotherapy.*
Yes
No
4. has had major surgery within 21 days before
cycle 1 day 1*
Yes
No
2 / 4
Eligibility Breast Cancer NCT02282345
5. gastrointestinal tract disease or defect with
associated malabsorption syndrome*
Yes
No
6. uncontrolled inflammatory bowel disease (e.g.,
crohn's disease, ulcerative colitis)*
Yes
No
7. myocardial infarction within 6 months before
starting therapy, symptomatic congestive heart
failure (new york heart association > class ii),
unstable angina, or unstable cardiac arrhythmia
requiring medication*
Yes
No
8. serious intercurrent infections or non-malignant
medical illness that are uncontrolled or the
control of which may be jeopardized by this
therapy*
Yes
No
9. psychiatric disorders or other conditions
rendering the subject incapable of complying with
the requirements of the protocols*
Yes
No
10. unable to take oral medications*
Yes
No
11. known to be human immunodeficiency virus
positive*
Yes
No
12. known active hepatitis c virus, or known
active hepatitis b virus*
Yes
No
13. concurrent disease or condition that would
interfere with study participation or safety, such
as any of the following: • active, clinically
significant infection either grade > 2 by national
cancer institute (nci) common terminology criteria
for adverse events (ctcae) v4.03 or requiring the
use of parenteral anti-microbial agents within 14
days before day 1 of study drug • clinically
significant bleeding diathesis or coagulopathy,
including known platelet function disorders • non-
healing wound, ulcer, or bone fracture*
Yes
No
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14. known hypersensitivity to any of the
components of bmn 673*
Yes
No
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Sleep Apnea - Child Protocol PhenX Toolkit
The Pediatric Sleep Questionnaire (PSQ) protocol is a
parent questionnaire for children from 2 through 18 years,
and rated on a simple three-point scale ("yes," "no," or
"don’t know") for all items except the
inattention/hyperactivity items that are rated on a four-point
Likert scale. This protocol provides an overall total score
and five sleep scales: (1) Sleep-Related Breathing
Disorders (SRBD), (2) Snoring, (3) Sleepiness, (4)
Behavior, and (5) Periodic Limb Movement Disorder
(PLMD).
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Sleep Apnea - Child Protocol PhenX
Toolkit
PhenX - respiratory - sleep apnea - child
protocol
Date of observation
Where are you completing this questionnaire?
Birth date
Sex
Male (1)
Female (2)
Body height --standing
cm
Body weight
kg
Grade in school, if applicable
Racial or ethnic background of your child
African-American  (African-American )
American Indian  (American Indian )
Asian-American     (Asian-American    )
Hispanic     (Hispanic    )
Other or unknown (Other or unknown)
White/Not Hispanic     (White/Not
Hispanic    )
While sleeping, does your child ever snore?
Don't know (Don't know)
No (No)
Yes (Yes)
While sleeping, does your child ever snore more
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than half the time?
Don't know (Don't know)
No (No)
Yes (Yes)
While sleeping, does your child always snore?
Don't know (Don't know)
No (No)
Yes (Yes)
While sleeping, does your child snore loudly?
Don't know (Don't know)
No (No)
Yes (Yes)
While sleeping, does your child have heavy or
loud breathing?
Don't know (Don't know)
No (No)
Yes (Yes)
While sleeping, does your child have trouble
breathing, or struggle to breathe?
Don't know (Don't know)
No (No)
Yes (Yes)
Have you ever seen your child stop breathing
during the night?
Don't know (Don't know)
No (No)
Yes (Yes)
Have you ever been concerned about your childs
breathing during sleep?
Don't know (Don't know)
No (No)
Yes (Yes)
Have you ever had to shake your sleeping child to
get him or her to breathe, or wake up and
breathe?
Don't know (Don't know)
No (No)
Yes (Yes)
Have you ever seen your child wake up with a
snorting sound?
Don't know (Don't know)
No (No)
Yes (Yes)
Does your child have restless sleep?
Don't know (Don't know)
No (No)
Yes (Yes)
Does your child describe restlessness of the legs
when in bed?
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Don't know (Don't know)
No (No)
Yes (Yes)
Does your child have growing pains (unexplained
leg pains)?
Don't know (Don't know)
No (No)
Yes (Yes)
Does your child have growing pains that are
worst in bed?
Don't know (Don't know)
No (No)
Yes (Yes)
While your child sleeps, have you seen brief kicks
of one leg or both legs?
Don't know (Don't know)
No (No)
Yes (Yes)
While your child sleeps, have you seen repeated
kicks or jerks of the legs at regular intervals (i.e.,
about every 20 to 40 seconds)?
Don't know (Don't know)
No (No)
Yes (Yes)
At night, does your child usually become sweaty,
or do the pajamas usually become wet with
perspiration?
Don't know (Don't know)
No (No)
Yes (Yes)
At night, does your child usually get out of bed for
any reason?
Don't know (Don't know)
No (No)
Yes (Yes)
At night, does your child usually get out of bed to
urinate?
Don't know (Don't know)
No (No)
Yes (Yes)
If your child usually gets out of bed to urinate,
how many times each night, on average?
Does your child usually sleep with the mouth
open?
Don't know (Don't know)
No (No)
Yes (Yes)
Is your child's nose usually congested or stuffed
at night?
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Don't know (Don't know)
No (No)
Yes (Yes)
Do any allergies affect your childs ability to
breathe through the nose?
Don't know (Don't know)
No (No)
Yes (Yes)
Does your child tend to breathe through the
mouth during the day?
Don't know (Don't know)
No (No)
Yes (Yes)
Does your child have a dry mouth on waking up
in the morning?
Don't know (Don't know)
No (No)
Yes (Yes)
Does your child complain of an upset stomach at
night?
Don't know (Don't know)
No (No)
Yes (Yes)
Does your child get a burning feeling in the throat
at night?
Don't know (Don't know)
No (No)
Yes (Yes)
Does your child grind his or her teeth at night?
Don't know (Don't know)
No (No)
Yes (Yes)
Does your child occasionally wet the bed?
Don't know (Don't know)
No (No)
Yes (Yes)
Has your child ever walked during sleep (sleep
walking)?
Don't know (Don't know)
No (No)
Yes (Yes)
Have you ever heard your child talk during sleep
(sleep talking)?
Don't know (Don't know)
No (No)
Yes (Yes)
Does your child have nightmares once a week or
more on average?
Don't know (Don't know)
No (No)
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Yes (Yes)
Has your child ever woken up screaming during
the night?
Don't know (Don't know)
No (No)
Yes (Yes)
Has your child ever been moving or behaving, at
night, in a way that made you think your child was
neither completely awake nor asleep?
Don't know (Don't know)
No (No)
Yes (Yes)
Does your child have difficulty falling asleep at
night?
Don't know (Don't know)
No (No)
Yes (Yes)
How long does it take your child to fall asleep at
night?
At bedtime does your child usually have difficult
routines or rituals, argue a lot, or otherwise
behave badly?
Don't know (Don't know)
No (No)
Yes (Yes)
Does your child bang his or her head or rock his
or her body when going to sleep?
Yes
No
Does your child wake up more than twice a night
on average?
Don't know (Don't know)
No (No)
Yes (Yes)
Does your child have trouble falling back asleep if
he or she wakes up at night?
Don't know (Don't know)
No (No)
Yes (Yes)
Does your child wake up early in the morning and
have difficulty going back to sleep?
Don't know (Don't know)
No (No)
Yes (Yes)
Does the time at which your child goes to bed
change a lot from day to day?
Yes
No
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Does the time at which your child gets up from
bed change a lot from day to day?
Yes
No
What time does your child usually go to bed
during the week?
What time does your child usually go to bed on
the weekend or vacation?
What time does your child usually get out of bed
on weekday mornings?
What time does your child usually get out of bed
on weekend or vacation mornings?
Does your child wake up feeling unrefreshed in
the morning?
Don't know (Don't know)
No (No)
Yes (Yes)
Does your child have a problem with sleepiness
during the day?
Don't know (Don't know)
No (No)
Yes (Yes)
Does your child complain that he or she feels
sleepy during the day?
Don't know (Don't know)
No (No)
Yes (Yes)
Has a teacher or other supervisor commented
that your child appears sleepy during the day?
Don't know (Don't know)
No (No)
Yes (Yes)
Does your child usually take a nap during the
day?
Don't know (Don't know)
No (No)
Yes (Yes)
Is it hard to wake your child up in the morning?
Don't know (Don't know)
No (No)
Yes (Yes)
Does your child wake up with headaches in the
morning?
Don't know (Don't know)
No (No)
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Yes (Yes)
Does your child get a headache at least once a
month, on average?
Don't know (Don't know)
No (No)
Yes (Yes)
Did your child stop growing at a normal rate at
any time since birth?
Don't know (Don't know)
No (No)
Yes (Yes)
What happened if child stopped growing at a
normal rate at any time since birth?
Does your child still have tonsils?
Don't know (Don't know)
No (No)
Yes (Yes)
When were they removed?
Why were they removed?
Has your child ever had a condition causing
difficulty with breathing?
Don't know (Don't know)
No (No)
Yes (Yes)
Condition causing difficulty with breathing
Has your child ever had surgery?
Don't know (Don't know)
No (No)
Yes (Yes)
Did any difficulties with breathing occur before,
during, or after surgery?
Don't know (Don't know)
No (No)
Yes (Yes)
Has your child ever become suddenly weak in the
legs, or anywhere else, after laughing or being
surprised by something?
Don't know (Don't know)
No (No)
Yes (Yes)
Has your child ever felt unable to move for a short
period, in bed, though awake and able to look
around?
Don't know (Don't know)
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No (No)
Yes (Yes)
Has your child felt an irresistible urge to take a
nap at times, forcing him or her to stop what he or
she is doing in order to sleep?
Don't know (Don't know)
No (No)
Yes (Yes)
Has your child ever sensed that he or she was
dreaming, seeing images or hearing sounds,
while still awake?
Don't know (Don't know)
No (No)
Yes (Yes)
Does your child drink caffeinated beverages on a
typical day (cola, tea, coffee)?
Don't know (Don't know)
No (No)
Yes (Yes)
How many cups or cans per day?
Does your child use any recreational drugs?
Don't know (Don't know)
No (No)
Yes (Yes)
Which recreational drugs does your child use?
How often does your child use recreational
drugs?
Does your child use cigarettes, smokeless
tobacco, snuff, or other tobacco products?
Don't know (Don't know)
No (No)
Yes (Yes)
Which tobacco products does your child use?
How often does your child use cigarettes,
smokeless tobacco, snuff, or other tobacco
products?
Is your child overweight?
Don't know (Don't know)
No (No)
Yes (Yes)
At what age did this first develop?
Has a doctor ever told you that your child has a
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high-arched palate, roof of the mouth?
Don't know (Don't know)
No (No)
Yes (Yes)
Has your child ever taken Ritalin,
methylphenidate, for behavioral problems?
Don't know (Don't know)
No (No)
Yes (Yes)
Has a health professional ever said that your
child has attention-deficit disorder (ADD), or
attention-deficit-hyperactivity disorder (ADHD)?
Don't know (Don't know)
No (No)
Yes (Yes)
If you are currently at a clinic with your child to
see a physician, what is the problem that brought
you?
Service comment
This child often does not seem to listen when
spoken to directly.
Applies just a little     (Applies just a little
)
Applies quite a bit  (Applies quite a bit )
Definitely applies most of the time
(Definitely applies most of the time)
Does not apply     (Does not apply    )
Long - term medical problem
If your child has long-term medical problems,
please list the three you think are most
significant?
Medication list
Current medication, Name
Please list any medications your child currently
takes: Size (mg) or amount per dose.
Please list any medications your child currently
takes: Taken how often?
Please list any medications your child currently
takes: Dates Taken.
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Please list any medications your child currently
takes: Effect.
Psychological, psychiatric, emotional, or
behavioral problem
List any psychological, psychiatric, emotional, or
behavioral problems diagnosed or suspected by a
physician in your child.
The date the psychological, psychiatric,
emotional, or behavioral problem started?
Is the psychological, psychiatric, emotional, or
behavioral problem still present?
Yes
No
Sleep disorders
List any sleep disorders diagnosed or suspected
by a physician in your child?
The date the sleep disorder started.
Is the sleep disorder still present?
Yes
No
Sleep or behavior disorders relatives
Please list any sleep or behavior disorders
diagnosed or suspected in your child's brothers,
sisters, or parents: Condition.
Please list any sleep or behavior disorders
diagnosed or suspected in your child's brothers,
sisters, or parents: Relative.
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Eligibility Advanced Non-small Cell Lung
Cancer NCT00708812
Paclitaxel Plus Carboplatin With or Without Endostar in
Patients With Advanced Non-small Cell Lung Cancer; ODM
derived from: https://clinicaltrials.gov/show/NCT00708812
All rights reserved. Please visit https://medical-data-
models.org/forms/14778
Eligibility Advanced Non-small Cell
Lung Cancer NCT00708812
Inclusion Criteria
histologically or cytologically confirmed,
previously untreated stage iiib or iv nsclc*
Yes
No
age of 18-75 years*
Yes
No
at least one measurable lesion (recist)*
Yes
No
patients evaluated as sd or above after 1 cycle
(21 days) of tc chemotherapy*
Yes
No
adequate hematologic, cardiac, renal, and
hepatic function*
Yes
No
ecog ps 0-2*
Yes
No
Exclusion Criteria
symptomatic brain metastases*
Yes
No
bone metastases with complications*
Yes
No
major organ dysfunction*
Yes
No
bleeding diathesis or coagulopathy*
Yes
No
pregnant or lactating woman*
Yes
No
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Eligibility Advanced Breast Cancer
NCT00793546
Study Evaluating Bosutinib-Exemestane Combination Vs
Exemestane Alone in Post Menopausal Women With
Breast Cancer; ODM derived from:
https://clinicaltrials.gov/show/NCT00793546
All rights reserved. Please visit https://medical-data-
models.org/forms/14779
Eligibility Advanced Breast Cancer
NCT00793546
Inclusion Criteria
woman aged 18 years or older.*
Yes
No
confirmed pathologic diagnosis of breast cancer*
Yes
No
locally advanced, metastatic, or locoregional
recurrent breast cancer not amenable to curative
treatment with surgery or radiotherapy.*
Yes
No
surgically sterile or postmenopausal woman*
Yes
No
documented er+ and/or pgr+ and erbb2- tumor*
Yes
No
progression of locally advanced or metastatic
disease during treatment with a nonsteroidal ai or
tamoxifen, or progression during treatment with
(or within 6 months of discontinuation of) an
adjuvant nonsteroidal ai.*
Yes
No
Exclusion Criteria
prior exemestane, prior bosutinib, or any other
prior anti-src therapy.*
Yes
No
more than 1 prior endocrine treatment for locally
advanced or mbc*
Yes
No
more than 1 prior cytotoxic chemotherapy
regimen in metastatic setting.*
Yes
No
bone or skin as the only site of disease.*
Yes
No
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Eligibility Advanced Solid Tumors
NCT00520637
A Phase I, Study to Evaluate the Safety and Tolerability of
Intravenous EZN-2208 in Patients With Advanced Solid
Tumors or Lymphoma (EZN-2208-01); ODM derived from:
https://clinicaltrials.gov/show/NCT00520637
All rights reserved. Please visit https://medical-data-
models.org/forms/14780
Eligibility Advanced Solid Tumors
NCT00520637
Inclusion Criteria
histologically or cytologically confirmed diagnosis
of  advanced and/or metastatic solid tumor or
lymphoma that is refractory to standard therapy*
Yes
No
measurable or evaluable disease*
Yes
No
score of 0 to 2 on the ecog performance scale*
Yes
No
Exclusion Criteria
concurrent serious medical illness*
Yes
No
known, clinically suspected, or history of central
nervous system (cns) tumor involvement*
Yes
No
active diarrhea*
Yes
No
known history of coagulation disorder*
Yes
No
patients requiring cytochrome p450 3a4 (cyp3a4)
enzyme inducing medications*
Yes
No
requirement for ketoconazole or other strong
inhibitor of cyp3a4 enzymes*
Yes
No
prior chemotherapy, immunotherapy,
investigational agent, or other therapy used to
treat the cancer within 4 weeks (6 weeks for prior
treatment with mitomycin c or nitrosoureas) prior
to the scheduled administration of ezn-2208*
Yes
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Eligibility Advanced Urothelial Carcinoma
NCT01487915
Gemcitabine-Carboplatin Versus Gemcitabine-Oxaliplatin in
Cisplatin-unfit Urothelial Carcinoma; ODM derived from:
https://clinicaltrials.gov/show/NCT01487915
All rights reserved. Please visit https://medical-data-
models.org/forms/14781
Eligibility Advanced Urothelial
Carcinoma NCT01487915
Inclusion Criteria
cytologically of histologically confirmed urothelial
carcinoma*
Yes
No
locally advanced or metastatic disease*
Yes
No
measurable disease according to recist v.1.1*
Yes
No
ecog ps 0-2*
Yes
No
cisplatin-unfit condition (any of the followings:
nyha functional class 3, creatinine clearance 30-
60 ml/min, and ecog ps=2)*
Yes
No
adequate organ function*
Yes
No
chemotherapy-naive*
Yes
No
Exclusion Criteria
histology other than urothelial carcinoma, but
squamous cell carcinoma or adenocarcinoma
mixed with urothelial carcinoma are allowed*
Yes
No
cns metastases*
Yes
No
peripheral neuropathy grade 2 or worse*
Yes
No
serious medical or surgical conditions*
Yes
No
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Eligibility Advanced Hepatocellular
Carcinoma (HCC) NCT02509169
Trans-catheter Arterial Embolization Combined With p53
Gene Therapy for Treatment of Advanced Hepatocellular
Carcinoma; ODM derived from:
https://clinicaltrials.gov/show/NCT02509169
All rights reserved. Please visit https://medical-data-
models.org/forms/14782
Eligibility Advanced Hepatocellular
Carcinoma (HCC) NCT02509169
Inclusion Criteria
histopathologically diagnosed unresectable hcc*
Yes
No
over 18 years old*
Yes
No
with an eastern cooperative oncology group
(ecog) score of 0-2*
Yes
No
with barcelona clinic liver cancer (bclc) stage of b
or c*
Yes
No
with child-pugh score a or b; with normal tests of
hemogram, blood   coagulation, liver and kidney
function*
Yes
No
signed the informed consent form.*
Yes
No
Exclusion Criteria
hypersensitive to study drug*
Yes
No
with an abnormal coagulation condition or
bleeding disorder*
Yes
No
infections*
Yes
No
with serious conditions which prevent using the
study treatment*
Yes
No
pregnant or lactating*
Yes
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Eligibility Advanced Prostate Cancer
NCT02420977
Evaluation of PSMA-based PET as an Imaging Biomarker
in Prostate Cancer; ODM derived from:
https://clinicaltrials.gov/show/NCT02420977
All rights reserved. Please visit https://medical-data-
models.org/forms/14783
Eligibility Advanced Prostate Cancer
NCT02420977
Inclusion Criteria
men 18 years of age or greater with recently
diagnosed prostate cancer with planned radiation
and adt.*
Yes
No
newly diagnosed prostate cancer pathologically
proven by prostate biopsy*
Yes
No
prostate biopsy histology grade ≥ gleason 8-10*
Yes
No
patients considered as candidates for and
medically fit to undergo radiation and adt*
Yes
No
at least 10 days after most recent prostate
biopsy*
Yes
No
Exclusion Criteria
prior pelvic external beam radiation therapy or
brachytherapy*
Yes
No
chemotherapy for prostate cancer*
Yes
No
hormone deprivation therapy*
Yes
No
investigational therapy for prostate cancer*
Yes
No
hemorrhagic cystitis or active prostatitis*
Yes
No
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NINDS CDE Participant/Subject
Characteristics Epilepsy
NINDS Common Data Elements (Participant/Subject
Characteristics Epilepsy) Used from the National Institute
of Neurological Disorders and Stroke Common Data
Elements
(https://www.commondataelements.ninds.nih.gov/)
References: Grinnon ST, Miller K, Marler JR, Lu Y, Stout A,
Odenkirchen J, Kunitz S. National Institute of Neurological
Disorders and Stroke Common Data Element Project -
approach and methods. Clin Trials. 2012;9(3):322-9.
All rights reserved. Please visit https://medical-data-
models.org/forms/14784
Demographics and Social Status
Demographics
Study ID
Study site name
Subject ID
Date of birth
Gender
Female (1)
Male (2)
Unknown (3)
Unspecified (4)
Not reported (5)
Ethnicity
Hispanic or Latino (1)
not Hispanic or Latino (2)
Not Reported (3)
Unknown (4)
Race
American Indian or Alaskan Native (1)
Asian (2)
Black or African American (3)
Native Hawaiian or Other Pacific Islander
(4)
Unknown (5)
White (6)
Not reported (7)
Years of education
years
Snomed CT code
Medical History Term
Primary Language
0 English (eng) (1)
0 Spanish (spa) (2)
Sign Languages (sgn) (3)
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Chinese languages (chi) (4)
French (fre) (5)
German (ger) (6)
Other, specify (7)
Primary Language:if other please specify
Social Status
Employment status
Working now (Answer 6b below) (1)
Unknown (10)
Student (2)
Looking for work, unemployed (3)
Only temporarily laid off (4)
Sick leave or maternity leave (5)
Retired (6)
Disabled, permanently or temporarily (7)
Keeping house (Regardless of marital
status)  (8)
Other, specify: (9)
If working now, do you work 35 hours or more per
week?
Yes	 (1)
No (2)
Hours vary (3)
Unknown (4)
Not reported (5)
Highest education level attained
Never attended/ Kindergarten only (1)
9th Grade (10)
10th Grade (11)
11th Grade (12)
12th Grade, no diploma (13)
High school graduate (14)
GED or equivalent (15)
Some college, no degree  (16)
Associate degree: occupational,
technical, or vocational program (17)
Associate degree: academic program
(18)
Bachelor´s degree (e.g., BA, AB, BS,
BBA) (19)
1st Grade (2)
Master´s degree (e.g., MA, MS, MEng,
MEd, MBA) (20)
Professional school degree (e.g., MD,
DDS, DVM, JD) (21)
Doctoral degree (e.g., PhD, EdD) (22)
Unknown (23)
2nd Grade (3)
3rd Grade (4)
4th Grade (5)
5th Grade (6)
6th Grade (7)
7th Grade (8)
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8th Grade (9)
If pediatric participant/subject (<18 yo), Mother’s
Education Level
Never attended/ Kindergarten only (1)
9th Grade (10)
10th Grade (11)
11th Grade (12)
12th Grade, no diploma (13)
High school graduate (14)
GED or equivalent (15)
Some college, no degree (16)
Associate degree: occupational,
technical, or vocational program (17)
Associate degree: academic program
(18)
Bachelor's degree (e.g., BA, AB, BS,
BBA) (19)
1st Grade (2)
Master's degree (e.g., MA, MS, MEng,
MEd, MBA) (20)
Professional school degree (e.g., MD,
DDS, DVM, JD) (21)
Doctoral degree (e.g., PhD, EdD)  (22)
Unknown (23)
2nd Grade  (3)
3rd Grade (4)
4th Grade  (5)
5th Grade  (6)
6th Grade (7)
7th Grade  (8)
8th Grade (9)
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NINDS CDE Participant/Subject
Characteristics Friedreich's Ataxia
NINDS Common Data Elements (Participant/Subject
Characteristics Friedreich's Ataxia) Used from the National
Institute of Neurological Disorders and Stroke Common
Data Elements
(https://www.commondataelements.ninds.nih.gov/)
References: Grinnon ST, Miller K, Marler JR, Lu Y, Stout A,
Odenkirchen J, Kunitz S. National Institute of Neurological
Disorders and Stroke Common Data Element Project -
approach and methods. Clin Trials. 2012;9(3):322-9.
All rights reserved. Please visit https://medical-data-
models.org/forms/14785
Demographics and Social Status
Demographics
Study ID
Study site name
Subject ID
Date of birth
Gender
Female (1)
Male (2)
Unknown (3)
Unspecified (4)
Not reported (5)
Ethnicity
Hispanic or Latino (1)
not Hispanic or Latino (2)
Not Reported (3)
Unknown (4)
Race
American Indian or Alaskan Native (1)
Asian (2)
Black or African American (3)
Native Hawaiian or Other Pacific Islander
(4)
Unknown (5)
White (6)
Not reported (7)
Years of education
years
Snomed CT code
Medical History Term
Primary Language
English (eng)	 (1)
Other, specify: (10)
Spanish (spa) (2)
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German (ger) (3)
Chinese (chi)	 (4)
French/Creole (cpf) (5)
Arabic (ara) (6)
Russian (rus) (7)
Italian (ita) (8)
Polish (pol) (9)
Primary Language:if other please specify
Country of Residence
USA (US) (1)
Canada (CA)	 (2)
United Kingdom (GB)	 (3)
Mexico (MX) (4)
Australia (AU) (5)
Other, specify (6)
Country of Residence: if other, please specify
ZIP Code (First three digits only)
Social Status
Employment status
Working now (Answer 6b below) (1)
Unknown (10)
Student (2)
Looking for work, unemployed (3)
Only temporarily laid off (4)
Sick leave or maternity leave (5)
Retired (6)
Disabled, permanently or temporarily (7)
Keeping house (Regardless of marital
status)  (8)
Other, specify: (9)
If working now, do you work 35 hours or more per
week?
Yes	 (1)
No (2)
Hours vary (3)
Unknown (4)
Not reported (5)
Highest education level attained
Never attended/ Kindergarten only (1)
9th Grade (10)
10th Grade (11)
11th Grade (12)
12th Grade, no diploma (13)
High school graduate (14)
GED or equivalent (15)
Some college, no degree  (16)
Associate degree: occupational,
technical, or vocational program (17)
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Associate degree: academic program
(18)
Bachelor´s degree (e.g., BA, AB, BS,
BBA) (19)
1st Grade (2)
Master´s degree (e.g., MA, MS, MEng,
MEd, MBA) (20)
Professional school degree (e.g., MD,
DDS, DVM, JD) (21)
Doctoral degree (e.g., PhD, EdD) (22)
Unknown (23)
2nd Grade (3)
3rd Grade (4)
4th Grade (5)
5th Grade (6)
6th Grade (7)
7th Grade (8)
8th Grade (9)
Marital status
Never Married (1)
Married (2)
Domestic Partnership (3)
Separated  (4)
Divorced (5)
Widowed (6)
Number of people the participant/subject lives or
stays with
Persons living with the participant (choose all that
apply)
Husband or wife (1)
Parent-in-law (10)
Son-in-law or daughter-in-law (11)
Other relative (12)
Roomer or boarder (13)
Housemate or roommate (14)
Unmarried partner (15)
Foster child (16)
Other patient/ resident in care facility
(17)
Personal care attendant (18)
Military unit member (19)
Biological son or daughter (2)
Other nonrelative (20)
N/A – Homeless (21)
N/A – Alone (22)
Unknown (23)
Adopted son or daughter (3)
Stepson or stepdaughter (4)
Brother or sister (5)
Father or mother (6)
Stepfather or stepmother (7)
Grandchild (8)
Grandparent   (9)
How many hours in a typical 24-hour day do you
have someone with you (paid assistance) to
provide physical assistance for personal care
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activities such as eating, bathing, dressing,
toileting and mobility (hours paid assistance):
hrs/24h
How many hours in a typical 24-hour day do you
have someone with you (unpaid assistance) to
provide physical assistance for personal care
activities such as eating, bathing, dressing,
toileting and mobility(hours unpaid assistance
family, others):
hrs/24h
How much time is someone with you in your
home to assist you with activities that require
remembering, decision making, or judgment?
Someone is always with me to observe
or supervise. (1)
Someone is always around, but they only
check on me now and then. (2)
Sometimes I am left alone for an hour or
two. (3)
Sometimes I am left alone for most of the
day. (4)
I have been left alone all day and all
night, but someone checks in on me. (5)
I am left alone without anyone checking
on me. (6)
Family size (including yourself, number of people
supported by family income):
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Eligibility Breast Cancer NCT02301988
A Study of Ipatasertib (GDC-0068) in Combination With
Paclitaxel as Neoadjuvant Treatment for Patients With Early
Stage Triple Negative Breast Cancer; ODM derived from:
https://clinicaltrials.gov/show/NCT02301988
All rights reserved. Please visit https://medical-data-
models.org/forms/14786
Eligibility Breast Cancer
NCT02301988
Inclusion Criteria
premenopausal or postmenopausal women, age
>/=18 years*
Yes
No
eastern cooperative oncology group (ecog)
performance status of 0 or 1*
Yes
No
histologically documented, stage ia to operable
stage iiia, triple-negative carcinoma of the breast
with primary tumor >/=1.5 cm in largest diameter
(ct1-3) by magnetic resonance imaging (mri)*
Yes
No
adequate hematologic and organ function within
14 days before the first study treatment*
Yes
No
availability of tumor tissue from formalin-fixed,
paraffin-embedded (ffpe) core biopsy of breast
primary tumor*
Yes
No
for female patients of childbearing potential,
agreement to use highly effective form(s) of
contraception for the duration of the study and for
at least 6 months after last dose of study
treatment*
Yes
No
Exclusion Criteria
known her2-positive, er-positive, or pgr-positive
breast cancer*
Yes
No
any prior treatment for the current primary
invasive breast cancer*
Yes
No
patients with ct4 or cn3 stage breast tumors*
Yes
No
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metastatic (stage iv) breast cancer*
Yes
No
bilateral invasive breast cancer*
Yes
No
multicentric breast cancer*
Yes
No
any disease, metabolic dysfunction, physical
examination finding, or clinical laboratory finding
that contraindicates the use of an investigational
drug or that may affect the interpretation of the
results or render the patient at high risk from
treatment complications*
Yes
No
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Eligibility Breast Cancer NCT02306265
Assessment of Diagnostic Accuracy and Performance of
Digital Breast Tomosynthesis Compared to Mammography;
ODM derived from:
https://clinicaltrials.gov/show/NCT02306265
All rights reserved. Please visit https://medical-data-
models.org/forms/14787
Eligibility Breast Cancer
NCT02306265
Inclusion Criteria
women aged 30 years or older (≥30 years old);*
Yes
No
asymptomatic women scheduled for screening
mammography or have completed a screening
mammogram within the past 30 days;*
Yes
No
mammography completed on a ge ffdm system
(with cc and mlo views) at the site or another
clinical facility;*
Yes
No
are able and willing to comply with study
procedures;*
Yes
No
have signed and dated the informed consent
form;*
Yes
No
are either surgically sterile or postmenopausal or,
if of childbearing potential, the possibility of
pregnancy is remote based on a documented
negative patient history and, optionally, a
negative urine pregnancy test (if subject requests
one).*
Yes
No
Exclusion Criteria
have been previously included in this study;*
Yes
No
have a history of breast cancer and are in active
treatment.  however, subjects with a prior
lumpectomy (> 5 years prior) who receive only
routine screening mammography views can be
included;*
Yes
No
have breasts too large to be adequately
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positioned on 24 x 31 centimeter (cm) ffdm digital
receptor without anatomical cut off during either
ffdm or dbt examination;*
Yes
No
have participated in (within the prior 30 days)
another trial of an investigational product
expected to interfere with study procedures or
outcomes;*
Yes
No
have breast implant(s);*
Yes
No
have reconstructed breast(s).*
Yes
No
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Eligibility Breast Cancer NCT02311543
Impact of a Surgical Sealing Patch on Lymphatic Drainage
After ALND for Breast Cancer; ODM derived from:
https://clinicaltrials.gov/show/NCT02311543
All rights reserved. Please visit https://medical-data-
models.org/forms/14788
Eligibility Breast Cancer
NCT02311543
Inclusion Criteria
at registration*
Yes
No
patient has given written informed consent before
registration*
Yes
No
female patients; eligible for primary alnd or
sentinel lymph node procedure with frozen
section and either:*
Yes
No
newly diagnosed*
Yes
No
or recurrent breast cancer in the conserved
breast, chest wall or axilla*
Yes
No
patients with histo- or cytology proven breast
cancer uicc/ajcc stage i-iii*
Yes
No
age ≥ 18 years*
Yes
No
fluency in either german, french, italian, spanish,
turkish or english*
Yes
No
the eq-5d questionnaire has been completed at
registration*
Yes
No
patient with child-bearing potential, willing to use
effective contraception, not currently pregnant
and agreeing not to become pregnant after trial
registration and during the 24 weeks after
surgery*
Yes
No
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a negative pregnancy test within 14 days prior to
inclusion is available for all women with child-
bearing potential*
Yes
No
inclusion criteria at randomization*
Yes
No
alnd indicated according to clinical standards,
either as single procedure or in combination with
breast conserving surgery*
Yes
No
exclusion criteria at registration:*
Yes
No
known hypersensitivity for tachosil® or fibrin
sealant*
Yes
No
patients with mastectomy (simultaneously or
within 1 month before registration); patients
undergoing completion mastectomy at a later day
will remain eligible and are evaluable for analysis
according to intention to treat. if the axillary drain
is still in place at the time of completion
mastectomy and a separate drain is inserted
underneath the skin flaps, only the axillary drain
will be considered*
Yes
No
prior axillary dissection (except prior sentinel
node procedure)*
Yes
No
prior axillary radiotherapy*
Yes
No
psychiatric disorder precluding understanding of
information on trial related topics, giving informed
consent, filling out qol forms*
Yes
No
concurrent treatment with other experimental
drugs or treatment in a clinical trial within 30 days
prior to trial entry*
Yes
No
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Eligibility Breast Cancer NCT02316509
Study of SRN-927 in Postmenopausal Women With Locally
Advanced or Metastatic Estrogen Receptor Positive Breast
Cancer; ODM derived from:
https://clinicaltrials.gov/show/NCT02316509
All rights reserved. Please visit https://medical-data-
models.org/forms/14790
Eligibility Breast Cancer
NCT02316509
Inclusion Criteria
histologically or cytologically proven diagnosis of
adenocarcinoma of the breast with evidence of
either locally recurrent disease not amenable to
resection or radiation therapy with curative intent,
or metastatic disease, both progressing after at
least 6 months of hormonal therapy for er+ breast
cancer*
Yes
No
er-positive, her2-negative*
Yes
No
no prior treatment with arn-810 (allowed only
during dose expansion stage)*
Yes
No
no more than 2 prior chemotherapies in the
advanced or metastatic setting*
Yes
No
at least 2 months must have elapsed from the
use of tamoxifen*
Yes
No
at least 6 months must have elapsed from the
use of fulvestrant*
Yes
No
at least 2 weeks must have elapsed from the use
of any other anti-cancer hormonal therapy*
Yes
No
at least 3 weeks must have elapsed from the use
of any chemotherapy*
Yes
No
females, 18 years of age or older*
Yes
No
postmenopausal status as defined by the
protocol*
Yes
1 / 2
No
eastern cooperative oncology group (ecog)
performance status </= 2*
Yes
No
adequate organ function*
Yes
No
Exclusion Criteria
untreated or symptomatic brain metastases*
Yes
No
current treatment with any systemic anti-cancer
therapies for advanced disease or any systemic
experimental treatment on another clinical trial*
Yes
No
any of the following within 12 months prior to
enrollment: myocardial infarction, severe/unstable
angina, ongoing cardiac dysrhythmias of grade
>/= 2, atrial fibrillation of any grade,
coronary/peripheral artery bypass graft,
symptomatic congestive heart failure, or
cerebrovascular accident including transient
ischemic attack*
Yes
No
active inflammatory bowel disease or chronic
diarrhea, short bowel syndrome, or upper
gastrointestinal surgery including gastric
resection*
Yes
No
known human immunodeficiency virus infection*
Yes
No
major surgery within 4 weeks prior to enrollment*
Yes
No
radiation therapy within 2 weeks prior to
enrollment*
Yes
No
2 / 2
Eligibility Breast Cancer NCT02316509
Eligibility Breast Cancer NCT02333890
A Phase 2 Randomized, Double-blind Trial Evaluating the
Effects of Chloroquine in Breast Cancer; ODM derived
from: https://clinicaltrials.gov/show/NCT02333890
All rights reserved. Please visit https://medical-data-
models.org/forms/14794
Eligibility Breast Cancer
NCT02333890
Inclusion Criteria
newly diagnosed histologically confirmed primary
invasive breast cancer who is currently not
undergoing any treatment while awaiting surgery
in the next 2-6 weeks*
Yes
No
tumour ≥ 1.5 cm by palpation or imaging*
Yes
No
ecog performance status 0-2*
Yes
No
written informed consent for the study*
Yes
No
Exclusion Criteria
known metastatic breast cancer*
Yes
No
history of pre-existing known retinal or ocular
pathology patient has only one functioning eye*
Yes
No
abnormal hepatic function (serum ast or alt >3x
upper limit of normal)*
Yes
No
currently on cq or hcq or has been on the drug
within the past 3 months for other conditions*
Yes
No
known history of psoriasis*
Yes
No
known history of epilepsy or seizures*
Yes
No
electrocardiogram showing qt prolongation based
on qtc interval >450 ms*
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Yes
No
inability to comply with a study protocol (abuse of
alcohol, drugs or psychotic states)*
Yes
No
current known pregnancy or actively nursing*
Yes
No
allergic reactions to quinolones or cq*
Yes
No
inability to consent.*
Yes
No
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Eligibility Breast Cancer NCT02336737
SentiMag® Intraoperative Comparison in Breast Cancer;
ODM derived from:
https://clinicaltrials.gov/show/NCT02336737
All rights reserved. Please visit https://medical-data-
models.org/forms/14795
Eligibility Breast Cancer
NCT02336737
Inclusion Criteria
subjects with a diagnosis of primary breast
cancer or subjects with pure ductal carcinoma in
situ (dcis).*
Yes
No
subjects scheduled for surgical intervention, with
a sentinel lymph node biopsy procedure being a
part of the surgical plan.*
Yes
No
subjects aged 18 years or more at the time of
consent.*
Yes
No
subjects with an ecog (eastern cooperative
oncology group) performance status of grade 0 -
2.*
Yes
No
subject has a clinical negative node status (i.e.
t0-3, n0, m0).*
Yes
No
Exclusion Criteria
the subject is pregnant or lactating.*
Yes
No
the subject has clinical or radiological evidence of
metastatic cancer including palpably abnormal or
enlarged lymph nodes.*
Yes
No
the subject has a known hypersensitivity to
isosulfan blue dye.*
Yes
No
the subject has participated in another
investigational drug study within 30 days of
scheduled surgery.*
Yes
No
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subject has had either a) previous axilla surgery,
b) reduction mammoplasty, or c) lymphatic
function that is impaired in the surgeon's
judgment.*
Yes
No
subject has had preoperative radiation therapy to
the affected breast or axilla.*
Yes
No
subject has received a feraheme® (ferumoxytol)
injection within the past 6 months.*
Yes
No
subject has intolerance or hypersensitivity to iron
or dextran compounds or to siennaxp.*
Yes
No
subject has an iron overload disease.*
Yes
No
subject has pacemaker or other implantable
device in the chest wall.*
Yes
No
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Eligibility Advanced Solid Malignancies
NCT02260661
Phase I, Dose Study to Look at the Safety and
Pharmacokinetics of AZD8835 in Patients With Advanced
Solid Tumours; ODM derived from:
https://clinicaltrials.gov/show/NCT02260661
All rights reserved. Please visit https://medical-data-
models.org/forms/14796
Eligibility Advanced Solid
Malignancies NCT02260661
Inclusion Criteria
understand the nature of the trial and provide
signed and dated written consent*
Yes
No
histological or cytological confirmation of a solid
tumor and disease progression*
Yes
No
histological or cytological confirmation of
er+her2- negative breast cancer and disease
progression or any other solid tumor with a
pik3ca gene mutation*
Yes
No
histological or cytological confirmation of
er+her2- negative postmenopausal breast cancer
with locally advanced or metastatic disease that
is eligible for fulvestrant treatment*
Yes
No
histological or cytological confirmation of
er+her2- negative postmenopausal breast cancer
with locally advanced or metastatic disease that
is eligible for fulvestrant treatment. patients must
also present with a tumor related mutation of the
pik3ca gene.*
Yes
No
Exclusion Criteria
recent chemotherapy, radiotherapy, hormonal
therapy, immunotherapy or investigational drugs
within 21 days or 5 half-days from enrolment*
Yes
No
received palliative/focal radiotherapy within 2
weeks of first dose of study treatment*
Yes
No
major surgery less than or equal to 21 days from
beginning of study drug*
Yes
No
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any of the following cardiac criteria: chf > class ii,
cardiac ventricular arrhythmia requiring therapy,
unstable angina, qtcf interval >470ms, abnormal
echo or muga at baseline (lvef <50%)*
Yes
No
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Eligibility Breast Cancer NCT00388115
Radiofrequency Ablation in Treating Patients With Early
Invasive Breast Cancer or Ductal Carcinoma in Situ; ODM
derived from: https://clinicaltrials.gov/show/NCT00388115
All rights reserved. Please visit https://medical-data-
models.org/forms/14797
Eligibility Breast Cancer
NCT00388115
Inclusion Criteria
females of ages ≥18 years.*
Yes
No
core biopsy proven invasive breast cancer or*
Yes
No
core biopsy proven low or intermediate grade
dcis.*
Yes
No
tumor less than or equal to 2.0 cm in diameter.*
Yes
No
no prior surgical treatment for breast cancer
within 30 days.*
Yes
No
life expectancy of > 10 years, not including the
diagnosis of cancer.*
Yes
No
ecog performance status of 0-2.*
Yes
No
informed consent given.*
Yes
No
multifocal invasive breast cancer patients are
eligible.  all tumors that are palpable or visualized
by uss can be treated.*
Yes
No
Exclusion Criteria
male subjects.*
Yes
No
ages < 18 years.*
Yes
No
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breast tumor > 2.0 cm in diameter.*
Yes
No
evidence of distant metastatic disease.*
Yes
No
evidence of diffuse calcification suggestive of
extensive or multifocal dcis.*
Yes
No
high grade dcis or presence of comedo-necrosis
because these lesions can be associated with
invasive breast cancer, which would go
undetected if the lesion is entirely destroyed by
the rf ablation.*
Yes
No
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Eligibility Advanced Breast Cancer
NCT00754325
Randomized Trial of Fulvestrant With or Without Dasatinib
in Men and Postmenopausal Women Who Have Hormone
Receptor-positive Advanced Breast Cancer Previously
Treated With an Aromatase Inhibitor; ODM derived from:
https://clinicaltrials.gov/show/NCT00754325
All rights reserved. Please visit https://medical-data-
models.org/forms/14798
Eligibility Advanced Breast Cancer
NCT00754325
Inclusion Criteria
histologically confirmed hormone receptor
positive (hr+) [(estrogen receptor (er+) and/or
progesterone receptors(pgr+)] breast cancer
according to immunohistochemistry (ihc)*
Yes
No
measureable or evaluable-only disease*
Yes
No
human epidermal growth factor receptor 2+
(her2+) or her2- breast cancer*
Yes
No
males and females ≥18 years of age*
Yes
No
females are post menopausal or surgically
sterile*
Yes
No
recurrent or progressive advanced breast cancer
(locally-advanced or metastatic), that has
progressed: (a) during or within 12 months after
completion of adjuvant aromatase inhibitor (ai)
treatment or (b) during ai treatment in advanced
setting (metastatic therapy)*
Yes
No
Exclusion Criteria
pregnant or breast feeding*
Yes
No
>1 chemotherapy regimen for advanced disease*
Yes
No
pleural or pericardial effusion*
Yes
No
serious cardiac condition*
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Yes
No
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Eligibility Agitation NCT01584440
Efficacy, Safety and Tolerability Study of AVP-923
(Dextromethorphan/Quinidine) for Treatment of Symptoms
of Agitation in Alzheimer's Patients; ODM derived from:
https://clinicaltrials.gov/show/NCT01584440
All rights reserved. Please visit https://medical-data-
models.org/forms/14799
Eligibility Agitation NCT01584440
Inclusion Criteria
diagnosis of probable alzheimer's disease (ad).*
Yes
No
the patient has clinically significant symptoms of
agitation secondary to ad, that interfere with daily
routine and for which a prescription medication is
deemed indicated, in the opinion of the
investigator.*
Yes
No
either out-patients or residents of an assisted-
living facility or a skilled nursing home.*
Yes
No
cgi-s score is ≥ 4 (moderately ill) at screening
and baseline.*
Yes
No
mini mental state examination (mmse) score at
screening between 8 and 28 (inclusive).*
Yes
No
caregiver who is able and willing to comply with
all required study procedures, ensuring that the
patient attends all study visits and takes the study
medication as instructed. in order to qualify as a
caregiver for this study, the individual should
spend time with the patient for a minimum of 4
hours on 4 separate days per week.*
Yes
No
Exclusion criteria
patient has other type of dementia (e.g., vascular
dementia, frontotemporal dementia, parkinson's
disease, substance-induced dementia).
Yes
No
patients with co-existent clinically significant or
unstable systemic diseases that could confound
the interpretation of the safety results of the study
(e.g. malignancy, poorly controlled diabetes,
poorly controlled hypertension, unstable
pulmonary, renal or hepatic disease, unstable
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ischemic cardiac disease, dilated
cardiomyopathy, certain cardiac conduction
abnormalities including qtc prolongation, or
unstable valvular heart disease).
Yes
No
patients with myasthenia gravis.
Yes
No
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Eligibility Advanced Colorectal Cancer
NCT00286000
High Dose Simplified Folfiri in Advanced Colorectal Cancer:
a Multicentre Phase II Study; ODM derived from:
https://clinicaltrials.gov/show/NCT00286000
All rights reserved. Please visit https://medical-data-
models.org/forms/14800
Eligibility Advanced Colorectal
Cancer NCT00286000
Inclusion Criteria
histologically or cytologically proven
adenocarcinoma of the colon or rectum*
Yes
No
documented progressive metastatic disease*
Yes
No
patients who have at least one uni-dimensional
measurable lesion by ct-scan or mri according to
response evaluation criteria in solid tumours
(recist)*
Yes
No
who performance status of 0 or 1*
Yes
No
adequate laboratory values of haematology,
liverfunction and renal function*
Yes
No
no previous chemotherapy for metastatic
colorectal cancer*
Yes
No
Exclusion Criteria
past or concurrent history of neoplasm other than
colorectal adenocarcinoma, except curatively
treated cancer free of disease for more than 10
years.*
Yes
No
bowel obstruction or sub-obstruction. crohn's
disease, or ulcerative colitis.*
Yes
No
other severe illness or medical condition such as
unstable cardiac disease under treatment,
myocardial infarction within 6 months before
inclusion.*
Yes
No
1 / 2
active uncontrolled infection*
Yes
No
other concomitant anticancer agent*
Yes
No
2 / 2
Eligibility Advanced Colorectal Cancer NCT00286000
Eligibility Breast Cancer NCT00770055
Internet Use Among Women With Recurrent Metastatic
Breast Cancer; ODM derived from:
https://clinicaltrials.gov/show/NCT00770055
All rights reserved. Please visit https://medical-data-
models.org/forms/14801
Eligibility Breast Cancer
NCT00770055
Criteria
diagnosis of recurrent breast cancer meeting
either of the following criteria:*
Yes
No
newly diagnosed metastatic disease*
Yes
No
recently diagnosed as progressive disease after
stable metastatic disease for at least 6 months*
Yes
No
must have received the same treatment for
metastatic breast cancer for at least 3 months*
Yes
No
have received no treatment for progressive
disease or have begun treatment for progressive
disease within the past month*
Yes
No
patient at the cancer institute of new jersey in
new brunswick or hamilton, new jersey*
Yes
No
hormone receptor status not specified*
Yes
No
patient characteristics:*
Yes
No
menopausal status not specified*
Yes
No
able to speak and write english*
Yes
No
free of diseases and cognitive impairments that
would interfere with comprehension of the survey
instruments or ability to provide informed
consent*
Yes
No
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prior concurrent therapy:*
Yes
No
see disease characteristics*
Yes
No
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Eligibility Advanced Non Small Cell Lung
Cancer NCT01631136
Strategies for Maintenance Therapies in Advanced Non
Small Cell Lung Cancer; ODM derived from:
https://clinicaltrials.gov/show/NCT01631136
All rights reserved. Please visit https://medical-data-
models.org/forms/14802
Eligibility Advanced Non Small Cell
Lung Cancer NCT01631136
Inclusion Criteria
non-squamous nsclc histologically or cytologically
confirmed*
Yes
No
stage iv with a cytologically or histologically
confirmation for an unique metastasis*
Yes
No
no egfr activating mutation or indeterminate egfr
mutational status*
Yes
No
at least one measurable lesion*
Yes
No
age between 18 and 70*
Yes
No
ps 0 or 1*
Yes
No
Exclusion Criteria
squamous cell lung cancer, small cell lung cancer
, neuroendocrine cell lung cancer*
Yes
No
knowledge of alk gene rearrangement*
Yes
No
symptomatic central nervous system metastases
or requiring immediate cerebral radiotherapy*
Yes
No
superior venous cave syndrome except if treated
by implantation of a prosthesis*
Yes
No
previous anti-tumoral treatment*
Yes
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No
concomitant radiotherapy*
Yes
No
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Eligibility Breast Cancer NCT00813878
Nipple Secretion Samples in Detecting Breast Cancer in
Patients and Healthy Participants Undergoing Breast
Cancer Screening, Breast Diagnostic Studies, or Treatment
for Benign Breast Disease; ODM derived from:
https://clinicaltrials.gov/show/NCT00813878
All rights reserved. Please visit https://medical-data-
models.org/forms/14803
Eligibility Breast Cancer
NCT00813878
Criteria
referred to the women's health center at the city
of hope national medical center for breast cancer
screening, breast diagnostic studies, or treatment
of breast disease*
Yes
No
meets 1 of the following criteria:*
Yes
No
asymptomatic and undergoing screening
mammography (normal controls)*
Yes
No
symptomatic and undergoing diagnostic
mammography*
Yes
No
history of an abnormal mammogram and
undergoing stereotactic or ultrasound-guided
fine-needle aspiration or core needle biopsy*
Yes
No
recently diagnosed biopsy-proven unilateral
breast cancer prior to initiation of surgical or
systemic therapy*
Yes
No
no prior breast surgery or surgical biopsy that
removed the current breast pathology*
Yes
No
no prior breast reconstruction or breast reduction
surgery that altered the ductal drainage pattern in
the affected breast*
Yes
No
patient characteristics:*
Yes
No
no other cancer within the past 5 years except
skin cancer*
1 / 2
Yes
No
not pregnant or nursing*
Yes
No
prior concurrent therapy:*
Yes
No
see disease characteristics*
Yes
No
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Eligibility Breast Cancer NCT02324205
Assessment of Diagnostic Accuracy and Performance of
Digital Breast Tomosynthesis Compared to Mammography
(ADAPT); ODM derived from:
https://clinicaltrials.gov/show/NCT02324205
All rights reserved. Please visit https://medical-data-
models.org/forms/14804
Eligibility Breast Cancer
NCT02324205
Inclusion Criteria
women aged 30 years or older (≥30 years old);*
Yes
No
initially asymptomatic women who underwent
routine screening ffdm, breast ultrasound (u/s),
breast magnetic resonance imaging (mri) and/or
dbt, followed by diagnostic work-up showing one
of more abnormalities and referred for breast
biopsy within of 30 days before study entry    2;*
Yes
No
are able and willing to comply with study
procedures;*
Yes
No
have signed and dated the informed consent
form;*
Yes
No
are either surgically sterile or post-menopausal3
or, if of childbearing potential, the possibility of
pregnancy is remote based on a documented
negative patient history and, optionally, has a
negative urine pregnancy test (if subject requests
one).*
Yes
No
Exclusion Criteria
have been previously included in this study;*
Yes
No
have a history of any symptoms and/or physical
signs of breast cancer in either breast (or if she
has had a mastectomy, have signs or symptoms
of breast cancer in the remaining breast);*
Yes
No
have breasts too large to be adequately
positioned on 24 x 31 centimeter (cm) ffdm digital
receptor without anatomical cut off during a dbt
examination (or ffdm, if required);*
Yes
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No
have participated in (within the prior 30 days),
another trial of an investigational product
expected to interfere with study procedures or
outcomes;*
Yes
No
have breast implant(s);*
Yes
No
have reconstructed breast(s).*
Yes
No
2 / 2
Eligibility Breast Cancer NCT02324205
Eligibility Breast Cancer NCT02338531
Biomarker Research Study for PF-03084014 in
cHEmoresistant Triple-negative Breast cAncer; ODM
derived from: https://clinicaltrials.gov/show/NCT02338531
All rights reserved. Please visit https://medical-data-
models.org/forms/14805
Eligibility Breast Cancer
NCT02338531
Inclusion Criteria
1. age ≥18 years old.*
Yes
No
2. female.*
Yes
No
3. histological diagnosis of triple-negative breast
cancer (tnbc) breast adenocarcinoma (er<1%,
pr<1% by (ihc) and her-2 0-1+ by ihc or ihc 2+
and fish or cish negative per updated asco
guidelines).*
Yes
No
4. no clinical or radiologic evidence of distant
metastasis.*
Yes
No
5. presence of residual primary disease of at
least 1.5 cm by u/s or mri within 14 days
preceding the last cycle of standard anthracycline
and taxane-based neoadjuvant chemotherapy.*
Yes
No
patients with synchronous synchronous bilateral
cancer and unilateral multifocal or multicentric or
bilateral disease breast cancer will be allowed
provided histologic diagnosis of tnbc is found on
all performed biopsies.*
Yes
No
6. completion of standard anthracycline and
taxane-based neoadjuvant chemotherapy. the
use of platinum agents in combination with
standard neoadjuvant chemotherapy is allowed.*
Yes
No
7. ecog performance status (ps) 0 or 1*
Yes
No
8. adequate bone marrow function: absolute
neutrophil count (anc)  ≥ 1500/μl or ≥1.5 x 109/l;
platelets ≥100000/μl or ≥100 x 109/l; hemoglobin
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≥ 9 g/dl.*
Yes
No
9. adequate renal function: serum creatinine ≤
1.5 x upper limit of normal (uln) or estimated
creatinine clearance ≥ 60 ml/min.*
Yes
No
10. adequate liver function:total serum bilirubin ≤
1.0 x uln or ≤ 2 x uln in cases of known gilberts
syndrome; aspartate and alanine
aminotransferase (ast and alt) ≤ 1.5 x uln;
alkaline phosphatase ≤ 2.5 x uln.*
Yes
No
11. for patients of childbearing potential: negative
serum/urine pregnancy test and use accepted
forms of non-hormonal contraception during the
study period and up to 6 months after treatment
completion.*
Yes
No
Exclusion Criteria
1. concurrent anti-cancer therapy for current
breast cancer (hormone therapy, chemotherapy,
radiotherapy, immunotherapy). patients already
included in another therapeutic trial involving an
experimental drug.*
Yes
No
2. pregnant or lactating women.*
Yes
No
3. any prior history of invasive breast cancer.*
Yes
No
4. any previous history of non-breast
malignancies (excepted basal cell carcinoma or
squamous cell carcinoma of the skin) in the
preceding 5 years.*
Yes
No
5. known hypersensitivity to the study drug or
excipients.*
Yes
No
6. patients with other concurrent severe and/or
uncontrolled medical disease or infection which
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could compromise participation in the study.*
Yes
No
7. subjects unable to swallow oral medications.*
Yes
No
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NINDS CDE General Health History
Friedreich's Ataxia
NINDS Common Data Elements (General Health History
Friedreich's Ataxia) Used from the National Institute of
Neurological Disorders and Stroke Common Data Elements
(https://www.commondataelements.ninds.nih.gov/)
References: Grinnon ST, Miller K, Marler JR, Lu Y, Stout A,
Odenkirchen J, Kunitz S. National Institute of Neurological
Disorders and Stroke Common Data Element Project -
approach and methods. Clin Trials. 2012;9(3):322-9.
All rights reserved. Please visit https://medical-data-
models.org/forms/14806
General Health History
Behavioral History
Date of evaluation
Study ID
Study site name
Subject ID
Current tobacco use?
Yes (1)
No (2)
Unknown (3)
Past tobacco use?
Yes (1)
No (2)
Unknown (3)
Age started tobacco use
yrs
Age stopped tobacco use
yrs
Ongoing tobacco use
Yes
No
Type(s) of tobacco used
Filtered cigarettes(Answer next Q) (1)
Cigars (2)
Other, specify (3)
Non-filtered cigarettes(Answer next Q)
(4)
Pipes (5)
Low tar cigarettes(Answer next Q) (6)
Chewing tobacco (7)
Type of tobacco used: if other type, please
specify
Average number of cigarettes smoked per day
Less than one cigarette per day (1)
1 / 18
1 cigarette per day (2)
2 to 5 cigarettes per day (3)
6 to 15 cigarettes per day(about ½ pack)
(4)
16 to 25 cigarettes per day (about 1
pack) (5)
26 to 35 cigarettes per day (about 1 ½
packs) (6)
More than 35 cigarettes per day (about 2
packs or more) (7)
Unknown (8)
Current drinker?
Yes (1)
No (2)
Unknown (3)
Past drinker?
Yes (1)
No (2)
Unknown (3)
Age started drinking
yrs
Age quit drinking
yrs
Ongoing use
Yes
No
How often do you have a drink containing
alcohol?
Monthly or less  (1)
2 - 4 times/ month  (2)
2 - 3 times/ week  (3)
4 or more times/ week (4)
Unknown(Skip if Question 1 and
Question 2 are both NO) (5)
How many alcoholic drinks do you have on a
typical day when you are drinking?
1 or 2  (1)
3 or 4  (2)
5 or 6  (3)
7, 8, or 9  (4)
10 or more (5)
Unknown (Skip if Q1 and Q2 are both
NO) (6)
How often do you have six or more drinks on one
occasion?
Never  (1)
Less than monthly  (2)
Monthly  (3)
Weekly  (4)
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Daily or almost daily (5)
Unknown (6)
Have you ever been hospitalized for an alcohol-
related problem?
Yes (1)
No (2)
Unknown (3)
Current drug user?
Yes (1)
No (2)
Unknown (3)
Current drug user: if yes, please specify illicit
drug type(s) used
Sedatives (e.g., sleeping pills,
barbiturates, Seconal, Quaaludes, or
Chloral Hydrate) (1)
Other, specify: (e.g., Methadone, Elavil,
steroids,Thorazine, or Haldol) (10)
Tranquilizers or anti-anxiety drugs (e.g.,
Valium®, Librium, muscle relaxants, or
Zanax) (2)
Painkillers (e.g., Codeine, Darvon,
Percodan, Dilaudid, or Demerol) (3)
Stimulants (e.g., Preludin, Benzedrine,
Methadrine, uppers, or speed) (4)
Marijuana, hash, THC, or grass (5)
Cocaine or crack (6)
Hallucinogens (e.g., Ecstasy, LSD,
mescaline, psilocybin, PCP, angel dust,
or peyote) (7)
Inhalants	or Solvents (e.g., amyl nitrate,
nitrous oxide, glue, tolune, or gasoline)
(8)
Heroin (9)
Current user: if other illicit drug(s), please specify
Family History
Does the participants first degree blood relative
have a history of Ataxia
Yes (1)
No (2)
Unknown (3)
Relationship of Family Member to Participant/
Subject (Choose all that apply)
Mother  (1)
Father  (2)
Sibling (3)
Half-Sibling (4)
Child (5)
Does the participant/subject’s first degree blood
relatives have a history of Cardiomyopathy?
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Yes (1)
No (2)
Unknown (3)
Relationship of Family Member to Participant/
Subject (Choose all that apply)
Mother  (1)
Father  (2)
Sibling (3)
Half-Sibling (4)
Child (5)
Does the participant/subject’s first degree blood
relatives have a history of Diabetes mellitus
Yes (1)
No (2)
Unknown (3)
Relationship of Family Member to Participant/
Subject (Choose all that apply)
Mother  (1)
Father  (2)
Sibling (3)
Half-Sibling (4)
Child (5)
Does the participant/subject’s first degree blood
relatives have a history of Friedreich’s Ataxia
Yes (1)
No (2)
Unknown (3)
Relationship of Family Member to Participant/
Subject (Choose all that apply)
Mother  (1)
Father  (2)
Sibling (3)
Half-Sibling (4)
Child (5)
Does the participant/subject’s first degree blood
relatives have a history of Mitochondrial Disease
Yes (1)
No (2)
Unknown (3)
Relationship of Family Member to Participant/
Subject (Choose all that apply)
Mother  (1)
Father  (2)
Sibling (3)
Half-Sibling (4)
Child (5)
History Data Source and Reliability
Indicate how the medical/family history
information was obtained
Participant/Subject (1)
4 / 18
NINDS CDE General Health History Friedreich's Ataxia
Family, specify relation: (2)
Friend (3)
Physician (4)
Chart/Medical record (5)
Other, specify (6)
If other information source, please specify
If the medical/ family history information was not
obtained from the participant/subject, indicate the
reason(s) the information were obtained from
alternate source(s
Dementia (1)
Aphasia (2)
Other cognitive impairment (3)
Not fluent in examiner’s language (4)
Poor historian (5)
Too young (6)
Other, specify (7)
If other reason for alternate information source,
please specify
Overall assessment of the reliability of the
medical/family history information obtained:
Definitely reliable  (1)
Probably reliable  (2)
Not reliable (3)
Medical history
Date Medical History Taken
Have you experienced problems with
constitutional symptoms in the past?
Yes
No
Please specify the constitutional symptom you
experienced. If there´s more than one, please
describe one be one.
Start date of constitutional symptom
End date of constitutional symptom
Is the symptom persistent?
Yes
No
Have you experienced problems with your eyes in
the past?
Yes
No
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Please specify the eye problems you
experienced. If there´s more than one, please
describe one be one.
Start date of eye problems
End date of eye problems
Is the symptom persistent?
Yes
No
Have you experienced ENT or mouth problems in
the past?
Yes
No
Please specify the otorhinolaryngologic
conditions or problems with your mouth you
experienced. If there´s more than one, please
describe one be one.
Start date of your ENT or mouth problems
End date of your ENT or mouth problems
Is the symptom persistent?
Yes
No
Have you experienced problems with your
cardiovascular system in the past?
Yes
No
Please specify the problems you experienced
with your cardiovascular system. If there´s more
than one, describe it one by one.
Start date of your cardiovascular problems
End date of your cardiovascular problems
Is the symptom persistent?
Yes
No
Have you experienced respiratory problems in the
past?
Yes
No
Please specify the respiratory problems you
6 / 18
NINDS CDE General Health History Friedreich's Ataxia
experienced. If there´s more than one, describe it
one by one.
Start date of your respiratory problems
End date of your respiratory problems
Is the symptom persistent?
Yes
No
Have you experienced gastrointestinal problems
in the past?
Yes
No
Please specify the gastrointestinal problem you
experienced. If there´s more than one, describe it
one by one
Start date of your gastrointestinal problems
End date of your gastrointestinal problems
Is the symptom persistent?
Yes
No
Have you experienced problems with your
genitourinary system in the past?
Yes
No
Please specify the problems with your
genitourinary system. If there´s more than one,
describe it one by one.
Start date of your genitourinary problems
End date of your genitourinary problems
Is the symptom persistent?
Yes
No
Have you experienced problems with
musculoskeletal system in the past?
Yes
No
Please specify the problem with your
musculoskeletal system. If there´s more than
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one, describe it one by one.
Start date of your musculoskeletal problem
End date of your musculoskeletal problem
Is the symptom persistent?
Yes
No
Have you experienced problems with your skin or
your breast in the past?
Yes
No
Please specify the problems with your
integumentary system you experienced. If there´s
more than one, describe it one by one.
Start date of your problems with the
integumentary system
End date of your problems with the
integumentary system
Is the symptom persistent?
Yes
No
Have you experienced neurological problems with
in the past?
Yes
No
Please specify the neurological problems you
experienced. If there´s more than one, please
describe it one be one.
Start date of the neurological problem
End date of the neurological problem
Is the symptom persistent?
Yes
No
Have you experienced problems with your mental
health in the past?
Yes
No
Please specify the mental problem you
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experienced. If there´s more than one, please
describe it one by one.
Start date of your mental illness
End date of your mental illness
Is the symptom persistent?
Yes
No
Have you experienced problems with your
endocrine system in the past?
Yes
No
Please specify the endocrine system disease you
experienced. If there´s more than one,please
describe it one by one
Start date of the endocrine system disease
End date of the endocrine system disease
Is the symptom persistent?
Yes
No
Have you experienced problems with diseases of
blood and bloodforming organs in the past?
Yes
No
Please specify the disease of blood and
bloodforming organs you experienced. If there´s
more than one,please describe it one by one.
Start date of your problems with the blood or
bloodforming system
End date of the problems with your blood or
bloodforming system
Is the symptom persistent?
Yes
No
Have you experienced problems with lymphatic
diseases in the past?
Yes
No
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Please specify the problem with your lymphatic
system you experienced. If there´s more than
one, please describe it one by one
Start date of your problems with the lymphatic
system
End date of your problems with the lymphatic
system
Is the symptom persistent?
Yes
No
Have you experienced problems with allergies in
the past?
Yes
No
Please specify the allergy you experienced. If
there´s more than one, please describe it one by
one.
Start date of the allergy
End date of the allergy
Is the allergy persistent?
Yes
No
Have you experienced problems with your
immune system in the past?
Yes
No
Please specify the problem with your immune
system you experienced. If there´s more than
one, please desribe it one by one
Start date of your problems with the immune
system
End date of the problems with your immune
system
Is the symptom persistent?
Yes
No
Cardiac condition
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Yes (1)
No (2)
Unknown (3)
Arrhythmia
Yes (1)
No (2)
Unknown (3)
If cardiac arrhythmia is present,please specify
type
Atrial fibrillation (1)
Atrial flutter (2)
Supraventricular tachycardia (3)
Ventricular tachycardia (4)
Bradycardia (5)
Other, specify (6)
If other Type of cardiac arrhythmia, please specify
Type of cardiac arrhythmia is unknown
Yes
No
Heart failure
Yes (1)
No (2)
Unknown (3)
Ischemia heart disease
Yes (1)
No (2)
Unknown (3)
Abnormal echocardiogram
Yes (1)
No (2)
Unknown (3)
If abnormal echocardiogram,LVH?
Yes (1)
No (2)
Unknown (3)
If abnormal echocardiogram: decreased LV
function
Yes (1)
No (2)
Unknown (3)
If other abnormal echocardiogram, please specify
Cardiac surgery/mechanical intervention
Yes (1)
No (2)
Unknown (3)
If Cardiac surgery/mechanical intervention,please
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specify
Coronary artery bypass graft (CABG) (1)
Cardiac valve surgery, including non-
open surgery (i.e., percutaneous
valvuloplasty) (2)
Pacemaker (3)
Implantable cardic defibrillator  (4)
Other, specify (5)
Date of most recent surgery
Congenital heart disease
Yes (1)
No (2)
Unknown (3)
Diabetes mellitus (type I or type II)?
Yes (1)
No (2)
Unknown (3)
Diabetes mellitus:If yes
Type I (1)
Type II (2)
Diabetes mellitus age at diagnosis
yrs
Diabetes mellitus complications
Nephropathy (1)
Neuropathy (2)
Retinopathy (3)
Other, specify (4)
None (5)
Diabetes mellitus: other complications,please
specify
Indicate the treatments taken for diabetes
Diet (1)
Oral medication (2)
Insulin (3)
None (4)
Clinical depression within the past year
Yes (1)
No (2)
Unknown (3)
Depressive disorder diagnosis
Yes (1)
No (2)
Unknown (3)
Age at which participant/subject experienced first
depressive episode or was first diagnosed with
depression, whichever is earlier (years):
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yrs
Clinical anxiety within the past year
Yes (1)
No (2)
Unknown (3)
Anxiety disorder diagnosis
Yes (1)
No (2)
Unknown (3)
Psychotic disorder diagnosis
Yes (1)
No (2)
Unknown (3)
Psychotic disorder diagnosis: If Yes, choose all
disorders that apply
Schizophrenia (1)
Bipolar disorder (2)
Depression with psychotic features (3)
Dementia with psychotic ideation (4)
Other, specify (5)
If other psychotic disorder diagnosis,please
specify
Cancer
Yes (1)
No (2)
Unknown (3)
Cancer diagnosis:if yes, please specify type of
cancer diagnosed with
Cancer diagnosis: treated with head or neck
radiation?
Yes (1)
No/Not documented (2)
Unknown (3)
Pediatric Developmental History
Does/did the participant/ subject have
ADHD/ADD?
Yes (1)
No (2)
Unknown (3)
Does/did the participant/ subject have delayed
acquisition of language/cognitive milestones,
diagnosed by a pediatrician or neurologist?
Yes (1)
No (2)
Unknown (3)
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Does/did the participant/ subject have delayed
acquisition of motor milestones, diagnosed by a
pediatrician or neurologist?
Yes (1)
No (2)
Unknown (3)
Does/did the participant/ subject have social
delay?
Yes (1)
No (2)
Unknown (3)
Does/did the participant/ subject have hand
preference before 12 months of age?
Yes (1)
No (2)
Unknown (3)
Does/did the participant/ subject have
abnormality of the gait noted by parents or a
physician at the time the child began walking?
Yes (1)
No (2)
Unknown (3)
Does/did the participant/ subject have special
education?
Yes (1)
No (2)
Unknown (3)
School placement
Full-time regular education without aide
(1)
Full-time regular education with one to
one aide (2)
Regular education with pull-out for
certain areas (3)
Special education w/ minimal inclusion
(e.g., lunch) (4)
Full-time special education with no
inclusion (5)
Special (MR/DD) school (6)
Home-school (7)
Not in school (8)
Other, specify (9)
If other school placement, please specify
Does/did the participant/subject receive any
specialized therapies and services?
Yes (1)
No (2)
Unknown (3)
Did the patient receive speech therapy?
Yes
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No
Did the patient receive Occupational Therapy?
Yes
No
Did the patient receive Physical Therapy?
Yes
No
Did the patient receive Sensory Integration
Yes
No
Did the patient receive Social Skills Training
Yes
No
Did the patient receive Adaptive Physical
Education
Yes
No
Did the patient receive Behavior Support Plan
Yes
No
Did the patient receive Crisis Management Plan
Yes
No
If patient received other specialized therapies and
services, please specify
Pregnancy History
Does participant/ subject have a history of prior
pregnancy? (both term and not to term)
Yes (1)
No (2)
Unknown (3)
Number of pregnancies
Year of last delivery or miscarriage
year
Number of miscarriages
Prenatal and Perinatal History
Mother’s age at the time she gave birth to the
participant/subject
yrs
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Number of live born children the
participant/subject’s mother has delivered
Total number of times the participant/subject’s
mother has been pregnant, regardless of whether
these pregnancies were carried to term
Previous pregnancy loss
Yes (1)
No (2)
Unknown (3)
Preeclampsia during pregnancy of the
participant/subject?
Yes (1)
No (2)
Unknown (3)
Another hypertensive disorder during pregnancy
of the participant/subject?
Yes (1)
No (2)
Unknown (3)
Oligohydramnios
Yes (1)
No (2)
Unknown (3)
Gestational onset diabetes during pregnancy of
the participant/subject?
Yes (1)
No (2)
Unknown (3)
Fever during delivery of participant/subject?
Yes (1)
No (2)
Unknown (3)
Prolonged rupture of membraines (i.e., > 24
hours) during delivery of participant/subject?
Yes (1)
No (2)
Unknown (3)
Second stage of labor more than two hours?
Yes (1)
No (2)
Unknown (3)
Meconium staining of the amniotic fluid?
Yes (1)
No (2)
Unknown (3)
Birth weight
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Gestational Age at Birth
weeks
APGAR 5 Minute score
0 (0)
1 (1)
10 (10)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
7 (7)
8 (8)
9 (9)
APGAR 10 Minute score
0 (0)
1 (1)
10 (10)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
7 (7)
8 (8)
9 (9)
Mode of delivery of the neonate
Spontaneous  (1)
Induced  (2)
Unknown (3)
Route of delivery of the neonate
Vaginal (1)
Caesarean (2)
If Caesarean section, timing of procedure
Emergency  (1)
Elective  (2)
Unknown (3)
Delivery modality type of the neonate
Breech  (1)
Cephalic  (2)
Unknown (3)
Instrument(s) used to assist with the delivery of
the participant/subject?
None  (1)
Vaccum  (2)
Forceps  (3)
Vaccum and Forceps  (4)
Unknown (5)
Resuscitation of the participant/subject at
delivery?
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Yes (1)
No (2)
Unknown (3)
Intravascular catheter placed in newborn period?
Yes (1)
No (2)
Unknown (3)
Placenta sent for pathology?
Yes (1)
No (2)
Unknown (3)
Placental abnormalities?
Yes (1)
No (2)
Unknown (3)
Cord abnormalities?
Yes (1)
No (2)
Unknown (3)
Fetal heart rate abnormality?
Yes (1)
No (2)
Unknown (3)
Decreased fetal movement?
Yes (1)
No (2)
Unknown (3)
Chorioamnionitis
Yes (1)
No (2)
Unknown (3)
Other pregnancy/delivery risk factors
Yes (1)
No (2)
Unknown (3)
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NINDS CDE Physical Examination
Friedreich´s Ataxia
NINDS Common Data Elements (Physical Examination
Friedreich´s Ataxia) Used from the National Institute of
Neurological Disorders and Stroke Common Data Elements
(https://www.commondataelements.ninds.nih.gov/)
References: Grinnon ST, Miller K, Marler JR, Lu Y, Stout A,
Odenkirchen J, Kunitz S. National Institute of Neurological
Disorders and Stroke Common Data Element Project -
approach and methods. Clin Trials. 2012;9(3):322-9.
All rights reserved. Please visit https://medical-data-
models.org/forms/14808
Physical Examination
Physical Exam
Study-ID:
Study site name
Subject ID
Date of examination
Hand preference
Left hand  (1)
Right hand  (2)
Both hands  (3)
Unknown (4)
Was a physical exam performed on the
participant/subject?
Yes
No
Allergic/Immunologic
Normal (1)
Abnormal (2)
Not examined (3)
Allergic/Immunologic: please specify abnormality
or if not examined
Cardiovascular
Normal (1)
Abnormal (2)
Not examined (3)
Cardiovascular:Please specify any abnormality or
if not examined
Constitutional symptoms (e.g., fever, weight loss)
Normal (1)
Abnormal (2)
Not examined (3)
Constitutional symptoms (e.g., fever, weight loss):
Please specify any abnormality or if not examined
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Ears, Nose, Mouth, and Throat
Normal (1)
Abnormal (2)
Not examined (3)
Ears, Nose, Mouth, and Throat: please specify
any abnormality or if not examined
Endocrine system
Normal  (1)
Abnormal  (2)
Not examined (3)
Endocrine system: please specify any
abnormality or if not examined
Eyes
Normal (1)
Abnormal (2)
Not examined (3)
Eyes: please specify any abnormality or if not
examined
Gastrointestinal
Normal (1)
Abnormal (2)
Not examined (3)
Gastrointestinal: please specify any abnormality
or if not examined
Genitourinary
Normal- (1)
Abnormal (2)
Not examined (3)
Genitourinary:please specify any abnormality or if
not examined
Hematologic/Lymphatic
Normal (1)
Abnormal (2)
Not examined (3)
Hematologic/Lymphatic:Please specify any
abnormality or if not examined
Integumentary (skin and/or breast)
Normal (1)
Abnormal (2)
Not examined (3)
Integumentary (skin and/or breast):Please
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specify any abnormality or if not examined
Musculoskeletal (separate from ALS exam)
Normal (1)
Abnormal (2)
Not examined (3)
Musculoskeletal (separate from ALS
exam):Please specify any abnormality or if not
examined
Neurological (separate from ALS exam)
Normal (1)
Abnormal (2)
Not examined (3)
Neurological (separate from ALS exam):Please
specify any abnormality or if not examined
Psychiatric
Normal (1)
Abnormal (2)
Not examined (3)
Psychiatric:Please specify any abnormality or if
not examined
Respiratory
Normal (1)
Abnormal (2)
Not examined (3)
Respiratory:Please specify any abnormality or if
not examined
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NINDS CDE Vital Signs Friedreich´s Ataxia
NINDS Common Data Elements (Vital Signs Friedreich´s
Ataxia) Used from the National Institute of Neurological
Disorders and Stroke Common Data Elements
(https://www.commondataelements.ninds.nih.gov/)
References: Grinnon ST, Miller K, Marler JR, Lu Y, Stout A,
Odenkirchen J, Kunitz S. National Institute of Neurological
Disorders and Stroke Common Data Element Project -
approach and methods. Clin Trials. 2012;9(3):322-9.
All rights reserved. Please visit https://medical-data-
models.org/forms/14809
Vital Signs
Vital Signs
Study-ID:
Study site name
Subject ID
Date and time
Heart rate
bpm
Respiratory Rate
/min
Blood pressure measurement systolic and
diastolic
mm/Hg
Body Temperature
Please specify body temperature measurement
unit
Degrees Fahrenheit (1)
Degrees Celsius (2)
Body weight
Please specify units used for body weight
measurement
kg (1)
pounds (2)
Body Height
Body Height: Please specify units used for
measurement
inches (1)
centimeters (2)
Body Mass Index
kg/m2
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Oxygen saturation
%
Heart Rhythm
Normal sinus rhythm (1)
Sinus tachycardia (2)
Sinus bradycardia (3)
Atrial arrhythmia (4)
Ventricular arrhythmia (5)
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Eligibility Breast Cancer NCT02340858
Percutaneous Irreversible Electroportion for Unresectable
Breast Cancer; ODM derived from:
https://clinicaltrials.gov/show/NCT02340858
All rights reserved. Please visit https://medical-data-
models.org/forms/14810
Eligibility Breast Cancer
NCT02340858
Inclusion Criteria
1. women 18 years or older with unresectable
breast cancer, not amenable/willing to
adenomammectomy.*
Yes
No
2. breast carcinoma diagnosed by core needle
biopsy.*
Yes
No
3. any menopausal status.*
Yes
No
4. no history of en bloc open surgical biopsy
and/or lumpectomy for diagnostic/treatment of the
index breast cancer.*
Yes
No
5. tumor size ≤ 5.0 cm in greatest diameter.
largest size measured by required scans
(mammogram, ultrasound and mri) will be used to
determine eligibility.*
Yes
No
6. tumor enhancement on pre-study mri.*
Yes
No
7. tumor with < 25% intraductal components in
the aggregate.*
Yes
No
8. progressed within 12 months from prior
adjuvant or progressed within 1 month from prior
advanced/metastatic endocrine breast cancer
therapy,*
Yes
No
9. non-pregnant and non-lactating. patients of
childbearing potential must have a negative
serum or urine pregnancy test.*
Yes
No
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10. adequate breast size for safe ire. male breast
cancer patients and female breast cancer
patients with breasts too small to allow safe ire
are not eligible as the minimal thickness of the
breast tissue does not lend itself to ire. note: for
patients with breast implants, the treating
physician must document that adequate distance
exists between the lesion and the implant to
ensure that the ablated lesion will not contact or
jeopardize the implant.*
Yes
No
11. adequate organ and marrow function,
resolution of all toxic effects of prior therapy or
surgical procedures*
Yes
No
12. patient must agree to provide tumor tissue
from metastatic tissue at baseline.*
Yes
No
Exclusion Criteria
1. patients with multifocal and/or multicentric
ipsilateral breast cancer, multifocal calcifications,
or evidence of excessive dcis.*
Yes
No
2. history of rotational vacuum assisted core
biopsies, en bloc open surgical biopsy and/or
lumpectomy for diagnosis/treatment of the index
breast cancer.*
Yes
No
3. prior or planned neoadjuvant chemotherapy for
breast cancer.*
Yes
No
4. patients with thrombocytopenia and or any
other coagulation abnormality*
Yes
No
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Discharge summary (physician) ELGA EIS-
FullSupport_Min
ODM derived from http://www.elga.gv.at/
ELGA-Entlassungsbrief_aerztlich_EIS-FullSupport_Min
Discharge summarization note (physician) LOINC 11490-0
NA
All rights reserved. Please visit https://medical-data-
models.org/forms/14811
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ClinicalDocument
realmCode.code*
typeId.root*
typeId.extension*
templateId.root*
templateId.root*
templateId.root*
id.root*
id.extension*
code.code*
code.displayName*
code.codeSystem*
code.codeSystemName*
title*
effectiveTime.value*
confidentialityCode.code*
confidentialityCode.displayName*
confidentialityCode.codeSystem*
confidentialityCode.codeSystemName*
languageCode.code*
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setId.root*
setId.extension*
versionNumber.value*
id.root*
id.extension*
id.nullFlavor*
addr*
given*
family*
administrativeGenderCode.nullFlavor*
birthTime.nullFlavor*
time.nullFlavor*
id.nullFlavor*
given*
family*
id.nullFlavor*
addr*
time.nullFlavor*
signatureCode.code*
id.nullFlavor*
given*
family*
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participant.typeCode*
templateId.root*
associatedEntity.classCode*
telecom.use*
telecom.value*
code.code*
code.displayName*
code.codeSystem*
code.codeSystemName*
low.value*
high.value*
id.nullFlavor*
code.code*
code.displayName*
code.codeSystem*
code.codeSystemName*
low.value*
high.value*
id.nullFlavor*
templateId.root*
code.code*
code.displayName*
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code.codeSystem*
code.codeSystemName*
title*
text*
content.styleCode*
content*
templateId.root*
templateId.root*
code.code*
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code.codeSystem*
code.codeSystemName*
title*
text*
templateId.root*
code.code*
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code.codeSystem*
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title*
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td.ID*
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text*
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content.ID*
content*
substanceAdministration.classCode*
substanceAdministration.moodCode*
templateId.root*
templateId.root*
templateId.root*
templateId.root*
templateId.root*
id.root*
id.extension*
code.code*
code.displayName*
code.codeSystem*
code.codeSystemName*
reference.value*
statusCode.code*
effectiveTime.type*
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effectiveTime.type*
effectiveTime.operator*
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effectiveTime.institutionSpecified*
period.value*
period.unit*
doseQuantity.value*
doseQuantity.unit*
manufacturedProduct.classCode*
templateId.root*
templateId.root*
manufacturedMaterial.classCode*
manufacturedMaterial.determinerCode*
templateId.root*
templateId.root*
code.nullFlavor*
reference.value*
id*
uri*
local*
entryRelationship.typeCode*
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supply.moodCode*
independentInd.value*
quantity.value*
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title*
text*
text*
templateId.root*
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title*
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item*
templateId.root*
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title*
templateId.root*
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Eligibility Breast Cancer NCT02341911
Gemcitabine Plus Cisplatin Versus Gemcitabine Plus
Carboplatin in Triple Negative Breast Cancer (TNBC); ODM
derived from: https://clinicaltrials.gov/show/NCT02341911
All rights reserved. Please visit https://medical-data-
models.org/forms/14812
Eligibility Breast Cancer
NCT02341911
Inclusion Criteria
1. histological proven unresectable recurrent or
advanced breast cancer, including de novo stage
iv disease.*
Yes
No
2. triple-negative for estrogen receptor (er),
progestogen receptor (pr), and human epithelial
receptor-2 (her2) by immunohistochemistry (er
<1%, pr <1% and her2 negative). a negative her2
gene amplification should be verified by fish test
for those patients with her2 (2+). for those with
her2 (1+), fish test might be considered by the
investigator.*
Yes
No
3. no prior chemotherapy for metastatic breast
cancer is permitted. prior administration of
chemotherapy in the adjuvant/neoadjuvant setting
is acceptable if completed 6 months before the
enrollment.*
Yes
No
4. at least one measurable disease according to
the response evaluation criteria in solid tumor
(recist 1.1)*
Yes
No
5. performance status no more than 1*
Yes
No
6. all patients enrolled are required to have
adequate hematologic, hepatic, and renal
function*
Yes
No
7. life expectancy longer than 12 weeks*
Yes
No
8. no serious medical history of heart, lung, liver
and kidney*
Yes
No
9. be able to understand the study procedures
and sign informed consent.*
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Yes
No
10. patients with good compliance*
Yes
No
Exclusion Criteria
1. pregnant or lactating women (female patients
of child-bearing potential must have a negative
serum pregnancy test within 14 days before the
first day of drug dosing, or, if positive, a
pregnancy should be ruled out by ultrasound)*
Yes
No
2. women of child-bearing potential, unwilling to
use adequate contraceptive protection during the
process of the study*
Yes
No
3. treatment with radiotherapy at the axial
skeleton within 4 weeks before the first treatment
or has not recovered from all toxicities of previous
radiotherapy*
Yes
No
4. treatment with an investigational product within
4 weeks before the first treatment*
Yes
No
5. patients with symptomatic central nervous
system metastases are not permitted, except for
those with stable and asymptomatic brain
metastases who have completed cranial
irradiation, and have at least one measurable
lesion outside the brain. radiotherapy should be
completed within 4 weeks prior to the
registration*
Yes
No
6. other active malignancies (including other
hematologic malignancies) or other malignancies
within the last 5 years, except for cured
nonmelanoma skin cancer or cervical
intraepithelial neoplasia.*
Yes
No
7. patients having a history of clinically significant
cardiovascular, hepatic, respiratory or renal
diseases, clinically significant hematological and
endocrinal abnormalities, clinically significant
neurological or psychiatric conditions*
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Yes
No
8. uncontrolled serious infection*
Yes
No
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Personal and Family History of Hearing
Loss Protocol PhenX Toolkit
The Age-Related Hearing Impairment instrument is a self-
administered questionnaire which asks about an
individual’s hearing impairment history, history of ear
diseases and operations, family history, and history of
exposure to loud noises.
ODM derived from: https://cde.nlm.nih.gov
Primary source: https://www.phenxtoolkit.org/
Recent publication: Hendershot, T., Pan, H., Haines, J.,
Harlan, W.R., Marazita, M.L., McCarty, C.A., Ramos, E.M.,
and Hamilton, C.M. (2015) Using the PhenX toolkit to add
standard measures to a study. Curr. Protoc. Hum. Genet.
86:1.21.1-1.21.17. doi: 10.1002/0471142905.hg0121s86
Permission to publish granted by
Carol M. Hamilton.
All rights reserved. Please visit https://medical-data-
models.org/forms/14813
Personal and Family History of
Hearing Loss Protocol PhenX Toolkit
PhenX - personal and family history of
hearing loss protocol
Do you have any difficulty with your hearing?
Yes
No
In which ear(s) do you have a hearing difficulty?
Both (Both)
Left (Left)
Right (Right)
At what age did you first notice a hearing
difficulty?
How quickly did your hearing difficulty develop?
Over a few months (Over a few months)
Over several years (Over several years)
Suddenly (over a few days)   (Suddenly
(over a few days)  )
Do you know the reason for your hearing
difficulty?
I have no idea about the cause of my
hearing problem     (I have no idea about
the cause of my hearing problem    )
Yes (Yes)
Do you know the reason for your hearing
difficulty? (if there is a separate cause for each of
your ears, please note them accordingly)
Describe:
Does your hearing vary from day to day?
No (No)
Yes, in both ears (Yes, in both ears)
Yes, in my left ear (Yes, in my left ear)
Yes, in my right ear (Yes, in my right ear)
Do you find it very difficult to follow a
conversation if there is background noise (e.g.
TV, radio, children playing)?
Yes
No
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Are you particularly sensitive to loud sounds?
Yes
No
Do you sometimes feel a fullness or blockage in
your ears?
No (No)
Yes, in both ears (Yes, in both ears)
Yes, in my left ear (Yes, in my left ear)
Yes, in my right ear (Yes, in my right ear)
Nowadays, do you ever get noises in your head
or ears (tinnitus) which usually last longer than
five minutes?
Yes
No
Have you ever had an ear disease that has
caused your hearing to get worse?
Yes
No
Have you ever had discharge of blood or pus, or
smelly discharge (not wax) from either ear?
Don't know (Don't know)
From my left ear (From my left ear)
From my right ear (From my right ear)
No (No)
Have you ever had an ear operation?
Don't know (Don't know)
No  (No )
Yes (Yes)
Have you ever suffered from attacks of dizziness
in which things seem to spin around you?
No     (No    )
Yes, more than a year ago (Yes, more
than a year ago)
Yes, within the last year     (Yes, within
the last year    )
Do you feel unsteady when walking in the dark?
Yes
No
Do you have any brothers or sisters with normal
hearing?
Yes
No
Do you have any brothers or sisters with normal
hearing? (how many of your brothers/sisters have
normal hearing?)
Do you have any brothers or sisters with hearing
difficulties?
Yes
No
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Do you have any brothers or sisters with hearing
difficulties? (how many of your brothers/sisters
have hearing difficulties?)
Do you have any children with normal hearing?
Yes
No
How many children with normal hearing?
Do you have any children with hearing
difficulties? (how many of your children have
hearing difficulties?)
Yes
No
How many children with hearing difficulties? (how
many of your children have hearing difficulties?)
Relative [PhenX]
Adopted son or daughter (Adopted son
or daughter)
Brother (Brother)
Child 1 (Child 1)
Daughter (Daughter)
Father (Father)
Half sibling (Half sibling)
Half-sister (Half-sister)
Maternal Aunt (Maternal Aunt)
Maternal Grandfather (Maternal
Grandfather)
Maternal Grandmother (Maternal
Grandmother)
Maternal Uncle (Maternal Uncle)
Mother (Mother)
Paternal Aunt (Paternal Aunt)
Paternal Grandfather (Paternal
Grandfather)
Paternal Grandmother (Paternal
Grandmother)
Paternal Uncle (Paternal Uncle)
Self (Self)
Sibling 1 (Sibling 1)
Sister (Sister)
Son  (Son )
Stepson or stepdaughter (Stepson or
stepdaughter)
Do you have uncles, aunts, cousins, nephews, or
nieces with hearing difficulties?
Yes
No
Do you know if any of your relatives have already
participated in this investigation?
As far as I know, none of my relatives
has already participated in this
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investigation     (As far as I know, none of
my relatives has already participated in
this investigation    )
One of my relatives has already
participated in this investigation (One of
my relatives has already participated in
this investigation)
Relative [PhenX]
Adopted son or daughter (Adopted son
or daughter)
Brother (Brother)
Child 1 (Child 1)
Daughter (Daughter)
Father (Father)
Half sibling (Half sibling)
Half-sister (Half-sister)
Maternal Aunt (Maternal Aunt)
Maternal Grandfather (Maternal
Grandfather)
Maternal Grandmother (Maternal
Grandmother)
Maternal Uncle (Maternal Uncle)
Mother (Mother)
Paternal Aunt (Paternal Aunt)
Paternal Grandfather (Paternal
Grandfather)
Paternal Grandmother (Paternal
Grandmother)
Paternal Uncle (Paternal Uncle)
Self (Self)
Sibling 1 (Sibling 1)
Sister (Sister)
Son  (Son )
Stepson or stepdaughter (Stepson or
stepdaughter)
Do you know if any of your relatives have already
participated in this investigation?
Name of your relative that have already
participated in this investigation
If yes, what is his/her relationship to you?
An acquaintance     (An acquaintance    )
Child     (Child    )
Client     (Client    )
Close friend (Close friend)
Co-worker, boss/superior, or subordinate
from a previous firm   (Co-worker,
boss/superior, or subordinate from a
previous firm  )
Compatriot (Compatriot)
Current boss/superior (Current
boss/superior)
Current co-worker     (Current co-worker
)
Current neighbor    (Current neighbor   )
Current subordinate  (Current
subordinate )
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Daughter-in-law (Daughter-in-law)
Else (Else)
Father-in-law/mother-in-law  (Father-in-
law/mother-in-law )
Indirect relationship (known via someone
else)   (Indirect relationship (known via
someone else)  )
Old neighbor (Old neighbor)
Ordinary friend     (Ordinary friend    )
Other relative  (Other relative )
Parent     (Parent    )
Person working for another firm, but
known through work relations (Person
working for another firm, but known
through work relations)
School/class mate     (School/class mate
)
Sibling     (Sibling    )
Someone from the same association,
club or group (Someone from the same
association, club or group)
Someone from the same religious group
(Someone from the same religious
group)
Someone know from the Internet
(Someone know from the Internet    )
Someone known because he/she
provides a service to me or my family
(Someone known because he/she
provides a service to me or my family    )
Son-in-law (Son-in-law)
Spouse (current or previous) (Spouse
(current or previous))
Student     (Student    )
Teacher     (Teacher    )
Do you suffer from migraine?
Yes
No
How often do you generally have attacks?
Often (more than one attack a month)
(Often (more than one attack a month) )
Rarely (less than one attack every 3
months) (Rarely (less than one attack
every 3 months))
Regularly (an attack once a month on
average)  (Regularly (an attack once a
month on average) )
Sporadically (between 4 and 10 times a
year)  (Sporadically (between 4 and 10
times a year) )
Have you ever suffered a hearing loss from
meningitis or encephalitis?
Don't know (Don't know)
No  (No )
Yes (Yes)
Have you ever had a whiplash injury?
5 / 14
Personal and Family History of Hearing Loss Protocol PhenX Toolkit
Don't know (Don't know)
No  (No )
Yes (Yes)
Have you ever been knocked unconscious (e.g.,
in a traffic accident, contact sport, a fight or after
a fall)?
Don't know (Don't know)
No  (No )
Yes (Yes)
Has a doctor ever told you that you had a
myocardial infarction or heart attack?
Don't know (Don't know)
No  (No )
Yes (Yes)
Have you ever had heart surgery?
Yes
No
What operation(s)? (Please describe)
Have you ever had coronary artery
catheterization?
Yes
No
What type of intervention(s) (e.g., stent, balloon
dilatation)?
Yes
No
Have you ever been told by a physician that you
had a stroke?
Yes
No
Date of health-related event
Have you ever had an operation on your carotid
artery?
Don't know (Don't know)
No  (No )
Yes (Yes)
Do you suffer from intermittent claudication?
Don't know (Don't know)
No  (No )
Yes (Yes)
Do you have other problems with your heart or
circulation?
Yes
No
Do you have other problems with your heart or
circulation?
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Do you suffer from diabetes?
Don't know (Don't know)
No  (No )
Yes (Yes)
Do you need insulin?
Yes
No
Disease history [PhenX]
Allergy     (Allergy    )
Blood diseases (Blood diseases)
Diseases of the stomach or intestine
(Diseases of the stomach or intestine )
Diseases of the thyroid gland (Diseases
of the thyroid gland)
Epilepsy     (Epilepsy    )
Kidney diseases     (Kidney diseases    )
Liver diseases (Liver diseases)
Lung problems     (Lung problems    )
Multiple sclerosis - MS    (Multiple
sclerosis - MS   )
Osteoarthritis     (Osteoarthritis    )
Osteoporosis   (Osteoporosis  )
Psychiatric problems     (Psychiatric
problems    )
Skin diseases   (Skin diseases  )
Please describe your disease(s):
Autoimmune diseases [PhenX]
Behcet’s syndrome   (Behcet’s syndrome
)
Cogan’s syndrome   (Cogan’s syndrome
)
Hashimoto thyroiditis     (Hashimoto
thyroiditis    )
Inflammatory bowel disease crohn’s
disease or colitis ulcerosa
(Inflammatory bowel disease crohn’s
disease or colitis ulcerosa   )
Lupus erythematosus  (Lupus
erythematosus )
Nephritis     (Nephritis    )
Other (Other)
Psoriasis     (Psoriasis    )
Rheumatoid arthritis - rheumatism
(Rheumatoid arthritis - rheumatism )
Vasculitis     (Vasculitis    )
Wegener’s granulomatosis (Wegener’s
granulomatosis)
Have you ever had other operations (not covered
by the previous questions)?
Do you have other serious health problems that
are not covered by the previous questions?
Yes
No
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Please describe these problems:
Have you ever been treated for a serious infection
with an antibiotic (other than penicillin) which was
administered by injection/drip for a week or
more?
Yes
No
If 'YES', for what sort of infections did you receive
these antibiotics?
Have you had cancer or leukemia?
Yes
No
Cancer Site/Type?
Have you been treated with chemotherapy or
other medication for this condition?
Yes
No
Chemotherapy treatment Cancer
Chem recommended (Chem
recommended)
Chemo - Multiple Agent     (Chemo -
Multiple Agent    )
Chemo - Single Agent     (Chemo -
Single Agent    )
Chemotherapy, NOS    (Chemotherapy,
NOS   )
None     (None    )
Not Administered, Unknown Reason
(Not Administered, Unknown Reason)
Not Recommended     (Not
Recommended    )
Patient Died Before Therapy     (Patient
Died Before Therapy    )
Refused     (Refused    )
Unknown, Death Cert Only (Unknown,
Death Cert Only)
Have you ever received radiotherapy to your head
or neck for a tumor?
Yes
No
What kind of tumor(s)?
Surgery Date?
On average how often do you take painkillers?
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Do you take aspirin on a daily basis for your heart
or to dilute your blood?
Yes
No
If 'YES', how long have you been taking aspirin
so far?
1-5 years  (1-5 years )
3 months – 1 year  (3 months – 1 year )
More than 5 years (More than 5 years)
Have you ever fired a gun?
Yes
No
Weapon type [PhenX]
Heavy weapons(artillery or bazookas)
(Heavy weapons(artillery or bazookas))
Light weapons (rifles or shotguns)
(Light weapons (rifles or shotguns)    )
Estimate the total number of shots fired.
1,001–10,000 shots     (1,001–10,000
shots    )
10–100 shots     (10–100 shots    )
101–1,000 shots     (101–1,000 shots    )
Less than 10 shots     (Less than 10
shots    )
More than 10,000 shots (More than
10,000 shots)
Did you use ear protection?
Always     (Always    )
Less than 50% of the time     (Less than
50% of the time    )
More than 50% of the time     (More than
50% of the time    )
Most of the time   (Most of the time  )
Never (Never)
If any, which type of ear protection did you use?
'Active' protection ('Active' protection)
Earmuff    (Earmuff   )
Plugs     (Plugs    )
During your leisure time, are you/have you been
regularly (more than once a week) exposed to
loud sound or noise (so that you have to shout to
make yourself heard by someone who was more
than 1 m away from you)?
Yes
No
What kind of loud sound?
For how many years have you been exposed to
this loud sound?
years
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How many hours per week have you been
exposed to this loud sound?
1-3 hours each day     (1-3 hours each
day    )
1-3 hours each week     (1-3 hours each
week    )
3-10 hours each week (3-10 hours each
week)
More than 3 hours each day (More than
3 hours each day)
Did you use ear protection?
Always     (Always    )
Less than 50% of the time     (Less than
50% of the time    )
More than 50% of the time     (More than
50% of the time    )
Most of the time   (Most of the time  )
Never (Never)
What kind of work {were you/was SP} doing?
Have you been exposed to solvents (e.g.,
thrichloroethylene, toluene, evaporations from
paints or lacquers) for more than one year in one
of your jobs?
Yes
No
Which solvents?
In which year did the solvent exposure start?
How many hours per day were you exposed to
noise?
1-5 hours each day   (1-5 hours each day
)
Less than 1 hour each day     (Less than
1 hour each day    )
More than 5 hours each day (More than
5 hours each day)
Do you suffer from white finger
syndrome/Raynaud's syndrome caused by
excessive vibration (e.g., pneumatic hammers or
drills)?
Don't know (Don't know)
No  (No )
Yes (Yes)
Have you ever worked for more than 1 year in a
place where you had to raise your voice to make
yourself heard by someone standing 1 m away
from you?
Yes
No
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Please describe the most important noise
source(s)
What was the noise level (if you are aware of it) in
dB?
What was the noise dose (equivalent noise level
if you are aware of it) in dBs?
How many hours per day were you exposed to
noise?
1-5 hours each day   (1-5 hours each day
)
Less than 1 hour each day     (Less than
1 hour each day    )
More than 5 hours each day (More than
5 hours each day)
Was this a constant loud noise or an impulse
noise (i.e., noise with (ir)regular high peaks of
sound, like hammering)?
Both (Both)
Constant noise     (Constant noise    )
Impulse noise     (Impulse noise    )
Body height --standing
cm
Body weight
kg
Dominant hand
Right (1)
Left (2)
Are you susceptible to sunburn?
Much     (Much    )
Not at all (Not at all)
Not very much (Not very much)
Very much     (Very much    )
What is the color of your eyes?
Blue (Blue)
Dark brown (Dark brown)
Green (Green)
Grey (Grey)
Light brown (Light brown)
Very light blue or very light grey  (Very
light blue or very light grey )
Have you ever smoked regularly?
Yes
No
At which age did you start smoking?
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For how many years did you (have you) smoke(d)
up to now?
years
Approximately how many cigarettes do (did) you
smoke on average?
10-20 each day (10-20 each day)
5-10 each day  (5-10 each day )
Less than 5 each day    (Less than 5
each day   )
More than 20 each day (More than 20
each day)
Do you drink alcohol regularly (every week)?
Yes
No
How many drinks do you have on average? (A
small bottle of beer - 25cl, red or white wine -
12cl, or a small glass of spirits - 4cl counts as 1
drink)
1–3 drinks each day (1–3 drinks each
day)
1–5 drinks each week (1–5 drinks each
week)
Less than 1 drink a week   (Less than 1
drink a week  )
More than 3 drinks each day (More than
3 drinks each day)
List of operations
Which ear?
Both (Both)
Left (Left)
Right (Right)
Date of trauma or procedure
Grandparents Origin
Where did your mother's father (your maternal
grandfather) originate from? Specify Country
Where did your mother's father (your maternal
grandfather) originate from? Specify Region
Mother/Father History
Natural parent [PhenX]
Father (Father)
Mother (Mother)
As far as you know, does/did your mother have
hearing problems?
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Yes
No
What was his/her occupation?
Age of onset
What is/was the cause of her hearing problem (if
known)?
Age at death
Hearing difficulty: Siblings
Relative [PhenX]
Adopted son or daughter (Adopted son
or daughter)
Brother (Brother)
Child 1 (Child 1)
Daughter (Daughter)
Father (Father)
Half sibling (Half sibling)
Half-sister (Half-sister)
Maternal Aunt (Maternal Aunt)
Maternal Grandfather (Maternal
Grandfather)
Maternal Grandmother (Maternal
Grandmother)
Maternal Uncle (Maternal Uncle)
Mother (Mother)
Paternal Aunt (Paternal Aunt)
Paternal Grandfather (Paternal
Grandfather)
Paternal Grandmother (Paternal
Grandmother)
Paternal Uncle (Paternal Uncle)
Self (Self)
Sibling 1 (Sibling 1)
Sister (Sister)
Son  (Son )
Stepson or stepdaughter (Stepson or
stepdaughter)
Sex
Male (1)
Female (2)
Birth Date Family member
Age of onset of health-related event family
member
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List of other operations
History of surgical procedures
Other operation year
Medication list
Current medication, Name
Please write down the medical reason why you
had or have to take this medication. If necessary
you can add an additional copy of this page
Duration of treatment
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Eligibility Breast Cancer NCT02426489
Improving Diagnosis of Breast Cancer by Using a
Combined MRI and Positron Emission Mammography
(MRI-PEM) System; ODM derived from:
https://clinicaltrials.gov/show/NCT02426489
All rights reserved. Please visit https://medical-data-
models.org/forms/14814
Eligibility Breast Cancer
NCT02426489
Inclusion Criteria
female over 21 years of age;*
Yes
No
with a suspicious lesion found in the breast and
recommended for biopsy or have a confirmed
diagnosis of cancer;*
Yes
No
and in good health (other than having breast
lesions);*
Yes
No
and can lie still in a prone position for 30 minutes
in an mri scanner.*
Yes
No
Exclusion Criteria
pregnancy;*
Yes
No
unwilling to give informed consent;*
Yes
No
have implanted prosthetic heart valve,*
Yes
No
pacemaker,*
Yes
No
neurostimulator,*
Yes
No
surgical clips or other metallic implants;*
Yes
No
have engaged in occupations or received
orthodontic work which may have caused lodging
of ferromagnetic materials in the body;*
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Yes
No
are claustrophobic;*
Yes
No
have been allergic to contrast agents;*
Yes
No
are diabetic;*
Yes
No
or have a history of kidney disease.*
Yes
No
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Eligibility Advanced Malignancy
NCT01723020
A Phase 1 Study Evaluating AMG 232 in Advanced Solid
Tumors or Multiple Myeloma; ODM derived from:
https://clinicaltrials.gov/show/NCT01723020
All rights reserved. Please visit https://medical-data-
models.org/forms/14816
Eligibility Advanced Malignancy
NCT01723020
Inclusion Criteria
men or women > 18 years old*
Yes
No
pathologically documented, definitively
diagnosed, advanced solid tumor that is
refractory to standard treatment, or which no
standard therapy is available, or the subject
refuses standard therapy or multiple myeloma*
Yes
No
willing to undergo pre-dose core needle tumor
biopsies or bone marrow aspirate for subjects
with multiple myeloma.*
Yes
No
ability to take oral medications and willing to
record daily adherance to investigational product*
Yes
No
adequate hematological, renal, hepatic, and
coagulation laboratory assessments*
Yes
No
Exclusion Criteria
active brain metastases*
Yes
No
for solid tumor-history or presence of
hematological malignancies unless curatively
treated with no evidence of disease for greater
than or equal to 5 years*
Yes
No
active infection requiring intravenous (iv)
antibiotics*
Yes
No
anti-tumor therapy*
Yes
No
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therapeutic or palliative radiation therapy within
30 days of starting treatment*
Yes
No
currently enrolled in another investigational
device or drug study*
Yes
No
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Eligibility Advanced Breast Cancer
NCT00915369
A Clinical Trial to Study the Effects of Nanoparticle Based
Paclitaxel Drug, Which Does Not Contain the Solvent
Cremophor, in Advanced Breast Cancer; ODM derived
from: https://clinicaltrials.gov/show/NCT00915369
All rights reserved. Please visit https://medical-data-
models.org/forms/14817
Eligibility Advanced Breast Cancer
NCT00915369
Inclusion Criteria
female patients with histopathologically
/cytologically confirmed advanced breast cancer,
refractory / recurrent* to previous anthracycline
treatment as adjuvant or first line therapy for
metastasis.*
Yes
No
patients with er/pr -ve or er/pr receptor status
unknown (defined as no histopathological
evidence for confirmation of er/pr status)*
Yes
No
patients must be of 18-65 years of age (inclusive
of both)*
Yes
No
patients with ecog performance status between 0
- 2*
Yes
No
patients with at least one measurable lesion as
per recist*
Yes
No
Exclusion Criteria
patients with er/pr positive status. patients who
demonstrate her2 over expression will be
excluded. alternatively, the patients enrolled
should have previously received trastuzumab.
her2 over expression should be demonstrated by
ihc 3+, ihc 2+*
Yes
No
her2+ detected with fish/cis*
Yes
No
patients with known history of hypersensitivity to
paclitaxel or any other taxane or compounds
chemically / biologically related to paclitaxel or
excipients.*
Yes
No
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patients requiring any concurrent chemotherapy,
hormonal therapy immunotherapy, therapy with
biologicals or radiotherapy for the disease.
(patients requiring local radiotherapy for non-
target bone lesion will be included).*
Yes
No
patients with known cns lesions (brain metastasis
or carcinomatous meningitis).*
Yes
No
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Quality of Life as Affected by Respiratory
Disease Protocol PhenX Toolkit
Self-administered questionnaire contains 50 items and 76
weighted responses divided into three components:
Symptoms (frequency and severity); Activity (activities that
cause or are limited by breathlessness); and Impacts
(social unctioning, psychological disturbances resulting
from airways disease). The protocol is designed to
measure health impairment in patients with asthma and
chronic obstructive pulmonary disease (COPD). It is also
valid for use in bronchiectasis and has been used
successfully in patients with kyphoscoliosis and
sarcoidosis.
ODM derived from: https://cde.nlm.nih.gov
Primary source: https://www.phenxtoolkit.org/
Recent publication: Hendershot, T., Pan, H., Haines, J.,
Harlan, W.R., Marazita, M.L., McCarty, C.A., Ramos, E.M.,
and Hamilton, C.M. (2015) Using the PhenX toolkit to add
standard measures to a study. Curr. Protoc. Hum. Genet.
86:1.21.1-1.21.17. doi: 10.1002/0471142905.hg0121s86
Permission to publish granted by
Carol M. Hamilton.
All rights reserved. Please visit https://medical-data-
models.org/forms/14819
Quality of Life as Affected by
Respiratory Disease Protocol PhenX
Toolkit
PhenX - respiratory - quality of life
protocol
How do you describe your current health?
Fair (Fair)
Good (Good)
Poor (Poor)
Very Good (Very Good)
Very poor (Very poor)
Over the past 3 months, I have coughed:
1 attack     (1 attack    )
2 attacks     (2 attacks    )
3 attacks (3 attacks)
More than 3 attacks     (More than 3
attacks    )
No attacks (No attacks)
Over the past 3 months, I have brought up
phlegm (sputum):
1 attack     (1 attack    )
2 attacks     (2 attacks    )
3 attacks (3 attacks)
More than 3 attacks     (More than 3
attacks    )
No attacks (No attacks)
Over the past 3 months, I have had shortness of
breath:
1 attack     (1 attack    )
2 attacks     (2 attacks    )
3 attacks (3 attacks)
More than 3 attacks     (More than 3
attacks    )
No attacks (No attacks)
Over the past 3 months, I have had attacks of
wheezing:
1 attack     (1 attack    )
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2 attacks     (2 attacks    )
3 attacks (3 attacks)
More than 3 attacks     (More than 3
attacks    )
No attacks (No attacks)
During the past 3 months, how many severe or
very unpleasant attacks of chest trouble have you
had?
1 attack     (1 attack    )
2 attacks     (2 attacks    )
3 attacks (3 attacks)
More than 3 attacks     (More than 3
attacks    )
No attacks (No attacks)
How long did the worst attack of chest trouble
last?
1 or 2 days    (1 or 2 days   )
3 or more days (3 or more days)
A week or more     (A week or more    )
Less than a day (Less than a day)
Over the past 3 months, in an average week, how
many good days (with little chest trouble) have
you had?
1 or 2 good days    (1 or 2 good days   )
3 or 4 good days     (3 or 4 good days    )
Every day is good (Every day is good)
Nearly every day is good   (Nearly every
day is good  )
No good days     (No good days    )
If you have a wheeze, is it worse in the morning?
Yes
No
How would you describe your chest condition?
Causes me a few problems   (Causes
me a few problems  )
Causes me no problems (Causes me no
problems)
Causes me quite a lot of problems
(Causes me quite a lot of problems   )
The most important problem I have
(The most important problem I have  )
If you have ever had paid employment.
My chest trouble does not affect my work
(My chest trouble does not affect my
work)
My chest trouble interferes with my work
or made me change my work  (My chest
trouble interferes with my work or made
me change my work )
My chest trouble made me stop work
altogether     (My chest trouble made me
stop work altogether    )
Activity that usually makes you feel breathless
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these days [PhenX]
Getting washed or dressed  (Getting
washed or dressed )
Playing sports or games (Playing sports
or games)
Sitting or lying still     (Sitting or lying still
)
Walking around the home    (Walking
around the home   )
Walking outside on the level   (Walking
outside on the level  )
Walking up a flight of stairs    (Walking
up a flight of stairs   )
Walking up hills  (Walking up hills )
This activity usually makes you feel breathless
these days [PhenX]
False (False)
True (True)
My cough hurts.
False (False)
True (True)
My cough makes me tired.
False (False)
True (True)
I am breathless when I talk.
False (False)
True (True)
I am breathless when I bend over.
False (False)
True (True)
My cough or breathing disturbs my sleep.
False (False)
True (True)
I get exhausted easily.
False (False)
True (True)
My cough or breathing is embarrassing in public.
False (False)
True (True)
My chest trouble is a nuisance to my family,
friends or neighbors.
False (False)
True (True)
I get afraid or panic when I cannot get my breath.
False (False)
True (True)
I feel that I am not in control of my chest problem.
False (False)
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True (True)
I do not expect my chest to get any better
False (False)
True (True)
I have become frail or an invalid because of my
chest.
False (False)
True (True)
Exercise is not safe for me.
False (False)
True (True)
Everything seems too much of an effort.
False (False)
True (True)
My medication does not help me very much.
False (False)
True (True)
I get embarrassed using my medication in public.
False (False)
True (True)
I have unpleasant side effects from my
medication.
False (False)
True (True)
My medication interferes with my life a lot.
False (False)
True (True)
I take a long time to get washed or dressed.
False (False)
True (True)
I cannot take a bath or shower, or I take a long
time.
False (False)
True (True)
I walk slower than other people, or I stop for
rests.
False (False)
True (True)
Jobs such as housework take a long time, or I
have to stop for rests.
False (False)
True (True)
If I walk up one flight of stairs, I have to go slowly
or stop.
False (False)
True (True)
4 / 5
Quality of Life as Affected by Respiratory Disease Protocol PhenX Toolkit
If I hurry or walk fast, I have to stop or slow down.
False (False)
True (True)
My breathing makes it difficult to do things such
as walk up hills, carrying things up stairs, light
gardening such as weeding, dance, play bowls or
play golf.
False (False)
True (True)
My breathing makes it difficult to do things such
as carry heavy loads, dig the garden or shovel
snow, jog or walk at 5 miles per hour, play tennis
or swim.
False (False)
True (True)
My breathing makes it difficult to do things such
as very heavy manual work, run, cycle, swim fast
or play competitive sport.
False (False)
True (True)
I cannot play sports or games.
False (False)
True (True)
I cannot go out for entertainment or recreation.
False (False)
True (True)
I cannot go out of the house to do the shopping.
False (False)
True (True)
Please write in any other important activities that
your chest trouble may stop you doing.
I cannot do housework.
False (False)
True (True)
I cannot move far from my bed or chair.
False (False)
True (True)
Which you think best describes how your chest
affects you?
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Eligibility Advanced Refractory Left
Ventricular Heart Failure NCT02170363
Thoratec Corporation HeartMate III™ CE Mark Clinical
Investigation Plan; ODM derived from:
https://clinicaltrials.gov/show/NCT02170363
All rights reserved. Please visit https://medical-data-
models.org/forms/14820
Eligibility Advanced Refractory Left
Ventricular Heart Failure
NCT02170363
Inclusion Criteria
patient or legal representative has signed
informed consent form (icf)*
Yes
No
age ≥ 18 years*
Yes
No
bsa ≥ 1.2 m2*
m2
Yes
No
nyha iiib or iv or acc/aha stage d*
Yes
No
lvef ≤ 25%*
Yes
No
ci ≤ 2.2 l/min/m2, while not on inotropes*
l/min/m2
Yes
No
on optimal medical management (omm), based
on current heart failure practice guidelines for at
least 45 out of the last 60 days and are failing to
respond,*
Yes
No
in nyha class iiib or iv heart failure for at least 14
days and dependent on intraaortic balloon pump
(iabp) for at least 7 days,*
Yes
No
inotrope dependent/unable to wean from
inotropes*
Yes
No
listed for transplant*
Yes
No
females of child bearing age must agree to use
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adequate contraception*
Yes
No
Exclusion Criteria
etiology of hf due to or associated with
uncorrected thyroid disease, obstructive
cardiomyopathy, pericardial disease, amyloidosis
or restrictive cardiomyopathy*
Yes
No
technical obstacles which pose an inordinately
high surgical risk, in the judgment of the
investigator*
Yes
No
existence of ongoing mechanical circulatory
support (mcs) other than iabp*
Yes
No
positive pregnancy test if of childbearing
potential*
Yes
No
lactating mothers*
Yes
No
presence of mechanical aortic cardiac valve that
will not be converted to a bioprosthesis at the
time of lvad implant*
Yes
No
history of any organ transplant*
Yes
No
platelet count < 100,000 x 103/l (< 100,000/ml)*
Yes
No
psychiatric disease/disorder, irreversible cognitive
dysfunction or psychosocial issues that are likely
to impair compliance with the study protocol and
lvas management*
Yes
No
history of confirmed, untreated aaa > 5 cm in
diameter*
Yes
No
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presence of an active, uncontrolled infection*
Yes
No
intolerance to anticoagulant or antiplatelet
therapies or any other peri/post-operative therapy
the investigator will require based upon the
patients'*
Yes
No
health status*
Yes
No
presence of any one of the following risk factors
for indications of severe end organ dysfunction or
failure:*
Yes
No
an inr ≥ 2.5 not due to anticoagulation therapy*
Yes
No
total bilirubin > 43 umol/l (2.5 mg/dl), shock liver,
or biopsy proven liver cirrhosis*
umol
Yes
No
history of severe chronic obstructive pulmonary
disease (copd) defined by fev1/fvc < 0.7, or fev1
<50% predicted*
Yes
No
fixed pulmonary hypertension with a most recent
pvr ≥ 8 wood units that is unresponsive to
pharmacologic intervention*
Yes
No
history of stroke within 90 days prior to
enrollment, or a history of cerebrovascular
disease with significant (> 80%) carotid artery
stenosis*
Yes
No
serum creatinine ≥221umol/l (2.5 mg/dl) or the
need for chronic renal replacement therapy*
umol
Yes
No
significant peripheral vascular disease (pvd)
accompanied by rest pain or extremity ulceration*
Yes
No
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patient has moderate to severe aortic
insufficiency without plans for correction during
pump implant*
Yes
No
pre albumin < 150 mg/l, or albumin < 30g/l (3
g/dl)*
g/dl
Yes
No
planned bi-vad support prior to enrollment*
Yes
No
patient has known hypo or hyper coagulable
states such as disseminated intravascular
coagulation and heparin induced
thrombocytopenia*
Yes
No
participation in any other clinical investigation that
is likely to confound study results or affect the
study*
Yes
No
any condition other than hf that could limit
survival to less than 24 months*
Yes
No
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Eligibility Advanced or Metastatic Breast
Cancer, NCT01625286
Investigating Safety, Tolerability and Efficacy of AZD5363
When Combined With Paclitaxel in Breast Cancer Patients;
ODM derived from:
https://clinicaltrials.gov/show/NCT01625286
All rights reserved. Please visit https://medical-data-
models.org/forms/14821
Eligibility Advanced or Metastatic
Breast Cancer, NCT01625286
Inclusion Criteria
provision of informed consent*
Yes
No
female patient*
Yes
No
aged at least 18 years*
Yes
No
histological or cytological confirmation of breast
cancer with evidence of advanced or metastatic
disease (must be er+ve, her2-ve, in part b).*
Yes
No
world health organisation (who) performance
status 0-1 with no deterioration over the previous
2 weeks and minimum life expectancy of 12
weeks.*
Yes
No
Exclusion Criteria
clinically significant abnormalities of glucose
metabolism*
Yes
No
spinal cord compression or brain metastases
unless asymptomatic, treated and stable (not
requiring steroids).*
Yes
No
evidence of severe or uncontrolled systemic
diseases, including active bleeding diatheses or
active infections including hepatitis b, c and hiv.*
Yes
No
any prior exposure to agents which inhibit akt as
the primary pharmacological activity.*
Yes
No
part a: more than two prior courses of
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chemotherapy (including taxanes) for advanced
or metastatic breast cancer.*
Yes
No
part b: any prior chemotherapy for advanced or
metastatic breast cancer.*
Yes
No
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Eligibility Aggressive Lymphoma
NCT01562977
Study to Evaluate Efficacy and Tolerance of R-GemOx in
DLBCL and MCL; ODM derived from:
https://clinicaltrials.gov/show/NCT01562977
All rights reserved. Please visit https://medical-data-
models.org/forms/14822
Eligibility Aggressive Lymphoma
NCT01562977
Inclusion Criteria
age ≥ 18 years.*
Yes
No
dlbcl and mcl diagnosed patients in primary
resistance or relapsed not  eligible for
intensification chemotherapy followed by
autologous stem cell transplantation (asct) for
age, comorbidity or previous asct.*
Yes
No
any ipi or ecog, capable of understanding the
nature of the trial.*
Yes
No
writtern informed consent.*
Yes
No
Exclusion Criteria
nursing pregnant or lactation period women, or
fertile age adults not using effective contraceptive
method.*
Yes
No
cns lymphoma patients*
Yes
No
patients with severa renal (creatinine> 2,5 unl) or
hepatic (bilirrubin or alt/ast> 2,5 unl) impairement
not provided by the same disease*
Yes
No
hiv positive patients.*
Yes
No
serious psychiatric diseases patients that could
interfere with their skill to understand the study
(including alcoholism or drug addiction).*
Yes
No
murine proteins or any other component of the
medicines of the study hypersensitivity patients.*
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Yes
No
patients who have received more than 2
therapeutic previous lines. (for previous asct
patients, induction and conditioning for the taph
treatment is considered a single line therapy).*
Yes
No
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Eligibility Advanced Metastatic Breast
Cancer NCT01597388
AZD2014 and Fulvestrant in Patients With ER+ Advanced
Metastatic Breast Cancer; ODM derived from:
https://clinicaltrials.gov/show/NCT01597388
All rights reserved. Please visit https://medical-data-
models.org/forms/14823
Eligibility Advanced Metastatic
Breast Cancer NCT01597388
Inclusion Criteria
provision of signed and dated written informed
consent prior to any study specific procedures,
sampling analysis*
Yes
No
aged at least 18*
Yes
No
at least one lesion (measurable and/or non-
measurable) that can be accurately assessed at
baseline by computerised tomography (ct)
magnetic resonance imaging (mri) or plain x-ray
and is suitable for repeated assessment*
Yes
No
histological or cytological confirmation of an er+
advanced metastatic breast cancer tumour that is
eligible for treatment with fulvestrant*
Yes
No
eastern cooperative oncology group (ecog)
performance status of 0 or 1*
Yes
No
patients must have evidence of non-child-bearing
potential.*
Yes
No
Exclusion Criteria
prior chemotherapy, biological therapy, radiation
therapy, androgens, thalidomide, immunotherapy,
other anticancer agents, and any investigational
agents within 14 days of starting study treatment
(not including palliative radiotherapy at focal
sites)*
Yes
No
major surgery within 4 weeks prior to entry to the
study (excluding placement of vascular access),
or minor surgery within 2 weeks of entry into the
study.*
Yes
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No
patients with severe cardiac condition of
ischemia, impaired ventricular function and
arrhythmias, evidence of severe or uncontrolled
systemic or current unstable or uncompensated
respiratory or cardiac conditions.*
Yes
No
patients with diabetes type 1 or uncontrolled type
ii (hba1c > 8% assessed locally)*
Yes
No
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Eligibility Advanced Hepatocellular
Carcinoma NCT00517920
Phase 2 Study of ABT-869 in Advanced Hepatocellular
Carcinoma (HCC); ODM derived from:
https://clinicaltrials.gov/show/NCT00517920
All rights reserved. Please visit https://medical-data-
models.org/forms/14824
Eligibility Advanced Hepatocellular
Carcinoma NCT00517920
Inclusion Criteria
subject must be greater than or equal to 18 years
of age*
Yes
No
subject must be diagnosed with unresectable or
metastatic hcc*
Yes
No
subjects must have a measurable lesion by recist
on ct scan in at least one site which has not
received radiation*
Yes
No
subject has an eastern cooperative oncology
group (ecog) performance status of 0-2*
Yes
No
no other active malignancy within the past 5
years*
Yes
No
Exclusion Criteria
subject has received targeted vegf/pdgf/tki
therapy. prior avastin is allowed*
Yes
No
subject has child-pugh grade class c hepatic
impairment*
Yes
No
the subject has proteinuria common toxicity
criteria (ctc) grade > 1 as measured by routine
urinalysis or 24 hour urine collection during
screening assessment*
Yes
No
subject currently exhibits symptomatic or
persistent, uncontrolled hypertension defined as
diastolic blood pressure > 100 mmhg or systolic
blood pressure > 150 mmhg. subjects may be re-
screened if blood pressure is shown to be
controlled with or without intervention*
1 / 2
mmhg
Yes
No
the subject has a documented left ventricular
ejection fraction < 50%*
Yes
No
subject is receiving therapeutic anticoagulation
therapy*
Yes
No
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Eligibility Alcoholic Hepatitis NCT00200746
Treatment of Alcohol-Related Hepatitis With Arginine; ODM
derived from: https://clinicaltrials.gov/show/NCT00200746
All rights reserved. Please visit https://medical-data-
models.org/forms/14825
Eligibility Alcoholic Hepatitis
NCT00200746
Inclusion Criteria
diagnosis of alcoholic hepatitis*
Yes
No
maddrey's df score less than 33*
Yes
No
Exclusion Criteria
hepatitis c or b virus infected*
Yes
No
hiv infected*
Yes
No
history of cancer*
Yes
No
hepatic encephalopathy (a condition in which liver
failure affects the central nervous system)*
Yes
No
kidney failure*
Yes
No
a do not resuscitate order (a patient-directed
order not to resuscitate in the event that
resuscitation is necessary to prevent death)*
Yes
No
maddrey's df score of 33 or greater after vitamin
k administration during the study*
Yes
No
alcohol withdrawal at study entry*
Yes
No
active pneumonia at study entry*
Yes
No
allergy to iodine*
1 / 2
Yes
No
enrollment in any other clinical trials*
Yes
No
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Eligibility Breast Cancer NCT02448576
PCI in Advanced Triple Negative Breast Cancer Patients
Who Response to 1st Line Chemotherapy; ODM derived
from: https://clinicaltrials.gov/show/NCT02448576
All rights reserved. Please visit https://medical-data-
models.org/forms/14826
Eligibility Breast Cancer
NCT02448576
Inclusion Criteria
1. signed informed consent;*
Yes
No
2. age of 18 to 65 years;*
Yes
No
3. documented advanced breast cancer, clinical
and pathological confirmed;*
Yes
No
4. immunohistochemical examination:er<1%+,
progestin receptor (pr)<1%+, her-2 -/+ or her-
2(++)with negative result of fish;*
Yes
No
5. a response after four to eight cycles of first line
chemotherapy;*
Yes
No
6. life expectancy longer than six months
evaluated by investigator;*
Yes
No
7. a performance status of 0 to 2, according to
the criteria of the world health organization (with
a higher score indicating a poorer performance
status)*
Yes
No
8. less than grade 1( common terminology criteria
grade version 4.0) of treatment-related toxicities;*
Yes
No
9. adequate baseline organ function.*
Yes
No
Exclusion Criteria
1. history of another malignancy.*
Yes
No
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2. pregnancy or gestation*
Yes
No
3. definite diagnosed of central nervous system
(cns)or leptomeningeal metastases*
Yes
No
4. serious cardiac illness or medical condition*
Yes
No
5. known history of related central nervous
system or leptomeningeal disease*
Yes
No
6. cognition impairment or suffering from mental
illness*
Yes
No
7. demand a long-term oral administration of
psychotropic drugs*
Yes
No
8. have a concurrent disease or condition that
may interfere with study participation, or any
serious medical disorder that would interfere with
the subject's safety (for example, active or
uncontrolled infection, currently active/requiring
anti-viral therapy hepatic or biliary disease)*
Yes
No
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Eligibility Breast Neoplasms NCT00036270
Randomized Phase III Study Of Exemestane (Aromasin)
For 5 Years Versus Tamoxifen for 2.5 to 3 Years Followed
By Exemestane; ODM derived from:
https://clinicaltrials.gov/show/NCT00036270
All rights reserved. Please visit https://medical-data-
models.org/forms/14828
Eligibility Breast Neoplasms
NCT00036270
Inclusion Criteria
histologically/cytologically confirmed
adenocarcinoma of the breast, followed by
adequate surgical resection and/or radiotherapy,
and/or adjuvant chemotherapy, if indicated.*
Yes
No
stage t1-3 n0-2 mo, any tnm stage bc for whom
adjuvant hormonal therapy is being considered.*
Yes
No
Exclusion Criteria
those patients not deemed to have had
potentially curative primary surgical treatment or
one of the following criteria:*
Yes
No
inflammatory breast cancer*
Yes
No
histologically positive supraclavicular nodes*
Yes
No
ulceration/infiltration of local skin metastasis*
Yes
No
neoadjuvant chemotherapy*
Yes
No
ductal carcinoma in situ (dcis) or lobular
carcinoma in situ (lcis) without invasion*
Yes
No
er and pr negative primary tumor or er/pr
unknown status.*
Yes
No
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Eligibility Breast Neoplasms NCT00037609
Safety, Efficacy and Pharmacokinetic Between
Capecitabine and Exisulind in Metastatic Breast Cancer
Patients; ODM derived from:
https://clinicaltrials.gov/show/NCT00037609
All rights reserved. Please visit https://medical-data-
models.org/forms/14829
Eligibility Breast Neoplasms
NCT00037609
Inclusion Criteria
each patient must meet all these criteria in order
to be considered for enrollment in the phase i
study:*
Yes
No
histologically confirmed breast cancer and either
clinical, radiological or laboratory evidence of
metastatic disease.*
Yes
No
patients must have received both anthracycline-
containing and chemotherapy either as adjuvant
treatment or therapy for metastatic breast
cancer.*
Yes
No
there is no limit on prior chemotherapy regimens
or hormonal therapies received.*
Yes
No
concomitant bisphosphonate treatment is allowed
for patients with bone metastases.*
Yes
No
patients must have recovered from acute toxic
effects of any prior therapy including surgery and
radiation.*
Yes
No
zubrod performance status < 2. (see appendix a)*
Yes
No
adequate bone marrow function: platelets >
100,000/mm3, anc > 1500 cells/mm3,
hemoglobin > 8g/dl.*
Yes
No
normal renal function: creatinine < 2.0 mg/dl.*
Yes
No
adequate liver function: bilirubin < 1.5 mg/dl.
transaminases (sgot) or ldh, and alkaline
1 / 3
phosphatase must be <1.5 x of the upper limit of
normal in the absence of bone or liver
metastasis, or <2.5 x of the upper limit of normal
in the presence of radiologically apparent liver
metastasis or bone metastasis, respectively.*
Yes
No
female patients must be of non-childbearing
potential or non-lactating and using adequate
contraception. beta-hcg will be checked in
premenopausal patients if clinically indicated.*
Yes
No
patients with brain metastases whose disease
remained for more than 6 months after
completing therapy to the brain are eligible.*
Yes
No
written informed consent.*
Yes
No
in addition to the above, patients participating in
the phase ii portion of this study:*
Yes
No
must have bidimensionally measurable or
evaluable disease. lytic lesions seen on plain
radiographs will be considered evaluable in
conjunction with bone scan abnormalities. bone
scan abnormalities alone, pure blastic bone
metastases or irradiated lesions are not
considered measurable or evaluable and will not
be accepted. also, pleural or peritoneal effusions
will not be considered evaluable disease.*
Yes
No
Exclusion Criteria
a patient must not be enrolled if any of the
following criteria applies:*
Yes
No
known hypersensitivity to sulindac (clinoril).*
Yes
No
known hypersensitivity or contraindications to
capecitabine (xelodar) including prior therapy with
capecitabine.*
Yes
No
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clinical or laboratory evidence of significant liver
disease.*
Yes
No
concomitant treatment with cytotoxic agents other
than capecitabine or participation in any other
investigational study.*
Yes
No
uncontrolled psychiatric, or social (addictive)
disorders that would preclude obtaining informed
consent or patient participation in the study.*
Yes
No
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Eligibility Breast Neoplasms NCT00039793
Massage Therapy for Cancer-Related Fatigue; ODM
derived from: https://clinicaltrials.gov/show/NCT00039793
All rights reserved. Please visit https://medical-data-
models.org/forms/14830
Eligibility Breast Neoplasms
NCT00039793
Inclusion Criteria
confirmed tissue diagnosis of cancer of the
breast, ovary, prostate or colo-rectum*
Yes
No
have an anticipated completion of chemotherapy
no more than 2 weeks before the last bodywork
session.*
Yes
No
have a primary oncologist*
Yes
No
currently receiving chemotherapy or completed
chemotherapy treatment within the past 6
months*
Yes
No
Exclusion Criteria
active skin rash or open cutaneous lesions.*
Yes
No
history of venous thrombosis (or symptomatic
varicosity)*
Yes
No
identification of a thrombosis using an ultrasound
test of the legs.*
Yes
No
long term (> 3 months) steroid medications for
other medical conditions in past 5 years*
Yes
No
plans to move out of the study region within 6
months*
Yes
No
thyroid-stimulating hormone (tsh) level above the
upper limit of normal*
Yes
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No
hematocrit <25%*
Yes
No
platelet count of < 50,000*
Yes
No
patients who have been receiving regular (i.e. at
least twice a month) bodywork over the past 6
months.*
Yes
No
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Eligibility Breast Neoplasms NCT00046514
ABI-007 in Taxol Resistant Patients With Metastatic Breast
Cancer; ODM derived from:
https://clinicaltrials.gov/show/NCT00046514
All rights reserved. Please visit https://medical-data-
models.org/forms/14831
Eligibility Breast Neoplasms
NCT00046514
Criteria
if female, non-pregnant and not lactating, with a
negative serum pregnancy test, and either not of
child-bearing potential or practicing an approved
contraception method*
Yes
No
eighteen years of age or older*
Yes
No
karnofsky perfomance status of 70% or 0-2 swog
performance status*
Yes
No
no other malignancy, except non-melanoma skin
cancer, cin, or in-situ cervical cancer*
Yes
No
measurable disease*
Yes
No
suitable candidate for treatment with paclitaxel*
Yes
No
previously treated with taxol weekly or every
three weeks, including adjuvant therapy, for
metastatic breast cancer and relapsed within 12
months*
Yes
No
if, at baseline, patient has absolute neutrophil
count of at least 1500 cells/mm3, platelet count of
at least 100,000 cells/mm3,and hemoglobin of at
least 9 g/dl*
Yes
No
if, at baseline, patient has ast and alt of less than
or equal to 2.5 x the upper limit of normal range;
a total bilirubin less than or equal to 1.5 mg/dl;
creatinine levels less than or equal to 2 mg/dl;
and alkaline phosphatase levels less than or
equal to 5 x the upper limit of normal range
(unless there are bone but not liver metastases)*
Yes
No
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patient has an expected survival of at least 12
weeks*
Yes
No
patient or his/her representative has signed an
informed consent statement*
Yes
No
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Eligibility Breast Neoplasms NCT00046527
Study of ABI-007 and Taxol in Patients With Metastatic
Breast Cancer; ODM derived from:
https://clinicaltrials.gov/show/NCT00046527
All rights reserved. Please visit https://medical-data-
models.org/forms/14832
Eligibility Breast Neoplasms
NCT00046527
Criteria
female, non-pregnant, non-lactating, and, if of
child-bearing potential, have a negative serum
pregnancy test, and use approved contraception*
Yes
No
sixteen years of age or older*
Yes
No
histologically or cytologically confirmed breast
cancer (stage iii or iv) with evidence of inoperable
local recurrence or metastasis, with measurable
disease*
Yes
No
if patient has received taxane therapy as an
adjuvant he/she has not relapsed within one year
of completing adjuvant taxane*
Yes
No
no other malignancy present within the past 5
years, except non-melanoma skin cancer,
cervical intraepithelial neoplasia or in-situ cervical
cancer*
Yes
No
suitable candidate for paclitaxel therapy*
Yes
No
hematology levels at baseline of: absolute
neutrophil count of at least 1500 cells/mm3;
platelet count of at least 100,000 cells/mm3;
hemoglobin of at least 9 g/dl*
Yes
No
chemistry levels at baseline of:  ast and alt of less
than or equal to 2.5 x the upper limit of normal, if
no evidence of liver metastasis; total bilirubin of
less than or equal to 1.5 mg/dl; creatinine of less
than or equal to 2 mg/dl; alkaline phosphatase of
less than or equal to 5 x the upper limit of normal,
unless there is bone metastasis but not liver
metastasis*
Yes
No
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expected survival of at least 12 weeks*
Yes
No
patient or his/her representative has signed an
informed consent form*
Yes
No
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Eligibility Breast Neoplasms NCT00179348
Yoga-Based Cancer Rehabilitation Program; ODM derived
from: https://clinicaltrials.gov/show/NCT00179348
All rights reserved. Please visit https://medical-data-
models.org/forms/14833
Eligibility Breast Neoplasms
NCT00179348
Inclusion Criteria
diagnosis of breast cancer (stages i, ii, or iii),
colorectal cancer (stages i, ii, or iii), or lung
cancer (stages i, ii)*
Yes
No
diagnosed with new or recurrent cancer within
past 5 years*
Yes
No
language is english or spanish*
Yes
No
recovered from surgery and any postoperative
complications requiring hospitalization*
Yes
No
Exclusion Criteria
current yoga practice >1x month*
Yes
No
unable to attend yoga class due to time conflict*
Yes
No
advanced cancer with symptomatic pulmonary,
skeletal or brain metastases*
Yes
No
second primary cancer that is active*
Yes
No
ecog performance status of 3 or 4*
Yes
No
seizures*
Yes
No
arthritis or muscle pain, if severe enough to
interfere with simple yogic exercises*
Yes
No
1 / 2
asthma or difficulty breathing, if severe enough to
interfere with ability to perform deep breathing*
Yes
No
uncontrolled hypertension*
Yes
No
heart condition or problems*
Yes
No
current (uncontrolled) major psychiatric disorder*
Yes
No
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Eligibility Chronic Lymphocytic Leukemia
NCT00931645
Autologous Stem Cell Transplantation in Chronic
Lymphocytic Leukemia; ODM derived from:
https://clinicaltrials.gov/show/NCT00931645
All rights reserved. Please visit https://medical-data-
models.org/forms/14834
Eligibility Chronic Lymphocytic
Leukemia NCT00931645
Inclusion Criteria
patients with stage b & c cll, 18- 65 years.*
Yes
No
previously untreated*
Yes
No
given written informed consent*
Yes
No
Exclusion Criteria
childbearing women*
Yes
No
oms performance status > 2*
Yes
No
binet stage a*
Yes
No
autoimmune hemolytic anemia*
Yes
No
active or previous (< 5 years) malignant disease,
except cutaneous cell carcinoma.*
Yes
No
previous cll treatment*
Yes
No
hiv seropositivity*
Yes
No
abnormal renal or liver function tests (creatinine >
1,5n, transaminases > 2n, bilirubin > 1,5n)*
Yes
No
cardiac failure (ejection fraction < 50%)*
Yes
No
1 / 2
lung disease or perturbed ventilation tests*
Yes
No
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Eligibility Chronic Lymphocytic Leukemia
NCT01423032
Bendamustine Versus Fludarabine in Chronic Lymphocytic
Leukemia (CLL); ODM derived from:
https://clinicaltrials.gov/show/NCT01423032
All rights reserved. Please visit https://medical-data-
models.org/forms/14835
Eligibility Chronic Lymphocytic
Leukemia NCT01423032
Inclusion Criteria
histologically or immunologically confirmed
chronic b-cell leukemia*
Yes
No
refractory (i.e. no response or progression during
initial chemotherapy) or relapsed situation after
first-line treatment regimen*
Yes
No
disease stage ii-iv according to rai or b/c
according to binet staging system, respectively*
Yes
No
eastern cooperative oncology group (ecog)
performance status of 3 or better*
Yes
No
negative pregnancy test/ adequate method of
contraception*
Yes
No
Exclusion Criteria
t-cll, pll (prolymphocytic leukemia)*
Yes
No
presence of richter's transformation*
Yes
No
first-line treatment containing either fludarabine or
bendamustine*
Yes
No
acute infections or distinctly reduced organ
function precluding the application of
chemotherapy, as for pulmonary, heart, liver (total
bilirubin > 5mg/dl), renal system (creatinine > 2
mg/dl), or metabolic disorders*
Yes
No
secondary malignancy (except for curative
treated basal cell carcinoma or cervical cancer)*
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Yes
No
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Eligibility Chronic Myeloproliferative
Disorders NCT00069992
Total-Body Irradiation, Fludarabine, and Alemtuzumab
Followed By Stem Cell Transplant in Treating Patients With
Myeloproliferative Disorder, MS, AML, or CML; ODM
derived from: https://clinicaltrials.gov/show/NCT00069992
All rights reserved. Please visit https://medical-data-
models.org/forms/14836
Eligibility Chronic Myeloproliferative
Disorders NCT00069992
Inclusion Criteria
myelodysplastic syndrome with ipss score >
0.(appendix b) or*
Yes
No
myeloproliferative disorders*
Yes
No
primary myelofibrosis with lile score of 1 or 2
(appendix c)*
Yes
No
polycythemia vera or essential thrombocythemia
transformed to aml or myelofibrosis and pv "spent
phase" or*
Yes
No
acute myelogenous leukemia or*
Yes
No
chronic myelogenous leukemia*
Yes
No
available healthy donor without any
contraindications for donation.  5/6 or 6/6 related
donor or 5/6 or 6/6 unrelated donor (molecular
typing for drb1)*
Yes
No
able to give informed consent*
Yes
No
Exclusion Criteria
patient is pregnant or lactating or unwilling to use
contraceptives.*
Yes
No
hiv positive patient*
Yes
No
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uncontrolled intercurrent infection*
Yes
No
unstable angina and uncompensated congestive
heart failure (zubrod of 3 or greater)*
Yes
No
severe chronic pulmonary disease requiring
oxygen (zubrod of 3 or greater)*
Yes
No
hemodialysis  dependent.*
Yes
No
active hepatitis or cirrhosis with total bilirubin,
sgot, and sgpt greater than 3 x normal.*
Yes
No
concurrent solid organ malignancy not in
remission, except for stage 0 or a prostate
cancer.*
Yes
No
unstable cerebral vascular disease or recent
hemorrhagic stroke (less than 6 months)*
Yes
No
active cns disease from hematological disorder.*
Yes
No
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Eligibility Colorectal Cancer NCT01212718
Response Prediction in Metastasized Colorectal Cancer
Using Intratumoral Thymidylate Synthase; ODM derived
from: https://clinicaltrials.gov/show/NCT01212718
All rights reserved. Please visit https://medical-data-
models.org/forms/14837
Eligibility Colorectal Cancer
NCT01212718
Inclusion Criteria
patients (>= 18 years) with non-resectable
metastasized or recurrent histologically proven
crc with the presence of a reference lesion two-
dimensional measurable and accessible for a
biopsy*
Yes
No
a performance status who 0-2 (karnofsky >=
60%)*
Yes
No
an estimated life expectancy of at least 3 months*
Yes
No
written informed consent*
Yes
No
Exclusion Criteria
patients older than 75 years not fulfilling these
criteria*
Yes
No
brain metastases or a secondary cane*
Yes
No
a history of a systemic palliative chemotherapy*
Yes
No
and an adjuvant chemotherapy (within 6 months)*
Yes
No
pregnant or nursing women*
Yes
No
a known allergy toward irinotecanhydroclorid or of
any ingredients of campto or other severe
medical*
Yes
No
laboratory and social conditions not allowing
1 / 2
chemotherapy and follow-up*
Yes
No
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Eligibility Colorectal Carcinoma
NCT00176774
Irinotecan, 5-Fluorouracil, and Leucovorin in Colorectal
Carcinoma; ODM derived from:
https://clinicaltrials.gov/show/NCT00176774
All rights reserved. Please visit https://medical-data-
models.org/forms/14838
Eligibility Colorectal Carcinoma
NCT00176774
Inclusion Criteria
patients must have histologically proven
adenocarcinoma primary to the colon or rectum
and clinical or pathologic evidence of distant
metastasis.*
Yes
No
patients may have received adjuvant
chemotherapy and/or one regimen of
chemotherapy for metastatic disease.  patients
must not have been previously treated with the
combination of irinotecan/5-fu/lv.*
Yes
No
patients must be past their 18th birthday at the
time of enrollment.*
Yes
No
patients must have a performance status of 0-2 at
the time of registration.*
Yes
No
patients must have a life expectancy of > 3
months.*
Yes
No
if patients have undergone recent surgery, they
must have fully recovered from the effects of that
surgery prior to enrollment.*
Yes
No
patients must have a pretreatment leukocyte
count > 3,000/l, absolute neutrophil count
>1500/l, hemoglobin >8 mg/dl, and platelet count
of > 150,000/l within 2 weeks of enrollment.*
Yes
No
patients must have adequate renal function, as
documented by a serum creatinine < 2.0 mg/dl,
and have adequate hepatic function, as
documented by a serum bilirubin < 1.1 mg/dl
within 2 weeks of enrollment.*
Yes
No
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Exclusion Criteria
patients must not have active infection.*
Yes
No
patients must have no serious medical or
psychiatric illness, other than that treated by this
study, which would limit the ability of the patient
to receive protocol therapy or give informed
consent.*
Yes
No
patients must not have a history of active
malignancy, other than that treated by this study,
within the 12 months preceding enrollment.*
Yes
No
pregnant or lactating women may not participate.
women of reproductive age must undergo a
serum pregnancy test within 14 days of
enrollment.  men and women of reproductive
potential must use an effective contraceptive
method during the study.*
Yes
No
there must be no plans for the patient to receive
concomitant antineoplastic therapy while on this
protocol.*
Yes
No
all patients must be informed of the
investigational nature of this study and must sign
and give written informed consent in accordance
with institutional and federal guidelines.*
Yes
No
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Fasting C-peptide Assay Protocol PhenX
Toolkit
This protocol provides instructions for drawing, processing,
and storing blood according to the National Health and
Nutrition Examination Survey (NHANES) methods. As there
are no standard assays for C_peptide, the protocol also
provides basic guidelines to aid comparability among
different studies.
ODM derived from: https://cde.nlm.nih.gov
Primary source: https://www.phenxtoolkit.org/
Recent publication: Hendershot, T., Pan, H., Haines, J.,
Harlan, W.R., Marazita, M.L., McCarty, C.A., Ramos, E.M.,
and Hamilton, C.M. (2015) Using the PhenX toolkit to add
standard measures to a study. Curr. Protoc. Hum. Genet.
86:1.21.1-1.21.17. doi: 10.1002/0471142905.hg0121s86
Permission to publish granted by
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Fasting C-peptide Assay Protocol
PhenX Toolkit
PhenX - fasting C-peptide sssay for
residual beta cell function protocol
Did you eat or drink anything other than plain
water after 11:30 last night?
Yes (1)
No (2)
Refused (3)
Don´t know (4)
When did you last eat or drink anything other
than plain water?
Have you had any of the following since {insert
time from 1 here}? Coffee or tea with cream and
sugar? [Include milk or non-dairy creamers.]
Yes
No
If Yes, record date
Have you had any of the following since {insert
time from 1 here}? Alcohol, such as beer, wine,
or liquor?
Yes
No
If Yes, record date
Have you had any of the following since {insert
time from 1 here}? Gum, breath mints, lozenges,
or cough drops, or other cough or cold remedies?
Yes
No
If Yes, record date
Have you had any of the following since {insert
time from 1 here}? Antacids, laxatives, or anti-
diarrheals?
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Yes
No
If Yes, record date:
Have you had any of the following since {insert
time from 1 here}? Dietary Supplements such as
vitamins and minerals? [Include multivitamins and
single nutrient supplements.]
Yes
No
If Yes, record date
Do you have hemophilia?
Yes (1)
No (2)
Refused (3)
Don´t know (4)
Have you received cancer chemotherapy in the
past four weeks or do you anticipate such therapy
in the next four weeks?
Yes (1)
No (2)
Refused (3)
Don´t know (4)
Exclusion Criteria
Has not fasted at least 9 hours  (Has not
fasted at least 9 hours )
Hemophilia     (Hemophilia    )
None – proceed with blood draw (None –
proceed with blood draw)
Pregnant     (Pregnant    )
Received cancer chemotherapy in the
last 3 weeks (Received cancer
chemotherapy in the last 3 weeks)
Taking insulin     (Taking insulin    )
Taking oral medications for diabetes
(Taking oral medications for diabetes )
Was blood drawn?
Yes
No
Was full sample obtained?
Yes
No
Service comment
Service comment
Repeatability of the assay
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Coefficient of variation for the assay
Was the participant fasting?
Yes
No
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Integrated Fitness - Child Protocol PhenX
Toolkit
This is a series of fitness tests used to assess a child’s
fitness level. Tests include the Progressive Aerobic
Cardiovascular Endurance Run (PACER) test (similar to
shuttle run); curl-up, which is often referred to as a sit-up;
trunk lift; push-up (or modified push-up); and back-saver sit
and reach. Optional tests include a 1 mile run/walk,
modified pull-up or flexed arm hang (for muscular strength
and endurance), and a shoulder stretch (for flexibility).
Tests should be performed with the assistance of a partner
who counts and/or times the activity.
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Integrated Fitness - Child Protocol
PhenX Toolkit
PhenX - integrated fitness - child protocol
Sex
Male (1)
Female (2)
Body weight
kg
Age
Body height
cm
Length of laps
15 meters (15 meters)
20 meters (20 meters)
Number of laps
Time to complete entire 1 mile run
Number of curl-ups
Distance from the floor to the child's chin
cm
Number of push-ups completed
Length of time child retains position
Number of modified pull-ups completed
Distance reached
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mFingertips touch with left arm behind the back
and right arm behind the head
Yes
No
Fingertips touch with right arm behind the back
and left arm behind the head
Yes
No
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Occupation/Occupational History Protocol
PhenX Toolkit
This protocol includes several questions about the
respondent’s current job, including the job title, industry,
activities, when the job was started, hours spent working
each week, and normal hours of the day worked.
Occupation and industry entries are coded using the
Standardized Occupational Classification System (SOC)
and the North American Industry Classification System
(NAICS) codes from the U.S. Census Bureau.
The respondent is asked a number of questions about his
longest held job, including name of occupation, industry,
types of activities performed, and length of time worked.
As an alternative, the respondent is asked specific details
about every job he/she has had for 6 months or longer
since he/she was 16 years old. Information obtained about
each job includes: the name of the company, job title, when
the job started and stopped, address of the company,
whether it was full-time, part-time, or seasonal work, type of
business, main activities on the job, chemicals and
materials handled, and tools and equipment used.
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Occupation/Occupational History
Protocol PhenX Toolkit
PhenX - environmental exposures -
occupation - occupation history protocol
How many hours did {you/SP} work last week at
all jobs or businesses?
h
Do you usually work 35 hours or more per week
in total at all jobs or businesses?
Don't know (Don't know)
No (No)
Refused (Refused)
Yes (Yes)
For whom did {you/SP} work at {your/his/her}
main job or business? (what is the name of the
company, business, organization or employer?)
What kind of business or industry is this?
What kind of work {were you/was SP} doing?
What were {your/SP's} most important activities
on this job?
Which of the following best describes the hours
{you/SP} usually work at {your/his/her} main job
or business?
A regular daytime schedule     (A regular
daytime schedule    )
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A regular evening shift   (A regular
evening shift  )
A regular night shift  (A regular night shift
)
A rotating shift   (A rotating shift  )
Another schedule     (Another schedule
)
Don't know (Don't know)
Refused   (Refused  )
About how long {have you/has SP} worked for
{EMPLOYER} as a(n) {OCCUPATION}?
Thinking of all the paid jobs {you/SP} ever had,
what kind of work {were you/was s/he} doing the
longest?
What kind of business or industry {did you/did
SP} work in for the longest period of time as a
(DISPLAY LONGEST OCCUPATION)?
What were {your/SP's} most important activities
on this job or business?
About how long did {you/SP} work at that job or
business?
Since the age 16, did (you/your _______) ever
work for six months or more? we are interested in
every job, part-time or full-time, paid or unpaid,
that (you/he/she) held for 6 months or longer.
Don't know (Don't know)
No, housewife    (No, housewife   )
No, never worked     (No, never worked
)
Yes     (Yes    )
Job history
Job number [PhenX]
Job 1 (Job 1)
Job 2 (Job 2)
Job 3 (Job 3)
Job 4 (Job 4)
Job 5 (Job 5)
Job 6 (Job 6)
What was the name of the company where
(you/he/she) (first/next) worked for 6 months or
longer?
What was the job title of the (first/next) job
(you/your___) held at this company?
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In what year did (you/he/she) start working at this
job?
In what year did (you/he/she) stop working at this
job?
What was the location of this company? Address,
City/State
Was this a full-time or part-time job?
Full-time (Seasonal)     (Full-time
(Seasonal)    )
Full-time (Year-Round)   (Full-time (Year-
Round)  )
Part-time (Seasonal) (Part-time
(Seasonal))
Part-time (Year-Round)     (Part-time
(Year-Round)    )
What did they make, or what service did they
provide? What type of business was it?
Construction  (C )
Farming/ Fishing/ Forestry     (F )
Government     (G )
Manufacturer     (Ma )
Mining  (Mi )
Other (O )
Retailer   (R )
Service Provider     (S )
Wholesaler (W )
What did they make, or what service did they
provide? What type of business was it?
Construction  (C )
Farming/ Fishing/ Forestry     (F )
Government     (G )
Manufacturer     (Ma )
Mining  (Mi )
Other (O )
Retailer   (R )
Service Provider     (S )
Wholesaler (W )
What were (your/your _____'s) main activities or
duties for this job?
What kinds of chemicals or materials did
(you/he/she) handle in that job?
What kinds of tools and equipment did
(you/he/she) use?
Who provided most of the responses in this
section?
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Eligibility Agitation in Alzheimer's Disease
NCT02446132
Long Term, Extension Study of the Safety and Efficacy of
AVP-786 (Deuterated [d6] Dextromethorphan
Hydrobromide [d6-DM]/Quinidine Sulfate [Q]) for the
Treatment of Agitation in Patients With Dementia of the
Alzheimer's Type; ODM derived from:
https://clinicaltrials.gov/show/NCT02446132
All rights reserved. Please visit https://medical-data-
models.org/forms/14842
Eligibility Agitation in Alzheimer's
Disease NCT02446132
Inclusion Criteria
patient has successfully completed studies 15-
avp-786-301, 15-avp-786-302, or 12-avr-131*
Yes
No
patients from study 12-avr-131 with a diagnosis
of probable ad according to the 2011 nia-aa
working group criteria.*
Yes
No
either out-patients or residents of an assisted-
living facility or a skilled nursing home.*
Yes
No
patients from study 12-avr-131 who have
clinically significant, moderate/severe agitation at
least 2 weeks prior to baseline.*
Yes
No
patients from study 12-avr-131 with a diagnosis
of agitation that must meet the ipa provisional
definition of agitation.*
Yes
No
patients from study 12-avr-131 with a cgis score
assessing agitation of ≥ 4 (moderately ill) at
baseline.*
Yes
No
patients from study 12-avr-131 with a mmse
score between 6 and 26 (inclusive) at baseline.*
Yes
No
Exclusion Criteria
patients with co-existent clinically significant or
unstable systemic diseases that could confound
the interpretation of the safety results of the study
(e.g., malignancy, poorly controlled diabetes,
poorly controlled hypertension, unstable
pulmonary, renal or hepatic disease, unstable
ischemic cardiac disease, dilated
1 / 2
cardiomyopathy, or unstable valvular heart
disease).*
Yes
No
patients determined to have a high imminent risk
of falls during the study based on a clinical
evaluation by the investigator.*
Yes
No
patients who are currently using or were on
nuedexta® in the 4 weeks preceding baseline.*
Yes
No
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Bronchodilator Responsiveness (BDR)
Protocol PhenX Toolkit
A series of spirometry maneuvers is performed to obtain
acceptable and reproducible results. An inhaled
bronchodilator medication is administered, and a second
series of spirometry maneuvers is performed.
ODM derived from: https://cde.nlm.nih.gov
Primary source: https://www.phenxtoolkit.org/
Recent publication: Hendershot, T., Pan, H., Haines, J.,
Harlan, W.R., Marazita, M.L., McCarty, C.A., Ramos, E.M.,
and Hamilton, C.M. (2015) Using the PhenX toolkit to add
standard measures to a study. Curr. Protoc. Hum. Genet.
86:1.21.1-1.21.17. doi: 10.1002/0471142905.hg0121s86
Permission to publish granted by
Carol M. Hamilton.
All rights reserved. Please visit https://medical-data-
models.org/forms/14843
Bronchodilator Responsiveness
(BDR) Protocol PhenX Toolkit
PhenX - respiratory - bronchodilator
responsiveness - BDR protocol
Heart rate
/min
Spirometry Contraindicated
Yes
No
Reason for Contraindication
Percent of Baseline Forced Expiratory Volume in
1 second
%
FEV1/Predicted
%
Absolute Volume
L
Pre - Bronchodilator Forced Expiratory
Volume (FEV 1 ) in 1 second
Pre-bronchodilator forced expiratory volume,
FEV, in 1 second attempt
Pre FEV1 1st   (Pre FEV1 1st  )
Pre FEV1 2nd   (Pre FEV1 2nd  )
Pre FEV1 3rd (Pre FEV1 3rd)
FEV1 --pre bronchodilation
L
Post - Bronchodilator Forced Expiratory
Volume (FEV 1 ) in 1 second
post-bronchodilator fev1 of less than 30%
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Post FEV1 1st    (Post FEV1 1st   )
Post FEV1 2nd     (Post FEV1 2nd    )
Post FEV1 3rd (Post FEV1 3rd)
FEV1 --post bronchodilation
L
Pre - Bronchodilator Forced Vital Capacity
(FVC)
Pre-Bronchodilator Forced Vital Capacity (FVC)
attempt
Pre FVC 1st   (Pre FVC 1st  )
Pre FVC 2nd     (Pre FVC 2nd    )
Pre FVC 3rd (Pre FVC 3rd)
Forced vital capacity [Volume] Respiratory
system by Spirometry --pre bronchodilation
L
Post - Bronchodilator Forced Vital
Capacity (FVC)
Post-Bronchodilator Forced Vital Capacity (FVC)
attempt
Post FVC 1st     (Post FVC 1st    )
Post FVC 2nd    (Post FVC 2nd   )
Post FVC 3rd (Post FVC 3rd)
Forced vital capacity [Volume] Respiratory
system by Spirometry --post bronchodilation
L
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Eligibility Advanced or Refractory Leukemia
NCT00676728
A Study of the Histone-deacetylase Inhibitor JNJ-26481585
in Patients With Advanced or Refractory Leukemia or
Myelodysplastic Syndrome; ODM derived from:
https://clinicaltrials.gov/show/NCT00676728
All rights reserved. Please visit https://medical-data-
models.org/forms/14844
Eligibility Advanced or Refractory
Leukemia NCT00676728
Inclusion Criteria
histologically or cytologically confirmed advanced
or refractory acute myeloid leukemia, acute
lymphocytic leukemia, chronic myeloid leukemia
in blast phase, refractory chronic lymphocytic
leukemia, myelodysplastic syndrome, or chronic
myelomonocytic leukemia*
Yes
No
myelodysplastic syndrome*
Yes
No
eastern cooperative oncology group performance
status score 0, 1 or 2*
Yes
No
left ventricular ejection fraction greater than or
equal to 50%*
Yes
No
negative hepatitis b, c and human
immunodeficiency virus (hiv) test within last 3
months*
Yes
No
adequate liver and kidney function*
Yes
No
Exclusion Criteria
known or suspected involvement of the central
nervous system*
Yes
No
chemotherapy (nitrosoureas and mitomycin c
within 6 weeks), radiotherapy, immunotherapy or
treatment with investigative agent within 3 weeks
before study drug administration (except
hydroxyurea which should be stopped at least 24
hours prior to first dose)*
Yes
No
unstable angina or myocardial infarction within
1 / 2
the preceding 12 months; congestive heart
failure*
Yes
No
poorly controlled hypertension or diabetes,
ongoing active infection and psychiatric illness*
Yes
No
receiving medications known to have a risk of
causing qtc prolongation*
Yes
No
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Eligibility Advanced Parkinson's Disease
NCT02082249
An Extension Study to Assess the Safety, Tolerability and
Efficacy of ABT-SLV187 in Subjects With Advanced
Parkinson's Disease and Persistent Motor-Complications
Despite Optimized Treatment With Available Anti-
Parkinsonian Medications; ODM derived from:
https://clinicaltrials.gov/show/NCT02082249
All rights reserved. Please visit https://medical-data-
models.org/forms/14845
Eligibility Advanced Parkinson's
Disease NCT02082249
Inclusion Criteria
subjects completing 12 weeks treatment in study
m12-921 who would benefit from long-term
treatment from abt-slv187.  alternatively, subjects
who (i) participated in the phase 2 study m12-925
(ii) would, in the opinion of the investigator,
benefit from abt-slv187 treatment in the study
m12-923, (iii) did not discontinue the m12-925
study due to safety reason, and (iv) meet all entry
requirements.*
Yes
No
the subject must be able to understand the nature
of the study and must provide written informed
consent prior to the conduct of any study
procedures (including any changes occurring in
the subject's current therapeutic regimen).*
Yes
No
the subject must be willing to continue on
treatment.*
Yes
No
Exclusion Criteria
subject is enrolled in another clinical trial*
Yes
No
psychiatric, neurological or behavioral disorders
that may interfere with the ability of subjects to
give informed consent, or interfere with the
conduct of the study.*
Yes
No
medical, laboratory, or surgical issues deemed by
the investigator to be clinically significant and in
the opinion of the pi, would be a contraindication
to continued levodopa therapy.*
Yes
No
uncooperative attitude or reasonable likelihood
for non-compliance with the protocol*
Yes
No
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subject has current significant suicidal ideation as
evidenced by answering "yes" to questions 4 or 5
on the suicidal ideation portion of the columbia-
suicide severity rating scale completed at the
week 12 visit of study m12-921 or at the baseline
visit of the current study for m12-925 study
subjects.*
Yes
No
consideration by the investigator, for any reason,
that the subject is an unsuitable candidate to
continue to receive abt-slv187*
Yes
No
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Eligibility Agitation in Patients With Dementia
of the Alzheimer's Type NCT02442765
Efficacy, Safety and Tolerability of AVP-786 (Deuterated
[d6]-Dextromethorphan Hydrobromide [d6-DM]/Quinidine
Sulfate [Q]) for the Treatment of Agitation in Patients With
Dementia of the Alzheimer's Type; ODM derived from:
https://clinicaltrials.gov/show/NCT02442765
All rights reserved. Please visit https://medical-data-
models.org/forms/14846
Eligibility Agitation in Patients With
Dementia of the Alzheimer's Type
NCT02442765
Inclusion Criteria
diagnosis of probable alzheimer's disease (ad)*
Yes
No
the patient has clinically significant,
moderate/severe agitation at the time of
screening and for at least 2 weeks prior to
randomization*
Yes
No
the diagnosis of agitation must meet the ipa
provisional definition of agitation*
Yes
No
either out patients or residents of an assisted-
living facility or a skilled nursing home*
Yes
No
cgis score assessing agitation is >= 4
(moderately ill) at screening and baseline*
Yes
No
mmse score is between 6 and 26 (inclusive) at
screening and baseline*
Yes
No
caregiver who is able and willing to comply with
all required study procedures.  in order to qualify
as a reliable informant (i.e., caregiver) capable of
assessing changes in patient's condition during
the study, the individual must spend a minimum
of 2 hours per day for 4 days per week with the
patient*
Yes
No
Exclusion Criteria
patient has dementia predominantly of non-
alzheimer's type (e.g., vascular dementia,
frontotemporal dementia, parkinson's disease,
substance-induced dementia)*
Yes
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No
patients with co-existent clinically significant or
unstable systemic diseases that could confound
the interpretation of the safety results of the study
(e.g., malignancy, poorly controlled diabetes,
poorly controlled hypertension, unstable
pulmonary, renal or hepatic disease, unstable
ischemic cardiac disease, dilated
cardiomyopathy, or unstable valvular heart
disease)*
Yes
No
patient with myasthenia gravis*
Yes
No
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NCT02442765
Eligibility Agitation in Patients With Dementia
of the Alzheimer's Type NCT02442778
Efficacy, Safety, and Tolerability of AVP-786 (Deuterated
[d6]-Dextromethorphan Hydrobromide [d6-DM]/Quinidine
Sulfate [Q]) for the Treatment of Agitation in Patients With
Dementia of the Alzheimer's Type; ODM derived from:
https://clinicaltrials.gov/show/NCT02442778
All rights reserved. Please visit https://medical-data-
models.org/forms/14847
Eligibility Agitation in Patients With
Dementia of the Alzheimer's Type
NCT02442778
Inclusion Criteria
diagnosis of probable alzheimer's disease (ad)*
Yes
No
the patient has clinically significant,
moderate/severe agitation at the time of
screening and for at least 2 weeks prior to
randomization*
Yes
No
the diagnosis of agitation must meet the ipa
provisional definition of agitation*
Yes
No
either out patients or residents of an assisted-
living facility or a skilled nursing home*
Yes
No
cgis score assessing agitation is >=4 (moderately
ill) at screening and baseline*
Yes
No
mmse score is between 6 and 26 (inclusive) at
screening and baseline*
Yes
No
caregiver who is able and willing to comply with
all required study procedures.  in order to qualify
as a reliable informant (i.e., caregiver) capable of
assessing changes in patient's condition during
the study, the individual must spend a minimum
of 2 hours per day for 4 days per week with the
patient*
Yes
No
Exclusion Criteria
patient has dementia predominantly of non-
alzheimer's type (e.g., vascular dementia,
frontotemporal dementia, parkinson's disease,
substance-induced dementia)*
Yes
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No
patients with co-existent clinically significant or
unstable systemic diseases that could confound
the interpretation of the safety results of the study
(e.g., malignancy, poorly controlled diabetes,
poorly controlled hypertension, unstable
pulmonary, renal or hepatic disease, unstable
ischemic cardiac disease, dilated
cardiomyopathy, or unstable valvular heart
disease)*
Yes
No
patient with myasthenia gravis*
Yes
No
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NCT02442778
Eligibility Advanced Adult Hepatocellular
Carcinoma NCT01839604
A Phase I/Ib Study of AZD9150 (ISIS-STAT3Rx) in Patients
With Advanced/Metastatic Hepatocellular Carcinoma; ODM
derived from: https://clinicaltrials.gov/show/NCT01839604
All rights reserved. Please visit https://medical-data-
models.org/forms/14848
Eligibility Advanced Adult
Hepatocellular Carcinoma
NCT01839604
Inclusion Criteria
aged at least 18 years. patient from japan and
taiwan aged at least 20 years*
Yes
No
histologically or cytologically confirmed hcc (with
the exception of fibrolamellar carcinoma or mixed
variants of hcc with fibrolamellar histology or
clinically diagnosed hcc for patients with difficulty
in obtaining histological diagnosis)*
Yes
No
relapsed, refractory, intolerant or unlikely to
benefit from sorafenib (for example due to
comorbidity)*
Yes
No
hcc not suitable to receive local therapy*
Yes
No
disease recurred or was refractory to last therapy
(local or systemic)*
Yes
No
eastern cooperative oncology group (ecog)
performance status 0-1 with no deterioration over
the previous 2 weeks and minimum life
expectancy of 8 weeks*
Yes
No
Exclusion Criteria
more than 2 prior systemic treatments for hcc*
Yes
No
prior grade 3 hematologic toxicity related to
treatment with a jak or stat3 inhibitor*
Yes
No
presence of hepatic encephalopathy within 4
weeks of 1st dose*
Yes
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No
uncontrolled massive ascites*
Yes
No
high likelihood of bleeding*
Yes
No
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Examination Form Transplantation Nephrology
Waiting List Office University Clinic Muenster
Item used as routine documentation by University Clinic
Muenster, Waiting list office, Transplantation Nephrology,
Albert-Schweitzer-Campus 1, 48149 Muenster, Germany.
ODM derived from original form “Befundbogen”.
All rights reserved. Please visit https://medical-data-
models.org/forms/14850
Examination Form Transplantation
Nephrology
Personal Information
ET Number
Registration date
Patient surname
Patient first name
Date of birth
Place of birth
Gender
Nationality
Place of residence
Patient telephone number
Family or relative telephone number
Patient mobile number
Patient E- mail
Patient health insurance
Health insurance ID
Address of health insurance
Dialysis center
Address of dialysis center
Telephone number
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Fax number
Attending dialysis doctor or GP
Telephone number attending physician
E-mail attending physician
Immunological data
Blood group
Rhesus factor
HLA typing
HLA class I and II
HLA antibodies
% PRA
ELISA / Luminex
Transplantation Immunological Features
Consultation
Individual interview
Family medical history
Medical history of father
Medical history of mother
Medical history of siblings
Anamnesis
Social history (Occupation, marital status,
children)
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Previous medical condition
Cardiovascular risk factors (e.g. Hypertension,
diabetes mellitus, smoking with pack years etc.)
Operations
Childhood diseases
Vaccinations
Tuberculosis
Hepatitis/ HIV
Pregnancy
Renal history
Kidney diseases
Histology
Urinary tract infection
NSAR
Hypertension
Hypertensive Retinopathy
Blood pressure control
Date dialysis began
Residual diuresis
Dialysis type
Hemodialysis days
Dialysis access
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University Clinic Muenster
Osteopathy
Polyneuropathy
Allergy
Medication date
Obligatory medical examinations
Body height
cm
Body weight
kg
BMI
Urology consultation (in men over 40 years old
checkup with determination of t-PSA, in women
with
Reflux disease, recurrent urinary tract infections)
Urine volume/ 24 h
ml
Bladder capacity
Gynecological medical examination
(Gynecological preventive medical checkup)
Mammography (from 40 years old; from 35 years
old with a positive family history)
Date of ultrasonography of abdomen
Size of kidney
cm
Ultrasonography of liver
Ultrasonography of Bile tracts/ Gallbladder
Ultrasonography of Spleen
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Ultrasonography of Pancreas
Ultrasonography of blood vessels
Ultrasonography of thyroid and parathyroid
Chest X-ray
ECG (copy requested)
Echocardiography
Myocardial scintigraphy (with adenosine) / stress
echocardiography (with pharmacologic stress)
Doppler sonography neck, pelvis and leg vessels:
Optional Medical Examination
Coronary Angiography [only when indicated (e.g.
pathological stress test, diabetes of> 60 years)]
Pelvic and leg angiography, only when indicated
(for example, of severe PAD)
Pulmonary function test: only when indicated
(e.g. nicotine abuse, COPD, restrictive lung
disease)
Gastroscopy: only when indicated (for example,
recurrent gastritis, symptomatic)
Colonoscopy: By patients > 50
24-hour blood pressure monitoring: only when
indicated (difficult adjustable as hypertension)
ENT consultation/ paranasal sinus x-ray/
Ultrasonography of paranasal sinus: only when
indicated (e.g. chronic sinusitis)
Dermatology consultation only when indicated
(for example, multiple nevi, state after Basaliom,
actinic keratoses,
Mycoses, state after kidney transplantation)
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Dental consultation: only when indicated
Laboratory
Date of laboratory test
CRP
mg/dl
Hb
g/dl
Hematocrit
%
Erythrocytes
Mio.
Leukocytes
/ul
Platelets
/ul
Glucose
mg/dl
HBA1c
%
Urea
mg/dl
Creatinine
mg/dl
Uric acid
mg/dl
Prothrombin Time
%
PTT
sec.
INR
Sodium
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mmol/l
Potassium
mmol/l
Calcium
mmol/l
Phosphate
mg/dl
Iron
Transferrin saturation
%
Alkaline Phosphatase
U/l
Amylase
U/l
GOT
U/l
GPT
U/l
Gamma GT
U/l
PCHE
U/l
LDH
U/l
Bilirubin
mg/dl
Cholesterin
mg/dl
HDL
U/l
LDL
U/l
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Triglyceride
mg/dl
CK
U/l
CK-MB
U/l
iPTH
pmol/l
Tumor markers (> 40 years old)
PSA
TSH
T3
T4
Virus serology
CMV
EBV
HSV
VZV
Haemoccult (3x)
Laboratory urine
Reaction: pH
Urine culture
Pathogen
Sensitive to
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Urine protein
Urine glucose
Urine red blood cells
Urine leukocytes
Urine nitrite
Optional Laboratory tests
Glutamate Decarboxylase (by Type 1 diabetes
mellitus)
ICA (by Type 1 diabetes mellitus)
IA-2 antibody (by Type 1 diabetes mellitus)
Basal insulin (by Type 1 diabetes mellitus)
C-Peptide (by Type 1 diabetes mellitus)
APC resistance (by coagulopathy)
Protein C Activity (by coagulopathy)
%
Protein C concentration (by coagulopathy)
%
Protein S Total (by coagulopathy)
%
Free protein S (by coagulopathy)
%
Protein S activity (by coagulopathy)
%
ANA (by autoimmune disease)
c-ANCA (by autoimmune disease)
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p-ANCA (by autoimmune disease)
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Eligibility Alzheimer Disease NCT00908492
Supporting Caregivers of Persons With Dementia: A Pilot
Study; ODM derived from:
https://clinicaltrials.gov/show/NCT00908492
All rights reserved. Please visit https://medical-data-
models.org/forms/14852
Eligibility Alzheimer Disease
NCT00908492
Inclusion Criteria
the caregiver must be the primary caregiver*
Yes
No
caregiver reports that the care recipient has at
least one limitation in basic activities of daily
living (adl) or two dependencies in instrumental
activities of daily living (iadls)*
Yes
No
the caregiver must:*
Yes
No
provide at least 2 hours of care per day*
Yes
No
be caregiving for at least 6 months and*
Yes
No
be at least 21 years of age*
Yes
No
the care recipients need to have a diagnosis of
dementia*
Yes
No
Exclusion Criteria
caregiver:*
Yes
No
does not live with the care recipient*
Yes
No
has poor health (undergoing treatments for
cancer, hospitalized more than three times in
past year)*
Yes
No
planning to place care recipient in long term care
within the next year*
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Yes
No
care recipients who are confined to bed most of
the day or are minimally-responsive to touch or
the environment are excluded*
Yes
No
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Eligibility Alzheimer Disease NCT00912886
Pregnenolone Sulfate an Early Marker of the Memory Loss
in Alzheimer's Disease; ODM derived from:
https://clinicaltrials.gov/show/NCT00912886
All rights reserved. Please visit https://medical-data-
models.org/forms/14853
Eligibility Alzheimer Disease
NCT00912886
Inclusion Criteria
subjects aged over 70 years who have signed
informed consent for participation to the study
and are affiliated to a social security regimen.*
Yes
No
for patients: subjects with probable ad according
to the dsm-iv criteria and the nincds/adrda criteria
and with mild to moderate probable ad: mmse
score> 15.*
Yes
No
for controls: subjects without cognitive deficits on
neuropsychological tests: scores of mmse > 26
and of the 5 word test equal to 10/10 and of the
clock drawing test equal to 7/7.*
Yes
No
Exclusion Criteria
guardianship*
Yes
No
history of cerebrovascular disease, parkinson's
disease, other known dementia, epilepsy*
Yes
No
major depression*
Yes
No
serious sensory disorders; deficits in language &
comprehension*
Yes
No
serious heart or hepatic insufficiencies, renal or
respiratory failures*
Yes
No
unstable diabetes or endocrine disorders, thyroid
dysfunction, cancer, inflammatory syndrome,
malnutrition*
Yes
No
cognitive training during the 6 previous months*
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Yes
No
medications: steroids (hrt, androgens, corticoids),
anti-depressants, cholinesterase inhibitors,
thyroid hormones, synthetic anti-thyroids*
Yes
No
contraindications for mri: metallic implants &
claustrophobia*
Yes
No
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Eligibility Alzheimer Disease NCT00979316
Effect on the Electrocardiographic QT Interval Corrected for
Heart Rate (QTc) in Healthy Subjects; ODM derived from:
https://clinicaltrials.gov/show/NCT00979316
All rights reserved. Please visit https://medical-data-
models.org/forms/14855
Eligibility Alzheimer Disease
NCT00979316
Inclusion Criteria
body mass index (bmi) of 18 to 32 kg/m²,
inclusive.*
Yes
No
women who are not of childbearing potential (ie,
who are postmenopausal or surgically sterile)
and men, ages 18 to 55*
Yes
No
healthy subjects*
Yes
No
Exclusion Criteria
history of cardiac arrhythmias or palpitations
associated with presyncope or syncope, or
history of unexplained syncope*
Yes
No
sexually active fertile men not using effective birth
control (double barrier) if their partners are
wocbp*
Yes
No
women who are pregnant or breastfeeding*
Yes
No
history of allergy or intolerance to moxifloxacin or
any member of the quinolone class of
antimicrobial agents*
Yes
No
history of hypokalemia, history or family history of
prolonged qt interval, or family history of sudden
cardiac death at a young age*
Yes
No
any clinically significant ecg abnormality*
Yes
No
history of seizure disorders*
Yes
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No
history of drowning survival*
Yes
No
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Eligibility Breast Cancer NCT02476786
Endocrine Treatment Alone for Elderly Patients With
Estrogen Receptor Positive Operable Breast Cancer and
Low Recurrence Score; ODM derived from:
https://clinicaltrials.gov/show/NCT02476786
All rights reserved. Please visit https://medical-data-
models.org/forms/14858
Eligibility Breast Cancer
NCT02476786
Inclusion Criteria
newly diagnosed histologically or cytologically
confirmed operable invasive breast cancer
defined as ct1 or t2, n0-1, and m0.*
Yes
No
disease must be er+ (allred score ≥ 5) and her2-
.*
Yes
No
measurable disease defined as lesions that can
be accurately measured in at least one
dimension (longest diameter to be recorded) by
ultrasound or mammogram.*
Yes
No
75 years of age or older.*
Yes
No
ecog performance status ≤ 2*
Yes
No
able to understand and willing to sign an irb
approved written informed consent document (or
that of legally authorized representative, if
applicable).*
Yes
No
Exclusion Criteria
prior chemotherapy and/or hormone therapy for
cancer.*
Yes
No
a history of other malignancy ≤ 5 years previous
which would preclude endocrine treatment of
their cancer.*
Yes
No
currently receiving any other investigational
agents.*
Yes
No
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a history of allergic reactions attributed to
compounds of similar chemical or biologic
composition to any of the agents used in the
study.*
Yes
No
uncontrolled intercurrent illness as determined by
their treating physician which would limit
compliance with study requirements.*
Yes
No
known hiv-positivity on combination antiretroviral
therapy because of the potential for
pharmacokinetic interactions with endocrine
therapies.  appropriate studies will be undertaken
in patients receiving combination antiretroviral
therapy when indicated.*
Yes
No
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Eligibility Breast Carcinoma NCT02352779
Omega-3 Fatty Acid in Reducing Cancer-Related Fatigue in
Breast Cancer Survivors; ODM derived from:
https://clinicaltrials.gov/show/NCT02352779
All rights reserved. Please visit https://medical-data-
models.org/forms/14860
Eligibility Breast Carcinoma
NCT02352779
Inclusion Criteria
have a confirmed diagnosis of breast cancer;
participants can have had more than one primary
cancer diagnosis in the past*
Yes
No
have undergone some type or combination of
standard adjuvant treatment (surgery,
chemotherapy, radiation therapy) for breast
cancer*
Yes
No
have completed all forms of standard adjuvant
treatment (surgery, chemotherapy, radiation
therapy) for breast cancer between 4 and 36
months prior to enrollment in the study;
participants can be currently taking hormones
(such as tamoxifen) or monoclonal antibodies
(such as herceptin)*
Yes
No
must have cancer-related fatigue, as indicated by
a response of 4 or greater when asked to rate
their level of fatigue at its worst in the past week
on an 11-point scale anchored by "0" = no fatigue
and "10" = as bad as you can imagine*
Yes
No
be able to read english*
Yes
No
able to swallow medication*
Yes
No
give written informed consent*
Yes
No
Exclusion Criteria
have used marine omega-3 supplements at any
time within previous 3 months (this includes
prescription omega-3 drugs such as lovaza®)*
Yes
No
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be taking anticoagulant medication (does not
include aspirin)*
Yes
No
have sensitivity or allergy to fish and/or shellfish*
Yes
No
have sensitivity or allergy to soy and/or
soybeans*
Yes
No
have confirmed diagnosis of chronic fatigue
syndrome or other diagnosis known to cause
severe fatigue*
Yes
No
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Eligibility Breast Neoplasm NCT02370082
SAVI SCOUT Clinical Evaluation Study; ODM derived from:
https://clinicaltrials.gov/show/NCT02370082
All rights reserved. Please visit https://medical-data-
models.org/forms/14861
Eligibility Breast Neoplasm
NCT02370082
Inclusion Criteria
• patient has a non-palpable breast lesion that
requires excision*
Yes
No
lesion depth ≤ 3 cm from the skin surface in the
supine position*
Yes
No
patient is scheduled for excision or bct at a
participating institution*
Yes
No
patient is between the ages of 18 and 90 years*
Yes
No
patient is female*
Yes
No
patient is willing and able to comply with all study
procedures and be available to follow-up for the
duration of the study*
Yes
No
for lesions requiring multiple reflectors for
localization, they must allow for reflectors to be
placed ≥ 1cm from one another relative to the
coronal plane subject exclusion criteria*
Yes
No
an individual who meets any of the following
criteria will be excluded from participation in this
study:*
Yes
No
patient had a previous ipsilateral breast cancer*
Yes
No
patient has multicentric breast cancer*
Yes
No
patient has stage iv breast cancer*
Yes
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No
patient has been treated with neoadjuvant
chemotherapy*
Yes
No
patient is pregnant or lactating*
Yes
No
Exclusion Criteria
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Eligibility Breast Neoplasm NCT00194753
Adjuvant Therapy for High-Risk Breast Cancer With Wkly
Adriamycin & Oral Cytoxan With G-CSF for 12 Wks; Wkly
Taxol x 12; ODM derived from:
https://clinicaltrials.gov/show/NCT00194753
All rights reserved. Please visit https://medical-data-
models.org/forms/14862
Eligibility Breast Neoplasm
NCT00194753
Inclusion Criteria
patient must have a histologically confirmed
diagnosis of primary breast carcinoma that has
been surgically resected.  (this regimen is not
intended for neoadjuvant treatment.)*
Yes
No
the attending physician must judge the patient to
be an appropriate candidate for adriamycin based
adjuvant chemotherapy.  appropriate candidates
generally include those with stage ii or iii breast
cancer.  the individual attending physician,
however, should make the decision.*
Yes
No
tumor her-2/neu expression must be determined
prior to study enrollment.  assessment may be by
fluorescence in situ hybridization (fish) assay or
by immunocytochemistry (icc).  if determination is
"intermediate" by immunocytochemistry, fish must
be performed.  protocol therapy is determined by
her-2/neu result.*
Yes
No
patient must be at least 18.*
Yes
No
the patient must be informed of the
investigational nature of this study and must sign
and give written informed consent in accordance
with institutional and federal guidelines.*
Yes
No
pre-study hematologic values required for entry
onto trial are:  wbc greater than= 4,000/mm3, anc
greater than= 1,500/mm3 and platelets greater
than= 100,000/mm3.*
Yes
No
Exclusion Criteria
patients with significant renal dysfunction
(creatinine greater than 1.5 x institutional upper
limit of normal (iuln)) or hepatic dysfunction
(C1278039 greater than iuln; transaminases
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greater than 2.5 x iuln) are not eligible.*
Yes
No
except for the following, no prior malignancy is
allowed:  adequately treated basal cell or
squamous cell skin cancer, in situ cervical
cancer, adequately treated stage i or ii cancer
from which the patient has been disease free for
5 years.*
Yes
No
patients with clinically apparent cardiac disease,
or history of same, are not eligible.   patients who
are > 60 years of age or who have a history of
hypertension must have a muga prior to
enrollment.  lvef must be normal.*
Yes
No
patients who have received prior chemotherapy
or radiotherapy are not eligible.*
Yes
No
patients who are pregnant or breastfeeding are
not eligible.  women of child bearing potential
must have a serum pregnancy test that is
negative and agree to practice adequate
contraception.*
Yes
No
patients with active infection are not eligible.*
Yes
No
patients who are known to be infected with hiv, or
hepatitis c are not eligible.  testing is not required
unless there is a high index of clinical suspicion.*
Yes
No
patients suffering from psychiatric impairment are
not eligible.*
Yes
No
patients with known hypersensitivity to
trimethoprim or sulfonamides are not eligible.*
Yes
No
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NINDS CDE Laboratory tests Friedreich´s
Ataxia
NINDS Common Data Elements (Laboratory
tests;Friedreich´s Ataxia) Used from the National Institute
of Neurological Disorders and Stroke Common Data
Elements
(https://www.commondataelements.ninds.nih.gov/)
References: Grinnon ST, Miller K, Marler JR, Lu Y, Stout A,
Odenkirchen J, Kunitz S. National Institute of Neurological
Disorders and Stroke Common Data Element Project -
approach and methods. Clin Trials. 2012;9(3):322-9.
All rights reserved. Please visit https://medical-data-
models.org/forms/14863
Laboratory tests
Laboratory Tests Information
Study ID
Study site name
Subject ID
Was the participant fasting prior to sample
collection?
Yes
No
Where were the Lab Tests done?
Site Lab (1)
Central Lab (2)
Which lab panel was done, please select one
CHEMISTRY (1)
HEMATOLOGY (2)
URINALYSIS (3)
Other, specify (4)
If you selected "other", please specify what
laboratory tests have been done
Date and time of specimen collection
Please specify the time for specimen collection
AM (1)
PM (2)
24hr clock (3)
Accession Number
Complete Blood Count Laboratory Tests
White blood cell count result
White blood cell count:Please specify units used
for measurement
White blood cell count performed?
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Yes
No
White blood cell count:please specify why
procedure was not performed
White blood cell count
Abnormal (1)
Normal (2)
Unknown (3)
White blood cell count
Clinically significant (1)
Not clinically significant (2)
Lymphocytes result
Lymphocytes:please specify unit used for
measurement
Lymphocytes:Measurement performed
Yes
No
Lymphocytes:please specify why procedure was
not performed
Lymphocytes
Abnormal (1)
Normal (2)
Unknown (3)
Lymphocytes
Clinically significant (1)
Not clinically significant (2)
Neutrophil count result
Neutrophil count: Please specify unit used for
measurement
Neutrophil count:measurement performed
Yes
No
Neutrophil count:please specify why procedure
was not performed
Neutrophil count
Abnormal (1)
Normal (2)
Unknown (3)
Neutrophil count
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Clinically significant (1)
Not clinically significant (2)
Monocytes count result
Monocytes count:Please specify unit used for
measurement
Monocytes count: Measurement performed
Yes
No
Monocytes count:please specify why procedure
was not performed
Monocytes Count
Abnormal (1)
Normal (2)
Unknown (3)
Monocytes count
Clinically significant (1)
Not clinically significant (2)
Eosinophil count result
Eosinophil count:please specify unit used for
measurement
Eosinophil count:measurement performed
Yes
No
Eosinophil count:please specify why procedure
was not performed
Eosinophil count
Abnormal  (1)
Normal  (2)
Unknown (3)
Eosinophil count
Clinically significant (1)
Not clinically significant (2)
Hematocrit result
Hematocrit:please specify unit used for
measurement
Hematocrit:measurement performed
Yes
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No
Hematocrit:please specify why procedure was not
performed
Hematocrit
Abnormal (1)
Normal (2)
Unknown (3)
Hematocrit
Clinically significant (1)
Not clinically significant (2)
Hemoglobin result
Hemoglobin:please specify unit used for
measurement
Hemoglobin:measurement performed
Yes
No
Hemoglobin:please specify why procedure was
not performed
Hemoglobin
Abnormal (1)
Normal (2)
Unknown (3)
Hemoglobin
Clinically significant (1)
Not clinically significant (2)
Glycosylated Hemoglobin (HgbA1C) result
Glycosylated Hemoglobin (HgbA1C):please
specify unit used for measurement
Glycosylated Hemoglobin
(HgbA1C):measurement performed
Yes
No
Glycosylated Hemoglobin (HgbA1C):please
specify why procedure was not performed
Glycosylated Hemoglobin (HgbA1C)
Abnormal (1)
Normal (2)
Unknown (3)
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Glycosylated Hemoglobin (HgbA1C)
Clinically significant (1)
Not clinically significant (2)
Platelet count result
Platelet count:please specify unit used for
measurement
Platelet count:measurement performed
Yes
No
Platelet count:please specify why procedure was
not performed
Platelet count
Abnormal (1)
Normal (2)
Unknown (3)
Platelet count
Clinically significant (1)
Not clinically significant (2)
Serum Vitamin B12 Test performed
Yes
No
Vitamin B12 result
Vitamin B12: please specify unit used for
measurement
Vitamin B12
Abnormal (1)
Normal (2)
Unknown (3)
Vitamin B12
Clinically significant (1)
Not clinically significant (2)
Electrolyte Laboratory Tests
Sodium result
Sodium:please specify unit used for
measurement
Sodium:measurement not performed
Yes
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No
Sodium:please specify why procedure was not
performed
Sodium
Abnormal (1)
Normal (2)
Unknown (3)
Sodium
Clinically significant (1)
Not clinically significant (2)
Potassium result
Potassium:please specify unit used for
measurement
Potassium:measurement not performed
Yes
No
Potassium:please specify why procedure was not
performed
Potassium
Abnormal (1)
Normal (2)
Unknown (3)
Potassium
Clinically significant (1)
Not clinically significant (2)
Chloride result
Chloride:please specify unit used for
measurement
Chloride:measurement not performed
Yes
No
Chloride:please specify why procedure was not
performed
Chloride
Abnormal (1)
Normal (2)
Unknown (3)
Chloride
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Clinically significant (1)
Not clinically significant (2)
CO2 result
CO2:please specify unit used for measurement
CO2:measurement not performed
Yes
No
CO2:please specify why procedure was not
performed
CO2
Abnormal (1)
Normal (2)
Unknown (3)
CO2
Clinically significant (1)
Not clinically significant (2)
Anion Gap result
Anion Gap:Please specify units used for
measurement
Anion Gap measurement performed?
Yes
No
Anion Gap:please specify why measurement was
not performed
Anion Gap
Abnormal (1)
Normal (2)
Unknown (3)
Anion Gap
Clinically significant (1)
Not clinically significant (2)
Blood urea nitrogen (BUN) result
Blood urea nitrogen (BUN):please specify unit
used for measurement
Blood urea nitrogen (BUN):measurement not
performed
Yes
7 / 26
NINDS CDE Laboratory tests Friedreich´s Ataxia
No
Blood urea nitrogen (BUN):please specify why
procedure was not performed
Blood urea nitrogen (BUN):
Abnormal (1)
Normal (2)
Unknown (3)
Blood urea nitrogen (BUN):
Clinically significant (1)
Not clinically significant (2)
Creatinine result
Creatinine:please specify unit used for
measurement
Creatinine:measurement not performed
Yes
No
Creatinine:please specify why procedure was not
performed
Creatinine
Abnormal (1)
Normal (2)
Unknown (3)
Creatinine
Clinically significant (1)
Not clinically significant (2)
Glucose result
Glucose:please specify unit used for
measurement
Glucose:measurement not performed
Yes
No
Glucose:please specify why procedure was not
performed
Glucose
Abnormal (1)
Normal (2)
Unknown (3)
Glucose
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Clinically significant (1)
Not clinically significant (2)
Fasting Glucose result
Fasting Glucose:please specify units used for
measurement
Fasting Glucose measurement performed?
Yes
No
Fasting Glucose:please specify why
measurement was not performed
Fasting Glucose
Abnormal (1)
Normal (2)
Unknown (3)
Fasting Glucose
Clinically significant (1)
Not clinically significant (2)
Fasting Insulin result
Fasting Insulin:please specify units used for
measurement
Fasting Insulin measurement performed?
Yes
No
Fasting Insulin:please specify why measurement
was not performed
Fasting Insulin
Abnormal (1)
Normal (2)
Unknown (3)
Fasting Insulin
Clinically significant (1)
Not clinically significant (2)
Iron result
Iron:please specify units used for measurement
Iron measurement performed?
Yes
No
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Iron:please specify why measurement was not
performed
Iron
Abnormal (1)
Normal (2)
Unknown (3)
Iron
Clinically significant (1)
Not clinically significant (2)
Total Iron Binding Capacity result
Total Iron Binding Capacity:please specify units
used for measurement
Total Iron Binding Capacity measurement
performed?
Yes
No
Total Iron Binding Capacity:please specify why
measurement was not performed
Total Iron Binding Capacity
Abnormal (1)
Normal (2)
Unknown (3)
Total Iron Binding Capacity
Clinically significant (1)
Not clinically significant (2)
Ferritin result
Ferritin:please specify units used for
measurement
Ferritin measurement performed?
Yes
No
Ferritin:please specify why measurement was not
performed
Ferritin
Abnormal (1)
Normal (2)
Unknown (3)
Ferritin
Clinically significant (1)
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Not clinically significant (2)
Magnesium result
Magnesium:please specify units used for
measurement
Magnesium measurement performed?
Yes
No
Magnesium:please specify why measurement
was not performed
Magnesium
Abnormal (1)
Normal (2)
Unknown (3)
Magnesium
Clinically significant (1)
Not clinically significant (2)
Phosphate result
Phosphate:please specify unit used for
measurement
Phosphate:measurement not performed
Yes
No
Phosphate:please specify why procedure was not
performed
Phosphate
Abnormal (1)
Normal (2)
Unknown (3)
Phosphate
Clinically significant (1)
Not clinically significant (2)
Calcium result
Calcium:please specify unit used for
measurement
Calcium:measurement not performed
Yes
No
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Calcium:please specify why procedure was not
performed
Calcium
Abnormal (1)
Normal (2)
Unknown (3)
Calcium
Clinically significant (1)
Not clinically significant (2)
Bicarbonate result
Bicarbonate: please specify unit used for
measurement
Bicarbonate:measurement not performed
Yes
No
Bicarbonate:please specify why procedure was
not performed
Bicarbonate
Abnormal (1)
Normal (2)
Unknown (3)
Bicarbonate
Clinically significant (1)
Not clinically significant (2)
Lipid Laboratory Tests
Total cholesterol result
Total Cholesterol:please specify unit used for
measurment
Total Cholesterol:measurement not performed
Yes
No
Total Cholesterol:please specify why procedure
was not performed
Total Cholesterol
Abnormal (1)
Normal (2)
Unknown (3)
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Total Cholesterol
Clinically significant (1)
Not clinically significant (2)
LDL result
LDL:please specify unit used for measurement
LDL:measurement not performed
Yes
No
LDL:please specify why procedure was not
performed
LDL
Abnormal (1)
Normal (2)
Unknown (3)
LDL
Clinically significant (1)
Not clinically significant (2)
HDL result
HDL:please specify unit used for measurement
HDL:measurement not performed
Yes
No
HDL:please specify why procedure was not
performed
HDL
Abnormal (1)
Normal (2)
Unknown (3)
HDL
Clinically significant (1)
Not clinically significant (2)
Triglycerides result
Triglycerides: please specify unit used for
measurement
Triglycerides:measurement not performed
Yes
No
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Triglycerides:please specify why procedure was
not performed
Triglycerides
Abnormal (1)
Normal (2)
Unknown (3)
Triglycerides
Clinically significant (1)
Not clinically significant (2)
Very Low Density Lipoprotein result
Very low density lipoprotein:please specify units
used for measurement
Very low density lipoprotein measurement
performed?
Yes
No
Very low density lipoprotein:please specify why
measurement was not performed
Very low density lipoprotein
Abnormal (1)
Normal (2)
Unknown (3)
Very low density lipoprotein
Clinically significant (1)
Not clinically significant (2)
Lipoprotein (a) result
Lipoprotein (a):please specify units used for
measurement
Lipoprotein (a) measurement performed?
Yes
No
Lipoprotein (a):please specify why measurement
was not performed
Lipoprotein (a)
Abnormal (1)
Normal (2)
Unknown (3)
Lipoprotein (a)
Clinically significant (1)
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Not clinically significant (2)
Apolipoprotein-I result
Apolipoprotein-I: please specify units used for
measurement
Apolipoprotein-I measurement performed?
Yes
No
Apolipoprotein-I: please specify why
measurement was not performed
Apolipoprotein-I
Abnormal (1)
Normal (2)
Unknown (3)
Apolipoprotein-I
Clinically significant (1)
Not clinically significant (2)
Apolipoprotein B result
Apolipoprotein B:please specify units used for
measurement
Apolipoprotein B measurement performed?
Yes
No
Apolipoprotein B:please specify why
measurement was not performed
Apolipoprotein B
Abnormal (1)
Normal (2)
Unknown (3)
Apolipoprotein B
Clinically significant (1)
Not clinically significant (2)
Apolipoprotein E result
Apolipoprotein E:please specify units used for
measurement
Apolipoprotein E measurement performed?
Yes
No
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Apolipoprotein E:please specify why
measurement was not performed
Apolipoprotein E
Abnormal (1)
Normal (2)
Unknown (3)
Apolipoprotein E
Clinically significant (1)
Not clinically significant (2)
Chemistry Laboratory Tests
C-Reactive Protein (CRP) result
C-Reactive Protein (CRP):please specify unit
used for measurement
C-Reactive Protein (CRP):measurement not
performed
Yes
No
C-Reactive Protein (CRP):please specify why
procedure was not performed
C-Reactive Protein (CRP)
Abnormal (1)
Normal (2)
Unknown (3)
C-Reactive Protein (CRP)
Clinically significant (1)
Not clinically significant (2)
Frataxin level result
Frataxin level:please specify units used for
measurement
Frataxin level measurement performed?
Yes
No
Frataxin:please specify why measurement was
not performed
Frataxin level
Abnormal (1)
Normal (2)
Unknown (3)
Frataxin level
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Clinically significant (1)
Not clinically significant (2)
GAA repeat-expansion mutation result
GAA repeat-expansion mutation:please specify
units used for measurement
GAA repeat-expansion mutation measurement
performed?
Yes
No
GAA repeat-expansion mutation:please specify
why measurement was not performed
GAA repeat-expansion mutation
Abnormal (1)
Normal (2)
Unknown (3)
GAA repeat-expansion mutation
Clinically significant (1)
Not clinically significant (2)
Serum N-terminal atrial natriuretic peptide result
Serum N-terminal atrial natriuretic peptide:please
specify units used for measurement
Serum N-terminal atrial natriuretic peptide
measurement performed?
Yes
No
Serum N-terminal atrial natriuretic peptide:please
specify why measurement was not performed
Serum N-terminal atrial natriuretic peptide
Abnormal (1)
Normal (2)
Unknown (3)
Serum N-terminal atrial natriuretic peptide
Clinically significant (1)
Not clinically significant (2)
Atrial natriuretic peptide (ANP) result
Atrial natriuretic peptide (ANP):please specify
units used for measurement
Atrial natriuretic peptide (ANP) measurement
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performed?
Yes
No
Atrial natriuretic peptide (ANP):please specify
why measurement was not performed
Atrial natriuretic peptide (ANP)
Abnormal (1)
Normal (2)
Unknown (3)
Atrial natriuretic peptide (ANP)
Clinically significant (1)
Not clinically significant (2)
B-type natriuretic peptide (BNP) result
B-type natriuretic peptide (BNP):please specify
units used for measurement
B-type natriuretic peptide (BNP) measurement
performed?
Yes
No
B-type natriuretic peptide (BNP):please specify
why measurement was not performed
B-type natriuretic peptide (BNP)
Abnormal (1)
Normal (2)
Unknown (3)
B-type natriuretic peptide (BNP)
Clinically significant (1)
Not clinically significant (2)
Oral glucose tolerance result
Oral glucose tolerance:please specify units used
for measurement
Oral glucose tolerance measurement performed?
Yes
No
Oral glucose tolerance:please sepcify why
measurement was not performed
Oral glucose tolerance
Abnormal (1)
Normal (2)
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Unknown (3)
Oral glucose tolerance
Clinically significant (1)
Not clinically significant (2)
Vitamin E result
Vitamin E:please specify units used for
measurement
Vitamin E measurement performed
Yes
No
Vitamin E:please specify why measurement was
not performed
Vitamin E
Abnormal (1)
Normal (2)
Unknown (3)
Vitamin E
Clinically significant (1)
Not clinically significant (2)
Lactate result
Lactate:please specify units used for
measurement
Lactate measurement performed?
Yes
No
Lactate:please specify why measurement was
not performed
Lactate
Abnormal (1)
Normal (2)
Unknown (3)
Lactate
Clinically significant (1)
Not clinically significant (2)
Troponin I result
Troponin I:please specify units used for
measurement
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Troponin I measurement performed?
Yes
No
Troponin I:please specify why measurement was
not performed
Troponin I
Abnormal (1)
Normal (2)
Unknown (3)
Troponin I
Clinically significant (1)
Not clinically significant (2)
Troponin T result
Troponin T:please specify units used for
measurement
Troponin T measurement performed?
Yes
No
Troponin T:please specify why measurement was
not performed
Troponin T
Abnormal (1)
Normal (2)
Unknown (3)
Troponin T
Clinically significant (1)
Not clinically significant (2)
Creatine Kinase result
Creatine Kinase:please specify unit used for
measurement
Creatine Kinase:measurement not performed
Yes
No
Creatine Kinase:please specify why procedure
was not performed
Creatine Kinase
Abnormal (1)
Normal (2)
Unknown (3)
Creatine Kinase
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Clinically significant (1)
Not clinically significant (2)
Creatine Kinase - Myocardial Bands (CK-MB)
result
Creatine Kinase - Myocardial Bands (CK-
MB):please specify units used for measurement
Creatine Kinase - Myocardial Bands (CK-MB)
measurement performed?
Yes
No
Creatine Kinase - Myocardial Bands (CK-
MB):please specify why measurement was not
performed
Creatine Kinase - Myocardial Bands (CK-MB)
Abnormal (1)
Normal (2)
Unknown (3)
Creatine Kinase - Myocardial Bands (CK-MB)
Clinically significant (1)
Not clinically significant (2)
Hemoglobin Electrophoresis result
HbSS (1)
HbSA (2)
HbAA (3)
HbFF (4)
HbAF (5)
HbAT (6)
Hemoglobin Electrophoresis:please specify units
used for measurement
Hemoglobin Electrophoresis measurement
performed?
Yes
No
Hemoglobin Electrophoresis:please specify why
measurement was not performed
Hemoglobin Electrophoresis
Abnormal (1)
Normal (2)
Unknown (3)
Hemoglobin Electrophoresis
Clinically significant (1)
Not clinically significant (2)
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Liver Function Laboratory Tests
ALT result
ALT:please specify unit used for measurement
ALT:measurement not performed
Yes
No
ALT:please specify why procedure was not
performed
ALT
Abnormal (1)
Normal (2)
Unknown (3)
ALT
Clinically significant (1)
Not clinically significant (2)
AST result
AST:please specify unit used for measurement
AST:measurement not performed
Yes
No
AST:please specify why procedure was not
performed
AST
Abnormal (1)
Normal (2)
Unknown (3)
AST
Clinically significant (1)
Not clinically significant (2)
GGT result
GGT:please specify unit used for measurement
GGT:measurement not performed
Yes
No
GGT:please specify why procedure was not
performed
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GGT
Abnormal (1)
Normal (2)
Unknown (3)
GGT
Clinically significant (1)
Not clinically significant (2)
Urinalysis Tests
WBC Urine result
WBC Urine:please specify unit used for
measurement
WBC Urine:measurement performed?
Yes
No
WBC Urine:please specify why procedure was
not performed
WBC Urine
Abnormal (1)
Normal (2)
Unknown (3)
WBC Urine
Clinically significant (1)
Not clinically significant (2)
pH Urine result
pH Urine:please specify unit used for
measurement
pH Urine:measurement performed?
Yes
No
pH Urine:please specify why procedure was not
performed
pH Urine
Abnormal (1)
Normal (2)
Unknown (3)
pH Urine
Clinically significant (1)
Not clinically significant (2)
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Urine nitrite result
TBD
Urine Nitrite:measurement performed?
Yes
No
Urine Nitrite:please specify why procedure was
not performed
Urine Nitrite
Abnormal (1)
Normal (2)
Unknown (3)
Urine Nitrite
Clinically significant (1)
Not clinically significant (2)
Creatinine Urine result
Creatinine Urine:please specify unit used for
measurement
Creatinine Urine:measurement performed?
Yes
No
Creatinine Urine:please specify why procedure
was not performed
Creatinine Urine
Abnormal (1)
Normal (2)
Unknown (3)
Creatinine Urine
Clinically significant (1)
Not clinically significant (2)
Oxidative Stress Measures
Urine 8-OH-2-deoxyguanosine/ creatinine ratio
result
Urine 8-OH-2-deoxyguanosine/creatinine
ratio:please specify units used for measurement
Urine 8-OH-2-deoxyguanosine/ creatinine ratio
measurement performed?
Yes
No
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Urine 8-OH-2-deoxyguanosine/ creatinine
ratio:please specify why measurement was not
performed
Urine 8-OH-2-deoxyguanosine/ creatinine ratio
Abnormal (1)
Normal (2)
Unknown (3)
Urine 8-OH-2-deoxyguanosine/ creatinine ratio
Clinically significant (1)
Not clinically significant (2)
8-OH-2-deoxyguanosine result
8-OH-2-deoxyguanosine:please specify units
used for measurement
8-OH-2-deoxyguanosine measurement
performed?
Yes
No
8-OH-2-deoxyguanosine:please specify why
measurement was not performed
8-OH-2-deoxyguanosine
Abnormal (1)
Normal (2)
Unknown (3)
8-OH-2-deoxyguanosine
Clinically significant (1)
Not clinically significant (2)
8-isoprostanes result
8-isoprostanes:please specify units used for
measurement
8-isoprostanes measurement performed?
Yes
No
8-isoprostanes:please specify why measurement
was not performed
8-isoprostanes
Abnormal (1)
Normal (2)
Unknown (3)
8-isoprostanes
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Clinically significant (1)
Not clinically significant (2)
Plasma malondialdehyde result
Plasma malondialdehyde:please specify units
used for measurement
Plasma malondialdehyde measurement
performed?
Yes
No
Plasma malondialdehyde:please specify why
measurement was not performed
Plasma malondialdehyde
Abnormal (1)
Normal (2)
Unknown (3)
Plasma malondialdehyde
Clinically significant (1)
Not clinically significant (2)
Pregnancy Tests
Was a pregnancy test performed?
Yes (1)
No (2)
Not applicable (3)
Date of pregnancy test
Pregnancy test method
Blood (1)
Urine (2)
Pregnancy Test Result
positive (1)
negative (2)
Pregnancy Test not applicable,please specify
reason why
Post-Menopausal  (1)
Surgically sterile  (2)
Non-surgically sterile  (3)
Male (4)
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Eligibility Breast Neoplasms NCT01801878
Pilot Study of Skin Quality Improvement After Adipose-
drived Stem Cell Transfer in Irradiated Breasts; ODM
derived from: https://clinicaltrials.gov/show/NCT01801878
All rights reserved. Please visit https://medical-data-
models.org/forms/14871
Eligibility Breast Neoplasms
NCT01801878
Inclusion Criteria
female aged between 40 and 60*
Yes
No
subjects who diagnosed breast ductal carcinoma
in situ of surgical staging t1an0, negative
resection margin of below 2mm in histopathologic
examination*
Yes
No
subjects who have a relapse-free interval of
more than one year after breast-conserving
surgery for breast cancer and radiation therapy*
Yes
No
subjects who understand the study contents and
sign the informed consent*
Yes
No
Exclusion Criteria
subjects who have radiodermatitis*
Yes
No
subjects who planned breast reconstruction with
autogenous tissue (ex.transverse rectus
abdominis muscle flap)*
Yes
No
subjects who have a history of smoking within
3months recently*
Yes
No
subjects who participated in other clinical trial
within 30 days recently*
Yes
No
pregnant or lactating subjects*
Yes
No
subjects who have a active infectious disease*
Yes
No
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subjects who are not eligible for this study at the
discretion of the investigator*
Yes
No
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Eligibility Breast Neoplasms NCT02229084
Vaccination of High Risk Breast Cancer Patients; ODM
derived from: https://clinicaltrials.gov/show/NCT02229084
All rights reserved. Please visit https://medical-data-
models.org/forms/14872
Eligibility Breast Neoplasms
NCT02229084
Inclusion Criteria
females of all races with clinical stage i, ii, or iii
er-positive breast cancer who qualify for standard
neoadjuvant treatment*
Yes
No
age 18 years and older*
Yes
No
ecog performance status 0 or 1.*
Yes
No
white blood cell (wbc) count ≥ 3,000/mm3 within
2 weeks prior to registration.*
Yes
No
platelet count ≥ 100,000/mm3 within 2 weeks
prior to registration.*
Yes
No
serum glutamic-oxaloacetic transaminase (sgot)
≤ 2 x institutional upper limit (iul) of normal
obtained within 2 weeks prior to registration.*
Yes
No
aspartate aminotransferase test (ast) ≤ 2 x
institutional upper limit (iul) of normal obtained
within 2 weeks prior to registration.*
Yes
No
bilirubin ≤ 2 x institutional upper limit (iul) of
normal  obtained within 2 weeks prior to
registration.*
Yes
No
serum creatinine ≤ 1.8 mg/dl obtained within 2
weeks prior to registration.*
Yes
No
must sign an informed consent approved by the
uams institutional review board (irb).*
Yes
No
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Exclusion Criteria
active infection requiring treatment with
antibiotics.*
Yes
No
diagnosis or evidence of organic brain syndrome
that might preclude participation in the full
protocol.*
Yes
No
diagnosis or evidence of significant impairment of
basal cognitive function that might preclude
participation in the full protocol.*
Yes
No
no other current malignancies.  subjects with
prior history at any time of any in situ cancer,
including lobular carcinoma of the breast in situ,
cervical cancer in situ, atypical melanocytic
hyperplasia or clark i melanoma in situ or basal
or squamous skin cancer are eligible, provided
they are disease-free at the time of registration.
subjects with other malignancies are eligible if
they have been continuously disease free for ≥ 5
years prior to the time of registration.*
Yes
No
autoimmune disorders or conditions of
immunosuppression. this includes, but is not
limited to being treated with corticosteroids,
including oral steroids (i.e. prednisone,
dexamethasone [except when used as an
antiemetic in standard therapy]), continuous use
of topical steroid creams or ointments or any
steroid-containing inhalers. subjects who
discontinue the use of these classes of
medication for at least 6 weeks prior to
registration are eligible if, in the judgment of the
treating physician, the subject is not likely to
require these classes of drugs during the
treatment period. replacement doses of steroids
for subjects with adrenal insufficiency are
allowed.*
Yes
No
pregnancy or breast feeding (due to the unknown
effects of peptide/mimotope vaccines on a fetus
or infant).  women of childbearing potential must
have a negative urine pregnancy test within 72
hours prior to receiving the first dose of study
drug and must be counseled to use an accepted
and effective method of contraception (including
abstinence) while on treatment and for a period of
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18 months after completing or discontinuing
treatment.  accepted methods of contraception
include oral contraceptives, barrier methods, iuds,
and abstinence.*
Yes
No
any other significant medical or psychiatric
conditions which, in the opinion of the enrolling
investigator, may interfere with consent or
compliance of the treatment regimen.*
Yes
No
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Eligibility Breast Neoplasms NCT02239315
Study of Tumor RNA Disruption Assay™ (RDA); ODM
derived from: https://clinicaltrials.gov/show/NCT02239315
All rights reserved. Please visit https://medical-data-
models.org/forms/14873
Eligibility Breast Neoplasms
NCT02239315
Inclusion Criteria
female,18 years or older;*
Yes
No
able to read and write in english:*
Yes
No
with palpable cancer > 2cm (t2, t3) on clinical
examination or clinical diagnosis of locally
advanced breast cancer (labc) (t3 or t4; or n2 or
n3, according to tnm cancer staging including
inflammatory breast cancer);*
Yes
No
must have histological proof of breast cancer
(invasive ductal or infiltrating lobular);*
Yes
No
scheduled to receive neoadjuvant chemotherapy
as part of their treatment plan;*
Yes
No
agree to have fnab after the first, second and
third cycle of chemotherapy, and if the
chemotherapy regimen is changed, an additional
fnab after the first cycle of the new
chemotherapy.*
Yes
No
Exclusion Criteria
subjects who have had surgery, neoadjuvant
chemotherapy or radiotherapy for the current
breast cancer;*
Yes
No
subjects who are pregnant or breast feeding;*
Yes
No
subjects with stage iv breast cancer;*
Yes
No
psychiatric or addictive disorders that may limit
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the ability to give informed consent or complete
the trial.*
Yes
No
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NINDS CDE Medical History of Friedreich´s
Ataxia
NINDS Common Data Elements (Medical history of
Friedreich´s Ataxia) Used from the National Institute of
Neurological Disorders and Stroke Common Data Elements
(https://www.commondataelements.ninds.nih.gov/)
References: Grinnon ST, Miller K, Marler JR, Lu Y, Stout A,
Odenkirchen J, Kunitz S. National Institute of Neurological
Disorders and Stroke Common Data Element Project -
approach and methods. Clin Trials. 2012;9(3):322-9.
All rights reserved. Please visit https://medical-data-
models.org/forms/14875
Medical History of Friedreich´s
Ataxia
Special medical history
Study ID
Study site name
Subject ID
Age at Symptom Onset
yrs
Age of diagnosis
yrs
First symptom experienced by the patient
Scoliosis (1)
Cardiomyopathy (2)
Diabetes (3)
Instability (4)
Falls (5)
Other, specify (6)
First symptoms: please specify other
Problems during neonatal period?
Yes
No
Problems during neonatal period:if yes, please
specify
Impaired physical abilities during infancy
Yes
No
Delayed motor milestones
Yes
No
Delayed motor milestones : if yes, please specify
Was genetic diagnosis established?
Yes
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No
If genetic diagnosis was established, confirmed
by
Participant Report  (1)
Medical Record  (2)
Commerical Testing  (3)
Research Testing (4)
When was genetic diagnosis established?
year
Where was genetic diagnosis established?
Please give name,city and country of clinical
laboratory that performed genetic testing
Result of genetic testing
Was patient diagnosed with scoliosis?
Yes (1)
No (2)
Unknown (3)
Scoliosis:If yes, please indicate degree of
maximum curvature
Scoliosis:If yes, please indicate location of
maximum curvature
Cervical  (1)
Thoracic  (2)
Lumbar  (3)
Unknown/Not documented (4)
Scoliosis: If yes, indicate date of last assessment
Scoliosis:If yes, please indicate if the participant
has had surgery
Yes (1)
No (2)
Unknown (3)
Was participants vision affected?
Yes (1)
No (2)
Unknown (3)
Was participants hearing affected?
Yes (1)
No (2)
Unknown (3)
Was participants speech affected?
Yes (1)
No (2)
Unknown (3)
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Did the participant have foot surgery?
Yes (1)
No (2)
Unknown (3)
Was participants ambulation status affected?
Yes (1)
No (2)
Unknown (3)
Does the participant use an assistive walking
device?
Yes (1)
No (2)
Unknown (3)
Assistive walking device: if yes, please indicate
age when participant required assistance with
walking
yrs
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Eligibility Breast Neoplasms NCT02258451
Study of Radium-223 Dichloride Versus Placebo and
Treatment With Exemestane / Everolimus in Subjects With
Bone Predominant HER2 (Human Epidermal Growth
Factor Receptor 2) Negative Hormone Receptor Positive
Metastatic Breast Cancer; ODM derived from:
https://clinicaltrials.gov/show/NCT02258451
All rights reserved. Please visit https://medical-data-
models.org/forms/14876
Eligibility Breast Neoplasms
NCT02258451
Inclusion Criteria
women (≥18 years of age) with metastatic breast
cancer not amenable to curative treatment by
surgery or radiotherapy.*
Yes
No
documentation of histological or cytological
confirmation of estrogen receptor positive (er+)
and her2 negative adenocarcinoma of the breast
must be available.*
Yes
No
documentation of menopausal status:
postmenopausal subjects are eligible pre-
menopausal subjects with ovarian radiation or
concomitant treatment with an lh-rf
agonist/antagonist must have a plasma/serum
estradiol assay of <20 pg/ml at screening within 7
days prior to randomization.  negative pregnancy
test is also required at screening.  agreement to
use adequate method of contraception as
recommended by their treating physician.*
Yes
No
subjects with bone dominant disease with at least
2 skeletal metastases identified at baseline by
bone scintigraphy and confirmed by computed
tomography (ct)/magnetic resonance imaging
(mri).*
Yes
No
subjects must have received at least one line of
hormonal therapy in the metastatic setting.*
Yes
No
subjects who are eligible as per the investigator's
assessment and according to the local label for
treatment with exemestane and everolimus as a
second line or greater of hormone therapy in a
metastatic setting.*
Yes
No
subjects must have experienced
recurrent/progressive disease following treatment
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with a non-steroidal aromatase inhibitor (letrozole
or anastrozole) in an adjuvant or metastatic
setting*
Yes
No
subjects must have experienced no more than
two skeletal-related events (sres) prior to study
entry defined as: external beam radiotherapy
(ebrt) for bone pain, pathological bone fracture
(excluding major trauma), spinal cord
compression and/or orthopedic surgical
procedure. subjects with no prior sres are not
permitted.*
Yes
No
subjects must be on therapy with
bisphosphonates or denosumab for at least 1
month before start of study treatment.*
Yes
No
asymptomatic or mildly symptomatic breast
cancer.*
Yes
No
adequate hematological, liver and kidney
function*
Yes
No
Exclusion Criteria
subjects with any of the following cancers:*
Yes
No
inflammatory breast cancer*
Yes
No
bilateral breast cancer or a history of 2 distinct
breast cancers.*
Yes
No
patients with immediately life-threatening visceral
disease for whom chemotherapy is preferred
treatment option*
Yes
No
subjects who have either received chemotherapy
for metastatic disease or are considered by the
treating investigator to be appropriate candidates
for chemotherapy as current treatment for
metastatic breast cancer are excluded.
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chemotherapy administered for adjuvant/neo
adjuvant disease is acceptable provided it was
administered at least 1 year prior to study entry.*
Yes
No
subjects who received prior treatment or are
already receiving everolimus treatment prior to
study entry are not eligible*
Yes
No
subjects with known or history of brain
metastases or leptomeningeal disease: subjects
with neurological symptoms must undergo a
contrast ct scan or mri of the brain within 28 days
prior to randomization to exclude active brain
metastasis. imaging of the central nervous
system (cns) is otherwise not required.*
Yes
No
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NINDS CDE Imaging and Non-Imaging
Diagnostics Friedreich´s Ataxia
NINDS Common Data Elements (Imaging and Non-Imaging
Diagnostics; Friedreich´s Ataxia) Used from the National
Institute of Neurological Disorders and Stroke Common
Data Elements
(https://www.commondataelements.ninds.nih.gov/)
References: Grinnon ST, Miller K, Marler JR, Lu Y, Stout A,
Odenkirchen J, Kunitz S. National Institute of Neurological
Disorders and Stroke Common Data Element Project -
approach and methods. Clin Trials. 2012;9(3):322-9.
All rights reserved. Please visit https://medical-data-
models.org/forms/14878
Imaging and Non-Imaging
Diagnostics
Echocardiogram
Study ID
Study site name
Subject ID
Was an echocardiogram completed?
Yes (1)
No (2)
Unknown (3)
If echocardiography was performed, please
indicate date of echocardiogram
Left ventricular end-diastolic posterior wall
thickness (cm)
Left ventricular end-diastolic posterior wall
thickness (Z-score)
Left ventricular end-diastolic septal thickness
(cm)
Left ventricular end-diastolic septal thickness (z-
score)
Left ventricular end-diastolic internal dimension
(cm)
Left ventricular end-diastolic internal dimension
(z-score)
Left ventricular end-systolic internal dimension
(cm)
Left ventricular end-systolic internal dimension (z-
score)
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Left atrial antero-posterior dimension (cm)
Left atrial antero-posterior dimension (z-score)
Right Ventricular Wall Thickness in diastole (cm)
Right Ventricular Wall Thickness in diastole (z-
score)
Right atrial enlargement
Present (1)
Absent (2)
Right ventricular enlargement
Present (1)
Absent (2)
Right ventricular systolic dysfunction
Present (1)
Absent (2)
Left Ventricle Mass index (grams)
Left ventricle mass index (z-score)
Does subject have left ventricular hypertrophy?
Yes (1)
No (2)
Unknown (3)
Was the subjects left ventricle dilated?
Yes (1)
No (2)
Unknown (3)
Was there a LVOT obstruction?
Yes (1)
No (2)
Unknown (3)
LVOT obstruction:if yes, please specify peak
systolic pressure gradient
mmHg
LVOT obstruction: if yes, please specify mean
pressure gradient
Left Ventricular Ejection Fraction
%
Degree of Aortic Regurgitation
None  (1)
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Mild  (2)
Moderate  (3)
Severe (4)
Degree of Mitral Regurgitation
None  (1)
Mild  (2)
Moderate  (3)
Severe (4)
Degree of Tricuspid Regurgitation
None  (1)
Mild  (2)
Moderate  (3)
Severe (4)
Fractional shortening
%
Early mitral inflow velocity
cm/s
Late Mitral Inflow Velocity
cm/s
Mitral Inflow (E) deceleration time
msec
Tissue doppler: Septum E velocity
cm/s
Tissue doppler: Septum A velocity
cm/s
Tissue doppler: Septum S velocity
cm/s
Tissue doppler: Mitral annulus E velocity
cm/s
Tissue doppler: Mitral annulus A velocity
cm/s
Tissue doppler: Mitral annulus S velocity
cm/s
Cardiac Magnetic Resonance Imaging
Ejection fraction
%
Left ventricle mass
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gm
Relative wall thickness
cm
Was myocardial hyper-enhancement by LGE
present?
Yes (1)
No (2)
Unknown (3)
Further comments on Cardiac Magnetic
Resonance Imaging results
Electrocardiography
Was an ECG performed?
Yes (1)
No (2)
Unknown (3)
ECG:If Yes, indicate date of ECG
Heart rate
bpm
PR interval
msec
QRS duration
ms
QT Interval
msec
QTC interval
msec
ECG result
Normal (1)
Abnormal, not clinically significant (2)
Abnormal, clinically significant (3)
Non-specific STT changes (4)
Heart rhythm
Normal sinus rhythm (1)
Ventricular tachycardia (10)
Ventricular Other (11)
Other, specify (12)
Sinus tachycardia (2)
Sinus bradycardia (3)
Atrial arrhythmia (4)
Atrial fibrillation (5)
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Atrial flutter (6)
Atrial Other (7)
Ventricular arrhythmia (8)
Ventricular fibrillation (9)
Heart Rhythm:if other,please specify
ST segment abnormality
Present (1)
Absent (2)
T wave abnormality
Present (1)
Absent (2)
Right ventricular hypertrophy
Present (1)
Absent (2)
Left Ventricular Hypertrophy
Present (1)
Absent (2)
Patterns of previous myocardial infarction
Present (1)
Absent (2)
Patterns of complete bundle branch block
Present (1)
Absent (2)
Premature atrial contractions
Present (1)
Absent (2)
Paroxysmal supraventricular tachycardia
Present (1)
Absent (2)
Wolff-Parkinson-White syndrome
Present (1)
Absent (2)
Premature ventricular contractions
Present (1)
Absent (2)
Were voltage criteria met for LVH?
Yes (1)
No (2)
Unknown (3)
Voltage criteria for LVH:if yes, please select
R or S in limb leads ≥ 20 mm; (1)
S in V1 or V2 ≥ 30 mm; (2)
R in V5 or V6 ≥ 30 mm (3)
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Holter exam
Date of Holter exam
Maximum Heart rate
bpm
Minimum Heart rate
bpm
Mean Heart rate
bpm
Episodes of heart block?
None (1)
First degree (2)
Second degree (3)
Third degree (4)
Where any arrhythmias identified?
Yes (1)
No (2)
Unknown (3)
Arrhythmia:if yes ventricular tachycardia present?
Yes
No
Arrhythmia:if yes Atrial Dysrhythmias present?
Yes
No
Arrhythmia:if yes, Premature ventricular
contractions present?
Yes
No
Arrhythmia:if yes, Premature atrial contractions
present?
Yes
No
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Eligibility Breast Neoplasms NCT02258464
Study of Radium-223 Dichloride Versus Placebo and
Hormonal Treatment as Background Therapy in Subjects
With Bone Predominant HER2 (Human Epidermal Growth
Factor Receptor 2) Negative Hormone Receptor Positive
Metastatic Breast Cancer; ODM derived from:
https://clinicaltrials.gov/show/NCT02258464
All rights reserved. Please visit https://medical-data-
models.org/forms/14879
Eligibility Breast Neoplasms
NCT02258464
Inclusion Criteria
documentation of histological or cytological
confirmation of estrogen receptor positive (er+)
and her2 negative adenocarcinoma of the breast
must be available.*
Yes
No
women (≥18 years of age) with metastatic breast
cancer not amenable to curative treatment by
surgery or radiotherapy.*
Yes
No
documentation of menopausal status: post
menopausal or premenopausal subjects are
eligible.*
Yes
No
subjects with bone dominant disease (with or
without metastases in soft tissue including lymph
nodes) with at least 2 skeletal metastases
identified at baseline by bone scintigraphy and
confirmed by computed tomography (ct)/magnetic
resonance imaging (mri).*
Yes
No
measurable or non-measurable disease (but
radiologically evaluable) according to response
evaluation criteria in solid tumors (recist) v1.1
criteria.*
Yes
No
subjects must have received at least one line of
hormonal therapy in the metastatic setting*
Yes
No
subjects who are eligible for further standard of
care endocrine treatment.*
Yes
No
subjects enrolled in the current study will start
treatment with the single hormone agent  after
randomization either before or simultaneously to
the first injection of ra-223. patients already
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receiving the single agent hormone treatment
prior to study entry are not eligible. combination
hormonal treatment is not allowed.*
Yes
No
subjects must have experienced no more than
two skeletal-related events (sres) prior to study
entry defined as: external beam radiotherapy
(ebrt) for bone pain, pathological bone fracture
(excluding major trauma), spinal cord
compression and/or orthopedic surgical
procedure. subjects with no prior sres are not
permitted.*
Yes
No
subjects must be on therapy with bisphosphonate
and denosumab. and are required to have been
on such therapy for at least 3 months before start
of study treatment.*
Yes
No
asymptomatic or mildly symptomatic breast
cancer*
Yes
No
adequate hematological, liver and kidney
function*
Yes
No
Exclusion Criteria
subjects with any of the following cancers:*
Yes
No
inflammatory breast cancer*
Yes
No
bilateral breast cancer or a history of 2 distinct
breast cancers.*
Yes
No
history and/or presence of confirmed visceral
metastases.*
Yes
No
subjects who have either received chemotherapy
for metastatic disease or are considered by the
treating investigator to be appropriate candidates
for chemotherapy as current treatment for
metastatic breast cancer are excluded.
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chemotherapy administered for adjuvant/neo
adjuvant disease is acceptable provided it was
administered at least 1 year prior to study entry.*
Yes
No
subjects with known or history of brain
metastases or leptomeningeal disease: subjects
with neurological symptoms must undergo a
contrast ct scan or mri of the brain within 28 days
prior to randomization to exclude active brain
metastasis. imaging of the central nervous
system (cns) is otherwise not required.*
Yes
No
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Eligibility Breast Neoplasms NCT02271828
Omitting Sentinel Node Procedure in Breast Cancer
Patients Undergoing Breast Conserving Therapy; ODM
derived from: https://clinicaltrials.gov/show/NCT02271828
All rights reserved. Please visit https://medical-data-
models.org/forms/14880
Eligibility Breast Neoplasms
NCT02271828
Inclusion Criteria
female*
Yes
No
aged 18 years or older*
Yes
No
pathologically confirmed invasive breast
carcinoma*
Yes
No
a clinical t1-2 tumor*
Yes
No
will be treated with lumpectomy and whole breast
radiotherapy*
Yes
No
clinically node negative status: no signs of
axillary lymph node metastases at physical
examination and preoperative axillary ultrasound
(or negative cyto-/histopathology)*
Yes
No
written informed consent*
Yes
No
Exclusion Criteria
clinically node positive pre-operative*
Yes
No
bilateral breast cancer*
Yes
No
evidence of metastatic disease*
Yes
No
history of invasive breast cancer*
Yes
No
1 / 2
previous treatment of the axilla with surgery or
radiotherapy (except surgery for hidradenitis
suppurativa or for other superficially located skin
lesions, such as naevi)*
Yes
No
pregnant or nursing*
Yes
No
other prior malignancies within the past 5 years
(except successfully treated basal cell and
squamous cell skin cancer, carcinoma in situ of
the cervix or carcinoma in situ of the ipsilateral or
contralateral breast) or unsuccessfully treated
malignancies > 5 years before randomization*
Yes
No
unable or unwilling to give informed consent*
Yes
No
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Eligibility Breast Neoplasms NCT02297438
A Study Of Palbociclib (PD-0332991) + Letrozole VS.
Placebo+ Letrozole For 1st Line Treatment Of Asian
Postmenopausal Women With ER+/HER2- Advanced
Breast Cancer [PALOMA-4]; ODM derived from:
https://clinicaltrials.gov/show/NCT02297438
All rights reserved. Please visit https://medical-data-
models.org/forms/14881
Eligibility Breast Neoplasms
NCT02297438
Inclusion Criteria
adult asian women with locoregionally recurrent
or metastatic disease not amenable to curative
therapy*
Yes
No
confirmed diagnosis of er positive breast cancer*
Yes
No
no prior systemic anti-cancer therapy for
advanced er+ disease*
Yes
No
postmenopausal women*
Yes
No
measurable disease as per response evaluation
criterion in solid tumors [recist] or bone-only
disease*
Yes
No
eastern cooperative oncology group [ecog] 0-1*
Yes
No
adequate organ and marrow function*
Yes
No
patient must agree to provide tumor tissue*
Yes
No
Exclusion Criteria
confirmed diagnosis of her2 positive disease*
Yes
No
patients with advanced, symptomatic, visceral
spread that are at risk of life threatening
complication in the short term*
Yes
No
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known uncontrolled or symptomatic cns
metastases*
Yes
No
prior neoadjuvant or adjuvant treatment with a
non steroidal aromatase inhibitor (ie, anastrozole
or letrozole) with disease recurrence while on or
within 12 months of completing treatment*
Yes
No
prior treatment with any cdk 4/6 inhibitor*
Yes
No
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Eligibility Breast Neoplasms NCT02338804
Safety and Efficacy Study of Mix Vaccine in Breast
Carcinoma Patient; ODM derived from:
https://clinicaltrials.gov/show/NCT02338804
All rights reserved. Please visit https://medical-data-
models.org/forms/14882
Eligibility Breast Neoplasms
NCT02338804
Inclusion Criteria
1.patients diagnosed with breast carcinoma
based on histology*
Yes
No
2.evaluable lesions on imaging study*
Yes
No
3.without known immunodeficiency*
Yes
No
4.age >18 and <80 years ago*
Yes
No
Exclusion Criteria
1.patients is unable or unwilling to sign informed
consent*
Yes
No
2.any autoimmune disorder, which is currently
being treated with prednisone or any other
immune suppressive medication*
Yes
No
3.positive hiv and/or rpr (rapid plasma reagin)*
Yes
No
4.female patient who is pregnant or breast
feeding*
Yes
No
5.patients, based on the opinion pf the
investigator, should not be enrolled into this
study*
Yes
No
6.prior anti-cancer vaccine or biological
immunotherapy*
Yes
No
7.allergic to any known ingredient of the mv
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compound*
Yes
No
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Outpatient Department Form Dermatology
Clinic Erlangen
Item used as routine documentation by Clinic Erlangen,
Dermatology, Outpatient Department.  ODM derived from
original form “Derma- Ambulanz Erlangen”.
All rights reserved. Please visit https://medical-data-
models.org/forms/14884
Outpatient Department Form
Dermatology
Principal diagnosis
Principal diagnosis 1
Diagnosis unchanged since
Principal diagnosis 2
Diagnosis unchanged since
Attending physician today
Today's visit without appointment?
Yes
No
Important note (e.g. Infection)
Patient's occupation
Medical History
Previous diseases
Diagnosis unchanged
Long- term medication
Medication unchanged since
Allergies
Allergy unchanged since
Medical history of family
Family history unchanged since
Current average alcohol consumption
Current nicotine consumption
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Medical history
Medical Examination
Physical examination carried out today?
Yes
No
Physical examination
Date of last physical examination
Dermatological Diagnosis
Principal diagnosis 1
Date of diagnosis
Principal diagnosis 2
Date of diagnosis
Procedure
Procedure
Senior physician
Follow- up in (days/ weeks/ months)
Follow- up
as required (1)
by GP (2)
Nursing measures and procedures
Photograph instructed today?
Yes
No
Last photo taken on
Other
Study participation status
previous study participation of the patient
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(1)
current consultation is part of a study (2)
Studies
Memo (For letters and outdoor patient list e.g.
addressees, etc.)
Internal Notes
Nursing notes
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NINDS CDE Activities of Daily
Living/Performance Friedreich´s Ataxia
NINDS Common Data Elements (Activities of Daily
Living/Performance; Friedreich´s Ataxia) Used from the
National Institute of Neurological Disorders and Stroke
Common Data Elements
(https://www.commondataelements.ninds.nih.gov/)
References: Grinnon ST, Miller K, Marler JR, Lu Y, Stout A,
Odenkirchen J, Kunitz S. National Institute of Neurological
Disorders and Stroke Common Data Element Project -
approach and methods. Clin Trials. 2012;9(3):322-9.
All rights reserved. Please visit https://medical-data-
models.org/forms/14886
Activities of Daily Living/Performance
Activities of Daily Living and Gait
Indicate the description that reflects the
participants/ subjects current level of speech
Normal (1)
Mildly affected; no difficulty being
understood (2)
Moderately affected; sometimes asked to
repeat statements (3)
Severely affected; frequently asked to
repeat statements (4)
Unintelligible most of the time (5)
Indicate the description that reflects the
participants/subjects current level of swallowing
Normal (1)
Rare choking (less than once a month)
(2)
Frequent choking (less than once a
week, greater than once a month) (3)
Requires modified food or chokes
multiple times a week or subject avoids
certain foods (4)
Requires NG tube or gastrostomy
feedings (5)
Indicate the description that reflects the
participants/subjects current level of functioning
for cutting food/ use of items
Normal (1)
Somewhat slow and clumsy, but no help
needed (2)
Clumsy and slow, but can cut most foods
with some help needed or needs
assistance when in a hurry (3)
Food must still be cut by someone, but
can still feed self slowly (4)
Needs to be fed (5)
Indicate the description that reflects the
participants/subjects current level of dressing
Normal (1)
Somewhat slow, but no help needed (2)
Occasional assistance with buttoning,
getting arms in sleeves, etc. or has to
modify activity in some way (e.g. having
to sit to get dressed; use Velcro for
shoes, stop wearing ties, etc.) (3)
Considerable help required but can do
some things alone (4)
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Helpless (5)
Indicate the description that reflects the
participants/subjects current level of personal
hygiene
Normal (1)
Somewhat slow, but no help needed (2)
Very slow hygiene care or has need for
devices such as special grab bars, tub
bench, shower chair, etc. (3)
Requires personal help with washing,
brushing teeth, combing hair or using
toilet (4)
Fully dependent (bed-bound) (5)
Indicate the description that reflects the
participants/subjects current rate of falls
Normal (1)
Rare falling (less than once a month) (2)
Occasional falls (once a week to once a
month) (3)
Falls multiple times a week or requires
device to prevent falls (4)
Unable to stand (5)
Indicate the description that reflects the
participants/subjects current ability to walk
Normal (1)
Mild difficulty, perception of imbalance
(2)
Moderate difficulty, but requires little or
no assistance (3)
Severe disturbance of walking, requires
assistance or walking aids (4)
Cannot walk at all even with assistance
(wheelchair bound) (5)
Indicate the description that reflects the
participants/subjects current ability to sit
Normal (1)
Slight imbalance of the trunk, but needs
no back support (2)
Unable to sit without back support (3)
Can sit only with extensive support
(geriatric chair, posy, etc.) (4)
Unable to sit (5)
Indicate the description that reflects the
participants/subjects current level of bladder
control
Normal (1)
Mild urinary hesitance, urgency or
retention (less than once a month) (2)
Moderate hesitance,urgency,rate
retention/incontinence (greater than once
a month, but less than once a week) (3)
Frequent urinary incontinence (greater
than once a week) (4)
Loss of bladder function requiring
intermittent catheterization/ indwelling
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catheter (5)
Indicate the description that reflects the
participants/subjects current level of difficulty
walking
Without any difficulty (Stop here) (1)
With some difficulties walking or getting
around (Skip to question 12) (2)
With difficulty, difficulty walking interfered
with activities of daily living (Skip to
question 12) (3)
Unable to walk on their own (4)
If participant/ subject is unable to walk on their
own, indicate reason why
If participant/subject walks with some difficulties
or with difficulty, indicate age when participant
first noticed problems with walking
yrs
Age of participant when he/she first noticed
problems with walking is unknown
Yes
No
If participant /subject walks with some difficulties
or with difficulty, indicate age when other people
noticed gait disturbances
yrs
Age of participant when others first noticed gait
disturbances is unknown
Yes
No
If participant/subject needs intermittent support
for walking, indicate age of participant when
support was first needed
yrs
Age of participant when intermittent walking
support was first needed, is unknown
Yes
No
If participant/subject needs permanent support
for walking, indicate age of participant when
support was first needed
yrs
Age of participant when permanent walking
support was first needed,is unknown
Yes
No
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If participant/subject is permanently bound to the
wheelchair, indicate age of participant when first
permanently bound to wheelchair
yrs
Age of participant when first bound to wheelchair
is unknown
Yes
No
Indicate if the participant/subject uses an
assistive device.
Yes  (1)
No (Stop here)  (2)
Unknown (Stop here) (3)
Indicate if the participant/subject uses a cane
Yes  (1)
No (Skip to next device)  (2)
Unknown (Skip to next device) (3)
If yes to cane, indicate age
participant/subjectbegan using a cane
yrs
Age when participant began using a cane is
unknown
Yes
No
Indicate if the participant/subjectuses two canes/
crutches
Yes  (1)
No (Skip to next device)  (2)
Unknown (Skip to next device) (3)
If yes to canes/ crutches, indicate age
participant/subjectbegan using two canes/
crutches
yrs
Age when participant began first using two
canes/crutches is unknown
Yes
No
Indicate if participant/subject uses a walker
Yes  (1)
No (Skip to next device)  (2)
Unknown (Skip to next device) (3)
If yes to using a walker, indicate age
participant/subject began using a walker
yrs
Age when participant began first using a walker is
4 / 6
NINDS CDE Activities of Daily Living/Performance Friedreich´s Ataxia
unknown
Yes
No
Indicate if participant/subject uses canine
assistance
Yes  (1)
No (Skip to next device)  (2)
Unknown (Skip to next device) (3)
If yes to canine assistance, indicate age
participant/subject began using canine
assistance
Age when participant began first using canine
assistance is unknown
Yes
No
Indicate if the participant/subject uses a
wheelchair
Yes  (1)
No (Skip to next device)  (2)
Unknown (Skip to next device) (3)
If yes to wheelchair, indicate age when the
participant/subject began using a wheelchair
yrs
Age when participant began first using a
wheelchair is unknown
Yes
No
Indicate if the participant/subjectuses any other
assistive device
Yes  (1)
No (Skip to last question)  (2)
Unknown (Skip to last question) (3)
If yes to other assistive device, indicate age
participant/subject began using other assistive
device
yrs
Age when participant began first using other
assistive device is unknown
Yes
No
Indicate the amount of time the
participant/subject uses the primary assistive
walking device if applicable
Indication of time the participant/subject is using
primary walking assistive device is not applicable
Yes
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NINDS CDE Cardiac End Points
Friedreich´s Ataxia
NINDS Common Data Elements (Cardiac End Points;
Friedreich´s Ataxia) Used from the National Institute of
Neurological Disorders and Stroke Common Data Elements
(https://www.commondataelements.ninds.nih.gov/)
References: Grinnon ST, Miller K, Marler JR, Lu Y, Stout A,
Odenkirchen J, Kunitz S. National Institute of Neurological
Disorders and Stroke Common Data Element Project -
approach and methods. Clin Trials. 2012;9(3):322-9.
All rights reserved. Please visit https://medical-data-
models.org/forms/14887
Cardiac End Points
Cardiac End Points
Study ID
Study site name
Subject ID
Classify the subject using the ACC/AHA Stage of
Heart Failure
(A) Patients at high risk of developing HF
because of the presence of conditions
that are strongly associated with the
development of HF; such patients have
no identified structural or functional
abnormalities of the pericardium,
myocardium, or cardiac valves and have
never shown signs or symptoms of HF
(1)
(B) Patients who have developed
structural heart disease that is strongly
associated with the development of HF
but who have never shown signs or
symptoms of HF (2)
(C) Patients who have current or prior
symptoms of HF associated with
underlying structural heart disease (3)
(D) Patients with advanced structural
heart disease and marked symptoms of
HF at rest despite maximal medical
therapy and who require specialized
interventions (4)
Indicate the number of hospitalizations the
participant had in the past year
Indicate the start date of participants
hospitalization
Indicate cause for hospitalization
Cardiovascular  (1)
Other, specify (2)
Reason for hospitalization:please specify if other
reason than cardiovascular
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Eligibility Breast Neoplasms NCT02364492
A Phase I Study of a Therapeutic Vaccine Candidate in
Patients With Localized Breast Cancer at High-Risk of
Relapse; ODM derived from:
https://clinicaltrials.gov/show/NCT02364492
All rights reserved. Please visit https://medical-data-
models.org/forms/14888
Eligibility Breast Neoplasms
NCT02364492
Inclusion Criteria
1. all patients must have a diagnosis of epithelial
breast carcinoma which is, according to tnm
classification:*
Yes
No
any t*
Yes
No
with positive (n+) or negative (n-) lymph-node
depending on the patient profile*
Yes
No
and non metastatic (m0)*
Yes
No
2. her2/neu-negative (immunohistochemical
expression "0-1+", and/or fish/cish "non
amplified" according to asco 2012 criteria)*
Yes
No
3. first line treatment population with a high-risk
of relapse as defined by:*
Yes
No
with at least 4 positive lymph nodes (ln) at
primary surgery, or at least one positive lymph
node >pn1mi after completion of 6-8 cycles of
anthracyclins/taxanes-based neoadjuvant
chemotherapy*
Yes
No
or, negative hormone receptors: er- and pr- ,
(<10%), i.e "triple negative breast cancer" with at
least one positive lymph node >pn1mi or negative
lymph node if a pathological complete remission
was not achieved (persistence of invasive
carcinoma) after completion of 6-8 cycles of
anthracyclins/taxanes-based neoadjuvant
chemotherapy*
Yes
No
4. patients must have completed all their local
and regional treatments including adequate
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surgery and radiation therapy, and at least 6
cycles of chemotherapy (neoadjuvant and/or
adjuvant) according to institutional and national
standards.*
Yes
No
5. the time interval between the end of all the first
line standard treatment (completion of surgery,
chemotherapy and radiation therapy) should be at
least 3 months and within a maximum of 18
months before inclusion in the study.*
Yes
No
Exclusion Criteria
1. any breast cancer recurrence or metastasis.*
Yes
No
2. patients with her2/neu positive breast
carcinoma (ihc score 2+ or 3+ and/or fish/cish-
amplified).*
Yes
No
3. patients with any uncontrolled bleeding
disorder including coagulation disorder or
thrombocytopenia or prothrombotic disorder.*
Yes
No
4. patients with a personal history of autoimmune
disease (including but not limited to multiple
sclerosis, lupus, rheumatoid polyarthritis,
inflammatory bowel diseases, graves' disease
and hashimoto's disease).*
Yes
No
5. patients with a history of previous anaphylaxis
or severe allergic reaction to vaccines or other
known or unknown allergens.*
Yes
No
6. patients who have received any commercial
vaccine within one month before the first dose of
study vaccine or are planned to receive any
vaccine till 3 weeks after the 6th vaccine
injection.*
Yes
No
2 / 2
Eligibility Breast Neoplasms NCT02364492
Eligibility Cancer of the Breast
NCT02302196
Autologous Fat Grafting of the Breast in Women With Post
Lumpectomy Contour Defects; ODM derived from:
https://clinicaltrials.gov/show/NCT02302196
All rights reserved. Please visit https://medical-data-
models.org/forms/14890
Eligibility Cancer of the Breast
NCT02302196
Inclusion Criteria
women*
Yes
No
age 18 > y/o*
Yes
No
if patient has had lumpectomy and radiation,
need to be at least 3 years out from completion of
radiation*
Yes
No
must be a kaiser permanente northwest member*
Yes
No
Exclusion Criteria
active smokers, cannot quit smoking for at least
one month before and after procedures*
Yes
No
patients who have such extensive skin scarring
that elasticity is lost*
Yes
No
patients who have little to no subcutaneous donor
fat*
Yes
No
patients with birad's 3 or greater mammograms
after treatment*
Yes
No
patients with aggressive cancer for which cure is
the goal (do not want to exclude patients that
want palliative procedure) - inflammatory breast
cancer*
Yes
No
patients with triple negative cancer - er -, pr -,
her2-neu -*
Yes
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No
patients with brca or chek-2 gene mutations or
those with strong family history of breast cancer
[more than 2 first degree relatives with breast
cancer]*
Yes
No
patients that have had a lumpectomy for breast
cancer who have declined radiation therapy when
it was recommended to reduce risk of local
recurrence (should not exclude patients over 70
y/o who have elected to have lumpectomy and
anti-estrogen therapy instead of lumpectomy and
radiation)*
Yes
No
oncoplastic reduction patients*
Yes
No
comorbidities that preclude multiple procedures
being done*
Yes
No
pregnant women*
Yes
No
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NINDS CDE Participant/Subject
Characteristics Headache
NINDS Common Data Elements (Participant/Subject
Characteristics; Headache) Used from the National Institute
of Neurological Disorders and Stroke Common Data
Elements
(https://www.commondataelements.ninds.nih.gov/)
References: Grinnon ST, Miller K, Marler JR, Lu Y, Stout A,
Odenkirchen J, Kunitz S. National Institute of Neurological
Disorders and Stroke Common Data Element Project -
approach and methods. Clin Trials. 2012;9(3):322-9.
All rights reserved. Please visit https://medical-data-
models.org/forms/14891
Demographics and Social Status
Demographics
Study ID
Study site name
Subject ID
Date of birth
Gender
Female (1)
Male (2)
Unknown (3)
Unspecified (4)
Not reported (5)
Ethnicity
Hispanic or Latino (1)
not Hispanic or Latino (2)
Not Reported (3)
Unknown (4)
Race
American Indian or Alaskan Native (1)
Asian (2)
Black or African American (3)
Native Hawaiian or Other Pacific Islander
(4)
Unknown (5)
White (6)
Not reported (7)
Years of education
years
Snomed CT code
Medical History Term
Primary Language
0 English (eng) (1)
0 Spanish (spa) (2)
Sign Languages (sgn) (3)
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Chinese languages (chi) (4)
French (fre) (5)
German (ger) (6)
Other, specify (7)
Primary Language:if other please specify
Country of birth
First 3 digits of zip code
Patient Social Security Number
Age
months (1)
years (2)
Age of child
Birth order
1st (1)
2nd (2)
3rd (3)
4th (4)
5th (5)
Other, specify (6)
Birth order:if other,please specify
Part of a multiple birth
Yes (1)
No (2)
Unknown (3)
Maternal ethnicity
Hispanic or Latino (1)
Not Hispanic or Latino (2)
Unknown (3)
Not Reported (4)
Maternal Race
American Indian Or Alaska Native (1)
Asian (2)
Black Or African American (3)
Native Hawaiian Or Other Pacific
Islander (4)
White (5)
Not Reported (6)
Unknown (7)
Paternal ethnicity
Hispanic or Latino (1)
not Hispanic or Latino (2)
Not Reported (3)
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Unknown (4)
Paternal race
American Indian Or Alaska Native (1)
Asian (2)
Black Or African American (3)
Native Hawaiian Or Other Pacific
Islander (4)
White (5)
Not Reported (6)
Unknown (7)
Social Status
Highest education level attained
Never attended/ Kindergarten only (1)
9th Grade (10)
10th Grade (11)
11th Grade (12)
12th Grade, no diploma (13)
High school graduate (14)
GED or equivalent (15)
Some college, no degree  (16)
Associate degree: occupational,
technical, or vocational program (17)
Associate degree: academic program
(18)
Bachelor´s degree (e.g., BA, AB, BS,
BBA) (19)
1st Grade (2)
Master´s degree (e.g., MA, MS, MEng,
MEd, MBA) (20)
Professional school degree (e.g., MD,
DDS, DVM, JD) (21)
Doctoral degree (e.g., PhD, EdD) (22)
Unknown (23)
2nd Grade (3)
3rd Grade (4)
4th Grade (5)
5th Grade (6)
6th Grade (7)
7th Grade (8)
8th Grade (9)
Type of education
Public (1)
Private (2)
Home school (3)
Other, specify (4)
Years of education
years
Were grades repeated
Yes (1)
No (2)
Unknown (3)
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Marital status
Never Married (1)
Married (2)
Domestic Partnership (3)
Separated  (4)
Divorced (5)
Widowed (6)
Employment status
Working now (1)
Unknown (10)
Student (2)
Looking for work, unemployed (3)
Only temporarily laid off (4)
Sick leave or maternity leave (5)
Retired (6)
Disabled, permanently or temporarily (7)
Keeping house (8)
Other, specify: (9)
If student,what is the course load
Full-time (1)
Part-time (2)
Unknown (3)
If employed,how many hours per week
If employed, indicate the number of paid jobs
If unemployed, indicate the main reason for no
job
Which of the following best describes the
occupation?
Official/Manger (1)
Unknown (10)
Professional (2)
Technician (3)
Sales Worker (4)
Administrative Support Worker (5)
Craft Worker (6)
Operative (7)
Laborer/Helper (8)
Social Worker (9)
Military service status
Active duty military (1)
Active reserves (or national guard) (2)
Inactive reserve (3)
Retired from military (4)
No military service or previous or current
(5)
If Active, Active reserves, Inactive or Civilian
military contractor, specify military branch of
service
Air force (1)
Army (2)
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Navy (3)
Marine Corps (4)
Coast Guard (5)
Other, specify (6)
If other military branch of service, please specify
If Active, Active reserves, Inactive or Civilian
military contractor, specify military rank
Field grade officer or above (1)
Company grade officer (2)
Warrant officer (3)
Non-commissioned officer (e.g.,
sergeant/corporal) (4)
Other, enlisted rank (5)
Current or most recent military occupation
Combat (1)
Non-combat (2)
If ever deployed to combat zone, indicate number
of deployments in a combat role
If ever deployed to combat zone, indicate number
of deployments in a non combat role
If ever deployed to combat zone, indicate start
date of most recent deployment
If ever deployed to combat zone, indicate end
date of most recent deployment
Number of people the participant/subject lives or
stays with
Indicate the Person(s) living with
Husband or wife (1)
Parent-in-law (10)
Son-in-law or daughter-in-law (11)
Other relative (12)
Roomer or boarder (13)
Housemate or roommate (14)
Unmarried partner (15)
Foster child (16)
Other patient/resident in care facility (17)
Personal care attendant (18)
Military unit member (19)
Biological son or daughter (2)
Other non-relative (20)
N/A – Homeless (21)
N/A – Alone (22)
Unknown (23)
Adopted son or daughter (3)
Stepson or stepdaughter (4)
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Brother or sister (5)
Father or mother (6)
Stepfather or stepmother (7)
Grandchild (8)
Grandparent (9)
Number of dependent children
Number of dependent children living in the
household
Household income
Under $15,000 (1)
$15,000 to $24,999 (2)
$25,000 to $34,999 (3)
$35,000 to $49,999 (4)
$50,000 to $74,999 (5)
$75,000 to $99,999 (6)
$100,000 and over (7)
Refused (8)
Unknown (9)
Number of wage earners in the household
Number of people supported by this income
Type of health insurance
Medicaid (1)
Veterans Affairs/Military (2)
Medicare (3)
Self-pay (4)
Employer-sponsored disability insurance
(5)
Unknown (6)
Private or group health insurance (7)
National Health Insurance (8)
Other, specify (9)
Health Insurance:please specify other
Who takes care of the child or adolescent?
Mother (1)
Father (2)
Other,specify (3)
Mothers Education Level
Never attended/ Kindergarten only (1)
9th Grade (10)
10th Grade (11)
11th Grade (12)
12th Grade, no diploma (13)
High school graduate (14)
GED or equivalent (15)
Some college, no degree (16)
Associate degree: occupational,
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technical, or vocational program (17)
Associate degree: academic program
(18)
Bachelor's degree (e.g., BA, AB, BS,
BBA) (19)
1st Grade (2)
Master's degree (e.g., MA, MS, MEng,
MEd, MBA) (20)
Professional school degree (e.g., MD,
DDS, DVM, JD) (21)
Doctoral degree (e.g., PhD, EdD)  (22)
Unknown (23)
2nd Grade  (3)
3rd Grade (4)
4th Grade  (5)
5th Grade  (6)
6th Grade (7)
7th Grade  (8)
8th Grade (9)
Fathers education level
Never attended/ Kindergarten only (1)
9th Grade (10)
10th Grade (11)
11th Grade (12)
12th Grade, no diploma (13)
High school graduate (14)
GED or equivalent (15)
Some college, no degree  (16)
Associate degree: occupational,
technical, or vocational program (17)
Associate degree: academic program
(18)
Bachelor´s degree (e.g., BA, AB, BS,
BBA) (19)
1st Grade (2)
Master´s degree (e.g., MA, MS, MEng,
MEd, MBA) (20)
Professional school degree (e.g., MD,
DDS, DVM, JD) (21)
Doctoral degree (e.g., PhD, EdD) (22)
Unknown (23)
2nd Grade (3)
3rd Grade (4)
4th Grade (5)
5th Grade (6)
6th Grade (7)
7th Grade (8)
8th Grade (9)
Child rearing: please specify other caregiver
Education level of other caregiver
Never attended/ Kindergarten only (1)
9th Grade (10)
10th Grade (11)
11th Grade (12)
12th Grade, no diploma (13)
High school graduate (14)
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GED or equivalent (15)
Some college, no degree  (16)
Associate degree: occupational,
technical, or vocational program (17)
Associate degree: academic program
(18)
Bachelor´s degree (e.g., BA, AB, BS,
BBA) (19)
1st Grade (2)
Master´s degree (e.g., MA, MS, MEng,
MEd, MBA) (20)
Professional school degree (e.g., MD,
DDS, DVM, JD) (21)
Doctoral degree (e.g., PhD, EdD) (22)
Unknown (23)
2nd Grade (3)
3rd Grade (4)
4th Grade (5)
5th Grade (6)
6th Grade (7)
7th Grade (8)
8th Grade (9)
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Eligibility Carcinoma, Basal Cell
NCT02285790
One-stop-shop Study for Treatment of Basal Cell
Carcinoma Using Reflectance Confocal Microscopy; ODM
derived from: https://clinicaltrials.gov/show/NCT02285790
All rights reserved. Please visit https://medical-data-
models.org/forms/14892
Eligibility Carcinoma, Basal Cell
NCT02285790
Inclusion Criteria
patients with clinically suspected new primary bcc
as assessed by an experienced board certified
dermatologist*
Yes
No
patients seen at the outpatient clinic before
12h00 am will be eligible to participate*
Yes
No
patient is willing and able to give written informed
consent*
Yes
No
bcc lesion is suitable for conventional surgical
excision under local anesthetics*
Yes
No
bcc lesion is present since at least 1 month*
Yes
No
Exclusion Criteria
bcc lesion in a high-risk location of the face (h-
zone and ears)*
Yes
No
contra-indication for conventional surgical
excision (primary surgical closure seems not
achievable)*
Yes
No
recurrent bcc lesion (bcc that has been previously
unsuccessfully treated) macroscopic ulcerating
bcc lesions (not feasible for rcm analysis due to
technical reasons)*
Yes
No
patients with basal cell nevus syndrome*
Yes
No
patients treated with hedgehog inhibitor
medication*
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Yes
No
patients with a history of hypersensitivity to and/
or a history of allergy to local anesthesia*
Yes
No
unavailability within the following 6 weeks (for
example due to holiday or sports)*
Yes
No
patients not competent to understand the
procedures involved*
Yes
No
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Eligibility Carcinoma, Hepatocellular
NCT02192671
HR Versus RFA for HCC in Patients With PHT; ODM
derived from: https://clinicaltrials.gov/show/NCT02192671
All rights reserved. Please visit https://medical-data-
models.org/forms/14893
Eligibility Carcinoma, Hepatocellular
NCT02192671
Inclusion Criteria
age 18-75 years*
Yes
No
in the hr group, clinical diagnosis of hcc was
confirmed by histopathological examination of
surgical samples in all patients; in the rfa group,
hcc diagnosis was confirmed by two types of
clinical imaging (ultrasonography, computed
tomography, or magnetic resonance imaging),
togetherwith a serum level of α-fetoprotein higher
than 400 ng/ml. if diagnosis based on imaging
andα-fetoprotein level was uncertain, needle
biopsy was performed.*
Yes
No
tumor stage fitted into milan criteria*
Yes
No
patients with clinically relevant portal
hypertension, which is defined as the presence of
esophageal varices and/or a platelet count of less
than 100 000 per μl in association with
splenomegaly.*
Yes
No
patients have child-pugh a or b liver function*
Yes
No
no previous neoadjuvant treatment*
Yes
No
no evidence of metastasis to the lymph nodes
and/or distant metastases on the basis of
preoperative imaging results and perioperative
findings*
Yes
No
no malignancy other than hcc for 5 years prior to
the initial hcc treatment*
Yes
No
Exclusion Criteria
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history of cardiac disease*
Yes
No
known history of human immunodeficiency virus
(hiv) infection*
Yes
No
known central nervous system tumors including
metastatic brain disease*
Yes
No
history of organ allograft*
Yes
No
substance abuse, medical, psychological or
social conditions that may interfere with the
patient's participation in the study or evaluation of
the study results*
Yes
No
any condition that is unstable or which could
jeopardize the safety of the patient and his/her
compliance in the study*
Yes
No
pregnant or breast-feeding patients.*
Yes
No
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Eligibility Carcinoma, Hepatocellular
NCT02308319
Prompt Or Watchful Monitoring for Hepatitis B Virus
Related Hepatocellular Carcinoma Without Elevated viRal
Load; ODM derived from:
https://clinicaltrials.gov/show/NCT02308319
All rights reserved. Please visit https://medical-data-
models.org/forms/14894
Eligibility Carcinoma, Hepatocellular
NCT02308319
Inclusion Criteria
hepatocellular carcinoma (clinically or
histologically)*
Yes
No
chronic hepatitis b*
Yes
No
serum hbv dna < 2000 iu/ml*
Yes
No
hcc stage bclc  0 or a*
Yes
No
treated or will be treated with rfa or surgical
resection*
Yes
No
Exclusion Criteria
co-infected with hcv, hiv*
Yes
No
currently using antiviral drug (lamivudine,
adefovir, clevudine, tenofovir, entecavir,
telbivudine) or interferon*
Yes
No
other malignancy*
Yes
No
dialysis*
Yes
No
pregnancy*
Yes
No
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Screening Safety and Immunogenicity Study of a Booster Dose of GSK
Biologicals 10-valent Pneumococcal Conjugate Vaccine NCT00370396
This study will evaluate the safety, reactogenicity and
immunogenicity of a booster dose of GSK Biologicals'
pneumococcal conjugate vaccine compared to Prevenar™
given at 12-18 mo of age to children primed with either
pneumococcal vaccine or Prevenar™ in study 105553.
Antibody persistence will be evaluated at 8-14 mo after
completion of the 3-dose immunization course in study
105553. The immune response to a booster dose of GSK
Biologicals' pneumococcal conjugate vaccine will also be
evaluated when given at 12-18 mo to subjects not primed
with GSK Biologicals' vaccine but with Prevenar™.
The study has 3 groups. 1 group of children primed with
GSK Biologicals' pneumococcal conjugate vaccine will
receive a booster dose of the same vaccine. 2nd group of
children primed with Prevenar™ will receive a booster dose
of Prevenar™ (control group). 3rd group of children primed
with Prevenar™ will receive a booster dose of GSK
Biologicals' pneumococcal conjugate vaccine. All children
will receive concomitantly a booster dose of DTPa-HBV-
IPV/Hib vaccine.
NCT00370396
Part: Screening
All rights reserved. Please visit https://medical-data-
models.org/forms/14901
Screening "Safety and
Immunogenicity Study of a Booster
Dose of GSK Biologicals' 10-valent
Pneumococcal Conjugate Vaccine"
NCT00370396
Identification
Center number:
Subject ID
Treatment Number
Administrative
Number of Visit
Visit 1 (1)
Visit 2 (2)
Visit Date
Informed Consent
Yes
No
Informed Consent Date
Demographics
Date of birth
Gender
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Female (f)
Male (m)
Adverse Events
Has the Patient had any serious adverse Event
since the end of the primatry study and before
the beginning of this Booster vaccination
Yes
No
adverse event type
Eligibility
Did the subject meet all the entry criteria
Yes
No
Eligibility: Inclusion Criteria
Male or female between, and including, 12-18
months of age at the time of vaccination.
Yes
No
Subjects who previously participated in the study
1 OPN-PD-DIT-001 and received at least one
dose of pneumococcal conjugate vaccine during
the primary study.
Yes
No
Subjects for whom the investigator believes that
their parents/guardians can and will comply
with the requirements of the protocol (e.g.,
completion of the diary cards, return for follow-up
visit).
Yes
No
Written informed consent obtained from the
parent or guardian of the subject.
Yes
No
Free of obvious health problems as established
by medical history and clinical examination
before entering into the study.
Yes
No
Eligibility: Exclusion Criteria
Use of any investigational or non-registered
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product (drug or vaccine) other than the study
vaccine within 30 days preceding the first dose of
study vaccine, or planned use during the
entire study period (active phase and extended
safety follow-up).
Yes
No
Chronic administration (defined as more than 14
days) of immunosuppressants or other immune-
modifying drugs within six months prior to the
dose of vaccine(s). (For corticosteroids, this will
mean prednisone, or equivalent, 2 0.5 mg/kg/day.
Inhaled and topical steroids are allowed.)
Yes
No
Planned administration/ administration of a
vaccine not foreseen by the study protocol
during the period starting one month before the
dose of vaccine(s) up to Visit 2.
Yes
No
Administration of any additional pneumococcal
vaccine or DTPa-combined vaccine since
end of 10PN-PD-DIT-001 study.
Yes
No
Any confirmed or suspected immunosuppressive
or immunodeficient condition based on
medical history and physical examination (no
laboratory testing required).
Yes
No
A family history of congenital or hereditary
immunodeficiency
Yes
No
History of allergic disease or reactions likely to be
exacerbated by any component of the
vaccines.
Yes
No
Major congenital defects or serious chronic
illness.
Yes
No
History of seizures (subjects who have had a
single, uncomplicated febrile convulsion in the
past can be included) or progressive neurological
disease.
Yes
No
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Administration of immunoglobulins and/or any
blood products since birth or planned
administration during the active phase of the
study.
Yes
No
Anaphylactic reaction following the administration
ofvaccine(s).
Yes
No
Acute disease at the time of enrolment. (Acute
disease is defined as the presence of a
moderate or severe illness with or without fever.
All vaccines can be administered to
persons with a minor illness such as diarrhoea or
mild upper respiratory infections with or
without low-grade fever, i.e oral/axillary/tympanic
temperature <37.5°C I rectal temperature
<38.0°C).
Yes
No
Febrile illness defined as oral, axillary or
tympanic temperature 37.5°C, rectal temperature
38.0°C. A temperature greater than or equal to
these cut-offs warrants deferral of the
vaccination pending recovery of the subject.
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Eligibility Cancer of Breast NCT02375048
Randomized Study on Postmenopausal Women With Early
Stage Breast Cancer: WBI Versus APBI; ODM derived
from: https://clinicaltrials.gov/show/NCT02375048
All rights reserved. Please visit https://medical-data-
models.org/forms/14904
Eligibility Cancer of Breast
NCT02375048
Inclusion Criteria
55< age <70*
Yes
No
tumor size ≤ 2 cm*
Yes
No
pn0 (sn biopsy or alnd)*
Yes
No
er/pgr positive*
Yes
No
margins > 5 mm (either at initial surgery or at re-
excision)*
Yes
No
clips placed in the surgical bed (minimum of 4
clips)*
Yes
No
unicentric only*
Yes
No
no lymphovascular invasion*
Yes
No
any grade*
Yes
No
no extensive intraductal component (>25%)*
Yes
No
written informed consent*
Yes
No
Exclusion Criteria
prior thoracic radiation therapy*
Yes
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No
oncoplastic surgery / no clips in the surgical bed*
Yes
No
multicentric cancer*
Yes
No
autoimmune disease, vasculitis, collagenopathy
or scleroderma that    may predispose to late
sequelae*
Yes
No
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Eligibility Carcinoma, Non-Small-Cell Lung
NCT02272413
Phase III Trial BI 695502 Plus Chemotherapy vs. Avastin®
Plus Chemotherapy in Patients With Lung Cancer; ODM
derived from: https://clinicaltrials.gov/show/NCT02272413
All rights reserved. Please visit https://medical-data-
models.org/forms/14905
Eligibility Carcinoma, Non-Small-Cell
Lung NCT02272413
Inclusion Criteria
adult patients aged >=18 years with histologically
or cytologically confirmed advanced
nonsquamous non-small cell lung cancer
(nsnsclc). mixed tumors should be categorized
according to the predominant histology.*
Yes
No
note: nsclc should be predominantly
nonsquamous. recurrent or metastatic disease
(stage iv) with an indication for therapy with
paclitaxel + carboplatin + avastin®.*
Yes
No
patients harboring tumors with unknown or
without activating epidermal growth factor
receptor (egfr) / anaplastic lymphoma receptor
tyrosine kinase (alk) mutation maybe included
provided chemotherapy is standard of care. at
least one measurable lesion according to
response evaluation criteria in solid tumors
(recist) 1.1 based on independent central review.*
Yes
No
eastern cooperative oncology group (ecog)
performance status (ps) 0 or 1.*
Yes
No
adequate hepatic, renal, and bone marrow
function:*
Yes
No
life expectancy > 6 months based on clinical
judgment. further inclusion criteria apply.*
Yes
No
Exclusion Criteria
prior therapy with monoclonal antibodies or small
molecule inhibitors against vascular endothelial
growth factor (vegf) or vegf receptors, including
avastin®.*
Yes
No
prior systemic therapy for metastatic disease.
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prior systemic anticancer therapy or radiotherapy
for locally advanced nsnsclc if completed <12
months prior to screening.*
Yes
No
previous malignancy other than nsclc in the last 5
years except for basal cell cancer of the skin or
pre-invasive cancer of the cervix.*
Yes
No
symptomatic brain metastasis. diagnosis of small
cell carcinoma of the lung, squamous cell
carcinoma of the lung, nsclc not specified (ns) or
nsclc not otherwise specified(nos).*
Yes
No
any unresolved toxicity > common toxicity criteria
grade 1 (except alopecia) from previous
anticancer therapy (including radiotherapy).*
Yes
No
history or evidence of inherited bleeding diathesis
or coagulopathy with the risk of bleeding.
thrombotic or hemorrhagic event =< 6 months
prior to screening. further exclusion criteria
apply.*
Yes
No
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Eligibility Carcinoma, Squamous Cell
NCT02269020
Neck Dissection Via a Robot-assisted Transaxillary
Approach in Patients With Squamous Cell Carcinoma of
the Epi-larynx; ODM derived from:
https://clinicaltrials.gov/show/NCT02269020
All rights reserved. Please visit https://medical-data-
models.org/forms/14906
Eligibility Carcinoma, Squamous Cell
NCT02269020
Inclusion Criteria
cancer of the epi-larynx:  (i) ranked t1 or t2 in the
tnm classification, (ii) supraglottic or glotto-
supraglottic location, (iii) cn0 nodal status*
Yes
No
absence of distant metastasis (m0)*
Yes
No
decision for unilateral endoscopic axillary neck
dissection at lymph node levels iia, iii and iv of
the robins classification is retained in a
multidisciplinary meeting*
Yes
No
the patient is available for 6 months of follow-up*
Yes
No
the patient must have given his/her informed and
signed consent*
Yes
No
the patient must be insured or beneficiary of a
health insurance plan*
Yes
No
Exclusion Criteria
patient participating in or having participated in
another study within the previous 3 months or
currently in an exclusion period determined by a
previous study*
Yes
No
adult under judicial protection or any kind of
guardianship*
Yes
No
refusal to sign the consent*
Yes
No
it is impossible to correctly inform the patient*
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Yes
No
the patient is pregnant, parturient, or
breastfeeding*
Yes
No
preoperative diagnosis of a second location of
cancerous disease*
Yes
No
body mass index > 25*
Yes
No
history of cervical spine surgery*
Yes
No
history of instability of the cervical spine*
Yes
No
history of surgery in the shoulder or pre-pectoral
region*
Yes
No
history of ipsilateral neck surgery*
Yes
No
history of cervical radiotherapy*
Yes
No
history of breast implants*
Yes
No
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Eligibility Cardiovascular Disease
NCT02379403
Effects of Tart Cherry and Aroniaberry Supplementation on
Endothelial Function and Cardiovascular Measures in
Healthy Older Adults: Interactions With Genotype and
Proteome; ODM derived from:
https://clinicaltrials.gov/show/NCT02379403
All rights reserved. Please visit https://medical-data-
models.org/forms/14907
Eligibility Cardiovascular Disease
NCT02379403
Criteria
an associate investigator will examine
participants and determine their eligibility
according to the inclusion and exclusion criteria
as documented by the eligibility checklist.*
Yes
No
men and women between the ages 55-70 years*
Yes
No
in good general health as determined by physical
exam and normal ranges obtained during
screening*
Yes
No
post-menopausal women (no menses within 12
months)*
Yes
No
normal or pre-hypertensive blood pressure (e.g.,
sbp less than or equal to 139 mmhg and dbp less
than or equal to 89 mmhg)*
Yes
No
normal or mild hyperlipidemia (e.g., tc less than
or equal to 239, ldl less than or equal to159,
triglycerides less than or equal to 199, hdl < 45
mg/dl)*
Yes
No
bmi between 18.5 to 25kg/m2*
Yes
No
willing and ability to sign consent*
Yes
No
willing to make time commitment for study*
Yes
No
individuals who are fluent in english*
Yes
No
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Exclusion Criteria
progressive or unstable known disease of any
body system including cardiovascular, pulmonary,
gastrointestinal, central nervous system,
psychiatric, endocrine, hematologic, renal, or
immunologic disorders*
Yes
No
known acute and chronic inflammatory disease
(i.e. rheumatoid arthritis, systemic lupus
erythematous, hepatitis)*
Yes
No
elevated c-reactive protein level (> 3.0mg/l)*
Yes
No
current (or within the last 3 months) smoking of
any tobacco products, i.e., cigarettes, pipe*
Yes
No
abnormal complete metabolic panel (cmp),
complete blood count (cbc), cholesterol panel,
thyroid stimulating hormone (tsh), erythrocyte
sedimentation rate (esr) --*
Yes
No
(laboratory values outside of acceptable
reference range for older adults if determined to*
Yes
No
be clinically significant)*
Yes
No
indications of current or within last 3 years
substance or alcohol abuse*
Yes
No
alcohol consumption > 1 drink/day, i.e., 1 bottle of
beer, half glass of wine, 1 shot hard liquor*
Yes
No
known sensitivity or allergy to tart cherry or
aroniaberry*
Yes
No
currently on cholesterol-lowering, anti-
hypertensive, thyroid, steroid or hormonal
medications*
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Yes
No
routine use of vitamins, supplements, or over the
counter medications including aspirin, aspirin-
containing products, non-steroidal anti-
inflammatory drugs (nsaids), i.e., motrin, advil,
aleve, unless they were discontinued 14 days
prior to their first visit.*
Yes
No
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Eligibility Cardiovascular Disease
NCT02422745
COcoa Supplement and Multivitamin Outcomes Study;
ODM derived from:
https://clinicaltrials.gov/show/NCT02422745
All rights reserved. Please visit https://medical-data-
models.org/forms/14908
Eligibility Cardiovascular Disease
NCT02422745
Inclusion Criteria
1. women  ≥ 65 years of age participating in the
whi extension study.  if fewer than 12,000 women
from whi agree to participate, additional women
aged ≥ 65 years who were contacted for but not
randomized into the vital trial will also be
included.*
Yes
No
2. men ≥ 60 years of age who were contacted for
but not randomized into the vital trial.*
Yes
No
3. willing to participate, as evidenced by providing
informed consent and completing all required
baseline forms.*
Yes
No
Exclusion Criteria
1. history of myocardial infarction or stroke.*
Yes
No
2. diagnosed with invasive cancer other than non-
melanoma skin cancer in the last 2 years prior to
randomization.*
Yes
No
3. any serious illness that would preclude
participation or completion of the trial.*
Yes
No
4. taking cocoa extract or multivitamin
supplements and not willing to forego use during
the trial.*
Yes
No
5. taking total supplemental vitamin d > 1,000
iu/day and not willing to forego use during the
trial*
Yes
No
6. taking total supplemental calcium > 1,200
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mg/day and not willing to forego use during the
trial*
Yes
No
7. extreme sensitivity to caffeine.*
Yes
No
8. consume < 75% of the expected number of
both types of supplements during the run-in
phase.*
Yes
No
9. unable to communicate in english due to
language barrier or mental incapacity.*
Yes
No
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Eligibility Chronic Heart Failure
NCT02322034
Interval Training and Hormones in Chronic Heart Failure;
ODM derived from:
https://clinicaltrials.gov/show/NCT02322034
All rights reserved. Please visit https://medical-data-
models.org/forms/14910
Eligibility Chronic Heart Failure
NCT02322034
Inclusion Criteria
stable new york heart association (nyha) class ii
or iii*
Yes
No
resting left ventricular ejection fraction below
40%*
Yes
No
measured peak vo2 below 14 ml/kg/min [patients
must be stable on prescribed cardiac medication
for 1 month prior to entering the study]*
Yes
No
Exclusion Criteria
myocardial infarction within 12 months prior to
study entry;*
Yes
No
unstable angina; resting systolic blood pressure
above 200 mmhg, or diastolic blood pressure
above 110 mmhg;*
Yes
No
fever of unknown significance;*
Yes
No
critical aortic stenosis (peak systolic pressure
gradient > 50 mm hg with an aortic valve orifice
area < 0.75 cm2 in average size adult);*
Yes
No
uncontrolled atrial or ventricular arrhythmias such
as uncontrolled sinus tachycardia (> 120
beats.min-1);*
Yes
No
ii or greater atrio-ventricular block;*
Yes
No
active pericarditis or myocarditis;*
Yes
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No
recent embolism and thrombophlebitis;*
Yes
No
uncontrolled diabetes hba1c%>9.5%;*
Yes
No
severe orthopedic or other medical conditions
that would prohibit exercise;*
Yes
No
metabolic conditions such as acute thyroiditis,
hypokalemia or hyperkalemia and hypovolemia;*
Yes
No
severe renal dysfunction (i.e. creatinine plasma
levels >2.5 mg/dl);*
Yes
No
severe concomitant non-cardiac diseases such
as cancer, dementia or any systemic disease
limiting exercise;*
Yes
No
inability to participate in a prospective study for
any logistic reason*
Yes
No
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Eligibility Chronic Hepatitis C
NCT02250807
Efficacy and Safety Study of Simeprevir in Combination
With Sofosbuvir in Subjects With Chronic Genotype 4
Hepatitis C Virus Infection; ODM derived from:
https://clinicaltrials.gov/show/NCT02250807
All rights reserved. Please visit https://medical-data-
models.org/forms/14911
Eligibility Chronic Hepatitis C
NCT02250807
Inclusion Criteria
subjects with confirmed hepatitis c virus (hcv)
with hcv rna greater than (>) 10000 international
unit per milliliter (iu/ml)*
Yes
No
subjects who are treatment naive or treatment-
experienced.*
Yes
No
subjects must have documentation of a liver
biopsy or fibroscan or agree to have one during
screening*
Yes
No
subjects with cirrhosis must have an hepatic
imaging procedure (ultrasound, ct scan or
magnetic resonance imaging [mri]) within 6
months before the screening visit (or during the
screening period) with no findings suspicious for
hepatocellular carcinoma (hcc)*
Yes
No
women of childbearing potential or men with a
female partner of childbearing potential must
agree to use an effective form of contraception, or
not be heterosexually active, or of
nonchildbearing potential*
Yes
No
Exclusion Criteria
evidence of clinical hepatic decompensation*
Yes
No
any liver disease of non-hcv etiology*
Yes
No
subjects with a past history of treatment with an
approved or investigational daa*
Yes
No
co-infection with human immunodeficiency virus
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(hiv) type 1 or type 2 (hiv-1 or hiv-2) (positive hiv-
1 or hiv-2 antibodies test at screening)*
Yes
No
infection/co-infection with hcv non-genotype 4*
Yes
No
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Eligibility Chronic Kidney Disease
NCT02258074
The COMBINE Study: The CKD Optimal Management With
BInders and NicotinamidE; ODM derived from:
https://clinicaltrials.gov/show/NCT02258074
All rights reserved. Please visit https://medical-data-
models.org/forms/14912
Eligibility Chronic Kidney Disease
NCT02258074
Inclusion Criteria
1. patients with estimated glomerular filtration
rate (egfr) 20-45 ml/min/1.73m2*
Yes
No
2. age 18-85 years*
Yes
No
3. serum phosphate ≥ 2.8 mg/dl*
Yes
No
4. platelet count ≥ 125,000/mm3*
Yes
No
5. able to provide consent*
Yes
No
6. able to travel to study visits*
Yes
No
7. able to eat at least two meals a day*
Yes
No
8. in the opinion of the site investigator, willing
and able to follow the study treatment regimen
and comply with the site investigator's
recommendations.*
Yes
No
Exclusion Criteria
1. history of allergic reaction to nicotinamide,
niacin (excluding flushing), multivitamin
preparations, or lanthanum carbonate*
Yes
No
2. liver disease, defined as known cirrhosis by
imaging or physician diagnosis, documented
alcohol use > 14 drinks/week, or aspartate
aminotransferase (ast), alanine aminotransferase
(alt), alkaline phosphatase, or total bilirubin
concentrations > 2 times the upper limit of the
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local laboratory reference range*
Yes
No
3. creatine kinase (ck) concentrations > 2 times
the upper limit of the local laboratory reference
range*
Yes
No
4. major hemorrhagic event within the past six
months requiring in-patient admission*
Yes
No
5. blood or platelet transfusion within the past six
months*
Yes
No
6. secondary hyperparathyroidism (pth > 5 times
the upper limit of normal range for the laboratory)
or currently taking cinacalcet (sensipar)*
Yes
No
7. current, clinically significant malabsorption, as
determined at the discretion of the site
investigator*
Yes
No
8. anemia (screening hg < 9.0 g/dl)*
Yes
No
9. serum albumin < 2.5 mg/dl*
Yes
No
10. anticipated initiation of dialysis or kidney
transplantation within 12 months as assessed by
and at the discretion of the site investigator.*
Yes
No
11. use of immunosuppressive medications
(stable oral steroids ≤ 10 mg of prednisone/day or
inhaled steroids are exempted)*
Yes
No
12. in the opinion of the site investigator, active
abuse of alcohol or drugs*
Yes
No
13. recent (within the last 14 days) initiation or
change in dose of treatment with 1,25 (oh)2
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vitamin d or active vitamin d analogues
(paricalcitol or hectorol).  patients on stable
doses of these agents initiated more than 14
days prior to screening are eligible to participate.*
Yes
No
14. current or recent treatment (within the last 14
days) with phosphate binder or
niacin/nicotinamide > 100 mg/day*
Yes
No
15. current participation in another clinical trial or
other interventional research*
Yes
No
16. currently taking investigational drugs*
Yes
No
17. institutionalized individuals, including
prisoners and nursing home residents*
Yes
No
18. malignancy requiring therapy within 2 years
(basal or squamous cell skin carcinoma and
localized prostate cancer are exempted)*
Yes
No
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Eligibility Chronic Kidney Disease
NCT02266823
Diabetes CKD Lifestyle Technology Study; ODM derived
from: https://clinicaltrials.gov/show/NCT02266823
All rights reserved. Please visit https://medical-data-
models.org/forms/14913
Eligibility Chronic Kidney Disease
NCT02266823
Inclusion Criteria
in order to be eligible for the study, the individual
must be 40 years of age or older; have a drg
code of t2dm, gfr of 15-89 ml/min/1.73m2 and a
bmi >30 kg/m2. the participant's physician of
record will have verified that his/her patient can
safely participant in an intervention study that
involves weight loss and a goal of 150
minutes/week of moderate physical activity
(comparable to brisk walking).*
Yes
No
Exclusion Criteria
those with the following characteristics will be
excluded by the investigators:*
Yes
No
1. unable or unwilling to provide informed
consent; (2) unable to participate meaningfully in
an intervention that involves group sessions (e.g.,
due to uncorrected hearing impairment, non-
english-speaking); (3) unable to read or otherwise
use an ipad to monitor dietary intake, physical
activity, and weight (e.g., blind, illiterate);  (4)
unwilling to accept randomization assignment; (5)
pregnant, or plans to become pregnant in the
next 12 months, less than 3 months postpartum,
or nursing or within 6 weeks of having completed
nursing; (6) weight loss of > 10% in the past 6
months except for postpartum weight loss; and
(7) individuals who are institutionalized (e.g., in a
nursing home or personal care facility, or those
who are incarcerated and have no control over
their diet).*
Yes
No
will exclude from the study those with underlying
diseases which would increase the risk of
participating in an intervention involving caloric
restriction and physical activity. such individuals
would include those requiring treatment for
cancer, exclusive of skin cancer other than
melanoma, in the past 2 years; infectious
diseases including untreated aids and active
tuberculosis; uncontrolled hypertension of >190
mmhg sbp or >105 mmhg dbp despite treatment;
stroke or tia in the past 6 months; conditions
requiring the use of home oxygen; or other
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chronic disease or condition likely to limit life
span to < 1 year. a recent institute of medicine
report suggests that reducing dietary sodium
below 1,840 mg/day in those with mid- to late-
stage heart failure may increase adverse events
or mortality.  thus investigators will exclude those
with heart failure.*
Yes
No
because of the dietary requirements of a
pregnant woman, and the nature of weight loss
and gain with pregnancy, inclusion of pregnant
women in the study would confound the study
results. those who become pregnant during the
study will be withdrawn from the study.*
Yes
No
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Eligibility Chronic Kidney Disease
NCT02342639
Rifaximin Therapy in Chronic Kidney Disease; ODM
derived from: https://clinicaltrials.gov/show/NCT02342639
All rights reserved. Please visit https://medical-data-
models.org/forms/14914
Eligibility Chronic Kidney Disease
NCT02342639
Inclusion Criteria
chronic kidney disease with egfr ≤ 39
ml/min/1.73m2*
Yes
No
Exclusion Criteria
patients with normal renal function or those with
less advanced kidney disease*
Yes
No
inability or unwillingness to provide consent*
Yes
No
patients undergoing hemodialysis or peritoneal
dialysis therapy or those who have undergone
organ transplant*
Yes
No
patients who may be pregnant*
Yes
No
hemodynamically unstable patients*
Yes
No
patients with liver failure, pancreatic insufficiency,
or inflammatory bowel disease*
Yes
No
patients with ongoing or recent infection and
those with history of c-diff infection*
Yes
No
patients with abnormal bowel structure secondary
to surgical or anatomic variations*
Yes
No
patients on certain medications including
immunosuppressants, antidiarrheal agents, bile
acid sequestrants and current or recent (within
the last 3 months) use of antibiotics*
Yes
No
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NCT02351349
Frail Elderlies With CKD; ODM derived from:
https://clinicaltrials.gov/show/NCT02351349
All rights reserved. Please visit https://medical-data-
models.org/forms/14915
Eligibility Chronic Kidney Disease
NCT02351349
Inclusion Criteria
eligible participants must be ≥65 years as of
december 2014, with estimated glomerular
filtration rate (egfr) of ≤30ml/min, and
experiencing frailty defined as 3 out of 5 criterias:
unintentional weight loss (self-reported or january
11, 2015 revised objective 10 lbs in past year)*
Yes
No
self-reported exhaustion*
Yes
No
weakness (measured by grip strength)*
Yes
No
slow walking speed (measured by the 6 minute
walking test)*
Yes
No
low physical activity.*
Yes
No
Exclusion Criteria
exclusion criteria are: persons aged <65*
Yes
No
unable to grasp dynamometer due to various
reasons*
Yes
No
expected life expectancy <6 months due to a
non-renal cause*
Yes
No
patient refusal to participate*
Yes
No
plan to travel or transfer treatment site during
study period and unable to be contacted*
Yes
No
1 / 2
severe cognitive impairment (as screened with
moca <18).*
Yes
No
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Eligibility Chronic Kidney Disease
NCT02364648
Mitochondrial Oxidative Stress and Vascular Health in
Chronic Kidney Disease; ODM derived from:
https://clinicaltrials.gov/show/NCT02364648
All rights reserved. Please visit https://medical-data-
models.org/forms/14916
Eligibility Chronic Kidney Disease
NCT02364648
Inclusion Criteria
stage 3 - 5 chronic kidney disease*
Yes
No
Exclusion Criteria
history of cardiovascular disease;*
Yes
No
current pregnancy;*
Yes
No
uncontrolled hypertension;*
Yes
No
uncontrolled hyperlipidemia;*
Yes
No
current hormone replacement therapy;*
Yes
No
current use of tobacco products;*
Yes
No
elevated liver enzymes;*
Yes
No
current autoimmune disease;*
Yes
No
daily use of of antioxidants >300mg*
Yes
No
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NCT02427594
Acid-Base Compensation in Chronic Kidney Disease; ODM
derived from: https://clinicaltrials.gov/show/NCT02427594
All rights reserved. Please visit https://medical-data-
models.org/forms/14917
Eligibility Chronic Kidney Disease
NCT02427594
Inclusion Criteria
estimated glomerular filtration rate ≥45
ml/min/1.73m2*
Yes
No
serum bicarbonate 22-28 meq/l*
Yes
No
Exclusion Criteria
diabetes mellitus*
Yes
No
uncontrolled hypertension or recent (<3 weeks)
titration of blood pressure medications*
Yes
No
clinically significant volume overload on
screening physical examination*
Yes
No
selected medical conditions other than kidney
disease and hypertension (active cancer, chronic
liver failure, moderate to severe copd, new york
heart association class 2 or greater congestive
heart failure, obstructive sleep apnea requiring
nightly continuous positive airway pressure)*
Yes
No
use of alkali supplementation*
Yes
No
body mass index <18.5 or >40 kg/m2*
Yes
No
ideal body weight <45.5 kg*
Yes
No
anemia at screening (hematocrit <29% in
participants with kidney disease or <33% in
healthy participants)*
Yes
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No
use of alkali supplements*
Yes
No
pregnancy or breastfeeding*
Yes
No
allergy or intolerance of study foods or
supplements*
Yes
No
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Eligibility Chronic Kidney Diseases
NCT02370069
The Effect of Previous Pneumococcal Immunization on the
Immune Response of Patients With Severe CKD to Prevnar
13; ODM derived from:
https://clinicaltrials.gov/show/NCT02370069
All rights reserved. Please visit https://medical-data-
models.org/forms/14918
Eligibility Chronic Kidney Diseases
NCT02370069
Inclusion Criteria
males and females of 18 years of age or older at
the time of the vaccination*
Yes
No
severe chronic kidney disease (stage 4 and 5)*
Yes
No
Exclusion Criteria
immunization with ppv23 within the last year*
Yes
No
any confirmed or suspected immunodeficiency
condition, including human immunodeficiency
virus (hiv) infection, haematological malignancy,
or a congenital immunodeficiency*
Yes
No
history of allergic disease or reactions likely to be
exacerbated by any component of the vaccine*
Yes
No
history of allergic disease likely to be stimulated
by the vaccination*
Yes
No
history or records of immunosuppressive therapy
(with the exception of topical corticosteroids) for
more than 14 days and within 6 months of
vaccination*
Yes
No
history or evidence of administration of
immunoglobulins and/or any blood products
during the study period or within the three months
preceding the study vaccine*
Yes
No
use of any other investigational or non-registered
drug or vaccine during the study period or within
30 days preceding the study vaccine*
Yes
1 / 2
No
administration of a vaccine during the period
starting one month before the dose of vaccine
and ending one month after*
Yes
No
pregnancy*
Yes
No
2 / 2
Eligibility Chronic Kidney Diseases NCT02370069
Eligibility Chronic Lymphocytic Leukaemia
(CLL) NCT02273856
Multicentre Registry of Treatments and Outcomes in
Patients With Chronic Lymphocytic Leukaemia (CLL) Or
Indolent Non Hodgkin's Lymphoma (iNHL); ODM derived
from: https://clinicaltrials.gov/show/NCT02273856
All rights reserved. Please visit https://medical-data-
models.org/forms/14919
Eligibility Chronic Lymphocytic
Leukaemia (CLL) NCT02273856
Inclusion Criteria
informed consent*
Yes
No
cll patients or*
Yes
No
inhl patients*
Yes
No
clinical decision made to initiate or adapt
treatment of cll/inhl("need to treat")*
Yes
No
Exclusion Criteria
patient deemed unfit for enrollment by the
documented opinion of the investigator*
Yes
No
watch and wait patients*
Yes
No
richter's transformation*
Yes
No
patients otherwise not eligible for
(pharmacological) intervention*
Yes
No
moribund patients*
Yes
No
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Vaccine Administration Safety and Immunogenicity Study of a Booster Dose of
GSK Biologicals 10-valent Pneumococcal Conjugate Vaccine NCT00370396
This study will evaluate the safety, reactogenicity and
immunogenicity of a booster dose of GSK Biologicals'
pneumococcal conjugate vaccine compared to Prevenar™
given at 12-18 mo of age to children primed with either
pneumococcal vaccine or Prevenar™ in study 105553.
Antibody persistence will be evaluated at 8-14 mo after
completion of the 3-dose immunization course in study
105553. The immune response to a booster dose of GSK
Biologicals' pneumococcal conjugate vaccine will also be
evaluated when given at 12-18 mo to subjects not primed
with GSK Biologicals' vaccine but with Prevenar™.
The study has 3 groups. 1 group of children primed with
GSK Biologicals' pneumococcal conjugate vaccine will
receive a booster dose of the same vaccine. 2nd group of
children primed with Prevenar™ will receive a booster dose
of Prevenar™ (control group). 3rd group of children primed
with Prevenar™ will receive a booster dose of GSK
Biologicals' pneumococcal conjugate vaccine. All children
will receive concomitantly a booster dose of DTPa-HBV-
IPV/Hib vaccine.
NCT00370396
Part: Vaccine administration
All rights reserved. Please visit https://medical-data-
models.org/forms/14924
Vaccine Administration "Safety and
Immunogenicity Study of a Booster
Dose of GSK Biologicals' 10-valent
Pneumococcal Conjugate Vaccine"
NCT00370396
Identification
Center number
Subject ID
Treatment Number
Visit Number
1 (1)
2 (2)
Vaccine Administration Meta
Vaccine Administratrion Date
Pre-Vaccination temperature
Pre-Vaccination Temperature Route of
Measurement
Axillary (A)
Oral (O)
Rectal (R)
Tympanic (oral conversion) (X)
Tympanic (rectal conversion) (Y)
Vaccine Administration Details: 10Pn-PD-
DiT Vaccine OR Prevenar Vaccine
1 / 3
Vaccine Administration
Not administered (N)
Replacement vial  (R)
10Pn-PD-DiT Vaccine OR Prevenar
Vaccine (S)
Wrong vial number (W)
Replacement vial Number
Wrong vial number
Side / Route Site
deltoid (1)
thigh (3)
Has the study vaccine been administered
according to protocol?
Yes
No
Injection side
Left  (L)
Right (R)
Injection site
deltoid (1)
thigh (3)
buttock (6)
Injection Route
I.M. (im)
S.C. (sc)
Vaccine Administration Details: DTPa-
HBV-IPV/Hib Vaccine
Vaccine Administration
Not administered (N)
Replacement vial  (R)
DTPa-HBV-IPV/Hib Vaccine (S)
Wrong vial number (W)
Replacement vial Number
Wrong vial number
Side / Route Site
deltoid (1)
thigh (3)
Has the study vaccine been administered
according to protocol?
Yes
No
Injection side
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GSK Biologicals 10-valent Pneumococcal Conjugate Vaccine NCT00370396
Left  (L)
Right (R)
Injection site
deltoid (1)
thigh (3)
buttock (6)
Injection Route
I.M. (im)
S.C. (sc)
Non Administration
Why not administered
Non-Serious adverse event (AEX)
Other (OTH)
Serious adverse event (SAE)
Number of serious adverse event
Number of non-serious adverse event
Description of other adverse event
Who made the decision
Investigator  (I)
Parents/Guardians (P)
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Vaccine Administration Safety and Immunogenicity Study of a Booster Dose of
GSK Biologicals 10-valent Pneumococcal Conjugate Vaccine NCT00370396
Adverse Events Safety and Immunogenicity Study of a Booster Dose of GSK
Biologicals 10-valent Pneumococcal Conjugate Vaccine NCT00370396
This study will evaluate the safety, reactogenicity and
immunogenicity of a booster dose of GSK Biologicals'
pneumococcal conjugate vaccine compared to Prevenar™
given at 12-18 mo of age to children primed with either
pneumococcal vaccine or Prevenar™ in study 105553.
Antibody persistence will be evaluated at 8-14 mo after
completion of the 3-dose immunization course in study
105553. The immune response to a booster dose of GSK
Biologicals' pneumococcal conjugate vaccine will also be
evaluated when given at 12-18 mo to subjects not primed
with GSK Biologicals' vaccine but with Prevenar™.
The study has 3 groups. 1 group of children primed with
GSK Biologicals' pneumococcal conjugate vaccine will
receive a booster dose of the same vaccine. 2nd group of
children primed with Prevenar™ will receive a booster dose
of Prevenar™ (control group). 3rd group of children primed
with Prevenar™ will receive a booster dose of GSK
Biologicals' pneumococcal conjugate vaccine. All children
will receive concomitantly a booster dose of DTPa-HBV-
IPV/Hib vaccine.
NCT00370396
Part: Adverse Events
All rights reserved. Please visit https://medical-data-
models.org/forms/14926
Adverse Events "Safety and
Immunogenicity Study of a Booster
Dose of GSK Biologicals' 10-valent
Pneumococcal Conjugate Vaccine"
NCT00370396
Identification
Center number
Subject ID
Treatment Number
Visit Number
1 (1)
2 (2)
Local Symptoms
Type of Vaccine Administered
10Pn-PD-DiT or Prevenar vaccine (1)
DTPa-HBV-IPV/Hib vaccine (2)
Local Symptoms
No  (N)
No vaccine administered (NA)
Information not available  (U)
Yes (Y)
Type of symptoms
Pain (PA)
Redness (RE)
Swelling (SW)
Size/Intensity Day 0
1 / 3
Size/Intensity Day 1
Size/Intensity Day 2
Size/Intensity Day 3
Ongoing after Day 3
Yes
No
Date of last day of symptoms
Medically attended
visit
Yes
No
Facility of Medical Attendance
Emergency Room (ER)
Hospitalization (HO)
Medical Personnel (MD)
General Symptoms
Has the subject experienced any of the following
signs/symptoms during the solicited period
No (N)
No Vaccine administered (NA)
Information not available (U)
Yes (Y)
General Symptoms specification
General Symptom
Drowsiness (DR)
Fever (FE)
Irritablity/Fussiness (IR)
Loss of appetite (LO)
Fever Measuring Route
Axillary  (A)
Oral (O)
Rectal (R)
Tympanic Oral (X)
Tympanic Rectal (Y)
Intensity/°C Day 0
Intensity/°C Day 1
Intensity/°C Day 2
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Intensity/°C Day 0
Ongiong after Day 3
Date of last day of symptoms
Casualty
Yes
No
Medically Attended visit
Yes
No
Visited Facility
Emergency Room (ER)
Hospitalization (HO)
Medical Personnel (MD)
Unsolicited Adverse Events
Has the subject experienced any serious or non-
serious unsolicited adverse events within one
month
(minimum 30 days) post-vaccination
No (N)
No vaccine administered (NA)
Information not available (U)
Yes (Y)
Has the subject experienced any meningitis ?
Yes
No
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Adverse Events Safety and Immunogenicity Study of a Booster Dose of GSK
Biologicals 10-valent Pneumococcal Conjugate Vaccine NCT00370396
Check for Study Continuation Safety and Immunogenicity Study of a Booster Dose
of GSK Biologicals 10-valent Pneumococcal Conjugate Vaccine NCT00370396
This study will evaluate the safety, reactogenicity and
immunogenicity of a booster dose of GSK Biologicals'
pneumococcal conjugate vaccine compared to Prevenar™
given at 12-18 mo of age to children primed with either
pneumococcal vaccine or Prevenar™ in study 105553.
Antibody persistence will be evaluated at 8-14 mo after
completion of the 3-dose immunization course in study
105553. The immune response to a booster dose of GSK
Biologicals' pneumococcal conjugate vaccine will also be
evaluated when given at 12-18 mo to subjects not primed
with GSK Biologicals' vaccine but with Prevenar™.
The study has 3 groups. 1 group of children primed with
GSK Biologicals' pneumococcal conjugate vaccine will
receive a booster dose of the same vaccine. 2nd group of
children primed with Prevenar™ will receive a booster dose
of Prevenar™ (control group). 3rd group of children primed
with Prevenar™ will receive a booster dose of GSK
Biologicals' pneumococcal conjugate vaccine. All children
will receive concomitantly a booster dose of DTPa-HBV-
IPV/Hib vaccine.
NCT00370396
Part: Check for Study Continuation
All rights reserved. Please visit https://medical-data-
models.org/forms/14928
Check for Study Continuation "Safety
and Immunogenicity Study of a
Booster Dose of GSK Biologicals'
10-valent Pneumococcal Conjugate
Vaccine" NCT00370396
Identification
Center number
Subject ID
Treatment Number
Visit Number
1 (1)
2 (2)
Check for Study Continuation
Did the subject return for visit 2
Yes
No
most appropriate reason
Non-Serious adverse event (AEX)
Other (OTH)
Serious adverse event (SAE)
Code of SAE,AE or solicited AE
Who made the decision
Investigator (I)
Parents/Guardians (P)
1 / 2
Laboratory Tests:Blood Sample
Has a Blood Sample been taken
Yes
No
Date of sample
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Check for Study Continuation Safety and Immunogenicity Study of a Booster Dose
of GSK Biologicals 10-valent Pneumococcal Conjugate Vaccine NCT00370396
HR-1 therapy documentation AIEOP-BFM
ALL 2009 NCT01117441
International Collaborative Treatment Protocol For Children
And Adolescents With Acute Lymphoblastic Leukemia.
Phase 3 Study.
Documentation part.
Clinical Trial Number: NCT01117441.
All rights reserved. Please visit https://medical-data-
models.org/forms/14930
HR-1 therapy documentation AIEOP-
BFM ALL 2009 NCT01117441
Patient Information
Stud.-Nr. (Pat.-ID)
Patient date of birth
Body weight
kg
Body height
cm
Body surface
mˆ2
Chemotherapy Regimen
Dexamethasone 
administration form
i.v. (i.v.)
p.o (p.o)
Dexamethasone dosage
20 mg/mˆ2/d
mg
Dexamethasone
Date of administration
VCR
administration form
i.v.
Yes
No
VCR dosage
(max. 2 mg)
1,5 mg/mˆ2/ED
mg
VCR
Date of administration
ARA-C 
administration form
1 / 4
p.i. (3h)
Yes
No
ARA-C dosage
2000 mg/mˆ2/ED
mg
ARA-C
Date of administration
HD-MTX 
administration form
p.i. (24h)
(10% in 0,5 h, 90% in 23,5h)
Yes
No
HD-MTX dosage
5000 mg/ˆ2
mg
HD-MTX 
Date of administration
LCV-Rescue 
administration form
i.v.
Yes
No
LCV-rescue dosage
15 mg/ˆ2
mg/ED
LCV-rescue 
Date of administration
(at hour 42, 48, 54)
CPM 
administration form
p.i. (1h)
(with MESNA: 70 mg/ˆ2 at hour 0, 4 and 8 of
CPM-infusion regimen)
Yes
No
CPM dosage
200 mg/mˆ2/ED
mg
CPM
Date of administration
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PEG-L-ASP 
administration form
p.i. (2h)
Yes
No
PEG-L-ASP dosage
2500 mg/mˆ2/ED
(ONCASPAR: 3750 E/ED)
E
PEG-L-ASP
Date of administration
MTX
administration form
i.th
Yes
No
MTX dosage
(Age-dependent:
1 - < 2 y/o: 8 mg
2 - < 3y/o: 10 mg
>= 3 y/o: 12 mg
mg
MTX 
Date of administration
(while MTX infusion)
PEG-L-ASP/ Erwinase
Change from PEG-L-ASP to Erwinase in this
element
Yes
No
If "yes", specify:
Erwinase: 
date of first administration
If "yes", specify: 
Erwinase: date of last administration
If "yes", specify:
Numbers of Erwinase doses
If "yes", specify: 
Reason for change to erwinase:
Hypersensitivity
Yes
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No
If "yes", specify: 
Reason for change to erwinase:
Date of allergic reaction
If "yes", specify: 
Reason for change to erwinase: 
Other reason
Identification and Signature
Date and signature of the doctor who calculated
and created chemotherapy regimen
Date and signature of the person who
administered chemotherapy
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HR-2 therapy documentation AIEOP-BFM
ALL 2009 NCT01117441
International Collaborative Treatment Protocol For Children
And Adolescents With Acute Lymphoblastic Leukemia.
Phase 3 Study.
Documentation part.
Clinical Trial Number: NCT01117441.
All rights reserved. Please visit https://medical-data-
models.org/forms/14931
HR-2 therapy documentation AIEOP-
BFM ALL 2009 NCT01117441
Patient Information
Stud.-Nr. (Pat.-ID)
Patient date of birth
Body weight
kg
Body height
cm
Body surface
mˆ2
Chemotherapy Regimen
Dexamethasone 
administration form
i.v. (i.v.)
p.o (p.o)
Dexamethasone dosage
20 mg/mˆ2/d
mg
Dexamethasone
Date of administration
VDS
administration form
i.v.
Yes
No
VDS dosage
(max. 5 mg)
3 mg/mˆ2/ED
mg
VDS
Date of administration
DNR
administration form
1 / 4
p.i. (24h)
Yes
No
DNR dosage
30 mg/mˆ2/ED
mg
DNR
Date of administration
HD-MTX 
administration form
p.i. (24h)
(10% in 0,5 h, 90% in 23,5h)
Yes
No
HD-MTX dosage
5000 mg/ˆ2
mg
HD-MTX 
Date of administration
LCV-Rescue 
administration form
i.v.
Yes
No
LCV-rescue dosage
15 mg/ˆ2
mg/ED
LCV-rescue 
Date of administration
(at hour 42, 48, 54)
CPM 
administration form
p.i. (1h)
Yes
No
IFO dosage
800 mg/mˆ2/ED
(with MESNA: 300 mg/mˆ2 at hour 0, 4 and 8 of
IFO infusion)
mg
IFO
Date of administration
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PEG-L-ASP 
administration form
p.i. (2h)
Yes
No
PEG-L-ASP dosage
2500 mg/mˆ2/ED
(ONCASPAR: 3750 E/ED)
E
PEG-L-ASP
Date of administration
MTX
administration form
i.th
Yes
No
MTX dosage
(Age-dependent:
1 - < 2 y/o: 8 mg
2 - < 3y/o: 10 mg
>= 3 y/o: 12 mg
mg
MTX 
Date of administration
(while MTX infusion)
If CNS leukemia, extra MTX dose (while MTX
infusion):
Date of administration
PEG-L-ASP/ Erwinase
Change from PEG-L-ASP to Erwinase in this
element
Yes
No
If "yes", specify:
Erwinase: 
date of first administration
If "yes", specify: 
Erwinase: date of last administration
If "yes", specify:
Numbers of Erwinase doses
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If "yes", specify: 
Reason for change to erwinase:
Hypersensitivity
Yes
No
If "yes", specify: 
Reason for change to erwinase:
Date of allergic reaction
If "yes", specify: 
Reason for change to erwinase: 
Other reason
Identification and Signature
Date and signature of the doctor who calculated
and created chemotherapy regimen
Date and signature of the person who
administered chemotherapy
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HR-3 therapy documentation AIEOP-BFM
ALL 2009 NCT01117441
International Collaborative Treatment Protocol For Children
And Adolescents With Acute Lymphoblastic Leukemia.
Phase 3 Study.
Documentation part.
Clinical Trial Number: NCT01117441.
All rights reserved. Please visit https://medical-data-
models.org/forms/14932
HR-3 therapy documentation AIEOP-
BFM ALL 2009 NCT01117441
Patient Information
Stud.-Nr. (Pat.-ID)
Patient date of birth
Body weight
kg
Body height
cm
Body surface
mˆ2
Chemotherapy Regimen
Dexamethasone 
administration form
i.v. (i.v.)
p.o (p.o)
Dexamethasone dosage
20 mg/mˆ2/d
mg
Dexamethasone
Date of administration
ARA-C 
administration form
p.i. (3h)
Yes
No
ARA-C dosage
2000 mg/mˆ2/ED
mg
ARA-C
Date of administration
VP-16
administration form
p.i. (1h)
1 / 3
(with MESNA: 70 mg/ˆ2 at hour 0, 4 and 8 of
CPM-infusion regimen)
Yes
No
VP-16 dosage
200 mg/mˆ2/ED
mg
VP-16
Date of administration
PEG-L-ASP 
administration form
p.i. (2h)
Yes
No
PEG-L-ASP dosage
2500 mg/mˆ2/ED
(ONCASPAR: 3750 E/ED)
E
PEG-L-ASP
Date of administration
MTX
administration form
i.th
Yes
No
MTX dosage
(Age-dependent:
1 - < 2 y/o: 8 mg
2 - < 3y/o: 10 mg
>= 3 y/o: 12 mg
mg
MTX 
Date of administration
PEG-L-ASP/ Erwinase
Change from PEG-L-ASP to Erwinase in this
element
Yes
No
If "yes", specify:
Erwinase: 
date of first administration
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If "yes", specify: 
Erwinase: date of last administration
If "yes", specify:
Numbers of Erwinase doses
If "yes", specify: 
Reason for change to erwinase:
Hypersensitivity
Yes
No
If "yes", specify: 
Reason for change to erwinase:
Date of allergic reaction
If "yes", specify: 
Reason for change to erwinase: 
Other reason
Identification and Signature
Date and signature of the doctor who calculated
and created chemotherapy regimen
Date and signature of the person who
administered chemotherapy
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DNX-FLA regimen AIEOP-BFM ALL 2009
NCT01117441
International Collaborative Treatment Protocol For Children
And Adolescents With Acute Lymphoblastic Leukemia.
Phase 3 Study.
Documentation part.
Clinical Trial Number: NCT01117441.
All rights reserved. Please visit https://medical-data-
models.org/forms/14933
DNX-FLA regimen AIEOP-BFM ALL
2009 NCT01117441
Patient Information
Stud.-Nr. (Pat.-ID)
Patient date of birth
Body weight
kg
Body height
cm
Body surface
mˆ2
Chemotherapy Regimen
Fludarabine
administration form
p.i. (30 min)
Yes
No
Fludarabine dosage
30 mg/mˆ2/ED
mg
Fludarabine
Date of administration
ARA-C 
administration form
p.i. (3h) (at least 4h after finishing fludarabine-
infusion)
Yes
No
ARA-C dosage
2000 mg/mˆ2/ED
mg
ARA-C
Date of administration
Daunoxome
1 / 2
administration form
p.i. (1h)
Yes
No
Daunoxome dosage
60 mg/mˆ2/ED
mg
Daunoxome
Date of administration
MTX
administration form
i.th
Yes
No
MTX dosage
(Age-dependent:
1 - < 2 y/o: 8 mg
2 - < 3y/o: 10 mg
>= 3 y/o: 12 mg
mg
MTX 
Date of administration
Identification and Signature
Date and signature of the doctor who calculated
and created chemotherapy regimen
Date and signature of the person who
administered chemotherapy
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Eligibility Chronic Lymphocytic Leukemia
NCT02144623
Pretreatment With Valproate Prior to Immunotherapy
Targeting Cluster of Differentiation Antigen 20 in Chronic
Lymphocytic Leukemia; ODM derived from:
https://clinicaltrials.gov/show/NCT02144623
All rights reserved. Please visit https://medical-data-
models.org/forms/14934
Eligibility Chronic Lymphocytic
Leukemia NCT02144623
Inclusion Criteria
age 18-80 years*
Yes
No
histologically confirmed chronic lymphocytic
leukemia*
Yes
No
leucocyte count more than 20 x 10 9/l*
Yes
No
no other simultaneous treatment for lymphoma*
Yes
No
no treatment indicated for chronic lymphocytic
leukemia*
Yes
No
who performance status 0-2*
Yes
No
hiv negativity*
Yes
No
negativity for hepatitis c virus , hbsag, anti-
hepatitis b core antigen, or other active infection
uncontrolled by treatment*
Yes
No
agree to abstain from donating blood while taking
study drug therapy and for one week following
discontinuation of study drug therapy*
Yes
No
agree not to share study medication with another
person and to return all unused study drug to the
investigator*
Yes
No
written informed concent*
Yes
No
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Exclusion Criteria
psychiatric illness or condition which could
interfere with the subjects' ability to understand
the requirements of the study*
Yes
No
neurological or neuropsychiatric disorder,
interfering with the requirements of the study*
Yes
No
hearing impairment over grade 2*
Yes
No
porphyria*
Yes
No
history of acute or chronic hepatitis*
Yes
No
family history of severe drug-induced hepatitis*
Yes
No
pregnancy and lactation*
Yes
No
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Case Report Form Day 5 MEDUSA project
The MEDUSA project (medical education for sepsis source
control and antibiotics) is a scientific study of the integrated
research and treatment center "Center for Sepsis Control
and Care" (CSCC) of the University Hospital Jena,
Thuringia, Germany.
Its aim is to investigate whether a multimodal and
interdisciplinary training concept for the early recognition
and standardized treatment of patients with sepsis
improves time to administration of first antibiotic and
survival of patients.
Original forms obtained from:
http://www.medusa.uniklinikum-
jena.de/Datenerfassung.html
All rights reserved. Please visit https://medical-data-
models.org/forms/14935
Diagnosis of blood culture report
form
Header module
Study Subject ID
document creator
Day 5 - general aspects of treatment
Was the diagnosis of sepsis confirmed?
Yes
No
Other causes for organ dysfunction
not applicable, becuase organ
dysfunction caused by sepsis (1)
cardiogenic shock  (2)
hemorrhagic shock (3)
hypovolaemia (4)
other cause (5)
unknown (6)
How was the diagnosis carried out?
microbiology procedure (1)
clinical criteria (2)
suspected infection (3)
Lactate at day 2
mmol/l
Procalcitonin at day 3
ng/ml
Procalcitonin at day 4
ng/ml
Procalcitonin at day 5
ng/ml
Blood culture results
1 / 3
Result of blood culture
positive (pathogen) (1)
positive (bacterial contamination) (2)
negative (3)
No blood culture (4)
unknown (5)
Identification of pathogenic agent
sensitive to treatment? (1)
Blood culture result from primary source
of infection
Blood culture result from primary source of
infection
positive (pathogen) (1)
positive (bacterial contamination, human
microbiome) (2)
negative (3)
no blood culture (4)
unknown (5)
Identification of pathogenic agent from primary
source of infection
Pathogen (1)
unknown (2)
Is the pathogen sensitive to antibiotics?
Yes
No
Therapy alterations within first five days of
treatment
Was the treatment changed within the first five
days?
Yes
No
Typ of therapy change: Enhancement
date of therapy enhancement (1)
clinical deterioration (2)
calculated enhancement without clinical
deterioration (3)
resistance oriented enhancement (4)
Therapy change: de-escalation
date of de-escalation (date of de-
escalation)
de-escalation in accordance with
resistance (de-escalation in accordance
with resitence)
Clinical outcome
Dialysis-dependent within first 14 days of
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treatment?
Yes
No
Day 28
Status at day 28
Deceased (1)
Survived (2)
Discharge from intensive care unit
Reason for discharge from intensive care unit
Date of discharge (1)
Survived (2)
Deceased (3)
Hospital discharge
Hospital discharge
Date (1)
Survived (2)
Deceased (3)
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Event recording AIEOP-BFM ALL 2009
NCT01117441
International Collaborative Treatment Protocol For Children
And Adolescents With Acute Lymphoblastic Leukemia.
Phase 3 Study.
Event Recording. All events have to be reported to the
study centre within two weeks after event.
Clinical Trial Number: NCT01117441.
All rights reserved. Please visit https://medical-data-
models.org/forms/14936
Event recording AIEOP-BFM ALL
2009 NCT01117441
Patient Information
Patient Study ID
Patient Initials
Patient birth date
Hospital (GCCR)
Malignancy identification (GCCR)
Patient Identification number 
(GHOP - Society for Paediatric Oncology and
Haematology)
Relapse
Date of relapse
Number of relapses
1st relapse (1st relapse)
2nd relapse (2nd relapse)
3rd relapse (3rd relapse)
4th relapse (4th relapse)
Site of relapse
Bone marrow (Bone marrow)
CNS (CNS)
Other (Other)
Testicles (Testicles)
Site of relapse
If other, specify:
Second neoplasms
Date of second neoplasm
Second neoplasms specification
ALCL (ALCL)
ALL (ALL)
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AML (AML)
B-ALL (B-ALL)
Brain tumour (Brain tumour)
Burkitt-Lymphoma (Burkitt-Lymphoma)
M. Hodgkin (M. Hodgkin)
MDS (MDS)
Other (Other)
Other solid tumour (Other solid tumour)
pB-LBL (pB-LBL)
T-LBL (T-LBL)
Second neoplasms: brain tumor
If the second neoplasm is a "brain tumor",
specify:
Second neoplasms: brain tumor 
If the second neoplasm is a "brain tumor",
specify:
benign (benign)
malignant (malignant)
Other second neoplasms
If the second neoplasm is "other", specify:
Other second neoplasms
If the second neoplasm is "other", specify:
benign (benign)
malignant (malignant)
Death
Date of death
Autopsy performed?
Yes
No
Cause of death
ALL after chemotherapy, before 1st CR
(ALL after chemotherapy, before 1st CR)
ALL before chemotherapy (ALL before
chemotherapy)
ALL/ therapy complication before 1st CR
(not decidable) (ALL/ therapy
complication before 1st CR (not
decidable))
Other (Other)
relapseor other complication of therapy
of relapse (relapseor other complication
of therapy of relapse)
SCT-associated complications (SCT-
associated complications)
Second neoplasm or complication of
therapy of relapse  (Second neoplasm or
complication of therapy of relapse )
Therapy complication before 1st CR
(Therapy complication before 1st CR)
Therapy complication in 1st CR (except
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after SCT) (Therapy complication in 1st
CR (except after SCT))
If cause of death is "Therapy complication before
1st CR", specify:
If cause of death is "ALL/ therapy complication
before 1st CR (not decidable)", specify:
If cause of death is "Therapy complication in 1st
CR", specify:
If cause of death is "SCT-associated
complication", specify:
If cause of death is "Other", specify:
Therapy discontinuation
Date of discontinuation
Discontinuation
Point of time within the protocol
Reason for discontinuation
Comments
Comments
Identification and Signature
Doctor's name
Date of report
Signature
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Eligibility Chronic Lymphocytic Leukemia
NCT02315768
Ibrutinib in Combination With GA101 (Obinutuzumab) in
Previously Untreated Chronic Lymphocytic Leukemia (CLL)
Patients.; ODM derived from:
https://clinicaltrials.gov/show/NCT02315768
All rights reserved. Please visit https://medical-data-
models.org/forms/14937
Eligibility Chronic Lymphocytic
Leukemia NCT02315768
Inclusion Criteria
1. diagnosis of cll*
Yes
No
2. indication for treatment as defined by the
international workshop on chronic lymphocytic
leukaemia  (iwcll) guidelines*
Yes
No
3. no previous treatment for cll*
Yes
No
4. males and females 65 years of age and older.
subjects over 65 years of age that meet any of
the following criteria:*
Yes
No
a. documented refusal to be treated with
chemotherapy agents b. subjects that are not
candidates for treatment with chemotherapy
based on poor performance status (ecog g>= 2),
cumulative illness rating scale (cirs score) >= 6 or
creatinine clearance less than 70 ml/min*
Yes
No
5. laboratory parameters as specified below:*
Yes
No
hematologic: hemoglobin > 8 g/dl (may be post-
transfusion); platelet count > 40 x103/mm3 (may
be post-transfusion). absolute neutrophil count >
1.0 109 cells/l (growth factor use is allowed)*
Yes
No
hepatic:  total bilirubin < 3 x uln, and alt and ast <
3 x uln*
Yes
No
renal: creatinine clearance > 30 ml/min
(calculated according to institutional standards or
using cockcroft-gault formula. subjects with
requirement of hemodialysis will be excluded)*
Yes
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No
6. anticipated survival of at least 6 months*
Yes
No
7. effective contraception is required while
receiving ibrutinib in combination with ga101-
obinutuzumab.  for women of childbearing
potential and men, effective contraception is
required while receiving ga101-obinutuzumab
and for 365 days (12 months) after the last dose
of the study drug*
Yes
No
Exclusion Criteria
1. pregnant or nursing women*
Yes
No
2. treatment with chemotherapy, monoclonal
antibodies, or biological agents (e.g.
lenalidomide) other than the investigational
agents during the time of participation in this trial*
Yes
No
3. grade 3 or 4 cardiac disease as defined by the
new york heart association functional
classification*
Yes
No
4. severe or debilitating pulmonary disease
(dyspnea at rest, significant shortness of breath,
copd)*
Yes
No
5. participation in any investigational drug study
within 28 days prior to initiation of treatment
within this protocol. (subject must have recovered
from all acute effects of previously administered
investigational agents)*
Yes
No
6. history of second malignancy, other than non-
melanoma skin cancer or in situ carcinoma of the
cervix or the breast, unless the tumor was
successfully treated at least 2 years before trial
entry and with no evidence of relapse or active
cancer.*
Yes
No
7. active symptomatic fungal, bacterial and/or
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viral infection including evidence of infection with
hiv, human t-cell leukemia virus 1 (htlv-1)
seropositive status.*
Yes
No
8. evidence of active acute or chronic hepatitis b
(hbv)*
Yes
No
9. evidence of active hepatitis c (hcv):  subjects
with positive hepatitis c serology and positive hcv
rna test*
Yes
No
10. history of severe allergic or anaphylactic
reactions to monoclonal antibody therapy*
Yes
No
11. known hypersensitivity to any of the study
drugs*
Yes
No
12. major surgery (within 4 weeks prior to the
start of cycle 1), except for procedures that are
performed for diagnostic purposes*
Yes
No
13. vaccination with a live vaccine within 28 days
of the initiation of treatment.*
Yes
No
14. concomitant use of warfarin or other vitamin k
antagonists*
Yes
No
15. requirement to receive treatment with a
strong cytochrome p450 (cyp) 3a inhibitor*
Yes
No
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Maintenance therapy R2 AIEOP-BFM ALL
2009 NCT01117441
International Collaborative Treatment Protocol For Children
And Adolescents With Acute Lymphoblastic Leukemia.
Phase 3 Study.
Documentation part.
Clinical Trial Number: NCT01117441.
All rights reserved. Please visit https://medical-data-
models.org/forms/14942
Maintenance therapy R2 AIEOP-
BFM ALL 2009 NCT01117441
Patient Information
Patient Study ID
Patient bith date
Examinations
Date of examination
White Blood Count
/μl
White Blood Count
Gpt/L
Neutrophil count
%
Lymphocyte count
%
Hemoglobin
g/dL
Hemoglobin
mmol/L
Platelet count
/μl
Weight
kg
Height
cm
Therapy start date
Therapy end date
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6-MP: Cumulative dose
(Given during the above mentioned period of
time)
mg
MTX: Cumulative dose
(Given during the above mentioned period of
time)
mg
Therapy pauses: number of days
(during the above mentioned period of time)
Comorbidity:
Infections, reasons to stop the therapy
Identification and Signature
Doctor's name
Date of report
Signature
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Eligibility Chronic Myeloid Leukemia
NCT02317159
Efficacy and Safety of Imatinib Mesylate as First-line
Treatment for the Patients With Chronic Phase of Chronic
Myeloid Leukemia; ODM derived from:
https://clinicaltrials.gov/show/NCT02317159
All rights reserved. Please visit https://medical-data-
models.org/forms/14944
Eligibility Chronic Myeloid Leukemia
NCT02317159
Inclusion Criteria
age≥18；*
Yes
No
the new diagnosis of cml patients in six months
；*
Yes
No
no proof of extra-medullary infiltration of
leukemia；*
Yes
No
ecog ps score：0-2；*
Yes
No
hepatic and renal functions are normal，serum
bilirubin≤1.5*uln, serum alt and ast≤2.5*uln,
serum cr≤1.5*uln;*
Yes
No
do not  receive the treatment of anti-cml；*
Yes
No
subjects signed informed consent form in line
with gcp requirements。*
Yes
No
Exclusion Criteria
pregnant or lactating women；*
Yes
No
received tkis any time before；*
Yes
No
failure to control systemic infection or multiple
organ failure；*
Yes
No
according to the investigator's judgment, there
are concomitant diseases with a serious safety
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hazard or affect the patients completed the
study；*
Yes
No
being diagnosed with other malignancies in the
prior 12 months；*
Yes
No
have a history of neurological or psychiatric
disorders, including epilepsy or dementia；*
Yes
No
known or suspected allergy to imatinib；*
Yes
No
bsa≤1.5m2；*
Yes
No
using other experimental drugs or participating in
other clinical trials in the prior one months。*
Yes
No
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Eligibility Chronic Schizophrenia
NCT02298985
Curcumin Addition to Antipsychotic Treatment in Chronic
Schizophrenia Patients; ODM derived from:
https://clinicaltrials.gov/show/NCT02298985
All rights reserved. Please visit https://medical-data-
models.org/forms/14952
Eligibility Chronic Schizophrenia
NCT02298985
Inclusion Criteria
age 18-60 years, male or female*
Yes
No
dsm-iv criteria for schizophrenia.*
Yes
No
ability and willingness to sign informed consent
for participation in the study*
Yes
No
sans (scale of negative symptoms of
schizophrenia ) > 30 points*
Yes
No
fixed antipsychotic dosages at least 3 months*
Yes
No
steady mental state of patients at least 3 months*
Yes
No
Exclusion Criteria
current substance use disorder except nicotine
dependence*
Yes
No
regular use of nsaid (non-steroidal anti-
inflammatory drugs)*
Yes
No
cancer history*
Yes
No
untreated or severe hypertension*
Yes
No
poorly controlled diabetes mellitus type i or type
ii*
Yes
No
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chronic liver & gallbladder diseases*
Yes
No
recent gerd (gastroesophageal reflux disorder)*
Yes
No
neurological disorders: epilepsy, stroke*
Yes
No
hamilton depression scale hamilton depression
rating scale (ham-d-17 item) > 24 points*
Yes
No
patients with a known hypersensitivity to
curcumin*
Yes
No
pregnant women or a woman who intends to
become pregnant*
Yes
No
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Eligibility Cirrhosis NCT02389127
Relationship Between HbA1c and Chronic Glycemia in
Patients With Cirrhosis; ODM derived from:
https://clinicaltrials.gov/show/NCT02389127
All rights reserved. Please visit https://medical-data-
models.org/forms/14953
Eligibility Cirrhosis NCT02389127
Inclusion Criteria
group a*
Yes
No
cirrhosis, either clinically- or biopsy-proven*
Yes
No
child-pugh-turcotte (ctp) a, b, and c (only biopsy-
proven in the case of ctp-a)*
Yes
No
random glucose <200 mg/dl on at least 3
occasions*
Yes
No
no use of insulin or any hypoglycemic agent*
Yes
No
group b*
Yes
No
cirrhosis, either clinically- or biopsy-proven*
Yes
No
child-pugh-turcotte (ctp) a, b, and c (only biopsy-
proven in the case of ctp-a)*
Yes
No
prior diagnosis of t2dm as based on any of ada
criteria*
Yes
No
use of insulin or any hypoglycemic agent*
Yes
No
Exclusion Criteria
hemoglobin <10 mg/dl*
Yes
No
any transfusional requirement within 3 months
before inclusion.*
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Yes
No
high-dose vitamin c*
Yes
No
cr ≥1.3*
Yes
No
hepatocellular carcinoma (any stage)*
Yes
No
any splanchnic thrombosis (portal, mesenteric, or
splenic)*
Yes
No
persistent or difficult-to-treat hepatic
encephalopathy*
Yes
No
refractory ascites*
Yes
No
status post-tips*
Yes
No
status post-liver transplant*
Yes
No
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Sepsis Case Report Form MEDUSA project
The MEDUSA project (medical education for sepsis source
control and antibiotics) is a scientific study of the integrated
research and treatment center "Center for Sepsis Control
and Care" (CSCC) of the University Hospital Jena,
Thuringia, Germany.
Its aim is to investigate whether a multimodal and
interdisciplinary training concept for the early recognition
and standardized treatment of patients with sepsis
improves time to administration of first antibiotic and
survival of patients.
Original forms obtained from:
http://www.medusa.uniklinikum-
jena.de/Datenerfassung.html
All rights reserved. Please visit https://medical-data-
models.org/forms/14954
SAPS II- Score Report Form
Header module
Study Subject ID
document creator
SAPS II- Score
Chronic disease
metastatic cancer (1)
Hematologic Neoplasms  (2)
AIDS (3)
none (4)
Systolic blood pressure
mmHg
<70 mmHg (1)
70 – 99 mmHg (2)
100 – 199 mmHg (3)
≥ 200 mmHg (4)
Urea
mg/dl
Potassium
mmol/l
< 3,0 (1)
3 – 4,9 (2)
≥ 5,0 (3)
Sodium
mmol/l
< 125 (1)
125 – 144 (2)
≥ 145 (3)
Bicarbonates
mmol/l
< 15 (1)
15 – 19 (2)
≥ 20 (3)
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Eligibility Advanced Solid Tumors
NCT01327612
Open Label Extension Study of Conatumumab and AMG
479; ODM derived from:
https://clinicaltrials.gov/show/NCT01327612
All rights reserved. Please visit https://medical-data-
models.org/forms/14955
Eligibility Advanced Solid Tumors
NCT01327612
Inclusion Criteria
to be enrolled in this study, subjects must be
currently enrolled in a prior amgen-sponsored
conatumumab or amg 479 study and are eligible
according to the parent study to receive their next
dose of conatumumab (with or without co-
therapy), or amg 479 alone.*
Yes
No
subjects must have their eligibility assessed for
this study and be enrolled within 30 days of their
last treatment on the parent protocol*
Exclusion Criteria
discontinued from a conatumumab study due to
an adverse event considered by the investigator
to be related to conatumumab treatment,
including intolerance to conatumumab*
Yes
No
subjects determined to have disease progression
during their participation in the parent amgen
study*
Yes
No
woman or man with partner of childbearing
potential not consenting to use adequate
contraceptive precautions ie, double barrier
contraceptive methods (eg, diaphragm plus
condom), or abstinence during the course of the
study and for 6 months after the last dose of
protocol-specified therapy administration*
Yes
No
subject is pregnant or breast feeding, or planning
to become pregnant within 6 months after the last
dose of protocol-specified therapy administration*
Yes
No
male subject with a pregnant partner who is not
willing to use a condom during treatment and for
an additional 6 months after the last dose of
protocol-specified therapy administration*
Yes
No
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subject has previously entered this study*
Yes
No
subject will not be available for protocol required
study visits, to the best of the subject and
investigator's knowledge*
Yes
No
subject has any kind of disorder that, in the
opinion of the investigator, may compromise the
ability of the subject to give written informed
consent and/or to comply with all required study
procedures*
Yes
No
2 / 2
Eligibility Advanced Solid Tumors NCT01327612
Eligibility Advanced Breast Cancer
NCT00717951
A Randomised,Multi-Center Study of Docetaxol Plus
Capecitabine or Cisplatin in Anthracycline-Pretreated
Patients With Advanced Breast Cancer; ODM derived from:
https://clinicaltrials.gov/show/NCT00717951
All rights reserved. Please visit https://medical-data-
models.org/forms/14956
Eligibility Advanced Breast Cancer
NCT00717951
Inclusion Criteria
age≥18y*
Yes
No
kps≥ 70*
Yes
No
pathologic diagnosis of breast cancer*
Yes
No
at least 1 measurable lesion as defined by
modified recist criteria*
Yes
No
screening laboratory values with the following
parameters: hemoglobin:≥10.0 g/dl absolute
neutrophils count:≥1.5×109/l platelet:≥100×109/l
creatinine clearance rate:*
Yes
No
≥60ml/min total bilirubin: ≤1.5 ×upper limits of
normal alkaline phosphatase,aspartate
aminotransferase and alanine aminotransferase:≤
2.5×upper limits of normal（≤5×upper limits of
normal if liver metastasis are present)*
Yes
No
signed informed consent*
Yes
No
for women of child bearing potential,a negative
serum or urine pregnancy test result before study
entry.*
Yes
No
Exclusion Criteria
more than 2 cytotoxic chemotherapy treatment
regimens for metastatic disease.*
Yes
No
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prior exposure to 5-fluorouracil continuous
infusion.*
Yes
No
prior exposure docetaxol for metastatic disease*
Yes
No
any other cancer within 5 years prior to screening
with the exception of contralateral breast
cancer,adequately treated cervical carcinoma in
situ,or adequately treated basal or squamous cell
carcinoma of skin*
Yes
No
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Eligibility Advanced Solid Tumors
NCT01520389
Safety Study of the Drug MM-151 in Patients With
Advanced Solid Tumors Resisting Ordinary Treatment;
ODM derived from:
https://clinicaltrials.gov/show/NCT01520389
All rights reserved. Please visit https://medical-data-
models.org/forms/14957
Eligibility Advanced Solid Tumors
NCT01520389
Inclusion Criteria
patients must have histologically or cytologically
confirmed advanced malignant solid tumor that
has recurred or progressed following standard
therapy, or that has not responded to standard
therapy, or for which there is no standard therapy,
or who are not candidates for standard therapy*
Yes
No
patients must be > 18 years of age*
Yes
No
patients of their legal representatives must be
able to understand and sign an informed consent
form*
Yes
No
patients must have evaluable or measurable
tumor(s)*
Yes
No
patients must be recovered from the effects of
any prior surgery, radiotherapy or other
antineoplastic therapy. up to ctcae grade 1 is
acceptable for patients with known peripheral
neuropathy*
Yes
No
women of childbearing potential as well as fertile
men and their partners must agree to abstain
from sexual intercourse or to use an effective
form of contraception during the study and for 90
days following the last dose of mm-151 (an
effective form of contraception is an oral
contraceptive or a double barrier method)*
Yes
No
Exclusion Criteria
patients for whom potentially curative
antineoplastic therapy is available*
Yes
No
patients who are pregnant or lactating*
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Yes
No
patients with an active infection or with an
unexplained fever > 38.5°c during screening visits
or on the first scheduled day of dosing. (at the
discretion of the investigator, patients with tumor
fever may be enrolled.)*
Yes
No
patients with untreated and/or symptomatic cns
malignancies (primary or metastatic); patients
with cns metastases who have undergone
surgery or radiotherapy, whose disease is stable,
and who have been on a stable dose of
corticosteroids for at least 2 weeks prior to the
first scheduled day of dosing will be eligible for
the trial*
Yes
No
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Eligibility Advanced Castrate-resistant
Prostate Cancer (CRPC); NCT01884285
AZD8186 First Time In Patient Ascending Dose Study;
ODM derived from:
https://clinicaltrials.gov/show/NCT01884285
All rights reserved. Please visit https://medical-data-
models.org/forms/14958
Eligibility Advanced Castrate-
resistant Prostate Cancer (CRPC);
NCT01884285
Inclusion Criteria
provision of signed and dated, written informed
consent prior to any study specific procedures*
Yes
No
male or female, aged 18 years and older*
Yes
No
histologically or cytologically proven diagnosis of
prostate cancer, squamous non small cell lung
cancer (sqnsclc), triple negative breast cancer
(tnbc), or a known pten-deficient solid
malignancy, that is refractory to standard
therapies*
Yes
No
females should be using adequate contraceptive
measures (see section 4.3), should not be breast
feeding and must have a negative pregnancy test
prior to start of dosing if of child-bearing
potential*
Yes
No
world health organisation (who)/ecog
performance status 0 to 1 with no deterioration
over the previous 2 weeks and minimum life
expectancy of 12 weeks*
Yes
No
Exclusion Criteria
treatment before study with  (a) nitrosourea or
mitomycin c; (b) investigational agents from a
previous clinical study; (c) chemotherapy,
immunotherapy or anticancer agents; (d)
hormonal therapy (e.g., steroids)*
Yes
No
treatment before study with  (a) strong inhibitors
and strong or moderate inducers of cyp3a4 (b)
radiotherapy with a wide field of radiation*
Yes
No
1 / 2
with the exception of alopecia or toxicities related
to the use of gonadotropin-releasing hormone
agonists any unresolved toxicities from prior
therapy greater than common terminology criteria
for adverse events  grade 1 at the time of study
treatment*
Yes
No
spinal cord compression or brain metastases
unless asymptomatic, treated and stable and not
requiring steroids*
Yes
No
any evidence of severe or uncontrolled systemic
diseases including active liver disease (other than
malignancy), active bleeding diatheses, or active
infection including hepatitis b, hepatitis c and
human immunodeficiency virus (hiv).*
Yes
No
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Eligibility Advanced Cancers NCT01444716
Phase II Study of Ofatumumab in Elderly Patients With
Chronic Lymphocytic Leukemia (CLL); ODM derived from:
https://clinicaltrials.gov/show/NCT01444716
All rights reserved. Please visit https://medical-data-
models.org/forms/14959
Eligibility Advanced Cancers
NCT01444716
Inclusion Criteria
patients with chronic lymphocytic leukemia
requiring treatment age >65 at the time of signing
informed consent.*
Yes
No
the eastern cooperative oncology group
(ecog)/world health organization (who)
performance status of 2-3.or patients with chronic
lymphocytic leukemia requiring treatment age
>65 years at the time of signing informed consent
and ecog/who performance status of 0-1 and a
cirs or charlson co-morbidity score of 2 or
higher.*
Yes
No
adequate renal and hepatic function (creatinine
<2mg/dl and egfr more than 30cc/minute, bilirubin
<2mg/dl). patients with renal or liver dysfunction
due to organ infiltration by lymphocytes may be
eligible after discussion with the study chairman.
patients with gilbert's syndrome are eligible.*
Yes
No
Exclusion Criteria
patients with documented prolymphocytic
leukemia (prolymphocytes more than 55% in the
blood).*
Yes
No
known positivity for hiv*
Yes
No
hepatitis b (hb) defined as a positive test for
hbsag. in addition, if negative for hgsag but hbcab
positive (regardless of hbsab status), a hb dna
test will be performed and if positive the subject
will be excluded.*
Yes
No
prior treatment for chronic lymphocytic leukemia*
Yes
No
concurrent chemotherapy, radiotherapy, or
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immunotherapy, including other monoclonal
antibodies. localized radiotherapy to an area not
compromising bone marrow function does not
apply. patients with malignancies with indolent
behavior such as prostate cancer treated with
radiation or surgery can be enrolled in the study
as long as they have a reasonable expectation to
have been cured with the treatment modality
received.*
Yes
No
any serious medical condition, laboratory
abnormality, or psychiatric illness that places the
subject at unacceptable risk if he/she were to
participate in the study.*
Yes
No
any known hypersensitivity to ofatumumab or its
components.*
Yes
No
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Eligibility Advanced Non-Small Cell Lung
Cancer NCT00528281
A Phase II Trial of Lapatinib (TYKERB) + Pemetrexed
(ALIMTA) in Advanced Non Small Cell Lung Cancer With
an Initial Dose Finding Phase; ODM derived from:
https://clinicaltrials.gov/show/NCT00528281
All rights reserved. Please visit https://medical-data-
models.org/forms/14960
Eligibility Advanced Non-Small Cell
Lung Cancer NCT00528281
Inclusion Criteria
Written informed consent*
Yes
No
patients must be 18 years old*
Yes
No
subjects must have stage iiib or iv nsclc*
Yes
No
recurrent or persistent nsclc following one
previous line of cytotoxic chemotherapy*
Yes
No
eastern cooperative oncology group (ecog)
performance status (ps) 0-2;*
Yes
No
life expectancy of 12 weeks*
Yes
No
have adequate organ function baseline laboratory
values for inclusion*
Yes
No
Exclusion Criteria
history of other malignancy. subjects who have
been disease-free for 5 years, or subjects with a
history of completely resected non-melanoma
skin cancer or successfully treated in situ
carcinoma are eligible;*
Yes
No
known history of or clinical evidence of central
nervous system (cns) metastases or
leptomeningeal carcinomatosis except for
individuals who have previously treated cns
metastases, are asymptomatic, and have had no
requirement for steroids or antiseizure medication
for = 3 months prior to study enrollment.*
Yes
No
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peripheral neuropathy of grade 3 or higher*
Yes
No
concurrent cancer therapy (chemotherapy,
radiation therapy, surgery, immunotherapy,
biologic therapy, hormonal therapy, and tumor
embolization).*
Yes
No
prior exposure to pemetrexed or an egfr inhibitor
in combination with 5-fu or a 5fu prodrug.*
Yes
No
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Celiac Sprue Assay Protocol PhenX Toolkit
This protocol uses two-step serologic testing of serum to
determine the presence of antihuman recombinant tissue
transglutaminase (TTG) and endomysial antibody (EMA).
When both tests are positive, the subject is notified that
they are positive for celiac sprue. The test is most accurate
if patients have not been on a gluten-free diet in the weeks
leading up to the assay, as a gluten-free diet may cause the
serologic assays to normalize in many patients.
ODM derived from: https://cde.nlm.nih.gov
Primary source: https://www.phenxtoolkit.org/
Recent publication: Hendershot, T., Pan, H., Haines, J.,
Harlan, W.R., Marazita, M.L., McCarty, C.A., Ramos, E.M.,
and Hamilton, C.M. (2015) Using the PhenX toolkit to add
standard measures to a study. Curr. Protoc. Hum. Genet.
86:1.21.1-1.21.17. doi: 10.1002/0471142905.hg0121s86
Permission to publish granted by
Carol M. Hamilton.
All rights reserved. Please visit https://medical-data-
models.org/forms/14962
Celiac Sprue Assay Protocol PhenX
Toolkit
PhenX - celiac sprue assay protocol
Do you have hemophilia?
Yes (1)
No (2)
Refused (3)
Don´t know (4)
Have you received cancer chemotherapy in the
past four weeks or do you anticipate such therapy
in the next four weeks?
Yes (1)
No (2)
Refused (3)
Don´t know (4)
Exclusion Criteria
Hemophilia (1)
Received cancer chemotherapy in the
last 3 weeks (2)
None – proceed with blood draw (3)
Was blood drawn?
Yes
No
Was full sample obtained?
Yes
No
Service comment
Service comment
Make of the equipment used to perform...
Manufacturer of the equipment used to perform...
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Repeatability of the assay
Coefficient of variation for the assay
Make of the equipment used to perform...
Manufacturer of the equipment used to perform...
Repeatability of the assay
Coefficient of variation for the assay
2 / 2
Celiac Sprue Assay Protocol PhenX Toolkit
Exercise Capacity/Six-Minute Walk Test
Protocol PhenX Toolkit
The Six-Minute Walk Test is a timed test that requires
minimal technical resources to measure the distance that a
patient can quickly walk on a flat, hard surface in a period
of 6 minutes (the six-minute walk distance, 6MWD). This
measure has been shown to be a reproducible, objective
indicator of functional capacity and is a part of the
multicomponent BODE index (body-mass index, airflow
obstruction, dyspnea, and exercise capacity) that correlates
with survival. It is important to emphasize that this is a test
of maximum exercise performance; subjects should be
instructed and encouraged to push themselves to achieve
maximal distance.
ODM derived from: https://cde.nlm.nih.gov
Primary source: https://www.phenxtoolkit.org/
Recent publication: Hendershot, T., Pan, H., Haines, J.,
Harlan, W.R., Marazita, M.L., McCarty, C.A., Ramos, E.M.,
and Hamilton, C.M. (2015) Using the PhenX toolkit to add
standard measures to a study. Curr. Protoc. Hum. Genet.
86:1.21.1-1.21.17. doi: 10.1002/0471142905.hg0121s86
Permission to publish granted by
Carol M. Hamilton.
All rights reserved. Please visit https://medical-data-
models.org/forms/14963
Exercise Capacity/Six-Minute Walk
Test Protocol PhenX Toolkit
PhenX - respiratory - exercise capacity - 6
minute walk test protocol
Contraindication
Number of laps
Systolic Blood Pressure
mmHg
Diastolic Blood Pressure
mmHg
Oxygen therapy [Minimum Data Set]
No (No)
UTD (UTD)
Yes (Yes)
Inhaled oxygen flow rate
1 liter/min (1 liter/min)
2 liters/min (2 liters/min)
3 liters/min (3 liters/min)
4 liters/min (4 liters/min)
5 liters/min (5 liters/min)
6 liters/min (6 liters/min)
Room air (Room air)
Supplemental oxygen during the test type
Baseline Time
Heart rate --resting
bpm
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Baseline Dyspnea (from the Borg scale)
Nothing at all     (0 )
Very, very slight (just noticeable)     (0.5 )
Very slight     (1 )
Very, very severe (maximal) (10 )
Slight (light)  (2 )
Moderate  (3 )
Somewhat severe     (4 )
Severe (heavy)   (5 )
6 (6)
Very severe     (7 )
8 (8)
9 (9)
Baseline Fatigue (from the Borg scale)
Nothing at all     (0 )
Very, very slight (just noticeable)     (0.5 )
Very slight     (1 )
Very, very severe (maximal) (10 )
Slight (light)  (2 )
Moderate  (3 )
Somewhat severe     (4 )
Severe (heavy)   (5 )
6 (6)
Very severe     (7 )
8 (8)
9 (9)
Oxygen saturation in Arterial blood by Pulse
oximetry --resting
%
End of test time
Heart rate --post exercise
bpm
End of Test Dyspnea (from Borg scale)
Nothing at all     (0 )
Very, very slight (just noticeable)     (0.5 )
Very slight     (1 )
Very, very severe (maximal) (10 )
Slight (light)  (2 )
Moderate  (3 )
Somewhat severe     (4 )
Severe (heavy)   (5 )
6 (6)
Very severe     (7 )
8 (8)
9 (9)
End of Test Fatigue (from Borg scale)
Nothing at all     (0 )
Very, very slight (just noticeable)     (0.5 )
Very slight     (1 )
Very, very severe (maximal) (10 )
Slight (light)  (2 )
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Moderate  (3 )
Somewhat severe     (4 )
Severe (heavy)   (5 )
6 (6)
Very severe     (7 )
8 (8)
9 (9)
Oxygen saturation in Arterial blood by Pulse
oximetry --post exercise
%
Stopped or paused before 6 minutes?
Yes
No
Reason stopped or paused before 6 minutes
Other symptoms at end of exercise
Number of laps
Final partial lap distance
m
Total distance walked in 6 minutes (Number of
laps X 60 meters + Final partial lap distance)
Service comment
Interpretation (including comparison with a
preintervention 6MWD)
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Exercise Capacity/Six-Minute Walk Test
Protocol PhenX Toolkit
The Six-Minute Walk Test is a timed test that requires
minimal technical resources to measure the distance that a
patient can quickly walk on a flat, hard surface in a period
of 6 minutes (the six-minute walk distance, 6MWD). This
measure has been shown to be a reproducible, objective
indicator of functional capacity and is a part of the
multicomponent BODE index (body-mass index, airflow
obstruction, dyspnea, and exercise capacity) that correlates
with survival. It is important to emphasize that this is a test
of maximum exercise performance; subjects should be
instructed and encouraged to push themselves to achieve
maximal distance.
ODM derived from: https://cde.nlm.nih.gov
Primary source: https://www.phenxtoolkit.org/
Recent publication: Hendershot, T., Pan, H., Haines, J.,
Harlan, W.R., Marazita, M.L., McCarty, C.A., Ramos, E.M.,
and Hamilton, C.M. (2015) Using the PhenX toolkit to add
standard measures to a study. Curr. Protoc. Hum. Genet.
86:1.21.1-1.21.17. doi: 10.1002/0471142905.hg0121s86
Permission to publish granted by
Carol M. Hamilton.
All rights reserved. Please visit https://medical-data-
models.org/forms/14964
Exercise Capacity/Six-Minute Walk
Test Protocol PhenX Toolkit
PhenX - respiratory - exercise capacity - 6
minute walk test protocol
Contraindication
Number of laps
Systolic Blood Pressure
mmHg
Diastolic Blood Pressure
mmHg
Oxygen therapy [Minimum Data Set]
No (No)
UTD (UTD)
Yes (Yes)
Inhaled oxygen flow rate
1 liter/min (1 liter/min)
2 liters/min (2 liters/min)
3 liters/min (3 liters/min)
4 liters/min (4 liters/min)
5 liters/min (5 liters/min)
6 liters/min (6 liters/min)
Room air (Room air)
Supplemental oxygen during the test type
Baseline Time
Heart rate --resting
bpm
1 / 3
Baseline Dyspnea (from the Borg scale)
Nothing at all     (0 )
Very, very slight (just noticeable)     (0.5 )
Very slight     (1 )
Very, very severe (maximal) (10 )
Slight (light)  (2 )
Moderate  (3 )
Somewhat severe     (4 )
Severe (heavy)   (5 )
6 (6)
Very severe     (7 )
8 (8)
9 (9)
Baseline Fatigue (from the Borg scale)
Nothing at all     (0 )
Very, very slight (just noticeable)     (0.5 )
Very slight     (1 )
Very, very severe (maximal) (10 )
Slight (light)  (2 )
Moderate  (3 )
Somewhat severe     (4 )
Severe (heavy)   (5 )
6 (6)
Very severe     (7 )
8 (8)
9 (9)
Oxygen saturation in Arterial blood by Pulse
oximetry --resting
%
End of test time
Heart rate --post exercise
bpm
End of Test Dyspnea (from Borg scale)
Nothing at all     (0 )
Very, very slight (just noticeable)     (0.5 )
Very slight     (1 )
Very, very severe (maximal) (10 )
Slight (light)  (2 )
Moderate  (3 )
Somewhat severe     (4 )
Severe (heavy)   (5 )
6 (6)
Very severe     (7 )
8 (8)
9 (9)
End of Test Fatigue (from Borg scale)
Nothing at all     (0 )
Very, very slight (just noticeable)     (0.5 )
Very slight     (1 )
Very, very severe (maximal) (10 )
Slight (light)  (2 )
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Moderate  (3 )
Somewhat severe     (4 )
Severe (heavy)   (5 )
6 (6)
Very severe     (7 )
8 (8)
9 (9)
Oxygen saturation in Arterial blood by Pulse
oximetry --post exercise
%
Stopped or paused before 6 minutes?
Yes
No
Reason stopped or paused before 6 minutes
Other symptoms at end of exercise
Number of laps
Final partial lap distance
m
Total distance walked in 6 minutes (Number of
laps X 60 meters + Final partial lap distance)
Service comment
Interpretation (including comparison with a
preintervention 6MWD)
3 / 3
Exercise Capacity/Six-Minute Walk Test Protocol PhenX Toolkit
Eligibility Colorectal Cancer NCT02280694
Metronomic Poly-chemotherapy for Metastatic CRC; ODM
derived from: https://clinicaltrials.gov/show/NCT02280694
All rights reserved. Please visit https://medical-data-
models.org/forms/14969
Eligibility Colorectal Cancer
NCT02280694
Inclusion Criteria
1. histological (or cytological) proof of colorectal
carcinoma (crc)*
Yes
No
2. measurable metastases*
Yes
No
3. ecog (eastern cooperative oncology group)
performance status  0-2*
Yes
No
4. progressing disease following all available
chemotherapy treatment lines (including
chemotherapy, bevacizumab+/-ziv-aflibercept,
and an epidermal growth factor receptor (egfr)
inhibitor [if wt(wild type)-kras]*
Yes
No
5. the central-radiologist's confirmation of pd*
under the last (previous) line of "conventional
treatment" and determination of pfs1, according
to recist criteria*
Yes
No
pd (progressive disease) by recist(response
evaluation criteria in solid tumors) criteria : a)
there is 20% or more relative increment in the
sum of diameters of target lesions in comparison
with the base line sum, and their absolute
increase is 5 mm. or more, or b) there appeared
one or more new lesions, or c)there is substantial
worsening in non-target disease*
Yes
No
6. age: between 18 and 85*
Yes
No
7. prior radiotherapy either as adjuvant treatment
or for palliation is allowed, unless this was
delivered to the only measurable lesion*
Yes
No
8. complete blood counts showing normal values
or any toxicity limited to grade 1.*
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Yes
No
9. blood chemistry tests showing liver and renal
functions < 1.5 upper normal limit (unl)*
Yes
No
10. absence of any non-hematological toxicity at
grade 2 or higher*
Yes
No
11. the experimental treatment should start within
3 to 7 weeks from the last cycle of conventional
treatment*
Yes
No
12. the patient is able to understand and ready to
sign the informed consent*
Yes
No
Exclusion Criteria
1. lack of confirmation of pd (under the pre-study
treatment) by the central radiologist*
Yes
No
2. any concurrent other active cancer (except
basal cell or squamous cell carcinoma of skin
and early prostate cancer or dcis- in situ breast
cancer)*
Yes
No
3. inability to adhere to monthly visits to the
oncological unit for evaluation*
Yes
No
4. presence of brain metastases*
Yes
No
5. continuous treatment with steroids or with
nsaids or with anticoagulants during the last year
(except micropirin)*
Yes
No
6. previous radiotherapy to the only site of
measurable disease*
Yes
No
7. existence of active peptic ulcer or symptomatic
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coronary disease*
Yes
No
8. existence of chronic inflammatory diseases,
such as ulcerative colitis or crohn's disease or
rheumatoid arthritis*
Yes
No
9. presence of ascites, and/or any other "third
space" finding (eg. significant leg edema)*
Yes
No
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Doctor's letter Release report external Routine
documentation in German hospitals DMI
Routine documentation in German hospitals. Source file
name: AD010104 Entlassungsbericht extern/ Arztbrief
extern.059 and Arztbrief extern.061. Examplary forms
provided by DMI (http://www.dmi.de/)
All rights reserved. Please visit https://medical-data-
models.org/forms/14970
Doctor's letter Release report
external
Release report
Patient name
Diagnosis
Therapy
Histology
Therapeutic process
Procedure
Physician
Discharge medication list
Medication
Tumor markers
Tumor markers
Diagnosis Date
1 / 1
Confirmation of hospitalization Other certificate
Routine documentation in German hospitals DMI
Routine documentation in German hospitals. Source file
name: AD020199_Sonstige Bescheinigung/ Bestätigung
Krakenhausaufenthalt.085
Examplary forms provided by DMI (http://www.dmi.de/)
All rights reserved. Please visit https://medical-data-
models.org/forms/14971
Confirmation of hospitalization Other
certificate
Confirmation of Hospitalization
Patient name
Date of birth
Hospitalization start date
Hospitalization end date
Physician
Date
1 / 1
Eligibility Congestive Heart Failure
NCT02346097
Electrophysiological Optimization of Left Ventricular Lead
Placement in CRT; ODM derived from:
https://clinicaltrials.gov/show/NCT02346097
All rights reserved. Please visit https://medical-data-
models.org/forms/14973
Eligibility Congestive Heart Failure
NCT02346097
Inclusion Criteria
symptomatic heart failure (new york heart
association (nyha) functional class ii -*
Yes
No
iv) despite optimal medical therapy*
Yes
No
ecg with left bundle branch block and qrs ≥ 120
ms*
Yes
No
lvef ≤ 35 %*
Yes
No
age > 40 years*
Yes
No
written informed consent patients with an
indwelling single- or dual chamber pacemaker
and a paced qrs > 180 ms are eligible for
enrollment.*
Yes
No
Exclusion Criteria
expected lifetime < 6 months*
Yes
No
expected heart-surgery within the next 6 months*
Yes
No
recent (< 3 months) myocardial infarction or
coronary artery bypass graft (cabg)*
Yes
No
pregnant or lactating*
Yes
No
no written informed consent cardiac ct will not be
performed in patients where this is
contraindicated, i.e. in the presence of depressed
1 / 2
renal function (estimated glomerular filtration rate
(egfr) < 30 ml (milliters)/minute), thyrotoxicosis or
in the case of former serious reactions to the
contrast media.*
Yes
No
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Reason for non participation Safety and Immunogenicity Study of a Booster Dose of
GSK Biologicals 10-valent Pneumococcal Conjugate Vaccine NCT00370396
This study will evaluate the safety, reactogenicity and
immunogenicity of a booster dose of GSK Biologicals'
pneumococcal conjugate vaccine compared to Prevenar™
given at 12-18 mo of age to children primed with either
pneumococcal vaccine or Prevenar™ in study 105553.
Antibody persistence will be evaluated at 8-14 mo after
completion of the 3-dose immunization course in study
105553. The immune response to a booster dose of GSK
Biologicals' pneumococcal conjugate vaccine will also be
evaluated when given at 12-18 mo to subjects not primed
with GSK Biologicals' vaccine but with Prevenar™.
The study has 3 groups. 1 group of children primed with
GSK Biologicals' pneumococcal conjugate vaccine will
receive a booster dose of the same vaccine. 2nd group of
children primed with Prevenar™ will receive a booster dose
of Prevenar™ (control group). 3rd group of children primed
with Prevenar™ will receive a booster dose of GSK
Biologicals' pneumococcal conjugate vaccine. All children
will receive concomitantly a booster dose of DTPa-HBV-
IPV/Hib vaccine.
NCT00370396
Part: Reason for non participation
All rights reserved. Please visit https://medical-data-
models.org/forms/14974
Reason for non participation Safety
and Immunogenicity Study of a
Booster Dose of GSK Biologicals 10-
valent Pneumococcal Conjugate
Vaccine NCT00370396
Identification
Center number
Subject ID
Treatment Number
Date of birth
Gender
Female (f)
Male (m)
Tracking Document Reason for non
participation
Previous subject number:
Date of birth
Please document reason for non participation
Subject not eligible (1)
Subject lost to follow-up or not reached
(2)
Subject eligible but not willing to
participate (3)
Adverse events, or serious adverse event
1 / 2
(4)
Other (5)
Subject died (6)
please specify criteria that
are not fullfilled
Subject not willing due to: adverse events, or
serious adverse event:
please specify:
Subject not willing due to other: please specify:
Subject died on:
Number of SAEs
2 / 2
Reason for non participation Safety and Immunogenicity Study of a Booster Dose of
GSK Biologicals 10-valent Pneumococcal Conjugate Vaccine NCT00370396
EBMT Multiple Myeloma
Bacteria:S. pneumoniae, Other gram positive (i.e.: other
streptococci, staphylococci, listeria …), Haemophilus
influenzae, Other gram negative (i.e.: E. coli klebsiella,
proteus, serratia, pseudomonas …), Legionella sp,
Mycobacteria sp, Other
Fungi: Candida sp, Aspergillus sp, Pneumocystis carinii,
Other
Parasites: Toxoplasma gondii, Other
Viruses: HSV, VZV, EBV,CMV, HHV-6,RSV, Other
respiratory virus (influenza, parainfluenza, rhinovirus),
Adenovirus, HBV, HCV, HIV, Papovavirus, Parvovirus,Other
All rights reserved. Please visit https://medical-data-
models.org/forms/14976
16pp EBMT Multiple Myeloma
10PCD
GENERAL INFORMATION, Team
EBMT Centre Identification Code (CIC)
Name of the hospital
Unit
Name of contact person
Telephone number of contact person
Fax
E-mail
Date of this report
Patient following national / international study /
trial
No (1)
Yes (2)
Not evaluated (3)
Unknown (4)
Name of study trial
PATIENT
To be entered only if patient previously reported
Hospital Unique Patient Number or Code
First name(s) - surname(s)
(Registration will not be accepted if this item is
left blank)
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Date of Birth
Sex:
Female (Female)
Male (Male)
ABO Group
Rh factor
Absent  (Absent )
Not evaluated (Not evaluated)
Present (Present)
DISEASE
Date of Diagnosis
Check the disease for which this transplant was
performed
Acute Leukaemia (Acute Leukaemia)
Acute Lymphoblastic Leukaemia (ALL)
(Acute Lymphoblastic Leukaemia (ALL))
Acute Myelogenous Leukaemia (AML)
(Acute Myelogenous Leukaemia (AML))
Autoimmune disease (Autoimmune
disease)
Bone marrow failure including Aplastic
anaemia (Bone marrow failure including
Aplastic anaemia)
Chronic Leukaemia (Chronic Leukaemia)
Chronic Lymphocytic Leukaemia
(Chronic Lymphocytic Leukaemia)
Chronic Myeloid Leukaemia (CML)
(Chronic Myeloid Leukaemia (CML))
Haemoglobinopathiy
(Haemoglobinopathiy)
Histiocytic disorders (Histiocytic
disorders)
Hodgkin´s Disease (Hodgkin´s Disease)
Inherited disorders (Inherited disorders)
Juvenile Idiopathic Arthritis (Juvenile
Idiopathic Arthritis)
Lymphoma (Lymphoma)
MD/ MPN (MD/ MPN)
MDS (MDS)
Metabolic disorders (Metabolic
disorders)
Multiple Sclerosis (Multiple Sclerosis)
Myelodysplastic syndromes
(Myelodysplastic syndromes)
Myeloma/ Plasma cell disorder
(Myeloma/ Plasma cell disorder)
Myeloproliferative neoplasm
(Myeloproliferative neoplasm)
Non Hodgkin (Non Hodgkin)
Other diagnosis (Other diagnosis)
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Primary immune deficiencies (Primary
immune deficiencies)
Secondary Acute Leukaemia (do not use
if transformed from MDS/MPN)
(Secondary Acute Leukaemia (do not
use if transformed from MDS/MPN))
Solid Tumour (Solid Tumour)
Systemic Lupus (Systemic Lupus)
Systemic Sclerosis (Systemic Sclerosis)
Non infection related complications
Yes
No
PLASMA CELL DISORDERS
(INCLUDING MULTIPLE MYELOMA)
Has the information requested in this section
been submitted with a previous HSCT registration
for this patient?
Yes: go to page 2, Pre HSCT Treatment
(1)
No: proceed with this section (2)
SUBCLASSIFICATION, Select one
Multiple myeloma (1)
Plasma Cell Leukaemia (2)
Solitary plasmacytoma of bone (3)
POEMS (4)
Monoclonal light and heavy chain
deposition disease (LCDD/HCDD) (5)
Other (6)
Heavy chain and light chain
(check light and heavy chain types)
IgA (IgA)
IgD (IgD)
IgE (IgE)
IgG (IgG)
IgM (IgM)
Kappa (Kappa)
Lambda (Lambda)
Light chain only
(check light chain type only)
Kappa (1)
Lambda (2)
STAGE AT DIAGNOSIS
I (I)
II (II)
III (III)
ISS Stage
1 (1)
2 (2)
3 (3)
Chromosome analysis
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Normal (1)
Abnormal (2)
Not done or failed (3)
Unknown (4)
Number of metaphases with anomalies:
Number of metaphases examined
IF ABNORMAL, INDICATE ABNORMALITIES
FOUND
Absent (1)
Present (2)
Not evaluated (3)
IF ABNORMAL, INDICATE ABNORMALITIES
FOUND
Absent (1)
Present (2)
Not evaluated (3)
IF ABNORMAL, INDICATE ABNORMALITIES
FOUND
Absent (1)
Present (2)
Not evaluated (3)
IF ABNORMAL, INDICATE ABNORMALITIES
FOUND
Absent (1)
Present (2)
Not evaluated (3)
IF ABNORMAL, INDICATE ABNORMALITIES
FOUND
Absent (1)
Present (2)
Not evaluated (3)
IF ABNORMAL, INDICATE ABNORMALITIES
FOUND
Absent (1)
Present (2)
Not evaluated (3)
IF ABNORMAL, INDICATE ABNORMALITIES
FOUND
Absent (1)
Present (2)
Not evaluated (3)
IF ABNORMAL, INDICATE ABNORMALITIES
FOUND
Absent (1)
Present (2)
Not evaluated (3)
IF ABNORMAL, INDICATE ABNORMALITIES
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FOUND, please specify
IF ABNORMAL, INDICATE ABNORMALITIES
FOUND
Molecular analysis
Done but failed (1)
Done, successful (2)
Not evaluated (3)
Unknown (4)
Hb (g/dl)
Serum creatinine (_mol/L)
Serum calcium (mmol/L)
Serum albumin (g/L)
BM aspirate: % plasmacytosis
BM trephine: % plasmacytosis
Monoclonal Ig in serum (g/L)
Monoclonal Ig in urine (g/24 h)
Serum _2 microglobulin (mg/L)
Hb (g/dL)
Not evaluated (1)
Serum creatinine (_mol/L)
Not evaluated (1)
Serum calcium (mmol/L)
Not evaluated (1)
Serum albumin (g/L)
Not evaluated (1)
BM aspirate: % plasmacytosis
Not evaluated (1)
BM trephine: % plasmacytosis
Not evaluated (1)
Monoclonal Ig in serum (g/L)
Not evaluated (1)
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Monoclonal Ig in urine (g/24 h)
Not evaluated (1)
Serum _2 microglobulin (mg/L)
Not evaluated (1)
INVOLVEMENT AT DIAGNOSIS Bone structure
Normal (1)
Minor (2)
Major (3)
Not evaluated (4)
Extramedullary involvement
No (1)
Yes (2)
Unknown (3)
if yes, please specify location
PRE-HSCT TREATMENT
Was the patient treated before the HSCT
procedure?
No (proceed to `Date of HSCT`) (No
(proceed to `Date of HSCT`))
Unknown (Unknown)
Yes (Yes)
counted from diagnosis, or last HSCT if
applicable
Modality Chemo/Drugs
Yes
No
Modality Chemo/Drugs regimen
Modality Radiotherapy
Yes
No
Response see manual for full definition of each
response
sCR (0)
CR (1)
vgPR (2)
PR (3)
Stable disease (5)
Progression (6)
Not evaluated (7)
Unknown (8)
HSCT
Date of HSCT
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HSCT Type
Allogenic (Allogenic)
Autologuos (Autologuos)
Autologous Date of 1st collection or pheresis
STATUS OF DISEASE AT COLLECTION
SEE MANUAL FOR FULL DEFINITION OF
EACH DISEASE STATUS
Stringent complete remission (sCR) (1)
Complete remission (CR) (2)
Very good PR (VGPR) (3)
PR (4)
Relapse from CR (5)
Stable disease (no change, includes old
MR) (6)
Progression (7)
Unknown (8)
If sCR or CR: NUMBER OF THIS COMPLETE
REMISSION
1st  (1st )
2nd (2nd)
3rd or higher (3rd or higher)
If VGPR or PR: NUMBER OF THIS PARTIAL
REMISSION
1st  (1st )
2nd (2nd)
3rd or higher (3rd or higher)
NUMBER OF THIS RELAPSE
1st  (1st )
2nd (2nd)
3rd or higher (3rd or higher)
COMPLETE ONLY IF STATUS IS STABLE
DIEASE OR PR
no (1)
yes (2)
unknown (3)
DISEASE STATUS AT HSCT
Hb (g/dL)
Serum creatinine (_mol/L)
Serum calcium (mmol/L)
Serum albumin (g/L)
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BM aspirate: % plasmacytosis
BM trephine: % plasmacytosis
Monoclonal Ig in serum (g/L)
Immunofixation of serum
Negative (1)
Positive (2)
Not evaluated (3)
Unknown (4)
Monoclonal Ig in urine (g/24 h)
Immunofixation of urine
Negative (1)
Positive (2)
Not evaluated (3)
Unknown (4)
Serum _2 microglobulin (mg/L)
Hb (g/dL)
Not evaluated (1)
Serum creatinine (_mol/L)
Not evaluated (1)
Serum calcium (mmol/L)
Not evaluated (1)
Serum albumin (g/L)
Not evaluated (1)
BM aspirate: % plasmacytosis
Not evaluated (1)
BM trephine: % plasmacytosis
Not evaluated (1)
Monoclonal Ig in serum (g/L)
Not evaluated (1)
Monoclonal Ig in urine (g/24 h)
Not evaluated (1)
Serum _2 microglobulin (mg/L)
Not evaluated (1)
Lytic lesions
Normal (1)
Minor (2)
Major (3)
Not evaluated (4)
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ADDITIONAL TREATMENT POST-HSCT
Additional Disease Treatment
No (No)
Unknown (Unknown)
Yes (Yes)
If Yes
Planned (planned before HSCT took
place) (1)
Not planned (for relapse/progression or
persistent disease), Date started (2)
(including MoAB, etc.)
Other (Other)
Thalidomide (Thalidomide)
Unknown (Unknown)
Chemo/drug/agent
Radiotherapy
No (1)
Yes (2)
Unknown (3)
If additional treatment:
Other treatment
No (No)
Unknown (Unknown)
Yes (Yes)
STATUS OF DISEASE AT 100 DAYS
AFTER HSCT
(see manual for full definition of each response)
Stringent complete remission (sCR) (1)
Complete remission (CR) (2)
Very good PR (VGPR) (3)
PR (4)
Stable disease (no change, includes old
MR) (5)
Progression (6)
Unknown (7)
If sCR or CR: NUMBER OF THIS COMPLETE
REMISSION
1st  (1st )
2nd (2nd)
3rd or higher (3rd or higher)
If VGPR or PR: NUMBER OF THIS PARTIAL
REMISSION
1st  (1st )
2nd (2nd)
3rd or higher (3rd or higher)
If complete response: date of CR
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yyyy/mm/dd
Otherwise: date of evaluation
Plateau (COMPLETE ONLY IF STATUS IS
STABLE DISEASE OR PR)
(not applicable for non secretory myelona)
No (1)
Yes (2)
Unknown (3)
FORMS TO BE FILLED IN
Type of Transplant
ALLOgraft or Syngeneic graft (proceed to
Allograft form) (ALLOgraft or Syngeneic
graft (proceed to Allograft form))
AUTOgraft (proceed to Autograft form)
(AUTOgraft (proceed to Autograft form))
Other (contact the EBMT Central
Registry for instructions) (Other (contact
the EBMT Central Registry for
instructions))
PLASMA CELL DISORDERS
(INCLUDING MULTIPLE MYELOMA)
Unique Identification Code (UIC)
(if known)
Hospital Unique Patient Number
Date of this report
Patient following national / international study /
trial
No (1)
Yes (2)
Not evaluated (3)
Unknown (4)
Name of study / trial
First name(s)_surname(s)
Date of Birth
Date of last HSCT for this patient
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PATIENT LAST SEEN
Date of Last Contact or Death
Complete haematological remission obtained
after the HSCT in the absence of additional
disease treatment
Previously reported (1)
Yes, date (2)
No  (3)
Unknown (4)
GRAFT VERSUS HOST DISEASE
(GvHD) SINCE LAST REPORT
Acute Graft versus Host Disease (aGvHD) -
Grade
grade 0 (Absent) (1)
grade I (2)
grade II (3)
grade III (4)
grade IV (5)
Not evaluated (6)
If present
New onset (New onset)
Persistent (Persistent)
Recurrent (Recurrent)
aGvHD Reason
Tapering (1)
DLI (2)
Unexplained (3)
Date onset of this episode (if new or recurrent)
yyyy/mm/dd
Stage skin
None (0)
Stage 1 (1)
Stage 2 (2)
Stage 3 (3)
Stage 4 (4)
Stage liver
0 (1)
1 (2)
2 (3)
3 (4)
4 (5)
Not evaluated (6)
unknown (7)
Resolution
No  (1)
Yes (2)
Date of resolution
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yyyy/mm/dd
Presence of cGvHD
No (No)
Present continuously since last reported
episode (Present continuously since last
reported episode)
Resolved (Resolved)
Yes (Yes)
If Yes
First episode (1)
Recurrence (2)
Date of onset
If present continously since last report, specify
cGvHD gade:
Extensive (Extensive)
Limited (Limited)
Organs affected
Skin (1)
Gut (2)
Liver (3)
Mouth (4)
Eyes (5)
Lung (6)
Other, specify (7)
Unknown (8)
If resolved, specify the date of resolution:
OTHER COMPLICATIONS SINCE LAST
REPORT
Infection related complications
Yes
No
Pathogen
Use the list of pathogens listed after this table for
guidance.
Use “unknown” if necessary.
Date
Provide different dates for different episodes of
the same complication if applicable.
Pathogen
Use the list of pathogens listed after this table for
guidance.
Use “unknown” if necessary.
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Date
Provide different dates for different episodes of
the same complication if applicable.
Pathogen
Use the list of pathogens listed after this table for
guidance.
Use “unknown” if necessary.
Date
Provide different dates for different episodes of
the same complication if applicable
Pathogen
Use the list of pathogens listed after this table for
guidance.
Use “unknown” if necessary.
Date
Provide different dates for different episodes of
the same complication if applicable.
Pathogen
Use the list of pathogens listed after this table for
guidance.
Use “unknown” if necessary.
Date
Provide different dates for different episodes of
the same complication if applicable.
Pathogen
Use the list of pathogens listed after this table for
guidance.
Use “unknown” if necessary.
Date
Provide different dates for different episodes of
the same complication if applicable.
Pathogen
Use the list of pathogens listed after this table for
guidance.
Use “unknown” if necessary.
Date
Provide different dates for different episodes of
the same complication if applicable.
Pathogen
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Use the list of pathogens listed after this table for
guidance.
Use “unknown” if necessary.
Date
Provide different dates for different episodes of
the same complication if applicable.
Pathogen
Use the list of pathogens listed after this table for
guidance.
Use “unknown” if necessary.
Date
Provide different dates for different episodes of
the same complication if applicable.
Pathogen
Use the list of pathogens listed after this table for
guidance.
Use “unknown” if necessary.
Date
Provide different dates for different episodes of
the same complication if applicable.
Pathogen
Use the list of pathogens listed after this table for
guidance.
Use “unknown” if necessary.
Date
Provide different dates for different episodes of
the same complication if applicable.
Pathogen
Use the list of pathogens listed after this table for
guidance.
Use “unknown” if necessary.
Date
Provide different dates for different episodes of
the same complication if applicable.
Non infection related complications
Yes
No
Specify: Idiopathic pneumonia syndrome
No  (No )
Unknown (Unknown)
Yes (Yes)
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Specify: 
VOD
No  (No )
Unknown (Unknown)
Yes (Yes)
Specify:
Cataract
No (No)
Unknown (Unknown)
Yes (Yes)
Specify:
Haemorrhagic cystitis, non infectious
No  (No )
Unknown (Unknown)
Yes  (Yes )
Specify:
ARDS, non infectious
No (No)
Unknown (Unknown)
Yes (Yes)
Multiorgan failure, non infectious
Yes (1)
No (2)
Unknown (3)
Specify:
HSCT-associated microangiopathy
No (No)
Unknown (Unknown)
Yes (Yes)
Specify:
Renal failure requiring dialysis
No (No)
Unknown (Unknown)
Yes (Yes)
Specify:
15 / 22
EBMT Multiple Myeloma
Haemolytic anaemia due to blood group
No (No)
Unknown (Unknown)
Yes (Yes)
Specify:
Aseptic bone necrosis
No (No)
Unknown (Unknown)
Yes (Yes)
if other, please specify
Graft loss
No (1)
Yes (2)
Not evaluated (3)
Overall chimaerism
Aplasia (Aplasia)
95%) (Autologuos reconstitution
(recipient >)
95%) (Full (donor >)
Mixed (partial) (Mixed (partial))
Not evaluated (Not evaluated)
Identification of donor or Cord Blood Unit given
by the centre
Date of Test
Number in the infusion order (if applicable)
......... (1)
N/A (2)
Cell type on which test was performed (% Donor
Cells):
BM
%
Cell type on which test was performed (% Donor
cells):
PB mononuclear cells (PBMC)
%
Cell type on which test was performed (% Donor
cells):
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T-Cells
(Indicate the date(s) and results of all tests done
for all donors. Split the results by donor and by
the cell type on which the test was performed if
applicable. Copy this table as many times as
necessary.)
%
Cell type on which test was performed (% Donor
cells):
B-Cells
%
Cell type on which test was performed (% Donor
cells):
Red blood cells
%
Cell type on which test was performed (% Donor
cells):
Monocytes
%
Cell type on which test was performed (% Donor
cells):
PMNs (neutrophils)
%
Cell type on which test was performed (% Donor
cells):
Lymphocytes, NOS
%
Cell type on which test was performed (% Donor
cells):
Myeloid cells, NOS
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%Cell type on which test was performed
SECONDARY MALIGNANCY,
LYMPHOPROLIFERATIVE OR
MYELOPROLIFRATIVE DISORDER
DIAGNOSED
No at date of this follow-up (No at date of
this follow-up)
Previously reported (Previously reported)
Yes (Yes)
If yes, specify date of diagnosis
SECONDARY MALIGNANCY,
LYMPHOPROLIFERATIVE OR
MYELOPROLIFRATIVE DISORDER
DIAGNOSED
AML (AML)
Lymphoproliferative disorder
(Lymphoproliferative disorder)
MDS (MDS)
Other (Other)
if other, please specify
ADDITIONAL THERAPIES SINCE LAST
FOLLOW UP
Treatment given since last report
No (No)
Unknown (Unknown)
Yes, date started (Yes, date started)
ADDITIONAL THERAPIES SINCE LAST
FOLLOW UP
If yes: Cellular therapy (One cell therapy regimen
is defined as any number of infusions given within
10 weeks for the same indication. If more than
one regimen of cell therapy has been given since
last report, copy this section and complete it as
many times as necessary.)
No  (1)
Yes (Mark disease status before this
cellular therapy) (2)
Unknown (3)
if yes, Disease status before this cellular therapy
CR (CR)
Not evaluated (Not evaluated)
Not in CR (Not in CR)
If yes: Type of cells
Donor lymphocyte infusion (DLI) (1)
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Mesenchymal cells (2)
Other (3)
Unknown (4)
Number of Nucleated cells infused (DLI only)
10^8/kg
Number (1)
Not evaluated (2)
Unknown (3)
If DLI, specify the number of cells infused by
type:
CD 34+
Evaluated (Evaluated)
Not Evaluated (Not Evaluated)
Unknown (Unknown)
If DLI, specify the number of cells infused by
type: 
CD 3+
Evaluated  (Evaluated )
Not evaluated (Not evaluated)
Unknown (Unknown)
Total number of cells infused (non DLI only)
x10^6/kg
Number (1)
Not evaluated (2)
Unknown (3)
Chronological number of this cell therapy for this
patient
Indication 
(check all that apply)
Loss/decreased chimaerism
(Loss/decreased chimaerism)
Mixed chimaerism (Mixed chimaerism)
Other (Other)
Planned/ protocol (Planned/ protocol)
Prophylactic (Prophylactic)
Treatment for disease (Treatment for
disease)
Treatment of GvHD (Treatment of GvHD)
Treatment PTLD, EBV, lymphoma
(Treatment PTLD, EBV, lymphoma)
Treatment viral infection (Treatment viral
infection)
Number of Infusions (within 10 weeks)
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(count only infusions that are part of same
regimen and given for the same indication)
Acute Graft versus Host Disease 
(after this infusion but before any further infusion/
transplant)
Maximum grade:
grade 0 (absent) (grade 0 (absent))
grade 1 (grade 1)
grade 2 (grade 2)
grade 3 (grade 3)
grade 4 (grade 4)
present, grade unknown (present, grade
unknown)
Disease treatment (apart from donor cell infusion
or other type of cell therapy)
No (1)
Yes: Planned (planned before HSCT took
place) (2)
Yes: Not planned (for
relapse/progression or persistent
disease) (3)
FIRST EVIDENCE OF RELAPSE OR
PROGRESSION SINCE LAST HSCT
Relapse or Progression
Continous progression since transplant
(Continous progression since transplant)
No (No)
Previously reported (Previously reported)
Unknown (Unknown)
Yes (Yes)
RELAPSE OR PROGRESSION
LAST DISEASE AND PATIENT STATUS
last disease status
Complete Remission (Complete
Remission)
Relapse (Relapse)
Stable disease (Stable disease)
Treatment failure/ progression (Treatment
failure/ progression)
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Has patient or partner become  pregnant after
this HSCT?
No (No)
Unknown (Unknown)
Yes (Yes)
Survival Status
alive (0)
dead (1)
If alive: Type of score used:
Karnofsky (Karnofsky)
Lansky (Lansky)
Not evaluated (Not evaluated)
Unknown (Unknown)
Score
100 (Normal, NED) (1)
10 (Moribund) (10)
Not evaluated (11)
Unknown (12)
90 (Normal activity)  (2)
80 (Normal with effort) (3)
70 (Cares for self) (4)
60 (Requires occasional assistance) (5)
50 (Requires assistance) (6)
40 (Disabled) (7)
30 (Severely disabled) (8)
20 (Very sick) (9)
CAUSE OF DEATH
HSCT related cause (HSCT related
cause)
Other (Other)
Relapse or progression (Relapse or
progression)
Secondary malignancy (Secondary
malignancy)
Unknown (Unknown)
HSCT related cause
GvHD (1)
Veno-occlusive disease (VOD) (10)
Haemorrhage (11)
Cardiac toxicity (12)
Central nervous system toxicity (13)
Gastro intestinal toxicity (14)
Skin toxicity (15)
Renal failure (16)
Multiple organ failure (17)
Other (18)
Interstitial pneumonitis (2)
Pulmonary toxicity (3)
Infection bacterial (4)
Infection viral (5)
Infection fungal (6)
Infection parasitic (7)
Infection unknown (8)
Rejection / poor graft function (9)
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ADDITIONAL NOTES IF APPLICABLE
Comments
IDENTIFICATION & SIGNATURE
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Aftercare Other wound documentation Routine
documentation in German hospitals DMI
Routine documentation in German hospitals. Source file
name: VL230199_Sonstiger Wunddokumentationsbogen/
Nachsorge.039
Examplary forms provided by DMI (http://www.dmi.de/)
All rights reserved. Please visit https://medical-data-
models.org/forms/14977
Aftercare Other wound
documentation
Aftercare
Patient ID
Patient name
Date
Performed OP
Operation date
Current medical condition
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Request for molecular pathological
examination Pathology UKM
Request for molecular pathological examination Pathology
UKM 
Please use this form for requests for molecular pathological
examination. 
Gerhard-Domagk-Institute of Pathology
Univ.-Prof.Dr.med.Eva Wardelmann
Albert-Schweitzer-Campus 1 Building D17
48149 Münster
Phone:0251-83-57550
Fax:0251-83-55481
E-mail:pathologie@ukmuenster.de
All rights reserved. Please visit https://medical-data-
models.org/forms/14980
Request for molecular pathological
examination
Patientendaten
Patient Name
Patient Familienname
Patient Geburtsdatum
Patient Addresse
Patient Krankenversicherung
Wahlleistung
Outpatient (1)
Inpatient (2)
Kasse
Outpatient (1)
Inpatient (2)
Eingangsnummer
Diagnose
Mutationsanalysen
KRAS Mutation Exon 2;3
Ja
Nein
KRAS Mutation Exon 4
Ja
Nein
NRAS Mutation Exon 2;3
Ja
Nein
NRAS Mutation Exon 4
Ja
Nein
1 / 6
Ras panel: Kolorektale CA, KRAS2-4; NRAS 2-4
Ja
Nein
EGFR Exon 18,19,21
Ja
Nein
EGFR Exon 20
Ja
Nein
cKIT Exon 9,11 (GIST)
Ja
Nein
cKIT Exon 11,17
Ja
Nein
cKIT Exon 11,13,17 (Melanom)
Ja
Nein
cKIT Exon 8
Ja
Nein
PDGFRA Exon 18
Ja
Nein
PDGFRA Exon 12,14
Ja
Nein
BRAF Exon 15 (V600)
Ja
Nein
GNA11 Exon 4,5
Ja
Nein
GNAQ Exon 4,5
Ja
Nein
PIK3CA Exon 9,20
Ja
Nein
CTNNB1 Exon 3
Ja
Nein
GNAS1 Exon 8
Ja
Nein
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AKT1 Exon 2
Ja
Nein
P53 Exon 4-10
Ja
Nein
PTEN Exon 5-8
Ja
Nein
NOTCH1 Exon 26,27,34
Ja
Nein
RET Exon 10,11,16
Ja
Nein
IDH1 Exon 4
Ja
Nein
IDH2 Exon 4
Ja
Nein
Amplifikationen/Deletionen/Translokatione
n (FISH)
HER2 FISH
Ja
Nein
n-MYK FISH
Ja
Nein
TOP2A FISH
Ja
Nein
EGFR FISH
Ja
Nein
EWSR1
Ja
Nein
ALK FISH
Ja
Nein
ROS1 FISH
Ja
Nein
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FUS FISH
Ja
Nein
BCL2 FISH
Ja
Nein
CCND1 FISH
Ja
Nein
c-MYK FISH
Ja
Nein
USP6 FISH
Ja
Nein
Translokationen (RT-PCR)
EWSR1/FLI1 t (11;22)(q24;q12)
Ja
Nein
EWSR1/ERG t (21;22)(q22;q12)
Ja
Nein
EWSR1/FEV t(2;22)(q33;q12)
Ja
Nein
EWSR1/ETV1 t(7;22)(p22;q12)
Ja
Nein
SYT/SSX1,SSX2 t(X;18)(p11;q11)
Ja
Nein
EWSR1/ATF1 t(12;22)(q13;q12)
Ja
Nein
EWSR1/WT1 t(11;22)(p13;q12)
Ja
Nein
PAX7/FKHR t(1;13)(p36;q14)
Ja
Nein
PAX3/FKHR t(2;13)(q35;q14)
Ja
Nein
TLS/CHOP t(12;16)(q13;p11)
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Ja
Nein
EWSR1/TEC t(9;22)(q22;q12)
Ja
Nein
ASPL/TFE3 t(X;17)(p11;q25)
Ja
Nein
Klonalitätsanalyse
IgH
Ja
Nein
TCRg
Ja
Nein
Virusnachweise
EBV
Ja
Nein
HPV Hochrisikotypen
Ja
Nein
HPV Niedrigrisikotypen
Ja
Nein
Erregernachweise (PCR)
Mycobacterium tuberculosis Komplex
Ja
Nein
T.whipplei
Ja
Nein
Resistenzen H.Pylori (PCR)
Helicobacter pylori Resistenz:Clarithromycin
Ja
Nein
Helicobacter pylori Resistenz:Ciprofloxacin
Ja
Nein
Helicobacter pylori Resistenz:Tetracycline
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Ja
Nein
HNPCC Diagnostik
Mikrosatelliteninstabilität
Ja
Nein
Hämochromatose
HFE C 282Y
Ja
Nein
HFE H63D,S65C,E168X
Ja
Nein
Sonstige Leistungen
DNA Isolation
Ja
Nein
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Fruits and Vegetables Intake Protocol
PhenX Toolkit
These questions from the Five-Factor Screener may be
useful to assess an individual’s approximate intake of
several foods. These particular questions address fruit and
vegetable intake. No portion-size questions are asked. This
screener does not attempt to assess total diet.
ODM derived from: https://cde.nlm.nih.gov
Primary source: https://www.phenxtoolkit.org/
Recent publication: Hendershot, T., Pan, H., Haines, J.,
Harlan, W.R., Marazita, M.L., McCarty, C.A., Ramos, E.M.,
and Hamilton, C.M. (2015) Using the PhenX toolkit to add
standard measures to a study. Curr. Protoc. Hum. Genet.
86:1.21.1-1.21.17. doi: 10.1002/0471142905.hg0121s86
Permission to publish granted by
Carol M. Hamilton.
All rights reserved. Please visit https://medical-data-
models.org/forms/14981
Fruits and Vegetables Intake
Protocol PhenX Toolkit
PhenX - fruits and veg protocol
During the past month, how often did you drink
100% FRUIT JUICE, such as orange, mango,
apple, and grape juices?
1 time per day   (1 time per day  )
1-2 times per week   (1-2 times per week
)
1-3 times per month  (1-3 times per
month )
2 times per day     (2 times per day    )
3 times per day     (3 times per day    )
3-4 times per week   (3-4 times per week
)
4 times per day     (4 times per day    )
5 or more times per day     (5 or more
times per day    )
5-6 times per week  (5-6 times per week
)
Don't know (Don't know)
Never     (Never    )
Refused (Refused)
During the past month . . . How often did you eat
FRUIT?
1 time per day   (1 time per day  )
1-2 times per week   (1-2 times per week
)
1-3 times per month  (1-3 times per
month )
2 times per day     (2 times per day    )
3 times per day     (3 times per day    )
3-4 times per week   (3-4 times per week
)
4 times per day     (4 times per day    )
5 or more times per day     (5 or more
times per day    )
5-6 times per week  (5-6 times per week
)
Don't know (Don't know)
Never     (Never    )
Refused (Refused)
During the past month, how often did you eat a
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green leafy or lettuce SALAD, with or without
other vegetables?
1 time per day     (1 time per day    )
1-2 times per week     (1-2 times per
week    )
1-3 times per month (1-3 times per
month)
2 times per day     (2 times per day    )
3 times per day (3 times per day)
3-4 times per week (3-4 times per week)
4 times per day     (4 times per day    )
5 or more times per day     (5 or more
times per day    )
5-6 times per week      (5-6 times per
week     )
Don´t know (Don´t know)
Never    (Never   )
Refused     (Refused    )
During the past month . . . How often did you eat
FRENCH FRIES, home fries, or hash brown
potatoes?
1 time per day     (1 time per day    )
1-2 times per week     (1-2 times per
week    )
1-3 times per month (1-3 times per
month)
2 times per day     (2 times per day    )
3 times per day (3 times per day)
3-4 times per week (3-4 times per week)
4 times per day     (4 times per day    )
5 or more times per day     (5 or more
times per day    )
5-6 times per week      (5-6 times per
week     )
Don´t know (Don´t know)
Never    (Never   )
Refused     (Refused    )
During the past month . . . How often did you eat
other WHITE POTATOES?
1 time per day     (1 time per day    )
1-2 times per week     (1-2 times per
week    )
1-3 times per month (1-3 times per
month)
2 times per day     (2 times per day    )
3 times per day (3 times per day)
3-4 times per week (3-4 times per week)
4 times per day     (4 times per day    )
5 or more times per day     (5 or more
times per day    )
5-6 times per week      (5-6 times per
week     )
Don´t know (Don´t know)
Never    (Never   )
Refused     (Refused    )
During the past month . . . How often did you eat
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COOKED DRIED BEANS, such as refried beans,
baked beans, bean soup, and pork and beans?
1 time per day     (1 time per day    )
1-2 times per week     (1-2 times per
week    )
1-3 times per month (1-3 times per
month)
2 times per day     (2 times per day    )
3 times per day (3 times per day)
3-4 times per week (3-4 times per week)
4 times per day     (4 times per day    )
5 or more times per day     (5 or more
times per day    )
5-6 times per week      (5-6 times per
week     )
Don´t know (Don´t know)
Never    (Never   )
Refused     (Refused    )
During the past month . . . Not counting what you
just told me about (lettuce salads, white potatoes,
cooked dried beans), and not counting rice, how
often did you eat OTHER VEGETABLES?
1 time per day     (1 time per day    )
1-2 times per week     (1-2 times per
week    )
1-3 times per month (1-3 times per
month)
2 times per day     (2 times per day    )
3 times per day (3 times per day)
3-4 times per week (3-4 times per week)
4 times per day     (4 times per day    )
5 or more times per day     (5 or more
times per day    )
5-6 times per week      (5-6 times per
week     )
Don´t know (Don´t know)
Never    (Never   )
Refused     (Refused    )
During the past month . . . How often did you
have TOMATO SAUCES such as spaghetti sauce
or pizza with tomato sauce?
1 time per day     (1 time per day    )
1-2 times per week     (1-2 times per
week    )
1-3 times per month (1-3 times per
month)
2 times per day     (2 times per day    )
3 times per day (3 times per day)
3-4 times per week (3-4 times per week)
4 times per day     (4 times per day    )
5 or more times per day     (5 or more
times per day    )
5-6 times per week      (5-6 times per
week     )
Don´t know (Don´t know)
Never    (Never   )
Refused     (Refused    )
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During the past month . . . How often did you
have SALSA?
1 time per day     (1 time per day    )
1-2 times per week     (1-2 times per
week    )
1-3 times per month (1-3 times per
month)
2 times per day     (2 times per day    )
3 times per day (3 times per day)
3-4 times per week (3-4 times per week)
4 times per day     (4 times per day    )
5 or more times per day     (5 or more
times per day    )
5-6 times per week      (5-6 times per
week     )
Don´t know (Don´t know)
Never    (Never   )
Refused     (Refused    )
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History of Prepubertal Development - Male
PhenX Toolkit
Male participants answer questions about the timing of
various maturation milestones.
ODM derived from: https://cde.nlm.nih.gov
Primary source: https://www.phenxtoolkit.org/
Recent publication: Hendershot, T., Pan, H., Haines, J.,
Harlan, W.R., Marazita, M.L., McCarty, C.A., Ramos, E.M.,
and Hamilton, C.M. (2015) Using the PhenX toolkit to add
standard measures to a study. Curr. Protoc. Hum. Genet.
86:1.21.1-1.21.17. doi: 10.1002/0471142905.hg0121s86
Permission to publish granted by
Carol M. Hamilton.
All rights reserved. Please visit https://medical-data-
models.org/forms/14982
History of Prepubertal Development -
Male PhenX Toolkit
PhenX - history of prepubertal
development - male protocol
At about what age did you reach your full height?
13-17 years of age    (13-17 years of age
)
After age 17 (After age 17)
Before age 13     (Before age 13    )
Don't know (Don't know)
Your voice changed. Compared to your friends
was this:
About the same time     (About the same
time    )
Don't know (Don't know)
Earlier     (Earlier    )
Later  (Later )
What is your age when your voice changed?
Your penis started increasing in size. Compared
to your friends was this:
About the same time     (About the same
time    )
Don't know (Don't know)
Earlier     (Earlier    )
Later  (Later )
What is your age when your penis started
increasing in size?
Your testicles started increasing in size.
Compared to your friends was this:
About the same time     (About the same
time    )
Don't know (Don't know)
Earlier     (Earlier    )
Later  (Later )
What is your age when your testicles started
increasing in size?
You developed pubic hair. Compared to your
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friends was this:
About the same time     (About the same
time    )
Don't know (Don't know)
Earlier     (Earlier    )
Later  (Later )
What is your age when you developed pubic
hair?
Would you say these changes:
Are definitely underway   (Are definitely
underway  )
Have barely started     (Have barely
started    )
Have not yet begun  (Have not yet begun
)
Seem completed (Seem completed)
How old were you when you entered puberty, that
is, when these changes began?
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Specialized pathological assessment with
critical opinion Pathology UKM
Specialized pathological assessment with critical opinion 
Gerhard-Domagk-Institute of Pathology
Univ.-Prof.Dr.med.Eva Wardelmann
Albert-Schweitzer-Campus 1 Building D17
48149 Münster
Phone:0251-83-57550
Fax:0251-83-55481
E-mail:pathologie@ukmuenster.de
All rights reserved. Please visit https://medical-data-
models.org/forms/14983
Specialized pathological assessment
with critical opinion
Fachpathologische Beurteilung mit
kritischer Stellungnahme
Übersandtes Material
Molekularpathologie: Mutationsanalyse EGFR
Ergebnis
Molekularpathologie: Untersuchung auf
chromosomale Translokationen mit Chromosom
2p23 (ALK) als Translokationspartner
Ergebnis
Molekularpathologie: Untersuchung auf
chromosomale Translokationen mit Chromosom
6q22 (ROS1) als Translokationspartner
Ergebnis
Diagnose
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Eligibility Coronary Artery Disease
NCT02284750
Complexity of Bifurcation Lesions Treated With Optimal
Strategies; ODM derived from:
https://clinicaltrials.gov/show/NCT02284750
All rights reserved. Please visit https://medical-data-
models.org/forms/14985
Eligibility Coronary Artery Disease
NCT02284750
Inclusion Criteria
provision of informed consent prior to any study
specific procedures;*
Yes
No
men and women 18 years and older;.*
Yes
No
established indication to pci according to the
guidelines of american heart association and
american college of cardiology;*
Yes
No
native coronary lesion suitable for drug-eluting
stent placement;*
Yes
No
true bifurcation lesions (medina 0,1,1/1,1,1
/1,0,1);*
Yes
No
reference vessel diameter in side branch ≥2.5mm
by visual estimation.*
Yes
No
Exclusion Criteria
pregnancy and breast feeding mother;*
Yes
No
co-morbidity with an estimated life expectancy of
< 50 % at 12 months;*
Yes
No
scheduled major surgery in the next 12 months;*
Yes
No
inability to follow the protocol and comply with
follow-up requirements or any other reason that
the investigator feels would place the patient at
increased risk;*
Yes
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No
previous enrolment in this study or treatment with
an investigational drug or device under another
study protocol in the past 30 days;*
Yes
No
known allergy against ticagrelor, or against
clopidogrel, or aspirin history of major
hemorrhage (intracranial, gastrointestinal, etc.);*
Yes
No
chronic total occlusion lesion in either lad, or lcx
or rca not re-canalized;*
Yes
No
severe calcification needing rotational
atherectomy；*
Yes
No
patient with stemi (within 24-hour from the onset
of chest pain to admission).*
Yes
No
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Performed diagnosis Other proof of execution
Routine documentation in German hospitals DMI
Routine documentation in German hospitals. Source file
name: VL040399_Sonstiger Durchführungsnachweis/
Erfolgte Diagnostik.021
Examplary forms provided by DMI (http://www.dmi.de/)
All rights reserved. Please visit https://medical-data-
models.org/forms/14992
Performed diagnosis Other proof of
execution
Diagnostic measures
Informed consent discussion, beyond the normal
level
Yes
No
Comment
Palpation
Yes
No
Comment
Proctoscopy
Yes
No
Comment
Endosonography
Yes
No
Comment
Defecography
Yes
No
Comment
Transit time determination
Yes
No
Comment
CT/ MRI
Yes
No
Comment
Rectoscopy
Yes
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No
Comment
Pudendal latency test
Yes
No
Comment
Date
Physician
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German hospitals DMI
Histology Histology findings Routine
documentation in German hospitals DMI
Routine documentation in German hospitals. Source file
name: PT080102_Histologiebefund/ Histologie.071
Examplary forms provided by DMI (http://www.dmi.de/)
All rights reserved. Please visit https://medical-data-
models.org/forms/14993
Histology Histology findings
Histological finding
Register number
Patient ID
Patient name
Date of birth
Arrival date
Outcome date
Test material
Clinical details
Histological finding
Assessment
Physician
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Eligibility Coronary Artery Disease
NCT02379923
The Asahi Intecc PTCA Chronic Total Occlusion Study;
ODM derived from:
https://clinicaltrials.gov/show/NCT02379923
All rights reserved. Please visit https://medical-data-
models.org/forms/14995
Eligibility Coronary Artery Disease
NCT02379923
Inclusion Criteria
general inclusion criteria:*
Yes
No
1. subject is ≥ 18 years of age at the time of
consent*
Yes
No
2. subject is experiencing clinical symptoms
considered suggestive of ischemic heart disease
(e.g., chest pain or discomfort, heart failure, etc.)
or has evidence of myocardial ischemia (e.g.,
abnormal functional study) attributed to the cto
target vessel and is scheduled for clinically
indicated percutaneous revascularization*
Yes
No
3. subject is eligible and consents to undergo pci
procedure*
Yes
No
4. subject is an acceptable candidate for
percutaneous transluminal coronary angioplasty
(ptca), stenting, and emergency coronary artery
bypass grafting (cabg)*
Yes
No
5. subject is willing and able to sign an informed
consent form approved by a local institutional
review board*
Yes
No
6. female subjects of child-bearing potential must
have a negative qualitative or quantitative
pregnancy test within 7 days before the study
procedure*
Yes
No
angiographic inclusion criteria:*
Yes
No
7. a minimum of one de novo lesion with at least
one target segment in a native coronary vessel
meeting definition of chronic total occlusion. non-
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study lesions will be treated first. a "chronic total
occlusion" is any non-acute total coronary
occlusion fulfilling the angiographic
characteristics consistent with high-grade native
coronary stenosis (timi 0 or 1) and estimated in
duration at least 3 months by clinical history
and/or comparison with antecedent angiogram or
electrocardiogram. an attempt to cross the target
lesion with at least one asahi guidewire or a
corsair microcatheter must be made.*
Yes
No
Exclusion Criteria
general exclusion criteria:*
Yes
No
1. subjects with any history of allergy to iodinated
contrast that cannot be effectively managed
medically*
Yes
No
2. evidence of acute mi within 72 hours of the
intended treatment defined as cardiac enzymes
greater than uln.*
Yes
No
3. previous coronary interventional procedure of
any kind within the 30 days prior to the
procedure*
Yes
No
4. any contraindication to cardiac catheterization
or to any of the standard concomitant therapies
used during routine cardiac catheterization and
pci (e.g., aspirin, clopidogrel, unfractionated
heparin, etc.)*
Yes
No
5. target lesion requires treatment with a device
after successful crossing other than ptca prior to
stent placement*
Yes
No
6. subjects with known history of clinically
significant abnormal laboratory findings
including:*
Yes
No
neutropenia (<1000 neutrophils/mm3) within the
previous 2 weeks*
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Yes
No
thrombocytopenia (<100,000 platelets/mm3)*
Yes
No
ast, alt, alkaline phosphatase, or bilirubin > 1.5 ×
uln*
Yes
No
serum creatinine > 2.0 mg/dl*
Yes
No
7. subjects with evidence of ongoing or active
clinical instability including the following:*
Yes
No
sustained systolic blood pressure < 100 mmhg or
cardiogenic shock*
Yes
No
acute pulmonary edema or severe congestive
heart failure*
Yes
No
suspected acute myocarditis, pericarditis,
endocarditis, or cardiac tamponade*
Yes
No
suspected dissecting aortic aneurysm*
Yes
No
hemodynamically significant valvular heart
disease, hypertrophic cardiomyopathy, restrictive
cardiomyopathy, or congenital heart disease*
Yes
No
8. history of stroke or transient ischemic attack
within the prior 6 months*
Yes
No
9. active peptic ulcer or upper gastrointestinal (gi)
bleeding within the prior 6 months*
Yes
No
10. history of bleeding diathesis or coagulopathy
or refusal of blood transfusions*
Yes
No
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11. subjects with any other pathology such as
cancer, mental illness, etc., which in the opinion
of the investigator, might put the patient at risk,
preclude follow-up, or in any way confound the
results of the study*
Yes
No
12. known previous medical condition yielding
expected survival less than 1 year*
Yes
No
13. subjects who are unable or unwilling to
comply with the protocol or not expected to
complete the study period, including its follow-up
requirements*
Yes
No
14. currently participating in an investigational
drug or another device study that has not
completed the primary endpoint or that clinically
interferes with the current study endpoints; or
requires coronary angiography, intravascular
ultrasound (ivus), or other coronary artery
imaging procedures*
Yes
No
angiographic exclusion criteria:*
Yes
No
15. occlusion involves segment within previous
stent*
Yes
No
16. extensive lesion-related thrombus (timi
thrombus grade 3 or 4)*
Yes
No
17. previous stenting (drug-eluting or bare metal)
in the target vessel unless the following
conditions are met:*
Yes
No
it has been at least 9 months since the previous
stenting*
Yes
No
that target lesion is at least 15 mm away from the
previously placed stent*
Yes
No
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the previously stented segment (stent plus 5 mm
on either side) has no more than 40% diameter
stenosis, based on visual estimate*
Yes
No
18. the target vessel has other lesions proximal to
the total occlusion identified with greater than
75% diameter stenosis based on visual estimate.
however, planned stenting of the lesion in target
vessel which is proximal to the target lesion and
can be covered by a single stent (i.e., tandem
lesions) are acceptable.*
Yes
No
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Eligibility Coronary Disease NCT02409446
Metabolic, Vascular and Cognitive Effects of Treatment
With Anthocyanins; ODM derived from:
https://clinicaltrials.gov/show/NCT02409446
All rights reserved. Please visit https://medical-data-
models.org/forms/14996
Eligibility Coronary Disease
NCT02409446
Inclusion Criteria
age above 50 years and coronary suspect chest
pain with angiographically cad without
physiologically stenosis*
Yes
No
mild cognitive impairment (icd 10) or mild
dementia, defined as fulfilling the dementia
criteria (icd 10) but with an mmse score of 24 or
higher.*
Yes
No
stable medical treatment for the last 3 months.*
Yes
No
Exclusion Criteria
moderate to severe dementia (mmse < 24)*
Yes
No
clinical significant depression (gds-15 score of 7
or higher)*
Yes
No
unstable coronary heart disease*
Yes
No
heart failure in need of treatment*
Yes
No
inflammatory illnesses such at rheumatoid
arthritis etc.*
Yes
No
another severe illness with < 5 year expected
survival time.*
Yes
No
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Diary Card: Local Symptoms Safety and Immunogenicity Study of a Booster Dose
of GSK Biologicals 10-valent Pneumococcal Conjugate Vaccine NCT00370396
This study will evaluate the safety, reactogenicity and
immunogenicity of a booster dose of GSK Biologicals'
pneumococcal conjugate vaccine compared to Prevenar™
given at 12-18 mo of age to children primed with either
pneumococcal vaccine or Prevenar™ in study 105553.
Antibody persistence will be evaluated at 8-14 mo after
completion of the 3-dose immunization course in study
105553. The immune response to a booster dose of GSK
Biologicals' pneumococcal conjugate vaccine will also be
evaluated when given at 12-18 mo to subjects not primed
with GSK Biologicals' vaccine but with Prevenar™.
The study has 3 groups. 1 group of children primed with
GSK Biologicals' pneumococcal conjugate vaccine will
receive a booster dose of the same vaccine. 2nd group of
children primed with Prevenar™ will receive a booster dose
of Prevenar™ (control group). 3rd group of children primed
with Prevenar™ will receive a booster dose of GSK
Biologicals' pneumococcal conjugate vaccine. All children
will receive concomitantly a booster dose of DTPa-HBV-
IPV/Hib vaccine.
NCT00370396
Part: Diary Card: Local Symptoms
All rights reserved. Please visit https://medical-data-
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Diary Card: Local Symptoms "Safety
and Immunogenicity Study of a
Booster Dose of GSK Biologicals'
10-valent Pneumococcal Conjugate
Vaccine" NCT00370396
Identification
Center number
Subject ID
Treatment Number
Date of birth
Gender
Female (f)
Male (m)
Date of vaccination
Local Symptoms (At Injection Sites)
Type of Vaccine Administered
10Pn-PD-DiT or Prevenar vaccine (1)
DTPa-HBV-IPV/Hib vaccine (2)
Injection side
Left  (L)
Right (R)
Injection site
Arm (1)
thigh (3)
1 / 3
buttock (6)
Local Symptoms
Redness (1)
Swelling (2)
Pain (3)
Symptom Size/Intensity Day 0
Symptom Size/Intensity Day 1
Symptom Size/Intensity Day 2
Symptom Size/Intensity Day 3
Ongoing after Day 3
Yes
No
Date of last Symptoms
Medically Attended visit
Yes
No
Other Local Symptoms
Description - please specify side(s) and site(s)
Intensity
Mild: An adverse event which is easily
tolerated by the subject, causing minimal
discomfort and not (1)
Moderate: An adverse event which is
sufficiently discomforting to interfere with
normal everyday activities. (2)
Severe: An adverse event which
prevents normal, everyday activities. (In
a young child, such an adverse
spontaneously painful event would, for
example, prevent attendance at
school/kindergarten/a day-care center
and would cause the parents/guardians
to seek. medical advice). (3)
Start date
dd/mm/yy
End date
dd/mm/yy
Is the symptom persistent?
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Yes
No
Medically Attended visit
Yes
No
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Diary Card: General Symptoms Safety and Immunogenicity Study of a Booster
Dose of GSK Biologicals 10-valent Pneumococcal Conjugate Vaccine
NCT00370396
This study will evaluate the safety, reactogenicity and
immunogenicity of a booster dose of GSK Biologicals'
pneumococcal conjugate vaccine compared to Prevenar™
given at 12-18 mo of age to children primed with either
pneumococcal vaccine or Prevenar™ in study 105553.
Antibody persistence will be evaluated at 8-14 mo after
completion of the 3-dose immunization course in study
105553. The immune response to a booster dose of GSK
Biologicals' pneumococcal conjugate vaccine will also be
evaluated when given at 12-18 mo to subjects not primed
with GSK Biologicals' vaccine but with Prevenar™.
The study has 3 groups. 1 group of children primed with
GSK Biologicals' pneumococcal conjugate vaccine will
receive a booster dose of the same vaccine. 2nd group of
children primed with Prevenar™ will receive a booster dose
of Prevenar™ (control group). 3rd group of children primed
with Prevenar™ will receive a booster dose of GSK
Biologicals' pneumococcal conjugate vaccine. All children
will receive concomitantly a booster dose of DTPa-HBV-
IPV/Hib vaccine.
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Diary Card: General Symptoms
"Safety and Immunogenicity Study of
a Booster Dose of GSK Biologicals'
10-valent Pneumococcal Conjugate
Vaccine" NCT00370396
Identification
Center number
Subject ID
Treatment Number
Date of birth
Gender
Female (f)
Male (m)
Date of vaccination
General Symptoms
Symptom
Temperature (1)
Irritability/Fussiness (2)
Drowsiness (3)
Loss of Appetite (4)
Temperature / Intensity
Temperature Measurement site
Axillary (1)
1 / 3
Oral (2)
Tymp (oral setting) (3)
Tymp (rectal setting) (4)
Rectal (preferably) (5)
Temperature / Intensity Day 1
Temperature / Intensity Day 2
Temperature / Intensity Day 3
Ongoing after Day 3
Yes
No
Date of last Symptoms
Medically attended visit
Yes
No
Other General Symptoms
Description
Intensity
Start date:
End date
dd/mm/yy
Medically attended visit
Yes
No
Medication
Trade/Generic name
Reason
total daily dose
mg
Start date
dd/mm/yy
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NCT00370396
End date
dd/mm/yy
Continuing
Yes
No
Administration
Please Do Not Forget To Bring Back The Diary
Card On
In Case Of Hospitalisation, Please Inform
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Large Swelling Reaction Safety and Immunogenicity Study of a Booster Dose of
GSK Biologicals 10-valent Pneumococcal Conjugate Vaccine NCT00370396
This study will evaluate the safety, reactogenicity and
immunogenicity of a booster dose of GSK Biologicals'
pneumococcal conjugate vaccine compared to Prevenar™
given at 12-18 mo of age to children primed with either
pneumococcal vaccine or Prevenar™ in study 105553.
Antibody persistence will be evaluated at 8-14 mo after
completion of the 3-dose immunization course in study
105553. The immune response to a booster dose of GSK
Biologicals' pneumococcal conjugate vaccine will also be
evaluated when given at 12-18 mo to subjects not primed
with GSK Biologicals' vaccine but with Prevenar™.
The study has 3 groups. 1 group of children primed with
GSK Biologicals' pneumococcal conjugate vaccine will
receive a booster dose of the same vaccine. 2nd group of
children primed with Prevenar™ will receive a booster dose
of Prevenar™ (control group). 3rd group of children primed
with Prevenar™ will receive a booster dose of GSK
Biologicals' pneumococcal conjugate vaccine. All children
will receive concomitantly a booster dose of DTPa-HBV-
IPV/Hib vaccine.
NCT00370396
Part: Large Swelling Reaction
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Large Swelling Reaction "Safety and
Immunogenicity Study of a Booster
Dose of GSK Biologicals' 10-valent
Pneumococcal Conjugate Vaccine"
NCT00370396
Identification
Center number
Subject ID
Treatment Number
Visit Number
1 (1)
2 (2)
Vaccine administered for which the large swelling
reaction reported:
1 OPn-PD-DiT Vaccine or Prevenar
Vaccine (901)
DTPa-HBV-IPV/Hib Vaccine (93)
Report of physical examination
Date of physical
examination
Was the examination performed by a member of
study personnel
during the large swelling reaction period:
Yes
No
Date when the swelling
1 / 3
was first considered to be 
a large swelling reaction:
If occurring within 24 hours after vaccination,
please
I I I hours specify how loni:i after vaccination:
Size of swelling
Type of swelling
Local swelling around injection site, not
involving adjacent joint (1)
Diffuse swelling, not involving adjacent
joint (2)
Swelling, involving adjacent joint (3)
Circumference of swollen limb (at the site of
maximum
swelling)
Circumference of the opposite limb (at the same
level):
Associated signs: Temperature
Route of temperature Measurement
Axillary (A)
Oral (O)
Rectal (R)
Tympanic oral (X)
Tympanic rectal (Y)
Associated signs: Redness
Yes
No
Redness Diameter
lnduration
Yes
No
Largest Diameter of Induration
Pain
Yes
No
Pain Intensity
grade 1  (1)
grade 2 (2)
grade 3 (3)
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Functional impairment
Intensity of functional impairment
Grade 1 (1)
Grade 2  (2)
Grade 3 (3)
Clinical case descri tion and outcome of
the adverse event
Case description
Last date when the
swelling was still
considered to be large
swellin reaction:
Duration (hours)
Outcome of the large
swelling reaction:
Recovered / resolved (1)
Recovering / resolving (2)
Not recovered / not resolved  (3)
Recovered with sequelae / resolved with
sequelae (4)
Is there an alternative
explanation for the
swelling?
Yes
No
Alternative Explanation: Specification
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Concomitant Vaccination Safety and Immunogenicity Study of a Booster Dose
of GSK Biologicals 10-valent Pneumococcal Conjugate Vaccine NCT00370396
This study will evaluate the safety, reactogenicity and
immunogenicity of a booster dose of GSK Biologicals'
pneumococcal conjugate vaccine compared to Prevenar™
given at 12-18 mo of age to children primed with either
pneumococcal vaccine or Prevenar™ in study 105553.
Antibody persistence will be evaluated at 8-14 mo after
completion of the 3-dose immunization course in study
105553. The immune response to a booster dose of GSK
Biologicals' pneumococcal conjugate vaccine will also be
evaluated when given at 12-18 mo to subjects not primed
with GSK Biologicals' vaccine but with Prevenar™.
The study has 3 groups. 1 group of children primed with
GSK Biologicals' pneumococcal conjugate vaccine will
receive a booster dose of the same vaccine. 2nd group of
children primed with Prevenar™ will receive a booster dose
of Prevenar™ (control group). 3rd group of children primed
with Prevenar™ will receive a booster dose of GSK
Biologicals' pneumococcal conjugate vaccine. All children
will receive concomitantly a booster dose of DTPa-HBV-
IPV/Hib vaccine.
NCT00370396
Part: Concomitant Vaccination
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Concomitant Vaccination "Safety and
Immunogenicity Study of a Booster
Dose of GSK Biologicals' 10-valent
Pneumococcal Conjugate Vaccine"
NCT00370396
Identification
Center number
Subject ID
Treatment Number
Visit Number
1 (1)
2 (2)
Concomitant Vaccination
Has any vaccine other than the study vaccine(s)
been administered during the timeframe as
specified
in the Protocol?
Yes
No
Concomitant Vaccination List
Trade / (Generic) Name
Route
lntradermal (ID)
Inhalation (IH)
Intramuscular (IM)
1 / 2
Intravenous (IV)
Intranasal (NA)
Other (OTH)
Parenteral (PE)
Oral (PO)
Subcutaneous (SC)
Sublingual (SL)
Transdermal (TD)
Unknown (UNK)
Administration date
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Medication Safety and Immunogenicity Study of a Booster Dose of GSK
Biologicals 10-valent Pneumococcal Conjugate Vaccine NCT00370396
This study will evaluate the safety, reactogenicity and
immunogenicity of a booster dose of GSK Biologicals'
pneumococcal conjugate vaccine compared to Prevenar™
given at 12-18 mo of age to children primed with either
pneumococcal vaccine or Prevenar™ in study 105553.
Antibody persistence will be evaluated at 8-14 mo after
completion of the 3-dose immunization course in study
105553. The immune response to a booster dose of GSK
Biologicals' pneumococcal conjugate vaccine will also be
evaluated when given at 12-18 mo to subjects not primed
with GSK Biologicals' vaccine but with Prevenar™.
The study has 3 groups. 1 group of children primed with
GSK Biologicals' pneumococcal conjugate vaccine will
receive a booster dose of the same vaccine. 2nd group of
children primed with Prevenar™ will receive a booster dose
of Prevenar™ (control group). 3rd group of children primed
with Prevenar™ will receive a booster dose of GSK
Biologicals' pneumococcal conjugate vaccine. All children
will receive concomitantly a booster dose of DTPa-HBV-
IPV/Hib vaccine.
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Medication "Safety and
Immunogenicity Study of a Booster
Dose of GSK Biologicals' 10-valent
Pneumococcal Conjugate Vaccine"
NCT00370396
Identification
Center number
Subject ID
Treatment Number
Visit Number
1 (1)
2 (2)
Medication
Have any medications/treatments been
administered during study period?
Yes
No
Medication List
Trade / Generic Name
Medical Indication
Prophylactic treatment
Yes
No
1 / 2
Total daily
dose
Route
External (EXT)
lntradermal (ID)
Inhalation (IH)
Intramuscular (IM)
lntraarticular (IR)
lntrathecal (IT)
Intravenous (IV)
Intranasal (NA)
Other (OTH)
Parenteral (PE)
Oral (PO)
Rectal (PR)
Subcutaneous (SC)
Sublinqual (SL)
Transdermal (TD)
Topical (TO)
Unknown (UNK)
Vaqinal (VA)
Start Date of Medication
End Date of Medication
End Date is End Date of Study
Yes
No
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Non-Serious Adverse Events Safety and Immunogenicity Study of a Booster Dose
of GSK Biologicals 10-valent Pneumococcal Conjugate Vaccine NCT00370396
This study will evaluate the safety, reactogenicity and
immunogenicity of a booster dose of GSK Biologicals'
pneumococcal conjugate vaccine compared to Prevenar™
given at 12-18 mo of age to children primed with either
pneumococcal vaccine or Prevenar™ in study 105553.
Antibody persistence will be evaluated at 8-14 mo after
completion of the 3-dose immunization course in study
105553. The immune response to a booster dose of GSK
Biologicals' pneumococcal conjugate vaccine will also be
evaluated when given at 12-18 mo to subjects not primed
with GSK Biologicals' vaccine but with Prevenar™.
The study has 3 groups. 1 group of children primed with
GSK Biologicals' pneumococcal conjugate vaccine will
receive a booster dose of the same vaccine. 2nd group of
children primed with Prevenar™ will receive a booster dose
of Prevenar™ (control group). 3rd group of children primed
with Prevenar™ will receive a booster dose of GSK
Biologicals' pneumococcal conjugate vaccine. All children
will receive concomitantly a booster dose of DTPa-HBV-
IPV/Hib vaccine.
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Non-Serious Adverse Events "Safety
and Immunogenicity Study of a
Booster Dose of GSK Biologicals'
10-valent Pneumococcal Conjugate
Vaccine" NCT00370396
Identification
Center number
Subject ID
Treatment Number
Visit Number
1 (1)
2 (2)
Non Serious Adverse Events
Has any non-serious adverse events occurred
within one month (minimum 30 days) post-
vaccination,
excluding those recorded on the Solicited
Adverse Events pages?
Yes
No
Non Serious Adverse Events: List
Number of Adverse Event
Yes
No
Description of Adverse Event
1 / 2
Site of Adverse Event
Non-administration site (G)
Administration sites: 10Pn-PD-DiT
vaccineor Prevenar vaccine (L901)
Administration sites: DTPa-HBV-IPV/Hib
vaccine (L93)
Start date
dd/mm/yy
Stop Date
Start during immediate Post Vaccination Period
Yes
No
Maximum Intensity:
Mild (1)
Moderate (2)
Severe (3)
Is there a reasonable
possibility that the AE may
have been caused by the
investigational product?
No (N)
Yes (Y)
Outcome:
Recovered / resolved (1)
Recovering / resolving (2)
Not recovered / not resolved (3)
Recovered with sequelae / resolved with
sequelae (4)
Medically attended visit
Yes
No
Medically Attended visit Specification
Emergency Room (ER)
Hospitalisation (HO)
Medical Personnel (MD)
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Study Conclusion Safety and Immunogenicity Study of a Booster Dose of
GSK Biologicals 10-valent Pneumococcal Conjugate Vaccine NCT00370396
This study will evaluate the safety, reactogenicity and
immunogenicity of a booster dose of GSK Biologicals'
pneumococcal conjugate vaccine compared to Prevenar™
given at 12-18 mo of age to children primed with either
pneumococcal vaccine or Prevenar™ in study 105553.
Antibody persistence will be evaluated at 8-14 mo after
completion of the 3-dose immunization course in study
105553. The immune response to a booster dose of GSK
Biologicals' pneumococcal conjugate vaccine will also be
evaluated when given at 12-18 mo to subjects not primed
with GSK Biologicals' vaccine but with Prevenar™.
The study has 3 groups. 1 group of children primed with
GSK Biologicals' pneumococcal conjugate vaccine will
receive a booster dose of the same vaccine. 2nd group of
children primed with Prevenar™ will receive a booster dose
of Prevenar™ (control group). 3rd group of children primed
with Prevenar™ will receive a booster dose of GSK
Biologicals' pneumococcal conjugate vaccine. All children
will receive concomitantly a booster dose of DTPa-HBV-
IPV/Hib vaccine.
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Study Conclusion "Safety and
Immunogenicity Study of a Booster
Dose of GSK Biologicals' 10-valent
Pneumococcal Conjugate Vaccine"
NCT00370396
Identification
Center number
Subject ID
Treatment Number
Visit Number
1 (1)
2 (2)
Study Conclusion
Was the subject withdrawn from the study?
Yes
No
Major reason for withdrawal
Non-Serious adverse event (AEX)
Consent withdrawal, not due to an
adverse event. (CWS)
Lost to follow-up. (LFU)
Migrated I moved from the study area
(MIG)
Other (OTH)
Protocol violation, please specify: (PTV)
Serious adverse event (SAE)
SAE No
1 / 2
AE No or solicited AE No
Violation of Protocol
Other, specification
Who made the decision
Investigator  (I)
Parents/Guardians (P)
Date of last contact
Was the subject in good condition at date of last
contact
Yes
No
Investigators Signature
Date of Signature
Printed Investigator's
name
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Extended safety follow-up contact Safety and Immunogenicity Study of a Booster
Dose of GSK Biologicals 10-valent Pneumococcal Conjugate Vaccine
NCT00370396
This study will evaluate the safety, reactogenicity and
immunogenicity of a booster dose of GSK Biologicals'
pneumococcal conjugate vaccine compared to Prevenar™
given at 12-18 mo of age to children primed with either
pneumococcal vaccine or Prevenar™ in study 105553.
Antibody persistence will be evaluated at 8-14 mo after
completion of the 3-dose immunization course in study
105553. The immune response to a booster dose of GSK
Biologicals' pneumococcal conjugate vaccine will also be
evaluated when given at 12-18 mo to subjects not primed
with GSK Biologicals' vaccine but with Prevenar™.
The study has 3 groups. 1 group of children primed with
GSK Biologicals' pneumococcal conjugate vaccine will
receive a booster dose of the same vaccine. 2nd group of
children primed with Prevenar™ will receive a booster dose
of Prevenar™ (control group). 3rd group of children primed
with Prevenar™ will receive a booster dose of GSK
Biologicals' pneumococcal conjugate vaccine. All children
will receive concomitantly a booster dose of DTPa-HBV-
IPV/Hib vaccine.
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Extended safety follow-up contact
"Safety and Immunogenicity Study of
a Booster Dose of GSK Biologicals'
10-valent Pneumococcal Conjugate
Vaccine" NCT00370396
Identification
Center number
Subject ID
Treatment Number
Date of birth
Gender
Female (f)
Male (m)
Study Conclusion Extended Safety Follow-
Up Contact
Could the subject I subject's parents/guardians
be contacted after the end of the active phase?
Yes
No
Date of last contact
Has the subject received any other investigational
and/or non-registered vaccine and/or
drug since the end of the active phase?
Yes
No
1 / 2
Reason for no successive Contract
Consent withdrawal (CWS)
Lost to follow-up (LFU)
Did the subject experience any serious adverse
event(s) (SAE(s) since the end of the active
phase?
No (N)
Subject could not be contacted (NA)
Yes (Y)
Has the subject experienced any meningitis ?
Yes
No
Investigator's Signature
Date of Signature
Name of Investigator
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Medical History Safety and Immunogenicity Study of a Booster Dose of GSK
Biologicals 10-valent Pneumococcal Conjugate Vaccine NCT00370396
This study will evaluate the safety, reactogenicity and
immunogenicity of a booster dose of GSK Biologicals'
pneumococcal conjugate vaccine compared to Prevenar™
given at 12-18 mo of age to children primed with either
pneumococcal vaccine or Prevenar™ in study 105553.
Antibody persistence will be evaluated at 8-14 mo after
completion of the 3-dose immunization course in study
105553. The immune response to a booster dose of GSK
Biologicals' pneumococcal conjugate vaccine will also be
evaluated when given at 12-18 mo to subjects not primed
with GSK Biologicals' vaccine but with Prevenar™.
The study has 3 groups. 1 group of children primed with
GSK Biologicals' pneumococcal conjugate vaccine will
receive a booster dose of the same vaccine. 2nd group of
children primed with Prevenar™ will receive a booster dose
of Prevenar™ (control group). 3rd group of children primed
with Prevenar™ will receive a booster dose of GSK
Biologicals' pneumococcal conjugate vaccine. All children
will receive concomitantly a booster dose of DTPa-HBV-
IPV/Hib vaccine.
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Medical History "Safety and
Immunogenicity Study of a Booster
Dose of GSK Biologicals' 10-valent
Pneumococcal Conjugate Vaccine"
NCT00370396
Identification
Center number
Subject ID
Treatment Number
GENERAL MEDICAL HISTORY I
PHYSICAL EXAMINATION
Are you aware of any pre-existing conditions,
signs or symptoms present prior to the start of
the study?
Yes
No
Medical History List
MedDRA System Organ Class
Skin and subcutaneous tissue (1)
Eye (10)
Ear and labyrinth (11)
Endocrine (12)
Metabolism and nutrition (13)
Blood and lymphatic system (14)
Immune system (incl allergies,
autoimmune disorders) (15)
Infections and infestations (16)
Neoplasms benign, malignantand
1 / 2
unspecified (incl cysts. polyps) (17)
Surgical and medicalprocedures (18)
Musculoskeletal and connective tissue
(2)
Cardiac (3)
Vascular (4)
Respiratory, thoracic and mediastinal (5)
Gastrointestinal (6)
Hepatobiliary (7)
Renal and urinary (8)
Nervous system (9)
Other (99)
Diagnosis
Past or current
current  (1)
past (2)
Laboratory Tests
Has a bloodsample been taken?
Yes
No
Date of Bloodsample
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Request for iliac crest biopsy, Pathology
UKM
Request for iliac crest biopsy, Pathology UKM
Please use this form for requests for iliac crest biopsy.
Gerhard-Domagk-Institute of Pathology Univ.-
Prof.Dr.med.Eva Wardelmann Albert-Schweitzer-Campus 1
Building D17 48149 Münster Phone:0251-83-57550
Fax:0251-83-55481 E-mail:pathologie@ukmuenster.de
All rights reserved. Please visit https://medical-data-
models.org/forms/15007
Request for iliac crest biopsy
Patientendaten
Patient Name
Patient ID
Patient Geburtsdatum
Fallnummer
Patient Krankenversicherung
Auftragsnummer
Auftragstatus
Dringlichkeit
Leistende Stelle
Auftragsdatum
Anfordernde Fachabteilung
Anfordernde Stelle
Anfordernder Arzt
Terminwunsch
Kommentar
Cave
Mobilität
Vorbefunde
Infektiosität
1 / 4
Keine (1)
Nicht bekannt (2)
Hep B (3)
Hep C (4)
Tbc (5)
HIV (6)
VRE (7)
MRSA (8)
Sonstiges (9)
Infektiosität:bitte spezifizieren Sie sonstige
infektiöse Erkrankung
Versicherungsstatus stationär
Regelleistung (1)
Wahlleistung/Arzt (2)
Versicherungsstatus Ambulant
Krankenkasse (1)
Privat (2)
Material
Schnellschnitt (1)
Gewebe (2)
Punktat (3)
Ausstrich (4)
Befunde
Klinische Befunde: Splenomegalie
Ja
Nein
Klinische Befunde: Hepatomegalie
Ja
Nein
Klinische Befunde:Lymphadenopathie
Ja
Nein
Lokalisation vergrößerter Lymphknoten
Blutbild und Laborwerte
Blutsenkung
Lactate Dehydrogenase (LDH)
U/L
Serumeisen
Ferritin
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Request for iliac crest biopsy, Pathology UKM
Paraprotein
g/dl
Hämoglobin
Erythrozyten
Retikulozyten
Hämatokrit
MCV
Leukozyten
Thrombozyten
ALP
Peripheres Blut:sonstige
Differentialblutbild
Stabkernige
%
Segmentkernige
%
Eosinophile
%
Basophile
%
Monozyten
%
Lymphozyten
%
Blasten
%
Plasmazellen
%
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Request for iliac crest biopsy, Pathology UKM
Sonstige
Diagnose
Ärztlicher Ansprechpartner
Telefonnummer für
Rückfragen/Benachrichtigungen
Fax Nummer
Klinische Diagnose
Spezifische Vortherapien
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Request for iliac crest biopsy, Pathology UKM
Eligibility Colorectal Neoplasms
NCT00506168
Study of Irinotecan & Capecitabine in Metastatic Colorectal
Cancer; ODM derived from:
https://clinicaltrials.gov/show/NCT00506168
All rights reserved. Please visit https://medical-data-
models.org/forms/15008
Eligibility Colorectal Neoplasms
NCT00506168
Inclusion Criteria
histologically confirmed metastatic colorectal
cancer*
Yes
No
Ecog performance status 0-2*
Yes
No
mesurable lesions*
Yes
No
No prior chemotherapy or radiotherapy for
metastatic disease. prior radiotherapy is
permitted if it was not administered to target
lesions selected for this study and provided it has
been completed at least 4 weeks before
registration*
Yes
No
Adjuvnat chemo or radiotherapy was completed
at least 6 months prior to start study treatment*
Yes
No
Adequate organ functions*
Yes
No
Expected survival is longer then 6 months*
Yes
No
Informed consent*
Yes
No
Exclusion Criteria
Prior systemic chemotherapy for metastatic
disease*
Yes
No
Prior treatment with oxaliplatin or irinotecan*
Yes
No
Cns metastases*
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Yes
No
Uncontrolled or severe cardiovascular disease*
Yes
No
Serious concurrent infection or nonmalignant
illness that is uncontrolled or whose control may
be jeopardized by complications of study therapy*
Yes
No
Other malignancy within the past 3 years except
cured non-melanomatous skin cancer or
carcinoma in situ of the cervix*
Yes
No
Psychiatric disorder or uncontrolled seizure that
would preclude compliance*
Yes
No
pregnant, nursing women or patients with
reproductive potential without contraception*
Yes
No
Patients receiving a concomitant treatment with
drugs interacting with capecitabine such as
flucytosine, phenytoin, or warfarin et al.*
Yes
No
prior unanticipated severe reaction to
fluoropyrimidine therapy, or known
dihydropyrimidine dehydrogenase (dpd)
deficiency*
Yes
No
Major surgery within 3 weeks prior to study
treatment starts, or lack of complete recovery
from the effects of major surgery*
Yes
No
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Eligibility Colorectal Neoplasms NCT00506168
Specialized pathological assessment with
critical opinion Pathology UKM
Specialized pathological assessment with critical opinion
Gerhard-Domagk-Institute of Pathology Univ.-
Prof.Dr.med.Eva Wardelmann Albert-Schweitzer-Campus 1
Building D17 48149 Münster Phone:0251-83-57550
Fax:0251-83-55481 E-mail:pathologie@ukmuenster.de
All rights reserved. Please visit https://medical-data-
models.org/forms/15010
Specialized pathological assessment
with critical opinion
Fachpathologische Beurteilung mit
kritischer Stellungnahme
Befundnummer
Klinische Angaben
Makroskopie
Mikroskopie
Diagnose
1 / 1
General Information: Quality Management Trauma
Registry German Society for Trauma Surgery
DGU TraumaRegister® questionnaire; 
Data are collected prospectively in four consecutive time
phases from the site of the accident until discharge from
hospital: A) Pre-hospital phase, B) Emergency room and
initial surgery, C) Intensive care unit and D) Discharge. The
documentation includes detailed information on
demographics, injury pattern, comorbidities, pre- and in-
hospital management, course on intensive care unit,
relevant laboratory findings including data on transfusion
and outcome of each individual. The inclusion criterion is
admission to hospital via emergency room with subsequent
ICU/ICM care or reach the hospital with vital signs and die
before admission to ICU.  
The infrastructure for documentation, data management,
and data analysis is provided by AUC - Academy for
Trauma Surgery (AUC - Akademie der Unfallchirurgie
GmbH), a company affiliated to the German Trauma
Society. The scientific leadership is provided by the
Committee on Emergency Medicine, Intensive Care and
Trauma Management (Sektion NIS) of the German Trauma
Society. The participating hospitals submit their data anon-
ymously into a central database via a web-based
application. Scientific data analysis is approved according
to a peer review procedure established by Sektion NIS. 
TraumaRegister DGU® - Hinweise für die Publikation von
Ergebnissen 5 März 2014  
Seite 3 von 3 
© 2014 TraumaRegister DGU® / AUC GmbH 
The participating hospitals are primarily located in
Germany (90%), but a rising number of hospitals of other
countries contribute data as well (at the moment from
Austria, Belgium, China, Finland, Luxembourg, Slovenia,
Switzerland, The Netherlands, and the United Arab
Emirates). Currently, approx. 25,000 cases from more than
600 hospitals are entered into the database per year. 
Participation in TraumaRegister DGU® is voluntary. For
hospitals associated with TraumaNetzwerk DGU®,
however, the entry of at least a basic data set is obligatory
for reasons of quality assurance. 
www.traumaregister-dgu.de
All rights reserved. Please visit https://medical-data-
models.org/forms/15012
General Information: Quality
Management Trauma Registry
German Society for Trauma Surgery
Patient information
date
country
zip code
Patient ID
Date of birth
gender
male (1)
female (2)
ASA Physical Status (before accident)
healthy  (1)
mild systemic disease (2)
severe systemic disease (3)
moribund (4)
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Patient Transfer
Yes
No
if previous item answered with yes, from:
General Information
Date of accident
Cause of Accident
Accident (1)
violent felony (2)
suicidal intention (3)
Trauma
blunt force (1)
sharp force (2)
Type of accident
Car / Truck passenger (1)
Stab (10)
Other (11)
Motorcyclist (2)
Cyclist (3)
Pedestrian (4)
Other (Train, boat,...) (5)
Fall: 3m and above (6)
Fall:: less than 3m (7)
Other: Impact (item, branch,...) (8)
Shot (9)
if previous answered with other, please specify
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General Information: Quality Management Trauma Registry German
Society for Trauma Surgery
Emergency Department: Quality Management Trauma
Registry German Society for Trauma Surgery
DGU TraumaRegister® questionnaire; 
Data are collected prospectively in four consecutive time
phases from the site of the accident until discharge from
hospital: A) Pre-hospital phase, B) Emergency room and
initial surgery, C) Intensive care unit and D) Discharge. The
documentation includes detailed information on
demographics, injury pattern, comorbidities, pre- and in-
hospital management, course on intensive care unit,
relevant laboratory findings including data on transfusion
and outcome of each individual. The inclusion criterion is
admission to hospital via emergency room with subsequent
ICU/ICM care or reach the hospital with vital signs and die
before admission to ICU.  
The infrastructure for documentation, data management,
and data analysis is provided by AUC - Academy for
Trauma Surgery (AUC - Akademie der Unfallchirurgie
GmbH), a company affiliated to the German Trauma
Society. The scientific leadership is provided by the
Committee on Emergency Medicine, Intensive Care and
Trauma Management (Sektion NIS) of the German Trauma
Society. The participating hospitals submit their data anon-
ymously into a central database via a web-based
application. Scientific data analysis is approved according
to a peer review procedure established by Sektion NIS. 
TraumaRegister DGU® - Hinweise für die Publikation von
Ergebnissen 5 März 2014  
Seite 3 von 3 
© 2014 TraumaRegister DGU® / AUC GmbH 
The participating hospitals are primarily located in
Germany (90%), but a rising number of hospitals of other
countries contribute data as well (at the moment from
Austria, Belgium, China, Finland, Luxembourg, Slovenia,
Switzerland, The Netherlands, and the United Arab
Emirates). Currently, approx. 25,000 cases from more than
600 hospitals are entered into the database per year. 
Participation in TraumaRegister DGU® is voluntary. For
hospitals associated with TraumaNetzwerk DGU®,
however, the entry of at least a basic data set is obligatory
for reasons of quality assurance. 
www.traumaregister-dgu.de
All rights reserved. Please visit https://medical-data-
models.org/forms/15016
Emergency Department: Quality
Management Trauma Registry
German Society for Trauma Surgery
Vitalzeichen
Systolischer Blutdruck
>= 0
mmHg
Atemfrequenz
/min
Allgemeine Informationen
Aufnahmezeitpunkt
Diagnostik
Sono Abdomen
Ja
Nein
Zeitpunkt Sono Abdomen
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Röntgen Thorax
Ja
Nein
Zeitpunkt Röntgen Thorax
Röntgen Becken
Ja
Nein
Zeitpunkt Röntgen Becken
CT
Ja
Nein
Zeitpunkt CT
Ganzkörper-CT
Ja
Nein
Zeitpunkt Ganzkörper-CT
Therapie
Bluttransfusion
FFP
Erster operativer Notfalleingriff
Craniotomie (1)
Thorakotomie (2)
Laparotomie (3)
Revaskularisation  (4)
Embolisation  (5)
Stabilis. Becken (6)
Stabilis. Extremität (7)
Beginn der OP
Labor
Base Excess
mmol/l
Quick-Wert (in Prozent)
%
Hb-Wert
g/dl
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Emergency Department: Quality Management Trauma Registry German
Society for Trauma Surgery
Intensive Care and Outcome: Quality Management
Trauma Registry German Society for Trauma Surgery
DGU TraumaRegister® questionnaire; 
Data are collected prospectively in four consecutive time
phases from the site of the accident until discharge from
hospital: A) Pre-hospital phase, B) Emergency room and
initial surgery, C) Intensive care unit and D) Discharge. The
documentation includes detailed information on
demographics, injury pattern, comorbidities, pre- and in-
hospital management, course on intensive care unit,
relevant laboratory findings including data on transfusion
and outcome of each individual. The inclusion criterion is
admission to hospital via emergency room with subsequent
ICU/ICM care or reach the hospital with vital signs and die
before admission to ICU.  
The infrastructure for documentation, data management,
and data analysis is provided by AUC - Academy for
Trauma Surgery (AUC - Akademie der Unfallchirurgie
GmbH), a company affiliated to the German Trauma
Society. The scientific leadership is provided by the
Committee on Emergency Medicine, Intensive Care and
Trauma Management (Sektion NIS) of the German Trauma
Society. The participating hospitals submit their data anon-
ymously into a central database via a web-based
application. Scientific data analysis is approved according
to a peer review procedure established by Sektion NIS. 
TraumaRegister DGU® - Hinweise für die Publikation von
Ergebnissen 5 März 2014  
Seite 3 von 3 
© 2014 TraumaRegister DGU® / AUC GmbH 
The participating hospitals are primarily located in
Germany (90%), but a rising number of hospitals of other
countries contribute data as well (at the moment from
Austria, Belgium, China, Finland, Luxembourg, Slovenia,
Switzerland, The Netherlands, and the United Arab
Emirates). Currently, approx. 25,000 cases from more than
600 hospitals are entered into the database per year. 
Participation in TraumaRegister DGU® is voluntary. For
hospitals associated with TraumaNetzwerk DGU®,
however, the entry of at least a basic data set is obligatory
for reasons of quality assurance.
All rights reserved. Please visit https://medical-data-
models.org/forms/15020
Intensive Care and Outcome: Quality
Management Trauma Registry
German Society for Trauma Surgery
Intensivstation
Intensivtherapie
Ja
Nein
Dauer der Intensivtherapie
Tage
Mechanische Beatmung
Ja
Nein
Dauer der mech. Beatmung
Tage
Outcome
Datum
Verstorben
Ja
Nein
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Todeszeitpunkt
Überlebt
nach Hause entlassen (1)
verlegt Reha (2)
verlegt Krankenhaus (3)
Welches KH?
Zeitpunkt der Entlassung
Zustand bei Entlassung/Verlegung
gut erholt (1)
mäßig behindert (2)
schwer behindert (3)
nicht ansprechbar/vegetativ (4)
Verletzungen/Diagnosen
AIS Code
AIS Text
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Intensive Care and Outcome: Quality Management Trauma Registry
German Society for Trauma Surgery
Eligibility Coronary Artery Disease
NCT00232765
Study of Sirolimus-Coated BX VELOCITY Balloon-
Expandable Stent in Treatment of de Novo Native Coronary
Artery Lesions (SIRIUS); ODM derived from:
https://clinicaltrials.gov/show/NCT00232765
All rights reserved. Please visit https://medical-data-
models.org/forms/15023
Eligibility Coronary Artery Disease
NCT00232765
Inclusion Criteria
1. male or non-pregnant female patients
minimum 18 years of age*
Yes
No
2. diagnosis of angina pectoris as defined by
canadian cardiovascular society classification
(ccs i, ii, iii, iv) or unstable angina pectoris
(braunwald classification b&c, i-ii) or patients with
documented silent ischemia;*
Yes
No
3. target lesion is  2.50mm and  3.5mm in
diameter (visual estimate);*
Yes
No
4. target lesion is 15mm and 30mm in length
(visual estimate);*
Yes
No
5. target lesion stenosis is >50% and <100%
(visual estimate);*
Yes
No
Exclusion Criteria
1. patient has experienced a q-wave or non-q-
wave myocardial infarction with documented total
ck >2 times normal within the preceding 24 hours
and the ck and ck-mb enzymes remains above
normal at the time of treatment;*
Yes
No
2. has unstable angina classified as braunwald iii
b or c, or is having a peri infarction;*
Yes
No
3. documented left ventricular ejection fraction
25%;*
Yes
No
4. impaired renal function (creatinine > 3.0 mg/dl)
at the time of treatment;*
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Yes
No
5. target lesion involves bifurcation including a
diseased side branch 2.5mm in diameter (either
stenosis of both main vessel and major branch or
stenosis of just major branch) that would require
treatment;*
Yes
No
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Eligibility Coronary Artery Disease NCT00232765
Specialized pathological assessment with
critical opinion Pathology UKM
Specialized pathological assessment with critical opinion
Gerhard-Domagk-Institute of Pathology Univ.-
Prof.Dr.med.Eva Wardelmann Albert-Schweitzer-Campus 1
Building D17 48149 Münster Phone:0251-83-57550
Fax:0251-83-55481 E-mail:pathologie@ukmuenster.de
All rights reserved. Please visit https://medical-data-
models.org/forms/15024
Specialized pathological assessment
with critical opinion
Fachpathologische Beurteilung mit
kritischer Stellungnahme
Befunddatum
Eingangsdatum
Befundnummer
Übersandtes Material
Makroskopie
Immunhistologie
Molekularpathologie:Untersuchung auf
chromosomale Translokationen mit Chromosom
17p13.2 (USP6) als Translokationspartner
Ergebnis
Diagnose
Nachbericht
Befunddatum
Eingangsdatum
Befundnummer
Molekularpathologie :Untersuchung der
Genamplifikation von MDM2 mittels FISH
Ergebnis
Diagnose
1 / 1
Personal and Family History of Eye Disease
and Treatments Protocol PhenX Toolkit
Questions are asked to determine personal and family
history of glaucoma, macular degeneration, cataract, and
diabetic retinopathy. Questions are also asked to determine
the participant’s history of laser and/or eye surgery for
cataract, glaucoma and diabetic retinopathy.
ODM derived from: https://cde.nlm.nih.gov
Primary source: https://www.phenxtoolkit.org/
Recent publication: Hendershot, T., Pan, H., Haines, J.,
Harlan, W.R., Marazita, M.L., McCarty, C.A., Ramos, E.M.,
and Hamilton, C.M. (2015) Using the PhenX toolkit to add
standard measures to a study. Curr. Protoc. Hum. Genet.
86:1.21.1-1.21.17. doi: 10.1002/0471142905.hg0121s86
Permission to publish granted by
Carol M. Hamilton.
All rights reserved. Please visit https://medical-data-
models.org/forms/15025
Personal and Family History of Eye
Disease and Treatments Protocol
PhenX Toolkit
PhenX - personal and family history of eye
disease and treatments protocol
At the present time, would you say your eyesight
using both eyes (with glasses or contact lenses, if
you wear them) is:
Excellent (1)
Good (2)
Fair (3)
Poor (4)
Very poor (5)
Completely blind (6)
Refused (7)
Don't know (8)
Adult eye problem [PhenX]
Cataracts     (Cataracts    )
Glaucoma (Glaucoma)
Macular degeneration (Macular
degeneration)
Blood relative with eye problem [PhenX]
Adopted son or daughter (Adopted son
or daughter)
Brother (Brother)
Child (Child)
Daughter (Daughter)
Father (Father)
Half sibling (Half sibling)
Half-sister (Half-sister)
Maternal Aunt (Maternal Aunt)
Maternal Grandfather (Maternal
Grandfather)
Maternal Grandmother (Maternal
Grandmother)
Maternal Uncle (Maternal Uncle)
Mother     (Mother    )
Paternal Aunt (Paternal Aunt)
Paternal Grandfather (Paternal
Grandfather)
Paternal Grandmother (Paternal
Grandmother)
Paternal Uncle (Paternal Uncle)
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Self (Self)
Sibling (Sibling)
Sister  (Sister )
Son (Son)
Stepson or stepdaughter (Stepson or
stepdaughter)
Has a doctor ever told you that you had this eye
problem [PhenX]
Don't know (Don't know)
No (No)
Refused (Refused)
Yes (Yes)
Did you ever have cataract surgery?
Don't know (Don't know)
No (No)
Refused (Refused)
Yes (Yes)
Do or did his or her relative have this eye problem
[PhenX]
Don't know (Don't know)
No (No)
Refused (Refused)
Yes (Yes)
Do or did any of your relatives have this eye
problem [PhenX]
Don't know (Don't know)
No (No)
Refused (Refused)
Yes (Yes)
How many of your sisters have had, or were
suspected of having this eye problem [#] [PhenX]
How many of your brothers have had, or were
suspected of having this eye problem [#] [PhenX]
How many of your daughters have had, or were
suspected of having this eye problem [#] [PhenX]
How many of your sons have had, or were
suspected of having this eye problem [#] [PhenX]
How many of your mother's sisters have had, or
were suspected of having this eye problem [#]
[PhenX]
How many of your mother's brothers have had, or
were suspected of having this eye problem [#]
[PhenX]
How many of your father's sisters have had, or
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Personal and Family History of Eye Disease and Treatments Protocol
PhenX Toolkit
were suspected of having this eye problem [#]
[PhenX]
How many of your father's brothers have had, or
were suspected of having this eye problem [#]
[PhenX]
Have you ever been treated for your glaucoma?
Don't know (Don't know)
No (No)
Refused (Refused)
Yes (Yes)
In the past 12 months, how many times have you
seen an eye doctor for your glaucoma?
Treatment for your glaucoma [PhenX]
Eye drops (Eye drops)
Laser (Laser)
Other (Other)
Surgery (Surgery)
Did you receive this treatment for your glaucoma
[PhenX]
Eye drops (Eye drops)
Laser (Laser)
Other (Other)
Surgery (Surgery)
Other treatment or treatments you are receiving
or you received for your eye problem [PhenX]
Has a medical doctor ever told you that diabetes
has affected blood vessels in your eyes or that
you had diabetic retinopathy or diabetic eye
disease?
Eye drops (Eye drops)
Laser (Laser)
Other (Other)
Surgery (Surgery)
Did you ever have laser treatment or surgery for
your diabetic eye disease?
Don't know (Don't know)
No (No)
Refused (Refused)
Yes, both (Yes, both)
Yes, laser treatment (Yes, laser
treatment)
Yes, surgery (Yes, surgery)
How many different times have you had laser
treatment or surgery for diabetic eye disease?
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Personal and Family History of Eye Disease and Treatments Protocol
PhenX Toolkit
Request for general histologic assessment,
Pathology UKM
Request for general histologic assessment, Pathology UKM
Please use this form for requests of general histologic
assessment. Gerhard-Domagk-Institute of Pathology Univ.-
Prof.Dr.med.Eva Wardelmann Albert-Schweitzer-Campus 1
Building D17 48149 Münster Phone:0251-83-57550
Fax:0251-83-55481 E-mail:pathologie@ukmuenster.de
All rights reserved. Please visit https://medical-data-
models.org/forms/15028
Request for general histologic
assessment
Patientendaten
Patient Name
Patient ID
Patient Geburtsdatum
Fallnummer
Patient Krankenversicherung
Auftragsnummer
Auftragstatus
Dringlichkeit
Leistende Stelle
Auftragsdatum
Anfordernde Fachabteilung
Anfordernde Stelle
Anfordernder Arzt
Terminwunsch
Kommentar
Cave
Mobilität
Vorbefunde
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Infektiosität
Keine (1)
Nicht bekannt (2)
Hep B (3)
Hep C (4)
Tbc (5)
HIV (6)
VRE (7)
MRSA (8)
Sonstiges (9)
Infektiosität:bitte spezifizieren Sie sonstige
infektiöse Erkrankung
Versicherungsstatus stationär
Regelleistung (1)
Wahlleistung/Arzt (2)
Versicherungsstatus Ambulant
Krankenkasse (1)
Privat (2)
Material
Schnellschnitt (1)
Gewebe (2)
Punktat (3)
Ausstrich (4)
Voruntersuchungen
Klinische Diagnose
Färbungen
HE (1)
PAS (2)
Ma (3)
Anzahl HE Färbungen
Anzahl PAS Färbungen
Anzahl Ma Färbungen
Spezifische Vortherapien
Fragestellung
Ärztlicher Ansprechpartner
Telefonnummer für
Rückfragen/Benachrichtigungen
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Request for general histologic assessment, Pathology UKM
Fax Nummer
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Request for general histologic assessment, Pathology UKM
Specialized pathological assessment with
critical opinion Pathology UKM  Study
Specialized pathological assessment with critical opinion
Gerhard-Domagk-Institute of Pathology Univ.-
Prof.Dr.med.Eva Wardelmann Albert-Schweitzer-Campus 1
Building D17 48149 Münster Phone:0251-83-57550
Fax:0251-83-55481 E-mail:pathologie@ukmuenster.de
All rights reserved. Please visit https://medical-data-
models.org/forms/15030
Specialized pathological assessment
with critical opinion
Fachpathologische Beurteilung mit
kritischer Stellungnahme
Befunddatum
Eingangsdatum
Befundnummer
Klinische Angaben
Makroskopie
Mikroskopie
Immunhistologie
Immunfluoreszenzuntersuchung
Electronenmikroskopie
Diagnose
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Personal History of Allergies, Infectious Diseases,
and Immunizations - Adult PhenX Toolkit
This protocol is a self- or proxy-administered personal
health record from the American Health Information
Management Association (AHIMA). The respondent is
asked to provide details on the following categories:
Medical History, Infectious Diseases, Immunizations,
Allergies/Drug Sensitivities, Health Log, Doctor Visits,
Hospitalizations, Surgeries, Lab or Imaging, Medical
Devices, and Physical/Occupational Therapy.
ODM derived from: https://cde.nlm.nih.gov
Primary source: https://www.phenxtoolkit.org/
Recent publication: Hendershot, T., Pan, H., Haines, J.,
Harlan, W.R., Marazita, M.L., McCarty, C.A., Ramos, E.M.,
and Hamilton, C.M. (2015) Using the PhenX toolkit to add
standard measures to a study. Curr. Protoc. Hum. Genet.
86:1.21.1-1.21.17. doi: 10.1002/0471142905.hg0121s86
Permission to publish granted by
Carol M. Hamilton.
All rights reserved. Please visit https://medical-data-
models.org/forms/15031
Personal History of Allergies,
Infectious Diseases, and
Immunizations - Adult PhenX Toolkit
PhenX - personal medical history of
allergies, infectious diseases, and
immunizations - adult protocol
Noninfectious major illness
Noninfectious major illness [PhenX]
Date first Dx Unspecified body region
Physician [Identifier]
Managing physician unknown or ID
number not assigned (Managing
physician unknown or ID number not
assigned)
Noninfectious Major Illness 1 - Nature of Health
Problems
Age range at onset of disease [USSG-FHT]
20-29 (20-29)
30-39 (30-39)
40-49 (40-49)
50-59 (50-59)
Adolescence (Adolescence)
Childhood (Childhood)
Infancy (Infancy)
Newborn (Newborn)
over 60 (over 60)
Pre-Birth (Pre-Birth)
unknown (unknown)
Noninfectious Major Illness - Condition Status
Service comment
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Doctor visit sequency
Doctor visit sequence [PhenX]
Assessment reference date
Physician [Identifier]
Reason for visit
Diagnosis
Hospitalization sequence
Hospitalization sequence [PhenX]
Hospitalization - Type
Hospital Admission Date
Hospital Discharge Date
Physician [Identifier]
Hospitalized at
Reason for hospitalization [OASIS]
Chemotherapy   (Chemotherapy  )
Deep vein thrombosis, pulmonary
embolus (Deep vein thrombosis,
pulmonary embolus)
Exacerbation of CHF, fluid overload,
heart failure  (Exacerbation of CHF, fluid
overload, heart failure )
GI bleeding, obstruction (GI bleeding,
obstruction)
Hypo/Hyperglycemia, diabetes out of
control (Hypo/Hyperglycemia, diabetes
out of control)
Improper medication administration,
medication side effects, toxicity,
anaphylaxis    (Improper medication
administration, medication side effects,
toxicity, anaphylaxis   )
Injury caused by fall or accident at home
(Injury caused by fall or accident at home
)
IV catheter-related infection   (IV
catheter-related infection  )
Myocardial infarction, stroke (Myocardial
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Personal History of Allergies, Infectious Diseases, and Immunizations -
Adult PhenX Toolkit
infarction, stroke)
Other than above reasons (Other than
above reasons)
Psychotic episode (Psychotic episode)
Respiratory problems (SOB, infection,
obstruction)  (Respiratory problems
(SOB, infection, obstruction) )
Scheduled surgical procedure
(Scheduled surgical procedure   )
Uncontrolled pain  (Uncontrolled pain )
Urinary tract infection (Urinary tract
infection)
Wound or tube site infection,
deteriorating wound status, new
lesion/ulcer  (Wound or tube site
infection, deteriorating wound status,
new lesion/ulcer )
Hospital admission diagnosis
Complications
Surgery sequence
Surgery sequence [PhenX]
Please specify date.
Physician [Identifier]
Hospitalized at
Surgery procedure
Surgery description
Operative note findings
Service comment
Lab or Imaging - Instance
Lab or Imaging - Instance
Date of observation
Ordering practitioner name
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Personal History of Allergies, Infectious Diseases, and Immunizations -
Adult PhenX Toolkit
Lab or Imaging 1 - Reason
Service comment
Vendor device name
Medical Device - Device Type
Physician [Identifier]
Hospitalized at
Date of observation
Physical/Occupational therapy sequence
Physical/Occupational therapy sequence [PhenX]
Physical/Occupation Therapy - Therapy Type
Physical Therapy - Therapy Start Date
Physical therapy treatment plan, End date
Physical therapy treatment plan, Visit frequency
TQ2
As needed (As needed)
Day (Day)
Month (Month)
Quarter (Quarter)
Week (Week)
Physical/Occupation Therapy 1 - Therapist
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Personal History of Allergies, Infectious Diseases, and Immunizations -
Adult PhenX Toolkit
Eligibility Coronary Disease NCT02513004
Evaluation of Antiplatelet Effects and Safety of
Intraoperative Administration of Ticagrelor Versus
Clopidogrel; ODM derived from:
https://clinicaltrials.gov/show/NCT02513004
All rights reserved. Please visit https://medical-data-
models.org/forms/15032
Eligibility Coronary Disease
NCT02513004
Inclusion Criteria
1. provision of informed consent prior to any
study specific procedures*
Yes
No
2. a patient who is considered as ethnic chinese*
Yes
No
3. 80years >aged> 18years, male or female*
Yes
No
4. patient is willing to perform hcr with the
following conditions: multi-vessel coronary artery
disease with unfavorable lad for pci (i.e., chronic
total occlusion, excessive tortuosity, severely
diffuse lesion), unprotected left main coronary
artery disease, and non-lad lesions were
technically feasible for pci with a drug-eluting
stent (des) .limitations to traditional cabg, such as
pre-existing organ dysfunction, heavily calciﬁed
proximal aorta, or lack of suitable graft conduits*
Yes
No
Exclusion Criteria
1. involvement in the planning and/or conduct of
the study*
Yes
No
2. previous enrolment or randomization in the
present study*
Yes
No
3. participation in another clinical study with an
investigational product during the last 30 days*
Yes
No
4. contraindication or other reason that
clopidogrel or ticagrelor should not be
administered (eg, hypersensitivity, active
bleeding, moderate or severe liver disease,
history of previous intracranial bleed, gi bleed
within the past 6 months, major surgery within 30
1 / 4
days)*
Yes
No
5. with coagulation disorder*
Yes
No
6. with uric acid nephropathy*
Yes
No
7. history of intolerance or allergy to asa or
clopidogrel or ticagrelor*
Yes
No
8. patient has a coronary artery bypass graft
(cabg) history.*
Yes
No
9. left subclavian  artery  and  lima  stenosis*
Yes
No
10. buried  intramyocardial lad*
Yes
No
11. need for a concomitant operation (e.g., valve
repair or replacement)*
Yes
No
12. overt congestive heart failure*
Yes
No
13. unsuccessful lima-lad graft*
Yes
No
14. hemodynamic instability*
Yes
No
15. other conditions rendering pci unsuitable
(e.g., fresh thrombus, coronary vessel diameter
<1.5 mm)*
Yes
No
16. platelet count less than 100*10^9/l*
Yes
No
17. haemoglobin (hb) level less than 110g/l*
Yes
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No
18. white blood cell count less than 4*10^12/l*
Yes
No
19. recent (within 30 days of dosing) blood
donation*
Yes
No
20. fibrinolytic therapy in the 24 hours prior to
randomisation, or planned fibrinolytic treatment
following randomisation (eg, for stemi or
pulmonary embolism)*
Yes
No
21. p2y12 receptor inhibitor therapy in 7 days
before hcr surgery.*
Yes
No
22. nonselective non-steroidal anti-inflammatory
drugs (nsaids) and prostacyclins (pgi2) therapy
that cannot be stopped*
Yes
No
23. increased risk of bradycardic events (eg, no
pacemaker and known sick sinus syndrome,
second degree av block, third degree av block or
previous documented syncope suspected to be
due to bradycardia).*
Yes
No
24. concomitant oral or intravenous therapy (see
examples below) with strong cyp3a inhibitors,
cyp3a substrates with narrow therapeutic indices,
or strong cyp3a inducers within 14 days of study
treatment or cannot be stopped for the course of
the study.*
Yes
No
strong inhibitors: ketoconazole, itraconazole,
voriconazole, telithromycin, clarithromycin,
nefazadone, ritonavir, saquinavir, nelfinavir,
indinavir, atanazavir, over 1 litre daily of grapefruit
juice.*
Yes
No
substrates with narrow therapeutic index:
cyclosporine, quinidine. strong inducers:
rifampin/rifampicin, phenytoin, carbamazepine.
the sponsor should be consulted for enrolment
with any concomitant medicines which are
suspected of undergoing strong drug-drug
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interaction*
Yes
No
25. any other condition which in the opinion of the
investigator, may either put the patient at risk or
influence the result of the study (e.g., cardiogenic
shock or active cancer)*
Yes
No
26. moderate or severe renal disease;*
Yes
No
27. moderate or severe chronic lung disease or
asthma;*
Yes
No
28. pregnancy or lactation*
Yes
No
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Eligibility Cutaneous T-Cell Lymphoma
NCT02448381
Topical SGX301 (Synthetic Hypericin) for the Treatment of
Cutaneous T-Cell Lymphoma (Mycosis Fungoides); ODM
derived from: https://clinicaltrials.gov/show/NCT02448381
All rights reserved. Please visit https://medical-data-
models.org/forms/15033
Eligibility Cutaneous T-Cell
Lymphoma NCT02448381
Inclusion Criteria
subjects must have a clinical diagnosis of ctcl
(mycosis fungoides), stage ia, stage ib, or stage
iia.*
Yes
No
subjects must have a minimum of three (3)
evaluable, discrete lesions.*
Yes
No
subjects must be willing to refrain from
sunbathing for the duration of the study.*
Yes
No
Exclusion Criteria
history of sun hypersensitivity and photosensitive
dermatoses including porphyria, systemic lupus
erythematosus, sjögren's syndrome, xeroderma
pigmentosum, and melanoma, or polymorphous
light or radiation therapy within 30 days of
enrolling.*
Yes
No
pregnancy or mothers who are breast feeding.*
Yes
No
males and females not willing to use effective
contraception.*
Yes
No
unhealed sunburn.*
Yes
No
subjects receiving systemic or topical steroids,
nitrogen mustard, psoralen uva radiation therapy
(puva), or carmustine (bcnu) or other systemic
therapies for ctcl within 3 weeks of enrollment.*
Yes
No
subjects with significant history of systemic
immunosuppression due to drugs or infection with
hiv or htlv 1.*
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Yes
No
subjects taking other investigational drugs or
drugs of abuse within 30 days of entry into this
study.*
Yes
No
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Eligibility Coronary Artery Disease
NCT00381420
The Study of the BX Velocity Stent in the Treatment of De
Novo Artery Lesions.; ODM derived from:
https://clinicaltrials.gov/show/NCT00381420
All rights reserved. Please visit https://medical-data-
models.org/forms/15034
Eligibility Coronary Artery Disease
NCT00381420
Inclusion Criteria
diagnosis of angina pectoris as defined by
canadian cardiovascular society classification
(ccs i, ii, iii, iv) or unstable angina pectoris
(braunwald classification b&c, i-ii) or patients with
documented silent ischemia;*
Yes
No
single treatment of de novo lesion in a major
coronary artery in patients with single or multi-
vessel disease; patients with multiple lesions can
be included only if the other lesions do not
require treatment;*
Yes
No
target vessel diameter at the lesion site is
>=2.50mm and <=3.0mm in diameter (visual
estimate);*
Yes
No
target lesion is >=15mm and <=32mm in length
(visual estimate);*
Yes
No
target lesion stenosis is >50% and <100% (visual
estimate);*
Yes
No
Exclusion Criteria
patient has experienced a q-wave or non-q-wave
myocardial infarction with documented total ck >2
times normal within the preceding 24 hours and
the ck and ck-mb enzymes remains above
normal at the time of treatment;*
Yes
No
has unstable angina classified as braunwald iii b
or c and a i-ii-iii, or is having a peri infarction;*
Yes
No
unprotected left main coronary disease with
>=50% stenosis;*
Yes
No
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significant (>50%) stenoses proximal or distal to
the target lesion that might require
revascularization or impede runoff;*
Yes
No
have an ostial target lesion;*
Yes
No
angiographic evidence of thrombus within target
lesion;*
Yes
No
heavily calcified lesion which cannot be
successfully predilated;*
Yes
No
documented left ventricular ejection fraction
<=25%.*
Yes
No
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Eligibility Coronary Artery Disease
NCT00234455
A Study of the Cypher Sirolimus-Eluting Stent to Treat
Bifurcation Lesions.; ODM derived from:
https://clinicaltrials.gov/show/NCT00234455
All rights reserved. Please visit https://medical-data-
models.org/forms/15035
Eligibility Coronary Artery Disease
NCT00234455
Inclusion Criteria
diagnosis of angina pectoris as defined by
canadian cardiovascular society classification
(ccs i, ii, iii, iv) or unstable angina pectoris
(braunwald classification b&c, i-ii) or patients with
documented silent ischemia;*
Yes
No
2. involves a single treatment of a de novo
bifurcation lesion in native coronary arteries of
patients with single or multivessel disease;
patients with multiple lesions can be included
only if other lesions treated during the index
procedure are successfully treated prior to the
treatment of the bifurcation lesion;*
Yes
No
3. has a true bifurcation lesion defined as
stenosis > 50% in both the main branch and the
ostium of the side branch;*
Yes
No
4. has a main branch vessel that is <=2.5 mm
and <=3.5 mm in diameter by on-line qca
proximal to the bifurcation;*
Yes
No
5. has a side branch vessel that is <=2.5 mm and
<=3.5 mm in diameter by on-line qca.*
Yes
No
Exclusion Criteria
1. patient has experienced a q-wave or non-q-
wave myocardial infarction with documented
elevation of ck levels > 2 times normal or ck-mb
levels > 3 times normal within the preceding 24
hours and/or the ck and ck-mb enzymes remain
above normal at the time of treatment;*
Yes
No
2. has unstable angina classified as braunwald a
i-iii, or iii b or c, or is having a peri infarction;*
Yes
No
1 / 2
3. has a bifurcation lesion in a non protected left
main;*
Yes
No
4. has an ejection fraction <=35%;*
Yes
No
5. there is presence of thrombus in the bifurcation
lesion;*
Yes
No
6. has a totally occluded vessel.*
Yes
No
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Eligibility Depression NCT02057042
Veteran Peer-Assisted Computerized Cognitive Behavioral
Therapy for Depression; ODM derived from:
https://clinicaltrials.gov/show/NCT02057042
All rights reserved. Please visit https://medical-data-
models.org/forms/15037
Eligibility Depression NCT02057042
Inclusion Criteria
have new episodes of depression in primary care,
defined as those with a new diagnoses of
depression and no prior depression diagnoses or
antidepressant fills within 120 days of the index
date of their depression diagnosis any of three va
study sites or associated cbocs. patients must
enroll within 90 days of their diagnosis.*
Yes
No
have a current phq-9 score > 10.*
Yes
No
are not receiving mental health care outside of
vha.*
Yes
No
have broadband internet access at home or
confirm willingness, ability, and a plan to go to
their va facility to complete ccbt modules.*
Yes
No
have familiarity with email and internet use.*
Yes
No
have stable access to and ability to communicate
by telephone.*
Yes
No
Exclusion Criteria
a diagnosis of schizophrenia, schizoaffective
disorder, mdd with psychotic features, or bipolar i
in the past 24 months.*
Yes
No
a positive screen for moderate or severe
substance use (audit-c >7).*
Yes
No
an immediate risk of suicide, requiring
hospitalization or urgent evaluation (as evidenced
by suicidal plan or intent).*
Yes
No
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participating in other research studies.*
Yes
No
diagnosis of depression in the past 4 months
from a non-va provider*
Yes
No
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Eligibility Coronary Artery Stenosis
NCT00375063
Study of Unprotected Left Main Stenting Versus Bypass
Surgery (LE MANS Study); ODM derived from:
https://clinicaltrials.gov/show/NCT00375063
All rights reserved. Please visit https://medical-data-
models.org/forms/15038
Eligibility Coronary Artery Stenosis
NCT00375063
Inclusion Criteria
the patients' age 18 to 80*
Yes
No
significant lm stenosis (>50%)*
Yes
No
the target vessel reference diameter 2.5mm.*
Yes
No
concomitant multivessel disease suitable for pci is
allowed.*
Yes
No
the patient is an acceptable candidate for
coronary artery bypass surgery.*
Yes
No
the patient agreement for 6 month follow-up
cardiac catheterization, which will include left
ventricular angiogram.*
Yes
No
the patient written informed consent.*
Yes
No
Exclusion Criteria
an allergy or contraindication to aspirin,
ticlopidine or clopidogrel.*
Yes
No
presence of diffuse, significant (>++)
calcifications in lm*
Yes
No
left ventricular ejection fraction < 35%*
Yes
No
history of bleeding diathesis or coagulopathy.*
Yes
No
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any previous pci or cabg surgery*
Yes
No
acute mi within 48 hours, cardiogenic shock.*
Yes
No
bail-out stenting of dissected lm during
complicated pci.*
Yes
No
the patient suffered a stroke or transient ischemic
neurological attack (tia) within 3 months.*
Yes
No
chronic renal insufficiency.*
Yes
No
positive pregnancy test.*
Yes
No
any disease that may shorten the life expectancy
of the patient.*
Yes
No
the patient is currently participating in another
research study.*
Yes
No
2 / 2
Eligibility Coronary Artery Stenosis NCT00375063
Eligibility Coronary Disease NCT00014040
Nitric Oxide Inhalation Therapy to Relieve Chest Pain in
Patients With Coronary Artery Disease; ODM derived from:
https://clinicaltrials.gov/show/NCT00014040
All rights reserved. Please visit https://medical-data-
models.org/forms/15039
Eligibility Coronary Disease
NCT00014040
Inclusion Criteria
presence of angiographically determined cad.*
Yes
No
at least 1 attempt at revascularization by
catheter-based technique or by surgery.*
Yes
No
myocardial ischemia as determined by stress
echocardiography.*
Yes
No
canadian cardiovascular society functional class ii
or iii angina pectoris despite conventional medical
management.*
Yes
No
left ventricular ejection fraction greater than 30%
(assessed by radionuclide angiography or by
echocardiography).*
Yes
No
subject understands protocol and provides
written, informed consent in addition to
willingness to comply with specified follow-up
evaluations.*
Yes
No
Exclusion Criteria
left ventricular ejection fraction less than 30%.*
Yes
No
active cigarette smoker.*
Yes
No
history of congestive heart failure.*
Yes
No
history of bronchospasm requiring treatment.*
Yes
No
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cardiac disease in addition to cad (e.g.
hypertrophic or dilated cardiomyopathy, valvular
heart disease) as determined by
echocardiography.*
Yes
No
angina pectoris at rest, prolonged in duration
(greater than 20 minutes), or does not respond to
nitroglycerin (2 tablets) during 2 months prior to
study.*
Yes
No
evidence of extra-cardiac disease other than
diabetes mellitus as determined by physical
examination and screening lab work (e.g.,
creatinine greater than 1.5x upper limit of
reference, liver enzymes greater than 2x upper
limit of reference, hemoglobin less than 10 g/dl).*
Yes
No
patients who are hiv positive, have chronic
inflammatory diseases, or are on chronic
immunosuppressive medications.*
Yes
No
women of childbearing age unless recent
pregnancy test is negative.*
Yes
No
lactating women.*
Yes
No
age less than 21 years.*
Yes
No
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Blood Liquor Collection Liquor Biobank Department
of Neurology University Hospital Münster
ODM files derived from Liquor Biobank, Department of
Neurology, University Hospital Münster.
Documentation of collection of biomaterial (blood and
liquor) from patients with neuroinflammatory diseases and
healthy donors.
Collected data: Date of visit,patient/donor personal
information,information about collected bio-samples and
medical information
All rights reserved. Please visit https://medical-data-
models.org/forms/15041
Blood Liquor Collection
Demographische Daten
Bearbeitungsdatum
Name des Managers
Projekt Name
Studienzentrum
Patient ID
Nummer der Visite
Datum der Visite
Formularfamilie
Formular
Röhrchen-ID dieser Visite
Projekt:Erkrankungen
MS (1)
NMO (2)
SuSac (3)
Autoimmunenzephalitis (4)
Onkologie (5)
Gesunde Spender (6)
Projekt: Studie
KKNMS (1)
Z2 (2)
DTI (3)
Gerinnungsstudie (4)
Projekt: Behandlung/Medikation
IIT-Alemtuzumab (1)
IIT-BG12 (2)
Fingolimod (FTY) (3)
Natalizumab/CD62L (4)
Teriflunomide (5)
Vatelizumab (6)
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Alter zum Zeitpunkt der Blutentnahme
Jahre
Alter in Tagen
Tage
Altersgruppe
<=15 (1)
16-25 (2)
26-35 (3)
36-45 (4)
46-55 (5)
56-65 (6)
>=66 (7)
Altersgruppe 15
<=5 (1)
6-10 (2)
11-15 (3)
>=16 (4)
Aktuelle Krankheitsdaten
Aktuelle Diagnose
Diagnosedatum
Diagnosegruppe
Krankheitsaktivität
Diagnose-Unterform/Typ
Aktuelle Therapie
Aktuelle Therapie begonnen am
Therapiedauer in Monaten
Therapie bei Erstaufnahme (falls abweichend)
Therapienaiv?
Ja
Nein
Liegt aktuell (zum Zeitpunkt der Blutabnahme)
ein Schubereignis vor?
Keine Angabe (1)
Ja (2)
Nein (3)
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University Hospital Münster
JCV-Antikörper
Keine Angabe (1)
Ja (2)
Nein (3)
Letzte vorherige Medikation
Medikation
Datum der Einnahme
Uhrzeit der Einnahme
Studienzentrum
Biomaterialentnahme lokal in Münster, UK?
Ja
Nein
Falls nicht in Münster, wo?
Gemäß zentrumsspezifischer SOP
Keine Angabe (1)
Ja (2)
Nein (3)
Blutentnahme
Datum der Blutentnahme
Uhrzeit der Blutentnahme
Datum der Prozessierung
Beginn der Prozessierung
Liquorentnahme
Datum der Liquorentnahme
Uhrzeit der Liquorentnahme
Punktion artifiziell blutig?
Keine Angabe (1)
Ja (2)
Nein (3)
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University Hospital Münster
Liquor innerhalb einer Std aliquotiert?
Keine Angabe (1)
Ja (2)
Nein (3)
Falls nein,bitte spezifizieren
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Eligibility Depression NCT02133898
The Use Of L-Methylfolate As A Treatment For Depression;
ODM derived from:
https://clinicaltrials.gov/show/NCT02133898
All rights reserved. Please visit https://medical-data-
models.org/forms/15042
Eligibility Depression NCT02133898
Inclusion Criteria
diagnosis of major depressive disorder based on
structured clinical interview for dsm-iv (scid)*
Yes
No
hamilton depression rating scale-24 (hrsd-24)
score of 8-24.*
Yes
No
no antidepressant medication in past 3 months*
Yes
No
Exclusion Criteria
pregnancy/breastfeeding/reproductive age female
not using contraception*
Yes
No
schizophrenia or other psychotic disorders*
Yes
No
bipolar disorder*
Yes
No
cluster b personality disorder*
Yes
No
electroconvulsive therapy (ect) failure in past*
Yes
No
concurrent ect or repetitive transcranial magnetic
stimulation (rtms)*
Yes
No
active substance abuse within past 6 months*
Yes
No
use of antiepileptics*
Yes
No
thyroid stimulating hormone (tsh) greater than 4*
Yes
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No
untreated vitamin b12 deficiency (vitamin b12
less than 400)*
Yes
No
neurodegenerative disease or dementia (mini
mental status examination (mmse) less than or
equal to 24)*
Yes
No
suicidal ideation*
Yes
No
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Eligibility Depression NCT02276807
Improving Mood in Veterans in Primary Care; ODM derived
from: https://clinicaltrials.gov/show/NCT02276807
All rights reserved. Please visit https://medical-data-
models.org/forms/15043
Eligibility Depression NCT02276807
Inclusion Criteria
veterans:*
Yes
No
aged 18 years*
Yes
No
seeking or receiving primary care services at the
syracuse, canandaigua, or buffalo va medical
centers*
Yes
No
reporting at least moderate depressive
symptoms*
Yes
No
stable course of antidepression medications*
Yes
No
stable course of outpatient treatment for anxiety
or substance use disorders*
Yes
No
Exclusion Criteria
veterans who are:*
Yes
No
unable to demonstrate an understanding of the
informed consent*
Yes
No
non-english speaking*
Yes
No
reporting imminent risk of suicide*
Yes
No
have an unstable psychiatric condition*
Yes
No
currently involved in treatment for depression*
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Yes
No
recently started antidepression medication or
outpatient treatment for anxiety or substance use
disorder*
Yes
No
currently involved or completed inpatient or
intensive outpatient treatment*
Yes
No
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Eligibility Depression NCT02286440
A PK/PD Genetic Variation Treatment Algorithm Versus
Treatment As Usual for Adolescent Management Of
Depression; ODM derived from:
https://clinicaltrials.gov/show/NCT02286440
All rights reserved. Please visit https://medical-data-
models.org/forms/15044
Eligibility Depression NCT02286440
Inclusion Criteria
age 13-18, male or female, any race/ethnicity*
Yes
No
treating clinician, patient, and family feel that
pharmacotherapy is indicated as part of a
comprehensive treatment plan.*
Yes
No
major depressive episode diagnosis or bipolar
disorder based on ksads-pl semi-structured
psychiatric interview with a severity criteria-40 or
greater on childhood depression rating scale-
revised (cdrs-r)*
Yes
No
ability to provide informed consent*
Yes
No
Exclusion Criteria
inability to speak english*
Yes
No
inability or lack of willingness to provide informed
consent and assent.*
Yes
No
axis i diagnoses: autism spectrum disorder,
anorexia nervosa, schizophreniform, and
schizophrenia.*
Yes
No
psychotropic medication change (including
dosage) between screening & randomization
visits.*
Yes
No
patients who meet dsm 5 criteria for any
significant current substance use disorder other
than nicotine, caffeine, or cannabis. must have at
least early, partial or full, remission x 3 months*
Yes
No
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serious suicidal risk and/or in need of immediate
hospitalization as judged by the investigator.*
Yes
No
significant unstable medical condition.*
Yes
No
anticipated inability to attend scheduled study
visits.*
Yes
No
patients who in the judgment of the investigator
may be unreliable or uncooperative with the
evaluation procedure outlined in this protocol.*
Yes
No
cytochrome (cyp) & serotonin transporter
genomic testing within 5 years.*
Yes
No
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Eligibility Depression NCT02312583
Efficacy of an Online Program for the Treatment of Mild and
Moderate Depression; ODM derived from:
https://clinicaltrials.gov/show/NCT02312583
All rights reserved. Please visit https://medical-data-
models.org/forms/15045
Eligibility Depression NCT02312583
Inclusion Criteria
diagnosis of major depressive disorder according
to diagnostic and statistical manual (dsm-iv-tr)
criteria.*
Yes
No
clinical severity between mild and moderate
(according to icg severity scale).*
Yes
No
a minimum of reading comprehension and
knowledge of internet browsing.*
Yes
No
availability to access internet during the 7 weeks
of the intervention.*
Yes
No
informed written consent provided.*
Yes
No
Exclusion Criteria
suicidal ideation (assessed by the hdrs and
clinical interview).*
Yes
No
presence of delusional ideas or hallucinations,
consistent or not with the mood.*
Yes
No
other concomitant psychiatric pathologies of the
axis i or axis ii according to diagnostic and
statistical manual (dsm-iv-tr) at the time of entry
to the study.*
Yes
No
to be currently enrolled in a structured
programme/treatment of psychotherapy.*
Yes
No
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Ovulation History Protocol PhenX Toolkit
These self-administered questions ask about menstruation
and pregnancy history. Female respondents are asked
about age at first menstruation, onset and cause of
menopause, and pregnancy history and outcomes.
ODM derived from: https://cde.nlm.nih.gov
Primary source: https://www.phenxtoolkit.org/
Recent publication: Hendershot, T., Pan, H., Haines, J.,
Harlan, W.R., Marazita, M.L., McCarty, C.A., Ramos, E.M.,
and Hamilton, C.M. (2015) Using the PhenX toolkit to add
standard measures to a study. Curr. Protoc. Hum. Genet.
86:1.21.1-1.21.17. doi: 10.1002/0471142905.hg0121s86
Permission to publish granted by
Carol M. Hamilton.
All rights reserved. Please visit https://medical-data-
models.org/forms/15047
Ovulation History Protocol PhenX
Toolkit
PhenX - ovulation history protocol
Age at first menstrual period?
Have you had a menstrual period within the last
year?
Yes
No
Age at last menstrual period?
Cause of menopause?
Chemotherapy/medication induced
(Chemotherapy/medication induced  )
Natural     (Natural    )
Other (Other)
Surgery on reproductive organs
(Surgery on reproductive organs    )
Cause of menopause if other
Have you ever been pregnant?
Yes
No
Pregnancies
Pregnancy number [PhenX]
Date of end of pregnancy?
Outcome of pregnancy?
Induced abortion (Induced abortion)
Live birth (Live birth)
Miscarriage (Miscarriage)
Stillborn (Stillborn)
Number of birth?
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Breast feeding?
Yes
No
Months of breast feeding?
months
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Personality Traits Protocol PhenX Toolkit
The Big Five Inventory (BFI) is a self administered, 44
question instrument designed to measure the big five
dimensions of personality - extraversion, agreeableness,
conscientiousness, neuroticism and openness/intellect.
ODM derived from: https://cde.nlm.nih.gov
Primary source: https://www.phenxtoolkit.org/
Recent publication: Hendershot, T., Pan, H., Haines, J.,
Harlan, W.R., Marazita, M.L., McCarty, C.A., Ramos, E.M.,
and Hamilton, C.M. (2015) Using the PhenX toolkit to add
standard measures to a study. Curr. Protoc. Hum. Genet.
86:1.21.1-1.21.17. doi: 10.1002/0471142905.hg0121s86
Permission to publish granted by
Carol M. Hamilton.
All rights reserved. Please visit https://medical-data-
models.org/forms/15048
Personality Traits Protocol PhenX
Toolkit
PhenX - personality traits protocol
I see myself as someone who is talkative.
Strongly disagree     (1)
Disagree     (2)
Neither agree nor disagree (3)
Agree (4)
Strongly agree (5)
I see myself as someone who tends to find fault
with others.
Strongly disagree     (1)
Disagree     (2)
Neither agree nor disagree (3)
Agree (4)
Strongly agree (5)
I see myself as someone who does a thorough
job.
Strongly disagree     (1)
Disagree     (2)
Neither agree nor disagree (3)
Agree (4)
Strongly agree (5)
I see myself as someone who is depressed, blue.
Strongly disagree     (1)
Disagree     (2)
Neither agree nor disagree (3)
Agree (4)
Strongly agree (5)
I see myself as someone who is original, comes
up with new ideas.
Strongly disagree     (1)
Disagree     (2)
Neither agree nor disagree (3)
Agree (4)
Strongly agree (5)
I see myself as someone who is reserved.
Strongly disagree     (1)
Disagree     (2)
Neither agree nor disagree (3)
Agree (4)
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Strongly agree (5)
I see myself as someone who is helpful and
unselfish with others.
Strongly disagree     (1)
Disagree     (2)
Neither agree nor disagree (3)
Agree (4)
Strongly agree (5)
I see myself as someone who can be somewhat
careless.
Strongly disagree     (1)
Disagree     (2)
Neither agree nor disagree (3)
Agree (4)
Strongly agree (5)
I see myself as someone who is relaxed, handles
stress well.
Strongly disagree     (1)
Disagree     (2)
Neither agree nor disagree (3)
Agree (4)
Strongly agree (5)
I see myself as someone who is curious about
many different things.
Strongly disagree     (1)
Disagree     (2)
Neither agree nor disagree (3)
Agree (4)
Strongly agree (5)
I see myself as someone who is full of energy.
Strongly disagree     (1)
Disagree     (2)
Neither agree nor disagree (3)
Agree (4)
Strongly agree (5)
I see myself as someone who starts quarrels with
others.
Strongly disagree     (1)
Disagree     (2)
Neither agree nor disagree (3)
Agree (4)
Strongly agree (5)
I see myself as someone who is a reliable worker.
Strongly disagree     (1)
Disagree     (2)
Neither agree nor disagree (3)
Agree (4)
Strongly agree (5)
I see myself as someone who can be tense.
Strongly disagree     (1)
Disagree     (2)
Neither agree nor disagree (3)
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Agree (4)
Strongly agree (5)
I see myself as someone who is ingenious, a
deep thinker.
Strongly disagree     (1)
Disagree     (2)
Neither agree nor disagree (3)
Agree (4)
Strongly agree (5)
I see myself as someone who generates a lot of
enthusiasm.
Strongly disagree     (1)
Disagree     (2)
Neither agree nor disagree (3)
Agree (4)
Strongly agree (5)
I see myself as someone who has a forgiving
nature.
Strongly disagree     (1)
Disagree     (2)
Neither agree nor disagree (3)
Agree (4)
Strongly agree (5)
I see myself as someone who tends to be
disorganized.
Strongly disagree     (1)
Disagree     (2)
Neither agree nor disagree (3)
Agree (4)
Strongly agree (5)
I see myself as someone who worries a lot.
Strongly disagree     (1)
Disagree     (2)
Neither agree nor disagree (3)
Agree (4)
Strongly agree (5)
I see myself as someone who has an active
imagination.
Strongly disagree     (1)
Disagree     (2)
Neither agree nor disagree (3)
Agree (4)
Strongly agree (5)
I see myself as someone who tends to be quiet.
Strongly disagree     (1)
Disagree     (2)
Neither agree nor disagree (3)
Agree (4)
Strongly agree (5)
I see myself as someone who is generally
trusting.
Strongly disagree     (1)
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Disagree     (2)
Neither agree nor disagree (3)
Agree (4)
Strongly agree (5)
I see myself as someone who tends to be lazy.
Strongly disagree     (1)
Disagree     (2)
Neither agree nor disagree (3)
Agree (4)
Strongly agree (5)
I see myself as someone who is emotionally
stable, not easily upset.
Strongly disagree     (1)
Disagree     (2)
Neither agree nor disagree (3)
Agree (4)
Strongly agree (5)
I see myself as someone who is inventive.
Strongly disagree     (1)
Disagree     (2)
Neither agree nor disagree (3)
Agree (4)
Strongly agree (5)
I see myself as someone who has an assertive
personality.
Strongly disagree     (1)
Disagree     (2)
Neither agree nor disagree (3)
Agree (4)
Strongly agree (5)
I see myself as someone who can be cold and
aloof.
Strongly disagree     (1)
Disagree     (2)
Neither agree nor disagree (3)
Agree (4)
Strongly agree (5)
I see myself as someone who perseveres until
the task is finished.
Strongly disagree     (1)
Disagree     (2)
Neither agree nor disagree (3)
Agree (4)
Strongly agree (5)
I see myself as someone who can be moody.
Strongly disagree     (1)
Disagree     (2)
Neither agree nor disagree (3)
Agree (4)
Strongly agree (5)
I see myself as someone who values artistic,
aesthetic experiences.
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Strongly disagree     (1)
Disagree     (2)
Neither agree nor disagree (3)
Agree (4)
Strongly agree (5)
I see myself as someone who is sometimes shy,
inhibited.
Strongly disagree     (1)
Disagree     (2)
Neither agree nor disagree (3)
Agree (4)
Strongly agree (5)
I see myself as someone who is considerate, kind
to almost everyone.
Strongly disagree     (1)
Disagree     (2)
Neither agree nor disagree (3)
Agree (4)
Strongly agree (5)
I see myself as someone who does things
efficiently.
Strongly disagree     (1)
Disagree     (2)
Neither agree nor disagree (3)
Agree (4)
Strongly agree (5)
I see myself as someone who remains calm in
tense situations.
Strongly disagree     (1)
Disagree     (2)
Neither agree nor disagree (3)
Agree (4)
Strongly agree (5)
I see myself as someone who prefers work that is
routine.
Strongly disagree     (1)
Disagree     (2)
Neither agree nor disagree (3)
Agree (4)
Strongly agree (5)
I see myself as someone who is outgoing,
sociable.
Strongly disagree     (1)
Disagree     (2)
Neither agree nor disagree (3)
Agree (4)
Strongly agree (5)
I see myself as someone who is sometimes rude
to others.
Strongly disagree     (1)
Disagree     (2)
Neither agree nor disagree (3)
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Agree (4)
Strongly agree (5)
I see myself as someone who makes plans and
follows through on them.
Strongly disagree     (1)
Disagree     (2)
Neither agree nor disagree (3)
Agree (4)
Strongly agree (5)
I see myself as someone who gets nervous
easily.
Strongly disagree     (1)
Disagree     (2)
Neither agree nor disagree (3)
Agree (4)
Strongly agree (5)
I see myself as someone who likes to reflect, play
with ideas.
Strongly disagree     (1)
Disagree     (2)
Neither agree nor disagree (3)
Agree (4)
Strongly agree (5)
I see myself as someone who has few artistic
interests.
Strongly disagree     (1)
Disagree     (2)
Neither agree nor disagree (3)
Agree (4)
Strongly agree (5)
I see myself as someone who likes to cooperate
with others.
Strongly disagree     (1)
Disagree     (2)
Neither agree nor disagree (3)
Agree (4)
Strongly agree (5)
I see myself as someone who is easily distracted.
Strongly disagree     (1)
Disagree     (2)
Neither agree nor disagree (3)
Agree (4)
Strongly agree (5)
I see myself as someone who is sophisticated in
art, music or literature.
Strongly disagree     (1)
Disagree     (2)
Neither agree nor disagree (3)
Agree (4)
Strongly agree (5)
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Human Immunodeficiency Virus (HIV)
Protocol PhenX Toolkit
This protocol provides instructions for drawing, processing
and storing blood for the human immunodeficiency virus
(HIV) assay from the National Health and Nutrition
Examination Survey (NHANES). Toolkit users are referred
to the U.S. Food and Drug Administration’s (FDA’s)
approved laboratory assays.
ODM derived from: https://cde.nlm.nih.gov
Primary source: https://www.phenxtoolkit.org/
Recent publication: Hendershot, T., Pan, H., Haines, J.,
Harlan, W.R., Marazita, M.L., McCarty, C.A., Ramos, E.M.,
and Hamilton, C.M. (2015) Using the PhenX toolkit to add
standard measures to a study. Curr. Protoc. Hum. Genet.
86:1.21.1-1.21.17. doi: 10.1002/0471142905.hg0121s86
Permission to publish granted by
Carol M. Hamilton.
All rights reserved. Please visit https://medical-data-
models.org/forms/15049
Human Immunodeficiency Virus
(HIV) Protocol PhenX Toolkit
Exclusion criteria - assays PhenX
Do you have hemophilia?*
Yes (1)
No (2)
Refused (7)
Don't know (9)
Have you received cancer chemotherapy in the
past four weeks or do you anticipate such therapy
in the next four weeks?*
Yes (1)
No (2)
Refused (7)
Don't know (9)
Process variables for assays PhenX
Exclusion Criteria*
Hemophilia (1)
Received cancer chemotherapy in the
last 3 weeks (2)
None – proceed with blood draw (3)
Was blood drawn?*
Yes
No
Was full sample obtained?*
Yes
No
Service comment*
Service comment*
Repeatability of the assay*
Coefficient of variation for the assay*
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Manufacturer variables for assays PhenX
Make of the equipment used to perform...*
Manufacturer of the equipment used to
perform...*
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Surgery report General and Visceral Surgery Report
Routine documentation in German hospitals DMI
Routine documentation in German hospitals. Source file
name: OP150103_OP-Bericht/ OP-Bericht.067 OP-
Bericht.069
Examplary forms provided by DMI (http://www.dmi.de/)
All rights reserved. Please visit https://medical-data-
models.org/forms/15050
Surgery report General and Visceral
Surgery Report
Surgery report
Patient ID
Patient name
Date of birth
Operation date
Operation ID
Surgeon
Assistant (Surgeon)
Anesthesist
Surgical nurse
Diagnosis
Therapy
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Routing slip Other oncology documentation sheet
Routine documentation in German hospitals DMI
Routine documentation in German hospitals. Source file
name: SD150199_Sonstiger onkologische
Dokumentationsbogen/ Laufzettel.019
Examplary forms provided by DMI (http://www.dmi.de/)
All rights reserved. Please visit https://medical-data-
models.org/forms/15051
Routing slip Other oncology
documentation sheet
Routing slip
Patient information
Date
Histology
malignant (1)
benign (2)
other (3)
Following histology
absent (1)
immune (2)
other (3)
When other, please choose one of the following
Other up to 14 days (1)
Prof. Lax up to 4 weeks (2)
Immunohistology result 1 week later?
Yes
No
TMK
yes (1)
no (2)
1 week later (3)
Specificity in patients before TMK
Staging (1)
Result present (2)
E-mail?
Yes
No
E-mail sent to surgeon
Date e-mail sent
Cancer registry?
Yes
No
Date of Cancer registry
File can be closed?
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Yes
No
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Routing slip Other oncology documentation sheet Routine documentation
in German hospitals DMI
Pathology request Histology request Routine
documentation in German hospitals DMI
Routine documentation in German hospitals. Source file
name: PT080101_Histologieanforderung/
Pathologieamforderung.145
Examplary forms provided by DMI (http://www.dmi.de/)
All rights reserved. Please visit https://medical-data-
models.org/forms/15052
Pathology request Histology request
Pathology request
Sender
Date of pathology request
Recipient
Pathology request ID number
Health insurance
Desired test
histology (1)
cytology (2)
Pathology material wanted?
Yes
No
Previous pathology test present?
Yes
No
ID number of previous pathology test
Treatment type
inpatient treatment (1)
outpatient treatment (2)
optional (3)
private (4)
Pathology specimen
Diagnosis
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MRI report MRI report Routine
documentation in German hospitals DMI
Routine documentation in German hospitals. Source file
name: DG020107_MRT-Befund/ MRT-Befund.053
Examplary forms provided by DMI (http://www.dmi.de/)
All rights reserved. Please visit https://medical-data-
models.org/forms/15053
MRI report
MRI report
MRI of
Date of MRI
Indication for MRI
Contrast agent (if applied)
MRI technique
Finding of MRI
Diagnosis
Physician
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X- ray report X- ray report Routine
documentation in German hospitals DMI
Routine documentation in German hospitals. Source file
name: DG020110_Röntgenbefund/ Röntgenbefund.049
Examplary forms provided by DMI (http://www.dmi.de/)
All rights reserved. Please visit https://medical-data-
models.org/forms/15054
X- ray report
X- ray report
X- ray of
Date of x- ray
Indication for x- ray
Diagnosis
Physician
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Eligibility Depression NCT02315781
tDCS in Parkinson's Disease With Depression; ODM
derived from: https://clinicaltrials.gov/show/NCT02315781
All rights reserved. Please visit https://medical-data-
models.org/forms/15056
Eligibility Depression NCT02315781
Inclusion Criteria
1. are outpatients,*
Yes
No
2. are voluntary and competent to consent to
treatment,*
Yes
No
3. have a mini-international neuropsychiatric
interview (mini) confirmed diagnosis of major
depressive disorder (mdd),*
Yes
No
4. have a diagnosis of pd according to the uk pd
brain bank criteria,*
Yes
No
5. are 19 years of age or more,*
Yes
No
6. have a score > 13 on the beck depression
inventory-ii (bdi-ii),*
Yes
No
7. still have depressive symptoms after 6 weeks
or more of antidepressant (ssri) medication
treatment (and on a stabilized dose of at least 4
weeks),*
Yes
No
8. are able to adhere to the treatment schedule,*
Yes
No
9. are proficient in written and verbal english.*
Yes
No
Exclusion Criteria
1. have a history of substance dependence or
abuse within the last 6 months,*
Yes
No
2. have a concomitant significant unstable
medical illness,*
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Yes
No
3. have active suicidal intent,*
Yes
No
4. have any history of seizure or medication-
resistant epilepsy in the family,*
Yes
No
5. have a lifetime mini-international
neuropsychiatric interview (mini) diagnosis of
bipolar i or ii disorder, schizophrenia,
schizoaffective disorder, schizophreniform
disorder, delusional disorder, or current psychotic
symptoms*
Yes
No
6. have a mini diagnosis of obsessive compulsive
disorder, post-traumatic stress disorder (current
or within the last year), anxiety disorder
(generalized anxiety disorder, social anxiety
disorder, panic disorder), or dysthymia, assessed
by a study investigator to be primary and causing
greater impairment than mdd,*
Yes
No
7. have failed a course of ect in the current
episode or previous episode,*
Yes
No
8. have received tdcs or other neurostimulation
therapy for any previous indication due to the
potential compromise of expectancy effects,*
Yes
No
9. have any significant neurological disorder or
insult including, but not limited to: any condition
likely to be associated with increased intracranial
pressure, space occupying brain lesion, any
history of seizure except those therapeutically
induced by ect, cerebral aneurysm, huntington's
chorea, multiple sclerosis, significant head
trauma with loss of consciousness for greater
than or equal to 5 minutes, or developmental
disorder,*
Yes
No
10. have an intracranial implant (e.g., aneurysm
clips, shunts, stimulators, cochlear implants, or
electrodes) or any other metal object within or
near the head, excluding the mouth, that cannot
be safely removed,*
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Yes
No
11. are taking a non-ssri antidepressant
medication,*
Yes
No
12. are pregnant (women of childbearing age
only).*
Yes
No
exclusion criteria for pet:*
Yes
No
1. unable to tolerate staying off anti-parkinsonian
medication for 12-18 hours pre-pet scan,*
Yes
No
2. have a history of radiation therapy treatment or
other high amounts of radiation.*
Yes
No
exclusion criteria for mri:*
Yes
No
artificial heart valve;*
Yes
No
brain aneurysm clip;*
Yes
No
electrical stimulator for nerves or bones;*
Yes
No
ear or eye implant;*
Yes
No
implanted drug infusion pump;*
Yes
No
coil, catheter, or filter in any blood vessel;*
Yes
No
orthopedic hardware (artificial joint, plate,
screws);*
Yes
No
other metallic prostheses;*
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Yes
No
shrapnel, bullets, or other metal fragments;*
Yes
No
surgery or tattoos (including tattooed eyeliner) in
the last six weeks.*
Yes
No
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Eligibility Depression NCT02358343
A Trial of Sertraline vs. CBT for End-stage Renal Disease
Patients With Depression {ASCEND}; ODM derived from:
https://clinicaltrials.gov/show/NCT02358343
All rights reserved. Please visit https://medical-data-
models.org/forms/15057
Eligibility Depression NCT02358343
Inclusion Criteria
1. age ≥ 21 years;*
Yes
No
2. undergoing thrice-weekly maintenance hd for ≥
3 months;*
Yes
No
3. able to speak either english or spanish;*
Yes
No
4. bdi-ii score ≥ 15; and*
Yes
No
5. meets diagnostic criteria for either current
major depressive episode or dysthymia on the
mini.*
Yes
No
Exclusion Criteria
1. active suicidal intent;*
Yes
No
2. ongoing psychotherapy or current treatment
with anti-depressant drugs;*
Yes
No
3. evidence of cognitive impairment on mini-cog;*
Yes
No
4. present or past psychosis or bipolar disorder i
or ii on the mini;*
Yes
No
5. alcohol or substance abuse diagnosed on the
mini or history of such abuse in the past three
months;*
Yes
No
6. life expectancy < 3 months, in the judgment of
the site principal investigator;*
Yes
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No
7. anticipated to receive living related donor
kidney transplantation within 3 months;*
Yes
No
8. pregnancy, or lactation, or women of
childbearing age not willing to use adequate birth
control;*
Yes
No
9. clinical and/or laboratory evidence of chronic
liver disease;*
Yes
No
10. history of significant active bleeding in the
past three months, such as hospitalization for
gastrointestinal bleeding;*
Yes
No
11. current use of class i anti-arrhythmic
medications (e.g., propafenone, flecainide),
pimozide, monoamine oxidase inhibitors,
reserpine, guanethidine, cimetidine, tri-cyclic anti-
depressants, triptans, tramadol, linezolid,
tryptophan, and st. john's wort; and*
Yes
No
12. known hypersensitivity to sertraline.*
Yes
No
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Eligibility Depression NCT02448433
Phototherapy in Young People With Depression; ODM
derived from: https://clinicaltrials.gov/show/NCT02448433
All rights reserved. Please visit https://medical-data-
models.org/forms/15058
Eligibility Depression NCT02448433
Inclusion Criteria
1. quick inventory of depressive symptomatology
score > 6;*
Yes
No
2. first episode of depression before age 25;*
Yes
No
3. currently engaged in, or about to start
treatment for an affective disorder at a mental
health clinic.*
Yes
No
Exclusion Criteria
1. evidence of other sleep, neurological or
primary medical conditions that could explain the
current depression and/or contribute to sleep-
wake dysfunction;*
Yes
No
2. other primary psychiatric disorders aside from
anxiety disorders;*
Yes
No
3. significant alcohol or other substance
dependence;*
Yes
No
4. use of medications that affect sleep, circadian
rhythms, or alertness within the past month
(participants stabilized on an antidepressant
medication, stimulants, lithium or melatoninergic
agents will not be excluded from the study);*
Yes
No
5. use of medications that may interact with light
to produce a photoallergic reaction;*
Yes
No
6. eye or skin condition which may interact with
bright light exposure;*
Yes
No
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7. regular shift-work within 60-days prior to entry
into the study;*
Yes
No
8. recent transmeridian travel.*
Yes
No
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Eligibility Coronary Disease NCT00123539
Estrogen Replacement to Reduce Risk of Neurologic Injury
After Coronary Artery Bypass Graft Surgery; ODM derived
from: https://clinicaltrials.gov/show/NCT00123539
All rights reserved. Please visit https://medical-data-
models.org/forms/15059
Eligibility Coronary Disease
NCT00123539
Inclusion Criteria
patients whose scheduled procedure is cabg
surgery or*
Yes
No
patients whose scheduled procedure is isolated
aortic surgery or*
Yes
No
patients whose scheduled procedure is mitral
valve surgery or*
Yes
No
patients whose scheduled procedure is cabg
combined with aortic or mitral valve surgery*
Yes
No
Exclusion Criteria
patients having re-operations*
Yes
No
patients having combined carotid endarterectomy
with cabg surgery*
Yes
No
patients having cabg with tricuspid valve surgery*
Yes
No
patients having mitral and aortic valvular surgery
(with or without cabg surgery)*
Yes
No
elevation of liver function test before surgery or
creatinine before surgery greater than 2 mg/dl*
Yes
No
emergency surgery*
Yes
No
severe cognitive impairment before surgery as
indicated by clinical history and/or a score greater
than 12 on the short blessed dementia screening
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test (see d11)*
Yes
No
inability to attend outpatient visits*
Yes
No
a history of venous thromboembolism*
Yes
No
unexplained vaginal bleeding*
Yes
No
a history of breast cancer or personal history of
endometrial cancer in the absence of
hysterectomy*
Yes
No
estrogen use within 6 months of the surgery*
Yes
No
patient refusal to participate*
Yes
No
inability to speak and read english or visual
impairment*
Yes
No
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ADT and Gekid shared uniform oncological
basic data set
The uniform oncological basic data set of ADT and GEKID
was adopted in March 2008 and updated in February,
2014. It applies to all types of cancer and is continuously
supplemented by tumor-specific modules. By harmonizing
Oncology base record, an instrument has been created
which provides a harmonized oncological standard ,
prevents multiple documentaries and allows comparable
acquisition and evaluation of cancer treatments in all
clinical structures and federal states .
Source: http://www.tumorzentren.de/onkol-
basisdatensatz.html
All rights reserved. Please visit https://medical-data-
models.org/forms/15060
Uniform oncological basic data set
Reason for report
Reason for report
Patient has been informed and did not
object (1)
Exception: Patient information  omitted
due to possible disadvantage in patient
health (2)
Report by physician without immediate
contact to patient (3)
Patient objected to personalized data
storage (4)
Deceased (5)
Patient Master Data
Health Insurance number
Insurance company number
Patient Name
Patient title
Patient name suffix
Patient given name
Patient birth name
Patient previous names
Patient gender
male (1)
female (2)
other/intersexual (3)
unknown (4)
Patient Birth Date
Street Adress of patient
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Patient residence number
Country of Residence
Postal Code (Patient Residence)
City of residence
Master data of reporting institution
Reporting institution ID
Name of reporting hospital and hospital ward or
(part of name of) doctor´s office
Reporting physician name
Reporting institution adress
Institution postal code
City Institution is located
Reporting date
Bank name
Name of account owner
BIC of health care provider
IBAN of healthcare provider
Diagnosis
Primary tumor ICD-Code
C00.0 – C96.9 Malignant neoplasms;
except C77.*, C78.* and
C79.*(secondary malignant neoplasms,
report primary tumor) Malignant
neoplasms as primary tumor at multiple
sites must be reported separately. (1)
D33.4 Benign neoplasm of spinal
marrow (10)
D33.7 Benign neoplasm of other
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specified parts of the central nervous
system (11)
D33.9 Benign neoplasm of the central
nervous system unspecified (12)
D35.2  Benign neoplasm of pituitary
gland (13)
D35.3 Benign neoplasm of the ductus
craniopharyngealis (14)
D35.4 Benign neoplasm of the epiphysis
(15)
D37.- Neoplasm of uncertain or unknown
behavior of oral cavity and digestive
organs (16)
D38.- Neoplasm of uncertain or unknown
behavior of middle ear, respiratory
organs and intrathoracic organs (17)
D39.- Neoplasm of uncertain or unknown
behavior of female genital organs (18)
D40.- Neoplasm of uncertain or unknown
behavior of male genital organs (19)
D00.0 – D09.9 In situ neoplasms (2)
D41.- Neoplasm of uncertain behavior of
the urinary system (20)
D42.- Neoplasm of uncertain behavior of
meninges (21)
D43.- Neoplasm of uncertain or unknown
behavior of brain and central nervous
system (22)
D44.-  Neoplasm of uncertain behavior
of endocrine glands (23)
D45 polycythemia vera (24)
D46.- Myelodysplastic syndromes (25)
D47.- Other neoplasms of uncertain or
unknown behavior of lymphoid,
haematopoietic and related tissue (26)
CodelistItem 838860 (27)
D32.0 Benign neoplasm of meninges (3)
D32.1 Benign neoplasm of spinal
meninges (4)
D32.9 Benign neoplasm of meninges
unspecified (5)
D33.0  Benign neoplasm of brain,
supratentorial (6)
D33.1  Benign neoplasm of brain,
infratentorial (7)
D33.2  Benign neoplasm of brain,
unspecified (8)
D33.3 Benign neoplasm of cerebral
nerves (9)
Primary tumor ICD Version
ICD 10 Version 2013 (1)
ICD 10 Version 2014 (2)
ICD 10 Version 2015 (3)
Primary tumor diagnosis
Primary tumor topography ICD-O
C00-C14 Lips, mouth and pharynx (1)
3 / 16
ADT and Gekid shared uniform oncological basic data set
C50-C50 Breast [Mammae] (10)
C51-C58 female genitals (11)
C60-C63 male genitals (12)
C64-C68 urinary tract (13)
C69-C72 Eyes, brain and other parts of
the central nervous system (14)
C73-C75 thyroid gland and other
endocrine glands (15)
C76-C80 other or insufficiently
designated location (16)
C15-C26 Intestines (2)
C30-C39 respiratory tract and
intrathoracic organs       (3)
C40-C41 bones, joints and cartilage (4)
C42-C42 Hematopoitic und
retikuloendothelial system (5)
C44-C44 skin (6)
C47-C47 Peripheral Nervs und
autonomic Nervous sytem (7)
C48-C48 Retroperitoneum und
Peritoneum (8)
C49-C49 connective tissue,
Subcutaneous tissue and other soft
tissue (9)
Primary tumor ICD-O Version
Date of diagnosis
Neoplasm diagnosis confirmation
clinically without tumor-specific
diagnostics (only physical examination)
(1 )
clinically: Clinical diagnosis performed
prior to the date of death; includes
diagnostic techniques, including X-ray,
endoscopy, other imaging techniques,
ultrasound, exploratory surgery
(laparotomy, etc.) and autopsy without
microscopic tissue diagnosis. (2 )
specific tumor markers (3)
cytology: examination of cells from
primary localizations including liquid
aspirations by endoscopies or needles.
Includes microscopic examination of
peripheral blood smears and smears of
iliac crest aspiration    (4)
Histology of metastasis (5)
Histology of the primary tumor:
Histological examination of tissue of the
primary tumor, including all cutting
techniques and bone marrow biopsies.
This includes samples of the primary
tumor from autopsies. Histological
examination of the tissue from a
metastasis, including at autopsy. (6)
Side of tumor localization
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left (1)
right (2)
both sides (should with certain tumors
result in 2 reports) (3)
Center line/centered (4)
unknown (5)
not applicable (indication of the side not
useful,including systemic disease) (6)
Earlier neoplastic diseases
Histology
Date of Histology
Histology specimen number
Morphology code
Morphology ICD-O-Version
Morphology: free text
Grading
malignant melanoma of conjunctiva (0)
well differentiated (1)
moderately differentiated (2)
poorly differentiated (3)
undifferentiated (4)
Borderline (B)
high grade (G3 oder G4) (H)
low grade (G1 oder G2) (L)
intermediate (G2 oder G3) (M)
not applicable (T)
unknown (U)
can not be determined (X)
Number of lymph nodes examined
Number of positive lymph nodes
Number of sentinel lymph nodes examined
Number of positive sentinel lymph nodes
TNM Classification
Date of TNM
5 / 16
ADT and Gekid shared uniform oncological basic data set
TNM Version
TNM y-Symbol
„native“ classification ((empty))
classification was performed during or
after Combined Modality Therapy (y)
TNM r-Symbol
„native“ classification before relapse
occured ((empty))
classification relates to a recurrent
disease (r)
TNM a-Symbol
classification was not performed during
autopsy ((empty))
classification was performed during
autopsy (a)
TNM c/p/u-Präfix T
Category was determined by clinical
information, or does not meet the criteria
for p (c oder (empty))
Determination of the grade was made by
histopathologic examination, with what
even the highest grade in each category
could be determined (p)
Detecting by ultrasound (subcategory of
c with special diagnostic relevance, i.e.
for rectal cancer) (u)
TNM c/p/u-Präfix N
Category was determined by clinical
information, or does not meet the criteria
for p (c oder (empty))
Determination of the grade was made by
histopathologic examination, with what
even the highest grade in each category
could be determined (p)
Detecting by ultrasound (subcategory of
c with special diagnostic relevance, i.e.
for rectal cancer) (u)
TNM c/p/u-Präfix M
Category was determined by clinical
information, or does not meet the criteria
for p (c oder (empty))
Determination of the grade was made by
histopathologic examination, with what
even the highest grade in each category
could be determined (p)
Detecting by ultrasound (subcategory of
c with special diagnostic relevance, i.e.
for rectal cancer) (u)
TNM T-Category
TNM m-Symbol
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CodelistItem 838921 ((leer))
multiple neoplasms without specifying
the number of entities ((m))
CodelistItem 838920 ((Zahl))
TNM N-Category
TNM M-Category
TNM L-Category
No lymphatic invasion (L0 )
lymphatic invasion (L1 )
lymphatic invasion undetermined (LX )
TNM V-Category
No venous invasion (V0 )
Microscopic venous invasion (V1 )
Macroscopic venous invasion (V2 )
venous invasion undetermined (VX )
TNM Pn-Category
No perineural Invasion (Pn0)
Perineural Invasion (Pn1)
perineural Invasion undetermined (PnX)
TNM S-Category
ULN (N)
serum tumor marker within normal range
(S0)
< 1,5N LDH and < 5000 HCG and <
1000AFP (S1)
1,5 – 10N LDH or 5000 – 50000 HCG or
1000 – 10000 AFP (S2)
> 10N LDH or > 50000 HCG or > 10000
AFP (S3)
Values of serum tumor markers
unavailable or appropriate investigations
not taken  (SX)
Other classifications
Hemato-oncological and other classifications
Name
Hemato-oncological and other classifications
stage
Hemato-oncological and other classifications
date
Residual status
Assessment of local Residual status after surgery
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No residue (R0)
Microsopic residue (R1)
In-Situ-remains (R1 (is))
Cytologic remains (R1(cy+))
Macroscopic residue (R2)
presence of residue undetermined (RX)
Overall assessment of residual status after
primary therapy
No residue (R0)
Microsopic residue (R1)
In-Situ-remains (R1 (is))
Cytologic remains (R1(cy+))
Macroscopic residue (R2)
presence of residue undetermined (RX)
Distant metastases
Localization of distant metastases
adrenal glands (ADR)
Brain (BRA)
Generalized metastasis (GEN)
Hepatic (HEP)
Lymphnodes (LYM)
Bone marrow (MAR)
Osseous (OSS)
Other organs (OTH)
Peritoneum (PER)
Pleura (PLE)
Pulmonary (PUL)
Skin (SKI)
Date of diagnostic confirmation of distant
metastases
Performance Status
Fully Active, Able To Carry On All Pre-
disease Performance Without
Restriction. (Karnofsky 90-100%) (0)
Restricted In Physically Strenuous
Activity But Ambulatory And Able To
Carry Out Work Of A Light Or Sedentary
Nature, E.g., Light Housework, Office
Work. (Karnofsky 70-80%) (1)
Ambulatory And Capable Of All Selfcare
But Unable To Carry Out Any Work
Activities. Up And About More Than 50%
Of Waking Hours. (Karnofsky 50-60%)
(2)
Capable Of Only Limited Selfcare,
Confined To Bed Or Chair More Than
50% Of Waking Hours. (Karnofsky 30-
40%) (3)
Completely Disabled. Cannot Carry On
Any Selfcare. Totally Confined To Bed Or
Chair. (Karnofsky 10-20%) (4)
Unknown (5)
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Surgery
Intention of surgery
diagnostic (D)
curative (K)
palliative (P)
Revision/complication (R)
other (S)
unknown (X)
Date of surgery
OPS-Code
OPS Version
Complications
Surgical complications
CodelistItem 839039 (ABD )
CodelistItem 839040 (ABS )
CodelistItem 839045 (AEE )
CodelistItem 839042 (AEP )
CodelistItem 839043 (ALR )
Acute kidney failure (ANI)
CodelistItem 839044 (ANS )
CodelistItem 839046 (API )
CodelistItem 839041 (ASF )
CodelistItem 839047 (BIF )
CodelistItem 839049 (BOE )
CodelistItem 839048 (BOG )
CodelistItem 839050 (BSI )
CodelistItem 839051 (CHI )
CodelistItem 839052 (DAI )
drug withdrawal psychosis (DEP)
Disseminated intravascular coagulopathy
(DIC)
Pressure and positioning damage, i. e.
pressure ulcer (DLU)
CodelistItem 839053 (DPS )
Duodenal stump insufficiency (DSI)
Enteral Fistula (ENF)
Coagulation disorder (GER)
Hemorrhagic Shock (HAE)
Hematemesis (HEM)
Urinary fistula (HFI)
Cranial nerve deficits (HNA)
Skin nekrosis in the area of surgery
(HNK)
Organic psychosyndrome (i. e. „transition
syndrome“) (HOP)
Arrhythmia (HRS)
Hematury (HUR)
Hyperbilirubinemia (HYB)
Hypopharynx fistula (HYF)
cardiac insufficiency (HZI)
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Ileofemoric venous thrombosis (IFV)
cardiogenic shock (KAS)
short bowel syndrome (KDS)
complications of ostomy (KES)
complication of implant (vessel
prosthesis, Total endoprosthesis,
catheter),i. e. Dislocation (KIM)
seizure (KRA)
liver failure (LEV)
pulmonary edema (LOE)
Lymphocele (LYE)
lymphatic fistula (LYF)
Mesentery artery- oder -venous
thrombosis (MAT)
Mediastinitis (MED)
gastric voiding disorder (MES)
Mechanical Ileus (MIL)
Myocardial infarction (MYI)
CodelistItem 839037 (N )
Bleeding, not requiring revision, not
mentioned elsewhere (NAB)
suture insufficiency, not mentioned
elsewhere (NIN)
Esophagitis (OES)
Osteitis, Osteomyelitis (OSM)
Perianal Bleeding (PAB)
Emboly of pulmonary artery (PAE)
Pancreatic fistula (PAF)
Peripheral arterial occlusion (Emboly,
Thrombosis) (PAV)
Protracted intestinal atony (paralytic
Ileus) (PDA)
Peritonitis (PER)
Pleuraempyem (PEY)
Pancreatitis (PIT)
Wound dehiscence of laparotomy wound
(PLB)
pleural effusion (PLE)
Pneumonia (PMN)
Pneumothorax (PNT)
Peripheral Paresis (PPA)
Respiratory insufficiency (RIN)
Reversible ischemic neurological Deficit
(Rind)
Bleeding, requiring revision, not
mentioned elsewhere (RNB)
Recurrent paresis (RPA)
Septic Shock (SES)
Disorders of fluid, electrolyte and acid
base balance (SFH)
Septic complication of an Implant (SKI)
Ostomy complication (i. e. bleeding,
Necrosis, Stenosis) (STK)
TIA (transitoric ischemic accident) or
(TIA)
Transfusion incident (TRZ)
Thrombocytopenia (TZP)
CodelistItem 839038 (U )
impaired wound healing, subcutaneous
(WSS)
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Wound hematoma (konservatively
treated) (WUH)
Radiotherapy
Intention of radiotherapy
curative (K)
palliative (P)
Other (S)
Unknown (X)
Radiotherapy in relation to surgery
adjuvant (A)
intraoperative (I)
neoadjuvant (N)
without relation to surgical procedure (O)
other (S)
Radiotherapy target:Central nervous system
whole brain (1)
part of the brain (2)
Neuraxis (3)
Radiotherapy target: Head,neck with or without
lymph nodes (In conjunction with respective
tumor)
Orbita (1)
Nose/sinuses (2)
oral cavitiy (3)
ear (4)
salivary gland (5)
Pharynx (6)
Larynx (7)
thyroid gland (8)
lymph nodes of the neck (without
primary neoplasm) (9)
Radiotherapy target: thorax with or without
regional lymph nodes (in conjunction with
respective tumor)
Mammae as whole breast (1)
Mammae as part of breast (2)
chest wall (i. e. relapse after ablatio,
sarcoma) (3)
Lung (4)
esophagus (5)
Thymus (6)
Mediastinal Lymph nodes (without
primary neoplasm) (7)
Radiotherapy target: abdomen (without pelvis)
with or without regional lymph nodes
stomach (1)
pancreas (2)
liver (3)
spleen (4)
kidney (5)
adrenal gland (6)
retroperitoneal lymph nodes (without
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primary neoplasm), (7)
retroperitoneum (i. e. Sarcoma) (8)
abdominal wall (i. e. Sarcoma) (9)
Radiotherapy target: pelvis with or without
regional lymph nodes
rectum (1)
vulva (10)
vagina (11)
pelvic wall (12)
pelvic lymph nodes (without primary
neoplasm) (13)
anal region (2)
urinary bladder (3)
prostate (4)
testicles (5)
penis (6)
uterus (7)
cervix (8)
ovary (9)
Radiotherapy target: supportive / musculoskeletal
system
cranial bone (1)
ribs (2)
sternum (3)
cervical spine (4)
thoracic spine (5)
lumbar spine (6)
pelvic bone (7)
hip (8)
Radiotherapy target: supportive / musculoskeletal
system of upper extremity
axilla (1)
upper arm (2)
forearm (3)
hand (4)
Radiotherapy target: supportive / musculoskeletal
system of lower extremity
groin (1)
thigh (2)
lower leg (3)
foot (4)
Radiotherapy target: skin
primary skin neoplasm (including
cutaneous lymphoma) (1)
metastases of the skin (2)
Radiotherapy target: other
whole body radiation (1)
mantle field irradiation (2)
Radiotherapy target side
both sides (B)
left (L)
median (M)
right (R)
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unknown (U)
Radiotherapy start date
Radiotherapy end date
Radiotherapy way of application
interstitial contact therapy
(brachytherapy) (I)
endocavity contact therapy
(brachytherapy) (K)
metabolic therapy (radionuclides) (M)
percutaneous (teletherapy) (P)
other (S)
Radiotherapy application: If "P", please specify
CodelistItem 839135 (RC j)
radiochemotherapy/sensitizer no (RC n)
Radiotherapy application: If "K" or "I", please
specify
high dose rate therapy (HDR)
low dose rate therapy (LDR)
pulsed dose rate therapy (PDR)
Radiotherapy application: If "M" ,please specify
peptide-radio-receptor-therapy (PRRT)
selektive internal radio-therapy (SIRT)
Radiotherapy total dose
Radiotherapy single dose
Reason for end of radiotherapy
CodelistItem 839141 (A )
CodelistItem 839142 (E )
CodelistItem 839145 (P )
CodelistItem 839144 (R )
CodelistItem 839147 (S )
CodelistItem 839146 (U )
CodelistItem 839143 (V )
Radiotherapy Side effects
CTC Grade radiotherapy side effects
strong / pronounced (3)
life threatening (4)
deadly (5)
none or max Grade 2 (K)
unknown (U)
Radiotherapy type of side effect according to
CTC
Radiotherapy CTCAE Version
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version 4 (1)
Systemic therapy
Intention of systemic therapy
curative (K)
palliative (P)
Other (S)
Unknown (X)
Systemic therapy in relation to surgery
adjuvant (A)
intraoperative (I)
neoadjuvant (N)
without relation to surgical procedure (O)
other (S)
Systemic therapy protocol. Please give the name
of protocol in usual abbreviations.
Systemic therapy start date
Systemic therapy substance. Trade name or
active ingredient
Reason systemic therapy was discontinued
CodelistItem 839163 (A )
CodelistItem 839164 (E )
CodelistItem 839167 (P )
CodelistItem 839166 (R )
CodelistItem 839169 (S )
CodelistItem 839168 (U )
CodelistItem 839165 (V )
Systemic therapy end date
Systemic or expectant treatment
Kind of systemic or expectant therapy
Active Surveillance (AS)
Chemotherapy (CH)
Hormone therapy (HO)
Immune- und antibody therapy (IM)
Bone marrow transplantation (KM)
Other (SO)
Wait and see (WS)
Targeted substance (ZS)
Systemic therapy side effects
CTC grade systemic therapy side effects
strong / pronounced (3)
life threatening (4)
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deadly (5)
none or max Grade 2 (K)
unknown (U)
Systemic therapy type of side effect according to
CTC
Systemic therapy CTCAE version
version 4 (1)
Follow-Up
Date of follow up
Evaluation of tumor status
CodelistItem 839189 (B )
CodelistItem 839188 (D )
no change, NC / stable disease (K )
CodelistItem 839187 (P )
CodelistItem 839190 (R )
at least 50% regression of tumor (partial
remission, PR) (T )
CodelistItem 839191 (U )
complete remission, CR (V )
CodelistItem 839192 (X )
Primary tumor status
CodelistItem 839198 (F )
CodelistItem 839193 (K )
CodelistItem 839196 (N )
CodelistItem 839195 (P )
CodelistItem 839197 (R )
CodelistItem 839194 (T )
CodelistItem 839199 (U )
CodelistItem 839200 (X )
Tumor status of lymph nodes
CodelistItem 839206 (F )
CodelistItem 839201 (K )
CodelistItem 839205 (N )
CodelistItem 839204 (P )
CodelistItem 839202 (R )
CodelistItem 839203 (T )
CodelistItem 839207 (U )
CodelistItem 839208 (X )
Distant metastases status
CodelistItem 839215 (F )
CodelistItem 839209 (K )
CodelistItem 839210 (M )
CodelistItem 839214 (N )
CodelistItem 839213 (P )
CodelistItem 839211 (R )
CodelistItem 839212 (T )
CodelistItem 839216 (U )
CodelistItem 839217 (X )
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Tumor conference
Date of tumor board
Tumor board type
CodelistItem 839219 (postop )
CodelistItem 839220 (postth )
CodelistItem 839218 (praeth )
Death
Date of death
Cause of death related to malignancy
CodelistItem 839221 (J )
CodelistItem 839222 (N )
CodelistItem 839223 (U )
Cause of death
Further comments
Name of surgeon
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"Glioma " - Additions to the ADT-base
record
The uniform oncological basic data set of ADT and GEKID
was adopted in March 2008 and updated in February,
2014. It applies to all types of cancer and is continuously
supplemented by tumor-specific modules. By harmonizing
Oncology base record, an instrument has been created
which provides a harmonized oncological standard ,
prevents multiple documentaries and allows comparable
acquisition and evaluation of cancer treatments in all
clinical structures and federal states . Source:
http://www.tumorzentren.de/onkol-basisdatensatz.html
All rights reserved. Please visit https://medical-data-
models.org/forms/15061
Organ specific data set for glioma:
September 2012
Data set glioma
Localization of glioma
CodelistItem 839229 (6)
eloquent (e)
Gliomatosis cerebri with ≥ 3 cerebral
lobes (g)
infratentorial (i)
not-eloquent (n)
supratentorial (s)
WHO grading
Grad I (1)
Grad II (2)
Grad III (3)
Grad IV (4)
unknown (U)
MGMT-Promotormethylation
CodelistItem 839236 (1 )
CodelistItem 839237 (2 )
CodelistItem 839238 (3 )
unknown (U)
1p19q Deletion
CodelistItem 839239 (1 )
CodelistItem 839240 (2 )
CodelistItem 839241 (3 )
CodelistItem 839242 (4 )
CodelistItem 839243 (5 )
CodelistItem 839244 (U )
IDH1,2-Mutation
CodelistItem 839245 (1 )
CodelistItem 839246 (2 )
CodelistItem 839247 (3 )
CodelistItem 839248 (U )
Level of resektion
CodelistItem 839249 (1 )
CodelistItem 839250 (2 )
CodelistItem 839251 (3 )
CodelistItem 839252 (4 )
CodelistItem 839253 (5 )
Neurological status
normal (1)
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pathological (2)
unknown (3)
Neurological follow up
CodelistItem 839257 (1 )
CodelistItem 839258 (2 )
CodelistItem 839259 (3 )
CodelistItem 839260 (U )
Steroid treatment
CodelistItem 839261 (1 )
CodelistItem 839262 (2 )
CodelistItem 839263 (3 )
Steroid treatment follow up
more comparing to prior examination (1)
unchanged comparing to prior
examination (2)
less comparing to prior examination (3)
unknown (U)
General condition of the patient (Karnofsky
Status): Score
%
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"Gynecological carcinoma"- Additions to the
ADT-base record
The uniform oncological basic data set of ADT and GEKID
was adopted in March 2008 and updated in February,
2014. It applies to all types of cancer and is continuously
supplemented by tumor-specific modules. By harmonizing
Oncology base record, an instrument has been created
which provides a harmonized oncological standard ,
prevents multiple documentaries and allows comparable
acquisition and evaluation of cancer treatments in all
clinical structures and federal states . Source:
http://www.tumorzentren.de/onkol-basisdatensatz.html
All rights reserved. Please visit https://medical-data-
models.org/forms/15062
Organ specific data set for
gynecological  carcinoma: October
2012
Data set gynecological carcinoma
Pelvic lymph nodes excision
Yes (1)
No (2)
Not done (3)
Unknown (4)
Pelvic lymph nodes: number of excised pelvic
lymph nodes
Pelvic lymph nodes:number of positive pelvic
lymph nodes
Periaortic lymph nodes excision
Yes (1)
No (2)
Not done (3)
Unknown (4)
Periaortic lymph nodes: Number of excised
periaortic lymph nodes
Periaortic lymph nodes: Number of positive
periaortic lymph nodes
Inguinal lymph nodes excision
Yes (1)
No (2)
Not done (3)
Unknown (4)
Inguinal lymph nodes:Number of excised inguinal
lymph nodes
Inguinal lymph nodes:Number of positive inguinal
lymph nodes
FIGO Staging calculated from TNM formula,
indicate TNM-Version used for coding
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"colorectal carcinoma"- Additions to the
ADT-base record
The uniform oncological basic data set of ADT and GEKID
was adopted in March 2008 and updated in February,
2014. It applies to all types of cancer and is continuously
supplemented by tumor-specific modules. By harmonizing
Oncology base record, an instrument has been created
which provides a harmonized oncological standard ,
prevents multiple documentaries and allows comparable
acquisition and evaluation of cancer treatments in all
clinical structures and federal states . Source:
http://www.tumorzentren.de/onkol-basisdatensatz.html
All rights reserved. Please visit https://medical-data-
models.org/forms/15064
Organ specific data set for colorectal
carcinoma: January 2015
Data set colorectal carcinoma
Position of rectal carcinoma from anocutaneous
line
CodelistItem 839280 ((n) )
CodelistItem 839281 (U )
Position of rectal carcinoma from anocutaneous
line
cm
Minimum distance from aboral resection margin
CodelistItem 839282 ((n) )
CodelistItem 839283 (U )
Minimum distance from aboral resection margin
mm
Distance to circumferential resection margin
CodelistItem 839284 ((n) )
CodelistItem 839285 (U )
Distance to circumferential resection margin
mm
Quality of TME Specimen
Grade 1 (good) (1 )
Grade 2 (moderate) (2 )
Grade 3 (bad) (3 )
other operation performed (A )
Local Excision performed (L )
PME performed (P )
Unknown (U )
MRI or thin-slice CT performed with specified
distance to mesorectal fascia
done without indicating the distance from
mesorectal fascia (D )
Not done (N )
Unknown (U )
MRI or thin-slice CT performed with specified
distance to mesorectal fascia
mm
Type of surgery
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CodelistItem 839296 (E )
CodelistItem 839297 (N )
CodelistItem 839298 (U )
Preoperative marking of stoma position
marking done (D )
no ostomy (K )
marking not done (N )
ostomy performed, marking unknown (S
)
unknown (U )
Insufficiency of anastomosis
Anastomosis insufficieny Grade Grade B
(B )
Anastomosis insufficieny Grade C (C )
No Insufficiency or maximum Grade A (K
)
unknown (U )
ASA Classification
CodelistItem 839308 (1 )
CodelistItem 839309 (2 )
CodelistItem 839310 (3 )
CodelistItem 839311 (4 )
CodelistItem 839312 (5 )
KRAS oncogene mutation
Mutation (M )
not done (N )
unknown (U )
Wild type (W )
Date of contact with social services
CodelistItem 839317 (N )
CodelistItem 839318 (U )
Date of contact with social service
Study recruitment date of enrollment
Study recruitment
CodelistItem 839319 (J )
CodelistItem 839320 (N )
CodelistItem 839321 (U )
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NINDS CDE [Medical History][Amyotrophic
Lateral Sclerosis]
NINDS Common Data Elements [Participant/Subject
History and Family History] [Amyotrophic Lateral Sclerosis]
Used from the National Institute of Neurological Disorders
and Stroke Common Data Elements
(https://www.commondataelements.ninds.nih.gov/)
References: Grinnon ST, Miller K, Marler JR, Lu Y, Stout A,
Odenkirchen J, Kunitz S. National Institute of Neurological
Disorders and Stroke Common Data Element Project -
approach and methods. Clin Trials. 2012;9(3):322-9.
All rights reserved. Please visit https://medical-data-
models.org/forms/15065
General Health History
Medical history
Study-ID
Study site name
Subject ID
Date Medical History Taken
Have you experienced problems with
constitutional symptoms in the past?
Yes
No
Please specify the constitutional symptom you
experienced. If there´s more than one, please
describe one be one.
Start date of constitutional symptom
End date of constitutional symptom
Is the symptom persistent?
Yes
No
Have you experienced problems with your eyes in
the past?
Yes
No
Please specify the eye problems you
experienced. If there´s more than one, please
describe one be one.
Start date of eye problems
End date of eye problems
Is the symptom persistent?
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Yes
No
Have you experienced ENT or mouth problems in
the past?
Yes
No
Please specify the otorhinolaryngologic
conditions or problems with your mouth you
experienced. If there´s more than one, please
describe one be one.
Start date of you ENT or mouth problems
End date of your ENT or mouth problems
Is the symptom persistent?
Yes
No
Have you experienced problems with your
cardiovascular system in the past?
Yes
No
Please specify the problems you experienced
with your cardiovascular system. If there´s more
than one, describe it one by one.
Start date of your cardiovascular problems
End date of your cardiovascular problems
Is the symptom persistent?
Yes
No
Have you experienced respiratory problems in the
past?
Yes
No
Please specify the respiratory problems you
experienced. If there´s more than one, describe it
one by one.
Start date of your respiratory problems
End date of your respiratory problems
Is the symptom persistent?
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Yes
No
Have you experienced gastrointestinal problems
in the past?
Yes
No
Please specify the gastrointestinal problem you
experienced. If there´s more than one, describe it
one by one
Start date of your gastrointestinal problems
End date of your gastrointestinal problems
Is the symptom persistent?
Yes
No
Have you experienced problems with your
genitourinary system in the past?
Yes
No
Please specify the problems with your
genitourinary system. If there´s more than one,
describe it one by one.
Start date of your genitourinary problems
End date of your genitourinary problems
Is the symptom persistent?
Yes
No
Have you experienced problems with
musculoskeletal system in the past?
Yes
No
Please specify the problem with your
musculoskeletal system. If there´s more than
one, describe it one by one.
Start date of your musculoskeletal problem
End date of your musculoskeletal problem
Is the symptom persistent
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Yes
No
Have you experienced problems with your skin or
your breast in the past?
Yes
No
Please specify the problems with your
integumentary system you experienced. If there´s
more than one, describe it one by one.
Start date of your problems with the
integumentary system
End date of your problems with the
integumentary system
Is the symptom persistent?
Yes
No
Have you experienced neurological problems with
in the past?
Yes
No
Please specify the neurological problems you
experienced. If there´s more than one, please
describe it one be one.
Start date of the neurological problem
End date of the neurological problem
Is the symptom persistent?
Yes
No
Have you experienced problems with your mental
health in the past?
Yes
No
Please specify the mental problem you
experienced. If there´s more than one, please
describe it one by one.
Start date of your mental illness
End date of your mental illness
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Is the symptom persistent?
Yes
No
Have you experienced problems with your
endocrine system in the past?
Yes
No
Please specify the endocrine system disease you
experienced. If there´s more than one,please
describe it one by one
Start date of the endocrine system disease
End date of the endocrine system disease
Is the symptom persistent?
Yes
No
Have you experienced problems with diseases of
blood and bloodforming organs in the past?
Yes
No
Please specify the disease of blood and
bloodforming organs you experienced. If there´s
more than one,please describe it one by one.
Start date of your problems with the blood or
bloodforming system
End date of the problems with your blood or
bloodforming system
Is the symptom persistent?
Yes
No
Have you experienced problems with lymphatic
diseases in the past?
Yes
No
Please specify the problem with your lymphatic
system you experienced. If there´s more than
one, please describe it one by one
Start date of your problems with the lymphatic
system
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End date of your problems with the lymphatic
system
Is the symptom persistent?
Yes
No
Have you experienced problems with allergies in
the past?
Yes
No
Please specify the allergy you experienced. If
there´s more than one, please describe it one by
one.
Start date of the allergy
End date of the allergy
Is the allergy persistent?
Yes
No
Have you experienced problems with your
immune system in the past?
Yes
No
Please specify the problem with your immune
system you experienced. If there´s more than
one, please desribe it one by one
Start date of your problems with the immune
system
End date of the problems with your immune
system
Is the symptom persistent?
Yes
No
Does the subject have allergies?
Yes
No
If the subject does have allergies, please specify
which type:
food (1)
seasonal (2)
medication (3)
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Is the subject of childbearing potential?
Yes
No
Females of childbearing potential, using safe
contraceptive measures? Please check one
below
Abstinence (1)
Hormonal (oral,implanted,injected...) (2)
Intrauterine device in place for ≥ 3
months (3)
Adequate barrier method in conjunction
with spermicide (4)
Postmenopausal (5)
Surgically sterile (6)
Non-surgically sterile  (7)
Other (8)
Please specify other contraceptive measures, if
none of the above applied.
If the subject was surgically sterilized, please
specify:
Hysterectomy (1)
Tubal ligation (2)
Other (3)
Please specify other method of surgical
sterilization if none of the above applied.
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"Mamma carcinoma"- Additions to the ADT-
base record
The uniform oncological basic data set of ADT and GEKID
was adopted in March 2008 and updated in February,
2014. It applies to all types of cancer and is continuously
supplemented by tumor-specific modules. By harmonizing
Oncology base record, an instrument has been created
which provides a harmonized oncological standard ,
prevents multiple documentaries and allows comparable
acquisition and evaluation of cancer treatments in all
clinical structures and federal states . Source:
http://www.tumorzentren.de/onkol-basisdatensatz.html
All rights reserved. Please visit https://medical-data-
models.org/forms/15066
Organ specific data set for mamma
carcinoma: January 2015
Data set mamma carcinoma
Pretherapeutic menopausal status
premenopausal (1)
postmenopausal (2)
unknown (3)
Hormone receptor status for estrogen
negative (N)
positive (P)
unknown (U)
Hormone receptor status for estrogen
CodelistItem 839342 (1)
CodelistItem 839343 (2)
CodelistItem 839344 (3)
CodelistItem 839345 (4)
CodelistItem 839346 (5)
Hormone recepetor status for estrogen
CodelistItem 839347 (keine )
CodelistItem 839349 (mäßig )
CodelistItem 839348 (schwach )
CodelistItem 839350 (stark )
Hormone receptor status for progesterone
negative (N)
positive (P)
unknown (U)
Hormone receptor status for progesterone
CodelistItem 839354 (1)
CodelistItem 839355 (2)
CodelistItem 839356 (3)
CodelistItem 839357 (4)
CodelistItem 839358 (5)
Hormone receptor status for progesterone
CodelistItem 839359 (keine )
CodelistItem 839361 (mäßig )
CodelistItem 839360 (schwach )
CodelistItem 839362 (stark )
Her2neu Status
negative (N)
positive, i.e. IHC +++ oder IHC ++ und
ISH (FISH, CISH o. Ä.) (P)
unknown (U)
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imaging controlled preoperative wire localization
CodelistItem 839366 (M )
CodelistItem 839369 (N )
CodelistItem 839367 (S )
CodelistItem 839368 (T )
CodelistItem 839370 (U )
Intraoperative specimen X-ray / Sonography
CodelistItem 839371 (M )
CodelistItem 839373 (N )
CodelistItem 839372 (S )
CodelistItem 839374 (U )
Tumor size invasive carcinoma
mm
Tumor size of invasive carcinoma
no invasive neoplasm (0)
cannot be assessed (U)
Tumor size DCIS
no DCIS or invasive part detected (0)
cannot be assessed (U)
Tumor size DCIS
mm
Date of contact with social service
Date of contact with social services
no contact (N)
unknown (U)
Study recruitment date of enrollment
Study recruitment
no enrollment into clinical trial (N)
unknown (U)
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"Pulmonary carcinoma"- Additions to the
ADT-base record
The uniform oncological basic data set of ADT and GEKID
was adopted in March 2008 and updated in February,
2014. It applies to all types of cancer and is continuously
supplemented by tumor-specific modules. By harmonizing
Oncology base record, an instrument has been created
which provides a harmonized oncological standard ,
prevents multiple documentaries and allows comparable
acquisition and evaluation of cancer treatments in all
clinical structures and federal states . Source:
http://www.tumorzentren.de/onkol-basisdatensatz.html
All rights reserved. Please visit https://medical-data-
models.org/forms/15067
Organ specific data set for
pulmonary carcinoma: November
2011
Data set pulmonary carcinoma
EGFR Mutation
Mutation (1)
Wild-Type (2)
Not done (3)
unknown (U)
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Eligibility Depressive Disorder
NCT02346539
Effect of Nicotine on Brain Reward Pathways; ODM derived
from: https://clinicaltrials.gov/show/NCT02346539
All rights reserved. Please visit https://medical-data-
models.org/forms/15068
Eligibility Depressive Disorder
NCT02346539
Criteria
1. provide written informed consent;*
Yes
No
2. both genders and all ethnic origins, age
between 18 and 45;*
Yes
No
3. meet dsm-iv diagnostic criteria for mdd
(diagnosed with the use of the scid);*
Yes
No
4. a baseline ham-d score of 16 or greater;*
Yes
No
5. absence of pregnancy;*
Yes
No
6. absence of any psychotropic medication for at
least 2 weeks:*
Yes
No
1. 6 weeks for fluoxetine*
Yes
No
2. 6 months for neuroleptics*
Yes
No
3. 2 weeks for benzodiazepines*
Yes
No
4. 2 weeks for any other antidepressants*
Yes
No
inclusion criteria for healthy controls*
Yes
No
1. absence of medical, neurological, and
psychiatric illness (including alcohol and
substance abuse); as assessed by subject history
and a structured clinical interview (scid);*
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Yes
No
2. provide written informed consent;*
Yes
No
3. both genders and all ethnic origins, age
between 18 and 45;*
Yes
No
4. absence of any medications for at least 3
weeks;*
Yes
No
5. absence of pregnancy.*
Yes
No
Exclusion Criteria
1. subjects with suicidal ideation where outpatient
treatment is determined unsafe. these patients
will be immediately referred to a licensed
psychologist or psychiatrist to determine the
appropriate clinical treatment;*
Yes
No
2. serious or unstable medical illness*
Yes
No
3. lifetime history of seizure disorder;*
Yes
No
4. lifetime history or current diagnosis of any of
the following dsm-iv psychiatric illnesses: organic
mental disorder, schizophrenia, schizoaffective
disorder, delusional disorder, psychotic disorders
not otherwise specified, bipolar disorder, adhd,
patients with mood congruent or mood
incongruent psychotic features; simple phobia,
social anxiety disorder and generalized anxiety
disorders will be allowed only if secondary to
mdd;*
Yes
No
5. patients with a lifetime history of
electroconvulsive therapy (ect);*
Yes
No
6. failure to meet standard mri safety
requirements;*
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Yes
No
7. may not have used any nicotine product in the
past year; must report fewer than 20 lifetime uses
of nicotine*
Yes
No
8. must have an expired carbon monoxide level of
less than or equal to 10 ppm.*
Yes
No
9. use of anticholinergic drugs in the past week*
Yes
No
10. any past or present history of cardiac
problems including known arrhythmias, acute
coronary syndrome, or ischemic heart disease*
Yes
No
11. uncontrolled hypertension*
Yes
No
12. history of substance abuse in the past 6
months (other than caffeine), self-reported use of
marijuana in past month, or history of treatment
with methadone*
Yes
No
13. heavy caffeine users (consume greater than
500 mg on a regular or daily basis)*
Yes
No
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Eligibility Depressive Disorder, Major
NCT02410616
E-Compared-CH: Comparative Effectiveness Research on
Internet-based Depression Treatment - Swiss Trial; ODM
derived from: https://clinicaltrials.gov/show/NCT02410616
All rights reserved. Please visit https://medical-data-
models.org/forms/15069
Eligibility Depressive Disorder, Major
NCT02410616
Inclusion Criteria
being 18 years of age or older*
Yes
No
• meet dsm-iv diagnostic criteria for mdd
confirmed by mini international neuropsychiatric
interview version 5.0*
Yes
No
informed consent*
Yes
No
• having access to a pc and internet connection*
Yes
No
• having a smartphone that is compatible with the
mobile component of the intervention*
Yes
No
• understanding of the german language spoken
and written*
Yes
No
Exclusion Criteria
• current high risk for suicide according to the
mini interview section c*
Yes
No
• serious psychiatric co-morbidity: substance
dependence, bipolar affective disorder, psychotic
illness, obsessive compulsive disorder, as
established at the mini interview*
Yes
No
• currently receiving psychological treatment for
depression*
Yes
No
• being unable to comprehend the spoken and
written language (german)*
Yes
1 / 2
No
• not having access to a pc and fast internet
connection (i.e. broadband or comparable).*
Yes
No
• not having a smartphone that is compatible with
the mobile component of the intervention that is
offered or not willing to carry a smartphone
during the duration of treatment*
Yes
No
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Eligibility Dermatitis, Atopic NCT02343783
A Study to Evaluate Use of Induced Skin Blisters in Adult
Participants With Atopic Dermatitis, Allergic Asthma and
Atopic Healthy Participants; ODM derived from:
https://clinicaltrials.gov/show/NCT02343783
All rights reserved. Please visit https://medical-data-
models.org/forms/15070
Eligibility Dermatitis, Atopic
NCT02343783
Inclusion Criteria
participant must have signed an informed
consent document prior to any study related
procedures indicating that they understand the
purpose of and procedures required for the study
and are willing to participate in the study*
Yes
No
participant must be willing/able to adhere to the
study visit schedule and other requirements,
prohibitions and restrictions specified in this
protocol*
Yes
No
* for participants with asthma:*
Yes
No
participant must have a physician documented
diagnosis of asthma for at least 12 months before
screening*
Yes
No
participant must have an asthma control
questionnaire 6 (acq6) less than (<) 1.5 at
screening*
Yes
No
* for participants with atopic dermatitis:*
Yes
No
participant must have a physician documented
diagnosis of atopic dermatitis for at least 12
months before screening based on uk refinement
of the hanifin and rajka's diagnostic criteria*
Yes
No
participant must have atopic dermatitis with and
investigators global assessment (iga) score of 2
to 4 at screening*
Yes
No
Exclusion Criteria
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participant has taken any prohibited or restricted
medications as noted below under prestudy and
concomitant therapy*
Yes
No
participant has received an investigational drug
(including investigational vaccines) or used an
invasive investigational medical device within 6
weeks or 5 half-lives (whichever is longer) before
the screening visit*
Yes
No
* for participants with asthma:*
Yes
No
participant has a history of life-threatening
asthma, defined as a history of respiratory arrest
or requiring intubation for asthma*
Yes
No
participant had been admitted to a hospital for
asthma in the 1 year before screening*
Yes
No
* for participants with atopic dermatitis:*
Yes
No
participant has evidence of any other skin
condition that would interfere with assessment of
atopic dermatitis (ad)*
Yes
No
participant has active ad related infection or has
had an active ad infection within 2 weeks of
screening (participants with evidence of
colonization on skin swab testing but with no
infection are allowed)*
Yes
No
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Eligibility Dementia NCT00236574
A Study to Evaluate the Efficacy and Safety of Galantamine
in Patients With Mild Cognitive Impairment; ODM derived
from: https://clinicaltrials.gov/show/NCT00236574
All rights reserved. Please visit https://medical-data-
models.org/forms/15071
Eligibility Dementia NCT00236574
Inclusion Criteria
clinical decline of cognitive ability consistent with
mild cognitive impairment*
Yes
No
delayed recall score less than or equal to 10 on
new york university paragraph recall test*
Yes
No
sufficient visual, hearing and communication
capabilities and willingness to complete serial
standard tests of cognitive function*
Yes
No
have a consistent informant to accompany them
on scheduled visits*
Yes
No
be able to read, write and fully understand the
language of the cognitive scales used in the
study*
Yes
No
Exclusion Criteria
contraindications for magnetic resonance
imaging, for example, presence of pacemaker or
presence of metal in high risk areas*
Yes
No
neurodegenerative disorders such as parkinson's
disease*
Yes
No
cognitive impairment resulting from acute
cerebral trauma, hypoxic cerebral damage,
vitamin deficiency states, infections such as
meningitis or aids, or primary of metastatic
cerebral neoplasia*
Yes
No
significant endocrine or metabolic disease*
Yes
No
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mental retardation*
Yes
No
women who are pregnant, nursing, or lacking
adequate contraception*
Yes
No
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Eligibility Dementia NCT00236431
A Study to Evaluate the Efficacy and Safety of Galantamine
in Patients With Mild Cognitive Impairment; ODM derived
from: https://clinicaltrials.gov/show/NCT00236431
All rights reserved. Please visit https://medical-data-
models.org/forms/15072
Eligibility Dementia NCT00236431
Inclusion Criteria
clinical decline of cognitive ability consistent with
mild cognitive impairment*
Yes
No
delayed recall score <= 10 on a new york
university paragraph recall test*
Yes
No
sufficient visual, hearing and communication
capabilities and be willing to complete serial
standard tests of cognitive function*
Yes
No
have a consistent informant to accompany them
on scheduled visits*
Yes
No
be able to read, write and fully understand the
language of the cognitive scales used in the
study*
Yes
No
Exclusion Criteria
neurodegenerative disorders such as parkinson's
disease*
Yes
No
cognitive impairment resulting from acute
cerebral trauma, hypoxic cerebral damage,
vitamin deficiency states, infections such as
meningitis or aids, or primary or metastatic
cerebral neoplasia*
Yes
No
epilepsy*
Yes
No
significant psychiatric disease*
Yes
No
peptic ulcer disease*
Yes
1 / 2
No
clinically significant heart, lung, liver or kidney
diseases*
Yes
No
pregnant or nursing women or those without
adequate contraception*
Yes
No
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Eligibility Diabetes Mellitus NCT02240381
Predicting Development of Diabetes Mellitus in Patients
Undergoing Allogeneic Stem Cell Transplant; ODM derived
from: https://clinicaltrials.gov/show/NCT02240381
All rights reserved. Please visit https://medical-data-
models.org/forms/15074
Eligibility Diabetes Mellitus
NCT02240381
Inclusion Criteria
patients undergoing mrd allogeneic hct*
Yes
No
donor: donors undergoing stem cell collection for
match related allogeneic stem cell transplant*
Yes
No
Exclusion Criteria
patients who have not received an allogeneic hct*
Yes
No
recent or current history of diabetes mellitus,
defined as:1) diabetes therapy within 6 months of
enrollment, or 2) fasting blood glucose at "pre-
admit" (screening) visit >= 126 mg/dl*
Yes
No
pregnancy or breastfeeding*
Yes
No
unrelated donor, umbilical cord blood,
mismatched, or haploidentical transplants*
Yes
No
patients receiving t cell depletion or
thymoglobulin as part of their transplant*
Yes
No
patients on established, chronic corticosteroid
therapy (> 5 mg /day of prednisone or prednisone
equivalent) prior to transplant; established,
chronic corticosteroid therapy is defined as daily
dosing of > 5 mg/day of prednisone or
prednisone equivalent for at least 2 weeks prior
to the start of conditioning/chemotherapy or plans
to continue pre-transplant corticosteroids (> 5
mg/day of prednisone or prednisone equivalent)
indefinitely after transplantation*
Yes
No
inability to give informed consent*
Yes
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No
any condition which, in the opinion of the
investigator, might interfere with study objective*
Yes
No
any reason which, in the opinion of the
investigator, adds additional risk to the patient*
Yes
No
donor: individuals not donating stem cells*
Yes
No
donor: pregnancy or breastfeeding*
Yes
No
donor: inability to give informed consent*
Yes
No
donor: any condition which, in the opinion of the
investigator, might interfere with study objective*
Yes
No
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Eligibility Diabetes Mellitus NCT02302443
A First-in-human Study to Evaluate the Safety, Tolerability,
Pharmacokinetics and Pharmacodynamics of HM12470;
ODM derived from:
https://clinicaltrials.gov/show/NCT02302443
All rights reserved. Please visit https://medical-data-
models.org/forms/15075
Eligibility Diabetes Mellitus
NCT02302443
Criteria
t2dm more than 12 monthm*
Yes
No
age ≥18 and ≤70 years*
Yes
No
body mass index between 18.0 and 35.0 kg/m2
inclusive.*
Yes
No
considered generally healthy upon completion of
medical history, physical examination and
biochemical investigations as judged by the
investigator.*
Yes
No
females must be non-pregnant and non-lactating,
and either surgically sterile (e.g., tubal occlusion,
hysterectomy, bilateral salpingectomy, bilateral
oophorectomy) or post-menopausal for >12
months. males must be surgically sterile,
abstinent or if engaged in sexual relations of
child-bearing potential, the subject must be using
an acceptable contraceptive method during and
for during a period of 60 days after the last dose
of study drug.*
Yes
No
signed and dated informed consent obtained
before any trial-related activities. (trial-related
activities are any procedure that would not have
been performed during normal management of
the subject).*
Yes
No
inclusion criteria for t2dm:*
Yes
No
t1dm more than 12 monthm*
Yes
No
age ≥18 and ≤70 years*
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Yes
No
body mass index between 18.0 and 30.0 kg/m2
inclusive.*
Yes
No
considered generally healthy upon completion of
medical history, physical examination and
biochemical investigations as judged by the
investigator.*
Yes
No
females must be non-pregnant and non-lactating,
and either surgically sterile (e.g., tubal occlusion,
hysterectomy, bilateral salpingectomy, bilateral
oophorectomy) or post-menopausal for >12
months. males must be surgically sterile,
abstinent or if engaged in sexual relations of
child-bearing potential, the subject must be using
an acceptable contraceptive method during and
for during a period of 60 days after the last dose
of study drug.*
Yes
No
signed and dated informed consent obtained
before any trial-related activities. (trial-related
activities are any procedure that would not have
been performed during normal management of
the subject).*
Yes
No
Exclusion Criteria
a subject who has proliferative retinopathy or
maculopathy, severe gastroparesis, and/or severe
neuropathy, in particular autonomic neuropathy,
as judged by the investigator*
Yes
No
recurrent major hypoglycemia or hypoglycemic
unawareness or recent ketoacidosis*
Yes
No
pregnant or lactating women*
Yes
No
participation in an investigational study within 30
days prior to dosing*
Yes
No
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clinically significant abnormal ecg at screening,
as judged by the investigator*
Yes
No
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Eligibility Diabetes Mellitus Type 2
NCT02372955
Mechanistic Study of the Systolic Blood Pressure Lowering
Effect of Dapagliflozin in Type 2 Diabetes; ODM derived
from: https://clinicaltrials.gov/show/NCT02372955
All rights reserved. Please visit https://medical-data-
models.org/forms/15076
Eligibility Diabetes Mellitus Type 2
NCT02372955
Inclusion Criteria
type 2 diabetes mellitus*
Yes
No
metformin treatment*
Yes
No
Exclusion Criteria
• type 1 diabetes mellitus*
Yes
No
hgb a1c > 9*
Yes
No
advanced diabetic complications, e.g. diabetic
renal disease (egfr < 60 cc/min), heavy
proteinuria, diabetic retinopathy, autonomic
neuropathy*
Yes
No
pregnancy or unwilling to practice contraception.*
Yes
No
uncontrolled hypertension (sbp > 150 mm hg;
dbp > 100 mm hg)*
Yes
No
chronic substance abusers*
Yes
No
carcinoma of the urinary bladder*
Yes
No
subjects deemed at risk for dehydration*
Yes
No
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Initial survey AIEOP-BFM ALL 2009
NCT01117441
International Collaborative Treatment Protocol For Children
And Adolescents With Acute Lymphoblastic Leukemia.
Phase 3 Study.
Initial survey. Please send this document within one month
after diagnosis to the study centre.
Clinical Trial Number: NCT01117441.
All rights reserved. Please visit https://medical-data-
models.org/forms/15077
Initial survey AIEOP-BFM ALL 2009
NCT01117441
Patient Information
Patient Study ID
Patient date of birth
Informed consent
Anamnesis
Hospital stay during the last four weeks before
diagnosis
Yes
No
Hospital stay:
If "Yes", specify hospital:
Hospital stay: 
If "Yes", specify date of hospitalisation:
Hospital stay: 
If "Yes", specify date of discharge:
Birth weight
g
Birth size
cm
Gestational age
Weeks of pregnancy
Medical assisted reproduction
Yes
No
Number of siblings
Number of half siblings
Number of not biological siblings
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Multiple birth offspring
no (no)
yes, multiples (yes, multiples)
yes, twins (yes, twins)
Multiple birth offspring
If "Yes", specify zygosity:
dizygotic (dizygotic)
monozygotic (monozygotic)
Fever
> 38,5 °C
Yes
No
Pathogen detection
Yes
No
Pathogen detection
If "Yes", specify:
CRP increase
Yes
No
CRP measurement:
If a positive CRP increase, specify:
mg/dL
Previous disease:
Malignancies
Yes
No
Previous disease:
Malignancies:
If "Yes", specify:
Previous disease:
Immune deficiency
Yes
No
Previous disease: 
Immune deficiency
If "Yes", specify:
Previous disease: 
Haematological disease
Yes
No
Previous disease: 
Haematological disease
If "Yes", specify:
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Previous disease: 
Chronic virus infection
Yes
No
Previous disease: 
Chronic virus infection
If "Yes", specify:
Previous disease: 
Chromosomal aberration/ hereditary disease
Yes
No
Previous disease: 
Chromosomal aberration/ hereditary disease
If "Yes", specify:
Previous disease: 
Metabolic disease
Yes
No
Previous disease: 
Metabolic disease
If "Yes", specify:
Previous disease: 
Autoimmune disease
Yes
No
Previous disease: 
Autoimmune disease
If "Yes", specify:
Previous disease: 
Cardiac disease
Yes
No
Previous disease: 
Cardiac disease
If "Yes", specify:
Previous disease: 
Chronic disease
Yes
No
Previous disease: 
Chronic disease
If "Yes", specify:
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Siblings suffering from malignancy
Yes
No
Siblings suffering from malignancy
If "Yes", specify:
Mother suffering from malignancy
Yes
No
Mother suffering from malignancy
If "Yes", specify:
Parents of mother suffering from malignancy
no (no)
yes, mother's father (yes, mother's
father)
yes, mother's mother (yes, mother's
mother)
Mother of mother suffering from malignancy
If "Yes, mother's mother", specify:
Father of mother suffering from malignancy
If "Yes, mother's father", specify:
Siblings of mother suffering from malignancy
Yes
No
Siblings of mother suffering from malignancy:
If "Yes", specify:
Niece/nephew of mother suffering from
malignancy
Yes
No
Niece/nephew of mother suffering from
malignancy specification
If "Yes", specify:
Father suffering from malignancy
Yes
No
Father suffering from malignancy
If "Yes", specify:
Parents of father suffering from malignancy
no (no)
yes, father's mother (yes, father's
mother)
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yes, father's father (yes, fathers father)
Mother of father suffering from malignancy
If "Yes, father's mother", specify:
Father of father suffering from malignancy
If "Yes, father's father", specify:
Siblings of father suffering from malignancy
Yes
No
Siblings of mother suffering from malignancy
Niece/nephew of father suffering from malignancy
Yes
No
Niece/nephew of father suffering from malignancy
If "Yes", specify:
Diagnosis
Hospital admission date
(in hospital of study centre)
Leukopheresis performed?
Yes
No
Leukopheresis:
If "Yes", specify start date:
Leukopheresis:
If "Yes", specify end date:
Weight
kg
Height
cm
Blood analysis
Date of initial blood analysis
(first hospital admission, before transfusion)
Initial blood analysis:
leukocytes
/μl
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Inital blood analysis:
blasts
%
Initial blood analysis:
platelets
/μl
Initial blood analysis:
haemoglobin
g/dL
Date of blood analysis at diagnosis
(usually at bone-marrow-puncture; if there was no
BMP perfomed before therapy start, take blood
analysis wich was relevant for diagnosis)
Blood analysis at diagnosis: 
leukocytes
/μl
Blood analysis at diagnosis: 
blasts
%
Date of blood analysis at therapy start
(Day 1 of the pre phase)
Blood analysis at therapy start: 
leukocytes
/μl
Blood analysis at therapy start: 
blasts
%
Initial CNS status
Initial lumbar puncture: 
date
Cerebrospinal fluid contaminated with blood
(macroscopically)
Yes
No
Cerebrospinal fluid:
Cell count performed?
(with haemocytometer)
Yes
No
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Cerebrospinal fluid:
If cell count performed, specify erythrocytes:
/μl
Cerebrospinal fluid: 
If cell count performed, specify nucleated cells:
/μl
Cytomorphological assessment of cytospin
not performed: cytospin compounds not
evaluable (not performed: cytospin
compounds not evaluable)
not performed: no cytospin compounds
prepared (not performed: no cytospin
compounds prepared)
performed: assessment in study centre
(performed: assessment in study centre)
performed: assessment locally only
(please add all results) (performed:
assessment locally only (please add all
results))
Cytomorphological blasts in cytospin compound?
Yes
No
Initial diagnostic imaging of CNS
not performed (not performed)
performed: CT (performed: CT)
performed: MRI (performed: MRI)
Initial diagnostic imaging of CNS 
If performed, specify date of procedure:
Cerebral mass or leptomeningeal involvement
found in imaging
no (no)
yes (please add results and images on
CD-ROM) (yes (please add results and
images on CD-ROM))
Examination of cranial nerves:
cranial nerves dysfunction?
Examination of cranial nerves not
performed (Examination of cranial
nerves not performed)
No (No)
Yes (Yes)
Examination of cranial nerves:
If performed, specify date:
Treatment of CNS
Like "CNS negative" (Like "CNS
negative")
Like "CNS negative" and additional MTX
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(i.th.) in protocol IA (Like "CNS negative"
and additional MTX (i.th.) in protocol IA)
Like "CNS positive" (Like "CNS positive")
Multi-organ involvement
Liver size (palpatoric):
performed?
Yes
No
Liver size (palpatoric)
If performed, specify value:
(in cm under costal arch in MCL)
cm
Spleen size (palpatoric): 
performed?
Yes
No
Spleen size (palpatoric) 
If performed, specify value: 
(in cm under costal arch in MCL)
cm
Involvement of mediastinum
No (No)
No examination performed (No
examination performed)
Yes (Yes)
Involvement of testicles
No  (No )
No examinatin performed (No examinatin
performed)
Yes (Yes)
Prednisone response (on day 8 of
cytoreductive pre-phase)
Date
(on day 8 of cytoreductive pre-phase)
Leukocytes
/μl
Blasts (peripher)
%
Cumulative dose of prednisone 
(7 days)
mg
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Comments
Comments
Identification and Signature
Investigator's name
Date of report
Investigator's signature
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Laboratory Parameters R-HR AIEOP-BFM
ALL 2009 NCT01117441
International Collaborative Treatment Protocol For Children
And Adolescents With Acute Lymphoblastic Leukemia.
Phase 3 Study. Laboratory documentation.
Clinical Trial Number: NCT01117441.
All rights reserved. Please visit https://medical-data-
models.org/forms/15078
Laboratory Parameters R-HR
AIEOP-BFM ALL 2009
NCT01117441
Patient Information
Patient Study ID
Patient Birth Date
Laboratory Parameters Study Section (of
Randomisation group HR, Prot. IB-ASP+)
PEG-L-ASP: 
date of administration
GOT measurement
(degree of toxicity:
Age norm (N))
0 (N) (0 (N))
1 (>N - 2.5xN) (1 (>N - 2.5xN))
2 (>2.5 - 5.0xN) (2 (>2.5 - 5.0xN))
3 (>5.0 - 20.0xN) (3 (>5.0 - 20.0xN))
4 (>20.0xN) (4 (>20.0xN))
GOT measurement 
(degree of toxicity: 
Age norm (N))
0 (N) (0 (N))
1 (>N - 2.5xN) (1 (>N - 2.5xN))
2 (>2.5 - 5.0xN) (2 (>2.5 - 5.0xN))
3 (>5.0 - 20.0xN) (3 (>5.0 - 20.0xN))
4 (>20.0xN) (4 (>20.0xN))
Bilirubin measurement 
(degree of toxicity: 
Age norm (N))
0 (N) (0 (N))
1 (>N - 1.5xN) (1 (>N - 1.5xN))
2 (>1.5 - 3.0xN) (2 (>1.5 - 3.0xN))
3 (>3.0 - 10.0xN) (3 (>3.0 - 10.0xN))
4 (>10.0xN) (4 (>10.0xN))
Amylases measurement
(degree of toxicity: 
Age norm (N))
0 (N) (0 (N))
1 (>N - 1.5xN) (1 (>N - 1.5xN))
2 (>1.5 - 2.0xN) (2 (>1.5 - 2.0xN))
3 (>2.0 - 5.0xN) (3 (>2.0 - 5.0xN))
4 (>5.0xN) (4 (>5.0xN))
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Lipase measurement 
(degree of toxicity: 
Age norm (N))
0 (N) (0 (N))
1 (>N - 1.5xN) (1 (>N - 1.5xN))
2 (>1.5 - 2.0xN) (2 (>1.5 - 2.0xN))
3 (>2.0 - 5.0xN) (3 (>2.0 - 5.0xN))
4 (>5.0xN) (4 (>5.0xN))
Laboratory Parameters Control Section (of
Randomisation group HR, Prot. IB)
Date in protocol
(Day 38 + 52)
GOT measurement 
(degree of toxicity: 
Age norm (N))
0 (N) (0 (N))
1 (>N - 2.5xN) (1 (>N - 2.5xN))
2 (>2.5 - 5.0xN) (2 (>2.5 - 5.0xN))
3 (>5.0 - 20.0xN) (3 (>5.0 - 20.0xN))
4 (>20.0xN) (4 (>20.0xN))
GOT measurement 
(degree of toxicity: 
Age norm (N))
0 (N) (0 (N))
1 (>N - 2.5xN) (1 (>N - 2.5xN))
2 (>2.5 - 5.0xN) (2 (>2.5 - 5.0xN))
3 (>5.0 - 20.0xN) (3 (>5.0 - 20.0xN))
4 (>20.0xN) (4 (>20.0xN))
Bilirubin measurement 
(degree of toxicity: 
Age norm (N))
0 (N) (0 (N))
1 (>N - 1.5xN) (1 (>N - 1.5xN))
2 (>1.5 - 3.0xN) (2 (>1.5 - 3.0xN))
3 (>3.0 - 10.0xN) (3 (>3.0 - 10.0xN))
4 (>10.0xN) (4 (>10.0xN))
Amylases measurement
(degree of toxicity: 
Age norm (N))
0 (N) (0 (N))
1 (>N - 1.5xN) (1 (>N - 1.5xN))
2 (>1.5 - 2.0xN) (2 (>1.5 - 2.0xN))
3 (>2.0 - 5.0xN) (3 (>2.0 - 5.0xN))
4 (>5.0xN) (4 (>5.0xN))
Lipase measurement 
(degree of toxicity: 
Age norm (N))
0 (N) (0 (N))
1 (>N - 1.5xN) (1 (>N - 1.5xN))
2 (>1.5 - 2.0xN) (2 (>1.5 - 2.0xN))
3 (>2.0 - 5.0xN) (3 (>2.0 - 5.0xN))
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4 (>5.0xN) (4 (>5.0xN))
Identification and Signature
Investigator's name
Date of report
Investigator's signature
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Laboratory Parameters R-R2 AIEOP-BFM
ALL 2009 NCT01117441
International Collaborative Treatment Protocol For Children
And Adolescents With Acute Lymphoblastic Leukemia.
Phase 3 Study. Laboratory documentation.
Clinical Trial Number: NCT01117441.
All rights reserved. Please visit https://medical-data-
models.org/forms/15079
Laboratory Parameters R-R2 AIEOP-
BFM ALL 2009 NCT01117441
Patient Information
Patient Study ID
Patient Birth Date
Laboratory Parameters Study Section (of
Randomisation group R2, Prot. II-ASP+)
PEG-L-ASP: 
date of administration
(within the protocol: IIA, IIB, maintenance
therapy)
GOT measurement
(degree of toxicity:
Age norm (N))
0 (N) (0 (N))
1 (>N - 2.5xN) (1 (>N - 2.5xN))
2 (>2.5 - 5.0xN) (2 (>2.5 - 5.0xN))
3 (>5.0 - 20.0xN) (3 (>5.0 - 20.0xN))
4 (>20.0xN) (4 (>20.0xN))
GOT measurement 
(degree of toxicity: 
Age norm (N))
0 (N) (0 (N))
1 (>N - 2.5xN) (1 (>N - 2.5xN))
2 (>2.5 - 5.0xN) (2 (>2.5 - 5.0xN))
3 (>5.0 - 20.0xN) (3 (>5.0 - 20.0xN))
4 (>20.0xN) (4 (>20.0xN))
Bilirubin measurement 
(degree of toxicity: 
Age norm (N))
0 (N) (0 (N))
1 (>N - 1.5xN) (1 (>N - 1.5xN))
2 (>1.5 - 3.0xN) (2 (>1.5 - 3.0xN))
3 (>3.0 - 10.0xN) (3 (>3.0 - 10.0xN))
4 (>10.0xN) (4 (>10.0xN))
Amylases measurement
(degree of toxicity: 
Age norm (N))
0 (N) (0 (N))
1 (>N - 1.5xN) (1 (>N - 1.5xN))
2 (>1.5 - 2.0xN) (2 (>1.5 - 2.0xN))
3 (>2.0 - 5.0xN) (3 (>2.0 - 5.0xN))
4 (>5.0xN) (4 (>5.0xN))
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Lipase measurement 
(degree of toxicity: 
Age norm (N))
0 (N) (0 (N))
1 (>N - 1.5xN) (1 (>N - 1.5xN))
2 (>1.5 - 2.0xN) (2 (>1.5 - 2.0xN))
3 (>2.0 - 5.0xN) (3 (>2.0 - 5.0xN))
4 (>5.0xN) (4 (>5.0xN))
Laboratory Parameters Control Section (of
Randomisation group R2, Prot. II)
Date in protocol
(Day 36, week 1, 5 and 9)
GOT measurement 
(degree of toxicity: 
Age norm (N))
0 (N) (0 (N))
1 (>N - 2.5xN) (1 (>N - 2.5xN))
2 (>2.5 - 5.0xN) (2 (>2.5 - 5.0xN))
3 (>5.0 - 20.0xN) (3 (>5.0 - 20.0xN))
4 (>20.0xN) (4 (>20.0xN))
GOT measurement 
(degree of toxicity: 
Age norm (N))
0 (N) (0 (N))
1 (>N - 2.5xN) (1 (>N - 2.5xN))
2 (>2.5 - 5.0xN) (2 (>2.5 - 5.0xN))
3 (>5.0 - 20.0xN) (3 (>5.0 - 20.0xN))
4 (>20.0xN) (4 (>20.0xN))
Bilirubin measurement 
(degree of toxicity: 
Age norm (N))
0 (N) (0 (N))
1 (>N - 1.5xN) (1 (>N - 1.5xN))
2 (>1.5 - 3.0xN) (2 (>1.5 - 3.0xN))
3 (>3.0 - 10.0xN) (3 (>3.0 - 10.0xN))
4 (>10.0xN) (4 (>10.0xN))
Amylases measurement
(degree of toxicity: 
Age norm (N))
0 (N) (0 (N))
1 (>N - 1.5xN) (1 (>N - 1.5xN))
2 (>1.5 - 2.0xN) (2 (>1.5 - 2.0xN))
3 (>2.0 - 5.0xN) (3 (>2.0 - 5.0xN))
4 (>5.0xN) (4 (>5.0xN))
Lipase measurement 
(degree of toxicity: 
Age norm (N))
0 (N) (0 (N))
1 (>N - 1.5xN) (1 (>N - 1.5xN))
2 (>1.5 - 2.0xN) (2 (>1.5 - 2.0xN))
3 (>2.0 - 5.0xN) (3 (>2.0 - 5.0xN))
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Laboratory Parameters R-R2 AIEOP-BFM ALL 2009 NCT01117441
4 (>5.0xN) (4 (>5.0xN))
Identification and Signature
Investigator's name
Date of report
Investigator's signature
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Laboratory Parameters R-R2 AIEOP-BFM ALL 2009 NCT01117441
Protocol IAD AIEOP-BFM ALL 2009
NCT01117441
International Collaborative Treatment Protocol For Children
And Adolescents With Acute Lymphoblastic Leukemia.
Phase 3 Study.
Study Protocol IAD (Study Protocol IA with
Dexamethasone).
Clinical Trial Number: NCT01117441.
All rights reserved. Please visit https://medical-data-
models.org/forms/15080
Protocol IAD AIEOP-BFM ALL 2009
NCT01117441
Patient Information
Stud.-Nr. (Pat.-ID)
Patient date of birth
Body weight
kg
Body height
cm
Body surface
mˆ2
Chemotherapy Regimen
Dexamethasone 
administration form
i.v. (i.v.)
p.o (p.o)
Prednisone dosage
60 mg/mˆ2/d
mg
Prednisone
Date of administration
Dexamethasone
administration form
i.v. (i.v.)
p.o. (p.o.)
Dexamethasone dosage
10 mg/mˆ2/d
mg
Dexamethasone
Date of administration
VCR
administration form
i.v.
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Yes
No
VCR dosage
(max. 2 mg)
1,5 mg/mˆ2/ED
mg
VCR
Date of administration
DNR
administration form
p.i. (1h)
Yes
No
DNR dosage
30 mg/mˆ2/d
mg
DNR
Date of administration
MTX
administration form
i.th
Yes
No
MTX dosage
(Age-dependent:
1 - < 2 y/o: 8 mg
2 - < 3y/o: 10 mg
>= 3 y/o: 12 mg
mg
MTX 
Date of administration
(while MTX infusion)
If CNS status CNS2 or CNS3, extra MTX dose
(i.th., on day 19 and 26):
Date of administration
PEG-L-ASP 
administration form
p.i. (2h)
Yes
No
PEG-L-ASP dosage
2500 mg/mˆ2/ED
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Protocol IAD AIEOP-BFM ALL 2009 NCT01117441
(ONCASPAR: 3750 E/ED)
E
PEG-L-ASP
(If Randomisation in Group HR-ASP+, continue
PEG-L-ASP therapy 14 days after dose on day
26)
Date of administration
PEG-L-ASP/ Erwinase
Change from PEG-L-ASP to Erwinase in this
element
Yes
No
If "yes", specify:
Erwinase: 
date of first administration
If "yes", specify: 
Erwinase: date of last administration
If "yes", specify:
Numbers of Erwinase doses
If "yes", specify: 
Reason for change to erwinase:
Hypersensitivity
Yes
No
If "yes", specify: 
Reason for change to erwinase:
Date of allergic reaction
If "yes", specify: 
Reason for change to erwinase: 
Other reason
Identification and Signature
Date and signature of the doctor who calculated
and created chemotherapy regimen
Date and signature of the person who
administered chemotherapy
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Protocol IAD AIEOP-BFM ALL 2009 NCT01117441
Preclinical: Quality Management Trauma
Registry German Society for Trauma Surgery
DGU TraumaRegister® questionnaire; 
Data are collected prospectively in four consecutive time
phases from the site of the accident until discharge from
hospital: A) Pre-hospital phase, B) Emergency room and
initial surgery, C) Intensive care unit and D) Discharge. The
documentation includes detailed information on
demographics, injury pattern, comorbidities, pre- and in-
hospital management, course on intensive care unit,
relevant laboratory findings including data on transfusion
and outcome of each individual. The inclusion criterion is
admission to hospital via emergency room with subsequent
ICU/ICM care or reach the hospital with vital signs and die
before admission to ICU.  
The infrastructure for documentation, data management,
and data analysis is provided by AUC - Academy for
Trauma Surgery (AUC - Akademie der Unfallchirurgie
GmbH), a company affiliated to the German Trauma
Society. The scientific leadership is provided by the
Committee on Emergency Medicine, Intensive Care and
Trauma Management (Sektion NIS) of the German Trauma
Society. The participating hospitals submit their data anon-
ymously into a central database via a web-based
application. Scientific data analysis is approved according
to a peer review procedure established by Sektion NIS. 
TraumaRegister DGU® - Hinweise für die Publikation von
Ergebnissen 5 März 2014  
Seite 3 von 3 
© 2014 TraumaRegister DGU® / AUC GmbH 
The participating hospitals are primarily located in
Germany (90%), but a rising number of hospitals of other
countries contribute data as well (at the moment from
Austria, Belgium, China, Finland, Luxembourg, Slovenia,
Switzerland, The Netherlands, and the United Arab
Emirates). Currently, approx. 25,000 cases from more than
600 hospitals are entered into the database per year. 
Participation in TraumaRegister DGU® is voluntary. For
hospitals associated with TraumaNetzwerk DGU®,
however, the entry of at least a basic data set is obligatory
for reasons of quality assurance. 
www.traumaregister-dgu.de
All rights reserved. Please visit https://medical-data-
models.org/forms/15082
Preclinical: Quality Management
Trauma Registry German Society for
Trauma Surgery
Therapie
Intubation
Ja
Nein
Herzmassage
Ja
Nein
Volumengabe
Kristalloide
ml
Kolloide
ml
hyperonk./hyperosmolare Lösung
ml
1 / 2
Vitalzeichen
Blutdruck syst.
mmHg
Atemfrequenz
/minute
Andere
Ankunft Notarzt
Transport
Bodengebunden mit NA  (1)
Bodengebunden ohne NA  (2)
RTH  (3)
privat / selbst (4)
Glasgow Coma Scale
Augenöffnen
keine (1)
Schmerz (2)
Aufforderung (3)
spontan (4)
Verbale Antwort
keine (1)
unverständlich (2)
inadäquat (3)
verwirrt (4)
orientiert (5)
Motorische Antwort
keine (1)
Streckkrämpfe (2)
Beugekrämpfe (3)
ungezielt (Schmerz) (4)
gezielt (Schmerz) (5)
Aufforderung (6)
Summe (Score)
<= 15
>= 1
2 / 2
Preclinical: Quality Management Trauma Registry German Society for
Trauma Surgery
General health and comorbidities, Social
Environment Nursing Documentation UK Erlangen
General health and comorbidities
Social Environment Nursing Documentation UK Erlangen
General information about patient's health and
comorbidities
All rights reserved. Please visit https://medical-data-
models.org/forms/15089
General health and comorbidities
General health and comorbidities
Smoker
Yes (1)
No (2)
Former smoker (3)
Alcohol consumption
Kind of alcohol consumed
Amount of alcohol consumed
Drug abuse
Yes
No
Allergies
Yes
No
Type of allergy
Diabetes mellitus
Yes
No
Dependent on renal dialysis
Yes
No
Artificial cardial pacemaker
Yes
No
Implantable defibrillator
Yes
No
Anticoagulation Therapy
Yes
No
Which anticoagulant?
INR target value
Infections
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Yes
No
Cerebral seizures
Yes
No
Port
Yes
No
Hickman catheter
Yes
No
Percutaneous endoscopic gastrostomy (PEG)
Yes
No
Percutaneous endoscopic jejunostomy (PEJ)
Yes
No
Other comorbidities or conditions
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General health and comorbidities, Social Environment Nursing
Documentation UK Erlangen
Vital signs, Social Environment Nursing
Documentation UK Erlangen
Vital signs
Social Environment Nursing Documentation UK Erlangen
Erlangen Pflegestammdaten: Soziales Umfeld/Wissen zum
Krankheitsgeschehen
All rights reserved. Please visit https://medical-data-
models.org/forms/15091
Vital signs, Social Environment
Nursing Documentation UK Erlangen
Vital signs
Pulse
beats/min
Cardiac arrhythmia
Yes
No
Blood pressure (left arm)
mm/Hg
Blood pressure (right arm)
mm/Hg
Blood pressure (left leg)
mm/Hg
Blood pressure (right leg)
mm/Hg
Body Temperature
°C
Body Height
cm
Body weight
>= 0
kg
Body Mass Index
kg/m2
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Documents, Social Environment Nursing
Documentation UK Erlangen
Documents
Social Environment Nursing Documentation UK Erlangen
Erlangen Pflegestammdaten: Soziales Umfeld/Wissen zum
Krankheitsgeschehen
All rights reserved. Please visit https://medical-data-
models.org/forms/15092
Documents, Social Environment
Nursing Documentation UK Erlangen
Brought in documents
Health Insurance card
Yes
No
X-ray findings
Yes
No
Original care records
Yes
No
Allergy passport
Yes
No
Vaccination card
Yes
No
Shunt pass
Yes
No
Hydrocortisone pass
Yes
No
Pregnancy record
Yes
No
Examination record (children)
Yes
No
Living will
Yes
No
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Basic patient data & attending physician, Social
Environment Nursing Documentation UK Erlangen
Social Environment Nursing Documentation UK Erlangen
Pflegestammdaten: Soziales Umfeld/Wissen zum
Krankheitsgeschehen
Basic patient data & attending physician
All rights reserved. Please visit https://medical-data-
models.org/forms/15093
Basic patient data & attending
physician, Social Environment
Nursing Documentation UK Erlangen
Basic patient data
Admission time
Admitting physician
Family physician
Telephone number of family physician
Street address of family physician
Zip code of family physician
City of family physician
Name of specialist physician
Telephone number of specialist physician
Street address of specialist physician
Zip code of specialist physician
City of specialist physician
Optional services
Former hospitalization
Yes
No
Location of former hospitalization
Certificate of incapacity
Yes
No
Patient's knowledge on diagnosis
Yes
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No
Patient's knowledge on planned diagnostics
Yes
No
Patient's knowledge on treatment plan
Yes
No
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Basic patient data & attending physician, Social Environment Nursing
Documentation UK Erlangen
Spiritual support and psycho-oncological care, Social
Environment Nursing Documentation UK Erlangen
Social Environment Nursing Documentation UK Erlangen
Erlangen Pflegestammdaten: Soziales Umfeld/Wissen zum
Krankheitsgeschehen
Spiritual support and psycho-oncological care
All rights reserved. Please visit https://medical-data-
models.org/forms/15094
Spiritual support and psycho-
oncological care, Social Environment
Nursing Documentation UK Erlangen
Spiritual welfare and psycho-oncological
care
Denomination
Spiritual support required?
Yes
No
Patient informed about the possibility of psycho-
oncological care?
Yes
No
Patient informed about support by the clinic's
social services?
Yes
No
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Living Situation and contact person, Social
Environment Nursing Documentation UK Erlangen
Social Environment Nursing Documentation UK Erlangen
Erlangen Pflegestammdaten: Soziales Umfeld/Wissen zum
Krankheitsgeschehen
Living situation, contact person
All rights reserved. Please visit https://medical-data-
models.org/forms/15095
Living Situation and contact person,
Social Environment Nursing
Documentation UK Erlangen
Living situation and contact person
Living situation
Number of offspring
Patient telephone number, private
Patient telephone number, business
Patient telephone number, mobile
Name of contact person
Telephone number of contact person, private
Telephone number of contact person, business
Telephone number of contact person, mobile
Other contact person
Telephone number of other contact person,
private
Telephone number of other contact person,
business
Telephone number of other contact person,
mobile
Are relatives informed about the patient's
hospitalization?
Yes
No
Restriction of contact and information?
Yes
No
Problems due to hospitalization?
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Yes
No
Is the patient dependent on care?
Yes
No
Classification into a care level
Information concerning admission/care
Contact person for home care
Telephone number of contact person, private
Telephone number of contact person, business
Telephone number of contact person, mobile
Legal supervision/custody/youth services
Yes (1)
No (2)
Applied for (3)
Rehabilitation therapy
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Living Situation and contact person, Social Environment Nursing
Documentation UK Erlangen
Orientation and communication, Social
Environment Nursing Documentation UK Erlangen
Social Environment Nursing Documentation UK Erlangen
Orientation and communication
All rights reserved. Please visit https://medical-data-
models.org/forms/15096
Orientation and communication,
Social Environment Nursing
Documentation UK Erlangen
Orientation and communication
Restricted cognitive orientation
Yes
No
Communication impairment
Yes
No
Kind of impairment
Visual aids brought by patient
Hearing aids brought by patient
Patient speaks foreign language
Yes
No
Interpreter
Yes
No
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Physical performance, Social Environment
Nursing Documentation UK Erlangen
Social Environment Nursing Documentation UK Erlangen
Movement, Physical performance
All rights reserved. Please visit https://medical-data-
models.org/forms/15097
Physical performance, Social
Environment Nursing Documentation
UK Erlangen
Movement
Micro-movements at admission
Yes
No
Restrictions in movement, physical performance,
coordination, motor function
Yes
No
Supporting aids
Yes
No
History of falls
Yes
No
Current risk of falling
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Pain, Social Environment Nursing
Documentation UK Erlangen
Social Environment Nursing Documentation UK Erlangen
Pain
All rights reserved. Please visit https://medical-data-
models.org/forms/15098
Pain, Social Environment Nursing
Documentation UK Erlangen
Pain
Pain problems
Yes
No
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Nutrition, respiration, personal body care, Social
Environment Nursing Documentation UK Erlangen
Social Environment Nursing Documentation UK Erlangen
Nutrition, respiration, personal body care
All rights reserved. Please visit https://medical-data-
models.org/forms/15099
Nutrition, respiration,  personal body
care, Social Environment Nursing
Documentation UK Erlangen
Nutrition
Food intake
Usual type of diet
Current diet type in hospital
Dental prosthesis
Yes
No
Type of dental prosthesis
Partial prosthesis/prosthesis brought by patient
Respiration
Restriction of respiration
Yes
No
Asthma
Yes
No
Personal body care
Restrictions concerning personal body care
Yes
No
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Sonography report Sonography findings Routine
documentation in German hospitals DMI
Routine documentation in German hospitals. Source file
name: DG020111_Sonographiebefund/
Sonographiebefund.039 Sonographiebefund.059
Sonographiebild.039
Examplary forms provided by DMI (http://www.dmi.de/)
All rights reserved. Please visit https://medical-data-
models.org/forms/15100
Sonography report Sonography
findings
Patient information
Patient surname
Patient forename
Date of birth
Age
Gender
Patient address
Patient ID
Date of diagnosis
Access number
Referring physician
User
Referral diagnosis
Attending physician
Report date
Date of last change
Status
Sonography findings
Anamnesis
1 / 2
Ultrasonography of liver
Ultrasonography of Gallbladder
Ultrasonography of Pancreas
Ultrasonography of  blood vessel
Ultrasonography of kidney
Ultrasonography of spleen
Diagnosis
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Sonography report Sonography findings Routine documentation in
German hospitals DMI
Defecography Other documentation diagnostic imaging
Routine documentation in German hospitals DMI
Routine documentation in German hospitals. Source file
name: DG020199_Sonstige Dokumentation bildgebende
Diagnostik/ Defäkogramm.057
Examplary forms provided by DMI (http://www.dmi.de/)
All rights reserved. Please visit https://medical-data-
models.org/forms/15101
Defecography Other documentation
diagnostic imaging
Defecography findings
Patient name
Date of birth
Date of defecography
Indication for defecography
Technique of defecography
Assessment
Attending physician
1 / 1
Hypopharynx- Esophagram Other documentation diagnostic
imaging Routine documentation in German hospitals DMI
Routine documentation in German hospitals. Source file
name: DG020199_Sonstige Dokumentation bildgebende
Diagnostik/ Hypopharyngo-Oesophagogramm.027
Examplary forms provided by DMI (http://www.dmi.de/)
All rights reserved. Please visit https://medical-data-
models.org/forms/15102
Hypopharynx- Esophagram Other
documentation diagnostic imaging
Hypopharynx- Esophagram findings
Patient name
Date of Hypopharynx- Esophagram
Indication for Hypopharynx- Esophagram
Technique for Hypopharynx- Esophagram
Hypopharynx- Esophagram findings
Assessment of Hypopharynx- Esophagram
Attending physician
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Photo documentation General surgery Operation photo
documentation Routine documentation in German hospitals DMI
Routine documentation in German hospitals. Source file
name: OP150104_OP-Bilddokumentation/
Fotodokumentation.059
Examplary forms provided by DMI (http://www.dmi.de/)
All rights reserved. Please visit https://medical-data-
models.org/forms/15103
Photo documentation General
surgery Operation photo
documentation
Photo documentation
Patient name
Date of birth
Case number
Order number
Status
Reference date
Indexing of images
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Vena cava catheter Surgery protocol Routine
documentation in German hospitals DMI
Routine documentation in German hospitals. Source file
name: OP150106_OP-Protokoll/ Vena Cava Katheter.037
Examplary forms provided by DMI (http://www.dmi.de/)
All rights reserved. Please visit https://medical-data-
models.org/forms/15104
Vena cava catheter Surgery protocol
Vena cava catheter
Date of Vena cava catheter
Diagnosis
Indication of Vena cava catheter
Surgery date
Surgery
Situation leading to Vena cava catheter
emergency (1)
optional (2)
Anaesthesia
local (1)
general (2)
Introduction of vena cava catheter under
x- ray (1)
ultrasonography (2)
Vena cava catheter
Right internal jugular vein (1)
Left internal jugular vein (2)
Vena anonyma (3)
Right Subclavian vein (4)
Right femoral vein (5)
Left femoral vein (6)
Right external jugular vein (7)
Left external jugular vein (8)
Number of unsuccessful punctures
Complications
Catheter tip site
correct (1)
ECG-derivation (2)
x- ray chest (3)
Malposition in
Date of correction
1 / 2
Correction by
Fixation (stitch)
Attending physician
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Vena cava catheter Surgery protocol Routine documentation in German
hospitals DMI
Alternatives to planned surgery Other Information
sheet Routine documentation in German hospitals DMI
Routine documentation in German hospitals. Source file
name: AM010399_Sonstiger Aufklärungsbogen/
Alternativen zur geplanten OP.037
Examplary forms provided by DMI (http://www.dmi.de/)
All rights reserved. Please visit https://medical-data-
models.org/forms/15105
Alternatives to planned surgery
Other Information sheet
Alternatives to planned surgery
Clarification carried out by
Date of clarification
Reflux
medication (1)
change of diet (2)
other (3)
If other, please specify
Laparoscopic lysis of adhesions
medication (1)
change of diet (2)
other (3)
If other, please specify
Hernia of abdominal wall
abdominal bandage  (1)
operation open with surgical suture (2)
operation open with mesh (3)
other (4)
If other, please specify
Inguinal hernia
truss (1)
operation open with surgical suture (2)
operation open with mesh (3)
other (4)
If other, please specify
I hereby certify that I have been informed in detail
about the above mentioned alternative treatments
Yes
No
Patient name
Attending physician
Date
1 / 1
Clarification for thromboprophylaxis Other Information
sheet Routine documentation in German hospitals DMI
Routine documentation in German hospitals. Source file
name: AM010399_Sonstiger Aufklärungsbogen/ Aufklärung
zur Thromboseprophylaxe.075
Examplary forms provided by DMI (http://www.dmi.de/)
All rights reserved. Please visit https://medical-data-
models.org/forms/15106
Clarification for thromboprophylaxis
Other Information sheet
Aufklärung zur Thromboseprophylaxe
Liebe Patientin, Lieber Patient,
im Rahmen Ihrer Operation besteht einer
erhebliche Gefährdung durch Thrombose
(Entzündung und Blutgerinnselbildung in Venen
der Beine) sowie einer Embolie (Blutgerinnsel,
das nach Herz, Lunge und Hirn ausgeschwemmt
werden kann).
Um diese Gefährdung auf ein Mindestmaß zu
reduzieren, ist es notwendig, dass Sie täglich
Spritzen mit sog. niedermolekularem Heparin
oder Heparin erhalten, welches zu einer
Blutverdünnung führt.
Im Ausnahmefall kann dieses Mittel auch zu
Blutungen, allergischen Reaktionen und zu einer,
wenn auch sehr seltenen Blutveränderung
führen, bei der nachhinein auch Thrombosen
entstehen können.
Unabhängig von diesen seltenen Komplikationen
empfehlen wir Ihnen aber dringend, die
Thromboseprophylaxe vornehmen zu lassen.
Ich bin mit der Thromboseprophylaxe
einverstanden.
Ja
Nein
Ich würde über die Risiken der
Thromboseprophylaxe aufgeklärt.
Ja
Nein
Patientenname
Operateur
Datum
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Eligibility Depression NCT00745017
Stress Generation and Recurrent Depression: The Role of
Differential Treatment Response; ODM derived from:
https://clinicaltrials.gov/show/NCT00745017
All rights reserved. Please visit https://medical-data-
models.org/forms/15109
Eligibility Depression NCT00745017
Inclusion Criteria
meet the criteria for dsm-iv diagnosis of non-
psychotic, major depression based on the
structured interview for dsm-iv, axis i disorders*
Yes
No
score > 16 the 17-item hamilton rating scale for
depression*
Yes
No
ages between 18 and 60*
Yes
No
are medication-free (i.e., of antidepressants) for a
minimum of two weeks prior to treatment are
eligible for entry into treatment protocols*
Yes
No
minimum eight grade education and fluency in
reading english*
Yes
No
ability to give informed consent and complete
assessment instruments unassisted*
Yes
No
Exclusion Criteria
a scid-i diagnosis of:*
Yes
No
bipolar disorder (past or present),*
Yes
No
schizoaffective disorder,*
Yes
No
schizophrenia,*
Yes
No
substance abuse disorder (current or within the
past 6 months),*
Yes
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No
borderline or antisocial personality disorder,*
Yes
No
organic brain syndrome*
Yes
No
electroconvulsive therapy (ect) within the past 6
months*
Yes
No
concurrent active medical illness*
Yes
No
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Eligibility Depression NCT00745017
Eligibility Depression NCT00711568
A Clinical Trial of Magnetic Stimulation in Depression; ODM
derived from: https://clinicaltrials.gov/show/NCT00711568
All rights reserved. Please visit https://medical-data-
models.org/forms/15110
Eligibility Depression NCT00711568
Inclusion Criteria
all patients will meet dsm-iv criteria for major
depressive episode (without psychotic features).*
Yes
No
all patients will have a total score of 18 or higher
and a score of at least 3 on item number 1 of the
24 item hamilton rating scale for depression
(ham-d).*
Yes
No
all patients will have failed to respond to at least
two separate trials of treatment for at least 4
weeks with therapeutic dosages of
antidepressant medication (including at least one
ssri) or will have been intolerant of at least three
different antidepressant medications (including at
least one ssri).*
Yes
No
Exclusion Criteria
patient medications will be reviewed prior to
enrollment in this study. patients taking
medications that may lower seizure threshold
(e.g. metronidazole) will be excluded if the
particular medication cannot be stopped or
altered without affecting the patient's routine
medical care.*
Yes
No
history of neurological illness, epilepsy or seizure
disorder, intracranial tumor, or major head trauma
leading to loss of consciousness of any length.*
Yes
No
evidence of central nervous system disease
based on baseline complete neurological
examination, eeg and contrast-enhanced
computerized tomography or magnetic resonance
imaging of the brain.*
Yes
No
history of implanted pacemaker or medication
pump, metal plate in skull, or metal objects in the
eye or skull.*
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Yes
No
axis ii diagnosis of cluster a (paranoid, schizoid,
or schizotypal) or cluster b (antisocial, borderline,
histrionic, or narcissistic) personality disorder.*
Yes
No
axis ii diagnosis of mental retardation.*
Yes
No
history of schizophrenia, schizoaffective disorder,
other functional psychosis, rapid-cycling bipolar
illness, or alcohol or drug abuse within the past
year.*
Yes
No
need for rapid clinical response due to conditions
such as inanition, psychosis, or suicidality
(defined as suicide attempt during the current
major depressive episode or having a specific
plan for committing suicide).*
Yes
No
a medical condition that is not well controlled,
such as diabetes or hypertension, or concomitant
medical or nutritional problems necessitating
hospitalization.*
Yes
No
patients taking anticonvulsant mood stabilizers
(e.g. carbamazepine, valproic acid).*
Yes
No
patients otherwise unable to grant informed
consent.*
Yes
No
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Parkinsonism Symptoms Protocol PhenX
Toolkit
The Motor Exam portion of the United Parkinson’s Disease
Rating Scale is a 27 item examiner-administered test that
measures the severity of symptoms in resting tremor,
resistance to movement and abnormal gait and posture.
ODM derived from: https://cde.nlm.nih.gov
Primary source: https://www.phenxtoolkit.org/
Recent publication: Hendershot, T., Pan, H., Haines, J.,
Harlan, W.R., Marazita, M.L., McCarty, C.A., Ramos, E.M.,
and Hamilton, C.M. (2015) Using the PhenX toolkit to add
standard measures to a study. Curr. Protoc. Hum. Genet.
86:1.21.1-1.21.17. doi: 10.1002/0471142905.hg0121s86
Permission to publish granted by
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Parkinsonism Symptoms Protocol
PhenX Toolkit
PhenX - parkinsonian protocol
Parkinson - speech
Marked impairent, difficult to understand
(Marked impairent, difficult to
understand)
Monotone, slurred but understandable;
moderately impaired (Monotone, slurred
but understandable; moderately
impaired)
Normal     (Normal    )
Slight loss of expression, direction,
and/or volume (Slight loss of expression,
direction, and/or volume)
Unintelligible (Unintelligible)
Parkinson - facial expression
Masked or fixed faces with severe or
complete loss of facial expression; lips
parted one fourth inch or more (Masked
or fixed faces with severe or complete
loss of facial expression; lips parted one
fourth inch or more)
Minimal hypomymia, could be normal
'Poker Face' (Minimal hypomymia, could
be normal 'Poker Face')
Moderate hypomimia; lips parted some
of time (Moderate hypomimia; lips parted
some of time)
Normal (Normal)
Slight but definitely abnormal diminution
of facial expression (Slight but definitely
abnormal diminution of facial expression)
Parkinson - tremor at rest - face
Absent (Absent)
Marked in amplitude and present most of
the time (Marked in amplitude and
present most of the time)
Mild in amplitude and persistent. Or
moderate in amplitude, but only
intermittently present (Mild in amplitude
and persistent. Or moderate in
amplitude, but only intermittently
present)
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Moderate in amplitude and present most
of the time (Moderate in amplitude and
present most of the time)
Slight and infrequently present (Slight
and infrequently present)
Tremor at rest Upper extremity - right [UPDRS]
Absent (Absent)
Marked in amplitude; interferes with
feeding (Marked in amplitude; interferes
with feeding)
Moderate in amplitude with posture
holding as well as action (Moderate in
amplitude with posture holding as well as
action)
Moderate in amplitude, present with
action (Moderate in amplitude, present
with action)
Slight; present with action (Slight;
present with action)
Parkinson - tremor at rest - LUE
Absent (Absent)
Marked in amplitude and present most of
the time (Marked in amplitude and
present most of the time)
Mild in amplitude and persistent. Or
moderate in amplitude, but only
intermittently present (Mild in amplitude
and persistent. Or moderate in
amplitude, but only intermittently
present)
Moderate in amplitude and present most
of the time (Moderate in amplitude and
present most of the time)
Slight and infrequently present (Slight
and infrequently present)
Parkinson - tremor at rest - RLE
Absent (Absent)
Marked in amplitude and present most of
the time (Marked in amplitude and
present most of the time)
Mild in amplitude and persistent. Or
moderate in amplitude, but only
intermittently present (Mild in amplitude
and persistent. Or moderate in
amplitude, but only intermittently
present)
Moderate in amplitude and present most
of the time (Moderate in amplitude and
present most of the time)
Slight and infrequently present (Slight
and infrequently present)
Parkinson - tremor at rest - LLE
Absent (Absent)
Marked in amplitude and present most of
the time (Marked in amplitude and
present most of the time)
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Mild in amplitude and persistent. Or
moderate in amplitude, but only
intermittently present (Mild in amplitude
and persistent. Or moderate in
amplitude, but only intermittently
present)
Moderate in amplitude and present most
of the time (Moderate in amplitude and
present most of the time)
Slight and infrequently present (Slight
and infrequently present)
Parkinson - postural tremor - RUE
Absent (Absent)
Marked in amplitude; interferes with
feeding (Marked in amplitude; interferes
with feeding)
Moderate in amplitude with posture
holding as well as action (Moderate in
amplitude with posture holding as well as
action)
Moderate in amplitude, present with
action (Moderate in amplitude, present
with action)
Slight; present with action (Slight;
present with action)
Parkinson - postural tremor - LUE
Absent (Absent)
Marked in amplitude; interferes with
feeding (Marked in amplitude; interferes
with feeding)
Moderate in amplitude with posture
holding as well as action (Moderate in
amplitude with posture holding as well as
action)
Moderate in amplitude, present with
action (Moderate in amplitude, present
with action)
Slight; present with action (Slight;
present with action)
Parkinson - rigidity - neck
Absent (Absent)
Marked, but full range of motion easily
achieved (Marked, but full range of
motion easily achieved)
Mild to moderate (Mild to moderate)
Severe, range of motion achieved with
difficulty (Severe, range of motion
achieved with difficulty)
Slight or detectable only when activated
by mirror or other movements (Slight or
detectable only when activated by mirror
or other movements)
Parkinson - rigidity - RUE
Absent (Absent)
Marked, but full range of motion easily
achieved (Marked, but full range of
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motion easily achieved)
Mild to moderate (Mild to moderate)
Severe, range of motion achieved with
difficulty (Severe, range of motion
achieved with difficulty)
Slight or detectable only when activated
by mirror or other movements (Slight or
detectable only when activated by mirror
or other movements)
Parkinson - rigidity - LUE
Absent (Absent)
Marked, but full range of motion easily
achieved (Marked, but full range of
motion easily achieved)
Mild to moderate (Mild to moderate)
Severe, range of motion achieved with
difficulty (Severe, range of motion
achieved with difficulty)
Slight or detectable only when activated
by mirror or other movements (Slight or
detectable only when activated by mirror
or other movements)
Parkinson - rigidity - RLE
Absent (Absent)
Marked, but full range of motion easily
achieved (Marked, but full range of
motion easily achieved)
Mild to moderate (Mild to moderate)
Severe, range of motion achieved with
difficulty (Severe, range of motion
achieved with difficulty)
Slight or detectable only when activated
by mirror or other movements (Slight or
detectable only when activated by mirror
or other movements)
Parkinson - rigidity - LLE
Absent (Absent)
Marked, but full range of motion easily
achieved (Marked, but full range of
motion easily achieved)
Mild to moderate (Mild to moderate)
Severe, range of motion achieved with
difficulty (Severe, range of motion
achieved with difficulty)
Slight or detectable only when activated
by mirror or other movements (Slight or
detectable only when activated by mirror
or other movements)
Finger taps - right
Can barely perform task (Can barely
perform task)
Mild slowing and/or reduction in
amplitude (Mild slowing and/or reduction
in amplitude)
Moderately impaired. Definite and early
fatiguing. May have occasional arrests in
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movement (Moderately impaired. Definite
and early fatiguing. May have occasional
arrests in movement)
Normal (Normal)
Severely impaired. Frequent hesitation in
initiating movements or arrests in
ongoing movement (Severely impaired.
Frequent hesitation in initiating
movements or arrests in ongoing
movement)
Finger taps - left
Can barely perform task (Can barely
perform task)
Mild slowing and/or reduction in
amplitude (Mild slowing and/or reduction
in amplitude)
Moderately impaired. Definite and early
fatiguing. May have occasional arrests in
movement (Moderately impaired. Definite
and early fatiguing. May have occasional
arrests in movement)
Normal (Normal)
Severely impaired. Frequent hesitation in
initiating movements or arrests in
ongoing movement (Severely impaired.
Frequent hesitation in initiating
movements or arrests in ongoing
movement)
Hand movements - right
Can barely perform task (Can barely
perform task)
Mild slowing and/or reduction in
amplitude (Mild slowing and/or reduction
in amplitude)
Moderately impaired. Definite and early
fatiguing. May have occasional arrests in
movement (Moderately impaired. Definite
and early fatiguing. May have occasional
arrests in movement)
Normal (Normal)
Severely impaired. Frequent hesitation in
initiating movements or arrests in
ongoing movement (Severely impaired.
Frequent hesitation in initiating
movements or arrests in ongoing
movement)
Hand movements - left
Can barely perform task (Can barely
perform task)
Mild slowing and/or reduction in
amplitude (Mild slowing and/or reduction
in amplitude)
Moderately impaired. Definite and early
fatiguing. May have occasional arrests in
movement (Moderately impaired. Definite
and early fatiguing. May have occasional
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arrests in movement)
Normal (Normal)
Severely impaired. Frequent hesitation in
initiating movements or arrests in
ongoing movement (Severely impaired.
Frequent hesitation in initiating
movements or arrests in ongoing
movement)
Rapidly alternating movements - right
Can barely perform task (Can barely
perform task)
Mild slowing and/or reduction in
amplitude (Mild slowing and/or reduction
in amplitude)
Moderately impaired. Definite and early
fatiguing. May have occasional arrests in
movement (Moderately impaired. Definite
and early fatiguing. May have occasional
arrests in movement)
Normal (Normal)
Severely impaired. Frequent hesitation in
initiating movements or arrests in
ongoing movement (Severely impaired.
Frequent hesitation in initiating
movements or arrests in ongoing
movement)
Rapidly alternating movements - left
Can barely perform task (Can barely
perform task)
Mild slowing and/or reduction in
amplitude (Mild slowing and/or reduction
in amplitude)
Moderately impaired. Definite and early
fatiguing. May have occasional arrests in
movement (Moderately impaired. Definite
and early fatiguing. May have occasional
arrests in movement)
Normal (Normal)
Severely impaired. Frequent hesitation in
initiating movements or arrests in
ongoing movement (Severely impaired.
Frequent hesitation in initiating
movements or arrests in ongoing
movement)
Leg agility - right
Can barely perform task (Can barely
perform task)
Mild slowing and/or reduction in
amplitude (Mild slowing and/or reduction
in amplitude)
Moderately impaired. Definite and early
fatiguing. May have occasional arrests in
movement (Moderately impaired. Definite
and early fatiguing. May have occasional
arrests in movement)
Normal (Normal)
Severely impaired. Frequent hesitation in
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initiating movements or arrests in
ongoing movement (Severely impaired.
Frequent hesitation in initiating
movements or arrests in ongoing
movement)
Leg agility - left
Can barely perform task (Can barely
perform task)
Mild slowing and/or reduction in
amplitude (Mild slowing and/or reduction
in amplitude)
Moderately impaired. Definite and early
fatiguing. May have occasional arrests in
movement (Moderately impaired. Definite
and early fatiguing. May have occasional
arrests in movement)
Normal (Normal)
Severely impaired. Frequent hesitation in
initiating movements or arrests in
ongoing movement (Severely impaired.
Frequent hesitation in initiating
movements or arrests in ongoing
movement)
Arising from chair
Normal (Normal)
Pushes self up from arms of seat
(Pushes self up from arms of seat)
Slow; or may need more than one
attempt (Slow; or may need more than
one attempt)
Tends to fall back and may have to try
more than one time, but can get up
without help (Tends to fall back and may
have to try more than one time, but can
get up without help)
Unable to arise without help (Unable to
arise without help)
Posture
Marked flexion with extreme abnormality
of posture (Marked flexion with extreme
abnormality of posture)
Moderately stopped posture, definitely
abnormal; can be slightly leaning to one
side (Moderately stopped posture,
definitely abnormal; can be slightly
leaning to one side)
Normal erect (Normal erect)
Not quite erect, slightly stopped posture;
could be normal for older person (Not
quite erect, slightly stopped posture;
could be normal for older person)
Severely stopped posture with kyphosis;
can be moderately leaning to one side
(Severely stopped posture with kyphosis;
can be moderately leaning to one side)
Gait - parkinsons
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Cannot walk at all, even with assistance
(Cannot walk at all, even with
assistance)
Normal (Normal)
Severe disturbance of gait, requiring
assistance (Severe disturbance of gait,
requiring assistance)
Walks slowly, may shuffle with short
steps, but no festination hastening steps
or propulsion (Walks slowly, may shuffle
with short steps, but no festination
hastening steps or propulsion)
Walks with difficulty, but requires little or
no assistance; may have some
festination, short steps, or propulsion
(Walks with difficulty, but requires little or
no assistance; may have some
festination, short steps, or propulsion)
Postural stability - retropulsion test
Absence of postural response; would fall
if not caught by examiner     (Absence of
postural response; would fall if not
caught by examiner    )
Normal     (Normal    )
Retropulsion, but recovers unaided
(Retropulsion, but recovers unaided  )
Unable to stand without assistance
(Unable to stand without assistance)
Very unstable, tends to lose balance
spontaneously (Very unstable, tends to
lose balance spontaneously)
Body bradykinesia - hypokinesia
Marked slowness, poverty or small
amplitude of movement (Marked
slowness, poverty or small amplitude of
movement)
Mild degree of slowness and poverty of
movement which is definitely abnormal.
Alternatively, some reduced amplitude
(Mild degree of slowness and poverty of
movement which is definitely abnormal.
Alternatively, some reduced amplitude)
Minimal slowness, giving movement a
deliberate character; could be normal for
some persons. Possibly reduced
amplitude     (Minimal slowness, giving
movement a deliberate character; could
be normal for some persons. Possibly
reduced amplitude    )
Moderate slowness, poverty or small
amplitude of movement     (Moderate
slowness, poverty or small amplitude of
movement    )
None (None)
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Retinal Digital Photography Protocol PhenX
Toolkit
Two 45¿ digital retinal images (Field 1 and 2) will be taken
of each eye of the participant using the Canon Non-
Mydriatic Retinal CR6-45NM camera with a digital Canon
D60 camera back (6.3 megapixels per image). Field 1 is
centered on the optic disc and Field 2 is centered on the
macula, providing photographic documentation of the optic
disc, macula, and substantial portions of the temporal
arcades. These photographs may be graded for retinal
microvascular characteristics, including focal arteriolar
narrowing, arterio-venous nicking, retinopathy (e.g.,
microaneurysms, retinal hemorrhages) and other
conditions. In addition, generalized arteriolar narrowing is
quantified using a computer assisted measure of retinal
vascular caliber.
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Retinal Digital Photography Protocol
PhenX Toolkit
PhenX - retinal digital photography
protocol
Patient number [OASIS]
Photographer ID
Retinal digital photography instrument model
Right Eye Fields photographed in the Retinal
Digital Photography
Can not be photographed (Can not be
photographed)
Field 1 (Field 1)
Field 2 (Field 2)
Other (Other)
Other eye field Eye - right [Retinal digital
photography]
Right Eye Flash Setting in the Retinal Digital
Photography
Right Eye Number of images captured in the
Retinal Digital Photography
Right Eye Estimated Diameter of Pupil at 1st
Photograph
mm
Right Eye Describe any problems or unusual
findings
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Left Eye Flash Setting in the Retinal Digital
Photography
Can not be photographed (Can not be
photographed)
Field 1 (Field 1)
Field 2 (Field 2)
Other (Other)
Left Eye Number of images captured in the
Retinal Digital Photography
Right Eye Flash Setting in the Retinal Digital
Photography
Right Eye Number of images captured in the
Retinal Digital Photography
Left Eye Estimated Diameter of Pupil at 1st
Photograph
mm
Left Eye Describe any problems or unusual
findings
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Eligibility Diabetes Mellitus, Type 2
NCT00118950
Effect of Metformin Versus Repaglinide Treatment in Non-
Obese Type 2 Diabetic Patients Uncontrolled by Diet; ODM
derived from: https://clinicaltrials.gov/show/NCT00118950
All rights reserved. Please visit https://medical-data-
models.org/forms/15114
Eligibility Diabetes Mellitus, Type 2
NCT00118950
Inclusion Criteria
type-2 diabetes, defined as:*
Yes
No
age at onset of diabetes ≥ 40 years*
Yes
No
fasting serum c-peptide ≥ 300 pmol/l or a non-
fasting or glucagon-stimulated serum c-peptide ≥
600 pmol/l*
Yes
No
no history of ketonuria or ketoacidosis .*
Yes
No
bmi ≤ 27 kg/m2.*
Yes
No
fasting plasma-glucose ≥ 6.5 mmol/l after at least
one month of diet-only treatment.*
Yes
No
hba1c ≤ 9.5% at ongoing oral anti-
hyperglycaemic agents. hba1c ≥ 6.5% after
minimum one month of diet-only treatment.*
Yes
No
weight-loss of no more than 5.0 kg during the last
6 months prior to enrolment.*
Yes
No
Exclusion Criteria
type-1 diabetes*
Yes
No
insulin-treated type-2 diabetes*
Yes
No
secondary diabetes, heart-failure*
Yes
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No
serum-creatinine above the upper limit*
Yes
No
serum-asat elevated more than 3 fold above the
upper limit*
Yes
No
factor ii-vii-x decreased below 0.7*
Yes
No
ongoing coexisting illnesses with a life-shortening
prognosis*
Yes
No
mental retardation or reduced intellectual
behaviour*
Yes
No
pregnancy*
Yes
No
history of drug-abuse or hba1c>10.5% at two
separate visits with at least one month interval
during treatment-periods.*
Yes
No
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Eligibility Diabetes NCT00400283
A Study Looking Into the Effect of NNC 55-0414 in Subjects
With Type 2 Diabetes; ODM derived from:
https://clinicaltrials.gov/show/NCT00400283
All rights reserved. Please visit https://medical-data-
models.org/forms/15115
Eligibility Diabetes NCT00400283
Inclusion Criteria
type 2 diabetes*
Yes
No
diet treatment only for at least two weeks*
Yes
No
body mass index (bmi) between 22-34 kg/m2
inclusive*
Yes
No
hba1c between 6.5-12.0% inclusive*
Yes
No
fasting blood glucose (fbg) between 7.0-18.0
mmol/l inclusive*
Yes
No
patients should be negative (lesser than 70 ku/l)
for antibodies against glutamic acid
decarboxylase (gad)*
Yes
No
Exclusion Criteria
pharmacological treatment with medication or
pancreatitis that the investigator expected to
interfere with blood glucose levels*
Yes
No
history of cancer or any clinically significant
cardiovascular respiratory, hepatic,
haematological, gastrointestinal, dermatological,
venereal, neurological or psychiatric disorder as
judged by the investigator*
Yes
No
impaired renal function, serum creatinine greater
than 150µmol/l*
Yes
No
patients, who were known to have serum
hepatitis or who were carriers of the hepatitis b
surface antigen (hbsag) or hepatitis c antibodies,
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or had a positive result to the test for hiv 1/2
antibodies*
Yes
No
patients, who had received an investigational
drug in the four months new chemical entity or
licensed product preceding the start of dosing*
Yes
No
patients, who had donated plasma or blood in the
past month, or in excess of 500 ml in the past 12
weeks*
Yes
No
patients who had a significant history of
alcoholism or drug/chemical abuse*
Yes
No
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Eligibility Diabetes NCT01508949
Effect of Liraglutide on Weight and Appetite in Obese
Subjects With Type 2 Diabetes; ODM derived from:
https://clinicaltrials.gov/show/NCT01508949
All rights reserved. Please visit https://medical-data-
models.org/forms/15117
Eligibility Diabetes NCT01508949
Inclusion Criteria
type 2 diabetes mellitus*
Yes
No
diet treated and/or subjects in monotherapy with
sulphonylurea or repaglinide*
Yes
No
hba1c for diet treated subjects 6.5-12%, both
inclusive*
Yes
No
hba1c for sulphonylurea or repaglinide treated
subjects maximum 10%*
Yes
No
body mass index (bmi) at least 27 kg/m^2*
Yes
No
euthyroid subjects*
Yes
No
fasting blood glucose 7-14 mmol/l*
Yes
No
Exclusion Criteria
impaired liver function*
Yes
No
impaired renal function*
Yes
No
cardiac problems*
Yes
No
uncontrolled treated/untreated hypertension*
Yes
No
recurrent severe hypoglycaemia as judged by the
investigator*
Yes
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No
known or suspected allergy to trial product or
related products*
Yes
No
use of any drug (except for ohas (oral
hypoglycaemic agents), which in the
investigator's opinion could interfere with the
glucose level or body weight. stable doses, for 3
months or greater, of thyroid hormone
replacement are allowed*
Yes
No
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Schizophrenia Screener Protocol PhenX
Toolkit
The DI-PAD or Diagnostic Instrument for Psychoses and
Affective Disorders is an 83 question interviewer-
administered instrument designed to elicit information
regarding a research subject’s functioning and
psychopathology with particular emphasis on affective
disorders and schizophrenia. It is an American-English
adaptation of the Diagnostic Interview for Psychoses ((DIP)
Castle et al., 2006)
ODM derived from: https://cde.nlm.nih.gov
Primary source: https://www.phenxtoolkit.org/
Recent publication: Hendershot, T., Pan, H., Haines, J.,
Harlan, W.R., Marazita, M.L., McCarty, C.A., Ramos, E.M.,
and Hamilton, C.M. (2015) Using the PhenX toolkit to add
standard measures to a study. Curr. Protoc. Hum. Genet.
86:1.21.1-1.21.17. doi: 10.1002/0471142905.hg0121s86
Permission to publish granted by
Carol M. Hamilton.
All rights reserved. Please visit https://medical-data-
models.org/forms/15119
Schizophrenia Screener Protocol
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PhenX - schizophrenia protocol
Source of rating (OPCRIT 1)
Combined sources including structured
interview (Combined sources including
structured interview)
Hospital case notes (charts)   (Hospital
case notes (charts)  )
Interview with informant  (Interview with
informant )
Prepared abstract (Prepared abstract)
Structured interview with subject
(Structured interview with subject   )
Age
Marital status PhenX
Are you married, have you ever been
married or lived with the same partner for
at least six months?    (Are you married,
have you ever been married or lived with
the same partner for at least six months?
)
Single; has never married or lived as
married (Single; has never married or
lived as married)
Age of first psychiatric problems [PhenX]
Onset psychiatric illness [PhenX]
Abrupt onset definable within hours or
days   (Abrupt onset definable within
hours or days  )
Acute onset definable within one month
(Acute onset definable within one month)
Gradual onset over period up to six
months   (Gradual onset over period up
to six months  )
Insidious onset over period greater than
six months (Insidious onset over period
1 / 15
greater than six months)
Moderately acute onset definable within
one month   (Moderately acute onset
definable within one month  )
No episode (No episode)
Age and mode of onset notes [PhenX]
Psychological stressor prior to onset of first
episode [PhenX]
Stressor not present   (Stressor not
present  )
Stressor present (Stressor present)
Psychological stressor notes [Text] [PhenX]
Employment status at onset of illness [PhenX]
Employed at onset (includes full time
students and homemakers)  (Employed
at onset (includes full time students and
homemakers) )
Not employed at onset (Not employed at
onset)
Premorbid work adjustment [PhenX]
Good premorbid social adjustment
(Good premorbid social adjustment    )
Poor premorbid social adjustment (Poor
premorbid social adjustment)
Premorbid social adjustment [PhenX]
Good premorbid social adjustment
(Good premorbid social adjustment    )
Poor premorbid social adjustment (Poor
premorbid social adjustment)
Premorbid adjustment notes [Text] [PhenX]
Coarse brain disorder prior to onset [PhenX]
No prior brain disease present     (No
prior brain disease present    )
Prior brain disease present (Prior brain
disease present)
Coarse brain disorder notes [Text] [PhenX]
Family history of schizophrenia [PhenX]
Family history of schizophrenia (Family
history of schizophrenia)
No family history of schizophrenia     (No
family history of schizophrenia    )
Family history of other psychiatric disorders
[PhenX]
Family history of psychiatric disorder
other than schizophrenia (Family history
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of psychiatric disorder other than
schizophrenia)
No family history   (No family history  )
Family history notes [Text] [PhenX]
Dysphoria - depression [PhenX]
Not present     (Not present    )
Present (Present)
Dysphoria - irritable impatient [PhenX]
Not present     (Not present    )
Present (Present)
Dysphoria notes [Text] [PhenX]
Anhedonia [PhenX]
Not present     (Not present    )
Present at least one month (Present at
least one month)
Present at least one week (Present at
least one week)
Present at least two weeks     (Present at
least two weeks    )
Anhedonia notes [Text] [PhenX]
Loss of energy or fatigue [PhenX]
Not present     (Not present    )
Present at least one month (Present at
least one month)
Present at least one week (Present at
least one week)
Present at least two weeks     (Present at
least two weeks    )
Slowed activity [PhenX]
Impaired concentration [PhenX]
Not present     (Not present    )
Present at least one month (Present at
least one month)
Present at least one week (Present at
least one week)
Present at least two weeks     (Present at
least two weeks    )
Altered libido [PhenX]
Increase in libido for at least one week
(Increase in libido for at least one week)
Loss of libido for at least one week
(Loss of libido for at least one week    )
No change     (No change    )
Excessive self reproach [PhenX]
Not present     (Not present    )
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Present at least one month (Present at
least one month)
Present at least one week (Present at
least one week)
Present at least two weeks     (Present at
least two weeks    )
Depressive symptom notes [Text] [PhenX]
Suicidality [PhenX]
Not present   (Not present  )
Suicidal ideation present at least one
month (Suicidal ideation present at least
one month)
Suicidal ideation present at least two
weeks (Suicidal ideation present at least
two weeks)
Suicidality notes [Text] [PhenX]
Decreased appetite [PhenX]
Not present     (Not present    )
Present at least one month (Present at
least one month)
Present at least one week (Present at
least one week)
Present at least two weeks     (Present at
least two weeks    )
Weight loss [PhenX]
Loss of at least 1+ lb (0.5 kg) per week
for 3 or more weeks or 4 lbs (2 kg) in
less than 3 weeks  (Loss of at least 1+ lb
(0.5 kg) per week for 3 or more weeks or
4 lbs (2 kg) in less than 3 weeks )
Loss of at least 10+ lbs (5 kg) in less
than 1 year (Loss of at least 10+ lbs (5
kg) in less than 1 year)
Loss of at least 2+ lbs (1 kg) per week
for 3 or more weeks or 5 to 9 lbs (2.5 to
4.5 kg) in less than 3 weeks  (Loss of at
least 2+ lbs (1 kg) per week for 3 or more
weeks or 5 to 9 lbs (2.5 to 4.5 kg) in less
than 3 weeks )
No loss  (No loss )
Increased appetite [PhenX]
Not present     (Not present    )
Present at least one month (Present at
least one month)
Present at least one week (Present at
least one week)
Present at least two weeks     (Present at
least two weeks    )
Weight gain [PhenX]
Gain of at least 1+ lb (0.5 kg) per week
for 3 or more weeks or 4 lbs (2 kg) in
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less than 3 weeks  (Gain of at least 1+ lb
(0.5 kg) per week for 3 or more weeks or
4 lbs (2 kg) in less than 3 weeks )
Gain of at least 10+ lbs (5 kg) in less
than 1 year (Gain of at least 10+ lbs (5
kg) in less than 1 year)
Gain of at least 2+ lbs (1 kg) per week
for 3 or more weeks or 5 to 9 lbs (2.5 to
4.5 kg) in less than 3 weeks (Gain of at
least 2+ lbs (1 kg) per week for 3 or more
weeks or 5 to 9 lbs (2.5 to 4.5 kg) in less
than 3 weeks)
No gain   (No gain  )
Initial insomnia [PhenX]
Not present     (Not present    )
Present at least one month (Present at
least one month)
Present at least one week (Present at
least one week)
Present at least two weeks     (Present at
least two weeks    )
Middle insomnia [PhenX]
Middle insomnia present (Middle
insomnia present)
No waking     (No waking    )
Terminal insomnia [PhenX]
Not present     (Not present    )
Present at least one month (Present at
least one month)
Present at least one week (Present at
least one week)
Present at least two weeks     (Present at
least two weeks    )
How many hours do you normally sleep [PhenX]
h
How many hours were you sleeping then [PhenX]
h
Excessive sleep [PhenX]
Not present     (Not present    )
Present at least one month (Present at
least one month)
Present at least one week (Present at
least one week)
Present at least two weeks     (Present at
least two weeks    )
Diurnal variation of depression [PhenX]
No depression, or not worse early    (No
depression, or not worse early   )
Regularly feels worse early in the day
(Regularly feels worse early in the day)
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Appetite or sleep change notes [Text] [PhenX]
Elevated mood [PhenX]
Not present     (Not present    )
Present at least four days   (Present at
least four days  )
Present at least one week   (Present at
least one week  )
Present at least two weeks or if lasted <
one week but hospitalized for affective
disorder (Present at least two weeks or if
lasted < one week but hospitalized for
affective disorder)
Irritable mood [PhenX]
Not present     (Not present    )
Present at least four days   (Present at
least four days  )
Present at least one week   (Present at
least one week  )
Present at least two weeks or if lasted <
one week but hospitalized for affective
disorder (Present at least two weeks or if
lasted < one week but hospitalized for
affective disorder)
Elevated or irritable mood notes [Text] [PhenX]
Pressured speech [PhenX]
Not present     (Not present    )
Present at least four days   (Present at
least four days  )
Present at least one week   (Present at
least one week  )
Present at least two weeks or if lasted <
one week but hospitalized for affective
disorder (Present at least two weeks or if
lasted < one week but hospitalized for
affective disorder)
Racing thoughts [PhenX]
Not present     (Not present    )
Present at least four days   (Present at
least four days  )
Present at least one week   (Present at
least one week  )
Present at least two weeks or if lasted <
one week but hospitalized for affective
disorder (Present at least two weeks or if
lasted < one week but hospitalized for
affective disorder)
Distractibility [PhenX]
Not present     (Not present    )
Present at least four days   (Present at
least four days  )
Present at least one week   (Present at
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least one week  )
Present at least two weeks or if lasted <
one week but hospitalized for affective
disorder (Present at least two weeks or if
lasted < one week but hospitalized for
affective disorder)
Reduced need for sleep [PhenX]
Not present     (Not present    )
Present at least four days   (Present at
least four days  )
Present at least one week   (Present at
least one week  )
Present at least two weeks or if lasted <
one week but hospitalized for affective
disorder (Present at least two weeks or if
lasted < one week but hospitalized for
affective disorder)
Excessive activity [PhenX]
Not present     (Not present    )
Present at least four days   (Present at
least four days  )
Present at least one week   (Present at
least one week  )
Present at least two weeks or if lasted <
one week but hospitalized for affective
disorder (Present at least two weeks or if
lasted < one week but hospitalized for
affective disorder)
Reckless activity [PhenX]
Not present     (Not present    )
Present at least four days   (Present at
least four days  )
Present at least one week   (Present at
least one week  )
Present at least two weeks or if lasted <
one week but hospitalized for affective
disorder (Present at least two weeks or if
lasted < one week but hospitalized for
affective disorder)
Increased sociability [PhenX]
Not present     (Not present    )
Present at least four days   (Present at
least four days  )
Present at least one week   (Present at
least one week  )
Present at least two weeks or if lasted <
one week but hospitalized for affective
disorder (Present at least two weeks or if
lasted < one week but hospitalized for
affective disorder)
Increased self-esteem [PhenX]
Not present     (Not present    )
Present at least four days   (Present at
least four days  )
Present at least one week   (Present at
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least one week  )
Present at least two weeks or if lasted <
one week but hospitalized for affective
disorder (Present at least two weeks or if
lasted < one week but hospitalized for
affective disorder)
Hypomanic or manic symptom notes [Text]
[PhenX]
Hallucinations in any modality [PhenX]
Not present     (Not present    )
Present less than one month or duration
unspecified     (Present less than one
month or duration unspecified    )
Present most of the time in a one month
period or longer (Present most of the
time in a one month period or longer)
Any modality hallucinations notes [Text] [PhenX]
Neutral voices or non-verbal hallucinations
[PhenX]
Not present    (Not present   )
Present less than one month or duration
unspecified (Present less than one
month or duration unspecified)
Present most of the time in a one month
period or longer (Present most of the
time in a one month period or longer)
Command, accusatory, abusive or persecusatory
voices [PhenX]
Not present     (Not present    )
Present less than one month or duration
unspecified     (Present less than one
month or duration unspecified    )
Present most of the time in a one month
period or longer (Present most of the
time in a one month period or longer)
Running commentary [PhenX]
Not present     (Not present    )
Present less than one month or duration
unspecified     (Present less than one
month or duration unspecified    )
Present most of the time in a one month
period or longer (Present most of the
time in a one month period or longer)
Third person auditory hallucinations [PhenX]
Not present     (Not present    )
Present less than one month or duration
unspecified     (Present less than one
month or duration unspecified    )
Present most of the time in a one month
period or longer (Present most of the
time in a one month period or longer)
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Hallucination notes [Text] [PhenX]
Thought insertion [PhenX]
Not present     (Not present    )
Present less than one month or duration
unspecified     (Present less than one
month or duration unspecified    )
Present most of the time in a one month
period or longer (Present most of the
time in a one month period or longer)
Thought broadcast [PhenX]
Not present    (Not present   )
Present less than one month or duration
unspecified (Present less than one
month or duration unspecified)
Present most of the time in a one month
period or longer (Present most of the
time in a one month period or longer)
Thought withdrawal [PhenX]
Not present    (Not present   )
Present less than one month or duration
unspecified (Present less than one
month or duration unspecified)
Present most of the time in a one month
period or longer (Present most of the
time in a one month period or longer)
Thought echo [PhenX]
Not present    (Not present   )
Present less than one month or duration
unspecified (Present less than one
month or duration unspecified)
Present most of the time in a one month
period or longer (Present most of the
time in a one month period or longer)
Subjective thought disturbance notes [Text]
[PhenX]
Delusion screen [PhenX]
Delusions present (Delusions present)
No delusions  (No delusions )
Delusions of guilt [PhenX]
No delusions of guilt     (No delusions of
guilt    )
Present at least one month (Present at
least one month)
Present at least one week   (Present at
least one week  )
Present at least two weeks  (Present at
least two weeks )
Delusions of poverty [PhenX]
No delusions of poverty   (No delusions
of poverty  )
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Present at least one month (Present at
least one month)
Present at least one week (Present at
least one week)
Present at least two weeks  (Present at
least two weeks )
Nihilistic delusions [PhenX]
No nihilistic delusions    (No nihilistic
delusions   )
Present at least one month (Present at
least one month)
Present at least one week  (Present at
least one week )
Present at least two weeks   (Present at
least two weeks  )
Delusions of passivity [PhenX]
Not present   (Not present  )
Present less than one month or duration
unspecified    (Present less than one
month or duration unspecified   )
Present most of the time in a one month
period or longer (Present most of the
time in a one month period or longer)
Delusions of influence [PhenX]
Not present   (Not present  )
Present less than one month or duration
unspecified    (Present less than one
month or duration unspecified   )
Present most of the time in a one month
period or longer (Present most of the
time in a one month period or longer)
Persecutory delusions [PhenX]
Not present   (Not present  )
Present less than one month or duration
unspecified    (Present less than one
month or duration unspecified   )
Present most of the time in a one month
period or longer (Present most of the
time in a one month period or longer)
Grandiose delusions [PhenX]
Not present   (Not present  )
Present less than one month or duration
unspecified    (Present less than one
month or duration unspecified   )
Present most of the time in a one month
period or longer (Present most of the
time in a one month period or longer)
Delusional moods [PhenX]
Not present   (Not present  )
Present less than one month or duration
unspecified    (Present less than one
month or duration unspecified   )
Present most of the time in a one month
period or longer (Present most of the
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time in a one month period or longer)
Primary delusional ideas [PhenX]
Not present   (Not present  )
Present less than one month or duration
unspecified    (Present less than one
month or duration unspecified   )
Present most of the time in a one month
period or longer (Present most of the
time in a one month period or longer)
Bizarre delusions [PhenX]
Not present   (Not present  )
Present less than one month or duration
unspecified    (Present less than one
month or duration unspecified   )
Present most of the time in a one month
period or longer (Present most of the
time in a one month period or longer)
Delusion notes [Text] [PhenX]
Insight into illness [PhenX]
Insight impaired (Insight impaired)
Insight present (Insight present)
Relationship between psychotic and affective
symptoms [PhenX]
Affective symptoms predominate
although psychotic symptoms may also
occur. (Affective symptoms predominate
although psychotic symptoms may also
occur.)
No co-occurrence     (No co-occurrence
)
Psychotic and affective symptoms are
balanced, with neither group of
symptoms dominating the overall course
of the illness.    (Psychotic and affective
symptoms are balanced, with neither
group of symptoms dominating the
overall course of the illness.   )
Psychotic symptoms dominate the
clinical picture although occasional
affective disturbance may also occur.
(Psychotic symptoms dominate the
clinical picture although occasional
affective disturbance may also occur.   )
Insight or relationship between psychotic and
affective symptom notes [Text] [PhenX]
Psychotic symptoms respond to antipsychotic
medications [PhenX]
No response to neuroleptics, never been
psychotic, or never taken neuroleptics
(No response to neuroleptics, never
been psychotic, or never taken
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neuroleptics    )
Positive response to neuroleptics
(Positive response to neuroleptics)
Well organized delusions [PhenX]
Not present   (Not present  )
Present less than one month or duration
unspecified    (Present less than one
month or duration unspecified   )
Present most of the time in a one month
period or longer (Present most of the
time in a one month period or longer)
Widespread delusions [PhenX]
Not present   (Not present  )
Present less than one month or duration
unspecified    (Present less than one
month or duration unspecified   )
Present most of the time in a one month
period or longer (Present most of the
time in a one month period or longer)
Delusions and hallucinations last for one week
[PhenX]
Not present   (Not present  )
Present less than one month or duration
unspecified    (Present less than one
month or duration unspecified   )
Present most of the time in a one month
period or longer (Present most of the
time in a one month period or longer)
Persecutory or jealous delusions and
hallucinations [PhenX]
Not present   (Not present  )
Present less than one month or duration
unspecified    (Present less than one
month or duration unspecified   )
Present most of the time in a one month
period or longer (Present most of the
time in a one month period or longer)
Illness duration [PhenX]
Impairment or incapacity [PhenX]
Evidence of objective functional
impairment in major life role with definite
reduction in productivity and/or criticism
about functioning or performance has
been received     (Evidence of objective
functional impairment in major life role
with definite reduction in productivity
and/or criticism about functioning or
performance has been received    )
Inpatient treatment (any duration) has
been received, or no functioning at all in
major life role for more than two days, or
active psychotic symptoms such as
delusions or hallucinations have
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occurred. (Inpatient treatment (any
duration) has been received, or no
functioning at all in major life role for
more than two days, or active psychotic
symptoms such as delusions or
hallucinations have occurred.)
No impairment   (No impairment  )
Subjective impairment only (at work,
school, family or social functioning)
(Subjective impairment only (at work,
school, family or social functioning)   )
Deterioration from premorbid level of functioning
[PhenX]
Deterioration from premorbid level of
functioning (Deterioration from premorbid
level of functioning)
No deterioration present     (No
deterioration present    )
Course of disorder [PhenX]
Continuous chronic illness    (Continuous
chronic illness   )
Continuous chronic illness with
deterioration (Continuous chronic illness
with deterioration)
Multiple episodes with good recovery
between  (Multiple episodes with good
recovery between )
Multiple episodes with partial recovery
between   (Multiple episodes with partial
recovery between  )
Single episode with good recovery
(Single episode with good recovery)
Rapport [PhenX]
Rapport difficult (Rapport difficult)
Rapport established without difficulty
(Rapport established without difficulty    )
Credibility of information [PhenX]
Information credible    (Information
credible   )
Information not credible (Information not
credible)
Catatonia [PhenX]
Not present   (Not present  )
Present less than one month or duration
unspecified    (Present less than one
month or duration unspecified   )
Present most of the time in a one month
period or longer (Present most of the
time in a one month period or longer)
Bizarre behavior [PhenX]
Not present     (Not present    )
Present (Present)
Agitated activity [PhenX]
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Not present     (Not present    )
Present at least one month (Present at
least one month)
Present at least one week (Present at
least one week)
Present at least two weeks     (Present at
least two weeks    )
Restricted affect [PhenX]
Not present     (Not present    )
Present less than one month or duration
unspecified     (Present less than one
month or duration unspecified    )
Present most of the time in a one month
period or longer (Present most of the
time in a one month period or longer)
Blunted affect [PhenX]
Not present     (Not present    )
Present less than one month or duration
unspecified     (Present less than one
month or duration unspecified    )
Present most of the time in a one month
period or longer (Present most of the
time in a one month period or longer)
Inappropriate affect [PhenX]
Not present     (Not present    )
Present less than one month or duration
unspecified     (Present less than one
month or duration unspecified    )
Present most of the time in a one month
period or longer (Present most of the
time in a one month period or longer)
Speech difficult to understand [PhenX]
Not present     (Not present    )
Present (Present)
Speech incoherent [PhenX]
Not present     (Not present    )
Present less than one month or duration
unspecified     (Present less than one
month or duration unspecified    )
Present most of the time in a one month
period or longer (Present most of the
time in a one month period or longer)
Positive formal thought disorder [PhenX]
Not present     (Not present    )
Present less than one month or duration
unspecified     (Present less than one
month or duration unspecified    )
Present most of the time in a one month
period or longer (Present most of the
time in a one month period or longer)
Negative formal thought disorder [PhenX]
Not present     (Not present    )
Present less than one month or duration
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unspecified     (Present less than one
month or duration unspecified    )
Present most of the time in a one month
period or longer (Present most of the
time in a one month period or longer)
15 / 15
Schizophrenia Screener Protocol PhenX Toolkit
Self-esteem Protocol PhenX Toolkit
The Rosenberg Self-Esteem Scale is a 10-item scale used
to evaluate a person’s general self-worth, with 5 positive
statements and 5 negative statements about a person’s
sense of self-respect and value. It is commonly scored as a
4-point Likert scale, reversing the negative items and
combining all 10 items into a single index of global self-
esteem. The scale includes values of 1 (strongly agree), 2
(agree), 3 (disagree), and 4 (strongly disagree).
ODM derived from: https://cde.nlm.nih.gov
Primary source: https://www.phenxtoolkit.org/
Recent publication: Hendershot, T., Pan, H., Haines, J.,
Harlan, W.R., Marazita, M.L., McCarty, C.A., Ramos, E.M.,
and Hamilton, C.M. (2015) Using the PhenX toolkit to add
standard measures to a study. Curr. Protoc. Hum. Genet.
86:1.21.1-1.21.17. doi: 10.1002/0471142905.hg0121s86
Permission to publish granted by
Carol M. Hamilton.
All rights reserved. Please visit https://medical-data-
models.org/forms/15120
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PhenX - self-esteem protocol
I feel that I'm a person of worth, at least on an
equal plane with others.
A little (A little)
A lot (A lot)
Not at all (Not at all)
Some (Some)
I feel that I have a number of good qualities.
Agree (Agree)
Disagree (Disagree)
Strongly agree (Strongly agree)
Strongly disagree (Strongly disagree)
All in all, I am inclined to feel that I am a failure.
Agree (Agree)
Disagree (Disagree)
Strongly agree (Strongly agree)
Strongly disagree (Strongly disagree)
I am able to do things as well as most other
people.
Agree (Agree)
Disagree (Disagree)
Strongly agree (Strongly agree)
Strongly disagree (Strongly disagree)
I feel I do not have much to be proud of.
Agree (Agree)
Disagree (Disagree)
Strongly agree (Strongly agree)
Strongly disagree (Strongly disagree)
I take a positive attitude toward myself.
Agree (Agree)
Disagree (Disagree)
Strongly agree (Strongly agree)
Strongly disagree (Strongly disagree)
On the whole, I am satisfied with myself.
Agree (Agree)
Disagree (Disagree)
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Strongly agree (Strongly agree)
Strongly disagree (Strongly disagree)
I wish I could have more respect for myself.
Agree (Agree)
Disagree (Disagree)
Strongly agree (Strongly agree)
Strongly disagree (Strongly disagree)
I certainly feel useless at times.
Agree (Agree)
Disagree (Disagree)
Strongly agree (Strongly agree)
Strongly disagree (Strongly disagree)
At times I think I am no good at all.
Agree (Agree)
Disagree (Disagree)
Strongly agree (Strongly agree)
Strongly disagree (Strongly disagree)
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Eligibility Diabetes Mellitus, Type 1
NCT02411578
Mini-Dose Glucagon for Adults With Type 1 Diabetes; ODM
derived from: https://clinicaltrials.gov/show/NCT02411578
All rights reserved. Please visit https://medical-data-
models.org/forms/15122
Eligibility Diabetes Mellitus, Type 1
NCT02411578
Inclusion Criteria
1. clinical diagnosis of presumed autoimmune t1d
and receiving daily insulin*
Yes
No
2. age: 18.0 to < 65.0 years*
Yes
No
3. duration of t1d: ≥2.0 years*
Yes
No
4. body mass index 20.0 to <35.0 kg/m2 and
weight 110 to <250 lbs*
Yes
No
5. hba1c <8.5% (point of care or local lab, within
past month)*
Yes
No
6. using csii therapy (i.e., insulin pump) for at
least 3 months, with no plans to discontinue use
during the study (and no use of active low
glucose suspend feature within the last 4 weeks)*
Yes
No
7. using continuous glucose monitor ≥6
days/week in the last 4 weeks, with no plans to
discontinue continuous glucose monitor use
during the study*
Yes
No
8. continuous glucose monitor glucose level <70
mg/dl during daytime hours (e.g., 8am -*
Yes
No
10pm) on at least 7 of the past 28 days (a
modification can be made for participants with
non-traditional waking hours) evaluated from
downloaded cgm data*
Yes
No
9. females must meet one of the following
criteria:*
Yes
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No
of childbearing potential and not currently
pregnant (negative pregnancy test) or lactating,
and agrees to use an accepted contraceptive
regimen as described in the study procedure
manual throughout the entire duration of the
study (from screening visit until study
completion); or*
Yes
No
of non-childbearing potential, defined as a female
who has had a hysterectomy or tubal ligation, is
clinically considered infertile or is in a
menopausal state (at least 1 year without
menses)*
Yes
No
10. in good general health with no conditions that
could influence the outcome of the trial, and in
the judgment of the investigator is a good
candidate for the study based on review of
available medical history, physical examination
and clinical laboratory evaluations*
Yes
No
11. willing to adhere to the protocol requirements
for the duration of the study*
Yes
No
12. participant has a smart phone available and
is able to use it daily*
Yes
No
13. must be enrolled in the t1d exchange clinic
registry or willing to join the clinic registry*
Yes
No
Exclusion Criteria
1. more than 1 severe hypoglycemic episode in
the past 12 months (as defined by an episode
that required third party assistance for
treatment)*
Yes
No
2. more than 1 episode of diabetic ketoacidosis in
the past 12 months (as defined by an episode
diagnosed as diabetic ketoacidosis that required
treatment in an emergency department or
hospitalization)*
Yes
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No
3. presence of cardiovascular, gastrointestinal,
liver or kidney disease, or any medical condition
which, in the judgment of the investigator, could
potentiate or predispose to undesired effects or
could interfere with the absorption, distribution,
metabolism, or excretion of glucagon or ability to
respond appropriately to mild to moderate
hypoglycemia.*
Yes
No
4. known presence of hereditary problems of
glycogen storage disease, galactose and/or
lactose intolerance*
Yes
No
5. males with alcohol use in excess of 3 or more
drinks per day, on average and females with
alcohol use in excess of 2 or more drinks per day,
on average*
Yes
No
6. use of non-insulin anti-diabetic medications*
Yes
No
7. use of daily systemic beta-blocker*
Yes
No
8. use of beta-adrenergic agonists, theophylline
(or other methylxanthines)*
Yes
No
9. use of 1st generation anticholinergic drugs
(such as brompheniramine, chlorpheniramine,
dimenhydrinate, diphenhydramine, and
doxylamine)*
Yes
No
10. use of systemic corticosteroids*
Yes
No
11. history of hypersensitivity to glucagon or any
related product or excipient or severe
hypersensitivity reactions (such as angioedema)
to any drugs*
Yes
No
12. history of epilepsy or seizure disorder*
Yes
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No
13. uncontrolled hypertension, >160 mmhg
systolic or >100 mmhg diastolic*
Yes
No
14. currently a high endurance exerciser or plans
to perform high endurance exercise during study
(from screening visit until study completion)*
Yes
No
high endurance exerciser defined as a person
who regularly competes in running, cycling,
rowing, swimming or any other endurance-based
activity for the purpose of competition (>2100 met
minutes per week [i.e. 7 mets x 60 minutes x 5
days a week, where 7 mets is equivalent to
jogging])*
Yes
No
15. currently following a very low calorie or other
weight-loss diet*
Yes
No
16. participation in other studies involving
administration of an investigational drug or device
within 30 days or 5 half-lives, whichever is longer,
before screening for the current study or
planning to participate in another such study
during participation in the current study*
Yes
No
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Eligibility Diabetes Mellitus, Type 2
NCT02256332
Plant-based Ingredient on Post Prandial Glucose in Type II
Diabetes; ODM derived from:
https://clinicaltrials.gov/show/NCT02256332
All rights reserved. Please visit https://medical-data-
models.org/forms/15123
Eligibility Diabetes Mellitus, Type 2
NCT02256332
Inclusion Criteria
male and female volunteers with confirmed type ii
diabetes not treated with pharmaceutical-based
glucose lowering treatment for past three months
(controlled solely through diet and exercise);*
Yes
No
age ≥ 20 and ≤ 65 year at screening;*
Yes
No
body mass index (bmi) between ≥18 and ≤ 32
kg/m2;*
Yes
No
hba1c ≥48 mmol/mol and ≤53 mmol/mol (≥ 6.5%
and ≤ 7.0%). at discretion of the study physician,
subjects with hba1c >53 mmol/mol and <58
mmol/mol (>7.0% and < 7.5%) controlled solely
through diet and exercise are also allowed to
participate.*
Yes
No
Exclusion Criteria
being an employee of unilever or research site;*
Yes
No
chronic smokers, tobacco chewers and drinkers;*
Yes
No
no medication, including vitamins and tonics,
except for cholesterol, as determined by the
physician;*
Yes
No
reported weight loss/gain ≥ 10% of body weight
in the 6 months preceding screening;*
Yes
No
allergy to any food or cosmetics;*
Yes
No
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if female, not being pregnant or planning
pregnancy during the study period;*
Yes
No
if female, lactating or has been lactating for 6
weeks before pre-study investigation and/or
during the study period.*
Yes
No
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Eligibility Diabetes Mellitus, Type 2
NCT02266576
A Patient-Centered Strategy for Improving Diabetes
Prevention in Urban American Indians; ODM derived from:
https://clinicaltrials.gov/show/NCT02266576
All rights reserved. Please visit https://medical-data-
models.org/forms/15125
Eligibility Diabetes Mellitus, Type 2
NCT02266576
Inclusion Criteria
self-identified urban aian men and women*
Yes
No
bmi between 30-55*
Yes
No
not diagnosed with type ii diabetes*
Yes
No
at least one of the following criterion*
Yes
No
1. triglycerides: 150mg/dl or higher*
Yes
No
2. reduced hdl: <40mg/dl (men); <50mg/dl
(women)*
Yes
No
3. blood pressure: >130/80 or current treatment
with antihypertensives*
Yes
No
4. fasting glucose: >100mg/dl*
Yes
No
Exclusion Criteria
significant medical comorbidities, including
uncontrolled metabolic disorders (e.g., thyroid,
diabetes, renal, liver), unstable heart disease,
heart failure, and ongoing substance abuse;*
Yes
No
on greater than 10 prescription medications.*
Yes
No
psychiatric disorders requiring atypical
antipsychotics or multiple medications;*
Yes
No
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inappropriate for moderate exercise according to
the revised physical activity readiness
questionnaire;*
Yes
No
pregnant, planning to become pregnant, or
lactating;*
Yes
No
family household member already enrolled in the
study;*
Yes
No
already enrolled or planning to enroll in a clinical
trial that would limit full participation in the study;*
Yes
No
resident of a long term care facility;*
Yes
No
lack of spoken english by patient or a household
member > 18 y who can serve as interpreter;*
Yes
No
plans to move during the study period (9 months
post-randomization);*
Yes
No
investigator discretion for clinical safety or
adherence reasons (e.g., unstable housing,
chronic pain).*
Yes
No
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Eligibility Diabetes Mellitus, Type 2
NCT02342834
Effects of a Small Protein and Lipid Preload on Glucose
Tolerance in Subjects With Impaired Glucose Homeostasis;
ODM derived from:
https://clinicaltrials.gov/show/NCT02342834
All rights reserved. Please visit https://medical-data-
models.org/forms/15127
Eligibility Diabetes Mellitus, Type 2
NCT02342834
Inclusion Criteria
healthy, prediabetic or diet-controlled type 2
diabetic patients*
Yes
No
subjects ≥ 18 and ≤65 years of age*
Yes
No
lean, overweight or obese (bmi: 18 to 35 kg/m2)*
Yes
No
normal liver and kidney function*
Yes
No
normal thyroid function*
Yes
No
read and understood the informed consent form
and signed it voluntarily*
Yes
No
Exclusion Criteria
liver, heart, kidney, lung, infectious, neurological,
psychiatric, immunological or neoplastic
diseases.*
Yes
No
type 1 or insulin treated diabetes.*
Yes
No
pregnancy or lactation*
Yes
No
illicit drug abuse or alcoholism*
Yes
No
subject treated with insulin or treatment*
Yes
No
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subjects taking anoretic drugs*
Yes
No
subjects on steroid treatment*
Yes
No
subjects after bariatric surgery.*
Yes
No
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Eligibility Diabetes NCT02215408
MEDication Focused Outpatient Care for Underutilization of
Secondary Prevention; ODM derived from:
https://clinicaltrials.gov/show/NCT02215408
All rights reserved. Please visit https://medical-data-
models.org/forms/15128
Eligibility Diabetes NCT02215408
Inclusion Criteria
english speakers age 55 or greater*
Yes
No
must have a medical history of at least one of the
following:*
Yes
No
coronary artery disease*
Yes
No
myocardial infarction*
Yes
No
stroke*
Yes
No
transient ischemic attack*
Yes
No
atrial fibrillation*
Yes
No
systolic heart failure*
Yes
No
peripheral vascular disease/claudication*
Yes
No
carotid artery disease*
Yes
No
diabetes with either: low density lipoprotein (ldl)
100 or greater and/or systolic blood pressure 140
or higher or diastolic blood pressure 90 or higher*
Yes
No
Exclusion Criteria
signs of acute angina, stroke, heart failure or
renal failure*
Yes
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No
systolic blood pressure 200 or greater or diastolic
blood pressure 115 or greater*
Yes
No
significant hepatic disease, including: cirrhosis,
hepatitis b or c infection, alanine
aminotransferase (alt) or aspartate
aminotransferase (ast) 3 times control or higher,
or total bilirubin 2.0 mg/dl or higher*
Yes
No
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Eligibility Diabetes NCT02246959
Process Versus Outcomes Incentives for Lipid
Management; ODM derived from:
https://clinicaltrials.gov/show/NCT02246959
All rights reserved. Please visit https://medical-data-
models.org/forms/15129
Eligibility Diabetes NCT02246959
Inclusion Criteria
diabetes and/or history of cvd (defined as
diagnosis with myocardial infarction, stroke, or
peripheral vascular disease)*
Yes
No
ldl greater than or equal to 130 mg/dl measured
during screening of potential participants*
Yes
No
a prescription filled for a statin medication within
the last 12 months (derived from pharmacy
records)*
Yes
No
medication possession ratio (mpr) less than
80%.*
Yes
No
Exclusion Criteria
under 18 years old*
Yes
No
a contraindication to further statin use or have
suffered statin side effects, such as myopathy*
Yes
No
will not or cannot give consent*
Yes
No
a history of active liver disease or abnormal liver
function tests on baseline screening [alanine
aminotransferase (alt) or aspartate
aminotransferase (ast) greater than 3x the upper
limit of normal].*
Yes
No
participating in another clinical trial with related
aims*
Yes
No
co-morbidities likely to lead to death within a
short period (e.g. metastatic cancer)*
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Yes
No
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Eligibility Dipeptidyl-Peptidase 4 Inhibitors
NCT02330406
Randomized Evaluation of Anagliptin Versus Sitagliptin On
Low-density lipoproteiN Cholesterol in Diabetes Trial; ODM
derived from: https://clinicaltrials.gov/show/NCT02330406
All rights reserved. Please visit https://medical-data-
models.org/forms/15130
Eligibility Dipeptidyl-Peptidase 4
Inhibitors NCT02330406
Inclusion Criteria
patients with type 2 diabetes with coronary heart
diseases who treated with diet, exercise or
antidiabetic medications*
Yes
No
patients who were treated with statins for 8
weeks or longer*
Yes
No
patients with low-density lipoprotein cholesterol
equal to or greater than 100 mg/dl in the at least
two of three measurements after the
administration of statins*
Yes
No
patients with glycerated hemoglobin (hba1c,
ngsp) equal to or greater than 6.0 % (7.0*
Yes
No
% if patients were not treated with dipeptidyl-
peptidase 4 inhibitors) and lesser than 10.5 %*
Yes
No
Exclusion Criteria
patients with type 1 diabetes*
Yes
No
patients with triglyceride equal to or greater than
400 mg/dl in the previous fasting measuments*
Yes
No
patients who were received insulin therapy or
considered to need insulin therapy*
Yes
No
patients with pregnancy, possible pregnancy, or
on breast-feeding*
Yes
No
patients with severe infections, perioperative
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status, or severe trauma*
Yes
No
patients who were received glucagon-like
peptide-1receptor agonists, rapid insulin
secretagogue, or sodium glucose cotransporter 2
inhibitor*
Yes
No
patients whom physician in charge considered
inappropriate for the study*
Yes
No
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Eligibility Early Stage Breast Cancer
NCT02335671
Evaluating Mass Spectrometry And Intraoperative MRI In
The Advanced Multimodality Image Guided Operating Suite
(Amigo) In Breast-Conserving Therapy; ODM derived from:
https://clinicaltrials.gov/show/NCT02335671
All rights reserved. Please visit https://medical-data-
models.org/forms/15133
Eligibility Early Stage Breast Cancer
NCT02335671
Inclusion Criteria
patients must be female*
Yes
No
participants must have a pre-operative standard
mammogram with or without ultrasound. these
may be performed at outside institutions.*
Yes
No
participants must have biopsy confirmed and
clinical stage 1 or stage 2 breast carcinoma. if
biopsy was done at an outside hospital,
pathology will be reviewed at bwh/dfci.*
Yes
No
participants must be candidates for definitive
local therapy with breast conserving therapy (this
takes into account tumor to breast size ratio
appropriate for bcs, and the ability to undergo
standard radiation therapy post-operatively).*
Yes
No
patient must meet standard mri guidelines and be
able and willing to undergo mri*
Yes
No
age  ≥18 years and < 75.*
Yes
No
ability to understand and the willingness to sign a
written informed consent document.*
Yes
No
Exclusion Criteria
participants with a known brca 1 or 2 mutation.*
Yes
No
participants with known li-fraumeni or cowden's
disease.*
Yes
No
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participants with prior mantle radiation.*
Yes
No
participants with locally advanced breast cancer
such as inflammatory breast cancer or cancer
grossly involving skin.*
Yes
No
participants who are pregnant.*
Yes
No
participants who enroll in a preoperative therapy
trial or who have been treated with neoadjuvant
chemotherapy.*
Yes
No
participants with known active collagen vascular
disease.*
Yes
No
participants with prior history of ipsilateral breast
carcinoma.*
Yes
No
patients who have biopsy confirmed multi-centric
disease.*
Yes
No
participants who have documented contra-
indications for contrast-enhanced mri, including
but not limited to renal failure.*
Yes
No
participants who exceed the weight limit for the
surgical table at amigo, 350 lbs or who will not fit
into the 70 cm diameter bore of the mri scanner
at amigo or the 60 cm diameter bore of the pre-
procedure imaging mri scanner.*
Yes
No
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Eligibility EBV-positive Nasopharyngeal
Carcinoma NCT02065362
TGF-beta Resistant Cytotoxic T-lymphocytes in Treatment
of EBV-positive Nasopharyngeal Carcinoma / RESIST-
NPC; ODM derived from:
https://clinicaltrials.gov/show/NCT02065362
All rights reserved. Please visit https://medical-data-
models.org/forms/15138
Eligibility EBV-positive
Nasopharyngeal Carcinoma
NCT02065362
Inclusion Criteria
the patient must meet the following eligibility
inclusion criteria at the time of procurement:*
Yes
No
nasopharyngeal carcinoma in first or subsequent
relapse or with primary refractory disease*
Yes
No
ebv positive tumor*
Yes
No
informed consent explained to, understood by
and signed by patient/guardian. patient/guardian
given copy of informed consent*
Yes
No
the patient must meet the following eligibility
criteria to be included for treatment:*
Yes
No
nasopharyngeal carcinoma in first or subsequent
relapse or with primary refractory disease*
Yes
No
ebv positive tumor*
Yes
No
patients with life expectancy greater than or equal
to 6 weeks*
Yes
No
bilirubin less than or equal to 3x upper limit of
normal*
Yes
No
ast less than or equal to 5x upper limit of normal*
Yes
No
hgb > 8.0g/dl (can be transfused)*
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Yes
No
creatinine less than or equal to  2x upper limit of
normal for age*
Yes
No
pulse oximetry of > 90% on room air*
Yes
No
off investigational therapy for 4 weeks prior to
study entry*
Yes
No
karnofsky or lansky score of greater than or equal
to 50%*
Yes
No
sexually active patients must be willing to utilize
one of the more effective birth control methods
during the study and for 6 months after the study
is concluded. the male partner should use a
condom.*
Yes
No
informed consent explained to, understood by
and signed by patient/guardian. patient/guardian
given copy of informed consent.*
Yes
No
Exclusion Criteria
at time of procurement:*
Yes
No
•known hiv positivity*
Yes
No
at time of treatment:*
Yes
No
pregnant or lactating*
Yes
No
severe intercurrent infection*
Yes
No
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Eligibility Electrical Cardioversion of Atrial
Fibrillation NCT02378155
Cerebral Oxygen Saturation Measurement During
Cardioversion Because of Atrial Fibrillation; ODM derived
from: https://clinicaltrials.gov/show/NCT02378155
All rights reserved. Please visit https://medical-data-
models.org/forms/15139
Eligibility Electrical Cardioversion of
Atrial Fibrillation NCT02378155
Inclusion Criteria
older than 18 years and able to give informed
consent*
Yes
No
diagnosis of paroxysmal or persistent atrial
fibrillation*
Yes
No
scheduled for electrical cardioversion or atrial
fibrillation development in the first days after
cardiac surgery followed by pharmacological
treatment with amiodarone*
Yes
No
dutch speaking*
Yes
No
Exclusion Criteria
younger than 18 years or not able to give
informed consent*
Yes
No
diagnosis of permanent atrial fibrillation*
Yes
No
atrial fibrillation with thrombus in left atrial
appendage*
Yes
No
chronic obstructive pulmonary disease gold class
3 or 4*
Yes
No
airway manipulation during cardioversion*
Yes
No
pregnant women*
Yes
No
medical history of cerebrovascular accident or
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brain injury*
Yes
No
medical history of cardiopulmonary resuscitation*
Yes
No
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Angina Protocol PhenX Toolkit
The interviewer asks the respondent about his/her personal
history of angina and chest discomfort characteristics to
determine presence of angina.
ODM derived from: https://cde.nlm.nih.gov
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Angina Protocol PhenX Toolkit
PhenX - angina protocol
Has a doctor ever told you that you had angina?
Don't know (Don't know)
No (No)
Yes (Yes)
Any chest discomfort ever/since last exam or
medical history update?
Don't know (Don't know)
Maybe (Maybe)
No (No)
Yes (Yes)
Chest discomfort with exertion or excitement
Don't know (Don't know)
Maybe (Maybe)
No (No)
Yes (Yes)
Chest discomfort when quiet or resting
Don't know (Don't know)
Maybe (Maybe)
No (No)
Yes (Yes)
Date of onset of chest discomfort
Usual duration of chest discomfort
s
Longest duration of chest discomfort
min
Location of chest discomfort [Anatomy]
Central sternum and upper chest
(Central sternum and upper chest)
Combination    (Combination   )
Left lower ribcage (Left lower ribcage)
Left upper quadrant (Left upper
quadrant)
No (No)
Other (Other)
Right chest  (Right chest )
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Unknown (Unknown)
Radiation of chest discomfort
Abdomen (Abdomen)
Back (Back)
Combination (Combination)
Left shoulder or left arm (Left shoulder or
left arm)
Neck (Neck)
No (No)
Other (Other)
Right shoulder or arm (Right shoulder or
arm)
Unknown (Unknown)
Frequency (number in past month) of Chest
Discomfort
Frequency (number in past year) of Chest
Discomfort
Type of chest discomfort
Dull (Dull)
Other (Other)
Pressure, heavy, vise    (Pressure, heavy,
vise   )
Sharp (Sharp)
Unknown (Unknown)
Relief of chest discomfort by nitroglycerine in <15
minutes
No (No)
Not tried (Not tried)
Unknown (Unknown)
Yes (Yes)
Relief of chest discomfort by rest in <15 minutes
No (No)
Not tried (Not tried)
Unknown (Unknown)
Yes (Yes)
Relief of chest discomfort spontaneously in <15
minutes
No (No)
Not tried (Not tried)
Unknown (Unknown)
Yes (Yes)
Relief of chest discomfort by other cause in <15
minutes
No (No)
Not tried (Not tried)
Unknown (Unknown)
Yes (Yes)
Since your last exam, have you been told by a
doctor you had a heart attack?
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Maybe (Maybe)
No  (No )
Unknown (Unknown)
Yes (Yes)
Angina pectoris in interim
Maybe (Maybe)
No  (No )
Unknown (Unknown)
Yes (Yes)
Angina pectoris since revascularization
procedure
Maybe (Maybe)
No  (No )
Unknown (Unknown)
Yes (Yes)
Coronary insufficiency in interim
Maybe (Maybe)
No  (No )
Unknown (Unknown)
Yes (Yes)
Myocardial infarction in interim
Maybe (Maybe)
No  (No )
Unknown (Unknown)
Yes (Yes)
3 / 3
Angina Protocol PhenX Toolkit
Eligibility End Stage Renal Disease
NCT02358967
Palm Tocotrienols in Chronic Hemodialysis (USA); ODM
derived from: https://clinicaltrials.gov/show/NCT02358967
All rights reserved. Please visit https://medical-data-
models.org/forms/15141
Eligibility End Stage Renal Disease
NCT02358967
Inclusion Criteria
patient is willing and able to give informed
consent for participation in the trial.*
Yes
No
male or female, aged 18 years to 70 yrs.
undergoing chronic hemodialysis treatment for
more than 3 months (life expectancy > 1 year).*
Yes
No
able and willing to comply with all trial
requirements.*
Yes
No
willing to allow his or her
/physician/nephrologist/general practitioner and
consultant, if appropriate, to be notified of
participation in the trial.*
Yes
No
Exclusion Criteria
participants who have participated in another
research trial involving an investigational product
in the past 12 weeks.*
Yes
No
history of functional kidney transplant 6 months
before study entry; anticipated live donor kidney
transplant over the study duration;*
Yes
No
participants who are taking vitamin e- containing
supplements >60 iu/d during the past 30 days*
Yes
No
history of poor adherence to hemodialysis or
medical regimen*
Yes
No
participants who are currently on active treatment
for cancer, excluding basal cell carcinoma of the
skin*
Yes
No
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participants who have been diagnosed as
hiv/aids and/or on the anti-hiv therapy. (hiv
seropositivity is not an exclusion criterion)*
Yes
No
patients taking anti-inflammatory medication,
except aspirin<325 mg/d, over the past 30 days*
Yes
No
female participant who is pregnant, lactating or
planning pregnancy during the course of the trial*
Yes
No
participants who are receiving nutritional support
(i.e. enteral and intra-venous route)*
Yes
No
patients using a temporary catheter for dialysis
access at baseline or patients receiving a
graft/fistula within the 6-month study period*
Yes
No
more than two hospitalizations within the last 90
days or one hospitalization within the 30 days
preceding enrollment*
Yes
No
any other significant disease or disorder which, in
the opinion of their nephrologist, may either put
the participants at risk because of participation in
the trial, or may influence the result of the trial, or
the participant's ability to participate in the trial.*
Yes
No
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Anxiety Disorders Screener - Adult PhenX
Toolkit
This protocol is divided into two separate parts. The first
part contains the subsections of the Composite
International Diagnostic Interview - Short Form (CIDI-SF)
that screen for the presence or absence of generalized
anxiety disorder, specific phobia, social phobia,
agoraphobia and panic attack. The second part contains
specific questions from the Symptom Check List 90 (SCL-
90) that provide a more quantitative measure of anxiety
symptom severity.
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Anxiety Disorders Screener - Adult
PhenX Toolkit
PhenX - anxiety disorders screener - adult
protocol
Have you ever had a period lasting one month or
longer when most of the time you felt worried,
tense, or anxious?
No (No)
Not asked (Not asked)
Refused (Refused)
Yes (Yes)
Did you ever have a time when you worried a lot
more than most people would in your situation?
No (No)
Not asked (Not asked)
Refused (Refused)
Yes (Yes)
What is the longest period of time that this kind of
worrying has ever continued?
During that period, was your worry stronger than
in other people?
No (No)
Not asked (Not asked)
Refused (Refused)
Yes (Yes)
Did you worry most days?
No (No)
Not asked (Not asked)
Refused (Refused)
Yes (Yes)
Did you usually worry about one particular thing,
such as your job security or the failing health of a
loved one, or more than one thing?
More than one thing (More than one
thing)
Not asked (Not asked)
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One thing (One thing)
Refused (Refused)
Did you find it difficult to stop worrying?
No (No)
Not asked (Not asked)
Refused (Refused)
Yes (Yes)
Did you ever have different worries on your mind
at the same time?
No (No)
Not asked (Not asked)
Refused (Refused)
Yes (Yes)
How often was your worry so strong that you
couldn't put it out of your mind no matter how
hard you tried?
Never (Never)
Not asked (Not asked)
Often (Often)
Rarely (Rarely)
Refused (Refused)
Sometimes (Sometimes)
How often did you find it difficult to control your
worry
Never (Never)
Not asked (Not asked)
Often (Often)
Rarely (Rarely)
Refused (Refused)
Sometimes (Sometimes)
Other things occurring while worried or anxious
[PhenX]
Difficulty keeping your mind on what you
were doing (Difficulty keeping your mind
on what you were doing)
Easily tired (Easily tired)
Keyed up or on edge (Keyed up or on
edge)
More irritable than usual (More irritable
than usual)
Restless (Restless)
Tense, sore, or aching muscles (Tense,
sore, or aching muscles)
When you were worried or anxious did this thing
also occur [PhenX]
Yes
No
Did you ever tell a professional about these
problems (medical doctor, psychologist, social
worker, counselor, nurse, clergy, or other helping
professional)?
No (No)
Not asked (Not asked)
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Refused (Refused)
Yes (Yes)
Did you take medication or use drugs or alcohol
more than once for the worry or the problems it
was causing?
No (No)
Not asked (Not asked)
Refused (Refused)
Yes (Yes)
How much did the worry or anxiety interfere with
your life or activities?
A little (A little)
A lot (A lot)
Not asked (Not asked)
Not at all (Not at all)
Refused (Refused)
Some (Some)
Specific things you have an unreasonable fear
about or avoid [PhenX]
Being in a closed space like a cave,
tunnel, elevator, or airplane (Being in a
closed space like a cave, tunnel,
elevator, or airplane)
Heights, storms, thunder, lightning, or
being in still water, like a swimming pool
or lakes   (Heights, storms, thunder,
lightning, or being in still water, like a
swimming pool or lakes  )
Seeing blood, getting a shot or injection,
seeing a dentist, or going to a hospital
(Seeing blood, getting a shot or injection,
seeing a dentist, or going to a hospital)
Snakes, birds, rats, bugs, or other
animals (Snakes, birds, rats, bugs, or
other animals)
Do you have an unreasonably strong fear or
avoid this specific thing [PhenX]
Yes
No
How often do you get upset when you are in that
situation?
Every time (Every time)
Most of the time (Most of the time)
Never (Never)
Not asked (Not asked)
Only one or two times ever (Only one or
two times ever)
Refused (Refused)
Some of the time (Some of the time)
How long have you had any of these fears?
Between 1 and 5 years  (Between 1 and
5 years )
Less than 1 year  (Less than 1 year )
More than 5 years (More than 5 years)
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How long have you had any of these fears?
mo
How much have any of these fears ever interfered
with your life or activities?
A little (A little)
A lot (A lot)
Not asked (Not asked)
Not at all (Not at all)
Refused (Refused)
Some (Some)
Have you ever been very upset with yourself for
having any of these fears?
No (No)
Not asked (Not asked)
Refused (Refused)
Yes (Yes)
Is your fear unreasonable - that is, much stronger
than it should be?
No (No)
Not asked (Not asked)
Refused (Refused)
Yes (Yes)
Is your fear much stronger than in other people?
No (No)
Not asked (Not asked)
Refused (Refused)
Yes (Yes)
Social phobias [PhenX]
Eating or drinking where someone could
watch you  (Eating or drinking where
someone could watch you )
Giving a speech or speaking in public
(Giving a speech or speaking in public)
Going to a party or other social outing
(Going to a party or other social outing)
Taking part or speaking in a meeting or
class  (Taking part or speaking in a
meeting or class )
Talking to people because you might
have nothing to say or might sound
foolish  (Talking to people because you
might have nothing to say or might sound
foolish )
Writing while someone watches (Writing
while someone watches)
Do you have an unreasonably strong fear or
avoid this social situation [PhenX]
Yes
No
How often do you get upset when you are in that
situation?
Every time (Every time)
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Most of the time (Most of the time)
Never (Never)
Not asked (Not asked)
Only one or two times ever (Only one or
two times ever)
Refused (Refused)
Some of the time (Some of the time)
How long have you had any of these fears?
Between 1 and 5 years     (Between 1
and 5 years    )
Less than 1 year (Less than 1 year)
More than 5 years (More than 5 years)
How long have you had any of these fears?
mo
How much have any of these fears ever interfered
with your life or activities?
A little (A little)
A lot (A lot)
Not asked (Not asked)
Not at all (Not at all)
Refused (Refused)
Some (Some)
Have you ever been very upset with yourself for
having any of these fears?
No (No)
Not asked (Not asked)
Refused (Refused)
Yes (Yes)
Is your fear unreasonable - that is, much stronger
than it should be?
No (No)
Not asked (Not asked)
Refused (Refused)
Yes (Yes)
Is your fear much stronger than in other people?
No (No)
Not asked (Not asked)
Refused (Refused)
Yes (Yes)
Agoraphobias [PhenX]
Being away from home alone    (Being
away from home alone   )
Being in a crowd or standing in line
(Being in a crowd or standing in line   )
Being in a public place like a department
store (Being in a public place like a
department store)
Traveling alone     (Traveling alone    )
Traveling in a bus, train, or car
(Traveling in a bus, train, or car    )
Do you have an unreasonably strong fear for or
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avoid this situation [PhenX]
Yes
No
How often do you get upset when you are in that
situation?
Every time (Every time)
Most of the time (Most of the time)
Never (Never)
Not asked (Not asked)
Only one or two times ever (Only one or
two times ever)
Refused (Refused)
Some of the time (Some of the time)
How long have you had any of these fears?
Between 1 and 5 years     (Between 1
and 5 years    )
Less than 1 year (Less than 1 year)
More than 5 years (More than 5 years)
How long have you had any of these fears?
mo
Were you ever afraid that you might faint, lose
control, or embarrass yourself in other ways?
No (No)
Not asked (Not asked)
Refused (Refused)
Yes (Yes)
Do you worry that you might be trapped without
any way to escape?
No (No)
Not asked (Not asked)
Refused (Refused)
Yes (Yes)
Do you worry that help might not be available if
you needed it?
No (No)
Not asked (Not asked)
Refused (Refused)
Yes (Yes)
How much have any of these fears ever interfered
with your life or activities?
A little (A little)
A lot (A lot)
Not asked (Not asked)
Not at all (Not at all)
Refused (Refused)
Some (Some)
About how many attacks have you had in your
life?
Did you ever have a spell or an attack when all of
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a sudden you felt frightened, anxious, or very
uneasy?
No (No)
Not asked (Not asked)
Refused (Refused)
Yes (Yes)
Did any of these attacks occur when you were
not in a life-threatening situation?
No (No)
Not asked (Not asked)
Refused (Refused)
Yes (Yes)
Did any of these attacks occur when you were in
a life-threatening situation?
No (No)
Not asked (Not asked)
Refused (Refused)
Yes (Yes)
How long ago did you have the most recent
attack?
mo
Did some of your attacks happen in a situation
when you were not in danger or not the center of
attention?
No (No)
Not asked (Not asked)
Refused (Refused)
Yes (Yes)
When you have sudden anxiety attacks, do they
usually occur in specific situations that cause you
unreasonably strong fear?
No (No)
Not asked (Not asked)
Refused (Refused)
Yes (Yes)
Did you ever have an attack when you were not in
a situation that usually causes you to have
unreasonably strong fears?
No (No)
Not asked (Not asked)
Refused (Refused)
Yes (Yes)
Things accompanying a panic attack [PhenX]
Hot flashes or chills (Hot flashes or
chills)
Sweat (Sweat)
Tightness, pain, or discomfort in your
chest or stomach  (Tightness, pain, or
discomfort in your chest or stomach )
Tremble or shake (Tremble or shake)
You, or things around you, seem unreal
(You, or things around you, seem unreal)
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When you have panic attacks do you experience
this thing [PhenX]
Yes
No
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Social Networks Protocol PhenX Toolkit
The Important and Health Matters Social Network Battery
is an interviewer-administered survey that captures the
names of all individuals within a respondent’s social
network and the relationship between these individuals.
The high-burden protocol is a semi-structured interview that
has both open-ended and close-ended questions. On
average, it takes 15-20 minutes to complete because
individuals usually provide 4-7 names.
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models.org/forms/15144
Social Networks Protocol PhenX
Toolkit
PhenX - social networks protocol
Name
Person
From which name generator was this person
mentioned?
Both (B )
Health     (H )
Important Matters     (I )
Person [PhenX]
Section name generator
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
7 (7)
8 (8)
Sex
Male (1)
Female (2)
Age
If yes, what is his/her relationship to you?
An acquaintance     (An acquaintance    )
Child     (Child    )
Client     (Client    )
Close friend (Close friend)
Co-worker, boss/superior, or subordinate
from a previous firm   (Co-worker,
boss/superior, or subordinate from a
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previous firm  )
Compatriot (Compatriot)
Current boss/superior (Current
boss/superior)
Current co-worker     (Current co-worker
)
Current neighbor    (Current neighbor   )
Current subordinate  (Current
subordinate )
Daughter-in-law (Daughter-in-law)
Else (Else)
Father-in-law/mother-in-law  (Father-in-
law/mother-in-law )
Indirect relationship (known via someone
else)   (Indirect relationship (known via
someone else)  )
Old neighbor (Old neighbor)
Ordinary friend     (Ordinary friend    )
Other relative  (Other relative )
Parent     (Parent    )
Person working for another firm, but
known through work relations (Person
working for another firm, but known
through work relations)
School/class mate     (School/class mate
)
Sibling     (Sibling    )
Someone from the same association,
club or group (Someone from the same
association, club or group)
Someone from the same religious group
(Someone from the same religious
group)
Someone know from the Internet
(Someone know from the Internet    )
Someone known because he/she
provides a service to me or my family
(Someone known because he/she
provides a service to me or my family    )
Son-in-law (Son-in-law)
Spouse (current or previous) (Spouse
(current or previous))
Student     (Student    )
Teacher     (Teacher    )
How close are you to this person?
Not very close (Not very close)
Sort of close (Sort of close)
Very close (Very close)
How often do you see or talk to the person?
Hardly ever (Hardly ever)
Occasionally (Occasionally)
Often (Often)
Do they trust doctors to take care of people's
problems?
A lot (A lot)
Don't know/not sure (Don't know/not
sure)
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Most of the time (Most of the time)
Not very much (Not very much)
Has this person done any of the following for you
or helped you out?
Give you suggestions when you have a
problem (Give you suggestions when
you have a problem)
Help out when you are short of money by
giving or loaning you money (Help out
when you are short of money by giving
or loaning you money)
Listen to you when you were feeling
down or upset (Listen to you when you
were feeling down or upset)
Tell you they care about what happens to
you (Tell you they care about what
happens to you)
Try to help you with daily chores (Try to
help you with daily chores)
Does this person hassle you, cause you
problems, or make your life difficult?
A lot (A lot)
No (No)
No, not really (No, not really)
Sometimes (Sometimes)
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Sudden Cardiac Arrest Protocol PhenX
Toolkit
This measure assesses if a patient died of sudden cardiac
arrest by reviewing symptoms prior to death, timing of
death, possible cardiac origin via autopsy evidence, and/or
demonstration of a history of cardiac disease via physician
questionnaire and medical records review.
ODM derived from: https://cde.nlm.nih.gov
Primary source: https://www.phenxtoolkit.org/
Recent publication: Hendershot, T., Pan, H., Haines, J.,
Harlan, W.R., Marazita, M.L., McCarty, C.A., Ramos, E.M.,
and Hamilton, C.M. (2015) Using the PhenX toolkit to add
standard measures to a study. Curr. Protoc. Hum. Genet.
86:1.21.1-1.21.17. doi: 10.1002/0471142905.hg0121s86
Permission to publish granted by
Carol M. Hamilton.
All rights reserved. Please visit https://medical-data-
models.org/forms/15145
Sudden Cardiac Arrest Protocol
PhenX Toolkit
PhenX - sudden cardiac arrest protocol
Are you familiar with the events surrounding the
decedent's death?
Yes
No
Did you witness the death?
Yes
No
Was there any pain in the chest, left arm or
shoulder or jaw within 72 hours of death?
No (No)
Uncertain (Uncertain)
Yes (Yes)
Did the pain include the chest?
No (No)
Uncertain (Uncertain)
Yes (Yes)
Did you think this pain was of a cardiac origin?
No (No)
Uncertain (Uncertain)
Yes (Yes)
Was cardiopulmonary resuscitation (CPR) and/or
cardioversion performed within 24 hours of
death?
No (No)
Uncertain (Uncertain)
Yes (Yes)
Please give time between onset of acute
symptoms to death.
At least 1 hour, but less than 4 hours
(At least 1 hour, but less than 4 hours   )
At least 12 hours, but less than 24 hours
(At least 12 hours, but less than 24 hours
)
At least 4 hours, but less than 12 hours
(At least 4 hours, but less than 12 hours
)
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Death instantaneous, no symptoms
(Death instantaneous, no symptoms )
Less than 1 hour (Less than 1 hour)
More than three days     (More than three
days    )
One day     (One day    )
Two - three days (Two - three days)
Unknown (Unknown)
Would you classify the decedent's cause of death
as due to Coronary Heart Disease (CHD)?
No (No)
Uncertain (Uncertain)
Yes (Yes)
Location of death
Emergency Room (not dead on arrival -
DOA)     (Emergency Room (not dead on
arrival - DOA)    )
In Hospital  (In Hospital )
Nursing Home, Skilled Nursing Facility
(SCTF), or Extended Care Facility (ECF)
(Nursing Home, Skilled Nursing Facility
(SCTF), or Extended Care Facility (ECF)
)
Other, specify (Other, specify)
Out-of-Hospital   (Out-of-Hospital  )
Was the death witnessed?
Yes
No
Multi-Ethnic Study of Atherosclerosis (MESA)
classification of underlying cause of death
Atherosclerotic coronary heart disease
(complete questions 10, 11 and 12 only)
(Atherosclerotic coronary heart disease
(complete questions 10, 11 and 12 only)
)
Atherosclerotic disease other than
coronary disease or stroke (specify)
(complete question 12 only)
(Atherosclerotic disease other than
coronary disease or stroke (specify)
(complete question 12 only)   )
Non-cardiovascular disease (specify)
(skip to end)    (Non-cardiovascular
disease (specify) (skip to end)   )
Other cardiovascular disease, not
defined above (specify) (complete
question 12 only)     (Other
cardiovascular disease, not defined
above (specify) (complete question 12
only)    )
Stroke (skip to end)    (Stroke (skip to
end)   )
Unknown because death certificate
unavailable (skip to end) (Unknown
because death certificate unavailable
(skip to end))
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Type of fatal coronary heart disease
Definite fatal coronary heart disease
(CHD) (no known non-atherosclerotic
cause, and one or both of the following:
chest pain within 72 hours of death or a
history of chronic ischemic heart
disease)  (Definite fatal coronary heart
disease (CHD) (no known non-
atherosclerotic cause, and one or both of
the following: chest pain within 72 hours
of death or a history of chronic ischemic
heart disease) )
Definite fatal myocardial infaction (MI)
(no known non-artherosclerotic cause
and definite myocardial infarction within 4
weeks of death)   (Definite fatal
myocardial infaction (MI) (no known non-
artherosclerotic cause and definite
myocardial infarction within 4 weeks of
death)  )
Possible fatal coronary heart disease
(CHD) (no known non-atherosclerotic
cause, and death certificate underlying
cause: 120-25, 146, 151.6, R96 or R98-
99) (Possible fatal coronary heart
disease (CHD) (no known non-
atherosclerotic cause, and death
certificate underlying cause: 120-25,
146, 151.6, R96 or R98-99))
Estimated time between onset of acute cardiac
symptoms and death
five minutes to one hour  (five minutes to
one hour )
Less than five minutes     (Less than five
minutes    )
more than 24 hours     (more than 24
hours    )
one hour to 24 hours  (one hour to 24
hours )
Unknown (Unknown)
Mechanism of death in patient's dying of
cardiovascular causes
Cardiac procedure such as coronary
artery bypass graft (CABG) or
angioplasty   (Cardiac procedure such as
coronary artery bypass graft (CABG) or
angioplasty  )
Congestive heart failure (CHF)
(Congestive heart failure (CHF))
Hemorrhage from thrombolytic therapy
(Hemorrhage from thrombolytic therapy
)
Other (specify)   (Other (specify)  )
Primary arrhythmic death  (Primary
arrhythmic death )
Secondary arrhythmic/mechanical death
(Secondary arrhythmic/mechanical
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death)
Unknown or uncertain (Unknown or
uncertain)
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Eligibility End-stage Renal Disease
NCT02259413
Effect of an Exercise Rehabilitation Program in Patients
Starting Hemodialysis; ODM derived from:
https://clinicaltrials.gov/show/NCT02259413
All rights reserved. Please visit https://medical-data-
models.org/forms/15146
Eligibility End-stage Renal Disease
NCT02259413
Inclusion Criteria
within 4 weeks of commencing chronic
hemodialysis and not expected to recover renal
function*
Yes
No
no planned change in hemodialysis modality or
relocation outside of winnipeg during study period
(52 weeks)*
Yes
No
ability to communicate in english and provide
informed written consent*
Yes
No
Exclusion Criteria
hemoglobin < 95 g/l*
Yes
No
crescendo or unstable angina*
Yes
No
unstable arrhythmia*
Yes
No
using home oxygen*
Yes
No
shortness of breath at rest or with minimal activity
(nyha class 4)*
Yes
No
planned elective surgery during the study period
other than hemodialysis access creation or
repair*
Yes
No
severe musculoskeletal injury or pain which
would preclude participation in exercise classes
or cycling during hd*
Yes
No
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unstable hd sessions with frequent hypotension
or hd access issues (fistula blows/infiltration*
Yes
No
poor catheter function with frequent alarms with
change of position)*
Yes
No
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Eligibility End-stage Renal Disease
NCT02361268
End-Stage Renal Disease Intra-dialysis Lifestyle Education
Study; ODM derived from:
https://clinicaltrials.gov/show/NCT02361268
All rights reserved. Please visit https://medical-data-
models.org/forms/15148
Eligibility End-stage Renal Disease
NCT02361268
Inclusion Criteria
maintenance hemodialysis for ≥3 or months*
Yes
No
adequately dialyzed (kt/v ≥1.2 measured within
last 3 months)*
Yes
No
expected to remain in present hemodialysis shift
for next 4 months*
Yes
No
expected to remain on hemodialysis for at least 6
months*
Yes
No
18 years or older*
Yes
No
Exclusion Criteria
acute or chronic medical conditions that would
make intra-dialysis yoga potentially hazardous*
Yes
No
unstable cardiac disease e.g. angina, life
threatening arrhythmia*
Yes
No
chronic lung disease that prevents gentle
exercise or deep breathing exercises*
Yes
No
active cerebrovascular disease*
Yes
No
major depression*
Yes
No
chronic symptoms of nausea, vomiting, or
diarrhea*
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Yes
No
current participation in exercise or mind body
program/practice*
Yes
No
cognitive impairment (mme ≤ 24) measured at
baseline testing visit*
Yes
No
2 / 2
Eligibility End-stage Renal Disease NCT02361268
Colorectal Procedures and Outcomes (Medical
Record Review) Protocol PhenX Toolkit
This measure uses existing medical records to obtain
information about colorectal exams and procedures.
ODM derived from: https://cde.nlm.nih.gov
Primary source: https://www.phenxtoolkit.org/
Recent publication: Hendershot, T., Pan, H., Haines, J.,
Harlan, W.R., Marazita, M.L., McCarty, C.A., Ramos, E.M.,
and Hamilton, C.M. (2015) Using the PhenX toolkit to add
standard measures to a study. Curr. Protoc. Hum. Genet.
86:1.21.1-1.21.17. doi: 10.1002/0471142905.hg0121s86
Permission to publish granted by
Carol M. Hamilton.
All rights reserved. Please visit https://medical-data-
models.org/forms/15149
Colorectal Procedures and
Outcomes (Medical Record Review)
Protocol PhenX Toolkit
PhenX - colorectal procedures and
outcomes protocol
Date Abstracted
Abstractor ID Number
Nosologist ID Number
CTR ID Number
Study Year
Purpose of Abstract
Initial abstract   (Initial abstract  )
Re-abstract for QA (Re-abstract for QA)
Multiple Primary Cancer Number
Form Receipted into SMS
Yes
No
Manual Review Completed
Yes
No
Data Entry of Non-Scannable Items
Completed     (Completed    )
None required (None required)
Data Retrieval
Attempted   (Attempted  )
None required (None required)
Disposition
Final complete (FCM)   (Final complete
(FCM)  )
Final incomplete (FIG) (Final incomplete
(FIG))
Interim complete (ICM)     (Interim
complete (ICM)    )
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Diagnostic Procedures Performed
No, participant self-report (No,
participant self-report)
No, physician report    (No, physician
report   )
Yes (Yes)
Reason for initial visit for clinical assessment
Follow-up of positive PLCO screen
(Follow-up of positive PLCO screen)
Other (Other)
Symptomatic     (Symptomatic    )
Specify Other Reason for Initial Visit for Clinical
Assessment
Sigmoidoscopy or Colonoscopy
No (No)
Unknown (Unknown)
Yes (Yes)
Date of trauma or procedure
Cecum visualization
No (No)
Not available (Not available)
Yes (Yes)
Bowel preparation
Adequate  (Adequate )
Inadequate    (Inadequate   )
Not available (Not available)
Hyperplastic polyps
Multiple (Multiple)
None (None)
One (One)
Procedure type
Colonoscopy     (Colonoscopy    )
Endoscopy, NOS (Endoscopy, NOS)
Sigmoidoscopy     (Sigmoidoscopy    )
Adenomas on Sigmoidoscopy or Colonoscopy
No (No)
Not available (Not available)
Yes (Yes)
Multiple polyps in specimen jar
Yes
No
Procedure
Colonoscopy     (Colonoscopy    )
Endoscopy, NOS (Endoscopy, NOS)
Sigmoidoscopy   (Sigmoidoscopy  )
Location of polyps [PhenX]
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Appendix     (Appendix    )
Ascending colon  (Ascending colon )
Cecum     (Cecum    )
Descending colon  (Descending colon )
Hepatic flexure     (Hepatic flexure    )
Not available (Not available)
Rectum     (Rectum    )
Sigmoid colon    (Sigmoid colon   )
Splenic flexure   (Splenic flexure  )
Transverse colon  (Transverse colon )
LOCATION - Distance in cm
cm
SIZE - Longest dimension in cm
cm
SIZE - Description
Diminutive     (Diminutive    )
Large (Large)
Not available (Not available)
Small (Small)
Histology
Adenoma (NOS) (Adenoma (NOS))
Tubular adenoma   (Tubular adenoma  )
Tubular villous adenoma (Tubular villous
adenoma)
Villous adenoma (Villous adenoma)
Dysplasia
Mild (low grade)  (Mild (low grade) )
Moderate (low grade)  (Moderate (low
grade) )
None   (None  )
Not available (Not available)
Severe (high grade)   (Severe (high
grade)  )
Number of Non-advanced adenomas
Number of Advanced adenomas
Can exact number of adenomas be determined?
Yes
No
Other Diagnostic/Staging Procedures
No (No)
Unknown (Unknown)
Yes (Yes)
Type of procedure
Abdominal flat plate (plain film)
(Abdominal flat plate (plain film) )
Abdominal ultrasound  (Abdominal
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ultrasound )
Barium enema radiograph    (Barium
enema radiograph   )
Biopsy (Biopsy)
Chest radiograph     (Chest radiograph
)
Clinical evaluation (Clinical evaluation)
CT scan - abdomen and pelvis combined
(CT scan - abdomen and pelvis
combined )
CT scan - abdominal  (CT scan -
abdominal )
CT scan - other     (CT scan - other    )
CT scan - pelvic (CT scan - pelvic)
Cystoscopy (Cystoscopy)
DRE (DRE)
Hemicolectomy (Hemicolectomy)
Intravenous pyelography (IVP)/excretory
urography (Intravenous pyelography
(IVP)/excretory urography)
Laparoscopy (Laparoscopy)
Laparotomy (Laparotomy)
Lymphadenectomy/Lymph node
sampling (Lymphadenectomy/Lymph
node sampling)
MRI scan - abdominal     (MRI scan -
abdominal    )
MRI scan - other     (MRI scan - other    )
MRI scan - pelvic     (MRI scan - pelvic
)
Other (Other)
Other radiograph  (Other radiograph )
PreoperatIve carcinoembryonic antigen
(CEA)   (PreoperatIve carcinoembryonic
antigen (CEA)  )
Record review (Record review)
Resection (Resection)
Stool occult blood   (Stool occult blood  )
Ultrasound (Ultrasound)
Upper GI evaluation –
endoscopic/radiographic (Upper GI
evaluation – endoscopic/radiographic)
Other biopsy [PhenX]
Other CT scan [PhenX]
Other MRI scan [PhenX]
Other resection [PhenX]
Other radiograph [PhenX]
Other ultrasound [PhenX]
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Type of procedure - specify
Diagnostic/Staging procedures supplement form
completed
Yes
No
Medical Complications of Diagnostic Evaluation
and Staging
No (No)
Unknown (Unknown)
Yes (Yes)
Type of complication
Acute/chronic respiratory failure
(Acute/chronic respiratory failure )
Blood In stool (Blood In stool)
Blood loss requiring transfusion  (Blood
loss requiring transfusion )
Cardiac arrest  (Cardiac arrest )
Cardiac arrhythmia (Cardiac arrhythmia)
Cerebral vascular accident (CVA)/Stroke
(Cerebral vascular accident (CVA)/Stroke
)
Congestive heart failure (CHF)
(Congestive heart failure (CHF))
Deep vein thrombosis (Deep vein
thrombosis)
Diarrhea (Diarrhea)
Fever requiring antibiotics  (Fever
requiring antibiotics )
Hemorrhage (Hemorrhage)
Hospitalization (Hospitalization)
Hypokalemia (Hypokalemia)
Hypotension (Hypotension)
Ileus (Ileus)
Infection (Infection)
Myocardial infarction    (Myocardial
infarction   )
Perforation (Perforation)
Pulmonary embolus/emboli  (Pulmonary
embolus/emboli )
Rectal damage (Rectal damage)
Respiratory arrest  (Respiratory arrest )
Small bowel obstruction/partial or
complete (Small bowel
obstruction/partial or complete)
Stroke (CVA) or TIA (Stroke (CVA) or
TIA)
Wound dehiscence  (Wound dehiscence
)
Type of complication - infection - specify
Date of complication
Result of Diagnostic Evaluation for Colorectal
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Cancer
Colorectal malignancy confirmed
cytologically   (Colorectal malignancy
confirmed cytologically  )
Colorectal malignancy confirmed
histologically (exclude carcinoma in situ)
(Colorectal malignancy confirmed
histologically (exclude carcinoma in situ)
)
Colorectal malignancy diagnosed by
clinical examination only  (Colorectal
malignancy diagnosed by clinical
examination only )
No information available (No information
available)
No malignancy    (No malignancy   )
No malignancy and no diagnostic/staging
procedures performed     (No malignancy
and no diagnostic/staging procedures
performed    )
Other malignancy confirmed
histologicaly or cytologically    (Other
malignancy confirmed histologicaly or
cytologically   )
Other Cancer Diagnosis
Yes
No
Diagnosis ICD code
Description of Colorectal Carcinoma
Procedure for primary diagnosis of colorectal
carcinoma [PhenX]
Colonoscopy (Colonoscopy)
Endoscopy (Endoscopy)
Local transanal or other resection (Local
transanal or other resection)
Polypectomy (Polypectomy)
Sigmoidoscopy (Sigmoidoscopy)
Surgical resection  (Surgical resection )
Gross morphology
Annular (Annular)
Diffusely infiltrative  (Diffusely infiltrative )
Endophytic (Endophytic)
Exophytic (Exophytic)
Not available (Not available)
Date first Dx Cancer
Verbatim Description of Primary Colorectal
Cancer Diagnosis
ICD-O-2 Cancer Classification: Topography
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ICD-O-2 Cancer Classification: Morphology
ICD-O-2 Cancer Classification: Behavior
1 (1)
3 (2)
9 (3)
ICD-O-2 Cancer Classification: Grade
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
7 (7)
9 (8)
Photocopy of Report Confirming Primary
Colorectal Cancer
Cytology/Cytopathology (ATTACH
COPY) (Cytology/Cytopathology
(ATTACH COPY))
Not available (Not available)
Pathology/Histopathology (ATTACH
COPY)    (Pathology/Histopathology
(ATTACH COPY)   )
Histopathologic Type for Primary Colorectal
Cancer
Adenocarcinoma (Adenocarcinoma)
Adenosquamous carcinoma
(Adenosquamous carcinoma )
Carcinoma (Carcinoma)
Mucinous (colloid) adenocarcinoma
(Mucinous (colloid) adenocarcinoma    )
Other (Other)
Signet ring cell carcinoma (Signet ring
cell carcinoma)
Squamous cell (epidermoid) carcinoma
(Squamous cell (epidermoid) carcinoma)
Undifferentiated carcinoma
(Undifferentiated carcinoma  )
Unknown (Unknown)
Specify Other Histopathologic Type for Primary
Colorectal Cancer
Histopathologic Grade for Primary Colorectal
Cancer
Grade cannot be assessed (GX) (Grade
cannot be assessed (GX))
Moderately differentiated (G2)
(Moderately differentiated (G2) )
Poorly differentiated (G3) (Poorly
differentiated (G3))
Undifferentiated (G4)   (Undifferentiated
(G4)  )
Unknown (Unknown)
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Well differentiated (G1) (Well
differentiated (G1))
If TNM Staging performed, what AJCC Cancer
Staging Manual did you use?
4th edition    (4th edition   )
5th edition (5th edition)
TNM Clinical Staging
Yes
No
TNM Clinical Staging: PRIMARY TUMOR (T)
Not available (Not available)
T0 (T0)
T1 (T1)
T2 (T2)
T3 (T3)
T4 (T4)
TX (TX)
TNM Clinical Staging: NODAL INVOLVEMENT
(N)
N0 (N0)
N1 (N1)
N2 (N2)
N3 (N3)
Not available (Not available)
NX (NX)
TNM Clinical Staging: DISTANT METASTASES
(M)
M0 (M0)
M1 (M1)
MX (MX)
Not available (Not available)
TNM Pathologic Staging
Yes
No
TNM Pathologic Staging: PRIMARY TUMOR (T)
Not available (Not available)
T0 (T0)
T1 (T1)
T2 (T2)
T3 (T3)
T4 (T4)
TX (TX)
TNM Pathologic Staging: NODAL INVOLVEMENT
(N)
N0 (N0)
N1 (N1)
N2 (N2)
N3 (N3)
Not available (Not available)
NX (NX)
TNM Pathologic Staging: DISTANT
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METASTASES (M)
M0 (M0)
M1 (M1)
MX (MX)
Not available (Not available)
Record Stage
Yes
No
Stage only
I (I)
II (II)
III (III)
IV (IV)
Dukes
A (A)
B (B)
C (C)
Not available (Not available)
Modified Dukes (Astler-Coller)
A (A)
B1 (B1)
B2 (B2)
C1 (C1)
C2 (C2)
D (D)
Not available (Not available)
Summary staging
Distant (Distant)
Localized (Localized)
Not available (Not available)
Regional (Regional)
Date of diagnosis?
Have you been diagnosed with Crohn's disease
or another inflammatory bowel disorder?
Explanation: (diagnosis if known, date of
diagnosis, doctor who made the diagnosis)
Address Facility
Phone number
Medical record number
Hospitalized at
Service comment
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Eligibility Erosive Hand Osteoarthritis
NCT02370771
Proteomic Analysis in Sera From Patients With Erosive
Hand Osteoarthritis; ODM derived from:
https://clinicaltrials.gov/show/NCT02370771
All rights reserved. Please visit https://medical-data-
models.org/forms/15151
Eligibility Erosive Hand Osteoarthritis
NCT02370771
Inclusion Criteria
female gender*
Yes
No
less than 70 years old*
Yes
No
diagnosis of hand osteoarthritis according to acr
criteria acr after exclusion of thumb base
osteoarthritis:*
Yes
No
1. hand pain, aching or stiffness most of the days
during the preceding month*
Yes
No
2. hard tissue enlargement of at least two of 8
selected joints **
Yes
No
3. hard tissue enlargement of at least two distal
interphalangeal joint*
Yes
No
4. swelling of fewer than three
metacarpophalangeal joint*
Yes
No
5. deformity of at least one of 10 selected joints *
patients have to fulfil criteria 1, 2 and 3 + 4 or 5 *
the 8 selected joints are the second and third
distal interphalangeal joint and the second and
third proximal interphalangeal of both hands then
confirm by experts' committee*
Yes
No
exclusively symptomatic treatment*
Yes
No
for women of child-bearing age, use of an
effective contraceptive method*
Yes
No
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french spoken and read*
Yes
No
Exclusion Criteria
male gender*
Yes
No
more than 70 years old*
Yes
No
hemochromatosis*
Yes
No
inflammatory arthritis*
Yes
No
cristal induced arthritis*
Yes
No
active diseases such as infection or cancer*
Yes
No
use of dmards*
Yes
No
pregnant or breast-feeding woman*
Yes
No
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Eligibility Esophageal Squamous Cell
Carcinoma NCT02325986
Concurrent Radiotherapy and Weekly Chemotherapy of PF
for Postoperative Locoregional Recurrence of Esophageal
Cancer; ODM derived from:
https://clinicaltrials.gov/show/NCT02325986
All rights reserved. Please visit https://medical-data-
models.org/forms/15152
Eligibility Esophageal Squamous
Cell Carcinoma NCT02325986
Inclusion Criteria
1. r0 resection for primary esophageal squamous
cell carcinoma with two-incision esophagectomy
(ivor lewis approach)25 or three-incision (right
thoracotomy, midline laparotomy and left cervical
incisions) esophagectomy with cervical
esophagogastric anastomosis.*
Yes
No
2. absence of previous thoracic radiotherapy.*
Yes
No
3. cervical and/or thoracic postoperative
recurrence (biopsy proven or positron emission
tomography/computed tomography (pet/ct)
proven or follow-up computed tomography (ct)
showed progression of disease).*
Yes
No
4. absence of distant metastasis at recurrence.*
Yes
No
5. eastern cooperative oncology group (ecog)
performance status (ps) ≤ 2*
Yes
No
Exclusion Criteria
1. younger than 18 or older than 70 years of
age.*
Yes
No
2. eastern cooperative oncology group (ecog)
performance status of 3 or above*
Yes
No
3. other cancer history.*
Yes
No
4. serious cardiac, liver, or pulmonary disease.*
Yes
No
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5. previous radiotherapy history*
Yes
No
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Eligibility Essential Hypertension
NCT02214498
Treatment of HYpertension: Morning Versus Evening; ODM
derived from: https://clinicaltrials.gov/show/NCT02214498
All rights reserved. Please visit https://medical-data-
models.org/forms/15153
Eligibility Essential Hypertension
NCT02214498
Inclusion Criteria
essential hypertension*
Yes
No
stable blood pressure on treatment with
angiotensin converting enzyme inhibitor (acei) or
angiotensin ii receptor blocker (arb) and
hydrochlorothiazide*
Yes
No
age between 18 and 85 years*
Yes
No
who performance status 0-1*
Yes
No
available for a time period of 15 weeks*
Yes
No
written informed consent*
Yes
No
dippers: nocturnal blood pressure fall of 10-20%
of daytime values.20*
Yes
No
non-dippers: -nocturnal blood pressure fall of
<10% of daytime values*
Yes
No
Exclusion Criteria
secondary cause of hypertension*
Yes
No
use of arb because of intolerability (e.g. dry
cough) of acei*
Yes
No
nocturnal blood pressure fall of >20% or rise*
Yes
No
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renal insufficiency (gfr<60 ml/min)*
Yes
No
shift work*
Yes
No
pregnancy or wish to get pregnant*
Yes
No
use of other antihypertensive medication than
acei, arb, hydrochlorothiazide or a calcium
channel blocker*
Yes
No
use of sleeping medication*
Yes
No
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Skin condition, urological & gynaecological anamnesis, sleep,
Social Environment Nursing Documentation UK Erlangen
Routine documentation: Social Environment Nursing
Documentation UK Erlangen
Skin condition, urological & gynaecological anamnesis,
sleep
All rights reserved. Please visit https://medical-data-
models.org/forms/15154
Skin condition, urological &
gynaecological anamnesis, sleep,
Social Environment Nursing
Documentation UK Erlangen
Default Itemgroup
Skin disease
Yes
No
Pressure ulcer
One or more (1)
No decubitus (2)
No detection possible (3)
Braden scale: Mobility
<= 4
>= 1
Braden scale: Activity
<= 4
>= 1
Braden scale: Shear force and friction
<= 3
>= 1
Braden scale: Sensorial perception
<= 4
>= 1
Braden scale: Nutrition
<= 4
>= 1
Braden scale: Moisture
<= 4
>= 1
Braden scale: Total score
<= 23
>= 6
Defecation
Impaired defecation
Yes
No
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Fecal incontinence
Yes
No
Micturition
Impaired micturition
Yes
No
Urinary incontinence
Yes
No
Gynaecological status
Last menstrual period (start date)
Last menstrual period (end date)
Amenorrhea
Yes
No
Pregnancy
Yes
No
Rest/sleep
Sleeping habits
Yes
No
Sleep disorders
Yes
No
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Skin condition, urological & gynaecological anamnesis, sleep, Social
Environment Nursing Documentation UK Erlangen
Eligibility Estrogen Receptor Positive Breast
Cancer NCT02238808
A Study to See Whether Estrogen Can Slow the Growth of
Some ER Positive Breast Cancers; ODM derived from:
https://clinicaltrials.gov/show/NCT02238808
All rights reserved. Please visit https://medical-data-
models.org/forms/15155
Eligibility Estrogen Receptor Positive
Breast Cancer NCT02238808
Inclusion Criteria
female gender*
Yes
No
estrogen receptor positive (er+) breast cancer*
Yes
No
her2 negative breast cancer*
Yes
No
post-menopausal by greater than 5 years*
Yes
No
no previous hormonal replacement therapy*
Yes
No
low to intermediate histologic grade*
Yes
No
ecog performance status of 0 of 1*
Yes
No
adequate hematological, renal and hepatic
function is required*
Yes
No
ability to take oral medication*
Yes
No
patient must have adequate tissue for diagnosis,
biomarkers and ki67 assays*
Yes
No
Exclusion Criteria
pre-menopausal women*
Yes
No
locally advanced or metastatic breast cancer*
Yes
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No
current, previous or planning for pre-operative
treatment with chemotherapy, hormone therapy
including corticosteroids, radiation therapy for
malignancy or other condition*
Yes
No
known hypersensitivity or intolerance to estradiol*
Yes
No
ischemic changes on baseline electrocardiogram*
Yes
No
symptomatic but untreated cholelithiasis*
Yes
No
history of deep vein thrombosis, pulmonary
embolism, stroke, acute myocardial infarction,
congestive cardiac failure, untreated
hypertension or known inherited hypercoagulable
disorder*
Yes
No
undiagnosed abnormal vaginal bleeding or prior
history of endometrial cancer*
Yes
No
untreated metabolic disturbances (glucose > 11.0
mmol/l and triglycerides > 400 mg/dl)*
Yes
No
current treatment with drugs known to be
moderate or strong inhibitors of inducers of
isoenzyme cyp3a4*
Yes
No
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Eligibility Fallopian Tube Carcinoma
NCT02315469
Comprehensive Patient Questionnaires in Predicting
Complications in Older Patients With Gynecologic Cancer
Undergoing Surgery; ODM derived from:
https://clinicaltrials.gov/show/NCT02315469
All rights reserved. Please visit https://medical-data-
models.org/forms/15156
Eligibility Fallopian Tube Carcinoma
NCT02315469
Inclusion Criteria
patients with suspected ovarian, fallopian tube,
primary peritoneal carcinomas or advanced stage
papillary serous uterine carcinoma irrespective of
performance status; this clinical determination is
made by the treating physician*
Yes
No
patients must have signed an approved informed
consent and authorization permitting release of
personal health information*
Yes
No
patients who can understand sufficiently to be
able to respond to questions posed by the study
instruments*
Yes
No
patients and/or caregiver (durable power of
attorney) can give consent and caregiver can
assist with the responses to questionnaire*
Yes
No
note: it is the intent of this trial that all patients 70
years or older presenting to the participating
physician/center be offered enrollment onto this
study; eligible patients may enroll and
subsequently receive neoadjuvant chemotherapy
followed by interval surgery, primary
cytoreductive surgery or no surgery at all*
Yes
No
post-operative pathology will not exclude patients
from this study*
Yes
No
Exclusion Criteria
patients whose circumstances at the time of
study entry do not permit completion of the study
or required follow-up*
Yes
No
patients who would have planned surgery
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performed by the minimally invasive technique;
institutions which perform cytoreductive surgery
via the minimally invasive technique should not
participate in this study; the minimally invasive
surgery (mis) technique is also not considered
standard technique for primary cytoreductive
surgery for advanced stage ovarian, fallopian
tube or peritoneal cancers*
Yes
No
patients who receive chemotherapy treatment (for
a gynecologic malignancy) prior to consideration
of enrollment into this trial and taking the geriatric
assessment will be excluded*
Yes
No
patients who have a known pre-operative primary
uterine cancer, confirmed by endometrial biopsy*
Yes
No
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Eligibility Gastro-entero-pancreatic
Carcinoma NCT02409849
Octreotide LAR as Maintenance Treatment for Patients
With NEC; ODM derived from:
https://clinicaltrials.gov/show/NCT02409849
All rights reserved. Please visit https://medical-data-
models.org/forms/15162
Eligibility Gastro-entero-pancreatic
Carcinoma NCT02409849
Inclusion Criteria
1. histologic diagnosis of high grade (poorly
differentiated) gastro-entero-pancreatic
neuroendocrine carcinoma.*
Yes
No
2. high grade neuroendocrine carcinoma of
esophageal or unknown primary site (if a
pulmonary primary has been excluded)*
Yes
No
3. metastatic or unresectable disease*
Yes
No
4. measurable disease*
Yes
No
5. accepted chemotherapy with ep or ip regimen
for no less than three months*
Yes
No
6. effectiveness with cr/pr/sd*
Yes
No
7. informed consent*
Yes
No
8. performance status of 0 or 1*
Yes
No
9. adequate bone marrow function (defined as
absolute neutrophil count [anc] >= 1500, platelet
count [plt] >= 75,000 and a hemoglobin [hgb] >=
9).*
Yes
No
10. adequate hepatic function with a bilirubin of
<= 2.0 mg/dl, and aspartate aminotransferase
(ast or sgot) and alanine aminotransferase (alt or
sgpt) <= 2.5 times the upper limits of normal,
unless caused by liver metastasis. if caused by
metastasis, then should be sgpt and sgot <= 5
times the upper limits of normal.*
Yes
1 / 3
No
adequate renal function defined as serum
creatinine <= 1.5 mg/dl.*
Yes
No
Exclusion Criteria
1. patients who are on ep or ip chemotherapy for
less than three months .*
Yes
No
2. effectiveness with pd.*
Yes
No
3. patients with brain metastases are not eligible.*
Yes
No
4. patients with new york heart association (nyha)
class iii or iv heart disease are not eligible as well
as those patients with history of angina,
myocardial infarction, or congestive heart failure
within six months.*
Yes
No
5. pregnant or lactating women. all women of
child bearing potential must have a negative
pregnancy test prior to entry into the study. all
patients of child bearing potential must be
advised of the importance of avoiding pregnancy
and using appropriate methods of contraception
while participating in this investigational trial.*
Yes
No
6. patients with serious complicated infections, or
nonmalignant medical illnesses that are
uncontrolled or whose control may be
jeopardized by the complications of this therapy.*
Yes
No
7. patients with psychiatric disorders rendering
them incapable of complying with the
requirements of the protocol.*
Yes
No
8. patients with serum calcium > 12 mg/dl or
symptomatic hypercalcemia under treatment.*
Yes
No
9. patients with osseous metastasis as only site
of disease.*
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Yes
No
10. patients with any concurrent active
malignancy other than non-melanoma skin
cancers or carcinoma-in-situ of the cervix.
patients with previous malignancies but without
evidence of disease for > 5 years will be allowed
to enter the trial.*
Yes
No
11. patients with known gilbert's syndrome are
ineligible.*
Yes
No
3 / 3
Eligibility Gastro-entero-pancreatic Carcinoma NCT02409849
Eligibility Early Stage Breast Cancer
NCT02364960
Targeted Intraoperative Therapy Registry at Bethesda
North Hospital (TARGIT); ODM derived from:
https://clinicaltrials.gov/show/NCT02364960
All rights reserved. Please visit https://medical-data-
models.org/forms/15163
Eligibility Early Stage Breast Cancer
NCT02364960
Inclusion Criteria
female*
Yes
No
age 45 or greater*
Yes
No
diagnosed with operable invasive breast cancer,
t1 and t2 (< 3.5 cm), n0, m0, confirmed by
cytological or histological examination*
Yes
No
suited for breast conserving surgery*
Yes
No
have had an ipsilateral (same side as current
cancer) diagnostic mammogram within 12
months of enrollment*
Yes
No
Exclusion Criteria
age 44 or less*
Yes
No
axillary lymph node positive breast cancer*
Yes
No
invasive lobular cancer*
Yes
No
tumor size > 3.5 cm*
Yes
No
extensive intraductal component (eic= > 25% of
the lumpectomy specimen involved with ductal
carcinoma in situ, dcis) as assessed on surgical
pathologic lumpectomy specimen*
Yes
No
multicentric cancer in the same breast not
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amenable to excision with a single lumpectomy*
Yes
No
inability to assess pathologic margin status*
Yes
No
synchronous bilateral breast cancer at the time of
diagnosis.*
Yes
No
ipsilateral breast had a previous cancer and/or
prior in-field radiation.*
Yes
No
patients known to have brca1/2 gene mutations*
Yes
No
neoadjuvant treatment (hormones or
chemotherapy)*
Yes
No
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Eligibility Gestational Diabetes Mellitus
NCT02368600
Lifestyle Intervention and Prevention of Gestational
Diabetes Mellitus; ODM derived from:
https://clinicaltrials.gov/show/NCT02368600
All rights reserved. Please visit https://medical-data-
models.org/forms/15164
Eligibility Gestational Diabetes
Mellitus NCT02368600
Inclusion Criteria
chinese origin*
Yes
No
reside normally in hong kong*
Yes
No
singleton pregnancy*
Yes
No
gestational age <= 12 weeks at the time of
recruitment*
Yes
No
could speak and understand chinese*
Yes
No
fulfill at least one of the following criteria for high
risk of gdm at the time of recruitment based on
the update hospital protocol implemented since
1st may 2014*
Yes
No
maternal age >= 35 years old at expected date of
confinement.*
Yes
No
prior history of gdm or birth of child >= 4 kg*
Yes
No
pre-pregnant bmi or bmi at 1st trimester >= 25
kg/m2*
Yes
No
family history of diabetes at 1st degree relatives*
Yes
No
willing to give informed written consent and follow
the study procedures*
Yes
No
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Exclusion Criteria
concurrent participation in any clinical trial or
study*
Yes
No
with renal, liver or thyroid dysfunction, cognitive
impairment, or any other indication of a major
medical or psychological illness, as judged by the
investigators as ineligible to participate the study*
Yes
No
multiple pregnancies*
Yes
No
pre-existing dm*
Yes
No
with physical restriction that prevents from
exercising*
Yes
No
substance abuse*
Yes
No
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Eligibility Head and Neck Squamous Cell
Carcinoma NCT02365662
A Study Evaluating Safety and Pharmacokinetics of ABBV-
221 in Subjects With Advanced Solid Tumor Types Likely to
Exhibit Elevated Levels of Epidermal Growth Factor
Receptor; ODM derived from:
https://clinicaltrials.gov/show/NCT02365662
All rights reserved. Please visit https://medical-data-
models.org/forms/15170
Eligibility Head and Neck Squamous
Cell Carcinoma NCT02365662
Inclusion Criteria
eastern cooperative oncology group (ecog)
performance status 0 or 2.*
Yes
No
has a solid tumor likely to exhibit elevated levels
of egfr (e.g. head and neck squamous cell
carcinoma, non-small cell lung cancer, triple
negative breast cancer*
Yes
No
,colorectal carcinoma and glioblastoma
multiforme).*
Yes
No
has an archived, diagnostic tumor tissue available
for analysis.*
Yes
No
has adequate hematologic, renal, cardiac and
hepatic function.*
Yes
No
expanded safety cohort participants must have
confirmed metastatic lung cancer and progressed
after receiving prior platinum-containing
chemotherapy.*
Yes
No
Exclusion Criteria
previously received an egfr-directed monoclonal
antibody within the past 4 weeks.*
Yes
No
has unresolved, clinically significant toxicities
from prior anti-cancer therapy defined as > grade
1 on common terminology criteria for adverse
events.*
Yes
No
history of major immunologic reaction to any igg
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containing agent.*
Yes
No
any medical condition which in the opinion of the
investigator places the participant at an
unacceptably high risk for toxicities.*
Yes
No
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Eligibility Healthy NCT02343471
The Effect of Whey Protein Consumed as a Pre-meal on
Postprandial Lipemia in Healthy and Subjects With Type 2
Diabetes; ODM derived from:
https://clinicaltrials.gov/show/NCT02343471
All rights reserved. Please visit https://medical-data-
models.org/forms/15171
Eligibility Healthy NCT02343471
Criteria
weight stable for the last three month.*
Yes
No
bmi<40*
Yes
No
inclusion criteria for subjects with type 2
diabetes:*
Yes
No
diagnosed type 2 diabetes (hba1c > 48 mmol/l)*
Yes
No
stable dose of metformin, sulfonylurea (su),
insulin and sglt inhibitors are accepted.*
Yes
No
exclusion criteria - general:*
Yes
No
type 1 diabetes*
Yes
No
type 2 diabetes (hba1c ≥ 48 mmol/l)*
Yes
No
fasting plasma triglycerides > 5.0 mmol/l*
Yes
No
blood pressure > 160/100 mmhg*
Yes
No
cardiovascular, liver, kidney or metabolic disease*
Yes
No
corticosteroid treatment*
Yes
No
pregnancy or lactation*
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Yes
No
alcohol or drug abuse*
Yes
No
legal incapacity*
Yes
No
exclusion criteria for subjects with type 2
diabetes:*
Yes
No
treatment with dpp-4 inhibitors, glp-1 agonists
and basal bolus insulin.*
Yes
No
fasting blood glucose ≥ 14 mmol/l.*
Yes
No
exclusion criteria for healthy subjects:*
Yes
No
prediabetes, defined from the who criteria (igf ≥
6.1 mmol/l).*
Yes
No
2 / 2
Eligibility Healthy NCT02343471
Eligibility Healthy Volunteers NCT02323217
I2PETHV - Imidazoline2 Binding Site in Healthy Volunteers;
ODM derived from:
https://clinicaltrials.gov/show/NCT02323217
All rights reserved. Please visit https://medical-data-
models.org/forms/15173
Eligibility Healthy Volunteers
NCT02323217
Inclusion Criteria
male between 40 and 65 years at the time of
signing the informed consent non-smoker*
Yes
No
willing to comply with protocol and lifestyle
restrictions*
Yes
No
excellent understanding of english (for
questionnaires)*
Yes
No
subject is ambulant and capable of attending a
pet scan visit as an outpatient.*
Yes
No
subjects with female partners of child-bearing
potential must agree to use one of the
contraception methods permitted by the study.
this criterion must be followed from after the first
pet scan until after the follow-up contact.*
Yes
No
adequate collateral flow to the radial and ulnar
arteries in both hands as determined by an
allen's test.*
Yes
No
body weight ≥50 kg.*
Yes
No
healthy subjects are defined as individuals who
are free from clinically significant illness or
disease as determined by their medical history
(including family), physical examination, objective
physiological measures, previous laboratory
studies, and other tests.*
Yes
No
successful completion of the camcog.*
Yes
No
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Exclusion Criteria
current or past history of major psychiatric
disorder*
Yes
No
current or past history of substance use disorder*
Yes
No
clinically significant brain injury or abnormality*
Yes
No
current or chronic history of liver disease, or
known hepatic or biliary abnormalities (with the
exception of gilbert's syndrome or asymptomatic
gallstones).*
Yes
No
history of or suffers from claustrophobia or
subject feels unable to lie flat and still on their
back for a period of up to 2 hours in the pet/ct
scanner.*
Yes
No
previous inclusion in a research and/or medical
protocol involving nuclear medicine, pet or
radiological investigations or occupational
exposure resulting in radiation exposure greater
than 10 msv over the past 3 years or greater than
10 msv in a single year including the proposed
study. clinical exposure from which the subject
receives a direct benefit is not included in these
calculations.*
Yes
No
previous inclusion in a research and/or medical
protocol involving study medication within the last
3 months*
Yes
No
in the opinion of the study team they are unlikely
to comply with the study protocol and restrictions
that it imposes.*
Yes
No
contraindications for subjects undergoing an mr
scan (including but not limited to metal implants
pacemakers, etc.)*
Yes
No
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Eligibility Healthy Volunteers NCT02323217
Protocol IA AIEOP-BFM ALL 2009
NCT01117441
International Collaborative Treatment Protocol For Children
And Adolescents With Acute Lymphoblastic Leukemia.
Phase 3 Study.
Study Protocol IA (Study Protocol IA: 4 doses of
Daunorubicin, Study Protocol IA': 2 doses of Daunorubicin).
Clinical Trial Number: NCT01117441.
All rights reserved. Please visit https://medical-data-
models.org/forms/15174
Protocol IA AIEOP-BFM ALL 2009
NCT01117441
Patient Information
Stud.-Nr. (Pat.-ID)
Patient date of birth
Body weight
kg
Body height
cm
Body surface
mˆ2
Chemotherapy Regimen
Prednisone
administration form
i.v. (i.v.)
p.o (p.o)
Prednisone dosage
60 mg/mˆ2/d
mg
Prednisone
Date of administration
VCR
administration form
i.v.
Yes
No
VCR dosage
1,5 mg/mˆ2/ED
(max. 2 mg/ED)
mg
VCR
Date of administration
DNR
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administration form
p.i. (1h)
Yes
No
DNR dosage
30 mg/mˆ2/d
mg
DNR
Date of administration
(If Randomisation in Group R1: reduced arm, no
3rd or 4th dose of DNR = Prot.IA')
MTX
administration form
i.th
Yes
No
MTX dosage
(Age-dependent:
1 - < 2 y/o: 8 mg
2 - < 3y/o: 10 mg
>= 3 y/o: 12 mg
mg
MTX 
Date of administration
(while MTX infusion)
If CNS status CNS2 or CNS3, extra MTX dose
(i.th., on day 19 and 26):
Date of administration
PEG-L-ASP 
administration form
p.i. (2h)
Yes
No
PEG-L-ASP dosage
2500 mg/mˆ2/ED
(ONCASPAR: 3750 E/ED)
E
PEG-L-ASP
(If Randomisation in Group HR-ASP+, continue
PEG-L-ASP therapy 14 days after dose on day
26)
Date of administration
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PEG-L-ASP/ Erwinase
Change from PEG-L-ASP to Erwinase in this
element
Yes
No
If "yes", specify:
Erwinase: 
date of first administration
If "yes", specify: 
Erwinase: date of last administration
If "yes", specify:
Numbers of Erwinase doses
If "yes", specify: 
Reason for change to erwinase:
Hypersensitivity
Yes
No
If "yes", specify: 
Reason for change to erwinase:
Date of allergic reaction
If "yes", specify: 
Reason for change to erwinase: 
Other reason
Hospitalization
Number of Nights in Hospital 
(Day 1 until start of Protocol IB)
nights
Identification and Signature
Date and signature of the doctor who calculated
and created chemotherapy regimen
Date and signature of the person who
administered chemotherapy
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Protocol IA-CPM AIEOP-BFM ALL 2009
NCT01117441
International Collaborative Treatment Protocol For Children
And Adolescents With Acute Lymphoblastic Leukemia.
Phase 3 Study.
Study Protocol IA-CPM (Study Protocol IA with additional
Cyclophosphamid).
Clinical Trial Number: NCT01117441.
All rights reserved. Please visit https://medical-data-
models.org/forms/15175
Protocol IA-CPM AIEOP-BFM ALL
2009 NCT01117441
Patient Information
Stud.-Nr. (Pat.-ID)
Patient date of birth
Body weight
kg
Body height
cm
Body surface
mˆ2
Chemotherapy Regimen
Prednisone
administration form
i.v. (i.v.)
p.o (p.o)
Prednisone dosage
60 mg/mˆ2/d
mg
Prednisone
Date of administration
VCR
administration form
i.v.
Yes
No
VCR dosage
1,5 mg/mˆ2/ED
(max. 2 mg/ED)
mg
VCR
Date of administration
DNR
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administration form
p.i. (1h)
Yes
No
DNR dosage
30 mg/mˆ2/d
mg
DNR
Date of administration
Cyclophosphamide 
administration form 
p.i.
Yes
No
Cyclophosphamide
1000 mg/mˆ2/ED
mg
Cyclophosphamide
Date of administration
MTX
administration form
i.th
Yes
No
MTX dosage
(Age-dependent:
1 - < 2 y/o: 8 mg
2 - < 3y/o: 10 mg
>= 3 y/o: 12 mg
mg
MTX 
Date of administration
(while MTX infusion)
If CNS status CNS2 or CNS3, extra MTX dose
(i.th., on day 19 and 26):
Date of administration
PEG-L-ASP 
administration form
p.i. (2h)
Yes
No
PEG-L-ASP dosage
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2500 mg/mˆ2/ED
(ONCASPAR: 3750 E/ED)
E
PEG-L-ASP
(If Randomisation in Group HR-ASP+, continue
PEG-L-ASP therapy 14 days after dose on day
26)
Date of administration
PEG-L-ASP/ Erwinase
Change from PEG-L-ASP to Erwinase in this
element
Yes
No
If "yes", specify:
Erwinase: 
date of first administration
If "yes", specify: 
Erwinase: date of last administration
If "yes", specify:
Numbers of Erwinase doses
If "yes", specify: 
Reason for change to erwinase:
Hypersensitivity
Yes
No
If "yes", specify: 
Reason for change to erwinase:
Date of allergic reaction
If "yes", specify: 
Reason for change to erwinase: 
Other reason
Identification and Signature
Date and signature of the doctor who calculated
and created chemotherapy regimen
Date and signature of the person who
administered chemotherapy
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Protocol IB-ASP+ AIEOP-BFM ALL 2009
NCT01117441
International Collaborative Treatment Protocol For Children
And Adolescents With Acute Lymphoblastic Leukemia.
Phase 3 Study.
Study Protocol IB (Study Protocol IB with PEG-L-ASP).
Clinical Trial Number: NCT01117441.
All rights reserved. Please visit https://medical-data-
models.org/forms/15176
Protocol IB-ASP+ AIEOP-BFM ALL
2009 NCT01117441
Patient Information
Stud.-Nr. (Pat.-ID)
Patient date of birth
Body weight
kg
Body height
cm
Body surface
mˆ2
Chemotherapy Regimen
PEG-L-ASP 
administration form
p.i. (2h)
Yes
No
PEG-L-ASP dosage
2500 mg/mˆ2/ED
(ONCASPAR: 3750 E/ED)
E
PEG-L-ASP
(First dose of PEG-L-ASP in Phase IB: 14 days
after last dose in Phase IA. 
No delay because of uncomplicated
myelosupression or coagulopathy)
Date of administration
Cyclophosphamide
administration form
p.i. (1h)
(+ MESNA)
Yes
No
Cyclophosphamide
1000 mg/mˆ2/ED
mg
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Cyclophosphamide
Date of administration
ARA-C 
administration form
i.v.
Yes
No
ARA-C dosage
75 mg/mˆ2/ED
mg
ARA-C
Date of administration
6-MP
administration form
p.o. (28d)
Yes
No
6-MP dosage
60 mg/mˆ2/d
mg
6-MP
Start date of therapy
6-MP
End date of therapy
MTX
administration form
i.th
Yes
No
MTX dosage
(Age-dependent:
1 - < 2 y/o: 8 mg
2 - < 3y/o: 10 mg
>= 3 y/o: 12 mg
mg
MTX 
Date of administration
(while MTX infusion)
PEG-L-ASP discontinuation
Discontinuation of PEG-L-ASP therapy in this
element?
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Yes
No
If discontinuation of PEG-L-ASP therapy, specify: 
PEG-L-ASP: date of last administration
If discontinuation of PEG-L-ASP therapy, specify:
Reason for discontinuation:
allergic reaction to PEG-L-ASP (allergic
reaction to PEG-L-ASP)
DVT or SVT (DVT or SVT)
Insulin-dependent hyperglycaemia
(Insulin-dependent hyperglycaemia)
other medical reason (other medical
reason)
other non-medical reason (other non-
medical reason)
Pancreatitis (Pancreatitis)
If discontinuation of PEG-L-ASP therapy, specify: 
Reason for discontinuation:
If other medical or non-medical reason, specify:
Hospitalization
Number of Nights in Hospital 
(Day 1 until start of Protocol IB)
nights
Identification and Signature
Date and signature of the doctor who calculated
and created chemotherapy regimen
Date and signature of the person who
administered chemotherapy
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Protocol IB AIEOP-BFM ALL 2009
NCT01117441
International Collaborative Treatment Protocol For Children
And Adolescents With Acute Lymphoblastic Leukemia.
Phase 3 Study.
Study Protocol IB.
Clinical Trial Number: NCT01117441.
All rights reserved. Please visit https://medical-data-
models.org/forms/15177
Protocol IB AIEOP-BFM ALL 2009
NCT01117441
Patient Information
Stud.-Nr. (Pat.-ID)
Patient date of birth
Body weight
kg
Body height
cm
Body surface
mˆ2
Chemotherapy Regimen
Cyclophosphamide
administration form
p.i. (1h)
(+ MESNA)
Yes
No
Cyclophosphamide
1000 mg/mˆ2/ED
mg
Cyclophosphamide
Date of administration
ARA-C 
administration form
i.v.
Yes
No
ARA-C dosage
75 mg/mˆ2/ED
mg
ARA-C
Date of administration
6-MP
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administration form
p.o. (28d)
Yes
No
6-MP dosage
60 mg/mˆ2/d
mg
6-MP
Start date of therapy
6-MP
End date of therapy
MTX
administration form
i.th
Yes
No
MTX dosage
(Age-dependent:
1 - < 2 y/o: 8 mg
2 - < 3y/o: 10 mg
>= 3 y/o: 12 mg
mg
MTX 
Date of administration
(while MTX infusion)
Hospitalization
If member of randomization group R-HR, specify:
Number of Nights in Hospital 
(Day 36 until start of HR-Block)
nights
Identification and Signature
Date and signature of the doctor who calculated
and created chemotherapy regimen
Date and signature of the person who
administered chemotherapy
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Protocol IIA AIEOP-BFM ALL 2009
NCT01117441
International Collaborative Treatment Protocol For Children
And Adolescents With Acute Lymphoblastic Leukemia.
Phase 3 Study.
Study Protocol IIA.
Clinical Trial Number: NCT01117441.
All rights reserved. Please visit https://medical-data-
models.org/forms/15178
Protocol IIA AIEOP-BFM ALL 2009
NCT01117441
Patient Information
Stud.-Nr. (Pat.-ID)
Patient date of birth
Body weight
kg
Body height
cm
Body surface
mˆ2
Chemotherapy Regimen
Dexamethasone 
administration form
i.v. (i.v.)
p.o (p.o)
Dexamethasone dosage
10 mg/mˆ2/d
mg
Dexamethasone
Date of administration
VCR
administration form
i.v.
Yes
No
VCR dosage
1,5 mg/mˆ2/ED
(max. 2 mg/ED)
mg
VCR
Date of administration
Doxorubicin
administration form
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p.i. (1h)
Yes
No
Doxorubicin dosage
30 mg/mˆ2/ED
mg
Doxorubicin
Date of administration
PEG-L-ASP 
administration form
p.i. (2h)
Yes
No
PEG-L-ASP dosage
2500 mg/mˆ2/ED
(ONCASPAR: 3750 E/ED)
E
PEG-L-ASP
Date of administration
MTX
administration form
i.th
Yes
No
MTX dosage
(Age-dependent:
1 - < 2 y/o: 8 mg
2 - < 3y/o: 10 mg
>= 3 y/o: 12 mg
mg
MTX 
Date of administration
(while MTX infusion)
If initial CNS status CNS3, MTX dose (i.th., on
day 1 and 18):
Date of administration
PEG-L-ASP/ Erwinase
Change from PEG-L-ASP to Erwinase in this
element
Yes
No
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If "yes", specify:
Erwinase: 
date of first administration
If "yes", specify: 
Erwinase: date of last administration
If "yes", specify:
Numbers of Erwinase doses
If "yes", specify: 
Reason for change to erwinase:
Hypersensitivity
Yes
No
If "yes", specify: 
Reason for change to erwinase:
Date of allergic reaction
If "yes", specify: 
Reason for change to erwinase: 
Other reason
Hospitalization
If member of randomization group R2, specify:
Number of Nights in Hospital 
(Day 1 until start of Protocol IIB)
nights
Identification and Signature
Date and signature of the doctor who calculated
and created chemotherapy regimen
Date and signature of the person who
administered chemotherapy
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Protocol IB-ASP+ AIEOP-BFM ALL 2009
NCT01117441
International Collaborative Treatment Protocol For Children
And Adolescents With Acute Lymphoblastic Leukemia.
Phase 3 Study.
Study Protocol IB (Study Protocol IB with PEG-L-ASP).
Clinical Trial Number: NCT01117441.
All rights reserved. Please visit https://medical-data-
models.org/forms/15179
Protocol IB-ASP+ AIEOP-BFM ALL
2009 NCT01117441
Patient Information
Stud.-Nr. (Pat.-ID)
Patient date of birth
Body weight
kg
Body height
cm
Body surface
mˆ2
Chemotherapy Regimen
Dexamethasone 
administration form
Dexamethasone dosage
10 mg/mˆ2/d
mg
Dexamethasone
Date of administration
VCR
administration form
i.v.
Yes
No
VCR dosage
1,5 mg/mˆ2/ED
(max. 2 mg/ED)
mg
VCR
Date of administration
Doxorubicin
administration form
p.i. (1h)
1 / 4
Yes
No
Doxorubicin dosage
30 mg/mˆ2/ED
mg
Doxorubicin
Date of administration
MTX
administration form
i.th
Yes
No
MTX dosage
(Age-dependent:
1 - < 2 y/o: 8 mg
2 - < 3y/o: 10 mg
>= 3 y/o: 12 mg
mg
MTX 
Date of administration
(while MTX infusion)
If initial CNS status CNS3, MTX dose (i.th., on
day 1 and 18):
Date of administration
PEG-L-ASP 
administration form
p.i. (2h)
Yes
No
PEG-L-ASP dosage
2500 E/mˆ2/ED
(ONCASPAR: 3750 E/ED)
E
PEG-L-ASP
(Next PEG-L-ASP dose: 14 days after dose of
day 22))
Date of administration
PEG-L-ASP discontinuation
Discontinuation of PEG-L-ASP therapy in
Protocol IIA-ASP+?
Yes
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No
If discontinuation of PEG-L-ASP therapy, specify:
Reason for discontinuation:
allergic reaction to PEG-L-ASP (allergic
reaction to PEG-L-ASP)
DVT or SVT (DVT or SVT)
Insulin-dependent hyperglycaemia
(Insulin-dependent hyperglycaemia)
other medical reason (other medical
reason)
other non-medical reason (other non-
medical reason)
Pancreatitis (Pancreatitis)
If discontinuation of PEG-L-ASP therapy, specify: 
Reason for discontinuation:
If other medical or non-medical reason, specify:
If discontinuation of PEG-L-ASP therapy, specify: 
PEG-L-ASP: date of last administration
Protocol Day 22 (Protocol Day 22)
Protocol Day 8 (Protocol Day 8)
Change to Erwinase?
Yes
No
If change to Erwinase, specify:
Erwinase: 
date of first administration
If change to Erwinase, specify: 
Erwinase: date of last administration
If change to Erwinase, specify:
Numbers of Erwinase doses
If change to Erwinase, specify:
Erwinase dose
E
Hospitalization
Number of Nights in Hospital 
(Day 1 until start of Protocol IIB-ASP+)
nights
Identification and Signature
Date and signature of the doctor who calculated
and created chemotherapy regimen
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Date and signature of the person who
administered chemotherapy
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Protocol IB AIEOP-BFM ALL 2009
NCT01117441
International Collaborative Treatment Protocol For Children
And Adolescents With Acute Lymphoblastic Leukemia.
Phase 3 Study.
Study Protocol IB.
Clinical Trial Number: NCT01117441.
All rights reserved. Please visit https://medical-data-
models.org/forms/15180
Protocol IB AIEOP-BFM ALL 2009
NCT01117441
Patient Information
Stud.-Nr. (Pat.-ID)
Patient date of birth
Body weight
kg
Body height
cm
Body surface
mˆ2
Chemotherapy Regimen
Cyclophosphamide
administration form
p.i. (1h)
(+ MESNA)
Yes
No
Cyclophosphamide
1000 mg/mˆ2/ED
mg
Cyclophosphamide
Date of administration
ARA-C 
administration form
i.v.
Yes
No
ARA-C dosage
75 mg/mˆ2/ED
mg
ARA-C
Date of administration
Thioguanine
1 / 2
administration form
p.o. (14d)
Yes
No
Thioguanine dosage
60 mg/mˆ2/d
mg
Thioguanine
Start date of therapy
Thioguanine
End date of therapy
MTX
administration form
i.th
Yes
No
MTX dosage
(Age-dependent:
1 - < 2 y/o: 8 mg
2 - < 3y/o: 10 mg
>= 3 y/o: 12 mg
mg
MTX 
Date of administration
(while MTX infusion)
Hospitalization
If member of randomization group R2, specify:
Number of Nights in Hospital 
(Day 36 until start of maintenance treatment)
nights
Identification and Signature
Date and signature of the doctor who calculated
and created chemotherapy regimen
Date and signature of the person who
administered chemotherapy
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Protocol IIB-ASP+ AIEOP-BFM ALL 2009
NCT01117441
International Collaborative Treatment Protocol For Children
And Adolescents With Acute Lymphoblastic Leukemia.
Phase 3 Study.
Study Protocol IIB (Study Protocol IIB with PEG-L-ASP).
Clinical Trial Number: NCT01117441.
All rights reserved. Please visit https://medical-data-
models.org/forms/15181
Protocol IIB-ASP+ AIEOP-BFM ALL
2009 NCT01117441
Patient Information
Stud.-Nr. (Pat.-ID)
Patient date of birth
Body weight
kg
Body height
cm
Body surface
mˆ2
Chemotherapy Regimen
PEG-L-ASP 
administration form
p.i. (2h)
Yes
No
PEG-L-ASP dosage
2500 E/mˆ2/ED
(ONCASPAR: 3750 E/ED)
E
PEG-L-ASP
(First dose of PEG-L-ASP in Phase IB: 14 days
after last dose in Phase IIA. 
No delay because of uncomplicated
myelosupression or coagulopathy)
Date of administration
Cyclophosphamide
administration form
p.i. (1h)
(+ MESNA)
Yes
No
Cyclophosphamide
1000 mg/mˆ2/ED
mg
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Cyclophosphamide
Date of administration
ARA-C 
administration form
i.v.
Yes
No
ARA-C dosage
75 mg/mˆ2/ED
mg
ARA-C
Date of administration
Thioguanine
administration form
p.o. (14d)
Yes
No
Thioguanine dosage
60 mg/mˆ2/d
mg
Thioguanine
Start date of therapy
Thioguanine
End date of therapy
MTX
administration form
i.th
Yes
No
MTX dosage
(Age-dependent:
1 - < 2 y/o: 8 mg
2 - < 3y/o: 10 mg
>= 3 y/o: 12 mg
mg
MTX 
Date of administration
PEG-L-ASP discontinuation
Discontinuation of PEG-L-ASP therapy in this
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element?
Yes
No
If discontinuation of PEG-L-ASP therapy, specify: 
PEG-L-ASP: date of last administration
If discontinuation of PEG-L-ASP therapy, specify:
Reason for discontinuation:
allergic reaction to PEG-L-ASP (allergic
reaction to PEG-L-ASP)
DVT or SVT (DVT or SVT)
Insulin-dependent hyperglycaemia
(Insulin-dependent hyperglycaemia)
other medical reason (other medical
reason)
other non-medical reason (other non-
medical reason)
Pancreatitis (Pancreatitis)
If discontinuation of PEG-L-ASP therapy, specify: 
Reason for discontinuation:
If other medical or non-medical reason, specify:
Hospitalization
Number of Nights in Hospital 
(Day 36 until start of maintenance treatment)
nights
Identification and Signature
Date and signature of the doctor who calculated
and created chemotherapy regimen
Date and signature of the person who
administered chemotherapy
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Protocol IIIA AIEOP-BFM ALL 2009
NCT01117441
International Collaborative Treatment Protocol For Children
And Adolescents With Acute Lymphoblastic Leukemia.
Phase 3 Study.
Study Protocol IIIA.
Clinical Trial Number: NCT01117441.
All rights reserved. Please visit https://medical-data-
models.org/forms/15182
Protocol IIIA AIEOP-BFM ALL 2009
NCT01117441
Patient Information
Stud.-Nr. (Pat.-ID)
Patient date of birth
Body weight
kg
Body height
cm
Body surface
mˆ2
Chemotherapy Regimen
Number of Protocol III
1st (1st)
2nd (2nd)
3rd (3rd)
Dexamethasone 
administration form
i.v. (i.v.)
p.o (p.o)
Dexamethasone dosage
10 mg/mˆ2/d
mg
Dexamethasone
Date of administration
VCR
administration form
i.v.
Yes
No
VCR dosage
1,5 mg/mˆ2/ED
(max. 2 mg/ED)
mg
VCR
1 / 3
Date of administration
Doxorubicin
administration form
p.i. (1h)
Yes
No
Doxorubicin dosage
30 mg/mˆ2/ED
mg
Doxorubicin
Date of administration
PEG-L-ASP 
administration form
p.i. (2h)
Yes
No
PEG-L-ASP dosage
2500 E/mˆ2/ED
(ONCASPAR: 3750 E/ED)
E
PEG-L-ASP
Date of administration
MTX
administration form
i.th
Yes
No
MTX dosage
(Age-dependent:
1 - < 2 y/o: 8 mg
2 - < 3y/o: 10 mg
>= 3 y/o: 12 mg
mg
MTX 
Date of administration
(while MTX infusion)
If initial CNS status CNS3, MTX dose (i.th., on
day 1):
Date of administration
PEG-L-ASP/ Erwinase
Change from PEG-L-ASP to Erwinase in this
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element
Yes
No
If "yes", specify:
Erwinase: 
date of first administration
If "yes", specify: 
Erwinase: date of last administration
If "yes", specify:
Numbers of Erwinase doses
If change to Erwinase, specify:
Erwinase dose
E
If "yes", specify: 
Reason for change to erwinase:
Hypersensitivity
Yes
No
If "yes", specify: 
Reason for change to erwinase:
Date of allergic reaction
If "yes", specify: 
Reason for change to erwinase: 
Other reason
Identification and Signature
Date and signature of the doctor who calculated
and created chemotherapy regimen
Date and signature of the person who
administered chemotherapy
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Registry Formular AIEOP-BFM ALL 2009
NCT01117441
International Collaborative Treatment Protocol For Children
And Adolescents With Acute Lymphoblastic Leukemia.
Phase 3 Study.
Registry Formular (Please send this to study centre until
Day 8)
Clinical Trial Number: NCT01117441.
All rights reserved. Please visit https://medical-data-
models.org/forms/15183
Registry Formular AIEOP-BFM ALL
2009 NCT01117441
Patient Information
Patient name
Patient Birth Date
Patient's gender
Female (Female)
Male (Male)
Date of diagnosis
Therapy start date
(start of pre-phase)
Eligibility Criteria
Diagnosis of primary ALL
Yes
No
Exclusion of BCR/ABL-rearrangement or
translocation t(9;22)?
Yes
No
Exclusion of pregnancy or nursing?
Yes
No
Does patient participate in another study trial?
(Except for associated studies)
Yes
No
Informed consent given by person who has
custody of child (if patient > 15 y/o, informed
consent given by patient himself/ herself) to
participate in study and data storage
Yes
No
Did patient receive steroids (longer than 2 weeks;
dosage >= 1 mg/kg/d) or cytostatics 4 weeks
before diagnosis?
Yes
1 / 3
No
Does the patient has any comorbidity which is
interferring with study protocol?
Yes
No
If Patient received steroid therapy (longer
than 2 weeks; dosage >= 1 mg/kg/d) or
cytostatics 4 weeks before diagnosis,
specify:
Specify steroid therapy and chemotherapy
regimen:
Specify received daily dose:
Specify start date of therapy:
Specify last date of therapy:
Informed consent to participate in
Concomitant studies and for storage of
clinical samples
Early diagnosis of high risk patient for relapse?
Yes
No
Moleculargenetic evidence of minimal CNS
leukemia?
Yes
No
Diagnostic meaning of IL-15 in CNS-leukemia?
Yes
No
Genetic change in leukemic cells and its
prognostic meaning?
Yes
No
Genetic variation as risk factors for severe
infections (during chemotherapy)?
Yes
No
Storage of clinical samples for future trials about
leukemia?
Yes
No
Storage of clinical samples for future trials about
host cells -target?
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Yes
No
Storage of clinical samples for future trials about
host cells -whole genom?
Yes
No
Laboratory Diagnostic
Immunologic tests
Not performed (Not performed)
Performed: in referrence laboratory
(Berlin-Buch, Prof. Ludwig) (Performed:
in referrence laboratory (Berlin-Buch,
Prof. Ludwig))
Performed: not in referrence laboratory
(Performed: not in referrence laboratory)
If immunologic tests were performed in not-
referrence laboratory, specify:
Karyotypization and Moleculargenetics (RT-PCR,
FISH for diagnosis of TEL/AML1, BCR/ABL, MLL-
Rearrangements, others)
Not performed (Not performed)
Performed: in referrence laboratory
(Performed: in referrence laboratory )
Performed: not in referrence laboratory
(Performed: not in referrence laboratory)
If Karyotypization and Moleculargenetics were
performed, specify laboratory:
Identification and Signature
Doctor's Name
Date of report
Doctor's signature
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Eligibility Heart Failure (NYHA Class III and
Ambulatory IV) NCT02374801
Continued Access Clinical Trial of the SonRtip Lead and
Automatic AV-VV Optimization Algorithm in the PARADYM
RF SonR CRT-D (CAS RESPOND CRT); ODM derived
from: https://clinicaltrials.gov/show/NCT02374801
All rights reserved. Please visit https://medical-data-
models.org/forms/15185
Eligibility Heart Failure (NYHA Class
III and Ambulatory IV) NCT02374801
Inclusion Criteria
patients who meet all the following criteria at the
time of enrollment may be included:*
Yes
No
1. patient with a class i and iia indication for
implantation of a crt-d device according to current
available guidelines*
Yes
No
2. moderate/severe hf (nyha class iii or
ambulatory iv)*
Yes
No
3. lvef ≤ 35 %*
Yes
No
4. lbbb: qrs ≥ 120 ms ; non-lbbb : qrs ≥ 150 ms*
Yes
No
5. on a stable optimal drug regimen*
Yes
No
6. patient is in sinus rhythm at the time of signing
the informed consent*
Yes
No
7. signed and dated informed consent*
Yes
No
Exclusion Criteria
patients who meet any one of these criteria will
be excluded from the investigation:*
Yes
No
1. ventricular tachyarrhythmia of transient or
reversible causes such as acute myocardial
infarction, digitalis intoxication, drowning,
electrocution, electrolyte imbalance, hypoxia or
1 / 3
sepsis, uncorrected at the time of the enrollment*
Yes
No
2. incessant ventricular tachyarrhythmia*
Yes
No
3. unstable angina, or mi, cabg, or ptca within the
past 4 weeks*
Yes
No
4. correctable valvular disease that is the primary
cause of heart failure*
Yes
No
5. recent cva or tia (within the previous 3
months)*
Yes
No
6. persistent or permanent atrial arrhythmias (or
cardioversion for atrial fibrillation) within the past
month***
Yes
No
7. post heart transplant (patients who are waiting
for a heart transplant are allowed in the study)*
Yes
No
8. renal failure (gfr<15 ml/min/1.73m2) or on
dialysis*
Yes
No
9. previous implant with a crt- p or crt-d device*
Yes
No
10. concurrent implant with another pacemaker or
icd system in which all or some of the
components will not be extracted and/or utilized
in the new system. previously implanted ra leads
must be removed prior to implant of the sonrtip
lead.*
Yes
No
11. already included in another clinical study that
could confound the results of this study*
Yes
No
12. life expectancy less than 1 year*
Yes
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No
13. inability to understand the purpose of the
study or to understand and complete the qol
questionnaire*
Yes
No
14. unavailability for scheduled follow-up or
refusal to cooperate*
Yes
No
15. sensitivity to 1 mg dexamethasone sodium
phosphate (dsp)*
Yes
No
16. age of less than 18 years*
Yes
No
17. pregnancy*
Yes
No
18. substance addiction or abuse*
Yes
No
19. under guardianship*
Yes
No
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Eligibility Heart Failure NCT02279888
CardioMEMS HF System Post Approval Study; ODM
derived from: https://clinicaltrials.gov/show/NCT02279888
All rights reserved. Please visit https://medical-data-
models.org/forms/15186
Eligibility Heart Failure
NCT02279888
Inclusion Criteria
diagnosis of nyha class iii heart failure*
Yes
No
at least 1 heart failure hospitalization within
previous 12 months*
Yes
No
patients with reduced lvef heart failure should be
receiving a beta blocker for 3 months and an ace-
i or arb for one month unless in the investigator's
opinion, the patient is intolerant to beta blockers,
ace-i or arb*
Yes
No
bmi ≤ 35.  patients with bmi >35 will require their
chest circumference to be measured at the
axillary level.  if > 65 inches the patient will not be
eligible for the study.*
Yes
No
pulmonary artery branch diameter ≥ 7mm -
(implant target artery - assessed during the right
heart catheterization)*
Yes
No
Exclusion Criteria
active infection*
Yes
No
history of recurrent (> 1) pulmonary embolism or
deep vein thrombosis*
Yes
No
inability to tolerate a right heart catheterization*
Yes
No
a major cardiovascular event (e.g., myocardial
infarction, open heart surgery, stroke, etc.) within
previous 2 months*
Yes
No
1 / 2
cardiac resynchronization device (crt) implanted
within previous 3 months*
Yes
No
glomerular filtration rate (gfr) < 25 ml/min
(obtained within 2 weeks of  implant) who are
non-responsive to diuretic therapy or who are on
chronic renal dialysis*
Yes
No
congenital heart disease or mechanical right
heart valve*
Yes
No
likely to undergo heart transplantation or vad
within the next 6 months*
Yes
No
known coagulation disorders*
Yes
No
hypersensitivity or allergy to aspirin, and/or
clopidogrel*
Yes
No
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Eligibility Heart Failure NCT02305095
Genomic Response Analysis of Heart Failure Therapy in
African Americans; ODM derived from:
https://clinicaltrials.gov/show/NCT02305095
All rights reserved. Please visit https://medical-data-
models.org/forms/15192
Eligibility Heart Failure
NCT02305095
Inclusion Criteria
18 years and older*
Yes
No
history of heart failure with an lvef (less than or
equal to) < 0.35 for at least 6 months or an lvef <
0.45 with left ventricular internal end diastole
(defined by a diameter of more than 2.9 cm per
square meter of body surface area or more than
6.5 cm on the basis of echocardiography).*
Yes
No
new york heart association (nyha) class ii-iv*
Yes
No
background heart failure therapy that includes
angiotensin converting enzyme inhibitors (acei)
or angiotensin receptor blockers (arbs), and beta
blockers (bbs) for at least 3 months (or
documentation of intolerance to acei/arbs and
bbs)*
Yes
No
Exclusion Criteria
no history of intolerance to either nitrates or
hydralazine*
Yes
No
no treatment with the combination of hydralazine
and nitrates for the previous 3 months*
Yes
No
no revascularization or myocardial infarction
within last 90 days*
Yes
No
can not be enrolled for at least 90 days after
receiving cardiac resynchronization therapy (crt)
and must have an lvef (less than or equal to) <
0.35 at least 3 months after crt.*
Yes
No
presence of clinically significant valvular heart
1 / 2
disease, hypertrophic or restrictive
cardiomyopathy, active myocarditis, or
uncontrolled hypertension.*
Yes
No
women who are currently pregnant, planning on
becoming pregnant in the next two years, or
those who do not agree to prevent pregnancy.*
Yes
No
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Eligibility Heart Failure NCT02312427
DPP-4 Inhibitor and Serum BNP Level of Diabetic Patients
With Congestive Heart Failure; ODM derived from:
https://clinicaltrials.gov/show/NCT02312427
All rights reserved. Please visit https://medical-data-
models.org/forms/15193
Eligibility Heart Failure
NCT02312427
Criteria
Inclusion Criteria
type 2 diabetes patient with congestive heart
failure under treatment with dpp-4 inhibitor
(sitagliptin, vildagliptin, alogliptin, linagliptin,
teneligliptin, anagliptin or saxagliptin) .*
Yes
No
high serum bnp (100-2000pg/ml).*
Yes
No
patients who have given informed consent to
participation in the study.*
Yes
No
Exclusion Criteria
hba1c over 9.0%.*
Yes
No
patients who changed medication within 1
months before inclusion.*
Yes
No
judged as ineligible by clinical investigators.*
Yes
No
hospitalization arm*
Yes
No
Inclusion Criteria
type 2 diabetes patient who were hospitalized for
congestive heart failure.*
Yes
No
patients who have given informed consent to
participation in the study.*
Yes
No
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Exclusion Criteria
patients on insulin therapy.*
Yes
No
judged as ineligible by clinical investigators.*
Yes
No
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Eligibility Heart Failure NCT02340364
Patient NAVIgation to Reduce Readmissions Among Black
Men With Heart Failure; ODM derived from:
https://clinicaltrials.gov/show/NCT02340364
All rights reserved. Please visit https://medical-data-
models.org/forms/15194
Eligibility Heart Failure
NCT02340364
Inclusion Criteria
african american*
Yes
No
male*
Yes
No
age > 40*
Yes
No
inpatient admission at uab hospital with a
diagnosis of hf as a principle or     one of the first
3 diagnostic codes according to hf-specific icd-9
or drg codes (specific codes listed in protection of
human subjects).*
Yes
No
residence in jefferson county, alabama*
Yes
No
english speaking*
Yes
No
physically and cognitively able to listen to 30-
minute video undergo a home visit and telephone
contacts over several weeks.*
Yes
No
Exclusion Criteria
heart transplant or awaiting heart transplant
(admitted to uab advanced hf/transplant
service).*
Yes
No
currently participating in another clinical research
study.*
Yes
No
current or anticipated long term (>2 weeks)
residence in a skilled nursing facility.*
Yes
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No
patients who indicated that they were unwilling to
make lifestyle changes now or in the near future.*
Yes
No
patients whose symptoms may be eliminated by
surgery (e.g., severe aortic stenosis) or who had
undergone surgery (e.g., coronary artery bypass
grafting valvular replacement/repair) in the last
month.*
Yes
No
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Eligibility Heart Failure NCT02340546
Trajectory Changes of Coronary Sinus Lead Tip and
Cardiac Resynchronization Therapy Outcome; ODM
derived from: https://clinicaltrials.gov/show/NCT02340546
All rights reserved. Please visit https://medical-data-
models.org/forms/15195
Eligibility Heart Failure
NCT02340546
Inclusion Criteria
1. informed consent;*
Yes
No
2. chronic systolic heart failure recognized for
more than 6 months, with left ventricular systolic
disfunction (ejection fraction ≤ 35%) and nyha ii-iii
or ambulatory iv class symptoms despite optimal
medical treatment;*
Yes
No
3. qrs complex on the surface electrocardiogram
with left bundle branch block morphology and
duration  ≥ 120 ms, either typical or atypical or
induced by right ventricular pacing due to stable
chronic advanced atrio-ventricular block; qrs with
with non-specific intraventricular delay lasting  ≥
150 ms;*
Yes
No
4. a regular ventricular rhythm, either with
spontaneous atrio-ventricular conduction or with
ventricular pacing via a chronically implanted
antibradycardia device; with sinus rhythm unless
atrial fibrillation is permanent and associated with
a  permanent high-degree atrio-ventricular block
with a spontaneous ventricular rate constantly ≤*
Yes
No
45 beats per minute;*
Yes
No
5. no concomitant bradyarrhythmias being per se
an indication for new implant ventricular pacing;
upgrade to cardiac resynchronization therapy
only if a previous pacemaker or implantable
cardioverter-defibrillator was implanted more than
6 months previously;*
Yes
No
6. a stable clinical and hemodynamic condition
during cardiac resynchronization therapy device
implant, and at the acquisition time heat rate
between 50 and 100 beats per minute and
respiratory rate ≤ 25 breaths per minute;*
Yes
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No
Exclusion Criteria
1. inability to give informed consent;*
Yes
No
2. occurrence of myocardial infarction, valve
repair or surgery, or coronary revascularization in
the past 6 months;*
Yes
No
3. any arrhythmia at the acquisition time which
frequently alters the  regularity of a minimum of
five consecutive heart beats;*
Yes
No
4. participation in any other competing clinical
study, with the exception of registries ruled by
national health service authorities or  agencies,
and observational studies/registries which are not
conflicting and do not interfere with any of the
following aspects:*
Yes
No
1. the program of procedures/assessments
requested by the present study;*
Yes
No
2. the outcome of the present study due to the
requirement of medical treatments or
interventions which are able to modify the clinical
conditions of patients.*
Yes
No
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Eligibility Heart Failure NCT02343523
Pilot Study of the QI Device for Monitoring of Patients With
Congestive Heart Failure; ODM derived from:
https://clinicaltrials.gov/show/NCT02343523
All rights reserved. Please visit https://medical-data-
models.org/forms/15196
Eligibility Heart Failure
NCT02343523
Inclusion Criteria
adults over age 18*
Yes
No
own, and comfortable using, a home computer
with internet access (phase 2 only)*
Yes
No
acute hospitalization with a primary diagnosis of
acute decompensated heart failure (adhf)
diagnosed on the basis of all of the following:*
Yes
No
1. symptoms:*
Yes
No
onset or worsening of dyspnea within the past 2
weeks*
Yes
No
2. physical exam (at least 1 present):*
Yes
No
rales/ crackles on auscultation*
Yes
No
elevated jvp > 10 cmh2o*
Yes
No
weight gain*
Yes
No
le edema*
Yes
No
3. diagnostic imaging/ labs (at least 1 present):*
Yes
No
evidence of pulmonary congestion or edema on
chest x-ray/ chest ct*
Yes
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No
elevated bnp or nt-pro-bnp (age-adjusted)*
Yes
No
Exclusion Criteria
psychological or social situation that would make
the study difficult for the patient*
Yes
No
inability to consent*
Yes
No
chronic atrial fibrillation or other dysrhythmia with
a high (>10%) burden of ectopic beats.*
Yes
No
pregnant women*
Yes
No
pneumonia - currently, or within the past 30 days*
Yes
No
non-cardiogenic pulmonary edema (e.g. ards)*
Yes
No
interstitial lung disease*
Yes
No
end-stage renal disease and on hemodialysis*
Yes
No
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Eligibility Heart Failure NCT02344199
Eplerenone in Heart Failure Treatment; ODM derived from:
https://clinicaltrials.gov/show/NCT02344199
All rights reserved. Please visit https://medical-data-
models.org/forms/15197
Eligibility Heart Failure
NCT02344199
Inclusion Criteria
eligible ages for the study:> 18 years*
Yes
No
patients who are to receive eprelenone according
to standard clinical practice*
Yes
No
patients with heart failure of ischemic / non-
ischemic etiology*
Yes
No
patients receiving standard therapy including
beta-blockers, to reduce the risk of cardiovascular
mortality and morbidity*
Yes
No
stable patients*
Yes
No
patients with left ventricular dysfunction (lvef ≤
40%)*
Yes
No
patients with clinically proven heart failure after
recent myocardial infarction.*
Yes
No
patients who have fully understood the study
protocol and signed the consent form*
Yes
No
Exclusion Criteria
patients <18 years*
Yes
No
hypersensitivity to eplerenone in any of the
excipients*
Yes
No
patients with a serum potassium level> 5,0 mmol
1 / 2
/ l at the start of therapy*
Yes
No
patients with moderate to severe renal
impairment (creatinine clearance <50 ml / min)*
Yes
No
patients with severe hepatic impairment (child-
pugh class c)*
Yes
No
patients taking diuretics guard potassium loss or
strong inhibitors of cyp3a4 (eg itraconazole,
ketoconazole, ritonavir, nelfinavir, clarithromycin,
telithromycin and nefazodone)*
Yes
No
patients who have not fully understood the study
protocol and have not signed the consent form*
Yes
No
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Eligibility Heart Failure NCT02344342
University of Michigan Advanced Heart Failure Tele-
Monitoring and Flexible Diuretic Project; ODM derived from:
https://clinicaltrials.gov/show/NCT02344342
All rights reserved. Please visit https://medical-data-
models.org/forms/15200
Eligibility Heart Failure
NCT02344342
Inclusion Criteria
1. university of michigan patients hospitalized for
the treatment of heart failure, within the past 30
days.*
Yes
No
2. patients must be receiving an oral loop diuretic
on their home regimen or have received
intravenous loop diuretic during the index
hospitalization at the time of enrollment.*
Yes
No
3. patients must have an assessment of left
ventricular function within the previous 2 years.*
Yes
No
4. patients must have lvef ≤ 40%, or lvef >40 with
evidence of left atrial enlargement (la dimension
> 40 mm), bnp > 200 ng/ml or pcw > 18 mmhg.*
Yes
No
Exclusion Criteria
prisoners*
Yes
No
residents of long term nursing facilities*
Yes
No
enrollment into a hospice program*
Yes
No
receiving dialysis*
Yes
No
patients with dementia*
Yes
No
patients with dgfr less than 20ml/min.*
Yes
No
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patients being worked up for heart surgery.*
Yes
No
patients being worked up for heart transplant.*
Yes
No
patients being evaluated for revasuculariztion.*
Yes
No
patients being evaluated for heart valve
intervention.*
Yes
No
patients with primary pulmonary hypertension.*
Yes
No
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Eligibility Heart Failure NCT02344420
Clinical Investigation on Differences in the Magnitude of
CRT Response in WOmen Versus MEN; ODM derived
from: https://clinicaltrials.gov/show/NCT02344420
All rights reserved. Please visit https://medical-data-
models.org/forms/15201
Eligibility Heart Failure
NCT02344420
Inclusion Criteria
indication for a "de novo" implantation of a crt
device according to esc guidelines*
Yes
No
understand the nature of the procedure*
Yes
No
give written informed consent*
Yes
No
Exclusion Criteria
crt device replacements*
Yes
No
crt upgrades*
Yes
No
permanent / persistent atrial fibrillation*
Yes
No
age< 18 years*
Yes
No
pregnant and breastfeeding women*
Yes
No
subjects with irreversible brain damage from pre
existing cerebral disease*
Yes
No
subjects with acutely de compensated heart
failure*
Yes
No
nyha class iv heart failure*
Yes
No
heart transplantation six months prior to the
enrolment or expected within next 3 months.*
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Yes
No
cardiac surgery 3 months prior to the enrolment
or planned within next 3 months.*
Yes
No
have a life expectancy of less than 12 months*
Yes
No
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Cost absorption declaration Other billing documentation
Routine documentation in German hospitals DMI
Routine documentation in German hospitals. Source file
name: AM010199_Sonstige Abrechnungsdokumentation/
Kostenübernahmerklärung.009
Examplary forms provided by DMI (http://www.dmi.de/)
All rights reserved. Please visit https://medical-data-
models.org/forms/15209
Cost absorption declaration Other
billing documentation
Kostenübernahmeerklärung
Kostenübernahmeerklärung für
Patient
Geburtsdatum
Aufnahme- Nr.
Aufnahmetag:
Diagnose
Diese Kostenübernahmeerklärung gilt für die
Dauer der medizinisch notwendigen stationären
Heilbehandlung.
Grundlage dieser Kostenübernahmeerklärung bei
der Abrechnung nach dem DRG- System sind die
Bestimmungen der Fallpauschalenvereinbarung
(FPV) und das Krankenhausentgeltgesetz
(KHEntgG). Die Abrechnung psychiatrischer und
psychosomatischer Einrichtungen erfolgt nach
der Verodnung zum pauschalierenden
Entgeltsystem für psychiatrische und
psychosomatische Einrichtungen (PEPPV). 
Wir zahlen
30% für allgemeine Krankenhausleistung, 30%
für angemessenen Unterkunftszuschlag
Zweibettzimmer, 0% für angemessenen
Unterkunftszuschlag Einbettzimmer.
Bitte senden Sie uns die Rechnungen oder
Schreiben unter Angabe der Service- Nr an:
Geschäftsstelle
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Memo Other checklist Administration Routine
documentation in German hospitals DMI
Routine documentation in German hospitals. Source file
name: AM030199_Sonstige Checkliste Administration/
Gesprächsnotiz.049
Examplary forms provided by DMI (http://www.dmi.de/)
All rights reserved. Please visit https://medical-data-
models.org/forms/15210
Memo Other checklist Administration
Memo
Patient name
Date of birth
Surgery date
Record of discussion
Date of documentation
Physician
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Quality assurance gall bladders and bile duct diseases Quality
assurance sheet Routine documentation in German hospitals DMI
Routine documentation in German hospitals. Source file
name: AM170105_Qualitätssicherungsbogen/
Qualitätssicherung.021
Examplary forms provided by DMI (http://www.dmi.de/)
All rights reserved. Please visit https://medical-data-
models.org/forms/15211
Quality assurance gall bladders and
bile duct diseases Quality assurance
sheet
Medical history
Anamnesis
Colics
Yes
No
Pain in the right upper abdomen
Yes
No
Cholestasis
Yes
No
Diagnostic
Gallstone detection confirmed?
Yes
No
When yes, confirmed through
X- ray
Yes
No
Ultrasonography
Yes
No
MRCP
Yes
No
CT
Yes
No
ERCP
Yes
No
If ERCP was performed, Biliary Stone Extraction?
Yes
No
Other
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Yes
No
Acute inflammation
Acute inflammation
Yes
No
If yes, confirmed through:
Clinical findings
Yes
No
Leukocytes > 12000 cells/ mm^2
Yes
No
CRP
Yes
No
Body temperature (> 38° rectal)
Yes
No
Ultrasonography
Yes
No
Extrahepatic cholestasis
Extrahepatic cholestasis
Yes
No
Confirmed through x- ray
Yes
No
Confirmed through ultrasonography?
Yes
No
Confirmed through ERCP?
Yes
No
Confirmed through MRCP?
Yes
No
Confirmed through CT?
Yes
No
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Other
Yes
No
Information for quality assurance completely
collected?
Yes
No
Date of documentaion
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Quality assurance gall bladders and bile duct diseases Quality assurance
sheet Routine documentation in German hospitals DMI
Patient information cover page first contact Admission
sheet Routine documentation in German hospitals DMI
Routine documentation in German hospitals. Source file
name: AU010103_Aufnahmebogen/ Patientendeckblatt.009
Examplary forms provided by DMI (http://www.dmi.de/)
All rights reserved. Please visit https://medical-data-
models.org/forms/15212
Patient information cover page first
contact Admission sheet
Patient information cover page
Case number
Patient firstname
Patient surname
Date of birth
Telephone
Referring physician
BF
Yes
No
PAP
Yes
No
ROE'S
Yes
No
Referral
Yes
No
Health insurance
statutory insurance (1)
no insurance (2)
private general (3)
private Single  bed room (4)
private double bed room (5)
private doctor of choise (6)
Diagnosis
Planned surgery date
New surgery date
Note
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Did you previously hear about the clinic or doctor
before the referring physician informed you?
Yes
No
If yes, through:
recommendation (1)
internet (2)
advertisement in paper (3)
radio (4)
TV (5)
Copy of surgery information handed out?
Yes
No
Copy of anesthesia information handed out?
Yes
No
Copy of contract of admission and treatment
handed out?
Yes
No
Date of admission
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documentation in German hospitals DMI
Verification of hospital treatment Correspondence
MDK Routine documentation in German hospitals DMI
Routine documentation in German hospitals. Source file
name: AM190103_Schriftverkehr MDK/ Überprüfung
Krankenhausbehandlung.007
Examplary forms provided by DMI (http://www.dmi.de/)
All rights reserved. Please visit https://medical-data-
models.org/forms/15213
Verification of hospital treatment
Correspondence MDK
Vertrag zur Überprüfung der
Notwendigkeit und Dauer der
Krankenhausbehandlung gemäß § 112
Absatz 2 Nr. 2 SGB V vom 01. November
20014
Gesprächspartnerin
Telefon
Fax
E- Mail
Datum
Vorname und Nachname
Geburtsdatum
Geschlecht
männlich (1)
weiblich (2)
Krankenversichertennummer
Aufnahme- Nr.
Aufnahmetag
Fachabteilung
Aufnahmediagnose
Anlass der Abfrage- Dauer der Krankheit
Ja
Nein
Begründung
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Eligibility Heart Failure NCT02358525
Effects of a Rehabilitation Program on Immune Activation
and Mood in Heart Failure Patients; ODM derived from:
https://clinicaltrials.gov/show/NCT02358525
All rights reserved. Please visit https://medical-data-
models.org/forms/15216
Eligibility Heart Failure
NCT02358525
Inclusion Criteria
diagnosis of heart failure with reduced ejection
fraction (hfref) with an ef ≤ 45%, nyha (new york
heart association) i - iii; acc/aha (american
college of cariology/*
Yes
No
american heart association) stage c, irrespective
of etiology*
Yes
No
clinically stable patients without deterioration or
hospitalization due to heart failure within the   last
4 weeks*
Yes
No
neuro-hormonal medication according to the esc
(european society of cardiology) guidelines for
the treatment of chronic heart failure consisting of
antagonists of the renin-angiotensin-aldosterone
system (raas) and beta-blockers as indicated.*
Yes
No
ability to fully understand all elements of and sign
the written informed consent before initiation of
the study*
Yes
No
Exclusion Criteria
fluid retention of cardiac decompensation,
necessitating i.v. diuretic therapy*
Yes
No
myocardial infarction within the last 2 months*
Yes
No
surgery including cardiovascular or valvular
surgery within 3 months*
Yes
No
uncontrolled proinflammatory comorbidities  (e.g.
diabetes mellitus hba1c >9%, copd ( chronic
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obstructive pulmonary disease) >ii, active
rheumatic diseases and autoimmune disorders)*
Yes
No
current infectious diseases ( e.g. pneumonia,
copd exacerbations or urinary tract infections)*
Yes
No
morbid obesity: bmi > 40*
Yes
No
alcohol or drug abuse*
Yes
No
psychiatric disorders*
Yes
No
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Eligibility criteria, Relapsing Remitting Multiple
Sclerosis, DIMAT-MS, NCT02461069
Study documentation part: Visits 1 (Screening)/Visit 2
(Core study), Study week -4 to 0
Study Details: DIMAT-MS, A 24-week, multicenter,
exploratory, two arm study to
assess the effect of Dimethyl fumarate on
ImmuneModulatory
Action on T cells in patients with relapsing
remitting Multiple Sclerosis.
Principle Investigator: PF Dr. Luisa Klotz, University
Hospital Münster
EudraCT - No.: 2014-003481-25.
Clinical Trial No.r: NCT02461069.
All rights reserved. Please visit https://medical-data-
models.org/forms/15217
Inclusion and exclusion criteria,
Relapsing Remitting Multiple
Sclerosis, DIMAT-MS, NCT02461069
Inclusion criteria
Written informed consent must be obtained
before any assessment is performed.
Yes
No
Male and female subjects aged 18 - 60 years.
Yes
No
Patients with RRMS, defined by 2010 revised
McDonald criteria.
Yes
No
Patients with an Expanded Disability Status Scale
(EDSS) score of 0-6.0.
Yes
No
Patients with one of the following treatment
status:
• naïve to disease modifying (DM) treatment,
• no DM treatment for at least 6 months,
• currently on MS therapy with interferon β-1 or
glatiramer acetate and willing
to switch to dimethyl fumarate (Tec dera®).
Yes
No
MRI-scan of the brain ≤ 3 months at screening.
Yes
No
Exclusion criteria
Known hypersensitivity to dimethyl fumarate or
any ingredients of Tecfidera® (microcrystalline
cellulose; croscarmellose-sodium; talcum; high
dispersion, hydrophobic silicon dioxide;
magnesiumstearate (Ph. Eur.); triethylcitrate;
methacrylic acid-methacrylate copolymer (1:1)
(Ph. Eur.); methacrylic acid-ethylacrylate
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copolymer (1:1)-dispersion 30% (Ph. Eur.),
simeticon, sodiumdodecylsulfate, polysorbate 80,
gelantine, titanium oxide (E171), brilliant blue
(E133), hydrated Iron(III)-oxide hydroxide (E172),
shellac, potassium hydroxide.
Yes
No
A MS-relapse within 30 days prior to screening.
Yes
No
Known history of active tuberculosis or active
tuberculosis determined by a positive
QuantiFERON® TB Gold test.
Yes
No
Moderate to severe impairment of liver function or
persisting elevations > 2 x ULN (con rmed by
retest) of serum glutamic pyruvic transaminase/
alanine aminotransferase (SGPT/ALT), serum
glutamic oxaloacetic transaminase/aspartate
aminotransferase (SGOT/AST), or direct bilirubin
> 2 x ULN, except patients with con rmed Gilbert
́s syndrome (Meulengracht ́s disease).
Yes
No
Moderate to severe impairment of renal function,
as shown by serum creatinine > 133 μmol/L (or >
1.5 mg/dL).
Yes
No
Patients with significantly impaired bone marrow
function or significant anemia, leukopenia,
neutropenia or thrombocytopenia
• Hematocrit <24% and/or hemoglobin < 8.0 g/dl
and/or
• Absolute white blood cell count < 4,000 cells/
mm3 (μL) and/or
• Absolute neutrophils ≤ 1,500 cells/mm3 (μL)
and/or 
• Platelet count < 150,000 cells/ mm3 (μL).
Yes
No
Women of childbearing potential not utilizing
highly effective contraception.
yes (1)
no (2)
NA (3)
Mental condition rendering the subject unable to
understand the nature,
scope, and possible consequences of the study.
Yes
2 / 4
Eligibility criteria, Relapsing Remitting Multiple Sclerosis, DIMAT-MS,
NCT02461069
No
Subjects unlikely to comply with protocol as
determined by investigator, e.g., uncooperative
attitude, inability to return for follow-up visits (e.g.
major physical disability), and known unlikelihood
of completing the study.
Yes
No
Clinically relevant cardiovascular, neurological,
endocrine, or other major systemic disease
making implementation of the protocol or
interpretation of the study results difficult or that
would put the subject at risk by participating in
the study.
Yes
No
Subjects with ulcerative colitis or Crohn ́s
disease.
Yes
No
Subjects with a congenital or acquired severe
immunodeficiency, a history of cancer (except for
basal or squamous cell skin lesions which have
been surgically excised, with no evidence of
metastasis), lymph proliferative disease, or any
subject who has received lymphoid irradiation.
Yes
No
Human immunodeficiency virus (HIV) positive,
hepatitis B virus positive or hepatitis C virus
positive subjects.
Yes
No
Acute or chronic infection.
Yes
No
History of drug or alcohol abuse.
Yes
No
Use of adrenocorticotrophic hormone (ACTH) or
systemic corticosteroids for 4 weeks prior to
screening.
Yes
No
Prior or concomitant use of cytokine therapy or
intravenous immunoglobulins in the 3 months
prior to screening.
Yes
No
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Prior use of alemtuzumab or cladribine.
Yes
No
Prior use (within 1 year) of fingolimod (Gilenya®)
or natalizumab (Tysab- ri®).
Yes
No
Prior use (within 2 years) of mitoxantrone, or
other immunosuppressant agents such as
azathioprine, cyclophosphamide, cyclosporine,
methotrexate or mycophenolate mofetil.
Yes
No
Prior treatment with teriflunomide or leflunomide,
unless successful washout, confirmed by plasma
concentration of < 0.02 μg/ml.
Yes
No
Prior use of any investigational drug in the 6
months preceding screening.
Yes
No
Pregnant or breast-feeding women.
yes (1)
no (2)
NA (3)
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Eligibility Heart Failure NCT02359227
Safety Study of Cenderitide in Stable Chronic Heart Failure;
ODM derived from:
https://clinicaltrials.gov/show/NCT02359227
All rights reserved. Please visit https://medical-data-
models.org/forms/15221
Eligibility Heart Failure
NCT02359227
Criteria
male or female, ≥ 18 years of age*
Yes
No
body mass index (bmi) of 18-40 kg/m2, inclusive*
Yes
No
current or historical new york heart association
(nyha) functional class ≥ ii*
Yes
No
at least one of the following: documented systolic
heart failure with an ejection fraction (ef) ≤ 40%
and/or a historical measurement of plasma bnp ≥
150 pg/ml (or nt-probnp ≥ 600 pg/ml)*
Yes
No
systolic blood pressure 100-160 mmhg*
Yes
No
stable and compliant treatment with oral heart
failure medications for at least 4 weeks prior to
screening*
Yes
No
key exclusion criteria:*
Yes
No
known hypersensitivity or allergy to natriuretic
peptide or its components, nesiritide, other
natriuretic peptides or related compounds*
Yes
No
current clinical diagnosis of acute
decompensated heart failure (adhf)*
Yes
No
clinical diagnosis of acute coronary syndrome
(acs) within 30 days prior to screening.*
Yes
No
symptomatic postural hypotension*
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Yes
No
evidence of uncorrected volume or sodium ≤ 130
mmol/l or other condition that would predispose
the patient to adverse events*
Yes
No
clinically significant aortic or mitral valve stenosis*
Yes
No
acute myocarditis or hypertrophic obstructive,
restrictive, or constrictive cardiomyopathy (not
including restrictive mitral filling patterns)*
Yes
No
severe renal failure defined as creatinine
clearance < 45 ml/min as estimated by either the
cockcroft-gault or the mdrd equations*
Yes
No
significant pulmonary disease (e.g., history of oral
daily steroid dependency, history of carbon
dioxide (co2) retention or need for intubation for
acute exacerbation, or currently receiving iv
steroids)*
Yes
No
known hepatic impairment as indicated by any of
the following: a) total bilirubin > 3 mg/dl; b)
albumin < 2.8 mg/dl, with other signs or
symptoms of hepatic dysfunction; c) increased
ammonia levels, if performed, with other signs or
symptoms of hepatic dysfunction*
Yes
No
2 / 2
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Lab and Medical Examination Visit 3 (Core Study), DIMAT-
MS, Relapsing Remitting Multiple Sclerosis NCT02461069
Study documentation part: Visit 3 (Core Study), Study week
8
Study Details: A 24-week, multicenter, exploratory, two arm
study to
assess the effect of Dimethyl fumarate on
ImmuneModulatory
Action on T cells in patients with relapsing
remitting Multiple Sclerosis.
EudraCT - No.: 2014-003481-25.
Clinical Trial No.r: NCT02461069.
All rights reserved. Please visit https://medical-data-
models.org/forms/15222
Lab and Medical Examination
Visit Details
Date of visit
Did the patient experience a relapse since
screening?
If yes, please document p. 29
Yes
No
Did the patient have an infection since screening?
If yes, please document on Adverse Event form
Yes
No
Further Visit Information
Laboratory Urine Pregnancy Test (Please
perform the test only on suspicion of
pregnancy.)
Test done, specify: Test Date:
Urinary Pregnancy Test Result
negative (negative)
positive (positive)
Urine pregnancy test not done, reason
female participant with no childbearing
potential (female participant with no
childbearing potential)
male participant (male participant)
no suspicion of pregnancy (no suspicion
of pregnancy)
other (other)
Date of blood sampling
Date of blood sampling
Hematology
Leucocytes
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Leucocytes measurement unit
/mm^3 (/µL )
10^3 /µL  (10^3 /µL )
other (other)
Leucocytes Count  not done
Yes
No
Lymphocytes
Lymphocytes measurement unit
/mm^3 (/µL )
10^3 /µL  (10^3 /µL )
other (other)
Lymphocytes Count Procedure not done
Yes
No
Liver Function
Aspartate transaminase (AST) (SGOT)
U/L
AST Measurement Unit
nkat/L (nmol/s*L )
other (other)
U/L (U/L)
µkat/L (µmol/s*L )
AST measurement not done
Yes
No
Alanine transaminase (ALT) (SGPT)
ALT Measurement Unit
nkat/L (nmol/s*L )
other (other)
U/L (U/L)
ALT measurement not done
Yes
No
Gamma Glutamyl Transpeptidase Measurement
GGT Measurement Unit
nkat/L (nmol/s*L )
other (other)
U/L (U/L)
µkat/L (µmol/s*L )
GGT Measurement not done
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Yes
No
Renal function
Creatinine
Serum Creatinine  Measurment Unit
mg/dL (mg/dL)
other (other)
µmol/L (µmol/L)
Serum Creatinine Measurment not done
Yes
No
Blood Urea Nitrogen (BUN)
Blood urea nitrogen measurement unit
mg/dL (mg/dL)
other (other)
µmol/L (µmol/L)
Blood urea nitrogen measurement not done
Yes
No
Medical Examination
Medical Examination performed at:
Heart rate (in bpm):
bpm
Systolic blood pressure
>= 0
mmHg
Diastolic blood pressure
>= 0
mmHg
Temperature
°C
Expanded disability status scale (EDSS)
EDSS performed at
Visual testing
0 (1)
1 (2)
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2 (3)
3 (4)
4 (5)
5 (6)
6 (7)
Brianstem testing
0 (1)
1 (2)
2 (3)
3 (4)
4 (5)
5 (6)
Pyramidal testing
0 (0)
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
Cerebellar testing
0 (0)
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
X (X)
Bowel/Bladder
Cerebellar testing (1)
Cerebral testing
0 (0)
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
Ambulation Score
0 (0)
1 (1)
10 (10)
11 (11)
12 (12)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
7 (7)
8 (8)
9 (9)
EDSS step
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Signature
Study Drug Prescription information
Please hand out a Patient's Diary to the patient.
Date
Name/Signature Investigator
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Lab and Medical Examination Visit 5 (Core Study), DIMAT-
MS, Relapsing Remitting Multiple Sclerosis NCT02461069
Study documentation part: Visit 5 (Core Study), Study week
24
Study Details: A 24-week, multicenter, exploratory, two arm
study to
assess the effect of Dimethyl fumarate on
ImmuneModulatory
Action on T cells in patients with relapsing
remitting Multiple Sclerosis.
EudraCT - No.: 2014-003481-25.
Clinical Trial No.r: NCT02461069.
All rights reserved. Please visit https://medical-data-
models.org/forms/15223
Lab and Medical Examination
Visit Details
Date of visit
Did the patient experience a relapse since
screening?
If yes, please document p. 29
Yes
No
Did the patient have an infection since screening?
If yes, please document on Adverse Event form
Yes
No
Further Visit Information
Laboratory Urine Pregnancy Test (Please
perform the test only on suspicion of
pregnancy.)
Test done, specify: Test Date:
Urinary Pregnancy Test Result
negative (negative)
positive (positive)
Urine pregnancy test not done, reason
female participant with no childbearing
potential (female participant with no
childbearing potential)
male participant (male participant)
no suspicion of pregnancy (no suspicion
of pregnancy)
other (other)
Date of blood sampling
Date of blood sampling
Hematology
Leucocytes
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Leucocytes measurement unit
/mm^3 (/µL )
10^3 /µL  (10^3 /µL )
other (other)
Leucocytes Count  not done
Yes
No
Lymphocytes
Lymphocytes measurement unit
/mm^3 (/µL )
10^3 /µL  (10^3 /µL )
other (other)
Lymphocytes Count Procedure not done
Yes
No
Liver Function
Aspartate transaminase (AST) (SGOT)
U/L
AST Measurement Unit
nkat/L (nmol/s*L )
other (other)
U/L (U/L)
µkat/L (µmol/s*L )
AST measurement not done
Yes
No
Alanine transaminase (ALT) (SGPT)
ALT Measurement Unit
nkat/L (nmol/s*L )
other (other)
U/L (U/L)
ALT measurement not done
Yes
No
Gamma Glutamyl Transpeptidase Measurement
GGT Measurement Unit
nkat/L (nmol/s*L )
other (other)
U/L (U/L)
µkat/L (µmol/s*L )
GGT Measurement not done
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Yes
No
Renal function
Creatinine
Serum Creatinine  Measurment Unit
mg/dL (mg/dL)
other (other)
µmol/L (µmol/L)
Serum Creatinine Measurment not done
Yes
No
Blood Urea Nitrogen (BUN)
Blood urea nitrogen measurement unit
mg/dL (mg/dL)
other (other)
µmol/L (µmol/L)
Blood urea nitrogen measurement not done
Yes
No
Medical Examination
Medical Examination performed at:
Heart rate (in bpm):
bpm
Systolic blood pressure
>= 0
mmHg
Diastolic blood pressure
>= 0
mmHg
Temperature
°C
Body weight
>= 0
kg
Expanded disability status scale (EDSS)
EDSS performed at
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Visual testing
0 (1)
1 (2)
2 (3)
3 (4)
4 (5)
5 (6)
6 (7)
Brianstem testing
0 (1)
1 (2)
2 (3)
3 (4)
4 (5)
5 (6)
Pyramidal testing
0 (0)
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
Cerebellar testing
0 (0)
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
X (X)
Bowel/Bladder
Cerebellar testing (1)
Cerebral testing
0 (0)
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
Ambulation Score
0 (0)
1 (1)
10 (10)
11 (11)
12 (12)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
7 (7)
8 (8)
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9 (9)
EDSS step
Treatment after the core study phase
How will the patient be treated after the core
study phase (Visit 5)?
Further treatment with dimethyl fumarate
(1)
Other treatment (2)
If "other treatment", specify:
If "other treatment", please give a reason for
discontinuation of dimethyl fumarate:
Signature
Date
Name/Signature Investigator
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Lab and Medical Examination Visit 4 (Core Study), DIMAT-
MS, Relapsing Remitting Multiple Sclerosis NCT02461069
Study documentation part: Visit 3 (Core Study), Study week
16
Study Details: A 24-week, multicenter, exploratory, two arm
study to
assess the effect of Dimethyl fumarate on
ImmuneModulatory
Action on T cells in patients with relapsing
remitting Multiple Sclerosis.
EudraCT - No.: 2014-003481-25.
Clinical Trial No.r: NCT02461069.
All rights reserved. Please visit https://medical-data-
models.org/forms/15224
Lab and Medical Examination
Visit Details
Date of visit
Did the patient experience a relapse since
screening?
If yes, please document p. 29
Yes
No
Did the patient have an infection since screening?
If yes, please document on Adverse Event form
Yes
No
Further Visit Information
Laboratory Urine Pregnancy Test (Please
perform the test only on suspicion of
pregnancy.)
Test done, specify: Test Date:
Urinary Pregnancy Test Result
negative (negative)
positive (positive)
Urine pregnancy test not done, reason
female participant with no childbearing
potential (female participant with no
childbearing potential)
male participant (male participant)
no suspicion of pregnancy (no suspicion
of pregnancy)
other (other)
Date of blood sampling
Date of blood sampling
Hematology
Leucocytes
1 / 5
Leucocytes measurement unit
/mm^3 (/µL )
10^3 /µL  (10^3 /µL )
other (other)
Leucocytes Count  not done
Yes
No
Lymphocytes
Lymphocytes measurement unit
/mm^3 (/µL )
10^3 /µL  (10^3 /µL )
other (other)
Lymphocytes Count Procedure not done
Yes
No
Liver Function
Aspartate transaminase (AST) (SGOT)
U/L
AST Measurement Unit
nkat/L (nmol/s*L )
other (other)
U/L (U/L)
µkat/L (µmol/s*L )
AST measurement not done
Yes
No
Alanine transaminase (ALT) (SGPT)
ALT Measurement Unit
nkat/L (nmol/s*L )
other (other)
U/L (U/L)
ALT measurement not done
Yes
No
Gamma Glutamyl Transpeptidase Measurement
GGT Measurement Unit
nkat/L (nmol/s*L )
other (other)
U/L (U/L)
µkat/L (µmol/s*L )
GGT Measurement not done
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Remitting Multiple Sclerosis NCT02461069
Yes
No
Renal function
Creatinine
Serum Creatinine  Measurment Unit
mg/dL (mg/dL)
other (other)
µmol/L (µmol/L)
Serum Creatinine Measurment not done
Yes
No
Blood Urea Nitrogen (BUN)
Blood urea nitrogen measurement unit
mg/dL (mg/dL)
other (other)
µmol/L (µmol/L)
Blood urea nitrogen measurement not done
Yes
No
Medical Examination
Medical Examination performed at:
Heart rate (in bpm):
bpm
Systolic blood pressure
>= 0
mmHg
Diastolic blood pressure
>= 0
mmHg
Temperature
°C
Expanded disability status scale (EDSS)
EDSS performed at
Visual testing
0 (1)
1 (2)
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Remitting Multiple Sclerosis NCT02461069
2 (3)
3 (4)
4 (5)
5 (6)
6 (7)
Brianstem testing
0 (1)
1 (2)
2 (3)
3 (4)
4 (5)
5 (6)
Pyramidal testing
0 (0)
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
Cerebellar testing
0 (0)
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
X (X)
Bowel/Bladder
Cerebellar testing (1)
Cerebral testing
0 (0)
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
Ambulation Score
0 (0)
1 (1)
10 (10)
11 (11)
12 (12)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
7 (7)
8 (8)
9 (9)
EDSS step
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Lab and Medical Examination Visit 4 (Core Study), DIMAT-MS, Relapsing
Remitting Multiple Sclerosis NCT02461069
Signature
Study Drug Prescription information
Please hand out a Patient's Diary to the patient.
Date
Name/Signature Investigator
5 / 5
Lab and Medical Examination Visit 4 (Core Study), DIMAT-MS, Relapsing
Remitting Multiple Sclerosis NCT02461069
Eligibility Heart Failure NCT02371642
Strain Echo in Acute Heart Failure; ODM derived from:
https://clinicaltrials.gov/show/NCT02371642
All rights reserved. Please visit https://medical-data-
models.org/forms/15228
Eligibility Heart Failure
NCT02371642
Inclusion Criteria
18 years of age or greater*
Yes
No
ability for the patient to provide written informed
consent*
Yes
No
planned treatment with intravenous (iv)
medications (diuretics, vasodilators, inotropes) for
acute hf*
Yes
No
Exclusion Criteria
need for emergent, resuscitative intervention
(e.g., cardiopulmonary resuscitation,
endotracheal intubation)*
Yes
No
rapid atrial fibrillation or other arrhythmia that
requires iv rate or rhythm control*
Yes
No
plans for emergent percutaneous coronary
intervention (pci) from the ed*
Yes
No
pregnancy*
Yes
No
incarceration*
Yes
No
history of cardiac transplant*
Yes
No
planned transfer to another institution*
Yes
No
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Eligibility Heart Failure With Reactive
Pulmonary Hypertension NCT02304705
Sildenafil in Heart Failure With Reactive Pulmonary
Hypertension; ODM derived from:
https://clinicaltrials.gov/show/NCT02304705
All rights reserved. Please visit https://medical-data-
models.org/forms/15229
Eligibility Heart Failure With Reactive
Pulmonary Hypertension
NCT02304705
Inclusion Criteria
known chronic heart failure appropriately treated
with ace inhibitors and beta blockers, unless
contraindicated or poorly tolerated*
Yes
No
indication for right heart catheterization*
Yes
No
pulmonary artery mean pressure >25 mmhg*
Yes
No
pulmonary capillary wedge pressure > 15 mmhg*
Yes
No
pulmonary vascular resistance > 3 wu*
Yes
No
Exclusion Criteria
hypersensitivity, allergy, or intolerable side effect
to sildenafil*
Yes
No
history of primary pulmonary hypertension,
connective tissue disorder, severe copd,
pulmonary embolism, or left to right shunt*
Yes
No
co-morbidities, limited exercise intolerance:*
Yes
No
morbid obesity (bmi >40)*
Yes
No
copd with oxygen dependence*
Yes
No
severe peripheral vascular disease with
intermittent claudication*
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Yes
No
status post amputation of lower extremity at any
level*
Yes
No
severe degenerative joint disease preventing
normal walking*
Yes
No
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Eligibility Heart Failure With Reactive Pulmonary Hypertension
NCT02304705
Version 2 Würzburger Screening for
Sociomedical Documentation
Version 2 Würzburger Screening for Sociomedical
Documentation.
Original German Description:
Beim Würzburger Screening handelt es sich um einen
einfach handhabbaren einseitigen Fragebogen zur
Erhebung von beruflichen Problemlagen sowie des Bedarfs
an berufsorientierten Rehabilitationsmaßnahmen. Das
Würzburger Screening findet sowohl im Zugangsverfahren
zur Rehabilitation durch den Leistungsträger als auch in
medizinischen Rehabilitationseinrichtungen Verwendung.
Im Rahmen der Instrumentenentwicklung und -validierung
haben sich die interne Konsistenz und die Test-Retest-
Reliabilität der Skalen sowie die Trennschärfe der Items als
zufriedenstellend erwiesen.
Mit Hilfe eines einfachen Algorithmus bestehend aus dem
Erwerbsstatus zu Rehabilitationsbeginn und der Kurzskala
„Subjektive Erwerbsprognose“ gelang eine korrekte
Klassifikation von 86% der Personen, die sechs Monate
nach Beendigung der Rehabilitationsmaßnahme nicht
erwerbstätig waren (Sensitivität). Von den Personen, die an
den Arbeitsplatz zurückkehrten, konnten 82% korrekt
identifiziert werden (Spezifität). Bei der
Konstruktvalidierung ergaben sich zwischen den Skalen
des „Würzburger Screenings“ und weiteren berufs- und
gesundheitsbezogenen Fragebögen z. B. mit der Skala
„Berufliche Sorgen“ (IRES-BS) aus dem IRES-Fragebogen,
Zusammenhänge im mittleren Bereich.
Das Würzburger Screening umfasst drei Skalen:
„Berufliche Belastungen“,
„Subjektive Erwerbsprognose“ und
„Interesse an berufsbezogenen Therapieangeboten“
Das kurze, reliable und valide Instrument kann sowohl bei
der Reha-Zugangssteuerung durch die sozialmedizinische
Dienste als auch bei der Aufnahmeuntersuchung in der
Reha-Klinik eingesetzt werden. Mit Hilfe eines einfachen
Algorithmus – bestehend aus dem Erwerbsstatus zu
Rehabilitationsbeginn und der Kurzskala „Subjektive
Erwerbsprognose“ – kann der Erwerbsstatus sechs Monate
nach Rehabilitationsaufenthalt indikationsübergreifend sehr
gut vorhergesagt werden.
Die in den sozialmedizinischen Diensten zum Einsatz
kommende Version des Würzburger Screenings besteht
aus den Skalen „Subjektive Erwerbsprognose“ und
„Berufliche Belastungen“. Die Skala „Interesse an
berufsbezogenen Therapieangeboten” fehlt. Damit soll
Unklarheiten bei denjenigen Antragstellern vorgebeugt
werden, deren Antrag auf Rehabilitation später abgelehnt
wird.
Eine ausführlichere Beschreibung der psychometrischen
Eigenschaften des Würzburger Screenings, der Ergebnisse
der Fragebogenvalidierung sowie der Angaben zur
Anwendung des Würzburger Screenings finden sich im
Manual.
Publication granted by 
Dipl.-Psych. Hans-Dieter Wolf
Universität Würzburg
Abteilung für Medizinische Psychologie und
Psychotherapie,
Medizinische Soziologie und Rehabilitationswissenschaften
am Institut für klinische Epidemiologie und Biometrie
Klinikstr. 3, 97070 Würzburg
Tel.: 0931/3186092, Fax: 0931/3186080
All rights reserved. Please visit https://medical-data-
models.org/forms/15231
Version 2 Würzburger Screening for
Sociomedical Documentation
Patientendaten
Alter
1 / 3
Geschlecht
männlich (1)
weiblich (2)
Berufstätigkeit
Sind Sie zurzeit berufstätig?
Hausfrau /-mann (Falls dies für Sie
zutrifft: Betrachten Sie bei der
Beantwortung der folgenden Fragen Ihre
Tätigkeit für Haushalt und Familie wie
eine berufliche Tätigkeit) (House-
wife/husband)
nein, dauerhaft berentet (Altersrente,
Erwerbsunfähigkeits-,
Erwerbsminderungs- oder
Berufsunfähigkeitsrente) (no,
permanently retired)
nein, Zeitrente bis (no, temporary
annuity)
nein, arbeitslos seit (no, unemployed
since)
ja, Vollzeit (6 Stunden/Tag und mehr)
(yes, full time (6 hours/day and more))
ja, in Ausbildung (yes, in training)
ja, Teilzeit (1 bis unter 3 Stunden/Tag)
(yes, part time (1 - 3 hours/ day))
ja, Teilzeit (3 bis unter 6 Stunden/Tag)
(yes, part time (3 - 6 hours/day))
arbeitslos seit
Zeitrente bis
Glauben Sie, dass Sie nach der Reha-
Maßnahme wieder an Ihrem bisherigen
Arbeitsplatz tätig sein können?
Ja
Nein
Tragen Sie sich zurzeit mit dem Gedanken, einen
Rentenantrag (Frührente aus
Gesundheitsgründen) zu stellen?
Ja
Nein
Wie bald nach Abschluss der Reha-Maßnahme
hoffen Sie, Ihre berufliche Tätigkeit wieder
aufzunehmen?
Innerhalb von …
mehr als einem Monat (more than one
month)
überhaupt nicht (not at all)
einem Monat (one month)
Wie stark ist Ihr berufliches Leistungsvermögen
eingeschränkt?
etwas (a little)
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überhaupt nicht (not at all)
ziemlich (quite a bit)
kaum  (rarely )
sehr (very much)
Tragen Belastungen am Arbeitsplatz zu Ihren
gesundheitlichen Beschwerden bei?
etwas (a little)
überhaupt nicht (not at all)
ziemlich (quite a bit)
kaum  (rarely )
sehr (very much)
Wie stark fühlen Sie sich durch Ihre berufliche
Tätigkeit belastet?
etwas (a little)
überhaupt nicht (not at all)
ziemlich (quite a bit)
kaum  (rarely )
sehr (very much)
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Version 1 Würzburger Screening for
Medical Documentation
Version 1 Würzburger Screening for Medical
Documentation.
Original German Description:
Beim Würzburger Screening handelt es sich um einen
einfach handhabbaren einseitigen Fragebogen zur
Erhebung von beruflichen Problemlagen sowie des Bedarfs
an berufsorientierten Rehabilitationsmaßnahmen. Das
Würzburger Screening findet sowohl im Zugangsverfahren
zur Rehabilitation durch den Leistungsträger als auch in
medizinischen Rehabilitationseinrichtungen Verwendung.
Im Rahmen der Instrumentenentwicklung und -validierung
haben sich die interne Konsistenz und die Test-Retest-
Reliabilität der Skalen sowie die Trennschärfe der Items als
zufriedenstellend erwiesen.
Mit Hilfe eines einfachen Algorithmus bestehend aus dem
Erwerbsstatus zu Rehabilitationsbeginn und der Kurzskala
„Subjektive Erwerbsprognose“ gelang eine korrekte
Klassifikation von 86% der Personen, die sechs Monate
nach Beendigung der Rehabilitationsmaßnahme nicht
erwerbstätig waren (Sensitivität). Von den Personen, die an
den Arbeitsplatz zurückkehrten, konnten 82% korrekt
identifiziert werden (Spezifität). Bei der
Konstruktvalidierung ergaben sich zwischen den Skalen
des „Würzburger Screenings“ und weiteren berufs- und
gesundheitsbezogenen Fragebögen z. B. mit der Skala
„Berufliche Sorgen“ (IRES-BS) aus dem IRES-Fragebogen,
Zusammenhänge im mittleren Bereich.
Das Würzburger Screening umfasst drei Skalen:
„Berufliche Belastungen“,
„Subjektive Erwerbsprognose“ und
„Interesse an berufsbezogenen Therapieangeboten“
Das kurze, reliable und valide Instrument kann sowohl bei
der Reha-Zugangssteuerung durch die sozialmedizinische
Dienste als auch bei der Aufnahmeuntersuchung in der
Reha-Klinik eingesetzt werden. Mit Hilfe eines einfachen
Algorithmus – bestehend aus dem Erwerbsstatus zu
Rehabilitationsbeginn und der Kurzskala „Subjektive
Erwerbsprognose“ – kann der Erwerbsstatus sechs Monate
nach Rehabilitationsaufenthalt indikationsübergreifend sehr
gut vorhergesagt werden.
Die in den sozialmedizinischen Diensten zum Einsatz
kommende Version des Würzburger Screenings besteht
aus den Skalen „Subjektive Erwerbsprognose“ und
„Berufliche Belastungen“. Die Skala „Interesse an
berufsbezogenen Therapieangeboten” fehlt. Damit soll
Unklarheiten bei denjenigen Antragstellern vorgebeugt
werden, deren Antrag auf Rehabilitation später abgelehnt
wird.
Eine ausführlichere Beschreibung der psychometrischen
Eigenschaften des Würzburger Screenings, der Ergebnisse
der Fragebogenvalidierung sowie der Angaben zur
Anwendung des Würzburger Screenings finden sich im
Manual.
Publication granted by 
Dipl.-Psych. Hans-Dieter Wolf
Universität Würzburg
Abteilung für Medizinische Psychologie und
Psychotherapie,
Medizinische Soziologie und Rehabilitationswissenschaften
am Institut für klinische Epidemiologie und Biometrie
Klinikstr. 3, 97070 Würzburg
Tel.: 0931/3186092, Fax: 0931/3186080
All rights reserved. Please visit https://medical-data-
models.org/forms/15232
Version 1 Würzburger Screening for
Medical Documentation
Patientendaten
Alter
1 / 3
Geschlecht
männlich (1)
weiblich (2)
Berufstätigkeit
Sind Sie zurzeit berufstätig?
Hausfrau /-mann (Falls dies für Sie
zutrifft: Betrachten Sie bei der
Beantwortung der folgenden Fragen Ihre
Tätigkeit für Haushalt und Familie wie
eine berufliche Tätigkeit) (House-
wife/husband)
nein, dauerhaft berentet (Altersrente,
Erwerbsunfähigkeits-,
Erwerbsminderungs- oder
Berufsunfähigkeitsrente) (no,
permanently retired)
nein, Zeitrente bis (no, temporary
annuity)
nein, arbeitslos seit (no, unemployed
since)
ja, Vollzeit (6 Stunden/Tag und mehr)
(yes, full time (6 hours/day and more))
ja, in Ausbildung (yes, in training)
ja, Teilzeit (1 bis unter 3 Stunden/Tag)
(yes, part time (1 - 3 hours/ day))
ja, Teilzeit (3 bis unter 6 Stunden/Tag)
(yes, part time (3 - 6 hours/day))
arbeitslos seit
Zeitrente bis
Glauben Sie, dass Sie nach der Reha-
Maßnahme wieder an Ihrem bisherigen
Arbeitsplatz tätig sein können?
Ja
Nein
Tragen Sie sich zurzeit mit dem Gedanken, einen
Rentenantrag (Frührente aus
Gesundheitsgründen) zu stellen?
Ja
Nein
Wie bald nach Abschluss der Reha-Maßnahme
hoffen Sie, Ihre berufliche Tätigkeit wieder
aufzunehmen?
Innerhalb von …
mehr als einem Monat (more than one
month)
überhaupt nicht (not at all)
einem Monat (one month)
Wie stark ist Ihr berufliches Leistungsvermögen
eingeschränkt?
etwas (a little)
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überhaupt nicht (not at all)
ziemlich (quite a bit)
kaum  (rarely )
sehr (very much)
Tragen Belastungen am Arbeitsplatz zu Ihren
gesundheitlichen Beschwerden bei?
etwas (a little)
überhaupt nicht (not at all)
ziemlich (quite a bit)
kaum  (rarely )
sehr (very much)
Wie stark fühlen Sie sich durch Ihre berufliche
Tätigkeit belastet?
etwas (a little)
überhaupt nicht (not at all)
ziemlich (quite a bit)
kaum  (rarely )
sehr (very much)
Haben Sie Interesse, berufliche Probleme im
Rahmen der Reha-Maßnahme zu bearbeiten?
etwas (a little)
überhaupt nicht (not at all)
ziemlich (quite a bit)
kaum  (rarely )
sehr (very much)
Haben Sie Interesse, an einer berufsbezogenen
Schulungsgruppe teilzunehmen?
etwas (a little)
überhaupt nicht (not at all)
ziemlich (quite a bit)
kaum  (rarely )
sehr (very much)
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Eligibility Hepatic Carcinoma NCT02332551
Pilot Study of Percutaneous Irreversible Electroporation to
Treat Unresectable Hepatic Carcinoma Close to the
Gallbladder; ODM derived from:
https://clinicaltrials.gov/show/NCT02332551
All rights reserved. Please visit https://medical-data-
models.org/forms/15233
Eligibility Hepatic Carcinoma
NCT02332551
Inclusion Criteria
hepatic carcinoma diagnosed by positive biopsy
or non-invasive criteria,*
Yes
No
tumor from gallbladder is ＜0.5 cm*
Yes
No
not suitable for surgical resection or
transplantation,*
Yes
No
have at least one, but less than or equal to 3
tumors,*
Yes
No
of the tumour(s) identified, each tumor must be ≤
7 cm in diameter,*
Yes
No
child-pugh class a,b*
Yes
No
eastern cooperative oncology group (ecog) score
of 0-1,*
Yes
No
american society of anaesthesiologists (asa)
score ≤ 3,*
Yes
No
a prothrombin time ratio > 50%,*
Yes
No
platelet count > 80x109/l,*
Yes
No
ability of patient to stop anticoagulant and anti-
platelet therapy for seven days prior to and seven
days post nanoknife procedure,*
Yes
No
1 / 2
are able to comprehend and willing to sign the
written informed consent form (icf),*
Yes
No
have a life expectancy of at least 3 months.*
Yes
No
Exclusion Criteria
eligible for surgical treatment or transplantation
for hcc,*
Yes
No
hepatic carcinoma developed on an already
transplanted liver,*
Yes
No
cardiac insufficiency, ongoing coronary artery
disease or arrhythmia,*
Yes
No
any active implanted device (eg pacemaker),*
Yes
No
women who are pregnant or women of child-
bearing potential who are not using an
acceptable method of contraception,*
Yes
No
have received treatment with an investigational
agent/ procedure within 30 days prior to
treatment with the nanoknife™ ledc system, are
in the opinion of the investigator unable to comply
with the visit schedule and protocol evaluations.*
Yes
No
2 / 2
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Diagoses Operations Therapy regimen Point
D2 in Time DGU TraumaRegister questionnaire
DGU TraumaRegister® questionnaire; Data are collected
prospectively in four consecutive time phases from the site
of the accident until discharge from hospital: A) Pre-hospital
phase, B) Emergency room and initial surgery, C) Intensive
care unit and D) Discharge. The documentation includes
detailed information on demographics, injury pattern,
comorbidities, pre- and in-hospital management, course on
intensive care unit, relevant laboratory findings including
data on transfusion and outcome of each individual. The
inclusion criterion is admission to hospital via emergency
room with subsequent ICU/ICM care or reach the hospital
with vital signs and die before admission to ICU. The
infrastructure for documentation, data management, and
data analysis is provided by AUC - Academy for Trauma
Surgery (AUC - Akademie der Unfallchirurgie GmbH), a
company affiliated to the German Trauma Society. The
scientific leadership is provided by the Committee on
Emergency Medicine, Intensive Care and Trauma
Management (Sektion NIS) of the German Trauma Society.
The participating hospitals submit their data anon-ymously
into a central database via a web-based application.
Scientific data analysis is approved according to a peer
review procedure established by Sektion NIS.
TraumaRegister DGU® - Hinweise für die Publikation von
Ergebnissen 5 März 2014 Seite 3 von 3 © 2014
TraumaRegister DGU® / AUC GmbH The participating
hospitals are primarily located in Germany (90%), but a
rising number of hospitals of other countries contribute data
as well (at the moment from Austria, Belgium, China,
Finland, Luxembourg, Slovenia, Switzerland, The
Netherlands, and the United Arab Emirates). Currently,
approx. 25,000 cases from more than 600 hospitals are
entered into the database per year. Participation in
TraumaRegister DGU® is voluntary. For hospitals
associated with TraumaNetzwerk DGU®, however, the
entry of at least a basic data set is obligatory for reasons of
quality assurance. www.traumaregister-dgu.de
All rights reserved. Please visit https://medical-data-
models.org/forms/15239
Diagoses Operations Therapy
regimen Point D2 in Time DGU
TraumaRegister questionnaire
Informationen über den Patienten
Eintreffen
Land
Postleitzahl
Buchstabe
Patienten ID
Geburtsdatum
Year
Verletzungen, Operationen, Therapie
AIS Code
AIS Text
1 / 2
Offene Fraktur
Ja
Nein
Grad:
<= 4
>= 1
Diagnosestellung nach Intensiv-Aufnahme?
Ja
Nein
Operation 1
OPS 301 (Operation 1)
Datum Operation 1
Operation 2
OPS 301 (Operation 2)
Datum Operation 2
Damage Control-OP
Ja
Nein
Anzahl weiterer OPs (z.B. Revisionen)
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Eligibility Hepatic Carcinoma NCT02352935
Percutaneous Irreversible Electroporation for Unresectable
Hepatic Carcinoma in Poor Liver Function; ODM derived
from: https://clinicaltrials.gov/show/NCT02352935
All rights reserved. Please visit https://medical-data-
models.org/forms/15240
Eligibility Hepatic Carcinoma
NCT02352935
Inclusion Criteria
hepatic carcinoma diagnosed by positive biopsy
or non-invasive criteria,*
Yes
No
not suitable for surgical resection or
transplantation,*
Yes
No
have at least one, but less than or equal to 3
tumors,*
Yes
No
of the tumour(s) identified, each tumor must be ≤
5 cm in diameter,*
Yes
No
child-pugh class b or ≤12，*
Yes
No
eastern cooperative oncology group (ecog) score
of 0-1,*
Yes
No
american society of anaesthesiologists (asa)
score ≤ 3,*
Yes
No
a prothrombin time ratio > 50%,*
Yes
No
platelet count > 80x109/l,*
Yes
No
ability of patient to stop anticoagulant and anti-
platelet therapy for seven days prior to and seven
days post nanoknife procedure,*
Yes
No
are able to comprehend and willing to sign the
written informed consent form (icf),*
Yes
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No
have a life expectancy of at least 3 months.*
Yes
No
Exclusion Criteria
eligible for surgical treatment or transplantation
for hcc,*
Yes
No
hepatic carcinoma developed on an already
transplanted liver,*
Yes
No
cardiac insufficiency, ongoing coronary artery
disease or arrhythmia,*
Yes
No
any active implanted device (eg pacemaker),*
Yes
No
women who are pregnant or women of child-
bearing potential who are not using an
acceptable method of contraception,*
Yes
No
have received treatment with an investigational
agent/ procedure within 30 days prior to
treatment with the nanoknife™ ledc system, are
in the opinion of the investigator unable to comply
with the visit schedule and protocol evaluations.*
Yes
No
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Flowchart inpatient admission Checklist Admission
Routine documentation in German hospitals DMI
Routine documentation in German hospitals. Source file
name: AU010104_Checkliste Aufnahme/ Ablaufplan
stationäre Aufnahme.045
Examplary forms provided by DMI (http://www.dmi.de/)
All rights reserved. Please visit https://medical-data-
models.org/forms/15242
Flowchart inpatient admission
Checklist Admission
Flowchart inpatient admission
Admission date and time
Ward
Expected patient discharge date
Surgery date
Blood collection (CA- Standard: BB, Sodium,
Potassium, Creatinine, Urea, CA 19-9, CEA,
Coagulation, TSH
Yes
No
Other blood collection
X- ray
Chest X- ray
yes, registered (1)
yes, referral already by the X- ray
department (2)
yes, referral in Patient's file (3)
no (4)
Date and time of Chest X- ray
CT abdomen
yes, registered (1)
yes, referral already by the X- ray
department (2)
yes, referral in Patient's file (3)
no (4)
CT abdomen Date and time
MRI
yes, registered (1)
yes, referral already by the X- ray
department (2)
yes, referral in Patient's file (3)
no (4)
MRI Date and time
1 / 3
Other
yes, registered (1)
yes, referral already by the X- ray
department (2)
yes, referral in Patient's file (3)
no (4)
Date and time Other
Ultrasonography/ Endoscopy
Ultrasonography of liver
yes, registered (1)
yes, referral already by the
Ultrasonography department (2)
yes, referral in Patient's file (3)
no (4)
Date and time of Ultrasonography of liver
Colonoscopy
yes, registered (1)
yes, referral already by the
Ultrasonography department (2)
yes, referral in Patient's file (3)
no (4)
Date and time of Colonoscopy
Gastroscopy
yes, registered (1)
yes, referral already by the
Ultrasonography department (2)
yes, referral in Patient's file (3)
no (4)
Date and time of Gastroscopy
Endosonography
yes, registered (1)
yes, referral already by the
Ultrasonography department (2)
yes, referral in Patient's file (3)
yes, appointment in LC/ Outpatient
department (4)
no (5)
Date and time of Endosonography
Other
yes, registered (1)
yes, referral already by the
Ultrasonography department (2)
yes, referral in Patient's file (3)
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no (4)
Date and time of Other
Other Examinations
Other Examinations
Other Examinations
yes, registered (1)
yes, referral already by the
Ultrasonography department (2)
yes, referral in Patient's file (3)
no (4)
Date and time of Other Examinations
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Eligibility Hepatitis B Infection
NCT02304315
A Phase 2 Study of GC1102 (Recombinant Hepatitis B
Immunoglobulin) in HBV-related Liver Transplant
Recipients; ODM derived from:
https://clinicaltrials.gov/show/NCT02304315
All rights reserved. Please visit https://medical-data-
models.org/forms/15243
Eligibility Hepatitis B Infection
NCT02304315
Inclusion Criteria
given written informed consent*
Yes
No
aged 19 - 65 years*
Yes
No
expected liver transplantation related to hepatitis
b*
Yes
No
positive hbsag*
Yes
No
Exclusion Criteria
patients has participated in any other clinical trial
within 30 days*
Yes
No
patients who are scheduled re-operation for liver
transplantation*
Yes
No
patients with are co-infected with hav, hcv or hiv*
Yes
No
history of malignant tumor within 5 years except
primary liver cancer*
Yes
No
patients with moderate or severe renal disorder
(serum creatinine > 1.5 x ulm) or anuria, acute
renal failure or dialysis*
Yes
No
patients who had experienced cardiovascular
attack, myocardiac infarction, ptca or coronary
bypass or with angina, arrhythmia, or any other
clinically meaningful valvular heart disease,
cerebral infarction or cerebral hemorrhage within
6 months*
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Yes
No
history of anaphylaxis against active ingredient or
excipients of study drug*
Yes
No
patients who had been vaccinated with parenteral
live vaccine (measles vaccine, epidemic parotitis
vaccine, rubella vaccine, cholera vaccine,
chickenpox vaccine) within 3 months*
Yes
No
patients who had been treated with any other
immuno globulin within 3 months*
Yes
No
pregnant or breast-feeding women*
Yes
No
women of childbearing potential who do not
agree to use appropriate contraceptive methods
(condom, an intrauterine device, oral
contraceptive hormones, or a vasectomy of male
sex partner) during this study*
Yes
No
alcohol or drug abuse within 6 months*
Yes
No
patients who has any clinically meaningful
disease in investigator's judgement to prevent
participating in this study*
Yes
No
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Eligibility Hepatitis B, Chronic
NCT02327676
Emtricitabine for Naive Child Chinese Chronic Hepatitis B
Patients; ODM derived from:
https://clinicaltrials.gov/show/NCT02327676
All rights reserved. Please visit https://medical-data-
models.org/forms/15244
Eligibility Hepatitis B, Chronic
NCT02327676
Inclusion Criteria
children with body weight ≥ 33 kg and who can
swallow entire emtricitabine capsle(200mg)*
Yes
No
hbsag positive for more than 6 months*
Yes
No
hbeag positive patients: hbv dna ≥ 5log10
copies/ml*
Yes
No
hbeag positive patients: alt≥2×uln;or liver biopsy
g≥2;or liver biopsy s ≥2;or liver biopsy knodell hai
≥ 4*
Yes
No
hbeag negative patients: hbv dna ≥ 4log10
copies/ml*
Yes
No
hbeag positive patients: alt≥2×uln;or liver biopsy
g≥2;or liver biopsy s ≥2;or liver biopsy knodell hai
≥ 4*
Yes
No
nucleoside/nucleotide naive patients*
Yes
No
Exclusion Criteria
- diagnosed hcc with afp and ultrasound, ct or
mri*
Yes
No
creatine ＞130μmol/l or ccr < 70ml/min*
Yes
No
hemoglobin <100g/l*
Yes
No
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neutrophils <1.5e+9/l*
Yes
No
plt<80e+9/l*
Yes
No
coinfected with hav,hev,hcv,hdv or hiv*
Yes
No
ana ＞ 1:100*
Yes
No
uncontrolled cardiovascular diseases, kidney
diseases,lung diseases, neurological diseases,
digestive diseases,metabolic disorders, immune-
compromised diseases or cancer*
Yes
No
drug abuse or alcohol addiction*
Yes
No
previous history of taking agents of lamivudine,
adefovir, tenofovir entecavir or telbivudine*
Yes
No
long-term use of immunosuppressor or
immunomodulator 6 months before enrollment to
this trial*
Yes
No
underwent liver transplantation or liver
transplantation in schedule*
Yes
No
allergic to nucleoside or nucleotide analogues*
Yes
No
pregnancy or in breastfeeding*
Yes
No
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Referral Prescription for hospital treatment
Routine documentation in German hospitals DMI
Routine documentation in German hospitals. Source file
name: AU050101_Verordnung von
Krankenhausbehandlung/ Einweisungsschein 1.007
Examplary forms provided by DMI (http://www.dmi.de/)
All rights reserved. Please visit https://medical-data-
models.org/forms/15245
Referral Prescription for hospital
treatment
Referral
Health insurance
Type of treatment:
GP (1)
Emergency (2)
Accident (3)
BVG (4)
Nearest suitable hospital
Diagnosis
Medical examinations and diagnosis findings
Previous measures e.g. Medication
Problem/ Indications e.g. Allergies
Given medical records/ findings
Attending physician
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Referral for Private patients Prescription for hospital
treatment Routine documentation in German hospitals DMI
Routine documentation in German hospitals. Source file
name: AU050101_Verordnung von
Krankenhausbehandlung/ Einweisungsschein 2.007
Examplary forms provided by DMI (http://www.dmi.de/)
All rights reserved. Please visit https://medical-data-
models.org/forms/15246
Referral for Private patients
Prescription for hospital treatment
Referral for private patients
Patient name
Date of birth
Health insurance ID
Health insurance
Status
Date
Nearest suitable hospital
Type of treatment:
GP (1)
Emergency (2)
Accident (3)
BVG (4)
Diagnosis
Medical examinations and diagnosis findings
Previous measures e.g. Medication
Problem/ Indications e.g. Allergies
Given medical records/ findings
Attending physician
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Eligibility Diabetic Neuropathies
NCT00231673
A Study To Evaluate The Effect Of Topiramate On Clinical
And Electrophysiological Parameters In Subjects With
Diabetic Peripheral Polyneuropathy; ODM derived from:
https://clinicaltrials.gov/show/NCT00231673
All rights reserved. Please visit https://medical-data-
models.org/forms/15247
Eligibility Diabetic Neuropathies
NCT00231673
Inclusion Criteria
diagnosis of type 2 diabetes mellitus*
Yes
No
pain for at least 6 months prior to randomization
that the investigator attributes to diabetic
peripheral polyneuropathy*
Yes
No
two sets of baseline nerve conduction studies
and quantitative sensory testing*
Yes
No
hba1c =< 9%*
Yes
No
diabetes controlled on stable regimen*
Yes
No
female patients must be postmenopausal for at
least 1 year, surgically incapable of childbearing,
practicing abstinence, or practicing an acceptable
method of contraception (requires negative
pregnancy test)*
Yes
No
Exclusion Criteria
diagnosis of type 1 diabetes mellitus*
Yes
No
polyneuropathy due to other underlying causes*
Yes
No
hospitalization within the past 3 months due to
episodes of hyper/hypoglycemia*
Yes
No
other unstable medical conditions*
Yes
No
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history of suicidal attempts*
Yes
No
exposure to any other experimental drugs or
device within the past 30 days*
Yes
No
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Echocardiography Medical Report of findings Echocardiography
findings Routine documentation in German hospitals DMI
Routine documentation in German hospitals. Source file
name: DG020104_Echokardiographiebefund/
Echokardiographie.055
Examplary forms provided by DMI (http://www.dmi.de/)
All rights reserved. Please visit https://medical-data-
models.org/forms/15248
Echocardiography Medical Report of
findings Echocardiography findings
Echocardiography findings
Attending physician
Date
Recipient
Diagnosis
Anamnesis
Medication
Transthoracic echocardiography findings
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Colonoscopy Findings Endoscopy findings
Routine documentation in German hospitals DMI
Routine documentation in German hospitals. Source file
name: DG020105_Endoskopiebefund/
Koloskopiebefund.079
Examplary forms provided by DMI (http://www.dmi.de/)
All rights reserved. Please visit https://medical-data-
models.org/forms/15249
Colonoscopy Findings Endoscopy
findings
Colonoscopy findings
Date of Colonoscopy findings
Patient name
Date of birth
Indications for colonoscopy
Diagnosis
Findings
Therapy suggestions
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Eligibility HIV Infections NCT00227500
Pravastatin for Hyperlipidaemia in HIV.; ODM derived from:
https://clinicaltrials.gov/show/NCT00227500
All rights reserved. Please visit https://medical-data-
models.org/forms/15250
Eligibility HIV Infections
NCT00227500
Inclusion Criteria
provide written informed consent to participate in
the trial*
Yes
No
hiv-1 sero-positive*
Yes
No
male/female >18 years age*
Yes
No
currently receiving hiv protease inhibitor therapy
for > 12 weeks and unlikely to require change in
existing regimen during the 16 week study
period*
Yes
No
fasting cholesterol > 6.5 mmol/l (mean of 2
samples collected > 3 days apart)*
Yes
No
Exclusion Criteria
any condition which may interfere with ability to
comply with study*
Yes
No
gastrointestinal disorder which may affect drug
absorption*
Yes
No
hypertension or congestive cardiac failure*
Yes
No
lactic acidemia (serum lactate level >2.2 mmol/l)*
Yes
No
any serious medical condition which may
compromise the patient’s safety, including
pancreatitis or hepatitis within past 6 months*
Yes
No
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active aids defining conditions*
Yes
No
concurrent therapy with any other lipid lowering
agents, oral hypoglycaemics, anabolic steroids or
insulin*
Yes
No
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Eligibility Juvenile Rheumatoid Arthritis
NCT00078806
Safety and Efficacy Study of Etanercept (Enbrel®) In
Children With Systemic Onset Juvenile Rheumatoid
Arthritis; ODM derived from:
https://clinicaltrials.gov/show/NCT00078806
All rights reserved. Please visit https://medical-data-
models.org/forms/15251
Eligibility Juvenile Rheumatoid
Arthritis NCT00078806
Inclusion Criteria
2 - 18 years of age*
Yes
No
sojra for at least 3 months, with stable systemic
features*
Yes
No
if taking methotrexate, hydroxychloroquine, or
nsaids, dose must be stable*
Yes
No
must take prednisone at a stable dose*
Yes
No
Exclusion Criteria
need for other dmards or prestudy requirements
for oral or parenteral pulse steroids or intra-
articular steroids
Yes
No
pregnant or nursing female
Yes
No
clinically significant abnormal laboratory test
results for blood cells, liver or kidney function, or
serology
Yes
No
previous receipt of any tnf inhibitor
Yes
No
live virus vaccine within 12 weeks of study entry
Yes
No
participation in another study requiring informed
consent within 12 weeks of entry
Yes
No
diabetes that requires insulin treatment
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Yes
No
infection, chronic, recurrent, or currently active
Yes
No
any serious medical or psychiatric condition or
history of alcohol or drug abuse
Yes
No
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Eligibility Lymphoma NCT00031902
Rituximab Plus Combination Chemotherapy in Treating
Patients With HIV-Related Non-Hodgkin's Lymphoma;
ODM derived from:
https://clinicaltrials.gov/show/NCT00031902
All rights reserved. Please visit https://medical-data-
models.org/forms/15252
Eligibility Lymphoma NCT00031902
Criteria
diagnosis of poor-prognosis, hiv-related non-
hodgkin's lymphoma (hiv-nhl)*
Yes
No
prior diagnosis of aids*
Yes
No
ecog performance status 3-4*
Yes
No
cd4 count less than 100/mm3*
Yes
No
no primary cerebral lymphoma*
Yes
No
age: 18 and over*
Yes
No
performance status: 	see disease characteristics*
Yes
No
life expectancy: not specified*
Yes
No
hematopoietic: not specified*
Yes
No
hepatic: not specified*
Yes
No
renal: 	not specified*
Yes
No
biologic therapy: not specified*
Yes
No
chemotherapy: no prior chemotherapy for hiv-nhl*
Yes
No
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at least 1 year since prior chemotherapy for
kaposi's sarcoma (ks)*
Yes
No
endocrine therapy: not specified*
Yes
No
radiotherapy: prior radiotherapy for hiv-nhl
allowed*
Yes
No
at least 1 year since prior radiotherapy for ks*
Yes
No
surgery: not specified*
Yes
No
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Eligibility Lymphoma NCT00032149
Combination Chemotherapy Plus Filgrastim in Treating
Patients With HIV-Related Non-Hodgkin's Lymphoma;
ODM derived from:
https://clinicaltrials.gov/show/NCT00032149
All rights reserved. Please visit https://medical-data-
models.org/forms/15253
Eligibility Lymphoma NCT00032149
Criteria
histologically confirmed previously untreated hiv-
related non-hodgkin's lymphoma with 1 of the
following:*
Yes
No
prior diagnosis of acquired immune deficiency
syndrome (aids)*
Yes
No
cd4 count < 100,000/mm3*
Yes
No
ecog performance status > 2*
Yes
No
age: 18 and over*
Yes
No
performance status: 	see disease characteristics*
Yes
No
life expectancy: 	not specified*
Yes
No
hematopoietic: see disease characteristics*
Yes
No
hepatic: 	not specified*
Yes
No
renal: not specified*
Yes
No
biologic: 	not specified*
Yes
No
chemotherapy: not specified*
Yes
No
endocrine: not specified*
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Yes
No
radiotherapy: 	not specified*
Yes
No
surgery: 	not specified*
Yes
No
2 / 2
Eligibility Lymphoma NCT00032149
Eligibility Obesity NCT00231530
A Study of the Safety and Efficacy of Topiramate in the
Treatment of Obese, Type 2 Diabetes Patients on a
Controlled Diet; ODM derived from:
https://clinicaltrials.gov/show/NCT00231530
All rights reserved. Please visit https://medical-data-
models.org/forms/15254
Eligibility Obesity NCT00231530
Inclusion Criteria
body mass index >= 27 and < 50*
Yes
No
diagnosis of type 2 diabetes according to either
swedish guideline or the american diabetes
association (ada) criteria*
Yes
No
hba1c < 10.5% at enrollment*
Yes
No
no previous oral antidiabetic medication or insulin
therapy*
Yes
No
stable body weight*
Yes
No
female patients must be postmenopausal for at
least 1 year, surgically incapable of childbearing,
practicing an acceptable method of contraception
(requires negative pregnancy test)*
Yes
No
Exclusion Criteria
known contraindication or hypersensitivity to
topiramate*
Yes
No
fasting plasma glucose (fpg) >= 13.1
millimolesl/liter (240 milligrams/deciliter) at
baseline, visit 4 (week 0)*
Yes
No
hba1c of >10.5% at enrollment*
Yes
No
history of severe recurrent hypoglycemic
episodes prior to study entry*
Yes
No
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use of any systemic corticosteroids within 30
days of enrollment*
Yes
No
diagnosed type 1 diabetes*
Yes
No
history of significant cardiovascular disease,
uncontrolled thyroid disease, or kidney stones*
Yes
No
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Eligibility Obesity NCT00231634
A Study of the Efficacy and Safety of Topiramate in Obese,
Type 2 Diabetic Patients Inadequately Controlled on
Sulfonylurea Therapy; ODM derived from:
https://clinicaltrials.gov/show/NCT00231634
All rights reserved. Please visit https://medical-data-
models.org/forms/15255
Eligibility Obesity NCT00231634
Inclusion Criteria
diagnosis of type 2 diabetes, receiving only
second generation sulfonylurea therapy (may
include: glipizide, gliclazide, glimepiride,
glibenclamide/glyburide, and gliquadone) for at
least 4 months and on stable dose for at least 2
months*
Yes
No
body mass index >= 27 and < 50*
Yes
No
hba1c < 11% at enrollment*
Yes
No
diagnosed hypertension or hyperlipidemia must
be controlled*
Yes
No
female patients must be postmenopausal for at
least 1 year, surgically incapable of childbearing,
practicing an acceptable method of contraception
(requires negative pregnancy test)*
Yes
No
Exclusion Criteria
known contraindication or hypersensitivity to
topiramate or sulfonylurea therapy*
Yes
No
pregnancy or women who are nursing or plan to
become pregnant during the study*
Yes
No
diagnosed with type 1 diabetes*
Yes
No
history of severe or recurrent hypoglycemic
episodes*
Yes
No
treatment with any antidiabetic agent other than
1 / 2
sulfonylurea*
Yes
No
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Eligibility Hepatitis C NCT02358044
Efficacy and Safety of Combination Grazoprevir (MK-
5172)/Elbasvir (MK-8742) Versus Sofosbuvir + Pegylated
Interferon + Ribavirin in Hepatitis C Virus Genotype 1, 4 or
6 Infection; ODM derived from:
https://clinicaltrials.gov/show/NCT02358044
All rights reserved. Please visit https://medical-data-
models.org/forms/15267
Eligibility Hepatitis C NCT02358044
Inclusion Criteria
weigh ≥ 40 kg and ≤125 kg*
Yes
No
documented chronic hcv gt1, gt4, or gt6 infection*
Yes
No
cirrhosis/absence of cirrhosis defined by liver
biopsy, fibroscan, or fibrosure®*
Yes
No
either treatment naïve or pr null responder, pr
partial responder, or pr prior relapser*
Yes
No
participant and partner both agree to use at least
use at least 2 effective methods of contraception
from at least 2 weeks prior to day 1 and continue
until up to 6 months after last dose of study drug,
or longer if dictated by local regulations*
Yes
No
Exclusion Criteria
has evidence of decompensated liver disease*
Yes
No
is coinfected with hepatitis b virus (e.g. hepatitis b
surface antigen positive) or human
immunodeficiency virus*
Yes
No
history of malignancy ≤5 years prior to signing
informed consent, or is under evaluation for other
active or suspected malignancy*
Yes
No
has cirrhosis and liver imaging within 6 months of
day 1 showing evidence of hepatocellular
carcinoma (hcc) or is under evaluation for hcc*
Yes
No
1 / 2
has any of the following conditions:
immunologically-mediated disease, organ
transplants other than cornea and hair, poor
venous access that precludes routine peripheral
blood sampling, history of gastric surgery or
malabsorption disorders, or any medical
condition requiring, or likely to require, chronic
systemic administration of corticosteroids during
the course of the trial, history of chronic hepatitis
not caused by hcv*
Yes
No
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Eligibility Hepatitis C Virus NCT02349048
Study to Assess Efficacy, Safety, Tolerability and
Pharmacokinetics of Simeprevir, Daclatasvir and
Sofosbuvir in Treatment-naive Participants With Chronic
Hepatitis C Virus Genotype 1 Infection; ODM derived from:
https://clinicaltrials.gov/show/NCT02349048
All rights reserved. Please visit https://medical-data-
models.org/forms/15269
Eligibility Hepatitis C Virus
NCT02349048
Inclusion Criteria
hcv genotype 1 infection and hcv rna plasma
level greater than (>) 10,000 international units
per milliliter (iu/ml), both determined at
screening*
Yes
No
participants of arm a should have evidence of
early stages of liver fibrosis, defined by a
fibrosure score less than or equal to (<=) 0.48
and aspartate aminotransferase to platelet ratio
index (apri) score <=1*
Yes
No
participants of arm b should have evidence of
cirrhosis, defined by a fibrosure score >0.75 and
apri score >2, or a previous (historical) biopsy
documenting a metavir score f4. in addition,
participants should have absence of esophageal
varices or presence of small (grade 1)
esophageal varices determined by upper
gastrointestinal endoscopy, and absence of
findings indicative of hepatocellular carcinoma in
an ultrasonography*
Yes
No
hcv treatment-naive, defined as not having
received treatment with any approved or
investigational drug for chronic hcv infection*
Yes
No
pegylated interferon (pegifn) and ribavirin (rbv)
eligible, defined as not having any
contraindication to the use of pegifn and rbv, in
line with the prescribing information for each
compound*
Yes
No
Exclusion Criteria
a. main study:*
Yes
No
co-infection with hcv of another genotype than
1 / 2
genotype 1 and/or human immunodeficiency
virus (hiv) type 1 or 2 (positive hiv-1 or hiv 2
antibody test at screening)*
Yes
No
any evidence of liver disease of non-hcv etiology.
this includes, but is not limited to, acute hepatitis
a infection, hepatitis b infection (hepatitis b
surface antigen positive), drug- or alcohol-related
liver disease, autoimmune hepatitis,
hemochromatosis, wilson's disease, alpha-1
antitrypsin deficiency, non-alcoholic
steatohepatitis, primary biliary cirrhosis, or any
other non-hcv liver disease considered clinically
significant by the investigator*
Yes
No
evidence of clinical hepatic decompensation or
presence of grade 2/3 esophageal varices*
Yes
No
any of the protocol defined laboratory
abnormalities*
Yes
No
b. sub-study:*
Yes
No
presence of coagulopathy (hemophilia) or
hemoglobinopathy (including sickle cell disease,
thalassemia)*
Yes
No
use of any anti-coagulant (for example, warfarin,
heparin) or anti-platelet medications within 1
week of the screening visit*
Yes
No
any of the protocol defined laboratory
abnormalities*
Yes
No
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Eligibility Hepatitis C, Chronic
NCT02268864
A Study to Assess the Efficacy and Safety of the
Combination of Simeprevir and Daclatasvir in Chronic
Hepatitis C Genotype 1b-Infected Participants; ODM
derived from: https://clinicaltrials.gov/show/NCT02268864
All rights reserved. Please visit https://medical-data-
models.org/forms/15273
Eligibility Hepatitis C, Chronic
NCT02268864
Inclusion Criteria
participant must have chronic hepatitis c virus
(hcv) genotype 1b infection confirmed at
screening*
Yes
No
participant must have hcv ribonucleic acid (rna)
greater than (>) 10,000 international unit per
milliliter (iu/ml) at screening*
Yes
No
participant must have documented fibrosis stage
at screening (or between screening and day 1
[baseline]). liver disease will be staged based on
one of the following methods. a) shear wave
elastography (fibroscan) within less than or equal
to (<=) 6 months before screening or between
screening and day 1 (baseline). metavir f3 > 9.6
kilopascals (kpa) and the cut-off for cirrhosis is
greater than or equal to (>=) 14.6 kpa. b) a
biopsy documenting metavir f3-f4. biopsy
performed within the 24 months before screening
will be accepted for participants with metavir
score f3. for cirrhotic participants (metavir score
f4) a biopsy performed at any previous time is
acceptable*
Yes
No
participants who have cirrhosis must have an
hepatic imaging procedure (ultrasound,
computed tomography [ct] scan or magnetic
resonance imaging [mri]) within 6 months prior to
the screening visit (or between screening and day
1) with no findings suspicious for hepatocellular
carcinoma*
Yes
No
participant must have a body mass index (bmi)
>= 18 kilogram per meter^2 (kg/m^2)*
Yes
No
participant must be treatment naive (that is, have
not received prior treatment for hcv with any
approved or investigational drug)*
Yes
No
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Exclusion Criteria
participant has co-infection with hcv of another
genotype; a) participant who has hcv genotype
1b has coinfection with hcv of a genotype other
than genotype 1b*
Yes
No
chronic hcv genotype 1b-infected participant who
has the presence of genetic variants coding for
the ns5a-y93h and/or l31m/v amino acid
substitutions at screening*
Yes
No
participant has evidence of current or previous
episodes of hepatic decompensation (including
controlled or uncontrolled ascites, bleeding
varices or hepatic encephalopathy)*
Yes
No
participant has chronic liver disease of a non-hcv
etiology (including but not limited to
hemochromatosis, wilson's disease, alfa 1-
antitrypsin deficiency, cholangitis, drug- or
alcohol-related liver disease, primary biliary
cirrhosis)*
Yes
No
participant has any other uncontrolled clinically
significant disease or clinically significant findings
during screening that in the opinion of the
investigator could compromise the participants'
safety or could interfere with the participant
participating in and completing the study*
Yes
No
participant has coinfection with hepatitis a or
hepatitis b virus (hepatitis a antibody
immunoglobulin m [igm] or hepatitis b surface
antigen [hbsag] positive at screening)*
Yes
No
participant has received a solid organ transplant*
Yes
No
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Eligibility Postmenopausal Women With
Advanced Breast Cancer NCT00237211
Study of High-dose Letrozole Therapy in Postmenopausal
Patients With Breast Cancer; ODM derived from:
https://clinicaltrials.gov/show/NCT00237211
All rights reserved. Please visit https://medical-data-
models.org/forms/15274
Eligibility Postmenopausal Women
With Advanced Breast Cancer
NCT00237211
Inclusion Criteria
patients with histologically documented breast
cancer.*
Yes
No
patients with hormone receptor (er and/or pgr)
status of positive or unknown*
Yes
No
patients who have been amenorrheic for the
preceding 12 months or more.*
Yes
No
patients who are 20 years or older and younger
than 75 years.*
Yes
No
patients with a history of postoperative adjuvant
therapy or a history of endocrine therapy with
tamoxifen for the treatment of progression or
recurrence of the lesion. the endocrine therapy,
however, should not exceed one regimen.*
Yes
No
patients with progressing lesions.*
Yes
No
patients with sufficient organ function to evaluate
the safety*
Yes
No
patients whose performance status (ps) is
classified in 0～2.*
Yes
No
patients who have no residual effects from
previous treatments*
Yes
No
Exclusion Criteria
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patients with other concurrent or previous
malignant disease (excluding uterine carcinoma
in-situ).*
Yes
No
patients with hypercalcemia and uncontrollable
cardiac disease (including a history of serious
cardiac disease)*
Yes
No
patients who have previously received aromatase
inhibitor.*
Yes
No
patients who have lymphangitis-type lung
metastasis or symptomatic brain metastasis.*
Yes
No
other protocol-defined inclusion / exclusion
criteria may apply.*
Yes
No
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NCT00237211
Eligibility Prostatic Neoplasms
NCT00188513
Intensity Modulated Radiation Therapy - Prostate Cancer;
ODM derived from:
https://clinicaltrials.gov/show/NCT00188513
All rights reserved. Please visit https://medical-data-
models.org/forms/15275
Eligibility Prostatic Neoplasms
NCT00188513
Inclusion Criteria
histologic diagnosis of adenocarcinoma of the
prostate within six months of entry*
Yes
No
clinical stage t1b, t1c, t2a-c nx mo (see appendix
1 for staging).  any gleason score is eligible for
entry, but gleason score must be determined.*
Yes
No
patients with a psa >10.0 and gleason score of 7;
or patients with any psa value and gleason score
of >8 must have clinically negative lymph nodes
as determined by a pelvic ct scan done within 12
weeks of entry.  a negative bone scan is required
before entry for all patients with gleason score
>8, or any patient with a gleason score of 7, and
a psa >10.*
Yes
No
the patient must not have received any cytotoxic
anticancer therapy.  previous or concurrent
hormonal therapy for local disease is acceptable.*
Yes
No
ecog performance status of 1 or less*
Yes
No
age 80 years old or less*
Yes
No
serum psa <25 ng/ml within 4 weeks of study
entry*
Yes
No
informed consent*
Yes
No
Exclusion Criteria
patients with history of inflammatory bowel
disease or other contraindication to radical
radiation therapy*
Yes
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No
patients with prior colorectal surgery*
Yes
No
any prior pelvic radiotherapy.  any prior turp done
<12 weeks from study entry.*
Yes
No
any previous cytotoxic chemotherapy*
Yes
No
patients with prior malignancy except non-
melanoma skin carcinoma within 5 years of the
diagnosis of prostate cancer*
Yes
No
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Eligibility Hepatocellular Carcinoma
NCT02232490
Liver Cancer Immunotherapy: Placebo-controlled Clinical
Trial of Hepcortespenlisimu (V5); ODM derived from:
https://clinicaltrials.gov/show/NCT02232490
All rights reserved. Please visit https://medical-data-
models.org/forms/15276
Eligibility Hepatocellular Carcinoma
NCT02232490
Inclusion Criteria
subjects who are at least 18 years old and are
willing and capable of providing informed
consent. both men and non-pregnant women will
be included.*
Yes
No
hcc diagnosis documented prior to study entry by
either cytology/histology, ct scan, and afp serum
test higher or equal to 30 iu/ml.*
Yes
No
all subjects with reproductive potential are
advised to utilize effective contraception
throughout the course of this study.*
Yes
No
health score status at baseline. agreement to
participate in the study and to give at least 3
samples of blood for lab tests.*
Yes
No
readily available home or o other address where
patient can be found. -*
Yes
No
Exclusion Criteria
subjects who might have already taken v5 in prior
trials and have no baseline data. those who met
inclusion criteria can be retrospectively enrolled.
pregnant or breast-feeding women are excluded.*
Yes
No
subjects who have taken other
immunomodulatory therapies within 2 months
prior to entry: systemic corticosteroids, immune
globulin (iv gamma globulin, ivig), interferons,
interleukins, pentoxifylline (trental), thalidomide,
filgrastim (g-csf), sargramostim (gm-csf);
dinitrochlorobenzene (dncb), thymosin alpha 1
(thymosin alpha), thymopentin, inosiplex
(isoprinosine),  polyribonucleoside (ampligen),
ditiocarb sodium (imuthiol), any locally available
immune modulators, and any other therapeutic or
preventive hcc vaccine. subjects requiring
1 / 2
concurrent participation in another experimental
research treatment study, or who received an
experimental agent within four weeks prior to
study entry.*
Yes
No
evidence of active or acute cardiac disease,
epilepsy, or life-threatening diseases unrelated to
hcc.*
Yes
No
medical conditions such as active alcohol or
substance abuse, or psychological issues that in
the opinion of the local investigator would
interfere with adherence to the requirements of
this study.*
Yes
No
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Eligibility Diabetes NCT01620424
Pharmacokinetics and Pharmacodynamics of Biphasic
Insulin Aspart 30 and 50 in Subjects With Type 2 Diabetes;
ODM derived from:
https://clinicaltrials.gov/show/NCT01620424
All rights reserved. Please visit https://medical-data-
models.org/forms/15277
Eligibility Diabetes NCT01620424
Inclusion Criteria
type 2 diabetes*
Yes
No
duration of diabetes for at least 1 year*
Yes
No
body mass index (bmi) maximum 30.0 kg/m^2*
Yes
No
hba1c maximum 10.0%*
Yes
No
Exclusion Criteria
recurrent severe hypoglycaemia*
Yes
No
proliferative or preproliferative retinopathy
diagnosed within the last 12 weeks or laser
therapy for retinopathy within the last 12 weeks*
Yes
No
impaired hepatic function*
Yes
No
impaired renal function*
Yes
No
cardiac problems*
Yes
No
uncontrolled treated / untreated hypertension*
Yes
No
hepatitis b surface antigen, hepatitis c antibodies
or hiv (human immunodeficiency virus) antibodies
positive*
Yes
No
total daily insulin dose exceeding 40 iu*
1 / 2
Yes
No
treatment with ohas (oral hypoglycaemic agents)
or insulin preparations twice or more frequently a
day*
Yes
No
treatment with ohas or insulin preparations once
a day later than noon*
Yes
No
subjects who smoke more than 15 cigarettes per
day*
Yes
No
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Visit 2 (Core Study) Lab and Medical Examination, DIMAT-
MS, Relapsing Remitting Multiple Sclerosis NCT02461069
Study documentation part: Visit 2 (Core Study), Study week
0
Study Details: A 24-week, multicenter, exploratory, two arm
study to
assess the effect of Dimethyl fumarate on
ImmuneModulatory
Action on T cells in patients with relapsing
remitting Multiple Sclerosis.
Principal Investigator PD Dr. Luisa Klotz, University
Hospital Münster
EudraCT - No.: 2014-003481-25.
Clinical Trial No.r: NCT02461069.
All rights reserved. Please visit https://medical-data-
models.org/forms/15278
Visit 2 (Core Study) Lab and Medical
Examination, DIMAT-MS, Relapsing
Remitting Multiple Sclerosis
NCT02461069
Visit Details
Date of visit
Did the patient experience a relapse since
screening?
If yes, please document p. 29
Yes
No
Did the patient have an infection since screening?
If yes, please document on Adverse Event form
Yes
No
Further Visit Information
Laboratory Urine Pregnancy Test (Please
perform the test only on suspicion of
pregnancy.)
Test done, specify: Test Date:
Urinary Pregnancy Test Result
negative (negative)
positive (positive)
Urine pregnancy test not done, reason
female participant with no childbearing
potential (female participant with no
childbearing potential)
male participant (male participant)
no suspicion of pregnancy (no suspicion
of pregnancy)
other (other)
Date of blood sampling
Date of blood sampling
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Hematology
Leucocytes
Leucocytes measurement unit
/mm^3 (/µL )
10^3 /µL  (10^3 /µL )
other (other)
Leucocytes Count  not done
Yes
No
Lymphocytes
/mm^3 (/µL )
10^3 /µL  (10^3 /µL )
other (other)
Lymphocytes Count Procesdure not done
Yes
No
Liver Function
Aspartate transaminase (AST) (SGOT)
AST Measurement Unit
nkat/L (nmol/s*L )
other (other)
U/L (U/L)
µkat/L (µmol/s*L )
AST measurement not done
Yes
No
Alanine transaminase (ALT) (SGPT)
ALT Measurement Unit
nkat/L (nmol/s*L )
other (other)
U/L (U/L)
ALT measurement not done
Yes
No
Gamma Glutamyl Transpeptidase Measurement
GGT Measurement Unit
nkat/L (nmol/s*L )
other (other)
U/L (U/L)
µkat/L (µmol/s*L )
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GGT Measurement not done
Yes
No
Renal function
Creatinine
Serum Creatinine  Measurment Unit
mg/dL (mg/dL)
other (other)
µmol/L (µmol/L)
Serum Creatinine Measurment not done
Yes
No
Blood urea nitrogen
Blood urea nitrogen measurement unit
mg/dL (mg/dL)
other (other)
µmol/L (µmol/L)
Blood urea nitrogen measurement not done
Yes
No
Medical Examination
Medical Examination performed at:
Heart rate (in bpm):
bpm
Systolic blood pressure
>= 0
mmHg
Diastolic blood pressure
>= 0
mmHg
Temperature
°C
Expanded disability status scale (EDSS)
EDSS performed at
Visual testing
0 (1)
1 (2)
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2 (3)
3 (4)
4 (5)
5 (6)
6 (7)
Brianstem testing
0 (1)
1 (2)
2 (3)
3 (4)
4 (5)
5 (6)
Pyramidal testing
0 (0)
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
Cerebellar testing
0 (0)
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
X (X)
Bowel/Bladder
Cerebellar testing (1)
Cerebral testing
0 (0)
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
Ambulation Score
0 (0)
1 (1)
10 (10)
11 (11)
12 (12)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
7 (7)
8 (8)
9 (9)
EDSS step
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Signature
Study Drug Prescription information
Please hand out a Patient's Diary to the patient.
Date
Name/Signature Investigator
5 / 5
Visit 2 (Core Study) Lab and Medical Examination, DIMAT-MS, Relapsing
Remitting Multiple Sclerosis NCT02461069
Visit 1 (Screening) Part 2/2, Lab & Medical Examination, DIMAT-
MS, Relapsing Remitting Multiple Sclerosis NCT02461069
Study documentation part: Visit 1 (Screening), Study week
-4 to 0
Study Details: A 24-week, multicenter, exploratory, two arm
study to
assess the effect of Dimethyl fumarate on
ImmuneModulatory
Action on T cells in patients with relapsing
remitting Multiple Sclerosis.
Principal Investigator PD Dr. Luisa Klotz, University
Hospital Münster
EudraCT - No.: 2014-003481-25.
Clinical Trial No.r: NCT02461069.
All rights reserved. Please visit https://medical-data-
models.org/forms/15279
Visit 1 (Screening) Part 2/2, Lab &
Medical Examination, DIMAT-MS,
Relapsing Remitting Multiple
Sclerosis NCT02461069
Date of blood sampling
Date of blood sampling
Hematology
Leucocytes
Leucocytes measurement unit
/mm^3 (/µL )
10^3 /µL  (10^3 /µL )
other (other)
Leucocytes Count  not done
Yes
No
Lymphocytes
Lymphocytes measurement unit
/mm^3 (/µL )
10^3 /µL  (10^3 /µL )
other (other)
Lymphocytes Count Procesdure not done
Yes
No
Liver Function
Aspartate transaminase (AST) (SGOT)
AST Measurement Unit
nkat/L (nmol/s*L )
other (other)
U/L (U/L)
µkat/L (µmol/s*L )
1 / 4
AST measurement not done
Yes
No
Alanine transaminase (ALT) (SGPT)
ALT Measurement Unit
nkat/L (nmol/s*L )
other (other)
U/L (U/L)
µkat/L (µmol/s*L )
ALT measurement not done
Yes
No
Gamma Glutamyl Transpeptidase Measurement
GGT Measurement Unit
nkat/L (nmol/s*L )
other (other)
U/L (U/L)
µkat/L (µmol/s*L )
GGT Measurement not done
Yes
No
Renal function
Serum creatinine
Serum Creatinine  Measurment Unit
mg/dL (mg/dL)
other (other)
µmol/L (µmol/L)
Serum Creatinine Measurment not done
Yes
No
Blood Urea Nitrogen
Blood urea nitrogen measurement unit
mg/dL (mg/dL)
other (other)
µmol/L (µmol/L)
Blood urea nitrogen measurement not done
Yes
No
Medical Examination
Medical Examination performed at:
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Heart rate (in bpm):
bpm
Systolic blood pressure
>= 0
mmHg
Diastolic
>= 0
°C
Temperature
°C
Body weight
>= 0
kg
Height
>= 0
cm
Expanded disability status scale (EDSS)
EDSS performed at
Visual testing
0 (1)
1 (2)
2 (3)
3 (4)
4 (5)
5 (6)
6 (7)
Brianstem testing
0 (1)
1 (2)
2 (3)
3 (4)
4 (5)
5 (6)
Pyramidal testing
0 (0)
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
Cerebellar testing
0 (0)
1 (1)
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2 (2)
3 (3)
4 (4)
5 (5)
X (X)
Bowel/Bladder
Cerebellar testing (1)
Cerebral testing
0 (0)
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
Ambulation Score
0 (0)
1 (1)
10 (10)
11 (11)
12 (12)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
7 (7)
8 (8)
9 (9)
EDSS step
Signature
Date
Name/Signature Investigator
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Visit 1 (Screening) Part 2/2, Lab & Medical Examination, DIMAT-MS,
Relapsing Remitting Multiple Sclerosis NCT02461069
Visit 1 (Screening) Part 1/2, DIMAT-MS, Relapsing
Remitting Multiple Sclerosis NCT02461069
Study documentation part: Visits 1 (Screening), Study week
-4 to 0
Study Details: A 24-week, multicenter, exploratory, two arm
study to
assess the effect of Dimethyl fumarate on
ImmuneModulatory
Action on T cells in patients with relapsing
remitting Multiple Sclerosis.
Principal Investigator PD Dr. Luisa Klotz, University
Hospital Münster
EudraCT - No.: 2014-003481-25.
Clinical Trial No.r: NCT02461069.
All rights reserved. Please visit https://medical-data-
models.org/forms/15280
Visit 1 (Screening) Part 1/2, DIMAT-
MS, Relapsing Remitting Multiple
Sclerosis NCT02461069
Administration and Instructions for CRF
Completion
Subject ID
Patient Name (initials acceptable)
Instructions for CRF Completion
Date of written Informed Consent
Demographic Data
Age
years
Sex
female (f)
male (m)
Blood pregnancy test
Blood Pregnancy Test done, specify test date
Result:
Blood pregnancy test not done, reason:
female participant with no childbearing
potential (female participant with no
childbearing potential)
male participant (male participant)
other: (other:)
Testing for JC virus antibodies
JC virus antibodies test done, specify test date:
1 / 10
Result:
positive (1)
negative (2)
JC virus antibodies test not done, reason
Medical History
Medical History Description: Please state
diagnosis, if known
Start Date
End Date
Ongoing at Start of Study
NO (N)
YES (Y)
MS Medical History
Date of MS diagnosis
Date of MS diagnosis unknown
Yes
No
Date of first MS symptoms
Date of first MS symptoms unknown
Yes
No
Number of relapses since MS diagnosis
Number of relapses since MS diagnosis unknown
Number of relapses in the last 12 months
Number of relapses in the last 12 months
unknown
Yes
No
Onset date of most recent relapse
Onset date of most recent relapse unknown
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MS Treatment History
Active substance/nondrug therapy
1 Alemtuzumab (1)
10 Mitoxantrone (10)
11 Natalizumab (11)
12 Rituximab (12)
13 Teriflunomide (13)
14 Other active substance (14)
15 Physiotherapy (15)
16 Plasmapheresis (16)
17 Other Non-drug therapy (17)
2 Azathioprine (2)
3 Cyclophosphamide (3)
4 Dimethyl fumarate  (4)
5 Fingolimod (5)
6 Glatiramer acetate (6)
7 Immunoglobulins (7)
8 Interferon beta (8)
9 Methylprednisolone* (9)
Treatment of MS relapse
Yes
No
Start Date
End Date
ongoing
Yes
No
Blood samples for safety laboratory
tests
Date of blood sampling
Date of blood sampling
Hematology
Leukozyten
Leucocytes measurement unit
/mm^3 (/µL )
10^3 /µL  (10^3 /µL )
other (other)
Leucocytes Me
Yes
No
Lymphocytes
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Lymphocytes measurement unit
/mm^3 (/µL )
10^3 /µL  (10^3 /µL )
other (other)
Lymphocytes Count Procesdure not done
Yes
No
Liver Function
Aspartate transaminase
(AST) (SGOT)
U/L
AST Measurement Unit
nkat/L (nmol/s*L )
other (other)
U/L (U/L)
µkat/L (µmol/s*L )
AST measurement not done
Yes
No
Gamma Glutamyl Transpeptidase Measurement
GGT Measurement Unit
nkat/L (nmol/s*L )
other (other)
U/L (U/L)
µkat/L (µmol/s*L )
GGT Measurement not done
Yes
No
Renal function
Serum creatinine
Serum Creatinine  Measurment Unit
mg/dL (mg/dL)
other (other)
µmol/L (µmol/L)
Serum Creatinine Measurment not done
Yes
No
NON-MS Treatment and
symptomatic MS Treatment
General Instructions
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Instructions
Medical Examination
Medical Examination performed at:
Heart rate (in bpm):
bpm
Systolic blood pressure
>= 0
mmHg
Diastolic
>= 0
mmHg
Temperature
°C
Body weight
>= 0
kg
Height
>= 0
cm
Expanded disability status scale (EDSS)
EDSS performed at
Visual testing
0 (1)
1 (2)
2 (3)
3 (4)
4 (5)
5 (6)
6 (7)
Brianstem testing
0 (1)
1 (2)
2 (3)
3 (4)
4 (5)
5 (6)
Pyramidal testing
0 (0)
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1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
Cerebellar testing
0 (0)
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
X (X)
Bowel/Bladder
Cerebellar testing (1)
Cerebral testing
0 (0)
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
Ambulation Score
0 (0)
1 (1)
10 (10)
11 (11)
12 (12)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
7 (7)
8 (8)
9 (9)
EDSS step
Signature
Date
Name/Signature Investigator
Eligibility
Inclusion criteria
Written informed consent must be obtained
before any assessment is performed
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Yes
No
Male and female subjects aged 18 - 60 years.
Yes
No
Patients with RRMS, defined by 2010 revised
McDonald criteria
Yes
No
Patients with an Expanded Disability Status Scale
(EDSS) score of 0-6.0.
Yes
No
Patients with one of the following treatment
status:
Yes
No
MRI-scan of the brain ≤ 3 months at screening.
Yes
No
Exclusion criteria
Known hypersensitivity to dimethyl fumarate or
any ingredients of Tecfidera®
(microcrystalline cellulose; croscarmellose-
sodium; talcum; high
dispersion, hydrophobic silicon dioxide;
magnesiumstearate (Ph. Eur.);
triethylcitrate; methacrylic acid-methacrylate
copolymer (1:1) (Ph. Eur.);
methacrylic acid-ethylacrylate copolymer (1:1)-
dispersion 30% (Ph. Eur.),
simeticon, sodiumdodecylsulfate, polysorbate 80,
gelantine, titanium
oxide (E171), brilliant blue (E133), hydrated
Iron(III)-oxide hydroxide
(E172), shellac, potassium hydroxide.
Yes
No
A MS-relapse within 30 days prior to screening.
Yes
No
Known history of active tuberculosis or active
tuberculosis determined by
a positive QuantiFERON® TB Gold test.
Yes
No
Moderate to severe impairment of liver function or
persisting elevations >
2 x ULN (confirmed by retest) of serum glutamic
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pyruvic transaminase/
alanine aminotransferase (SGPT/ALT), serum
glutamic oxaloacetic transaminase/aspartate
aminotransferase (SGOT/AST), or direct bilirubin
> 2 x
ULN, except patients with confirmed Gilbert´s
syndrome (Meulengracht´s
disease).
Yes
No
Moderate to severe impairment of renal function,
as shown by serum
creatinine > 133 μmol/L (or > 1.5 mg/dL).
Yes
No
Patients with significantly impaired bone marrow
function or significant
anemia, leukopenia, neutropenia or
thrombocytopenia
• Hematocrit <24% and/or hemoglobin < 8.0 g/dl
and/or
• Absolute white blood cell count < 4,000 cells/
mm³ (μL) and/or
• Absolute neutrophils ≤ 1,500 cells/mm³ (μL)
and/or
• Platelet count < 150,000 cells/ mm³ (μL).
Yes
No
Women of childbearing potential not utilizing
highly effective contraception
Yes
No
Mental condition rendering the subject unable to
understand the nature,
scope, and possible consequences of the study.
Yes
No
Subjects unlikely to comply with protocol as
determined by investigator,
e.g., uncooperative attitude, inability to return for
follow-up visits (e.g.
major physical disability), and known unlikelihood
of completing the study.
Yes
No
Clinically relevant cardiovascular, neurological,
endocrine, or other major
systemic disease making implementation of the
protocol or interpretation
of the study results difficult or that would put the
subject at risk by participating
in the study.
Yes
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No
Subjects with ulcerative colitis or Crohn´s disease
Yes
No
Subjects with a congenital or acquired severe
immunodeficiency, a history
of cancer (except for basal or squamous cell skin
lesions which have been
surgically excised, with no evidence of
metastasis), lymph proliferative
disease, or any subject who has received
lymphoid irradiation.
Yes
No
Human immunodeficiency virus (HIV) positive,
hepatitis B virus positive or
hepatitis C virus positive subjects.
Yes
No
Acute or chronic infection
Yes
No
History of drug or alcohol abuse.
Yes
No
Use of adrenocorticotrophic hormone (ACTH) or
systemic corticosteroids
for 4 weeks prior to screening.
Yes
No
Prior or concomitant use of cytokine therapy or
intravenous immunoglobulins
in the 3 months prior to screening.
Yes
No
Prior use of alemtuzumab or cladribine.
Yes
No
Prior use (within 1 year) of fingolimod (Gilenya®)
or natalizumab (Tysabri®).
Yes
No
Prior use (within 2 years) of mitoxantrone, or
other immunosuppressant
agents such as azathioprine, cyclophosphamide,
cyclosporine, methotrexate
or mycophenolate mofetil.
Yes
No
Prior treatment with teriflunomide or leflunomide,
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unless successful washout,
confirmed by plasma concentration of < 0.02
µg/ml.
Yes
No
Prior use of any investigational drug in the 6
months preceding screening
Yes
No
Pregnant or breast-feeding women.
Yes
No
Signature Screening Visit 1
Signature Date
Signature investigator
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Lab and Medical Examination Visit 6 (Follow Up), DIMAT-
MS, Relapsing Remitting Multiple Sclerosis NCT02461069
Study documentation part: Visit 6 (Follow Up), Study week
48
Study Details: A 24-week, multicenter, exploratory, two arm
study to
assess the effect of Dimethyl fumarate on
ImmuneModulatory
Action on T cells in patients with relapsing
remitting Multiple Sclerosis.
Principal Investigator PD Dr. Luisa Klotz, University
Hospital Münster
EudraCT - No.: 2014-003481-25.
Clinical Trial No.r: NCT02461069.
All rights reserved. Please visit https://medical-data-
models.org/forms/15281
Lab and Medical Examination
Visit Details
Date of visit
Did the patient experience a relapse since
screening?
If yes, please document p. 29
Yes
No
Did the patient have an infection since screening?
If yes, please document on Adverse Event form
Yes
No
Further Visit Information
Laboratory Urine Pregnancy Test (Please
perform the test only on suspicion of
pregnancy.)
Test done, specify: Test Date:
Urinary Pregnancy Test Result
negative (negative)
positive (positive)
Urine pregnancy test not done, reason
female participant with no childbearing
potential (female participant with no
childbearing potential)
male participant (male participant)
no suspicion of pregnancy (no suspicion
of pregnancy)
other (other)
Date of blood sampling
Date of blood sampling
Hematology
Leucocytes
1 / 5
Leucocytes measurement unit
/mm^3 (/µL )
10^3 /µL  (10^3 /µL )
other (other)
Leucocytes Count  not done
Yes
No
Lymphocytes
Lymphocytes measurement unit
/mm^3 (/µL )
10^3 /µL  (10^3 /µL )
other (other)
Lymphocytes Count Procesdure not done
Yes
No
Liver Function
Aspartate transaminase (AST) (SGOT)
U/L
AST Measurement Unit
nkat/L (nmol/s*L )
other (other)
U/L (U/L)
µkat/L (µmol/s*L )
AST measurement not done
Yes
No
Alanine transaminase (ALT) (SGPT)
ALT Measurement Unit
nkat/L (nmol/s*L )
other (other)
U/L (U/L)
ALT measurement not done
Yes
No
Gamma Glutamyl Transpeptidase Measurement
GGT Measurement Unit
nkat/L (nmol/s*L )
other (other)
U/L (U/L)
µkat/L (µmol/s*L )
GGT Measurement not done
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Yes
No
Renal function
Creatinine
Serum Creatinine  Measurment Unit
mg/dL (mg/dL)
other (other)
µmol/L (µmol/L)
Serum Creatinine Measurment not done
Yes
No
Blood Urea Nitrogen
Blood urea nitrogen measurement unit
mg/dL (mg/dL)
other (other)
µmol/L (µmol/L)
Blood urea nitrogen measurement not done
Yes
No
Medical Examination
Medical Examination performed at:
Heart rate (in bpm):
bpm
Systolic blood pressure
>= 0
mmHg
Diastolic blood pressure
>= 0
mmHg
Body temperature
°C
Body weight
>= 0
kg
Expanded disability status scale (EDSS)
EDSS performed at
3 / 5
Lab and Medical Examination Visit 6 (Follow Up), DIMAT-MS, Relapsing
Remitting Multiple Sclerosis NCT02461069
Visual testing
0 (1)
1 (2)
2 (3)
3 (4)
4 (5)
5 (6)
6 (7)
Brianstem testing
0 (1)
1 (2)
2 (3)
3 (4)
4 (5)
5 (6)
Pyramidal testing
0 (0)
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
Cerebellar testing
0 (0)
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
X (X)
Bowel/Bladder
Cerebellar testing (1)
Cerebral testing
0 (0)
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
Ambulation Score
0 (0)
1 (1)
10 (10)
11 (11)
12 (12)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
7 (7)
8 (8)
4 / 5
Lab and Medical Examination Visit 6 (Follow Up), DIMAT-MS, Relapsing
Remitting Multiple Sclerosis NCT02461069
9 (9)
EDSS step
Signature
Date
Name/Signature Investigator
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Eligibility Diabetes NCT01697657
Frequency of Hypoglycaemic Episodes During Treatment
With Insulin Detemir in Well Controlled Subjects With Type
1 Diabetes; ODM derived from:
https://clinicaltrials.gov/show/NCT01697657
All rights reserved. Please visit https://medical-data-
models.org/forms/15283
Eligibility Diabetes NCT01697657
Inclusion Criteria
type 1 diabetes*
Yes
No
fasting c-peptide below lower limit of normal
fasting range*
Yes
No
duration of type 1 diabetes for at least 12
months*
Yes
No
current treatment: basal - bolus regimen for at
least 4 months with intermediate or long-acting
insulin once, twice or three times daily as basal
insulin and 3-4 premeal insulin aspart or lispro
injections*
Yes
No
hba1c maximum 9.0% (using biorad variant
method)*
Yes
No
able and willing to perform self-monitoring of
blood glucose*
Yes
No
basal insulin requirement at least 30% of the total
daily insulin dose*
Yes
No
bmi (body mass index) maximum 35 kg/m^2*
Yes
No
Exclusion Criteria
proliferative retinopathy or maculopathy requiring
acute treatment*
Yes
No
total daily insulin dose above 1.4 iu/kg/day*
Yes
No
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known unawareness of hypoglycaemia*
Yes
No
impaired hepatic function*
Yes
No
impaired renal function*
Yes
No
cardiac problems*
Yes
No
uncontrolled, treated/untreated hypertension*
Yes
No
known or suspected allergy to trial product or
related products*
Yes
No
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Eligibility Esophageal Carcinoma
NCT00176800
Chemoradiation and Tetrathiomolybdate (TM) in Patients
With Esophageal Carcinoma; ODM derived from:
https://clinicaltrials.gov/show/NCT00176800
All rights reserved. Please visit https://medical-data-
models.org/forms/15284
Eligibility Esophageal Carcinoma
NCT00176800
Criteria
1. histologically confirmed adenocarcinoma or
squamous cell carcinoma of  the esophagus or
gastroesophageal junction*
Yes
No
2. no prior treatment for the esophageal cancer
allowed.*
Yes
No
3. no prior thoracic or upper abdominal radiation.*
Yes
No
4. disease should be limited to the esophagus
and regional lymph nodes.  regional lymph nodes
are described in section 4.0.  however, celiac
node enlargement will be acceptable for tumors
of the distal esophagus, because they will be
included in the radiation field.*
Yes
No
5. disease must be able to be encompassed in a
single radiation field.*
Yes
No
6. no medical contraindication to surgery*
Yes
No
7. all treatment is to be administered at the
university of michigan medical center.*
Yes
No
8. karnofsky performance status > 70 %.*
Yes
No
9. age range: 18 - 75 years old.*
Yes
No
10. adequate baseline hematopoetic function:*
Yes
No
platelet count equal to or greater than
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100,000/mm3 absolute granulocyte count equal
to or greater than 1500/mm3 hematocrit equal to
or greater than 29% (patients may be transfused
to this level)*
Yes
No
11. adequate baseline organ function :*
Yes
No
creatinine clearance >/= 60 mls/min bilirubin
equal to or less than 1.5 x upper limits of normal
ast/alt equal to or less than 2.5 x upper limits of
normal*
Yes
No
12. patients with any complaint of hearing loss
should be evaluated with an audiogram. the
average pure tone average hearing loss from
500-2000hz should not exceed 30 db. if it does,
the patient should be warned that further hearing
loss may be very noticeable and permanent.*
Yes
No
13. prior malignancy is acceptable if the patient is
considered to be cured.  in most cases this will
mean a 5-year disease-free period.  contact the
principal investigator for any specific question
regarding this requirement.*
Yes
No
14. patients with active infection, serious inter-
current medical conditions are ineligible,
according to the judgment of the investigators.*
Yes
No
15. pregnant or lactating females are not eligible.
women of childbearing potential must be using
contraception throughout the entire period of
treatment.*
Yes
No
16. ability to give informed consent.*
Yes
No
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Eligibility Hypertension NCT00207194
Interactive Multirisk-Factor Intervention for Hypertension
(HTN) Blacks; ODM derived from:
https://clinicaltrials.gov/show/NCT00207194
All rights reserved. Please visit https://medical-data-
models.org/forms/15285
Eligibility Hypertension
NCT00207194
Inclusion Criteria
a patient with a primary care provider at one of
boston medical center's adult primary care
medical practices or one of three healthnet health
centers participating in the study*
Yes
No
have a physician diagnosis of hypertension*
Yes
No
be african american by self-report*
Yes
No
be 35 years of age or older*
Yes
No
be prescribed at least one medication for
hypertension*
Yes
No
have poorly controlled blood pressure*
Yes
No
be non-adherent to at least one hypertensive
medication*
Yes
No
understand spoken english*
Yes
No
have a home telephone*
Yes
No
Exclusion Criteria
patients for whom a medication, diet or exercise
regiment adherence improvement or
maintenance program would be inappropriate*
Yes
No
patients with a terminal illness*
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Yes
No
patients with severe medical or psychiatric
illness*
Yes
No
patients with cognitive difficulty*
Yes
No
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Eligibility Hypertension NCT00207194
Eligibility Larynx Carcinoma NCT00147732
Randomized Trial of ARCON in Larynx Cancer; ODM
derived from: https://clinicaltrials.gov/show/NCT00147732
All rights reserved. Please visit https://medical-data-
models.org/forms/15286
Eligibility Larynx Carcinoma
NCT00147732
Inclusion Criteria
pathological confirmed squamous cell carcinoma
of the larynx.*
Yes
No
tnm-classification (uicc 1997, appendix i):*
Yes
No
t3-4 glottic or supraglottic carcinoma*
Yes
No
t2 glottic carcinoma with impaired cord mobility or
subglottic extension*
Yes
No
t2 supraglottic carcinoma with invasion of mucosa
of base of tongue or  vallecula or invasion of the
medial wall of the piriform sinus.*
Yes
No
any n-stage, m0.*
Yes
No
who performance status 0 or 1 (appendix ii).*
Yes
No
age > 18 years.*
Yes
No
written informed consent.*
Yes
No
quality of life questionnaire completed.*
Yes
No
Exclusion Criteria
prior or concurrent treatment for this tumour.*
Yes
No
severe stridor and adequate debulking of airway
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not possible.*
Yes
No
impaired renal function: serum creatinine above
upper normal limit.*
Yes
No
use of nefrotoxic medication (including ace-
inhibitors) that cannot be discontinued for the
duration of the radiation treatment.*
Yes
No
impaired hepatic function: asat and alat more
than 1.5 times the upper normal limit.*
Yes
No
use of anti-convulsants that cannot be
discontinued for the duration of the radiation
treatment.*
Yes
No
history of malignancy during the previous 5 years
except basal cell carcinoma of skin, carcinoma in
situ of the cervix, or superficial bladder neoplasm
(pta).*
Yes
No
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Eligibility Larynx Carcinoma NCT00147732
Eligibility Hormone Receptor Positive, HER2-
negative, Advanced Breast Cancer NCT02333370
Phase Ib Dose-escalation, Phase II Study of LEE011 and
Letrozole for Treatment of Postmenopausal Women With
Hormone Receptor Positive, HER2-negative, Advanced
Breast Cancer; ODM derived from:
https://clinicaltrials.gov/show/NCT02333370
All rights reserved. Please visit https://medical-data-
models.org/forms/15287
Eligibility Hormone Receptor
Positive, HER2-negative, Advanced
Breast Cancer NCT02333370
Inclusion Criteria
women with advanced (locoregionally recurrent
or metastatic) breast cancer not amenable to
curative therapy (surgery and/or radiotherapy).*
Yes
No
patient is postmenopausal.*
Yes
No
patient has a histologically and/or cytologically
confirmed diagnosis of estrogen receptor positive
and/or progesterone receptor positive breast
cancer*
Yes
No
patient has her2-negative breast cancer*
Yes
No
patient has adequate bone marrow and organ
function*
Yes
No
Exclusion Criteria
patient who received any cdk4/6 inhibitor.*
Yes
No
patient has a known hypersensitivity to any of the
excipients of lee011 or letrozole*
Yes
No
patients with inflammatory breast cancer.*
Yes
No
patient who received any prior systemic anti-
cancer therapy (including hormonal therapy and
chemotherapy) for advanced breast cancer*
Yes
No
patient is currently using other anti-cancer
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therapy*
Yes
No
patient has had major surgery within 14 days
prior to starting study drug or has not recovered
from major side effects.*
Yes
No
patient who has received radiotherapy ≤ 4 weeks*
Yes
No
patient has a concurrent malignancy or
malignancy within 3 years*
Yes
No
patient has metastases to the central nervous
system (cns).*
Yes
No
patient has a known history of hiv infection*
Yes
No
other protocol-defined inclusion/exclusion criteria
may apply*
Yes
No
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Eligibility Hormone Receptor Positive, HER2-negative, Advanced Breast
Cancer NCT02333370
Eligibility Hypertension NCT02133885
Study 2: Effect of Minocycline Treatment on Drug-Resistant
Hypertensive Patients; ODM derived from:
https://clinicaltrials.gov/show/NCT02133885
All rights reserved. Please visit https://medical-data-
models.org/forms/15288
Eligibility Hypertension
NCT02133885
Criteria
greater than 18 and less than 80 years of age;*
Yes
No
on stable medication regimen*
Yes
No
o full-tolerated doses of 3 or more anti-
hypertensive medications of different classes,
one of which must be a diuretic (with no changes
for a minimum of two weeks prior to screening)
that is expected to be maintained without
changes for at least 6-9 months.*
Yes
No
office systolic blood pressure (sbp) of greater
than 160 mmhg based on an average of 3 blood
pressure readings measured at both initial
screening visit*
Yes
No
the individual agrees to have all study procedures
performed*
Yes
No
willing to provide written consent*
Yes
No
females with childbearing potential must not be
pregnant.*
Yes
No
exclusion*
Yes
No
egfr of < 45 ml/min/1.73m2, using the mdrd
calculation.*
Yes
No
more than one in-patient hospitalization for an
anti-hypertensive crisis within the year.*
Yes
No
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more than one episode(s) of orthostatic
hypotension (reduction of sbp of ≥ 20 mmhg of
diastolic blood pressure (dbp) of ≥ 10 mmhg
within 3 minutes of standing).*
Yes
No
history of myocardial infarction (mi), unstable
angina pectoris, syncope or a cardiovascular
accident within 6 months of screening period*
Yes
No
clinically significant atrioventricular (av)
conduction disturbances and/or arrhythmias (e.g.
2nd or 3rd degree av block);*
Yes
No
current of past history of heart failure (≤40% left
ventricular ejection fraction (ef).*
Yes
No
major of psychotropic agents and
antidepressants.*
Yes
No
use of nonsteroidal anti-inflammatory drug
(nsaids)*
Yes
No
known hypersensitivity or contraindication to
minocycline or other tetracycline.*
Yes
No
smoking*
Yes
No
concurrent severe disease (such as neoplasm or
hiv positive or aids).*
Yes
No
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Eligibility Hypertension NCT02133885
Eligibility Hypertension NCT02283697
Dietary Counseling to Reduce Salt Intake in Patients With
High Blood Pressure; ODM derived from:
https://clinicaltrials.gov/show/NCT02283697
All rights reserved. Please visit https://medical-data-
models.org/forms/15289
Eligibility Hypertension
NCT02283697
Inclusion Criteria
adult patients (>18 years) with hypertension
defined as*
Yes
No
daytime bp readings above 140/90 mmhg (as
assessed from 24-hr abpm)) without treatment
and/or*
Yes
No
any patient with treated hypertension irrespective
of bp load based on 24-hr abpm.*
Yes
No
Exclusion Criteria
pregnant patients and*
Yes
No
patients with following conditions:*
Yes
No
glomerular filtration rate <45 ml/min/1.75 m2,*
Yes
No
active infection,*
Yes
No
acute coronary syndrome,*
Yes
No
severe liver disease;*
Yes
No
psychiatric disorders and/or otherwise unable to
sign consent;*
Yes
No
patients with clinically manifested generalized
and/or cardiac volume overload who may require
immediate changes in diuretic therapy (at the
discretion of treating hypertension specialist).*
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Yes
No
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Eligibility Hypertension NCT02283697
Eligibility Hypertension NCT02357017
Mechanisms of Refractory Hypertension (High and Low
Salt Diet); ODM derived from:
https://clinicaltrials.gov/show/NCT02357017
All rights reserved. Please visit https://medical-data-
models.org/forms/15290
Eligibility Hypertension
NCT02357017
Inclusion Criteria
adult subjects ≥ 19 years of age*
Yes
No
refractory hypertension defined as office bp >
140/90 that is uncontrolled with at least 5 different
classes of antihypertensive medications*
Yes
No
self-reported adherence >80% with prescribed
antihypertensive medications*
Yes
No
Exclusion Criteria
severe hypertension (office bp >160/100 mm hg)*
Yes
No
history of congestive heart failure (ejection
fraction of <40%)*
Yes
No
chronic kidney disease (creatinine clearance <60
ml/min)*
Yes
No
history of cardiovascular disease (stroke, tia,
myocardial infarction, or revascularization
procedure)*
Yes
No
white coat hypertension defined as office bp
>140/90 mm hg and ambulatory daytime bp
<135/85 mm hg*
Yes
No
pregnant or nursing women*
Yes
No
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Eligibility Hypertension NCT02362893
Treatment of Hypertension: an Interventional Approach to
Improve Blood Pressure Control; ODM derived from:
https://clinicaltrials.gov/show/NCT02362893
All rights reserved. Please visit https://medical-data-
models.org/forms/15292
Eligibility Hypertension
NCT02362893
Inclusion Criteria
18 years and above*
Yes
No
residing in oslo/akershus*
Yes
No
ambulatory systolic daytime blood pressure ≥ 135
mmhg*
Yes
No
≥ 2 antihypertensive medications*
Yes
No
be able to read and write norwegian*
Yes
No
Exclusion Criteria
critical illness, ongoing treatment*
Yes
No
known atrial fibrillation*
Yes
No
known heart valve stenosis*
Yes
No
myocardial infarction, angina pectoris or stroke
the past 6 months*
Yes
No
known severe renal impairment (egfr < 30
ml/min/1.73 m2)*
Yes
No
history of dot prior to abpm*
Yes
No
participation in other interventional study*
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Yes
No
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Eligibility Hypertension NCT02364310
Economic Evaluation of Baroreceptor STIMulation for the
Treatment of Resistant HyperTensioN; ODM derived from:
https://clinicaltrials.gov/show/NCT02364310
All rights reserved. Please visit https://medical-data-
models.org/forms/15293
Eligibility Hypertension
NCT02364310
Criteria
18-75 y old men or women*
Yes
No
resistant hypertension on 4 medications incl.
thiazide or thiazide-like diuretics at appropriate
doses + spironolactone (unless spironolactone
intolerance)*
Yes
No
essential hypertension documented (bilan < 2
years old)*
Yes
No
egfr ≥ 30 ml/min/1,73 m2*
Yes
No
no carotid condition associated with a contra-
indication for barostim neotm use*
Yes
No
main exclusion criteria:*
Yes
No
patients with documented secondary
hypertension, besides obstructive sleep apnea*
Yes
No
symptomatic orthostatic hypotension*
Yes
No
patient with prior syncope or myocardial
infarction, unstable angina pectoris, or
cerebrovascular within 3 months before inclusion*
Yes
No
patient with type 1 diabetes mellitus*
Yes
No
patient with permanent atrial fibrillation*
Yes
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No
patient with brachial circumference of ≥ 46cm*
Yes
No
patient with bmi>45kg/m2*
Yes
No
pregnancy, breastfeeding or planning a
pregnancy within 2 years*
Yes
No
neotm implantation anatomic contra-indications*
Yes
No
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Eligibility Hypertension NCT02364310
Eligibility Hypertension NCT02377960
Check and Support -Enhancing the Treatment of
Hypertension in Outpatient Care, a Multicenter Study; ODM
derived from: https://clinicaltrials.gov/show/NCT02377960
All rights reserved. Please visit https://medical-data-
models.org/forms/15295
Eligibility Hypertension
NCT02377960
Inclusion Criteria
a clinical diagnosis of hypertension*
Yes
No
about to start medication for hypertension for the
first time*
Yes
No
aged 40-75 years*
Yes
No
must own a mobile phone*
Yes
No
must be able to read text messages*
Yes
No
must be able to master own medication*
Yes
No
must be able to perform home bp measurements*
Yes
No
must agree in using electric drug prescription
(standard in finnish health care)*
Yes
No
Exclusion Criteria
having or is suspected to have depression or
psychosis*
Yes
No
serious disease, which is evaluated to have an
impact on life expectancy*
Yes
No
atrial flutter or atrial fibrillation*
Yes
No
previous history of antihypertensive medication*
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Yes
No
pregnancy*
Yes
No
not willing to give informed consent and take part
in the study*
Yes
No
systolic bp more than 200 mmhg*
Yes
No
diastolic bp more than 120 mmhg*
Yes
No
sudden onset or worsening of hypertension*
Yes
No
clinical signs of kidney disease: proteinuria (du-
prot > 500 mg), glomerulus filtration rate (egfr)
less than 45 ml/min or hypokalemia*
Yes
No
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Eligibility Hypertension NCT02377960
Eligibility Lymphoma, Non-Hodgkin's
NCT00143871
Study of Rituximab Plus High-Dose Chemotherapy Non-
Hodgkin's Lymphoma; ODM derived from:
https://clinicaltrials.gov/show/NCT00143871
All rights reserved. Please visit https://medical-data-
models.org/forms/15296
Eligibility Lymphoma, Non-Hodgkin's
NCT00143871
Inclusion Criteria
histologically documented, aggressive and/ or
intermediate grade and high-grade b cell nhl,
cd20 positive.*
Yes
No
in relapse after primary conventional
chemotherapy*
Yes
No
tumor sensitive (at least a partial response) to
induction chemotherapy and/ or radiation therapy
after treatment for relapse*
Yes
No
treatment of cns or meningeal disease (cytology-
negative csf) if present*
Yes
No
cumulative total doxorubicin dosage <500
mg/m2*
Yes
No
performance score: 0-2*
Yes
No
prior malignancies eligible if treated for cure and
without active disease*
Yes
No
patients must not be pregnant or nursing.*
Yes
No
prior immunotherapy is allowed*
Yes
No
signed informed consent*
Yes
No
absolute neutrophil count > 1500/ µl, platelet
count >100,000/ µl*
Yes
1 / 2
No
bilirubin <1.5 x normal, sgot <2.5 x normal*
Yes
No
serum creatinine <1.5 mg/dl*
Yes
No
ejection fraction > 45% or > 40% with normal wall
motion*
Yes
No
hiv negative*
Yes
No
fev1, dlco > 50% predicted*
Yes
No
Exclusion Criteria
pregnant or nursing*
Yes
No
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Eligibility Lymphoma, Non-Hodgkin's NCT00143871
Eligibility Idiopathic Parkinson's Disease
NCT02242487
Twelve Month Safety and Efficacy Study of CVT-301 In
Parkinson's Disease Patients With OFF Episodes; ODM
derived from: https://clinicaltrials.gov/show/NCT02242487
All rights reserved. Please visit https://medical-data-
models.org/forms/15297
Eligibility Idiopathic Parkinson's
Disease NCT02242487
Inclusion Criteria
idiopathic parkinson's disease (pd) diagnosed
between the ages of 30 and 80 years;*
Yes
No
hoehn and yahr stage 1-3 in an "on" state;*
Yes
No
require levodopa-containing medication regimen
at least 4 times during the waking day;*
Yes
No
experience motor fluctuations with a minimum of
2 hours of average daily "off" time per waking day
(excluding early morning "off" time) and
demonstrate levodopa responsiveness;*
Yes
No
are on stable pd medication regimen;*
Yes
No
total daily levodopa (ld) dose <1600 mg/day;*
Yes
No
able to perform a spirometry maneuver in the on
and off states*
Yes
No
normal cognition confirmed by mini mental state
examination (mmse) score ≥25 ;*
Yes
No
Exclusion Criteria
pregnant or lactating females;*
Yes
No
previous surgery for pd or plan to have
stereotactic surgery during the study period;*
Yes
No
history of psychotic symptoms requiring
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treatment, or suicide ideation or attempt within
last year;*
Yes
No
known contraindication to the use of levodopa;*
Yes
No
any significant condition, severe concurrent
disease, abnormality or finding that would make
patients unsuitable or may compromise patient
safety;*
Yes
No
any any contraindication to performing routine
spirometry.*
Yes
No
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Eligibility Idiopathic Parkinson's Disease NCT02242487
Eligibility Major Depression NCT00177996
Pharmacotherapy in Depression With Panic Spectrum;
ODM derived from:
https://clinicaltrials.gov/show/NCT00177996
All rights reserved. Please visit https://medical-data-
models.org/forms/15299
Eligibility Major Depression
NCT00177996
Inclusion Criteria
male or female ages 18-60;*
Yes
No
current diagnosis of major depression, and a
rating of ³15 on the hrs-d-25;  --presence of
significant, co-existing panic-agoraphobic
spectrum symptoms,*
Yes
No
absence of ongoing therapy with psychotropic
medications (except for intermittent use of
nonbenzodiazepine hypnotics) or willingness to
be withdrawn from an ineffective ongoing
antidepressant medications*
Yes
No
physically healthy,*
Yes
No
female participants of childbearing potential must
be practicing a medically acceptable form of
double-barrier birth control or using oral
contraceptives such as birth control pills,
implants, or injections;*
Yes
No
Exclusion Criteria
females who are pregnant or breast-feeding;*
Yes
No
history of suicide attempt in the 6 months prior to
entry, active suicidal ideation, or significant
suicide risk;*
Yes
No
history of hypersensitivity to or current use of
sertraline;*
Yes
No
unstable or untreated medical conditions,*
Yes
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No
participants who do not wish to discontinue
current, ineffective antidepressant treatment;*
Yes
No
participants who have recently begun
psychotherapy (less than 3 months prior to study
entry);*
Yes
No
diagnosis of  current panic disorder, psychosis,
substance or alcohol abuse, anorexia, bulimia,
dissociative, bipolar disorder, or any other
psychiatric or medical illness that would interfere
with the best treatment strategy for the potential
participant.*
Yes
No
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Eligibility Major Depression NCT00177996
Eligibility Metastatic Colorectal Cancer
NCT01219920
FOLFOXIRI Compared With FOLFIRI for Metastatic
Colorectal Cancer; ODM derived from:
https://clinicaltrials.gov/show/NCT01219920
All rights reserved. Please visit https://medical-data-
models.org/forms/15300
Eligibility Metastatic Colorectal
Cancer NCT01219920
Inclusion Criteria
adenocarcinoma of the colon or rectum*
Yes
No
unresectable metastatic disease*
Yes
No
age 18 to 75 years*
Yes
No
eastern cooperative oncology group (ecog)
performance status of 2 or lower if age 70 years
or younger or ecog performance status of 0 if age
71 to 75 years measurable disease according to
whocriteria*
Yes
No
leukocyte count of at least 3,500/mm3,
neutrophils count of at least 1,500/mm3, platelet
count of at least 100,000/mm3*
Yes
No
serum creatinine of 1.3 mg/dl or less*
Yes
No
serum bilirubin less than 1.5 mg/dl and ast, alt,
and alkaline phosphatase 2.5 x normal values or
less (</= 5 if liver metastases)*
Yes
No
previous fluoropyrimidine-based adjuvant
chemotherapy was allowed if ended more than 6
months before random assignment*
Yes
No
Exclusion Criteria
previous palliative chemotherapy for metastatic
disease*
Yes
No
previous chemotherapy including irinotecan or
oxaliplatin*
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Yes
No
symptomatic cardiac disease, myocardial
infarction in the last 24 months or uncontrolled
arrhythmia*
Yes
No
active infections*
Yes
No
inflammatory bowel disease*
Yes
No
total colectomy*
Yes
No
2 / 2
Eligibility Metastatic Colorectal Cancer NCT01219920
Eligibility Multiple Sclerosis NCT01487096
Safety and Efficacy of Teriflunomide (HMR1726) in Multiple
Sclerosis With Relapses; ODM derived from:
https://clinicaltrials.gov/show/NCT01487096
All rights reserved. Please visit https://medical-data-
models.org/forms/15301
Eligibility Multiple Sclerosis
NCT01487096
Inclusion Criteria
clinically confirmed multiple sclerosis [ms];*
Yes
No
expanded disability status scale [edss] score less
or equal to 6;*
Yes
No
two documented relapses in the previous 3 years,
and one clinical relapse during the preceding
year;*
Yes
No
screening magnetic resonance imaging [mri]
scan fulfilling the criteria for a diagnosis of ms.*
Yes
No
Exclusion Criteria
clinically relevant cardiovascular, hepatic,
hematologic, neurological, endocrine or other
major systemic disease;*
Yes
No
pregnant or nursing woman;*
Yes
No
wish to parent children during the trial or following
the trial (men and women were required to
practice effective contraception during the trial
and for 24 months after drug discontinuation);*
Yes
No
prior treatment with interferon [ifn], gamma-
globulin, glatiramer acetate, or other
noncorticosteroid immunomodulatory therapies in
the 4 months prior to the trial;*
Yes
No
use of cladribine, mitoxantrone, or other
immunosuppressant agents such as
azathioprine, cyclophosphamide, cyclosporin,
methotrexate or mycophenolate before
enrollment;*
1 / 2
Yes
No
any known condition or circumstance that would
prevent in the investigator's opinion compliance
or completion of the study.*
Yes
No
the above information is not intended to contain
all considerations relevant to a patient's potential
participation in a clinical trial.*
Yes
No
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Eligibility Non-Small-Cell Lung Cancer
NCT00049998
Oral Topotecan Versus Intravenous Docetaxel In
Pretreated, Advanced Non-Small Cell Lung Cancer; ODM
derived from: https://clinicaltrials.gov/show/NCT00049998
All rights reserved. Please visit https://medical-data-
models.org/forms/15302
Eligibility Non-Small-Cell Lung
Cancer NCT00049998
Inclusion Criteria
written informed consent*
Yes
No
patients with advanced non-small cell lung cancer
(nsclc).*
Yes
No
patients who have received one previous
chemotherapy for nsclc.*
Yes
No
full recovery from previous chemotherapy.*
Yes
No
presence of either measurable or non-
measurable disease by radiologic study or
physical examination.*
Yes
No
at least 3 weeks since last major surgery (a
lesser period is acceptable if deemed in the best
interest of the patient).*
Yes
No
at least 24 hours since prior radiotherapy
providing that marked bone marrow suppression
is not expected.  patients who have received
radiotherapy must have recovered from any
reversible side effects (e.g. nausea and
vomiting).*
Yes
No
laboratory criteria:  patients must have adequate
bone marrow reserve and adequate kidney and
liver function.*
Yes
No
Exclusion Criteria
symptoms of brain metastasis (cancer spreading
to the brain), requiring treatment with steroids.*
Yes
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No
active infection.*
Yes
No
severe medical problems other than the diagnosis
of nsclc, that would limit the ability of the patient
to follow study guidelines or expose the patient to
extreme risk.*
Yes
No
ongoing or planned chemotherapy,
immunotherapy, radiotherapy, or investigational
therapy for the treatment of nsclc.*
Yes
No
use of investigational drug within 30 days prior to
the first dose of study medication.*
Yes
No
women who are pregnant or lactating.*
Yes
No
patients of child-bearing potential refusing to
practice adequate birth control methods.*
Yes
No
patients with conditions which might alter
absorption of an oral drug.*
Yes
No
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Eligibility Non-Small-Cell Lung Cancer NCT00049998
Eligibility Obesity NCT00236665
A Study of Efficacy and Safety of Topiramate in the
Treatment of Obese Patients With Mild to Moderate
Essential Hypertension; ODM derived from:
https://clinicaltrials.gov/show/NCT00236665
All rights reserved. Please visit https://medical-data-
models.org/forms/15303
Eligibility Obesity NCT00236665
Inclusion Criteria
diagnosis of mild to moderate essential
hypertension (sitting diastolic blood pressure >=
90 and < 110 and/or sitting systolic blood
pressure >= 140 and < 180)*
Yes
No
diagnosis of obesity (body mass index >= 27 and
< 50 and steady body weight)*
Yes
No
female patients must be postmenopausal for at
least 1 year, surgically incapable of childbearing,
practicing abstinence, or practicing an acceptable
method of contraception (requires negative
pregnancy test)*
Yes
No
Exclusion Criteria
prior exposure or known contraindication or
hypersensitivity to topiramate*
Yes
No
pregnancy, nursing or subjects who plan to
become pregnant during the study*
Yes
No
diagnosis of severe hypertension*
Yes
No
history or diagnosis of diabetes mellitus*
Yes
No
a history of diastolic or systolic hypertension
secondary to a known cause*
Yes
No
significant cardiovascular or liver disease*
Yes
No
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Eligibility Primary Central Nervous System
Lymphoma NCT00193973
Idarubicin Based Combined Modality Therapy in Primary
CNS Lymphoma; ODM derived from:
https://clinicaltrials.gov/show/NCT00193973
All rights reserved. Please visit https://medical-data-
models.org/forms/15304
Eligibility Primary Central Nervous
System Lymphoma NCT00193973
Inclusion Criteria
histologically proven primary cns lymphoma.*
Yes
No
absence of disease outside the cns.*
Yes
No
ecog performance status 0-3*
Yes
No
negative hiv status.*
Yes
No
peripheral blood counts with granulocytes >1.5 x
109l and platelets > 100 x 109l. serum creatinine
<150mmol/l. serum bilirubin <1.5 times and ast
<2 times upper limit of normal.*
Yes
No
age >18 and <=70 years.*
Yes
No
patients must give written informed consent.*
Yes
No
corticosteroids prior to histological diagnosis are
allowed.*
Yes
No
Exclusion Criteria
previous history of malignancy (other than non-
melanomatous skin carcinoma, or carcinoma in
situ of cervix completely excised).*
Yes
No
patients who are pregnant or lactating.*
Yes
No
nyha (new york state heart association
classification) cardiac failure grade 3*
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Yes
No
macroscopic spinal thecal or spinal cord
disease.*
Yes
No
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Eligibility Primary Central Nervous System Lymphoma NCT00193973
Eligibility Diabetes NCT01511198
Efficacy and Safety of Metformin and Liraglutide in Obese
Subjects With Type 2 Diabetes Previously Treated With an
Oral Hypoglycemic Agent; ODM derived from:
https://clinicaltrials.gov/show/NCT01511198
All rights reserved. Please visit https://medical-data-
models.org/forms/15305
Eligibility Diabetes NCT01511198
Inclusion Criteria
type 2 diabetic*
Yes
No
treated with oha (oral hypoglycaemic agent
monotherapy for at least 3 months. prior use of
metformin is allowed*
Yes
No
body mass index (bmi) between 27.0-42.0
kg/m^2 (inclusive)*
Yes
No
hba1c maximum 10% based on analysis from
central laboratory*
Yes
No
Exclusion Criteria
cardiac problems*
Yes
No
uncontrolled treated/untreated hypertension*
Yes
No
proliferative retinopathy or known autonomic
neuropathy*
Yes
No
recurrent severe hypoglycemia as judged by the
investigator*
Yes
No
known or suspected allergy to trial product or
related products*
Yes
No
use of any drug (except for ohas), which in the
investigators opinion could interfere with the
glucose level or body weight or any
contraindication to metformin use or intolerance
to metformin 1000 mg (prior to trial entry or
during run-in period). stable doses, for 3 months
or greater, of thyroid hormone replacement are
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allowed*
Yes
No
known or suspected abuse of alcohol or
narcotics*
Yes
No
current treatment with thiazolidinediones or
chronic daily use of insulin (more than 7 days)
within three months in the absence of intercurrent
illness*
Yes
No
tsh (thyroid stimulating hormone) below 0.2 or
above 15 u/ml*
Yes
No
type 1 or other specific causes of diabetes*
Yes
No
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Residential History Protocol PhenX Toolkit
This protocol captures information about every residence
the respondent has lived in for 3 months or longer. It
includes questions concerning topics such as the dates
lived, exact address and/or landmarks near the residence,
whether the residence was located on or near a farm, the
type of water supply, whether the residence was near fields
or orchards, and whether it was located in the center or
margin of town.
After the interview has been completed the interviewer
should determine the geocoordinates of each residence.
Some geocoordinates will not be accurate based on the
data obtained from these questions and may be improved
with additional quality control measures or by obtaining a
GPS measurement at the residence.
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Residential History Protocol PhenX
Toolkit
PhenX - environmental exposures -
residential history protocol
Residence
Residence [PhenX]
From What date did you live in the residence?
To what date did/do you live in the residence?
What is the residence address?
Street/Crosstreets City, State or Landmark
Was this on a farm?
Yes
No
What was your water supply?
Bottled water (Bottled water)
City (City)
Filtered water (Filtered water)
Other (Other)
Private well (Private well)
What was your water supply?
Near fields or orchards?
Yes
No
Did you live close to the center or margin of
town?
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Center (Center)
Margin (Margin)
After the interview has been completed, enter the
geocoordinates for the residence. Latitude -
deg
After the interview has been completed, enter the
geocoordinates for the residence. Longitude -
deg
Were the geocoordinates verified?
Yes
No
How were the geocoordinates verified?
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Disinhibiting Behaviors - Impulsivity - Child
Protocol PhenX Toolkit
The UPPS-P Impulsive Behavior Scale for Children
includes 40 self-administered items that are scored as five
subscales (urgency, premeditation, perseverance,
sensation seeking, and positive urgency). The respondent
is asked to read each item and circle the number on a scale
that best describes him/her. The 4-item Likert scale
includes values for 1 (not at all like me), 2 (not like me), 3
(somewhat like me), and 4 (very much like me).
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Disinhibiting Behaviors - Impulsivity -
Child Protocol PhenX Toolkit
PhenX - disinhibiting behaviors -
impulsivity - child protocol UPPS-P
If I feel like doing something, I tend to do it, even
if it's bad.
Not at all like me (Not at all like me)
Not like me (Not like me)
Somewhat like me (Somewhat like me)
Very much like me (Very much like me)
I like new, thrilling things to happen.
Not at all like me (Not at all like me)
Not like me (Not like me)
Somewhat like me (Somewhat like me)
Very much like me (Very much like me)
I like to see things through to the end.
Not at all like me (Not at all like me)
Not like me (Not like me)
Somewhat like me (Somewhat like me)
Very much like me (Very much like me)
I tend to blurt out things without thinking.
Not at all like me (Not at all like me)
Not like me (Not like me)
Somewhat like me (Somewhat like me)
Very much like me (Very much like me)
I am upset when I am not finished with things.
Not at all like me (Not at all like me)
Not like me (Not like me)
Somewhat like me (Somewhat like me)
Very much like me (Very much like me)
I like to stop and think about something before I
do it.
Not at all like me (Not at all like me)
Not like me (Not like me)
Somewhat like me (Somewhat like me)
Very much like me (Very much like me)
When I feel bad, I often do things I later regret in
1 / 5
order to make myself feel better now.
Not at all like me (Not at all like me)
Not like me (Not like me)
Somewhat like me (Somewhat like me)
Very much like me (Very much like me)
I would like water skiing.
Not at all like me (Not at all like me)
Not like me (Not like me)
Somewhat like me (Somewhat like me)
Very much like me (Very much like me)
I like to know just what to do before I start a
project.
Not at all like me (Not at all like me)
Not like me (Not like me)
Somewhat like me (Somewhat like me)
Very much like me (Very much like me)
Sometimes when I feel bad, I keep doing
something even though it is making me feel
worse.
Not at all like me (Not at all like me)
Not like me (Not like me)
Somewhat like me (Somewhat like me)
Very much like me (Very much like me)
I enjoy taking risks
Not at all like me (Not at all like me)
Not like me (Not like me)
Somewhat like me (Somewhat like me)
Very much like me (Very much like me)
It is easy for me to think hard
Not at all like me (Not at all like me)
Not like me (Not like me)
Somewhat like me (Somewhat like me)
Very much like me (Very much like me)
I would like parachute jumping.
Not at all like me (Not at all like me)
Not like me (Not like me)
Somewhat like me (Somewhat like me)
Very much like me (Very much like me)
I finish what I start
Not at all like me (Not at all like me)
Not like me (Not like me)
Somewhat like me (Somewhat like me)
Very much like me (Very much like me)
I try to take a careful approach to things.
Not at all like me (Not at all like me)
Not like me (Not like me)
Somewhat like me (Somewhat like me)
Very much like me (Very much like me)
I like new, thrilling things, even if they are a little
scary.
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Not at all like me (Not at all like me)
Not like me (Not like me)
Somewhat like me (Somewhat like me)
Very much like me (Very much like me)
I tend to get things done on time.
Not at all like me (Not at all like me)
Not like me (Not like me)
Somewhat like me (Somewhat like me)
Very much like me (Very much like me)
When I feel rejected, I often say things that I later
regret.
Not at all like me (Not at all like me)
Not like me (Not like me)
Somewhat like me (Somewhat like me)
Very much like me (Very much like me)
I would like to learn to fly an airplane.
Not at all like me (Not at all like me)
Not like me (Not like me)
Somewhat like me (Somewhat like me)
Very much like me (Very much like me)
I am a person who always gets the job done.
Not at all like me (Not at all like me)
Not like me (Not like me)
Somewhat like me (Somewhat like me)
Very much like me (Very much like me)
I am very careful.
Not at all like me (Not at all like me)
Not like me (Not like me)
Somewhat like me (Somewhat like me)
Very much like me (Very much like me)
I almost always finish projects that I start.
Not at all like me (Not at all like me)
Not like me (Not like me)
Somewhat like me (Somewhat like me)
Very much like me (Very much like me)
I like to know what to expect, before doing
something new.
Not at all like me (Not at all like me)
Not like me (Not like me)
Somewhat like me (Somewhat like me)
Very much like me (Very much like me)
I often make matters worse because I act without
thinking when I am upset.
Not at all like me (Not at all like me)
Not like me (Not like me)
Somewhat like me (Somewhat like me)
Very much like me (Very much like me)
I would like to ski very fast down a high mountain
slope.
Not at all like me (Not at all like me)
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Not like me (Not like me)
Somewhat like me (Somewhat like me)
Very much like me (Very much like me)
I tend to stop and think before doing things.
Not at all like me (Not at all like me)
Not like me (Not like me)
Somewhat like me (Somewhat like me)
Very much like me (Very much like me)
Before making a choice, I tend to think about both
the good things and the bad things about the
choice.
Not at all like me (Not at all like me)
Not like me (Not like me)
Somewhat like me (Somewhat like me)
Very much like me (Very much like me)
When I am mad, I sometimes say things that I
later regret.
Not at all like me (Not at all like me)
Not like me (Not like me)
Somewhat like me (Somewhat like me)
Very much like me (Very much like me)
I would enjoy fast driving.
Not at all like me (Not at all like me)
Not like me (Not like me)
Somewhat like me (Somewhat like me)
Very much like me (Very much like me)
When I am very happy, I can't stop myself from
going overboard.
Not at all like me (Not at all like me)
Not like me (Not like me)
Somewhat like me (Somewhat like me)
Very much like me (Very much like me)
When I am really thrilled, I tend not to think about
the results of my actions.
Not at all like me (Not at all like me)
Not like me (Not like me)
Somewhat like me (Somewhat like me)
Very much like me (Very much like me)
When I am in a great mood, I tend to do things
that could cause me problems.
Not at all like me (Not at all like me)
Not like me (Not like me)
Somewhat like me (Somewhat like me)
Very much like me (Very much like me)
I tend to act without thinking when I am very, very
happy.
Not at all like me (Not at all like me)
Not like me (Not like me)
Somewhat like me (Somewhat like me)
Very much like me (Very much like me)
When I get really happy about something, I tend
to do things that can lead to trouble.
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Not at all like me (Not at all like me)
Not like me (Not like me)
Somewhat like me (Somewhat like me)
Very much like me (Very much like me)
When I am really happy, I tend to get out of
control.
Not at all like me (Not at all like me)
Not like me (Not like me)
Somewhat like me (Somewhat like me)
Very much like me (Very much like me)
I tend to lose control when I am in a great mood.
Not at all like me (Not at all like me)
Not like me (Not like me)
Somewhat like me (Somewhat like me)
Very much like me (Very much like me)
When I am very happy, I tend to do things that
may cause problems in my life.
Agree some (Agree some)
Agree strongly (Agree strongly)
Disagree some (Disagree some)
Disagree strongly (Disagree strongly)
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Family History of Speech and Language
Impairment Protocol PhenX Toolkit
The Family History Questionnaire is a 9-item proxy-
administered questionnaire completed by a parent for their
young child. It asks about the child’s personal and family
history of speech and language impairment.
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Family History of Speech and
Language Impairment Protocol
PhenX Toolkit
PhenX - family history of speech and
language impairment protocol
By age 2, was your child talking in short phrases
or sentences?
Don't know (Don't know)
No  (No )
Yes  (Yes )
When your child was two years old, were you
concerned that he/she was having difficulty
learning to talk?
Don't know (Don't know)
No  (No )
Yes  (Yes )
At this time, do people frequently have trouble
understanding your child?
Don't know (Don't know)
No  (No )
Yes  (Yes )
Has anyone in your child's family had speech or
language therapy?
Don't know (Don't know)
No  (No )
Yes  (Yes )
Has anyone in your child's family had speech or
language therapy? If Yes, What for?
Has anyone in your child's family had difficulty
learning to read or had problems with school
work?
Don't know (Don't know)
No  (No )
Yes  (Yes )
Has anyone in your child's family had difficulty
learning to read or had problems with school
work? (e.g. repeated a grade)If Yes, what are the
details?
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Has anyone in your child's family been diagnosed
as mentally retarded?
Don't know (Don't know)
No  (No )
Yes  (Yes )
Does anyone in your child's family have a hearing
difficulty?
Don't know (Don't know)
No  (No )
Yes  (Yes )
Has anyone in your child's family been slow in
learning to talk?
Don't know (Don't know)
No  (No )
Yes  (Yes )
Has anyone in your child's family had any other
type of communication disorder such as:
Stuttering
Yes
No
Has anyone in your child's family had any other
type of communication disorder such as: Is less
talkative
Yes
No
Has anyone in your child's family had any other
type of communication disorder such as: Has a
hard time carrying on a conversation
Yes
No
Has anyone in your child's family had any other
type of communication disorder such as: Doesn't
like to read
Yes
No
Has anyone in your child's family had any other
type of communication disorder such as: Doesn't
read well
Yes
No
Has anyone in your child's family had any other
type of communication disorder such as: Has
difficulty thinking of words (s)he wants to say
when talking
Yes
No
Has anyone in your child's family had any other
type of communication disorder such as: Has a
poorer vocabulary than other family members
Yes
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No
Has anyone in your child's family had any other
type of communication disorder such as: Is a
poor speller
Yes
No
Has anyone in your child's family had any other
type of communication disorder such as: Has
awkward sentence structures when writing or
talking
Yes
No
Has anyone in your child's family had any other
type of communication disorder such as:
Mispronounces long words
Yes
No
Has anyone in your child's family had any other
type of communication disorder such as: Is hard
to follow when (s)he tells you something, such as
a personal experience
Yes
No
Has anyone in your child's family had any other
type of communication disorder such as: Has
difficulty explaining things
Yes
No
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Chronic Stress Protocol PhenX Toolkit
The chronic stress scale includes a list of 51 items about
common life conditions and situations (e.g., financial
issues, work, love and marriage, family and children, social
life). The interviewer reads each item aloud and asks the
respondent to reply with not true (0), somewhat true (1), or
very true (2).
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Chronic Stress Protocol PhenX
Toolkit
PhenX - chronic stress protocol
You're trying to take on too many things at once.
Not true (Not true)
Somewhat true (Somewhat true)
Very true (Very true)
There is too much pressure on you to be like
other people.
Not true (Not true)
Somewhat true (Somewhat true)
Very true (Very true)
Too much is expected of you by others.
Not true (Not true)
Somewhat true (Somewhat true)
Very true (Very true)
You don't have enough money to buy the things
you or your kids need.
Not true (Not true)
Somewhat true (Somewhat true)
Very true (Very true)
You have a long-term debt or loan.
Not true (Not true)
Somewhat true (Somewhat true)
Very true (Very true)
Your rent or mortgage is too much.
Not true (Not true)
Somewhat true (Somewhat true)
Very true (Very true)
You don't have enough money to take vacations.
Not true (Not true)
Somewhat true (Somewhat true)
Very true (Very true)
You don't have enough money to make a down
payment on a home.
Not true (Not true)
Somewhat true (Somewhat true)
Very true (Very true)
1 / 5
You have more work to do than most people.
Not true (Not true)
Somewhat true (Somewhat true)
Very true (Very true)
Your supervisor is always monitoring what you do
at work.
Not true (Not true)
Somewhat true (Somewhat true)
Very true (Very true)
You want to change jobs or career but don't feel
you can.
Not true (Not true)
Somewhat true (Somewhat true)
Very true (Very true)
Your job often leaves you feeling both mentally
and physically tired.
Not true (Not true)
Somewhat true (Somewhat true)
Very true (Very true)
You want to achieve more at work but things get
in the way.
Not true (Not true)
Somewhat true (Somewhat true)
Very true (Very true)
You don't get paid enough for what you do.
Not true (Not true)
Somewhat true (Somewhat true)
Very true (Very true)
Your work is boring and repetitive.
Not true (Not true)
Somewhat true (Somewhat true)
Very true (Very true)
You are looking for a job and can't find the one
you want.
Not true (Not true)
Somewhat true (Somewhat true)
Very true (Very true)
You have a lot of conflict with your partner.
Not true (Not true)
Somewhat true (Somewhat true)
Very true (Very true)
Your relationship restricts your freedom.
Not true (Not true)
Somewhat true (Somewhat true)
Very true (Very true)
Your partner doesn't understand you.
Not true (Not true)
Somewhat true (Somewhat true)
Very true (Very true)
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Your partner expects too much of you.
Not true (Not true)
Somewhat true (Somewhat true)
Very true (Very true)
You don't get what you deserve out of your
relationship.
Not true (Not true)
Somewhat true (Somewhat true)
Very true (Very true)
Your partner doesn't show enough affection.
Not true (Not true)
Somewhat true (Somewhat true)
Very true (Very true)
Your partner is not committed enough to your
relationship.
Not true (Not true)
Somewhat true (Somewhat true)
Very true (Very true)
Your sexual needs are not fulfilled by this
relationship.
Not true (Not true)
Somewhat true (Somewhat true)
Very true (Very true)
Your partner is always threatening to leave or end
the relationship.
Not true (Not true)
Somewhat true (Somewhat true)
Very true (Very true)
You wonder whether you will ever get married.
Not true (Not true)
Somewhat true (Somewhat true)
Very true (Very true)
You find it is too difficult to find someone
compatible with you.
Not true (Not true)
Somewhat true (Somewhat true)
Very true (Very true)
You have a lot of conflict with your ex-spouse.
Not true (Not true)
Somewhat true (Somewhat true)
Very true (Very true)
You don't see your children from a former
marriage as much as you would like.
Not true (Not true)
Somewhat true (Somewhat true)
Very true (Very true)
You are alone too much.
Not true (Not true)
Somewhat true (Somewhat true)
Very true (Very true)
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You wish you could have children but you cannot.
Not true (Not true)
Somewhat true (Somewhat true)
Very true (Very true)
One of your children seems very unhappy.
Not true (Not true)
Somewhat true (Somewhat true)
Very true (Very true)
You feel your children don't listen to you.
Not true (Not true)
Somewhat true (Somewhat true)
Very true (Very true)
A child's behavior is a source of serious concern
to you.
Not true (Not true)
Somewhat true (Somewhat true)
Very true (Very true)
One or more children do not do well enough at
school or work.
Not true (Not true)
Somewhat true (Somewhat true)
Very true (Very true)
Your children don't help around the house.
Not true (Not true)
Somewhat true (Somewhat true)
Very true (Very true)
One of your children spends too much time away
from the house.
Not true (Not true)
Somewhat true (Somewhat true)
Very true (Very true)
You feel like being a housewife is not appreciated.
Not true (Not true)
Somewhat true (Somewhat true)
Very true (Very true)
You have to go to social events alone and you
don't want to.
Not true (Not true)
Somewhat true (Somewhat true)
Very true (Very true)
Your friends are a bad influence.
Not true (Not true)
Somewhat true (Somewhat true)
Very true (Very true)
You don't have enough friends.
Not true (Not true)
Somewhat true (Somewhat true)
Very true (Very true)
4 / 5
Chronic Stress Protocol PhenX Toolkit
You don't have time for your favorite leisure time
activities.
Not true (Not true)
Somewhat true (Somewhat true)
Very true (Very true)
You want to live farther away from your family.
Not true (Not true)
Somewhat true (Somewhat true)
Very true (Very true)
You would like to move but you cannot.
Not true (Not true)
Somewhat true (Somewhat true)
Very true (Very true)
The place you live is too noisy or too polluted.
Not true (Not true)
Somewhat true (Somewhat true)
Very true (Very true)
Your family lives too far away.
Not true (Not true)
Somewhat true (Somewhat true)
Very true (Very true)
Someone in your family or a close friend has a
long-term illness or handicap.
Not true (Not true)
Somewhat true (Somewhat true)
Very true (Very true)
You have a parent, a child, or a spouse or partner
who is in very bad health and may die.
Not true (Not true)
Somewhat true (Somewhat true)
Very true (Very true)
Someone in your family has an alcohol or drug
problem.
Not true (Not true)
Somewhat true (Somewhat true)
Very true (Very true)
A long- term health problem prevents you from
doing the things you like to do.
Not true (Not true)
Somewhat true (Somewhat true)
Very true (Very true)
You take care of an aging parent almost every
day.
Not true (Not true)
Somewhat true (Somewhat true)
Very true (Very true)
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Hypomania/Mania Symptoms - Child
PhenX Toolkit
The Parent Version of the General Behavior Inventory is a
10 question, parent report instrument based on the original
General Behavior Inventory that screens children (less than
18 years old) for symptoms of bipolar disorder over the past
year.
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Hypomania/Mania Symptoms - Child
PhenX Toolkit
PhenX - hypomania - mania symptoms -
child protocol
Has your child experienced periods of several
days or more when, although he/she was feeling
unusually happy and intensely energetic (clearly
more than your child's usual self), he/she was
also physically restless, unable to sit still, and had
to keep moving or jumping from one activity to
another?
Never or hardly ever (Never or hardly
ever)
Often (Often)
Sometimes (Sometimes)
Very often, almost constantly (Very often,
almost constantly)
Have there been periods of several days or more
when your child's friends or other family members
told you that your child seemed unusually happy
or high - clearly different from his/her usual self or
from a typical good mood?
Never or hardly ever (Never or hardly
ever)
Often (Often)
Sometimes (Sometimes)
Very often, almost constantly (Very often,
almost constantly)
Has your child's mood or energy shifted rapidly
back and forth from happy to sad or high to low?
Never or hardly ever (Never or hardly
ever)
Often (Often)
Sometimes (Sometimes)
Very often, almost constantly (Very often,
almost constantly)
Has your child had periods of extreme happiness
and intense energy lasting several days or more
when he/she also felt much more anxious or
tense (jittery, nervous, uptight) than usual (other
than related to the menstrual cycle)?
Never or hardly ever (Never or hardly
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ever)
Often (Often)
Sometimes (Sometimes)
Very often, almost constantly (Very often,
almost constantly)
Have there been times of several days or more
when, although your child was feeling unusually
happy and intensely energetic (clearly more than
his/her usual self), he/she also had to struggle
very hard to control inner feelings of rage or an
urge to smash or destroy things?
Never or hardly ever (Never or hardly
ever)
Often (Often)
Sometimes (Sometimes)
Very often, almost constantly (Very often,
almost constantly)
Has your child had periods of extreme happiness
and intense energy (clearly more than his/her
usual self) when, for several days or more, it took
him/her over an hour to get to sleep at night?
Never or hardly ever (Never or hardly
ever)
Often (Often)
Sometimes (Sometimes)
Very often, almost constantly (Very often,
almost constantly)
Have you found that your child's feelings or
energy are generally up or down, but rarely in the
middle?
Never or hardly ever (Never or hardly
ever)
Often (Often)
Sometimes (Sometimes)
Very often, almost constantly (Very often,
almost constantly)
Has your child had periods lasting several days or
more when he/she felt depressed or irritable, and
then other periods of several days or more when
he/she felt extremely high, elated, and
overflowing with energy?
Never or hardly ever (Never or hardly
ever)
Often (Often)
Sometimes (Sometimes)
Very often, almost constantly (Very often,
almost constantly)
Have there been periods when, although your
child was feeling unusually happy and intensely
energetic, almost everything got on his/her
nerves and made him/her irritable or angry (other
than related to the menstrual cycle)?
Never or hardly ever (Never or hardly
ever)
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Often (Often)
Sometimes (Sometimes)
Very often, almost constantly (Very often,
almost constantly)
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International Travel History Protocol PhenX
Toolkit
From the Global Surveillance Network of the International
Society of Travel Medicine (ISTM) and the Centers for
Disease Control and Prevention (CDC), The GeoSentinel
protocol is a self-reported questionnaire that collects
information on a respondent’s recent (within the last 6
months) and previous (within the last 5 years) travel history.
It also provides a template for the clinician to use in
assessing the exposure details.
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International Travel History Protocol
PhenX Toolkit
PhenX - international travel history
protocol
Sex
Male (1)
Female (2)
Age
Date assessment information completed [OASIS]
Birthplace
Primary country of residency before age 10
Country of citizenship
Country of Current Residence
Immigrant
Yes
No
If you were not born in USA, indicate as closely
as possible the date you first arrived here:
Country of Exposure/Other
Exposure country not ascertainable
(Exposure country not ascertainable)
Plane (Plane)
Ship (Ship)
Country of Exposure/Other - Country 1
More Specific Place of Exposure
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Reason for Travel Related to Current Illness
(Check One)
Business (Business)
Immigration (Immigration)
Medical tourism (Medical tourism)
Military (Military)
Missionary/volunteer/researcher/aid work
(Missionary/volunteer/researcher/aid
work   )
Student (Student)
Tourism (Tourism)
Visiting friends & relatives  (Visiting
friends & relatives )
Risk Level Qualifier (Check One)
Expatriate (Expatriate)
Pre-arranged or organized travel     (Pre-
arranged or organized travel    )
Risk travel (Risk travel)
Clinical Setting (Check One)
Immigration travel only (Immigration
travel only)
Seen after travel     (Seen after travel    )
Seen during travel     (Seen during travel
)
Patient Type (Check One)
Inpatient (Inpatient)
Outpatient (Outpatient)
Teleconsult-inpatient (Teleconsult-
inpatient)
Teleconsult-outpatient (Teleconsult-
outpatient)
Did the patient have a pre-travel encounter with a
health care provider? (Check One)
Don't know (Don't know)
No (No)
Yes (Yes)
Main Presenting Symptoms (Check at least one
symptom below, but include all symptoms that
apply): Abnormal Lab Test
Yes
No
Main Presenting Symptoms (Check at least one
symptom below, but include all symptoms that
apply): Asymptomatic Screening
Yes
No
Main presenting symptom [PhenX]
Cardiac/MI (Cardiac/MI)
Fatigue (Fatigue)
Gastrointestinal (Gastrointestinal)
Genitourinary     (Genitourinary    )
HEENT (HEENT)
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Lymphatic (Lymphatic)
Musculoskeletal     (Musculoskeletal    )
Neurologic (Neurologic)
Other (Other)
Psychologic (Psychologic)
Respiratory (Respiratory)
Skin  (Skin )
Main Presenting Symptoms If "Other," Specify:
Trips
Trip number [PhenX]
Country number
History of Recent Travel - Trip Start Date
History of Recent Travel - Trip End Date
History of Previous Travel - Country 1 - Check if
travelled to country this year.
Yes
No
History of Previous Travel - Country 1 - Check if
travelled to country last year.
Yes
No
History of Previous Travel - Country 1 - Check if
travelled to country two years ago.
Yes
No
History of Previous Travel - Country 1 - Check if
travelled to country three years ago.
Yes
No
History of Previous Travel - Country 1 - Check if
travelled to country four years ago.
Yes
No
History of Previous Travel - Country 1 - Check if
travelled to country five years ago.
Yes
No
History of previous travel
History of Previous Travel - Country 1 - Stay was
longer than 30 consecutive days this year
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Yes
No
History of Previous Travel - Country 1 - Stay was
longer than 30 consecutive days last year
Yes
No
History of Previous Travel - Country 1 - Stay was
longer than 30 consecutive days two years ago
Yes
No
History of Previous Travel - Country 1 - Stay was
longer than 30 consecutive days three years ago
Yes
No
History of Previous Travel - Country 1 - Stay was
longer than 30 consecutive days four years ago
Yes
No
History of Previous Travel - Country 1 - Stay was
longer than 30 consecutive days five years ago
Yes
No
Diagnoses
Working diagnosis number [PhenX]
Working Diagnosis 1 Status (circle one)
Confirmed (Confirmed)
Exclusion of (Exclusion of)
Probable (Probable)
Status post (confirmed) (Status post
(confirmed))
Status post (probable) (Status post
(probable))
Status post (suspected) (Status post
(suspected))
Suspected (Suspected)
Check this box if patient was primarily diagnosed
with an infection or disease that was acquired or
existed at home prior to departure or which was
acquired after travel but prior to the clinic visit.
Yes
No
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Life Events - Child PhenX Toolkit
The Adverse Life Events Scale is a self- or proxy-
administered, 25-item questionnaire that reports events
experienced during the previous year over which the child
had little or no control. The respondent reviews the list of
items and indicates which events have occurred.
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Life Events - Child PhenX Toolkit
PhenX - life events - child protocol
Someone in family died
Yes
No
If "Yes", Was this a good or bad experience?
Don't know (Don't know)
Mostly bad (Mostly bad)
Mostly good (Mostly good)
Not applicable (Not applicable)
How much did the event affect you?
A little (A little)
A lot (A lot)
Don't know (Don't know)
Not applicable (Not applicable)
Not at all (Not at all)
Some (Some)
Family member was seriously injured
Yes
No
Saw crime/accident
Yes
No
Lost a close friend
Yes
No
Close friend was seriously sick/injured
Yes
No
Negative change in parent's financial situation
Yes
No
Family member had drug/alcohol problem
Yes
No
Got seriously sick or injured
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Yes
No
Parents argued more than previously
Yes
No
Mother/father figure lost job
Yes
No
One parent was away from home more often
Yes
No
Someone in the family was arrested
Yes
No
Close friend died
Yes
No
Family member had mental/emotional problem
Yes
No
Brother or sister left home
Yes
No
Being a victim of crime/violence/assault
Yes
No
Parents separated in last 12 months
Yes
No
Parents got into trouble with the law
Yes
No
Attended a new school
Yes
No
Family moved
Yes
No
Parents got divorced
Yes
No
One of the parents went to jail
Yes
No
Got new stepmother or stepfather
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Yes
No
Parent got a new job
Yes
No
Got new brother or sister
Yes
No
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School Social Environment Protocol PhenX
Toolkit
The protocol includes 39 self-administered questions
developed by Zullig et al. (2010). The items are scored with
a five-point Likert scale, from strongly disagree to strongly
agree, and include eight subscales: teacher relationships,
school connectedness, academic support, order and
discipline, school physical environment, school social
environment, perceived exclusion/privilege, and academic
satisfaction. The respondent reviews a list of items and
chooses the answer that best relates to herself or himself.
ODM derived from: https://cde.nlm.nih.gov
Primary source: https://www.phenxtoolkit.org/
Recent publication: Hendershot, T., Pan, H., Haines, J.,
Harlan, W.R., Marazita, M.L., McCarty, C.A., Ramos, E.M.,
and Hamilton, C.M. (2015) Using the PhenX toolkit to add
standard measures to a study. Curr. Protoc. Hum. Genet.
86:1.21.1-1.21.17. doi: 10.1002/0471142905.hg0121s86
Permission to publish granted by
Carol M. Hamilton.
All rights reserved. Please visit https://medical-data-
models.org/forms/15316
School Social Environment Protocol
PhenX Toolkit
PhenX - school social environment
protocol
Teachers understand my problems
Agree (Agree)
Disagree (Disagree)
Neither agree nor disagree (Neither
agree nor disagree)
Strongly agree (Strongly agree)
Strongly disagree (Strongly disagree)
Teachers and staff seem to take a real interest in
my future
Agree (Agree)
Disagree (Disagree)
Neither agree nor disagree (Neither
agree nor disagree)
Strongly agree (Strongly agree)
Strongly disagree (Strongly disagree)
Teachers are available when I need to talk with
them
Agree (Agree)
Disagree (Disagree)
Neither agree nor disagree (Neither
agree nor disagree)
Strongly agree (Strongly agree)
Strongly disagree (Strongly disagree)
It is easy to talk with teachers
Agree (Agree)
Disagree (Disagree)
Neither agree nor disagree (Neither
agree nor disagree)
Strongly agree (Strongly agree)
Strongly disagree (Strongly disagree)
Students get along well with teachers
Agree (Agree)
Disagree (Disagree)
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Neither agree nor disagree (Neither
agree nor disagree)
Strongly agree (Strongly agree)
Strongly disagree (Strongly disagree)
At my school, there is a teacher or some other
adult who notices when I'm not there
Agree (Agree)
Disagree (Disagree)
Neither agree nor disagree (Neither
agree nor disagree)
Strongly agree (Strongly agree)
Strongly disagree (Strongly disagree)
Teachers at my school help us children with our
problems
Agree (Agree)
Disagree (Disagree)
Neither agree nor disagree (Neither
agree nor disagree)
Strongly agree (Strongly agree)
Strongly disagree (Strongly disagree)
My teachers care about me
Agree (Agree)
Disagree (Disagree)
Neither agree nor disagree (Neither
agree nor disagree)
Strongly agree (Strongly agree)
Strongly disagree (Strongly disagree)
My teacher makes me feel good about myself
Agree (Agree)
Disagree (Disagree)
Neither agree nor disagree (Neither
agree nor disagree)
Strongly agree (Strongly agree)
Strongly disagree (Strongly disagree)
My schoolwork is exciting
Agree (Agree)
Disagree (Disagree)
Neither agree nor disagree (Neither
agree nor disagree)
Strongly agree (Strongly agree)
Strongly disagree (Strongly disagree)
Students can make suggestions on courses that
are offered
Agree (Agree)
Disagree (Disagree)
Neither agree nor disagree (Neither
agree nor disagree)
Strongly agree (Strongly agree)
Strongly disagree (Strongly disagree)
Students are publicly recognized for their
outstanding performances in speech, drama, art,
music, etc.
Agree (Agree)
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Disagree (Disagree)
Neither agree nor disagree (Neither
agree nor disagree)
Strongly agree (Strongly agree)
Strongly disagree (Strongly disagree)
If this school had an extra period during the day, I
would take an additional academic class
Agree (Agree)
Disagree (Disagree)
Neither agree nor disagree (Neither
agree nor disagree)
Strongly agree (Strongly agree)
Strongly disagree (Strongly disagree)
This school makes students enthusiastic about
learning
Agree (Agree)
Disagree (Disagree)
Neither agree nor disagree (Neither
agree nor disagree)
Strongly agree (Strongly agree)
Strongly disagree (Strongly disagree)
Students are frequently rewarded or praised by
faculty and staff for following school rules
Agree (Agree)
Disagree (Disagree)
Neither agree nor disagree (Neither
agree nor disagree)
Strongly agree (Strongly agree)
Strongly disagree (Strongly disagree)
I usually understand my homework assignments
Agree (Agree)
Disagree (Disagree)
Neither agree nor disagree (Neither
agree nor disagree)
Strongly agree (Strongly agree)
Strongly disagree (Strongly disagree)
Teachers make it clear what work needs to be
done to get the grade I want
Agree (Agree)
Disagree (Disagree)
Neither agree nor disagree (Neither
agree nor disagree)
Strongly agree (Strongly agree)
Strongly disagree (Strongly disagree)
I believe that teachers expect all students to learn
Agree (Agree)
Disagree (Disagree)
Neither agree nor disagree (Neither
agree nor disagree)
Strongly agree (Strongly agree)
Strongly disagree (Strongly disagree)
I feel that I can do well in this school
Agree (Agree)
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Disagree (Disagree)
Neither agree nor disagree (Neither
agree nor disagree)
Strongly agree (Strongly agree)
Strongly disagree (Strongly disagree)
My teachers believe that I can do well in my
school work
Agree (Agree)
Disagree (Disagree)
Neither agree nor disagree (Neither
agree nor disagree)
Strongly agree (Strongly agree)
Strongly disagree (Strongly disagree)
I try hard to succeed in my classes
Agree (Agree)
Disagree (Disagree)
Neither agree nor disagree (Neither
agree nor disagree)
Strongly agree (Strongly agree)
Strongly disagree (Strongly disagree)
Classroom rules are applied equally
Agree (Agree)
Disagree (Disagree)
Neither agree nor disagree (Neither
agree nor disagree)
Strongly agree (Strongly agree)
Strongly disagree (Strongly disagree)
Problems in this school are solved by students
and staff
Agree (Agree)
Disagree (Disagree)
Neither agree nor disagree (Neither
agree nor disagree)
Strongly agree (Strongly agree)
Strongly disagree (Strongly disagree)
Students get in trouble if they do not follow school
rule
Agree (Agree)
Disagree (Disagree)
Neither agree nor disagree (Neither
agree nor disagree)
Strongly agree (Strongly agree)
Strongly disagree (Strongly disagree)
The rules of the school are fair
Agree (Agree)
Disagree (Disagree)
Neither agree nor disagree (Neither
agree nor disagree)
Strongly agree (Strongly agree)
Strongly disagree (Strongly disagree)
School rules are enforced consistently and fairly
Agree (Agree)
Disagree (Disagree)
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Neither agree nor disagree (Neither
agree nor disagree)
Strongly agree (Strongly agree)
Strongly disagree (Strongly disagree)
My teachers make it clear to me when I have
misbehaved in class
Agree (Agree)
Disagree (Disagree)
Neither agree nor disagree (Neither
agree nor disagree)
Strongly agree (Strongly agree)
Strongly disagree (Strongly disagree)
Discipline is fair
Agree (Agree)
Disagree (Disagree)
Neither agree nor disagree (Neither
agree nor disagree)
Strongly agree (Strongly agree)
Strongly disagree (Strongly disagree)
The school grounds are kept clean
Agree (Agree)
Disagree (Disagree)
Neither agree nor disagree (Neither
agree nor disagree)
Strongly agree (Strongly agree)
Strongly disagree (Strongly disagree)
My school is neat and clean
Agree (Agree)
Disagree (Disagree)
Neither agree nor disagree (Neither
agree nor disagree)
Strongly agree (Strongly agree)
Strongly disagree (Strongly disagree)
My school buildings are generally pleasant and
well maintained
Agree (Agree)
Disagree (Disagree)
Neither agree nor disagree (Neither
agree nor disagree)
Strongly agree (Strongly agree)
Strongly disagree (Strongly disagree)
My school is usually clean and tidy
Agree (Agree)
Disagree (Disagree)
Neither agree nor disagree (Neither
agree nor disagree)
Strongly agree (Strongly agree)
Strongly disagree (Strongly disagree)
I am happy with kinds of students who go to my
school
Agree (Agree)
Disagree (Disagree)
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Neither agree nor disagree (Neither
agree nor disagree)
Strongly agree (Strongly agree)
Strongly disagree (Strongly disagree)
I am happy, in general, with the other students
who go to my school
Agree (Agree)
Disagree (Disagree)
Neither agree nor disagree (Neither
agree nor disagree)
Strongly agree (Strongly agree)
Strongly disagree (Strongly disagree)
At my school, the same person always gets to
help the teacher
Agree (Agree)
Disagree (Disagree)
Neither agree nor disagree (Neither
agree nor disagree)
Strongly agree (Strongly agree)
Strongly disagree (Strongly disagree)
At my school, the same kids get chosen every
time to take part in after-school or special
activities
Agree (Agree)
Disagree (Disagree)
Neither agree nor disagree (Neither
agree nor disagree)
Strongly agree (Strongly agree)
Strongly disagree (Strongly disagree)
The same kids always get to use things, like a
computer, a ball or a piano, when we play
Agree (Agree)
Disagree (Disagree)
Neither agree nor disagree (Neither
agree nor disagree)
Strongly agree (Strongly agree)
Strongly disagree (Strongly disagree)
I am happy about the number of tests I have
Agree (Agree)
Disagree (Disagree)
Neither agree nor disagree (Neither
agree nor disagree)
Strongly agree (Strongly agree)
Strongly disagree (Strongly disagree)
I am happy about the amount of homework I have
Agree (Agree)
Disagree (Disagree)
Neither agree nor disagree (Neither
agree nor disagree)
Strongly agree (Strongly agree)
Strongly disagree (Strongly disagree)
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Fracture History Protocol PhenX Toolkit
This protocol is divided into two parts. Part I consists of the
Study of Osteoporotic Fractures (SOF) Fractures and Falls
History: History of Fractures Questionnaire, which is a self-
administered questionnaire to assess the location of the
respondent’s broken bone(s) and the age(s) at which the
break(s) occurred. Part II contains the Framingham
Osteoporosis Study Fracture Assessment form to confirm
the respondent’s self-reported fracture history.
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Fracture History Protocol PhenX
Toolkit
PhenX - fracture history protocol
Has a doctor ever said that you had a broken or
fractured bone?
Don't know (Don't know)
No  (No )
Yes (Yes)
IF YES, please write down the names of all the
bones you have broken (for example, wrist or
spine) and your age when you broke that bone.
BrokBone
IF YES, please write down the names of all the
bones you have broken (for example, wrist or
spine) and your age when you broke that bone.
Age When Bro"
Source of fracture confirmation [PhenX]
Discharge summary (Discharge
summary)
ER notes (ER notes)
OR report (OR report)
Orthopedic notes (Orthopedic notes)
Other (Other)
X-ray report (X-ray report)
Was this the source of fracture confirmation
[PhenX]
Yes
No
Other source of fracture confirmation [PhenX]
Side [PhenX]
Left (Left)
Right (Right)
Hip fracture location
Femoral neck (subcapital) (Femoral neck
(subcapital))
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Intertrochanteric     (Intertrochanteric    )
Other (Other)
Unknown (Unknown)
Hip fracture location
Fracture treatment [PhenX]
Arthroplasty/hemiarthroplasty (femoral
head replacement)
(Arthroplasty/hemiarthroplasty (femoral
head replacement)  )
Cast or other immobilization (Cast or
other immobilization)
None (None)
Open reduction internal fixation (ORIF or
pinning)    (Open reduction internal
fixation (ORIF or pinning)   )
Other (Other)
Unknown (Unknown)
Other fracture treatment [PhenX]
Other fracture(s) occurred at the same time
Circumstances of hip fracture
Fall from standing height or less (Fall
from standing height or less)
Motor vehicle accident or fall from
greater than standing height     (Motor
vehicle accident or fall from greater than
standing height    )
Other (Other)
Unknown (Unknown)
Location of fall or trauma
Inside (Inside)
N/A (N/A)
Other (Other)
Outside (Outside)
Unknown (Unknown)
Location of fall or trauma. Other, specify
Time of day fracture occurred
Daytime (6am-6pm)   (Daytime (6am-
6pm)  )
Night (6:01pm to 5:59am)  (Night
(6:01pm to 5:59am) )
Other (Other)
Unknown (Unknown)
Death occurred during hospitalization [PhenX]
N/A, no hospitalization (N/A, no
hospitalization)
No (No)
Unknown (Unknown)
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Yes (Yes)
Detailed circumstances of fracture
Fall from more than standing height, but
NOT on stairs (Fall from more than
standing height, but NOT on stairs)
Fall from standing height or less (Fall
from standing height or less)
Falls on stairs, steps or curbs (Falls on
stairs, steps or curbs)
Minimal trauma other than a fall (Minimal
trauma other than a fall)
Moderate trauma other than a fall
(Moderate trauma other than a fall)
Pathologic fracture-usually associated
with cancer in bone (Pathologic fracture-
usually associated with cancer in bone)
Severe trauma other than a fall (Severe
trauma other than a fall)
Unknown (Unknown)
Date data retrieval completed
DATE OF ADJUDICATION BY MD FRACTURE
COORDINATOR:
FINAL ADJUDICATION BY ENDPOINTS
COMMITTEE REQUIRED:
Service comment
Fracture location
Ankle (Ankle)
Arm (unspecified) (Arm (unspecified))
Both distal radius and ulna (Both distal
radius and ulna)
Both fibia/fibula (Both fibia/fibula)
Chest/sternum (Chest/sternum)
Clavicle or collar bone (Clavicle or collar
bone)
Distal radius (Colles'; Smith) (Distal
radius (Colles'; Smith))
Distal ulna (Distal ulna)
Eighth thoracic vertebra (Eighth thoracic
vertebra)
Elbow (Elbow)
Eleventh thoracic vertebra (Eleventh
thoracic vertebra)
Facial bones (includes jaw, nose, cheek)
(Facial bones (includes jaw, nose,
cheek))
Femoral neck (subcapital) (Femoral neck
(subcapital))
Femur (not hip) (Femur (not hip))
Fibula (Fibula)
Fifth cervical vertebra (Fifth cervical
vertebra)
Fifth lumbar vertebra (Fifth lumbar
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vertebra)
Fifth thoracic vertebra (Fifth thoracic
vertebra)
Fingers (Fingers)
First cervical vertebra (First cervical
vertebra)
First lumbar vertebra (First lumbar
vertebra)
First thoracic vertebra (First thoracic
vertebra)
Foot/metatarsal (Foot/metatarsal)
Fourth cervical vertebra (Fourth cervical
vertebra)
Fourth lumbar vertebra (Fourth lumbar
vertebra)
Fourth thoracic vertebra (Fourth thoracic
vertebra)
Hand (Hand)
Heel/os calcis (Heel/os calcis)
Hip (Hip)
Humerus (upper arm) (Humerus (upper
arm))
Intertrochanteric (Intertrochanteric)
Leg (unspecified) (Leg (unspecified))
Lumbar spine (unspecified) (Lumbar
spine (unspecified))
Multiple cervical vertebrae (Multiple
cervical vertebrae)
Multiple lumbar vertebrae (Multiple
lumbar vertebrae)
Multiple thoracic vertebrae (Multiple
thoracic vertebrae)
Neck (Neck)
Ninth thoracic vertebra (Ninth thoracic
vertebra)
Other (Other)
Other small bones in wrist (Other small
bones in wrist)
Patella (Patella)
Pelvis (Pelvis)
Radius a/o ulna, proximal or mid shaft
(Radius a/o ulna, proximal or mid shaft)
Ribs (Ribs)
Scapula (shoulder blade) (Scapula
(shoulder blade))
Second cervical vertebra (Second
cervical vertebra)
Second lumbar vertebra (Second lumbar
vertebra)
Second thoracic vertebra (Second
thoracic vertebra)
Seventh cervical vertebra (Seventh
cervical vertebra)
Shoulder (Shoulder)
Sixth cervical vertebra (Sixth cervical
vertebra)
Skull (Skull)
Tailbone/coccyx/sacrum
(Tailbone/coccyx/sacrum)
Tenth thoracic vertebra (Tenth thoracic
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vertebra)
Third cervical vertebra (Third cervical
vertebra)
Third lumbar vertebra (Third lumbar
vertebra)
Third thoracic vertebra (Third thoracic
vertebra)
Thoracic spine (unspecified) (Thoracic
spine (unspecified))
Tibia (Tibia)
Toes (Toes)
Twelfth thoracic vertebra (Twelfth
thoracic vertebra)
Wrist (unspecified) (Wrist (unspecified))
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Discharge Letter Items 1174726752
Multiple Sclerosis
Discharge Letter Items for Patient diagnosed with Multiple
Sclerosis from Neurology Department of University Clinic
Muenster
All rights reserved. Please visit https://medical-data-
models.org/forms/15319
Discharge Letter Items 1174726752
Multiple Sclerosis
Administrative Data
Document ID
Patient`s Name
Date of birth:
Inpatient or Outpatient
Inpatient (Inpatient)
Outpatient (Outpatient)
Date of Appointment/Stay
Principal Diagnosis
Principal Diagnosis Multiple Sclerosis
Onset
Earliest date of diagnosis
EDSS
Previous Therapy Medication
Time Range of Previous Therapy
Previous Therapie Benefit
Current Immunosuppressive Therapy
Date of start of current therapy
Secondary Diagnosis
Secondary Diagnosis
1 / 6
Risk Stratification of Therapy with
Natalizumab
Previous Immunosuppressive Therapy
Yes
No
Use of Natalizumab
months
JCV Antibodies
JCV-Index
Date of JCV-Antibody Measurement
L-Selectin-Signature
Date of L-Selectin Measurement
Reason for Admission
Reason for admission
Summary and Assessment
Introduction: Reason for current Admission
Current Immunosuppressive Therapy
Did any adverse effects occur?
Did any new focal neurologic deficits occur?
Yes
No
Did any new symptoms that indicate a flare of MS
occur?
Yes
No
When did the latest flare occur?
Current Symptoms
Did a loss of bladder function control occur?
Yes
No
2 / 6
Discharge Letter Items 1174726752 Multiple Sclerosis
Did a loss of bowl function control occur?
Yes
No
Walking Distance
km
Does an impairment of everyday life occur due to
fatigue?
Yes
No
Anamnestic hints to a progressive Multifocal
Leukoencephalopathy?
Yes
No
Results of latest MRI of Head and Brain
Findings of MRI of Throcacic spine?
Pathological findings of neurological examination
Findings of laboratory tests
Summary of the current progression and stage of
disease
Summary of paraclinical findings
Summary of Procedures during hospitalisation
Procedures
Date Follow-Up Visit
Recommendation to bring a current blood count,
CRP and Urine status
Yes
No
Physical Therapy has been recommended?
Yes
No
Recommendation to compare MRI images
Yes
No
Neurological Examination: Cranial Nerves
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Orientation
Meningism
Lhermitte's sign
negative (negative)
positive (positive)
Percussion Pain Skull
Yes
No
Visual Field Fingerperimetric
Examination of Eye Movement
Nystagmus Test
Diplopia
Facial Sensory Function
Facial Muscles abnormal?
Findings on finger rub auditory screening test
Further Cranial Nerves function impaired?
Aphasia?
Yes
No
Neglect
Yes
No
Apraxia?
Neurological Examination: Motor
Paresis of Lower Exremity
Muscle strength of Hip Flexion
0/5 (0/5)
1/5 (1/5)
2/5 (2/5)
3/5 (3/5)
4/5 (4/5)
5/5 (5/5)
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Muscle strength Knee flexion
0/5 (0/5)
1/5 (1/5)
2/5 (2/5)
3/5 (3/5)
4/5 (4/5)
5/5 (5/5)
Muscle strength Dorsiflexion Foot
0/5 (0/5)
1/5 (1/5)
2/5 (2/5)
3/5 (3/5)
4/5 (4/5)
5/5 (5/5)
Paresis of Upper Exremity
Muscle strength of arm
0/5 (0/5)
1/5 (1/5)
2/5 (2/5)
3/5 (3/5)
4/5 (4/5)
5/5 (5/5)
Pronator Drift Test
Leg drift test
Function of Muscular reflex (MER) on arm
Patellar Reflex
Achilles Reflex
Babinski Reflex
Spastic Gait
both sides (both sides)
left side (left sides)
right side (right sides)
Toe-walking gait possible
Heel to toe gait possible
Heel Gait possible
One Leg Jump possible
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Neurological Examination: Coordination
and Gait
Gait, Manner of walking
Standing on toes
Standing on heels
Rhomberg Test abnormal?
One leg stand test
Fine motor skills abnormal?
Finger-to-nose test abnormal?
Neurological Examination: Sensibility
Hypesthesia Upper Extremity
Hypesthesia Lower Extremity
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Eligibility Idiopathic Parkinson's Disease
NCT02306863
Whole-body Vibration as a Treatment for Parkinson's
Disease; ODM derived from:
https://clinicaltrials.gov/show/NCT02306863
All rights reserved. Please visit https://medical-data-
models.org/forms/15321
Eligibility Idiopathic Parkinson's
Disease NCT02306863
Inclusion Criteria
diagnosed with idiopathic parkinson's disease by
a neurologist*
Yes
No
currently taking anti-parkinsonian medication*
Yes
No
able to stand for 2 minutes without assistance*
Yes
No
able to walk 10 meters without assistance*
Yes
No
ability to understand english instructions*
Yes
No
normal or corrected vision*
Yes
No
Exclusion Criteria
a neurological disease other than pd*
Yes
No
recent stroke*
Yes
No
cardiovascular disease*
Yes
No
previous major hemorrhage*
Yes
No
artificial pacemaker*
Yes
No
currently pregnant*
Yes
No
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current participation in any physical therapy or
experimental treatments*
Yes
No
peripheral neuropathy, severe osteoporosis*
Yes
No
visual impairments that cannot be corrected*
Yes
No
clinically diagnosed with dementia*
Yes
No
greater than mild dementia (screened using
montreal cognitive assessment (moca) <24 being
excluded)*
Yes
No
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Eligibility Idiopathic Parkinson's Disease NCT02306863
Discharge Letter Items 1215271678
Multiple Sclerosis
Discharge Letter Items for Patient diagnosed with Multiple
Sclerosis from Neurology Department of University Clinic
Muenster
All rights reserved. Please visit https://medical-data-
models.org/forms/15323
Discharge Letter Items 1215271678
Multiple Sclerosis
Administrative Data
Document ID of Discharge Letter
Patient`s Name
Patients date of birth
Date of Appointment/Stay
Inpatient or Outpatient
Inpatient (Inpatient)
Outpatient (Outpatient)
Principal Diagnosis
Principal Diagnosis Multiple Sclerosis
Onset
Earliest date of diagnosis
EDSS
History of Retrobulbar Neuritis
Yes
No
Summary and Assessment
Introduction: Reason for current Admission
Introduction: Department
Past medical history
Previous MRI findings
Visual evoked potential findings
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Central motor evoked potential results
Cerebrospinal fluid
Oligoclonal Bands
Immunoglobulin G synthesis in Cerebrospinal
fluid
Cerebrospinal fluid viral antibody test
(measles, rubella, varicella)
Previous Therapy Medication
Previous Therapie Benefit
Did a loss of bladder function control occur?
Yes
No
Did a loss of bowl function control occur?
Yes
No
Does an impairment of everyday life occur due to
fatigue?
Yes
No
Follow-up MRI
Number of T2-hyperintense Lesions in cMRT
Localisation of Lesions
Criteria Dissemination in Time
Yes
No
Criteria Dissemination in Space
Yes
No
Neurological Examination
Therapeutic Options
Study Participation
Yes
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No
Procedures
Anti-aquaporin-4 antibody Blood Test
Borrelia test
Vasculitis Laboratory Tests
Therapy Recommendation
Neurological Exam
MRI Follow-Up
Neurological Examination: Cranial Nerves
Orientation
Meningism
Nerve stretch tests
Lhermitte's sign
negative (negative)
positive (positive)
Visual Field Fingerperimetric
Pupils Size
Pupils regularity
Pupils reaction
Direct pupil reaction to light
Consensual pupil reaction to light
Examination of Eye Movement
Nystagmus Test
3 / 4
Discharge Letter Items 1215271678 Multiple Sclerosis
Gaze Palsy
Diplopia
Facial Paralysis
Trigeminal Sensory Function
Trigeminal Motor Function abnormal?
Yes
No
Function of caudal cranial nerves
Neurological Examination: Motor
Pareses
present (1)
not present (2)
not examined (3)
Pronator Drift Test
Leg drift test
Muscle Tonus
Fine motor skills abnormal?
Gait, Manner of walking
Standing, Manner of Standing
Function of Muscular reflex
Pyramidal signs
Sensibility on neurological exam abnormal?
Yes
No
Abnormal motor coordination tests?
Motor Coordination Tests abnormal?
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Eligibility Idiopathic Parkinson's Disease
NCT02339064
Infusion of Apomorphine: Long-term Safety Study; ODM
derived from: https://clinicaltrials.gov/show/NCT02339064
All rights reserved. Please visit https://medical-data-
models.org/forms/15324
Eligibility Idiopathic Parkinson's
Disease NCT02339064
Inclusion Criteria
advanced idiopathic parkinson's disease (pd)
where overall control remains unsatisfactory,
despite optimal treatment with non-invasive
approved pd medications*
Yes
No
experience "off" periods averaging greater than
2.5 hours per day*
Yes
No
other criteria will be discussed in detail with
potential subjects by site investigator*
Yes
No
Exclusion Criteria
known, suspected, or planned pregnancy*
Yes
No
recent history of alcohol or substance abuse*
Yes
No
history of deep brain stimulation or any other
surgical intervention for the treatment of pd*
Yes
No
known or suspected clinically significant
orthostatic hypotension*
Yes
No
lifetime history of impulsive/compulsive behaviors
primarily associated with the use of dopamine
agonists*
Yes
No
previously treated or current malignant
melanoma*
Yes
No
other criteria will be discussed in detail with
potential subjects by site investigator*
Yes
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No
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Discharge Letter Items 1232376516
Multiple Sclerosis
Discharge Letter Items for Patient diagnosed with Multiple
Sclerosis from Neurology Department of University Clinic
Muenster Publication granted by PD Dr. Klotz
All rights reserved. Please visit https://medical-data-
models.org/forms/15325
Discharge Letter Items 1232376516
Multiple Sclerosis
Administrative Data
Document ID of Discharge Letter
Patient`s Name
Patients date of birth
Inpatient or Outpatient
Inpatient (Inpatient)
Outpatient (Outpatient)
Date of Appointment/Stay
Principal Diagnosis
Principal Diagnosis Multiple Sclerosis
Onset
Earliest date of diagnosis
EDSS
Immunosuppressive Therapy: Fingolimod
Date of start of therapy
Current Symptoms: Fatigue
Yes
No
Reason for Admission
Reason for admission
Study Participation
Summary and Assessment
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Introduction: Reason for current Admission
Introduction: Department
Medical history
Therapy Benefit of Therapie during hospital stay
Current Symptoms
Adverse Effect
Current symptoms: Bronchitis
Yes
No
Antibiotics necessary due to infection (i.e.
bronchitis)?
Yes
No
More infections since immunosuppresion with
Fingolimod?
Yes
No
Did a loss of bladder function control occur?
Yes
No
Did a loss of bowl function control occur?
Yes
No
Concentration difficulties
Yes
No
Attention deficit?
Yes
No
Memory impairment
Yes
No
Does an impairment of everyday life occur due to
fatigue?
Yes
No
Does Therapy of Fatigue with Amantadine help
the patient?
Yes
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No
Therapy Fatigue Vigil
Walking Distance
Neurological Examination
Date of MRI
Number of T2-hyperintense Lesions in cMRT
Localisation of Lesions
Date of Finding of Lesion
Procedures
Therapy Recommendation
MRI Follow-Up
Neurological Exam
Recommendation ECG
Yes
No
Recommendation to bring a current blood count,
CRP and Urine status
Yes
No
Differential blood count
Recommendation to evaluate liver enzymes on a
regularly base
If hints of pulmonary function loss occurs please
absolve pulmonary function tests (concerning
therapy with fingolimod)
When visus gets worse we recommend
opthalmologic examination
Yes
No
We recommend dermatological exams
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Date Follow-Up Visit
We recommend to substitute vitamin D
Yes
No
Neurological Examination
Orientation
Meningism
Nerve stretch tests
Lhermitte's sign
negative (negative)
positive (positive)
Percussion Pain Skull
Yes
No
Percussion Pain Spine
Yes
No
Visus measurement
Examination of Eye Movement
Nystagmus Test
Gaze Palsy
Diplopia
Visual Field Fingerperimetric
Pupils Size
Pupils regularity
Consensual pupil reaction to light
Direct pupil reaction to light
Trigeminal Sensory Function
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Facial Paralysis
Function of caudal cranial nerves
Function of Muscular reflex
Pyramidal signs
Abdominal Reflex normal?
Yes
No
Pronator Drift Test
Leg drift test
Pareses
Gait, Manner of walking
Toe-walking gait possible
Heel Gait possible
Heel to toe gait possible
One Leg Jump possible
Finger-to-nose test abnormal?
Heel-to-knee test abnormal?
Diadochokinesis abnormal?
Dysdiadochokinesis
(Dysdiadochokinesis)
Eudiadochokinesis (Eudiadochokinesis)
Sensibility on neurological exam abnormal?
Yes
No
Rhomberg Test abnormal?
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Eligibility Inflammation Plaque,
Atherosclerotic NCT02378064
Comparison of Fimasartan Versus Amlodipine Therapy on
Carotid PlaquE Inflammation; ODM derived from:
https://clinicaltrials.gov/show/NCT02378064
All rights reserved. Please visit https://medical-data-
models.org/forms/15326
Eligibility Inflammation Plaque,
Atherosclerotic NCT02378064
Inclusion Criteria
men or women at least 18 years of age inclusive*
Yes
No
patients with acute coronary syndromes or
unstable angina pectoris*
Yes
No
hypertension or blood pressure more than
140/90mmhg*
Yes
No
fdg pet/ct shows at least 1 hot uptakes at carotid
and or ascending aorta*
Yes
No
the patient or guardian agrees to the study
protocol and the schedule of clinical and fdg
pet/ct follow-up, and provides informed, written
consent, as approved by the appropriate
institutional review board/ethical committee of the
respective clinical site.*
Yes
No
Exclusion Criteria
patients treated with carotid endarterectomy or
stent placement*
Yes
No
chronic disease requiring treatment with oral,
intravenous, or intra-articular corticosteroids (use
of topical, inhaled, or nasal corticosteroids is
permissible).*
Yes
No
untreated hyperthyroidism, or hypothyroidism*
Yes
No
any clinically significant abnormality identified at
the screening visit, physical examination,
laboratory tests, or electrocardiogram which, in
the judgment of the investigator, would preclude
safe completion of the study.*
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Yes
No
evidence of congestive heart failure, or left
ventricular ejection fraction < 40%.*
Yes
No
significant renal disease manifested by serum
creatinine > 2.0mg/dl, or creatinine clearance of <
40 ml/min (by cockcroft-gault method).*
Yes
No
hepatic disease or biliary tract obstruction, or
significant hepatic enzyme elevation (alt or ast >
3 times upper limit of normal).*
Yes
No
history of adult asthma manifested by
bronchospasm in the past 6 months, or currently
taking regular anti-asthmatic medication(s).*
Yes
No
unwillingness or inability to comply with the
procedures described in this protocol.*
Yes
No
patient's pregnant or breast-feeding or child-
bearing potential.*
Yes
No
type i diabetes*
Yes
No
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Eligibility Insomnia NCT02290496
CBT Insomnia Teens: Augmenting SSRIs to Improve Youth
Depression; ODM derived from:
https://clinicaltrials.gov/show/NCT02290496
All rights reserved. Please visit https://medical-data-
models.org/forms/15327
Eligibility Insomnia NCT02290496
Inclusion Criteria
age 12 to 19*
Yes
No
major depression based on diagnostic and
statistical manual of mental disorders (dsm-5)
criteria*
Yes
No
recent dispense of ssri antidepressant*
Yes
No
subjective complaint of insomnia ≥ one month*
Yes
No
score of ≥ 9 on insomnia severity index*
Yes
No
Exclusion Criteria
active, progressive physical illness or
neurological degenerative disease*
Yes
No
sleep apnea, restless legs, or limb movements
during sleep*
Yes
No
diagnosis of delayed sleep phase syndrome
(dsps)*
Yes
No
mental retardation, autism spectrum disorder
(asd), or other significant pervasive
developmental disability (pdd)*
Yes
No
sleep treatments including over-the-counter (otc)
sleep medication or cbt for insomnia*
Yes
No
medications known to alter sleep*
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Yes
No
diagnosis of bipolar disorder, schizophrenia, or
other psychotic disorder*
Yes
No
2 / 2
Eligibility Insomnia NCT02290496
Emergency Room Point B in time DGU
TraumaRegister questionnaire
DGU TraumaRegister® questionnaire; 
Data are collected prospectively in four consecutive time
phases from the site of the accident until discharge from
hospital: A) Pre-hospital phase, B) Emergency room and
initial surgery, C) Intensive care unit and D) Discharge. The
documentation includes detailed information on
demographics, injury pattern, comorbidities, pre- and in-
hospital management, course on intensive care unit,
relevant laboratory findings including data on transfusion
and outcome of each individual. The inclusion criterion is
admission to hospital via emergency room with subsequent
ICU/ICM care or reach the hospital with vital signs and die
before admission to ICU.  
The infrastructure for documentation, data management,
and data analysis is provided by AUC - Academy for
Trauma Surgery (AUC - Akademie der Unfallchirurgie
GmbH), a company affiliated to the German Trauma
Society. The scientific leadership is provided by the
Committee on Emergency Medicine, Intensive Care and
Trauma Management (Sektion NIS) of the German Trauma
Society. The participating hospitals submit their data anon-
ymously into a central database via a web-based
application. Scientific data analysis is approved according
to a peer review procedure established by Sektion NIS. 
TraumaRegister DGU® - Hinweise für die Publikation von
Ergebnissen 5 März 2014  
Seite 3 von 3 
© 2014 TraumaRegister DGU® / AUC GmbH 
The participating hospitals are primarily located in
Germany (90%), but a rising number of hospitals of other
countries contribute data as well (at the moment from
Austria, Belgium, China, Finland, Luxembourg, Slovenia,
Switzerland, The Netherlands, and the United Arab
Emirates). Currently, approx. 25,000 cases from more than
600 hospitals are entered into the database per year. 
Participation in TraumaRegister DGU® is voluntary. For
hospitals associated with TraumaNetzwerk DGU®,
however, the entry of at least a basic data set is obligatory
for reasons of quality assurance. 
www.traumaregister-dgu.de
All rights reserved. Please visit https://medical-data-
models.org/forms/15328
Emergency Room Point B in time
DGU TraumaRegister questionnaire
Informationen über den Patienten
Eintreffen
Land
Postleitzahl
Buchstabe
Patienten ID
Geburtsdatum
Geschlecht
male (1)
female (2)
Zuverlegung aus anderem KH
Ja
Nein
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wenn ja, welches KH?
KH-Code
Optionale klinikinterne Zusatz-ID
Vitalzeichen
Blutdruck syst.
mmHg
Atemfrequenz
/minute
Puls
bpm
Sauerstoffsättigung (Sp O2)
%
Bereits bei Ankunft intubiert?
Ja
Nein
FiO2
PaO2
mmHg
Diagnostik
Sono Abdomen
Ja
Nein
Zeitpunkt Sono Abdomen
Röntgen Thorax
Ja
Nein
Zeitpunkt Röntgen Thorax
Röntgen Becken
Ja
Nein
Zeitpunkt Röntgen Becken
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Röntgen Wirbelsäule
Ja
Nein
Zeitpunkt Wirbelsäulen Röntgen
CT
Ja
Nein
Zeitpunkt CT
Ganzkörper-CT
Ja
Nein
Zeitpunkt Ganzkörper-CT
Rotem/Rotec
Ja
Nein
Zeitpunkt Rotem/Rotec
Labor
Base Excess
mmol/l
Quick-Wert (in Prozent)
%
Hb-Wert
mmol/l
Thrombozyten
/uL
Quick
%
PTT
seconds
INR
Laktat
Temperatur
°C
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Erster operativer Notfalleingriff
Craniotomie (dekompressive Craniotomie)
Ja
Nein
Thorakotomie (ohne Thoraxdrainage/mini-
Thorakotomie)
Ja
Nein
Laparotomie
Ja
Nein
Revaskularisation
Ja
Nein
Embolisierung
Ja
Nein
Stabilisierung Becken
Ja
Nein
Stabilisierung Extremität
Ja
Nein
Beginn der OP-Schnitt:
Therapie
Kristalloide
ml
Kolloide
mmol/l
Hyperonk./Hyperosm. Lösung
mmol/l
Blut
Units
FFP/Frischplasma
Units
Thrombozyten
Units
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Intubation
Ja
Nein
Herzmassage
Ja
Nein
Katecholamine
Ja
Nein
Thoraxdrainage
Ja
Nein
Embolisation
Ja
Nein
Akute externe Frakturstabilisierung (außerhalb
des OP)
Ja
Nein
Weiterversorgung
SR-Diagnostik regulär beendet?
Ja
Nein
wenn ja: Weiterverlegung
Früh-OP (1)
Intensiv (2)
andere(s) (3)
Uhrzeit
wenn nein: Abbruch wegen:
Not-OP (1)
sonstiges (2)
Uhrzeit
Komplettierung der Diagnostik vor ICU?
Ja
Nein
Hämostase-Therapie
rfVIIa
Ja
Nein
PPSB
Ja
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Nein
Antifibrinolytika
Ja
Nein
Fibrinogen
Ja
Nein
andere hämost. Medikamente
Ja
Nein
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Preclinical Point A in time DGU
TraumaRegister questionnaire
DGU TraumaRegister® questionnaire; 
Data are collected prospectively in four consecutive time
phases from the site of the accident until discharge from
hospital: A) Pre-hospital phase, B) Emergency room and
initial surgery, C) Intensive care unit and D) Discharge. The
documentation includes detailed information on
demographics, injury pattern, comorbidities, pre- and in-
hospital management, course on intensive care unit,
relevant laboratory findings including data on transfusion
and outcome of each individual. The inclusion criterion is
admission to hospital via emergency room with subsequent
ICU/ICM care or reach the hospital with vital signs and die
before admission to ICU.  
The infrastructure for documentation, data management,
and data analysis is provided by AUC - Academy for
Trauma Surgery (AUC - Akademie der Unfallchirurgie
GmbH), a company affiliated to the German Trauma
Society. The scientific leadership is provided by the
Committee on Emergency Medicine, Intensive Care and
Trauma Management (Sektion NIS) of the German Trauma
Society. The participating hospitals submit their data anon-
ymously into a central database via a web-based
application. Scientific data analysis is approved according
to a peer review procedure established by Sektion NIS. 
TraumaRegister DGU® - Hinweise für die Publikation von
Ergebnissen 5 März 2014  
Seite 3 von 3 
© 2014 TraumaRegister DGU® / AUC GmbH 
The participating hospitals are primarily located in
Germany (90%), but a rising number of hospitals of other
countries contribute data as well (at the moment from
Austria, Belgium, China, Finland, Luxembourg, Slovenia,
Switzerland, The Netherlands, and the United Arab
Emirates). Currently, approx. 25,000 cases from more than
600 hospitals are entered into the database per year. 
Participation in TraumaRegister DGU® is voluntary. For
hospitals associated with TraumaNetzwerk DGU®,
however, the entry of at least a basic data set is obligatory
for reasons of quality assurance. 
www.traumaregister-dgu.de
All rights reserved. Please visit https://medical-data-
models.org/forms/15330
Preclinical Point A in time DGU
TraumaRegister questionnaire
Vitalzeichen
Blutdruck syst.
mmHg
Atemfrequenz
/minute
Heart rate
bpm
Oxygen saturation
%
Glasgow Coma Scale
Augenöffnen
keine (1)
Schmerz (2)
Aufforderung (3)
spontan (4)
Verbale Antwort
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keine (1)
unverständlich (2)
inadäquat (3)
verwirrt (4)
orientiert (5)
Motorische Antwort
keine (1)
Streckkrämpfe (2)
Beugekrämpfe (3)
ungezielt (Schmerz) (4)
gezielt (Schmerz) (5)
Aufforderung (6)
Summe (Score)
<= 15
>= 1
size of pupil right
tight (1)
normal (2)
wide (3)
size of pupil left
tight (1)
normal (2)
wide (3)
General Information
Time of Alarm
Arrival of A&E doctor
time of departure
Transport mode to hospital
ambulance; with physician attendance
(1)
ambulance; without physician attendance
(2)
SAR helicopter  (3)
private (4)
Injuries
craniocerebral trauma
none (1)
light (2)
moderate (3)
severe (4)
facial injury
none (1)
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light (2)
moderate (3)
severe (4)
thoracic injury
none (1)
light (2)
moderate (3)
severe (4)
abdominal injury
none (1)
light (2)
moderate (3)
severe (4)
injury of spine
none (1)
light (2)
moderate (3)
severe (4)
injury of pelvis
none (1)
light (2)
moderate (3)
severe (4)
injury of upper limb
none (1)
light (2)
moderate (3)
severe (4)
injuries of lower limb
none (1)
light (2)
moderate (3)
severe (4)
injury of soft tissue
none (1)
light (2)
moderate (3)
severe (4)
Therapie
Intubation
Ja
Nein
Herzmassage
Ja
Nein
analgosedation
Ja
Nein
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Catecholamine therapy
Ja
Nein
e
chest tube
Ja
Nein
Administration of electrolytes
ml
Administration of colloids
ml
hyperosmolar infusion
ml
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Outcome Prognosis Thromboembolic Events Point
D1 in Time DGU TraumaRegister questionnaire
2
3
4
5
DGU TraumaRegister® questionnaire; Data are collected
prospectively in four consecutive time phases from the site
of the accident until discharge from hospital: A) Pre-hospital
phase, B) Emergency room and initial surgery, C) Intensive
care unit and D) Discharge. The documentation includes
detailed information on demographics, injury pattern,
comorbidities, pre- and in-hospital management, course on
intensive care unit, relevant laboratory findings including
data on transfusion and outcome of each individual. The
inclusion criterion is admission to hospital via emergency
room with subsequent ICU/ICM care or reach the hospital
with vital signs and die before admission to ICU. The
infrastructure for documentation, data management, and
data analysis is provided by AUC - Academy for Trauma
Surgery (AUC - Akademie der Unfallchirurgie GmbH), a
company affiliated to the German Trauma Society. The
scientific leadership is provided by the Committee on
Emergency Medicine, Intensive Care and Trauma
Management (Sektion NIS) of the German Trauma Society.
The participating hospitals submit their data anon-ymously
into a central database via a web-based application.
Scientific data analysis is approved according to a peer
review procedure established by Sektion NIS.
TraumaRegister DGU® - Hinweise für die Publikation von
Ergebnissen 5 März 2014 Seite 3 von 3 © 2014
TraumaRegister DGU® / AUC GmbH The participating
hospitals are primarily located in Germany (90%), but a
rising number of hospitals of other countries contribute data
as well (at the moment from Austria, Belgium, China,
Finland, Luxembourg, Slovenia, Switzerland, The
Netherlands, and the United Arab Emirates). Currently,
approx. 25,000 cases from more than 600 hospitals are
entered into the database per year. Participation in
TraumaRegister DGU® is voluntary. For hospitals
associated with TraumaNetzwerk DGU®, however, the
entry of at least a basic data set is obligatory for reasons of
quality assurance. www.traumaregister-dgu.de
All rights reserved. Please visit https://medical-data-
models.org/forms/15331
Outcome Prognosis
Thromboembolic Events Point D1 in
Time DGU TraumaRegister
questionnaire
General Information
date
Patient deceased
Yes
No
Time of death
Patient survived: transfered to:
Home (1)
Rehabilitation facility (2)
Hospital (3)
Other (4)
specify hospital
specify other
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Glasgow Outcome Scale
vegetative state (2)
severe disability (3)
moderate disability (4)
good recovery (5)
Thromboembolic event
None (1)
Heart Attack (2)
Pulmonary Embolism (3)
Deep Vein Thrombosis (4)
Stroke (5)
Other thromboembolic events (6)
Thrombosis prophylaxis
Yes
No
For Germany only
DRG-Nr.:
Intensive care costs
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Intensive Care Point C in time DGU
TraumaRegister questionnaire
DGU TraumaRegister® questionnaire; 
Data are collected prospectively in four consecutive time
phases from the site of the accident until discharge from
hospital: A) Pre-hospital phase, B) Emergency room and
initial surgery, C) Intensive care unit and D) Discharge. The
documentation includes detailed information on
demographics, injury pattern, comorbidities, pre- and in-
hospital management, course on intensive care unit,
relevant laboratory findings including data on transfusion
and outcome of each individual. The inclusion criterion is
admission to hospital via emergency room with subsequent
ICU/ICM care or reach the hospital with vital signs and die
before admission to ICU.  
The infrastructure for documentation, data management,
and data analysis is provided by AUC - Academy for
Trauma Surgery (AUC - Akademie der Unfallchirurgie
GmbH), a company affiliated to the German Trauma
Society. The scientific leadership is provided by the
Committee on Emergency Medicine, Intensive Care and
Trauma Management (Sektion NIS) of the German Trauma
Society. The participating hospitals submit their data anon-
ymously into a central database via a web-based
application. Scientific data analysis is approved according
to a peer review procedure established by Sektion NIS. 
TraumaRegister DGU® - Hinweise für die Publikation von
Ergebnissen 5 März 2014  
Seite 3 von 3 
© 2014 TraumaRegister DGU® / AUC GmbH 
The participating hospitals are primarily located in
Germany (90%), but a rising number of hospitals of other
countries contribute data as well (at the moment from
Austria, Belgium, China, Finland, Luxembourg, Slovenia,
Switzerland, The Netherlands, and the United Arab
Emirates). Currently, approx. 25,000 cases from more than
600 hospitals are entered into the database per year. 
Participation in TraumaRegister DGU® is voluntary. For
hospitals associated with TraumaNetzwerk DGU®,
however, the entry of at least a basic data set is obligatory
for reasons of quality assurance. 
www.traumaregister-dgu.de
All rights reserved. Please visit https://medical-data-
models.org/forms/15332
Intensive Care Point C in time DGU
TraumaRegister questionnaire
Informationen über den Patienten
Eintreffen
Land
Postleitzahl
Buchstabe
Patienten ID
Geburtsdatum
Geschlecht
männlich (1)
weiblich (2)
SAPS-II- Score
points
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Intensivtage
days
Dauer der mechanischen Beatmung
days
Organversagen (SOFA Score >2)
Atmung
Ja
Nein
Koagulation
Ja
Nein
Leber
Ja
Nein
Herz-Kreislauf
Ja
Nein
ZNS
Ja
Nein
Niere
Ja
Nein
Multiorganversagen (MOV)
Ja
Nein
Sepsis
Ja
Nein
Labor
Base Excess
mmol/l
Quick-Wert (in Prozent)
%
Hb-Wert
mmol/l
Thrombozyten
/uL
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Quick
%
PTT
seconds
INR
Laktat
mmol/l
Temperatur
°C
Therapie
FFP Einheiten innerhalb der ersten 48h auf ICU
Units
EK Einheiten innerhalb der ersten 48h auf ICU
Units
Nierenersatzverfahren
Ja
Nein
Hämostase-Therapie
rfVIIa
Ja
Nein
PPSB
Ja
Nein
Antifibrinolytika
Ja
Nein
Fibrinogen
Ja
Nein
andere hämost. Medikamente
Ja
Nein
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Eligibility Kidney Disease NCT02369354
Transplant Social Worker Support for Live Kidney Donation
in African Americans; ODM derived from:
https://clinicaltrials.gov/show/NCT02369354
All rights reserved. Please visit https://medical-data-
models.org/forms/15333
Eligibility Kidney Disease
NCT02369354
Criteria
Inclusion Criteria
adult (18 yrs or older)*
Yes
No
african american*
Yes
No
duke kidney and pancreas transplant patients
with end stage kidney disease*
Yes
No
currently on the deceased donor kidney waiting
list from the duke kidney and pancreas transplant
program*
Yes
No
give consent to participate*
Yes
No
Exclusion Criteria
previous kidney transplant*
Yes
No
cognitively impaired/change in cognition*
Yes
No
impaired hearing or speech*
Yes
No
non-english speaking*
Yes
No
for family members or friends of potential kidney
transplant recipients (talk and talk plus arms):*
Yes
No
inclusion critera:*
Yes
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No
18 or older*
Yes
No
come to swi meeting with patient*
Yes
No
give consent to participate*
Yes
No
for potential live kidney donors (talks plus arm
only)*
Yes
No
Inclusion Criteria
18 or older*
Yes
No
contact the study*
Yes
No
give consent to participate*
Yes
No
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Eligibility Advanced Adult Hepatocellular
Carcinoma NCT01405573
Sorafenib in First-line Treatment of Advanced B Child
Hepatocellular Carcinoma; ODM derived from:
https://clinicaltrials.gov/show/NCT01405573
All rights reserved. Please visit https://medical-data-
models.org/forms/15334
Eligibility Advanced Adult
Hepatocellular Carcinoma
NCT01405573
Inclusion Criteria
patients with diagnosis of hepatic cell carcinoma
(hcc) according to the aasld- easl criteria*
Yes
No
age >18 years*
Yes
No
advanced stage of disease defined as hcc not
eligible for locoregional treatments (ab initio or
following progression after such treatments)*
Yes
No
liver function classified as child-pugh class b*
Yes
No
ecog performance status < or = 2*
Yes
No
life expectancy of at least 2 months*
Yes
No
adequate contraception for fertile male and
female patients*
Yes
No
signed informed consent*
Yes
No
Exclusion Criteria
prior exposure to sorafenib or antiangiogenesis
drugs*
Yes
No
concomitant diseases that contraindicate the use
of sorafenib*
Yes
No
gastro-intestinal bleeding in the previous 30 days*
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Yes
No
altered renal function(creatinine > 1.5 x uln), or
haematological function (platelet count < 60 x
10^9/l, hemoglobin < 9 g/dl)*
Yes
No
serious active infections (> grade 2 ctcae version
3.0)*
Yes
No
congestive heart failure, history of congestive
heart failure, unstable angina pectoris,
myocardial infarct or significant valvular heart
disease or uncontrolled heart arrhythmia*
Yes
No
patients who are unable or unwilling to participate
in the study*
Yes
No
pregnant or lactating females*
Yes
No
hepatic encephalopathy of any grade*
Yes
No
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Eligibility Advanced Adult Hepatocellular
Carcinoma NCT02409524
An Individualized Anti-Cancer Vaccine in Advanced
Hepatocellular Carcinoma Subjects; ODM derived from:
https://clinicaltrials.gov/show/NCT02409524
All rights reserved. Please visit https://medical-data-
models.org/forms/15338
Eligibility Advanced Adult
Hepatocellular Carcinoma
NCT02409524
Inclusion Criteria
males and females who are at least 18 years of
age at time of enrollment*
Yes
No
histologically confirmed hepatocellular carcinoma
with or without positive hbv and/or hcv*
Yes
No
minimum of 90 days of sorafenib treatment and
unresectable*
Yes
No
child-pugh stage a-b (score ≥ 5 and ≤ 9)*
Yes
No
performance status: ecog < 2 with no
deterioration over the previous 2 weeks*
Yes
No
measurable disease (for recist)*
Yes
No
lesion amenable for percutaneous tumor harvest
and follow up biopsy*
Yes
No
hemoglobin > 10.0 g/dl*
Yes
No
absolute neutrophil count (anc) > 1,500/mm3*
Yes
No
platelet count > 75,000/μl*
Yes
No
alt and ast < 2.5 x uln*
Yes
No
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alkaline phosphatase < 4 x uln*
Yes
No
serum creatinine < 1.5*
Yes
No
women of child-bearing potential: negative
pregnancy test*
Yes
No
patients of child producing potential: usage of
contraception or avoidance of pregnancy
measures while enrolled on study and receiving
the experimental product*
Yes
No
ability to understand the study, its inherent risks,
side effects and potential benefits and ability to
give written informed consent to participate*
Yes
No
Exclusion Criteria
severe ascites, massive or uncontrolled (+3 on
child-pugh calculator)*
Yes
No
severe encephalopathy, uncontrolled (+3 on child-
pugh calculator)*
Yes
No
inr > 1.5*
Yes
No
participation in another clinical trial evaluating
experimental treatments or procedures or
receiving medication/treatment for hcc other than
sorafenib*
Yes
No
any autoimmune disorder*
Yes
No
any clinical condition requiring systemic steroids
or current immunosuppressive therapy, including:
cyclosporine, antithymocyte globulin, or
tacrolimus within 1 month of study entry*
Yes
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No
hiv positive or syphilis*
Yes
No
history of cardiac disease: congestive heart
failure > nyha class 2; cardiac arrhythmias
requiring anti-arrhythmic therapy (beta blockers
or digoxin are permitted) or uncontrolled
hypertension*
Yes
No
active clinically serious infections (> grade 2 nci-
ctcae version 4.0)*
Yes
No
history of organ or tissue allograft*
Yes
No
advanced liver cirrhosis*
Yes
No
interferon or thalidomide within 1 month prior to
signing informed consent*
Yes
No
uncontrolled concurrent serious medical or
psychiatric illness*
Yes
No
clinically apparent central nervous system
metastases or carcinomatous meningitis*
Yes
No
history of blood transfusion reactions*
Yes
No
known allergy to murine monoclonal antibodies or
bovine products or cow milk*
Yes
No
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Eligibility Knee Osteoarthritis
NCT02352636
Auriculotherapy for Osteoarthritis Knee; ODM derived from:
https://clinicaltrials.gov/show/NCT02352636
All rights reserved. Please visit https://medical-data-
models.org/forms/15340
Eligibility Knee Osteoarthritis
NCT02352636
Inclusion Criteria
the oa condition will be assessed by physical
examination based on the clinical criteria of the
american college of rheumatology criteria. the
clinical criteria consisted of pain in the knee and
any three of the following:*
Yes
No
1. aged 50 years of age or over;*
Yes
No
2. <=30 minutes of morning stiffness;*
Yes
No
3. crepitus on active joint motion;*
Yes
No
4. bony tenderness;*
Yes
No
5. bony enlargement; or*
Yes
No
6. no palpable joint warmth.*
Yes
No
this classification has been reported to yield 84%
specificity and 89% sensitivity for diagnosis of oa
knee.*
Yes
No
Exclusion Criteria
1. other connective tissue diseases affecting the
knee;*
Yes
No
2. knee joint steroid injections within the
preceding three months;*
Yes
No
3. having a hearing aid or pacemaker in situ (this
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is to avoid possible interaction between the
pacemaker and the magnetic pellets);*
Yes
No
4. receiving at within the preceding three
months;*
Yes
No
5. suffering from aural injuries or infections; and*
Yes
No
6. inability to understand instructions or give
consent.*
Yes
No
the assessment is conducted by a research
assistant who will receive intensive coaching on
the physical assessment and therapy
administration by the research team. potential
subjects will be further assessed by a registered
medical practitioner who has over 15 years of
clinical experience when the assessment on the
oa condition by the ra and the research team is in
doubt.*
Yes
No
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Discharge Letter Items -18546 Multiple
Sclerosis
Discharge Letter for Patient diagnosed with Multiple
Sclerosis from Neurology Department of University Clinic
Muenster Publication granted by PD Dr. Klotz
All rights reserved. Please visit https://medical-data-
models.org/forms/15341
Discharge Letter Items -18546
Multiple Sclerosis
Administrative Data
Document ID
Patient`s Name
Date of birth:
Inpatient or Outpatient
Inpatient (Inpatient)
Outpatient (Outpatient)
Date of Appointment/Stay
Principal Diagnosis
Principal Diagnosis Multiple Sclerosis
Onset
Earliest date of diagnosis
EDSS
Previous Therapy Medication
Time Range of Previous Therapy
Previous Therapie Benefit
Indicate the dates of previous flares of MS.
Neutralizing Antibodies (Nab) against Interferone
Beta
Yes
No
Neutralizing Antibodies Test Date
Risk Stratification of Therapy with
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Natalizumab
Previous Immunosuppressive Therapy
Yes
No
Use of Natalizumab
months
JCV Antibodies
Date of JCV-Antibody Measurement
Therapy with Alemtuzumab
Yes
No
Therapy Alemtuzumab Date of Treatment
Secondary Diagnosis
Secondary Diagnosis
Reason for Admission
Reason for admission
Rituximab Induction to treat Multiple Sclerosis
Medical History
Introduction: Reason for current Admission
Past medical history
Continuous progression of MS under Therapie
with Natalizumab
Yes
No
Therapy with Alemtuzumab
Symptoms
Therapy with Corticosteroid
Urge Incontinence
Yes
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No
Did a loss of bowl function control occur?
Yes
No
Medication on Admission
Medication name:
Medication dosage (6:00-12:00-18:00-22:00)
mg
Neurological Examination: Cranial Nerves
Orientation
Meningism
Lhermitte's sign
negative (negative)
positive (positive)
Cranial Nerves: Visus
Visual Field Fingerperimetric
Pupils Size
Pupils reaction
Pupils regularity
Examination of Eye Movement
Nystagmus Test
Gaze Palsy
Diplopia
Trigeminal Sensory Function
Function of caudal cranial nerves
Facial Sensory Function
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Neurological Examination: Motor
Pronator Drift Test
Leg drift test
Fine motor skills abnormal?
Neurological Examination: Reflexes
Function of Muscular reflex
Pyramidal signs
Neurological Examination: Sensibility
Hypesthesia Upper Extremity
Hypesthesia Lower Extremity
Neurological Examination: Coordination
and Gait
Diadochokinesis
Finger-to-nose test abnormal?
Heel-to-knee test abnormal?
Rhomberg Test abnormal?
Aphasia?
Yes
No
Neglect
Yes
No
Apraxia?
Neurological Examination: On Discharge
Changes Neurological Exam
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Laboratory Results Urine
Urine Specific Gravity
g/ml
Urine pH
Urine leukocytes
Anz./µl
neg  (neg )
pos (pos)
Urine Nitrite
neg (neg)
pos (pos)
Urine Protein
mg/dl
neg (neg)
pos (pos)
Urine Glucose
mg/dl
Urine Ketone Bodies
mg/dl
Urine Urobilinogen
mg/dl
Urine Bilirubin
mg/dl
Urine Erythrocytes
Anz./µl
Laboratory Results Urine Analysis FACS
Urine Erythrocytes (FACS)
Anz/l
Urine leukocytes (FACS)
Anz./µl
neg  (neg )
pos (pos)
Urine Epithelial Cells (FACS)
Anz./µl
Urine Cylinder Cells (FACS)
Anz./µl
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Urine Bacteria (FACS)
Anz./µl
Urine Crystals  (FACS)
Anz./µl
Urine Yeast (FACS)
Anz./µl
Urine Pathological Cylinder (FACS)
Anz./µl
Urine Round Epithelial Cell Count (FACS)
Anz./µl
Laboratory Results Pregnancy
Pregnancy test result
negative (negative)
positive (positive)
Laboratory Results Serum
Sodium Measurement
mmol/l
Potassium
mmol/l
Calcium
mmol/l
Chloride
mmol/l
Glucose
mg/dl
Blood Urea Nitrogen
mg/dl
Creatinin
μmol/l
Bilirubin Total
mg/dl
AST (SGOT)
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U/L
ALT (SGPT)
U/L
gamma-GT
U/l
Alkaline Phosphatase
U/l
Albumin
g/dL
Uric acid
md/dl
Urea
mg/dl
Lactate Dehydrogenase (LDH)
U/L
CPK
U/l
CK MB
U/l
CRP
md/dl
Laboratory Results Small EDTA
Leucocytes
Tsd/µl
Erythrocytes
Mio/μl
Haemoglobin
g/dl
Haematocrit
%
Mean Corpuscular Volume
fl
MCH
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pg
Mean corpuscular hemoglobin concentration
g/dl
Thrombocytes
Tsd/µl
Laboratory Results Differential EDTA
Neutrophils relative
%
Neutrophils absolute
Tsd/µl
Lymphocytes relative
%
Lymphocytes absolute
Tsd/µl
Monocytes relative
%
Monocytes absolute
Tsd/µl
Eosinophils relative
%
Eosinophils absolute
Tsd/µl
Basophils relative
%
Basophils absolute
Tsd/µl
Mean Platelet Volume
fl
Immature Granulocytes
Tsd/µl
Laboratory Results Blood coagulation
tests
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TPZ
%
INR
PTT
sec.
Laboratory Results Thyroid Function Tests
TSH
µU/ml
Laboratory Results Calculated
eGFR
Laboratory Results Cellular Immune State
Lymphocytes (Beads)
cells/µl
CD3+
cells/µl
CD4+
cells/µl
CD4+
%
CD8+
cells/µl
CD8+
%
CD4/CD8 Ratio
CD19+
cells/µl
Natural Killer Cells
cells/µl
Summary and Procedures
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Introduction: Reason for current Admission
Current Immunosuppressive Therapy
Results of latest MRI of Head and Brain
Pathological findings of neurological examination
Summary of the current progression and stage of
disease
Summary of paraclinical findings
Summary of Procedures during hospitalisation
Recommendation Blood Sample
Medication on Discharge
Medication name:
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Eligibility Advanced Adult Hepatocellular
Carcinoma NCT02418988
Trans-catheter Chemo-embolization Combined With rAd-
p53 Gene Injection in Treatment of Advanced
Hepatocellular Carcinoma; ODM derived from:
https://clinicaltrials.gov/show/NCT02418988
All rights reserved. Please visit https://medical-data-
models.org/forms/15342
Eligibility Advanced Adult
Hepatocellular Carcinoma
NCT02418988
Inclusion Criteria
histopathologically diagnosed hcc*
Yes
No
unresectable*
Yes
No
over 18 years old*
Yes
No
with an eastern cooperative oncology group
(ecog) score of 0-2;*
Yes
No
with barcelona clinic liver cancer (bclc) stage of b
or c*
Yes
No
with child-pugh score a or b*
Yes
No
signed the informed consent form*
Yes
No
Exclusion Criteria
serious blood coagulation disorder, bleeding
tendency, platelet < 6 * 1000000000/l;*
Yes
No
have serious heart, lung function abnormalities or
severe diabetes patients*
Yes
No
active infection*
Yes
No
liver function child-pugh grade c*
Yes
No
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secondary and diffuse hepatocellular carcinoma
patients*
Yes
No
extensive metastasis*
Yes
No
severe atherosclerosis*
Yes
No
aids patients*
Yes
No
serious thrombotic or embolic events within 6
months*
Yes
No
renal insufficiency requiring hemodialysis or
peritoneal dialysis*
Yes
No
pregnant or lactating women*
Yes
No
mental disorder or disease*
Yes
No
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Eligibility Knee Osteoarthritis
NCT02373631
Dry Needling Versus Conventional Physical Therapy in
Patients With Knee Osteoarthritis; ODM derived from:
https://clinicaltrials.gov/show/NCT02373631
All rights reserved. Please visit https://medical-data-
models.org/forms/15344
Eligibility Knee Osteoarthritis
NCT02373631
Inclusion Criteria
1. report of knee pain of at least 2/10 per nprs
(0--‐10 scale) for >3 months*
Yes
No
2. report of at least 3 of the following per altman
et al. (1986)*
Yes
No
over 50 years of age*
Yes
No
less than 30 minutes of morning stiffness*
Yes
No
crepitus on active motion*
Yes
No
bony tenderness*
Yes
No
bony enlargement*
Yes
No
no palpable warmth of synovium*
Yes
No
Exclusion Criteria
1. report of red flags to manual physical therapy
to include: hypertension, infection, diabetes,
peripheral neuropathy, heart disease, stroke,
chronic  ischemia, edema, severe varicosities,
tumor, metabolic disease, prolonged steroid use,
fracture, ra, osteoporosis, severe vascular
disease, malignancy, etc.*
Yes
No
2. history of previous surgery to the knee*
Yes
No
3. history of physical therapy, massage therapy,
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chiropractic treatment, or injections for knee pain
in the last 4 weeks*
Yes
No
4. history of a surgical procedure on either lower
extremity in last 6 months*
Yes
No
5. two or more positive neurologic signs
consistent with nerve root compression, including
any two of the following:*
Yes
No
weakness involving a major muscle group of the
lower extremity.*
Yes
No
diminished patella or achilles tendon reflex*
Yes
No
diminished or absent sensation to pinprick in
lower extremity dermatome*
Yes
No
6. involvement in litigation or worker's
compensation regarding knee pain.*
Yes
No
7. any condition that might contraindicate the use
of electro-needling*
Yes
No
8. the patient is pregnant.*
Yes
No
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End of Study Multiple Sclerosis ALAIN01
NCT02419378
Alemtuzumab in Autoimmune Inflammatory
Neurodegeneration: Mechanisms of Action and
Neuroprotective Potential (ALAIN01)
https://clinicaltrials.gov/ct2/show/NCT02419378
Principal Investigator Prof. Dr. Dr. Sven Meuth, University
Hospital Muenster, Germany
All rights reserved. Please visit https://medical-data-
models.org/forms/15345
End of Study Multiple Sclerosis
ALAIN01 NCT02419378
End of Study
Patient ID (derived)
Date of End of Study/Discontinuation
End of Study: regular/early
Regular end of study (1)
Early discontinuation (2)
Reason for Disc. (Patient s request)
Patient s request (1)
Reason for Disc. (Medical, cognitive,...)
Medical, cognitive, or other conditions...
(1)
Reason for Disc. (Screening failure)
Screening failure (1)
Reason for Disc. (Other reason)
Other reason (9)
End of Study: Reason for Discontinuation Text
End of Study: Date of Signature
End of Study: Signature yes/no
no (0)
yes (1)
Comment End of Study
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Treatment deferral Multiple Sclerosis
ALAIN01 NCT02419378
Alemtuzumab in Autoimmune Inflammatory
Neurodegeneration: Mechanisms of Action and
Neuroprotective Potential (ALAIN01)
https://clinicaltrials.gov/ct2/show/NCT02419378
Principal Investigator Prof. Dr. Dr. Sven Meuth, University
Hospital Muenster, Germany
All rights reserved. Please visit https://medical-data-
models.org/forms/15346
Treatment deferral Multiple Sclerosis
ALAIN01 NCT02419378
Criteria for Treatment deferral
Patient ID (derived)
Recent relapse of MS
Yes
No
Recent vaccination ≤ 6 weeks
Yes
No
Malignancy, except basal skin cell carcinoma
Yes
No
Known bleeding disorder (e.g.,
dysfibrinogenemia, factor IX deficiency,
hemophilia,
Von Willebrands disease, DIC, fibrinogen
deficiency, clotting factor deficiency)
Yes
No
Of childbearing potential with a positive urine or
serum pregnancy test, pregnant,
or lactating. A blood pregnancy test must have
been performed within 3
days prior to the first treatment day. If performed
on the same day, the result of
a urine dipstick test may be used instead.
Yes
No
Major systemic disease or other illness that
would, in the opinion of the Investigator,
compromise patient safety
Yes
No
Most recent platelet count < the LLN of the
evaluating laboratory, or patients
with suspicion of incipient ITP
Yes
No
CD4+, CD8+, or CD19+ ≤50 cells/microliter (ie,
absolute CD3+CD4+,
CD3+CD8+, or CD19+/mm3); if abnormal cell
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count(s) subsequently rises above
50, eligibility may be reassessed
Yes
No
Neutrophil cell count ≤1000 cells/microliter; if
abnormal cell count subsequently
rises above 1000 cells/microliter, eligibility may
be reassessed
Yes
No
Any other illness or infection (latent or active)
that, in the Investigator’s opinion,
could be exacerbated by alemtuzumab
Yes
No
Treatment with immunosuppressive or
antineoplastic drugs
no (0)
yes (1)
Is the patient free of the above listed deferral
criteria?
Yes
No
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Concomitant Medication Multiple Sclerosis
ALAIN01 NCT02419378
Alemtuzumab in Autoimmune Inflammatory
Neurodegeneration: Mechanisms of Action and
Neuroprotective Potential (ALAIN01)
https://clinicaltrials.gov/ct2/show/NCT02419378
Principal Investigator Prof. Dr. Dr. Sven Meuth, University
Hospital Muenster, Germany
All rights reserved. Please visit https://medical-data-
models.org/forms/15347
Concomitant Medication Multiple
Sclerosis ALAIN01 NCT02419378
Con. Med.
Patient ID (derived)
Concomitant Medication: Sheet No
Concomitant Med.: Date of Signature
Concomitant Med.: Signature yes/no
no (0)
yes (1)
Comment Concommittant Medication
Concomitant Medication RQG
Concomitant Medication: Generic Name/Trade
Name
Concomitant Medication: Indication
Concomitant Medication: Dose Morning
Concomitant Medication: Dose Noon
Concomitant Medication: Dose Evening
Concomitant Medication: Dose Bed
Concomitant Medication: Start Date
Concomitant Medication: End Date
Concomitant Medication: ongoing
ongoing (1)
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ALAIN01 NCT02419378
Alemtuzumab in Autoimmune Inflammatory
Neurodegeneration: Mechanisms of Action and
Neuroprotective Potential (ALAIN01)
https://clinicaltrials.gov/ct2/show/NCT02419378
Principal Investigator Prof. Dr. Dr. Sven Meuth, University
Hospital Muenster, Germany
All rights reserved. Please visit https://medical-data-
models.org/forms/15348
Protocol Deviations Multiple
Sclerosis ALAIN01 NCT02419378
Protocol Deviations
Patient ID (derived)
Protocol Deviations: Sheet No
Protocol Deviations: Date of Signature
Protocol Deviations: Date of Signature Status
T (1)
TM (2)
M (3)
Protocol Deviations: Signature yes/no
no (0)
yes (1)
Comment Prot. Deviations
Protocol Deviations RQG
Protocol Deviations: Number
Protocol Deviations: Planned month
Protocol Deviations: Description
Protocol Deviations: Reason
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ALAIN01 NCT02419378
Alemtuzumab in Autoimmune Inflammatory
Neurodegeneration: Mechanisms of Action and
Neuroprotective Potential (ALAIN01)
https://clinicaltrials.gov/ct2/show/NCT02419378
Principal Investigator Prof. Dr. Dr. Sven Meuth, University
Hospital Muenster, Germany
All rights reserved. Please visit https://medical-data-
models.org/forms/15349
Safety Assessment Multiple
Sclerosis ALAIN01 NCT02419378
Safety Assessment
Patient ID (derived)
Safety Lab. Assessments: Sheet No
Safety Lab. Assessments: Date of Signature
Safety Lab. Assessments: Signature yes/no
no (0)
yes (1)
Comment Safety Assessment
Safety Lab. Assessments RQG
Safety Lab. Assessments: Date
Safety Lab. Assessments: Serum Creatinine
normal (1)
abnormal, without clinical significance (2)
abnormal, with clinical significance (3)
ND (9)
Safety Lab. Assessments: Platelets
normal (1)
abnormal, without clinical significance (2)
abnormal, with clinical significance (3)
ND (9)
Safety Lab. Assessments: TSH
normal (1)
abnormal, without clinical significance (2)
abnormal, with clinical significance (3)
ND (9)
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Discontinue Trial Medication Multiple
Sclerosis ALAIN01 NCT02419378
Alemtuzumab in Autoimmune Inflammatory
Neurodegeneration: Mechanisms of Action and
Neuroprotective Potential (ALAIN01)
https://clinicaltrials.gov/ct2/show/NCT02419378
Principal Investigator Prof. Dr. Dr. Sven Meuth, University
Hospital Muenster, Germany
All rights reserved. Please visit https://medical-data-
models.org/forms/15354
Discontinue Trial Medication Multiple
Sclerosis ALAIN01 NCT02419378
Discontinue Trial Medication
Patient ID (derived)
Discont. of Trial Medication: Date
If other reason was selected, please specify
Reason for discontinuation
Investigator considers it would be in the
best interests of the patient (1)
Unacceptable toxicity of the study drug
(2)
HIV infection (3)
Patient requests discontinuation (4)
Patient is unable or unwilling to comply
with planned study safety monitoring (5)
Other reason: ____________ (6)
Discont. of Trial Medication: Reason Text
Discont. of Trial Medication: Date of Signature
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Remitting NCT02419378
Alemtuzumab in Autoimmune Inflammatory
Neurodegeneration: Mechanisms of Action and
Neuroprotective Potential; ODM derived from:
https://clinicaltrials.gov/show/NCT02419378
Principal Investigator Prof. Dr. Dr. Sven Meuth, University
Hospital Muenster, Germany
All rights reserved. Please visit https://medical-data-
models.org/forms/15355
Eligibility Multiple Sclerosis,
Relapsing-Remitting NCT02419378
Inclusion Criteria
1. signed informed consent form (icf)*
Yes
No
2. age 18 to 55 years old (inclusive) as of the
date the icf is signed*
>= 18
<= 55
years
Yes
No
3. diagnosis of ms according to the mcdonald
criteria 2010 and cranial mri scan demonstrating
white matter lesions attributable to ms within 5
years before screening*
Yes
No
4. onset of ms symptoms (as determined by a
neurologist, either at present or retrospectively)
within 5 years of the date the icf is signed*
Yes
No
5. edss score 0.0 to 4.0 (inclusive) at screening*
<= 4
>= 0
Yes
No
6. ≥2 ms relapses within 24 months or clinical (≥1
relapse) or mri (new gadolinium enhancing
lesions) disease activity under therapy with
interferon beta, glatirameracetate, natalizumab or
fingolimod*
Yes
No
7. indicated to receive alemtuzumab according to
the investigator's assessment*
Yes
No
8. completion of all vaccinations required by the
applicable immunization guidelines published by
"ständige impfkommission" (stiko)*
Yes
No
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9. history of chickenpox or positive test for
antibodies against varicella zoster virus (vzv)*
Yes
No
Exclusion Criteria
1. participation in another clinical trial at present
or within 4 weeks of study entry. there may be
exceptions at the discretion of the investigator.*
Yes
No
2. has any progressive form of ms*
Yes
No
3. hypersensitivity to the active substance, or to
any of the excipients of lemtrada*
Yes
No
4. medical, psychiatric, cognitive, or other
conditions that, in the investigator's opinion,
compromise the patient's ability to understand the
patient information, to give informed consent, to
comply with the trial protocol, or to complete the
study*
Yes
No
5. any disability acquired from trauma or another
illness that could interfere with evaluation of
disability due to ms*
Yes
No
6. major systemic disease or other illness that
would, in the opinion of the investigator,
compromise patient safety or interfere with the
interpretation of study results, e.g., current peptic
ulcer disease or other conditions that may
predispose to hemorrhage*
Yes
No
7. known bleeding disorder (e.g,.
dysfibrinogenemia, factor ix deficiency,
hemophilia, von willebrand's disease,
disseminated intravascular coagulation (dic),
fibrinogen deficiency, or clotting factor
deficiency)*
Yes
No
8. significant autoimmune disease including but
not limited to immune cytopenias, rheumatoid
arthritis, systemic lupus erythematosus, other
connective tissue disorders, vasculitis,
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inflammatory bowel disease, severe psoriasis*
Yes
No
9. history of malignancy, except basal skin cell
carcinoma*
Yes
No
10. major psychiatric disorder that is not
adequately controlled by treatment*
Yes
No
11. epileptic seizures that are not adequately
controlled by treatment*
Yes
No
12. active infection, e.g., deep-tissue infection,
that the investigator considers sufficiently serious
to preclude study participation*
Yes
No
13. in the investigator's opinion, is at high risk for
infection (e.g., indwelling catheter, dysphagia with
aspiration, decubitus ulcer, history of prior
aspiration pneumonia or recurrent urinary tract
infection)*
Yes
No
14. seropositivity for human immunodeficiency
virus (hiv)*
Yes
No
15. infection with hepatitis c virus*
Yes
No
16. past or present hepatitis b infection (positive
hepatitis b serology)*
Yes
No
17. active infection with human cytomegaly virus
(hcmv), epstein-barr virus (ebv), varicella-zoster
virus (vzv)*
Yes
No
18. latent tuberculosis unless effective anti-
tuberculosis therapy has been completed, or
active tuberculosis.*
Yes
No
19. invasive fungal infections in history and at
3 / 5
Eligibility Multiple Sclerosis, Relapsing-Remitting NCT02419378
present*
Yes
No
20. cervical cytology other than pap I or pap II
(papanicolaou) or cervical high risk human
papillomavirus (hpv) positivity*
Yes
No
21. any other illness or infection (latent or active)
that, in the investigator's opinion, could be
exacerbated by study medication*
Yes
No
22. cd4+ t-cell count (absolute cd3+cd4+) <lower
limit of normal (lln) at screening*
Yes
No
23. cd8+ t-cell count (absolute cd3+cd8+) <lln at
screening*
Yes
No
24. b-cell count (absolute cd19+) <lln at
screening*
Yes
No
25. absolute neutrophil count <lln at screening*
Yes
No
26. confirmed platelet count < the lln of the
evaluating laboratory at screening or documented
at <100,000/μl within the past year on a sample
without platelet clumping*
Yes
No
27. presence (i.e., above the uln) of anti-thyroid
stimulating hormone receptor antibodies (anti-
tshr) and anti-thyroid peroxidase antibody (anti-
tpo)*
Yes
No
28. any hepatic or renal function value grade 2 or
higher at screening, with the exception of
hyperbilirubinemia due to gilbert's syndrome. see
table below, drawn from the national cancer
institute (nci) common terminology criteria for
adverse events v4.0 (ctcae), published 28 may
2009.*
Yes
No
4 / 5
Eligibility Multiple Sclerosis, Relapsing-Remitting NCT02419378
bilirubin    >1.5 × uln*
Yes
No
sgot/ast   >3.0 × uln*
Yes
No
sgpt/alt   >3.0 × uln*
Yes
No
alkaline phosphatase  >2.5 × uln*
Yes
No
creatinine   > 1.5 × uln*
Yes
No
29. vaccination less than 6 weeks prior to study
inclusion.*
Yes
No
30. treatment with antineoplastic or
immunosuppressive drugs within 8 weeks prior to
study inclusion*
Yes
No
31. intolerance of pulsed corticosteroids,
especially a history of steroid psychosis*
Yes
No
32. inability to undergo mri with gadolinium
administration*
Yes
No
33. of childbearing potential with a positive serum
pregnancy test, pregnant or lactating*
Yes
No
34. female patients of childbearing potential:
unwilling to agree to use a reliable and
acceptable contraceptive method (pearl index <1)
throughout the study period. these methods
include: hormone releasing intrauterine device
(iud), hormonal-based contraception, surgical
sterilization, abstinence, or double-barrier
contraception (condom and occlusive cap
[diaphragm or cervical cap combined with
spermicide]).*
Yes
No
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Eligibility Multiple Sclerosis, Relapsing-Remitting NCT02419378
MSFC Multiple Sclerosis ALAIN01
NCT02419378
Alemtuzumab in Autoimmune Inflammatory
Neurodegeneration: Mechanisms of Action and
Neuroprotective Potential (ALAIN01)
https://clinicaltrials.gov/ct2/show/NCT02419378
Principal Investigator Prof. Dr. Dr. Sven Meuth, University
Hospital Muenster, Germany
All rights reserved. Please visit https://medical-data-
models.org/forms/15361
MSFC Multiple Sclerosis ALAIN01
NCT02419378
Multiple Sclerosis Functional Composite
Patient ID (derived)
MSFC+ Quest.: add. quarterly inf. consent yes/no
no (0)
yes (1)
MSFC+ Quest.: add. semiannual inf. consent
yes/no
no (0)
yes (1)
MSFC + Questionnaires: Date
Timed 25-Foot Walk
Timed 25-Foot Walk: AFO yes/no
no (0)
yes (1)
Timed 25-Foot Walk: assistive device yes/no
no (0)
yes (1)
Timed 25-Foot Walk: Unilateral Ass.
Unilateral Assistance (1)
Timed 25-Foot Walk: Bilateral Ass.
Bilateral Assistance (1)
Timed 25-Foot Walk: Unilateral Ass. (Category)
Cane (1)
Crutch (2)
Timed 25-Foot Walk: Bilateral Ass. (Category)
Cane (1)
Crutch (2)
Walker/Rollator (3)
Timed 25-Foot Walk: Time Trial 1
sec
Timed 25-Foot Walk: not completed Trial 1
Unable due to physical limitations (1)
Other (9)
Timed 25-Foot Walk: Time Trial 2
1 / 3
sec
Timed 25-Foot Walk: not completed Trial 2
Unable due to physical limitations (1)
Other (9)
9-Hole Peg Test
9-Hole Peg Test: dominant hand
right (1)
left (2)
9-Hole Peg Test: Time dom. Trial 1
sec
9-Hole Peg Test: not completed dom. Trial 1
Unable due to physical limitations (1)
Other (9)
9-Hole Peg Test: Time non-dom. Trial 1
sec
9-Hole Peg Test: not completed non-dom. Trial 1
Unable due to physical limitations (1)
Other (9)
9-Hole Peg Test: Time (sec) dom. Trial 2
9-Hole Peg Test: not completed dom. Trial 2
Unable due to physical limitations (1)
Other (9)
9-Hole Peg Test: Time (sec) non-dom. Trial 2
9-Hole Peg Test: not completed non-dom. Trial 2
Unable due to physical limitations (1)
Other (9)
PASAT
PASAT Form used
Form A (1)
Form B (2)
PASAT3: Total correct
PASAT3: not completed
Unable due to physical limitations (1)
Other (9)
PASAT2: Total correct
PASAT2: not completed
Unable due to physical limitations (1)
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Other (9)
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Adverse Event Multiple Sclerosis ALAIN01
NCT02419378
Alemtuzumab in Autoimmune Inflammatory
Neurodegeneration: Mechanisms of Action and
Neuroprotective Potential (ALAIN01)
https://clinicaltrials.gov/ct2/show/NCT02419378
Principal Investigator Prof. Dr. Dr. Sven Meuth, University
Hospital Muenster, Germany
All rights reserved. Please visit https://medical-data-
models.org/forms/15365
Adverse Event Multiple Sclerosis
ALAIN01 NCT02419378
Adverse Event
AE: Sheet number
AE: Signature date
AERQG
AE: Number
AE: Term
AE: Start date
AE: Serious event
No (0)
No - AE of Special Interest (AESI) (1)
Yes (2)
AE: Toxicity (CTCAE) Grade
0 (0)
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
AE: Relationship to study treatment
No reasonable possibility (0)
Reasonable possibility (1)
AE: Action taken with study treatment
Dose not changed (0)
Dose reduced (1)
Dose increased (2)
Drug withdrawn (3)
Unknown (4)
Not applicable (5)
AE: End date
AE: Ongoing
yes (1)
AE: Outcome
1 / 2
Recovered/Resolved (0)
Recovering/Resolving (1)
Not recovered/Not resolved (2)
Recovered/Resolved with sequelae (3)
Fatal (4)
Unknown (5)
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Eligibility Diabetes NCT01511185
Effect of Liraglutide on the Beta-cell Responsiveness in
Subjects With Type 2 Diabetes Compared to a Healthy
Control Group; ODM derived from:
https://clinicaltrials.gov/show/NCT01511185
All rights reserved. Please visit https://medical-data-
models.org/forms/15369
Eligibility Diabetes NCT01511185
Inclusion Criteria
diagnosed with type 2 diabetes, either newly
diagnosed with at least 2 months of diet or on
oad monotherapy for at least 3 months*
Yes
No
body mass index (bmi): 24-35 kg/m^2 inclusive*
Yes
No
Exclusion Criteria
subjects with type 2 diabetes*
Yes
No
receipt of any investigational drug within three
months prior to this trial*
Yes
No
recurrent severe hypoglycemia as judged by the
investigator*
Yes
No
cardiac disease*
Yes
No
use of any drug (except an oad (oral anti-diabetic
drug)) that in the investigator's opinion could
interfere with the blood glucose level*
Yes
No
haemoglobin maximum 10 g/l*
Yes
No
hba1c above 12%*
Yes
No
loss of more than 400 ml blood during the 3
months prior to trial start*
Yes
No
healthy subjects*
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Yes
No
clinically relevant cardiac disease or any clinically
significant abnormal ecg (electrocardiogram)*
Yes
No
hba1c at least 6%*
Yes
No
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Eligibility Diabetes NCT01511185
Unscheduled Visit Lab and Medical Examination, DIMAT-
MS, Relapsing Remitting Multiple Sclerosis NCT02461069
Study documentation part:  Unscheduled Visit
Study Details: A 24-week, multicenter, exploratory, two arm
study to
assess the effect of Dimethyl fumarate on
ImmuneModulatory
Action on T cells in patients with relapsing
remitting Multiple Sclerosis.
Principal Investigator PD Dr. Luisa Klotz, University
Hospital Münster
EudraCT - No.: 2014-003481-25.
Clinical Trial No.r: NCT02461069.
All rights reserved. Please visit https://medical-data-
models.org/forms/15370
Lab and Medical Examination
Visit Details
Unscheduled Visit No
Date of visit
Further Visit Information
Reason for unscheduled visit
Side effect (1)
Relapse (please perform EDSS and
document on p. 29) (2)
Infection (3)
Other (4)
If "other", please specify:
Laboratory Urine Pregnancy Test (Please
perform the test only on suspicion of
pregnancy.)
Test done, specify: Test Date:
Urinary Pregnancy Test Result
negative (negative)
positive (positive)
Urine pregnancy test not done, reason
female participant with no childbearing
potential (female participant with no
childbearing potential)
male participant (male participant)
no suspicion of pregnancy (no suspicion
of pregnancy)
other (other)
Date of blood sampling
Date of blood sampling
Hematology
Leucocytes
1 / 5
Leucocytes measurement unit
/mm^3 (/µL )
10^3 /µL  (10^3 /µL )
other (other)
Leucocytes Count  not done
Yes
No
Lymphocytes
Lymphocytes measurement unit
/mm^3 (/µL )
10^3 /µL  (10^3 /µL )
other (other)
Lymphocytes Count Procesdure not done
Yes
No
Liver Function
Aspartate transaminase (AST) (SGOT)
U/L
AST Measurement Unit
nkat/L (nmol/s*L )
other (other)
U/L (U/L)
µkat/L (µmol/s*L )
AST measurement not done
Yes
No
Alanine transaminase (ALT) (SGPT)
ALT Measurement Unit
nkat/L (nmol/s*L )
other (other)
U/L (U/L)
ALT measurement not done
Yes
No
Gamma Glutamyl Transpeptidase Measurement
GGT Measurement Unit
nkat/L (nmol/s*L )
other (other)
U/L (U/L)
µkat/L (µmol/s*L )
GGT Measurement not done
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Yes
No
Renal function
Creatinine
Serum Creatinine  Measurment Unit
mg/dL (mg/dL)
other (other)
µmol/L (µmol/L)
Serum Creatinine Measurment not done
Yes
No
Blood urea nitrogen
Blood urea nitrogen measurement unit
mg/dL (mg/dL)
other (other)
µmol/L (µmol/L)
Blood urea nitrogen measurement not done
Yes
No
Medical Examination
Medical Examination performed at:
Heart rate (in bpm):
bpm
Systolic blood pressure
>= 0
mmHg
Diastolic blood pressure
>= 0
mmHg
Body temperature
°C
Expanded disability status scale (EDSS)
EDSS performed at
Visual testing
0 (1)
1 (2)
3 / 5
Unscheduled Visit Lab and Medical Examination, DIMAT-MS, Relapsing
Remitting Multiple Sclerosis NCT02461069
2 (3)
3 (4)
4 (5)
5 (6)
6 (7)
Brianstem testing
0 (1)
1 (2)
2 (3)
3 (4)
4 (5)
5 (6)
Pyramidal testing
0 (0)
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
Cerebellar testing
0 (0)
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
X (X)
Bowel/Bladder
Cerebellar testing (1)
Cerebral testing
0 (0)
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
Ambulation Score
0 (0)
1 (1)
10 (10)
11 (11)
12 (12)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
7 (7)
8 (8)
9 (9)
EDSS step
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Signature
Study Drug Prescription information
Date
Name/Signature Investigator
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Unscheduled Visit Lab and Medical Examination, DIMAT-MS, Relapsing
Remitting Multiple Sclerosis NCT02461069
Relapse Evaluation DIMAT-MS, Relapsing
Remitting Multiple Sclerosis NCT02461069
Study documentation part: Relapse Evaluation
Study short name: DIMAT MS
Study Details: A 24-week, multicenter, exploratory, two arm
study to
assess the effect of Dimethyl fumarate on
ImmuneModulatory
Action on T cells in patients with relapsing
remitting Multiple Sclerosis.
Principal Investigator PD Dr. Luisa Klotz, University
Hospital Münster
EudraCT - No.: 2014-003481-25.
Clinical Trial No.r: NCT02461069.
Please document clinically significant symptoms as
Adverse Events on form Adverse Events. (and
also additionally as SAE if a seriousness criterion is
fulfilled).
Please document all Medications which are administered to
treat the relapse on form concomitant medication.
Please document all Study Medication dose adjustments
and interruptions on form study medication.
All rights reserved. Please visit https://medical-data-
models.org/forms/15372
Relapse Evaluation DIMAT-MS,
Relapsing Remitting Multiple
Sclerosis NCT02461069Relapse
Evaluation
Confirmation of Relapse
Start date of relapse symptoms
Confirmation of the relapse?
Yes
No
If yes, date of relapse confirmation:
Treatment of Relapse
no treatment
Yes
No
Plasmapheresis / Immunoadsorption
Yes
No
If Plasmapheresis / Immunoadsorption= yes,
enter number of cycles
other treatment
Intravenous Steroid Treatment
Treatment Start Date
Treatment End Date
Dose
1 / 2
g/day
Signature
Date
Signature Investigator
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NCT02461069
Study medication, DIMAT-MS, Relapsing
Remitting Multiple Sclerosis NCT02461069
Study documentation part: Study medication
Study short name: DIMAT MS Study Details: A 24-week,
multicenter, exploratory, two arm study to assess the effect
of Dimethyl fumarate on ImmuneModulatory Action on T
cells in patients with relapsing remitting Multiple Sclerosis. 
Principal Investigator PD Dr. Luisa Klotz, University
Hospital Münster 
EudraCT - No.: 2014-003481-25. 
Clinical Trial No.r: NCT02461069.
Please document below only temporary changes in the
dosing schedule.
If the Study Medication is permanently discontinued, please
complete the Discontinuation of Study Medication Form on
page 33.
All rights reserved. Please visit https://medical-data-
models.org/forms/15373
Study medication, DIMAT-MS,
Relapsing Remitting Multiple
Sclerosis NCT02461069
Study Medication dose adjustments and
interruptions
Date of first Tecfidera® administration:
Date of last Tecfidera® administration:
No. of dose adjustment
Adjusted daily dose
>= 0
mg
or interruption
Yes
No
Start date
dd/mm/yy
End date
dd/mm/yy
Reason for adjustment/interruption
Adverse event (1)
Serious adverse event (2)
MS relapse (3)
Suspicion of pregnancy (4)
Use of prohibited concomitant
medication (5)
Other (9)
If other, please specify
Signature
1 / 2
Date
Signature Investigator
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NCT02461069
Concomitant medication, DIMAT-MS Relapsing
Remitting Multiple Sclerosis NCT02461069
Study documentation part: Concomitant medication
Study short name: DIMAT MS 
Study Details: A 24-week, multicenter, exploratory, two arm
study to assess the effect of Dimethyl fumarate on
ImmuneModulatory Action on T cells in patients with
relapsing remitting Multiple Sclerosis. 
Principal Investigator PD Dr. Luisa Klotz, University
Hospital Münster 
EudraCT - No.: 2014-003481-25. 
Clinical Trial No.: NCT02461069. 
Please list below concomitant medications which are taken
within a period from 30 days prior to Screening until the
end of the study participation.
Please list below signi cant non-drug therapies which are
performed over the course of study participation.
All rights reserved. Please visit https://medical-data-
models.org/forms/15375
Concomitant medication, DIMAT-MS
Relapsing Remitting Multiple
Sclerosis NCT02461069
Concomitant medication
Sheet No.
Concomitant medication (Generic Name or Trade
Name)/NON-drug therapy (e.g. physical therapy,
blood transfusion)
Indication
Start date
dd/mm/yy
End date
dd/mm/yy
or ongoing at End of Study
Yes
No
Signature
Date
Signature Investigator
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Discontinuation of Study medication, DIMAT-MS
Relapsing Remitting Multiple Sclerosis NCT02461069
Study documentation part: Discontinuation of Study
medication 
Study short name: DIMAT MS 
Study Details: A 24-week, multicenter, exploratory, two arm
study to assess the effect of Dimethyl fumarate on
ImmuneModulatory Action on T cells in patients with
relapsing remitting Multiple Sclerosis. 
Principal Investigator PD Dr. Luisa Klotz, University
Hospital Münster 
EudraCT - No.: 2014-003481-25. 
Clinical Trial No.: NCT02461069.
All rights reserved. Please visit https://medical-data-
models.org/forms/15376
Discontinuation of Study medication,
DIMAT-MS Relapsing Remitting
Multiple Sclerosis NCT02461069
Discontinuation of Study Medication
Date
dd/mm/yy
Primary reason for discontinuation of
study medication
Patient requests discontinuation of Study
Medication
Yes
No
Investigator determines that continuing it would
result in a significant risk for that patient
Yes
No
Patient becomes pregnant
Yes
No
Patient withdraws informed consent
Yes
No
Lymphocyte count is < 500/μl, confirmed by two
independent measurements 2 weeks apart
Yes
No
Leukocyte count is < 3,000/μl, confirmed by two
independent measurements 2 weeks apart
Yes
No
Suspicion of a PML (progressive multifocal
leukoencephalopathy)
Yes
No
Adverse event
Yes
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No
Serious adverse event (e.g. cardiac failure,
diagnosed malignancy, serious infections)
Yes
No
Abnormal laboratory value(s) including liver
function tests or abnormal test result(s)
Yes
No
Use of prohibited medications
Yes
No
Protocol deviation(s)
Yes
No
Unsatisfactory therapeutic effect
Yes
No
Patient's condition no longer requires study
treatment
Yes
No
Administrative problems (e.g. patient's non-
compliance)
Yes
No
Other reason:
Signature
Date
Signature Investigator
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Eligibility Left Ventricular Hypertrophy
NCT02226510
MetfoRmin and Its Effects on Left Ventricular Hypertrophy
in Normotensive Patients With Coronary Artery Disease;
ODM derived from:
https://clinicaltrials.gov/show/NCT02226510
All rights reserved. Please visit https://medical-data-
models.org/forms/15377
Eligibility Left Ventricular
Hypertrophy NCT02226510
Inclusion Criteria
aged 18 years or over*
Yes
No
participant willing and able to give informed
consent.*
Yes
No
documented ischaemic heart disease: either
angio-graphically documented coronary artery
disease or a previous history of myocardial
infarction/angina.*
Yes
No
screening echocardiography based diagnosis of
lvh based on ase criteria (males >115g/m2,
females >95g/m2)*
Yes
No
fasting insulin resistance index ≥ 2.7 and/or
hba1c >5.6 and less than 6.5 at screening*
Yes
No
blood pressure < 140/85 mm hg or 24hr bp
<135/85 daytime average in screening*
Yes
No
able (in the investigators opinion) and willing to
comply with all study requirements.*
Yes
No
Exclusion Criteria
cognitive impairment*
Yes
No
type 1 or 2 diabetes mellitus*
Yes
No
chronic heart failure as evidenced by
echocardiogram or documented diagnosis of chf*
Yes
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No
left ventricular ejection fraction <45% on
screening echocardiography*
Yes
No
contraindications to cardiac mri (pacemakers,
claustrophobia, metal implants, history of
penetrative eye injury or exposure to metal
fragments in eye requiring  medical attention)*
Yes
No
malignancy (receiving active treatment) or other
life threatening disease,  renal disease (ckd class
3b or worse)*
Yes
No
pregnancy/lactating females*
Yes
No
any other reason considered inappropriate by a
study physician*
Yes
No
participants who have participated in any other
clinical trial within the previous 30 days.*
Yes
No
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Eligibility Leukemia NCT02257138
Study of Ruxolitinib Plus Decitabine in Patients With Acute
Myeloid Leukemia (AML); ODM derived from:
https://clinicaltrials.gov/show/NCT02257138
All rights reserved. Please visit https://medical-data-
models.org/forms/15378
Eligibility Leukemia NCT02257138
Inclusion Criteria
1. diagnosis of aml (who classification definition
of > or = to 20% blasts)*
Yes
No
2. in the phase i portion of the study all patients
with relapsed or refractory aml are eligible. for the
phase ii portion of the study, patients must have
aml progressing from prior mpn (mpn-bp) or have
mds/mpn with more than 20% blasts. temporary
prior measures to control blood counts, such as
apheresis or hydrea are allowed. patients with
newly diagnosed or previously treated disease
are eligible as long as prior therapy does not
include hypomethylating agents. prior therapy for
ruxolitinib for mpn is allowed.*
Yes
No
3. serum biochemical values with the following
limits unless considered due to leukemia:---
creatinine < or= to 1.5mg/dl ---- total bilirubin < or
= to 1.5 mg/dl, unless increase is due to
hemolysis or congenital disorder ----
transaminases (sg pt) < or = to 2.5x uln*
Yes
No
4. ability to take oral medication.*
Yes
No
5. ability to understand and provide signed
informed consent.*
Yes
No
6. performance status < or = to 3, unless directly
related to disease process as determined by the
principal investigator.*
Yes
No
7. age > or = 18 years*
Yes
No
Exclusion Criteria
1. any coexisting medical condition that in the
judgment of the treating physician is likely to
interfere with study procedures or results
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including uncontrolled severe infections, as well
as uncontrolled cardiac disease, or other organ
dysfunction. patients with history of tuberculosis,
hiv or hepatitis b and c are excluded.*
Yes
No
2. nursing women, women of childbearing
potential with positive blood pregnancy test within
30 days of study start, or women of childbearing
potential who are not willing to maintain adequate
contraception (such as birth control pills, iud,
diaphragm, abstinence, or condoms by their
partner) over the entire course of the study.*
Yes
No
3. incomplete recovery from any prior surgical
procedures or had surgery within 4 weeks prior to
study entry, excluding the placement of vascular
access.*
Yes
No
4. active clinically serious and uncontrolled
infection.*
Yes
No
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Eligibility Diabetes NCT01526941
Comparison of Single Dose and Steady State
Pharmacodynamics of Biphasic Insulin Aspart 30 and 70 in
Subjects With Type 1 Diabetes; ODM derived from:
https://clinicaltrials.gov/show/NCT01526941
All rights reserved. Please visit https://medical-data-
models.org/forms/15379
Eligibility Diabetes NCT01526941
Inclusion Criteria
type 1 diabetes for at least 12 months*
Yes
No
currently on basal bolus treatment with soluble
human insulin, lispro and nph insulin or lantus.
nph insulin may be administered once or twice
daily*
Yes
No
bmi (body mass index) maximum 35 kg/m^2*
Yes
No
able and willing to perform self-blood glucose
monitoring*
Yes
No
Exclusion Criteria
the receipt of any investigational drug within the
last 30 days prior to this trial*
Yes
No
total daily insulin dose at least 1.8 u/kg/day*
Yes
No
currently being treated with insulin aspart
products*
Yes
No
a history of drug abuse or alcohol dependence
within the last 5 years*
Yes
No
impaired hepatic function*
Yes
No
impaired renal function*
Yes
No
blood donation (exceeding 500 ml) within the last
nine weeks or haemoglobin below the lower
reference limit according to the local laboratory*
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Yes
No
cardiac problems*
Yes
No
severe, uncontrolled hypertension*
Yes
No
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Eligibility Drug/Agent Toxicity by
Tissue/Organ NCT00055718
Silymarin (Milk Thistle Extract) in Treating Patients With
Acute Lymphoblastic Leukemia Who Are Receiving
Chemotherapy; ODM derived from:
https://clinicaltrials.gov/show/NCT00055718
All rights reserved. Please visit https://medical-data-
models.org/forms/15381
Eligibility Drug/Agent Toxicity by
Tissue/Organ NCT00055718
Criteria
diagnosis of acute lymphoblastic leukemia (all)*
Yes
No
currently receiving maintenance or continuation
phase chemotherapy for all*
Yes
No
regimen comprising intrathecal and oral
methotrexate; vincristine iv; oral prednisone or
dexamethasone; and oral mercaptopurine*
Yes
No
elevated liver function tests, evidenced by 1 of the
following criteria:*
Yes
No
bilirubin greater than 1.5 times upper limit of
normal (uln)*
Yes
No
ast greater than 2.5 times uln*
Yes
No
alt greater than 2.5 times uln*
Yes
No
Patient Caracteristics
2 to 21
Yes
No
performance status
Yes
No
life expectancy
Yes
No
Disease Caracteristics
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renal
Yes
No
liver
Yes
No
hematopoesis
Yes
No
Prior concurrent therapy
biologic therapy
Yes
No
chemotherapy
Yes
No
endocrine therapy
Yes
No
radiotherapy
Yes
No
surgery
Yes
No
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Eligibility Heart Failure NCT00391456
Animal-Assisted Therapy for Hospitalized Heart Failure
Patients; ODM derived from:
https://clinicaltrials.gov/show/NCT00391456
All rights reserved. Please visit https://medical-data-
models.org/forms/15382
Eligibility Heart Failure
NCT00391456
Inclusion Criteria
diagnosis of heart failure requiring medical
management with an indwelling pulmonary artery
catheter*
Yes
No
age between 18 and 80 years*
Yes
No
ability to read, write, and speak english*
Yes
No
mental status: alert and oriented to person, place,
and time*
Yes
No
svr greater than 1200 dyne · sec · cm-5 at least
once within 12 hours from the start of data
collection*
Yes
No
Exclusion Criteria
svr less than 1200 dyne · sec · cm-5*
Yes
No
allergies to dogs*
Yes
No
immunosuppression, defined as a white blood
cell count of less than 4500 cells/mm3*
Yes
No
infection as determined by an elevated white
blood cell count exceeding 11,000 cells/mm3*
Yes
No
body temperature greater than 38ºc*
Yes
No
decreased level of consciousness*
Yes
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No
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Eligibility Leukemia NCT02280525
Cord Blood Natural Killer (NK) Cells in Chronic
Lymphocytic Leukemia (CLL); ODM derived from:
https://clinicaltrials.gov/show/NCT02280525
All rights reserved. Please visit https://medical-data-
models.org/forms/15383
Eligibility Leukemia NCT02280525
Inclusion Criteria
1. patients with history of b-cll who have received
at least 2 lines of standard chemoimmunotherapy
and have persistent disease.*
Yes
No
2. patients with acute lymphoblastic leukemia
(all), acute myelogenous leukemia (aml), chronic
myelogenous leukemia (cml) with relapsed or
refractory disease.*
Yes
No
3. patients with histologically confirmed
aggressive b cell nhl with chemotherapy-
refractory disease. chemotherapy refractory
disease is defined as one or more of the
following: stable disease or progressive disease
as best response to most recent chemotherapy
containing regimen or disease progression or
recurrence within 12 months of prior autologous
or allogeneic stem cell transplant. subjects must
have received adequate prior therapy including at
a minimum: anti-cd20 monoclonal antibody
unless tumor is cd20-negative, an anthracycline
containing chemotherapy regimen. subjects with
transformed fl must have received prior
chemotherapy for follicular lymphoma and
subsequently have chemo-refractory disease
after transformation to diffuse large b-cell
lymphoma (dlbcl).*
Yes
No
4. patient with hodgkin's lymphoma with relapsed
or refractory disease.*
Yes
No
5. patients who are at least 3 weeks from the
time of consent. patients may continue ibrutinib,
idelalisib, or lenalidomide till the day of study
consent.*
Yes
No
6. karnofsky performance scale > 60%.*
Yes
No
7. adequate hepatic function, as defined by sgpt
<3 x upper limit of normal; serum bilirubin and
alkaline phosphatase <2 x upper limit of normal,
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or considered not clinically significant by the
study doctor or designee, serum creatinine of
</=2 mg/dl.*
Yes
No
8. able to provide written informed consent.*
Yes
No
9. 18-80 years of age.*
Yes
No
10. all study participants must be registered into
the mandatory revlimid remstm program, and be
willing and able to comply with the requirements
of the revlimid remstm program. females of
childbearing potential must adhere to the
scheduled pregnancy testing and contraception
as required in the revlimid remstm program. a
female of childbearing potential (fcbp) is a
sexually mature female who: 1) has not
undergone a hysterectomy or bilateral
oophorectomy; or 2) has not been naturally
postmenopausal for at least 24 consecutive
months (i.e., has had menses at any time in the
preceding 24 consecutive months).*
Yes
No
11. men must agree to use a latex condom during
sexual contact with females of child bearing
potential even if they have had a successful
vasectomy.*
Yes
No
12. patients must have a cb unit available which
is matched with the patient at 3, 4, 5, or 6/6 hla
class i (serological) and ii (molecular) antigens.*
Yes
No
Exclusion Criteria
1. positive beta hcg in female of child-bearing
potential defined as not postmenopausal for 24
months or no previous surgical sterilization or
lactating females.*
Yes
No
2. known positive serology for hiv.*
Yes
No
3. presence of grade 3 or greater toxicity from the
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previous treatment.*
Yes
No
4. concomitant use of other investigational
agents.*
Yes
No
5. not consenting to participate in lab00-099.*
Yes
No
6. patients with known hypersensitivity to
lenalidomide and/or rituximab.*
Yes
No
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Eligibility Life-threatening NCT02232659
SynCardia 70cc TAH-t for Destination Therapy (DT); ODM
derived from: https://clinicaltrials.gov/show/NCT02232659
All rights reserved. Please visit https://medical-data-
models.org/forms/15384
Eligibility Life-threatening
NCT02232659
Criteria
Inclusion Criteria
1. patients with ife-threatening, irreversible
biventricular heart failure (intermacs patient
profile classifications 1 - 4)*
Yes
No
2. ineligible for cardiac transplantation (e.g.,
contraindication to immunosuppression, cancer,
elevated panel reactive antibodies [pras]) as
determined by the implanting center at time of
implant screening assessment.*
Yes
No
3. on optimal medical management and failing to
respond or failing dt vad therapy (continuing to
decline)*
Yes
No
4. ambulatory without assistance*
Yes
No
5. patients between 19 and 75 years of age*
Yes
No
6. patients with body surface area (bsa) of ≥
1.7m2*
Yes
No
7. sternum to t10 distance > 10cm or adequate
room in chest as determined by 3-d imaging
assessment or by other standard clinical
assessments*
Yes
No
Exclusion Criteria
1. cardiac transplant-eligible patients*
Yes
No
2. patients who cannot be adequately
anticoagulated on the tah-t*
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Yes
No
3. patients with insufficient space in the chest*
Yes
No
4. patients on ecmo support*
Yes
No
5. patients with cirrhosis (evidenced by
ultrasound, ct scan, or positive biopsy)*
Yes
No
6. patients with acute or chronic renal dysfunction
(per intermacs ae definitions)*
Yes
No
7. patients with cardiac cachexia (e.g., pre-
albumin <17, fragility, and catabolic/anabolic
imbalance)*
Yes
No
8. patients with a comorbidity that has a poor
prognosis of survival beyond six months*
Yes
No
9. patients with insufficient social support or who
have demonstrated non-compliance with medical
instructions (as determined by the principal
investigator)*
Yes
No
secondary arm*
Yes
No
Inclusion Criteria
1. patients who are not eligible to participate in
the primary arm*
Yes
No
2. patients with life-threatening, irreversible
biventricular heart failure (intermacs patient
profile classifications 1 - 7)*
Yes
No
3. ineligible for cardiac transplantation (as
determined by the implanting center at time of
implant screening assessment).*
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Yes
No
4. on optimal medical management and failing to
respond or failing dt vad therapy (continuing to
decline)*
Yes
No
5. patients 19 years of age or older*
Yes
No
6. sternum to t10 distance > 10cm or adequate
room in chest as determined by 3-d imaging
assessment or by other standard clinical
assessments*
Yes
No
Exclusion Criteria
1. patients who are less than 19 years old*
Yes
No
2. cardiac transplant-eligible patients*
Yes
No
3. patients with cirrhosis (evidenced by
ultrasound, ct scan, or positive biopsy)*
Yes
No
4. patients with chronic renal dysfunction (per
intermacs ae definitions)*
Yes
No
5. patients with insufficient space in the chest*
Yes
No
6. patients who cannot be adequately
anticoagulated on the tah-t*
Yes
No
7. patients with insufficient social support or who
have demonstrated non-compliance with medical
instructions (as determined by the principal
investigator)*
Yes
No
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Eligibility Local Recurrence of Malignant
Tumor of Breast NCT02376413
Oncoplastic Breast-conserving Surgery in Non-metastatic
Breast Cancer Patients; ODM derived from:
https://clinicaltrials.gov/show/NCT02376413
All rights reserved. Please visit https://medical-data-
models.org/forms/15386
Eligibility Local Recurrence of
Malignant Tumor of Breast
NCT02376413
Inclusion Criteria
informed consent signed*
Yes
No
ecog<=2*
Yes
No
non-metastatic breast cancer patients with
unilateral breast cancer confirmed by pathology.*
Yes
No
operable or operable after neoadjuvant
chemotherapy.*
Yes
No
extensive, diffuse micro-calcifications on
mammography before surgery*
Yes
No
no history of breast surgery or breast radiation
therapy before.*
Yes
No
able to follow the standard of care in adjuvant
chemotherapy, radiation therapy, endocrine
therapy and targeted therapy after surgery.*
Yes
No
Exclusion Criteria
multifocal/multicentric diseases noticed before
surgery.*
Yes
No
inflammatory breast cancer or invasive micro-
papillary carcinoma of the breast confirmed by
pathology before surgery.*
Yes
No
tumor size > 5 cm revealed by physical
examination, ultrasound or mammography before
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surgery.*
Yes
No
tumor size/breast size ratio >0.5 revealed by by
physical examination, ultrasound or
mammography before surgery.*
Yes
No
have other malignant tumors.*
Yes
No
have severe co-morbidities that compromise the
patients' compliance to our protocol, or endanger
the patients.*
Yes
No
participated in other clinical trials.*
Yes
No
pathologically confirmed metastatic breast
cancer, bilateral breast cancer or dcis patients.*
Yes
No
patients with any organ failure.*
Yes
No
pregnancy women*
Yes
No
patients who desire to have mastectomy before
surgery.*
Yes
No
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Adverse Events, DIMAT-MS Relapsing
Remitting Multiple Sclerosis NCT02461069
Study documentation part: Discontinuation of Study
medication 
Study short name: DIMAT MS 
Study Details: A 24-week, multicenter, exploratory, two arm
study to assess the effect of Dimethyl fumarate on
ImmuneModulatory Action on T cells in patients with
relapsing remitting Multiple Sclerosis. 
Principal Investigator PD Dr. Luisa Klotz, University
Hospital Münster 
EudraCT - No.: 2014-003481-25. 
Clinical Trial No.: NCT02461069.
All rights reserved. Please visit https://medical-data-
models.org/forms/15387
Adverse Events, DIMAT-MS
Relapsing Remitting Multiple
Sclerosis NCT02461069
Adverse Events
Adverse Events Sheet No.
>= 1
Consecutive AE-No.
>= 1
Adverse Event (AE)
Date of onset of AE
dd/mm/yy
Seriousness
Yes
No
Intensity/Severity
mild: usually transient in nature and
generally not interfering with normal
activities (1)
moderate: sufficiently discomforting to
interfere with normal activities (2)
severe: prevents normal activities (3)
Relationship to invest. medicinal product
no reasonable possibility: time
relationship is improbable, and/or
another explanation is more likely (e.g.
disease or other drugs provide plausible
explanation) (0)
reasonable possibility: there are facts or
arguments to suggest a causal
relationship (1)
Action taken with invest. medicinal product
dose not changed (0 )
dose reduced (1)
dose increased (2)
drug withdrawn temporarily (3)
drug withdrawn permanently (4)
unknown (5)
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not applicable (6)
Withdrawal from trial due to this event
Yes
No
Date of end of AE
dd/mm/yy
or ongoing
Yes
No
Outcome
recovered/resolved (0)
recovering/resolving (1)
not recovered/not resolved (2)
recovered/resolved with sequelae (3)
fatal (4)
unknown (5)
Signature
Date
Signature Investigator
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End of Study/Discontinuation, DIMAT-MS Relapsing
Remitting Multiple Sclerosis NCT02461069
Study documentation part: End of Study/Discontinuation
Study short name: DIMAT MS 
Study Details: A 24-week, multicenter, exploratory, two arm
study to assess the effect of Dimethyl fumarate on
ImmuneModulatory Action on T cells in patients with
relapsing remitting Multiple Sclerosis. 
Principal Investigator PD Dr. Luisa Klotz, University
Hospital Münster 
EudraCT - No.: 2014-003481-25. 
Clinical Trial No.: NCT02461069.
All rights reserved. Please visit https://medical-data-
models.org/forms/15388
End of Study/Discontinuation,
DIMAT-MS Relapsing Remitting
Multiple Sclerosis NCT02461069
End of Study / Discontinuation
Date
dd/mm/yy
Regular end of study
after week 24 (Core study phase)
Yes
No
after week 48 (Follow up phase)
Yes
No
Early discontinuation
during the Screening phase (Screening failure)
Yes
No
If screening failure, please specify:
during the Core study phase
Yes
No
during Follow up phase
Reason for discontinuation of the Core study
phase / Follow up phase:
Patient withdraws informed consent (1)
Lack of efficacy (2)
Other medical, cognitive, or other
conditions, in the Investigator’s opinion,
com- promise the patient’s ability to
understand the nature, signi cance,
implications and risks of the study, to
comply with the protocol or to complete
the study (3)
Adverse Event (4)
Serious Adverse Event (5)
Lost to Follow up (6)
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Other reason (7)
If "other reason", please specify:
Signature
Date
Signature Investigator
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Eligibility Lung Cancer NCT02321540
A Phase I/II Study of Ibrutinib in Previously Treated
Epidermal Growth Factor Receptor (EGFR) Mutant Non-
Small Cell Lung Cancer; ODM derived from:
https://clinicaltrials.gov/show/NCT02321540
All rights reserved. Please visit https://medical-data-
models.org/forms/15389
Eligibility Lung Cancer
NCT02321540
Inclusion Criteria
1. patients must have histologically or
cytologically confirmed stage iv non-small cell
lung cancer, or recurrent non-small cell lung
cancer which is not amenable to curative intent
therapy.*
Yes
No
2. patients must have measurable disease by
response evaluation criteria in solid tumors(recist)
1.1 criteria*
Yes
No
3. documented egfr mutation by clinical
laboratory improvement amendments (clia)-
certified test*
Yes
No
4. documented disease progression on treatment
with erlotinib, gefitinib, afatinib, or other egfr-
targeted tyrosine kinase inhibitor*
Yes
No
5. there must be tissue available from a biopsy or
surgical procedure performed after progression
on an egfr targeted tyrosine kinase inhibitor. if
tissue is not available, the patient must have
biopsy accessible disease and must be willing to
undergo a biopsy*
Yes
No
6. age >/=18 years*
Yes
No
7. eastern cooperative oncology group (ecog)
performance status </=2*
Yes
No
8. ability to take pills by mouth*
Yes
No
9. patients must have normal organ and marrow
function as defined: leukocytes >/= 3,000/mcl;
absolute neutrophil count >/= 1,500/mcl;
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hemoglobin >/= 9 g/dl; total bilirubin </= 1.5 x
institutional upper limit of normal (uln);
ast(sgot)/alt(sgpt) </= 2.5 × uln or </= 5 x uln if
metastases to the liver; creatinine clearance >/=
45 ml/min*
Yes
No
10. patients with asymptomatic brain metastases
are allowed, as long as they are stable and do
not require treatment with anticonvulsants or
escalating doses of steroids. maximum daily dose
of steroids should be prednisone 20 mg or
equivalent. radiation therapy for brain metastases
must be completed at least 14 days prior to
treatment on protocol*
Yes
No
11. the effects of ibrutinib on the developing
human fetus are unknown. women of child-
bearing potential and men must agree to use
highly effective contraception (if using hormonal
birth control must add a second barrier method;
abstinence) prior to study entry, for the duration
of study participation as well as for at least 1
month after the last dose of ibrutinib. should a
woman become pregnant or suspect she is
pregnant while she or her partner is participating
in this study, she should inform her treating
physician immediately. men treated or enrolled on
this protocol must also agree to use highly
effective contraception prior to the study, for the
duration of study participation and 3 months after
completion of ibrutinib administration.*
Yes
No
12. ability to understand and the willingness to
sign a written informed consent document*
Yes
No
Exclusion Criteria
1. patients who have received egfr tyrosine
kinase inhibitors within 72 hours of initiation of
study treatment, or treatment with other anti-
cancer agents within 21 days of study treatment*
Yes
No
2. prior treatment with ibrutinib*
Yes
No
3. known hypersensitivity to ibrutinib*
Yes
No
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4. concurrent use of agents that strongly inhibit or
induce cyp3a unless use is approved by the
medical monitor*
Yes
No
5. uncontrolled intercurrent illness including, but
not limited to, ongoing or active infection,
symptomatic congestive heart failure, unstable
angina pectoris, cardiac arrhythmia, or psychiatric
illness/social situations that would limit
compliance with study requirements*
Yes
No
6. pregnant and nursing women*
Yes
No
7. patients with a history of another active
malignancy within the past two years, with the
exception of non-melanoma cutaneous
malignancy, cervical carcinoma in situ, or ductal
carcinoma in situ which has been successfully
treated with curative intent therapy*
Yes
No
8. any gastrointestinal disorder expected to limit
absorption of ibrutinib*
Yes
No
9. treatment with warfarin or other vitamin k
antagonist. patients with using warfarin who
switch to another form of anticoagulation will be
eligible*
Yes
No
10. patients with persistent and uncontrolled atrial
fibrillation.*
Yes
No
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Eligibility Advanced/Recurrent Non-small-
cell Lung Cancer NCT01251796
A Study of ARQ 197 in Combination With Erlotinib; ODM
derived from: https://clinicaltrials.gov/show/NCT01251796
All rights reserved. Please visit https://medical-data-
models.org/forms/15390
Eligibility Advanced/Recurrent Non-
small-cell Lung Cancer
NCT01251796
Inclusion Criteria
voluntary written informed consent for study
participation must be obtained*
Yes
No
a histologically or cytologically confirmed
advanced/recurrent non-small-cell lung cancer*
Yes
No
history of ≥1 prior chemotherapy regimen
(treatment with egfr tyrosine kinase inhibitors will
be counted as one regimen)*
Yes
No
ecog ps of 0 or 1*
Yes
No
life expectancy of ≥3 months*
Yes
No
poor metabolizers as defined by cyp2c19
genotype*
Yes
No
Exclusion Criteria
anti-cancer chemotherapy, anti-cancer therapy
with egfr-tki, hormone therapy, radiotherapy,
immunotherapy, other investigational agents or
anti-cancer antibody therapy within 28 days prior
to arq 197 dose*
Yes
No
surgery for cancer within 28 days prior to arq 197
dose*
Yes
No
active double cancer*
Yes
No
known symptomatic brain metastases*
Yes
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No
an intercurrent illness that is uncontrolled (e.g.,
infection, symptomatic congestive heart failure,
unstable angina pectoris, symptomatic
arrhythmia, interstitial pneumonia)*
Yes
No
pregnant or lactating*
Yes
No
subjects who wish to have a child and who would
not agree to use contraceptive measures*
Yes
No
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Eligibility Advanced Solid Tumors
NCT00947739
Phase I and Pharmacology Study of Camptothecin-20-O-
Propionate Hydrate (CZ48) in Patients With Solid Tumors or
Lymphoma; ODM derived from:
https://clinicaltrials.gov/show/NCT00947739
All rights reserved. Please visit https://medical-data-
models.org/forms/15391
Eligibility Advanced Solid Tumors
NCT00947739
Inclusion Criteria
all patients, 18 years of age or older, with
incurable advanced solid tumors or lymphomas
are eligible.*
Yes
No
patients must have a zubrod performance status
of 0-1.*
Yes
No
patients must sign an informed consent
document.*
Yes
No
patients should have adequate bone marrow
function defined by an absolute peripheral
granulocyte count of > 1,500 or cells/mm3 and
platelet count >100,000/mm3 -along with an
absence of a red blood cell transfusion in the two
weeks prior to their participation in the trial.*
Yes
No
patients should have adequate hepatic function
with a total bilirubin within normal range and sgot
or sgpt < two times the upper limit of normal, and
adequate renal function as defined by a serum
creatinine within the upper limit of normal.*
Yes
No
patients may receive no other concurrent
anticancer treatments such as chemotherapy,
hormonotherapy (except for prostate cancer
patients on lhrh agonists), immunotherapy,
biological agents, investigational agents, or
radiation therapy during this trial, and should be
off these treatments for at least 2 weeks, or until
they have completely recovered from the side
effects of these treatments, whichever is longest,
except for persistent grade 1 neuropathy in
patients who received prior platinum or taxanes.*
Yes
No
Exclusion Criteria
patients with symptomatic brain metastases are
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excluded from this study.*
Yes
No
pregnant women or nursing mothers are not
eligible for this trial. patients of child bearing
potential must use adequate contraception
(contraceptive pill, or iud, or two mechanical
barriers).*
Yes
No
patients with severe uncontrolled medical
problems are not eligible for this trial.*
Yes
No
patients who have too much esterase activity in
the blood, with a conversion rate yielding
concentration of cpt > 20 ng/ml in vitro. please
see section 6.5 for sample collection, preparation
and shipping. a validated analysis will be
performed according to sponsor sop sfcr.ph.r.01.*
Yes
No
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Eligibility Advanced Breast Cancer
NCT00106145
A Notch Signalling Pathway Inhibitor for Patients With
Advanced Breast Cancer (0752-014); ODM derived from:
https://clinicaltrials.gov/show/NCT00106145
All rights reserved. Please visit https://medical-data-
models.org/forms/15392
Eligibility Advanced Breast Cancer
NCT00106145
Inclusion Criteria
women or men greater than or equal to 18 years
of age*
Yes
No
ecog status less than or equal to 2 (a
measurement to determine your ability to perform
daily activities)*
Yes
No
in parts i, iii, and iv, patient must have a
histologically confirmed, metastatic or locally
advanced solid tumor that has failed to respond
to standard therapy, progressed despite standard
therapy, or for which standard therapy does not
exist. there is no limit on the number of prior
treatment regimens*
Yes
No
in part ii, only breast cancer patients are eligible*
Yes
No
in part v, only patients with numb negative breast
cancer (i.e., tumor shows numb immunoreactivity
in less than 10% of the neoplastic cells
assessed) are eligible*
Yes
No
patient has recovered from and is at least 2
weeks from previous antineoplastic therapy,
including chemotherapy, biological therapy
(including herceptin), hormonal therapy,
radiotherapy, or surgery*
Yes
No
Exclusion Criteria
patient has had an investigational treatment in
the preceding 21 days*
Yes
No
uncontrolled congestive heart failure or
myocardial infarction (heart attack) within 3
months of study start*
Yes
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No
history of hepatitis b or c or hiv*
Yes
No
patient has the presence of clinically apparent
central nervous system metastases or
carcinomatous meningitis.  patients with cns
metastases who have completed a course of
radiotherapy and are clinically stable in the
judgment of the investigator are eligible*
Yes
No
patients with "currently active" second
malignancy, other than non-melanoma skin
cancer, should not be enrolled.  patients are not
considered to have a "currently active"
malignancy if they have completed therapy for
prior malignancy and are considered by their
physician to be at <30% risk of relapse*
Yes
No
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Eligibility Advanced Hepatocellular
Carcinoma NCT02150317
Transarterial Chemoembolization (TACE) Plus Sorafenib
Versus TACE for Advanced Hepatocellular Carcinoma;
ODM derived from:
https://clinicaltrials.gov/show/NCT02150317
All rights reserved. Please visit https://medical-data-
models.org/forms/15393
Eligibility Advanced Hepatocellular
Carcinoma NCT02150317
Inclusion Criteria
male or female patients > 18 years and <=70
years of age.*
Yes
No
at least 2 radiologic imaging showing
characteristic features of hepatocellular
carcinoma  or cytologic/histologic evidence.*
Yes
No
tumor in liver and radiologically definable vascular
invasion or extrahepatic metastasis.*
Yes
No
criteria of liver function: child a-b level, serum
bilirubin ≤ 1.5 times the upper limit of normal
value,alanine aminotransferase and aspartate
aminotransferase ≤ 2 times the upper limit of
normal value.*
Yes
No
no dysfunction in major organs; blood routine,
kidney function, cardiac function and lung
function are basically normal.*
Yes
No
hb ≥90g/l,white blood cell count ≥3.000
cells/mm³,platelets ≥80.000 cells/mm³*
Yes
No
patients who can understand this trial and have
signed informed consent*
Yes
No
Exclusion Criteria
patients with apparent cardiac, pulmonary,
cerebral and renal dysfunction, which may affect
the treatment of liver cancer.*
Yes
No
patients with a medical history of other malignant
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tumors*
Yes
No
subjects participating in other clinical trials*
Yes
No
liver function:child c*
Yes
No
no pathological evidence of hepatocellular
carcinoma.*
Yes
No
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Eligibility Advanced or Metastatic (Medically or Surgically
Unresectable) Clear-cell Renal Cell Carcinoma NCT01668784
Study of Nivolumab (BMS-936558) vs. Everolimus in Pre-
Treated Advanced or Metastatic Clear-cell Renal Cell
Carcinoma (CheckMate 025); ODM derived from:
https://clinicaltrials.gov/show/NCT01668784
All rights reserved. Please visit https://medical-data-
models.org/forms/15394
Eligibility Advanced or Metastatic
(Medically or Surgically
Unresectable) Clear-cell Renal Cell
Carcinoma NCT01668784
Inclusion Criteria
men & women ≥18 years of age*
Yes
No
histologic confirmation of renal cell carcinoma
(rcc) with clear-cell component*
Yes
No
advanced/metastatic rcc*
Yes
No
measurable disease per response evaluation
criteria in solid tumors (recist) 1.1 criteria*
Yes
No
received 1 or 2 prior anti-angiogenic therapy
regimens in advanced or metastatic setting*
Yes
No
karnofsky performance score ≥70%*
Yes
No
Exclusion Criteria
any central nervous system (cns) metastases or
history of cns metastases*
Yes
No
prior therapy with an mammalian target of
rapamycin (mtor) inhibitor*
Yes
No
any active known or suspected autoimmune
disease*
Yes
No
uncontrolled adrenal insufficiency*
Yes
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No
active chronic liver disease*
Yes
No
prior malignancy active within past 3 years,
except for locally curable cancers*
Yes
No
2 / 2
Eligibility Advanced or Metastatic (Medically or Surgically Unresectable)
Clear-cell Renal Cell Carcinoma NCT01668784
Eligibility Alcoholic Hepatitis NCT00388323
Adipose Tissue Involvement in Alcohol-induced Liver
Inflammation in Human; ODM derived from:
https://clinicaltrials.gov/show/NCT00388323
All rights reserved. Please visit https://medical-data-
models.org/forms/15395
Eligibility Alcoholic Hepatitis
NCT00388323
Inclusion Criteria
alcoholic patients of both sex aged from 18 to 75,
hospitalized for alcoholic liver disease*
Yes
No
hbs antigen negative, hiv negative, anti -vhc
negative*
Yes
No
daily consumption exceeded 40-50 grams per
day during the last year*
Yes
No
elevated ast level and liver biopsy during the
hospitalisation patients who signed the informed
consent document*
Yes
No
patients affiliated to the national health insurance
system*
Yes
No
Exclusion Criteria
patients having another cause than alcohol for
liver injury*
Yes
No
hepatocellular carcinoma or another developing
cancer, severe associated pathology (cardiac
disease, respiratory insufficiency, severe
psychiatric problems), pancreatitis, infection,
diabetes or a dyslipidemia*
Yes
No
patients treated with fibrates or other
hypolipidaemic drugs, oral antidiabetics or
insulin*
Yes
No
patients having hemostasis which does not
permit the transcostal liver biopsy, platelet level
<60 giga/l, or quick test < 50 %, or (tca higher
than 1,5 times the time of the witness)*
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Yes
No
patients refuse an adipose tissue biopsy*
Yes
No
patients treated with long-duration dose of
clopidogrel (plavix®)*
Yes
No
patients who significantly diminished alcohol
consumption in comparison with the average
consumption during the year preceding the
inclusion*
Yes
No
patients not-affiliated to the national health
insurance system*
Yes
No
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Eligibility Advanced Cancers NCT01259284
Fish Oil Versus Statins Versus Placebos in Reducing Atrial
Fibrillation in Patients Undergoing Thoracic Surgery for
Lung Cancer; ODM derived from:
https://clinicaltrials.gov/show/NCT01259284
All rights reserved. Please visit https://medical-data-
models.org/forms/15396
Eligibility Advanced Cancers
NCT01259284
Inclusion Criteria
patients need to be in a normal sinus rhythm
preoperatively*
Yes
No
participants undergoing planned lobectomy and
60 years of age or older or participants
undergoing planned pneumonectomy and 18
years of age or older.*
Yes
No
planned procedure is 5 days after the start of
taking study drugs*
Yes
No
signed written informed consent*
Yes
No
women of childbearing potential must have a
negative pregnancy test (a woman of
childbearing potential is a women who has not
been naturally postmenopausal for at least 12
consecutive months or who has not undergone
previous surgical sterilization)*
Yes
No
adequate liver function evidenced by; aspartate
aminotransferase (ast or sgot) </= 2.5 * upper
limits of normal (uln), and alanine
aminotransferase (alt or sgpt) </= 2.5 * uln*
Yes
No
Exclusion Criteria
any history of supraventricular arrhythmia for
which the patient is taking medications.*
Yes
No
current use of antiarrhythmic medications other
than beta-receptor antagonists, calcium-channel
antagonists, or digitalis.*
Yes
No
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use of any supplemental n-3 fatty acids during
the previous three months.*
Yes
No
use of any statin therapy during the previous
three months.*
Yes
No
patients known to have a history of recent drug or
alcohol abuse*
Yes
No
known allergy to seafood*
Yes
No
current use of gemfibrozil and fenofibrate.*
Yes
No
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Eligibility Lymphoma NCT02169505
Brentuximab Vedotin in High-Risk CD30+ Lymphoma Post
Allogeneic Stem Cell Transplantation (AlloSCT); ODM
derived from: https://clinicaltrials.gov/show/NCT02169505
All rights reserved. Please visit https://medical-data-
models.org/forms/15397
Eligibility Lymphoma NCT02169505
Inclusion Criteria
1. patients with cd30 positive hodgkin lymphoma
(hl) or anaplastic large cell lymphoma (alcl) that
have undergone allogeneic sct in the past 60
days (matched related or matched unrelated
donors only).*
Yes
No
2. age 18 to 65 years.*
Yes
No
3. performance status: zubrod 0-1 or karnofsky
80-100.*
Yes
No
4. serum creatinine < 1.5 mg/dl or creatinine
clearance greater than or equal to 40 cc/min as
defined by mdrd method from national kidney
disease education program (nkdep).*
Yes
No
5. serum direct bilirubin < 1.5 mg/dl (unless
gilbert's syndrome).*
Yes
No
6. serum glutamate pyruvate transaminase (sgpt)
< 200 iu/l unless related to patient's malignancy.*
Yes
No
7. evidence of neutrophil and platelet
engraftment, defined as platelet count equal or
greater than 50,000 mm3 independent of platelet
transfusion and absolute neutrophil count (anc)
equal or greater to 1000 without growth factor
support for at least 5 days.*
Yes
No
8. patients with previous exposure to brentuximab
pre-transplant are eligible for the study.*
Yes
No
Exclusion Criteria
1. pregnancy or breast-feeding (women of
childbearing potential, any female who has
experienced menarche and who has not
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undergone surgical sterilization or is post-
menopausal with a positive serum pregnancy
test.*
Yes
No
2. presence of steroid-refractory acute graft-
versus-host disease (gvhd).*
Yes
No
3. patients that underwent allogeneic
transplantation as a treatment of graft failure.*
Yes
No
4. dual refractory cmv reactivation to foscarnet
and ganciclovir or evidence of cmv disease.*
Yes
No
2 / 2
Eligibility Lymphoma NCT02169505
Eligibility Lymphoma NCT02260414
Effects of Anticoagulant Preventive Injection in Patients
With Blood Cancer; ODM derived from:
https://clinicaltrials.gov/show/NCT02260414
All rights reserved. Please visit https://medical-data-
models.org/forms/15398
Eligibility Lymphoma NCT02260414
Inclusion Criteria
1. body weight between 40 and 100 kg*
Yes
No
2. patient:*
Yes
No
2a- with multiple myeloma indication with de novo
standard treatment thalidomide or lenalidomide
or erythropoietin (group 1) 2b- or hospitalized for
aggressive lymphoma treated with chemotherapy
(group 2) 2c- or older than 40 years and
hospitalized at least three days for an acute
medical pathology type of acute respiratory or
cardiac (group 3) decompensation*
Yes
No
Exclusion Criteria
patient requiring anticoagulant therapy at curative
doses*
Yes
No
patients with a lower platelet count 80 g / l*
Yes
No
subject with a history of heparin-induced
thrombocytopenia*
Yes
No
subject with a history of hemorrhagic disease*
Yes
No
history of severe trauma within 6 weeks prior to
enrollment*
Yes
No
organic lesion at risk of bleeding*
Yes
No
poor renal with creatinine clearance <30 ml / min*
Yes
No
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hypersensitivity to tinzaparin*
Yes
No
events or bleeding tendencies associated with
coagulation disorders*
Yes
No
subject on oral anticoagulant*
Yes
No
for group 3: presence of hematological
malignancy or active cancer*
Yes
No
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Discharge Letter Items 1229450930
Multiple Sclerosis
Discharge Letter Items for Patient diagnosed with Multiple
Sclerosis from Neurology Department of University Clinic
Muenster Publication granted by PD Dr. Klotz
All rights reserved. Please visit https://medical-data-
models.org/forms/15399
Discharge Letter Items 1229450930
Multiple Sclerosis
Administrative Data
Document ID
Patient`s Name
Date of birth:
Inpatient or Outpatient
Inpatient (Inpatient)
Outpatient (Outpatient)
Date of Appointment/Stay
Principal Diagnosis
Principal Diagnosis Multiple Sclerosis
Onset
Earliest date of diagnosis
EDSS
Previous Therapy with Copaxone
(Glatirameractetat)
Yes
No
Time Range of Previous Therapy with Copaxone
Previous Therapie Benefit during Treatment with
Copaxone
Previous Therapy with  Tysabri (Natalizumab)
Yes
No
Time Range of Previous Therapy with Tysabri
Previous Therapie Benefit during Treatment with
Tysabri (Natalizumab)
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Previous Therapy with Lemtrada (Alemtuzumab)
Yes
No
Time Range of Previous Therapy with
Alemtuzumab
Risk Stratification of Therapy with
Natalizumab
Previous Immunosuppressive Therapy
Yes
No
Months of use of Natalizumab
months
JCV Antibodies
Date of JCV-Antibody Measurement
L-Selectin-State of Risk
Secondary Diagnosis
Arterial Hypertension
Yes
No
Chronic venous insufficiency
Yes
No
Recurrent Cystitis
Yes
No
Hints of a Collagen Disease?
Yes
No
Collagen Disease:   Anti-nuclear antibody
measurement
negative (negative)
positive  (positive )
Collagen Disease:  Antibodies, Antinuclear
Yes
No
Collagen Disease: Results of Indirect
Immunofluorescence Staining
Mixed Connective Tissue Disease-Screening
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negative (negative)
positive (positive)
Anti-dsDNA Antibody present
negative (negative)
positive (positive)
Beta 2 glycoprotein I IgG antibody test
positive/negative?
negative (negative)
positive (positive)
Capillary Microscopy Results
Recurrent Depressive Episodes
Reason for Admission
Reason for admission
Summary and Assessment
Introduction: Reason for current Admission
Introduction: Department
Medical history
Current Symptoms
Quality of life decreased
Yes
No
Stress
Susceptibility to infections increased?
Yes
No
Laboratory Results abnormal?
Yes
No
Pathological findings of neurological examination
Walking Distance
km
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Gait, Manner of walking
Muscle strength of legs
better than before (better than before)
same (same)
worse than before (worse than before)
EDSS
Procedures
Current Immunosuppressive Therapy
Date Follow-Up Visit
Recommendation to bring a current blood count,
CRP and Urine status
Yes
No
Physical Therapy has been recommended?
Yes
No
Recommendation to compare MRI images
Yes
No
Multiple sclerosis relapse during therapy with
Lemtrada
Further diagnostic procedures planned during
hospitalisation
Induction of other therapy to stop MS flare
Neurological Examination: Cranial Nerves
Orientation
Meningism
Lhermitte's sign
negative (negative)
positive (positive)
Percussion Pain Skull
Yes
No
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Cranial Nerves: Visus
Pupils regularity
Consensual pupil reaction to light
Direct pupil reaction to light
Visual Field Fingerperimetric
Examination of Eye Movement
Saccades
Yes
No
Gaze Palsy
Diplopia
Facial Sensory Function
M.temporalis strength
M. masseter strength
Facial Muscles abnormal?
Findings on finger rub auditory screening test
Soft Palate Movement
Deviation of uvula
Yes
No
Tongue deviation
Yes
No
M. sternocleidomastoideus
M. trapezius strength
Taste Perception abnormal
Yes
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No
Smell Perception abnormal?
Yes
No
Neurological Examination: Motor
Trophic change of Muscles
Muscle Tonus
Involuntary muscle movements
Yes
No
Paresis of Lower Exremity
Muscle strength of Hip Flexion
better than before (better than before)
same (same)
worse than before (worse than before)
Muscle strength Knee extension
0/5 (0/5)
1/5 (1/5)
2/5 (2/5)
3/5 (3/5)
4/5 (4/5)
5/5 (5/5)
Pronator Drift Test
Function of Muscular reflex (MER) on arm
Babinski Reflex
Neurological Examination: Coordination
and Gait
Gait, Manner of walking
Heel to toe gait possible
Toe-walking gait possible
Heel Gait possible
Rhomberg Test abnormal?
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Diadochokinesis abnormal?
Dysdiadochokinesis
(Dysdiadochokinesis)
Eudiadochokinesis (Eudiadochokinesis)
Finger-to-nose test abnormal?
Heel-to-knee test abnormal?
Neurological Examination: Sensibility
Hypesthesia Upper Extremity
Hypesthesia Lower Extremity
Pallesthesia of ankle
0/8 (0/8)
1/8 (1/8)
2/8 (2/8)
3/8 (3/8)
4/8 (4/8)
5/8 (5/8)
6/8 (6/8)
7/8 (7/8)
8/8 (8/8)
Pallesthesia of knee
0/8 (0/8)
1/8 (1/8)
2/8 (2/8)
3/8 (3/8)
4/8 (4/8)
5/8 (5/8)
6/8 (6/8)
7/8 (7/8)
8/8 (8/8)
Psychological findings
Mood alterations with depressive symptoms
Yes
No
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Eligibility Lymphoma NCT02278250
An Open-Label Study of the Safety, Tolerability, and
Pharmacokinetic/Pharmacodynamic Profile of VX-803 as a
Single Agent and in Combination With Carboplatin in
Subjects With Advanced Solid Tumors or Lymphoma; ODM
derived from: https://clinicaltrials.gov/show/NCT02278250
All rights reserved. Please visit https://medical-data-
models.org/forms/15401
Eligibility Lymphoma NCT02278250
Inclusion Criteria
part a: subjects with histologically or cytologically
confirmed malignant advanced solid tumors or
lymphoma, for whom either no standard therapy
should be available which may convey clinical
benefit, or*
Yes
No
part b:  subjects with histologically or cytologically
confirmed malignant advanced solid tumors or
lymphoma, for whom no standard therapy should
be available which may convey clinical benefit
and/or patients must have progressed after at
least 1 prior chemotherapy regimen in the
metastatic setting, and carboplatin would be
considered standard of care.*
Yes
No
part c: subjects with advanced (locally advanced
incurable or metastatic) histologically or
cytologically confirmed high-grade serous ovarian
cancer (high nuclear grades 2 or 3). subjects
should have either platinum-refractory (disease
progression during initial platinum therapy) or
platinum-resistant (disease progression <6
months after completion of platinum therapy)
disease.*
Yes
No
measurable disease according to recist criteria
(version 1.1)*
Yes
No
who performance status of 0 or 1*
Yes
No
life expectancy of ≥12 weeks*
Yes
No
hematological and biochemical indices within
acceptable ranges at screening.*
Yes
No
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Exclusion Criteria
radiotherapy, unless brief course for palliative
therapy, endocrine therapy, immunotherapy, or
chemotherapy during the 4 weeks (6 weeks for
nitrosoureas and mitomycin-c, and 4 weeks for
investigational medicinal products) or 4 drug half-
lives before first dose of study drug, whichever is
greater*
Yes
No
part b: more than 6 cycles of prior therapy with
carboplatin*
Yes
No
parts b and c: during prior platinum therapy,
requirement for dose reduction or discontinuation
of carboplatin for toxicity or lack of tolerability*
Yes
No
ongoing toxic manifestations of previous
treatments.  exceptions to this are alopecia or
certain grade 1 toxicities, which in the opinion of
the investigator should not exclude the subject*
Yes
No
a. any known history of grade 4
thrombocytopenia with any prior
chemotherapy regimen*
Yes
No
spinal cord compression or brain metastases
unless asymptomatic, treated, stable, and not
requiring steroids for at least 4 weeks before first
dose of study drug*
Yes
No
female subjects who are already pregnant or
lactating, or plan to become pregnant within 6
months of the last dose of study drug are
excluded.  female subjects of childbearing
potential must adhere to contraception
guidelines.  female subjects will be considered to
be of nonchildbearing potential if they have
undergone surgical hysterectomy or bilateral
oophorectomy or have been amenorrheic for over
2 years with a screening serum follicle-stimulating
hormone (fsh) level within the laboratory's
reference range for postmenopausal females.*
Yes
No
male subjects with partners of childbearing
potential must agree to adhere to contraception
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guidelines. men with pregnant or lactating
partners or partners who plan to become
pregnant during the study or within 6 months of
the last dose of study drug are excluded.*
Yes
No
major surgery ≤4 weeks before first dose of study
drug or incomplete recovery from a prior major
surgical procedure*
Yes
No
serious co-morbid medical conditions, including
clinically-significant cardiac disease*
Yes
No
3 / 3
Eligibility Lymphoma NCT02278250
Discharge Letter Items 1227440267
Multiple Sclerosis
Discharge Letter Items for Patient diagnosed with Multiple
Sclerosis from Neurology Department of University Clinic
Muenster Publication granted by PD Dr. Klotz
All rights reserved. Please visit https://medical-data-
models.org/forms/15402
Discharge Letter Items 1227440267
Multiple Sclerosis
Administrative Data
Document ID
Patient`s Name
Date of birth:
Inpatient or Outpatient
Inpatient (Inpatient)
Outpatient (Outpatient)
Date of Appointment/Stay
Principal Diagnosis
Principal Diagnosis Multiple Sclerosis
Onset
Earliest date of diagnosis
EDSS
Previous Therapy with Copaxone
(Glatirameractetat)
Yes
No
Time Range of Previous Therapy with Copaxone
Previous Therapy Benefit during Treatment with
Copaxone
Previous Therapy with Interferone Beta 1a (Rebif)
Yes
No
Time Range of Previous Therapy with Interferon
Beta 1a  (Rebif)
Previous Therapy Benefit during Treatment with
Interferon Beta 1a
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Previous Therapy with  Tysabri (Natalizumab)
Yes
No
Time Range of Previous Therapy with Tysabri
Previous Therapy Benefit during Treatment with
Tysabri (Natalizumab)
Previous Therapy Fingolimod
Yes
No
Time Range of Previous Therapy with Fingolimod
Previous Therapie Benefit Fingolimod
Study Participation
Yes
No
Risk Stratification of Therapy with
Natalizumab
Previous Immunosuppressive Therapy
Yes
No
Months of use of Natalizumab
months
JCV Antibodies
Date of JCV-Antibody Measurement
JCV-Index
L-Selectin-State of Risk
Secondary Diagnosis
Disease suspected: Visual auras without
Migraine
Yes
No
Disease suspected: Carpal Tunnel Syndrome
Yes
No
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Diabetic sensory polyneuropathy
Median nerve, thenar motor branch function loss
Yes
No
Has the patient had a hysterectomy?
Yes
No
Diabetes mellitus
Yes
No
Hemogloblin A1C
%
Date last Hemogloblin A1C control
Hypertriglyceridemia
Yes
No
Recurrent Depressive Episodes
Reason for Admission
Reason for admission
Summary and Assessment
Past medical history
Introduction: Reason for current Admission
Introduction: Department
Current therapy with Teriflunomid
Yes
No
Benefit of current therapy with Teriflunomid
Laboratory Results abnormal?
Yes
No
Transaminases
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Hyperlipidemia?
Yes
No
Hemogloblin A1C
%
MRI
Date of MRI
Current Symptoms
Walking Distance
km
Did a loss of bladder function control occur?
Yes
No
Diarrhea
Yes
No
New Focal neurological signs
Yes
No
Transition to Secondary Progressive MS
Yes
No
Therapy Recommendation
Recommendation to bring differential blood count
Recommendation to evaluate liver enzymes on a
regularly base
Date of Next Clinical Assessment
Neurological Examination: Cranial Nerves
Pupils regularity
Consensual pupil reaction to light
Direct pupil reaction to light
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Cranial Nerves: Visus
Gaze Palsy
Visual Field Fingerperimetric
Diplopia
Saccades
Yes
No
Nystagmus Test
Hypesthesia V1
Yes
No
Hypesthesia V2
Yes
No
Facial Muscles abnormal?
Soft Palate Movement
Dysarthria
Yes
No
Neurological Examination: Motor
Trophic change of Muscles
Muscle Tonus
Involuntary muscle movements
Yes
No
Paresis of Lower Exremity
Muscle strength of Hip Flexion
better than before (better than before)
same (same)
worse than before (worse than before)
Muscle strength Knee extension
0/5 (0/5)
1/5 (1/5)
2/5 (2/5)
3/5 (3/5)
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4/5 (4/5)
5/5 (5/5)
Pronator Drift Test
Babinski Reflex
any kind of paralysis
Yes
No
Neurological Examination: Reflexes
Function of Muscular reflex (MER) on arm
Achilles Reflex
Pyramidal signs
Neurological Examination: Coordination
and Gait
Barany's Test
Diadochokinesis abnormal?
Dysdiadochokinesis
(Dysdiadochokinesis)
Eudiadochokinesis (Eudiadochokinesis)
Fine motor skills abnormal?
Rhomberg Test abnormal?
Gait evaluation abnormal?
Yes
No
Neurological Examination: Sensibility
Hypesthesia Upper Extremity
Hypesthesia Lower Extremity
Hypesthesia Upper Extremity
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Eligibility Heart Failure, Congestive
NCT00038077
Reversal of Ventricular Remodeling With Toprol-XL; ODM
derived from: https://clinicaltrials.gov/show/NCT00038077
All rights reserved. Please visit https://medical-data-
models.org/forms/15403
Eligibility Heart Failure, Congestive
NCT00038077
Inclusion Criteria
diagnosis of stable asymptomatic heart failure.*
Yes
No
documented ejection fraction less than 0.40.*
Yes
No
must be able to comply with all study
procedures.*
Yes
No
Exclusion Criteria
taken b-blocker therapy for longer than 1 week
within 6 months prior to randomization.*
Yes
No
have heart problems that would not allow b-
blocker therapy.*
Yes
No
receiving b-blockers therapy for any medical
reason including topical b-blockers that might
cause systemic absorption   (e.g., glaucoma).*
Yes
No
undergone certain heart surgeries, such as, prior
heart transplant or cardiomyoplasty.*
Yes
No
have certain heart diseases.*
Yes
No
pregnant or breast feeding.*
Yes
No
unlikely to survive.*
Yes
No
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Eligibility Heart Failure, Congestive
NCT00270361
FUSION I Assesses Safety and Tolerability of Two Doses of
NATRECOR (Nesiritide) Administered to Patients With
Worsening Congestive (Decompensated) Heart Failure
Who Are Concurrently Receiving Their Usual Cardiac
Medications and Are at High Risk for Hospitalization.; ODM
derived from: https://clinicaltrials.gov/show/NCT00270361
All rights reserved. Please visit https://medical-data-
models.org/forms/15404
Eligibility Heart Failure, Congestive
NCT00270361
Inclusion Criteria
subjects having had at least two hospital
admissions (or equivalent treatment) for acutely
decompensated chf within the last 12 months,
with at least one of these admissions in the past
30 days, and having received treatment with
intravenous vasoactive agents (such as
intravenous inotropes, natrecor®, or
nitroglycerin)*
Yes
No
able to be enrolled and initiate treatment with
study drug within 5 to 30 days of last hospital
discharge (or equivalent treatment) of acutely
decompensated chf*
Yes
No
have a baseline nyha (new york heart
association) functional classification iii or iv for at
least 2 months prior to randomization*
Yes
No
currently receiving optimal treatment with long
term oral medications (e.g., diuretics, ace
inhibitors, and beta blockers, unless beta blockers
or ace inhibitors are documented to be
contraindicated or not tolerated)*
Yes
No
willing to receive infusions of natrecor®, or
possibly other medications, at least as frequently
as once per week for 12 weeks.*
Yes
No
Exclusion Criteria
subjects having systolic blood pressure
consistently less than 90 mm hg*
Yes
No
having had organ transplantation (heart, liver,
lung and kidney) in the past or anticipating organ
transplantation during the study*
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Yes
No
not able or willing to discontinue intermittent or
continuous infusions of inotropes if randomized to
a natrecor® treatment group*
Yes
No
having had a bi-ventricular pacemaker placed
within the past 60 days or an automatic
implantable cardiac defibrillator placed within the
past 30 days*
Yes
No
requiring chronic dialysis or have an expectation
that dialysis will be required during the course of
the study.*
Yes
No
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Eligibility Heart Failure, Congestive
NCT00389649
Effect of Chronic Changes in Heart Rate on Congestive
Heart Failure; ODM derived from:
https://clinicaltrials.gov/show/NCT00389649
All rights reserved. Please visit https://medical-data-
models.org/forms/15405
Eligibility Heart Failure, Congestive
NCT00389649
Inclusion Criteria
symptomatic congestive heart failure*
Yes
No
nyha class ii to iv symptoms
ejection fraction < 40% by nuclear
ventriculography within the previous 6 months.
patients must be stable with no change in dosage
on conventional therapy (including digoxin,
diuretics, ace inhibitors, hydralazine, nitrates,
angiotensin ii receptor blockers and/or beta
blocker) for at least 4 weeks
Exclusion Criteria
active alcohol or illicit drug use*
Yes
No
myocardial infarction or unstable angina within
the previous 3 months*
Yes
No
obstructive valvular disease*
Yes
No
exercise induced sustained arrhythmias or
symptomatic myocardial ischemia*
Yes
No
pregnancy*
Yes
No
psychiatric disorder*
Yes
No
non-compliance with medical regimen*
Yes
No
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Eligibility Lymphoma NCT02369653
Safety and Efficacy Study of Apixaban to Prevent Clots in
Children With Leukemia Who Have a Central Venous
Catheter and Are Treated With PEG Asparaginase; ODM
derived from: https://clinicaltrials.gov/show/NCT02369653
All rights reserved. Please visit https://medical-data-
models.org/forms/15406
Eligibility Lymphoma NCT02369653
Criteria
Inclusion Criteria
new diagnosis of de novo all or lymphomas (t or b
cell)*
Yes
No
planned induction chemotherapy with a
corticosteroid, vincristine and peg l-asparaginase,
with or without daunorubicin consistent with the
children's oncology group (cog) all trials*
Yes
No
functioning central venous access device*
Yes
No
must be able to tolerate oral medication or have it
administered via an nasogastric tube (ngt) or gt
tube*
Yes
No
males and females,age 1 year(365 days) to < 18
(17 years and 364 days) years.*
Yes
No
platelet counts ≥ 20000/microl*
Yes
No
Exclusion Criteria
central nervous system (cns) 3 status  leukemia*
Yes
No
prior history of documented dvt or pe in the past
3 months*
Yes
No
known inherited bleeding disorder or
coagulopathy*
Yes
No
major surgery (excluding cvad placement and
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bone marrow aspiration and biopsy) within the
last 30 days that may be associated with a risk of
bleeding*
Yes
No
uncontrolled severe hypertension at enrollment.
severe hypertension is defined as a systolic or
diastolic blood pressure (bp) > 5 mm hg above
the 95th percentile as defined by the national
high blood pressure education program working
group (nhbpep) established guidelines for the
definition of normal and elevated blood pressure
in children*
Yes
No
extreme hyperleukocytosis, white blood cell (wbc)
counts over 200 x 109/l (200,000/microl) at the
time of diagnosis*
Yes
No
liver dysfunction manifested by sgtp (alt) > 5x
upper limit of normal (uln) and/or aspartate
aminotransferase (ast) >5 x uln and/or direct
(conjugated) bilirubin > 2x uln*
Yes
No
renal function < 30% of normal for age and size
as determined by the schwartz formula*
Yes
No
prothrombin time(pt)> 1 second above the upper
limit of normal for age,partial thromboplastin time
(ptt) > 3 seconds above the upper limit of normal
for age and international normalized ratio(inr)
above the upper limit of normal for age, within 1
week prior to enrollment.*
Yes
No
history of allergy to apixaban or factor xa
inhibitors*
Yes
No
history of significant adverse reaction or major
bleeding related adverse reaction to other
anticoagulant or antiplatelet agents*
Yes
No
history of any significant drug allergy (such as
anaphylaxis or hepatotoxicity*
Yes
No
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Eligibility Lymphoma, Extranodal NK-T-Cell
NCT02359162
Efficacy and Safety Study of P-Gemox vs.EPOCH as First-
line Chemotherapy to Treat NK/T-cell Lymphoma With Early
Stage; ODM derived from:
https://clinicaltrials.gov/show/NCT02359162
All rights reserved. Please visit https://medical-data-
models.org/forms/15408
Eligibility Lymphoma, Extranodal NK-
T-Cell NCT02359162
Inclusion Criteria
newly diagnosed enktl*
Yes
No
age:18-69years*
Yes
No
ann arbor stage ie,or stage iie with cervical lymph
node involvement*
Yes
No
at lease one measurable lesion*
Yes
No
receive no chemotherapy or radiotherapy before*
Yes
No
eastern cooperativeoncology group performance
status of 0 to 2.*
Yes
No
adequate hematologic function (eg, white blood
cell ≥ 3×10e9/l,neutrophils count*
Yes
No
≥1.5×10e9/l, and platelet count≥
100×10e9/l),renal function (eg, serum creatinine
≤1.5 mg/dl and creatinine clearance ≥50 ml
minute), and hepatic function (e.g, total bilirubin≤
2 times the upper limit of normal and aspartate
and alanine transaminase levels ≤ 3 times the
upper limit of normal)*
Yes
No
Exclusion Criteria
mismatch the inclusion criteria*
Yes
No
systematic central nervous system involvement,
previous or concomitant malignancies and any
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coexisting medical problems that could cause
poor compliance with the study protocol.*
Yes
No
primary lesion not from the upper respiratory*
Yes
No
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Eligibility Lymphoma, Lymphoblastic
NCT02396043
Modified BFM-95 Regimen as First-Line Chemotherapy in
Adults With T- Lymphoblastic Lymphoma; ODM derived
from: https://clinicaltrials.gov/show/NCT02396043
All rights reserved. Please visit https://medical-data-
models.org/forms/15410
Eligibility Lymphoma, Lymphoblastic
NCT02396043
Inclusion Criteria
newly diagnosedt-lbl*
Yes
No
age:18-65years*
Yes
No
ann arbor stage ieto stage ive*
Yes
No
at lease one measurable lesion*
Yes
No
receive no chemotherapy or radiotherapy before*
Yes
No
adequate renal function (eg, serum creatinine
≤1.5 mg/dl and creatinine clearance ≥50 ml
minute), and hepatic function (e.g, total bilirubin≤
2 times the upper limit of normal and aspartate
and alanine transaminase levels ≤ 3 times the
upper limit of normal)*
Yes
No
Exclusion Criteria
mismatch the inclusion criteria*
Yes
No
systematic central nervous system involvement,
previous or concomitant malignancies and any
coexisting medical problems that could cause
poor compliance with the study protocol.*
Yes
No
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Eligibility Major Depressive Disorder
NCT01450150
Transcranial Direct Current Stimulation as an Augmenting
Intervention for Major Depression; ODM derived from:
https://clinicaltrials.gov/show/NCT01450150
All rights reserved. Please visit https://medical-data-
models.org/forms/15411
Eligibility Major Depressive Disorder
NCT01450150
Inclusion Criteria
presence of a current major depressive disorder
(according to the diagnostic and statistical
manual, fourth edition, text revision [dsm-iv-tr])*
Yes
No
baseline score ≥ 13 on the qids-c*
Yes
No
stable medication regimen (> 4 weeks)*
Yes
No
Exclusion Criteria
psychotic features in the current episode*
Yes
No
lifetime history of psychotic disorders and/or
bipolar i or ii disorders*
Yes
No
substance or alcohol abuse/dependence in the
past 6 months*
Yes
No
lifetime history of a major neurological disease
(e.g., parkinson's, stroke)*
Yes
No
uncontrolled medical disease (e.g.,
cardiovascular, renal)*
Yes
No
pregnancy and/or lactation*
Yes
No
presence of a specific contraindication for tdcs
(e.g., personal history of epilepsy, metallic head
implant, cardiac pacemaker)*
Yes
No
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Outpatient services for private patients surgery Form for billing relevant
diagnosis and procedures Routine documentation in German hospitals DMI
Routine documentation in German hospitals. Source file
name:
AM010101_Bogen_abrechnungsrelevanter_Diagnosen
_Prozeduren/ Ambulante Leistungen Privatpatienten
Chirurgie.015
Examplary forms provided by DMI (http://www.dmi.de/)
All rights reserved. Please visit https://medical-data-
models.org/forms/15413
Outpatient services for private
patients surgery Form for billing
relevant diagnosis and procedures
Erbrachte leistungen
Arzt
Datum
Eingehende Beratung/ OP- Aufklärung mind. 10
Minuten
Ja
Nein
Anzahl
Eingehende Beratung/ OP - Aufklärung 20
Minuten
Ja
Nein
Anzahl
Aufklärung bei Risikopatienten Malignomverdacht
Ja
Nein
Anzahl
Untersuchung/ Ganzkörperstatus
Ja
Nein
Anzahl
Symptombezogene untersuchung
Ja
Nein
Anzahl
Ultraschalluntersuchung Leber
Ja
Nein
Anzahl
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Ultraschalluntersuchung Gallenblase
Ja
Nein
Anzahl
Ultraschalluntersuchung Niere
Ja
Nein
Anzahl
Ultraschalluntersuchung Niere
Ja
Nein
Anzahl
Ultraschalluntersuchung Leiste rechts
Ja
Nein
Anzahl
Ultraschalluntersuchung Leiste links
Ja
Nein
Anzahl
Ultraschalluntersuchung Schilddrüse rechts
Ja
Nein
Anzahl
Ultraschalluntersuchung Schilddrüse links
Ja
Nein
Anzahl
Dopplersonographie
Ja
Nein
Anzahl
Zuschlag Sonographie transkavitär
Ja
Nein
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Anzahl
Bescheinigung/ Kurzbrief
Ja
Nein
Anzahl
Fremdanamnese
Ja
Nein
Anzahl
Telefonat Arzt
Ja
Nein
Anzahl
Verband
Ja
Nein
Anzahl
Behandlung einer nicht heilenden Wunde
Ja
Nein
Anzahl
Entfernung von Fäden oder Klammern
Ja
Nein
Anzahl
Blutabnahme
Ja
Nein
Anzahl
Weitere Anmerkungen/ Ergänzungen:
Proktologie
Proktoskopie
Ja
Nein
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Anzahl
Rektoskopie
Ja
Nein
Anzahl
Defäkographie
Ja
Nein
Anzahl
Pudenduslatenztest
Ja
Nein
Anzahl
CT
Ja
Nein
Anzahl
MRT Abdomen/ Becken
Ja
Nein
Anzahl
Endosonographie
Ja
Nein
Anzahl
Analtonometrie
Ja
Nein
Anzahl
Transitzeitbestimmung
Ja
Nein
Anzahl
Rektale Untersuchung
Ja
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Nein
Anzahl
Vollständige körperliche Untersuchung eines
Organsystems
Ja
Nein
Anzahl
Unblutige Sphinkterdehnung
Ja
Nein
Anzahl
Zuschläge für erbrachte leistungen
Außerhalb der Sprechstunde
Ja
Nein
Zwischen 20 und 22 oder 6 Und 8 Uhr
Ja
Nein
Zwischen 22 oder 6 Uhr
Ja
Nein
am Samstagen, Sonn- und Feiertagen
Ja
Nein
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Outpatient services for private patients anesthesia Form for billing relevant
diagnosis and procedures Routine documentation in German hospitals DMI
Routine documentation in German hospitals. Source file
name:
AM010101_Bogen_abrechnungsrelevanter_Diagnosen
_Prozeduren/ Ambulante Leistungen Privatpatienten
Anästhesie.013 
Examplary forms provided by DMI (http://www.dmi.de/)
All rights reserved. Please visit https://medical-data-
models.org/forms/15414
Outpatient services for private
patients anesthesia Form for billing
relevant diagnosis and procedures
Erbrachte leistungen
Arzt
Datum
Eingehende Beratung/ Narkose - Aufklärung
mind. 10 Minuten
Ja
Nein
Anzahl
Eingehende Beratung/ Narkose - Aufklärung
mind. 20 Minuten
Ja
Nein
Anzahl
Aufklärung bei Risikopatienten Malignomverdacht
Ja
Nein
Anzahl
Untersuchung/ Ganzkörperstatus
Ja
Nein
Anzahl
Symptombezogene untersuchung
Ja
Nein
Anzahl
Oxymetrische Untersuchung (O2- Sättigung)
Ja
Nein
Anzahl
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Transcutane Messung des Hb- Wertes mittels
Fingerclipgerät
Ja
Nein
Anzahl
Blutdruckmessung
Ja
Nein
Anzahl
EKG in Ruhe
Ja
Nein
Anzahl
Lungenfunktionstest
Ja
Nein
Anzahl
Bescheinigung/ Kurzbrief
Ja
Nein
Anzahl
Fremdanamnese
Ja
Nein
Anzahl
Telefonat Arzt
Ja
Nein
Anzahl
Weitere Anmerkungen/ Ergänzungen:
Zuschläge für erbrachte leistungen
Außerhalb der Sprechstunde
Ja
Nein
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Zwischen 20 und 22 oder 6 Und 8 Uhr
Ja
Nein
Zwischen 22 oder 6 Uhr
Ja
Nein
am Samstagen, Sonn- und Feiertagen
Ja
Nein
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Consent to data transfer Privacy policy Routine
documentation in German hospitals DMI
Routine documentation in German hospitals. Source file
name: AM050101_Datenschutzerklärung/ Einwilligung in
der Datenweitergabe
Examplary forms provided by DMI (http://www.dmi.de/)
All rights reserved. Please visit https://medical-data-
models.org/forms/15415
Consent to data transfer Privacy
policy
Einwilligung in der Datenweitergabe
Vorname
Nachname
Geburtsdatum
Adresse
Telefon
Ich erteile hiermit die jederzeit widerrufliche
Einwilligung, dass die die zur Abrechnung
erforderlichen wesentlichen Daten der
Behandlung, insbesondere solche aus der
Patientkartei (Name, Geburtsdatum, Anschrift,
Krankenversicher, Befunde,
Behandlungsverläufe), auch somit es sich dabei
um ,, besondere Arten personenbezogener
Daten" i.S.v § 3 Abs. 9 des
Bundesdatenschutzsgesetzes (BDSG) handelt,
der damit beauftragten Abrechnungsstelle, der
unimed Abrechnungsservice für Kliniken und
Chefärzte, ausschließlich zum Zwecke der
Rechnungsstellung und des Inkassos zur
Verfügung stellt. Insoweit entbinde ich die
ausdrücklich von der ärztlichen Schweigepflicht.
Ja
Nein
Datum
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Eligibility Major Depressive Disorder
NCT02129751
Efficacy and Safety of Bupropion Hydrobromide in
Adolescents and Children With Major Depressive Disorder;
ODM derived from:
https://clinicaltrials.gov/show/NCT02129751
All rights reserved. Please visit https://medical-data-
models.org/forms/15416
Eligibility Major Depressive Disorder
NCT02129751
Inclusion Criteria
1. male or female outpatients aged ≥7 to <18
years (at screening visit 1). 2. provide assent
(subject) and written informed consent
(parent/legal representative) and health
insurance portability and accountability act
(hipaa) for study participation (at screening visit
1).*
Yes
No
3. meet diagnostic criteria for mdd as defined in
the dsm iv-tr5 at screening visits 1 and 1a (k-
sads-pl; see appendix 17.2).*
Yes
No
4. current depressive episode of at least 4 weeks'
duration as noted in the subject's history
(screening visit 1).*
Yes
No
5. total cdrs-r raw score ≥45 at both the screening
and baseline visits (visits 1 and 2) (see appendix
17.3).*
Yes
No
6. cgi-s score of ≥4 at the baseline visit (visit 2)
(see appendix 17.4).*
Yes
No
Exclusion Criteria
are unable to swallow medications without
difficulty*
Yes
No
•  have known hypersensitivity to bupropion
hydrobromide*
Yes
No
are pregnant or planning to get pregnant or are
lactating*
Yes
No
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women of childbearing age unable to use at least
one method of effective contraception for the
duration of the study*
Yes
No
previous history of attempted suicide are unable
to understand and communicate effectively with
parent, investigator, and study coordinator*
Yes
No
are at immediate risk of requiring hospitalization,
in the investigator's opinion*
Yes
No
have current seizure disorder or history of
seizures or head trauma*
Yes
No
have history or presence of clinically significant
medical conditions or clinically important
laboratory abnormalities*
Yes
No
have ecg or physical examination abnormality at
screening*
Yes
No
have body weight less than the 3rd percentile or
greater than the 97th percentile for age.*
Yes
No
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General Info EBMT Lymphoma
ODM form derived from EBMT Lymphoma please refer to:
http://www.ebmt.org/Contents/Data-
Management/Registrystructure/MED-
ABdatacollectionforms/Pages/MED-AB-data-collection-
forms.aspx
All rights reserved. Please visit https://medical-data-
models.org/forms/15417
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GENERAL INFORMATION Team
EBMT Centre Identification Code (CIC)
Name of the hospital
Unit
Contact person
Telephone number
Fax
E-Mail
Date of this report
Patient following national / international study /
trial
No (1)
Yes (2)
Not evaluated (3)
Unknown (4)
Name of study / trial
GENERAL INFORMATION Patient
To be entered only if patient previously reported
Hospital Unique Patient Number or Code
First name(s)_surname(s)
Date of birth:
Sex
Male (1)
Female (2)
1 / 24
ABO Group
Rh factor Donor a
Yes
No
DISEASE
Date of diagnosis
Check the disease for which this transplant was
performed
Acute Leukaemia (Acute Leukaemia)
Acute Lymphoblastic Leukaemia (ALL)
(Acute Lymphoblastic Leukaemia (ALL))
Acute Myelogenous Leukaemia (AML)
(Acute Myelogenous Leukaemia (AML))
Autoimmune disease (Autoimmune
disease)
Bone marrow failure including Aplastic
anaemia (Bone marrow failure including
Aplastic anaemia)
Chronic Leukaemia (Chronic Leukaemia)
Chronic Lymphocytic Leukaemia
(Chronic Lymphocytic Leukaemia)
Chronic Myeloid Leukaemia (CML)
(Chronic Myeloid Leukaemia (CML))
Haemoglobinopathiy
(Haemoglobinopathiy)
Histiocytic disorders (Histiocytic
disorders)
Hodgkin´s Disease (Hodgkin´s Disease)
Inherited disorders (Inherited disorders)
Juvenile Idiopathic Arthritis (Juvenile
Idiopathic Arthritis)
Lymphoma (Lymphoma)
MD/ MPN (MD/ MPN)
MDS (MDS)
Metabolic disorders (Metabolic
disorders)
Multiple Sclerosis (Multiple Sclerosis)
Myelodysplastic syndromes
(Myelodysplastic syndromes)
Myeloma/ Plasma cell disorder
(Myeloma/ Plasma cell disorder)
Myeloproliferative neoplasm
(Myeloproliferative neoplasm)
Non Hodgkin (Non Hodgkin)
Other diagnosis (Other diagnosis)
Primary immune deficiencies (Primary
immune deficiencies)
Secondary Acute Leukaemia (do not use
if transformed from MDS/MPN)
(Secondary Acute Leukaemia (do not
use if transformed from MDS/MPN))
Solid Tumour (Solid Tumour)
Systemic Lupus (Systemic Lupus)
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Systemic Sclerosis (Systemic Sclerosis)
If other diagnosis, specify:
LYMPHOMA INITIAL DIAGNOSIS
Has the information requested in this section
been submitted with a previous transplant
registration for this patient?
Yes: go to page 4, Treatment given
before the 1st transplant (1)
No: proceed with this section (2)
Non Hodgkin Lymphoma (NHL) (3)
Mature B-cell Neoplasms
Yes
No
Mature B-cell Neoplasms
Yes
No
Mature B-cell Neoplasms
Yes
No
Mature B-cell Neoplasms
Yes
No
Mature B-cell Neoplasms
Yes
No
Mature B-cell Neoplasms
Yes
No
Mature B-cell Neoplasms
Grade I  (1)
Grade II  (2)
Grade III  (3)
Not evaluated (4)
Mature B-cell Neoplasms
Yes
No
Mature B-cell Neoplasms
Yes
No
Mature B-cell Neoplasms
T-cell/hystiocyte rich large B cell
lymphoma (1)
Primary DLBCL of the CNS (2)
Primary cutaneous DLBCL, leg type (3)
EBV positive DLBCL of the elderly (4)
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Mature B-cell Neoplasms
Yes
No
Mature B-cell Neoplasms
Yes
No
Mature B-cell Neoplasms
Yes
No
Mature B-cell Neoplasms
Yes
No
Mature B-cell Neoplasms
Yes
No
Mature B-cell Neoplasms
Yes
No
Mature B-cell Neoplasms
Yes
No
Mature B-cell Neoplasms
Yes
No
Mature B-cell Neoplasms
Yes
No
Mature B-cell Neoplasms
Yes
No
Mature B-cell Neoplasms
Yes
No
Mature B-cell Neoplasms
Transformed from another type of lymphoma at
HSCT?
No (1)
Yes (2)
Unknown (3)
T-CELL AND NK-CELL NON HODGKIN
LYMPHOMAS (NHL)
T-cell large granular lymphocytic
leukaemia_ (1)
Mycosis fungoides (MF) (10)
Sézary syndrome _ (11)
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Lymphomatoid papulosis_ (12)
Primary cutaneous anaplastic large cell
lymphoma_ (13)
Primary cutaneous gamma-delta T-cell
lymphoma_ (14)
Primary cutaneous CD8 positive
aggressive epidermotropic cytotoxic T-
cell lymphoma (15)
Primary cutaneous CD4 positive
small/medium T-cell lymphoma (16)
Peripheral T-cell lymphoma, NOS
(PTCL) (17)
Angioimmunoblastic T-cell lymphoma_
(18)
Anaplastic large-cell lymphoma (ALCL),
ALK-positive_ (19)
Aggressive NK-cell leukaemia_ (2)
Anaplastic large-cell lymphoma (ALCL),
ALK-negative (20)
Other T-cell, specify (21)
Systemic EBV positive T-cell
lymphoproliferative disease of
childhood_ (3)
Hydroa vacciniforme-like lymphoma_ (4)
Adult T-cell leukaemia/lymphoma (5)
Extranodal NK/T-cell lymphoma, nasal
type (6)
Enteropathy-associated T-cell
lymphoma_ (7)
Hepatosplenic T-cell lymphoma_ (8)
Subcutaneous panniculitis-like T-cell
lymphoma (9)
HODGKIN LYMPHOMAS
Classical predominant (Classical
predominant)
Lymphocyte-depleted classical
(Lymphocyte-depleted classical)
Lymphocyte-rich classical (Lymphocyte-
rich classical)
Mixed cellularity classical (Mixed
cellularity classical)
Nodular lymphocyte predominant
(Nodular lymphocyte predominant)
Nodular sclerosis classical (Nodular
sclerosis classical)
Other, specify (Other, specify)
Stage at diagnosis
I (I)
II (II)
III (III)
IV (IV)
STAGE AT DIAGNOSIS
Absent (A) (Absent (A))
Not evaluated (Not evaluated)
Present (B) (Present (B))
Unknown (Unknown)
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DISEASE INVOLVEMENT AT DIAGNOSIS
< 5 cm  (1)
5-10 cm  (2)
> 10 cm  (3)
No mass  (4)
Unknown (5)
LDH LEVELS
Normal  (1)
Elevated  (2)
Not evaluated  (3)
Unknown (4)
Specific sites of involvement
Nodes below the diaphragm  (1)
Other (10)
Bone marrow  (2)
Extranodal (CNS) (3)
Mediastinum  (4)
Extranodal (testis /ovary)  (5)
Nodes above the diaphragm (6)
Lung  (7)
Liver  (8)
Spleen (9)
TREATMENT GIVEN BEFORE THE 1ST
TRANSPLANT
Has the information requested in this section
been submitted with a previous transplant
registration for this patient?
No: proceed with this section (No:
proceed with this section)
Yes: go to page 5, ”Disease History
before HSCT" (Yes: go to page 5,
”Disease History before HSCT")
WAS THE PATIENT TREATED BEFORE THE
1ST TRANSPLANT PROCEDURE?
WAS THE PATIENT TREATED BEFORE
THE 1ST TRANSPLANT PROCEDURE?
(1)
Yes Date started (2)
Sequential number of this treatment
(counted from diagnosis)
Modality Chemo/drug/agent (including MoAB,
etc.)
No  (No )
Unknown (Unknown)
Yes: Regimen (Yes: Regimen)
If MoAB, radiolabelled
No  (No )
Unknown (Unknown)
Yes (Yes)
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Radiotherapy
Yes
No
Response to this line of therapy
No response (< 50 %) ( No response (<
50 %))
Partial remission (> 50 %)  ( Partial
remission (> 50 %) )
Complete remission  (Complete
remission )
ADDITIONAL TREATMENT GIVEN BEFORE
THE 1ST TRANSPLANT?
Yes Date started ( Yes Date started)
No – Proceed to page 5, ”Disease
History before HSCT" (No – Proceed to
page 5, ”Disease History before HSCT")
Unknown (Unknown)
Sequential number of this treatment
(counted from diagnosis)
Chemo/drug/agent
Yes
No
Treatment Regimen
If MoAB, radiolabelled
No (1)
Yes (2)
Unknown (3)
Radiotherapy
Yes
No
Response to this line of therapy
Partial remission (> 50 %)  ( Partial
remission (> 50 %) )
Complete remission  (Complete
remission )
No response (< 50 %) (No response (<
50 %))
DISEASE HISTORY BEFORE HSCT
Date of transplant
Total number of lines before this transplant
(since diagnosis if 1st transplant, or since last
reported transplant)
Modality used at least once
No  (1)
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Yes (2)
Unknown (3)
Modality used at least once
No  (1)
Yes (2)
Unknown (3)
Modality used at least once
No (1)
Yes (2)
Unknown (3)
Splenectomy
Yes
No
Splenectomy
CR achieved before the 1st transplant
No (No)
Yes: Date of first CR (Yes: Date of first
CR)
Number of treatment lines necessary to reach
this first remission
Number of CR’s
1st Relapse before the 1st transplant
TO BE COMPLETED ONLY IF PATIENT HAD A
CR BEFORE THE 1ST TRANSPLANT
Yes: Date of first relapse (1)
No (2)
STATUS OF DISEASE AT HSCT
If patient has ever achieved Complete remission
Complete remission (CR) (Complete
remission (CR))
Confirmed -By CT scan (Confirmed -By
CT scan)
Confirmed -By PET (Confirmed -By PET)
Relapse (Relapse)
Unconfirmed (Unconfirmed)
NUMBER OF THIS REMISSION
1st (1)
2nd (2)
3rd or higher (3)
NUMBER OF THIS RELAPSE
1st (1)
2nd (2)
3rd or higher (3)
TYPE OF RELAPSE
Resistant (Resistant)
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Sensitive (responding) (Sensitive
(responding))
Untreated (untested) (Untreated
(untested))
If patient has never achieved a Complete
remission
PR ( PR)
Primary refractory disease ( Primary
refractory disease)
At diagnosis (untreated) (At diagnosis
(untreated))
Progression (Progression)
Very good 1st PR (> 90 %) (Very good
1st PR (> 90 %))
NUMBER OF THIS PR
1st (1st)
2nd (2nd)
3rd or higher (3rd or higher)
DISEASE INVOLVEMENT AT TRANSPLANT
No  ( No )
Not evaluated _ ( Not evaluated _)
Unknown (Unknown)
Yes  (Yes )
Size of largest mass
(if patient in CR at HSCT, indicate “No mass”)
> 10 cm  ( > 10 cm )
5-10 cm  ( 5-10 cm )
No mass  ( No mass )
Not evaluated ( Not evaluated)
< 5 cm  (< 5 cm )
Specific sites of disease (to be completed ONLY
if patient NOT in CR at transplant)
Nodes below the diaphragm _ Bone
marrow  (1)
Extranodal (CNS) (2)
Mediastinum  (3)
Extranodal (testis /ovary)  (4)
Nodes above the diaphragm (5)
Lung  (6)
Liver  (7)
Spleen (8)
Other (9)
ADDITIONAL TREATMENT POST-HSCT
Additional Disease Treatment
Not planned (for relapse/progression or
persistent disease) ( Not planned (for
relapse/progression or persistent
disease))
No (No)
Unknown (Unknown)
Yes:  Planned (planned before HSCT
took place) (Yes:  Planned (planned
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before HSCT took place))
ADDITIONAL DISEASE TREATMENT
Chemo/drug/agent
(including MoAB, vaccination, etc.)
Text (Text)
Unknown (Unknown)
Radiotherapy
yes no=no not known=not known (yes)
BEST DISEASE RESPONSE AT 100
DAYS POST-HSCT
BEST RESPONSE AT 100 DAYS AFTER
TRANSPLANTATION
By CT scan ( By CT scan)
By PET ( By PET)
Confirmed:  ( Confirmed: )
Early death/Not evaluable ( Early
death/Not evaluable)
No response (< 50 %) ( No response (<
50 %))
Partial remission (> 50 %)  ( Partial
remission (> 50 %) )
Progression  ( Progression )
Unconfirmed CRCONFI1  ( Unconfirmed
CRCONFI1 )
Complete remission (maintained or
achieved)  (Complete remission
(maintained or achieved) )
If Complete remission: Date of CR
FORMS TO BE FILLED IN
TYPE OF TRANSPLANT
AUTOgraft, proceed to Autograft form (1)
ALLOgraft or Syngeneic graft, proceed to
Allograft form (2)
If _ Other, contact the EBMT Central Registry
Office for instructions
LYMPHOMA FOLLOW UP
Unique Identification Code (UIC) (if known)
Date of this report
Patient following national / international study /
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trial
No (1)
Yes (2)
Not evaluated (3)
Unknown (4)
Name of study / trial
Hospital Unique Patient Number
First name(s)_surname(s)
Date of birth
Date of last HSCT for this patient
DATE OF LAST CONTACT OR DEATH
GRAFT VERSUS HOST DISEASE
(GvHD) SINCE LAST REPORT
Maximum Grade of Acute GVHD
Agvhd Grade 0 (0)
Agvhd Grade I (I)
Agvhd Grade Ii (II)
Agvhd Grade Iii (III)
Agvhd Grade Iv (IV)
Agvhd Present, Grade Unknown
(Present, grade unknown)
If present
New onset  (1)
Recurrent  (2)
Persistent (3)
Maximum grade
Unexplained ( Unexplained)
DLI (DLI)
Tapering  (Tapering )
Date onset of this episode (if new or recurrent)
yyyy/mm/dd
Date onset of this episode
Not applicable (1)
Stage skin
0 (1)
1 (2)
2 (3)
3 (4)
4 (5)
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Not evaluated (6)
unknown (7)
Stage liver
0 (1)
1 (2)
2 (3)
3 (4)
4 (5)
Not evaluated (6)
unknown (7)
Stage gut
0 (1)
1 (2)
2 (3)
3 (4)
4 (5)
Not evaluated (6)
unknown (7)
Resolution
No  (1)
Yes (2)
Date of resolution
yyyy/mm/dd
Presence of cGvHD
No (No)
Present continously since last reported
episode (Present continously since last
reported episode)
Resolved (Resolved)
Yes (Yes)
Presence of cGVHD
No (1)
Yes, First Episode (2)
Yes, Recurrence (3)
Date of onset
Date of onset
cGvHD grade
Limited (1)
Extensive (2)
Organs affected
Skin (1)
Gut (2)
Liver (3)
Mouth (4)
Eyes (5)
Lung (6)
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Other, specify (7)
Unknown (8)
If resolved, specify the date of resolution:
OTHER COMPLICATIONS SINCE LAST
REPORT
Infection related complications
Yes
No
Pathogen
Use the list of pathogens listed after this table for
guidance.
Use “unknown” if necessary
Date
Provide different dates for different episodes
of the same complication if applicable
Pathogen
Use the list of pathogens listed
after this table for guidance.
Use “unknown” if necessary
Date
Provide different dates for different episodes
of the same complication if applicable.
Pathogen
Use the list of pathogens listed
after this table for guidance.
Use “unknown” if necessary.
Date
Provide different dates for different episodes
of the same complication if applicable.
Pathogen
Use the list of pathogens listed
after this table for guidance.
Use “unknown” if necessary.
Date
Provide different dates for different episodes
of the same complication if applicable.
Pathogen
Use the list of pathogens listed
after this table for guidance.
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Use “unknown” if necessary.
Date
Provide different dates for different episodes
of the same complication if applicable.
Pathogen
Use the list of pathogens listed
after this table for guidance.
Use “unknown” if necessary.
Date
Provide different dates for different episodes
of the same complication if applicable.
Pathogen
Use the list of pathogens listed
after this table for guidance.
Use “unknown” if necessary.
Date
Provide different dates for different episodes
of the same complication if applicable.
Pathogen
Use the list of pathogens listed
after this table for guidance.
Use “unknown” if necessary.
Date
Provide different dates for different episodes
of the same complication if applicable.
Pathogen
Use the list of pathogens listed
after this table for guidance.
Use “unknown” if necessary.
Date
Provide different dates for different episodes
of the same complication if applicable.
Pathogen
Use the list of pathogens listed
after this table for guidance.
Use “unknown” if necessary.
Date
Provide different dates for different episodes
of the same complication if applicable.
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Pathogen
Use the list of pathogens listed
after this table for guidance.
Use “unknown” if necessary.
Date
Provide different dates for different episodes
of the same complication if applicable
Non infection related complications
Yes
No
Specify: Idiopathic pneumonia syndrome
No  (No )
Unknown (Unknown)
Yes (Yes)
Specify: 
VOD
No  (No )
Unknown (Unknown)
Yes (Yes)
Specify:
Cataract
No (No)
Unknown (Unknown)
Yes (Yes)
Specify:
Haemorrhagic cystitis, non infectious
No  (No )
Unknown (Unknown)
Yes  (Yes )
Specify:
ARDS, non infectious
No (No)
Unknown (Unknown)
Yes (Yes)
Multiorgan failure, non infectious
Yes (1)
No (2)
Unknown (3)
Specify:
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HSCT-associated microangiopathy
No (No)
Unknown (Unknown)
Yes (Yes)
Specify:
Renal failure requiring dialysis
No (No)
Unknown (Unknown)
Yes (Yes)
Specify:
Haemolytic anaemia due to blood group
No (No)
Unknown (Unknown)
Yes (Yes)
Specify:
Aseptic bone necrosis
No (No)
Unknown (Unknown)
Yes (Yes)
Other
Yes
No
Idiopathic pneumonia syndrome
Date VOD
Date Cataract
Date Haemorrhagic cystitis, non infectious
Date ARDS, non infectious
Date Multiorgan failure, non infectious
Date HSCT-associated microangiopathy
Date Renal failure requiring dialysis
16 / 24
General Info EBMT Lymphoma
DAte Haemolytic anaemia due to blood group
Date Aseptic bone necrosis
Graft loss
No (No)
Not evaluated (Not evaluated)
Yes (Yes)
Overall chimaerism
Aplasia (Aplasia)
95%) (Autologuos reconstitution
(recipient >)
95%) (Full (donor >)
Mixed (partial) (Mixed (partial))
Not evaluated (Not evaluated)
DATE(S) AND RESULTS OF ALL TESTS
DONE FOR ALL DONORS
Date of Test
Identification of donor or Cord Blood Unit given
by the centre
Number in the infusion order (if applicable)
......... (1)
N/A (2)
Cell type on which test was performed (% Donor
Cells):
BM
%
Cell type on which test was performed (% Donor
cells):
PB mononuclear cells (PBMC)
%
Cell type on which test was performed (% Donor
cells):
T-Cells
%
17 / 24
General Info EBMT Lymphoma
Cell type on which test was performed (% Donor
cells):
B-Cells
%
Cell type on which test was performed (% Donor
cells):
Red blood cells
%
Cell type on which test was performed (% Donor
cells):
Monocytes
%
Cell type on which test was performed (% Donor
cells):
PMNs (neutrophils)
%
Cell type on which test was performed (% Donor
cells):
Lymphocytes, NOS
%
Cell type on which test was performed (% Donor
cells):
Myeloid cells, NOS
%
Cell type on which test was performed (% Donor
cells):
Other
(Indicate the date(s) and results of all tests done
for all donors. Split the results by donor and by
the cell type on which the test was performed if
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applicable. Copy this table as many times as
necessary.)
%
Test used:
ABO group (ABO group)
Cytogenetic (Cytogenetic)
FISH (FISH)
Molecular (Molecular)
Other (Other)
unknown (unknown)
Test used:
If other, specify:
SECONDARY MALIGNANCY,
LYMPHOPROLIFERATIVE OR
MYELOPROLIFRATIVE DISORDER
DIAGNOSED
No at date of this follow-up (No at date of
this follow-up)
Previously reported (Previously reported)
Yes, date of diagnosis (Yes, date of
diagnosis)
Diagnosis
AML (AML)
Lymphoproliferative disorder
(Lymphoproliferative disorder)
MDS (MDS)
Other (Other)
If other diagnosis, please specify
ADDITIONAL THERAPIES SINCE LAST
FOLLOW UP
Treatment given since last report
No (No)
Unknown (Unknown)
Yes (Yes)
if yes, date started
If yes: Cellular therapy (One cell therapy regimen
is defined as any number of infusions given within
10 weeks for the same indication. If more than
one regimen of cell therapy has been given since
last report, copy this section and complete it as
many times as necessary.)
No  (1)
Yes (Mark disease status before this
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cellular therapy) (2)
Unknown (3)
Disease status before this cellular therapy
CR  (1)
Not in CR  (2)
Not evaluated (3)
If yes: Type of cells
Donor lymphocyte infusion (DLI) (1)
Mesenchymal cells (2)
Other (3)
Unknown (4)
Number of Nucleated cells infused (DLI only)
10^8/kg
Number (1)
Not evaluated (2)
Unknown (3)
Number of CD3+ cells infused (DLI only)
x10^6/kg
Number (1)
Not evaluated (2)
Unknown (3)
If DLI, specify the number of cells infused by
type: 
CD 3+
Evaluated  (Evaluated )
Not evaluated (Not evaluated)
Unknown (Unknown)
Total number of cells infused (non DLI only)
x10^6/kg
Number (1)
Not evaluated (2)
Unknown (3)
Chronological number of this cell therapy for this
patient
Indication 
(check all that apply)
Loss/decreased chimaerism
(Loss/decreased chimaerism)
Mixed chimaerism (Mixed chimaerism)
Other (Other)
Planned/ protocol (Planned/ protocol)
Prophylactic (Prophylactic)
Treatment for disease (Treatment for
disease)
Treatment of GvHD (Treatment of GvHD)
Treatment PTLD, EBV, lymphoma
(Treatment PTLD, EBV, lymphoma)
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Treatment viral infection (Treatment viral
infection)
Number of Infusions (within 10 weeks)
(count only infusions that are part of same
regimen and given for the same indication)
Acute Graft versus Host Disease 
(after this infusion but before any further infusion/
transplant)
Maximum grade:
grade 0 (absent) (grade 0 (absent))
grade 1 (grade 1)
grade 2 (grade 2)
grade 3 (grade 3)
grade 4 (grade 4)
present, grade unknown (present, grade
unknown)
Disease treatment (apart from donor cell infusion
or other type of cell therapy)
No (1)
Yes: Planned (planned before HSCT took
place) (2)
Yes: Not planned (for
relapse/progression or persistent
disease) (3)
Unknown (4)
Chemo/drug/agent
Yes
No
Radiotherapy
yes no=no not known=not known (yes)
Other treatment
No (No)
Unknown (Unknown)
Yes (Yes)
FIRST EVIDENCE OF RELAPSE OR
PROGRESSION SINCE LAST HSCT
Relapse or Progression
Continous progression since transplant
(Continous progression since transplant)
No (No)
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Previously reported (Previously reported)
Unknown (Unknown)
Yes, date (Yes)
last disease status
Complete Remission (Complete
Remission)
Relapse (Relapse)
Has patient or partner become  pregnant after
this HSCT?
No (No)
Unknown (Unknown)
Yes (Yes)
Survival Status
alive (0)
dead (1)
If alive: Type of score used:
Karnofsky (Karnofsky)
Lansky (Lansky)
Not evaluated (Not evaluated)
Unknown (Unknown)
Score
100 (Normal, NED) (1)
10 (Moribund) (10)
Not evaluated (11)
Unknown (12)
90 (Normal activity)  (2)
80 (Normal with effort) (3)
70 (Cares for self) (4)
60 (Requires occasional assistance) (5)
50 (Requires assistance) (6)
40 (Disabled) (7)
30 (Severely disabled) (8)
20 (Very sick) (9)
If dead, specify cause of death:
HSCT related cause  (HSCT related
cause )
Other (Other)
Relapse or progression (Relapse or
progression)
Secondary malignancy (including
lymphoproliferative disease) (Secondary
malignancy (including lymphoproliferative
disease))
Unknown  (Unknown )
If dead and HSCT related cause of death, specify
(check as many as apppropriate):
GvHD
No  (No )
Unknown (Unknown)
Yes (Yes)
If dead and HSCT related cause of death, specify
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(check as many as apppropriate):
Interstitial Pneumonitis
No  (No )
Unknown (Unknown)
Yes (Yes)
If dead and HSCT related cause of death, specify
(check as many as apppropriate): 
Pulmonary toxicity
No  (No )
Unknown (Unknown)
Yes (Yes)
If dead and HSCT related cause of death, specify
(check as many as apppropriate): 
Infection
No  (No )
Unknown (Unknown)
Yes (Yes)
Infection
bacterial (1)
viral (2)
fungal (3)
parasitic (4)
unknown (5)
Rejection / poor graft function
(check as many as appropriate)
Yes  (1)
No (2)
Unknown (3)
If dead and HSCT related cause of death, specify
(check as many as apppropriate): 
Veno-Occlusive disease (VOD)
No  (No )
Unknown (Unknown)
Yes (Yes)
If dead and HSCT related cause of death, specify
(check as many as apppropriate): 
Haemorrhage
No  (No )
Unknown (Unknown)
Yes (Yes)
If dead and HSCT related cause of death, specify
(check as many as apppropriate): 
Cardiac toxicity
No  (No )
Unknown (Unknown)
Yes (Yes)
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If dead and HSCT related cause of death, specify
(check as many as apppropriate): 
Central nervous system toxicity
No  (No )
Unknown (Unknown)
Yes (Yes)
If dead and HSCT related cause of death, specify
(check as many as apppropriate): 
Gastro intestinal toxicity
No  (No )
Unknown (Unknown)
Yes (Yes)
If dead and HSCT related cause of death, specify
(check as many as apppropriate): 
Skin toxicity
No  (No )
Unknown (Unknown)
Yes (Yes)
If dead and HSCT related cause of death, specify
(check as many as apppropriate): 
Renal failure
No  (No )
Unknown (Unknown)
Yes (Yes)
If dead and HSCT related cause of death, specify
(check as many as apppropriate): 
Multiple organ failure
No  (No )
Unknown (Unknown)
Yes (Yes)
If dead and HSCT related cause of death, specify
(check as many as apppropriate): 
Other
Yes
No
ADDITIONAL NOTES IF APPLICABLE
Comments
Identification
24 / 24
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Eligibility Major Depressive Disorder
NCT02192099
Open Label Extension for GLYX13-C-202, NCT01684163;
ODM derived from:
https://clinicaltrials.gov/show/NCT02192099
All rights reserved. Please visit https://medical-data-
models.org/forms/15418
Eligibility Major Depressive Disorder
NCT02192099
Inclusion Criteria
1. participants who have completed 8 weeks of
treatment in the preceding study (glyx13-c-202,
nct01684163.*
Yes
No
2. participants who wish to continue treatment
with glyx-13 after the preceding study.*
Yes
No
3. meets diagnostic and statistical manual, fourth
edition, text revision (dsm-iv-tr) criteria for major
depressive disorder (mdd).*
Yes
No
4. female subjects of childbearing potential with a
negative serum pregnancy test prior to entry into
the study and who are practicing an adequate
method of birth control (eg oral or parenteral
contraceptives, intrauterine device, barrier,
abstinence) and who do not plan to become
pregnant during the course of the study. female
subjects may be included without a negative
serum pregnancy test if they are surgically sterile
or at least 2 years post-menopausal.*
Yes
No
5. clinical laboratory values <2 times the upper
limit of normal (uln) or deemed not clinically
significant per the investigator and naurex
medical monitor.*
Yes
No
6. ability to understand the requirements of the
study, provide written informed consent, abide by
the study restrictions, and agree to return for the
required assessments.*
Yes
No
7. based on the investigator and naurex medical
monitor's clinical judgment, subjects with eating
disorders, obsessive compulsive disorder (ocd),
panic disorder, post-traumatic stress disorder
(ptsd), and generalized anxiety disorders
secondary to major depressive episodes (mdes)
are permitted.*
1 / 3
Yes
No
Exclusion Criteria
1. axis i diagnosis of delirium, dementia,
dysthymia, amnestic or other cognitive disorder,
schizophrenia or other psychotic disorder, bipolar
i or ii disorder, eating disorder (anorexia or
bulimia nervosa), obsessive-compulsive disorder,
panic disorder, acute stress disorder,
agoraphobia, social phobia, attention-deficit
hyperactivity disorder (adhd), or ptsd.*
Yes
No
2. a clinically significant current axis ii diagnosis
of borderline, antisocial, paranoid, schizoid,
schizotypal, or histrionic personality disorder*
Yes
No
3. experiencing hallucinations, delusions, or any
psychotic symptomatology in the current episode;
lifetime history of psychosis.*
Yes
No
4. huntington's, parkinson's, alzheimer's, multiple
sclerosis, or a history of seizures or strokes.*
Yes
No
5. currently hospitalized or residing in an in-
patient facility during study participation.*
Yes
No
6. substance abuse since the end of participation
in glyx13-c-202, including greater than or equal to
5 units of alcohol per day where 1 unit = ½ pint of
beer, 1 glass of wine 4 oz, or 1 oz. of spirits
consumed most weeks or in the opinion of the
investigator*
Yes
No
7. women who are planning to become pregnant
during the course of the study.*
Yes
No
8. allergy or intolerance to current antidepressant
or other current medications.*
Yes
No
9. participation in any clinical trial of an
investigational product or device within 30 days of
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enrollment in this trial with the exception of
glyx13-c-202.*
Yes
No
10. positive screen for drugs of abuse: cocaine,
marijuana, pcp, ketamine, opioid or other agent
that in the opinion of the investigator is being
abused*
Yes
No
11. pose current (past 6 months) suicide risk
based on administration of the c ssrs and the
investigator's clinical judgment.*
Yes
No
12. human immunodeficiency virus (hiv) infection
(based on the based on the hiv-1 & hiv-2
antibody screen) or other ongoing infectious
disease.*
Yes
No
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ToFingo Screening V1 Patient Information
Background Information NCT02325440
Principal Investigator: Luisa Klotz
Collaborator: Novartis
Information provided by (Responsible Party):University
Hospital Muenster
-Study to Assess Immune Function and MRI Disease
Activity in RRMS Patients When Switching From
Natalizumab to Gilenya (ToFingo2)
Purpose 
A trial in patients with relapsing remitting multiple sclerosis
(RRMS)
Main objectives:
•To evaluate changes in the reconstitution of immune
surveillance over time upon switching from natalizumab to
fingolimod assessed by a change in the expression of
CD49d.
•To evaluate changes in the migratory capacity of immune
cells/peripheral blood mononuclear cells (PBMCs) upon
switching from natalizumab to fingolimod in an in-vitro
model of the blood-brain-barrier (BBB).
•To evaluate changes in paraclinical disease activity over
time upon switching from natalizumab to fingolimod
assessed by MRI (changes in Gd+, T2w lesions and DTI).
•To evaluate changes in T1w / FLAIR lesions upon
switching from natalizumab to fingolimod.
For further Information please visit
https://clinicaltrials.gov/ct2/show/NCT02325440
All rights reserved. Please visit https://medical-data-
models.org/forms/15419
ToFingo Screening V1 Patient
Information Background Information
NCT02325440
Study Administration
Data entry for this CRF completed
Yes
No
Assessment date
Current patient (ID)
Patient information
Last name
First name
Sex
male (1)
female (2)
Race
Date of birth
Screening failure (Patient signed Informed
Consent, but failed eligibility-criteria)
1 / 3
Yes
No
Specify reason
Informed consent
Informed consent (Study)
Yes
No
Date of Informed consent (Study)
Informed consent lumbal puncture (optional)
Yes
No
Date of Informed Consent lumbar puncture
Inclusion/Exclusion Criteria
Inclusion criteria: Patient meets all inclusion
criteria
Yes
No
Exclusion criteria: Patient meets any exclusion
criteria
Yes
No
Relevant medical history/current medical
conditions
Diagnosis/Surgery
Date of Diagnosis/Surgery
Active at start of study
Comments
MS history
Date of confirmed MS diagnosis
Date of first MS symptoms
Previous MS therapies received
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NCT02325440
Yes
No
if yes, please specify
if other, please specify
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NCT02325440
Eligibility Hepatitis C NCT00383864
Pegylated Interferon and Ribavirin in Hepatitis C Virus
Infection After Liver Transplantation.; ODM derived from:
https://clinicaltrials.gov/show/NCT00383864
All rights reserved. Please visit https://medical-data-
models.org/forms/15420
Eligibility Hepatitis C NCT00383864
Inclusion Criteria
chronic hepatitis c defined by liver biopsy and
presence of hcv-rna*
Yes
No
more than 6 months from liver transplantation*
Yes
No
written inform consent*
Yes
No
Exclusion Criteria
severe hepatitis c recurrence (f3-f4 fibrosis stage,
cholestatic hepatitis)*
Yes
No
double liver-kidney transplantation*
Yes
No
leucopenia (2000) or thrombocytopenia (40.000)*
Yes
No
anemia (hemoglobin lower than 10 g/dl)*
Yes
No
renal failure (creatinine > 2 mg/dl)*
Yes
No
autoimmune disease*
Yes
No
all contraindications for interferon and ribavirin
therapy*
Yes
No
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Eligibility Major Depressive Disorder
NCT02309060
Storytelling Video Intervention for Depressed Primary Care
Patients - Open Trial; ODM derived from:
https://clinicaltrials.gov/show/NCT02309060
All rights reserved. Please visit https://medical-data-
models.org/forms/15421
Eligibility Major Depressive Disorder
NCT02309060
Inclusion Criteria
1. meets dsm-5 criteria for current or lifetime
major depressive disorder.*
Yes
No
2. no lifetime diagnosis of bipolar disorder,
schizophrenia, or chronic psychotic condition.*
Yes
No
3. no current hazardous illicit drug or alcohol
use.*
Yes
No
4. no suicidal ideation or behavior requiring
immediate attention.*
Yes
No
5. depression symptom severity:  a quick
inventory of depressive symptoms (qids) score
>11.*
Yes
No
6. taking an antidepressant medication for at
least 6 weeks; prescribed by their primary care
provider.*
Yes
No
7. not in psychotherapy during the study period.*
Yes
No
8. have a pcp at our enrollment site.*
Yes
No
9. if pregnant, less than 24 weeks gestation.*
Yes
No
10. english speaking.*
Yes
No
11. aged 18 or older.*
Yes
No
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ToFingo V5 Study relevant assessments
NCT02325440
Principal Investigator: Luisa Klotz Collaborator: Novartis
Information provided by (Responsible Party):University
Hospital Muenster -Study to Assess Immune Function and
MRI Disease Activity in RRMS Patients When Switching
From Natalizumab to Gilenya (ToFingo2) Purpose A trial in
patients with relapsing remitting multiple sclerosis (RRMS)
Main objectives: •To evaluate changes in the reconstitution
of immune surveillance over time upon switching from
natalizumab to fingolimod assessed by a change in the
expression of CD49d. •To evaluate changes in the
migratory capacity of immune cells/peripheral blood
mononuclear cells (PBMCs) upon switching from
natalizumab to fingolimod in an in-vitro model of the blood-
brain-barrier (BBB). •To evaluate changes in paraclinical
disease activity over time upon switching from natalizumab
to fingolimod assessed by MRI (changes in Gd+, T2w
lesions and DTI). •To evaluate changes in T1w / FLAIR
lesions upon switching from natalizumab to fingolimod. For
further Information please visit
https://clinicaltrials.gov/ct2/show/NCT02325440
All rights reserved. Please visit https://medical-data-
models.org/forms/15423
ToFingo Screening V5 Study relevant
assessments NCT02325440
Study administration
Data entry for this CRF completed
Yes
No
Assessment date
Current patient (ID)
MRI
MRI performed
Yes
No
GD+
Yes
No
T2w
Number of GD+ lesions
Number of enlarging GD+ lesions
Number of new T2w lesions
Number of enlarging T2w lesions
Blood
Peripheral blood taken
Yes
1 / 2
No
Date of collection
PBMCs isolated
Yes
No
Date of isolation
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ToFingo Screening V1 Pre-examination
NCT02325440
Principal Investigator: Luisa Klotz Collaborator: Novartis
Information provided by (Responsible Party):University
Hospital Muenster -Study to Assess Immune Function and
MRI Disease Activity in RRMS Patients When Switching
From Natalizumab to Gilenya (ToFingo2) Purpose A trial in
patients with relapsing remitting multiple sclerosis (RRMS)
Main objectives: •To evaluate changes in the reconstitution
of immune surveillance over time upon switching from
natalizumab to fingolimod assessed by a change in the
expression of CD49d. •To evaluate changes in the
migratory capacity of immune cells/peripheral blood
mononuclear cells (PBMCs) upon switching from
natalizumab to fingolimod in an in-vitro model of the blood-
brain-barrier (BBB). •To evaluate changes in paraclinical
disease activity over time upon switching from natalizumab
to fingolimod assessed by MRI (changes in Gd+, T2w
lesions and DTI). •To evaluate changes in T1w / FLAIR
lesions upon switching from natalizumab to fingolimod. For
further Information please visit
https://clinicaltrials.gov/ct2/show/NCT02325440
All rights reserved. Please visit https://medical-data-
models.org/forms/15424
ToFingo Screening V1 Pre-
examination NCT02325440
Study administration
Data entry for this CRF completed
Yes
No
Assessment date
Current patient (ID)
MSFC (Multiple Sclerosis Functional
Composite Measure)
Endscore
Last natalizumab dose
Last natalizumab dose taken (300mg)
Ophthalmologic examination
Opthalmologic examination: Result
Opthalmologic examination: Comment
History of uveitis or diabetes mellitus: Result
History of uveitis or diabetes mellitus: Comment
Abnormalities: Result
Abnormalities: Comment
1 / 3
Virus antibody status
Anti-JCV-IgG: Result
Anti-JCV-IgG: Comment
Anti-VZV-IgG: Result
mU/ml
Anti-VZV-IgG: Comment
Anti-HIV 1+2: Result
Anti-HIV 1+2: Comment
HBsAg (Hepatitis B Surface Antigen): Result
HBsAg (Hepatitis B Surface Antigen): Comment
Anti-HCV: Result
Anti-HCV: Comment
Anti-HSV 1/2-IgG (Herpes Simplex virus): Result
Anti-HSV 1/2-IgG (Herpes Simplex virus):
Comment
Anti-Rubeola-IgG (Measles virus): Result
Anti-Rubeola-IgG (Measles virus): Comment
ECG
AV-Block 2nd degree, Type II: Result
Yes
No
AV-Block 2nd degree, Type II: Comment
AV-Block 3rd degree: Result
Yes
No
AV-Block 3rd degree: Comment
QTc intervall: Result
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msec
QTc intervall: Comment
Abnormalities: Result
Yes
No
Abnormalities: Comment
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Screening: Demography Multiple Sclerosis
ALAIN01 NCT02419378
Alemtuzumab in Autoimmune Inflammatory
Neurodegeneration: Mechanisms of Action and
Neuroprotective Potential (ALAIN01)
https://clinicaltrials.gov/ct2/show/NCT02419378
Principal Investigator Prof. Dr. Dr. Sven Meuth, University
Hospital Muenster, Germany
Part: Screening
All rights reserved. Please visit https://medical-data-
models.org/forms/15425
Screening: Demography Multiple
Sclerosis ALAIN01 NCT02419378
Demography
Patient ID (derived)
Date Informed Consent Signed
Date of Birth (Month)
Date of Birth (Year)
Sex
female (f)
male (m)
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Screening: Medical History Multiple
Sclerosis ALAIN01 NCT02419378
Alemtuzumab in Autoimmune Inflammatory
Neurodegeneration: Mechanisms of Action and
Neuroprotective Potential (ALAIN01)
https://clinicaltrials.gov/ct2/show/NCT02419378
Principal Investigator Prof. Dr. Dr. Sven Meuth, University
Hospital Muenster, Germany
Part: Screening
All rights reserved. Please visit https://medical-data-
models.org/forms/15427
Screening: Medical History Multiple
Sclerosis ALAIN01 NCT02419378
Medical History
Patient ID (derived)
Medical history List
Medical History: Description
Medical History: Start Date
Medical History: End Date
Medical History: ongoing
ongoing (1)
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Screenning: EDSS Multiple Sclerosis
ALAIN01 NCT02419378
Alemtuzumab in Autoimmune Inflammatory
Neurodegeneration: Mechanisms of Action and
Neuroprotective Potential (ALAIN01)
https://clinicaltrials.gov/ct2/show/NCT02419378
Principal Investigator Prof. Dr. Dr. Sven Meuth, University
Hospital Muenster, Germany
Part: Screenning
All rights reserved. Please visit https://medical-data-
models.org/forms/15428
Screenning: EDSS Multiple Sclerosis
ALAIN01 NCT02419378
EDSS
Patient ID (derived)
EDSS: Date
EDSS: Visual System Score
0 (0)
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
EDSS: Brainstem System Score
0 (0)
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
EDSS: Pyramidal System Score
0 (0)
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
EDSS: Cerebellar System Score
0 (0)
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
EDSS: Sensory System Score
0 (0)
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
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EDSS: Bowel/Bladder System Score
0 (0)
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
EDSS: Cerebral System Score
0 (0)
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
EDSS: Ambulation Score
0 (0)
1 (1)
10 (10)
11 (11)
12 (12)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
7 (7)
8 (8)
9 (9)
EDSS: Cerebellar System Score (X)
X (X)
EDSS Step
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Baseline: EDSS + Blood sampling Multiple
Sclerosis ALAIN01 NCT02419378
Alemtuzumab in Autoimmune Inflammatory
Neurodegeneration: Mechanisms of Action and
Neuroprotective Potential (ALAIN01)
https://clinicaltrials.gov/ct2/show/NCT02419378
Principal Investigator Prof. Dr. Dr. Sven Meuth, University
Hospital Muenster, Germany
Part: Baseline
All rights reserved. Please visit https://medical-data-
models.org/forms/15430
Baseline: EDSS + Blood sampling
Multiple Sclerosis ALAIN01
NCT02419378
EDSS
Patient ID (derived)
EDSS: Date
EDSS: Visual System Score
0 (0)
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
EDSS: Brainstem System Score
0 (0)
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
EDSS: Pyramidal System Score
0 (0)
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
EDSS: Cerebellar System Score
0 (0)
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
EDSS: Sensory System Score
0 (0)
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
1 / 2
6 (6)
EDSS: Bowel/Bladder System Score
0 (0)
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
EDSS: Cerebral System Score
0 (0)
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
EDSS: Ambulation Score
0 (0)
1 (1)
10 (10)
11 (11)
12 (12)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
7 (7)
8 (8)
9 (9)
EDSS: Cerebellar System Score (X)
X (X)
EDSS Step
Blood Sampling for Efficacy Assessments
Date of Sampling
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Baseline: EDSS + Blood sampling Multiple Sclerosis ALAIN01
NCT02419378
Month 12: EDSS Multiple Sclerosis
ALAIN01 NCT02419378
Alemtuzumab in Autoimmune Inflammatory
Neurodegeneration: Mechanisms of Action and
Neuroprotective Potential (ALAIN01)
https://clinicaltrials.gov/ct2/show/NCT02419378
Principal Investigator Prof. Dr. Dr. Sven Meuth, University
Hospital Muenster, Germany
Part: Month 12
All rights reserved. Please visit https://medical-data-
models.org/forms/15431
Month 12: EDSS Multiple Sclerosis
ALAIN01 NCT02419378
EDSS
Patient ID (derived)
EDSS: Date
EDSS: Visual System Score
0 (0)
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
EDSS: Brainstem System Score
0 (0)
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
EDSS: Pyramidal System Score
0 (0)
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
EDSS: Cerebellar System Score
0 (0)
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
EDSS: Sensory System Score
0 (0)
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
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EDSS: Bowel/Bladder System Score
0 (0)
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
EDSS: Cerebral System Score
0 (0)
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
EDSS: Ambulation Score
0 (0)
1 (1)
10 (10)
11 (11)
12 (12)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
7 (7)
8 (8)
9 (9)
EDSS: Cerebellar System Score (X)
X (X)
EDSS Step
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Discharge Letter Items 1146404369
Multiple Sclerosis
Discharge Letter Items for Patient diagnosed with Multiple
Sclerosis from Neurology Department of University Clinic
Muenster Publication granted by PD Dr. Klotz
All rights reserved. Please visit https://medical-data-
models.org/forms/15432
Discharge Letter Items 1146404369
Multiple Sclerosis
Administrative Data
Document ID
Patient`s Name
Date of birth:
Inpatient or Outpatient
Inpatient (Inpatient)
Outpatient (Outpatient)
Date of Appointment/Stay
Principal Diagnosis
Principal Diagnosis Multiple Sclerosis
Onset
Earliest date of diagnosis
EDSS
Previous Therapy with Copaxone
(Glatirameractetat)
Yes
No
Time Range of Previous Therapy with Copaxone
Previous Therapie Benefit during Treatment with
Copaxone
Current Therapy with Lemtrada (Alemtuzumab)
Yes
No
Dosage of Alemtuzumab
mg/d
Alemtuzumab Duration of Therapy
d
1 / 12
Secondary Diagnosis
Tremor
Yes
No
Metatarsal bone fracture
Yes
No
Ankle Joint Fracture
Yes
No
Strabismus surgery
Yes
No
Date Strabismus Surgery
Eye operation complication
Summary and Assessment
Introduction: Reason for current Admission
Introduction: Department
Medical history
Current Symptoms
Hypesthesia of trunk (specify which half of the
trunk)
MRI findings of last MRI
Orientation
Paresis of M. rectus medialis
Yes
No
Strabismus surgery
Yes
No
Date Strabismus Surgery
EDSS
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Cerebrospinal fluid inflammation parameters
Yes
No
Oligoclonal Bands
negative (negative)
positive  (positive )
Intrathecal Plasma Cells
negative (negative)
positive (positive)
A recent infection has been clinically excluded
Yes
No
A recent infection has been excluded by lab
procedures
Yes
No
Current Therapy with Lemtrada (Alemtuzumab)
Yes
No
Alemtuzumab Duration of Therapy
d
Neurological Examination
Orientation
Meningism
Percussion Pain Skull
Yes
No
Nerve Exit Points painful
Yes
No
Nerve stretch tests
Neurological Examination: Cranial Nerves
Cranial Nerves: Visus
Pupils Motor abnormal?
Yes
No
Paresis of M. rectus medialis
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Yes
No
Facial Sensory Function
Facial Muscles abnormal?
Function of caudal cranial nerves
Neurological Examination: Motor
Muscle Tonus
Pareses
latent (latent)
manifest (manifest)
none (none)
Muscle strength (Oxford Scale)
Function of Muscular reflex (MER) on arm
Pyramidal signs
Neurological Examination: Coordination
and Gait
Gait, Manner of walking
Standing, Manner of Standing
Past pointing test findings
Postural Tremor
Yes
No
Diadochokinesis abnormal?
Dysdiadochokinesis
(Dysdiadochokinesis)
Eudiadochokinesis (Eudiadochokinesis)
Neurological Examination: Sensibility
Hypesthesia of trunk (specify which half of the
trunk)
EDSS
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Procedures
Current Immunosuppressive Therapy
Date Follow-Up Visit
Physical Therapy has been recommended?
Yes
No
Recommendation to compare MRI images
Yes
No
Multiple sclerosis relapse during therapy with
Lemtrada
Further diagnostic procedures planned during
hospitalisation
Induction of other therapy to stop MS flare
Adverse effects Alemtuzumab: Acute idiopathic
thrombocytopenic purpura
Adverse effects Alemtuzumab: Nephropathy
Adverse effects Alemtuzumab: Thryoideal
Recommendation to bring differential blood count
Recommendation Urine Analysis
Clinical Presentation ITP
haematoma (haematoma)
mucosal hemorrhage  (mucosal
hemorrhage )
petechia (petechia)
Date of follow up visit
Prophylactic Treatment of Herpesvirus Infections
with Aciclovir
Yes
No
Aciclovir dosage
mg
Aciclovir Duration of Treatment
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dStudy Participation of Immunmonitoring
Yes
No
Due to Listeria Infection during therapy with
amlemtuzumab we recommend to avoid raw milk
products.
Yes
No
Laboratory Results Serum
Sodium Measurement
mmol/l
Potassium
U/L
Calcium
U/L
Cholesterol
mg/dl
Glucose
mg/dl
Uric acid
md/dl
Blood Urea Nitrogen
mg/dl
Creatinin
μmol/l
Bilirubin Total
mg/dl
AST (SGOT)
U/L
ALT (SGPT)
g/dL
gamma-GT
U/l
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Alkaline Phosphatase
md/dl
Lactate Dehydrogenase (LDH)
g/dL
CPK
md/dl
CK MB
md/dl
CRP
md/dl
Laboratory Results Small EDTA
Leucocytes
Tsd/µl
Erythrocytes
Tsd/µl
Haemoglobin
Tsd/µl
Haematocrit
Tsd/µl
Mean Corpuscular Volume
Tsd/µl
MCH
Tsd/µl
Mean corpuscular hemoglobin concentration
Tsd/µl
Thrombocytes
md/dl
Laboratory Results Differential EDTA
Neutrophils relative
%
Neutrophils absolute
Tsd/µl
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Lymphocytes relative
Tsd/µl
Lymphocytes absolute
md/dl
Monocytes relative
Tsd/µl
Monocytes absolute
md/dl
Eosinophils relative
Tsd/µl
Eosinophils absolute
md/dl
Basophils relative
Tsd/µl
Basophils absolute
md/dl
Mean Platelet Volume
fl
Immature Granulocytes
md/dl
Laboratory Results Blood coagulation
tests
TPZ
%
INR
PTT
sec.
Laboratory Results Urine
Urine Specific Gravity
g/ml
Urine pH
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Urine leukocytes
Anz./µl
neg  (neg )
pos (pos)
Urine Nitrite
neg  (neg )
pos (pos)
Urine Protein
mg/dl
neg  (neg )
pos (pos)
Urine Glucose
mg/dl
Urine Ketone Bodies
mg/dl
Urine Urobilinogen
mg/dl
Urine Bilirubin
mg/dl
Urine Erythrocytes
mmol/l
Laboratory Results Urine Analysis FACS
Urine Erythrocytes (FACS)
Anz/l
Urine leukocytes (FACS)
Anz./µl
neg  (neg )
pos (pos)
Urine Epithelial Cells (FACS)
mmol/l
Urine Cylinder Cells (FACS)
mmol/l
Urine Bacteria (FACS)
mmol/l
Urine Crystals  (FACS)
mmol/l
Urine Yeast (FACS)
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mmol/l
Urine Pathological Cylinder (FACS)
mmol/l
Urine Round Epithelial Cell Count (FACS)
mmol/l
Laboratory Results Pregnancy
Pregnancy test result
negative (negative)
positive (positive)
Laboratory Results Thyroid Function Tests
TSH
µU/ml
Laboratory Results Calculated
eGFR
Laboratory Results CSF Cell Count
Location of CSF puncture
Cerebrospinal Fluid Consistency
CSF Cell Count: Lymphocytes
/µl
CSF Cell Count: Granulocytes
/µl
CSF Cell Count: Erythrocytes
/µl
CSF Cell Count: Other Cells
/µl
CSF Cell Count: Total Cell Count
/µl
Laboratory Results CSF Flow Cytometry
CSF Flow Cytometry: CD4/CD8 Ratio
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CSF Flow Cytometry: HLA-DR pos CD4
Tsd/µl
CSF Flow Cytometry: HLA-DR pos CD8
Tsd/µl
CSF Flow Cytometry: Plasma cells
Laboratory Results CSF Proteins
CSF Proteins: Total Protein
mg/l
CSF Protein: Albumin
mg/l
CSF Protein: Albumin Serum
g/l
CSF Protein: Albumin cerebrospinal fluid/serum
ratio
CSF Protein: IgG in CSF
mg/l
CSF Protein: IgG Serum measurement
g/l
CSF Protein: IgG Ratio Serum/CSF
CSF Protein: IgA
mg/l
IgA measurement
g/l
CSF Protein: IgA Ratio
CSF Protein: IgM in CSF
mg/l
Immunoglobulin M measurement
g/l
CSF Protein: IgM Ratio
Oligoclonal Bands IgG
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Oligoclonal Bands Type 3
Laboratory Results CSF
CSF: Glucose
mg/dl
Glucose
mg/dl
CSF: Glucose Ratio
CSF: Lactate
mmol/l
CSF: Bilirubin
negative (negative)
positive (positive)
CSF: Hemoglobin
negative (negative)
positive (positive)
CSF: Plasma Cells
negative (negative)
positive  (positive )
CSF: B-Lymphocytes
Tsd/µl
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Baseline: Repitition of Assessments: EDSS
Multiple Sclerosis ALAIN01 NCT02419378
Alemtuzumab in Autoimmune Inflammatory
Neurodegeneration: Mechanisms of Action and
Neuroprotective Potential (ALAIN01)
https://clinicaltrials.gov/ct2/show/NCT02419378
Principal Investigator Prof. Dr. Dr. Sven Meuth, University
Hospital Muenster, Germany
Part: Repitition of Assessments
Please complete the following pages only if Baseline
Assessments
had to be repeated prior to initiation of Lemtrada® (relapse
after first
examination, see Study Protocol 8.1.1.2)
All rights reserved. Please visit https://medical-data-
models.org/forms/15433
Baseline: Repitition of Assessments
EDSS Multiple Sclerosis ALAIN01
NCT02419378
EDSS
Patient ID (derived)
EDSS: Date
EDSS: Visual System Score
0 (0)
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
EDSS: Brainstem System Score
0 (0)
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
EDSS: Pyramidal System Score
0 (0)
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
EDSS: Cerebellar System Score
0 (0)
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
EDSS: Sensory System Score
0 (0)
1 (1)
1 / 2
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
EDSS: Bowel/Bladder System Score
0 (0)
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
EDSS: Cerebral System Score
0 (0)
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
EDSS: Ambulation Score
0 (0)
1 (1)
10 (10)
11 (11)
12 (12)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
7 (7)
8 (8)
9 (9)
EDSS: Cerebellar System Score (X)
X (X)
EDSS Step
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Discharge Letter Items 1146401133
Multiple Sclerosis
Discharge Letter Items for Patient diagnosed with Multiple
Sclerosis from Neurology Department of University Clinic
Muenster Publication granted by PD Dr. Klotz
All rights reserved. Please visit https://medical-data-
models.org/forms/15434
Discharge Letter Items 1146401133
Multiple Sclerosis
Administrative Data
Document ID
Patient`s Name
Date of birth:
Inpatient or Outpatient
Inpatient (Inpatient)
Outpatient (Outpatient)
Dates of Appointment/Stay
Principal Diagnosis
Principal Diagnosis Multiple Sclerosis
Onset
Earliest date of diagnosis
EDSS
Previous Therapy with Interferone Beta 1a (Rebif)
Yes
No
Previous Therapy Benefit during Treatment with
Interferon Beta 1a
Time Range of Previous Therapy with Interferon
Beta 1a  (Rebif)
Previous Therapy Fingolimod
Yes
No
Time Range of Previous Therapy with Fingolimod
Previous Therapie Benefit Fingolimod
1 / 10
Previous Therapy with  Tysabri (Natalizumab)
Yes
No
Time Range of Previous Therapy with Tysabri
Previous Therapie Benefit during Treatment with
Tysabri (Natalizumab)
Current Therapy with Lemtrada (Alemtuzumab)
Yes
No
Dosage of Alemtuzumab
mg/d
Alemtuzumab Duration of Therapy
d
Recurrent optic neuritis
Yes
No
Secondary Diagnosis
Tension Headache
Yes
No
Migraine without aura
Yes
No
Depression
Yes
No
Summary and Assessment
Introduction: Reason for current Admission
Introduction: Department
Medical history
Current Symptoms
Previous Therapy with  Tysabri (Natalizumab)
Yes
No
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Time Range of Previous Therapy with Tysabri
Previous Therapie Benefit during Treatment with
Tysabri (Natalizumab)
MRI findings of last MRI
Previous glucocorticoid treatment
Yes
No
Hypesthesia Upper Extremity
Orientation
Neurological Examination
Prophylactic Treatment of Herpesvirus Infections
with Aciclovir
Yes
No
Prophylactic Treatment with Azithromycin
Yes
No
Current Therapy with Lemtrada (Alemtuzumab)
Yes
No
Alemtuzumab Duration of Therapy
d
Date of follow up visit
Neurological Examination
Orientation
Meningism
Percussion Pain Skull
Yes
No
Nerve Exit Points painful
Yes
No
Nerve stretch tests
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Neurological Examination: Cranial Nerves
Cranial Nerves: Visus
Pupils Motor abnormal?
Yes
No
Examination of Eye Movement
Facial Sensory Function
Facial Muscles abnormal?
Function of caudal cranial nerves
Waldeyers ring is red as in inflammation
Yes
No
Neurological Examination: Motor
Muscle Tonus
Pareses
latent (latent)
manifest (manifest)
none (none)
Muscle strength (Oxford Scale)
Function of Muscular reflex (MER) on arm
Pyramidal signs
Patellar Reflex
Achilles Reflex
Neurological Examination: Coordination
and Gait
Gait, Manner of walking
Standing, Manner of Standing
Past pointing test findings
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Diadochokinesis abnormal?
Dysdiadochokinesis
(Dysdiadochokinesis)
Eudiadochokinesis (Eudiadochokinesis)
Neurological Examination: Sensibility
Sensibility on neurological exam abnormal?
Yes
No
EDSS
Procedures
Current Immunosuppressive Therapy
Date Follow-Up Visit
Physical Therapy has been recommended?
Yes
No
Recommendation to compare MRI images
Yes
No
Multiple sclerosis relapse during therapy with
Lemtrada
Further diagnostic procedures planned during
hospitalisation
Induction of other therapy to stop MS flare
Adverse effects Alemtuzumab: Acute idiopathic
thrombocytopenic purpura
Adverse effects Alemtuzumab: Nephropathy
Adverse effects Alemtuzumab: Thryoideal
Recommendation to bring differential blood count
Recommendation Urine Analysis
Clinical Presentation ITP
haematoma (haematoma)
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mucosal hemorrhage  (mucosal
hemorrhage )
petechia (petechia)
Date of follow up visit
Prophylactic Treatment of Herpesvirus Infections
with Aciclovir
Yes
No
Aciclovir dosage
mg
Aciclovir Duration of Treatment
d
Study Participation of Immunmonitoring
Yes
No
Due to Listeria Infection during therapy with
amlemtuzumab we recommend to avoid raw milk
products.
Yes
No
Laboratory Results Serum
Sodium Measurement
mmol/l
Potassium
U/L
Calcium
U/L
Cholesterol
mg/dl
Glucose
mg/dl
Uric acid
md/dl
Blood Urea Nitrogen
mg/dl
Creatinin
μmol/l
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Bilirubin Total
mg/dl
AST (SGOT)
U/L
ALT (SGPT)
g/dL
gamma-GT
U/l
Alkaline Phosphatase
md/dl
Lactate Dehydrogenase (LDH)
g/dL
CPK
md/dl
CK MB
md/dl
CRP
md/dl
Laboratory Results Small EDTA
Leucocytes
Tsd/µl
Erythrocytes
Tsd/µl
Haemoglobin
Tsd/µl
Haematocrit
Tsd/µl
Mean Corpuscular Volume
Tsd/µl
MCH
Tsd/µl
Mean corpuscular hemoglobin concentration
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Tsd/µl
Thrombocytes
md/dl
Laboratory Results Differential EDTA
Neutrophils relative
%
Neutrophils absolute
Tsd/µl
Lymphocytes relative
Tsd/µl
Lymphocytes absolute
md/dl
Monocytes relative
Tsd/µl
Monocytes absolute
md/dl
Eosinophils relative
Tsd/µl
Eosinophils absolute
md/dl
Basophils relative
Tsd/µl
Basophils absolute
md/dl
Mean Platelet Volume
fl
Immature Granulocytes
md/dl
Laboratory Results Blood coagulation
tests
TPZ
%
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INR
PTT
sec.
Laboratory Results Urine
Urine Specific Gravity
g/ml
Urine pH
Urine leukocytes
Anz./µl
neg  (neg )
pos (pos)
Urine Nitrite
neg  (neg )
pos (pos)
Urine Protein
mg/dl
neg  (neg )
pos (pos)
Urine Glucose
mg/dl
Urine Ketone Bodies
mg/dl
Urine Urobilinogen
mg/dl
Urine Bilirubin
mg/dl
Urine Erythrocytes
mmol/l
Laboratory Results Urine Analysis FACS
Urine Erythrocytes (FACS)
Anz/l
Urine leukocytes (FACS)
Anz./µl
neg  (neg )
pos (pos)
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Urine Epithelial Cells (FACS)
mmol/l
Urine Cylinder Cells (FACS)
mmol/l
Urine Bacteria (FACS)
mmol/l
Urine Crystals  (FACS)
mmol/l
Urine Yeast (FACS)
mmol/l
Urine Pathological Cylinder (FACS)
mmol/l
Urine Round Epithelial Cell Count (FACS)
mmol/l
Laboratory Results Pregnancy
Pregnancy test result
negative (negative)
positive (positive)
Laboratory Results Thyroid Function Tests
TSH
µU/ml
Laboratory Results Calculated
eGFR
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Discharge Letter Items 1146401133
Multiple Sclerosis
Discharge Letter Items for Patient diagnosed with Multiple
Sclerosis from Neurology Department of University Clinic
Muenster Publication granted by PD Dr. Klotz
All rights reserved. Please visit https://medical-data-
models.org/forms/15435
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Multiple Sclerosis
Administrative Data
Document ID
Patient`s Name
Date of birth:
Inpatient or Outpatient
Inpatient (Inpatient)
Outpatient (Outpatient)
Dates of Appointment/Stay
Principal Diagnosis
Principal Diagnosis Multiple Sclerosis
Onset
Earliest date of diagnosis
EDSS
Previous Therapy with Interferone Beta 1a (Rebif)
Yes
No
Previous Therapy Benefit during Treatment with
Interferon Beta 1a
Time Range of Previous Therapy with Interferon
Beta 1a  (Rebif)
Previous Therapy Fingolimod
Yes
No
Time Range of Previous Therapy with Fingolimod
Previous Therapie Benefit Fingolimod
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Previous Therapy with  Tysabri (Natalizumab)
Yes
No
Time Range of Previous Therapy with Tysabri
Previous Therapie Benefit during Treatment with
Tysabri (Natalizumab)
Current Therapy with Lemtrada (Alemtuzumab)
Yes
No
Dosage of Alemtuzumab
mg/d
Alemtuzumab Duration of Therapy
d
Recurrent optic neuritis
Yes
No
Secondary Diagnosis
Tension Headache
Yes
No
Migraine without aura
Yes
No
Depression
Yes
No
Summary and Assessment
Introduction: Reason for current Admission
Introduction: Department
Medical history
Current Symptoms
Previous Therapy with  Tysabri (Natalizumab)
Yes
No
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Time Range of Previous Therapy with Tysabri
Previous Therapie Benefit during Treatment with
Tysabri (Natalizumab)
MRI findings of last MRI
Previous glucocorticoid treatment
Yes
No
Hypesthesia Upper Extremity
Orientation
Neurological Examination
Prophylactic Treatment of Herpesvirus Infections
with Aciclovir
Yes
No
Prophylactic Treatment with Azithromycin
Yes
No
Current Therapy with Lemtrada (Alemtuzumab)
Yes
No
Alemtuzumab Duration of Therapy
d
Date of follow up visit
Neurological Examination
Orientation
Meningism
Percussion Pain Skull
Yes
No
Nerve Exit Points painful
Yes
No
Nerve stretch tests
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Neurological Examination: Cranial Nerves
Cranial Nerves: Visus
Pupils Motor abnormal?
Yes
No
Examination of Eye Movement
Facial Sensory Function
Facial Muscles abnormal?
Function of caudal cranial nerves
Waldeyers ring is red as in inflammation
Yes
No
Neurological Examination: Motor
Muscle Tonus
Pareses
latent (latent)
manifest (manifest)
none (none)
Muscle strength (Oxford Scale)
Function of Muscular reflex (MER) on arm
Pyramidal signs
Patellar Reflex
Achilles Reflex
Neurological Examination: Coordination
and Gait
Gait, Manner of walking
Standing, Manner of Standing
Past pointing test findings
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Diadochokinesis abnormal?
Dysdiadochokinesis
(Dysdiadochokinesis)
Eudiadochokinesis (Eudiadochokinesis)
Neurological Examination: Sensibility
Sensibility on neurological exam abnormal?
Yes
No
EDSS
Procedures
Current Immunosuppressive Therapy
Date Follow-Up Visit
Physical Therapy has been recommended?
Yes
No
Recommendation to compare MRI images
Yes
No
Multiple sclerosis relapse during therapy with
Lemtrada
Further diagnostic procedures planned during
hospitalisation
Induction of other therapy to stop MS flare
Adverse effects Alemtuzumab: Acute idiopathic
thrombocytopenic purpura
Adverse effects Alemtuzumab: Nephropathy
Adverse effects Alemtuzumab: Thryoideal
Recommendation to bring differential blood count
Recommendation Urine Analysis
Clinical Presentation ITP
haematoma (haematoma)
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mucosal hemorrhage  (mucosal
hemorrhage )
petechia (petechia)
Date of follow up visit
Prophylactic Treatment of Herpesvirus Infections
with Aciclovir
Yes
No
Aciclovir dosage
mg
Aciclovir Duration of Treatment
d
Study Participation of Immunmonitoring
Yes
No
Due to Listeria Infection during therapy with
amlemtuzumab we recommend to avoid raw milk
products.
Yes
No
Laboratory Results Serum
Sodium Measurement
mmol/l
Potassium
U/L
Calcium
U/L
Cholesterol
mg/dl
Glucose
mg/dl
Uric acid
md/dl
Blood Urea Nitrogen
mg/dl
Creatinin
μmol/l
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Bilirubin Total
mg/dl
AST (SGOT)
U/L
ALT (SGPT)
g/dL
gamma-GT
U/l
Alkaline Phosphatase
md/dl
Lactate Dehydrogenase (LDH)
g/dL
CPK
md/dl
CK MB
md/dl
CRP
md/dl
Laboratory Results Small EDTA
Leucocytes
Tsd/µl
Erythrocytes
Tsd/µl
Haemoglobin
Tsd/µl
Haematocrit
Tsd/µl
Mean Corpuscular Volume
Tsd/µl
MCH
Tsd/µl
Mean corpuscular hemoglobin concentration
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Tsd/µl
Thrombocytes
md/dl
Laboratory Results Differential EDTA
Neutrophils relative
%
Neutrophils absolute
Tsd/µl
Lymphocytes relative
Tsd/µl
Lymphocytes absolute
md/dl
Monocytes relative
Tsd/µl
Monocytes absolute
md/dl
Eosinophils relative
Tsd/µl
Eosinophils absolute
md/dl
Basophils relative
Tsd/µl
Basophils absolute
md/dl
Mean Platelet Volume
fl
Immature Granulocytes
md/dl
Laboratory Results Blood coagulation
tests
TPZ
%
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INR
PTT
sec.
Laboratory Results Urine
Urine Specific Gravity
g/ml
Urine pH
Urine leukocytes
Anz./µl
neg  (neg )
pos (pos)
Urine Nitrite
neg  (neg )
pos (pos)
Urine Protein
mg/dl
neg  (neg )
pos (pos)
Urine Glucose
mg/dl
Urine Ketone Bodies
mg/dl
Urine Urobilinogen
mg/dl
Urine Bilirubin
mg/dl
Urine Erythrocytes
mmol/l
Laboratory Results Urine Analysis FACS
Urine Erythrocytes (FACS)
Anz/l
Urine leukocytes (FACS)
Anz./µl
neg  (neg )
pos (pos)
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Urine Epithelial Cells (FACS)
mmol/l
Urine Cylinder Cells (FACS)
mmol/l
Urine Bacteria (FACS)
mmol/l
Urine Crystals  (FACS)
mmol/l
Urine Yeast (FACS)
mmol/l
Urine Pathological Cylinder (FACS)
mmol/l
Urine Round Epithelial Cell Count (FACS)
mmol/l
Laboratory Results Pregnancy
Pregnancy test result
negative (negative)
positive (positive)
Laboratory Results Thyroid Function Tests
TSH
µU/ml
Laboratory Results Calculated
eGFR
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Eligibility Major Depressive Disorder
NCT02332954
Assessment in Work Productivity and the Relationship With
Cognitive Symptoms in Patients With MDD Taking
Vortioxetine; ODM derived from:
https://clinicaltrials.gov/show/NCT02332954
All rights reserved. Please visit https://medical-data-
models.org/forms/15436
Eligibility Major Depressive Disorder
NCT02332954
Inclusion Criteria
the patient is a man or woman, aged ≥18 years
and <65 years (in the province of british
columbia, the patient must be aged 19 years  or
older in order to give informed consent)*
Yes
No
the patient is engaged in volunteer work or
gainful employment (working ≥20 hours per
week) or is enrolled full-time in post-secondary
studies or vocational training.*
Yes
No
the patient is an outpatient consulting a primary
care physician or a psychiatrist.*
Yes
No
patients must have a diagnosis of mdd according
to the diagnostic and statistical manual of mental
disorders, 5th edition (dsm-5™) classification
code 296.3x.*
Yes
No
the current mde is confirmed by the investigator.*
Yes
No
the reported duration of the current mde is at
least 3 months.*
Yes
No
the patient has a baseline score ≥15 on the qids-
sr.*
Yes
No
the patient reports at least a minimal level of
cognitive symptoms as defined by baseline score
of ≥30 on the pdq-d-20.*
Yes
No
the patient is capable of communicating with the
site personnel and is able to conduct the digit-
symbol substitution test (dsst).*
Yes
1 / 2
No
Exclusion Criteria
the patient score is >69 on the dsst at
screening/baseline.*
Yes
No
the patient is, in the opinion of the investigator,
not able to complete all the study assessments
including, but not limited to, patient-reported
assessments and the dsst.*
Yes
No
the patient has a current diagnosis or history of
manic or hypomanic episode, schizophrenia or
any other psychotic disorder, including major
depression with psychotic features.*
Yes
No
the current depressive symptoms are considered
by the investigator to have been resistant to 2
adequate antidepressant treatments of at least 6
weeks duration each at the maximum
recommended dose (according to canadian
labeling).*
Yes
No
other protocol defined inclusion and exclusion
criteria do apply.*
Yes
No
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Eligibility Major Depressive Disorder
NCT02339285
Transcranial alternatinG Current stimuLation for mAjor
Depressive Disorder; ODM derived from:
https://clinicaltrials.gov/show/NCT02339285
All rights reserved. Please visit https://medical-data-
models.org/forms/15438
Eligibility Major Depressive Disorder
NCT02339285
Inclusion Criteria
male or female, 18-65 years old*
Yes
No
dsm-iv diagnosis of mdd; unipolar, non-psychotic*
Yes
No
6 months free of any mdd related medications*
Yes
No
hamilton depression rating scale score >17*
Yes
No
capacity to understand all relevant risks and
potential benefits of the study (informed
consent)*
Yes
No
meet criteria for low suicide risk*
Yes
No
willing to comply with all study procedures and be
available to do so for the duration of the study*
Yes
No
women of reproductive potential must use highly
effective contraception*
Yes
No
Exclusion Criteria
dsm-iv diagnosis of alcohol of substance abuse
(other than nicotine) within the last month or a
dsm-iv diagnosis of alcohol or substance
dependence (other than nicotine) within the last 6
months*
Yes
No
medical or neurological illness (unstable cardiac
disease, aids, malignancy, liver or renal
impairment) or treatment for a medical disorder
that could interfere with study participation*
Yes
1 / 2
No
history of traumatic brain injury, reoccurring
seizures or later cognitive rehabilitation, or
causing cognitive sequelae*
Yes
No
prior brain surgery*
Yes
No
any brain devices/implants, including cochlear
implants and aneurysm clips*
Yes
No
co-morbid neurological condition (i.e. seizure
disorder, brain tumor)*
Yes
No
non english speakers*
Yes
No
pregnancy, nursing, or if female and fertile,
unwilling to use appropriate birth control
measures during study participation*
Yes
No
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SAE documentation AIEOP-BFM ALL 2009
NCT01117441
Study Description Stamm:
International Collaborative Treatment Protocol For Children
And Adolescents With Acute Lymphoblastic Leukemia.
Phase 3 Study. Documentation.
Clinical Trial Number: NCT01117441.
All rights reserved. Please visit https://medical-data-
models.org/forms/15439
SAE documentation AIEOP-BFM
ALL 2009 NCT01117441
Patient Information
Patient Study ID
Patient Date of Birth
Therapy
Specify Protocol I:
Prot. IA (Prot. IA)
Prot. IA-CPM (Prot. IA-CPM)
Prot. IA' (Prot. IA')
Prot. IAD (Prot. IAD)
Prot. IB (Prot. IB)
Prot. IB-ASP+ (Prot. IB-ASP+)
Specify Methotrexate protocol:
1st HD-MTX (1st HD-MTX)
2nd HD-MTX (2nd HD-MTX)
3rd HD-MTX (3rd HD-MTX)
4th HD-MTX (4th HD-MTX)
Specify Protocol II:
Prot. IIA (Prot. IIA)
Prot. IIA-ASP+ (Prot. IIA-ASP+)
Prot. IIB (Prot. IIB)
Prot. IIB-ASP+ (Prot. IIB-ASP+)
Specify high risk block:
DNX-FLA (DNX-FLA)
HR-1' (HR-1')
HR-2' (HR-2')
HR-3' (HR-3')
Specify interval therapy:
1st interval therapy (1st interval therapy)
2nd interval therapy (2nd interval
therapy)
Specify maintenance therapy:
Maintenance therapy (Maintenance
therapy)
Specify other therapeutic aspects:
Therapy start date
1 / 4
Severe adverse event: reported SAE must
meet criteria 1) at least one of the
following (a) death of patient, b) life-
threatening, c) not planned hospitalization
or necessary prelongiation of stay, d...
Severe adverse event:
Infection
Yes
No
Severe adverse event:
Infection:
If "Yes", has it been reported?
Yes
No
Severe adverse event:
Pancreas
Yes
No
Severe adverse event:
Pancreas: 
If "Yes", has it been reported?
Yes
No
Severe adverse event:
Thrombosis
Yes
No
Severe adverse event: 
Thrombosis: 
If "Yes", has it been reported?
Yes
No
Severe adverse event: 
Liver
Yes
No
Severe adverse event: 
Liver: 
If "Yes", has it been reported?
Yes
No
Severe adverse event: 
Neurologic/ Psychologic aspects
Yes
No
Severe adverse event: 
Neurologic/ Psychologic aspects: 
If "Yes", has it been reported?
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Yes
No
Severe adverse event: 
Gastrointestinal aspects
Yes
No
Severe adverse event: 
Gastrointestinal aspects: 
If "Yes", has it been reported?
Yes
No
Severe adverse event: 
Dermatologic aspects
Yes
No
Severe adverse event: 
Dermatologic aspects: 
If "Yes", has it been reported?
Yes
No
Severe adverse event: 
Cardiac aspects
Yes
No
Severe adverse event: 
Cardiac aspects: 
If "Yes", has it been reported?
Yes
No
Severe adverse event: 
Renal aspects
Yes
No
Severe adverse event: 
Renal aspects: 
If "Yes", has it been reported?
Yes
No
Severe adverse event: 
Metabolic/ endocrinologic aspects
Yes
No
Severe adverse event: 
Metabolic/ endocrinologic aspects: 
If "Yes", has it been reported?
Yes
No
Severe adverse event: 
Drug intolerance
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Yes
No
Severe adverse event: 
Drug intolerance: 
If "Yes", has it been reported?
Yes
No
Severe adverse event: 
Skeleton aspects
Yes
No
Severe adverse event: 
Skeleton aspects: 
If "Yes", has it been reported?
Yes
No
Severe adverse event: 
Not classified aspects
Yes
No
Severe adverse event: 
Not classified aspects: 
If "Yes", has it been reported?
Yes
No
Identification and Signature
Date of report
Docotor's name
Doctor's signature
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Eligibility Major Depressive Disorder
NCT02348827
Family Psychoeducation to Reduce the Risk of New
Depressive Episodes; ODM derived from:
https://clinicaltrials.gov/show/NCT02348827
All rights reserved. Please visit https://medical-data-
models.org/forms/15440
Eligibility Major Depressive Disorder
NCT02348827
Criteria
Inclusion Criteria
age between 18 and 75*
Yes
No
major depression diagnosis according to the icd-
10 established by a board certified psychiatrist
and verified by the mini international
neuropsychiatric interview*
Yes
No
currently in remission or partial remission defined
as ham-d17<13*
Yes
No
living together , or in very regular contact (every
day or almost every day), with an adult relative
that the patient considers as emotionally
important  and who are available for intervention*
Yes
No
Exclusion Criteria
insufficient knowledge of danish*
Yes
No
clinical suspicion of dementia*
Yes
No
alcohol, drug or medicine abuse*
Yes
No
psychotic symptoms*
Yes
No
co-morbidity of severe personality disorder*
Yes
No
having undergone ect treatment during the index
depressive episode*
Yes
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No
maximum duration of the current depressive
episode may not exceed 2 years*
Yes
No
maximum duration of a period with stable
remission may not exceed 3 consecutive months*
Yes
No
regarding to the relatives following criteria for
participation apply:*
Yes
No
Inclusion Criteria
• age between 18 and 75*
Yes
No
Exclusion Criteria
• insufficient knowledge of danish*
Yes
No
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COVER PAGE FOR HISTOCOMPATIBILITY
REPORTS
ODM form derived from COVER PAGE FOR
HISTOCOMPATIBILITY REPORTS 
please refer to: http://www.ebmt.org/Contents/Data-
Management/Registrystructure/MED-
ABdatacollectionforms/Pages/MED-AB-data-collection-
forms.aspx
All rights reserved. Please visit https://medical-data-
models.org/forms/15441
COVER PAGE FOR
HISTOCOMPATIBILITY REPORTS
CENTRE IDENTIFICATION
EBMT Centre Identification Code (CIC)
Hospital
Hospital Units
Contact person
Contact Person E-Mail
PATIENT IDENTIFICATION
Has the HSCT been registered in the EBMT
database ?
Yes
No
Hospital Unique Patient Number/ Code
Initials
Gender
Male (1)
Female (2)
Date of Birth
Date of HSCT
DONOR
Identification of donor or Cord Blood Unit given
by the centre
Footer module
Study contact
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Documentation of therapy toxicity AIEOP-
BFM ALL 2009 NCT01117441
Study Description Stamm:
International Collaborative Treatment Protocol For Children
And Adolescents With Acute Lymphoblastic Leukemia.
Phase 3 Study. Documentation of therapy toxicity.
Clinical Trial Number: NCT01117441.
All rights reserved. Please visit https://medical-data-
models.org/forms/15442
Documentation of therapy toxicity
AIEOP-BFM ALL 2009
NCT01117441
Patient Information
Patient Study ID
Patient Date of Birth
Therapy
Randomization group 1: 2 vs 4 doses of
Daunorubicin in Protc. IA
Prot. IA (Prot. IA)
Prot. IA' (Prot. IA')
Start date of documentation (day 22 in protocol
IA/IA')
End date of documentation (day before start of
protocol IB)
Blood analysis (performed on day 22 of
protocol IA/IA')
Haemoglobin
g/dL
White blood count
/μl
Granulocyte measurement
/μl
Platelets measurement
Toxicity
Haemoglobin measurement performed?
Yes
No
If Haemoglobin measurement performed, specify
toxicity grade:
0-2 (≥ 8.0 g/dL) (0-2 (≥ 8.0 g/dL))
3 (6.5 -< 8.0 g/dL) (3 (6.5 -< 8.0 g/dL))
4 (< 6.5 g/dL) (4 (< 6.5 g/dL))
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White blood count measurement performed?
Yes
No
If White blood count performed, specify toxicity
grade:
0-2 (≥ 2.0 Gp/L) (0-2 (≥ 2.0 Gp/L))
3 (1.0 -< 2.0 Gp/L) (3 (1.0 -< 2.0 Gp/L))
4 (< 1.0 Gp/L) (4 (< 1.0 Gp/L))
Granulocyte measurement performed?
Yes
No
If Granulocyte measurement performed, specify
toxicity grade:
0-2 (≥ 1.0 Gp/L) (0-2 (≥ 1.0 Gp/L))
3 (0.5 -< 1.0 Gp/L) (3 (0.5 -< 1.0 Gp/L))
4 (< 0.5 Gp/L) (4 (< 0.5 Gp/L))
Platelets measurement performed?
Yes
No
If Platelets measurement performed, specify
toxicity grade:
0-2 (≥ 50 Gp/L) (0-2 (≥ 50 Gp/L))
3 (10 -< 50 Gp/L) (3 (10 -< 50 Gp/L))
4 (< 10 Gp/L) (4 (< 10 Gp/L))
Numbers of days in aplasia (leukopenia) during
the period from day 22 in Prot. IA/IA' to start of
Protocol IB)
Leukozytes < 1000/μl
days
Numbers of days in aplasia (leukopenia) during
the period from day 22 in Prot. IA/IA' to start of
Protocol IB) 
Granulocytes < 500/μl
Examination for stomatits performed?
Yes
No
If examination for stomatitis performed, specify
toxicity grade:
0-2 (no painless/ painful ulcera, eating
still possible) (0-2 (no painless/ painful
ulcera, eating still possible))
3 (painful ulcera, eating not possible) (3
(painful ulcera, eating not possible))
4 (parenteral nutrition necessary due to
stomatitis) (4 (parenteral nutrition
necessary due to stomatitis))
Comments
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Documentation of therapy toxicity AIEOP-BFM ALL 2009 NCT01117441
Comments
Identification and Signature
Doctor's name
Date of report
Doctor's signature
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EBMT Donor Outcome Report on donation
procedure and up to 30 days after
reference: http://www.ebmt.org/Contents/Data-
Management/Registrystructure/MED-
ABdatacollectionforms/Pages/MED-AB-data-collection-
forms.aspx
All rights reserved. Please visit https://medical-data-
models.org/forms/15443
EBMT Donor Outcome Report on
donation procedure and up to 30
days after
Report
Report on donation procedure and up to 30 days
after
TRANSPLANT CENTRE AND
RECIPIENT IDENTIFICATION
EBMT CIC
EBMT database number
Center of HSCT
Hospital/ unit
Unique Patient Number or Code
Initials
Date of birth
Date of HSCT
PRODUCT
Bone marrow
Yes
No
PBSC
Yes
No
Both BM and PBSC
Yes
No
Unstimulated leukapheresis
Yes
No
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other specify product
DONOR DATA
Donor number/ID
Donor signed Informed consent for data
transmission to the EBMT Registry
Yes
No
Initials
Relationship to recipient
syngeneic (identical twin) (1)
identical sibling/non identical twin (2)
other family member: matched (3)
unmatched (4)
unrelated donor (unrelated donor)
Describe relation to the recipient
Date of Birth
Sex
Male (1)
Female (2)
DONATION PROCEDURE
First day of this collection
COLLECTION DATA
EBMT Code (CIC)
Collection center
Donor registry or CB bank
Contact person
Date of this report
Start date of donation procedure
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EBMT Donor Outcome Report on donation procedure and up to 30 days
after
Chronological Number of this donation procedure
Number (1)
If > 1: Same recipient: (2)
Yes (3)
No (4)
Centre of previous donation
Date of previous donation
Was the product collection completed
Yes
No
Were haematopoietic growth factors used
Yes
No
Were cell binding inhibitors used?
Yes (1)
No (2)
If yes, specify: (3)
Was erythropoietin used
Yes
No
Were other drugs used for mobilization
Yes
No
COMPLICATIONS in temporal association
with the donation procedure
Serious Adverse Events (SAE/SAR)
yes (1)
no (2)
unknown (3)
ICD 10 Coding Serious Adverse Events
(SAE/SAR) if yes (4)
Date of the SAE/SAR
DONOR BEHAVIOUR
Would the donor donate again
Yes
No
If no: reason
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EBMT Donor Outcome Report on donation procedure and up to 30 days
after
Discharge Letter Items 1132945139
Multiple Sclerosis
Discharge Letter Items for Patient diagnosed with Multiple
Sclerosis from Neurology Department of University Clinic
Muenster
All rights reserved. Please visit https://medical-data-
models.org/forms/15444
Discharge Letter Items 1132945139
Multiple Sclerosis
Administrative Data
Document ID of Discharge Letter
Patient`s Name
Patients date of birth
Inpatient or Outpatient
Inpatient (Inpatient)
Outpatient (Outpatient)
Date of Appointment/Stay
Principal Diagnosis
Principal Diagnosis Multiple Sclerosis
Earliest date of diagnosis
Onset
EDSS
Number of T2-hyperintense Lesions in cMRT
Localisation of Lesions
Date of Finding of Lesion
Cerebrospinal fluid
Oligoclonal Bands
negative (negative)
positive  (positive )
Current Immunosuppressive Therapy
Date of start of therapy Dimethylfumarat
(Tecfidera)
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Does the patient participate in a study ?
Yes
No
Current Therapy with Dimethylfumarat (Tecfidera)
Yes
No
Secondary Diagnosis
Factor V Leiden mutation?
Yes
No
Thrombosis of vein of lower leg
Yes
No
Reason for Admission
Reason for admission
Summary and Assessment
Introduction: Reason for current Admission
Introduction: Department
Current Immunosuppressive Therapy
Adverse Effect
Current Symptoms
Neurological Examination
Therapeutic Attempt
SEP (Somatosensory Evoked Potentials)
Results of further investigations
Walking Distance
km
Neurologic Symptoms
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Discharge Letter Items 1132945139 Multiple Sclerosis
Clinical Findings
Follow-up MRI
Procedures
Therapy Recommendation
Differential blood count
Neurological Exam
Date Follow-Up Visit
MRI Follow-Up
Medication
Medication Name
Medication Trade Name
Drug Dosage
mg
Amount of Medication
Neurological Examination
Orientation
Meningism
Nerve stretch tests
Lhermitte's sign
negative (negative)
positive (positive)
Percussion Pain Spine
Yes
No
Percussion Pain Skull
Yes
No
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Visus measurement
Examination of Eye Movement
Nystagmus Test
Gaze Palsy
Diplopia
Visual Field Fingerperimetric
Pupils Size
Pupils regularity
Pupils reaction
Direct pupil reaction to light
Consensual pupil reaction to light
Trigeminal Sensory Function
Facial Paralysis
Function of caudal cranial nerves
Function of Muscular reflex
Can an Ankle Clonus be provoked?
Upper motor neuron signs
Pronator Drift Test
Leg drift test
Palsy dorsiflexion
Muscle strength (Oxford Scale)
0/5 (0/5)
1/5 (1/5)
2/5 (2/5)
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3/5 (3/5)
4/5 (4/5)
5/5 (5/5)
Paralysed knee flexion
Muscle strength Knee flexion (Oxford Scale)
Spastic Gait
both sides (both sides)
left side (left sides)
right side (right sides)
Toe-walking gait possible
Heel to toe gait possible
Heel Gait possible
One Leg Jump possible
Finger-to-nose test abnormal?
Heel-to-knee test abnormal?
Diadochokinesis abnormal?
Dysdiadochokinesis
(Dysdiadochokinesis)
Eudiadochokinesis (Eudiadochokinesis)
Pallesthesia
Yes
No
Location of Pallesthesia
left (left)
right  (right )
Grade of Pallesthesia
0/8 (0/8)
1/8 (1/8)
2/8 (2/8)
3/8 (3/8)
4/8 (4/8)
5/8 (5/8)
6/8 (6/8)
7/8 (7/8)
8/8 (8/8)
Rhomberg Test abnormal?
Aphasia?
Yes
No
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Apraxia?
Neglect
Yes
No
Laboratory results
Date of Blood Sample
Laboratory Results Serum
Sodium Measurement
mmol/l
Potassium
mmol/l
Calcium
mmol/l
Chloride
mmol/l
Phosphate
mmol/l
Glucose
mg/dl
Blood Urea Nitrogen
mg/dl
Creatinin
μmol/l
Bilirubin Total
mg/dl
AST (SGOT)
U/l
Alanine transaminase (ALT) (SGPT)
U/l
gamma-GT
U/l
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Discharge Letter Items 1132945139 Multiple Sclerosis
Alkaline Phosphatase
U/l
Albumin
g/dl
Laboratory Results Small EDTA
Leucocytes
Tsd/µl
Erythrocytes
Mio/μl
Haemoglobin
g/dl
Haematocrit
%
Mean Corpuscular Volume
fl
MCH
pg
Mean corpuscular hemoglobin concentration
g/dl
Thrombocytes
Tsd/µl
Laboratory Results Differential EDTA
Neutrophils relative
%
Neutrophils absolute
Tsd/µl
Lymphocytes relative
%
Lymphocytes absolute
Tsd/µl
Monocytes relative
%
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Monocytes absolute
Tsd/µl
Eosinophils relative
%
Eosinophils absolute
Tsd/µl
Basophils relative
%
Basophils absolute
Tsd/µl
Mean Platelet Volume
fl
Immature Granulocytes
Tsd/µl
Laboratory Results Urine
Urine Specific Gravity
g/ml
Urine pH
Urine leukocytes
Anz./µl
neg  (neg )
pos (pos)
Urine Nitrite
neg (neg)
pos (pos)
Urine Protein
mg/dl
neg (neg)
pos (pos)
Urine Glucose
mg/dl
Urine Ketone Bodies
mg/dl
Urine Urobilinogen
mg/dl
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Urine Bilirubin
mg/dl
Urine Erythrocytes
Anz./µl
Laboratory Results Calculated
eGFR (CKD-EPI)
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Discharge Letter Items -31562 Multiple
Sclerosis
Discharge Letter Items for Patient diagnosed with Multiple
Sclerosis from Neurology Department of University Clinic
Muenster Publication granted by PD Dr. Klotz
All rights reserved. Please visit https://medical-data-
models.org/forms/15447
Discharge Letter Items -31562
Multiple Sclerosis
Administrative Data
Document ID of Discharge Letter
Patient`s Name
Patients date of birth
Inpatient or Outpatient
Inpatient (Inpatient)
Outpatient (Outpatient)
Date of Appointment/Stay
Principal Diagnosis
Principal Diagnosis Multiple Sclerosis
Onset
Earliest date of diagnosis
EDSS
Previous Therapy with  Tysabri (Natalizumab)
Yes
No
Previous Therapy Benefit during Treatment with
Tysabri (Natalizumab)
Time Range of Previous Therapy with Tysabri
Previous Therapy Fingolimod
Yes
No
Previous Therapy Benefit Fingolimod
Time Range of Previous Therapy with Fingolimod
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Reason for Admission
Reason for admission
Summary and Assessment
Introduction: Reason for current Admission
Introduction: Department
Medical history
Current Symptoms
Current Immunosuppressive Therapy with Steroid
Immunosuppressive Therapy: Fingolimod
Immunosuppressive Therapy: Alemtuzumab
Adverse Effect
Neurological Examination
Therapeutic Procedure during hospital stay
Therapy Benefit of Therapie during hospital stay
Patient has been informed about therapeutic
recommendation
Procedures
Therapy Recommendation
Date of start of treatment
MRI Follow-Up
Medication on Discharge
Medication name
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Date of discharge
Long-Term Medication
Name of Long-Term Medication
Neurological Examination
Orientation
Meningism
Lhermitte's sign
negative (negative)
positive (positive)
Pupils reaction
Examination of Eye Movement
Diplopia
Facial Paralysis
Trigeminal Sensory Function
Trophic change of Tongue
Soft Palate Movement
Muscle strength of arm
0/5 (0/5)
1/5 (1/5)
2/5 (2/5)
3/5 (3/5)
4/5 (4/5)
5/5 (5/5)
Muscle strength Lower Extremity
0/5 (0/5)
1/5 (1/5)
2/5 (2/5)
3/5 (3/5)
4/5 (4/5)
5/5 (5/5)
Pronator Drift Test
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Leg drift test
Babinski Reflex
Pallesthesia
Yes
No
Location of Pallesthesia
left (left)
right  (right )
Grade of Pallesthesia
0/8 (0/8)
1/8 (1/8)
2/8 (2/8)
3/8 (3/8)
4/8 (4/8)
5/8 (5/8)
6/8 (6/8)
7/8 (7/8)
8/8 (8/8)
Function of Muscular reflex
MRI Result
Date of MRI
Number of T2-hyperintense Lesions in cMRT
Localisation of Lesions
Date of Finding of Lesion
Criteria Dissemination in Time
Yes
No
Criteria Dissemination in Space
Yes
No
Laboratory results
Date of Blood Sample
Laboratory Results Serum
Sodium Measurement
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mmol/l
Potassium
mmol/l
Glucose
mg/dl
Creatinin
μmol/l
AST (SGOT)
U/l
gamma-GT
U/l
Lactate Dehydrogenase (LDH)
U/l
Creatin Kinase
U/l
C-Reactive Protein Measurement
mg/dl
Laboratory Results Small EDTA
Leucocytes
Tsd/µl
Erythrocytes
Mio/μl
Haemoglobin
g/dl
Haematocrit
%
Mean Corpuscular Volume
fl
MCH
pg
Mean corpuscular hemoglobin concentration
g/dl
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Thrombocytes
Tsd/µl
Laboratory Results Blood coagulation
tests
TPZ
%
International Normalization Ratio (INR)
PTT
seconds
Laboratory Results Thyroid Function Tests
TSH
µU/ml
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Eligibility Major Depressive Disorder
NCT02356107
5-hydroxytryptophan and Creatine for Treatment Resistant
Depression Associated With Hypoxia in Females; ODM
derived from: https://clinicaltrials.gov/show/NCT02356107
All rights reserved. Please visit https://medical-data-
models.org/forms/15448
Eligibility Major Depressive Disorder
NCT02356107
Inclusion Criteria
female gender, ages 18-64 years inclusive*
Yes
No
current diagnosis of major depressive disorder
identified by the scid-5-ct*
Yes
No
current ham-d17 score of > 15*
Yes
No
adequate adherence to any fda approved ssri for
at least 8 weeks*
Yes
No
Exclusion Criteria
diagnosis of bipolar disorder, schizophrenia, or
schizoaffective disorder, identified by the scid-5-
ct*
Yes
No
history of or current diagnosis of renal disease,
such as chronic renal failure, acute renal failure
or end stage renal disease*
Yes
No
diabetes type i or ii*
Yes
No
colitis or diverticulitis*
Yes
No
history of pulmonary disease*
Yes
No
history of fibromyalgia, lupus, eosinophilia
myalgia syndrome, dermatomyositis,
polymyositis, rheumatoid arthritis, psoriatic
arthritis, mixed connective tissue disease,
ankylosing spondylitis, or other related
rheumatological condition*
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Yes
No
seizure disorder*
Yes
No
current serious suicide risk identified by the
columbia severity suicide rating scale*
Yes
No
current treatment with an antipsychotic, mood
stabilizer, or non-ssri antidepressant*
Yes
No
positive pregnancy test*
Yes
No
previous diagnosis of serotonin syndrome*
Yes
No
use of any excluded drugs or medications
including serotonergic drugs or medications*
Yes
No
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Eligibility Major Depressive Disorder
NCT02361684
e-Compared-S: Comparative Effectiveness Research on
Internet-based Depression Treatment - Spanish Trial; ODM
derived from: https://clinicaltrials.gov/show/NCT02361684
All rights reserved. Please visit https://medical-data-
models.org/forms/15449
Eligibility Major Depressive Disorder
NCT02361684
Inclusion Criteria
being 18 years of age or older*
Yes
No
meet dsm-iv diagnostic criteria for mdd confirmed
by mini international neuropsychiatric interview
version 5.0*
Yes
No
a score a score of 5 or higher on the phq-9
screening questionnaire.*
Yes
No
Exclusion Criteria
current high risk for suicide according to the mini
interview section c*
Yes
No
serious psychiatric co-morbidity: substance
dependence, bipolar affective disorder, psychotic
illness, obsessive compulsive disorder, as
established at the mini interview*
Yes
No
currently receiving psychological treatment for
depression in primary or specialised mental
health care*
Yes
No
being unable to comprehend the spoken and
written language (spanish)*
Yes
No
not having access to a pc and fast internet
connection (i.e. broadband or comparable).*
Yes
No
not having a smartphone that is compatible with
the mobile component of the intervention that is
offered or not willing to carry a smartphone
during the duration of treatment*
Yes
No
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EBMT Donor outcome Long term follow up
report after last donation procedure
reference: http://www.ebmt.org/Contents/Data-
Management/Registrystructure/MED-
ABdatacollectionforms/Pages/MED-AB-data-collection-
forms.aspx
All rights reserved. Please visit https://medical-data-
models.org/forms/15450
EBMT Donor outcome Long term
follow up report after last donation
procedure
Donor outcome Long term follow up report
after last donation procedure
Long term follow up report after last donation
procedure
TRANSPLANT CENTRE AND
RECIPIENT IDENTIFICATION
EBMT CIC
EBMT database number
Center of HSCT
Hospital/unit
Unique Patient Number or Code
Initials
Date of birth
Date of HSCT
COLLECTION CENTRE
IDENTIFICATION
EBMT Code (CIC)
Collection center
Registry:
Contact person
PRODUCT
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BM (Including collection of MSC)
Yes
No
PBSC
Yes
No
Both (BM and PBSC)
Yes
No
Unstimulated leukapheresis
Yes
No
other specify product
DONOR DATA
Donor number/ID
Donor signed Informed consent for data
transmission to
the EBMT Registry
Yes
No
Initials
Relationship to recipient
syngeneic (identical twin) (1)
identical sibling/non identical twin (2)
other family member (3)
matched (4)
unmatched (5)
unrelated donor (6)
Describe relation to the recipient
Donor date of birth
Sex
Male (1)
Female (2)
FOLLOW UP OR DEATH REPORT
Date of last follow up or death
Date of follow up report
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EBMT Donor outcome Long term follow up report after last donation
procedure
SAE/SAR SINCE LAST REPORT
Hematological malignancy?
no (1)
yes (2)
unknown (3)
If yes: ICD 10 Code
Date of the SAE/SAR
Confirmed by medical data
no (1)
yes  (2)
unknown (3)
Non-hematological malignancy?
no (1)
yes (2)
unknown (3)
if yes: ICD 10 Code
Date of the SAE/SAR
Confirmed by medical data
no (no)
unknown (unknown)
yes (yes)
DONOR STATUS ON THIS DATE
Donor Alive
Yes
No
Donor Dead
Donation related death
no (1)
yes (2)
unknown (3)
ICD 10 code for main cause of death
ICD 10 code(s) for contributory causes of death
Describe below the cause of death if necessary
Check here if donor lost to follow up
Yes
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EBMT Donor outcome Long term follow up report after last donation
procedure
No
DONOR BEHAVIOUR
Would the donor donate again?
no (1)
yes (2)
unknown (3)
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EBMT Donor outcome Long term follow up report after last donation
procedure
EBMT Donor outcome Long term follow up
report after last donation procedure
reference: http://www.ebmt.org/Contents/Data-
Management/Registrystructure/MED-
ABdatacollectionforms/Pages/MED-AB-data-collection-
forms.aspx
All rights reserved. Please visit https://medical-data-
models.org/forms/15451
EBMT Donor outcome Long term
follow up report after last donation
procedure
Donor outcome Long term follow up report
after last donation procedure
Long term follow up report after last donation
procedure
TRANSPLANT CENTRE AND
RECIPIENT IDENTIFICATION
EBMT CIC
EBMT database number
Center of HSCT
Hospital/unit
Unique Patient Number or Code
Initials
Date of birth
Date of HSCT
COLLECTION CENTRE
IDENTIFICATION
EBMT Code (CIC)
Collection center
Registry:
Contact person
PRODUCT
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BM (Including collection of MSC)
Yes
No
PBSC
Yes
No
Both (BM and PBSC)
Yes
No
Unstimulated leukapheresis
Yes
No
other specify product
DONOR DATA
Donor number/ID
Donor signed Informed consent for data
transmission to
the EBMT Registry
Yes
No
Initials
Relationship to recipient
syngeneic (identical twin) (1)
identical sibling/non identical twin (2)
other family member (3)
matched (4)
unmatched (5)
unrelated donor (6)
Describe relation to the recipient
Donor date of birth
Sex
Male (1)
Female (2)
FOLLOW UP OR DEATH REPORT
Date of last follow up or death
Date of follow up report
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EBMT Donor outcome Long term follow up report after last donation
procedure
SAE/SAR SINCE LAST REPORT
Hematological malignancy?
no (1)
yes (2)
unknown (3)
If yes: ICD 10 Code
Date of the SAE/SAR
Confirmed by medical data
no (1)
yes  (2)
unknown (3)
Non-hematological malignancy?
no (1)
yes (2)
unknown (3)
if yes: ICD 10 Code
Date of the SAE/SAR
Confirmed by medical data
no (no)
unknown (unknown)
yes (yes)
DONOR STATUS ON THIS DATE
Donor Alive
Yes
No
Donor Dead
Donation related death
no (1)
yes (2)
unknown (3)
ICD 10 code for main cause of death
ICD 10 code(s) for contributory causes of death
Describe below the cause of death if necessary
Check here if donor lost to follow up
Yes
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No
DONOR BEHAVIOUR
Would the donor donate again?
no (1)
yes (2)
unknown (3)
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EBMT Donor outcome Long term follow up report after last donation
procedure
Eligibility Major Depressive Disorder
NCT02366364
Study of Safety, Tolerability and Pharmacokinetics of NRX-
1074 in Normal Healthy Volunteers; ODM derived from:
https://clinicaltrials.gov/show/NCT02366364
All rights reserved. Please visit https://medical-data-
models.org/forms/15453
Eligibility Major Depressive Disorder
NCT02366364
Inclusion Criteria
male and female subjects*
Yes
No
aged 18 to 55 years*
Yes
No
for female subjects, surgically sterile or at least 2
years menopausal, or using an acceptable
method of birth control.  if of childbearing
potential, have a documented negative blood or
urine pregnancy test within 24 hours prior to
dosing.*
Yes
No
clinical laboratory values <2 times upper limit of
normal (uln) or deemed not clinically significant
by the investigator*
Yes
No
ability to understand the requirements of the
study, provide written informed consent, abide by
the study restrictions, and agree to return for the
required assessments*
Yes
No
Exclusion Criteria
human immunodeficiency virus (hiv) infection, or
hepatitis or other ongoing infectious disease.*
Yes
No
current evidence of alcohol abuse (greater than 4
units of alcohol on most days; 1 unit = 1/2 pint of
beer, 1 glass of wine or 1 oz. of spirits), or in the
option of the investigator that subject may be
alcoholic.*
Yes
No
current abuse of illicit substances, using the
diagnostic and statistical manual (dsm) iv
definition of drug abuse.*
Yes
No
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current smoker or use of other tobacco products.*
Yes
No
currently pregnant, planning to become pregnant
during the course of the study, or nursing
mother.*
Yes
No
type i or type ii diabetes.*
Yes
No
malignancy in the last 5 years, with the exception
of nonmetastatic basal cell or squamous  cell
carcinoma of the skin or localized carcinoma in
situ of the cervix.*
Yes
No
currently taking prescription or over-the-counter
medications including herbal therapies, within 14
days of enrollment into the study.*
Yes
No
history of allergy, sensitivity, or intolerance to
nmdar ligands including ketamine,
dextromethorphan, memantine, methadone,
dextropropoxyphene, or ketobemidone or
concomitant use of such agents.*
Yes
No
received another investigational drug  or device
within 30 days of enrollment in this study.*
Yes
No
previously participated in this study.*
Yes
No
psychiatric disease including major depression,
bipolar disorder, anxiety, or schizophrenia, or
other medical condition that, in the opinion of the
investigator, would interfere with the evaluation of
the study drug safety.  13) in the option of the
investigator or the sponsor's study monitor, has a
history of severe renal or hepatic impairment,
severe active hepatic disease, or other clinically
significant medical condition that may preclude
safe study participation.*
Yes
No
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NINDS CDE General Health History
Headache
NINDS Common Data Elements (General Health History;
Headache) Used from the National Institute of Neurological
Disorders and Stroke Common Data Elements
(https://www.commondataelements.ninds.nih.gov/)
References: Grinnon ST, Miller K, Marler JR, Lu Y, Stout A,
Odenkirchen J, Kunitz S. National Institute of Neurological
Disorders and Stroke Common Data Element Project -
approach and methods. Clin Trials. 2012;9(3):322-9.
All rights reserved. Please visit https://medical-data-
models.org/forms/15454
General Health History
Medical and Family History
Study ID
Study site name
Subject ID
Indicate how the medical/family history
information was obtained
Participant/Subject (1)
Family, specify relation: (2)
Unknown (3)
Information source:please specify relation to
family member
Biological Mother (1 )
Full biologic child Female (10 )
Half-Sibling Male (11 )
Half-Sibling Female  (12 )
Maternal Grandmother (13 )
Maternal Grandfather (14 )
Paternal Grandmother (15)
Paternal Grandfather (16 )
Maternal Aunt (17 )
Maternal Uncle (18 )
Paternal Aunt (19 )
Biological Father (2 )
Paternal Uncle (20 )
Grandchild Male (21 )
Grandchild Female (22 )
Nephew (23 )
Niece (24 )
Sibling Male (3 )
Sibling Female (4 )
Non-identical or dizygotic twin Male (5 )
Non-identical or dizygotic twin Female (6
)
Identical twin Male (7 )
Identical twin Female (8 )
Full biologic child Male (9 )
Are you adopted?
Yes (1)
No (2)
Unknown (3)
Total number of first degree relatives
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If total number of first degree relatives is
unknown,please specify
Number of first degree relatives alive
Number of first degree relatives alive is unknown
Yes
No
Number of first degree relatives deceased
Number of first degree relatives deceased is
unknown
Yes
No
Total number of second-degree relatives
If total number of second degree relatives is
unknown, please specify
Number of second degree relatives alive
Number of second degree relatives alive is
unknown
Yes
No
Number of second degree relatives deceased
Number of second degree relatives deceased is
unknown
Yes
No
First degree relatives: Number unknown
information
Second degree relatives: number unknown
information
Do you have a history of cancer?
Yes (1)
No (2)
Unknown (3)
Does a relative (1st/2nd degree only) have a
history of cancer?
Yes (1)
No (2)
Unknown (3)
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NINDS CDE General Health History Headache
Number of first-degree relatives affected
Number of first degree relatives with physicians
diagnosis
Relationship of first-degree relative(s) to
participant/subject
Biological Mother (1 )
Full biologic child Female (10 )
Biological Father (2 )
Sibling Male (3 )
Sibling Female (4 )
Non-identical or dizygotic twin Male (5 )
Non-identical or dizygotic twin Female (6
)
Identical twin Male (7 )
Identical twin Female (8 )
Full biologic child Male (9 )
Number of second-degree relatives affected
Number of second-degree relatives with
physician diagnosis
Relationship of second-degree relative(s) to
participant/subject
Half-Sibling Male (1)
Paternal Uncle (10)
Grandchild Male (11)
Grandchild Female (12)
Nephew (13)
Niece (14)
Half-Sibling Female  (2)
Maternal Grandmother (3)
Maternal Grandfather (4)
Paternal Grandmother (5)
Paternal Grandfather (6)
Maternal Aunt (7)
Maternal Uncle (8)
Paternal Aunt (9)
Do you have a history of Heart disease?
Yes (1)
No (2)
Unknown (3)
Does a relative (1st/2nd degree only) have a
history of heart disease?
Yes (1)
No (2)
Unknown (3)
Number of first-degree relatives affected
Number of first degree relatives with physicians
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NINDS CDE General Health History Headache
diagnosis
Relationship of first-degree relative(s) to
participant/subject
Biological Mother (1 )
Full biologic child Female (10 )
Biological Father (2 )
Sibling Male (3 )
Sibling Female (4 )
Non-identical or dizygotic twin Male (5 )
Non-identical or dizygotic twin Female (6
)
Identical twin Male (7 )
Identical twin Female (8 )
Full biologic child Male (9 )
Number of second-degree relatives affected
Number of second-degree relatives with
physician diagnosis
Relationship of second-degree relative(s) to
participant/subject
Half-Sibling Male (1)
Paternal Uncle (10)
Grandchild Male (11)
Grandchild Female (12)
Nephew (13)
Niece (14)
Half-Sibling Female  (2)
Maternal Grandmother (3)
Maternal Grandfather (4)
Paternal Grandmother (5)
Paternal Grandfather (6)
Maternal Aunt (7)
Maternal Uncle (8)
Paternal Aunt (9)
Do you have a history of high blood
pressure/hypertension?
Yes (1)
No (2)
Unknown (3)
Does a relative (first and second degree only)
have a history of high blood
pressure/hypertension?
Yes (1)
No (2)
Unknown (3)
Number of first-degree relatives affected
Number of first degree relatives with physicians
diagnosis
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Relationship of first-degree relative(s) to
participant/subject
Biological Mother (1 )
Full biologic child Female (10 )
Biological Father (2 )
Sibling Male (3 )
Sibling Female (4 )
Non-identical or dizygotic twin Male (5 )
Non-identical or dizygotic twin Female (6
)
Identical twin Male (7 )
Identical twin Female (8 )
Full biologic child Male (9 )
Number of second-degree relatives affected
Number of second-degree relatives with
physician diagnosis
Relationship of second-degree relative(s) to
participant/subject
Half-Sibling Male (1)
Paternal Uncle (10)
Grandchild Male (11)
Grandchild Female (12)
Nephew (13)
Niece (14)
Half-Sibling Female  (2)
Maternal Grandmother (3)
Maternal Grandfather (4)
Paternal Grandmother (5)
Paternal Grandfather (6)
Maternal Aunt (7)
Maternal Uncle (8)
Paternal Aunt (9)
Do you have a history of low blood
pressure/hypotension?
Yes (1)
No (2)
Unknown (3)
Does a relative (first and second degree only)
have a history of low blood
pressure/hypotension?
Yes (1)
No (2)
Unknown (3)
Number of first-degree relatives affected
Number of first degree relatives with physicians
diagnosis
Relationship of first-degree relative(s) to
participant/subject
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Biological Mother (1 )
Full biologic child Female (10 )
Biological Father (2 )
Sibling Male (3 )
Sibling Female (4 )
Non-identical or dizygotic twin Male (5 )
Non-identical or dizygotic twin Female (6
)
Identical twin Male (7 )
Identical twin Female (8 )
Full biologic child Male (9 )
Number of second-degree relatives affected
Number of second-degree relatives with
physician diagnosis
Relationship of second-degree relative(s) to
participant/subject
Half-Sibling Male (1)
Paternal Uncle (10)
Grandchild Male (11)
Grandchild Female (12)
Nephew (13)
Niece (14)
Half-Sibling Female  (2)
Maternal Grandmother (3)
Maternal Grandfather (4)
Paternal Grandmother (5)
Paternal Grandfather (6)
Maternal Aunt (7)
Maternal Uncle (8)
Paternal Aunt (9)
Do you have a history of hypercholesterolemia?
Yes (1)
No (2)
Unknown (3)
Does a relative (first and second degree only)
have a history of hypercholesterolemia?
Yes (1)
No (2)
Unknown (3)
Number of first-degree relatives affected
Number of first degree relatives with physicians
diagnosis
Relationship of first-degree relative(s) to
participant/subject
Biological Mother (1 )
Full biologic child Female (10 )
Biological Father (2 )
Sibling Male (3 )
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Sibling Female (4 )
Non-identical or dizygotic twin Male (5 )
Non-identical or dizygotic twin Female (6
)
Identical twin Male (7 )
Identical twin Female (8 )
Full biologic child Male (9 )
Number of second-degree relatives affected
Number of second-degree relatives with
physicians diagnosis
Relationship of second-degree relative(s) to
participant/subject
Half-Sibling Male (1)
Paternal Uncle (10)
Grandchild Male (11)
Grandchild Female (12)
Nephew (13)
Niece (14)
Half-Sibling Female  (2)
Maternal Grandmother (3)
Maternal Grandfather (4)
Paternal Grandmother (5)
Paternal Grandfather (6)
Maternal Aunt (7)
Maternal Uncle (8)
Paternal Aunt (9)
Do you have a history of mitral valve prolapse?
Yes (1)
No (2)
Unknown (3)
Does a relative (first or second degree only) have
a history of mitral valve prolapse?
Yes (1)
No (2)
Unknown (3)
Number of first-degree relatives affected
Number of first degree relatives with physicians
diagnosis
Relationship of first-degree relative(s) to
participant/subject
Biological Mother (1 )
Full biologic child Female (10 )
Biological Father (2 )
Sibling Male (3 )
Sibling Female (4 )
Non-identical or dizygotic twin Male (5 )
Non-identical or dizygotic twin Female (6
)
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Identical twin Male (7 )
Identical twin Female (8 )
Full biologic child Male (9 )
Number of second-degree relatives affected
Number of second-degree relatives with
physician diagnosis
Relationship of second-degree relative(s) to
participant/subject
Half-Sibling Male (1)
Paternal Uncle (10)
Grandchild Male (11)
Grandchild Female (12)
Nephew (13)
Niece (14)
Half-Sibling Female  (2)
Maternal Grandmother (3)
Maternal Grandfather (4)
Paternal Grandmother (5)
Paternal Grandfather (6)
Maternal Aunt (7)
Maternal Uncle (8)
Paternal Aunt (9)
Do you have a history of Patent Foramen Ovale
(PFO)/ Right-left shunt (RLS)?
Yes (1)
No (2)
Unknown (3)
Does a relative (first and secind degree only)
have a history of Patent Foramen Ovale (PFO)/
Right-left shunt (RLS)?
Yes (1)
No (2)
Unknown (3)
Number of first-degree relatives affected
Number of first degree relatives with physicians
diagnosis
Relationship of first-degree relative(s) to
participant/subject
Biological Mother (1 )
Full biologic child Female (10 )
Biological Father (2 )
Sibling Male (3 )
Sibling Female (4 )
Non-identical or dizygotic twin Male (5 )
Non-identical or dizygotic twin Female (6
)
Identical twin Male (7 )
Identical twin Female (8 )
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Full biologic child Male (9 )
Number of second-degree relatives affected
Number of second-degree relatives with
physicians diagnosis
Relationship of second-degree relative(s) to
participant/subject
Half-Sibling Male (1)
Paternal Uncle (10)
Grandchild Male (11)
Grandchild Female (12)
Nephew (13)
Niece (14)
Half-Sibling Female  (2)
Maternal Grandmother (3)
Maternal Grandfather (4)
Paternal Grandmother (5)
Paternal Grandfather (6)
Maternal Aunt (7)
Maternal Uncle (8)
Paternal Aunt (9)
Do you have a history of Cerebral aneurysm?
Yes (1)
No (2)
Unknown (3)
Does a relative (first or second degree only) have
a history of Cerebral aneurysm?
Yes (1)
No (2)
Unknown (3)
Number of first-degree relatives affected
Number of first degree relatives with physicians
diagnosis
Relationship of first-degree relative(s) to
participant/subject
Biological Mother (1 )
Full biologic child Female (10 )
Biological Father (2 )
Sibling Male (3 )
Sibling Female (4 )
Non-identical or dizygotic twin Male (5 )
Non-identical or dizygotic twin Female (6
)
Identical twin Male (7 )
Identical twin Female (8 )
Full biologic child Male (9 )
Number of second-degree relatives affected
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Number of second-degree relatives with
physicians diagnosis
Relationship of second-degree relative(s) to
participant/subject
Half-Sibling Male (1)
Paternal Uncle (10)
Grandchild Male (11)
Grandchild Female (12)
Nephew (13)
Niece (14)
Half-Sibling Female  (2)
Maternal Grandmother (3)
Maternal Grandfather (4)
Paternal Grandmother (5)
Paternal Grandfather (6)
Maternal Aunt (7)
Maternal Uncle (8)
Paternal Aunt (9)
Do you have a history of Intracerebral
hemorrhage?
Yes (1)
No (2)
Unknown (3)
Does a relative (first or second degree only) have
a history of Intracerebral hemorrhage?
Yes (1)
No (2)
Unknown (3)
Number of first-degree relatives affected
Number of first degree relatives with physicians
diagnosis
Relationship of first-degree relative(s) to
participant/subject
Biological Mother (1 )
Full biologic child Female (10 )
Biological Father (2 )
Sibling Male (3 )
Sibling Female (4 )
Non-identical or dizygotic twin Male (5 )
Non-identical or dizygotic twin Female (6
)
Identical twin Male (7 )
Identical twin Female (8 )
Full biologic child Male (9 )
Number of second-degree relatives affected
Number of second-degree relatives with
physicians diagnosis
10 / 65
NINDS CDE General Health History Headache
Relationship of second-degree relative(s) to
participant/subject
Half-Sibling Male (1)
Paternal Uncle (10)
Grandchild Male (11)
Grandchild Female (12)
Nephew (13)
Niece (14)
Half-Sibling Female  (2)
Maternal Grandmother (3)
Maternal Grandfather (4)
Paternal Grandmother (5)
Paternal Grandfather (6)
Maternal Aunt (7)
Maternal Uncle (8)
Paternal Aunt (9)
Do you have a history of ischemic stroke?
Yes (1)
No (2)
Unknown (3)
Does a relative (first or second degree only) have
a history of ischemic stroke?
Yes (1)
No (2)
Unknown (3)
Number of first-degree relatives affected
Number of first degree relatives with physicians
diagnosis
Relationship of first-degree relative(s) to
participant/subject
Biological Mother (1 )
Full biologic child Female (10 )
Biological Father (2 )
Sibling Male (3 )
Sibling Female (4 )
Non-identical or dizygotic twin Male (5 )
Non-identical or dizygotic twin Female (6
)
Identical twin Male (7 )
Identical twin Female (8 )
Full biologic child Male (9 )
Number of second-degree relatives affected
Number of second-degree relatives with
physicians diagnosis
Relationship of second-degree relative(s) to
participant/subject
Half-Sibling Male (1)
Paternal Uncle (10)
Grandchild Male (11)
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Grandchild Female (12)
Nephew (13)
Niece (14)
Half-Sibling Female  (2)
Maternal Grandmother (3)
Maternal Grandfather (4)
Paternal Grandmother (5)
Paternal Grandfather (6)
Maternal Aunt (7)
Maternal Uncle (8)
Paternal Aunt (9)
Do you have a history of Extracranial aneurysm?
Yes (1)
No (2)
Unknown (3)
Does a relative (first or second degree only) have
a history of Extracranial aneurysm?
Yes (1)
No (2)
Unknown (3)
Number of first-degree relatives affected
Number of first degree relatives with physicians
diagnosis
Relationship of first-degree relative(s) to
participant/subject
Biological Mother (1 )
Full biologic child Female (10 )
Biological Father (2 )
Sibling Male (3 )
Sibling Female (4 )
Non-identical or dizygotic twin Male (5 )
Non-identical or dizygotic twin Female (6
)
Identical twin Male (7 )
Identical twin Female (8 )
Full biologic child Male (9 )
Number of second-degree relatives affected
Number of second-degree relatives with
physicians diagnosis
Relationship of second-degree relative(s) to
participant/subject
Half-Sibling Male (1)
Paternal Uncle (10)
Grandchild Male (11)
Grandchild Female (12)
Nephew (13)
Niece (14)
Half-Sibling Female  (2)
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Maternal Grandmother (3)
Maternal Grandfather (4)
Paternal Grandmother (5)
Paternal Grandfather (6)
Maternal Aunt (7)
Maternal Uncle (8)
Paternal Aunt (9)
Do you have a history of Peripheral Vascular
Disease?
Yes (1)
No (2)
Unknown (3)
Does a relative (first or second degree only) have
a history of Periphereal vascular disease?
Yes (1)
No (2)
Unknown (3)
Number of first-degree relatives affected
Number of first degree relatives with physicians
diagnosis
Relationship of first-degree relative(s) to
participant/subject
Biological Mother (1 )
Full biologic child Female (10 )
Biological Father (2 )
Sibling Male (3 )
Sibling Female (4 )
Non-identical or dizygotic twin Male (5 )
Non-identical or dizygotic twin Female (6
)
Identical twin Male (7 )
Identical twin Female (8 )
Full biologic child Male (9 )
Number of second-degree relatives affected
Number of second-degree relatives with
physicians diagnosis
Relationship of second-degree relative(s) to
participant/subject
Half-Sibling Male (1)
Paternal Uncle (10)
Grandchild Male (11)
Grandchild Female (12)
Nephew (13)
Niece (14)
Half-Sibling Female  (2)
Maternal Grandmother (3)
Maternal Grandfather (4)
Paternal Grandmother (5)
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Paternal Grandfather (6)
Maternal Aunt (7)
Maternal Uncle (8)
Paternal Aunt (9)
Do you have a history of Raynaud Syndrome?
Yes (1)
No (2)
Unknown (3)
Does a relative (first or second degree only) have
a history of Raynaud Syndrome?
Yes (1)
No (2)
Unknown (3)
Number of first-degree relatives affected
Number of first degree relatives with physicians
diagnosis
Relationship of first-degree relative(s) to
participant/subject
Biological Mother (1 )
Full biologic child Female (10 )
Biological Father (2 )
Sibling Male (3 )
Sibling Female (4 )
Non-identical or dizygotic twin Male (5 )
Non-identical or dizygotic twin Female (6
)
Identical twin Male (7 )
Identical twin Female (8 )
Full biologic child Male (9 )
Number of second-degree relatives affected
Number of second-degree relatives with
physicians diagnosis
Relationship of second-degree relative(s) to
participant/subject
Half-Sibling Male (1)
Paternal Uncle (10)
Grandchild Male (11)
Grandchild Female (12)
Nephew (13)
Niece (14)
Half-Sibling Female  (2)
Maternal Grandmother (3)
Maternal Grandfather (4)
Paternal Grandmother (5)
Paternal Grandfather (6)
Maternal Aunt (7)
Maternal Uncle (8)
Paternal Aunt (9)
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Do you have a history of Diabetes mellitus?
Yes (1)
No (2)
Unknown (3)
Does a relative (first or second degree only) have
a history of Diabetes mellitus?
Yes (1)
No (2)
Unknown (3)
Number of first-degree relatives affected
Number of first degree relatives with physicians
diagnosis
Relationship of first-degree relative(s) to
participant/subject
Biological Mother (1 )
Full biologic child Female (10 )
Biological Father (2 )
Sibling Male (3 )
Sibling Female (4 )
Non-identical or dizygotic twin Male (5 )
Non-identical or dizygotic twin Female (6
)
Identical twin Male (7 )
Identical twin Female (8 )
Full biologic child Male (9 )
Number of second-degree relatives affected
Number of second-degree relatives with
physicians diagnosis
Relationship of second-degree relative(s) to
participant/subject
Half-Sibling Male (1)
Paternal Uncle (10)
Grandchild Male (11)
Grandchild Female (12)
Nephew (13)
Niece (14)
Half-Sibling Female  (2)
Maternal Grandmother (3)
Maternal Grandfather (4)
Paternal Grandmother (5)
Paternal Grandfather (6)
Maternal Aunt (7)
Maternal Uncle (8)
Paternal Aunt (9)
Do you have a history of gastroparesis?
Yes (1)
No (2)
Unknown (3)
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Does a relative (first or second degree only) have
a history of Gastroparesis?
Yes (1)
No (2)
Unknown (3)
Number of first-degree relatives affected
Number of first degree relatives with physicians
diagnosis
Relationship of first-degree relative(s) to
participant/subject
Biological Mother (1 )
Full biologic child Female (10 )
Biological Father (2 )
Sibling Male (3 )
Sibling Female (4 )
Non-identical or dizygotic twin Male (5 )
Non-identical or dizygotic twin Female (6
)
Identical twin Male (7 )
Identical twin Female (8 )
Full biologic child Male (9 )
Number of second-degree relatives affected
Number of second-degree relatives with
physicians diagnosis
Relationship of second-degree relative(s) to
participant/subject
Half-Sibling Male (1)
Paternal Uncle (10)
Grandchild Male (11)
Grandchild Female (12)
Nephew (13)
Niece (14)
Half-Sibling Female  (2)
Maternal Grandmother (3)
Maternal Grandfather (4)
Paternal Grandmother (5)
Paternal Grandfather (6)
Maternal Aunt (7)
Maternal Uncle (8)
Paternal Aunt (9)
Do you have a history of Irritable Bowel
Syndrome?
Yes (1)
No (2)
Unknown (3)
Does a relative (first or second degree only) have
a history of Irritable Bowel Syndrome?
Yes (1)
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No (2)
Unknown (3)
Number of first-degree relatives affected
Number of first degree relatives with physicians
diagnosis
Relationship of first-degree relative(s) to
participant/subject
Biological Mother (1 )
Full biologic child Female (10 )
Biological Father (2 )
Sibling Male (3 )
Sibling Female (4 )
Non-identical or dizygotic twin Male (5 )
Non-identical or dizygotic twin Female (6
)
Identical twin Male (7 )
Identical twin Female (8 )
Full biologic child Male (9 )
Number of second-degree relatives affected
Number of second-degree relatives with
physicians diagnosis
Relationship of second-degree relative(s) to
participant/subject
Half-Sibling Male (1)
Paternal Uncle (10)
Grandchild Male (11)
Grandchild Female (12)
Nephew (13)
Niece (14)
Half-Sibling Female  (2)
Maternal Grandmother (3)
Maternal Grandfather (4)
Paternal Grandmother (5)
Paternal Grandfather (6)
Maternal Aunt (7)
Maternal Uncle (8)
Paternal Aunt (9)
Do you have a history of painful bladder?
Yes (1)
No (2)
Unknown (3)
Does a relative (1st/2nd degree only) have a
history of painful bladder?
Yes (1)
No (2)
Unknown (3)
Number of first-degree relatives affected
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Number of first degree relatives with physicians
diagnosis
Relationship of first-degree relative(s) to
participant/subject
Biological Mother (1 )
Full biologic child Female (10 )
Biological Father (2 )
Sibling Male (3 )
Sibling Female (4 )
Non-identical or dizygotic twin Male (5 )
Non-identical or dizygotic twin Female (6
)
Identical twin Male (7 )
Identical twin Female (8 )
Full biologic child Male (9 )
Number of second-degree relatives affected
Number of second-degree relatives with
physicians diagnosis
Relationship of second-degree relative(s) to
participant/subject
Half-Sibling Male (1)
Paternal Uncle (10)
Grandchild Male (11)
Grandchild Female (12)
Nephew (13)
Niece (14)
Half-Sibling Female  (2)
Maternal Grandmother (3)
Maternal Grandfather (4)
Paternal Grandmother (5)
Paternal Grandfather (6)
Maternal Aunt (7)
Maternal Uncle (8)
Paternal Aunt (9)
Do you have a history of endometriosis?
Yes (1)
No (2)
Unknown (3)
Does a relative (1st/2nd degree only) have a
history of endometriosis?
Yes (1)
No (2)
Unknown (3)
Number of first-degree relatives affected
Number of first degree relatives with physicians
diagnosis
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Relationship of first-degree relative(s) to
participant/subject
Biological Mother (1 )
Full biologic child Female (10 )
Biological Father (2 )
Sibling Male (3 )
Sibling Female (4 )
Non-identical or dizygotic twin Male (5 )
Non-identical or dizygotic twin Female (6
)
Identical twin Male (7 )
Identical twin Female (8 )
Full biologic child Male (9 )
Number of second-degree relatives affected
Number of second-degree relatives with
physician diagnosis
Relationship of second-degree relative(s) to
participant/subject
Half-Sibling Male (1)
Paternal Uncle (10)
Grandchild Male (11)
Grandchild Female (12)
Nephew (13)
Niece (14)
Half-Sibling Female  (2)
Maternal Grandmother (3)
Maternal Grandfather (4)
Paternal Grandmother (5)
Paternal Grandfather (6)
Maternal Aunt (7)
Maternal Uncle (8)
Paternal Aunt (9)
Do you have a history of preeclampsia?
Yes (1)
No (2)
Unknown (3)
Does a relative (1st/2nd degree only) have a
history of preeclampsia?
Yes (1)
No (2)
Unknown (3)
Number of first-degree relatives affected
Number of first degree relatives with physicians
diagnosis
Relationship of first-degree relative(s) to
participant/subject
Biological Mother (1 )
Full biologic child Female (10 )
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Biological Father (2 )
Sibling Male (3 )
Sibling Female (4 )
Non-identical or dizygotic twin Male (5 )
Non-identical or dizygotic twin Female (6
)
Identical twin Male (7 )
Identical twin Female (8 )
Full biologic child Male (9 )
Number of second-degree relatives affected
Number of second-degree relatives with
physicians diagnosis
Relationship of second-degree relative(s) to
participant/subject
Half-Sibling Male (1)
Paternal Uncle (10)
Grandchild Male (11)
Grandchild Female (12)
Nephew (13)
Niece (14)
Half-Sibling Female  (2)
Maternal Grandmother (3)
Maternal Grandfather (4)
Paternal Grandmother (5)
Paternal Grandfather (6)
Maternal Aunt (7)
Maternal Uncle (8)
Paternal Aunt (9)
Do you have a history of emotional/verbal abuse?
Yes (1)
No (2)
Unknown (3)
Does a relative (first and second degree only)
have a history of emotional/verbal abuse?
Yes (1)
No (2)
Unknown (3)
Number of first-degree relatives affected
Number of first degree relatives with physicians
diagnosis
Relationship of first-degree relative(s) to
participant/subject
Biological Mother (1 )
Full biologic child Female (10 )
Biological Father (2 )
Sibling Male (3 )
Sibling Female (4 )
Non-identical or dizygotic twin Male (5 )
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Non-identical or dizygotic twin Female (6
)
Identical twin Male (7 )
Identical twin Female (8 )
Full biologic child Male (9 )
Number of second-degree relatives affected
Number of second-degree relatives with
physician diagnosis
Relationship of second-degree relative(s) to
participant/subject
Half-Sibling Male (1)
Paternal Uncle (10)
Grandchild Male (11)
Grandchild Female (12)
Nephew (13)
Niece (14)
Half-Sibling Female  (2)
Maternal Grandmother (3)
Maternal Grandfather (4)
Paternal Grandmother (5)
Paternal Grandfather (6)
Maternal Aunt (7)
Maternal Uncle (8)
Paternal Aunt (9)
Do you have a history of physical abuse?
Yes (1)
No (2)
Unknown (3)
Does a relative (first and second degree only)
have a history of physical abuse?
Yes (1)
No (2)
Unknown (3)
Number of first-degree relatives affected
Number of first degree relatives with physicians
diagnosis
Relationship of first-degree relative(s) to
participant/subject
Biological Mother (1 )
Full biologic child Female (10 )
Biological Father (2 )
Sibling Male (3 )
Sibling Female (4 )
Non-identical or dizygotic twin Male (5 )
Non-identical or dizygotic twin Female (6
)
Identical twin Male (7 )
Identical twin Female (8 )
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Full biologic child Male (9 )
Number of second-degree relatives affected
Number of second-degree relatives with
physicians diagnosis
Relationship of second-degree relative(s) to
participant/subject
Half-Sibling Male (1)
Paternal Uncle (10)
Grandchild Male (11)
Grandchild Female (12)
Nephew (13)
Niece (14)
Half-Sibling Female  (2)
Maternal Grandmother (3)
Maternal Grandfather (4)
Paternal Grandmother (5)
Paternal Grandfather (6)
Maternal Aunt (7)
Maternal Uncle (8)
Paternal Aunt (9)
Do you have a history of sexual abuse?
Yes (1)
No (2)
Unknown (3)
Does a relative (first and second degree only)
have a history of sexual abuse?
Yes (1)
No (2)
Unknown (3)
Number of first-degree relatives affected
Number of first degree relatives with physicians
diagnosis
Relationship of first-degree relative(s) to
participant/subject
Biological Mother (1 )
Full biologic child Female (10 )
Biological Father (2 )
Sibling Male (3 )
Sibling Female (4 )
Non-identical or dizygotic twin Male (5 )
Non-identical or dizygotic twin Female (6
)
Identical twin Male (7 )
Identical twin Female (8 )
Full biologic child Male (9 )
Number of second-degree relatives affected
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Number of second-degree relatives with
physicians diagnosis
Relationship of second-degree relative(s) to
participant/subject
Half-Sibling Male (1)
Paternal Uncle (10)
Grandchild Male (11)
Grandchild Female (12)
Nephew (13)
Niece (14)
Half-Sibling Female  (2)
Maternal Grandmother (3)
Maternal Grandfather (4)
Paternal Grandmother (5)
Paternal Grandfather (6)
Maternal Aunt (7)
Maternal Uncle (8)
Paternal Aunt (9)
Do you have a history of Allergy(ies)?
Yes (1)
No (2)
Unknown (3)
Does a relative (first and second degree only)
have a history of allergy(ies)?
Yes (1)
No (2)
Unknown (3)
Number of first-degree relatives affected
Number of first degree relatives with physicians
diagnosis
Relationship of first-degree relative(s) to
participant/subject
Biological Mother (1 )
Full biologic child Female (10 )
Biological Father (2 )
Sibling Male (3 )
Sibling Female (4 )
Non-identical or dizygotic twin Male (5 )
Non-identical or dizygotic twin Female (6
)
Identical twin Male (7 )
Identical twin Female (8 )
Full biologic child Male (9 )
Number of second-degree relatives affected
Number of second-degree relatives with
physician diagnosis
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Relationship of second-degree relative(s) to
participant/subject
Half-Sibling Male (1)
Paternal Uncle (10)
Grandchild Male (11)
Grandchild Female (12)
Nephew (13)
Niece (14)
Half-Sibling Female  (2)
Maternal Grandmother (3)
Maternal Grandfather (4)
Paternal Grandmother (5)
Paternal Grandfather (6)
Maternal Aunt (7)
Maternal Uncle (8)
Paternal Aunt (9)
Do you have a history of Asthma?
Yes (1)
No (2)
Unknown (3)
Does a relative (first and second degree only)
have a history of Asthma?
Yes (1)
No (2)
Unknown (3)
Number of first-degree relatives affected
Number of first degree relatives with physicians
diagnosis
Relationship of first-degree relative(s) to
participant/subject
Biological Mother (1 )
Full biologic child Female (10 )
Biological Father (2 )
Sibling Male (3 )
Sibling Female (4 )
Non-identical or dizygotic twin Male (5 )
Non-identical or dizygotic twin Female (6
)
Identical twin Male (7 )
Identical twin Female (8 )
Full biologic child Male (9 )
Number of second-degree relatives affected
Number of second-degree relatives with
physicians diagnosis
Relationship of second-degree relative(s) to
participant/subject
Half-Sibling Male (1)
Paternal Uncle (10)
Grandchild Male (11)
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Grandchild Female (12)
Nephew (13)
Niece (14)
Half-Sibling Female  (2)
Maternal Grandmother (3)
Maternal Grandfather (4)
Paternal Grandmother (5)
Paternal Grandfather (6)
Maternal Aunt (7)
Maternal Uncle (8)
Paternal Aunt (9)
Do you have a history of Eczema?
Yes (1)
No (2)
Unknown (3)
Does a relative (first and second degree only)
have a history of Eczema?
Yes (1)
No (2)
Unknown (3)
Number of first-degree relatives affected
Number of first degree relatives with physicians
diagnosis
Relationship of first-degree relative(s) to
participant/subject
Biological Mother (1 )
Full biologic child Female (10 )
Biological Father (2 )
Sibling Male (3 )
Sibling Female (4 )
Non-identical or dizygotic twin Male (5 )
Non-identical or dizygotic twin Female (6
)
Identical twin Male (7 )
Identical twin Female (8 )
Full biologic child Male (9 )
Number of second-degree relatives affected
Number of second-degree relatives with
physicians diagnosis
Relationship of second-degree relative(s) to
participant/subject
Half-Sibling Male (1)
Paternal Uncle (10)
Grandchild Male (11)
Grandchild Female (12)
Nephew (13)
Niece (14)
Half-Sibling Female  (2)
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Maternal Grandmother (3)
Maternal Grandfather (4)
Paternal Grandmother (5)
Paternal Grandfather (6)
Maternal Aunt (7)
Maternal Uncle (8)
Paternal Aunt (9)
Do you have a history of Systemic lupus
erythematosus (SLE)?
Yes (1)
No (2)
Unknown (3)
Does a relative (first and second degree only)
have a history of Systemic lupus erythematosus
(SLE)?
Yes (1)
No (2)
Unknown (3)
Number of first-degree relatives affected
Number of first degree relatives with physicians
diagnosis
Relationship of first-degree relative(s) to
participant/subject
Biological Mother (1 )
Full biologic child Female (10 )
Biological Father (2 )
Sibling Male (3 )
Sibling Female (4 )
Non-identical or dizygotic twin Male (5 )
Non-identical or dizygotic twin Female (6
)
Identical twin Male (7 )
Identical twin Female (8 )
Full biologic child Male (9 )
Number of second-degree relatives affected
Number of second-degree relatives with
physicians diagnosis
Relationship of second-degree relative(s) to
participant/subject
Half-Sibling Male (1)
Paternal Uncle (10)
Grandchild Male (11)
Grandchild Female (12)
Nephew (13)
Niece (14)
Half-Sibling Female  (2)
Maternal Grandmother (3)
Maternal Grandfather (4)
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Paternal Grandmother (5)
Paternal Grandfather (6)
Maternal Aunt (7)
Maternal Uncle (8)
Paternal Aunt (9)
Do you have a history of other immunological
disorders?
Yes (1)
No (2)
Unknown (3)
Does a relative (first and second degree only)
have a history of other immunological disorders?
Yes (1)
No (2)
Unknown (3)
Other Immunological Disorders, please specify:
Number of first-degree relatives affected
Number of first degree relatives with physicians
diagnosis
Relationship of first-degree relative(s) to
participant/subject
Biological Mother (1 )
Full biologic child Female (10 )
Biological Father (2 )
Sibling Male (3 )
Sibling Female (4 )
Non-identical or dizygotic twin Male (5 )
Non-identical or dizygotic twin Female (6
)
Identical twin Male (7 )
Identical twin Female (8 )
Full biologic child Male (9 )
Number of second-degree relatives affected
Number of second-degree relatives with
physicians diagnosis
Relationship of second-degree relative(s) to
participant/subject
Half-Sibling Male (1)
Paternal Uncle (10)
Grandchild Male (11)
Grandchild Female (12)
Nephew (13)
Niece (14)
Half-Sibling Female  (2)
Maternal Grandmother (3)
Maternal Grandfather (4)
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Paternal Grandmother (5)
Paternal Grandfather (6)
Maternal Aunt (7)
Maternal Uncle (8)
Paternal Aunt (9)
Do you have a history of Arthritis?
Yes (1)
No (2)
Unknown (3)
Does a relative (first and second degree only)
have a history of arthritis?
Yes (1)
No (2)
Unknown (3)
Number of first-degree relatives affected
Number of first degree relatives with physicians
diagnosis
Relationship of first-degree relative(s) to
participant/subject
Biological Mother (1 )
Full biologic child Female (10 )
Biological Father (2 )
Sibling Male (3 )
Sibling Female (4 )
Non-identical or dizygotic twin Male (5 )
Non-identical or dizygotic twin Female (6
)
Identical twin Male (7 )
Identical twin Female (8 )
Full biologic child Male (9 )
Number of second-degree relatives affected
Number of second-degree relatives with
physicians diagnosis
Relationship of second-degree relative(s) to
participant/subject
Half-Sibling Male (1)
Paternal Uncle (10)
Grandchild Male (11)
Grandchild Female (12)
Nephew (13)
Niece (14)
Half-Sibling Female  (2)
Maternal Grandmother (3)
Maternal Grandfather (4)
Paternal Grandmother (5)
Paternal Grandfather (6)
Maternal Aunt (7)
Maternal Uncle (8)
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Paternal Aunt (9)
Do you have a history of Fibromyalgia?
Yes (1)
No (2)
Unknown (3)
Does a relative (first and second degree only)
have a history of Fibromyalgia?
Yes (1)
No (2)
Unknown (3)
Number of first-degree relatives affected
Number of first degree relatives with physicians
diagnosis
Relationship of first-degree relative(s) to
participant/subject
Biological Mother (1 )
Full biologic child Female (10 )
Biological Father (2 )
Sibling Male (3 )
Sibling Female (4 )
Non-identical or dizygotic twin Male (5 )
Non-identical or dizygotic twin Female (6
)
Identical twin Male (7 )
Identical twin Female (8 )
Full biologic child Male (9 )
Number of second-degree relatives affected
Number of second-degree relatives with
physicians diagnosis
Relationship of second-degree relative(s) to
participant/subject
Half-Sibling Male (1)
Paternal Uncle (10)
Grandchild Male (11)
Grandchild Female (12)
Nephew (13)
Niece (14)
Half-Sibling Female  (2)
Maternal Grandmother (3)
Maternal Grandfather (4)
Paternal Grandmother (5)
Paternal Grandfather (6)
Maternal Aunt (7)
Maternal Uncle (8)
Paternal Aunt (9)
Do you have a history of Muscle disease?
Yes (1)
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No (2)
Unknown (3)
Does a relative (first and second degree only)
have a history of muscle disease?
Yes (1)
No (2)
Unknown (3)
Number of first-degree relatives affected
Number of first degree relatives with physicians
diagnosis
Relationship of first-degree relative(s) to
participant/subject
Biological Mother (1 )
Full biologic child Female (10 )
Biological Father (2 )
Sibling Male (3 )
Sibling Female (4 )
Non-identical or dizygotic twin Male (5 )
Non-identical or dizygotic twin Female (6
)
Identical twin Male (7 )
Identical twin Female (8 )
Full biologic child Male (9 )
Number of second-degree relatives affected
Number of second-degree relatives with
physicians diagnosis
Relationship of second-degree relative(s) to
participant/subject
Half-Sibling Male (1)
Paternal Uncle (10)
Grandchild Male (11)
Grandchild Female (12)
Nephew (13)
Niece (14)
Half-Sibling Female  (2)
Maternal Grandmother (3)
Maternal Grandfather (4)
Paternal Grandmother (5)
Paternal Grandfather (6)
Maternal Aunt (7)
Maternal Uncle (8)
Paternal Aunt (9)
Do you/Does the participant have a history of
Autism?
Yes (1)
No (2)
Unknown (3)
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Does a relative (first and second degree only)
have a history of autism?
Yes (1)
No (2)
Unknown (3)
Number of first-degree relatives affected
Number of first degree relatives with physicians
diagnosis
Relationship of first-degree relative(s) to
participant/subject
Biological Mother (1 )
Full biologic child Female (10 )
Biological Father (2 )
Sibling Male (3 )
Sibling Female (4 )
Non-identical or dizygotic twin Male (5 )
Non-identical or dizygotic twin Female (6
)
Identical twin Male (7 )
Identical twin Female (8 )
Full biologic child Male (9 )
Number of second-degree relatives affected
Number of second-degree relatives with
physicians diagnosis
Relationship of second-degree relative(s) to
participant/subject
Half-Sibling Male (1)
Paternal Uncle (10)
Grandchild Male (11)
Grandchild Female (12)
Nephew (13)
Niece (14)
Half-Sibling Female  (2)
Maternal Grandmother (3)
Maternal Grandfather (4)
Paternal Grandmother (5)
Paternal Grandfather (6)
Maternal Aunt (7)
Maternal Uncle (8)
Paternal Aunt (9)
Do you/Does the participant have a history of
Alzheimers Disease?
Yes (1)
No (2)
Unknown (3)
Does a relative (first and second degree only)
have a history of Alzheimers Disease?
Yes (1)
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No (2)
Unknown (3)
Number of first-degree relatives affected
Number of first degree relatives with physicians
diagnosis
Relationship of first-degree relative(s) to
participant/subject
Biological Mother (1 )
Full biologic child Female (10 )
Biological Father (2 )
Sibling Male (3 )
Sibling Female (4 )
Non-identical or dizygotic twin Male (5 )
Non-identical or dizygotic twin Female (6
)
Identical twin Male (7 )
Identical twin Female (8 )
Full biologic child Male (9 )
Number of second-degree relatives affected
Number of second-degree relatives with
physicians diagnosis
Relationship of second-degree relative(s) to
participant/subject
Half-Sibling Male (1)
Paternal Uncle (10)
Grandchild Male (11)
Grandchild Female (12)
Nephew (13)
Niece (14)
Half-Sibling Female  (2)
Maternal Grandmother (3)
Maternal Grandfather (4)
Paternal Grandmother (5)
Paternal Grandfather (6)
Maternal Aunt (7)
Maternal Uncle (8)
Paternal Aunt (9)
Do you/does the participant have a history of
Amyotrophic Lateral Sclerosis (ALS)?
Yes (1)
No (2)
Unknown (3)
Does a relative (first and second degree only)
have a history of Amyotrophic Lateral Sclerosis
(ALS)?
Yes (1)
No (2)
Unknown (3)
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Number of first-degree relatives affected
Number of first degree relatives with physicians
diagnosis
Relationship of first-degree relative(s) to
participant/subject
Biological Mother (1 )
Full biologic child Female (10 )
Biological Father (2 )
Sibling Male (3 )
Sibling Female (4 )
Non-identical or dizygotic twin Male (5 )
Non-identical or dizygotic twin Female (6
)
Identical twin Male (7 )
Identical twin Female (8 )
Full biologic child Male (9 )
Number of second-degree relatives affected
Number of second-degree relatives with
physicians diagnosis
Relationship of second-degree relative(s) to
participant/subject
Half-Sibling Male (1)
Paternal Uncle (10)
Grandchild Male (11)
Grandchild Female (12)
Nephew (13)
Niece (14)
Half-Sibling Female  (2)
Maternal Grandmother (3)
Maternal Grandfather (4)
Paternal Grandmother (5)
Paternal Grandfather (6)
Maternal Aunt (7)
Maternal Uncle (8)
Paternal Aunt (9)
Do you/does the participant have a history of
Ataxia?
Yes (1)
No (2)
Unknown (3)
Does a relative (first and second degree only)
have a history of Ataxia?
Yes (1)
No (2)
Unknown (3)
Number of first-degree relatives affected
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Number of first degree relatives with physicians
diagnosis
Relationship of first-degree relative(s) to
participant/subject
Biological Mother (1 )
Full biologic child Female (10 )
Biological Father (2 )
Sibling Male (3 )
Sibling Female (4 )
Non-identical or dizygotic twin Male (5 )
Non-identical or dizygotic twin Female (6
)
Identical twin Male (7 )
Identical twin Female (8 )
Full biologic child Male (9 )
Number of second-degree relatives affected
Number of second-degree relatives with
physicians diagnosis
Relationship of second-degree relative(s) to
participant/subject
Half-Sibling Male (1)
Paternal Uncle (10)
Grandchild Male (11)
Grandchild Female (12)
Nephew (13)
Niece (14)
Half-Sibling Female  (2)
Maternal Grandmother (3)
Maternal Grandfather (4)
Paternal Grandmother (5)
Paternal Grandfather (6)
Maternal Aunt (7)
Maternal Uncle (8)
Paternal Aunt (9)
Do you/Does the participant have a history of
Chronic ataxia?
Yes (1)
No (2)
Unknown (3)
Does a relative (first and second degree only)
have a history of Chronic ataxia?
Yes (1)
No (2)
Unknown (3)
Number of first-degree relatives affected
Number of first degree relatives with physicians
diagnosis
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Relationship of first-degree relative(s) to
participant/subject
Biological Mother (1 )
Full biologic child Female (10 )
Biological Father (2 )
Sibling Male (3 )
Sibling Female (4 )
Non-identical or dizygotic twin Male (5 )
Non-identical or dizygotic twin Female (6
)
Identical twin Male (7 )
Identical twin Female (8 )
Full biologic child Male (9 )
Number of second-degree relatives affected
Number of second-degree relatives with
physicians diagnosis
Relationship of second-degree relative(s) to
participant/subject
Half-Sibling Male (1)
Paternal Uncle (10)
Grandchild Male (11)
Grandchild Female (12)
Nephew (13)
Niece (14)
Half-Sibling Female  (2)
Maternal Grandmother (3)
Maternal Grandfather (4)
Paternal Grandmother (5)
Paternal Grandfather (6)
Maternal Aunt (7)
Maternal Uncle (8)
Paternal Aunt (9)
Do you/does the participant have a history of
Dementia?
Yes (1)
No (2)
Unknown (3)
Does a relative (first and second degree only)
have a history of Dementia?
Yes (1)
No (2)
Unknown (3)
Number of first-degree relatives affected
Number of first degree relatives with physicians
diagnosis
Relationship of first-degree relative(s) to
participant/subject
Biological Mother (1 )
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Full biologic child Female (10 )
Biological Father (2 )
Sibling Male (3 )
Sibling Female (4 )
Non-identical or dizygotic twin Male (5 )
Non-identical or dizygotic twin Female (6
)
Identical twin Male (7 )
Identical twin Female (8 )
Full biologic child Male (9 )
Number of second-degree relatives affected
Number of second-degree relatives with
physicians diagnosis
Relationship of second-degree relative(s) to
participant/subject
Half-Sibling Male (1)
Paternal Uncle (10)
Grandchild Male (11)
Grandchild Female (12)
Nephew (13)
Niece (14)
Half-Sibling Female  (2)
Maternal Grandmother (3)
Maternal Grandfather (4)
Paternal Grandmother (5)
Paternal Grandfather (6)
Maternal Aunt (7)
Maternal Uncle (8)
Paternal Aunt (9)
Do you/Does the participant have a history of
Dystonia?
Yes (1)
No (2)
Unknown (3)
Does a relative (first and second degree only)
have a history of  Dystonia?
Yes (1)
No (2)
Unknown (3)
Number of first-degree relatives affected
Number of first degree relatives with physicians
diagnosis
Relationship of first-degree relative(s) to
participant/subject
Biological Mother (1 )
Full biologic child Female (10 )
Biological Father (2 )
Sibling Male (3 )
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Sibling Female (4 )
Non-identical or dizygotic twin Male (5 )
Non-identical or dizygotic twin Female (6
)
Identical twin Male (7 )
Identical twin Female (8 )
Full biologic child Male (9 )
Number of second-degree relatives affected
Number of second-degree relatives with
physicians diagnosis
Relationship of second-degree relative(s) to
participant/subject
Half-Sibling Male (1)
Paternal Uncle (10)
Grandchild Male (11)
Grandchild Female (12)
Nephew (13)
Niece (14)
Half-Sibling Female  (2)
Maternal Grandmother (3)
Maternal Grandfather (4)
Paternal Grandmother (5)
Paternal Grandfather (6)
Maternal Aunt (7)
Maternal Uncle (8)
Paternal Aunt (9)
Do you/does the participant have a history of
Epilepsy?
Yes (1)
No (2)
Unknown (3)
Does a relative (first and second degree only)
have a history of Epilepsy?
Yes (1)
No (2)
Unknown (3)
Number of first-degree relatives affected
Number of first degree relatives with physicians
diagnosis
Relationship of first-degree relative(s) to
participant/subject
Biological Mother (1 )
Full biologic child Female (10 )
Biological Father (2 )
Sibling Male (3 )
Sibling Female (4 )
Non-identical or dizygotic twin Male (5 )
Non-identical or dizygotic twin Female (6
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)
Identical twin Male (7 )
Identical twin Female (8 )
Full biologic child Male (9 )
Number of second-degree relatives affected
Number of second-degree relatives with
physicians diagnosis
Relationship of second-degree relative(s) to
participant/subject
Half-Sibling Male (1)
Paternal Uncle (10)
Grandchild Male (11)
Grandchild Female (12)
Nephew (13)
Niece (14)
Half-Sibling Female  (2)
Maternal Grandmother (3)
Maternal Grandfather (4)
Paternal Grandmother (5)
Paternal Grandfather (6)
Maternal Aunt (7)
Maternal Uncle (8)
Paternal Aunt (9)
Do you/Does the participant have a history of
Mild Cognitive Decline (Memory Loss)?
Yes (1)
No (2)
Unknown (3)
Does a relative (first and second degree only)
have a history of Mild Cognitive Decline (Memory
Loss)?
Yes (1)
No (2)
Unknown (3)
Number of first-degree relatives affected
Number of first degree relatives with physicians
diagnosis
Relationship of first-degree relative(s) to
participant/subject
Biological Mother (1 )
Full biologic child Female (10 )
Biological Father (2 )
Sibling Male (3 )
Sibling Female (4 )
Non-identical or dizygotic twin Male (5 )
Non-identical or dizygotic twin Female (6
)
Identical twin Male (7 )
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Identical twin Female (8 )
Full biologic child Male (9 )
Number of second-degree relatives affected
Number of second-degree relatives with
physicians diagnosis
Relationship of second-degree relative(s) to
participant/subject
Half-Sibling Male (1)
Paternal Uncle (10)
Grandchild Male (11)
Grandchild Female (12)
Nephew (13)
Niece (14)
Half-Sibling Female  (2)
Maternal Grandmother (3)
Maternal Grandfather (4)
Paternal Grandmother (5)
Paternal Grandfather (6)
Maternal Aunt (7)
Maternal Uncle (8)
Paternal Aunt (9)
Do you/Does the participant have a history of
Developmental delay?
Yes (1)
No (2)
Unknown (3)
Does a relative (first and second degree only)
have a history of Developmental delay?
Yes (1)
No (2)
Unknown (3)
Number of first-degree relatives affected
Number of first degree relatives with physicians
diagnosis
Relationship of first-degree relative(s) to
participant/subject
Biological Mother (1 )
Full biologic child Female (10 )
Biological Father (2 )
Sibling Male (3 )
Sibling Female (4 )
Non-identical or dizygotic twin Male (5 )
Non-identical or dizygotic twin Female (6
)
Identical twin Male (7 )
Identical twin Female (8 )
Full biologic child Male (9 )
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Number of second-degree relatives affected
Relationship of second-degree relative(s) to
participant/subject
Half-Sibling Male (1)
Paternal Uncle (10)
Grandchild Male (11)
Grandchild Female (12)
Nephew (13)
Niece (14)
Half-Sibling Female  (2)
Maternal Grandmother (3)
Maternal Grandfather (4)
Paternal Grandmother (5)
Paternal Grandfather (6)
Maternal Aunt (7)
Maternal Uncle (8)
Paternal Aunt (9)
Do you/Does the participant have a history of
Multiple Sclerosis (MS)?
Yes (1)
No (2)
Unknown (3)
Does a relative (first and second degree only)
have a history of Multiple Sclerosis (MS)?
Yes (1)
No (2)
Unknown (3)
Number of first-degree relatives affected
Number of first degree relatives with physicians
diagnosis
Relationship of first-degree relative(s) to
participant/subject
Half-Sibling Male (1)
Paternal Uncle (10)
Grandchild Male (11)
Grandchild Female (12)
Nephew (13)
Niece (14)
Half-Sibling Female  (2)
Maternal Grandmother (3)
Maternal Grandfather (4)
Paternal Grandmother (5)
Paternal Grandfather (6)
Maternal Aunt (7)
Maternal Uncle (8)
Paternal Aunt (9)
Number of second-degree relatives affected
Number of second-degree relatives with
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physicians diagnosis
Relationship of second-degree relative(s) to
participant/subject
Half-Sibling Male (1)
Paternal Uncle (10)
Grandchild Male (11)
Grandchild Female (12)
Nephew (13)
Niece (14)
Half-Sibling Female  (2)
Maternal Grandmother (3)
Maternal Grandfather (4)
Paternal Grandmother (5)
Paternal Grandfather (6)
Maternal Aunt (7)
Maternal Uncle (8)
Paternal Aunt (9)
Do you/Does the participant have a history of
Restless Leg Syndrome (RLS)?
Yes (1)
No (2)
Unknown (3)
Does a relative (first and second degree only)
have a history of Restless Leg Syndrome (RLS)?
Yes (1)
No (2)
Unknown (3)
Number of first-degree relatives affected
Number of first degree relatives with physicians
diagnosis
Relationship of first-degree relative(s) to
participant/subject
Biological Mother (1 )
Full biologic child Female (10 )
Biological Father (2 )
Sibling Male (3 )
Sibling Female (4 )
Non-identical or dizygotic twin Male (5 )
Non-identical or dizygotic twin Female (6
)
Identical twin Male (7 )
Identical twin Female (8 )
Full biologic child Male (9 )
Number of second-degree relatives affected
Number of second-degree relatives with
physicians diagnosis
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Relationship of second-degree relative(s) to
participant/subject
Half-Sibling Male (1)
Paternal Uncle (10)
Grandchild Male (11)
Grandchild Female (12)
Nephew (13)
Niece (14)
Half-Sibling Female  (2)
Maternal Grandmother (3)
Maternal Grandfather (4)
Paternal Grandmother (5)
Paternal Grandfather (6)
Maternal Aunt (7)
Maternal Uncle (8)
Paternal Aunt (9)
Do you/does the participant have a history of
Tourette’s Syndrome?
Yes (1)
No (2)
Unknown (3)
Does a relative (first and second degree only)
have a history of Tourette’s Syndrome?
Yes (1)
No (2)
Unknown (3)
Number of first-degree relatives affected
Number of first degree relatives with physicians
diagnosis
Relationship of first-degree relative(s) to
participant/subject
Biological Mother (1 )
Full biologic child Female (10 )
Biological Father (2 )
Sibling Male (3 )
Sibling Female (4 )
Non-identical or dizygotic twin Male (5 )
Non-identical or dizygotic twin Female (6
)
Identical twin Male (7 )
Identical twin Female (8 )
Full biologic child Male (9 )
Number of second-degree relatives affected
Number of second-degree relatives with
physicians diagnosis
Relationship of second-degree relative(s) to
participant/subject
Half-Sibling Male (1)
Paternal Uncle (10)
Grandchild Male (11)
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Grandchild Female (12)
Nephew (13)
Niece (14)
Half-Sibling Female  (2)
Maternal Grandmother (3)
Maternal Grandfather (4)
Paternal Grandmother (5)
Paternal Grandfather (6)
Maternal Aunt (7)
Maternal Uncle (8)
Paternal Aunt (9)
Do you/Does the participant have a history of
Traumatic brain injury?
Yes (1)
No (2)
Unknown (3)
Does a relative (first and second degree only)
have a history of Traumatic brain injury?
Yes (1)
No (2)
Unknown (3)
Number of first-degree relatives affected
Number of first degree relatives with physicians
diagnosis
Relationship of first-degree relative(s) to
participant/subject
Biological Mother (1 )
Full biologic child Female (10 )
Biological Father (2 )
Sibling Male (3 )
Sibling Female (4 )
Non-identical or dizygotic twin Male (5 )
Non-identical or dizygotic twin Female (6
)
Identical twin Male (7 )
Identical twin Female (8 )
Full biologic child Male (9 )
Number of second-degree relatives affected
Number of second-degree relatives with
physicians diagnosis
Relationship of second-degree relative(s) to
participant/subject
Half-Sibling Male (1)
Paternal Uncle (10)
Grandchild Male (11)
Grandchild Female (12)
Nephew (13)
Niece (14)
Half-Sibling Female  (2)
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Maternal Grandmother (3)
Maternal Grandfather (4)
Paternal Grandmother (5)
Paternal Grandfather (6)
Maternal Aunt (7)
Maternal Uncle (8)
Paternal Aunt (9)
Do you/Does the participant have a history of
Tremor?
Yes (1)
No (2)
Unknown (3)
Does a relative (first and second degree only)
have a history of Tremor?
Yes (1)
No (2)
Unknown (3)
Number of first-degree relatives affected
Number of first degree relatives with physicians
diagnosis
Relationship of first-degree relative(s) to
participant/subject
Biological Mother (1 )
Full biologic child Female (10 )
Biological Father (2 )
Sibling Male (3 )
Sibling Female (4 )
Non-identical or dizygotic twin Male (5 )
Non-identical or dizygotic twin Female (6
)
Identical twin Male (7 )
Identical twin Female (8 )
Full biologic child Male (9 )
Number of second-degree relatives affected
Number of second-degree relatives with
physicians diagnosis
Relationship of second-degree relative(s) to
participant/subject
Half-Sibling Male (1)
Paternal Uncle (10)
Grandchild Male (11)
Grandchild Female (12)
Nephew (13)
Niece (14)
Half-Sibling Female  (2)
Maternal Grandmother (3)
Maternal Grandfather (4)
Paternal Grandmother (5)
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Paternal Grandfather (6)
Maternal Aunt (7)
Maternal Uncle (8)
Paternal Aunt (9)
Do you/Does the participant have a history of
Vertigo?
Yes (1)
No (2)
Unknown (3)
Does a relative (first and second degree only)
have a history of Vertigo?
Yes (1)
No (2)
Unknown (3)
Number of first-degree relatives affected
Number of first-degree relatives with physicians
diagnosis
Relationship of first-degree relative(s) to
participant/subject
Biological Mother (1 )
Full biologic child Female (10 )
Biological Father (2 )
Sibling Male (3 )
Sibling Female (4 )
Non-identical or dizygotic twin Male (5 )
Non-identical or dizygotic twin Female (6
)
Identical twin Male (7 )
Identical twin Female (8 )
Full biologic child Male (9 )
Number of second-degree relatives affected
Number of second-degree relatives with
physicians diagnosis
Relationship of second-degree relative(s) to
participant/subject
Half-Sibling Male (1)
Paternal Uncle (10)
Grandchild Male (11)
Grandchild Female (12)
Nephew (13)
Niece (14)
Half-Sibling Female  (2)
Maternal Grandmother (3)
Maternal Grandfather (4)
Paternal Grandmother (5)
Paternal Grandfather (6)
Maternal Aunt (7)
Maternal Uncle (8)
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Paternal Aunt (9)
Please specify any other neurological disorder
you or a relative have a history of
Do you/Does the participant have a history of
prior specified neurological disorder?
Yes (1)
No (2)
Unknown (3)
Does a relative (first and second degree only)
have a history of prior specified neurological
disorder?
Yes (1)
No (2)
Unknown (3)
Number of first-degree relatives affected
Number of first-degree relatives with physicians
diagnosis
Relationship of first-degree relative(s) to
participant/subject
Biological Mother (1 )
Full biologic child Female (10 )
Biological Father (2 )
Sibling Male (3 )
Sibling Female (4 )
Non-identical or dizygotic twin Male (5 )
Non-identical or dizygotic twin Female (6
)
Identical twin Male (7 )
Identical twin Female (8 )
Full biologic child Male (9 )
Number of second degree relatives affected
Number of second degree relatives with
physicians diagnosis
Relationship of second-degree relative(s) to
participant/subject
Half-Sibling Male (1)
Paternal Uncle (10)
Grandchild Male (11)
Grandchild Female (12)
Nephew (13)
Niece (14)
Half-Sibling Female  (2)
Maternal Grandmother (3)
Maternal Grandfather (4)
Paternal Grandmother (5)
Paternal Grandfather (6)
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Maternal Aunt (7)
Maternal Uncle (8)
Paternal Aunt (9)
Do you/Does the participant have a history of
Anxiety?
Yes (1)
No (2)
Unknown (3)
Does a relative (first and second degree only)
have a history of Anxiety?
Yes (1)
No (2)
Unknown (3)
Number of first-degree relatives affected
Number of first-degree relatives with physicians
diagnosis
Relationship of first-degree relative(s) to
participant/subject
Biological Mother (1 )
Full biologic child Female (10 )
Biological Father (2 )
Sibling Male (3 )
Sibling Female (4 )
Non-identical or dizygotic twin Male (5 )
Non-identical or dizygotic twin Female (6
)
Identical twin Male (7 )
Identical twin Female (8 )
Full biologic child Male (9 )
Number of second-degree relatives affected
Number of second-degree relatives with
physicians diagnosis
Relationship of second-degree relative(s) to
participant/subject
Half-Sibling Male (1)
Paternal Uncle (10)
Grandchild Male (11)
Grandchild Female (12)
Nephew (13)
Niece (14)
Half-Sibling Female  (2)
Maternal Grandmother (3)
Maternal Grandfather (4)
Paternal Grandmother (5)
Paternal Grandfather (6)
Maternal Aunt (7)
Maternal Uncle (8)
Paternal Aunt (9)
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Do you/Does the participant have a history of
bipolar disorder?
Yes (1)
No (2)
Unknown (3)
Does a relative (first and second degree only)
have a history of bipolar disorder?
Yes (1)
No (2)
Unknown (3)
Number of first-degree relatives affected
Number of first-degree relatives with physicians
diagnosis
Relationship of first-degree relative(s) to
participant/subject
Biological Mother (1 )
Full biologic child Female (10 )
Biological Father (2 )
Sibling Male (3 )
Sibling Female (4 )
Non-identical or dizygotic twin Male (5 )
Non-identical or dizygotic twin Female (6
)
Identical twin Male (7 )
Identical twin Female (8 )
Full biologic child Male (9 )
Number of second-degree relatives affected
Number of second degree relatives with
physicians diagnosis
Relationship of second-degree relative(s) to
participant/subject
Half-Sibling Male (1)
Paternal Uncle (10)
Grandchild Male (11)
Grandchild Female (12)
Nephew (13)
Niece (14)
Half-Sibling Female  (2)
Maternal Grandmother (3)
Maternal Grandfather (4)
Paternal Grandmother (5)
Paternal Grandfather (6)
Maternal Aunt (7)
Maternal Uncle (8)
Paternal Aunt (9)
Do you/Does the participant have a history of
depression?
Yes (1)
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No (2)
Unknown (3)
Does a relative (first and second degree only)
have a history of Depression?
Yes (1)
No (2)
Unknown (3)
Number of first-degree relatives affected
Number of first degree relatives with physicians
diagnosis
Relationship of first-degree relative(s) to
participant/subject
Biological Mother (1 )
Full biologic child Female (10 )
Biological Father (2 )
Sibling Male (3 )
Sibling Female (4 )
Non-identical or dizygotic twin Male (5 )
Non-identical or dizygotic twin Female (6
)
Identical twin Male (7 )
Identical twin Female (8 )
Full biologic child Male (9 )
Number of second-degree relatives affected
Number of second-degree relatives with
physicians diagnosis
Relationship of second-degree relative(s) to
participant/subject
Half-Sibling Male (1)
Paternal Uncle (10)
Grandchild Male (11)
Grandchild Female (12)
Nephew (13)
Niece (14)
Half-Sibling Female  (2)
Maternal Grandmother (3)
Maternal Grandfather (4)
Paternal Grandmother (5)
Paternal Grandfather (6)
Maternal Aunt (7)
Maternal Uncle (8)
Paternal Aunt (9)
Do you/Does the participant have a history of
Obsessive-compulsive Disorder?
Yes (1)
No (2)
Unknown (3)
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Does a relative (first and second degree only)
have a history of Obsessive-compulsive
Disorder?
Yes (1)
No (2)
Unknown (3)
Number of first-degree relatives affected
Number of first-degree relatives with physicians
diagnosis
Relationship of first-degree relative(s) to
participant/subject
Biological Mother (1 )
Full biologic child Female (10 )
Biological Father (2 )
Sibling Male (3 )
Sibling Female (4 )
Non-identical or dizygotic twin Male (5 )
Non-identical or dizygotic twin Female (6
)
Identical twin Male (7 )
Identical twin Female (8 )
Full biologic child Male (9 )
Number of second-degree relatives affected
Number of second-degree relatives with
physicians diagnosis
Relationship of second-degree relative(s) to
participant/subject
Half-Sibling Male (1)
Paternal Uncle (10)
Grandchild Male (11)
Grandchild Female (12)
Nephew (13)
Niece (14)
Half-Sibling Female  (2)
Maternal Grandmother (3)
Maternal Grandfather (4)
Paternal Grandmother (5)
Paternal Grandfather (6)
Maternal Aunt (7)
Maternal Uncle (8)
Paternal Aunt (9)
Do you/Does the participant have a history of
PTSD?
Yes (1)
No (2)
Unknown (3)
Does a relative (first and second degree only)
have a history of PTSD?
Yes (1)
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No (2)
Unknown (3)
Number of first-degree relatives affected
Number of first-degree relatives with physicians
diagnosis
Relationship of first-degree relatives to
participant/subject
Biological Mother (1 )
Full biologic child Female (10 )
Biological Father (2 )
Sibling Male (3 )
Sibling Female (4 )
Non-identical or dizygotic twin Male (5 )
Non-identical or dizygotic twin Female (6
)
Identical twin Male (7 )
Identical twin Female (8 )
Full biologic child Male (9 )
Number of second-degree relatives affected
Number of second-degree relatives with
physicians diagnosis
Relationship of second-degree relative(s) to
participant/subject
Half-Sibling Male (1)
Paternal Uncle (10)
Grandchild Male (11)
Grandchild Female (12)
Nephew (13)
Niece (14)
Half-Sibling Female  (2)
Maternal Grandmother (3)
Maternal Grandfather (4)
Paternal Grandmother (5)
Paternal Grandfather (6)
Maternal Aunt (7)
Maternal Uncle (8)
Paternal Aunt (9)
Do you/Does the participant have a history of
schizophrenia?
Yes (1)
No (2)
Unknown (3)
Does a relative (first and second degree only)
have a history of schizophrenia?
Yes (1)
No (2)
Unknown (3)
Number of first-degree relatives affected
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Number of first-degree relatives with physicians
diagnosis
Relationship of first-degree relative(s) to
participant/subject
Biological Mother (1 )
Full biologic child Female (10 )
Half-Sibling Male (11 )
Half-Sibling Female  (12 )
Maternal Grandmother (13 )
Maternal Grandfather (14 )
Paternal Grandmother (15)
Paternal Grandfather (16 )
Maternal Aunt (17 )
Maternal Uncle (18 )
Paternal Aunt (19 )
Biological Father (2 )
Paternal Uncle (20 )
Grandchild Male (21 )
Grandchild Female (22 )
Nephew (23 )
Niece (24 )
Sibling Male (3 )
Sibling Female (4 )
Non-identical or dizygotic twin Male (5 )
Non-identical or dizygotic twin Female (6
)
Identical twin Male (7 )
Identical twin Female (8 )
Full biologic child Male (9 )
Number of second-degree relatives affected
Number of second-degree relatives with
physicians diagnosis
Relationship of second-degree relative(s) to
participant/subject
Half-Sibling Male (1)
Paternal Uncle (10)
Grandchild Male (11)
Grandchild Female (12)
Nephew (13)
Niece (14)
Half-Sibling Female  (2)
Maternal Grandmother (3)
Maternal Grandfather (4)
Paternal Grandmother (5)
Paternal Grandfather (6)
Maternal Aunt (7)
Maternal Uncle (8)
Paternal Aunt (9)
Do you/Does the participant have a history of
Suicide and/or suicide attempt?
Yes (1)
No (2)
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Unknown (3)
Does a relative (first and second degree only)
have a history of Suicide and/or suicide attempt?
Yes (1)
No (2)
Unknown (3)
Number of first-degree relatives affected
Number of first-degree relatives with physicians
diagnosis
Relationship of first-degree relative(s) to
participant/subject
Biological Mother (1 )
Full biologic child Female (10 )
Biological Father (2 )
Sibling Male (3 )
Sibling Female (4 )
Non-identical or dizygotic twin Male (5 )
Non-identical or dizygotic twin Female (6
)
Identical twin Male (7 )
Identical twin Female (8 )
Full biologic child Male (9 )
Number of second-degree relatives affected
Number of second-degree relatives with
physicians diagnosis
Relationship of second-degree relative(s) to
participant/subject
Half-Sibling Male (1)
Paternal Uncle (10)
Grandchild Male (11)
Grandchild Female (12)
Nephew (13)
Niece (14)
Half-Sibling Female  (2)
Maternal Grandmother (3)
Maternal Grandfather (4)
Paternal Grandmother (5)
Paternal Grandfather (6)
Maternal Aunt (7)
Maternal Uncle (8)
Paternal Aunt (9)
Do you/Does the participant have a history of
alcohol addiction?
Yes (1)
No (2)
Unknown (3)
Does a relative (first and second degree only)
have a history of alcohol addiction?
Yes (1)
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No (2)
Unknown (3)
Number of first-degree relatives affected
Number of first-degree relatives with physicians
diagnosis
Relationship of first-degree relative(s) to
participant/subject
Biological Mother (1 )
Full biologic child Female (10 )
Biological Father (2 )
Sibling Male (3 )
Sibling Female (4 )
Non-identical or dizygotic twin Male (5 )
Non-identical or dizygotic twin Female (6
)
Identical twin Male (7 )
Identical twin Female (8 )
Full biologic child Male (9 )
Number of second-degree relatives affected
Number of second-degree relatives with
physicians diagnosis
Relationship of second-degree relative(s) to
participant/subject
Half-Sibling Male (1)
Paternal Uncle (10)
Grandchild Male (11)
Grandchild Female (12)
Nephew (13)
Niece (14)
Half-Sibling Female  (2)
Maternal Grandmother (3)
Maternal Grandfather (4)
Paternal Grandmother (5)
Paternal Grandfather (6)
Maternal Aunt (7)
Maternal Uncle (8)
Paternal Aunt (9)
Do you/does the participant have a history of illicit
drug addiction?
Yes (1)
No (2)
Unknown (3)
Does a relative (first and second degree only)
have a history of illicit drug addiction?
Yes (1)
No (2)
Unknown (3)
Number of first-degree relatives affected
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Number of first-degree relatives with physicians
diagnosis
Relationship of first-degree relative(s) to
participant/subject
Biological Mother (1 )
Full biologic child Female (10 )
Biological Father (2 )
Sibling Male (3 )
Sibling Female (4 )
Non-identical or dizygotic twin Male (5 )
Non-identical or dizygotic twin Female (6
)
Identical twin Male (7 )
Identical twin Female (8 )
Full biologic child Male (9 )
Number of second-degree relatives affected
Number of second-degree relatives with
physicians diagnosis
Relationship of second-degree relative(s) to
participant/subject
Half-Sibling Male (1)
Paternal Uncle (10)
Grandchild Male (11)
Grandchild Female (12)
Nephew (13)
Niece (14)
Half-Sibling Female  (2)
Maternal Grandmother (3)
Maternal Grandfather (4)
Paternal Grandmother (5)
Paternal Grandfather (6)
Maternal Aunt (7)
Maternal Uncle (8)
Paternal Aunt (9)
Do you/Does the participant have a history of
prescription drug addiction?
Yes (1)
No (2)
Unknown (3)
Does a relative (first and second degree only)
have a history of prescription drug addiction?
Yes (1)
No (2)
Unknown (3)
Number of first-degree relatives affected
Number of first-degree relatives with physicians
diagnosis
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Relationship of first-degree relative(s) to
participant/subject
Biological Mother (1 )
Full biologic child Female (10 )
Biological Father (2 )
Sibling Male (3 )
Sibling Female (4 )
Non-identical or dizygotic twin Male (5 )
Non-identical or dizygotic twin Female (6
)
Identical twin Male (7 )
Identical twin Female (8 )
Full biologic child Male (9 )
Number of second-degree relatives affected
Number of second-degree relatives with
physicians diagnosis
Relationship of second-degree relative(s) to
participant/subject
Half-Sibling Male (1)
Paternal Uncle (10)
Grandchild Male (11)
Grandchild Female (12)
Nephew (13)
Niece (14)
Half-Sibling Female  (2)
Maternal Grandmother (3)
Maternal Grandfather (4)
Paternal Grandmother (5)
Paternal Grandfather (6)
Maternal Aunt (7)
Maternal Uncle (8)
Paternal Aunt (9)
Do you/Does the participant have a history of
anorexia?
Yes (1)
No (2)
Unknown (3)
Does a relative (first and second degree only)
have a history of anorexia?
Yes (1)
No (2)
Unknown (3)
Number of first-degree relatives affected
Number of first-degree relatives with physicians
diagnosis
Relationship of first-degree relative(s) to
participant/subject
Biological Mother (1 )
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Full biologic child Female (10 )
Biological Father (2 )
Sibling Male (3 )
Sibling Female (4 )
Non-identical or dizygotic twin Male (5 )
Non-identical or dizygotic twin Female (6
)
Identical twin Male (7 )
Identical twin Female (8 )
Full biologic child Male (9 )
Number of second-degree relatives affected
Number of second-degree relatives with
physicians diagnosis
Relationship of second-degree relative(s) to
participant/subject
Half-Sibling Male (1)
Paternal Uncle (10)
Grandchild Male (11)
Grandchild Female (12)
Nephew (13)
Niece (14)
Half-Sibling Female  (2)
Maternal Grandmother (3)
Maternal Grandfather (4)
Paternal Grandmother (5)
Paternal Grandfather (6)
Maternal Aunt (7)
Maternal Uncle (8)
Paternal Aunt (9)
Do you/Does the participant have a history of
bulimia?
Yes (1)
No (2)
Unknown (3)
Does a relative (first and second degree only)
have a history of bulimia?
Yes (1)
No (2)
Unknown (3)
Number of first-degree relatives affected
Number of first-degree relatives with physicians
diagnosis
Relationship of first-degree relative(s) to
participant/subject
Biological Mother (1 )
Full biologic child Female (10 )
Biological Father (2 )
Sibling Male (3 )
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Sibling Female (4 )
Non-identical or dizygotic twin Male (5 )
Non-identical or dizygotic twin Female (6
)
Identical twin Male (7 )
Identical twin Female (8 )
Full biologic child Male (9 )
Number of second-degree relatives affected
Number of second-degree relatives with
physicians diagnosis
Relationship of second-degree relative(s) to
participant/subject
Half-Sibling Male (1)
Paternal Uncle (10)
Grandchild Male (11)
Grandchild Female (12)
Nephew (13)
Niece (14)
Half-Sibling Female  (2)
Maternal Grandmother (3)
Maternal Grandfather (4)
Paternal Grandmother (5)
Paternal Grandfather (6)
Maternal Aunt (7)
Maternal Uncle (8)
Paternal Aunt (9)
Do you/Does the participant have a history of
binge eating?
Yes (1)
No (2)
Unknown (3)
Does a relative (first and second degree only)
have a history of binge eating?
Yes (1)
No (2)
Unknown (3)
Number of first-degree relatives affected
Number of first-degree relatives with physicians
diagnosis
Relationship of first-degree relative(s) to
participant/subject
Biological Mother (1 )
Full biologic child Female (10 )
Biological Father (2 )
Sibling Male (3 )
Sibling Female (4 )
Non-identical or dizygotic twin Male (5 )
Non-identical or dizygotic twin Female (6
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)
Identical twin Male (7 )
Identical twin Female (8 )
Full biologic child Male (9 )
Number of second-degree relatives affected
Number of second-degree relatives with
physicians diagnosis
Relationship of second-degree relative(s) to
participant/subject
Half-Sibling Male (1)
Paternal Uncle (10)
Grandchild Male (11)
Grandchild Female (12)
Nephew (13)
Niece (14)
Half-Sibling Female  (2)
Maternal Grandmother (3)
Maternal Grandfather (4)
Paternal Grandmother (5)
Paternal Grandfather (6)
Maternal Aunt (7)
Maternal Uncle (8)
Paternal Aunt (9)
Do you/Does the participant have a history of
insomnia?
Yes (1)
No (2)
Unknown (3)
Does a relative (first and second degree only)
have a history of insomnia?
Yes (1)
No (2)
Unknown (3)
Number of first-degree relatives affected
Number of first-degree relatives with physicians
diagnosis
Relationship of first-degree relative(s) to
participant/subject
Biological Mother (1 )
Full biologic child Female (10 )
Biological Father (2 )
Sibling Male (3 )
Sibling Female (4 )
Non-identical or dizygotic twin Male (5 )
Non-identical or dizygotic twin Female (6
)
Identical twin Male (7 )
Identical twin Female (8 )
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Full biologic child Male (9 )
Number of second-degree relatives affected
Number of second-degree relatives with
physicians diagnosis
Relationship of second-degree relative(s) to
participant/subject
Half-Sibling Male (1)
Paternal Uncle (10)
Grandchild Male (11)
Grandchild Female (12)
Nephew (13)
Niece (14)
Half-Sibling Female  (2)
Maternal Grandmother (3)
Maternal Grandfather (4)
Paternal Grandmother (5)
Paternal Grandfather (6)
Maternal Aunt (7)
Maternal Uncle (8)
Paternal Aunt (9)
Do you/Does the participant have a history of
sleep apnea?
Yes (1)
No (2)
Unknown (3)
Does a relative (first and second degree only)
have a history of sleep apnea?
Yes (1)
No (2)
Unknown (3)
Number of first-degree relatives affected
Number of first-degree relatives with physicians
diagnosis
Relationship of first-degree relative(s) to
participant/subject
Biological Mother (1 )
Full biologic child Female (10 )
Biological Father (2 )
Sibling Male (3 )
Sibling Female (4 )
Non-identical or dizygotic twin Male (5 )
Non-identical or dizygotic twin Female (6
)
Identical twin Male (7 )
Identical twin Female (8 )
Full biologic child Male (9 )
Number of second-degree relatives affected
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Number of second-degree relatives with
physicians diagnosis
Relationship of second-degree relatives to
participant/subject
Half-Sibling Male (1)
Paternal Uncle (10)
Grandchild Male (11)
Grandchild Female (12)
Nephew (13)
Niece (14)
Half-Sibling Female  (2)
Maternal Grandmother (3)
Maternal Grandfather (4)
Paternal Grandmother (5)
Paternal Grandfather (6)
Maternal Aunt (7)
Maternal Uncle (8)
Paternal Aunt (9)
Do you/Does the participant have a history of
narcolepsy?
Yes (1)
No (2)
Unknown (3)
Does a relative (first and second degree only)
have a history of narcolepsy?
Yes (1)
No (2)
Unknown (3)
Number of first-degree relatives affected
Number of first-degree relatives with physicians
diagnosis
Relationship of first-degree relatives to
participant/subject
Biological Mother (1 )
Full biologic child Female (10 )
Biological Father (2 )
Sibling Male (3 )
Sibling Female (4 )
Non-identical or dizygotic twin Male (5 )
Non-identical or dizygotic twin Female (6
)
Identical twin Male (7 )
Identical twin Female (8 )
Full biologic child Male (9 )
Number of second-degree relatives affected
Number of second-degree relatives with
physicians diagnosis
61 / 65
NINDS CDE General Health History Headache
Relationship of second-degree relative(s) to
participant/subject
Half-Sibling Male (1)
Paternal Uncle (10)
Grandchild Male (11)
Grandchild Female (12)
Nephew (13)
Niece (14)
Half-Sibling Female  (2)
Maternal Grandmother (3)
Maternal Grandfather (4)
Paternal Grandmother (5)
Paternal Grandfather (6)
Maternal Aunt (7)
Maternal Uncle (8)
Paternal Aunt (9)
Other sleep condition, please specify
Do you/Does the participant have a history of
prior specified sleep condition?
Yes (1)
No (2)
Unknown (3)
Does a relative (first and second degree only)
have a history of prior specified sleep condition?
Yes (1)
No (2)
Unknown (3)
Number of first-degree relatives affected
Number of first-degree relatives with physicians
diagnosis
Relationship of first-degree relative(s) to
participant/subject
Biological Mother (1 )
Full biologic child Female (10 )
Biological Father (2 )
Sibling Male (3 )
Sibling Female (4 )
Non-identical or dizygotic twin Male (5 )
Non-identical or dizygotic twin Female (6
)
Identical twin Male (7 )
Identical twin Female (8 )
Full biologic child Male (9 )
Number of second-degree relatives affected
Number of second-degree relatives with
physicians diagnosis
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Relationship of second-degree relatives to
participant/subject
Half-Sibling Male (1)
Paternal Uncle (10)
Grandchild Male (11)
Grandchild Female (12)
Nephew (13)
Niece (14)
Half-Sibling Female  (2)
Maternal Grandmother (3)
Maternal Grandfather (4)
Paternal Grandmother (5)
Paternal Grandfather (6)
Maternal Aunt (7)
Maternal Uncle (8)
Paternal Aunt (9)
Do you/Does the participant have a history of
obesity?
Yes (1)
No (2)
Unknown (3)
Does a relative (first and second degree only)
have a history of obesity?
Yes (1)
No (2)
Unknown (3)
Number of first-degree relatives affected
Number of first-degree relatives with physicians
diagnosis
Relationship of first-degree relative(s) to
participant/subject
Biological Mother (1 )
Full biologic child Female (10 )
Biological Father (2 )
Sibling Male (3 )
Sibling Female (4 )
Non-identical or dizygotic twin Male (5 )
Non-identical or dizygotic twin Female (6
)
Identical twin Male (7 )
Identical twin Female (8 )
Full biologic child Male (9 )
Number of second degree relatives affected
Number of second-degree relatives with
physicians diagnosis
Relationship of second-degree relative(s) to
participant/subject
Half-Sibling Male (1)
Paternal Uncle (10)
Grandchild Male (11)
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Grandchild Female (12)
Nephew (13)
Niece (14)
Half-Sibling Female  (2)
Maternal Grandmother (3)
Maternal Grandfather (4)
Paternal Grandmother (5)
Paternal Grandfather (6)
Maternal Aunt (7)
Maternal Uncle (8)
Paternal Aunt (9)
Other comorbidity, please specify
Do you/Does the participant have a history of
prior specified comorbidity?
Yes (1)
No (2)
Unknown (3)
Does a relative (first and second degree only)
have a history of prior specified comorbidity?
Yes (1)
No (2)
Unknown (3)
Number of first-degree relatives affected
Number of first-degree relatives with physicians
diagnosis
Relationship of first-degree relative(s) to
participant/subject
Biological Mother (1 )
Full biologic child Female (10 )
Biological Father (2 )
Sibling Male (3 )
Sibling Female (4 )
Non-identical or dizygotic twin Male (5 )
Non-identical or dizygotic twin Female (6
)
Identical twin Male (7 )
Identical twin Female (8 )
Full biologic child Male (9 )
Number of second-degree relatives affected
Number of second-degree relatives with
physicians diagnosis
Relationship of second-degree relatives to
participant/subject
Half-Sibling Male (1)
Paternal Uncle (10)
Grandchild Male (11)
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Grandchild Female (12)
Nephew (13)
Niece (14)
Half-Sibling Female  (2)
Maternal Grandmother (3)
Maternal Grandfather (4)
Paternal Grandmother (5)
Paternal Grandfather (6)
Maternal Aunt (7)
Maternal Uncle (8)
Paternal Aunt (9)
Additional comments
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Month 3: EDSS Multiple Sclerosis ALAIN01
NCT02419378
Alemtuzumab in Autoimmune Inflammatory
Neurodegeneration: Mechanisms of Action and
Neuroprotective Potential (ALAIN01)
https://clinicaltrials.gov/ct2/show/NCT02419378
Principal Investigator Prof. Dr. Dr. Sven Meuth, University
Hospital Muenster, Germany
Part: Month 3
All rights reserved. Please visit https://medical-data-
models.org/forms/15455
Month 3: EDSS Multiple Sclerosis
ALAIN01 NCT02419378
EDSS
Patient ID (derived)
EDSS: Date
EDSS: Visual System Score
0 (0)
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
EDSS: Brainstem System Score
0 (0)
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
EDSS: Pyramidal System Score
0 (0)
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
EDSS: Cerebellar System Score
0 (0)
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
EDSS: Sensory System Score
0 (0)
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
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EDSS: Bowel/Bladder System Score
0 (0)
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
EDSS: Cerebral System Score
0 (0)
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
EDSS: Ambulation Score
0 (0)
1 (1)
10 (10)
11 (11)
12 (12)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
7 (7)
8 (8)
9 (9)
EDSS: Cerebellar System Score (X)
X (X)
EDSS Step
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Month 3: EDSS Multiple Sclerosis ALAIN01 NCT02419378
Month 6: EDSS Multiple Sclerosis ALAIN01
NCT02419378
Alemtuzumab in Autoimmune Inflammatory
Neurodegeneration: Mechanisms of Action and
Neuroprotective Potential (ALAIN01)
https://clinicaltrials.gov/ct2/show/NCT02419378
Principal Investigator Prof. Dr. Dr. Sven Meuth, University
Hospital Muenster, Germany
Part: Month 6
All rights reserved. Please visit https://medical-data-
models.org/forms/15456
Month 6: EDSS Multiple Sclerosis
ALAIN01 NCT02419378
EDSS
Patient ID (derived)
EDSS: Date
EDSS: Visual System Score
0 (0)
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
EDSS: Brainstem System Score
0 (0)
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
EDSS: Pyramidal System Score
0 (0)
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
EDSS: Cerebellar System Score
0 (0)
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
EDSS: Sensory System Score
0 (0)
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
1 / 2
EDSS: Bowel/Bladder System Score
0 (0)
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
EDSS: Cerebral System Score
0 (0)
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
EDSS: Ambulation Score
0 (0)
1 (1)
10 (10)
11 (11)
12 (12)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
7 (7)
8 (8)
9 (9)
EDSS: Cerebellar System Score (X)
X (X)
EDSS Step
2 / 2
Month 6: EDSS Multiple Sclerosis ALAIN01 NCT02419378
Month 9: EDSS Multiple Sclerosis ALAIN01
NCT02419378
Alemtuzumab in Autoimmune Inflammatory
Neurodegeneration: Mechanisms of Action and
Neuroprotective Potential (ALAIN01)
https://clinicaltrials.gov/ct2/show/NCT02419378
Principal Investigator Prof. Dr. Dr. Sven Meuth, University
Hospital Muenster, Germany
Part: Month 9
All rights reserved. Please visit https://medical-data-
models.org/forms/15457
Month 9: EDSS Multiple Sclerosis
ALAIN01 NCT02419378
EDSS
Patient ID (derived)
EDSS: Date
EDSS: Visual System Score
0 (0)
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
EDSS: Brainstem System Score
0 (0)
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
EDSS: Pyramidal System Score
0 (0)
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
EDSS: Cerebellar System Score
0 (0)
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
EDSS: Sensory System Score
0 (0)
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
1 / 2
EDSS: Bowel/Bladder System Score
0 (0)
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
EDSS: Cerebral System Score
0 (0)
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
EDSS: Ambulation Score
0 (0)
1 (1)
10 (10)
11 (11)
12 (12)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
7 (7)
8 (8)
9 (9)
EDSS: Cerebellar System Score (X)
X (X)
EDSS Step
2 / 2
Month 9: EDSS Multiple Sclerosis ALAIN01 NCT02419378
Eligibility Major Depressive Disorder
NCT02375308
Efficacy of Cognitive Behavioral to Hypnotherapeutic
Treatment of Depression; ODM derived from:
https://clinicaltrials.gov/show/NCT02375308
All rights reserved. Please visit https://medical-data-
models.org/forms/15458
Eligibility Major Depressive Disorder
NCT02375308
Inclusion Criteria
dsm-5 (diagnostic and statistical manual) criteria
for current mild to moderate major depressive
episode (mde)*
Yes
No
informed consent*
Yes
No
fluent in german*
Yes
No
time for weekly therapy sessions*
Yes
No
stable antidepressant medication since three
months*
Yes
No
Exclusion Criteria
a history of lifetime bipolar disorder, psychotic
symptoms*
Yes
No
a diagnosis of a chronic major depressive
disorder (total duration of two years and more)*
Yes
No
fulfilling the dsm-5 criteria for current severe mde
or scores in madrs >/= 35 or qidsc16 (quick
inventory of depressive symptomatology) >/= 16*
Yes
No
remission of current mde since more than four
weeks prior to inclusion assessment*
Yes
No
acute risk for suicide*
Yes
No
1 / 2
severe cognitive impairment (confirmed suspicion
with mini-mental-state-test > 25)*
Yes
No
a dominating primary diagnosis of another axis i
disorder including anxiety disorders (e.g. panic
disorder, posttraumatic stress disorder, anorexia
nervosa, borderline personality disorder), or any
severe substance-related abuse or dependence
disorder*
Yes
No
a physical illness which would interfere with
regular psychotherapy sessions*
Yes
No
outpatient psychotherapy during the last 12
months*
Yes
No
2 / 2
Eligibility Major Depressive Disorder NCT02375308
Month 15: EDSS Multiple Sclerosis
ALAIN01 NCT02419378
Alemtuzumab in Autoimmune Inflammatory
Neurodegeneration: Mechanisms of Action and
Neuroprotective Potential (ALAIN01)
https://clinicaltrials.gov/ct2/show/NCT02419378
Principal Investigator Prof. Dr. Dr. Sven Meuth, University
Hospital Muenster, Germany
Part: Month 15
All rights reserved. Please visit https://medical-data-
models.org/forms/15459
Month 15: EDSS Multiple Sclerosis
ALAIN01 NCT02419378
EDSS
Patient ID (derived)
EDSS: Date
EDSS: Visual System Score
0 (0)
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
EDSS: Brainstem System Score
0 (0)
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
EDSS: Pyramidal System Score
0 (0)
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
EDSS: Cerebellar System Score
0 (0)
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
EDSS: Sensory System Score
0 (0)
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
1 / 2
EDSS: Bowel/Bladder System Score
0 (0)
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
EDSS: Cerebral System Score
0 (0)
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
EDSS: Ambulation Score
0 (0)
1 (1)
10 (10)
11 (11)
12 (12)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
7 (7)
8 (8)
9 (9)
EDSS: Cerebellar System Score (X)
X (X)
EDSS Step
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Month 15: EDSS Multiple Sclerosis ALAIN01 NCT02419378
Month 18: EDSS Multiple Sclerosis
ALAIN01 NCT02419378
Alemtuzumab in Autoimmune Inflammatory
Neurodegeneration: Mechanisms of Action and
Neuroprotective Potential (ALAIN01)
https://clinicaltrials.gov/ct2/show/NCT02419378
Principal Investigator Prof. Dr. Dr. Sven Meuth, University
Hospital Muenster, Germany
Part: Month 18
All rights reserved. Please visit https://medical-data-
models.org/forms/15460
Month 18: EDSS Multiple Sclerosis
ALAIN01 NCT02419378
EDSS
Patient ID (derived)
EDSS: Date
EDSS: Visual System Score
0 (0)
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
EDSS: Brainstem System Score
0 (0)
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
EDSS: Pyramidal System Score
0 (0)
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
EDSS: Cerebellar System Score
0 (0)
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
EDSS: Sensory System Score
0 (0)
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
1 / 2
EDSS: Bowel/Bladder System Score
0 (0)
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
EDSS: Cerebral System Score
0 (0)
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
EDSS: Ambulation Score
0 (0)
1 (1)
10 (10)
11 (11)
12 (12)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
7 (7)
8 (8)
9 (9)
EDSS: Cerebellar System Score (X)
X (X)
EDSS Step
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Month 18: EDSS Multiple Sclerosis ALAIN01 NCT02419378
Month 21: EDSS Multiple Sclerosis
ALAIN01 NCT02419378
Alemtuzumab in Autoimmune Inflammatory
Neurodegeneration: Mechanisms of Action and
Neuroprotective Potential (ALAIN01)
https://clinicaltrials.gov/ct2/show/NCT02419378
Principal Investigator Prof. Dr. Dr. Sven Meuth, University
Hospital Muenster, Germany
Part: Month 21
All rights reserved. Please visit https://medical-data-
models.org/forms/15462
Month 21: EDSS Multiple Sclerosis
ALAIN01 NCT02419378
EDSS
Patient ID (derived)
EDSS: Date
EDSS: Visual System Score
0 (0)
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
EDSS: Brainstem System Score
0 (0)
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
EDSS: Pyramidal System Score
0 (0)
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
EDSS: Cerebellar System Score
0 (0)
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
EDSS: Sensory System Score
0 (0)
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
1 / 2
EDSS: Bowel/Bladder System Score
0 (0)
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
EDSS: Cerebral System Score
0 (0)
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
EDSS: Ambulation Score
0 (0)
1 (1)
10 (10)
11 (11)
12 (12)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
7 (7)
8 (8)
9 (9)
EDSS: Cerebellar System Score (X)
X (X)
EDSS Step
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Month 21: EDSS Multiple Sclerosis ALAIN01 NCT02419378
Month 24: EDSS Multiple Sclerosis
ALAIN01 NCT02419378
Alemtuzumab in Autoimmune Inflammatory
Neurodegeneration: Mechanisms of Action and
Neuroprotective Potential (ALAIN01)
https://clinicaltrials.gov/ct2/show/NCT02419378
Principal Investigator Prof. Dr. Dr. Sven Meuth, University
Hospital Muenster, Germany
Part: Month 24
All rights reserved. Please visit https://medical-data-
models.org/forms/15463
Month 24: EDSS Multiple Sclerosis
ALAIN01 NCT02419378
EDSS
Patient ID (derived)
EDSS: Date
EDSS: Visual System Score
0 (0)
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
EDSS: Brainstem System Score
0 (0)
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
EDSS: Pyramidal System Score
0 (0)
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
EDSS: Cerebellar System Score
0 (0)
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
EDSS: Sensory System Score
0 (0)
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
1 / 2
EDSS: Bowel/Bladder System Score
0 (0)
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
EDSS: Cerebral System Score
0 (0)
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
EDSS: Ambulation Score
0 (0)
1 (1)
10 (10)
11 (11)
12 (12)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
7 (7)
8 (8)
9 (9)
EDSS: Cerebellar System Score (X)
X (X)
EDSS Step
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Month 24: EDSS Multiple Sclerosis ALAIN01 NCT02419378
Month 27: EDSS Multiple Sclerosis
ALAIN01 NCT02419378
Alemtuzumab in Autoimmune Inflammatory
Neurodegeneration: Mechanisms of Action and
Neuroprotective Potential (ALAIN01)
https://clinicaltrials.gov/ct2/show/NCT02419378
Principal Investigator Prof. Dr. Dr. Sven Meuth, University
Hospital Muenster, Germany
Part: Month 27
All rights reserved. Please visit https://medical-data-
models.org/forms/15464
Month 27: EDSS Multiple Sclerosis
ALAIN01 NCT02419378
EDSS
Patient ID (derived)
EDSS: Date
EDSS: Visual System Score
0 (0)
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
EDSS: Brainstem System Score
0 (0)
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
EDSS: Pyramidal System Score
0 (0)
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
EDSS: Cerebellar System Score
0 (0)
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
EDSS: Sensory System Score
0 (0)
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
1 / 2
EDSS: Bowel/Bladder System Score
0 (0)
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
EDSS: Cerebral System Score
0 (0)
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
EDSS: Ambulation Score
0 (0)
1 (1)
10 (10)
11 (11)
12 (12)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
7 (7)
8 (8)
9 (9)
EDSS: Cerebellar System Score (X)
X (X)
EDSS Step
2 / 2
Month 27: EDSS Multiple Sclerosis ALAIN01 NCT02419378
Month 30: EDSS Multiple Sclerosis
ALAIN01 NCT02419378
Alemtuzumab in Autoimmune Inflammatory
Neurodegeneration: Mechanisms of Action and
Neuroprotective Potential (ALAIN01)
https://clinicaltrials.gov/ct2/show/NCT02419378
Principal Investigator Prof. Dr. Dr. Sven Meuth, University
Hospital Muenster, Germany
Part: Month 30
All rights reserved. Please visit https://medical-data-
models.org/forms/15465
Month 30: EDSS Multiple Sclerosis
ALAIN01 NCT02419378
EDSS
Patient ID (derived)
EDSS: Date
EDSS: Visual System Score
0 (0)
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
EDSS: Brainstem System Score
0 (0)
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
EDSS: Pyramidal System Score
0 (0)
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
EDSS: Cerebellar System Score
0 (0)
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
EDSS: Sensory System Score
0 (0)
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
1 / 2
EDSS: Bowel/Bladder System Score
0 (0)
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
EDSS: Cerebral System Score
0 (0)
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
EDSS: Ambulation Score
0 (0)
1 (1)
10 (10)
11 (11)
12 (12)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
7 (7)
8 (8)
9 (9)
EDSS: Cerebellar System Score (X)
X (X)
EDSS Step
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Month 30: EDSS Multiple Sclerosis ALAIN01 NCT02419378
Month 33: EDSS Multiple Sclerosis
ALAIN01 NCT02419378
Alemtuzumab in Autoimmune Inflammatory
Neurodegeneration: Mechanisms of Action and
Neuroprotective Potential (ALAIN01)
https://clinicaltrials.gov/ct2/show/NCT02419378
Principal Investigator Prof. Dr. Dr. Sven Meuth, University
Hospital Muenster, Germany
Part: Month 33
All rights reserved. Please visit https://medical-data-
models.org/forms/15466
Month 33: EDSS Multiple Sclerosis
ALAIN01 NCT02419378
EDSS
Patient ID (derived)
EDSS: Date
EDSS: Visual System Score
0 (0)
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
EDSS: Brainstem System Score
0 (0)
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
EDSS: Pyramidal System Score
0 (0)
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
EDSS: Cerebellar System Score
0 (0)
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
EDSS: Sensory System Score
0 (0)
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
1 / 2
EDSS: Bowel/Bladder System Score
0 (0)
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
EDSS: Cerebral System Score
0 (0)
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
EDSS: Ambulation Score
0 (0)
1 (1)
10 (10)
11 (11)
12 (12)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
7 (7)
8 (8)
9 (9)
EDSS: Cerebellar System Score (X)
X (X)
EDSS Step
2 / 2
Month 33: EDSS Multiple Sclerosis ALAIN01 NCT02419378
Month 36: EDSS Multiple Sclerosis
ALAIN01 NCT02419378
Alemtuzumab in Autoimmune Inflammatory
Neurodegeneration: Mechanisms of Action and
Neuroprotective Potential (ALAIN01)
https://clinicaltrials.gov/ct2/show/NCT02419378
Principal Investigator Prof. Dr. Dr. Sven Meuth, University
Hospital Muenster, Germany
Part: Month 36
All rights reserved. Please visit https://medical-data-
models.org/forms/15467
Month 36: EDSS Multiple Sclerosis
ALAIN01 NCT02419378
EDSS
Patient ID (derived)
EDSS: Date
EDSS: Visual System Score
0 (0)
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
EDSS: Brainstem System Score
0 (0)
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
EDSS: Pyramidal System Score
0 (0)
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
EDSS: Cerebellar System Score
0 (0)
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
EDSS: Sensory System Score
0 (0)
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
1 / 2
EDSS: Bowel/Bladder System Score
0 (0)
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
EDSS: Cerebral System Score
0 (0)
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
EDSS: Ambulation Score
0 (0)
1 (1)
10 (10)
11 (11)
12 (12)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
7 (7)
8 (8)
9 (9)
EDSS: Cerebellar System Score (X)
X (X)
EDSS Step
2 / 2
Month 36: EDSS Multiple Sclerosis ALAIN01 NCT02419378
Relapse Evaluation Visit 1: EDSS Multiple
Sclerosis ALAIN01 NCT02419378
Alemtuzumab in Autoimmune Inflammatory
Neurodegeneration: Mechanisms of Action and
Neuroprotective Potential (ALAIN01)
https://clinicaltrials.gov/ct2/show/NCT02419378
Principal Investigator Prof. Dr. Dr. Sven Meuth, University
Hospital Muenster, Germany
Part: Relapse Evaluation Visit 1
All rights reserved. Please visit https://medical-data-
models.org/forms/15468
Relapse Evaluation Visit 1: EDSS
Multiple Sclerosis ALAIN01
NCT02419378
EDSS
Patient ID (derived)
EDSS: Date
EDSS: Visual System Score
0 (0)
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
EDSS: Brainstem System Score
0 (0)
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
EDSS: Pyramidal System Score
0 (0)
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
EDSS: Cerebellar System Score
0 (0)
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
EDSS: Sensory System Score
0 (0)
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
1 / 2
6 (6)
EDSS: Bowel/Bladder System Score
0 (0)
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
EDSS: Cerebral System Score
0 (0)
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
EDSS: Ambulation Score
0 (0)
1 (1)
10 (10)
11 (11)
12 (12)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
7 (7)
8 (8)
9 (9)
EDSS: Cerebellar System Score (X)
X (X)
EDSS Step
2 / 2
Relapse Evaluation Visit 1: EDSS Multiple Sclerosis ALAIN01
NCT02419378
Relapse Evaluation Visit 2: EDSS Multiple
Sclerosis ALAIN01 NCT02419378
Alemtuzumab in Autoimmune Inflammatory
Neurodegeneration: Mechanisms of Action and
Neuroprotective Potential (ALAIN01)
https://clinicaltrials.gov/ct2/show/NCT02419378
Principal Investigator Prof. Dr. Dr. Sven Meuth, University
Hospital Muenster, Germany
Part: Relapse Evaluation Visit 2
All rights reserved. Please visit https://medical-data-
models.org/forms/15469
Relapse Evaluation Visit 2: EDSS
Multiple Sclerosis ALAIN01
NCT02419378
EDSS
Patient ID (derived)
EDSS: Date
EDSS: Visual System Score
0 (0)
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
EDSS: Brainstem System Score
0 (0)
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
EDSS: Pyramidal System Score
0 (0)
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
EDSS: Cerebellar System Score
0 (0)
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
EDSS: Sensory System Score
0 (0)
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
1 / 2
6 (6)
EDSS: Bowel/Bladder System Score
0 (0)
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
EDSS: Cerebral System Score
0 (0)
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
EDSS: Ambulation Score
0 (0)
1 (1)
10 (10)
11 (11)
12 (12)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
7 (7)
8 (8)
9 (9)
EDSS: Cerebellar System Score (X)
X (X)
EDSS Step
2 / 2
Relapse Evaluation Visit 2: EDSS Multiple Sclerosis ALAIN01
NCT02419378
Relapse Evaluation Visit 3: EDSS Multiple
Sclerosis ALAIN01 NCT02419378
Alemtuzumab in Autoimmune Inflammatory
Neurodegeneration: Mechanisms of Action and
Neuroprotective Potential (ALAIN01)
https://clinicaltrials.gov/ct2/show/NCT02419378
Principal Investigator Prof. Dr. Dr. Sven Meuth, University
Hospital Muenster, Germany
Part: Relapse Evaluation Visit 3
All rights reserved. Please visit https://medical-data-
models.org/forms/15470
Relapse Evaluation Visit 3: EDSS
Multiple Sclerosis ALAIN01
NCT02419378
EDSS
Patient ID (derived)
EDSS: Date
EDSS: Visual System Score
0 (0)
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
EDSS: Brainstem System Score
0 (0)
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
EDSS: Pyramidal System Score
0 (0)
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
EDSS: Cerebellar System Score
0 (0)
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
EDSS: Sensory System Score
0 (0)
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
1 / 2
6 (6)
EDSS: Bowel/Bladder System Score
0 (0)
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
EDSS: Cerebral System Score
0 (0)
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
EDSS: Ambulation Score
0 (0)
1 (1)
10 (10)
11 (11)
12 (12)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
7 (7)
8 (8)
9 (9)
EDSS: Cerebellar System Score (X)
X (X)
EDSS Step
2 / 2
Relapse Evaluation Visit 3: EDSS Multiple Sclerosis ALAIN01
NCT02419378
Relapse Evaluation Visit X: EDSS Multiple
Sclerosis ALAIN01 NCT02419378
Alemtuzumab in Autoimmune Inflammatory
Neurodegeneration: Mechanisms of Action and
Neuroprotective Potential (ALAIN01)
https://clinicaltrials.gov/ct2/show/NCT02419378
Principal Investigator Prof. Dr. Dr. Sven Meuth, University
Hospital Muenster, Germany
Part: Relapse Evaluation Visit X
All rights reserved. Please visit https://medical-data-
models.org/forms/15471
Relapse Evaluation Visit X: EDSS
Multiple Sclerosis ALAIN01
NCT02419378
EDSS
Patient ID (derived)
Relapse Evaluation Visit Number
EDSS: Date
EDSS: Visual System Score
0 (0)
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
EDSS: Brainstem System Score
0 (0)
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
EDSS: Pyramidal System Score
0 (0)
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
EDSS: Cerebellar System Score
0 (0)
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
EDSS: Sensory System Score
0 (0)
1 (1)
2 (2)
1 / 2
3 (3)
4 (4)
5 (5)
6 (6)
EDSS: Bowel/Bladder System Score
0 (0)
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
EDSS: Cerebral System Score
0 (0)
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
EDSS: Ambulation Score
0 (0)
1 (1)
10 (10)
11 (11)
12 (12)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
7 (7)
8 (8)
9 (9)
EDSS: Cerebellar System Score (X)
X (X)
EDSS Step
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Relapse Evaluation Visit X: EDSS Multiple Sclerosis ALAIN01
NCT02419378
DWG-Register COMI Nacken konservativ
Deutsche Wirbelsäulen Gesellschaft DWG-Register,
http://www.dwg.org ;OA Dr. Hartensuer
All rights reserved. Please visit https://medical-data-
models.org/forms/15472
COMI Nacken konservativ
Demographische Daten
Patient Nachname
Patient Vorname
Geschlecht*
Straße
Patienten-Nr:*
Land
Postleitzahl
Wohnort
Sozialversicherungsnummer
Geburtsjahr*
Geburtstag (Monat und Tag)
Patientenbefragung
Untersuchungsintervall
vor Behandlung (1)
6 Monate (10)
3 Monate (11)
6 Wochen (12)
anderes Intervall (bitte angeben) (13)
bei Entlassung (Abschluss) (2)
>5 Jahre (3)
5 Jahre (4)
4 Jahre (5)
3 Jahre (6)
2 Jahre (7)
1 Jahr (8)
9 Monate (9)
Anderes Untersuchungsintervall (in Monaten)
Welche Beschwerden belasten Sie am stärksten?
Schmerzen im Nacken (1)
Schmerzen im Arm/Schulter (2)
1 / 4
Kribbeln, Taubheit oder andere
Missempfindungen im Nacken-/Arm-
/Schulterbereich (3)
Keine der aufgeführten Beschwerden (4)
Wie stark waren Ihre Nackenschmerzen in der
letzten Woche?
0 keine Schmerzen (1)
9 (10)
10 stärkste Schmerzen, die ich mir
vorstellen kann (11)
1 (2)
2 (3)
3 (4)
4 (5)
5 (6)
6 (7)
7 (8)
8 (9)
Wie stark waren Ihre Arm-/Schulterschmerzen in
der letzten Woche?
0 keine Schmerzen (1)
9 (10)
10 stärkste Schmerzen, die ich mir
vorstellen kann (11)
1 (2)
2 (3)
3 (4)
4 (5)
5 (6)
6 (7)
7 (8)
8 (9)
Wie stark haben Ihre Nackenbeschwerden Ihre
(Arbeit und zu Hause) normalen Aufgaben in der
letzten Woche beeinträchtigt?
gar nicht (1)
ein wenig (2)
mässig (3)
erheblich (4)
sehr stark (5)
Wie würden Sie sich fühlen, wenn Sie den Rest
Ihres Lebens mit Ihren derzeitigen
Nackenbeschwerden leben müssten?
sehr zufrieden (1)
etwas zufrieden (2)
weder zufrieden noch unzufrieden (3)
etwas unzufrieden (4)
sehr unzufrieden (5)
Bitte blicken Sie auf die letzte Woche zurück. Wie
würden Sie Ihre Lebensqualität beurteilen?
sehr gut (1)
gut (2)
mittelmässig (3)
schlecht (4)
sehr schlecht (5)
2 / 4
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An wievielen Tagen in den letzten 4 Wochen
haben Ihre Nackenbeschwerden
Sie gezwungen, Ihre gewohnten Tätigkeiten
(Arbeit, Hausarbeit, Schule,
Freizeitaktivitäten) einzuschränken?
0 Tage (1)
zwischen 1 und 7 Tagen (2)
zwischen 8 und 14 Tagen (3)
zwischen 15 und 21 Tagen (4)
an mehr als 21 Tagen (5)
An wievielen Tagen in den letzten vier Wochen
haben Ihre Nackenbeschwerden Sie
daran gehindert , zur Arbeit zu gehen (Arbeit,
Schule, Hausarbeit)?
0 Tage (1)
zwischen 1 und 7 Tagen (2)
zwischen 8 und 14 Tagen (3)
zwischen 15 und 21 Tagen (4)
an mehr als 21 Tagen (5)
Fragen nach der Behandlung
Sind als Folge der Behandlung in unserer
Einrichtung (Klinik/ Praxis) Komplikationen
aufgetreten (wie z.B. Störung der Wundheilung,
Lähmung, Gefühlsstörungen) ?
Ja
Nein
Falls Komplikationen aufgetreten sind, bitte
beschreiben Sie diese
Wie beeinträchtigend/störend waren diese
Komplikationen?
gar nicht beeinträchigend/störend (1)
ein wenig beeinträchigend/störend (2)
mässig beeinträchigend/störend (3)
erheblich beeinträchigend/störend (4)
sehr stark beeinträchigend/störend (5)
Wurden Sie seit der Behandlung bei uns in einer
anderen Einrichtung (Klinik/ Praxis) oder erneut
bei uns an der Halswirbelsäule (am Nacken)
behandelt?
nein (1)
ja, aber an einer anderen Stelle der
Halswirbelsäule (2)
ja, an derselben Stelle der
Halswirbelsäule (gleiches Segment) (3)
Wie zufrieden waren Sie bisher mit der
Behandlung Ihrer Nackenbeschwerden
in unserer Einrichtung (Klinik/ Praxis) ?
sehr zufrieden (1)
etwas zufrieden (2)
weder zufrieden noch unzufrieden (3)
etwas unzufrieden (4)
sehr unzufrieden (5)
3 / 4
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Wie hat Ihnen die Behandlung Ihrer
Nackenbeschwerden in unserer Einrichtung
(Klinik/ Praxis) insgesamt geholfen?
sehr geholfen (1)
geholfen (2)
nur wenig geholfen (3)
nicht geholfen (4)
geschadet (5)
Datum
Unterschrift
4 / 4
DWG-Register COMI Nacken konservativ
Discontinuation Visit: EDSS Multiple
Sclerosis ALAIN01 NCT02419378
Alemtuzumab in Autoimmune Inflammatory
Neurodegeneration: Mechanisms of Action and
Neuroprotective Potential (ALAIN01)
https://clinicaltrials.gov/ct2/show/NCT02419378
Principal Investigator Prof. Dr. Dr. Sven Meuth, University
Hospital Muenster, Germany
Part: Discontinuation Visit
All rights reserved. Please visit https://medical-data-
models.org/forms/15474
Discontinuation Visit: EDSS Multiple
Sclerosis ALAIN01 NCT02419378
EDSS
Patient ID (derived)
EDSS: Date
EDSS: Visual System Score
0 (0)
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
EDSS: Brainstem System Score
0 (0)
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
EDSS: Pyramidal System Score
0 (0)
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
EDSS: Cerebellar System Score
0 (0)
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
EDSS: Sensory System Score
0 (0)
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
1 / 2
EDSS: Bowel/Bladder System Score
0 (0)
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
EDSS: Cerebral System Score
0 (0)
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
EDSS: Ambulation Score
0 (0)
1 (1)
10 (10)
11 (11)
12 (12)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
7 (7)
8 (8)
9 (9)
EDSS: Cerebellar System Score (X)
X (X)
EDSS Step
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Baseline: MSFC Multiple Sclerosis
ALAIN01 NCT02419378
Alemtuzumab in Autoimmune Inflammatory
Neurodegeneration: Mechanisms of Action and
Neuroprotective Potential (ALAIN01)
https://clinicaltrials.gov/ct2/show/NCT02419378
Principal Investigator Prof. Dr. Dr. Sven Meuth, University
Hospital Muenster, Germany
Part: Baseline
All rights reserved. Please visit https://medical-data-
models.org/forms/15475
Baseline: MSFC Multiple Sclerosis
ALAIN01 NCT02419378
Multiple Sclerosis Functional Composite
Patient ID (derived)
MSFC+ Quest.: add. quarterly inf. consent yes/no
no (0)
yes (1)
MSFC+ Quest.: add. semiannual inf. consent
yes/no
no (0)
yes (1)
MSFC + Questionnaires: Date
Timed 25-Foot Walk
Timed 25-Foot Walk: AFO yes/no
no (0)
yes (1)
Timed 25-Foot Walk: assistive device yes/no
no (0)
yes (1)
Timed 25-Foot Walk: Unilateral Ass.
Unilateral Assistance (1)
Timed 25-Foot Walk: Bilateral Ass.
Bilateral Assistance (1)
Timed 25-Foot Walk: Unilateral Ass. (Category)
Cane (1)
Crutch (2)
Timed 25-Foot Walk: Bilateral Ass. (Category)
Cane (1)
Crutch (2)
Walker/Rollator (3)
Timed 25-Foot Walk: Time Trial 1
sec
Timed 25-Foot Walk: not completed Trial 1
Unable due to physical limitations (1)
Other (9)
1 / 3
Timed 25-Foot Walk: Time Trial 2
sec
Timed 25-Foot Walk: not completed Trial 2
Unable due to physical limitations (1)
Other (9)
9-Hole Peg Test
9-Hole Peg Test: dominant hand
right (1)
left (2)
9-Hole Peg Test: Time dom. Trial 1
sec
9-Hole Peg Test: not completed dom. Trial 1
Unable due to physical limitations (1)
Other (9)
9-Hole Peg Test: Time non-dom. Trial 1
sec
9-Hole Peg Test: not completed non-dom. Trial 1
Unable due to physical limitations (1)
Other (9)
9-Hole Peg Test: Time (sec) dom. Trial 2
9-Hole Peg Test: not completed dom. Trial 2
Unable due to physical limitations (1)
Other (9)
9-Hole Peg Test: Time (sec) non-dom. Trial 2
9-Hole Peg Test: not completed non-dom. Trial 2
Unable due to physical limitations (1)
Other (9)
PASAT
PASAT Form used
Form A (1)
Form B (2)
PASAT3: Total correct
PASAT3: not completed
Unable due to physical limitations (1)
Other (9)
PASAT2: Total correct
2 / 3
Baseline: MSFC Multiple Sclerosis ALAIN01 NCT02419378
PASAT2: not completed
Unable due to physical limitations (1)
Other (9)
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Baseline: MSFC Multiple Sclerosis ALAIN01 NCT02419378
Baseline: Repitition of AssessmentsMSFC
Multiple Sclerosis ALAIN01 NCT02419378
Alemtuzumab in Autoimmune Inflammatory
Neurodegeneration: Mechanisms of Action and
Neuroprotective Potential (ALAIN01)
https://clinicaltrials.gov/ct2/show/NCT02419378
Principal Investigator Prof. Dr. Dr. Sven Meuth, University
Hospital Muenster, Germany
Part: Baseline: Repitition of Assessments
Please complete the following pages only if Baseline
Assessments
had to be repeated prior to initiation of Lemtrada® (relapse
after first
examination, see Study Protocol 8.1.1.2)
All rights reserved. Please visit https://medical-data-
models.org/forms/15477
Baseline: Repitition of
AssessmentsMSFC Multiple
Sclerosis ALAIN01 NCT02419378
Multiple Sclerosis Functional Composite
Patient ID (derived)
MSFC+ Quest.: add. quarterly inf. consent yes/no
no (0)
yes (1)
MSFC+ Quest.: add. semiannual inf. consent
yes/no
no (0)
yes (1)
MSFC + Questionnaires: Date
Timed 25-Foot Walk
Timed 25-Foot Walk: AFO yes/no
no (0)
yes (1)
Timed 25-Foot Walk: assistive device yes/no
no (0)
yes (1)
Timed 25-Foot Walk: Unilateral Ass.
Unilateral Assistance (1)
Timed 25-Foot Walk: Bilateral Ass.
Bilateral Assistance (1)
Timed 25-Foot Walk: Unilateral Ass. (Category)
Cane (1)
Crutch (2)
Timed 25-Foot Walk: Bilateral Ass. (Category)
Cane (1)
Crutch (2)
Walker/Rollator (3)
Timed 25-Foot Walk: Time Trial 1
sec
Timed 25-Foot Walk: not completed Trial 1
1 / 3
Unable due to physical limitations (1)
Other (9)
Timed 25-Foot Walk: Time Trial 2
sec
Timed 25-Foot Walk: not completed Trial 2
Unable due to physical limitations (1)
Other (9)
9-Hole Peg Test
9-Hole Peg Test: dominant hand
right (1)
left (2)
9-Hole Peg Test: Time dom. Trial 1
sec
9-Hole Peg Test: not completed dom. Trial 1
Unable due to physical limitations (1)
Other (9)
9-Hole Peg Test: Time non-dom. Trial 1
sec
9-Hole Peg Test: not completed non-dom. Trial 1
Unable due to physical limitations (1)
Other (9)
9-Hole Peg Test: Time (sec) dom. Trial 2
9-Hole Peg Test: not completed dom. Trial 2
Unable due to physical limitations (1)
Other (9)
9-Hole Peg Test: Time (sec) non-dom. Trial 2
9-Hole Peg Test: not completed non-dom. Trial 2
Unable due to physical limitations (1)
Other (9)
PASAT
PASAT Form used
Form A (1)
Form B (2)
PASAT3: Total correct
PASAT3: not completed
Unable due to physical limitations (1)
Other (9)
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Baseline: Repitition of AssessmentsMSFC Multiple Sclerosis ALAIN01
NCT02419378
PASAT2: Total correct
PASAT2: not completed
Unable due to physical limitations (1)
Other (9)
3 / 3
Baseline: Repitition of AssessmentsMSFC Multiple Sclerosis ALAIN01
NCT02419378
Month 3: MSFC Multiple Sclerosis ALAIN01
NCT02419378
Alemtuzumab in Autoimmune Inflammatory
Neurodegeneration: Mechanisms of Action and
Neuroprotective Potential (ALAIN01)
https://clinicaltrials.gov/ct2/show/NCT02419378
Principal Investigator Prof. Dr. Dr. Sven Meuth, University
Hospital Muenster, Germany
Part: Month 3
All rights reserved. Please visit https://medical-data-
models.org/forms/15478
Month 3: MSFC Multiple Sclerosis
ALAIN01 NCT02419378
Multiple Sclerosis Functional Composite
Patient ID (derived)
MSFC+ Quest.: add. quarterly inf. consent yes/no
no (0)
yes (1)
MSFC+ Quest.: add. semiannual inf. consent
yes/no
no (0)
yes (1)
MSFC + Questionnaires: Date
Timed 25-Foot Walk
Timed 25-Foot Walk: AFO yes/no
no (0)
yes (1)
Timed 25-Foot Walk: assistive device yes/no
no (0)
yes (1)
Timed 25-Foot Walk: Unilateral Ass.
Unilateral Assistance (1)
Timed 25-Foot Walk: Bilateral Ass.
Bilateral Assistance (1)
Timed 25-Foot Walk: Unilateral Ass. (Category)
Cane (1)
Crutch (2)
Timed 25-Foot Walk: Bilateral Ass. (Category)
Cane (1)
Crutch (2)
Walker/Rollator (3)
Timed 25-Foot Walk: Time Trial 1
sec
Timed 25-Foot Walk: not completed Trial 1
Unable due to physical limitations (1)
Other (9)
1 / 3
Timed 25-Foot Walk: Time Trial 2
sec
Timed 25-Foot Walk: not completed Trial 2
Unable due to physical limitations (1)
Other (9)
9-Hole Peg Test
9-Hole Peg Test: dominant hand
right (1)
left (2)
9-Hole Peg Test: Time dom. Trial 1
sec
9-Hole Peg Test: not completed dom. Trial 1
Unable due to physical limitations (1)
Other (9)
9-Hole Peg Test: Time non-dom. Trial 1
sec
9-Hole Peg Test: not completed non-dom. Trial 1
Unable due to physical limitations (1)
Other (9)
9-Hole Peg Test: Time (sec) dom. Trial 2
9-Hole Peg Test: not completed dom. Trial 2
Unable due to physical limitations (1)
Other (9)
9-Hole Peg Test: Time (sec) non-dom. Trial 2
9-Hole Peg Test: not completed non-dom. Trial 2
Unable due to physical limitations (1)
Other (9)
PASAT
PASAT Form used
Form A (1)
Form B (2)
PASAT3: Total correct
PASAT3: not completed
Unable due to physical limitations (1)
Other (9)
PASAT2: Total correct
2 / 3
Month 3: MSFC Multiple Sclerosis ALAIN01 NCT02419378
PASAT2: not completed
Unable due to physical limitations (1)
Other (9)
3 / 3
Month 3: MSFC Multiple Sclerosis ALAIN01 NCT02419378
Month 6: MSFC Multiple Sclerosis ALAIN01
NCT02419378
Alemtuzumab in Autoimmune Inflammatory
Neurodegeneration: Mechanisms of Action and
Neuroprotective Potential (ALAIN01)
https://clinicaltrials.gov/ct2/show/NCT02419378
Principal Investigator Prof. Dr. Dr. Sven Meuth, University
Hospital Muenster, Germany
Part: Month 6
All rights reserved. Please visit https://medical-data-
models.org/forms/15479
Month 6: MSFC Multiple Sclerosis
ALAIN01 NCT02419378
Multiple Sclerosis Functional Composite
Patient ID (derived)
MSFC+ Quest.: add. quarterly inf. consent yes/no
no (0)
yes (1)
MSFC+ Quest.: add. semiannual inf. consent
yes/no
no (0)
yes (1)
MSFC + Questionnaires: Date
Timed 25-Foot Walk
Timed 25-Foot Walk: AFO yes/no
no (0)
yes (1)
Timed 25-Foot Walk: assistive device yes/no
no (0)
yes (1)
Timed 25-Foot Walk: Unilateral Ass.
Unilateral Assistance (1)
Timed 25-Foot Walk: Bilateral Ass.
Bilateral Assistance (1)
Timed 25-Foot Walk: Unilateral Ass. (Category)
Cane (1)
Crutch (2)
Timed 25-Foot Walk: Bilateral Ass. (Category)
Cane (1)
Crutch (2)
Walker/Rollator (3)
Timed 25-Foot Walk: Time Trial 1
sec
Timed 25-Foot Walk: not completed Trial 1
Unable due to physical limitations (1)
Other (9)
1 / 3
Timed 25-Foot Walk: Time Trial 2
sec
Timed 25-Foot Walk: not completed Trial 2
Unable due to physical limitations (1)
Other (9)
9-Hole Peg Test
9-Hole Peg Test: dominant hand
right (1)
left (2)
9-Hole Peg Test: Time dom. Trial 1
sec
9-Hole Peg Test: not completed dom. Trial 1
Unable due to physical limitations (1)
Other (9)
9-Hole Peg Test: Time non-dom. Trial 1
sec
9-Hole Peg Test: not completed non-dom. Trial 1
Unable due to physical limitations (1)
Other (9)
9-Hole Peg Test: Time (sec) dom. Trial 2
9-Hole Peg Test: not completed dom. Trial 2
Unable due to physical limitations (1)
Other (9)
9-Hole Peg Test: Time (sec) non-dom. Trial 2
9-Hole Peg Test: not completed non-dom. Trial 2
Unable due to physical limitations (1)
Other (9)
PASAT
PASAT Form used
Form A (1)
Form B (2)
PASAT3: Total correct
PASAT3: not completed
Unable due to physical limitations (1)
Other (9)
PASAT2: Total correct
2 / 3
Month 6: MSFC Multiple Sclerosis ALAIN01 NCT02419378
PASAT2: not completed
Unable due to physical limitations (1)
Other (9)
3 / 3
Month 6: MSFC Multiple Sclerosis ALAIN01 NCT02419378
Eligibility Metastatic Breast Cancer
NCT02275403
Standard Care Alone or With Acupuncture for CIPN in
Metastatic Breast Cancer and Multiple Myeloma; ODM
derived from: https://clinicaltrials.gov/show/NCT02275403
All rights reserved. Please visit https://medical-data-
models.org/forms/15480
Eligibility Metastatic Breast Cancer
NCT02275403
Inclusion Criteria
patients with metastatic breast cancer or multiple
myeloma who are receiving or who have received
neurotoxic chemotherapy treatment for their
condition*
Yes
No
the capacity to understand the patient information
sheet and the ability to give written informed
consent*
Yes
No
willingness and ability to comply with scheduled
visits and study procedures, including the self-
report qol questionnaires*
Yes
No
age ≥ 18 years; no upper age limit*
Yes
No
cipn of ≥ grade ii (ctcae v4.03)*
Yes
No
platelet count of ≥ 30 x 10*9/l*
Yes
No
neutrophil count of ≥ 0.5 x 10*9/l*
Yes
No
mymop2 score of their most troubling cipn
symptom ≥ 3*
Yes
No
Exclusion Criteria
patients who have previously received
acupuncture for neuropathy*
Yes
No
patients who have received acupuncture for any
indication, other than neuropathy, within the
1 / 2
previous 6 months*
Yes
No
women who are pregnant or breast feeding*
Yes
No
co-morbidity with a bleeding disorder*
Yes
No
patients with an aversion to needles*
Yes
No
abnormal coagulation profile: international
normalised ratio (inr) > 5*
Yes
No
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Month 9: MSFC Multiple Sclerosis ALAIN01
NCT02419378
Alemtuzumab in Autoimmune Inflammatory
Neurodegeneration: Mechanisms of Action and
Neuroprotective Potential (ALAIN01)
https://clinicaltrials.gov/ct2/show/NCT02419378
Principal Investigator Prof. Dr. Dr. Sven Meuth, University
Hospital Muenster, Germany
Part: Month 9
All rights reserved. Please visit https://medical-data-
models.org/forms/15481
Month 9: MSFC Multiple Sclerosis
ALAIN01 NCT02419378
Multiple Sclerosis Functional Composite
Patient ID (derived)
MSFC+ Quest.: add. quarterly inf. consent yes/no
no (0)
yes (1)
MSFC+ Quest.: add. semiannual inf. consent
yes/no
no (0)
yes (1)
MSFC + Questionnaires: Date
Timed 25-Foot Walk
Timed 25-Foot Walk: AFO yes/no
no (0)
yes (1)
Timed 25-Foot Walk: assistive device yes/no
no (0)
yes (1)
Timed 25-Foot Walk: Unilateral Ass.
Unilateral Assistance (1)
Timed 25-Foot Walk: Bilateral Ass.
Bilateral Assistance (1)
Timed 25-Foot Walk: Unilateral Ass. (Category)
Cane (1)
Crutch (2)
Timed 25-Foot Walk: Bilateral Ass. (Category)
Cane (1)
Crutch (2)
Walker/Rollator (3)
Timed 25-Foot Walk: Time Trial 1
sec
Timed 25-Foot Walk: not completed Trial 1
Unable due to physical limitations (1)
Other (9)
1 / 3
Timed 25-Foot Walk: Time Trial 2
sec
Timed 25-Foot Walk: not completed Trial 2
Unable due to physical limitations (1)
Other (9)
9-Hole Peg Test
9-Hole Peg Test: dominant hand
right (1)
left (2)
9-Hole Peg Test: Time dom. Trial 1
sec
9-Hole Peg Test: not completed dom. Trial 1
Unable due to physical limitations (1)
Other (9)
9-Hole Peg Test: Time non-dom. Trial 1
sec
9-Hole Peg Test: not completed non-dom. Trial 1
Unable due to physical limitations (1)
Other (9)
9-Hole Peg Test: Time (sec) dom. Trial 2
9-Hole Peg Test: not completed dom. Trial 2
Unable due to physical limitations (1)
Other (9)
9-Hole Peg Test: Time (sec) non-dom. Trial 2
9-Hole Peg Test: not completed non-dom. Trial 2
Unable due to physical limitations (1)
Other (9)
PASAT
PASAT Form used
Form A (1)
Form B (2)
PASAT3: Total correct
PASAT3: not completed
Unable due to physical limitations (1)
Other (9)
PASAT2: Total correct
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Month 9: MSFC Multiple Sclerosis ALAIN01 NCT02419378
PASAT2: not completed
Unable due to physical limitations (1)
Other (9)
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Month 9: MSFC Multiple Sclerosis ALAIN01 NCT02419378
Month 12: MSFC Multiple Sclerosis
ALAIN01 NCT02419378
Alemtuzumab in Autoimmune Inflammatory
Neurodegeneration: Mechanisms of Action and
Neuroprotective Potential (ALAIN01)
https://clinicaltrials.gov/ct2/show/NCT02419378
Principal Investigator Prof. Dr. Dr. Sven Meuth, University
Hospital Muenster, Germany
Part: Month 12
All rights reserved. Please visit https://medical-data-
models.org/forms/15482
Month 12: MSFC Multiple Sclerosis
ALAIN01 NCT02419378
Multiple Sclerosis Functional Composite
Patient ID (derived)
MSFC+ Quest.: add. quarterly inf. consent yes/no
no (0)
yes (1)
MSFC+ Quest.: add. semiannual inf. consent
yes/no
no (0)
yes (1)
MSFC + Questionnaires: Date
Timed 25-Foot Walk
Timed 25-Foot Walk: AFO yes/no
no (0)
yes (1)
Timed 25-Foot Walk: assistive device yes/no
no (0)
yes (1)
Timed 25-Foot Walk: Unilateral Ass.
Unilateral Assistance (1)
Timed 25-Foot Walk: Bilateral Ass.
Bilateral Assistance (1)
Timed 25-Foot Walk: Unilateral Ass. (Category)
Cane (1)
Crutch (2)
Timed 25-Foot Walk: Bilateral Ass. (Category)
Cane (1)
Crutch (2)
Walker/Rollator (3)
Timed 25-Foot Walk: Time Trial 1
sec
Timed 25-Foot Walk: not completed Trial 1
Unable due to physical limitations (1)
Other (9)
1 / 3
Timed 25-Foot Walk: Time Trial 2
sec
Timed 25-Foot Walk: not completed Trial 2
Unable due to physical limitations (1)
Other (9)
9-Hole Peg Test
9-Hole Peg Test: dominant hand
right (1)
left (2)
9-Hole Peg Test: Time dom. Trial 1
sec
9-Hole Peg Test: not completed dom. Trial 1
Unable due to physical limitations (1)
Other (9)
9-Hole Peg Test: Time non-dom. Trial 1
sec
9-Hole Peg Test: not completed non-dom. Trial 1
Unable due to physical limitations (1)
Other (9)
9-Hole Peg Test: Time (sec) dom. Trial 2
9-Hole Peg Test: not completed dom. Trial 2
Unable due to physical limitations (1)
Other (9)
9-Hole Peg Test: Time (sec) non-dom. Trial 2
9-Hole Peg Test: not completed non-dom. Trial 2
Unable due to physical limitations (1)
Other (9)
PASAT
PASAT Form used
Form A (1)
Form B (2)
PASAT3: Total correct
PASAT3: not completed
Unable due to physical limitations (1)
Other (9)
PASAT2: Total correct
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Month 12: MSFC Multiple Sclerosis ALAIN01 NCT02419378
PASAT2: not completed
Unable due to physical limitations (1)
Other (9)
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Month 12: MSFC Multiple Sclerosis ALAIN01 NCT02419378
Month 15: MSFC Multiple Sclerosis
ALAIN01 NCT02419378
Alemtuzumab in Autoimmune Inflammatory
Neurodegeneration: Mechanisms of Action and
Neuroprotective Potential (ALAIN01)
https://clinicaltrials.gov/ct2/show/NCT02419378
Principal Investigator Prof. Dr. Dr. Sven Meuth, University
Hospital Muenster, Germany
Part: Month 15
All rights reserved. Please visit https://medical-data-
models.org/forms/15483
Month 15: MSFC Multiple Sclerosis
ALAIN01 NCT02419378
Multiple Sclerosis Functional Composite
Patient ID (derived)
MSFC+ Quest.: add. quarterly inf. consent yes/no
no (0)
yes (1)
MSFC+ Quest.: add. semiannual inf. consent
yes/no
no (0)
yes (1)
MSFC + Questionnaires: Date
Timed 25-Foot Walk
Timed 25-Foot Walk: AFO yes/no
no (0)
yes (1)
Timed 25-Foot Walk: assistive device yes/no
no (0)
yes (1)
Timed 25-Foot Walk: Unilateral Ass.
Unilateral Assistance (1)
Timed 25-Foot Walk: Bilateral Ass.
Bilateral Assistance (1)
Timed 25-Foot Walk: Unilateral Ass. (Category)
Cane (1)
Crutch (2)
Timed 25-Foot Walk: Bilateral Ass. (Category)
Cane (1)
Crutch (2)
Walker/Rollator (3)
Timed 25-Foot Walk: Time Trial 1
sec
Timed 25-Foot Walk: not completed Trial 1
Unable due to physical limitations (1)
Other (9)
1 / 3
Timed 25-Foot Walk: Time Trial 2
sec
Timed 25-Foot Walk: not completed Trial 2
Unable due to physical limitations (1)
Other (9)
9-Hole Peg Test
9-Hole Peg Test: dominant hand
right (1)
left (2)
9-Hole Peg Test: Time dom. Trial 1
sec
9-Hole Peg Test: not completed dom. Trial 1
Unable due to physical limitations (1)
Other (9)
9-Hole Peg Test: Time non-dom. Trial 1
sec
9-Hole Peg Test: not completed non-dom. Trial 1
Unable due to physical limitations (1)
Other (9)
9-Hole Peg Test: Time (sec) dom. Trial 2
9-Hole Peg Test: not completed dom. Trial 2
Unable due to physical limitations (1)
Other (9)
9-Hole Peg Test: Time (sec) non-dom. Trial 2
9-Hole Peg Test: not completed non-dom. Trial 2
Unable due to physical limitations (1)
Other (9)
PASAT
PASAT Form used
Form A (1)
Form B (2)
PASAT3: Total correct
PASAT3: not completed
Unable due to physical limitations (1)
Other (9)
PASAT2: Total correct
2 / 3
Month 15: MSFC Multiple Sclerosis ALAIN01 NCT02419378
PASAT2: not completed
Unable due to physical limitations (1)
Other (9)
3 / 3
Month 15: MSFC Multiple Sclerosis ALAIN01 NCT02419378
Month 18: MSFC Multiple Sclerosis
ALAIN01 NCT02419378
Alemtuzumab in Autoimmune Inflammatory
Neurodegeneration: Mechanisms of Action and
Neuroprotective Potential (ALAIN01)
https://clinicaltrials.gov/ct2/show/NCT02419378
Principal Investigator Prof. Dr. Dr. Sven Meuth, University
Hospital Muenster, Germany
Part: Month 18
All rights reserved. Please visit https://medical-data-
models.org/forms/15484
Month 18: MSFC Multiple Sclerosis
ALAIN01 NCT02419378
Multiple Sclerosis Functional Composite
Patient ID (derived)
MSFC+ Quest.: add. quarterly inf. consent yes/no
no (0)
yes (1)
MSFC+ Quest.: add. semiannual inf. consent
yes/no
no (0)
yes (1)
MSFC + Questionnaires: Date
Timed 25-Foot Walk
Timed 25-Foot Walk: AFO yes/no
no (0)
yes (1)
Timed 25-Foot Walk: assistive device yes/no
no (0)
yes (1)
Timed 25-Foot Walk: Unilateral Ass.
Unilateral Assistance (1)
Timed 25-Foot Walk: Bilateral Ass.
Bilateral Assistance (1)
Timed 25-Foot Walk: Unilateral Ass. (Category)
Cane (1)
Crutch (2)
Timed 25-Foot Walk: Bilateral Ass. (Category)
Cane (1)
Crutch (2)
Walker/Rollator (3)
Timed 25-Foot Walk: Time Trial 1
sec
Timed 25-Foot Walk: not completed Trial 1
Unable due to physical limitations (1)
Other (9)
1 / 3
Timed 25-Foot Walk: Time Trial 2
sec
Timed 25-Foot Walk: not completed Trial 2
Unable due to physical limitations (1)
Other (9)
9-Hole Peg Test
9-Hole Peg Test: dominant hand
right (1)
left (2)
9-Hole Peg Test: Time dom. Trial 1
sec
9-Hole Peg Test: not completed dom. Trial 1
Unable due to physical limitations (1)
Other (9)
9-Hole Peg Test: Time non-dom. Trial 1
sec
9-Hole Peg Test: not completed non-dom. Trial 1
Unable due to physical limitations (1)
Other (9)
9-Hole Peg Test: Time (sec) dom. Trial 2
9-Hole Peg Test: not completed dom. Trial 2
Unable due to physical limitations (1)
Other (9)
9-Hole Peg Test: Time (sec) non-dom. Trial 2
9-Hole Peg Test: not completed non-dom. Trial 2
Unable due to physical limitations (1)
Other (9)
PASAT
PASAT Form used
Form A (1)
Form B (2)
PASAT3: Total correct
PASAT3: not completed
Unable due to physical limitations (1)
Other (9)
PASAT2: Total correct
2 / 3
Month 18: MSFC Multiple Sclerosis ALAIN01 NCT02419378
PASAT2: not completed
Unable due to physical limitations (1)
Other (9)
3 / 3
Month 18: MSFC Multiple Sclerosis ALAIN01 NCT02419378
Month 21: MSFC Multiple Sclerosis
ALAIN01 NCT02419378
Alemtuzumab in Autoimmune Inflammatory
Neurodegeneration: Mechanisms of Action and
Neuroprotective Potential (ALAIN01)
https://clinicaltrials.gov/ct2/show/NCT02419378
Principal Investigator Prof. Dr. Dr. Sven Meuth, University
Hospital Muenster, Germany
Part: Month 21
All rights reserved. Please visit https://medical-data-
models.org/forms/15485
Month 21: MSFC Multiple Sclerosis
ALAIN01 NCT02419378
Multiple Sclerosis Functional Composite
Patient ID (derived)
MSFC+ Quest.: add. quarterly inf. consent yes/no
no (0)
yes (1)
MSFC+ Quest.: add. semiannual inf. consent
yes/no
no (0)
yes (1)
MSFC + Questionnaires: Date
Timed 25-Foot Walk
Timed 25-Foot Walk: AFO yes/no
no (0)
yes (1)
Timed 25-Foot Walk: assistive device yes/no
no (0)
yes (1)
Timed 25-Foot Walk: Unilateral Ass.
Unilateral Assistance (1)
Timed 25-Foot Walk: Bilateral Ass.
Bilateral Assistance (1)
Timed 25-Foot Walk: Unilateral Ass. (Category)
Cane (1)
Crutch (2)
Timed 25-Foot Walk: Bilateral Ass. (Category)
Cane (1)
Crutch (2)
Walker/Rollator (3)
Timed 25-Foot Walk: Time Trial 1
sec
Timed 25-Foot Walk: not completed Trial 1
Unable due to physical limitations (1)
Other (9)
1 / 3
Timed 25-Foot Walk: Time Trial 2
sec
Timed 25-Foot Walk: not completed Trial 2
Unable due to physical limitations (1)
Other (9)
9-Hole Peg Test
9-Hole Peg Test: dominant hand
right (1)
left (2)
9-Hole Peg Test: Time dom. Trial 1
sec
9-Hole Peg Test: not completed dom. Trial 1
Unable due to physical limitations (1)
Other (9)
9-Hole Peg Test: Time non-dom. Trial 1
sec
9-Hole Peg Test: not completed non-dom. Trial 1
Unable due to physical limitations (1)
Other (9)
9-Hole Peg Test: Time (sec) dom. Trial 2
9-Hole Peg Test: not completed dom. Trial 2
Unable due to physical limitations (1)
Other (9)
9-Hole Peg Test: Time (sec) non-dom. Trial 2
9-Hole Peg Test: not completed non-dom. Trial 2
Unable due to physical limitations (1)
Other (9)
PASAT
PASAT Form used
Form A (1)
Form B (2)
PASAT3: Total correct
PASAT3: not completed
Unable due to physical limitations (1)
Other (9)
PASAT2: Total correct
2 / 3
Month 21: MSFC Multiple Sclerosis ALAIN01 NCT02419378
PASAT2: not completed
Unable due to physical limitations (1)
Other (9)
3 / 3
Month 21: MSFC Multiple Sclerosis ALAIN01 NCT02419378
Month 24: MSFC Multiple Sclerosis
ALAIN01 NCT02419378
Alemtuzumab in Autoimmune Inflammatory
Neurodegeneration: Mechanisms of Action and
Neuroprotective Potential (ALAIN01)
https://clinicaltrials.gov/ct2/show/NCT02419378
Principal Investigator Prof. Dr. Dr. Sven Meuth, University
Hospital Muenster, Germany
Part: Month 24
All rights reserved. Please visit https://medical-data-
models.org/forms/15487
Month 24: MSFC Multiple Sclerosis
ALAIN01 NCT02419378
Multiple Sclerosis Functional Composite
Patient ID (derived)
MSFC+ Quest.: add. quarterly inf. consent yes/no
no (0)
yes (1)
MSFC+ Quest.: add. semiannual inf. consent
yes/no
no (0)
yes (1)
MSFC + Questionnaires: Date
Timed 25-Foot Walk
Timed 25-Foot Walk: AFO yes/no
no (0)
yes (1)
Timed 25-Foot Walk: assistive device yes/no
no (0)
yes (1)
Timed 25-Foot Walk: Unilateral Ass.
Unilateral Assistance (1)
Timed 25-Foot Walk: Bilateral Ass.
Bilateral Assistance (1)
Timed 25-Foot Walk: Unilateral Ass. (Category)
Cane (1)
Crutch (2)
Timed 25-Foot Walk: Bilateral Ass. (Category)
Cane (1)
Crutch (2)
Walker/Rollator (3)
Timed 25-Foot Walk: Time Trial 1
sec
Timed 25-Foot Walk: not completed Trial 1
Unable due to physical limitations (1)
Other (9)
1 / 3
Timed 25-Foot Walk: Time Trial 2
sec
Timed 25-Foot Walk: not completed Trial 2
Unable due to physical limitations (1)
Other (9)
9-Hole Peg Test
9-Hole Peg Test: dominant hand
right (1)
left (2)
9-Hole Peg Test: Time dom. Trial 1
sec
9-Hole Peg Test: not completed dom. Trial 1
Unable due to physical limitations (1)
Other (9)
9-Hole Peg Test: Time non-dom. Trial 1
sec
9-Hole Peg Test: not completed non-dom. Trial 1
Unable due to physical limitations (1)
Other (9)
9-Hole Peg Test: Time (sec) dom. Trial 2
9-Hole Peg Test: not completed dom. Trial 2
Unable due to physical limitations (1)
Other (9)
9-Hole Peg Test: Time (sec) non-dom. Trial 2
9-Hole Peg Test: not completed non-dom. Trial 2
Unable due to physical limitations (1)
Other (9)
PASAT
PASAT Form used
Form A (1)
Form B (2)
PASAT3: Total correct
PASAT3: not completed
Unable due to physical limitations (1)
Other (9)
PASAT2: Total correct
2 / 3
Month 24: MSFC Multiple Sclerosis ALAIN01 NCT02419378
PASAT2: not completed
Unable due to physical limitations (1)
Other (9)
3 / 3
Month 24: MSFC Multiple Sclerosis ALAIN01 NCT02419378
Eligibility Hepatocellular Carcinoma
NCT01438437
Trial of Ablation of Small Hepatocellular Carcinomas in
Patients of Cirrhosis; ODM derived from:
https://clinicaltrials.gov/show/NCT01438437
All rights reserved. Please visit https://medical-data-
models.org/forms/15488
Eligibility Hepatocellular Carcinoma
NCT01438437
Inclusion Criteria
child's a or b cirrhosis with liver mass.*
Yes
No
number of liver masses not more than 5 and the
size of each <5cm in diameter.*
Yes
No
no extrahepatic disease.*
Yes
No
absence of malignant portal vein thrombosis.*
Yes
No
platelet count more than 70,000/mm3*
Yes
No
prothrombin time more than 50%.*
Yes
No
written consent of patient.*
Yes
No
Exclusion Criteria
childs'c cirrhosis with liver mass.*
Yes
No
liver mass >5cm in diameter.*
Yes
No
number of liver masses more than 3*
Yes
No
peripherally located masses with no hepatic
parenchyma around*
Yes
No
liver mass not discernable on ultrasound.*
Yes
No
1 / 2
extra hepatic disease like rp adenopathy, distant
metastasis.*
Yes
No
coagulation disorders.*
Yes
No
unwilling patient*
Yes
No
2 / 2
Eligibility Hepatocellular Carcinoma NCT01438437
Month 27: MSFC Multiple Sclerosis
ALAIN01 NCT02419378
Alemtuzumab in Autoimmune Inflammatory
Neurodegeneration: Mechanisms of Action and
Neuroprotective Potential (ALAIN01)
https://clinicaltrials.gov/ct2/show/NCT02419378
Principal Investigator Prof. Dr. Dr. Sven Meuth, University
Hospital Muenster, Germany
Part: Month 27
All rights reserved. Please visit https://medical-data-
models.org/forms/15489
Month 27: MSFC Multiple Sclerosis
ALAIN01 NCT02419378
Multiple Sclerosis Functional Composite
Patient ID (derived)
MSFC+ Quest.: add. quarterly inf. consent yes/no
no (0)
yes (1)
MSFC+ Quest.: add. semiannual inf. consent
yes/no
no (0)
yes (1)
MSFC + Questionnaires: Date
Timed 25-Foot Walk
Timed 25-Foot Walk: AFO yes/no
no (0)
yes (1)
Timed 25-Foot Walk: assistive device yes/no
no (0)
yes (1)
Timed 25-Foot Walk: Unilateral Ass.
Unilateral Assistance (1)
Timed 25-Foot Walk: Bilateral Ass.
Bilateral Assistance (1)
Timed 25-Foot Walk: Unilateral Ass. (Category)
Cane (1)
Crutch (2)
Timed 25-Foot Walk: Bilateral Ass. (Category)
Cane (1)
Crutch (2)
Walker/Rollator (3)
Timed 25-Foot Walk: Time Trial 1
sec
Timed 25-Foot Walk: not completed Trial 1
Unable due to physical limitations (1)
Other (9)
1 / 3
Timed 25-Foot Walk: Time Trial 2
sec
Timed 25-Foot Walk: not completed Trial 2
Unable due to physical limitations (1)
Other (9)
9-Hole Peg Test
9-Hole Peg Test: dominant hand
right (1)
left (2)
9-Hole Peg Test: Time dom. Trial 1
sec
9-Hole Peg Test: not completed dom. Trial 1
Unable due to physical limitations (1)
Other (9)
9-Hole Peg Test: Time non-dom. Trial 1
sec
9-Hole Peg Test: not completed non-dom. Trial 1
Unable due to physical limitations (1)
Other (9)
9-Hole Peg Test: Time (sec) dom. Trial 2
9-Hole Peg Test: not completed dom. Trial 2
Unable due to physical limitations (1)
Other (9)
9-Hole Peg Test: Time (sec) non-dom. Trial 2
9-Hole Peg Test: not completed non-dom. Trial 2
Unable due to physical limitations (1)
Other (9)
PASAT
PASAT Form used
Form A (1)
Form B (2)
PASAT3: Total correct
PASAT3: not completed
Unable due to physical limitations (1)
Other (9)
PASAT2: Total correct
2 / 3
Month 27: MSFC Multiple Sclerosis ALAIN01 NCT02419378
PASAT2: not completed
Unable due to physical limitations (1)
Other (9)
3 / 3
Month 27: MSFC Multiple Sclerosis ALAIN01 NCT02419378
Month 30: MSFC Multiple Sclerosis
ALAIN01 NCT02419378
Alemtuzumab in Autoimmune Inflammatory
Neurodegeneration: Mechanisms of Action and
Neuroprotective Potential (ALAIN01)
https://clinicaltrials.gov/ct2/show/NCT02419378
Principal Investigator Prof. Dr. Dr. Sven Meuth, University
Hospital Muenster, Germany
Part: Month 30
All rights reserved. Please visit https://medical-data-
models.org/forms/15490
Month 30: MSFC Multiple Sclerosis
ALAIN01 NCT02419378
Multiple Sclerosis Functional Composite
Patient ID (derived)
MSFC+ Quest.: add. quarterly inf. consent yes/no
no (0)
yes (1)
MSFC+ Quest.: add. semiannual inf. consent
yes/no
no (0)
yes (1)
MSFC + Questionnaires: Date
Timed 25-Foot Walk
Timed 25-Foot Walk: AFO yes/no
no (0)
yes (1)
Timed 25-Foot Walk: assistive device yes/no
no (0)
yes (1)
Timed 25-Foot Walk: Unilateral Ass.
Unilateral Assistance (1)
Timed 25-Foot Walk: Bilateral Ass.
Bilateral Assistance (1)
Timed 25-Foot Walk: Unilateral Ass. (Category)
Cane (1)
Crutch (2)
Timed 25-Foot Walk: Bilateral Ass. (Category)
Cane (1)
Crutch (2)
Walker/Rollator (3)
Timed 25-Foot Walk: Time Trial 1
sec
Timed 25-Foot Walk: not completed Trial 1
Unable due to physical limitations (1)
Other (9)
1 / 3
Timed 25-Foot Walk: Time Trial 2
sec
Timed 25-Foot Walk: not completed Trial 2
Unable due to physical limitations (1)
Other (9)
9-Hole Peg Test
9-Hole Peg Test: dominant hand
right (1)
left (2)
9-Hole Peg Test: Time dom. Trial 1
sec
9-Hole Peg Test: not completed dom. Trial 1
Unable due to physical limitations (1)
Other (9)
9-Hole Peg Test: Time non-dom. Trial 1
sec
9-Hole Peg Test: not completed non-dom. Trial 1
Unable due to physical limitations (1)
Other (9)
9-Hole Peg Test: Time (sec) dom. Trial 2
9-Hole Peg Test: not completed dom. Trial 2
Unable due to physical limitations (1)
Other (9)
9-Hole Peg Test: Time (sec) non-dom. Trial 2
9-Hole Peg Test: not completed non-dom. Trial 2
Unable due to physical limitations (1)
Other (9)
PASAT
PASAT Form used
Form A (1)
Form B (2)
PASAT3: Total correct
PASAT3: not completed
Unable due to physical limitations (1)
Other (9)
PASAT2: Total correct
2 / 3
Month 30: MSFC Multiple Sclerosis ALAIN01 NCT02419378
PASAT2: not completed
Unable due to physical limitations (1)
Other (9)
3 / 3
Month 30: MSFC Multiple Sclerosis ALAIN01 NCT02419378
Month 33: MSFC Multiple Sclerosis
ALAIN01 NCT02419378
Alemtuzumab in Autoimmune Inflammatory
Neurodegeneration: Mechanisms of Action and
Neuroprotective Potential (ALAIN01)
https://clinicaltrials.gov/ct2/show/NCT02419378
Principal Investigator Prof. Dr. Dr. Sven Meuth, University
Hospital Muenster, Germany
Part: Month 33
All rights reserved. Please visit https://medical-data-
models.org/forms/15491
Month 33: MSFC Multiple Sclerosis
ALAIN01 NCT02419378
Multiple Sclerosis Functional Composite
Patient ID (derived)
MSFC+ Quest.: add. quarterly inf. consent yes/no
no (0)
yes (1)
MSFC+ Quest.: add. semiannual inf. consent
yes/no
no (0)
yes (1)
MSFC + Questionnaires: Date
Timed 25-Foot Walk
Timed 25-Foot Walk: AFO yes/no
no (0)
yes (1)
Timed 25-Foot Walk: assistive device yes/no
no (0)
yes (1)
Timed 25-Foot Walk: Unilateral Ass.
Unilateral Assistance (1)
Timed 25-Foot Walk: Bilateral Ass.
Bilateral Assistance (1)
Timed 25-Foot Walk: Unilateral Ass. (Category)
Cane (1)
Crutch (2)
Timed 25-Foot Walk: Bilateral Ass. (Category)
Cane (1)
Crutch (2)
Walker/Rollator (3)
Timed 25-Foot Walk: Time Trial 1
sec
Timed 25-Foot Walk: not completed Trial 1
Unable due to physical limitations (1)
Other (9)
1 / 3
Timed 25-Foot Walk: Time Trial 2
sec
Timed 25-Foot Walk: not completed Trial 2
Unable due to physical limitations (1)
Other (9)
9-Hole Peg Test
9-Hole Peg Test: dominant hand
right (1)
left (2)
9-Hole Peg Test: Time dom. Trial 1
sec
9-Hole Peg Test: not completed dom. Trial 1
Unable due to physical limitations (1)
Other (9)
9-Hole Peg Test: Time non-dom. Trial 1
sec
9-Hole Peg Test: not completed non-dom. Trial 1
Unable due to physical limitations (1)
Other (9)
9-Hole Peg Test: Time (sec) dom. Trial 2
9-Hole Peg Test: not completed dom. Trial 2
Unable due to physical limitations (1)
Other (9)
9-Hole Peg Test: Time (sec) non-dom. Trial 2
9-Hole Peg Test: not completed non-dom. Trial 2
Unable due to physical limitations (1)
Other (9)
PASAT
PASAT Form used
Form A (1)
Form B (2)
PASAT3: Total correct
PASAT3: not completed
Unable due to physical limitations (1)
Other (9)
PASAT2: Total correct
2 / 3
Month 33: MSFC Multiple Sclerosis ALAIN01 NCT02419378
PASAT2: not completed
Unable due to physical limitations (1)
Other (9)
3 / 3
Month 33: MSFC Multiple Sclerosis ALAIN01 NCT02419378
Month 36: MSFC Multiple Sclerosis
ALAIN01 NCT02419378
Alemtuzumab in Autoimmune Inflammatory
Neurodegeneration: Mechanisms of Action and
Neuroprotective Potential (ALAIN01)
https://clinicaltrials.gov/ct2/show/NCT02419378
Principal Investigator Prof. Dr. Dr. Sven Meuth, University
Hospital Muenster, Germany
Part: Month 36
All rights reserved. Please visit https://medical-data-
models.org/forms/15492
Month 36: MSFC Multiple Sclerosis
ALAIN01 NCT02419378
Multiple Sclerosis Functional Composite
Patient ID (derived)
MSFC+ Quest.: add. quarterly inf. consent yes/no
no (0)
yes (1)
MSFC+ Quest.: add. semiannual inf. consent
yes/no
no (0)
yes (1)
MSFC + Questionnaires: Date
Timed 25-Foot Walk
Timed 25-Foot Walk: AFO yes/no
no (0)
yes (1)
Timed 25-Foot Walk: assistive device yes/no
no (0)
yes (1)
Timed 25-Foot Walk: Unilateral Ass.
Unilateral Assistance (1)
Timed 25-Foot Walk: Bilateral Ass.
Bilateral Assistance (1)
Timed 25-Foot Walk: Unilateral Ass. (Category)
Cane (1)
Crutch (2)
Timed 25-Foot Walk: Bilateral Ass. (Category)
Cane (1)
Crutch (2)
Walker/Rollator (3)
Timed 25-Foot Walk: Time Trial 1
sec
Timed 25-Foot Walk: not completed Trial 1
Unable due to physical limitations (1)
Other (9)
1 / 3
Timed 25-Foot Walk: Time Trial 2
sec
Timed 25-Foot Walk: not completed Trial 2
Unable due to physical limitations (1)
Other (9)
9-Hole Peg Test
9-Hole Peg Test: dominant hand
right (1)
left (2)
9-Hole Peg Test: Time dom. Trial 1
sec
9-Hole Peg Test: not completed dom. Trial 1
Unable due to physical limitations (1)
Other (9)
9-Hole Peg Test: Time non-dom. Trial 1
sec
9-Hole Peg Test: not completed non-dom. Trial 1
Unable due to physical limitations (1)
Other (9)
9-Hole Peg Test: Time (sec) dom. Trial 2
9-Hole Peg Test: not completed dom. Trial 2
Unable due to physical limitations (1)
Other (9)
9-Hole Peg Test: Time (sec) non-dom. Trial 2
9-Hole Peg Test: not completed non-dom. Trial 2
Unable due to physical limitations (1)
Other (9)
PASAT
PASAT Form used
Form A (1)
Form B (2)
PASAT3: Total correct
PASAT3: not completed
Unable due to physical limitations (1)
Other (9)
PASAT2: Total correct
2 / 3
Month 36: MSFC Multiple Sclerosis ALAIN01 NCT02419378
PASAT2: not completed
Unable due to physical limitations (1)
Other (9)
3 / 3
Month 36: MSFC Multiple Sclerosis ALAIN01 NCT02419378
Discontinuation Visit: MSFC Multiple
Sclerosis ALAIN01 NCT02419378
Alemtuzumab in Autoimmune Inflammatory
Neurodegeneration: Mechanisms of Action and
Neuroprotective Potential (ALAIN01)
https://clinicaltrials.gov/ct2/show/NCT02419378
Principal Investigator Prof. Dr. Dr. Sven Meuth, University
Hospital Muenster, Germany
Part: Discontinuation Visit
All rights reserved. Please visit https://medical-data-
models.org/forms/15493
Discontinuation Visit: MSFC Multiple
Sclerosis ALAIN01 NCT02419378
Multiple Sclerosis Functional Composite
Patient ID (derived)
MSFC+ Quest.: add. quarterly inf. consent yes/no
no (0)
yes (1)
MSFC+ Quest.: add. semiannual inf. consent
yes/no
no (0)
yes (1)
MSFC + Questionnaires: Date
Timed 25-Foot Walk
Timed 25-Foot Walk: AFO yes/no
no (0)
yes (1)
Timed 25-Foot Walk: assistive device yes/no
no (0)
yes (1)
Timed 25-Foot Walk: Unilateral Ass.
Unilateral Assistance (1)
Timed 25-Foot Walk: Bilateral Ass.
Bilateral Assistance (1)
Timed 25-Foot Walk: Unilateral Ass. (Category)
Cane (1)
Crutch (2)
Timed 25-Foot Walk: Bilateral Ass. (Category)
Cane (1)
Crutch (2)
Walker/Rollator (3)
Timed 25-Foot Walk: Time Trial 1
sec
Timed 25-Foot Walk: not completed Trial 1
Unable due to physical limitations (1)
Other (9)
1 / 3
Timed 25-Foot Walk: Time Trial 2
sec
Timed 25-Foot Walk: not completed Trial 2
Unable due to physical limitations (1)
Other (9)
9-Hole Peg Test
9-Hole Peg Test: dominant hand
right (1)
left (2)
9-Hole Peg Test: Time dom. Trial 1
sec
9-Hole Peg Test: not completed dom. Trial 1
Unable due to physical limitations (1)
Other (9)
9-Hole Peg Test: Time non-dom. Trial 1
sec
9-Hole Peg Test: not completed non-dom. Trial 1
Unable due to physical limitations (1)
Other (9)
9-Hole Peg Test: Time (sec) dom. Trial 2
9-Hole Peg Test: not completed dom. Trial 2
Unable due to physical limitations (1)
Other (9)
9-Hole Peg Test: Time (sec) non-dom. Trial 2
9-Hole Peg Test: not completed non-dom. Trial 2
Unable due to physical limitations (1)
Other (9)
PASAT
PASAT Form used
Form A (1)
Form B (2)
PASAT3: Total correct
PASAT3: not completed
Unable due to physical limitations (1)
Other (9)
PASAT2: Total correct
2 / 3
Discontinuation Visit: MSFC Multiple Sclerosis ALAIN01 NCT02419378
PASAT2: not completed
Unable due to physical limitations (1)
Other (9)
3 / 3
Discontinuation Visit: MSFC Multiple Sclerosis ALAIN01 NCT02419378
Eligibility Impaired Glucose Tolerance
NCT00095654
The DREAM (Diabetes Reduction Assessment With
Ramipril and Rosiglitazone Medication) Trial; ODM derived
from: https://clinicaltrials.gov/show/NCT00095654
All rights reserved. Please visit https://medical-data-
models.org/forms/15494
Eligibility Impaired Glucose
Tolerance NCT00095654
Inclusion Criteria
impaired glucose tolerance (fpg < 7 mmol/l or 126
mg/dl and 2 hr pg >= 7.8 mmol/l and < 11.1
mmol/l (140 mg/dl and < 200 mg/dl)or,*
Yes
No
isolated impaired fasting glucose (fpg >= 6.1
mmol/l and < 7 mmol/l (fpg >= 95 mg/dl and <
126 mg/dl) and 2 hr pg < 7.8 mmol/l (140 mg/dl).*
Yes
No
Exclusion Criteria
current use of an ace-inhibitor (ace-i) or
thiazolidinedione(tzd)*
Yes
No
known hypersensitivity to ace-i*
Yes
No
prior use of anti-diabetic medications (with the
exception of during pregnancy)*
Yes
No
use of systemic glucocorticoids or niacin*
Yes
No
congestive heart failure or ef < 40%*
Yes
No
existing cardiovascular disease (previous mi,
stroke, angina, uncontrolled hypertension)*
Yes
No
diabetes*
Yes
No
renal or hepatic disease*
Yes
No
major illness*
Yes
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No
use of another experimental drug*
Yes
No
pregnant or unwilling to use reliable
contraception*
Yes
No
major psychiatric disorder*
Yes
No
diseases that affect glucose tolerance*
Yes
No
unwillingness to be randomized or sign informed
consent*
Yes
No
known uncontrolled substance abuse*
Yes
No
inability to communicate with research staff*
Yes
No
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Eligibility Impaired Glucose Tolerance NCT00095654
Eligibility Lung Neoplasms NCT00067691
Acupuncture for Shortness of Breath in Cancer Patients;
ODM derived from:
https://clinicaltrials.gov/show/NCT00067691
All rights reserved. Please visit https://medical-data-
models.org/forms/15495
Eligibility Lung Neoplasms
NCT00067691
Inclusion Criteria
diagnosis of local or metastatic breast or lung
cancer*
Yes
No
shortness of breath with onset after cancer
diagnosis*
Yes
No
life expectancy of at least 4 weeks*
Yes
No
Exclusion Criteria
prior acupuncture*
Yes
No
other conditions suspected of causing shortness
of breath, such as congestive heart failure,
sarcoid disease, pneumonia, or obesity*
Yes
No
no chest wall deformity*
Yes
No
neuromuscular disorders*
Yes
No
pulmonary vascular disease*
Yes
No
anemia*
Yes
No
uncontrolled pain or infection*
Yes
No
heart valve dysfunction*
Yes
No
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Eligibility Metastatic Breast Cancer
NCT01423695
Weekly Paclitaxel and Trastuzumab in Metastatic Breast
Cancer; ODM derived from:
https://clinicaltrials.gov/show/NCT01423695
All rights reserved. Please visit https://medical-data-
models.org/forms/15496
Eligibility Metastatic Breast Cancer
NCT01423695
Inclusion Criteria
histologically confirmed metastatic breast cancer
overexpressing her2*
Yes
No
pretreatment with anthracycline in either the
adjuvant or palliative setting.*
Yes
No
her2 positivity was defined as 2+ or 3+
overexpression using the dako herceptest,
confirmed by fluorescence in-situ hybridization
(fish) if 2+.*
Yes
No
informed consent*
Yes
No
Exclusion Criteria
more than 1 chemotherapy for advanced
disease*
Yes
No
taxane or trastuzumab pretreatment*
Yes
No
brain metastases*
Yes
No
eastern cooperative oncology group (ecog)
performance status >1*
Yes
No
pregnancy or lactation, childbearing potential
without reliable contraception*
Yes
No
clinically significant cardiac disease,*
Yes
No
neutrophils <1500/µl, platelets <75,000/µl*
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Yes
No
total bilirubin and creatinine >1.5 × the upper limit
of normal*
Yes
No
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Eligibility Hodgkin's Disease NCT00165308
Tamoxifen in the Prevention of Breast Cancer in Hodgkin's
Disease Survivors; ODM derived from:
https://clinicaltrials.gov/show/NCT00165308
All rights reserved. Please visit https://medical-data-
models.org/forms/15497
Eligibility Hodgkin's Disease
NCT00165308
Inclusion Criteria
females diagnosed with hodgkin's disease at age
< 35 years*
Yes
No
> 5 years from mantle or chest radiation*
Yes
No
current age > 30 years*
Yes
No
has completed childbearing*
Yes
No
willingness to discontinue use of oral
contraceptives or other hormonal contraception
for duration of the study*
Yes
No
Exclusion Criteria
history of secondary malignancy after hodgkin's
disease, except thyroid cancer of basal cell
cancer*
Yes
No
recurrence of hodgkin's disease in the 5 years
before study entry*
Yes
No
current participation in any other cancer
prevention study*
Yes
No
current or prior use of tamoxifen*
Yes
No
current use of coumadin*
Yes
No
history of deep venous thrombosis, pulmonary
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embolism, or a condition known to be associated
with hypercoagulability*
Yes
No
history of cerebrovascular accident*
Yes
No
history of macular degeneration*
Yes
No
current use of chemotherapy for benign disease*
Yes
No
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Eligibility Non Small-cell Lung Cancer
NCT01652820
Chemotherapy/Radiotherapy Versus Concomitant
Chemotherapy Followed by Radiotherapy in Stage IIIB
Non-small Cell Lung Cancer; ODM derived from:
https://clinicaltrials.gov/show/NCT01652820
All rights reserved. Please visit https://medical-data-
models.org/forms/15498
Eligibility Non Small-cell Lung
Cancer NCT01652820
Inclusion Criteria
unresectable stage iiia or b nsclc patients*
Yes
No
who ps 0 or 1*
Yes
No
weight loss < 5 %  within the last 3 months*
Yes
No
at least one measurable lesion*
Yes
No
planning ct scan previous to randomization*
Yes
No
written informed consent*
Yes
No
Exclusion Criteria
malignant effusion, supraclavicular node or svcs*
Yes
No
ptv > 2000 cm3*
Yes
No
v20 > 35%*
Yes
No
fev1  and dlco both < 30% or 1 liter at study
entry*
Yes
No
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Administrative Data The CoDe (”Coding of
Death in HIV”) Project
The CoDe (”Coding of Death in HIV”) Project
A significant proportion of deaths in HIV-1 infected persons
are now caused by non-AIDS events. It is important to
closely monitor the causes of death in this population in
order to target interventions appropriately, should specific
causes of death emerge or become predominant. It is
possible that deaths from diseases related to an
accelerated aging process will become more frequent. The
same applies for causes of death related to co-infections
(e.g. hepatitis) or other co-morbidities (e.g. sequelae of
intravenous drug use). Furthermore, it is important to be
able to evaluate the risk factors for such emerging
diseases, including their possible relationship with
immunodeficiency.
Until now there has not been a uniform classification
system for causes of death in HIV patients. Studies have
either created their own coding systems based on frequent
and/or ‘important’ causes (e.g. rare but important adverse
events such as lactic acidosis and pancreatitis), or have
used ICD9 or ICD10 codes from death certificates. In many
cases, the ICD system cannot be directly adapted to HIV
infected persons. Many AIDS defining illnesses are poorly
identified in the ICD system, and some diseases (e.g. CNS
diseases) have a different aetiology in HIV patients and are
therefore not covered by the ICD system, or at great risk of
mis-classification.
In July 2004, a meeting was held in Copenhagen with the
participation from executive committees of a large number
of pivotal observational studies and clinical trials that
routinely collect data on causes of death. At this meeting,
it became clear that there was a need for a harmonization
and standardization of the approach taken when collecting
data on cause of death and when reviewing these deaths.
As a result, the CoDe Project was initiated.
The CoDe Project is a uniform coding system that can be
applied to studies of individuals with HIV infection, including
a detailed data collection on the causes of death and
contributing factors, as well as a centralised review process
of the data collected.
http://www.cphiv.dk/Tools-Standards/CoDe/About
Contains:  Study and Patient ID, Date of Death, Data
Source, Demographics
All rights reserved. Please visit https://medical-data-
models.org/forms/15499
Administrative Data
Administrative Data
Specify Name of study/ trial*
Patient ID code:*
Date of death*
Section 1 Background demographics
A. Year of birth:*
B. Gender:
female (female)
male (male)
C. Height (cm):
cm
1 / 3
D. Weight:
>= 0
kg
E. Date Weight Measured
Section 2 Data Sources
A. Hospital files
No (No)
Yes, complete  (Yes, complete )
Yes, incomplete (Yes, incomplete)
B. Outpatient clinic chart
No (No)
Yes, complete  (Yes, complete )
Yes, incomplete (Yes, incomplete)
C. Autopsy report
No (No)
Yes, complete  (Yes, complete )
Yes, incomplete (Yes, incomplete)
D. Registry
Yes
No
E. Obituary
Yes
No
F. Patients relatives or partner
Yes
No
G. Patients medical provider
Yes
No
H. Nursing home
I. Other Source
Completed by
Completed by: Name (in print)
Position:
Nurse           (Nurse          )
Other, describe (Other, describe)
Physician    (Physician   )
Other, describe
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Administrative Data The CoDe (”Coding of Death in HIV”) Project
Directly involved in the medical care of the patient
around the time of death?
Yes
No
Date:
Signature:
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Administrative Data The CoDe (”Coding of Death in HIV”) Project
Eligibility Osteoarthritis of Glenohumeral
Joint NCT01488006
Columbia Shoulder Study (CSS); ODM derived from:
https://clinicaltrials.gov/show/NCT01488006
All rights reserved. Please visit https://medical-data-
models.org/forms/15500
Eligibility Osteoarthritis of
Glenohumeral Joint NCT01488006
Inclusion Criteria
patient must be 18 years of age or over.*
Yes
No
patient must have signed the informed consent
and release of medical information forms.*
Yes
No
the patient can be a man, postmenopausal
woman, or a woman who is likely to become
pregnant but is using adequate contraceptive
precautions (defined as oral contraceptives,
intrauterine devices, surgical contraception or a
combination of a condom and spermicide).*
Yes
No
patient needs a total shoulder arthroplasty
(humeral head and glenoid).*
Yes
No
patient has a diagnosis of primary osteoarthritis.*
Yes
No
Exclusion Criteria
obstacles, which pose an inordinately high
surgical risk, in the judgment of the certified
surgeon.*
Yes
No
class iv or higher anesthetic risk.*
Yes
No
patient has a recent history of psychiatric disease
(including drug or alcohol abuse) that is likely to
impair the compliance with the study protocol.*
Yes
No
patient has had a shoulder fracture.*
Yes
No
patient had previous shoulder surgeries with the
exception of an arthroscopic debridement
procedure.*
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Yes
No
the patients has a massive rotator cuff tear
(rupture >3 cm or total cicatrisation)
demonstrated at time of the surgery that
precludes the total shoulder replacement.*
Yes
No
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Eligibility Osteoarthritis of Glenohumeral Joint NCT01488006
Eligibility Prostate Cancer NCT00021450
Radiation Therapy With or Without Bicalutamide and
Goserelin in Treating Patients With Prostate Cancer; ODM
derived from: https://clinicaltrials.gov/show/NCT00021450
All rights reserved. Please visit https://medical-data-
models.org/forms/15501
Eligibility Prostate Cancer
NCT00021450
Criteria
histologically confirmed stage ii prostate cancer*
Yes
No
t1b-c, n0, m0 with prostate-specific antigen (psa)
at least 10 ng/ml and/or gleason score at least 7
(uicc 1997 classification) or*
Yes
No
t2a, n0, m0 (uicc 1997 classification)*
Yes
No
serum psa no greater than 50 ng/ml*
Yes
No
no involvement of pelvic lymph nodes*
Yes
No
age: 80 and under*
Yes
No
performance status: who 0-2*
Yes
No
life expectancy: not specified*
Yes
No
hematopoietic: not specified*
Yes
No
hepatic: not specified*
Yes
No
renal: not specified*
Yes
No
no other malignancy within the past 5 years
except adequately treated basal cell skin cancer*
Yes
No
no psychological, familial, sociological, or
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geographical condition that would preclude study
participation*
Yes
No
biologic therapy: not specified*
Yes
No
chemotherapy: not specified*
Yes
No
endocrine therapy: no prior hormonal therapy*
Yes
No
radiotherapy: no prior pelvic radiotherapy*
Yes
No
surgery: no prior radical prostatectomy*
Yes
No
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Eligibility Prostate Cancer NCT00021450
Eligibility Prostate Cancer NCT00151086
Oral Estramustine and Oral Vinorelbine in the Treatment of
Hormone-Refractory Prostate Cancer; ODM derived from:
https://clinicaltrials.gov/show/NCT00151086
All rights reserved. Please visit https://medical-data-
models.org/forms/15502
Eligibility Prostate Cancer
NCT00151086
Inclusion Criteria
patients must have a histologic diagnosis of
adenocarcinoma of the prostate. (no evidence of
brain metastasis or untreated spinal cord
compression.)*
Yes
No
patients on total androgen suppression therapy
must undergo nonsteroidal antiandrogen
withdrawal and demonstrate at rising psa
(prostate specific antigen) 4 weeks after
withdrawal for flutamide and 6 weeks after
withdrawal for bicalutamide or nilutamide.*
Yes
No
patients must have measurable soft tissue
disease or evaluable (abnormal bone scan and/or
elevated psa). if psa is the only evidence of
progressive disease it must be greater than or
equal to 4ng/ml.*
Yes
No
adequate bone marrow, renal and liver function*
Yes
No
ecog (eastern cooperative oncology group)
performance status of 0-2 (a measure of general
well being on a scale of 0-5 where 0 represents
asymptomatic and 5 represents death)*
Yes
No
must be at least 18 years of age*
Yes
No
must have a life expectancy of greater than or
equal to 12 weeks*
Yes
No
Exclusion Criteria
have previously received vinca alkaloid-based
cytotoxic chemotherapy or radiation to greater
than or equal to 50% of the total bone marrow.
Yes
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No
evidence of brain metastasis
Yes
No
spinal cord compression
Yes
No
prior malignancy except for in situ carcinoma,
nonmelanoma skin cancer, or adequately treated
malignancy that has been inactive for less than 3
years
Yes
No
patients with preexisting neuropathy of greater
than or equal to grade 2
Yes
No
active gastrointestinal disease, or a disorder that
alters gastrointestinal motility or absorption
Yes
No
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Eligibility Metastatic HER2-Positive Breast
Cancer NCT02252887
Gemcitabine, Trastuzumab, and Pertuzumab in the
Treatment of Metastatic HER2-Positive Breast Cancer After
Prior Trastuzumab/Pertuzumab, or Pertuzumab Based
Therapy; ODM derived from:
https://clinicaltrials.gov/show/NCT02252887
All rights reserved. Please visit https://medical-data-
models.org/forms/15503
Eligibility Metastatic HER2-Positive
Breast Cancer NCT02252887
Inclusion Criteria
age ≥ to 18*
Yes
No
stage iv her2 (+) breast cancer*
Yes
No
histologically documented her2 (+) breast cancer
as defined as ihc 3+ or fish amplification of ≥ 2.0
of primary or metastatic site; results from the
local lab are acceptable.*
Yes
No
lecog performance status 0 -1*
Yes
No
prior treatment with trastuzumab + pertuzumab
(hp)-based therapy or pertuzumab-based in the
neoadjuvantadjuvant, unresectable, locally
advanced, or metastatic setting.*
Yes
No
≤ 3 prior chemotherapies in the metastatic
setting. prior anthracycline, taxane, gemcitabine,
and anti-her2 agents (i.e. trastuzumab,
pertuzumab, lapatinib, neratinib, tdm-1, etc.) are
allowed. if patients received prior gemcitabine, it
could not have been combined with pertuzumab.
patients should have progression of disease on
current therapy.*
Yes
No
measurable or non-measurable disease.*
Yes
No
lvef ≥ 50%*
Yes
No
hematologic parameters: white blood cell (wbc)
count of  ≥ 3000/ul, absolute neutrophil count
(anc) ≥ 1000/ul, platelets ≥  100,000/ul,
hemoglobin  ≥10.0 g/dl*
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Yes
No
non-hematologic parameters: bilirubin ≤ 1.5
mg/dl, ast/alt≤  2.5 x upper limit of normal (uln),
alkaline phosphatase ≤ 5 x uln.*
Yes
No
creatinine ≤ 1.5 mg/dl*
Yes
No
patients with "treated and stable" brain lesions of
a duration of  ≥  2 months may be enrolled.*
Yes
No
Exclusion Criteria
history of prior unstable angina, myocardial
infarction, chf, uncontrolled ventricular
arrhythmias within 12 months*
Yes
No
history of prior  ≥ g 3 hypersensitivity (hsr) or any
toxicity to trastuzumab or pertuzumab that
warranted permanent cessation of this agent*
Yes
No
≥ to g 2 peripheral neuropathy*
Yes
No
history of hepatitis b or c*
Yes
No
pregnant patients*
Yes
No
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Eligibility Metastatic HER2-Positive Breast Cancer NCT02252887
Eligibility Multiple Myeloma (MM)
NCT02211014
An Open-Label, Phase 1b Study of ACP-196 With and
Without Dexamethasone in Subjects With Multiple
Myeloma; ODM derived from:
https://clinicaltrials.gov/show/NCT02211014
All rights reserved. Please visit https://medical-data-
models.org/forms/15504
Eligibility Multiple Myeloma (MM)
NCT02211014
Inclusion Criteria
men and women ≥ 18 years of age.*
Yes
No
a confirmed diagnosis of mm, which has relapsed
after, or been refractory to ≥ 1 prior therapy for
mm, and is progressing at the time of study
entry.*
Yes
No
eastern cooperative oncology group (ecog)
performance status of ≤ 2.*
Yes
No
agreement to use contraception during the study
and for 30 days after the last dose of study drugs
if sexually active and able to bear or beget
children.*
Yes
No
Exclusion Criteria
a life-threatening illness, medical condition or
organ system dysfunction which, in the
investigator's opinion, could compromise the
subject's safety, interfere with the absorption or
metabolism of acp-196, or put the study
outcomes at undue risk*
Yes
No
significant cardiovascular disease such as
uncontrolled or symptomatic arrhythmias,
congestive heart failure, or myocardial infarction
within 6 months of screening, or any class 3 or 4
cardiac disease as defined by the new york heart
association functional classification*
Yes
No
malabsorption syndrome, disease significantly
affecting gastrointestinal function, gastric bypass,
resection of the stomach or small bowel,
symptomatic inflammatory bowel disease, or
partial or complete bowel obstruction.*
Yes
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No
breast feeding or pregnant*
Yes
No
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Eligibility Multiple Myeloma (MM) NCT02211014
DWG-Register COMI Nacken operativ
Deutsche Wirbelsäulen Gesellschaft DWG-Register,
http://www.dwg.org ;OA Dr. Hartensuer
All rights reserved. Please visit https://medical-data-
models.org/forms/15505
COMI Nacken operativ
Demographische Daten
Patient Nachname
Patient Vorname
Geschlecht*
Straße
Patienten-Nr:*
Land
Postleitzahl
Wohnort
Sozialversicherungsnummer (AHV)
Geburtsjahr*
Geburtstag (Monat und Tag)
Patientenbefragung
Untersuchungsintervall
vor Operation (1)
3 Jahre (10)
4 Jahre (11)
5 Jahre (12)
anderes Intervall in Jahren (bitte
angeben) (13)
4 Wochen (2)
6 Wochen (3)
2 Monate (4)
3 Monate (5)
6 Monate (6)
9 Monate (7)
1 Jahr (8)
2 Jahre (9)
Anderes Untersuchungsintervall (in Jahren)
Welche Beschwerden belasten Sie am stärksten?
Schmerzen im Nacken (1)
1 / 4
Schmerzen im Arm/Schulter (2)
Kribbeln, Taubheit oder andere
Missempfindungen im Nacken-/Arm-
/Schulterbereich (3)
Keine der aufgeführten Beschwerden (4)
Wie stark waren Ihre Nackenschmerzen in der
letzten Woche?
0 keine Schmerzen (1)
9 (10)
10 stärkste Schmerzen, die ich mir
vorstellen kann (11)
1 (2)
2 (3)
3 (4)
4 (5)
5 (6)
6 (7)
7 (8)
8 (9)
Wie stark waren Ihre Arm-/Schulterschmerzen in
der letzten Woche?
0 keine Schmerzen (1)
9 (10)
10 stärkste Schmerzen, die ich mir
vorstellen kann (11)
1 (2)
2 (3)
3 (4)
4 (5)
5 (6)
6 (7)
7 (8)
8 (9)
Wie stark haben Ihre Nackenbeschwerden Ihre
(Arbeit und zu Hause) normalen Aufgaben in der
letzten Woche beeinträchtigt?
gar nicht (1)
ein wenig (2)
mässig (3)
erheblich (4)
sehr stark (5)
Wie würden Sie sich fühlen, wenn Sie den Rest
Ihres Lebens mit Ihren derzeitigen
Nackenbeschwerden leben müssten?
sehr zufrieden (1)
etwas zufrieden (2)
weder zufrieden noch unzufrieden (3)
etwas unzufrieden (4)
sehr unzufrieden (5)
Bitte blicken Sie auf die letzte Woche zurück. Wie
würden Sie Ihre Lebensqualität beurteilen?
sehr gut (1)
gut (2)
mittelmässig (3)
schlecht (4)
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sehr schlecht (5)
An wievielen Tagen in den letzten 4 Wochen
haben Ihre Nackenbeschwerden
Sie gezwungen, Ihre gewohnten Tätigkeiten
(Arbeit, Hausarbeit, Schule,
Freizeitaktivitäten) einzuschränken?
0 Tage (1)
zwischen 1 und 7 Tagen (2)
zwischen 8 und 14 Tagen (3)
zwischen 15 und 21 Tagen (4)
an mehr als 21 Tagen (5)
An wievielen Tagen in den letzten vier Wochen
haben Ihre Nackenbeschwerden Sie
daran gehindert , zur Arbeit zu gehen (Arbeit,
Schule, Hausarbeit)?
0 Tage (1)
zwischen 1 und 7 Tagen (2)
zwischen 8 und 14 Tagen (3)
zwischen 15 und 21 Tagen (4)
an mehr als 21 Tagen (5)
Fragen nach der Operation
Sind als Folge der Operation in unserer Klinik
Komplikationen aufgetreten (wie z.B. Störung der
Wundheilung, Lähmung, Gefühlsstörungen) ?
Ja
Nein
Falls Komplikationen aufgetreten sind, bitte
beschreiben Sie diese
Wie beeinträchtigend/störend waren diese
Komplikationen?
gar nicht beeinträchigend/störend (1)
ein wenig beeinträchigend/störend (2)
mässig beeinträchigend/störend (3)
erheblich beeinträchigend/störend (4)
sehr stark beeinträchigend/störend (5)
Wurden Sie seit der Operation bei uns in einer
anderen Einrichtung (Klinik/ Praxis) oder erneut
bei uns an der Halswirbelsäule (am Nacken)
operiert ?
nein (1)
ja, aber an einer anderen Stelle der
Halswirbelsäule (2)
ja, an derselben Stelle der
Halswirbelsäule (gleiches Segment) (3)
Wie zufrieden waren Sie bisher mit der
Behandlung Ihrer Nackenbeschwerden
in unserer Klinik ?
sehr zufrieden (1)
etwas zufrieden (2)
weder zufrieden noch unzufrieden (3)
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etwas unzufrieden (4)
sehr unzufrieden (5)
Wie hat Ihnen die Behandlung Ihrer
Nackenbeschwerden in unserer Klinik
(Operation)
insgesamt geholfen?
sehr geholfen (1)
geholfen (2)
nur wenig geholfen (3)
nicht geholfen (4)
geschadet (5)
Datum
Unterschrift
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DWG-Register COMI Rücken operativ
Deutsche Wirbelsäulen Gesellschaft DWG-Register,
http://www.dwg.org ;OA Dr. Hartensuer
All rights reserved. Please visit https://medical-data-
models.org/forms/15506
COMI Rücken operativ
Demographische Daten
Patient Nachname
Patient Vorname
Geschlecht*
Straße
Patienten-Nr:*
Land
Postleitzahl
Wohnort
Sozialversicherungsnummer (AHV)
Geburtsjahr*
Geburtstag (Monat und Tag)
Patientenbefragung
Untersuchungsintervall
vor Operation (1)
3 Jahre (10)
4 Jahre (11)
5 Jahre (12)
anderes Intervall in Jahren (bitte
angeben) (13)
4 Wochen (2)
6 Wochen (3)
2 Monate (4)
3 Monate (5)
6 Monate (6)
9 Monate (7)
1 Jahr (8)
2 Jahre (9)
Anderes Untersuchungsintervall (in Jahren)
Welche Beschwerden belasten Sie am stärksten?
Schmerzen im Rücken (1)
1 / 4
Schmerzen im Bein/Gesäss (2)
Kribbeln, Taubheit oder andere
Missempfindungen im
Rücken/Bein/Gesäss (3)
Keine der aufgeführten Beschwerden (4)
Wie stark waren Ihre Rückenschmerzen in der
letzten Woche?
0 keine Schmerzen (1)
9 (10)
10 stärkste Schmerzen, die ich mir
vorstellen kann (11)
1 (2)
2 (3)
3 (4)
4 (5)
5 (6)
6 (7)
7 (8)
8 (9)
Wie stark waren Ihre Bein-/Gesäßschmerzen in
der letzten Woche?
0 keine Schmerzen (1)
9 (10)
10 stärkste Schmerzen, die ich mir
vorstellen kann (11)
1 (2)
2 (3)
3 (4)
4 (5)
5 (6)
6 (7)
7 (8)
8 (9)
Wie stark haben Ihre Rückenbeschwerden Ihre
(Arbeit und zu Hause) normalen Aufgaben in der
letzten Woche beeinträchtigt?
gar nicht (1)
ein wenig (2)
mässig (3)
erheblich (4)
sehr stark (5)
Wie würden Sie sich fühlen, wenn Sie den Rest
Ihres Lebens mit Ihren derzeitigen
Rückenbeschwerden leben müssten?
sehr zufrieden (1)
etwas zufrieden (2)
weder zufrieden noch unzufrieden (3)
etwas unzufrieden (4)
sehr unzufrieden (5)
Bitte blicken Sie auf die letzte Woche zurück. Wie
würden Sie Ihre Lebensqualität beurteilen?
sehr gut (1)
gut (2)
mittelmässig (3)
schlecht (4)
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sehr schlecht (5)
An wievielen Tagen in den letzten 4 Wochen
haben Ihre Rückenbeschwerden
Sie gezwungen, Ihre gewohnten Tätigkeiten
(Arbeit, Hausarbeit, Schule,
Freizeitaktivitäten) einzuschränken?
0 Tage (1)
zwischen 1 und 7 Tagen (2)
zwischen 8 und 14 Tagen (3)
zwischen 15 und 21 Tagen (4)
an mehr als 21 Tagen (5)
An wievielen Tagen in den letzten vier Wochen
haben Ihre Rückenbeschwerden Sie
daran gehindert , zur Arbeit zu gehen (Arbeit,
Schule, Hausarbeit)?
0 Tage (1)
zwischen 1 und 7 Tagen (2)
zwischen 8 und 14 Tagen (3)
zwischen 15 und 21 Tagen (4)
an mehr als 21 Tagen (5)
Fragen nach der Operation
Sind als Folge der Operation in unserer Klinik
Komplikationen aufgetreten (wie z.B. Störung der
Wundheilung, Lähmung, Gefühlsstörungen) ?
Ja
Nein
Falls Komplikationen aufgetreten sind, bitte
beschreiben Sie diese
Wie beeinträchtigend/störend waren diese
Komplikationen?
gar nicht beeinträchigend/störend (1)
ein wenig beeinträchigend/störend (2)
mässig beeinträchigend/störend (3)
erheblich beeinträchigend/störend (4)
sehr stark beeinträchigend/störend (5)
Wurden Sie seit der Operation bei uns in einer
anderen Einrichtung (Klinik/ Praxis) oder erneut
bei uns an der Wirbelsäule (am mittleren/unteren
Rücken) operiert ?
nein (1)
ja, aber an einer anderen Stelle der
Wirbelsäule (2)
ja, an derselben Stelle der Wirbelsäule
(gleiches Segment) (3)
Wie zufrieden waren Sie bisher mit der
Behandlung Ihrer Rückenbeschwerden
in unserer Klinik ?
sehr zufrieden (1)
etwas zufrieden (2)
weder zufrieden noch unzufrieden (3)
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etwas unzufrieden (4)
sehr unzufrieden (5)
Wie hat Ihnen die Behandlung Ihrer
Rückenbeschwerden in unserer Klinik
(Operation)
insgesamt geholfen?
sehr geholfen (1)
geholfen (2)
nur wenig geholfen (3)
nicht geholfen (4)
geschadet (5)
Datum
Unterschrift
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DWG-Register COMI Rücken konservativ
Deutsche Wirbelsäulen Gesellschaft DWG-Register,
http://www.dwg.org ;OA Dr. Hartensuer
All rights reserved. Please visit https://medical-data-
models.org/forms/15507
COMI Rücken konservativ
Demographische Daten
Patient Nachname
Patient Vorname
Geschlecht*
Straße
Patienten-Nr:*
Land
Postleitzahl
Wohnort
Sozialversicherungsnummer
Geburtsjahr*
Geburtstag (Monat und Tag)
Patientenbefragung
Untersuchungsintervall
vor Behandlung (1)
6 Monate (10)
3 Monate (11)
6 Wochen (12)
anderes Intervall (bitte angeben) (13)
bei Entlassung (Abschluss) (2)
>5 Jahre (3)
5 Jahre (4)
4 Jahre (5)
3 Jahre (6)
2 Jahre (7)
1 Jahr (8)
9 Monate (9)
Anderes Untersuchungsintervall (in Monaten)
Welche Beschwerden belasten Sie am stärksten?
Schmerzen im Rücken (1)
Schmerzen im Bein/Gesäss (2)
1 / 4
Kribbeln, Taubheit oder andere
Missempfindungen im
Rücken/Bein/Gesäss (3)
Keine der aufgeführten Beschwerden (4)
Wie stark waren Ihre Rückenschmerzen in der
letzten Woche?
0 keine Schmerzen (1)
9 (10)
10 stärkste Schmerzen, die ich mir
vorstellen kann (11)
1 (2)
2 (3)
3 (4)
4 (5)
5 (6)
6 (7)
7 (8)
8 (9)
Wie stark waren Ihre Bein-/Gesäßschmerzen in
der letzten Woche?
0 keine Schmerzen (1)
9 (10)
10 stärkste Schmerzen, die ich mir
vorstellen kann (11)
1 (2)
2 (3)
3 (4)
4 (5)
5 (6)
6 (7)
7 (8)
8 (9)
Wie stark haben Ihre Rückenbeschwerden Ihre
(Arbeit und zu Hause) normalen Aufgaben in der
letzten Woche beeinträchtigt?
gar nicht (1)
ein wenig (2)
mässig (3)
erheblich (4)
sehr stark (5)
Wie würden Sie sich fühlen, wenn Sie den Rest
Ihres Lebens mit Ihren derzeitigen
Rückenbeschwerden leben müssten?
sehr zufrieden (1)
etwas zufrieden (2)
weder zufrieden noch unzufrieden (3)
etwas unzufrieden (4)
sehr unzufrieden (5)
Bitte blicken Sie auf die letzte Woche zurück. Wie
würden Sie Ihre Lebensqualität beurteilen?
sehr gut (1)
gut (2)
mittelmässig (3)
schlecht (4)
sehr schlecht (5)
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An wievielen Tagen in den letzten 4 Wochen
haben Ihre Rückenbeschwerden
Sie gezwungen, Ihre gewohnten Tätigkeiten
(Arbeit, Hausarbeit, Schule,
Freizeitaktivitäten) einzuschränken?
0 Tage (1)
zwischen 1 und 7 Tagen (2)
zwischen 8 und 14 Tagen (3)
zwischen 15 und 21 Tagen (4)
an mehr als 21 Tagen (5)
An wievielen Tagen in den letzten vier Wochen
haben Ihre Rückenbeschwerden Sie
daran gehindert , zur Arbeit zu gehen (Arbeit,
Schule, Hausarbeit)?
0 Tage (1)
zwischen 1 und 7 Tagen (2)
zwischen 8 und 14 Tagen (3)
zwischen 15 und 21 Tagen (4)
an mehr als 21 Tagen (5)
Fragen nach der Behandlung
Sind als Folge der Behandlung in unserer
Einrichtung (Klinik/ Praxis) Komplikationen
aufgetreten (wie z.B. Störung der Wundheilung,
Lähmung, Gefühlsstörungen) ?
Ja
Nein
Falls Komplikationen aufgetreten sind, bitte
beschreiben Sie diese
Wie beeinträchtigend/störend waren diese
Komplikationen?
gar nicht beeinträchigend/störend (1)
ein wenig beeinträchigend/störend (2)
mässig beeinträchigend/störend (3)
erheblich beeinträchigend/störend (4)
sehr stark beeinträchigend/störend (5)
Wurden Sie seit der Behandlung bei uns in einer
anderen Einrichtung (Klinik/ Praxis) oder erneut
bei uns an der Wirbelsäule (am mittleren/unteren
Rücken) behandelt?
nein (1)
ja, aber an einer anderen Stelle der
Wirbelsäule (2)
ja, an derselben Stelle der Wirbelsäule
(gleiches Segment) (3)
Wie zufrieden waren Sie bisher mit der
Behandlung Ihrer Rückenbeschwerden
in unserer Einrichtung (Klinik/ Praxis) ?
sehr zufrieden (1)
etwas zufrieden (2)
weder zufrieden noch unzufrieden (3)
etwas unzufrieden (4)
sehr unzufrieden (5)
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Wie hat Ihnen die Behandlung Ihrer
Rückenbeschwerden in unserer Einrichtung
(Klinik/ Praxis) insgesamt geholfen?
sehr geholfen (1)
geholfen (2)
nur wenig geholfen (3)
nicht geholfen (4)
geschadet (5)
Datum
Unterschrift
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DWG-Register Japanese Orthopaedic Association
Scoring System - bei zervikaler Myelopathie
Deutsche Wirbelsäulen Gesellschaft DWG-Register,
http://www.dwg.org
All rights reserved. Please visit https://medical-data-
models.org/forms/15509
Japanese Orthopaedic Association
Scoring System - bei zervikaler
Myelopathie
Demographische Daten
Patient Nachname
Patient Vorname
Geschlecht*
Straße
Patienten-Nr:*
Land
Postleitzahl
Wohnort
Sozialversicherungsnummer (AHV)
Geburtsjahr*
Geburtstag (Monat und Tag)
Generell
Datum
Untersuchungsintervall
vor Eingriff (1)
5 Jahre (10)
>5 Jahre (11)
anderes Intervall in Monaten (bitte
angeben) (12)
6 Wochen (2)
3 Monate (3)
6 Monate (4)
9 Monate (5)
1 Jahr (6)
2 Jahre (7)
3 Jahre (8)
4 Jahre (9)
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Anderes Untersuchungsintervall (in Jahren)
Motorische Funktion
Motorische Funktion der Finger
Unfähig, selbst mit Löffel und Gabel zu
essen; unfähig, selbst große Knöpfe zu
knöpfen (1)
Fähig, sich selbst mit Löffel und Gabel zu
ernähren, jedoch ungeschickt (2)
Schreiben möglich, wenngleich sehr
ungeschickt; große Knöpfe können
geknöpft werden (3)
Schreiben etwas eingeschränkt, aber
möglich; Manschettenknöpfe können
geknöpft werden (4)
Normal (5)
Motorische Funktion von Schulter und Oberarm
Kraftgrad 2 oder geringer (1)
Kraftgrad 3 (2)
Kraftgrad 4 (3)
Kraftgrad 5 (4)
Motorische Funktion der unteren Extremität
Nicht in der Lage, aufzustehen und zu
gehen (1)
Fähig, aufzustehen, jedoch nicht zu
gehen (2)
Unfähig, selbst auf ebenem Untergrund
ohne Gehhilfe zu gehen (3)
Fähig, ohne Unterstützung zu gehen, bei
jedoch unsicherem Gangbild (4)
Fähig, auf ebenem Untergrund frei zu
gehen; Treppensteigen nur mit
Unterstützung (5)
Treppaufgehen ohne Unterstützung;
Treppabgehen nur mit Unterstützung
möglich (6)
Rasches Gehen möglich, jedoch etwas
unsicheres Gangbild (7)
Normal (8)
Sensibilität
Sensibilität der oberen Extremität
Vollständiger Verlust der Berührungs-
und Schmerzempfindung (1)
Bis 50%ige Sensibilitätsminderung
und/oder erhebliche Schmerzen oder
Taubheit (2)
Bis 40%ige Sensibilitätsminderung
und/oder mäßige Schmerzen oder
Taubheit (3)
Taubheitsgefühl ohne sensibles Defizit
(4)
Normal (5)
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Sensibilität des Stamms
Vollständiger Verlust der Berührungs-
und Schmerzempfindung (1)
Bis 50%ige Sensibilitätsminderung
und/oder erhebliche Schmerzen oder
Taubheit (2)
Bis 40%ige Sensibilitätsminderung
und/oder mäßige Schmerzen oder
Taubheit (3)
Taubheitsgefühl ohne sensibles Defizit
(4)
Normal (5)
Sensibilität der unteren Extemität
Vollständiger Verlust der Berührungs-
und Schmerzempfindung (1)
Bis 50%ige Sensibilitätsminderung
und/oder erhebliche Schmerzen oder
Taubheit (2)
Bis 40%ige Sensibilitätsminderung
und/oder mäßige Schmerzen oder
Taubheit (3)
Taubheitsgefühl ohne sensibles Defizit
(4)
Normal (5)
Blasenfunktion
Harnretention und/oder Inkontinenz (1)
Gefühl der unvollständigen
Blasenentleerung und/oder Nachtröpfeln
und/oder spärlicher Urinstrahl und/oder
nur teilweise erhaltene Kontinenz (2)
Verzögerte Blasenentleerung und/oder
Pollakisurie (3)
Normal (4)
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Eligibility Multiple Myeloma NCT02192775
A Phase II Trial of Oncolytic Virotherapy by Systemic
Administration of Edmonston Strain of Measles Virus; ODM
derived from: https://clinicaltrials.gov/show/NCT02192775
All rights reserved. Please visit https://medical-data-
models.org/forms/15510
Eligibility Multiple Myeloma
NCT02192775
Inclusion Criteria
relapsed patients must have a confirmed mm
diagnosis with high-risk disease as defined by
gep70 risk score ≥ 0.66 or gep80 gene score of ≥
2.48 or metaphase cytogenetic abnormalities or
ldh ≥ 360 u/l due to mm (rule out hemolysis,
infection and contact pi for clarification if any
doubt). patients must have relapsed after auto-
pbsct followed by further chemotherapy*
Yes
No
≥2 months must have elapsed after the last
peripheral blood stem cell transplant prior to
enrollment*
Yes
No
zubrod ≤ 2, unless solely due to symptoms of
mm-related (bone) disease*
Yes
No
patients must have a platelet count of ≥ 20,000/µl
within 45 days of registration, unless lower levels
are explained by extensive bm plasmacytosis or
extensive prior therapy*
Yes
No
patients must be at least 18 years of age and not
older than 75 years of age at the time of
registration*
Yes
No
participants must have preserved renal function
as defined by a serum creatinine level of ≤ 3
mg/dl within 45 days of registration*
Yes
No
participants must have an ejection fraction by
echo or muga scan ≥ 40% within 45 days prior to
registration*
Yes
No
patients must have adequate pulmonary function
studies > 50% of predicted on mechanical
aspects (fev1, etc) and diffusion capacity (dlco) >
50% of predicted within 45 days prior to
1 / 3
registration. if the patient is unable to complete
pulmonary function tests due to mm related pain
or condition, exception may be granted*
Yes
No
patients must have signed an irb-approved
informed consent and health insurance portability
and accountability act (hipaa) authorization form*
Yes
No
patients must have anti-mv igg titer of ≤ 0.5u/ml
(mayo clinic assay).  mayo clinic will also assay
the patients' igm titer and perform a neutralizing
antibody plaque-assay to determine recent mv
exposure and the ability of the patients'*
Yes
No
circulating antibodies to inhibit mv propagation on
vero cells, respectively.  while these tests are
additional indicators of patient eligibility, final
enrollment decision will be determined by igg
levels*
Yes
No
Exclusion Criteria
patients may not be positive for the human
immunodeficiency virus (hiv)*
Yes
No
history of poorly controlled hypertension,
diabetes mellitus, or any other serious medical
illness or psychiatric illness that could potentially
interfere with the completion of treatment
according to this protocol or could be considered
to be an exclusion criterion deemed by the pi*
Yes
No
patients must not have prior malignancy, except
for adequately treated basal cell or squamous cell
skin cancer, in situ cervical cancer, or other
cancer for which the patient has not received
treatment for one year prior to enrollment. other
cancers will only be acceptable if the patient's life
expectancy exceeds three years as determined
by the pi*
Yes
No
pregnant or nursing women may not participate.
women of childbearing potential must have a
negative pregnancy test documented within one
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week of registration. women/men of reproductive
potential may not participate unless they have
agreed to use an effective contraceptive method*
Yes
No
exposure to household contacts ≤ 15 months old
or household contact with known
immunodeficiency*
Yes
No
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DWG-Register Neck disability index
Deutsche Wirbelsäulen Gesellschaft DWG-Register,
http://www.dwg.org
All rights reserved. Please visit https://medical-data-
models.org/forms/15511
Neck disability index
Demographische Daten
Patient Nachname
Patient Vorname
Geschlecht*
Straße
Patienten-Nr:*
Land
Postleitzahl
Wohnort
Sozialversicherungsnummer (AHV)
Geburtsjahr*
Geburtstag (Monat und Tag)
Patientenbefragung
Datum
Untersuchungsintervall
vor Eingriff (1)
5 Jahre (10)
6 Jahre (11)
7 Jahre (12)
8 Jahre (13)
9 Jahre (14)
10 Jahre (15)
11 Jahre (16)
12 Jahre (17)
13 Jahre (18)
14 Jahre (19)
6Wochen (2)
15 Jahre (20)
>15 Jahren (21)
anderes Intervall (bitte angeben) (22)
3 Monaten (3)
6 Monaten (4)
1 / 4
9 Monaten (5)
1 Jahr (6)
2 Jahre (7)
3 Jahre (8)
4 Jahre (9)
Anderes Untersuchungsintervall
Intensität des Schmerzes
Ich habe keinen Schmerz im Moment.
(1)
Der Schmerz ist im Moment sehr mild.
(2)
Der Schmerz ist im Moment mässig. (3)
Der Schmerz ist im Moment ziemlich
streng. (4)
Der Schmerz ist im Moment sehr streng.
(5)
Der Schmerz ist der schlechteste
Vorstellbare im Moment. (6)
Körperpflege (Waschen,Ankleiden,usw)
Ich kann um mich kümmern, ohne
Extraschmerzen zu verursachen. (1)
Ich kann um mich kümmern, aber es
verursacht Extraschmerzen. (2)
Es ist schmerzhaft, mich um mich zu
kümmern, und ich bin langsam und
vorsichtig. (3)
Ich brauche etwas Hilfe, aber führe den
grössten Teil meiner persönlichen Pflege
selber durch. (4)
Ich benötige jeden Tag für die meisten
Aspekten meiner persönlichen Pflege
Hilfe. (5)
Ich werde nicht angekleidet, ich wasche
mich mit große Schwierigkeit und ich
bleibe im Bett. (6)
Gewichte anheben
Ich kann schwere Gewichte ohne
Extraschmerzen heben (1)
Ich kann schwere Gewichte heben, aber
mit Extraschmerz (2)
Schmerz hält mich davon ab, schwere
Gewichte vom Fussboden zu heben,
aber ich kann schwere Gewichte heben,
wenn sie zum Beispiel auf einem Tisch
gestellt werden. (3)
Schmerz hält mich davon ab, schwere
Gewichte vom Fussboden zu heben,
aber ich kann mässige Gewichte heben,
wenn sie zum Beispiel auf einem Tisch
gestellt werden. (4)
Ich kann nur sehr leichte Gewichte
heben (5)
Ich kann überhaupt nichts heben oder
tragen (6)
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Lesen
Ich kann lesen so viel ich will ohne
Nackenschmerzen. (1)
Ich kann lesen so viel ich will mit
geringen Nackenschmerzen. (2)
Ich kann lesen so viel ich will mit
mässigen Nackenschmerzen. (3)
Ich kann nicht lesen, so viel ich will auf
Grund von mässigen Nackenschmerzen.
(4)
Ich kann kaum lesen auf Grund von
starken Nackenschmerzen. (5)
Ich kann überhaupt nicht lesen. (6)
Kopfschmerzen
Ich habe überhaupt keine
Kopfschmerzen. (1)
Ich habe selten leichte Kopfschmerzen.
(2)
Ich habe selten mässige Kopfschmerzen.
(3)
Ich habe öfters mässige Kopfschmerzen.
(4)
Ich habe öfters starke Kopfschmerzen.
(5)
Ich habe fast die ganze Zeit
Kopfschmerzen. (6)
Konzentration
Ich kann mich ohne Schwierigkeiten
völlig konzentrieren, wenn ich will. (1)
Ich kann mich mit geringen
Schwierigkeiten völlig konzentrieren,
wenn ich will. (2)
Ich habe einige Schwierigkeiten, mich zu
konzentrieren, wenn ich will (3)
Ich habe grosse Schwierigkeiten, mich
zu konzentrieren, wenn ich will. (4)
Ich habe sehr grosse Schwierigkeiten,
mich zu konzentrieren, wenn will. (5)
Ich kann mich überhaupt nicht
konzentrieren. (6)
Arbeit
Ich kann so viel arbeiten wie ich will. (1)
Ich kann meine übliche Arbeit erledigen,
aber nicht mehr. (2)
Ich kann den grössten Teil meiner
üblichen Arbeit erledigen, aber nicht
mehr. (3)
Ich kann meine übliche Arbeit nicht
erledigen. (4)
Ich kann überhaupt kaum eine Arbeit
erledigen. (5)
Ich kann überhaupt keine Arbeit
erledigen. (6)
Autofahren
Ich kann Auto fahren ohne
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Nackenschmerzen. (1)
Ich kann Auto fahren mit geringen
Nackenschmerzen. (2)
Ich kann Auto fahren mit mässigen
Nackenschmerzen. (3)
Ich kann nicht Auto fahren so lange ich
will auf Grund vom mässigen
Nackenschmerzen. (4)
Ich kann kaum Autofahren auf Grund von
starken Nachenschmerzen. (5)
Ich kann überhaupt nicht Auto fahren auf
Grund von Nackenschmerzen. (6)
Schlaf
Mein Schlaf ist nicht beeinträchtigt. (1)
Mein Schlaf ist kaum beeinträchtigt
(weniger als 1 Stunde Schlaflosigkeit).
(2)
Mein Schlaf wird mild gestört (1-2
Stunden Schlaflosigkeit). (3)
Mein Schlaf wird mässig gestört (2-3
Stunden Schlaflosigkeit). (4)
Mein Schlaf wird ausserordentlich
gestört (3-5 Stunden Schlaflosigkeit). (5)
Mein Schlaf wird völlig gestört (5-7
Stunden Schlaflosigkeit). (6)
Freizeitaktivitäten
Ich kann alle meine Freizeitaktivitäten
ausüben, ohne überhaupt
Nackenschmerzen zu haben. (1)
Ich kann alle meine Freizeitaktivitäten
ausüben mit geringen Nachenschmerzen
(2)
Ich bin im Stande, mich mit meisten,
aber nicht allen von meiner üblichen
Freizeitaktivitäten zu beschäftigen auf
Grund von Nackenschmerzen. (3)
Ich bin im Stande, mich mit sehr wenigen
von meiner üblichen Freizeitaktivitäten zu
beschäftigen auf Grund von
Nackenschmerzen. (4)
Ich kann mich kaum mit meiner
Freizeitaktivitäten beschäftigen auf
Grund von Nackenschmerzen. (5)
Ich bin nicht im Stande, mich mit meiner
Freizeitaktivitäten zu beschäftigen. (6)
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Discharge Letter Items 1215271678
Multiple Sclerosis
Discharge Letter Items for Patient diagnosed with Multiple
Sclerosis from Neurology Department of University Clinic
Muenster
All rights reserved. Please visit https://medical-data-
models.org/forms/15513
Discharge Letter Items 1215271678
Multiple Sclerosis
Administrative Data
Document ID of Discharge Letter
Patient`s Name
Patients date of birth
Date of Appointment/Stay
Inpatient or Outpatient
Inpatient (Inpatient)
Outpatient (Outpatient)
Principal Diagnosis
Principal Diagnosis Multiple Sclerosis
Onset
Earliest date of diagnosis
EDSS
History of Retrobulbar Neuritis
Yes
No
Reason for Admission
Reason for admission
Summary and Assessment
Introduction: Reason for current Admission
Introduction: Department
Past medical history
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Previous MRI findings
Visual evoked potential findings
Central motor evoked potential results
Cerebrospinal fluid
Oligoclonal Bands
Immunoglobulin G synthesis in Cerebrospinal
fluid
Cerebrospinal fluid viral antibody test
(measles, rubella, varicella)
Previous Therapy Medication
Previous Therapie Benefit
Did a loss of bladder function control occur?
Yes
No
Did a loss of bowl function control occur?
Yes
No
Does an impairment of everyday life occur due to
fatigue?
Yes
No
Follow-up MRI
Number of T2-hyperintense Lesions in cMRT
Localisation of Lesions
Criteria Dissemination in Time
Yes
No
Criteria Dissemination in Space
Yes
No
Neurological Examination
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Therapeutic Options
Study Participation
Yes
No
Procedures
Anti-aquaporin-4 antibody Blood Test
Borrelia test
Vasculitis Laboratory Tests
Therapy Recommendation
Neurological Exam
MRI Follow-Up
Medication
Neurological Examination: Cranial Nerves
Orientation
Meningism
Nerve stretch tests
Lhermitte's sign
negative (negative)
positive (positive)
Visual Field Fingerperimetric
Pupils Size
Pupils regularity
Pupils reaction
Direct pupil reaction to light
Consensual pupil reaction to light
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Examination of Eye Movement
Nystagmus Test
Gaze Palsy
Diplopia
Facial Paralysis
Trigeminal Sensory Function
Trigeminal Motor Function abnormal?
Yes
No
Function of caudal cranial nerves
Neurological Examination: Motor
Pareses
present (1)
not present (2)
not examined (3)
Pronator Drift Test
Leg drift test
Muscle Tonus
Fine motor skills abnormal?
Gait, Manner of walking
Standing, Manner of Standing
Function of Muscular reflex
Pyramidal signs
Sensibility on neurological exam abnormal?
Yes
No
Abnormal motor coordination tests?
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DWG-Register Oswestry disability index
Deutsche Wirbelsäulen Gesellschaft DWG-Register,
http://www.dwg.org
All rights reserved. Please visit https://medical-data-
models.org/forms/15515
Oswestry Low Back Pain Disability
Index 2.1
Demographische Daten
Patient Nachname
Patient Vorname
Geschlecht*
Geschlecht*
Straße
Patienten-Nr:*
Land
Postleitzahl
Wohnort
Sozialversicherungsnummer (AHV)
Geburtsjahr*
Geburtstag (Monat und Tag)
Patientenbefragung
Datum
Untersuchungsintervall
vor Eingriff (1)
5 Jahre (10)
6 Jahre (11)
7 Jahre (12)
8 Jahre (13)
9 Jahre (14)
10 Jahre (15)
11 Jahre (16)
12 Jahre (17)
13 Jahre (18)
14 Jahre (19)
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6Wochen (2)
15 Jahre (20)
>15 Jahren (21)
anderes Intervall (bitte angeben) (22)
3 Monaten (3)
6 Monaten (4)
9 Monaten (5)
1 Jahr (6)
2 Jahre (7)
3 Jahre (8)
4 Jahre (9)
Anderes Untersuchungsintervall
Intensität des Schmerzes
Ich habe momentan keine Schmerzen.
(1)
Die Schmerzen sind im Moment sehr
schwach. (2)
Die Schmerzen sind im Moment mässig.
(3)
Die Schmerzen sind im Moment ziemlich
stark (4)
Die Schmerzen sind im Moment sehr
stark. (5)
Die Schmerzen sind im Moment so
schlimm wie nur vorstellbar. (6)
Körperpflege (Waschen,Ankleiden,usw)
Ich kann meine Körperpflege normal
durchführen, ohne dass die Schmerzen
dadurch stärker werden. (1)
Ich kann meine Körperpflege normal
durchführen, aber es ist schmerzhaft. (2)
Meine Körperpflege durchzuführen ist
schmerzhaft, und ich bin langsam und
vorsichtig. (3)
Ich brauche bei der Körperpflege etwas
Hilfe, bewältige aber das meiste selbst.
(4)
Ich brauche täglich Hilfe bei den meisten
Aspekten meiner Körperpflege. (5)
Ich kann mich nicht selbst anziehen,
wasche mich mit Mühe und bleibe im
Bett. (6)
Gehen
Schmerzen hindern mich nicht daran, so
weit zu gehen, wie ich möchte. (1)
Die Schmerzen hindern mich daran,
mehr als 1-2 km zu gehen. (2)
Die Schmerzen hindern mich daran,
mehr als 0,5 km zu gehen. (3)
Die Schmerzen hindern mich daran,
mehr als 100 m zu gehen. (4)
Ich kann nur mit einem Stock oder
Krücken gehen. (5)
Ich bin die meiste Zeit im Bett und muss
mich zur Toilette schleppen. (6)
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Heben
Ich kann schwere Gegenstände heben,
ohne dass die Schmerzen dadurch
stärker werden. (1)
Ich kann schwere Gegenstände heben,
aber die Schmerzen werden dadurch
stärker. (2)
Schmerzen hindern mich daran, schwere
Gegenstände zu heben, aber es
geht,wenn diese geeignet stehen, z.B.
auf Tisch. (3)
Schmerzen hindern mich daran, schwere
Gegenstände vom Boden zu heben,
aber ich kann leichte bis mittelschwere
Gegenstände heben, wenn sie geeignet
stehen. (4)
Ich kann nur sehr leichte
Gegegenstände heben (5)
Ich kann überhaupt nichts heben oder
tragen (6)
Sitzen
Ich kann auf jedem Stuhl so lange sitzen,
wie ich möchte. (1)
Ich kann auf meinem Lieblingsstuhl so
lange sitzen, wie ich möchte. (2)
Schmerzen hindern mich daran, länger
als eine Stunde zu sitzen. (3)
Schmerzen hindern mich daran, länger
als eine halbe Stunde zu sitzen. (4)
Schmerzen hindern mich daran, länger
als 10 Minuten zu sitzen. (5)
Schmerzen hindern mich daran,
überhaupt zu sitzen. (6)
Stehen
Ich kann so lange stehen wie ich
möchte, ohne dass die Schmerzen
dadurch stärker werden. (1)
Ich kann so lange stehen wie ich
möchte, aber die Schmerzen werden
dadurch stärker. (2)
Die Schmerzen hindern mich daran,
länger als eine Stunde zu stehen. (3)
Die Schmerzen hindern mich daran,
länger als 30 Minuten zu stehen. (4)
Die Schmerzen hindern mich daran,
länger als 10 Minuten zu stehen. (5)
Die Schmerzen halten mich völlig vom
Stehen ab. (6)
Schlafen
Mein Schlaf ist nie durch Schmerzen
gestört. (1)
Mein Schlaf ist gelegentlich durch
Schmerzen gestört. (2)
Ich schlafe auf Grund von Schmerzen
weniger als 6 Stunden. (3)
Ich schlafe auf Grund von Schmerzen
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weniger als 4 Stunden. (4)
Ich schlafe auf Grund von Schmerzen
weniger als 2 Stunden. (5)
Schmerzen hindern mich daran,
überhaupt zu schlafen. (6)
Sexualleben
Mein Sexualleben ist normal und die
Schmerzen werden dadurch nicht
stärker. (1)
Mein Sexualleben ist normal, aber die
Schmerzen werden dadurch stärker. (2)
Mein Sexualleben ist fast normal, aber
sehr schmerzhaft. (3)
Mein Sexualleben ist durch die
Schmerzen stark eingeschränkt. (4)
Ich habe auf Grund von Schmerzen fast
kein Sexualleben. (5)
Schmerzen verhindern jegliches
Sexualleben (6)
Gesellschaftliche Aktivitäten
Mein Sozialleben ist normal und die
Schmerzen werden dadurch nicht
stärker. (1)
Mein Sozialleben ist normal, aber die
Schmerzen werden dadurch stärker. (2)
Schmerzen haben keinen wesentlichen
Einfluss auf mein Sozialleben,ausser
dass sie meine aktiveren Interessen wie
z.B. Sport einschränken. (3)
Schmerzen schränken mein Sozialleben
ein und ich gehe nicht mehr so oft aus.
(4)
Schmerzen schränken mein Sozialleben
auf mein Zuhause ein. (5)
Ich habe auf Grund von Schmerzen kein
Sozialleben. (6)
Reisen
Ich kann überallhin reisen und die
Schmerzen werden dadurch nicht
stärker. (1)
Ich kann überallhin reisen, aber die
Schmerzen werden dadurch stärker. (2)
Trotz starker Schmerzen kann ich länger
als 2 Stunden unterwegs sein. (3)
Auf Grund meiner Schmerzen kann ich
höchstens 1 Stunde unterwegs sein. (4)
Auf Grund von Schmerzen kann ich nur
kurze notwendige Fahrten unter 30
Minuten machen. (5)
Meine Schmerzen hindern mich daran,
Fahrten zu machen, ausser zur
medizinischen Behandlung. (6)
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Eligibility Multiple Myeloma NCT02252172
Study Comparing Daratumumab, Lenalidomide, and
Dexamethasone With Lenalidomide and Dexamethasone in
Participants With Previously Untreated Multiple Myeloma;
ODM derived from:
https://clinicaltrials.gov/show/NCT02252172
All rights reserved. Please visit https://medical-data-
models.org/forms/15516
Eligibility Multiple Myeloma
NCT02252172
Inclusion Criteria
participant must have documented multiple
myeloma and measurable disease defined as: 1)
monoclonal plasma cells in the bone marrow
greater than or equal to (>=) 10 percent (%) or
presence of a biopsy proven plasmacytoma; 2)
measurable disease as defined by any of the
following: (a) immunoglobulin (ig) g myeloma
(serum monoclonal paraprotein [m-protein] level
>=1.0 gram/deciliter [g/dl] or urine m-protein level
>=200 milligram[mg]/24 hours[hrs]; or (b) iga,
igm, igd, or ige multiple myeloma (serum m-
protein level >=0.5 g/dl or urine m-protein level
>=200 mg/24 hrs); or (c) light chain multiple
myeloma (serum immunoglobulin free light chain
>=10 mg/dl and abnormal serum immunoglobulin
kappa lambda free light chain ratio)*
Yes
No
participant must have an eastern cooperative
oncology group (ecog) performance status score
of 0, 1, or 2*
Yes
No
participants who are newly diagnosed and not
considered for high-dose chemotherapy due to:
being age >=65 years; or participants less than
(<) 65 years with presence of important comorbid
condition(s) likely to have a negative impact on
tolerability of high dose chemotherapy with stem
cell transplantation. sponsor review and approval
of participants below 65 years of age is required
before randomization*
Yes
No
women of childbearing potential must commit to
either abstain continuously from sexual
intercourse or to use 2 methods of reliable birth
control simultaneously as deemed appropriate by
the investigator. contraception must begin 4
weeks prior to dosing*
Yes
No
man, who is sexually active with a woman of
child-bearing potential and has not had a
vasectomy, must agree to use an adequate
contraception method as deemed appropriate by
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the investigator, and must also agree to not
donate sperm during the study and for 4 weeks
after last dose of lenalidomide and 4 months after
last dose of daratumumab*
Yes
No
Exclusion Criteria
participant has a diagnosis of primary
amyloidosis, monoclonal gammopathy of
undetermined significance (presence of serum m-
protein <3 g/dl; absence of lytic bone lesions,
anemia, hypercalcemia, and renal insufficiency
related to the m-protein), or smoldering multiple
myeloma (asymptomatic multiple myeloma with
absence of related organ or tissue impairment
end organ damage)*
Yes
No
participant has a diagnosis of waldenström's
disease, or other conditions in which igm m
protein is present in the absence of a clonal
plasma cell infiltration with lytic bone lesions*
Yes
No
participant has a history of malignancy (other
than multiple myeloma) within 5 years before the
date of randomization (exceptions are squamous
and basal cell carcinomas of the skin and
carcinoma in situ of the cervix, or malignancy that
in the opinion of the investigator, with
concurrence with the sponsor's medical monitor,
is considered cured with minimal risk of
recurrence within 5 years)*
Yes
No
participant has prior or current systemic therapy
or sct for multiple myeloma, with the exception of
an emergency use of a short course (equivalent
of dexamethasone 40 mg/day for a maximum 4
days) of corticosteroids before treatment*
Yes
No
participant has had radiation therapy within 14
days of randomization*
Yes
No
participant has known chronic obstructive
pulmonary disease (copd) (defined as a forced
expiratory volume in 1 second [fev1] <60% of
predicted normal), persistent asthma, or a history
of asthma within the last 2 years (intermittent
asthma is allowed). participants with known or
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suspected copd or asthma must have a fev1 test
during screening*
Yes
No
participant is known to be seropositive for history
of human immunodeficiency virus (hiv) or known
to have active hepatitis b or hepatitis c*
Yes
No
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Eligibility Multiple Myeloma NCT02272803
Phase II Study of Lenalidomide/Dexamethasone With or
Without Elotuzumab for Newly Diagnosed MM Patients in
Japan; ODM derived from:
https://clinicaltrials.gov/show/NCT02272803
All rights reserved. Please visit https://medical-data-
models.org/forms/15518
Eligibility Multiple Myeloma
NCT02272803
Criteria
Inclusion Criteria
newly diagnosed with symptomatic multiple
myeloma (mm)*
Yes
No
have not received any prior systemic anti-
myeloma therapy*
Yes
No
have measurable disease*
Yes
No
are not candidates for high-dose therapy plus
stem-cell transplantation (sct) because of age (≥
65 years) or coexisting conditions. refusal to
undergo high dose therapy with sct is not
sufficient for entry onto ca204-116 for a subject <
65 years old. there must be a comorbidity that
prevents sct for a subject < 65 years old*
Yes
No
Exclusion Criteria
non-secretory or oligo-secretory or free light-
chain only myeloma*
Yes
No
smoldering mm, defined as asymptomatic mm
with absence of lytic bone lesions*
Yes
No
monoclonal gammopathy of undetermined
significance (mgus)*
Yes
No
active plasma cell leukemia*
Yes
No
known human immunodeficiency virus (hiv)
infection or active hepatitis a, b, or c*
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Erhebungsbogen Bildgebung SHT-Register
Erhebungsbogen Bildgebung SHT-Register
All rights reserved. Please visit https://medical-data-
models.org/forms/15520
Erhebungsbogen Bildgebung
Erhebungsbogen Bildgebung
Datum der Bildgebung*
Uhrzeit der Bildgebung*
Unfalldatum*
Modalitäten: erfolgt
Natives CCT*
Ja
Nein
Kontrast-CCT*
Ja
Nein
CT-Angio*
Ja
Nein
MRT*
Ja
Nein
MR-Angio*
Ja
Nein
Doppler der intrakraniellen Gefäße*
Ja
Nein
Schädelsono*
Ja
Nein
Schädelröntgen*
Ja
Nein
cMRT
FLAIR*
Ja
Nein
T2**
Ja
Nein
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SWI*
Ja
Nein
T1*
Ja
Nein
sag. T2 über Balkenregion*
Ja
Nein
DWI*
Ja
Nein
Fraktur:
Fraktur*
ja (1)
nein (2)
wahrscheinlich (3)
Lokalisation1*
Mittellinie (1)
frontal (2)
parietal (3)
temporal (4)
okzipital (5)
Schädelbasis (6)
Gesichtsschädel (7)
Lokalisation2*
rechts (1)
links (2)
beidseitig (3)
Impressionsfraktur*
Ja
Nein
Penetrierende Verletzung*
Ja
Nein
Pneumocephalus*
Ja
Nein
Hämatome:
Epidural*
Ja
Nein
Lokalisation1*
Mittellinie (1)
frontal (2)
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parietal (3)
temporal (4)
okzipital (5)
hintere Schädelgrube (6)
Lokalisation2*
rechts (1)
links (2)
beidseitig (3)
raumfordernder Effekt*
Ja
Nein
neurochirurgische Operation/Drainage*
Ja
Nein
Subdural*
Ja
Nein
Subdural*
akut (1)
subakut (2)
chronisch (3)
unklar (4)
Lokalisation1*
Mittellinie (1)
frontal (2)
parietal (3)
temporal (4)
okzipital (5)
hintere Schädelgrube (6)
interhemisphärisch (7)
tentoriell (8)
Lokalisation2*
rechts (1)
links (2)
beidseitig (3)
raumfordernder Effekt*
Ja
Nein
neurochirurgische Operation/Drainage*
Ja
Nein
Hygrome*
Ja
Nein
Subarachnoidalblutung*
Ja
Nein
Lokalisation1*
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Mittellinie (1)
frontal (2)
parietal (3)
temporal (4)
okzipital (5)
hintere Schädelgrube (6)
interhemisphärisch (7)
tentoriell (8)
Hirnstamm (9)
Lokalisation2*
rechts (1)
links (2)
beidseitig (3)
Verteilung*
fokal (1)
diffus (2)
Gefäßdissektion*
Ja
Nein
Lokalisation1*
ACI (1)
VA (2)
Lokalisation2*
rechts (1)
links (2)
beidseitig (3)
Infarkt im abhängigen Gebiet (s.u.)*
Ja
Nein
Sinusvenenverletzung*
Ja
Nein
Lokalisation1*
sagittal (1)
transversal (2)
sigmoidal (3)
Lokalisation2*
rechts (1)
links (2)
Mitte (3)
Masseneffekte
Zisternenkompression*
Ja
Nein
Lokalisation Zisternenkompression*
rechts (1)
links (2)
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beidseitig (3)
Ausmaß Zisternenkompression*
sichtbar komprimiert (1)
verstrichen (2)
Hirnödem*
Ja
Nein
Ausmaß Hirnödem*
fokal (1)
global (2)
Herniation*
Ja
Nein
Mittellinienverlagerung*
ja (1)
nein (2)
nicht gemessen (3)
max. Verlagerung*
Kontusion*
ja (1)
nein (2)
unklar (3)
Anzahl Kontusionen*
0 (0)
1 (1)
2 (2)
>2 (3)
Lokalisation1*
frontal (1)
parietal (2)
temporal (3)
okzipital (4)
zerebellär (5)
andere (6)
Lokalisation2*
rechts (1)
links (2)
beidseitig (3)
Lokalisation3*
kortikal (1)
subkortikal (2)
tiefe Hirnstrukturen (3)
contre coup-Läsion*
Ja
Nein
Intrazerebrale Blutung*
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ja (1)
nein (2)
unklar (3)
Lokalisation1*
frontal (1)
Basalganglien (10)
andere (11)
parietal (2)
temporal (3)
okzipital (4)
zerebellär (5)
pontin (6)
medullär (7)
thalamisch (8)
hypothalamisch (9)
Lokalisation2*
rechts (1)
links (2)
beidseitig (3)
neurochirurgische Intervention*
Ja
Nein
Intraventrikuläre Blutung*
Ja
Nein
Lokalisation1*
SVlinks  (1 )
SVrechts  (2 )
3.V. (3)
4.V. (4)
Hydrocephalus*
Ja
Nein
Drainage*
Ja
Nein
Traumatic and/or Diffuse Axonal Injury:
T2*-white matter lesions*
0 (0)
1-2 (1)
>2 (2)
unklar (3)
Lokalisation1*
frontal (1)
Capsula interna (10)
Corpus callosum (11)
diffus (12)
parietal (2)
temporal (3)
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okzipital (4)
zerebellär (5)
thalamisch (6)
Basalganglien (7)
pontin (8)
medullär (9)
Lokalisation2*
rechts (1)
links (2)
beidseitig (3)
Ischämie/Infarkt/Hypoxie-Ischämie*
ja (1)
nein (2)
unklar (3)
Lokalisation1*
frontal (1)
parietal (2)
temporal (3)
okzipital (4)
zerebellär (5)
Hirnstamm (6)
deep gray matter (7)
Lokalisation2*
rechts (1)
links (2)
beidseitig (3)
Ausmaß Ischämie/Infarkt/Hypoxie-Ischämie*
fokal (1)
lobar (2)
multilobar (3)
hemisphäriell (4)
posterior fossa (5)
global (6)
Zeitpunkt*
akut (1)
subakut (2)
Art Ischämie/Infarkt/Hypoxie-Ischämie*
Wasserscheide (1)
arteriell (2)
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Eligibility Multiple Myeloma NCT02274519
Novel Support Options in Autologous Stem Cell Transplant
for Multiple Myeloma; ODM derived from:
https://clinicaltrials.gov/show/NCT02274519
All rights reserved. Please visit https://medical-data-
models.org/forms/15524
Eligibility Multiple Myeloma
NCT02274519
Inclusion Criteria
diagnosis of multiple myeloma*
Yes
No
18 years of age or greater*
Yes
No
english speaking*
Yes
No
general proficiency to read and write in english*
Yes
No
able to attend training session per study protocol*
Yes
No
ecog performance status 0-1*
Yes
No
Exclusion Criteria
currently performs tai chi, qi gong, or yoga at
least once weekly or more*
Yes
No
syncopal event in prior 60 days*
Yes
No
current grade 3 or > neuropathy*
Yes
No
concurrent major depressive disorder or anxiety
disorder (dsmiv)*
Yes
No
chronic dizziness and/or vestibular disorders*
Yes
No
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Deutsche Wirbelsäulen Gesellschaft DWG-Register,
http://www.dwg.org
All rights reserved. Please visit https://medical-data-
models.org/forms/15525
SRS-22 Patientenfragebogen
Version 22
Demographische Daten
Patient Nachname
Patient Vorname
Geschlecht*
Straße
Patienten-Nr:*
Land
Postleitzahl
Wohnort
Sozialversicherungsnummer (AHV)
Geburtsjahr*
Geburtstag (Monat und Tag)
Patientenbefragung
Datum
Untersuchungsintervall
vor Eingriff (1)
5 Jahre (10)
6 Jahre (11)
7 Jahre (12)
8 Jahre (13)
9 Jahre (14)
10 Jahre (15)
11 Jahre (16)
12 Jahre (17)
13 Jahre (18)
14 Jahre (19)
6Wochen (2)
15 Jahre (20)
>15 Jahren (21)
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anderes Intervall (bitte angeben) (22)
3 Monaten (3)
6 Monaten (4)
9 Monaten (5)
1 Jahr (6)
2 Jahre (7)
3 Jahre (8)
4 Jahre (9)
Anderes Untersuchungsintervall
Mit welcher der folgenden Antworten lassen sich
die Schmerzen, die Sie in den vergangenen 6
Monaten
erlitten haben, am besten beschreiben?
keine  (1)
leichte  (2)
mässige  (3)
mässige bis starke  (4)
starke (5)
Mit welcher der folgenden Antworten lassen sich
die Schmerzen, die Sie im vergangenen Monat
erlitten haben, am besten beschreiben?
keine  (1)
leichte  (2)
mässige  (3)
mässige bis starke  (4)
starke (5)
Waren Sie in den vergangenen 6 Monaten sehr
nervös?
zu keinem Zeitpunkt  (1)
für kurze Zeit  (2)
einige Zeit  (3)
die meiste Zeit  (4)
die ganze Zeit (5)
Wie würden Sie sich dabei fühlen, wenn Sie Ihr
restliches Leben mit Ihrer momentanen
Rückenform verbringen müssten?
sehr glücklich (1)
ziemlich glücklich (2)
weder glücklich noch unglücklich (3)
ziemlich unglücklich  (4)
sehr unglücklich (5)
Auf welcher Ebene bewegen sich Ihre Aktivitäten
gegenwärtig?
bettlägrig/Rollstuhl (1)
im Wesentlichen keine Aktivitäten (2)
leichte Arbeit, wie z.B. Hausarbeit (3)
mässige körperliche Arbeit und mässige
sportliche Betätigung, wie z.B. Wandern
u. Radfahren (4)
sämtliche Aktivitäten ohne
Einschränkung (5)
Wie sehen Sie mit Kleidung aus?
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sehr gut  (1)
gut  (2)
einigermassen gut  (3)
schlecht  (4)
sehr schlecht (5)
Wie häufig haben Sie sich in den vergangenen 6
Monaten so niedergeschalgen gefühlt, dass
nichts Sie
aufheitern konnte?
sehr häufig  (1)
häufig  (2)
gelegentlich  (3)
selten  (4)
nie (5)
Haben Sie Rückenschmerzen in Ruhe?
sehr häufig  (1)
häufig  (2)
gelegentlich  (3)
selten  (4)
nie (5)
Auf welcher Ebene bewegen sich gegenwärtig
Ihre beruflichen/schulischen Aktivitäten?
100% normal  (1)
75% normal  (2)
50% normal  (3)
25% normal  (4)
0% normal (5)
Mit welcher der folgenden Antworten lässt sich
das Aussehen Ihres Rumpfes - definiert als
menschlicher Körper
ohne Kopf und Glieder - beschreiben?
sehr gut  (1)
gut  (2)
einigermassen gut  (3)
schlecht  (4)
sehr schlecht (5)
Was für Medikamente nehmen Sie aufgrund Ihrer
Beschwerden ein?
keine (1)
Nichtbetäubungsmittel wöchentlich oder
weniger (2)
Nichtbetäubungsmittel täglich (3)
Betäubungsmittel wöchentlich oder
weniger (4)
Betäubungsmittel täglich (5)
Andere (bitte angeben) (6)
Welche anderen Medikamente nehmen Sie
aufgrund Ihrer Beschwerden ein?
Schränkt Ihr Rücken Ihre Fähigkeit ein, zu Hause
etwas zu tun?
nie  (1)
selten  (2)
gelegentlich  (3)
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häufig  (4)
sehr häufig (5)
Waren Sie in den vergangenen 6 Monaten ruhig
und gelassen?
zu keinem Zeitpunkt  (1)
für kurze Zeit  (2)
einige Zeit  (3)
die meiste Zeit  (4)
die ganze Zeit (5)
Sind Sie der Meinung, dass sich Ihre
Rückenerkrankung auf Ihre persönlichen
Beziehungen auswirkt?
überhaupt nicht  (1)
kaum  (2)
schwach  (3)
mässig  (4)
stark (5)
Haben Sie und/oder Ihre Familie wegen Ihres
Rückens finanizelle Schwierigkeiten?
Starke (1)
Mäßige (2)
Leichte (3)
Kaum (4)
Überhaupt nicht (5)
Waren Sie in den vergangenen 6 Monaten
niedergeschlagen und traurig?
nie  (1)
selten  (2)
gelegentlich  (3)
häufig  (4)
sehr häufig (5)
Haben Sie sich in den vergangenen 3 Monaten
bei der Arbeit bzw. in der Schule aufgrund von
Rückenschmerzen
krank gemeldet? Falls ja, wie viele Tage?
0 (1)
1 (2)
2 (3)
3 (4)
4 oder mehr (5)
Gehen Sie häufiger oder seltener aus als Ihre
Freunde?
gleich viel  (gleich viel )
häufiger  (häufiger )
seltener  (seltener )
viel häufiger  (viel häufiger )
viel seltener (viel seltener)
Halten Sie sich mit dem gegenwärtigen Zustand
Ihres Rückens für attraktiv?
ja, sehr (1)
ja, ziemlich (2)
weder attraktiv, noch unattraktiv (3)
nein, nicht sehr (4)
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nein, überhaupt nicht (5)
Waren Sie in den vergangenen 6 Monaten
glücklich?
zu keinem Zeitpunkt  (1)
für kurze Zeit  (2)
einige Zeit  (3)
die meiste Zeit  (4)
die ganze Zeit (5)
Sind Sie mit den Ergebnissen Ihrer
Rückenbehandlung zufrieden?
Sehr zufrieden (1)
Zufrieden (2)
Weder zufrieden noch unzufrieden (3)
Unzufrieden (4)
Sehr unzufrieden (5)
Würden Sie sich noch einmal der selben
Behandlung unterziehen, wenn Sie an den
selben Beschwerden litten?
ja, bestimmt  (1)
wahrscheinlich (2)
weiss nicht/keine Behandlung (3)
wahrscheinlich nicht (4)
bestimmt nicht (5)
Kommentar
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Deutsche Wirbelsäulen Gesellschaft DWG-Register,
http://www.dwg.org
All rights reserved. Please visit https://medical-data-
models.org/forms/15526
SRS-30 Patientenfragebogen
Skoliose
Demographische Daten
Patient Nachname
Patient Vorname
Geschlecht*
Straße
Patienten-Nr:*
Land
Postleitzahl
Wohnort
Sozialversicherungsnummer (AHV)
Geburtsjahr*
Geburtstag (Monat und Tag)
Patientenbefragung
Datum
Untersuchungsintervall
vor Eingriff (1)
5 Jahre (10)
6 Jahre (11)
7 Jahre (12)
8 Jahre (13)
9 Jahre (14)
10 Jahre (15)
11 Jahre (16)
12 Jahre (17)
13 Jahre (18)
14 Jahre (19)
6Wochen (2)
15 Jahre (20)
>15 Jahren (21)
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anderes Intervall (bitte angeben) (22)
bei Entlassung (23)
3 Monaten (3)
6 Monaten (4)
9 Monaten (5)
1 Jahr (6)
2 Jahre (7)
3 Jahre (8)
4 Jahre (9)
Anderes Untersuchungsintervall
Mit welcher der folgenden Antworten lassen sich
die Schmerzen, die Sie in den vergangenen 6
Monaten
erlitten haben, am besten beschreiben?
keine  (1)
leichte  (2)
mässige  (3)
mässige bis starke  (4)
starke (5)
Mit welcher der folgenden Antworten lassen sich
die Schmerzen, die Sie im vergangenen Monat
erlitten haben, am besten beschreiben?
keine  (1)
leichte  (2)
mässige  (3)
mässige bis starke  (4)
starke (5)
Waren Sie in den vergangenen 6 Monaten sehr
nervös?
zu keinem Zeitpunkt  (1)
für kurze Zeit  (2)
einige Zeit  (3)
die meiste Zeit  (4)
die ganze Zeit (5)
Wie würden Sie sich dabei fühlen, wenn Sie Ihr
restliches Leben mit Ihrer momentanen
Rückenform verbringen müssten?
sehr glücklich (1)
ziemlich glücklich (2)
weder glücklich noch unglücklich (3)
ziemlich unglücklich  (4)
sehr unglücklich (5)
Auf welcher Ebene bewegen sich Ihre Aktivitäten
gegenwärtig?
bettlägrig/Rollstuhl (1)
im Wesentlichen keine Aktivitäten (2)
leichte Arbeit, wie z.B. Hausarbeit (3)
mässige körperliche Arbeit und mässige
sportliche Betätigung, wie z.B. Wandern
u. Radfahren (4)
sämtliche Aktivitäten ohne
Einschränkung (5)
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Wie sehen Sie mit Kleidung aus?
sehr gut  (1)
gut  (2)
einigermassen gut  (3)
schlecht  (4)
sehr schlecht (5)
Wie häufig haben Sie sich in den vergangenen 6
Monaten so niedergeschalgen gefühlt, dass
nichts Sie
aufheitern konnte?
sehr häufig  (1)
häufig  (2)
gelegentlich  (3)
selten  (4)
nie (5)
Haben Sie Rückenschmerzen in Ruhe?
sehr häufig  (1)
häufig  (2)
gelegentlich  (3)
selten  (4)
nie (5)
Auf welcher Ebene bewegen sich gegenwärtig
Ihre beruflichen/schulischen Aktivitäten?
100% normal  (1)
75% normal  (2)
50% normal  (3)
25% normal  (4)
0% normal (5)
Mit welcher der folgenden Antworten lässt sich
das Aussehen Ihres Rumpfes - definiert als
menschlicher Körper
ohne Kopf und Glieder - beschreiben?
sehr gut  (1)
gut  (2)
einigermassen gut  (3)
schlecht  (4)
sehr schlecht (5)
Was für Medikamente nehmen Sie aufgrund Ihrer
Beschwerden ein?
keine (1)
Nichtbetäubungsmittel wöchentlich oder
weniger (z. B. Paracetamol, Ibuprofen)
(2)
Nichtbetäubungsmittel täglich (3)
Betäubungsmittel wöchentlich oder
weniger (z.B. Oxycodon,Hydrocon,
Codein, Propoxyphen) (4)
Betäubungsmittel täglich (5)
Andere (bitte angeben) (6)
Welche anderen Medikamente nehmen Sie
aufgrund Ihrer Beschwerden ein?
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Wie häufig nehmen Sie die anderen
Medikamente aufgrund Ihrer Beschwerden ein?
Täglich (1)
Wöchentlich oder weniger (2)
Schränkt Ihr Rücken Ihre Fähigkeit ein, zu Hause
etwas zu tun?
nie  (1)
selten  (2)
gelegentlich  (3)
häufig  (4)
sehr häufig (5)
Waren Sie in den vergangenen 6 Monaten ruhig
und gelassen?
zu keinem Zeitpunkt  (1)
für kurze Zeit  (2)
einige Zeit  (3)
die meiste Zeit  (4)
die ganze Zeit (5)
Sind Sie der Meinung, dass sich Ihre
Rückenerkrankung auf Ihre persönlichen
Beziehungen auswirkt?
überhaupt nicht  (1)
kaum  (2)
schwach  (3)
mässig  (4)
stark (5)
Haben Sie und/oder Ihre Familie wegen Ihres
Rückens finanizelle Schwierigkeiten?
Starke (1)
Mäßige (2)
Leichte (3)
Kaum (4)
Überhaupt nicht (5)
Waren Sie in den vergangenen 6 Monaten
niedergeschlagen und traurig?
nie  (1)
selten  (2)
gelegentlich  (3)
häufig  (4)
sehr häufig (5)
Haben Sie sich in den vergangenen 3 Monaten
bei der Arbeit bzw. in der Schule aufgrund von
Rückenschmerzen
krank gemeldet? Falls ja, wie viele Tage?
0 (1)
1 (2)
2 (3)
3 (4)
4 oder mehr (5)
Gehen Sie häufiger oder seltener aus als Ihre
Freunde?
gleich viel  (gleich viel )
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häufiger  (häufiger )
seltener  (seltener )
viel häufiger  (viel häufiger )
viel seltener (viel seltener)
Halten Sie sich mit dem gegenwärtigen Zustand
Ihres Rückens für attraktiv?
ja, sehr (1)
ja, ziemlich (2)
weder attraktiv, noch unattraktiv (3)
nein, nicht sehr (4)
nein, überhaupt nicht (5)
Waren Sie in den vergangenen 6 Monaten
glücklich?
zu keinem Zeitpunkt  (1)
für kurze Zeit  (2)
einige Zeit  (3)
die meiste Zeit  (4)
die ganze Zeit (5)
Sind Sie mit den Ergebnissen Ihrer
Rückenbehandlung zufrieden?
Sehr zufrieden (1)
Zufrieden (2)
Weder zufrieden noch unzufrieden (3)
Unzufrieden (4)
Sehr unzufrieden (5)
Würden Sie sich noch einmal der selben
Behandlung unterziehen, wenn Sie an den
selben Beschwerden litten?
ja, bestimmt  (1)
wahrscheinlich (2)
weiss nicht/keine Behandlung (3)
wahrscheinlich nicht (4)
bestimmt nicht (5)
Wie würden Sie Ihr Selbstbild auf einer Skala von
1 bis 9 bewerten, auf der 1 der schlechteste und
9 der beste Wert ist?
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
7 (7)
8 (8)
9 (9)
Wie finden Sie Ihr Aussehen jetzt im Vergleich zu
vor der Behandlung?
viel besser (1)
besser (2)
gleich (3)
schlechter  (4)
viel schlechter (5)
Haben sich durch die Rückenbehandlung Ihre
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Leistungsfähigkeit und Ihre täglichen Aktivitäten
verändert?
gesteigert (1)
nicht verändert (2)
vermindert (3)
Hat sich durch die Rückenbehandlung Ihre
Fähigkeit verändert,
Sport/Hobbys zu genießen?
gesteigert (1)
nicht verändert (2)
vermindert (3)
Wie haben sich Ihre Rückenschmerzen durch die
Rückenbehandlung verändert?
gesteigert (1)
nicht verändert (2)
vermindert (3)
Hat die Behandlung Ihr Selbstvertrauen
hinsichtlich
persönlicher Beziehungen mit anderen
Menschen verändert?
gesteigert (1)
nicht verändert (2)
vermindert (3)
Hat die Behandlung die Art verändert, wie andere
Menschen Sie sehen?
viel besser (1)
besser (2)
gleich (3)
schlechter  (4)
viel schlechter (5)
Hat die Behandlung Ihr Selbstbild verändert?
verbessert (1)
nicht verändert (2)
verschlechtert (3)
Bitte zeichnen Sie auf den Körperzeichnungen
ein, wo Sie Schmerzen haben. Benutzen Sie
"Kribbeln = 0 ; stechender Schmerz = / ;
brennender Schmerz = X ; Tiefenschmerz = Z "
um die Qualität der Schmerzen zu beschreiben.
Kommentar
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Screening: Vital Signs Multiple Sclerosis
ALAIN01 NCT02419378
Alemtuzumab in Autoimmune Inflammatory
Neurodegeneration: Mechanisms of Action and
Neuroprotective Potential (ALAIN01)
https://clinicaltrials.gov/ct2/show/NCT02419378
Principal Investigator Prof. Dr. Dr. Sven Meuth, University
Hospital Muenster, Germany
Please document clinically significant findings as Adverse
Events. Clinical Significance is
defined as any variation in physical findings that has
medical relevance and may result in an
alteration in medical care.
Safety Blood and Urine Examinations: Please document
the results for Serum Creatinine, Platelets and TSH on
CRF-Pages "Safety
Laboratory Assessments".
Part: Screening
All rights reserved. Please visit https://medical-data-
models.org/forms/15527
Screening: Vital Signs Multiple
Sclerosis ALAIN01 NCT02419378
Vital Signs
Patient ID (derived)
Vital Signs and Physical Examination: Date
Heart rate
>= 0
bpm
Respiratory Rate
/min
Height
>= 0
cm
Systolic blood pressure
>= 0
mmHg
Diastolic blood pressure
>= 0
mmHg
Temperature
°C
Body weight
>= 0
kg
Physical Examination: General Appearance
no (0)
yes (1)
1 / 3
Physical Examination: General Appearance, Text
Physical Examination: Skin
no (0)
yes (1)
Physical Examination: Skin, Text
Physical Examination: HEENT
no (0)
yes (1)
Physical Examination: HEENT, Text
Physical Examination: Lymph Nodes
no (0)
yes (1)
Physical Examination: Lymph Nodes, Text
Physical Examination: Heart
no (0)
yes (1)
Physical Examination: Heart, Text
Physical Examination: Lungs
no (0)
yes (1)
Physical Examination: Lungs, Text
Physical Examination: Abdomen
no (0)
yes (1)
Physical Examination: Abdomen, Text
Physical Examination: Extremeties/Joints
no (0)
yes (1)
Physical Examination: Extremeties/Joints, Text
Physical Examination: Mental Status
no (0)
yes (1)
Physical Examination: Mental Status, Text
Initial Blood Pregnancy Test
Test not done (0)
2 / 3
Screening: Vital Signs Multiple Sclerosis ALAIN01 NCT02419378
Test done (1)
Initial Blood Pregnancy Test: Date
Initial Blood Pregnancy Test: Result
negative (0)
positive (1)
Initial Blood Pregnancy Test: Reason
no childbearing potential (0)
other (9)
Initial Blood Pregnancy Test: Reason, Text
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Screening: Vital Signs Multiple Sclerosis ALAIN01 NCT02419378
Month 3: Vital Signs Multiple Sclerosis
ALAIN01 NCT02419378
Alemtuzumab in Autoimmune Inflammatory
Neurodegeneration: Mechanisms of Action and
Neuroprotective Potential (ALAIN01)
https://clinicaltrials.gov/ct2/show/NCT02419378
Principal Investigator Prof. Dr. Dr. Sven Meuth, University
Hospital Muenster, Germany
Please document clinically significant findings as Adverse
Events. Clinical Significance is
defined as any variation in physical findings that has
medical relevance and may result in an
alteration in medical care.
Safety Blood and Urine Examinations: Please document
the results for Serum Creatinine, Platelets and TSH on
CRF-Pages "Safety
Laboratory Assessments".
Part: Month 3
All rights reserved. Please visit https://medical-data-
models.org/forms/15528
Month 3: Vital Signs Multiple
Sclerosis ALAIN01 NCT02419378
Vital Signs
Patient ID (derived)
Vital Signs and Physical Examination: Date
Heart rate
>= 0
bpm
Respiratory Rate
/min
Height
>= 0
cm
Systolic blood pressure
>= 0
mmHg
Diastolic blood pressure
>= 0
mmHg
Temperature
°C
Body weight
>= 0
kg
Physical Examination: General Appearance
no (0)
yes (1)
Physical Examination: General Appearance, Text
1 / 3
Physical Examination: Skin
no (0)
yes (1)
Physical Examination: Skin, Text
Physical Examination: HEENT
no (0)
yes (1)
Physical Examination: HEENT, Text
Physical Examination: Lymph Nodes
no (0)
yes (1)
Physical Examination: Lymph Nodes, Text
Physical Examination: Heart
no (0)
yes (1)
Physical Examination: Heart, Text
Physical Examination: Lungs
no (0)
yes (1)
Physical Examination: Lungs, Text
Physical Examination: Abdomen
no (0)
yes (1)
Physical Examination: Abdomen, Text
Physical Examination: Extremeties/Joints
no (0)
yes (1)
Physical Examination: Extremeties/Joints, Text
Physical Examination: Mental Status
no (0)
yes (1)
Physical Examination: Mental Status, Text
Vital Signs and Physical Examination: ND
Not performed (0)
Name of the Investigator
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Month 3: Vital Signs Multiple Sclerosis ALAIN01 NCT02419378
Physical Examination: Date of Signature
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Month 3: Vital Signs Multiple Sclerosis ALAIN01 NCT02419378
Month 6: Vital Signs Multiple Sclerosis
ALAIN01 NCT02419378
Alemtuzumab in Autoimmune Inflammatory
Neurodegeneration: Mechanisms of Action and
Neuroprotective Potential (ALAIN01)
https://clinicaltrials.gov/ct2/show/NCT02419378
Principal Investigator Prof. Dr. Dr. Sven Meuth, University
Hospital Muenster, Germany
Please document clinically significant findings as Adverse
Events. Clinical Significance is
defined as any variation in physical findings that has
medical relevance and may result in an
alteration in medical care.
Safety Blood and Urine Examinations: Please document
the results for Serum Creatinine, Platelets and TSH on
CRF-Pages "Safety
Laboratory Assessments".
Part: Month 6
All rights reserved. Please visit https://medical-data-
models.org/forms/15529
Month 6: Vital Signs Multiple
Sclerosis ALAIN01 NCT02419378
Vital Signs
Patient ID (derived)
Vital Signs and Physical Examination: Date
Heart rate
>= 0
bpm
Respiratory Rate
/min
Height
>= 0
cm
Systolic blood pressure
>= 0
mmHg
Diastolic blood pressure
>= 0
mmHg
Temperature
°C
Body weight
>= 0
kg
Physical Examination: General Appearance
no (0)
yes (1)
1 / 3
Physical Examination: General Appearance, Text
Physical Examination: Skin
no (0)
yes (1)
Physical Examination: Skin, Text
Physical Examination: HEENT
no (0)
yes (1)
Physical Examination: HEENT, Text
Physical Examination: Lymph Nodes
no (0)
yes (1)
Physical Examination: Lymph Nodes, Text
Physical Examination: Heart
no (0)
yes (1)
Physical Examination: Heart, Text
Physical Examination: Heart, Text
Physical Examination: Lungs
no (0)
yes (1)
Physical Examination: Lungs, Text
Physical Examination: Abdomen
no (0)
yes (1)
Physical Examination: Abdomen, Text
Physical Examination: Extremeties/Joints
no (0)
yes (1)
Physical Examination: Extremeties/Joints, Text
Physical Examination: Mental Status
no (0)
yes (1)
Physical Examination: Mental Status, Text
2 / 3
Month 6: Vital Signs Multiple Sclerosis ALAIN01 NCT02419378
Blood Sampling for Eff. Ass.: add. Inf. Consent
no (0)
yes (1)
Blood Sampling for Eff. Ass.: Date
Vital Signs and Physical Examination: ND
Not performed (0)
Physical Examination: Date of Signature
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Month 6: Vital Signs Multiple Sclerosis ALAIN01 NCT02419378
Month 9: Vital Signs Multiple Sclerosis
ALAIN01 NCT02419378
Alemtuzumab in Autoimmune Inflammatory
Neurodegeneration: Mechanisms of Action and
Neuroprotective Potential (ALAIN01)
https://clinicaltrials.gov/ct2/show/NCT02419378
Principal Investigator Prof. Dr. Dr. Sven Meuth, University
Hospital Muenster, Germany
Please document clinically significant findings as Adverse
Events. Clinical Significance is
defined as any variation in physical findings that has
medical relevance and may result in an
alteration in medical care.
Safety Blood and Urine Examinations: Please document
the results for Serum Creatinine, Platelets and TSH on
CRF-Pages "Safety
Laboratory Assessments".
Part: Month 9
All rights reserved. Please visit https://medical-data-
models.org/forms/15530
Month 9: Vital Signs Multiple
Sclerosis ALAIN01 NCT02419378
Vital Signs
Patient ID (derived)
Vital Signs and Physical Examination: Date
Heart rate
>= 0
bpm
Respiratory Rate
/min
Height
>= 0
cm
Systolic blood pressure
>= 0
mmHg
Diastolic blood pressure
>= 0
mmHg
Temperature
°C
Body weight
>= 0
kg
Physical Examination: General Appearance
no (0)
yes (1)
1 / 3
Physical Examination: General Appearance, Text
Physical Examination: Skin
no (0)
yes (1)
Physical Examination: Skin, Text
Physical Examination: HEENT
no (0)
yes (1)
Physical Examination: HEENT, Text
Physical Examination: Lymph Nodes
no (0)
yes (1)
Physical Examination: Lymph Nodes, Text
Physical Examination: Heart
no (0)
yes (1)
Physical Examination: Heart, Text
Physical Examination: Lungs
no (0)
yes (1)
Physical Examination: Lungs, Text
Physical Examination: Abdomen
no (0)
yes (1)
Physical Examination: Abdomen, Text
Physical Examination: Extremeties/Joints
no (0)
yes (1)
Physical Examination: Extremeties/Joints, Text
Physical Examination: Mental Status
no (0)
yes (1)
Physical Examination: Mental Status, Text
Vital Signs and Physical Examination: ND
Not performed (0)
2 / 3
Month 9: Vital Signs Multiple Sclerosis ALAIN01 NCT02419378
Physical Examination: Date of Signature
Name of Investigator
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Month 9: Vital Signs Multiple Sclerosis ALAIN01 NCT02419378
Month 12: Vital Signs Multiple Sclerosis
ALAIN01 NCT02419378
Alemtuzumab in Autoimmune Inflammatory
Neurodegeneration: Mechanisms of Action and
Neuroprotective Potential (ALAIN01)
https://clinicaltrials.gov/ct2/show/NCT02419378
Principal Investigator Prof. Dr. Dr. Sven Meuth, University
Hospital Muenster, Germany
Please document clinically significant findings as Adverse
Events. Clinical Significance is
defined as any variation in physical findings that has
medical relevance and may result in an
alteration in medical care.
Safety Blood and Urine Examinations: Please document
the results for Serum Creatinine, Platelets and TSH on
CRF-Pages "Safety
Laboratory Assessments".
Part: Month 12
All rights reserved. Please visit https://medical-data-
models.org/forms/15531
Month 12: Vital Signs Multiple
Sclerosis ALAIN01 NCT02419378
Vital Signs
Patient ID (derived)
Vital Signs and Physical Examination: Date
Heart rate
>= 0
bpm
Respiratory Rate
/min
Height
>= 0
cm
Systolic blood pressure
>= 0
mmHg
Diastolic blood pressure
>= 0
mmHg
Temperature
°C
Body weight
>= 0
kg
Physical Examination: General Appearance
no (0)
yes (1)
1 / 3
Physical Examination: General Appearance, Text
Physical Examination: Skin
no (0)
yes (1)
Physical Examination: Skin, Text
Physical Examination: HEENT
no (0)
yes (1)
Physical Examination: HEENT, Text
Physical Examination: Lymph Nodes
no (0)
yes (1)
Physical Examination: Lymph Nodes, Text
Physical Examination: Heart
no (0)
yes (1)
Physical Examination: Heart, Text
Physical Examination: Lungs
no (0)
yes (1)
Physical Examination: Lungs, Text
Physical Examination: Abdomen
no (0)
yes (1)
Physical Examination: Abdomen, Text
Physical Examination: Extremeties/Joints
no (0)
yes (1)
Physical Examination: Extremeties/Joints, Text
Physical Examination: Mental Status
no (0)
yes (1)
Physical Examination: Mental Status, Text
Blood Sampling for Eff. Ass.: Date
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Month 12: Vital Signs Multiple Sclerosis ALAIN01 NCT02419378
Vital Signs and Physical Examination: ND
Not performed (0)
Physical Examination: Date of Signature
Name of Investigator
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Month 12: Vital Signs Multiple Sclerosis ALAIN01 NCT02419378
Month 15: Vital Signs Multiple Sclerosis
ALAIN01 NCT02419378
Alemtuzumab in Autoimmune Inflammatory
Neurodegeneration: Mechanisms of Action and
Neuroprotective Potential (ALAIN01)
https://clinicaltrials.gov/ct2/show/NCT02419378
Principal Investigator Prof. Dr. Dr. Sven Meuth, University
Hospital Muenster, Germany
Please document clinically significant findings as Adverse
Events. Clinical Significance is
defined as any variation in physical findings that has
medical relevance and may result in an
alteration in medical care.
Safety Blood and Urine Examinations: Please document
the results for Serum Creatinine, Platelets and TSH on
CRF-Pages "Safety
Laboratory Assessments".
Part: Month 15
All rights reserved. Please visit https://medical-data-
models.org/forms/15532
Month 15: Vital Signs Multiple
Sclerosis ALAIN01 NCT02419378
Vital Signs
Patient ID (derived)
Vital Signs and Physical Examination: Date
Heart rate
>= 0
bpm
Respiratory Rate
/min
Height
>= 0
cm
Systolic blood pressure
>= 0
mmHg
Diastolic blood pressure
>= 0
mmHg
Temperature
°C
Body weight
>= 0
kg
Physical Examination: General Appearance
no (0)
yes (1)
1 / 3
Physical Examination: General Appearance, Text
Physical Examination: Skin
no (0)
yes (1)
Physical Examination: Skin, Text
Physical Examination: HEENT
no (0)
yes (1)
Physical Examination: HEENT, Text
Physical Examination: Lymph Nodes
no (0)
yes (1)
Physical Examination: Lymph Nodes, Text
Physical Examination: Heart
no (0)
yes (1)
Physical Examination: Heart, Text
Physical Examination: Lungs
no (0)
yes (1)
Physical Examination: Lungs, Text
Physical Examination: Abdomen
no (0)
yes (1)
Physical Examination: Abdomen, Text
Physical Examination: Extremeties/Joints
no (0)
yes (1)
Physical Examination: Extremeties/Joints, Text
Physical Examination: Mental Status
no (0)
yes (1)
Physical Examination: Mental Status, Text
Vital Signs and Physical Examination: ND
Not performed (0)
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Month 15: Vital Signs Multiple Sclerosis ALAIN01 NCT02419378
Physical Examination: Date of Signature
Name of Investigator
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Month 15: Vital Signs Multiple Sclerosis ALAIN01 NCT02419378
Month 18: Vital Signs Multiple Sclerosis
ALAIN01 NCT02419378
Alemtuzumab in Autoimmune Inflammatory
Neurodegeneration: Mechanisms of Action and
Neuroprotective Potential (ALAIN01)
https://clinicaltrials.gov/ct2/show/NCT02419378
Principal Investigator Prof. Dr. Dr. Sven Meuth, University
Hospital Muenster, Germany
Please document clinically significant findings as Adverse
Events. Clinical Significance is
defined as any variation in physical findings that has
medical relevance and may result in an
alteration in medical care.
Safety Blood and Urine Examinations: Please document
the results for Serum Creatinine, Platelets and TSH on
CRF-Pages "Safety
Laboratory Assessments".
Part: Month 18
All rights reserved. Please visit https://medical-data-
models.org/forms/15533
Month 18: Vital Signs Multiple
Sclerosis ALAIN01 NCT02419378
Vital Signs
Patient ID (derived)
Vital Signs and Physical Examination: Date
Heart rate
>= 0
bpm
Respiratory Rate
/min
Height
>= 0
cm
Systolic blood pressure
>= 0
mmHg
Diastolic blood pressure
>= 0
mmHg
Temperature
°C
Body weight
>= 0
kg
Physical Examination: General Appearance
no (0)
yes (1)
1 / 3
Physical Examination: General Appearance, Text
Physical Examination: Skin
no (0)
yes (1)
Physical Examination: Skin, Text
Physical Examination: HEENT
no (0)
yes (1)
Physical Examination: HEENT, Text
Physical Examination: Lymph Nodes
no (0)
yes (1)
Physical Examination: Lymph Nodes, Text
Physical Examination: Heart
no (0)
yes (1)
Physical Examination: Heart, Text
Physical Examination: Lungs
no (0)
yes (1)
Physical Examination: Lungs, Text
Physical Examination: Abdomen
no (0)
yes (1)
Physical Examination: Abdomen, Text
Physical Examination: Extremeties/Joints
no (0)
yes (1)
Physical Examination: Extremeties/Joints, Text
Physical Examination: Mental Status
no (0)
yes (1)
Physical Examination: Mental Status, Text
Blood Sampling for Eff. Ass.: Date
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Month 18: Vital Signs Multiple Sclerosis ALAIN01 NCT02419378
Vital Signs and Physical Examination: ND
Not performed (0)
Physical Examination: Date of Signature
Name of Investigator
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Month 18: Vital Signs Multiple Sclerosis ALAIN01 NCT02419378
Month 21: Vital Signs Multiple Sclerosis
ALAIN01 NCT02419378
Alemtuzumab in Autoimmune Inflammatory
Neurodegeneration: Mechanisms of Action and
Neuroprotective Potential (ALAIN01)
https://clinicaltrials.gov/ct2/show/NCT02419378
Principal Investigator Prof. Dr. Dr. Sven Meuth, University
Hospital Muenster, Germany
Please document clinically significant findings as Adverse
Events. Clinical Significance is
defined as any variation in physical findings that has
medical relevance and may result in an
alteration in medical care.
Safety Blood and Urine Examinations: Please document
the results for Serum Creatinine, Platelets and TSH on
CRF-Pages "Safety
Laboratory Assessments".
Part: Month 21
All rights reserved. Please visit https://medical-data-
models.org/forms/15534
Month 21: Vital Signs Multiple
Sclerosis ALAIN01 NCT02419378
Vital Signs
Patient ID (derived)
Vital Signs and Physical Examination: Date
Heart rate
>= 0
bpm
Respiratory Rate
/min
Height
>= 0
cm
Systolic blood pressure
>= 0
mmHg
Diastolic blood pressure
>= 0
mmHg
Temperature
°C
Body weight
>= 0
kg
Physical Examination: General Appearance
no (0)
yes (1)
1 / 3
Physical Examination: General Appearance, Text
Physical Examination: Skin
no (0)
yes (1)
Physical Examination: Skin, Text
Physical Examination: HEENT
no (0)
yes (1)
Physical Examination: HEENT, Text
Physical Examination: Lymph Nodes
no (0)
yes (1)
Physical Examination: Lymph Nodes, Text
Physical Examination: Heart
no (0)
yes (1)
Physical Examination: Heart, Text
Physical Examination: Lungs
no (0)
yes (1)
Physical Examination: Lungs, Text
Physical Examination: Abdomen
no (0)
yes (1)
Physical Examination: Abdomen, Text
Physical Examination: Extremeties/Joints
no (0)
yes (1)
Physical Examination: Extremeties/Joints, Text
Physical Examination: Mental Status
no (0)
yes (1)
Physical Examination: Mental Status, Text
Vital Signs and Physical Examination: ND
Not performed (0)
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Month 21: Vital Signs Multiple Sclerosis ALAIN01 NCT02419378
Physical Examination: Date of Signature
Name of Investigator
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Month 21: Vital Signs Multiple Sclerosis ALAIN01 NCT02419378
Month 24: Vital Signs Multiple Sclerosis
ALAIN01 NCT02419378
Alemtuzumab in Autoimmune Inflammatory
Neurodegeneration: Mechanisms of Action and
Neuroprotective Potential (ALAIN01)
https://clinicaltrials.gov/ct2/show/NCT02419378
Principal Investigator Prof. Dr. Dr. Sven Meuth, University
Hospital Muenster, Germany
Please document clinically significant findings as Adverse
Events. Clinical Significance is
defined as any variation in physical findings that has
medical relevance and may result in an
alteration in medical care.
Safety Blood and Urine Examinations: Please document
the results for Serum Creatinine, Platelets and TSH on
CRF-Pages "Safety
Laboratory Assessments".
Part: Month 24
All rights reserved. Please visit https://medical-data-
models.org/forms/15535
Month 24: Vital Signs Multiple
Sclerosis ALAIN01 NCT02419378
Vital Signs
Patient ID (derived)
Vital Signs and Physical Examination: Date
Heart rate
>= 0
bpm
Respiratory Rate
/min
Height
>= 0
cm
Systolic blood pressure
>= 0
mmHg
Diastolic blood pressure
>= 0
mmHg
Temperature
°C
Body weight
>= 0
kg
Physical Examination: General Appearance
no (0)
yes (1)
1 / 3
Physical Examination: General Appearance, Text
Physical Examination: Skin
no (0)
yes (1)
Physical Examination: Skin, Text
Physical Examination: HEENT
no (0)
yes (1)
Physical Examination: HEENT, Text
Physical Examination: Lymph Nodes
no (0)
yes (1)
Physical Examination: Lymph Nodes, Text
Physical Examination: Heart
no (0)
yes (1)
Physical Examination: Heart, Text
Physical Examination: Lungs
no (0)
yes (1)
Physical Examination: Lungs, Text
Physical Examination: Abdomen
no (0)
yes (1)
Physical Examination: Abdomen, Text
Physical Examination: Extremeties/Joints
no (0)
yes (1)
Physical Examination: Extremeties/Joints, Text
Physical Examination: Mental Status
no (0)
yes (1)
Physical Examination: Mental Status, Text
Blood Sampling for Eff. Ass.: add. Inf. Consent
no (0)
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Month 24: Vital Signs Multiple Sclerosis ALAIN01 NCT02419378
yes (1)
Blood Sampling for Eff. Ass.: Date
Vital Signs and Physical Examination: ND
Not performed (0)
Physical Examination: Date of Signature
Name of Investigator
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Month 24: Vital Signs Multiple Sclerosis ALAIN01 NCT02419378
Month 27: Vital Signs Multiple Sclerosis
ALAIN01 NCT02419378
Alemtuzumab in Autoimmune Inflammatory
Neurodegeneration: Mechanisms of Action and
Neuroprotective Potential (ALAIN01)
https://clinicaltrials.gov/ct2/show/NCT02419378
Principal Investigator Prof. Dr. Dr. Sven Meuth, University
Hospital Muenster, Germany
Please document clinically significant findings as Adverse
Events. Clinical Significance is
defined as any variation in physical findings that has
medical relevance and may result in an
alteration in medical care.
Safety Blood and Urine Examinations: Please document
the results for Serum Creatinine, Platelets and TSH on
CRF-Pages "Safety
Laboratory Assessments".
Part: Month 27
All rights reserved. Please visit https://medical-data-
models.org/forms/15536
Month 27: Vital Signs Multiple
Sclerosis ALAIN01 NCT02419378
Vital Signs
Patient ID (derived)
Vital Signs and Physical Examination: Date
Heart rate
>= 0
bpm
Respiratory Rate
/min
Height
>= 0
cm
Systolic blood pressure
>= 0
mmHg
Diastolic blood pressure
>= 0
mmHg
Temperature
°C
Body weight
>= 0
kg
Physical Examination: General Appearance
no (0)
yes (1)
1 / 3
Physical Examination: General Appearance, Text
Physical Examination: Skin
no (0)
yes (1)
Physical Examination: Skin, Text
Physical Examination: HEENT
no (0)
yes (1)
Physical Examination: HEENT, Text
Physical Examination: Lymph Nodes
no (0)
yes (1)
Physical Examination: Lymph Nodes, Text
Physical Examination: Heart
no (0)
yes (1)
Physical Examination: Heart, Text
Physical Examination: Lungs
no (0)
yes (1)
Physical Examination: Lungs, Text
Physical Examination: Abdomen
no (0)
yes (1)
Physical Examination: Abdomen, Text
Physical Examination: Extremeties/Joints
no (0)
yes (1)
Physical Examination: Extremeties/Joints, Text
Physical Examination: Mental Status
no (0)
yes (1)
Physical Examination: Mental Status, Text
Vital Signs and Physical Examination: ND
Not performed (0)
2 / 3
Month 27: Vital Signs Multiple Sclerosis ALAIN01 NCT02419378
Physical Examination: Date of Signature
Name of Investigator
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Month 27: Vital Signs Multiple Sclerosis ALAIN01 NCT02419378
Month 30: Vital Signs Multiple Sclerosis
ALAIN01 NCT02419378
Alemtuzumab in Autoimmune Inflammatory
Neurodegeneration: Mechanisms of Action and
Neuroprotective Potential (ALAIN01)
https://clinicaltrials.gov/ct2/show/NCT02419378
Principal Investigator Prof. Dr. Dr. Sven Meuth, University
Hospital Muenster, Germany
Please document clinically significant findings as Adverse
Events. Clinical Significance is
defined as any variation in physical findings that has
medical relevance and may result in an
alteration in medical care.
Safety Blood and Urine Examinations: Please document
the results for Serum Creatinine, Platelets and TSH on
CRF-Pages "Safety
Laboratory Assessments".
Part: Month 30
All rights reserved. Please visit https://medical-data-
models.org/forms/15537
Month 30: Vital Signs Multiple
Sclerosis ALAIN01 NCT02419378
Vital Signs
Patient ID (derived)
Vital Signs and Physical Examination: Date
Heart rate
>= 0
bpm
Respiratory Rate
/min
Height
>= 0
cm
Systolic blood pressure
>= 0
mmHg
Diastolic blood pressure
>= 0
mmHg
Temperature
°C
Body weight
>= 0
kg
Physical Examination: General Appearance
no (0)
yes (1)
1 / 3
Physical Examination: General Appearance, Text
Physical Examination: Skin
no (0)
yes (1)
Physical Examination: Skin, Text
Physical Examination: HEENT
no (0)
yes (1)
Physical Examination: HEENT, Text
Physical Examination: Lymph Nodes
no (0)
yes (1)
Physical Examination: Lymph Nodes, Text
Physical Examination: Heart
no (0)
yes (1)
Physical Examination: Heart, Text
Physical Examination: Lungs
no (0)
yes (1)
Physical Examination: Lungs, Text
Physical Examination: Abdomen
no (0)
yes (1)
Physical Examination: Abdomen, Text
Physical Examination: Extremeties/Joints
no (0)
yes (1)
Physical Examination: Extremeties/Joints, Text
Physical Examination: Mental Status
no (0)
yes (1)
Physical Examination: Mental Status, Text
Vital Signs and Physical Examination: ND
Not performed (0)
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Month 30: Vital Signs Multiple Sclerosis ALAIN01 NCT02419378
Physical Examination: Date of Signature
Name of Investigator
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Month 30: Vital Signs Multiple Sclerosis ALAIN01 NCT02419378
Month 33: Vital Signs Multiple Sclerosis
ALAIN01 NCT02419378
Alemtuzumab in Autoimmune Inflammatory
Neurodegeneration: Mechanisms of Action and
Neuroprotective Potential (ALAIN01)
https://clinicaltrials.gov/ct2/show/NCT02419378
Principal Investigator Prof. Dr. Dr. Sven Meuth, University
Hospital Muenster, Germany
Please document clinically significant findings as Adverse
Events. Clinical Significance is
defined as any variation in physical findings that has
medical relevance and may result in an
alteration in medical care.
Safety Blood and Urine Examinations: Please document
the results for Serum Creatinine, Platelets and TSH on
CRF-Pages "Safety
Laboratory Assessments".
Part: Month 33
All rights reserved. Please visit https://medical-data-
models.org/forms/15538
Month 33: Vital Signs Multiple
Sclerosis ALAIN01 NCT02419378
Vital Signs
Patient ID (derived)
Vital Signs and Physical Examination: Date
Heart rate
>= 0
bpm
Respiratory Rate
/min
Height
>= 0
cm
Systolic blood pressure
>= 0
mmHg
Diastolic blood pressure
>= 0
mmHg
Temperature
°C
Body weight
>= 0
kg
Physical Examination: General Appearance
no (0)
yes (1)
1 / 3
Physical Examination: General Appearance, Text
Physical Examination: Skin
no (0)
yes (1)
Physical Examination: Skin, Text
Physical Examination: HEENT
no (0)
yes (1)
Physical Examination: HEENT, Text
Physical Examination: Lymph Nodes
no (0)
yes (1)
Physical Examination: Lymph Nodes, Text
Physical Examination: Heart
no (0)
yes (1)
Physical Examination: Heart, Text
Physical Examination: Lungs
no (0)
yes (1)
Physical Examination: Lungs, Text
Physical Examination: Abdomen
no (0)
yes (1)
Physical Examination: Abdomen, Text
Physical Examination: Extremeties/Joints
no (0)
yes (1)
Physical Examination: Extremeties/Joints, Text
Physical Examination: Mental Status
no (0)
yes (1)
Physical Examination: Mental Status, Text
Vital Signs and Physical Examination: ND
Not performed (0)
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Month 33: Vital Signs Multiple Sclerosis ALAIN01 NCT02419378
Physical Examination: Date of Signature
Name of Investigator
3 / 3
Month 33: Vital Signs Multiple Sclerosis ALAIN01 NCT02419378
Month 36: Vital Signs Multiple Sclerosis
ALAIN01 NCT02419378
Alemtuzumab in Autoimmune Inflammatory
Neurodegeneration: Mechanisms of Action and
Neuroprotective Potential (ALAIN01)
https://clinicaltrials.gov/ct2/show/NCT02419378
Principal Investigator Prof. Dr. Dr. Sven Meuth, University
Hospital Muenster, Germany
Please document clinically significant findings as Adverse
Events. Clinical Significance is
defined as any variation in physical findings that has
medical relevance and may result in an
alteration in medical care.
Safety Blood and Urine Examinations: Please document
the results for Serum Creatinine, Platelets and TSH on
CRF-Pages "Safety
Laboratory Assessments".
Part: Month 36
All rights reserved. Please visit https://medical-data-
models.org/forms/15540
Month 36: Vital Signs Multiple
Sclerosis ALAIN01 NCT02419378
Vital Signs
Patient ID (derived)
Vital Signs and Physical Examination: Date
Heart rate
>= 0
bpm
Respiratory Rate
/min
Height
>= 0
cm
Systolic blood pressure
>= 0
mmHg
Diastolic blood pressure
>= 0
mmHg
Temperature
°C
Body weight
>= 0
kg
Physical Examination: General Appearance
no (0)
yes (1)
1 / 3
Physical Examination: General Appearance, Text
Physical Examination: Skin
no (0)
yes (1)
Physical Examination: Skin, Text
Physical Examination: HEENT
no (0)
yes (1)
Physical Examination: HEENT, Text
Physical Examination: Lymph Nodes
no (0)
yes (1)
Physical Examination: Lymph Nodes, Text
Physical Examination: Heart
no (0)
yes (1)
Physical Examination: Heart, Text
Physical Examination: Lungs
no (0)
yes (1)
Physical Examination: Lungs, Text
Physical Examination: Abdomen
no (0)
yes (1)
Physical Examination: Abdomen, Text
Physical Examination: Extremeties/Joints
no (0)
yes (1)
Physical Examination: Extremeties/Joints, Text
Physical Examination: Mental Status
no (0)
yes (1)
Physical Examination: Mental Status, Text
Blood Sampling for Eff. Ass.: Date
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Month 36: Vital Signs Multiple Sclerosis ALAIN01 NCT02419378
Vital Signs and Physical Examination: ND
Not performed (0)
Physical Examination: Date of Signature
Name of Investigator
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Month 36: Vital Signs Multiple Sclerosis ALAIN01 NCT02419378
Relapse Evaluation Visit No. 1 Vital Signs
Multiple Sclerosis ALAIN01 NCT02419378
Alemtuzumab in Autoimmune Inflammatory
Neurodegeneration: Mechanisms of Action and
Neuroprotective Potential (ALAIN01)
https://clinicaltrials.gov/ct2/show/NCT02419378
Principal Investigator Prof. Dr. Dr. Sven Meuth, University
Hospital Muenster, Germany
Please document clinically significant findings as Adverse
Events. Clinical Significance is
defined as any variation in physical findings that has
medical relevance and may result in an
alteration in medical care.
Safety Blood and Urine Examinations: Please document
the results for Serum Creatinine, Platelets and TSH on
CRF-Pages "Safety
Laboratory Assessments".
Part: Relapse Evaluation Visit No. 1
All rights reserved. Please visit https://medical-data-
models.org/forms/15542
Relapse Evaluation Visit No. 1 Vital
Signs Multiple Sclerosis ALAIN01
NCT02419378
Vital Signs
Patient ID (derived)
Vital Signs and Physical Examination: Date
Heart rate
>= 0
bpm
Respiratory Rate
/min
Height
>= 0
cm
Systolic blood pressure
>= 0
mmHg
Diastolic blood pressure
>= 0
mmHg
Temperature
°C
Body weight
>= 0
kg
Physical Examination: General Appearance
no (0)
yes (1)
1 / 2
Physical Examination: General Appearance, Text
Physical Examination: Skin
no (0)
yes (1)
Physical Examination: Skin, Text
Physical Examination: HEENT
no (0)
yes (1)
Physical Examination: HEENT, Text
Physical Examination: Lymph Nodes
no (0)
yes (1)
Physical Examination: Lymph Nodes, Text
Physical Examination: Heart
no (0)
yes (1)
Physical Examination: Heart, Text
Physical Examination: Lungs
no (0)
yes (1)
Physical Examination: Lungs, Text
Physical Examination: Abdomen
no (0)
yes (1)
Physical Examination: Abdomen, Text
Physical Examination: Extremeties/Joints
no (0)
yes (1)
Physical Examination: Extremeties/Joints, Text
Physical Examination: Mental Status
no (0)
yes (1)
Physical Examination: Mental Status, Text
Vital Signs and Physical Examination: ND
Not performed (0)
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Relapse Evaluation Visit No. 1 Vital Signs Multiple Sclerosis ALAIN01
NCT02419378
Relapse Evaluation Visit No. 2 Vital Signs
Multiple Sclerosis ALAIN01 NCT02419378
Alemtuzumab in Autoimmune Inflammatory
Neurodegeneration: Mechanisms of Action and
Neuroprotective Potential (ALAIN01)
https://clinicaltrials.gov/ct2/show/NCT02419378
Principal Investigator Prof. Dr. Dr. Sven Meuth, University
Hospital Muenster, Germany
Please document clinically significant findings as Adverse
Events. Clinical Significance is
defined as any variation in physical findings that has
medical relevance and may result in an
alteration in medical care.
Safety Blood and Urine Examinations: Please document
the results for Serum Creatinine, Platelets and TSH on
CRF-Pages "Safety
Laboratory Assessments".
Part: Relapse Evaluation Visit No. 2
All rights reserved. Please visit https://medical-data-
models.org/forms/15543
Relapse Evaluation Visit No. 2 Vital
Signs Multiple Sclerosis ALAIN01
NCT02419378
Vital Signs
Patient ID (derived)
Vital Signs and Physical Examination: Date
Heart rate
>= 0
bpm
Respiratory Rate
/min
Height
>= 0
cm
Systolic blood pressure
>= 0
mmHg
Diastolic blood pressure
>= 0
mmHg
Temperature
°C
Body weight
>= 0
kg
Physical Examination: General Appearance
no (0)
yes (1)
1 / 2
Physical Examination: General Appearance, Text
Physical Examination: Skin
no (0)
yes (1)
Physical Examination: Skin, Text
Physical Examination: HEENT
no (0)
yes (1)
Physical Examination: HEENT, Text
Physical Examination: Lymph Nodes
no (0)
yes (1)
Physical Examination: Lymph Nodes, Text
Physical Examination: Heart
no (0)
yes (1)
Physical Examination: Heart, Text
Physical Examination: Lungs
no (0)
yes (1)
Physical Examination: Lungs, Text
Physical Examination: Abdomen
no (0)
yes (1)
Physical Examination: Abdomen, Text
Physical Examination: Extremeties/Joints
no (0)
yes (1)
Physical Examination: Extremeties/Joints, Text
Physical Examination: Mental Status
no (0)
yes (1)
Physical Examination: Mental Status, Text
Vital Signs and Physical Examination: ND
Not performed (0)
2 / 2
Relapse Evaluation Visit No. 2 Vital Signs Multiple Sclerosis ALAIN01
NCT02419378
Relapse Evaluation Visit No. 3 Vital Signs
Multiple Sclerosis ALAIN01 NCT02419378
Alemtuzumab in Autoimmune Inflammatory
Neurodegeneration: Mechanisms of Action and
Neuroprotective Potential (ALAIN01)
https://clinicaltrials.gov/ct2/show/NCT02419378
Principal Investigator Prof. Dr. Dr. Sven Meuth, University
Hospital Muenster, Germany
Please document clinically significant findings as Adverse
Events. Clinical Significance is
defined as any variation in physical findings that has
medical relevance and may result in an
alteration in medical care.
Safety Blood and Urine Examinations: Please document
the results for Serum Creatinine, Platelets and TSH on
CRF-Pages "Safety
Laboratory Assessments".
Part: Relapse Evaluation Visit No. 3
All rights reserved. Please visit https://medical-data-
models.org/forms/15544
Relapse Evaluation Visit No. 3 Vital
Signs Multiple Sclerosis ALAIN01
NCT02419378
Vital Signs
Patient ID (derived)
Vital Signs and Physical Examination: Date
Heart rate
>= 0
bpm
Respiratory Rate
/min
Height
>= 0
cm
Systolic blood pressure
>= 0
mmHg
Diastolic blood pressure
>= 0
mmHg
Temperature
°C
Body weight
>= 0
kg
Physical Examination: General Appearance
no (0)
yes (1)
1 / 2
Physical Examination: General Appearance, Text
Physical Examination: Skin
no (0)
yes (1)
Physical Examination: Skin, Text
Physical Examination: HEENT
no (0)
yes (1)
Physical Examination: HEENT, Text
Physical Examination: Lymph Nodes
no (0)
yes (1)
Physical Examination: Lymph Nodes, Text
Physical Examination: Heart
no (0)
yes (1)
Physical Examination: Heart, Text
Physical Examination: Lungs
no (0)
yes (1)
Physical Examination: Lungs, Text
Physical Examination: Abdomen
no (0)
yes (1)
Physical Examination: Abdomen, Text
Physical Examination: Extremeties/Joints
no (0)
yes (1)
Physical Examination: Extremeties/Joints, Text
Physical Examination: Mental Status
no (0)
yes (1)
Physical Examination: Mental Status, Text
Vital Signs and Physical Examination: ND
Not performed (0)
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Relapse Evaluation Visit No. 3 Vital Signs Multiple Sclerosis ALAIN01
NCT02419378
Relapse Evaluation Visit No. 4 Vital Signs
Multiple Sclerosis ALAIN01 NCT02419378
Alemtuzumab in Autoimmune Inflammatory
Neurodegeneration: Mechanisms of Action and
Neuroprotective Potential (ALAIN01)
https://clinicaltrials.gov/ct2/show/NCT02419378
Principal Investigator Prof. Dr. Dr. Sven Meuth, University
Hospital Muenster, Germany
Please document clinically significant findings as Adverse
Events. Clinical Significance is
defined as any variation in physical findings that has
medical relevance and may result in an
alteration in medical care.
Safety Blood and Urine Examinations: Please document
the results for Serum Creatinine, Platelets and TSH on
CRF-Pages "Safety
Laboratory Assessments".
Part: Relapse Evaluation Visit No. 4
All rights reserved. Please visit https://medical-data-
models.org/forms/15545
Relapse Evaluation Visit No. 4 Vital
Signs Multiple Sclerosis ALAIN01
NCT02419378
Vital Signs
Patient ID (derived)
Vital Signs and Physical Examination: Date
Heart rate
>= 0
bpm
Respiratory Rate
/min
Height
>= 0
cm
Systolic blood pressure
>= 0
mmHg
Diastolic blood pressure
>= 0
mmHg
Temperature
°C
Body weight
>= 0
kg
Physical Examination: General Appearance
no (0)
yes (1)
1 / 2
Physical Examination: General Appearance, Text
Physical Examination: Skin
no (0)
yes (1)
Physical Examination: Skin, Text
Physical Examination: HEENT
no (0)
yes (1)
Physical Examination: HEENT, Text
Physical Examination: Lymph Nodes
no (0)
yes (1)
Physical Examination: Lymph Nodes, Text
Physical Examination: Heart
no (0)
yes (1)
Physical Examination: Heart, Text
Physical Examination: Lungs
no (0)
yes (1)
Physical Examination: Lungs, Text
Physical Examination: Abdomen
no (0)
yes (1)
Physical Examination: Abdomen, Text
Physical Examination: Extremeties/Joints
no (0)
yes (1)
Physical Examination: Extremeties/Joints, Text
Physical Examination: Mental Status
no (0)
yes (1)
Physical Examination: Mental Status, Text
Vital Signs and Physical Examination: ND
Not performed (0)
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Relapse Evaluation Visit No. 4 Vital Signs Multiple Sclerosis ALAIN01
NCT02419378
Relapse Evaluation Visit No. X Vital Signs
Multiple Sclerosis ALAIN01 NCT02419378
Alemtuzumab in Autoimmune Inflammatory
Neurodegeneration: Mechanisms of Action and
Neuroprotective Potential (ALAIN01)
https://clinicaltrials.gov/ct2/show/NCT02419378
Principal Investigator Prof. Dr. Dr. Sven Meuth, University
Hospital Muenster, Germany
Please document clinically significant findings as Adverse
Events. Clinical Significance is
defined as any variation in physical findings that has
medical relevance and may result in an
alteration in medical care.
Safety Blood and Urine Examinations: Please document
the results for Serum Creatinine, Platelets and TSH on
CRF-Pages "Safety
Laboratory Assessments".
Part: Relapse Evaluation Visit No. X, Please enter Number
of Visit below
All rights reserved. Please visit https://medical-data-
models.org/forms/15546
Relapse Evaluation Visit No. X Vital
Signs Multiple Sclerosis ALAIN01
NCT02419378
Vital Signs
Number of Relapse Evaluation Visit
Patient ID (derived)
Vital Signs and Physical Examination: Date
Heart rate
>= 0
bpm
Respiratory Rate
/min
Height
>= 0
cm
Systolic blood pressure
>= 0
mmHg
Diastolic blood pressure
>= 0
mmHg
Temperature
°C
Body weight
>= 0
kg
1 / 3
Physical Examination: General Appearance
no (0)
yes (1)
Physical Examination: General Appearance, Text
Physical Examination: Skin
no (0)
yes (1)
Physical Examination: Skin, Text
Physical Examination: HEENT
no (0)
yes (1)
Physical Examination: HEENT, Text
Physical Examination: Lymph Nodes
no (0)
yes (1)
Physical Examination: Lymph Nodes, Text
Physical Examination: Heart
no (0)
yes (1)
Physical Examination: Heart, Text
Physical Examination: Lungs
no (0)
yes (1)
Physical Examination: Lungs, Text
Physical Examination: Abdomen
no (0)
yes (1)
Physical Examination: Abdomen, Text
Physical Examination: Extremeties/Joints
no (0)
yes (1)
Physical Examination: Extremeties/Joints, Text
Physical Examination: Mental Status
no (0)
yes (1)
2 / 3
Relapse Evaluation Visit No. X Vital Signs Multiple Sclerosis ALAIN01
NCT02419378
Physical Examination: Mental Status, Text
Vital Signs and Physical Examination: ND
Not performed (0)
3 / 3
Relapse Evaluation Visit No. X Vital Signs Multiple Sclerosis ALAIN01
NCT02419378
Discontinuation Visit: Vital Signs Multiple
Sclerosis ALAIN01 NCT02419378
Alemtuzumab in Autoimmune Inflammatory
Neurodegeneration: Mechanisms of Action and
Neuroprotective Potential (ALAIN01)
https://clinicaltrials.gov/ct2/show/NCT02419378
Principal Investigator Prof. Dr. Dr. Sven Meuth, University
Hospital Muenster, Germany
Please document clinically significant findings as Adverse
Events. Clinical Significance is
defined as any variation in physical findings that has
medical relevance and may result in an
alteration in medical care.
Safety Blood and Urine Examinations: Please document
the results for Serum Creatinine, Platelets and TSH on
CRF-Pages "Safety
Laboratory Assessments".
Part: Discontinuation Visit
All rights reserved. Please visit https://medical-data-
models.org/forms/15547
Discontinuation Visit: Vital Signs
Multiple Sclerosis ALAIN01
NCT02419378
Vital Signs
Patient ID (derived)
Vital Signs and Physical Examination: Date
Heart rate
>= 0
bpm
Respiratory Rate
/min
Height
>= 0
cm
Systolic blood pressure
>= 0
mmHg
Diastolic blood pressure
>= 0
mmHg
Temperature
°C
Body weight
>= 0
kg
Physical Examination: General Appearance
no (0)
yes (1)
1 / 3
Physical Examination: General Appearance, Text
Physical Examination: Skin
no (0)
yes (1)
Physical Examination: Skin, Text
Physical Examination: HEENT
no (0)
yes (1)
Physical Examination: HEENT, Text
Physical Examination: Lymph Nodes
no (0)
yes (1)
Physical Examination: Lymph Nodes, Text
Physical Examination: Heart
no (0)
yes (1)
Physical Examination: Heart, Text
Physical Examination: Lungs
no (0)
yes (1)
Physical Examination: Lungs, Text
Physical Examination: Abdomen
no (0)
yes (1)
Physical Examination: Abdomen, Text
Physical Examination: Extremeties/Joints
no (0)
yes (1)
Physical Examination: Extremeties/Joints, Text
Physical Examination: Mental Status
no (0)
yes (1)
Physical Examination: Mental Status, Text
Blood Sampling for Eff. Ass.: Date
2 / 3
Discontinuation Visit: Vital Signs Multiple Sclerosis ALAIN01
NCT02419378
Vital Signs and Physical Examination: ND
Not performed (0)
Physical Examination: Date of Signature
3 / 3
Discontinuation Visit: Vital Signs Multiple Sclerosis ALAIN01
NCT02419378
Eligibility Multiple Myeloma NCT02336815
Phase 2b Open-Label Single-Arm Study With KPT-330 &
Dexamethasone in Patients w/ Quad-refractory Multiple
Myeloma; ODM derived from:
https://clinicaltrials.gov/show/NCT02336815
All rights reserved. Please visit https://medical-data-
models.org/forms/15548
Eligibility Multiple Myeloma
NCT02336815
Inclusion Criteria
symptomatic mm, based on imwg guidelines.
patients must have measurable disease as
defined by at least one of the following:*
Yes
No
1. serum m-protein ≥ 0.5 g/dl by serum
electrophoresis (spep) or for iga myeloma, by
quantitative iga; or*
Yes
No
2. urinary m-protein excretion at least 200 mg/24
hours; or*
Yes
No
3. serum free light chain (flc) whereby the
involved light chain measures ≥ 10 mg/dl and
with an abnormal light chain ratio.*
Yes
No
patients must have received ≥ 3 prior anti-mm
regimens including the following: an alkylating
agent, lenalidomide, pomalidomide, bortezomib,
carfilzomib and a glucocorticoid. there is no
upper limit on the number of prior therapies
provided that all other inclusion/exclusion criteria
are met.*
Yes
No
quad-refractory mm: mm refractory to
lenalidomide, pomalidomide, bortezomib, and
carfilzomib. refractory is defined as ≤ 25%
response to therapy, or progression during
therapy or progression within 60 days after
completion of therapy.*
Yes
No
penta-refractory mm: 25% of patients must have
mm refractory to lenalidomide, pomalidomide,
bortezomib, carfilzomib, and at least one anti-
cd38 mab (e.g., sar 650984 or daratumumab)*
Yes
No
1 / 2
multiple myeloma refractory to the patient's most
recent anti-mm regimen.*
Yes
No
Exclusion Criteria
smoldering mm.*
Yes
No
plasma cell leukemia.*
Yes
No
mm that does not express m-protein or flc (i.e.,
non-secretory mm is excluded; plasmacytomas
without m-protein or flc are excluded).*
Yes
No
documented systemic amyloid light chain
amyloidosis.*
Yes
No
active cns mm.*
Yes
No
2 / 2
Eligibility Multiple Myeloma NCT02336815
FOMT Neck disability index
"FOMT"- Fortbildungen für orthopädische Medizin und
Manuelle Therapie
Neck Disability Index –validierte deutsche Version(Cramer
2014)
http://creativecommons.org/licenses/by/4.0/
All rights reserved. Please visit https://medical-data-
models.org/forms/15549
Neck disability index Validierte
Übersetzung
Patientenbefragung
Schmerzintensität
Momentan habe ich keine Schmerzen (1)
Ich habe im Moment sehr geringe
Schmerzen (2)
Ich habe im Moment mäßige Schmerzen
(3)
Ich habe im Moment ziemlich starke
Schmerzen (4)
Ich habe im Moment sehr starke
Schmerzen (5)
Ich habe im Moment die stärksten
Schmerzen, die ich mir vorstellen kann
(6)
Persönliche Körperpflege (z.B
Waschen,Anziehen)
Ich kann meine Körperpflege erledigen,
ohne dass dies zusätzliche Schmerzen
verursacht (1)
Ich kann meine Körperpflege erledigen,
aber es verursacht mir zusätzliche
Schmerzen (2)
Das Erledigen der Körperpflege ist
schmerzhaft, und ich bin dabei langsam
und vorsichtig (3)
Ich brauche etwas Hilfe, aber ich kann
den größten Teil meiner Körperpflege
selbst besorgen (4)
Ich brauche täglich Hilfe bei den meisten
Verrichtungen meiner Körperpflege (5)
Ich ziehe mich nicht an, wasche mich nur
mit Mühe und bleibe im Bett (6)
Heben
Ich kann schwere Gegenstände ohne
zusätzliche Schmerzen heben (1)
Ich kann schwere Gegenstände heben,
aber dies verursacht zusätzliche
Schmerzen (2)
Meine Schmerzen hindern mich daran,
schwere Gegenstände vom Boden
aufzuheben. Aber ich kann schwere
Gegenstände heben, wenn sie günstig
positioniert sind (z.B. auf dem Tisch) (3)
Meine Schmerzen hindern mich daran,
schwere Gegenstände vom Boden
aufzuheben. Aber ich kann
mittelschwere Gegenstände heben,
wenn sie günstig positioniert sind (4)
Ich kann nur sehr leichte Gegenstände
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heben (5)
Ich kann überhaupt nichts heben oder
tragen (6)
Lesen
Ich kann lesen, so viel ich will, ohne
Nackenschmerzen zu bekommen (1)
Ich kann lesen, soviel ich will, aber ich
bekomme davon leichte
Nackenschmerzen (2)
Ich kann lesen, so viel ich will, aber ich
bekomme davon mässige
Nackenschmerzen. (3)
Ich kann wegen mäßiger
Nackenschmerzen nicht soviel lesen, wie
ich will (4)
Ich kann wegenstarker
Nackenschmerzen kaum lesen (5)
Ich kann überhaupt nicht mehr lesen. (6)
Kopfschmerzen
Ich habe überhaupt keine
Kopfschmerzen. (1)
Ich habe leichte Kopfschmerzen, die
unregelmäßig auftreten (2)
Ich habe mäßige Kopfschmerzen, die
unregelmäßig auftreten (3)
Ich habe mäßige Kopfschmerzen, die
regelmäßig auftreten (4)
Ich habe starke Kopfschmerzen, die
regelmäßig auftreten (5)
Ich habe die meiste Zeit Kopfschmerzen.
(6)
Konzentration
Ich kann mich, wenn ich will, ohne
Schwierigkeiten voll konzentrieren (1)
Ich kann mich, wenn ich will, mit leichten
Schwierigkeiten voll konzentrieren (2)
Ich habe ziemliche Schwierigkeiten mich
zu konzentrieren, wenn ich es will (3)
Ich habe grosse Schwierigkeiten, mich
zu konzentrieren, wenn ich es will. (4)
Ich habe sehr grosse Schwierigkeiten,
mich zu konzentrieren, wenn ich es will.
(5)
Ich kann mich überhaupt nicht
konzentrieren. (6)
Arbeit
Ich kann soviel Arbeit erledigen, wie ich
möchte (1)
Ich kann nur meine übliche Arbeit
erledigen, aber nicht mehr. (2)
Ich kann den grössten Teil meiner
üblichen Arbeit verrichten, aber nicht
mehr. (3)
Ich kann meine übliche Arbeit nicht
erledigen. (4)
Ich kann kaum eine Arbeit erledigen. (5)
2 / 3
FOMT Neck disability index
Ich kann überhaupt keine Arbeit
erledigen. (6)
Auto fahren
Ich kann Auto fahren ohne
Nackenschmerzen zu bekommen. (1)
Ich kann Auto fahren so lange ich will,
mit leichten Nackenschmerzen (2)
Ich kann Auto fahren, so lange ich will,
mit mässigen Nackenschmerzen. (3)
Ich kann wegen mäßiger
Nackenschmerzen nicht Auto fahren,
solange ich will (4)
Ich kann wegen starker
Nackenschmerzen kaum Auto fahren. (5)
Ich kann überhaupt nicht Auto fahren. (6)
Schlaf
Ich habe keine Schlafprobleme (1)
Mein Schlaf ist kaum gestört (weniger
als 1 Stunde schlaflos). (2)
Mein Schlaf ist leicht gestört (1-2
Stunden schlaflos). (3)
Mein Schlaf ist mässig gestört (2-3
Stunden schlaflos). (4)
Mein Schlaf ist stark gestört (3-5
Stunden schlaflos). (5)
Mein Schlaf ist komplett gestört (5-7
Stunden schlaflos). (6)
Freizeitaktivitäten
Ich kann alle meine Freizeitaktivitäten
ohne Nackenschmerzen ausüben. (1)
Ich kann, wenn auch mit einigen
Nackenschmerzen,alle meine
Freizeitaktivitäten ausüben (2)
Wegen Nackenschmerzen kann ich die
meisten, aber nicht alle meiner täglichen
(3)
Ich kann wegen meiner
Nackenschmerzen nur einige meiner
Freizeitaktivitäten ausüben (4)
Ich kann wegen meiner
Nackenschmerzen kaum irgendwelche
Freizeitaktivitäten ausüben (5)
Ich kann überhaupt keine
Freizeitaktivitäten ausüben (6)
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FOMT Neck disability index
DWG-Register VAS Rückenschmerzen
Deutsche Wirbelsäulen Gesellschaft DWG-Register,
http://www.dwg.org
All rights reserved. Please visit https://medical-data-
models.org/forms/15551
Fragen zur Beeinträchtigungen durch
Rückenschmerzen (VAS)
Visuelle Analogskala bei
Rückenschmerzen
Wie oft stören Rückenschmerzen Ihren Schlaf?
0 ständig/immer (1)
90 (10)
100 Nie/sehr selten (11)
10 (2)
20 (3)
30 (4)
40 (5)
50 (6)
60 (7)
70 (8)
80 (9)
Wie oft haben Sie in körperlicher Ruhe
Rückenschmerzen?
0 ständig/immer (1)
90 (10)
100 Nie/sehr selten (11)
10 (2)
20 (3)
30 (4)
40 (5)
50 (6)
60 (7)
70 (8)
80 (9)
Wie stark sind dann in körperlicher Ruhe die
Rückenschmerzen?
0 Nicht auszuhalten,unerträglich (1)
90 (10)
100 Keine Schmerzen (11)
10 (2)
20 (3)
30 (4)
40 (5)
50 (6)
60 (7)
70 (8)
80 (9)
Wie oft haben Sie bei körperlicher Belastung
Rückenschmerzen?
0 ständig/immer (1)
90 (10)
100 Nie/sehr selten (11)
10 (2)
20 (3)
30 (4)
40 (5)
50 (6)
1 / 5
60 (7)
70 (8)
80 (9)
Wie stark sind dann bei körperlicher Belastung
die Rückenschmerzen?
0 Nicht auszuhalten,unerträglich (1)
90 (10)
100 Keine Schmerzen (11)
10 (2)
20 (3)
30 (4)
40 (5)
50 (6)
60 (7)
70 (8)
80 (9)
Wie oft nehmen Sie Schmerzmittel gegen
Rückenschmerzen ein?
0 ständig/immer (1)
90 (10)
100 Nie/sehr selten (11)
10 (2)
20 (3)
30 (4)
40 (5)
50 (6)
60 (7)
70 (8)
80 (9)
Wie lange können Sie ohne Rückenbeschwerden
sitzen?
0 Gar nicht, nur kurz oder mit Hilfsmitteln
(1)
90 (10)
100 Stundenlang, ohne
Einschränkungen (11)
10 (2)
20 (3)
30 (4)
40 (5)
50 (6)
60 (7)
70 (8)
80 (9)
Wie stark schränken Rückenbeschwerden das
Vorbeugen ein (wie z.B. beim Abwaschen)?
0 Vorbeugen unmöglich (1)
90 (10)
100 Vorbeugen ohne Einschränkungen
möglich (11)
10 (2)
20 (3)
30 (4)
40 (5)
50 (6)
60 (7)
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70 (8)
80 (9)
Wie stark schränken Rückenbeschwerden Ihren
Beruf ein?
0 Alter Beruf kann nicht mehr ausgeübt
werden (1)
90 (10)
100 Keine Einschränkungen im Beruf
(11)
10 (2)
20 (3)
30 (4)
40 (5)
50 (6)
60 (7)
70 (8)
80 (9)
Wie stark schränken Rückenbeschwerden das
Hochheben ein?
0 Auch leichtes Heben unmöglich (1)
90 (10)
100 Schweres Heben ohne
Einschränkungen möglich (11)
10 (2)
20 (3)
30 (4)
40 (5)
50 (6)
60 (7)
70 (8)
80 (9)
Wie stark schränken Rückenbeschwerden
Hausarbeiten ein?
0 Auch leicht Arbeiten unmöglich (1)
90 (10)
100 Schwere Arbeit ohne
Einschränkungen möglich (11)
10 (2)
20 (3)
30 (4)
40 (5)
50 (6)
60 (7)
70 (8)
80 (9)
Wie lange können Sie ohne Rückenbeschwerden
stehen?
0 Gar nicht, nur kurz oder mit Hilfsmitteln
(1)
90 (10)
100 Stundenlang, ohne
Einschränkungen (11)
10 (2)
20 (3)
30 (4)
40 (5)
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50 (6)
60 (7)
70 (8)
80 (9)
Wie lange können Sie ohne Rückenbeschwerden
gehen?
0 Gar nicht, nur kurz oder mit Hilfsmitteln
(1)
90 (10)
100 Stundenlang, ohne
Einschränkungen (11)
10 (2)
20 (3)
30 (4)
40 (5)
50 (6)
60 (7)
70 (8)
80 (9)
Wie stark schränken Rückenbeschwerden das
Laufen ein (z.B. Jogging, Waldlauf etc)?
0 Auch kurzes Laufen unmöglich (1)
90 (10)
100 Längeres Laufen ohne
Einschränkungen möglich (11)
10 (2)
20 (3)
30 (4)
40 (5)
50 (6)
60 (7)
70 (8)
80 (9)
Wie stark schränken Rückenbeschwerden
Aktivitäten des täglichen Lebens ein (z.B. Esse,
Wachen, etc.)?
0 Allein unmöglich,immer hilfsbedürftig
(1)
90 (10)
100 Stundenlang,ohne Einschränkung
(11)
10 (2)
20 (3)
30 (4)
40 (5)
50 (6)
60 (7)
70 (8)
80 (9)
Wie stark schränken Rückenbeschwerden das
Laufen ein (z.B. Jogging, Waldlauf etc)?
0 Gar nicht, nur kurz oder mit Hilfsmitteln
(1)
90 (10)
100 Stundenlang, ohne
Einschränkungen (11)
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10 (2)
20 (3)
30 (4)
40 (5)
50 (6)
60 (7)
70 (8)
80 (9)
Wie stark schränken Rückenbeschwerden Ihr
Sexualleben ein?
0 Vollständig,wegen der
Rückenprobleme (1)
90 (10)
100 Keine Einschränkung (11)
10 (2)
20 (3)
30 (4)
40 (5)
50 (6)
60 (7)
70 (8)
80 (9)
Wie stark schränken Rückenbeschwerden das
Tragen ein?
0 Auch leichtes Tragen unmöglich (1)
90 (10)
100 Schweres Tragen ohne
Einschränkungen möglich (11)
10 (2)
20 (3)
30 (4)
40 (5)
50 (6)
60 (7)
70 (8)
80 (9)
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DWG-Register VAS Rückenschmerzen
Baseline: Evoked Potentials Multiple
Sclerosis ALAIN01 NCT02419378
Alemtuzumab in Autoimmune Inflammatory
Neurodegeneration: Mechanisms of Action and
Neuroprotective Potential (ALAIN01)
https://clinicaltrials.gov/ct2/show/NCT02419378
Principal Investigator Prof. Dr. Dr. Sven Meuth, University
Hospital Muenster, Germany
Part: Baseline
All rights reserved. Please visit https://medical-data-
models.org/forms/15553
Baseline:  Evoked Potentials Multiple
Sclerosis ALAIN01 NCT02419378
Evoked Potentials
Patient ID (derived)
Evoked Potentials: Add. Inf. Consent yes/no
no (0)
yes (1)
Evoked Potentials: Date
VEP Amp, right [µV]
VEP Amp, right: no response
no response to stimulus (0)
VEP Amp, left [µV]
VEP Amp, left: no response
no response to stimulus (0)
VEP Lat, right [ms]
VEP Lat, right: no response
no response to stimulus (0)
VEP Lat, left [ms]
VEP Lat, left: no response
no response to stimulus (0)
SEP Amp, right [µV]
SEP Amp, right: no response
no response to stimulus (0)
SEP Amp, left [µV]
SEP Amp, left: no response
no response to stimulus (0)
SEP Lat, right [ms]
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SEP Lat, right: no response
no response to stimulus (0)
SEP Lat, left [ms]
SEP Lat, left: no response
no response to stimulus (0)
MEP Amp cortical, right [µV]
MEP Amp cortical, right: no response
no response to stimulus (0)
MEP Amp cortical, left [µV]
MEP Amp cortical, left: no response
no response to stimulus (0)
MEP Lat cortical, right [ms]
MEP Lat cortical, right: no response
no response to stimulus (0)
MEP Lat cortical, left [ms]
MEP Lat cortical, left: no response
no response to stimulus (0)
MEP Lat lumbal, right [ms]
MEP Lat lumbal, right: no response
no response to stimulus (0)
MEP Lat lumbal, left [ms]
MEP Lat lumbal, left: no response
no response to stimulus (0)
OCT: Date
Average retinal nerve fiber layer thickness [µm]
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Baseline: Evoked Potentials Multiple Sclerosis ALAIN01 NCT02419378
Month 6: Evoked Potentials Multiple
Sclerosis ALAIN01 NCT02419378
Alemtuzumab in Autoimmune Inflammatory
Neurodegeneration: Mechanisms of Action and
Neuroprotective Potential (ALAIN01)
https://clinicaltrials.gov/ct2/show/NCT02419378
Principal Investigator Prof. Dr. Dr. Sven Meuth, University
Hospital Muenster, Germany
Part: Month 6
All rights reserved. Please visit https://medical-data-
models.org/forms/15554
Month 6: Evoked Potentials Multiple
Sclerosis ALAIN01 NCT02419378
Evoked Potentials
Patient ID (derived)
Evoked Potentials: Add. Inf. Consent yes/no
no (0)
yes (1)
Evoked Potentials: Date
VEP Amp, right [µV]
VEP Amp, right: no response
no response to stimulus (0)
VEP Amp, left [µV]
VEP Amp, left: no response
no response to stimulus (0)
VEP Lat, right [ms]
VEP Lat, right: no response
no response to stimulus (0)
VEP Lat, left [ms]
VEP Lat, left: no response
no response to stimulus (0)
SEP Amp, right [µV]
SEP Amp, right: no response
no response to stimulus (0)
SEP Amp, left [µV]
SEP Amp, left: no response
no response to stimulus (0)
SEP Lat, right [ms]
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SEP Lat, right: no response
no response to stimulus (0)
SEP Lat, left [ms]
SEP Lat, left: no response
no response to stimulus (0)
MEP Amp cortical, right [µV]
MEP Amp cortical, right: no response
no response to stimulus (0)
MEP Amp cortical, left [µV]
MEP Amp cortical, left: no response
no response to stimulus (0)
MEP Lat cortical, right [ms]
MEP Lat cortical, right: no response
no response to stimulus (0)
MEP Lat cortical, left [ms]
MEP Lat cortical, left: no response
no response to stimulus (0)
MEP Lat lumbal, right [ms]
MEP Lat lumbal, right: no response
no response to stimulus (0)
MEP Lat lumbal, left [ms]
MEP Lat lumbal, left: no response
no response to stimulus (0)
OCT: Date
Average retinal nerve fiber layer thickness [µm]
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Month 6: Evoked Potentials Multiple Sclerosis ALAIN01 NCT02419378
Month 12: Evoked Potentials Multiple
Sclerosis ALAIN01 NCT02419378
Alemtuzumab in Autoimmune Inflammatory
Neurodegeneration: Mechanisms of Action and
Neuroprotective Potential (ALAIN01)
https://clinicaltrials.gov/ct2/show/NCT02419378
Principal Investigator Prof. Dr. Dr. Sven Meuth, University
Hospital Muenster, Germany
Part: Month 12
All rights reserved. Please visit https://medical-data-
models.org/forms/15555
Month 12: Evoked Potentials Multiple
Sclerosis ALAIN01 NCT02419378
Evoked Potentials
Patient ID (derived)
Evoked Potentials: Add. Inf. Consent yes/no
no (0)
yes (1)
Evoked Potentials: Date
VEP Amp, right [µV]
VEP Amp, right: no response
no response to stimulus (0)
VEP Amp, left [µV]
VEP Amp, left: no response
no response to stimulus (0)
VEP Lat, right [ms]
VEP Lat, right: no response
no response to stimulus (0)
VEP Lat, left [ms]
VEP Lat, left: no response
no response to stimulus (0)
SEP Amp, right [µV]
SEP Amp, right: no response
no response to stimulus (0)
SEP Amp, left [µV]
SEP Amp, left: no response
no response to stimulus (0)
SEP Lat, right [ms]
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SEP Lat, right: no response
no response to stimulus (0)
SEP Lat, left [ms]
SEP Lat, left: no response
no response to stimulus (0)
MEP Amp cortical, right [µV]
MEP Amp cortical, right: no response
no response to stimulus (0)
MEP Amp cortical, left [µV]
MEP Amp cortical, left: no response
no response to stimulus (0)
MEP Lat cortical, right [ms]
MEP Lat cortical, right: no response
no response to stimulus (0)
MEP Lat cortical, left [ms]
MEP Lat cortical, left: no response
no response to stimulus (0)
MEP Lat lumbal, right [ms]
MEP Lat lumbal, right: no response
no response to stimulus (0)
MEP Lat lumbal, left [ms]
MEP Lat lumbal, left: no response
no response to stimulus (0)
OCT: Date
Average retinal nerve fiber layer thickness [µm]
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Month 12: Evoked Potentials Multiple Sclerosis ALAIN01 NCT02419378
Month 18: Evoked Potentials Multiple
Sclerosis ALAIN01 NCT02419378
Alemtuzumab in Autoimmune Inflammatory
Neurodegeneration: Mechanisms of Action and
Neuroprotective Potential (ALAIN01)
https://clinicaltrials.gov/ct2/show/NCT02419378
Principal Investigator Prof. Dr. Dr. Sven Meuth, University
Hospital Muenster, Germany
Part: Month 18
All rights reserved. Please visit https://medical-data-
models.org/forms/15556
Month 18: Evoked Potentials Multiple
Sclerosis ALAIN01 NCT02419378
Evoked Potentials
Patient ID (derived)
Evoked Potentials: Add. Inf. Consent yes/no
no (0)
yes (1)
Evoked Potentials: Date
VEP Amp, right [µV]
VEP Amp, right: no response
no response to stimulus (0)
VEP Amp, left [µV]
VEP Amp, left: no response
no response to stimulus (0)
VEP Lat, right [ms]
VEP Lat, right: no response
no response to stimulus (0)
VEP Lat, left [ms]
VEP Lat, left: no response
no response to stimulus (0)
SEP Amp, right [µV]
SEP Amp, right: no response
no response to stimulus (0)
SEP Amp, left [µV]
SEP Amp, left: no response
no response to stimulus (0)
SEP Lat, right [ms]
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SEP Lat, right: no response
no response to stimulus (0)
SEP Lat, left [ms]
SEP Lat, left: no response
no response to stimulus (0)
MEP Amp cortical, right [µV]
MEP Amp cortical, right: no response
no response to stimulus (0)
MEP Amp cortical, left [µV]
MEP Amp cortical, left: no response
no response to stimulus (0)
MEP Lat cortical, right [ms]
MEP Lat cortical, right: no response
no response to stimulus (0)
MEP Lat cortical, left [ms]
MEP Lat cortical, left: no response
no response to stimulus (0)
MEP Lat lumbal, right [ms]
MEP Lat lumbal, right: no response
no response to stimulus (0)
MEP Lat lumbal, left [ms]
MEP Lat lumbal, left: no response
no response to stimulus (0)
OCT: Date
Average retinal nerve fiber layer thickness [µm]
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Month 18: Evoked Potentials Multiple Sclerosis ALAIN01 NCT02419378
Month 24: Evoked Potentials Multiple
Sclerosis ALAIN01 NCT02419378
Alemtuzumab in Autoimmune Inflammatory
Neurodegeneration: Mechanisms of Action and
Neuroprotective Potential (ALAIN01)
https://clinicaltrials.gov/ct2/show/NCT02419378
Principal Investigator Prof. Dr. Dr. Sven Meuth, University
Hospital Muenster, Germany
Part: Month 24
All rights reserved. Please visit https://medical-data-
models.org/forms/15557
Month 24: Evoked Potentials Multiple
Sclerosis ALAIN01 NCT02419378
Evoked Potentials
Patient ID (derived)
Evoked Potentials: Add. Inf. Consent yes/no
no (0)
yes (1)
Evoked Potentials: Date
VEP Amp, right [µV]
VEP Amp, right: no response
no response to stimulus (0)
VEP Amp, left [µV]
VEP Amp, left: no response
no response to stimulus (0)
VEP Lat, right [ms]
VEP Lat, right: no response
no response to stimulus (0)
VEP Lat, left [ms]
VEP Lat, left: no response
no response to stimulus (0)
SEP Amp, right [µV]
SEP Amp, right: no response
no response to stimulus (0)
SEP Amp, left [µV]
SEP Amp, left: no response
no response to stimulus (0)
SEP Lat, right [ms]
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SEP Lat, right: no response
no response to stimulus (0)
SEP Lat, left [ms]
SEP Lat, left: no response
no response to stimulus (0)
MEP Amp cortical, right [µV]
MEP Amp cortical, right: no response
no response to stimulus (0)
MEP Amp cortical, left [µV]
MEP Amp cortical, left: no response
no response to stimulus (0)
MEP Lat cortical, right [ms]
MEP Lat cortical, right: no response
no response to stimulus (0)
MEP Lat cortical, left [ms]
MEP Lat cortical, left: no response
no response to stimulus (0)
MEP Lat lumbal, right [ms]
MEP Lat lumbal, right: no response
no response to stimulus (0)
MEP Lat lumbal, left [ms]
MEP Lat lumbal, left: no response
no response to stimulus (0)
OCT: Date
Average retinal nerve fiber layer thickness [µm]
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Month 24: Evoked Potentials Multiple Sclerosis ALAIN01 NCT02419378
Month 30: Evoked Potentials Multiple
Sclerosis ALAIN01 NCT02419378
Alemtuzumab in Autoimmune Inflammatory
Neurodegeneration: Mechanisms of Action and
Neuroprotective Potential (ALAIN01)
https://clinicaltrials.gov/ct2/show/NCT02419378
Principal Investigator Prof. Dr. Dr. Sven Meuth, University
Hospital Muenster, Germany
Part: Month 30
All rights reserved. Please visit https://medical-data-
models.org/forms/15558
Month 30: Evoked Potentials Multiple
Sclerosis ALAIN01 NCT02419378
Evoked Potentials
Patient ID (derived)
Evoked Potentials: Add. Inf. Consent yes/no
no (0)
yes (1)
Evoked Potentials: Date
VEP Amp, right [µV]
VEP Amp, right: no response
no response to stimulus (0)
VEP Amp, left [µV]
VEP Amp, left: no response
no response to stimulus (0)
VEP Lat, right [ms]
VEP Lat, right: no response
no response to stimulus (0)
VEP Lat, left [ms]
VEP Lat, left: no response
no response to stimulus (0)
SEP Amp, right [µV]
SEP Amp, right: no response
no response to stimulus (0)
SEP Amp, left [µV]
SEP Amp, left: no response
no response to stimulus (0)
SEP Lat, right [ms]
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SEP Lat, right: no response
no response to stimulus (0)
SEP Lat, left [ms]
SEP Lat, left: no response
no response to stimulus (0)
MEP Amp cortical, right [µV]
MEP Amp cortical, right: no response
no response to stimulus (0)
MEP Amp cortical, left [µV]
MEP Amp cortical, left: no response
no response to stimulus (0)
MEP Lat cortical, right [ms]
MEP Lat cortical, right: no response
no response to stimulus (0)
MEP Lat cortical, left [ms]
MEP Lat cortical, left: no response
no response to stimulus (0)
MEP Lat lumbal, right [ms]
MEP Lat lumbal, right: no response
no response to stimulus (0)
MEP Lat lumbal, left [ms]
MEP Lat lumbal, left: no response
no response to stimulus (0)
OCT: Date
Average retinal nerve fiber layer thickness [µm]
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Month 30: Evoked Potentials Multiple Sclerosis ALAIN01 NCT02419378
Month 36: Evoked Potentials Multiple
Sclerosis ALAIN01 NCT02419378
Alemtuzumab in Autoimmune Inflammatory
Neurodegeneration: Mechanisms of Action and
Neuroprotective Potential (ALAIN01)
https://clinicaltrials.gov/ct2/show/NCT02419378
Principal Investigator Prof. Dr. Dr. Sven Meuth, University
Hospital Muenster, Germany
Part: Month 36
All rights reserved. Please visit https://medical-data-
models.org/forms/15559
Month 36: Evoked Potentials Multiple
Sclerosis ALAIN01 NCT02419378
Evoked Potentials
Patient ID (derived)
Evoked Potentials: Add. Inf. Consent yes/no
no (0)
yes (1)
Evoked Potentials: Date
VEP Amp, right [µV]
VEP Amp, right: no response
no response to stimulus (0)
VEP Amp, left [µV]
VEP Amp, left: no response
no response to stimulus (0)
VEP Lat, right [ms]
VEP Lat, right: no response
no response to stimulus (0)
VEP Lat, left [ms]
VEP Lat, left: no response
no response to stimulus (0)
SEP Amp, right [µV]
SEP Amp, right: no response
no response to stimulus (0)
SEP Amp, left [µV]
SEP Amp, left: no response
no response to stimulus (0)
SEP Lat, right [ms]
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SEP Lat, right: no response
no response to stimulus (0)
SEP Lat, left [ms]
SEP Lat, left: no response
no response to stimulus (0)
MEP Amp cortical, right [µV]
MEP Amp cortical, right: no response
no response to stimulus (0)
MEP Amp cortical, left [µV]
MEP Amp cortical, left: no response
no response to stimulus (0)
MEP Lat cortical, right [ms]
MEP Lat cortical, right: no response
no response to stimulus (0)
MEP Lat cortical, left [ms]
MEP Lat cortical, left: no response
no response to stimulus (0)
MEP Lat lumbal, right [ms]
MEP Lat lumbal, right: no response
no response to stimulus (0)
MEP Lat lumbal, left [ms]
MEP Lat lumbal, left: no response
no response to stimulus (0)
OCT: Date
Average retinal nerve fiber layer thickness [µm]
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Month 36: Evoked Potentials Multiple Sclerosis ALAIN01 NCT02419378
Eligibility Multiple Myeloma NCT02343042
Phase 1b/2 Study of Selinexor (KPT-330) in Combination
w/ Backbone Treatments for Resistant/Refractory Multiple
Myeloma; ODM derived from:
https://clinicaltrials.gov/show/NCT02343042
All rights reserved. Please visit https://medical-data-
models.org/forms/15560
Eligibility Multiple Myeloma
NCT02343042
Inclusion Criteria
histologically confirmed diagnosis, measurable
disease and evidence of disease progression of
multiple myeloma, as described below.*
Yes
No
symptomatic multiple myeloma, based on imwg
guidelines. patients must have measurable
disease as defined by at least one of the
following:*
Yes
No
1. serum m-protein ≥ 5 g/l by serum
electrophoresis (spep) or for immunoglobulin a
(iga) myeloma, by quantitative iga; or*
Yes
No
2. urinary m-protein excretion at least 200 mg/24
hours; or*
Yes
No
3. involved serum free light chains ≥ 100 mg/l,
provided that free light chain ratio is abnormal*
Yes
No
4. if serum protein electrophoresis is felt to be
unreliable for routine m-protein measurement,
then quantitative immunoglobulin levels by
nephelometry or turbidometry are acceptable.*
Yes
No
resolution of prior drug-related toxicities to ≤
grade 1.*
Yes
No
relapsed and/or refractory multiple myeloma.*
Yes
No
Exclusion Criteria
smoldering mm.*
Yes
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No
multiple myeloma that does not express m-
protein or free light chain(flc) (i.e., non-secretory
mm is excluded), and quantitative
immunoglobulin levels cannot be used instead.*
Yes
No
documented systemic amyloid light chain
amyloidosis.*
Yes
No
active mm involving the central nervous system
(cns).*
Yes
No
plasma cell leukemia.*
Yes
No
on the selinexor + dexamethasone + bortezomib
(sdb) arm only: prior history of neuropathy grade
> 2, or grade 2 neuropathy with pain at baseline
(within 14 days prior to cycle 1 day 1).*
Yes
No
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Eligibility Multiple Myeloma NCT02343042
Eligibility Major Depressive Disorder
NCT02332291
Connectivity Affecting the Antidepressant REsponse Study;
ODM derived from:
https://clinicaltrials.gov/show/NCT02332291
All rights reserved. Please visit https://medical-data-
models.org/forms/15561
Eligibility Major Depressive Disorder
NCT02332291
Inclusion Criteria
1. age 60 years or older.*
Yes
No
2. current diagnosis of major depressive disorder
(dsm-iv-tr), single episode, recurrent or chronic,
without psychotic features, as detected by mini
and clinical exam.*
Yes
No
3. minimum madrs score ≥ 15.*
Yes
No
4. mini-mental state exam ≥ 24.*
Yes
No
5. fluent in english.*
Yes
No
Exclusion Criteria
1. current or past diagnoses of other axis i
psychiatric disorders, except for generalized
anxiety disorder (gad) symptoms occurring during
a depressive episode*
Yes
No
2. history of alcohol or drug dependence or
abuse in the last three years*
Yes
No
3. history of developmental disorder or iq score <
70*
Yes
No
4. presence of acute suicidality*
Yes
No
5. acute grief (< 1 month)*
Yes
No
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6. current or past psychosis*
Yes
No
7. primary neurological disorder, including but not
limited to dementia, stroke, brain tumors,
epilepsy, parkinson's disease, or demyelinating
diseases*
Yes
No
8. mri contraindications*
Yes
No
9. any physical or intellectual disability adversely
affecting ability to complete assessments*
Yes
No
10. electroconvulsive therapy in last 6 months*
Yes
No
11. use of antidepressant medications or other
psychotropic medications in the last 4 weeks (or
the last 6 weeks for fluoxetine).  occasional use of
benzodiazepines or non-benzodiazepine
sedatives (such as zolpidem, eszopiclone, or
zaleplon) during this period is allowable.*
Yes
No
12. a failed therapeutic trial of escitalopram in the
current depressive episode (defined as at least 6
weeks of treatment at a daily dose of 10mg or
higher)*
Yes
No
13. known allergy or hypersensitivity to
escitalopram or bupropion*
Yes
No
14. current or planned psychotherapy*
Yes
No
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Eligibility Major Depressive Disorder NCT02332291
Discontinuation Visit: Evoked Potentials
Multiple Sclerosis ALAIN01 NCT02419378
Alemtuzumab in Autoimmune Inflammatory
Neurodegeneration: Mechanisms of Action and
Neuroprotective Potential (ALAIN01)
https://clinicaltrials.gov/ct2/show/NCT02419378
Principal Investigator Prof. Dr. Dr. Sven Meuth, University
Hospital Muenster, Germany
Part: Discontinuation Visit
All rights reserved. Please visit https://medical-data-
models.org/forms/15562
Discontinuation Visit: Evoked
Potentials Multiple Sclerosis
ALAIN01 NCT02419378
Evoked Potentials
Patient ID (derived)
Evoked Potentials: Add. Inf. Consent yes/no
no (0)
yes (1)
Evoked Potentials: Date
VEP Amp, right [µV]
VEP Amp, right: no response
no response to stimulus (0)
VEP Amp, left [µV]
VEP Amp, left: no response
no response to stimulus (0)
VEP Lat, right [ms]
VEP Lat, right: no response
no response to stimulus (0)
VEP Lat, left [ms]
VEP Lat, left: no response
no response to stimulus (0)
SEP Amp, right [µV]
SEP Amp, right: no response
no response to stimulus (0)
SEP Amp, left [µV]
SEP Amp, left: no response
no response to stimulus (0)
SEP Lat, right [ms]
1 / 2
SEP Lat, right: no response
no response to stimulus (0)
SEP Lat, left [ms]
SEP Lat, left: no response
no response to stimulus (0)
MEP Amp cortical, right [µV]
MEP Amp cortical, right: no response
no response to stimulus (0)
MEP Amp cortical, left [µV]
MEP Amp cortical, left: no response
no response to stimulus (0)
MEP Lat cortical, right [ms]
MEP Lat cortical, right: no response
no response to stimulus (0)
MEP Lat cortical, left [ms]
MEP Lat cortical, left: no response
no response to stimulus (0)
MEP Lat lumbal, right [ms]
MEP Lat lumbal, right: no response
no response to stimulus (0)
MEP Lat lumbal, left [ms]
MEP Lat lumbal, left: no response
no response to stimulus (0)
OCT: Date
Average retinal nerve fiber layer thickness [µm]
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Discontinuation Visit: Evoked Potentials Multiple Sclerosis ALAIN01
NCT02419378
Screening: MRI Multiple Sclerosis ALAIN01
NCT02419378
Alemtuzumab in Autoimmune Inflammatory
Neurodegeneration: Mechanisms of Action and
Neuroprotective Potential (ALAIN01)
https://clinicaltrials.gov/ct2/show/NCT02419378
Principal Investigator Prof. Dr. Dr. Sven Meuth, University
Hospital Muenster, Germany
Part: Screening
All rights reserved. Please visit https://medical-data-
models.org/forms/15564
Screening: MRI Multiple Sclerosis
ALAIN01 NCT02419378
MRI
Patient ID (derived)
Did the patient provide additional informed
consent for semiannual
assessments of MRI?
Yes
No
MRI performed to verify Inclusion criteria
no (0)
yes (1)
MRI: Pregnancy Test
Test not done (0)
Test done (1)
MRI: Pregnancy Test, Kind of test
blood (1)
urine (2)
MRI Pregnancy Test: Date
MRI Pregnancy Test: Result
negative (0)
positive (1)
MRI Pregnancy Test: Reason
no childbearing potential (0)
other (9)
MRI Pregnancy Test: Reason, Text
MRI: Date
MRI: Date of Signature
MRI: Gd-enhancing lesions (Number)
MRI: T2 lesion volume
cm3
MRI: T2-weighted lesions (Number)
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MRI: T1-measured cerebral volume
cm3
MRI: T1-measured hypointense lesions (Number)
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Screening: MRI Multiple Sclerosis ALAIN01 NCT02419378
Baseline: MRI Multiple Sclerosis ALAIN01
NCT02419378
Alemtuzumab in Autoimmune Inflammatory
Neurodegeneration: Mechanisms of Action and
Neuroprotective Potential (ALAIN01)
https://clinicaltrials.gov/ct2/show/NCT02419378
Principal Investigator Prof. Dr. Dr. Sven Meuth, University
Hospital Muenster, Germany
Part: Baseline
If already performed at screening, please enter results of
screening MRI.
All rights reserved. Please visit https://medical-data-
models.org/forms/15568
Baseline: MRI Multiple Sclerosis
ALAIN01 NCT02419378
MRI
Patient ID (derived)
MRI: Date
MRI: Pregnancy Test
Test not done (0)
Test done (1)
MRI: Pregnancy Test, Kind of test
blood (1)
urine (2)
MRI Pregnancy Test: Date
MRI Pregnancy Test: Result
negative (0)
positive (1)
MRI Pregnancy Test: Reason
no childbearing potential (0)
other (9)
MRI Pregnancy Test: Reason, Text
MRI: Gd-enhancing lesions (Number)
MRI: T2 lesion volume
cm3
MRI: T2-weighted lesions (Number)
Date of Screening MRI
MRI: T1-measured cerebral volume
cm3
MRI: T1-measured hypointense lesions (Number)
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MRI: Date of Signature
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Baseline: MRI Multiple Sclerosis ALAIN01 NCT02419378
Baseline: Repitition of Assessments: MRI
Multiple Sclerosis ALAIN01 NCT02419378
Alemtuzumab in Autoimmune Inflammatory
Neurodegeneration: Mechanisms of Action and
Neuroprotective Potential (ALAIN01)
https://clinicaltrials.gov/ct2/show/NCT02419378
Principal Investigator Prof. Dr. Dr. Sven Meuth, University
Hospital Muenster, Germany
Part: Baseline: Repitition of Assessments
If already performed at screening, please enter results of
screening MRI.
All rights reserved. Please visit https://medical-data-
models.org/forms/15569
Baseline: Repitition of Assessments:
MRI Multiple Sclerosis ALAIN01
NCT02419378
MRI
Patient ID (derived)
MRI: Date
MRI: Pregnancy Test
Test not done (0)
Test done (1)
MRI: Pregnancy Test, Kind of test
blood (1)
urine (2)
MRI Pregnancy Test: Date
MRI Pregnancy Test: Result
negative (0)
positive (1)
MRI Pregnancy Test: Reason
no childbearing potential (0)
other (9)
MRI Pregnancy Test: Reason, Text
MRI: Gd-enhancing lesions (Number)
MRI: T2 lesion volume
cm3
MRI: T2-weighted lesions (Number)
Date of Screening MRI
MRI: T1-measured cerebral volume
cm3
MRI: T1-measured hypointense lesions (Number)
1 / 2
MRI: Date of Signature
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Baseline: Repitition of Assessments: MRI Multiple Sclerosis ALAIN01
NCT02419378
Month 6: MRI Multiple Sclerosis ALAIN01
NCT02419378
Alemtuzumab in Autoimmune Inflammatory
Neurodegeneration: Mechanisms of Action and
Neuroprotective Potential (ALAIN01)
https://clinicaltrials.gov/ct2/show/NCT02419378
Principal Investigator Prof. Dr. Dr. Sven Meuth, University
Hospital Muenster, Germany
Part: Month 6
All rights reserved. Please visit https://medical-data-
models.org/forms/15572
Month 6: MRI Multiple Sclerosis
ALAIN01 NCT02419378
MRI
Patient ID (derived)
MRI: Date
MRI: Pregnancy Test
Test not done (0)
Test done (1)
MRI: Pregnancy Test, Kind of test
blood (1)
urine (2)
MRI Pregnancy Test: Date
MRI Pregnancy Test: Result
negative (0)
positive (1)
MRI Pregnancy Test: Reason
no childbearing potential (0)
other (9)
MRI Pregnancy Test: Reason, Text
MRI: Gd-enhancing lesions (Number)
MRI: T2 lesion volume
cm3
MRI: T2-weighted lesions (Number)
MRI: T1-measured cerebral volume
cm3
MRI: T1-measured hypointense lesions (Number)
MRI: Date of Signature
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Month 12: MRI Multiple Sclerosis ALAIN01
NCT02419378
Alemtuzumab in Autoimmune Inflammatory
Neurodegeneration: Mechanisms of Action and
Neuroprotective Potential (ALAIN01)
https://clinicaltrials.gov/ct2/show/NCT02419378
Principal Investigator Prof. Dr. Dr. Sven Meuth, University
Hospital Muenster, Germany
Part: Month 12
All rights reserved. Please visit https://medical-data-
models.org/forms/15574
Month 12: MRI Multiple Sclerosis
ALAIN01 NCT02419378
MRI
Patient ID (derived)
MRI: Date
MRI: Pregnancy Test
Test not done (0)
Test done (1)
MRI: Pregnancy Test, Kind of test
blood (1)
urine (2)
MRI Pregnancy Test: Date
MRI Pregnancy Test: Result
negative (0)
positive (1)
MRI Pregnancy Test: Reason
no childbearing potential (0)
other (9)
MRI Pregnancy Test: Reason, Text
MRI: Gd-enhancing lesions (Number)
MRI: T2 lesion volume
cm3
MRI: T2-weighted lesions (Number)
MRI: T1-measured cerebral volume
cm3
MRI: T1-measured hypointense lesions (Number)
MRI: Date of Signature
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Month 18: MRI Multiple Sclerosis ALAIN01
NCT02419378
Alemtuzumab in Autoimmune Inflammatory
Neurodegeneration: Mechanisms of Action and
Neuroprotective Potential (ALAIN01)
https://clinicaltrials.gov/ct2/show/NCT02419378
Principal Investigator Prof. Dr. Dr. Sven Meuth, University
Hospital Muenster, Germany
Part: Month 18
All rights reserved. Please visit https://medical-data-
models.org/forms/15575
Month 18: MRI Multiple Sclerosis
ALAIN01 NCT02419378
MRI
Patient ID (derived)
MRI: Date
MRI: Pregnancy Test
Test not done (0)
Test done (1)
MRI: Pregnancy Test, Kind of test
blood (1)
urine (2)
MRI Pregnancy Test: Date
MRI Pregnancy Test: Result
negative (0)
positive (1)
MRI Pregnancy Test: Reason
no childbearing potential (0)
other (9)
MRI Pregnancy Test: Reason, Text
MRI: Gd-enhancing lesions (Number)
MRI: T2 lesion volume
cm3
MRI: T2-weighted lesions (Number)
MRI: T1-measured cerebral volume
cm3
MRI: T1-measured hypointense lesions (Number)
MRI: Date of Signature
1 / 1
Month 24: MRI Multiple Sclerosis ALAIN01
NCT02419378
Alemtuzumab in Autoimmune Inflammatory
Neurodegeneration: Mechanisms of Action and
Neuroprotective Potential (ALAIN01)
https://clinicaltrials.gov/ct2/show/NCT02419378
Principal Investigator Prof. Dr. Dr. Sven Meuth, University
Hospital Muenster, Germany
Part: Month 24
All rights reserved. Please visit https://medical-data-
models.org/forms/15576
Month 24: MRI Multiple Sclerosis
ALAIN01 NCT02419378
MRI
Patient ID (derived)
MRI: Date
MRI: Pregnancy Test
Test not done (0)
Test done (1)
MRI: Pregnancy Test, Kind of test
blood (1)
urine (2)
MRI Pregnancy Test: Date
MRI Pregnancy Test: Result
negative (0)
positive (1)
MRI Pregnancy Test: Reason
no childbearing potential (0)
other (9)
MRI Pregnancy Test: Reason, Text
MRI: Gd-enhancing lesions (Number)
MRI: T2 lesion volume
cm3
MRI: T2-weighted lesions (Number)
MRI: T1-measured cerebral volume
cm3
MRI: T1-measured hypointense lesions (Number)
MRI: Date of Signature
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Month 30: MRI Multiple Sclerosis ALAIN01
NCT02419378
Alemtuzumab in Autoimmune Inflammatory
Neurodegeneration: Mechanisms of Action and
Neuroprotective Potential (ALAIN01)
https://clinicaltrials.gov/ct2/show/NCT02419378
Principal Investigator Prof. Dr. Dr. Sven Meuth, University
Hospital Muenster, Germany
Part: Month 30
All rights reserved. Please visit https://medical-data-
models.org/forms/15577
Month 30: MRI Multiple Sclerosis
ALAIN01 NCT02419378
MRI
Patient ID (derived)
MRI: Date
MRI: Pregnancy Test
Test not done (0)
Test done (1)
MRI: Pregnancy Test, Kind of test
blood (1)
urine (2)
MRI Pregnancy Test: Date
MRI Pregnancy Test: Result
negative (0)
positive (1)
MRI Pregnancy Test: Reason
no childbearing potential (0)
other (9)
MRI Pregnancy Test: Reason, Text
MRI: Gd-enhancing lesions (Number)
MRI: T2 lesion volume
cm3
MRI: T2-weighted lesions (Number)
MRI: T1-measured cerebral volume
cm3
MRI: T1-measured hypointense lesions (Number)
MRI: Date of Signature
1 / 1
Month 36: MRI Multiple Sclerosis ALAIN01
NCT02419378
Alemtuzumab in Autoimmune Inflammatory
Neurodegeneration: Mechanisms of Action and
Neuroprotective Potential (ALAIN01)
https://clinicaltrials.gov/ct2/show/NCT02419378
Principal Investigator Prof. Dr. Dr. Sven Meuth, University
Hospital Muenster, Germany
Part: Month 36
All rights reserved. Please visit https://medical-data-
models.org/forms/15578
Month 36: MRI Multiple Sclerosis
ALAIN01 NCT02419378
MRI
Patient ID (derived)
MRI: Date
MRI: Pregnancy Test
Test not done (0)
Test done (1)
MRI: Pregnancy Test, Kind of test
blood (1)
urine (2)
MRI Pregnancy Test: Date
MRI Pregnancy Test: Result
negative (0)
positive (1)
MRI Pregnancy Test: Reason
no childbearing potential (0)
other (9)
MRI Pregnancy Test: Reason, Text
MRI: Gd-enhancing lesions (Number)
MRI: T2 lesion volume
cm3
MRI: T2-weighted lesions (Number)
MRI: T1-measured cerebral volume
cm3
MRI: T1-measured hypointense lesions (Number)
MRI: Date of Signature
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Discontinuation Visit: MRI Multiple Sclerosis
ALAIN01 NCT02419378
Alemtuzumab in Autoimmune Inflammatory
Neurodegeneration: Mechanisms of Action and
Neuroprotective Potential (ALAIN01)
https://clinicaltrials.gov/ct2/show/NCT02419378
Principal Investigator Prof. Dr. Dr. Sven Meuth, University
Hospital Muenster, Germany
Part: Discontinuation Visit
All rights reserved. Please visit https://medical-data-
models.org/forms/15579
Discontinuation Visit: MRI Multiple
Sclerosis ALAIN01 NCT02419378
MRI
Patient ID (derived)
MRI: Date
MRI: Pregnancy Test
Test not done (0)
Test done (1)
MRI: Pregnancy Test, Kind of test
blood (1)
urine (2)
MRI Pregnancy Test: Date
MRI Pregnancy Test: Result
negative (0)
positive (1)
MRI Pregnancy Test: Reason
no childbearing potential (0)
other (9)
MRI Pregnancy Test: Reason, Text
MRI: Gd-enhancing lesions (Number)
MRI: T2 lesion volume
cm3
MRI: T2-weighted lesions (Number)
MRI: T1-measured cerebral volume
cm3
MRI: T1-measured hypointense lesions (Number)
MRI: Date of Signature
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ToFingo Screening V1 Adverse Event
NCT02325440
Principal Investigator: Luisa Klotz Collaborator: Novartis
Information provided by (Responsible Party):University
Hospital Muenster -Study to Assess Immune Function and
MRI Disease Activity in RRMS Patients When Switching
From Natalizumab to Gilenya (ToFingo2) Purpose A trial in
patients with relapsing remitting multiple sclerosis (RRMS)
Main objectives: •To evaluate changes in the reconstitution
of immune surveillance over time upon switching from
natalizumab to fingolimod assessed by a change in the
expression of CD49d. •To evaluate changes in the
migratory capacity of immune cells/peripheral blood
mononuclear cells (PBMCs) upon switching from
natalizumab to fingolimod in an in-vitro model of the blood-
brain-barrier (BBB). •To evaluate changes in paraclinical
disease activity over time upon switching from natalizumab
to fingolimod assessed by MRI (changes in Gd+, T2w
lesions and DTI). •To evaluate changes in T1w / FLAIR
lesions upon switching from natalizumab to fingolimod. For
further Information please visit
https://clinicaltrials.gov/ct2/show/NCT02325440
All rights reserved. Please visit https://medical-data-
models.org/forms/15580
ToFingo Screening V1 Adverse
Event NCT02325440
Adverse Event
Adverse Event
AE Start date
AE meets definition of SAE
Yes
No
SAE-ID
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ToFingo Screening V1 Study relevant
assessments NCT02325440
Principal Investigator: Luisa Klotz Collaborator: Novartis
Information provided by (Responsible Party):University
Hospital Muenster -Study to Assess Immune Function and
MRI Disease Activity in RRMS Patients When Switching
From Natalizumab to Gilenya (ToFingo2) Purpose A trial in
patients with relapsing remitting multiple sclerosis (RRMS)
Main objectives: •To evaluate changes in the reconstitution
of immune surveillance over time upon switching from
natalizumab to fingolimod assessed by a change in the
expression of CD49d. •To evaluate changes in the
migratory capacity of immune cells/peripheral blood
mononuclear cells (PBMCs) upon switching from
natalizumab to fingolimod in an in-vitro model of the blood-
brain-barrier (BBB). •To evaluate changes in paraclinical
disease activity over time upon switching from natalizumab
to fingolimod assessed by MRI (changes in Gd+, T2w
lesions and DTI). •To evaluate changes in T1w / FLAIR
lesions upon switching from natalizumab to fingolimod. For
further Information please visit
https://clinicaltrials.gov/ct2/show/NCT02325440
All rights reserved. Please visit https://medical-data-
models.org/forms/15581
ToFingo Screening V1 Study relevant
assessments NCT02325440
Study relevant assessments
Pregnancy test; Serum
U/L
Peripheral blood taken
Yes
No
Date of collection
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Eligibility Multiple Myeloma NCT02362165
CyBorD vs. PAD in the Treatment of Newly Diagnosed
Multiple Myeloma; ODM derived from:
https://clinicaltrials.gov/show/NCT02362165
All rights reserved. Please visit https://medical-data-
models.org/forms/15583
Eligibility Multiple Myeloma
NCT02362165
Inclusion Criteria
newly diagnosis of multiple myeloma*
Yes
No
eastern cooperative oncology group (ecog) status
0-3,*
Yes
No
estimated survival time > 3 months*
Yes
No
acceptable liver function (bilirubin＜2.5×uln,
alanine transaminase (alt)      or aspartate
aminotransferase (ast)＜2.5×uln)*
Yes
No
no history of other malignancies*
Yes
No
no previous treatments including chemotherapy,
radiotherapy, targeted therapy or stem cell
transplantation*
Yes
No
no other serious diseases which conflict with the
treatment in the present trial*
Yes
No
no concurrent treatments that conflict with the
treatments in the present trial*
Yes
No
voluntary participation and signed the informed
consent.*
Yes
No
Exclusion Criteria
the patients had the conditions below: clinically
significant ventricular tachycardia (vt), atrial
fibrillation (af), heart block, myocardial infarction
(mi), congestive heart failure (chf), symptomatic
1 / 2
coronary artery heart disease requiring
medication;*
Yes
No
the patients participated in other clinical trials
within the 30 days before enrollment or who are
participating in other clinical studies*
Yes
No
the patients with neuropathy*
Yes
No
the patients with mentally ill / unable to obtain
informed consent*
Yes
No
the patients with drug addiction, alcohol abuse
which affects the long-term evaluation of test
results*
Yes
No
the patients in pregnancy, lactation and women of
childbearing age who do not want to take
contraceptive measures subjects*
Yes
No
the patients with a history of allergy to test drug*
Yes
No
the patients not suitable to participate in the
investigator judged by researchers.*
Yes
No
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Eligibility Multiple Myeloma NCT02362165
Eligibility Multiple Sclerosis NCT02283671
Treatment of Multiple Sclerosis and Neuromyelitis Optica
With Regulatory Dendritic Cell: Clinical Trial Phase 1 B;
ODM derived from:
https://clinicaltrials.gov/show/NCT02283671
All rights reserved. Please visit https://medical-data-
models.org/forms/15584
Eligibility Multiple Sclerosis
NCT02283671
Inclusion Criteria
patients with multiple sclerosis or neuromyelitis
optica*
Yes
No
diagnosed more than a year before inclusion*
Yes
No
expanded disability status scale between 3.0 and
8.5*
Yes
No
all subtypes of multiple sclerosis or neuromyelitis
optica*
Yes
No
multiple sclerosis patients who have previously
been offered therapeutic alternatives available in
indications and either decline or that after
receiving treatment for at least 6 months have
had an outbreak or an increase of at least 1 point
on the expanded disability status scale (edss)
(non-responders) or who have not tolerated
treatment*
Yes
No
patients with neuromyelitis optica (nmo) in stable
immunomodulatory treatment in the past 6
months or without treatment because they are not
candidates to receive it*
Yes
No
Exclusion Criteria
corticosteroid treatment in the last 30 days*
Yes
No
presence of an outbreak in the last month*
Yes
No
inability to perform brain magnetic resonance
imaging (with paramagnetic contrast)*
Yes
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No
serious systemic diseases, including hepatitis b
virus, hepatitis c virus, and human
immunodeficiency virus. uncontrolled
hypertension, insulin-dependent diabetes
mellitus, heart disease or kidney failure or severe
respiratory*
Yes
No
personal history of cancer or family history of
known hereditary cancer*
Yes
No
patient participating in other experimental study
in the last 3 months*
Yes
No
women childbearing-aged that do not use
effective contraceptive methods*
Yes
No
pregnant or breastfeeding women*
Yes
No
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Eligibility Multiple Sclerosis NCT02283671
Eligibility Multiple Sclerosis NCT02340754
Mindfulness-based Stress Reduction for Multiple Sclerosis;
ODM derived from:
https://clinicaltrials.gov/show/NCT02340754
All rights reserved. Please visit https://medical-data-
models.org/forms/15587
Eligibility Multiple Sclerosis
NCT02340754
Inclusion Criteria
men and women 18 years of age or older*
Yes
No
definite relapsing remitting, secondary
progressive, or primary progressive ms by
revised mcdonald criteria;*
Yes
No
expanded disability severity scale ≤ 8 at
baseline;*
Yes
No
stable on ms disease modifying, anxiolytic, or
antidepressant medications for three months prior
to baseline visit;*
Yes
No
mild to moderate stress defined by a score of ≥
10 on the perceived stress scale at screening;*
Yes
No
ability to read and write in english;*
Yes
No
willingness to provide informed consent and
comply with study activities, including weekly
mbsr sessions and daily practice or weekly
education control classes.*
Yes
No
Exclusion Criteria
mbsr or cognitive behavioral therapy training
within the last 5 years;*
Yes
No
current regular meditation or yoga practice
(weekly or more often);*
Yes
No
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ms exacerbation within 30 days of baseline visit;*
Yes
No
mini-mental status examination (mmse) score of
≤ 26 at screening visit;*
Yes
No
active suicidal ideation (beck depression
inventory) at screening visit;*
Yes
No
reported or medically recorded diagnoses of
current serious psychological disorders other
than depression and anxiety;*
Yes
No
other current life-threatening or severely disabling
physical disorders;*
Yes
No
positive pregnancy urine test at baseline and
women planning pregnancy during the study
period (contraception not required);*
Yes
No
cancer, other than basal or squamous skin
cancers; or*
Yes
No
inability or unwillingness of individual or legal
guardian/representative to give written informed
consent.*
Yes
No
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Eligibility Multiple Sclerosis NCT02340754
Eligibility Multiple Sclerosis NCT02365259
Phototherapy in Persons With Multiple Sclerosis; ODM
derived from: https://clinicaltrials.gov/show/NCT02365259
All rights reserved. Please visit https://medical-data-
models.org/forms/15588
Eligibility Multiple Sclerosis
NCT02365259
Inclusion Criteria
female with multiple sclerosis*
Yes
No
Exclusion Criteria
inability to stand still in a stabilized fashion
without risk of falling for up to 6 minutes*
Yes
No
known medical history of calcium disorder or
knowledge of high calcium levels*
Yes
No
known medical history of hyper-parathyroidism*
Yes
No
current supplementation with oral vitamin d*
Yes
No
known allergy to vitamin d*
Yes
No
history of cancer of any type including but not
limited to skin cancer*
Yes
No
obesity defined as bmi > 30*
Yes
No
known history of fat malabsorption conditions
(i.e., steatorrhea)*
Yes
No
current use of anti-epileptic medication*
Yes
No
current use of glucocorticoids*
Yes
No
fitzpatrick skin types i and vi using the fitzpatrick
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skin type analysis*
Yes
No
recent use of tanning facilities*
Yes
No
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Eligibility Multiple Sclerosis NCT02365259
Eligibility Multiple Sclerosis NCT02369224
Multicenter Validation of The Evergreen Myometric Strength
Test for Lower Extremities (EMST-LE) in Multiple Sclerosis:
Protocol for Strength Testing and Reliability Characteristics;
ODM derived from:
https://clinicaltrials.gov/show/NCT02369224
All rights reserved. Please visit https://medical-data-
models.org/forms/15589
Eligibility Multiple Sclerosis
NCT02369224
Inclusion Criteria
stable patients with clinically definite ms, aged
≥18, edss of 0-7.5*
Yes
No
clinical stability defined as no ms exacerbation or
change in disease modifying therapy for 30 days
prior to screening.*
Yes
No
edss as described above*
Yes
No
Exclusion Criteria
contraindications to strength testing:*
Yes
No
inflammatory myopathy*
Yes
No
endocarditis,  pericarditis or other unstable heart
disease*
Yes
No
cardiac surgery or myocardial infarction in the last
3 months*
Yes
No
decompensated congestive heart failure*
Yes
No
severe aortic stenosis*
Yes
No
severe pulmonary hypertension*
Yes
No
pulmonary embolus or infarction in the last 6
months*
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Yes
No
uncontrolled hypertension by history or by
screening or baseline diastolic blood pressure
>170, or systolic blood pressure > 105)*
Yes
No
marfan's syndrome*
Yes
No
pacemaker or cardiac defibrillator*
Yes
No
concomitant neurodegenerative neurological
disease, such as als or parkinson disease or
hemiplegic stroke*
Yes
No
females who are pregnant*
Yes
No
cognitive deficits that would interfere with the
subject's ability to give informed consent or
perform study testing.*
Yes
No
anticipated treatment with novantrone
(mitoxantrone) or cancer chemotherapy or
surgical procedure during the study period*
Yes
No
painful orthopedic condition affecting the lower
extremities*
Yes
No
any other serious and/or unstable medical
condition*
Yes
No
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Eligibility Multiple Sclerosis NCT02369224
Eligibility Multiple Sclerosis NCT02427997
VR-treadmill Combined Intervention for Enhancing Mobility
and Cognitive Function in Patients With Multiple Sclerosis;
ODM derived from:
https://clinicaltrials.gov/show/NCT02427997
All rights reserved. Please visit https://medical-data-
models.org/forms/15590
Eligibility Multiple Sclerosis
NCT02427997
Inclusion Criteria
they are between 18-60 years of age.*
Yes
No
they have a confirmed diagnosis of ms (any type,
e.g., rr, or sp, pp ).*
Yes
No
they have a score of 2 or higher on the expanded
disability status scale (edss)*
Yes
No
they are free from dementia as determined using
the montreal cognitive assessment battery (>21)
and dsm iv criteria.*
Yes
No
they can walk on the treadmill without partial
body weight support harness for 5 minutes at
their preferred walking speed; this is set as the
smallest bout length at the start of training.*
Yes
No
they have no history of epileptic seizures.*
Yes
No
they have no ms exacerbation within the
preceding 4 weeks, as determined by interview
and medical notes review.*
Yes
No
they have stable ms disease treatments (e.g., last
intake of steroids occurred at least 50 days
before the enrolment, ms-specific drugs stable
from at least 3 months, symptomatic drugs stable
from at least 1 month before the enrolment).*
Yes
No
they have adequate hearing (as evaluated by the
whisper test and adequate vision capabilities (as
measured using a snellen chart, 6.20 cut-off).*
Yes
No
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they are willing to commit to treadmill training
program week and participate in all of the
assessments.*
Yes
No
they provide informed written consent and are
willing to be randomized to any of the 2 study
arms.*
Yes
No
Exclusion Criteria
they cannot follow safety or training instructions.*
Yes
No
they have another neurological disorder, unstable
cardiovascular disease, diabetes, lower limb
arthritis, acute lower back or lower extremity pain,
peripheral neuropathy, rheumatic or severe
orthopaedic problems that may interfere with
walking, or have diagnosed psychiatric
problems.*
Yes
No
they are pregnant.*
Yes
No
they are undergoing any experimental drug or
other kind of therapy.*
Yes
No
their medication regime is likely to change during
the course of the study.*
Yes
No
they are already participating in an intensive
exercise program. the use of walking aids will not
exclude participation.*
Yes
No
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Eligibility Multiple Sclerosis NCT02427997
Eligibility Prostate Cancer NCT00978718
Selenium in Preventing Prostate Cancer; ODM derived
from: https://clinicaltrials.gov/show/NCT00978718
All rights reserved. Please visit https://medical-data-
models.org/forms/15591
Eligibility Prostate Cancer
NCT00978718
Criteria
clinical indicators consistent with the community
standards of medical care that would justify a
biopsy of the prostate for the diagnosis of cancer,
including ≥ 1 of the following:*
Yes
No
psa level above the absolute value of 4 ng/ml or
above a published age-ethnic adjusted psa level
appropriate for the community*
Yes
No
rising psa that should represent a clinically
significant psa velocity (e.g., an estimated annual
change in the psa velocity ≥ 0.75 ng/ml)*
Yes
No
abnormal digital rectal examination of the
prostate that identifies a clinically significant
change in the prostate (e.g., a prostate nodule or
a change in the firmness of the prostate)*
Yes
No
documentation of the clinical assessment that
justified the prostate biopsy that allows
classification of the patient to high-risk groups*
Yes
No
prostate biopsy negative for cancer within the
past 12 months*
Yes
No
prostate biopsy negative for high-grade prostatic
intraepithelial neoplasia (pin)*
Yes
No
pin allowed provided it is grade 1*
Yes
No
creatinine < 2 times upper limit of normal (uln)*
Yes
No
bilirubin < 2 times uln*
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Yes
No
sgot and sgpt < 2 times uln*
Yes
No
alkaline phosphatase < 2 times uln*
Yes
No
no history of a prior malignancy except for the
following:*
Yes
No
adequately treated basal cell or squamous cell
carcinoma*
Yes
No
adequately treated (i.e., complete surgical
removal with negative margins) stage i cancer
from which the patient is currently in complete
remission*
Yes
No
any other cancer from which the patient has been
disease-free for 5 years*
Yes
No
no prior systemic chemotherapy or radiotherapy*
Yes
No
at least 90 days since prior and no other
concurrent selenium > 55 μg/day as a dietary
supplement (including multivitamin supplements)*
Yes
No
more than 30 days since prior and no concurrent
participation in any other clinical trial involving a
medical, surgical, nutritional, or life-style
intervention (e.g., dietary modifications,
exercise)*
Yes
No
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Eligibility Prostate Cancer NCT00978718
Eligibility Breast Neoplasms NCT00046514
ABI-007 in Taxol Resistant Patients With Metastatic Breast
Cancer; ODM derived from:
https://clinicaltrials.gov/show/NCT00046514
All rights reserved. Please visit https://medical-data-
models.org/forms/15592
Eligibility Breast Neoplasms
NCT00046514
Criteria
if female, non-pregnant and not lactating, with a
negative serum pregnancy test, and either not of
child-bearing potential or practicing an approved
contraception method*
Yes
No
eighteen years of age or older*
Yes
No
karnofsky perfomance status of 70% or 0-2 swog
performance status*
Yes
No
no other malignancy, except non-melanoma skin
cancer, cin, or in-situ cervical cancer*
Yes
No
measurable disease*
Yes
No
suitable candidate for treatment with paclitaxel*
Yes
No
previously treated with taxol weekly or every
three weeks, including adjuvant therapy, for
metastatic breast cancer and relapsed within 12
months*
Yes
No
if, at baseline, patient has absolute neutrophil
count of at least 1500 cells/mm3, platelet count of
at least 100,000 cells/mm3,and hemoglobin of at
least 9 g/dl*
Yes
No
if, at baseline, patient has ast and alt of less than
or equal to 2.5 x the upper limit of normal range;
a total bilirubin less than or equal to 1.5 mg/dl;
creatinine levels less than or equal to 2 mg/dl;
and alkaline phosphatase levels less than or
equal to 5 x the upper limit of normal range
(unless there are bone but not liver metastases)*
Yes
No
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patient has an expected survival of at least 12
weeks*
Yes
No
patient or his/her representative has signed an
informed consent statement*
Yes
No
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Eligibility Breast Neoplasms NCT00046514
ABI-007 in Taxol Resistant Patients With Metastatic Breast
Cancer; ODM derived from:
https://clinicaltrials.gov/show/NCT00046514
All rights reserved. Please visit https://medical-data-
models.org/forms/15593
Eligibility Breast Neoplasms
NCT00046514
Criteria
if female, non-pregnant and not lactating, with a
negative serum pregnancy test, and either not of
child-bearing potential or practicing an approved
contraception method*
Yes
No
eighteen years of age or older*
Yes
No
karnofsky perfomance status of 70% or 0-2 swog
performance status*
Yes
No
no other malignancy, except non-melanoma skin
cancer, cin, or in-situ cervical cancer*
Yes
No
measurable disease*
Yes
No
suitable candidate for treatment with paclitaxel*
Yes
No
previously treated with taxol weekly or every
three weeks, including adjuvant therapy, for
metastatic breast cancer and relapsed within 12
months*
Yes
No
if, at baseline, patient has absolute neutrophil
count of at least 1500 cells/mm3, platelet count of
at least 100,000 cells/mm3,and hemoglobin of at
least 9 g/dl*
Yes
No
if, at baseline, patient has ast and alt of less than
or equal to 2.5 x the upper limit of normal range;
a total bilirubin less than or equal to 1.5 mg/dl;
creatinine levels less than or equal to 2 mg/dl;
and alkaline phosphatase levels less than or
equal to 5 x the upper limit of normal range
(unless there are bone but not liver metastases)*
Yes
No
1 / 2
patient has an expected survival of at least 12
weeks*
Yes
No
patient or his/her representative has signed an
informed consent statement*
Yes
No
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Eligibility Breast Neoplasms NCT00046514
Eligibility Multiple Sclerosis NCT02459821
Effects of GE-O System on Gait Impairments in Multiple
Sclerosis Subjects; ODM derived from:
https://clinicaltrials.gov/show/NCT02459821
All rights reserved. Please visit https://medical-data-
models.org/forms/15594
Eligibility Multiple Sclerosis
NCT02459821
Inclusion Criteria
expanded disability status scale (edss) between 3
and 6.5;*
Yes
No
mini mental examination state >24;*
Yes
No
absence of cognitive impairment;*
Yes
No
age <75 years;*
Yes
No
absence of heart failure;*
Yes
No
ability to sit without trunk support;*
Yes
No
ability to stand for at least 10 seconds with
support;*
Yes
No
absence of concurrent neurological or
orthopaedic diseases that interfere with
deambulation;*
Yes
No
Exclusion Criteria
those patients with disease reccurence that
worsens significantly during the 8 weeks before
recruitment;*
Yes
No
changes in pharmacological therapy that could
modified disease course in the previous three
months;*
Yes
No
changes in pharmacological therapy for fatigue
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treatment in the previous three months;*
Yes
No
performance of any type of rehabilitation
treatment in the month prior to recruitment.*
Yes
No
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Eligibility Kidney Disease NCT01068080
Involvement of FFA Metabolism and Insulin Resistance in
Cardiac Death; ODM derived from:
https://clinicaltrials.gov/show/NCT01068080
All rights reserved. Please visit https://medical-data-
models.org/forms/15595
Eligibility Kidney Disease
NCT01068080
Inclusion Criteria
hemodialysis patients who had normal coronary
arteries identified by coronary angiography and
underwent the examination of bmipp spect and
measurement of homa-ir as a parameter of
insulin resistance.*
Yes
No
Exclusion Criteria
patients who had not done bmipp spect within
one month of coronary angiography*
Yes
No
congestive heart failure (nyha 3-4)*
Yes
No
significant valvular heart disease*
Yes
No
pacemaker*
Yes
No
idiopathic cardiomyopathy*
Yes
No
malignancy*
Yes
No
patients who had not measured homa-ir within
one month after coronary angiography*
Yes
No
patients receiving extrinsic insulin or medication
of sulfonylurea*
Yes
No
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Eligibility Non-small Cell Lung Cancer
NCT00050674
Docetaxel and Gemcitabine With Filgrastim-SD/01 Support
in Patients With Advanced Non-Small Cell Lung
Carcinoma; ODM derived from:
https://clinicaltrials.gov/show/NCT00050674
All rights reserved. Please visit https://medical-data-
models.org/forms/15596
Eligibility Non-small Cell Lung
Cancer NCT00050674
Criteria
subjects must have stage iv or iiib nsclc*
Yes
No
0-1 prior treatment regimens of chemotherapy*
Yes
No
subjects must have bi-dimensionally measurable
disease or evaluable disease by physical exam or
radiological studies*
Yes
No
age > 18 years*
Yes
No
1st line - ecog 0-2*
Yes
No
2nd line - ecog 0-1*
Yes
No
absolute neutrophil count > or = 1.5 x 10 to the
9th power/l*
Yes
No
platelet count > or = 100 x 10 to the 9th power/l*
Yes
No
adequate renal function with screening serum
creatinine < or = 2.0 mg/dl*
Yes
No
adequate ast and alt no more than 1.5 x the
upper limit of normal and serum bilirubin < or =
upper limit of normal*
Yes
No
subjects must be at least two weeks from prior
major thoracic or abdominal surgery and at least
two weeks from completion of radiation therapy,
and recovered from all toxicities associated with
these treatments*
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Yes
No
negative hcg by urine or blood test in subject of
child-bearing potential*
Yes
No
life expectancy > 2 months*
Yes
No
ethical - before any study specific procedure is
done or before study medication is administered,
the subject or legally acceptable representative
must give informed consent for participation in
the study*
Yes
No
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Eligibility Parkinson Disease NCT00200525
Continued Efficacy and Safety of Apomorphine in Patients
With Late-Stage Parkinsons Disease; ODM derived from:
https://clinicaltrials.gov/show/NCT00200525
All rights reserved. Please visit https://medical-data-
models.org/forms/15597
Eligibility Parkinson Disease
NCT00200525
Inclusion Criteria
adults of any age ≥ 18*
Yes
No
men and non-pregnant, non-lactating women*
Yes
No
women of childbearing potential had a negative
serum (beta hcg) pre-study pregnancy test prior
to randomization*
Yes
No
women of childbearing potential used an
acceptable form of contraception*
Yes
No
patients with a clinical diagnosis of idiopathic
parkinson's disease, i.e., not induced by drugs or
caused by other diseases;*
Yes
No
patients classified as stage (ii-iv) of the hoehn
and yahr scale for staging the severity of
parkinson's disease*
Yes
No
the patient must have been on an optimally
maximized oral therapy regimen.  optimized oral
anti-parkinson medications must have included
levodopa/carbidopa inhibitors, in either immediate
or delayed release forms, plus at least one direct
acting oral dopamine agonist for at least 30 days
prior to randomization*
Yes
No
patients must have been receiving apomorphine
subcutaneous injections for rescue therapy for off
events for at least three months*
Yes
No
the minimum apomorphine baseline-dosing
requirement was an average of at least 2 doses
per day over the week prior to enrollment.*
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Yes
No
patients participating in protocol apo401, an
open-label study primarily designed to collect
safety data, were eligible for participation in this
trial without termination of participation in
apo401*
Yes
No
Exclusion Criteria
patients under medical therapy for clinically
significant psychoses or dementia not related to
ingestion of anti-parkinson medications.  (patients
with hallucinations or other central adverse
reactions associated solely with anti-parkinson
medications were not excluded.)*
Yes
No
patients with a history of drug or alcohol
dependency within one year prior to study
enrollment*
Yes
No
patients with unstable and clinically significant
disease of cardiovascular (including orthostatic
hypotension), hematologic (including coombs'
positive hemolytic anemia), hepatic, renal,
metabolic, respiratory, gastrointestinal or
endocrinological systems or neoplasm within the
three months before the start of the study.*
Yes
No
patinets with a history of true allergy to morphine
or its derivatives (including apomorphine), sulfur,
sulfur containing medications, sulfites, sulfates,
tigan(r)(trimethobenzamide).*
Yes
No
patients treated with experimental agents (other
than apomorphine intermittent subcutaneous
injections) within 30 days before study entry.
patients with participation in mylan-sponsored
study apo202 were excluded from participation in
this study.*
Yes
No
patients whose apomorphine regimen was
characterized by administration methods other
than intermittent subcutaneous injection.*
Yes
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No
patients who could not or would not sign an
informed consent form.*
Yes
No
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Eligibility Prostate Cancer NCT00779402
Provenge (TM) for the Treatment of Hormone Sensitive
Prostate Cancer; ODM derived from:
https://clinicaltrials.gov/show/NCT00779402
All rights reserved. Please visit https://medical-data-
models.org/forms/15598
Eligibility Prostate Cancer
NCT00779402
Criteria
histologic diagnosis of adenocarcinoma of the
prostate;*
Yes
No
at least 3 months but no more than 8 years prior
to study entry, undergone a radical prostatectomy
for stage t1b – t3c, n0-n1, m0 disease, with or
without subsequent adjuvant or salvage radiation
therapy.  patients who experience their first psa
recurrence within 2 years post completion of
initial therapy of curative intent are eligible without
consideration of the gleason score of the tumor
specimen.*  patients who experience their first
psa relapse between 2 and 8 years post
completion of initial therapy of curative intent are
eligible only if the gleason score of the tumor
specimen was > 7; (* for patients who received
adjuvant radiation, the date of the final dose of
radiotherapy is used to mark the date of
completion of therapy of curative intent.  for
patients who received salvage radiation for post-
operative psa recurrence but no adjuvant
radiation, the date of surgery marks the date of
completion of therapy of curative intent.)*
Yes
No
therapeutic psa response to primary therapy
below 0.4 ng/ml;*
Yes
No
tumor specimen positive for pap, the vaccine’s
target.   immunohistological staining of a
specimen from the surgically excised tumor for
expression of pap is conducted by impath, and
may be completed even after lh-rh-analogue
placement, as long as a positive (+) result is
confirmed prior to randomization (week 0).  if a
slide of the tumor cannot be obtained from the
pathology archive, a chart record from a pre-
surgery blood sample showing serum pap
elevated above the upper limit of the local
reference range may serve as a proxy.*
Yes
No
experienced psa relapse while not currently
receiving androgen ablation therapy. specifically,
on record must be 2 psa values separated by at
least 3 months, both in the detectable range (>0.5
1 / 3
ng/ml), showing an increase of at least 0.3 ng/ml
between the 2 measurements.  the first of these 2
psa values must rise above a previously recorded
post-operative nadir value (which may be an
undetectable psa).   in patients who received
androgen ablation for a previous psa relapse, psa
must have increased to a level at least 25%
above the nadir observed while on this therapy
and to an absolute level of at least 3 ng/ml;*
Yes
No
prior hormone treatment for an earlier episode of
psa relapse is neither an exclusion nor an
inclusion requirement for study entry.  patients
who have previously been treated with adjuvant
or salvage radiation following radical
prostatectomy, or with either lh-rh-analogue (i.e.,
leuprolide or goserelin acetate) or non-steroidal
anti-androgen therapy (i.e., bicalutamide 150
mg/day) for a prior psa relapse, may enter the
study provided:*
Yes
No
post-prostatectomy psa was never > 20 ng/ml;*
Yes
No
psa was not rising while receiving adequately
dosed hormonal therapy;*
Yes
No
for any hormonal therapy received, the last
effective day of androgen deprivation was at least
6 months prior to study entry;*
Yes
No
confirmed m0; a bone scan with no evidence of
osseous metastasis must be on record, dated
within 6 months prior to entry into the study;*
Yes
No
estimated life-expectancy, inclusive consideration
of co-morbidities, of at least 1 year;*
Yes
No
ecog performance status of 0 or 1;*
Yes
No
ability to understand the trial procedures and
requirements;*
Yes
No
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age >18 and < 80 years;*
Yes
No
ability to understand, and willingness to sign,
informed consent.*
Yes
No
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Eligibility Multiple Sclerosis, Relapsing-
Remitting NCT02427776
A Trial for Evaluating Both Safety and Preliminary Efficacy
of a Single Infusion of Stimulated Autologous CD4+T Cells
in Patients With Relapsing- Remitting Multiple Sclerosis;
ODM derived from:
https://clinicaltrials.gov/show/NCT02427776
All rights reserved. Please visit https://medical-data-
models.org/forms/15599
Eligibility Multiple Sclerosis,
Relapsing-Remitting NCT02427776
Inclusion Criteria
males and females 18 to 50 years of age*
Yes
No
patients closely followed up for at least one year
prior to inclusion (i.e. prior to the start of the
baseline phase) if the diagnosis of the disease
was made more than one year ago, to ensure
that all possible episodes of clinical relapses
which occurred during this interval of time were
recorded and documented*
Yes
No
multiple sclerosis that meets the 2010 revised
mcdonald criteria*
Yes
No
relapsing/remitting type of multiple sclerosis
(which includes clinically isolated syndromes if
imaging shows brain lesions disseminated in
space and time)*
Yes
No
disease onset, defined as date of first symptom
suggestive for multiple sclerosis, not older than
10 years*
Yes
No
radiologically active disease defined by at least
one gadolinium-enhancing lesion on a t1-
weighted magnetic resonance imaging brain scan
performed recently (i.e. within 3 months prior to
inclusion)*
Yes
No
disease-modifying drug naïve patients or patients
with stable and adequately taken disease-
modifying therapy  (interferon β-1, glatiramer
acetate, or dimethyl fumarate) for at least six
months before inclusion (note: other disease
modifying drugs might be added at a later date,
depending on the results of current
investigations)*
Yes
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No
edss score <= 5.5*
Yes
No
positive for the hla drb1*1501 allele*
Yes
No
positive predictive test in vitro for patient's cd4+
cell reactivity to immunogenic peptide*
Yes
No
women of childbearing age must have a negative
pregnancy test and must use adequate
contraception during the treatment and follow-up
phase of the study (three pregnancy tests will be
required prior to and during the study: (1) during
the screening phase, (2) about one week prior to
leukapheresis, and (3) about one week prior to
re-infusion of autologous cells)*
Yes
No
fully informed written consent obtained*
Yes
No
Exclusion Criteria
evidence of clinical relapse and use of
intravenous or oral corticosteroids within 30 days
prior to inclusion*
Yes
No
therapeutic escalation anticipated (including
change of disease modifying drug), other than
the cell-based immunotherapy of this study, within
the next six months*
Yes
No
significant coexisting systemic disease including
renal insufficiency*
Yes
No
positive serology for hepatitis b and c, aids and
syphilis*
Yes
No
participation in another interventional clinical
study, currently or during the past three months*
Yes
No
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Eligibility Prostate Cancer NCT00819247
The Efficacy and Safety of FE 200486 in Treatment of
Patients Suffering From Prostate Cancer; ODM derived
from: https://clinicaltrials.gov/show/NCT00819247
All rights reserved. Please visit https://medical-data-
models.org/forms/15600
Eligibility Prostate Cancer
NCT00819247
Inclusion Criteria
signed informed consent before any trial related
activity*
Yes
No
proven prostate cancer with a need for endocrine
treatment*
Yes
No
testosterone level within the normal range for the
age*
Yes
No
Exclusion Criteria
previous or current hormonal treatment of
prostate cancer*
Yes
No
candidate for prostatectomy or radiotherapy*
Yes
No
history of severe asthma, anaphylactic reactions
or quincke's oedema*
Yes
No
hypersensitivity towards any component of
fe200486*
Yes
No
cancer disease within the last ten years except
for prostate cancer and some skin cancers*
Yes
No
presenting with significant neurological,
gastrointestinal, renal, hepatic, cardiovascular,
psychological, pulmonary, metabolic, endocrine,
haematological, dermatological or infectious
disorder. in addition any other condition such as
excessive alcohol or drug abuse that may
interfere with trial participation or influence the
conclusion of the trial as judged by the
investigator*
Yes
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No
mental incapacity or language barrier*
Yes
No
having received an investigational product within
the last 12 weeks preceding the trial*
Yes
No
previous participation in this trial*
Yes
No
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Eligibility Prostatic Neoplasms
NCT00050687
Safety and Pharmacokinetics of Orally Administered
Gallium Maltolate in Various Refractory Malignancies; ODM
derived from: https://clinicaltrials.gov/show/NCT00050687
All rights reserved. Please visit https://medical-data-
models.org/forms/15601
Eligibility Prostatic Neoplasms
NCT00050687
Inclusion Criteria
patients with hormone refractory prostate cancer,
refractory multiple myeloma, refractory bladder
cancer, or malignant lymphoma;*
Yes
No
life expectancy of ≥6 months,*
Yes
No
zubrod performance status of ≤2,*
Yes
No
adequate bone marrow function, renal function,
liver function and pulmonary function;*
Yes
No
age ≥ 18 years;*
Yes
No
willing and able to give informed consent; and*
Yes
No
effective contraceptive use or non child-bearing
potential.*
Yes
No
Exclusion Criteria
10% weight loss in the previous 3 months;*
Yes
No
active serious infection not controlled by
antibiotics;*
Yes
No
initiation of bisphosphonates treatment within 30
days;*
Yes
No
participation in other research study within 30
days;*
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Yes
No
uncontrolled brain metastasis,*
Yes
No
prior intrathecal chemotherapy or whole-brain
radiotherapy,*
Yes
No
inability to comply with protocol or undergo
specified tests;*
Yes
No
other active malignancy;*
Yes
No
optic neuritis, and*
Yes
No
routine use of diuretics (for initial phase of study
only).*
Yes
No
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Eligibility Leukemia NCT00038610
Study of Hyper-CVAD Plus Imatinib Mesylate for
Philadelphia-Positive Acute Lymphocytic Leukemia; ODM
derived from: https://clinicaltrials.gov/show/NCT00038610
All rights reserved. Please visit https://medical-data-
models.org/forms/15602
Eligibility Leukemia NCT00038610
Inclusion Criteria
1. diagnosis of previously untreated ph-positive
all or previously treated in cr after 1-2 courses of
therapy or failure after one course of induction
chemotherapy without imatinib mesylate.*
Yes
No
2. age > or = 15 years. those < 15 years of age
will be treated under compassionate ind.*
Yes
No
3. zubrod performance status < or = 2 (ecog
scale, appendix a).*
Yes
No
4. adequate liver function (bilirubin < or = to 3.0
mg/dl, unless considered due to tumor), and
renal function (creatinine < or = to 3.0 mg/dl,
unless considered due to tumor).*
Yes
No
5. adequate cardiac function as assessed
clinically by physical examination.*
Yes
No
6. signed informed consent.*
Yes
No
Exclusion Criteria
1. active serious infection not controlled by oral or
intravenous antibiotics.*
Yes
No
2. treatment with investigational antileukemic
agent or chemotherapy agents in the last 7 days
before study entry, unless full recovery from side-
effects has occurred or patient has rapidly
progressive disease judged life-threatening.*
Yes
No
3. active secondary malignancy other than skin
cancer (e.g. basal cell carcinoma or squamous
cell carcinoma) than in investigator's opinion will
shorten survival to less than 1 year.*
Yes
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No
4. history of grade iii/iv cardiac problems as
defined by the new york heart association
criteria.*
Yes
No
5. prior history of treatment with imatinib
mesylate.*
Yes
No
6. pregnancy or lactating in women of
childbearing potential.*
Yes
No
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Eligibility Leukemia NCT00274807
Combination Chemotherapy in Treating Patients With Newly
Diagnosed Acute Myeloid Leukemia; ODM derived from:
https://clinicaltrials.gov/show/NCT00274807
All rights reserved. Please visit https://medical-data-
models.org/forms/15603
Eligibility Leukemia NCT00274807
Criteria
diagnosis of acute myeloid leukemia*
Yes
No
previously untreated disease*
Yes
No
previous hydroxyurea and/or corticosteroids are
acceptable*
Yes
No
no preexisting history of a hematologic disorder*
Yes
No
myelodysplastic features allowed*
Yes
No
no acute leukemia secondary to previous
therapy*
Yes
No
no leukemic meningitis*
Yes
No
bilirubin < 2.0 mg/dl (unless felt to be increased
because of hepatic infiltration with leukemia)*
Yes
No
creatinine < 2.0 mg/dl*
Yes
No
pregnant or lactating patients are ineligible*
Yes
No
fertile patients must use effective contraception*
Yes
No
no history of or active congestive heart failure*
Yes
No
prior concurrent therapy: see disease
characteristics*
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Yes
No
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Eligibility Leukemia, Lymphocytic, Chronic
NCT00038883
Campath-1H and Allogeneic Blood Stem Cell
Transplantation for Lymphoid Malignancies; ODM derived
from: https://clinicaltrials.gov/show/NCT00038883
All rights reserved. Please visit https://medical-data-
models.org/forms/15604
Eligibility Leukemia, Lymphocytic,
Chronic NCT00038883
Inclusion Criteria
1. 15-65 years old*
Yes
No
2. b or t-cell lymphoid disease, not eligible for
non-myeloablative transplantation.*
Yes
No
3. patients in relapse after failing conventional
chemotherapy.*
Yes
No
4. patients with hla-identical or one-antigen
mismatched sibling, or a matched unrelated
donor.*
Yes
No
5. performance status </=2.*
Yes
No
Exclusion Criteria
1. past history of anaphylaxis following exposure
to rat or mouse derived cdr-grafted humanized
monoclonal antibodies.*
Yes
No
2. less than 4 weeks since prior chemotherapy.*
Yes
No
3. pregnancy or lactation.*
Yes
No
4. hiv or htlv-i positivity.*
Yes
No
5. serum creatinine >1.6 mg/dl or serum bilirubin
>0.2 mg/dl unless due to tumor, sgpt >/= 2 x ni*
Yes
No
6. pft-dclo<50%, cardiac ef <50% of predicted
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levels.*
Yes
No
2 / 2
Eligibility Leukemia, Lymphocytic, Chronic NCT00038883
Eligibility Major Depression NCT00286546
Testosterone and Major Depression; ODM derived from:
https://clinicaltrials.gov/show/NCT00286546
All rights reserved. Please visit https://medical-data-
models.org/forms/15605
Eligibility Major Depression
NCT00286546
Inclusion Criteria
meets dsm iv criteria for a diagnosis of major
depressive disorder as per an assessment by the
pren physician-investigator.*
Yes
No
subjects must have a hamilton depression rating
scale (ham-d-17) of at least 16.*
Yes
No
subjects must be male between the ages of 40
and 65.*
Yes
No
subjects must be judged by the investigator to be
in generally good health.*
Yes
No
body mass index (bmi) between 20 to 29 kg/m2.*
Yes
No
able and willing to give meaningful written
consent.*
Yes
No
educational level and a degree of understanding
such that they can communicate effectively with
the investigator.*
Yes
No
subjects must have had normal sexual
functioning prior to the onset of depression.*
Yes
No
Exclusion Criteria
subjects must not suffer from clinically significant
medical conditions.  examples include
neurological, cardiovascular, gastrointestinal,
hepatic, renal, haematological, respiratory or
endocrine illnesses.*
Yes
No
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recent history of drug or alcohol
abuse/dependence within the past 6 months as
defined by dsm-iv or in the opinion of the
investigator.*
Yes
No
uncorrected hypothyroidism or hyperthyroidism.*
Yes
No
current use of hormone replacement therapy.*
Yes
No
current diagnosis of schizophrenia or other
psychotic disorder (including psychotic disorder
due to general medical condition, substance-
induced psychotic disorder, psychotic disorder
not otherwise specified) as defined in the dsm-iv.*
Yes
No
current diagnosis of depressive disorder not
otherwise specified or bipolar i disorder, most
recent episode major depression mixed or manic
bipolar ii disorder as defined in the dsm-iv.*
Yes
No
electroconvulsive therapy (ect) within the 3
months prior to visit 1.*
Yes
No
not currently on any antidepressants or must
have an interval of the following prior to entry into
the study: fluoxetine-4 weeks; maois-                2
weeks*
Yes
No
all other psychotic medications and herbal
preparations with putative antidepressant
properties (e.g. paroxetine hci, other
antidepressant not specified above, st. john's
wort, kava-kava or valerian: 1 week)*
Yes
No
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Eligibility Metastases, Neoplasm
NCT00041808
Magnetic-Targeted Doxorubicin in Treating Patients With
Cancer Metastatic to the Liver; ODM derived from:
https://clinicaltrials.gov/show/NCT00041808
All rights reserved. Please visit https://medical-data-
models.org/forms/15606
Eligibility Metastases, Neoplasm
NCT00041808
Inclusion Criteria
patients with a karnofsky (or equivalent)
performance status > 60 and an expected
survival of > 2 months*
Yes
No
patients agreeing to use a medically effective
method of contraception*
Yes
No
patients able to understand and give written
informed consent*
Yes
No
the center of the tumor mass must be < or = 14
cm from the anterior or lateral abdominal wall as
determined by cross sectional imaging measured
at baseline. this is required for optimal retention
of mtc-dox by the magnetic field.  if more than
one tumor mass is present, all of the treated
tumor masses must meet this criterion*
Yes
No
Exclusion Criteria
women who are pregnant or lactating*
Yes
No
patient’s with metastatic liver cancer, or other
primary liver cancer excluding hcc, with diffuse
disease that does not have focal area(s)
conducive to local regional therapy*
Yes
No
patients with the following laboratory
abnormalities:hemoglobin < 10.0 g/dl;granulocyte
count < 1,500 per mm3;platelet count < 50,000
per mm3; lymphocyte count < 0.5 x 10 to the 9th
per l; total bilirubin >/= 3.0 mg/dl;ast or alt >/= 5x
the upper limit of normal;inr >/= 1.3; creatinine
>/= 2.0 mg/dl*
Yes
No
patients with either significant cardiovascular
disease or any other organ system dysfunction
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which, in the opinion of the investigator, would
either compromise the patient's safety or interfere
with the evaluation of the test material.  patients
with evidence of a myocardial infarction within six
(6) months prior to this trial will be excluded.*
Yes
No
patients with an indwelling cardiac pacemaker,
cerebral aneurysm clips, or any other indwelling
device or appliance that could be adversely
affected by the use of the external magnet*
Yes
No
patients at the time of study entry with a second
invasive cancer other than basal cell and
squamous cell carcinoma of the skin, or
carcinoma in situ of the cervix*
Yes
No
patients with documented evidence of
hemachromatosis or hemosiderosis*
Yes
No
patients with ct or ultrasound evidence of portal
vein invasion or thrombosis*
Yes
No
patients who have had prior anthracycline therapy
with a left ventricular ejection fraction (lvef) <50%,
as measured by either multigated radionuclide
angiography (muga) scan or echocardiogram.*
Yes
No
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Eligibility Osteoarthritis, Knee
NCT00405470
A Prospective Randomized Trial Using Roentgen
Stereophotogrammetric Analysis of the Advance Medial
Pivot Knee; ODM derived from:
https://clinicaltrials.gov/show/NCT00405470
All rights reserved. Please visit https://medical-data-
models.org/forms/15607
Eligibility Osteoarthritis, Knee
NCT00405470
Inclusion Criteria
primary osteoarthritis of the knee*
Yes
No
mono-articular disease (charnley modified type
a)*
Yes
No
Exclusion Criteria
significant co-morbidity affecting ability to
ambulate*
Yes
No
flexion contracture greater than 15°*
Yes
No
tibial subluxation greater than 10 mm on standing
ap radiograph*
Yes
No
greater than 10° of varus or 15° of valgus*
Yes
No
extension lag greater than 10°*
Yes
No
lateral or medial collateral ligament instability (>
10° varus/valgus)*
Yes
No
previous osteotomy about the knee*
Yes
No
previous arthroplasty of the knee*
Yes
No
previous patellectomy*
Yes
No
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leg length discrepancy greater than 10 mm*
Yes
No
morbid obesity (obesity that results in significant
systemic problems)*
Yes
No
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Eligibility HER2-positive Breast Cancer
NCT00436254
Vaccine Therapy With Sargramostim (GM-CSF) in Treating
Patients With Her-2 Positive Stage III-IV Breast Cancer or
Ovarian Cancer; ODM derived from:
https://clinicaltrials.gov/show/NCT00436254
All rights reserved. Please visit https://medical-data-
models.org/forms/15608
Eligibility HER2-positive Breast
Cancer NCT00436254
Inclusion Criteria
breast cancer: stage iii or stage iv breast cancer
with metastasis in remission and defined as ned
(no evidence of disease); stable or healing bone
disease by radiologic evaluation which may
include, but is not limited to, bone scan, mri, or
pet scan documented within 90 days of
enrollment to study and ned status for
extraskeletal metastasis*
Yes
No
ovarian cancer: stage iii or stage iv ovarian
cancer in first complete remission with a normal
and stable ca-125; thus, two sequential normal
ca-125 values will need to be documented; a
minimum of 30 days between 2 sequential ca-125
values; the most recent will be within 2 weeks of
enrollment into study*
Yes
No
her2 overexpression by immunohistochemistry
(ihc) of 2+ or 3+ in their primary tumor or
metastasis, and if overexpression is 2+ by ihc or
in the absence of ihc, then patients must have
documentation of her2 gene amplification by fish*
Yes
No
eligible subjects must have completed
appropriate treatment for their primary disease
and be off cytotoxic chemotherapy and
corticosteroids for at least 1 month prior to
enrollment; patients with stage iii/iv breast cancer
who have completed chemotherapy and are
continued on trastuzumab monotherapy are
eligible; hormonal and bisphosphanate therapies
are allowed*
Yes
No
subjects must have a performance status score
(zubrod/ecog scale) = 0*
Yes
No
all subjects must no longer be able to bear
children*
Yes
No
1 / 3
hematocrit >= 30*
Yes
No
platelet count >= 100,000*
Yes
No
wbc >= 3,000/ul*
Yes
No
creatinine =< 2.0 or creatinine clearance >= 60
ml/minute*
Yes
No
serum bilirubin < 1.5 mg/dl*
Yes
No
sgot < 2 x uln*
Yes
No
subjects must have recovered from major
infections and/or surgical procedures and, in the
opinion of the investigator, not have a significant
active concurrent medical illness precluding
protocol treatment or survival*
Yes
No
normal ana, anti-dsdna and c3*
Yes
No
patients on trastuzumab monotherapy must have
adequate cardiac function as demonstrated by
normal ejection fraction (ef) of muga scan or
echocardiogram*
Yes
No
Exclusion Criteria
subjects cannot be simultaneously enrolled on
other treatment studies*
Yes
No
any contraindication to receiving gm-csf based
vaccine products*
Yes
No
prior known history of cardiac disease,
specifically restrictive cardiomyopathy, unstable
angina within the last 6 months prior to
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enrollment, new york heart association functional
class iii-iv heart or symptomatic pericardial
effusion*
Yes
No
prior known history of pulmonary disease other
than controlled asthma*
Yes
No
active autoimmune disease*
Yes
No
subjects cannot have active immunodeficiency
disorder, e.g., hiv*
Yes
No
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Eligibility Knee Osteoarthritis
NCT00726492
An Examination of the Value of Shortwave Diathermy and
Hydrotherapy for Patients With Osteoarthritis of Their
Knees; ODM derived from:
https://clinicaltrials.gov/show/NCT00726492
All rights reserved. Please visit https://medical-data-
models.org/forms/15609
Eligibility Knee Osteoarthritis
NCT00726492
Inclusion Criteria
patients had to have a documented diagnosis of
osteoarthritis of their knees.*
Yes
No
patients had to be between 50 and 70 years
inclusive.*
Yes
No
patients had to have x-ray evidence of
osteoarthritis of their knees.*
Yes
No
Exclusion Criteria
patients with another rheumatological condition
other than osteoarthritis.*
Yes
No
patients who were unable to understand the
concepts, assessment and treatment involved.*
Yes
No
patients who had received a cortisone injection
into the knee in the previous 30 days.*
Yes
No
patients for whom cswd or hydrotherapy has been
contraindicated.*
Yes
No
patients who have had either cswd or
hydrotherapy in the past.*
Yes
No
patients who had undergone a surgical procedure
on either lower limb in the past 6 months.*
Yes
No
patients who were receiving other physiotherapy
treatment.*
Yes
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No
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Eligibility Knee Osteoarthritis NCT00726492
Eligibility Leukemia NCT00038805
Nonmyeloablative Preparative Regimen Using Mylotarg for
Patients With High Risk Acute Myeloid Leukemia (AML),
Acute Lymphocytic Leukemia (ALL), Chronic Myeloid
Leukemia (CML) and Myelodysplastic Syndrome (MDS);
ODM derived from:
https://clinicaltrials.gov/show/NCT00038805
All rights reserved. Please visit https://medical-data-
models.org/forms/15610
Eligibility Leukemia NCT00038805
Inclusion Criteria
patients 12-75 years of age*
Yes
No
patients are eligible if deemed ineligible for
conventional high dose chemotherapy programs
because of concurrent medical conditions.
patients with refractory aml are eligible provided
ejection fraction >= 35%; fev1, fvc, or dlco >=
40%; gpt < 3 x normal, direct bilirubin < 2.*
Yes
No
patients must have recovered from previous
grade iii-iv toxicity due to prior antineoplastic
therapy (except alopecia).*
Yes
No
patients with aml with induction failure, relapse or
2nd remission*
Yes
No
patients with mds with ipi int-2 or high-risk
disease or cmml.*
Yes
No
patients with cml in accelerated phase or blast
crisis*
Yes
No
patients with all with induction failure, relapse or
2nd remission*
Yes
No
patients receiving prior bmt are eligible.  if
myeloablative chemoradiotherapy was used in
the prior transplant patients must be >90 days
from transplant.  if non-myeloablative therapy was
used patients must be >30 days post-transplant.*
Yes
No
leukemia cells must express cell surface cd33
evaluated by flow cytometry in > 20% of leukemia
cells.*
Yes
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No
patients must have an hla identical related donor
capable of donating g-csf stimulated peripheral
blood stem cells using apheresis techniques.  if
patient has a contraindication to pbsc collection
bone marrow can be used.*
Yes
No
patients must have a zubrod ps <2, cr <2.0, direct
bilirubin <2, and transaminases sgpt <3x normal*
Yes
No
patients must have an estimated life expectancy
> 3 months*
Yes
No
patient and donor must sign informed consent*
Yes
No
Exclusion Criteria
no uncontrolled active infection*
Yes
No
no hiv disease*
Yes
No
no pregnancy and no nursing*
Yes
No
no active, uncontrolled cns leukemia*
Yes
No
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Eligibility Multiple Sclerosis NCT00151801
Safety and Tolerability of Interferon-Beta-1a and
Estroprogestins Association in MS Patients; ODM derived
from: https://clinicaltrials.gov/show/NCT00151801
All rights reserved. Please visit https://medical-data-
models.org/forms/15612
Eligibility Multiple Sclerosis
NCT00151801
Inclusion Criteria
female patients*
Yes
No
clinically definite relapsing-remitting ms according
to the mcdonald criteria*
Yes
No
age between 18-40 y.o.*
Yes
No
edss from 0 to 4.0, inclusive*
Yes
No
Exclusion Criteria
history of migraine or thromboembolic events*
Yes
No
reproductive system disorders*
Yes
No
pregnancy or suspension of pregnancy within 12
months prior to randomisation*
Yes
No
prior use of estroprogestins within the last 3
months prior to randomisation*
Yes
No
prior use of immunosuppressive drugs within the
last 12 months prior to randomisation*
Yes
No
prior use of immunomodulating drugs within the
last 6 months prior to randomisation*
Yes
No
prior use of corticosteroids within the last 3
months prior to randomisation*
Yes
No
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have clinical relapse 30 days prior to
randomisation*
Yes
No
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Eligibility Prostate Cancer NCT00147212
ET 743 (Yondelis) in Men With Advanced Prostate Cancer;
ODM derived from:
https://clinicaltrials.gov/show/NCT00147212
All rights reserved. Please visit https://medical-data-
models.org/forms/15613
Eligibility Prostate Cancer
NCT00147212
Inclusion Criteria
histologically confirmed adenocarcinoma of the
prostate*
Yes
No
radiographically documented metastatic disease*
Yes
No
surgical or chemical castration*
Yes
No
prostate specific antigen (psa) > 5 ng/ml*
Yes
No
castration resistant prostate cancer (crpc)*
Yes
No
one previous taxane-based chemotherapy
regimen*
Yes
No
eastern cooperative group (ecog) performance
status 0,1 or 2*
Yes
No
neutrophil count > 1,500/ul*
Yes
No
platelet count > 100,000/ul*
Yes
No
serum bilirubin < 1.0 x upper limit normal (uln)*
Yes
No
serum alkaline phosphatase < 1.5 x uln*
Yes
No
asparate aminotransferase/alanine
aminotransferase < 2.5 x uln*
Yes
No
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albumin > 2.5 g/dl*
Yes
No
serum creatinine < 1.5 x uln*
Yes
No
prior hormonal therapy*
Yes
No
Exclusion Criteria
chemotherapy treatment within 4 weeks of study
entry*
Yes
No
patient not employing adequate contraception*
Yes
No
serious illness or medical conditions, specifically:
uncontrolled congestive heart failure or history of
myocardial infection or active angina pectoris
within 6 months; active infectious process;
chronic active liver disease, including chronic
hepatitis b, c or cirrhosis*
Yes
No
current anti-cancer treatment with any non-fda
approved investigational drug*
Yes
No
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Eligibility Stage IA Non-Small Cell Lung
Carcinoma NCT02154399
EF5 in Measuring Tumor Hypoxia in Patients With Stage I-
III Non-Small Cell Lung Cancer; ODM derived from:
https://clinicaltrials.gov/show/NCT02154399
All rights reserved. Please visit https://medical-data-
models.org/forms/15614
Eligibility Stage IA Non-Small Cell
Lung Carcinoma NCT02154399
Inclusion Criteria
known or suspected non-small cell lung cancer;
patients without histologically or cytologically
documented non-small cell lung cancer (nsclc)
must be estimated by their physician to have at
least 75% probability of having nsclc; the
probability of malignancy will be predicted on the
basis of known probabilities of individual clinical
characteristics using a bayesian model*
Yes
No
clinical or pathologic stage i to iii; patients in
whom pre-surgical staging has not definitively
establish stage iv disease are eligible*
Yes
No
tumor mass at least 1.5 cm in maximum diameter
must be present on computed tomography (ct)
scan and must be included in the planned
surgical biopsy or resection*
Yes
No
patient must be planning to undergo a surgical
staging or treatment procedure (including
mediastinoscopy, wedge resection, lobectomy, or
pneumonectomy) and have the clinical and
physiological status appropriate for this
procedure*
Yes
No
performance status 0-2*
Yes
No
bilirubin within normal limits*
Yes
No
creatinine within normal limits or, if elevated, a
creatinine clearance of at least 60 ml/min/m^2
(ef5 is primarily excreted via the kidney)*
Yes
No
white blood cell (wbc) > 2000/mm^3*
Yes
No
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platelets > 100,000/mm^3*
Yes
No
Exclusion Criteria
pregnancy or breast feeding; a negative serum
pregnancy test is required of any woman of
childbearing potential prior to enrollment;
pregnant women are excluded from this study;
breastfeeding should be discontinued if the
mother is treated with ef5*
Yes
No
allergy to iv contrast dye*
Yes
No
history of grade iii or iv peripheral neuropathy as
defined by the national cancer institute (nci)
common terminology criteria (ctc)*
Yes
No
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Eligibility Type 1 Diabetes NCT00142922
Breaking Down Barriers to Diabetes Self-Care; ODM
derived from: https://clinicaltrials.gov/show/NCT00142922
All rights reserved. Please visit https://medical-data-
models.org/forms/15615
Eligibility Type 1 Diabetes
NCT00142922
Inclusion Criteria
for patients with type 1 diabetes*
Yes
No
aged 18-65*
Yes
No
presence of type 1 diabetes mellitus.*
Yes
No
2-25 year duration.*
Yes
No
for patients with type 2 diabetes*
Yes
No
aged 25-65 years*
Yes
No
presence of type 2 diabetes mellitus.*
Yes
No
2 years since initial diagnosis.*
Yes
No
Exclusion Criteria
renal disease, microalbumin >300 ug/mg)*
Yes
No
severe peripheral diabetic neuropathy and/or
severe peripheral vascular disease*
Yes
No
symptomatic severe autonomic neuropathy who
may be at risk when increasing activity levels.*
Yes
No
women who are currently pregnant*
Yes
No
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proliferative diabetic retinopathy based on dilated
eye examination within one year of study entry.
patients whose eye disease is successfully
treated will be included.*
Yes
No
hba1c  levels less than 7.0% (normal range 4.0 -
6.0%).*
Yes
No
hba1c  levels greater than 14.0%*
Yes
No
patients who underwent intensive insulin
treatment within one year*
Yes
No
a history of severe, unstable myocardial
infarction, congestive heart failure or other severe
cardiac disease, severe hypertension (systolic
more than 160 mmhg or diastolic 90 mmhg) who
may be at risk when mildly increasing physical
activity*
Yes
No
a dsmiv diagnosis of eating disorders including
anorexia nervosa, bulimia, and severe weight-
related insulin omission.*
Yes
No
patients with recent diagnosis (past 6 months) of
bipolar disorder, schizophrenia, mental
retardation, organic mental disorder, and alcohol
or drug abuse*
Yes
No
patients whose diabetes diagnosed cannot be
clearly classified as type 1 or type 2.*
Yes
No
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Eligibility Type 1 Diabetes NCT00142922
Input and Output Input and Output protocol
Routine documentation in German hospitals DMI
Routine documentation in German hospitals. Source file
name: VL040301_Ein- und Ausfuhrprotokoll/ Einfuhr
Ausfuhr.045
Examplary forms provided by DMI (http://www.dmi.de/)
All rights reserved. Please visit https://medical-data-
models.org/forms/15621
Input and Output protocol
Einfuhr
Zeit
Oral
Intravenös ein
Spülungen
Output
Zeit
Spülung ablassen
Drainagen
Urin/ DK
Erbrechen
Datum
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Spirometry Documentation form for lung function test
Routine documentation in German hospitals DMI
Routine documentation in German hospitals. Source file
name: DG060108_Dokumentationsbogen
Lungenfunktionsprüfung/ Spirometrie.061
Examplary forms provided by DMI (http://www.dmi.de/)
All rights reserved. Please visit https://medical-data-
models.org/forms/15622
Spirometry Documentation form for
lung function test
Patienteninformation
Name
Vorname
Geburtsdatum
Geschlecht
Größe
cm
Gewicht
kg
BMI
kg/ m^2
Ethnik
Raucher
Ja
Nein
Asthma
Ja
Nein
Aufnahmeinformation
Typ
Datum/ Zeit
Refernzdatum
Werteauswahl
Umgebung
Position
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Assistent
Patientenmitarbeit
Ruhe (Akzeptiert)
Ruhe (Reproduzierbar)
Ruhe (ERS/ ATS)
Bestwerte
TV
L
FVC (ex)
L
FVC (ex) (REF)
L
FVC (ex) (Pre%)
L
FVC (ex) (Referenz)
L
FEV1
L
FEV1 (REF)
L
FEV1 (Pre%)
L
FEV1 (Referenz)
L
FEV1/ FVC
FEV1/ FVC (REF)
FEV1/ FVC (Pre%)
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FEV1/ FVC (Referenz)
FEF 25_27
L/s
FEF 25_27 (REF)
L/s
FEF 25_27 (Pre%)
L/s
FEF 25_27 (Referenz)
L/s
PEF
L/s
FVC (in)
L
FVC (in) (REF)
L
FVC (in) (Pre%)
L
FVC (in) (Referenz)
L
FIV1
L
FIV1/ FVC (in)
Bericht
Bericht
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Radiometer Blood gas analysis Routine
documentation in German hospitals DMI
Routine documentation in German hospitals. Source file
name: LB020101_Blutgasanalyse/ Radiometer.065
Examplary forms provided by DMI (http://www.dmi.de/)
All rights reserved. Please visit https://medical-data-
models.org/forms/15623
Radiometer Blood gas analysis
Patienteninformation
Datum/ Zeit
Probe Nr. :
Patienten ID
Name
Patient vorname
Probentyp
Temperatur
°C
Blutgas Ergebnis
pH
pCO2
mmHg
pO2
mmHg
Oxymetrie Ergebnis
ctHb
g/dL
sO2
%
Elektrolyt Ergebnis
cK+
mmol/L
cNa+
mmol/L
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cCa+
mmol/L
Metabolit Ergebnis
cGlu
mg/ dL
Temperatur Korrektion
pH(T)
pCO2 (T)
mmHg
pO2 (T)
mmHg
Sauerstoff status
ctO2e
Vol%
p5Oe
mmHg
Säure Basen Status
cBase(Ecf)c
mmol/L
cHCO3-(P, st)c
mmol/L
Abgeleitete Parameter
Hctc
%
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Radiometer Blood gas analysis Routine documentation in German
hospitals DMI
Test Result Intern Routine documentation in
German hospitals DMI
Routine documentation in German hospitals. Source file
name: LB120103_Laborbefund intern/ Laborbefund.087
Examplary forms provided by DMI (http://www.dmi.de/)
All rights reserved. Please visit https://medical-data-
models.org/forms/15624
Test Result Intern
Befundbericht
Datum
Patient
Geburtsdatum
Patient number
Day number
Leukozyten
/ul
Erythrozyten
Tpt/l
Hämoglobin
g/dl
Hämatokrit
%
MCV
fl
MCH
pg
MCHC
g/dl
RDW
%
Thrombozyten
Gpt/l
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Eligibility Multivessel Coronary Artery
Disease NCT02334826
Revascularization With BVS or CABG in Patients With
Advanced CAD; ODM derived from:
https://clinicaltrials.gov/show/NCT02334826
All rights reserved. Please visit https://medical-data-
models.org/forms/15625
Eligibility Multivessel Coronary
Artery Disease NCT02334826
Inclusion Criteria
patient age ≥18 years*
Yes
No
patient with symptomatic stable cad or silent
ischemia, with 3-vessel disease and/or significant
stenosis of left main coronary artery on
angiography, with significant ischemia evaluated
in stress cmr*
Yes
No
patient suitable for both pci or cabg after local
heart team evaluation*
Yes
No
patient understands and accepts the meaning
and the aims of the study and is willing to sign
written informed consent*
Yes
No
Exclusion Criteria
prior cabg*
Yes
No
concomitant valve disease requiring cardiac
surgery*
Yes
No
metal implants that may be the contraindication
for cmr examination (e.g. peacemaker, icd)*
Yes
No
other contraindication for stress cmr or computed
tomography (claustrophobia, asthma, a-v bloc,
allergy to radiographic contrast or any prior
anaphylaxis to contrast)*
Yes
No
contraindication for 12 months dual antiplatelet
therapy (dapt) or known allergy to acetylsalicylic
acid, clopidogrel or ticagrelor*
Yes
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No
female patient with child bearing potential*
Yes
No
acute coronary syndrome within 2 weeks prior to
revascularization*
Yes
No
significant stenosis of any vessel, including lm if
reference diameter > 4mm*
Yes
No
left ventricular ejection fraction (lvef) <35%*
Yes
No
life expectancy < 12 months*
Yes
No
stroke or transient ischemic attack (tia) within 3
months prior to revascularization*
Yes
No
chronic kidney disease, estimated glomerular
filtration rate (egfr) <30 ml/min/1.73m2*
Yes
No
planned surgery (other than cabg) within 12
months after randomization*
Yes
No
diathesis, chronic oral anticoagulation therapy or
history of bleeding*
Yes
No
current participation in another trial or registry*
Yes
No
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Eligibility Myocardial Ischemia
NCT02427867
Ischaemic PReconditioning In Non Cardiac surgEry; ODM
derived from: https://clinicaltrials.gov/show/NCT02427867
All rights reserved. Please visit https://medical-data-
models.org/forms/15626
Eligibility Myocardial Ischemia
NCT02427867
Inclusion Criteria
written informed consent*
Yes
No
intermedial and high risk non cardiac surgery*
Yes
No
general anesthesia*
Yes
No
ongoing or recently suspended antiplatelet
therapy*
Yes
No
Exclusion Criteria
pregnancy*
Yes
No
planned locoregional anesthesia without general
anesthesia*
Yes
No
unstable or ongoing angina*
Yes
No
recent (< 1 month) or ongoing acute myocardial
infarction*
Yes
No
inclusion in other randomised controlled studies
in the previous 30 days*
Yes
No
peripheral vascular disease affecting the upper
limbs*
Yes
No
cardiac surgery*
Yes
No
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Medical diagnosis report Microbiology findings
Routine documentation in German hospitals DMI
Routine documentation in German hospitals. Source file
name: LB130101_Mikrobiologiebefund/
Mikrobiologiebefund.039 and Mikrobiologiebefund.041
Examplary forms provided by DMI (http://www.dmi.de/)
All rights reserved. Please visit https://medical-data-
models.org/forms/15627
Medical diagnosis report
Microbiology findings
Mikrobiologiebefund
Patient
Geburtsdatum
Geschlecht
Krankenversicherung
Auftragsnummer
Eingang
Ausgang
Material
Anforderung
Ergebnis
Arzt
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Surgery registration Form for surgery registration
Routine documentation in German hospitals DMI
Routine documentation in German hospitals. Source file
name: OP150102_OP-Anmeldungsbogen/ OP-
Anmeldung.009
Examplary forms provided by DMI (http://www.dmi.de/)
All rights reserved. Please visit https://medical-data-
models.org/forms/15628
Surgery registration Form for surgery
registration
OP-Anmeldung
Patientenidentifikation
Telefon/ Handy
Datum der Registrierung
Diagnose
Operation
Operateur
Gyn- Sprechstunde
Anästhesiesprechstunde
OP Termin
Op- Dauer
OP- Sieb
Zusatzinstrumente
Lagerung
Assistenz
Implantate
Tumeszenzlösung
L
Tumeszenzlösung ohne Lokalanästhetikum
L
Infiltrationspumpe- Vakuumsauger- Lipokanülen
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Röntgenlokalisation
Sonstiges
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Eligibility Nasopharyngeal Carcinoma
NCT02289807
Concurrent Chemotherapy in Intermediate Risk Patients
Treated With Intensity-modulated Radiotherapy; ODM
derived from: https://clinicaltrials.gov/show/NCT02289807
All rights reserved. Please visit https://medical-data-
models.org/forms/15629
Eligibility Nasopharyngeal
Carcinoma NCT02289807
Inclusion Criteria
patients with newly histologically confirmed non-
keratinizing (according to who histologically
type).*
Yes
No
tumor staged as t1-2n1/t2-3n0(according to the
7th ajcc edition). no evidence of distant
metastasis (m0). satisfactory performance status:
karnofsky scale (kps) ≥ 70. adequate marrow:
leucocyte count ≥ 4000/μl, hemoglobin ≥ 90g/l
and platelet count ≥ 100000/μl.*
Yes
No
normal liver function test: alanine
aminotransferase (alt), aspartate
aminotransferase (ast) < 1.5×upper limit of
normal (uln) concomitant with alkaline
phosphatase (alp) ≤*
Yes
No
2.5×uln, and bilirubin ≤ uln.*
Yes
No
adequate renal function: creatinine clearance ≥
60 ml/min. patients must be informed of the
investigational nature of this study and give
written informed consent.*
Yes
No
Exclusion Criteria
who type keratinizing squamous cell carcinoma
or basaloid squamous cell carcinoma.*
Yes
No
age > 65 or < 18. treatment with palliative intent.
prior malignancy except adequately treated basal
cell or squamous cell skin cancer, in situ cervical
cancer.*
Yes
No
pregnancy or lactation (consider pregnancy test
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in women of child-bearing age and emphasize
effective contraception during the treatment
period).*
Yes
No
history of previous rt (except for non-
melanomatous skin cancers outside intended rt
treatment volume).*
Yes
No
prior chemotherapy or surgery (except
diagnostic) to primary tumor or nodes. any severe
intercurrent disease, which may bring
unacceptable risk or affect the compliance of the
trial, for example, unstable cardiac disease
requiring treatment, renal disease, chronic
hepatitis, diabetes with poor control (fasting
plasma glucose > 1.5×uln), and emotional
disturbance.*
Yes
No
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Nursing graph Routine documentation in
German hospitals DMI
Routine documentation in German hospitals. Source file
name: VL160106_Pflegekurve/ Pflegekurve.087 and
Pflegekurve.088
Examplary forms provided by DMI (http://www.dmi.de/)
All rights reserved. Please visit https://medical-data-
models.org/forms/15630
Nursing graph
Pflegekurve
Patient
Geburtsdatum
Patienten ID
Aufnahmedatum
Post- OP- Tage
Gewicht
Kostform
Temperatur
°C
ZVD
Erbrechen
Einfuhr gesamt
Ausfuhr gesamt
Bilanz
Urin (DK/ Cystofix)
Drainagen
Stuhl
Blutdruck
Blutdruckmessungszeit
BZ
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Blutzuckermessungszeit
Verlaufsnotizen Arzt
Krankengymnastik (Durchführugn + Verlauf)
Enteral
Datum
Stop datum
Arzt
Parenteral
Datum
Stop datum
Arzt
Antikoagulantien
Datum
Stop datum
Arzt
Insulin s.c
Datum
Stop datum
Arzt
Insulin i.v
Datum
Stop datum
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Arzt
Antibiotika/ -mykotika
Datum
Stop datum
Arzt
Infusionen
Datum
Stop datum
Arzt
Plasma
Datum
Stop datum
Arzt
Blut
Datum
Stop datum
Arzt
Prophylaxen-Therapie
Datum Prophylaxen-Therapie
Anfang datum
Sr./ Pf./ A.
Stop Datum
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Sr./ Pf./ A.
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Eligibility Nodular Basal Cell Carcinoma
NCT02242929
Surgery Versus Combined Treatment With Curettage and
Imiquimod for Nodular Basal Cell Carcinoma; ODM derived
from: https://clinicaltrials.gov/show/NCT02242929
All rights reserved. Please visit https://medical-data-
models.org/forms/15631
Eligibility Nodular Basal Cell
Carcinoma NCT02242929
Inclusion Criteria
adults aged 18 years or older*
Yes
No
primary histologically proven nodular bcc ≥ 4mm
and ≤ 20mm in diameter. (if the tumour exhibits
additional sbcc characteristics, but also contains
nodular component that extend into the reticular
dermis, the tumour will be classified as nbcc with
superficial components and will be included).*
Yes
No
comorbidities may not interfere with study
treatment*
Yes
No
capable to understand instructions*
Yes
No
Exclusion Criteria
a nodular bcc located in the h-zone of the face or
hairy scalp*
Yes
No
recurrent (previously treated) nbcc*
Yes
No
aggressive bcc subtypes (morphoea,
micronodular, or bcc with squamous
differentiation)*
Yes
No
life expectancy of less than five years*
Yes
No
breast-feeding or pregnant women*
Yes
No
serious comorbidities*
Yes
No
use of immunosuppressive medication during the
1 / 2
trial period or within 30 days before enrolment*
Yes
No
patients with genetic skin cancer disorders*
Yes
No
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Nerventra Study Screening
Nerventra Study (Eudra CT 2007-003226-19) Study MS-
LAQ-301: A multinational, multicenter,
randomized, double-blind, parallel-group, placebo-
controlled study, to evaluate the safety,
tolerability and efficacy of daily oral administration of
laquinimod 0.6 mg in subjects with
relapsing remitting multiple sclerosis (RRMS)
All rights reserved. Please visit https://medical-data-
models.org/forms/15632
Nerventra Study Sreening
Informed Consent and Demography Data
Protocol Number
Visit Type
Date of visit
Study site number
Subject number:
Section blank?
Yes
No
Date of informed consent
Has the subject been previously screened?
Yes
No
Previous Screening number
Subjects Initials
Date of birth
Race
Gender
male (1)
female (2)
Is the subject of childbearing potential?
Yes
No
If Female is not of childbearing potential is she
post menopausal?
Yes
No
If Female is not of childbearing potential did she
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have hysterectomy and/or oophorectomy (add
procedure and reason to medical history form)
Yes
No
If Female is not of childbearing potential, please
specify other reason
If Female is of childbearing potential,please
specify method of birth control (select all that
apply)
Transdermal contraception (1)
Oral contraception (2)
Injectable contraception (3)
IUD (4)
Double barrier methods (two
of:diaphragm,condom,sponge,spermicid
e products) (5)
Surgical sterilization (6)
Partners vasectomy (7)
Other, please specify (8)
Multiple sclerosis history
Date of first symptom
Date of MS diagnosis
EDSS
EDSS unknown
Yes
No
Onset date of last exacerbation
EDSS
EDSS unknown
Yes
No
Date of stabilization of last exacerbation
EDSS
EDSS unknown
Yes
No
Total number of exacerbations in the last year
Total number of exacerbations in the last 2 years
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Nerventra Study Screening
Date of last MRI with T1-GD enhancing lesions
Date of last MRI with T1-GD enhancing lesions:
not applicable
Yes
No
Medication name
Interferon 1beta a (1)
Interferon 1beta b (2)
Glatiramer Acetate (3)
Mitoxantrone (4)
Other (5)
Medication name,please specify other
Therapy discontinuation reason
IFN NAB titer
IFN NAB titer not applicable
Yes
No
Medical history
Does the subject have any significant abnormal
conditions other than MS?
Yes
No
Abnormal condition
Comorbidity related to MS
Yes
No
Date of onset
Date ceased
Condition ongoing?
Yes
No
Tobacco use
Never used (1)
Former user (2)
Currently uses (3)
Date smoking ceased
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Nerventra Study Screening
Type of smoking
Cigarettes (1)
Pipe (2)
Cigars (3)
Other (please specify) (4)
Type of smoking: please specify other type
Cigarettes per day
Number of smoking years
years
Smoking months
Safety measurements
Height
Units used for measurement
inch (1)
cm (2)
Measurement not done
Yes
No
Weight
Units used for measurement
lbs (1)
kg (2)
Measurement not done
Yes
No
Temperature
Temperature type of measurement
oral (1)
axillary (2)
aural (3)
temporal (4)
Units used for measurement
F (1)
C (2)
Measurement not done
Yes
No
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Blood pressure measurement
mm/Hg
Measurement not done
Yes
No
Pulse
beats/min
Measurement not done
Yes
No
Investigators ECG interpretation
ECG interpretation not done
Yes
No
ECG Repetition
Yes
No
Investigators ECG interpretation
ECG interpretation not done
Yes
No
Date of chest x-ray
Chest x-ray not done
Yes
No
Chest x-ray interpretation
Chest x-ray, if abnormal, please specify
Where all required laboratory samples obtained?
Yes
No
Menstruation
Yes
No
Physical examination
Head and Neck examination
Normal (1)
Not done (2)
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Abnormal (specify) (3)
Head and Neck examination,if abnormal please
specify
Ear-Nose-Throat examination
Normal (1)
Not done (2)
Abnormal (specify) (3)
Ear-Nose-Throat examination,if abnormal,please
specify
Eye examination
Normal (1)
Abnormal (specify) (2)
Not done (3)
Eyes please specify if abnormal
Heart examination
Normal (1)
Not done (2)
Abnormal (specify) (3)
Heart examination please specify, if abnormal
Lungs/chest examination
Normal (1)
Not done (2)
Abnormal (specify) (3)
Abdominal examination
Normal (1)
Not done (2)
Abnormal (specify) (3)
Abdominal examination if abnormal, please
specify
Examination of extremities and back
Normal (1)
Not done (2)
Abnormal (specify) (3)
Examination of extremities and back if abnormal,
please specify
Examination of lymph nodes
Normal (1)
Not done (2)
Abnormal (specify) (3)
Examination of lymph nodes, if abnormal please
specify
6 / 15
Nerventra Study Screening
Examination of skin
Normal (1)
Not done (2)
Abnormal (specify) (3)
Neurological Examination
Normal (1)
Not done (2)
Abnormal (specify) (3)
Neurological Examination,if abnormal please
specify
Other Examination, please specify Body system
Other Examination
Normal (1)
Not done (2)
Abnormal (specify) (3)
Other Examination, if abnormal please specify
FS,Ambulation,EDSS,AI
Complete neurological exam performed?
Yes
No
Complete neurological exam performed? If "no",
please specify
Additional (not MS-related) findings, that may
influence the neurological exam?
Yes
No
Additional (not MS-related) findings, that may
influence the neurological exam? If yes, please
specify
Yes
No
EDSS: Visual System Score
0 (0)
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
EDSS visual converted 0-4
EDSS score Brainstem 0-5
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EDSS score Pyramidal 0-6
EDSS score Cerebellar 0-5
EDSS score Sensory 0-6
EDSS score Bladder/Bowel 0-6
EDSS score Bladder/Bowel converted 0-5
EDSS score Cerebral/Mental 0,1a,1b,2-5
Was ambulation evaluated?
Yes
No
If ambulation was not evaluated, please specify.
Otherwise continue with section A,B or C
"A": Actual distance without rest or assistance in
meters
meters
>=100-<200 (1)
>=200-<300 (2)
>=300-<500 (3)
>=500 (4)
"B": Needs unilateral assistance to walk up to
100m
<50m (1)
>50m (2)
"C": Needs bilateral assistance to walk up to
100m
meters
<10 (1)
>=10-<120 (2)
>=120 (3)
Ambulation index
Actual EDSS
EDSS converted
EDSS score
Timed 25-foot walk
Did the subject wear an Ankle-Foot-Orthosis?
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Yes
No
Was assistive device used?
Yes
No
Assistive device used
unilateral assisstance (1)
bilateral assistance (2)
Type of assistive device
Cane (1)
crutch (2)
Walker/rollator (bilateral only) (3)
other (specify) (4)
Please specify other assistive  device used
Timed 25-Foot Walk: Time Trial 1
sec
For a complete trial, please record any
circumstances that affected the subjects
performance
Timed 25-Foot Walk: not completed Trial 1
Unable due to physical limitations (1)
Other (2)
Timed 25-Foot Walk: not completed Trial 1
specify physical limitations and/or other reason
Timed 25-Foot Walk: Time Trial 2
sec
For a completed trial,record any circumstances
that affected the subjects performance
Timed 25-Foot Walk: not completed Trial 2
Unable due to physical limitations (1)
Other (2)
Timed 25-Foot Walk: not completed Trial 2
specify physical limitations and/or other reason
Did it take more than 2 attempts to get two
successful trials?
Yes
No
If it took more than two attempts, please specify
reason(s) why trial had to be repeated
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Inclusion criteria
Does the subject have a confirmed and
documented MS diagnosis as defined by the
revised McDonald criteria [Ann Neuro]
2005:58:840-846], with a relapsing-remitting
disease course?
Yes
No
Is the subject ambulatory with converted Kurtzke
EDSS score of 0-5.5?
Yes
No
Has the subject been in stable neurological
condition for 30 days prior to screening (month-1)
Yes
No
Has the subject been free of corticosteroid
treatment [intravenous (iv), intramuscular (im),
and/or per os (po)] for 30 days prior to screening
(month-1)?
Yes
No
Has the subject experienced one of the following:
-at least one documented relapse in the 12
months prior to screening
-at least two documented relapses in the 24
months prior to screening
-one documented relapse between 12 and 24
months prior to screening with at least one
documented T1-Gd enhancing lesion in an MRI
performed within 12 months prior to screening
Yes
No
Is the subject between 18 Years and 55 Years of
age,inclusive?
Yes
No
Does the subject have a disease duration of at
least 6 months (from the first symptom) prior to
screening?
Yes
No
Is the subject a woman of childbearing potential
who practices an acceptable method of birth
control [ acceptable methods of birth control in
this study include: surgical
sterilization,intrauterine devices,oral
contraceptives,contraceptive patch,long-acting
injectable contraceptive,partners vasectomy, or
double barrier method (condom or diaphragm
with spermicide)]?
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Yes
No
Is the subject able to sign and date a written
informed consentprior to entering this study?
Yes
No
Is the subject willing and able to comply with the
protocol requirements for the dureation of the
study?
Yes
No
Exclusion criteria
Does the subject have a progressive form of MS?
Yes
No
Has the subject used experimental or
investigational drugs and/or participated in drug
clinical studies within the 6 months prior to the
screening visit?
Yes
No
Has the subject used immunosuppressive
(including Mitoxantrone-NovantroneⓇ) or
cytotoxic agents within 6 months prior to the
screening visit?
Yes
No
Has the subject previously used either of the
following: Natalizumab (TysabriⓇ), Cladribine,
Laquinimod?
Yes
No
Has the subject had a previous treatment with
glatiramer acetate,Interferon-beta (either 1a or
1b) or IVIG, within 2 months prior to screening
visit?
Yes
No
Has the subject had systemic chronic
corticosteroid treatment (30 or more consecutive
days) within 2 months prior to screening visit?
Yes
No
Has the subject had previous total body
irradiation or total lymphoid irradiation?
Yes
No
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Has the subject had previous stem cell treatment,
autologous bone marrow transplantation or
allogeneic bone marrow transplantation
Yes
No
Does the subject have a known history of
tuberculosis
Yes
No
Please confirm if this exclusion criteria in the
amendment was approved
Yes
No
If not: Does the subject have a history of vascular
thrombosis (excluding catheter site superficial
venous thrombophlebitis)?
Yes
No
Please confirm if this exclusion criteria in the
amendment was approved
Yes
No
If not: Does the subject have a carrier state of
factor V Leiden mutation (either homo- or
heterozygous as disclosed at screening)?
Yes
No
If this exclusion criteria in the amendment was
approved: Does the subject have known human
imunodefiency virus (HIV) positive status?
Yes
No
If not: Does the subject have a positive screening
test for Hepatitits B surface antigen, Hepatitis C
antibodies, or HIV antibodies as disclosed at
screening visit?
Yes
No
Has the subject used amiodarone within 2 years
prior to screening visit?
Yes
No
Is the subject pregnant or breastfeeding?
Yes (1)
No (2)
NR (3)
Does the subject have a clinically significant or
unstable medical or surgical condition, as defined
by protocol, that would preclude safe and
complete study participation
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Yes
No
Does the subject have a known history of
sensitivity to GD?
Yes
No
Is the subject unable to successfully undergo MRI
scanning?
Yes
No
Does the subject have a known drug
hypersensitivity that would preclude
administration of Laquinimod such as
hypersensitivity to mannitol, meglumine or
sodium stearyl fumarate
Yes
No
Ancillary studies
Will the subject participate in the ancillary PBMC
study?
Yes
No
Will the subject participate in the ancillary study
of Immune system proteins, serum cytokines and
antibodies
Yes
No
Will the subject participate in the ancillary mRNA
study?
Yes
No
Will the subject participate in the ancillary PGx
study?
Yes
No
Will the subject participate in frequent MRI?
Yes
No
Will the subject participate in magnetization
Transfer MRI ?
Yes
No
Will the subject participate in magnetic resonance
spectroscopy MRI?
Yes
No
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Pharmacogenetic information
Was written informed consent for
pharmacogenetics obtained?
Yes
No
If yes, please give the date of informed consent
If informed consent was not obtained, please
specify reason
Country of birth
Did you immigrate from your birth country?
yes (1)
no (2)
do not wish to provide information (3)
If yes, please specify year(s) and place(s)
Family MS history
yes (1)
no (2)
do not wish to provide information (3)
If yes, please specify how many near relatives
(next of kin) with MS?
Please specify relationship
How many other relatives with MS
Please specify relationship
Additional family history of autoimmune diseases
(not including MS)
yes (1)
no (2)
do not wish to provide information (3)
If yes, please specify how many near relatives
(next of kin) with autoimmune disease(s)?
Please specify autoimmune disease(s)
If yes, please specify how many other relatives
with autoimmune disease(s)?
Please specify autoimmune disease(s)
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Subject disposition
Does the subject qualify to continue this clinical
trial?
Yes
No
Please specify reason why subject is not eligible
Comments
Section/Module name
Deviation
Yes
No
Comments
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Nerventra Study Screening
Eligibility Non Small Cell Lung Cancer
NCT02368990
T790M Mutation Positive 2nd Line STandard of cAre
Registry; ODM derived from:
https://clinicaltrials.gov/show/NCT02368990
All rights reserved. Please visit https://medical-data-
models.org/forms/15634
Eligibility Non Small Cell Lung
Cancer NCT02368990
Inclusion Criteria
provision of signed and dated written informed
consent prior to any study specific procedure.*
Yes
No
patients with histologically- or cytologically-
documented nsclc who present with stage iiib/
stage iv disease.*
Yes
No
evidence of radiological disease progression
following 1st line treatment for
advanced/metastatic nsclc with an approved egfr-
targeted tki monotherapy without any additional
concurrent nsclc treatment.  chemotherapy
received in the adjuvant setting is permitted.*
Yes
No
patients prescribed platinum based doublet
chemotherapy (pemetrexed +*
Yes
No
cisplatin/carboplatin) for 2nd line treatment of
nsclc. treatment must have been selected by
physician as part of routine standard of care,
prior to confirming eligibility for the study.  patient
must be enrolled into the study within two cycles
of beginning treatment.  treatment must be given
in accordance with local prescribing information.*
Yes
No
confirmation prior to enrolment into the study that
the tumour harbours the following egfr mutations
known to be associated with egfr-targeted tki
sensitivity: ex19del, l858r, l861q, and g719x.*
Yes
No
patients must have had confirmation that tumour
is t790m mutation positive from a biopsy or
cytology sample taken after confirmed disease
progression on 1st line treatment with an
approved egfr-targeted tki.*
Yes
No
who performance status 0-1 with no deterioration
over the previous 2 weeks and a minimum life
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expectancy of 12 weeks.*
Yes
No
Exclusion Criteria
treatment with any of the following:*
Yes
No
prior treatment with more than one line of
treatment for advanced nsclc.*
Yes
No
major surgery (excluding placement of vascular
access) within 4 weeks prior to enrolment.*
Yes
No
palliative radiotherapy with a limited field of
radiation within 1 week prior to enrolment, with
the exception of patients receiving radiation to
more than 30% of the bone marrow or with a
wide field of radiation which must be completed
within 4 weeks prior to enrolment.*
Yes
No
spinal cord compression or brain metastases
unless asymptomatic, stable and not requiring
steroids for at least 4 weeks prior to enrolment.*
Yes
No
patients who are known to be entering an
alternative interventional clinical study at the time
of enrolment into this study will be excluded.
however, inclusion in this study does not preclude
participation in any other clinical study after
enrolment. patients who participate in clinical
studies after enrolment into this study will be
followed to the extent possible as permitted by
the sponsor of that clinical study.*
Yes
No
involvement in the planning and conduct of the
study (applies to astrazeneca staff or staff at the
site).*
Yes
No
judgment by the physician that the patient should
not participate in the study if the patient is
unlikely to comply with procedures, restrictions,
and requirements.*
Yes
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Eligibility Non Small Cell Lung Cancer NCT02368990
No
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Eligibility Non Small Cell Lung Cancer NCT02368990
Baseline: CSF Multiple Sclerosis ALAIN01
NCT02419378
Alemtuzumab in Autoimmune Inflammatory
Neurodegeneration: Mechanisms of Action and
Neuroprotective Potential (ALAIN01)
https://clinicaltrials.gov/ct2/show/NCT02419378
Principal Investigator Prof. Dr. Dr. Sven Meuth, University
Hospital Muenster, Germany
Part: Baseline
All rights reserved. Please visit https://medical-data-
models.org/forms/15635
Baseline: CSF Multiple Sclerosis
ALAIN01 NCT02419378
Cerebrospinal Fluid
Patient ID (derived)
CSF: informed consent
no (0)
yes (1)
CSF: Date
CSF: Cell Counts not done
ND (0)
CSF: Total White Blood Cell Count
/µl
CSF: Granulocytes [/µl]
CSF: Erythrocytes
/µl
CSF: Lymphocytes
/µl
CSF: Other cells [/µl]
CSF: Atypical cells [/µl]
CSF: Total protein
mg/l
CSF: Total protein not done
ND (0)
CSF: Albumin (CSF) [mg/l]
CSF: Albumin (CSF) not done
ND (0)
CSF: Albumin (Serum) [g/l]
CSF: Albumin (Serum) not done
1 / 2
ND (0)
CSF: IgA [mg/l]
CSF: IgA not done
ND (0)
CSF: IgG [mg/l]
CSF: IgG not done
ND (0)
CSF: IgM [mg/l]
CSF: IgM not done
ND (0)
CSF: Lactate
mmol/l
CSF: Lactate not done
ND (0)
CSF: Glucose (CSF)
mg/dl
CSF: Glucose (CSF) not done
ND (0)
Glucose (Serum)
mg/dl
CSF: Glucose (Serum) not done
ND (0)
CSF: Oligoclonal bands present
no (0)
yes (1)
CSF: Oligoclonal bands, number
CSF: Oligoclonal bands not done
ND (0)
CSF: Date of Signature
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Baseline: CSF Multiple Sclerosis ALAIN01 NCT02419378
Month 12: CSF Multiple Sclerosis ALAIN01
NCT02419378
Alemtuzumab in Autoimmune Inflammatory
Neurodegeneration: Mechanisms of Action and
Neuroprotective Potential (ALAIN01)
https://clinicaltrials.gov/ct2/show/NCT02419378
Principal Investigator Prof. Dr. Dr. Sven Meuth, University
Hospital Muenster, Germany
Part: Month 12
All rights reserved. Please visit https://medical-data-
models.org/forms/15636
Month 12: CSF Multiple Sclerosis
ALAIN01 NCT02419378
Cerebrospinal Fluid
Patient ID (derived)
CSF: informed consent
no (0)
yes (1)
CSF: Date
CSF: Cell Counts not done
ND (0)
CSF: Total White Blood Cell Count
/µl
CSF: Granulocytes [/µl]
CSF: Erythrocytes
/µl
CSF: Lymphocytes
/µl
CSF: Other cells [/µl]
CSF: Atypical cells [/µl]
CSF: Total protein
mg/l
CSF: Total protein not done
ND (0)
CSF: Albumin (CSF) [mg/l]
CSF: Albumin (CSF) not done
ND (0)
CSF: Albumin (Serum) [g/l]
CSF: Albumin (Serum) not done
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ND (0)
CSF: IgA [mg/l]
CSF: IgA not done
ND (0)
CSF: IgG [mg/l]
CSF: IgG not done
ND (0)
CSF: IgM [mg/l]
CSF: IgM not done
ND (0)
CSF: Lactate
mmol/l
CSF: Lactate not done
ND (0)
CSF: Glucose (CSF)
mg/dl
CSF: Glucose (CSF) not done
ND (0)
Glucose (Serum)
mg/dl
CSF: Glucose (Serum) not done
ND (0)
CSF: Oligoclonal bands present
no (0)
yes (1)
CSF: Oligoclonal bands, number
CSF: Oligoclonal bands not done
ND (0)
CSF: Date of Signature
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Month 12: CSF Multiple Sclerosis ALAIN01 NCT02419378
Month 24: CSF Multiple Sclerosis ALAIN01
NCT02419378
Alemtuzumab in Autoimmune Inflammatory
Neurodegeneration: Mechanisms of Action and
Neuroprotective Potential (ALAIN01)
https://clinicaltrials.gov/ct2/show/NCT02419378
Principal Investigator Prof. Dr. Dr. Sven Meuth, University
Hospital Muenster, Germany
Part: Month 24
All rights reserved. Please visit https://medical-data-
models.org/forms/15637
Month 24: CSF Multiple Sclerosis
ALAIN01 NCT02419378
Cerebrospinal Fluid
Patient ID (derived)
CSF: informed consent
no (0)
yes (1)
CSF: Date
CSF: Cell Counts not done
ND (0)
CSF: Total White Blood Cell Count
/µl
CSF: Granulocytes [/µl]
CSF: Erythrocytes
/µl
CSF: Lymphocytes
/µl
CSF: Other cells [/µl]
CSF: Atypical cells [/µl]
CSF: Total protein
mg/l
CSF: Total protein not done
ND (0)
CSF: Albumin (CSF) [mg/l]
CSF: Albumin (CSF) not done
ND (0)
CSF: Albumin (Serum) [g/l]
CSF: Albumin (Serum) not done
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ND (0)
CSF: IgA [mg/l]
CSF: IgA not done
ND (0)
CSF: IgG [mg/l]
CSF: IgG not done
ND (0)
CSF: IgM [mg/l]
CSF: IgM not done
ND (0)
CSF: Lactate
mmol/l
CSF: Lactate not done
ND (0)
CSF: Glucose (CSF)
mg/dl
CSF: Glucose (CSF) not done
ND (0)
Glucose (Serum)
mg/dl
CSF: Glucose (Serum) not done
ND (0)
CSF: Oligoclonal bands present
no (0)
yes (1)
CSF: Oligoclonal bands, number
CSF: Oligoclonal bands not done
ND (0)
CSF: Date of Signature
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Month 24: CSF Multiple Sclerosis ALAIN01 NCT02419378
Month 36: CSF Multiple Sclerosis ALAIN01
NCT02419378
Alemtuzumab in Autoimmune Inflammatory
Neurodegeneration: Mechanisms of Action and
Neuroprotective Potential (ALAIN01)
https://clinicaltrials.gov/ct2/show/NCT02419378
Principal Investigator Prof. Dr. Dr. Sven Meuth, University
Hospital Muenster, Germany
Part: Month 36
All rights reserved. Please visit https://medical-data-
models.org/forms/15638
Month 36: CSF Multiple Sclerosis
ALAIN01 NCT02419378
Cerebrospinal Fluid
Patient ID (derived)
CSF: informed consent
no (0)
yes (1)
CSF: Date
CSF: Cell Counts not done
ND (0)
CSF: Total White Blood Cell Count
/µl
CSF: Granulocytes [/µl]
CSF: Erythrocytes
/µl
CSF: Lymphocytes
/µl
CSF: Other cells [/µl]
CSF: Atypical cells [/µl]
CSF: Total protein
mg/l
CSF: Total protein not done
ND (0)
CSF: Albumin (CSF) [mg/l]
CSF: Albumin (CSF) not done
ND (0)
CSF: Albumin (Serum) [g/l]
CSF: Albumin (Serum) not done
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ND (0)
CSF: IgA [mg/l]
CSF: IgA not done
ND (0)
CSF: IgG [mg/l]
CSF: IgG not done
ND (0)
CSF: IgM [mg/l]
CSF: IgM not done
ND (0)
CSF: Lactate
mmol/l
CSF: Lactate not done
ND (0)
CSF: Glucose (CSF)
mg/dl
CSF: Glucose (CSF) not done
ND (0)
Glucose (Serum)
mg/dl
CSF: Glucose (Serum) not done
ND (0)
CSF: Oligoclonal bands present
no (0)
yes (1)
CSF: Oligoclonal bands, number
CSF: Oligoclonal bands not done
ND (0)
CSF: Date of Signature
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Month 36: CSF Multiple Sclerosis ALAIN01 NCT02419378
Discontinuation Visit: CSF Multiple
Sclerosis ALAIN01 NCT02419378
Alemtuzumab in Autoimmune Inflammatory
Neurodegeneration: Mechanisms of Action and
Neuroprotective Potential (ALAIN01)
https://clinicaltrials.gov/ct2/show/NCT02419378
Principal Investigator Prof. Dr. Dr. Sven Meuth, University
Hospital Muenster, Germany
Part: Discontinuation Visit
All rights reserved. Please visit https://medical-data-
models.org/forms/15639
Discontinuation Visit: CSF Multiple
Sclerosis ALAIN01 NCT02419378
Cerebrospinal Fluid
Patient ID (derived)
CSF: informed consent
no (0)
yes (1)
CSF: Date
CSF: Cell Counts not done
ND (0)
CSF: Total White Blood Cell Count
/µl
CSF: Granulocytes [/µl]
CSF: Erythrocytes
/µl
CSF: Lymphocytes
/µl
CSF: Other cells [/µl]
CSF: Atypical cells [/µl]
CSF: Total protein
mg/l
CSF: Total protein not done
ND (0)
CSF: Albumin (CSF) [mg/l]
CSF: Albumin (CSF) not done
ND (0)
CSF: Albumin (Serum) [g/l]
CSF: Albumin (Serum) not done
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ND (0)
CSF: IgA [mg/l]
CSF: IgA not done
ND (0)
CSF: IgG [mg/l]
CSF: IgG not done
ND (0)
CSF: IgM [mg/l]
CSF: IgM not done
ND (0)
CSF: Lactate
mmol/l
CSF: Lactate not done
ND (0)
CSF: Glucose (CSF)
mg/dl
CSF: Glucose (CSF) not done
ND (0)
Glucose (Serum)
mg/dl
CSF: Glucose (Serum) not done
ND (0)
CSF: Oligoclonal bands present
no (0)
yes (1)
CSF: Oligoclonal bands, number
CSF: Oligoclonal bands not done
ND (0)
CSF: Date of Signature
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Discontinuation Visit: CSF Multiple Sclerosis ALAIN01 NCT02419378
Baseline 1st cycle Trial Medication Multiple
Sclerosis ALAIN01 NCT02419378
Alemtuzumab in Autoimmune Inflammatory
Neurodegeneration: Mechanisms of Action and
Neuroprotective Potential (ALAIN01)
https://clinicaltrials.gov/ct2/show/NCT02419378
Principal Investigator Prof. Dr. Dr. Sven Meuth, University
Hospital Muenster, Germany
Part: Baseline 1st cycle Trial Medication
All rights reserved. Please visit https://medical-data-
models.org/forms/15640
Baseline 1st cycle Trial Medication
Multiple Sclerosis ALAIN01
NCT02419378
Trial Medication
Patient ID (derived)
Trial Medication: Deferral Comment
Trial Medication: Pregnancy Test
Test not done (0)
Test done (1)
Trial Medication: Pregnancy Test, Kind of test
blood (1)
urine (2)
Trial Medication Pregnancy Test: Date
Trial MedicationI Pregnancy Test: Result
negative (0)
positive (1)
Trial Medication Pregnancy Test: Reason
no childbearing potential (0)
other (9)
Trial Medication Pregnancy Test: Reason, Text
Trial Medication: Date of Signature
Trial Medication: Signature yes/no
no (0)
yes (1)
Comment Trial Medication
Trial Medication RQG
Trial Medication: Date of Administration
Trial Medication: Dose administered
mg
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Trial Medication: Batch No
Trial Medication: Expiry Date
Trial Medication: Reason if less than 12 mg
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Baseline 1st cycle Trial Medication Multiple Sclerosis ALAIN01
NCT02419378
Month 12 2nd cycle Trial Medication
Multiple Sclerosis ALAIN01 NCT02419378
Alemtuzumab in Autoimmune Inflammatory
Neurodegeneration: Mechanisms of Action and
Neuroprotective Potential (ALAIN01)
https://clinicaltrials.gov/ct2/show/NCT02419378
Principal Investigator Prof. Dr. Dr. Sven Meuth, University
Hospital Muenster, Germany
Part: Month 12 2nd cycle Trial Medication
All rights reserved. Please visit https://medical-data-
models.org/forms/15641
Month 12 2nd cycle Trial Medication
Multiple Sclerosis ALAIN01
NCT02419378
Trial Medication
Patient ID (derived)
Trial Medication: Deferral Comment
Trial Medication: Pregnancy Test
Test not done (0)
Test done (1)
Trial Medication: Pregnancy Test, Kind of test
blood (1)
urine (2)
Trial Medication Pregnancy Test: Date
Trial MedicationI Pregnancy Test: Result
negative (0)
positive (1)
Trial Medication Pregnancy Test: Reason
no childbearing potential (0)
other (9)
Trial Medication Pregnancy Test: Reason, Text
Trial Medication: Date of Signature
Trial Medication: Signature yes/no
no (0)
yes (1)
Comment Trial Medication
Trial Medication RQG
Trial Medication: Date of Administration
Trial Medication: Dose administered
mg
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Trial Medication: Batch No
Trial Medication: Expiry Date
Trial Medication: Reason if less than 12 mg
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Month 12 2nd cycle Trial Medication Multiple Sclerosis ALAIN01
NCT02419378
Relapse Evaluation Visit No. 1: Relapse Confirmation
Multiple Sclerosis ALAIN01 NCT02419378
Alemtuzumab in Autoimmune Inflammatory
Neurodegeneration: Mechanisms of Action and
Neuroprotective Potential (ALAIN01)
https://clinicaltrials.gov/ct2/show/NCT02419378
Principal Investigator Prof. Dr. Dr. Sven Meuth, University
Hospital Muenster, Germany
Part: Relapse Evaluation Visit No. 1
All rights reserved. Please visit https://medical-data-
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BrUOG L301 With Non-Small Cell Lung Cancer and Bone
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https://clinicaltrials.gov/show/NCT02283749
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Eligibility Non Small Cell Lung
Cancer With Bone Metastatses
NCT02283749
Inclusion Criteria
age ≥ 18 years. advanced non-small cell lung
cancer with bone metastases. stable or
responding disease after completion of initial
systemic chemotherapy as defined by recist
criteria. site to submit confirmation to bruog.*
Yes
No
at least 3 weeks must have elapsed since
completion of last chemotherapy or radiation prior
to first dose of xofigo. patients are not permitted
to receive any form of*
Yes
No
'maintenance' chemotherapy or biologic/targeted
anticancer therapy while being treated on this
study life expectancy of at least 12 weeks (3
months). patients with treated brain metastases
are allowed, but must have brain imaging
showing evidence of stability since most recent
treatment for brain mets, prior to first dose of
xofigo. scan must be sent to bruog with
registration information before patient is
registered on study.*
Yes
No
eastern cooperative oncology group (ecog)
performance status of 0 - 1. required entry
laboratory parameters within 14 days of study
entry: white blood cell  count (wbc) ≥*
Yes
No
3,000/mm3; absolute neutrophil count (anc) ≥
1,500/mm3; platelet  (plt) count ≥*
Yes
No
100,000/mm3; hemoglobin (hgb) > 9g/dl, total
bilirubin level ≤ 1.5 x institutional upper limit of
normal (uln); aspartate aminotransferase (ast)
and alanine aminotransferase (alt)*
Yes
No
≤ 2.5 x uln ; creatinine ≤ 1.5 x uln; albumin > 2.5
g/dl.*
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Yes
No
concurrent treatment with bisphosphonates and
denosumab is allowed. information on start and
stop date and drug with dose to be sent to bruog
if patient to be treated concurrently.*
Yes
No
prior skeletal related events (pathologic fracture,
radiation or surgery to bone, or spinal  cord
compression) are allowed if they have been
managed and now patient is stable for 4 weeks
prior to study entry. must submit how events
managed to bruog for documentation to confirm
eligibility criterion. (for example, if a patient
experienced a sse and had radiation for 2 weeks
they must then be stable for 4 weeks after the
completion of radiation prior to study entry)
subjects must be able to understand and be
willing to sign the written informed consent
form.*
Yes
No
all acute toxic effects related to prior treatment(s)
must have resolved to nci-ctcae v4 grade 1 or
less at the time of signing the informed consent
form (icf) except for alopecia.*
Yes
No
women of childbearing potential must have a
negative serum pregnancy test performed within
7 days prior to the start of study drug.  post-
menopausal women (defined as no menses for at
least 1 year) and surgically sterilized women are
not required to undergo a pregnancy test.*
Yes
No
subjects (men and women) of childbearing
potential must agree to use adequate
contraception beginning at the signing of the icf
until at least 30 days after the last dose  of study
drug.  the definition of adequate contraception
will be based on the judgment of  the treating
physician.*
Yes
No
willing and able to comply with the protocol,
including follow-up visits and  examinations*
Yes
No
Exclusion Criteria
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received systemic therapy with radionuclides
(e.g., strontium-89, samarium-153, rhenium-186,
or rhenium-188, or radium ra 223 dichloride) for
the treatment of bony metastases no prior
invasive malignancy within the prior two years.
however, patients with an early  stage malignancy
that is not expected to require treatment in the
next 2 years (such as  early stage, resected
breast cancer or asymptomatic prostate cancer)
are eligible untreated brain metastases. any other
serious illness or medical condition that in the
investigator's opinion would interfere with protocol
treatment, such as but not limited to: any active
infection ≥ national cancer institute common
terminology criteria for adverse events (nci-ctcae)
version 4 grade 2: cardiac failure new york heart
association (nyha) iii or iv women who are
pregnant or breast-feeding. inability to comply
with the protocol and/or not willing or who will not
be available for follow-up assessments.*
Yes
No
any condition which, in the investigator's opinion,
makes the subject unsuitable for trial
participation.*
Yes
No
concurrent anti-cancer therapy (chemotherapy,
radiation therapy, surgery,  immunotherapy,
biologic therapy, or tumor embolization) other
than ra 223 dichloride.*
Yes
No
major surgery within 28 days of starting study
drug. central venous catheter placement is not
considered major surgery.*
Yes
No
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Pädiatrische Rheumatologie
Symptomtagebuch
Jede Reihe entspricht einem Tag des Monats. Bitte füllen
Sie das Tagebuch an jedem Tag der Attacken aus. Geben
sie die Symptome als vorhanden (1) oder nicht-vorhanden
(0) an.
Nutzen Sie für jeden Monate eine neue Tagebuch-Seite.
Wenn keine Attacke bestand, geben Sie die leere
Tagebuch-Seite ab.
Bitte geben Sie nur Symptome an, die im Zusammenhang
mit dem familiären Mittelmeerfieber stehen (falls unsicher,
bitte angeben).
Zur Verfügung gestellt von Prof. Dirk Föll,
Universitätsklinikum Münster
All rights reserved. Please visit https://medical-data-
models.org/forms/15655
Syptomtagebuch (AIDAI)
Symptomtagebuch familiäres
Mittelmeerfieber
Name
Monat der Aufzeichnung
Jahr der Aufzeichnung
Tag Nummer (1-31)
Fieber > 38°C
Ja
Nein
Gesamtbeschwerden
Ja
Nein
Bauchschmerzen
Ja
Nein
Übelkeit/Erbrechen
Ja
Nein
Diarrhoe
Ja
Nein
Kopfschmerzen
Ja
Nein
Brustschmerzen
Ja
Nein
Schmerzhafte Lymphknoten
Ja
Nein
Gelenk- oder Muskelschmerzen
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Ja
Nein
Gelenkschwellung
Ja
Nein
Augenprobleme
Ja
Nein
Hautrötung
Ja
Nein
Schmerzmitteleinnahme
Ja
Nein
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Pädiatrische Rheumatologie Symptomtagebuch
Eligibility Non-melanoma Skin Cancer
NCT02409628
EktoTherix™ Regenerative Tissue Scaffold for Repair of
Surgical Excision Wounds; ODM derived from:
https://clinicaltrials.gov/show/NCT02409628
All rights reserved. Please visit https://medical-data-
models.org/forms/15656
Eligibility Non-melanoma Skin
Cancer NCT02409628
Inclusion Criteria
is the patient at least 18 years of age*
Yes
No
is the patient male, or is not pregnant or lactating
and is using contraception*
Yes
No
has the patient been diagnosed with a non-
melanoma skin cancer (basal cell carcinoma bcc
or squamous cell carcinoma scc) for which the
chosen therapeutic option is surgical excision
followed by secondary intention healing*
Yes
No
is the excisional wound greater than 10mm x
10mm in size and less than or equal to 35mm x
35mm after any attempt at primary closure*
Yes
No
does the patient have limited skin laxity which
would make primary closure of the surgical
excision difficult*
Yes
No
is the patient able to understand the aims and
objectives of the trial and are they willing to
consent*
Yes
No
Exclusion Criteria
has the patient been diagnosed with any
transmittable viral diseases (hiv, hepatitis b or c)*
Yes
No
has the patient been diagnosed with, or is it
suspected that they have metastatic disease*
Yes
No
does the patient have a history of malignant
melanoma or any concomitant disease likely to
impede wound healing*
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Yes
No
has the patient been diagnosed with pre-existing
wound infection*
Yes
No
is the patient taking any medication known to
interfere with skin grafts (i.e. warfarin and other
anticoagulants, steroids, nsaids and
immunosuppressants)*
Yes
No
has the excised wound been entirely treated by
primary closure*
Yes
No
does the patient have a history of any significant
cardiac, pulmonary, renal, hepatic, neurological
and/ or immune dysfunction that may affect
wound healing*
Yes
No
does the patient know of any allergy to any of the
device materials to be used in the trial*
Yes
No
does the patient have a known history of poor
compliance with medical treatment*
Yes
No
has the patient participated in this trial previously
and healed or been withdrawn*
Yes
No
is the patient currently participating in any other
clinical trial*
Yes
No
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Eligibility Non-melanoma Skin Cancer NCT02409628
18pp EBMT Amyloidosis
DOCUMENTED PATHOGENS (Use this table for guidance
on the pathogens of interest)
Bacteria: S. pneumoniae, Other gram positive (i.e.: other
streptococci, staphylococci, listeria …),Haemophilus
influenzae,  Other gram negative (i.e.: E. coli klebsiella,
proteus, serratia, pseudomonas …), Legionella sp,
Mycobacteria sp, Other
Fungi: Candida sp, Aspergillus sp, Pneumocystis carinii,
Other
Parasites: Toxoplasma gondii, Other
Viruses: HSV, VZV, EBV, CMV, HHV-6, RSV. Other
respiratory virus (influenza, parainfluenza, rhinovirus),
Adenovirus, HBV, HCV, HIV,Papovavirus, Parvovirus, Other
All rights reserved. Please visit https://medical-data-
models.org/forms/15657
18pp EBMT Amyloidosis
GENERAL INFORMATION TEAM
EBMT Centre Identification Code (CIC)
Name of the hospital
Unit
Name of contact person
Telephone number
Fax
E-Mail
Date of this report
Patient following national / international study /
trial
No (1)
Yes (2)
Not evaluated (3)
Unknown (4)
Name of study / trial
GENERAL INFORMATION PATIENT
To be entered only if patient previously reported
Hospital Unique Patient Number or Code
First name(s)_surname(s)
Date of birth
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Sex
Male (1)
Female (2)
ABO Group
Rh factor Donor a
Yes
No
DISEASE
Date of diagnosis
Check the disease for which this transplant was
performed
Acute Leukaemia (Acute Leukaemia)
Acute Lymphoblastic Leukaemia (ALL)
(Acute Lymphoblastic Leukaemia (ALL))
Acute Myelogenous Leukaemia (AML)
(Acute Myelogenous Leukaemia (AML))
Autoimmune disease (Autoimmune
disease)
Bone marrow failure including Aplastic
anaemia (Bone marrow failure including
Aplastic anaemia)
Chronic Leukaemia (Chronic Leukaemia)
Chronic Lymphocytic Leukaemia
(Chronic Lymphocytic Leukaemia)
Chronic Myeloid Leukaemia (CML)
(Chronic Myeloid Leukaemia (CML))
Haemoglobinopathiy
(Haemoglobinopathiy)
Histiocytic disorders (Histiocytic
disorders)
Hodgkin´s Disease (Hodgkin´s Disease)
Inherited disorders (Inherited disorders)
Juvenile Idiopathic Arthritis (Juvenile
Idiopathic Arthritis)
Lymphoma (Lymphoma)
MD/ MPN (MD/ MPN)
MDS (MDS)
Metabolic disorders (Metabolic
disorders)
Multiple Sclerosis (Multiple Sclerosis)
Myelodysplastic syndromes
(Myelodysplastic syndromes)
Myeloma/ Plasma cell disorder
(Myeloma/ Plasma cell disorder)
Myeloproliferative neoplasm
(Myeloproliferative neoplasm)
Non Hodgkin (Non Hodgkin)
Other diagnosis (Other diagnosis)
Primary immune deficiencies (Primary
immune deficiencies)
Secondary Acute Leukaemia (do not use
if transformed from MDS/MPN)
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18pp EBMT Amyloidosis
(Secondary Acute Leukaemia (do not
use if transformed from MDS/MPN))
Solid Tumour (Solid Tumour)
Systemic Lupus (Systemic Lupus)
Systemic Sclerosis (Systemic Sclerosis)
AL AMYLOIDOSIS INITIAL DIAGNOSIS
Has the information requested in this section
been submitted with a previous HSCT registration
for this patient?
Yes: go to page 3, Pre-HSCT Treatment
(1)
No: proceed with this section (2)
EVIDENCE OF UNDERLYING PLASMA CELL
DISORDER
Yes
No
if yes
Monoclonal Gammopathy (Monoclonal
Gammopathy)
Multiple Myeloma (Multiple Myeloma)
Other B-cell malignancy (Other B-cell
malignancy)
If Other B-cell malignancy, specify
Select one as applicable
IgG (1)
IgA (2)
IgD (3)
IgE (4)
IgM (5)
Absent (6)
Not evaluated (7)
Select one as applicable
Kappa (1)
Lambda (2)
Absent (3)
Not evaluated (4)
If Multiple myeloma
I (I)
II (II)
III (III)
If Multiple myeloma
Yes
No
DIAGNOSIS OF AMYLOIDOSIS
Excluded (1)
Not evaluated (2)
DIAGNOSIS OF AMYLOIDOSIS
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Done (Done)
Not evaluated (Not evaluated)
Hb (g/dl)
CLINICAL AND LABORATORY DATA
Hb (g/dl)
CLINICAL AND LABORATORY DATA
Not evaluated (1)
CLINICAL AND LABORATORY DATA
CLINICAL AND LABORATORY DATA
Serum creatinine
mg/dL (mg/dL)
μmol/L (μmol/L)
CLINICAL AND LABORATORY DATA
Serum creatinine
Not evaluated (1)
CLINICAL AND LABORATORY DATA
Creatinine clearance (mL/min)
Creatinine clearance (mL/min)
CLINICAL AND LABORATORY DATA
Not evaluated (1)
Total urinary protein excretion (mg/24 h)
CLINICAL AND LABORATORY DATA
CLINICAL AND LABORATORY DATA
Total urinary protein excretion (mg/24 h)
Not evaluated (1)
Total urinary albumin excretion (mg/24 h)
CLINICAL AND LABORATORY DATA
Total urinary albumin excretion (mg/24 h)
CLINICAL AND LABORATORY DATA
Not evaluated (1)
Serum calcium (mmol/L)
CLINICAL AND LABORATORY DATA
Serum calcium (mmol/L)
CLINICAL AND LABORATORY DATA
Not evaluated (1)
Serum albumin (g/L)
CLINICAL AND LABORATORY DATA
Serum albumin (g/L)
CLINICAL AND LABORATORY DATA
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Not evaluated (1)
Serum alkaline phosphatase (IU/L)
CLINICAL AND LABORATORY DATA
Serum alkaline phosphatase (IU/L)
CLINICAL AND LABORATORY DATA
Not evaluated (1)
Serum bilirubin
CLINICAL AND LABORATORY DATA
μmol/L  (1)
mg/dL (2)
Serum bilirubin
CLINICAL AND LABORATORY DATA
Serum bilirubin
CLINICAL AND LABORATORY DATA
Not evaluated (1)
Serum NT-pro-BNP (ng/L)
CLINICAL AND LABORATORY DATA
CLINICAL AND LABORATORY DATA
Serum NT-pro-BNP (ng/L)
Not evaluated (1)
Serum c-Troponin T (μg/L)
CLINICAL AND LABORATORY DATA
Serum c-Troponin T (μg/L)
CLINICAL AND LABORATORY DATA
Not evaluated (1)
BM aspirate: % plasmacytosis
BM aspirate % plasmacytosis
Not evaluated (1)
BM trephine % plasmacytosis
BM trephine: % plasmacytosis
Not evaluated (1)
Monoclonal Ig in serum
g/L
Immunofixation of serum
Negative  (1)
Positive  (2)
Not evaluated  (3)
Unknown (4)
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Free light chains in serum
Kappa light chains
mg/L
Kappa light chains Not evaluated
Yes
No
Lambda light chains
mg/L
Lambda light chains Not evaluated
Yes
No
Immunofixation of urine
Negative  (1)
Positive  (2)
Not evaluated  (3)
Unknown (4)
Monoclonal light chains in urine
g/24h
Serum Beta2 microglobulin
mg/L
Bone structure (X-ray)
Normal  (1)
Lytic lesion present  (2)
Not evaluated  (3)
Unknown (4)
Macroglossy 
Typical clinical symptoms
Absent  (1)
Present  (2)
Not evaluated  (3)
Unknown (4)
Periorbital bleeding
Typical clinical symptoms
Absent  (1)
Present  (2)
Not evaluated  (3)
Unknown (4)
Shoulder pad sign
Typical clinical symptoms
Absent  (1)
Present  (2)
Not evaluated  (3)
Unknown (4)
ORGAN INVOLVEMENT AT DIAGNOSIS
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18pp EBMT Amyloidosis
Soft Tissues
Additional organ involvement (Additional
organ involvement)
Biopsy (Biopsy)
Dominant organ(s) involved (Dominant
organ(s) involved)
No involvement (No involvement)
Gastrointestinal Tract
Dominant organ(s) involved (1)
Additional organ involvement (2)
Biopsy (3)
No involvement (4)
Heart
Dominant organ(s) involved (1)
Additional organ involvement (2)
Biopsy (3)
No involvement (4)
Liver
Dominant organ(s) involved (1)
Additional organ involvement (2)
Biopsy (3)
No involvement (4)
Kidney
Dominant organ(s) involved (1)
Additional organ involvement (2)
Biopsy (3)
No involvement (4)
Peripheral nerves
Dominant organ(s) involved (1)
Additional organ involvement (2)
Biopsy (3)
No involvement (4)
Autonomic nerves
Dominant organ(s) involved (1)
Additional organ involvement (2)
Biopsy (3)
No involvement (4)
if other, please specify
Dominant organ(s) involved (1)
Additional organ involvement (2)
Biopsy (3)
No involvement (4)
Liver span in ultrasound or CT scan (cm
craniocaudal diameter)
Liver span in ultrasound or CT scan (cm
craniocaudal diameter) Not evaluated
Yes
No
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NYHA class
I (1)
II (2)
III (3)
IV (4)
not done (99)
Left Ventricular Ejection Fraction
%
Left ventricular ejection fraction Not evaluated
%
Yes
No
Interventricular septal wall thickness (mean # mm
in echocardiogram)
Interventricular septal wall thickness (mean # mm
in echocardiogram) Not evaluated
Yes
No
Weight loss
No  (1)
Yes  (2)
Not evaluated  (3)
Unknown (4)
Malabsorption
No  (1)
Yes  (2)
Not evaluated  (3)
Unknown (4)
GI bleeding
No  (1)
Yes  (2)
Not evaluated  (3)
Unknown (4)
If other evidence of gastrointestinal involvement,
please specify
Neurological exam
Abnormal  ( Abnormal )
Not evaluated or failed  ( Not evaluated
or failed )
Unknown ( Unknown)
Normal  (Normal )
If abnormal:
Specify abnormality
PNP severity
grade I  (1)
grade II  (2)
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grade III  (3)
grade IV (4)
Orthostatic hypotension
Yes  (1)
No  (2)
Not evaluated  (3)
Unknown (4)
Intractable diarrhoea
Yes  (1)
No  (2)
Not evaluated  (3)
Unknown (4)
Inflexible pulse rate
Yes  (1)
No  (2)
Not evaluated  (3)
Unknown (4)
Clinical evidence for involvement of other sites
PRE-HSCT TREATMENT
WAS THE PATIENT TREATED BEFORE THE
HSCT PROCEDURE?
No  (1)
Yes, Date started (2)
Chemotherapy
Modality
Yes
No
Modality, if Chemotherapy
Chemotherapy regimen (Chemotherapy
regimen)
Number of cycles (Number of cycles)
If Other, please specify
HSCT
DATE OF HSCT
HSCT TYPE Allogeneic: proceed to “Status at
Start of Conditioning” on page 4
Yes
No
Autologous: Date of 1st collection or pheresis
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STATUS OF DISEASE AT COLLECTION
(AUTOGRAFTS ONLY)
Haematological status
>CR2 VNUMSTM ( >CR2 VNUMSTM)
>PR2  ( >PR2 )
CR1  ( CR1 )
CR2  ( CR2 )
No change  ( No change )
PR1  ( PR1 )
Progression  ( Progression )
Unknown ( Unknown)
At diagnosis  (At diagnosis )
MR (MR)
PR2  (PR2 )
Organ status
At diagnosis  (1)
Response  (2)
No change  (3)
Progression  (4)
Unknown (5)
STATUS OF DISEASE AT START OF
CONDITIONING FOR BMT
Haematological status
>CR2  ( >CR2 )
>PR2  ( >PR2 )
CR2  ( CR2 )
MR ( MR)
No change  ( No change )
PR1  ( PR1 )
PR2  ( PR2 )
At diagnosis  (At diagnosis )
CR1  (CR1 )
Progression  (Progression )
Unknown (Unknown)
Organ status
At diagnosis  (1)
Response  (2)
No change  (3)
Progression  (4)
Unknown (5)
Hb (g/dl)
CLINICAL AND LABORATORY DATA
Hb (g/dl)
CLINICAL AND LABORATORY DATA
Not evaluated (1)
CLINICAL AND LABORATORY DATA
CLINICAL AND LABORATORY DATA
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Serum creatinine
mg/dL (mg/dL)
μmol/L (μmol/L)
CLINICAL AND LABORATORY DATA
Serum creatinine
Not evaluated (1)
CLINICAL AND LABORATORY DATA
Creatinine clearance (mL/min)
Creatinine clearance (mL/min)
CLINICAL AND LABORATORY DATA
Not evaluated (1)
Total urinary protein excretion (mg/24 h)
CLINICAL AND LABORATORY DATA
CLINICAL AND LABORATORY DATA
Total urinary protein excretion (mg/24 h)
Not evaluated (1)
Total urinary albumin excretion (mg/24 h)
CLINICAL AND LABORATORY DATA
Total urinary albumin excretion (mg/24 h)
CLINICAL AND LABORATORY DATA
Not evaluated (1)
Serum calcium (mmol/L)
CLINICAL AND LABORATORY DATA
Serum calcium (mmol/L)
CLINICAL AND LABORATORY DATA
Not evaluated (1)
Serum albumin (g/L)
CLINICAL AND LABORATORY DATA
Serum albumin (g/L)
CLINICAL AND LABORATORY DATA
Not evaluated (1)
Serum alkaline phosphatase (IU/L)
CLINICAL AND LABORATORY DATA
Serum alkaline phosphatase (IU/L)
CLINICAL AND LABORATORY DATA
Not evaluated (1)
Serum bilirubin
CLINICAL AND LABORATORY DATA
μmol/L  (1)
mg/dL (2)
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Serum bilirubin
CLINICAL AND LABORATORY DATA
Serum bilirubin
CLINICAL AND LABORATORY DATA
Not evaluated (1)
Serum NT-pro-BNP (ng/L)
CLINICAL AND LABORATORY DATA
CLINICAL AND LABORATORY DATA
Serum NT-pro-BNP (ng/L)
Not evaluated (1)
Serum c-Troponin T (μg/L)
CLINICAL AND LABORATORY DATA
Serum c-Troponin T (μg/L)
CLINICAL AND LABORATORY DATA
Not evaluated (1)
BM aspirate: % plasmacytosis
BM aspirate % plasmacytosis
Not evaluated (1)
BM trephine % plasmacytosis
BM trephine: % plasmacytosis
Not evaluated (1)
Monoclonal Ig in serum
g/L
Immunofixation of serum
Negative  (1)
Positive  (2)
Not evaluated  (3)
Unknown (4)
Free light chains in serum
Kappa light chains
mg/L
Kappa light chains Not evaluated
Yes
No
Lambda light chains
mg/L
Lambda light chains Not evaluated
Yes
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No
Immunofixation of urine
Negative  (1)
Positive  (2)
Not evaluated  (3)
Unknown (4)
Monoclonal light chains in urine
g/24h
Serum Beta2 microglobulin
mg/L
Soft Tissues
Additional organ involvement (Additional
organ involvement)
Biopsy (Biopsy)
Dominant organ(s) involved (Dominant
organ(s) involved)
No involvement (No involvement)
Gastrointestinal Tract
Dominant organ(s) involved (1)
Additional organ involvement (2)
Biopsy (3)
No involvement (4)
Heart
Dominant organ(s) involved (1)
Additional organ involvement (2)
Biopsy (3)
No involvement (4)
Liver
Dominant organ(s) involved (1)
Additional organ involvement (2)
Biopsy (3)
No involvement (4)
Kidney
Dominant organ(s) involved (1)
Additional organ involvement (2)
Biopsy (3)
No involvement (4)
Peripheral nerves
Dominant organ(s) involved (1)
Additional organ involvement (2)
Biopsy (3)
No involvement (4)
Autonomic nerves
Dominant organ(s) involved (1)
Additional organ involvement (2)
Biopsy (3)
No involvement (4)
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Liver span in ultrasound or CT scan (cm
craniocaudal diameter)
Liver span in ultrasound or CT scan (cm
craniocaudal diameter) Not evaluated
Yes
No
NYHA class
I (1)
II (2)
III (3)
IV (4)
not done (99)
Left Ventricular Ejection Fraction
%
Left ventricular ejection fraction Not evaluated
%
Yes
No
Interventricular septal wall thickness (mean # mm
in echocardiogram)
Interventricular septal wall thickness (mean # mm
in echocardiogram) Not evaluated
Yes
No
Weight loss
No  (1)
Yes  (2)
Not evaluated  (3)
Unknown (4)
Malabsorption
No  (1)
Yes  (2)
Not evaluated  (3)
Unknown (4)
GI bleeding
No  (1)
Yes  (2)
Not evaluated  (3)
Unknown (4)
If other evidence of gastrointestinal involvement,
please specify
Neurological exam
Abnormal  ( Abnormal )
Not evaluated or failed  ( Not evaluated
or failed )
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Unknown ( Unknown)
Normal  (Normal )
If abnormal:
Specify abnormality
PNP severity
grade I  (1)
grade II  (2)
grade III  (3)
grade IV (4)
Orthostatic hypotension
Yes  (1)
No  (2)
Not evaluated  (3)
Unknown (4)
Intractable diarrhoea
Yes  (1)
No  (2)
Not evaluated  (3)
Unknown (4)
Inflexible pulse rate
Yes  (1)
No  (2)
Not evaluated  (3)
Unknown (4)
Clinical evidence for involvement of other sites
STATUS OF DISEASE AT 100 DAYS
AFTER HSCT
BEST HAEMATOLOGICAL RESPONSE TO
HSCT AT 100 DAYS
>CR2 ( >CR2)
>PR2  ( >PR2 )
CR2  ( CR2 )
MR ( MR)
Progression  ( Progression )
Unknown ( Unknown)
CR1  (CR1 )
No change  (No change )
Not evaluable  (Not evaluable )
PR1  (PR1 )
PR2  (PR2 )
DATE RESPONSE ACHIEVED OR ASSESSED
Hb (g/dl)
CLINICAL AND LABORATORY DATA
Not evaluated (1)
CLINICAL AND LABORATORY DATA
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CLINICAL AND LABORATORY DATA
Serum creatinine
mg/dL (mg/dL)
μmol/L (μmol/L)
CLINICAL AND LABORATORY DATA
Serum creatinine
Not evaluated (1)
CLINICAL AND LABORATORY DATA
Creatinine clearance (mL/min)
Creatinine clearance (mL/min)
CLINICAL AND LABORATORY DATA
Not evaluated (1)
Total urinary protein excretion (mg/24 h)
CLINICAL AND LABORATORY DATA
CLINICAL AND LABORATORY DATA
Total urinary protein excretion (mg/24 h)
Not evaluated (1)
Total urinary albumin excretion (mg/24 h)
CLINICAL AND LABORATORY DATA
Total urinary albumin excretion (mg/24 h)
CLINICAL AND LABORATORY DATA
Not evaluated (1)
Serum calcium (mmol/L)
CLINICAL AND LABORATORY DATA
Serum calcium (mmol/L)
CLINICAL AND LABORATORY DATA
Not evaluated (1)
Serum albumin (g/L)
CLINICAL AND LABORATORY DATA
Serum albumin (g/L)
CLINICAL AND LABORATORY DATA
Not evaluated (1)
Serum alkaline phosphatase (IU/L)
CLINICAL AND LABORATORY DATA
Serum alkaline phosphatase (IU/L)
CLINICAL AND LABORATORY DATA
Not evaluated (1)
Serum bilirubin
CLINICAL AND LABORATORY DATA
μmol/L  (1)
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mg/dL (2)
Serum bilirubin
CLINICAL AND LABORATORY DATA
Serum bilirubin
CLINICAL AND LABORATORY DATA
Not evaluated (1)
Serum NT-pro-BNP (ng/L)
CLINICAL AND LABORATORY DATA
CLINICAL AND LABORATORY DATA
Serum NT-pro-BNP (ng/L)
Not evaluated (1)
Serum c-Troponin T (μg/L)
CLINICAL AND LABORATORY DATA
Serum c-Troponin T (μg/L)
CLINICAL AND LABORATORY DATA
Not evaluated (1)
BM aspirate: % plasmacytosis
BM aspirate % plasmacytosis
Not evaluated (1)
BM trephine % plasmacytosis
BM trephine: % plasmacytosis
Not evaluated (1)
Monoclonal Ig in serum
g/L
Immunofixation of serum
Negative  (1)
Positive  (2)
Not evaluated  (3)
Unknown (4)
Free light chains in serum
Kappa light chains
mg/L
Kappa light chains Not evaluated
Yes
No
Lambda light chains
mg/L
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Lambda light chains Not evaluated
Yes
No
Immunofixation of urine
Negative  (1)
Positive  (2)
Not evaluated  (3)
Unknown (4)
Monoclonal light chains in urine
g/24h
Serum Beta2 microglobulin
mg/L
ORGAN-SPECIFIC RESPONSES AT 100
DAYS AFTER HSCT
Kidney
Response  (1)
No response/stable disease  (2)
Progressive disease (3)
Not evaluable  (4)
Not evaluated/not applicable  (5)
Unknown (6)
Liver
Liver span in ultrasound or CT scan (cm
craniocaudal diameter)
Liver Not evaluated
Liver span in ultrasound or CT scan (cm
craniocaudal diameter)
Yes
No
Hepatic response
Response  (1)
No response/stable disease  (2)
Progressive disease (3)
Not evaluable  (4)
Not evaluated/not applicable  (5)
Unknown (6)
Heart
NYHA class
I (I)
II (II)
III (III)
IV (IV)
Unknown (Unknown)
Left ventricular ejection fraction
%
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Left ventricular ejection fraction
Not evaluated (1)
evaluated (2)
Interventricular septal wall thickness
(mean # mm in echocardiogram)
Interventricular septal wall thickness
(mean # mm in echocardiogram)
Not evaluated (1)
evaluated (2)
Cardiac response
No response/stable disease  ( No
response/stable disease )
Not evaluable  ( Not evaluable )
Not evaluated/not applicable  ( Not
evaluated/not applicable )
Progressive disease ( Progressive
disease)
Unknown ( Unknown)
Response  (Response )
Weight loss
No  (1)
Yes  (2)
Not evaluated  (3)
Unknown (4)
Malabsorption
No  (1)
Yes  (2)
Not evaluated  (3)
Unknown (4)
GI bleeding
No  (1)
Yes  (2)
Not evaluated  (3)
Unknown (4)
GI response
Response  (1)
No response/stable disease  (2)
Progressive disease (3)
Not evaluable  (4)
Not evaluated/not applicable  (5)
Unknown (6)
Neurological exam
Peripheral neuropathy
(Compare current situation to situation before
HSCT)
Improved  (1)
Worsened  (2)
Unchanged  (3)
Unknown (4)
PNP severity
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Peripheral neuropathy
(Compare current situation to situation before
HSCT)
grade I  (1)
grade II  (2)
grade III  (3)
grade IV (4)
PN response
Peripheral neuropathy
(Compare current situation to situation before
HSCT)
No response/stable disease  (No
response/stable disease )
Not evaluable  (Not evaluable )
Not evaluated/not applicable  (Not
evaluated/not applicable )
Progressive disease (Progressive
disease)
Response  (Response )
Unknown (Unknown)
AN response
Autonomic neuropathy
No response/stable disease  (No
response/stable disease )
Not evaluable  (Not evaluable )
Not evaluated/not applicable  (Not
evaluated/not applicable )
Progressive disease (Progressive
disease)
Response  (Response )
Unknown (Unknown)
Clinical evidence for involvement of new sites
Evidence of new organ involvement
KARNOFSKY
FORMS TO BE FILLED IN
Type of Transplant
ALLOgraft or Syngeneic graft (proceed to
Allograft form) (ALLOgraft or Syngeneic
graft (proceed to Allograft form))
AUTOgraft (proceed to Autograft form)
(AUTOgraft (proceed to Autograft form))
Other (contact the EBMT Central
Registry for instructions) (Other (contact
the EBMT Central Registry for
instructions))
FOLLOW UP AL AMYLOIDOSIS
Unique Identification Code (UIC)
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(if known)
Hospital Unique Patient Number
Initials
Date of birth
Date of HSCT
PATIENT LAST SEEN
Date of Last Contact or Death
Complete haematological remission obtained
after the HSCT in the absence of additional
disease treatment
Previously reported (1)
Yes, date (2)
No (3)
Unknown (4)
GRAFT VERSUS HOST DISEASE
(GvHD) SINCE LAST REPORT
Maximum Grade of Acute GVHD
Agvhd Grade 0 (0)
Agvhd Grade I (I)
Agvhd Grade Ii (II)
Agvhd Grade Iii (III)
Agvhd Grade Iv (IV)
Agvhd Present, Grade Unknown
(Present, grade unknown)
If present
New onset  (1)
Recurrent  (2)
Persistent (3)
Reason if present
DLI  (DLI )
Tapering  (Tapering )
Unexplained (Unexplained)
Date onset of this episode (if new or recurrent)
yyyy/mm/dd
Date onset of this episode Not applicable
Yes
No
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Stage skin
0 (1)
1 (2)
2 (3)
3 (4)
4 (5)
Not evaluated (6)
unknown (7)
Stage liver
0 (1)
1 (2)
2 (3)
3 (4)
4 (5)
Not evaluated (6)
unknown (7)
Stage gut
0 (1)
1 (2)
2 (3)
3 (4)
4 (5)
Not evaluated (6)
unknown (7)
Resolution
No  (1)
Yes (2)
Date of resolution
yyyy/mm/dd
Presence of cGvHD
No (No)
Present continously since last reported
episode (Present continously since last
reported episode)
Resolved (Resolved)
Yes (Yes)
Presence of cGVHD if yes
First episode (1)
Recurrence (2)
Date of onset
yyyy/mm/dd
cGvHD grade
limited (1)
Extensive (2)
Organs affected
Skin (1)
Gut (2)
Liver (3)
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Mouth (4)
Eyes (5)
Lung (6)
Other, specify (7)
Unknown (8)
If resolved, specify the date of resolution:
OTHER COMPLICATIONS SINCE LAST
REPORT
Infection related complications
Yes
No
Pathogen
Use the list of pathogens listed after this table for
guidance.
Use “unknown” if necessary
Date
Provide different dates for different episodes of
the same complication if applicable.
Pathogen
Use the list of pathogens listed after this table for
guidance.
Use “unknown” if necessary.
Date
Provide different dates for different episodes of
the same complication if applicable.
Pathogen
Use the list of pathogens listed after this table for
guidance.
Use “unknown” if necessary.
Date
Provide different dates for different episodes of
the same complication if applicable.
Pathogen
Use the list of pathogens listed after this table for
guidance.
Use “unknown” if necessary.
Date
Provide different dates for different episodes of
the same complication if applicable.
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Pathogen
Use the list of pathogens listed after this table for
guidance.
Use “unknown” if necessary.
Date
Provide different dates for different episodes of
the same complication if applicable.
Pathogen
Use the list of pathogens listed after this table for
guidance.
Use “unknown” if necessary.
Date
Provide different dates for different episodes of
the same complication if applicable.
Pathogen
Use the list of pathogens listed after this table for
guidance.
Use “unknown” if necessary.
Date
Provide different dates for different episodes of
the same complication if applicable.
Pathogen
Use the list of pathogens listed after this table for
guidance.
Use “unknown” if necessary
Date
Provide different dates for different episodes of
the same complication if applicable.
Pathogen
Use the list of pathogens listed after this table for
guidance.
Use “unknown” if necessary.
Date
Provide different dates for different episodes of
the same complication if applicable.
Pathogen
Use the list of pathogens listed after this table for
guidance.
Use “unknown” if necessary.
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Date
Provide different dates for different episodes of
the same complication if applicable.
Pathogen
Use the list of pathogens listed after this table for
guidance.
Use “unknown” if necessary.
Date
Provide different dates for different episodes of
the same complication if applicable
Pathogen
Use the list of pathogens listed after this table for
guidance.
Use “unknown” if necessary
Date
Provide different dates for different episodes of
the same complication if applicable.
Non infection related complications
Yes
No
CTC grade Cardiovascular
0 (1)
1 (2)
2 (3)
3 (4)
4 (5)
Date Cardiovascular
Comments
CTC grade Dermatologic
0 (1)
1 (2)
2 (3)
3 (4)
4 (5)
Date Dermatologic
Comments
CTC grade Gastrointestinal
0 (1)
1 (2)
2 (3)
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3 (4)
4 (5)
Date Gastrointestinal
Comments
CTC grade Haemorrhage
0 (1)
1 (2)
2 (3)
3 (4)
4 (5)
Date Haemorrhage
Haemorrhage Comments
CTC grade Hepatic
0 (1)
1 (2)
2 (3)
3 (4)
4 (5)
Date Hepatic
Comments
CTC grade Neurologic
0 (1)
1 (2)
2 (3)
3 (4)
4 (5)
Date Neurologic
Neurologic Comments
CTC grade Pulmonary
0 (1)
1 (2)
2 (3)
3 (4)
4 (5)
Pulmonary Date
Pulmonary Comments
CTC grade Renal
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0 (1)
1 (2)
2 (3)
3 (4)
4 (5)
Renal Date
Renal Comments
Other CTC grade
0 (1)
1 (2)
2 (3)
3 (4)
4 (5)
Date of other Typte
Comments of Other type
Graft loss
No (No)
Not evaluated (Not evaluated)
Yes (Yes)
Overall chimaerism
Full (donor >95 %)  (1)
Mixed (partial) (2)
Autologous reconstitution (recipient >95
%)  (3)
Aplasia (4)
Not evaluated (5)
GRAFT ASSESSMENT AND
HAEMOPOIETIC CHIMAERISM
Date of Test
Identification of donor or Cord Blood Unit given
by the centre
Number in the infusion order (if applicable)
Number in the infusion order
N/A (1)
Cell type on which test was performed (% Donor
Cells):
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BM
%
Cell type on which test was performed (% Donor
cells):
PB mononuclear cells (PBMC)
%
Cell type on which test was performed (% Donor
cells):
T-Cells
%
Cell type on which test was performed (% Donor
cells):
B-Cells
%
Cell type on which test was performed (% Donor
cells):
Red blood cells
%
Cell type on which test was performed (% Donor
cells):
Monocytes
%
Cell type on which test was performed (% Donor
cells):
PMNs (neutrophils)
%
Cell type on which test was performed (% Donor
cells):
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Lymphocytes, NOS
%
Cell type on which test was performed (% Donor
cells):
Myeloid cells, NOS
%
Cell type on which test was performed (% Donor
cells):
%
Test used:
ABO group (ABO group)
Cytogenetic (Cytogenetic)
FISH (FISH)
Molecular (Molecular)
Other (Other)
unknown (unknown)
SECONDARY MALIGNANCY,
LYMPHOPROLIFERATIVE OR
MYELOPROLIFRATIVE DISORDER
DIAGNOSED
Previously reported (1)
Yes (2)
No at date of this follow-up (3)
Date of diagnosis
Diagnosis
AML  (1)
MDS  (2)
Lymphoproliferative disorder  (3)
Other (4)
If other diagnosis, please specify
ADDITIONAL THERAPIES SINCE LAST
FOLLOW UP
Treatment given since last report
No (No)
Unknown (Unknown)
Yes (Yes)
Date started
If yes: CELLULAR THERAPY
One cell therapy regimen is defined as any
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number of infusions given within 10 weeks for the
same indication. If more than one regimen of cell
therapy has been given since last report, copy
this section and complete it as many times as
necessary.
No (1)
Yes (2)
Unknown (3)
Disease status before this cellular therapy
CR  (1)
Not in CR  (2)
Not evaluated (3)
If yes: Type of cells
Donor lymphocyte infusion (DLI) (1)
Mesenchymal cells (2)
Other (3)
Unknown (4)
If DLI, specify the number of cells infused by
type:
Nucleated cells
Evaluated (Evaluated)
Not evaluated (Not evaluated)
unknown (unknown)
Number of Nucleated cells infused (DLI only)
10^8/kg
If DLI, specify the number of cells infused by
type:
CD 34+
Evaluated (Evaluated)
Not Evaluated (Not Evaluated)
Unknown (Unknown)
specify the number of cells infused by type:
CD 34+
If DLI, specify the number of cells infused by
type: 
CD 3+
Evaluated  (Evaluated )
Not evaluated (Not evaluated)
Unknown (Unknown)
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specify the number of cells infused by type: 
CD 3+
Total number of cells infused (non DLI only)
x10^6/kg
All cells
Evaluated (Evaluated)
Not Evaluated (Not Evaluated)
Unknown (Unknown)
Chronological number of this cell therapy for this
patient
Indication 
(check all that apply)
Loss/decreased chimaerism
(Loss/decreased chimaerism)
Mixed chimaerism (Mixed chimaerism)
Other (Other)
Planned/ protocol (Planned/ protocol)
Prophylactic (Prophylactic)
Treatment for disease (Treatment for
disease)
Treatment of GvHD (Treatment of GvHD)
Treatment PTLD, EBV, lymphoma
(Treatment PTLD, EBV, lymphoma)
Treatment viral infection (Treatment viral
infection)
Number of infusions within 10 weeks (count only
infusions that are part of same regimen and given
for the same indication)
Maximum Grade of Acute GVHD
Agvhd Grade 0 (0)
Agvhd Grade I (I)
Agvhd Grade Ii (II)
Agvhd Grade Iii (III)
Agvhd Grade Iv (IV)
Agvhd Present, Grade Unknown
(Present, grade unknown)
Disease treatment (apart from donor cell infusion
or other type of cell therapy)
No (1)
Yes: Planned (planned before HSCT took
place) (2)
Yes: Not planned (for
relapse/progression or persistent
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disease) (3)
FIRST EVIDENCE OF DISEASE
WORSENING SINCE LAST HSCT
EVIDENCE OF DISEASE ACTIVITY
Continuous worsening since HSCT
(Continuous worsening since HSCT)
No (No)
Previously reported (Previously reported)
Unknown (Unknown)
Yes (Yes)
If yes, date first noted
LAST DISEASE AND PATIENT STATUS
HAEMATOLOGICAL DISEASE STATUS
Complete remission (Complete
remission)
Not evaluable (Not evaluable)
Partial remission (Partial remission)
Progression (Progression)
Stable disease (Stable disease)
Unknown (Unknown)
Organ Response
Response (1)
Non Response (2)
Progression (3)
Not evaluable (4)
Unknown (5)
Hb (g/dl)
CLINICAL AND LABORATORY DATA
Not evaluated (1)
CLINICAL AND LABORATORY DATA
CLINICAL AND LABORATORY DATA
Serum creatinine
mg/dL (mg/dL)
μmol/L (μmol/L)
CLINICAL AND LABORATORY DATA
Serum creatinine
Not evaluated (1)
CLINICAL AND LABORATORY DATA
Creatinine clearance (mL/min)
Creatinine clearance (mL/min)
CLINICAL AND LABORATORY DATA
Not evaluated (1)
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Total urinary protein excretion (mg/24 h)
CLINICAL AND LABORATORY DATA
CLINICAL AND LABORATORY DATA
Total urinary protein excretion (mg/24 h)
Not evaluated (1)
Total urinary albumin excretion (mg/24 h)
CLINICAL AND LABORATORY DATA
Total urinary albumin excretion (mg/24 h)
CLINICAL AND LABORATORY DATA
Not evaluated (1)
Serum calcium (mmol/L)
CLINICAL AND LABORATORY DATA
Serum calcium (mmol/L)
CLINICAL AND LABORATORY DATA
Not evaluated (1)
Serum albumin (g/L)
CLINICAL AND LABORATORY DATA
Serum albumin (g/L)
CLINICAL AND LABORATORY DATA
Not evaluated (1)
Serum alkaline phosphatase (IU/L)
CLINICAL AND LABORATORY DATA
Serum alkaline phosphatase (IU/L)
CLINICAL AND LABORATORY DATA
Not evaluated (1)
Serum bilirubin
CLINICAL AND LABORATORY DATA
μmol/L  (1)
mg/dL (2)
Serum bilirubin
CLINICAL AND LABORATORY DATA
Serum bilirubin
CLINICAL AND LABORATORY DATA
Not evaluated (1)
Serum NT-pro-BNP (ng/L)
CLINICAL AND LABORATORY DATA
CLINICAL AND LABORATORY DATA
Serum NT-pro-BNP (ng/L)
Not evaluated (1)
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Serum c-Troponin T (μg/L)
CLINICAL AND LABORATORY DATA
Serum c-Troponin T (μg/L)
CLINICAL AND LABORATORY DATA
Not evaluated (1)
BM aspirate: % plasmacytosis
BM aspirate % plasmacytosis
Not evaluated (1)
BM trephine % plasmacytosis
BM trephine: % plasmacytosis
Not evaluated (1)
Monoclonal Ig in serum
g/L
Immunofixation of serum
Negative  (1)
Positive  (2)
Not evaluated  (3)
Unknown (4)
Free light chains in serum
Kappa light chains
mg/L
Kappa light chains Not evaluated
Yes
No
Lambda light chains
mg/L
Lambda light chains Not evaluated
Yes
No
Immunofixation of urine
Negative  (1)
Positive  (2)
Not evaluated  (3)
Unknown (4)
Monoclonal light chains in urine
g/24h
Serum Beta2 microglobulin
mg/L
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Renal response 
ORGAN-SPECIFIC RESPONSES AT THIS
FOLLOW UP
Response (1)
No response/stable disease (2)
Progressive disease (3)
Not evaluable (4)
Not evaluated/not applicable (5)
Unknown (6)
Liver
(cm craniocaudal diameter)
Liver
(cm craniocaudal diameter)
Not evaluated (1)
Hepatic response
No response/stable disease (No
response/stable disease)
Not evaluable (Not evaluable)
Not evaluated/not applicable (Not
evaluated/not applicable)
Progressive disease (Progressive
disease)
Response (Response)
Unknown (Unknown)
NYHA class
I (1)
II (2)
III (3)
IV (4)
unknown (5)
Left Ventricular Ejection Fraction
%
Left Ventricular Ejection Fraction
Not evaluated (1)
Interventricular septal wall thickness
(mean # mm in echocardiogram)
Interventricular septal wall thickness
(mean # mm in echocardiogram)
Not evaluated (1)
Cardiac response
Response  (1)
No response/stable disease  (2)
Progressive disease (3)
Not evaluable  (4)
Not evaluated/not applicable  (5)
Unknown (6)
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Weight loss
No  (1)
Yes  (2)
Not evaluated  (3)
Unknown (4)
Malabsorption
No  (1)
Yes  (2)
Not evaluated  (3)
Unknown (4)
GI bleeding
No  (1)
Yes  (2)
Not evaluated  (3)
Unknown (4)
GI response
Response  (1)
No response/stable disease  (2)
Progressive disease (3)
Not evaluable  (4)
Not evaluated/not applicable  (5)
Unknown (6)
Neurological exam
Improved  (1)
Worsened  (2)
Unchanged  (3)
Unknown (4)
PNP severity
grade I  (1)
grade II  (2)
grade III  (3)
grade IV (4)
PN response
Response  (1)
No response/stable disease  (2)
Progressive disease (3)
Not evaluable  (4)
Not evaluated/not applicable  (5)
Unknown (6)
AN response
Response  (1)
No response/stable disease  (2)
Progressive disease (3)
Not evaluable  (4)
Not evaluated/not applicable  (5)
Unknown (6)
Evidence of new organ involvement
Clinical evidence for involvement of new sites
Has patient or partner become pregnant after this
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HSCT?
Yes  (1)
No  (2)
Unknown (3)
Survival Status
alive (0)
dead (1)
Type of score used
PERFORMANCE SCORE (if alive)
Karnofsky (1)
Lansky (2)
Score
100 (Normal, NED) (1)
10 (Moribund) (10)
Not evaluated (11)
Unknown (12)
90 (Normal activity)  (2)
80 (Normal with effort) (3)
70 (Cares for self) (4)
60 (Requires occasional assistance) (5)
50 (Requires assistance) (6)
40 (Disabled) (7)
30 (Severely disabled) (8)
20 (Very sick) (9)
CAUSE OF DEATH
(check only one main cause)
Due to amyloidosis (progression of
disease) (1)
Secondary malignancy (including
lymphoproliferative disease) (2)
HSCT related cause (3)
unknown (4)
other (5)
cGvHD
Yes  (1)
No  (2)
Unknown (3)
Interstitial pneumonitis Cause
No  (1)
Yes (2)
Unknown (3)
Pulmonary toxicity Cause
Yes (1)
No (2)
Unknown (3)
Infection
Yes (1)
No (2)
Unknown (3)
Infection:
bacterial  (1)
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viral  (2)
fungal  (3)
parasitic  (4)
unknown (5)
Rejection / poor graft function
Yes (1)
No (2)
Unknown (3)
Veno-Occlusive disease (VOD)
Yes (1)
No (2)
Unknown (3)
Haemorrhage
Yes (1)
No (2)
Unknown (3)
Cardiac toxicity
Yes (1)
No (2)
Unknown (3)
Central nervous system toxicity
Yes (1)
No (2)
Unknown (3)
Gastro intestinal toxicity
Yes (1)
No (2)
Unknown (3)
Skin toxicity
Yes  (1)
No (2)
Unknown (3)
Renal failure
Yes (1)
No (2)
Unknown (3)
Multiple organ failure
Yes (1)
No (2)
Unknown (3)
If other HSCT related cause, please specify
ADDITIONAL NOTES IF APPLICABLE
Comments
IDENTIFICATION & SIGNATURE
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Eligibility Non-Small Cell Lung Cancer
(NSCLC) NCT02352948
A Global Study to Assess the Effects of MEDI4736, Given
as Monotherapy or in Combination With Tremelimumab
Determined by PD-L1 Expression Versus Standard of Care
in Patients With Locally Advanced or Metastatic Non Small
Cell Lung Cancer; ODM derived from:
https://clinicaltrials.gov/show/NCT02352948
All rights reserved. Please visit https://medical-data-
models.org/forms/15658
Eligibility Non-Small Cell Lung
Cancer (NSCLC) NCT02352948
Inclusion Criteria
aged at least 18 years*
Yes
No
documented evidence of nsclc (stage iiib/ iv
disease)*
Yes
No
disease progression or recurrence after both a
platinum-based chemotherapy regimen and at
least 1 additional regimen for treatment of nsclc*
Yes
No
world health organization (who) performance
status of 0 or 1*
Yes
No
estimated life expectancy more than 12 weeks*
Yes
No
Exclusion Criteria
prior exposure to any anti-pd-1 or anti-pd-l1
antibody or anti ctla4*
Yes
No
brain metastases or spinal cord compression
unless asymptomatic, treated and stable (not
requiring steroids)*
Yes
No
active or prior documented autoimmune disease
within the past 2 years*
Yes
No
evidence of severe or uncontrolled systemic
disease, including active bleeding diatheses or
active infections including hepatitis b, c and hiv*
Yes
No
any unresolved toxicity ctcae (common
1 / 2
terminology criteria of adverse events) >grade 2
from previous anti-cancer therapy*
Yes
No
known egfr tk activating mutations or alk
rearrangements*
Yes
No
any prior grade ≥3 immune-related adverse event
(irae) while receiving any previous
immunotherapy agent, or any unresolved irae
>grade 1*
Yes
No
active or prior documented inflammatory bowel
disease (eg, crohn's disease, ulcerative colitis)*
Yes
No
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Pädiatrische Rheumatologie JAMAR
Juvenile Arthritis -Multidimensionaler Assessment Report--
(JAMAR): Deutsche Übersetzung, zur Verfügung gestellt
von Prof. Dirk Föll, Universitätsklinikum Münster
All rights reserved. Please visit https://medical-data-
models.org/forms/15659
Juvenile Arthritis --
Multidimensionaler Assessment
Report- (JAMAR)
Demographische Informationen
Patienten ID
Datum der Visite
Vor-und Nachname d. Patienten (oder Initialen)
Datum
Bewertung der Fähigkeiten
Auf ebenem Boden mindestens 10 Meter rennen
Problemlos (1)
Leicht erschwert (2)
Stark erschwert (3)
Nicht möglich (4)
Fünf Treppenstufen steigen
Problemlos (1)
Leicht erschwert (2)
Stark erschwert (3)
Nicht möglich (4)
Vorwärts springen
Problemlos (1)
Leicht erschwert (2)
Stark erschwert (3)
Nicht möglich (4)
In die Hocke gehen
Problemlos (1)
Leicht erschwert (2)
Stark erschwert (3)
Nicht möglich (4)
Sich bücken um etwas vom Boden aufzuheben
Problemlos (1)
Leicht erschwert (2)
Stark erschwert (3)
Nicht möglich (4)
Durchführung von Aktivitäten, bei denen Du
Deine Finger benutzt
Problemlos (1)
Leicht erschwert (2)
Stark erschwert (3)
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Nicht möglich (4)
Öffnen und SChließen Deiner Fäuste
Problemlos (1)
Leicht erschwert (2)
Stark erschwert (3)
Nicht möglich (4)
Zusammendrücken eines Gegenstandes mit
Deinen Händen
Problemlos (1)
Leicht erschwert (2)
Stark erschwert (3)
Nicht möglich (4)
Öffnen einer Türe durch Herunterdrücken der
Klinke
Problemlos (1)
Leicht erschwert (2)
Stark erschwert (3)
Nicht möglich (4)
Wasserhähne auf und zudrehen oder bereits
zuvor geöffnete Konservengläser aufmachen
Problemlos (1)
Leicht erschwert (2)
Stark erschwert (3)
Nicht möglich (4)
Deine Arme ausstrecken
Problemlos (1)
Leicht erschwert (2)
Stark erschwert (3)
Nicht möglich (4)
Deine Hände hinter den Nacken legen
Problemlos (1)
Leicht erschwert (2)
Stark erschwert (3)
Nicht möglich (4)
Deinen Kopf drehen und über Deine Schultern
schauen
Problemlos (1)
Leicht erschwert (2)
Stark erschwert (3)
Nicht möglich (4)
Deinen Kopf in den Nacken legen und an die
Decke schauen
Problemlos (1)
Leicht erschwert (2)
Stark erschwert (3)
Nicht möglich (4)
In ein Butterbrot oder einen Apfel beißen
Problemlos (1)
Leicht erschwert (2)
Stark erschwert (3)
Nicht möglich (4)
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Wie groß waren die Schmerzen, die Du in der
letzten Woche aufgrund der Krankheit ertragen
musstest? (Wähle die genaueste Punktzahl)
0 Kein Schmerz (1)
4.5 (10)
5 (11)
5.5 (12)
6 (13)
6.5 (14)
7 (15)
7.5 (16)
8 (17)
8.5 (18)
9 (19)
0.5 (2)
9.5 (20)
10 Extremer Schmerz (21)
1 (3)
1.5 (4)
2 (5)
2.5 (6)
3 (7)
3.5 (8)
4 (9)
Schmerzen oder Schwellungen
Schmerzen oder Schwellungen linke Seite
Finger (1)
Handgelenk (2)
Ellenbogen (3)
Schulter (4)
Hüfte (5)
Knie (6)
Knöchel/Sprunggelenk (7)
Zehen (8)
Schmerzen oder Schwellungen rechte Seite
Finger (1)
Handgelenk (2)
Ellenbogen (3)
Schulter (4)
Hüfte (5)
Knie (6)
Knöchel/Sprunggelenk (7)
Zehen (8)
Schmerzen oder Schwellungen
Nacken (1)
unterer Rückenbereich (2)
Ich habe keine Gelenkschmerzen oder
Schwellungen
Ja
Nein
Hattest Du in der letzten Woche eine
Morgensteife beim Aufwachen?
Ja
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Nein
Falls Du Morgensteife hattest, wie lange dauerte
dieser Zustand an?
15 min oder weniger (1)
15-30 min (2)
30min bis zu einer Stunde (3)
1-2 Stunden (4)
Länger als 2 Stunden (5)
Hattest Du in der letzten Woche Fieber über 38°C
(Falls durch Arthritis verursacht)
Ja
Nein
Hattest Du in der letzten Woche Hautausschlag
(Falls durch Arthritis verursacht)
Ja
Nein
Wenn Du alle Beschwerden wie Schmerzen,
Gelenkschwellungen, Morgensteifigkeit, Fieber
(Falls durch Gelenkerkrankung verursacht) und
Hautausschlag (Falls durch Gelenkerkrankung
verursacht) betrachtest, wie würdest Du dann
Deine Krankheitsaktivität zum jetzigen Zeitpunkt
bewerten?
0 Keine Aktivität (1)
4.5 (10)
5 (11)
5.5 (12)
6 (13)
6.5 (14)
7 (15)
7.5 (16)
8 (17)
8.5 (18)
9 (19)
0.5 (2)
9.5 (20)
10 Maximale Aktivität (21)
1 (3)
1.5 (4)
2 (5)
2.5 (6)
3 (7)
3.5 (8)
4 (9)
Wie würdest Du den aktuellen Zustand Deiner
Krankheit bewerten?
Überhaupt keine Beschwerden
(Remission) (1)
Fortwährendes Vorhandensein von
Beschwerden (anhaltende Aktivität) (2)
Wiederauftreten der Beschwerden nach
einer längeren Zeit ohne Beschwerden
(Rückfall) (3)
Wie würdest Du den Verlauf Deiner Krankheit im
4 / 9
Pädiatrische Rheumatologie JAMAR
Vergleich zum letzten Arztbesuch bewerten?
Sehr viel besser (1)
Ein wenig besser (2)
Stabil/unverändert (3)
Etwas schlechter (4)
Viel schlechter (5)
Medikamente
Nimmst Du Medikamente zur Behandlung der
Arthritis ein?
Ja
Nein
Welche Medikamente nimmst Du zur Zeit ein?
NSAIDs (z.B.Ibuprofen,Naproxen) (1)
Canakinumab (Ilaris) (10)
Adalimumab (Humira) (11)
Abatacept (Orencia) (12)
Rilonacept (Arcalyst) (13)
Andere (bitte angeben) (14)
Steroide (z.B. Prednisolon) (2)
Methotrexat (z.B. MTX, Lantarel) (3)
Salazopyrin (z.B. Azulfidine) (4)
Etanercept (Enbrel) (5)
Anakinra (Kineret) (6)
Tocilizumab (Roactemra) (7)
Infliximab (Remicade) (8)
Certolizumab (Cimzia) (9)
Bitte gib an, welche Art NSAID (z.B.
Ibuprofen,Naproxen) Du nimmst
Bitte gib an, welche Art Steroide (z.B.
Prednisolon) Du nimmst
Falls Du Methotrexat nimmst, wie nimmst Du es
ein?
Oral (1)
Subkutan-Spritze (2)
Intramuskulär (3)
Welche anderen Medikamente nimmst Du zur
Behandlung der Arthritis?
Hast Du seit dem letzten Besuch Beschwerden
verspürt, die durch die von Dir genommenen
Medikamente verursacht sein könnten?
Ja
Nein
Falls Du mögliche Nebenwirkungen verspürt
hast, gib bitte an, welche
Fieber (1)
Schlafstörungen (10)
Magenschmerzen oder brennendes
Gefühl im Magen (11)
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Übelkeit (12)
Erbrechen (13)
Verstopfung (14)
Durchfall (15)
Schwarzer oder blutiger Stuhlgang (16)
Blut im Urin (17)
Schwellungen,Blutergüsse,Schmerzen,R
ötungen usw an der Einstichstelle (bei
Spritzen) (18)
Sonstige (Bitte beschreiben) (19)
Kopfschmerzen (2)
Hautausschlag (3)
Wunde Stellen im Mund (4)
Geschwollenes/blutendes Zahnfleisch
(5)
Vermehrter Haarwuchs am Körper (6)
Gewichtszunahme (7)
Gewichtsverlust (8)
Stimmungsschwankungen
(Erregung,Depressionen,Angstzustände)
(9)
Bitte beschreibe, welche anderen Beschwerden
Du hattest, die von den Medikamenten
verursacht sein könnten.
Nimmst Du Zuhause Deine Medikamente
regelmäßig (so wie sie der Arzt verordnet hat)?
Ja
Nein
Falls Du die Medikamente nicht regelmäßig
nimmst, warum nicht?
Ich weigere mich (1)
Organisatorische Probleme (z.B.
Probleme die Medikamente in der
Schule zu nehmen) (2)
Ich nehme zuviele Medikamente (3)
Zuviele Medikamentengaben am Tag (4)
Angst vor Nebenwirkungen (5)
Sonstige Gründe (bitte beschreiben) (6)
Falls Du die Medikamente nicht regelmäßig
nimmst, warum nicht (sonstige Gründe bitte
beschreiben)?
Welches Medikament lässt sich am schwierigsten
regelmäßig einnehmen?
Lebensqualitaet
Gehst Du zur Schule?
Ja
Nein
Falls Du zur Schule gehst, welche Probleme in
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der Schule verursacht die Krankheit?
Keine (1)
Häufige Fehlzeiten (2)
Schwierigkeiten lange zu sitzen (3)
Probleme im Verhältnis zu Lehrern (4)
Abnahme der Schulischen Leistungen
(5)
Sonstige (bitte beschreiben) (6)
Welche anderen Probleme gibt es mit der
Krankheit in der Schule?
Hattest Du Schwierigkeiten, für Dich selbst zu
sorgen, z.B. zu essen,Dich anzuziehen oder Dich
zu waschen
Nie (1)
Manchmal (2)
Oft (3)
Täglich (4)
Hattest Du Schwierigkeiten,einen Spaziergang
von 15 min zu unternehmen oder ein Stockwerk
höher zu steigen?
Nie (1)
Manchmal (2)
Oft (3)
Täglich (4)
Hattest Du Schwierigkeiten,Aktivitäten
durchzuführen, die viel Energie erfordern wie
z.B. Laufen,Fußball spielen, Tanzen usw.
Nie (1)
Manchmal (2)
Oft (3)
Täglich (4)
Hattest Du Schwierigkeitenschulische Tätigkeiten
zu verrichten oder mit Freunden zu spielen?
Nie (1)
Manchmal (2)
Oft (3)
Täglich (4)
Hattest Du irgendwelche Schmerzen?
Nie (1)
Manchmal (2)
Oft (3)
Täglich (4)
Hast Du Dich traurig oder niedergeschlagen
gefühlt?
Nie (1)
Manchmal (2)
Oft (3)
Täglich (4)
Hast Du Dich nervös oder ängstlich gefühlt?
Nie (1)
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Manchmal (2)
Oft (3)
Täglich (4)
Hattest Du Schwierigkeiten im Umgang mit
anderen Kindern?
Nie (1)
Manchmal (2)
Oft (3)
Täglich (4)
Hattest Du Schwierigkeiten Dich zu konzentrieren
oder aufmerksam zu sein?
Nie (1)
Manchmal (2)
Oft (3)
Täglich (4)
Warst Du mit Deinem Aussehen oder Deinen
Fähigkeiten unzufrieden?
Nie (1)
Manchmal (2)
Oft (3)
Täglich (4)
Warst Du mit Deinem Aussehen oder Deinen
Fähigkeiten unzufrieden?
Nie (1)
Manchmal (2)
Oft (3)
Täglich (4)
Wenn Du insgesamt berücksichtigst,wie die
Krankheit Dich beeiniträchtigt, teile uns bitte mit,
wie Du Dich im Moment fühlst
0 sehr gut (1)
4.5 (10)
5 (11)
5.5 (12)
6 (13)
6.5 (14)
7 (15)
7.5 (16)
8 (17)
8.5 (18)
9 (19)
0.5 (2)
9.5 (20)
10 sehr schlecht (21)
1 (3)
1.5 (4)
2 (5)
2.5 (6)
3 (7)
3.5 (8)
4 (9)
Wenn Du insgesamt daran denkst,welche
Probleme die Krankheit Dir macht, wärest Du
damit zufrieden, wenn dieser Zustand über die
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nächsten Monate so wie im Moment bliebe?
Ja
Nein
Einwilligungserklärung
Bitte gib an, ob Du Deine Zustimmung dazu
erteilst, dass die in diesem Fragebogen
enthaltenen Informationen für wissenschaftliche
Zwecke verwendet werden
Ich stimme zu (1)
Ich stimme nicht zu (2)
Unterschrift
Vor- und Nachname des Patienten bzw. Initialen
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ICPS - International Classification for
Patient Safety
ICPS Be 2013
International Classification for Patient Safety, Belgium
adaptation
provided by Prof. Dr. Jean-Marie Rodrigues
ODM-Version Prof. Dr. Martin Dugas
a) Incident Type_ICPS.2013.xml
b) Patient Outcomes_ICPS.2013.xml
c) Patient Characteristics_ICPS.2013.xml
d) Incident Characteristics_ICPS.2013.xml
e) Contributing FactorsHazards - External
Factors_ICPS.2013.xml
f) Mitigating Factors_ICPS.2013.xml
g) Detection_ICPS.2013.xml
h) Organizational Outcomes_ICPS.2013.xml
i) Ameliorating Actions_ICPS.2013.xml
j) Actions To Reduce Risk_ICPS.2013.xml
All rights reserved. Please visit https://medical-data-
models.org/forms/15660
a) Incident Type
Clinical Administration:Process
Handover*
Appointment*
Waiting List*
Admission*
Patient Identification*
Informed Consent*
Task Allocation*
Response To Emergency*
Discharge*
Referral  / Consultation*
Transfer Of Care*
Clinical Administration:Problem
Not Performed When Indicated*
Incomplete / Inadequate*
Unavailable*
Wrong Process / Service*
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Wrong Patient*
Clinical Process/Procedure:Process
Screening / Prevention / Routine Checkup*
Diagnosis / Assessment*
Procedure / Treatment / Intervention*
General Care / Management*
Tests / Investigations*
Specimens / Results*
Detention / Restraint*
Clinical Process/Procedure:Problem
Not Performed When Indicated*
Incomplete / Inadequate*
Unavailable*
Wrong Process / Treatment / Procedure*
Wrong Body Part / Side / Site*
Wrong Patient*
Documentation:Document Involved
Orders / Requests*
Charts / Medical Records / Assessments /
Consultations*
Check Lists*
Forms / Certificates*
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Instructions / Information / Policies / Procedures /
Guidelines*
Labels / Stickers / Identification Bands / Cards*
Letters / E-Mails / Records Of Communication*
Reports / Results / Images*
Documentation:Problem
Document Missing Or Unavailable*
Delay In Accessing Document*
Document For Wrong Patient Or Wrong
Document*
Unclear / Ambiguous / Illegible / Incomplete
Information In Document*
Healthcare Associated Infection:Type Of
Organism
Bacteria*
Virus*
Fungus*
Parasite*
Protozoa*
Rickettsia*
Prion*
Causative Organism Not Identified*
Healthcare Associated Infection:Type/Site
Of Infection
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Bloodstream*
Surgical Site*
Abscess*
Pneumonia*
Intravascular Cannulae*
Infected Prosthesis / Site*
Urinary Drain / Tube*
Soft Tissue*
Medication/Fluids:Involved
Medication List*
Iv Fluid List*
Medication/Fluids:Process
Preparation / Dispensing*
Presentation / Packaging*
Delivery*
Supply / Ordering*
Storage*
Monitoring*
Administration*
Prescribing*
Medication/Fluids:Problem
Wrong Drug*
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Wrong Dose / Strength Or Frequency*
Wrong Formulation Or Presentation*
Wrong Route*
Wrong Quantity*
Wrong Dispensing Label / Instruction*
Contraindication*
Wrong Storage*
Omitted Medicine Or Dose*
Expired Medicine*
Adverse Drug Reaction*
Wrong Patient*
Blood/Blood Products:Blood/Blood
Products Involved
Cellular Products*
Clotting Factors*
Albumin / Plasma Protein*
Immunoglobulin*
Blood/Blood Products:Process
Pre-Transfusion Testing*
Preparation / Dispensing*
Delivery*
Storage*
Monitoring*
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Presentation / Packaging*
Supply / Ordering*
Administration*
Prescribing*
Blood/Blood Products:Problem
Wrong Blood / Blood Product*
Wrong Dose Or Frequency*
Wrong Quantity*
Wrong Dispensing Label / Instruction*
Contraindication*
Wrong Storage*
Omitted Medicine Or Dose*
Expired Blood / Blood Product*
Adverse Effect*
Wrong Patient*
Nutrition:Nutrition Involved
General Diet*
Special Diet*
Gavage (agaba)
Drink nutrition (agabb)
Breastfeeding (agabc)
Bottle feeding in babies (agabd)
Nutrition:Process
Preparation / Manufacturing / Cooking*
Supply / Ordering*
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Presentation*
Dispensing / Allocation*
Delivery*
Storage*
Administration*
Prescribing / Requesting*
Nutrition:Problem
Wrong Diet*
Wrong Quantity*
Wrong Frequency*
Wrong Consistency*
Wrong Storage*
Wrong Patient*
Oxygen/Gas/Vapor:Gases Involved
Oxygen*
Vacuum*
Nitric oxide*
Compresses air*
Nitrous oxyde*
Carbon dioxide*
Other*
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Oxygen/Gas/Vapor:Process
Cylinder Labeling / Color Coding / Pin Indexing*
Delivery*
Supply / Ordering*
Storage*
Administration*
Prescription*
Oxygen/Gas/Vapor:Problem
Wrong Gas / Vapor*
Wrong Rate / Flow / Concentration*
Wrong Delivery Mode*
Contraindication*
Wrong Storage*
Failure To Administer*
Contamination*
Wrong Patient*
Medical Device/Equipment:Process
Device / Equipment / Property List*
Medical Device/Equipment:Problem
Poor Presentation / Packaging*
Lack Of Availability*
Inappropriate For Task*
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Unclean / Unsterile*
Failure / Malfunction*
Dislodgement / Misconnection / Removal*
User Error*
Behavior:Staff
Noncompliant / Uncooperative / Obstructive*
Inconsiderate / Rude / Hostile / Inappropriate*
Risky / Reckless / Dangerous*
Problem With Substance Use / Abuse*
Harassment*
Discrimination / Prejudice*
Wandering / Absconding*
Intended Self Harm / Suicide*
Verbal Aggression*
Physical Assault*
Sexual Assault*
Aggression Toward An Inanimate Object*
Death Threat*
Behavior:Patient
Noncompliant / Uncooperative / Obstructive*
Inconsiderate / Rude / Hostile / Inappropriate*
Risky / Reckless / Dangerous*
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Problem With Substance Use / Abuse*
Harassment*
Discrimination / Prejudice*
Wandering / Absconding*
Intended Self Harm / Suicide*
Verbal Aggression*
Physical Assault*
Sexual Assault*
Aggression Toward An Inanimate Object*
Death Threat*
Behavior:Involvement of a third
Noncompliant / Uncooperative / Obstructive*
Inconsiderate / Rude / Hostile / Inappropriate*
Risky / Reckless / Dangerous*
Problem With Substance Use / Abuse*
Harassment*
Discrimination / Prejudice*
Wandering / Absconding*
Intended Self Harm / Suicide*
Patient Accidents:Blunt Force
Contact With Object Or Animal*
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Contact With Person*
Crushing*
Abrading / Rubbing*
Patient Accidents:Piercing / Penetrating
Force
Scratching / Cutting / Tearing  / Severing*
Puncturing / Stabbing*
Biting / Stinging / Invenomating*
Other Specified Piercing / Penetrating Force*
Patient Accidents:Other Mechanical Force
Struck By Explosive Blast*
Contact With Machinery*
Patient Accidents:Thermal Mechanism
Excessive Heat / Fire*
Excessive Cooling / Freezing*
Patient Accidents:Threat To Breathing
Mechanical Threat To Breathing*
Drowning / Near Drowning*
Confinement To Oxygen-Deficient Place*
Patient Accidents:Exposure To Chemical
Or Other Substance
Poisoning By Chemical Or Other Substance*
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Corrosion By Chemical Or Other Substance*
Patient Accidents:Other Specified
Mechanism Of Injury
Exposure To Electricity / Radiation*
Exposure To Sound / Vibration*
Exposure To Air Pressure*
Exposure To Low Gravity*
Patient Accidents:Exposure To (Effect Of)
Weather, Natural Disaster, Or Other Force
Of Nature
Patient Accidents:Falls
Type Of Fall*
Trip / Stumble (akiaa)
Slip (akiab)
Collapse (akiac)
Loss Of Balance (akiad)
Fall Involving*
Cot (akiba)
Bed (akibb)
Chair (akibc)
Stretcher (akibd)
Therapeutic Equipment (akibe)
Toilet / Toiletstool (akibf)
Stairs / Steps (akibg)
Being Carried / Supported By Another
Individual (akibh)
Infrastructure/Building/Fixtures:Structure/B
uilding/Fixture Involved
Structure List*
Building List*
Fixture List*
Infrastructure/Building/Fixtures:Problem
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Non-Existent / Inadequate*
Damaged / Faulty / Worn*
Resources/Organizational/Management:M
atching Of Workload Management
Resources/Organizational/Management:B
ed Service Availability / Adequacy
Resources/Organizational/Management:H
uman Resource / Staff Availability /
Adequacy
Resources/Organizational/Management:O
rganization Of Teams / People
Resources/Organizational/Management:P
rotocols / Policy / Procedure /
Resources/Organizational/Management:P
rotocols / Policy / Procedure /
b) Patient Outcomes
Type Of Harm:Pathophysiology
International Classification Of Diseases*
International Classification Of Primary Care 2Nd
Ed*
Type Of Harm:Injury
International Classification Of Diseases*
International Classification Of External Causes
Of Injury*
Type Of Harm:Other
Degree Of Harm:None
Degree Of Harm:Mild
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Degree Of Harm:Moderate
Degree Of Harm:Severe
Degree Of Harm:Death
Degree Of Harm:Unknown yet
Social And/Or Economic
Impact:International Classification Of
Functioning, Disability And Death
c) Patient Characteristics
Patient Demographics:Age
Patient Demographics:Gender
Reason For Encounter:Procedure
International Classification Of Diseases*
International Classification Of Diseases - Country
Specific Derivatives*
Opcs Classification Of Interventions And
Procedures (Uk)*
Nordic Medico-Statistical Committee
Classification Of Surgical Procedures*
Reason For Encounter:Primary Diagnoses
International Classification Of Diseases*
International Classification Of Diseases - Country
Specific Derivatives*
Opcs Classification Of Interventions And
Procedures (Uk)*
Nordic Medico-Statistical Committee
Classification Of Surgical Procedures*
Other Diagnosis / Procedure:International
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Classification Of Diseases
Other Diagnosis / Procedure:International
Classification Of Diseases - Country
Specific Derivatives
Other Diagnosis / Procedure:Opcs
Classification Of Interventions And
Procedures (Uk)
Other Diagnosis / Procedure:Nordic
Medico-Statistical Committee
Classification Of Surgical Procedures
d) Incident Characteristics
Origin Of Incident:People Involved
Who*
Healthcare professional (daaaa)
Healthcare worker (daaab)
Emergency service personnel (daaac)
Another patient (daaad)
Relative (daaae)
Volunteer (daaaf)
Guardian (daaag)
Friend / visitor (daaah)
Carer / home aid / assistant (daaai)
Interpreter / translator (daaaj)
Pastoral care personnel (daaak)
Others (daaal)
Discipline/Specialty*
Origin Of Incident:When
Stage/Phase Of Care*
Primary Medical Care (dabaa)
Primary Medical Care:Pre-Visit (dabaaa)
Primary Medical Care:Post-Consultation
(dabaac)
Primary Medical Care:Follow-Up
(dabaaf)
Primary Medical Care:During
Consultation (dabaar)
Primary Medical Care:During Referral /
Consult (dabaas)
Primary Medical Care:Transfer Of Care
(dabaat)
Community Care Facility (dabab)
Community Care Facility:Inpatient
Services (dababv)
Community Care Facility:Inpatient
Services:Treatment (dababvd)
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Community Care Facility:Inpatient
Services:Assessment (dababvo)
Community Care Facility:Inpatient
Services:Discharge (dababvp)
Community Care Facility:Inpatient
Services:Care On Admission (dababvq)
Community Care Facility:Inpatient
Services:Transfer Of Care (dababvt)
Community Care Facility:Inpatient
Services:Post-Discharge (dababvu)
Community Care Facility:Inpatient
Services:Pre-Admission (dababvy)
Community Care Facility:Outpatient
Services (dababw)
Community Care Facility:Outpatient
Services:Pre-Visit (dababwa)
Community Care Facility:Outpatient
Services:Post-Consultation (dababwc)
Community Care Facility:Outpatient
Services:During Consultation (dababwr)
Community Care Facility:Outpatient
Services:Referral (dababws)
Community Care Facility:Outpatient
Services:Transfer Of Care (dababwt)
Mental Health Service (dabac)
Mental Health Service:Community
Mental Health Services (dabacc)
Mental Health Service:Community
Mental Health Services:Treatment
(dabaccb)
Mental Health Service:Community
Mental Health Services:Assessment
(dabacco)
Mental Health Service:Community
Mental Health Services:Discharge
(dabaccp)
Mental Health Service:Community
Mental Health Services:Transfer Of Care
(dabacct)
Mental Health Service:Inpatient Mental
Health Services (dabacv)
Mental Health Service:Inpatient Mental
Health Services:Treatment (dabacvd)
Mental Health Service:Inpatient Mental
Health Services:Assessment (dabacvo)
Mental Health Service:Inpatient Mental
Health Services:Discharge (dabacvp)
Mental Health Service:Inpatient Mental
Health Services:Care On Admission
(dabacvq)
Mental Health Service:Inpatient Mental
Health Services:Transfer Of Care
(dabacvt)
Mental Health Service:Inpatient Mental
Health Services:Post-Discharge
(dabacvu)
Mental Health Service:Inpatient Mental
Health Services:Pre-Admission
(dabacvy)
Mental Health Service:Outpatient Mental
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Health Services (dabacw)
Mental Health Service:Outpatient Mental
Health Services:Pre-Visit (dabacwa)
Mental Health Service:Outpatient Mental
Health Services:Post-Consultation
(dabacwc)
Mental Health Service:Outpatient Mental
Health Services:During Consultation
(dabacwr)
Mental Health Service:Outpatient Mental
Health Services:Referral (dabacws)
Mental Health Service:Outpatient Mental
Health Services:Transfer Of Care
(dabacwt)
Disability Service (dabad)
Disability Service:Inpatient Services
(dabadv)
Disability Service:Inpatient
Services:Treatment (dabadvd)
Disability Service:Inpatient
Services:Assessment (dabadvo)
Disability Service:Inpatient
Services:Discharge (dabadvp)
Disability Service:Inpatient
Services:Care On Admission (dabadvq)
Disability Service:Inpatient
Services:Transfer Of Care (dabadvt)
Disability Service:Inpatient
Services:Post-Discharge (dabadvu)
Disability Service:Inpatient Services:Pre-
Admission (dabadvy)
Disability Service:Outpatient Services
(dabadw)
Disability Service:Outpatient
Services:Pre-Visit (dabadwa)
Disability Service:Outpatient
Services:Post-Consultation (dabadwc)
Disability Service:Outpatient
Services:During Consultation (dabadwr)
Disability Service:Outpatient
Services:Referral (dabadws)
Disability Service:Outpatient
Services:Transfer Of Care (dabadwt)
Nursing Facility (dabae)
Nursing Facility:Treatment (dabaed)
Nursing Facility:Assessment (dabaeo)
Nursing Facility:Discharge (dabaep)
Nursing Facility:Care On Admission
(dabaeq)
Nursing Facility:Transfer Of Care
(dabaet)
Nursing Facility:Post-Discharge (dabaeu)
Nursing Facility:Pre-Admission (dabaey)
General Hospital (dabaf)
General Hospital:Inpatient (dabafv)
General Hospital:Inpatient :Care On
Admission Including Pre-Op Care
(dabafvb)
General Hospital:Inpatient :Care During
Procedure (dabafvc)
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General Hospital:Inpatient :Immediate
Post-Op Or Icu / High Dependency Unit
Care (dabafvd)
General Hospital:Inpatient :General
Ward Care (dabafve)
General Hospital:Inpatient :Discharge
(dabafvp)
General Hospital:Inpatient :Transfer Of
Care (dabafvt)
General Hospital:Inpatient :Post
Discharge (dabafvu)
General Hospital:Inpatient :Pre-
Admission (dabafvy)
General Hospital:Outpatient (dabafw)
General Hospital:Outpatient:Pre-Visit
(dabafwa)
General Hospital:Outpatient:Post-
Consultation (dabafwc)
General Hospital:Outpatient:During
Consultation (dabafwr)
General Hospital:Outpatient:Referral
(dabafws)
General Hospital:Outpatient:Transfer Of
Care (dabafwt)
Community Pharmacy (dabag)
Home Care (dabah)
Home Care:Provision Of Care /
Medication (dabahb)
Home Care:Treatment (dabahc)
Home Care:Counseling (dabahd)
Home Care:Monitoring Of Clinical Status
(dabahe)
Home Care:Management Of Household
Routine (dabahf)
Home Care:Follow-Up (dabahg)
Home Care:Assessment (dabaho)
Home Care:Transfer Of Care (dabaht)
Transport Services (Including
Ambulances) (dabai)
Dental Care (dabaj)
Dental Care:Pre-Visit (dabaja)
Dental Care:Post-Consultation (dabajc)
Dental Care:Follow-Up (dabajf)
Dental Care:During Consultation (dabajr)
Dental Care:Referral / Consult (dabajs)
Dental Care:Transfer Of Care (dabajt)
Timing Of Incident*
Date Of Incident*
Origin Of Incident:Where
Care Setting*
Primary Medical Care (dacaa)
Community Care Facility (dacab)
Mental Health Service (dacac)
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Disability Service (dacad)
Nursing Facility (dacae)
General Hospital (dacaf)
Community Pharmacy (dacag)
Home Care (dacah)
Transport Services (Including
Ambulances) (dacai)
Dental Care (dacaj)
Other (dacak)
Country*
Discovery Of Incident:Person reporting
Who*
Healthcare professional (dbaaa)
Healthcare worker (dbaab)
Emergency service personnel (dbaac)
Another patient (dbaad)
Relative (dbaae)
Volunteer (dbaaf)
Guardian (dbaag)
Friend / visitor (dbaah)
Carer / home aid / assistant (dbaai)
Interpreter / translator (dbaaj)
Pastoral care personnel (dbaak)
Others (dbaal)
Discipline/Specialty*
Discovery Of Incident:When
Stage/Phase Of Care*
Primary Medical Care (dbbaa)
Primary Medical Care:Pre-Visit (dbbaaa)
Primary Medical Care:Post-Consultation
(dbbaac)
Primary Medical Care:Follow-Up
(dbbaaf)
Primary Medical Care:During
Consultation (dbbaar)
Primary Medical Care:During Referral /
Consult (dbbaas)
Primary Medical Care:Transfer Of Care
(dbbaat)
Community Care Facility (dbbab)
Community Care Facility:Inpatient
Services (dbbabv)
Community Care Facility:Inpatient
Services:Treatment (dbbabvd)
Community Care Facility:Inpatient
Services:Assessment (dbbabvo)
Community Care Facility:Inpatient
Services:Discharge (dbbabvp)
Community Care Facility:Inpatient
Services:Care On Admission (dbbabvq)
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Community Care Facility:Inpatient
Services:Transfer Of Care (dbbabvt)
Community Care Facility:Inpatient
Services:Post-Discharge (dbbabvu)
Community Care Facility:Inpatient
Services:Pre-Admission (dbbabvy)
Community Care Facility:Outpatient
Services (dbbabw)
Community Care Facility:Outpatient
Services:Pre-Visit (dbbabwa)
Community Care Facility:Outpatient
Services:Post-Consultation (dbbabwc)
Community Care Facility:Outpatient
Services:During Consultation (dbbabwr)
Community Care Facility:Outpatient
Services:Referral (dbbabws)
Community Care Facility:Outpatient
Services:Transfer Of Care (dbbabwt)
Mental Health Service (dbbac)
Mental Health Service:Community
Mental Health Services (dbbacc)
Mental Health Service:Community
Mental Health Services:Treatment
(dbbaccb)
Mental Health Service:Community
Mental Health Services:Assessment
(dbbacco)
Mental Health Service:Community
Mental Health Services:Discharge
(dbbaccp)
Mental Health Service:Community
Mental Health Services:Transfer Of Care
(dbbacct)
Mental Health Service:Inpatient Mental
Health Services (dbbacv)
Mental Health Service:Inpatient Mental
Health Services:Treatment (dbbacvd)
Mental Health Service:Inpatient Mental
Health Services:Assessment (dbbacvo)
Mental Health Service:Inpatient Mental
Health Services:Discharge (dbbacvp)
Mental Health Service:Inpatient Mental
Health Services:Care On Admission
(dbbacvq)
Mental Health Service:Inpatient Mental
Health Services:Transfer Of Care
(dbbacvt)
Mental Health Service:Inpatient Mental
Health Services:Post-Discharge
(dbbacvu)
Mental Health Service:Inpatient Mental
Health Services:Pre-Admission
(dbbacvy)
Mental Health Service:Outpatient Mental
Health Services (dbbacw)
Mental Health Service:Outpatient Mental
Health Services:Pre-Visit (dbbacwa)
Mental Health Service:Outpatient Mental
Health Services:Post-Consultation
(dbbacwc)
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Mental Health Service:Outpatient Mental
Health Services:During Consultation
(dbbacwr)
Mental Health Service:Outpatient Mental
Health Services:Referral (dbbacws)
Mental Health Service:Outpatient Mental
Health Services:Transfer Of Care
(dbbacwt)
Disability Service (dbbad)
Disability Service:Inpatient Services
(dbbadv)
Disability Service:Inpatient
Services:Treatment (dbbadvd)
Disability Service:Inpatient
Services:Assessment (dbbadvo)
Disability Service:Inpatient
Services:Discharge (dbbadvp)
Disability Service:Inpatient
Services:Care On Admission (dbbadvq)
Disability Service:Inpatient
Services:Transfer Of Care (dbbadvt)
Disability Service:Inpatient
Services:Post-Discharge (dbbadvu)
Disability Service:Inpatient Services:Pre-
Admission (dbbadvy)
Disability Service:Outpatient Services
(dbbadw)
Disability Service:Outpatient
Services:Pre-Visit (dbbadwa)
Disability Service:Outpatient
Services:Post-Consultation (dbbadwc)
Disability Service:Outpatient
Services:During Consultation (dbbadwr)
Disability Service:Outpatient
Services:Referral (dbbadws)
Disability Service:Outpatient
Services:Transfer Of Care (dbbadwt)
Nursing Facility (dbbae)
Nursing Facility:Treatment (dbbaed)
Nursing Facility:Assessment (dbbaeo)
Nursing Facility:Discharge (dbbaep)
Nursing Facility:Care On Admission
(dbbaeq)
Nursing Facility:Transfer Of Care
(dbbaet)
Nursing Facility:Post-Discharge (dbbaeu)
Nursing Facility:Pre-Admission (dbbaey)
General Hospital (dbbaf)
General Hospital:Inpatient (dbbafv)
General Hospital:Inpatient :Care On
Admission Including Pre-Op Care
(dbbafvb)
General Hospital:Inpatient :Care During
Procedure (dbbafvc)
General Hospital:Inpatient :Immediate
Post-Op Or Icu / High Dependency Unit
Care (dbbafvd)
General Hospital:Inpatient :General
Ward Care (dbbafve)
General Hospital:Inpatient :Discharge
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(dbbafvp)
General Hospital:Inpatient :Transfer Of
Care (dbbafvt)
General Hospital:Inpatient :Post
Discharge (dbbafvu)
General Hospital:Inpatient :Pre-
Admission (dbbafvy)
General Hospital:Outpatient (dbbafw)
General Hospital:Outpatient:Pre-Visit
(dbbafwa)
General Hospital:Outpatient:Post-
Consultation (dbbafwc)
General Hospital:Outpatient:During
Consultation (dbbafwr)
General Hospital:Outpatient:Referral
(dbbafws)
General Hospital:Outpatient:Transfer Of
Care (dbbafwt)
Community Pharmacy (dbbag)
Home Care (dbbah)
Home Care:Provision Of Care /
Medication (dbbahb)
Home Care:Treatment (dbbahc)
Home Care:Counseling (dbbahd)
Home Care:Monitoring Of Clinical Status
(dbbahe)
Home Care:Management Of Household
Routine (dbbahf)
Home Care:Follow-Up (dbbahg)
Home Care:Assessment (dbbaho)
Home Care:Transfer Of Care (dbbaht)
Transport Services (Including
Ambulances) (dbbai)
Dental Care (dbbaj)
Dental Care:Pre-Visit (dbbaja)
Dental Care:Post-Consultation (dbbajc)
Dental Care:Follow-Up (dbbajf)
Dental Care:During Consultation (dbbajr)
Dental Care:Referral / Consult (dbbajs)
Dental Care:Transfer Of Care (dbbajt)
Timing Of Incident*
Date Of Incident*
Discovery Of Incident:Where
Care Setting*
Primary Medical Care (dbcaa)
Community Care Facility (dbcab)
Mental Health Service (dbcac)
Disability Service (dbcad)
Nursing Facility (dbcae)
General Hospital (dbcaf)
Community Pharmacy (dbcag)
Home Care (dbcah)
Transport Services (Including
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Ambulances) (dbcai)
Dental Care (dbcaj)
Other (dbcak)
Country*
Reporting Of Incident:Person reporting
Who*
Healthcare professional (dcaaa)
Healthcare worker (dcaab)
Emergency service personnel (dcaac)
Another patient (dcaad)
Relative (dcaae)
Volunteer (dcaaf)
Guardian (dcaag)
Friend / visitor (dcaah)
Carer / home aid / assistant (dcaai)
Interpreter / translator (dcaaj)
Pastoral care personnel (dcaak)
Others (dcaal)
Discipline/Specialty*
Reporting Of Incident:When
Stage/Phase Of Care*
Primary Medical Care (dcbaa)
Primary Medical Care:Pre-Visit (dcbaaa)
Primary Medical Care:Post-Consultation
(dcbaac)
Primary Medical Care:Follow-Up
(dcbaaf)
Primary Medical Care:During
Consultation (dcbaar)
Primary Medical Care:During Referral /
Consult (dcbaas)
Primary Medical Care:Transfer Of Care
(dcbaat)
Community Care Facility (dcbab)
Community Care Facility:Inpatient
Services (dcbabv)
Community Care Facility:Inpatient
Services:Treatment (dcbabvd)
Community Care Facility:Inpatient
Services:Assessment (dcbabvo)
Community Care Facility:Inpatient
Services:Discharge (dcbabvp)
Community Care Facility:Inpatient
Services:Care On Admission (dcbabvq)
Community Care Facility:Inpatient
Services:Transfer Of Care (dcbabvt)
Community Care Facility:Inpatient
Services:Post-Discharge (dcbabvu)
Community Care Facility:Inpatient
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Services:Pre-Admission (dcbabvy)
Community Care Facility:Outpatient
Services (dcbabw)
Community Care Facility:Outpatient
Services:Pre-Visit (dcbabwa)
Community Care Facility:Outpatient
Services:Post-Consultation (dcbabwc)
Community Care Facility:Outpatient
Services:During Consultation (dcbabwr)
Community Care Facility:Outpatient
Services:Referral (dcbabws)
Community Care Facility:Outpatient
Services:Transfer Of Care (dcbabwt)
Mental Health Service (dcbac)
Mental Health Service:Community
Mental Health Services (dcbacc)
Mental Health Service:Community
Mental Health Services:Treatment
(dcbaccb)
Mental Health Service:Community
Mental Health Services:Assessment
(dcbacco)
Mental Health Service:Community
Mental Health Services:Discharge
(dcbaccp)
Mental Health Service:Community
Mental Health Services:Transfer Of Care
(dcbacct)
Mental Health Service:Inpatient Mental
Health Services (dcbacv)
Mental Health Service:Inpatient Mental
Health Services:Treatment (dcbacvd)
Mental Health Service:Inpatient Mental
Health Services:Assessment (dcbacvo)
Mental Health Service:Inpatient Mental
Health Services:Discharge (dcbacvp)
Mental Health Service:Inpatient Mental
Health Services:Care On Admission
(dcbacvq)
Mental Health Service:Inpatient Mental
Health Services:Transfer Of Care
(dcbacvt)
Mental Health Service:Inpatient Mental
Health Services:Post-Discharge
(dcbacvu)
Mental Health Service:Inpatient Mental
Health Services:Pre-Admission
(dcbacvy)
Mental Health Service:Outpatient Mental
Health Services (dcbacw)
Mental Health Service:Outpatient Mental
Health Services:Pre-Visit (dcbacwa)
Mental Health Service:Outpatient Mental
Health Services:Post-Consultation
(dcbacwc)
Mental Health Service:Outpatient Mental
Health Services:During Consultation
(dcbacwr)
Mental Health Service:Outpatient Mental
Health Services:Referral (dcbacws)
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Mental Health Service:Outpatient Mental
Health Services:Transfer Of Care
(dcbacwt)
Disability Service (dcbad)
Disability Service:Inpatient Services
(dcbadv)
Disability Service:Inpatient
Services:Treatment (dcbadvd)
Disability Service:Inpatient
Services:Assessment (dcbadvo)
Disability Service:Inpatient
Services:Discharge (dcbadvp)
Disability Service:Inpatient
Services:Care On Admission (dcbadvq)
Disability Service:Inpatient
Services:Transfer Of Care (dcbadvt)
Disability Service:Inpatient
Services:Post-Discharge (dcbadvu)
Disability Service:Inpatient Services:Pre-
Admission (dcbadvy)
Disability Service:Outpatient Services
(dcbadw)
Disability Service:Outpatient
Services:Pre-Visit (dcbadwa)
Disability Service:Outpatient
Services:Post-Consultation (dcbadwc)
Disability Service:Outpatient
Services:During Consultation (dcbadwr)
Disability Service:Outpatient
Services:Referral (dcbadws)
Disability Service:Outpatient
Services:Transfer Of Care (dcbadwt)
Nursing Facility (dcbae)
Nursing Facility:Treatment (dcbaed)
Nursing Facility:Assessment (dcbaeo)
Nursing Facility:Discharge (dcbaep)
Nursing Facility:Care On Admission
(dcbaeq)
Nursing Facility:Transfer Of Care
(dcbaet)
Nursing Facility:Post-Discharge (dcbaeu)
Nursing Facility:Pre-Admission (dcbaey)
General Hospital (dcbaf)
General Hospital:Inpatient (dcbafv)
General Hospital:Inpatient :Care On
Admission Including Pre-Op Care
(dcbafvb)
General Hospital:Inpatient :Care During
Procedure (dcbafvc)
General Hospital:Inpatient :Immediate
Post-Op Or Icu / High Dependency Unit
Care (dcbafvd)
General Hospital:Inpatient :General
Ward Care (dcbafve)
General Hospital:Inpatient :Discharge
(dcbafvp)
General Hospital:Inpatient :Transfer Of
Care (dcbafvt)
General Hospital:Inpatient :Post
Discharge (dcbafvu)
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General Hospital:Inpatient :Pre-
Admission (dcbafvy)
General Hospital:Outpatient (dcbafw)
General Hospital:Outpatient:Pre-Visit
(dcbafwa)
General Hospital:Outpatient:Post-
Consultation (dcbafwc)
General Hospital:Outpatient:During
Consultation (dcbafwr)
General Hospital:Outpatient:Referral
(dcbafws)
General Hospital:Outpatient:Transfer Of
Care (dcbafwt)
Community Pharmacy (dcbag)
Home Care (dcbah)
Home Care:Provision Of Care /
Medication (dcbahb)
Home Care:Treatment (dcbahc)
Home Care:Counseling (dcbahd)
Home Care:Monitoring Of Clinical Status
(dcbahe)
Home Care:Management Of Household
Routine (dcbahf)
Home Care:Follow-Up (dcbahg)
Home Care:Assessment (dcbaho)
Home Care:Transfer Of Care (dcbaht)
Transport Services (Including
Ambulances) (dcbai)
Dental Care (dcbaj)
Dental Care:Pre-Visit (dcbaja)
Dental Care:Post-Consultation (dcbajc)
Dental Care:Follow-Up (dcbajf)
Dental Care:During Consultation (dcbajr)
Dental Care:Referral / Consult (dcbajs)
Dental Care:Transfer Of Care (dcbajt)
Timing Of Incident*
Date Of Incident*
Reporting Of Incident:Where
Care Setting*
Primary Medical Care (dccaa)
Community Care Facility (dccab)
Mental Health Service (dccac)
Disability Service (dccad)
Nursing Facility (dccae)
General Hospital (dccaf)
Community Pharmacy (dccag)
Home Care (dccah)
Transport Services (Including
Ambulances) (dccai)
Dental Care (dccaj)
Other (dccak)
Country*
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e) Contributing Factors/Hazards -
External Factors
Staff Factors:Cognitive factors
Perception/understanding*
Knowledge based/problem solving*
Failure to synthesize/act on available
information (eaaba)
Problems with causality (eaabb)
Problems with complexity (eaabc)
Illusory correlation*
Hallo effects*
Staff Factors:Performance factors
Technical error in execution (physical-skill
based)*
Slip/lapse/error (eabaa)
Rule base*
Misapplication of good rules (eabba)
Application of bad rules (eabbb)
Selectivity*
Bias*
Biased reviewing (eabda)
Confirmation bias (eabdb)
Staff Factors:Behavior
Attention issues*
Distraction/inattention (eacaa)
Absentmindedness/forgetfulness (eacab)
Overattention (eacac)
Out of sight, out of mind (eacad)
Fatigue/exhaustion*
Overconfidence*
Noncompliance*
Routine violation*
Risky behavior*
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Reckless behavior*
Sabotage/criminal act*
Staff Factors:Communication factors
Communication method*
Paper base (eadaa)
Electronic (eadab)
Verbal (eadac)
Language difficulties*
Health literacy*
With whom*
With staff (eadda)
With patient (eaddb)
Staff Factors:Pathophysiologic/disease
related factors
International classification of diseases*
International classification of primary care 2nd
ed*
Problems with substance abuse/use*
Staff Factors:Emotional factors
Staff Factors:Social factors
Patient Factors:Cognitive factors
Perception/understanding*
Knowledge based/problem solving*
Failure to synthesize/act on available
information (ebaba)
Problems with causality (ebabb)
Problems with complexity (ebabc)
Illusory correlation*
Halo effects*
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Patient Factors:Performance factors
Technical error in execution (physical-skill
based)*
Slip/lapse/error (ebbaa)
Rule base*
Misapplication of good rules (ebbba)
Application of bad rules (ebbbb)
Selectivity*
Bias*
Biased reviewing (ebbda)
Confirmation bias (ebbdb)
Patient Factors:Behavior
Attention issues*
Distraction/inattention (ebcaa)
Absentmindedness/forgetfulness (ebcab)
Overattention (ebcac)
Out of sight, out of mind (ebcad)
Fatigue/exhaustion*
Overconfidence*
Noncompliance*
Routine violation*
Risky behavior*
Reckless behavior*
Sabotage/criminal act*
Patient Factors:Communication factors
Communication method*
Paper base (ebdaa)
Electronic (ebdab)
Verbal (ebdac)
Language difficulties*
Health literacy*
With whom*
With staff (ebdda)
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With patient (ebddb)
Patient Factors:Pathophysiologic/disease
related factors
International classification of diseases*
International classification of primary care 2nd
ed*
Problems with substance abuse/use*
Patient Factors:Emotional factors
Patient Factors:Social factors
Work/Environment Factors:Physical
environment/infrastructure
Work/Environment Factors:Remote/long
distance from service
Work/Environment Factors:Environmental
risk assessment/safety evaluation
Work/Environment Factors:Current
code/specifications/regulations
Organizational/Service
Factors:Protocols/policies/procedures/pro
cesses
Organizational/Service
Factors:Organizational decisions/culture
Organizational/Service
Factors:Organization of teams
Organizational/Service
Factors:Resources/workload
External Factors:Natural environment
External Factors:Products, technology &
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infrastructure
External Factors:Services, systems,
policies
f) Mitigating Factors
Directed To Patient:Help called for
Directed To
Patient:Management/treatment/care
undertaken
Directed To Patient:Patient referred
Directed To Patient:Patient
education/explanation
Directed To Patient:Apology
Directed To Staff:Good
supervision/leadership
Directed To Staff:Good team work
Directed To Staff:Effective communication
Directed To Staff:Relevant person(s)
attended
Directed To Staff:Relevant person(s)
educated
Directed To Staff:Good luck/chance
Directed To Organization:Effective
protocol available
Directed To
Organization:Product/equipment/device
management & availability/accessibility
Directed To Organization:Document error
corrected
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Directed To An Agent:Security/physical
environment measure
Directed To An Agent:Infection control
strategies managed/implemented
Directed To An Agent:Therapeutic agent
error corrected
Directed To An Agent:Equipment usage
error corrected
g) Detection
People involved:Healthcare professional
People involved:Healthcare worker
People involved:Emergency service
personnel
People involved:Another patient
People involved:Relative
People involved:(2) Volunteer
People involved:(4) Guardian
People involved:Friend/visitor
People involved:Carer/home aid/assistant
People involved:Interpreter/translator
People involved:Pastoral care personnel
Process:Error recognition
Process:By change of patient's status
Process:By machine/environmental
change/alarm
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Process:By a Count / audit / review
Process:Proactive risk management
h) Organizational Outcomes
Increase In Required Resource Allocation
For Patient:Increased Length Of Stay
Increase In Required Resource Allocation
For Patient:Admission To Special Care
Area
Increase In Required Resource Allocation
For Patient:Additional Treatment / Tests
Increase In Required Resource Allocation
For Patient:Disrupted Workflow / Delays
For Other Patients
Increase In Required Resource Allocation
For Patient:Additional Staff Required
Increase In Required Resource Allocation
For Patient:Additional Equipment
Required
Other:Effects on employee
Physical effects on employee*
Unknown injury: no information (hgaaa)
Wounds and superficial injuries (hgaab)
Bone fractures (hgaac)
Sprains, strains and dislocations (hgaad)
Traumatic amputations (hgaae)
Concussions and internal injuries (hgaaf)
Burns, scalds and frostbites (hgaag)
Poisonings and infections (hgaah)
Drowning and suffocation (hgaai)
Effects of noise, vibrations and pressure
(hgaaj)
Effects of extreme temperatures, light
and radiation (hgaak)
Shock after assault and menace (hgaal)
Traumatic shocks (hgaam)
Other types of shock (hgaan)
Multiple injuries (hgaao)
Other specified injuries, not elsewhere
included (hgaap)
Psychological and social consequences for the
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employee*
Anxiety disorders (hgaba)
Burnout (hgabb)
Communication disorders (hgabc)
Breakdown (hgabd)
Eating disorders (hgabe)
Behavioural disorders (hgabf)
Memory disorders (hgabg)
Personality disorders (hgabh)
Psychosomatic complaints (hgabi)
Psychotic disorders (hgabj)
Relational and post-relational problems
(hgabk)
Bereavement and loss process (hgabl)
Sleep disorders (hgabm)
Mood disorders (hgabn)
Stress-related complaints (hgabo)
Suicide and suicidal behaviour (hgabp)
Addiction (hgabq)
i) Ameliorating Actions
Patient Related:Management of
disease/disorder
Patient Related:Management of injury
Patient Related:Management of disability
Patient Related:Compensation
Patient Related:Open disclosure/apology
Organization Related:Media
management/public relations
Organization Related:Compliant
management
Organization Related:Claims/risk
management
Organization Related:Stress
debriefing/staff counseling
Organization Related:Local notification
and restitution
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Organization
Related:Reconciliation/mediation
Organization Related:Culture change
Organization Related:Education/training
j) Actions To Reduce Risk
Patient Factors:Provision of adequate
care/support
Patient Factors:Provision of patient
education/training
Patient Factors:Provision of
protocols/decision support
Patient Factors:Provision of monitoring
equipment
Patient Factors:Provision of medication
dispensing aid
Staff factors:Training
Staff factors:Orientation
Staff factors:Supervision/assistance
Staff factors:Strategies to manage fatigue
Staff factors:Availability of
checklists/protocols/policies
Staff factors:Adequate staff
numbers/quality
Organizational/environmental
factors:Matching physical environment to
needs
Organizational/environmental
factors:Making arrangements for access
tot a service
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Organizational/environmental
factors:Performing risk assessment/root
cause analyses
Organizational/environmental
factors:Current
code/specifications/regulations being met
Organizational/environmental
factors:Arranging ready access to
protocols/policies/decision support
Organizational/environmental
factors:Improved leadership/guidance
Organizational/environmental
factors:Matching to staff to tasks/skills
Organizational/environmental
factors:Improving safety culture
Agent/Equipment factors:Provision of
equipment
Agent/Equipment factors:Forcing functions
Agent/Equipment factors:Regular audits
Other
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Eligibility Non-small Cell Lung Cancer
NCT02274038
Serial [18F]Thymidine (FLT)PET/CT as a Biomarker of
Response in Pemetrexed Therapy for Non-Small Cell Lung
Cancer; ODM derived from:
https://clinicaltrials.gov/show/NCT02274038
All rights reserved. Please visit https://medical-data-
models.org/forms/15661
Eligibility Non-small Cell Lung
Cancer NCT02274038
Inclusion Criteria
1. adult patients, at least 18 years of age*
Yes
No
2. histologically confirmed non-small cell lung
cancer with at least one site of disease > 1 cm by
at least one type of standard imaging (e.g. ct,
chest x-ray, mri)*
Yes
No
3. recommmended to start systemic therapy
which includes pemetrexed and a platinum-based
agent.*
Yes
No
4. participants must be informed of the
investigational nature of this study and provide
written informed consent in accordance with
institutional and federal guidelines prior to study-
specific procedures.*
Yes
No
5. participants must be willing and able to comply
with scheduled visits and imaging procedures in
the opinion of the investigator or treating
physician.*
Yes
No
Exclusion Criteria
1. females who are pregnant or breast-feeding at
the time of screening will not be eligible for this
study. female participants of child-bearing
potential will have a urine pregnancy test at the
time of the screening visit.*
Yes
No
2. patients with only a single site of primary lung
cancer who have undergone or are
recommended to undergo  radiation therapy to
that site will not be eligible, the inclusion of
patients who may be undergoing radiation
therapy to ancillary disease sites may be allowed
to enter the study at the discretion of the pi if it is
not felt to affect the ability to capture flt
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information for at least one primary site of
disease.*
Yes
No
3. patients who have received chemotherapy
within 2 weeks of enrollment will be excluded
from the study.*
Yes
No
4. patients who have undergone cancer surgery
removing a significant portion of active disease,
in the opinion of an investigator, within 2 months
prior to study enrollment will be excluded.*
Yes
No
5. inability to tolerate imaging procedures in the
opinion of the investigator or treating physician*
Yes
No
6. serious or unstable medical or psychological
conditions that, in the opinion of the investigator
would compromise the subject's safety or
successful participation in the study.*
Yes
No
7. unwilling or unable to provide informed
consent*
Yes
No
2 / 2
Eligibility Non-small Cell Lung Cancer NCT02274038
Pädiatrische Rheumatologie CHAQ
CHAQ-Childhood Health Assessment Questionnaire:
Juvenile idiopathische Arthritis
Zur Verfügung gestellt von Prof. Dirk Föll,
Universitätsklinikum Münster
All rights reserved. Please visit https://medical-data-
models.org/forms/15662
CHAQ-Childhood Health
Assessment Questionnaire
CHAQ-Fragebogen zur Bewertung der
Gesundheit bei Kindern
Name
Geburtsdatum
Datum
Kann sich Ihr Kind allein anziehen,die
Schnürsenkel binden,Knöpfe schließen oder
öffnen?
Problemlos (1)
Leicht erschwert (2)
Stark erschwert (3)
Nicht möglich (4)
Trifft nicht zu (5)
Kann sich Ihr Kind allein die Haare waschen?
Problemlos (1)
Leicht erschwert (2)
Stark erschwert (3)
Nicht möglich (4)
Trifft nicht zu (5)
Kann sich Ihr Kind allein die Socken an und
ausziehen?
Problemlos (1)
Leicht erschwert (2)
Stark erschwert (3)
Nicht möglich (4)
Trifft nicht zu (5)
Kann sich Ihr Kind allein die Fingernägel
schneiden?
Problemlos (1)
Leicht erschwert (2)
Stark erschwert (3)
Nicht möglich (4)
Trifft nicht zu (5)
Kann Ihr Kind von einem niedrigen Stuhl oder
vom Boden aufstehen?
Problemlos (1)
Leicht erschwert (2)
Stark erschwert (3)
Nicht möglich (4)
Trifft nicht zu (5)
Kann Ihr Kind sich ins Bett legen,aus dem Bett
1 / 7
aufstehen oder sich im Laufstall aufrichten?
Problemlos (1)
Leicht erschwert (2)
Stark erschwert (3)
Nicht möglich (4)
Trifft nicht zu (5)
Kann Ihr Kind bei Tisch ein Messer zum
Schneiden benutzen?
Problemlos (1)
Leicht erschwert (2)
Stark erschwert (3)
Nicht möglich (4)
Trifft nicht zu (5)
Kann Ihr Kind eine Tasse oder ein Glas zum
Mund führen?
Problemlos (1)
Leicht erschwert (2)
Stark erschwert (3)
Nicht möglich (4)
Trifft nicht zu (5)
Kann Ihr Kind eine neue Packung Cornflakes
oder Müsli öffnen?
Problemlos (1)
Leicht erschwert (2)
Stark erschwert (3)
Nicht möglich (4)
Trifft nicht zu (5)
Kann Ihr Kind allein draußen auf ebenem Boden
gehen?
Problemlos (1)
Leicht erschwert (2)
Stark erschwert (3)
Nicht möglich (4)
Trifft nicht zu (5)
Kann Ihr Kind allein fünf Stufen hinaufgehen?
Problemlos (1)
Leicht erschwert (2)
Stark erschwert (3)
Nicht möglich (4)
Trifft nicht zu (5)
Kann Ihr Kind sich allein am ganzen Körper
waschen und abtrocken?
Problemlos (1)
Leicht erschwert (2)
Stark erschwert (3)
Nicht möglich (4)
Trifft nicht zu (5)
Kann Ihr Kind sich allein baden (und in die
Wanne ein- und aussteigen?
Problemlos (1)
Leicht erschwert (2)
Stark erschwert (3)
2 / 7
Pädiatrische Rheumatologie CHAQ
Nicht möglich (4)
Trifft nicht zu (5)
Kann Ihr Kind allein auf die Toilette bzw. das
Töpfchen gehen und wieder aufstehen?
Problemlos (1)
Leicht erschwert (2)
Stark erschwert (3)
Nicht möglich (4)
Trifft nicht zu (5)
Kann Ihr Kind sich allein die Zähne putzen?
Problemlos (1)
Leicht erschwert (2)
Stark erschwert (3)
Nicht möglich (4)
Trifft nicht zu (5)
Kann Ihr Kind sich allein die Haare kämmen bzw.
bürsten?
Problemlos (1)
Leicht erschwert (2)
Stark erschwert (3)
Nicht möglich (4)
Trifft nicht zu (5)
Kann Ihr Kind einen schweren Gegenstand z.B.
ein großes Spiel oder Bücher, über Kopfhöhe
erreichen oder herunterholen?
Problemlos (1)
Leicht erschwert (2)
Stark erschwert (3)
Nicht möglich (4)
Trifft nicht zu (5)
Kann Ihr Kind sich bücken,um ein Kleidungsstück
oder ein Blatt Papier vom Boden aufzuheben?
Problemlos (1)
Leicht erschwert (2)
Stark erschwert (3)
Nicht möglich (4)
Trifft nicht zu (5)
Kann Ihr Kind sich einen Pullover über den Kopf
ziehen?
Problemlos (1)
Leicht erschwert (2)
Stark erschwert (3)
Nicht möglich (4)
Trifft nicht zu (5)
Kann Ihr Kind den Kopf drehen,um über die
Schulter zurückzuschauen?
Problemlos (1)
Leicht erschwert (2)
Stark erschwert (3)
Nicht möglich (4)
Trifft nicht zu (5)
Kann Ihr Kind mit Kugelschreiber oder Bleistift
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schreiben?
Problemlos (1)
Leicht erschwert (2)
Stark erschwert (3)
Nicht möglich (4)
Trifft nicht zu (5)
Kann Ihr Kind Autotüren öffnen?
Problemlos (1)
Leicht erschwert (2)
Stark erschwert (3)
Nicht möglich (4)
Trifft nicht zu (5)
Kann Ihr Kind Schraubverschlüsse öffnen, die
schon einmal geöffnet waren?
Problemlos (1)
Leicht erschwert (2)
Stark erschwert (3)
Nicht möglich (4)
Trifft nicht zu (5)
Kann Ihr Kind Wasserhähne auf- und zudrehen?
Problemlos (1)
Leicht erschwert (2)
Stark erschwert (3)
Nicht möglich (4)
Trifft nicht zu (5)
Kann Ihr Kind eine Tür mit einem Türknauf
öffnen?
Problemlos (1)
Leicht erschwert (2)
Stark erschwert (3)
Nicht möglich (4)
Trifft nicht zu (5)
Kann Ihr Kind allein einkaufen und Kleinigkeiten
erledigen?
Problemlos (1)
Leicht erschwert (2)
Stark erschwert (3)
Nicht möglich (4)
Trifft nicht zu (5)
Kann Ihr Kind allein in Auto,Bus oder
Straßenbahn ein- und aussteigen?
Problemlos (1)
Leicht erschwert (2)
Stark erschwert (3)
Nicht möglich (4)
Trifft nicht zu (5)
Kann Ihr Kind im Haushalt helfen (z.B.
abwaschen,Müll wegbringen, Staub saugen, bei
der Gartenarbeit helfen, sein Bett machen, sein
Zimmer aufräumen)?
Problemlos (1)
Leicht erschwert (2)
4 / 7
Pädiatrische Rheumatologie CHAQ
Stark erschwert (3)
Nicht möglich (4)
Trifft nicht zu (5)
Kann Ihr Kind rennen und spielen?
Problemlos (1)
Leicht erschwert (2)
Stark erschwert (3)
Nicht möglich (4)
Trifft nicht zu (5)
Hilfsmittel
Mein Kind benötigt keine Hilfsmittel
Ja
Nein
Mein Kind benötigt für die angegebenen
Tätigkeiten folgende Hilfsmittel: Anziehen und
Körperpflege
Hilfsmittel zum Anziehen (1)
Knöpfhaken (2)
Reißverschlusszieher (3)
verlängerter Schuhlöffel (4)
Mein Kind benötigt für die angegebenen
Tätigkeiten folgende Hilfsmittel:Aufstehen
Spezialstuhl (1)
erhöhter Stuhl (2)
Mein Kind benötigt für die angegebenen
Tätigkeiten folgende Hilfsmittel:Essen und Trinken
Besonderes Besteck (1)
Mein Kind benötigt für die angegebenen
Tätigkeiten folgende Hilfsmittel:Gehen
Gehstützen (1)
Therapieroller (2)
Therapiefahrrad (3)
Rollstuhl (4)
Mein Kind benötigt für die angegebenen
Tätigkeiten folgende Hilfsmittel:Körperpflege
Erhöhter Toilettensitz (1)
Badewannensitz (2)
Haltegriff an der Badewannenstange (3)
Mein Kind benötigt für die angegebenen
Tätigkeiten folgende Hilfsmittel:Erreichen von
Gegenständen
Geräte mit langen Stielen zum Erreichen
bestimmter Gegenstände (1)
Geräte mit langen Stielen im
Badezimmer (2)
Schraubverschlussöffner für Gläser (die
schon vorher geöffnet waren) (3)
Bleistiftverdickung (4)
Spezielle Schere (5)
Spezielle Schreibgeräte (6)
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Mein Kind benötigt für die angegebenen
Tätigkeiten andere Hilfsmittel
Mein Kind benötigt keine fremde Hilfe
Ja
Nein
Mein Kind benötigt Hilfe in folgenden Bereichen
Anziehen (1)
Aufstehen (2)
Essen und Trinken (3)
Gehen (4)
Körperpflege (5)
Erreichen von Gegenständen (6)
Greifen (7)
Aktivitäten und häusliche Aufgaben (8)
Aktueller Krankheitsstatus
Wie stark war Ihr Kind in den vergangenen 7
Tagen bei der Erledigung seiner täglichen
Aufgaben eingeschränkt?
0 nicht eingeschränkt (1)
9 (10)
10 maximal eingeschränkt (11)
1 (2)
2 (3)
3 (4)
4 (5)
5 (6)
6 (7)
7 (8)
8 (9)
Wie würden Sie die Stärke der Schmerzen Ihres
Kindes in den vergangenen 7 Tagen
einschätzen?
0 keine Schmerzen (1)
9 (10)
10 unerträgliche Schmerzen (11)
1 (2)
2 (3)
3 (4)
4 (5)
5 (6)
6 (7)
7 (8)
8 (9)
Wie beurteilen Sie im Großen und Ganzen den
derzeitigen Gesundheitszustand Ihres Kindes?
0 sehr gut (1)
9 (10)
10 sehr schlecht (11)
1 (2)
2 (3)
3 (4)
4 (5)
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5 (6)
6 (7)
7 (8)
8 (9)
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Pädiatrische Rheumatologie Einschätzung
der Erkrankungsaktivität
Einschätzung der derzeitigen Erkrankungsaktivität durch
Patienten oder Eltern
Zur Verfügung gestellt von Prof.Dirk Föll,
Universitätsklinikum Münster
All rights reserved. Please visit https://medical-data-
models.org/forms/15663
Einschätzung der
Erkrankungsaktivität durch Patienten
oder Eltern
Erkrankungsaktivität
Patientenname
Ausfüllende Person
Patient  (1)
Mutter (2)
Vater  (3)
Andere (4)
Datum der Einschätzung:
Bewerte bitte die derzeitige Aktivität deiner
Erkrankung, indem du eine Markierung auf
dieser Linie platzierst: Ein freundliches Gesicht
mit der Beschriftung "Keine Anzeichen einer
Erkrankungsaktivität" sowie eine zweigeteilte
Linie an deren anderem Ende ein trauriges
Gesicht steht mit der Beschriftung "Extrem
schwere Erkrankungsaktivität"
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Eligibility Non-Small Cell Lung Cancer
NCT02277457
Personalized Adaptive Radiation Therapy With
Individualized Systemic Targeted Therapy (PARTIST) for
Locally Advanced, Non-small Cell Lung Cancer With
Genomic Driver Mutations; ODM derived from:
https://clinicaltrials.gov/show/NCT02277457
All rights reserved. Please visit https://medical-data-
models.org/forms/15664
Eligibility Non-Small Cell Lung
Cancer NCT02277457
Inclusion Criteria
patients with fdg-avid (radioactive glucose) and
pathologically proven stage iia-iib or iiia-iiib non-
small cell lung cancer (according to ajcc
[american joint committee on cancer] staging, 7th
edition).*
Yes
No
patients with tumors that harbor either egfr
sensitizing mutations or alk rearrangement.*
Yes
No
patients must be considered unresectable or
medically inoperable; patients who decline
surgery are also eligible.*
Yes
No
patients must be 18 years of age or older.*
Yes
No
patients with ecog (eastern cooperative oncology
group) performance status of 0-2.*
Yes
No
patients must have adequate organ function.*
Yes
No
patients must be able to take oral medications.*
Yes
No
women with reproductive capability must be
willing to use effective contraception.*
Yes
No
patients must be informed of the investigational
nature of this study and sign written informed
consent in accordance with institutional and
federal guidelines.*
Yes
No
patients must be willing to comply with study
procedures.*
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Yes
No
Exclusion Criteria
patients with tumors that have a component of
small cell carcinoma.*
Yes
No
patients wtih stage i, ii, or iv disease, including
malignant pleural or pericardial effusion.*
Yes
No
prior radiotherapy to the thorax such that
composite radiation would significantly over-dose
critical structures, either per estimation of the
treating radiation oncologist or defined by failure
to meet normal tissue tolerance constraints.*
Yes
No
patients who cannot tolerate thoracic
radiotherapy or targeted therapy.*
Yes
No
patients wtih a prior diagnosis of interstitial lung
disease or pulmonary fibrosis.*
Yes
No
patients who cannot take oral medication, require
intravenous alimentation, had prior surgical
procedures affecting gastrointestinal absorption,
or have active peptic ulcer disease.*
Yes
No
hypersensitivity to erlotinib, crizotinib, or to any of
the excipients.*
Yes
No
pregnant women are excluded from this study
because radiation has the potential for
teratogenic or abortifacient effects.*
Yes
No
prisoners are excluded from this study.*
Yes
No
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Eligibility Non-Small Cell Lung Cancer NCT02277457
Determining factor The CoDe (”Coding of
Death in HIV”) Project
The CoDe (”Coding of Death in HIV”) Project
A significant proportion of deaths in HIV-1 infected persons
are now caused by non-AIDS events. It is important to
closely monitor the causes of death in this population in
order to target interventions appropriately, should specific
causes of death emerge or become predominant. It is
possible that deaths from diseases related to an
accelerated aging process will become more frequent. The
same applies for causes of death related to co-infections
(e.g. hepatitis) or other co-morbidities (e.g. sequelae of
intravenous drug use). Furthermore, it is important to be
able to evaluate the risk factors for such emerging
diseases, including their possible relationship with
immunodeficiency.
Until now there has not been a uniform classification
system for causes of death in HIV patients. Studies have
either created their own coding systems based on frequent
and/or ‘important’ causes (e.g. rare but important adverse
events such as lactic acidosis and pancreatitis), or have
used ICD9 or ICD10 codes from death certificates. In many
cases, the ICD system cannot be directly adapted to HIV
infected persons. Many AIDS defining illnesses are poorly
identified in the ICD system, and some diseases (e.g. CNS
diseases) have a different aetiology in HIV patients and are
therefore not covered by the ICD system, or at great risk of
mis-classification.
In July 2004, a meeting was held in Copenhagen with the
participation from executive committees of a large number
of pivotal observational studies and clinical trials that
routinely collect data on causes of death. At this meeting,
it became clear that there was a need for a harmonization
and standardization of the approach taken when collecting
data on cause of death and when reviewing these deaths.
As a result, the CoDe Project was initiated.
The CoDe Project is a uniform coding system that can be
applied to studies of individuals with HIV infection, including
a detailed data collection on the causes of death and
contributing factors, as well as a centralised review process
of the data collected.
http://www.cphiv.dk/Tools-Standards/CoDe/About
Contains:  Risk factors, co-morbidities
All rights reserved. Please visit https://medical-data-
models.org/forms/15665
Determining factor
Section 3 A. Ongoing risk factors in the
year prior to death:
1. Cigarette smoking
No  (No )
Unknown (Unknown)
Yes (Yes)
2. Excessive alcohol consumption
No  (No )
Unknown (Unknown)
Yes (Yes)
3. Active illicit injecting drug use
No  (No )
Unknown (Unknown)
Yes (Yes)
4. Active illicit non-injecting drug use
No  (No )
Unknown (Unknown)
Yes (Yes)
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5. Opiate substitution (methadone)
No  (No )
Unknown (Unknown)
Yes (Yes)
Section 4 A. Comorbidities - Ongoing
chronic conditions:
1. Hypertension
No  (No )
Unknown (Unknown)
Yes (Yes)
2. Diabetes mellitus
No  (No )
Unknown (Unknown)
Yes (Yes)
3. Dyslipidemia
No  (No )
Unknown (Unknown)
Yes (Yes)
Section 4 B. Comorbidities Prior
cardiovascular Disease
Prior Cardiovascular Disease (myocardial
infarction, stroke or invasive cardiovascular
procedure)
No  (No )
Unknown (Unknown)
Yes (Yes)
Section 4 C. Comorbidities History of
depression
History of depression
No  (No )
Unknown (Unknown)
Yes (Yes)
Section 4 D. Comorbidities History of
psychosis
History of psychosis
No  (No )
Unknown (Unknown)
Yes (Yes)
Section 4 E. Comorbidities Liver Disease
1. Chronic elevation of liver transaminases
No  (No )
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Unknown (Unknown)
Yes (Yes)
2. Chronic HBV infection
No  (No )
Unknown (Unknown)
Yes (Yes)
3. Chronic HCV infection
No  (No )
Unknown (Unknown)
Yes (Yes)
4. HDV infection
No  (No )
Unknown (Unknown)
Yes (Yes)
5. History of previous liver decompensation
No  (No )
Unknown (Unknown)
Yes (Yes)
6. Clinical signs of liver failure in the 4 weeks
before death
No  (No )
Unknown (Unknown)
Yes (Yes)
7. Liver histology available (ever)
No  (No )
Unknown (Unknown)
Yes (Yes)
Date of Liver Biopsy
Stage of fibrosis (0-4)
0 (1)
1 (2)
2 (3)
3 (4)
4 (5)
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Cause of Death The CoDe (”Coding of
Death in HIV”) Project
The CoDe (”Coding of Death in HIV”) Project A significant
proportion of deaths in HIV-1 infected persons are now
caused by non-AIDS events. It is important to closely
monitor the causes of death in this population in order to
target interventions appropriately, should specific causes of
death emerge or become predominant. It is possible that
deaths from diseases related to an accelerated aging
process will become more frequent. The same applies for
causes of death related to co-infections (e.g. hepatitis) or
other co-morbidities (e.g. sequelae of intravenous drug
use). Furthermore, it is important to be able to evaluate the
risk factors for such emerging diseases, including their
possible relationship with immunodeficiency. Until now
there has not been a uniform classification system for
causes of death in HIV patients. Studies have either
created their own coding systems based on frequent
and/or ‘important’ causes (e.g. rare but important adverse
events such as lactic acidosis and pancreatitis), or have
used ICD9 or ICD10 codes from death certificates. In many
cases, the ICD system cannot be directly adapted to HIV
infected persons. Many AIDS defining illnesses are poorly
identified in the ICD system, and some diseases (e.g. CNS
diseases) have a different aetiology in HIV patients and are
therefore not covered by the ICD system, or at great risk of
mis-classification. In July 2004, a meeting was held in
Copenhagen with the participation from executive
committees of a large number of pivotal observational
studies and clinical trials that routinely collect data on
causes of death. At this meeting, it became clear that there
was a need for a harmonization and standardization of the
approach taken when collecting data on cause of death
and when reviewing these deaths. As a result, the CoDe
Project was initiated. The CoDe Project is a uniform coding
system that can be applied to studies of individuals with
HIV infection, including a detailed data collection on the
causes of death and contributing factors, as well as a
centralised review process of the data collected.
http://www.cphiv.dk/Tools-Standards/CoDe/About Contains:
Cause of Death, Post Mortem/ Autopsy
All rights reserved. Please visit https://medical-data-
models.org/forms/15666
Cause of Death The CoDe (”Coding
of Death in HIV”) Project
Section 5 Cause of Death
A. Was the death sudden?
No  (No )
Unknown (Unknown)
Yes  (Yes )
B. Was the death unexpected?
No  (No )
Unknown (Unknown)
Yes  (Yes )
C. Conditions at Time of Death
Illness / Condition / Injury
Date of onset
Certainty of Diagnosis
Definite (Definite)
Likely (Likely)
Possible (Possible)
Events Leading to Death
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D.  Brief narrative of the sequence of events
leading to death (please include means of
diagnosis of 
illnesses):
E. 1. Condition that directly caused death
(immediate cause):
E. 2. Due to or as a consequence of:
E. 3. Due to or as a consequence of:
E. 4. Condition that initiated the train of morbid
events (the underlying condition):
Section 6 Post - mortem / Autopsy
A. Has autopsy been performed:
No  (No )
Unknown (Unknown)
Yes  (Yes )
B. Did the autopsy reveal any evidence of
intoxication?
No  (No )
Unknown (Unknown)
Yes  (Yes )
Yes, with the agent:
Please provide a brief summary of the findings
from the autopsy report (please also include a
copy 
of the full report):
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Nerventra Study Baseline
Nerventra Study (Eudra CT 2007-003226-19) Study MS-
LAQ-301: A multinational, multicenter,
randomized, double-blind, parallel-group, placebo-
controlled study, to evaluate the safety,
tolerability and efficacy of daily oral administration of
laquinimod 0.6 mg in subjects with
relapsing remitting multiple sclerosis (RRMS)
All rights reserved. Please visit https://medical-data-
models.org/forms/15668
Nerventra Study Baseline
Informed Consent and Demography Data
Protocol Number
Visit Type
Date of visit
Study site number
Subject number:
Section blank?
Yes
No
Safety measurements
Temperature
Temperature type of measurement
oral (1)
axillary (2)
aural (3)
temporal (4)
Units used for measurement
F (1)
C (2)
Measurement not done
Yes
No
Blood pressure measurement
mm/Hg
Measurement not done
Yes
No
Pulse
beats/min
Measurement not done
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Yes
No
Investigators ECG interpretation
ECG interpretation not done
Yes
No
ECG Repetition
Yes
No
Investigators ECG interpretation
ECG interpretation not done
Yes
No
ECG second Repetition
Yes
No
Investigators ECG interpretation
ECG interpretation not done
Yes
No
Where all required laboratory samples obtained?
Yes
No
Menstruation
Yes
No
Pasat Summary Score Sheet
PASAT Form used
Form A (1)
Form B (2)
PASAT3: Total correct (range 0-60)
For a complete PASAT3, record any
circumstances that affected the subjects
performance
PASAT3: if test was not completed
Unable due to physical limitations (1)
Other (2)
PASAT3: please specify physical limitations
2 / 10
Nerventra Study Baseline
and/or other reason
9-Hole Peg test
9-Hole Peg Test: dominant hand
right (1)
left (2)
9-Hole Peg Test: Time dominant hand Trial 1
sec
9-Hole Peg Test: Time non-dominant hand Trial 1
sec
For a complete trial, record any circumstances
that affected the subjects performance
9-Hole Peg Test: not completed dominant hand
Trial 1
Unable due to physical limitations (1)
Other (2)
9-Hole Peg Test: not completed non-dominant
hand Trial 1
Unable due to physical limitations (1)
Other (2)
If trial was not completed, please specify physical
limitations and/or other reasons
9-Hole Peg Test: Time dominant hand Trial 2
sec
9-Hole Peg Test: Time non-dominant hand Trial 2
sec
For a complete trial, record any circumstances
that affected the subjects performance
9-Hole Peg Test: not completed dominant hand
Trial 2
Unable due to physical limitations (1)
Other (2)
9-Hole Peg Test: not completed non-dominant
hand Trial 2
Unable due to physical limitations (1)
Other (2)
If trial was not completed, please specify physical
limitations and/or other reasons
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Binocular low contrast visual acuity
100percent chart: total correct score
2,5 percent chart: total correct score
1,25 percent chart: total correct score
MRI Scan performance
Date of MRI
MRI not done
Yes
No
Type of Gadolinium-based contrast agent used
Magnevist (1)
Omniscan (2)
Dotarem (3)
Other (specify) (4)
Other contrast agent used
Was MRI completed according to the protocol?
Yes
No
Reason MRI was not completed
Where there any pathological,non-MS findings?
Yes
No
Please specify pathological findings
MT Scan Performance
Date of MT Scan
MT-Scan not done
Yes
No
Was MT-Scan completed according to protocol?
Yes
No
If not completed, specify
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MRS Scan Performance
Date of MRS Scan
MRS scan not done
Yes
No
Was MRS-Scan completed according to
protocol?
Yes
No
If MRS-Scan was not completed,specify
Modified Fatigue Impact Scale
I have been less alert
Never (1)
Rarely (2)
Sometimes (3)
Often (4)
Almost always (5)
I have difficulty paying attention for long periods
of time
Never (1)
Rarely (2)
Sometimes (3)
Often (4)
Almost always (5)
I have been unable to think clearly
Never (1)
Rarely (2)
Sometimes (3)
Often (4)
Almost always (5)
I have been clumsy and uncoordinated
Never (1)
Rarely (2)
Sometimes (3)
Often (4)
Almost always (5)
I have been forgetful
Never (1)
Rarely (2)
Sometimes (3)
Often (4)
Almost always (5)
I have had to pace myself in my physical activities
Never (1)
Rarely (2)
Sometimes (3)
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Often (4)
Almost always (5)
I have been less motivated to do anything that
requires physical effort
Never (1)
Rarely (2)
Sometimes (3)
Often (4)
Almost always (5)
I have been less motivated to participate in social
activities
Never (1)
Rarely (2)
Sometimes (3)
Often (4)
Almost always (5)
I have been limited in my ability to do things away
from home
Never (1)
Rarely (2)
Sometimes (3)
Often (4)
Almost always (5)
I have had trouble maintaining physical effort for
long periods
Never (1)
Rarely (2)
Sometimes (3)
Often (4)
Almost always (5)
I have difficulties making decisions
Never (1)
Rarely (2)
Sometimes (3)
Often (4)
Almost always (5)
I have been less motivated to do anything that
requires thinking
Never (1)
Rarely (2)
Sometimes (3)
Often (4)
Almost always (5)
My muscles have felt weak
Never (1)
Rarely (2)
Sometimes (3)
Often (4)
Almost always (5)
I have been physicaly uncomfortable
Never (1)
Rarely (2)
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Sometimes (3)
Often (4)
Almost always (5)
I have trouble finishing tasks that require thinking
Never (1)
Rarely (2)
Sometimes (3)
Often (4)
Almost always (5)
I have had difficulty organizing my thoughts when
doing things at home or at work
Never (1)
Rarely (2)
Sometimes (3)
Often (4)
Almost always (5)
I have been less able to complete tasks that
require physical effort
Never (1)
Rarely (2)
Sometimes (3)
Often (4)
Almost always (5)
My thinking has slowed down
Never (1)
Rarely (2)
Sometimes (3)
Often (4)
Almost always (5)
I have trouble concentrating
Never (1)
Rarely (2)
Sometimes (3)
Often (4)
Almost always (5)
I have limited my physical activities
Never (1)
Rarely (2)
Sometimes (3)
Often (4)
Almost always (5)
I have needed to rest more often or for longer
periods
Never (1)
Rarely (2)
Sometimes (3)
Often (4)
Almost always (5)
General Health assessment
SF-36 Health survey
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Nerventra Study Baseline
EQ5D Questionnaire
Final eligibility
Has the subject been in an unstable neurological
condition or experienced an onset of relapse
between screening (month-1) and baseline
(month 0) visits?
Yes
No
Has the subject undergone any treatment with
corticosteroids (intravenous[iv], intramuscular[im],
and/or per os [po]) or ACTH between month -1
(screening) and 0 (baseline)?
Yes
No
Has the subject experienced acute infection
within 2 weeks prior to baseline visit?
Yes
No
Has the subject experienced major trauma or
surgery within 2 weeks prior to baseline visit?
Yes
No
Has the subject used inhibitors of CYP3A4 within
2 weeks, for fluoxetine 1 month, prior to baseline
visit?
Yes
No
Were any pathologies other than MS found in
MRI, and confirmed by local radiologist, that
would jeopardize the subjects participation in the
study?
Yes
No
Does the subject have a clinically significant or
unstable medical or surgical condition, as defined
by protocol, that would preclude safe and
complete study participation?
Yes
No
Subject disposition
Does the subject qualify to continue this clinical
trial? If no, complete below
Yes
No
Please specify reason why subject is not eligible
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Subject screening number
Subject number:
Date of Randomization
Date and time of Study drug administration
Post -Dose Vital signs
Blood pressure 30 min post Dose
mmHg
Measurement not done
Yes
No
Blood pressure 60 min post Dose
mmHg
Measurement not done
Yes
No
Pulse 30 min post Dose
bpm
Measurement not done
Yes
No
Pulse 60 min post Dose
bpm
Measurement not done
Yes
No
Phone thrombosis questionnaire
Have you been suffering in the last two weeks
from a new pain or swelling in the back part of
one of your legs?
Yes
No
Have you been suffering from shortness of breath
in the last two weeks?
Yes
No
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Have you been suffering from a new chest pain in
the last two weeks?
Yes
No
Have you been suffering from a new,intensifying,
abdominal pain for more than 3 days?
Yes
No
Have you been suffering from a new continuous,
intensifying headache in the last two weeks?
Yes
No
If the answer to any of the above is yes, Does the
subject need any further evaluation?
Yes
No
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Eligibility Non-small Cell Lung Cancer
NCT02284139
Pilot Trial of EGF Ointment for the Patients With EGFR-i
Related Skin Side Effects; ODM derived from:
https://clinicaltrials.gov/show/NCT02284139
All rights reserved. Please visit https://medical-data-
models.org/forms/15669
Eligibility Non-small Cell Lung
Cancer NCT02284139
Inclusion Criteria
1. age: older than 20*
Yes
No
2. eastern cooperative oncology group (ecog)
performance status 0 -2*
Yes
No
3. histologically confirmed lung cancer,
pancreatic cancer, or colon cancer*
Yes
No
4. patients take egfr inhibitor following the
reason*
Yes
No
egfr mutation (+) nsclc - adenocarcinoma for 1st
line treatment*
Yes
No
nsclc - for ≥ 2nd line treatment*
Yes
No
pancreatic cancer - adenocarcinoma for 1st line
treatment with gemcitabine*
Yes
No
colon cancer - adenocarcinoma 1st line treatment
with irinotecan (folfiri)*
Yes
No
5. patients who have egfr inhibitor related skin
side effects (erse) gr≥2  (ncictc v4.0)*
Yes
No
6. a patient with the willingness to comply with
the study protocol during the study period and
capable of complying with it*
Yes
No
7. a patient who signed the informed consent
1 / 3
prior to the participation of the study and who
understands that he/she has a right to withdrawal
from participation in the study at any time without
any disadvantages*
Yes
No
Exclusion Criteria
1. a patient with previous active or passive
immunotherapy*
Yes
No
2. a pregnant or lactating patient*
Yes
No
3. a patient of childbearing potential without being
tested for pregnancy at baseline for positive. (a
postmenopausal woman with the amenorrhea
period of at least 12 months or longer is
considered to have non-childbearing potential.)*
Yes
No
4. a patient with history of uncontrolled seizures,
central nervous system disorder or psychiatric
disorders that are considered clinically significant
by the investigator that would prohibit the
understanding of informed consent or that may
be considered to interfere with the compliance of
the administration of the study medications*
Yes
No
5. a patient with history of dermatologic care
(except transient urticaria) within 4 weeks*
Yes
No
6. a patient with clinically significant (i.e. active)
heart disease (e.g. congestive heart failure,
symptomatic coronary artery diseases, cardiac
arrhythmias, etc) or myocardial infarction within
past 12 months*
Yes
No
7. a patient with interstitial pneumonia or diffused
symptomatic fibrosis of the lungs.*
Yes
No
8. organ allogenic transplantation requiring
immunosuppressive therapy. any waiver of these
inclusion and exclusion criteria must be approved
by the investigator and the sponsor on a case-by
case basis prior to enrolling the subject*
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Yes
No
9. known allergies, hypersensitivity, or intolerance
to study drugs, chemotherapy drugs using this
clinical trial*
Yes
No
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Eligibility Non-small Cell Lung Cancer NCT02284139
Nerventra Study Visit 1
Nerventra Study (Eudra CT 2007-003226-19) Study MS-
LAQ-301: A multinational, multicenter,
randomized, double-blind, parallel-group, placebo-
controlled study, to evaluate the safety,
tolerability and efficacy of daily oral administration of
laquinimod 0.6 mg in subjects with
relapsing remitting multiple sclerosis (RRMS)
All rights reserved. Please visit https://medical-data-
models.org/forms/15670
Nerventra Study Visit 1
Demographic Information Visit 1
Protocol Number
Visit Type
Date of visit
Study site number
Subject number:
Section blank?
Yes
No
Safety measurements Visit 1
Temperature
Temperature type of measurement
oral (1)
axillary (2)
aural (3)
temporal (4)
Units used for measurement
F (1)
C (2)
Measurement not done
Yes
No
Blood pressure measurement
mm/Hg
Measurement not done
Yes
No
Pulse
beats/min
Measurement not done
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Yes
No
Investigators ECG interpretation
ECG interpretation not done
Yes
No
Where all required laboratory samples obtained?
Yes
No
Menstruation
Yes
No
Population Pharmacokinetics Visit 1
Was Population Pharmacokinetics performed?
Yes
No
Please specify why population pharmacokinetics
was not done
If Population Pharmacokinetics was performed,
did the subject eat this morning?
Yes
No
Meal time
Did the subject take the study drug regularly
during the past week?
Yes
No
If the study drug was not taken regularly, please
specify
Date of last study drug dose prior to blood
sample
Time of last study drug dose prior to blood
sample
Date of PPK Blood sample
Time of PPK Blood sample
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Nerventra Study Visit 3
Nerventra Study (Eudra CT 2007-003226-19) Study MS-
LAQ-301: A multinational, multicenter,
randomized, double-blind, parallel-group, placebo-
controlled study, to evaluate the safety,
tolerability and efficacy of daily oral administration of
laquinimod 0.6 mg in subjects with
relapsing remitting multiple sclerosis (RRMS)
All rights reserved. Please visit https://medical-data-
models.org/forms/15671
Nerventra Study Visit 3
Demographic Information Visit 3
Protocol Number
Visit Type
Date of visit
Study site number
Subject number:
Section blank?
Yes
No
Frequent MRI Scan Performance Visit 3
Date of MRI
MRI not done
Yes
No
Type of Gadolinium-based contrast agent used
Magnevist (1)
Omniscan (2)
Dotarem (3)
Other (specify) (4)
Other contrast agent used
Was MRI completed according to the protocol?
Yes
No
Reason MRI was not completed
Where there any pathological,non-MS findings?
Yes
No
Please specify pathological findings
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Repeated Frequent MRI Scan
Performance Visit 3
Date of MRI
MRI not done
Yes
No
Type of Gadolinium-based contrast agent used
Magnevist (1)
Omniscan (2)
Dotarem (3)
Other (specify) (4)
Other contrast agent used
Was MRI completed according to the protocol?
Yes
No
Reason MRI was not completed
Where there any pathological,non-MS findings?
Yes
No
Please specify pathological findings
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Nerventra Study Visit 4
Nerventra Study (Eudra CT 2007-003226-19) Study MS-
LAQ-301: A multinational, multicenter,
randomized, double-blind, parallel-group, placebo-
controlled study, to evaluate the safety,
tolerability and efficacy of daily oral administration of
laquinimod 0.6 mg in subjects with
relapsing remitting multiple sclerosis (RRMS)
All rights reserved. Please visit https://medical-data-
models.org/forms/15672
Nerventra Study Visit 4
Demographic Information Visit 4
Protocol Number
Visit Type
Date of visit
Study site number
Subject number:
Section blank?
Yes
No
9-Hole Peg test Visit 4
9-Hole Peg Test: dominant hand
right (1)
left (2)
9-Hole Peg Test: Time dominant hand Trial 1
sec
9-Hole Peg Test: Time non-dominant hand Trial 1
sec
For a complete trial, record any circumstances
that affected the subjects performance
9-Hole Peg Test: not completed dominant hand
Trial 1
Unable due to physical limitations (1)
Other (2)
9-Hole Peg Test: not completed non-dominant
hand Trial 1
Unable due to physical limitations (1)
Other (2)
If trial was not completed, please specify physical
limitations and/or other reasons
9-Hole Peg Test: Time dominant hand Trial 2
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sec
9-Hole Peg Test: Time non-dominant hand Trial 2
sec
For a complete trial, record any circumstances
that affected the subjects performance
9-Hole Peg Test: not completed dominant hand
Trial 2
Unable due to physical limitations (1)
Other (2)
9-Hole Peg Test: not completed non-dominant
hand Trial 2
Unable due to physical limitations (1)
Other (2)
If trial was not completed, please specify physical
limitations and/or other reasons
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Nerventra Study Visit 5
Nerventra Study (Eudra CT 2007-003226-19) Study MS-
LAQ-301: A multinational, multicenter,
randomized, double-blind, parallel-group, placebo-
controlled study, to evaluate the safety,
tolerability and efficacy of daily oral administration of
laquinimod 0.6 mg in subjects with
relapsing remitting multiple sclerosis (RRMS)
All rights reserved. Please visit https://medical-data-
models.org/forms/15673
Nerventra Study Visit 5
Demographic Information Visit 1
Protocol Number
Visit Type
Date of visit
Study site number
Subject number:
Section blank?
Yes
No
Safety measurements Visit 1
Temperature
Temperature type of measurement
oral (1)
axillary (2)
aural (3)
temporal (4)
Units used for measurement
F (1)
C (2)
Measurement not done
Yes
No
Blood pressure measurement
mm/Hg
Measurement not done
Yes
No
Pulse
beats/min
Measurement not done
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Yes
No
Where all required laboratory samples obtained?
Yes
No
Menstruation
Yes
No
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Nerventra Study Visit 6
Nerventra Study (Eudra CT 2007-003226-19) Study MS-
LAQ-301: A multinational, multicenter,
randomized, double-blind, parallel-group, placebo-
controlled study, to evaluate the safety,
tolerability and efficacy of daily oral administration of
laquinimod 0.6 mg in subjects with
relapsing remitting multiple sclerosis (RRMS)
All rights reserved. Please visit https://medical-data-
models.org/forms/15674
Nerventra Study Visit 6
Demographic Information Visit 3
Protocol Number
Visit Type
Date of visit
Study site number
Subject number:
Section blank?
Yes
No
Repeated  MRI Scan Performance Visit 6
Date of MRI
MRI not done
Yes
No
Type of Gadolinium-based contrast agent used
Magnevist (1)
Omniscan (2)
Dotarem (3)
Other (specify) (4)
Other contrast agent used
Was MRI completed according to the protocol?
Yes
No
Reason MRI was not completed
Where there any pathological,non-MS findings?
Yes
No
Please specify pathological findings
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Nerventra Study Visit 8
Nerventra Study (Eudra CT 2007-003226-19) Study MS-
LAQ-301: A multinational, multicenter,
randomized, double-blind, parallel-group, placebo-
controlled study, to evaluate the safety,
tolerability and efficacy of daily oral administration of
laquinimod 0.6 mg in subjects with
relapsing remitting multiple sclerosis (RRMS)
All rights reserved. Please visit https://medical-data-
models.org/forms/15675
Nerventra Study Visit 8
Informed Consent and Demography Data
Protocol Number
Visit Type
Date of visit
Study site number
Subject number:
Section blank?
Yes
No
Pasat Summary Score Sheet
PASAT Form used
Form A (1)
Form B (2)
PASAT3: Total correct (range 0-60)
For a complete PASAT3, record any
circumstances that affected the subjects
performance
PASAT3: if test was not completed
Unable due to physical limitations (1)
Other (2)
PASAT3: please specify physical limitations
and/or other reason
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Nerventra Study Visit 10
Nerventra Study (Eudra CT 2007-003226-19) Study MS-
LAQ-301: A multinational, multicenter,
randomized, double-blind, parallel-group, placebo-
controlled study, to evaluate the safety,
tolerability and efficacy of daily oral administration of
laquinimod 0.6 mg in subjects with
relapsing remitting multiple sclerosis (RRMS)
All rights reserved. Please visit https://medical-data-
models.org/forms/15676
Nerventra Study Visit 10
Demographic Information Visit 10
Protocol Number
Visit Type
Date of visit
Study site number
Subject number:
Section blank?
Yes
No
Safety measurements
Weight
Units used for measurement
lbs (1)
kg (2)
Measurement not done
Yes
No
Temperature
Temperature type of measurement
oral (1)
axillary (2)
aural (3)
temporal (4)
Units used for measurement
F (1)
C (2)
Measurement not done
Yes
No
Blood pressure measurement
mm/Hg
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Measurement not done
Yes
No
Pulse
beats/min
Measurement not done
Yes
No
Investigators ECG interpretation
ECG interpretation not done
Yes
No
Date of chest x-ray
Chest x-ray not done
Yes
No
Chest x-ray interpretation
Chest x-ray, if abnormal, please specify
Where all required laboratory samples obtained?
Yes
No
Menstruation
Yes
No
2 / 2
Nerventra Study Visit 10
Eligibility Non-small Cell Lung Cancer
NCT02292550
Study of Safety and Efficacy of LEE011 and Ceritinib in
Patients With ALK-positive Non-small Cell Lung Cancer.;
ODM derived from:
https://clinicaltrials.gov/show/NCT02292550
All rights reserved. Please visit https://medical-data-
models.org/forms/15677
Eligibility Non-small Cell Lung
Cancer NCT02292550
Inclusion Criteria
patients must be diagnosed with alk-positive
advanced nsclc. the tumor must be alk-positive
as determined by alk rearrangement in ≥15% of
cells (as measured by fish using the vysis break-
apart alk probe) or by using the ventana alk ihc
test. the analysis may be performed locally.*
Yes
No
eastern cooperative oncology group (ecog)
performance status ≤ 2.*
Yes
No
measurable disease as per recist v1.1*
Yes
No
availability of tumor sample:*
Yes
No
for alk inhibitor naïve patients:*
Yes
No
o a representative tumor sample must be
submitted. an archival tumor specimen is
acceptable*
Yes
No
for patients after progression on an alk inhibitor:*
Yes
No
o a new tumor biopsy is required unless a biopsy
performed after progression on the patient's most
recent alk inhibitor is available for submission for
all patients a newly obtained tumor specimen
must be submitted if no appropriate archival
sample is available. in the event that no sample is
available and a new biopsy cannot be obtained,
enrollment may be considered after discussion
with the sponsor.*
Yes
No
Exclusion Criteria
for phase ii part:*
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Yes
No
group a: prior therapy with any alk inhibitor is not
permitted.*
Yes
No
group b: progression following any alk inhibitor(s)
other than ceritinib is required and the last dose
of the alk inhibitor must be no more than 60 days
prior to the first dose of study drug. prior ceritinib
is not permitted.*
Yes
No
group c: progression following ceritinib is required
and the last dose of ceritinib must be no more
than 60 days prior to the first dose of study drug.*
Yes
No
patients who have previously received ceritinib
must have tolerated a dose of ceritinib 600 mg
qd, or greater.*
Yes
No
patients with symptomatic central nervous
system (cns) metastases who are neurologically
unstable or require increasing doses of steroids
or local cns-directed therapy  to control their cns
disease*
Yes
No
impaired cardiac function or any clinically
significant cardiac disease*
Yes
No
patients with abnormal laboratory values during
screening and on day 1 of pre-dose*
Yes
No
impairment of gastrointestinal (gi) function or gi
disease that may significantly alter the absorption
of ceritinib or lee011*
Yes
No
patients who are currently receiving treatment
(that cannot be discontinued at least 1 week prior
to the initiation of the study) with agents that are
known to be any of the following: strong inducers
or inhibitors of cyp3a4/5; sensitive substrates of
cyp3a; substrates of cyp3a4/5 or cyp2c9 with a
narrow therapeutic index.*
2 / 3
Eligibility Non-small Cell Lung Cancer NCT02292550
Yes
No
patient has a history of pancreatitis or history of
increased amylase or lipase that was due to
pancreatic disease.*
Yes
No
other protocol-defined inclusion/exclusion criteria
may apply.*
Yes
No
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Nerventra Study Termination/Early
termination
Nerventra Study (Eudra CT 2007-003226-19) Study MS-
LAQ-301: A multinational, multicenter,
randomized, double-blind, parallel-group, placebo-
controlled study, to evaluate the safety,
tolerability and efficacy of daily oral administration of
laquinimod 0.6 mg in subjects with
relapsing remitting multiple sclerosis (RRMS)
All rights reserved. Please visit https://medical-data-
models.org/forms/15678
Nerventra Study Termination/Early
termination
Demographic Information Termination Visit
Protocol Number
Visit Type
Date of visit
Study site number
Subject number:
Section blank?
Yes
No
Termination/Early termination
Date of last dose of study drug
Was the study drug code broken
Yes
No
If Study drug code was broken, please specify
Did the subject complete the entire duration of
the study? If yes, stop here and do not complete
the remainder of this module
Yes
No
What was the primary reason for withdrawal?
Death (complete AE Log and SAE
report) (1)
Other,please specify (10)
Adverse event (complete AE Log)
specify (2)
Refusal to sign re-consent form following
a confirmed relapse or an increase in
EDSS in >2.0 points, sustained for >=3
months (3)
Subject withdrew consent, specify (4)
Request of primary care physician or
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investigator, please specify (5)
Non-compliance/protocol violation,
please specify (6)
Pregnancy (7)
TEVA requested subject to be withdrawn,
please specify (8)
Failed to return/Lost to follow-up (9)
Please specify reason for withdrawal if applicable
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Nerventra Study Sustained increase in
EDSS
Nerventra Study (Eudra CT 2007-003226-19) Study MS-
LAQ-301: A multinational, multicenter,
randomized, double-blind, parallel-group, placebo-
controlled study, to evaluate the safety,
tolerability and efficacy of daily oral administration of
laquinimod 0.6 mg in subjects with
relapsing remitting multiple sclerosis (RRMS)
All rights reserved. Please visit https://medical-data-
models.org/forms/15679
Nerventra Study Sustained increase
in EDSS
Demographic Information
Protocol Number
Visit Type
Date of visit
Study site number
Subject number:
Section blank?
Yes
No
Sustained increase in EDSS
According to the investigator, did the subject
experience a sustained increase in EDSS?
Yes
No
If there is no increase in EDSS, please specify
Neuroexam visit date the EDSS increase is
based on
Did the subject sign the re-consent form? If no,
please complete the early termination visit
Yes
No
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Eligibility Non-Small Cell Lung Cancer.
NCT02299505
Pharmacokinetic and Safety Study of Lower Doses of
Ceritinib Taken With a Low-fat Meal Versus 750 mg of
Ceritinib in the Fasted State in Adult Patients With (ALK-
positive) Metastatic Non-small Cell Lung Cancer (NSCLC);
ODM derived from:
https://clinicaltrials.gov/show/NCT02299505
All rights reserved. Please visit https://medical-data-
models.org/forms/15680
Eligibility Non-Small Cell Lung
Cancer. NCT02299505
Criteria
1. histologically or cytologically confirmed
diagnosis of stage iiib (and is not a candidate for
definitive multimodality therapy) or iv alk-positive
nsclc.*
Yes
No
2. all patients must have a tumor tissue sample
available as an archival sample (collected either
at the time of diagnosis of nsclc or any time
since) or as a new biopsy to send to the novartis
designated central laboratory.*
Yes
No
3. patients may have received one prior treatment
regimen with crizotinib (all other alk inhibitors are
excluded).*
Yes
No
4. patients may have received prior
chemotherapy, biologic therapy, or other
investigational agents. alk inhibitors other than
crizotinib are excluded.*
Yes
No
5. patient has a world health organization (who)
performance status 0-2.*
Yes
No
exclusion:*
Yes
No
1. prior treatment with an alk inhibitor other than
crizotinib.*
Yes
No
2. history of carcinomatous meningitis.*
Yes
No
3. presence or history of a malignant disease
other than an alk-positive advanced tumor that
has been diagnosed and/or required therapy
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within the past 3 years.*
Yes
No
5.  clinically significant, uncontrolled heart
disease and/or recent cardiac event (within 6
months) 6. patient has history of interstitial lung
disease or interstitial pneumonitis, including
clinically significant radiation pneumonitis (i.e.,
affecting activities of daily living or requiring
therapeutic intervention).*
Yes
No
7. patient has other severe, acute, or chronic
medical conditions 8. patient is currently
receiving treatment with warfarin sodium
(coumadin®) or any other coumarin-derivative
anticoagulants.*
Yes
No
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Eligibility Non-Small Cell Lung Cancer. NCT02299505
Baseline Visit (Day 1): Inclusion/Exclusion BG00012 Monotherapy Safety and
Efficacy Extension Study in Multiple Sclerosis (MS) (ENDORSE) NCT00835770
The primary objective of this study is to evaluate the long-
term safety profile of BG00012 (dimethyl fumarate).
Secondary objectives of this study are to evaluate the long-
term efficacy of BG00012 using clinical endpoints and
disability progression, to evaluate further the long-term
effects of BG00012 on multiple sclerosis (MS) brain lesions
on magnetic resonance imaging (MRI) scans in participants
who had MRI scans as part of Studies 109MS301
(NCT00420212) and 109MS302 (NCT00451451) and to
evaluate the long-term effects of BG00012 on health
economics assessments and the visual function test.
NCT00835770
Part: Baseline Visit (Day 1)
All rights reserved. Please visit https://medical-data-
models.org/forms/15682
Baseline Visit (Day 1):
Inclusion/Exclusion BG00012
Monotherapy Safety and Efficacy
Extension Study in Multiple Sclerosis
(MS) (ENDORSE) NCT00835770
Subject Identification
Number of Facility
Subject number
Subject Initials
Inclusion/Exclusion
Protocol Version under which the subject is
entered
informed consent date
Did the subject meet the eligibility criteria for the
study?
Yes
No
Inclusion Criteria 1
Inclusion Criteria 2
Inclusion Criteria 3
Inclusion Criteria 1
Exclusion Criteria 2
Exclusion Criteria 3
1 / 2
Exclusion Criteria 4
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Baseline Visit (Day 1): Inclusion/Exclusion BG00012 Monotherapy Safety and
Efficacy Extension Study in Multiple Sclerosis (MS) (ENDORSE) NCT00835770
Nerventra Study Medication log
Nerventra Study (Eudra CT 2007-003226-19) Study MS-
LAQ-301: A multinational, multicenter,
randomized, double-blind, parallel-group, placebo-
controlled study, to evaluate the safety,
tolerability and efficacy of daily oral administration of
laquinimod 0.6 mg in subjects with
relapsing remitting multiple sclerosis (RRMS)
All rights reserved. Please visit https://medical-data-
models.org/forms/15684
Nerventra Study Medication log
Demographic Information
Protocol Number
Visit Type
Date of visit
Study site number
Subject number:
No data to report
Yes
No
Medication log
Date of automatic update
Date of manual update
Medication name,ongoing
Visit Type
Concomitant medications log
Medication name
Start date
End Date
Ongoing
Yes
No
Concomitant medication use indication
1 / 2
Total daily dose
Unit of dosage
Medication frequency
Route of administration
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Nerventra Study Adverse event log
Nerventra Study (Eudra CT 2007-003226-19) Study MS-
LAQ-301: A multinational, multicenter,
randomized, double-blind, parallel-group, placebo-
controlled study, to evaluate the safety,
tolerability and efficacy of daily oral administration of
laquinimod 0.6 mg in subjects with
relapsing remitting multiple sclerosis (RRMS)
All rights reserved. Please visit https://medical-data-
models.org/forms/15685
Nerventra Study Adverse event log
Demographic Information
Protocol Number
Visit Type
Date of visit
Study site number
Subject number:
Section blank
Yes
No
Ongoing adverse events
Date of automatic update
Date of manual update
Adverse event
Visit Type
Adverse events log Baseline
Adverse event
Adverse event intermittent
Yes
No
Time since dose
Time since dose unknown
Yes
No
Prior to first dose
Yes
1 / 3
No
Date of onset
Is the Adverse Event Ongoing?
Yes
No
Adverse Event less than one day
Yes
No
Severity
Serious (If yes, complete SAE report)
Yes
No
Action Taken with Study Treatment
If study drug is discontinued, is this the primary
AE?
Yes
No
Outcome to event
Relation to study drug
Adverse events Visit 1
Adverse event
Adverse event intermittent
Yes
No
Time since dose
Time since dose unknown
Yes
No
Prior to first dose
Yes
No
Date of onset
Is the Adverse Event Ongoing?
Yes
No
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Adverse Event less than one day
Yes
No
Severity
Serious (If yes, complete SAE report)
Yes
No
Action Taken with Study Treatment
If study drug is discontinued, is this the primary
AE?
Yes
No
Outcome to event
Relation to study drug
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Proof of execution Nursing report Routine
documentation in German hospitals DMI
Routine documentation in German hospitals. Source file
name: VL160105_Pflegebericht/ Pflegebericht.107 and
Pflegebericht.108
Examplary forms provided by DMI (http://www.dmi.de/)
All rights reserved. Please visit https://medical-data-
models.org/forms/15686
Proof of execution Nursing report
Patienteninformation
Vorname
Nachname des Patienten
Körperpflege
Datum/ Zeit
Selbstständig
Ja
Nein
Hilfe bei überwiegend selbstständiger
Körperpflege
Ja
Nein
Stellen d. Wasch.Sch+ Waschutens + Nachb.
Ja
Nein
Mithilfe beim Waschen
Bett (1)
Waschbecken (2)
Hilfe beim
Duschen (1)
Baden (2)
Teilkörperpflege mit
Hilfe bei Mundhygiene
Ja
Nein
Übernahme der Körperpflege
Ja
Nein
Ganzwaschung
Duschen (1)
Baden (2)
Ganzkörperpflege mit
Mundhygiene  mit
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Gesichtrasur
Ja
Nein
Augenpflege mit
Ernährung
Datum/ Zeit
Selbständig
Ja
Nein
Nahrungsaufbereitung
Ja
Nein
Sondenernährung Dauertropf
Ja
Nein
Sondenernährung portioniert
Ja
Nein
Hilfe bei Nahrungsaufnahme
Ja
Nein
Ausscheidung
Datum/ Zeit
Selbständig
Ja
Nein
Ünterstützung zur kontrollierten Blasenentleerung
Ja
Nein
Begleitung zum WC
Ja
Nein
Unterstützung zur kontrollierten Darmentleerung
Ja
Nein
Entleeren von Katheterbeuteln
Ja
Nein
Wechseln von Stomabeutel
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Ja
Nein
Versorgen bei häufigem Erbrechen
Ja
Nein
Versorgen bei unkontrollierter Blasenentleerung
Ja
Nein
Versorgen bei unkontrollierter Blasenentleerung
Ja
Nein
Bewegung und Lagerung
Datum/ Zeit
Selbständig
Ja
Nein
Hilfe beim Aufstehen
Ja
Nein
Hilfe beim Gehen
Ja
Nein
Einfaches Lagerung
Ja
Nein
Mobilisieren
Ja
Nein
Pneumonieprophylaxe
Ja
Nein
Thromboseprophylaxe
Ja
Nein
Antithrombosestrümpfe Gr.
Dekubitusprophylaxe
Ja
Nein
Häufiges Körperlagern (2-4 stündlich)
Ja
Nein
3 / 6
Proof of execution Nursing report Routine documentation in German
hospitals DMI
Intensives Mobilisieren
Ja
Nein
Lagerung in Zusammenhang mit: OP,
Invasiven Maßnahmen, akuten
Krankheitsphasen
Leistungen in Zusammenhang mit: OP- Invasiven
Maßnahmen- akuten Krankheitsphasen
Ja
Nein
RR, Puls & Temp. Kontrolle
Ja
Nein
Beobachten des Patienten und
Vitalzeichenkontrolle von mindestens zwei
Parametern, 4-6 mal innerhalb 8 Std
Ja
Nein
Spontanurin
Ja
Nein
Nachblutungskontrolle
Ja
Nein
Aufwendiges Versorgen von Ableitungs- u.
Absaugsystem
Ja
Nein
Blasenkatheter
Legen (1)
Wechseln (2)
Blasenkatheter wechseln am
Beobachten des Patienten und
Vitalzeichenkontrolle von mindestens drei
Parametern, fort. innerhalb von wenigst. 12 Std.
zum Erkennen einer akuten Bedrohung
Ja
Nein
Medikation
Prämedikation
Ja
Nein
i.m. Injektionen
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Ja
Nein
s.c. Injektionen
Ja
Nein
Inhalationen
Ja
Nein
Mehrfach wiederholte u. kontinuierliche
Infusionstherapie
Ja
Nein
Mehrere Transfusionen
Ja
Nein
Intravenös Verabreichung von Zytostatika
Ja
Nein
Fortlaufendes Beobachten und Betreuen des
Patienten bei schwerwiegenden
Arzneimittelwirkung
Ja
Nein
BZ- Kontrolle
Ja
Nein
Wund- / Hautbehandlung
Wundbehandlung
Ja
Nein
Hautbehandlung
Ja
Nein
Nabel gereignit und desinfiziert
Ja
Nein
Verbandwechsel
Ja
Nein
Behandlung großflächiger Wunden
Ja
Nein
Behandlung tiefer Wunden
Ja
Nein
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Behandlung großer Hautareale
Ja
Nein
Aufwendiger Verbandwechsel, mehrmals täglich
Ja
Nein
Behandlung großflächiger Wunden, merhmals
täglich
Ja
Nein
Behandlung tiefer Wunden, mehrmals täglich
Ja
Nein
Behandlung großer Hautareale, mehrmals täglich
Ja
Nein
Pflegestufe
Berichte
Berichte
Datum und Uhrzeit
Pflegepersonal
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Eligibility Non-small Cell Lung Cancer
NCT02319408
Immune Boost In Non-Small Cell Lung Cancer; ODM
derived from: https://clinicaltrials.gov/show/NCT02319408
All rights reserved. Please visit https://medical-data-
models.org/forms/15687
Eligibility Non-small Cell Lung
Cancer NCT02319408
Inclusion Criteria
histologically proven clinical stage i to iia
pulmonary adenocarcinoma*
Yes
No
lung tumor is felt to be curatively resectable by
the treating physicians*
Yes
No
sufficient pulmonary function for lobectomy
according to current guidelines*
Yes
No
the patient is free of distant metastases as
confirmed by contrast-enhanced chest and upper
abdomen ct-scan and by contrast-enhanced ct or
mri of the brain*
Yes
No
age over 50years at the time of consent due to
federal radiation protection law*
Yes
No
in female patients of childbearing potential there
must be a negative pregnancy test*
Yes
No
eastern cooperative oncology group performance
status of 0,1, 2 or 3 at the time of randomization*
Yes
No
patients who the investigator believes can and
will comply with the requirements of this protocol*
Yes
No
written informed consent according to good
clinical practise and national/regional regulations*
Yes
No
Exclusion Criteria
the patient shows clinical signs of pneumonia*
Yes
1 / 2
No
the patient receives immunosuppressive drugs
(alkylating agents, antimetabolites, methotrexate,
azathioprine, mercaptopurine, cytotoxic
antibodies, ciclosporin, tacrolimus, sirolimus,
interferon, mycophenolate, small biological
agents)*
Yes
No
the patient has been diagnosed with a potential
immune mediated disease*
Yes
No
elevated blood leukocyte count or erythrocyte
sedimentation rate*
Yes
No
pregnancy*
Yes
No
the patient has received any cancer specific
treatment, including radiotherapy, immunotherapy,
hormonal therapy or chemotherapy*
Yes
No
the patient is diagnosed with a concomitant
malignancy and/or has a history of malignancy
within the past five years or has had a
malignancy that has been in complete remission
for less than 5 years*
Yes
No
the patient needs chronic long term oxygen
therapy*
Yes
No
the patient has undergone splenectomy*
Yes
No
the patient is known to be hiv positive*
Yes
No
the patient has an uncontrolled bleeding disorder*
Yes
No
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Nerventra Study Study drug dispensing and
return
Nerventra Study (Eudra CT 2007-003226-19) Study MS-
LAQ-301: A multinational, multicenter,
randomized, double-blind, parallel-group, placebo-
controlled study, to evaluate the safety,
tolerability and efficacy of daily oral administration of
laquinimod 0.6 mg in subjects with
relapsing remitting multiple sclerosis (RRMS)
All rights reserved. Please visit https://medical-data-
models.org/forms/15688
Nerventra Study Study drug
dispensing and return
Demographic Information
Protocol Number
Visit Type
Date of visit
Study site number
Subject number:
No data to report
Yes
No
Drug dispensed Baseline
Date Study drug dispensed
No. of capsules dispensed
Bottle number
Batch code
Expiry date
Drug dispensing and return
Date study drug returned from previous visit
Number of unused capsules
Date Study drug dispensed
No. of capsules dispensed
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Bottle number
Batch code
Expiry date
Was study drug temporarily discontinued? If yes,
complete below
Yes
No
Start date of temporary discontinuation
dd/mm/yy
End date of temporary discontinuation
dd/mm/yy
Reason for temporary discontinuation
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Delivery note Preserve Dispatch note Routine
documentation in German hospitals DMI
Routine documentation in German hospitals. Source file
name: TH200104_Konservenbegleitschein/
Lieferschein.045
Examplary forms provided by DMI (http://www.dmi.de/)
All rights reserved. Please visit https://medical-data-
models.org/forms/15689
Delivery note Preserve Dispatch
note
Lieferschein
Anforderungs-Nr.
Lieferschein Nr.
Lieferdatum
Lieferzeit
Kunden Nr.
Sachbearbeiter
Tour- Nr.
Nachname des Patienten
Vorname
Geburtsdatum
Blutformel
Selbstabholer
Konserven
Behältern
Gesamtzahl Produktgruppe EK
Übernahmebestätigung
Taxi (1)
Kurierdienst (2)
Kkhs.-F. (3)
Stadtbote (4)
Übergabe Transportfirma
Empfangsbestätigung
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Eligibility Breast Cancer NCT01579734
Phase III, Randomized, Double Blind Trial Low Dose
Tamoxifen Versus Placebo in Hormone Replacement
Therapy (HRT) Users; ODM derived from:
https://clinicaltrials.gov/show/NCT01579734
All rights reserved. Please visit https://medical-data-
models.org/forms/15690
Eligibility Breast Cancer
NCT01579734
Inclusion Criteria
postmenopausal women candidates to hrt for
control of menopausal symptoms or prevention of
postmenopausal disorders. women currently
undergoing hrt for any duration; (women off hrt
for 1 year or longer are considered de novo
users);*
Yes
No
negative bilateral mammography (within the last 6
months);*
Yes
No
written informed consent.*
Yes
No
Exclusion Criteria
any type of malignancy, with the exclusion of cin
and non-melanoma skin cancer;*
Yes
No
active proliferative disorders of the endometrium
such as atypical hyperplasia, history of active
endometriosis, unresected polyps, symptomatic
myomata;*
Yes
No
alterations of metabolic, liver, renal and cardiac
grade 2 function (nci criteria grade 2 or higher);*
Yes
No
any type of retinal disorders, severe cataract and
glaucoma;*
Yes
No
presence of significant risk factors for venous
events, including immobilization within the last 3
months for longer than 2 weeks following surgery
or trauma, history of estrogen-associated and
"sine causa" superficial phlebitis, deep venous
thrombophlebitis or other significant vte
(pulmonary embolism, stroke, etc.);*
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Yes
No
use of tamoxifen, raloxifene or other serms within
the last 4 weeks;*
Yes
No
anticoagulant therapy in progress (heparin or
dicoumarol);*
Yes
No
active infections;*
Yes
No
severe psychiatric disorders or inability to comply
to the protocol procedures; any other factor that
at the investigator's discretion contraindicates the
use of either tamoxifen or hrt.*
Yes
No
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Nerventra Study Liver enzyme evaluation
Nerventra Study (Eudra CT 2007-003226-19) Study MS-
LAQ-301: A multinational, multicenter,
randomized, double-blind, parallel-group, placebo-
controlled study, to evaluate the safety,
tolerability and efficacy of daily oral administration of
laquinimod 0.6 mg in subjects with
relapsing remitting multiple sclerosis (RRMS)
All rights reserved. Please visit https://medical-data-
models.org/forms/15691
Nerventra Study Liver enzyme
evaluation
Demographic Information
Protocol Number
Visit Type
Date of visit
Study site number
Subject number:
No data to report
Yes
No
Evaluation of liver enzymes
Date of sample in which elevation of ALT/AST
>3XULN was first noted
Were any signs and symptoms compatible with
liver disease reported/observed from subjects
complaints/physical examination?
Yes
No
History of liver enzyme elevations or any liver
disease prior to entering the study
Yes
No
Checking with the subject that all medical history
conditions and adverse events of the subject
were reported and captured in the appropriate
eCRF e.g. AE,MH
Done (1)
Not Done (2)
Alcohol use (chronic or acute)
Yes
No
If alcohol is being used, specify when the subject
started using
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If alcohol has been used, specify when the
subject stopped using
ongoing alcohol abuse
Yes
No
Type and amount of alcohol consumption
Use of prescribed and/or over the counter
drugs,including herbs, dietary
supplements,recreational drugs
Yes
No
Exposure to environmental chemical agents? If
yes, specify
Yes
No
Exposure to environmental chemical
agents,please specify type
Start date of environmental exposure
End date of environmental exposure
Ongoing environmental exposure
Yes
No
Hepatitis A
Done (1)
Not Done (2)
Hepatitis B
Done (1)
Not Done (2)
Hepatitis C
Done (1)
Not Done (2)
Anti-nuclear Antibodies
Done (1)
Not Done (2)
Anti-SM
Done (1)
Not Done (2)
Anti-LKM Antibodies
Done (1)
Not Done (2)
Ultrasound of liver and biliary tract
2 / 3
Nerventra Study Liver enzyme evaluation
Done (1)
Not Done (2)
Ultrasound date performed
Result of Ultrasound
Other diagnostic procedure i.e experts
consultation
Done (1)
Not Done (2)
Date of procedure
Specification of procedure
Resolution date/Stabilization of laboratory
abnormalities
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Nerventra Study Laboratory data
Nerventra Study (Eudra CT 2007-003226-19) Study MS-
LAQ-301: A multinational, multicenter,
randomized, double-blind, parallel-group, placebo-
controlled study, to evaluate the safety,
tolerability and efficacy of daily oral administration of
laquinimod 0.6 mg in subjects with
relapsing remitting multiple sclerosis (RRMS)
All rights reserved. Please visit https://medical-data-
models.org/forms/15692
Nerventra Study Laboratory data
Demographic Information
Protocol Number
Visit Type
Date of visit
Study site number
Subject number:
No data to report
Yes
No
Laboratory parameter
Laboratory parameter
Date of laboratory test
Laboratory value
Unit
Normal range upper limit
Normal range lower limit
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Nerventra Study Unscheduled Visit
Nerventra Study (Eudra CT 2007-003226-19) Study MS-
LAQ-301: A multinational, multicenter,
randomized, double-blind, parallel-group, placebo-
controlled study, to evaluate the safety,
tolerability and efficacy of daily oral administration of
laquinimod 0.6 mg in subjects with
relapsing remitting multiple sclerosis (RRMS)
All rights reserved. Please visit https://medical-data-
models.org/forms/15693
Nerventra Study Unscheduled Visit
Demographic Information
Protocol Number
Visit Type
Date of visit
Study site number
Subject number:
Section blank?
Yes
No
Reason for unscheduled visit
Reason for unscheduled visit
Adverse event (complete AE-Log) (1)
Change in concomitant medication
(complete concomitant medication log)
(2)
A possible exacerbation (Complete
neuro-exam and exacerbation
confirmation form) (3)
Follow-up of exacerbation (Complete
neuro-exam and exacerbation
confirmation form if applicable) (4)
Unscheduled study drug dispensing
(complete dispensing and compliance
log) (5)
Laboratory follow-up (6)
ET follow-up visit (7)
Other, specify (8)
Other reason
Safety measurements
Temperature
Temperature type of measurement
oral (1)
axillary (2)
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aural (3)
temporal (4)
Units used for measurement
F (1)
C (2)
Measurement not done
Yes
No
Blood pressure measurement
mm/Hg
Measurement not done
Yes
No
Pulse
beats/min
Measurement not done
Yes
No
Investigators ECG interpretation
ECG interpretation not done
Yes
No
Date of chest x-ray
Chest x-ray not done
Yes
No
Chest x-ray interpretation
Chest x-ray, if abnormal, please specify
Where all required laboratory samples obtained?
Yes
No
Menstruation
Yes
No
Exacerbation
Date of onset of symptoms of suspected
exacerbation
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Relatively stable or improving neurological state
for 30 days prior to onset
Yes
No
One or more neurological abnormalities
appeared or re-appeared if seen previously
Yes
No
Neurological abnormalities lasted 48 hours or
more
Yes
No
In the opinion of the investigator, the change in
EDSS score is not solely attributed to normal
fluctuations of the subjects MS symptoms and is
consistent with acute exacerbation
Yes
No
There was an increase of at least one of the
below: 0.5 or more on EDSS or 2 grades in score
for one function of the FS or one grade in score
for 2 or more functions of the FS
Yes
No
Change in EDSS or FS scores cannot be
attributed solely to change in bowel/bladder
function or to change in cognitive function
Yes
No
Based on neuroexam visit date
Did subject experience a confirmed
exacerbation?
Yes
No
Re- consent signed
Yes
No
Was i.v Methylprednisolone treatment instituted?
If yes, complete concomitant medication log
Yes
No
Event resulted in a hospitalization
No (1)
Yes-due to neurological deterioration (2)
Yes-due to i.v methylprednisolone
treatment (3)
Approximate date of stabilization
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Based on neuroexam visit date
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Notification sheet Cancer registries Routine
documentation in German hospitals DMI
Routine documentation in German hospitals. Source file
name: SD150102_Meldebogen Krebsregister/ Meldung an
das gemeinsame Krebsregister.017
Examplary forms provided by DMI (http://www.dmi.de/)
All rights reserved. Please visit https://medical-data-
models.org/forms/15694
Notification sheet Cancer registries
Identitätsdaten des Patienten
Nachname des Patienten
Vorname
Geburtsdatum
Geschlecht
männlich (1)
weiblich (2)
Staatsangehörigkeit
Adresse des Patienten
Wurder der Patient über die Anmeldung
informiert?
Ja
Nein
Anamnestische Daten
Mehrlinge
Ja
Nein
Geburten (Bitte erwähnen die Anzahl von
Lebend, Totegeburten oder Fehlgeburten)
Zuletzt ausgeübter Beruf und Dauer des Berufs
Am längsten ausgeübten Beruf und Dauer des
Berufs
Früherer Tumor
Ja
Nein
Welche Tumor und wann?
Angaben zum Primärtumor
Diagnosedatum
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Anlass der Diagnosestellung
organisiertes Screening (1)
Tumorsymptomatik (2)
Früherkennungs-/ Vorsorgeuntersuchung
(3)
Selbstuntersuchung (4)
Unbekannt (5)
Sonstiges (6)
Sontiges:
Nur bei Basaliomen: Wievieltes Basaliom des
Patienten?
Tumordiagnose
ICD-10
Tumorlokalisation
Seitenangabe
rechts (1)
links (2)
beidseits (3)
unbekannt (4)
Tumorhistologie
ICD-O-3
Dignität
maligne (1)
in- Situ (2)
borderline (3)
benigne (4)
unbekannt (5)
Diagnosesicherung
histologisch (1)
zytologisch/ hämatologisch (2)
klin. Untersuchungsverfahren (3)
autoptisch mit Histologie (4)
ubekannt (5)
Sonstiges (6)
Sonstiges
Grading
G1 (1)
B-Zell (10)
Null Zell (11)
NK- Zell (12)
G2 (2)
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G3 (3)
G4 (4)
low grade (5)
intermidär (6)
high grade (7)
unbekannt (8)
T- zell (9)
TNM-Klassifikation
Tumorausbreitung
lokal begrenzt (1)
regionäre Lymphknoten (2)
kontinuerl. Ausdehnung (3)
Fernmetastase (4)
Andere Klassifikation
Clark- level
Breslow
Gleason score
UICC
Operation
ja (1)
nein (2)
unbekannt (3)
OP- Klartext
Datum Operation
Strahlentherapie
ja (1)
nein (2)
unbekannt (3)
Datum Strahlentherapie
Chemotherapie
ja (1)
nein (2)
unbekannt (3)
Datum Chemotherapie
Hormontherapie
ja (1)
nein (2)
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unbekannt (3)
sonstige Therapie (4)
Datum Hormontherapie
Immuntherapie
ja (1)
nein (2)
unbekannt (3)
kein Therapie (4)
Datum Immuntherapie
Therapieintention
kurativ (1)
palliativ (2)
unbekannt (3)
Todesdaten
Todesursache
Todesursache
Leichenschauschein (1)
Obduktionsschein (2)
Sterbedatum
Tod tumorbedingt
ja (1)
nein (2)
unbekannt (3)
Sektion durchgeführt
ja (1)
nein (2)
unbekannt (3)
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Eligibility Non-small Cell Lung Cancer
NCT02322281
TIGER-3: Open Label, Multicenter Study of Rociletinib (CO-
1686) Mono Therapy Versus Single-agent Cytotoxic
Chemotherapy in Patients With Mutant EGFR NSCLC Who
Have Failed at Least One Previous EGFR-Directed TKI and
Platinum-doublet Chemotherapy; ODM derived from:
https://clinicaltrials.gov/show/NCT02322281
All rights reserved. Please visit https://medical-data-
models.org/forms/15695
Eligibility Non-small Cell Lung
Cancer NCT02322281
Inclusion Criteria
all patients must meet all of the following
inclusion criteria:*
Yes
No
1. histologically or cytologically confirmed
metastatic or unresectable locally advanced nsclc
with radiological progression on the most recent
therapy received*
Yes
No
2. documented evidence of a tumor with 1 or
more egfr activating mutations excluding exon 20
insertion*
Yes
No
3. disease progression confirmed by radiological
assessment while receiving treatment with single
agent egfr-tki (e.g., erlotinib, gefitinib, afatinib, or
dacomitinib).*
Yes
No
4. multiple lines of prior treatment are permitted
and there is no specified order of treatment, but
in the course of their treatment history, patients
must have received and have radiologically
documented disease progression following:*
Yes
No
at least 1 line of prior treatment with a single-
agent egfr tki (e.g., erlotinib, gefitinib, afatinib, or
dacomitinib)*
Yes
No
if egfr-tki is a component of the most recent
treatment line, the washout period for the egfr-tki
is a minimum of 3 days before the start of
rociletinib treatment*
Yes
No
a platinum-containing doublet chemotherapy
(either progressed during therapy or completed at
least 4 cycles without progression with
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subsequent progression after a treatment-free
interval or after a maintenance treatment).*
Yes
No
if cytotoxic chemotherapy is a component of the
most recent treatment line, treatment with
chemotherapy should have been completed at
least 14 days prior to start of study treatment.
when an egfr-tki is given in combination with
platinum-containing doublet chemotherapy,
treatment with the egfr-tki may continue until at
least 3 days before start of treatment.*
Yes
No
5. have undergone a biopsy of either primary or
metastatic tumor tissue within 60 days prior to
start of treatment and have tissue available to
send to sponsor laboratory or are able to undergo
a biopsy during screening and provide tissue to
sponsor laboratory*
Yes
No
6. measureable disease according to recist
version 1.1*
Yes
No
7. life expectancy of at least 3 months*
Yes
No
8. ecog performance status of 0 to 1*
Yes
No
9. age ≥ 18 years (in certain territories, the
minimum age requirement may be higher e.g.,
age ≥ 20 years in japan and taiwan, age ≥ 21
years in singapore)*
Yes
No
10. patients should have recovered to national
cancer institute (nci) common terminology criteria
for adverse events (ctcae) grade ≤ 1 from any
significant chemotherapy-related toxicities*
Yes
No
11. adequate hematological and biological
function*
Yes
No
12. written consent on an institutional review
board (irb)/independent ethics committee (iec)-
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approved icf before any study specific evaluation*
Yes
No
Exclusion Criteria
any of the following criteria will exclude patients
from study participation:*
Yes
No
1. any other malignancy associated with a high
mortality risk within the next 5 years and for
which the patients may be (but not necessarily)
currently receiving treatment*
Yes
No
patients with a history of malignancy that has
been completely treated, with no evidence of that
cancer currently, are permitted to enroll in the trial
provided all chemotherapy was completed > 6
months prior and/or bone marrow transplant > 2
years prior*
Yes
No
2. known pre-existing interstitial lung disease*
Yes
No
3. tumor small cell transformation by local
assessment, irrespective of presence of t790m+
component*
Yes
No
4. patients with leptomeningeal carcinomatosis
are excluded. other central nervous system (cns)
metastases are only permitted if treated,
asymptomatic, and stable (not requiring steroids
for at least 2 weeks prior to randomization and
the patient is neurologically stable i.e. free from
new symptoms of brain metastases).*
Yes
No
5. patients who are currently receiving treatment
with any medications that have the potential to
prolong the qt interval and that treatment cannot
be either discontinued or switched to a different
medication (known to have no effect on qt) before
starting protocol-specified treatment (see
http://crediblemeds.org/ for a list of qt-prolonging
medications)*
Yes
No
6. prior treatment with rociletinib, or other drugs
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that target t790m+ mutant egfr with sparing of wt-
egfr including but not limited to azd9291,
hm61713, and tas-121*
Yes
No
7. any contraindications for therapy with
pemetrexed, paclitaxel, gemcitabine or docetaxel
unless a contraindication with respect to one of
these drugs will not affect the use of any of the
others as a comparator to rociletinib*
Yes
No
8. any of the following cardiac abnormalities or
history:*
Yes
No
1. clinically significant abnormal 12-lead ecg, qt
interval corrected using fridericia's method (qtcf)
> 450 msec*
Yes
No
2. inability to measure qt interval on ecg*
Yes
No
3. personal or family history of long qt syndrome*
Yes
No
4. implantable pacemaker or implantable
cardioverter defibrillator*
Yes
No
5. resting bradycardia < 55 beats/min*
Yes
No
9. non-study related surgical procedures ≤ 7 days
prior to randomization. in all cases, the patient
must be sufficiently recovered and stable before
treatment administration*
Yes
No
10. females who are pregnant or breastfeeding*
Yes
No
11. refusal to use adequate contraception for
fertile patients (females and males) while on
treatment and for 6 months after the last dose of
study treatment (rociletinib and chemotherapy
irrespective of single cytotoxic agent used)*
Yes
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No
12. presence of any serious or unstable
concomitant systemic disorder incompatible with
the clinical study (e.g., substance abuse,
uncontrolled intercurrent illness including
uncontrolled diabetes, active infection, arterial
thrombosis, and symptomatic pulmonary
embolism)*
Yes
No
13. any other reason the investigator considers
the patient should not participate in the study*
Yes
No
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Baseline Visit (Day 1): Demography BG00012 Monotherapy Safety and Efficacy
Extension Study in Multiple Sclerosis (MS) (ENDORSE) NCT00835770
The primary objective of this study is to evaluate the long-
term safety profile of BG00012 (dimethyl fumarate).
Secondary objectives of this study are to evaluate the long-
term efficacy of BG00012 using clinical endpoints and
disability progression, to evaluate further the long-term
effects of BG00012 on multiple sclerosis (MS) brain lesions
on magnetic resonance imaging (MRI) scans in participants
who had MRI scans as part of Studies 109MS301
(NCT00420212) and 109MS302 (NCT00451451) and to
evaluate the long-term effects of BG00012 on health
economics assessments and the visual function test.
NCT00835770 
Part: Baseline Visit (Day 1)
All rights reserved. Please visit https://medical-data-
models.org/forms/15696
Baseline Visit (Day 1): Demography
BG00012 Monotherapy Safety and
Efficacy Extension Study in Multiple
Sclerosis (MS) (ENDORSE)
NCT00835770
Subject Identification
Number of Facility
Subject number
Subject Initials
Demography
Sex
male (1)
female (2)
Date of birth
Race
American Indian or Alaska Native (1)
Asian (2)
Black or African American (3)
Native Hawaiian or other pacific Islander
(4)
White (5)
Other, specify (6)
Other Race, specified
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Baseline Visit (Day 1): Medical History BG00012 Monotherapy Safety and Efficacy
Extension Study in Multiple Sclerosis (MS) (ENDORSE) NCT00835770
The primary objective of this study is to evaluate the long-
term safety profile of BG00012 (dimethyl fumarate).
Secondary objectives of this study are to evaluate the long-
term efficacy of BG00012 using clinical endpoints and
disability progression, to evaluate further the long-term
effects of BG00012 on multiple sclerosis (MS) brain lesions
on magnetic resonance imaging (MRI) scans in participants
who had MRI scans as part of Studies 109MS301
(NCT00420212) and 109MS302 (NCT00451451) and to
evaluate the long-term effects of BG00012 on health
economics assessments and the visual function test.
NCT00835770 
Part: Baseline Visit (Day 1)
All rights reserved. Please visit https://medical-data-
models.org/forms/15698
Baseline Visit (Day 1): Medical
History BG00012 Monotherapy
Safety and Efficacy Extension Study
in Multiple Sclerosis (MS)
(ENDORSE) NCT00835770
Subject Identification
Number of Facility
Subject number
Subject Initials
Medical history Update
Has the subject had any new medical or surgical
history since enrolling in 109-MS-301 or 109-MS-
302
Yes
No
Medical history List
Medical History, Category
Allergy  (1)
Endocrine/Metabolic (10)
Musculoskeletal (11)
Dermatilogical  (12)
Psychosocial/ Psychiatric  (13)
Infectious disease (14)
Other (15)
Hepatic (2)
Respiratory  (3)
Cardiovascular (4)
Gastrointestinal  (5)
Hepatic (6)
Genitourinary  (7)
Hematopoetic/Lymphatic (8)
Neurological (9)
ongoing
Yes
No
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Medical Condition
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Eligibility Cardiovascular Diseases
NCT00119847
Balloon Catheters and Stents to Prevent Heart Rhythm
Irregularities in Individuals Post-Heart Attack; ODM derived
from: https://clinicaltrials.gov/show/NCT00119847
All rights reserved. Please visit https://medical-data-
models.org/forms/15699
Eligibility Cardiovascular Diseases
NCT00119847
Inclusion Criteria
has experienced a heart attack 3 to 28 days prior
to study entry*
Yes
No
persistently occluded ira defined as either: 1)
thrombolysis in myocardial infarction (timi) 0, with
no flow beyond the site of occlusion; or 2) timi 1,
with penetration of dye beyond the site of
occlusion without dye reaching the distal vessel*
Yes
No
lvef less than 50% or proximal occlusion in a
large vessel*
Yes
No
normal sinus rhythm*
Yes
No
qrs duration less than 120 ms*
Yes
No
able to return for follow-up assessment of
arrhythmia markers one month and one year after
study entry*
Yes
No
Exclusion Criteria
has a clinical indication for revascularization
(post-heart attack angina at rest; significant
inducible ischemia; or significant left main or
triple vessel disease requiring ptca or cabg)*
Yes
No
current serious illness or condition that limits 3-
year survival*
Yes
No
severe valvular disease*
Yes
No
chronic total occlusion*
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Yes
No
new york heart association class iii-iv congestive
heart failure*
Yes
No
prior left ventricular aneurysm in the recent heart
attack location*
Yes
No
is a poor candidate for ptca/stent on the basis of
angiographic or clinical criteria*
Yes
No
cannot medically survive anticoagulation during
ptca/stent or antiplatelet therapy after stent*
Yes
No
pregnant*
Yes
No
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Eligibilitiy Criteria RICH Study
NCT02669589
NCT02669589 EudraCT-Nr. 2014-004854-33
REGIONAL CITRATE VERSUS SYSTEMIC HEPARIN
ANTICOAGULATION FOR CONTINUOUS RENAL
REPLACEMENT THERAPY IN CRITICALLY ILL
PATIENTS WITH ACUTE KIDNEY INJURY
Study Chair: Alexander Zarbock, MD University Hospital
Muenster
All rights reserved. Please visit https://medical-data-
models.org/forms/15701
Eligibilitiy Criteria RICH Study
NCT02669589
Patient Information
ID of Center
ID of Patient
Start Date of Screening
Start timem of Screening
Inclusion Criteria
Patients who are critical ill with acute kidney
injury
(KDIGO Stadium 3)
Yes
No
Urinary excretion:
< 0,3mL/kg/h for ≥ 24h
(measured or estimated)
no (no)
unknown (unknown)
yes (yes)
Serum Creatinine three times higher than
baseline (baseline value of the last 7 days. If
there is no baseline value, estimate value as
described in WI (see also tables of KDIGO)
no (no)
unknown (unknown)
yes (yes)
Serum creatine ≥ 4,0 mg/dL with acute increase
around ≥ 0,5 mg/dL
no (no)
unknown (unknown)
yes  (yes )
Clinical Indication for Renal Replacement
Therapy:
Serum Urea > 150 mg/dL
no (no)
unknown (unknown)
yes (yes)
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Clinical indication for Renal Replacement
Therapy:
Potassium > 6 mmol/L
no (no)
unknown (unknown)
yes (yes)
Clinical Indication for Renal Replacement
Therapy:
Magnesium > 4 mmol/L
and
anuria
no (no)
unknown (unknown)
yes (yes)
Clinical Indication for Renal Replacement
Therapy:
Blood pH < 7.15
no (no)
unknown (unknown)
yes (yes)
Clinical indication for Renal Replacement
Therapy:
Urinary excretion < 200 mL/12h 
or
Anuria
no (no)
unknown (unknown)
yes (yes)
Clinical indication for Renal Replacement
Therapy:
Oedema in organs resistant to diuretics
no (no)
unknown (unknown)
yes (yes)
Written informed consent
Written informed consent?
no, but confirmation by relatives --> seek
informed consent given by patient
subsequently (no, but confirmation by
relatives --> seek informed consent given
by patient subsequently)
no, but emergency situation
(confirmation by consular doctor) --> if
necessary supervisory relationship or
seek informed consent given by patient
subsequently (no, but emergency
situation (confirmation by consular
doctor) --> if necessary supervisory
relationship or seek informed consent
given by patient subsequently)
yes, given by legal representative -->
seek informed consent given by patient
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subsequently (yes, given by legal
representative --> seek informed consent
given by patient subsequently)
yes, given by patient (yes, given by
patient)
Date of informed consent
Time of informed consent
If clinical indication, possibility to start treatment
immediately or within 24 hours after achieving
KDIGO stadium 3 after randomization?
Yes
No
Exclusion Criteria - if one or more of the
criteria is correct, exclude the patient
Any increased bleeding risks?
(e.g. active bleeding from ulceration of
gastrointestinal tract,
Hypertension with diastolic pressure > 105
mmHg,
injuries of the brain (intracranial bleeding, brain
artery aneurysms), or CNS operations which
cannot achieve target PTT 45 - 60 sec,
severe retinopathies,
vitreous body bleeding,
ophthalmic operations or injuries,
active tuberculosis,
infectious endocarditis)
Yes
No
Any disorders and organ damages which are
connected to haemorrhagic diathesis?
(Coagulopathies, thrombocytopenia, severe
diseases of liver and pancreas)
Yes
No
Any Chronic Kidney Disease (KDOQI IV without
requiring dialysis (GFR< 30 ml/min calculated on
Cockroft-Gault-formular))?
Yes
No
Acute Kidney Injury requiring dialysis during the
last 90 days?
Yes
No
Chronic kidney failure requiring dialysis?
Yes
No
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Systemic anticoagulation therapy?
(Effective anticoagulation: PTT > 60s, Anti-Xa >
0,6 IE/mL, INR > 2)
Yes
No
Any Hypersensitivity to one of the anticoagulants
or
heparin-induced thrombocytopenia
Yes
No
Acute Kidney Injury due to renal artery occlusion 
or
surgical lesion of renal artery?
Yes
No
Acute Kidney Injury due to (glomerulo-) nephritis,
interstital nephritis, vasculitis, postrenal
obstruction?
Yes
No
DNR-order?
Yes
No
Haemolytic uremic syndrome
and/or
thrombotic thrombocytopenic purpura?
Yes
No
Persisting and severe lactate acidosis (pH < 7.2
in two measurments for > 2h; lactate > 8 mmol/L)
in the context of acute liver failure or shock?
Yes
No
Kidney transplantation in the last 12 months?
Yes
No
Positive pregnancy test in women of childbearing
age 
or 
breast feeding?
Yes
No
Abortus imminens?
Yes
No
No access to free continous dialysis machines at
time of inclusion?
Yes
No
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Participation in other intervention studies in the
last 3 months?
Yes
No
Any personal relations to person who is
responsible for study conduct?
Yes
No
Living in an institution due to legal or official
order?
Yes
No
Identification and Signature
Date of report (inclusion and exclusion criteria)
Time of report (inclusion and exclusion criteria)
Name of authorised physician
Signature of physician
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Randomization RICH study NCT02669589
NCT02669589 EudraCT-Nr. 2014-004854-33
REGIONAL CITRATE VERSUS SYSTEMIC HEPARIN
ANTICOAGULATION FOR CONTINUOUS RENAL
REPLACEMENT THERAPY IN CRITICALLY ILL
PATIENTS WITH ACUTE KIDNEY INJURY
Study Chair: Alexander Zarbock, MD University Hospital
Muenster
All rights reserved. Please visit https://medical-data-
models.org/forms/15702
Randomization RICH study
NCT02669589
Patient Information
ID of Center
ID of patient
Inclusion Criteria at randomization (at
least one of the first two (1. - 2.) questions
has to be answered with "yes" and at least
one of the last three criterias (I. - III.) must
be fulfilled))
1) Patients who are critical ill with acute kidney
injury (KDIGO Stadium 3)
Yes
No
2) Clinical indication for Renal Replacement
Therapy?
Yes
No
Written informed consent?
(given by patient or authorized representative or
relative or carers or confirmation of emergency
situation)
Yes
No
Cardiovascular score
(please record point value)
Urine amount
Normuria (Normuria)
Oliguria (Oliguria)
Patient's gender
female (female)
male (male)
Unlimited intesive care is planned at least for 3
days?
Yes
No
Age: 18 - 90 years old?
Yes
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No
I. Severe sepsis or septic shock?
no (no)
unknown (unknown)
yes (yes)
II. Higher usage of catecholamine therapy?
(Norepinephrine or Epinephrin ≥ 0,1 μg/kg/min 
OR
Norepinephrine ≥ 0,05 μg/kg/min + Dobutamine
each dose
OR
Norepinephrine ≥ 0,05 μg/kg/min + Vasopressin
each dose
OR
Norepinephrine ≥ 0,05 μg/kg/min + Epinephrine ≥
0,05 μg/kg/min
no (no)
unknown) (unknown))
yes (yes)
III. Development or deterioration of lung oedema
due to refractory fluid overload (PaO2/ FiO2 <
300 mmHg 
and/or 
fluid balance > 10% of starting body weight)
no (no)
unknown (unknown)
yes (yes)
Exclusion Criteria at Randomization
If there is any exclusion Criteria at Randomization
fulfilled, exclude the patient and do not randomize
him/her.
Is any of the exclusion Criteria positive?
Yes
No
Randomization Groups - Randomization
has to be done with help of
www.sepnet.de. The result will be issued
automatically and a fax with the
confirmation of randomisation will be sent)
Result of Randomization:
Regional citrate group (Regional citrate
group)
Systemic heparin group (Systemic
heparin group)
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Eligibility Type 2 Diabetes NCT01993121
Exercise and Type 2 Diabetes: Gender and Endothelial
Function; ODM derived from:
https://clinicaltrials.gov/show/NCT01993121
All rights reserved. Please visit https://medical-data-
models.org/forms/15703
Eligibility Type 2 Diabetes
NCT01993121
Inclusion Criteria
men and women between the ages of 30 and 55
years*
Yes
No
persons with type 2 diabetes taking only certain
oral medications (*
Yes
No
pre-menopausal women*
Yes
No
persons with type 2 diabetes who have a total
hba1c level <9%*
Yes
No
persons with a bmi between 25-35.*
Yes
No
Exclusion Criteria
current smokers or anyone who has smoked
within the last year*
Yes
No
persons who have clinically evident distal
symmetrical neuropathy*
Yes
No
abnormal lipid levels (total cholesterol >200, ldl-
cholesterol level >130, or triglyceride level
>250).*
Yes
No
persons with regional wall motion abnormalities,
left ventricular wall thickness >1.1 cm , or
decreased contractility.*
Yes
No
persons will also be excluded if they have
evidence of ischemic heart disease by history or
abnormal resting or exercise electrocardiogram
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(ecg).*
Yes
No
presence of systolic blood pressure >140 mmhg
at rest or >250 mmhg with exercise or diastolic
pressure >90 mmhg at rest or >105 mmhg with
exercise will be grounds for exclusion.*
Yes
No
subjects will be excluded who have peripheral
arterial disease.*
Yes
No
persons with autonomic insufficiency, assessed
by measuring variation in rr intervals with cycled
breathing and by presence of a >20 mm fall in
upright blood pressure without a change in heart
rate, will be excluded.*
Yes
No
subjects with proteinuria (urine protein >200
mg/dl) or a creatinine > 2 mg/dl, suggestive of
renal disease will be excluded.*
Yes
No
controls will not be accepted with an immediate
family history of type 2 diabetes mellitus*
Yes
No
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Eligibility Type 2 Diabetes NCT01240070
Multifactorial Intervention in Type 2 Diabetes - Italy; ODM
derived from: https://clinicaltrials.gov/show/NCT01240070
All rights reserved. Please visit https://medical-data-
models.org/forms/15704
Eligibility Type 2 Diabetes
NCT01240070
Inclusion Criteria
both genders*
Yes
No
age 50-70 years*
Yes
No
type two diabetes with at least two-year history of
disease and without insulin treatment in the first
two years after diagnosis*
Yes
No
negative medical history for documented previous
cardiovascular events or macrovascular
complications*
Yes
No
written consent to participate*
Yes
No
ldl cholesterol > 130 mg/dl (regardless of
treatment)*
Yes
No
triglycerides > 200 mg/dl*
Yes
No
hdl cholesterol < 35 (males) or 45 (females)
mg/dl*
Yes
No
blood pressure > 140/90 mmhg*
Yes
No
cigarette smoking*
Yes
No
Exclusion Criteria
age below 50 or above 70 years*
Yes
No
1 / 2
type 1 diabetes, diagnosis before 40 years of
age, known presence of auto-antibodies or insulin
requirement in the first 2 years of disease.*
Yes
No
chronic kidney failure (plasma creatinine > 2
mg/dl)*
Yes
No
significant liver damage (ast and/or alt > 2 times
the upper limits of normality)*
Yes
No
history of previous cardiovascular events*
Yes
No
active neoplasms or any concomitant disease
limiting life expectancy*
Yes
No
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Eligibility Subjects Had Unipolar, Non-
psychotic Major Depression NCT01282632
Risperidone vs. Olanzapine as add-on Treatment in
Treatment Resistant Depression; ODM derived from:
https://clinicaltrials.gov/show/NCT01282632
All rights reserved. Please visit https://medical-data-
models.org/forms/15705
Eligibility Subjects Had Unipolar,
Non-psychotic Major Depression
NCT01282632
Inclusion Criteria
1. male or female out-patients;*
Yes
No
2. aged between 18 and 65 years (extremes
included);*
Yes
No
3. subjects suffering from a current episode of
non-psychotic, unipolar depression as
determined by the depression section of the scid-
iv.*
Yes
No
4. subjects with treatment resistant depression
defined as failure to respond  to two successive
courses of monotherapy given in adequate doses
for a minimum of 4 weeks with different
antidepressants (the current course of
antidepressant can be considered to second
failed course) and;*
Yes
No
5. subjects currently taking a ssri or a snri for at
least 4 weeks, at adequate dosage and not
responding, as defined by a score of 3 or more
on the cgi-i. and no dose change for 2 weeks
prior to entry.*
Yes
No
6. a minimum score of 16 on the 17 item ham-d*
Yes
No
7. ability to provide informed consent.*
Yes
No
Exclusion Criteria
1. subjects who are actively suicidal as
determined by a score of 3 on the suicide item on
the ham-d or in the opinion of the treating
physician;*
Yes
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No
2. other current (active symptomatology within
the last 2 months) axis i dsm iv diagnosis other
than nicotine or caffeine dependence or other
than an anxiety disorder.*
Yes
No
3. use of disallowed concomitant therapy; or
other psychotropic medication except occasional
benzodiazepines. (see "rescue medication");*
Yes
No
4. history of alcohol or drug abuse or
dependence, within 3 months of entry into the
trial);*
Yes
No
5. seizure disorder requiring medication;*
Yes
No
6. active medical condition that requires urgent
attention or that would contra-indicate the use of
risperidone or olanzapine. for example stable
thyroid disease or asthma would be acceptable,
whereas acute hepatitis would not;*
Yes
No
7. participation in an investigational drug trial
within 30 days prior to the start of the trial*
Yes
No
8. known sensitivity to risperidone, olanzapine or
the antidepressant;*
Yes
No
9. history of neuroleptic malignant syndrome
(nms);*
Yes
No
10. subjects who are at imminent risk of injury to
self or others, or causing significant damage to
property, as judged by the investigator;*
Yes
No
11. female subjects who are pregnant or breast-
feeding;*
Yes
No
12. female subject of childbearing potential
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without adequate contraception (sterilization,
barrier, iud, oral contraceptives, intramuscular or
subdermal administration of depot-
progestagens);*
Yes
No
15. previous exposure to risperidone or
olanzapine during the current episode.*
Yes
No
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NCT01282632
Eligibility Myocardial Ischemia
NCT00143585
NOGA Angiogenesis Revascularization Therapy:
Evaluation by RadioNuclide Imaging - The Northern Trial;
ODM derived from:
https://clinicaltrials.gov/show/NCT00143585
All rights reserved. Please visit https://medical-data-
models.org/forms/15706
Eligibility Myocardial Ischemia
NCT00143585
Inclusion Criteria
canadian cardiovascular class iii-iv angina
despite treatment with maximal medical therapy*
Yes
No
lvef>20%*
Yes
No
ischemic defects on myocardial stress spect
imaging*
Yes
No
Exclusion Criteria
nyha>2*
Yes
No
history of or diagnosis of age related macular
degeneration, retinopathy*
Yes
No
atrial fibrillation*
Yes
No
primary valvular heart disease*
Yes
No
evidence of or known history of cancer with in
past 10 years*
Yes
No
uncontrolled hypertension*
Yes
No
liability to receive dipyridamole*
Yes
No
history or diagnosis of rheumatoid arthritis*
Yes
No
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recent mi(within 4 weeks)*
Yes
No
important ilio-femoral peripheral vascular
disease, limiting catheter access*
Yes
No
history of unexplained gastrointestinal
hemorrhage with the past 5 years*
Yes
No
lv thrombus visualized by either
echocardiography or contrast lv angiogram*
Yes
No
other severe concurrent illnesses*
Yes
No
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Postoperative Instructions for ICU Routine
documentation in German hospitals DMI
Routine documentation in German hospitals. Source file
name: OP150107_Postoperative Verordnungen/
Postoperative Anweisungen.077
Examplary forms provided by DMI (http://www.dmi.de/)
All rights reserved. Please visit https://medical-data-
models.org/forms/15707
Postoperative Instructions
Postoperative Anweisung Operateur
Operateur
Datum Operation
Drainage
Robinsondrain (1)
Redon mit Sog (2)
Redon ohne Sog (3)
Easy- Flow (4)
Spüldrain (5)
andere (6)
Andere Drainage
Anzahl
Lage
OB (1)
mittig (10)
links (11)
andere (12)
MB (2)
UB (3)
Hals (4)
Brust (5)
Rücken (6)
Leiste (7)
Gesäß (8)
rechts (9)
Andere
Spülung
Klarspülung (1)
Adhäsionsspülung (2)
septische Spülung (3)
nur Ablauf (4)
Katheter (Dauerkatheter)
Tamponade
vaginal (1)
anal (2)
resorbierbar anal (Spongostan) (3)
Entfernen
Ja
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Nein
Uhr
Enterostoma
Ileostoma (1)
Colostoma (2)
Ampicillin comp. 1,5g
Ja
Nein
Zeit
Ampicillin 2g
Ja
Nein
Zeit
Cefazolin 2000mg
Ja
Nein
Zeit
Ceftriaxon
Ja
Nein
Zeit
Metronidazol 500mg
Ja
Nein
Zeit
Cefotaxim 2g
Ja
Nein
Zeit
Gentamycin 80mg
Ja
Nein
Tgl
1X (1)
2X (2)
3X (3)
Andere (4)
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Andere Dosis
Tag
1 (1)
3 (2)
5 (3)
7 (4)
Bemerkung
Keine Anweisung
Postoperative Anweisung Anesthetist
Novaminsulfon
Ja
Nein
Dosis
m/g
Trpf/ supp
i.v
Kurzinf.
bei Bed.
Uhr
Intervall/ h
Dipidolor- Piritramid
Ja
Nein
Dosis
m/g
Trpf/ supp
i.v
Kurzinf.
bei Bed.
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Uhr
Intervall/ h
Tramadol
Ja
Nein
Dosis
m/g
Trpf/ supp
i.v
Kurzinf.
bei Bed.
Uhr
Intervall/ h
Paracetamol
Ja
Nein
Dosis
m/g
Trpf/ supp
i.v
Kurzinf.
bei Bed.
Uhr
Intervall/ h
MCP
Ja
Nein
Dosis
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m/g
Trpf/ supp
i.v
Kurzinf.
bei Bed.
Uhr
Intervall/ h
Ondansetron/ Zofran
Ja
Nein
Dosis
m/g
Trpf/ supp
i.v
Kurzinf.
bei Bed.
Uhr
Intervall/ h
Fortecortin
Ja
Nein
Dosis
m/g
Trpf/ supp
i.v
Kurzinf.
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bei Bed.
Uhr
Intervall/ h
Vomex A- Dimenhydrinat
Ja
Nein
Dosis
m/g
Trpf/ supp
i.v
Kurzinf.
bei Bed.
Uhr
Intervall/ h
Infusion
Sterofundin (1)
Ringer- Lactat (2)
Aminoven 3,5% (3)
Menge
500ml (1)
1000ml (2)
1500ml (3)
Dauer/h
Zugang ZVK zur Infusionstherapie freigeben
ja (1)
nein (2)
Magensonde (3)
Sauerstoffgabe
ml/min
Bis
Uhr
RR- Kontrolle
Ja
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Nein
RR über
mmHg
Bei Bed. 1 Kaps. Adalat geben, dosis:
mg/sl
BZ- Kontrolle
Ja
Nein
BZ über
mg/dl
Alt-Insulin
IE
Trinken
sofort (1)
schluckweise (2)
Kost
sofort (1)
flüssig (2)
Mobilisierung sofort?
Ja
Nein
Bemerkung
Anästhesist
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Eligibility Non-Small Cell Lung Cancer
NCT02349633
Study For Patients With NSCLC EGFR Mutations (Del 19
or L858R +/- T790M); ODM derived from:
https://clinicaltrials.gov/show/NCT02349633
All rights reserved. Please visit https://medical-data-
models.org/forms/15708
Eligibility Non-Small Cell Lung
Cancer NCT02349633
Criteria
evidence of histologically or cytologically
confirmed diagnosis of locally advanced or
metastatic egfrm (del19 or l858r) nsclc that has
progressed after at least 1 prior line of therapy.*
Yes
No
patients must have had disease progression on
treatment with an approved egfr tki.*
Yes
No
in phase 1, patients  may have also received
other lines of therapy before or after the egfr tki.*
Yes
No
in phase 2, while patients may have had multiple
lines of therapy, the last therapy prior to study
treatment must have been an approved egfr tki
and received within 6 weeks prior to study
registration.*
Yes
No
in the phase 1 portion:*
Yes
No
in the dose escalation and mtd expansion
portions patients must be t790m positive or
unknown status.*
Yes
No
in the pk sub-studies, patients with egfrm (del 19
or l858r) with any t790m status are eligible to
enroll.*
Yes
No
in the phase 2 portion:*
Yes
No
• patients must have egfrm (del 19 and t790m  or
l858r and t790m) nsclc tumors*
Yes
No
patients must have at least one measurable
lesion as defined by recist version 1.1*
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Yes
No
tumor tissue available (ie, formalin fixed paraffin
embedded (ffpe) block or 10 unstained sections
(5 micron).  an archival specimen is acceptable
for phase 1; a de novo specimen is required for
phase 2.*
Yes
No
patients must have adequate bone marrow,
hepatic and renal functions*
Yes
No
negative serum pregnancy test*
Yes
No
exclusion criteria (partial list)*
Yes
No
previously diagnosed brain metastases, unless
the patient has completed their treatment and
has recovered from the acute effects of radiation
therapy or surgery prior to study registration,
have discontinued corticosteroid treatment for
these metastases for at least 2 weeks, and are
neurologically stable.*
Yes
No
major surgery within 4 weeks prior to registration*
Yes
No
radiation therapy within 2 weeks prior to
registration.*
Yes
No
systemic anti cancer therapy within 2  weeks or 5
half-lives (whichever is longer) of registration
excluding egfr tkis.  patients on egfr tkis must
discontinue the agent for a minimum of 5 half-
lives, or 5 days, whichever is longer, prior to
registration*
Yes
No
concurrent use of drugs that are strong p-
glycoprotein (p-gp) inhibitors (such as but not
limited to: dronedarone, erythromycin, indinavir,
indinavir/ritonavir, itraconazole, ketoconazole,
lapatinib, lopinavir/ritonavir, quinidine, rifampin,
ritonavir, valspodar, verapamil, vorapaxar).
patients must avoid the use of  drugs that are
known strong p-gp inhibitors for the duration of
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the study. therapy with a t790m directed agent*
Yes
No
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Eligibility Non-Small Cell Lung Cancer
NCT02367781
A Phase III Study of MPDL3280A (Anti-PD-L1 Antibody) in
Combination With Carboplatin + Nab-Paclitaxel in Patients
With Non-Squamous Non-Small Cell Lung Cancer
[IMpower 130]; ODM derived from:
https://clinicaltrials.gov/show/NCT02367781
All rights reserved. Please visit https://medical-data-
models.org/forms/15709
Eligibility Non-Small Cell Lung
Cancer NCT02367781
Inclusion Criteria
18 years of age or older*
Yes
No
eastern cooperative oncology group (ecog)
performance status of 0 or 1*
Yes
No
histologically or cytologically confirmed,
treatment-naive stage iv non-squamous nsclc*
Yes
No
measurable disease, as defined by recist v1.1*
Yes
No
previously obtained archival tumor or tissue
obtained from a biopsy at screening*
Yes
No
adequate hematologic and end organ function*
Yes
No
Exclusion Criteria
active or untreated central nervous system (cns)
metastases*
Yes
No
malignancies other than nsclc within 5 years prior
to randomization, with the exception of those with
a negligible risk of metastasis or death treated
with expected curative outcome*
Yes
No
pregnant or lactating women*
Yes
No
history of autoimmune disease*
Yes
No
1 / 2
history of idiopathic pulmonary fibrosis,
organizing pneumonia, drug-induced
pneumonitis, idiopathic pneumonitis, or evidence
of active pneumonitis on screening chest
computed tomography (ct) scan; history of
radiation pneumonitis in the radiation field
(fibrosis) is permitted*
Yes
No
positive test for human immunodeficiency virus
(hiv)*
Yes
No
active hepatitis b or hepatitis c*
Yes
No
prior treatment with cd137 agonists or immune
checkpoint blockade therapies, anti-pd-1, and
anti-pd-l1 therapeutic antibody*
Yes
No
severe infection within 4 weeks prior to
randomization*
Yes
No
significant history of cardiovascular disease*
Yes
No
2 / 2
Eligibility Non-Small Cell Lung Cancer NCT02367781
Eligibility Non-Small Cell Lung Cancer
NCT02367794
A Phase III Study of MPDL3280A (Anti-PD-L1) in
Combination With Carboplatin + Paclitaxel or Carboplatin +
Nab-paclitaxel Compared With Carboplatin + Nab-paclitaxel
in Patients With Stage IV Squamous Non-Small Cell Lung
Cancer (NSCLC) [IMpower 131]; ODM derived from:
https://clinicaltrials.gov/show/NCT02367794
All rights reserved. Please visit https://medical-data-
models.org/forms/15710
Eligibility Non-Small Cell Lung
Cancer NCT02367794
Inclusion Criteria
18 years or older*
Yes
No
eastern cooperative oncology group (ecog)
performance status 0 or 1*
Yes
No
histologically or cytologically confirmed,
treatment-naïve stage iv squamous nsclc*
Yes
No
previously obtained archival tumor tissue or
tissue obtained from biopsy at screening*
Yes
No
measurable disease as defined by recist v1.1*
Yes
No
adequate hematologic and end organ function*
Yes
No
Exclusion Criteria
active or untreated central nervous system (cns)
metastasis*
Yes
No
malignancies other than nsclc within 5 years prior
to randomization, with the exception of those with
a negligible risk of metastasis or death treated
with expected curative outcome*
Yes
No
pregnant or lactating women*
Yes
No
history of autoimmune disease*
Yes
No
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history of idiopathic pulmonary fibrosis,
organizing pneumonia, drug-induced
pneumonitis, idiopathic pneumonitis, or evidence
of active pneumonitis on screening chest
computed tomography (ct) scan, history of
radiation pneumonitis in the radiation field
(fibrosis) is permitted*
Yes
No
positive test for human immunodeficiency virus
(hiv)*
Yes
No
active hepatitis b or hepatitis c*
Yes
No
prior treatment with cd137 agonists or immune
checkpoint blockade therapies, anti pd-1, and
anti-pd-l1 therapeutic antibody*
Yes
No
severe infection within 4 weeks prior to
randomization*
Yes
No
significant history of cardiovascular disease*
Yes
No
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Eligibility Non-Small Cell Lung Cancer NCT02367794
Eligibility Non-Squamous Non-Small Cell
Lung Cancer NCT02366143
A Phase III Study of MPDL3280A (Anti-PD-L1 Antibody) in
Combination With Carboplatin + Paclitaxel With or Without
Bevacizumab in Patients With Stage IV Non-squamous
Non-small Cell Lung Cancer [IMpower 150]; ODM derived
from: https://clinicaltrials.gov/show/NCT02366143
All rights reserved. Please visit https://medical-data-
models.org/forms/15711
Eligibility Non-Squamous Non-Small
Cell Lung Cancer NCT02366143
Inclusion Criteria
18 years of age or older*
Yes
No
eastern cooperative oncology group (ecog)
performance status 0 or 1*
Yes
No
histologically or cytologically confirmed,
treatment-naïve stage iv non-squamous nsclc*
Yes
No
previously obtained archival tumor tissue or
tissue obtained from a biopsy at screening*
Yes
No
measurable disease as defined by recist v1.1*
Yes
No
adequate hematologic and end organ function*
Yes
No
Exclusion Criteria
active or untreated central nervous system (cns)
metastases*
Yes
No
malignancies other than nsclc within 5 years prior
to randomization, with the exception of those with
a negligible risk of metastasis or death treated
with expected curative outcome*
Yes
No
pregnant or lactating women*
Yes
No
history of autoimmune disease*
Yes
No
1 / 2
history of idiopathic pulmonary fibrosis,
organizing pneumonia, drug induced
pneumonitis, idiopathic pneumonitis, or evidence
of active pneumonitis on screening chest
computed tomography (ct) scan. history of
radiation pneumonitis in the radiation field
(fibrosis) is permitted.*
Yes
No
positive test for human immunodeficiency virus
(hiv)*
Yes
No
active hepatitis b or hepatitis c*
Yes
No
prior treatment with cd137 agonists or immune
checkpoint blockade therapies, anti pd1, and anti-
pd-l1 therapeutic antibody*
Yes
No
severe infection within 4 weeks prior to
randomization*
Yes
No
significant history of cardiovascular disease*
Yes
No
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Eligibility Non-Squamous Non-Small Cell Lung Cancer NCT02366143
AID-Register (Kinderrheumatologie)
Kerndokumentation 2015
Register für autoinflammatorische Erkrankungen
AID-Register (Kinderrheumatologie)(PD Dr. med. Elke
Lainka, Prof. Dr. med. Dirk Föll)
https://prst.gpoh.de/aid/formulare.asp
All rights reserved. Please visit https://medical-data-
models.org/forms/15713
Kerndokumentation 2015:Arztbogen
für rheumakranke Kinder und
Jugendliche
Demographische Informationen
ID-Nummer
Erhebungsdatum
Geburtsmonat des Patienten
Geburtsjahr des Patienten
Geschlecht
männlich (1)
weiblich (2)
Körpergröße
cm
Körpergewicht
kg
Beginn der Erkrankung
Betreuungsbeginn
Rheumatologische Hauptdiagnose
Rheumatologische Hauptdiagnose: Diagnose
Code dreistellig
Rheumatologische Hauptdiagnose
gesichert (1)
Verdacht (2)
Weitere rheumatologische Diagnosen
Weitere rheumatologische Diagnosen
Diagnosecode dreistellig
Anamnese
Besteht eine gesicherte Zöliakie?
1 / 7
Ja
Nein
Besteht eine gesicherte Zöliakie? Wenn ja, seit
wann?
Besteht eine Autoimmunthyreoiditis?
Ja
Nein
Besteht eine Autoimmunthyreoiditis? Wenn ja,
seit wann?
Besteht ein Diabetes mellitus?
Ja
Nein
Besteht ein Diabetes mellitus? Wenn ja, seit
wann?
Erfolgt eine Insulintherapie?
Ja
Nein
Erfolgt eine Insulintherapie? Wenn ja, Tagesdosis
von Vortag
IE
Fieber
Aktuell (1)
zu Beginn (2)
Nie (3)
Exanthem
Aktuell (1)
zu Beginn (2)
Nie (3)
Generalisierte Lymphknotenschwellung
Aktuell (1)
zu Beginn (2)
Nie (3)
Hepatomegalie
Aktuell (1)
zu Beginn (2)
Nie (3)
Splenomegalie
Aktuell (1)
zu Beginn (2)
Nie (3)
Serositis
Aktuell (1)
zu Beginn (2)
Nie (3)
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Allgemeine Therapie
NSAR
aktuell (1)
letzte 12 Monate (2)
Glukokortikoide,systemisch < 0,2mg/kgKG
aktuell (1)
letzte 12 Monate (2)
Glukokortikoide,systemisch >= 0,2mg/kgKG
aktuell (1)
letzte 12 Monate (2)
Stoßtherapie
aktuell (1)
letzte 12 Monate (2)
Stoßtherapien: Anzahl
Glukokortikoide,intraartikulär
aktuell (1)
letzte 12 Monate (2)
Glukokortikoide,intraartikulär:Anzahl
Calcium/Vitamin D
aktuell (1)
letzte 12 Monate (2)
Keine Therapie
aktuell (1)
letzte 12 Monate (2)
Basistherapie
MTX
aktuell (1)
letzte 12 Monate (2)
MTX
oral (1)
parenteral (2)
MTX Beginn Monat/Jahr
Sulfasalazin
aktuell (1)
letzte 12 Monate (2)
Sulfasalazin Beginn Monat/Jahr
Etanercept
aktuell (1)
letzte 12 Monate (2)
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Etanercept Beginn Monat/Jahr
Adalimumab
aktuell (1)
letzte 12 Monate (2)
Adalimumab Beginn Monat/Jahr
Abatacept
aktuell (1)
letzte 12 Monate (2)
Abatacept Beginn Monat/Jahr
Canakinumab
aktuell (1)
letzte 12 Monate (2)
Canakinumab Beginn Monat/Jahr
Andere
Andere
aktuell (1)
letzte 12 Monate (2)
Andere Beginn Monat/Jahr
Keine Basistherapie
aktuell (1)
letzte 12 Monate (2)
Operationen,letzte 12 Monate
Operationen in den letzten 12 Monaten
Synovektomie (1)
Endoprothese (2)
andere OP (3)
keine OP (4)
Krankheitsaktivität
Wie aktiv ist die Krankheit im Augenblick?
0 inaktiv (1)
4.5 (10)
5 (11)
5.5 (12)
6 (13)
6.5 (14)
7 (15)
7.5 (16)
8 (17)
8.5 (18)
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9 (19)
0.5 (2)
9.5 (20)
10 hoch aktiv (21)
1 (3)
1.5 (4)
2 (5)
2.5 (6)
3 (7)
3.5 (8)
4 (9)
Gelenkbefall Arthritis
Kiefer rechts (1)
LWS (10)
SI Gelenke rechts (11)
SI Gelenke links (12)
Hüfte rechts (13)
Hüfte links (14)
Knie rechts (15)
Knie links (16)
Sprunggelenk rechts (17)
Sprunggelenk links (18)
Fußwurzel/Mittelfuß rechts (19)
Kiefer links (2)
Fußwurzel/Mittelfuß links (20)
Finger (21)
Zehen (22)
Kein Gelenk befallen (23)
Schulter rechts (3)
Schulter links (4)
Ellenbogen rechts (5)
Ellenbogen links (6)
Handgelenk rechts (7)
Handgelenk links (8)
HWS (9)
Welcher Finger befallen?
Welcher Zeh befallen?
Gelenkbefall Funktionsdefizit
Kiefer rechts (1)
LWS (10)
SI Gelenke rechts (11)
SI Gelenke links (12)
Hüfte rechts (13)
Hüfte links (14)
Knie rechts (15)
Knie links (16)
Sprunggelenk rechts (17)
Sprunggelenk links (18)
Fußwurzel/Mittelfuß rechts (19)
Kiefer links (2)
Fußwurzel/Mittelfuß links (20)
Finger (21)
Zehen (22)
Kein Gelenk befallen (23)
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Schulter rechts (3)
Schulter links (4)
Ellenbogen rechts (5)
Ellenbogen links (6)
Handgelenk rechts (7)
Handgelenk links (8)
HWS (9)
Welcher Finger befallen?
Welcher Zeh befallen?
Befunde jemals im Verlauf
Spondyloarthritis bei Verwandten ersten Grades
Ja
Nein
Psoriasis (ärztlich gesichert)
Ja
Nein
Daktylitis
Ja
Nein
Enthesitis
Ja
Nein
Uveitis
Ja
Nein
Spätfolgen am Auge
Ja
Nein
Malassimilationssyndrom
Ja
Nein
Laborbefunde
HLA-B27
negativ (1)
positiv (2)
nicht bestimmt (3)
ANA titer (aktuell)
negativ (1)
positiv (2)
nicht bestimmt (3)
Rheumafaktor (aktuell)
negativ (1)
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positiv (2)
nicht bestimmt (3)
BSG
mm/h
BSG nicht bestimmt
Ja
Nein
Ferritin
ng/ml
Ferritin nicht bestimmt
Ja
Nein
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Baseline Visit (Day 1): Vital Signs/Physical Examination BG00012 Monotherapy
Safety and Efficacy Extension Study in Multiple Sclerosis (MS) (ENDORSE)
NCT00835770
The primary objective of this study is to evaluate the long-
term safety profile of BG00012 (dimethyl fumarate).
Secondary objectives of this study are to evaluate the long-
term efficacy of BG00012 using clinical endpoints and
disability progression, to evaluate further the long-term
effects of BG00012 on multiple sclerosis (MS) brain lesions
on magnetic resonance imaging (MRI) scans in participants
who had MRI scans as part of Studies 109MS301
(NCT00420212) and 109MS302 (NCT00451451) and to
evaluate the long-term effects of BG00012 on health
economics assessments and the visual function test.
NCT00835770 
Part: Baseline Visit (Day 1)
All rights reserved. Please visit https://medical-data-
models.org/forms/15714
Baseline Visit (Day 1): Vital
Signs/Physical Examination
BG00012 Monotherapy Safety and
Efficacy Extension Study in Multiple
Sclerosis (MS) (ENDORSE)
NCT00835770
Subject Identification
Number of Facility
Subject number
Subject Initials
Vital Signs
Date of examination
Blood Pressure
Pulse
Temperature
Weight
Physical examination
Body System
Skin (1)
Rectal  (10)
Neurological  (11)
Extremities/Joints (12)
HEENT  (2)
Lymph nodes (3)
Neck and Thyroid  (4)
Breasts (5)
Chest/Lungs (6)
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Heart  (7)
Vascular (8)
Abdomen (9)
Examination Status
Not done (1)
Normal (2)
Abnormal (please specify) (3)
Abnormal examination findings
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Baseline Visit (Day 1): Vital Signs/Physical Examination BG00012 Monotherapy
Safety and Efficacy Extension Study in Multiple Sclerosis (MS) (ENDORSE)
NCT00835770
Baseline Visit (Day 1): EDSS evaluation BG00012 Monotherapy Safety and Efficacy
Extension Study in Multiple Sclerosis (MS) (ENDORSE) NCT00835770
The primary objective of this study is to evaluate the long-
term safety profile of BG00012 (dimethyl fumarate).
Secondary objectives of this study are to evaluate the long-
term efficacy of BG00012 using clinical endpoints and
disability progression, to evaluate further the long-term
effects of BG00012 on multiple sclerosis (MS) brain lesions
on magnetic resonance imaging (MRI) scans in participants
who had MRI scans as part of Studies 109MS301
(NCT00420212) and 109MS302 (NCT00451451) and to
evaluate the long-term effects of BG00012 on health
economics assessments and the visual function test.
NCT00835770 
Part: Baseline Visit (Day 1)
All rights reserved. Please visit https://medical-data-
models.org/forms/15717
Baseline Visit (Day 1): EDSS
evaluation BG00012 Monotherapy
Safety and Efficacy Extension Study
in Multiple Sclerosis (MS)
(ENDORSE) NCT00835770
Subject Identification
Number of Facility
Subject number
Subject Initials
EDSS Evaluation
Date of Evaluation
Functional System Scores
Visual
Brinstem
Pyramidal
Cerebellar
Sensory
Bowel or Bladder
Cerebral
Additional and Results
Actual Distance Walked
1 / 2
<100 metres (<100 metres)
>100 metres and <200 metres (>100
metres and <200 metres)
>200 metres and <300 metres (>200
metres and <300 metres)
>300 metres and <500 metres (>300
metres and <500 metres)
>500 metres (>500 metres)
Actual Distance Walked
<100 metres (1)
>100 metres and <200 metres (2)
>200 metres and <300 metres (3)
>300 metres and <500 metres (4)
>500 metres (5)
EDSS Score
Name of Neurologist
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Baseline Visit (Day 1): EDSS evaluation BG00012 Monotherapy Safety and Efficacy
Extension Study in Multiple Sclerosis (MS) (ENDORSE) NCT00835770
Eligibility Non-valvular Atrial Fibrillation
NCT02362659
Antithrombotic Strategy Variability In ATrial Fibrillation and
Obstructive Coronary Disease Revascularized With PCI -
The AVIATOR 2 Registry; ODM derived from:
https://clinicaltrials.gov/show/NCT02362659
All rights reserved. Please visit https://medical-data-
models.org/forms/15718
Eligibility Non-valvular Atrial
Fibrillation NCT02362659
Inclusion Criteria
diagnosis of non-valvular atrial fibrillation during
hospitalization.*
Yes
No
preexisting atrial fibrillation.*
Yes
No
successful all-comer percutaneous coronary
intervention:*
Yes
No
procedural success is defined as a reduction of
residual luminal diameter stenosis to <50%
without in-hospital death, ami or the need for
emergency cabg.*
Yes
No
over 18 years of age*
Yes
No
able to provide written informed consent*
Yes
No
Exclusion Criteria
atrial fibrillation due to reversible causes (e.g.,
thyrotoxicosis, pericarditis)*
Yes
No
valvular atrial fibrillation secondary to severe
mitral stenosis or prosthetic heart valve*
Yes
No
women who are  of childbearing potential
treatment with other investigational drugs or
devices within 30 days before enrolment or
planned use of investigational drugs or devices
during the study*
Yes
No
life expectancy <12 months due to non-cardiac
1 / 2
comorbidities*
Yes
No
active alcohol, drug abuse, psychosocial reasons
making study participation impractical*
Yes
No
severe  renal  insufficiency  (calculated
creatinine  clearance  < 30  ml/min)  or dialysis*
Yes
No
clinically overt stroke within the last 3 months*
Yes
No
known hypersensitivity or contraindication to
aspirin, clopidogrel, prasugrel, ticagrelor,
dabigatran,  rivaroxaban, apixaban,  edoxaban or
warfarin*
Yes
No
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Eligibility Non-valvular Atrial Fibrillation NCT02362659
Visit 1 (Week 4): Vital Signs BG00012 Monotherapy Safety and Efficacy
Extension Study in Multiple Sclerosis (MS) (ENDORSE) NCT00835770
The primary objective of this study is to evaluate the long-
term safety profile of BG00012 (dimethyl fumarate).
Secondary objectives of this study are to evaluate the long-
term efficacy of BG00012 using clinical endpoints and
disability progression, to evaluate further the long-term
effects of BG00012 on multiple sclerosis (MS) brain lesions
on magnetic resonance imaging (MRI) scans in participants
who had MRI scans as part of Studies 109MS301
(NCT00420212) and 109MS302 (NCT00451451) and to
evaluate the long-term effects of BG00012 on health
economics assessments and the visual function test.
NCT00835770 
Part: Visit 1 (Week 4)
All rights reserved. Please visit https://medical-data-
models.org/forms/15720
Visit 1 (Week 4): Vital Signs
BG00012 Monotherapy Safety and
Efficacy Extension Study in Multiple
Sclerosis (MS) (ENDORSE)
NCT00835770
Subject Identification
Number of Facility
Subject number
Subject Initials
Vital Signs
Date of examination
Blood Pressure
Pulse
Temperature
1 / 1
Visit 1 (Week 4): Study Drug Accountability BG00012 Monotherapy Safety and
Efficacy Extension Study in Multiple Sclerosis (MS) (ENDORSE) NCT00835770
The primary objective of this study is to evaluate the long-
term safety profile of BG00012 (dimethyl fumarate).
Secondary objectives of this study are to evaluate the long-
term efficacy of BG00012 using clinical endpoints and
disability progression, to evaluate further the long-term
effects of BG00012 on multiple sclerosis (MS) brain lesions
on magnetic resonance imaging (MRI) scans in participants
who had MRI scans as part of Studies 109MS301
(NCT00420212) and 109MS302 (NCT00451451) and to
evaluate the long-term effects of BG00012 on health
economics assessments and the visual function test.
NCT00835770 
Part: Visit 1 (Week 4)
All rights reserved. Please visit https://medical-data-
models.org/forms/15721
Visit 1 (Week 4): Study Drug
Accountability BG00012
Monotherapy Safety and Efficacy
Extension Study in Multiple Sclerosis
(MS) (ENDORSE) NCT00835770
Subject Identification
Number of Facility
Subject number
Subject Initials
Study Drug Accountability
date of first dose
Number of capsules not taken since previous visit
to this visit
Was there a protocol-defined dose
reduction/interruption since the previous visit?
Yes
No
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Visit 2 (Week 8): Vital Signs BG00012 Monotherapy Safety and Efficacy
Extension Study in Multiple Sclerosis (MS) (ENDORSE) NCT00835770
The primary objective of this study is to evaluate the long-
term safety profile of BG00012 (dimethyl fumarate).
Secondary objectives of this study are to evaluate the long-
term efficacy of BG00012 using clinical endpoints and
disability progression, to evaluate further the long-term
effects of BG00012 on multiple sclerosis (MS) brain lesions
on magnetic resonance imaging (MRI) scans in participants
who had MRI scans as part of Studies 109MS301
(NCT00420212) and 109MS302 (NCT00451451) and to
evaluate the long-term effects of BG00012 on health
economics assessments and the visual function test.
NCT00835770 
Part: Visit 2 (Week 8)
All rights reserved. Please visit https://medical-data-
models.org/forms/15722
Visit 2 (Week 8): Vital Signs
BG00012 Monotherapy Safety and
Efficacy Extension Study in Multiple
Sclerosis (MS) (ENDORSE)
NCT00835770
Subject Identification
Number of Facility
Subject number
Subject Initials
Vital Signs
Date of examination
Blood Pressure
Pulse
Temperature
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Visit 2 (Week 8): Study Drug Accountability BG00012 Monotherapy Safety and
Efficacy Extension Study in Multiple Sclerosis (MS) (ENDORSE) NCT00835770
The primary objective of this study is to evaluate the long-
term safety profile of BG00012 (dimethyl fumarate).
Secondary objectives of this study are to evaluate the long-
term efficacy of BG00012 using clinical endpoints and
disability progression, to evaluate further the long-term
effects of BG00012 on multiple sclerosis (MS) brain lesions
on magnetic resonance imaging (MRI) scans in participants
who had MRI scans as part of Studies 109MS301
(NCT00420212) and 109MS302 (NCT00451451) and to
evaluate the long-term effects of BG00012 on health
economics assessments and the visual function test.
NCT00835770 
Part: Visit 2 (Week 8)
All rights reserved. Please visit https://medical-data-
models.org/forms/15723
Visit 2 (Week 8): Study Drug
Accountability BG00012
Monotherapy Safety and Efficacy
Extension Study in Multiple Sclerosis
(MS) (ENDORSE) NCT00835770
Subject Identification
Number of Facility
Subject number
Subject Initials
Study Drug Accountability
date of first dose
Number of capsules not taken since previous visit
to this visit
Was there a protocol-defined dose
reduction/interruption since the previous visit?
Yes
No
1 / 1
Visit 3 (Week 12): Vital Signs BG00012 Monotherapy Safety and Efficacy
Extension Study in Multiple Sclerosis (MS) (ENDORSE) NCT00835770
The primary objective of this study is to evaluate the long-
term safety profile of BG00012 (dimethyl fumarate).
Secondary objectives of this study are to evaluate the long-
term efficacy of BG00012 using clinical endpoints and
disability progression, to evaluate further the long-term
effects of BG00012 on multiple sclerosis (MS) brain lesions
on magnetic resonance imaging (MRI) scans in participants
who had MRI scans as part of Studies 109MS301
(NCT00420212) and 109MS302 (NCT00451451) and to
evaluate the long-term effects of BG00012 on health
economics assessments and the visual function test.
NCT00835770 
Part: Visit 3 (Week 12)
All rights reserved. Please visit https://medical-data-
models.org/forms/15724
Visit 3 (Week 12): Vital Signs
BG00012 Monotherapy Safety and
Efficacy Extension Study in Multiple
Sclerosis (MS) (ENDORSE)
NCT00835770
Subject Identification
Number of Facility
Subject number
Subject Initials
Vital Signs
Date of examination
Blood Pressure
Pulse
Temperature
1 / 1
Visit 3 (Week 12): EDSS evaluation BG00012 Monotherapy Safety and Efficacy
Extension Study in Multiple Sclerosis (MS) (ENDORSE) NCT00835770
The primary objective of this study is to evaluate the long-
term safety profile of BG00012 (dimethyl fumarate).
Secondary objectives of this study are to evaluate the long-
term efficacy of BG00012 using clinical endpoints and
disability progression, to evaluate further the long-term
effects of BG00012 on multiple sclerosis (MS) brain lesions
on magnetic resonance imaging (MRI) scans in participants
who had MRI scans as part of Studies 109MS301
(NCT00420212) and 109MS302 (NCT00451451) and to
evaluate the long-term effects of BG00012 on health
economics assessments and the visual function test.
NCT00835770 
Part: Visit 3 (Week 12)
All rights reserved. Please visit https://medical-data-
models.org/forms/15725
Visit 3 (Week 12): EDSS evaluation
BG00012 Monotherapy Safety and
Efficacy Extension Study in Multiple
Sclerosis (MS) (ENDORSE)
NCT00835770
Subject Identification
Number of Facility
Subject number
Subject Initials
EDSS Evaluation
Date of Evaluation
Functional System Scores
Visual
Brinstem
Pyramidal
Cerebellar
Sensory
Bowel or Bladder
Cerebral
Additional and Results
Actual Distance Walked
1 / 2
<100 metres (<100 metres)
>100 metres and <200 metres (>100
metres and <200 metres)
>200 metres and <300 metres (>200
metres and <300 metres)
>300 metres and <500 metres (>300
metres and <500 metres)
>500 metres (>500 metres)
Actual Distance Walked
<100 metres (1)
>100 metres and <200 metres (2)
>200 metres and <300 metres (3)
>300 metres and <500 metres (4)
>500 metres (5)
EDSS Score
Name of Neurologist
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Visit 3 (Week 12): EDSS evaluation BG00012 Monotherapy Safety and Efficacy
Extension Study in Multiple Sclerosis (MS) (ENDORSE) NCT00835770
Visit 3 (Week 12): Study Drug Accountability BG00012 Monotherapy Safety and
Efficacy Extension Study in Multiple Sclerosis (MS) (ENDORSE) NCT00835770
The primary objective of this study is to evaluate the long-
term safety profile of BG00012 (dimethyl fumarate).
Secondary objectives of this study are to evaluate the long-
term efficacy of BG00012 using clinical endpoints and
disability progression, to evaluate further the long-term
effects of BG00012 on multiple sclerosis (MS) brain lesions
on magnetic resonance imaging (MRI) scans in participants
who had MRI scans as part of Studies 109MS301
(NCT00420212) and 109MS302 (NCT00451451) and to
evaluate the long-term effects of BG00012 on health
economics assessments and the visual function test.
NCT00835770 
Part: Visit 3 (Week 12)
All rights reserved. Please visit https://medical-data-
models.org/forms/15726
Visit 3 (Week 12): Study Drug
Accountability BG00012
Monotherapy Safety and Efficacy
Extension Study in Multiple Sclerosis
(MS) (ENDORSE) NCT00835770
Subject Identification
Number of Facility
Subject number
Subject Initials
Study Drug Accountability
date of first dose
Number of capsules not taken since previous visit
to this visit
Was there a protocol-defined dose
reduction/interruption since the previous visit?
Yes
No
1 / 1
Eligibility Obesity NCT02117700
Fatty Liver Disease in Obese Children; ODM derived from:
https://clinicaltrials.gov/show/NCT02117700
All rights reserved. Please visit https://medical-data-
models.org/forms/15727
Eligibility Obesity NCT02117700
Inclusion Criteria
age 7 years and older*
Yes
No
nash confirmed in a previous biopsy*
Yes
No
hbaic <6.4%*
Yes
No
alt > 60 u/l or 1.5 times the upper limit of normal*
Yes
No
Exclusion Criteria
chronic liver disease including alpha-1-antitrypsin
deficiency, wilson's disease, autoimmune and
viral hepatitis*
Yes
No
medications such as adrenergic β-blockers,
steroids and other drugs known to interfere with
the measurement of liver enzymes and risk
factors for cardiovascular disease*
Yes
No
heart disease, chronic renal disease, adrenal,
hepatic or thyroid   dysfunction; active
malignancy; and anemia*
Yes
No
history of prior treatment with nac*
Yes
No
evidence of hypersensitivity/allergy to nac*
Yes
No
alcoholism or drug abuse and smoking*
Yes
No
inter-current illness over 7 days before the study
& surgery in the past 3 mo.*
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Yes
No
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Eligibility Obesity NCT02117700
Eligibility Osteoarthritis NCT02247882
Effectiveness of Aquatic Physical Therapy for Knee
Osteoarthritis Patients; ODM derived from:
https://clinicaltrials.gov/show/NCT02247882
All rights reserved. Please visit https://medical-data-
models.org/forms/15728
Eligibility Osteoarthritis
NCT02247882
Inclusion Criteria
patients aged between 60 and 85 years;*
Yes
No
patients with knee oa by a physician confirmed by
the criteria of american college of rheumatology;*
Yes
No
patients with clinical and cognitive activities for
the realization of the pool conditions, confirmed
by the mini-exam mental state.*
Yes
No
Exclusion Criteria
patients undergoing surgical procedures in the
last six months;*
Yes
No
patients with chronic diseases such as coronary,
other rheumatic diseases such as rheumatoid
arthritis; serious diseases such as cancer;
chronic obstructive pulmonary diseases;
uncontrolled hypertensive;*
Yes
No
patients unable to walk without aid equipment;*
Yes
No
patients who have contraindications to practice
exercises;*
Yes
No
patients who have contraindications for entry into
the pool, such as urinary or fecal incontinence
and skin problems;*
Yes
No
patients participating in nutrition programs or
physical activity in the last two months (or
resisted aerobic activity more than once a week
for at least two months);*
Yes
No
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patients with metal implants in the lower limbs;*
Yes
No
patients with morbid obesity (body mass index
(bmi)> 40 kg / m 2);*
Yes
No
patients unable to continue the study by
programmed change of address or
hospitalization.*
Yes
No
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Eligibility Osteoarthritis NCT02247882
Eligibility Osteoarthritis NCT02343705
Evaluation of the Latella Knee Implant System for Medial
Osteoarthritis Pain Reduction (Latella-2 Study); ODM
derived from: https://clinicaltrials.gov/show/NCT02343705
All rights reserved. Please visit https://medical-data-
models.org/forms/15729
Eligibility Osteoarthritis
NCT02343705
Inclusion Criteria
history of pain due to medial osteoarthritis*
Yes
No
qualifying baseline pain scores*
Yes
No
kellgren-lawrence grades 2-3*
Yes
No
Exclusion Criteria
osteoporosis*
Yes
No
rheumatoid arthritis*
Yes
No
joint instability*
Yes
No
metal ion allergy*
Yes
No
permanent implant in or around the knee joint*
Yes
No
prior anterior cruciate ligament reconstruction*
Yes
No
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Eligibility Diabetes Mellitus, Type 1
NCT00179777
TRIGR - Primary Prevention Study for Type 1 Diabetes in
Children at Risk; ODM derived from:
https://clinicaltrials.gov/show/NCT00179777
All rights reserved. Please visit https://medical-data-
models.org/forms/15730
Eligibility Diabetes Mellitus, Type 1
NCT00179777
Inclusion Criteria
biological parent and/or full (not half) sibling of
the newborn infant has type 1 diabetes as
defined by the world health organization*
Yes
No
the infant's parent or legal guardians give signed
consent to participate*
Yes
No
Exclusion Criteria
an older sibling of the newborn infant has been
included in the trigr intervention*
Yes
No
multiple gestation*
Yes
No
the parents are unwilling or unable to feed the
infant cow's milk based products for any reason
(e.g., religious, cultural).*
Yes
No
the newborn infant has a recognizable severe
illness such as those due to chromosomal
abnormality, congenital malformation, respiratory
failure needing assisted ventilation, enzyme
deficiencies, etc.*
Yes
No
the gestational age of the newborn infant is less
than 35 weeks.*
Yes
No
the infant is older than 7 days at randomization.*
Yes
No
inability of the family to take part in the study (e.g.
the family has no access to any of the study
centers, the family has no telephone).*
Yes
No
the infant has received any infant formula other
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than nutramigen prior to randomization.*
Yes
No
no hla sample drawn before the age of 8 days.*
Yes
No
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Eligibility Diabetes Mellitus, Type 1 NCT00179777
Eligibility Osteoarthritis NCT02347384
Project JAY THA Registration Study; ODM derived from:
https://clinicaltrials.gov/show/NCT02347384
All rights reserved. Please visit https://medical-data-
models.org/forms/15731
Eligibility Osteoarthritis
NCT02347384
Inclusion Criteria
male or female subjects, aged between 50 and
75 years inclusive of chinese ethnicity.*
Yes
No
subject presents with osteoarthritis, rheumatoid
arthritis, post-traumatic arthritis, avascular
necrosis of hip joint, developmental dysplasia of
the hip, or femoral neck fracture requiring primary
total hip replacement.*
Yes
No
subject who is able to give voluntary, written
informed consent to participate in the study and
from whom consent has been obtained by signing
and dating an ec-approved consent form.*
Yes
No
subject who is able to understand this clinical
study, co-operates with the investigational
procedures and is willing to return to the hospital
for all the required post-operative follow-ups for
up to 12 months.*
Yes
No
life expectancy of subject is over 2 years.*
Yes
No
Exclusion Criteria
bilateral hip disease with the anticipated need for
bilateral hip implant during study participation
(i.e., within the next 12 months).*
Yes
No
subject experienced prior joint replacement
surgery on any major joint (hip, knee) in lower
limb within the last 12 months.*
Yes
No
subject with developmental dysplasia of the hip of
crowe grade 3 or 4.*
Yes
No
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subject has known or suspected metal
sensitivity.*
Yes
No
subject is known to have insufficient bone stock
resulting from conditions such as cancer,
significant osteoporosis or metabolic bone
disorders, which cannot provide adequate
support and/or fixation to the prosthesis.*
Yes
No
subject is severely obese (bmi>35).*
Yes
No
subject had an active infection or sepsis (treated
or untreated).*
Yes
No
subject has conditions that may compromise
implant stability or postoperative recovery (i.e.,
paget's or charcot's disease, vascular
insufficiency, muscular atrophy, uncontrolled
diabetes, moderate to severe renal insufficiency,
hip abduction muscle strength less than grade iv
or complete loss, or neuromuscular disease).*
Yes
No
subject has an emotional or neurological
condition that would affect their ability or
willingness to participate in the study (e.g.
cognitive disorder, mental illness, mental
retardation).*
Yes
No
subject is immunosuppressed, has an
autoimmune disorder, or an immunosuppressive
disorder. for examples, subject is on
immunosuppressive therapy (corticosteroid
hormones in large amounts, cytotoxic drugs,
antilymphocytic serum or irradiation in large
doses) or has acquired immunodeficiency
syndrome (aids).*
Yes
No
subject is known to be at risk for lost to follow-up,
or failure to return for scheduled visits.*
Yes
No
subject was enrolled in another investigational
drug, biologic, or device study in the last 12
months.*
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Eligibility Osteoarthritis NCT02347384
Yes
No
subject is a woman who is pregnant or lactating
，or intends to become pregnant during the
course of the study.*
Yes
No
known alcohol and/or drug abuse*
Yes
No
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Eligibility Osteoarthritis NCT02347384
Relapse Evaluation Visit No. 3: Recent Symptoms
Multiple Sclerosis ALAIN01 NCT02419378
Alemtuzumab in Autoimmune Inflammatory
Neurodegeneration: Mechanisms of Action and
Neuroprotective Potential (ALAIN01)
https://clinicaltrials.gov/ct2/show/NCT02419378
Principal Investigator Prof. Dr. Dr. Sven Meuth, University
Hospital Muenster, Germany
Part: Relapse Evaluation Visit No. 3
All rights reserved. Please visit https://medical-data-
models.org/forms/15732
Relapse Evaluation Visit No. 3:
Recent Symptoms Multiple Sclerosis
ALAIN01 NCT02419378
Recent symptoms
Patient ID (derived)
Relapse: Recent symptoms RQG
Relapse: Recent symptoms description
Relapse: Recent symptoms Start Date
Relapse: Recent symptoms End Date
Relapse: Recent symptoms ongoing
ongoing (1)
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Eligibility Osteoarthritis NCT02350387
Efficacy of Eccentric Resistance Training in Persons With
Knee Osteoarthritis; ODM derived from:
https://clinicaltrials.gov/show/NCT02350387
All rights reserved. Please visit https://medical-data-
models.org/forms/15733
Eligibility Osteoarthritis
NCT02350387
Inclusion Criteria
at least 55 years old,*
Yes
No
cognitively able to understand directions,*
Yes
No
able to ambulate at least 50 feet without
stopping,*
Yes
No
are currently experiencing knee pain and*
Yes
No
meet at least 3 out of 6 criteria of the european
league against rheumatism (eular) criteria for
knee osteoarthritis diagnosis.*
Yes
No
Exclusion Criteria
a diagnosed medical condition that would limit
physical ability, including acute or active fractures,
myocardial infarctions, stroke,*
Yes
No
a traumatic brain injury within the last 6 months,
or*
Yes
No
joint replacement within the last 12 months.
individuals with chronic neurological disorders
limiting motion or present with any known
contraindication for balance training will also be
excluded from the study.*
Yes
No
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Eligibility Osteoarthritis NCT02355236
Gastro-protective Effect and Pain Relief Effect of Naxozol
Compared to Celecoxib in Patients With Osteoarthritis;
ODM derived from:
https://clinicaltrials.gov/show/NCT02355236
All rights reserved. Please visit https://medical-data-
models.org/forms/15734
Eligibility Osteoarthritis
NCT02355236
Inclusion Criteria
koreans given informed consent*
Yes
No
patients who have ability of reading
comprehension and completing questionnaires
(eq-5d and vas)and have willingness to follow-up
12 weeks*
Yes
No
patients with osteoarthritis symptoms confirmed
by his/her medical history and with pain-vas of 40
and more*
Yes
No
Exclusion Criteria
patients who participate into other interventional
study or had participated within 30 days before
screening*
Yes
No
alcohol or drug abuse within 6 months or alcohol
consumption of 21 units and more in a week*
Yes
No
peptic ulcers accompanied with a complication
such as bleeding, perforation, penetration or
gastric outlet obstruction within 5 years, or a
history of active peptic ulcer or peptic ulcer
without a complication within 6 months at
screening*
Yes
No
patients who are known with helicobacter pylori
infection but have not received any bacteriostatic
treatment*
Yes
No
known gastroesophageal reflux disease (gerd)*
Yes
No
any following joint diseases which may significant
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effect to the efficacy and safety assessments:
septic arthritis, inflammatory joint arthritis such as
rheumatoid arthritis, gout, recurrent pseudo-pain,
paget's disease, joint fracture, joint ochronosis,
acromegaly, hematochromatosis, wilson's
disease, primary osteochondrosis, ehlers danlos
syndrome, or other collagen genetic disorder*
Yes
No
patients who are scheduled admissions to
hospital for elective surgery during this study*
Yes
No
history of gastrointestinal cancer*
Yes
No
gastrointestinal disorders related to drug
malabsorption*
Yes
No
gastrointestinal bleeding, cerebral bleeding, other
bleeding disorders, or severe hematological
disorders*
Yes
No
clinically significant diseases such as moderate
or severe liver diseases (child pough class ii or
more), severe heart failure or a history of
coronary artery bypass graft (cabg), severe
kidney diseases (crcl<30ml/min)*
Yes
No
know allergy experiences with any ingredient of
study drugs or with other nasids or protocol pump
inhibitors (ppis)*
Yes
No
patients who had had a joint surgery for
osteoarthritis within 1 year*
Yes
No
women of childbearing potential who do not
agree with clinically appropriate contraception
during this study*
Yes
No
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Eligibility Osteoarthritis NCT02355236
Eligibility Osteoarthritis NCT02370420
Intra-Articular Injections of Platelet-Rich Plasma in Knee
Osteoarthritis: Unique Application Versus Triple Application;
ODM derived from:
https://clinicaltrials.gov/show/NCT02370420
All rights reserved. Please visit https://medical-data-
models.org/forms/15735
Eligibility Osteoarthritis
NCT02370420
Inclusion Criteria
age between 18 and 90 years*
Yes
No
patients with no previous treatment*
Yes
No
patients with knee osteoarthritis grade 1-2 (
kellgren-lawrence based on radiographic
findings)*
Yes
No
Exclusion Criteria
age <18 and > 90 years*
Yes
No
patients with knee osteoarthritis grade 3-4 (
kellgren-lawrence based on radiographic
findings)*
Yes
No
patients with asociated rheumatic syndromes*
Yes
No
patients with anticoagulant therapy*
Yes
No
patients with hepatic problems, diabetes mellitus,
coagulopathy, hearth conditions,
immunodepressed, or infections*
Yes
No
pregnant patients*
Yes
No
patients with prosthetic or orthotic.*
Yes
No
patients with hemoglobin values  < 11g/dl ,
platelets < 150,000/ul*
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Yes
No
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Eligibility Osteoarthritis NCT02370420
Visit 4 (Week 16): Vital Signs, Study Drug accountability BG00012 Monotherapy
Safety and Efficacy Extension Study in Multiple Sclerosis (MS) (ENDORSE)
NCT00835770
The primary objective of this study is to evaluate the long-
term safety profile of BG00012 (dimethyl fumarate).
Secondary objectives of this study are to evaluate the long-
term efficacy of BG00012 using clinical endpoints and
disability progression, to evaluate further the long-term
effects of BG00012 on multiple sclerosis (MS) brain lesions
on magnetic resonance imaging (MRI) scans in participants
who had MRI scans as part of Studies 109MS301
(NCT00420212) and 109MS302 (NCT00451451) and to
evaluate the long-term effects of BG00012 on health
economics assessments and the visual function test.
NCT00835770
Part: Visit 4 (Week 16)
All rights reserved. Please visit https://medical-data-
models.org/forms/15736
Visit 4 (Week 16): Vital Signs, Study
Drug accountability BG00012
Monotherapy Safety and Efficacy
Extension Study in Multiple Sclerosis
(MS) (ENDORSE) NCT00835770
Subject Identification
Number of Facility
Subject number
Subject Initials
Vital Signs
Date of examination
Blood Pressure
Pulse
Temperature
Study Drug Accountability
date of first dose
Number of capsules not taken since previous visit
to this visit
Was there a protocol-defined dose
reduction/interruption since the previous visit?
Yes
No
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Visit 5 (Week 20): Vital Signs, Study Drug accountability BG00012 Monotherapy
Safety and Efficacy Extension Study in Multiple Sclerosis (MS) (ENDORSE)
NCT00835770
The primary objective of this study is to evaluate the long-
term safety profile of BG00012 (dimethyl fumarate).
Secondary objectives of this study are to evaluate the long-
term efficacy of BG00012 using clinical endpoints and
disability progression, to evaluate further the long-term
effects of BG00012 on multiple sclerosis (MS) brain lesions
on magnetic resonance imaging (MRI) scans in participants
who had MRI scans as part of Studies 109MS301
(NCT00420212) and 109MS302 (NCT00451451) and to
evaluate the long-term effects of BG00012 on health
economics assessments and the visual function test.
NCT00835770
Part: Visit 5 (Week 20)
All rights reserved. Please visit https://medical-data-
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Visit 5 (Week 20): Vital Signs, Study
Drug accountability BG00012
Monotherapy Safety and Efficacy
Extension Study in Multiple Sclerosis
(MS) (ENDORSE) NCT00835770
Subject Identification
Number of Facility
Subject number
Subject Initials
Vital Signs
Date of examination
Blood Pressure
Pulse
Temperature
Study Drug Accountability
date of first dose
Number of capsules not taken since previous visit
to this visit
Was there a protocol-defined dose
reduction/interruption since the previous visit?
Yes
No
1 / 1
Visit 6 (Week 24): Vital Signs/Physical Examination BG00012 Monotherapy Safety
and Efficacy Extension Study in Multiple Sclerosis (MS) (ENDORSE)
NCT00835770
The primary objective of this study is to evaluate the long-
term safety profile of BG00012 (dimethyl fumarate).
Secondary objectives of this study are to evaluate the long-
term efficacy of BG00012 using clinical endpoints and
disability progression, to evaluate further the long-term
effects of BG00012 on multiple sclerosis (MS) brain lesions
on magnetic resonance imaging (MRI) scans in participants
who had MRI scans as part of Studies 109MS301
(NCT00420212) and 109MS302 (NCT00451451) and to
evaluate the long-term effects of BG00012 on health
economics assessments and the visual function test.
NCT00835770 
Part: Visit 6 (Week 24)
All rights reserved. Please visit https://medical-data-
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Visit 6 (Week 24): Vital
Signs/Physical Examination
BG00012 Monotherapy Safety and
Efficacy Extension Study in Multiple
Sclerosis (MS) (ENDORSE)
NCT00835770
Subject Identification
Number of Facility
Subject number
Subject Initials
Vital Signs
Date of examination
Blood Pressure
Pulse
Temperature
Weight
Physical examination
Body System
Skin (1)
Rectal  (10)
Neurological  (11)
Extremities/Joints (12)
HEENT  (2)
Lymph nodes (3)
Neck and Thyroid  (4)
Breasts (5)
Chest/Lungs (6)
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Heart  (7)
Vascular (8)
Abdomen (9)
Examination Status
Not done (1)
Normal (2)
Abnormal (please specify) (3)
Abnormal examination findings
EDSS Evaluation
Date of Evaluation
Functional System Scores
Visual
Brinstem
Pyramidal
Cerebellar
Sensory
Bowel or Bladder
Cerebral
Additional and Results
Actual Distance Walked
<100 metres (<100 metres)
>100 metres and <200 metres (>100
metres and <200 metres)
>200 metres and <300 metres (>200
metres and <300 metres)
>300 metres and <500 metres (>300
metres and <500 metres)
>500 metres (>500 metres)
Actual Distance Walked
<100 metres (1)
>100 metres and <200 metres (2)
>200 metres and <300 metres (3)
>300 metres and <500 metres (4)
>500 metres (5)
EDSS Score
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Visit 6 (Week 24): Vital Signs/Physical Examination BG00012 Monotherapy Safety
and Efficacy Extension Study in Multiple Sclerosis (MS) (ENDORSE)
NCT00835770
Name of Neurologist
Visual Function Test
Date of Evaluation
Contrast Sensitivity Evaluation Binocular
100% Chart, Total # Correct
2,5% Chart, Total # Correct
1,25% Chart, Total # Correct
Snellen visual acuity equivalent
Study Drug Accountability
date of first dose
Number of capsules not taken since previous visit
to this visit
Was there a protocol-defined dose
reduction/interruption since the previous visit?
Yes
No
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Visit 6 (Week 24): Vital Signs/Physical Examination BG00012 Monotherapy Safety
and Efficacy Extension Study in Multiple Sclerosis (MS) (ENDORSE)
NCT00835770
Visit 7 (Week 28): Vital Signs, Study Drug accountability BG00012 Monotherapy
Safety and Efficacy Extension Study in Multiple Sclerosis (MS) (ENDORSE)
NCT00835770
The primary objective of this study is to evaluate the long-
term safety profile of BG00012 (dimethyl fumarate).
Secondary objectives of this study are to evaluate the long-
term efficacy of BG00012 using clinical endpoints and
disability progression, to evaluate further the long-term
effects of BG00012 on multiple sclerosis (MS) brain lesions
on magnetic resonance imaging (MRI) scans in participants
who had MRI scans as part of Studies 109MS301
(NCT00420212) and 109MS302 (NCT00451451) and to
evaluate the long-term effects of BG00012 on health
economics assessments and the visual function test.
NCT00835770
Part: Visit 7 (Week 28)
All rights reserved. Please visit https://medical-data-
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Visit 7 (Week 28): Vital Signs, Study
Drug accountability BG00012
Monotherapy Safety and Efficacy
Extension Study in Multiple Sclerosis
(MS) (ENDORSE) NCT00835770
Subject Identification
Number of Facility
Subject number
Subject Initials
Vital Signs
Date of examination
Blood Pressure
Pulse
Temperature
Study Drug Accountability
date of first dose
Number of capsules not taken since previous visit
to this visit
Was there a protocol-defined dose
reduction/interruption since the previous visit?
Yes
No
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ART and laboratory values The CoDe
(”Coding of Death in HIV”) Project
The CoDe (”Coding of Death in HIV”) Project A significant
proportion of deaths in HIV-1 infected persons are now
caused by non-AIDS events. It is important to closely
monitor the causes of death in this population in order to
target interventions appropriately, should specific causes of
death emerge or become predominant. It is possible that
deaths from diseases related to an accelerated aging
process will become more frequent. The same applies for
causes of death related to co-infections (e.g. hepatitis) or
other co-morbidities (e.g. sequelae of intravenous drug
use). Furthermore, it is important to be able to evaluate the
risk factors for such emerging diseases, including their
possible relationship with immunodeficiency. Until now
there has not been a uniform classification system for
causes of death in HIV patients. Studies have either
created their own coding systems based on frequent
and/or ‘important’ causes (e.g. rare but important adverse
events such as lactic acidosis and pancreatitis), or have
used ICD9 or ICD10 codes from death certificates. In many
cases, the ICD system cannot be directly adapted to HIV
infected persons. Many AIDS defining illnesses are poorly
identified in the ICD system, and some diseases (e.g. CNS
diseases) have a different aetiology in HIV patients and are
therefore not covered by the ICD system, or at great risk of
mis-classification. In July 2004, a meeting was held in
Copenhagen with the participation from executive
committees of a large number of pivotal observational
studies and clinical trials that routinely collect data on
causes of death. At this meeting, it became clear that there
was a need for a harmonization and standardization of the
approach taken when collecting data on cause of death
and when reviewing these deaths. As a result, the CoDe
Project was initiated. The CoDe Project is a uniform coding
system that can be applied to studies of individuals with
HIV infection, including a detailed data collection on the
causes of death and contributing factors, as well as a
centralised review process of the data collected.
http://www.cphiv.dk/Tools-Standards/CoDe/About Contains:
ART and laboratory values prior to death and adverse
effects to medical treatment
All rights reserved. Please visit https://medical-data-
models.org/forms/15742
ART and laboratory values The
CoDe (”Coding of Death in HIV”)
Project
Section 7 ART
A. Has the patient EVER received ART:
No (No)
Unknown (Unknown)
Yes (Yes)
If YES, when was ART started (in months before
death):
B. Did the patient receive ART at the time of
death?
No (No)
Unknown (Unknown)
Yes (Yes)
If No, Date of stopping
C. Laboratory values
Laboratory values
CD4+ cell count (CD4+ cell count)
Haemoglobin (Haemoglobin)
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HIV RNA (HIV RNA)
1. Most recent prior to last stopping ART
2. Most recent prior to death
Value
Unit
/ (/)
Cells/mm³ (Cells/mm³)
Copies/mL (Copies/mL)
Date
Section 8  Adverse effects to medical
treatment
A. Was the death considered to be related to a
medical treatment?
No  (No )
Possibly (Possibly)
Yes (Yes)
B. The suspected relation was to:
Antiretroviral treatment  (Antiretroviral
treatment )
Other medical treatment (Other medical
treatment)
Please provide a brief narrative of the suspected
association including the name of the medication
and the date of starting:
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ART and laboratory values The CoDe (”Coding of Death in HIV”) Project
Eligibility Colorectal Liver Metastases
NCT00119899
Utility of FDG-PET Scan on the Selection of Patients for
Resection of Hepatic Colorectal Metastases; ODM derived
from: https://clinicaltrials.gov/show/NCT00119899
All rights reserved. Please visit https://medical-data-
models.org/forms/15743
Eligibility Colorectal Liver Metastases
NCT00119899
Inclusion Criteria
one to four colorectal liver metastases on spiral
ct, judged potentially resectable by an
experienced liver surgeon from the institution
participating in the trial.*
Yes
No
who performance status 0, 1 or 2.*
Yes
No
age 18-75 years*
Yes
No
written informed consent*
Yes
No
Exclusion Criteria
evidence of extrahepatic disease as
demonstrated by spiral ct scan of chest and
abdomen with oral and intravenous contrast with
contiguous reconstruction algorithm. in case of
previous rectal cancer spiral ct should include the
pelvic area. ct readings should be performed by
an experienced radiologist from the institution
participating in the trial.*
Yes
No
signs of recurrent or second colorectal carcinoma
on barium enema or colonoscopy.*
Yes
No
any other previous malignancy other than
adequately treated in situ carcinoma of the cervix
or non-melanoma skin cancer (unless there has
been a disease-free interval of at least 10
years).*
Yes
No
major hepatic insufficiency.*
Yes
No
active infection and diabetes mellitus*
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Yes
No
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Eligibility Colorectal Liver Metastases NCT00119899
Eligibility Osteoarthritis of the Knee
NCT02357459
Study of FX006 for the Treatment of Pain in Patients With
Osteoarthritis of the Knee; ODM derived from:
https://clinicaltrials.gov/show/NCT02357459
All rights reserved. Please visit https://medical-data-
models.org/forms/15744
Eligibility Osteoarthritis of the Knee
NCT02357459
Inclusion Criteria
willingness and ability to comply with the study
procedures and visit schedules and ability to
follow verbal and written instructions*
Yes
No
male or female >=40 years of age*
Yes
No
has symptoms associated with oa of the index
knee for at least 6 months prior to screening*
Yes
No
currently meets american college of
rheumatology (acr) criteria (clinical and
radiological) for oa*
Yes
No
kellgren-lawrence (k-l) grade 2 or 3 in the index
knee per screening x-ray*
Yes
No
index knee pain for > 15 days over the last
month*
Yes
No
qualifying mean score on the 24-h average pain
score (0-10 numeric rating scale)*
Yes
No
body mass index (bmi) ≤ 40 kg/m2*
Yes
No
willingness to abstain from use of restricted
medications*
Yes
No
Exclusion Criteria
any condition that could possibly confound the
patient's assessment of index knee pain in
judgement of the investigator (i.e., iipsilateral hip
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oa, gout, radicular low back pain and hip pain that
is referred to the knee that could cause
misclassification, pain in any other area of the
lower extremities or back that is equal or greater
than the index knee pain)*
Yes
No
fibromyalgia, reiter's syndrome, rheumatoid
arthritis, psoriatic arthritis, ankylosing spondylitis,
arthritis associated with inflammatory bowel
disease*
Yes
No
history of infection in the index knee*
Yes
No
clinical signs and symptoms of active knee
infection or crystal disease of the index knee
within 1 month of screening*
Yes
No
unstable joint within 12 months of screening*
Yes
No
ia corticosteroid (investigational or marketed) in
any joint within 3 months of screening*
Yes
No
ia hyaluronic acid (investigational or marketed) in
the index knee within 6 months of screening*
Yes
No
intramuscular (im) or oral corticosteroids
(investigational or marketed) within 1 month of
screening*
Yes
No
any other ia investigational drug/biologic within 6
months of screening*
Yes
No
prior use of fx006*
Yes
No
women of child-bearing potential not using
effective contraception or who are pregnant or
nursing*
Yes
No
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Eligibility Osteoarthritis of the Knee NCT02357459
Eligibility Diabetes NCT01620463
Safety, Tolerability, Pharmacokinetics and
Pharmacodynamics of Liraglutide in Healthy Japanese
Volunteers; ODM derived from:
https://clinicaltrials.gov/show/NCT01620463
All rights reserved. Please visit https://medical-data-
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Eligibility Diabetes NCT01620463
Inclusion Criteria
body mass index (bmi) between 18 and 27
kg/m^2, inclusive*
Yes
No
Exclusion Criteria
clinically relevant abnormalities of physical
examination, laboratory values, vital signs or ecg
findings at the screening, as judged by the
investigator or sub-investigator*
Yes
No
presence of acute or chronic illness sufficient to
invalidate the subject's participation in the study
or to make it unnecessarily hazardous, as judged
by the investigator*
Yes
No
blood pressure in supine position at the
screening, after resting for 5 min, outside the
ranges 90-150 mmhg systolic or 40-90 mmhg
diastolic*
Yes
No
heart rate in supine position at the screening,
after resting for 5 min, outside the range 40-100
beats/min*
Yes
No
alcohol intake within 48 hours prior to the
screening*
Yes
No
hepatitis b surface antigen, hepatitis c antibodies
or hiv (human immunodeficiency virus) antibodies
positive*
Yes
No
clinically relevant abnormal history or physical
findings at the screening, which could interfere
with the objectives of the study or the safety of
the subject's participation, as judged by the
investigator*
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Yes
No
history of significant allergy or hypersensitivity*
Yes
No
known or suspected allergy to trial product or
related products*
Yes
No
history of drug or alcohol abuse*
Yes
No
smoking 10 cigarettes or more, or the equivalent,
per day and is unwilling to refrain from smoking
during 3 days prior to dosing and during the
confinement period*
Yes
No
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Eligibility Diabetes NCT01620463
Eligibility Diabetes NCT01697631
Glycemic Control of Biphasic Insulin Aspart 30 in Type 2
Diabetes; ODM derived from:
https://clinicaltrials.gov/show/NCT01697631
All rights reserved. Please visit https://medical-data-
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Eligibility Diabetes NCT01697631
Inclusion Criteria
type 2 diabetes*
Yes
No
current treatment with conventional biphasic
human insulin 30/70 b.i.d. (twice daily) for at least
3 months*
Yes
No
hba1c (glycosylated haemoglobin) equal to or
below 12%*
Yes
No
willing and able to perform self blood glucose
monitoring (smbg)*
Yes
No
Exclusion Criteria
history of drug or alcohol dependence*
Yes
No
mental incapacity, unwillingness or language
barriers precluding adequate understanding or
co-operation*
Yes
No
previous participation in this trial*
Yes
No
receipt of any investigational drug within the last
month prior to this trial*
Yes
No
known or suspected allergy to trial products or
related products*
Yes
No
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Eligibility Diabetes NCT01698931
Efficacy of Repaglinide in Subjects With Type 2 Diabetes;
ODM derived from:
https://clinicaltrials.gov/show/NCT01698931
All rights reserved. Please visit https://medical-data-
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Eligibility Diabetes NCT01698931
Inclusion Criteria
type 2 diabetes*
Yes
No
hba1c (glycosylated haemoglobin a1c) above 7
%*
Yes
No
bmi (body mass index) below 32 kg/m^2*
Yes
No
fbg (fasting blood glucose) after wash out period
130-220 mg/dl*
Yes
No
currently treated with diet or oha (oral
hypoglycaemic agent)*
Yes
No
Exclusion Criteria
current systemic treatment with concomitant
medication*
Yes
No
known or suspected history of drug or alcohol
dependence*
Yes
No
any other significant concomitant disease such as
cerebrovascular or symptomatic peripheral
vascular disease, malignant, disease or severe
treated or untreated hypertension*
Yes
No
hepatic disease*
Yes
No
cardiac problems*
Yes
No
active proliferative retinopathy*
Yes
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No
known or suspected allergy to trial product or
related products*
Yes
No
women in fertile age and women having the
intention of becoming pregnant*
Yes
No
body mass index (bmi) above 32 kg/m^2*
Yes
No
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Eligibility Osteoarthritis, Knee
NCT02299713
Electro-Acupuncture Treatment in Patients With
Osteoarthritis Of The Knee (EATOAK); ODM derived from:
https://clinicaltrials.gov/show/NCT02299713
All rights reserved. Please visit https://medical-data-
models.org/forms/15748
Eligibility Osteoarthritis, Knee
NCT02299713
Inclusion Criteria
patients of either sex with primary osteoarthritis
of one or both knees fulfilling diagnostic criteria
for osteoarthritis knee laid down by american
college of rheumatology.*
Yes
No
patients also had to have a kellgren-lawrence
(radiologic criterion) score of at least 2 and
chronic pain in the knee joint for more than 3
months.*
Yes
No
Exclusion Criteria
the patients with secondary osteoarthritis of
knees*
Yes
No
associated systemic arthropathies, e.g.
rheumatoid arthritis and gout*
Yes
No
patients on steroids*
Yes
No
disease modifying drugs, e.g. methotrexate and
azathioprine*
Yes
No
patients with recent trauma in the area of
acupuncture*
Yes
No
history of intra articular injection of steroid within
last two months*
Yes
No
patients missing two or more sessions of electro-
acupuncture consecutively were excluded from
the study*
Yes
No
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Eligibility Diabetes, Gestational
NCT00069576
Gestational Diabetes Mellitus Trial (GDM); ODM derived
from: https://clinicaltrials.gov/show/NCT00069576
All rights reserved. Please visit https://medical-data-
models.org/forms/15749
Eligibility Diabetes, Gestational
NCT00069576
Inclusion Criteria
pregnant*
Yes
No
gestational age at enrollment 24 - 31 weeks*
Yes
No
Exclusion Criteria
diabetes diagnosed prior to pregnancy*
Yes
No
abnormal gestational diabetes (>= 135 mg/dl)
testing prior to 24 weeks' gestation*
Yes
No
gestational diabetes in a previous pregnancy*
Yes
No
history of stillbirth or fetal death*
Yes
No
pregnancy with more than one fetus*
Yes
No
known major fetal anomaly*
Yes
No
current or planned corticosteroid therapy*
Yes
No
asthma requiring medication*
Yes
No
current or planned beta adrenergic therapy*
Yes
No
chronic hypertension requiring medication within
6 months of or during pregnancy*
Yes
No
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chronic medical conditions such as hiv/aids,
kidney disease, or congenital heart disease*
Yes
No
hematologic or autoimmune disease such as
sickle cell disease, other hemoglobinopathies,
lupus, or antiphospholipid syndrome*
Yes
No
maternal or fetal conditions likely to require
preterm delivery, such as pre-eclampsia, preterm
labor, or intrauterine growth retardation*
Yes
No
previous or planned tocolytic therapy to induce
labor or increase contraction strength*
Yes
No
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Follow-Up 1 Parkinson Köln Core Data Set
Ambulanz und Euroinf DBS
Parkinson Köln Core Data Set Ambulanz und Euroinn DBS
Documentation part: Follow-Up 1
Source: Core Data Set Parkinson (Cologne, Prof. Dr. Lars
Timmermann)
All rights reserved. Please visit https://medical-data-
models.org/forms/15751
Follow-Up 1 Parkinson Köln Core
Data Set Ambulanz und Euroinf DBS
Patient information
Patient ID
Date of birth
Treatment
Date of follow up
Age
>= 0
years
Disease duration
Baseline to Follow up 1 days
Treatment
medical (1)
stim (DBS) (2)
med+stim (3)
Apomorphin s.c. (4)
intraintestinal L-Dopa (5)
untreated (6)
L-Dopa
mg
L-Dopa Retard
mg
Entacapone
mg
Tolcapone
mg
Safinamide
mg
Apomorphine
mg
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Pramipexole
mg
Rotigotine
mg
Ropinirole
mg
Piribedil
mg
Amantadine
mg
Selegiline
mg
Rasagiline
mg
Anticholinergic drugs
Yes
No
LEDD
mg
Budipine
Yes
No
Benzodiazepine
Yes
No
Antidepressant
Yes
No
Neuroleptic
Yes
No
Deep brain stimulation
Stim site
STN (1)
Vim (2)
GPi (3)
Stim uni-/bilateral
bilateral (1)
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unilateral (2)
Date of surgery
Age at surgery
Disease duration at surgery
UPDRS III 1FU MED ON/STIM OFF
UPDRS III 1FU MED ON/STIM OFF total
UPDRS III 1FU MED ON/STIM OFF 18
UPDRS III 1FU MED ON/STIM OFF 19
UPDRS III 1FU MED ON/STIM OFF 20
UPDRS III 1FU MED ON/STIM OFF 21
UPDRS III 1FU MED ON/STIM OFF 22
UPDRS III 1FU MED ON/STIM OFF 23
UPDRS III 1FU MED ON/STIM OFF 24
UPDRS III 1FU MED ON/STIM OFF 25
UPDRS III 1FU MED ON/STIM OFF 26
UPDRS III 1FU MED ON/STIM OFF 27
UPDRS III 1FU MED ON/STIM OFF 28
UPDRS III 1FU MED ON/STIM OFF 29
UPDRS III 1FU MED ON/STIM OFF 30
UPDRS III 1FU MED ON/STIM OFF 31
UPDRS III 1FU MED ON/STIM OFF subscore
axial
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UPDRS III 1FU MED ON/STIM OFF subscore
tremor
UPDRS III 1FU MED ON/STIM OFF subscore
akinesia/rigidity
UPDRS III 1FU MED OFF/STIM OFF
UPDRS III 1FU MED OFF/STIM OFF total
UPDRS III 1FU MED OFF/STIM OFF 18
UPDRS III 1FU MED OFF/STIM OFF 19
UPDRS III 1FU MED OFF/STIM OFF 20
UPDRS III 1FU MED OFF/STIM OFF 21
UPDRS III 1FU MED OFF/STIM OFF 22
UPDRS III 1FU MED OFF/STIM OFF 23
UPDRS III 1FU MED OFF/STIM OFF 24
UPDRS III 1FU MED OFF/STIM OFF 25
UPDRS III 1FU MED OFF/STIM OFF 26
UPDRS III 1FU MED OFF/STIM OFF 27
UPDRS III 1FU MED OFF/STIM OFF 28
UPDRS III 1FU MED OFF/STIM OFF 29
UPDRS III 1FU MED OFF/STIM OFF 30
UPDRS III 1FU MED OFF/STIM OFF 31
UPDRS III 1FU MED OFF/STIM OFF subscore
axial
UPDRS III 1FU MED OFF/STIM OFF subscore
tremor
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UPDRS III 1FU MED OFF/STIM OFF subscore
akinesia/rigidity
UPDRS III 1FU MED ON/STIM ON
UPDRS III 1FU MED ON/STIM ON total
UPDRS III 1FU MED ON/STIM ON 18
UPDRS III 1FU MED ON/STIM ON 19
UPDRS III 1FU MED ON/STIM ON 20
UPDRS III 1FU MED ON/STIM ON 21
UPDRS III 1FU MED ON/STIM ON 22
UPDRS III 1FU MED ON/STIM ON 23
UPDRS III 1FU MED ON/STIM ON 24
UPDRS III 1FU MED ON/STIM ON 25
UPDRS III 1FU MED ON/STIM ON 26
UPDRS III 1FU MED ON/STIM ON 27
UPDRS III 1FU MED ON/STIM ON 28
UPDRS III 1FU MED ON/STIM ON 29
UPDRS III 1FU MED ON/STIM ON 30
UPDRS III 1FU MED ON/STIM ON 31
UPDRS III 1FU MED ON/STIM ON subscore
axial
UPDRS III 1FU MED ON/STIM ON subscore
tremor
UPDRS III 1FU MED ON/STIM ON subscore
akinesia/rigidity
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UPDRS III 1FU MED OFF/STIM ON
UPDRS III 1FU MED OFF/STIM ON total
UPDRS III 1FU MED OFF/STIM ON 18
UPDRS III 1FU MED OFF/STIM ON 19
UPDRS III 1FU MED OFF/STIM ON 20
UPDRS III 1FU MED OFF/STIM ON 21
UPDRS III 1FU MED OFF/STIM ON 22
UPDRS III 1FU MED OFF/STIM ON 23
UPDRS III 1FU MED OFF/STIM ON 24
UPDRS III 1FU MED OFF/STIM ON 25
UPDRS III 1FU MED OFF/STIM ON 26
UPDRS III 1FU MED OFF/STIM ON 27
UPDRS III 1FU MED OFF/STIM ON 28
UPDRS III 1FU MED OFF/STIM ON 29
UPDRS III 1FU MED OFF/STIM ON 30
UPDRS III 1FU MED OFF/STIM ON 31
UPDRS III 1FU MED OFF/STIM ON subscore
axial
UPDRS III 1FU MED OFF/STIM ON subscore
tremor
UPDRS III 1FU MED OFF/STIM ON subscore
akinesia/rigidity
Other scores
MMSE
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AES
BDI
PANDA
EASY
DemTect
Mattis
MoCA
DESC-I
DESC-II
GDS-15
Benton
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Baseline Parkinson Köln Core Data Set
Ambulanz und Euroinf DBS
Parkinson Köln Core Data Set Ambulanz und Euroinn DBS
Documentation part: Baseline
Source: Core Data Set Parkinson (Cologne, Prof. Dr. Lars
Timmermann)
All rights reserved. Please visit https://medical-data-
models.org/forms/15752
Baseline Parkinson Köln Core Data
Set Ambulanz und Euroinf DBS
Patient information
Patient ID
Source
Original Patient ID
Date of birth
Gender
male (1)
female (2)
Disease information
Age disease onset
Handedness
First diagnosis
Age at diagnosis
Symptom onset
Subtype
equivalent (1)
akinetic-rigid (2)
tremor-dominant (3)
Tremor R
Yes
No
Tremor L
Yes
No
Tremor dominance
Yes
No
Tremor unclear
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Yes
No
RBD
Yes
No
Treatment
Date
Age
>= 0
years
Disease duration
Treatment
medical (1)
stim (DBS) (2)
med+stim (3)
Apomorphin s.c. (4)
intraintestinal L-Dopa (5)
untreated (6)
L-Dopa
mg
L-Dopa Retard
mg
Entacapone
mg
Tolcapone
mg
Safinamide
mg
Apomorphine
mg
Pramipexole
mg
Rotigotine
mg
Ropinirole
mg
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Piribedil
mg
Amantadine
mg
Selegiline
mg
Rasagiline
mg
Anticholinergic drugs
Yes
No
LEDD
mg
Budipine
Yes
No
Benzodiazepine
Yes
No
Antidepressant
Yes
No
Neuroleptic
Yes
No
Deep brain stimulation
Stim site
STN (1)
Vim (2)
GPi (3)
Stim uni-/bilateral
bilateral (1)
unilateral (2)
Date of surgery
Age at surgery
Disease duration at surgery
3 / 8
Baseline Parkinson Köln Core Data Set Ambulanz und Euroinf DBS
UPDRS III 1FU MED ON/STIM OFF
UPDRS III 1FU MED ON/STIM OFF total
UPDRS III 1FU MED ON/STIM OFF 18
UPDRS III 1FU MED ON/STIM OFF 19
UPDRS III 1FU MED ON/STIM OFF 20
UPDRS III 1FU MED ON/STIM OFF 21
UPDRS III 1FU MED ON/STIM OFF 22
UPDRS III 1FU MED ON/STIM OFF 23
UPDRS III 1FU MED ON/STIM OFF 24
UPDRS III 1FU MED ON/STIM OFF 25
UPDRS III 1FU MED ON/STIM OFF 26
UPDRS III 1FU MED ON/STIM OFF 27
UPDRS III 1FU MED ON/STIM OFF 28
UPDRS III 1FU MED ON/STIM OFF 29
UPDRS III 1FU MED ON/STIM OFF 30
UPDRS III 1FU MED ON/STIM OFF 31
UPDRS III 1FU MED ON/STIM OFF subscore
axial
UPDRS III 1FU MED ON/STIM OFF subscore
tremor
UPDRS III 1FU MED ON/STIM OFF subscore
akinesia/rigidity
UPDRS III 1FU MED OFF/STIM OFF
UPDRS III 1FU MED OFF/STIM OFF total
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UPDRS III 1FU MED OFF/STIM OFF 18
UPDRS III 1FU MED OFF/STIM OFF 19
UPDRS III 1FU MED OFF/STIM OFF 20
UPDRS III 1FU MED OFF/STIM OFF 21
UPDRS III 1FU MED OFF/STIM OFF 22
UPDRS III 1FU MED OFF/STIM OFF 23
UPDRS III 1FU MED OFF/STIM OFF 24
UPDRS III 1FU MED OFF/STIM OFF 25
UPDRS III 1FU MED OFF/STIM OFF 26
UPDRS III 1FU MED OFF/STIM OFF 27
UPDRS III 1FU MED OFF/STIM OFF 28
UPDRS III 1FU MED OFF/STIM OFF 29
UPDRS III 1FU MED OFF/STIM OFF 30
UPDRS III 1FU MED OFF/STIM OFF 31
UPDRS III 1FU MED OFF/STIM OFF subscore
axial
UPDRS III 1FU MED OFF/STIM OFF subscore
tremor
UPDRS III 1FU MED OFF/STIM OFF subscore
akinesia/rigidity
UPDRS III 1FU MED ON/STIM ON
UPDRS III 1FU MED ON/STIM ON total
UPDRS III 1FU MED ON/STIM ON 18
UPDRS III 1FU MED ON/STIM ON 19
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UPDRS III 1FU MED ON/STIM ON 20
UPDRS III 1FU MED ON/STIM ON 21
UPDRS III 1FU MED ON/STIM ON 22
UPDRS III 1FU MED ON/STIM ON 23
UPDRS III 1FU MED ON/STIM ON 24
UPDRS III 1FU MED ON/STIM ON 25
UPDRS III 1FU MED ON/STIM ON 26
UPDRS III 1FU MED ON/STIM ON 27
UPDRS III 1FU MED ON/STIM ON 28
UPDRS III 1FU MED ON/STIM ON 29
UPDRS III 1FU MED ON/STIM ON 30
UPDRS III 1FU MED ON/STIM ON 31
UPDRS III 1FU MED ON/STIM ON subscore
axial
UPDRS III 1FU MED ON/STIM ON subscore
tremor
UPDRS III 1FU MED ON/STIM ON subscore
akinesia/rigidity
UPDRS III 1FU MED OFF/STIM ON
UPDRS III 1FU MED OFF/STIM ON total
UPDRS III 1FU MED OFF/STIM ON 18
UPDRS III 1FU MED OFF/STIM ON 19
UPDRS III 1FU MED OFF/STIM ON 20
UPDRS III 1FU MED OFF/STIM ON 21
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UPDRS III 1FU MED OFF/STIM ON 22
UPDRS III 1FU MED OFF/STIM ON 23
UPDRS III 1FU MED OFF/STIM ON 24
UPDRS III 1FU MED OFF/STIM ON 25
UPDRS III 1FU MED OFF/STIM ON 26
UPDRS III 1FU MED OFF/STIM ON 27
UPDRS III 1FU MED OFF/STIM ON 28
UPDRS III 1FU MED OFF/STIM ON 29
UPDRS III 1FU MED OFF/STIM ON 30
UPDRS III 1FU MED OFF/STIM ON 31
UPDRS III 1FU MED OFF/STIM ON subscore
axial
UPDRS III 1FU MED OFF/STIM ON subscore
tremor
UPDRS III 1FU MED OFF/STIM ON subscore
akinesia/rigidity
Other scores
MMSE
AES
BDI
PANDA
EASY
DemTect
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Mattis
MoCA
DESC-I
DESC-II
GDS-15
Benton
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Eligibility Osteoarthritis, Knee
NCT02326961
Celution Prepared Adipose Derived Regenerative Cells in
the Treatment of Osteoarthritis of the Knee; ODM derived
from: https://clinicaltrials.gov/show/NCT02326961
All rights reserved. Please visit https://medical-data-
models.org/forms/15753
Eligibility Osteoarthritis, Knee
NCT02326961
Inclusion Criteria
1. males or females ≥ 40 and  < 70 years of age*
Yes
No
2. able to provide written informed consent*
Yes
No
3. diagnosis of osteoarthritis in one or both knees
by american college of rheumatology (acr)
criteria*
Yes
No
4. kellgren and lawrence grade 2 or 3 (standing
ap x-ray) of the target knee within the preceding 6
months*
Yes
No
5. pain due to osteoarthritis in the target knee ≥ 6
months*
Yes
No
6. minimum score of "moderate" from koos
question about pain on walking on a flat surface.*
Yes
No
7. minimum score of "moderate" from koos
question about degree of difficulty during walking
on a flat surface.*
Yes
No
8. continued knee pain and limitations in knee
function despite prescription of conservative
therapy for at least 6 months.*
Yes
No
9. ability to safely undergo liposuction that will
result in the harvest of a sufficient quantity of
adipose tissue (approximately 300 ml)*
Yes
No
10. on stable regimen of one analgesic
medication (rescue medication) for their knee
pain due to osteoarthritis and ability and
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willingness to use the same analgesic medication
during the study (screening period through to
final study visit).*
Yes
No
11. ability to perform procedures required of the
pain index evaluations (unassisted walking 50
feet on a flat surface and going up and down
stairs)*
Yes
No
Exclusion Criteria
1. any major injury to the target knee within the
12 months prior to the screening visit*
Yes
No
2. need for cane or other assistance device for
walking*
Yes
No
3. any surgery to the target knee within the 6
months prior to the screening visit, or surgery to
the contralateral knee or other weight-bearing
joint if it will interfere with knee assessments*
Yes
No
4. prior articular transplant procedures*
Yes
No
5. prior ligament reconstruction to the target knee
within 12 months prior to the screening visit*
Yes
No
6. inflammatory arthropathies such as
rheumatoid arthritis, lupus arthropathy, or
psoriatic arthritis*
Yes
No
7. gout or calcium pyrophosphate (pseudogout)
diseases that have flared within the previous 6
months prior to the screening visit*
Yes
No
8. x-ray findings of acute fractures, known severe
loss of bone density (as determined by the
investigator), avascular necrosis, and/or severe
bone or joint deformity in the target knee (>5
degree valgus or varus deviation from mechanical
axis)*
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Yes
No
9. fibromyalgia, pes anserine bursitis, lumbar
radiculopathy, and/or neurogenic or vascular
claudication*
Yes
No
10. primary knee pain due to diagnosed isolated
patella-femoral arthritis or chondromalacia in the
target knee*
Yes
No
11. significant target knee joint infection or skin
disorder/infection within the previous 6 months
prior to the screening visit*
Yes
No
12. symptomatic oa of the hips, spine, or ankle, if
it would interfere with the evaluation of the target
knee*
Yes
No
13. any condition requiring immunosuppressive
medication or use of systemic steroids*
Yes
No
14. intra-articular injection of steroids in previous
3 months or hyaluronic acid in previous 6 months
in one or both knees prior to the screening visit*
Yes
No
15. patients that have received prp, other platelet-
based product, or investigational treatment in
another cell/biologic study for the targeted
treatment injury in the 12 months prior to the
injection procedure*
Yes
No
16. participation in any experimental drug or
device study within the 6 months prior to the
screening visit*
Yes
No
17. obesity defined as bmi > 35 kg/m2*
Yes
No
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Eligibility Osteoarthritis, Knee
NCT02363712
APOS Therapy for Osteoarthritis of the Knee: a
Randomized Controlled Trial BIOTOK; ODM derived from:
https://clinicaltrials.gov/show/NCT02363712
All rights reserved. Please visit https://medical-data-
models.org/forms/15754
Eligibility Osteoarthritis, Knee
NCT02363712
Inclusion Criteria
men or non-pregnant women*
Yes
No
aged <= 40*
Yes
No
outpatient setting*
Yes
No
acr clinical criteria for oa of the knee*
Yes
No
radiologically confirmed symptomatic uni- or
bilateral oa of the knee for at least 6 months*
Yes
No
radiological criteria: x-rays showing tibiofemoral
knee osteoarthritis defined as at least kellgren
and lawrence grade 2*
Yes
No
at least moderate pain on the womac pain scale
(>3 on a standardized scale range from a
minimum of 0 to a maximum of 10)*
Yes
No
must understand german*
Yes
No
informed consent documented by participant
signature*
Yes
No
Exclusion Criteria
pregnant women*
Yes
No
aged > 40*
Yes
No
1 / 2
history of an inflammatory rheumatic disease*
Yes
No
non-knee musculoskeletal pain as or more severe
than the knee pain*
Yes
No
glucocorticoid injections in the knees in the
previous three month*
Yes
No
previous osteotomy*
Yes
No
unilateral hemiprosthesis*
Yes
No
unilateral total joint replacement*
Yes
No
being treated for cancer*
Yes
No
participation in another clinical trial*
Yes
No
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Eligibility Osteoarthritis, Knee
NCT02370667
A Biomechanical Exercise Program for Knee OA; ODM
derived from: https://clinicaltrials.gov/show/NCT02370667
All rights reserved. Please visit https://medical-data-
models.org/forms/15755
Eligibility Osteoarthritis, Knee
NCT02370667
Inclusion Criteria
50 years of age or older*
Yes
No
knee pain on most days of the week*
Yes
No
less than 30 minutes of morning stiffness*
Yes
No
bony enlargement*
Yes
No
bony tenderness to palpation*
Yes
No
signs of inflammation*
Yes
No
able to safely climb 2 flights of stairs without aid*
Yes
No
Exclusion Criteria
any other forms of arthritis*
Yes
No
osteoporosis*
Yes
No
history of patellofemoral symptoms*
Yes
No
active non-arthritic knee disease*
Yes
No
knee surgery*
Yes
No
use of cane or walking aid*
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Yes
No
unstable heart condition*
Yes
No
neurological conditions*
Yes
No
skin allergy to medical tape*
Yes
No
hip or ankle injuries in past 3 months*
Yes
No
any injuries that would prohibit participation in
yoga*
Yes
No
ipsilateral hip or ankle conditions*
Yes
No
currently receiving cancer treatment*
Yes
No
currently pregnant*
Yes
No
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Eligibility Multiple Myeloma NCT01341262
THAL-DEX Incorporated Into Double PBSC
Autotransplantation for Untreated Multiple Myeloma (MM);
ODM derived from:
https://clinicaltrials.gov/show/NCT01341262
All rights reserved. Please visit https://medical-data-
models.org/forms/15756
Eligibility Multiple Myeloma
NCT01341262
Inclusion Criteria
confirmed diagnosis of symptomatic mm based
on standard criteria.*
Yes
No
no prior or current systemic therapy for mm, with
exception of steroids.*
Yes
No
at least 18 years and less than 65 years of age.*
Yes
No
presence of quantifiable m protein in serum or
urine.*
Yes
No
durie & salmon stage ii-iii or i with disease
progression.*
Yes
No
adequate organ function (heart, lung).*
Yes
No
no previous deep vein thrombosis and/or
recurring thrombophlebitis and/or pulmonary
embolisms, confirmed by doppler ultrasound or
computed tomography scan.*
Yes
No
willing and able to comply with the protocol
requirements.*
Yes
No
Exclusion Criteria
diagnosis of smouldering or asymptomatic mm,
plasmacell leukemia, solitary plasmocytoma of
the bone o extramedullary plasmocytoma.*
Yes
No
diagnosis of non-secretory mm.*
Yes
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No
prior or current systemic therapy for mm, with
exception of steroids.*
Yes
No
more than 65 years of age.*
Yes
No
female subjects pregnant.*
Yes
No
non adequate organ function (heart, lung).*
Yes
No
patient has a prior history of thrombosis or
venous thromboembolism or pulmonary
embolism.*
Yes
No
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Eligibility Lymphoblastic Leukemia, Acute
NCT00131027
High-Dose Methotrexate (MTX) for Adult Acute
Lymphoblastic Leukemia (ALL); ODM derived from:
https://clinicaltrials.gov/show/NCT00131027
All rights reserved. Please visit https://medical-data-
models.org/forms/15757
Eligibility Lymphoblastic Leukemia,
Acute NCT00131027
Inclusion Criteria
previously untreated bcr-abl-negative all*
Yes
No
age between 25 and 64 years*
Yes
No
performance status between 0 and 3 (ecog
criteria)*
Yes
No
adequate functioning of the liver (serum bilirubin
level < 2.0 mg/dl); kidneys (serum creatinine level
< 2.0 mg/dl); and heart (left ventricular ejection
fraction greater than 50% and no severe
abnormalities detected on electrocardiograms
and echocardiographs).*
Yes
No
written informed consent to participate in the trial*
Yes
No
Exclusion Criteria
uncontrolled active infection*
Yes
No
another severe and/or life-threatening disease*
Yes
No
positive for hiv antibody and/or hepatitis b surface
(hbs) antigen tests*
Yes
No
another primary malignancy which is clinically
active and/or requires medical interventions*
Yes
No
pregnant and/or lactating women*
Yes
No
past history of renal failure*
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Yes
No
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Eligibility Colorectal Cancer NCT00126256
Trial Comparing Two Strategies of Chemotherapy for
Metastatic Colorectal Cancer; ODM derived from:
https://clinicaltrials.gov/show/NCT00126256
All rights reserved. Please visit https://medical-data-
models.org/forms/15758
Eligibility Colorectal Cancer
NCT00126256
Inclusion Criteria
histologically confirmed metastatic colorectal
adenocarcinoma*
Yes
No
unresectable metastasis*
Yes
No
bidimensionally measurable disease (world
health organization [who] criteria)*
Yes
No
who performance status of 2 or less*
Yes
No
adequate hematologic functions (neutrophil
count, at least 1500 per cubic millimeter; and
platelet count, at least 100,000 per cubic
millimetre)*
Yes
No
adequate renal function (serum creatinine, less
than 125 micromol per liter)*
Yes
No
adequate liver function (bilirubin, not more than 5
times the upper limit of normal)*
Yes
No
no previous chemotherapy other than previous
adjuvant chemotherapy or concomitant
chemoradiotherapy with 5-fluorouracil and
leucovorin for the treatment of the primary tumor
completed at least 6 months before inclusion*
Yes
No
signed written inform consent*
Yes
No
quality of life questionnaire (qlq c-30) filled out*
Yes
No
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Exclusion Criteria
pregnant or breast – feeding women*
Yes
No
impossibility of regular follow-up for
psychological, social or geographical reason*
Yes
No
severe cardiac, respiratory, renal or hepatic
failure*
Yes
No
active coronary heart disease*
Yes
No
patients with a history of a psychological illness
or condition such as to interfere with the patient’s
ability to understand the requirements of the
study*
Yes
No
central nervous system metastases*
Yes
No
past history of second malignancies*
Yes
No
another investigational drug*
Yes
No
chronic inflammatory bowel disease*
Yes
No
previous chemotherapy with irinotecan or
oxaliplatin based regimens*
Yes
No
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Eligibility Rheumatoid Arthritis
NCT02408471
Ascension® Post- Approval Study; PyroCarbon
Metacarpophalangeal Total Joint Prosthesis; ODM derived
from: https://clinicaltrials.gov/show/NCT02408471
All rights reserved. Please visit https://medical-data-
models.org/forms/15759
Eligibility Rheumatoid Arthritis
NCT02408471
Inclusion Criteria
indications consistent with the fda approved
indications for use: index, long, ring, or small
finger metacarpophalangeal (mcp) joints that
exhibit symptoms of pain, limited motion, or
inadequate bony alignment (i.e.,
subluxation/dislocation) secondary to articular
destruction or degenerative disease related to
rheumatoid arthritis, systemic lupus
erythematosus, osteoarthritis, or post-traumatic
arthritis where soft tissue reconstruction can
provide adequate stabilization*
Yes
No
willing to participate in the study*
Yes
No
signed an informed consent form*
Yes
No
the means and ability to return for all required
study visits*
Yes
No
are not transient*
Yes
No
Exclusion Criteria
inadequate bone stock at the implantation site*
Yes
No
active infection in the mcp joint*
Yes
No
nonfunctioning and irreparable mcp
musculotendinous system*
Yes
No
physical interference with or by other prostheses
during implantation or use*
Yes
No
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procedures requiring modification of the
prosthesis*
Yes
No
skin, bone, circulatory and/or neurological
deficiency at the implantation site*
Yes
No
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Eligibility Prostate Cancer NCT00117949
Study Investigating the Pharmacokinetics,
Pharmacodynamics and Safety of FE200486; ODM derived
from: https://clinicaltrials.gov/show/NCT00117949
All rights reserved. Please visit https://medical-data-
models.org/forms/15760
Eligibility Prostate Cancer
NCT00117949
Inclusion Criteria
has given written consent before any study
related activity is performed (a study related
activity is defined as any procedure that would
not have been performed during the normal
management of the patient.)*
Yes
No
is a male patient with histologically proven
adenocarcinoma of the prostate (all stages) in
whom endocrine treatment is indicated, except
for neoadjuvant hormonal therapy.  for patients,
prostate-specific antigen (psa) increases on two
consecutive determinations at least 2 weeks
apart prior to visit 1 must be documented.*
Yes
No
is at least 18 years.*
Yes
No
has an ecog score of 2.*
Yes
No
has a baseline testosterone level within the age
specific normal range as measured by the central
laboratory.*
Yes
No
has a psa value of  2 ng/ml as measured by the
central laboratory.*
Yes
No
has a life expectancy of at least 6 months.*
Yes
No
Exclusion Criteria
previous or present hormonal management of
prostate cancer (surgical castration or other
hormonal manipulation, e.g. gnrh agonists, gnrh
antagonists, antiandrogens, estrogens, pc-spec)
except for neoadjuvant hormonal therapy of < 6
months duration and completed > 6 months prior
to visit 1.*
Yes
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No
requires hormonal therapy for neoadjuvant
purposes.*
Yes
No
is recently (within the last 12 weeks preceding
visit 1) or presently treated with any other drug
modifying the testosterone level or function.*
Yes
No
is considered to be a candidate for curative
therapy, i.e., radical prostatectomy or
radiotherapy within 6 months after visit 1.*
Yes
No
has a history of severe asthma requiring daily
treatment with inhalation steroids, angioedema or
anaphylactic reactions.*
Yes
No
has hypersensitivity towards any component of
the investigational product.*
Yes
No
has had a cancer disease within the last 10 years
except for prostate cancer, and surgically
removed basocellular or squamous cell
carcinoma of the skin.*
Yes
No
has a clinically significant neurologic,
gastrointestinal, renal, hepatic, cardiovascular,
psychological, pulmonary, metabolic, endocrine,
hematological, dermatological or infectious
disorder or any other condition, including
excessive alcohol or drug abuse, which may
interfere with trial participation, or which may
affect the conclusion of the study, as judged by
the investigator.*
Yes
No
any clinically significant laboratory abnormalities
which, in the judgment of the investigator, would
interfere with the patient's participation in this
study or evaluation of study results (liver
transaminases must be within normal limits).*
Yes
No
has a mental incapacity or language barrier
precluding adequate understanding or co-
operation.*
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Yes
No
has received an investigational drug within the
last 12 weeks preceding visit 1.*
Yes
No
has previously participated in this study.*
Yes
No
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Baseline RICH study NCT02669589
NCT02669589 EudraCT-Nr. 2014-004854-33
REGIONAL CITRATE VERSUS SYSTEMIC HEPARIN
ANTICOAGULATION FOR CONTINUOUS RENAL
REPLACEMENT THERAPY IN CRITICALLY ILL
PATIENTS WITH ACUTE KIDNEY INJURY
Study Chair: Alexander Zarbock, MD University Hospital
Muenster
All rights reserved. Please visit https://medical-data-
models.org/forms/15764
Baseline RICH study NCT02669589
Patient Information
ID of Center
ID of patient
Patient Data
Patient's age
years
Patient's body weight
kg
Patient's body height
cm
Date of admission to hospital
Date of admission to ICU
Time of admission to ICU
From which department was the patient
transferred to ICU?
directly (emergency ambulance/
medevac chopper) (directly (emergency
ambulance/ medevac chopper))
emergency room (emergency room)
operating room (operating room)
other hospital (other hospital)
other ICU (other ICU)
Reason for admission:
internistically (internistically)
surgically (surgically)
Emergency situation
Yes
No
Indication for RRT: start date
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Indication for RRT: start time
Kidney Disease: Improving Global
Outcomes (KDIGO)
Serum Creatinine
Urinary excretion
KDIGO: Kidney Disease Classification
KDIGO I (Serum creatinine: increase
about 0,3 mg/dL (within 48h) OR
increase about 1,5 - 1,9 times (within
7d); urinary excretion < 0,5 ml/kgKG/h
for 6-12h) (KDIGO I (Serum creatinine:
increase about 0,3 mg/dL (within 48h)
OR increase about 1,5 - 1,9 times (within
7d); urinary excretion < 0,5 ml/kgKG/h
for 6-12h))
KDIGO II (Serum creatinine: increase
about 2 - 2,9 times; urinary excretion <
0,5 ml/kgKG/h for ≥12h) (KDIGO II
(Serum creatinine: increase about 2 - 2,9
times; urinary excretion < 0,5 ml/kgKG/h
for ≥12h))
KDIGO III (Serum creatinine: increase
about ≥3 times OR increase up to ≥4
mg/dL OR start of Renal Replacement
Therapy OR Patient < 18 y/o: decrease
of eGFR <35mL/min/1,73m2; urinary
excretion: <0,3ml/kgKG/h for ≥24h OR
anuria for ≥12h) (KDIGO III (Serum
creatinine: increase about ≥3 times OR
increase up to ≥4 mg/dL OR start of
Renal Replacement Therapy OR Patient
< 18 y/o: decrease of eGFR
<35mL/min/1,73m2; urinary excretion:
<0,3ml/kgKG/h for ≥24h OR anuria for
≥12h))
Start Date of specific KDIGO classification:
Start Time of specific KDIGO classification:
End Date of specific KDIGO classification:
End Time of specific KDIGO classification:
Renal function (suspected reason for
acute kidney failure)
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Known reason for acute kidney failure?
Yes
No
Sepsis?
Yes
No
Nephrotoxin?
Yes
No
Surgical intervention?
Yes
No
Cardiac surgical intervention with heart-lung
machine?
Yes
No
Heart failure?
Yes
No
Hepatorenal syndrome?
Yes
No
Pre-renal renal failure?
Yes
No
Ischemia?
Yes
No
Increased serum creatinine?
≥ 0,3 mg/dL (26,4 μmol/L) within 48 h (≥
0,3 mg/dL (26,4 μmol/L) within 48 h)
increase ≥ 1,5 - 1,9 times (increase ≥ 1,5
- 1,9 times)
increase ≥ 3 times within 7 d (increase ≥
3 times within 7 d)
increase ≥ 4 mg (354 μmol/L) with acute
increase about at least 0,5 mg/dL (44
μmol/L) within 7 d (increase ≥ 4 mg (354
μmol/L) with acute increase about at
least 0,5 mg/dL (44 μmol/L) within 7 d)
increase 2 - 2,9 times within 7 d
(increase 2 - 2,9 times within 7 d)
no incrase/ increase < 1,5 times (no
incrase/ increase < 1,5 times)
Urinary excretion within the last 24h?
< 0,3 mL/kg/h for ≥ 24h or anuria for ≥
12h (< 0,3 mL/kg/h for ≥ 24h or anuria for
≥ 12h)
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< 0,5 mL/kg/h for ≥ 12h (< 0,5 mL/kg/h
for ≥ 12h)
< 0,5 mL/kg/h for ≥ 6h (< 0,5 mL/kg/h for
≥ 6h)
≥ 0,5 mL/kg/h for ≥ 6h (≥ 0,5 mL/kg/h for
≥ 6h)
Urinary excretion measurement accuracy?
estimated (estimated)
measured (measured)
Clinical indication for renal replacement therapy?
blood pH < 7.15 (blood pH < 7.15)
no (no)
oedema in organs in context of AKI,
despite diuretics (oedema in organs in
context of AKI, despite diuretics)
serum magnesium > 4 mmol/L or anuria
(serum magnesium > 4 mmol/L or
anuria)
serum potassium > 6 mmol/L (serum
potassium > 6 mmol/L)
serum urea > 150 mg/dL (serum urea >
150 mg/dL)
urinary production < 200 mL/12h or
anuria (urinary production < 200 mL/12h
or anuria)
Neurologic dysfunction (at screening)
Coma, stupor, decreased vigilance, delirium?
Yes
No
Epileptic seizure?
Yes
No
Focal Neurologic Deficits?
Yes
No
Intracranial Hemorrhage?
Yes
No
Intracranial mass?
Yes
No
Pulmonary dysfunction (respiratory
insufficiency) (at screening)
Chronic Obstructive Pulmonary Disease?
Yes
No
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Aspiration?
Yes
No
Pneumonia?
Yes
No
Acute Respiratory Distress Syndrome?
Yes
No
Pulmonary embolism?
Yes
No
Cardiovascular disorder (at screening)
Cardiac arrest with necessary resuscitation?
Yes
No
Septic shock?
Yes
No
Cardiogenic shock
Yes
No
Haemorrhagic shock
Yes
No
Acute coronary syndrome?
Yes
No
Supraventricular arrhythmia?
Yes
No
Ventricular arrhythmia?
Yes
No
Hypertensive crisis?
Yes
No
Heart failure without shock
Yes
No
Gastrointestinal dysfunction (at screening)
Severe pancreatitis?
Yes
No
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Acute abdomen?
Yes
No
Acute liver failure?
Yes
No
Chronic liver failure?
Yes
No
Other organ dysfunction (at screeing)
Sepsis?
Yes
No
Severe trauma?
Yes
No
Gynaecological/ obstetric dysfunction?
Yes
No
Post-operative care?
Yes
No
Other reasons?
Yes
No
If other reason, specify:
Main diagnosis for admission
Main diagnosis for admission:
(Diagnosis which permits admission to ICU)
Abdominal infections (Abdominal
infections)
Abdominal surgery (Abdominal surgery)
Acute Kidney Injury (Acute Kidney Injury)
Cardiac surgery (Cardiac surgery)
Cardiogenic shock (Cardiogenic shock)
Heart failure (Heart failure)
Liver failure (Liver failure)
Other (Other)
Pancreatitis (Pancreatitis)
Pneumonia/ ARDS (Pneumonia/ ARDS)
Sepsis (Sepsis)
Trauma (Trauma)
Vascular surgery (Vascular surgery)
Pre-existing illness
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Myocardial Infarction
Yes
No
Heart failure - NYHA
no NYHA (no NYHA)
NYHA I (NYHA I)
NYHA II (NYHA II)
NYHA III (NYHA III)
NYHA IV (NYHA IV)
Ejection fraction
%
Cardiac arrhythmia
Yes
No
Valvular heart disease
Yes
No
Peripheral arterial occlusive disease
Yes
No
Cerebrovascular disease
Yes
No
Stroke
Yes
No
Pulmonary fibrosis
Yes
No
Other severe chronic lung disease
(Climbing stairs or housework not possible)
Yes
No
Proven chronic hypoxia
Yes
No
Secondary polycythemia
Yes
No
Severe pulmonary hypertension
(> 40 mmHg)
Yes
No
Home mechanical ventilation
Yes
No
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Rheumatoid arthritis
Yes
No
Gastric/ Duodenal ulcer
Yes
No
Liver cirrhosis
Yes
No
Proven portal hypertension
Yes
No
Eearly oesophageal variceal bleeding
Yes
No
Hepatic encephalopathy/ coma
Yes
No
Diabetes mellitus without organ complication
Yes
No
Diabetes mellitus with organ complication
Yes
No
Alcohol abuse
Yes
No
Leukemia
Yes
No
Solid tumor
Yes
No
Solid tumor: metastatic
Yes
No
Haematologic malignancy
Yes
No
Haematologic malignancy: metastatic
Yes
No
Chemotherapy
(until 30 days before admission)
Yes
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No
Radiation
Yes
No
Therapeutic Immunosuppression due to organ
transplantation
Yes
No
AIDS
Yes
No
High dose steroids
(above cushing threshold (> 7.5 mg Decortin/d)
for > 3 d)
Yes
No
Premedication (existing at admission)
Antiplatelet therapy
Yes
No
ACE inhibitor
Yes
No
Angiotensin Receptor Antagonists
Yes
No
Beta-Antagonists
Yes
No
Diuretics
Yes
No
Statins
Yes
No
Other premedication
Yes
No
If other premedication, specify agent:
Glasgow Coma Scale (24h before
randomisation) (if analog sedated
patients, please regard to Working
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Instruction!)
Eye opening:
4 - Opens eyes spontaneously
3 - Opens eyes in response to voice
2 - Opens eyes in response to painful stimuli
1 - Does not open eyes
2
Verbal response:
5 - Oriented, converses normally
4 - Confused, disoriented
3 - Utters inappropriate words
2 - Incomprehensible sounds
1 - Makes no sounds
Motor response:
6 - Obeys commands
5 - Localizes painful stimuli
4 - Flexion / Withdrawal to painful stimuli
3 - Abnormal flexion to painful stimuli
2 - Extension to painful stimuli 
1 - Makes no movements
Was Glasgow Coma Scale estimated?
Yes
No
Mechanical ventilation (24h before
randomisation)
Please specify the most severe form of ventilation
which was used:
invasive ventilation (invasive ventilation)
no ventilation (no ventilation)
non-invasive ventilation (non-invasive
ventilation)
Catecholamine and inotropic therapy
Use of  Catecholamine or inotropic therapy?
(24h before randomisation)
Yes
No
Adrenaline therapy?
Yes
No
Adrenaline therapy:
If "Yes", specify highest dosage over at least 1h:
(possible units μg/ kg/ min or μg/ min or mg/h)
Noradrenaline therapy?
Yes
No
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Noradrenaline therapy:
If "Yes", specify highest dosage over at least 1h:
(possible units μg/ kg/ min or μg/ min or mg/h)
Dobutamine therapy?
Yes
No
Dobutamine therapy:
If "Yes", specify highest dosage over at least 1h:
(possible units μg/ kg/ min or μg/ min or mg/h)
Vasopressins therapy?
Yes
No
Vasopressins therapy: If "Yes", specify highest
dosage over at least 1h:
IE/h
Terlipressin therapy?
Yes
No
Milrinone therapy?
Yes
No
Milrinone therapy:
If "Yes", specify highest dosage over at least 1h:
(possible units μg/ kg/ min or mg/h)
Levosimendan therapy?
Yes
No
Levosimendan therapy: If "Yes", specify highest
dosage over at least 1h:
μg/ kg/ min
Vital signs
Body temperature: Minimum
°C
Body temperature: Maximum
°C
Systolic blood pressure: Minimum
mmHg
Systolic blood pressure: Maximum
mmHg
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Mean arterial pressure: Minimum
mmHg
Mean arterial pressure: Maximum
mmHg
Diastolic blood pressure: Minimum
mmHg
Diastolic blood pressure: Maximum
mmHg
Heart rate: Minimum
/min
Heart rate: Maximum
/min
Respiratory rate: Minimum
/min
Respiratory rate: Maximum
/min
Central venous pressure: Minimum
Central venous pressure: Maximum
ECMO therapy?
Yes
No
Intra-aortic balloon pump therapy?
Yes
No
Concomitant medication (within the last
24h before randomisation)
Diuretics?
Yes
No
X-ray contrast media?
Yes
No
Aminoglycosides?
Yes
No
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Amphotericin?
Yes
No
Vancomycin?
Yes
No
Low molecular weight heparin (prophylactic)?
(PTT < 60s; Anti-Xa < 0,6; INR < 2)
Yes
No
Systemic heparin (prophylactic)?
Yes
No
Laboratory Parameters and Blood Gas
Analysis (24h before randomisation)
Arterial pCO2: Minimum
(BGA with max. FiO2)
(possible units: kPa or mmHg)
Arterial pCO2: Maximum
(BGA with max. FiO2)
(possible units: kPa or mmHg)
Arterial pCO2:
possible units:
kPa  (kPa )
mmHg (mmHg)
Arterial pCO2: Minimum
(BGA with max. FiO2)
(possible units: kPa or mmHg)
Arterial pO2: Maximum
(BGA with max. FiO2)
(possible units: kPa or mmHg)
Arterial pO2: 
possible units:
kPa  (kPa )
mmHg (mmHg)
Fraction of inspired oxygen: Minimum
(for not ventilated patients (invasive + non-
invasive): 21% (0,21))
Fraction of inspired oxygen: Maximum
(for not ventilated patients (invasive + non-
invasive): 21% (0,21))
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Arterial pH: Minimum
Arterial pH: Maximum
Base Excess: Minimum
(measured in arterial blood)
mmol/L
Base Excess: Maximum
(measured in arterial blood)
mmol/L
Bicarbonate: Minimum
mmol/L
Bicarbonate: Maximum
mmol/L
Potassium: Minimum
(possible units: mg/dL or mmol/L)
Potassium: Maximum
(possible units: mg/dL or mmol/L)
Potassium: 
possible units:
mg/dL  (mg/dL )
mmol/L (mmol/L)
Sodium: Minimum
(possible units: mg/dL or mmol/L)
Sodium: Maximum
(possible units: mg/dL or mmol/L)
Sodium:
possible units:
mg/dL  (mg/dL )
mmol/L) (mmol/L))
Lactate: Maximum
(possible units: mg/dL or mmol/L)
Lactate: Maximum
possible units:
mg/dL  (mg/dL )
mmol/L (mmol/L)
Serum Creatinine: Minimum
(possible units: mg/dL or μmol/L)
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Serum Creatinine: Maximum
(possible units: mg/dL or μmol/L)
Serum Creatinine: 
possible units:
mg/dL  (mg/dL )
μmol/L (μmol/L)
Glomerular Filtration Rate 
(Please use Cockcroft-Gault-Formular)
mL/min
Urea: Maximum
(possible units: mmol/L or mg/dL or μmol/L)
Urea: 
possible units:
mg/dL  (mg/dL )
mmol/L  (mmol/L )
μmol/L (μmol/L)
Urea: specification
Urea (Urea)
Urea nitrogen (Urea nitrogen)
Leukocytes: Minimum
(possible units: G/I or 1/nL or 1000/μL=G/I or
1/nL or 1000/μL OR 1/μL=1/μL)
Leukocytes: Maximum
(possible units:  G/I or 1/nL or 1000/μL=G/I or
1/nL or 1000/μL OR 1/μL=1/μL)
Leukocytes: 
possible units:
1/μL (1/μL)
G/I or 1/nL or 1000/μL (G/I or 1/nL or
1000/μL)
Thrombocytes: Minimum
(possible units:  G/I or 1/nL or 1000/μL=G/I or
1/nL or 1000/μL OR 1/μL=1/μL)
Thrombocytes: Maximum
(possible units:  G/I or 1/nL or 1000/μL=G/I or
1/nL or 1000/μL OR 1/μL=1/μL)
Thrombocytes: 
possible units:
1/μL (1/μL)
G/I or 1/nL or 1000/μL (G/I or 1/nL or
1000/μL)
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Haemoglobin: Minimum
(possible units: mmol/L or g/dL)
Haemoglobin: Maximum
(possible units: mmol/L or g/dL)
Haemoglobin: 
possible units:
g/dL (g/dL)
mmol/L  (mmol/L )
Haematocrit: Minimum
(possible units: % or I/L)
Haematocrit: Maximum
(possible units: % or I/L))
Haematocrit: 
possible units:
%  (% )
I/L (I/L)
PTT: Minimum
s
PTT: Maximum
s
INR: Minimum
INR: Maximum
CRP: Maximum
(possible units: mg/L or mg/dL)
CRP: 
possible units:
mg/dL (mg/dL)
mg/L  (mg/L )
CRP: 
Description:
value with < described (value with <
described)
value with > described (value with >
described)
Albumin: Minimum
(possible units: g/L or g/dL)
Albumin: 
possible units:
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g/dL (g/dL)
g/L  (g/L )
Blood glucose: Minimum
(possible units: mg/dL or mmol/L)
Blood glucose: Maximum
(possible units: mg/dL or mmol/L)
Blood glucose: 
possible units:
mg/dL (mg/dL)
mmol/L (mmol/L)
Bilirubin: Maximum
(possible units: μmol/L or mg/dL)
Bilirubin: 
possible units:
mg/dL (mg/dL)
μmol/L (μmol/L)
Phosphate: Minimum
(possible units: mg/dL or mmol/L)
Phosphate: Maximum
(possible units: mg/dL or mmol/L)
Phosphate:
possible units:
mg/dL  (mg/dL )
mmol/L (mmol/L)
Magnesium: Minimum
(possible units: mg/dL or mmol/L)
Magnesium: Maximum
(possible units: mg/dL or mmol/L)
Magnesium:
possible units:
mg/dL  (mg/dL )
mmol/L (mmol/L)
Chloride: Minimum
(possible units: mmol/L, mEq/L or mg/dL or g/L)
Chloride: Maximum
(possible units: mmol/L, mEq/L or mg/dL or g/L)
Chloride: 
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possible units:
g/L (g/L)
mg/dL (mg/dL)
mmol/L, mEq/L  (mmol/L, mEq/L )
Procalcitonin
ng/mL
Procalcitonin: 
Description:
value with < described (value with <
described)
value with > described (value with >
described)
Ionized Calcium: Miniumum
mmol/L
Ionized Calcium: Maximum
mmol/L
Total Calcium: Miniumum
mmol/L
Total Calcium: Maximum
mmol/L
Fluid balance (from admission to ICU until
randomisation)
Fluid intake (cumulative)
(among others: i.v. infusions, thrombocyte
concentrates, erythrocyte concentrates, fresh
plasma and enteral nutrition)
mL
Fluid output (cumulative)
(among others: faeces, urin, dialysat, vomiting,
drainage and blood loss. Caution: irrigations are
excluded)
mL
Urinary excretion
mL
Urinary excretion duration
h
Transfusion (from admission to ICU until
randomisation)
Blood loss
mL
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Erythrocyte concentrate
mL
Fresh Frozen Plasma (FFP)
mL
Platelet concentrate
mL
Cell saver
mL
Microbiology (at screeing)
Infection proven by microbiology?
Yes
No
Gram-positive bacteria?
Yes
No
Gram-negative bacteria?
Yes
No
Multiresitant bacteria
Yes
No
Fungi
Yes
No
Virus
Yes
No
Test material:
Blood culture
Yes
No
Test material:
Tracheal secretion
Yes
No
Test material:
Urine
Yes
No
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Eligibility Osteoarthritis, Knee
NCT02370823
A Controlled Surveillance of the Osteoarthritic Knee
Microenvironment With Regenexx® SD Treatment; ODM
derived from: https://clinicaltrials.gov/show/NCT02370823
All rights reserved. Please visit https://medical-data-
models.org/forms/15765
Eligibility Osteoarthritis, Knee
NCT02370823
Inclusion Criteria
1. voluntary signature of the irb approved
informed consent*
Yes
No
2. unilateral osteoarthritic male or female ages
35-85*
Yes
No
3. pain, swelling, and/or functional disability in the
affected knee consistent with osteoarthritis in one
knee joint*
Yes
No
4. physical examination consistent with
osteoarthritis in one knee joint*
Yes
No
5. restricted range of motion of the affected knee
(<135 degrees in flexion and/or >0 degrees of
extension)*
Yes
No
6. kellgren-lawrence grade 2 or greater knee
osteoarthritis with diagnostic mr imaging of the
affected knee showing osteoarthritis*
Yes
No
7. limited knee effusion in osteoarthritic knee (i.e.
not more than 20 ml of visible joint fluid on
ultrasound examination of the knee.)*
Yes
No
8. normal range of motion of the unaffected knee*
Yes
No
9. no sign of  pain, swelling, and/or functional
disability of the unaffected knee*
Yes
No
10. no history of acute injury in the unaffected
knee*
Yes
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No
11. is independent, ambulatory, and can comply
with all post-operative evaluations and visits*
Yes
No
Exclusion Criteria
1. knee injections of any type within 6 months
prior to the study.*
Yes
No
2. inflammatory or auto-immune based joint
diseases or other lower extremity pathology (e.g.,
rheumatoid arthritis, systemic lupus
erythematosus, psoriatic arthritis, polymyalgia,
polymyositis, gout pseudogout)*
Yes
No
3. quinolone or statin induced
myopathy/tendinopathy*
Yes
No
4. symptomatic lumbar spine pathology (e.g.
radicular pain)*
Yes
No
5. severe neurogenic inflammation of the
cutaneous nerves about the knee or thigh (i.e.
evidence of complex regional pain syndrome or
central sensitization with allodynia present on
exam).*
Yes
No
6. contraindications for mri*
Yes
No
7. tested positive or has been treated for a
malignancy in the past five years or is suspected
of having a malignancy or is currently undergoing
radiation or chemotherapy treatment for a
malignancy anywhere in the body, whether
adjacent to or distant from the proposed injection
site*
Yes
No
8. condition represents a worker's compensation
case*
Yes
No
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9. currently involved in a health-related litigation
procedure*
Yes
No
10. is pregnant*
Yes
No
11. bleeding disorders*
Yes
No
12. currently taking anticoagulant or
immunosuppressive medication*
Yes
No
13. allergy or intolerance to study medication*
Yes
No
14. use of chronic opioid*
Yes
No
15. documented history of drug abuse within six
months of treatment*
Yes
No
18) any other condition, that in the opinion of the
investigator, that would preclude the patient from
enrollment*
Yes
No
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Eligibility Pain NCT02311881
A 12-Week Efficacy Study of Paracetamol 1000mg
Sustained-release Tablets in Patients With Osteoarthritis;
ODM derived from:
https://clinicaltrials.gov/show/NCT02311881
All rights reserved. Please visit https://medical-data-
models.org/forms/15766
Eligibility Pain NCT02311881
Inclusion Criteria
male or female participants between 40 and 80
years of age*
Yes
No
diagnosis of moderate to moderately-severe
osteoarthritis (oa) of either the knee or hip with
respect to the following:*
Yes
No
pain in one knee/hip over 3 months immediately
before screening visit*
Yes
No
use of non steroidal anti-inflammatory drugs
(nsaids), acetaminophen (paracetamol) or any
other analgesic for 3 or more days per week for at
least 3 months prior to screening visit*
Yes
No
clinical diagnosis of osteoarthritis of knee/hip for
minimum 6 month duration prior to screening
visit*
Yes
No
therapeutic benefit with acetaminophen use with
a score of ≥ 1 on 5-point categorical scale*
Yes
No
radiological evidence of ≥ grade 2 osteoarthritis
according to kellgren-lawrence radiographic
criteria*
Yes
No
increased womac pain subscale score of at least
20 % following untreated run-in period*
Yes
No
moderate to moderately-severe self-reported pain
on a 5-point categorical scale following untreated
run-in period*
Yes
No
historical self-reported positive therapeutic
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benefit with paracetamol use for osteoarthritis
pain relief*
Yes
No
Exclusion Criteria
history of surgery or major trauma to the study
joint*
Yes
No
clinically significant signs or symptoms of
inflammation upon completion of run-in period*
Yes
No
required ongoing use of analgesic therapy for
other indications, anticoagulants,
psychotherapeutic agents, aspirin at daily doses
greater than 325 mg, statin-class hypolipidemic
agents at doses that have not been stabilized, or
other treatments know to interfere with pain
perception*
Yes
No
history of hepatic or renal or liver or biliary
disease or gastrointestinal surgery*
Yes
No
participants with alanine aminotransferase (alt)
>2 times upper limit normal (2xuln) and bilirubin >
1.5 times upper limit normal (1.5xuln) (however, if
direct bilirubin is <35% and fractioned, isolated
bilirubin >1.5xuln is acceptable)*
Yes
No
other arthritis type, fibromyalgia or collagen
vascular disease or secondary oa of study joint or
chronic pain condition*
Yes
No
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Eligibility Multiple Sclerosis, Relapsing-
Remitting NCT00067327
Treatment of Multiple Sclerosis Using Over the Counter
Inosine; ODM derived from:
https://clinicaltrials.gov/show/NCT00067327
All rights reserved. Please visit https://medical-data-
models.org/forms/15767
Eligibility Multiple Sclerosis,
Relapsing-Remitting NCT00067327
Inclusion Criteria
nonpregnant, nonlactating females*
Yes
No
females of child bearing  potential must have a
negative human chorionic gonadotropin (hcg) test
result within 60 days before the first dose of study
material.*
Yes
No
males and females must practice adequate
contraception, in the judgement of the
investigator, during the course of the study.*
Yes
No
subjects must have a diagnosis of clinically
definite relapsing remitting multiple sclerosis
based on medical history, physical examination,
laboratory test results, and neurologic
examination.  alternatively, subjects may have
clinically probable ms characterized by 1 attack
and the presence of at least 4 lesions on mri
within 12 months before the initial baseline
evaluation.*
Yes
No
subjects must have an expanded disability status
scale (edss) test result of less than or equal to
5.0 within 60 days before the first dose of study
material.*
Yes
No
subjects will have serum uric acid levels less than
5 mg/dl.*
Yes
No
have 1 clinical relapse in the last year*
Yes
No
Exclusion Criteria
presence of any medical disability or laboratory
test result that, in the judgement of the
investigator, would interfere with assessment of
the tolerability, safety, or efficacy of study material
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or would compromise the subject's ability to
provide informed consent.*
Yes
No
evidence of active infection characterized by
requiring treatment with antibiotics within 7 days
before the first dose of study material.*
Yes
No
treatment with interferons, glatiramer acetate,
lymphoid irradiation, cyclophosphamide, or with
other immune modifying treatments within 3
months, or corticosteroids within 1 month before
the initial baseline mri assessment in this trial.*
Yes
No
recent history (within the previous 2 years) of
drug or alcohol abuse.*
Yes
No
known allergy to inosine products or history of
anaphylaxis.*
Yes
No
previous randomization into this study.*
Yes
No
treatment with an investigational agent within 30
days before the first dose of study material.*
Yes
No
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Eligibility Pain NCT02336529
Nerveblocks for Persistent Pain After Breast Cancer
Surgery; ODM derived from:
https://clinicaltrials.gov/show/NCT02336529
All rights reserved. Please visit https://medical-data-
models.org/forms/15768
Eligibility Pain NCT02336529
Inclusion Criteria
at least 1 year after surgery for breast cancer*
Yes
No
women aged 18 or over*
Yes
No
suffering from persistent pain in the breast, side
of chest, axilla or arm (nrs 4 or over)*
Yes
No
Exclusion Criteria
previous cosmetic surgery*
Yes
No
bilateral cancer*
Yes
No
pregnant or lactating*
Yes
No
other disease in the nervous system*
Yes
No
in treatment for psychiatric disease*
Yes
No
unable to understand danish*
Yes
No
unable to give informed concent*
Yes
No
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AAFP: Acute Mental Status Change
Admission Order
AAFP: Acute Mental Status Change Admission Order,
Standardizes Admission Orders, Author: Robert M. Wiprud,
MD
The primary purpose of these Ordersets is to decrease
unnecessary variability and to improve quality through
standardized Admission Orders.
Developed by the Scott & White Clinic at College Station,
Texas. Copyright © 2006 American Academy of Family
Physicians. Physicians may photocopy or adapt for use in
their own practices; all other rights reserved. Wiprud RM.
Providing consistent care with standardized admission
orders. Fam Pract Manag. September 2006: 49-52 
See http://www.aafp.org/fpm/2006/0900/p49.html
This ODM Form includes the first section ("Acute mental
status change admission order").
All rights reserved. Please visit https://medical-data-
models.org/forms/15769
AAFP: Acute Mental Status Change
Admission Order
Default Itemgroup
Name
Alter
Geburtsdatum
Patienten-ID
Status
Aufnahmestatus
Beobachtung (1)
Aufnahme (2)
Station (3)
Überwachungsstation/Intensivstation (4)
Andere (5)
Falls Andere, bitte spezifizieren
Facharzt
Facharzt
Telefonummer des Facharztes
Aufnahmegrund/Diagnose
Diagnose für die akute mentale Veränderung
Zustand
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Zustand
Stabil (1)
Gut/in Ordnung (2)
Ernstzunehmend (3)
Kritisch (4)
Code Status
ganzer Code (1)
DNR (2)
Allergien
Allergien
Ernährung
Ernährung
NPO (1)
klare Flüssigkeit (2)
AHA Stufe 2  (3)
ADA (X) Kalorien siehe folgendes Item
(4)
Andere (5)
Kalorienanzahl laut ADA
Falls Andere, bitte spezifizieren
Beweglichkeit
Beweglichkeit
Bettlägerig mit Toilette/ Hygiene am Bett
(1)
eigenständige Nutzung des
Badezimmers  (2)
Up ad lib (3)
Vorsichtsmaßnahmen gegen Stürze (4)
Pflege
Vitalzeichen mit Neuro alle 4 Std für 24 Std
danach einmal pro Schicht
Ja
Nein
Arzt benachrichtigen, wenn: T > 101.5, Herzrate
> 120, Blutdruck < 90/60 oder > 180/110, sinken
auf Neurostatus, Sauerstoffsättigung < 92%
Ja
Nein
Puls ox alle 8 std, Nasenbrille/Sauerstoffmaske
um Sauerstoffsättigung bei > 92% zu halten
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Ja
Nein
I & O
Ja
Nein
Medikation bei aggressivem oder
psychotischem Verhalten
Medikation: Akut unruhig bei über 90 kg
ohne Nieren- oder Leber-
Beeinträchtigung
Haldol 10 mg PO/IM, Ativan 4mg PO/IM und
Cogentin 1 mg PO/IM alle 6 std prn;
Zurückhaltung bei Blutdruck < 100/60 mmHg
ODER
Ja
Nein
Geodon 20mg IM alle 8 std prn; Zurückhaltung
bei Blutdruck < 100/60 mmHg
Ja
Nein
Medikation: Akut/moderat unruhig bei
unter 90 kg ohne Nieren- oder Leber-
Beeinträchtigung
Risperdal 2 mg und Ativan 2 mg PO alle 6 std
prn, ODER
Ja
Nein
Haldol 5 mg IM und Ativan 2 mg IM und Cogentin
1 mg IM alle 4 std prn; Zurückhaltung bei
Blutdruck < 100/60 mmHg, ODER
Ja
Nein
Geodon 20 mg IM alle 8 std prn; Zurückhaltung
bei Blutdruck < 100/60 mmHg
Ja
Nein
Medikation: Leicht unruhig bei Nieren-/
Leber- Beeinträchtigung
Risperdal 2 mg PO und Ativan 2 mg PO alle 8 std
prn
Ja
Nein
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Medikation: ältere/ gebrechliche
Menschen
Risperdal 0.5 mg PO und Ativan 0.5 mg PO alle 8
std prn (3 in 24 std nicht überschreiten), ODER
Ja
Nein
Haldol 2 mg IM und Ativan 1 mg alle 8 std prn;
Zurückhaltung bei Blutdruck < 100/60 mmHg
Ja
Nein
Infusion
Infusion
Infusion verschlossen; routinemäßig
durchspülen (1)
Infusion @mL/hr (2)
Falls Infusion @mL/hr, bitte @mL/hr spezifizieren
Labor
Labor
Aufnahme: CBC, ESR, CMP, serum
ammonia, HIV, RPR, TSH, Urin-Test auf
Drogenkonsum (1)
Prüfen: Serum für Blei und
Schwermetalle und Lumbarpunktion (2)
Andere Laboruntersuchungen (3)
Falls andere Laboruntersuchungen, bitte
spezifizieren
Diagnostik
Diagnostik
CT des Kopfes ohne Kontrastmittel (1)
CXR 2 Ansicht; Grund: Ausschluss von
knöchernen Abnormitäten/Infiltraten (2)
Prüfen von Halsschlagader Doppler (3)
Befragung
Befragung
Andere Verordnungen
Andere Verordnungen
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Patientenumfrage AID-Register (deutsch,
>/=13Jahre)
Register für autoinflammatorische Erkrankungen
NBO(PD Dr. med. Elke Lainka, Prof. Dr. med. Dirk Föll)
https://prst.gpoh.de/aid/formulare.asp
All rights reserved. Please visit https://medical-data-
models.org/forms/15774
Patientenumfrage AID-Register
(deutsch, >/=13Jahre)
Patientenumfrage
Kannst Du Dich allein anziehen,die Schnürsenkel
binden,Knöpfe schließen oder öffnen?
Problemlos (1)
Leicht erschwert (2)
Stark erschwert (3)
Nicht möglich (4)
Kannst Du Dir allein die Haare waschen?
Problemlos (1)
Leicht erschwert (2)
Stark erschwert (3)
Nicht möglich (4)
Kannst Du Dir allein die Socken an und
ausziehen?
Problemlos (1)
Leicht erschwert (2)
Stark erschwert (3)
Nicht möglich (4)
Kannst Du Dir allein die Fingernägel schneiden?
Problemlos (1)
Leicht erschwert (2)
Stark erschwert (3)
Nicht möglich (4)
Kannst Du von einem niedrigen Stuhl oder vom
Boden aufstehen?
Problemlos (1)
Leicht erschwert (2)
Stark erschwert (3)
Nicht möglich (4)
Kannst Du Dich ins Bett legen oder aus dem Bett
aufstehen
Problemlos (1)
Leicht erschwert (2)
Stark erschwert (3)
Nicht möglich (4)
Kannst Du bei Tisch ein Messer zum Schneiden
benutzen?
Problemlos (1)
Leicht erschwert (2)
Stark erschwert (3)
Nicht möglich (4)
Kannst Du eine Tasse oder ein Glas zum Mund
führen?
Problemlos (1)
Leicht erschwert (2)
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Stark erschwert (3)
Nicht möglich (4)
Kannst Du eine neue Packung Cornflakes oder
Müsli öffnen?
Problemlos (1)
Leicht erschwert (2)
Stark erschwert (3)
Nicht möglich (4)
Kannst Du draußen auf ebenem Boden gehen?
Problemlos (1)
Leicht erschwert (2)
Stark erschwert (3)
Nicht möglich (4)
Kannst Du fünf Stufen hinaufgehen?
Problemlos (1)
Leicht erschwert (2)
Stark erschwert (3)
Nicht möglich (4)
Kannst Du Dich allein am ganzen Körper
waschen und abtrocken?
Problemlos (1)
Leicht erschwert (2)
Stark erschwert (3)
Nicht möglich (4)
Kannst Du allein baden (und in die Wanne ein-
und aussteigen?
Problemlos (1)
Leicht erschwert (2)
Stark erschwert (3)
Nicht möglich (4)
Kannst du die Toilette benutzen und wieder
aufstehen?
Problemlos (1)
Leicht erschwert (2)
Stark erschwert (3)
Nicht möglich (4)
Kannst Du dir die Zähne putzen?
Problemlos (1)
Leicht erschwert (2)
Stark erschwert (3)
Nicht möglich (4)
Kannst Du dir die Haare kämmen oder bürsten?
Problemlos (1)
Leicht erschwert (2)
Stark erschwert (3)
Nicht möglich (4)
Kannst Du einen schweren Gegenstand, z.B. ein
großes Spiel oder Bücher, über Kopfhöhe
erreichen und herunterholen?
Problemlos (1)
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Leicht erschwert (2)
Stark erschwert (3)
Nicht möglich (4)
Kannst Du dich bücken, um ein Kleidungsstück
oder ein Blatt Papier vom Boden aufzuheben?
Problemlos (1)
Leicht erschwert (2)
Stark erschwert (3)
Nicht möglich (4)
Kannst Du einen Pullover über den Kopf ziehen?
Problemlos (1)
Leicht erschwert (2)
Stark erschwert (3)
Nicht möglich (4)
Kannst Du den Kopf drehen, um über die
Schulter zurückzuschauen?
Problemlos (1)
Leicht erschwert (2)
Stark erschwert (3)
Nicht möglich (4)
Kannst Du mit Kugelschreiber oder Bleistift
schreiben?
Problemlos (1)
Leicht erschwert (2)
Stark erschwert (3)
Nicht möglich (4)
Kannst Du Autotüren öffnen?
Problemlos (1)
Leicht erschwert (2)
Stark erschwert (3)
Nicht möglich (4)
Kannst Du Schraubverschlüsse öffnen, die schon
einmal geöffnet waren?
Problemlos (1)
Leicht erschwert (2)
Stark erschwert (3)
Nicht möglich (4)
Kannst Du Wasserhähne auf- und zudrehen?
Problemlos (1)
Leicht erschwert (2)
Stark erschwert (3)
Nicht möglich (4)
Kannst Du eine Tür mit einem Türknauf öffnen?
Problemlos (1)
Leicht erschwert (2)
Stark erschwert (3)
Nicht möglich (4)
Kannst Du einkaufen und Kleinigkeiten
erledigen?
Problemlos (1)
Leicht erschwert (2)
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Stark erschwert (3)
Nicht möglich (4)
Kannst Du in Auto, Bus oder Straßenbahn einund
aussteigen?
Problemlos (1)
Leicht erschwert (2)
Stark erschwert (3)
Nicht möglich (4)
Kannst Du Fahrradfahren?
Problemlos (1)
Leicht erschwert (2)
Stark erschwert (3)
Nicht möglich (4)
Kannst Du im Haushalt helfen (z.B.
abwaschen,Müll wegbringen, Staub saugen, bei
der Gartenarbeit helfen, sein Bett machen, sein
Zimmer aufräumen)?
Problemlos (1)
Leicht erschwert (2)
Stark erschwert (3)
Nicht möglich (4)
Kannst Du rennen und spielen?
Problemlos (1)
Leicht erschwert (2)
Stark erschwert (3)
Nicht möglich (4)
Hilfsmittel
Ankleiden und Körperpflege (z.B. Knöpfhaken,
verlängerte Schuhlöffel)
Ja
Nein
Aufstehen (Spezialstuhl oder erhöhter Stuhl)
Ja
Nein
Gehen (Gehstütze)
Ja
Nein
Gehen (Therapiefahrzeug)
Ja
Nein
Gehen (Rollstuhl)
Ja
Nein
Erreichen von Gegenständen (Geräte mit langen
Stielen zum Erreichen bestimmter Gegenstände
Ja
Nein
Greifen (Geräte mit langen Stielen im
Badezimmer)
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Ja
Nein
Greifen (Schraubverschluss-Öffner für Gläser, die
schon geöffnet waren)
Ja
Nein
Greifen (Bleistiftverdickung oder spezielle Schere
oder Schreibgeräte)
Ja
Nein
Welche anderen Hilfsmittel für die genannten
Tätigkeiten brauchen Sie?
Hilfe von anderen Personen
Mein Kind benötigt Hilfe beim Ankleiden
Ja
Nein
Mein Kind benötigt Hilfe beim Aufstehen
Ja
Nein
Mein Kind benötigt Hilfe beim Essen und Trinken
Ja
Nein
Mein Kind benötigt Hilfe bei der Körperpflege
Ja
Nein
Mein Kind benötigt Hilfe beim Greifen
Ja
Nein
Mein Kind benötigt Hilfe beim Gehen
Ja
Nein
Mein Kind benötigt Hilfe beim Erreichen von
Gegenständen
Ja
Nein
Mein Kind benötigt Hilfe bei Aktivitäten und
häuslichen Aufgaben
Ja
Nein
Aktueller Krankheitsstatus
Wie würden Sie die Stärke der Schmerzen Ihres
Kindes in den vergangenen 7 Tagen
einschätzen?
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0 keine Schmerzen (1)
9 (10)
10 unerträgliche Schmerzen (11)
1 (2)
2 (3)
3 (4)
4 (5)
5 (6)
6 (7)
7 (8)
8 (9)
Wie beurteilen Sie im Großen und Ganzen den
derzeitigen Gesundheitszustand Ihres Kindes?
0 sehr gut (1)
9 (10)
10 sehr schlecht (11)
1 (2)
2 (3)
3 (4)
4 (5)
5 (6)
6 (7)
7 (8)
8 (9)
Hast Du in den letzten 4 Wochen wegen Deiner
rheumatischen Krankheit in der Schule
oder an der Ausbildungsstätte gefehlt?
Ja
Nein
Wenn ja, wie viele Tage hast Du gefehlt?
Warst Du in den letzten 12 Monaten wegen
Deiner rheumatischen Krankheit stationär
im Krankenhaus?
Ja
Nein
Wenn ja, wie viele Wochen? (0 bis 52)
Wenn ja, wieviele Tage? (0 bis 7)
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Eligibility Parkinson's Disease
NCT02288468
One Pass thalamIc aNd subthalamIc stimulatiON; ODM
derived from: https://clinicaltrials.gov/show/NCT02288468
All rights reserved. Please visit https://medical-data-
models.org/forms/15775
Eligibility Parkinson's Disease
NCT02288468
Inclusion Criteria
1. male or female patients aged ≥ 35 and ≤ 75
years with a life expectancy of at least 5 years*
Yes
No
2. patients with parkinson's disease according to
the criteria of the british brain bank as diagnosed
by an in movement disorder specialized
neurologist*
Yes
No
3. parkinson patients are included with a medical
treatment resistant and disabling resting and/or
postural tremor as their major complaint and with
a less prominent or absent hypokinetic-rigid
component of their disease.*
Yes
No
4. absence of postural instability (which would be
aggravated under stn dbs)*
Yes
No
5. hoehn & yahr stage 1-3. after stadium 3
patients will show increased incidence of falling
that can be aggravated by (typical) stn dbs*
Yes
No
6. disease duration > 4 years*
Yes
No
7. pdq-39 to be completed within 42 days prior
surgery*
Yes
No
8. written informed consent*
Yes
No
Exclusion Criteria
1. major depression with suicidal thoughts*
Yes
No
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2. dementia (mattis dementia rating score ≤ 130)*
Yes
No
3. patients with lifetime primary psychotic
disorder, schizophrenia, or schizoaffective
disorder*
Yes
No
4. patients with acute psychosis as diagnosed by
a psychiatrist*
Yes
No
5. nursing care at home*
Yes
No
6. unable to give written informed consent*
Yes
No
7. surgical contraindications like deformed or
displaced or not discernable target region,
scarring after brain disease (infarction), need for
continuous anticoagulation that cannot be
bridged in order to obtain normal coagulation*
Yes
No
8. patients with advanced stage cardiovascular
disease*
Yes
No
9. patients under immunosuppressive or
chemotherapy because of malignant disease*
Yes
No
10. patients who had previous intracranial
surgery*
Yes
No
11. patients who are already under dbs therapy*
Yes
No
12. patients with aneurysm clips*
Yes
No
13. patients with cochlear implants*
Yes
No
14. simultaneous participation or previous
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participation within 30 days prior to start of
screening in a clinical trial involving
investigational medicinal product(s) or
investigational medical device(s)*
Yes
No
15. medications that are likely to cause
interactions in the opinion of the investigator*
Yes
No
16. known or persistent abuse of medication,
drugs or alcohol*
Yes
No
17. persons who are in a relationship of
dependence/employment with the sponsor or the
investigator*
Yes
No
18. fertile women not using adequate
contraceptive methods: female condoms,
diaphragm or coil, each used in combination with
spermicides; intra-uterine device; hormonal
contraception in combination with a mechanical
method of contraception;*
Yes
No
19. current or planned pregnancy, nursing period*
Yes
No
20. contraindications according to device
instructions or investigator's brochure:*
Yes
No
diathermy: shortwave, microwave, and/or
therapeutic ultrasound diathermy. the energy
generated by diathermy can be transferred to the
vercise™ dbs system, causing tissue damage at
the contact site resulting in severe patient injury
or death.*
Yes
No
magnetic resonance imaging (mri): patients
implanted with the vercise™ dbs system should
not be subjected to mri.*
Yes
No
patient incapability: patients who are unable to
properly operate the remote control and charging
system should not be implanted with the
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vercise™ dbs system.*
Yes
No
poor surgical risks: the vercise™ dbs system is
not recommended for patients who- because of
their primary disease or additional co-morbidities
- are not likely to benefit from the dbs system
implantation.*
Yes
No
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Patientenumfrage AID-Register (deutsch,
13Jahre)
Register für autoinflammatorische Erkrankungen
NBO(PD Dr. med. Elke Lainka, Prof. Dr. med. Dirk Föll)
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Patientenumfrage
Kann Ihr Kind sich alleine anziehen, die
Schnürsenkel binden, Knöpfe schließen oder
öffnen?
Problemlos (1)
Leicht erschwert (2)
Stark erschwert (3)
Nicht möglich (4)
Kann Ihr Kind sich alleine die Haare waschen?
Problemlos (1)
Leicht erschwert (2)
Stark erschwert (3)
Nicht möglich (4)
Kann Ihr Kind sich alleine die Socken an- und
ausziehen?
Problemlos (1)
Leicht erschwert (2)
Stark erschwert (3)
Nicht möglich (4)
Kann Ihr Kind sich alleine die Fingernägel
schneiden?
Problemlos (1)
Leicht erschwert (2)
Stark erschwert (3)
Nicht möglich (4)
Kann Ihr Kind von einem niedrigen Stuhl oder
vom Boden aufstehen?
Problemlos (1)
Leicht erschwert (2)
Stark erschwert (3)
Nicht möglich (4)
Kann Ihr Kind sich ins Bett legen oder aus dem
Bett aufstehen?
Problemlos (1)
Leicht erschwert (2)
Stark erschwert (3)
Nicht möglich (4)
Kann Ihr Kind bei Tisch ein Messer zum
Schneiden benutzen?
Problemlos (1)
Leicht erschwert (2)
Stark erschwert (3)
Nicht möglich (4)
Kann Ihr Kind eine Tasse oder ein Glas zum
Mund führen?
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Problemlos (1)
Leicht erschwert (2)
Stark erschwert (3)
Nicht möglich (4)
Kann Ihr Kind sich eine neue Packung Cornflakes
oder Müsli öffnen?
Problemlos (1)
Leicht erschwert (2)
Stark erschwert (3)
Nicht möglich (4)
Kann Ihr Kind draußen auf ebenem Boden
gehen?
Problemlos (1)
Leicht erschwert (2)
Stark erschwert (3)
Nicht möglich (4)
Kann Ihr Kind fünf Stufen hinaufgehen?
Problemlos (1)
Leicht erschwert (2)
Stark erschwert (3)
Nicht möglich (4)
Kann Ihr Kind sich allein am ganzen Körper
waschen?
Problemlos (1)
Leicht erschwert (2)
Stark erschwert (3)
Nicht möglich (4)
Kann Ihr Kind sich allein baden (und in die
Wanne ein- und aussteigen?
Problemlos (1)
Leicht erschwert (2)
Stark erschwert (3)
Nicht möglich (4)
Kann Ihr Kind die Toilette benutzen und wieder
aufstehen?
Problemlos (1)
Leicht erschwert (2)
Stark erschwert (3)
Nicht möglich (4)
Kann Ihr Kind sich die Zähne putzen?
Problemlos (1)
Leicht erschwert (2)
Stark erschwert (3)
Nicht möglich (4)
Kann Ihr Kind sich die Haare kämmen oder
bürsten?
Problemlos (1)
Leicht erschwert (2)
Stark erschwert (3)
Nicht möglich (4)
Kann Ihr Kind einen schweren Gegenstand, z.B.
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ein großes Spiel oder Bücher, über Kopfhöhe
erreichen und herunterholen?
Problemlos (1)
Leicht erschwert (2)
Stark erschwert (3)
Nicht möglich (4)
Kann Ihr Kind sich bücken, um ein
Kleidungsstück oder ein Blatt Papier vom Boden
aufzuheben?
Problemlos (1)
Leicht erschwert (2)
Stark erschwert (3)
Nicht möglich (4)
Kann Ihr Kind sich einen Pullover über den Kopf
anziehen?
Problemlos (1)
Leicht erschwert (2)
Stark erschwert (3)
Nicht möglich (4)
Kann Ihr Kind den Kopf drehen, um über die
Schulter zurückzuschauen?
Problemlos (1)
Leicht erschwert (2)
Stark erschwert (3)
Nicht möglich (4)
Kann Ihr Kind mit Kugelschreiber oder Bleistift
schreiben?
Problemlos (1)
Leicht erschwert (2)
Stark erschwert (3)
Nicht möglich (4)
Kann Ihr Kind Autotüren öffnen?
Problemlos (1)
Leicht erschwert (2)
Stark erschwert (3)
Nicht möglich (4)
Kann Ihr Kind Schraubverschlüsse öffnen, die
schon einmal geöffnet waren?
Problemlos (1)
Leicht erschwert (2)
Stark erschwert (3)
Nicht möglich (4)
Kann Ihr Kind Wasserhähne auf- und zudrehen?
Problemlos (1)
Leicht erschwert (2)
Stark erschwert (3)
Nicht möglich (4)
Kann Ihr Kind eine Tür mit einem Türknauf
öffnen?
Problemlos (1)
Leicht erschwert (2)
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Stark erschwert (3)
Nicht möglich (4)
Kann Ihr Kind einkaufen und Kleinigkeiten
erledigen?
Problemlos (1)
Leicht erschwert (2)
Stark erschwert (3)
Nicht möglich (4)
Kann Ihr Kind in Auto, Bus oder Straßenbahn
einund aussteigen?
Problemlos (1)
Leicht erschwert (2)
Stark erschwert (3)
Nicht möglich (4)
Kann Ihr Kind Fahrradfahren?
Problemlos (1)
Leicht erschwert (2)
Stark erschwert (3)
Nicht möglich (4)
Kann Ihr Kind im Haushalt helfen (z.B.
abwaschen,Müll wegbringen, Staub saugen, bei
der Gartenarbeit helfen, sein Bett machen, sein
Zimmer aufräumen)?
Problemlos (1)
Leicht erschwert (2)
Stark erschwert (3)
Nicht möglich (4)
Kann Ihr Kind rennen und spielen?
Problemlos (1)
Leicht erschwert (2)
Stark erschwert (3)
Nicht möglich (4)
Hilfsmittel
Ankleiden und Körperpflege (z.B. Knöpfhaken,
verlängerte Schuhlöffel)
Ja
Nein
Aufstehen (Spezialstuhl oder erhöhter Stuhl)
Ja
Nein
Gehen (Gehstütze)
Ja
Nein
Gehen (Therapiefahrzeug)
Ja
Nein
Gehen (Rollstuhl)
Ja
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Nein
Erreichen von Gegenständen (Geräte mit langen
Stielen zum Erreichen bestimmter Gegenstände
Ja
Nein
Greifen (Geräte mit langen Stielen im
Badezimmer)
Ja
Nein
Greifen (Schraubverschluss-Öffner für Gläser, die
schon geöffnet waren)
Ja
Nein
Greifen (Bleistiftverdickung oder spezielle Schere
oder Schreibgeräte)
Ja
Nein
Welche anderen Hilfsmittel für die genannten
Tätigkeiten brauchen Sie?
Hilfe von anderen Personen
Mein Kind benötigt Hilfe beim Ankleiden
Ja
Nein
Mein Kind benötigt Hilfe beim Aufstehen
Ja
Nein
Mein Kind benötigt Hilfe beim Essen und Trinken
Ja
Nein
Mein Kind benötigt Hilfe bei der Körperpflege
Ja
Nein
Mein Kind benötigt Hilfe beim Greifen
Ja
Nein
Mein Kind benötigt Hilfe beim Gehen
Ja
Nein
Mein Kind benötigt Hilfe beim Erreichen von
Gegenständen
Ja
Nein
Mein Kind benötigt Hilfe bei Aktivitäten und
häuslichen Aufgaben
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Ja
Nein
Aktueller Krankheitsstatus
Wie würden Sie die Stärke der Schmerzen Ihres
Kindes in den vergangenen 7 Tagen
einschätzen?
0 keine Schmerzen (1)
9 (10)
10 unerträgliche Schmerzen (11)
1 (2)
2 (3)
3 (4)
4 (5)
5 (6)
6 (7)
7 (8)
8 (9)
Wie beurteilen Sie im Großen und Ganzen den
derzeitigen Gesundheitszustand Ihres Kindes?
0 sehr gut (1)
9 (10)
10 sehr schlecht (11)
1 (2)
2 (3)
3 (4)
4 (5)
5 (6)
6 (7)
7 (8)
8 (9)
Hat ihr Kind in den letzten 4 Wochen wegen
Deiner rheumatischen Krankheit in der Schule
oder an der Ausbildungsstätte gefehlt?
Ja
Nein
Wenn ja, wie viele Tage hat es gefehlt?
War ihr Kind in den letzten 12 Monaten wegen
Deiner rheumatischen Krankheit stationär
im Krankenhaus?
Ja
Nein
Wenn ja, wie viele Wochen? (0 bis 52)
Wenn ja, wieviele Tage? (0 bis 7)
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Eligibility Heart Disease NCT00120991
Best Bypass Surgery (BBS) Trial; ODM derived from:
https://clinicaltrials.gov/show/NCT00120991
All rights reserved. Please visit https://medical-data-
models.org/forms/15777
Eligibility Heart Disease
NCT00120991
Inclusion Criteria
known ischemic three vessel heart disease
affecting one of the marginal coronary arteries*
Yes
No
age > 54 years*
Yes
No
scheduled for elective or subacute cabg*
Yes
No
euroscore > 4 and < 17*
Yes
No
the patient has signed written informed consent
before randomization and surgery.*
Yes
No
Exclusion Criteria
previous heart surgery*
Yes
No
ejection fraction < 30 %*
Yes
No
unstable preoperative condition, i.e., continuous
infusion of inotropics on the day of the operation*
Yes
No
patient unable to give informed consent.*
Yes
No
1 / 1
Eligibility Parkinson's Disease
NCT02349789
The Role of Cerebellar Hyperactivity in Parkinson's
Disease; ODM derived from:
https://clinicaltrials.gov/show/NCT02349789
All rights reserved. Please visit https://medical-data-
models.org/forms/15778
Eligibility Parkinson's Disease
NCT02349789
Inclusion Criteria
mild-moderate (hoehn and yahr scale: 1.5-3)
idiopathic, akinetic-rigid type parkinson's
disease.*
Yes
No
capable of walking for 5 minutes.*
Yes
No
Exclusion Criteria
severe dyskinesia*
Yes
No
congestive heart failure.*
Yes
No
peripheral artery disease with claudication.*
Yes
No
cancer. pulmonary or renal failure. unstable
angina. uncontrolled hypertension (> 190/110
mmhg). brain injury. history of seizure or a family
history of epilepsy. metal anywhere in the head
except the mouth. cardiac pacemakers. cochlear
implants. implanted medication pump. heart
disease. intracardiac lines. increased intracranial
pressure, such as after infarctions or trauma.
currently taking tricyclic anti-depressants or
neuroleptic medication. history of head trauma.
history of respiratory disease. dementia (montreal
cognitive assessment < 26; frontal assessment
battery < 13). orthopedic or pain conditions.
pregnancy.*
Yes
No
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Eligibility Kidney Disease NCT00067990
Angiotensin II Blockade for Chronic Allograft Nephropathy;
ODM derived from:
https://clinicaltrials.gov/show/NCT00067990
All rights reserved. Please visit https://medical-data-
models.org/forms/15779
Eligibility Kidney Disease
NCT00067990
Inclusion Criteria
age > 18 years.*
Yes
No
recipients of a first or a second renal transplant
alone or in combination with a pancreas
transplantation.*
Yes
No
informed consent*
Yes
No
adequate baseline biopsy; at least 10 cortical
projection fields.*
Yes
No
Exclusion Criteria
age < 18 years.*
Yes
No
serum creatinine  2.5mg/dl.*
Yes
No
persistent hyperkalemia; potassium > 5.4 meq/l.*
Yes
No
known hypersensitivity to losartan or iodine
allergy.*
Yes
No
documented renal artery stenosis by duplex
ultrasonography.*
Yes
No
recipients of grafts from an hla-identical sibling.*
Yes
No
recipients whose primary renal disease is primary
hyperoxaluria,dense-deposit disease, focal
segmental glomerulosclerosis or hemolytic
uremic syndrome.*
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Yes
No
women of childbearing age who wish to become
pregnant and/or are unwilling to use
contraceptive measures or who are pregnant.*
Yes
No
recipients requiring ace inhibitors or aii blockers
for a cardiovascular  indication (e.g. systolic
dysfunction).*
Yes
No
recipients who are > 55 years old and had a
history of cardiovascular  disease (coronary
artery disease, stroke or peripheral vascular
disease).*
Yes
No
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Eligibility Metastatic Breast Cancer
NCT00169104
Effects of Granulocyte Colony-stimulating Factor (G-CSF),
Trastuzumab, and Vinorelbine on Immune Cell Function;
ODM derived from:
https://clinicaltrials.gov/show/NCT00169104
All rights reserved. Please visit https://medical-data-
models.org/forms/15780
Eligibility Metastatic Breast Cancer
NCT00169104
Inclusion Criteria
all patients must have pathological confirmation
of carcinoma of the breast.*
Yes
No
patients must have metastatic breast cancer by
documented clinical or radiological assessment.*
Yes
No
immunohistochemical analysis of her-2/neu
expression on paraffin-embedded specimens will
be performed.  her-2/neu overexpression will be
qualitatively scored as 0, 1+, 2+, or 3+, with 3+
indicating the strongest positivity. fluorescence in
situ hybridization (fish) analyses will also be
performed on these patients.  patients with 2+ to
3+ overexpression of her-2/neu (membranous
staining) are eligible, regardless of the results of
the fish analysis.*
Yes
No
age ≥18 years.*
Yes
No
karnofsky performance status ≥ 60%.*
Yes
No
adequate hepatic, renal, and hematologic
function.*
Yes
No
prior treatment with trastuzumab will be allowed.*
Yes
No
all patients must have adequate cardiac function
(defined as left ventricular ejection fraction ≥
45%) documented by echocardiogram or muga
scan.*
Yes
No
premenopausal women will be required to have a
negative urine or serum pregnancy test and to
use an effective form of contraception.*
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Yes
No
patients with a history of brain metastases are
permitted as long as it has been at least 30 days
since definitive treatment, they are clinically
stable and a magnetic resonance imaging scan of
the brain demonstrates control of the lesion(s).*
Yes
No
all patients must give written informed consent
indicating they are aware of the investigational
nature of this treatment, as well as the risks and
benefits of this protocol.*
Yes
No
Exclusion Criteria
no treatment with chemotherapy or trastuzumab
will be allowed within four weeks of study entry.*
Yes
No
prior therapy with vinorelbine.*
Yes
No
known history of hypersensitivity to trastuzumab,
chinese hamster ovary (cho) cell proteins, or any
component of these products.*
Yes
No
history of current unstable angina, symptomatic
congestive heart failure, or myocardial infarction
within the last 6 months.*
Yes
No
pregnant women are excluded.*
Yes
No
history of a known hypersensitivity to e. coli-
derived proteins, filgrastim, or any component of
the product.*
Yes
No
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Eligibility Metastatic Breast Cancer NCT00169104
Eligibility Metastatic Renal Cell Carcinoma
NCT01689662
Safety and Efficacy of FolateScan (Technetium Tc 99m
EC20) in Subjects With Suspected Metastatic Renal Cell
Carcinoma; ODM derived from:
https://clinicaltrials.gov/show/NCT01689662
All rights reserved. Please visit https://medical-data-
models.org/forms/15781
Eligibility Metastatic Renal Cell
Carcinoma NCT01689662
Inclusion Criteria
1. subject must be 18 years of age or older.*
Yes
No
2. subject must have known or strongly
suspected metastatic renal cell carcinoma with at
least one target lesion as identified by
ultrasonography, mri, or ct.*
Yes
No
3. subject must have good kidney function.*
Yes
No
4. subject must provide written informed consent
prior to enrollment.*
Yes
No
Exclusion Criteria
1. subject is pregnant or breastfeeding.*
Yes
No
2. subject is simultaneously participating in
another investigational drug study, excluding the
follow-up phase.*
Yes
No
3. subject has received an investigational agent
within 7 days prior to enrollment.*
Yes
No
4. subject is unable to tolerate conditions for
radionuclide imaging.*
Yes
No
5. subject has been administered another
radiopharmaceutical that would interfere with the
assessment of technetium tc 99m ec20.*
Yes
No
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Eligibility Parkinson's Disease
NCT02369003
Cont. of a Study to Evaluate Implanting Peripheral Nerve
Grafts Into Subjects With Parkinson's Disease (PD) During
DBS; ODM derived from:
https://clinicaltrials.gov/show/NCT02369003
All rights reserved. Please visit https://medical-data-
models.org/forms/15782
Eligibility Parkinson's Disease
NCT02369003
Inclusion Criteria
undergoing dbs of the stn or gpi*
Yes
No
between the ages of 40-75*
Yes
No
able to give informed consent*
Yes
No
show a positive response to sinemet*
Yes
No
show no significant cognitive deficit per a formal
neuropsychological exam*
Yes
No
be able to tolerate the surgical procedure*
Yes
No
Exclusion Criteria
any condition that would not make the subject a
candidate for dbs of the stn or gpi*
Yes
No
under the age of 40 or over the age of 75*
Yes
No
unable to give informed consent*
Yes
No
previous pd surgery or intracranial surgery*
Yes
No
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General Information DGU TraumaRegister
questionnaire
DGU TraumaRegister® questionnaire; 
Data are collected prospectively in four consecutive time
phases from the site of the accident until discharge from
hospital: A) Pre-hospital phase, B) Emergency room and
initial surgery, C) Intensive care unit and D) Discharge. The
documentation includes detailed information on
demographics, injury pattern, comorbidities, pre- and in-
hospital management, course on intensive care unit,
relevant laboratory findings including data on transfusion
and outcome of each individual. The inclusion criterion is
admission to hospital via emergency room with subsequent
ICU/ICM care or reach the hospital with vital signs and die
before admission to ICU.  
The infrastructure for documentation, data management,
and data analysis is provided by AUC - Academy for
Trauma Surgery (AUC - Akademie der Unfallchirurgie
GmbH), a company affiliated to the German Trauma
Society. The scientific leadership is provided by the
Committee on Emergency Medicine, Intensive Care and
Trauma Management (Sektion NIS) of the German Trauma
Society. The participating hospitals submit their data anon-
ymously into a central database via a web-based
application. Scientific data analysis is approved according
to a peer review procedure established by Sektion NIS. 
TraumaRegister DGU® - Hinweise für die Publikation von
Ergebnissen 5 März 2014  
Seite 3 von 3 
© 2014 TraumaRegister DGU® / AUC GmbH 
The participating hospitals are primarily located in
Germany (90%), but a rising number of hospitals of other
countries contribute data as well (at the moment from
Austria, Belgium, China, Finland, Luxembourg, Slovenia,
Switzerland, The Netherlands, and the United Arab
Emirates). Currently, approx. 25,000 cases from more than
600 hospitals are entered into the database per year. 
Participation in TraumaRegister DGU® is voluntary. For
hospitals associated with TraumaNetzwerk DGU®,
however, the entry of at least a basic data set is obligatory
for reasons of quality assurance. 
www.traumaregister-dgu.de
All rights reserved. Please visit https://medical-data-
models.org/forms/15783
General Information DGU
TraumaRegister questionnaire
General Information
Date of accident
Cause of Accident
Accident (1)
violent felony (2)
suicidal intention (3)
Trauma
blunt force (1)
sharp force (2)
Type of accident
Car / Truck passenger (1)
Stab (10)
Other (11)
Motorcyclist (2)
Cyclist (3)
Pedestrian (4)
Other (Train, boat,...) (5)
Fall: 3m and above (6)
Fall:: less than 3m (7)
Other: Impact (item, branch,...) (8)
Shot (9)
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if previous answered with other, please specify
Patient information
date
country
zip code
Patient ID
Date of birth
gender
male (1)
female (2)
ASA Physical Status (before accident)
healthy  (1)
mild systemic disease (2)
severe systemic disease (3)
moribund (4)
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Eligibility Ocular Hypertension
NCT01655758
24-hour Control of Intraocular Pressure (IOP) in Ocular
Hypertension; ODM derived from:
https://clinicaltrials.gov/show/NCT01655758
All rights reserved. Please visit https://medical-data-
models.org/forms/15784
Eligibility Ocular Hypertension
NCT01655758
Inclusion Criteria
iop > 22 mmhg and < 30 mmhg on at least three
readings on separate days ,*
Yes
No
open angle on gonioscopy,*
Yes
No
cct > 550 m,*
Yes
No
optic disk classified as "within normal limits" by
moorfields regression analysis, hrtii,*
Yes
No
normal visual field (standard achromatic
perimetry, humphrey field analyzer, 24/2 sita
standard),*
Yes
No
age > 40 and < 70 years,*
Yes
No
refraction between - 5 and + 2 dyopters,*
Yes
No
best corrected visual acuity better than 0.2
logmar,*
Yes
No
Exclusion Criteria
pex*
Yes
No
pds*
Yes
No
ocular comorbidiities other than refractive
problems and/or mild dry eye*
Yes
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No
history of diabetes*
Yes
No
treatment with systemic beta blockers and
steroids*
Yes
No
previous treatment with ocular hypotensive
drugs*
Yes
No
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General Patients Data and Accident Report:
Trauma Protocol UKM
Report/Protocol collecting patient and treatment information
like the circumstances of the accident and initial ER
treatment.
Documentation in traum room.
ODM derived from EHR form: MS Schockraumprotokoll 2
by University Hospital Muenster
http://klinikum.uni-muenster.de/
All rights reserved. Please visit https://medical-data-
models.org/forms/15785
General Patients Data and Accident
Report: Emergency Room Report
UKM
Patient information
Nachname
Vorname
Geschlecht
m (1)
w (2)
Geburtsdatum
Addresse
Fallnummer
Krankenkasse
Unfall-Anamnese
Index
Unfalldatum
Unfallort
Arbeitsunfall
Ja
Nein
Unfallursache
Ursache (1)
V.a. Gewaltverbrechen (2)
V.a. Suizid (3)
Andere (4)
Trauma
stumpf (1)
penetrierend (2)
Alkoholeinfluss
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Ja
Nein
Drogeneinfluss
Ja
Nein
Hergang
KFZ Insasse (1)
Motorradfahrer (2)
Fahrradfahrer (3)
Fußgänger  (4)
Sturz über 3 m Höhe (6)
Sturz unter 3 m Höhe  (7)
Sonstiges (8)
Helm
Ja
Nein
Zuverlegung
Ja
Nein
Aufnahmedatum dort
Klinik
Anamnese
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ToFingo Screening V1 Physical examination
NCT02325440
Principal Investigator: Luisa Klotz Collaborator: Novartis
Information provided by (Responsible Party):University
Hospital Muenster -Study to Assess Immune Function and
MRI Disease Activity in RRMS Patients When Switching
From Natalizumab to Gilenya (ToFingo2) Purpose A trial in
patients with relapsing remitting multiple sclerosis (RRMS)
Main objectives: •To evaluate changes in the reconstitution
of immune surveillance over time upon switching from
natalizumab to fingolimod assessed by a change in the
expression of CD49d. •To evaluate changes in the
migratory capacity of immune cells/peripheral blood
mononuclear cells (PBMCs) upon switching from
natalizumab to fingolimod in an in-vitro model of the blood-
brain-barrier (BBB). •To evaluate changes in paraclinical
disease activity over time upon switching from natalizumab
to fingolimod assessed by MRI (changes in Gd+, T2w
lesions and DTI). •To evaluate changes in T1w / FLAIR
lesions upon switching from natalizumab to fingolimod. For
further Information please visit
https://clinicaltrials.gov/ct2/show/NCT02325440
All rights reserved. Please visit https://medical-data-
models.org/forms/15786
ToFingo Screening V1 Physical
examination NCT02325440
Study administration
Data entry for this CRF completed
Yes
No
Assessment date
Current patient (ID)
Physical examination
Head and neck: Result
Head and neck: Comment
Lung: Result
Lung: Comment
Skin: Result
Skin: Comment
Heart: Result
Heart: Comment
Abdomen: Result
Abdomen: Comment
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General appearance: Result
General appearance: Comment
Vital signs
Body Height
cm
Body weight
kg
Sitting pulse rate
bpm
Oral temperature
°C
systolic blood pressure
mmHg
Diastolic blood pressure
mmHg
Neurological examination
Neurological abnormality other than MS
Neurological examination result
Neurological examination comment
EDSS Score
>= 0,0
<= 10,0
MS relapses
MS exacerbations since last visit
Steroid therapy used for recent MS relapses
Laboratory (Blood
chemistry/Heamatology)
ALT-level (GPT)
U/L
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ToFingo Screening V1 Physical examination NCT02325440
AST-level (GOT)
U/L
HbA1C
mmol/mol
Alkaline phosphatase
U/L
GGT
U/L
Total Bilirubin
mg/dL
WBC
Tsd./uL
Lymphocytes
Tsd./uL
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ToFingo Screening V1 Physical examination NCT02325440
ToFingo Screening V1 Previous and concomitant
medication non drug therapies NCT02325440
Principal Investigator: Luisa Klotz Collaborator: Novartis
Information provided by (Responsible Party):University
Hospital Muenster -Study to Assess Immune Function and
MRI Disease Activity in RRMS Patients When Switching
From Natalizumab to Gilenya (ToFingo2) Purpose A trial in
patients with relapsing remitting multiple sclerosis (RRMS)
Main objectives: •To evaluate changes in the reconstitution
of immune surveillance over time upon switching from
natalizumab to fingolimod assessed by a change in the
expression of CD49d. •To evaluate changes in the
migratory capacity of immune cells/peripheral blood
mononuclear cells (PBMCs) upon switching from
natalizumab to fingolimod in an in-vitro model of the blood-
brain-barrier (BBB). •To evaluate changes in paraclinical
disease activity over time upon switching from natalizumab
to fingolimod assessed by MRI (changes in Gd+, T2w
lesions and DTI). •To evaluate changes in T1w / FLAIR
lesions upon switching from natalizumab to fingolimod. For
further Information please visit
https://clinicaltrials.gov/ct2/show/NCT02325440
All rights reserved. Please visit https://medical-data-
models.org/forms/15787
ToFingo Screening V1 Previous and
concomitant medication non drug
therapies NCT02325440
Study administration
Data entry for this CRF completed
Yes
No
Assessment date
Current patient (ID)
Previous and concomitant medication
Medication/non-drug therapy
Start date of therapy
End date of therapy
Single dose/Unit
mg
Amount/Unit
Frequency/Unit
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AID-Register (Kinderrheumatologie)
Diagnoseblatt
Register für autoinflammatorische Erkrankungen
AID-Register (Kinderrheumatologie)(PD Dr. med. Elke
Lainka, Prof. Dr. med. Dirk Föll)
https://prst.gpoh.de/aid/formulare.asp
All rights reserved. Please visit https://medical-data-
models.org/forms/15788
AID-Register Diagnoseblatt
Zentrum
Ansprechpartner
E- Mail
Telefon
Datum der Diagnose
Zentrumsnummer
Patienten PID
Diagnoseblatt
Diagnose
Art der Diagnose
Verdacht auf (1)
Sicher (2)
Weitere relevante Begleiterkrankungen
Genetik
Einsender
Klinik  (1)
Praxis (2)
Umfang der molekulargenetischen Untersuchung
komplettes GenScreening (1)
relevante Exone (2)
häufigste Mutationen (3)
alle Exone und Intron/Exon Transition (4)
unbekannt (5)
Diagnose
1.Mutation
2.Mutation
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3.Mutation
4.Mutation
Vererbungsmodus
compound heterozygot (1)
complex heterozygot (2)
homozygot (3)
heterozygot (4)
compound complex heterozygot (5)
Vererbungsmuster
autosomal dominant (1)
autosomal rezessiv (2)
xchromosomal (3)
unbekannt (4)
Zur Mutationsanalyse verwendete Methode
Sequenzanalyse (1)
Hybridization (2)
Restriction digest (3)
Chip (4)
Positive Anamnese beim Vater
Ja
Nein
Positive Anamnese beim Vater: Diagnose
nachgewiesen…
molekulargenetisch (1)
klinisch  (2)
unbekannt (3)
Positive Anamnese bei der Mutter
Ja
Nein
Positive Anamnese bei der Mutter: Diagnose
nachgewiesen…
molekulargenetisch (1)
klinisch  (2)
unbekannt (3)
Positive Anamnese bei Geschwister
Ja
Nein
Positive Anamnese bei Geschwister: Diagnose
nachgewiesen…
molekulargenetisch (1)
klinisch  (2)
unbekannt (3)
Positive Anamnese bei weiteren Verwandten
Positive Anamnese bei weiteren Verwandten:
Diagnose nachgewiesen…
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molekulargenetisch (1)
klinisch  (2)
unbekannt (3)
Symptome zur Diagnose
Wann traten die ersten Symptome auf?
Allgemeinbefinden während eines Schubes
gut (1)
mäßig (2)
schlecht (3)
Allgemeinbefinden zwischen den Schüben
gut (1)
mäßig (2)
schlecht (3)
Fieber > 38,5°C
kontinuierlich (1)
intermittierend (2)
kein Fieber (3)
unbekannt (4)
Anzahl der Fieberepisoden vor
Diagnosesicherung
Durchschnittliche Dauer der Fieberepisoden in
Tagen
Haut/
Schleimhautbeteiligung
Ja
Nein
Haut/ Schleimhautbeteiligung: Falls ja
Urticaria (1)
migratorisches Exanthem (10)
Fasciitis (11)
Panniculitis (12)
Purpura SchönleinHennoch (13)
Polyarteritis nodosa (14)
Vaskulitis (15)
Pharyngitis (16)
Psoriasis (17)
andere Pustulosis (18)
Aphten (2)
Ulcera (3)
Erythem (4)
makulopapulöses Exanthem (5)
masernähnliches Exanthem (6)
Erysipel (7)
palmoplantare Pustulosis (8)
Akne (9)
Tonsillitis
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AID-Register (Kinderrheumatologie) Diagnoseblatt
Ja
Nein
Serositis
Pleura (1)
Pericard (2)
Peritoneum (3)
Gelenkbeteiligung
Monoarthritis (1)
Oligoarthritis (2)
Polyarthritis (3)
Sakroiliitis (4)
destruierende Arthropathie (5)
Arthralgie (6)
keine Beteiligung (7)
Gelenkbeteiligung: wenn ja, welche Gelenke?
Abdominelle Probleme
akutes Abdomen (akutes Abdomen)
Colitis Ulcerosa (Colitis Ulcerosa)
Durchfall (Durchfall)
Erbrechen (Erbrechen)
Hepatomegalie (Hepatomegalie)
Hepatosplenomegalie
(Hepatosplenomegalie)
Morbus Crohn (Morbus Crohn)
Schmerzen (Schmerzen)
Splenomegalie (Splenomegalie)
Übelkeit (Übelkeit)
Lymphadenopathie
cervical (1)
axillar (2)
mediastinal (3)
abdominell (4)
inguinal (5)
keine Beteiligung (6)
Begleitbeschwerden
Kopfschmerzen (1)
Skelettanomalien (10)
Brustschmerzen (11)
Morgensteifigkeit (12)
Halsschmerzen (13)
Myalgie (2)
periorbitales Ödem (3)
Konjunktivitis (4)
Orchitis (5)
Sepsis (6)
Malignom (7)
Kardiomyopathie (8)
Thyroiditis (9)
Neurologische
Veränderungen
aseptische Meningitis (1)
Schwerhörigkeit (2)
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AID-Register (Kinderrheumatologie) Diagnoseblatt
Krampfanfälle (3)
Retardierung (4)
Myopathie (5)
Ataxie (6)
muskuläre Hypotonie (7)
Augen (Uveitis, (8)
Katarakt, Blindheit) (9)
Amyloidose
Ja
Nein
Amyloidose:bitte Organ benennen
Gedeihstörung (unter der 3. Perzentile)
Ja
Nein
Ärztliche Gesamtbeurteilung / Epikrise 0 (inaktiv)
10 (hohe Aktivität)
0 (1)
9 (10)
10 (11)
1 (2)
2 (3)
3 (4)
4 (5)
5 (6)
6 (7)
7 (8)
8 (9)
Triggerfaktoren
Erkältung (1)
Infektion (2)
Menstruation (3)
Operation (4)
Impfung (5)
Trauma (6)
Stress (7)
Pubertät (8)
Kälte (9)
Laborwerte vor Diagnosedatum
Hämoglobin
g/dL
Leukozyten
/nl
Neutropenie
Ja
Nein
Segmentkernige
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%Kreatinin
mg/dl
Serumamyloid A
mg/dl
CRP
md/dl
BSG 1. Stunde
mm/h
BSG 2. Stunde
mm/h
Procalcitonin
ng/ml
Biomarker S100 A12
ng/ml
Biomarker S100 A8/A9
ng/ml
IgD
mg/l
IgA
mg/dl
IgG
mg/dl
IgM
mg/dl
GPT
U/l
Bilirubin gesamt
mg/dl
Gamma-GT
U/L
Urinanalsye
unauffällig (1)
Creatinin Clearance < 90ml/min/1,73m²
(5)
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nicht durchgeführt (6)
250mg/dl oder einfach pos. im Stix
(Glukosurie >)
10μl (Hämaturie >)
30mg/dl (Proteinurie >)
positiv getestete Autoantikörper
Allgemeine Daten
Macrophagenaktivierungssyndrom
Ja
Nein
Mevalonic aciduria
Ja
Nein
Mevalonate kinase activity
erhöht  (1)
erniedrigt  (2)
normal (3)
Psoriasis
Ja
Nein
Ethnische Zugehörigkeit
Konsanguinität
Ja
Nein
Appendektomie
Ja
Nein
Dysmorphiezeichen
Sattelnase (1)
prominente Stirn (2)
hypoplastisches Mittelgesicht (3)
kurze Hände (4)
dicke Hände (5)
7 / 7
AID-Register (Kinderrheumatologie) Diagnoseblatt
Preclinical Point A in Time: Trauma Protocol
UKM
Report/Protocol collecting patient and treatment information
like the circumstances of the accident and initial ER
treatment.
Documentation in traum room.
ODM derived from EHR form: MS Schockraumprotokoll 2
by University Hospital Muenster
http://klinikum.uni-muenster.de/
All rights reserved. Please visit https://medical-data-
models.org/forms/15793
Preclinical Point A in Time:
Emergency Room Report UKM
General Information
Alarm
Eintreffen des Notarztes im SR
Abfahrt vom Unfallort
Transport mode to hospital
RTH (1)
NAW/NEF (2)
RTW (3)
selbst/privat (4)
Leitstelle
Fax Notarzt
Brief an Notarzt
Ja
Nein
NACA-Index
>= 1
<= 7
Vitalparameter am Unfallort
RRsys
mmHg
Herzfrequenz
>= 0
bpm
Atemfrequenz
/minute
SpO2
%
GCS Score
>= 3
<= 14
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Pupillengröße rechts
eng (1)
mittel (2)
weit (3)
nicht feststellbar (4)
Pupillengröße links
eng (1)
mittel (2)
weit (3)
nicht feststellbar (4)
Lichtreaktion rechts
prompt (1)
träge (2)
keine (3)
nicht feststellbar (4)
Lichtreaktion left
prompt (1)
träge (2)
keine (3)
nicht feststellbar (4)
Therapie
Kristalloide
ml
Kolloide
mmol/l
Hyperonk./Hyperosm. Lösung
ml
Alternative Atemwegssicherung
Ja
Nein
Analgosedierung
Ja
Nein
Herzdruckmassage
Ja
Nein
Katecholamine
Ja
Nein
Cervikalstütze
Ja
Nein
Thoraxdrainage
Ja
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Nein
Peripherer Zugang Anzahl
>= 0
Zentral Zugang Anzahl
>= 0
Kapnometrie
Ja
Nein
Beckengurt
Ja
Nein
Injuries
SHT
keine (1)
leicht  (2)
mittel (3)
schwer (4)
Gesicht
keine (1)
leicht  (2)
mittel (3)
schwer (4)
Thorax
keine (1)
leicht  (2)
mittel (3)
schwer (4)
Abdomen
keine (1)
leicht  (2)
mittel (3)
schwer (4)
Wirbelsäule
keine (1)
leicht  (2)
mittel (3)
schwer (4)
Becken
keine (1)
leicht  (2)
mittel (3)
schwer (4)
Obere Extr.
keine (1)
leicht  (2)
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mittel (3)
schwer (4)
Untere Extr.
keine (1)
leicht  (2)
mittel (3)
schwer (4)
Weichteile
keine (1)
leicht  (2)
mittel (3)
schwer (4)
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Eligibility Parkinson's Disease
NCT02509325
Parkinson's KinetiGraph as Tool for DBS Eligibility
Assessment; ODM derived from:
https://clinicaltrials.gov/show/NCT02509325
All rights reserved. Please visit https://medical-data-
models.org/forms/15795
Eligibility Parkinson's Disease
NCT02509325
Inclusion Criteria
patients are diagnosed with pd.*
Yes
No
patients are presented to the clinical sites to
evaluate dbs candidacy or optimize their pd
treatment eventually with dbs therapy.*
Yes
No
patients are at least 18 years old.*
Yes
No
patients are able to provide written data release
consent as required by ec institutions or local law
and regulations.*
Yes
No
Exclusion Criteria
patients have restricted movement, e.g. bed
bound.*
Yes
No
patients operate heavy machinery for prolonged
periods.*
Yes
No
patients have serious medical conditions that
compromise safety or interfere with mobility in
addition to pd (e.g. arthritis and rheumatisms).*
Yes
No
patients have been already screened by stimulus
or earlystimulus questionnaires*
Yes
No
patients present no response to levodopa
medication or have atypical parkinsonism.*
Yes
No
patients have major medical or psychiatric illness
other than stable, treated depression or anxiety
that may jeopardize the patient's ability to give
informed consent, follow study requirements, or
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that may confound the patient's diagnosis or
assessments.*
Yes
No
patients have major neurological diagnoses other
than pd.*
Yes
No
patients are not capable of following the required
clinical instructions*
Yes
No
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Eligibility Patients Undergoing Open Resection
of Colorectal Tumours NCT02136277
Vascular Changes During Colorectal Surgery; ODM derived
from: https://clinicaltrials.gov/show/NCT02136277
All rights reserved. Please visit https://medical-data-
models.org/forms/15797
Eligibility Patients Undergoing Open
Resection of Colorectal Tumours
NCT02136277
Inclusion Criteria
aged 18 - 80 years*
Yes
No
confirmed colorectal cancer*
Yes
No
offered surgery by derbyshire colorectal
multidisciplinary team*
Yes
No
no metastatic disease*
Yes
No
able to consent in english by themselves*
Yes
No
Exclusion Criteria
metastatic disease*
Yes
No
oesophageal varices*
Yes
No
patients with recent acute coronary syndrome
(symptoms involving the heart) or unstable
ischaemic cardiac disease (reduced blood supply
to the heart);*
Yes
No
patients known to have right-to-left shunts
(abnormal movement of blood within the heart),
severe pulmonary hypertension (high blood
pressure in the pulmonary artery, the blood
vessel that leads from the heart to the lungs),
uncontrolled hypertension (high blood pressure)
or adult respiratory distress syndrome (severe
fluid build-up in both lungs);*
Yes
No
pregnant or breast-feeding women;*
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Yes
No
known sensitivity to sonovue;*
Yes
No
prolonged qt syndrome*
Yes
No
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FOLLOW UP EBMT Lymphoma
ODM form derived from 16pp General Info EBMT
Lymphoma 04Lym. please refer to:
http://www.ebmt.org/Contents/Data-
Management/Registrystructure/MED-
ABdatacollectionforms/Pages/MED-AB-data-collection-
forms.aspx
All rights reserved. Please visit https://medical-data-
models.org/forms/15798
FOLLOW UP EBMT Lymphoma
LYMPHOMA FOLLOW UP
Unique Identification Code (UIC) (if known)
Date of this report
Patient following national / international study /
trial
No (1)
Yes (2)
Not evaluated (3)
Unknown (4)
Name of study / trial
Hospital Unique Patient Number
First name(s)_surname(s)
Date of birth
Date of last HSCT for this patient
DATE OF LAST CONTACT OR DEATH
GRAFT VERSUS HOST DISEASE
(GvHD) SINCE LAST REPORT
ACUTE GRAFT VERSUS HOST DISEASE
(AGVHD)
Agvhd Grade 0 (0)
Agvhd Grade I (I)
Agvhd Grade Ii (II)
Agvhd Grade Iii (III)
Agvhd Grade Iv (IV)
Agvhd Present, Grade Unknown
(Present, grade unknown)
AGVHD present? Pleae indicate
New onset  (1)
Recurrent  (2)
Persistent (3)
Reason for aGvHD
DLI (DLI)
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Tapering (Tapering)
Unexplained (Unexplained)
Date onset of this episode (if new or recurrent)
yyyy/mm/dd
Acute graft versus host disease in skin
0 (1)
1 (2)
2 (3)
3 (4)
4 (5)
Not evaluated (6)
unknown (7)
Acute graft versus host disease in liver
0 (1)
1 (2)
2 (3)
3 (4)
4 (5)
Not evaluated (6)
unknown (7)
Acute graft versus host disease in intestine
0 (1)
1 (2)
2 (3)
3 (4)
4 (5)
Not evaluated (6)
unknown (7)
Resolution
No  (1)
Yes (2)
Date (3)
Date of resolution
yyyy/mm/dd
Chronic Graft versus Host Disease
No (No)
Present continously since last reported
episode (Present continously since last
reported episode)
Resolved (Resolved)
Yes (Yes)
Presence of cGVHD
No (1)
Yes, First Episode (2)
Yes, Recurrence (3)
Date of onset
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Date of onset
cGvHD grade
Limited (1)
Extensive (2)
Organs affected
Skin (1)
Gut (2)
Liver (3)
Mouth (4)
Eyes (5)
Lung (6)
Other, specify (7)
Unknown (8)
If resolved, specify the date of resolution:
OTHER COMPLICATIONS SINCE LAST
REPORT
Infection related complications
Yes
No
Bacteremia / fungemia / viremia / parasites
Date (Date)
Pathogen (Pathogen)
Use “unknown” if necessary (Use
“unknown” if necessary)
Septic shock
Pathogen (1)
Use “unknown” if necessary (2)
Date (3)
ARDS
Pathogen (1)
unknown (2)
Date (3)
Multiorgan failure due to infection
Pathogen (1)
Unknown (2)
Date (3)
Pneumonia
Pathogen (1)
unknown (2)
Date (3)
Hepatitis
Pathogen (1)
unknown (2)
Date (3)
CNS infection
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Pathogen (1)
unknown (2)
date (3)
Gut infection
Pathogen (1)
unknown (2)
date (3)
Skin infection
Pathogen (1)
unknown (2)
date (3)
Cystitis
Pathogen (1)
unknown (2)
date (3)
Other
Pathogen (1)
unknown (2)
date (3)
Non infection related complications
Yes
No
Idiopathic pneumonia syndrome
Date (Date)
No  (No )
Unknown (Unknown)
Yes (Yes)
VOD
No  (No )
Unknown (Unknown)
Yes (Yes)
Cataract
Cataract
No (No)
Unknown (Unknown)
Yes (Yes)
Haemorrhagic cystitis, non infectious
Haemorrhagic cystitis, non infectious
No  (No )
Unknown (Unknown)
Yes  (Yes )
ARDS, non infectious
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ARDS, non infectious
No (No)
Unknown (Unknown)
Yes (Yes)
Multiorgan failure, non infectious
Yes (1)
No (2)
Unknown (3)
HSCT-associated microangiopathy
HSCT-associated microangiopathy
No (No)
Unknown (Unknown)
Yes (Yes)
Renal failure requiring dialysis
Renal failure requiring dialysis
No (No)
Unknown (Unknown)
Yes (Yes)
Haemolytic anaemia due to blood group
Haemolytic anaemia due to blood group
No (No)
Unknown (Unknown)
Yes (Yes)
Aseptic bone necrosis
Aseptic bone necrosis
No (No)
Unknown (Unknown)
Yes (Yes)
Graft loss
No (No)
Not evaluated (Not evaluated)
Yes (Yes)
Overall chimaerism
Aplasia (Aplasia)
Autologous reconstitution (recipient >95
%) (Autologuos reconstitution (recipient
>)
Full (donor >95 %) (Full (donor >)
Mixed (partial) (Mixed (partial))
Not evaluated (Not evaluated)
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DATE(S) AND RESULTS OF ALL TESTS
DONE FOR ALL DONORS
Date of Test
Identification of donor or Cord Blood Unit given
by the centre
Number in the infusion order (if applicable)
......... (1)
N/A (2)
Cell type on which test was performed (% Donor
Cells):
BM
%
BM (1)
Other, specify (10)
PB mononuclear cells (PBMC) (2)
T-cell (3)
B-cells (4)
Red blood cells (5)
Monocytes (6)
PMNs (neutrophils) (7)
Lymphocytes, NOS (8)
Myeloid cells, NOS (9)
Test used
ABO group (ABO group)
Cytogenetic (Cytogenetic)
FISH (FISH)
Molecular (Molecular)
Other (Other)
unknown (unknown)
Test used:
If other, specify:
SECONDARY MALIGNANCY,
LYMPHOPROLIFERATIVE OR
MYELOPROLIFERATIVE Disease DIAGNOSED
No at date of this follow-up (No at date of
this follow-up)
Previously reported (Previously reported)
Yes, date of diagnosis (Yes, date of
diagnosis)
Diagnosis
No at date of this follow-up (5)
AML (AML)
Lymphoproliferative disorder
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(Lymphoproliferative disorder)
MDS (MDS)
Other (Other)
ADDITIONAL THERAPIES SINCE LAST
FOLLOW UP
Treatment given since last report
Yes
No
ADDITIONAL TREATMENT start date
Cellular therapy
No  (1)
Yes (Mark disease status before this
cellular therapy) (2)
Unknown (3)
Disease status before this cellular therapy
CR  (1)
Not in CR  (2)
Not evaluated (3)
Type of cells
Donor lymphocyte infusion (DLI) (1)
Mesenchymal cells (2)
Other (3)
Unknown (4)
Number of cells infused by type DLI only
CD 3+ (1)
Nucleated cells (2)
CD 34+ (3)
Total number of cells infused any non
DLI infusion (4)
Chronological number of this cell therapy for this
patient
Indication 
(check all that apply)
Loss/decreased chimaerism
(Loss/decreased chimaerism)
Mixed chimaerism (Mixed chimaerism)
Other (Other)
Planned/ protocol (Planned/ protocol)
Prophylactic (Prophylactic)
Treatment for disease (Treatment for
disease)
Treatment of GvHD (Treatment of GvHD)
Treatment PTLD, EBV, lymphoma
(Treatment PTLD, EBV, lymphoma)
Treatment viral infection (Treatment viral
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infection)
Number of 
Infusions 
(count only infusions that are part of same
regimen and given for the same indication)
Acute Graft versus Host Disease 
(after this infusion but before any further infusion/
transplant)
Maximum grade:
grade 0 (absent) (grade 0 (absent))
grade 1 (grade 1)
grade 2 (grade 2)
grade 3 (grade 3)
grade 4 (grade 4)
present, grade unknown (present, grade
unknown)
Disease treatment
No (1)
Yes: Planned (planned before HSCT took
place) (2)
Yes: Not planned (for
relapse/progression or persistent
disease) (3)
Unknown (4)
Chemo/drug/agent
Yes
No
Radiotherapy
yes no=no not known=not known (yes)
Other treatment
No (No)
Unknown (Unknown)
Yes (Yes)
FIRST EVIDENCE OF RELAPSE OR
PROGRESSION SINCE LAST HSCT
Relapse 
or Progression
Continous progression since transplant
(Continous progression since transplant)
No (No)
Previously reported (Previously reported)
Unknown (Unknown)
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Yes, date (Yes)
last disease status
Complete Remission (Complete
Remission)
Relapse (Relapse)
Has patient or partner become  pregnant after
this HSCT?
No (No)
Unknown (Unknown)
Yes (Yes)
Survival Status
alive (0)
dead (1)
If alive: Type of performance score used:
Karnofsky (Karnofsky)
Lansky (Lansky)
Not evaluated (Not evaluated)
Unknown (Unknown)
Score used
100 (Normal, NED) (1)
10 (Moribund) (10)
Not evaluated (11)
Unknown (12)
90 (Normal activity)  (2)
80 (Normal with effort) (3)
70 (Cares for self) (4)
60 (Requires occasional assistance) (5)
50 (Requires assistance) (6)
40 (Disabled) (7)
30 (Severely disabled) (8)
20 (Very sick) (9)
If dead, specify cause of death:
HSCT related cause  (HSCT related
cause )
Other (Other)
Relapse or progression (Relapse or
progression)
Secondary malignancy (including
lymphoproliferative disease) (Secondary
malignancy (including lymphoproliferative
disease))
Unknown  (Unknown )
GvHD
No  (No )
Unknown (Unknown)
Yes (Yes)
Interstitial Pneumonitis
No  (No )
Unknown (Unknown)
Yes (Yes)
Pulmonary toxicity
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No  (No )
Unknown (Unknown)
Yes (Yes)
Infection
No  (No )
Unknown (Unknown)
Yes (Yes)
Infection
bacterial (1)
viral (2)
fungal (3)
parasitic (4)
unknown (5)
Rejection / poor graft function
Yes  (1)
No (2)
Unknown (3)
Veno-Occlusive disease (VOD)
No  (No )
Unknown (Unknown)
Yes (Yes)
Haemorrhage
No  (No )
Unknown (Unknown)
Yes (Yes)
Cardiac toxicity
No  (No )
Unknown (Unknown)
Yes (Yes)
Central nervous system toxicity
No  (No )
Unknown (Unknown)
Yes (Yes)
Gastro intestinal toxicity
No  (No )
Unknown (Unknown)
Yes (Yes)
Skin toxicity
No  (No )
Unknown (Unknown)
Yes (Yes)
Renal failure
No  (No )
Unknown (Unknown)
Yes (Yes)
Multiple organ failure
No  (No )
Unknown (Unknown)
Yes (Yes)
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Other
Yes
No
ADDITIONAL NOTES IF APPLICABLE
Comments
IDENTIFICATION & SIGNATURE
11 / 11
FOLLOW UP EBMT Lymphoma
AID-Register (Kinderrheumatologie) NBO
-nicht bakterielle Osteomyelitis
Register für autoinflammatorische Erkrankungen
AID-Register (Kinderrheumatologie)(PD Dr. med. Elke
Lainka, Prof. Dr. med. Dirk Föll)
https://prst.gpoh.de/aid/formulare.asp
All rights reserved. Please visit https://medical-data-
models.org/forms/15799
AID-Register NBO -nicht bakterielle
Osteomyelitis
Zentrum
Ansprechpartner
E- Mail
Telefon
Datum der Diagnose
Zentrumsnummer
Patienten PID
Ergänzung zum:
Diagnoseblatt  (1)
Visitenblatt (2)
Nicht bakterielle Osteomyelitis
Knochenläsion
Ja
Nein
Knochenläsion(en) Anzahl
Knochenläsion(en) Lokalisation links
Kieferknochen (1)
Becken (10)
Füße (11)
Humerus (2)
Radius (3)
Ulna (4)
Femur (5)
Tibia (6)
Clavikula (7)
Sternum (8)
Rippen (9)
Knochenläsion(en) Lokalisation Wirbelsäule
cervikal  (1)
thorakal  (2)
lumbal (3)
Knochenläsion Lokalisation Wirbelsäule:
Nennung der betroffenen Wirbel
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Blutkultur
Ja
Nein
Blutkultur:falls ja,steril?
Ja
Nein
Blutkultur:falls ja,Keimnachweis
Mykobakterienkultur
Ja
Nein
Mykobakterienkultur falls ja,steril?
Ja
Nein
Mykobakterienkultur falls ja, Keimnachweis
Knochenbiopsie
Ja
Nein
Knochenbiopsie falls ja, steril?
Ja
Nein
Knochenbiopsie falls ja, Nachweis von
Lymphocyten (1)
Granulocyten (2)
Fibrose (3)
Andere (bitte genauer bezeichnen) (4)
Knochenbiopsie: falls "andere", bitte genauer
bezeichnen
Arthritis nahe der Lokalisiation der
Knochenläsion
Ja
Nein
NBO Bildgebung
Röntgen, lokal
Ja
Nein
Röntgen, lokal Ergebnis
positiv (1)
negativ (2)
Lokalisation
Osteolytisch/Sklerotisch (1)
Hyperostose  (2)
Periostitis (3)
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MRT, lokal
Ja
Nein
MRT, lokal Ergebnis
positiv (1)
negativ (2)
MRT, lokal Positiv in
T2  (1)
TIRM  (2)
STIR-Signal (3)
Kontrastmittelanreicherung
Ja
Nein
Parenchymbeteiligung
Ja
Nein
Ganzkörperszintigraphie
Ja
Nein
Ganzkörperszintigraphie:Anzahl der Läsionen
Ganzkörper MRT
Ja
Nein
Ganzkörper MRT:Anzahl der Läsionen
Ganzkörper MRT:Ergebnis
positiv (1)
negativ (2)
Ganzkörper MRT:Kontrastmittelanreicherung
Ja
Nein
Ganzkörper MRT:Parenchymbeteiligung
Ja
Nein
Knochenkomplikationen
Knochenhypertrophie (1)
Wirbelbruch (2)
Plattwirbel (3)
andere läsionsbedingte Frakturen (4)
Skoliose (5)
Kyphose (6)
Radiologischer Befund:
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AID-Register (Kinderrheumatologie)
Stammdaten
Register für autoinflammatorische Erkrankungen
AID-Register (Kinderrheumatologie)(PD Dr. med. Elke
Lainka, Prof. Dr. med. Dirk Föll)
https://prst.gpoh.de/aid/formulare.asp
All rights reserved. Please visit https://medical-data-
models.org/forms/15800
AID-Register Stammdaten
Zentrum
Ansprechpartner
E- Mail
Telefon
Ausfülldatum
Zentrumsnummer
Patienten PID
Kerndokumentations-ID
Kerndokumentation Zentrums Nr.
Patienten Stammdaten
Bestätigen Sie, dass die Diagnose des Patienten
in der Liste der relevanten Diagnosen des AID
Registers aufgeführt wird (FMF, TRAPS, CAPS,
HIDS, SJIA, PFAPA, NBO, uAID)
Ja
Nein
Einverständniserklärung des Patienten/der
Eltern/des gesetzl. Vertreters liegt vor
Ja
Nein
Geburtsmonat des Patienten
Geburtsjahr des Patienten
Geburtsland
Geschlecht
männlich (1)
weiblich (2)
Herkunftsland des Vaters
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Herkunftsland der Mutter
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Eligibility Peripheral Neuropathy
NCT02372149
IVIg for Demyelination in Diabetes Mellitus; ODM derived
from: https://clinicaltrials.gov/show/NCT02372149
All rights reserved. Please visit https://medical-data-
models.org/forms/15801
Eligibility Peripheral Neuropathy
NCT02372149
Inclusion Criteria
1. age ≥18 years.*
Yes
No
2. diabetes, as per american diabetes association
criteria.*
Yes
No
3. clinical evidence of polyneuropathy and ncs
shows 2 separate motor nerves (median, ulnar,
tibial, or peroneal) which meet criteria for
demyelination, defined as follows:*
Yes
No
1. conduction velocity <90% lower limit of normal
(lln), distal latency >110% upper limit of normal
(uln), or minimal f-wave latency >110% uln*
Yes
No
2. the changes are not exclusively due to median
neuropathy at the wrist, ulnar neuropathy at the
elbow, or peroneal neuropathy at the fibular
head.*
Yes
No
4. clinical suspicion of possible demyelinating
polyneuropathy (cidp).*
Yes
No
Exclusion Criteria
1. pregnant patients, or those of childbearing
potential not using contraception.*
Yes
No
2. patients <18 years of age.*
Yes
No
3. presence of an alternative etiology of
peripheral neuropathy, such as: hereditary
neuropathies (charcot marie-tooth disease); b-
vitamin deficiency- or excess-related neuropathy;
uremic neuropathy; neuropathy secondary to
monoclonal gammopathy; history of cancer- or
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chemotherapy-related neuropathy; other toxin
exposures; and alcoholic neuropathy.*
Yes
No
4. contraindication to ivig, including: history of
recurrent thrombosis, immunoglobulin a
deficiency, or severe hypersensitivity reaction to
ivig in past, renal failure, recurrent deep venous
thrombosis, pulmonary embolus, stroke, or
myocardial infarction.*
Yes
No
5. presence of serious or unstable medical
condition, which may preclude study completion
or lead to inability to tolerate ivig. this may include
active heart failure, uncontrolled hypertension, or
severe anemia, among other conditions.*
Yes
No
6. presence of concomitant neurological illness,
which may confound evaluation.*
Yes
No
7. fails or unable to provide informed consent.*
Yes
No
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AID-Register (Kinderrheumatologie)
Therapieblatt
Register für autoinflammatorische Erkrankungen
AID-Register (Kinderrheumatologie)(PD Dr. med. Elke
Lainka, Prof. Dr. med. Dirk Föll)
https://prst.gpoh.de/aid/formulare.asp
All rights reserved. Please visit https://medical-data-
models.org/forms/15802
AID-Register Therapieblatt
Zentrum
Ansprechpartner
E- Mail
Telefon
Zentrumsnummer
Patienten PID
Therapieblatt
NSAR
Acetylsalicylsäure (1)
Opioide (10)
nicht aufgeführt (11)
Diclofenac (2)
Naproxen (3)
Paracetamol (4)
alternative Medizin (5)
Ibuprofen (6)
Cox2 (7)
Hemmer (8)
Indometacin (9)
Colchizin
Ja
Nein
Dosis Colchizin
mg/Tag
Steroide
Ja
Nein
Steroide falls ja:
Prednison (1)
Prednisolon (2)
nicht aufgeführt (3)
Steroide maximale Dosis
mg/kg/d
Steroide Enddosis
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mg/kg/d
Steroide Dosisreduktion über wie viele Wochen?
Steroidpulstherapie (10-20mg/kg/d)
Ja
Nein
Biologicals
Etanercept (Enbrel) (1)
Infliximab (Remicade) (2)
Adalimumab (Humira) (3)
Anakinra (Kineret) (4)
Canakinumab (Ilaris) (5)
Rituximab (Mabthera) (6)
Tocilizumab (Roactemra) (7)
Abatacept (Orencia) (8)
Immunsuppressiva
Cyclosporin A… (1)
Tacrolimus (2)
Methotrexat (3)
Azathioprin (4)
Cyclosporin A spiegeladaptiert?
Ja
Nein
Cyclosporin A Höhe des Zielspiegels
ng/ml
Cyclosporin A Höhe der Dosis
mg/Tag
Tacrolimus spiegeladaptiert?
Ja
Nein
Tacrolimus Höhe des Zielspiegels
ng/ml
Tacrolimus Höhe der Dosis
mg/Tag
Methotrexat falls ja, in welcher Dosierung?
mg/m²/Woche
Azathioprin falls ja, in welcher Dosierung?
mg/kg/Tag
Weitere Therapien
Tonsillektomie
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Ja
Nein
Tonsillotomie
Ja
Nein
Antibiotika
Ja
Nein
HMGCoA Reduktase Hemmer
Ja
Nein
Stammzelltransplantation
Ja
Nein
Immunglobuline
Ja
Nein
Interferon alpha
Ja
Nein
Leflunomid (Arava)
Ja
Nein
Leukotrienantagonisten
Ja
Nein
Thalidomid
Ja
Nein
Sulfasalazin
Ja
Nein
Pamidronat
Ja
Nein
Bisphosphonate
Ja
Nein
Calcitonin
Ja
Nein
Notizen
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AID-Register (Kinderrheumatologie)
Anamnese
Register für autoinflammatorische Erkrankungen
AID-Register (Kinderrheumatologie)(PD Dr. med. Elke
Lainka, Prof. Dr. med. Dirk Föll)
https://prst.gpoh.de/aid/formulare.asp
All rights reserved. Please visit https://medical-data-
models.org/forms/15804
AID-Register  Anamnese
Zentrum
Patienten PID
Medikamente (aktuell)
Medikamente (aktuell)
Beschwerden
Beschwerden
Untersuchung
Augenarzt
Ja
Nein
Augenarzt Datum
Krankengymnastik
Ja
Nein
Ergotherapie
Ja
Nein
Körpergröße
cm
Körpergewicht
kg
Blutdruck
mmHg
Herzfrequenz
>= 0
bpm
Gelenke / Lokalisationen
Untersuchung
Arthalgie
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Ja
Nein
Kontrakturen
Ja
Nein
Funktionsdefizit
Ja
Nein
Myalgie
Ja
Nein
Tenosynovitis
Ja
Nein
Ärztliche Beurteilung: Wie aktiv ist die Krankheit
im Augenblick?
0 inaktiv (1)
9 (10)
10 hoch aktiv (11)
1 (2)
2 (3)
3 (4)
4 (5)
5 (6)
6 (7)
7 (8)
8 (9)
Beurteilung durch den Patienten: Wie aktiv ist die
Krankheit im Augenblick?
0 inaktiv (1)
9 (10)
10 hoch aktiv (11)
1 (2)
2 (3)
3 (4)
4 (5)
5 (6)
6 (7)
7 (8)
8 (9)
Procedere
Wiedervorstellungstermin
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AID-Register (Kinderrheumatologie) Anamnese
Eligibility Peritoneal Carcinomatosis
NCT02320448
Treating Peritoneal Carcinomatosis With PIPAC; ODM
derived from: https://clinicaltrials.gov/show/NCT02320448
All rights reserved. Please visit https://medical-data-
models.org/forms/15805
Eligibility Peritoneal Carcinomatosis
NCT02320448
Inclusion Criteria
clinical and radiological evidence of peritoneal
carcinomatosis.*
Yes
No
no indication for standard chemotherapy which
prolongs overall survival for at least three
months.*
Yes
No
performance status 0-2 and life expectancy of
more than 3 months.*
Yes
No
age > 18 years.*
Yes
No
written informed consent must be obtained
according to the local ethics committee
requirements.*
Yes
No
Exclusion Criteria
extraabdominal metastatic disease.*
Yes
No
symptomatic small bowel obstruction (total
parenteral nutrition, nasogastric tube).*
Yes
No
chemotherapy or surgery within the last four
weeks prior to the first pipac application.*
Yes
No
previous treatment with maximum cumulative
doses of doxorubicin, daunorubicin, epirubicin,
idarubicin, and/or other anthracyclines and
anthracenediones.*
Yes
No
a history of allergic reaction to cisplatin or other
platinum containing compounds or doxorubicin.*
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Yes
No
renal impairment, defined as gfr < 60 ml/min.*
Yes
No
myocardial insufficiency, defined as nyha class >
2.*
Yes
No
impaired liver function defined as bilirubin ≥ 1,5 x
unl (upper normal limit).*
Yes
No
inadequate haematological function defined as
anc ≤ 1.5 x 109/l and platelets ≤ 100 x 109/l.*
Yes
No
any other condition or therapy, which in the
investigator's opinion may pose a risk to the
patient or interfere with the study objectives.*
Yes
No
previous intraabdominal chemotherapy or
intraabdominal antibody therapy.*
Yes
No
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Eligibility Peritoneal Carcinomatosis NCT02320448
AID-Register (Kinderrheumatologie)
Anamnese vor Diagnose
Register für autoinflammatorische Erkrankungen
AID-Register (Kinderrheumatologie)(PD Dr. med. Elke
Lainka, Prof. Dr. med. Dirk Föll)
https://prst.gpoh.de/aid/formulare.asp
All rights reserved. Please visit https://medical-data-
models.org/forms/15806
AID-Register  Anamnese vor
Diagnose
Anamnese vor Diagnose
Datum der ersten Symptome
Betreuungsbeginn
Vorgeschichte
Bisherige Operationen (z.B. Appendektomie)
HLA-B27
Ja
Nein
ANA
Ja
Nein
Rheumafaktoren pos
Ja
Nein
BSG 1. Stunde
mm/h
CRP
md/dl
Biomarker S100 A12
ng/ml
Biomarker S100 A8/A9
ng/ml
Molekulargenetischer Befund
Dysmorphiezeichen
Ja
Nein
Dysmorphiezeichen
Psoriasis
Ja
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Nein
Psoriasis
Chonisch entzündliche Darmerkrankung
Ja
Nein
Chonisch entzündliche Darmerkrankung
Daktylitis
Ja
Nein
Daktylitis
Enthesitis
Ja
Nein
Enthesitis
Uveitis
Ja
Nein
Uveitis
Spätfolgen am Auge
Ja
Nein
Spätfolgen am Auge
Makrophagenaktivierungssyndrom
Ja
Nein
Makrophagenaktivierungssyndrom
Sonstiges
Herkunftsland des Vaters
Herkunftsland der Mutter
Konsanguinität
Ja
Nein
Konsanguinität Vater
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AID-Register (Kinderrheumatologie) Anamnese vor Diagnose
Konsanguinität Mutter
Konsanguinität Geschwister
Konsanguinität Geschwister
Konsanguinität Geschwister
Konsanguinität Geschwister
Konsanguinität Geschwister
Konsanguinität Geschwister
Erläuterungen zur Familienanamnese
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AID-Register (Kinderrheumatologie) Anamnese vor Diagnose
Eligibility Persistent Atrial Fibrillation
NCT02184013
Correlation of the Arrhythmia Mechanism and Substrate to
Ablate Persistent Atrial Fibrillation Study; ODM derived
from: https://clinicaltrials.gov/show/NCT02184013
All rights reserved. Please visit https://medical-data-
models.org/forms/15807
Eligibility Persistent Atrial Fibrillation
NCT02184013
Inclusion Criteria
age ≥18 years and ≤ 80 years;*
Yes
No
symptomatic persistent af and clinically indicated
for af catheter ablation*
Yes
No
at least one episode of af lasting more than 7
days, documented on 12-lead ecg, holter monitor,
2-week loop monitor or trans-telephonic monitor
(ttm) within 12 months of enrollment in the study*
Yes
No
able to provide informed consent.*
Yes
No
Exclusion Criteria
history of previous catheter or surgical ablation
for af*
Yes
No
presence of intracardiac thrombus*
Yes
No
contraindication to systemic oral anticoagulation
therapy*
Yes
No
subjects with reversible causes of af*
Yes
No
antero-posterior left atrial dimension > 60 mm on
echocardiography*
Yes
No
severe valvular disease (mitral/aortic stenosis or
regurgitation);*
Yes
No
1 / 2
subjects that are pregnant or breastfeeding;*
Yes
No
chronic kidney disease and creatinine clearance
<50ml/min.*
Yes
No
contraindication to mri imaging (e.g. permanent
pacemaker, metallic implants, etc)*
Yes
No
2 / 2
Eligibility Persistent Atrial Fibrillation NCT02184013
Eligibility Persistent Fetal Circulation
Syndrome NCT01891500
Early iNO for Oxidative Stress, Vascular Tone and
Inflammation in Babies With Hypoxic Respiratory Failure;
ODM derived from:
https://clinicaltrials.gov/show/NCT01891500
All rights reserved. Please visit https://medical-data-
models.org/forms/15808
Eligibility Persistent Fetal Circulation
Syndrome NCT01891500
Inclusion Criteria
gestational age ≥ 35 weeks gestation*
Yes
No
age of life ≤ 48 hours*
Yes
No
diagnosis of hypoxic respiratory failure (hrf) as
defined by a post-ductal sao2 ≤90% in ≥50%
oxygen with a peep of ≥ 6cm or an oxygenation
index (oi) ≥ 10 but ≤ 15 when mean airway
pressure and pao2 are known.*
Yes
No
Exclusion Criteria
gestational age < 35 weeks gestation.*
Yes
No
post-natal age > 48 hours.*
Yes
No
previous treatment with 100% oxygen for longer
than 4 hours.*
Yes
No
confirmed congenital diaphragmatic hernia.*
Yes
No
suspected or confirmed congenital airway or
pulmonary anomaly.*
Yes
No
suspected or confirmed chromosomal anomaly or
genetic aberration, with the exception of patients
with trisomy 21 who do not have complex
congenital heart disease.*
Yes
No
infants with pneumothorax as the primary cause
of their hrf.*
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Yes
No
infants with confirmed complex congenital heart
disease.*
Yes
No
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Eligibility Persistent Fetal Circulation Syndrome NCT01891500
Eligibility Postpartum Depression
NCT02191423
Oxytocin and Dyadic Psychotherapy in the Treatment of
Post Partum Depression; ODM derived from:
https://clinicaltrials.gov/show/NCT02191423
All rights reserved. Please visit https://medical-data-
models.org/forms/15809
Eligibility Postpartum Depression
NCT02191423
Inclusion Criteria
women of all ages who are 3 to 8 months post-
partum.*
Yes
No
women who have completed a minimum of 12
years of education.*
Yes
No
women who are willing and able to provide
informed consent for their participation and after
the study has been explained. infant participation
will be allowed after consent has been obtained
from mothers.*
Yes
No
current dsm-iv-tr diagnosis of ppd disorder as
confirmed by scid (administered as part of the
study of protocol number ppd1, proposed to the
helsinki committee on june 2014).*
Yes
No
symptoms: bdi total score >9, epds total score
>10*
Yes
No
treatment with antidepressants will be allowed
provided that patients have been on the
medication for at least 4 weeks prior to entry into
the pre-treatment assessment phase of the
study.*
Yes
No
Exclusion Criteria
unwilling or unable, in the opinion of the
investigator, to comply with study instructions.*
Yes
No
pregnant women.*
Yes
No
clinically significant medical disease (malignancy,
poorly controlled diabetes, active ischemic
1 / 2
cardiac disease, or cardiomyopathy, serious
pulmonary disease, kidney disease, impaired
liver functioning).*
Yes
No
women with significant risk of committing suicide
or harming others in the opinion of the
psychiatrist.*
Yes
No
women with a current dsm-iv-tr substance or
alcohol abuse. however, patients with a history of
and/or current recreational use of cannabinoids
or alcohol, and/or patients who smoke cigarettes
can be included.*
Yes
No
women who suffers from depression due to
physical condition.*
Yes
No
women who suffers from severe major
depression (madras>30)*
Yes
No
women who suffers from chronic depression
(over 6 months)*
Yes
No
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Eligibility Postpartum Depression NCT02191423
Visit 9 (Week 60): Vital Signs, Study Drug accountability BG00012 Monotherapy
Safety and Efficacy Extension Study in Multiple Sclerosis (MS) (ENDORSE)
NCT00835770
The primary objective of this study is to evaluate the long-
term safety profile of BG00012 (dimethyl fumarate).
Secondary objectives of this study are to evaluate the long-
term efficacy of BG00012 using clinical endpoints and
disability progression, to evaluate further the long-term
effects of BG00012 on multiple sclerosis (MS) brain lesions
on magnetic resonance imaging (MRI) scans in participants
who had MRI scans as part of Studies 109MS301
(NCT00420212) and 109MS302 (NCT00451451) and to
evaluate the long-term effects of BG00012 on health
economics assessments and the visual function test.
NCT00835770
Part: Visit 9 (Week 60)
All rights reserved. Please visit https://medical-data-
models.org/forms/15810
Visit 9 (Week 60): Vital Signs, Study
Drug accountability BG00012
Monotherapy Safety and Efficacy
Extension Study in Multiple Sclerosis
(MS) (ENDORSE) NCT00835770
Subject Identification
Number of Facility
Subject number
Subject Initials
Vital Signs
Date of examination
Blood Pressure
Pulse
Temperature
Study Drug Accountability
date of first dose
Number of capsules not taken since previous visit
to this visit
Was there a protocol-defined dose
reduction/interruption since the previous visit?
Yes
No
1 / 1
Visit 10 (Week 72): Vital Signs/Physical Examination BG00012 Monotherapy Safety
and Efficacy Extension Study in Multiple Sclerosis (MS) (ENDORSE)
NCT00835770
The primary objective of this study is to evaluate the long-
term safety profile of BG00012 (dimethyl fumarate).
Secondary objectives of this study are to evaluate the long-
term efficacy of BG00012 using clinical endpoints and
disability progression, to evaluate further the long-term
effects of BG00012 on multiple sclerosis (MS) brain lesions
on magnetic resonance imaging (MRI) scans in participants
who had MRI scans as part of Studies 109MS301
(NCT00420212) and 109MS302 (NCT00451451) and to
evaluate the long-term effects of BG00012 on health
economics assessments and the visual function test.
NCT00835770 
Part: Visit 10 (Week 72)
All rights reserved. Please visit https://medical-data-
models.org/forms/15811
Visit 10 (Week 72): Vital
Signs/Physical Examination
BG00012 Monotherapy Safety and
Efficacy Extension Study in Multiple
Sclerosis (MS) (ENDORSE)
NCT00835770
Subject Identification
Number of Facility
Subject number
Subject Initials
Vital Signs
Date of examination
Blood Pressure
Pulse
Temperature
Weight
Physical examination
Body System
Skin (1)
Rectal  (10)
Neurological  (11)
Extremities/Joints (12)
HEENT  (2)
Lymph nodes (3)
Neck and Thyroid  (4)
Breasts (5)
Chest/Lungs (6)
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Heart  (7)
Vascular (8)
Abdomen (9)
Examination Status
Not done (1)
Normal (2)
Abnormal (please specify) (3)
Abnormal examination findings
EDSS Evaluation
Date of Evaluation
Functional System Scores
Visual
Brinstem
Pyramidal
Cerebellar
Sensory
Bowel or Bladder
Cerebral
Additional and Results
Actual Distance Walked
<100 metres (<100 metres)
>100 metres and <200 metres (>100
metres and <200 metres)
>200 metres and <300 metres (>200
metres and <300 metres)
>300 metres and <500 metres (>300
metres and <500 metres)
>500 metres (>500 metres)
Actual Distance Walked
<100 metres (1)
>100 metres and <200 metres (2)
>200 metres and <300 metres (3)
>300 metres and <500 metres (4)
>500 metres (5)
EDSS Score
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Visit 10 (Week 72): Vital Signs/Physical Examination BG00012 Monotherapy Safety
and Efficacy Extension Study in Multiple Sclerosis (MS) (ENDORSE)
NCT00835770
Name of Neurologist
Visual Function Test
Date of Evaluation
Contrast Sensitivity Evaluation Binocular
100% Chart, Total # Correct
2,5% Chart, Total # Correct
1,25% Chart, Total # Correct
Snellen visual acuity equivalent
Study Drug Accountability
date of first dose
Number of capsules not taken since previous visit
to this visit
Was there a protocol-defined dose
reduction/interruption since the previous visit?
Yes
No
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Visit 10 (Week 72): Vital Signs/Physical Examination BG00012 Monotherapy Safety
and Efficacy Extension Study in Multiple Sclerosis (MS) (ENDORSE)
NCT00835770
Visit 11 (Week 84): Vital Signs, Study Drug accountability BG00012 Monotherapy
Safety and Efficacy Extension Study in Multiple Sclerosis (MS) (ENDORSE)
NCT00835770
The primary objective of this study is to evaluate the long-
term safety profile of BG00012 (dimethyl fumarate).
Secondary objectives of this study are to evaluate the long-
term efficacy of BG00012 using clinical endpoints and
disability progression, to evaluate further the long-term
effects of BG00012 on multiple sclerosis (MS) brain lesions
on magnetic resonance imaging (MRI) scans in participants
who had MRI scans as part of Studies 109MS301
(NCT00420212) and 109MS302 (NCT00451451) and to
evaluate the long-term effects of BG00012 on health
economics assessments and the visual function test.
NCT00835770
Part: Visit 11 (Week 84)
All rights reserved. Please visit https://medical-data-
models.org/forms/15813
Visit 11 (Week 84): Vital Signs,
Study Drug accountability BG00012
Monotherapy Safety and Efficacy
Extension Study in Multiple Sclerosis
(MS) (ENDORSE) NCT00835770
Subject Identification
Number of Facility
Subject number
Subject Initials
Vital Signs
Date of examination
Blood Pressure
Pulse
Temperature
Study Drug Accountability
date of first dose
Number of capsules not taken since previous visit
to this visit
Was there a protocol-defined dose
reduction/interruption since the previous visit?
Yes
No
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End of Study: Vital Signs BG00012 Monotherapy Safety and Efficacy
Extension Study in Multiple Sclerosis (MS) (ENDORSE) NCT00835770
The primary objective of this study is to evaluate the long-
term safety profile of BG00012 (dimethyl fumarate).
Secondary objectives of this study are to evaluate the long-
term efficacy of BG00012 using clinical endpoints and
disability progression, to evaluate further the long-term
effects of BG00012 on multiple sclerosis (MS) brain lesions
on magnetic resonance imaging (MRI) scans in participants
who had MRI scans as part of Studies 109MS301
(NCT00420212) and 109MS302 (NCT00451451) and to
evaluate the long-term effects of BG00012 on health
economics assessments and the visual function test.
NCT00835770
Part: End of Study
All rights reserved. Please visit https://medical-data-
models.org/forms/15815
End of Study: Vital Signs BG00012
Monotherapy Safety and Efficacy
Extension Study in Multiple Sclerosis
(MS) (ENDORSE) NCT00835770
Subject Identification
Number of Facility
Subject number
Subject Initials
Vital Signs
Date of examination
Blood Pressure
Pulse
Temperature
End of Study Survey
Date of last dose
End of Study Date
Did the subject complete the study?
Yes
No
Primary reason for not completing treatment
(mark one)
MS Relapse (1)
MS Progression (2)
Adverse Event (3)
Lost to follow up (4)
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Consent withdrawn (5)
Investigator decision (6)
Subject non-compliance (7)
Death (8)
Other (9)
Primary reason for not completing treatment,
description
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End of Study: Vital Signs BG00012 Monotherapy Safety and Efficacy
Extension Study in Multiple Sclerosis (MS) (ENDORSE) NCT00835770
Eligibility Precursor Cell Lymphoblastic
Leukemia-Lymphoma NCT02428517
Allogeneic Hematopoietic Cell Transplantation for Adult
Acute Lymphoblastic Leukemia (2015); ODM derived from:
https://clinicaltrials.gov/show/NCT02428517
All rights reserved. Please visit https://medical-data-
models.org/forms/15817
Eligibility Precursor Cell
Lymphoblastic Leukemia-Lymphoma
NCT02428517
Inclusion Criteria
patients who has been previously diagnosed as
one of the following disease;*
Yes
No
acute lymphoblastic leukemia*
Yes
No
biphenotypic acute leukemia with philadelphia-
positive chromosome or gene translocation*
Yes
No
patients whose disease status is one of the
following;*
Yes
No
first hematologic complete remission (hcr1)*
Yes
No
second hematologic complete remission (hcr2)*
Yes
No
15 years of age and over.*
Yes
No
with a suitable donor (matched sibling, well-
matched unrelated, partially-matched unrelated,
and haploidentical familial donor)*
Yes
No
adequate cardiac function (ef>45% via cardiac
scan or echocg)*
Yes
No
european clinical oncology group (ecog)
performance status ≥grade 2 or karnofsky scale
>60% at the time of screening*
Yes
No
all patients give written informed consent
according to guidelines at institution's committee
1 / 2
on human research.*
Yes
No
Exclusion Criteria
acute lymphoblastic leukemia l3 type (burkitt
leukemia/lymphoma)*
Yes
No
biphenotypic acute leukemia without bcr-abl1
translocation*
Yes
No
lymphoblastic lymphoma (bone marrow blast
count is below 20% of mononuclear cells of bone
marrow aspirate)*
Yes
No
patients with psychiatric disorder or mental
deficiency severe as to make compliance with the
treatment unlike, and making informed consent
impossible*
Yes
No
nursing women, pregnant women, women of
childbearing potential who do not want adequate
contraception*
Yes
No
male patient who reject the methods of avoiding
pregnancy via methods such as abstinence,
barrier method (condom etc).*
Yes
No
patients with a diagnosis of prior malignancy
(including hematologic malignancies such as
acute leukemia, lymphoma, multiple myeloma,
and myelodysplastic syndrome, etc) unless
disease-free for at least 5 years following therapy
with curative intent (except curatively treated
nonmelanoma skin cancer, in situ carcinoma, or
cervical intraepithelial neoplasia)*
Yes
No
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Eligibility Precursor Cell Lymphoblastic Leukemia-Lymphoma
NCT02428517
EBMT Multiple Myeloma GENERAL
INFORMATION
ODM form derived from 16pp EBMT Multiple Myeloma
10PCD. please refer to:
http://www.ebmt.org/Contents/Data-
Management/Registrystructure/MED-
ABdatacollectionforms/Pages/MED-AB-data-collection-
forms.aspx
All rights reserved. Please visit https://medical-data-
models.org/forms/15818
EBMT Multiple Myeloma GENERAL
INFORMATION
GENERAL INFORMATION, Team
EBMT Centre Identification Code (CIC)
Name of the hospital
Unit
Name of contact person
Telephone number of contact person
Fax #
E-mail
Date of this report
Patient following national / international study /
trial
No (1)
Yes (2)
Not evaluated (3)
Unknown (4)
Name of study trial
PATIENT
Unique Identification Code (UIC)
Hospital Unique Patient Number or Code
Initials
Date of Birth
Sex:
Female (Female)
Male (Male)
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ABO Group
Rh factor
Absent  (Absent )
Not evaluated (Not evaluated)
Present (Present)
DISEASE
Date of Diagnosis
Primary Disease Diagnosis
Acute Leukaemia (Acute Leukaemia)
Acute Lymphoblastic Leukaemia (ALL)
(Acute Lymphoblastic Leukaemia (ALL))
Acute Myelogenous Leukaemia (AML)
(Acute Myelogenous Leukaemia (AML))
Autoimmune disease (Autoimmune
disease)
Bone marrow failure including Aplastic
anaemia (Bone marrow failure including
Aplastic anaemia)
Chronic Leukaemia (Chronic Leukaemia)
Chronic Lymphocytic Leukaemia
(Chronic Lymphocytic Leukaemia)
Chronic Myeloid Leukaemia (CML)
(Chronic Myeloid Leukaemia (CML))
Haemoglobinopathy
(Haemoglobinopathiy)
Histiocytic disorders (Histiocytic
disorders)
Hodgkin´s Disease (Hodgkin´s Disease)
Inherited disorders (Inherited disorders)
Juvenile Idiopathic Arthritis (Juvenile
Idiopathic Arthritis)
Lymphoma (Lymphoma)
MD/ MPN (MD/ MPN)
MDS (MDS)
Metabolic disorders (Metabolic
disorders)
Multiple Sclerosis (Multiple Sclerosis)
Myelodysplastic syndromes
(Myelodysplastic syndromes)
Myeloma/ Plasma cell disorder
(Myeloma/ Plasma cell disorder)
Myeloproliferative neoplasm
(Myeloproliferative neoplasm)
Non Hodgkin (Non Hodgkin)
Other diagnosis (Other diagnosis)
Primary immune deficiencies (Primary
immune deficiencies)
Secondary Acute Leukaemia (do not use
if transformed from MDS/MPN)
(Secondary Acute Leukaemia (do not
use if transformed from MDS/MPN))
Solid Tumour (Solid Tumour)
Systemic Lupus (Systemic Lupus)
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EBMT Multiple Myeloma GENERAL INFORMATION
Systemic Sclerosis (Systemic Sclerosis)
Non infection related complications
Yes
No
PLASMA CELL DISORDERS
(INCLUDING MULTIPLE MYELOMA)
Has the information requested in this section
been submitted with a previous HSCT registration
for this patient?
Yes: go to page 2, Pre HSCT Treatment
(1)
No: proceed with this section (2)
SUBCLASSIFICATION
Multiple myeloma (1)
Plasma Cell Leukaemia (2)
Solitary plasmacytoma of bone (3)
POEMS (4)
Monoclonal light and heavy chain
deposition disease (LCDD/HCDD) (5)
Other (6)
Heavy chain and light chain
IgA (IgA)
IgD (IgD)
IgE (IgE)
IgG (IgG)
IgM (IgM)
Kappa (Kappa)
Lambda (Lambda)
Light chain only
Kappa (1)
Lambda (2)
STAGE AT DIAGNOSIS
I (I)
II (II)
III (III)
STAGE AT DIAGNOSIS: ISS Stage
1 (1)
2 (2)
3 (3)
Chromosome analysis
Normal (1)
Abnormal (2)
Not done or failed (3)
Unknown (4)
Number of metaphases with anomalies:
Number of metaphases examined
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EBMT Multiple Myeloma GENERAL INFORMATION
IF ABNORMAL, INDICATE ABNORMALITIES
FOUND
Del 13q14 (1)
t(11;14) (2)
abn 17q (3)
17p del (4)
t(4:14) (5)
t(14:16) (6)
1q amplification (7)
c-myc (8)
Other, specify (9)
IF ABNORMAL, INDICATE ABNORMALITIES
FOUND
Molecular analysis
Done but failed (1)
Done, successful (2)
Not evaluated (3)
Unknown (4)
CLINICAL AND LABORATORY DATA
Hb (g/dl)  (1)
Serum creatinine (ymol/L) (2)
Serum calcium (mmol/L) (3)
Serum albumin (g/L) (4)
BM aspirate: % plasmacytosis (5)
BM trephine: % plasmacytosis (6)
Monoclonal Ig in serum (g/L) (7)
Monoclonal Ig in urine (g/24 h) (8)
Serum beta-2 microglobulin (mg/L) (9)
Lytic lesions
Normal (1)
Minor (2)
Major (3)
Not evaluated (4)
Extramedullary involvement
No (1)
Yes (2)
Unknown (3)
if yes, please specify location
PRE-HSCT TREATMENT
Was the patient treated before the HSCT
procedure?
No (proceed to `Date of HSCT`) (No
(proceed to `Date of HSCT`))
Unknown (Unknown)
Yes (Yes)
Sequential number of this treatment
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EBMT Multiple Myeloma GENERAL INFORMATION
Modality Chemo/Drugs
Yes
No
Modality Chemo/Drugs regimen
Modality Radiotherapy
Yes
No
Response
sCR (0)
CR (1)
vgPR (2)
PR (3)
Stable disease (5)
Progression (6)
Not evaluated (7)
Unknown (8)
HSCT
Date of HSCT
HSCT Type
Allogenic (Allogenic)
Autologous (Autologuos)
Autologous Date of 1st collection or pheresis
STATUS OF DISEASE AT COLLECTION
STATUS OF DISEASE AT COLLECTION
Stringent complete remission (sCR) (1)
Complete remission (CR) (2)
Very good PR (VGPR) (3)
PR (4)
Relapse from CR (5)
Stable disease (no change, includes old
MR) (6)
Progression (7)
Unknown (8)
If sCR or CR: NUMBER OF THIS COMPLETE
REMISSION
1st  (1st )
2nd (2nd)
3rd or higher (3rd or higher)
If VGPR or PR: NUMBER OF THIS PARTIAL
REMISSION
1st  (1st )
2nd (2nd)
3rd or higher (3rd or higher)
NUMBER OF THIS RELAPSE
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1st  (1st )
2nd (2nd)
3rd or higher (3rd or higher)
Plateau
no (1)
yes (2)
unknown (3)
CLINICAL AND LABORATORY DATA
Hb (1)
Immunofixation of urine (10)
Serum beta-2 microglobulin (11)
Serum creatinine (2)
Serum calcium (3)
Serum albumin (4)
bone marrow aspirate (5)
bone marrow trephine (6)
Monoclonal Ig in serum (7)
Immunofixation of serum (8)
Monoclonal Ig in urine (9)
Lytic lesions
Normal (1)
Minor (2)
Major (3)
Not evaluated (4)
ADDITIONAL TREATMENT POST-HSCT
Additional Disease Treatment
No (No)
Unknown (Unknown)
Yes (Yes)
ADDITIONAL DISEASE TREATMENT, specify:
Planned (planned before HSCT took
place) (1)
Not planned (for relapse/progression or
persistent disease), Date started (2)
Chemo/drug/agent
Other (Other)
Thalidomide (Thalidomide)
Unknown (Unknown)
Chemo/drug/agent, if other, please specify
Radiotherapy
No (1)
Yes (2)
Unknown (3)
If additional treatment:
Other treatment
No (No)
Unknown (Unknown)
Yes (Yes)
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EBMT Multiple Myeloma GENERAL INFORMATION
STATUS OF DISEASE AT 100 DAYS
AFTER HSCT
BEST RESPONSE TO HSCT AT 100 DAYS
Stringent complete remission (sCR) (1)
Complete remission (CR) (2)
Very good PR (VGPR) (3)
PR (4)
Stable disease (no change, includes old
MR) (5)
Progression (6)
Unknown (7)
If sCR or CR: NUMBER OF THIS COMPLETE
REMISSION
1st  (1st )
2nd (2nd)
3rd or higher (3rd or higher)
If VGPR or PR: NUMBER OF THIS PARTIAL
REMISSION
1st  (1st )
2nd (2nd)
3rd or higher (3rd or higher)
If complete response: date of CR
yyyy/mm/dd
Otherwise: date of evaluation
Plateau
No (1)
Yes (2)
Unknown (3)
FORMS TO BE FILLED IN
Type of Transplant
ALLOgraft or Syngeneic graft (proceed to
Allograft form) (ALLOgraft or Syngeneic
graft (proceed to Allograft form))
AUTOgraft (proceed to Autograft form)
(AUTOgraft (proceed to Autograft form))
Other (contact the EBMT Central
Registry for instructions) (Other (contact
the EBMT Central Registry for
instructions))
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NINDS CDE Pregnancy Outcome
Headache
NINDS Common Data Elements (Pregnancy Outcome;
Headache) Used from the National Institute of Neurological
Disorders and Stroke Common Data Elements
(https://www.commondataelements.ninds.nih.gov/)
References: Grinnon ST, Miller K, Marler JR, Lu Y, Stout A,
Odenkirchen J, Kunitz S. National Institute of Neurological
Disorders and Stroke Common Data Element Project -
approach and methods. Clin Trials. 2012;9(3):322-9.
All rights reserved. Please visit https://medical-data-
models.org/forms/15819
Pregnancy Outcome
Demographics
Study ID
Study site name
Subject ID
Pregnancy History
Date pregnancy outcome obtained (m
m/dd/yyyy):
Was the outcome of the participant’s/subject’s
most recent pregnancy a live born infant?
Yes (skip to "Delivery type") (1)
No (Complete a-c only) (2)
Unknown (Stop,you are finished) (3)
Pregnancy outcome
Outcome Date
Was the fetus normal?
Yes  (1)
No (describe) (2)
Unknown (3)
Was the fetus normal? If no, please describe
Delivery type
Spontaneous (1)
Induced; specify reason (2)
Delivery type Induced; specify reason (Choose all
that apply)
Hemorrhage and Placental
Complications (1)
Unknown (10)
Hypertension, Preeclampsia or
Eclampsia (2)
Rupture of Membranes-Premature,
Prolonged (3)
Maternal Conditions Complicating
1 / 4
Pregnancy/Delivery (4)
Fetal Conditions Complicating
Pregnancy/Delivery (5)
Malposition and Malpresentation of
Fetus (6)
Late Pregnancy (7)
Prior Uterine Surgery (8)
Other, specify: (9)
Delivery type Induced; Other, specify
Delivery route
Vaginal (1)
Cesarean section please complete the
following (2)
Unknown (3)
Delivery route Cesarean section reason
Delivery route Cesarean section timing
Emergency (1)
Elective (2)
Delivery modality type
Breech (1)
Cephalic (2)
Unknown (3)
Did the participant/subject experience any
complications during labor/delivery?
Yes (1)
No (2)
Unknown (3)
Did the participant/subject experience any
complications during labor/delivery? If yes,
please specify
Did the participant/subject require tocolytic
agents during preterm labor?
Yes (1)
No (2)
Unknown (3)
Did the participant/subject require tocolytic
agents during preterm labor? If yes, please
specify
Details of Most Recent Live Birth
Birth Date
Birth sex
Male  (1)
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Female  (2)
Unknown (3)
Birth weight
Please specify units used for birth weight
ounces  (1)
grams (2)
Birth length
Please specify units used for birth length
inches (1)
cm (2)
Was the child delivered full-term
Yes (1)
No (2)
Unknown (3)
Indicate gestational age GA (weeks):
APGAR 5 Minute score
0 (0)
1 (1)
10 (10)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
7 (7)
8 (8)
9 (9)
APGAR 10 Minute score
0 (0)
1 (1)
10 (10)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
7 (7)
8 (8)
9 (9)
Mother’s weight at the time of birth
Please specify units used for body weight
pounds (1)
kilograms (2)
Any abnormal fetal diagnostic tests performed
during pregnancy?
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Yes (1)
No (2)
Unknown (3)
Any abnormal fetal diagnostic tests? If yes please
fill in the dates of testing and the test results
Were there any congenital anomalies?
Yes (1)
No (2)
Unknown (3)
Were there any congenital anomalies?If Yes,
specify
Were there other newborn complications?
Yes (1)
No (2)
Unknown (3)
Were there other newborn complications? If Yes,
specify
Did the newborn experience any abnormalities of
placenta or umbilical cord?
Yes (1)
No (2)
Unknown (3)
Did the newborn experience any abnormalities of
placenta or umbilical cord? If Yes, specify
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Eligibility Primary CNS Lymphoma.
NCT02313389
Maintenance Treatment Versus Observation in Elderly
Patients With PCNS Lymphoma; ODM derived from:
https://clinicaltrials.gov/show/NCT02313389
All rights reserved. Please visit https://medical-data-
models.org/forms/15820
Eligibility Primary CNS Lymphoma.
NCT02313389
Criteria
newly diagnosed primary cerebral lymphoma*
Yes
No
age ≥60 years*
Yes
No
pathology proven diagnosis or positive cytology
of the csf or vitreous*
Yes
No
karnofsky performance status ≥40*
Yes
No
no evidence of systemic nhl (body ct scan, bone
marrow biopsy)*
Yes
No
adequate haematological, renal and hepatic
function*
Yes
No
calculated creatinine clearance > 40 ml/min*
Yes
No
at randomization*
Yes
No
complete response on mri after induction
chemotherapy according to the ipcg criteria*
Yes
No
karnofsky performance status ≥40*
Yes
No
adequate haematological, renal and hepatic
function*
Yes
No
Exclusion Criteria
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positive hiv serology*
Yes
No
preexisting immunodeficiency (organ transplant
recipient)*
Yes
No
prior treatment for pcnsl*
Yes
No
isolated primary intra-ocular lymphoma*
Yes
No
low grade lymphoma*
Yes
No
any other active primary malignancy*
Yes
No
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NINDS CDE Pregnancy Information
Headache
NINDS Common Data Elements (Pregnancy Information;
Headache) Used from the National Institute of Neurological
Disorders and Stroke Common Data Elements
(https://www.commondataelements.ninds.nih.gov/)
References: Grinnon ST, Miller K, Marler JR, Lu Y, Stout A,
Odenkirchen J, Kunitz S. National Institute of Neurological
Disorders and Stroke Common Data Element Project -
approach and methods. Clin Trials. 2012;9(3):322-9.
All rights reserved. Please visit https://medical-data-
models.org/forms/15821
Pregnancy Information
Demographics
Study ID
Study site name
Subject ID
Pregnancy Information
Date pregnancy information obtained (m
m/dd/yyyy):
Is the participant/subject pregnant?
Yes	 (1)
No (Skip to Q8)	 (2)
Unknown (Skip to Q8) (3)
Current Pregnancy
Was birth control being used?
Yes	 (1)
No	 (2)
Unknown (3)
Was birth control being used? If Yes, indicate all
forms of contraception used (choose all that
apply):
Oral contraceptives–combined pill (“the
pill”) (1)
Oral contraceptives–progestin-only pill
(“mini-pill”) (2)
Transdermal patch (i.e., Ortho Evra) (3)
Shot/injection (i.e., Depo-Provera) (4)
Vaginal ring (i.e., NuvaRing) (5)
Implantable devices with hormone (i.e.,
ParaGuard, Mirena) (6)
Abstinence (7)
None of these (8)
Last date birth control used (m m/dd/yyyy):
Date of last menstrual period
Date pregnancy confirmed
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Estimated delivery date (EDD) (m m/dd/yyyy):
Was the EDD based on an ultrasound?
Yes	 (1)
No	 (2)
Unknown (3)
Was prenatal testing performed?
Yes	 (1)
No	 (2)
Unknown (3)
Was prenatal testing performed?If Yes, please
complete the following questions regarding
prenatal testing
Ultrasound (1)
Other, specify (10)
Amniocentesis (2)
Screening for neural tube defects (3)
Screening for gestational diabetes before
or at 28 weeks (4)
Screening for asymptomatic bacteriuria
before or at 16 weeks gestation (5)
Hepatitis B specific antigen screening at
first visit (6)
HIV screening at first visit (7)
Group B streptococcus screening (GBS)
at 35 to 37 weeks (8)
Maternal serum alpha fetoprotein (9)
Was prenatal testing performed?If Other, specify
Was prenatal testing performed?If Yes, please
specify the date of testing
Was prenatal testing performed?If Yes, please
specify the result of testing
Was prenatal testing performed? Comments
Did/Has the participant/subject experienced any
complications during this pregnancy?
Yes	 (1)
No	 (2)
Unknown (3)
Did/Has the participant/subject experienced any
complications during this pregnancy? If Yes,
specify
Did/Has the participant/subject experienced any
infections or illnesses during this pregnancy?
Yes	 (1)
No	 (2)
Unknown (3)
2 / 3
NINDS CDE Pregnancy Information Headache
Did/Has the participant/subject experienced any
infections or illnesses during this pregnancy? If
yes, specify
Pregnancy History
Has the participant/subject ever been pregnant?
Yes	 (1)
No (STOP)	 (2)
Unknown (STOP) (3)
Number of prior pregnancies (both to term and
not to term)
Full-term (≥ 37 weeks) births
Pre-term (≥ 37 weeks) births
Did a birth defect occur in any previous
pregnancy?
Yes	 (1)
No	 (2)
Unknown (3)
Did a birth defect occur in any previous
pregnancy? If Yes, specify birth defect
Did a miscarriage (≤ 20 weeks) or stillbirth (> 20
weeks) occur in any previous pregnancy?
Yes	 (1)
No	 (2)
Unknown (3)
If Yes, in what week of pregnancy did the
miscarriage or stillbirth occur? week(s):
Has the participant/subject ever had exposure to
any of the following during pregnancy?
Concurrent medication (1)
Exposure to X-ray (2)
Teratogens (3)
Alcohol (4)
Smoking (5)
Other specify (6)
Has the participant/subject ever had exposure to
any substance during pregnancy?If Other,specify
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Eligibility Prostate Cancer NCT01762241
Xbox Kinect Training in Men With Prostate Cancer; ODM
derived from: https://clinicaltrials.gov/show/NCT01762241
All rights reserved. Please visit https://medical-data-
models.org/forms/15822
Eligibility Prostate Cancer
NCT01762241
Inclusion Criteria
prostate cancer requiring androgen deprivation
therapy*
Yes
No
androgen deprivation therapy for at least 3 month
prior to inclusion*
Yes
No
cognitive well-functioning in order to be able to
answer questionnaires and   train according to
instructions*
Yes
No
signed informed consent*
Yes
No
Exclusion Criteria
prostate cancer with metastasis to other regions
than bones*
Yes
No
strength- or cardiovascular training 2 times or
more per week prior to inclusion*
Yes
No
haemoglobin percentage less than 6,1 mmol/l*
Yes
No
any mental or physical condition that makes the
patient unfit for participation*
Yes
No
men in risk of getting an osteoporotic fracture due
to long-term treatment    with steroids or earlier
fractures due to minimal trauma*
Yes
No
participation in other studies*
Yes
No
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Eligibility Prostate Cancer NCT02241122
MRI and Biomarkers in Prostate Cancer; ODM derived
from: https://clinicaltrials.gov/show/NCT02241122
All rights reserved. Please visit https://medical-data-
models.org/forms/15823
Eligibility Prostate Cancer
NCT02241122
Inclusion Criteria
age: 18 to 85 years*
Yes
No
clinical suspicion of prostate cancer, based on:
serum level of psa from 2,5 ng/ml to 20 ng/ml in
two following measurements and/or abnormal
digital rectal examination*
Yes
No
mental status: patients must be able to
understand the meaning of the study*
Yes
No
informed consent: the patient must sign the
appropriate ethics committee (ec) approved
informed consent documents in the presence of
the designated staff*
Yes
No
Exclusion Criteria
previous prostate biopsies within 6 months*
Yes
No
previous diagnosis of  prostate carcinoma*
Yes
No
previous prostate surgeries, e.g. turp
(transurethral prostatic resection)*
Yes
No
symptomatic of acute prostatitis*
Yes
No
contraindications for mri (cardiac pacemaker,
intracranial clips etc)*
Yes
No
uncontrolled serious infection*
Yes
No
claustrophobia*
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Yes
No
hip replacement surgery or other metal implants
in the pelvic area*
Yes
No
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AID-Register (Kinderrheumatologie)
Visitenblatt
Register für autoinflammatorische Erkrankungen
AID-Register (Kinderrheumatologie)(PD Dr. med. Elke
Lainka, Prof. Dr. med. Dirk Föll)
https://prst.gpoh.de/aid/formulare.asp
All rights reserved. Please visit https://medical-data-
models.org/forms/15825
AID-Register Visitenblatt
Zentrum
Ansprechpartner
E- Mail
Telefon
Datum der Diagnose
Zentrumsnummer
Patienten PID
Visitenblatt
Art der Wiedervorstellung
Routine (1)
ungeplant (2)
Wiedervorstellung erfolgt
ambulant (1)
stationär (2)
Krankheitsaktivität bei Wiedervorstellung
akut (1)
nicht akut (2)
Falls stationär, wieviele Tage?
Körpergröße
cm
Körpergewicht
kg
Symptome der letzten Woche
Ja
Nein
Symptome der letzten 3 Monate
Ja
Nein
Symptome zur Diagnose
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Krankheitszeichen seit der letzten
Wiedervorstellung?
Ja
Nein
Wie oft traten die Krankheitszeichen auf?
Allgemeinbefinden während eines Schubes
gut (1)
mäßig (2)
schlecht (3)
Allgemeinbefinden zwischen den Schüben
gut (1)
mäßig (2)
schlecht (3)
Fieber > 38,5°C
kontinuierlich (1)
intermittierend (2)
kein Fieber (3)
unbekannt (4)
Durchschnittliche Dauer der Fieberepisoden in
Tagen
Haut/
Schleimhautbeteiligung
Ja
Nein
Haut/ Schleimhautbeteiligung: Falls ja
Urticaria (1)
migratorisches Exanthem (10)
Fasciitis (11)
Panniculitis (12)
Purpura SchönleinHennoch (13)
Polyarteritis nodosa (14)
Vaskulitis (15)
Pharyngitis (16)
Psoriasis (17)
andere Pustulosis (18)
Aphten (2)
Ulcera (3)
Erythem (4)
makulopapulöses Exanthem (5)
masernähnliches Exanthem (6)
Erysipel (7)
palmoplantare Pustulosis (8)
Akne (9)
Tonsillitis
Ja
Nein
Serositis
Pleura (1)
Pericard (2)
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Peritoneum (3)
Gelenkbeteiligung
Monoarthritis (1)
Oligoarthritis (2)
Polyarthritis (3)
Sakroiliitis (4)
destruierende Arthropathie (5)
Arthralgie (6)
keine Beteiligung (7)
Gelenkbeteiligung: wenn ja, welche Gelenke?
Abdominelle Probleme
akutes Abdomen (akutes Abdomen)
Colitis Ulcerosa (Colitis Ulcerosa)
Durchfall (Durchfall)
Erbrechen (Erbrechen)
Hepatomegalie (Hepatomegalie)
Hepatosplenomegalie
(Hepatosplenomegalie)
Morbus Crohn (Morbus Crohn)
Schmerzen (Schmerzen)
Splenomegalie (Splenomegalie)
Übelkeit (Übelkeit)
Lymphadenopathie
cervical (1)
axillar (2)
mediastinal (3)
abdominell (4)
inguinal (5)
keine Beteiligung (6)
Begleitbeschwerden
Kopfschmerzen (1)
Skelettanomalien (10)
Brustschmerzen (11)
Morgensteifigkeit (12)
Halsschmerzen (13)
Myalgie (2)
periorbitales Ödem (3)
Konjunktivitis (4)
Orchitis (5)
Sepsis (6)
Malignom (7)
Kardiomyopathie (8)
Thyroiditis (9)
Neurologische
Veränderungen
aseptische Meningitis (1)
Schwerhörigkeit (2)
Krampfanfälle (3)
Retardierung (4)
Myopathie (5)
Ataxie (6)
muskuläre Hypotonie (7)
Augen (Uveitis, (8)
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Katarakt, Blindheit) (9)
Gedeihstörung (unter der 3. Perzentile)
Ja
Nein
Amyloidose
Ja
Nein
Amyloidose:bitte Organ benennen
Macrophagenaktivierungssyndrom
Ja
Nein
Triggerfaktoren
Erkältung (1)
Infektion (2)
Menstruation (3)
Operation (4)
Impfung (5)
Trauma (6)
Stress (7)
Pubertät (8)
Kälte (9)
Laborwerte vor Diagnosedatum
Hämoglobin
g/dL
Leukozyten
/nl
Neutropenie
Ja
Nein
Segmentkernige
%
Kreatinin
mg/dl
Serumamyloid A
mg/dl
CRP
md/dl
BSG 1. Stunde
mm/h
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BSG 2. Stunde
mm/h
Procalcitonin
ng/ml
Biomarker S100 A12
ng/ml
Biomarker S100 A8/A9
ng/ml
IgD
mg/l
IgA
mg/dl
IgG
mg/dl
IgM
mg/dl
GPT
U/l
Bilirubin gesamt
mg/dl
Gamma-GT
U/L
Urinanalsye
unauffällig (1)
Creatinin Clearance < 90ml/min/1,73m²
(5)
nicht durchgeführt (6)
250mg/dl oder einfach pos. im Stix
(Glukosurie >)
10μl (Hämaturie >)
30mg/dl (Proteinurie >)
Allgemeine Daten
Wird die Therapie vom Patienten/Eltern
eingehalten?
Ja
Nein
Therapieansprechen
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gut (1)
mäßig (2)
schlecht (3)
Nebenwirkungen der Therapie
WHO Toxizitätsscala I (1)
WHO Toxizitätsscala II (2)
WHO Toxizitätsscala III (3)
WHO Toxizitätsscala IV (4)
keine Toxizität (5)
Therapieveränderungen?
Ja
Nein
Ärztliche Gesamtbeurteilung / Epikrise 0 (inaktiv)
10 (hohe Aktivität)
0 (1)
9 (10)
10 (11)
1 (2)
2 (3)
3 (4)
4 (5)
5 (6)
6 (7)
7 (8)
8 (9)
Notizen
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NBO Kerndokumentation 2015
Register für autoinflammatorische Erkrankungen
NBO(PD Dr. med. Elke Lainka, Prof. Dr. med. Dirk Föll)
https://prst.gpoh.de/aid/formulare.asp
All rights reserved. Please visit https://medical-data-
models.org/forms/15826
Kerndokumentation 2015:Arztbogen
für rheumakranke Kinder und
Jugendliche
Demographische Informationen
ID-Nummer
Erhebungsdatum
Geburtsmonat des Patienten
Geburtsjahr des Patienten
Geschlecht
männlich (1)
weiblich (2)
Körpergröße
cm
Körpergewicht
kg
Beginn der Erkrankung
Betreuungsbeginn
Rheumatologische Hauptdiagnose
Rheumatologische Hauptdiagnose: Diagnose
Code dreistellig
Rheumatologische Hauptdiagnose
gesichert (1)
Verdacht (2)
Weitere rheumatologische Diagnosen
Weitere rheumatologische Diagnosen
Diagnosecode dreistellig
Allgemeine Therapie
NSAR
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aktuell (1)
letzte 12 Monate (2)
Azithromycin
aktuell (1)
letzte 12 Monate (2)
andere Antibiotika
aktuell (1)
letzte 12 Monate (2)
Glukokortikoide,systemisch < 0,2mg/kgKG
aktuell (1)
letzte 12 Monate (2)
Glukokortikoide,systemisch >= 0,2mg/kgKG
aktuell (1)
letzte 12 Monate (2)
Calcitonin
aktuell (1)
letzte 12 Monate (2)
Bisphosphonate
aktuell (1)
letzte 12 Monate (2)
Immunglobuline, intravenös
aktuell (1)
letzte 12 Monate (2)
Keine Therapie
aktuell (1)
letzte 12 Monate (2)
Basistherapie
MTX
aktuell (1)
letzte 12 Monate (2)
MTX Beginn Monat/Jahr
SASP
aktuell (1)
letzte 12 Monate (2)
Etanercept
aktuell (1)
letzte 12 Monate (2)
andere
Andere
aktuell (1)
letzte 12 Monate (2)
Andere Beginn Monat/Jahr
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Keine Therapie
aktuell (1)
letzte 12 Monate (2)
Laborbefunde
BSG
mm/h
BSG nicht bestimmt
Ja
Nein
IgG Wert
mg/dl
IgG Wert nicht bestimmt
Ja
Nein
IgA
mg/dl
IgA nicht bestimmt
Ja
Nein
Immunglobulin, IgM
mg/dl
Immunglobulin, IgM nicht bestimmt
Ja
Nein
HLA-B27
negativ (1)
positiv (2)
nicht bestimmt (3)
Krankheitsaktivität
Wie aktiv ist die Krankheit im Augenblick?
0 inaktiv (1)
4.5 (10)
5 (11)
5.5 (12)
6 (13)
6.5 (14)
7 (15)
7.5 (16)
8 (17)
8.5 (18)
9 (19)
0.5 (2)
9.5 (20)
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10 hoch aktiv (21)
1 (3)
1.5 (4)
2 (5)
2.5 (6)
3 (7)
3.5 (8)
4 (9)
Hautbeteiligung
Ja
Nein
Falls ja, welche Art der Hautbeteiligung?
Psoriasis (1)
Akne (2)
Pustulosis palmoplantaris (3)
andere pustolöse Hauterscheinungen (4)
andere, bitte angeben (5)
Andere Art der Hautbeteiligung, bitte genauer
bezeichnen
Chonisch entzündliche Darmerkrankung
Ja
Nein
Gelenkbeteiligung
Ja
Nein
Falls ja, Art der Gelenkbeteiligung
periphere Arthritis (1)
Sakroiliitis (2)
nahe einer Knochenläsion (3)
fern einer Knochenläsion (4)
Diagnosekriterien erfüllt: Enth.-assoz. Arthritis
Ja
Nein
Diagnosekriterien erfüllt: Psoriasisarthritis
Ja
Nein
Komplikationen
Hyperostose (1)
Wirbelkörperfrakturen/Vertebra plana (2)
sonstige pathologische Frakturen (3)
andere Komplikationen,bitte genauer
bezeichnen (4)
Andere Komplikationen,bitte genauer bezeichnen
Lokalisation und Anzahl osteomyelitischer
Herde
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Betroffene Knochenregion
Mandibula (1)
Metacarpalia (10)
Becken (11)
Proximaler Femur (12)
Distaler Femur (13)
Patella (14)
Proximale Tibia (15)
Distale Tibia (16)
Proximale Fibula (17)
Distale Fibula (18)
Calcaneus (19)
Sternum (2)
Metatarsalia (20)
andere, bitte genauer bezeichnen (21)
Clavicula (3)
Wirbelkörper (4)
Rippen (5)
Proximaler Humerus (6)
Distaler Humerus (7)
Proximale Ulna (8)
Distale Ulna (9)
Betroffene Knochenregion,andere, bitte genauer
bezeichnen
Anzahl der Herde zu Beginn, bitte betroffene
Region und Anzahl angeben
Anzahl der Herde zu Beginn, bitte betroffene
Region und Anzahl angeben
Anzahl der Herde jemals im Verlauf, bitte
betroffene Region und Anzahl angeben
Anzahl der Herde jemals im Verlauf, bitte
betroffene Region und Anzahl angeben
Erstdokumentation
Symptome/Befunde bei Erstmanifestation/-
Vorstellung
Fieber (>38°C) (1)
CRP (>1mg/dl) (2)
Blutbild/Diff. auffällig (3)
lokale Rötung (4)
keine derartigen Symptome/Befunde (5)
Falls Blutbild /Diff auffällig, welche?
Probeexzision
Ja
Nein
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Falls Probeexzision durchgeführt wurde, wann?
Histologischer Befund
Lymphozytär (1)
Granulozytär (2)
Mischbild (Lymphozytär-Granulozytär)
(3)
Fibrosierend (4)
Mikrobiologische Untersuchung des Biopsates
Keine mikrobiologische Untersuchung
durchgeführt (1)
Konventionell kulturell (2)
Diagnostik auf Mykobakterien (3)
PCR (4)
Konventionell kulturelle Untersuchung
Steril (1)
Keim (bitte genauer bezeichnen) (2)
Diagnostik auf Mykobakterien
Steril (1)
Keim (bitte genauer bezeichnen) (2)
Konventionell kulturelle Untersuchung:Keim
Diagnostik auf Mykobakterien:Keim
PCR
Negativ (1)
Produkt vorhanden (2)
Falls Produkt vorhanden, Ergebnis der
Sequenzierung
Röntgen
Osteolyse/sklerose (1)
Hyperostose (2)
Nicht durchgeführt (3)
MRT
positives T2/TIRM Signal (1)
KM-Aufnahme positiv (2)
Weichteilbeteiligung (3)
Arthritis (4)
Nicht durchgeführt (5)
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NINDS CDE Medical and Family History of
Headache/Migraine
NINDS Common Data Elements (Medical and Family
History of Headache/Migraine) Used from the National
Institute of Neurological Disorders and Stroke Common
Data Elements
(https://www.commondataelements.ninds.nih.gov/)
References: Grinnon ST, Miller K, Marler JR, Lu Y, Stout A,
Odenkirchen J, Kunitz S. National Institute of Neurological
Disorders and Stroke Common Data Element Project -
approach and methods. Clin Trials. 2012;9(3):322-9.
All rights reserved. Please visit https://medical-data-
models.org/forms/15827
Medical and Family History of
Headache/Migraine
Medical and Family History of Migraine
Headache
Study ID
Study site name
Subject ID
Do you have a history of migraine with aura?
Yes (1)
No (2)
Unknown (3)
Does a relative (1st/2nd degree only) have a
history of Migraine with aura?
Yes (1)
No (2)
Unknown (3)
Number of first-degree relatives affected
Number of first degree relatives with physicians
diagnosis
Relationship of first-degree relative(s) to
participant/subject
Biological Mother (1 )
Full biologic child Female (10 )
Biological Father (2 )
Sibling Male (3 )
Sibling Female (4 )
Non-identical or dizygotic twin Male (5 )
Non-identical or dizygotic twin Female (6
)
Identical twin Male (7 )
Identical twin Female (8 )
Full biologic child Male (9 )
Number of second-degree relatives affected
Number of second-degree relatives with
physician diagnosis
1 / 14
Relationship of second-degree relative(s) to
participant/subject
Half-Sibling Male (1)
Paternal Uncle (10)
Grandchild Male (11)
Grandchild Female (12)
Nephew (13)
Niece (14)
Half-Sibling Female  (2)
Maternal Grandmother (3)
Maternal Grandfather (4)
Paternal Grandmother (5)
Paternal Grandfather (6)
Maternal Aunt (7)
Maternal Uncle (8)
Paternal Aunt (9)
Do you have a history of Migraine without aura?
Yes (1)
No (2)
Unknown (3)
Does a relative (1st/2nd degree only) have a
history of Migraine without aura?
Yes (1)
No (2)
Unknown (3)
Number of first-degree relatives affected
Number of first degree relatives with physicians
diagnosis
Relationship of first-degree relative(s) to
participant/subject
Biological Mother (1 )
Full biologic child Female (10 )
Biological Father (2 )
Sibling Male (3 )
Sibling Female (4 )
Non-identical or dizygotic twin Male (5 )
Non-identical or dizygotic twin Female (6
)
Identical twin Male (7 )
Identical twin Female (8 )
Full biologic child Male (9 )
Number of second-degree relatives affected
Number of second-degree relatives with
physician diagnosis
Relationship of second-degree relative(s) to
participant/subject
Half-Sibling Male (1)
Paternal Uncle (10)
Grandchild Male (11)
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Grandchild Female (12)
Nephew (13)
Niece (14)
Half-Sibling Female  (2)
Maternal Grandmother (3)
Maternal Grandfather (4)
Paternal Grandmother (5)
Paternal Grandfather (6)
Maternal Aunt (7)
Maternal Uncle (8)
Paternal Aunt (9)
Do you have a history of Chronic migraine?
Yes (1)
No (2)
Unknown (3)
Does a relative (first and second degree only)
have a history of Chronic migraine?
Yes (1)
No (2)
Unknown (3)
Number of first-degree relatives affected
Number of first degree relatives with physicians
diagnosis
Relationship of first-degree relative(s) to
participant/subject
Biological Mother (1 )
Full biologic child Female (10 )
Biological Father (2 )
Sibling Male (3 )
Sibling Female (4 )
Non-identical or dizygotic twin Male (5 )
Non-identical or dizygotic twin Female (6
)
Identical twin Male (7 )
Identical twin Female (8 )
Full biologic child Male (9 )
Number of second-degree relatives affected
Number of second-degree relatives with
physician diagnosis
Relationship of second-degree relative(s) to
participant/subject
Half-Sibling Male (1)
Paternal Uncle (10)
Grandchild Male (11)
Grandchild Female (12)
Nephew (13)
Niece (14)
Half-Sibling Female  (2)
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Maternal Grandmother (3)
Maternal Grandfather (4)
Paternal Grandmother (5)
Paternal Grandfather (6)
Maternal Aunt (7)
Maternal Uncle (8)
Paternal Aunt (9)
Do you have a history of Hemiplegic migraine?
Yes (1)
No (2)
Unknown (3)
Does a relative (first and second degree only)
have a history of Hemiplegic migraine?
Yes (1)
No (2)
Unknown (3)
Number of first-degree relatives affected
Number of first degree relatives with physicians
diagnosis
Relationship of first-degree relative(s) to
participant/subject
Biological Mother (1 )
Full biologic child Female (10 )
Biological Father (2 )
Sibling Male (3 )
Sibling Female (4 )
Non-identical or dizygotic twin Male (5 )
Non-identical or dizygotic twin Female (6
)
Identical twin Male (7 )
Identical twin Female (8 )
Full biologic child Male (9 )
Number of second-degree relatives affected
Number of second-degree relatives with
physician diagnosis
Relationship of second-degree relative(s) to
participant/subject
Half-Sibling Male (1)
Paternal Uncle (10)
Grandchild Male (11)
Grandchild Female (12)
Nephew (13)
Niece (14)
Half-Sibling Female  (2)
Maternal Grandmother (3)
Maternal Grandfather (4)
Paternal Grandmother (5)
Paternal Grandfather (6)
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Maternal Aunt (7)
Maternal Uncle (8)
Paternal Aunt (9)
Do you have a history of Menstrual headache?
Yes (1)
No (2)
Unknown (3)
Does a relative (first and second degree only)
have a history of Menstrual headache?
Yes (1)
No (2)
Unknown (3)
Number of first-degree relatives affected
Number of first degree relatives with physicians
diagnosis
Relationship of first-degree relative(s) to
participant/subject
Biological Mother (1 )
Full biologic child Female (10 )
Biological Father (2 )
Sibling Male (3 )
Sibling Female (4 )
Non-identical or dizygotic twin Male (5 )
Non-identical or dizygotic twin Female (6
)
Identical twin Male (7 )
Identical twin Female (8 )
Full biologic child Male (9 )
Number of second-degree relatives affected
Number of second-degree relatives with
physicians diagnosis
Relationship of second-degree relative(s) to
participant/subject
Half-Sibling Male (1)
Paternal Uncle (10)
Grandchild Male (11)
Grandchild Female (12)
Nephew (13)
Niece (14)
Half-Sibling Female  (2)
Maternal Grandmother (3)
Maternal Grandfather (4)
Paternal Grandmother (5)
Paternal Grandfather (6)
Maternal Aunt (7)
Maternal Uncle (8)
Paternal Aunt (9)
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Do you have a history of Tension type headache?
Yes (1)
No (2)
Unknown (3)
Does a relative (first or second degree only) have
a history of Tension type headache?
Yes (1)
No (2)
Unknown (3)
Number of first-degree relatives affected
Number of first degree relatives with physicians
diagnosis
Relationship of first-degree relative(s) to
participant/subject
Biological Mother (1 )
Full biologic child Female (10 )
Biological Father (2 )
Sibling Male (3 )
Sibling Female (4 )
Non-identical or dizygotic twin Male (5 )
Non-identical or dizygotic twin Female (6
)
Identical twin Male (7 )
Identical twin Female (8 )
Full biologic child Male (9 )
Number of second-degree relatives affected
Number of second-degree relatives with
physician diagnosis
Relationship of second-degree relative(s) to
participant/subject
Half-Sibling Male (1)
Paternal Uncle (10)
Grandchild Male (11)
Grandchild Female (12)
Nephew (13)
Niece (14)
Half-Sibling Female  (2)
Maternal Grandmother (3)
Maternal Grandfather (4)
Paternal Grandmother (5)
Paternal Grandfather (6)
Maternal Aunt (7)
Maternal Uncle (8)
Paternal Aunt (9)
Do you have a history of Episodic tension type
headache?
Yes (1)
No (2)
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Unknown (3)
Does a relative (first and secind degree only)
have a history of Episodic tension type
headache?
Yes (1)
No (2)
Unknown (3)
Number of first-degree relatives affected
Number of first degree relatives with physicians
diagnosis
Relationship of first-degree relative(s) to
participant/subject
Biological Mother (1 )
Full biologic child Female (10 )
Biological Father (2 )
Sibling Male (3 )
Sibling Female (4 )
Non-identical or dizygotic twin Male (5 )
Non-identical or dizygotic twin Female (6
)
Identical twin Male (7 )
Identical twin Female (8 )
Full biologic child Male (9 )
Number of second-degree relatives affected
Number of second-degree relatives with
physicians diagnosis
Relationship of second-degree relative(s) to
participant/subject
Half-Sibling Male (1)
Paternal Uncle (10)
Grandchild Male (11)
Grandchild Female (12)
Nephew (13)
Niece (14)
Half-Sibling Female  (2)
Maternal Grandmother (3)
Maternal Grandfather (4)
Paternal Grandmother (5)
Paternal Grandfather (6)
Maternal Aunt (7)
Maternal Uncle (8)
Paternal Aunt (9)
Do you have a history of Chronic tension type
headache?
Yes (1)
No (2)
Unknown (3)
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Does a relative (first or second degree only) have
a history of Chronic tension type headache?
Yes (1)
No (2)
Unknown (3)
Number of first-degree relatives affected
Number of first degree relatives with physicians
diagnosis
Relationship of first-degree relative(s) to
participant/subject
Biological Mother (1 )
Full biologic child Female (10 )
Biological Father (2 )
Sibling Male (3 )
Sibling Female (4 )
Non-identical or dizygotic twin Male (5 )
Non-identical or dizygotic twin Female (6
)
Identical twin Male (7 )
Identical twin Female (8 )
Full biologic child Male (9 )
Number of second-degree relatives affected
Number of second-degree relatives with
physicians diagnosis
Relationship of second-degree relative(s) to
participant/subject
Half-Sibling Male (1)
Paternal Uncle (10)
Grandchild Male (11)
Grandchild Female (12)
Nephew (13)
Niece (14)
Half-Sibling Female  (2)
Maternal Grandmother (3)
Maternal Grandfather (4)
Paternal Grandmother (5)
Paternal Grandfather (6)
Maternal Aunt (7)
Maternal Uncle (8)
Paternal Aunt (9)
Do you have a history of Trigeminal Autonomic
Cephalgias (TACS) ?
Yes (1)
No (2)
Unknown (3)
Does a relative (first or second degree only) have
a history of Trigeminal Autonomic Cephalgias
(TACS)?
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Yes (1)
No (2)
Unknown (3)
Number of first-degree relatives affected
Number of first degree relatives with physicians
diagnosis
Relationship of first-degree relative(s) to
participant/subject
Biological Mother (1 )
Full biologic child Female (10 )
Biological Father (2 )
Sibling Male (3 )
Sibling Female (4 )
Non-identical or dizygotic twin Male (5 )
Non-identical or dizygotic twin Female (6
)
Identical twin Male (7 )
Identical twin Female (8 )
Full biologic child Male (9 )
Number of second-degree relatives affected
Number of second-degree relatives with
physicians diagnosis
Relationship of second-degree relative(s) to
participant/subject
Half-Sibling Male (1)
Paternal Uncle (10)
Grandchild Male (11)
Grandchild Female (12)
Nephew (13)
Niece (14)
Half-Sibling Female  (2)
Maternal Grandmother (3)
Maternal Grandfather (4)
Paternal Grandmother (5)
Paternal Grandfather (6)
Maternal Aunt (7)
Maternal Uncle (8)
Paternal Aunt (9)
Do you have a history of Cluster headache?
Yes (1)
No (2)
Unknown (3)
Does a relative (first or second degree only) have
a history of Cluster headache?
Yes (1)
No (2)
Unknown (3)
Number of first-degree relatives affected
9 / 14
NINDS CDE Medical and Family History of Headache/Migraine
Number of first degree relatives with physicians
diagnosis
Relationship of first-degree relative(s) to
participant/subject
Biological Mother (1 )
Full biologic child Female (10 )
Biological Father (2 )
Sibling Male (3 )
Sibling Female (4 )
Non-identical or dizygotic twin Male (5 )
Non-identical or dizygotic twin Female (6
)
Identical twin Male (7 )
Identical twin Female (8 )
Full biologic child Male (9 )
Number of second-degree relatives affected
Number of second-degree relatives with
physicians diagnosis
Relationship of second-degree relative(s) to
participant/subject
Half-Sibling Male (1)
Paternal Uncle (10)
Grandchild Male (11)
Grandchild Female (12)
Nephew (13)
Niece (14)
Half-Sibling Female  (2)
Maternal Grandmother (3)
Maternal Grandfather (4)
Paternal Grandmother (5)
Paternal Grandfather (6)
Maternal Aunt (7)
Maternal Uncle (8)
Paternal Aunt (9)
Do you have a history of Trigeminal headache?
Yes (1)
No (2)
Unknown (3)
Does a relative (first or second degree only) have
a history of Trigeminal headache?
Yes (1)
No (2)
Unknown (3)
Number of first-degree relatives affected
Number of first degree relatives with physicians
diagnosis
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Relationship of first-degree relative(s) to
participant/subject
Biological Mother (1 )
Full biologic child Female (10 )
Biological Father (2 )
Sibling Male (3 )
Sibling Female (4 )
Non-identical or dizygotic twin Male (5 )
Non-identical or dizygotic twin Female (6
)
Identical twin Male (7 )
Identical twin Female (8 )
Full biologic child Male (9 )
Number of second-degree relatives affected
Number of second-degree relatives with
physicians diagnosis
Relationship of second-degree relative(s) to
participant/subject
Half-Sibling Male (1)
Paternal Uncle (10)
Grandchild Male (11)
Grandchild Female (12)
Nephew (13)
Niece (14)
Half-Sibling Female  (2)
Maternal Grandmother (3)
Maternal Grandfather (4)
Paternal Grandmother (5)
Paternal Grandfather (6)
Maternal Aunt (7)
Maternal Uncle (8)
Paternal Aunt (9)
Do you have a history of Other TAC type?
Yes (1)
No (2)
Unknown (3)
Do you have a history of Other TAC type? Please
specify
Does a relative (first or second degree only) have
a history of Other TAC type?
Yes (1)
No (2)
Unknown (3)
Does a relative (first or second degree only) have
a history of Other TAC type? Please specify
Number of first-degree relatives affected
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Number of first degree relatives with physicians
diagnosis
Relationship of first-degree relative(s) to
participant/subject
Biological Mother (1 )
Full biologic child Female (10 )
Biological Father (2 )
Sibling Male (3 )
Sibling Female (4 )
Non-identical or dizygotic twin Male (5 )
Non-identical or dizygotic twin Female (6
)
Identical twin Male (7 )
Identical twin Female (8 )
Full biologic child Male (9 )
Number of second-degree relatives affected
Number of second-degree relatives with
physicians diagnosis
Relationship of second-degree relative(s) to
participant/subject
Half-Sibling Male (1)
Paternal Uncle (10)
Grandchild Male (11)
Grandchild Female (12)
Nephew (13)
Niece (14)
Half-Sibling Female  (2)
Maternal Grandmother (3)
Maternal Grandfather (4)
Paternal Grandmother (5)
Paternal Grandfather (6)
Maternal Aunt (7)
Maternal Uncle (8)
Paternal Aunt (9)
Do you have a history of Other primary type
headache?
Yes (1)
No (2)
Unknown (3)
Do you have a history of Other primary type
headache? Please specify
Does a relative (first or second degree only) have
a history of Other primary type headache?
Yes (1)
No (2)
Unknown (3)
Does a relative (first or second degree only) have
a history of Other primary type headache?
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Please specify
Number of first-degree relatives affected
Number of first degree relatives with physicians
diagnosis
Relationship of first-degree relative(s) to
participant/subject
Biological Mother (1 )
Full biologic child Female (10 )
Biological Father (2 )
Sibling Male (3 )
Sibling Female (4 )
Non-identical or dizygotic twin Male (5 )
Non-identical or dizygotic twin Female (6
)
Identical twin Male (7 )
Identical twin Female (8 )
Full biologic child Male (9 )
Number of second-degree relatives affected
Number of second-degree relatives with
physicians diagnosis
Relationship of second-degree relative(s) to
participant/subject
Half-Sibling Male (1)
Paternal Uncle (10)
Grandchild Male (11)
Grandchild Female (12)
Nephew (13)
Niece (14)
Half-Sibling Female  (2)
Maternal Grandmother (3)
Maternal Grandfather (4)
Paternal Grandmother (5)
Paternal Grandfather (6)
Maternal Aunt (7)
Maternal Uncle (8)
Paternal Aunt (9)
Do you have a history of Secondary headache?
Yes (1)
No (2)
Unknown (3)
Do you have a history of Secondary headache?
Please specify
Does a relative (first or second degree only) have
a history of Secondary headache?
Yes (1)
No (2)
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Unknown (3)
Does a relative (first or second degree only) have
a history of Secondary headache? Please specify
Number of first-degree relatives affected
Number of first degree relatives with physicians
diagnosis
Relationship of first-degree relative(s) to
participant/subject
Biological Mother (1 )
Full biologic child Female (10 )
Biological Father (2 )
Sibling Male (3 )
Sibling Female (4 )
Non-identical or dizygotic twin Male (5 )
Non-identical or dizygotic twin Female (6
)
Identical twin Male (7 )
Identical twin Female (8 )
Full biologic child Male (9 )
Number of second-degree relatives affected
Number of second-degree relatives with
physicians diagnosis
Relationship of second-degree relative(s) to
participant/subject
Half-Sibling Male (1)
Paternal Uncle (10)
Grandchild Male (11)
Grandchild Female (12)
Nephew (13)
Niece (14)
Half-Sibling Female  (2)
Maternal Grandmother (3)
Maternal Grandfather (4)
Paternal Grandmother (5)
Paternal Grandfather (6)
Maternal Aunt (7)
Maternal Uncle (8)
Paternal Aunt (9)
Additional comments
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Eligibility Prostate Cancer NCT02252978
Ciprofloxacin Compared to Placebo in Diagnosing Prostate
Cancer in Patients Undergoing Prostate Biopsy; ODM
derived from: https://clinicaltrials.gov/show/NCT02252978
All rights reserved. Please visit https://medical-data-
models.org/forms/15829
Eligibility Prostate Cancer
NCT02252978
Inclusion Criteria
abnormal serum psa (total > 2.5 ng/ml or other
clinically important biomarker parameters,
including psa velocity and density) associated
with or without normal digital rectal examination*
Yes
No
men who have elected to proceed with a
diagnostic prostate biopsy*
Yes
No
any prostate size*
Yes
No
willingness and ability to give informed consent*
Yes
No
Exclusion Criteria
history of prostate cancer*
Yes
No
urine culture positive for significant urinary tract
infection (uti)*
Yes
No
a history of antibiotic use within one month prior
to initial psa level measurement*
Yes
No
allergy to fluoroquinolones*
Yes
No
currently taking imperative medications with
significant drug-drug interaction with
ciprofloxacin*
Yes
No
compromised renal function with estimated
glomerular filtration rate (gfr) of < 30
ml/min/1.73m^2*
Yes
No
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NINDS CDE Symptoms, Frequency and
Severity - Headache
NINDS Common Data Elements (Symptoms, Frequency
and Severity - Baseline; Headache) Used from the National
Institute of Neurological Disorders and Stroke Common
Data Elements
(https://www.commondataelements.ninds.nih.gov/)
References: Grinnon ST, Miller K, Marler JR, Lu Y, Stout A,
Odenkirchen J, Kunitz S. National Institute of Neurological
Disorders and Stroke Common Data Element Project -
approach and methods. Clin Trials. 2012;9(3):322-9.
All rights reserved. Please visit https://medical-data-
models.org/forms/15830
Symptoms, Frequency and Severity -
Baseline
Demographics
Study ID
Study site name
Subject ID
Symptoms, Frequency and Severity -
Baseline
Data collected date (m m/dd/yyyy):
Does the participant/subject suffer from
headaches?
Yes  (1)
No (STOP) (2)
If the participant/subject suffers from headaches,
describe the typical pain severity:
Mild (Most of the time I can ignore my
headache and continue what I am doing)
(1)
Moderate (My headache makes
concentration difficult, but I can perform
undemanding tasks) (2)
Severe (I cannot concentrate nor do
much of anything) (3)
If the participant/subject suffers from severe
headaches, which of the following best describes
how the participant/subject is usually affected?
Able to work/function normally (1)
Working ability or activity impaired to
some degree (2)
Working ability or activity severely
impaired (3)
Bed rest required (4)
Rate your typical pain on a scale of 0 - 10 (“0” =
no pain & “10” = the worst pain):
When the participant/subject has a headache,
does he/she experience Nausea?
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0 Never (1)
1 Rarely (2)
2 Less than half the time (3)
3 Half the time or more (4)
When the participant/subject has a headache,
does he/she experience Vomiting
0 Never (1)
1 Rarely (2)
2 Less than half the time (3)
3 Half the time or more (4)
When the participant/subject has a headache,
does he/she experience Dizziness
0 Never (1)
1 Rarely (2)
2 Less than half the time (3)
3 Half the time or more (4)
When the participant/subject has a headache,
does he/she experience Vertigo
0 Never (1)
1 Rarely (2)
2 Less than half the time (3)
3 Half the time or more (4)
When the participant/subject has a headache,
does he/she experience Nonvertigo
0 Never (1)
1 Rarely (2)
2 Less than half the time (3)
3 Half the time or more (4)
When the participant/subject has a headache,
does he/she experience Increased neck pain or
stiffness
0 Never (1)
1 Rarely (2)
2 Less than half the time (3)
3 Half the time or more (4)
When the participant/subject has a headache,
does he/she experience Increased sensitivity to
light
0 Never (1)
1 Rarely (2)
2 Less than half the time (3)
3 Half the time or more (4)
When the participant/subject has a headache,
does he/she experience Increased sensitivity to
noise
0 Never (1)
1 Rarely (2)
2 Less than half the time (3)
3 Half the time or more (4)
When the participant/subject has a headache,
does he/she experience Increased sensitivity to
smell
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0 Never (1)
1 Rarely (2)
2 Less than half the time (3)
3 Half the time or more (4)
When the participant/subject has a headache,
does he/she experience pain made worse by
routine physical activity
0 Never (1)
1 Rarely (2)
2 Less than half the time (3)
3 Half the time or more (4)
When the participant/subject has a headache,
does he/she experience pain on one side of head
only
0 Never (1)
1 Rarely (2)
2 Less than half the time (3)
3 Half the time or more (4)
When the participant/subject has a headache,
does he/she experience pulsating/throbbing
headaches
0 Never (1)
1 Rarely (2)
2 Less than half the time (3)
3 Half the time or more (4)
When the participant/subject has a headache,
does he/she experience weakness on one side
0 Never (1)
1 Rarely (2)
2 Less than half the time (3)
3 Half the time or more (4)
When the participant/subject has a headache,
does he/she experience seeing shimmering
lights, lines, dark spots, other shapes or colors
before the eyes, before or during the headache
and lasts more than a few minutes but less than
an hour
0 Never (1)
1 Rarely (2)
2 Less than half the time (3)
3 Half the time or more (4)
When the participant/subject has a headache,
does he/she experience one-sided numbness of
lips, tongue, fingers, or legs that migrates or
moves and starts before the headache becomes
severe and lasts less than an hour
0 Never (1)
1 Rarely (2)
2 Less than half the time (3)
3 Half the time or more (4)
On average, how many days per month has the
participant/subject had headaches in the past 3
months (based on a 30 day month)?
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0-4 days per month (1)
5-9 days per month (2)
10-14 days per month (3)
15-19 days per month (4)
>24 days per month (5)
Continuous/nearly continuous
(essentially no headache-free time) (6)
Actual average number of days per month the
participant/subject had headaches in the past 3
months (numeric value between 0 and 30)
Does this recent 3 month frequency represent a
change compared to the prior 3 months?
Yes
No
Does this recent 3 month frequency represent a
change compared to the prior 3 months? If yes,
specify change:
Increased  (1)
Decreased  (2)
Unchanged (3)
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surgery treatment - tumortherapy
HIS form from Soarian. Urologie Erlangen" with friendly
permission of the urology Erlangen (Prof. Wullich) and the
medical informatics department Erlangen (PD Dr. Bürkle)
All rights reserved. Please visit https://medical-data-
models.org/forms/15833
HIS
Admininstrative Daten
Patienten-Nachname*
Patienten-Vorname*
Patienten-Titel*
früherer Name*
Patienten-Geburtsdatum*
Alter des Patienten*
Nationalität/Staatsangehörigkeit*
Straße*
Postleitzahl Patient*
Wohnort*
Fallnummer*
OP-Bogen
Tumordiagnose*
Datum der Diagnose*
Datum der OP*
Einhaltung der Leitlinen*
Ja
Nein
Grund für Einhaltung Leitlinien*
ASA*
A normal healthy patient (1)
A patient with mild systemic disease (2)
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A patient with severe systemic disease
(3)
A patient with severe systemic disease
that is a constant threat to life (4)
A moribund patient who is not expected
to survive without the operation (5)
Operation
Chirurgische und medizinische Prozeduren*
Körperseite*
einiseitg (einiseitg)
zweiseitig (zweiseitig)
Intention*
diagnostisch (D = diagnostisch)
Kurativ (K = kurativ)
Palliativ (P = palliativ)
unbekannt (unbekannt)
Welche Operation*
Nerverhalt*
Ja
Nein
Körperseite*
beidseits (beidseits)
links (links)
rechts (rechts)
Erster Operateur*
Erste Assistenz*
weitere Operation*
Chirurgische und medizinische Prozeduren*
Körperseite*
einiseitg (einiseitg)
zweiseitig (zweiseitig)
Intention*
diagnostisch (D = diagnostisch)
Kurativ (K = kurativ)
Palliativ (P = palliativ)
unbekannt (unbekannt)
intraoperative Komplikationen*
Ja
Nein
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Welche intraoperative Komplikation*
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NINDS CDE Headache Diagnosis
NINDS Common Data Elements (Headache Diagnosis;
Headache) Used from the National Institute of Neurological
Disorders and Stroke Common Data Elements
(https://www.commondataelements.ninds.nih.gov/)
References: Grinnon ST, Miller K, Marler JR, Lu Y, Stout A,
Odenkirchen J, Kunitz S. National Institute of Neurological
Disorders and Stroke Common Data Element Project -
approach and methods. Clin Trials. 2012;9(3):322-9.
All rights reserved. Please visit https://medical-data-
models.org/forms/15834
Headache Diagnosis
Demographics
Study ID
Study site name
Subject ID
Headache Diagnosis
Some people have changes in their vision with
their headache. BEFORE YOUR HEADACHE
BEGAN, did you see the following? (Choose all
that apply)
Spots (1)
Stars (2)
Lights (3)
Zigzag lines (4)
Heat waves (5)
No changes in vision (6)
Some people have changes in their skin
sensation with their headache. BEFORE YOUR
HEADACHE BEGAN, do you have numbness or
tingling in your face or arms?
Yes
No
BEFORE YOUR HEADACHE BEGAN, do you
have numbness or tingling in your face or arms?
If yes.
Which side(s)? (Choose one)
Right (1)
Left (2)
Bilateral (3)
BEFORE YOUR HEADACHE BEGAN, do you
have numbness or tingling in your face or arms?
If yes,
how often? (Choose one)
Rarely  (1)
Sometimes  (2)
Always (3)
In which parts of the head does the headache
typically occur? (Choose all that apply)
Left temple (1)
Right temple (2)
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Front (3)
Top (4)
Back (5)
Around eyes (6)
Behind eyes (7)
Other, specify (8)
In which parts of the head does the headache
typically occur? Please specify other:
Which of the following describes the headache
pain you feel? (Choose all that apply)
Throbbing (1)
Sharp (10)
Constant (11)
Dull (12)
Other, specify (13)
Squeezing (2)
Tightness (3)
Stabbing (4)
Pinching (5)
Pressure (6)
Burning (7)
Pounding (8)
Pulsating (9)
Which of the following describes the headache
pain you feel? PLease specify other:
How many hours does the TREATED headache
last? Shortest: (please specify) hours
How many hours does the TREATED headache
last? Longest:  (please specify) hours
How many hours does the TREATED headache
last? Average: (please specify) hours
How many hours does the NON-TREATED
headache last? Shortest: (please specify) hours
How many hours does the NON-TREATED
headache last? Longest:  (please specify) hours
How many hours does the NON-TREATED
headache last? Average: (please specify) hours
On average, how bad would you rate the severity
of the headaches?
Mild (1)
Moderate (2)
Severe (3)
How often do your headaches occur? (Choose
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one)
<1 /per month (1)
1 to 3 /per month (2)
1 /per week (3)
2 to 4 /per week (4)
5 to 6 /per week (5)
Once per day (6)
Other, specify (7)
How often do your headaches occur?Please
specify other
Over the last 3 months, on average how many
days PER MONTH did you have a headache?
(please specify) (between 0 and 30)
Does the headache hurt more when you walk up
stairs?
Yes (1)
No (2)
N/A (3)
Additional Pediatric-specific Elements
Does activity or playing make your headache
worse?
Yes (1)
No (2)
N/A (3)
Does the headache change your activity level
(i.e., stop playing)?
Yes (1)
No (2)
N/A (3)
When you get a headache at school at what level
are you able to function?
100% (1)
75% (2)
50% (3)
25% (4)
0% (5)
When you get a headache playing at what level
are you able to function?
100% (1)
75% (2)
50% (3)
25% (4)
0% (5)
3 / 3
NINDS CDE Headache Diagnosis
Eligibility Prostate Cancer NCT00117312
Extension Study Investigating the Long-Term Safety and
Tolerability of Repeat Doses of FE200486 in Prostate
Cancer Patients; ODM derived from:
https://clinicaltrials.gov/show/NCT00117312
All rights reserved. Please visit https://medical-data-
models.org/forms/15836
Eligibility Prostate Cancer
NCT00117312
Inclusion Criteria
has given written consent before any study
related activity is performed. a study related
activity is defined as any procedure that would
not have been performed during the normal
management of the patient.*
Yes
No
has had sufficient testosterone suppression (as
defined in the withdrawal criteria of fe200486
cs06) for at least 28 days.*
Yes
No
Exclusion Criteria
has been withdrawn from study fe200486 cs06
due to an adverse event, failure to achieve at
least 28 days of testosterone suppression,
insufficient prostate-specific antigen (psa)
suppression as defined in study fe200486 cs06 in
the absence of concomitant rise in testosterone
level or non-compliance with protocol required
procedures.*
Yes
No
requires hormonal therapy for neoadjuvant
purposes.*
Yes
No
requires treatment with any other drug modifying
the testosterone level or function.*
Yes
No
is considered to be a candidate for curative
therapy, i.e., radical prostatectomy or
radiotherapy, within 6 months after visit 1.*
Yes
No
has a history of severe asthma requiring daily
treatment with inhalation steroids, angioedema or
anaphylactic reactions.*
Yes
No
has hypersensitivity towards any component of
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the investigational product.*
Yes
No
has had a cancer disease within the last 10 years
except for prostate cancer, and surgically
removed basocellular or squamous cell
carcinoma of the skin.*
Yes
No
has a clinically significant neurologic,
gastrointestinal, renal, hepatic, cardiovascular,
psychological, pulmonary, metabolic, endocrine,
hematological, dermatological or infectious
disorder or any other condition, including
excessive alcohol or drug abuse, which may
interfere with trial participation or which may
affect the conclusion of the study, as judged by
the investigator.*
Yes
No
any clinically significant laboratory abnormalities
which, in the judgment of the investigator, would
interfere with the patient's participation in this
study or evaluation of study results (liver
transaminases and bilirubin must be within
normal limits).*
Yes
No
has a mental incapacity or language barrier
precluding adequate understanding or co-
operation.*
Yes
No
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Eligibility Prostate Cancer NCT00136487
Celecoxib (Celebrex) Versus Placebo in Men With
Recurrent Prostate Cancer; ODM derived from:
https://clinicaltrials.gov/show/NCT00136487
All rights reserved. Please visit https://medical-data-
models.org/forms/15837
Eligibility Prostate Cancer
NCT00136487
Inclusion Criteria
diagnosis of prostate cancer*
Yes
No
progression following prostatectomy or radiation
to the prostate, defined as 3 psa rises, with each
psa determination at least 4 weeks apart*
Yes
No
psa greater than or equal to 1.0 for men who had
a prostatectomy*
Yes
No
psa greater than or equal to 3.0 for men who
were treated with primary radiation therapy
(external beam and/or brachytherapy)*
Yes
No
psa doubling time between 6 and 24 months*
Yes
No
participants must be either fully active and
asymptomatic or symptomatic but fully
ambulatory*
Yes
No
adequate bone marrow function, kidney function
and liver function as evidenced by laboratory
results*
Yes
No
Exclusion Criteria
evidence of metastatic disease*
Yes
No
prior hormonal therapy for recurrent prostate
cancer*
Yes
No
prior chemotherapy for recurrent or metastatic
prostate cancer*
Yes
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No
radiation therapy within 6 months*
Yes
No
patients allergic to non-steroidal anti-
inflammatory drugs (nsaids), salicylates or
sulfonamide-type medications who experience
asthma or urticaria (hives) after taking aspirin or
other nsaids*
Yes
No
patients taking a dose of aspirin greater than or
equal to 325 mg a day within 4 weeks of study
entry*
Yes
No
patients taking selective cox-2 inhibitors or any
nsaids other than aspirin within 8 weeks of study
entry*
Yes
No
patients taking fluconazole, lithium or warfarin*
Yes
No
history of gastrointestinal or abdominal ulceration
or any history of significant gastrointestinal
bleeding in the past 12 months*
Yes
No
any history of myocardial infarction in the past 12
months*
Yes
No
any uncontrolled, serious medical or psychiatric
illness*
Yes
No
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Eligibility Prostate Cancer NCT02262910
Study of MOR209/ES414 in Metastatic Castration-
Resistant Prostate Cancer; ODM derived from:
https://clinicaltrials.gov/show/NCT02262910
All rights reserved. Please visit https://medical-data-
models.org/forms/15838
Eligibility Prostate Cancer
NCT02262910
Inclusion Criteria
histologically or cytologically confirmed
adenocarcinoma of the prostate.  no evidence of
neuroendocrine differentiation or small cell
features.*
Yes
No
surgically or medically castrated, with
testosterone ≤ 50 ng/dl (≤ 1.7 nmol/l).*
Yes
No
progressive prostate cancer by either serum psa
levels, soft tissue or bone disease as defined by
the pcwg2 criteria.*
Yes
No
in stage 1, patients may or may not have received
prior chemotherapy for mcrpc.  in stage 2,
patients will be enrolled into two cohorts based
on whether or not they have received prior
chemotherapy for mcrpc.  any prior
chemotherapy must have been completed ≥ 4
weeks prior to administration of es414.
additionally, in countries where abiraterone or
enzalutamide are commercially available, patients
in stage 1 and 2 must have progressed on
abiraterone and/or enzalutamide prior to study
entry.*
Yes
No
ecog ≤ 1*
Yes
No
life  expectancy > 6 months per investigator*
Yes
No
adequate hematologic, renal, and hepatic
parameters*
Yes
No
Exclusion Criteria
any chemotherapy or investigational drug in prior
4 weeks*
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Yes
No
any radiation therapy in prior 2 weeks*
Yes
No
any prior therapy targeted against psma*
Yes
No
history of seizures*
Yes
No
history of central nervous system metastasis*
Yes
No
history of nephrotic syndrome*
Yes
No
spot urine total protein:creatinine ratio >1,000
mg/gm*
Yes
No
planned palliative procedures for alleviation of
bone pain*
Yes
No
active infection requiring treatment with systemic
anti-infectives or major surgery in prior 4 weeks.*
Yes
No
any prednisone (or equivalent corticosteroids)
use within 4 weeks of study entry*
Yes
No
chronic immunosuppressive therapy*
Yes
No
known history of hiv, hepatitis b, or hepatitis c
infection*
Yes
No
evidence of severe or uncontrolled systemic
diseases*
Yes
No
history of bleeding disorders  or thromboembolic
events in prior 3 months*
Yes
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No
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Eligibility Schizophrenia NCT00049946
Schizophrenia Study In Adults; ODM derived from:
https://clinicaltrials.gov/show/NCT00049946
All rights reserved. Please visit https://medical-data-
models.org/forms/15839
Eligibility Schizophrenia
NCT00049946
Inclusion Criteria
patient must meet diagnostic criteria for
schizophrenia.*
Yes
No
Exclusion Criteria
patients with other psychotic disorders.*
Yes
No
patients whose condition is due to the direct
physiological effects of a substances (e.g., drug
abuse) or a general medical condition.*
Yes
No
patients with a history of autistic disorder or
another pervasive developmental disorder.*
Yes
No
patients with epilepsy or a history of seizures
requiring treatment.*
Yes
No
patients who are excluded from taking the drug
risperidone.*
Yes
No
patients who pose a current serious suicidal or
homicidal risk.*
Yes
No
patients who are adequately stabilized on their
treatment.*
Yes
No
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Eligibility Type 2 Diabetes Mellitus
NCT01570660
Phielix et al.: Hepatic Fat Content and Adipokines; ODM
derived from: https://clinicaltrials.gov/show/NCT01570660
All rights reserved. Please visit https://medical-data-
models.org/forms/15840
Eligibility Type 2 Diabetes Mellitus
NCT01570660
Inclusion Criteria
well controlled patients with type 2 diabetes
(hb1ac < 8%)*
Yes
No
no insulin therapy*
Yes
No
no co-morbidities*
Yes
No
stable medication use for the last 6 months*
Yes
No
stable body weight the last 6 months*
Yes
No
no diet in the last 6 months*
Yes
No
Exclusion Criteria
hb1ac > 8%*
Yes
No
insulin therapy*
Yes
No
diabetes-related co-morbidities, like
cardiovascular disease, neuropathology*
Yes
No
unstable medication use*
Yes
No
unstable body weight in the last 6 months (> 5
kg)*
Yes
No
following a diet in the last 6 months*
Yes
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No
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Eligibility Breast Cancer NCT00146588
Cytoxan, Epirubicin and Capecitabine in Women With
Breast Cancer; ODM derived from:
https://clinicaltrials.gov/show/NCT00146588
All rights reserved. Please visit https://medical-data-
models.org/forms/15841
Eligibility Breast Cancer
NCT00146588
Inclusion Criteria
histologically confirmed stage i-iii breast cancer.
if stage i, should be deemed of sufficiently high
risk of developing recurrent disease to warrant
participation.*
Yes
No
18 years of age or older*
Yes
No
anc > 1,000/mm3*
Yes
No
platelet count > 100,000/mm3*
Yes
No
hemoglobin > 10*
Yes
No
creatinine < 2.0*
Yes
No
sgot < 2 x uln*
Yes
No
bilirubin < 1.5mg/dl*
Yes
No
able to swallow and retain oral medication*
Yes
No
lvef greater than or equal to 50%*
Yes
No
ecog performance status of 0 or 1*
Yes
No
Exclusion Criteria
pregnant or lactating*
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Yes
No
prior malignancy within 5 years (excluding
squamous or basal cell skin cancers)*
Yes
No
prior chemotherapy within 5 years*
Yes
No
prior anthracycline therapy*
Yes
No
serious comorbid physical or psychological
condition*
Yes
No
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Eligibility Carcinoma, Hepatocellular
NCT00056992
Testing of ADI-PEG in Hepatocellular Carcinoma; ODM
derived from: https://clinicaltrials.gov/show/NCT00056992
All rights reserved. Please visit https://medical-data-
models.org/forms/15842
Eligibility Carcinoma, Hepatocellular
NCT00056992
Criteria
non-resectable disease.*
Yes
No
progressive disease after chemotherapy,
radiotherapy, surgery or immuno-therapy, and be
no longer responding to such therapy, or have
refused such therapy.*
Yes
No
been off previous treatment for at least 4 weeks.*
Yes
No
been fully recovered from all prior surgery.*
Yes
No
age of  > 18 years.*
Yes
No
karnofsky performance status of > 70.*
Yes
No
expected survival of > 12 weeks.*
Yes
No
total bilirubin < 3.0 mg/dl.*
Yes
No
serum albumin > 3.0 g/dl.*
Yes
No
serum sgot < 5 x upper limit of normal.*
Yes
No
serum alkaline phosphatase < 5 x upper limit of
normal.*
Yes
No
serum ammonia < 55  mg/dl.*
Yes
No
serum glucose > 60 mg/dl.*
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Yes
No
serum amylase < 1.5 x upper limit of normal.*
Yes
No
anc > 1,500 / ml.*
Yes
No
platelets > 100,000 /  ml.*
Yes
No
female subjects of childbearing age and male
subjects must be asked to use appropriate
contraception for both the male and female for
the duration of the study. subjects must agree to
use two forms of contraception or agree to refrain
from intercourse for the duration of the study.
females must not be pregnant at the start of the
study, and a serum hcg pregnancy test must be
negative before entry into the study.*
Yes
No
informed consent.*
Yes
No
not be enrolled in other ind studies.*
Yes
No
disease must be measurable or evaluable.*
Yes
No
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Eligibility Bronchioloalveolar Cell Variant of
Non-small Cell Lung Cancer NCT00590902
Ph II OSI-774 (Erlotinib,Tarceva) In Advanced
Bronchioloalveolar Cell Lung Cancer; ODM derived from:
https://clinicaltrials.gov/show/NCT00590902
All rights reserved. Please visit https://medical-data-
models.org/forms/15843
Eligibility Bronchioloalveolar Cell
Variant of Non-small Cell Lung
Cancer NCT00590902
Inclusion Criteria
either bronchioloalveolar cell carcinoma or a
variant thereof after review*
Yes
No
clinical stage iiib (malignant pleural or pericardial
effusion) or iv or recurrent/medically inoperable
disease*
Yes
No
measurable or evaluable indicator lesions*
Yes
No
no prior or one chemotherapy regimen for nsclc*
Yes
No
three weeks since last chemotherapy, and three
weeks since prior radiation therapy to a major
bone-marrow containing area*
Yes
No
karnofsky performance status > or = to 80% or
ecog performance status ≤ or = to 1*
Yes
No
life expectancy > or = to 8 weeks*
Yes
No
adequate hematologic, renal and/or hepatic
function: wbc > or = to 3,000/ul, hemoglobin > or
= to 9.0 g/dl, platelet count > or = to 100,000/ul,
total bilirubin < or = to 1.0 mg/dl, ast < than or =
to 2.5 x unl, creatinine < or = to 1.5 mg/dl or clcr
> or = to 55ml/min.*
Yes
No
effective contraception*
Yes
No
Exclusion Criteria
1 / 2
prior exposure to osi-774 or other treatments
targeting the her family axis (e.g.-trastuzumab,
zd1839, c225, etc.)*
Yes
No
two or more prior chemotherapy regimens*
Yes
No
concurrent active cancer*
Yes
No
uncontrolled central nervous system metastases
(i.e. any known cns lesion which is
radiographically unstable, symptomatic and/or
requiring escalating doses of corticosteroids)*
Yes
No
pregnant or lactating women*
Yes
No
malignancies within the past 5 years except for
adequately treated carcinoma of the cervix or
basal or squamous cell carcinomas of the skin*
Yes
No
prior systemic cytotoxic chemotherapy for other
malignant disease*
Yes
No
significant medical history or unstable medical
condition (unstable systemic disease: congestive
heart failure, recent mi, unstable angina, active
infection, uncontrolled hypertension).*
Yes
No
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Eligibility Depression, Postpartum
NCT00051246
Group Therapy for Postpartum Depression; ODM derived
from: https://clinicaltrials.gov/show/NCT00051246
All rights reserved. Please visit https://medical-data-
models.org/forms/15844
Eligibility Depression, Postpartum
NCT00051246
Inclusion Criteria
major depression with an infant under 7 months
of age*
Yes
No
Exclusion Criteria
bipolar disorder*
Yes
No
schizophrenia*
Yes
No
organic brain syndrome*
Yes
No
antisocial personality disorder*
Yes
No
current psychosis or mania*
Yes
No
lifetime history of mental retardation*
Yes
No
current alcohol or substance abuse*
Yes
No
cognitive disability*
Yes
No
infants born more than 6 weeks premature or with
major medical conditions or developmental
disabilities*
Yes
No
1 / 1
Eligibility Prostate Cancer NCT02339701
Stereotactic Body Radiotherapy vs Intensity-modulated
Radiotherapy in Prostate Cancer; ODM derived from:
https://clinicaltrials.gov/show/NCT02339701
All rights reserved. Please visit https://medical-data-
models.org/forms/15845
Eligibility Prostate Cancer
NCT02339701
Inclusion Criteria
histological confirmation of prostate
adenocarcinoma*
Yes
No
low or intermediate risk prostate cancer patients
(i.e. t1-t2c and psa 20 and gleason score < 8)
with the risk of pelvic node metastasis 15% as
calculated by roach's formula*
Yes
No
ecog performance score 0-1*
Yes
No
age ≥ 18*
Yes
No
history/physical examination within 2 weeks prior
to registration*
Yes
No
able to sign informed-consent*
Yes
No
Exclusion Criteria
patients with previous diagnosis of cancer other
than prostate cancer and non-melanoma skin
cancer.*
Yes
No
evidence of distant metastases*
Yes
No
regional lymph node involvement*
Yes
No
previous radical surgery (prostatectomy),
cryosurgery, or hifu for prostate cancer*
Yes
No
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previous pelvic irradiation, prostate
brachytherapy, or bilateral orchiectomy*
Yes
No
previous hormonal therapy, such as lhrh agonists
(e.g., goserelin, leuprolide) or lhrhantagonists
(e.g., degarelix), anti-androgens (e.g., flutamide,
bicalutamide), estrogens (e.g.des), or surgical
castration (orchiectomy)*
Yes
No
unstable angina and/or congestive heart failure
requiring hospitalization, transmural myocardial
infarction within the last 6 months, acute bacterial
or fungal infection requiring intravenous
antibiotics, chronic obstructive pulmonary
disease exacerbation or other respiratory illness
requiringhospitalization or precluding study
therapy at the time of registration*
Yes
No
patients who have received prior chemotherapy.*
Yes
No
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Eligibility HIV Infections NCT00285584
Bupropion For Reducing High-Risk Behaviors in Depressed
Men Who Have Sex With Men (MSM); ODM derived from:
https://clinicaltrials.gov/show/NCT00285584
All rights reserved. Please visit https://medical-data-
models.org/forms/15846
Eligibility HIV Infections
NCT00285584
Inclusion Criteria
available for at least 9 months, or the duration of
the study*
Yes
No
willing to complete hiv testing and counseling*
Yes
No
history of hiv testing and counseling*
Yes
No
at high risk of hiv infection, indicated by more
than one male sexual partner in the 3 months
prior to study entry*
Yes
No
meets criteria for either (a) major depression or
dysthymia within a mild-to-moderate level
according to standard criteria dsm-iv,  or (b)
minor depression as defined by one or more of
the following symptoms at any time and for any
duration during the past 12 months:  significant
weight loss or gain, or significant decrease or
increase in appetite; poor sleep pattern;
noticeable irritability or slowness; fatigue or lack
of energy; inappropriate feelings of
worthlessness or guilt; inability to concentrate;
indecisiveness; and recurrent thoughts of death
or suicide.*
Yes
No
Exclusion Criteria
hiv infected*
Yes
No
sexual intercourse in the 3 months prior to study
entry with only one partner, and in a
monogamous relationship*
Yes
No
currently enrolled in another study involving
repeated hiv testing and counseling*
Yes
No
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receiving treatment for depression with
antidepressant medication for any length of time
within the year prior to study entry*
Yes
No
currently in psychotherapy, psychoanalysis, or
any other form of talk therapy for any reason*
Yes
No
severe depression or at suicidal risk*
Yes
No
no evidence or prior history of depression*
Yes
No
homicidal or other similar problem that, in the
opinion of the investigator, may endanger study
staff and participants*
Yes
No
currently taking monoamine oxidase inhibitors
(maois).  participants may be allowed to enroll 14
days after discontinuing use of a maoi.*
Yes
No
history of seizures*
Yes
No
history or current symptoms of bipolar disorder*
Yes
No
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Eligibility Hypertension NCT00529750
Effect of the Angiotensin II Receptor Antagonist Irbesartan
on Biochemical and Functional Markers of Endothelial
Dysfunction in Patients With Hypertension; ODM derived
from: https://clinicaltrials.gov/show/NCT00529750
All rights reserved. Please visit https://medical-data-
models.org/forms/15847
Eligibility Hypertension
NCT00529750
Inclusion Criteria
hypertension grade 1 or 2*
Yes
No
with at least two of the following criteria for the
diagnosis of metabolic syndrome:*
Yes
No
body mass index > or = 25 kg/m2 and waist
circumference > or = 100 cm.*
Yes
No
dyslipidemia (triglycerides fasting serum levels >
or = 200 mg/dl or hdl serum levels < or = 40
mg/dl)*
Yes
No
fasting serum glucose > or = 110 mg/dl but < 126
mg/dl*
Yes
No
Exclusion Criteria
known hypersensitivity to irbesartan*
Yes
No
hypertension grade 3*
Yes
No
history of clinical vascular events such as tias,
stroke, peripheral arterial disease*
Yes
No
coronary artery disease*
Yes
No
renal insufficiency (creatinine serum levels > or =
1.2 mg/dl)*
Yes
No
presence of clinical heart failure*
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Yes
No
asthma and copd*
Yes
No
valvular cardiopathy clinically relevant*
Yes
No
current therapy with antioxidant drugs, statins*
Yes
No
therapy with aiira for at least 3 months during the
last semester*
Yes
No
presence of any acute illness or major trauma in
the last 8 weeks*
Yes
No
history of a chronic inflammatory disease such as
rheumatoid arthritis, immune disorders or
connective tissue disease.*
Yes
No
the above information is not intended to contain
all considerations relevant to a patient's potential
participation in a clinical trial.*
Yes
No
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Eligibility Lymphoma, Large-Cell, Diffuse
NCT00135499
R-ACVBP Versus R-CHOP in Patients Aged 60-65 With
Diffuse Large B-Cell Lymphoma; ODM derived from:
https://clinicaltrials.gov/show/NCT00135499
All rights reserved. Please visit https://medical-data-
models.org/forms/15848
Eligibility Lymphoma, Large-Cell,
Diffuse NCT00135499
Inclusion Criteria
patient with diffuse large b-cell lymphoma
according to the who classification (anti cd20
labeling)*
Yes
No
aged from 60 to 65 years.*
Yes
No
not previously treated.*
Yes
No
ann arbor stage ii, iii, iv.*
Yes
No
ecog performance status 0 to 2.*
Yes
No
minimum life expectancy of 3 months.*
Yes
No
negative hiv, hepatitis b virus (hbv) and hepatitis
c virus (hcv) serologies test _ 4 weeks (except
after vaccination).*
Yes
No
having previously signed a written informed
consent.*
Yes
No
Exclusion Criteria
t-cell lymphoma.*
Yes
No
any history of treated or non-treated indolent
lymphoma. however, patients not previously
diagnosed and having a diffuse large b-cell
lymphoma with some small cell infiltration in bone
marrow or lymph node may be included.*
Yes
No
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central nervous system or meningeal involvement
by lymphoma.*
Yes
No
contra-indication to any drug contained in the
chemotherapy regimens.*
Yes
No
any serious active disease (according to the
investigator’s decision).*
Yes
No
poor renal function (creatinine
level>150micromol/l), poor hepatic function (total
bilirubin level>30mmol/l, transaminases>2.5
maximum normal level) unless these
abnormalities are related to the lymphoma.*
Yes
No
poor bone marrow reserve as defined by
neutrophils<1.5g/l or platelets<100g/l, unless
related to bone marrow infiltration.*
Yes
No
any history of cancer during the last 5 years with
the exception of non-melanoma skin tumors or
stage 0 (in situ) cervical carcinoma.*
Yes
No
treatment with any investigational drug within 30
days before planned first cycle of chemotherapy
and during the study.*
Yes
No
adult patient under tutelage.*
Yes
No
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Eligibility Mantle Cell Lymphoma
NCT00285389
Treatment of Mantle Cell Lymphoma at Diagnosis for
Patients Under 65 Years; ODM derived from:
https://clinicaltrials.gov/show/NCT00285389
All rights reserved. Please visit https://medical-data-
models.org/forms/15849
Eligibility Mantle Cell Lymphoma
NCT00285389
Inclusion Criteria
mantle cell lymphoma*
Yes
No
cd 20+*
Yes
No
at diagnosis or without anterior chemotherapy*
Yes
No
age >18  and < 66 years*
Yes
No
ann arbor ii, iii or iv*
Yes
No
ecog <3*
Yes
No
contraindication for rituximab treatment*
Yes
No
informed consent signed*
Yes
No
no cancer anteriory*
Yes
No
renal and hepatic function compatible with the
treatment*
Yes
No
ventricular fraction > 50 % with echographic
method and > 40% with isotopic method*
Yes
No
Exclusion Criteria
other type of lymphoma*
Yes
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No
age<18 ou > 66 years*
Yes
No
informed consent not signed*
Yes
No
anterior cancer*
Yes
No
contraindication to rituximab*
Yes
No
cardiac insufficiency*
Yes
No
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EBMT PLASMA CELL DISORDERS
(INCLUDING MULTIPLE MYELOMA)
Bacteria:S. pneumoniae, Other gram positive (i.e.: other
streptococci, staphylococci, listeria …), Haemophilus
influenzae, Other gram negative (i.e.: E. coli klebsiella,
proteus, serratia, pseudomonas …), Legionella sp,
Mycobacteria sp, Other
Fungi: Candida sp, Aspergillus sp, Pneumocystis carinii,
Other
Parasites: Toxoplasma gondii, Other
Viruses: HSV, VZV, EBV,CMV, HHV-6,RSV, Other
respiratory virus (influenza, parainfluenza, rhinovirus),
Adenovirus, HBV, HCV, HIV, Papovavirus, Parvovirus,Other
All rights reserved. Please visit https://medical-data-
models.org/forms/15850
EBMT PLASMA CELL DISORDERS
(INCLUDING MULTIPLE
MYELOMA)
PLASMA CELL DISORDERS
(INCLUDING MULTIPLE MYELOMA)
Unique Identification Code (UIC)
(if known)
Hospital Unique Patient Number
Date of this report
Patient following national / international study /
trial
No (1)
Yes (2)
Not evaluated (3)
Unknown (4)
Name of study / trial
First name(s)_surname(s)
Date of Birth
Date of last HSCT for this patient
PATIENT LAST SEEN
Date of Last Contact or Death
Complete haematological remission obtained
after the HSCT in the absence of additional
disease treatment
Previously reported (1)
Yes, date (2)
No  (3)
Unknown (4)
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GRAFT VERSUS HOST DISEASE
(GvHD) SINCE LAST REPORT
Acute Graft versus Host Disease (aGvHD) -
Grade
grade 0 (Absent) (1)
grade I (2)
grade II (3)
grade III (4)
grade IV (5)
Not evaluated (6)
ACUTE GRAFT VERSUS HOST DISEASE
(AGVHD)
New onset (New onset)
Persistent (Persistent)
Recurrent (Recurrent)
aGvHD Reason
Tapering (1)
DLI (2)
Unexplained (3)
Date onset of this episode (if new or recurrent)
yyyy/mm/dd
aGvHD Stage liver
None (0)
Stage 1 (1)
Stage 2 (2)
Stage 3 (3)
Stage 4 (4)
aGvHD Stage skin
0 (1)
1 (2)
2 (3)
3 (4)
4 (5)
Not evaluated (6)
unknown (7)
aGvHD Resolution
Yes
No
aGvHD Date of resolution
yyyy/mm/dd
Chronic Graft versus Host Disease (cGvHD)
No (No)
Present continuously since last reported
episode (Present continuously since last
reported episode)
Resolved (Resolved)
Yes (Yes)
Chronic Graft versus Host Disease (cGvHD)
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MYELOMA)
First episode (1)
Recurrence (2)
Date of onset
If present continously since last report, specify
cGvHD gade:
Extensive (Extensive)
Limited (Limited)
cGvHD Organs affected
Skin (1)
Gut (2)
Liver (3)
Mouth (4)
Eyes (5)
Lung (6)
Other, specify (7)
Unknown (8)
If resolved, specify the date of resolution:
OTHER COMPLICATIONS SINCE LAST
REPORT
Infection related complications
Yes
No
Bacteremia / fungemia / viremia / parasites
Pathogen (1)
Date (2)
Septic shock
Pathogen (1)
Date (2)
ARDS
Date (1)
Pathogen (2)
Multiorgan failure due to infection
Pathogen (1)
Date (2)
Pneumonia
Pathogen (1)
Date (2)
Hepatitis
Pathogen (1)
Date (2)
CNS infection
Pathogen (1)
Date (2)
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Gut infection
Pathogen (1)
Date (2)
Skin infection
Pathogen (1)
Date (2)
Cystitis
Pathogen (1)
Date (2)
Retinitis
Pathogen (1)
Date (2)
Unknown (3)
Other
Pathogen (1)
Date (2)
Non infection related complications
Yes
No
Idiopathic pneumonia syndrome
Date (4)
No  (No )
Unknown (Unknown)
Yes (Yes)
VOD
Date (Date)
No  (No )
Unknown (Unknown)
Yes (Yes)
Cataract
Date (4)
No (No)
Unknown (Unknown)
Yes (Yes)
Haemorrhagic cystitis, non infectious
Date (4)
No  (No )
Unknown (Unknown)
Yes  (Yes )
ARDS, non infectious
Date (4)
No (No)
Unknown (Unknown)
Yes (Yes)
Multiorgan failure, non infectious
Yes (1)
No (2)
Unknown (3)
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HSCT-associated microangiopathy
Date (4)
No (No)
Unknown (Unknown)
Yes (Yes)
Renal failure requiring dialysis
Date (4)
No (No)
Unknown (Unknown)
Yes (Yes)
Haemolytic anaemia due to blood group
Date (4)
No (No)
Unknown (Unknown)
Yes (Yes)
Aseptic bone necrosis
Date (4)
No (No)
Unknown (Unknown)
Yes (Yes)
Other INFECTION RELATED COMPLICATIONS
if other, please specify
Graft loss
No (1)
Yes (2)
Not evaluated (3)
Overall Chimerism
Full (donor > 95%) (1)
Mixed (partial) (2)
Autologuos reconstitution (recipient >
95%) (3)
Aplasia (4)
Not evaluated (5)
Identification of donor or Cord Blood Unit given
by the centre
Date of Test
Number in the infusion order (if applicable)
......... (1)
N/A (2)
Cell type on which test was performed (% Donor
Cells):
BM
%
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Cell type on which test was performed (% Donor
cells):
PB mononuclear cells (PBMC)
%
Cell type on which test was performed (% Donor
cells):
T-Cells
(Indicate the date(s) and results of all tests done
for all donors. Split the results by donor and by
the cell type on which the test was performed if
applicable. Copy this table as many times as
necessary.)
%
Cell type on which test was performed (% Donor
cells):
B-Cells
%
Cell type on which test was performed (% Donor
cells):
Red blood cells
%
Cell type on which test was performed (% Donor
cells):
Monocytes
%
Cell type on which test was performed (% Donor
cells):
PMNs (neutrophils)
%
Cell type on which test was performed (% Donor
cells):
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Lymphocytes, NOS
%
Cell type on which test was performed (% Donor
cells):
Myeloid cells, NOS
%
Cell type on which test was performed
SECONDARY MALIGNANCY,
LYMPHOPROLIFERATIVE OR
MYELOPROLIFRATIVE DISORDER
DIAGNOSED
No at date of this follow-up (No at date of
this follow-up)
Previously reported (Previously reported)
Yes (Yes)
If yes, specify date of diagnosis
SECONDARY MALIGNANCY,
LYMPHOPROLIFERATIVE OR
MYELOPROLIFRATIVE DISORDER
DIAGNOSED
AML (AML)
Lymphoproliferative disorder
(Lymphoproliferative disorder)
MDS (MDS)
Other (Other)
if other, please specify
ADDITIONAL THERAPIES SINCE LAST
FOLLOW UP
ADDITIONAL Therapy SINCE LAST FOLLOW
UP
No (No)
Unknown (Unknown)
Yes, date started (Yes, date started)
Date ADDITIONAL THERAPIES SINCE LAST
FOLLOW UP started
If yes: Cellular therapy
No  (1)
Yes (Mark disease status before this
cellular therapy) (2)
Unknown (3)
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if yes, Disease status before this cellular therapy
CR (CR)
Not evaluated (Not evaluated)
Not in CR (Not in CR)
If yes: Type of cells
Donor lymphocyte infusion (DLI) (1)
Mesenchymal cells (2)
Other (3)
Unknown (4)
Number of cells infused by type
10^8/kg
Number of Nucleated cells infused (DLI
only) (1)
CD 34+ (cells/kg*) (DLI only) (2)
CD 3+ (cells/kg*) (DLI only) (3)
Total number of cells infused (non DLI only)
x10^6/kg
Number (1)
Not evaluated (2)
Unknown (3)
Chronological number of this cell therapy for this
patient
Indication 
(check all that apply)
Loss/decreased chimaerism
(Loss/decreased chimaerism)
Mixed chimaerism (Mixed chimaerism)
Other (Other)
Planned/ protocol (Planned/ protocol)
Prophylactic (Prophylactic)
Treatment for disease (Treatment for
disease)
Treatment of GvHD (Treatment of GvHD)
Treatment PTLD, EBV, lymphoma
(Treatment PTLD, EBV, lymphoma)
Treatment viral infection (Treatment viral
infection)
Number of Infusions (within 10 weeks)
(count only infusions that are part of same
regimen and given for the same indication)
Acute Graft versus Host Disease
grade 0 (absent) (grade 0 (absent))
grade 1 (grade 1)
grade 2 (grade 2)
grade 3 (grade 3)
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grade 4 (grade 4)
present, grade unknown (present, grade
unknown)
Disease treatment (apart from donor cell infusion
or other type of cell therapy)
No (1)
Yes: Planned (planned before HSCT took
place) (2)
Yes: Not planned (for
relapse/progression or persistent
disease) (3)
FIRST EVIDENCE OF RELAPSE OR
PROGRESSION SINCE LAST HSCT
Relapse or Progression
Continous progression since transplant
(Continous progression since transplant)
No (No)
Previously reported (Previously reported)
Unknown (Unknown)
Yes (Yes)
If yes, date diagnosed RELAPSE OR
PROGRESSION
LAST DISEASE AND PATIENT STATUS
last disease status
Complete Remission (Complete
Remission)
Relapse (Relapse)
Stable disease (Stable disease)
Treatment failure/ progression (Treatment
failure/ progression)
Has patient or partner become  pregnant after
this HSCT?
No (No)
Unknown (Unknown)
Yes (Yes)
Survival Status
alive (0)
dead (1)
If alive: Type of score used:
Karnofsky (Karnofsky)
Lansky (Lansky)
Not evaluated (Not evaluated)
Unknown (Unknown)
Performance score
100 (Normal, NED) (1)
10 (Moribund) (10)
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Not evaluated (11)
Unknown (12)
90 (Normal activity)  (2)
80 (Normal with effort) (3)
70 (Cares for self) (4)
60 (Requires occasional assistance) (5)
50 (Requires assistance) (6)
40 (Disabled) (7)
30 (Severely disabled) (8)
20 (Very sick) (9)
CAUSE OF DEATH
HSCT related cause (HSCT related
cause)
Other (Other)
Relapse or progression (Relapse or
progression)
Secondary malignancy (Secondary
malignancy)
Unknown (Unknown)
HSCT related cause of death
GvHD (1)
Veno-occlusive disease (VOD) (10)
Haemorrhage (11)
Cardiac toxicity (12)
Central nervous system toxicity (13)
Gastro intestinal toxicity (14)
Skin toxicity (15)
Renal failure (16)
Multiple organ failure (17)
Other (18)
Interstitial pneumonitis (2)
Pulmonary toxicity (3)
Infection bacterial (4)
Infection viral (5)
Infection fungal (6)
Infection parasitic (7)
Infection unknown (8)
Rejection / poor graft function (9)
ADDITIONAL NOTES IF APPLICABLE
Comments
IDENTIFICATION & SIGNATURE
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Eligibility Prostate Cancer NCT02344017
Safety and Pharmacokinetics of ODM-204 in Patients With
Metastatic Castration-Resistant Prostate Cancer; ODM
derived from: https://clinicaltrials.gov/show/NCT02344017
All rights reserved. Please visit https://medical-data-
models.org/forms/15851
Eligibility Prostate Cancer
NCT02344017
Inclusion Criteria
written informed consent (ic) obtained.*
Yes
No
male aged ≥ 18 years.*
Yes
No
histologically or cytologically confirmed
adenocarcinoma of prostate.*
Yes
No
ongoing gnrh agonist or antagonist therapy, or
after bilateral orchiectomy.*
Yes
No
progressive metastatic disease*
Yes
No
adequate bone marrow, hepatic, and renal
function*
Yes
No
acceptable and regular bowel movements without
any gi disorder or procedure which may interfere
with absorption of study treatment*
Yes
No
ability to swallow study treatments*
Yes
No
Exclusion Criteria
history of pituitary or adrenal dysfunction.*
Yes
No
known brain metastases.*
Yes
No
active infection or other medical condition that
would make prednisone (corticosteroid)
contraindicated.*
Yes
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No
uncontrolled hypertension*
Yes
No
clinically significant heart disease*
Yes
No
prolonged qtc interval*
Yes
No
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Eligibility Prostate Cancer NCT02353715
Men With Metastatic Castrate-Resistant Prostate Cancer
Treated With Either Sipuleucel-T (Provenge®), Abiraterone
Acetate (Zytiga®) or Enzalutamide (Xtandi®) Undergoing
Cardiopulmonary EXercise Testing; ODM derived from:
https://clinicaltrials.gov/show/NCT02353715
All rights reserved. Please visit https://medical-data-
models.org/forms/15856
Eligibility Prostate Cancer
NCT02353715
Inclusion Criteria
1. male age ≥ 18 years*
Yes
No
2. histologically-confirmed adenocarcinoma of the
prostate*
Yes
No
3. metastatic lesions on bone scan or ct/mri, in
the opinion of the treating provider*
Yes
No
4. progressive prostate cancer, in the opinion of
the investigator*
Yes
No
5. surgically or medically castrated, with
testosterone levels of < 50 ng/dl*
Yes
No
6. not regularly using opioid pain medication for
prostate cancer pain, in the opinion of the treating
provider*
Yes
No
7. starting either enzalutamide or abiraterone for
at least 12 weeks or starting a course of
sipuleucel-t*
Yes
No
8. ecog performance status 0 or 1*
Yes
No
9. able to read and understand english, in the
opinion of the treating provider, well enough to
complete the study questionnaires*
Yes
No
10. subjects on other treatment research
protocols are allowed*
Yes
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No
11. able to comply with study requirements*
Yes
No
Exclusion Criteria
1. prior treatment with chemotherapy for
metastatic, castrate-resistant prostate cancer*
Yes
No
2. prior treatment with either enzalutamide or
abiraterone*
Yes
No
3. subjects who have had any surgical procedure
(i.e. turp, etc.) within 4 weeks prior to entering the
study.*
Yes
No
4. subjects receiving treatment with both
abiraterone and enzalutamide*
Yes
No
5. for arm c (sipuleucel-t) only:*
Yes
No
1. subjects receiving abiraterone or enzalutamide
concomitantly with sipuleucel-t*
Yes
No
2. subjects who have received prior sipuleucel-t*
Yes
No
6. subjects who have been enrolled on the study
previously on a different arm (for example,
enrollment on arm c and then transition to arm a
on progression is not allowed due to possible
selection bias)*
Yes
No
7. subjects who are receiving any other
investigational agents (i.e. enzalutamide or
abiraterone plus an investigational drug).*
Yes
No
8. subjects with any of the following absolute
contraindications to maximal exercise testing as
recommended by the american thoracic society
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and the exercise testing guidelines for cancer
subjects, in the opinion of the treating provider:
(a) acute myocardial infarction (3-5 days), (b)
unstable angina, (c) uncontrolled arrhythmias
causing symptoms or hemodynamic compromise,
(d) syncope, (e) acute endocarditis, (f) acute
myocarditis or pericarditis, (g) uncontrolled heart
failure, (h) acute pulmonary embolus or
pulmonary infarction, (i) thrombosis of lower
extremities, (j) suspected dissecting aneurysm,
(k) uncontrolled asthma, (l) pulmonary edema,
(m) room air desaturation at rest <85%, (n)
respiratory failure, (o) acute noncardiopulmonary
disorder that may affect exercise performance or
be aggravated by exercise, (p) mental impairment
leading to inability to cooperate, and (q) extensive
bone metastases.*
Yes
No
9. significant cardiovascular disease, including:*
Yes
No
1. symptomatic left ventricular dysfunction or
known baseline left ventricular ejection fraction
(lvef) by multigated acquisition scan (muga) or
echocardiogram (echo) of < lower limit of
institutional normal (lln).  "symptomatic" is
defined as new york heart association (nyha)
class ii or greater. note: muga and echco do not
need to be measured to establish eligibility for
this study.*
Yes
No
2. uncontrolled hypertension*
Yes
No
3. myocardial infarction, severe angina, or
unstable angina within 6 months prior to
administration of first dose of study drug*
Yes
No
4. history of serious ventricular arrhythmia (i.e.,
ventricular tachycardia or ventricular fibrillation)
within 12 months of first dose of study drug*
Yes
No
5. uncontrolled cardiac arrhythmias*
Yes
No
6. coronary or peripheral artery bypass graft
within 6 months of first dose of study drug*
Yes
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No
7. history of cva, tia, or rest claudication within 6
months of first dose of study drug*
Yes
No
10. uncontrolled intercurrent illness including, but
not limited to, ongoing or active infection,
symptomatic congestive heart failure, unstable
angina pectoris, cardiac arrhythmia, or psychiatric
illness/social situations that would limit
compliance with study requirements*
Yes
No
11. known or suspected brain metastasis or
leptomeningeal disease*
Yes
No
4 / 4
Eligibility Prostate Cancer NCT02353715
Premature Study Withdrawal Visit BG00012 Monotherapy Safety and Efficacy
Extension Study in Multiple Sclerosis (MS) (ENDORSE) NCT00835770
The primary objective of this study is to evaluate the long-
term safety profile of BG00012 (dimethyl fumarate).
Secondary objectives of this study are to evaluate the long-
term efficacy of BG00012 using clinical endpoints and
disability progression, to evaluate further the long-term
effects of BG00012 on multiple sclerosis (MS) brain lesions
on magnetic resonance imaging (MRI) scans in participants
who had MRI scans as part of Studies 109MS301
(NCT00420212) and 109MS302 (NCT00451451) and to
evaluate the long-term effects of BG00012 on health
economics assessments and the visual function test.
NCT00835770 
Part: Premature Study Withdrawal Visit
All rights reserved. Please visit https://medical-data-
models.org/forms/15857
Premature Study Withdrawal Visit
BG00012 Monotherapy Safety and
Efficacy Extension Study in Multiple
Sclerosis (MS) (ENDORSE)
NCT00835770
Subject Identification
Number of Facility
Subject number
Subject Initials
Vital Signs
Date of examination
Blood Pressure
Pulse
Temperature
Weight
Physical examination
Body System
Skin (1)
Rectal  (10)
Neurological  (11)
Extremities/Joints (12)
HEENT  (2)
Lymph nodes (3)
Neck and Thyroid  (4)
Breasts (5)
Chest/Lungs (6)
Heart  (7)
Vascular (8)
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Abdomen (9)
Examination Status
Not done (1)
Normal (2)
Abnormal (please specify) (3)
Abnormal examination findings
EDSS Evaluation
Date of Evaluation
Functional System Scores
Visual
Brinstem
Pyramidal
Cerebellar
Sensory
Bowel or Bladder
Cerebral
Additional and Results
Actual Distance Walked
<100 metres (<100 metres)
>100 metres and <200 metres (>100
metres and <200 metres)
>200 metres and <300 metres (>200
metres and <300 metres)
>300 metres and <500 metres (>300
metres and <500 metres)
>500 metres (>500 metres)
Actual Distance Walked
<100 metres (1)
>100 metres and <200 metres (2)
>200 metres and <300 metres (3)
>300 metres and <500 metres (4)
>500 metres (5)
EDSS Score
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Name of Neurologist
Visual Function Test
Date of Evaluation
Contrast Sensitivity Evaluation Binocular
100% Chart, Total # Correct
2,5% Chart, Total # Correct
1,25% Chart, Total # Correct
Snellen visual acuity equivalent
Study Drug Accountability
date of first dose
Number of capsules not taken since previous visit
to this visit
Was there a protocol-defined dose
reduction/interruption since the previous visit?
Yes
No
Additional Surveys
EQ5D Questionnaire
SF-36 Questionaire
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Telephone Visit BG00012 Monotherapy Safety and Efficacy Extension
Study in Multiple Sclerosis (MS) (ENDORSE) NCT00835770
The primary objective of this study is to evaluate the long-
term safety profile of BG00012 (dimethyl fumarate).
Secondary objectives of this study are to evaluate the long-
term efficacy of BG00012 using clinical endpoints and
disability progression, to evaluate further the long-term
effects of BG00012 on multiple sclerosis (MS) brain lesions
on magnetic resonance imaging (MRI) scans in participants
who had MRI scans as part of Studies 109MS301
(NCT00420212) and 109MS302 (NCT00451451) and to
evaluate the long-term effects of BG00012 on health
economics assessments and the visual function test.
NCT00835770 
Part: Telephone Visit
All rights reserved. Please visit https://medical-data-
models.org/forms/15858
Telephone Visit Vital Signs BG00012
Monotherapy Safety and Efficacy
Extension Study in Multiple Sclerosis
(MS) (ENDORSE) NCT00835770
Subject Identification
Number of Facility
Subject number
Subject Initials
Telepone Visit Details
Date of telephone call
Person contacted
subject (1)
other  (2)
unable to make contact (3)
Other person
Since the subject was last contacted, has the
subject experienced any new or continuing
adverse events?
Yes
No
Since the subject was last contacted, has the
subject received any concomitant medications?*
Yes
No
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Adverse Event BG00012 Monotherapy Safety and Efficacy Extension
Study in Multiple Sclerosis (MS) (ENDORSE) NCT00835770
The primary objective of this study is to evaluate the long-
term safety profile of BG00012 (dimethyl fumarate).
Secondary objectives of this study are to evaluate the long-
term efficacy of BG00012 using clinical endpoints and
disability progression, to evaluate further the long-term
effects of BG00012 on multiple sclerosis (MS) brain lesions
on magnetic resonance imaging (MRI) scans in participants
who had MRI scans as part of Studies 109MS301
(NCT00420212) and 109MS302 (NCT00451451) and to
evaluate the long-term effects of BG00012 on health
economics assessments and the visual function test.
NCT00835770 
Part: Adverse Event
All rights reserved. Please visit https://medical-data-
models.org/forms/15859
Adverse Event BG00012
Monotherapy Safety and Efficacy
Extension Study in Multiple Sclerosis
(MS) (ENDORSE) NCT00835770
Subject Identification
Number of Facility
Subject number
Subject Initials
Adverse Event
Adverse Event: List Diagnosis if possible
Serious adverse event
Yes
No
SAE Tracking number
Start Date
Adverse Event Stop Date
not resolved
Yes
No
Severity
Mild  (1)
Moderate (2)
Severe (3)
Action taken with study treatment
None  (1)
Interrupdet  (2)
Reduced  (3)
Discontinued (4)
1 / 2
Relationship to blinded study treatment
unrelated  (1)
unlikely  (2)
possible  (3)
related (4)
Concomitant treatment given
Yes
No
Resulted in withdrawal from study?
Yes
No
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Eligibility Prostate Cancer NCT02366494
Micro RNAs to Predict Response to Androgen Deprivation
Therapy; ODM derived from:
https://clinicaltrials.gov/show/NCT02366494
All rights reserved. Please visit https://medical-data-
models.org/forms/15860
Eligibility Prostate Cancer
NCT02366494
Inclusion Criteria
histologically proven prostate cancer.*
Yes
No
testosterone level >30ng/ml and at least 6
months since last dose of     hormonal therapy.*
Yes
No
history/physical examination including a detailed
description of the stage of prostate cancer within
8 weeks prior to registration.*
Yes
No
ct scan of abdomen and pelvis with iv contrast
and bone scan should be performed within 8
weeks  prior to registration.*
Yes
No
ecog performance status 0-2.*
Yes
No
age ≥ 18.*
Yes
No
patients must provide study-specific informed
consent prior to study entry for this project and
mandatory blood specimen for banking for future
studies (future studies may include  genetic
testing).*
Yes
No
Exclusion Criteria
received hormonal therapy less than 6 months
prior to registration.*
Yes
No
history of active secondary malignancy.*
Yes
No
decline hormone therapy for prostate cancer.*
Yes
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No
current or previous treatment with 5-alpha
reductase inhibitors within 6 months prior to
enrollment.*
Yes
No
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Eligibility Prostate Cancer NCT02425592
Active Surveillance in Prostate Cancer, Imaging to Detect
Radiographic Progression as an Endpoint (ASPIRE); ODM
derived from: https://clinicaltrials.gov/show/NCT02425592
All rights reserved. Please visit https://medical-data-
models.org/forms/15861
Eligibility Prostate Cancer
NCT02425592
Inclusion Criteria
age 30-80*
Yes
No
completed mri fusion prostate biopsy either in the
past that demonstrated gleason 6 prostate
cancer and are either currently enrolled in active
surveillance or are interested in active
surveillance, or have completed an mri fusion
prostate biopsy at the first visit that demonstrates
gleason 6 prostate cancer and are interested in
active surveillance*
Yes
No
diagnosed with gleason 6 prostate cancer*
Yes
No
psa <20*
Yes
No
<ct3 prostate cancer*
Yes
No
ability to receive an mri with iv gadolinium
contrast*
Yes
No
life expectancy >10 years (by physician
estimate)*
Yes
No
understanding and willingness to provide
consent*
Yes
No
english speaking*
Yes
No
Exclusion Criteria
received treatment for prostate cancer (hormone
manipulation, surgery, radiation).*
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Yes
No
known metastatic disease*
Yes
No
high risk prostate cancer by epstein criteria*
Yes
No
any gleason 7 or higher prostate cancer on
prostate biopsy*
Yes
No
inability to receive an mri with iv gadolinium
contrast*
Yes
No
life expectancy  <10 years*
Yes
No
unwillingness to undergo monitoring and imaging
studies*
Yes
No
non-english speaking*
Yes
No
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Eligibility Prostatic Neoplams
NCT02362464
Long-Term TARP Vaccination Using a Multi-Epitope TARP
Peptide Autologous Dendritic Cell Vaccination in Previously
Vaccinated Men on NCI 09-C-0139; ODM derived from:
https://clinicaltrials.gov/show/NCT02362464
All rights reserved. Please visit https://medical-data-
models.org/forms/15862
Eligibility Prostatic Neoplams
NCT02362464
Criteria
males greater than or equal to 18 years of age
with histologically confirmed adenocarcinoma of
the prostate.*
Yes
No
prior enrollment in nci protocol 09-c-0139 with
receipt of at least 5 doses of tarp peptide vaccine
(i.e. completion of primary vaccination series).*
Yes
No
performance status: ecog 0-1, life expectancy of
greater than or equal to 1 year.*
Yes
No
hemoglobin greater than or equal to 10.0 gm/dl,
wbc greater than or equal to 2,500/mm3, alc
greater than or equal to 500/mm3, anc greater
than or equal to 1,000/mm3, platelet count
greater than or equal to 100,000/mm3.*
Yes
No
pt/ptt less than or equal to 1.5x uln unless
receiving clinically indicated anticoagulant
therapy.*
Yes
No
sgot/sgpt less than or equal to 2.5x uln, total
bilirubin less than or equal to 1.5x uln, cr less
than or equal to 1.5x uln, estimated gfr (egfr)
greater than or equal to 60 ml/min.*
Yes
No
hepatitis b and c negative, unless the result is
consistent with prior vaccination or prior infection
with full recovery.*
Yes
No
hiv negative*
Yes
No
no use of investigational agents within 4 weeks of
study enrollment or use of immunosuppressive or
immunomodulating agents (including ivig) within
1 / 3
8 weeks of study entry. note: use of topical,
inhaled and intranasal steroid therapy is
permitted.*
Yes
No
greater than or equal to 6 weeks since the receipt
of chemotherapy or radiation therapy.*
Yes
No
standard of care medical management of current
prostate cancer disease status by the patient   s
local oncologist, e.g. androgen deprivation
therapy is allowed.*
Yes
No
able to understand and provide informed
consent.*
Yes
No
must be able and willing to adhere to protocol
requirements, visits and vaccination*
Yes
No
timeline.*
Yes
No
Exclusion Criteria
patients with a second malignancy requiring
active treatment.*
Yes
No
patients with an active infection.*
Yes
No
patients on immunosuppressive therapy
including:*
Yes
No
-systemic corticosteroid therapy for any reason.
patients receiving inhaled, intranasal or topical
corticosteroids may participate.*
Yes
No
other significant or uncontrolled medical illness.
patients with a remote history of or active mild
asthma may participate.*
Yes
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No
patients who, in the opinion of the principal
investigator, have significant medical or
psychosocial problems that warrant exclusion
including:*
Yes
No
other serious non-malignancy-associated medical
conditions that may be*
Yes
No
expected to limit life expectancy to less than 2
years.*
Yes
No
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Eligibility Prostatic Neoplasm
NCT02311764
Carboplatin in Castration-resistant Prostate Cancer; ODM
derived from: https://clinicaltrials.gov/show/NCT02311764
All rights reserved. Please visit https://medical-data-
models.org/forms/15864
Eligibility Prostatic Neoplasm
NCT02311764
Inclusion Criteria
1. written informed consent*
Yes
No
2. adult patients with histological diagnosis of
adenocarcinoma of the prostate.*
Yes
No
3. metastatic castration-resistant prostate cancer
(mcrpc)*
Yes
No
4. progression after at least one taxane-based
chemotherapy (or contraindication against
taxanes) and at least one therapy with a newer
hormonal agent (cyp17 inhibitor or a new
generation aa like enzalutamide).*
Yes
No
5. loss of pten by ihc (h-scores ≤ 30) and/or
evidence of dna repair defects by ngs*
Yes
No
6. eastern cooperative oncology group (ecog)
performance status (ps) 0 - 2*
Yes
No
7. progression of disease by any of the criteria
listed here:*
Yes
No
psa utilizing pcwg 2 criteria*
Yes
No
bone scan*
Yes
No
recist 1.1*
Yes
No
8. adequate organ and bone marrow function as
evidenced by:*
1 / 3
Yes
No
haemoglobin ≥8.0 g/dl*
Yes
No
absolute neutrophil count ≥1.5 x 109/l*
Yes
No
platelet count ≥ 100 x 109/l*
Yes
No
ast and/or alt < 2.5 x uln, in the presence of liver
metastases: ast ≥5 x uln, alt <5 x uln*
Yes
No
total bilirubin < 2.0 x uln (except for patients with
gilbert's disease)*
Yes
No
creatinine clearance ≥30ml/min*
Yes
No
9. patient must agree in the biomarker studies
including the fresh tumour biopsies*
Yes
No
Exclusion Criteria
1. contraindications to the class of drugs under
study, e.g. known hypersensitivity or allergy to
class of drugs or the investigational product
carboplatin*
Yes
No
2. prior treatment with any prior platinum based
chemotherapy,*
Yes
No
3. major surgery within 4 weeks prior to planned
start of treatment*
Yes
No
4. known brain or leptomeningeal involvement
unless clinically stable and on stable dose of
steroids*
Yes
No
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5. inability to follow the procedures of the study,
e.g. due to language problems, psychological
disorders, dementia, etc. of the participant*
Yes
No
6. previous enrolment into the current study*
Yes
No
7. active secondary malignancy that requires
systemic therapy.*
Yes
No
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Eligibility Prostatic Neoplasms
NCT02344667
Feasibility Study of Stereotactic Body Radiotherapy (SBRT)
for Localized Prostate Cancer: Cyberknife vs. VMAT; ODM
derived from: https://clinicaltrials.gov/show/NCT02344667
All rights reserved. Please visit https://medical-data-
models.org/forms/15865
Eligibility Prostatic Neoplasms
NCT02344667
Inclusion Criteria
histologically confirmed diagnosis of
adenocarcinoma of the prostate*
Yes
No
histological evaluation of prostate biopsy with
assignment of a gleason score to the biopsy
material; gleason scores ≤ 7*
Yes
No
clinical stage t1-2b (ajcc 7th edition)*
Yes
No
psa ≤ 10 ng/ml. psa should not be obtained within
10 days after prostate biopsy.*
Yes
No
ecog performance status 0-1*
Yes
No
Exclusion Criteria
prior or concurrent invasive malignancy (except
non-melanomatous skin cancer) or
lymphomatous/hematogenous malignancy unless
continually disease free for a minimum of 5
years.*
Yes
No
evidence of distant metastases*
Yes
No
regional lymph node involvement*
Yes
No
previous radical surgery (prostatectomy),
cryosurgery, or hifu for prostate cancer. previous
pelvic irradiation, prostate brachytherapy, or
bilateral orchiectomy*
Yes
No
previous hormonal therapy, such as lhrh agonists
1 / 2
or lhrh antagonists, anti-androgens, estrogens, or
surgical castration*
Yes
No
use of finasteride or dutasteride within 30 days
prior to registration. psa should not be obtained
prior to 30 days after stopping finasteride or
dutasteride.*
Yes
No
previous or concurrent cytotoxic chemotherapy
for prostate cancer*
Yes
No
age < 18*
Yes
No
patient unable to provide study-specific informed
consent*
Yes
No
inability to complete the expanded prostate
cancer index composite (epic) questionnaire*
Yes
No
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Eligibility Prostatic Neoplasms NCT02344667
CDISC Example Study
This example file was originally developed by David
Iberson-Hurst (Assero).It was further extended and adapted
for ODM 1.3 by Jozef Aerts (XML4Pharma) adding German
and French Translations.Translations into Korean were
provided by the Catholic University of Seoul.
All rights reserved. Please visit https://medical-data-
models.org/forms/15866
Baseline Visit Form
Common
Site number*
Subject ID*
Visit Date*
Visit Start Time*
Demographics
Date of Birth*
Sex*
Female (F)
Male (M)
Race
Asian (ASIAN)
Black (BLACK)
Caucasian (CAUCASIAN)
Other (OTHER)
Smoking History
Check when the subject is a smoker*
Yes
No
Number of cigarettes per day
10 to 20 cigarettes per day (10TO20)
Greater Than 20 cigarettes per day
(GT20)
Less Than 10 cigarettes per day (LT10)
Complaints related to smoking
Breathing
No (0)
Yes (1)
Coughing
No (0)
Yes (1)
1 / 11
Heart
No (0)
Yes (1)
No. of illness days last year
Number of bronchitis cases during the last year
Number of pneumonia cases last year
Drinking history
Number of alcoholic drinks per day*
1 to 2 drinks per day (1TO2)
Greater Than 2 drinks per day (GT2)
Less Than 1 drink per day (LT1)
Physical examination: Base
Height*
< 220
< 90
in
Weight*
< 150
< 300
lbs
BMI*
Systolic blood pressure
< 180
mm Hg
Diastolic blood pressure*
< 120
mm Hg
Does the subject feel dizzy when standing up
from a sitting position*
No (0)
Yes (1)
X-Ray
Server or File location of X-Ray photograph*
Prior or Concomitant Medications
(ACRO)
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Common
Site number*
Subject ID*
Visit Date*
Visit Start Time*
Non-study related medication
Were any non-study medications taken*
No (0)
Yes (1)
Concomittant medication
Medication No.*
Drug Name (Brand or Generic)*
Total Dose Per Freqeuncy Checked*
Unit*
Frequency*
Single Dose (1)
Daily (2)
Weekly (3)
Monthly (4)
PRN (5)
Other (99)
Start Date*
Is medication still continuing*
No (0)
Yes (1)
Stop Date*
Pre-existing illness No.*
Adverse Event No.*
Prophylaxis*
No (0)
Yes (1)
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Prophylaxis, Specify*
Laboratory
Common
Site number*
Subject ID*
Visit Date*
Visit Start Time*
Hematology Lab
Laboratory Name*
Laboratory ID*
Accession #*
Check when not done*
Yes
No
Red Blood Count*
<= 8.0
>= 2.0
<= 6.5
>= 4.0
million/uL
Red Blood Count, Normal Range, Low*
Red Blood Count, Normal Range, High*
Check when not Done*
Yes
No
White Blood Count*
<= 15
>= 2.0
<= 12.0
>= 3.5
White Blood Count, Normal Range, Low*
4 / 11
CDISC Example Study
White Blood Count, Normal Range, High*
Complaints related to smoking
Complaints related to smoking
Breathing
No (0)
Yes (1)
Coughing
No (0)
Yes (1)
Heart
No (0)
Yes (1)
No. of illness days last year
Number of bronchitis cases during the last year
Number of pneumonia cases last year
Week 1 and 2 Form
Common
Site number*
Subject ID*
Visit Date*
Visit Start Time*
Physical Examination: Week
Weight*
< 150
< 300
lbs
Systolic blood pressure*
< 180
mm Hg
Diastolic blood pressure*
< 120
mm Hg
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Common
Site number*
Subject ID*
Visit Date*
Visit Start Time*
Hematology Lab
Laboratory Name*
Laboratory ID*
Accession #*
Check when not done*
Yes
No
Red Blood Count*
<= 8.0
>= 2.0
<= 6.5
>= 4.0
million/uL
Red Blood Count, Normal Range, Low*
Red Blood Count, Normal Range, High*
Check when not Done*
Yes
No
White Blood Count*
<= 15
>= 2.0
<= 12.0
>= 3.5
White Blood Count, Normal Range, Low*
White Blood Count, Normal Range, High*
Common
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Site number*
Subject ID*
Visit Date*
Visit Start Time*
Physical Examination: Week
Weight*
< 150
< 300
lbs
Systolic blood pressure*
< 180
mm Hg
Diastolic blood pressure*
< 120
mm Hg
Common
Site number*
Subject ID*
Visit Date*
Visit Start Time*
Hematology Lab
Laboratory Name*
Laboratory ID*
Accession #*
Check when not done*
Yes
No
Red Blood Count*
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<= 8.0
>= 2.0
<= 6.5
>= 4.0
million/uL
Red Blood Count, Normal Range, Low*
Red Blood Count, Normal Range, High*
Check when not Done*
Yes
No
White Blood Count*
<= 15
>= 2.0
<= 12.0
>= 3.5
White Blood Count, Normal Range, Low*
White Blood Count, Normal Range, High*
Diary Form
Common
Site number*
Subject ID*
Visit Date*
Visit Start Time*
Patient diary
Day*
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
7 (7)
Date*
Discomfort Severity*
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None (1)
Mild (2)
Moderate (3)
Severe (4)
Adverse Event Form (ACRO)
Common
Site number*
Subject ID*
Visit Date*
Visit Start Time*
Adverse events
Has the subject experienced any adverse events*
No (0)
Yes (1)
Adverse events
Event No.*
Adverse event*
Start Date*
Is the adverse event still continuing
No (0)
Yes (1)
Stop Date
Duration of the adverse event
Was event serious*
No (0)
Yes (1)
Severity*
Mild (1)
Moderate (2)
Severe (3)
Is there a reasonable possibility that the AE may
have been caused by the study drug*
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No (0)
Yes (1)
Action taken with study drug*
None (1)
Study drug regimen changed (2)
Temporarily stopped study drug (3)
Study drug discontinued (4)
Subject outcome*
Subject remains in study (1)
Withdrawn from study (2)
Lost to follow-up (3)
Death (4)
Common
Site number*
Subject ID*
Visit Date*
Visit Start Time*
Non-study related medication
Were any non-study medications taken*
No (0)
Yes (1)
Concomittant medication
Medication No.*
Drug Name (Brand or Generic)*
Total Dose Per Freqeuncy Checked*
Unit*
Frequency*
Single Dose (1)
Daily (2)
Weekly (3)
Monthly (4)
PRN (5)
Other (99)
Start Date*
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Is medication still continuing*
No (0)
Yes (1)
Stop Date*
Pre-existing illness No.*
Adverse Event No.*
Prophylaxis*
No (0)
Yes (1)
Prophylaxis, Specify*
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Concomitant Medication BG00012 Monotherapy Safety and Efficacy
Extension Study in Multiple Sclerosis (MS) (ENDORSE) NCT00835770
The primary objective of this study is to evaluate the long-
term safety profile of BG00012 (dimethyl fumarate).
Secondary objectives of this study are to evaluate the long-
term efficacy of BG00012 using clinical endpoints and
disability progression, to evaluate further the long-term
effects of BG00012 on multiple sclerosis (MS) brain lesions
on magnetic resonance imaging (MRI) scans in participants
who had MRI scans as part of Studies 109MS301
(NCT00420212) and 109MS302 (NCT00451451) and to
evaluate the long-term effects of BG00012 on health
economics assessments and the visual function test.
NCT00835770 
Part: Concomitant Medication
All rights reserved. Please visit https://medical-data-
models.org/forms/15867
Concomitant Medication BG00012
Monotherapy Safety and Efficacy
Extension Study in Multiple Sclerosis
(MS) (ENDORSE) NCT00835770
Subject Identification
Number of Facility
Subject number
Subject Initials
Any new or changed medication
Yes
No
Concomitant Medication list
Medication No.
Medication name:
Indication
Dose
Units
Route
Frequency
Start date
Agent End Date
Ongoing
Yes
1 / 2
No
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Concomitant Medication BG00012 Monotherapy Safety and Efficacy
Extension Study in Multiple Sclerosis (MS) (ENDORSE) NCT00835770
Concomitat Non-Drug Treatment BG00012 Monotherapy Safety and Efficacy
Extension Study in Multiple Sclerosis (MS) (ENDORSE) NCT00835770
The primary objective of this study is to evaluate the long-
term safety profile of BG00012 (dimethyl fumarate).
Secondary objectives of this study are to evaluate the long-
term efficacy of BG00012 using clinical endpoints and
disability progression, to evaluate further the long-term
effects of BG00012 on multiple sclerosis (MS) brain lesions
on magnetic resonance imaging (MRI) scans in participants
who had MRI scans as part of Studies 109MS301
(NCT00420212) and 109MS302 (NCT00451451) and to
evaluate the long-term effects of BG00012 on health
economics assessments and the visual function test.
NCT00835770 
Part: Concomitat Non-Drug Treatment
All rights reserved. Please visit https://medical-data-
models.org/forms/15868
Concomitat Non-Drug Treatment
BG00012 Monotherapy Safety and
Efficacy Extension Study in Multiple
Sclerosis (MS) (ENDORSE)
NCT00835770
Subject Identification
Number of Facility
Subject number
Subject Initials
Concomitant Medication list
Treatment Number
Treatment/Procedure
Indication
Dose
Units
Route
Frequency
Start date
Agent End Date
Ongoing
Yes
No
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Record of Death BG00012 Monotherapy Safety and Efficacy Extension
Study in Multiple Sclerosis (MS) (ENDORSE) NCT00835770
The primary objective of this study is to evaluate the long-
term safety profile of BG00012 (dimethyl fumarate).
Secondary objectives of this study are to evaluate the long-
term efficacy of BG00012 using clinical endpoints and
disability progression, to evaluate further the long-term
effects of BG00012 on multiple sclerosis (MS) brain lesions
on magnetic resonance imaging (MRI) scans in participants
who had MRI scans as part of Studies 109MS301
(NCT00420212) and 109MS302 (NCT00451451) and to
evaluate the long-term effects of BG00012 on health
economics assessments and the visual function test.
NCT00835770 
Part: Record of Death
All rights reserved. Please visit https://medical-data-
models.org/forms/15869
Record of Death BG00012
Monotherapy Safety and Efficacy
Extension Study in Multiple Sclerosis
(MS) (ENDORSE) NCT00835770
Subject Identification
Number of Facility
Subject number
Subject Initials
Record of Death
Date of death
Cause of death
Is the cause of death related to an adverse
event?
Yes
No
Adverse Event CRF page number
Relationship of death to study treatment
not related  (0)
unlikely  (1)
possible  (2)
related (3)
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Eligibility Psoriatic Arthritis NCT02319759
Efficacy and Safety Study of Guselkumab in the Treatment
of Participants With Active Psoriatic Arthritis (PsA); ODM
derived from: https://clinicaltrials.gov/show/NCT02319759
All rights reserved. Please visit https://medical-data-
models.org/forms/15871
Eligibility Psoriatic Arthritis
NCT02319759
Inclusion Criteria
has had psoriatic arthritis (psa) for at least 6
months before the first administration of study
drug and meet classification criteria for psoriatic
arthritis (caspar) at screening*
Yes
No
had active psa as defined by:*
Yes
No
1. at least 3 swollen joints and at least 3 tender
joints at screening and at baseline*
Yes
No
2. c-reactive protein (crp) greater than or equal to
(>=) 0.3 milligram (mg)/deciliter (dl) at screening
from the central laboratory*
Yes
No
has at least 1 of the psa subsets: distal
interphalangeal joint involvement, polyarticular
arthritis with absence of rheumatoid nodules,
arthritis mutilans, asymmetric peripheral arthritis,
or spondylitis with peripheral arthritis*
Yes
No
has plaque psoriasis with body surface area (bsa)
involvement greater than or equal to (>=) 3% at
screening and baseline*
Yes
No
has active psa despite current or previous non-
biologic disease-modifying antirheumatic drugs
(dmard), oral corticosteroid, and/or nonsteroidal
anti-inflammatory drug (nsaid) therapy*
Yes
No
if using methotrexate (mtx), oral corticosteroids or
nsaids, the dose must be stable*
Yes
No
Exclusion Criteria
have other inflammatory diseases that might
1 / 2
confound the evaluations of benefit of
guselkumab therapy, including but not limited to
rheumatoid arthritis (ra), ankylosing spondylitis
(as), systemic lupus erythematosus, or lyme
disease*
Yes
No
has previously received guselkumab or
ustekinumab*
Yes
No
has received more than 1 type of biologic anti-
tumor necrosis factor (tnf) agent previously*
Yes
No
have received infliximab (or its biosimilars) or
golimumab intraveneous (iv) within 12 weeks
before the first administration of study drug*
Yes
No
have received adalimumab (or its biosimilars),
golimumab subcutaneous (sc), certolizumab
pegol or etanercept (or its biosimilars) within 8
weeks before the first administration of study
drug*
Yes
No
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Eligibility Psoriatic Arthritis NCT02319759
Protocol deviation and Investigator Sign off BG00012 Monotherapy Safety and
Efficacy Extension Study in Multiple Sclerosis (MS) (ENDORSE) NCT00835770
The primary objective of this study is to evaluate the long-
term safety profile of BG00012 (dimethyl fumarate).
Secondary objectives of this study are to evaluate the long-
term efficacy of BG00012 using clinical endpoints and
disability progression, to evaluate further the long-term
effects of BG00012 on multiple sclerosis (MS) brain lesions
on magnetic resonance imaging (MRI) scans in participants
who had MRI scans as part of Studies 109MS301
(NCT00420212) and 109MS302 (NCT00451451) and to
evaluate the long-term effects of BG00012 on health
economics assessments and the visual function test.
NCT00835770 
Part: Protocol deviation and Investigator Sign off
All rights reserved. Please visit https://medical-data-
models.org/forms/15872
Protocol deviation and Investigator
Sign off BG00012 Monotherapy
Safety and Efficacy Extension Study
in Multiple Sclerosis (MS)
(ENDORSE) NCT00835770
Subject Identification
Number of Facility
Subject number
Subject Initials
Protocol deviations
Deviation number
Category Code
Eligibility Criteria violation (1)
All dosing issues including missed partial
or incorrect doses as well as non-
compliance (2)
Prohibited concomitant treatment (3)
Evalutation performed outside of
acceptable visit window (4)
Efficacy evaluation not performed or not
valid (5)
Safety evaluation not performed or not
valid (6)
Missed study visit  (7)
Other (8)
Timed point or visit name (if appropriate)
Deviation
Action
Investigator sign off
1 / 2
Investigating physician's signature
Date of signature
Investigating physician (print name)
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Protocol deviation and Investigator Sign off BG00012 Monotherapy Safety and
Efficacy Extension Study in Multiple Sclerosis (MS) (ENDORSE) NCT00835770
Visit 13 (Week 108): Vital Signs, Study Drug accountability BG00012 Monotherapy
Safety and Efficacy Extension Study in Multiple Sclerosis (MS) (ENDORSE)
NCT00835770
The primary objective of this study is to evaluate the long-
term safety profile of BG00012 (dimethyl fumarate).
Secondary objectives of this study are to evaluate the long-
term efficacy of BG00012 using clinical endpoints and
disability progression, to evaluate further the long-term
effects of BG00012 on multiple sclerosis (MS) brain lesions
on magnetic resonance imaging (MRI) scans in participants
who had MRI scans as part of Studies 109MS301
(NCT00420212) and 109MS302 (NCT00451451) and to
evaluate the long-term effects of BG00012 on health
economics assessments and the visual function test.
NCT00835770
Part: Visit 13 (Week 108)
All rights reserved. Please visit https://medical-data-
models.org/forms/15873
Visit 13 (Week 108): Vital Signs,
Study Drug accountability BG00012
Monotherapy Safety and Efficacy
Extension Study in Multiple Sclerosis
(MS) (ENDORSE) NCT00835770
Subject Identification
Number of Facility
Subject number
Subject Initials
Vital Signs
Date of examination
Blood Pressure
Pulse
Temperature
Study Drug Accountability
date of first dose
Number of capsules not taken since previous visit
to this visit
Was there a protocol-defined dose
reduction/interruption since the previous visit?
Yes
No
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Visit 14 (Week 120): Vital Signs/Physical Examination BG00012 Monotherapy
Safety and Efficacy Extension Study in Multiple Sclerosis (MS) (ENDORSE)
NCT00835770
The primary objective of this study is to evaluate the long-
term safety profile of BG00012 (dimethyl fumarate).
Secondary objectives of this study are to evaluate the long-
term efficacy of BG00012 using clinical endpoints and
disability progression, to evaluate further the long-term
effects of BG00012 on multiple sclerosis (MS) brain lesions
on magnetic resonance imaging (MRI) scans in participants
who had MRI scans as part of Studies 109MS301
(NCT00420212) and 109MS302 (NCT00451451) and to
evaluate the long-term effects of BG00012 on health
economics assessments and the visual function test.
NCT00835770 
Part: Visit 14 (Week 120)
All rights reserved. Please visit https://medical-data-
models.org/forms/15874
Visit 14 (Week 120): Vital
Signs/Physical Examination
BG00012 Monotherapy Safety and
Efficacy Extension Study in Multiple
Sclerosis (MS) (ENDORSE)
NCT00835770
Subject Identification
Number of Facility
Subject number
Subject Initials
Vital Signs
Date of examination
Blood Pressure
Pulse
Temperature
Weight
Physical examination
Body System
Skin (1)
Rectal  (10)
Neurological  (11)
Extremities/Joints (12)
HEENT  (2)
Lymph nodes (3)
Neck and Thyroid  (4)
Breasts (5)
Chest/Lungs (6)
1 / 3
Heart  (7)
Vascular (8)
Abdomen (9)
Examination Status
Not done (1)
Normal (2)
Abnormal (please specify) (3)
Abnormal examination findings
EDSS Evaluation
Date of Evaluation
Functional System Scores
Visual
Brinstem
Pyramidal
Cerebellar
Sensory
Bowel or Bladder
Cerebral
Additional and Results
Actual Distance Walked
<100 metres (<100 metres)
>100 metres and <200 metres (>100
metres and <200 metres)
>200 metres and <300 metres (>200
metres and <300 metres)
>300 metres and <500 metres (>300
metres and <500 metres)
>500 metres (>500 metres)
Actual Distance Walked
<100 metres (1)
>100 metres and <200 metres (2)
>200 metres and <300 metres (3)
>300 metres and <500 metres (4)
>500 metres (5)
EDSS Score
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Visit 14 (Week 120): Vital Signs/Physical Examination BG00012 Monotherapy
Safety and Efficacy Extension Study in Multiple Sclerosis (MS) (ENDORSE)
NCT00835770
Name of Neurologist
Visual Function Test
Date of Evaluation
Contrast Sensitivity Evaluation Binocular
100% Chart, Total # Correct
2,5% Chart, Total # Correct
1,25% Chart, Total # Correct
Snellen visual acuity equivalent
Study Drug Accountability
date of first dose
Number of capsules not taken since previous visit
to this visit
Was there a protocol-defined dose
reduction/interruption since the previous visit?
Yes
No
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Visit 14 (Week 120): Vital Signs/Physical Examination BG00012 Monotherapy
Safety and Efficacy Extension Study in Multiple Sclerosis (MS) (ENDORSE)
NCT00835770
Visit 15 (Week 132): Vital Signs BG00012 Monotherapy Safety and Efficacy
Extension Study in Multiple Sclerosis (MS) (ENDORSE) NCT00835770
The primary objective of this study is to evaluate the long-
term safety profile of BG00012 (dimethyl fumarate).
Secondary objectives of this study are to evaluate the long-
term efficacy of BG00012 using clinical endpoints and
disability progression, to evaluate further the long-term
effects of BG00012 on multiple sclerosis (MS) brain lesions
on magnetic resonance imaging (MRI) scans in participants
who had MRI scans as part of Studies 109MS301
(NCT00420212) and 109MS302 (NCT00451451) and to
evaluate the long-term effects of BG00012 on health
economics assessments and the visual function test.
NCT00835770 
Part: Visit 15 (Week 132)
All rights reserved. Please visit https://medical-data-
models.org/forms/15875
Visit 15 (Week 132): Vital Signs
BG00012 Monotherapy Safety and
Efficacy Extension Study in Multiple
Sclerosis (MS) (ENDORSE)
NCT00835770
Subject Identification
Number of Facility
Subject number
Subject Initials
Vital Signs
Date of examination
Blood Pressure
Pulse
Temperature
Study Drug Accountability
date of first dose
Number of capsules not taken since previous visit
to this visit
Was there a protocol-defined dose
reduction/interruption since the previous visit?
Yes
No
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Visit 17 (Week 168): Vital Signs, Study Drug accountability BG00012 Monotherapy
Safety and Efficacy Extension Study in Multiple Sclerosis (MS) (ENDORSE)
NCT00835770
The primary objective of this study is to evaluate the long-
term safety profile of BG00012 (dimethyl fumarate).
Secondary objectives of this study are to evaluate the long-
term efficacy of BG00012 using clinical endpoints and
disability progression, to evaluate further the long-term
effects of BG00012 on multiple sclerosis (MS) brain lesions
on magnetic resonance imaging (MRI) scans in participants
who had MRI scans as part of Studies 109MS301
(NCT00420212) and 109MS302 (NCT00451451) and to
evaluate the long-term effects of BG00012 on health
economics assessments and the visual function test.
NCT00835770
Part: Visit 17 (Week 168)
All rights reserved. Please visit https://medical-data-
models.org/forms/15877
Visit 17 (Week 168): Vital Signs,
Study Drug accountability BG00012
Monotherapy Safety and Efficacy
Extension Study in Multiple Sclerosis
(MS) (ENDORSE) NCT00835770
Subject Identification
Number of Facility
Subject number
Subject Initials
Vital Signs
Date of examination
Blood Pressure
Pulse
Temperature
Study Drug Accountability
date of first dose
Number of capsules not taken since previous visit
to this visit
Was there a protocol-defined dose
reduction/interruption since the previous visit?
Yes
No
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Eligibility Psoriatic Arthritis NCT02472717
Psoriatic Arthritis Treated With Liraglutide Therapy: a
QUality of Life and Efficacy Study; ODM derived from:
https://clinicaltrials.gov/show/NCT02472717
All rights reserved. Please visit https://medical-data-
models.org/forms/15878
Eligibility Psoriatic Arthritis
NCT02472717
Inclusion Criteria
patients with active psoriatic arthritis (3 tender
and swollen joints) meeting caspar study group
criteria*
Yes
No
Exclusion Criteria
bmi > 35 kg/m2*
Yes
No
uncontrolled diabetes, hba1c > 10.5%*
Yes
No
current biological treatment for any inflammatory
disorder within the past three months*
Yes
No
renal dysfunction (egfr < 50 ml/min/1.73m or
macroalbuminuria >300mg)*
Yes
No
hepatic dysfunction (ast (aspartate
aminotransferase), alt (alanine
aminotransferase), total bilirubin > 3 times upper
limit of normal)*
Yes
No
history of pancreatitis or personal or family
history of medullary thyroid cancer, c-cell
hyperplasia, or men-2 syndrome*
Yes
No
current pregnancy or current breast feeding*
Yes
No
use of dpp-4 (dipeptidyl peptidase-4 inhibitor) or
glp-1 receptor agonist within 2 months (washout
is permitted)*
Yes
No
drug or alcohol dependence*
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Yes
No
resting tachycardia > 100 bpm or conduction
abnormalities associated with tachycardia*
Yes
No
current enrollment in any other clinical trial*
Yes
No
symptomatic gastroparesis*
Yes
No
concomitant serious medical conditions*
Yes
No
all medication for the treatment of psoriatic
arthritis such as mtx (methotrexate) < 25 mg, lfn
(leflunomide) < 20 mg, and nsaids (non-steroidal
anti-inflammatory drugs) will have been used at
stable doses for at least 4 weeks, having been
initiated at least 3 months prior to study start (8
weeks before screening, 4 weeks before
baseline) for mtx and lfn and at least 4 weeks for
nsaids*
Yes
No
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Eligibility Psoriatic Arthritis NCT02472717
Eligibility Pulmonary Arterial Hypertension
NCT02253394
The Combination Ambrisentan Plus Spironolactone in
Pulmonary Arterial Hypertension Study; ODM derived from:
https://clinicaltrials.gov/show/NCT02253394
All rights reserved. Please visit https://medical-data-
models.org/forms/15895
Eligibility Pulmonary Arterial
Hypertension NCT02253394
Inclusion Criteria
1. voluntarily gives informed consent to
participate in the study.*
Yes
No
2. right heart catheterization demonstrating
conventional mean pulmonary artery pressure
(mpap) >25, pulmonary vascular resistance (pvr)
>3.0 wood units, pulmonary capillary wedge
pressure (pcwp) <16 mmhg within one year of
enrollment*
Yes
No
3. subject is 16-75 years of age at screening.*
Yes
No
4. diagnosis of symptomatic idiopathic or
heritable pah, pah associated with connective
tissue disease (ctd), pah associated with
repaired/unrepaired  congenital systemic-to-
pulmonary shunt, portopulmonary hypertension
or  pah associated with hiv infection.*
Yes
No
5. new york heart association functional class ii or
iii*
Yes
No
6. stable therapy with ambrisentan 5 or 10 mg
every day for > 90 days.*
Yes
No
7. baseline 6-minute walk distance 50-450m*
Yes
No
Exclusion Criteria
1. substantial primary lung disease*
Yes
No
forced expiratory volume at one second (fev-
1)/forced vital capacity (fvc) <0.6 and fev-1 <70%
predicted*
Yes
1 / 3
No
diffusing capacity of lung for carbon monoxide
(dlco) <30% predicted*
Yes
No
pulmonary fibrosis*
Yes
No
2. left ventricular ejection fraction < 50%*
Yes
No
3. pulmonary capillary wedge pressure > 16 mm
hg*
Yes
No
4. aortic valve disease*
Yes
No
5. ischemic heart disease*
Yes
No
6. systemic hypotension (sbp <90 mm hg)*
Yes
No
7. co-existing treatment with other endothelin
receptor antagonists or prostacyclin analogues*
Yes
No
8. new york heart association functional class iv*
Yes
No
9. chronic thromboembolic pulmonary
hypertension*
Yes
No
10. known or suspected pulmonary veno-
occlusive disease*
Yes
No
11. serum creatinine >2.0 mg/dl in women, serum
creatinine >2.5 mg/dl in men*
Yes
No
12. baseline serum potassium >5.0
milliequivalent (meq)/l*
Yes
No
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Eligibility Pulmonary Arterial Hypertension NCT02253394
13. participation in ongoing drug/intervention-
based clinical trial*
Yes
No
14. pregnancy*
Yes
No
15. unable to provide consent*
Yes
No
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Eligibility Pulmonary Arterial Hypertension NCT02253394
Visit 18 (Week 168): Vital Signs/Physical Examination BG00012 Monotherapy
Safety and Efficacy Extension Study in Multiple Sclerosis (MS) (ENDORSE)
NCT00835770
The primary objective of this study is to evaluate the long-
term safety profile of BG00012 (dimethyl fumarate).
Secondary objectives of this study are to evaluate the long-
term efficacy of BG00012 using clinical endpoints and
disability progression, to evaluate further the long-term
effects of BG00012 on multiple sclerosis (MS) brain lesions
on magnetic resonance imaging (MRI) scans in participants
who had MRI scans as part of Studies 109MS301
(NCT00420212) and 109MS302 (NCT00451451) and to
evaluate the long-term effects of BG00012 on health
economics assessments and the visual function test.
NCT00835770 
Part: Visit 18 (Week 168)
All rights reserved. Please visit https://medical-data-
models.org/forms/15896
Visit 18 (Week 168): Vital
Signs/Physical Examination
BG00012 Monotherapy Safety and
Efficacy Extension Study in Multiple
Sclerosis (MS) (ENDORSE)
NCT00835770
Subject Identification
Number of Facility
Subject number
Subject Initials
Vital Signs
Date of examination
Blood Pressure
Pulse
Temperature
Weight
Physical examination
Body System
Skin (1)
Rectal  (10)
Neurological  (11)
Extremities/Joints (12)
HEENT  (2)
Lymph nodes (3)
Neck and Thyroid  (4)
Breasts (5)
Chest/Lungs (6)
1 / 3
Heart  (7)
Vascular (8)
Abdomen (9)
Examination Status
Not done (1)
Normal (2)
Abnormal (please specify) (3)
Abnormal examination findings
EDSS Evaluation
Date of Evaluation
Functional System Scores
Visual
Brinstem
Pyramidal
Cerebellar
Sensory
Bowel or Bladder
Cerebral
Additional and Results
Actual Distance Walked
<100 metres (<100 metres)
>100 metres and <200 metres (>100
metres and <200 metres)
>200 metres and <300 metres (>200
metres and <300 metres)
>300 metres and <500 metres (>300
metres and <500 metres)
>500 metres (>500 metres)
Actual Distance Walked
<100 metres (1)
>100 metres and <200 metres (2)
>200 metres and <300 metres (3)
>300 metres and <500 metres (4)
>500 metres (5)
EDSS Score
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Visit 18 (Week 168): Vital Signs/Physical Examination BG00012 Monotherapy
Safety and Efficacy Extension Study in Multiple Sclerosis (MS) (ENDORSE)
NCT00835770
Name of Neurologist
Visual Function Test
Date of Evaluation
Contrast Sensitivity Evaluation Binocular
100% Chart, Total # Correct
2,5% Chart, Total # Correct
1,25% Chart, Total # Correct
Snellen visual acuity equivalent
Study Drug Accountability
date of first dose
Number of capsules not taken since previous visit
to this visit
Was there a protocol-defined dose
reduction/interruption since the previous visit?
Yes
No
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Visit 18 (Week 168): Vital Signs/Physical Examination BG00012 Monotherapy
Safety and Efficacy Extension Study in Multiple Sclerosis (MS) (ENDORSE)
NCT00835770
Visit 19 (Week 180): Vital Signs BG00012 Monotherapy Safety and Efficacy
Extension Study in Multiple Sclerosis (MS) (ENDORSE) NCT00835770
The primary objective of this study is to evaluate the long-
term safety profile of BG00012 (dimethyl fumarate).
Secondary objectives of this study are to evaluate the long-
term efficacy of BG00012 using clinical endpoints and
disability progression, to evaluate further the long-term
effects of BG00012 on multiple sclerosis (MS) brain lesions
on magnetic resonance imaging (MRI) scans in participants
who had MRI scans as part of Studies 109MS301
(NCT00420212) and 109MS302 (NCT00451451) and to
evaluate the long-term effects of BG00012 on health
economics assessments and the visual function test.
NCT00835770 
Part: Visit 19 (Week 180)
All rights reserved. Please visit https://medical-data-
models.org/forms/15897
Visit 19 (Week 180): Vital Signs
BG00012 Monotherapy Safety and
Efficacy Extension Study in Multiple
Sclerosis (MS) (ENDORSE)
NCT00835770
Subject Identification
Number of Facility
Subject number
Subject Initials
Vital Signs
Date of examination
Blood Pressure
Pulse
Temperature
1 / 1
Visit 21 (Week 204): Vital Signs, Study Drug accountability BG00012 Monotherapy
Safety and Efficacy Extension Study in Multiple Sclerosis (MS) (ENDORSE)
NCT00835770
The primary objective of this study is to evaluate the long-
term safety profile of BG00012 (dimethyl fumarate).
Secondary objectives of this study are to evaluate the long-
term efficacy of BG00012 using clinical endpoints and
disability progression, to evaluate further the long-term
effects of BG00012 on multiple sclerosis (MS) brain lesions
on magnetic resonance imaging (MRI) scans in participants
who had MRI scans as part of Studies 109MS301
(NCT00420212) and 109MS302 (NCT00451451) and to
evaluate the long-term effects of BG00012 on health
economics assessments and the visual function test.
NCT00835770
Part: Visit 21 (Week 204)
All rights reserved. Please visit https://medical-data-
models.org/forms/15899
Visit 21 (Week 204): Vital Signs,
Study Drug accountability BG00012
Monotherapy Safety and Efficacy
Extension Study in Multiple Sclerosis
(MS) (ENDORSE) NCT00835770
Subject Identification
Number of Facility
Subject number
Subject Initials
Vital Signs
Date of examination
Blood Pressure
Pulse
Temperature
Study Drug Accountability
date of first dose
Number of capsules not taken since previous visit
to this visit
Was there a protocol-defined dose
reduction/interruption since the previous visit?
Yes
No
1 / 1
Visit 22 (Week 216): Vital Signs/Physical Examination BG00012 Monotherapy
Safety and Efficacy Extension Study in Multiple Sclerosis (MS) (ENDORSE)
NCT00835770
The primary objective of this study is to evaluate the long-
term safety profile of BG00012 (dimethyl fumarate).
Secondary objectives of this study are to evaluate the long-
term efficacy of BG00012 using clinical endpoints and
disability progression, to evaluate further the long-term
effects of BG00012 on multiple sclerosis (MS) brain lesions
on magnetic resonance imaging (MRI) scans in participants
who had MRI scans as part of Studies 109MS301
(NCT00420212) and 109MS302 (NCT00451451) and to
evaluate the long-term effects of BG00012 on health
economics assessments and the visual function test.
NCT00835770 
Part: Visit 22 (Week 216)
All rights reserved. Please visit https://medical-data-
models.org/forms/15900
Visit 22 (Week 216): Vital
Signs/Physical Examination
BG00012 Monotherapy Safety and
Efficacy Extension Study in Multiple
Sclerosis (MS) (ENDORSE)
NCT00835770
Subject Identification
Number of Facility
Subject number
Subject Initials
Vital Signs
Date of examination
Blood Pressure
Pulse
Temperature
Weight
Physical examination
Body System
Skin (1)
Rectal  (10)
Neurological  (11)
Extremities/Joints (12)
HEENT  (2)
Lymph nodes (3)
Neck and Thyroid  (4)
Breasts (5)
Chest/Lungs (6)
1 / 3
Heart  (7)
Vascular (8)
Abdomen (9)
Examination Status
Not done (1)
Normal (2)
Abnormal (please specify) (3)
Abnormal examination findings
EDSS Evaluation
Date of Evaluation
Functional System Scores
Visual
Brinstem
Pyramidal
Cerebellar
Sensory
Bowel or Bladder
Cerebral
Additional and Results
Actual Distance Walked
<100 metres (<100 metres)
>100 metres and <200 metres (>100
metres and <200 metres)
>200 metres and <300 metres (>200
metres and <300 metres)
>300 metres and <500 metres (>300
metres and <500 metres)
>500 metres (>500 metres)
Actual Distance Walked
<100 metres (1)
>100 metres and <200 metres (2)
>200 metres and <300 metres (3)
>300 metres and <500 metres (4)
>500 metres (5)
EDSS Score
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Visit 22 (Week 216): Vital Signs/Physical Examination BG00012 Monotherapy
Safety and Efficacy Extension Study in Multiple Sclerosis (MS) (ENDORSE)
NCT00835770
Name of Neurologist
Visual Function Test
Date of Evaluation
Contrast Sensitivity Evaluation Binocular
100% Chart, Total # Correct
2,5% Chart, Total # Correct
1,25% Chart, Total # Correct
Snellen visual acuity equivalent
Study Drug Accountability
date of first dose
Number of capsules not taken since previous visit
to this visit
Was there a protocol-defined dose
reduction/interruption since the previous visit?
Yes
No
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Visit 22 (Week 216): Vital Signs/Physical Examination BG00012 Monotherapy
Safety and Efficacy Extension Study in Multiple Sclerosis (MS) (ENDORSE)
NCT00835770
Visit 23 (Week 228): Vital Signs, Study Drug accountability BG00012 Monotherapy
Safety and Efficacy Extension Study in Multiple Sclerosis (MS) (ENDORSE)
NCT00835770
The primary objective of this study is to evaluate the long-
term safety profile of BG00012 (dimethyl fumarate).
Secondary objectives of this study are to evaluate the long-
term efficacy of BG00012 using clinical endpoints and
disability progression, to evaluate further the long-term
effects of BG00012 on multiple sclerosis (MS) brain lesions
on magnetic resonance imaging (MRI) scans in participants
who had MRI scans as part of Studies 109MS301
(NCT00420212) and 109MS302 (NCT00451451) and to
evaluate the long-term effects of BG00012 on health
economics assessments and the visual function test.
NCT00835770
Part: Visit 23 (Week 228)
All rights reserved. Please visit https://medical-data-
models.org/forms/15901
Visit 23 (Week 228): Vital Signs,
Study Drug accountability BG00012
Monotherapy Safety and Efficacy
Extension Study in Multiple Sclerosis
(MS) (ENDORSE) NCT00835770
Subject Identification
Number of Facility
Subject number
Subject Initials
Vital Signs
Date of examination
Blood Pressure
Pulse
Temperature
Study Drug Accountability
date of first dose
Number of capsules not taken since previous visit
to this visit
Was there a protocol-defined dose
reduction/interruption since the previous visit?
Yes
No
1 / 1
Hospitalization BG00012 Monotherapy Safety and Efficacy Extension
Study in Multiple Sclerosis (MS) (ENDORSE) NCT00835770
The primary objective of this study is to evaluate the long-
term safety profile of BG00012 (dimethyl fumarate).
Secondary objectives of this study are to evaluate the long-
term efficacy of BG00012 using clinical endpoints and
disability progression, to evaluate further the long-term
effects of BG00012 on multiple sclerosis (MS) brain lesions
on magnetic resonance imaging (MRI) scans in participants
who had MRI scans as part of Studies 109MS301
(NCT00420212) and 109MS302 (NCT00451451) and to
evaluate the long-term effects of BG00012 on health
economics assessments and the visual function test.
NCT00835770 
Part: Hospitalization
All rights reserved. Please visit https://medical-data-
models.org/forms/15903
Hospitalization BG00012
Monotherapy Safety and Efficacy
Extension Study in Multiple Sclerosis
(MS) (ENDORSE) NCT00835770
Subject Identification
Number of Facility
Subject number
Subject Initials
Hospitalization List
Event number
Event Term for Hospitalization
Date of Admission
Date of Discharge
Primary reason for Hospitalization
MS Relapse (1)
Other MS related complicaton (2)
Other (3)
1 / 1
Eligibility Pulmonary Hypertension
NCT02267655
Exploratory, 2-Part Study to Assess Pulsed Inhaled Nitric
Oxide on Functional Pulmonary Imaging Parameters in
Subjects With WHO Grp 3 Pulmonary Hypertension
Associated With COPD on LTOT; ODM derived from:
https://clinicaltrials.gov/show/NCT02267655
All rights reserved. Please visit https://medical-data-
models.org/forms/15904
Eligibility Pulmonary Hypertension
NCT02267655
Inclusion Criteria
subjects must meet all of the following inclusion
criteria to be enrolled and eligible to participate in
the study:*
Yes
No
1. a confirmed diagnosis of copd by the global
initiative for chronic obstructive lung disease
(gold) criteria*
Yes
No
2. pulmonary hypertension determined by one of
the following within the past 12 months:*
Yes
No
1. a right heart catheterization (not obtained
within ± 7 days of an exacerbation) with an mpap
≥ 25 mmhg, or*
Yes
No
2. an echocardiogram (not obtained within ± 7
days of an exacerbation) with a trv ≥ 2.9 m/s or
spap ≥ 38 mmhg (note: a subject with an
acceptable mpap ≥*
Yes
No
25 mmhg determined by right heart
catheterization will meet this inclusion criteria
even with a trv < 2.9 m/s)*
Yes
No
3. current or former smokers with at least 10
pack-years of tobacco cigarette smoking before
study entry*
Yes
No
4. age ≥ 40 years, ≤ 80 years*
Yes
No
5. a post-bronchodilatory fev1/fvc < 0.7 and a
fev1 < 60% predicted (values obtained within 6
months prior to screening can be used unless
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obtained within ±*
Yes
No
7 days of an exacerbation; otherwise, the test
must be performed during screening)*
Yes
No
6. receiving ltot for ≥ 3 months and ≥ 10 hours
per day as determined by history*
Yes
No
7. females of childbearing potential must have a
negative pre-treatment urine pregnancy test*
Yes
No
8. signed informed consent prior to the initiation
of any study mandated procedures or
assessments*
Yes
No
Exclusion Criteria
subjects who meet any of the following criteria
are not eligible for enrollment:*
Yes
No
1. a diagnosis of asthma or other non-copd
respiratory disease, in the opinion of the
investigator*
Yes
No
2. lack of patency of nares upon physical
examination*
Yes
No
3. experienced during the last month an
exacerbation requiring:*
Yes
No
1. start of or increase in systemic oral
corticosteroid therapy and/or*
Yes
No
2. hospitalization*
Yes
No
4. left ventricular dysfunction as measured by:*
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Eligibility Pulmonary Hypertension NCT02267655
Yes
No
1. screening echocardiographic evidence of left
ventricular systolic dysfunction (left ventricular
ejection fraction [lvef] < 40%), or*
Yes
No
2. screening echocardiographic evidence of left
ventricular diastolic dysfunction*
Yes
No
> moderate (i.e., > grade 2), or*
Yes
No
3. any history of pulmonary capillary wedge
pressure (pcwp), left atrial pressure (lap) or left
ventricular end diastolic pressure (lvedp) > 18
mmhg as measured during cardiac
catheterization within the past 6 months unless
documented to have resolved by a subsequent
cardiac catheterization*
Yes
No
5. renal impairment (i.e., an estimated gfrmdrd <
60 ml/min/1.73 m2) or history of renal failure
using the equation (levey et al., 2007):*
Yes
No
estimated gfrmdrd = 175×scr -1.154×age-0.203
×1.212 (if black) ×0.742 (if female)*
Yes
No
where scr = standardized serum creatinine*
Yes
No
6. known allergy to contrast media.*
Yes
No
7. clinically significant valvular heart disease that
may contribute to ph, including mild or greater
aortic valvular disease (aortic stenosis or
regurgitation) and/or moderate or greater mitral
valve disease (mitral stenosis or regurgitation), or
status post mitral valve replacement*
Yes
No
8. use within 30 days of screening or current use
of approved ph medications such as sildenafil or
bosentan (use of cialis® or viagra® for erectile
dysfunction is permitted)*
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Eligibility Pulmonary Hypertension NCT02267655
Yes
No
9. use of investigational drugs or devices within
30 days prior to enrollment into the study*
Yes
No
10. any underlying medical or psychiatric
condition that, in the opinion of the investigator,
makes the subject an unsuitable candidate for the
study*
Yes
No
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Eligibility Pulmonary Hypertension NCT02267655
Baseline Visit (Day 1): Visual Function Test BG00012 Monotherapy Safety and
Efficacy Extension Study in Multiple Sclerosis (MS) (ENDORSE) NCT00835770
The primary objective of this study is to evaluate the long-
term safety profile of BG00012 (dimethyl fumarate).
Secondary objectives of this study are to evaluate the long-
term efficacy of BG00012 using clinical endpoints and
disability progression, to evaluate further the long-term
effects of BG00012 on multiple sclerosis (MS) brain lesions
on magnetic resonance imaging (MRI) scans in participants
who had MRI scans as part of Studies 109MS301
(NCT00420212) and 109MS302 (NCT00451451) and to
evaluate the long-term effects of BG00012 on health
economics assessments and the visual function test.
NCT00835770 
Part: Baseline Visit (Day 1)
All rights reserved. Please visit https://medical-data-
models.org/forms/15908
Baseline Visit (Day 1): Visual
Function Test BG00012
Monotherapy Safety and Efficacy
Extension Study in Multiple Sclerosis
(MS) (ENDORSE) NCT00835770
Subject Identification
Number of Facility
Subject number
Subject Initials
Visual Function Test
Date of Evaluation
Contrast Sensitivity Evaluation Binocular
100% Chart, Total # Correct
2,5% Chart, Total # Correct
1,25% Chart, Total # Correct
Snellen visual acuity equivalent
Additional Surveys
EQ5D Questionnaire
EQ5D Questionnaire
SF-36 Questionaire
SF 36: vitality
1 / 2
SF-36: physical functioning
SF-36: bodily pain
SF-36: general health perceptions
SF-36 physical function
SF-36: emotional role functioning
SF-36: social role functioning
SF-36: Mental health
2 / 2
Baseline Visit (Day 1): Visual Function Test BG00012 Monotherapy Safety and
Efficacy Extension Study in Multiple Sclerosis (MS) (ENDORSE) NCT00835770
Unsceduled relapse assessment visit BG00012 Monotherapy Safety and Efficacy
Extension Study in Multiple Sclerosis (MS) (ENDORSE) NCT00835770
The primary objective of this study is to evaluate the long-
term safety profile of BG00012 (dimethyl fumarate).
Secondary objectives of this study are to evaluate the long-
term efficacy of BG00012 using clinical endpoints and
disability progression, to evaluate further the long-term
effects of BG00012 on multiple sclerosis (MS) brain lesions
on magnetic resonance imaging (MRI) scans in participants
who had MRI scans as part of Studies 109MS301
(NCT00420212) and 109MS302 (NCT00451451) and to
evaluate the long-term effects of BG00012 on health
economics assessments and the visual function test.
NCT00835770 
Part: Unsceduled relapse assessment visit
All rights reserved. Please visit https://medical-data-
models.org/forms/15909
Unsceduled relapse assessment visit
BG00012 Monotherapy Safety and
Efficacy Extension Study in Multiple
Sclerosis (MS) (ENDORSE)
NCT00835770
Subject Identification
Number of Facility
Subject number
Subject Initials
Vital Signs
Date of examination
Blood Pressure
Pulse
Temperature
Physical examination
Body System
Skin (1)
Rectal  (10)
Neurological  (11)
Extremities/Joints (12)
HEENT  (2)
Lymph nodes (3)
Neck and Thyroid  (4)
Breasts (5)
Chest/Lungs (6)
Heart  (7)
Vascular (8)
Abdomen (9)
Examination Status
1 / 4
Not done (1)
Normal (2)
Abnormal (please specify) (3)
Abnormal examination findings
EDSS Evaluation
Date of Evaluation
Functional System Scores
Visual
Brinstem
Pyramidal
Cerebellar
Sensory
Bowel or Bladder
Cerebral
Relapse assessment
Date treating neurologist contacted by subject
Date treating neurologist performed neurological
examination and collected vitals
Has the subject experienced a protocol-defined
relapse ( having new or recurrent symptoms
more than 24 hours not associated with fever or
stress ans with new objective findings)?
Yes
No
Onset date of MS relapse symptoms?
Onset date of MS relapse symptoms?
Was the subject treated with IV
Methylprednisolon per protocol?
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Unsceduled relapse assessment visit BG00012 Monotherapy Safety and Efficacy
Extension Study in Multiple Sclerosis (MS) (ENDORSE) NCT00835770
Yes
No
Subject Identification
Number of Facility
Subject number
Subject Initials
Visual Function Test
Date of Evaluation
Contrast Sensitivity Evaluation Binocular
100% Chart, Total # Correct
2,5% Chart, Total # Correct
1,25% Chart, Total # Correct
Snellen visual acuity equivalent
Additional Surveys
EQ5D Questionnaire
EQ5D Questionnaire
SF-36 Questionaire
SF 36: vitality
SF-36: physical functioning
SF-36: bodily pain
SF-36: general health perceptions
SF-36 physical function
SF-36: emotional role functioning
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Unsceduled relapse assessment visit BG00012 Monotherapy Safety and Efficacy
Extension Study in Multiple Sclerosis (MS) (ENDORSE) NCT00835770
SF-36: social role functioning
SF-36: Mental health
4 / 4
Unsceduled relapse assessment visit BG00012 Monotherapy Safety and Efficacy
Extension Study in Multiple Sclerosis (MS) (ENDORSE) NCT00835770
Visit 20 (Week 192) BG00012 Monotherapy Safety and Efficacy
Extension Study in Multiple Sclerosis (MS) (ENDORSE) NCT00835770
The primary objective of this study is to evaluate the long-
term safety profile of BG00012 (dimethyl fumarate).
Secondary objectives of this study are to evaluate the long-
term efficacy of BG00012 using clinical endpoints and
disability progression, to evaluate further the long-term
effects of BG00012 on multiple sclerosis (MS) brain lesions
on magnetic resonance imaging (MRI) scans in participants
who had MRI scans as part of Studies 109MS301
(NCT00420212) and 109MS302 (NCT00451451) and to
evaluate the long-term effects of BG00012 on health
economics assessments and the visual function test.
NCT00835770 
Part: Visit 20 (Week 192)
All rights reserved. Please visit https://medical-data-
models.org/forms/15910
Visit 20 (Week 192) BG00012
Monotherapy Safety and Efficacy
Extension Study in Multiple Sclerosis
(MS) (ENDORSE) NCT00835770
Subject Identification
Number of Facility
Subject number
Subject Initials
Vital Signs
Date of examination
Blood Pressure
Pulse
Temperature
Weight
Physical examination
Body System
Skin (1)
Rectal  (10)
Neurological  (11)
Extremities/Joints (12)
HEENT  (2)
Lymph nodes (3)
Neck and Thyroid  (4)
Breasts (5)
Chest/Lungs (6)
Heart  (7)
Vascular (8)
1 / 4
Abdomen (9)
Examination Status
Not done (1)
Normal (2)
Abnormal (please specify) (3)
Abnormal examination findings
EDSS Evaluation
Date of Evaluation
Functional System Scores
Visual
Brinstem
Pyramidal
Cerebellar
Sensory
Bowel or Bladder
Cerebral
Additional and Results
Actual Distance Walked
<100 metres (<100 metres)
>100 metres and <200 metres (>100
metres and <200 metres)
>200 metres and <300 metres (>200
metres and <300 metres)
>300 metres and <500 metres (>300
metres and <500 metres)
>500 metres (>500 metres)
Actual Distance Walked
<100 metres (1)
>100 metres and <200 metres (2)
>200 metres and <300 metres (3)
>300 metres and <500 metres (4)
>500 metres (5)
EDSS Score
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Visit 20 (Week 192) BG00012 Monotherapy Safety and Efficacy
Extension Study in Multiple Sclerosis (MS) (ENDORSE) NCT00835770
Name of Neurologist
Visual Function Test
Date of Evaluation
Contrast Sensitivity Evaluation Binocular
100% Chart, Total # Correct
2,5% Chart, Total # Correct
1,25% Chart, Total # Correct
Snellen visual acuity equivalent
Study Drug Accountability
date of first dose
Number of capsules not taken since previous visit
to this visit
Was there a protocol-defined dose
reduction/interruption since the previous visit?
Yes
No
Additional Surveys
EQ5D Questionnaire
EQ5D Questionnaire
SF-36 Questionaire
SF 36: vitality
SF-36: physical functioning
SF-36: bodily pain
SF-36: general health perceptions
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Visit 20 (Week 192) BG00012 Monotherapy Safety and Efficacy
Extension Study in Multiple Sclerosis (MS) (ENDORSE) NCT00835770
SF-36 physical function
SF-36: emotional role functioning
SF-36: social role functioning
SF-36: Mental health
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Visit 20 (Week 192) BG00012 Monotherapy Safety and Efficacy
Extension Study in Multiple Sclerosis (MS) (ENDORSE) NCT00835770
Visit 24 (Week 240) BG00012 Monotherapy Safety and Efficacy
Extension Study in Multiple Sclerosis (MS) (ENDORSE) NCT00835770
The primary objective of this study is to evaluate the long-
term safety profile of BG00012 (dimethyl fumarate).
Secondary objectives of this study are to evaluate the long-
term efficacy of BG00012 using clinical endpoints and
disability progression, to evaluate further the long-term
effects of BG00012 on multiple sclerosis (MS) brain lesions
on magnetic resonance imaging (MRI) scans in participants
who had MRI scans as part of Studies 109MS301
(NCT00420212) and 109MS302 (NCT00451451) and to
evaluate the long-term effects of BG00012 on health
economics assessments and the visual function test.
NCT00835770 
Part: Visit 24 (Week 240)
All rights reserved. Please visit https://medical-data-
models.org/forms/15911
Visit 24 (Week 240) BG00012
Monotherapy Safety and Efficacy
Extension Study in Multiple Sclerosis
(MS) (ENDORSE) NCT00835770
Subject Identification
Number of Facility
Subject number
Subject Initials
Vital Signs
Date of examination
Blood Pressure
Pulse
Temperature
Weight
Physical examination
Body System
Skin (1)
Rectal  (10)
Neurological  (11)
Extremities/Joints (12)
HEENT  (2)
Lymph nodes (3)
Neck and Thyroid  (4)
Breasts (5)
Chest/Lungs (6)
Heart  (7)
Vascular (8)
1 / 4
Abdomen (9)
Examination Status
Not done (1)
Normal (2)
Abnormal (please specify) (3)
Abnormal examination findings
EDSS Evaluation
Date of Evaluation
Functional System Scores
Visual
Brinstem
Pyramidal
Cerebellar
Sensory
Bowel or Bladder
Cerebral
Additional and Results
Actual Distance Walked
<100 metres (<100 metres)
>100 metres and <200 metres (>100
metres and <200 metres)
>200 metres and <300 metres (>200
metres and <300 metres)
>300 metres and <500 metres (>300
metres and <500 metres)
>500 metres (>500 metres)
Actual Distance Walked
<100 metres (1)
>100 metres and <200 metres (2)
>200 metres and <300 metres (3)
>300 metres and <500 metres (4)
>500 metres (5)
EDSS Score
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Visit 24 (Week 240) BG00012 Monotherapy Safety and Efficacy
Extension Study in Multiple Sclerosis (MS) (ENDORSE) NCT00835770
Name of Neurologist
Visual Function Test
Date of Evaluation
Contrast Sensitivity Evaluation Binocular
100% Chart, Total # Correct
2,5% Chart, Total # Correct
1,25% Chart, Total # Correct
Snellen visual acuity equivalent
Study Drug Accountability
date of first dose
Number of capsules not taken since previous visit
to this visit
Was there a protocol-defined dose
reduction/interruption since the previous visit?
Yes
No
Additional Surveys
EQ5D Questionnaire
EQ5D Questionnaire
SF-36 Questionaire
SF 36: vitality
SF-36: physical functioning
SF-36: bodily pain
SF-36: general health perceptions
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Visit 24 (Week 240) BG00012 Monotherapy Safety and Efficacy
Extension Study in Multiple Sclerosis (MS) (ENDORSE) NCT00835770
SF-36 physical function
SF-36: emotional role functioning
SF-36: social role functioning
SF-36: Mental health
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Visit 24 (Week 240) BG00012 Monotherapy Safety and Efficacy
Extension Study in Multiple Sclerosis (MS) (ENDORSE) NCT00835770
Visit 16 (Week 144) BG00012 Monotherapy Safety and Efficacy
Extension Study in Multiple Sclerosis (MS) (ENDORSE) NCT00835770
The primary objective of this study is to evaluate the long-
term safety profile of BG00012 (dimethyl fumarate).
Secondary objectives of this study are to evaluate the long-
term efficacy of BG00012 using clinical endpoints and
disability progression, to evaluate further the long-term
effects of BG00012 on multiple sclerosis (MS) brain lesions
on magnetic resonance imaging (MRI) scans in participants
who had MRI scans as part of Studies 109MS301
(NCT00420212) and 109MS302 (NCT00451451) and to
evaluate the long-term effects of BG00012 on health
economics assessments and the visual function test.
NCT00835770 
Part: Visit 16 (Week 144)
All rights reserved. Please visit https://medical-data-
models.org/forms/15912
Visit 16 (Week 144) BG00012
Monotherapy Safety and Efficacy
Extension Study in Multiple Sclerosis
(MS) (ENDORSE) NCT00835770
Subject Identification
Number of Facility
Subject number
Subject Initials
Vital Signs
Date of examination
Blood Pressure
Pulse
Temperature
Weight
Physical examination
Body System
Skin (1)
Rectal  (10)
Neurological  (11)
Extremities/Joints (12)
HEENT  (2)
Lymph nodes (3)
Neck and Thyroid  (4)
Breasts (5)
Chest/Lungs (6)
Heart  (7)
Vascular (8)
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Abdomen (9)
Examination Status
Not done (1)
Normal (2)
Abnormal (please specify) (3)
Abnormal examination findings
EDSS Evaluation
Date of Evaluation
Functional System Scores
Visual
Brinstem
Pyramidal
Cerebellar
Sensory
Bowel or Bladder
Cerebral
Additional and Results
Actual Distance Walked
<100 metres (<100 metres)
>100 metres and <200 metres (>100
metres and <200 metres)
>200 metres and <300 metres (>200
metres and <300 metres)
>300 metres and <500 metres (>300
metres and <500 metres)
>500 metres (>500 metres)
Actual Distance Walked
<100 metres (1)
>100 metres and <200 metres (2)
>200 metres and <300 metres (3)
>300 metres and <500 metres (4)
>500 metres (5)
EDSS Score
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Visit 16 (Week 144) BG00012 Monotherapy Safety and Efficacy
Extension Study in Multiple Sclerosis (MS) (ENDORSE) NCT00835770
Name of Neurologist
Visual Function Test
Date of Evaluation
Contrast Sensitivity Evaluation Binocular
100% Chart, Total # Correct
2,5% Chart, Total # Correct
1,25% Chart, Total # Correct
Snellen visual acuity equivalent
Study Drug Accountability
date of first dose
Number of capsules not taken since previous visit
to this visit
Was there a protocol-defined dose
reduction/interruption since the previous visit?
Yes
No
Additional Surveys
EQ5D Questionnaire
EQ5D Questionnaire
SF-36 Questionaire
SF 36: vitality
SF-36: physical functioning
SF-36: bodily pain
SF-36: general health perceptions
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Visit 16 (Week 144) BG00012 Monotherapy Safety and Efficacy
Extension Study in Multiple Sclerosis (MS) (ENDORSE) NCT00835770
SF-36 physical function
SF-36: emotional role functioning
SF-36: social role functioning
SF-36: Mental health
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Visit 16 (Week 144) BG00012 Monotherapy Safety and Efficacy
Extension Study in Multiple Sclerosis (MS) (ENDORSE) NCT00835770
Visit 12 (Week 96) BG00012 Monotherapy Safety and Efficacy Extension
Study in Multiple Sclerosis (MS) (ENDORSE) NCT00835770
The primary objective of this study is to evaluate the long-
term safety profile of BG00012 (dimethyl fumarate).
Secondary objectives of this study are to evaluate the long-
term efficacy of BG00012 using clinical endpoints and
disability progression, to evaluate further the long-term
effects of BG00012 on multiple sclerosis (MS) brain lesions
on magnetic resonance imaging (MRI) scans in participants
who had MRI scans as part of Studies 109MS301
(NCT00420212) and 109MS302 (NCT00451451) and to
evaluate the long-term effects of BG00012 on health
economics assessments and the visual function test.
NCT00835770 
Part: Visit 12 (Week 96)
All rights reserved. Please visit https://medical-data-
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Visit 12 (Week 96) BG00012
Monotherapy Safety and Efficacy
Extension Study in Multiple Sclerosis
(MS) (ENDORSE) NCT00835770
Subject Identification
Number of Facility
Subject number
Subject Initials
Vital Signs
Date of examination
Blood Pressure
Pulse
Temperature
Weight
Physical examination
Body System
Skin (1)
Rectal  (10)
Neurological  (11)
Extremities/Joints (12)
HEENT  (2)
Lymph nodes (3)
Neck and Thyroid  (4)
Breasts (5)
Chest/Lungs (6)
Heart  (7)
Vascular (8)
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Abdomen (9)
Examination Status
Not done (1)
Normal (2)
Abnormal (please specify) (3)
Abnormal examination findings
EDSS Evaluation
Date of Evaluation
Functional System Scores
Visual
Brinstem
Pyramidal
Cerebellar
Sensory
Bowel or Bladder
Cerebral
Additional and Results
Actual Distance Walked
<100 metres (<100 metres)
>100 metres and <200 metres (>100
metres and <200 metres)
>200 metres and <300 metres (>200
metres and <300 metres)
>300 metres and <500 metres (>300
metres and <500 metres)
>500 metres (>500 metres)
Actual Distance Walked
<100 metres (1)
>100 metres and <200 metres (2)
>200 metres and <300 metres (3)
>300 metres and <500 metres (4)
>500 metres (5)
EDSS Score
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Visit 12 (Week 96) BG00012 Monotherapy Safety and Efficacy Extension
Study in Multiple Sclerosis (MS) (ENDORSE) NCT00835770
Name of Neurologist
Visual Function Test
Date of Evaluation
Contrast Sensitivity Evaluation Binocular
100% Chart, Total # Correct
2,5% Chart, Total # Correct
1,25% Chart, Total # Correct
Snellen visual acuity equivalent
Study Drug Accountability
date of first dose
Number of capsules not taken since previous visit
to this visit
Was there a protocol-defined dose
reduction/interruption since the previous visit?
Yes
No
Additional Surveys
EQ5D Questionnaire
EQ5D Questionnaire
SF-36 Questionaire
SF 36: vitality
SF-36: physical functioning
SF-36: bodily pain
SF-36: general health perceptions
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Visit 12 (Week 96) BG00012 Monotherapy Safety and Efficacy Extension
Study in Multiple Sclerosis (MS) (ENDORSE) NCT00835770
SF-36 physical function
SF-36: emotional role functioning
SF-36: social role functioning
SF-36: Mental health
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Visit 12 (Week 96) BG00012 Monotherapy Safety and Efficacy Extension
Study in Multiple Sclerosis (MS) (ENDORSE) NCT00835770
Visit 8 (Week 32) BG00012 Monotherapy Safety and Efficacy Extension
Study in Multiple Sclerosis (MS) (ENDORSE) NCT00835770
The primary objective of this study is to evaluate the long-
term safety profile of BG00012 (dimethyl fumarate).
Secondary objectives of this study are to evaluate the long-
term efficacy of BG00012 using clinical endpoints and
disability progression, to evaluate further the long-term
effects of BG00012 on multiple sclerosis (MS) brain lesions
on magnetic resonance imaging (MRI) scans in participants
who had MRI scans as part of Studies 109MS301
(NCT00420212) and 109MS302 (NCT00451451) and to
evaluate the long-term effects of BG00012 on health
economics assessments and the visual function test.
NCT00835770 
Part: Visit 8 (Week 32)
All rights reserved. Please visit https://medical-data-
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Visit 8 (Week 32) BG00012
Monotherapy Safety and Efficacy
Extension Study in Multiple Sclerosis
(MS) (ENDORSE) NCT00835770
Subject Identification
Number of Facility
Subject number
Subject Initials
Vital Signs
Date of examination
Blood Pressure
Pulse
Temperature
Weight
Physical examination
Body System
Skin (1)
Rectal  (10)
Neurological  (11)
Extremities/Joints (12)
HEENT  (2)
Lymph nodes (3)
Neck and Thyroid  (4)
Breasts (5)
Chest/Lungs (6)
Heart  (7)
Vascular (8)
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Abdomen (9)
Examination Status
Not done (1)
Normal (2)
Abnormal (please specify) (3)
Abnormal examination findings
EDSS Evaluation
Date of Evaluation
Functional System Scores
Visual
Brinstem
Pyramidal
Cerebellar
Sensory
Bowel or Bladder
Cerebral
Additional and Results
Actual Distance Walked
<100 metres (<100 metres)
>100 metres and <200 metres (>100
metres and <200 metres)
>200 metres and <300 metres (>200
metres and <300 metres)
>300 metres and <500 metres (>300
metres and <500 metres)
>500 metres (>500 metres)
Actual Distance Walked
<100 metres (1)
>100 metres and <200 metres (2)
>200 metres and <300 metres (3)
>300 metres and <500 metres (4)
>500 metres (5)
EDSS Score
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Visit 8 (Week 32) BG00012 Monotherapy Safety and Efficacy Extension
Study in Multiple Sclerosis (MS) (ENDORSE) NCT00835770
Name of Neurologist
Visual Function Test
Date of Evaluation
Contrast Sensitivity Evaluation Binocular
100% Chart, Total # Correct
2,5% Chart, Total # Correct
1,25% Chart, Total # Correct
Snellen visual acuity equivalent
Study Drug Accountability
date of first dose
Number of capsules not taken since previous visit
to this visit
Was there a protocol-defined dose
reduction/interruption since the previous visit?
Yes
No
Additional Surveys
EQ5D Questionnaire
EQ5D Questionnaire
SF-36 Questionaire
SF 36: vitality
SF-36: physical functioning
SF-36: bodily pain
SF-36: general health perceptions
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Visit 8 (Week 32) BG00012 Monotherapy Safety and Efficacy Extension
Study in Multiple Sclerosis (MS) (ENDORSE) NCT00835770
SF-36 physical function
SF-36: emotional role functioning
SF-36: social role functioning
SF-36: Mental health
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Visit 8 (Week 32) BG00012 Monotherapy Safety and Efficacy Extension
Study in Multiple Sclerosis (MS) (ENDORSE) NCT00835770
Eligibility Childhood Acute Lymphoblastic
Leukemia in Remission NCT00022737
Combination Chemotherapy With or Without Peripheral
Stem Cell Transplant in Treating Children With Acute
Lymphoblastic Leukemia; ODM derived from:
https://clinicaltrials.gov/show/NCT00022737
All rights reserved. Please visit https://medical-data-
models.org/forms/15915
Eligibility Childhood Acute
Lymphoblastic Leukemia in
Remission NCT00022737
Inclusion Criteria
diagnosis of acute lymphoblastic leukemia*
Yes
No
received prior front-line therapy on a pediatric
oncology group (pog),children's cancer group
(ccg), or central oncology group (cog) study*
Yes
No
received induction therapy comprising vincristine,
asparaginase, prednisone/dexamethasone, and
daunorubicin as in ccg, pog, or cog protocols*
Yes
No
m1 or m2 bone marrow status after front-line
induction therapy and presenting with at least 1of
the following:*
Yes
No
philadelphia chromosome positive (ph+) with
t(9;22)(q34;q11) by cytogenetics or fluorescence
in situ hybridization*
Yes
No
bcr-abl fusion transcript by reverse transcription
polymerase chain reaction*
Yes
No
hypodiploid with less than 44 chromosomes
and/or dna index less than0.81*
Yes
No
mll translocation (11q23) by cytogenetics and a
slow early response (ser) to induction therapy,
defined as at least 5% blasts at day 15 of
induction and/or at least .1% minimal residual
disease (mrd) after induction therapy*
Yes
No
failed to achieve remission after front-line
induction therapy*
Yes
No
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m3 bone marrow status (greater than 25% blasts)
after induction therapy*
Yes
No
m2 bone marrow status (5-25% blasts) or at least
1% mrd after induction therapy and m2 or m3or
at least 1% mrd after consolidation therapy (ccg
studies) or extended induction therapy (pog or
cog  studies)*
Yes
No
see disease characteristics*
Yes
No
not pregnant or nursing*
Yes
No
negative pregnancy test*
Yes
No
fertile patients must use effective contraception*
Yes
No
see disease characteristics*
Yes
No
see disease characteristics*
Yes
No
no concurrent prophylactic cranial radiotherapy*
Yes
No
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Eligibility Childhood Acute Lymphoblastic Leukemia in Remission
NCT00022737
Eligibility Carcinoma, Basal Cell
NCT00204555
Safety and Efficacy Study of Imiquimod 5% Cream Applied
3x Per Week for 8 or 12 Weeks in Low Risk Nodular Basal
Cell Carcinoma; ODM derived from:
https://clinicaltrials.gov/show/NCT00204555
All rights reserved. Please visit https://medical-data-
models.org/forms/15916
Eligibility Carcinoma, Basal Cell
NCT00204555
Inclusion Criteria
patients who are able to understand and willing to
give informed consent prior to study procedures*
Yes
No
age 18+*
Yes
No
have one bcc which meets the following criteria: a
primary tumor (not recurrent, not previously
biopsied or treated; non-infected; located on the
limbs, trunk (anogenital area excluded), neck, or
head. the target tumor must be visible; maximum
tumor area of 1.5 cm in diameter;
macroscopically (clinically) consistent with
nodular bcc; nodular subtype, with circumscribed
growth pattern; histologically consistent with
nbcc, and having no histological evidence of
aggressive growth patterns; easily identifiable
and treatable by subject or reliable subject
representative;*
Yes
No
are willing and able to participate in the study as
an outpatient, making necessary visits to the
clinic during the treatment period and comply with
study requirements, including the following: a
minimum of 1 and a maximum of 3 prestudy
confirmatory biopsies of different tumors before
beginning study drug treatment (each biopsy will
remove no more than 25% of the target tumor); at
least 4 or 5 clinic visits during the study; blood
sampling at screening/initiation visit and end of
treatment; urine pregnancy testing for females of
childbearing potential at the screening/initiation
visit and the end of treatment visits*
Yes
No
are free of any significant physical abnormalities
at the potential application site area, which would
interfere with assessment of possible site
reactions (eg, eczema, psoriasis, tattoos)*
Yes
No
if female and of childbearing potential, has
negative urine pregnancy tests during
screening/initiation visit, and is willing to use a
1 / 3
medically acceptable method of contraception
during the treatment period*
Yes
No
Exclusion Criteria
high-risk areas within 0.5 cm of the eyes*
Yes
No
have evidence of clinically significant, unstable
medical conditions such as metastatic tumor or
tumor with high probability of metastatic spread,
cardiovascular (nyha class iii, iv),
immunomodulation or immunosuppressive
therapies, hematologic, hepatic, renal, neurologic,
endocrine, collagen-vascular, gastrointestinal*
Yes
No
have or had other malignant tumors of the skin
within the target tumor site or surrounding area
(eg, malignant melanoma, epithelioma
spinocellular, squamous cell carcinoma).  the
surrounding area includes the skin within 2 cm of
the target site margins in all directions*
Yes
No
have received the following treatments for any
indication in the target tumor site or surrounding
area within the designated time period (6 weeks)
before treatment initiation: topical retinoids,
topical steroids, surgical excision, curettage,
cryo-, thermo- or chemodestruction,
photodynamic therapy, therapeutic uv-radiation*
Yes
No
have received the following systemic treatments
within the designated period before study
treatment initiation: interferon (6 weeks),
immunomodulators or immunosuppressive
therapies (10 weeks), cytotoxic drugs (6 months),
investigational drugs (8 weeks), drugs known to
have major organ toxicity (8 weeks),
corticosteroids (oral or injectable) (6 weeks),
inhaled corticosteroids (>1200 ng/day for
beclomethasone, or >600 ng/day for
fluticasone)(4 weeks)*
Yes
No
have received any systemic cancer
chemotherapy within 6 months before study
treatment initiation*
Yes
No
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Eligibility Carcinoma, Basal Cell NCT00204555
have known allergies to any excipient in the study
cream (isostearic acid, benzyl alcohol, cetyl
alcohol, stearyl alcohol, polysorbate 60, sorbitan
monostearate, white petrolatum, glycerin, methyl
paraben, propyl paraben, purified water, and
xanthan gum*
Yes
No
are known to be pregnant or lactating (currently
or within the past 3 months).  if the subject was
pregnant, at least 3 months must have elapsed
since parturition or termination*
Yes
No
have any dermatological disease in the target
tumor site or surrounding area that may be
exacerbated by treatment with imiquimod or
cause difficulty with examination (eg psoriasis,
eczema)*
Yes
No
are currently or within the past 8 weeks
participating in another clinical study*
Yes
No
have active chemical dependency or alcoholism
as assessed by the investigator*
Yes
No
have had a systemic bacterial or viral infection
within 2 weeks prior to study initiation*
Yes
No
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Eligibility Carcinoma, Basal Cell NCT00204555
Eligibility Carcinoma, Non-small-cell Lung
NCT00040638
Phase 2 Study of TLK286 Administered Weekly in
Advanced Non-Small Cell Lung Cancer; ODM derived from:
https://clinicaltrials.gov/show/NCT00040638
All rights reserved. Please visit https://medical-data-
models.org/forms/15917
Eligibility Carcinoma, Non-small-cell
Lung NCT00040638
Inclusion Criteria
histologic or cytologic diagnosis of non-small cell
lung carcinoma*
Yes
No
progressed while on or after treatment on
platinum-based regimen*
Yes
No
patients may not have had more than one prior
cytotoxic chemotherapy regimen*
Yes
No
stage iv or iiib*
Yes
No
age at least 18 years*
Yes
No
adequate liver and kidney function*
Yes
No
adequate bone marrow function*
Yes
No
Exclusion Criteria
pregnancy or lactation*
Yes
No
unstable medical conditions*
Yes
No
chemotherapy, hormonal therapy, radiotherapy,
radiopharmaceuticals or immunotherapy within 3
weeks of tlk286*
Yes
No
cns metastasis unless controlled by treatment*
Yes
No
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Eligibility Carcinoma, Non-Small-Cell-Lung
Cancer NCT00191763
Neo-Adjuvant Gemcitabine and Cisplatin in Treating
Patients With Early Stage of Non Small Cell Lung Cancer;
ODM derived from:
https://clinicaltrials.gov/show/NCT00191763
All rights reserved. Please visit https://medical-data-
models.org/forms/15918
Eligibility Carcinoma, Non-Small-
Cell-Lung Cancer NCT00191763
Inclusion Criteria
define histologic or cytologic diagnosis of non
small cell lung cancer.*
Yes
No
determine the presence of clinical stage ib, iia-b
or iiia disease in accordance with the revision by
mountain cf of american joint committee on
cancer.*
Ib (1)
IIa-b (2)
IIIa (3)
define performance status of 0-1 on ecog scale*
Yes
No
do not have any prior tumor therapy*
Yes
No
to be suitable for curative resection*
Yes
No
Exclusion Criteria
to have any treatment within the last 30 days with
any investigational drug.*
Yes
No
to get concurrent administration of any other
tumor therapy*
Yes
No
to be pregnant*
Yes
No
to have poorly controlled diabetes mellitus*
Yes
No
to have serious concomitant disorders.*
Yes
No
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Eligibility Cardiovascular Diseases
NCT00127452
Alpha Omega Trial: Study of Omega-3 Fatty Acids and
Coronary Mortality; ODM derived from:
https://clinicaltrials.gov/show/NCT00127452
All rights reserved. Please visit https://medical-data-
models.org/forms/15919
Eligibility Cardiovascular Diseases
NCT00127452
Inclusion Criteria
men and women*
Yes
No
aged 60 through 80 y*
Yes
No
verified clinically diagnosed myocardial infarction
up to 10 y before randomization*
Yes
No
written informed consent*
Yes
No
Exclusion Criteria
living in a nursing home or other institution*
Yes
No
participation in another scientific study*
Yes
No
habitual margarine intake < 10 g per day*
Yes
No
habitual fish intake > 150 g per day*
Yes
No
habitual alcohol intake > 6 drinks per day*
Yes
No
use of fish oil capsules or other supplements
containing omega-3 fatty acids*
Yes
No
presence of cancer with < 1 y of life expectancy*
Yes
No
cognitive impairment, as indicated by the mini
mental state examination (score <= 21)*
Yes
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No
unintended weight loss > 5 kg in the past year*
Yes
No
lack of facilities for cooled margarine storage at
home*
Yes
No
inability or unwillingness to comply with study
procedures*
Yes
No
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Eligibility Cardiovascular Diseases NCT00127452
Eligibility Cardiovascular Diseases
NCT00182039
POISE Trial: Perioperative Ischemic Evaluation Study;
ODM derived from:
https://clinicaltrials.gov/show/NCT00182039
All rights reserved. Please visit https://medical-data-
models.org/forms/15920
Eligibility Cardiovascular Diseases
NCT00182039
Inclusion Criteria
patients undergoing noncardiac surgery*
Yes
No
≥ 45 years of age; either sex.*
Yes
No
have an expected length of stay ≥ 24 hours*
Yes
No
fulfill any one of the following 6 criteria:*
Yes
No
coronary artery disease;*
Yes
No
peripheral vascular disease;*
Yes
No
history of stroke due to atherothrombotic
disease;*
Yes
No
hospitalization for congestive heart failure within
3 years of randomization;*
Yes
No
undergoing major vascular surgery; or*
Yes
No
any 3 of the following 7 criteria: scheduled for
high risk surgery (i.e. intraperitoneal or
intrathoracic); emergency/urgent surgery; any
history of congestive heart failure; history of a
transient ischemic attack (tia); diabetes and
currently on an oral hypoglycemic agent or insulin
therapy; preoperative serum creatinine > 175
µmol/l (> 2.0 mg/dl); or age > 70 years.*
Yes
No
Exclusion Criteria
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contraindication to metoprolol including any of the
following: significant bradycardia (heart rate < 50
beats per minute); second or third degree heart
block without a pacemaker; asthma that has been
active within the last decade; and history of
chronic obstructive pulmonary disease (copd)
with bronchospasm on pulmonary function tests.*
Yes
No
clinical plan to use a beta-blocker preoperatively
or during the first 30 postoperative days*
Yes
No
prior adverse reaction to a beta-blocker*
Yes
No
coronary artery bypass graft (cabg) surgery with
complete revascularization in the preceding 5
years and no evidence of cardiac ischemia since
the cabg surgery*
Yes
No
patients undergoing low risk surgical procedures
(potential examples include transurethral
procedures [transurethral prostatectomies (turps),
stone baskets, etc.], ophthalmologic procedures
under topical or regional anesthesia [cornea
transplants, cataract surgery, etc.], and surgeries
with limited physiological stresses [digital re-
implantation, nerve repairs, etc.] )*
Yes
No
concurrent use of verapamil*
Yes
No
prior enrollment in this trial*
Yes
No
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Eligibility Breast Cancer NCT00204477
Soy Protein and Breast Cancer Risk Reduction; ODM
derived from: https://clinicaltrials.gov/show/NCT00204477
All rights reserved. Please visit https://medical-data-
models.org/forms/15922
Eligibility Breast Cancer
NCT00204477
Inclusion Criteria
healthy premenopausal women*
Yes
No
30 to 40 years old*
Yes
No
normal mammograms*
Yes
No
regular menstrual cycles*
Yes
No
Exclusion Criteria
abnormal mammograms*
Yes
No
first degree relatives with breast cancer*
Yes
No
pregnant or lactating*
Yes
No
peri- or post-menopause*
Yes
No
breast augmentation, reduction, and lifting*
Yes
No
on oral contraceptive medications or exogenous
hormones*
Yes
No
medically prescribed diets*
Yes
No
allergic reaction to soy or cow's milk*
Yes
No
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Eligibility Breast Neoplasms NCT02254005
Single Dose Escalation Study of Bivatuzumab Mertansine
in Female Patients With CD44v6 Positive Metastatic Breast
Cancer; ODM derived from:
https://clinicaltrials.gov/show/NCT02254005
All rights reserved. Please visit https://medical-data-
models.org/forms/15923
Eligibility Breast Neoplasms
NCT02254005
Inclusion Criteria
1. female patients aged 18 years or older*
Yes
No
2. patients with breast cancer positive for cd44v6
in at least 50 % of the tumour cells*
Yes
No
3. patients with metastases pretreated with
anthracyclines and taxanes (unless
contraindications to taxanes and / or
anthracyclines) or not amenable to established
treatments*
Yes
No
4. measurable tumour deposits by one or more
radiological techniques (mri, ct)*
Yes
No
5. life expectancy of at least 6 months*
Yes
No
6. eastern cooperative oncology group (ecog)
performance score ≤ 2*
Yes
No
7. patients must have given written informed
consent (which must be consistent with
international conference on harmonisation-good
clinical practice (ich-gcp) and local legislation)*
Yes
No
Exclusion Criteria
1. hypersensitivity to humanised or murine
antibodies, immunoconjugates or the excipients
of the trial drugs*
Yes
No
2. known secondary malignancy requiring
therapy*
Yes
No
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3. active infectious disease*
Yes
No
4. brain metastases requiring therapy*
Yes
No
5. neuropathy common toxicity criteria (ctc) grade
2 or above*
Yes
No
6. absolute neutrophil count less than
1,500/mm3*
Yes
No
7. platelet count less than 100,000/mm3*
Yes
No
8. bilirubin greater than 1.5 mg/dl (> 26 μmol/l,
système internationale (si) unit equivalent)*
Yes
No
9. aspartate amino transferase (ast) and/or
alanine amino transferase (alt) greater than 3
times the upper limit of normal*
Yes
No
10. serum creatinine greater than 1.5 mg/dl (>
132 μmol/l, si unit equivalent)*
Yes
No
11. concomitant non-oncological diseases which
are considered relevant for the evaluation of the
safety of the trial drug*
Yes
No
12. chemo- or immunotherapy within the past four
weeks prior to treatment with the trial drug or
during the trial (except for present trial drug)*
Yes
No
13. radiotherapy to breast and thorax region
within the past four weeks before inclusion or
during the trial*
Yes
No
14. women who are sexually active and unwilling
to use a medically acceptable method of
contraception*
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Yes
No
15. pregnancy or lactation*
Yes
No
16. treatment with other investigational drugs or
participation in another clinical trial within the
past four weeks before start of therapy or
concomitantly with this trial (except for present
trial drug)*
Yes
No
17. patients unable to comply with the protocol*
Yes
No
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Eligibility Breast Cancer NCT00445562
Blood Sample Collection and Health Information Collection
From Patients With Invasive Breast Cancer and Their
Brothers and Sisters; ODM derived from:
https://clinicaltrials.gov/show/NCT00445562
All rights reserved. Please visit https://medical-data-
models.org/forms/15924
Eligibility Breast Cancer
NCT00445562
Criteria
meets 1 of the following criteria:*
Yes
No
pathologically confirmed invasive breast cancer
(patient)*
Yes
No
no ductal carcinoma in situ*
Yes
No
affected or unaffected sibling*
Yes
No
affected sibling must have had (or currently has)
breast cancer only*
Yes
No
unaffected sibling must be female*
Yes
No
no deceased siblings*
Yes
No
must be a full-blood related sibling*
Yes
No
patients receiving treatment on clinical trial ecog-
e1y97 or ecog-e3y92 are not eligible*
Yes
No
patient characteristics:*
Yes
No
not specified*
Yes
No
prior concurrent therapy:*
Yes
No
not specified*
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Yes
No
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Eligibility Breast Cancer NCT00445562
Eligibility Breast Cancer NCT00582478
Investigating Mechanisms to Explain Age Associated
Differences in Quality of Life Among Breast Cancer
Patients; ODM derived from:
https://clinicaltrials.gov/show/NCT00582478
All rights reserved. Please visit https://medical-data-
models.org/forms/15925
Eligibility Breast Cancer
NCT00582478
Inclusion Criteria
female*
Yes
No
aged 18 or older at the time of breast cancer
diagnosis*
Yes
No
english-speaking*
Yes
No
community dwelling (i.e. not living in a residential
care or correctional facility)*
Yes
No
diagnosed with invasive breast cancer stage i, ii,
or iii within the previous 6 months*
Yes
No
first time diagnosis*
Yes
No
have physician agreement for participation*
Yes
No
provide informed consent*
Yes
No
Exclusion Criteria
psychiatric or psychological abnormality
precluding informed consent or ability to
complete questionnaires*
Yes
No
previous or concurrent malignancy (except basal
and squamous skin cancer and stage 0 cervical
cancer)*
Yes
No
stage iv breast malignancy*
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Yes
No
residency outside of the united states*
Yes
No
for women ages 45 years and younger only:
those participants < 45 years who were having
regular menstrual cycles at the time of diagnosis
will be excluded from this protocol. this study will
only be enrolling women in this age category who
have had a prior hysterectomy or were having
irregular menstrual cycles at the time of
diagnosis. women with regular menstrual cycles
will be enrolled into a companion project (i.e.,
menstrual cycle maintenance*
Yes
No
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Eligibility Breast Cancer NCT00632723
IRESSA™ (Gefitinib) in Breast Cancer Patients; ODM
derived from: https://clinicaltrials.gov/show/NCT00632723
All rights reserved. Please visit https://medical-data-
models.org/forms/15926
Eligibility Breast Cancer
NCT00632723
Inclusion Criteria
histological or cytological confirmation of breast
cancer that is either*
Yes
No
a primary tumor in a patient unfit for or who has
declined surgery*
Yes
No
advanced (locally or metastatic) disease*
Yes
No
acquired resistance to tamoxifen or er negative
tumour*
Yes
No
at least one measurable or assessable lesion*
Yes
No
who performance status 0 - 2*
Yes
No
life expectancy of 12 weeks or more*
Yes
No
Exclusion Criteria
more than one previous chemotherapy regimens
for advanced disease*
Yes
No
prior anthracycline chemotherapy (> 250 mg/m2
adriamycin)*
Yes
No
radiotherapy completed within 14 days prior to
day 1 of treatment*
Yes
No
incomplete healing from prior oncologic or other
major surgery*
Yes
No
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signs of neurological symptoms consistent with
spinal cord compression*
Yes
No
any evidence of clinically active interstitial lung
disease (patients with chronic stable*
Yes
No
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Eligibility Leukemia, Lymphocytic, Chronic
NCT00038415
A Phase I/II Trial of Idiotypic Vaccination for Chronic
Lymphocytic Leukemia Using a Genetic Approach; ODM
derived from: https://clinicaltrials.gov/show/NCT00038415
All rights reserved. Please visit https://medical-data-
models.org/forms/15927
Eligibility Leukemia, Lymphocytic,
Chronic NCT00038415
Inclusion Criteria
patients with binet stage a chronic lymphocytic
leukemia (cll)*
Yes
No
who performance status of 2 or less.*
Yes
No
a life expectancy of at least one year.*
Yes
No
greater than 18 years of age.*
Yes
No
availability of cll cells which can be used for dna
extraction and processing.*
Yes
No
a platelet count greater than 100 x 109/l.*
Yes
No
ability to provide full informed consent.*
Yes
No
Exclusion Criteria
previous chemotherapy or radiotherapy.*
Yes
No
presence of a monoclonal band on serum
electrophoresis.*
Yes
No
presence of clinically significant levels of anti-dna
antibodies, anti-muscle antibodies or rheumatoid
factors or who have active autoimmune disease.*
Yes
No
presence of antibodies to human
immunodeficiency virus (hiv) and known carriers
of hepatitis b or hepatitis c virus.*
Yes
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No
presence of other serious medical condition e.g.
congestive heart failure.*
Yes
No
presence of other malignancies.*
Yes
No
pregnancy, lactation, or not using contraceptive
measures.*
Yes
No
concurrent use of other anti-cancer therapy.*
Yes
No
patients allergic to tetanus vaccine.*
Yes
No
2 / 2
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Eligibility Leukemia, Myeloid, Philadelphia-
Positive NCT00037882
PEG-Intron For Chronic Myelogenous Leukemia Patients
Unresponsive To Or Intolerant Of Roferon Or Intron; ODM
derived from: https://clinicaltrials.gov/show/NCT00037882
All rights reserved. Please visit https://medical-data-
models.org/forms/15928
Eligibility Leukemia, Myeloid,
Philadelphia-Positive NCT00037882
Inclusion Criteria
chronic phase cml, documented by the presence
of philadelphia chromosome or bcr/abl
rearrangement at time of diagnosis, confirmed by
either cytogenetics or pcr.*
Yes
No
wbc >/= 3000/ul </=100,000/ul.*
Yes
No
patients must have received prior interferon
therapy & proven to have primary refractory
disease, secondary resistance or intolerance to
interferon-a*
Yes
No
patient must have ecog status of 0, 1, or 2*
Yes
No
labs: sgot/sgpt<2xuln; serum bilirubin<2xuln;
serum creatinine  <2.0mg/dl*
Yes
No
recovered from effects of major surgery*
Yes
No
life expectancy > 12 wks.*
Yes
No
signed informed consent.*
Yes
No
women of childbearing potential must have
negative serum pregnancy test within 72 hrs prior
to administration of peg-intron & use effective
contraception during the study.*
Yes
No
Exclusion Criteria
no accelerated phase cml patients with peripheral
blood: blasts>/=15%, basophils>/=20%,
blasts+promyelocytes>/=30%,
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platelets<100,000/ul (unrelated to therapy).
blastic phase cml:>/=30% in peripheral
blood/bone marrow.*
Yes
No
no patients with known hypersensitivity to
interferon-a.*
Yes
No
no severe cardiovascular disease, i.e.
arrhythmias requiring chronic treatment or
congestive heart failure (nyha classification iii/iv).*
Yes
No
no history of neuropsychiatric disorder requiring
hospitalization.*
Yes
No
no patients requiring therapy for refractory thyroid
dysfunction*
Yes
No
no patients with uncontrolled diabetes mellitus.*
Yes
No
no patients who have had treatment for a 2nd
malignancy in the past 5 yrs, except for localized
basal cell/squamous cell carcinoma of the skin or
cervical carcinoma in situ.*
Yes
No
no pregnant or lactating patients.*
Yes
No
no patients known to be actively using alcohol or
drugs*
Yes
No
no patients receiving any experimental therapy
within 30 days of enrollment in study.*
Yes
No
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Eligibility Schizophrenia NCT00515723
Glucose and Lipid Metabolism on Antipsychotic Medication;
ODM derived from:
https://clinicaltrials.gov/show/NCT00515723
All rights reserved. Please visit https://medical-data-
models.org/forms/15929
Eligibility Schizophrenia
NCT00515723
Inclusion Criteria
aged 18-60 years*
Yes
No
patients: otherwise healthy and meets dsm-iv
criteria for schizophrenia or schizoaffective
disorder, any type, treated with haloperidol,
olanzapine, clozapine, quetiapine, ziprasidone,
aripiprazole, or risperidone for at least 3 months*
Yes
No
controls: healthy*
Yes
No
able to give informed consent*
Yes
No
no antipsychotic medication changes for 3
months, and no other medication changes for 2
weeks prior to baseline evaluations.*
Yes
No
Exclusion Criteria
axis i psychiatric disorder criteria met in self
except for substance use disorders as below*
Yes
No
patients and controls: meets dsm-iv criteria for
the diagnoses of substance abuse within the past
3 months*
Yes
No
involuntary legal status (as per missouri law)*
Yes
No
the presence of any serious medical disorder that
may confound the assessment of relevant
biologic measures or diagnosis, including:
significant organ system dysfunction, metabolic
diseases, type 1 diabetes mellitus, symptomatic
type 2 diabetes mellitus (see below), pregnancy,
endocrine disease, coagulopathy, clinically
significant anemia, that would preclude blood
1 / 2
sampling (as determined by the pi) or acute
infection;*
Yes
No
patients taking more than one atypical
antipsychotic medication;*
Yes
No
subjects taking certain prescription medications
(as determined by pi on a case by case basis).*
Yes
No
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Eligibility Refractory Diffuse Large B Cell
Lymphoma NCT02348216
A Phase 1-2 Multi-Center Study Evaluating KTE-C19 in
Subjects With Refractory Aggressive Non-Hodgkin
Lymphoma (NHL); ODM derived from:
https://clinicaltrials.gov/show/NCT02348216
All rights reserved. Please visit https://medical-data-
models.org/forms/15930
Eligibility Refractory Diffuse Large B
Cell Lymphoma NCT02348216
Criteria
1. histologically confirmed:*
Yes
No
diffuse large b cell lymphoma (dlbcl)*
Yes
No
primary mediastinal large b cell lymphoma
(pmbcl)*
Yes
No
transformation follicular lymphoma (tfl)*
Yes
No
2. chemotherapy-refractory disease, defined as
one or more of the following:*
Yes
No
stable disease (duration of stable disease must
be less than or equal to 12 months) or
progressive disease as best response to most
recent chemotherapy containing regimen*
Yes
No
disease progression or recurrence less than or
equal to 12 months of prior autologous sct*
Yes
No
3. subjects must have received adequate prior
therapy including at a minimum:*
Yes
No
anti-cd20 monoclonal antibody unless
investigator determines that tumor is cd20-
negative and*
Yes
No
an anthracycline containing chemotherapy
regimen*
Yes
No
for subjects with transformed fl must have
received prior chemotherapy for follicular
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lymphoma and subsequently have
chemorefractory disease after transformation to
dlbcl*
Yes
No
4. at least one measurable lesion per revised iwg
response criteria*
Yes
No
5. age 18 or older*
Yes
No
6. eastern cooperative oncology group (ecog)
performance status of 0 or 1*
Yes
No
7. anc ≥ 1000/ul*
Yes
No
8. platelet count ≥ 50,000/ul*
Yes
No
9. adequate renal, hepatic, and cardiac function
defined as:*
Yes
No
serum creatinine ≤ 1.5 mg/dl*
Yes
No
serum alt/ast ≤ 2.5 uln*
Yes
No
total bilirubin ≤ 1.5 mg/dl, except in subjects with
gilbert's syndrome.*
Yes
No
cardiac ejection fraction ≥ 50% and no evidence
of pericardial effusion as determined by an echo.*
Yes
No
10. all subjects or legally appointed
representatives/caregivers, must personally sign
and date the irb/iec approved consent form
before initiating any study specific procedures or
activities.*
Yes
No
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key exclusion criteria*
Yes
No
1. history of malignancy other than nonmelanoma
skin cancer or carcinoma in situ (e.g. cervix,
bladder, breast) or follicular lymphoma unless
disease free for at least 3 years*
Yes
No
2. history of allogeneic stem cell transplantation*
Yes
No
3. prior car therapy or other genetically modified t
cell therapy*
Yes
No
4. clinically significant active infection (e.g. simple
uti, bacterial pharyngitis allowed) or currently
receiving iv antibiotics or have received iv
antibiotics within 7 days prior to enrollment.
prophylaxis antibiotics, antivirals and antifungals
are permitted*
Yes
No
5. known history of infection with hiv or hepatitis b
(hbsag positive) or hepatitis c virus (anti-hcv
positive)*
Yes
No
6. subjects with detectable cerebrospinal fluid
malignant cells or brain metastases or with a
history of cerebrospinal fluid malignant cells or
brain metastases*
Yes
No
7. history of a seizure disorder, cerebrovascular
ischemia/hemorrhage, dementia, cerebellar
disease, or any autoimmune disease with cns
involvement*
Yes
No
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18pp EBMT Amyloidosis
ODM form derived from 18pp EBMT Amyloidosis. please
refer to: http://www.ebmt.org/Contents/Data-
Management/Registrystructure/MED-
ABdatacollectionforms/Pages/MED-AB-data-collection-
forms.aspx
All rights reserved. Please visit https://medical-data-
models.org/forms/15932
18pp EBMT Amyloidosis
GENERAL INFORMATION TEAM
EBMT Centre Identification Code (CIC)
Name of the hospital
Unit
Name of contact person
Telephone number
Fax
E-Mail
Date of this report
Patient following national / international study /
trial
No (1)
Yes (2)
Not evaluated (3)
Unknown (4)
Name of study / trial
GENERAL INFORMATION PATIENT
Unique Identification Code (UIC)
Hospital Unique Patient Number or Code
First name(s)_surname(s)
Date of birth
Sex
Male (1)
Female (2)
ABO Group
1 / 28
Rh factor Donor a
Yes
No
DISEASE
Date of diagnosis
Check the disease for which this transplant was
performed
Acute Leukaemia (Acute Leukaemia)
Acute Lymphoblastic Leukaemia (ALL)
(Acute Lymphoblastic Leukaemia (ALL))
Acute Myelogenous Leukaemia (AML)
(Acute Myelogenous Leukaemia (AML))
Autoimmune disease (Autoimmune
disease)
Bone marrow failure including Aplastic
anaemia (Bone marrow failure including
Aplastic anaemia)
Chronic Leukaemia (Chronic Leukaemia)
Chronic Lymphocytic Leukaemia
(Chronic Lymphocytic Leukaemia)
Chronic Myeloid Leukaemia (CML)
(Chronic Myeloid Leukaemia (CML))
Haemoglobinopathies
(Haemoglobinopathies)
Histiocytic disorders (Histiocytic
disorders)
Hodgkin´s Disease (Hodgkin´s Disease)
Inherited disorders (Inherited disorders)
Juvenile Idiopathic Arthritis (Juvenile
Idiopathic Arthritis)
Lymphoma (Lymphoma)
MD/ MPN (MD/ MPN)
MDS (MDS)
Metabolic disorders (Metabolic
disorders)
Multiple Sclerosis (Multiple Sclerosis)
Myelodysplastic syndromes
(Myelodysplastic syndromes)
Myeloma/ Plasma cell disorder
(Myeloma/ Plasma cell disorder)
Myeloproliferative neoplasm
(Myeloproliferative neoplasm)
Non Hodgkin (Non Hodgkin)
Other diagnosis (Other diagnosis)
Primary immune deficiencies (Primary
immune deficiencies)
Secondary Acute Leukaemia (do not use
if transformed from MDS/MPN)
(Secondary Acute Leukaemia (do not
use if transformed from MDS/MPN))
Solid Tumour (Solid Tumour)
Systemic Lupus (Systemic Lupus)
Systemic Sclerosis (Systemic Sclerosis)
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AL AMYLOIDOSIS INITIAL DIAGNOSIS
Has the information requested in this section
been submitted with a previous HSCT registration
for this patient?
Yes: go to page 3, Pre-HSCT Treatment
(1)
No: proceed with this section (2)
EVIDENCE OF UNDERLYING PLASMA CELL
DISORDER
Yes
No
In case of EVIDENCE OF UNDERLYING
PLASMA CELL DISORDER, please specify:
Monoclonal Gammopathy (Monoclonal
Gammopathy)
Multiple Myeloma (Multiple Myeloma)
Other B-cell malignancy (Other B-cell
malignancy)
If Other B-cell malignancy, specify
Select one as applicable
IgG (1)
IgA (2)
IgD (3)
IgE (4)
IgM (5)
Absent (6)
Not evaluated (7)
Select one as applicable
Kappa (1)
Lambda (2)
Absent (3)
Not evaluated (4)
If Multiple myeloma: Stage at diagnosis (Salmon
and Durie) A
I (I)
II (II)
III (III)
If Multiple myeloma: Stage at diagnosis (Salmon
and Durie) B
Yes
No
DIAGNOSIS OF AMYLOIDOSIS
Excluded (1)
Not evaluated (2)
DIAGNOSIS OF AMYLOIDOSIS via
Immunohistochemistry
Done (Done)
Not evaluated (Not evaluated)
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CLINICAL AND LABORATORY DATA
Serum creatinine (1)
Serum c-Troponin T (μg/L) (10)
Hb (g/dL) (2)
Total urinary protein excretion (mg/24 h)
(3)
Total urinary albumin excretion (mg/24 h)
(4)
Serum calcium (mmol/L) (5)
Serum albumin (g/L) (6)
Serum alkaline phosphatase (IU/L) (7)
Serum bilirubin (8)
NT-proBNP  (ng/L) (9)
BM aspirate: % plasmacytosis
%
BM trephine % plasmacytosis
%
Monoclonal Ig in serum
g/L
Immunofixation of serum
Negative  (1)
Positive  (2)
Not evaluated  (3)
Unknown (4)
Free Kappa light chains in serum
mg/L
Not evaluated (1)
Lambda light chains
mg/L
Not evaluated (1)
Immunofixation of urine
Negative  (1)
Positive  (2)
Not evaluated  (3)
Unknown (4)
Monoclonal light chains in urine
g/24h
Serum Beta2 microglobulin
mg/L
Bone structure (X-ray)
Normal  (1)
Lytic lesion   (2)
Not evaluated  (3)
Unknown (4)
Macroglossia
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Absent  (1)
Present  (2)
Not evaluated  (3)
Unknown (4)
Periorbital bleeding
Absent  (1)
Present  (2)
Not evaluated  (3)
Unknown (4)
Shoulder pad sign
Absent  (1)
Present  (2)
Not evaluated  (3)
Unknown (4)
ORGAN INVOLVEMENT AT DIAGNOSIS
Soft Tissues
Additional organ involvement (Additional
organ involvement)
Biopsy (Biopsy)
Dominant organ(s) involved (Dominant
organ(s) involved)
No involvement (No involvement)
Gastrointestinal Tract
Dominant organ(s) involved (1)
Additional organ involvement (2)
Biopsy (3)
No involvement (4)
Heart
Dominant organ(s) involved (1)
Additional organ involvement (2)
Biopsy (3)
No involvement (4)
Liver
Dominant organ(s) involved (1)
Additional organ involvement (2)
Biopsy (3)
No involvement (4)
Kidney
Dominant organ(s) involved (1)
Additional organ involvement (2)
Biopsy (3)
No involvement (4)
Peripheral nerves
Dominant organ(s) involved (1)
Additional organ involvement (2)
Biopsy (3)
No involvement (4)
Autonomic nerves
Dominant organ(s) involved (1)
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Additional organ involvement (2)
Biopsy (3)
No involvement (4)
if other, please specify
Dominant organ(s) involved (1)
Additional organ involvement (2)
Biopsy (3)
No involvement (4)
Liver span in ultrasound or CT scan (cm
craniocaudal diameter)
Not evaluated (1)
NYHA class
I (1)
II (2)
III (3)
IV (4)
not done (99)
Left Ventricular Ejection Fraction
%
Interventricular septal wall thickness
mm
Weight loss
No  (1)
Yes  (2)
Not evaluated  (3)
Unknown (4)
Malabsorption
No  (1)
Yes  (2)
Not evaluated  (3)
Unknown (4)
GI bleeding
No  (1)
Yes  (2)
Not evaluated  (3)
Unknown (4)
If other evidence of gastrointestinal involvement,
please specify
Neurological exam
Abnormal  ( Abnormal )
Not evaluated or failed  ( Not evaluated
or failed )
Unknown ( Unknown)
Normal  (Normal )
Neurological exam: If abnormal:
Specify abnormality
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PNP severity
grade I  (1)
grade II  (2)
grade III  (3)
grade IV (4)
Orthostatic hypotension
Yes  (1)
No  (2)
Not evaluated  (3)
Unknown (4)
Intractable diarrhoea
Yes  (1)
No  (2)
Not evaluated  (3)
Unknown (4)
Inflexible pulse rate
Yes  (1)
No  (2)
Not evaluated  (3)
Unknown (4)
Clinical evidence for involvement of other sites
PRE-HSCT TREATMENT
WAS THE PATIENT TREATED BEFORE THE
HSCT PROCEDURE?
Yes
No
Chemotherapy
Yes
No
Modality Chemotherapy
Chemotherapy regimen (Chemotherapy
regimen)
Number of cycles (Number of cycles)
If Other Modality, please specify
HSCT
DATE OF HSCT
HSCT TYPE Allogeneic:
Yes
No
Autologous: Date of 1st collection or pheresis
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STATUS OF DISEASE AT COLLECTION
(AUTOGRAFTS ONLY)
Haematological status
>CR2  ( >CR2 VNUMSTM)
>PR2  ( >PR2 )
CR1  ( CR1 )
CR2  ( CR2 )
No change  ( No change )
PR1  ( PR1 )
Progression  ( Progression )
Unknown ( Unknown)
At diagnosis  (At diagnosis )
MR (MR)
PR2  (PR2 )
Organ status
Response  (2)
No change  (3)
Progression  (4)
Unknown (5)
STATUS OF DISEASE AT START OF
CONDITIONING FOR BMT
Haematological status
>CR2  ( >CR2 )
>PR2  ( >PR2 )
CR2  ( CR2 )
MR ( MR)
No change  ( No change )
PR1  ( PR1 )
PR2  ( PR2 )
At diagnosis  (At diagnosis )
CR1  (CR1 )
Progression  (Progression )
Unknown (Unknown)
Organ status
Response  (2)
No change  (3)
Progression  (4)
Unknown (5)
Hb
g/dl
CLINICAL AND LABORATORY DATA
Serum creatinine (1)
Serum c-Troponin T (μg/L) (10)
Hb (g/dL) (2)
Total urinary protein excretion (mg/24 h)
(3)
Total urinary albumin excretion (mg/24 h)
(4)
Serum calcium (mmol/L) (5)
Serum albumin (g/L) (6)
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Serum alkaline phosphatase (IU/L) (7)
Serum bilirubin (8)
NT-proBNP  (ng/L) (9)
BM aspirate: % plasmacytosis
%
BM trephine % plasmacytosis
%
Monoclonal Ig in serum
g/L
Immunofixation of serum
Negative  (1)
Positive  (2)
Not evaluated  (3)
Unknown (4)
Free Kappa light chains in serum
mg/L
Not evaluated (1)
Lambda light chains
mg/L
Not evaluated (1)
Immunofixation of urine
Negative  (1)
Positive  (2)
Not evaluated  (3)
Unknown (4)
Monoclonal light chains in urine
g/24h
Serum Beta2 microglobulin
mg/L
Soft Tissues
Additional organ involvement (Additional
organ involvement)
Biopsy (Biopsy)
Dominant organ(s) involved (Dominant
organ(s) involved)
No involvement (No involvement)
Gastrointestinal Tract
Dominant organ(s) involved (1)
Additional organ involvement (2)
Biopsy (3)
No involvement (4)
Heart
Dominant organ(s) involved (1)
Additional organ involvement (2)
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Biopsy (3)
No involvement (4)
Liver
Dominant organ(s) involved (1)
Additional organ involvement (2)
Biopsy (3)
No involvement (4)
Kidney
Dominant organ(s) involved (1)
Additional organ involvement (2)
Biopsy (3)
No involvement (4)
Peripheral nerves
Dominant organ(s) involved (1)
Additional organ involvement (2)
Biopsy (3)
No involvement (4)
Autonomic nerves
Dominant organ(s) involved (1)
Additional organ involvement (2)
Biopsy (3)
No involvement (4)
Liver span in ultrasound or CT scan (cm
craniocaudal diameter)
Not evaluated (1)
NYHA class
I (1)
II (2)
III (3)
IV (4)
not done (99)
Left Ventricular Ejection Fraction
%
Interventricular septal wall thickness
mm
Weight loss
No  (1)
Yes  (2)
Not evaluated  (3)
Unknown (4)
Malabsorption
No  (1)
Yes  (2)
Not evaluated  (3)
Unknown (4)
GI bleeding
No  (1)
Yes  (2)
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Not evaluated  (3)
Unknown (4)
If other evidence of gastrointestinal involvement,
please specify
Neurological exam
Abnormal  ( Abnormal )
Not evaluated or failed  ( Not evaluated
or failed )
Unknown ( Unknown)
Normal  (Normal )
Neurological exam: If abnormal:
Specify abnormality
PNP severity
grade I  (1)
grade II  (2)
grade III  (3)
grade IV (4)
Orthostatic hypotension
Yes  (1)
No  (2)
Not evaluated  (3)
Unknown (4)
Intractable diarrhoea
Yes  (1)
No  (2)
Not evaluated  (3)
Unknown (4)
Inflexible pulse rate
Yes  (1)
No  (2)
Not evaluated  (3)
Unknown (4)
Clinical evidence for involvement of other sites
STATUS OF DISEASE AT 100 DAYS
AFTER HSCT
BEST HAEMATOLOGICAL RESPONSE TO
HSCT AT 100 DAYS
>CR2 ( >CR2)
>PR2  ( >PR2 )
CR2  ( CR2 )
MR ( MR)
Progression  ( Progression )
Unknown ( Unknown)
CR1  (CR1 )
No change  (No change )
Not evaluable  (Not evaluable )
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PR1  (PR1 )
PR2  (PR2 )
DATE RESPONSE ACHIEVED OR ASSESSED
CLINICAL AND LABORATORY DATA
Serum creatinine (1)
Serum c-Troponin T (μg/L) (10)
Hb (g/dL) (2)
Total urinary protein excretion (mg/24 h)
(3)
Total urinary albumin excretion (mg/24 h)
(4)
Serum calcium (mmol/L) (5)
Serum albumin (g/L) (6)
Serum alkaline phosphatase (IU/L) (7)
Serum bilirubin (8)
NT-proBNP  (ng/L) (9)
Serum creatinine
Creatinine clearance (mL/min)
Total urinary protein excretion (mg/24 h)
Total urinary albumin excretion (mg/24 h)
Serum NT-pro-BNP (ng/L)
CLINICAL AND LABORATORY DATA
Serum c-Troponin T (μg/L)
CLINICAL AND LABORATORY DATA
BM aspirate: % plasmacytosis
%
BM trephine % plasmacytosis
%
Monoclonal Ig in serum
g/L
Immunofixation of serum
Negative  (1)
Positive  (2)
Not evaluated  (3)
Unknown (4)
Free Kappa light chains in serum
mg/L
Not evaluated (1)
Lambda light chains
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mg/L
Not evaluated (1)
Immunofixation of urine
Negative  (1)
Positive  (2)
Not evaluated  (3)
Unknown (4)
Monoclonal light chains in urine
g/24h
Serum Beta2 microglobulin
mg/L
ORGAN-SPECIFIC RESPONSES AT 100
DAYS AFTER HSCT
Kidney
Response  (1)
No response/stable disease  (2)
Progressive disease (3)
Not evaluable  (4)
Not evaluated/not applicable  (5)
Unknown (6)
Liver
Liver span in ultrasound or CT scan (cm
craniocaudal diameter)
Hepatic response
Response  (1)
No response/stable disease  (2)
Progressive disease (3)
Not evaluable  (4)
Not evaluated/not applicable  (5)
Unknown (6)
Heart
NYHA class
I (I)
II (II)
III (III)
IV (IV)
Unknown (Unknown)
Left ventricular ejection fraction
%
Interventricular septal wall thickness
(mean # mm in echocardiogram)
Cardiac response
No response/stable disease  ( No
response/stable disease )
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Not evaluable  ( Not evaluable )
Not evaluated/not applicable  ( Not
evaluated/not applicable )
Progressive disease ( Progressive
disease)
Unknown ( Unknown)
Response  (Response )
Weight loss
No  (1)
Yes  (2)
Not evaluated  (3)
Unknown (4)
Malabsorption
No  (1)
Yes  (2)
Not evaluated  (3)
Unknown (4)
GI bleeding
No  (1)
Yes  (2)
Not evaluated  (3)
Unknown (4)
GI response
Response  (1)
No response/stable disease  (2)
Progressive disease (3)
Not evaluable  (4)
Not evaluated/not applicable  (5)
Unknown (6)
Neurological exam
Peripheral neuropathy
(Compare current situation to situation before
HSCT)
Improved  (1)
Worsened  (2)
Unchanged  (3)
Unknown (4)
PNP severity
Peripheral neuropathy
(Compare current situation to situation before
HSCT)
grade I  (1)
grade II  (2)
grade III  (3)
grade IV (4)
PN response
Peripheral neuropathy
(Compare current situation to situation before
HSCT)
No response/stable disease  (No
response/stable disease )
Not evaluable  (Not evaluable )
Not evaluated/not applicable  (Not
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evaluated/not applicable )
Progressive disease (Progressive
disease)
Response  (Response )
Unknown (Unknown)
AN response
Autonomic neuropathy
No response/stable disease  (No
response/stable disease )
Not evaluable  (Not evaluable )
Not evaluated/not applicable  (Not
evaluated/not applicable )
Progressive disease (Progressive
disease)
Response  (Response )
Unknown (Unknown)
Clinical evidence for involvement of new sites
Evidence of new organ involvement
KARNOFSKY
FORMS TO BE FILLED IN
Type of Transplant
ALLOgraft or Syngeneic graft (proceed to
Allograft form) (ALLOgraft or Syngeneic
graft (proceed to Allograft form))
AUTOgraft (proceed to Autograft form)
(AUTOgraft (proceed to Autograft form))
Other (contact the EBMT Central
Registry for instructions) (Other (contact
the EBMT Central Registry for
instructions))
FOLLOW UP AL AMYLOIDOSIS
Unique Identification Code (UIC)
(if known)
Hospital Unique Patient Number
Initials
Date of birth
Date of HSCT
PATIENT LAST SEEN
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Date of Last Contact or Death
Complete haematological remission obtained
after the HSCT in the absence of additional
disease treatment
Previously reported (1)
Yes, date (2)
No (3)
Unknown (4)
GRAFT VERSUS HOST DISEASE
(GvHD) SINCE LAST REPORT
Maximum Grade of Acute GVHD
Agvhd Grade 0 (0)
Agvhd Grade I (I)
Agvhd Grade Ii (II)
Agvhd Grade Iii (III)
Agvhd Grade Iv (IV)
Agvhd Present, Grade Unknown
(Present, grade unknown)
If present type of GvHD
New onset  (1)
Recurrent  (2)
Persistent (3)
Reason for aGvHD
DLI (DLI)
Tapering (Tapering)
Unexplained (Unexplained)
Date onset of this episode (if new or recurrent)
yyyy/mm/dd
aGvHD Stage
Stage skin (1)
Stage liver (2)
Stage gut (3)
aGvHD Resolution
No  (1)
Yes (2)
Date of resolution
yyyy/mm/dd
Presence of cGvHD
No (No)
Present continously since last reported
episode (Present continously since last
reported episode)
Resolved (Resolved)
Yes (Yes)
Presence of cGVHD if yes
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First episode (1)
Recurrence (2)
cGvHD Date of onset
yyyy/mm/dd
cGvHD grade
limited (1)
Extensive (2)
Organs affected
Skin (1)
Gut (2)
Liver (3)
Mouth (4)
Eyes (5)
Lung (6)
Other, specify (7)
Unknown (8)
If resolved, specify the date of resolution:
OTHER COMPLICATIONS SINCE LAST
REPORT
Infection related complications
Yes
No
Bacteraemia / fungemia / viremia / parasites
Pathogen (1)
Date (2)
Septic shock
Pathogen (1)
Date (2)
ARDS
Pathogen (1)
Date (2)
Multiorgan failure due to infection
Pathogen (1)
Date (2)
Pneumonia
Pathogen (1)
Date (2)
Hepatitis
Pathogen (1)
Date (2)
CNS infection
Pathogen (1)
Gut infection
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Pathogen (1)
Date (2)
Skin infection
Pathogen (1)
Date (2)
Date
Provide different dates for different episodes of
the same complication if applicable.
Cystitis
Pathogen (1)
Date (2)
Retinitis
Pathogen (1)
Date (2)
Other
Pathogen (1)
Date (2)
Non infection related complications
Yes
No
CTC grade Cardiovascular
0 (1)
1 (2)
2 (3)
3 (4)
4 (5)
Date Cardiovascular
Cardiovascular comments
CTC grade Dermatologic
0 (1)
1 (2)
2 (3)
3 (4)
4 (5)
Date Dermatologic
Comments
CTC grade Gastrointestinal
0 (1)
1 (2)
2 (3)
3 (4)
4 (5)
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Date Gastrointestinal
Gastrointestinal Comments
CTC grade Haemorrhage
0 (1)
1 (2)
2 (3)
3 (4)
4 (5)
Date Haemorrhage
Haemorrhage Comments
CTC grade Hepatic
0 (1)
1 (2)
2 (3)
3 (4)
4 (5)
Date Hepatic
Hepatic Comments
CTC grade Neurologic
0 (1)
1 (2)
2 (3)
3 (4)
4 (5)
Date Neurologic
Neurologic Comments
CTC grade Pulmonary
0 (1)
1 (2)
2 (3)
3 (4)
4 (5)
Pulmonary Date
Pulmonary Comments
CTC grade Renal
0 (1)
1 (2)
2 (3)
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3 (4)
4 (5)
Renal Date
Renal Comments
Other CTC grade
0 (1)
1 (2)
2 (3)
3 (4)
4 (5)
Date of other Type
Comments of Other type
Graft loss
No (No)
Not evaluated (Not evaluated)
Yes (Yes)
Overall chimaerism
Full (donor >95 %)  (1)
Mixed (partial) (2)
Autologous reconstitution (recipient >95
%)  (3)
Aplasia (4)
Not evaluated (5)
GRAFT ASSESSMENT AND
HAEMOPOIETIC CHIMAERISM
Date of Test
Identification of donor or Cord Blood Unit given
by the centre
Number in the infusion order (if applicable)
Cell type on which test was performed
BM
%
Bone marrow (1)
Other (10)
PB mononuclear cells (PBMC) (2)
T-cell (3)
B-cells (4)
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Red blood cells (5)
Monocytes (6)
PMNs (neutrophils) (7)
Lymphocytes (8)
Myeloid cells (9)
Laboratory tests used:
ABO group (ABO group)
Cytogenetic (Cytogenetic)
FISH (FISH)
Molecular (Molecular)
Other (Other)
unknown (unknown)
SECONDARY MALIGNANCY,
LYMPHOPROLIFERATIVE OR
MYELOPROLIFRATIVE DISORDER
DIAGNOSED
Previously reported (1)
Yes (2)
No at date of this follow-up (3)
Date of diagnosis
Diagnosis Secondary Malignant Neoplasm
AML  (1)
MDS  (2)
Lymphoproliferative disorder  (3)
Other (4)
If other diagnosis, please specify
ADDITIONAL THERAPIES SINCE LAST
FOLLOW UP
Treatment given since last report
No (No)
Unknown (Unknown)
Yes (Yes)
Date started
If yes: CELLULAR THERAPY
One cell therapy regimen is defined as any
number of infusions given within 10 weeks for the
same indication. If more than one regimen of cell
therapy has been given since last report, copy
this section and complete it as many times as
necessary.
No (1)
Yes (2)
Unknown (3)
Disease status before this cellular therapy
CR  (1)
Not in CR  (2)
Not evaluated (3)
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If yes: Type of cells
Donor lymphocyte infusion (DLI) (1)
Mesenchymal cells (2)
Other (3)
Unknown (4)
If DLI, specify the number of cells infused by
type:
Nucleated cells
Evaluated (Evaluated)
Not evaluated (Not evaluated)
unknown (unknown)
Number of cells infused by type
Nucleated cells (1)
CD 34+ (2)
CD 3+ (3)
Total number of cells
Evaluated (Evaluated)
Not Evaluated (Not Evaluated)
Unknown (Unknown)
Chronological number of this cell therapy for this
patient
Indication 
(check all that apply)
Loss/decreased chimaerism
(Loss/decreased chimaerism)
Mixed chimaerism (Mixed chimaerism)
Other (Other)
Planned/ protocol (Planned/ protocol)
Prophylactic (Prophylactic)
Treatment for disease (Treatment for
disease)
Treatment of GvHD (Treatment of GvHD)
Treatment PTLD, EBV, lymphoma
(Treatment PTLD, EBV, lymphoma)
Treatment viral infection (Treatment viral
infection)
Number of infusions within 10 weeks (count only
infusions that are part of same regimen and given
for the same indication)
Maximum Grade of Acute GVHD
Agvhd Grade 0 (0)
Agvhd Grade I (I)
Agvhd Grade Ii (II)
Agvhd Grade Iii (III)
Agvhd Grade Iv (IV)
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Agvhd Present, Grade Unknown
(Present, grade unknown)
Disease treatment (apart from donor cell infusion
or other type of cell therapy)
No (1)
Yes: Planned (planned before HSCT took
place) (2)
Yes: Not planned (for
relapse/progression or persistent
disease) (3)
FIRST EVIDENCE OF DISEASE
WORSENING SINCE LAST HSCT
EVIDENCE OF DISEASE ACTIVITY
Continuous worsening since HSCT
(Continuous worsening since HSCT)
No (No)
Previously reported (Previously reported)
Unknown (Unknown)
Yes (Yes)
If yes, date first noted
LAST DISEASE AND PATIENT STATUS
HAEMATOLOGICAL DISEASE STATUS
Complete remission (Complete
remission)
Not evaluable (Not evaluable)
Partial remission (Partial remission)
Progression (Progression)
Stable disease (Stable disease)
Unknown (Unknown)
Organ Response
Response (1)
Non Response (2)
Progression (3)
Not evaluable (4)
Unknown (5)
CLINICAL AND LABORATORY DATA
Serum creatinine (1)
Serum c-Troponin T (μg/L) (10)
Hb (g/dL) (2)
Total urinary protein excretion (mg/24 h)
(3)
Total urinary albumin excretion (mg/24 h)
(4)
Serum calcium (mmol/L) (5)
Serum albumin (g/L) (6)
Serum alkaline phosphatase (IU/L) (7)
Serum bilirubin (8)
NT-proBNP  (ng/L) (9)
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BM aspirate: % plasmacytosis
%
BM trephine % plasmacytosis
%
Monoclonal Ig in serum
g/L
Immunofixation of serum
Negative  (1)
Positive  (2)
Not evaluated  (3)
Unknown (4)
Free Kappa light chains in serum
mg/L
Not evaluated (1)
Lambda light chains
mg/L
Not evaluated (1)
Immunofixation of urine
Negative  (1)
Positive  (2)
Not evaluated  (3)
Unknown (4)
Monoclonal light chains in urine
g/24h
Serum Beta2 microglobulin
mg/L
Renal response
Response (1)
No response/stable disease (2)
Progressive disease (3)
Not evaluable (4)
Not evaluated/not applicable (5)
Unknown (6)
Liver span 
(cm craniocaudal diameter)
Hepatic response
No response/stable disease (No
response/stable disease)
Not evaluable (Not evaluable)
Not evaluated/not applicable (Not
evaluated/not applicable)
Progressive disease (Progressive
disease)
Response (Response)
Unknown (Unknown)
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NYHA class
I (1)
II (2)
III (3)
IV (4)
unknown (5)
Left Ventricular Ejection Fraction
%
Interventricular septal wall thickness
(mean # mm in echocardiogram)
Cardiac response
Response  (1)
No response/stable disease  (2)
Progressive disease (3)
Not evaluable  (4)
Not evaluated/not applicable  (5)
Unknown (6)
Weight loss
No  (1)
Yes  (2)
Not evaluated  (3)
Unknown (4)
Malabsorption
No  (1)
Yes  (2)
Not evaluated  (3)
Unknown (4)
GI bleeding
No  (1)
Yes  (2)
Not evaluated  (3)
Unknown (4)
GI response
Response  (1)
No response/stable disease  (2)
Progressive disease (3)
Not evaluable  (4)
Not evaluated/not applicable  (5)
Unknown (6)
Neurological exam
Improved  (1)
Worsened  (2)
Unchanged  (3)
Unknown (4)
PNP severity
grade I  (1)
grade II  (2)
grade III  (3)
grade IV (4)
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PN response
Response  (1)
No response/stable disease  (2)
Progressive disease (3)
Not evaluable  (4)
Not evaluated/not applicable  (5)
Unknown (6)
Autonomic neuropathy
Response  (1)
No response/stable disease  (2)
Progressive disease (3)
Not evaluable  (4)
Not evaluated/not applicable  (5)
Unknown (6)
Evidence of new organ involvement
Has patient or partner become pregnant after this
HSCT?
Yes  (1)
No  (2)
Unknown (3)
Survival Status
alive (0)
dead (1)
Type of score used
PERFORMANCE SCORE (if alive)
Karnofsky (1)
Lansky (2)
Score
100 (Normal, NED) (1)
10 (Moribund) (10)
Not evaluated (11)
Unknown (12)
90 (Normal activity)  (2)
80 (Normal with effort) (3)
70 (Cares for self) (4)
60 (Requires occasional assistance) (5)
50 (Requires assistance) (6)
40 (Disabled) (7)
30 (Severely disabled) (8)
20 (Very sick) (9)
CAUSE OF DEATH
(check only one main cause)
Due to amyloidosis (progression of
disease) (1)
Secondary malignancy (including
lymphoproliferative disease) (2)
HSCT related cause (3)
unknown (4)
other (5)
cGvHD
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Yes  (1)
No  (2)
Unknown (3)
Interstitial pneumonitis Cause of death
No  (1)
Yes (2)
Unknown (3)
Pulmonary toxicity Cause
Yes (1)
No (2)
Unknown (3)
Infection
Yes (1)
No (2)
Unknown (3)
Infection:
bacterial  (1)
viral  (2)
fungal  (3)
parasitic  (4)
unknown (5)
Rejection / poor graft function
Yes (1)
No (2)
Unknown (3)
Veno-Occlusive disease (VOD)
Yes (1)
No (2)
Unknown (3)
Haemorrhage
Yes (1)
No (2)
Unknown (3)
Cardiac toxicity
Yes (1)
No (2)
Unknown (3)
Central nervous system toxicity
Yes (1)
No (2)
Unknown (3)
Gastro intestinal toxicity
Yes (1)
No (2)
Unknown (3)
Skin toxicity
Yes  (1)
No (2)
Unknown (3)
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Renal failure
Yes (1)
No (2)
Unknown (3)
Multiple organ failure
Yes (1)
No (2)
Unknown (3)
If other HSCT related cause, please specify
ADDITIONAL NOTES IF APPLICABLE
Comments
IDENTIFICATION & SIGNATURE
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Eligibility Relapsed or Refractory
Lymphomas NCT02249429
Phase I Study of Oral PQR309 in Patients With Relapsed
or Refractory Lymphomas; ODM derived from:
https://clinicaltrials.gov/show/NCT02249429
All rights reserved. Please visit https://medical-data-
models.org/forms/15933
Eligibility Relapsed or Refractory
Lymphomas NCT02249429
Inclusion Criteria
histologically confirmed diagnosis of relapsed or
refractory lymphoma and received at least one
prior line of therapy.*
Yes
No
age ≥ 18 years*
Yes
No
use of adequate contraceptive measures for male
patients.*
Yes
No
eastern cooperative oncology group (ecog)
performance score of 0-1.*
Yes
No
signed informed consent.*
Yes
No
Exclusion Criteria
previous allogeneic hematopoietic stem cell
transplant (hsct transplant).*
Yes
No
autologous stem cell transplant within the last 6
months.*
Yes
No
concomitant anticancer therapy (e.g.,
chemotherapy, radiotherapy, hormonal,
immunotherapy, biological response modifier,
signal transduction inhibitors).*
Yes
No
patients with a history of myocardial infarction or
coronary artery bypass within the last 3 years.*
Yes
No
patients with severe/unstable angina,
coronary/peripheral arterial bypass, symptomatic
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congestive heart failure nyha class 3 or 4,
hypertension bp>150/100mmhg.*
Yes
No
pre-diagnosed diabetes mellitus.*
Yes
No
fasting glucose > 7.0 mmol/l or hba1c > 6.4%.*
Yes
No
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Eligibility Relapsed or Refractory Lymphomas NCT02249429
Eligibility Relapsed/Refractory B-precursor Acute
Lymphoblastic Leukemia (ALL) NCT02412306
Study of Blinatumomab in Japanese Adults With
Relapsed/Refractory B-precursor Acute Lymphoblastic
Leukemia; ODM derived from:
https://clinicaltrials.gov/show/NCT02412306
All rights reserved. Please visit https://medical-data-
models.org/forms/15934
Eligibility Relapsed/Refractory B-
precursor Acute Lymphoblastic
Leukemia (ALL) NCT02412306
Inclusion Criteria
adult subjects with philadelphia-negative b-
precursor all, with any of the following:*
Yes
No
relapsed or refractory after first line therapy with
first remission duration*
Yes
No
≤ 12 months; or*
Yes
No
relapsed or refractory after first salvage therapy;
or*
Yes
No
relapsed or refractory within 12 months of
allohsct*
Yes
No
5% or more blasts in bone marrow*
Yes
No
in case of clinical signs of extramedullary disease
in addition to medullary disease, disease must be
measurable (at least one lesion ≥ 1.5 cm)*
Yes
No
Exclusion Criteria
subjects with burkitt's leukemia according to
world health organization (who) classification*
Yes
No
history or presence of clinically relevant cental
nervous system (cns) pathology such as epilepsy,
seizure, paresis, aphasia, stroke, severe brain
injuries, dementia, parkinson's disease,
cerebellar disease, organic brain syndrome,
psychosis; with the exception of well controlled
cns leukemia*
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Yes
No
active all in the cns or testes*
Yes
No
current autoimmune disease or history of
autoimmune disease with potential cns
involvement*
Yes
No
autologous hsct within 6 weeks prior to start of
blinatumomab treatment*
Yes
No
allohsct within 12 weeks prior to start of
blinatumomab treatment*
Yes
No
any active acute graft-versus-host disease (gvhd)
grade 2-4 according to glucksberg criteria or
active chronic gchd requiring systemic treatment*
Yes
No
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Eligibility Relapsed/Refractory B-precursor Acute Lymphoblastic
Leukemia (ALL) NCT02412306
Eligibility Renal Cell Carcinoma
NCT01762592
REDECT 2: REnal Masses: Pivotal Trial to DEteCT Clear
Cell Renal Cell Carcinoma With PET/CT; ODM derived
from: https://clinicaltrials.gov/show/NCT01762592
All rights reserved. Please visit https://medical-data-
models.org/forms/15935
Eligibility Renal Cell Carcinoma
NCT01762592
Inclusion Criteria
1. ≥18 years of age.*
Yes
No
2. presence of indeterminate ct1 renal mass by
screening ct with and without contrast or mri with
and without contrast (mri only if ct is contra-
indicated).*
Yes
No
3. negative serum pregnancy test; to be
performed on female patients of childbearing
potential within 24 hours prior to receiving
investigational product.*
Yes
No
4. recovered from toxicity of any prior therapy to
grade 1 or better.*
Yes
No
5. able to take oral medication (ki).*
Yes
No
6. written informed consent available.*
Yes
No
Exclusion Criteria
1. renal mass known to be a metastasis of
another primary tumor.*
Yes
No
2. known histology of renal mass (e.g. by
biopsy).*
Yes
No
3. active non-renal malignancy requiring therapy
during the time frame of individual patient study
participation.*
Yes
No
4. chemotherapy, radiotherapy, or immunotherapy
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within 4 weeks prior to iodine (124i) girentuximab
infusion on day 0 or continuing adverse effects
(>grade 1) from such therapy.*
Yes
No
5. exposure to murine proteins or chimeric
antibodies within the last 5 years.*
Yes
No
6. intercurrent medical condition that may limit
patient's study participation or compliance.*
Yes
No
7. history of autoimmune hepatitis.*
Yes
No
8. mental impairment that may compromise the
ability to give informed consent and comply with
the requirements of the study.*
Yes
No
9. participation in any other clinical trial involving
another investigational product within 4 weeks
prior to enrollment.*
Yes
No
10. women who are pregnant or breastfeeding.*
Yes
No
11. contraindication to ki intake (see package
insert/appendix vi).*
Yes
No
12. hyperthyroidism, or grave's disease.*
Yes
No
13. contraindication for pet/ct.*
Yes
No
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NINDS CDE Headache Mail Questionnaire
NINDS Common Data Elements (Headache Mail
Questionnaire) Used from the National Institute of
Neurological Disorders and Stroke Common Data Elements
(https://www.commondataelements.ninds.nih.gov/)
References: Grinnon ST, Miller K, Marler JR, Lu Y, Stout A,
Odenkirchen J, Kunitz S. National Institute of Neurological
Disorders and Stroke Common Data Element Project -
approach and methods. Clin Trials. 2012;9(3):322-9.
All rights reserved. Please visit https://medical-data-
models.org/forms/15942
Headache Mail Questionnaire
Demographics
Study ID
Study site name
Subject ID
Headache Mail Questionnaire
In the past year, have you had at least one
headache that WAS NOT caused by a head
injury, hangover or an illness such as a cold or
the flu?
Yes
No
In the past year, have you ever had a headache
that WAS NOT caused by a head injury, hangover
or an illness such as a cold or the flu?
Yes
No
On how many days in the last 3 months did you
have a headache, if a headache lasted more than
1 day, count each day?
Days
Because of your headaches, on how many days
in the last 3 months did you miss work or school
Days
Because of your headaches, on how many days
in the last 3 months was your productivity at work
or school reduced by half or more?
Days
Because of your headaches, on how many days
in the last 3 months did you not do household
work?
Days
Because of your headaches, on how many days
in the last 3 months was your productivity in
household work reduced by half or more?
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Days
Because of your headaches, on how many days
in the last 3 months did you miss family, social, or
leisure activities?
Days
On a scale of 0-10 (where 0 = no pain at all and
10 = pain as bad as it can be), on average how
painful were these headaches?
0 No Pain (1)
9 (10)
10 Pain Is As Bad As It Could Be (11)
1 (2)
2 (3)
3 (4)
4 (5)
5 (6)
6 (7)
7 (8)
8 (9)
Number In Past Month of Most severe type of
headache
Number In Past Month of Most severe type of
headache
Number In Past Month of Most severe type of
headache
When was the last time you had a headache? #
of months ago:
When was the last time you had a headache?
During the past month:
How many different types of headache do you
have? Specify number of headache types:
Number In Past Month of Most severe type of
headache
Number In Past 12 Month of Most severe type of
headache
Number In Past Month of Second Most severe
type of headache
Number In Past 12 Month of Second Most severe
type of headache
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Number In Past Month of other types of
headache
Number In Past 12 Month of other types of
headache
Most Severe Type Of Headache:The pain is
worse on just one side
Never (1)
Rarely (2)
Less Than Half The Time (3)
Half The Time Or More (4)
Most Severe Type Of Headache:The pain is
pounding, pulsating or throbbing
Never (1)
Rarely (2)
Less Than Half The Time (3)
Half The Time Or More (4)
Most Severe Type Of Headache:The pain has
moderate or severe intensity
Never (1)
Rarely (2)
Less Than Half The Time (3)
Half The Time Or More (4)
Most Severe Type Of Headache:The pain is
made worse by routine activities such as walking
or climbing stairs
Never (1)
Rarely (2)
Less Than Half The Time (3)
Half The Time Or More (4)
Most Severe Type Of Headache:You feel
nauseated or sick to your stomach
Never (1)
Rarely (2)
Less Than Half The Time (3)
Half The Time Or More (4)
Most Severe Type Of Headache:Light bothers
you (more than when you do not have
headaches)
Never (1)
Rarely (2)
Less Than Half The Time (3)
Half The Time Or More (4)
Most Severe Type Of Headache:Sound bothers
you (more than when you do not have
headaches)
Never (1)
Rarely (2)
Less Than Half The Time (3)
Half The Time Or More (4)
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Second Most Severe Type Of Headache:The pain
is worse on just one side
Never (1)
Rarely (2)
Less Than Half The Time (3)
Half The Time Or More (4)
Second Most Severe Type Of Headache:The pain
is pounding, pulsating or throbbing
Never (1)
Rarely (2)
Less Than Half The Time (3)
Half The Time Or More (4)
Second Most Severe Type Of Headache:The pain
has moderate or severe intensity
Never (1)
Rarely (2)
Less Than Half The Time (3)
Half The Time Or More (4)
Second Most Severe Type Of Headache:The pain
is made worse by routine activities such as
walking or climbing stairs
Never (1)
Rarely (2)
Less Than Half The Time (3)
Half The Time Or More (4)
Second Most Severe Type Of Headache:You feel
nauseated or sick to your stomach
Never (1)
Rarely (2)
Less Than Half The Time (3)
Half The Time Or More (4)
Second Most Severe Type Of Headache:Light
bothers you (more than when you do not have
headaches)
Never (1)
Rarely (2)
Less Than Half The Time (3)
Half The Time Or More (4)
Second Most Severe Type Of Headache:Sound
bothers you (more than when you do not have
headaches)
Never (1)
Rarely (2)
Less Than Half The Time (3)
Half The Time Or More (4)
Other Types Of Headache:The pain is worse on
just one side
Never (1)
Rarely (2)
Less Than Half The Time (3)
Half The Time Or More (4)
Other Types Of Headache:The pain is pounding,
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pulsating or throbbing
Never (1)
Rarely (2)
Less Than Half The Time (3)
Half The Time Or More (4)
Other Types Of Headache:The pain has
moderate or severe intensity
Never (1)
Rarely (2)
Less Than Half The Time (3)
Half The Time Or More (4)
Other Types Of Headache:The pain is made
worse by routine activities such as walking or
climbing stairs
Never (1)
Rarely (2)
Less Than Half The Time (3)
Half The Time Or More (4)
Other Types Of Headache:You feel nauseated or
sick to your stomach
Never (1)
Rarely (2)
Less Than Half The Time (3)
Half The Time Or More (4)
Other Types Of Headache:Light bothers you
(more than when you do not have headaches)
Never (1)
Rarely (2)
Less Than Half The Time (3)
Half The Time Or More (4)
Other Types Of Headache:Sound bothers you
(more than when you do not have headaches)
Never (1)
Rarely (2)
Less Than Half The Time (3)
Half The Time Or More (4)
When I TAKE medication, my headaches last
...minutes or ...hours or ...days
When I TAKE medication, my headaches last
Don't know, I usually go to sleep (1)
Not sure (2)
When I DON'T take  medication, my headaches
last ...minutes or ...hours or ...days
When I DON'T take medication, my headaches
last
Don't know, I usually go to sleep (1)
Not sure (2)
On a scale of 0-10 (where 0 = no pain at all and
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10 = pain as bad as it can be), on average how
painful was your most severe type of headache
0 No Pain (1)
9 (10)
10 Pain Is As Bad As It Could Be (11)
1 (2)
2 (3)
3 (4)
4 (5)
5 (6)
6 (7)
7 (8)
8 (9)
About how old were you when you had your first
attack of your most severe type of headache?
Years old
Have you ever seen things like spots, stars, lines,
flashing lights, zigzag lines, or "heat waves"
around the time of your most severe type of
headache
Yes (Continue)  (1)
No (Skip to Qu. 12)  (2)
Don't know (Continue) (3)
Have you had at least 1 headache in the last year
with these visual changes?
Yes   (1)
No  (2)
Don't know (3)
How often do you have these changes in vision
with your most severe type of headache?
Never (1)
Rarely (2)
Less Than Half The Time (3)
Half The Time Or More (4)
How long do these changes in your vision last on
average?
Minutes
With your most severe type of headache, how
often have you had a feeling such as numbness
or tingling in any part of your body or face?
Never (1)
Rarely (2)
Less Than Half The Time (3)
Half The Time Or More (4)
How often do you have a warning before your
most severe type of headache begins?
Never (1)
Rarely (2)
Less Than Half The Time (3)
Half The Time Or More (4)
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After the headache pain ends, how long does it
take until you can function normally
After the headache pain ends, how long does it
take until you can function normally:not
applicable
Yes
No
How often does your most severe type of
headache occur near the time of menstruation
(from a day before to two days after)?
Never (1)
Rarely (2)
Less Than Half The Time (3)
Half The Time Or More (4)
Which best describes how you are usually
affected by your most severe type of headache?
I work or function normally (1)
Working ability or activity impaired to
some degree (2)
Working ability or activity severely
impaired, but no bed rest required (3)
Bed rest required (4)
On average, how long are you unable to work or
undertake normal activities, when you have your
most severe type of headache? Hours: OR Days:
How often do you experience increased pain or
an unpleasant sensation on your skin during your
most severe type of headache when you are
combing your hair
Never	 (1)
Rarely	 (2)
Less Than Half The Time	 (3)
Half The Time Or More	 (4)
Does Not Apply To Me (5)
How often do you experience increased pain or
an unpleasant sensation on your skin during your
most severe type of headache when you are
pulling your hair back (for example like a ponytail)
Never	 (1)
Rarely	 (2)
Less Than Half The Time	 (3)
Half The Time Or More	 (4)
Does Not Apply To Me (5)
How often do you experience increased pain or
an unpleasant sensation on your skin during your
most severe type of headache when you are
shaving your face
Never	 (1)
Rarely	 (2)
Less Than Half The Time	 (3)
Half The Time Or More	 (4)
Does Not Apply To Me (5)
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How often do you experience increased pain or
an unpleasant sensation on your skin during your
most severe type of headache when you are
wearing eyeglasses
Never	 (1)
Rarely	 (2)
Less Than Half The Time	 (3)
Half The Time Or More	 (4)
Does Not Apply To Me (5)
How often do you experience increased pain or
an unpleasant sensation on your skin during your
most severe type of headache when you are
wearing contact lenses
Never	 (1)
Rarely	 (2)
Less Than Half The Time	 (3)
Half The Time Or More	 (4)
Does Not Apply To Me (5)
How often do you experience increased pain or
an unpleasant sensation on your skin during your
most severe type of headache when you are
wearing earrings
Never	 (1)
Rarely	 (2)
Less Than Half The Time	 (3)
Half The Time Or More	 (4)
Does Not Apply To Me (5)
How often do you experience increased pain or
an unpleasant sensation on your skin during your
most severe type of headache when you are
wearing a necklace
Never	 (1)
Rarely	 (2)
Less Than Half The Time	 (3)
Half The Time Or More	 (4)
Does Not Apply To Me (5)
How often do you experience increased pain or
an unpleasant sensation on your skin during your
most severe type of headache when you are
wearing tight clothing
Never	 (1)
Rarely	 (2)
Less Than Half The Time	 (3)
Half The Time Or More	 (4)
Does Not Apply To Me (5)
How often do you experience increased pain or
an unpleasant sensation on your skin during your
most severe type of headache when you are
taking a shower (when shower water hits your
face)
Never	 (1)
Rarely	 (2)
Less Than Half The Time	 (3)
Half The Time Or More	 (4)
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Does Not Apply To Me (5)
How often do you experience increased pain or
an unpleasant sensation on your skin during your
most severe type of headache when you are
resting your face or head on a pillow
Never	 (1)
Rarely	 (2)
Less Than Half The Time	 (3)
Half The Time Or More	 (4)
Does Not Apply To Me (5)
How often do you experience increased pain or
an unpleasant sensation on your skin during your
most severe type of headache when you are
exposed to heat (examples: cooking; washing
your face with hot water)
Never	 (1)
Rarely	 (2)
Less Than Half The Time	 (3)
Half The Time Or More	 (4)
Does Not Apply To Me (5)
How often do you experience increased pain or
an unpleasant sensation on your skin during your
most severe type of headache when you are
exposed to cold (using an ice pack, washing with
cold water)
Never	 (1)
Rarely	 (2)
Less Than Half The Time	 (3)
Half The Time Or More	 (4)
Does Not Apply To Me (5)
Has the frequency of your most severe type of
headaches changed during the past 3 months
compared to the 3 months before that?
Significantly increased in frequency (1)
Stayed about the same frequency (2)
Significantly decreased in frequency (3)
Have you ever discussed your headaches with a
doctor or other health professional?
Yes
No
How old were you when you talked with a doctor
or other health professional for the first time
specifically about your headaches?
Years old
I have never talked with a doctor about my
headaches (if yes, Skip to Qu. 23a)
Yes
No
When was the last time you talked with a doctor
or other health professional about your
headaches?
9 / 25
NINDS CDE Headache Mail Questionnaire
Within the last month (1)
Within last 2-6 mos (2)
Within last 7-12 mo (3)
More than 12 mos. ago (4)
Have you ever been told by a doctor or other
health professional that you have…?
Migraine headaches (1)
Other (Specify) (10)
Menstrual headaches or menstrual
migraines (2)
Sinus headaches (3)
Tension headaches (4)
Stress headaches (5)
Chronic migraine or transformed
migraine (6)
Chronic daily headache (7)
Rebound headache due to medication
overuse (8)
Cluster headaches (9)
If you answered “migraine headaches” in
question 21a: How old were you when you were
first told by a medical doctor or other health
professional that you have migraine headaches
Years old
What type(s) of doctor or other health
professional do you see most often for your
headaches?
Chiropractor (1)
Ear, Nose, and Throat Specialist (10)
Allergist (11)
Naturopath/Homeopath (12)
Pharmacist (13)
Nurse/Nurse practitioner (14)
Physicians assistant (15)
Other (specify) (16)
Never seen any doctor about headaches
(17)
Don't currently see any doctor about
headaches (18)
Ophthalmologist (2)
Emergency room doctor (3)
Pain/Headache clinic doctor (4)
General/Family practitioner (5)
Pediatrician (6)
Internist (7)
Obstetrician/Gynecologist (8)
Neurologist (9)
Please specify other:
What type(s) of doctors or health professionals
have you ever seen or consulted for your
headaches?
Chiropractor (1)
Ear, Nose, and Throat Specialist (10)
10 / 25
NINDS CDE Headache Mail Questionnaire
Allergist (11)
Naturopath/Homeopath (12)
Pharmacist (13)
Nurse/Nurse practitioner (14)
Physicians assistant (15)
Other (specify) (16)
Never seen any doctor about headaches
(17)
Don't currently see any doctor about
headaches (18)
Ophthalmologist (2)
Emergency room doctor (3)
Pain/Headache clinic doctor (4)
General/Family practitioner (5)
Pediatrician (6)
Internist (7)
Obstetrician/Gynecologist (8)
Neurologist (9)
Please specify other
How many times in the past 12 months did you
visit your primary care doctor's office specifically
for the treatment of your headaches?
How many times in the past 12 months did you
visit a hospital emergency room (where you did
not stay
overnight) specifically for the treatment of your
headaches?
How many times in the past 12 months did you
visit an urgent care center specifically for the
treatment of your headaches?
How many times in the past 12 months did you
visit your neurologist's or headache specialist's
office specifically for the treatment of your
headaches?
How many times in the past 12 months did you
visit a pain clinic specifically for the treatment of
your headaches?
How many times in the past 12 months did you
visit other place for medical treatment (Specify):
specifically for the treatment of your headaches?
Other place for medical treatment (Specify):
In total, over the past 12 months, how many
nights, if any, did you stay overnight in the
hospital due to your headaches or other reasons?
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In total, over the past 12 months, how many
nights, if any, did you stay overnight in the
hospital due to your headaches or other reasons?
In total, over the past 12 months, how many
nights, if any, did you stay overnight in the
hospital due to other reasons?
In total, over the past 12 months, how many
nights, if any, did you stay overnight in the
hospital due to your headaches
Which of the following treatments do you
currently use to treat your most severe type of
headache pain?
Natural products such as
herbal/alternative remedies (1)
Over the counter products such as
aspirin, Tylenol, Excedrin, Aleve (2)
Prescription medications (3)
No treatment at all (Skip to Qu. 27) (4)
Please "X" each medication you currently use to
treat your most severe type of headaches.
Tylenol (or other brand of
acetaminophen) (1)
Amerge tablets (naratriptan) (10)
Axert tablets (almotriptan) (11)
Demerol (oral or injected meperidine)
(12)
Ergomar/Bellergal-S/Cafergot (or other
brand of ergotamine) (13)
Fiorinal/Fioricet
(butalbital+caffeine+acetaminophen) with
or without codeine (14)
Frova tablets (frovatriptan) (15)
Imitrex tablets (sumatriptan) (16)
Imitrex nasal spray (sumatriptan) (17)
Imitrex STAT dose (injection)
(sumatriptan) (18)
Midrin/Duradrin
(Isometheptene+dichoralphenazone+ace
taminophen) (19)
Aleve/Naprosyn/Anaprox (or other brand
of naproxen) (2)
Maxalt MLT (oral wafer) (rizatriptan) (20)
Maxalt tablets (rizatriptan) (21)
Migranal nasal spray or DHE-45 injection
(dihydroergotamine) (22)
Oral narcotics (Darvocet,Tylenol with
codeine, Vicodin, Vicoprofen)	 (23)
Phrenilin (butalbital+acetaminophen)
(24)
Relpax tablets (eletriptan) (25)
Zomig nasal spray (zolmitriptan) (26)
Stadol NS (nasal spray) (butorphanol)
(27)
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Toradol (ketorolac) other non-narcotic
(28)
Zomig tablet (zolmitriptan) (29)
Aspirin (3)
Zomig ZMT (melt) (zolmitriptan) (30)
Any other injected pain reliever (specify):
(31)
Other prescription (specify): (32)
Excedrin/Excedrin Migraine/Generic
"Excedrin"
(acetaminophen+aspirin+caffeine) (4)
Advil, Motrin (or other brand of ibuprofen)
(5)
Orudis/Oruvail (ketoprofen) (6)
Other non-prescription (specify): (7)
Other non-prescription (specify): (8)
PRESCRIPTION MEDICATIONS (9)
Please specify any other medication you take for
your most severe type of headache
For each medication you currently use, write in
the name of medication and number of days you
take this medication in a typical month.
Have you ever taken preventive medication,
whether or not you had a headache, to help
prevent your most severe type of headache from
happening in the first place?
I use or have used a preventive
medication that I took every day (Please
Answer next Qu) (1)
I use or have used a preventive
medication that I took when I felt a
headache coming (2)
I use or have used a medication for other
reasons that also prevented my
headaches (3)
Have never taken preventive medication
for headache (4)
When did you last take preventive medications for
headache ON A DAILY BASIS, to help prevent
your most severe type of headache from
happening in the first place?
Currently taking (Skip to Qu. 30a) (1)
Last took within the past 3 months (2)
Last took 3-12 months ago (3)
Last took more than 12 months ago (4)
Why did you stop taking preventive medication: I
got better and my doctor and I agreed I should
stop
Strongly Agree	 (1)
Agree	 (2)
Neutral	 (3)
Disagree	 (4)
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Strongly Disagree (5)
Why did you stop taking preventive medication: I
got better and stopped by myself
Strongly Agree	 (1)
Agree	 (2)
Neutral	 (3)
Disagree	 (4)
Strongly Disagree (5)
Why did you stop taking preventive medication:
The medication did not help me enough to make
it worth taking
Strongly Agree	 (1)
Agree	 (2)
Neutral	 (3)
Disagree	 (4)
Strongly Disagree (5)
Why did you stop taking preventive medication: I
had side effects
Strongly Agree	 (1)
Agree	 (2)
Neutral	 (3)
Disagree	 (4)
Strongly Disagree (5)
Why did you stop taking preventive medication: I
gained weight on the medication
Strongly Agree	 (1)
Agree	 (2)
Neutral	 (3)
Disagree	 (4)
Strongly Disagree (5)
Why did you stop taking preventive medication: It
was inconvenient to take the medicine
Strongly Agree	 (1)
Agree	 (2)
Neutral	 (3)
Disagree	 (4)
Strongly Disagree (5)
Why did you stop taking preventive medication:
The medication was too expensive
Strongly Agree	 (1)
Agree	 (2)
Neutral	 (3)
Disagree	 (4)
Strongly Disagree (5)
Why did you stop taking preventive medication: I
had to take the medication several times per day
Strongly Agree	 (1)
Agree	 (2)
Neutral	 (3)
Disagree	 (4)
Strongly Disagree (5)
Why did you stop taking preventive medication: I
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lost weight on the medication
Strongly Agree	 (1)
Agree	 (2)
Neutral	 (3)
Disagree	 (4)
Strongly Disagree (5)
Why did you stop taking preventive medication:
Insurance would not cover
Strongly Agree	 (1)
Agree	 (2)
Neutral	 (3)
Disagree	 (4)
Strongly Disagree (5)
Why did you stop taking preventive medication:
Other (Specify)
Strongly Agree	 (1)
Agree	 (2)
Neutral	 (3)
Disagree	 (4)
Strongly Disagree (5)
Why did you stop taking preventive medication:
Other (Specify)
Please “X” each medication that you have ever
used (for any purpose).
Depakote (divalproex sodium) (1)
Prozac (fluoxetine) (10)
Zoloft (sertraline) (11)
Other anti-depressant (specify): (12)
Blocadren (timolol) (13)
Calan/Covera-HS/Isoptin (verapamil)
(14)
Corgard (nadolol) (15)
Inderal (propranolol) (16)
Lopressor/Toprol XL (metoprolol) (17)
Procardia (nifedipine) (18)
Tenormin (atenolol) (19)
Neurontin (gabapentin) (2)
Other blood pressure/heart medications
(specify) (20)
Butterbur (Petasites) (21)
Feverfew (22)
Magnesium (23)
Vitamin B2 (riboflavin) (24)
Vitamin B6 (pyridoxine) (25)
Other vitamin, mineral or herbal
combination (26)
Botulinum Toxin (27)
Other (Specify) (28)
Topamax (topiramate) (3)
Other anti-seizure (specify) (4)
Cymbalta (duloxetine) (5)
Effexor (venlafaxine) (6)
Elavil (amitriptylline) (7)
Pamelor (nortriptylline) (8)
Paxil (paroxetine) (9)
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Please specify any other medication you have
ever used
Please “X” each medication that you have ever
used to prevent headaches
Depakote (divalproex sodium) (1)
Prozac (fluoxetine) (10)
Zoloft (sertraline) (11)
Other anti-depressant (specify): (12)
Blocadren (timolol) (13)
Calan/Covera-HS/Isoptin (verapamil)
(14)
Corgard (nadolol) (15)
Inderal (propranolol) (16)
Lopressor/Toprol XL (metoprolol) (17)
Procardia (nifedipine) (18)
Tenormin (atenolol) (19)
Neurontin (gabapentin) (2)
Other blood pressure/heart medications
(specify) (20)
Butterbur (Petasites) (21)
Feverfew (22)
Magnesium (23)
Vitamin B2 (riboflavin) (24)
Vitamin B6 (pyridoxine) (25)
Other vitamin, mineral or herbal
combination (26)
Botulinum Toxin (27)
Other (Specify) (28)
Topamax (topiramate) (3)
Other anti-seizure (specify) (4)
Cymbalta (duloxetine) (5)
Effexor (venlafaxine) (6)
Elavil (amitriptylline) (7)
Pamelor (nortriptylline) (8)
Paxil (paroxetine) (9)
Please specify any other medication you have
ever used to prevent headaches
Please “X” each medication that you currently
use
Depakote (divalproex sodium) (1)
Prozac (fluoxetine) (10)
Zoloft (sertraline) (11)
Other anti-depressant (specify): (12)
Blocadren (timolol) (13)
Calan/Covera-HS/Isoptin (verapamil)
(14)
Corgard (nadolol) (15)
Inderal (propranolol) (16)
Lopressor/Toprol XL (metoprolol) (17)
Procardia (nifedipine) (18)
Tenormin (atenolol) (19)
Neurontin (gabapentin) (2)
Other blood pressure/heart medications
(specify) (20)
Butterbur (Petasites) (21)
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Feverfew (22)
Magnesium (23)
Vitamin B2 (riboflavin) (24)
Vitamin B6 (pyridoxine) (25)
Other vitamin, mineral or herbal
combination (26)
Botulinum Toxin (27)
Other (Specify) (28)
Topamax (topiramate) (3)
Other anti-seizure (specify) (4)
Cymbalta (duloxetine) (5)
Effexor (venlafaxine) (6)
Elavil (amitriptylline) (7)
Pamelor (nortriptylline) (8)
Paxil (paroxetine) (9)
Please specify any other medication you currently
use
Please “X” each medication that you currently
use to prevent headaches
Depakote (divalproex sodium) (1)
Prozac (fluoxetine) (10)
Zoloft (sertraline) (11)
Other anti-depressant (specify): (12)
Blocadren (timolol) (13)
Calan/Covera-HS/Isoptin (verapamil)
(14)
Corgard (nadolol) (15)
Inderal (propranolol) (16)
Lopressor/Toprol XL (metoprolol) (17)
Procardia (nifedipine) (18)
Tenormin (atenolol) (19)
Neurontin (gabapentin) (2)
Other blood pressure/heart medications
(specify) (20)
Butterbur (Petasites) (21)
Feverfew (22)
Magnesium (23)
Vitamin B2 (riboflavin) (24)
Vitamin B6 (pyridoxine) (25)
Other vitamin, mineral or herbal
combination (26)
Botulinum Toxin (27)
Other (Specify) (28)
Topamax (topiramate) (3)
Other anti-seizure (specify) (4)
Cymbalta (duloxetine) (5)
Effexor (venlafaxine) (6)
Elavil (amitriptylline) (7)
Pamelor (nortriptylline) (8)
Paxil (paroxetine) (9)
Please specify any other medication you currently
use to prevent headaches
Please specify the number of months using
current medications:Fill in the name of
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medication and the number of months taking it.
Overall I am satisfied with the medication I use to
prevent my headaches
Strongly Agree	 (1)
Agree	 (2)
Neutral	 (3)
Disagree	 (4)
Strongly Disagree (5)
Since I started to use my preventive medication, I
have had at least a 50% decrease in headache
frequency
Strongly Agree	 (1)
Agree	 (2)
Neutral	 (3)
Disagree	 (4)
Strongly Disagree (5)
Since I started to use my preventive medication,
my headaches are not as bad as before
Strongly Agree	 (1)
Agree	 (2)
Neutral	 (3)
Disagree	 (4)
Strongly Disagree (5)
Since I started to use my preventive medication, I
miss less time at work, school or household work
because of my headaches
Strongly Agree	 (1)
Agree	 (2)
Neutral	 (3)
Disagree	 (4)
Strongly Disagree (5)
Since I started to use my preventive medication, I
miss less time at family, social and leisure
activities because of my headaches
Strongly Agree	 (1)
Agree	 (2)
Neutral	 (3)
Disagree	 (4)
Strongly Disagree (5)
My preventive medication does not produce very
many side effects
Strongly Agree	 (1)
Agree	 (2)
Neutral	 (3)
Disagree	 (4)
Strongly Disagree (5)
The medication that I use to treat the headache
attack (acute medication) works better
Strongly Agree	 (1)
Agree	 (2)
Neutral	 (3)
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Disagree	 (4)
Strongly Disagree (5)
Overall I am satisfied with the medication I use to
prevent my headaches
Strongly Agree	 (1)
Agree	 (2)
Neutral	 (3)
Disagree	 (4)
Strongly Disagree (5)
Since I started to use my preventive medication, I
have had at least a 50% decrease in headache
frequency
Strongly Agree	 (1)
Agree	 (2)
Neutral	 (3)
Disagree	 (4)
Strongly Disagree (5)
Since I started to use my preventive medication,
my headaches are not as bad as before
Strongly Agree	 (1)
Agree	 (2)
Neutral	 (3)
Disagree	 (4)
Strongly Disagree (5)
Since I started to use my preventive medication, I
miss less time at work, school or household work
because of my headaches
Strongly Agree	 (1)
Agree	 (2)
Neutral	 (3)
Disagree	 (4)
Strongly Disagree (5)
Since I started to use my preventive medication, I
miss less time at family, social and leisure
activities because of my headaches
Strongly Agree	 (1)
Agree	 (2)
Neutral	 (3)
Disagree	 (4)
Strongly Disagree (5)
My preventive medication does not produce very
many side effects
Strongly Agree	 (1)
Agree	 (2)
Neutral	 (3)
Disagree	 (4)
Strongly Disagree (5)
The medication that I use to treat the headache
attack (acute medication) works better
Strongly Agree	 (1)
Agree	 (2)
Neutral	 (3)
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Disagree	 (4)
Strongly Disagree (5)
Having a medication that prevents at least half of
my headaches
Extremely Important	 (1)
Moderately Important	 (2)
Neither Important Nor Unimportant	 (3)
Moderately Unimportant	 (4)
Not At All Important (5)
Having a medication that prevents at least three-
fourths of my headaches
Extremely Important	 (1)
Moderately Important	 (2)
Neither Important Nor Unimportant	 (3)
Moderately Unimportant	 (4)
Not At All Important (5)
Having a medication that prevents all of my
headaches
Extremely Important	 (1)
Moderately Important	 (2)
Neither Important Nor Unimportant	 (3)
Moderately Unimportant	 (4)
Not At All Important (5)
Having a medication that makes the treatment I
take for headache attacks work more quickly and
effectively
Extremely Important	 (1)
Moderately Important	 (2)
Neither Important Nor Unimportant	 (3)
Moderately Unimportant	 (4)
Not At All Important (5)
Having a medication that does not increase my
appetite or cause weight gains
Extremely Important	 (1)
Moderately Important	 (2)
Neither Important Nor Unimportant	 (3)
Moderately Unimportant	 (4)
Not At All Important (5)
Having a medication that decreases my appetite
or causes weight loss
Extremely Important	 (1)
Moderately Important	 (2)
Neither Important Nor Unimportant	 (3)
Moderately Unimportant	 (4)
Not At All Important (5)
Having a medication that does not cause
sleepiness or slow down my thinking
Extremely Important	 (1)
Moderately Important	 (2)
Neither Important Nor Unimportant	 (3)
Moderately Unimportant	 (4)
Not At All Important (5)
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Having a medication that I can take once or twice
a day
Extremely Important	 (1)
Moderately Important	 (2)
Neither Important Nor Unimportant	 (3)
Moderately Unimportant	 (4)
Not At All Important (5)
Have you been told by a doctor or any other
health professional that you have any of the
following health problems?
Allergies/Hay fever (1)
Depression (10)
Dermatitis/Eczema (11)
Diabetes (12)
Emphysema/COPD (13)
Heart disease/Angina (chest pain) (14)
High blood pressure (15)
High cholesterol (16)
Low blood pressure (17)
Nervousness or anxiety (18)
Obesity (19)
Rheumatoid Arthritis / Osteoarthritis (2)
PMS/Menstrual problems (20)
Seizures, epilepsy, fits or convulsions
(21)
Sinusitis or sinus infection (22)
Stroke (23)
Ulcers of the stomach or intestines (24)
Other (Specify) (25)
Asthma (3)
Bronchitis (4)
Bipolar disorder/Mania (5)
Cancer (of any type) (6)
Chronic bronchitis (7)
Chronic pain (Specify location) (8)
Circulation problems (cold hands or feet)
(9)
Have you been told by a doctor or any other
health professional that you have a health
problem? Please specify other
Are you currently...?
Employed full time (35 or more
hours/week) (1)
Other (Specify) (10)
Employed part time (less than 35
hours/week) (2)
Unemployed (Skip to Qu 51 ) (3)
Retired (Skip to Qu 51 ) (4)
Student (Skip to Qu 51 ) (5)
Homemaker (Skip to Qu 51 ) (6)
Disabled ((Skip to Qu 51 ) (7)
Volunteer (Skip to Qu 51 ) (8)
On medical or maternity leave (Skip to
Qu 51 ) (9)
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Please specify other employment status
How many DAYS do you usually work each
WEEK? Write In DAYS per week
How many HOURS do you usually work each
DAY? Write in HOURS per DAY
Did you miss a full day of work for any reason in
the PAST TWO WEEKS? If no, skip to Qu 43
Yes
No
How many workdays did you miss in the PAST
TWO WEEKS because you were not feeling well?
If 0, skip to Qu 41
What were the reason(s) you were not feeling
well? (X ALL That Apply)
Asthma (1)
Heart problems (10)
Injury (11)
Joint pain/Arthritis (12)
Menstrual pain (13)
Sad/Blue (14)
Seasonal allergies (15)
Other (Specify) (16)
Back pain (2)
Breathing problems (not asthma or cold)
(3)
Cancer (4)
Cold (5)
Diabetes (6)
Digestive problems (7)
Flu (8)
Headache (9)
How many workdays did you miss in the PAST
TWO WEEKS because of short term disability,
long term disability, family medical leave, or
maternity leave? If 0, leave out next Qu
Check the reason or reasons why you missed
work
Maternity leave (1)
Short term disability (2)
Long term disability (3)
Family medical leave (4)
On how many days in the PAST TWO WEEKS
did you go to work when you were not feeling
well? If 0, skip to Qu 51
What were the reason(s) that you were not
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feeling well at work?
Asthma (1)
Heart problems (10)
Injury (11)
Joint pain/Arthritis (12)
Menstrual pain (13)
Sad/Blue (14)
Seasonal allergies (15)
Other (Specify) (16)
Back pain (2)
Breathing problems (not asthma or cold)
(3)
Cancer (4)
Cold (5)
Diabetes (6)
Digestive problems (7)
Flu (8)
Headache (9)
When you weren't feeling well, how long, on
average, did it take you to start working after you
got to work? Write in hours and minutes
When you weren't feeling well, how long, on
average, did it take you to start working after you
got to work?
I started right away  (1)
I don’t know (2)
On average, how much of the time did you just do
no work when you were supposed to be working?
Did not work at all (1)
Did not work most of the time (2)
Did not work about half of the time (3)
Did not work some of the time (4)
Worked the whole time (5)
On average, how much of the time did you spend
doing a job over because you made a mistake or
your supervisor told you to do a job over?
Spent all of the time doing a job over (1)
Most of the time (2)
About half of the time (3)
Some of the time (4)
None of the time (5)
On average, how much of the time did you find it
difficult to concentrate on what you needed to
do?
Difficult to concentrate all of the time (1)
Most of the time (2)
About half of the time (3)
Some of the time (4)
None of the time (5)
On average, how much of the time did you work
more slowly or take longer to complete tasks than
usual or expected?
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Worked more slowly all of the time (1)
Most of the time (2)
About half of the time (3)
Some of the time (4)
None of the time (5)
On average, how much of the time were you very
tired, fell asleep at work or just felt too exhausted
to do your work?
Felt tired all of the time (1)
Most of the time (2)
About half of the time (3)
Some of the time (4)
None of the time (5)
How much have you been bothered by little
interest or pleasure in doing things
Not At All	 (1)
Several Days	 (2)
More Than Half The Days	 (3)
Nearly Every Day (4)
How much have you been bothered by feeling
down, depressed, or hopeless
Not At All	 (1)
Several Days	 (2)
More Than Half The Days	 (3)
Nearly Every Day (4)
How much have you been bothered by trouble
falling or staying asleep, or sleeping too much
Not At All	 (1)
Several Days	 (2)
More Than Half The Days	 (3)
Nearly Every Day (4)
How much have you been bothered by feeling
tired or having little energy
Not At All	 (1)
Several Days	 (2)
More Than Half The Days	 (3)
Nearly Every Day (4)
How much have you been bothered by poor
appetite or overeating
Not At All	 (1)
Several Days	 (2)
More Than Half The Days	 (3)
Nearly Every Day (4)
How much have you been bothered by feeling
bad about yourself - or that you are a failure or
have let yourself or your family down
Not At All	 (1)
Several Days	 (2)
More Than Half The Days	 (3)
Nearly Every Day (4)
How much have you been bothered by trouble
concentrating on things, such as reading the
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newspaper or watching television
Not At All	 (1)
Several Days	 (2)
More Than Half The Days	 (3)
Nearly Every Day (4)
How much have you been bothered by moving or
speaking so slowly that other people could have
noticed? Or the opposite - being so fidgety or
restless that you have been moving around a lot
more than usual
Not At All	 (1)
Several Days	 (2)
More Than Half The Days	 (3)
Nearly Every Day (4)
How much have you been bothered by thoughts
that you would be better off dead or of hurting
yourself in some way
Not At All	 (1)
Several Days	 (2)
More Than Half The Days	 (3)
Nearly Every Day (4)
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Eligibility Renal Cell Carcinoma
NCT02338570
Outcome-related Factors in Patients With Metastatic Renal
Cell Carcinoma Treated With Everolimus (ORCHIDEE);
ODM derived from:
https://clinicaltrials.gov/show/NCT02338570
All rights reserved. Please visit https://medical-data-
models.org/forms/15945
Eligibility Renal Cell Carcinoma
NCT02338570
Inclusion Criteria
1. male or female, aged 18 years or older, with
histologically or cytologically confirmed  mrcc
(clear cell or not clear cell);*
Yes
No
2. ecog-ps 0-1-2;*
Yes
No
3. with target and/or non-target lesions according
to response evaluation criteria in solid tumours
(recist) 1.1;*
Yes
No
4. following failure of a previous treatment with
vegf-targeted therapy (e.g. sunitinib, sorafenib,
pazopanib, or bevacizumab+interferon);*
Yes
No
5. for whom a decision has been taken to initiate
everolimus treatment or patient currently
receiving treatment with everolimus by a period of
time ≤30 days;*
Yes
No
6. willing and able to comply with follow-up and all
other protocol requirements and able to
commence treatment within 21 days;*
Yes
No
7. written informed consent obtained before any
screening procedure and according to local
guidelines.*
Yes
No
Exclusion Criteria
patients   who meet   any of the  following  criteria
will  be excluded from study entry:*
Yes
No
1. previous treatment with everolimus or at the
date of written informed consent provision
receiving everolimus by more than 30 days;*
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Yes
No
2. symptomatic  central nervous system
metastases. patients may be eligible if the central
nervous system metastases have been
adequately treated (surgery or radiotherapy), and
do not require ongoing corticosteroids for control
of symptoms and have had no evidence of
progression for at least three months;*
Yes
No
3. other malignancy diagnosed within the last 5
years, except the following, if adequately treated:
superficial squamous cell carcinoma or basal cell
carcinoma of skin, superficial bladder cancer (t1
and g1 or t1 and g2), stage 1 cervical cancer;*
Yes
No
4. treatment with an investigational agent in the
past 4 weeks;*
Yes
No
5. clinically relevant human immunodeficiency
virus, hepatitis b virus, hepatitis c virus infection;*
Yes
No
6. non adequate liver function as shown by:*
Yes
No
serum or plasma alt and ast >3.0x upper limit of
normal (uln) >5 if hepatic metastases are
present;*
Yes
No
serum or plasma total bilirubin: >1.5xuln
(excepted for patients with gilbert's syndrome);*
Yes
No
7. non adequate renal function as shown by
serum creatinine >2.5xuln;*
Yes
No
8. any of the following in the last year: myocardial
infarction, severe/ unstable angina,
coronary/peripheral artery bypass graft,
symptomatic congestive heart failure,
cerebrovascular accident or transient ischemic
attack or pulmonary embolism;*
Yes
No
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9. ongoing grade ≥2 cardiac dysrhythmias, atrial
fibrillation of any grade or prolongation of the
corrected qt interval to >450 msec for males or
>470 msec for females;*
Yes
No
10. pregnancy (negative pregnancy test required
for women of child-bearing potential), breast
feeding;*
Yes
No
11. inadequate contraception. women must be
post-menopausal, surgically sterile, or use a
reliable form of contraception. men must be
surgically sterile or use a barrier method of
contraception;*
Yes
No
12. known allergy or hypersensitivity to
everolimus or its excipients.*
Yes
No
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NINDS CDE Physical Examination
Headache
NINDS Common Data Elements [Physical Examination]
[Headache] Used from the National Institute of Neurological
Disorders and Stroke Common Data Elements
(https://www.commondataelements.ninds.nih.gov/)
References: Grinnon ST, Miller K, Marler JR, Lu Y, Stout A,
Odenkirchen J, Kunitz S. National Institute of Neurological
Disorders and Stroke Common Data Element Project -
approach and methods. Clin Trials. 2012;9(3):322-9.
All rights reserved. Please visit https://medical-data-
models.org/forms/15950
Physical Examination
Physical Exam
Study-ID:
Study site name
Subject ID
Date of examination
Was a physical exam performed on the
participant/subject?
Yes
No
Constitutional symptoms (e.g., fever, weight loss)
Normal (1)
Abnormal (2)
Not examined (3)
Constitutional symptoms (e.g., fever, weight loss):
Please specify any abnormality or if not examined
Constitutional symptoms (e.g., fever, weight loss)
Clinically significant (1)
Not clinically significant (2)
Eyes
Normal (1)
Abnormal (2)
Not examined (3)
Eyes: please specify any abnormality or if not
examined
Eyes
Clinically significant (1)
Not clinically significant (2)
Ears, Nose, Mouth, and Throat
Normal (1)
Abnormal (2)
Not examined (3)
Ears, Nose, Mouth, and Throat: please specify
any abnormality or if not examined
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Ears, Nose, Mouth, and Throat
Clinically significant (1)
Not clinically significant (2)
Cardiovascular
Normal (1)
Abnormal (2)
Not examined (3)
Cardiovascular:Please specify any abnormality or
if not examined
Cardiovascular
Clinically significant (1)
Not clinically significant (2)
Respiratory
Normal (1)
Abnormal (2)
Not examined (3)
Respiratory:Please specify any abnormality or if
not examined
Respiratory
Clinically significant (1)
Not clinically significant (2)
Gastrointestinal
Normal (1)
Abnormal (2)
Not examined (3)
Gastrointestinal: please specify any abnormality
or if not examined
Gastrointestinal
Clinically significant (1)
Not clinically significant (2)
Genitourinary
Normal- (1)
Abnormal (2)
Not examined (3)
Genitourinary:please specify any abnormality or if
not examined
Genitourinary
Clinically significant (1)
Not clinically significant (2)
Musculoskeletal
Normal (1)
Abnormal (2)
Not examined (3)
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Musculoskeletal:Please specify any abnormality
or if not examined
Musculoskeletal
Clinically significant (1)
Not clinically significant (2)
Integumentary (skin and/or breast)
Normal (1)
Abnormal (2)
Not examined (3)
Integumentary (skin and/or breast):Please
specify any abnormality or if not examined
Integumentary (skin and/or breast)
Clinically significant (1)
Not clinically significant (2)
Neurological
Normal (1)
Abnormal (2)
Not examined (3)
Neurological:Please specify any abnormality or if
not examined
Neurological
Clinically significant (1)
Not clinically significant (2)
Psychiatric
Normal (1)
Abnormal (2)
Not examined (3)
Psychiatric:Please specify any abnormality or if
not examined
Psychiatric
Clinically significant (1)
Not clinically significant (2)
Endocrine system
Normal  (1)
Abnormal  (2)
Not examined (3)
Endocrine system: please specify any
abnormality or if not examined
Endocrine system
Clinically significant (1)
Not clinically significant (2)
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Hematologic/Lymphatic
Normal (1)
Abnormal (2)
Not examined (3)
Hematologic/Lymphatic:Please specify any
abnormality or if not examined
Hematologic/Lymphatic
Clinically significant (1)
Not clinically significant (2)
Allergic/Immunologic
Normal (1)
Abnormal (2)
Not examined (3)
Allergic/Immunologic: please specify abnormality
or if not examined
Allergic/Immunologic
Clinically significant (1)
Not clinically significant (2)
Hand preference
Left hand  (1)
Right hand  (2)
Both hands  (3)
Unknown (4)
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NINDS CDE Vital Signs Headache
NINDS Common Data Elements [Vital Signs][Headache]
Used from the National Institute of Neurological Disorders
and Stroke Common Data Elements
(https://www.commondataelements.ninds.nih.gov/)
References: Grinnon ST, Miller K, Marler JR, Lu Y, Stout A,
Odenkirchen J, Kunitz S. National Institute of Neurological
Disorders and Stroke Common Data Element Project -
approach and methods. Clin Trials. 2012;9(3):322-9.
All rights reserved. Please visit https://medical-data-
models.org/forms/15951
Vital Signs
Vital Signs
Study-ID:
Study site name
Subject ID
Date and time
Heart rate
bpm
Blood pressure measurement systolic and
diastolic
mm/Hg
Blood pressure measurement position
mm/Hg
Supine  (1)
Sitting (preferred position)  (2)
Standing (3)
Second Blood pressure measurement systolic
and diastolic
mm/Hg
Blood pressure measurement position
mm/Hg
Supine  (1)
Sitting (preferred position)  (2)
Standing (3)
Third Blood pressure measurement systolic and
diastolic
mm/Hg
Blood pressure measurement position
mm/Hg
Supine  (1)
Sitting (preferred position)  (2)
Standing (3)
Body Temperature
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Body Temperature measurement location
(Choose one):
Oral (1)
Rectal (2)
Tympanic (3)
Axillary (4)
Forehead Cutaneous Infrared (5)
Other, specify (6)
Body Temperature measurement location: Please
specify other
Please specify body temperature measurement
unit
Degrees Fahrenheit (1)
Degrees Celsius (2)
Respiratory Rate
/min
Oxygen saturation
%
Body weight
Please specify units used for body weight
measurement
kg (1)
pounds (2)
Body weight measurement type (Choose one)
Self-reported  (1)
Measured (2)
Body weight measurement Weight percentile
(Pediatric ONLY):
Body Height
Body Height: Please specify units used for
measurement
inches (1)
centimeters (2)
Body Height: measurement type
Self-reported  (1)
Measured (2)
Body Height Height percentile (pediatric only)
Body Weight/Height ratio
Body Mass Index
2 / 3
NINDS CDE Vital Signs Headache
kg/m2
Body Mass Index measurement type
Self-reported (1)
Measured (2)
Mixed (e.g., Height/Weight measured
and the other self-reported) (3)
BMI percentile (Pediatric ONLY):
Head circumference
Head circumference unit of measurement
inches (1)
centimeters (2)
Waist Circumference
Waist Circumference unit of measurement
inches (1)
centimeters (2)
Hip Circumference
Hip Circumference unit of measurement
inches (1)
centimeters (2)
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Eligibility Rest Tremor NCT02370108
The Study of Rest Tremor Suppression by Using Electrical
Muscle Stimulation; ODM derived from:
https://clinicaltrials.gov/show/NCT02370108
All rights reserved. Please visit https://medical-data-
models.org/forms/15952
Eligibility Rest Tremor NCT02370108
Inclusion Criteria
for pd patients*
Yes
No
adults ≥ 18 years old.*
Yes
No
patients with parkinson's disease diagnosed
according to the ukpdsbb criteria with
predominantly feature of rest tremor that
intractable to medically treatment.*
Yes
No
informed consent for other tremor patients*
Yes
No
adults ≥ 18 years old.*
Yes
No
patients with essential tremor diagnosed
according to the trig criteria for essential tremor
or patients with dystonic tremor diagnosed
according to the proposed definition in which their
symptoms shared similar trait of medically
intractable tremor.*
Yes
No
informed consent*
Yes
No
Exclusion Criteria
for pd patients*
Yes
No
patients with a history of cardiac arrhythmia,
renal failure, hepatic failure, and pregnancy as
well as those who had history of seizure or had
the risk for tended to become seizure such as
those who had focal brain lesions, encephalitis,
and stroke patients.*
Yes
No
patients with a history of hand surgery and
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implanted screws or wires in hand area that
supposed to place a surface emg or ems, as well
as those patients who were implanted for
electrical devices such as cardiac pacemaker,
pulse generator of deep brain stimulation,and
intrathecal baclofen pump.*
Yes
No
patients who cannot avoid the medication that
may potentiate or attenuate tremor such as
antihistamines, benzodiazepine, illicit drugs, and
thyroid hormone supplement.*
Yes
No
for other tremor patients*
Yes
No
patients with a history of cardiac arrhythmia,
renal failure, hepatic failure, and pregnancy as
well as those who had history of seizure or had
the risk for tended to become seizure such as
those who had focal brain lesions, encephalitis,
and stroke patients.*
Yes
No
patients with a history of hand surgery and
implanted screws or wires in hand area that
supposed to place a surface emg or ems, as well
as those patients who were implanted for
electrical devices such as cardiac pacemaker,
pulse generator of deep brain stimulation, and
intrathecal baclofen pump.*
Yes
No
patients who cannot avoid the medication that
may potentiate or attenuate tremor such as
antihistamines, benzodiazepine, illicit drugs, and
thyroid hormone supplement.*
Yes
No
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Eligibility Rheumatoid Arthritis
NCT02242474
Anti-TNF_ Use During Elective Foot and Ankle Surgery in
Patients With Rheumatoid Arthritis; ODM derived from:
https://clinicaltrials.gov/show/NCT02242474
All rights reserved. Please visit https://medical-data-
models.org/forms/15953
Eligibility Rheumatoid Arthritis
NCT02242474
Inclusion Criteria
male and female 18 years of age or older*
Yes
No
rheumatoid arthritis diagnostic according to the
american college rheumatology (acr) 1987
criteria [38]*
Yes
No
patient treated with anti-tnfα for at least six
months*
Yes
No
elective unilateral surgery of the foot and ankle*
Yes
No
Exclusion Criteria
patient unable to give informed consent*
Yes
No
surgery on an infected site*
Yes
No
severe distal peripheral vascular disease (no
distal pulse)*
Yes
No
medical condition contraindicating surgery*
Yes
No
patient treated with biologic dmard other than
anti-tnfα*
Yes
No
circumstances preventing an adequate
postoperative follow-up*
Yes
No
revision surgery*
Yes
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No
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Eligibility Rheumatoid Arthritis
NCT02287922
A Phase IIb Study for ALX-0061 Monotherapy in Subjects
With Rheumatoid Arthritis; ODM derived from:
https://clinicaltrials.gov/show/NCT02287922
All rights reserved. Please visit https://medical-data-
models.org/forms/15954
Eligibility Rheumatoid Arthritis
NCT02287922
Inclusion Criteria
diagnosis of ra (according to the 2010
eular/americal college of rheumatology (acr)
classification criteria) for at least 6 months prior
to screening, and acr functional class i-iii.*
Yes
No
received previous or current treatment with
methotrexate (mtx), and is considered intolerant
to mtx, or for whom continued treatment with mtx
is inappropriate or has contraindications for mtx
use.*
Yes
No
subjects must not have received mtx for at least 4
weeks before first administration of the study
drug.*
Yes
No
have active ra with at least 6 swollen and 6
tender joints(66/68 joint count) at the time of
screening and baseline, and c reactive protein
(crp) >= 1.2 times uln (upper limit of normal) at
screening*
Yes
No
others as defined in the protocol*
Yes
No
Exclusion Criteria
have been treated with dmards(disease
modifying antirheumatic drugs)/systemic
immunosuppressives during the 4 weeks, or 12
weeks for hydroxychloroquine, chloroquine, or
leflunomide (except when an adequate wash-out
procedure for leflunomide was completed), prior
to first administration of study drug.*
Yes
No
have received approved or investigational
biological or targeted synthetic dmard therapies
for ra (including tumor necrosis factor alpha-
inhibitors, abatacept, rituximab, or janus kinase
[jak]-inhibitors) less than 6 months prior to
screening.*
1 / 2
Yes
No
have a history of toxicity, non-tolerance, primary
non-response or inadequate response to a
biological therapy, or targeted synthetic dmards
(including jak inhibitors), for ra.*
Yes
No
have received prior therapy blocking the
interleukin-6 (il-6) pathway, at any time.*
Yes
No
others as defined in the protocol.*
Yes
No
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Eligibility Rheumatoid Arthritis
NCT02304354
Relationship Between T LYmphocytes Depletion and
Clinical Response to RITUXimab in Rheumatoid Arthritis
(LYRITUX); ODM derived from:
https://clinicaltrials.gov/show/NCT02304354
All rights reserved. Please visit https://medical-data-
models.org/forms/15956
Eligibility Rheumatoid Arthritis
NCT02304354
Inclusion Criteria
ra according to the american college of
rheumatology (acr) criteria*
Yes
No
treatment with adalimumab in accordance to the
spc*
Yes
No
disease modifying anti rheumatic drugs (dmards)
prescribed since 3 months   and stable 4 weeks
before enrollment and during 16 weeks.*
Yes
No
signed consent*
Yes
No
Exclusion Criteria
no anti tnf-alpha failure*
Yes
No
previous rituximab treatment*
Yes
No
contraindication to adalimumab, methotrexate or
methylprednisolone*
Yes
No
methotrexate-naive patient*
Yes
No
any hematologic disease affecting the
lymphocytes (in particular lymphomas)*
Yes
No
any osteo-articular disease which could interfere
with the interpretation of the influence of the
rituximab on ra*
Yes
No
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Eligibility Rheumatoid Arthritis
NCT02332590
Efficacy and Safety of Sarilumab and Adalimumab
Monotherapy in Patients With Rheumatoid Arthritis (SARIL-
RA-MONARCH); ODM derived from:
https://clinicaltrials.gov/show/NCT02332590
All rights reserved. Please visit https://medical-data-
models.org/forms/15958
Eligibility Rheumatoid Arthritis
NCT02332590
Inclusion Criteria
diagnosis of rheumatoid arthritis ≥3 months
duration. american college of rheumatology (acr)
class i-iii functional status.*
Yes
No
active ra defined as:*
Yes
No
at least 6 of 66 swollen joints and 8 of 68 tender
joints,*
Yes
No
high sensitivity c-reactive protein (hs-crp) ≥8 mg/l
or esr ≥28 mm/h, and*
Yes
No
das28esr >5.1. patients who per investigator
judgment were either intolerant of, or considered
inappropriate candidates for continued treatment
with methotrexate (mtx), or after at least 12
weeks of continuous treatment with mtx, or
inadequate responders treated with an adequate
mtx dose for at least 12 weeks.*
Yes
No
Exclusion Criteria
age <18 years or the legal age of consent in the
country of the study site, whichever is higher.*
Yes
No
current treatment with disease-modifying
antirheumatic drug (dmards)/immunosuppressive
agents including mtx, cyclosporine,
mycophenolate, tacrolimus, gold, penicillamine,
sulfasalazine or hydroxychloroquine within 2
weeks prior to the baseline (randomization visit)
or azathioprine, cyclophosphamide within 12
weeks prior to baseline (randomization visit) or
leflunomide within 8 weeks prior to the
randomization visit, or 4 weeks after
cholestyramine washout.*
Yes
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No
treatment with any prior biologic agent, including
anti-interleukin 6 (il-6), il-6 receptor (il-6r)
antagonists, and prior treatment with a janus
kinase inhibitor.*
Yes
No
use of parenteral corticosteroids or intra-articular
corticosteroids within 4 weeks prior to screening.*
Yes
No
the above information is not intended to contain
all considerations relevant to a patient's potential
participation in a clinical trial.*
Yes
No
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Eligibility Rheumatoid Arthritis
NCT02373813
Study of Etanercept Monotherapy vs Methotrexate
Monotherapy for Maintenance of Rheumatoid Arthritis
Remission; ODM derived from:
https://clinicaltrials.gov/show/NCT02373813
All rights reserved. Please visit https://medical-data-
models.org/forms/15960
Eligibility Rheumatoid Arthritis
NCT02373813
Inclusion Criteria
subjects must be adults with a history of
moderate to severe rheumatoid arthritis;*
Yes
No
subjects must be in very good rheumatoid
arthritis disease control for ≥ 6 months and be in
remission as defined by a simplified disease
activity index ≤ 3.3 at screening and at the end of
the run-in period.*
Yes
No
subjects must be on etanercept plus
methotrexate therapy for ≥ 6 months prior to the
start of the run-in period. the methotrexate dose
must be 10 to 25 mg per week for ≥*
Yes
No
6 months prior to the start of the run-in period
and the dose must be stable for ≥ 8 weeks prior
to the start of the run-in period.*
Yes
No
subject has no known history of active
tuberculosis, and has a negative test for
tuberculosis during screening.*
Yes
No
exclusion criteria:- subject has used biologic
disease modifying antirheumatic drug other than
etanercept or has used an oral janus kinase
inhibitor ≤ 6 months prior to run-in visit 1*
Yes
No
subject has any active infection (including chronic
or localized infections) for which anti-infectives
were indicated within 4 weeks prior to run-in visit
1.*
Yes
No
subject has known alcohol addiction or
dependency or uses alcohol daily.*
Yes
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No
subject has one or more significant concurrent
medical conditions per investigator judgment,
including the following:*
Yes
No
poorly controlled diabetes*
Yes
No
chronic kidney disease stage iiib, iv, or v*
Yes
No
symptomatic heart failure (new york heart
association class ii, iii, or iv)*
Yes
No
myocardial infarction or unstable angina pectoris
within the past 12 months prior to randomization*
Yes
No
uncontrolled hypertension*
Yes
No
severe chronic pulmonary disease (eg, requiring
oxygen therapy)*
Yes
No
multiple sclerosis or any other demyelinating
disease*
Yes
No
major chronic inflammatory disease or connective
tissue disease other than rheumatoid arthritis
(eg, systemic lupus erythematosus with the
exception of secondary sjögren's syndrome)*
Yes
No
2 / 2
Eligibility Rheumatoid Arthritis NCT02373813
Single Item List
In diesem Formular speichere ich alle noch nicht in der
Wissensbasis verfügbaren Einzelcodes, die in in
kombinierten Kodierungen brauche, um sie ab sofort in der
Wissensbasis auch isoliert abrufen zu können.
Niklas
All rights reserved. Please visit https://medical-data-
models.org/forms/15963
Single Item List
Default Itemgroup
status
Pyramidal System
Sensory System
SEP
mep
retinal nerve fiber
date
no response
comment
information
cortical
lumbar
verification
Cell Count
execution
Atypical cells
iga
csf
igg
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Informed consent discussion, beyond the normal
level
Yes
No
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Eligibility Schizophrenia NCT02205437
Novel Candidate Genes for Treatment Response to
Antipsychotics in Schizophrenia; ODM derived from:
https://clinicaltrials.gov/show/NCT02205437
All rights reserved. Please visit https://medical-data-
models.org/forms/15966
Eligibility Schizophrenia
NCT02205437
Inclusion Criteria
patients followed up for 3 years in the first
episode psychosis clinical program (pafip).*
Yes
No
15-60 years.*
Yes
No
living in the catchment area.*
Yes
No
experiencing their first episode of psychosis.*
Yes
No
no prior treatment with antipsychotic medication
or, if previously treated, a total life time of
adequate antipsychotic treatment of less than 6
weeks.*
Yes
No
diagnostic and statistical manual of mental
disorders, fourth edition (dsm-iv) criteria for brief
psychotic disorder, schizophreniform disorder,
schizophrenia, or schizoaffective disorder.*
Yes
No
Exclusion Criteria
meeting dsm-iv criteria for drug dependence.*
Yes
No
meeting dsm-iv criteria for mental retardation.*
Yes
No
having a history of neurological disease or head
injury.*
Yes
No
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Record description central archive of
perioperative data (Zapod)
Source:
Project central archive of perioperative Data (ZaPoD) of the
German Society of Anesthesiology and Intensive Care
Medicine (DGAI).
Project lead: PD Dr. Sven Zenker, http://amp.uni-bonn.de
All rights reserved. Please visit https://medical-data-
models.org/forms/15967
Record description central archive of
perioperative data- Current data
set(Zapod)
Übernahme von Daten aus dem
Datensatz nach §21 KHEntgG
Institutskennzeichen
Entlassender-Standort
Entgeltbereich
IK der Krankenkasse
Geschlecht
männlich (1)
weiblich (2)
Aufnahme
Entlassung
Aufnahmeanlass Einweisung durch Arzt
Ja
Nein
Aufnahmeanlass Einweisung durch Zahnarzt
Ja
Nein
Aufnahmeanlass Notfall
Ja
Nein
Aufnahmeanlass Übernahme aus Rehaklinik
Ja
Nein
Aufnahmeanlass Übernahme aus Krankenhaus
>24h
Ja
Nein
Aufnahmeanlass Übernahme aus Krankenhaus
<24h
Ja
Nein
Aufnahmeanlass Geburt
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Ja
Nein
Aufnahmeanlass Begleitperson
Ja
Nein
Aufnahmegrund
Fallzusammenführung
Ja
Nein
Fallzusammenführungsgrund
Aufnahmegewicht
Entlassungsgrund Behandlung beendet
Ja
Nein
Entlassungsgrund Behandlung beendet
nachstationäre Behandlung
Ja
Nein
Entlassungsgrund Behandlung beendet sonstiger
Grund
Ja
Nein
Entlassungsgrund: Behandlung beendet
sonstiger Grund; nachstationäre Behandlung
Ja
Nein
Entlassungsgrund Behandlung beendet gegen
ärztlichen Rat
Ja
Nein
Entlassungsgrund: Behandlung beendet gegen
ärztlichen Rat; nachstationäre Behandlung
Ja
Nein
Entlassungsgrund Zuständigkeitswechsel
Kostenträger
Ja
Nein
Entlassungsgrund Verlegung anderes
Krankenhaus
Ja
Nein
Entlassungsgrund Tod
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Ja
Nein
Entlassungsgrund Verlegung anderes
Krankenhaus; Kooperation
Ja
Nein
Entlassungsgrund Entlassung in Rehaklinik
Ja
Nein
Entlassungsgrund Entlassung in Pflege
Ja
Nein
Entlassungsgrund Entlassung in Hospiz
Ja
Nein
Entlassungsgrund Verlegung in Psychiatrie
Ja
Nein
Entlassungsgrund Verlegung intern
Ja
Nein
Entlassungsgrund Fallabschluss
Ja
Nein
Alter in Tagen am Aufnahmetag
Alter in Jahren am Aufnahmetag
Interkurrente Dialysen
Beatmungsstunden
Datum Behandlungsbeginn vorstationär
Behandlungstage vorstationär
Ende der Behandlung nachstationär
Behandlungstage nachstationär
Institutskennzeichen Verlegungskrankenhaus
Belegungstage in anderem Entgeltbereich
3 / 5
Record description central archive of perioperative data (Zapod)
Beurlaubungstage in der Psychiatrie
ICD Diagnoseart
ICD-Version
ICD10-Kode
ICD Lokalisation
ICD Lokalisation 2
ICD Diagnosensicherheit
ICD Diagnosensicherheit 2
ICD Sekundär-Kode
OPS Version
OPS-Kode
OPS Lokalisation
OPS Datum
OPS Belegoperateur
OPS Beleganästhesist
OPS Beleganästhesist
OPS Beleghebamme
Entgeldart
Entgeltbetrag
Abrechnung
Abrechnung
Entgeltanzahl
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Tage ohne Berechnung-Behandlung
Datum Tag der Behandlung
Fachabteilung
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Eligibility Schizophrenia NCT02246426
Treatment of Social Cognition in Schizophrenia Trial; ODM
derived from: https://clinicaltrials.gov/show/NCT02246426
All rights reserved. Please visit https://medical-data-
models.org/forms/15969
Eligibility Schizophrenia
NCT02246426
Inclusion Criteria
1. subjects must be at least 18 years old at the
time of study screening*
Yes
No
2. subjects must have a diagnosis of
schizophrenia as defined by dsm-v129 criteria
and confirmed by the structured clinical interview
for dsm-iv (scid-p).*
Yes
No
3. subjects must demonstrate adequate
decisional capacity, in the judgment of the
consenting study staff member, to make a choice
about participating in this research study.*
Yes
No
4. subjects must have been clinically stable (non-
acute) for 8 weeks prior to consent; in the
judgment of the site principal investigator.*
Yes
No
5. subjects must have been maintained on a
stable treatment of antipsychotics and/or other
concomitant psychotropic treatment for at least 6
weeks prior to consent.*
Yes
No
6. subjects must have learned english before the
age of 12 to ensure valid neuropsychological
results*
Yes
No
7. subjects must have the visual, auditory, and
motor capacity to use the computerized
intervention in the judgment of the consenting
study staff person.*
Yes
No
8. subjects must have no more than a moderate
severity rating on hallucinations and unusual
thought content as shown by a score of ≤ 4 on
the positive and negative symptoms scale
(panss).*
Yes
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No
Exclusion Criteria
1. subjects should not have had a psychiatric
hospitalization in the 8 weeks prior to consent.*
Yes
No
2. subjects who appear to be intoxicated or under
the influence of a controlled substance on any
day of assessment must be rescheduled or
discontinued based upon the discretion of the site
staff evaluator.*
Yes
No
3. subjects should not have a history of mental
retardation (iq<70 based on wtar132) or
pervasive developmental disorder; or other
neurological disorder (e.g., traumatic brain injury,
epilepsy, parkinson's disease.)*
Yes
No
4. subjects should not have been treated within 5
years of the date of consent with a computer-
based cognitive training program manufactured
by posit science.*
Yes
No
5. subjects should not be participating in a
concurrent clinical trial that, in the judgment of
the site principal investigator, could affect the
outcome of this one.*
Yes
No
6. subjects should not be prescribed more than
two anti-psychotics.  subjects should not be
routinely treated with adjunctive medication with
known significant anticholinergic side effects
including diphenhydramine and/or benztropine.*
Yes
No
7. subjects who have answered 'yes' to question
5 (active suicidal ideation with specific plan and
intent) on the columbia-suicide severity rating
scale, c-ssrs, or who have answered 'yes' to any
of the suicide-related behaviors (actual attempt,
interrupted attempt, aborted attempt, preparatory
act or behavior) on the c-ssrs "suicidal behavior"
portion shall be excluded from the study if
ideation or behavior occurred within one month of
consent. subjects excluded for this reason will be
referred for appropriate treatment.*
Yes
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No
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Eligibility Schizophrenia NCT02246426
Record description central archive of perioperative
data - anesthesia procedures (Zapod)
Source:
Project central archive of perioperative Data (ZaPoD) of the
German Society of Anesthesiology and Intensive Care
Medicine (DGAI).
Project lead: PD Dr. Sven Zenker, http://amp.uni-bonn.de
All rights reserved. Please visit https://medical-data-
models.org/forms/15970
Record description central archive of
perioperative data-anesthesia
procedures
Anästhesieverfahren
Prämedikation allgemein
Ja
Nein
Prämedikation allgemein TIVA
Ja
Nein
Prämedikation allgemein Analgosedierung
Ja
Nein
Prämedikation regional Spinalanaesthesie
Ja
Nein
Prämedikation regional PDA lumbal
Ja
Nein
Prämedikation regional PDA thorakal
Ja
Nein
Prämedikation Regional periphere
Nervenblockade
Ja
Nein
Prämedikation Medikamentenpumpe
patientenkontrolliert intravenös
Ja
Nein
Prämedikation regional Medikamentenpumpe
epidural
Ja
Nein
Prämedikation allgemein RSI
Ja
Nein
Aufwachraum Allgemein
Ja
Nein
Aufwachraum Allgemein Medikamentenpumpe
intravenös
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Ja
Nein
Aufwachraum Allgemein Medikamentenpumpe iv
patientenkontrolliert
Ja
Nein
Aufwachraum Allgemein Medikamentenpumpe
epidural
Ja
Nein
Aufwachraum Allgemein Medikamentenpumpe
epidural patientenkontrolliert
Ja
Nein
Aufwachraum regional Medikamentenpumpe
peripherer Nerv
Ja
Nein
Aufwachraum regional Medikamentenpumpe
peripherer Nerv patientenkontrolliert
Ja
Nein
Narkoseeinleitung Allgemein
Ja
Nein
Narkoseeinleitung Regional
Ja
Nein
Narkoseeinleitung Kombination
Ja
Nein
Narkoseeinleitung Allgemein Analgosedierung
Ja
Nein
Narkoseeinleitung Allgemein Einleitung iv
Ja
Nein
Narkoseeinleitung Allgemein Einleitung inhalativ
Ja
Nein
Narkoseeinleitung Allgemein Aufrechterhaltung iv
Ja
Nein
Narkoseeinleitung Allgemein Aufrechterhaltung
inhalativ
Ja
Nein
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Narkoseeinleitung Allgemein RSI
Ja
Nein
Narkoseeinleitung Verfahrenswechsel
Ja
Nein
Narkoseeinleitung regional Katheteranlage
Ja
Nein
Narkoseeinleitung regional Spinalanästhesie
Ja
Nein
Narkoseeinleitung regional lumbale PDA
Ja
Nein
Narkoseeinleitung regional thorakale PDA
Ja
Nein
Narkoseeinleitung regional kaudale PDA
Ja
Nein
Narkoseeinleitung regional Blockade des Plexus
axialis
Ja
Nein
Narkoseeinleitung regional sonstige
Plexusblockade
Ja
Nein
Narkoseeinleitung regional Blockade des nervus
ischiadicus
Ja
Nein
Narkoseeinleitung regional Blockade des nervus
femoralis
Ja
Nein
Narkoseeinleitung regionale Blockade IVRA
Ja
Nein
Narkoseeinleitung regionale Blockade Peripherer
Nerv
Ja
Nein
Narkoseeinleitung regional Hilfsmittel
Sonographie
Ja
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Nein
Narkoseeinleitung regional Hilfsmittel
Nervenstimulation
Ja
Nein
Narkoseeinleitung regional Bolusgabe Katheter
Ja
Nein
Narkoseeinleitung regional Bolusgabe Single
Shot
Ja
Nein
Narkoseeinleitung regional Bolusgabe Testdosis
Ja
Nein
Narkoseeinleitung regional Bolusgabe vor Schnitt
Ja
Nein
Intraoperative regionale Anästhesie Bolusgabe
nach Schnitt
Ja
Nein
Postoperative regionale Bolusgabe
Ja
Nein
Narkoseeinleitung regional Bolusgabe Opiat
Ja
Nein
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Eligibility Schizophrenia NCT02357797
Adjunctive Vortioxetine in Schizophrenia; ODM derived
from: https://clinicaltrials.gov/show/NCT02357797
All rights reserved. Please visit https://medical-data-
models.org/forms/15971
Eligibility Schizophrenia
NCT02357797
Inclusion Criteria
1. outpatient*
Yes
No
2. scid diagnosis of schizophrenia*
Yes
No
3. age 18-65 years old*
Yes
No
4. treated with an adequate dose of one or a
maximum of two antipsychotic medications for at
least 3 months, with a stable dose for at least the
last 4 weeks, and willing to continue for up to 16
weeks.*
Yes
No
5. no antidepressant treatment for at least 8
weeks prior to randomization.*
Yes
No
6. treatment with other concomitant, non-
antipsychotic, psychiatric medications is allowed,
but must be unchanged for at least 8 weeks, with
a stable dose for at least the last 4 weeks, and
willing to continue for 16 weeks. benzodiazepines
must not be given within 8 hours of the cognitive
assessment. treatment with non-psychiatric
medications is unrestricted.*
Yes
No
7. panss negative subscore >14 with at least two
of the items at a level >/=4 (moderate)*
Yes
No
8. panss positive subscore </=14 with not more
than one of the items at a level >/=4 (moderate)*
Yes
No
9. hamd-17 total score </=12*
Yes
No
10. simpson angus score of any item <3*
Yes
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No
11. english-speaking*
Yes
No
12. competent and willing to sign informed
consent*
Yes
No
Exclusion Criteria
1. structural brain disease*
Yes
No
2. mental retardation by history and estimated iq
<70 (wrat-iii word reading)*
Yes
No
3. autism-spectrum disorder diagnosis by history*
Yes
No
4. any serious chronic medical illnesses that in
the view of the investigator will interfere with the
patient's ability to comply with the study
procedures or that will interfere with cognition.*
Yes
No
5. active substance abuse or dependence in the
past 8 weeks*
Yes
No
6. intolerance to or inefficacy of vortioxetine in the
past*
Yes
No
7. acute anger to self or others as per investigator
assessment*
Yes
No
8. pregnant or breastfeeding females*
Yes
No
9. unwilling or unable to be sexually abstinent or
not using an effective form of birth control if they
are sexually active*
Yes
No
10. current treatment with a monoamine oxidase
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inhibitor (maoi)*
Yes
No
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Eligibility Sedentary Lifestyle NCT02317003
Physical Exercise Prescription With PEdometeR in General
Practice for Patients With Cardiovascular Risk Factors -
The PEPPER Pragmatic Trial; ODM derived from:
https://clinicaltrials.gov/show/NCT02317003
All rights reserved. Please visit https://medical-data-
models.org/forms/15973
Eligibility Sedentary Lifestyle
NCT02317003
Inclusion Criteria
patients consulting their general practitioner for a
non-urgent matter*
Yes
No
with regular follow-up every 3 months for
hypertension, hypercholesterolaemia or non
insulin dependent type 2 diabetes.*
Yes
No
judged insufficiently active by their general
practitioner based on negative answers to the
questions : "do you practice a physical activity or
cycling more than an hour per week?" and "does
your occupation involve physical exertion?"*
Yes
No
Exclusion Criteria
contraindication to moderate physical activity,*
Yes
No
non autonomous for walking,*
Yes
No
with cognitive or psychiatric impairment limiting
the full understanding of the study,*
Yes
No
suffering from another limiting disease (coronary
insufficiency, chronic cardiac failure, etc),*
Yes
No
who don't speak french,*
Yes
No
refusing to participate.*
Yes
No
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Eligibility Smoldering Multiple Myeloma
(SMM) NCT02316106
A Study to Evaluate 3 Dose Schedules of Daratumumab in
Participants With Smoldering Multiple Myeloma; ODM
derived from: https://clinicaltrials.gov/show/NCT02316106
All rights reserved. Please visit https://medical-data-
models.org/forms/15974
Eligibility Smoldering Multiple
Myeloma (SMM) NCT02316106
Inclusion Criteria
diagnosis of smoldering multiple myeloma (smm)
for less than 5 years*
Yes
No
have a confirmed diagnosis of intermediate or
high-risk smm, and an eastern cooperative
oncology group (ecog) performance status score
of 0 or 1.*
Yes
No
Exclusion Criteria
active multiple myeloma,requiring treatment as
defined by the study protocol*
Yes
No
primary systemic al (immunoglobulin light chain)
amyloidosis*
Yes
No
prior or concurrent exposure to any of the
following: approved or investigational treatments
for smm or/and multiple myeloma, daratumumab
or other anti cd-38 therapies, treatment with
corticosteroids with a dose greater than (>) 10
milligram (mg) prednisone per day or equivalent
and bone-protecting agents (eg,
bisphosphonates, denosumab) or are only
allowed if given in a stable dose and for a
nonmalignant condition, or received an
investigational drug (including investigational
vaccines) or used an invasive investigational
medical device within 4 weeks before cycle 1, day
1*
Yes
No
history of malignancy (other than smm) within 3
years before the date of randomization, except for
the following if treated and not active: basal cell
or nonmetastatic squamous cell carcinoma of the
skin, cervical carcinoma in situ, ductal carcinoma
in situ of breast, or international federation of
gynecology and obstetrics (figo) stage 1
carcinoma of the cervix*
Yes
No
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known chronic obstructive pulmonary disease
(copd) or moderate or severe persistent asthma
within the past 2 years*
Yes
No
any concurrent medical or psychiatric condition or
disease (eg, autoimmune disease, active
systemic disease, myelodysplasia) that is likely to
interfere with the study procedures or results, or
that in the opinion of the investigator, would
constitute a hazard for participating in this study*
Yes
No
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Eligibility Stage I Multiple Myeloma
NCT02082405
Bortezomib, Dexamethasone, and Cyclophosphamide in
Treating Older Patients With Multiple Myeloma; ODM
derived from: https://clinicaltrials.gov/show/NCT02082405
All rights reserved. Please visit https://medical-data-
models.org/forms/15976
Eligibility Stage I Multiple Myeloma
NCT02082405
Inclusion Criteria
patients must have a confirmed diagnosis of
symptomatic myeloma in accordance with
international myeloma working group (imwg)
criteria*
Yes
No
bone marrow plasmacytosis with > 10% plasma
cells or sheets of plasma cells or biopsy proven
plasmacytoma*
Yes
No
symptomatic disease, i.e., end-organ damage
due to multiple myeloma (mm) including at least
one of the following: anemia, hypercalcemia,
bone disease (lytic bone lesions or pathologic
fracture), or renal dysfunction*
Yes
No
absolute neutrophil count (anc) >= 1000
cells/mm^3 (without use of growth factors)*
Yes
No
platelets >= 50,000 cells/mm^3*
Yes
No
direct bilirubin =< 1.5 x upper limit of normal (uln);
elevated bilirubin is permissible if patient has a
known history of elevated bilirubin due to gilbert's
or if elevated bilirubin is due to hemolysis*
Yes
No
alanine aminotransferase (alt) (serum glutamate
pyruvate transaminase [sgpt]) =< 1.5 x uln*
Yes
No
subjects must have the ability to understand and
the willingness to sign a written informed consent
document*
Yes
No
Exclusion Criteria
prior treatment with > 1 cycle of any plasma cell
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myeloma (pcm) induction regimen (maximum 6
weeks of prior treatment)*
Yes
No
prior radiation therapy is allowed*
Yes
No
prior treatment for other cancers is allowed as
long as patient meets criteria for adequate
hematopoietic and organ function and is not
actively on chemotherapy for another cancer*
Yes
No
grade >= 2 peripheral neuropathy*
Yes
No
second malignancy currently undergoing
chemotherapy or radiotherapy; hormonal therapy
for breast or prostate cancer is allowed*
Yes
No
patients may not be receiving any other
investigational agents*
Yes
No
history of allergic reactions attributed to
compounds of similar chemical or biologic
composition to bortezomib, cyclophosphamide,
dexamethasone or other agents used in this
study*
Yes
No
patients with uncontrolled intercurrent illness
including, but not limited to ongoing or active
infection, symptomatic congestive heart failure,
unstable angina pectoris, cardiac arrhythmia, or
psychiatric illness/social situations that would
limit compliance with study requirements*
Yes
No
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Record description central archive of perioperative data
(Zapod) artificial respiration and fluid management
Source:
Project central archive of perioperative Data (ZaPoD) of the
German Society of Anesthesiology and Intensive Care
Medicine (DGAI).
Project lead: PD Dr. Sven Zenker, http://amp.uni-bonn.de
All rights reserved. Please visit https://medical-data-
models.org/forms/15977
Record description central archive of
perioperative data- artificial
respiration and fluid management
Beatmung und Bilanzierung
Beatmung Prämedikation FOI
Ja
Nein
Beatmung intraoperativ Insufflation
Ja
Nein
Beatmung intraoperativ Maske
Ja
Nein
Beatmung intraoperativ Larynxmaske
Ja
Nein
Beatmung Narkoseeinleitung orale Intubation
Ja
Nein
Beatmung Narkoseeinleitung nasale Intubation
Ja
Nein
Beatmung Narkoseeinleitung beatmet
Ja
Nein
Beatmung Narkoseeinleitung Tracheostoma
beatmet
Ja
Nein
Beatmung Narkoseeinleitung Intubation ohne
Cuff
Ja
Nein
Beatmung Narkoseeinleitung Umintubation
Ja
Nein
Beatmung Narkoseeinleitung FOI
Ja
Nein
Beatmung intraoperative Jet-Beatmung
Ja
Nein
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Beatmung intraoperative Spontanatmung
Ja
Nein
Beatmung intraoperative manuelle Beatmung
Ja
Nein
Beatmung intraoperative maschinelle Beatmung
Ja
Nein
Bilanz Ausfuhr Blut
Bilanz Ausfuhr Absaugung
Bilanz Ausfuhr Drainage
Bilanz Ausfuhr Sonstige
Bilanz Ausfuhr Urin
Bilanz Ausfuhr Wasser
Bilanz Einfuhr Blut
Bilanz Einfuhr Kolloidale
Bilanz Einfuhr Kristalloide
Bilanz Einfuhr Wasser
Bilanz Ausfuhr total
Bilanz Einfuhr total
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Eligibility Stage III Squamous Cell Carcinoma
of the Lip and Oral Cavity NCT02295540
Hypofractionated Radiation Therapy Followed by Surgery in
Treating Patients With Advanced Squamous Cell
Carcinoma of the Oral Cavity; ODM derived from:
https://clinicaltrials.gov/show/NCT02295540
All rights reserved. Please visit https://medical-data-
models.org/forms/15978
Eligibility Stage III Squamous Cell
Carcinoma of the Lip and Oral Cavity
NCT02295540
Inclusion Criteria
patient is willing to sign study specific informed
consent*
Yes
No
pathologically proven (histologically or
cytologically) diagnosis of squamous cell
carcinoma (including histological variants like
papillary squamous cell carcinoma and basaloid
squamous cell carcinoma)*
Yes
No
advanced stage but not metastatic scc of the oral
cavity (iii or iva, b); sites in the oral cavity include
oral tongue, floor of mouth, hard palate, gingiva,
buccal mucosa, retromolar trigone; often, head &
neck tumors may involve other adjacent sites,
such as the oropharynx- in these cases, the
criteria is that the tumor must appear to have
originated in the oral cavity per ear, nose, and
throat (ent)/radiation oncology*
Yes
No
patient is deemed to be a surgical candidate by
ent*
Yes
No
karnofsky performance status (kps) 0-2*
Yes
No
for women of childbearing potential, a negative
serum pregnancy test completed prior to any
radiation therapy*
Yes
No
patients with human immunodeficiency virus (hiv)
infection are not automatically excluded, but must
meet the following criteria: cluster of
differentiation 4 (cd4) count is > 499/cu mm and
their viral load is < 50 copies/ml; use of highly
active antiretroviral therapy (haart) is allowed*
Yes
No
patient is free of any prior invasive malignancy
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(except non-melanomatous skin cancer) for a
minimum of the past 3 years*
Yes
No
Exclusion Criteria
metastatic disease beyond the neck or
supraclavicular area as demonstrated by positron
emission tomography (pet)/ct or biopsy*
Yes
No
kps 3 or worse*
Yes
No
gross disease in the retrostyloid (high level ii) or
retropharyngeal lymph node regions by ct or
pet/ct*
Yes
No
patients may not have received previous therapy
for their head and neck scc, including
chemotherapy, radiation therapy, or surgery
beyond biopsy*
Yes
No
second primary malignancy; exceptions are 1)
patient had a second primary malignancy but has
been treated and disease free for at least 3
years, 2) in situ carcinoma (e.g. in situ carcinoma
of the cervix), 3) non-melanomatous carcinoma
of the skin*
Yes
No
serious concomitant systemic disorders
(including active infections) that would
compromise the safety of the patient or
compromise the patient's ability to complete the
study, at the discretion of the investigator; this
includes scleroderma*
Yes
No
women who are pregnant; women of childbearing
age must agree to undergo a urine pregnancy
test prior to therapy and to use adequate
contraception (hormonal or barrier method of
birth control; abstinence) prior to study entry, for
the duration of study participation and for 6
months after; should a woman become pregnant
or suspect she is pregnant while participating in
this study, she should inform her treating
physician immediately*
Yes
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No
patient is deemed to not be a surgical candidate
by ent*
Yes
No
3 / 3
Eligibility Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity
NCT02295540
Record description central archive of
perioperative data (Zapod) - Diagnosis
Source:
Project central archive of perioperative Data (ZaPoD) of the
German Society of Anesthesiology and Intensive Care
Medicine (DGAI).
Project lead: PD Dr. Sven Zenker, http://amp.uni-bonn.de
All rights reserved. Please visit https://medical-data-
models.org/forms/15979
Record description central archive of
perioperative data - Diagnosis
Diagnose-Prämedikation
Hirntod
Ja
Nein
Gesunder Patient
Ja
Nein
Gesundheitszustand nicht beurteilbar
Ja
Nein
Herz ohne Befund
Ja
Nein
Herzinsuffizenz
Ja
Nein
Zustand nach Herzinsuffizienz
Ja
Nein
Dilatative Kardiomyopathie
Ja
Nein
Zustand nach dilatativer Kardiomyopathie
Ja
Nein
Koronare Herzerkrankung
Ja
Nein
PTCA
Ja
Nein
Zustand nach PTCA
Ja
Nein
Myokardinfarkt
Ja
Nein
Zustand nach Myokardinfarkt
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Ja
Nein
Aortenklappeninsuffizienz
Ja
Nein
Zustand nach Aortenklappeninsuffizienz
Ja
Nein
Aortenklappenstenose
Ja
Nein
Zutand nach Aortenklappenstenose
Ja
Nein
Mitralklappenvitium
Ja
Nein
Zustand nach Mitralklappenvitium
Ja
Nein
Klappenersatz
Ja
Nein
Zustand nach Klappenersatz
Ja
Nein
Endokarditis
Ja
Nein
Zustand nach Endokarditis
Ja
Nein
AV-Block II
Ja
Nein
Zustand nach AV-Block II
Ja
Nein
AV-Block III
Ja
Nein
Zustand nach AV-Block III
Ja
Nein
Ventriculäre tachycardie
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Ja
Nein
Zustand nach ventriculärer tachycardie
Ja
Nein
Paroxysmale Tachykardie
Ja
Nein
Zustand nach Paroxysmaler Tachykardie
Ja
Nein
Vorhofflimmern
Ja
Nein
Zustand nach Vorhofflimmern
Ja
Nein
Kammerflimmern
Ja
Nein
Zustand nach Kammerflimmern
Ja
Nein
Sonstige Rhythmusstörung
Ja
Nein
Zustand nach sonstiger Rhythmusstörung
Ja
Nein
Herzschrittmacher
Ja
Nein
Zustand nach Herzschrittmacher
Ja
Nein
Defibrillator
Ja
Nein
Zustand nach Defibrillator
Ja
Nein
Herzstillstand
Ja
Nein
Zustand nach Herzstillstand
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Diagnosis
Ja
Nein
Kreislauf ohne Befund
Hypertonie
Ja
Nein
Zustand nach Hypertonie
Ja
Nein
Hypotonie
Ja
Nein
Zustand nach Hypotonie
Ja
Nein
Orthostase
Ja
Nein
Zustand nach Orthostase
Ja
Nein
PAVK
Ja
Nein
Zustand nach PAVK
Ja
Nein
Stenose Hirnarterien
Ja
Nein
Zustand nach Hirnarterienstenose
Ja
Nein
Embolie
Ja
Nein
Zustand nach Embolie
Ja
Nein
Zustand nach Lungenembolie
Ja
Nein
Thrombose
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Ja
Nein
Zustand nach Thrombose
Ja
Nein
Sepsis
Ja
Nein
Zustand nach Sepsis
Ja
Nein
Traumatischer Schock
Ja
Nein
Zustand nach traumatischem Schock
Ja
Nein
Schock
Ja
Nein
Zustand nach Schock
Ja
Nein
Hypovolaemie
Ja
Nein
Zustand nach Hypovolaemie
Ja
Nein
Gerinnung ohne Befund
Ja
Nein
Koagulopathie
Ja
Nein
Zustand nach Koagulopathie
Ja
Nein
Thrombozytopathie
Ja
Nein
Zustand nach Thrombozytopathie
Ja
Nein
Thrombozytopenie
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Ja
Nein
Zustand nach Thrombozytopenie
Ja
Nein
Lunge ohne Befund
Ja
Nein
COPD
Ja
Nein
Zustand nach COPD
Ja
Nein
Giemen
Ja
Nein
Zustand nach Giemen
Ja
Nein
Asthma
Ja
Nein
Zustand nach Asthma
Ja
Nein
Chronische Bronchitis
Ja
Nein
Zustand nach chronischer Bronchitis
Ja
Nein
Atemwegsinfektion
Ja
Nein
Zustand nach Atemwegsinfektion
Ja
Nein
Pneumonie
Ja
Nein
Zustand nach Pneumonie
Ja
Nein
Emphysem
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Ja
Nein
Zustand nach Emphysem
Ja
Nein
Innere Organe ohne Befund
Ja
Nein
Niereninsuffizienz
Ja
Nein
Zustand nach Niereninsuffizienz
Ja
Nein
Nierenversagen
Ja
Nein
Zustand nach Nierenversagen
Ja
Nein
Dialysepflichtigkeit
Ja
Nein
Zustand nach Dialysepflichtigkeit
Ja
Nein
Leberzirrhose
Ja
Nein
Pankreatitis
Ja
Nein
Zustand nach Pankreatitis
Ja
Nein
Stoffwechsel ohne Befund
Ja
Nein
Lipidstörung
Ja
Nein
Hyperthyreose
Ja
Nein
Zustand nach Hyperthyreose
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Ja
Nein
Hypothyreose
Ja
Nein
Zustand nach Hypothyreose
Ja
Nein
Diabetes mellitus Typ 1
Ja
Nein
Typ 2 Diabetes mellitus
Ja
Nein
Gestationsdiabetes
Ja
Nein
Zustand nach Gestationsdiabetes
Ja
Nein
Neurologie ohne Befund
Ja
Nein
Morbus Parkinson
Ja
Nein
Multiple Sklerose
Ja
Nein
Primäre Epilepsie
Ja
Nein
Zustand nach primärer Epilepsie
Ja
Nein
Schizophrenie
Ja
Nein
Zustand nach Schizophrenie
Ja
Nein
Demenz
Ja
Nein
Polyneuropathie
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Ja
Nein
Zustand nach Polyneuropathie
Ja
Nein
Subarachnoidalblutung
Ja
Nein
Zustand nach Subarachnoidalblutung
Ja
Nein
Aneurysma
Ja
Nein
Zustand nach Aneurysma
Ja
Nein
Angiom
Ja
Nein
Zustand nach Angiom
Ja
Nein
Apoplex
Ja
Nein
Zustand nach Apoplex
Ja
Nein
TIA
Ja
Nein
Zustand nach TIA
Ja
Nein
Zustand nach Synkope
Ja
Nein
Muskulatur ohne Befund
Ja
Nein
Maligne Hyperthermie
Ja
Nein
Zustand nach maligner Hyperthermie
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Diagnosis
Ja
Nein
Myopathie
Ja
Nein
Zustand nach Myopathie
Ja
Nein
Immobilisation
Ja
Nein
Psychiatrie ohne Befund
Ja
Nein
Alkohol Abusus
Ja
Nein
Zustand nach Alkohol Abusus
Ja
Nein
Substanzabusus
Ja
Nein
Zustand nach Substanzabusus
Ja
Nein
Nikotinabusus
Ja
Nein
Zustand nach Nikotinabusus
Ja
Nein
Schwierige Intubation
Ja
Nein
Zustand nach schwieriger Intubation
Ja
Nein
Erhoehtes Aspirationsrisiko
Ja
Nein
Hypokaliämie
Ja
Nein
Azidose
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Ja
Nein
Ileus
Ja
Nein
Zustand nach Ileus
Ja
Nein
Zustand nach PONV
Ja
Nein
Zustand nach Kinetose
Ja
Nein
Zustand nach Autoimmunerkrankung
Ja
Nein
Immunsuppression
Ja
Nein
Zustand nach Immunsuppression
Ja
Nein
Radiatio
Ja
Nein
Zustand nach Radiatio
Ja
Nein
Allergie
Ja
Nein
Zustand nach Allergie
Ja
Nein
Gravidität
Ja
Nein
Wochenbett
Ja
Nein
Chronisches Schmerzsyndrom
Ja
Nein
Zustand nach chronischem Schmerzsyndrom
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Diagnosis
Ja
Nein
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Diagnosis
Eligibility Therapy-related Acute Myeloid Leukemia
and Myelodysplastic Syndrome NCT02438761
PF-05212384 (PKI-587) for t-AML/MDS or de Novo
Relapsed or Refractory Acute Myeloid Leukemia (AML);
ODM derived from:
https://clinicaltrials.gov/show/NCT02438761
All rights reserved. Please visit https://medical-data-
models.org/forms/15980
Eligibility Therapy-related Acute
Myeloid Leukemia and
Myelodysplastic Syndrome
NCT02438761
Inclusion Criteria
1. patients belong to one of three categories:*
Yes
No
myeloid neoplasm secondary to chemo-
radiotherapy (t-aml/mds) aged 60 and over with
unfavorable cytogenetics (european leukemia
network definition 2010), the first cancer must
have been in remission for more than two years,
except in situ carcinoma, basal cell carcinoma
and squamous cell carcinoma*
Yes
No
relapsed or refractory de novo aml aged 18 and
over (multiple relapses allowed), regardless of the
risk group, provided not being eligible for
allogeneic bone marrow transplantation*
Yes
No
de novo aml at diagnosis, aged 60 and over and
considered unfit to benefit from induction
chemotherapy associated with aplasia (at the
discretion of the investigator)*
Yes
No
2. adequate glycemic balance defined by
glycated hemoglobin ≤ 8%*
Yes
No
3. females of childbearing potential (fcbp) should
receive effective contraception: a negative
pregnancy blood test is required within 2 weeks
before starting experimental treatment.*
Yes
No
4. eastern cooperative oncology group (ecog)
performance status (ps) ≤ 2*
Yes
No
5. absence of severe or active infection*
Yes
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No
6. adequate systolic cardiac function : left
ventricular ejection fraction (lvef) ≥ 50%*
Yes
No
7. adequate hepatic function: aspartate
aminotransferase test (ast) and alanine
aminotransferase test (alt) ≤ 3 times the upper
limit of normal (uln), bilirubin ≤*
Yes
No
1.5 x uln*
Yes
No
8. adequate renal function: serum creatinine ≤
1.5 x uln or calculated creatinine clearance > 60
ml/min.*
Yes
No
9. signed informed consent*
Yes
No
Exclusion Criteria
1. glucose intolerance or diabetes mellitus,
treated or untreated*
Yes
No
2. first cancer in evolution(solid tumor or
lymphoma) or in remission for less than two
years, except in situ carcinoma, basal cell
carcinoma and squamous cell carcinoma*
Yes
No
3. aml secondary to mds or myeloproliferative
syndrome (who 2008 definitions)*
Yes
No
4. acute promyelocytic leukaemia (apl or aml
french american british (fab) classification 3) de
novo or secondary to treatment (t-apl)*
Yes
No
5. de novo or secondary core binding factor
(cbf)/aml*
Yes
No
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6. de novo or secondary philadelphia
chromosome (ph) 1 positive aml defined by the
presence of a t(9.22) or a breakpoint cluster
region-abelson murine leukemia viral oncogene
homolog (bcr-abl) transcript*
Yes
No
7. leukocytes above 30.000/mm3 (30 g/l) at
enrollment*
Yes
No
8. antileukemic treatment within 15 days before
enrollment, with the exception of hydroxyurea*
Yes
No
9. central nervous system leukemic involvement*
Yes
No
10. pregnant or lactating women, or women of
childbearing potential without effective
contraception*
Yes
No
11. prior history of allogeneic bone marrow
transplantation*
Yes
No
12. prior history of organ transplantation or other
cause of severe or chronic immunodeficiency
human*
Yes
No
13. seropositivity for human immunodeficiency
virus (hiv) or human t-lymphotropic virus-1 (htlv-
1) viruses, active b or c hepatitis*
Yes
No
14. inclusion in another experimental anti-cancer
clinical trial**
Yes
No
15. patients unable to undergo medical
monitoring for geographical, social or
psychological issues*
Yes
No
16. patient under measure of legal protection*
Yes
No
3 / 4
Eligibility Therapy-related Acute Myeloid Leukemia and Myelodysplastic
Syndrome NCT02438761
17. no social security*
Yes
No
for ethical reasons, the exclusion period before
considering the possibility of participating in
another clinical study with a new experimental
molecule cannot be determined, yet each case
will be discussed on an individual basis with the
study coordinator.*
Yes
No
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Record description central archive of
perioperative data (Zapod) - procedure
Source:
Project central archive of perioperative Data (ZaPoD) of the
German Society of Anesthesiology and Intensive Care
Medicine (DGAI).
Project lead: PD Dr. Sven Zenker, http://amp.uni-bonn.de
All rights reserved. Please visit https://medical-data-
models.org/forms/15981
Record description central archive of
perioperative data-procedures
Eingriff
Transplantation
Ja
Nein
Sectio
Ja
Nein
Geburtshilfe
Ja
Nein
Neonatologie
Ja
Nein
Explantation
Ja
Nein
Keine OP
Ja
Nein
Eingriff in Einleitung
Ja
Nein
Folgeeingriff Re-Op
Ja
Nein
Wiederholungsanaesthesie
Ja
Nein
Eingriff Haut-Weichteile 1
Ja
Nein
Eingriff Haut-Weichteile 2
Ja
Nein
Eingriff Knochen-Bindegewebe 1
Ja
Nein
Eingriff Knochen-Bindegewebe 2
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Ja
Nein
Eingriff Gefäße 1
Ja
Nein
Eingriff Gefäße 2
Ja
Nein
Eingriff ZNS Nerv 1
Ja
Nein
Eingriff ZNS Nerv 2
Ja
Nein
Eingriff Viszerum 1
Ja
Nein
Eingriff Viszerum 2
Ja
Nein
Eingriff Herz 1
Ja
Nein
Eingriff Herz 2
Ja
Nein
Eingriff Sonstige 1
Ja
Nein
Eingriff Sonstige 2
Ja
Nein
Operationsort Kopf 1
Ja
Nein
Operationsort Kopf 2
Ja
Nein
Operationsort Hals 1
Ja
Nein
Operationsort Hals 2
Ja
Nein
Operationsort Thorax 1
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Ja
Nein
Operationsort Thorax 2
Ja
Nein
Operationsort Abdomen 1
Ja
Nein
Operationsort Abdomen 2
Ja
Nein
Operationsort Extremitäten 1
Ja
Nein
Operationsort Extremitäten 2
Ja
Nein
Operationsort Wirbelsäule 1
Ja
Nein
Operationsort Wirbelsäule 2
Ja
Nein
Operationsort Urogenitaltrakt 1
Ja
Nein
Operationsort Urogenitaltrakt 2
Ja
Nein
Sonstiger Operationsort 1
Ja
Nein
Sonstiger Operationsort 2
Ja
Nein
Polytrauma
Ja
Nein
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Eligibility Rheumatoid Arthritis
NCT02322723
Real Life Evaluation of Rheumatoid Arthritis Patients in
Israel Treated With HUMIRA; ODM derived from:
https://clinicaltrials.gov/show/NCT02322723
All rights reserved. Please visit https://medical-data-
models.org/forms/15982
Eligibility Rheumatoid Arthritis
NCT02322723
Inclusion Criteria
1. patient is eligible to adalimumab treatment
according to the israeli national health basket and
for whom a decision of initiating adalimumab has
already been taken. patients that are naïve to
adalimumab therapy, that have been prescribed
adalimumab in accordance to physician's clinical
decision and according to local guidelines, up to
30 days prior to screening.*
Yes
No
2. patient has performed tuberculosis (tb)
screening and treatment according to national
guidelines for tb screening prior to anti tumor
necrosis factor (anti-tnf) treatment.*
Yes
No
3. patient has been diagnosed with rheumatoid
arthritis (ra) and has disease duration < 3 years.*
Yes
No
4. patient has moderately to severely active ra
defined by disease activity score (das)
(moderately (3.2 ≤ das ≤ 5.1) severely (das
≥5.1))*
Yes
No
5. patient is able to sign written informed
consent.*
Yes
No
6. patient is treated with methotrexate (mtx) alone
or in combination with other disease modifying
antirheumatic drugs (dmards)*
Yes
No
7. patient might have been treated with another
anti-tnf inhibitor agent if discontinued due to
secondary loss of efficacy or side effects.*
Yes
No
Exclusion Criteria
1. patient with known hypersensitivity to
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adalimumab, or any of its components.*
Yes
No
2. patients suffering from serious infection, latent
tb or other conditions prohibiting the use of
adalimumab.*
Yes
No
3. patient had previous non-response to an anti-
tnf agent.*
Yes
No
4. patients currently treated with other biologic
therapy.*
Yes
No
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Record description central archive of
perioperative data (Zapod) -Hospital department
Source:
Project central archive of perioperative Data (ZaPoD) of the
German Society of Anesthesiology and Intensive Care
Medicine (DGAI).
Project lead: PD Dr. Sven Zenker, http://amp.uni-bonn.de
All rights reserved. Please visit https://medical-data-
models.org/forms/15983
Record description central archive of
perioperative data-Hospital
department
Fachabteilung
Anforderung Anästhesie
Ja
Nein
Durchführung Anästhesie
Ja
Nein
Anforderung allgemeine Chirurgie
Ja
Nein
Durchführung allgemeine Chirurgie
Ja
Nein
Anforderung Unfallchirurgie
Ja
Nein
Durchführung Unfallchirurgie
Ja
Nein
Anforderung Thoraxchirurgie
Ja
Nein
Durchführung Thoraxchirurgie
Ja
Nein
Anforderung Gefäßchirurgie
Ja
Nein
Durchführung Gefäßchirurgie
Ja
Nein
Anforderung Neurochirurgie
Ja
Nein
Durchführung Neurochirurgie
Ja
Nein
Anforderung Kinderchirurgie
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Ja
Nein
Durchführung Kinderchirurgie
Ja
Nein
Anforderung Plastische Chirurgie
Ja
Nein
Durchführung Plastische Chirurgie
Ja
Nein
Anforderung Herzchirurgie
Ja
Nein
Durchführung Herzchirurgie
Ja
Nein
Anforderung Innere Medizin
Ja
Nein
Durchführung Innere Medizin
Ja
Nein
Anforderung Gynäkologie
Ja
Nein
Durchführung Gynäkologie
Ja
Nein
Anforderung Reproduktionsmedizin
Ja
Nein
Durchführung Reproduktionsmedizin
Ja
Nein
Anforderung Geburtshilfe
Ja
Nein
Durchführung Geburtshilfe
Ja
Nein
Anforderung Pädiatrie
Ja
Nein
Durchführung Pädiatrie
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Ja
Nein
Anforderung HNO
Ja
Nein
Durchführung HNO
Ja
Nein
Anforderung Zahnheilkunde
Ja
Nein
Durchführung Zahnheilkunde
Ja
Nein
Anforderung MKG
Ja
Nein
Durchführung MKG
Ja
Nein
Anforderung Ophtalmologie
Ja
Nein
Durchführung Ophtalmologie
Ja
Nein
Anforderung Orthopädie
Ja
Nein
Durchführung Orthopädie
Ja
Nein
Anforderung Urologie
Ja
Nein
Durchführung Urologie
Ja
Nein
Anforderung Psychiatrie
Ja
Nein
Durchführung Psychiatrie
Ja
Nein
Anforderung Dermatologie
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Ja
Nein
Durchführung Dermatologie
Ja
Nein
Anforderung Neurologie
Ja
Nein
Durchführung Neurologie
Ja
Nein
Anforderung Nuklearmedizin
Ja
Nein
Durchführung Nuklearmedizin
Ja
Nein
Anforderung Radiologie
Ja
Nein
Durchführung Radiologie
Ja
Nein
Anforderung Neuroradiologie
Ja
Nein
Durchführung Neuroradiologie
Ja
Nein
Anforderung sonstige
Ja
Nein
Durchführung Sonstige
Ja
Nein
Anforderung nicht erfasst
Ja
Nein
Durchführung nicht erfasst
Ja
Nein
4 / 4
Record description central archive of perioperative data (Zapod) -Hospital
department
Record description central archive of perioperative data
(Zapod) - intraoperative Laboratory and Monitoring
Source:
Project central archive of perioperative Data (ZaPoD) of the
German Society of Anesthesiology and Intensive Care
Medicine (DGAI).
Project lead: PD Dr. Sven Zenker, http://amp.uni-bonn.de
All rights reserved. Please visit https://medical-data-
models.org/forms/15985
Record description central archive of
perioperative data- intraoperative
Laboratory and Monitoring
Labor
Arterielle BGA
Ja
Nein
Venöse BGA
Ja
Nein
Monitoring
Präoperatives invasives arterielles Monitoring
Ja
Nein
EKG
Ja
Nein
Pulsoxymetrie
Ja
Nein
NIBD
Ja
Nein
Kapnometrie
Ja
Nein
EKG ST-Analyse
Ja
Nein
EKG 12-Kanal
Ja
Nein
Intraoperatives invasives arterielles Monitoring
Ja
Nein
ZVD
Ja
Nein
HZV
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Ja
Nein
PAK neu
Ja
Nein
PAP
Ja
Nein
LAP
Ja
Nein
Picco
Ja
Nein
Transösophageale Echokardiographie
Ja
Nein
ICP
Ja
Nein
TCD
Ja
Nein
EEG
Ja
Nein
EP
Ja
Nein
Relaxometrie
Ja
Nein
Urinmenge
Ja
Nein
Temperatur
Ja
Nein
Präkordialer Doppler
Ja
Nein
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Eligibility Treatment-resistant Depression
NCT02360280
Efficacy of Repeated Ketamine Infusions for Treatment-
resistant Depression; ODM derived from:
https://clinicaltrials.gov/show/NCT02360280
All rights reserved. Please visit https://medical-data-
models.org/forms/15986
Eligibility Treatment-resistant
Depression NCT02360280
Inclusion Criteria
male or female veterans aged 18 to 75 years.*
Yes
No
have a telephone in their home and able to hear
telephone conversations.*
Yes
No
must meet current dsm-iv criteria for mdd, single
or recurrent, without psychotic features confirmed
by depression subset of the structured clinical
interview-clinical trial for dsm-iv (scid).*
Yes
No
have score  32 on the inventory of depressive
symptomatology-clinician rated (ids-c30)for
severity of major depressive episode (mde) at
screening.*
Yes
No
current major depressive episode resistant to
treatment defined as failure to achieve
improvement from at least 2 antidepressant trials
of different pharmacological classes. systematic
evaluation of previous antidepressant trials will be
assessed by the antidepressant treatment history
form (athf) .*
Yes
No
if applicable, current antidepressant dosages
including augmenting agents and/or frequency
and duration of psychotherapy sessions must
remain stable for at least 6 weeks prior to
beginning of the study.*
Yes
No
Exclusion Criteria
inability to speak english.*
Yes
No
inability or unwillingness to provide written
informed consent.*
Yes
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No
moderate/severe cognitive impairment by mini
mental state examination (mmse) scores 27.*
Yes
No
current or lifetime dsm-v criteria for post-
traumatic stress disorder (ptsd), acute stress
disorder, psychosis-related disorder, bipolar
disorder i or ii disorder, substance-induced mood
disorder, any mood disorder due to a general
medical condition or any axis i disorder other than
mdd as the primary presenting problem.*
Yes
No
history of moderate or severe traumatic brain
injury, parkinson's disease, dementia of any type,
multiple sclerosis, seizures or other cns related
disorders.*
Yes
No
history of comorbid substance disorder within 6
months of assessment plus positive urine
toxicology screen test during baseline
assessments.*
Yes
No
clinically unstable medical illness that could
compromise the patient's ability to tolerate or
likely interfere with the study procedures (e.g.,
history of or current myocardial ischemia or
arrhythmias, congestive heart failure, severe
pulmonary, renal, or hepatic disease,
uncontrolled hypertension).*
Yes
No
current or within less than 14 days use of
barbiturates or monoamine oxidase inhibitors
(maoi).*
Yes
No
for women: pregnancy (confirmed by lab test),
initiation of female hormonal treatments within 3
months of screening, or inability/ unwillingness to
use a medically accepted contraceptive method
during the study.*
Yes
No
imminent risk of suicidal/homicidal ideation
and/or behavior with intent and/or plan.*
Yes
No
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Eligibility Cardiovascular Health Study
(CHS)
Documentation part: Record 1 Eligibility
The Cardiovascular Health Study (CHS) was initiated by
the National Heart, Lung and Blood Institute (NHLBI) in
1987 to determine the risk factors for development and
progression of cardiovascular disease (CVD) in older
adults, with an emphasis on subclinical measures. The
study recruited 5,888 adults aged 65 or older at entry in
four U.S. communities and conducted extensive annual
clinical exams between 1989-1999 along with semi-annual
phone calls, events adjudication, and subsequent data
analyses and publications. Additional data were collected
by studies ancillary to CHS. With the exception of annual
clinic visits, these activities are still ongoing.
Data obtained from: https://chs-nhlbi.org/
Permission granted by: Erika Enright.
All rights reserved. Please visit https://medical-data-
models.org/forms/15987
Eligibility Cardiovascular Health
Study (CHS)
Administrative data
Name
#ID:
Sample person
Other household member:
Eligibility Form
1. Could you please tell me your full name
including middle initial? Last name:
1. Could you please tell me your full name
including middle initial? First, middle initial:
Could you tell me your complete home address
starting with street number? Street:
Could you tell me your complete home address
starting with street number? City:
Could you tell me your complete home address
starting with street number? State:
Could you tell me your complete home address
starting with street number? Zip:
What is your home telephone number, beginning
with area code? Phone:
What is your age?
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What is your birthdate? Birthdate:
What is your Social Security Number?
2.a Please look at this card and tell me which
best describes your race.
White (1)
Black (2)
American Indian/ Alaskan native (3)
Asian/ Pacific Islander (4)
Other: specify (5)
Other: specify
b Do you consider yourself of Hispanic origin?
Yes
No
3. Gender
female (0)
male (1)
4. What is your marital status? Are you:
married? (1)
widowed? (2)
divorced? (3)
separated? (4)
never married? (5)
5. What is the highest grade or year of school you
have ever completed, including trade school or
vocational school or college? Grades
<= 12
>= 0
5. What is the highest grade or year of school you
have ever completed, including trade school or
vocational school or college?
GED (13)
1 year vocational school (14)
2 years vocational school (15)
3 years vocational school (16)
1 year college (17)
2 years college (18)
3 years college (19)
4 years college (20 )
Graduate or professional (21)
Refuses to answer (99)
6. Please look at the card and tell me which one
best describes the kind of work you have done
most of your life:
professional/technical/managerial/admini
strative (1)
sales/clerical service (2)
craffsman/machine operator/laborer (3)
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farming/forestry (4)
housewife (5)
other (specify) (6)
refuses to answer (9)
Other:
7. Please look at this card while I read it all to
you. Then tell me which one best describes your
current occupation:
employed at a job for pay, either full- or
part-time (1)
homemaking, not working outside the
home (2)
employed, but temporarily away from my
regular job (3)
retired from my usual occupation and not
working (4)
retired from my usual occupation but
working for pay (5)
retired from my usual occupation, but
volunteering (6)
unemployed, looking for work (7)
unemployed, not looking for work (8)
other (specify) (9)
Other:
8. Which of the income groups on this card
represents your total combined family income,
before taxes, for the past 12 months? Include
income from all sources such as wages, salaries,
social security or retirement benefits, help from
relatives, rent from property and so forth. Please
tell me the letter only.
A (1)
B (2)
C (3)
D (4)
E (5)
F (6)
G (7)
H (8)
refuses to answer (9)
9. Would you say, in general, your health is:
excellent? (1)
very good? (2)
good? (3)
fair? (4)
poor? (5)
10. How would you say your health compares to
other persons of your age? Would you say your
health is:
Better than others of your age? (1)
About the same as others your age? (2)
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Worse than others your age? (3)
Don't know (9)
11. During the past two weeks, how many days
have you stayed in bed all or most of the day
because of illness or injury? Do not include days
in a hospital or nursing home.
>= 0
<= 14
number of days
12. What illness caused you to stay in bed?
13. Have you been told by a doctor that you
currently have any of the following conditions:
Lung disease, emphysema, or bronchitis?
no (0)
yes (1)
unclear (9)
13. Have you been told by a doctor that you
currently have any of the following conditions:
Nervous or emotional disorder?
no (0)
yes (1)
unclear (9)
13. Have you been told by a doctor that you
currently have any of the following conditions:
High blood pressure?
no (0)
yes (1)
unclear (9)
13. Have you been told by a doctor that you
currently have any of the following conditions:
Hearing problems?
no (0)
yes (1)
unclear (9)
13. Have you been told by a doctor that you
currently have any of the following conditions:
Vision problems not corrected with glasses?
no (0)
yes (1)
unclear (9)
13. Have you been told by a doctor that you
currently have any of the following conditions:
Kidney disease?
no (0)
yes (1)
unclear (9)
13. Have you been told by a doctor that you
currently have any of the following conditions:
Heart disease?
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no (0)
yes (1)
unclear (9)
13. Have you been told by a doctor that you
currently have any of the following conditions:
Diabetes?
no (0)
yes (1)
unclear (9)
13. Have you been told by a doctor that you
currently have any of the following conditions:
Arthritis?
no (0)
yes (1)
unclear (9)
13. Have you been told by a doctor that you
currently have any of the following conditions:
Disability from stroke?
no (0)
yes (1)
unclear (9)
14. Have you ever been diagnosed with cancer?
Yes
No
a Are you currently undergoing active treatment
for cancer?
Yes
No
b Have you had cancer during the past five
years?
Yes
No
c Please tell me the type of cancer you had: Lung
Yes
No
c Please tell me the type of cancer you had:
Breast
Yes
No
c Please tell me the type of cancer you had:
Stomach
Yes
No
c Please tell me the type of cancer you had: Liver
Yes
No
c Please tell me the type of cancer you had:
Colon
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Yes
No
c Please tell me the type of cancer you had:
Rectal
Yes
No
c Please tell me the type of cancer you had:
Pancreas
Yes
No
c Please tell me the type of cancer you had:
Esophagus
Yes
No
c Please tell me the type of cancer you had:
Lymphoma
Yes
No
c Please tell me the type of cancer you had:
Multiple myeloma
Yes
No
c Please tell me the type of cancer you had: Brain
Yes
No
c Please tell me the type of cancer you had:
Prostate
Yes
No
c Please tell me the type of cancer you had:
Acute leukemia
Yes
No
c Please tell me the type of cancer you had:
Melanoma
Yes
No
c Please tell me the type of cancer you had:
Nonmelanoma skin cancer
Yes
No
c Please tell me the type of cancer you had:
Chronic leukemia
Yes
No
c Please tell me the type of cancer you had:
Other (specify)
Yes
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No
Other:
15. Have you smoked more than 100 cigarettes
or 5 packs of cigarettes in your lifetime?
no (0)
yes (1)
unclear (9)
16. Have you smoked cigarettes during the last
30 days?
no (0)
yes (1)
unclear (9)
17. How tall are you?
feet
18. How much do you weight?
pounds
19. Because of any physical or health problem,
do you need the help of other persons with your
personal care needs, such as eating, bathing,
dressing or getting around the home?
no (0)
yes (1)
unclear (9)
20. Because of any physical or health problem,
do you need the help of other persons in handling
your routine needs, such as everyday household
chores, doing necessary business, shopping or
getting around for other purposes?
no (0)
yes (1)
unclear (9)
21. Can you do the following activities without
difficulty: Walk a 1/2 mile or about 5-6 blocks?
no (0)
yes (1)
unclear (9)
21. Can you do the following activities without
difficulty: Walk up 10 steps?
no (0)
yes (1)
unclear (9)
21. Can you do the following activities without
difficulty: Get out of bed or a chair?
no (0)
yes (1)
unclear (9)
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21. Can you do the following activities without
difficulty: Walk around your home?
no (0)
yes (1)
unclear (9)
22. Are you able to walk from room to room
independently or with a cane or walker?
Yes
No
23. Are you planning to live in this community for
the next three years?
no (0)
yes (1)
unclear (9)
24. Are you able to travel by car, van or bus to the
clinic center?
no (0)
yes (1)
unclear (9)
25. Are you on a waiting list to enter a nursing
home?
no (0)
yes (1)
unclear (9)
26. Are you participating in the Atherosclerotic
Risk in Communities Study, the Systolic
Hypertension in Elderly Study or NHANES III?
no (0)
yes (1)
unclear (9)
27. Is the individual eligible?
Yes
No
28. Are you willing to participate in this study?
Yes
No
Date of interview
Interviewer
Interview:
First edit:
Second edit:
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Record description central archive of perioperative data
(Zapod) - Measures, pre-, peri-,intra- and postoperative
Source:
Project central archive of perioperative Data (ZaPoD) of the
German Society of Anesthesiology and Intensive Care
Medicine (DGAI).
Project lead: PD Dr. Sven Zenker, http://amp.uni-bonn.de
All rights reserved. Please visit https://medical-data-
models.org/forms/15988
Record description central archive of
perioperative data-Measures, pre-,
peri-,intra- and postoperative
Perioperative Maßnahmen
Rückenlagerung
Ja
Nein
Bauchlage
Ja
Nein
Trendelenburg
Ja
Nein
Steinschnitt-Lagerung
Ja
Nein
Knie-Ellenbogen Lagerung
Ja
Nein
Umlagerung
Ja
Nein
Sitzende Lagerung
Ja
Nein
Seitenlagerung rechts
Ja
Nein
Seitenlagerung links
Ja
Nein
Auslagerung Arm rechts
Ja
Nein
Auslagerung Arm links
Ja
Nein
Sonstige Lagerung
Ja
Nein
EMLA
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Ja
Nein
Wärmematte
Ja
Nein
Warmluft
Ja
Nein
Wärmelampe
Ja
Nein
Warme Infusion
Ja
Nein
Kühlung
Ja
Nein
Magensonde
Ja
Nein
Bronchoskopie
Ja
Nein
Schnellinfusion
Ja
Nein
Hypotension
Ja
Nein
Transvenöser Schrittmacher
Ja
Nein
Transthorakaler Schrittmacher
Ja
Nein
Epimyokardialer Schrittmacher
Ja
Nein
Kardioversion
Ja
Nein
Defibrillation
Ja
Nein
Reanimation
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Ja
Nein
Hämodilution
Ja
Nein
Cellsaver
Ja
Nein
Sonographie
Ja
Nein
Augenschutz
Ja
Nein
Atemtherapie
Ja
Nein
Dauerkatheter
Ja
Nein
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Eligibility Treatment-Resistant Hypertension
NCT02342808
Lifestyle Interventions in Treatment-Resistant
Hypertension; ODM derived from:
https://clinicaltrials.gov/show/NCT02342808
All rights reserved. Please visit https://medical-data-
models.org/forms/15989
Eligibility Treatment-Resistant
Hypertension NCT02342808
Inclusion Criteria
diagnosis of resistant hypertension (rh) within the
last 6 months.  in the absence of a specific rh
diagnosis, individuals being treated for two or
more weeks with at least 3 antihypertensive
medications of different classes, including a
diuretic, with clinic sbp ≥ 140 mm hg or dbp ≥ 90
mm hg, will be eligible.  individuals being treated
with 4 or more anti-hypertensive medications
(including a diuretic) with sbp*
Yes
No
≥ 130 or dbp ≥ 85 mm hg will also be eligible.*
Yes
No
adherent to prescribed medications*
Yes
No
overweight (bmi > 25 kg/m2 with max weight of
300 lbs)*
Yes
No
sedentary*
Yes
No
willing to be randomized to one of the 2 treatment
groups and able to fully participate in
intervention*
Yes
No
informed consent*
Yes
No
Exclusion Criteria
secondary htn, non-adherence to anti-htn
medications*
Yes
No
severe ckd (egfr <45 ml/min/1.73m2)*
Yes
No
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severe ischemic heart disease (ccs class 3 or 4
angina or evidence of ischemia at <85% heart
rate reserve on treadmill testing)*
Yes
No
severe heart failure (nyha association class 3 or
4), high grade arrhythmias, severe valvular heart
disease*
Yes
No
severe asthma or chronic obstructive lung
disease*
Yes
No
diabetes requiring insulin*
Yes
No
musculoskeletal or neurologic problems that
would preclude participation in aerobic exercise
training*
Yes
No
major psychiatric disorder, a history of drug
abuse, alcohol consumption >14 drinks/week*
Yes
No
life-limiting comorbid medical condition such as
cancer*
Yes
No
prior gastric bypass surgery*
Yes
No
currently pregnant*
Yes
No
cognitively impaired*
Yes
No
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Eligibility Type 1 Diabetes Mellitus
NCT02192450
Insulin Degludec and Symptomatic Nocturnal
Hypoglycaemia; ODM derived from:
https://clinicaltrials.gov/show/NCT02192450
All rights reserved. Please visit https://medical-data-
models.org/forms/15990
Eligibility Type 1 Diabetes Mellitus
NCT02192450
Inclusion Criteria
type 1 diabetes > 5 years*
Yes
No
one or more episodes of nocturnal severe
hypoglycaemia during the preceding two years*
Yes
No
treated with multiple dose insulin injection (>2) or
insulin pump. both human insulin and insulin
analogues are allowed*
Yes
No
willingness to a once daily (od) regimen
concerning insulin degludec and insulin glargine*
Yes
No
willingness to do self-monitoring of blood glucose
(smbg) and keep a diary*
Yes
No
signed informed consent*
Yes
No
Exclusion Criteria
history of primary and secondary adrenal
insufficiency, growth hormone deficiency, or
untreated myxoedema*
Yes
No
history of unstable angina or major
cardiovascular events (myocardial infarction,
coronary re-vascularisation, transient ischaemic
attack, or stroke within the last three months)*
Yes
No
heart failure, new york heart association (nyha)
class iv*
Yes
No
history of malignancy unless a disease-free
period exceeding five years*
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Yes
No
history of alcohol or drug abuse*
Yes
No
treatment with glucose lowering agent(s) other
than insulin*
Yes
No
pregnant or lactating women*
Yes
No
women of childbearing potential who are not
using chemical (p-pills or gestagen depots) or
mechanical (intra-uterine device) contraception*
Yes
No
participation in another investigational drug study
within the last 3 months*
Yes
No
inability to understand the informed consent*
Yes
No
hba1c > 86 mmol/mol (10%)*
Yes
No
shifting working hours*
Yes
No
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Eligibility Rheumatoid Arthritis
NCT02341066
Endothelial Dysfunction Evaluation for Coronary Heart
Disease Risk Estimation in Rheumatoid Arthritis (EDRA
Study); ODM derived from:
https://clinicaltrials.gov/show/NCT02341066
All rights reserved. Please visit https://medical-data-
models.org/forms/15991
Eligibility Rheumatoid Arthritis
NCT02341066
Inclusion Criteria
ra as defined by american college of
rheumatology/european league against
rheumatisms 2010 ra classification criteria*
Yes
No
in the opinion of investigators, patients must be
able to adhere to the study visit schedule and
must be capable of giving informed consent*
Yes
No
Exclusion Criteria
previous cardiovascular or cerebrovascular
events (acute coronary syndrome, stable angina,
stroke, interventional procedures, carotid
endarterectomy, symptomatic peripheral artery
ischemia)*
Yes
No
pathological ecg at rest*
Yes
No
sign or symptoms of autonomous nervous
system dysfunction*
Yes
No
serious infections in the previous 6 months*
Yes
No
concomitant severe illness: overt hepatic
insufficiency; end stage renal disease (glomerular
filtration rate <30 ml/h at cockrofts-gault formula);
recent diagnosis of cancer*
Yes
No
pregnancy*
Yes
No
plans to leave target areas of each study site
within three years*
Yes
No
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Eligibility Type 1 Diabetes Mellitus
NCT02293837
Tocilizumab (TCZ) in New-onset Type 1 Diabetes; ODM
derived from: https://clinicaltrials.gov/show/NCT02293837
All rights reserved. Please visit https://medical-data-
models.org/forms/15992
Eligibility Type 1 Diabetes Mellitus
NCT02293837
Inclusion Criteria
1. participants who meet the american diabetes
association type 1 diabetes mellitus (t1dm)
criteria*
Yes
No
2. diagnosis of t1dm within 100 days of
enrollment*
Yes
No
3. positive for at least one diabetes-related
autoantibody, including but not limited to:*
Yes
No
1. glutamate decarboxylase (gad-65)*
Yes
No
2. insulin, if obtained within 10 days of the onset
of exogenous insulin therapy*
Yes
No
3. insulinoma antigen-2 (ia-2)*
Yes
No
4. zinc transporter- (znt)*
Yes
No
5. islet-cell antibodies (ica).*
Yes
No
4. peak stimulated c-peptide level >= 0.2 pmol/ml
following a mixed-meal tolerance test (mmtt)
conducted at least 21 days from diagnosis and
within 37 days of randomization*
Yes
No
5. signed informed consent (and informed assent
of minor, if applicable).*
Yes
No
Exclusion Criteria
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1. severe reaction or anaphylaxis to human,
humanized or murine monoclonal antibodies*
Yes
No
2. history of malignancy or serious uncontrolled
cardiovascular, nervous system, pulmonary,
renal, or gastrointestinal disease, or significant
dyslipidemia*
Yes
No
3. any history of recent serious bacterial, viral,
fungal, or other opportunistic infections*
Yes
No
4. have serologic evidence of current or past hiv
(human immunodeficiency virus), hepatitis b, or
hepatitis c*
Yes
No
5. positive quantiferon tuberculosis (tb) test,
history of tb, or active tb infection*
Yes
No
6. active infection with epstein-barr virus (ebv) as
defined by ebv viral load >=10,000 copies per ml
of  whole blood*
Yes
No
7. active infection with cytomegalovirus (cmv) as
defined by cmv viral load >= 10,000 copies per ml
of whole blood*
Yes
No
8. diagnosis of liver disease or elevated hepatic
enzymes, as defined by alanine aminotransferase
(alt), aspartate aminotransferase (ast), or both >
1.5 x the upper limit of age-determined normal
(uln) or total bilirubin > uln*
Yes
No
9. current or prior treatment that is known to
cause a significant, ongoing change in the course
of t1d or immunologic status*
Yes
No
10. current or prior (within last 30 days) use of
drugs other than insulin to treat hyperglycemia
(e.g. metformin, sulfonylureas, glinides,
thiazolidinediones, exenatide, liraglutide, dpp-iv
inhibitors, or amylin)*
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Yes
No
11. current use of any medication known to
significantly influence glucose tolerance (e.g.,
atypical antipsychotics, diphenylhydantoin,
niacin)*
Yes
No
12. any of the following hematologic
abnormalities, confirmed by repeat tests:*
Yes
No
1. white blood count <3,000/microl or
>14,000/microl*
Yes
No
2. lymphocyte count <500/microl*
Yes
No
3. platelet count <150,000 /microl hemoglobin <.5
g/dl*
Yes
No
4. neutrophil count <2,000 cells/microl.*
Yes
No
13. females who are pregnant, lactating, or
planning on pregnancy during the 2- year study
period*
Yes
No
14. history or diagnoses of other autoimmune
diseases with the exception of stable thyroid or
celiac disease*
Yes
No
15. history of alcohol, drug or chemical abuse
within 1 year prior to screening*
Yes
No
16. any medical or psychological condition that in
the opinion of the principal investigator would
interfere with safe completion of the trial*
Yes
No
17. prior participation in a clinical trial that could
increase risks associated with this clinical trial*
Yes
No
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18. receipt of live vaccine (e.g. varicella, measles,
mumps, rubella, cold-attenuated intranasal
influenza vaccine, bacillus calmette-guérin, and
small pox) in the 6 weeks before randomization*
Yes
No
19. high lipid levels (fasting low-density
lipoprotein (ldl) cholesterol >=160 mg/dl).*
Yes
No
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Eligibility Type 1 Diabetes Mellitus NCT02293837
Eligibility Type 2 Diabetes Mellitus
NCT01824264
Dose-finding Study of LIK066 Compared With Placebo or
Sitagliptin to Evaluate Change in HbA1c in Patients With
Diabetes; ODM derived from:
https://clinicaltrials.gov/show/NCT01824264
All rights reserved. Please visit https://medical-data-
models.org/forms/15993
Eligibility Type 2 Diabetes Mellitus
NCT01824264
Inclusion Criteria
1. confirmed diagnosis of t2dm by standard
criteria*
Yes
No
2. drug-naïve patients, defined as patients not
having received any anti-diabetic medication
previously,*
Yes
No
3. currently untreated patients , who, after the
diagnosis of t2dm, have received anti-diabetic
medication for not more than 12 consecutive
weeks, and have not received any anti-diabetic
treatment within 12 weeks prior to visit 1*
Yes
No
4. patients being treated with  mono-therapy for at
least 8 consecutive weeks prior to visit 1 with the
following oads: metformin, dipeptidyl peptidase-4
inhibitors (dpp-4i), su, glinide, alpha-glucosidase
inhibitor (agi)*
Yes
No
5. hba1c ≥ 7 to ≤ 10.5%  at visit 1 for drug-
naïve/currently untreated patients*
Yes
No
6. hba1c ≥ 7 to ≤ 9.5%  at visit 1 for patients
treated with oad monotherapy*
Yes
No
7. hba1c ≥ 7 to ≤ 10.5%  at visit 199 for all
patients*
Yes
No
8. age: ≥18 and ≤ 75 years old at visit 1*
Yes
No
9. bmi ≥22 to ≤45 kg/m2 at visit 1*
Yes
No
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Exclusion Criteria
1. fpg ≥270 mg/dl (15 mmol/l) for drug-
naïve/currently untreated patients or ≥240 mg/dl
(13.3 mmol/l) for patients on oad monotherapy at
visit 1*
Yes
No
2. insulin treatment >4 consecutive weeks in the
last 6 months, corticosteroid use >7 days in the
last 8 weeks, use of growth hormones in the last
6 months, or use of weight control products > 4
weeks in the last 6 months*
Yes
No
3. history of acute metabolic complications, cv
disease, type 1 diabetes mellitus, hepatic
disorders, pancreatitis, chronic diarrhea*
Yes
No
4. significant lab abnormalities such as tsh
outside of normal range, uacr>300 mg/g
creatinine, egfr <60 ml/min/1.73m2, hemoglobin
<12 g/l in men and <11 g/l in women, hematuria*
Yes
No
5. ecg abnormalities including av block, long qt
syndrome or qtc>450 msec for men and >470
msec for women*
Yes
No
6. history of malignancy*
Yes
No
7. women of child-bearing potential not using
effective methods of contraception other protocol-
defined inclusion/exclusion criteria may apply*
Yes
No
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Eligibility Type 2 Diabetes Mellitus
NCT02268916
Physical Activity and Participation; ODM derived from:
https://clinicaltrials.gov/show/NCT02268916
All rights reserved. Please visit https://medical-data-
models.org/forms/15994
Eligibility Type 2 Diabetes Mellitus
NCT02268916
Inclusion Criteria
veterans*
Yes
No
aged 60 years or older*
Yes
No
has type 2 diabetes mellitus*
Yes
No
able to operate accelerometer*
Yes
No
competent to consent to the study*
Yes
No
no dementia diagnosis*
Yes
No
ambulatory with or without assistive device*
Yes
No
english-speaking*
Yes
No
community living (i.e., not a nursing home
resident)*
Yes
No
Exclusion Criteria
medically unstable*
Yes
No
hospitalized within the last 6 months*
Yes
No
2 or more days of complete bed rest in the last
month*
Yes
No
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hemiplegia or limb amputation*
Yes
No
self-reported illness or conditions that would
impair the cooperation with the study team or the
ability to complete the study*
Yes
No
work involved in shift schedule*
Yes
No
current enrollment of a physical activity program*
Yes
No
replacement of hip or knee within the last 6
months.*
Yes
No
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Eligibility Type 2 Diabetes Mellitus
NCT02292511
Mind-motor Exercise in Older Adults With Type 2 Diabetes
and Self-reported Cognitive Complaints; ODM derived
from: https://clinicaltrials.gov/show/NCT02292511
All rights reserved. Please visit https://medical-data-
models.org/forms/15995
Eligibility Type 2 Diabetes Mellitus
NCT02292511
Inclusion Criteria
age 55 years of age or older*
Yes
No
stable type 2 diabetes (i.e. a1c <9.0 for at least 6
months)*
Yes
No
self report a cognitive complaint (i.e answer yes
to: do you feel your memory and/or thinking skills
have gotten worse recently?)*
Yes
No
Exclusion Criteria
participants must be able to comprehend the
letter of information and provide consent.*
Yes
No
participants cannot have*
Yes
No
major depression, measured by center of
epidemiologic studies depression scale (ces-d)
and study physician consult,*
Yes
No
diagnosis of dementia, or score <24 on mini-
mental state examination (mmse)*
Yes
No
other significant neurological disorder or
psychiatric conditions*
Yes
No
severe history of cardiovascular events*
Yes
No
severe orthopedic limitations*
Yes
No
uncontrolled diabetes (i.e a1c <4.0mmol/l or
>9.0mmol/l)*
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Yes
No
unstable angina*
Yes
No
untreated retinopathy*
Yes
No
foot ulcers with or without severe peripheral
neuropathy*
Yes
No
severe sensory impairment (i.e. blind).*
Yes
No
finally, participants must plan to attend at least
75% of the sessions over the 24-week period;
this is to ensure adequate compliance of the
program.*
Yes
No
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AAFP: Acute Myocardial Infarction
Admission Order
AAFP: Acute Myocardial Infarction Admission Order ,
Standardizes Admission Orders, Author: Robert M. Wiprud,
MD The primary purpose of these Ordersets is to decrease
unnecessary variability and to improve quality through
standardized Admission Orders. Developed by the Scott &
White Clinic at College Station, Texas. Copyright © 2006
American Academy of Family Physicians. Physicians may
photocopy or adapt for use in their own practices; all other
rights reserved. Wiprud RM. Providing consistent care with
standardized admission orders. Fam Pract Manag.
September 2006: 49-52 See
http://www.aafp.org/fpm/2006/0900/p49.html This ODM
Form includes the second section ("Acute Myocardial
Infarction Admission Order").
All rights reserved. Please visit https://medical-data-
models.org/forms/15996
AAFP: Acute Myocardial Infarction
Admission Order
Default Itemgroup
Name
Alter
Geburtstdatum
Patienten-ID
Status
Aufnahmestatus
Beobachtung (1)
Aufnahme (2)
Station (3)
Intensivstation (4)
Andere (5)
Falls Andere, bitte spezifizieren
Facharzt
Facharzt
Telefonnummer des Facharztes
Aufnahmediagnose
Ursache für akuten Herzinfarkt / Diagnose:
Zustand
Zustand
stabil (1)
1 / 5
gut / in Ordnung (2)
ernstzunehmend (3)
kritisch (4)
Allergien
Allergien
Ernährung
Ernährung
Ja
Nein
Falls Andere, bitte spezifizieren
Ja
Nein
Diet
Mobilität
Mobilität
bettlägerig mit Toilettenstuhl am Bett (1)
vollständig bettlägerig (2)
Pflege
Pflege
Ja
Nein
2D Echo fertiggestellt, bis
Ja
Nein
Nursing
Ja
Nein
Nursing
Ja
Nein
Nursing
Ja
Nein
Nursing
Ja
Nein
Nursing
Ja
Nein
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Nursing: 2D Echo
Medikation
Medikation
Ja
Nein
Medications
Ja
Nein
Medications
Ja
Nein
Medications
Ja
Nein
Medications
Ja
Nein
Medications
Ja
Nein
Medications
Ja
Nein
Medications
Ja
Nein
Medications
Ja
Nein
Falls Metoprolol, bitte Menge spezifizieren
mg
Falls Zocor, bitte Menge spezifizieren
mg
Falls Lovenox, bitte Menge spezifizieren
mg
Falls Nitropaste, bitte Menge spezifizieren
Labor
Labor
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Ja
Nein
Lab
Ja
Nein
Lab
Ja
Nein
Lab
Ja
Nein
Lab
Ja
Nein
Lab
Ja
Nein
Lab
Ja
Nein
Lab
Ja
Nein
Falls Wiederholung von CK, CK-MB und Troponin
I, bitte Menge nach 8 Std spezifizieren
Falls Wiederholung von CK, CK-MB und Troponin
I, bitte Menge nach 16 Std spezifizieren
Prüfen
Prüfen
Ja
Nein
Consider
Ja
Nein
Consider
Ja
Nein
Consider
Ja
Nein
Consider
Ja
Nein
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Consider
Ja
Nein
Falls Integrilin, bitte Gesamtmenge an Integrilin
spezifizieren
mcg
Signature
Print Name
Date and Time
5 / 5
AAFP: Acute Myocardial Infarction Admission Order
AAFP: Asa Overdose Admission Order
AAFP: Asa Overdose Admission Order, Standardizes
Admission Orders, Author: Robert M. Wiprud, MD The
primary purpose of these Ordersets is to decrease
unnecessary variability and to improve quality through
standardized Admission Orders. Developed by the Scott &
White Clinic at College Station, Texas. Copyright © 2006
American Academy of Family Physicians. Physicians may
photocopy or adapt for use in their own practices; all other
rights reserved. Wiprud RM. Providing consistent care with
standardized admission orders. Fam Pract Manag.
September 2006: 49-52 See
http://www.aafp.org/fpm/2006/0900/p49.html This ODM
Form includes the third section ("Asa Overdose Admission
Order").
All rights reserved. Please visit https://medical-data-
models.org/forms/15997
AAFP: Asa Overdose Admission
Order
Default Itemgroup
Name
Age
Date of Birth
Medical record
Status
Status
Observation (1)
Admission (2)
Medical Floor (3)
ICU (4)
Other telemetry (5)
Attending
Name of attending physician
Phone number of attending physician
Admitting Diagnosis
ASA Overdose Associated Diagnoses
Condition
Condition
Stable (1)
Fair (2)
Serious (3)
Critical (4)
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Code Status
Full Code (1)
DNR (2)
Allergies
Allergies
Diet
Diet
NPO (1)
Clear liquid (2)
AHA step 2  (3)
ADA __ calories (4)
Other (5)
If diet according to ADA, please specify amount
of calories
If Other, please specify
Activity
Bed rest with bathroom privileges
Yes
No
Nursing
Vital signs every 4 hrs for 24 hrs then every 4 hrs
if stable
Yes
No
Suicide precautions
Yes
No
Gastric lavage in ER with activated charcoal
Yes
No
Consider dialysis if serum salicylate greater than
70 mg/dl
Yes
No
Medications
Vitamin K 10 mg IM now
Yes
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No
Guaiac all stools
Yes
No
Other
Yes
No
Other
IV
Dextrose 5% in 1/2 normal saline with 44mEq
bicarbonate/L @ 300mL/hr (forced alkaline
diuresis)
Yes
No
Lab
ABGs
Yes
No
Hemogram
Yes
No
Lytes
Yes
No
Glucose
Yes
No
Salicylate level, if not done in ER
Yes
No
Consult
Psych
Yes
No
Social services
Yes
No
MHMR
Yes
No
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Signature
Print Name
Date and time
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AAFP: Asthma Admission Order
AAFP: Asthma Admission Order, Standardizes Admission
Orders, Author: Robert M. Wiprud, MD The primary
purpose of these Ordersets is to decrease unnecessary
variability and to improve quality through standardized
Admission Orders. Developed by the Scott & White Clinic at
College Station, Texas. Copyright © 2006 American
Academy of Family Physicians. Physicians may photocopy
or adapt for use in their own practices; all other rights
reserved. Wiprud RM. Providing consistent care with
standardized admission orders. Fam Pract Manag.
September 2006: 49-52 See
http://www.aafp.org/fpm/2006/0900/p49.html This ODM
Form includes the fourth section ("Asthma Admission
Order").
All rights reserved. Please visit https://medical-data-
models.org/forms/15998
AAFP: Asthma Admission Order
Default Itemgroup
Name
Alter
Geburtsdatum
Patienten-ID
Status
Aufnahmestatus
Beobachtung (1)
Aufnahme (2)
Station (3)
Intensivstation (4)
Andere (5)
Facharzt
Name des Facharztes
Telefonnummer des Facharztes
Aufnahmegrund/Diagnose
Diagnose in Bezug auf die Verschlechterung des
Asthma
Zustand
Zustand
Stabil (1)
Gut/ in Ordnung (2)
Ernstzunehmend  (3)
Kritisch (4)
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Code Status
Wiederbelebung (1)
keine Wiederbelebung (2)
Allergien
Allergien
Ernährung
Ernährung
NPO (1)
klare Flüssigkeit (2)
AHA Stufe 2 (3)
ADA___Kalorien (4)
Andere (5)
Falls Ernährung nach ADA, bitte Menge an
Kalorien angeben
Falls Andere, bitte spezifizieren
Mobilität
Mobilität
Ja
Nein
Activity
Ja
Nein
Activity
Ja
Nein
Pflege
Pflege
Ja
Nein
Nursing
Ja
Nein
Nursing
Ja
Nein
Medikation
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Medikation
Ja
Nein
Medications
Ja
Nein
Medications
Ja
Nein
Medications
Ja
Nein
Falls Albuterol, bitte Häufigkeit angeben
Infusion
Infusion
Ja
Nein
IV
Ja
Nein
Falls Infusion @mL/std, bitte @mL/std
spezifizieren
Labor
Labor
Ja
Nein
Lab
Ja
Nein
Diagnostik
Diagnostik
Ja
Nein
Diagnostic Studies
Ja
Nein
Diagnostic Studies
Ja
Nein
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Empfehlung
Empfehlung
Unterschrift
Name
Datum und Uhrzeit
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AAFP: Chest Pain Admission Order
AAFP: Chest Pain Admission Order, Standardizes
Admission Orders, Author: Robert M. Wiprud, MD The
primary purpose of these Ordersets is to decrease
unnecessary variability and to improve quality through
standardized Admission Orders. Developed by the Scott &
White Clinic at College Station, Texas. Copyright © 2006
American Academy of Family Physicians. Physicians may
photocopy or adapt for use in their own practices; all other
rights reserved. Wiprud RM. Providing consistent care with
standardized admission orders. Fam Pract Manag.
September 2006: 49-52 See
http://www.aafp.org/fpm/2006/0900/p49.html This ODM
Form includes the fifth section ("Chest Pain Admission
Order).
All rights reserved. Please visit https://medical-data-
models.org/forms/15999
AAFP: Chest Pain Admission Order
Default Itemgroup
Name
Alter
Geburtsdatum
Patienten-ID
Status
Status
Beobachtung (1)
Aufnahme (2)
Station (3)
Intensivstation (4)
Andere (5)
Falls Andere, bitte spezifizieren
Facharzt
Name des Facharztes
Telefonnummer des Facharztes
Aufnahmegrund/ Diagnose
Diagnose in Bezug auf Brustschmerzen;
ausgeschlossen akutes Koronarsyndrom
Zustand
Zustand
Stabil (1)
1 / 4
Gut / in Ordnung (2)
Ernstzunehmend (3)
Kritisch (4)
Code Status
Wiederbelebung (1)
keine Wiederbelebung (2)
Allergien
Allergien
Ernährung
Ernährung
NPO (1)
klare Flüssigkeit (2)
ADA__Kalorien (3)
ADA__Kalorien (3)
Andere (4)
Falls Ernährung nach ADA, bitte Menge an
Kalorien spezifizieren
Falls Andere, bitte spezifizieren
Mobilität
Mobilität
Ja
Nein
Activity
Ja
Nein
Activity
Ja
Nein
Pflege
Pflege
Ja
Nein
Nursing
Ja
Nein
Nursing
Ja
Nein
Nursing
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Ja
Nein
Nursing
Ja
Nein
Nursing
Ja
Nein
Medikation
Medikation
Ja
Nein
Medications
Ja
Nein
Medications
Ja
Nein
Medications
Ja
Nein
Medications
Ja
Nein
Medications
Ja
Nein
Medications
Ja
Nein
Medications
Ja
Nein
Infusion
Infusion
Ja
Nein
IV
Ja
Nein
Falls Infusion__@mL/std, bitte Menge an mL/std
spezifizieren
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Labor
Labor
Ja
Nein
Lab
Ja
Nein
Diagnostik
Diagnostik
Ja
Nein
Diagnostic Studies
Ja
Nein
Diagnostic Studies
Ja
Nein
Diagnostic Studies
Ja
Nein
Diagnostic Studies
Ja
Nein
Echokardiogramm -soll gelesen werden durch
___?
Empfehlung
Empfehlung
Unterschrift
Name
Datum und Uhrzeit
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AAFP: Congestive Heart Failure Admission
Order
AAFP: Congestive Heart Failure Admission Order,
Standardizes Admission Orders, Author: Robert M. Wiprud,
MD The primary purpose of these Ordersets is to decrease
unnecessary variability and to improve quality through
standardized Admission Orders. Developed by the Scott &
White Clinic at College Station, Texas. Copyright © 2006
American Academy of Family Physicians. Physicians may
photocopy or adapt for use in their own practices; all other
rights reserved. Wiprud RM. Providing consistent care with
standardized admission orders. Fam Pract Manag.
September 2006: 49-52 See
http://www.aafp.org/fpm/2006/0900/p49.html This ODM
Form includes the sixth section ("Congestive Heart Failure
Admission Order").
All rights reserved. Please visit https://medical-data-
models.org/forms/16000
AAFP: Congestive Heart Failure
Admission Order
Default Itemgroup
Name
Alter
Geburtsdatum
Patienten-ID
Status
Status
Beobachtung (1)
Aufnahme (2)
Station (3)
Intensivstation (4)
Facharzt
Name des Facharztes
Telefonnummer des Facharztes
Aufnahmegrund/Diagnose
Diagnose in Bezug auf Herzinsuffizienz
Zustand
Zustand
Stabil (1)
Gut/ in Ordnung (2)
Ernstzunehmend (3)
Kritisch (4)
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Code Status
Wiederbelebung (1)
keine Wiederbelebung (2)
Allergien
Allergien
Ernährung
Ernährung
Ja
Nein
Diet
Ja
Nein
Diet
Ja
Nein
Diet
Ja
Nein
Diet
Ja
Nein
Falls Ernährung nach ADA, bitte Menge an
Kalorien angeben
Falls Flüssigkeitsrestriktion, bitte mL/24 std
angeben
Mobilität
Mobilität
Ja
Nein
Activity
Ja
Nein
Activity
Ja
Nein
Acitivity
Ja
Nein
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Falls Andere, bitte spezifizieren
Pflege
Pflege
Ja
Nein
Nursing
Ja
Nein
Nursing
Ja
Nein
Nursing
Ja
Nein
Nursing
Ja
Nein
Nursing
Ja
Nein
Nursing
Ja
Nein
Medications
Medications
Ja
Nein
Medications
Ja
Nein
Medications
Ja
Nein
Medications
Ja
Nein
Medications
Ja
Nein
Medications
Ja
Nein
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Medications
Ja
Nein
Medications
Ja
Nein
Medications
Ja
Nein
Medications
Ja
Nein
Medications
Ja
Nein
ASA specification
mg
ACE specification
Lasix specification
mg
Lasix specification
hrs
NTG paste specification
inch(es)
NTG paste specification
hrs
Betablocker specification
Digoxin specification
mg
Spironolactone specification
mg
IV
IV
IV lock; flush per routine (1)
Lab
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Lab
Lab
Ja
Nein
Lab
Ja
Nein
Lab
Ja
Nein
Specification of Other
Diagnostic Studies
Diagnostic Studies
Ja
Nein
Diagnostic Studies
Ja
Nein
Diagnostic Studies
Ja
Nein
CXR specification
CXR specification
Consult
Consult
Patient Education
Patient Education
Other Orders
Other Orders
Signature
Name
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Date and Time
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AAFP: Childhood Bacterial Meningitis
Admission Order
AAFP: Childhood Bacterial Meningitis Admission Order,
Standardizes Admission Orders, Author: Robert M. Wiprud,
MD The primary purpose of these Ordersets is to decrease
unnecessary variability and to improve quality through
standardized Admission Orders. Developed by the Scott &
White Clinic at College Station, Texas. Copyright © 2006
American Academy of Family Physicians. Physicians may
photocopy or adapt for use in their own practices; all other
rights reserved. Wiprud RM. Providing consistent care with
standardized admission orders. Fam Pract Manag.
September 2006: 49-52 See
http://www.aafp.org/fpm/2006/0900/p49.html. This ODM
Form includes the seventh section ("Childhood Bacterial
Meningitis Admission Order").
All rights reserved. Please visit https://medical-data-
models.org/forms/16001
AAFP: Childhood Bacterial
Meningitis Admission Order
Default Itemgroup
Name
Age
Date of Birth
Medical Record
Status
Status
ICU (1)
Pediatrics (2)
Attending
Name of attending physician
Phone number of attending physician
Admitting Diagnosis
Childhood Bacterial Meningitis Associated
Diagnoses
Condition
Condition
Stable (1)
Fair (2)
Serious (3)
Critical (4)
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Allergies
Allergies
Diet
Diet
NPO (1)
Age appropriate diet (2)
Activity
Routine for age
Yes
No
Crib
Yes
No
Bassinet
Yes
No
Bed rest
Yes
No
Nursing
Vital signs with BP: every __ hrs
Yes
No
Neuro vitals: every __ hrs
Yes
No
If Vital signs with BP, please specify frequency
hrs
If Neuro vitals, please specify frequency
hrs
Medications
< 1 month of age: ampicillin 50 mg/kg/dose IVPB
every 8 hrs; gentamicin 2.5 mg/kg/dose IVPB
every 12 hrs
Yes
No
Age 1-3 month: ampicillin (50mg/kg)__ mg IVPB
every 8 hrs; cefotaxime (50mg/kg)__ mg IVPB
every 6 hrs
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Yes
No
> 3 months: cefotaxime (50mg/kg)__ mg IVPB
every 6 hrs
Yes
No
Other
Yes
No
If ampicillin at the age of 1-3 month, please
specify amount
If cefotaxime at the age of 1-3 month please
specify amount
If cefotaxime at the age of > 3 month, please
specify amount
If cefotaxime at the age of > 3 month, please
specify amount
If Other, please specify
IV
Normal saline @__mL/hrs with 5 mEq
KCI/250mL should be 2/3 maintenance
Yes
No
Maintenance: 100 mL/kg/day up to 10 kg plus 50
mL/kg/day for each kg between 10-20 plus 20
mL/kg/day for each kg > 20 kg
Yes
No
If Saline, please specify amount
mL/hrs
Lab
Send CSF for: tube 1: C&S, gram stain on
centrifuge spun specimen; tube 2: glucose,
protein; tube 3: cell count and diff; tube 4: hold
Yes
No
Blood cultures X2, CBC, basal metabolic profile
Yes
No
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UA, Urine C&S
Yes
No
If concerned about SIADH: serum Lytes every 8
hrs, urine Lytes with Osm every day, urine SG
every shift
Yes
No
Consult
Consult
Signature
Name
Date and Time
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AAFP: Community Acquired Pneumonia
Admission Order
AAFP: Community Acquired Pneumonia Admission Order,
Standardized Admission Orders, Author: Robert M. Wiprud,
MD The primary purpose of these Ordersets is to decrease
unnecessary variability and to improve quality through
standardized Admission Orders. Developed by the Scott &
White Clinic at College Station, Texas. Copyright © 2006
American Academy of Family Physicians. Physicians may
photocopy or adapt for use in their own practices; all other
rights reserved. Wiprud RM. Providing consistent care with
standardized admission orders. Fam Pract Manag.
September 2006: 49-52 See
http://www.aafp.org/fpm/2006/0900/p49.html This ODM
Form includes the eighth section ("Community Acquired
Pneumonia Admission Order").
All rights reserved. Please visit https://medical-data-
models.org/forms/16002
AAFP: Community Acquired
Pneumonia Admission Order
Default Itemgroup
Name
Age
Date of Birth
Medical Record
Status
Status
Medical floor (1)
ICU (2)
Attending
Name of attending physician
Phone number of attending physician
Admitting Diagnosis
Pneumonia Associated Diagnoses
Condition
Condition
Stable (1)
Fair (2)
Serious (3)
Critical (4)
Allergies
1 / 4
Allergies
Diet
Diet
Regular as tolerated (1)
Activity
Activity
Bed rest with bathroom privileges with
assistance (1)
Nursing
Vital signs: every 4 hrs
Yes
No
ABG if Pulse ox < 90% or severe respiratory
distress
Yes
No
Notify MD for BP < 90/60 or > 180/120; HR < 60
or > 120; T > 102.5; RR < 12 or > 28
Yes
No
Spot pulse ox on room air upon arrival
Yes
No
Respiratory distress or decreased LOC
Yes
No
IV
Dextrose 5% in 1/2 normal saline with 20 mEq
KCL @___mL/hr
Yes
No
IV lock; flush per routine
Yes
No
If KCL, please specify amount
mL/hr
Medications
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O2 @ 2,4,6 L/min via: NC, OR or FM
Yes
No
Ceftriaxone (Rocephin) 1 GM IVPB STAT after
culture, PLUS (next Item)
Yes
No
Zithromycin or Levaquin
Zithromycin 500mg IV or PO daily OR (1)
Levaquin 500 mg IV or PO daily (2)
Tylenol 650 mg PO every 4-6 hrs prn pain/fever
Yes
No
MOM 30 mL PO every 12 hrs prn constipation
Yes
No
Ambien 10 mg PO @ bedtime prn insomnia
Yes
No
Other meds
Yes
No
If O2 please specify via
NC (1)
OR (2)
FM (3)
If Other meds, please specify
Lab
CBC, basal metabolic profile
Yes
No
Blood cultures x2 STAT prior to antibiotics
Yes
No
Sputum for gram stain, C&S and consider AFB
Yes
No
Chest X-ray
Chest X-ray
PA & Lat if not done previously (1)
Patient Education
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Smoking cessation counseling
Yes
No
Immunizations
Immunizations: Influenza Vaccine (September-
March)
Administer influenza vaccine 0.5 mL on
day of discharge (1)
Patient has been immunized this flu
season (2)
Immunization not indicated due to__ (3)
If Immunization not indicated, please specify
reason
Immunizations: Pneumococcal vaccine (year
around)
Administer pneumococcal vaccine 0.5
mL on day of discharge (1)
Patient previously immunized after age
65 years (2)
Patient previously immunized before age
65, but < 5 years ago (3)
Immunization not indicated due to___ (4)
If Immunization not indicated, please specify
reason
Signature
Name
Date and Time
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AAFP: Croup Admission Order
AAFP: Croup Admission Order, Standardizes Admission
Orders, Author: Robert M. Wiprud, MD The primary
purpose of these Ordersets is to decrease unnecessary
variability and to improve quality through standardized
Admission Orders. Developed by the Scott & White Clinic at
College Station, Texas. Copyright © 2006 American
Academy of Family Physicians. Physicians may photocopy
or adapt for use in their own practices; all other rights
reserved. Wiprud RM. Providing consistent care with
standardized admission orders. Fam Pract Manag.
September 2006: 49-52 See
http://www.aafp.org/fpm/2006/0900/p49.html This ODM
Form includes the ninth section ("Croup Admission Order").
All rights reserved. Please visit https://medical-data-
models.org/forms/16003
AAFP: Croup Admission Order
Default Itemgroup
Name
Age
Date of Birth
Medical record
Status
Admission
Yes
No
Observation in pediatric unit
Yes
No
Attending
Name of attending physician
Phone number of attending physician
Admitting Diagnosis
Croup Associated Diagnoses
Condition
Condition
Stable (1)
Fair (2)
Serious (3)
Critical (4)
1 / 4
Allergies
Allergies
Diet
Clear liquids
Yes
No
Diet for age
Yes
No
Activity
Bed rest
Yes
No
Up ad lib
Yes
No
Nursing
Vital signs per unit routine
Yes
No
Vital signs every 4 hrs if on oxygen therapy
Yes
No
I&O every shift
Yes
No
Lab
CBC
Yes
No
Lytes
Yes
No
AP/Lateral Neck X-ray
AP/Lateral Neck X-ray
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Respiratory
If croup score > 5, notify MD
Yes
No
If score 2 or greater: continue oximetry; racemic
epinephrine (2.25%) nebulizer
Yes
No
0.25 mL in 3 mL normal saline if < 1 year old or
less than 20 kg
Yes
No
0.50 mL in 3 mL normal saline if > 1 year old
Yes
No
May repeat dose every 4 hrs; notify MD if child
need more frequent doses
Yes
No
O2 @ 2-4 L/min via nasal cannula or face mask
to keep O2 sat > 95%
Yes
No
Medications
Medications
Decadron __mg IM now (0.6mg/kg body
weight) OR (1)
Decadron elixir 0.5 mg/5mL___mg PO
now (0.6 mg/kg body weight) OR (2)
Prelone elixir 12mg/mL__mg PO BID for
__ days (1mg/kg/dose) (3)
Please specify amount of the chosen medication
If Prelone elixir, please specify duration in days
Medications
Tylenol ___mg PO or PR every 4 hrs prn;
temp > 100.4 (10-15 mg/kg/dose) OR (1)
Motrin__ mg PO every 6 hrs prn; temp >
100.4 (10 mg/kg/dose) (2)
If Tylenol, please specify amount
If Motrin, please specify amount
IV
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No IV required
Yes
No
Bolus with__mL normal saline over 1-2 hrs (10-
20 mL/kg bolus)
Yes
No
If Bolus with normal saline, please specify
amount
Maintenance IV with Dextrose 5% in 1/4 normal
saline @___mL/hr; add 20 mEq KCL after first
void
Yes
No
If Dextrose, please specify amount mL/hr
Other Orders
Other Orders
Signature
Print Name
Date and Time
4 / 4
AAFP: Croup Admission Order
Eligibility Breast Cancer NCT01831076
Preoperative Hormone Therapy for Postmenopausal
Women With ER+ Clinical Stage T2-4 Tumors; ODM
derived from: https://clinicaltrials.gov/show/NCT01831076
All rights reserved. Please visit https://medical-data-
models.org/forms/16004
Eligibility Breast Cancer
NCT01831076
Inclusion Criteria
histologically or cytologically confirmed breast
cancer*
Yes
No
er positive (+)*
Yes
No
primary tumor 2-4 regional lymph nodes 0-2 (t2-
4n0-2); patients may have metastatic disease,
provided local-regional surgery is clinically
indicated*
Yes
No
clinical stage ii/iii*
Yes
No
postmenopausal- defined as having had a
previous bilateral oophorectomy or, for women
with no prior hysterectomy, the absence of
spontaneous menstrual cycles for more than 1
year*
Yes
No
newly diagnosed*
Yes
No
patients with prior non-breast malignancies are
eligible if they have been disease free for >= 5
years before study entry; patients with squamous
or basal cell carcinoma of the skin that has been
effectively treated, carcinoma in situ of the cervix
that has been treated by surgery only, or lobular
carcinoma in situ (lcis) of the ipsilateral or
contralateral breast that has been treated by
surgery only are eligible, even if the cancer was
diagnosed within 5 years before randomization*
Yes
No
serum creatinine =< 1.5 x institutional upper limit
of normal (uln)*
Yes
No
hemoglobin within normal limits for institution*
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Yes
No
absolute granulocyte count >= 1500*
Yes
No
platelet count >= 100,000*
Yes
No
serum glutamic oxaloacetic transaminase (sgot),
aspartate aminotransferase (ast) or serum
glutamate pyruvate transaminase (sgpt), alanine
aminotransferase (alt) =< 2.5 x uln*
Yes
No
total bilirubin < 2 x uln for institution*
Yes
No
alkaline phosphatase < 2 x the uln*
Yes
No
Exclusion Criteria
completely resected*
Yes
No
prior hormone or chemotherapy*
Yes
No
unable to take oral medication*
Yes
No
patients who have nonmalignant systemic
disease (cardiovascular, renal, hepatic, etc.) that
would preclude their being subjected to protocol
therapy*
Yes
No
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Eligibility Breast Neoplasms NCT00188669
The Use of Pentoxifylline and Vitamin E in the Treatment of
Chronic Breast Pain; ODM derived from:
https://clinicaltrials.gov/show/NCT00188669
All rights reserved. Please visit https://medical-data-
models.org/forms/16005
Eligibility Breast Neoplasms
NCT00188669
Inclusion Criteria
uicc tnm stage 0 (i.e. in situ disease), 1 or 2
breast cancer patients treated with conservative
surgery and adjuvant radiotherapy with chronic
breast pain or tenderness, with or without
fibrosis, within 3 months to 3 years following
completion of radiotherapy*
Yes
No
age 18 to 75 years of age*
Yes
No
chronic symptoms localised to the breast treated
with radiation, i.e. any one or more of the
following- pain (not attributable to infection) or
tenderness with or without associated oedema,
fibrosis, necrosis or ulceration.*
Yes
No
breast pain (maximum in the previous 24 hours)
measurable on a linear analogue scale with a
length of 3cm or greater*
Yes
No
prior treatment with radiation to the affected area
i.e. in tangential breast fields or boost area*
Yes
No
radiation completed at least 3 months and no
longer than 3 years prior to study entry*
Yes
No
informed consent*
Yes
No
Exclusion Criteria
active cellulitis in the breast*
Yes
No
active malignant disease*
Yes
No
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any medical illness or condition judged likely by
the local investigator to preclude safe
administration of protocol treatment*
Yes
No
contraindication to treatment with pentoxifylline
(i.e. previously exhibited intolerance to
pentoxifylline or other xanthines such as caffeine,
theophylline or theobromine; recent cerebral
and/or retinal haemorrhage; ischaemic heart
disease; hypotension*
Yes
No
pregnant or lactating women*
Yes
No
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Eligibility Breast Cancer NCT00029224
Treatment With Zoledronic Acid in Patients With Breast
Cancer, Multiple Myeloma, and Prostate Cancer With
Cancer Related Bone Lesions; ODM derived from:
https://clinicaltrials.gov/show/NCT00029224
All rights reserved. Please visit https://medical-data-
models.org/forms/16006
Eligibility Breast Cancer
NCT00029224
Inclusion Criteria
signed informed consent*
Yes
No
greater than 18 years of age*
Yes
No
proof of breast cancer, multiple myeloma or
prostate cancer*
Yes
No
diagnosis of at least one cancer-related bone
lesion*
Yes
No
if patient is of child-bearing potential, negative
pregnancy test and on a medically recognized
form of contraception*
Yes
No
ecog performance status of 0,1 or 2*
Yes
No
ability to read, understand and write english or
spanish language*
Yes
No
normal renal function*
Yes
No
corrected serum calcium equal to or greater than
8mg/dl exclusion criteria*
Yes
No
clinically symptomatic brain metastases*
Yes
No
hypersensitivity to zometa or other
bisphosphonates*
Yes
No
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pregnant or lactating*
Yes
No
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Eligibility Breast Cancer NCT00050141
Study of Letrozole Plus Tipifarnib or Placebo in the
Treatment of Advanced Breast Cancer; ODM derived from:
https://clinicaltrials.gov/show/NCT00050141
All rights reserved. Please visit https://medical-data-
models.org/forms/16007
Eligibility Breast Cancer
NCT00050141
Inclusion Criteria
locally advanced, inoperable loco-regionally-
recurrent, or metastatic breast cancer*
Yes
No
estrogen and/or progesterone positive disease*
Yes
No
progression of disease after antiestrogen
therapy*
Yes
No
measurable disease*
Yes
No
postmenopausal*
Yes
No
eastern cooperative oncology group (ecog)
performance status 0, 1, or 2.*
Yes
No
Exclusion Criteria
previous endocrine therapy, other than
antiestrogen therapy*
Yes
No
more than 1 prior chemotherapy regimen*
Yes
No
previous therapy with farnesyl transferase
inhibitor*
Yes
No
presence of rapidly progressive, life-threatening
metastases*
Yes
No
concomitant anticancer treatment*
Yes
No
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other malignancy within the past 5 years*
Yes
No
symptomatic peripheral neuropathy.*
Yes
No
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AAFP: CVA Admission Order
AAFP: CVA Admission Order, Standardizes Admission
Orders, Author: Robert M. Wiprud, MD The primary
purpose of these Ordersets is to decrease unnecessary
variability and to improve quality through standardized
Admission Orders. Developed by the Scott & White Clinic at
College Station, Texas. Copyright © 2006 American
Academy of Family Physicians. Physicians may photocopy
or adapt for use in their own practices; all other rights
reserved. Wiprud RM. Providing consistent care with
standardized admission orders. Fam Pract Manag.
September 2006: 49-52 See
http://www.aafp.org/fpm/2006/0900/p49.html This ODM
Form includes the tenth section ("CVA Admission Order").
All rights reserved. Please visit https://medical-data-
models.org/forms/16008
AAFP: CVA Admission Order
Default Itemgroup
Name
Age
Date of Birth
Medical record
Status
Status
Observation (1)
Admission (2)
Medical floor (3)
Monitored bed (4)
Other (5)
Attending
Name of attending physician
Phone number of attending physician
Admitting Diagnosis
CVA Associated Diagnoses
Condition
Condition
Stable (1)
Fair (2)
Serious (3)
Critical (4)
1 / 4
Code Status
full status (1)
DNR (2)
Diet
NPO
Yes
No
Clear liquid
Yes
No
AHA step 2
Yes
No
ADA___calories
Yes
No
If diet according to ADA, please specify amount
of calories
Other
Yes
No
If Other, please specify
Activity
Activity
Bed rest (1)
Bed rest with bedside commode (2)
Bathroom privileges with assistance (3)
Nursing
Vital signs with neuro checks every 4hrs for 24
hrs then per routine
Yes
No
Notify MD for: BP systolic < 90 or > 180 or > 105
diastolic; P < 60 or > 120; declining mental status
or worsening of neurological symptoms
Yes
No
Weigth on arrival
Yes
No
I&O every shift
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Yes
No
O2 @ 2,4,6 L/min via NC or FM
Yes
No
Check pulse ox on arrival and pen to maintain O2
sat > 92%
Yes
No
Medications
ASA 81 mg PO daily
Yes
No
Folate 1 mg PO daily
Yes
No
IV
Dextrose 5% in 1/2 normal saline with 20 mEq
KCl/L at 80 mL/hr
Yes
No
Hep lock
Yes
No
Other
Yes
No
If other, please specify
Lab
Admission: CBC, PT/INR, comp med profile,
cardiac profile
Yes
No
a.m.: lipid profile, TSH
Yes
No
Diagnostic Studies
CT Head without contrast (if not done in ER)
Yes
No
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ECG (if not done in ER)
Yes
No
Portable CXR (if not done in ER)
Yes
No
Echocardiogram - to be read by__
Yes
No
If Echocardiogram, please specify: to be read
by___
Diagnostic Studies
Yes
No
If Other, please specify
If Other, please specify
Consult
PT evaluation
Yes
No
OT evaluation
Yes
No
Speech/swallow evaluation
Yes
No
Signature
Print Name
Date and Time
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Eligibility Breast Cancer NCT00153907
Navelbine and Capecitabine in the Treatment of Metastatic
Breast Cancer; ODM derived from:
https://clinicaltrials.gov/show/NCT00153907
All rights reserved. Please visit https://medical-data-
models.org/forms/16009
Eligibility Breast Cancer
NCT00153907
Inclusion Criteria
histologically confirmed breast cancer with
evidence of locally advanced or metastatic
disease*
Yes
No
female patients age 18 or older*
Yes
No
no more than three prior chemotherapeutic
regimens in the metastatic setting*
Yes
No
anc > 1,500/mm3*
Yes
No
platelet count > 100,000/mm3*
Yes
No
sgot < 3 x uln*
Yes
No
bilirubin < 1.5 x uln*
Yes
No
performance status of 0 or 1*
Yes
No
at least 3 weeks since prior chemotherapy or 2
weeks since prior radiation, surgery or any
anticancer investigational agent*
Yes
No
able to swallow and retain oral medications*
Yes
No
measurable disease*
Yes
No
Exclusion Criteria
1 / 2
prior vinca alkaloids*
Yes
No
active gastrointestinal disease or disorder*
Yes
No
pregnant or lactating*
Yes
No
serious co-morbid medical or psychological
condition*
Yes
No
prior bone marrow or stem cell transplant*
Yes
No
prior documented severe sensitivity to 5-fu*
Yes
No
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Eligibility Breast Cancer NCT00191152
A Phase III Trial For Patients With Metastatic Breast
Cancer; ODM derived from:
https://clinicaltrials.gov/show/NCT00191152
All rights reserved. Please visit https://medical-data-
models.org/forms/16010
Eligibility Breast Cancer
NCT00191152
Inclusion Criteria
histologic or cytologic confirmation of breast
cancer with locally advanced and/or metastatic
disease*
Yes
No
patients may have received prior neo-adjuvant or
adjuvant taxane regimen as long as it has been
greater than or equal to 6 months since
completion of the regimen*
Yes
No
patients may have had 0-1, but no more than one
prior course of chemotherapy for metastatic
disease*
Yes
No
patients must have either measurable or non-
measurable (evaluable) disease*
Yes
No
prior radiation therapy allowed of less than 25%
of the bone marrow*
Yes
No
Exclusion Criteria
second primary malignancy (except in situ
carcinoma of the cervix or adequately treated
nonmelanomatous carcinoma of the skin or other
malignancy treated at least 5 years previously
with no evidence of recurrence)*
Yes
No
parenchymal or leptomeningeal brain
metastases*
Yes
No
peripheral neuropathy greater than or equal to
grade 2*
Yes
No
prior treatment with gemcitabine and
1 / 2
capecitabine will not be allowed. prior treatment
with a taxane in the metastatic setting will not be
allowed. prior taxane therapy in the neo-adjuvant
or adjuvant setting is allowed if completion of
therapy greater than or equal to 6 months prior to
enrollment.*
Yes
No
active cardiac disease not controlled by therapy
and/or myocardial infarction within the preceding
6 months.*
Yes
No
concomitant herceptin is not allowed*
Yes
No
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Eligibility Breast Cancer NCT00191243
Docetaxel vs. Docetaxel-Gemcitabine in Breast Cancer;
ODM derived from:
https://clinicaltrials.gov/show/NCT00191243
All rights reserved. Please visit https://medical-data-
models.org/forms/16011
Eligibility Breast Cancer
NCT00191243
Inclusion Criteria
histologically verified diagnosis of breast
carcinoma, at first diagnosis*
Yes
No
restricted previous adjuvant chemotherapy
(completed >6 months prior the study)*
Yes
No
measurable and/or non-measurable disease*
Yes
No
previous radiotherapy is allowed if:terminated at
least 10 days prior the  sudy therapy, at least one
target lesion for evaluation of tumor response has
not been irradiated*
Yes
No
performance status 0-2 (who, zubrod)*
Yes
No
adequate bone marrow reserve defined*
Yes
No
adequate liver / renal functions defined*
Yes
No
Exclusion Criteria
any prior systematic chemotherapy for metastatic
breast cancer*
Yes
No
expected survival time less than 12 weeks*
Yes
No
past or current history of malignant neoplasm
other than breast carcinoma*
Yes
No
except for cured non-melanoma skin cancer or
curatively treated in situ carcinoma of the cervix
1 / 2
uteri*
Yes
No
known brain metastases/leptomeningeal
involvement*
Yes
No
active uncontrolled infection*
Yes
No
symptomatic peripheral neuropathy > grade 2
according to nci*
Yes
No
patients whose lesions are assessable  only by
radionuclide scan or patients with sclerotic bone
lesions as the only site of disease*
Yes
No
concomitant illness that is contraindication to the
use of corticosteroids*
Yes
No
other concomitant serious illness or medical
condition, which may worsen due to the
treatment*
Yes
No
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Eligibility Breast Cancer NCT00193011
Weekly Docetaxel and CMF in the Adjuvant Treatment of
Elderly Women With High-Risk Breast Cancer; ODM
derived from: https://clinicaltrials.gov/show/NCT00193011
All rights reserved. Please visit https://medical-data-
models.org/forms/16012
Eligibility Breast Cancer
NCT00193011
Inclusion Criteria
to be included in this study, you must meet the
following criteria:*
Yes
No
female patients with adenocarcinoma of the
breast confirmed by biopsy*
Yes
No
age 65 or older*
Yes
No
under age 65 must have significant medical
illness, or general frailty*
Yes
No
adequate bone marrow, liver or kidney function*
Yes
No
normal heart function*
Yes
No
less than 84 days from mastectomy/lumpectomy
or axillary dissection*
Yes
No
signed consent obtained prior to initiation of any
study procedures*
Yes
No
Exclusion Criteria
you cannot participate in this study if any of the
following apply to you:*
Yes
No
received neo-adjuvant therapy*
Yes
No
primary tumor is locally advanced at diagnosis*
Yes
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No
received prior chemotherapy within five years*
Yes
No
received previous radiation therapy within 5
years*
Yes
No
peripheral neuropathy*
Yes
No
please note:  there are additional
inclusion/exclusion criteria.  the study center will
determine if you meet all of the criteria.  if you do
not qualify for the trial, study personnel will
explain the reasons.  if you do qualify, study
personnel will explain the trial in detail and
answer any questions you may have.*
Yes
No
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Eligibility Breast Cancer NCT00201929
A Decision Aid for Women With Early Stage Breast Cancer;
ODM derived from:
https://clinicaltrials.gov/show/NCT00201929
All rights reserved. Please visit https://medical-data-
models.org/forms/16013
Eligibility Breast Cancer
NCT00201929
Inclusion Criteria
chemotherapy group:*
Yes
No
female*
Yes
No
histologically documented invasive carcinoma of
the breast treated with modified radical
mastectomy or lumpectomy*
Yes
No
axillary node dissection*
Yes
No
chemotherapy alone or in addition to tamoxifen
as an appropriate treatment option*
Yes
No
surgery group:*
Yes
No
female*
Yes
No
newly diagnosed carcinoma of the breast
diagnosed either by cytology or pathological
examination, or if no biopsy, a strong clinical
suspicion of malignancy*
Yes
No
clinical stage i or ii disease*
Yes
No
candidate for breast conserving surgery*
Yes
No
Exclusion Criteria
chemotherapy group:*
Yes
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No
candidate for cef chemotherapy*
Yes
No
clinical evidence of metastatic disease*
Yes
No
serious comorbidity that would preclude receiving
chemotherapy treatment*
Yes
No
unable to speak or read english fluently (including
visual impairment)*
Yes
No
mentally incompetent including any psychiatric or
addictive disorders that would preclude shared
decision-making*
Yes
No
surgery group:*
Yes
No
previous surgery for breast cancer*
Yes
No
previous breast irradiation*
Yes
No
pregnant*
Yes
No
clinical suspicion of bilateral breast cancer*
Yes
No
serious comorbidity that would preclude definitive
surgery*
Yes
No
unable to speak or read english fluently (including
visual impairment)*
Yes
No
mentally incompetent including any psychiatric or
addictive disorder that would preclude shared
decision making*
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Yes
No
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Eligibility Breast Cancer NCT00026117
Shark Cartilage in Treating Patients With Advanced
Colorectal or Breast Cancer; ODM derived from:
https://clinicaltrials.gov/show/NCT00026117
All rights reserved. Please visit https://medical-data-
models.org/forms/16015
Eligibility Breast Cancer
NCT00026117
Criteria
breast or colorectal primary tumor sites*
Yes
No
considered incurable*
Yes
No
breast cancer patients must have disease
progression after at least 2 different
chemotherapy regimens (may include
chemotherapy given as an adjuvant treatment)*
Yes
No
18 and over
Yes
No
male or female
Yes
No
ECOG 0-2
Yes
No
more than 3 months
Yes
No
bilirubin no greater than 3 times upper limit of
normal (uln)
Yes
No
calcium less than 1.2 times uln
Yes
No
not pregnant or nursing*
Yes
No
fertile patients must use effective contraception*
Yes
No
prior concurrent therapy:*
Yes
No
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chemotherapy:*
Yes
No
concurrent chemotherapy allowed*
Yes
No
no concurrent participation in a cytotoxic
chemotherapy clinical trial*
Yes
No
at least 60 days since prior shark cartilage*
Yes
No
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Eligibility Breast Cancer NCT00008346
Screening and Diagnostic Trial to Compare the
Effectiveness of Two Types of Mammography in Detecting
Breast Cancer in Women; ODM derived from:
https://clinicaltrials.gov/show/NCT00008346
All rights reserved. Please visit https://medical-data-
models.org/forms/16016
Eligibility Breast Cancer
NCT00008346
Criteria
asymptomatic women presenting for screening
mammography*
Yes
No
no focal dominant lump or bloody or clear nipple
discharge*
Yes
No
no prior breast cancer treated with lumpectomy*
Yes
No
prior mastectomy for breast cancer allowed*
Yes
No
no breast implants*
Yes
No
hormone receptor status:*
Yes
No
any age*
Yes
No
female*
Yes
No
menopausal status:*
Yes
No
performance status:*
Yes
No
life expectancy:*
Yes
No
hematopoietic:*
Yes
No
hepatic:*
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Yes
No
renal:*
Yes
No
other:*
Yes
No
not pregnant*
Yes
No
prior concurrent therapy:*
Yes
No
biologic therapy:*
Yes
No
chemotherapy:*
Yes
No
endocrine therapy:*
Yes
No
radiotherapy:*
Yes
No
surgery:*
Yes
No
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Basic Subject Data & Eligibility Topical SB-275833 Ointment
1% For The Treatment Of Impetigo NCT00133874
Documentation part: Basic Subject Data & Eligibility
A Randomised, Observer-blind, Multicentre, Non-inferiority,
Comparative, Phase III Study of the Safety and Efficacy of
Topical 1% SB-275833 Ointment, Applied Twice Daily for 5
Days, versus Topical 2% Sodium Fusidate Ointment
Applied Three Times Daily for 7 Days in the Treatment of
Adult and Paediatric Subjects with Impetigo.
ClinicalTrials.gov  Identifier: NCT00133874
Other Study ID Numbers: TOC100224
Responsible Party: GlaxoSmithKline
All rights reserved. Please visit https://medical-data-
models.org/forms/16017
Basic Subject Data & Eligibility
Topical SB-275833 Ointment 1% For
The Treatment Of Impetigo
NCT00133874
Inform Screening (SCREEN)
Subject Initials
Date of birth
DDMONYYYY
Inform enrolment (ENROL)
Subject number
Date of visit
Date of visit
DDMONYYYY
SDV Performed at this visit
Yes (Y)
Subject Identification
This item will be mapped from the InForm
enrollment form so that the number can be
changed if needed
Subject number
Eligibility Question
Did the subject meet all the entry criteria?
Yes
No
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Subject demography & Vital Signs Topical SB-275833
Ointment 1% For The Treatment Of Impetigo NCT00133874
Documentation part: Subject demography & Vital Signs
A Randomised, Observer-blind, Multicentre, Non-inferiority,
Comparative, Phase III Study of the Safety and Efficacy of
Topical 1% SB-275833 Ointment, Applied Twice Daily for 5
Days, versus Topical 2% Sodium Fusidate Ointment
Applied Three Times Daily for 7 Days in the Treatment of
Adult and Paediatric Subjects with Impetigo.
ClinicalTrials.gov  Identifier: NCT00133874
Other Study ID Numbers: TOC100224
Responsible Party: GlaxoSmithKline
All rights reserved. Please visit https://medical-data-
models.org/forms/16018
Subject demography & Vital Signs
Topical SB-275833 Ointment 1% For
The Treatment Of Impetigo
NCT00133874
Demography (DEMOG)
Date of birth
DDMONYYYY
Sex
Female (F)
Male (M)
If "Female", record child-bearing potential
Pre-menarcheal (1)
Post-menopausal (2)
Sterile (of child-bearing age) (3)
Potentially able to bear children (4)
Ethnicity
Hispanic or Latino (1)
Not Hispanic or Latino (2)
Race
African American/African Heritage (11)
American Indian or Alaskan Native (12)
Asian - Central/South Asian Heritage
(13)
Asian - East Asian Heritage (14)
Asian - Japanese Heritage (15)
Asian - South East Asian Heritage (16)
Native Hawaiian or Other Pacific Islander
(17)
White - Arabic/North African Heritage
(18)
White - White/Caucasian/European
Heritage (19)
Vital Signs (vS)
Height
>= 0
cm
Body weight
>= 0
kg
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Systolic blood pressure
>= 0
mmHg
Diastolic blood pressure
>= 0
mmHg
Heart rate
bpm
Body Temperature
°C
Location of temperature
Oral (1)
Rectal (2)
Axilla (3)
Tympanic (4)
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The Treatment Of Impetigo NCT00133874
Eligibility Bradycardia NCT01912326
Prevention of Atrial Fibrillation by Optimized Overdrive
Stimulation; ODM derived from:
https://clinicaltrials.gov/show/NCT01912326
All rights reserved. Please visit https://medical-data-
models.org/forms/16019
Eligibility Bradycardia NCT01912326
Inclusion Criteria
indication for dual chamber pacemaker*
Yes
No
documented paroxysmal or persistent atrial
fibrillation*
Yes
No
p-wave >1.0 mv in sinus rhythm or sufficient
detection of afib*
Yes
No
stable antyarrhythmic therapy*
Yes
No
age >= 19 years*
Yes
No
written informed consent*
Yes
No
implantation of a identity dr 5370/5376 or later*
Yes
No
bipolar atrial lead*
Yes
No
Exclusion Criteria
permanent afib*
Yes
No
reversible etiology of afib*
Yes
No
hyha ii or iv*
Yes
No
coronary artery disease with stable angina
pectoris*
Yes
No
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implanted icd or planned implantation of a icd*
Yes
No
cardiac surgery within the last 6 months or
planned within 12 months*
Yes
No
life expectancy < 12 months*
Yes
No
pregnancy*
Yes
No
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Eligibility Chronic Hepatitis C
NCT00028275
Gamma Interferon Therapy for Chronic Hepatitis C; ODM
derived from: https://clinicaltrials.gov/show/NCT00028275
All rights reserved. Please visit https://medical-data-
models.org/forms/16020
Eligibility Chronic Hepatitis C
NCT00028275
Inclusion Criteria
age 18 years or above, male or female.*
Yes
No
serum alanine or asparate aminotransferase
activities that are above the upper limit of normal
(alt greater than 41 or ast greater than 31 iu/l).*
Yes
No
presence of anti-hcv in serum.*
Yes
No
presence of hcv rna genotype1 in serum at levels
above 10,000 copies/ml.*
Yes
No
previous adequate therapy with alpha interferon
and ribavirin without a sustained virological
response.  an adequate course of therapy is
defined as at least 24 weeks of alpha interferon in
starting doses of 3 million units thrice weekly and
ribavirin in starting doses of at least 1000 mg
daily.  patients who initiated therapy at these
doses, but required dose modification due to side
effects will also be eligible.*
Yes
No
written informed consent.*
Yes
No
Exclusion Criteria
decompensated liver disease, as marked by
bilirubin greater than 4 mg%, albumin less than
3.0 gm%, prothrombin time greater than 2 sec
prolonged, or history of bleeding esophageal
varices, ascites or hepatic encephalopathy.
patients with alt levels greater than 1000 u/l
(greater than 25 times uln) will not be enrolled but
may be followed until three determinations are
below this level.*
Yes
No
pregnancy, or in women of child-bearing potential
or in spouses of such women, inability to practice
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adequate contraception, defined as vasectomy in
men, tubal ligation in women, or use of condoms
and spermacide, or birth control pills, or an
intrauterine device.*
Yes
No
significant systemic or major illnesses other than
liver disease, including congestive heart failure,
ischemic heart disease, angina pectoris,
cerebrovascular disease, renal failure (creatinine
clearance less than 50 ml/min), organ
transplantation, serious psychiatric disease or
depression.*
Yes
No
pre-existing, severe bone marrow compromise;
anemia (hematocrit less than 34%), neutropenia
(less than 1000 polymorphonuclear cells/mm(3))
or thrombocytopenia (less than 70,000
cells/mm(3)).*
Yes
No
evidence of another form of liver disease in
addition to viral hepatitis (for example
autoimmune liver disease, wilson's disease,
alcoholic liver disease, hemochromatosis, alpha-
1-antitrypsin deficiency).*
Yes
No
active substance abuse, such as alcohol, inhaled
or injection drugs within the previous six months.*
Yes
No
serious autoimmune disease that, in the opinion
of the investigators, might be worsened by
interferon therapy, such as lupus erythematous,
rheumatoid arthritis or crohn's disease.*
Yes
No
evidence of hepatocellular carcinoma; either
alphafetoprotein (afp) levels greater than 50
ng/ml  (normal less than 9 ng/ml) and/or
ultrasound (or other imaging study)
demonstrating a mass suggestive of liver cancer.*
Yes
No
human immunodeficiency virus infection, as
shown by presence of anti-hiv.*
Yes
No
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Eligibility Chronic Lymphocytic Leukemia
NCT00201682
Etanercept and Rituximab in Patients With Chronic
Lymphocytic Leukemia and Small Lymphocytic Lymphoma;
ODM derived from:
https://clinicaltrials.gov/show/NCT00201682
All rights reserved. Please visit https://medical-data-
models.org/forms/16022
Eligibility Chronic Lymphocytic
Leukemia NCT00201682
Inclusion Criteria
must have been previously treated cll/sll*
Yes
No
must have cd20 expression*
Yes
No
ecog ps =<3*
Yes
No
no prior campath-1h*
Yes
No
no active infection requiring antibiotics*
Yes
No
no concurrent immunosuppressive therapy*
Yes
No
no prior history demyelinating neurologic
disease*
Yes
No
no active viral hepatitis*
Yes
No
Exclusion Criteria
no pregnant or breastfeeding women*
Yes
No
ecog ps =4*
Yes
No
life expectancy of >12 weeks*
Yes
No
patients with bilirubin or creatinine>3.0 mg/dl*
Yes
No
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Eligibility Colorectal Cancer NCT00212589
Patients Preference for Oral or i.v. Therapy; ODM derived
from: https://clinicaltrials.gov/show/NCT00212589
All rights reserved. Please visit https://medical-data-
models.org/forms/16023
Eligibility Colorectal Cancer
NCT00212589
Inclusion Criteria
indication for treatment with a fu-regime*
Yes
No
who performance status 0-1*
Yes
No
life expectancy > 3 months*
Yes
No
adequate haematological, renal and hepatic
functions*
Yes
No
adequate contraceptives*
Yes
No
written informed consent*
Yes
No
Exclusion Criteria
known cns-metastases*
Yes
No
prior treatment with chemotherapy*
Yes
No
pregnant or breast feeding women*
Yes
No
current infection, unresolved bowel obstruction or
subobstruction, uncontrolled crohn's disease or
ulcerative colitis*
Yes
No
other serious illness or medical conditions*
Yes
No
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Eligibility Colorectal Neoplasms
NCT00034034
Acupuncture to Reduce Symptoms of Advanced Colorectal
Cancer; ODM derived from:
https://clinicaltrials.gov/show/NCT00034034
All rights reserved. Please visit https://medical-data-
models.org/forms/16024
Eligibility Colorectal Neoplasms
NCT00034034
Inclusion Criteria
advanced colon cancer that has not responded to
two rounds of chemotherapy*
Yes
No
speak, read, write english*
Yes
No
live within a 50 mile radius of pittsburgh, pa*
Yes
No
not taking any steroid medication*
Yes
No
a platelet count of 75,000 or greater*
Yes
No
never had acupuncture before*
Yes
No
Exclusion Criteria
allergy to stainless steal*
Yes
No
implanted pacemaker*
Yes
No
current skin infection*
Yes
No
needle phobia*
Yes
No
metastatic disease to the central nervous system
(brain, spinal cord)*
Yes
No
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Palliative and Hospice Care Paliative and
Hospice Care Prognosis
https://www.hope-clara.de/ The HOPE Hospice and
Palliative Care Recording standard documentation is used
for documentation of palliative care and as an instrument
for quality assurance in pallatiave wards, hospices and
oncological wards as well as in ambulatory services and
palliative teams.
All rights reserved. Please visit https://medical-data-
models.org/forms/16025
Palliative and Hospice Care
Prognosis
Administrative Data
Basis documentation No.
1. IDNR
13. Date
PR1. Palliative Prognostic Score (PAP-S)
Dyspnea
Yes
No
Score
Anorexia
Yes
No
Score
PR2. Karnofsky Performance Status
No complaints; no evidence of disease - 100%
Able to carry on normal activity; minor signs or
symptoms of disease - 90%
Normal activity with effort; some signs or
symptoms of disease - 80%
Cares for self; unable to carry on normal activity
or to do active work - 70%
Requires occasional assistance but is able to
care for most personal needs - 60%
Requires considerable assistance and frequent
medical care - 50%
Disabled; requires special care and assistance -
40%
Severely disabled; hospital admission indicated
although death not imminent - 30%
0 (1)
Very sick; hospital admission necessary; active
supportive treatment necessary - 20%
Moribund; fatal processes progressing rapidly -
10%
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Dead - 0%
2.5 (1)
Score
PR3. Clinical prognosis of survival
Clinical prognosis of survival
CodelistItem 863938 (>12 Wochen)
CodelistItem 863944 (1-2 Wochen)
CodelistItem 863939 (11-12 Wochen)
CodelistItem 863943 (3-4 Wochen)
CodelistItem 863942 (5-6 Wochen)
CodelistItem 863941 (7-8 Wochen)
CodelistItem 863940 (9-10 Wochen)
Score
PR4. Hemogram
Leucocytes
>11000 (>11000)
4800-8500 (4800-8500)
8500-11000 (8500-11000)
Score
Lymphocytes
<11,9% (<11,9%)
12-19,9% (12-19,9%)
20-40%  (20-40% )
Score
PaP Score (maximal 17.5 Points)
PaP Score
PR5. Palliative Performance Scale
PPS 60%-100% 
Score 0
Yes
No
PPS 30%-50% 
Score 2,5
Yes
No
PPS 10%-20% 
Score 4
Yes
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No
PPS 0%
Yes
No
Life expectancy of 6 months 10%
in case of < 50% PPS
Yes
No
Total Score PPS
PR6. Oral Intake
Oral intake: Normal
Score: 0
Yes
No
Oral intake: Sligthly reduced (> entire mouth)
Score: 1
Yes
No
Oral intake: Clearly reduced (<= entire mouth)
Score: 2,5
Yes
No
Total Score:
PR7. Symptoms
Edema
Yes
No
Shortness of breath at rest
Yes
No
Delir
Yes
No
Palliative Prognostic Index
Palliative Prognostic Index (maximal 15 Points)
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Medical conditions & Lab Topical SB-275833 Ointment
1% For The Treatment Of Impetigo NCT00133874
Documentation part: Medical conditions & Lab
A Randomised, Observer-blind, Multicentre, Non-inferiority,
Comparative, Phase III Study of the Safety and Efficacy of
Topical 1% SB-275833 Ointment, Applied Twice Daily for 5
Days, versus Topical 2% Sodium Fusidate Ointment
Applied Three Times Daily for 7 Days in the Treatment of
Adult and Paediatric Subjects with Impetigo.
ClinicalTrials.gov  Identifier: NCT00133874
Other Study ID Numbers: TOC100224
Responsible Party: GlaxoSmithKline
All rights reserved. Please visit https://medical-data-
models.org/forms/16026
Medical conditions & Lab Topical SB-
275833 Ointment 1% For The
Treatment Of Impetigo
NCT00133874
Medical Conditions (MEDHX)
Blood and lymphatic system disorders
Current (1)
Past (2)
No Medical Condition (3)
Cardiac disorders
Current (1)
Past (2)
No Medical Condition (3)
Ear and labyrinth disorders
Current (1)
Past (2)
No Medical Condition (3)
Endocrine disorders
Current (1)
Past (2)
No Medical Condition (3)
Eye disorders
Current (1)
Past (2)
No Medical Condition (3)
Gastrointestinal disorders
Current (1)
Past (2)
No Medical Condition (3)
Hepatobiliary disorders
Current (1)
Past (2)
No Medical Condition (3)
Immune system disorders
Current (1)
Past (2)
No Medical Condition (3)
Metabolism and nutrition disorders
Current (1)
Past (2)
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No Medical Condition (3)
Musculoskeletal and connective tissue disorders
Current (1)
Past (2)
No Medical Condition (3)
Neoplasms benign, malignant and unspecified
(including cysts and polyps)
Current (1)
Past (2)
No Medical Condition (3)
Nervous system disorders
Current (1)
Past (2)
No Medical Condition (3)
Psychiatric disorders
Current (1)
Past (2)
No Medical Condition (3)
Renal and urinary disorders
Current (1)
Past (2)
No Medical Condition (3)
Reproductive system and breast disorders
Current (1)
Past (2)
No Medical Condition (3)
Respiratory, thoracic and mediastinal disorders
Current (1)
Past (2)
No Medical Condition (3)
Skin and subcutaneous tissue disorders
Current (1)
Past (2)
No Medical Condition (3)
Vascular disorders
Current (1)
Past (2)
No Medical Condition (3)
Infections and infestations
Current (1)
Past (2)
No Medical Condition (3)
Congenital, familial and genetic disorders
Current (1)
Past (2)
No Medical Condition (3)
General disorders and administration site
conditions
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Current (1)
Past (2)
No Medical Condition (3)
Injury, poisoning and procedural complications
Current (1)
Past (2)
No Medical Condition (3)
Investigations
Current (1)
Past (2)
No Medical Condition (3)
Electronically transferred Lab Data
Date sample taken
DDMONYYYY
Not done
Yes
No
Haem Lab type code
Chem Lab type code
Urin Lab type code
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NINDS CDE Behavioral History Multiple
Sclerosis
NINDS Common Data Elements, Multiple Sclerosis
Behavioral History
Used from the National Institute of Neurological Disorders
and Stroke Common Data Elements
(https://www.commondataelements.ninds.nih.gov/)
References:
Grinnon ST, Miller K, Marler JR, Lu Y, Stout A, Odenkirchen
J, Kunitz S. National Institute of Neurological Disorders and
Stroke Common Data Element Project - approach and
methods. Clin Trials. 2012;9(3):322-9.
All rights reserved. Please visit https://medical-data-
models.org/forms/16027
Behavioral History
General Information
Study ID
Study site name
Subject ID
Date behavioral history taken
Smoking History
1)	Current tobacco use? (Regular use of
cigarettes, cigars, chewing tobacco or pipes
within past year)
yes (1)
no (2)
unknown (3)
2)	Past tobacco use? (Regular use of cigarettes,
cigars, chewing tobacco or pipes prior to the past
year)
yes (1)
no (2)
unknown (3)
3)	Age started tobacco use: (please specify) years
(Skip if Q1 and Q2 are both NO)
4)	Age stopped tobacco use: N/A – still using
tobacco (Skip if Q1 and Q2 are both NO)
years
5)	Type(s) of tobacco used: (Choose all that
apply)
Filtered cigarettes (Answer Q6) (1)
Non-filtered cigarettes (Answer Q6) (2)
Low tar cigarettes (Answer Q6) (3)
Cigars (4)
Pipes (5)
Chewing tobacco (6)
Other, specify (7)
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6)	Average number of cigarettes smoked per day:
(Skip if cigarettes is NOT an answer in Q5)
Less than one cigarette per day (1)
1 cigarette per day (2)
2 to 5 cigarettes per day (3)
6 to 15 cigarettes per day (about ½ pack)
(4)
16 to 25 cigarettes per day (about 1
pack) (5)
26 to 35 cigarettes per day (about 1 ½
packs) (6)
More than 35 cigarettes per day (about 2
packs or more) (7)
Unknown (8)
Alcohol History
1)	Current drinker? (Consumed at least one drink
within past year)
yes (1)
no (2)
unknown (3)
2)	Past drinker? (Consumed at least one drink
prior to the past year
yes (1)
no (2)
unknown (3)
3)	Age started drinking: (please specify) years
(Skip if Q1 and Q2 are both NO)
4)	Age quit drinking: (please specify) years N/A –
still drinking alcohol (Skip if Q1 and Q2 are both
NO)
5)	How often do you have a drink containing
alcohol?
Never (Skip to Q8) (1)
Monthly or less (2)
2 - 4 times/ month (3)
2 - 3 times/ week (4)
4 or more times/ week (5)
Unknown (6)
6) How many alcoholic drinks do you have on a
typical day when you are drinking?
1 or 2  (1)
3 or 4  (2)
5 or 6  (3)
7, 8, or 9  (4)
10 or more  (5)
Unknown (6)
7)	How often do you have six or more drinks on
one occasion?
Never  (1)
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Less than monthly  (2)
Monthly  (3)
Weekly  (4)
Daily or almost daily  (5)
Unknown (6)
8)	Have you ever been hospitalized for an alcohol-
related problem? (e.g., esophageal varices,
delirium tremens (DTs), cirrhosis, etc.)
yes (1)
no (2)
unknown (3)
Drug History
1)	Current drug user? (Use of any illicit drug within
the past year
yes (1)
no (2)
unknown (3)
2)	IF YES, specify illicit drug type(s) used:
(Choose all that apply)
Amphetamines (1)
Cocaine (2)
Inhalants (3)
Cannabis (marijuana) (4)
Hallucinogens (5)
Opioids (6)
Other, specify: (7)
If other, please specify
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Impetigo Diagnosis & Lesion measurement Topical SB-275833
Ointment 1% For The Treatment Of Impetigo NCT00133874
Documentation part: Impetigo Diagnosis & Lesion
measurement
A Randomised, Observer-blind, Multicentre, Non-inferiority,
Comparative, Phase III Study of the Safety and Efficacy of
Topical 1% SB-275833 Ointment, Applied Twice Daily for 5
Days, versus Topical 2% Sodium Fusidate Ointment
Applied Three Times Daily for 7 Days in the Treatment of
Adult and Paediatric Subjects with Impetigo.
ClinicalTrials.gov  Identifier: NCT00133874
Other Study ID Numbers: TOC100224
Responsible Party: GlaxoSmithKline
All rights reserved. Please visit https://medical-data-
models.org/forms/16028
Impetigo Diagnosis & Lesion
measurement Topical SB-275833
Ointment 1% For The Treatment Of
Impetigo NCT00133874
Clinical diagnosis of Primary Impetigo
Clinical diagnosis of primary impetigo
Bollous (B)
Non-bollous (NB)
Duration of Impetigo Lesions
Days
Primary Lesion Measurement and
Dressing Type (LESION)
Lesion site (front-site)
Face neck (1)
Feet (dorsal) (10)
Toes (11)
Anterior trunk (2)
Genitalia (3)
Arms (4)
Forearms (5)
Palms (6)
Thighs (7)
Knees (8)
Legs (9)
Lesion site (back-site)
Scalp neck (1)
Soles (10)
Fingers (11)
Back (2)
Buttocks (3)
Arms (4)
Elbow (5)
Forearms (6)
Hand (dorsal) (7)
Thighs (8)
Legs (9)
Left or right side
Right (1)
Left (2)
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Midline (3)
Lesion length
>= 0
mm
Lesion width
>= 0
mm
Lesion area
>= 0
cm^2
Lesion dressing type
None (N)
Occlusive (O)
Semi-occlusive (S)
Secondary Lesion Measurement and
Dressing Type (LESION2)
Lesion site (front-site)
Face neck (1)
Feet (dorsal) (10)
Toes (11)
Anterior trunk (2)
Genitalia (3)
Arms (4)
Forearms (5)
Palms (6)
Thighs (7)
Knees (8)
Legs (9)
Lesion site (back-site)
Scalp neck (1)
Soles (10)
Fingers (11)
Back (2)
Buttocks (3)
Arms (4)
Elbow (5)
Forearms (6)
Hand (dorsal) (7)
Thighs (8)
Legs (9)
Left or right side
Right (1)
Left (2)
Midline (3)
Lesion length
>= 0
mm
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Lesion width
>= 0
mm
Lesion area
>= 0
cm^2
Lesion dressing type
None (N)
Occlusive (O)
Semi-occlusive (S)
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NINDS CDE History Data Source and
Reliability Multiple Sclerosis
NINDS Common Data Elements, History Data Source and
Reliability 
Used from the National Institute of Neurological Disorders
and Stroke Common Data Elements
(https://www.commondataelements.ninds.nih.gov/)
References:
Grinnon ST, Miller K, Marler JR, Lu Y, Stout A, Odenkirchen
J, Kunitz S. National Institute of Neurological Disorders and
Stroke Common Data Element Project - approach and
methods. Clin Trials. 2012;9(3):322-9.
All rights reserved. Please visit https://medical-data-
models.org/forms/16029
History Data Source and Reliability
Medical history
Study ID
Study site name
Subject ID
1.  From whom/ what were the medical history
data obtained? (Choose all that apply.)
Participant/ subject (1)
Friend  (2)
Chart/ Medical record (3)
Physician  (4)
Family, specify relation (5)
Other, specify (6)
Specify
2.  If the medical history data were not obtained
from the participant/ subject, indicate the
reason(s) 
why: (Mention all that apply) Dementia/ Aphasia /
Not fluent in examiner's language / Other
cognitive impairment / Poor historian/ Other
(Specify)
3.  Overall assessment of the reliability of the
medical history data obtained:
Definitely reliable  (1)
Probably reliable (2)
Not reliable (3)
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SIRS & Nasal swab Topical SB-275833 Ointment
1% For The Treatment Of Impetigo NCT00133874
Documentation part: SIRS & Nasal swab
A Randomised, Observer-blind, Multicentre, Non-inferiority,
Comparative, Phase III Study of the Safety and Efficacy of
Topical 1% SB-275833 Ointment, Applied Twice Daily for 5
Days, versus Topical 2% Sodium Fusidate Ointment
Applied Three Times Daily for 7 Days in the Treatment of
Adult and Paediatric Subjects with Impetigo.
ClinicalTrials.gov  Identifier: NCT00133874
Other Study ID Numbers: TOC100224
Responsible Party: GlaxoSmithKline
All rights reserved. Please visit https://medical-data-
models.org/forms/16030
SIRS & Nasal swab Topical SB-
275833 Ointment 1% For The
Treatment Of Impetigo
NCT00133874
Skin Infection Rating Scale
Instructions for rating
Exsudate/Pus
0; Absent (0)
1 (1)
2; Mild (2)
3 (3)
4; Moderate (4)
5 (5)
6; Severe (6)
Crusting
0; Absent (0)
1 (1)
2; Mild (2)
3 (3)
4; Moderate (4)
5 (5)
6; Severe (6)
Erythema/Inflammation
0; Absent (0)
1 (1)
2; Mild (2)
3 (3)
4; Moderate (4)
5 (5)
6; Severe (6)
Tissue warmth
0; Absent (0)
1 (1)
2; Mild (2)
3 (3)
4; Moderate (4)
5 (5)
6; Severe (6)
Tissue oedema
0; Absent (0)
1 (1)
2; Mild (2)
1 / 4
3 (3)
4; Moderate (4)
5 (5)
6; Severe (6)
Itching
0; Absent (0)
1 (1)
2; Mild (2)
3 (3)
4; Moderate (4)
5 (5)
6; Severe (6)
Pain
0; Absent (0)
1 (1)
2; Mild (2)
3 (3)
4; Moderate (4)
5 (5)
6; Severe (6)
Total Score
Culture Results for Nasal Swab (NASAL)
Was there any growth after 2 days?
No (no growth) (N)
Yes (Y)
If "yes", please specify:
Normal flora (1)
Candida species, yeast or mould (2)
Pathogen isolated for culture (3)
Pathogen Isolation for Nasal Swab
(NASAL_P)
Isolate number
Quantitation: Colony count/growth estimate
1+ (10)
2+ (11)
3+ (12)
4+ (13)
Identification
Unidentified organsim (0000-00)
Mixed microbial flora (0012-00)
Acinetobacter species (0100-10)
Acinetobacter anitratus (0100-20)
Acinetobacter calcoaceticus (0100-30)
Acinetobacter lwoffi (0100-40)
Bacillus species (0310-10)
Moraxella catarrhalis (0400-20)
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Citrobacter species (0500-10)
Citrobacter diversus (0500-20)
Citrobacter freundii (0500-30)
Corynebacterium species (0520-10)
Enterobacter species (0700-10)
Enterobacter aerogenes (0700-20)
Enterobacter agglomerans (0700-30)
Enterobacter amnigenus (0700-35)
Enterobacter cloacae (0700-40)
Enterobacter gergoviae (0700-45)
Enterobacter skazakii (0700-60)
Enterococcus species (0800-10)
Enterococcus faecium (0800-35)
Enterococcus faecalis (0800-40)
Escherichia coli (0900-20)
Enterobacteriaceae (0995-50)
Gram negative non-Enterobacteriaceae
(0995-60)
Haemophilus species (1000-10)
Haemophilus influenzae (1000-30)
Haemophilus parainfluenzae (1000-40)
Klebsiella species (1100-10)
Klebsiella oxytoca (1100-20)
Klepsiella pneumoniae (1100-40)
Klebsiella pneumoniae I (1100-41)
Moraxella species (1250-10)
Morganella morganii (1300-20)
Neisseria species (1400-10)
Neisseria meningitidis (1400-30)
Non-fermenting gram negative bacilli
(1430-10)
Oxidase positive gram negative rod
(1442-10)
Pantoea species (1443-10)
Pasteurella species (1450-10)
Pasteurella haemolytica (1450-15)
Pasteurella multocida (1450-20)
Proteus species (1500-10)
Proteus mirabilis (1500-20)
Proteus penneri (1500-40)
Pseudomonas species (1700-10)
Pseudomonas aeruginosa (1700-20)
Pseudomonas alcaligenes (1700-22)
Pseudomonas fluorescens (1700-25)
Pseudomonas fluorescente/putida group
(1700-27)
Pseudomonas paucimobilis (1700-35)
Pseudomonas stutzeri (1700-50)
Pseudomonas vesicularis (1700-60)
Ralstonia pickettii (1725-10)
Serratia species (2000-10)
Serratia marcescens (2000-20)
Serratia odorifera (2000-35)
Staphylococcus aureus (2200-20)
Streptococcus species - non-haemolytic
(2300-05)
Streptococcus species (2300-10)
Streptococcus agalactiae (2300-20)
Streptococcus anginosis (2300-24)
Beta haemolytic streptococcus (2300-25)
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Beta haemolytic streptococcus - non-
groupable (2300-26)
Streptococcus constellatus (2300-32)
Streptococcus dysgalactiae (2300-35)
Streptococcus equi (2300-36)
Streptococcus dysgalactiae - equisimilis
(2300-37)
Streptococcus equisimilis (2300-38)
Gamma haemolytic streptococcus (2300-
44)
Beta haemolytic streptococcus group A
(2300-45)
Beta haemolytic streptococcus group B
(2300-50)
Beta haemolytic streptococcus group C
(2300-55)
Beta haemolytic streptococcus group D
(2300-56)
Beta haemolytic streptococcus group D
not Enterococcus (2300-57)
Beta haemolytic streptococcus group G
(2300-58)
Streptococcus intermedius (2300-59)
Beta haemolytic streptococcus group F
(2300-62)
Streptococcus pneumoniae (2300-70)
Streptococcus pyogenes (2300-80)
Streptococcus viridans (2300-90)
If "other", specify:
If pathogen(s) was recovered, were isolates sent
from the local laboratory to the Central
Laboratory (QUEST)?
No (N)
Yes (Y)
If "no", specify reason:
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Medical History
General Information
Study ID
Study site name
Subject ID
Date Medical History Taken
Does the participant/subject have a history of any
medical problems/conditions in the following body
systems?
No (leave rest of form blank) (1)
Yes (2)
Medical History Data Table
Body System
Medical History Term
Start Date
Ongoing?
Yes
No
End Date
Medical history
1.  Gestational age at birth:
weeks
2.  Birth weight:
kg
3.  Any stroke:
yes (mention year) (1)
1 / 7
no (2)
unknown (3)
Year diagnosed with stroke
4.  Transient ischemic attack (TIA):
yes (mention year) (1)
no (2)
unknown (3)
Year diagnosed with Transient ischemic attack
5.  Migraine(s):
yes (mention year) (1)
no (2)
unknown (3)
Year diagnosed with Migraine
6.  Epilepsy/ Seizure disorder:
yes (mention year) (1)
no (2)
unknown (3)
Year diagnosed with Epilepsy
7.  Central nervous system infection:
yes (mention year) (1)
no (2)
unknown (3)
Year diagnosed with Central nervous system
infection
8.  Dementia:
yes (mention year) (1)
no (2)
unknown (3)
Year diagnosed with Dementia
9.  Depressive disorder diagnosis:
yes (mention year) (1)
no (2)
unknown (3)
Year diagnosed with Depressive disorder
10. Anxiety disorder diagnosis:
yes (mention year) (1)
no (2)
unknown (3)
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Year diagnosed with Anxiety disorder
11. Bipolar disorder diagnosis:
yes (mention year) (1)
no (2)
unknown (3)
Year diagnosed with Bipolar disorder
12. Psychotic disorder:
yes (mention year) (1)
no (2)
unknown (3)
Year diagnosed with Psychotic disorder
Schizophrenia
Yes
No
Depression w/ psychotic features
Yes
No
Bipolar disorder
Yes
No
Dementia with psychotic ideation
Yes
No
Other Psychotic disorders, specify:
13. Cardiac arrhythmia:
yes (mention year) (1)
no (2)
unknown (3)
If YES, specify type:
Year diagnosed with Cardiac arrhythmia
14. Coronary artery disease:
yes (mention year) (1)
no (2)
unknown (3)
If YES, specify type:
Year diagnosed with Coronary artery disease
15. Valvular heart disease:
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yes (mention year) (1)
no (2)
unknown (3)
Year diagnosed with Valvular heart disease
16. Congestive heart failure:
yes (mention year) (1)
no (2)
unknown (3)
Year diagnosed with Congestive heart failure
17. Peripheral arterial disease:
yes (mention year) (1)
no (2)
unknown (3)
Year diagnosed with Peripheral arterial disease
18. Hypertension:
yes (mention year) (1)
no (2)
unknown (3)
Year diagnosed with Hypertension
19. Diabetes mellitus:
yes (mention year) (1)
no (2)
unknown (3)
If YES, specify type:
Type I (Juvenile Onset) (1)
Type II (adult onset or related to obesity)
(2)
Year diagnosed with Diabetes mellitus
20. High blood cholesterol /
Hypercholesterolemia:
yes (mention year) (1)
no (2)
unknown (3)
Year diagnosed with Hypercholesterolemia
21. Cancer:
yes (mention year) (1)
no (2)
unknown (3)
Year diagnosed with Cancer
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Brain cancer
Yes
No
Breast cancer
Yes
No
Colorectal cancer
Yes
No
Endometrial cancer
Yes
No
Esophagus cancer
Yes
No
Lung cancer
Yes
No
Prostate cancer
Yes
No
Renal cancer
Yes
No
Skin cancer
Yes
No
Hematologic cancer
Yes
No
Other, specify:
22. Connective tissue disease:
yes (mention year) (1)
no (2)
unknown (3)
Year diagnosed with Connective tissue disease
If YES, specify type:
23. Inflammatory bowel disease:
yes (mention year) (1)
no (2)
unknown (3)
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Year diagnosed with Inflammatory bowel disease
24. Thyroid disease (except cancer):
yes (mention year) (1)
no (2)
unknown (3)
Year diagnosed with Thyroid disease
If YES, specify type:
25. Glaucoma:
yes (mention year) (1)
no (2)
unknown (3)
Year diagnosed with Glaucoma
26. Cataracts:
yes (mention year) (1)
no (2)
unknown (3)
Year diagnosed with Cataracts
27. Macular edema:
yes (mention year) (1)
no (2)
unknown (3)
Year diagnosed with Macular edema
28. Sleep apnea:
yes (mention year) (1)
no (2)
unknown (3)
Year diagnosed with Sleep apnea
29. Renal (kidney) failure:
yes (mention year) (1)
no (2)
unknown (3)
Year diagnosed with Renal failure
30. Chronic liver failure:
yes (mention year) (1)
no (2)
unknown (3)
Year diagnosed with Chronic liver failure
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31. Irritable bowel syndrome:
yes (mention year) (1)
no (2)
unknown (3)
Year diagnosed with Irritable bowel syndrome
32. Fibromyalgia:
yes (mention year) (1)
no (2)
unknown (3)
Year diagnosed with Fibromyalgia
33. Arthritis:
yes (mention year) (1)
no (2)
unknown (3)
Year diagnosed with Arthritis
If YES, specify type:
34. ADHD:
yes (mention year) (1)
no (2)
unknown (3)
Year diagnosed with ADHD
If YES, specify type:
35. Autism Spectrum Disorder:
yes (mention year) (1)
no (2)
unknown (3)
If YES, specify type:
Year diagnosed with Autism Spectrum Disorder
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Pediatric Developmental History
Early Life Nutrition
Study ID
Study site name
Subject ID
Breast fed?
yes (1)
no (2)
unknown (3)
If Yes, indicate duration in months
Formula fed?
yes (1)
no (2)
unknown (3)
If Yes, indicate duration: months and formula
type:
Early Development
Did patient walk by 17 months old?
yes (1)
no (2)
unknown (3)
Did patient speak his/her first words by 12
months?
yes (1)
no (2)
unknown (3)
Did patient speak in two word combinations by 2
years?
yes (1)
no (2)
unknown (3)
Did patient speak in completed sentences by 3
years?
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yes (1)
no (2)
unknown (3)
Did patient have a cognitive/learning  ?
yes (1)
no (2)
unknown (3)
Did patient attend a day care group (with > 5
other children)?
yes (1)
no (2)
unknown (3)
Has participant/subject ever had a menstrual
period?
yes (1)
no (2)
unknown (3)
If so, youngest age the female participant/subject
had a menstrual period? years
Educational History
Type of educational services received:
Special education (1)
Regular education  (2)
Early intervention  (3)
None  (4)
Unknown (5)
Has the participant/subject ever repeated a grade
in school?
yes (1)
no (2)
unknown (3)
Cognitive
Above average (receives mostly As in school)
Yes
No
Normal (functions well in school, receives mostly
Bs, Cs)
Yes
No
Minimal difficulty (struggling but obtains passing
grades)
Yes
No
Moderate difficulty (needs assistance with school
work such as an Educational Assistant)
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Yes
No
Special needs class setting, actively participating
in learning
Yes
No
Severe (unable to function in regular classroom
even in special class setting, not an active 
participant in learning activities)
Yes
No
Limited cognition (unrelated to demyelination or
predates demyelination)
Yes
No
N/A (patient is too young for school)
Yes
No
Unknown
Yes
No
Vaccinations
Routine: Measles, mumps, rubella
yes (1)
no (2)
unknown (3)
not asked (4)
Hospitalized?
yes, specify (1)
no (2)
Specify
Routine: Tetanus, pertussis, diptheria, polio
yes (1)
no (2)
unknown (3)
not asked (4)
Hospitalized?
yes, specify (1)
no (2)
Specify
Hepatitis B
yes (1)
no (2)
unknown (3)
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not asked (4)
Hospitalized?
yes, specify (1)
no (2)
Specify
Haemophilus Influenza Type B
yes (1)
no (2)
unknown (3)
not asked (4)
Hospitalized?
yes, specify (1)
no (2)
Specify
Chicken Pox Vaccine
yes (1)
no (2)
unknown (3)
not asked (4)
natural infection, specify age: yrs (5)
Specify age in years
Hospitalized?
yes, specify (1)
no (2)
Specify
Vaccination within one month of 1 st
demyelinating attack
yes, specify (1)
no (2)
unknown (3)
not asked (4)
Specify vaccine
Hospitalized?
yes, specify (1)
no (2)
Specify
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Family History - Affected Relatives
and Pedigree
Biological Parents Data Table
Date pedigree taken
Is your biological mother a relative of your
biological father?
yes, first cousin (1)
yes, niece (2)
yes, other (3)
no (4)
unknown (5)
If other, specify:
Date of Birth (mother)
Diagnosis of MS (mother)?
yes (1)
no (2)
unknown (3)
Age at Death of mother (if applicable)
Cause of Death of mother (if applicable)
Is this parent a twin?
yes, Monozygotic  (1)
yes, Dizygotic  (2)
yes, unknown (3)
no (4)
unknown (5)
Date of Birth (father)
Diagnosis of MS (father)?
yes (1)
no (2)
unknown (3)
Age at Death of father (if applicable)
Cause of Death of father (if applicable)
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Is this parent a twin?
yes, Monozygotic  (1)
yes, Dizygotic  (2)
yes, unknown (3)
no (4)
unknown (5)
Family history
Are you a twin?
yes, Identical Twin  (1)
yes, Fraternal Twin  (2)
no (3)
unknown (4)
Is your twin alive?
Yes
No
If no, specify age at death:
Are you adopted?
yes (1)
no (2)
unknown (3)
If Yes, age at time of adoption
Do you have any adopted children who were
adopted before age 1?
yes (1)
no (2)
unknown (3)
Do you have any adopted siblings who were
adopted before age 1?
yes (1)
no (2)
unknown (3)
Have any of your siblings been diagnosed with
MS?
yes (1)
no (2)
unknown (3)
Sibling Information Data Table
Date of Birth
Gender
male (1)
female (2)
Full Sibling
Yes
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No
Maternal Half Sibling
Yes
No
Paternal Half Sibling
Yes
No
Adopted Sibling?
Yes
No
Step Sibling
Yes
No
Affected Relatives Information
If you are married, has your spouse been
diagnosed with MS?
yes (1)
no (2)
unknown (3)
not applicable (4)
Do you have any children who have been
diagnosed with MS?
yes (1)
no (2)
unknown (3)
If Yes, specify total number of children diagnosed
with MS
Do you have any aunts and/or uncles who have
been diagnosed with MS?
yes (1)
no (2)
unknown (3)
If Yes, specify total number of aunts with MS:
If Yes, specify total number of uncles with MS:
Do you have any first cousins who have been
diagnosed with MS?
yes (1)
no (2)
unknown (3)
If Yes, specify total number of cousins:
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Affected Relatives Information Data Table
Gender
male (1)
female (2)
Date of Birth
Age at Death (if applicable)
Cause of Death (if applicable)
Relationship Details (how related to MS index
case):
Age at onset of MS
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Eligibility Coronary Heart Disease
NCT00185042
Efficacy and Safety of the ACAT Inhibitor CS-505
(Pactimibe) for Reducing the Progression of Coronary
Artery Disease; ODM derived from:
https://clinicaltrials.gov/show/NCT00185042
All rights reserved. Please visit https://medical-data-
models.org/forms/16034
Eligibility Coronary Heart Disease
NCT00185042
Inclusion Criteria
standard:*
Yes
No
1. male or female subjects, age 18 years or
greater; and*
Yes
No
2. diagnosed or suspected coronary artery
disease with a clinical indication for coronary
angiography.*
Yes
No
angiographic:*
Yes
No
1. evidence of coronary heart disease*
Yes
No
2. identification of a target native coronary artery
for the plaque volume measurement.*
Yes
No
Exclusion Criteria
standard:*
Yes
No
1. breast feeding or lactating women, or women
who have had a pregnancy (regardless of
outcome) within the past 12 months;*
Yes
No
2. previous heart or other organ transplantation;*
Yes
No
3. treatment with any of the following agents
within 4 weeks prior to randomization:*
Yes
No
immunosuppressive agents (cyclosporine,
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azathioprine);*
Yes
No
rifampin; and*
Yes
No
phenytoin, phenobarbital, valproic acid, or other
anticonvulsants.*
Yes
No
4. any of the following manifestations of cardiac
disease:*
Yes
No
myocardial infarction or unstable angina within 24
hours prior to randomization or clinically
unstable;*
Yes
No
clinically significant heart disease; and*
Yes
No
coronary artery bypass surgery within previous 3
months.*
Yes
No
5. stroke (cva) within previous 3 months;*
Yes
No
6. evidence of severe symptomatic heart failure
(nyha class iii or iv) or known ejection fraction
less than 30%;*
Yes
No
7. uncontrolled diabetes mellitus;*
Yes
No
8. uncontrolled hypertension; and*
Yes
No
9. nephrotic syndrome, significant nephropathy,
or other significant renal disease.*
Yes
No
angiographic:*
Yes
No
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1. presence of any lesion with greater than 50%
reduction in lumen diameter; or*
Yes
No
2. any lesion with a greater than 50% occlusion in
the left main coronary artery;*
Yes
No
3. a target vessel, including any of its branches,
that has undergone or will be undergoing
coronary artery bypass grafting (cabg) or
percutaneous coronary intervention (pci);*
Yes
No
4. a target vessel that is itself a bypass graft.*
Yes
No
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Quality Assurance Checklist For Potential Genetic
Liability By Breast Cancer and Ovarian Cancer
Documentation form for quality assurance in German
Health Care by the Aerztekammer Wesfalen-Lippe,
http://www.aekwl.de/index.php?id=1788, Form version  30.
März  2016 (C)
All rights reserved. Please visit https://medical-data-
models.org/forms/16035
Checklist
Patienteninformation
Name der Patientin
Geburtsdatum
A. Patientin oder Patient und deren
Geschwister/Kinder
Auftreten eines Mamma-Karzinoms bei der
Patientin vor dem 36. LJ. Ggf. Anzahl= 1
Ja
Nein
Auftreten eines Mamma-Karzinoms bei der
Patientin vor dem 36. LJ. Gewichtung = 3
Ja
Nein
Auftreten eines Mamma-Karzinoms bei der
Patientin vor dem 36. LJ. Ergebnis= Anzahl X
Gewichtung
Auftreten eines unilateralen Mamma-Karzinoms
bei der Patientin vor dem 51. LJ. Anzahl=1
Ja
Nein
Auftreten eines unilateralen Mamma-Karzinoms
bei der Patientin vor dem 51. LJ. Gewichtung = 2
Ja
Nein
Auftreten eines unilateralen Mamma-Karzinoms
bei der Patientin vor dem 51. LJ. Ergebnis=
Anzahl X Gewichtung
Auftreten  bilateralen Mamma-Karzinoms bei der
Patientin, das erste vor dem 51. LJ. Ggf. Anzahl=
1
Ja
Nein
Auftreten bilateralen Mamma-Karzinoms bei der
Patientin, das erste vor dem 51. LJ. Gewichtung
= 3
Ja
Nein
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Auftreten bilateralen Mamma-Karzinoms bei der
Patientin, das erste vor dem 51. LJ. Ergebnis=
Anzahl X Gewichtung
Auftreten eines uni- oder bilateralen Mamma-
Karzinoms bei der Patientin nach dem 50. LJ.
Ggf. Anzahl= 1
Ja
Nein
Auftreten eines uni- oder bilateralen Mamma-
Karzinoms bei der Patientin nach dem 50. LJ.
Gewichtung = 1
Ja
Nein
Auftreten eines uni- oder bilateralen Mamma-
Karzinoms bei der Patientin nach dem 50. LJ.
Ergebnis= Anzahl X Gewichtung
Auftreten eines Ovarial-/Tubenkarzinoms oder
einer primären Peritonealkarzinose bei der
Patientin. Ggf. Anzahl=1
Ja
Nein
Auftreten eines Ovarial-/Tubenkarzinoms oder
einer primären Peritonealkarzinose bei der
Patientin. Gewichtung =2
Ja
Nein
Auftreten eines Ovarial-/Tubenkarzinoms oder
einer primären Peritonealkarzinose bei der
Patientin. Ergebnis= Anzahl X Gewichtung
Auftreten eines uni- oder bilateralen
Mammakarzinoms bei einem Patienten (mnl.).
Ggf. Anzahl= 1
Ja
Nein
Auftreten eines uni- oder bilateralen
Mammakarzinoms bei einem Patienten (mnl.).
Gewichtung = 2
Ja
Nein
Auftreten eines uni- oder bilateralen
Mammakarzinoms bei einem Patienten (mnl.).
Ergebnis= Anzahl X Gewichtung
Auftreten eines Mamma-Karzinoms bei
Schwestern/Töchtern/Nichten vor dem 36. LJ.
Ggf. Anzahl=
1 (1)
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2 (2)
3 (3)
Auftreten eines Mamma-Karzinoms bei
Schwestern/Töchtern/Nichten vor dem 36. LJ.
Gewichtung= 3
Ja
Nein
Auftreten eines Mamma-Karzinoms bei
Schwestern/Töchtern/Nichten vor dem 36. LJ.
Ergebniss= Anzahl x Gewichtung
Auftreten eines unilateralen Mamma-Karzinoms
bei Schwestern/Töchtern/Nichten vor dem 51. LJ.
Ggf. Anzahl=
1 (1)
2 (2)
3 (3)
Auftreten eines unilateralen Mamma-Karzinoms
bei Schwestern/Töchtern/Nichten vor dem 51. LJ.
Gewichtung= 2
Ja
Nein
Auftreten eines unilateralen Mamma-Karzinoms
bei Schwestern/Töchtern/Nichten vor dem 51. LJ.
Ergebnis= Anzahl x Gewichtung
Auftreten eines bilat. Mamma-Karzinoms bei
Schwestern/Töchtern/Nichten, das erste vor dem
51. LJ. Ggf. Anzahl=
1 (1)
2 (2)
3 (3)
Auftreten eines bilat. Mamma-Karzinoms bei
Schwestern/Töchtern/Nichten, das erste vor dem
51. LJ. Gewichtung= 3
Ja
Nein
Auftreten eines bilat. Mamma-Karzinoms bei
Schwestern/Töchtern/Nichten, das erste vor dem
51. LJ. Ergebnis= Anzahl x Gewichtung
Auftreten eines uni-oder bilat. Mamma-Karzinoms
bei Schwestern/Töchtern/Nichten nach dem 50.
LJ. Ggf. Anzahl=
1 (1)
2 (2)
3 (3)
Auftreten eines uni-oder bilat. Mamma-Karzinoms
bei Schwestern/Töchtern/Nichten nach dem 50.
LJ. Gewichtung= 1
Ja
Nein
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Auftreten eines uni-oder bilat. Mamma-Karzinoms
bei Schwestern/Töchtern/Nichten nach dem 50.
LJ. Ergebnis= Anzahl x Gewichtung
Auftreten eines Mamma-Karzinoms bei
Brüdern/Söhnen/Neffen. Ggf. Anzahl=
1 (1)
2 (2)
3 (3)
Auftreten eines Mamma-Karzinoms bei
Brüdern/Söhnen/Neffen. Gewichtung=2
Ja
Nein
Auftreten eines Mamma-Karzinoms bei
Brüdern/Söhnen/Neffen. Ergebnis= Anzahl x
Gewichtung
Auftreten eines Ovarial/Tubenkarzinoms/primären
Peritonealkarzinose bei
Schwestern/Töchtern/Nichten. Ggf. Anzahl=
1 (1)
2 (2)
3 (3)
Auftreten eines Ovarial/Tubenkarzinoms/primären
Peritonealkarzinose bei
Schwestern/Töchtern/Nichten. Gewichtung= 2
Ja
Nein
Auftreten eines Ovarial/Tubenkarzinoms/primären
Peritonealkarzinose bei
Schwestern/Töchtern/Nichten. Ergebnis = Anzahl
x Gewichtung
Summe Patientin und deren Geschwister/Kinder.
A=
B. Weitere mütterliche Linie
Auftreten eines Mamma-Karzinoms bei einer
Angehörigen vor dem 36. LJ. Ggf. Anzahl=
1 (1)
2 (2)
3 (3)
Auftreten eines Mamma-Karzinoms bei einer
Angehörigen vor dem 36. LJ. Ggf. Gewichtung= 3
Ja
Nein
Auftreten eines Mamma-Karzinoms bei einer
Angehörigen vor dem 36. LJ. Ggf. Ergebnis=
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Anzahl x Gewichtung
Auftreten eines unilateralen Mamma-Karzinoms
bei einer Angehörigen vor dem 51. LJ. Anzahl=
1 (1)
2 (2)
3 (3)
Auftreten eines unilateralen Mamma-Karzinoms
bei einer Angehörigen vor dem 51. LJ.
Gewichtung= 2
Ja
Nein
Auftreten eines unilateralen Mamma-Karzinoms
bei einer Angehörigen vor dem 51. LJ. Ergebnis=
Anzahl x Gewichtung
Auftreten eines bilateralen Mamma-Karzinoms
bei einer Angehörigen vor dem 51. LJ. Anzahl=
1 (1)
2 (2)
3 (3)
Auftreten eines bilateralen Mamma-Karzinoms
bei einer Angehörigen vor dem 51. LJ.
Gewichtung= 3
Ja
Nein
Auftreten eines bilateralen Mamma-Karzinoms
bei einer Angehörigen vor dem 51. LJ. Ergebnis=
Anzahl x Gewichtung
Auftreten eines  uni- oder bilateralen Mamma-
Karzinoms bei einer Angehörigen nach dem 50.
LJ. Anzahl=
1 (1)
2 (2)
3 (3)
Auftreten eines  uni- oder bilateralen Mamma-
Karzinoms bei einer Angehörigen nach dem 50.
LJ. Gewichtung= 1
Ja
Nein
Auftreten eines  uni- oder bilateralen Mamma-
Karzinoms bei einer Angehörigen nach dem 50.
LJ. Ergebnis= Anzahl x Gewichtung
Auftreten eines Mamma-Karzinoms bei einem
angehörigen Mann. Anzahl=
1 (1)
2 (2)
3 (3)
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Auftreten eines Mamma-Karzinoms bei einem
angehörigen Mann. Gewichtung= 2
Ja
Nein
Auftreten eines Mamma-Karzinoms bei einem
angehörigen Mann. Ergebnis = Anzahl x
Gewichtung
Auftreten eines Ovarial/Tubenkarzinoms/primären
Peritonealkarzinose bei einer Angehörigen.
Anzahl=
1 (1)
2 (2)
3 (3)
Auftreten eines Ovarial/Tubenkarzinoms/primären
Peritonealkarzinose bei einer Angehörigen.
Gewichtung=2
Ja
Nein
Auftreten eines Ovarial/Tubenkarzinoms/primären
Peritonealkarzinose bei einer Angehörigen.
Ergebnis= Anzahl x Gewichtung
Summe weitere mütterliche Linie. B=
C. weitere väterliche Linie
Auftreten eines Mamma-Karzinoms bei einer
Angehörigen vor dem 36. LJ. Ggf. Anzahl=
1 (1)
2 (2)
3 (3)
Auftreten eines Mamma-Karzinoms bei einer
Angehörigen vor dem 36. LJ. Ggf. Gewichtung= 3
Ja
Nein
Auftreten eines Mamma-Karzinoms bei einer
Angehörigen vor dem 36. LJ. Ggf. Ergebnis=
Anzahl x Gewichtung
Auftreten eines unilateralen Mamma-Karzinoms
bei einer Angehörigen vor dem 51. LJ. Anzahl=
1 (1)
2 (2)
3 (3)
Auftreten eines unilateralen Mamma-Karzinoms
bei einer Angehörigen vor dem 51. LJ.
Gewichtung=2
Ja
Nein
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Auftreten eines unilateralen Mamma-Karzinoms
bei einer Angehörigen vor dem 51. LJ. Ergebnis=
Anzahl x Gewichtung
Auftreten eines bilateralen Mamma-Karzinoms
bei einer Angehörigen vor dem 51. LJ.  Anzahl=
1 (1)
2 (2)
3 (3)
Auftreten eines bilateralen Mamma-Karzinoms
bei einer Angehörigen vor dem 51. LJ.
Gewichtung=3
Ja
Nein
Auftreten eines bilateralen Mamma-Karzinoms
bei einer Angehörigen vor dem 51. LJ.  Ergebnis=
Anzahl x Gewichtung
Auftreten eines uni- oder bilateralen Mamma-
Karzinoms bei einer Angehörigen nach dem 50.
LJ.  Anzahl=
1 (1)
2 (2)
3 (3)
Auftreten eines uni- oder bilateralen Mamma-
Karzinoms bei einer Angehörigen nach dem 50.
LJ.  Gewichtung= 1
Ja
Nein
Auftreten eines uni- oder bilateralen Mamma-
Karzinoms bei einer Angehörigen nach dem 50.
LJ.  Ergebnis= Anzahl x Gewichtung
Auftreten eines Mamma-Karzinoms bei einem
angehörigen Mann. Anzahl=
1 (1)
2 (2)
3 (3)
Auftreten eines Mamma-Karzinoms bei einem
angehörigen Mann. Gewichtung= 2
Ja
Nein
Auftreten eines Mamma-Karzinoms bei einem
angehörigen Mann. Ergebnis= Anzahl x
Gewichtung
Auftreten eines Ovarial/Tubenkarzinoms/primären
Peritonealkarzinose bei einer Angehörigen.
Anzahl=
1 (1)
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2 (2)
3 (3)
Auftreten eines Ovarial/Tubenkarzinoms/primären
Peritonealkarzinose bei einer Angehörigen.
Gewichtung=2
Ja
Nein
Auftreten eines Ovarial/Tubenkarzinoms/primären
Peritonealkarzinose bei einer Angehörigen.
Ergebnis= Anzahl x Gewichtung
Summe weitere väterliche Linie. C=
D. Der höhere Wert aus B und C. D=
E. Summe aus A und D (A+D)= Risiko-Score =
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
7 (7)
>7 (8)
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AAFP: Diabetic Ketoacidosis Admission
Order
AAFP: Diabetic Ketoacidosis Admission Order,
Standardizes Admission Orders, Author: Robert M. Wiprud,
MD The primary purpose of these Ordersets is to decrease
unnecessary variability and to improve quality through
standardized Admission Orders. Developed by the Scott &
White Clinic at College Station, Texas. Copyright © 2006
American Academy of Family Physicians. Physicians may
photocopy or adapt for use in their own practices; all other
rights reserved. Wiprud RM. Providing consistent care with
standardized admission orders. Fam Pract Manag.
September 2006: 49-52 See
http://www.aafp.org/fpm/2006/0900/p49.html This ODM
Form includes the ninth section ("Diabetic Ketoacidosis
Admission Order").
All rights reserved. Please visit https://medical-data-
models.org/forms/16036
AAFP: Diabetic Ketoacidosis
Admission Order
Default Itemgroup
Name
Age
Date of birth
Medical record
Status
ICU
Yes
No
Attending
Name of attending physician
Phone number of attending physician
Admitting Diagnosis
Diabetic Ketoacidosis Contributing Diagnoses
Condition
Condition
Stable (1)
Fair (2)
Serious (3)
Critical (4)
Allergies
1 / 5
Allergies
Diet
NPO for 12 hrs, then CL as tolerated; progress to
2,000 calorie ADA as tolerated
Yes
No
Activity
Bed rest with bathroom privileges ad lib,
beginning tomorrow if stable
Yes
No
Nursing
BP
Yes
No
Pulse and respiratory every 1 hr X6, every 2 hrs
X3, then every 4 hrs if stable
Yes
No
T every 4 hrs
Yes
No
I&O every 1 X6, every 4 hrs X3, then daily
Yes
No
Notify MD for: T > 39 C; P < 60 or > 130; BP <
90/60 or > 170/110; all lab results
Yes
No
Medications
Regular insulin (0.1 units/kg)___ units IV bolus,
then regular insulin infusion (0.1
units/kg/hr)__units/hr
Yes
No
If regular insulin, please specify amount of units
If regular insulin, please specify amount of
regular insulin infusion units
Lantus insulin if takes @home___units SQ at
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bedtime
Yes
No
If Lantus insulin, please specify amount of units
Medications
Yes
No
IV
1000mL normal saline at 1000ml/hr
Yes
No
1000mL normal saline with 20 mEq KCl at 500
mL/hr (add KCl after patient voids)
Yes
No
1000mL normal saline with 20 mEq KCl at 500
mL/hr
Yes
No
1000mL 1/2 normal saline with 20 mEq KCl at
250 mL/hr
Yes
No
Change IVF to 1000mL Dextrose 5% in 1/2
normal saline with 20 mEq KCl at 250 mL/hr
when glucose < 250 mg/dl
Yes
No
Lab
Basal metabolic profile on admission and 4,8,
and 12 hrs after admission
Yes
No
Serum ketones with first, second and third blood
draw
Yes
No
Hemogram, UA, urine C&S
Yes
No
ABGs on admission
Yes
No
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Serum osmolality, PO4, Mg and Ca at admission
Yes
No
Mg
If Mg 1.4-1.8 mg/gl, apply 1g MgSO4 with IV
Piggyback over 30 minutes
Yes
No
If Mg < 1.4 mg/dl apply 2 g MgSO4 with IV
Piggyback Over 30-60 minutes
Yes
No
PO4
With all IV PO4 supplementation, check calcium
every 4 hrs
Yes
No
After all infusions, complete immediately, check
PO4 level
Yes
No
If calcium supplementation necessary, do not
give in same IV line as PO4
Yes
No
Other
If pH < 7.1, then add 1 amp (44mEq) of NA
bicarbonate to bag
Yes
No
Normal saline every 2 hrs until pH > 7.1 ABG
every 4 hrs (if treating with bicarbonate)
Yes
No
Consider DVT prophylaxis with Lovenox 40 mg sq
daily
Yes
No
If PO4 1.0-1.8 mg/dl supply orally, if possible with
milk or neutral-phos
Yes
No
If 1.0-1.8 mg/dl please specify solution
ln
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If 1.0-1.8 mg/dl please specify duration
hrs
If PO4 0.5-1.0 mg/dl supply IV with 0.08 mM/Kg
KPO4 in 250 cc NS for 4 hrs
Yes
No
If PO4 < 0.5 mg/dl supply IV with 0.16 mM/Kg
KPO4 in 250 cc NS for 4 hrs
Yes
No
Signature
Print Name
Date and Time
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Eligibility Type 2 Diabetes Mellitus
NCT02294474
Comparison of SAR342434 to Humalog as the Rapid
Acting Insulin in Adult Patients With Type 2 Diabetes
Mellitus Also Using Insulin Glargine; ODM derived from:
https://clinicaltrials.gov/show/NCT02294474
All rights reserved. Please visit https://medical-data-
models.org/forms/16037
Eligibility Type 2 Diabetes Mellitus
NCT02294474
Inclusion Criteria
patients with t2dm diagnosed for at least 12
months and treated with insulin glargine and
humalog or novolog®/novorapid® (at least 3
times daily, before each meal) in the 6 months
prior to the screening visit*
Yes
No
written informed consent*
Yes
No
Exclusion Criteria
at screening visit, age under legal age of
adulthood*
Yes
No
hba1c <6.5% or >10.0% at screening*
Yes
No
diabetes other than t2dm*
Yes
No
pregnancy and lactation*
Yes
No
women of childbearing potential not protected by
highly effective contraceptive method of birth
control*
Yes
No
use of insulin pump in the  6 months before
screening visit*
Yes
No
use of insulin other than insulin glargine and
humalog or novolog/novorapid in the 6 months
prior to screening visit.  liprolog®  is an eu
approved insulin lispro and is allowed in those
countries where it is marketed*
Yes
No
1 / 2
use of humalog or novolog/novorapid less than 3
times daily, before each meal*
Yes
No
use of non-injectable peptides (eg, glp-1-
receptor-agonists or other peptides) in the 6
months prior to screening visit*
Yes
No
body mass index (bmi) ≥40kg/m² at screening
visit*
Yes
No
hospitalization for diabetic ketoacidosis in the last
6 months before screening visit*
Yes
No
unstable proliferative diabetic retinopathy or any
other rapidly progressive diabetic retinopathy or
macular edema likely to require treatment (eg,
laser, surgical treatment, or injectable drugs)
during the study period*
Yes
No
the above information is not intended to contain
all considerations relevant to a patient's potential
participation in a clinical trial*
Yes
No
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AAFP: DVT (Lovenox Therapy) Admission
Order
AAFP:DVT (Lovenox Therapy) Admission Order,
Standardizes Admission Orders, Author: Robert M. Wiprud,
MD The primary purpose of these Ordersets is to decrease
unnecessary variability and to improve quality through
standardized Admission Orders. Developed by the Scott &
White Clinic at College Station, Texas. Copyright © 2006
American Academy of Family Physicians. Physicians may
photocopy or adapt for use in their own practices; all other
rights reserved. Wiprud RM. Providing consistent care with
standardized admission orders. Fam Pract Manag.
September 2006: 49-52 See
http://www.aafp.org/fpm/2006/0900/p49.html This ODM
Form includes the ninth section ("DVT (Lovenox Therapy)
Admission Order").
All rights reserved. Please visit https://medical-data-
models.org/forms/16039
AAFP: DVT (Lovenox Therapy)
Admission Order
Default Itemgroup
Name
Age
Date of Birth
Medical record
Status
Status
Observation (1)
Admission (2)
Medical floor (3)
Monitored bed (4)
Other (5)
If Other, please specify
Attending
Name of attending physician
Phone number of attending physician
Admitting Diagnosis
Please specify Deep Vein Thrombosis___lower
extremity
Deep Vein Thrombosis ___lower extremity
Associated Diagnoses
1 / 3
Condition
Condition
Stable (1)
Fair (2)
Serious (3)
Critical (4)
Allergies
Allergies
Activity
Bed rest with bathroom privileges; elevate
affected leg while in bed
Yes
No
Diet
Regular
Yes
No
Other
Yes
No
If Other, please specify
Nursing
Vital signs: every 4 hrs X2, then every shift
Yes
No
Notify MD for: T > 101 PO; P < 55 or > 120 bpm;
systolic BP < 90 or > 180; diastolic BP > 120
Yes
No
Admission weight
Yes
No
Assess size, color, temp and pulses of lower
extremities each shift
Yes
No
Notify MD of changes from baseline
Yes
No
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Medications
Enoxaparin (Levonox) 1 mg/kg body weight
subcutaneously now and BID
Yes
No
Coumadin 5 mg PO now and then daily
Yes
No
Tylenol 325 mg 1-2 PO every 4-6 hrs prn pain or
fever
Yes
No
MOM 15-30 mL every 12 hrs prn constipation
Yes
No
No NSAIDS, ASA or IM injunctions
Yes
No
Other Medications
Yes
No
If Other, please specify
IV
IV lock; flush per routine
Yes
No
Other
Yes
No
If Other, please specify
Lab
PT/INR, PTT, CBC, basal metabolic profile on
admission if not already done
Yes
No
PT/INR every morning
Yes
No
Other Orders
Other Orders
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AAFP: DVT (Lovenox Therapy) Admission
Order
AAFP:DVT (Lovenox Therapy) Admission Order,
Standardizes Admission Orders, Author: Robert M. Wiprud,
MD The primary purpose of these Ordersets is to decrease
unnecessary variability and to improve quality through
standardized Admission Orders. Developed by the Scott &
White Clinic at College Station, Texas. Copyright © 2006
American Academy of Family Physicians. Physicians may
photocopy or adapt for use in their own practices; all other
rights reserved. Wiprud RM. Providing consistent care with
standardized admission orders. Fam Pract Manag.
September 2006: 49-52 See
http://www.aafp.org/fpm/2006/0900/p49.html This ODM
Form includes the ninth section ("DVT (Lovenox Therapy)
Admission Order").
All rights reserved. Please visit https://medical-data-
models.org/forms/16040
AAFP: DVT (Lovenox Therapy)
Admission Order
Default Itemgroup
Name
Age
Date of Birth
Medical record
Status
Status
Observation (1)
Admission (2)
Medical floor (3)
Monitored bed (4)
Other (5)
If Other, please specify
Attending
Name of attending physician
Phone number of attending physician
Admitting Diagnosis
Please specify Deep Vein Thrombosis___lower
extremity
Deep Vein Thrombosis ___lower extremity
Associated Diagnoses
1 / 4
Condition
Condition
Stable (1)
Fair (2)
Serious (3)
Critical (4)
Allergies
Allergies
Activity
Bed rest with bathroom privileges; elevate
affected leg while in bed
Yes
No
Diet
Regular
Yes
No
Other
Yes
No
If Other, please specify
Nursing
Vital signs: every 4 hrs X2, then every shift
Yes
No
Notify MD for: T > 101 PO; P < 55 or > 120 bpm;
systolic BP < 90 or > 180; diastolic BP > 120
Yes
No
Admission weight
Yes
No
Assess size, color, temp and pulses of lower
extremities each shift
Yes
No
Notify MD of changes from baseline
Yes
No
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Medications
Enoxaparin (Levonox) 1 mg/kg body weight
subcutaneously now and BID
Yes
No
Coumadin 5 mg PO now and then daily
Yes
No
Tylenol 325 mg 1-2 PO every 4-6 hrs prn pain or
fever
Yes
No
MOM 15-30 mL every 12 hrs prn constipation
Yes
No
No NSAIDS, ASA or IM injunctions
Yes
No
Other Medications
Yes
No
If Other, please specify
IV
IV lock; flush per routine
Yes
No
Other
Yes
No
If Other, please specify
Lab
PT/INR, PTT, CBC, basal metabolic profile on
admission if not already done
Yes
No
PT/INR every morning
Yes
No
Other Orders
Other Orders
3 / 4
AAFP: DVT (Lovenox Therapy) Admission Order
Other Orders
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Eligibility Type 2 Diabetes Mellitus
NCT02320721
Comparison of the Safety and Efficacy of HOE901-U300
With Lantus in Older Patients With Type2 Diabetes
Insufficiently Controlled on Their Current Antidiabetic
Medications; ODM derived from:
https://clinicaltrials.gov/show/NCT02320721
All rights reserved. Please visit https://medical-data-
models.org/forms/16041
Eligibility Type 2 Diabetes Mellitus
NCT02320721
Inclusion Criteria
patients ≥65 years old with type 2 diabetes
mellitus, inadequately controlled on antidiabetic
regimens either including no insulin, or with basal
insulin as their only insulin.*
Yes
No
signed informed consent.*
Yes
No
Exclusion Criteria
hba1c at screening visit:*
Yes
No
<7.0% or >10.0% for patients taking basal
insulin.*
Yes
No
<7.5% or >11.0% for insulin-naïve patients.*
Yes
No
history of type 2 diabetes mellitus for less than 1
year before screening.*
Yes
No
patients not on stable basal insulin dose (±10% in
the last 8 weeks prior to screening visit).*
Yes
No
change in dose of antidiabetic treatment or
initiation of new glucose-lowering medications in
the last 8 weeks prior to screening.*
Yes
No
chronic (>10 days continuous use in previous 6
months) use of bolus insulin injections, whether
given separately or as part of a combination with
basal insulin, eg, premix insulin; for insulin-naïve
individuals: current or previous insulin use except
for a maximum of 10 consecutive days (e.g. acute
illness, surgery) during the last year prior to
1 / 2
screening.*
Yes
No
cognitive disorder and dementia assessed
clinically and by mini-mental state examination
(mmse) score <24, or any neurologic disorder
that will likely affect the patient's ability to follow
the study procedure. the patient will be eligible
despite an mmse score <24 if the investigator
determines that the low score reflects educational
or cultural background and not dementia as long
as the patient is otherwise able to meet the study
requirements.*
Yes
No
patients who have end-stage renal disease (<15
ml/min/1.73m^2, per estimated glomerular
filtration rate [egfr] measurement by modification
of diet in renal disease [mdrd]).*
Yes
No
the above information is not intended to contain
all considerations relevant to a patient's potential
participation in a clinical trial.*
Yes
No
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AAFP: CVT Outpatient Screening Criteria
AAFP: CVT Outpatient Screening Criteria , Standardizes
Admission Orders, Author: Robert M. Wiprud, MD The
primary purpose of these Ordersets is to decrease
unnecessary variability and to improve quality through
standardized Admission Orders. Developed by the Scott &
White Clinic at College Station, Texas. Copyright © 2006
American Academy of Family Physicians. Physicians may
photocopy or adapt for use in their own practices; all other
rights reserved. Wiprud RM. Providing consistent care with
standardized admission orders. Fam Pract Manag.
September 2006: 49-52 See
http://www.aafp.org/fpm/2006/0900/p49.html This ODM
Form includes the thirteenth section ("AAFP: CVT
Outpatient Screening Criteria").
All rights reserved. Please visit https://medical-data-
models.org/forms/16042
AAFP: CVT Outpatient Screening
Criteria
Inclusion Criteria
Acute, symptomatic, proximal or distal DVT
documented by venogram/Doppler U/S
Yes
No
Patient agrees to outpatient therapy
Yes
No
Exclusion Criteria
Current, active bleeding, active peptic or ulcer
disease, congenital or acquired bleeding disorder
or disease process in which, in the judgement of
the physician, there may be an increased risk of
bleeding (e.g. hepatic or renal insufficiency,
recent surgery or stroke)
Yes
No
Concurrent symptomatic pulmonary emboli
Yes
No
Expected hospitalization greater than five days
due to co-existing conditions
Yes
No
Known hypercoagulability: familiar or acquired
Yes
No
Pregnant or breast-feeding
Yes
No
Uncontrolled hypertension
Yes
No
Extensive iliofemoral DVT
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Yes
No
Likelihood of non-compliance due to cognitive
limitations, alcohol/drug abuse, dementia,
psychiatric disorders, etc.
Yes
No
if yes, please describe
Decision
Patient meets criteria for outpatient Lovenox
therapy. Begin patient education.
Yes
No
Lovenox self-administration and anticoagulation
precautions.
Yes
No
Patient does not qualify for outpatient Lovenox
therapy.
Yes
No
Signature
Print Name
Date and Time
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Record description central archive of perioperative
data (Zapod) -Premedication and anesthesia induction
Source:
Project central archive of perioperative Data (ZaPoD) of the
German Society of Anesthesiology and Intensive Care
Medicine (DGAI).
Project lead: PD Dr. Sven Zenker, http://amp.uni-bonn.de
All rights reserved. Please visit https://medical-data-
models.org/forms/16043
Record description central archive of
perioperative data-Premedication
and anesthesia induction
Prämedikation
Keine Prämedikation
Ja
Nein
Prämedikation: Digitalis
Ja
Nein
Prämedikation: Nitrate
Ja
Nein
Prämedikation: ACE-Hemmer
Ja
Nein
Prämedikation: AT-Antagonisten
Ja
Nein
Prämedikation: Beta-Blocker
Ja
Nein
Prämedikation: Calcium Antagonisten
Ja
Nein
Prämedikation: Diuretika
Ja
Nein
Prämedikation: Antihypertensiva
Ja
Nein
Prämedikation: Cumarine
Ja
Nein
Prämedikation: Heparine
Ja
Nein
Prämedikation: ASS
Ja
Nein
Prämedikation:
Thrombozytenaggregationshemmer
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Ja
Nein
Prämedikation: Mukolytika
Ja
Nein
Prämedikation: Kortikoide oral
Ja
Nein
Prämedikation: Kortikoide inhalativ
Ja
Nein
Prämedikation: H2-Antagonisten
Ja
Nein
Prämedikation: Leukotrien-Antagonisten
Ja
Nein
Prämedikation: orale beta-Mimetika
Ja
Nein
Prämedikation: inhalative Beta Mimetika
Ja
Nein
Prämedikation: Theophyllin
Ja
Nein
Prämedikation: O2
Ja
Nein
Prämedikation: Statine
Ja
Nein
Prämedikation: Sulfonylharnstoffe
Ja
Nein
Prämedikation: orale Antidiabetika
Ja
Nein
Prämedikation: Insuline
Ja
Nein
Prämedikation: Antiepileptika
Ja
Nein
Prämedikation: Benzodiazepine
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Ja
Nein
Prämedikation: Antidepressiva
Ja
Nein
Prämedikation: nicht-opioide Analgetika
Ja
Nein
Prämedikation: schwache Opioide
Ja
Nein
Prämedikation: starke Opioide
Ja
Nein
Prämedikation: orale Kontrazeptiva
Ja
Nein
Prämedikation: Sonstige
Ja
Nein
Narkoseeinleitung
Narkoseeinleitung: Thiopental
Ja
Nein
Narkoseeinleitung
Ja
Nein
Narkoseeinleitung: Etomidate
Ja
Nein
Narkoseeinleitung
Ja
Nein
Narkoseeinleitung: Propofol
Ja
Nein
Narkoseeinleitung
Ja
Nein
Narkoseeinleitung: Mivacurium
Ja
Nein
Narkoseeinleitung
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Ja
Nein
Narkoseeinleitung: Atracurium
Ja
Nein
Narkoseeinleitung
Ja
Nein
Narkoseeinleitung: Cis-Atracurium
Ja
Nein
Narkoseeinleitung
Ja
Nein
Narkoseeinleitung: Rocuronium
Ja
Nein
Narkoseeinleitung
Ja
Nein
Narkoseeinleitung: Succinylcholin
Ja
Nein
Narkoseeinleitung
Ja
Nein
Narkoseeinleitung: Pancuronium
Ja
Nein
Narkoseeinleitung
Ja
Nein
Narkoseeinleitung: Vecuronium
Ja
Nein
Narkoseeinleitung
Ja
Nein
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Record description central archive of perioperative data (Zapod)
-Premedication and anesthesia induction
Eligibility Type 2 Diabetes Mellitus
NCT02328599
Alliance of Randomized Trials of Medicine vs Metabolic
Surgery in Type 2 Diabetes; ODM derived from:
https://clinicaltrials.gov/show/NCT02328599
All rights reserved. Please visit https://medical-data-
models.org/forms/16044
Eligibility Type 2 Diabetes Mellitus
NCT02328599
Inclusion Criteria
original inclusion criteria for participation in the
rcts at all sites included:*
Yes
No
candidate for general anesthesia or unsupervised
exercise.*
Yes
No
age ≥20 and ≤65 years.*
Yes
No
body mass index >27 and ≤45 kg/m2.*
Yes
No
diagnosis of type 2 diabetes confirmed by either
requiring diabetes medication and/or having
elevated glycemia based on hba1c, fasting
plasma glucose, and/or oral glucose tolerance
test (ogtt) results, according to american diabetes
association criteria.*
Yes
No
ability and willingness to participate in the study
and agree to any of the research arms.*
Yes
No
able to understand the options and to comply with
the requirements of each program.*
Yes
No
negative urine pregnancy test at screening and
baseline visits (prior to surgery) for women of
childbearing potential (i.e., biologically capable of
becoming pregnant).*
Yes
No
Exclusion Criteria
subjects who were randomized in one of the four
rcts but never initiated intervention*
Yes
No
1 / 2
/ did not receive randomized treatment*
Yes
No
refusal to sign informed consent*
Yes
No
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AAFP: Endometritis Admission Order
AAFP: Endometritis Admission Order, Standardizes
Admission Orders, Author: Robert M. Wiprud, MD The
primary purpose of these Ordersets is to decrease
unnecessary variability and to improve quality through
standardized Admission Orders. Developed by the Scott &
White Clinic at College Station, Texas. Copyright © 2006
American Academy of Family Physicians. Physicians may
photocopy or adapt for use in their own practices; all other
rights reserved. Wiprud RM. Providing consistent care with
standardized admission orders. Fam Pract Manag.
September 2006: 49-52 See
http://www.aafp.org/fpm/2006/0900/p49.html This ODM
Form includes the fourteenth section ("Endometritis
Admission Order").
All rights reserved. Please visit https://medical-data-
models.org/forms/16045
AAFP: Endometritis Admission Order
Default Itemgroup
Name
Age
Date of Birth
Medical record
Status
Status
Observation (1)
Admission (2)
Medical floor (3)
Monitored Bed (4)
Other (5)
If Other, please specify
Attending
Name of attending physician
Phone number of attending physician
Admitting Diagnosis
Post-Partum Endometritis Associated Diagnoses
Condition
Condition
Stable (1)
Fair (2)
1 / 4
Serious (3)
Critical (4)
Code Status
Full Code (1)
DNR (2)
Allergies
Allergies
Diet
NPO
Yes
No
Clear liquid
Yes
No
AHA step 2
Yes
No
ADA__calories
Yes
No
If Diet according to ADA, please specify amount
of calories
Other
Yes
No
If Other, please specify
Activity
Bed rest with bedside commode
Yes
No
Bathroom privileges
Yes
No
Up ad lib
Yes
No
Nursing
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Vital signs ever 4 hrs for 24 hrs then every shift
Yes
No
Notify MD for: T > 101.5, P > 120, BP < 90/60 or
> 180/110
Yes
No
Daily weight
Yes
No
I&O
Yes
No
Medications
Unasyn 3 mg IVPB every 6 hrs
Yes
No
Clindamycin 900mg IVPB every 8 hrs (if patient
PCN sensitive)
Yes
No
If patient is toxic add to the above:
Gentamycin 80 mg IVPB every 8 hrs
obtain trough before 4th dose OR (1)
Metronidazole 15 mg/kg load = ____mg
x1 dose and Metroidazole 7.5 mg/kg (up
to 500mg)=___mg IVPB every 8 hrs (2)
If Metronidazole please specify 15 mg/kg load
=___mg
If Metronidazole, please specify 7.5 mg/kg(up to
500 mg)=____mg
Tylenol 500 mg 2 tabs PO every 4 hrs prn
fever/pain
Yes
No
Prenatal vitamin 1 PO daily if breast-feeding
Yes
No
IV
IV lock; flush per routine
Yes
No
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IV___at mL/hr
Yes
No
If IV____at mL/hr, please specify amount
Lab
Admission: CBC, basal metabolic profile
Yes
No
Culture
Yes
No
If culture: lochia
Yes
No
If culture: blood x2
Yes
No
If culture: urine
Yes
No
If culture: abdominal incision
Yes
No
Daily CBC
Yes
No
Other
Signature
Print Name
Date and Time
4 / 4
AAFP: Endometritis Admission Order
Renal Replacement Therapy RICH study
NCT02669589
NCT02669589 EudraCT-Nr. 2014-004854-33
REGIONAL CITRATE VERSUS SYSTEMIC HEPARIN
ANTICOAGULATION FOR CONTINUOUS RENAL
REPLACEMENT THERAPY IN CRITICALLY ILL
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Renal Replacement Therapy RICH
study NCT02669589
Patient Information
ID of Center
ID of patient
Dialysis information
Code list number for Filter number:
(Codes can be used several times)
Filter 1 start until ≤ 24h (1)
Filter 4 start until ≤ 24h (10)
Filter 4 > 24h ≤ 48h (11)
Filter 4 > 48 ≤ 72h (12)
Filter 5 start until ≤ 24h (13)
Filter 5 > 24h ≤ 48h (14)
Filter 5 > 48 ≤ 72h (15)
Filter 6 start until ≤ 24h (16)
Filter 6 > 24h ≤ 48h (17)
Filter 6 > 48 ≤ 72h (18)
Filter 7 start until ≤ 24h (19)
Filter 1 > 24h ≤ 48h (2)
Filter 7 > 24h ≤ 48h (20)
Filter 7 > 48 ≤ 72h (21)
Filter 8 start until ≤ 24h (22)
Filter 8 > 24h ≤ 48h (23)
Filter 8 > 48 ≤ 72h (24)
Filter 9 start until ≤ 24h (25)
Filter 9 > 24h ≤ 48h (26)
Filter 9 > 48 ≤ 72h (27)
Filter 10 start until ≤ 24h (28)
Filter 10 > 24h ≤ 48h (29)
Filter 1 > 48 ≤ 72h (3)
Filter 10 > 48 ≤ 72h (30)
Filter 2 start until ≤ 24h (4)
Filter 2 > 24h ≤ 48h (5)
Filter 2 > 48 ≤ 72h (6)
Filter 3 start until ≤ 24h (7)
Filter 3 > 24h ≤ 48h (8)
Filter 3 > 48 ≤ 72h (9)
Filter Start Date:
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Filter Start Time:
Code list for Dialysis machine:
Multifiltrate, FMC (1)
Prismaflex, Gambro (2)
Code list for Modality:
CVVH (1)
CVVHD (2)
CVVHDF (3)
Code list Filter:
ST100 (1)
AV 1000 S (2)
AV600S (3)
AV1000 (4)
AV100 (5)
100DS (6)
1400 (7)
M150 (8)
Filter replacement?
Yes
No
If filter replacement, specify reason:
clotting (01)
filter replacement after 72h (02)
conversion of process (03)
recovery of renal function (04)
death of patient (05)
Filter End Date:
Filter End Time:
Addition of Citrate Antikoagulation:
Calcium chloride 1 N (0,5 mol) (1)
not used (2)
Addition of Heparin Antikoagulation:
Multifiltrat Kit4 (1)
Liquemin (2)
Multibic (3)
not used (4)
Code List for Complications of Renal Replacment
Therapy:
no complications (1)
First use reaction (2)
Hypotension with discontinuation (3)
air embolism (4)
haemorrhage (5)
new severe arrythmyia (6)
iatrogenic fluid and electrolyte imbalance
(7)
seizure (8)
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problems with inserting catheter (9)
Dialysis flow (at least 3 times each day at
department AND at least once each shift
(+/- 1h) - representing actual state)
Point in time: Measurement
early shift (1)
late shift (2)
night shift (3)
Temperature adjustment of dialyisis machine:
°C
Dialysis flow rate:
mL/h
Citrate flow:
(dose in mmol per Shift)
mmol/shift
Calcium substitution:
(dose in mmol per shift)
mmol/shift
Flow of substituition:
mL/h
Extra-corporal Calcium post-Filter
mmol/L
Blood flow:
mL/min
Ultrafiltration rate:
mL/h
Time: interruption:
(e.g. Operations, transport to CT)
min
Patient withdrawal:
mL/h
Catheter: Adjustment
Start Date Catheter
Start time Catheter:
3 / 4
Renal Replacement Therapy RICH study NCT02669589
End Date Catheter:
End Time Catheter:
Type of Catheter:
2 lumen (1)
3 lumen (2)
Codelist for Catheter diameter:
11 French (11)
12 French (12)
13 French (13)
Other (Other)
Codelist for Catheter diameter:
If "other", specify:
Codelist for Catheter length:
150 mm (150)
175 mm (175)
200 mm (200)
240 mm (240)
Other (Other)
Codelist for Catheter length:
If "other", specify:
Codelist for Location of Catheter:
V. jugularis (1)
V. subclavia (2)
V. femoralis (3)
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Record description central archive of perioperative
data (Zapod) -Intraoperative medication
Source:
Project central archive of perioperative Data (ZaPoD) of the
German Society of Anesthesiology and Intensive Care
Medicine (DGAI).
Project lead: PD Dr. Sven Zenker, http://amp.uni-bonn.de
All rights reserved. Please visit https://medical-data-
models.org/forms/16047
Record description central archive of
perioperative data-Intraoperative
medication
Intraoperative Medikamente
Thrombozytenkonzentrat
Ja
Nein
Erythrozytenkonzentrat
Ja
Nein
Erythrozytenkonzentrat, Eigenblut
Ja
Nein
Erythrozytenkonzentrat, Cellsaver
Ja
Nein
FFP
Ja
Nein
FFP, Eigenblut
Ja
Nein
Plasma, Eigenblut
Ja
Nein
Vollelektrolytlösung
Ja
Nein
NaCl
Ja
Nein
Paediafusin
Ja
Nein
HES
Ja
Nein
Gelafundin
Ja
Nein
Flascheninhalt
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Midazolam
Ja
Nein
Intraoperative Medikamente
Ja
Nein
s-Ketamin
Ja
Nein
Intraoperative Medikamente
Ja
Nein
Esmolol
Ja
Nein
Intraoperative Medikamente
Ja
Nein
a2-Antagonisten
Ja
Nein
Intraoperative Medikamente
Ja
Nein
Sufentanil
Ja
Nein
Intraoperative Medikamente
Ja
Nein
Remifentanil
Ja
Nein
Intraoperative Medikamente
Ja
Nein
Piritramid
Ja
Nein
Intraoperative Medikamente
Ja
Nein
Morphin
Ja
Nein
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-Intraoperative medication
Intraoperative Medikamente
Ja
Nein
Pethidin
Ja
Nein
Intraoperative Medikamente
Ja
Nein
Tramadol
Ja
Nein
Intraoperative Medikamente
Ja
Nein
Fentanyl
Ja
Nein
Intraoperative Medikamente
Ja
Nein
Intraoperative Medikamente
Ja
Nein
Alfentanil
Ja
Nein
Intraoperative Medikamente
Ja
Nein
5HT3-Antagonisten
Ja
Nein
Intraoperative Medikamente
Ja
Nein
Dexamethason
Ja
Nein
Intraoperative Medikamente
Ja
Nein
Droperidol
Ja
Nein
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-Intraoperative medication
Intraoperative Medikamente
Ja
Nein
O2
Ja
Nein
Luft
Ja
Nein
N2O
Ja
Nein
Isofluran
Ja
Nein
Enfluran
Ja
Nein
Sevofluran
Ja
Nein
Desfluran
Ja
Nein
NO
Ja
Nein
Dobutamin
Ja
Nein
Intraoperative Medikamente
Ja
Nein
Adrenalin
Ja
Nein
Intraoperative Medikamente
Ja
Nein
Noradrenalin
Ja
Nein
Intraoperative Medikamente
Ja
Nein
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Etilefrin
Ja
Nein
Intraoperative Medikamente
Ja
Nein
Phenylefrin
Ja
Nein
Intraoperative Medikamente
Ja
Nein
Ameziniummetilsulfat
Ja
Nein
Intraoperative Medikamente
Ja
Nein
Phosphodiesterasehemmer
Ja
Nein
Intraoperative Medikamente
Ja
Nein
Beta-Blocker
Ja
Nein
Intraoperative Medikamente
Ja
Nein
Akrinor
Ja
Nein
Intraoperative Medikamente
Ja
Nein
Dopamin
Ja
Nein
Intraoperative Medikamente
Ja
Nein
Arginin- Vasopressin
Ja
Nein
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-Intraoperative medication
Intraoperative Medikamente
Ja
Nein
Nitroglycerin
Ja
Nein
Intraoperative Medikamente
Ja
Nein
Nifedipin
Ja
Nein
Intraoperative Medikamente
Ja
Nein
Natriumnitroprussid
Ja
Nein
Intraoperative Medikamente
Ja
Nein
Eicosanoide
Ja
Nein
Intraoperative Medikamente
Ja
Nein
Atropin
Ja
Nein
Intraoperative Medikamente
Ja
Nein
Histamin-Antagonist
Ja
Nein
Intraoperative Medikamente
Ja
Nein
Antibiotika
Ja
Nein
Intraoperative Medikamente
Ja
Nein
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-Intraoperative medication
Heparin
Ja
Nein
Intraoperative Medikamente
Ja
Nein
Insuline
Ja
Nein
Intraoperative Medikamente
Ja
Nein
Protamin
Ja
Nein
Intraoperative Medikamente
Ja
Nein
Puffer
Ja
Nein
Intraoperative Medikamente
Ja
Nein
Tranexamsäure:
Ja
Nein
Intraoperative Medikamente
Ja
Nein
Aprotinin
Ja
Nein
Intraoperative Medikamente
Ja
Nein
Desmopressin
Ja
Nein
Intraoperative Medikamente
Ja
Nein
Metamizol
Ja
Nein
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-Intraoperative medication
Intraoperative Medikamente
Ja
Nein
Paracetamol
Ja
Nein
Intraoperative Medikamente
Ja
Nein
NSAR
Ja
Nein
Intraoperative Medikamente
Ja
Nein
Cox-2-Hemmer
Ja
Nein
Intraoperative Medikamente
Ja
Nein
Intraoperative Medikamente:Sonstige
Ja
Nein
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Visit documentation RICH study
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Patient Information
ID of Center
ID of patient
Details about documentation period:
primary continous RRT has to be reported
until the end. Visit documentaiton ends
with transfer from primary ICU. IMC data
can be taken (depending on availabilty).
Name of time interval:
0 (Randomisation until start of day 1 of
stay) (0 (Randomisation until start of day
1 of stay))
1 (day of stay: 1) (1 (day of stay: 1))
10 (day of stay: 10) (10 (day of stay: 10))
11 (day of stay: 11) (11 (day of stay: 11))
12 (day of stay: 12) (12 (day of stay: 12))
13 (day of stay: 13) (13 (day of stay: 13))
14 (day of stay: 14) (14 (day of stay: 14))
15 (day of stay: 15) (15 (day of stay: 15))
16 (day of stay: 16) (16 (day of stay: 16))
17 (day of stay: 17) (17 (day of stay: 17))
18 (day of stay: 18) (18 (day of stay: 18))
19 (day of stay: 19) (19 (day of stay: 19))
2 (day of stay: 2) (2 (day of stay: 2))
20 (day of stay: 20) (20 (day of stay: 20))
21 (day of stay: 21) (21 (day of stay: 21))
22 (day of stay: 22) (22 (day of stay: 22))
23 (day of stay: 23) (23 (day of stay: 23))
24 (day of stay: 24) (24 (day of stay: 24))
25 (day of stay: 25) (25 (day of stay: 25))
26 (day of stay: 26) (26 (day of stay: 26))
27 (day of stay: 27) (27 (day of stay: 27))
28 (day of stay: 28) (28 (day of stay: 28))
3 (day of stay: 3) (3 (day of stay: 3))
4 (day of stay: 4) (4 (day of stay: 4))
5 (day of stay: 5) (5 (day of stay: 5))
6 (day of stay: 6) (6 (day of stay: 6))
7 (day of stay: 7) (7 (day of stay: 7))
8 (day of stay: 8) (8 (day of stay: 8))
9 (day of stay: 9) (9 (day of stay: 9))
Start Date:
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Start Time:
End Date:
End Time:
Adverse Event
Newly occured adverse event?
Yes
No
Newly occured adverse event:
If "yes", specify (AE-number and if necessary
SAE-report)
Yes
No
Glasgow Coma Scale (if analog sedated
patient, please not the working instruction)
Glasgow Coma Scale: Eyes opening:
4-spontaneuously
3-Eye opening to speech
2-Eye opening in response to pain stimulus
1-No eye opening
Glasgow Coma Scale: Verbal response:
5-Oriented
4-Confused
3-Inappropriate words
2-Incomprehensible sounds
1-No verbal response
Glasgow Coma Scale: Eyes opening:
6-Obeys commands
5-Localizes to pain
4-Withdrawal from pain
3-Flexor response
2-Extensor response
1-No motor response
Was the GCS estimated?
Yes
No
Mechanical ventilation
Mechanical ventilation:
(the most severe form of mechanical ventilation)
invasive ventilation (invasive ventilation)
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no ventilation (no ventilation)
non-invasive ventilation (non-invasive
ventilation)
Catecholamine and inotropic therapy
Have Vasopressors or inotropics been
administered?
Yes
No
Adrenaline Therapy?
Yes
No
Adrenaline Therapy:
If "yes", specify highest dosage over at least 1h:
Adrenaline Therapy:
If "yes", specify the unit of the dosage:
mg/h (mg/h)
μg/kg/min (μg/kg/min)
μg/min (μg/min)
Noradrenaline Therapy?
Yes
No
Noradrenaline Therapy:
If "yes", specify highest dosage over at least 1h:
Noradrenaline Therapy:
If "yes", specify the unit of the dosage:
mg/h (mg/h)
μg/kg/min (μg/kg/min)
μg/min (μg/min)
Dobutamine Therapy?
Yes
No
Dobutamine Therapy:
If "yes", specify highest dosage over at least 1h:
Dobutamine Therapy:
If "yes", specify the unit of the dosage:
mg/h (mg/h)
μg/kg/min (μg/kg/min)
μg/min (μg/min)
Vasopressins therapy?
Yes
No
Vasopressins therapy: 
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If "Yes", specify highest dosage:
IE/h
Terlipressin therapy?
Yes
No
Milrinone therapy?
Yes
No
Milrinone therapy:
If "Yes", specify highest dosage over at least 1h:
(possible units μg/ kg/ min or mg/h)
Milrinone Therapy:
If "yes", specify the unit of the dosage:
mg/h (mg/h)
μg/kg/min (μg/kg/min)
Levosimendan therapy?
Yes
No
Levosimendan therapy:
If "Yes", specify highest dosage over at least 1h:
μg/ kg/ min
Clinical Data
Body temperature - Minimum:
°C
Body temperature - Maximum:
°C
Systolic Blood Pressure - Minimum:
mmHg
Systolic Blood Pressure - Maximum:
mmHg
Mean arterial pressure - Minimum:
mmHg
Mean arterial pressure - Maximum:
mmHg
Diastolic blood pressure - Minimum:
mmHg
Diastolic blood pressure - Maximum:
mmHg
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Heart rate - Minimum:
/min
Heart rate - Maximum:
/min
Respiratory Rate - Minimum:
(Spontaneously or ventilated)
/min
Respiratory Rate - Maximum:
(Spontaneously or ventilated)
/min
Central venous pressure - Minimum:
Central venous pressure - Maximum:
ECMO therapy?
Yes
No
Intra-Aortic Balloon Pumping Therapy?
Yes
No
Concomitant medication
Diuretics?
Yes
No
X-ray contrast media?
Yes
No
Aminoglycosides?
Yes
No
Amphotericin?
Yes
No
Vancomycin?
Yes
No
Low molecular weight heparin (prophylactic)?
(PTT < 60s; Anti-Xa < 0,6; INR < 2)
Yes
No
Systemic heparin (prophylactic)?
Yes
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No
Laboratory Parameters and Blood Gas
Analysis
Arterial pCO2 - Minimum
(BGA with max. FiO2)
(possible units: kPa or mmHg)
Arterial pCO2 - Maximum
(BGA with max. FiO2)
(possible units: kPa or mmHg)
Arterial pCO2:
possible units:
kPa  (kPa )
mmHg (mmHg)
Arterial pCO2 - Minimum
(BGA with max. FiO2)
(possible units: kPa or mmHg)
Arterial pO2 - Maximum
(BGA with max. FiO2)
(possible units: kPa or mmHg)
Arterial pO2: 
possible units:
kPa  (kPa )
mmHg (mmHg)
FiO2 - Minimum:
(for not intubated patients is this value equal to
21% (0,21))
%
FiO2 - Maximum:
(for not intubated patients is this value equal to
21% (0,21))
%
Arterial pH - Minimum:
Arterial pH - Maximum:
Base excess - Minimum:
(measured in arterial blood)
mmol/L
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Base excess - Maximum:
(measured in arterial blood)
mmol/L
Bicarbonate - Minimum:
mmol/L
Bicarbonate - Maximum:
mmol/L
Potassium - Minimum:
Potassium - Maximum:
Potassium:
possible units:
mg/dL (mg/dL)
mmol/L (mmol/L)
Sodium - Minimum:
Sodium - Maximum:
Sodium:
possible units:
mg/dL (mg/dL)
mmol/L (mmol/L)
Lactic acid - Maximum:
Lactic acid:
possible Units:
mg/dL (mg/dL)
mmol/L (mmol/L)
Creatinine - Minimum:
Creatinine - Maximum:
Creatinine:
possible units:
mg/dL (mg/dL)
μmol/L (μmol/L)
Glomerular Filtration Rate 
(Please use Cockcroft-Gault-Formular)
mL/min
Serum Urea - Maximum:
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Serum Urea:
possible units:
mg/DL (mg/DL)
mmol/L (mmol/L)
μmol/L (μmol/L)
Urea -  determination:
Urea (Urea)
Urea-nitrogen (Urea-nitrogen)
Leukocytes - Minimum:
Leukocytes - Maximum:
Leukocytes :
possible units:
1/μL (1/μL)
G/I or 1/nL or 1000/μL (G/I or 1/nL or
1000/μL)
Thrombocytes - Minimum:
Thrombocytes - Maximum:
Thrombocytes:
possible units:
1/μL (1/μL)
G/I or 1/nL or 1000/μL (G/I or 1/nL or
1000/μL)
Haemoglobin - Minimum:
Haemoglobin - Maximum:
Haemoglobin:
possible units:
g/dL (g/dL)
mmol/L (mmol/L)
Haematocrit - Minimum:
Haematocrit - Maximum:
Haematocrit:
possible units:
[/] ([/])
% (%)
PTT - Minimum:
sec.
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PTT - Maximum:
sec.
International Normalization Ratio (INR) -
Minimum:
International Normalization Ratio (INR) -
Maximum:
CRP - Maximum:
CRP: 
possible units:
mg/dL (mg/dL)
mg/L  (mg/L )
CRP: 
Description:
value with < described (value with <
described)
value with > described (value with >
described)
Bilirubin - Maximum:
Bilirubin:
possible units:
mg/dL (mg/dL)
μmol/L (μmol/L)
Phosphate - Minimum:
Phosphate - Maximum:
Phosphate:
possible units:
mg/dL  (mg/dL )
mmol/L (mmol/L)
Magnesium - Minimum:
Magnesium - Maximum:
Magnesium:
possible units:
mg/dL  (mg/dL )
mmol/L (mmol/L)
Chloride - Minimum:
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Chloride - Maximum:
Chloride: 
possible units:
g/L (g/L)
mg/dL (mg/dL)
mmol/L, mEq/L  (mmol/L, mEq/L )
Procalcitonin:
ng/mL
Procalcitonin: 
Description:
value with < described (value with <
described)
value with > described (value with >
described)
Ionized Calcium - Miniumum:
mmol/L
Ionized Calcium - Maximum:
mmol/L
Total Calcium - Miniumum:
mmol/L
Total Calcium - Maximum:
mmol/L
Fluid balance
Fluid intake (cumulative)
(among others: i.v. infusions, thrombocyte
concentrates, erythrocyte concentrates, fresh
plasma and enteral nutrition)
mL
Fluid output (cumulative)
(among others: faeces, urin, dialysat, vomiting,
drainage and blood loss. Caution: irrigations are
excluded)
mL
Urinary excretion
mL
Duration of Urine Test:
h
Transfusion
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Bleeding complication?
Yes
No
Blood loss:
mL
Erythrocyte concentrate:
mL
Fresh Frozen Plasma (FFP):
mL
Thrombocyte concentrate:
mL
Cell saver
mL
Microbiology
Any microbiological proven infection?
Yes
No
Gram-positive bacteria?
Yes
No
Gram-negative bacteria?
Yes
No
Multiresitant bacteria?
Yes
No
Fungal infection?
Yes
No
Viral infection?
Yes
No
Test material:
Blood culture
Yes
No
Test material:
Tracheal secretion
Yes
No
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Test material:
Urine
Yes
No
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Documentation of Course: Solid Tumors
NCT00000000
Documentation of Course NCT00000000
Verlaufsbogen solide Tumoren
Part
All rights reserved. Please visit https://medical-data-
models.org/forms/16049
Documentation of Course: Solid
Tumors NCT00000000
Visit Information
Patient Name
Date
Registration
appointment date
Attending physician
Basic Tumor Information
Diagnosis
Location
Date of first diagnosis
Tumor Stage
Clinical Stage
Participation in study or special follow-up
Yes
No
Specification
Medical history
Karnofsky Performance Status
Weight
new skin finding
Yes
No
1 / 3
unexplained weight loss
Yes
No
Unexplained fever
Yes
No
unexplained night sweat
Yes
No
psychooncological support
planned (1)
not necessary (2)
refused (3)
Physical examination
Desciption of Tumor site and surroundings
lymph drainage region and Lymph node Status
Rest of skin and visible Mucosa examination
List of Examinations
Type of examination
Laboratory (1)
Sonography of Lymph nodes (2)
Sonography of Abdomen (3)
PET-CT (4)
CT of thorax (5)
CT of Abdomen (6)
MRI of Head (7)
Other (8)
last done on
Done Today
Yes
No
Examination caused by
Uni-MS (1)
Other doctor involved (2)
Result, Comments
Other
Recommendations
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Follow-up interval
12 (12)
3 (3)
6 (6)
Altering follow-up
Yes
No
Follow up date
Attending physician
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Skin Swab Topical SB-275833 Ointment 1%
For The Treatment Of Impetigo NCT00133874
Documentation part: Skin Swab
A Randomised, Observer-blind, Multicentre, Non-inferiority,
Comparative, Phase III Study of the Safety and Efficacy of
Topical 1% SB-275833 Ointment, Applied Twice Daily for 5
Days, versus Topical 2% Sodium Fusidate Ointment
Applied Three Times Daily for 7 Days in the Treatment of
Adult and Paediatric Subjects with Impetigo.
ClinicalTrials.gov  Identifier: NCT00133874
Other Study ID Numbers: TOC100224
Responsible Party: GlaxoSmithKline
All rights reserved. Please visit https://medical-data-
models.org/forms/16050
Skin Swab Topical SB-275833
Ointment 1% For The Treatment Of
Impetigo NCT00133874
Culture Results for Skin Swab of Primary
Lesion
Was there any growth after 2 days?
No (no growth) (N)
Yes (Y)
If "yes", please specify:
Normal flora (1)
Candida species, yeast or mould (2)
Pathogen isolated for culture (3)
Pathogen Isolation for Skin Swab of
Primary Lesion (SKIN_P)
Isolate number
Quantitation: Colony count/growth estimate
1+ (10)
2+ (11)
3+ (12)
4+ (13)
Identification
Unidentified organsim (0000-00)
Mixed microbial flora (0012-00)
Acinetobacter species (0100-10)
Acinetobacter anitratus (0100-20)
Acinetobacter calcoaceticus (0100-30)
Acinetobacter lwoffi (0100-40)
Bacillus species (0310-10)
Moraxella catarrhalis (0400-20)
Citrobacter species (0500-10)
Citrobacter diversus (0500-20)
Citrobacter freundii (0500-30)
Corynebacterium species (0520-10)
Enterobacter species (0700-10)
Enterobacter aerogenes (0700-20)
Enterobacter agglomerans (0700-30)
Enterobacter amnigenus (0700-35)
Enterobacter cloacae (0700-40)
Enterobacter gergoviae (0700-45)
Enterobacter skazakii (0700-60)
Enterococcus species (0800-10)
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Enterococcus faecium (0800-35)
Enterococcus faecalis (0800-40)
Escherichia coli (0900-20)
Enterobacteriaceae (0995-50)
Gram negative non-Enterobacteriaceae
(0995-60)
Haemophilus species (1000-10)
Haemophilus influenzae (1000-30)
Haemophilus parainfluenzae (1000-40)
Klebsiella species (1100-10)
Klebsiella oxytoca (1100-20)
Klepsiella pneumoniae (1100-40)
Klebsiella pneumoniae I (1100-41)
Moraxella species (1250-10)
Morganella morganii (1300-20)
Neisseria species (1400-10)
Neisseria meningitidis (1400-30)
Non-fermenting gram negative bacilli
(1430-10)
Oxidase positive gram negative rod
(1442-10)
Pantoea species (1443-10)
Pasteurella species (1450-10)
Pasteurella haemolytica (1450-15)
Pasteurella multocida (1450-20)
Proteus species (1500-10)
Proteus mirabilis (1500-20)
Proteus penneri (1500-40)
Pseudomonas species (1700-10)
Pseudomonas aeruginosa (1700-20)
Pseudomonas alcaligenes (1700-22)
Pseudomonas fluorescens (1700-25)
Pseudomonas fluorescente/putida group
(1700-27)
Pseudomonas paucimobilis (1700-35)
Pseudomonas stutzeri (1700-50)
Pseudomonas vesicularis (1700-60)
Ralstonia pickettii (1725-10)
Serratia species (2000-10)
Serratia marcescens (2000-20)
Serratia odorifera (2000-35)
Staphylococcus aureus (2200-20)
Streptococcus species - non-haemolytic
(2300-05)
Streptococcus species (2300-10)
Streptococcus agalactiae (2300-20)
Streptococcus anginosis (2300-24)
Beta haemolytic streptococcus (2300-25)
Beta haemolytic streptococcus - non-
groupable (2300-26)
Streptococcus constellatus (2300-32)
Streptococcus dysgalactiae (2300-35)
Streptococcus equi (2300-36)
Streptococcus dysgalactiae - equisimilis
(2300-37)
Streptococcus equisimilis (2300-38)
Gamma haemolytic streptococcus (2300-
44)
Beta haemolytic streptococcus group A
(2300-45)
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Beta haemolytic streptococcus group B
(2300-50)
Beta haemolytic streptococcus group C
(2300-55)
Beta haemolytic streptococcus group D
(2300-56)
Beta haemolytic streptococcus group D
not Enterococcus (2300-57)
Beta haemolytic streptococcus group G
(2300-58)
Streptococcus intermedius (2300-59)
Beta haemolytic streptococcus group F
(2300-62)
Streptococcus pneumoniae (2300-70)
Streptococcus pyogenes (2300-80)
Streptococcus viridans (2300-90)
If "other", specify:
If pathogen(s) was recovered, were isolates sent
from the local laboratory to the Central
Laboratory (QUEST)?
No (N)
Yes (Y)
If "no", specify reason:
Gram Stain Results for Skin Swab of
Primary Lesion (SKIN_G1)
White Blood Cells (per 100x LPF)
0 or none (0)
1-9 or few (1)
10-24 or moderate (2)
>=25 or many (3)
Epithelial Cells (per 100x LPF)
0 or none (0)
1-9 or few (1)
10-24 or moderate (2)
>=25 or many (3)
Did the result indicate that organisms were
present?
No (N)
Yes (Y)
Gram stain results for skin swab of
primary lesion
Gram positive bacilli
0 or none (0)
5-9 (10)
10-50 or moderate (6)
>50 or many (7)
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1-4 (9)
Gram negative diplococci
0 or none (0)
5-9 (10)
10-50 or moderate (6)
>50 or many (7)
1-4 (9)
Gram positive diplococci
0 or none (0)
5-9 (10)
10-50 or moderate (6)
>50 or many (7)
1-4 (9)
Gram positive cocci in clusters
0 or none (0)
5-9 (10)
10-50 or moderate (6)
>50 or many (7)
1-4 (9)
Gram postive cocci in chains
0 or none (0)
5-9 (10)
10-50 or moderate (6)
>50 or many (7)
1-4 (9)
Gram variable bacilli
0 or none (0)
5-9 (10)
10-50 or moderate (6)
>50 or many (7)
1-4 (9)
Gram negative bacilli
0 or none (0)
5-9 (10)
10-50 or moderate (6)
>50 or many (7)
1-4 (9)
Gram negative cocci
0 or none (0)
5-9 (10)
10-50 or moderate (6)
>50 or many (7)
1-4 (9)
Gram negative coccobacilli
0 or none (0)
5-9 (10)
10-50 or moderate (6)
>50 or many (7)
1-4 (9)
Hyphal elements
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0 or none (0)
5-9 (10)
10-50 or moderate (6)
>50 or many (7)
1-4 (9)
Yeast
0 or none (0)
5-9 (10)
10-50 or moderate (6)
>50 or many (7)
1-4 (9)
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Clinical evaluation & outcome evaluation Topical SB-275833
Ointment 1% For The Treatment Of Impetigo NCT00133874
Documentation part: Clinical evaluation & outcome
evaluation
A Randomised, Observer-blind, Multicentre, Non-inferiority,
Comparative, Phase III Study of the Safety and Efficacy of
Topical 1% SB-275833 Ointment, Applied Twice Daily for 5
Days, versus Topical 2% Sodium Fusidate Ointment
Applied Three Times Daily for 7 Days in the Treatment of
Adult and Paediatric Subjects with Impetigo.
ClinicalTrials.gov  Identifier: NCT00133874
Other Study ID Numbers: TOC100224
Responsible Party: GlaxoSmithKline
All rights reserved. Please visit https://medical-data-
models.org/forms/16052
Clinical evaluation & outcome
evaluation Topical SB-275833
Ointment 1% For The Treatment Of
Impetigo NCT00133874
Clinical Evaluation
Clinical Evaluation
Improvement (1)
Worsening (2)
No change (3)
Withdrawal
Is the subject withdrawing from treatment at this
visit?
No (N)
Yes (Y)
Clinical outcome determination (OUT)
Clinical success
No (N)
Yes (Y)
Clinical failure
No (N)
Yes (Y)
If "Yes", please specify if this was due to Primary
or Secondary lesion:
Primary lesion (P)
Secondary lesion (S)
Date of failure
DDMONYYYY
Unable to determine, please specify:
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Documentation part: Lesion measurement & Skin Swab 2
A Randomised, Observer-blind, Multicentre, Non-inferiority,
Comparative, Phase III Study of the Safety and Efficacy of
Topical 1% SB-275833 Ointment, Applied Twice Daily for 5
Days, versus Topical 2% Sodium Fusidate Ointment
Applied Three Times Daily for 7 Days in the Treatment of
Adult and Paediatric Subjects with Impetigo.
ClinicalTrials.gov  Identifier: NCT00133874
Other Study ID Numbers: TOC100224
Responsible Party: GlaxoSmithKline
All rights reserved. Please visit https://medical-data-
models.org/forms/16053
Lesion measurement & Skin Swab 2
Topical SB-275833 Ointment 1% For
The Treatment Of Impetigo
NCT00133874
Primary lesion measurement and dressing
type (LESION)
Lesion length
>= 0
mm
Lesion width
>= 0
mm
Lesion area
>= 0
cm^2
Lesion dressing type
None (N)
Occlusive (O)
Semi-occlusive (S)
Secondary lesion measurement and
dressing type (LESION2)
Lesion length
>= 0
mm
Lesion width
>= 0
mm
Lesion area
>= 0
cm^2
Lesion dressing type
None (N)
Occlusive (O)
Semi-occlusive (S)
Results for Skin Swab of secondary lesion
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(SKIN2)
Was there any growth after 2 days?
No (no growth) (N)
Yes (Y)
If "yes", please specify:
Normal flora (1)
Candida species, yeast or mould (2)
Pathogen isolated for culture (3)
Pathogen isolation for skin of secondary
lesion (SKIN2_P)
Isolate number
Quantitation: Colony count/growth estimate
1+ (10)
2+ (11)
3+ (12)
4+ (13)
Identification
Unidentified organsim (0000-00)
Mixed microbial flora (0012-00)
Acinetobacter species (0100-10)
Acinetobacter anitratus (0100-20)
Acinetobacter calcoaceticus (0100-30)
Acinetobacter lwoffi (0100-40)
Bacillus species (0310-10)
Moraxella catarrhalis (0400-20)
Citrobacter species (0500-10)
Citrobacter diversus (0500-20)
Citrobacter freundii (0500-30)
Corynebacterium species (0520-10)
Enterobacter species (0700-10)
Enterobacter aerogenes (0700-20)
Enterobacter agglomerans (0700-30)
Enterobacter amnigenus (0700-35)
Enterobacter cloacae (0700-40)
Enterobacter gergoviae (0700-45)
Enterobacter skazakii (0700-60)
Enterococcus species (0800-10)
Enterococcus faecium (0800-35)
Enterococcus faecalis (0800-40)
Escherichia coli (0900-20)
Enterobacteriaceae (0995-50)
Gram negative non-Enterobacteriaceae
(0995-60)
Haemophilus species (1000-10)
Haemophilus influenzae (1000-30)
Haemophilus parainfluenzae (1000-40)
Klebsiella species (1100-10)
Klebsiella oxytoca (1100-20)
Klepsiella pneumoniae (1100-40)
Klebsiella pneumoniae I (1100-41)
Moraxella species (1250-10)
Morganella morganii (1300-20)
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Neisseria species (1400-10)
Neisseria meningitidis (1400-30)
Non-fermenting gram negative bacilli
(1430-10)
Oxidase positive gram negative rod
(1442-10)
Pantoea species (1443-10)
Pasteurella species (1450-10)
Pasteurella haemolytica (1450-15)
Pasteurella multocida (1450-20)
Proteus species (1500-10)
Proteus mirabilis (1500-20)
Proteus penneri (1500-40)
Pseudomonas species (1700-10)
Pseudomonas aeruginosa (1700-20)
Pseudomonas alcaligenes (1700-22)
Pseudomonas fluorescens (1700-25)
Pseudomonas fluorescente/putida group
(1700-27)
Pseudomonas paucimobilis (1700-35)
Pseudomonas stutzeri (1700-50)
Pseudomonas vesicularis (1700-60)
Ralstonia pickettii (1725-10)
Serratia species (2000-10)
Serratia marcescens (2000-20)
Serratia odorifera (2000-35)
Staphylococcus aureus (2200-20)
Streptococcus species - non-haemolytic
(2300-05)
Streptococcus species (2300-10)
Streptococcus agalactiae (2300-20)
Streptococcus anginosis (2300-24)
Beta haemolytic streptococcus (2300-25)
Beta haemolytic streptococcus - non-
groupable (2300-26)
Streptococcus constellatus (2300-32)
Streptococcus dysgalactiae (2300-35)
Streptococcus equi (2300-36)
Streptococcus dysgalactiae - equisimilis
(2300-37)
Streptococcus equisimilis (2300-38)
Gamma haemolytic streptococcus (2300-
44)
Beta haemolytic streptococcus group A
(2300-45)
Beta haemolytic streptococcus group B
(2300-50)
Beta haemolytic streptococcus group C
(2300-55)
Beta haemolytic streptococcus group D
(2300-56)
Beta haemolytic streptococcus group D
not Enterococcus (2300-57)
Beta haemolytic streptococcus group G
(2300-58)
Streptococcus intermedius (2300-59)
Beta haemolytic streptococcus group F
(2300-62)
Streptococcus pneumoniae (2300-70)
Streptococcus pyogenes (2300-80)
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Streptococcus viridans (2300-90)
If "other", specify:
If pathogen(s) was recovered, were isolates sent
from the local laboratory to the Central
Laboratory (QUEST)?
No (N)
Yes (Y)
If "no", specify reason:
Gram stain results for skin swab of
secondary lesion (SKIN2_G1)
White Blood Cells (per 100x LPF)
0 or none (0)
1-9 or few (1)
10-24 or moderate (2)
>=25 or many (3)
Epithelial Cells (per 100x LPF)
0 or none (0)
1-9 or few (1)
10-24 or moderate (2)
>=25 or many (3)
Did the result indicate that organisms were
present?
No (N)
Yes (Y)
Gram stain results for skin swab of
secondary lesion (SKIN2_G2)
Gram positive bacilli
0 or none (0)
5-9 (10)
10-50 or moderate (6)
>50 or many (7)
1-4 (9)
Gram negative diplococci
0 or none (0)
5-9 (10)
10-50 or moderate (6)
>50 or many (7)
1-4 (9)
Gram positive diplococci
0 or none (0)
5-9 (10)
10-50 or moderate (6)
>50 or many (7)
1-4 (9)
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Gram positive cocci in clusters
0 or none (0)
5-9 (10)
10-50 or moderate (6)
>50 or many (7)
1-4 (9)
Gram postive cocci in chains
0 or none (0)
5-9 (10)
10-50 or moderate (6)
>50 or many (7)
1-4 (9)
Gram variable bacilli
0 or none (0)
5-9 (10)
10-50 or moderate (6)
>50 or many (7)
1-4 (9)
Gram negative bacilli
0 or none (0)
5-9 (10)
10-50 or moderate (6)
>50 or many (7)
1-4 (9)
Gram negative cocci
0 or none (0)
5-9 (10)
10-50 or moderate (6)
>50 or many (7)
1-4 (9)
Gram negative coccobacilli
0 or none (0)
5-9 (10)
10-50 or moderate (6)
>50 or many (7)
1-4 (9)
Hyphal elements
0 or none (0)
5-9 (10)
10-50 or moderate (6)
>50 or many (7)
1-4 (9)
Yeast
0 or none (0)
5-9 (10)
10-50 or moderate (6)
>50 or many (7)
1-4 (9)
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Eligibility Type 2 Diabetes Mellitus
NCT02366351
The PK/PD, Efficacy, Safety and Tolerability Study of
SHR3824 in Type 2 Diabetes Mellitus Patients; ODM
derived from: https://clinicaltrials.gov/show/NCT02366351
All rights reserved. Please visit https://medical-data-
models.org/forms/16054
Eligibility Type 2 Diabetes Mellitus
NCT02366351
Inclusion Criteria
patients must have a diagnosis of type 2 diabetes
mellitus;*
Yes
No
hemoglobin a1c levels >=7.5% and <=10.5%;*
Yes
No
body mass index (bmi) 25 to 45 kg/m2;*
Yes
No
patient either has not been previously treated
with antihyperglycemic medication or has not
been treated with antihyperglycemic  in the last
10 weeks.*
Yes
No
Exclusion Criteria
type i diabetes mellitus, diabetes mellitus
resulting from pancreatic disorder, or secondary
diabetes mellitus (acromegaly, cushing's
syndrome, etc.);*
Yes
No
past or current history of severe diabetic
complications (proliferative diabetic retinopathy,
stage iii or later stage overt nephropathy, diabetic
ketoacidosis, or serious diabetic neuropathy);*
Yes
No
systolic blood pressure of ≥160 mmhg or diastolic
blood pressure of ≥100 mmhg on the start or end
day of the run-in period;*
Yes
No
history of myocardial infarction, unstable angina,
or cerebrovascular disorder within 6 months
before the start of the run-in period;*
Yes
No
past or current history of malignant tumor;*
Yes
No
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past or current history of drug hypersensitivity
such as shock and anaphylactoid symptoms;*
Yes
No
pregnant women, lactating mothers, or women of
childbearing potential;*
Yes
No
any condition that subjects are assessed to be
ineligible by the investigator (sub investigator).*
Yes
No
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Pregnancy Information Topical SB-275833 Ointment
1% For The Treatment Of Impetigo NCT00133874
Documentation part: Pregnancy Information
A Randomised, Observer-blind, Multicentre, Non-inferiority,
Comparative, Phase III Study of the Safety and Efficacy of
Topical 1% SB-275833 Ointment, Applied Twice Daily for 5
Days, versus Topical 2% Sodium Fusidate Ointment
Applied Three Times Daily for 7 Days in the Treatment of
Adult and Paediatric Subjects with Impetigo.
ClinicalTrials.gov  Identifier: NCT00133874
Other Study ID Numbers: TOC100224
Responsible Party: GlaxoSmithKline
All rights reserved. Please visit https://medical-data-
models.org/forms/16055
Pregnancy Information Topical SB-
275833 Ointment 1% For The
Treatment Of Impetigo
NCT00133874
Pregnancy Information (PREG)
Did the subject become pregnant during the
study?
No (N)
Yes (Y)
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Documentation part: Status of Treatment Bling & Study
Conclusion
A Randomised, Observer-blind, Multicentre, Non-inferiority,
Comparative, Phase III Study of the Safety and Efficacy of
Topical 1% SB-275833 Ointment, Applied Twice Daily for 5
Days, versus Topical 2% Sodium Fusidate Ointment
Applied Three Times Daily for 7 Days in the Treatment of
Adult and Paediatric Subjects with Impetigo.
ClinicalTrials.gov  Identifier: NCT00133874
Other Study ID Numbers: TOC100224
Responsible Party: GlaxoSmithKline
All rights reserved. Please visit https://medical-data-
models.org/forms/16056
Status of Treatment Bling & Study
Conclusion Topical SB-275833
Ointment 1% For The Treatment Of
Impetigo NCT00133874
Status of Treatment Blind (BLIND)
Was the treatment blind broken during the study?
No (N)
Yes (Y)
Date blind broken
DDMONYYYY
Reason blind broken
Medical emergency requiring
identification of investigational product
for further treatment (1)
Other (2)
If "Other", please specify:
Study Conclusion (CONC)
Date of subject completion or date of subject
withdrawal
Was the subject withdrawn from the study?
No (N)
Yes (Y)
If "Yes", select primary reason for withdrawal
Adverse event (1)
Lost to follow-up (2)
Protocol violation (3)
Subject decided to withdraw from the
study (4)
Lack of efficacy (5)
Sponsor terminated study (6)
Disease progression (7)
Other (OT)
If "other", specify:
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Documentation part: Log Status & Randomisation Number
A Randomised, Observer-blind, Multicentre, Non-inferiority,
Comparative, Phase III Study of the Safety and Efficacy of
Topical 1% SB-275833 Ointment, Applied Twice Daily for 5
Days, versus Topical 2% Sodium Fusidate Ointment
Applied Three Times Daily for 7 Days in the Treatment of
Adult and Paediatric Subjects with Impetigo.
ClinicalTrials.gov  Identifier: NCT00133874
Other Study ID Numbers: TOC100224
Responsible Party: GlaxoSmithKline
All rights reserved. Please visit https://medical-data-
models.org/forms/16057
Log Status & Randomisation
Number Topical SB-275833
Ointment 1% For The Treatment Of
Impetigo NCT00133874
Log Status
Did the subject experience any adverse events
during the study?
No (N)
Yes (Y)
Were any concomitant medications taken by the
subject prior to screening and/or during the
study?
No (N)
Yes (Y)
Case book ready for signature
Yes (Y)
For inform only: Do not data enter
Q1
No (N)
Yes (Y)
Q2
PF_SC_LOST (1)
PF_SC_DEATH (2)
PF_SC_SPONSORDECISlON (3)
PF_SC_PHYS[ClANDEClSlON (4)
PF_SC_PATIENTDEClSION (5)
PF_SC_AE (6)
PF_SC_CRlTERIA (7)
PF_SC_OTHER (8)
Randomisation Number (RAND)
Randomisation number
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Documentation part: Investigation Product Information
A Randomised, Observer-blind, Multicentre, Non-inferiority,
Comparative, Phase III Study of the Safety and Efficacy of
Topical 1% SB-275833 Ointment, Applied Twice Daily for 5
Days, versus Topical 2% Sodium Fusidate Ointment
Applied Three Times Daily for 7 Days in the Treatment of
Adult and Paediatric Subjects with Impetigo.
ClinicalTrials.gov  Identifier: NCT00133874
Other Study ID Numbers: TOC100224
Responsible Party: GlaxoSmithKline
All rights reserved. Please visit https://medical-data-
models.org/forms/16058
Investigation Product Information
Topical SB-275833 Ointment 1% For
The Treatment Of Impetigo
NCT00133874
Investigational Product Container Number
(PACK)
Investigational product container number
Investigational Product
Start date
DDMONYYYY
Start time
hh:mm
Stop Date
DDMONYYYY
Stop time
hh:mm
Total number of applications
Investigational Product Use (IP USE)
How much of the investigational product was
returned
<50% (0)
50% (1)
>50% (2)
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Subject/Guardian Activity Diary & Concomitant Medication Topical SB-
275833 Ointment 1% For The Treatment Of Impetigo NCT00133874
Documentation part: Subject/Guardian Activity Diary &
Concomitant Medication
A Randomised, Observer-blind, Multicentre, Non-inferiority,
Comparative, Phase III Study of the Safety and Efficacy of
Topical 1% SB-275833 Ointment, Applied Twice Daily for 5
Days, versus Topical 2% Sodium Fusidate Ointment
Applied Three Times Daily for 7 Days in the Treatment of
Adult and Paediatric Subjects with Impetigo.
ClinicalTrials.gov  Identifier: NCT00133874
Other Study ID Numbers: TOC100224
Responsible Party: GlaxoSmithKline
All rights reserved. Please visit https://medical-data-
models.org/forms/16059
Subject/Guardian Activity Diary &
Concomitant Medication Topical SB-
275833 Ointment 1% For The
Treatment Of Impetigo
NCT00133874
Subject/Guardian Activity Diary (DIARY)
How much effort has your child having had
impetigo had on your daily activities (attendance
at work, household chores, etc.) today?
0 - Not at All (0)
1 (1)
2 (2)
3 (3)
4 - Very Much (4)
Has your child having impetigo had any effect on
his or her normal daily activities (Attendance at
school, day care, play dates, recreational activity,
etc) today?
No (N)
Yes (Y)
Concomitant Medications (CONMEDS)
Drug name (Trade Name preferred)
Modified reported term
Total Daily Dose
Route
Epidural (EP)
Gastrostomy tube (GTT)
Intra-arterial (IA)
Intra-bursa (IB)
Inhalation (IH)
Intramuscular (IM)
Intranasal (IN)
Injection (INJ)
Inraocular (IO)
Intraosteal (IOS)
Intrathekal (IT)
Intrauterine (IU)
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Intravenous (IV)
Nasal (NS)
Bouth eyes (OU)
Oral (PO)
Rectal (PR)
Subcutaneous (SC)
Sublingual (SL)
Transdermal (TD)
Topical (TP)
Unknown (UNK)
Vaginal (VG)
Reason for Medication
Start date
DDMONYYYY
Ongoing?
No (N)
Yes (Y)
If "No", specify End date
DDMONYYYY
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Adverse Events & Clinical Outcome Evaluation Topical SB-275833
Ointment 1% For The Treatment Of Impetigo NCT00133874
Documentation part: Adverse Events & Clinical Outcome
Evaluation
A Randomised, Observer-blind, Multicentre, Non-inferiority,
Comparative, Phase III Study of the Safety and Efficacy of
Topical 1% SB-275833 Ointment, Applied Twice Daily for 5
Days, versus Topical 2% Sodium Fusidate Ointment
Applied Three Times Daily for 7 Days in the Treatment of
Adult and Paediatric Subjects with Impetigo.
ClinicalTrials.gov  Identifier: NCT00133874
Other Study ID Numbers: TOC100224
Responsible Party: GlaxoSmithKline
All rights reserved. Please visit https://medical-data-
models.org/forms/16061
Adverse Events & Clinical Outcome
Evaluation Topical SB-275833
Ointment 1% For The Treatment Of
Impetigo NCT00133874
Adverse Events (AE)
Event (diagnosis only, otherwise sign/symptom)
Modified term
Start date
DDMONYYYY
Outcome
Recovered/Resolved (1)
Recovering/Resolving (2)
Not recovered/Not resolved (3)
Recovered with sequelae (4)
Fatal (5)
If "Recovered/Resolved" or "Recovered/Resolved
with sequelae", provide End Date and Time
If "Fatal", record Date and Time of Death
Maximum Intensity
Mild (1)
Moderate (2)
Severe (3)
Not applicable (X)
Actions taken with Investigational Product(s) as a
Result of the AE
Investigational product(s) withdrawn (1)
Dose reduced (2)
Doce increased (3)
Dose not changed (4)
Dose interrupted (5)
Not applicable (X)
Did the subject withdraw from study as a result of
this AE?
Yes
No
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Is there a reasonable possibility that the AE may
have been caused by the investigational product?
Yes
No
Does the Adverse Event meet the definition of
serious?
No (N)
Yes (Y)
If "Yes", check all that apply
Results in death (A)
Is life-threatening (B)
Requires hospitalisation or prolongation
of existing hospitalisation  (C)
Results in disability/incapacity (D)
Congenital anomaly/birth defect (E)
Other (F)
If "Other", please specify
Was SAE caused by an activity related to study
participation (e.g., procedures)?
No (N)
Yes (Y)
Clinical Outcome Determination (OUT)
Clinical success
No (N)
Yes (Y)
Clinical recurrence
No (N)
Yes (Y)
If "Yes", please specify if this was due to Primary
or Secondary lesion:
Primary lesion (P)
Secondary lesion (S)
Date of recurrence
DDMONYYYY
Unable to determine clinical outcome, please
specify:
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Eligibility Type 2 Diabetes Mellitus
NCT02366377
The PK/PD, Efficacy, Safety and Tolerability Study of
SHR3824 in Combination With Metformin in Type 2
Diabetes Mellitus Patients; ODM derived from:
https://clinicaltrials.gov/show/NCT02366377
All rights reserved. Please visit https://medical-data-
models.org/forms/16062
Eligibility Type 2 Diabetes Mellitus
NCT02366377
Inclusion Criteria
patients must have a diagnosis of type 2 diabetes
mellitus;*
Yes
No
hemoglobin a1c levels >=7.5% and <=10.5%;*
Yes
No
body mass index (bmi) 25 to 45 kg/m2;*
Yes
No
patient either has been treated with metformin for
more than 8 weeks with dose more than
1500mg/day.*
Yes
No
Exclusion Criteria
type i diabetes mellitus, diabetes mellitus
resulting from pancreatic disorder, or secondary
diabetes mellitus (acromegaly, cushing's
syndrome, etc.);*
Yes
No
past or current history of severe diabetic
complications (proliferative diabetic retinopathy,
stage iii or later stage overt nephropathy, diabetic
ketoacidosis, or serious diabetic neuropathy);*
Yes
No
systolic blood pressure of ≥160 mmhg or diastolic
blood pressure of ≥100 mmhg on the start or end
day of the run-in period;*
Yes
No
history of myocardial infarction, unstable angina,
or cerebrovascular disorder within 6 months
before the start of the run-in period;*
Yes
No
past or current history of malignant tumor;*
Yes
No
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past or current history of drug hypersensitivity
such as shock and anaphylactoid symptoms;*
Yes
No
pregnant women, lactating mothers, or women of
childbearing potential;*
Yes
No
any condition that subjects are assessed to be
ineligible by the investigator (sub investigator).*
Yes
No
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General Info EBMT Lymphoma
ODM form derived from 16pp General Info EBMT
Lymphoma 04. please refer to:
http://www.ebmt.org/Contents/Data-
Management/Registrystructure/MED-
ABdatacollectionforms/Pages/MED-AB-data-collection-
forms.aspx
All rights reserved. Please visit https://medical-data-
models.org/forms/16064
16pp General Info EBMT Lymphoma
04
GENERAL INFORMATION Team
EBMT Centre Identification Code (CIC)
Hospital
Unit
Contact person
Telephone number
Fax
E-Mail
Date of this report
Patient following national / international study /
trial
No (1)
Yes (2)
Not evaluated (3)
Unknown (4)
Name of study / trial
GENERAL INFORMATION Patient
Unique Identification Code (UIC)
Hospital Unique Patient Number or Code
Initials
Date of birth:
Sex
Male (1)
Female (2)
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ABO Group
Rh factor
Absent (1)
Present  (2)
Not evaluated (3)
DISEASE
Date of diagnosis
Primary Disease Diagnosis
Acute Leukaemia (Acute Leukaemia)
Acute Lymphoblastic Leukaemia (ALL)
(Acute Lymphoblastic Leukaemia (ALL))
Acute Myelogenous Leukaemia (AML)
(Acute Myelogenous Leukaemia (AML))
Autoimmune disease (Autoimmune
disease)
Bone marrow failure including Aplastic
anaemia (Bone marrow failure including
Aplastic anaemia)
Chronic Leukaemia (Chronic Leukaemia)
Chronic Lymphocytic Leukaemia
(Chronic Lymphocytic Leukaemia)
Chronic Myeloid Leukaemia (CML)
(Chronic Myeloid Leukaemia (CML))
Haemoglobinopathy
(Haemoglobinopathiy)
Histiocytic disorders (Histiocytic
disorders)
Hodgkin´s Disease (Hodgkin´s Disease)
Inherited disorders (Inherited disorders)
Juvenile Idiopathic Arthritis (Juvenile
Idiopathic Arthritis)
Lymphoma (Lymphoma)
MD/ MPN (MD/ MPN)
MDS (MDS)
Metabolic disorders (Metabolic
disorders)
Multiple Sclerosis (Multiple Sclerosis)
Myelodysplastic syndromes
(Myelodysplastic syndromes)
Myeloma/ Plasma cell disorder
(Myeloma/ Plasma cell disorder)
Myeloproliferative neoplasm
(Myeloproliferative neoplasm)
Non Hodgkin (Non Hodgkin)
Other diagnosis (Other diagnosis)
Primary immune deficiencies (Primary
immune deficiencies)
Secondary Acute Leukaemia (do not use
if transformed from MDS/MPN)
(Secondary Acute Leukaemia (do not
use if transformed from MDS/MPN))
Solid Tumour (Solid Tumour)
Systemic Lupus (Systemic Lupus)
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Systemic Sclerosis (Systemic Sclerosis)
LYMPHOMA INITIAL DIAGNOSIS
Has the information requested in this section
been submitted with a previous transplant
registration for this patient?
Yes: go to page 4, Treatment given
before the 1st transplant (1)
No: proceed with this section (2)
Non Hodgkin Lymphoma (NHL) (3)
Non Hodgkin Lymphoma (NHL)
B-Cell Lymphomas (1)
Primary cutaneous follicle centre
lymphoma (10)
Mantle cell lymphoma (11)
Diffuse large B-cell lymphoma (DLBCL),
(NOS) (12)
T-cell/hystiocyte rich large B cell
lymphoma (13)
Primary DLBCL of the CNS (14)
Primary cutaneous DLBCL, leg type (15)
EBV positive DLBCL of the elderly (16)
DLBCL associated with chronic
inflammation (17)
Lymphomatoid granulomatosis (18)
Primary mediastinal (thymic) large B-cell
lymphoma (19)
Splenic marginal zone lymphoma (2)
Intravascular large B-cell lymphoma (20)
ALK positive large B-cell lymphoma (21)
Plasmablastic lymphoma (22)
Large B-cell lymphoma arising in HHV8-
associated multicentric Castleman
disease (23)
Primary effusion lymphoma (PEL) (24)
Burkitt lymphoma (BL) (25)
B-cell lymphoma, unclassifiable, with
features intermediate between diffuse
large B-cell lymphoma and Burkitt
lymphoma (Intermediate DLCBL/BL) (26)
B-cell lymphoma, unclassifiable, with
features intermediate between diffuse
large B-cell lymphoma and classical
Hodgkin lymphoma (Intermediate
DLCBL/HD) (27)
Other B-cell, specify: (28)
Extranodal marginal zone lymphoma of
mucosa associated lymphoid tissue
(MALT)  (3)
Nodal marginal zone lymphoma (4)
Lymphoplasmacytic lymphoma (LPL) (5)
Waldenstrom macroglobulinaemia (6)
(LPL with monoclonal IgM)  (7)
Follicular lymphoma (8)
CodelistItem 865324 (9)
Transformed from another type of lymphoma at
3 / 9
General Info EBMT Lymphoma
HSCT?
Yes
No
T-CELL AND NK-CELL NON HODGKIN
LYMPHOMAS (NHL)
T-cell large granular lymphocytic
leukaemia (1)
Mycosis fungoides (MF) (10)
Sézary syndrome  (11)
Lymphomatoid papulosis (12)
Primary cutaneous anaplastic large cell
lymphoma (13)
Primary cutaneous gamma-delta T-cell
lymphoma (14)
Primary cutaneous CD8 positive
aggressive epidermotropic cytotoxic T-
cell lymphoma (15)
Primary cutaneous CD4 positive
small/medium T-cell lymphoma (16)
Peripheral T-cell lymphoma, NOS
(PTCL) (17)
Angioimmunoblastic T-cell lymphoma
(18)
Anaplastic large-cell lymphoma (ALCL),
ALK-positive (19)
Aggressive NK-cell leukaemia (2)
Anaplastic large-cell lymphoma (ALCL),
ALK-negative (20)
Other T-cell, specify (21)
Systemic EBV positive T-cell
lymphoproliferative disease of childhood
(3)
Hydroa vacciniforme-like lymphoma (4)
Adult T-cell leukaemia/lymphoma (5)
Extranodal NK/T-cell lymphoma, nasal
type (6)
Enteropathy-associated T-cell lymphoma
(7)
Hepatosplenic T-cell lymphoma (8)
Subcutaneous panniculitis-like T-cell
lymphoma (9)
HODGKIN LYMPHOMA
Classical predominant (Classical
predominant)
Lymphocyte-depleted classical
(Lymphocyte-depleted classical)
Lymphocyte-rich classical (Lymphocyte-
rich classical)
Mixed cellularity classical (Mixed
cellularity classical)
Nodular lymphocyte  (Nodular
lymphocyte predominant)
Nodular sclerosis classical (Nodular
sclerosis classical)
Other, specify (Other, specify)
Stage at diagnosis
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I (I)
II (II)
III (III)
IV (IV)
Systemic symptoms
Absent (A) (Absent (A))
Not evaluated (Not evaluated)
Present (B) (Present (B))
Unknown (Unknown)
Size of largest mass
< 5 cm  (1)
5-10 cm  (2)
> 10 cm  (3)
No mass  (4)
Unknown (5)
LDH Level
Normal  (1)
Elevated  (2)
Not evaluated  (3)
Unknown (4)
Specific sites of involvement
Nodes below the diaphragm  (1)
Other (10)
Bone marrow  (2)
Extranodal (CNS) (3)
Mediastinum  (4)
Extranodal (testis /ovary)  (5)
Nodes above the diaphragm (6)
Lung  (7)
Liver  (8)
Spleen (9)
TREATMENT GIVEN BEFORE THE 1ST
TRANSPLANT
Has the information requested in this section
been submitted with a previous transplant
registration for this patient?
No: proceed with this section (No:
proceed with this section)
Yes: go to page 5, ”Disease History
before HSCT" (Yes: go to page 5,
”Disease History before HSCT")
WAS THE PATIENT TREATED BEFORE THE
1ST TRANSPLANT PROCEDURE?
WAS THE PATIENT TREATED BEFORE
THE 1ST TRANSPLANT PROCEDURE?
(1)
Yes Date started (2)
Sequential number of this treatment
(counted from diagnosis)
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Modality Chemo/drug/agent (including MoAB,
etc.)
No  (No )
Unknown (Unknown)
Yes: Regimen (Yes: Regimen)
If MoAB, radiolabelled
No  (No )
Unknown (Unknown)
Yes (Yes)
Radiotherapy
Yes
No
Response to this line of therapy
No response (< 50 %) ( No response (<
50 %))
Partial remission (> 50 %)  ( Partial
remission (> 50 %) )
Complete remission  (Complete
remission )
ADDITIONAL TREATMENT GIVEN BEFORE
THE 1ST TRANSPLANT?
No – Proceed to page 5, ”Disease
History before HSCT" (No – Proceed to
page 5, ”Disease History before HSCT")
Unknown (Unknown)
Yes Date started (Yes Date started)
Chemo/drug/agent
Yes
No
Treatment Regimen
Radiotherapy
Yes
No
Response to this line of therapy
Partial remission (> 50 %)  ( Partial
remission (> 50 %) )
Complete remission  (Complete
remission )
No response (< 50 %) (No response (<
50 %))
DISEASE HISTORY BEFORE HSCT
Date of transplant
Total number of lines before this transplant
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Modality used at least once
Chemotherapy (1)
MoAB (Immunotherapy) (2)
Radiotherapy (3)
Splenectomy
Yes
No
TYPE OF RELAPSE
Resistant (Resistant)
Sensitive (responding) (Sensitive
(responding))
Untreated (untested) (Untreated
(untested))
Complete remission achieved before the 1st
transplant
Number of treatment lines necessary to
reach this first remission (3)
Number of CR’s (4)
No (No)
Yes: Date of first CR (Yes: Date of first
CR)
1st Relapse before the 1st transplant
Yes (1)
No (2)
STATUS OF DISEASE AT HSCT
If patient has ever achieved Complete remission
Complete remission (CR) (Complete
remission (CR))
Confirmed -By CT scan (Confirmed -By
CT scan)
Confirmed -By PET (Confirmed -By PET)
Relapse (Relapse)
Unconfirmed (Unconfirmed)
RELAPSE
Yes
No
TYPE OF RELAPSE
Resistant (Resistant)
Sensitive (responding) (Sensitive
(responding))
Untreated (untested) (Untreated
(untested))
If patient has never achieved a Complete
remission
PR ( PR)
Primary refractory disease ( Primary
refractory disease)
At diagnosis (untreated) (At diagnosis
(untreated))
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Progression (Progression)
Very good 1st PR (> 90 %) (Very good
1st PR (> 90 %))
NUMBER OF THIS partial response
1st (1st)
2nd (2nd)
3rd or higher (3rd or higher)
DISEASE INVOLVEMENT AT TRANSPLANT
No  (No )
Not evaluated  (Not evaluated )
Unknown (Unknown)
Yes  (Yes )
Size of largest mass
> 10 cm  ( > 10 cm )
5-10 cm  ( 5-10 cm )
No mass  ( No mass )
Not evaluated ( Not evaluated)
< 5 cm  (< 5 cm )
Specific sites of disease (to be completed ONLY
if patient NOT in CR at transplant)
Nodes below the diaphragm  Bone
marrow  (1)
Extranodal (CNS) (2)
Mediastinum  (3)
Extranodal (testis /ovary)  (4)
Nodes above the diaphragm (5)
Lung  (6)
Liver  (7)
Spleen (8)
Bone marrow (9)
Number of relapses in the last 12 months
unknown
1st (1)
2nd (2)
3rd or higher (3)
ADDITIONAL TREATMENT POST-HSCT
Additional Disease Treatment
Not planned (for relapse/progression or
persistent disease) ( Not planned (for
relapse/progression or persistent
disease))
No (No)
Unknown (Unknown)
Yes:  Planned (planned before HSCT
took place) (Yes:  Planned (planned
before HSCT took place))
Start of treatment
Modality
agent (including MoAB, vaccination, etc.)
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(agent (including MoAB, vaccination,
etc.))
Chemo (Chemo)
drug (drug)
Radiotherapy
yes no=no not known=not known (yes)
BEST DISEASE RESPONSE AT 100
DAYS POST-HSCT
BEST RESPONSE AT 100 DAYS AFTER
TRANSPLANTATION
( )
Complete remission confirmed by CT
scan ( By CT scan)
Complete remission confirmed by PET (
By PET)
Early death/Not evaluable ( Early
death/Not evaluable)
No response (< 50 %) ( No response (<
50 %))
Partial remission (> 50 %)  ( Partial
remission (> 50 %) )
Progression  ( Progression )
Complete remission (maintained or
achieved)  (Complete remission
(maintained or achieved) )
If Complete remission: Date of CR
FORMS TO BE FILLED IN
TYPE OF TRANSPLANT
AUTOgraft, proceed to Autograft form (1)
ALLOgraft or Syngeneic graft, proceed to
Allograft form (2)
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EBMT Multiple Sclerosis Form General
Information
ODM form derived from 15pp EBMT Multiple Sclerosis
13MS please refer to: http://www.ebmt.org/Contents/Data-
Management/Registrystructure/MED-
ABdatacollectionforms/Pages/MED-AB-data-collection-
forms.aspx 
All rights reserved. Please visit https://medical-data-
models.org/forms/16066
15pp EBMT Multiple Sclerosis Form
General Information
GENERAL INFORMATION Team
EBMT Centre Identification Code (CIC)
Hospital
Unit
Name of contact person
Telephone
Fax
E-mail
Date of this report
Patient following national / international study /
trial
No (1)
Yes (2)
Not evaluated (3)
Unknown (4)
Name of study / trial
PATIENT
To be entered only if patient previously reported
Hospital Unique Patient Number or Code
First name(s)_surname(s)
Date of birth
Sex
Male (1)
Female (2)
1 / 8
ABO Group
Rh factor
Absent (1)
Present (2)
Not evaluated (3)
DISEASE
Date of Diagnosis
Primary Disease Diagnosis
Acute Leukaemia (Acute Leukaemia)
Acute Lymphoblastic Leukaemia (ALL)
(Acute Lymphoblastic Leukaemia (ALL))
Acute Myelogenous Leukaemia (AML)
(Acute Myelogenous Leukaemia (AML))
Autoimmune disease (Autoimmune
disease)
Bone marrow failure including Aplastic
anaemia (Bone marrow failure including
Aplastic anaemia)
Chronic Leukaemia (Chronic Leukaemia)
Chronic Lymphocytic Leukaemia
(Chronic Lymphocytic Leukaemia)
Chronic Myeloid Leukaemia (CML)
(Chronic Myeloid Leukaemia (CML))
Hemoglobinopathies
(Haemoglobinopathiy)
Histiocytic disorders (Histiocytic
disorders)
Hodgkin´s Disease (Hodgkin´s Disease)
Inherited disorders (Inherited disorders)
Juvenile Idiopathic Arthritis (Juvenile
Idiopathic Arthritis)
Lymphoma (Lymphoma)
MD/ MPN (MD/ MPN)
MDS (MDS)
Metabolic disorders (Metabolic
disorders)
Multiple Sclerosis (Multiple Sclerosis)
Myelodysplastic syndromes
(Myelodysplastic syndromes)
Myeloma/ Plasma cell disorder
(Myeloma/ Plasma cell disorder)
Myeloproliferative neoplasm
(Myeloproliferative neoplasm)
Non Hodgkin (Non Hodgkin)
Other diagnosis (Other diagnosis)
Primary immune deficiencies (Primary
immune deficiencies)
Secondary Acute Leukaemia (do not use
if transformed from MDS/MPN)
(Secondary Acute Leukaemia (do not
use if transformed from MDS/MPN))
Solid Tumour (Solid Tumour)
Systemic Lupus (Systemic Lupus)
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Systemic Sclerosis (Systemic Sclerosis)
If other primary disease diagnosis, specify:
MULTIPLE SCLEROSIS
Neurologist Name
Address
Fax
Email
INITIAL DIAGNOSIS
Previous HSCT registration
No: Proceed with this section (No:
Proceed with this section)
Yes: go to `Pre-HSCT treatment` (Yes:
go to `Pre-HSCT treatment`)
Did the patient meet the Poser criteria fo
clinically-definite Multiple Sclerosis?
no (1)
yes (2)
unknown (3)
Did the patient meet the criteria for laboratory-
supported Multiple Sclerosis?
no (1)
yes (2)
unknown (3)
FIRST LINE THERAPIES
First line therapy
no Proceed to ”Date of HSCT” (1)
yes (2)
First line therapy start date
Drugs
no (1)
yes (2)
unknown (3)
if Drugs were administered, mark appropriate box
Cyclophosphamide (1)
beta interferon (10)
Mitoxantrone (2)
Anti-lymphocyte antibodies/globulins
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(ALG) (3)
Corticosteroids (4)
Chronic low dose   (5)
Pulse high dose (6)
Azathioprine (7)
Cop-I (8)
alphainterferon (9)
Total lymph node (TLI) Irradiation (radiotherapy)
Site
no (1)
yes (2)
unknown (3)
Irradiation Craniospinal
no (1)
yes (2)
unknown (3)
Lymphocytopheresis
no (1)
yes (2)
unknown (3)
Plasmapheresis
no (1)
yes (2)
unknown (3)
Other, specify modality
DATE OF HSCT
Date of HSCT
TRANSPLANT TYPE
Allogeneic (1)
Autologous: Mobilised (2)
Autologous: Mobilised
Yes
No
Date of Autologous: Mobilised
STATUS OF DISEASE AT MOBILISATION
Scripps neurological rating scale Score
Kurtzke functional systems overall score
Kurtzke Expanded Disability Status
Unknown (1)
Not evaluated (2)
Composite Scale Score
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MRI BRAIN SCAN
Date unknown (Date unknown)
Not done prior to mobilisation (Not done
prior to mobilisation)
Yes (Yes)
Date of most recent MRI scan of brain
Gadolinium-enhancing lesions present results
None (None)
Not evaluated (Not evaluated)
Number (Number)
Unknown (Unknown)
If Gadolinium-enhancing lesions present
STATUS OF DISEASE AT HSCT
DISEASE COURSE
Not evaluable, explain (Not evaluable,
explain)
Primary progressive (Primary
progressive)
Progressive relapsing (malignant)
(Progressive relapsing (malignant))
Relapsing/Remitting
(Relapsing/Remitting)
Secondary progressive (may have had
previous Relapsing/Remitting)
(Secondary progressive (may have had
previous Relapsing/Remitting))
If DISEASE COURSE not evaluable please
explain
Did the patient progress during the 2-years prior
to mobilisation/HSCT?
no  (no )
unknown (unknown)
yes (yes)
If the patient progress during the 2-years prior to
mobilisation/HSCT? Number of
relapses/progressions
Scripps neurological rating scale
Unknown (1)
Not evaluated (2)
Kurtzke functional systems Overall score
Kurtzke Expanded Disability Status Scale (EDSS)
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Composite Scale Score
MRI BRAIN SCAN DONE
Not done prior to HSCT (Not done prior
to HSCT)
Yes: (Yes:)
If MRI BRAIN SCAN DONE Date of most recent
MRI scan of brain:
Date of most recent MRI scan of brain:
Date unknown (1)
Gadolinium-enhancing lesions present
ADDITIONAL TREATMENT POST-HSCT
ADDITIONAL TREATMENT FOR MULTIPLE
SCLERORIS
Yes
No
Date started if patient receive additional
treatment post-HSCT
Overall main reason
Relapse/progression (1)
Continued from pre-HSCT (2)
unknow (3)
Planned per protocol (4)
Other, specify (5)
If other, please specify:
Drugs administered?
No (No)
Unknown (Unknown)
Yes (Yes)
If drugs administered: Please mark
Cyclophosphamide (1)
Beta-interferon (10)
Mitoxantrone (2)
Anti-lymphocyte antibodies (3)
Corticosteroids (4)
low dose (5)
high dose (6)
Azathioprine (7)
CopI (8)
Alpha-interferon (9)
Irradiation (radiotherapy) Total lymph node (TLI)
no (no)
unknown (unknown)
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yes (yes)
Irradiation (radiotherapy) Craniospinal
no  (1)
yes (2)
unknown (3)
Other modality Lymphocytopheresis
no (1)
yes (2)
unknown (3)
Other modality Plasmapheresis
no  (1)
yes (2)
unknown (3)
If other modality please specify
STATUS AT 100 DAYS POST-HSCT
DATE OF EVALUATION
CLINICAL EVALUATION Scripps neurological
rating scale
CLINICAL EVALUATION Kurtzke functional
systems
CLINICAL EVALUATION Kurtzke Expanded
Disability Status
CLINICAL EVALUATION Composite Scale
MRI BRAIN SCAN DONE
Date unknown (Date unknown)
Not done within 100 days from HSCT
(Not done within 100 days from HSCT)
Yes (Yes)
Results Results MRI
No (1)
Yes, Indicate new lesions present (2)
Unknown (3)
FORMS TO BE FILLED IN
Type of Transplant
ALLOgraft or Syngeneic graft (proceed to
Allograft form) (ALLOgraft or Syngeneic
graft (proceed to Allograft form))
AUTOgraft (proceed to Autograft form)
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(AUTOgraft (proceed to Autograft form))
Other (contact the EBMT Central
Registry for instructions) (Other (contact
the EBMT Central Registry for
instructions))
If Other Type of Transplant please specify
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Eligibility Dementia NCT00177489
Coordinating Center for Caregiver Intervention Trial; ODM
derived from: https://clinicaltrials.gov/show/NCT00177489
All rights reserved. Please visit https://medical-data-
models.org/forms/16067
Eligibility Dementia NCT00177489
Inclusion Criteria
inclusion criteria:*
Yes
No
1. age: 21 years or older*
Yes
No
2. family member of the care recipient*
Yes
No
3. must live with care recipient or share cooking
facilities*
Yes
No
4. must have a telephone that will enable use of
ctis (computer telephone integration system)
system*
Yes
No
5. must plan to remain in the recruitment area for
the duration of the intervention and follow-up*
Yes
No
6. caregiver role for more than 6 months*
Yes
No
7. must provide on average 4 hours of
supervision or direct assistance per day for the
care recipient*
Yes
No
8. risk screening tool: must have a total score of
at least 1 for questions 1-3, and a total of at least
2 for questions 4-9*
Yes
No
Exclusion Criteria
1. non-english, non-spanish speaking*
Yes
No
2. active treatment (chemotherapy, radiation
therapy) for cancer*
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Yes
No
3. imminent placement of care recipient into a
nursing home or with another caregiver (within 6
months)*
Yes
No
4. involvement in another clinical trial for
caregivers*
Yes
No
5. participant in reach i study*
Yes
No
6. spmsq:> or = 4 errors**
Yes
No
if the caregiver has been inconsistent with
answers or repeated answers during the
screening process, then the interviewer
administers the short portable mental status
questionnaire (spmsq). if the caregiver missed 4
or more questions, he/she was excluded from the
study.*
Yes
No
care recipient inclusion/exclusion criteria*
Yes
No
Inclusion Criteria
a. nincds (md diagnosis) of dementia or cognitive
impairment (raw score on mmse of 23 or less)*
Yes
No
Exclusion Criteria
1. non-english, non-spanish speaking*
Yes
No
2. history of parkinson’s disease or a stroke with
no reported decline in memory over the past
year*
Yes
No
3. active treatment (chemotherapy, radiation
therapy) for cancer*
Yes
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No
4. more than three acute medical hospitalizations
in past year (other than psychiatric or alzheimer’s
disease related admission)*
Yes
No
5. schizophrenia (onset of delusions before age
45) or other severe mental illness*
Yes
No
6. dementia secondary to head trauma
(probable)*
Yes
No
7. blindness or deafness if either disability
prohibits them from completion of data collection
or participation in the interventions*
Yes
No
8. mmse = 0 and bedbound (confined to a bed or
chair for _ 22 hours per day, for at least 4 of the
past 7 days)*
Yes
No
9. planned nursing home admission in 6 months*
Yes
No
10. participant in reach i study*
Yes
No
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Eligibility Diabetes Mellitus, Type 1
NCT00034255
Single Dose and 34-Day Tolerance Study of INGAP Peptide
in Insulin Deficient Patients; ODM derived from:
https://clinicaltrials.gov/show/NCT00034255
All rights reserved. Please visit https://medical-data-
models.org/forms/16068
Eligibility Diabetes Mellitus, Type 1
NCT00034255
Inclusion Criteria
patients meeting all of the following inclusion
criteria at screening can be considered for
admission to the study.*
Yes
No
stage 1 and stage 2:*
Yes
No
1. male and female patients with, type 1 diabetes
mellitus that are 18 through 70 years of age, or
type 2 diabetes mellitus that are 30 through 70
years of age.*
Yes
No
2. patients who are insulin deficient and are
diagnosed with type 1 or type 2 diabetes mellitus,
and are currently well managed with insulin, with
or without metformin.*
Yes
No
3. patients who have been on stable doses of
insulin treatment for 90 days prior to study
randomization.*
Yes
No
Exclusion Criteria
patients meeting any of the following exclusion
criteria at screening will not be enrolled in the
study:*
Yes
No
1. patients with a history of any clinically
significant retinopathy, symptomatic autonomic
neuropathy, unstable angina, or kidney
problems.*
Yes
No
2. patients with an uncontrolled or untreated
significant pulmonary, neurological condition, or
cardiovascular disease, including hypertension,
congestive heart failure, angina, or peripheral
vascular disease.*
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Yes
No
3. patients who have received any investigational
product within 30 days of admission into the
study.*
Yes
No
4. patients with a history or clinical evidence of
multiple organ autoimmune disorders.*
Yes
No
5. patients with a medical condition, serious
intercurrent illness, or extenuating circumstance
that would significantly decrease study
compliance, including all prescribed follow-up.*
Yes
No
6. patients who are lactating and breastfeeding.*
Yes
No
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EBMT Multiple Sclerosis follow up form
ODM form derived from 15pp EBMT Multiple Sclerosis
13MS please refer to: http://www.ebmt.org/Contents/Data-
Management/Registrystructure/MED-
ABdatacollectionforms/Pages/MED-AB-data-collection-
forms.aspx 
All rights reserved. Please visit https://medical-data-
models.org/forms/16069
15pp EBMT Multiple Sclerosis Follow
up form
FOLLOW UP MULTIPLE SCLEROSIS
Unique Identification Code (UIC)
(if known)
Date of this report
Patient following national / international study /
trial
No (1)
Yes (2)
Not evaluated (3)
Unknown (4)
Name of study / trial
Hospital Unique Patient Number
First name(s)_surname(s)
Date of Birth
Date of last HSCT for this patient
DATE OF LAST CONTACT OR DEATH
GRAFT VERSUS HOST DISEASE
(GvHD) SINCE LAST REPORT
Acute Graft versus Host Disease (aGvHD) -
Maximum grade
grade 0 (absent) (grade 0 (absent))
grade I (grade I)
grade II (grade II)
grade III (grade III)
grade IV (grade IV)
not evaluated (not evaluated)
If present GvHD, Maximum grade
New onset (1)
Recurrent (2)
Persistent (3)
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Reason Maximum grade
Tapering (1)
DLI (2)
Unexplained (3)
Date onset of this episode (if new or recurrent)
yyyy/mm/dd
Date onset of this episode
Not applicable (1)
aGvHD Stage Skin
0 (1)
1 (2)
2 (3)
3 (4)
4 (5)
Not evaluated (6)
unknown (7)
aGvHD Stage liver
0 (1)
1 (2)
2 (3)
3 (4)
4 (5)
Not evaluated (6)
unknown (7)
aGvHD stage gut
0 (1)
1 (2)
2 (3)
3 (4)
4 (5)
Not evaluated (6)
unknown (7)
Resolution
No  (1)
Yes (2)
aGvHD Date of resolutions
Presence of cGvHD
No (No)
Present continuously since last reported
episode (Present continuously since last
reported episode)
Resolved (Resolved)
Yes (Yes)
Date of onset
cGvHD grade
limited (1)
Extensive (2)
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Organs affected
Skin (1)
Gut (2)
Liver (3)
Mouth (4)
Eyes (5)
Lung (6)
Other, specify (7)
Unknown (8)
If other organs affected, please specify
cGvHD Resolved: Date of resolution
OTHER COMPLICATIONS SINCE LAST
REPORT
INFECTION RELATED COMPLICATIONS
No complications (1)
Yes (2)
Bacteremia / fungemia / viremia / parasites
Pathogen (1)
Date (2)
Septic shock
Pathogen  (1)
Date (2)
ARDS
Pathogen  (1)
Date (2)
Multiorgan failure due to infection
Pathogen  (1)
Date (2)
Pneumonia
Pathogen  (1)
Date (2)
Hepatitis
Pathogen  (1)
Date (2)
CNS infection
Pathogen  (1)
Date (2)
Gut infection
Pathogen  (1)
Date (2)
Skin infection
Pathogen  (1)
Date (2)
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Cystitis
Date (Date)
Pathogen (Pathogen)
Retinitis
Date (Date)
Pathogen (Pathogen)
Other pathogen specified
NON INFECTION RELATED COMPLICATIONS
No complications (1)
Yes (2)
Idiopathic pneumonia syndrome
No  (No )
Unknown (Unknown)
Yes (Yes)
VOD
No  (No )
Unknown (Unknown)
Yes (Yes)
Cataract
No (No)
Unknown (Unknown)
Yes (Yes)
Haemorrhagic cystitis, non infectious
No  (No )
Unknown (Unknown)
Yes  (Yes )
Specify:
ARDS, non infectious
No (No)
Unknown (Unknown)
Yes (Yes)
Multiorgan failure, non infectious
no  (no )
unknown (unknown)
yes  (yes )
HSCT-associated microangiopathy
Date (4)
No (No)
Unknown (Unknown)
Yes (Yes)
Renal failure requiring dialysis
Date (Date)
No (No)
Unknown (Unknown)
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Yes (Yes)
Haemolytic anaemia due to blood group
Date (4)
No (No)
Unknown (Unknown)
Yes (Yes)
Aseptic bone necrosis
Date (Date)
No (No)
Unknown (Unknown)
Yes (Yes)
Other type of NON INFECTION RELATED
COMPLICATIONS, please specify
Idiopathic pneumonia syndrome
Graft loss
No (No)
Not evaluated (Not evaluated)
Yes (Yes)
Overall chimaerism
Full (donor >95%) (1)
Mixed (partial) (2)
Autologuos reconstitution (recipient >
95%) (3)
Aplasia (4)
Not evaluated (5)
Date of test
(Indicate the date(s) and results of all tests done
for all donors. Split the results by donor and by
the cell type on which the test was performed if
applicable. Copy this table as many times as
necessary.)
Identification of donor or Cord Blood Unit given
by the centre
Number in the infusion order (if applicable)
Cell type on which test was performed % Donor
cells
B-Cells
%
BM (1)
Other, specify (10)
PB mononuclear cells (PBMC) (2)
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T-cell (3)
B-cells (4)
Red blood cells (5)
Monocytes (6)
PMNs (neutrophils) (7)
Lymphocytes, NOS (8)
Myeloid cells, NOS (9)
Laboratory tests used
ABO group (ABO group)
Cytogenetic (Cytogenetic)
FISH (FISH)
Molecular (Molecular)
Other (Other)
unknown (unknown)
Test used:
If other, specify:
SECONDARY MALIGNANCY,
LYMPHOPROLIFERATIVE OR
MYELOPROLIFRATIVE DISORDER
DIAGNOSED
No at date of this follow-up (No at date of
this follow-up)
Previously reported (Previously reported)
Yes (Yes)
Date of Diagnosis
Diagnosis OTHER COMPLICATIONS SINCE
LAST REPORT
AML (AML)
Lymphoproliferative disorder
(Lymphoproliferative disorder)
MDS (MDS)
Other (Other)
Diagnosis, other:
ADDITIONAL THERAPIES SINCE LAST
FOLLOW UP
Additional treatment given since last report
Date (4)
No (No)
Unknown (Unknown)
Yes (Yes)
If treatment given since last report
If yes: Cellular therapy (One cell therapy regimen
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is defined as any number of infusions given within
10 weeks for the same indication. If more than
one regimen of cell therapy has been given since
last report, copy this section and complete it as
many times as necessary.)
No  (1)
Yes (Mark disease status before this
cellular therapy) (2)
Unknown (3)
Disease status before this cellular therapy
CR (CR)
Not evaluated (Not evaluated)
Not in CR (Not in CR)
If yes: Type of cells
Donor lymphocyte infusion (DLI) (1)
Mesenchymal cells (2)
Other (3)
Unknown (4)
If other
Chronological number of this cell therapy for this
patient
Number of Nucleated cells infused (DLI only)
10^8/kg
Number (1)
Not evaluated (2)
Unknown (3)
If DLI, specify the number of cells infused by
type:
CD 34+
Evaluated (Evaluated)
Not Evaluated (Not Evaluated)
Unknown (Unknown)
If DLI, specify the number of cells infused by
type: 
CD 3+
Evaluated  (Evaluated )
Not evaluated (Not evaluated)
Unknown (Unknown)
If non DLI, specify total number of cells infused:
Evaluated (Evaluated)
Not Evaluated (Not Evaluated)
Unknown (Unknown)
Cell therapy indication
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Planned/protocol  (1)
Treatment for disease (2)
Prophylactic (3)
Mixed chimaerism (4)
Treatment of GvHD  (5)
Treatment viral infection (6)
Loss/decreased chimaerism  (7)
Treatment PTLD, EBV lymphoma (8)
Other, specify (9)
Number of infusions within 10 weeks (count only
infusions that are part of same regimen and given
for the same indication)
Acute Graft versus Host Disease 
(after this infusion but before any further infusion/
transplant)
Maximum grade:
grade 0 (absent) (grade 0 (absent))
grade 1 (grade 1)
grade 2 (grade 2)
grade 3 (grade 3)
grade 4 (grade 4)
present, grade unknown (present, grade
unknown)
Disease treatment (apart from donor cell infusion
or other type of cell therapy)
No (1)
Yes: Planned (planned before HSCT took
place) (2)
Yes: Not planned (for
relapse/progression or persistent
disease) (3)
Date started
Overall main reason ADDITIONAL THERAPIES
Relapse/progression (1)
Continued from pre-HSCT (2)
unknow (3)
Planned per protocol (4)
Other (5)
Of Other, please specify
Drugs
no (no)
unknown (unknown)
yes (yes)
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If yes, mark appropriate box
Alpha interferon (Alpha interferon)
Anti-lymphocyte antibodies (Anti-
lymphocyte antibodies)
Azathioprine (Azathioprine)
Interferon Beta  (Beta Interferon)
low dose (Chronic low dose)
CopI (Cop-I)
Corticosteroids (Corticosteroids)
Cyclophosphamide (Cyclophosphamide)
Mitoxantron (Mitoxantron)
high dose (Pulse high dose)
Total lymph node (TLI)
NO (NO)
UNKNOWN (UNKNOWN)
YES (YES)
Craniospinal
no (no)
unknown (unknown)
yes (yes)
Lymphocytopheresis
no (no)
unknown (unknown)
yes  (yes )
if other modality please specify:
FIRST EVIDENCE OF DISEASE
WORSENING SINCE LAST HSCT
EVIDENCE OF DISEASE ACTIVITY
Continuous worsening since HSCT
(Continuous worsening since HSCT)
No (No)
Previously reported (Previously reported)
Yes (Yes)
Date First Noted (mm-dd-yyyy)
Number of relapses/progressions since last
HSCT
LAST DISEASE AND PATIENT STATUS
Scripps neurological rating scale Score
Kurtzke functional systems Overall score
Kurtzke Expanded Disability Status Scale (EDSS)
Composite Scale Score
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MRI BRAIN SCAN DONE
Not done (Not done)
Yes (Yes)
Date of most recent MRI scan of brain
Results, Are new lesions present on the MRI?
no (no)
unknown (unknown)
yes (yes)
If yes Indicate new lesions present
Both (Both)
Gadolinium-enhancing (Gadolinium-
enhancing)
Unenhancing (Unenhancing)
Unknown (Unknown)
Has patient or partner become  pregnant after
this HSCT?
No (No)
Unknown (Unknown)
Yes (Yes)
Survival Status
alive (0)
dead (1)
Performance score (if alive)
Karnofsky (1)
Lansky (2)
Score
100 (Normal, NED) (1)
10 (Moribund) (10)
Not evaluated (11)
Unknown (12)
90 (Normal activity)  (2)
80 (Normal with effort) (3)
70 (Cares for self) (4)
60 (Requires occasional assistance) (5)
50 (Requires assistance) (6)
40 (Disabled) (7)
30 (Severely disabled) (8)
20 (Very sick) (9)
Cause of death (if dead)
Relapse or progression (1)
Secondary malignancy (including
lymphoproliferative disease) (2)
HSCT related cause  (3)
Unknown (4)
Other (5)
HSCT related cause
GvHD (1)
Veno-occlusive disease (VOD) (10)
Haemorrhage (11)
Cardiac toxicity (12)
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Central nervous system toxicity (13)
Gastro intestinal toxicity (14)
Skin toxicity (15)
Renal failure (16)
Multiple organ failure (17)
Other (18)
Interstitial pneumonitis (2)
Pulmonary toxicity (3)
Infection bacterial (4)
Infection viral (5)
Infection fungal (6)
Infection parasitic (7)
Infection unknown (8)
Rejection / poor graft function (9)
ADDITIONAL NOTES IF APPLICABLE
COMMENTS
Identification
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NINDS CDE Reproductive and Hormonal
History  Multiple Sclerosis
NINDS Common Data Elements, Multiple Sclerosis
Reproductive and Hormonal History 
Used from the National Institute of Neurological Disorders
and Stroke Common Data Elements
(https://www.commondataelements.ninds.nih.gov/)
References:
Grinnon ST, Miller K, Marler JR, Lu Y, Stout A, Odenkirchen
J, Kunitz S. National Institute of Neurological Disorders and
Stroke Common Data Element Project - approach and
methods. Clin Trials. 2012;9(3):322-9.
All rights reserved. Please visit https://medical-data-
models.org/forms/16070
Reproductive and Hormonal History
General Information
Study ID
Study site name
Subject ID
1. Have you ever given birth or fathered a child?
(Include current pregnancy and any 
pregnancies that resulted in early pregnancy
loss, whether by choice or not)
Yes (Please go to the next question)  (1)
No (Women, please go to question 3) (2)
Unknown (Stop, you are finished) (3)
Pregnancy Data
Pregnancy Outcome
Currently pregnant  (1)
Live birth  (2)
Miscarriage (3)
Therapeutic abortion or elective
termination (4)
Still birth (5)
Date
Menstruation/Pregnancy
1.  Are you of child-bearing potential?
yes (1)
no (2)
unknown (3)
2.  Have you ever had a menstrual period?
yes (1)
no (If No, you are finished) (2)
a.  If Yes, what age was your first period?
3. Do you use any forms of contraception
(periods may be regular or irregular)?
1 / 3
yes ( If Yes, indicate all forms of
contraception used (choose all that
apply))  (1)
no  (2)
unknown (3)
Oral contraceptives – combined pill (“the pill”)
Yes
No
Oral contraceptives – progestin-only pill (“minnmi-
pill”)
Yes
No
Transdermal patch (i.e., Ortho Evra)
Yes
No
Shot/injection (i.e., Depo-Provera)
Yes
No
Vaginal ring (i.e., NuvaRing)
Yes
No
Implantable devices with hormone (i.e.,
ParaGuard, 
Mirena)
Yes
No
Abstinence
Yes
No
None of these
Yes
No
4.  Are you currently pregnant?
yes (1)
no (2)
unknown (3)
a.  If Yes, indicate your due date:
Menopause
5.  Do you believe you are currently experiencing
menopause?
Yes
No
a.  If Yes, indicate the approximate date of your
last menstrual period:
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b.  Have you taken hormonal therapy?
Yes
No
i.  If Yes, specify name of hormonal therapy
taken:
ii.  If Yes, indicate which years you started and
stopped hormonal therapy:
Post-menopause
6.  Are you post-menopausal?
yes (1)
no (2)
unknown (3)
a.  If Yes, indicate cause:
Natural (1)
Surgical (complete hysterectomy –
ovaries and uterus removed), (2)
Surgical (partial hysterectomy – only
uterus removed) (3)
Medications or chemotherapy (4)
Date of hysterectomy
Other hormone-related syndromes
7.  Any other known hormone-related/endocrine
syndromes or disorders?
yes (1)
no (2)
unknown (3)
a.  If Yes, specify:
Polycystic ovary syndrome  (1)
Hyperthyroidism  (2)
Cushing’s syndrome (3)
Other, specify (4)
Other
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NINDS CDE General Core  Multiple
Sclerosis
NINDS Common Data Elements, Multiple Sclerosis
General Core  
Used from the National Institute of Neurological Disorders
and Stroke Common Data Elements
(https://www.commondataelements.ninds.nih.gov/)
References:
Grinnon ST, Miller K, Marler JR, Lu Y, Stout A, Odenkirchen
J, Kunitz S. National Institute of Neurological Disorders and
Stroke Common Data Element Project - approach and
methods. Clin Trials. 2012;9(3):322-9.
All rights reserved. Please visit https://medical-data-
models.org/forms/16071
General Core
General Core
Study ID
Study site name
Subject ID
1)  Date of birth:
2)  Gender:
Female  (1)
Male  (2)
Unknown  (3)
Unspecified  (4)
Not reported (5)
3)  Ethnicity(“X” ONLY one with which you MOST
CLOSELY identify):
Hispanic or Latino (1)
Not Hispanic or Latino  (2)
Unknown  (3)
Not Reported (4)
4)  Race (Mark all those with which you identify):
American Indian or Alaska Native  (1)
Asian  (2)
Black or African American  (3)
Native Hawaiian or Other Pacific Islander
(4)
White  (5)
Unknown  (6)
Not Reported (7)
5)  Number of years of education 1 : years
6)  SNOMED CT Code:
7)  Medical History Term:
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Sclerosis
NINDS Common Data Elements, Multiple Sclerosis
Demographics
Used from the National Institute of Neurological Disorders
and Stroke Common Data Elements
(https://www.commondataelements.ninds.nih.gov/)
References:
Grinnon ST, Miller K, Marler JR, Lu Y, Stout A, Odenkirchen
J, Kunitz S. National Institute of Neurological Disorders and
Stroke Common Data Element Project - approach and
methods. Clin Trials. 2012;9(3):322-9.
All rights reserved. Please visit https://medical-data-
models.org/forms/16072
Demographics
Demographics
Study ID
Study site name
Subject ID
1.  *Date of Birth:
2.  *Gender:
Female (1)
Male  (2)
Unknown (3)
Unspecified  (4)
Not reported (5)
3.  *Ethnicity (Select which population group you
MOST CLOSELY identify with):
Hispanic or Latino  (1)
Unknown  (2)
Not Hispanic or Latino  (3)
Not Reported (4)
4.  *Race (Mark all those with which you identify)
American Indian or Alaska Native  (1)
Asian  (2)
White  (3)
Unknown  (4)
Black or African-American  (5)
Not Reported  (6)
Native Hawaiian or Other Pacific Islander
(7)
5.  Where do you live? 
Country: (please specify) State / Province:
(please specify) Zip/Postal Code: (please 
specify)
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Sclerosis
NINDS Common Data Elements, Multiple Sclerosis Social
Status 
Used from the National Institute of Neurological Disorders
and Stroke Common Data Elements
(https://www.commondataelements.ninds.nih.gov/)
References:
Grinnon ST, Miller K, Marler JR, Lu Y, Stout A, Odenkirchen
J, Kunitz S. National Institute of Neurological Disorders and
Stroke Common Data Element Project - approach and
methods. Clin Trials. 2012;9(3):322-9.
All rights reserved. Please visit https://medical-data-
models.org/forms/16073
Social Status
Social Status
Study ID
Study site name
Subject ID
1.  Marital/Partner Status (choose only one)
Never Married/Single  (1)
Separated  (2)
Married  (3)
Divorced  (4)
Domestic Partnership  (5)
Widowed (6)
2.  Years of education: (0-30)
3.  Employment Status (Choose only one)
Working now  (1)
Other, specify (10)
Only temporarily laid off  (2)
Sick leave or maternity leave  (3)
Looking for work, unemployed  (4)
Retired  (5)
Disabled, permanently or temporarily  (6)
Keeping house  (7)
Student  (8)
Unknown  (9)
Other
4.  Which  of  the  following  best  describes  your
occupation  (if  you  are  unemployed,  retired,  or
currently 
disabled for employment, please answer this
question for your most recent occupation)?
Official/Manger  (1)
Unknown (10)
Technician  (2)
Administrative Support Worker  (3)
Operative  (4)
Social Worker  (5)
Professional  (6)
Sales Worker  (7)
Craft Worker  (8)
Laborer/Helper  (9)
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NINDS Common Data Elements, Multiple Sclerosis
Relapse 
Used from the National Institute of Neurological Disorders
and Stroke Common Data Elements
(https://www.commondataelements.ninds.nih.gov/)
References:
Grinnon ST, Miller K, Marler JR, Lu Y, Stout A, Odenkirchen
J, Kunitz S. National Institute of Neurological Disorders and
Stroke Common Data Element Project - approach and
methods. Clin Trials. 2012;9(3):322-9.
All rights reserved. Please visit https://medical-data-
models.org/forms/16074
Relapse
Relapse
Study ID
Study site name
Subject ID
1.  Is the participant/subject having new
neurologic symptom(s) or an acute worsening of
preexisting 
neurologic symptoms?
yes (1)
no (stop) (2)
unknown (3)
a.  If Yes, Date of onset:
i.  Did the symptoms last more than 24 hours?
yes (1)
no (Skip to Q8) (2)
unknown (3)
2.  Did the participant/subject have a fever due to
intercurrent illness?
Yes (Skip to Q8)  (1)
No (2)
3.  Prior to the onset of this event, were the
participant’s/subject’s MS symptom(s) stable or
improving over the 
last 30 days?
yes (1)
no (2)
unknown (3)
a.  If Yes, was onset within the last 24 hours?
yes (1)
no (2)
unknown (3)
b.  If No, was the onset within the last 7 days?
yes (1)
no (2)
unknown (3)
4. Are the symptom(s) associated with new
neurologic findings?
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yes [If Yes, in which system(s) was/is the
deficit present? (Choose all that apply)]
(1)
no  (2)
unknown (3)
Pyramidal system
Yes
No
Sensory system
Yes
No
Cerebellar
Yes
No
Bowel and/or Bladder
Yes
No
Brainstem
Yes
No
Mental
Yes
No
Visual
Yes
No
5.  Are the participant’s/subject’s symptom(s)
ongoing?
yes (1)
no (2)
unknown (3)
a.  If No, End Date:
6.  Please describe event, symptom(s) and
treatment that occured with the
participant/subject:
7.  If applicable, is this a protocol defined
qualifying relapse according to the definition set
in the study protocol?
yes (1)
no (2)
unknown (3)
a.  If No, please indicate why the event is not a
qualifying relapse as defined in the protocol:
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Record description central archive of perioperative
data (Zapod) - Medication during anesthesia recovery
Source:
Project central archive of perioperative Data (ZaPoD) of the
German Society of Anesthesiology and Intensive Care
Medicine (DGAI).
Project lead: PD Dr. Sven Zenker, http://amp.uni-bonn.de
All rights reserved. Please visit https://medical-data-
models.org/forms/16075
Record description central archive of
perioperative data-Medication during
anesthesia recovery
Postoperative Medikamente
Opiat- Antagonisten
Ja
Nein
Postoperative Medikamente
Ja
Nein
Benzodiazepin-Antagonist
Ja
Nein
Postoperative Medikamente
Ja
Nein
Relaxantien-Antagonist
Ja
Nein
Postoperative Medikamente
Ja
Nein
Physostigmin
Ja
Nein
Postoperative Medikamente
Ja
Nein
Antiarrhythmika
Ja
Nein
Postoperative Medikamente
Ja
Nein
Antiallergika
Ja
Nein
Postoperative Medikamente
Ja
Nein
Piritramid
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Ja
Nein
Postoperative Medikamente
Ja
Nein
Morphin
Ja
Nein
Postoperative Medikamente
Ja
Nein
Pethidin
Ja
Nein
Postoperative Medikamente
Ja
Nein
Tramadol
Ja
Nein
Postoperative Medikamente
Ja
Nein
Antikoagulation
Ja
Nein
Postoperative Medikamente
Ja
Nein
Kortikoide
Ja
Nein
Postoperative Medikamente
Ja
Nein
5HT3-Antagonisten
Ja
Nein
Postoperative Medikamente
Ja
Nein
Clonidin
Ja
Nein
Postoperative Medikamente
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Ja
Nein
Droperidol
Ja
Nein
Postoperative Medikamente
Ja
Nein
Oxycodon
Ja
Nein
Postoperative Medikamente
Ja
Nein
Promethazin
Ja
Nein
Postoperative Medikamente
Ja
Nein
Metoclopramid
Ja
Nein
Postoperative Medikamente
Ja
Nein
Hydromorphon
Ja
Nein
Postoperative Medikamente
Ja
Nein
Antibiotika
Ja
Nein
Postoperative Medikamente
Ja
Nein
Heparin
Ja
Nein
Postoperative Medikamente
Ja
Nein
Insuline
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Medication during anesthesia recovery
Ja
Nein
Postoperative Medikamente
Ja
Nein
Puffer
Ja
Nein
Postoperative Medikamente
Ja
Nein
Metamizol
Ja
Nein
Postoperative Medikamente
Ja
Nein
Paracetamol
Ja
Nein
Postoperative Medikamente
Ja
Nein
NSAR
Ja
Nein
Postoperative Medikamente
Ja
Nein
Cox-2-Hemmer
Ja
Nein
Postoperative Medikamente
Ja
Nein
Kumulative Opioiddosis
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Eligibility Type 2 Diabetes Mellitus
NCT02367066
A Phase I Study to Assess the Pharmacodynamics of Oral
AR-C165395XX in Subjects With Type 2 Diabetes Mellitus
(T2DM); ODM derived from:
https://clinicaltrials.gov/show/NCT02367066
All rights reserved. Please visit https://medical-data-
models.org/forms/16076
Eligibility Type 2 Diabetes Mellitus
NCT02367066
Inclusion Criteria
provision of informed consent*
Yes
No
male or female of non-childbearing potential
(postmenopausal, and/or have undergone
hysterectomy and/or bilateral oophorectomy or
salpingectomy/tubal ligation) aged ≥18.*
Yes
No
patients with hba1c ≥7.5 but ≤11% at enrolment
visit (visit 1)*
Yes
No
ody mass index >19 to <38 kg/m2*
Yes
No
he fasting plasma glucose should be in the range
of 3-14 mmol/l (54-252 mg/dl, nclusive) on the
morning of visit 1.*
Yes
No
clinical diagnosis of type 2 diabetes mellitus*
Yes
No
metformin as only anti-diabetic treatment, at least
for the last 3 months*
Yes
No
Exclusion Criteria
history or sign of any clinically significant disease
or disorder which, in the opinion f the investigator,
may either put the subject at risk because of
participation in the sudy, or influence the results
or the subject's ability to participate in the study*
Yes
No
any clinically significant abnormalities in clinical
chemistry, haematology or urinalysis results as
judged by the investigator*
Yes
No
1 / 2
aspartate aminotransferase (ast) or alanine
aminotransferase (alt) laboratory results >3x
upper level of normal range (uln) clinical
diagnosis of type 1 diabetes mellitus and/or
history of diabetic ketoacidosis or positive
glutamic acid decarboxylase autoantibodies test
(gad antibodies test).*
Yes
No
patients treated with single insulin therapy within
the last 3 months*
Yes
No
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Eligibility Diabetes NCT00291590
Diabetes Health Enhancement Program to Improve Health
of People With Diabetes; ODM derived from:
https://clinicaltrials.gov/show/NCT00291590
All rights reserved. Please visit https://medical-data-
models.org/forms/16077
Eligibility Diabetes NCT00291590
Inclusion Criteria
insured under medicaid (ssi) or dual enrolled
under medicaid and medicare for at least one
year*
Yes
No
diagnosed type 1 or type 2 diabetes for at least 1
year (>1 inpatient or >2 outpatients visits with icd-
9 codes 250.00-250.9x, or prescriptions for
insulin and/or oral hyperglycemic medications)*
Yes
No
aged 40-85 years*
Yes
No
geographically close to the southeast senior
center in south king county, washington, and
have a primary care provider (not hmo).*
Yes
No
Exclusion Criteria
serious kidney disease (serum creatinine >2.5 or
end-stage renal disease)*
Yes
No
other serious illness that would preclude one-year
study participation (dementia, terminal illness,
organ transplantation)*
Yes
No
pregnancy*
Yes
No
inability to given informed consent.*
Yes
No
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Eligibility Diffuse Large B-cell Lymphoma
NCT00022971
Combination Antibody Therapy for Relapsed Lymphoma
and Chronic Lymphocytic Leukemia; ODM derived from:
https://clinicaltrials.gov/show/NCT00022971
All rights reserved. Please visit https://medical-data-
models.org/forms/16079
Eligibility Diffuse Large B-cell
Lymphoma NCT00022971
Criteria
diagnosis of b-cell lymphoma, waldenstrom's cll
with surface expression of both cd20 and 1d10
antigen by immunohistochemistry (ihc) or
fluorescence of activated cell sorting (facs) with
anti-cd20 and 1d10 antibody. positive 1d10
expression in a facs assay is defined as more
than 2 times the mean fluorescence intensity
(mfi) of the control antibody by facs or greater
than 20% of cells 1d10+ by ihc.*
Yes
No
confirmation of diagnosis in laboratory of
pathology, nci or osu.*
Yes
No
prior therapy with at least one systemic
treatment, and not a candidate for potentially
curative (i.e., transplant) treatment at the time of
study entry.  prior treatment with rituximab
greater than or equal to 1 month ago is
permitted.*
Yes
No
age greater than 18 years.*
Yes
No
ecog performance status less than or equal to 2.*
Yes
No
major organ function:  anc greater than or equal
to 500/microliter, platelet greater than or equal
25,000/microliter, creatinine less than or equal to
1.5 mg/dl or creatinine clearance greater than 60
cc/min; sgpt less than 5 x upper limit of normal;
bilirubin less than 2 mg/dl (total) except less than
5 mg/dl in patients with gilbert's syndrome as
defined by greater than 80% unconjugated;
unless impairment due to organ involvement by
lymphoma.*
Yes
No
provides informed consent.*
Yes
No
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Exclusion Criteria
pregnancy or nursing. both male and female
patients must be willing to use adequate
contraception.*
Yes
No
prior apolizumab treatment.*
Yes
No
sactive cardiac disease, cerebrovascular disease
or peripheral arterial vascular disease.*
Yes
No
active cns lymphoma.*
Yes
No
systemic cytotoxic chemotherapy within 3 weeks
of enrollment or systemic steroids (except stable
doses less than 10 mg/day) within 1 week of
enrollment.*
Yes
No
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Eligibility Type 2 Diabetes Mellitus
NCT02373150
Safety, Tolerability and PK of Imeglimin in Japanese
Volunteers; ODM derived from:
https://clinicaltrials.gov/show/NCT02373150
All rights reserved. Please visit https://medical-data-
models.org/forms/16081
Eligibility Type 2 Diabetes Mellitus
NCT02373150
Inclusion Criteria
male or female japanese subjects, deemed
healthy on the basis of a clinical history, physical
examination, ecg, vital signs, and laboratory tests
of blood and urine*
Yes
No
body mass index in the range 18.0-25.0 kg/m2*
Yes
No
willing to use reliable contraception*
Yes
No
able to give fully informed written consent.*
Yes
No
Exclusion Criteria
pregnant or lactating woman, or sexually active
woman of child-bearing potential not using
reliable contraception*
Yes
No
clinically relevant abnormal findings at the
screening assessment*
Yes
No
clinically significant vital signs outside the
acceptable range at screening*
Yes
No
clinically relevant abnormal medical history,
surgery or concurrent medical condition*
Yes
No
acute or chronic illness*
Yes
No
estimated glomerular filtration rate less than 80
ml/min/1.73 m2*
Yes
No
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severe adverse reaction to any drug or sensitivity
to the trial medication or its components*
Yes
No
significant food allergy; vegetarian or vegan*
Yes
No
use of vitamins, herbal medicines, or over-the-
counter medication (with the exception of
paracetamol [acetaminophen]) within 7 days
before first dose of trial medication, or prescribed
medication during the 14 days before first dose of
trial medication*
Yes
No
participation in other clinical trials of unlicensed
or prescription medicines, or loss of more than
400 ml blood, within the 3 months before first
dose of trial medication*
Yes
No
drug or alcohol abuse*
Yes
No
smoking of more than 5 cigarettes daily*
Yes
No
possibility that subject will not cooperate*
Yes
No
positive test for hepatitis b & c, hiv*
Yes
No
objection by a general practitioner.*
Yes
No
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Eligibility Type 2 Diabetes NCT02148250
PK/PD STUDY OF U-500 REGULAR INSULIN; ODM
derived from: https://clinicaltrials.gov/show/NCT02148250
All rights reserved. Please visit https://medical-data-
models.org/forms/16082
Eligibility Type 2 Diabetes
NCT02148250
Inclusion Criteria
type 2 diabetes*
Yes
No
ages 30-65 years*
Yes
No
a1c between 7-9.5% within the past month*
Yes
No
on >200 units of insulin per day (>150 units if also
on oral/glp-1 agents)*
Yes
No
willing to discontinue oral/injectable non-insulin
hypoglycemic agents for minimum of 1 week prior
to study*
Yes
No
willing to avoid exercise 48 hours prior to study*
Yes
No
willing to be fasting for up to 24 hours*
Yes
No
bmi between 25 and 38 kg/m2*
Yes
No
Exclusion Criteria
• on systemic corticosteroids in preceding 3
months*
Yes
No
heavy alcohol consumption (>21 drinks/week
men, >14 drinks/week women)*
Yes
No
unwillingness to stop alcohol consumption for 24
hours before each study visit*
Yes
No
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pregnant or actively trying to conceive*
Yes
No
current diagnosis of active infection, cancer
(other than basal cell carcinoma), vascular
disease, organ failure*
Yes
No
current transplant recipient*
Yes
No
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AAFP: Hyperkalemia Admission Order
AAFP: Hyperkalemia Admission Order, Standardizes
Admission Orders, Author: Robert M. Wiprud, MD The
primary purpose of these Ordersets is to decrease
unnecessary variability and to improve quality through
standardized Admission Orders. Developed by the Scott &
White Clinic at College Station, Texas. Copyright © 2006
American Academy of Family Physicians. Physicians may
photocopy or adapt for use in their own practices; all other
rights reserved. Wiprud RM. Providing consistent care with
standardized admission orders. Fam Pract Manag.
September 2006: 49-52 See
http://www.aafp.org/fpm/2006/0900/p49.html This ODM
Form includes the sixteenth section ("Hyperkalemia
Admission Order").
All rights reserved. Please visit https://medical-data-
models.org/forms/16084
AAFP: Hyperkalemia Admission
Order
Default Itemgroup
Name
Age
Date of Birth
Medical record number
Status
Status
Observation (1)
Admission (2)
Medical floor (3)
Monitored bed (4)
Other (5)
If Other, please specify
Attending
Name of attending physician
Phone number of attending physician
Admitting Diagnosis
Hyperkalemia Associated Diagnoses
Condition
Condition
Stable (1)
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Fair (2)
Serious (3)
Critical (4)
Code Status
Full Code (1)
DNR (2)
Allergies
Allergies
Diet
NPO
Yes
No
Clear liquid
Yes
No
AHA step 2
Yes
No
ADA___calories
Yes
No
If diet according to ADA, please specify amount
of calories
Other
Yes
No
If Other, please specify
Acitivity
Bed rest with bedside commode
Yes
No
Up in chair as tolerated
Yes
No
Up ad lib
Yes
No
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Nursing
Vital signs with neuro checks every 4 hrs for 24
hrs then every shift
Yes
No
Notify MD for: P < 50 or > 120, BP < 90/60 or >
180/110, R < 12 or > 28, T > 101.5, neuro
changes
Yes
No
Weight: on admission, then daily
Yes
No
I&O every shift
Yes
No
Continuous cardiac monitoring
Yes
No
Arrhythmia protocol
Yes
No
Medications
Calcium gluconate: 10% 5-10 mL IV over 2-5
min; 2 nd dose may be given in 5 min, may
repeat every 1 hrs prn; if dig toxicity suspected,
give over 30 min or ormit
Yes
No
NaHCO3 (sodium bicarbonate): one amp of 7.5%
IV over 5 min (give after calcium in separate IV),
repeat in 10-15 min followed by 1-2 amps added
to Dextrose 5% in water titrated over 2-4 hrs
Yes
No
Insulin: 10 units regular in 500 mL Dextrose 10%
in water OR 10 units IVP with 1 amp 50%
glucose (25mg) over 5 min; repeat as needed
every 3 hrs
Yes
No
Kayexalate: 15-50 mg in 100 mL of 20% sorbitol
solution PO now and 3-4 hrs; up to 4-5 hrs; up to
4-5 doses/day OR kayexalate retention enema
25-50 mg in 200 mL of 20% sorbitol; retain of 30-
60 min (may use cleansing enema before)
Yes
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No
Furosemide: 40-80 mg IV daily
Yes
No
Consider discontinuing NSAIDS, ACEI, beta-
blockers, K-sparing diuretics
Yes
No
Tylenol 500 mg 1 or 2 PO every 4-6 hrs prn pain,
T > 101
Yes
No
Maalox 15-30 mL PO every 4 hrs prn indigestion
Yes
No
MOM 30 mL PO every 12 hrs prn constipation
Yes
No
Ambien 10 mg PO at bedtime prn insomnia
Yes
No
IV
IV
Lab
Admission: hemagram, Mg, basal metabolic
profile
Yes
No
Daily: K+ every 4-6 hrs, urinanalysis with Micro,
Osm, Na, K, Bicarb, Cl
Yes
No
Consider serum lactate, sickle prep, retic count,
cortisol, renin, aldosterone, urine myoglobin and
24 hrs urine K, Na, Cr, Prot, cortisol
Yes
No
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Eligibility Type 2 Diabetes NCT02171351
Effect of Neuromuscular Electrostimulation on Sympathetic
Nerve Activity in Patients With Type 2 Diabetes
(ELECTROSYMP2); ODM derived from:
https://clinicaltrials.gov/show/NCT02171351
All rights reserved. Please visit https://medical-data-
models.org/forms/16085
Eligibility Type 2 Diabetes
NCT02171351
Inclusion Criteria
type 2 diabetes for at least 12 month*
Yes
No
treatment by oral hypoglycemic agents and/or
glp1 agonists*
Yes
No
hba1c : 6-10%*
Yes
No
suspected insulin-resistance (at least one criteria
below) :*
Yes
No
waist circumference > 80cm (female); > 94cm
(male)*
Yes
No
triglycerides > 150 mg/dl*
Yes
No
hdl-cholesterol < 50 mg/dl (female); < 40 mg/dl
(male)*
Yes
No
low background physical activity (ricci-gagnon
score < 27)*
Yes
No
Exclusion Criteria
type 1 diabetes*
Yes
No
treatment with insulin*
Yes
No
seizure*
Yes
No
1 / 2
pace maker*
Yes
No
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Eligibility Type 2 Diabetes NCT02235298
Effects of Dapagliflozin on Epicardial Fat in Subjects With
Type 2 Diabetes; ODM derived from:
https://clinicaltrials.gov/show/NCT02235298
All rights reserved. Please visit https://medical-data-
models.org/forms/16086
Eligibility Type 2 Diabetes
NCT02235298
Inclusion Criteria
• type 2 diabetes, as defined by ada criteria*
Yes
No
hba1c ≤ 8% measured at least 1 week prior to
the study*
Yes
No
bmi ≥27 kg/m2*
Yes
No
pre-treatment with metformin as monotherapy*
Yes
No
age > 18 and < 70 years old*
Yes
No
Exclusion Criteria
• known contra-indications to farxiga, in
accordance with risks and safety information
included in the latest updated prescribing
information*
Yes
No
type 1 diabetes, as defined by american diabetes
association (ada) criteria*
Yes
No
insulin dependent or treated type 2 diabetes*
Yes
No
current use of other sglt2 inhibitors, glp- 1
analogs or dpp4 inhibitors*
Yes
No
glomerular filtration rate (gfr) < 60 ml/min/1.73
m2*
Yes
No
patients with poor glycemic control will be
excluded to maximize long-term patient retention
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without need*
Yes
No
history of diabetes ketoacidosis*
Yes
No
clinical signs or symptoms of new york heart
association (nyha) class iii-iv heart failure*
Yes
No
clinical or laboratory evidences of chronic active
liver diseases*
Yes
No
acute or chronic infective diseases*
Yes
No
cancer or chemotherapy*
Yes
No
current use of systemic corticosteroids or in the 3
months prior this study*
Yes
No
known or suspected allergy to dapaglifozin,
excipients, or related products*
Yes
No
pregnant, breast-feeding or the intention of
becoming pregnant*
Yes
No
females of childbearing potential who are not
using adequate contraceptive methods*
Yes
No
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3.1 Charlson Comorbidity Index (CCI)
Charlson Comorbidity Index
Part 3.1 Co-morbidities
To be completed by: Clinician or trained coder, using the
key below the table. 
Notes: 
This is not the age-adjusted version of the index. 
This tool will be used within oncology trials; the tumor type
under investigation does not score. 
Score:  Total score by adding up coded answers. 
Source:
Charlson et al. A new method of classifying prognostic
comorbidity in longitudinal studies: development and
validation. 1987. J. Chronic Dis. 40, pp. 373–383.
All rights reserved. Please visit https://medical-data-
models.org/forms/16088
3.1 Charlson Comorbidity Index
(CCI)
Co-morbidities
Myocardial Infarction (1 Point)
Yes
No
Congestive cardiac failure (1 Point)
Yes
No
Peripheral vascular disease (1 Pont)
Yes
No
Cerebrovascular disease (except hemiplegia) (1
Point)
Yes
No
Dementia (1 Pont)
Yes
No
Chronic obstructive pulmonary disease (1 Point)
Yes
No
Connective tissue disease (1 Point)
Yes
No
Ulcers (1 Point)
Yes
No
Mild liver disease (1 Point)
Yes
No
Diabetes mellitus (without end-organ damage) (1
Point)
Yes
No
Diabetes mellitus (with end-organ damage) (2
1 / 2
Points)
Yes
No
Hemiplegia (2 Points)
Yes
No
Moderate/Severe chronic renal failure (2 Points)
Yes
No
Second malignancy (non metastatic) (2 Points)
Yes
No
Leukaemia (2 Points)
Yes
No
Lymphoma (2 Points)
Yes
No
Moderate / Severe liver disease (3 Points)
Yes
No
Second malignancy (metastatic) (6 Points)
Yes
No
AIDS (6 Points)
Yes
No
Total points (0-37)
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3.2 Charlson Comorbidity Index (CCI)
Charlson Comorbidity Index (CCI)
Part 3.2 G8 geriatric assessment screening tool
To be completed by: Clinician, nurse or trained coder.
Notes: This screening tool includes 7 items of the Mini
Nutritional Assessment and the age of the patient.
Score: Total score by adding up coded answers.
Ref.: P. Soubeyran et al. Validation of a screening test for
elderly patients in oncology. JCO. Vol 26, 15S, 2008
Source: Charlson et al. A new method of classifying
prognostic comorbidity in longitudinal studies: development
and validation. 1987. J. Chronic Dis. 40, pp. 373–383.
All rights reserved. Please visit https://medical-data-
models.org/forms/16089
3.2 Charlson Comorbidity Index
(CCI)
G8 Screening tool
Has food intake declined over the past 3 months
due to loss of appetite, digestive problems,
chewing or swallowing difficulties?
0: severe reduction in food intake (0)
1: moderate reduction in food intake (1)
2: normal food intake (2)
Weight loss during the last 3 months?
0: weight loss >3kg (0)
1: does not know (1)
2: weight loss between 1 and 3 kg (2)
3: no weight loss (3)
Mobility
0: bed or chair bound (0)
1: able to get out of bed/chair but does
not go out (1)
2: goes out (2)
Neuropsychological problems
0: severe dementia or depression (0)
1: mild dementia or depression (1)
2: no psychological problems (2)
Body Mass Index (weight in kg/height in m2)
0: BMI less than 19 (0)
1: BMI  19 to less than  21 (1)
2: BMI 21 to less than 23 (2)
3: BMI 23 or greater (3)
Takes more than 3 medications per day
0: yes (0)
1: no (1)
In comparison with other people of the same age,
how does the patient consider his/her health
status?
0: not as good (0)
0,5: does not know (1)
1: as good (2)
2: better (3)
Age
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0: >85 (0)
1: 80-85 (1)
2: <80 (2)
Total Score
<= 17
>= 0
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3.4 Charlson Comorbidity Index (CCI)
Charlson Comorbidity Index (CCI)
Part 3.4 Social Situation
To be completed by: Clinician or trained coder. 
Source: Charlson et al. A new method of classifying
prognostic comorbidity in longitudinal studies: development
and validation. 1987. J. Chronic Dis. 40, pp. 373–383.
All rights reserved. Please visit https://medical-data-
models.org/forms/16091
3.4 Charlson Comorbidity Index
(CCI)
Social situation
Which of the following statements best describes
where you live?
At home by myself. (1)
At home with someone. (2)
In institutional care (for example
residential home or nursing home). (3)
1 / 1
3.3 Charlson Comorbidity Index (CCI)
Charlson Comorbidity Index (CCI)
Part 3.3 Instrumental Activities of Daily Living (IADL)
To be completed by: Patient, clinician, nurse or trained
coder. 
Notes: Some domains may not be informative for all
people. For example some men (for cultural reasons) may
not do the laundry. Therefore each question is preceded by
a screening question, to assess relevance. 
Score: Record total domains which can be scored (i.e. not
designated N/A[not applicable]). Record number of
domains in which subject is dependent (i.e. scores 0).
Source: Charlson et al. A new method of classifying
prognostic comorbidity in longitudinal studies: development
and validation. 1987. J. Chronic Dis. 40, pp. 373–383.
All rights reserved. Please visit https://medical-data-
models.org/forms/16092
3.3 Charlson Comorbidity Index
(CCI)
Instrumental Activities of Daily Living
(IADL)
Ability to use telephone
N/A Has never used the telephone (1)
1 Operates telephone on own initiative,
looks up and dials numbers, etc. (2)
1 Dials a few well known-numbers (3)
1 Answers telephone but does not dial
(4)
1 Does not use telephone at all (5)
Shopping
N/A Has never done the shopping (1)
1 Takes care of all shopping needs
independently (2)
0 Shops independently for small
purchases (3)
0 Needs to be accompanied on any
shopping trip (4)
0 Completely unable to shop (5)
Food preparation
N/A Has never done the food preparation
(1)
1 Plans, prepares and serves adequate
meals independently (2)
1 Prepares adequate meals if supplied
with ingredients (3)
1 Heats, serves, and prepares meals but
does not maintain adequate diet (4)
1 Needs to have meals prepared and
served (5)
Housekeeping
N/A Has never done the housekeeping
(0)
1 Maintains house alone or with
occasional assistance (e.g. “heavy work
domestic help”) (1)
1 Performs light daily tasks such as dish-
washing, bed-making (2)
1 Performs light daily tasks but cannot
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maintain acceptable level of cleanliness
(3)
1 Needs help with all home maintenance
tasks (4)
0 Does not participate in any
housekeeping tasks (5)
Laundry
N/A Has never done the laundry (0)
1 Does personal laundry completely (1)
1 Launders small items-rinses socks,
stocking, etc. (2)
0 All laundry must be done by others (3)
Mode of transportation
N/A Has never travelled independently
(0)
1 Travels independently on public
transportation or drives own car (1)
1 Arranges own travel via taxi, but does
not otherwise use public transportation
(2)
1 Travels on public transportation when
accompanied by other (3)
0 Travel limited to taxi or automobile with
assistance of another (4)
0 Does not travel at all (5)
Responsibility for own medication
N/A Does not take tablets currently (0)
1 Is responsible for taking medication in
correct dosages at correct time (1)
0 Takes responsibility if medication is
prepared in advance in separate dosage
(2)
0 Is not capable of dispensing own
medication (3)
Ability to handle finances
N/A Never handled the finances (0)
1 Manages financial matters
independently (budgets, writes checks,
pays rent, bills, goes to the bank),
collects and keeps track of income (1)
1 Manages day to day purchases, but
needs help with banking, major
purchases, etc. (2)
0 Incapable of handling money (3)
Total domains which are assessable
>= 0
<= 8
Domains in which patient is dependent
>= 0
<= 8
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Eligibility Advanced Non-small Cell Lung
Cancer NCT01240447
Immunotherapy With Racotumomab Versus Support
Treatment in Advanced Non-small Cell Lung Cancer
Patients; ODM derived from:
https://clinicaltrials.gov/show/NCT01240447
All rights reserved. Please visit https://medical-data-
models.org/forms/16093
Eligibility Advanced Non-small Cell
Lung Cancer NCT01240447
Inclusion Criteria
the patient (aged over 21 years, either sex) can
comply with the protocol and scheduled
appointments and sign voluntarily the informed
consent form*
Yes
No
diagnosis of non-small cell lung cancer (nsclc)
stages iiia (surgically unresectable), iiib or iv,
according to the tnm classification (tumor-nodes-
metastases) version 6a, confirmed by cytology or
histology, if possible available for determination of
ganglioside expression*
Yes
No
patients may enter the study if they have
accomplished an objective response (complete
response or partial response) or disease
stabilisation (by response evaluation criteria in
solid tumours [recist]) after completion of
standard onco-specific treatment. in all cases,
response should be documented.*
Yes
No
for stage iiia and iiib without pleural effusion ("dry
iiib") standard treatment is considered as follows:
2 - 4 cycles of platinum-based chemotherapy
and/or radiotherapy with curative intent in
accordance with national comprehensive cancer
network (nccn) guidelines for stage iiib with
pleural effusion ("wet iiib") and stage iv standard
treatment is considered as follows: 4 - 6 cycles of
chemotherapy based on platinum. in case of
pleural or pericardial effusion requiring local
treatment, it will be provided prior to study entry.*
Yes
No
patients with an interval greater than 30 and not
more than 90 days between the completion of
oncospecific treatment and study entry.
completion of treatment is defined as the last day
of administration of chemotherapy or the last day
of radiotherapy. patients should have recovered
from any related episode of acute toxicity of
degree greater than 1 (except alopecia). patients
who have received a monoclonal antibody (eg
bevacizumab) should also have discontinued its
use for at least 30 days before inclusion.*
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Yes
No
the subject is male or female, aged greater than
or equal to 21 years*
Yes
No
performance status (eastern cooperative
oncology group [ecog]) less than or equal to 1*
Yes
No
acceptable organ functionality as defined by the
following parameters:*
Yes
No
electrocardiogram (ecg) without significant
abnormalities, performed within 14 days prior to
admission*
Yes
No
haemoglobin greater than or equal to 90 g/l*
Yes
No
total leukocyte count greater than or equal to 3.0
x 10^9/l*
Yes
No
absolute neutrophil count greater than or equal to
1.5 x 10^9/l*
Yes
No
total bilirubin less than or equal to 1.5 times
upper limit of normal or twice the limit normal
than in case liver metastases are present*
Yes
No
serum glutamic oxaloacetic transaminase (sgot)
and serum glutamic pyruvic transaminase (sgpt)
less than or equal to 2.5 times upper limit of
normal (less than or equal to five times the
normal maximum in case liver metastases are
present)*
Yes
No
creatinine less than or equal to 2 mg/dl*
Yes
No
life expectancy of at least four months*
Yes
No
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Exclusion Criteria
patient is pregnant or breastfeeding*
Yes
No
has received chemotherapy, radiotherapy,
immunotherapy or surgery within 30 days prior to
inclusion*
Yes
No
hypersensitivity to any component of the
formulation*
Yes
No
patients of childbearing potential of either sex
who are not using an adequate method of
contraception during treatment to avoid
pregnancy (own or of partner). for females:
intrauterine devices, hormonal contraceptives,
barrier methods or sterilisation. for males:
vasectomy or condoms with spermicide.*
Yes
No
patients receiving or having received other
investigational drugs 30 days prior to study entry*
Yes
No
history of autoimmune diseases*
Yes
No
decompensated chronic diseases*
Yes
No
acute allergic disorders or history of severe
allergic reactions*
Yes
No
known brain metastases uncontrolled with
surgery and/or radiation therapy or under current
corticosteroid therapy*
Yes
No
history of inflammatory or demyelinating disease
of the central or peripheral nervous system*
Yes
No
uncontrolled intercurrent illnesses, including
active infection, symptomatic congestive heart
failure, unstable angina or cardiac arrhythmia and
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psychiatric diseases implying patient
incompetence*
Yes
No
other malignancies, with the exception of basal
cell carcinoma, in situ cervical carcinoma,
incidental prostate cancer (t1a, gleason less than
or equal to 6, prostate specific antigen [psa] less
than 0.5 ng/ml), tumour or any other tumour
adequately treated and with a disease-free period
greater than or equal to 5 years*
Yes
No
chronic treatment with systemic corticosteroids at
doses greater than 0.5 mg/kg/day or a maximum
of 40 mg/day of prednisone or equivalent*
Yes
No
the subject has a history of drug abuse (illicit
drugs) or alcohol abuse (defined as regular or
periodic ingestion of more than four drinks a day)
in the last 2 years*
Yes
No
positive serology for hepatitis b, c or known
human immunodeficiency virus (hiv) infection*
Yes
No
uncontrolled hypercalcaemia greater than or
equal to 2.9 mmol/l (or grade greater than 1
according to the common terminology criteria for
adverse events [ctcae] version 3.0)*
Yes
No
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Eligibility Advanced Hepatocellular
Carcinoma NCT01356628
A Clinical Research Study to Determine Whether PD
0332991 May Be Effective in Treating Patients With Liver
Cancer; ODM derived from:
https://clinicaltrials.gov/show/NCT01356628
All rights reserved. Please visit https://medical-data-
models.org/forms/16094
Eligibility Advanced Hepatocellular
Carcinoma NCT01356628
Inclusion Criteria
male or female, age > or = 18 years with hcc
refractory to currently available therapies.*
Yes
No
documented hcc by at least 2 out of 3 mentioned
criteria and evidence of non-resectability by a
multidisciplinary team:*
Yes
No
radiological - mri with arterial enhancement and
rapid venous washout b. biopsy c. serum alpha-
fetoprotein level > or = 200*
Yes
No
positive staining for rb-function on tumor biopsy*
Yes
No
subject must be able to give written informed
consent and be able to follow protocol
requirements*
Yes
No
life expectancy greater than 3 months*
Yes
No
child's-pugh class a or b*
Yes
No
ecog performance status of < or = 2*
Yes
No
if female of childbearing potential must have
negative pregnancy test at screening and may
not be breast-feeding*
Yes
No
females of child-bearing potential (< one year
post-menopausal with documented fsh greater
than 30 iu/l or surgically not sterile), must agree
to practice an effective method of avoiding
pregnancy (including oral or implanted
contraceptives, intrauterine device, condom,
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diaphragm with spermicidal, cervical cap,
abstinence or sterile sex partner) from the time
informed consent is signed through follow-up.
males must agree to take appropriate precautions
to avoid fathering a child from screening through
follow-up.*
Yes
No
no other active malignancy requiring treatment in
the last 3 years other than adequately treated
non-melanomatous skin cancer, adequately
treated cervical carcinoma in-situ, superficial
adequately treated bladder cancer or prostatic
intraepithelial neoplasia without evidence of
prostate cancer.*
Yes
No
adequate bone marrow, liver and renal function
as assessed by the following:*
Yes
No
hemoglobin > or = 8 g/dl b. wbc > or = 4,000/ul c.
absolute neutrophil count > or = 1,500/ul d.
platelets > or = 75,000/ul e. total bilirubin < or =
1.5 times uln f. alt and ast < or = 5 times uln g.
creatinine < or = 1.5 times uln h. albumin > or =
2.5 mg/dl*
Yes
No
subjects who have received previous
radiotherapy, loco-regional, or systemic therapy
are eligible. a minimum interval of 4 weeks since
the last anti-cancer treatment of any kind is
required.*
Yes
No
subjects with brain metastases or a history of
previously treated brain metastasis are eligible
but must:*
Yes
No
have been treated by surgery or stereotactic
radiosurgery (srs) at least 4 weeks prior to
enrollment b. and have a baseline mri or ct that
shows no evidence of active intercranial disease
c. and be off steroids for at least 1 week prior to
study enrollment*
Yes
No
Exclusion Criteria
any concurrent active malignancy requiring
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treatment (other than basal or squamous cell
carcinoma of the skin, carcinoma in situ of the
cervix, superficial bladder tumors, or other
malignancies curatively treated > 3 years prior to
study entry)*
Yes
No
history of severe cardiovascular disease within
the last 12 months: symptomatic congestive heart
failure, myocardial infarction, coronary artery
disease (cad), life threatening arrhythmias,
uncontrolled hypertension*
Yes
No
renal failure requiring hemo- or peritoneal
dialysis*
Yes
No
unstable systemic diseases or active uncontrolled
infection*
Yes
No
known history of hiv infection*
Yes
No
clinically significant gastrointestinal bleeding
within 30 days prior to study entry*
Yes
No
major surgery, open biopsy or significant
traumatic injury within 4 weeks prior to study
entry*
Yes
No
child's-pugh class c*
Yes
No
any malabsorption problem that, in the
investigator's opinion, would prevent adequate
absorption of the study drug*
Yes
No
presence of any other medical complications that
in the investigator's opinion, suggests a survival
of < 3 months*
Yes
No
substance abuse, or medical, psychological or
social conditions that may interfere with the
patient's participation in the study or evaluation of
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the study results*
Yes
No
patient inability to swallow oral medications*
Yes
No
any condition that is unstable or which could
jeopardize the safety of the patient and his/her
compliance in the study*
Yes
No
pregnant or breast-feeding patients*
Yes
No
being of reproductive potential and unable or
unwilling to practice an effective contraceptive
method*
Yes
No
lack of positive staining for rb-function on tumor
biopsy*
Yes
No
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Record description central archive of perioperative data (Zapod) - Patient
demographics, Staffing details, scores and additional information
Source:
Project central archive of perioperative Data (ZaPoD) of the
German Society of Anesthesiology and Intensive Care
Medicine (DGAI).
Project lead: PD Dr. Sven Zenker, http://amp.uni-bonn.de
All rights reserved. Please visit https://medical-data-
models.org/forms/16095
Record description central archive of
perioperative data- Patient
demographics, Staffing details and
scores
Demographische Informationen Patient
Patienten Geschlecht
männlich (1)
weiblich (2)
Ethnie
Patient rothaarig
Ja
Nein
Körpergewicht
Körpergröße
Patientenstation
Status ambulant
Ja
Nein
Status stationär
Ja
Nein
Status ambulant privat versichert
Ja
Nein
Status stationär privat versichert
Ja
Nein
Status teilstationär
Ja
Nein
Beihilfe
Ja
Nein
Personal Details
Personal im Regeldienst
Ja
Nein
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Personal im Bereitschaftsdienst
Ja
Nein
Personal mit Überstunden
Ja
Nein
Personal am Wochenende/Feiertag
Ja
Nein
Anzahl Ärzte bei Doppelbesetzung
Anzahl Pflege bei Doppelbesetzung
Scores und sonstige Informationen
Risikoeinstufung ASA
Cormack score
Mallampati Score
MET score
NYHA class
Op-Klassifikation
PONV Score
rCRI
Score Schmerzstärke
Intraoperativ dunkel
Ja
Nein
Sonstige Leistungen Aufwachraum
Op-Priorität:elektiv
Ja
Nein
Op-Priorität:dringlich
Ja
2 / 3
Record description central archive of perioperative data (Zapod) - Patient
demographics, Staffing details, scores and additional information
Nein
Op-Priorität:Notfall
Ja
Nein
Kompetenznetzwerk zur Erforschung der
perioperativen Morbidität und Mortalität:
zugestimmt
Ja
Nein
Kompetenznetzwerk zur Erforschung der
perioperativen Morbidität und Mortalität:
abgelehnt
Ja
Nein
Kompetenznetzwerk zur Erforschung der
perioperativen Morbidität und Mortalität:
Ausschluss
Ja
Nein
PONV - Übelkeit
Ja
Nein
PONV - Erbrechen
Ja
Nein
Rea-Team - Intraoperativ
Ja
Nein
Operationssaal Nummer
Sonstiges:Transport
Ja
Nein
Zytostase letzte 3 Monate
Ja
Nein
Zytostase >3 Monate
Ja
Nein
Zytostase Immunsuppressiva
Ja
Nein
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demographics, Staffing details, scores and additional information
Eligibility Type 2 Diabetes NCT02280486
Safety and Efficacy of Saxagliptin vs.Glimepiride as Add-on
Therapy in T2DM Patients With Metformin
Monotherapytients; ODM derived from:
https://clinicaltrials.gov/show/NCT02280486
All rights reserved. Please visit https://medical-data-
models.org/forms/16096
Eligibility Type 2 Diabetes
NCT02280486
Inclusion Criteria
for inclusion in the study subjects should fulfill the
following criteria:*
Yes
No
provision of informed consent prior to any study
specific procedures*
Yes
No
type2 diabetic patients had been on stable,
maximum tolerated doses of metformin (
≧1500mg/d, ≧8 weeks)*
Yes
No
male or female age ≧ 25 years and ≦75 years
old*
Yes
No
hba1c ≧7.0 and ≦9.5%*
Yes
No
bmi ≧ 20 and ≦ 30 kg/m2*
Yes
No
Exclusion Criteria
subjects should not enter the study if any of the
following exclusion criteria are fulfilled:*
Yes
No
known or suspected allergy to trial products or
related products.*
Yes
No
impaired renal function defined as serum-
creatinine ≥ 1.5 mg/dl (≥ 132.6 μmol/l).*
Yes
No
acute or chronic disease which may cause tissue
hypoxia such as cardiac or respiratory failure,
shock.*
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Yes
No
hepatic insufficiency, acute alcohol intoxication,
alcoholism.*
Yes
No
subjects has a clinically significant, active (or over
the past 12 months) cardiovascular history
(including a history of myocardial infarction (mi),
arrhythmias or conduction delays on ecg,
unstable angina, or decompensated heart failure
(new york heart association-class ⅲ and ⅳ).*
Yes
No
proliferative retinopathy or muscular oedema
requiring acute treatment.*
Yes
No
lactation.*
Yes
No
pregnant or positive pregnancy test at screening,
nursing mother, or unwillingness to use adequate
contraception (adequate contraceptive measures
are sterilization, intrauterine device, oral
contraceptives or barrier methods).*
Yes
No
treatment with systemic corticosteroids within the
past two months prior to screening.*
Yes
No
tested positive for glutamic acid decarboxylase
antibody.*
Yes
No
receipt of any investigational drug within 1 month
prior to this trial.*
Yes
No
2 / 2
Eligibility Type 2 Diabetes NCT02280486
Record description central archive of perioperative
data (Zapod) - Patient transfer and timing details
Source:
Project central archive of perioperative Data (ZaPoD) of the
German Society of Anesthesiology and Intensive Care
Medicine (DGAI).
Project lead: PD Dr. Sven Zenker, http://amp.uni-bonn.de
All rights reserved. Please visit https://medical-data-
models.org/forms/16097
Record description central archive of
perioperative data- Patient transfer
and timing details
Verlegung
Verlegung:Aufwachraum zur Station
Ja
Nein
Verlegung:Aufwachraum zur Station
Ja
Nein
Verlegung:Aufwachraum zur IMC
Ja
Nein
Verlegung:Aufwachraum zur IMC
Ja
Nein
Verlegung:Aufwachraum zur ICU
Ja
Nein
Verlegung:Aufwachraum zur ICU
Ja
Nein
Verlegung: Aufwachraum nach Hause
Ja
Nein
Verlegung:Aufwachraum nach Hause
Ja
Nein
Verlegung:Aufwachraum in externes
Krankenhaus
Ja
Nein
Verlegung:Aufwachraum in externes
Krankenhaus
Ja
Nein
Verlegung:Aufwachraum zu Aufwachraum
Ja
Nein
Verlegung:Aufwachraum zu Aufwachraum
Ja
Nein
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Verlegung:Aufwachraum zurück in OP
Ja
Nein
Verlegung:Aufwachraum zurück in OP
Ja
Nein
Verlegung in Aufwachraum: Patient intubiert
Ja
Nein
Verlegung in Aufwachraum: Patient
tracheotomiert
Ja
Nein
Verlegung in Aufwachraum: Patient nicht intubiert
Ja
Nein
Details Zeitabläufe
Zeit HLM partieller Bypass
Zeit HLM partieller Bypass
Zeit HLM totaler Bypass
Zeit HLM totaler Bypass
Zeit HLM: Aortenklemmzeit
Zeit HLM: Aortenklemmzeit
Ankunftszeit im Einleitungsraum
Ankunftszeit Saal
Zeit Anaesthesiepräsenz
Zeit Anaesthesiepräsenz
Zeit Anaesthesiepräsenz
Zeit Anaesthesiepräsenz
Anästhesiezeit
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Anästhesiezeit
Anästhesiezeit
Anästhesiezeit
Zeit Einleitung
Zeit Einleitung
Zeit chirurgische Massnahmen
Zeit chirurgische Massnahmen
Zeit chirurgische Massnahmen
Zeit chirurgische Massnahmen
Zeit Operation intraoperativ
Zeit Operation intraoperativ
Zeit Operation intraoperativ
Zeit Operation intraoperativ
Zeit Operation intraoperativ
Zeit Aufwachraum
Zeit Aufwachraum
Zeit Aufwachraum
Zeit Aufwachraum
Prämedikation Datum
Zeit Prämedikation
Op ueber Mitternacht
Ja
Nein
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Eligibility Type 2 Diabetes NCT02301806
Effects of Sitaglpitin on Endothelial Function During the
OGTT in T2DM; ODM derived from:
https://clinicaltrials.gov/show/NCT02301806
All rights reserved. Please visit https://medical-data-
models.org/forms/16098
Eligibility Type 2 Diabetes
NCT02301806
Inclusion Criteria
provision of informed consent before any study
specific procedures*
Yes
No
type ii diabetes who have inadequate glycaemic
control (6.5%≦hba1c＜9.0%)*
Yes
No
age from 20 to 80 years old*
Yes
No
no history of using any antihyperglycemic drugs*
Yes
No
no history of cardiovascular complications*
Yes
No
no treatment or treatment with stable doses of
lipid-lowering, antihypertensive, and antiplatelet
agents for at least 3 months prior to
randomization*
Yes
No
4.5 % ≤ fasting fmd at baseline < 8.0 %*
Yes
No
Exclusion Criteria
・type i diabetes*
Yes
No
pregnancy*
Yes
No
liver disease (hepatic enzymes more than three
times the upper limit of normal ranges)*
Yes
No
impairared kidney function (serum crearinine
greater than 1.3 mg/dl in men, 1.2 mg/dl in
1 / 2
women)*
Yes
No
cigarette smokers*
Yes
No
contraindications to glimepiride and sitagliptin*
Yes
No
active proliferative diabetic retinopathy*
Yes
No
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EBMT Multiple Myeloma General
Information
ODM form derived fromEBMT Multiple Myeloma. please
refer to: http://www.ebmt.org/Contents/Data-
Management/Registrystructure/MED-
ABdatacollectionforms/Pages/MED-AB-data-collection-
forms.aspx
All rights reserved. Please visit https://medical-data-
models.org/forms/16099
16pp EBMT Multiple Myeloma
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GENERAL INFORMATION Team
EBMT Centre Identification Code (CIC)
Hospital
Unit
Name of contact person
Telephone
Fax
E-mail
Date of this report
Patient following national / international study /
trial
No (1)
Yes (2)
Not evaluated (3)
Unknown (4)
Name of study trial
PATIENT
To be entered only if patient previously reported
Hospital Unique Patient Number or Code
First name(s)_surname(s)
Date of Birth
Sex
Male (1)
Female (2)
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ABO Group
Rh factor
Absent (Absent)
Not evaluated (Not evaluated)
Present (Present)
DISEASE
Date of Diagnosis
Check the disease for which this transplant was
performed
Acute Leukaemia (Acute Leukaemia)
Acute Lymphoblastic Leukaemia (ALL)
(Acute Lymphoblastic Leukaemia (ALL))
Acute Myelogenous Leukaemia (AML)
(Acute Myelogenous Leukaemia (AML))
Autoimmune disease (Autoimmune
disease)
Bone marrow failure including Aplastic
anaemia (Bone marrow failure including
Aplastic anaemia)
Chronic Leukaemia (Chronic Leukaemia)
Chronic Lymphocytic Leukaemia
(Chronic Lymphocytic Leukaemia)
Chronic Myeloid Leukaemia (CML)
(Chronic Myeloid Leukaemia (CML))
Haemoglobinopathiy
(Haemoglobinopathiy)
Histiocytic disorders (Histiocytic
disorders)
Hodgkin´s Disease (Hodgkin´s Disease)
Inherited disorders (Inherited disorders)
Juvenile Idiopathic Arthritis (Juvenile
Idiopathic Arthritis)
Lymphoma (Lymphoma)
MD/ MPN (MD/ MPN)
MDS (MDS)
Metabolic disorders (Metabolic
disorders)
Multiple Sclerosis (Multiple Sclerosis)
Myelodysplastic syndromes
(Myelodysplastic syndromes)
Myeloma/ Plasma cell disorder
(Myeloma/ Plasma cell disorder)
Myeloproliferative neoplasm
(Myeloproliferative neoplasm)
Non Hodgkin (Non Hodgkin)
Other diagnosis (Other diagnosis)
Primary immune deficiencies (Primary
immune deficiencies)
Secondary Acute Leukaemia (do not use
if transformed from MDS/MPN)
(Secondary Acute Leukaemia (do not
use if transformed from MDS/MPN))
Solid Tumour (Solid Tumour)
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Systemic Lupus (Systemic Lupus)
Systemic Sclerosis (Systemic Sclerosis)
If other diagnosis, specify:
PLASMA CELL DISORDERS
(INCLUDING MULTIPLE MYELOMA)
Has the information requested in this section
been submitted with a previous HSCT registration
for this patient?
Yes: go to page 2, Pre HSCT Treatment
(1)
No: proceed with this section (2)
SUBCLASSIFICATION
Monoclonal light and heavy chain
deposition disease (LCDD/HCDD)
(Monoclonal light and heavy chain
deposition disease (LCDD/HCDD))
Multiple myeloma (Multiple myeloma)
Other (Other)
Plasma Cell Leukaemia (Plasma Cell
Leukaemia)
POEMS (POEMS)
Solitary plasmacytoma of bone (Solitary
plasmacytoma of bone)
if Multiple myeloma
Heavy chain and light chain (check light
and heavy chain types) (1)
Light chain only (check light chain type
only)  (2)
Non secretory (3)
Heavy chain and light chain
IgG (1)
IgA (2)
IgD (3)
IgE (4)
IgM (5)
Heavy chain and light chain
Kappa (1)
Lambda (2)
Light chain only
Kappa (1)
Lambda (2)
SALMON AND DURIE Stage at diagnosis
A I (1)
A II (2)
A III (3)
B I (4)
B II (5)
B III (6)
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ISS (Multiple Myeloma Prognosis) (Stage 1-3)
Chromosome analysis
Done: abnormal (Done: abnormal)
Done: normal (Done: normal)
Not Done or failed (Not Done or failed)
Unknown (Unknown)
Number of metaphases with anomalies:
Number of metaphases examined
IF ABNORMAL, INDICATE ABNORMALITIES
FOUND Del 13q14
Absent (Absent)
Not evaluated (Not evaluated)
Present (Present)
IF ABNORMAL, INDICATE ABNORMALITIES
FOUND t(11;14)
Absent (Absent)
Not evaluated (Not evaluated)
Present (Present)
IF ABNORMAL, INDICATE ABNORMALITIES
FOUND abn 17q
Absent (Absent)
Not evaluated (Not evaluated)
Present (Present)
IF ABNORMAL, INDICATE ABNORMALITIES
FOUND 17p del
Absent (Absent)
Not evaluated (Not evaluated)
Present (Present)
IF ABNORMAL, INDICATE ABNORMALITIES
FOUND t(4:14)
Absent (Absent)
Not evaluated (Not evaluated)
Present (Present)
IF ABNORMAL, INDICATE ABNORMALITIES
FOUND (14:16)
Absent (Absent)
Not evaluated (Not evaluated)
Present (Present)
IF ABNORMAL, INDICATE ABNORMALITIES
FOUND 1q amplification
Absent (Absent)
Not evaluated (Not evaluated)
Present (Present)
IF ABNORMAL, INDICATE ABNORMALITIES
FOUND c-myc
Absent (Absent)
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Not evaluated (Not evaluated)
Present (Present)
IF Other ABNORMAL, INDICATE
ABNORMALITIES FOUND, please specify
Absent (Absent)
Not evaluated (Not evaluated)
Present (Present)
Other or associated abnormalities (specify)
please specify
Molecular Analysis
Done but failed (1)
Done, successful (2)
Not evaluated (3)
Unknown (4)
Hb (g/dL)
Hb (g/dL)
Not evaluated (1)
Serum creatinine (mol/L)
Serum creatinine (mol/L)
Not evaluated (1)
Serum calcium (mmol/L)
Serum calcium (mmol/L)
Not evaluated (1)
Serum albumin (g/L)
Serum albumin (g/L)
Not evaluated (1)
BM aspirate: % plasmacytosis
BM aspirate: % plasmacytosis
Not evaluated (1)
BM trephine: % plasmacytosis
BM trephine: % plasmacytosis
Not evaluated (1)
Monoclonal Ig in serum (g/L)
Monoclonal Ig in serum (g/L)
Not evaluated (1)
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Monoclonal Ig in urine (g/24 h)
Monoclonal Ig in urine (g/24 h)
Not evaluated (1)
Serum ß2 microglobulin (mg/L)
Serum ß2 microglobulin (mg/L)
Not evaluated (1)
INVOLVEMENT AT DIAGNOSIS, Bone structure
Normal (1)
Minor (2)
Major (3)
Not evaluated (4)
INVOLVEMENT AT DIAGNOSIS, Bone structure
No (1)
Yes (2)
Unknown (3)
if yes, specify location
PRE-HSCT TREATMENT
Was the patient treated before the HSCT
procedure?
No (proceed to `Date of HSCT`) (No
(proceed to `Date of HSCT`))
Unknown (Unknown)
Yes (Yes)
(counted from diagnosis, or last HSCT if
applicable)
Chemo/Drugs
No (No)
Yes, Chemo/Drug regimen (Yes,
Chemo/Drug regimen)
Radiotherapy
No (1)
Yes (2)
Unknown (3)
see manual for full definition of each response
sCR (1)
CR (2)
VGPR (3)
PR (4)
Stable disease (5)
Progression (6)
Not evaluated (7)
Unknown (8)
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Additional Pre-HSCT treatment
No (No)
Unknown (Unknown)
Yes (Yes)
(counted from diagnosis, or last HSCT if
applicable)
Chemo/Drugs
No (1)
Yes, Chemo/Drug regimen (2)
Radiotherapy
No (1)
Yes (2)
(see manual for full definition of each response)
sCR (1)
CR (2)
VGPR (3)
PR (4)
Stable disease (5)
Progression (6)
Not evaluated (7)
Unknown (8)
ADDITIONAL PRE-HSCT TREATMENT?
No (1)
Yes, Date started (2)
Sequential number of this treatment
Chemo/Drugs
No (No)
Yes: Chemo/Drug regimen (Yes:
Chemo/Drug regimen)
Radiotherapy
No (1)
Yes (2)
Response
sCR (1)
CR (2)
VGPR (3)
PR (4)
Stable disease (5)
Progression (6)
Not evaluated (7)
Unknown (8)
HSCT
Date of HSCT
HSCT type
Autologous (1)
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Allogeneic (2)
Autologous
STATUS OF DISEASE AT COLLECTION
STATUS OF DISEASE AT COLLECTION
At diagnosis (untreated) (1)
Stringent complete remission (sCR) (2)
Complete remission (CR) (3)
Very good PR (VGPR) (4)
PR (5)
Relapse from CR (6)
Stable disease (7)
Progression (8)
Unknown (9)
If sCR or CR: NUMBER OF THIS COMPLETE
REMISSION
1st (1)
2nd (2)
3rd or higher (3)
If VGPR or PR: NUMBER OF THIS PARTIAL
REMISSION
1st (1)
2nd (2)
3rd or higher (3)
Relapse from CR, NUMBER OF THIS RELAPSE
1st (1)
2nd (2)
3rd or higher (3)
Relapse from CR, NUMBER OF THIS RELAPSE
1st (1)
2nd (2)
3rd or higher (3)
Plateau
No (1)
Yes (2)
Unknown (3)
Hb (g/dL)
Hb (g/dL)
Not evaluated (1)
Serum creatinine (mol/L)
Serum creatinine (_mol/L)
Not evaluated (1)
Serum calcium (mmol/L)
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Serum calcium (mmol/L)
Not evaluated (1)
Serum albumin (g/L)
Serum albumin (g/L)
Not evaluated (1)
BM aspirate: % plasmacytosis
BM aspirate: % plasmacytosis
Not evaluated (1)
BM trephine: % plasmacytosis
BM trephine: % plasmacytosis
Not evaluated (1)
Monoclonal Ig in serum (g/L)
Monoclonal Ig in serum (g/L)
Not evaluated (1)
Immunofixation of serum
Negative (1)
Positive (2)
Not evaluated (3)
Unknown (4)
Monoclonal Ig in urine (g/24 h)
Monoclonal Ig in urine (g/24 h)
Not evaluated (1)
Immunofixation of urine
Negative (1)
Positive (2)
Not evaluated (3)
Unknown (4)
Serum 2 microglobulin (mg/L)
Serum 2 microglobulin (mg/L)
Not evaluated (1)
Bone structure, Lytic lesions
Major (Major)
Minor (Minor)
Normal (Normal)
Not evaluated (Not evaluated)
DISEASE STATUS AT HSCT
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DISEASE STATUS AT HSCT
At diagnosis (1)
Stringent complete remission (sCR) (2)
Complete remission (CR) (3)
Very good PR (VGPR) (4)
PR (5)
Relapse from CR (6)
Stable disease (no change, includes old
MR) (7)
Progression (8)
Unknown (9)
NUMBER OF THIS COMPLETE REMISSION
1st (1)
2nd (2)
3rd or higher (3)
NUMBER OF THIS PARTIAL REMISSION
1st (1)
2nd (2)
3rd or higher (3)
NUMBER OF THIS RELAPSE
1st (1)
2nd (2)
3rd or higher (3)
(not applicable for non secretory myelona)
No (1)
Yes  (2)
Unknown (3)
Hb (g/dL)
Hb (g/dL)
Not evaluated (Not evaluated)
Serum creatinine (mol/L)
Serum creatinine (mol/L)
Not evaluated (Not evaluated)
Serum calcium (mmol/L)
Serum calcium (mmol/L)
Not evaluated (Not evaluated)
Serum albumin (g/L)
Serum albumin (g/L)
Not evaluated (Not evaluated)
BM aspirate: % plasmacytosis
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BM aspirate: % plasmacytosis
Not evaluated (Not evaluated)
Monoclonal Ig in serum (g/L)
Monoclonal Ig in serum (g/L)
Not evaluated (Not evaluated)
Immunofixation of serum
Negative (1)
Positive (2)
Not evaluated (3)
Unknown (4)
Monoclonal Ig in urine (g/24 h)
Monoclonal Ig in urine (g/24 h)
Negative (1)
Positive (2)
Not evaluated (3)
Unknown (4)
Immunofixation of urine
Negative (Negative)
Not evaluated (Not evaluated)
Positive (Positive)
Unknown (Unknown)
Serum 2 microglobulin (mg/L)
Serum 2 microglobulin (mg/L)
Not evaluated (1)
Lytic lesions
Normal (1)
Minor (2)
Major (3)
Not evaluated (4)
ADDITIONAL TREATMENT POST-HSCT
Additional Disease Treatment
No (No)
Unknown (Unknown)
Yes (Yes)
if yes
Not planned (for relapse/progression or
persistent disease) (Not planned (for
relapse/progression or persistent
disease))
Planned (planned before HSCT took
place) (Planned (planned before HSCT
took place))
Date started
11 / 26
EBMT Multiple Myeloma General Information
Chemo/drug/agen
Other (Other)
Thalidomide (Thalidomide)
Unknown (Unknown)
if other
Radiotherapy
No (No)
Unknown (Unknown)
Yes (Yes)
Other treatment
No  (1)
Yes (2)
Unknown (3)
if other treatment please specify
STATUS OF DISEASE AT 100 DAYS
AFTER HSCT
BEST RESPONSE TO HSCT AT 100 DAYS
Complete remission (CR) (Complete
remission (CR))
PR (PR)
Progression (Progression)
Stable disease (no change, includes old
MR) (Stable disease (no change,
includes old MR))
Stringent complete remission (sCR)
(Stringent complete remission (sCR))
Unknown (Unknown)
Very good PR (VGPR) (Very good PR
(VGPR))
If sCR or CR: NUMBER OF THIS COMPLETE
REMISSION
1st (1)
2nd (2)
3rd or higher (3)
If VGPR or PR: NUMBER OF THIS PARTIAL
REMISSION
1st (1)
2nd (2)
3rd or higher (3)
If complete response: Date of CR
Otherwise: date of evaluation
(COMPLETE ONLY IF STATUS IS STABLE
DISEASE OR PR)
No (No)
12 / 26
EBMT Multiple Myeloma General Information
Unknown (Unknown)
Yes (Yes)
BM aspirate: % plasmacytosis
BM aspirate: % plasmacytosis
Not evaluated (1)
BM trephine: % plasmacytosis
Monoclonal Ig in serum (g/L)
Monoclonal Ig in serum (g/L)
Not evaluated (1)
Immunofixation of serum
Negative (Negative)
Not evaluated (Not evaluated)
Positive (Positive)
Unknown (Unknown)
Monoclonal Ig in urine (g/24 h)
Monoclonal Ig in urine (g/24 h)
Not evaluated (1)
Immunofixation of urine
Negative (1)
Positive (2)
Not evaluated (3)
Unknown (4)
Serum 2 microglobulin (mg/L)
Serum 2 microglobulin (mg/L)
Not evaluated (1)
Lytic lesions
Normal (1)
Minor (2)
Major (3)
Not evaluated (4)
FORMS TO BE FILLED IN
Type of Transplant
ALLOgraft or Syngeneic graft (proceed to
Allograft form) (ALLOgraft or Syngeneic
graft (proceed to Allograft form))
AUTOgraft (proceed to Autograft form)
(AUTOgraft (proceed to Autograft form))
Other (contact the EBMT Central
Registry for instructions) (Other (contact
the EBMT Central Registry for
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instructions))
If Other contact the EBMT Central Registry Office
for instructions
PLASMA CELL DISORDERS
(INCLUDING MULTIPLE MYELOMA)
Unique Identification Code (UIC)
(if known)
Hospital Unique Patient Number
Date of this report
Patient following national / international study /
trial
No (1)
Yes (2)
Not evaluated (3)
Unknown (4)
Name of study / trial
First name(s)_surname(s)
Date of birth
Date of last HSCT for this patient
PATIENT LAST SEEN
Date of Last Contact or Death
Complete haematological remission obtained
after the HSCT in the absence of additional
disease treatment
Previously reported (1)
Yes (2)
No (3)
Unknown (4)
if yes, date
GRAFT VERSUS HOST DISEASE
(GvHD) SINCE LAST REPORT
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Acute Graft versus Host Disease (aGvHD) -
Grade
grade 0 (Absent) (1)
grade I (2)
grade II (3)
grade III (4)
grade IV (5)
Not evaluated (6)
if present
New onset (1)
Recurrent (2)
Persistent (3)
Reason
Tapering (1)
DLI (2)
Unexplained (3)
Date onset of this episode (if new or recurrent)
yyyy/mm/dd
Date onset of this episode
Not applicable (1)
Stage skin
0 (1)
1 (2)
2 (3)
3 (4)
4 (5)
Not evaluated (6)
unknown (7)
Stage liver
0 (1)
1 (2)
2 (3)
3 (4)
4 (5)
Not evaluated (6)
unknown (7)
Stage gut
0 (1)
1 (2)
2 (3)
3 (4)
4 (5)
Not evaluated (6)
unknown (7)
aGvHD
Resolution
Yes
No
Date of resolution
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yyyy/mm/dd
Presence of cGvHD
No (No)
Present continuously since last reported
episode (Present continuously since last
reported episode)
Resolved (Resolved)
Yes (Yes)
Presence of cGVHD, if yes
First episode (1)
Recurrence (2)
Date of onset
If present continously since last report, specify
cGvHD gade:
Extensive (Extensive)
Limited (Limited)
Organs affected
Skin (1)
Gut (2)
Liver (3)
Mouth (4)
Eyes (5)
Lung (6)
Other, specify (7)
Unknown (8)
if Other please specify
If Resolved: Date of resolution
OTHER COMPLICATIONS SINCE LAST
REPORT
Infection related complications
Yes
No
Pathogen
Use the list of pathogens listed after this table for
guidance.
Use “unknown” if necessary.
Pathogen
Use the list of pathogens listed after this table for
guidance.
Use “unknown” if necessary.
Pathogen
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Use the list of pathogens listed after this table for
guidance.
Use “unknown” if necessary.
Pathogen
Use the list of pathogens listed after this table for
guidance.
Use “unknown” if necessary.
Pathogen
Use the list of pathogens listed after this table for
guidance.
Use “unknown” if necessary.
Pathogen
Use the list of pathogens listed after this table for
guidance.
Use “unknown” if necessary.
Pathogen
Use the list of pathogens listed after this table for
guidance.
Use “unknown” if necessary.
Pathogen
Use the list of pathogens listed after this table for
guidance.
Use “unknown” if necessary.
Pathogen
Use the list of pathogens listed after this table for
guidance.
Use “unknown” if necessary.
Pathogen
Use the list of pathogens listed after this table for
guidance.
Use “unknown” if necessary.
Pathogen
Use the list of pathogens listed after this table for
guidance.
Use “unknown” if necessary.
Pathogen
Use the list of pathogens listed after this table for
guidance.
Use “unknown” if necessary.
Date
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Provide different dates for different episodes of
the same complication if applicable.
Date
Provide different dates for different episodes of
the same complication if applicable.
Date
Provide different dates for different episodes of
the same complication if applicable.
Date
Provide different dates for different episodes of
the same complication if applicable.
Date
Provide different dates for different episodes of
the same complication if applicable.
Date
Provide different dates for different episodes of
the same complication if applicable
Date
Provide different dates for different episodes of
the same complication if applicable
Date
Provide different dates for different episodes of
the same complication if applicable.
Date
Provide different dates for different episodes of
the same complication if applicable.
Date
Provide different dates for different episodes of
the same complication if applicable.
Date
Provide different dates for different episodes of
the same complication if applicable.
Non infection related complications
Yes
No
(Check all that are applicable for this period)
No  (No )
Unknown (Unknown)
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Yes (Yes)
Idiopathic pneumonia syndrome
(Check all that are applicable for this period)
No  (No )
Unknown (Unknown)
Yes (Yes)
VOD
(Check all that are applicable for this period)
No (No)
Unknown (Unknown)
Yes (Yes)
Cataract
Check all that are applicable for this period
Haemorrhagic cystitis, non infectious
No  (No )
Unknown (Unknown)
Yes  (Yes )
Haemorrhagic cystitis, non infectious
ARDS, non infectious
ARDS, non infectious
No (No)
Unknown (Unknown)
Yes (Yes)
ARDS, non infectious
Check all that are applicable for this period)
Yes (1)
No  (2)
Unknown (3)
Multiorgan failure, non infectious
(Check all that are applicable for this period
HSCT-associated microangiopathy
No (No)
Unknown (Unknown)
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Yes (Yes)
HSCT-associated microangiopathy
(Check all that are applicable for this period)
Renal failure requiring dialysis
No (No)
Unknown (Unknown)
Yes (Yes)
Renal failure requiring dialysis
(Check all that are applicable for this period)
Haemolytic anaemia due to blood group
No (No)
Unknown (Unknown)
Yes (Yes)
Haemolytic anaemia due to blood group
Check all that are applicable for this period)
Aseptic bone necrosis
No (No)
Unknown (Unknown)
Yes (Yes)
Aseptic bone necrosis
Other type of complication > CTCAE grade 2
Yes
No
Graft loss
No (1)
Yes (2)
Not evaluated (3)
Overall chimaerism
Aplasia (Aplasia)
95%) (Autologuos reconstitution
(recipient >)
95%) (Full (donor >)
Mixed (partial) (Mixed (partial))
Not evaluated (Not evaluated)
Date of Test
Identification of donor or Cord Blood Unit given
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by the centre
Number in the infusion order (if applicable)
Cell type on which test was performed (% Donor
Cells):
BM
%
Cell type on which test was performed (% Donor
cells):
PB mononuclear cells (PBMC)
%
Cell type on which test was performed (% Donor
cells):
T-Cells
%
Cell type on which test was performed (% Donor
cells):
B-Cells
%
Cell type on which test was performed (% Donor
cells):
Red blood cells
%
Cell type on which test was performed (% Donor
cells):
Monocytes
%
Cell type on which test was performed (% Donor
cells):
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PMNs (neutrophils)
%
Cell type on which test was performed (% Donor
cells):
Lymphocytes, NOS
%
Cell type on which test was performed (% Donor
cells):
Myeloid cells, NOS
%
Cell type on which test was performed % Donor
cells
Test used:
ABO group (ABO group)
Cytogenetic (Cytogenetic)
FISH (FISH)
Molecular (Molecular)
Other (Other)
unknown (unknown)
SECONDARY MALIGNANCY,
LYMPHOPROLIFERATIVE OR
MYELOPROLIFRATIVE DISORDER
DIAGNOSED
Previously reported (1)
Yes (2)
No at date of this follow-up (3)
Date of Diagnosis
Diagnosis
AML (AML)
Lymphoproliferative disorder
(Lymphoproliferative disorder)
MDS (MDS)
Other (Other)
if other, please specify
ADDITIONAL THERAPIES SINCE LAST
FOLLOW UP
Treatment given since last report
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No (No)
Unknown (Unknown)
Yes (Yes)
If yes:
CELLULAR THERAPY
One cell therapy regimen is defined as any
number of infusions given within 10 weeks for the
same indication. If more than one regimen of cell
therapy has been given since last report, copy
this section and complete it as many times as
necessary.
No (1)
Yes (2)
Unknown (3)
Disease status before this cellular therapy
CR (CR)
Not evaluated (Not evaluated)
Not in CR (Not in CR)
If yes: Type of cells
Donor lymphocyte infusion (DLI) (1)
Mesenchymal cells (2)
Other (3)
Unknown (4)
Number of Nucleated cells infused (DLI only)
10^8/kg
Number (1)
Not evaluated (2)
Unknown (3)
If DLI, specify the number of cells infused by
type:
CD 34+
Evaluated (Evaluated)
Not Evaluated (Not Evaluated)
Unknown (Unknown)
If DLI, specify the number of cells infused by
type: 
CD 3+
Evaluated  (Evaluated )
Not evaluated (Not evaluated)
Unknown (Unknown)
Total number of cells infused (non DLI only)
x10^6/kg
Number (1)
Not evaluated (2)
Unknown (3)
Chronological number of this cell therapy for this
patient
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Indication 
(check all that apply)
Loss/decreased chimaerism
(Loss/decreased chimaerism)
Mixed chimaerism (Mixed chimaerism)
Other (Other)
Planned/ protocol (Planned/ protocol)
Prophylactic (Prophylactic)
Treatment for disease (Treatment for
disease)
Treatment of GvHD (Treatment of GvHD)
Treatment PTLD, EBV, lymphoma
(Treatment PTLD, EBV, lymphoma)
Treatment viral infection (Treatment viral
infection)
If Other, please specify
Number of infusions within 10 weeks (count only
infusions that are part of same regimen and given
for the same indication)
Acute Graft versus Host Disease 
(after this infusion but before any further infusion/
transplant)
Maximum grade:
grade 0 (absent) (grade 0 (absent))
grade 1 (grade 1)
grade 2 (grade 2)
grade 3 (grade 3)
grade 4 (grade 4)
present, grade unknown (present, grade
unknown)
Disease treatment (apart from donor cell infusion
or other type of cell therapy)
No (1)
Yes: Planned (planned before HSCT took
place) (2)
Yes: Not planned (for
relapse/progression or persistent
disease) (3)
FIRST EVIDENCE OF RELAPSE OR
PROGRESSION SINCE LAST HSCT
Relapse or Progression
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Continous progression since transplant
(Continous progression since transplant)
No (No)
Previously reported (Previously reported)
Unknown (Unknown)
Yes (Yes)
if yes, date diagnosed
LAST DISEASE AND PATIENT STATUS
Last Disease Status
Complete Remission (Complete
Remission)
Progression (Progression)
Relapse (Relapse)
Stable disease (Stable disease)
Has patient or partner become  pregnant after
this HSCT?
No (No)
Unknown (Unknown)
Yes (Yes)
Survival Status
alive (0)
dead (1)
Type of score used
Karnofsky (Karnofsky)
Lansky (Lansky)
Score
100 (Normal, NED) (1)
10 (Moribund) (10)
Not evaluated (11)
Unknown (12)
90 (Normal activity)  (2)
80 (Normal with effort) (3)
70 (Cares for self) (4)
60 (Requires occasional assistance) (5)
50 (Requires assistance) (6)
40 (Disabled) (7)
30 (Severely disabled) (8)
20 (Very sick) (9)
If dead, specify cause of death:
HSCT related cause  (HSCT related
cause )
Other (Other)
Relapse or progression (Relapse or
progression)
Secondary malignancy (including
lymphoproliferative disease) (Secondary
malignancy (including lymphoproliferative
disease))
Unknown  (Unknown )
25 / 26
EBMT Multiple Myeloma General Information
If dead and HSCT related cause of death, specify
(check as many as apppropriate):
GvHD
No  (No )
Unknown (Unknown)
Yes (Yes)
If dead and HSCT related cause of death, specify
(check as many as apppropriate):
Interstitial Pneumonitis
No  (No )
Unknown (Unknown)
Yes (Yes)
If dead and HSCT related cause of death, specify
(check as many as apppropriate): 
Pulmonary toxicity
No  (No )
Unknown (Unknown)
Yes (Yes)
If dead and HSCT related cause of death, specify
(check as many as apppropriate): 
Infection
No  (No )
Unknown (Unknown)
Yes (Yes)
check as many as appropriate
bacterial (bacterial)
fungal (fungal)
parasitic (parasitic)
unknown (unknown)
viral (viral)
COMMENTS
IDENTIFICATION & SIGNATURE
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Eligibility Type 2 Diabetes NCT02315495
Combining Saxagliptin and Acarbose to Improve
Postprandial Glycaemia in Type 2 Diabetes; ODM derived
from: https://clinicaltrials.gov/show/NCT02315495
All rights reserved. Please visit https://medical-data-
models.org/forms/16100
Eligibility Type 2 Diabetes
NCT02315495
Inclusion Criteria
type 2 diabetes (world health organisation (who)
criteria), managed by diet alone (i.e. no oral
hypoglycaemic drugs or insulin)*
Yes
No
body mass index (bmi) 20 - 40 kg/m2*
Yes
No
age 18 - 70 years*
Yes
No
males and post-menopausal females (to control
for the effect of the menstrual cycle on gut
hormone secretion)*
Yes
No
glycated haemoglobin a1c (hba1c) ≥ 6.0% and ≤
7.9%*
Yes
No
haemoglobin above the lower limit of the normal
range (i.e. >135g/l for men and 115g/l for
women), and ferritin above the lower limit of
normal (i.e. >10mcg/l)*
Yes
No
Exclusion Criteria
use of any medication that may influence
gastrointestinal motor function, body weight or
appetite*
Yes
No
evidence of drug abuse, consumption of more
than 20 g alcohol or 10 cigarettes on a daily
basis*
Yes
No
history of gastrointestinal disease, including
significant upper or lower gastrointestinal
symptoms, pancreatitis, or previous
gastrointestinal surgery (other than
1 / 2
uncomplicated appendicectomy or
cholecystectomy)*
Yes
No
other significant illness, including epilepsy,
cardiovascular or respiratory disease*
Yes
No
autonomic nerve damage (as assessed by
standardised cardiovascular reflex tests [36])*
Yes
No
impaired renal or liver function (as assessed by
calculated creatinine clearance < 90 ml/min or
abnormal liver function tests (> 2 times upper
limit of normal range))*
Yes
No
allergy to vildagliptin or any other 'gliptin'*
Yes
No
donation of blood within the previous 3 months*
Yes
No
participation in any other research studies within
the previous 3 months*
Yes
No
females who are pre-menopausal*
Yes
No
inability to give informed consent*
Yes
No
vegetarians*
Yes
No
2 / 2
Eligibility Type 2 Diabetes NCT02315495
Record description central archive of
perioperative data (Zapod) - Vascular access
Source:
Project central archive of perioperative Data (ZaPoD) of the
German Society of Anesthesiology and Intensive Care
Medicine (DGAI).
Project lead: PD Dr. Sven Zenker, http://amp.uni-bonn.de
All rights reserved. Please visit https://medical-data-
models.org/forms/16101
Record description central archive of
perioperative data- Vascular access
Zugang
ZVK
Ja
Nein
Arterieller Zugang
Ja
Nein
Arteria radialis Katheter
Ja
Nein
Arteria femoralis Katheter
Ja
Nein
Arterieller Zugang, sonstige Arterie
Ja
Nein
Zugang Narkoseeinleitung
Ja
Nein
Zugang Narkoseeinleitung
Ja
Nein
Arterieller Zugang liegt
Ja
Nein
Arterieller Zugang Naht
Ja
Nein
Arterieller Zugang Lokalanästhesie
Ja
Nein
Periphere Venenverweilkanüle
Ja
Nein
Zugang Narkoseeinleitung
Ja
Nein
Zugang Narkoseeinleitung
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Ja
Nein
Periphere Venenverweilkanüle liegt
Ja
Nein
Periphere Venenverweilkanüle Lokalanästhesie
Ja
Nein
Periphere Venenverweilkanüle EMLA
Ja
Nein
Narkoseeinleitung ZVK
Ja
Nein
Narkoseeinleitung ZVK
Ja
Nein
Narkoseeinleitung ZVK
Ja
Nein
Pulmonalarterienkatheter
Ja
Nein
Pulmonalarterienkatheter
Ja
Nein
Gefäßschleuse
Ja
Nein
Gefäßschleuse
Ja
Nein
Zentraler Zugang HiFlow
Ja
Nein
Zentraler Zugang HiFlow
Ja
Nein
Zentraler Zugang, 1-lumig
Ja
Nein
Zentraler Zugang, 2-lumig
Ja
Nein
Zentraler Zugang, 3-lumig
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Ja
Nein
Zentraler Zugang, > 3-lumig
Ja
Nein
Venöser Zugang Vena cephalica
Ja
Nein
Venöser Zugang Vena basilica
Ja
Nein
Venöser Zugang Vena femoralis
Ja
Nein
Venöser Zugang Vena jugularis externa
Ja
Nein
Venöser Zugang Vena jugularis interna
Ja
Nein
Venöser Zugang Vena subclavia
Ja
Nein
Zugang Narkoseeinleitung
Ja
Nein
Zugang Narkoseeinleitung
Ja
Nein
Zentralvenöser Zugang liegt Narkoseeinleitung
Ja
Nein
Zentralvenöser Zugang Lokalanästhesie
Ja
Nein
Zentralvenöser Zugang Sonographie
Ja
Nein
Zentralvenöser Zugang EKG
Ja
Nein
Narkoseeinleitung ZVK
Ja
Nein
Narkoseeinleitung ZVK
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Vascular access
Ja
Nein
Narkoseeinleitung ZVK
Ja
Nein
Pulmonalarterienkatheter
Ja
Nein
Pulmonalarterienkatheter
Ja
Nein
Gefäßschleuse
Ja
Nein
Gefäßschleuse
Ja
Nein
Zentraler Zugang HiFlow
Ja
Nein
Zentraler Zugang HiFlow
Ja
Nein
Zentraler Zugang, 1-lumig
Ja
Nein
Zentraler Zugang, 2-lumig
Ja
Nein
Zentraler Zugang, 3-lumig
Ja
Nein
Zentraler Zugang, > 3-lumig
Ja
Nein
Venöser Zugang Vena cephalica
Ja
Nein
Venöser Zugang Vena basilica
Ja
Nein
Venöser Zugang Vena femoralis
Ja
Nein
Venöser Zugang Vena jugularis externa
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Vascular access
Ja
Nein
Venöser Zugang Vena jugularis interna
Ja
Nein
Venöser Zugang Vena subclavia
Ja
Nein
Zugang Narkoseeinleitung
Ja
Nein
Zugang Narkoseeinleitung
Ja
Nein
Zentralvenöser Zugang liegt Narkoseeinleitung
Ja
Nein
Zentralvenöser Zugang Lokalanästhesie
Ja
Nein
Zentralvenöser Zugang Sonographie
Ja
Nein
Zentralvenöser Zugang EKG
Ja
Nein
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Vascular access
Eligibility Type 2 Diabetes NCT02325960
A Comparison of Exenatide and Insulin Glargine on
Glycemic Variability in Type 2 Diabetes Patients
Inadequately Controlled With Metformin Monotherapy;
ODM derived from:
https://clinicaltrials.gov/show/NCT02325960
All rights reserved. Please visit https://medical-data-
models.org/forms/16108
Eligibility Type 2 Diabetes
NCT02325960
Inclusion Criteria
1. provision of informed consent prior to any
study specific procedures*
Yes
No
2. type2 diabetic patients had been on stable,
maximum tolerated doses of metformin (
≧1500mg/d, ≧8 weeks)*
Yes
No
3. male or female age ≧ 18 years and ≦70 years
old*
Yes
No
4. hba1c ≧7.0 and ≦10%*
Yes
No
5. bmi ≧ 24 kg/m2*
Yes
No
Exclusion Criteria
1. known or suspected allergy to trial products or
related products.*
Yes
No
2. impaired renal function defined as serum-
creatinine ≥ 1.5 mg/dl (≥ 133 umol/l).*
Yes
No
3. acute or chronic disease which may cause
tissue hypoxia such as respiratory failure or
shock.*
Yes
No
4. abnormal liver function, alanine transaminase
or aspartate aminotransferase  ≥ 3 fold normal
upper limit, total bilirubin ≥ 2 normal upper limit,
acute alcohol intoxication, alcoholism.*
Yes
No
1 / 2
5. subjects has a clinically significant, active (or
over the past 12 months) cardiovascular history
(including a history of myocardial infarction (mi),
arrhythmias  or conduction delays on ecg,
unstable angina, or decompensated heart failure
(new york heart association-class ⅲ and ⅳ).*
Yes
No
6. proliferative retinopathy or muscular oedema
requiring acute treatment.*
Yes
No
7. pregnant or positive pregnancy test at
screening, nursing mother, or unwillingness to
use adequate contraception (adequate
contraceptive measures are sterilization,
intrauterine device, oral contraceptives or barrier
methods).*
Yes
No
8. treatment with systemic corticosteroids within
the past two months prior to screening.*
Yes
No
9. type 1 diabetes mellitus.*
Yes
No
10. receipt of any investigational drug within 1
month prior to this trial.*
Yes
No
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Quality of Life  Cardiovascular Health Study
(CHS)
Documentation part: Record 3 Quality of Life 
The Cardiovascular Health Study (CHS) was initiated by
the National Heart, Lung and Blood Institute (NHLBI) in
1987 to determine the risk factors for development and
progression of cardiovascular disease (CVD) in older
adults, with an emphasis on subclinical measures. The
study recruited 5,888 adults aged 65 or older at entry in
four U.S. communities and conducted extensive annual
clinical exams between 1989-1999 along with semi-annual
phone calls, events adjudication, and subsequent data
analyses and publications. Additional data were collected
by studies ancillary to CHS. With the exception of annual
clinic visits, these activities are still ongoing.
Data obtained from: https://chs-nhlbi.org/
Permission granted by: Erika Enright.
All rights reserved. Please visit https://medical-data-
models.org/forms/16109
Quality of Life Cardiovascular Health
Study (CHS)
Administrative data
Name
#ID:
Quality of life
1. Based on the responses on this card how do
you feel about life as a whole?
delighted (1)
pleased (2)
mostly satisfied (3)
mostly dissatisfied (4)
unhappy (5)
terrible (6)
refuses to answer (9)
2. I want to ask you about how satisfied you are
with the meaning and purpose of your life. Here is
a card: the scale goes from 1 for extremely
satisfied to 10 for extremely dissatisfied. On this
scale of 1 to 10, how satisfied are you eith the
meaning and purpose of your life?
extremely satisfied (1)
extremly dissatisfied (10)
NA (2)
NA (3)
NA (4)
NA (5)
NA (6)
NA (7)
NA (8)
NA (9)
3. The first statement is: If I feel lonely, there are
several people I can talk to.
definitely true (1)
probably true (2)
probably false (3)
definitely false (4)
refuses to answer (9)
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4. The next statement ist: I often meet or talk with
family or friends.
definitely true (1)
probably true (2)
probably false (3)
definitely false (4)
refuses to answer (9)
5. The next statement is: If I were sick, I could
easily find someone to help me with my daily
chores.
definitely true (1)
probably true (2)
probably false (3)
definitely false (4)
refuses to answer (9)
6. The next statement is: When I need
suggestions on how to deal with a personal
problem, I know someone I can turn to.
definitely true (1)
probably true (2)
probably false (3)
definitely false (4)
refuses to answer (9)
7. The next statement is: There is at least one
person I know whose advice I really trust.
definitely true (1)
probably true (2)
probably false (3)
definitely false (4)
refuses to answer (9)
8. The next statement is: If I had to go out of town
for a few weeks, it would be difficult to find
someone who would look after my home, for
example the plants, pets, garden, etc.
definitely true (1)
probably true (2)
probably false (3)
definitely false (4)
refuses to answer (9)
9. How many different relatives do you see or
hear from at least once a month? Please include
your spouse and in-laws.
none (0)
one (1)
two (2)
three or four (3)
five to eight (4)
nine or more (5)
refused to answer (9)
10. Tell me about the relative with whom you
have the most contact. How often do you hear
from that person?
less than once a month (0)
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once a month (1)
a few times a month (2)
weekly (3)
a few times a week (4)
daily (5)
refused to answer (9)
11. How many relatives do you feel close to?
That is, how many of them do you feel at ease
with, can you talk about private matters, or can
you call on for help?
none (0)
one (1)
two (2)
three or four (3)
five to eight (4)
nine or more (5)
refused to answer (9)
12. How many close friends do you have? That
is, friends with whom you feel at ease, can talk to
about private matters or can call on for help.
none (0)
one (1)
two (2)
three or four (3)
five to eight (4)
nine or more (5)
refused to answer (9)
13. How many of these friends do you see or
hear from at least once a month?
none (0)
one (1)
two (2)
three or four (3)
five to eight (4)
nine or more (5)
refused to answer (9)
14.Tell me about the friend with whom you have
the most contact. How often do you see or hear
from that person?
less than once a month (0)
once a month (1)
a few times a month (2)
weekly (3)
a few times a week (4)
daily (5)
refused to answer (9)
15. When you have an important decision to
make, do you have someone you can talk to
about it?
no (0)
yes (1)
refused to answer (9)
When you have an important decision to make,
how often do you have someone to talk to about
3 / 5
Quality of Life  Cardiovascular Health Study (CHS)
it?
seldom? (1)
sometimes? (2)
often? (3)
very often? (4)
always? (5)
refused to answer (9)
16. When other people you know have an
important decision to make, do they talk to you
about it?
no (0)
yes (1)
refused to answer (9)
When other people you know have an important
decision to make, how often do they talk to you
about it?
seldom? (1)
sometimes? (2)
often? (3)
very often? (4)
always? (5)
refused to answer (9)
17. Does anybody rely on you to do something
for them each day? For example: shopping,
cooking diner, doing repairs, cleaning house,
providing child care, etc.
no (0)
yes (1)
refused to answer (9)
18. Do you help anybody with things like
shopping, filling out forms, doing repairs,
providing child care, etc.?
no (0)
yes (1)
refused to answer (9)
How often do you help someone with these kinds
of activities?
seldom? (1)
sometimes? (2)
often? (3)
very often? (4)
always? (5)
refused to answer (9)
19. Do you live alone or with other people?
alone (0)
with other people (1)
Who do you live with? (If more than one answer,
code response with highest score.)
spouse (1)
other relatives, inlaws, or friends (4)
unrelated individuals (for example paid
help) (5)
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refuses to answer (9)
Interviewer questions
A. On the whole, how well was the respondent
able to answer the questions asked?
very well (1)
fairly well (2)
not very well (3)
B. How cooperative was the respondent in
answering your questions?
very cooperative (1)
fairly cooperative (2)
not cooperative (3)
Date of interview
Interviewer
Interview:
First edit:
Second edit:
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NINDS CDE Physical Exam  Multiple
Sclerosis
NINDS Common Data Elements, Multiple Sclerosis
Physical Exam 
Used from the National Institute of Neurological Disorders
and Stroke Common Data Elements
(https://www.commondataelements.ninds.nih.gov/)
References:
Grinnon ST, Miller K, Marler JR, Lu Y, Stout A, Odenkirchen
J, Kunitz S. National Institute of Neurological Disorders and
Stroke Common Data Element Project - approach and
methods. Clin Trials. 2012;9(3):322-9.
All rights reserved. Please visit https://medical-data-
models.org/forms/16110
Physical Exam
Physical Exam
Study ID
Study site name
Subject ID
1.  Date of Exam:
2.  Was a physical exam performed on the
participant/subject?
Yes (Specify results below) (1)
No (2)
Table for Recording Results of Physical
Exam
Constitutional symptoms 
(e.g., fever, weight loss)
Normal (1)
Abnormal (2)
Not examined (3)
Describe Abnormality or Comment if Body
System is Not Examined
If Abnormality, Clinically Significant?
Clinically significant  (1)
Not clinically significant (2)
Eyes
Normal (1)
Abnormal (2)
Not examined (3)
Describe Abnormality or Comment if Body
System is Not Examined
If Abnormality, Clinically Significant?
Clinically significant  (1)
Not clinically significant (2)
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Ears, Nose, Mouth, and Throat
Normal (1)
Abnormal (2)
Not examined (3)
Describe Abnormality or Comment if Body
System is Not Examined
If Abnormality, Clinically Significant?
Clinically significant  (1)
Not clinically significant (2)
Cardiovascular
Normal (1)
Abnormal (2)
Not examined (3)
Describe Abnormality or Comment if Body
System is Not Examined
If Abnormality, Clinically Significant?
Clinically significant  (1)
Not clinically significant (2)
Respiratory
Normal (1)
Abnormal (2)
Not examined (3)
Describe Abnormality or Comment if Body
System is Not Examined
If Abnormality, Clinically Significant?
Clinically significant  (1)
Not clinically significant (2)
Gastrointestinal
Normal (1)
Abnormal (2)
Not examined (3)
Describe Abnormality or Comment if Body
System is Not Examined
If Abnormality, Clinically Significant?
Clinically significant  (1)
Not clinically significant (2)
Genitourinary
Normal (1)
Abnormal (2)
Not examined (3)
Describe Abnormality or Comment if Body
System is Not Examined
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If Abnormality, Clinically Significant?
Clinically significant  (1)
Not clinically significant (2)
Musculoskeletal
Normal (1)
Abnormal (2)
Not examined (3)
Describe Abnormality or Comment if Body
System is Not Examined
If Abnormality, Clinically Significant?
Clinically significant  (1)
Not clinically significant (2)
Integumentary (skin and/or breast)
Normal (1)
Abnormal (2)
Not examined (3)
Describe Abnormality or Comment if Body
System is Not Examined
If Abnormality, Clinically Significant?
Clinically significant  (1)
Not clinically significant (2)
Neurological
Normal (1)
Abnormal (2)
Not examined (3)
Describe Abnormality or Comment if Body
System is Not Examined
If Abnormality, Clinically Significant?
Clinically significant  (1)
Not clinically significant (2)
Psychiatric
Normal (1)
Abnormal (2)
Not examined (3)
Describe Abnormality or Comment if Body
System is Not Examined
If Abnormality, Clinically Significant?
Clinically significant  (1)
Not clinically significant (2)
Endocrine
Normal (1)
Abnormal (2)
Not examined (3)
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Describe Abnormality or Comment if Body
System is Not Examined
If Abnormality, Clinically Significant?
Clinically significant  (1)
Not clinically significant (2)
Hematologic/Lymphatic
Normal (1)
Abnormal (2)
Not examined (3)
Describe Abnormality or Comment if Body
System is Not Examined
If Abnormality, Clinically Significant?
Clinically significant  (1)
Not clinically significant (2)
Allergic/Immunologic
Normal (1)
Abnormal (2)
Not examined (3)
Describe Abnormality or Comment if Body
System is Not Examined
If Abnormality, Clinically Significant?
Clinically significant  (1)
Not clinically significant (2)
3.  Hand preference: (Hand participant/subject
uses predominately, not necessarily hand he/she
writes 
with exclusively)
Left hand  (1)
Right hand  (2)
Both hands   (3)
Unknown (4)
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NINDS CDE Vital Signs  Multiple Sclerosis
NINDS Common Data Elements, Multiple Sclerosis Vital
Signs 
Used from the National Institute of Neurological Disorders
and Stroke Common Data Elements
(https://www.commondataelements.ninds.nih.gov/)
References:
Grinnon ST, Miller K, Marler JR, Lu Y, Stout A, Odenkirchen
J, Kunitz S. National Institute of Neurological Disorders and
Stroke Common Data Element Project - approach and
methods. Clin Trials. 2012;9(3):322-9.
All rights reserved. Please visit https://medical-data-
models.org/forms/16111
Vital Signs
Vital Signs
Study ID
Study site name
Subject ID
1.  Date and Time:
2.  Heart Rate/Pulse:
beats per minute
3.  Respiratory Rate:
breaths per minute
4.  Blood Pressure:(systolic/diastolic)
mmHg
Participant’s/Subject’s Position
Sitting (1)
Standing  (2)
Supine (3)
5.  Temperature:
○ C
Temperature Method:
Oral  (1)
Axillary (2)
Rectal  (3)
Tympanic  (4)
Forehead Cutaneous Infrared  (5)
Other (6)
Other, specify:
6.  Weight:
kilograms
7.  Height/Length:
centimeters
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Additional Pediatric-specific Elements
8.  Head Circumference:
centimeters
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NINDS CDE Genetics  Multiple Sclerosis
NINDS Common Data Elements, Multiple Sclerosis
Genetics 
Used from the National Institute of Neurological Disorders
and Stroke Common Data Elements
(https://www.commondataelements.ninds.nih.gov/)
References:
Grinnon ST, Miller K, Marler JR, Lu Y, Stout A, Odenkirchen
J, Kunitz S. National Institute of Neurological Disorders and
Stroke Common Data Element Project - approach and
methods. Clin Trials. 2012;9(3):322-9.
All rights reserved. Please visit https://medical-data-
models.org/forms/16112
Genetics
Genetics
Study ID
Study site name
Subject ID
1.  Have you had a sample drawn for DNA
banking?
yes (1)
no (2)
unknown (3)
i.  Specify the type of sample drawn:
Blood draw  (1)
Buccal smear (cheek swab)  (2)
Saliva (3)
ii.  Specify the study for which the sample was
initially taken:
iii.  Specify where the sample is banked, if known:
iv.  Do you have the consent form you signed at
the time the sample was taken?
yes (1)
no (2)
unknown (3)
Table for Recording Family History of DNA
Sample Banking
Relative Type
DNA Sample Banked in a Repository?
yes (1)
no (2)
unknown (3)
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NINDS CDE MRI Multiple Sclerosis
NINDS Common Data Elements, Multiple Sclerosis MRI 
Used from the National Institute of Neurological Disorders
and Stroke Common Data Elements
(https://www.commondataelements.ninds.nih.gov/)
References:
Grinnon ST, Miller K, Marler JR, Lu Y, Stout A, Odenkirchen
J, Kunitz S. National Institute of Neurological Disorders and
Stroke Common Data Element Project - approach and
methods. Clin Trials. 2012;9(3):322-9.
All rights reserved. Please visit https://medical-data-
models.org/forms/16113
MRI
MRI
Study ID
Study site name
Subject ID
1.  Date of MRI:
2.  Date of Clinical Visit coinciding with scan:
3.  Clinical Visit type coinciding with scan (choose
only one):
Missing ( 4)
Baseline  (1)
End of treatment  (2)
End of study  (3)
4.  Scanner Manufacturer (choose only one):
GE  (1)
Siemens  (2)
Philips  (3)
Other (4)
Other specify
5.  Field Strength of Scanner Used (choose only
one):
1.5T  (1)
3.0T  (2)
4.0T  (3)
7.0T  (4)
Other (5)
Other specify
6.  MRI Software Version Number:
7.  Was Gadolinium administered in the protocol
window?
yes (1)
no (2)
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unknown (3)
a.  If No, explain:
8.  What was the delay in time from injection to
start of post-Gd T1-weighted sequence?
min
9.  Date estimated glomerular filtration rate
(eGFR) was performed:
10. Estimated glomerular filtration rate (eGFR)
result (note a caution warning if <55 and an
exclusion for Gd 
administration if <45):
mL/dL
11. Was scan-based QA/QC performed?
yes (1)
no (2)
unknown (3)
12. If Yes, indicate QA/QC results:
Pass    (1)
Fail, explain: (2)
If fail, explain:
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NINDS CDE OCT Information Multiple
Sclerosis
NINDS Common Data Elements, Multiple Sclerosis OCT
Information
Used from the National Institute of Neurological Disorders
and Stroke Common Data Elements
(https://www.commondataelements.ninds.nih.gov/)
References:
Grinnon ST, Miller K, Marler JR, Lu Y, Stout A, Odenkirchen
J, Kunitz S. National Institute of Neurological Disorders and
Stroke Common Data Element Project - approach and
methods. Clin Trials. 2012;9(3):322-9.
All rights reserved. Please visit https://medical-data-
models.org/forms/16114
OCT Information
OCT Information
Study ID
Study site name
Subject ID
1)  Date of OCT scans
2)  Date of Clinical Visit coinciding with scans
3)  Was time-domain OCT (Stratus-Zeiss)
performed?
yes (1)
no (2)
unknown (3)
4)  Was spectral-domain OCT (Cirrus-Zeiss)
performed?
yes (1)
no (2)
unknown (3)
5)  Was spectral-domain OCT (Spectralis-
Heidelberg) performed?
yes (1)
no (2)
unknown (3)
6)  Was ganglion cell layer thickness
(segmentation) OCT (Cirrus-Zeiss) performed?
yes (1)
no (2)
unknown (3)
7)  Was scan-based QA/QC performed?
yes (1)
no (2)
unknown (3)
a.  If Yes, indicate QA/QC results:
pass (1)
fail (Explain) (2)
If fail, explain:
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8)  Refraction right eye (OD):
9)  Refraction left eye (OS):
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Eligibility Type 2 Diabetes NCT02352246
HIIE and Abdominal Fat Mass in DT2 Postmenopausal
Women; ODM derived from:
https://clinicaltrials.gov/show/NCT02352246
All rights reserved. Please visit https://medical-data-
models.org/forms/16116
Eligibility Type 2 Diabetes
NCT02352246
Inclusion Criteria
postmenopausal women (55- 82 years)*
Yes
No
t2d*
Yes
No
bmi ≥ 25 and < 40*
Yes
No
able to follow an exercise protocol*
Yes
No
eating behavior and physical activity stable since
at least 3 month*
Yes
No
Exclusion Criteria
- subject not able to perform exercise after
medical examination*
Yes
No
subject not able to perform bicycle exercise
(pains)*
Yes
No
chronic infection*
Yes
No
use of β-blocker*
Yes
No
medical treatment that could interfere with the
different outcome measures*
Yes
No
hormonal replacement therapy (hrt)*
Yes
No
1 / 2
regular consumption of alcohol*
Yes
No
refusal to sign the consent form*
Yes
No
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Eligibility Type 2 Diabetes NCT02490085
Closed-loop Control of Glucose Levels (Artificial Pancreas)
for 24 Hours in Adults With Type 2 Diabetes Under
Intensive Insulin Therapy; ODM derived from:
https://clinicaltrials.gov/show/NCT02490085
All rights reserved. Please visit https://medical-data-
models.org/forms/16119
Eligibility Type 2 Diabetes
NCT02490085
Inclusion Criteria
1. type 2 diabetes.*
Yes
No
2. males and females ≥ 60 years of old.*
Yes
No
3. body mass index between 27 and 40 kg/m2
(inclusive)*
Yes
No
4. non fragile defined based on moorhouse et al.
scale [23].*
Yes
No
5. using at least 3 insulin injections per day.
however, basal insulin injection must be injected
at bedtime without injection of basal insulin in the
morning. combination with any other anti-diabetic
therapy is acceptable as long at this therapy was
introduced at least 6 weeks prior the 1s
intervention and is kept stable all along the
protocol.*
Yes
No
6. hba1c above 8%.*
Yes
No
Exclusion Criteria
1. advanced*
Yes
No
1. nephropathy defined by creatinine clearance
<30 ml/min.*
Yes
No
2. retinopathy as proliferative retinopathy or
recent (<3 month) eye  bleeding or laser therapy.
if the patient have undergone panphoto-
coagulation inclusion is acceptable.*
Yes
No
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3. autonomic neuropathy with clinically significant
gastroparesis according to investigator
evaluation.*
Yes
No
2. recent (< 6 months) acute macrovascular event
e.g. acute coronary syndrome or cardiac
surgery.*
Yes
No
3. a recent (< 2 months) injury to body or limb,
muscular disorder, use of any medication or other
significant medical disorder if that injury,
medication or disease in the judgment of the
investigator will affect the ability to walk.*
Yes
No
4. a recent (< 2 months) infection needing iv
antibiotic or hospitalization*
Yes
No
5. severe hypoglycemic episode within two weeks
of screening.*
Yes
No
6. current use of glucocorticoid medication (by
any route of administration except low dose
stable inhaled).*
Yes
No
7. recent initiation or dose modification (<2
months) of therapy known to interfere with
glucose metabolism (e.g. neuroleptics, anti-
psychotics, etc.)*
Yes
No
8. known or suspected allergy to the trial
products or meal contents.*
Yes
No
9. other serious medical illness likely to interfere
with study participation or with the ability to
complete the trial by the judgment of the
investigator.*
Yes
No
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Ministry of Health,Ethiopia-HIV Care/ART
Follow up
Form issued by Binyam Tilahun.
Source: http://www.moh.gov.et/ (Ministry of Health,
Ethiopia)
All rights reserved. Please visit https://medical-data-
models.org/forms/16120
HIV Care/ART Follow up
Demographics
Facility name
Patient card number
ART unique number
Tuberculosis Card number
PMTCT Confidentiality Code
Patient´s Name
Age
years
Gender
male (1)
female (2)
Body height
cm
Patient address: Region
Patient address: Wereda/Subcity
Patient address: Kebele
Patient address: House number
Telephone number
Date HIV positivity confirmed
HIV Test Type
Rapid HIV Tests (1)
ELISA (2)
PCR (in children) (3)
Eligibility Date
1 / 5
Why eligible? Please select
Clinical only (1)
CD4 (2)
TLC (3)
Transfer In (TI) (4)
Please enter the date when patient is medically
eligible and ready (counseled for adherence) for
ART
Follow up chart
Please specify whether patient receives free ART
or pays for ART
Pays for ART (1)
Free ART (2)
Visit Type
Scheduled (S)
unscheduled (US)
Follow up date
Months on ART
Weight
kg
Pregnancy
Yes
No
If pregnant, please specify estimated due date
Family planning method
Condome (1)
oral contraceptive pills (2)
injectable/implantable hormones (3)
Diaphragm/cervical cap (4)
Intrauterine device (5)
Vasectomy/tubal ligation (6)
Height of child
cm
Head circumference
cm
Patient functional status
Ambulatory (able to perform activities of
daily living) (A)
Bedridden (unable to perform activities of
daily living) (B)
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working (able to perform work in or out of
the house,harvest,go to school,for
children normal activities or play (W)
Developmental milestones
Appropriate (A)
Delay (D)
Regression (R)
WHO human immunodeficiency virus stage
I (1)
II (2)
III (3)
IV (4)
Tuberculosis screening
Positive  (1)
Negative (2)
Tuberculosis prophylaxis
Currently on INH prophylaxis (INH)
Currently on DOTS (TB Rx)
Tuberculosis prophylaxis:please specify months
on treatment
Other Infections
Bacterial Pneumonia (BP)
Cryptococcal Meningitis (CM)
CNS Toxoplasmosis (CT)
Diarrhea acute (DA)
Diarrhea chronic (DC)
Extrapulmonary TB (ETB)
Other (O)
Pneumocystis pneumonia (PCP)
Pulmonary TB (PTB)
Thrush- oral/vaginal (T)
Ulcers-mouth, genital (U)
Zoster (Z)
Cotrimoxazole
Yes
No
Dispensed dose, please note the number of
dispensed doses
Therapy adherence
Fair (F)
Good (G)
Poor (P)
If fair or poor therapy adherence, please specify
reason
Toxicity/side effects (1)
Inability to pay (10)
Alcohol (11)
Depression (12)
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Other (13)
Share with others (2)
Forgot (3)
Felt better (4)
Too ill (5)
Stigma,Disclosure (6)
Drug stock out (7)
Lost/ran out of pills (8)
Delivery/travel problems (9)
Any other medication dispensed
Antiretroviral therapy adherence
Fair (F)
Good (G)
Poor (P)
If therapy adherence is fair or poor,please specify
why
Toxicity/side effects (1)
Inability to pay (10)
Alcohol (11)
Depression (12)
Other (13)
Share with others (2)
Forgot (3)
Felt better (4)
Too ill (5)
Stigma,Disclosure (6)
Drug stock out (7)
Lost/ran out of pills (8)
Delivery/travel problems (9)
Antiretroviral therapy Dispense code
Antiretroviral therapy Dispense code
Antiretroviral therapy dispensed dose
Antiretroviral therapy side effects
Nausea (1)
Fat changes (10)
dizzy,anxiety, night mare (11)
Diarrhea (2)
Fatigue (3)
Headache (4)
Numbness/Tingling (5)
Rash (6)
Anemia (7)
Abdominal pain (8)
Jaundice (9)
Reason for change of treatment
Toxicity/side effects (1)
Pregnancy (2)
Risk of Pregnancy (3)
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Due to new TB (4)
New Drug available (5)
Drug out of stock (6)
Other (7)
immunologic failure (8)
Virologic failure (9)
Reason for treatment stop
Toxicity/side effects (1)
Other (10)
Pregnancy (2)
Treatment failure (3)
Poor adherence (4)
Illness,hospitalization (5)
Drugs out of stock (6)
Patient lacks finances (7)
Other patient decision (8)
Planned treatment interruption (9)
CD4/mm3 or percent if <5yrs or TLC
mm³/%
Hemoglobine
ALT/AST
Next visit date
Please select if one of the below applies
Dead (Dead)
Lost to follow up for > 3 months (Drop)
not seen since>/=1month<3months
(Lost)
transferred out (TO)
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Eligibility Type 2 Diabetic Patients
NCT02164578
Microvascular and Antiinflammatory Effects of Rivaroxaban
Compared to Aspirin in Type-2 Diabetic Patients With
Cardiovascular Disease; ODM derived from:
https://clinicaltrials.gov/show/NCT02164578
All rights reserved. Please visit https://medical-data-
models.org/forms/16121
Eligibility Type 2 Diabetic Patients
NCT02164578
Inclusion Criteria
type 2 diabetes duration between 2 and 20 years*
Yes
No
documented atherosclerotic cvd:*
Yes
No
major cardiovascular event in medical history or*
Yes
No
coronary angiography showing a coronary artery
stenosis of > 50 % or*
Yes
No
carotid ultrasound showing an imt > 1 mm and
plaque of carotid artery or*
Yes
No
left ventricular hypertrophy or*
Yes
No
macroalbuminuria in the absence of other renal
diseases*
Yes
No
increased hscrp (> 2 mg/l but < 10 mg/l) and/or
increased pai 1 (> 15 ng/ml)*
Yes
No
stable treatment with statins (if tolerated)*
Yes
No
age 40 - 75 years*
Yes
No
Exclusion Criteria
cv event with need for oral anticoagulation or dual
platelet inhibitor therapy or acute coronary
syndrome < 12 month before study entry*
Yes
No
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sustained uncontrolled hypertension: systolic bp
> 180 mmhg or diastolic bp > 100 mmhg*
Yes
No
hypersensitivity to the active substance*
Yes
No
active clinically significant bleeding*
Yes
No
significant risks for major bleeding*
Yes
No
concomitant treatment of acs with antiplatelet
therapy in patients with a prior stroke or a
transient ischaemic attack (tia)*
Yes
No
hepatic disease associated with coagulopathy
and clinically relevant bleeding risk*
Yes
No
chronic renal failure with egfr < 15 ml/min (mdrd
formula)*
Yes
No
pregnant or breast-feeding woman and woman
without adequate method of contraception.*
Yes
No
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Physical Activity Cardiovascular Health
Study (CHS)
Documentation part: Record 4 Physical Activity
The Cardiovascular Health Study (CHS) was initiated by
the National Heart, Lung and Blood Institute (NHLBI) in
1987 to determine the risk factors for development and
progression of cardiovascular disease (CVD) in older
adults, with an emphasis on subclinical measures. The
study recruited 5,888 adults aged 65 or older at entry in
four U.S. communities and conducted extensive annual
clinical exams between 1989-1999 along with semi-annual
phone calls, events adjudication, and subsequent data
analyses and publications. Additional data were collected
by studies ancillary to CHS. With the exception of annual
clinic visits, these activities are still ongoing.
Data obtained from: https://chs-nhlbi.org/
Permission granted by: Erika Enright.
All rights reserved. Please visit https://medical-data-
models.org/forms/16123
Physical Activity Cardiovascular
Health Study (CHS)
Administrative data
Name
ID#:
Physical Activity
1.a I am going to read a list of activities. Please
tell me which activities you have done in the past
two weeks:
Walking for exercise?
no (0)
yes (1)
refuse (9)
1.a I am going to read a list of activities. Please
tell me which activities you have done in the past
two weeks:
Moderately strenuous household chores, for
example, scrubbing or vacuuming?
no (0)
yes (1)
refuse (9)
1.a I am going to read a list of activities. Please
tell me which activities you have done in the past
two weeks:
Mowing the lawn?
no (0)
yes (1)
refuse (9)
1.a I am going to read a list of activities. Please
tell me which activities you have done in the past
two weeks:
Raking the lawn?
no (0)
yes (1)
refuse (9)
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1.a I am going to read a list of activities. Please
tell me which activities you have done in the past
two weeks:
Gardening?
no (0)
yes (1)
refuse (9)
1.a I am going to read a list of activities. Please
tell me which activities you have done in the past
two weeks:
Hiking?
no (0)
yes (1)
refuse (9)
1.a I am going to read a list of activities. Please
tell me which activities you have done in the past
two weeks:
Jogging?
no (0)
yes (1)
refuse (9)
1.a I am going to read a list of activities. Please
tell me which activities you have done in the past
two weeks:
Biking?
no (0)
yes (1)
refuse (9)
1.a I am going to read a list of activities. Please
tell me which activities you have done in the past
two weeks:
Exercise cycle?
no (0)
yes (1)
refuse (9)
1.a I am going to read a list of activities. Please
tell me which activities you have done in the past
two weeks:
Dancing?
no (0)
yes (1)
refuse (9)
1.a I am going to read a list of activities. Please
tell me which activities you have done in the past
two weeks:
Aerobics/aerobic dance?
no (0)
yes (1)
refuse (9)
1.a I am going to read a list of activities. Please
tell me which activities you have done in the past
two weeks:
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Bowling?
no (0)
yes (1)
refuse (9)
1.a I am going to read a list of activities. Please
tell me which activities you have done in the past
two weeks:
Golf?
1.a I am going to read a list of activities. Please
tell me which activities you have done in the past
two weeks:
Callsthenics/general exercise?
no (0)
yes (1)
refuse (9)
1.a I am going to read a list of activities. Please
tell me which activities you have done in the past
two weeks:
Swimming?
no (0)
yes (1)
refuse (9)
Have you done any other physical activities
during the past two weeks in addition to those
listed above?
If yes: Please tell me what they were:
Other:
B. How often have you [name of activity] in the
last two weeks? # of times:
B. How often have you [name of activity] in the
last two weeks? # of times:
B. How often have you [name of activity] in the
last two weeks? # of times:
B. How often have you [name of activity] in the
last two weeks? # of times:
B. How often have you [name of activity] in the
last two weeks? # of times:
B. How often have you [name of activity] in the
last two weeks? # of times:
B. How often have you [name of activity] in the
3 / 7
Physical Activity Cardiovascular Health Study (CHS)
last two weeks? # of times:
B. How often have you [name of activity] in the
last two weeks? # of times:
B. How often have you [name of activity] in the
last two weeks? # of times:
B. How often have you [name of activity] in the
last two weeks? # of times:
B. How often have you [name of activity] in the
last two weeks? # of times:
B. How often have you [name of activity] in the
last two weeks? # of times:
B. How often have you [name of activity] in the
last two weeks? # of times:
B. How often have you [name of activity] in the
last two weeks? # of times:
B. How often have you [name of activity] in the
last two weeks? # of times:
B. How often have you [name of activity] in the
last two weeks? # of times:
B. How often have you [name of activity] in the
last two weeks? # of times:
C. What is the average amount of time that you
spent per session? #hours #mins
C. What is the average amount of time that you
spent per session? #hours #mins
C. What is the average amount of time that you
spent per session? #hours #mins
C. What is the average amount of time that you
spent per session? #hours #mins
C. What is the average amount of time that you
spent per session? #hours #mins
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C. What is the average amount of time that you
spent per session? #hours #mins
C. What is the average amount of time that you
spent per session? #hours #mins
C. What is the average amount of time that you
spent per session? #hours #mins
C. What is the average amount of time that you
spent per session? #hours #mins
C. What is the average amount of time that you
spent per session? #hours #mins
C. What is the average amount of time that you
spent per session? #hours #mins
C. What is the average amount of time that you
spent per session? #hours #mins
C. What is the average amount of time that you
spent per session? #hours #mins
C. What is the average amount of time that you
spent per session? #hours #mins
C. What is the average amount of time that you
spent per session? #hours #mins
C. What is the average amount of time that you
spent per session? #hours #mins
C. What is the average amount of time that you
spent per session? #hours #mins
D. How many months per year do you [name of
activity]? #months
D. How many months per year do you [name of
activity]? #months
D. How many months per year do you [name of
activity]? #months
D. How many months per year do you [name of
activity]? #months
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D. How many months per year do you [name of
activity]? #months
D. How many months per year do you [name of
activity]? #months
D. How many months per year do you [name of
activity]? #months
D. How many months per year do you [name of
activity]? #months
D. How many months per year do you [name of
activity]? #months
D. How many months per year do you [name of
activity]? #months
D. How many months per year do you [name of
activity]? #months
D. How many months per year do you [name of
activity]? #months
D. How many months per year do you [name of
activity]? #months
D. How many months per year do you [name of
activity]? #months
D. How many months per year do you [name of
activity]? #months
D. How many months per year do you [name of
activity]? #months
2. Think about the walking you do outside your
home. During the last week, about how many city
blocks or miles did you walk?
Blocks or miles
blocks (1)
miles (2)
3. Look at this card and tell me, when you walk
outside your home, what is your usual pace?
no walking at all (1)
casual strolling (greater than 0 to 2.0
mph) (2)
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average or normal (greater than 2.0 to
3.0 mph) (3)
fairly briskly (greater than 3.0 to 4.0 mph)
(4)
brisk or striding (greater than 4 mph) (5)
unknown (9)
4. Think about how often you use stairs. Include
stairs outside your home and stairs at other
places, during the last week, about how many
flights of stairs did you climb up? (Ten steps=one
flight of stairs) #of flight of stairs
5. Look at this card and tell me, how would you
describe your level of activity since we saw you
last year?
a lot less active (1)
a little less active (2)
about as active (3)
a little more active (4)
a lot more active (5)
unknown (9)
6. In a usual 24 hour period, how many hours do
you spend seated or lying down? Include all time
spent sleeping, resting, and lying down, and also
include all time spent watching TV, eating,
reading, and any other time sitting down. # of
hours
Date of interview
Interviewer
Interview:
First edit:
Second edit:
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NHL-BFM Registry 2012 Non-response
NHL-BFM 2012 Registry. 
Principal Investigators: Birgit Burkhardt and Wilhelm
Woessmann. 
NHL study group University Hospital Münster
All rights reserved. Please visit https://medical-data-
models.org/forms/16124
Non-response
Non-responder day 33 (lymphoblastic
lymphoma (LBL) only)
Non-responder at day 33 (LBL)*
no (1)
yes (2)
Date of non-response day 33 (LBL)*
Non-responder at day 33: description*
Non-responder (all entities except of LBL)
Non-responder (all entities except of LBL)*
no (1)
yes (2)
Date of non-response (all entities except of LBL)*
Non-responder (all entities except of LBL):
description*
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NHL-BFM Registry 2012 Signed Informed
Consent
NHL-BFM 2012 Registry. 
Principal Investigators: Birgit Burkhardt and Wilhelm
Woessmann. 
NHL study group University Hospital Münster
All rights reserved. Please visit https://medical-data-
models.org/forms/16125
Signed Informed Consent
Signed informed consent available for
participation in the registry and
consultation
Participation in the NHL-BFM Registry 2012 (and
treatment according to the included treatment
recommendations)*
no (1)
yes (2)
Consultation of the NHL-BFM center with regard
to medical problems / questions*
no (1)
yes (2)
Signed informed consent available for data
transfer, data storage, and data handling
...
... in the NHL-BFM Registry 2012*
no (1)
yes (2)
... at the reference institutes*
no (1)
yes (2)
... at the German Children's Cancer Registry
(Deutsches Kinderkrebsregister)*
no (1)
yes (2)
... pseudonymized for research projects (see also
below)*
no (1)
yes (2)
Storage of remaining bio material with
contact for each scientific usage
The patient wants to be contacted and asked for
informed consent for each scientific usage*
no (1)
yes (2)
Please give patient's e-mail-address and / or
phone number for contact*
Storage and use of remaining bio material
for the following research projects
1 / 3
(pseudonymized) for all NHL
* genetic aberrations in lymphoma cells and their
prognostic impact*
no (1)
yes (2)
* genetic aberrations and polymorhisms in
lymphoma cells and their impact on treatment
response*
no (1)
yes (2)
Storage and use of remaining bio material
for the following research projects
(pseudonymized) FOR LYMPHOBLASTIC
LYMPHOMA
* examination of chromosome 6 deletions with
two methods*
no (1)
yes (2)
* frequency and impact of mutations of the genes
NOTCH and FBXW7*
no (1)
yes (2)
* prognostic impact of the immunophenotype of
the lymphoma cells*
no (1)
yes (2)
Storage and use of remaining bio material
for the following research projects
(pseudonymized) FOR MATURE B-CELL
LYMPHOMA
* impact of gene polymorphisms on treatment
response and outcome*
no (1)
yes (2)
Storage and use of remaining bio material
for the following research projects
(pseudonymized) FOR LARGE CELL
ANAPLASTIC LYMPHOMA (ALCL)
* quantification of minimal disseminated disease
(MDD) with three different methods*
no (1)
yes (2)
* prognostic impact of minimal residual disease
(MRD)*
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no (1)
yes (2)
* course of anti-ALK-antibody-titers during
treatment*
no (1)
yes (2)
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NHL-BFM Registry 2012 Classical
cytogenetic
NHL-BFM 2012 Registry. 
Principal Investigators: Birgit Burkhardt and Wilhelm
Woessmann. 
NHL study group University Hospital Münster
All rights reserved. Please visit https://medical-data-
models.org/forms/16127
Classical cytogenetic
Organisational aspects
Laboratory*
Gießen - Pathologie (1)
Prag (13)
Zürich (14)
Hannover – Institut für Zell- und
Molekularbiologie (15)
Kiel – Humangenetik (20)
Wien (8)
other laboratory (9)
Specify*
Material*
BM (1)
ascites (2)
pleural effusion (3)
pericardial effusion (4)
CSF (5)
effusion – not further specified (6)
tissue / tumor / lymph node (7)
peripheral blood (8)
other (9)
Specify*
Date of material withdrawal (date of biopsy /
puncture)*
Material malignant / lymphoma cells in material*
no (1)
yes (2)
unclear / could not be clarified / (not
interpretable) (3)
Karyotype
Karyotype*
Further remarks
Further remarks*
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NHL-BFM 2012 Registry. 
Principal Investigators: Birgit Burkhardt and Wilhelm
Woessmann. 
NHL study group University Hospital Münster
All rights reserved. Please visit https://medical-data-
models.org/forms/16128
Death
Death
Death*
no (1)
yes (2)
Date of death*
Time of death*
during therapy (1)
after therapy (2)
Autopsy done (If yes, please send a copy of the
report to the NHL-BFM study center!)*
no (1)
yes (2)
Death caused by*
initial complications (1)
lymphoma (2)
therapy complications (TRM) (3)
late effect (4)
second neoplasm (5)
other illness (6)
other reasons (7)
Cause of death: specify*
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NHL-BFM Registry 2012 Overall diagnosis
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Woessmann. 
NHL study group University Hospital Münster
All rights reserved. Please visit https://medical-data-
models.org/forms/16129
Overall Diagnosis
Overall Diagnosis
overall diagnosis*
Lymphoblastic lymphoma NOS (10)
Follicular Lymphoma (109)
precursor T-cell lymphoblastic lymphoma
(11)
precursor B-cell lymphoblastic lymphoma
(12)
Lymphomatoid granulomatosis (120)
Marginal zone lymphoma (121)
MALT (122)
Mediastinal grey zone lymphoma (123)
Grey zone lymphoma (DD DLBCL / DD
PMLBL) (124)
early-B-Cell lymphoblastic lymphoma
(13)
Bilineal / Biphenotypic precursor
lymphoblastic lymphoma (14)
Sezary syndrome (150)
Primary cutaneous peripheral T-cell
lymphomas, rare subtypes (151)
Angioimmunoblastic T-cell lymphoma
(152)
Burkitts Lymphoma (20)
Burkitts Leukemia / B-AL (21)
DLBCL, immunoblastic (IB) (32)
Primary Mediastinal Large B-Cell
Lymphoma (PMLBL) (39)
DLBCL, centroblastic (40)
T-Cell-rich B-Cell Lymphoma (43)
DLBCL, anaplastic (44)
Plasmoblastic B-cell lymphoma (45)
Grey zone lymphoma (DD Burkitt / DD
DLBCL) (48)
Diffuse Large B-Cell Lymphoma, NOS
(49)
Peripheral T-Cell Lymphoma, NOS (53)
Extranodal NK/T-cell lymphoma, nasal
type (angiocentric) (54)
aggressive NK-Cell Lymphoma (55)
gamma/delta-T-Cell-Lymphoma (56)
Hepatosplenic T-cell lymphoma (57)
Subcutaneous panniculitis-like T-cell
lymphoma (58)
Mycosis fungoides (59)
ALCL, ALK positive (74)
ALCL, ALK negative (75)
Primary cutaneous ALK-negative ALCL
(76)
CD30-positive cutaneous
lymphoproliferative disease NOS (78)
Lymphomatoid Papulosis (79)
other specific NHL (80)
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Lymphoproliferative Disease (81)
NHL not further classified (90)
NHL-T, not further classified (91)
NHL-B, not further classified (92)
genetically B-NHL (93)
Hodgkin's disease (97)
other (98)
no established diagnosis (99)
Specify*
Is the overall diagnosis a reference diagnosis?*
no (1)
yes (2)
The overall diagnosis based on*
Form Registration (1)
Form Initial Observation (3)
Form Histopathological Review (5)
Report of reference laboratory (6)
Report of local laboratory (7)
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NHL-BFM Registry 2012 additional
information
NHL-BFM 2012 Registry. 
Principal Investigators: Birgit Burkhardt and Wilhelm
Woessmann. 
NHL study group University Hospital Münster
All rights reserved. Please visit https://medical-data-
models.org/forms/16130
DA-EPOCH-R - additional
information
Treatment
Highest dose level reached*
Prednisolone was given in the following dosage*
60 mg/m2/d (1)
2 x 60 mg/m2/d (2)
other (9)
Dosage of prednisolon: specify*
Overall cumulative dose of antracyclines
(doxorubicin)*
Cumulative number of intrathecal triple
applications (MTX/ARA-C/PRED) given*
Heart function (worst heart function for
each time; if grade>0, please send copies
of the cardiac ultrasounds to the NHL-
BFM study center)
Heart function before start of treatment*
EF grade 0 (0)
EF grade 1 (1)
EF grade 2 (2)
EF grade 3 (3)
EF grade 4 (4)
Heart function after the 1st course*
EF grade 0 (0)
EF grade 1 (1)
EF grade 2 (2)
EF grade 3 (3)
EF grade 4 (4)
Heart function after the 2nd course*
EF grade 0 (0)
EF grade 1 (1)
EF grade 2 (2)
EF grade 3 (3)
EF grade 4 (4)
Heart function after the 3rd course*
EF grade 0 (0)
EF grade 1 (1)
EF grade 2 (2)
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EF grade 3 (3)
EF grade 4 (4)
Heart function after the 4th course*
EF grade 0 (0)
EF grade 1 (1)
EF grade 2 (2)
EF grade 3 (3)
EF grade 4 (4)
Heart function after the 5th course*
EF grade 0 (0)
EF grade 1 (1)
EF grade 2 (2)
EF grade 3 (3)
EF grade 4 (4)
Heart function after the 6th course*
EF grade 0 (0)
EF grade 1 (1)
EF grade 2 (2)
EF grade 3 (3)
EF grade 4 (4)
Other toxicity and/or remarks
Other relevant toxicity*
no (1)
yes (2)
Other relevant toxicity: specify*
Remarks*
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Eligibility Type 2 Diabetes NCT02338921
Triple Combination Therapy in Type 2 Diabetic Patients
Who Had Inadequate Glycemic Control With Combination
Therapy; ODM derived from:
https://clinicaltrials.gov/show/NCT02338921
All rights reserved. Please visit https://medical-data-
models.org/forms/16131
Eligibility Type 2 Diabetes
NCT02338921
Inclusion Criteria
20 ≤ age < 80 years*
Yes
No
hba1c ≥ 7 %*
Yes
No
combination therapy with glimepiride and
metformin over 2 months.*
Yes
No
dosage of glimepiride : 1-8mg/day*
Yes
No
dosage of metformin : 500-2550mg/day*
Yes
No
Exclusion Criteria
type 1 diabetes, gestational diabetes, or
secondary forms of diabetes*
Yes
No
contraindication to sitagliptin or dapagliflozin or
lobeglitazone*
Yes
No
pregnant or breast feeding women*
Yes
No
medication which affect glycemic control (ex.
steroid)*
Yes
No
disease which affect efficacy and safety of drugs*
Yes
No
any major illness (liver disease, renal failure,
heart disease, cancer, etc)*
Yes
No
1 / 2
not appropriate for oral antidiabetic agent*
Yes
No
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NHL-BFM Registry 2012 FISH-Analyses
NHL-BFM 2012 Registry. 
Principal Investigators: Birgit Burkhardt and Wilhelm
Woessmann. 
NHL study group University Hospital Münster
All rights reserved. Please visit https://medical-data-
models.org/forms/16132
FISH-Analyses
Organisational aspects
Laboratory*
Gießen - Pathologie (1)
Frankfurt (11)
Ulm (12)
Prag (13)
Zuerich (14)
Hannover – Institut für Zell- und
Molekularbiologie (15)
LKR Kiel (2)
Kiel – Humangenetik (20)
Wuerzburg (5)
Luebeck (7)
Wien (8)
other laboratory (9)
Specify*
Material*
BM (1)
ascites (2)
pleural effusion (3)
pericardial effusion (4)
CSF (5)
effusion – not further specified (6)
tissue / tumor / lymph node (7)
peripheral blood (8)
other (9)
Specify*
Date of material withdrawal (Date of biopsy /
puncture)*
Material malignant / lymphoma cells in material*
no (1)
yes (2)
unclear / could not be clarified / (not
interpretable) (3)
FISH-Analyses: results for mature B-NHL
Break apart: C-MYC / 8q24*
negative (1)
positive (2)
n.i. (not interpretable) (3)
Break apart: BCL2 / 18q21*
negative (1)
1 / 3
positive (2)
n.i. (not interpretable) (3)
Break apart: BCL6 / 3q27*
negative (1)
positive (2)
n.i. (not interpretable) (3)
Break apart: IGH / 14q32*
negative (1)
positive (2)
n.i. (not interpretable) (3)
Fusion: C-MYC/IGH / t(8;14)(q24;q32)*
negative (1)
positive (2)
n.i. (not interpretable) (3)
Fusion: C-MYC/IGK / t(2;8)(p12;q24)*
negative (1)
positive (2)
n.i. (not interpretable) (3)
Fusion: C-MYC/IGL / t(8;22)(q24;q11)*
negative (1)
positive (2)
n.i. (not interpretable) (3)
FISH-Analyses: results for ALCL
Break apart: ALK / 2p23*
negative (1)
positive (2)
n.i. (not interpretable) (3)
Fusion: NPM/ALK / t(2;5)(q23;p35)*
negative (1)
positive (2)
n.i. (not interpretable) (3)
Fusion: Other fusion involving ALK*
negative (1)
positive (2)
n.i. (not interpretable) (3)
Specify*
FISH-Analyses: Other
other positive FISH result*
negative (1)
positive (2)
n.i. (not interpretable) (3)
FISH-Analyses: Other
Specify*
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Further remarks
Further remarks*
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NHL-BFM Registry 2012 Last Follow-up
NHL-BFM 2012 Registry. 
Principal Investigators: Birgit Burkhardt and Wilhelm
Woessmann. 
NHL study group University Hospital Münster
All rights reserved. Please visit https://medical-data-
models.org/forms/16133
Last Follow-up
Last Follow-up
Date of last follow-up*
or Date of last information about survival*
Source of last follow-up / survival information*
treating study center (1)
German Childrens Cancer Registry
(DKKR) (2)
other clinic (no study centre) or medical
practitioner (3)
patient him-/herself or family member (4)
other source (9)
Source of last follow-up / survival information:
specify*
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NHL-BFM Registry 2012 Genetics
NHL-BFM 2012 Registry. 
Principal Investigators: Birgit Burkhardt and Wilhelm
Woessmann. 
NHL study group University Hospital Münster
All rights reserved. Please visit https://medical-data-
models.org/forms/16134
Genetics
Genetics performed?
Classical cytogenetics performed*
no (1)
yes (2)
FISH analyses performed*
no (1)
yes (2)
1 / 1
NHL-BFM Registry 2012 ALCL
NHL-BFM 2012 Registry. 
Principal Investigators: Birgit Burkhardt and Wilhelm
Woessmann. 
NHL study group University Hospital Münster
All rights reserved. Please visit https://medical-data-
models.org/forms/16135
ALCL
Diagnosis
Diagnosis*
ALK-positive ALCL (ICD-O 9714/3) (1)
ALK-negative ALCL (ICD-O 9702/3) (2)
primary cutaneous ALK-negative ALCL
(ICD-O 9718/3) (3)
lymphomatoid papulosis (ICD-O 9718/1)
(4)
CD30-positive cutaneous
lymphoproliferative disease, not further
specified (5)
other diagnosis (9)
ALK + ALCL: morphological features: common
type*
no (1)
yes (2)
ALK + ALCL: morphological features: small-cell
type*
no (1)
yes (2)
ALK + ALCL: morphological features:
lymphohistiocytic type*
no (1)
yes (2)
ALK + ALCL: morphological features: non-
common type not otherwise specified*
no (1)
yes (2)
ALK + ALCL: morphological features: other*
no (1)
yes (2)
ALK + ALCL: morphological features: other:
please specify*
Lymphomatoid papulosis: subtype*
Type A (1)
Type B (2)
Type C (3)
Other diagnosis: specify including ICD-O code*
Mandatory antibodies
ALK*
1 / 4
+ (1)
+/- (2)
-/+ (3)
- (4)
n.e. (not evaluable) (5)
ALK positivity: specify*
nuclear and cytoplasmatic (1)
only nuclear (2)
only cytoplasmatic, diffuse (3)
only cytoplasmatic, granular (4)
only cytoplasmatic, membrane
associated (5)
other (9)
other ALK positivity: specify*
CD30*
+ (1)
+/- (2)
-/+ (3)
- (4)
n.e. (not evaluable) (5)
CD3*
+ (1)
+/- (2)
-/+ (3)
- (4)
n.e. (not evaluable) (5)
CD2 (mandatory if CD3 negative)*
+ (1)
+/- (2)
-/+ (3)
- (4)
n.e. (not evaluable) (5)
CD5 (mandatory if CD3 negative)*
+ (1)
+/- (2)
-/+ (3)
- (4)
n.e. (not evaluable) (5)
Perforin*
+ (1)
+/- (2)
-/+ (3)
- (4)
n.e. (not evaluable) (5)
Granzyme*
+ (1)
+/- (2)
-/+ (3)
- (4)
n.e. (not evaluable) (5)
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Mandatory antibodies for ALK-negative
systemic ALCL
Pax5*
+ (1)
+/- (2)
-/+ (3)
- (4)
n.e. (not evaluable) (5)
Mandatory antibodies for cutaneous cases
EMA*
+ (1)
+/- (2)
-/+ (3)
- (4)
n.e. (not evaluable) (5)
Optional antibodies
Additional antibody 1: specify*
Additional antibody 1: result*
+ (1)
+/- (2)
-/+ (3)
- (4)
n.e. (not evaluable) (5)
Additional antibody 2: specify*
Additional antibody 2: result*
+ (1)
+/- (2)
-/+ (3)
- (4)
n.e. (not evaluable) (5)
Additional antibody 3: specify*
Additional antibody 3: result*
+ (1)
+/- (2)
-/+ (3)
- (4)
n.e. (not evaluable) (5)
Molecuar analyses
TCR-rearrangement*
clonal (1)
polyclonal (2)
n.e. (not evaluable) (3)
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Other analysis (e.g. FISH): please specify*
Other characteristics / remarks
Other characteristics / remarks*
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NHL-BFM Registry 2012 Mature B-cell
Lymphoma
NHL-BFM 2012 Registry. 
Principal Investigators: Birgit Burkhardt and Wilhelm
Woessmann. 
NHL study group University Hospital Münster
All rights reserved. Please visit https://medical-data-
models.org/forms/16136
Mature B-cell Lymphoma
Diagnosis
Diagnosis*
Burkitt lymphoma / B-AL (ICD-O 9687/3)
(1)
Diffuse large B-Cell lymphoma (DLBCL)
NOS (ICD-O 9680/3) (2)
Grey zone lymphoma (3)
Primary mediastinal (thymic) B-cell
lymphoma (PMLBL) (ICD-O 9679/3 (4)
Follicular lymphoma (ICD-O 9690/3) (5)
Marginal zone lymphoma (MZL) (ICD-O
9699/3) (6)
Other diagnosis (9)
DLBCL: specify*
DLBCL, centroblastic (CB) (1)
DLBCL, immunoblastic (IB) (2)
DLBCL, anaplastic (ICD-O 9737/3) (3)
DLBCL, T-cell rich B-cell lymphoma
(TCRB) (4)
DLBCL, no subtyping possible (5)
Grey zone lymphoma: specify*
intermediate features between Burkitt
and DLBCL (ICD-O 9680/3) (1)
intermediate features between DLBCL
and Hodgkin lymphoma (ICD-O 9596/3)
(2)
Follicular lymphoma: parts of grade I*
no (1)
yes (2)
Follicular lymphoma: parts of grade II*
no (1)
yes (2)
Follicular lymphoma: parts of grade IIIa*
no (1)
yes (2)
Follicular lymphoma: parts of grade IIIb*
no (1)
yes (2)
Follicular type*
follicular only (1)
follicular and diffuse pattern (2)
Other diagnosis: specify*
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Mandatory antibodies
CD20*
+++ (1)
++ (2)
+ (3)
- (4)
n.i. (not interpretable) (5)
or CD79a (if CD20 negative)*
+++ (1)
++ (2)
+ (3)
- (4)
n.i. (not interpretable) (5)
CD10*
+++ (1)
++ (2)
+ (3)
- (4)
n.i. (not interpretable) (5)
Ki67*
no (1)
yes (2)
Proliferation rate (%)*
%
BCL-2*
+++ (1)
++ (2)
+ (3)
- (4)
n.i. (not interpretable) (5)
TdT (mandatory only in Burkitt lymphoma)*
+++ (1)
++ (2)
+ (3)
- (4)
n.i. (not interpretable) (5)
Optional antibodies
CD30*
+++ (1)
++ (2)
+ (3)
- (4)
n.i. (not interpretable) (5)
EBER*
+++ (1)
++ (2)
+ (3)
- (4)
n.i. (not interpretable) (5)
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BCL6*
+++ (1)
++ (2)
+ (3)
- (4)
n.i. (not interpretable) (5)
MUM1*
+++ (1)
++ (2)
+ (3)
- (4)
n.i. (not interpretable) (5)
CD23*
+++ (1)
++ (2)
+ (3)
- (4)
n.i. (not interpretable) (5)
My-Expression*
+++ (1)
++ (2)
+ (3)
- (4)
n.i. (not interpretable) (5)
Kappa-Expression*
+++ (1)
++ (2)
+ (3)
- (4)
n.i. (not interpretable) (5)
Lambda-Expression*
+++ (1)
++ (2)
+ (3)
- (4)
n.i. (not interpretable) (5)
Additional antibody 1: specify*
Additional antibody 1: result*
+++ (1)
++ (2)
+ (3)
- (4)
n.i. (not interpretable) (5)
Additional antibody 2: specify*
Additional antibody 2: result*
+++ (1)
++ (2)
+ (3)
3 / 4
NHL-BFM Registry 2012 Mature B-cell Lymphoma
- (4)
n.i. (not interpretable) (5)
Additional antibody 3: specify*
Additional antibody 3: result*
+++ (1)
++ (2)
+ (3)
- (4)
n.i. (not interpretable) (5)
Molecular biology / FISH
Rearrangement of c-MYC by FISH*
no (1)
yes (2)
unclear / could not be clarified / (not
interpretable) (3)
Translocation t(8;14) by FISH*
no (1)
yes (2)
unclear / could not be clarified / (not
interpretable) (3)
Rearrangement IGH by FISH*
no (1)
yes (2)
unclear / could not be clarified / (not
interpretable) (3)
Rearrangement BCL6 by FISH*
no (1)
yes (2)
unclear / could not be clarified / (not
interpretable) (3)
Other rearrangement / translocation analysed by
FISH: specify*
Other rearrangement / translocation analysed by
FISH: result*
no (1)
yes (2)
unclear / could not be clarified / (not
interpretable) (3)
Other characteristics / remarks
Other characteristics / remarks*
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Eligibility Type II Diabetes Mellitus
NCT02274740
Effect of Lixisenatide on Postprandial Lipid Profile in Obese
Type 2 Diabetic Patients; ODM derived from:
https://clinicaltrials.gov/show/NCT02274740
All rights reserved. Please visit https://medical-data-
models.org/forms/16138
Eligibility Type II Diabetes Mellitus
NCT02274740
Inclusion Criteria
male and female patients, 18-70 years of age.*
Yes
No
diagnosis of type 2 diabetes treated with
metformin and obesity (body mass index [bmi]
>30 kg/m^2) and the following other
abnormalities:*
Yes
No
abdominal obesity (waist circumference >102 cm
in men and >88 cm in women). according to
national cholesterol education program-adult
treatment panel (ncep-atp) iii (2001).*
Yes
No
glycated hemoglobin a1c (hba1c)  ≥7 and ≤8.5%
(after sponsor approval providers might
reasonably suggest more stringent a1c goals
[such as 6.5%] for selected individual patients, if
this can be achieved without significant
hypoglycemia or other adverse effects of
treatment. appropriate patients might include
those with short duration of diabetes, long life
expectancy, and no significant cardiovascular
disease).*
Yes
No
hypertriglyceridemia (fasting triglyceride levels
between 150 mg/dl and 600 mg/dl, cholesterol
<300 mg/dl. in order to exclude patients who
might be suffering from a primitive dyslipidemia).*
Yes
No
low high-density lipoprotein (hdl) cholesterol
(serum hdl-cholesterol <40 mg/dl in men and <50
mg/dl in women).*
Yes
No
written informed consent.*
Yes
No
Exclusion Criteria
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smoking. thyroid disease even if under
appropriate hormonal replacement therapy or
thyroid suppressant (thyroid stimulating hormone
[tsh] >5 mu/l with clinical symptoms of
hypothyroidism).*
Yes
No
hepatic disease (aspartate aminotransferase
[asat] or alanine aminotransferase [alat] >2 times
the upper limit of normal).*
Yes
No
renal disease (serum creatinine >1.7 times the
upper limit of normal). a history of coronary heart
disease, cerebrovascular disease, or peripheral
arterial disease in the 6 months before
enrollment.*
Yes
No
history of malignancies. use of lipid lowering
therapy. systolic blood pressure ≥180 mmhg
and/or diastolic blood pressure ≥110 mmhg.
triglycerides >600 mg/dl. history of chronic
pancreatitis or of idiopathic acute pancreatitis.*
Yes
No
the above information is not intended to contain
all considerations relevant to a patient's potential
participation in a clinical trial.*
Yes
No
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NHL-BFM Registry 2012 Histopathological
Review
NHL-BFM 2012 Registry. 
Principal Investigators: Birgit Burkhardt and Wilhelm
Woessmann. 
NHL study group University Hospital Münster
All rights reserved. Please visit https://medical-data-
models.org/forms/16139
Histopathological Review (bone
marrow biopsy)
Organisational aspects
Referring pathology*
Histology number of referring pathology*
Reference pathology*
Frankfurt (11)
Ulm (12)
Prag (13)
Zuerich (14)
LKR Kiel (2)
Wuerzburg (5)
Luebeck (7)
Wien (8)
Histology number reference pathology*
Date of review*
Tissue type and quality
Size of biopsy (cm)*
Tissue quality*
excellent (1)
good (2)
average (3)
poor (4)
Bone marrow cellularity*
normal (1)
increased (2)
reduced (3)
Infiltration by lymphoma cells
Infiltration by lymphoma cells*
no (1)
yes (2)
Lymphoma cells*
if yes: Diagnosis*
Lymphoblastic lymphoma NOS (10)
Follicular Lymphoma (109)
precursor T-cell lymphoblastic lymphoma
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(11)
precursor B-cell lymphoblastic lymphoma
(12)
Lymphomatoid granulomatosis (120)
Marginal zone lymphoma (121)
MALT (122)
Mediastinal grey zone lymphoma (123)
Grey zone lymphoma (DD DLBCL / DD
PMLBL) (124)
early-B-Cell lymphoblastic lymphoma
(13)
Bilineal / Biphenotypic precursor
lymphoblastic lymphoma (14)
Sezary syndrome (150)
Primary cutaneous peripheral T-cell
lymphomas, rare subtypes (151)
Angioimmunoblastic T-cell lymphoma
(152)
Burkitts Lymphoma (20)
Burkitts Leukemia / B-AL (21)
DLBCL, immunoblastic (IB) (32)
Primary Mediastinal Large B-Cell
Lymphoma (PMLBL) (39)
DLBCL, centroblastic (40)
T-Cell-rich B-Cell Lymphoma (43)
DLBCL, anaplastic (44)
Plasmoblastic B-cell lymphoma (45)
Grey zone lymphoma (DD Burkitt / DD
DLBCL) (48)
Diffuse Large B-Cell Lymphoma, NOS
(49)
Peripheral T-Cell Lymphoma, NOS (53)
Extranodal NK/T-cell lymphoma, nasal
type (angiocentric) (54)
aggressive NK-Cell Lymphoma (55)
gamma/delta-T-Cell-Lymphoma (56)
Hepatosplenic T-cell lymphoma (57)
Subcutaneous panniculitis-like T-cell
lymphoma (58)
Mycosis fungoides (59)
ALCL, ALK positive (74)
ALCL, ALK negative (75)
Primary cutaneous ALK-negative ALCL
(76)
CD30-positive cutaneous
lymphoproliferative disease NOS (78)
Lymphomatoid Papulosis (79)
other specific NHL (80)
Lymphoproliferative Disease (81)
NHL not further classified (90)
NHL-T, not further classified (91)
NHL-B, not further classified (92)
genetically B-NHL (93)
Hodgkin's disease (97)
other (98)
no established diagnosis (99)
if yes: other Diagnosis: specify*
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if yes: ICD-O*
Mandatory antibodies for all entities
TdT*
+++ (1)
++ (2)
+ (3)
- (4)
n.i. (not interpretable) (5)
CD3*
+++ (1)
++ (2)
+ (3)
- (4)
n.i. (not interpretable) (5)
CD79a*
+++ (1)
++ (2)
+ (3)
- (4)
n.i. (not interpretable) (5)
MPO*
+++ (1)
++ (2)
+ (3)
- (4)
n.i. (not interpretable) (5)
Optional antibodies
CD22*
+++ (1)
++ (2)
+ (3)
- (4)
n.i. (not interpretable) (5)
CD19*
+++ (1)
++ (2)
+ (3)
- (4)
n.i. (not interpretable) (5)
Pax5*
+++ (1)
++ (2)
+ (3)
- (4)
n.i. (not interpretable) (5)
Additional antibody 1: specify*
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Additional antibody 1: result*
+++ (1)
++ (2)
+ (3)
- (4)
n.i. (not interpretable) (5)
Additional antibody 2: specify*
Additional antibody 2: result*
+++ (1)
++ (2)
+ (3)
- (4)
n.i. (not interpretable) (5)
Additional antibody 3: specify*
Additional antibody 3: result*
+++ (1)
++ (2)
+ (3)
- (4)
n.i. (not interpretable) (5)
Other characteristics / remarks
Comments*
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NHL-BFM Registry 2012 Organisation and
Tissue
NHL-BFM 2012 Registry. 
Principal Investigators: Birgit Burkhardt and Wilhelm
Woessmann. 
NHL study group University Hospital Münster
All rights reserved. Please visit https://medical-data-
models.org/forms/16140
Organisation and Tissue
Organisational aspects
Referring pathology*
Histology number of referring pathology*
Reference pathology*
Frankfurt (11)
Ulm (12)
Prag (13)
Zuerich (14)
LKR Kiel (2)
Wuerzburg (5)
Luebeck (7)
Wien (8)
Histology number reference pathology*
Date of review*
Tissue type and quality
Tissue localisation*
bone marrow (BM (1)
area of ear, nose and throat (ENT) (10)
head / neck: other manifestation(s) (11)
mediastinum (12)
pleura/pleural effusion (13)
pericardium / pericardial effusion (14)
lung(s) (15)
other thoracic manifestation(s) (16)
ascites (17)
bowel (18)
liver (19)
CNS: intra-cerebral tumor (2)
spleen (20)
kidney(s) (21)
abdominal LN (22)
other abdominal manifestation(s) (23)
testis (24)
soft tissue (25)
skin (26)
bone (27)
epidural (28)
other localisation(s) (29)
CNS: intra-medullary tumor (3)
CNS: nerve palsy (4)
CNS: lymphoma cells in CSF (5)
LN cervical, submandibular, nuchal (6)
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LN supra-/ infraclavicular / axillary (7)
LN inguinal (8)
LN: other peripheral LN (9)
Tissue localisation: specify*
Kind of surgery*
core-needle biopsy (1)
surgical biopsy (2)
other (9)
Kind of surgery: specify*
Tissue quality*
excellent (1)
good (2)
average (3)
poor (4)
Paraffin block available*
no (1)
yes (2)
Kryomaterial available*
no (1)
yes (2)
Tissue availability for review and
biobanking
Number of unstained slides available for review*
Number of stained slides available for review*
Number of blocks available for review*
Number of blocks stored at reference center*
Blocks stored at reference center TMA suitable?*
no (1)
yes (2)
DNA stored at reference center*
no (1)
yes (2)
RNA stored at reference center*
no (1)
yes (2)
Diagnostic group
2 / 3
NHL-BFM Registry 2012 Organisation and Tissue
Diagnostic Group*
Lymphoblastic Lymphoma (1)
Mature B-cell lymphoma (2)
ALCL (3)
PTCL (4)
Other (5)
Diagnostic Group*
3 / 3
NHL-BFM Registry 2012 Organisation and Tissue
NHL-BFM Registry 2012 Lymphoblastic
Lymphoma
NHL-BFM 2012 Registry. 
Principal Investigators: Birgit Burkhardt and Wilhelm
Woessmann. 
NHL study group University Hospital Münster
All rights reserved. Please visit https://medical-data-
models.org/forms/16141
Lymphoblastic Lymphoma
Diagnosis
Diagnosis*
Non-cortical-T (T V) (10)
Pro-B (pre-pre-B) (B I) (3)
Common (B II) (4)
T-lineage, no subtyping possible (40)
Mature T (41)
Pro-T (T I) (42)
Pre-B (B III) (5)
bilineal / biphentotypic (50)
mature B (6)
B-lineage, no subtyping possible (60)
Pre-T (T II) (7)
Cortical T (T III) (8)
Medullary T (T IV) (9)
Other (99)
Bilineal / biphenotypic: specify*
Other Diagnosis: specify*
Mandatory antibodies for all entities
TdT*
+++ (1)
++ (2)
+ (3)
- (4)
n.i. (not interpretable) (5)
CD3*
+++ (1)
++ (2)
+ (3)
- (4)
n.i. (not interpretable) (5)
CD79a*
+++ (1)
++ (2)
+ (3)
- (4)
n.i. (not interpretable) (5)
MPO*
+++ (1)
++ (2)
+ (3)
- (4)
n.i. (not interpretable) (5)
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Ki67/KiS5 done*
no (1)
yes (2)
Proliferation rate (%)*
%
Additional mandatory antibodies for B
precursor cell lymphoblastic lymphoma
CD10*
+++ (1)
++ (2)
+ (3)
- (4)
n.i. (not interpretable) (5)
CD22*
+++ (1)
++ (2)
+ (3)
- (4)
n.i. (not interpretable) (5)
or CD19*
+++ (1)
++ (2)
+ (3)
- (4)
n.i. (not interpretable) (5)
or Pax5*
+++ (1)
++ (2)
+ (3)
- (4)
n.i. (not interpretable) (5)
Optional antibodies for B precursor cell
lymphoblastic lymphoma
My-Expression*
negative (1)
positive (2)
My-Expression: specify*
surface (1)
cytoplasmic (2)
surface and cytoplasmic (3)
not decidable, surface/cytoplasmic (4)
Additional antibody : specify*
Additional antibody: result*
negative (1)
positive (2)
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n.i. (not interpretable) (3)
Additional mandatory antibodies for T
precursor cell lymphoblastic lymphoma
CD1a*
+++ (1)
++ (2)
+ (3)
- (4)
n.i. (not interpretable) (5)
Optional antibodies for T precursor cell
lymphoblastic lymphoma
CD4*
+++ (1)
++ (2)
+ (3)
- (4)
n.i. (not interpretable) (5)
CD8*
+++ (1)
++ (2)
+ (3)
- (4)
n.i. (not interpretable) (5)
CD56*
+++ (1)
++ (2)
+ (3)
- (4)
n.i. (not interpretable) (5)
BetaF1*
+++ (1)
++ (2)
+ (3)
- (4)
n.i. (not interpretable) (5)
Additional antibodies and other
characteristics / remarks
Additional antibody 1: specify*
Additional antibody 1: result*
+++ (1)
++ (2)
+ (3)
- (4)
n.i. (not interpretable) (5)
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Additional antibody 2: specify*
Additional antibody 2: result*
+++ (1)
++ (2)
+ (3)
- (4)
n.i. (not interpretable) (5)
Additional antibody 3: specify*
Additional antibody 3: result*
+++ (1)
++ (2)
+ (3)
- (4)
n.i. (not interpretable) (5)
Other characteristics / remarks*
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Eligibility Urinary Problems NCT02220829
Comparative Study of Use of Alpha-Blockers to Treat
Symptoms in Prostate Cancer Patients Undergoing
Radiation Therapy; ODM derived from:
https://clinicaltrials.gov/show/NCT02220829
All rights reserved. Please visit https://medical-data-
models.org/forms/16143
Eligibility Urinary Problems
NCT02220829
Inclusion Criteria
adult male 18 years of age or older*
Yes
No
patients with confirmed diagnosis of
adenocarcinoma of the prostate.*
Yes
No
the primary treatment should be external beam
radiation therapy (ebrt) with or without high dose
rate (hdr) brachytherapy boost.*
Yes
No
clinical or radiological diagnosis of t1a - t3b.*
Yes
No
no limitation with respect to gleason score.*
Yes
No
no limitation with respect to total psa value.*
Yes
No
karnofsky performance score (kps) of ≥ 70.*
Yes
No
Exclusion Criteria
small cell cancer of the prostate*
Yes
No
t4 disease, invading bladder or rectum.*
Yes
No
adjuvant or salvage radiation therapy*
Yes
No
brachy monotherapy*
Yes
No
kps < 70*
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Yes
No
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RRT Agents RICH study NCT02669589
NCT02669589 EudraCT-Nr. 2014-004854-33
REGIONAL CITRATE VERSUS SYSTEMIC HEPARIN
ANTICOAGULATION FOR CONTINUOUS RENAL
REPLACEMENT THERAPY IN CRITICALLY ILL
PATIENTS WITH ACUTE KIDNEY INJURY
Study Chair: Alexander Zarbock, MD University Hospital
Muenster
All rights reserved. Please visit https://medical-data-
models.org/forms/16144
RRT Agents RICH study
NCT02669589
Patient Information
ID of Center
ID of patient
Early Renal Replacement Therapy Agents
- until Day 28
Citrate infusion?
Yes
No
Specify Citrate agent:
CICA Dialysat K2 (CICA Dialysat K2)
CICA Dialysat K4 (CICA Dialysat K4)
Prismocitrat 10/2 (Prismocitrat 10/2)
Prismocitrat 18/0 (Prismocitrat 18/0)
Sodium-Citrat 4% (Sodium-Citrat 4%)
Heparin therapy?
Yes
No
Specify heparin agent:
Ratiopharm 25.000 IE/5mL (Ratiopharm
25.000 IE/5mL)
Rotexmedia 25 IE/5mL (Rotexmedia 25
IE/5mL)
Heparin: Cumulative Dose:
IE/d
Charge:
Was the Renal Replacement Therapy continued?
Yes
No
Late Renal Replacement Therapy Agents
- after Day 28
Start Date
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Start Time
End Date
End Time
Citrate infusion?
Yes
No
Specify Citrate agent:
CICA Dialysat K2 (CICA Dialysat K2)
CICA Dialysat K4 (CICA Dialysat K4)
Prismocitrat 10/2 (Prismocitrat 10/2)
Prismocitrat 18/0 (Prismocitrat 18/0)
Sodium-Citrat 4% (Sodium-Citrat 4%)
Heparin therapy?
Yes
No
Specify heparin agent:
Ratiopharm 25.000 IE/5mL (Ratiopharm
25.000 IE/5mL)
Rotexmedia 25 IE/5mL (Rotexmedia 25
IE/5mL)
Heparin: Cumulative Dose:
IE/d
Charge:
Was the Renal Replacement Therapy continued?
Yes
No
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End of Therapy RICH study NCT02669589
NCT02669589 EudraCT-Nr. 2014-004854-33
REGIONAL CITRATE VERSUS SYSTEMIC HEPARIN
ANTICOAGULATION FOR CONTINUOUS RENAL
REPLACEMENT THERAPY IN CRITICALLY ILL
PATIENTS WITH ACUTE KIDNEY INJURY
Study Chair: Alexander Zarbock, MD University Hospital
Muenster
All rights reserved. Please visit https://medical-data-
models.org/forms/16145
End of Therapy RICH study
NCT02669589
Patient Information
ID of Center
ID of patient
End of Therapy (continous Renal
Replacement Therapy - further
documentation of process according to
working construction)
End of Therapy: End Date
End of Therapy: End Time
Reason for End of Therapy:
(planned) transfer to normal ward
((planned) transfer to normal ward)
(planned) transfer to other hospital
((planned) transfer to other hospital)
(planned) transfer to other ICU/ IMC
((planned) transfer to other ITS/ IMC)
accumulation of citrate (total Ca2+/ Ca2+
ionized > 2,5) (accumulation of citrate
(total Ca2+/ Ca2+ ionized > 2,5))
consent cannot be given (consent cannot
be given)
consent rejected by caregiver (consent
rejected by caregiver)
consent rejected by patient (consent
rejected by patient)
consent rejected by representative
(consent rejected by representative)
Criteria for End of Therapy are met
(Criteria for End of Therapy are met)
death while therapy (death while therapy)
discharge (discharge)
HIT (HIT)
Medical decission (Medical decission)
not controllable alcalosis with
bicarbonate > 35 (not controllable
alcalosis with bicarbonate > 35)
other reason (other reason)
SAE in connection with test product or
procedure (SAE in connection with test
product or procedure)
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withdrawal of consent (withdrawal of
consent)
Reason for End of Therapy: 
If Reson for End of Therapy is "Medical", specify:
Reason for End of Therapy: 
If Reson for End of Therapy is "Other", specify:
End of documentation - (do not fill in if
death or withdrawal/ refusion of consent
are already documented)
End of documentation: End Date
End of documentation: End Time
Reason for End of Documentation:
(planned) transfer to normal ward
((planned) transfer to normal ward)
(planned) transfer to other hospital
((planned) transfer to other hospital)
(planned) transfer to other ICU/ IMC
((planned) transfer to other ITS/ IMC)
consent cannot be given (consent cannot
be given)
consent rejected by caregiver (consent
rejected by caregiver)
consent rejected by patient (consent
rejected by patient)
consent rejected by representative
(consent rejected by representative)
death while therapy (death while therapy)
discharge (discharge)
other reason (other reason)
regular end on Day 28 (regular end on
Day 28)
withdrawal of consent (withdrawal of
consent)
Reson for End of Documentation:
If Reson for End of Documentation is "Other",
specify:
Hospital stay
Discharge from ICU
Yes
No
Date of discharge from ICU
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Time of discharge from ICU
Discharge from hospital
Yes
No
Date of discharge from hospital
Time of discharge from hospital
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Follow Up RICH study NCT02669589
NCT02669589 EudraCT-Nr. 2014-004854-33
REGIONAL CITRATE VERSUS SYSTEMIC HEPARIN
ANTICOAGULATION FOR CONTINUOUS RENAL
REPLACEMENT THERAPY IN CRITICALLY ILL
PATIENTS WITH ACUTE KIDNEY INJURY
Study Chair: Alexander Zarbock, MD University Hospital
Muenster
All rights reserved. Please visit https://medical-data-
models.org/forms/16146
Follow Up RICH study
NCT02669589
Patient Information
ID of Center
ID of patient
Follow Up - Day 60, 90 and 365
Day of visit
Telephone visit?
Yes
No
Patient died?
no (no)
unknown, because lost to follow up
(unknown, because lost to follow up)
yes (yes)
If patient dead, specify date of death:
Serum Creatinine measurement
Unit of Serum Creatinine measurement
mg/dL (mg/dL)
μmol/L (μmol/L)
Date of Blood Sample:
Duration of mechanical ventilation (in hours or
days):
(For Follow Up Day 60: documentation only for
primary hospital stay until Day 60
For Follow Up Day 90: documentation only for
primary hospital stay from Day 61 until Day 90
For Follow Up Day 365: documentation only for
primary hospital stay from Day 91 until Day 365)
h or d
Renal Replacement Therapy
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Renal Replacement Therapy
Yes
No
Start Date
End Date
Amount of Days:
Specify kind of Renal Replacement Therapy:
CRRT, new continous RRT (CRRT, new
continous RRT)
IHD (IHD)
SLEDD/SCUF (SLEDD/SCUF)
Frequency of discontinous procedure
(e.g. every two days; three times each week)
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Eligibility Atrial Fibrillation NCT00157248
Long-term, Open-label Follow-up Treatment of Patients
With A-fib Who Have Been Previously Treated With BIBR
1048; ODM derived from:
https://clinicaltrials.gov/show/NCT00157248
All rights reserved. Please visit https://medical-data-
models.org/forms/16147
Eligibility Atrial Fibrillation
NCT00157248
Criteria
Inclusion Criteria
previous treatment with bibr 1048 in petro (trial
1160.20- nct01227629) and no premature
discontinuation of therapy*
Yes
No
paroxysmal, persistent, or permanent (chronic)
non-rheumatic atrial fibrillation, documented by
electrocardiogram (ecg) at least twice prior to
enrollment in petro*
Yes
No
concomitant coronary artery disease -an
additional risk factor for stroke (one or more of
the following conditions/events): hypertension,
diabetes mellitus (dm), congestive heart failure
(chf) or left ventricular dysfunction (lvd), previous
ischemic stroke or transient ischemic attack) tia,
or age greater than 75 years. -age >= 18 years*
Yes
No
written, informed consent*
Yes
No
Exclusion Criteria
Exclusion Criteria
valvular heart disease conferring significantly
increased risk of thromboembolic events (e.g.
clinically significant mitral stenosis or prosthetic
valves). planned cardioversion while patients are
in the study.*
Yes
No
contraindication to anticoagulant therapy
(previous intracranial hemorrhage, gastro-
intestinal (gi) hemorrhage within previous 3
months, previous severe hemorrhage with
warfarin at therapeutic international normalized
ratio (inr), regular use of non-steroidal anti-
inflammatory drugs, hemorrhagic diathesis) major
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bleeding within the last 6 months (other than gi
hemorrhage).*
Yes
No
severe renal impairment (estimated glomerular
filtration rate [gfr] <= 30 ml/min). uncontrolled
hypertension (systolic blood pressure [sbp] > 180
mm hg and/or diastolic blood pressure [dbp] >
100 mmhg).*
Yes
No
women who are pregnant or of childbearing
potential who refuse to use a medically
acceptable form of contraception throughout the
study (note: a negative pregnancy test must be
obtained for any woman of childbearing potential
prior to entry into the study).*
Yes
No
patients who have received an investigational
drug other than bibr 1048 within the last 30 days.*
Yes
No
patients considered unreliable by the investigator
concerning the requirements for follow-up during
the study and/or compliance with study drug
administration. another indication for
anticoagulant treatment (eg, deep vein
thrombosis or pulmonary embolus). clinically
significant anemia (note: patients with mild-
moderate anemia should only be enrolled after
the possibility of a gi bleeding source has been
evaluated, the etiology of the anemia identified,
and appropriate action taken). patients suffering
from thrombocytopenia (platelets < 100,000/ul).
any other condition which, in the discretion of the
investigator, would not allow safe participation in
the study.*
Yes
No
continuing or planned concomitant treatment with
antiplatelet agents other than acetylsalicylic acid
(asa).*
Yes
No
recent malignancy or radiation therapy (<= 6
months).*
Yes
No
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Stress Life Events Cardiovascular Health
Study (CHS)
Documentation part: Record 5 Stress Life Events
The Cardiovascular Health Study (CHS) was initiated by
the National Heart, Lung and Blood Institute (NHLBI) in
1987 to determine the risk factors for development and
progression of cardiovascular disease (CVD) in older
adults, with an emphasis on subclinical measures. The
study recruited 5,888 adults aged 65 or older at entry in
four U.S. communities and conducted extensive annual
clinical exams between 1989-1999 along with semi-annual
phone calls, events adjudication, and subsequent data
analyses and publications. Additional data were collected
by studies ancillary to CHS. With the exception of annual
clinic visits, these activities are still ongoing.
Data obtained from: https://chs-nhlbi.org/
Permission granted by: Erika Enright.
All rights reserved. Please visit https://medical-data-
models.org/forms/16151
Stress Life Events Cardiovascular
Health Study (CHS)
Stressful life events and depression scale
1. Have you moved since we spoke to you on the
phone six months ago?
no (0)
yes (1)
unknown (9)
When did this happen?
not during the last month (0)
during the last month (1)
don't know (9)
Was this move positive or negative?
positive (1)
negative (2)
don't know (9)
2. Have you retired or changed or lost a job since
we spoke to you on the phone six months ago?
no (0)
yes (1)
unknown (9)
When did this happen?
not during the last month (0)
during the last month (1)
don't know (9)
Was this job change, loss or retirement positive
or negative?
positive (1)
negative (2)
don't know (9)
3. Have you had a grandchild born since we
spoke to you six months ago?
positive (1)
negative (2)
don't know (9)
4. Has caring for a sick or disabled relative
become a significant problem for you since we
spoke to you six months ago?
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no (0)
yes (1)
unknown (9)
Has providing care become significantly harder in
the last month?
no (0)
yes (1)
unknown (9)
5. Has there been a sifnificant change in your
personal finances since we spoke to you six
months ago?
no (0)
yes (1)
unknown (9)
When did this happen?
not during the last month (0)
during the last month (1)
don't know (9)
Was this change positive or negative?
positive (1)
negative (2)
don't know (9)
6. Did you or a very close friend or close family
member have a serious accident or illness since
we spoke to you six months ago?
no (0)
yes (1)
unknown (9)
When did this accident or illness occur?
not during the last month (0)
during the last month (1)
don't know (9)
7. Have you, your spouse or partner, or a
member of you immediate family been assaulted
or robbed since we spoke to you six months age?
no (0)
yes (1)
unknown (9)
When did this assault or robbery occur?
not during the last month (0)
during the last month (1)
don't know (9)
8. Have you had any important relationship, for
example with your spouse or a good friend,
become significantly worse since we spoke to
you six months ago?
no (0)
yes (1)
unknown (9)
When did this relationship worsen?
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not during the last month (0)
during the last month (1)
don't know (9)
9. Did someone you were close to die since we
spoke to you six months ago?
no (0)
yes (1)
unknown (9)
When did this person die?
not during the last month (0)
during the last month (1)
don't know (9)
What was this person's relationship to you?
Spouse
no (0)
yes (1)
unknown (9)
What was this person's relationship to you?
Brother
no (0)
yes (1)
unknown (9)
What was this person's relationship to you? Sister
no (0)
yes (1)
unknown (9)
What was this person's relationship to you?
Mother
no (0)
yes (1)
unknown (9)
What was this person's relationship to you?
Father
no (0)
yes (1)
unknown (9)
What was this person's relationship to you? Child
no (0)
yes (1)
unknown (9)
What was this person's relationship to you? Other
relative
no (0)
yes (1)
unknown (9)
What was this person's relationship to you?
Friend
no (0)
yes (1)
unknown (9)
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What was this person's relationship to you? Pet
no (0)
yes (1)
unknown (9)
What was this person's relationship to you? Other
no (0)
yes (1)
unknown (9)
Other relationship name:
10. Have any other important things happened to
you or your spouse or partner since we spoke to
you six months ago that made this period
significantly different from the previous six
months?
no (0)
yes (1)
unknown (9)
What happened? (continue on a seperate page, if
necessary)
Was it positive or negative?
positive (1)
negative (2)
don't know (9)
11. During the paast week, I was bothered by
things that usually don't bother me. How often did
you feel this way?
rarely or none of the time (less than 1
day) (0)
some or a little of the time (1 to 2 days)
(1)
a moderatel amount of time (3 to 4 days)
(2)
most of the time (3)
refused or do not know (9)
12. I had trouble keeping my mind on what I was
doing:
rarely or none of the time (less than 1
day) (0)
some or a little of the time (1 to 2 days)
(1)
a moderatel amount of time (3 to 4 days)
(2)
most of the time (3)
refused or do not know (9)
13. I felt that everything I did was an effort:
rarely or none of the time (less than 1
day) (0)
some or a little of the time (1 to 2 days)
(1)
a moderatel amount of time (3 to 4 days)
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(2)
most of the time (3)
refused or do not know (9)
14. I felt depressed:
rarely or none of the time (less than 1
day) (0)
some or a little of the time (1 to 2 days)
(1)
a moderatel amount of time (3 to 4 days)
(2)
most of the time (3)
refused or do not know (9)
15. I felt hopeful about the future:
rarely or none of the time (less than 1
day) (0)
some or a little of the time (1 to 2 days)
(1)
a moderatel amount of time (3 to 4 days)
(2)
most of the time (3)
refused or do not know (9)
16. I felt fearful:
rarely or none of the time (less than 1
day) (0)
some or a little of the time (1 to 2 days)
(1)
a moderatel amount of time (3 to 4 days)
(2)
most of the time (3)
refused or do not know (9)
17. My sleep was restless:
rarely or none of the time (less than 1
day) (0)
some or a little of the time (1 to 2 days)
(1)
a moderatel amount of time (3 to 4 days)
(2)
most of the time (3)
refused or do not know (9)
18. I was happy:
rarely or none of the time (less than 1
day) (0)
some or a little of the time (1 to 2 days)
(1)
a moderatel amount of time (3 to 4 days)
(2)
most of the time (3)
refused or do not know (9)
19. I felt lonely:
rarely or none of the time (less than 1
day) (0)
some or a little of the time (1 to 2 days)
(1)
a moderatel amount of time (3 to 4 days)
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(2)
most of the time (3)
refused or do not know (9)
20. I could not get going:
rarely or none of the time (less than 1
day) (0)
some or a little of the time (1 to 2 days)
(1)
a moderatel amount of time (3 to 4 days)
(2)
most of the time (3)
refused or do not know (9)
Date of interview
Interviewer
Interview:
First edit:
Second edit:
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Medications Cardiovascular Health Study
(CHS)
Documentation part: Record 6 Medications
The Cardiovascular Health Study (CHS) was initiated by
the National Heart, Lung and Blood Institute (NHLBI) in
1987 to determine the risk factors for development and
progression of cardiovascular disease (CVD) in older
adults, with an emphasis on subclinical measures. The
study recruited 5,888 adults aged 65 or older at entry in
four U.S. communities and conducted extensive annual
clinical exams between 1989-1999 along with semi-annual
phone calls, events adjudication, and subsequent data
analyses and publications. Additional data were collected
by studies ancillary to CHS. With the exception of annual
clinic visits, these activities are still ongoing.
Data obtained from: https://chs-nhlbi.org/
Permission granted by: Erika Enright.
All rights reserved. Please visit https://medical-data-
models.org/forms/16152
Medications Cardiovascular Health
Study (CHS)
Section A Medication Reception
As you know, the Cardiovascular Health Study
will be describing prescription medications its
participants are using. We are particularly
interested in medications your doctor prescribed
for you and were filled by a pharmacist. These
include pills, dermal patches, eye drops, creams,
salves, and injections. Are these all the
medications that you took in the last two weeks?
no (0)
yes (1)
took no medicines (2)
refused (9)
Reasons for refusal:
Section B Prescription Medications
medication name
Strength (mg)
Number prescribed
Circle: day, week or month
D (D)
M (M)
W (W)
PRN medicine?
Yes
No
2. On average during the last two weeks, how
many of these pills did you take a day (for
week/month)?
day/week/month
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D (D)
M (M)
W (W)
Selection C Selected Over-The-Counter
Medications and Supplements
1. During the last two weeks, did you take any
aspirin or aspirin-containing medicines such as
Beffurin, Anacin, or Acriptin?
no (0)
yes (1)
unknown (9)
2. On about how many days during the last two
weeks did you take this medicine?
>= 1
<= 14
days
3. During the last two weeks did you take any
cod-liver oil or other fish oil supplements?
no (0)
yes (1)
unknown (9)
4. On about how many days during the last two
weeks did you take these supplements?
>= 1
<= 14
days
5. Antihistamines; for example, cold pills, allergy
pills?
no (0)
yes (1)
unknown (9)
6. Sleeping pills?
no (0)
yes (1)
unknown (9)
7. Laxatives?
no (0)
yes (1)
unknown (9)
8. Calcium supplements?
no (0)
yes (1)
unknown (9)
9. Have you had a flu shot in the past year?
no (0)
yes (1)
unknown (9)
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10. Have you ever had a shot to prevent
pneumonia, sometimes called pneumovax?
no (0)
yes (1)
unknown (9)
11. Did a doctor prescribe nitroglycerin for you in
the last year?
no (0)
yes (1)
unknown (9)
Date of interview
Interviewer
Interview:
First edit:
Second edit:
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Eligibility Atrial Fibrillation NCT00232219
Use of Fish Oils to Reduce Recurrence of Atrial Fibrillation
Following DC Cardioversion; ODM derived from:
https://clinicaltrials.gov/show/NCT00232219
All rights reserved. Please visit https://medical-data-
models.org/forms/16153
Eligibility Atrial Fibrillation
NCT00232219
Inclusion Criteria
patients with persistent atrial fibrillation on
warfarin.*
Yes
No
Exclusion Criteria
paroxysmal atrial fibrillation with self terminating
episodes.*
Yes
No
left atrial size>6.0cm*
Yes
No
myocardial infarction in the previous 6 months.*
Yes
No
contraindications to amiodarone use .*
Yes
No
cardiac surgery in the previous 3 months .*
Yes
No
an acute reversible illness contributing to the
development of af*
Yes
No
a qtc interval > 480ms.*
Yes
No
pregnancy*
Yes
No
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Eligibility Atrial Fibrillation NCT00189319
To Evaluate the Impact of Oral Flecainide on Quality of Life
in Patients With Paroxysmal Atrial Fibrillation; ODM derived
from: https://clinicaltrials.gov/show/NCT00189319
All rights reserved. Please visit https://medical-data-
models.org/forms/16154
Eligibility Atrial Fibrillation
NCT00189319
Inclusion Criteria
in sinus rhythm at treatment initiation*
Yes
No
experienced symptomatic af episodes*
Yes
No
left ventricular ejection fraction of at least 40%*
Yes
No
females of child bearing potential must be using
reliable method of contraception*
Yes
No
Exclusion Criteria
intolerance and/or failure of previous therapy with
flecainide immediate release*
Yes
No
currently receiving >200mg/day flecainide
immediate release*
Yes
No
severe symptoms during episodes of arrhythmia*
Yes
No
history of other cardiac conditions/abnormalities*
Yes
No
heart surgery within the last 2 months*
Yes
No
renal failure*
Yes
No
pregnant or lactating females*
Yes
No
significant extra cardiac or systemic disease*
Yes
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No
abnormal electrolyte levels*
Yes
No
receiving defined cardiac and/or other
treatments*
Yes
No
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Stammdaten 1 PSMA Therapie
NCT0000001
PSMA Therapie NCT0000001
Quelle:
PSMA-Studie Prostatakarzinom
PD Dr. med. Kambiz Rahbar
UKM, Nuklearmedizin
Teil: Stammdaten 1
All rights reserved. Please visit https://medical-data-
models.org/forms/16155
Stammdaten 1 PSMA Therapie
NCT0000001
Stammdaten
Name
Vorname
Geburtsdatum
verstorben
ED
Alter ED
Aufklärung/EV
Alter EV
Gleasonscore
pT
pN
cM
R
Grading
Knochenmetastasen
nein (0)
ja (1)
Ausmaß K.met.
< 6 met (1)
6-20 met (2)
> 20 met (3)
diffuse Met (Super scan) (4)
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LK-Metastasen
nein (0)
ja (1)
Ausmaß LK-Metastasen
parailiakal (1)
para ilikal und abdominell (2)
2+ thorakal (3)
Leber-Metastasen
nein (0)
ja (1)
Lungenmetastasen
nein (0)
ja (1)
Hirnmetastasen
nein (0)
ja (1)
Prostatektomie
nein (0)
ja (1)
Raditio Prostataloge
nein (0)
ja (1)
Radiatio Knochen
<25% (1)
<25<50% (2)
>50<75% (3)
Antihormontherapie
nein (0 )
ja (1 )
Z.n (2 )
Docetaxel
nein (0 )
ja (1 )
Z.n (2 )
Cabacitaxel
nein (0 )
ja (1 )
Z.n (2 )
Abiraterone
nein (0 )
ja (1 )
Z.n (2 )
Enzalutamide
nein (0 )
ja (1 )
Z.n (2 )
Z.n. Xofigo
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nein (0 )
ja (1 )
Xofigo Cycle
EK Gabe vor der Tx
nein (0 )
ja (1 )
EK nach Therapie
nein (0 )
ja (1 )
Anzahl EK
Grund EK Gabe
Bekannte KHK
nein (0 )
ja (1 )
Diabetes mellitus
nein (0)
ja (1)
Arterielle Hypertonie
nein (0)
ja (1)
Niereninsuffizienz
nein (0 )
ja (1 )
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Eligibility Atrial Fibrillation NCT00249795
Atrial Fibrillation Clopidogrel Trial With Irbesartan for
Prevention of Vascular Events (ACTIVE I); ODM derived
from: https://clinicaltrials.gov/show/NCT00249795
All rights reserved. Please visit https://medical-data-
models.org/forms/16156
Eligibility Atrial Fibrillation
NCT00249795
Inclusion Criteria
should fulfill the eligibility criteria for active a or
active w trial and:*
Yes
No
have a systolic blood pressure of at least 110
mmhg*
Yes
No
not already receiving an angiotensin receptor
blocking agent, unless they are willing and able to
be changed to another antihypertensive agent*
Yes
No
no previous intolerance to angiotensin receptor
blocking agents*
Yes
No
no proven indication for angiotensin receptor
blocking agents, unless an angiotensin
converting enzyme (ace) inhibitor can be
substituted*
Yes
No
Exclusion Criteria
patients will be excluded from active study if any
of the following are present:*
Yes
No
requirement for clopidogrel (such as recent
coronary stent procedure)*
Yes
No
requirement for oral anticoagulant (such as
prosthetic mechanical heart valve)*
Yes
No
prior intolerance to acetylsalicyclic acid (asa) or
clopidogrel*
Yes
No
documented peptic ulcer disease within the
1 / 2
previous 6 months*
Yes
No
prior intracerebral hemorrhage*
Yes
No
significant thrombocytopenia (platelet count <50 x
10(9)/l)*
Yes
No
psychosocial reason making study participation
impractical*
Yes
No
geographic reason making study participation
impractical*
Yes
No
ongoing alcohol abuse*
Yes
No
mitral stenosis*
Yes
No
pregnant or nursing woman or woman of child
bearing potential and not on effective birth control
for at least one month prior to start of study or not
willing to continue on birth control for duration of
study*
Yes
No
severe comorbid condition such that the patient is
not expected to survive 6 months*
Yes
No
patient currently receiving an investigational
pharmacologic agent*
Yes
No
requirement for chronic (> 3 months) non-
cyclooxygenase-2 (non-cox-2) inhibitor
nonsteroidal anti-inflammatory drug (nsaid)
therapy unless willing enrolled in active a*
Yes
No
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Stammdaten 2 PSMA-Studie
Prostatakarzinom NCT0000001
Quelle:
PSMA-Studie Prostatakarzinom
PD Dr. med. Kambiz Rahbar
UKM, Nuklearmedizin
Teil: Stammdaten 2
All rights reserved. Please visit https://medical-data-
models.org/forms/16158
Stammdaten 2 PSMA-Studie
Prostatakarzinom NCT0000001
Patientendaten
Name
Größe
EV
Gewicht
ECOG
<= 100
>= 0
Karnofsky
>= 0
<= 100
Schmerzen
keine (1)
gelegentlcih (2)
häufig/Analgetika (3)
immer (4)
nicht beherschbar (5)
Lokalisation
BWS/LWS (1)
Becken/Beine (2)
Schultern/Arme (3)
Abdomen (4)
Zyklus 1
Gewicht
ECOG
<= 100
>= 0
Karnofsky
>= 0
<= 100
Schmerzen
keine (1)
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gelegentlcih (2)
häufig/Analgetika (3)
immer (4)
nicht beherschbar (5)
Lokalisation
BWS/LWS (1)
Becken/Beine (2)
Schultern/Arme (3)
Abdomen (4)
Zyklus 2
Gewicht
ECOG
<= 100
>= 0
Karnofsky
>= 0
<= 100
Schmerzen
keine (1)
gelegentlcih (2)
häufig/Analgetika (3)
immer (4)
nicht beherschbar (5)
Lokalisation
BWS/LWS (1)
Becken/Beine (2)
Schultern/Arme (3)
Abdomen (4)
Zyklus 3
Gewicht
ECOG
<= 100
>= 0
Karnofsky
>= 0
<= 100
Schmerzen
keine (1)
gelegentlcih (2)
häufig/Analgetika (3)
immer (4)
nicht beherschbar (5)
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Lokalisation
BWS/LWS (1)
Becken/Beine (2)
Schultern/Arme (3)
Abdomen (4)
Zyklus 4
Gewicht
ECOG
<= 100
>= 0
Karnofsky
>= 0
<= 100
Schmerzen
keine (1)
gelegentlcih (2)
häufig/Analgetika (3)
immer (4)
nicht beherschbar (5)
Lokalisation
BWS/LWS (1)
Becken/Beine (2)
Schultern/Arme (3)
Abdomen (4)
Zyklus 5
Gewicht
ECOG
<= 100
>= 0
Karnofsky
>= 0
<= 100
Schmerzen
keine (1)
gelegentlcih (2)
häufig/Analgetika (3)
immer (4)
nicht beherschbar (5)
Lokalisation
BWS/LWS (1)
Becken/Beine (2)
Schultern/Arme (3)
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Abdomen (4)
Zyklus 6
Gewicht
ECOG
<= 100
>= 0
Karnofsky
>= 0
<= 100
Schmerzen
keine (1)
gelegentlcih (2)
häufig/Analgetika (3)
immer (4)
nicht beherschbar (5)
Lokalisation
BWS/LWS (1)
Becken/Beine (2)
Schultern/Arme (3)
Abdomen (4)
Zyklus 7
Gewicht
ECOG
<= 100
>= 0
Karnofsky
>= 0
<= 100
Schmerzen
keine (1)
gelegentlcih (2)
häufig/Analgetika (3)
immer (4)
nicht beherschbar (5)
Lokalisation
BWS/LWS (1)
Becken/Beine (2)
Schultern/Arme (3)
Abdomen (4)
Zyklus 8
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Gewicht
ECOG
<= 100
>= 0
Karnofsky
>= 0
<= 100
Schmerzen
keine (1)
gelegentlcih (2)
häufig/Analgetika (3)
immer (4)
nicht beherschbar (5)
Lokalisation
BWS/LWS (1)
Becken/Beine (2)
Schultern/Arme (3)
Abdomen (4)
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Eligibility Atrial Fibrillation NCT00279981
TRENDS: A Prospective Study of the Clinical Significance
of Atrial Arrhythmias Detected by Implanted Device
Diagnostics; ODM derived from:
https://clinicaltrials.gov/show/NCT00279981
All rights reserved. Please visit https://medical-data-
models.org/forms/16159
Eligibility Atrial Fibrillation
NCT00279981
Inclusion Criteria
subject provides written informed consent and
privacy/protection authorization.*
Yes
No
subjects 65 years of age or older.*
Yes
No
subjects with age >18 and  < 65 years and one of
the following stroke risk factors:*
Yes
No
prior stroke or tia*
Yes
No
diagnosis of hypertension (htn)*
Yes
No
diagnosis of diabetes mellitus (dm)*
Yes
No
diagnosis of congestive heart failure (chf)*
Yes
No
subjects who meet the class i/class ii indications
for a dual chamber implantable pulse generator
or dual chamber implanted cardioverter
defibrillator device*
Yes
No
• subjects who meet the criteria for indication of a
dual chamber resynchronization device with bi-
ventricular pacing (moderate to severe chf
symptoms [nyha class iii-iv] despite optimal
medical therapy, left ventricular ejection fraction ≤
35%, and a qrs duration ≥130 ms)13.*
Yes
No
Exclusion Criteria
subjects who are to receive a replacement ipg,
icd or crt device.*
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Yes
No
subjects with chronic (permanent) at/af.*
Yes
No
subjects with a history of av nodal dependent
arrhythmias.*
Yes
No
subjects with a terminal illness who are not
expected to survive more than 6 months.*
Yes
No
subjects who are unwilling or unable to cooperate
or give written informed consent and
privacy/protection authorization, or subjects
whose legal representatives or legal guardians
refuse to give informed consent or
privacy/protection authorization.*
Yes
No
subjects currently receiving treatment in another
drug and/or device study which could affect the
outcome of the trial.*
Yes
No
subjects who are or will be inaccessible for follow-
up at a qualified study center.*
Yes
No
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Eligibility Atrial Fibrillation NCT00287209
Reduction of Atrial Fibrillation Study in Patients Undergoing
Coronary Artery Bypass Grafting. (RASCABG 1 Study);
ODM derived from:
https://clinicaltrials.gov/show/NCT00287209
All rights reserved. Please visit https://medical-data-
models.org/forms/16161
Eligibility Atrial Fibrillation
NCT00287209
Inclusion Criteria
enlistment for an elective cabg*
Yes
No
age more than 18 years*
Yes
No
willingness to be randomised*
Yes
No
provision of informed consent*
Yes
No
Exclusion Criteria
enlistment for other types of heart surgery*
Yes
No
earlier heart surgery*
Yes
No
resting heart rate below 40 bpm.*
Yes
No
av-blockage of any degree*
Yes
No
preoperative atrial fibrillation or flutter*
Yes
No
former known atrial fibrillation or flutter lasting
more than one month*
Yes
No
hepatic dysfunction (alat > twice the upper
normal limit)*
Yes
No
hyperthyroidism*
Yes
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No
pregnancy*
Yes
No
breastfeeding*
Yes
No
known adverse reactions to amiodarone*
Yes
No
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Emergency Room Point B in Time Part 1:
Emergency Room Report UKM
Report/Protocol collecting patient and treatment information
like the circumstances of the accident and initial ER
treatment. http://klinikum.uni-muenster.de/
All rights reserved. Please visit https://medical-data-
models.org/forms/16162
Emergency Room Point B in Time
Part 1: Emergency Room Report
UKM
Patient information
Nachname
Vorname
Geburtsdatum
Index
Eintreffen
Angehörige benachrichtigt
Ja
Nein
Emergency Room Team
UCH
Ja
Nein
ACH
Ja
Nein
Anästh.
Ja
Nein
NCH
Ja
Nein
Radio
Ja
Nein
Sr./Pfl.
Ja
Nein
MKG
Ja
Nein
HNO
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Ja
Nein
Augen
Ja
Nein
sonst.
Ja
Nein
Medical history
Vorerkrankungen/-medikation
nicht eruierbar (1)
: (2)
bitte näher beschreiben
Tetanusschutz
besteht (1)
T&T im SR (2)
Vitalparameter am Unfallort
RRsys
mmHg
Herzfrequenz
>= 0
bpm
Atemfrequenz
/minute
SpO2
%
Bereits bei Ankunft intubiert?
Ja
Nein
FiO2
PaO2
mmHg
ETC O2
mmHg
Tubuslage korrekt?
Ja
Nein
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Operative Notfalleingriffe bis Aufnahme
ICU
Hirndrucksonde
Ja
Nein
Kraniektomy
Ja
Nein
Thorakotomie (ohne Thoraxdrainage/mini-
Thorakotomie)
Ja
Nein
Laparotomie
Ja
Nein
Revaskularisation
Ja
Nein
Embolisation
Ja
Nein
Stabilisierung Becken
Ja
Nein
Stabilisierung Extremität
Ja
Nein
Beginn der OP-Schnitt:
Diagnostik bis zur Aufnahme auf die
(Intensiv-) Station
Sono Abdomen
Ja
Nein
Zeitpunkt Sono Abdomen
Röntgen Thorax
Ja
Nein
Zeitpunkt Röntgen Thorax
Röntgen Becken
Ja
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Nein
Zeitpunkt Röntgen Becken
Röntgen Wirbelsäule
Ja
Nein
Zeitpunkt Wirbelsäulen Röntgen
Rö.-HWS
Ja
Nein
Rö.-HWS Zeitpunkt
Rö.-Extremitäten
Ja
Nein
Rö.-Extremitäten Zeitpunkt
CT
Ja
Nein
Zeitpunkt CT
Ganzkörper-CT
Ja
Nein
Zeitpunkt Ganzkörper-CT
MRT
Ja
Nein
MRT: Time
Rotem/Rotec
Ja
Nein
Zeitpunkt Rotem/Rotec
Neurologische Untersuchung
Augenöffnen
keine (1)
Schmerz (2)
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Aufforderung (3)
spontan (4)
Verbale Antwort
keine (1)
Schmerz (2)
Aufforderung (3)
spontan (4)
Motorische Antwort
keine (1)
Streckkrämpfe (2)
Beugekrämpfe (3)
ungezielt (Schmerz) (4)
gezielt (Schmerz) (5)
Aufforderung (6)
Summe (Score)
<= 15
>= 1
Pupillengröße links
eng (1)
mittel (2)
weit (3)
nicht feststellbar (4)
Pupillengröße rechts
eng (1)
mittel (2)
weit (3)
nicht feststellbar (4)
Lichtreaktion links
prompt (1)
träge (2)
keine (3)
nicht feststellbar (4)
Lichtreaktion rechts
prompt (1)
träge (2)
keine (3)
nicht feststellbar (4)
Labor
Hb-Wert
mmol/l
Thrombozyten
/uL
Quick
%
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PTT
%
Alkohol
g/l ‰
pH
Base Excess
mmol/l
Ca++
mmol
Temperatur
%
INR
Fibrinogen:
mmol
Clinical course
schlechtester Hb
mmol/l
schlechtester Quick
%
schlechtester BE
mmol/l
ASA vor Unfall
ASA vor Unfall
I (1)
II (2)
III (3)
IV (4)
Vorbestehende Gerinnungsstörung
Ja
Nein
Therapie
Kristalloide
ml
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Kolloide
ml
Hyperonk./Hyperosm. Lösung
ml
FFP/Frischplasma
Einheiten
Blut EK
Einheiten
Zeitpunkt erste Gabe
Thrombozyten
Einheiten
Alternative Atemwegssicherung
Ja
Nein
Herzdruckmassage
Ja
Nein
Katecholamine
Ja
Nein
Thoraxdrainage
Ja
Nein
Beckengurt
Ja
Nein
Akute externe Frakturstabilisierung (außerhalb
des OP)
Ja
Nein
Hämostase-Therapie
rfVIIa
Ja
Nein
Anzahl der Gaben
Ganzzahl_AnzEK
Gesamtdosis
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mg
Zeitpunkt Beginn Gerinnungstherapie
PPSB
Ja
Nein
Tranexamsäure:
Ja
Nein
Fibrinogen
Ja
Nein
Ca++ (andere hämost. Medikamente)
Ja
Nein
Weiterversorgung
SR-Diagnostik regulär beendet?
Ja
Nein
wenn ja: Weiterverlegung
Früh-OP (1)
ICU (2)
Tod im SR (3)
anderes KH (4)
sonstiges (5)
Uhrzeit
wenn nein: Abbruch wegen:
Not-OP (1)
sonstiges (2)
Uhrzeit
Komplettierung der Diagnostik vor ICU?
Ja
Nein
Harnableitung
Harnableitung
keine (1)
DK (2)
SPF (3)
Urin
klar (1)
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blutig (2)
PTS
Schädel (S)
Mittelgesichtsfraktur #(MF) (1)
GCS 3-5 (16)
GCS 9-12 / schwere MF (2)
GCS 6-8 (4)
Extremitäten (E)
Weichteilverletzung, Patella, OSG, UA,
Ellenbogen #, Kniebinnenschaden (1)
Gefäßverletzung US, UA / US # (2)
II+III° offene Fraktur (3)
Gefäßverletzung OA / OA und Schulter #
(4)
Gefäßverletzung OS (5)
OS-# (6)
OS-Trümmer # (8)
Alter (A)
<39 (1)
40-54 (2)
55-59 (3)
60-64 (4)
65-69 (5)
70-74 (6)
>=75 (7)
Abdomen (ABD)
Ausgedehnte LR (10)
Magen-, Darm- o. Nierenverletzung (2)
Milzruptur (5)
Leberruptur (LR) / Pankreasverletzung
(8)
Thorax
Sternum, Rippen # 1-3 / Hämatothorax
(1)
Rippenserien # bds (10)
Aortenruptur (16)
Pneumothorax (2)
Lungenkontusion (3)
Rippenserien # (4)
Lungenkontusion bds (5)
Becken (B)
Beckenquetschung (12)
Becken # einfach / Wirbelfraktur (2)
Becken # komplex (5)
Becken- u. Urogenitalverletzung /
Querschnitt (8)
Basendefizit (BD)
>= -3,9 (0)
-4 bis -5,9 (1)
-12 bis -13,9 (14)
-14 bis -15,9 (20)
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<= -16 (26)
-6 bis -7,9 (3)
-8 bis -9,9 (5)
-10 bis -11,9 (9)
paO2/FiO2 Quotient (Q)
>=350 (0)
300-349 (1)
50-99 (12)
<= 50 (22)
200-249 (3)
150-199 (5)
100-149 (8)
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Emergency Room Point B in Time Part 2:
Emergency Room Report UKM
Report/Protocol collecting patient and treatment information
like the circumstances of the accident and initial ER
treatment. http://klinikum.uni-muenster.de/
All rights reserved. Please visit https://medical-data-
models.org/forms/16163
Emergency Room Point B in Time
Part 2: Emergency Room Report
UKM
Patient information
Nachname
Vorname
Geburtsdatum
Index
Untersuchungsbefund
ATLS
A-Problem (Airway)
Ja
Nein
B-Problem (Breathing)
Ja
Nein
C-Problem (Circulation)
Ja
Nein
D-Problem (Disability)
Ja
Nein
E-Problem (Hypothermie)
Ja
Nein
Peripherer Neurologischer Status
Motorik
spontan (1)
seitengleich (2)
abgeschwächt (3)
keine (4)
Sesibilität
o.B. (1)
gestört (2)
nicht eurierbar (3)
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Reflexe
o.B. (1)
path. (2)
Babinski
Ja
Nein
Sphinktertonus
Ja
Nein
Sonstiges
Gefäßstatus
rechte A. carotis tastbar
Ja
Nein
linke A. carotis tastbar
Ja
Nein
rechte A. radialis tastbar
Ja
Nein
linke A. radialis tastbar
Ja
Nein
rechte A. femoralis tastbar
Ja
Nein
linke A. femoralis tastbar
Ja
Nein
rechte A. poplitea tastbar
Ja
Nein
linke A. poplitea tastbar
Ja
Nein
rechte A. dors. ped. tastbar
Ja
Nein
linke A. dors. ped. tastbar
Ja
Nein
rechte A. tib. post. tastbar
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Ja
Nein
linke A. tib. post. tastbar
Ja
Nein
Kopf/Hals
o.B.
Ja
Nein
Hämatom
Ja
Nein
Orbitalhämatom
Ja
Nein
Gehörgangsblutung
Ja
Nein
Liquorrhoe
Ja
Nein
Platzwunde
Ja
Nein
Mittelgesichtsinstabilität
Ja
Nein
Unterkieferfraktur
Ja
Nein
Augenverletzung
Ja
Nein
Sonstige:
Thorax
o.B.
Ja
Nein
Prellmarken
Ja
Nein
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Hämatom
Ja
Nein
Hautemphysem
Ja
Nein
Instabilität
Ja
Nein
atemabh. Schmerz
Ja
Nein
Kompressionsschmerz
Ja
Nein
offene Verletzung
Ja
Nein
Halsvenenstauung
Ja
Nein
path. Auskultationsbefund
Ja
Nein
Thoraxdrainage
Ja
Nein
Sonstige:
Abdomen und Urogenitaltrakt
o.B.
Ja
Nein
Prellmarken
Ja
Nein
Hämatom
Ja
Nein
aufgetrieben
Ja
Nein
Druckschmerz
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Ja
Nein
Abwehrspannung
Ja
Nein
offene Verletzung
Ja
Nein
Verletzung Anogenitaltrakt
Ja
Nein
path. rekt. digit. Befund
Ja
Nein
Sonstige:
Becken
o.B.
Ja
Nein
instabil
Ja
Nein
offene Verletzung
Ja
Nein
Sonstige:
Obere/Untere Extremität
Untere Extremität
drohendes Kompartmentsyndrom
Ja
Nein
Obere Extremität
drohendes Kompartmentsyndrom
Ja
Nein
Diagnoses
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Diagnose
Übergabeprotokoll / Anordnungen
Thromboseprophylaxe
Antibiotikatherapie
Analgetika
Kost
Infusionen
Medikamente
Lagerunshilfen
Kontroll Sono Abdomen
Ja
Nein
Zeitpunkt Kontroll Sono Abdomen
Kontroll CCT
Ja
Nein
Zeitpunkt Kontroll CCT
Kontroll CT
Thorax (1)
Abdomen (2)
Zeitpunkt Kontroll CT
Labor
Ja
Nein
Zeitpunkt Labor
Sonstiges
Bei Arbeitsunfällen (BG)
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Berufsgenossenschaft
Ort
Beschäftigt als
seit
Beginn der Arbeit
Betrieb
Verhalten nach Unfall
Erstbehandlung durch
Unfallunabhängige Krankheiten
Sprechen Hergang und Befund gegen eine AU
nein (1)
ja (2)
muss BG klären (3)
Weitere Behandlung
Ja
Nein
arbeitsfähig ab
AU - Bescheinigung ausgestellt
Ja
Nein
AU <3 Tage
Ja
Nein
AU Dauer ca.
allg. Behandlung durch
durch:_____ (1)
durch mich (2)
allg. Behandlung durch (bitte spezifizieren)
bes. Behandlung
stationär (1)
ambulant (2)
bes. Behandlung durch
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durch:______ (1)
durch uns (2)
bes. Behandlung durch (bitte spezifizieren)
BG-Ergänzungsbogen ausgefüllt (SHT,
Verbrennung, Hand, Finger, Knie)
Ja
Nein
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Eligibility Advanced Breast Cancer
NCT00398567
A Phase 1/2 Study Of HKI-272 (Neratinib) in Combination
With Trastuzumab (Herceptin) In Subjects With Advanced
Breast Cancer; ODM derived from:
https://clinicaltrials.gov/show/NCT00398567
All rights reserved. Please visit https://medical-data-
models.org/forms/16164
Eligibility Advanced Breast Cancer
NCT00398567
Inclusion Criteria
pathologic diagnosis of breast cancer with current
stage iiib, iiic or iv not curable by available
therapy*
Yes
No
progression following at least one herceptin-
containing cytotoxic chemotherapy regimen
(neoadjuvant, adjuvant, or metastatic setting)*
Yes
No
her2 positive breast cancer*
Yes
No
at least one measurable target lesion*
Yes
No
adequate performance status*
Yes
No
adequate cardiac, kidney, and liver function*
Yes
No
adequate blood counts*
Yes
No
willingness of all subjects who are not surgically
sterile or post menopausal to use acceptable
methods of birth control*
Yes
No
Exclusion Criteria
more than 3 prior cytotoxic chemotherapy
regimens for locally advanced or metastatic
disease*
Yes
No
major surgery, chemotherapy, radiotherapy,
investigational agents, herceptin or other cancer
therapy within 2 weeks of treatment day 1*
Yes
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No
prior treatment with anthracyclines with
cumulative dose of >400 mg/m^2*
Yes
No
extensive visceral disease*
Yes
No
active central nervous system metastases*
Yes
No
pregnant or breast feeding women*
Yes
No
significant chronic or recent acute gastrointestinal
disorder with diarrhea as a major symptom*
Yes
No
prior exposure to hki-272 or other her2 targeted
agents (except herceptin and tykerb)*
Yes
No
significant cardiac disease or dysfunction*
Yes
No
history of life-threatening hypersensitivity to
herceptin*
Yes
No
inability or unwillingness to swallow hki-272
capsules*
Yes
No
any other cancer within 5 years with the
exception of contralateral breast cancer,
adequately treated cervical carcinoma in situ, or
adequately treated basal or squamous cell
carcinoma of the skin*
Yes
No
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Eligibility Advanced Breast Cancer
NCT00546104
Phase II Dasatinib Study in Advanced Breast Cancer; ODM
derived from: https://clinicaltrials.gov/show/NCT00546104
All rights reserved. Please visit https://medical-data-
models.org/forms/16165
Eligibility Advanced Breast Cancer
NCT00546104
Inclusion Criteria
measurable stage iv or inoperable stage iii
advanced breast cancer.*
Yes
No
there is no limit on the number of prior therapies.*
Yes
No
at least 3 weeks since prior chemotherapy,
biological or hormonal therapy*
Yes
No
at least 2 weeks since surgical biopsy*
Yes
No
at least 3 weeks since major (open
thoracic/abdominal/cardiac) surgery.*
Yes
No
no central nervous system (cns) metastases
except solitary brain metastasis*
Yes
No
no cardiac dysfunction*
Yes
No
left ventricular ejection fraction (lvef) ≥ 50% as
determined by multiple gated acquisition scan
(muga)/echocardiogram*
Yes
No
adequate blood counts*
Yes
No
normal liver and kidney function*
Yes
No
negative serum pregnancy test.*
Yes
No
able to provide informed consent*
Yes
1 / 2
No
Exclusion Criteria
pregnant or breast feeding.*
Yes
No
prior treatment with dasatinib.*
Yes
No
bone as the only site of disease.*
Yes
No
significant gastrointestinal bleeding*
Yes
No
septicemia, infection, acute hepatitis,
hypokalemia, or hypomagnesemia*
Yes
No
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Baseline Medical History Cardiovascular
Health Study (CHS)
Documentation part: Record 7 Baseline Medical History
The Cardiovascular Health Study (CHS) was initiated by
the National Heart, Lung and Blood Institute (NHLBI) in
1987 to determine the risk factors for development and
progression of cardiovascular disease (CVD) in older
adults, with an emphasis on subclinical measures. The
study recruited 5,888 adults aged 65 or older at entry in
four U.S. communities and conducted extensive annual
clinical exams between 1989-1999 along with semi-annual
phone calls, events adjudication, and subsequent data
analyses and publications. Additional data were collected
by studies ancillary to CHS. With the exception of annual
clinic visits, these activities are still ongoing.
Data obtained from: https://chs-nhlbi.org/
Permission granted by: Erika Enright.
All rights reserved. Please visit https://medical-data-
models.org/forms/16166
Baseline Medical History
Cardiovascular Health Study (CHS)
Medical History: Myocardical Infarction
1. Has a doctor ever told you that you had a
myocardial infarction or heart attack?
no (0)
yes (1)
don't know (9)
A. What was the doctor's name and city? Name
A. What was the doctor's name and city? City
A. What was the doctor's name and city? State
B. Were you hospitalized for your myocardial
infarction or heart attack?
no (0)
yes (1)
don't know (9)
Hospital name:
City:
State:
Date of Hospitalization:
Medical History: Congestive heart failure
2 Has a doctor ever told you that you had
congestive heart failure?
no (0)
yes (1)
don't know (9)
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A. What was the doctor's name and city? Name
A. What was the doctor's name and city? City
A. What was the doctor's name and city? State
B. Were you hospitalized for congestive heart
failure?
no (0)
yes (1)
don't know (9)
Hospital name:
City:
State:
Date of Hospitalization:
Medical History: Intermittent claudication
3. Has a doctor ever told you that you had
intermittent claudication? If you are not sure,
please answer DON'T KNOW.
no (0)
yes (1)
don't know (9)
A. What was the doctor's name and city? Name
A. What was the doctor's name and city? City
A. What was the doctor's name and city? State
B. Were you hospitalized for intermittent
claudication?
no (0)
yes (1)
don't know (9)
Hospital name:
City:
State:
Date of Hospitalization:
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Medical History: Angina
4. Has a doctor ever told you that you had
angina? If you are not sure, please answer
DON'T KNOW.
no (0)
yes (1)
don't know (9)
A. What was the doctor's name and city? Name
A. What was the doctor's name and city? City
A. What was the doctor's name and city? State
B. Were you hospitalized for angina?
no (0)
yes (1)
don't know (9)
Hospital name:
City:
State:
Date of Hospitalization:
Medical History: Other conditions
5. Has a doctor ever told you that you had high
blood pressure=#?
no (0)
yes (1)
don't know (9)
6. Has a doctor ever told you that you had
rheumatic heart or heart valve problems?
no (0)
yes (1)
don't know (9)
7. Has a doctor ever told you that you had
diabetes?
no (0)
yes (1)
don't know (9)
8. Has a doctor ever told you that you had atrial
fibrillation? If you are not sure, please answer
DON'T KNOW.
no (0)
yes (1)
don't know (9)
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9. Has a doctor ever told you that you had deep
venous thrombosis or blood clots in your legs?
no (0)
yes (1)
don't know (9)
10. Has a doctor ever told you that you had
pulmonary embolus or blood clots in your lungs?
no (0)
yes (1)
don't know (9)
11. Has a doctor ever told you that you had other
heart or circulatory problems?
no (0)
yes (1)
don't know (9)
12. Have you ever had coronary bypass surgery?
no (0)
yes (1)
don't know (9)
13. Have you ever had other heart surgery?
no (0)
yes (1)
don't know (9)
14. Have you ever had a carotid endarterectomy,
which is surgery on the blood vessels in your
neck?
no (0)
yes (1)
don't know (9)
A. If you answered YES, what side did you have
the surgery on?
right (1)
left (2)
both sides (3)
15. Have you ever had a bypass procedure on
the arteries of your legs?
no (0)
yes (1)
don't know (9)
16. Have you ever had a repair of an aortic
aneurysm? If you are not sure, please answer
DON'T KNOW.
no (0)
yes (1)
don't know (9)
17. Have you ever had a pacemaker implant?
no (0)
yes (1)
don't know (9)
18. Have you ever had an angioplasty of the
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coronary arteries, which is a dilation of the
arteries of the heart with a balloon?
no (0)
yes (1)
don't know (9)
19. Have you ever had an angioplasty of the
lower extremity arteries, which is a dilation of the
arteries of the leg with a ballon?
no (0)
yes (1)
don't know (9)
20. Have you ever had any pain or discomfort in
your chest?
Yes
No
21. Do you get it when you walk uphill or hurry?
no (0)
yes (1)
never hurry or walk uphill (9)
22. Do you get it when you walk at an ordinary
pace on the level?
Yes
No
23. What do you do if you get it while you are
walking?
stop or slow down, or continue at same
pace after taking nitroglycerine (1)
continue at same pace (2)
24. If you stand still, what happens to it?
relieved (1)
not relieved (2)
A. If you answered RELIEVED, how soon is it
relieved?
10 minutes or less (1)
more than 10 minutes (2)
25. Where do you get this pain or discomfort?
sternum upper (1)
sternum lower (2)
chest (3)
arm (4)
other (5)
Other, specify:
26. Have you ever had a severe pain across the
front of your chest lasting for half an hour or
more?
Yes
No
A. If you answered YES, did you see a doctor
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because of this pain?
Yes
No
B. If you saw a doctor, what did your doctor say it
was?
angina (1)
heart attack (2)
other (3)
Diagnosis, other:
27. Have you ever had to sleep on 2 or more
pillows to help you breathe?
Yes
No
28. Have you ever been awakened at night by
trouble breathing?
Yes
No
29. Have you ever had swelling of your feet or
ankles? (Excluding during pregnancy)
Yes
No
A. If you answered YES, did it tend to come on
during the day and go down overnight?
Yes
No
30. Do you get pain in either leg on walking?
Yes
No
31. Does this pain ever begin when you are
standing still or sitting?
Yes
No
32. Do you get this pain in your calf or calves?
Yes
No
33. Do you get it when you walk uphill or hurry?
no (0)
yes (1)
never hurry or walk uphill (9)
34. Do you get it when you walk at an ordinary
pace on the level?
Yes
No
35. Does this pain ever disappear while you are
walking?
Yes
No
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36. What do you do if you get it while you are
walking?
stop or slow down (1)
continue at same pace (2)
37. If you stand still, what happens to it?
relieved (1)
not relieved (2)
38. Were you hospitalized for this problem in your
legs?
Yes
No
39. Have you ever had attacks or bronchitis?
Yes
No
A. Was it confirmed by a doctor?
Yes
No
B. At what age was your first attack?
40. Have you ever had chronic bronchitis?
Yes
No
A. Do you still have it?
Yes
No
B. Was it confirmed by a doctor?
Yes
No
C. At what age did it start?
41. Have you ever had pneumonia?
Yes
No
A. Was it confirmed by a doctor?
Yes
No
B. At what age was your first attack?
42. Have you ever had hay fever?
Yes
No
A. Was it confirmed by a doctor?
Yes
No
B. At what age was your first attack?
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43. Have you ever had emphysema?
Yes
No
A. Do you still have it?
Yes
No
B. Was it confirmed by a doctor?
Yes
No
C. At what age did it start?
44. Have you ever had asthma?
Yes
No
A. Do you still have it?
Yes
No
B. Was it confirmed by a doctor?
Yes
No
C. At what age did it start?
D. If you no longer have it, at what age did it
stop?
45. Have you ever had any other chest illness?
Yes
No
If answered YES, please specify the other chest
illness you have had:
46. Have you ever had any chest operations?
Yes
No
If you answered YES, please specify the chest
operations you have had:
47. Have you ever had any chest injuries?
Yes
No
If you answered YES, please specify the chest
injury you have had:
48. Do you usually have a cough? Include
coughing when you first smoke or first go out of
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doors. Exclude clearing your throat.
Yes
No
A. Do you usually cough as much as 4 to 6 times
a day, 4 or more days out of the week?
Yes
No
B. Do you usually cough at all when you get up or
first thing in the morning?
Yes
No
C. Do you usually cough at all during the rest of
the day or at night?
Yes
No
49. Do you usually cough like this on most days
for 3 consecutive months or more during the
year?
Yes
No
50. For how many years have you had this
cough?
years
51. Do you usually bring up phlegm, which is
thick mucus, from your chest? Count phlegm
brought up when you first smoke or first go out-
of-doors. Exclude phlegm from your nose. Count
swallowing phlegm.
Yes
No
A. Do you usually bring up phlegm like this as
mus as twice a day, 4 or more days out of the
week?
Yes
No
B. Do you usually bring up phlegm at all when
you get up, or first thing in the morning?
Yes
No
C. Do you usually bring up phlegm at all during
the rest of the day or at night?
Yes
No
52. Do you bring up phlegm like this on most
days for 3 consecutive months or more during the
year?
Yes
No
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53. For how many years have you had trouble
with phlegm?
years
54. A. Does your chest ever sound wheezy or
whistling when you have a cold?
Yes
No
B. Does your chest ever sound wheezy or
whistling occasionally apart from colds?
Yes
No
C. Does your chest ever sound wheezy or
whistling most days or nights?
Yes
No
55. For how many years has this been present?
years
56. Have you ever had an attack of wheezing that
made you feel short of breath?
Yes
No
A. How old were you when you had your first
such attack?
B. Have you had 2 or more such episodes?
Yes
No
C. Have you ever required medication or
treatment for these attacks?
Yes
No
57. Are you troubled by shortness of breath when
hurrying on the level or walking up a slight hill?
Yes
No
58. Do you have to walk slower than people of
your age on the level because of breathlessness?
Yes
No
59. Do you ever have to stop for breath when
walking at your own pace on the level?
Yes
No
60. Do you ever have to stop for breath after
walking about 100 yards (or after a few minutes)
on the level?
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Yes
No
61. Are you too breathless to leave the house, or
do you become breathless when dressing or
undressing?
Yes
No
62. A. Have you ever been breathless or short of
breath during the past two weeks?
Yes
No
B. Has there been an increase in the frequency
or severity of your breathlessness or shortness of
breath during the past two weeks?
Yes
No
63. Have you experienced palpitations during the
past two weeks?
Yes
No
B. Has there been an increase in the frequency
or severity of your palpitations during the past two
weeks?
Yes
No
64. A. Have you been dizzy during the past two
weeks?
Yes
No
B. Has there been an increase in the frequency
or severity of your dizziness during the past two
weeks?
Yes
No
65. A. Have you been fatigued during the past
two weeks?
Yes
No
B. Has there been an increase in the frequency
or severity of your fatigue during the past two
weeks?
Yes
No
66. A. Have you felt weak during the past two
weeks?
Yes
No
B. Has there been an increase in the frequency
or severity of your weakness during the past two
weeks?
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Yes
No
67. A. Have you been nauseous during the past
two weeks?
Yes
No
B. Has there been an increase in the frequency
or severity of your nausea during the past two
weeks?
Yes
No
68. A. Have you had indigestion during the past
two weeks?
Yes
No
B. Has there been an increase in the frequency
or severity of your indigestion during the past two
weeks?
Yes
No
69. A. Have you had chest pain during the past
two weeks?
Yes
No
B. Has there been an increase in the frequency
or severity of your chest pain during the past two
weeks?
Yes
No
70. A. Have you had upper abdominal pain during
the past two weeks?
Yes
No
B. Has there been an increase in the frequency
or severity of your upper abdominal pain during
the past two weeks?
Yes
No
71. A. Have you had a fever during the past two
weeks?
Yes
No
B. Has there been an increase in the frequency
or severity of your fever during the past two
weeks?
Yes
No
72. A. Have you had muscle aches during the
past two weeks?
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Yes
No
B. Has there been an increase in the frequency
or severity of your muscle aches during the past
two weeks?   +
Yes
No
73. A. Have you had diarrhea during the past two
weeks?
Yes
No
B. Has there been an increase in the frequency
or severity of your diarrhea during the past two
weeks?   +
Yes
No
74. Have you been to see a physician during the
past two weeks?
Yes
No
Date of interview
Interviewer
Interview:
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Eligibility Advanced Breast Cancer
NCT01095003
Trial of Vinflunine Plus Capecitabine in Advanced Breast
Cancer; ODM derived from:
https://clinicaltrials.gov/show/NCT01095003
All rights reserved. Please visit https://medical-data-
models.org/forms/16167
Eligibility Advanced Breast Cancer
NCT01095003
Inclusion Criteria
female patients*
Yes
No
21 years of age or older*
Yes
No
histologically/cytologically confirmed carcinoma
of the breast*
Yes
No
documented locally recurrent or metastatic
disease not amenable to curative surgery or
radiotherapy*
Yes
No
either one, two or three prior chemotherapy
regimens*
Yes
No
prior treatments including both an anthracycline
and a taxane and patient no longer candidate for
these drugs*
Yes
No
measurable or non-measurable disease
according to recist 1.1*
Yes
No
karnofsky performance score of at least 70 %*
Yes
No
adequate haematological, hepatic and renal
functions*
Yes
No
ecg without clinically relevant abnormality*
Yes
No
Exclusion Criteria
1 / 2
known or clinical evidence of brain metastasis or
leptomeningeal involvement*
Yes
No
pulmonary lymphangitis or symptomatic pleural
effusion*
Yes
No
any serious, concurrent uncontrolled medical
disorder*
Yes
No
history of second primary malignancy*
Yes
No
preexisting motor/sensory peripheral neuropathy*
Yes
No
known history of hiv infection*
Yes
No
prior therapy with capecitabine and/or vinca-
alkaloids*
Yes
No
history of severe hypersensitivity to vinca
alkaloids and/or to fluoropyrimidine or contra
indication to any of these drugs*
Yes
No
known or suspected dihydropyrimidine
dehydrogenase (dpd) deficiency*
Yes
No
pregnancy or breast feeding*
Yes
No
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NHL-BFM Registry 2012 Diagnostic Data
NHL-BFM 2012 Registry. 
Principal Investigators: Birgit Burkhardt and Wilhelm
Woessmann. 
NHL study group University Hospital Münster
All rights reserved. Please visit https://medical-data-
models.org/forms/16169
Diagnostic Data
Anamnesis
General condition at diagnosis*
normal activity, no impairment (1)
slight impairment of activity, requires no
occasional assistence (2)
obvious impairment of normal activity (3)
bedridden, requires special care and
assistance (4)
bedridden, very sick, in need of intensive
care (5)
Loss in weight (>10% in last 6 months)*
no (1)
yes (2)
Fever (>38°C for at least 7 days)*
no (1)
yes (2)
Night sweat*
no (1)
yes (2)
Diagnosis (general)
Diagnosis by cytology (malignant effusion or
bone marrow)*
no (1)
yes (2)
Cytologic diagnosis made out of bone marrow
(BM)?*
no (1)
yes (2)
Cytologic diagnosis made out of ascites?*
no (1)
yes (2)
Cytologic diagnosis made out of pleural
effusion?*
no (1)
yes (2)
Cytologic diagnosis made out of pericardial
effusion?*
no (1)
yes (2)
Cytologic diagnosis made out of cerebral spinal
fluid (CSF)?*
no (1)
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yes (2)
Diagnosis by histology*
no (1)
yes (2)
localization code*
bone marrow (BM (1)
area of ear, nose and throat (ENT) (10)
head / neck: other manifestation(s) (11)
mediastinum (12)
pleura/pleural effusion (13)
pericardium / pericardial effusion (14)
lung(s) (15)
other thoracic manifestation(s) (16)
ascites (17)
bowel (18)
liver (19)
CNS: intra-cerebral tumor (2)
spleen (20)
kidney(s) (21)
abdominal LN (22)
other abdominal manifestation(s) (23)
testis (24)
soft tissue (25)
skin (26)
bone (27)
epidural (28)
other localisation(s) (29)
CNS: intra-medullary tumor (3)
CNS: nerve palsy (4)
CNS: lymphoma cells in CSF (5)
LN cervical, submandibular, nuchal (6)
LN supra-/ infraclavicular / axillary (7)
LN inguinal (8)
LN: other peripheral LN (9)
localization description*
Type of surgery*
core-needle biopsy (1)
biopsy/partial resection (2)
complete resection of ALL
manifestations (3)
Date of diagnostic surgery / puncture*
Diagnostics BEFORE start of therapy:
Peripheral Blood (PB)
Date of blood withdrawal before therapy*
WBC (x 10 exp 9 / l)*
Platelets (x 10 exp 9 / l)*
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Hb (g/l)*
g/l
lymphoma cells / blasts in the peripheral blood
(%)*
Diagnostics BEFORE start of therapy:
Bone Marrow (BM)
BM aspirate done (before therapy)?*
no (1)
yes (2)
if yes: Date of BMP*
if yes: lymphoma cells / blasts in BM (%)*
%
BM biopsy done (before therapy)?*
no (1)
yes (2)
Biopsy result*
negative (1)
positive (2)
Diagnostics BEFORE start of therapy:
Cerebral Spinal Fluid (CSF)
Lumbar puncuture done (before therapy)?*
no (1)
yes (2)
Date lumbar puncture before therapy*
Nucleated Cells in CSF (/mikroL)*
Erythrocytes in CSF*
no (1)
yes (2)
Lymphoma-cells in CSF*
no (1)
yes (2)
unclear / could not be clarified / (not
interpretable) (3)
Reference diagnosis (Please send copies
of the reports to the NHL-BFM study
center!)
Reference histology initiated*
no (1)
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yes (2)
Reference histology lab.*
Frankfurt (11)
Ulm (12)
Prag (13)
Zuerich (14)
LKR Kiel (2)
Wuerzburg (5)
Luebeck (7)
Wien (8)
Reference cytomorphology initiated*
no (1)
yes (2)
Reference cytomorphology lab*
Giessen (1)
Prag (13)
Zuerich (14)
Hamburg (only for CoALL-patients) (16)
Wien (8)
Reference cytomorphology: FAB*
L1 (1)
L2 (2)
L3 (3)
L1/L2 (4)
lymphoblastic (5)
ALCL (6)
other (9)
Reference cytomorphology: please specify!*
Reference immunology initiated*
no (1)
yes (2)
Reference immunology lab*
Prag (13)
Zuerich (14)
Hamburg (only for CoALL-patients) (16)
Berlin (4)
Wien (8)
Diagnosis at local institution (Please send
copies of the local reports to the NHL-
BFM study center!)
Local histology*
lymphoblastic lymphoma (1)
precursor-B-cell lymphoblastic
lymphoma (2)
precursor-T-cell lymphoblastic lymphoma
(3)
mature B-cell lymphoma (4)
ALCL (5)
not definable (6)
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other (9)
Local histology other*
Local immunhistochemistry*
lymphoblastic lymphoma (1)
precursor-B-cell lymphoblastic
lymphoma (2)
precursor-T-cell lymphoblastic lymphoma
(3)
mature B-cell lymphoma (4)
ALCL (5)
not definable (6)
other (9)
Local immunhistochemistry other*
Local cytomorphology*
L1 (1)
L2 (2)
L3 (3)
L1/L2 (4)
lymphoblastic (5)
ALCL (6)
other (9)
Local cytomorphology other*
Local immunology*
lymphoblastic lymphoma (1)
precursor-B-cell lymphoblastic
lymphoma (2)
precursor-T-cell lymphoblastic lymphoma
(3)
mature B-cell lymphoma (4)
ALCL (5)
not definable (6)
other (9)
Local immunology other*
Stage (Murphy / St. Judes)
Stage*
Stage I (1)
Stage II (2)
Stage III (3)
Stage IV (4)
B-AL (5)
not evaluable (no pre-therapeutic bone
marrow puncture and / or lumbar
puncture) (9)
Therapy
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Therapy*
LBL stage I or II (11)
LBL stage III or IV (12)
LBL stage IV CNS positive (Type 2) with
cranial irradiation (13)
Follicular lymphoma: watch and wait (20)
B-NHL R1 (21)
B-NHL R2 (22)
B-NHL R3 (23)
B-NHL R4 (24)
B-NHL R4 CNS positive (25)
PMLBL, DA-EPOCH-R (26)
ALCL, watch and wait (isolated skin
disease) (31)
ALCL, 3 courses (stage I, completely
resected) (32)
ALCL, 6 courses (33)
ALCL, CNS-positive (34)
Other (99)
Therapy, specify+A2*
Date start therapy*
Initial complications before start of therapy
Cell lysis syndrome*
no (1)
yes (2)
Reduced renal function*
no (1)
yes (2)
Reduced cardial function*
no (1)
yes (2)
Paraplegia/paresis*
no (1)
yes (2)
Complication(s) of primary surgery*
no (1)
yes (2)
Respiratory impairment caused by mediastinal
tumor or effusions*
no (1)
yes (2)
Superior vena cava syndrome caused by
mediastinal tumor or effusions*
no (1)
yes (2)
Other complication(s)*
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no (1)
yes (2)
Complications: description*
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Eligibility Atypical Depression
NCT00215176
Modafinil for Atypical Depression; ODM derived from:
https://clinicaltrials.gov/show/NCT00215176
All rights reserved. Please visit https://medical-data-
models.org/forms/16170
Eligibility Atypical Depression
NCT00215176
Inclusion Criteria
adults 18-65 years of age*
Yes
No
dsm-iv criteria for major depressive episode with
atypical features as assessed by the atypical
depression diagnostic scale*
Yes
No
minimum score of 18 on the hamilton depression
scale (29-item version) at baseline*
Yes
No
baseline clinical global impressions severity score
of 4 or more*
Yes
No
written informed consent*
Yes
No
negative serum pregnancy test for women of
childbearing potential*
Yes
No
Exclusion Criteria
any current primary dsm-iv axis i disorder other
than depression*
Yes
No
history of dsm-iv diagnosis of bipolar i disorder,
schizophrenia or other psychotic disorder, mental
retardation or other pervasive developmental
disorder, or cognitive disorder due to a general
medical condition*
Yes
No
history of substance abuse or dependence within
the last 3 months*
Yes
No
suicide risk or serious suicide attempt with the
last year*
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Yes
No
clinically significant medical condition or
laboratory or ekg abnormality*
Yes
No
history of non-response to three prior adequate
trials of antidepressants*
Yes
No
women of childbearing potential who are
unwilling to practice an acceptable method of
contraception*
Yes
No
history of hypersensitivity to modafinil*
Yes
No
use of an investigational medication within the
last 28 days*
Yes
No
use of antidepressant medication with 28 days of
screening*
Yes
No
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NHL-BFM Registry 2012 Late effects
NHL-BFM 2012 Registry. 
Principal Investigators: Birgit Burkhardt and Wilhelm
Woessmann. 
NHL study group University Hospital Münster
All rights reserved. Please visit https://medical-data-
models.org/forms/16175
Late effects
Time of evaluation
Time of evaluation (years after diagnosis)*
Date of evaluation*
Late effect(s)
Cardiovascular system*
no (1)
yes (2)
Date of first diagnosis*
Description*
CNS/peripheral nerves*
no (1)
yes (2)
Date of first diagnosis*
Description*
Endocrinology*
no (1)
yes (2)
Date of first diagnosis*
Description*
Lung/respiratory tract*
no (1)
yes (2)
Date of first diagnosis*
Description*
Psychosocial late effects*
no (1)
yes (2)
Date of first diagnosis*
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Description*
Kidney/urinary tract*
no (1)
yes (2)
Date of first diagnosis*
Description*
Sensory organs*
no (1)
yes (2)
Date of first diagnosis*
Description*
Musculoskeletal system*
no (1)
yes (2)
Date of first diagnosis*
Description*
Liver*
no (1)
yes (2)
Date of first diagnosis*
Description*
Skin*
no (1)
yes (2)
Date of first diagnosis*
Description*
Hematology*
no (1)
yes (2)
Date of first diagnosis*
Description*
Gastrointestinal tract*
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no (1)
yes (2)
Date of first diagnosis*
Description*
Other*
no (1)
yes (2)
Date of first diagnosis*
Description*
Cause of late effect
Late effect related to*
lymphoma (1)
initial diagnostic surgery (2)
treatment (3)
other (4)
not determinable (5)
Please specify*
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NHL-BFM Registry 2012 Lost to follow up
NHL-BFM 2012 Registry. 
Principal Investigators: Birgit Burkhardt and Wilhelm
Woessmann. 
NHL study group University Hospital Münster
All rights reserved. Please visit https://medical-data-
models.org/forms/16176
Lost to Follow-Up
Lost to Follow-Up
Patient lost to follow-up in the treating center*
no (1)
yes (2)
Date of last visit in treating center*
Further follow-up via the German Children's
Cancer Registry (DKKR)?*
no (1)
yes (2)
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NHL-BFM 2012 Registry. 
Principal Investigators: Birgit Burkhardt and Wilhelm
Woessmann. 
NHL study group University Hospital Münster
All rights reserved. Please visit https://medical-data-
models.org/forms/16179
Manifestations
MANIFESTATIONS (Manifestiations
defined only by metabolic activity (PET)
without morhological correlate in CT scan
should NOT be indicated as positive!
BONE MARROW*
no (1)
yes (2)
CNS*
no (1)
yes (2)
unclear / could not be clarified / (not
interpretable) (3)
CNS: tumor intra-cerebral*
no (1)
yes (2)
CNS: tumor intra-medullary*
no (1)
yes (2)
CNS: cerebral nerve palsy*
no (1)
yes (2)
CNS: lymphoma-cells in CSF*
no (1)
yes (2)
Peripheral lymph nodes (LN)
LN cervical, submandibular, nuchal*
no (1)
yes (2)
LN supra- / infraclavicular / axillary*
no (1)
yes (2)
LN inguinal*
no (1)
yes (2)
other peripheral LN*
no (1)
yes (2)
other peripheral LN: specify*
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Head and neck
area of ear, nose and throat (ENT)*
no (1)
yes (2)
head / neck: other manifestation(s)*
no (1)
yes (2)
head / neck: other manifestation(s): specify*
Thorax
mediastinum*
no (1)
yes (2)
pleura / pleural effusion*
no (1)
yes (2)
pericardium / pericardial effusion*
no (1)
yes (2)
lung*
no (1)
yes (2)
other thoracic manifestation(s)*
no (1)
yes (2)
other thoracic manifestation(s): specify*
Abdomen
ascites*
no (1)
yes (2)
bowel*
no (1)
yes (2)
liver*
no (1)
yes (2)
spleen*
no (1)
yes (2)
kidney(s)*
no (1)
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yes (2)
abdominal LN*
no (1)
yes (2)
other abdominal manifestation(s)*
no (1)
yes (2)
other abdominal manifestation(s): specify*
Other Localisations
testis*
no (1)
yes (2)
testis: unilateral / bilateral*
unilateral (1)
bilateral (2)
soft tissue*
no (1)
yes (2)
soft tissue: unilokular / multilokular*
unilokular (1)
multilokular (2)
skin*
no (1)
yes (2)
skin: unilokular / multilokular*
unilokular (1)
multilokular (2)
bone*
no (1)
yes (2)
bone: unilokular / multilokular*
unilokular (1)
multilokular (2)
epidural*
no (1)
yes (2)
other localisation(s)*
no (1)
yes (2)
other localisation(s): specify*
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Eligibility B-cell Chronic Lymphocytic
Leukemia NCT00098670
Fludarabine, Rituximab, and Alemtuzumab in Treating
Patients With Chronic Lymphocytic Leukemia; ODM
derived from: https://clinicaltrials.gov/show/NCT00098670
All rights reserved. Please visit https://medical-data-
models.org/forms/16180
Eligibility B-cell Chronic Lymphocytic
Leukemia NCT00098670
Inclusion Criteria
specific diagnosis of b-cell cll*
Yes
No
an absolute lymphocytosis of > 5,000/μl*
Yes
No
morphologically, the lymphocytes must appear
mature with < 55% prolymphocytes*
Yes
No
bone marrow examination must include at least a
unilateral aspirate and biopsy; the aspirate smear
must show > 30% of all nucleated cells to be
lymphoid  or the bone marrow core biopsy must
show lymphoid infiltrates compatible with marrow
involvement by cll; the overall cellularity must be
normocellular or hypercellular*
Yes
No
local institution lymphocyte phenotype must
reveal a predominant b-cell monoclonal
population sharing a b-cell marker (cd19, cd20,
cd23) with the cd5 antigen, in the absence of
other pan-t-cell markers; additionally, the b-cells
must be monoclonal with regard to expression of
either κ or λ and have surface immunoglobulin
expression of low density; patients with bright
surface immunoglobulin levels must have cd23
co-expression*
Yes
No
patients must be in the intermediate- or high-risk
categories of the modified three-stage rai staging
system (i.e., stages i, ii, iii, or iv)*
Yes
No
patients in the intermediate-risk group must have
evidence of active disease as demonstrated by at
least one of the following criteria:*
Yes
No
massive or progressive splenomegaly,
hepatomegaly and/or lymphadenopathy;*
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Yes
No
presence of weight loss > 10% over the
preceding 6 month period;*
Yes
No
grade 2 or 3 fatigue;*
Yes
No
fevers > 100.5°f or night sweats for greater than 2
weeks without evidence of infection;*
Yes
No
progressive lymphocytosis with an increase of >
50% over a 2 month period or an anticipated
doubling time of less than 6 months*
Yes
No
no prior therapy for cll including corticosteroids
for autoimmune complications that have
developed since the initial diagnosis of cll*
Yes
No
no medical condition requiring chronic use of oral
corticosteroids*
Yes
No
performance status 0 - 2*
Yes
No
due to alterations in host immunity, patients with
hiv may not be enrolled*
Yes
No
due to the unknown teratogenic potential of
alemtuzumab, pregnant or nursing women may
not be enrolled; women and men of reproductive
potential should agree to use an effective means
of birth control*
Yes
No
creatinine =< 1.5 x upper limit of institutional
normal value*
Yes
No
coomb's testing negative*
Yes
No
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Baseline Personal History Cardiovascular
Health Study (CHS)
Documentation part: Record 8 Baseline Personal History
The Cardiovascular Health Study (CHS) was initiated by
the National Heart, Lung and Blood Institute (NHLBI) in
1987 to determine the risk factors for development and
progression of cardiovascular disease (CVD) in older
adults, with an emphasis on subclinical measures. The
study recruited 5,888 adults aged 65 or older at entry in
four U.S. communities and conducted extensive annual
clinical exams between 1989-1999 along with semi-annual
phone calls, events adjudication, and subsequent data
analyses and publications. Additional data were collected
by studies ancillary to CHS. With the exception of annual
clinic visits, these activities are still ongoing.
Data obtained from: https://chs-nhlbi.org/
Permission granted by: Erika Enright.
All rights reserved. Please visit https://medical-data-
models.org/forms/16181
Baseline Personal History
Cardiovascular Health Study (CHS)
Personal History
1. In the last year, have you gained or lost more
than 10 pounds?
lost more than 10 pounds (1)
gained more than 10 pounds (2)
both lost and gained more than 10
pounds (3)
no change (4)
don't know (9)
A. Was diet for the purpose of losing or gaining
weight a major factor in your weight change?
no (0)
yes (1)
don't know (9)
B. Was surgery, illness or medication a major
factor in your weight change?
no (0)
yes (1)
don't know (9)
C. Was exercise a major factor in your weight
change?
no (0)
yes (1)
don't know (9)
2. What was your usual weight at age 50?
pounds
3. In your early teens (11-14 years), were you
heavier than average, about average, or thinner
than average?
heavier than average (1)
about average (2)
thinner than average (3)
don't know (9)
4. Have you smoked more than 100 cigarettes or
5 packs of cigarettes in your lifetime?
no (0)
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yes (1)
don't know (9)
5. Have you smoked cigarettes during the last 30
days?
no (0)
yes (1)
don't know (9)
6. How old were you when you first started to
smoke cigarettes?
7. If you have stopped cigarettes completely,  how
old were you when you stopped? (If you still
smoke, leave this question blank.)
8. On the average of the entire time you smoked,
how many cigarettes did you smoke per day?
9. Does anyone living with you smoke cigarettes
regularly?
no (0)
yes (1)
don't know (9)
10. Are you usually sleepy in the daytime? (Do
not include taking a regular daily nap as "feeling
sleepy.")
no (0)
yes (1)
don't know (9)
11. Do you feel groggy and unrefreshed for more
than a half hour after waking up in the morning?
no (0)
yes (1)
don't know (9)
12. Has your spouse or roommate complained
about your loud snoring?
no (0)
yes (1)
don't know (9)
13. Has anyone observed you while sleeping to
have episodes where you stop breathing for a
while and then snore or snort loudly?
no (0)
yes (1)
don't know (9)
14. Do you usually have trouble falling asleep?
no (0)
yes (1)
don't know (9)
15. Do you usually wake up several times at
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night?
16. Do you usually wake up far too early?
no (0)
yes (1)
don't know (9)
17. Can you see well enough (with glasses if
needed) to drive?
no (0)
yes (1)
don't know (9)
18. Can you see well enough (with glasses if
needed) to watch TV?
no (0)
yes (1)
don't know (9)
19. Can you see well enough (with glasses if
needed) to recognize someone across the room?
no (0)
yes (1)
don't know (9)
20. Can you see well enough (with glasses if
needed) to read the newspaper?
21. Can you hear well enough (with a hearing aid
if necessary) to use the telephone?
no (0)
yes (1)
don't know (9)
22. Can you hear well enough (with a hearing aid
if necessary) to listen to a radio?
no (0)
yes (1)
don't know (9)
23. Can you hear well enough (with a hearing aid
if necessary) to carry on a conversation in a
crowded room?
no (0)
yes (1)
don't know (9)
Family History
24. In the table below, please write the first
names of all your brothers, then all your sisters,
including those who have died or with whom you
have lost touch, in the column labeled FIRST
NAME. Circle the appropriate gender for each
(M=male,  F=female).
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Male/Female
female (0)
male (1)
Year of birth:
26. Still alive?
no (0)
yes (1)
don't know (9)
Age at death
27. Please record whether any of your brothers or
sisters have ever had a heart attack by circling
the appropriate answer in the HEART ATTACK
column. If they had a heart attack, please write
their age at first heart attack in the AGE column.
no (0)
yes (1)
don't know (9)
Age
28. Please record whether any of your brothers or
sisters have ever had a stroke by circling the
appropriate answer in the STROKE column. If
they had a stroke, please write their age at first
stroke in the AGE column.
no (0)
yes (1)
don't know (9)
Age
Questions for female participants
29. How many times have you been pregnant?
A. How many live births have you had?
30. How old were you at the time of your last
natural mentrual period (menopause)?
31. Have you ever had a hysterectomy, that is,
surgery to remove your uterus or womb?
no (0)
yes (1)
don't know (9)
A. How old were you when you had this surgery?
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32. Have you ever had an ovary removed?
no (0)
yes (1)
don't know (9)
A. How many ovaries were removed?
one (1)
two (2)
don't know (9)
B. At what age did you have this done?
33. Have you ever taken Premarin for hot flashes
or other symptoms of menopause?
no (0)
yes (1)
don't know (9)
A. At what age did you start taking Premarin?
B. At what age did you stop taking Premarin?
34. Haver you ever taken any estrogens or female
hormones other than Premarin for hot flashes or
other symptoms of menopause?
Medication
Please specify which other medications you took:
Date of interview
Interviewer
Interview:
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NHL-BFM Registry 2012 Registration
NHL-BFM 2012 Registry. 
Principal Investigators: Birgit Burkhardt and Wilhelm
Woessmann. 
NHL study group University Hospital Münster
All rights reserved. Please visit https://medical-data-
models.org/forms/16184
Registration
Inclusion criteria
Newly diagnosed (Secondary malignancy) Non-
Hodgkin lymphoma*
no (1)
yes (2)
NHL subtype*
lymphoblastic lymphoma (LBL) (1)
mature B-cell lymphoma (B-NHL) (2)
anaplastic large cell lymphoma (ALCL)
(3)
peripheral T-cell lymphoma (PTCL) (4)
other NHL (9)
specify NHL subtype*
Diagnosis and treatment in a participating center
of the NHL-BFM group*
no (1)
yes (2)
Patient age at diagnosis below 18 years*
no (1)
yes (2)
Signed informed consent for participation in the
NHL-BFM Registry 2012 and data transfer*
no (1)
yes (2)
Date of signed informed consent*
Follow-up is expected to be available for at least
2 years*
no (1)
yes (2)
Personal data
Date of registration to Marvin*
Patient ID*
Surname (or initial)*
First name (or initial)*
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Date of birth*
Sex*
male (1)
female (2)
Marvin-ID*
Identification
Malig-ID (DKKR)*
GPOH-PID*
Additional information
Maximum increase of LDH before start of
therapy*
U/l
Upper normal limit of LDH in local laboratory*
U/l
Involvement of central nervous system (CNS+)*
no (1)
yes (2)
unclear / could not be clarified / (not
interpretable) (3)
Involvement of bone marrow (BM+)*
no (1)
yes (2)
Therapy arm (for mature B-NHL only)*
R1 (1)
R2 (2)
R3 (3)
R4 (4)
R4 CNS pos. (5)
Date of treatment start*
Some data on anamnesis
Chromosomal breakage syndrome,
immunodeficiency, or HIV infection*
no (1)
yes (2)
specify syndrome*
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Previous organ transplantation*
no (1)
yes (2)
specify TP*
Previous malignancy/neoplasm*
no (1)
yes (2)
specify previous malignancy*
Other pre-existing disease prohibiting standard
chemotherapy*
no (1)
yes (2)
specify preexisting disease*
Previous chemotherapy, radiotherapy, or systemic
corticosteroid treatment*
no (1)
yes (2)
specify previous therapy*
For female patients: Pregnancy or lactation
period*
no (1)
yes (2)
Simultaneous participation in a clinical study*
no (1)
yes (2)
specify other study*
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Eligibility Biliary Tract Carcinoma
NCT00490399
Trial of Gemcitabine and Cisplatin in Patients With
Inoperable Biliary Tract Carcinomas; ODM derived from:
https://clinicaltrials.gov/show/NCT00490399
All rights reserved. Please visit https://medical-data-
models.org/forms/16186
Eligibility Biliary Tract Carcinoma
NCT00490399
Inclusion Criteria
histologic or cytologic diagnosis of
adenocarcinoma of the gallbladder,
intra/extrahepatic bile ducts or papilla of vater
with locally advanced or metastatic disease (at
study entry) that is not amenable to curative
surgical resection or with recurrent disease after
prior surgical resection or radiotherapy.*
Yes
No
disease status must be measurable disease
defined as:  bi-dimensionally measurable lesions
with clearly defined margins and two
perpendicular diameters that are clearly
measurable by  following:*
Yes
No
computerized tomography (ct) or magnetic
resonance imaging (mri), with one diameter 2.0
cm or greater  and  the other diameter 1.0 cm or
greater.*
Yes
No
palpable lesion, with both diameters 2 cm or
greater. disease progressing in areas of prior
radiation therapy may be included.*
Yes
No
patients must have received no prior
chemotherapy for advanced disease.*
Yes
No
prior radiotherapy must be completed at least 4
weeks before study enrollment. patients must
have recovered from the acute toxic effects of the
treatment prior to study enrollment.*
Yes
No
Exclusion Criteria
treatment within the last 30 days with a drug that
has not received regulatory approval for any
indication at the time of study entry.*
Yes
No
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heart failure, angina pectoris or arrhythmia that
are poorly controlled in spite of medication or
acute myocardial infarction within 6 months
preceding study enrollment*
Yes
No
severe neurological or mental disorder.*
Yes
No
active infection that in the opinion of the
investigator would compromise the patient’s
ability to tolerate therapy.*
Yes
No
poorly controlled diabetes mellitus.*
Yes
No
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NHL-BFM Registry 2012 Late effects 2
NHL-BFM 2012 Registry. 
Principal Investigators: Birgit Burkhardt and Wilhelm
Woessmann. 
NHL study group University Hospital Münster
All rights reserved. Please visit https://medical-data-
models.org/forms/16188
Late effects
Head of femur
Head of femur: CT*
not tested (1)
Negative (2)
Positive (3)
Head of femur: MRI*
not tested (1)
Negative (2)
Positive (3)
Head of femur: x-ray*
not tested (1)
Negative (2)
Positive (3)
Head of femur : biopsy*
not tested (1)
Negative (2)
Positive (3)
Head of femur: NCI-CTC grading*
no osteonecrosis (0)
asymptomatic and detected by imaging
only (1)
symptomatic, but not interfering with
activities of daily living (2)
symptomatic and interfering with
activities of daily living (3)
symptomatic or disabling (4)
Spinal column
Spinal column: CT*
not tested (1)
Negative (2)
Positive (3)
Spinal column: MRI*
not tested (1)
Negative (2)
Positive (3)
Spinal column: x-ray*
not tested (1)
Negative (2)
Positive (3)
Spinal column: biopsy*
not tested (1)
Negative (2)
Positive (3)
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Spinal column: NCI-CTC grading*
no osteonecrosis (0)
asymptomatic and detected by imaging
only (1)
symptomatic, but not interfering with
activities of daily living (2)
symptomatic and interfering with
activities of daily living (3)
symptomatic or disabling (4)
Lower limb
Lower limb: CT*
not tested (1)
Negative (2)
Positive (3)
Lower limb: MRI*
not tested (1)
Negative (2)
Positive (3)
Lower limb: x-ray*
not tested (1)
Negative (2)
Positive (3)
Lower limb: biopsy*
not tested (1)
Negative (2)
Positive (3)
Lower limb: NCI-CTC grading*
no osteonecrosis (0)
asymptomatic and detected by imaging
only (1)
symptomatic, but not interfering with
activities of daily living (2)
symptomatic and interfering with
activities of daily living (3)
symptomatic or disabling (4)
Upper limb
Upper limb: CT*
not tested (1)
Negative (2)
Positive (3)
Upper limb: MRI*
not tested (1)
Negative (2)
Positive (3)
Upper limb: x-ray*
not tested (1)
Negative (2)
Positive (3)
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Upper limb: biopsy*
not tested (1)
Negative (2)
Positive (3)
Upper limb: NCI-CTC grading*
no osteonecrosis (0)
asymptomatic and detected by imaging
only (1)
symptomatic, but not interfering with
activities of daily living (2)
symptomatic and interfering with
activities of daily living (3)
symptomatic or disabling (4)
Involvement of articulation(s)
Involvement of articulation(s): CT*
not tested (1)
Negative (2)
Positive (3)
Involvement of articulation(s): MRI*
not tested (1)
Negative (2)
Positive (3)
Involvement of articulation(s): x-ray*
not tested (1)
Negative (2)
Positive (3)
Involvement of articulation(s): biopsy*
not tested (1)
Negative (2)
Positive (3)
Involvement of articulation(s): NCI-CTC grading*
no osteonecrosis (0)
asymptomatic and detected by imaging
only (1)
symptomatic, but not interfering with
activities of daily living (2)
symptomatic and interfering with
activities of daily living (3)
symptomatic or disabling (4)
Other localisation(s)
Other location(s): CT*
not tested (1)
Negative (2)
Positive (3)
Other location(s): MRI*
not tested (1)
Negative (2)
Positive (3)
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Other location(s): x-ray*
not tested (1)
Negative (2)
Positive (3)
Other location(s): biopsy*
not tested (1)
Negative (2)
Positive (3)
Other location(s): NCI-CTC grading*
no osteonecrosis (0)
asymptomatic and detected by imaging
only (1)
symptomatic, but not interfering with
activities of daily living (2)
symptomatic and interfering with
activities of daily living (3)
symptomatic or disabling (4)
Localisation of osteonecrosis specified
Please specify the localisation(s) of
osteonecrosis*
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Eligibility Bone Loss NCT00171340
Zoledronic Acid in the Prevention of Cancer Treatment
Related Bone Loss in Postmenopausal Women Receiving
Letrozole for Breast Cancer.; ODM derived from:
https://clinicaltrials.gov/show/NCT00171340
All rights reserved. Please visit https://medical-data-
models.org/forms/16190
Eligibility Bone Loss NCT00171340
Inclusion Criteria
stage i-iiia breast cancer*
Yes
No
postmenopausal or recently postmenopausal*
Yes
No
recent surgery for breast cancer*
Yes
No
estrogen receptor positive and/or progesterone
receptor positive hormone receptor status*
Yes
No
no prior treatment with letrozole*
Yes
No
other protocol-defined inclusion criteria may
apply.*
Yes
No
Exclusion Criteria
metastatic disease*
Yes
No
invasive bilateral disease*
Yes
No
clinical or radiological evidence of existing
fracture in spine or hip*
Yes
No
prior treatment with iv bisphosphonates in the
past 12 months*
Yes
No
current treatment with oral bisphosphonates (
must be discontinued within 3 weeks of baseline
evaluation)*
Yes
No
1 / 2
use of tibolone within 6 months*
Yes
No
prior use of parathyroid hormone for more than 1
week*
Yes
No
previous or concomitant malignancy*
Yes
No
abnormal renal function*
Yes
No
history of disease effecting bone metabolism*
Yes
No
other protocol-defined exclusion criteria may
apply.*
Yes
No
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NHL-BFM Registry 2012 Reference
Cytology
NHL-BFM 2012 Registry. 
Principal Investigators: Birgit Burkhardt and Wilhelm
Woessmann. 
NHL study group University Hospital Münster
All rights reserved. Please visit https://medical-data-
models.org/forms/16191
Reference Cytology
Reference cytology done?
Reference cytomorphology initiated*
no (1)
yes (2)
Reference cytomorphology lab*
Giessen (1)
Prag (13)
Zuerich (14)
Hamburg (only for CoALL-patients) (16)
Wien (8)
Reference cytology BEFORE start of
therapy: Bone Marrow (BM)
Reference cytology of BM aspirate done*
no (1)
yes (2)
Date of BMP (before therapy)*
Lymphoma cells / blasts in BM (%)*
%
Morphology*
L1 (1)
L2 (2)
L3 (3)
L1/L2 (4)
lymphoblastic (5)
ALCL (6)
other (9)
Specify*
Reference cytology BEFORE start of
therapy: Cerebral Spinal Fluid (CSF)
Reference cytology of CSF done*
no (1)
yes (2)
Date lumbar puncture (before therapy)*
Nucleated Cells in CSF (/mikroL)*
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Erythrocytes in CSF*
no (1)
yes (2)
Lymphoma-cells in CSF*
no (1)
yes (2)
Morphology*
L1 (1)
L2 (2)
L3 (3)
L1/L2 (4)
lymphoblastic (5)
ALCL (6)
other (9)
Specify*
Reference cytology BEFORE start of
therapy: Tumor
Reference cytology of tumor touch imprints
done?*
no (1)
yes (2)
Date of operation / material withdrawal*
Morphology*
L1 (1)
L2 (2)
L3 (3)
L1/L2 (4)
lymphoblastic (5)
ALCL (6)
other (9)
Specify*
Reference cytology BEFORE start of
therapy: Effusions
Reference cytology of pleural effusion cytospins
done*
no (1)
yes (2)
Date of puncture*
Morphology*
L1 (1)
L2 (2)
L3 (3)
L1/L2 (4)
lymphoblastic (5)
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ALCL (6)
other (9)
Specify*
Reference cytology of pericardial effusion
cytospins done*
no (1)
yes (2)
Date of puncture*
Morphology*
L1 (1)
L2 (2)
L3 (3)
L1/L2 (4)
lymphoblastic (5)
ALCL (6)
other (9)
Specify*
Reference cytology of ascites cytospins done*
no (1)
yes (2)
Date of puncture*
Morphology*
L1 (1)
L2 (2)
L3 (3)
L1/L2 (4)
lymphoblastic (5)
ALCL (6)
other (9)
Specify*
Further remarks
Further remarks*
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NHL-BFM Registry 2012 Reference
Immunology / FACS Analysis
NHL-BFM 2012 Registry. 
Principal Investigators: Birgit Burkhardt and Wilhelm
Woessmann. 
NHL study group University Hospital Münster
All rights reserved. Please visit https://medical-data-
models.org/forms/16192
Reference Immunology / FACS
Analysis
Organisational aspects
Reference Immunology (Laboratory)*
Prag (13)
Zuerich (14)
Hamburg (only for CoALL-patients) (16)
Berlin (4)
Wien (8)
Material*
BM (1)
ascites (2)
pleural effusion (3)
pericardial effusion (4)
CSF (5)
effusion – not further specified (6)
tissue / tumor / lymph node (7)
peripheral blood (8)
other (9)
Specify*
Date of material withdrawal (Date of biopsy /
puncture)*
Material malignant / lymphoma cells in material?*
no (1)
yes (2)
unclear / could not be clarified / (not
interpretable) (3)
Immunological diagnosis
Immunological Diagnosis*
no malignant material / Diagnosis not
possible (0)
Bilineal / biphenotypic (12)
Acute myeloid leukemia (AML) (13)
not classifiable (2)
Pro-B (pre-pre-B) (B I) (3)
Common (B II) (4)
T-lineage (not further classified) (40)
Pro-T (T I) (42)
Between cortical T (T III) and mature T
(T IV) (43)
Pre-B (B III) (5)
Mature B (B IV) (6)
B-lineage (not further classified) (60)
Pre-T (T II) (7)
Cortical T (T III) (8)
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Mature T (T IV) (9)
Other immunological subtype (98)
Specify*
Further remarks
Further remarks*
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Eligibility brca1 Mutation Carrier
NCT00080756
Deslorelin Combined With Low-Dose Add-Back Estradiol
and Testosterone in Preventing Breast Cancer in
Premenopausal Women Who Are at High Risk for This
Disease; ODM derived from:
https://clinicaltrials.gov/show/NCT00080756
All rights reserved. Please visit https://medical-data-
models.org/forms/16193
Eligibility brca1 Mutation Carrier
NCT00080756
Inclusion Criteria
patients must generally be in good health with lab
values and physical examination within normal
limits*
Yes
No
known high risk of breast cancer due to brca
mutation or empiric risk > 30% lifetime by the
claus model*
Yes
No
no evidence or history of pervious cancer, except
non-melanoma skin cancer*
Yes
No
premenopausal women planning risk reduction
mastectomy in 6 months or more (group 1) or
continued surveillance (group 2)*
Yes
No
prior tubal ligation or willing to use a non-
hormonal barrier method of contraception*
Yes
No
signed the informed consent form document for
this study in accordance with all federal, state
and institutional regulations*
Yes
No
must be current non-smoker*
Yes
No
Exclusion Criteria
gnrha treatment within 12 months of study entry*
Yes
No
nasal polyposis, atrophic rhinitis, severe allergic
or vasomotor rhinitis, or sinusitis requiring current
treatment or treatment for more than 3 months in
the previous year*
Yes
1 / 2
No
concurrent medications including: corticosteroids
(prednisone, prednisolone, cortisone acetate,
decadron, deltasone, hydrocortisone,
hydrocortone, medrol), estrogens, progestins or
androgens, including oral, implanted, or injected
contraceptive; (at least 6 months must have
elapsed since the last use of an implanted or
injected contraceptive such as norplant)*
Yes
No
pregnant or breast-feeding or have been so in the
last six months*
Yes
No
immeasurable breast density on mammogram*
Yes
No
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Eligibility brca1 Mutation Carrier NCT00080756
ICU - Hospital Stay RICH study
NCT02669589
NCT02669589 EudraCT-Nr. 2014-004854-33
REGIONAL CITRATE VERSUS SYSTEMIC HEPARIN
ANTICOAGULATION FOR CONTINUOUS RENAL
REPLACEMENT THERAPY IN CRITICALLY ILL
PATIENTS WITH ACUTE KIDNEY INJURY
Study Chair: Alexander Zarbock, MD University Hospital
Muenster
All rights reserved. Please visit https://medical-data-
models.org/forms/16194
ICU - Hospital Stay RICH study
NCT02669589
Patient Information
ID of Center
ID of patient
Discharge Date
Date of discharge: primary hospital stay
Discharge from hospital while study progress?
Yes
No
Date of discharge: primary ICU stay
Discharge from hospital while study progress?
Yes
No
Further Hospital Stays
Further Hospital Stays?
(after initial discharge)
Yes
No
Admission Date: Further Hospital Stay
Primary Reason for readmission to hospital:
Discharge Date from Hospital
Further ICU Stays?
(after initial discharge)
Yes
No
Admission Date: Further ICU Stay
Primary Reason for readmission to ICU:
1 / 2
Discharge Date from ICU
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ICU - Hospital Stay RICH study NCT02669589
Consent RICH study NCT02669589
NCT02669589 EudraCT-Nr. 2014-004854-33
REGIONAL CITRATE VERSUS SYSTEMIC HEPARIN
ANTICOAGULATION FOR CONTINUOUS RENAL
REPLACEMENT THERAPY IN CRITICALLY ILL
PATIENTS WITH ACUTE KIDNEY INJURY
Study Chair: Alexander Zarbock, MD University Hospital
Muenster
All rights reserved. Please visit https://medical-data-
models.org/forms/16195
Consent RICH study NCT02669589
Patient Information
ID of Center
ID of patient
Subsequent consent - please fill in for
patients who are primary not able to give
consent
Subsequent consent given by patient
(has the patient given written consent for
participation to clinical trial subsequently?)
Yes
No
If patient gave subsequent consent, specify date:
Subsequent consent given by representative
(has the representative given written consent for
participation to clinical trial subsequently?)
Yes
No
If representative gave subsequent consent,
specify date:
Lawsuit for legal caregiver applied?
Yes
No
Lawsuit for legal caregiver:
If yes, completed?
Yes
No
Date of deployment of caregiver:
Subsequent consent given by caregiver
(has the caregiver given written consent for
participation to clinical trial subsequently?)
Yes
No
If caregiver gave subsequent consent, specify
date:
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Withdrawal of consent
Withdrawal of consent
(fill in, if patients wants withdrawal of consent)
Yes
No
Reason for withdrawal of consent:
(fill in, if patients wants withdrawal of consent)
Date of withdrawal of consent by patient
(fill in, if patients wants withdrawal of consent)
Date of withdrawal of consent by representative
(fill in, if representative wants withdrawal of
consent)
Date of withdrawal of consent by caregiver
(fill in, if caregiver wants withdrawal of consent)
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NHL-BFM Registry 2012 Progression /
Relapse
NHL-BFM 2012 Registry. 
Principal Investigators: Birgit Burkhardt and Wilhelm
Woessmann. 
NHL study group University Hospital Münster
All rights reserved. Please visit https://medical-data-
models.org/forms/16196
Progression / Relapse
Progression / Relapse
Date of progression / relapse*
Time of progression / relapse*
during therapy (1)
after end of therapy (2)
Site of progression / relapse: BM*
no (1)
yes (2)
Site of progression / relapse: CNS*
no (1)
yes (2)
Site of progression / relapse: reappearance or
increase of residuals*
no (1)
yes (2)
Site of progression / relapse: reappearance or
increase of residuals: description*
Site of progression / relapse: appearance of new
localisation(s)*
no (1)
yes (2)
Site of progression / relapse: appearance of new
localisation(s): description*
Therapy of progression / relapse (planned/done)*
no (1)
yes (2)
Therapy of progression relapse: description*
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NHL-BFM Registry 2012 SCT as part of
first line therapy
NHL-BFM 2012 Registry. 
Principal Investigators: Birgit Burkhardt and Wilhelm
Woessmann. 
NHL study group University Hospital Münster
All rights reserved. Please visit https://medical-data-
models.org/forms/16197
SCT as part of first-line therapy
SCT as part of first-line therapy
Autologous stem cell transplantation (as part of
first line therapy)*
no (1)
yes (2)
Autologous SCT date*
Autologous SCT center*
A - Augsburg (1)
KA - Karlsruhe (11)
BB - Berlin-Buch (110)
C - Chemnitz (111)
CB - Cottbus (112)
DT - Dresden Uniklinik (113)
EF - Erfurt (115)
GW - Greifswald (116)
HW - Halle (117)
J - Jena (118)
L - Leipzig (119)
E - Essen (12)
MD - Magdeburg (120)
RO - Rostock (121)
SN - Schwerin (122)
KR - Krefeld (13)
MI - Minden (132)
KK - Köln - Städtisches
Kinderkrankenhaus (14)
MK - München v. Haunersches (15)
B - Berlin Charité (16)
HS - Homburg/Saar (17)
WB - Würzburg (18)
FB - Freiburg (19)
MZ - Mainz (2)
DB - Dornbirn (AT) (201)
FK - Feldkirch (AT) (202)
GZ - Graz (AT) (203)
IB - Innsbruck (AT) (204)
KF - Klagenfurt (AT) (205)
LA - Linz (AT) (206)
LE - Leoben (AT) (207)
LL - Linz (AT) (208)
SC - Schwarzach (AT) (209)
KO - Koblenz (21)
ST - Steyr (AT) (210)
SZ - Salzburg (AT) (211)
W - Wien (212)
KS - Kassel (23)
DA - Datteln (24)
KI - Kiel (26)
MA - Mannheim (28)
AU - St. Augustin (30)
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AR - Aarau (CH) (301)
BL - Basel (CH) (302)
LZ - Luzern (CH) (305)
SG - St. Gallen (CH) (306)
Z - Zürich (CH) (307)
BE - Bern (CH) (308)
LB - Lübeck (31)
T - Tübingen (32)
BI - Bielefeld (33)
M - Münster (34)
MS - München Schwabing (36)
HB - Bremen (4)
D - Düsseldorf (40)
AC - Aachen (41)
BS - Braunschweig (42)
HV - Hannover (45)
H - Heidelberg (5)
HH - Hamburg (52)
PR - Praha (CZ) (5251)
BR - Brno (CZ) (5252)
OL - Oldenburg (53)
G - Göttingen (54)
K - Köln Uniklinik (58)
ER - Erlangen (59)
RG - Regensburg (61)
N - Nürnberg (63)
S - Stuttgart (65)
U - Ulm (71)
DO - Dortmund (76)
SI - Siegen (78)
GI - Gießen (8)
HD - Herdecke (81)
BN - Bonn (85)
TR - Trier (86)
F - Frankfurt (9)
OT – Other (no study center) (999)
Specify*
Allogeneic stem cell transplantation (as part of
first line therapy)*
no (1)
yes (2)
Allogeneic SCT date*
Allogeneic SCT center*
A - Augsburg (1)
KA - Karlsruhe (11)
BB - Berlin-Buch (110)
C - Chemnitz (111)
CB - Cottbus (112)
DT - Dresden Uniklinik (113)
EF - Erfurt (115)
GW - Greifswald (116)
HW - Halle (117)
J - Jena (118)
L - Leipzig (119)
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E - Essen (12)
MD - Magdeburg (120)
RO - Rostock (121)
SN - Schwerin (122)
KR - Krefeld (13)
MI - Minden (132)
KK - Köln - Städtisches
Kinderkrankenhaus (14)
MK - München v. Haunersches (15)
B - Berlin Charité (16)
HS - Homburg/Saar (17)
WB - Würzburg (18)
FB - Freiburg (19)
MZ - Mainz (2)
DB - Dornbirn (AT) (201)
FK - Feldkirch (AT) (202)
GZ - Graz (AT) (203)
IB - Innsbruck (AT) (204)
KF - Klagenfurt (AT) (205)
LA - Linz (AT) (206)
LE - Leoben (AT) (207)
LL - Linz (AT) (208)
SC - Schwarzach (AT) (209)
KO - Koblenz (21)
ST - Steyr (AT) (210)
SZ - Salzburg (AT) (211)
W - Wien (212)
KS - Kassel (23)
DA - Datteln (24)
KI - Kiel (26)
MA - Mannheim (28)
AU - St. Augustin (30)
AR - Aarau (CH) (301)
BL - Basel (CH) (302)
LZ - Luzern (CH) (305)
SG - St. Gallen (CH) (306)
Z - Zürich (CH) (307)
BE - Bern (CH) (308)
LB - Lübeck (31)
T - Tübingen (32)
BI - Bielefeld (33)
M - Münster (34)
MS - München Schwabing (36)
HB - Bremen (4)
D - Düsseldorf (40)
AC - Aachen (41)
BS - Braunschweig (42)
HV - Hannover (45)
H - Heidelberg (5)
HH - Hamburg (52)
PR - Praha (CZ) (5251)
BR - Brno (CZ) (5252)
OL - Oldenburg (53)
G - Göttingen (54)
K - Köln Uniklinik (58)
ER - Erlangen (59)
RG - Regensburg (61)
N - Nürnberg (63)
S - Stuttgart (65)
U - Ulm (71)
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DO - Dortmund (76)
SI - Siegen (78)
GI - Gießen (8)
HD - Herdecke (81)
BN - Bonn (85)
TR - Trier (86)
F - Frankfurt (9)
OT – Other (no study center) (999)
Specify*
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NHL-BFM Registry 2012 SCT as part of first line therapy
NHL-BFM Registry 2012 Subsequent
neoplasm
NHL-BFM 2012 Registry. 
Principal Investigators: Birgit Burkhardt and Wilhelm
Woessmann. 
NHL study group University Hospital Münster
All rights reserved. Please visit https://medical-data-
models.org/forms/16198
Subsequent neoplasm
Subsequent neoplasm
Date of subsequent neoplasm*
Type of subsequent neoplasm*
ALL (1)
B-ALL (10)
ALCL (11)
AML (2)
B-NHL (3)
NB-NHL (4)
ALCL (5)
Brain tumor (6)
Other tumor (7)
Other (8)
MDS (9)
Subsequent neoplasm: Diagnosis (=> Please
sent a copy of the histological report to the NHL-
BFM study center!)*
Subsequent neoplasm: assessment of
malignancy*
benign (1)
semi-malignant (2)
malignant (3)
Therapy of subsequent neoplasm
(planned/done)*
no (1)
yes (2)
Therapy subsequent neoplasm: description*
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NHL-BFM Registry 2012 Significant treatment
modifications and other remarks concerning the treatment
NHL-BFM 2012 Registry. 
Principal Investigators: Birgit Burkhardt and Wilhelm
Woessmann. 
NHL study group University Hospital Münster
All rights reserved. Please visit https://medical-data-
models.org/forms/16199
Significant treatment modifications
and other remarks concerning the
treatment
Significant treatment modifications and
other remarks concerning the treatment
Significant treatment modifications (e.g. >10%
reduction or increase of cytostatic agents;
cytostatic agents omitted or added)*
no (1)
yes (2)
Treatment modifications specified*
Further remarks*
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NHL-BFM Registry 2012 Treatment for
mature B-NHL and ALCL
NHL-BFM 2012 Registry. 
Principal Investigators: Birgit Burkhardt and Wilhelm
Woessmann. 
NHL study group University Hospital Münster
All rights reserved. Please visit https://medical-data-
models.org/forms/16200
Treatment for mature B-NHL and
ALCL
Chemotherapy
1. element: course*
V (1)
AA24 (10)
AAZ1 (11)
AAZ2 (12)
BB24 (13)
BBZ1 (14)
BBZ2 (15)
CC (17)
DA-EPOCH-R (18)
VZ (2)
A4 (3)
AM (4)
B4 (6)
BM (7)
other treatment element (99)
Specify*
start 1. element*
2. element: course*
V (1)
AA24 (10)
AAZ1 (11)
AAZ2 (12)
BB24 (13)
BBZ1 (14)
BBZ2 (15)
CC (17)
DA-EPOCH-R (18)
VZ (2)
A4 (3)
AM (4)
B4 (6)
BM (7)
other treatment element (99)
Specify*
start 2. element*
3. element: course*
V (1)
AA24 (10)
AAZ1 (11)
AAZ2 (12)
BB24 (13)
BBZ1 (14)
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BBZ2 (15)
CC (17)
DA-EPOCH-R (18)
VZ (2)
A4 (3)
AM (4)
B4 (6)
BM (7)
other treatment element (99)
Specify*
start 3. element*
4. element: course*
V (1)
AA24 (10)
AAZ1 (11)
AAZ2 (12)
BB24 (13)
BBZ1 (14)
BBZ2 (15)
CC (17)
DA-EPOCH-R (18)
VZ (2)
A4 (3)
AM (4)
B4 (6)
BM (7)
other treatment element (99)
Specify*
start 4. element*
5. element: course*
V (1)
AA24 (10)
AAZ1 (11)
AAZ2 (12)
BB24 (13)
BBZ1 (14)
BBZ2 (15)
CC (17)
DA-EPOCH-R (18)
VZ (2)
A4 (3)
AM (4)
B4 (6)
BM (7)
other treatment element (99)
Specify*
start 5. element*
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6. element: course*
V (1)
AA24 (10)
AAZ1 (11)
AAZ2 (12)
BB24 (13)
BBZ1 (14)
BBZ2 (15)
CC (17)
DA-EPOCH-R (18)
VZ (2)
A4 (3)
AM (4)
B4 (6)
BM (7)
other treatment element (99)
Specify*
start 6. element*
7. element: course*
V (1)
AA24 (10)
AAZ1 (11)
AAZ2 (12)
BB24 (13)
BBZ1 (14)
BBZ2 (15)
CC (17)
DA-EPOCH-R (18)
VZ (2)
A4 (3)
AM (4)
B4 (6)
BM (7)
other treatment element (99)
Specify*
start 7. element*
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Eligibility Breast Cancer NCT00054418
Risedronate in Preventing Bone Loss in Premenopausal
Women Receiving Chemotherapy for Primary Breast
Cancer; ODM derived from:
https://clinicaltrials.gov/show/NCT00054418
All rights reserved. Please visit https://medical-data-
models.org/forms/16201
Eligibility Breast Cancer
NCT00054418
Criteria
1. premenopausal women*
Yes
No
≤ 6 months since last menstrual period*
Yes
No
no prior bilateral oophorectomy*
Yes
No
not on estrogen replacement therapy*
Yes
No
if tah is performed, with at least one intact ovary,
or if > 3 months since last menstrual period, then
patients must have premenopausal estrogen
levels ≤ 1 month of study entry*
Yes
No
2. scheduled to undergo adjuvant or neoadjuvant
chemotherapy for primary breast cancer (stages
i-iiib)*
Yes
No
3. ≥ 18 years of age*
Yes
No
4. ecog performance status (ps) 0 or 1*
Yes
No
2. contraindications*
Yes
No
1. hypercalcemia (calcium level > 1mg/dl above
unl ≤ 6 months*
Yes
No
2. hypocalcemia (calcium level > 0.5 mg/dl below
unl ≤ 6 months*
Yes
No
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3. inability to stand or sit upright for at least 30
minutes*
Yes
No
4. known swallowing disorder*
Yes
No
5. bone mineral density t score of ≤ - 2.0 at the
hip or lumbar spine*
Yes
No
a patient with a t score of - 2.1 is ineligible*
Yes
No
a patient with a t score of - 1.9 is eligible*
Yes
No
6. history of vertebral compression fracture*
Yes
No
exception: traumatic fracture of the coccyx would
not exclude a patient from participation*
Yes
No
7. corticosteroids at doses > 5 mg daily of
prednison or equivalent for > 2 weeks in the past
6 months*
Yes
No
8. previous treatment with bisphosphonates*
Yes
No
9. diseases affecting bone metabolism
(hyperthyroidism, hyperparathyroidism, and
hypercortisolism)*
Yes
No
10. history of severe renal impairment or
creatinine > 2.0 mg/dl*
Yes
No
11. malabsorption syndrome*
Yes
No
12. estrogen replacement therapy*
Yes
No
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Eligibility Breast Cancer NCT00054418
13. oral contraceptive use*
Yes
No
14. prior bilateral oophorectomy*
Yes
No
15. pregnant women*
Yes
No
nursing women*
Yes
No
women of childbearing potential who are
unwilling to employ adequate contraception
(condoms, diaphragm, injections, intrauterine
device [iud], surgical sterilization, abstinence,
etc.)*
Yes
No
this study involves an investigational agent whose
genotoxic, mutagenic and teratogenic effects on
the developing fetus and newborn are unknown*
Yes
No
16. dental extraction, root canal, or implants ≤ 3
months prior to registration or planned during
study treatment*
Yes
No
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Eligibility Breast Cancer NCT00054418
NHL-BFM Registry 2012 Treating center
NHL-BFM 2012 Registry. 
Principal Investigators: Birgit Burkhardt and Wilhelm
Woessmann. 
NHL study group University Hospital Münster
All rights reserved. Please visit https://medical-data-
models.org/forms/16202
Treating center
Treating center
Change of treating center: New treating center*
A - Augsburg (1)
KA - Karlsruhe (11)
BB - Berlin-Buch (110)
C - Chemnitz (111)
CB - Cottbus (112)
DT - Dresden Uniklinik (113)
EF - Erfurt (115)
GW - Greifswald (116)
HW - Halle (117)
J - Jena (118)
L - Leipzig (119)
E - Essen (12)
MD - Magdeburg (120)
RO - Rostock (121)
SN - Schwerin (122)
KR - Krefeld (13)
MI - Minden (132)
KK - Köln - Städtisches
Kinderkrankenhaus (14)
MK - München v. Haunersches (15)
B - Berlin Charité (16)
HS - Homburg/Saar (17)
WB - Würzburg (18)
FB - Freiburg (19)
MZ - Mainz (2)
DB - Dornbirn (AT) (201)
FK - Feldkirch (AT) (202)
GZ - Graz (AT) (203)
IB - Innsbruck (AT) (204)
KF - Klagenfurt (AT) (205)
LA - Linz (AT) (206)
LE - Leoben (AT) (207)
LL - Linz (AT) (208)
SC - Schwarzach (AT) (209)
KO - Koblenz (21)
ST - Steyr (AT) (210)
SZ - Salzburg (AT) (211)
W - Wien (212)
KS - Kassel (23)
DA - Datteln (24)
KI - Kiel (26)
MA - Mannheim (28)
AU - St. Augustin (30)
AR - Aarau (CH) (301)
BL - Basel (CH) (302)
LZ - Luzern (CH) (305)
SG - St. Gallen (CH) (306)
Z - Zürich (CH) (307)
BE - Bern (CH) (308)
LB - Lübeck (31)
T - Tübingen (32)
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BI - Bielefeld (33)
M - Münster (34)
MS - München Schwabing (36)
HB - Bremen (4)
D - Düsseldorf (40)
AC - Aachen (41)
BS - Braunschweig (42)
HV - Hannover (45)
H - Heidelberg (5)
HH - Hamburg (52)
PR - Praha (CZ) (5251)
BR - Brno (CZ) (5252)
OL - Oldenburg (53)
G - Göttingen (54)
K - Köln Uniklinik (58)
ER - Erlangen (59)
RG - Regensburg (61)
N - Nürnberg (63)
S - Stuttgart (65)
U - Ulm (71)
DO - Dortmund (76)
SI - Siegen (78)
GI - Gießen (8)
HD - Herdecke (81)
BN - Bonn (85)
TR - Trier (86)
F - Frankfurt (9)
OT – Other (no study center) (999)
Specify*
The new treating center cares since*
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NHL-BFM Registry 2012 Treatment for
lymphoblastic Lymphoma (LBL)
NHL-BFM 2012 Registry. 
Principal Investigators: Birgit Burkhardt and Wilhelm
Woessmann. 
NHL study group University Hospital Münster
All rights reserved. Please visit https://medical-data-
models.org/forms/16203
Treatment for lymphoblastic
Lymphoma (LBL)
Chemotherapy
Start of Prephase*
Start of Protocol Ia*
Start of Protocol Ib*
Start of Protocol M*
Start of Protocol IIa*
Start of Protocol IIb*
Start of Maintenance start*
CNS-Radiotherapy
CNS radiotherapy*
no (1)
yes (2)
Cumulative dose RT*
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NHL-BFM Registry 2012 Treatment
overview
NHL-BFM 2012 Registry. 
Principal Investigators: Birgit Burkhardt and Wilhelm
Woessmann. 
NHL study group University Hospital Münster
All rights reserved. Please visit https://medical-data-
models.org/forms/16204
Treatment overview
Treatment
Treatment branch*
LBL stage I or II (11)
LBL stage III or IV (12)
LBL stage IV CNS positive (Type 2) with
cranial irradiation (13)
Follicular lymphoma: watch and wait (20)
B-NHL R1 (21)
B-NHL R2 (22)
B-NHL R3 (23)
B-NHL R4 (24)
B-NHL R4 CNS positive (25)
PMLBL, DA-EPOCH-R (26)
ALCL, watch and wait (isolated skin
disease) (31)
ALCL, 3 courses (stage I, completely
resected) (32)
ALCL, 6 courses (33)
ALCL, CNS-positive (34)
Other (99)
Specify*
Start of treatment / first day*
End of treatment / last day*
Premature withdrawel*
no (1)
yes (2)
Withdrawel date*
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Eligibility Breast Cancer NCT00063570
Pemetrexed Plus Gemcitabine in Metastatic Breast Cancer
Patients After Receiving Taxane Therapy; ODM derived
from: https://clinicaltrials.gov/show/NCT00063570
All rights reserved. Please visit https://medical-data-
models.org/forms/16205
Eligibility Breast Cancer
NCT00063570
Inclusion Criteria
must have received prior chemotherapy with taxol
(paclitaxel) or taxotere (docetaxel).*
Yes
No
less than 3 different chemotherapy treatments for
metastatic disease.*
Yes
No
prior treatment with hormonal and/or radiation
therapy.*
Yes
No
must have disease that can be measured.*
Yes
No
must be able to take care of self needs for
example personal hygiene*
Yes
No
Exclusion Criteria
must not be pregnant or breast-feeding.*
Yes
No
cancer that has spread to the brain.*
Yes
No
treatment with gemcitabine or pemetrexed*
Yes
No
unable to take folic acid or vitamin b12*
Yes
No
treatment for another cancer within the last 5
years*
Yes
No
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Eligibility Breast Cancer NCT00065533
Pemetrexed as First Line Chemotherapy for Advanced
Breast Cancer; ODM derived from:
https://clinicaltrials.gov/show/NCT00065533
All rights reserved. Please visit https://medical-data-
models.org/forms/16206
Eligibility Breast Cancer
NCT00065533
Inclusion Criteria
be at least 18 years of old.*
Yes
No
have been diagnosed with breast cancer*
Yes
No
at least one year disease-free interval after initial
treatment.*
Yes
No
have pre-study laboratory tests that are within the
requirements of this study.*
Yes
No
be able to visit the doctor's office weekly during
the treatment period.*
Yes
No
Exclusion Criteria
to be pregnant or breastfeeding.*
Yes
No
to be currently taking aspirin or aspirin- like
medicine and unable to stop for a few days during
each cycle of therapy.*
Yes
No
to have received prior chemotherapy for the
treatment of metastatic cancer. patients may have
received prior hormonal treatment.*
Yes
No
to have another illness that your doctor thinks
would make you unable to participate.*
Yes
No
to be unable or not willing to take folic acid and
vitamin b12.*
Yes
No
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Eligibility Breast Cancer NCT00068328
Chemotherapy Decisions and Outcomes in Older Women
With Newly Diagnosed Breast Cancer; ODM derived from:
https://clinicaltrials.gov/show/NCT00068328
All rights reserved. Please visit https://medical-data-
models.org/forms/16209
Eligibility Breast Cancer
NCT00068328
Criteria
histologically confirmed primary adenocarcinoma
of the breast*
Yes
No
operable disease*
Yes
No
invasive and unilateral tumor*
Yes
No
no more than 20 weeks since diagnosis*
Yes
No
t1-4 (tumor size ≥ 1 cm), n0, m0 or*
Yes
No
t1-4, n1-3, m0*
Yes
No
no prior carcinoma in situ, lobular carcinoma in
situ, ductal carcinoma in situ, or invasive breast
cancer*
Yes
No
hormone receptor status:*
Yes
No
any estrogen receptor status*
Yes
No
patient characteristics:*
Yes
No
65 and over*
Yes
No
female*
Yes
No
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other*
Yes
No
no other malignancy except those for which the
patient has completed treatment and is
considered to be at less than 30% risk of
recurrence*
Yes
No
history of non-melanoma skin cancer allowed*
Yes
No
sufficient cognitive function to consent to and
complete interviews*
Yes
No
english or spanish speaking*
Yes
No
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Ministry of Health, Ethiopia- HIV–Exposed
Infant Follow up Card
Form provided by Binyam Tilahun. Source:
http://www.moh.gov.et/ (Ministry of Health, Ethiopia)
All rights reserved. Please visit https://medical-data-
models.org/forms/16212
HIV–Exposed Infant Follow up Card
Demographics
Facility name
Date of Enrollment
Infants Medical record number
Unique "HIV exposed infant- HEI" ID
Infant referred from
Name of Infant
Date of birth
Place of birth
Age at enrollment
Mothers name/caretakers name
Mothers MRN
If "Caretaker" describe relationship
Address:Region
Address: Subcity
Address: Kebelle
Address: House number
Patient contact: phone number
Mothers status
Alive (1)
Dead (2)
Mothers status: if alive
enrolled in HIV/ART care (1)
Not enrolled in HIV/ART care (2)
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Mothers status: if enrolled in HIV/ART care
Within the facility  (1)
Out of the facility (specify) (2)
Mothers status: specify facility
Mothers PMTCT intervention
None  (1)
sdNVP    (2)
AZT + sdNVP + 3TC (3)
Other:(specify regimen & duration) (4)
Mothers PMTCT intervention:specify other
regimen & duration
Infant Antiretroviral prophylaxis
None (1)
SdNVP (2)
SdNVP+AZT  for 7days (3)
Other specify (Regimen & duration) (4)
Infant Antiretroviral prophylaxis: specify other
Regimen & duration
Fathers HIV Status
Positive  (1)
Negative (2)
Unknown (3)
Father status
Alive (1)
Dead (2)
Father status:if alive
enrolled in HIV/ART care (1)
Not enrolled in HIV/ART care (2)
Father status:if on ART, specify ART number
Immunizations:BCG
Yes
No
Immunizations:OPV
1 (1)
2 (2)
3 (3)
Immunizations:DPT or Pentavalent
1 (1)
2 (2)
3 (3)
Immunizations:Measles
Yes
No
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Follow up chart
Date of visit
Age
Weight
kg
Infant length
cm
Head circumference
cm
Growth pattern
normal (1)
if there is growth failure (2)
Developmental milestones
Appropriate (A)
Delay (D)
Regression (R)
Infant Feeding  practice
Infant is on exclusive breastfeeding (1)
Infant is on exclusive replacement
feeding (2)
Infant  is on mixed feeding (3)
Infant is on breastfeeding and
complementar (4)
Breast condition
1 (1)
2 (2)
3 (3)
4 (4)
Abnormal findings or diagnosis that may suggest
HIV infection
none (0)
Generalized lymphadenopathy (1)
Oral Candidiasis (2)
Purulent ear discharge (3)
Findings suggestive of pneumonia or
lower  respiratory tract infections (4)
Persistent diarrhea (5)
Hepatosplenomegaly (6)
Severe skin lesions (7)
Persisten (8)
Treatment/medication given
Cotrimoxazole prophylaxis:dose
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Cotrimoxazole prophylaxis: Adherence
Good (1)
Fair (2)
Poor (3)
HIV test done?
No test done (0)
Sample collected for DNA PCR (1)
Sample collected for DNA PCR (1)
DNA/PCR  result negative (2)
DNA/PCR  result Positive (3)
Rapid antibodytest result negative (4)
Rapid antibodytest result positive (5)
DNA/PCR test result inditerminate (6)
Conclusion & Decision
Infant has no clinical or laboratory
evidence of HIV infection currently but
needs follow up (0)
Infant has clinical evidence of HIV
infection and is referred for Pediatric
HIV/ART care with in the facility (1)
Infant has lab evidence of HIV infection
and referred to pediatric HIV/ART care
with in the facility (2)
infant has clincial and laboratory
evidence of HIV infection and referred for
pediatric HIV care/ART with in the facility
(3)
Infant has clinical evidence of HIV
infection and is referred for Pediatric
HIVcare/ART outside the facility (4)
Infant has laboratory evidence of HIV
infection and is referred for Pediatric HIV
care/ART outside the facility (5)
Infant has clinical and laboratory
evidence of HIV infection and referred for
Pediatric HIV care/ART outside the
facility (6)
Infant is confirmed not to have clinical
and lab evidence of HIV infection and
discharged from follow up (7)
Any Other conclusion Specify (Including
Death & lost to follow up) (8)
Conclusion & Decision: Specify Any Other
conclusion (Including  Death & lost to follow up)
Name of Health Care provider who referred or
discharged the Infant from follow up
Signature of Health Care provider who referred or
discharged the Infant from follow up
Date of discharge
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Eligibility Breast Cancer NCT00081510
Anastrozole Plus Lonafarnib (SCH 66336) or Plus Placebo
for the Treatment of Advanced Breast Cancer (P03480);
ODM derived from:
https://clinicaltrials.gov/show/NCT00081510
All rights reserved. Please visit https://medical-data-
models.org/forms/16213
Eligibility Breast Cancer
NCT00081510
Inclusion Criteria
postmenopausal women who have histologically-
confirmed breast cancer with the following
characteristics:*
Yes
No
estrogen and/or progesterone receptor positive,*
Yes
No
locally advanced disease*
Yes
No
distant metastatic disease, stage 4*
Yes
No
subjects eligible for single-agent treatment with
aromatase inhibitors for current disease.*
Yes
No
subjects taking biophosphonates are allowed if
they begin bisphosphonate therapy at least two
weeks prior to randomization.*
Yes
No
measurable disease (masses with clearly defined
margins on radiological images and at least one
diameter >=20 mm[>=10 mm if spiral ct]) or
evaluable disease (masses with margins not
clearly defined on radiological images or with no
diameter >= 20 mm). subjects with bone disease
only are permitted if disease is evaluable.*
Yes
No
ecog performance status of 0 or 1.*
Yes
No
sufficient bone marrow reserve.*
Yes
No
adequate hepatic and renal function: laboratory
values within protocol requirements.*
Yes
No
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Exclusion Criteria
subjects who have received more than one
regimen of cytotoxic chemotherapy for advanced
disease.*
Yes
No
subjects with with clinically apparent brain
metastases or extensive visceral disease,
including extensive hepatic involvement or
pulmonary lymphangitic spread of tumor.*
Yes
No
subjects with prior treatments with ftis.*
Yes
No
subjects with a known or suspected
hypersensitivity to any excipients in the lonafarnib
formulation (providone, poloxamer 188,
croscarmellose sodium, silicon dioxide, and
magnesium stearate).*
Yes
No
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Eligibility Breast Cancer NCT00102219
A Study of Pemetrexed Plus Doxorubicin Given to Patients
With Advanced Breast Cancer; ODM derived from:
https://clinicaltrials.gov/show/NCT00102219
All rights reserved. Please visit https://medical-data-
models.org/forms/16215
Eligibility Breast Cancer
NCT00102219
Inclusion Criteria
diagnosis of locally advanced or metastatic
breast cancer that is not amenable to local
treatment.*
Yes
No
patients must be chemo-naive or have received
only neoadjuvant and/or adjuvant chemotherapy.*
Yes
No
at least one measurable lesion.*
Yes
No
no chemotherapy within 4 weeks prior to
enrollment.*
Yes
No
signed informed consent from the patient.*
Yes
No
Exclusion Criteria
prior chemotherapy for metastatic breast cancer.*
Yes
No
prior treatment with any anthracyclines or
anthracenedione-containing regimen.*
Yes
No
treatment within the last 30 days with any drug
that has not received regulatory approval.*
Yes
No
pregnancy and/or breast feeding.*
Yes
No
inability or unwillingness to take folic acid or
vitamin b12 supplementation.*
Yes
No
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Eligibility Breast Cancer NCT00126451
A Clinical Trial of Oral Suberoylanilide Hydroxamic Acid
(SAHA) in Patients With Relapsed or Refractory Breast,
Colorectal and Non-Small Cell Lung Cancer (0683-
011)(TERMINATED); ODM derived from:
https://clinicaltrials.gov/show/NCT00126451
All rights reserved. Please visit https://medical-data-
models.org/forms/16216
Eligibility Breast Cancer
NCT00126451
Inclusion Criteria
patient must be 18 years or older with confirmed
diagnosis of breast adenocarcinoma, colorectal
carcinoma or non-small cell lung cancer*
Yes
No
patients must have relapsed or refractory disease
following at least one chemotherapeutic
treatment regimen.*
Yes
No
has a measurable, positron emission tomography
(pet) assessable lesion*
Yes
No
adequate blood, liver, bone marrow and kidney
functions*
Yes
No
has not received any chemotherapy for at least 4
weeks prior to entry in this study*
Yes
No
agrees to take adequate measures to prevent
pregnancy.*
Yes
No
Exclusion Criteria
patient has had prior treatment with histone
deacetylase (hdac) inhibitor.*
Yes
No
patient has had treatment with investigational
agents within the last 30 days.*
Yes
No
patient has active infection or had intravenous (iv)
antibiotic, antiviral, or antifungal medications
within 2 weeks of the start of study drugs.*
Yes
No
1 / 2
patient has hiv, hepatitis b or hepatitis c
infection.*
Yes
No
patient is pregnant or lactating.*
Yes
No
patient has allergy to any component of the study
drug.*
Yes
No
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Ministry of Health, Ethiopia- HMIS HIV
exposed infant logbook card
Form provided by Binyam Tilahun. Source:
http://www.moh.gov.et/ (Ministry of Health, Ethiopia)
All rights reserved. Please visit https://medical-data-
models.org/forms/16220
HIV exposed infant logbook card
Logbook card
Registration number
Date of enrollment
Name of Infant
Name of father
Name of grandfather
Name of caregiver
Infant´s Medical record number (MRN)
Date of birth
Age at enrollment
Specify if age at enrollment is in weeks or in
months
Sex
male (1)
female (2)
Infant referred from (Name of source)
Did the infant receive ARV prophylaxis at birth?
Yes
No
Does the infant come for follow up at the age of 6
weeks?
Yes
No
Does the infant come for follow up at the age of
10 weeks?
Yes
No
Does the infant come for follow up at the age of
14 weeks?
Yes
No
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Does the infant come for follow up at the age of 4
months?
Yes
No
Does the infant come for follow up at the age of 5
months?
Yes
No
Does the infant come for follow up at the age of 6
months?
Yes
No
Does the infant come for follow up at the age of 9
months?
Yes
No
Does the infant come for follow up at the age of
12 months?
Yes
No
Does the infant come for follow up at the age of
15 months?
Yes
No
Does the infant come for follow up at the age of
18 months?
Yes
No
Final outcome
infected (I)
not infected (NI)
Enrolled in care?
Yes
No
If enrolled in care,please specify
Pre (1)
ART (2)
No (3)
UAN (4)
Remarks
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Eligibility Breast Cancer NCT00131950
Effect of Lifestyle Factors and Hormone Function on Breast
Density in Healthy Hispanic Women Who Are Undergoing
Mammography for Breast Cancer Screening; ODM derived
from: https://clinicaltrials.gov/show/NCT00131950
All rights reserved. Please visit https://medical-data-
models.org/forms/16221
Eligibility Breast Cancer
NCT00131950
Criteria
healthy hispanic women*
Yes
No
registered patient at the erie family health
centers' west town or humboldt park clinics*
Yes
No
no screening mammography within the past 12
months*
Yes
No
no abnormality on clinical breast exam*
Yes
No
no history of breast cancer*
Yes
No
hormone receptor status:*
Yes
No
not specified*
Yes
No
patient characteristics:*
Yes
No
40 and over*
Yes
No
female*
Yes
No
menopausal status*
Yes
No
not specified*
Yes
No
performance status*
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Yes
No
not specified*
Yes
No
life expectancy*
Yes
No
not specified*
Yes
No
hematopoietic*
Yes
No
not specified*
Yes
No
hepatic*
Yes
No
not specified*
Yes
No
renal*
Yes
No
not specified*
Yes
No
other*
Yes
No
not pregnant*
Yes
No
prior concurrent therapy:*
Yes
No
biologic therapy*
Yes
No
not specified*
Yes
No
chemotherapy*
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Yes
No
not specified*
Yes
No
endocrine therapy*
Yes
No
not specified*
Yes
No
radiotherapy*
Yes
No
not specified*
Yes
No
surgery*
Yes
No
not specified*
Yes
No
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Ministry of Health, Ethiopia- Health Center /
Clinic / Hospital Antenatal Care Register
Form provided by Binyam Tilahun. Source:
http://www.moh.gov.et/ (Ministry of Health, Ethiopia)
All rights reserved. Please visit https://medical-data-
models.org/forms/16222
Antenatal Care Register
Personal information
Serial number
Medical record number
Age
years
Last menstrual period
Focused antenatal care
Visit Number for basic care
Date of visit
Gestational Age in weeks (GA)
TT provided
Yes
No
TT Dose number
Ferrous sulphate provided
Yes
No
Folic acid provided
Yes
No
Identified and advised on danger signs
Yes
No
HIV Assessment,  Care and Follow up
HIV Test accepted
Yes
No
HIV Test result
R (1)
NR (2)
I (3)
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HIV Test result received with post test counseling
Yes
No
Counseled on infant feeding
Yes
No
Referred for care, treatment, and support
Yes
No
Partner HIV Test result
R (1)
NR (2)
I (3)
Type of ARV prophylaxis provided
NVP  (1)
AZT+3TC+NVP (2)
Appointment
Remarks
Total count
Count first attendances
Total number HIV tests accepted
Total number of positive HIV Tests
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Eligibility Breast Cancer NCT00146601
Fulvestrant in Premenopausal Women With Hormone
Receptor-Positive Breast Cancer; ODM derived from:
https://clinicaltrials.gov/show/NCT00146601
All rights reserved. Please visit https://medical-data-
models.org/forms/16223
Eligibility Breast Cancer
NCT00146601
Inclusion Criteria
histologically or cytologically confirmed invasive
breast cancer, with stage iv disease.*
Yes
No
tumors must be positive for estrogen receptors,
progesterone receptors, or both.*
Yes
No
patients must be premenopausal.*
Yes
No
prior anti-estrogen therapy (with or without
ovarian suppression)*
Yes
No
platelet count > 100,000/mm3*
Yes
No
age older than 18 years*
Yes
No
ecog performance status 0-2*
Yes
No
Exclusion Criteria
hormonal treatment for metastatic disease*
Yes
No
pregnant or breast-feeding women*
Yes
No
postmenopausal*
Yes
No
concurrent hormonal therapy or chemotherapy*
Yes
No
prior fulvestrant therapy*
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Yes
No
more than three prior chemotherapy regimens for
metastatic disease*
Yes
No
concurrent, long-term anticoagulation therapy*
Yes
No
severe, uncontrolled intercurrent illness*
Yes
No
history of hypersensitivity to castor oil*
Yes
No
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Eligibility Breast Cancer NCT00148668
Preoperative Herceptin/Navelbine Versus
Taxotere/Carboplatin/Herceptin in HER-2 Positive Breast
Cancer; ODM derived from:
https://clinicaltrials.gov/show/NCT00148668
All rights reserved. Please visit https://medical-data-
models.org/forms/16224
Eligibility Breast Cancer
NCT00148668
Inclusion Criteria
patients with stage ii or iii breast cancer*
Yes
No
her-2 positive tumors*
Yes
No
older than 18 years of age*
Yes
No
eastern cooperative oncology group (ecog)
performance status of greater or equal to 1.*
Yes
No
anc > 1,500/mm3*
Yes
No
hemoglobin > 9gm/dl*
Yes
No
platelets > 100,000mm3*
Yes
No
creatinine < 2mg/dl*
Yes
No
glucose < 200mg/dl*
Yes
No
bilirubin < 1.5 x uln*
Yes
No
Exclusion Criteria
previous treatment with herceptin, taxanes,
doxorubicin or other anthracycline-type therapy,
navelbine, or platinum-based therapy.*
Yes
No
pregnant or breast-feeding women*
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Yes
No
serious illness, or medical or psychiatric
condition*
Yes
No
uncontrolled infections*
Yes
No
active or severe cardiovascular or pulmonary
disease*
Yes
No
patients with left ventricular ejection fraction <
50%*
Yes
No
peripheral neuropathy of any etiology that
exceeds grade 1*
Yes
No
prior history of malignancy*
Yes
No
uncontrolled diabetes*
Yes
No
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Ministry of Health, Ethiopia- Health Center /
Clinic / Hospital Delivery Register
Form provided by Binyam Tilahun. Source:
http://www.moh.gov.et/ (Ministry of Health, Ethiopia)
All rights reserved. Please visit https://medical-data-
models.org/forms/16225
Delivery Register
Personal information
Serial number
Medical Record Number
Name of woman
Age
Labor and maternal outcome
Delivery date and time
Delivery Type
SVD (1)
Caesarean section (2)
Forceps / Vacuum Extraction (3)
Other procedures (4)
Delivery Type: Episiotomy
Yes
No
Maternal status
Stable (1)
Unstable / deteriorated and referred to
the next facility (2)
Died (3)
Obstetric complications
Eclampsia
Yes
No
Antepartum hemorrhage
Yes
No
Ruptured uterus
Yes
No
Postpartum hemorrhage
Yes
No
Premature Rupture of Membranes
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Yes
No
Sepsis
Yes
No
Obstructed / prolonged labor
Yes
No
Other complication
Yes
No
Complication referred
Yes
No
Newborn outcome
Newborn: life birth
Yes
No
Apgar score at first minute
Apgar score at 5 min
Sex
male (1)
female (2)
Weight
grams
Weight less than 2500 g
Yes
No
At term
Yes
No
Preterm delivery
Yes
No
Stillbirth
Yes
No
Live birth, died before arrival at facility
Yes
No
Live birth, died after arrival or delivery in facility
Yes
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Register
No
Vitamin A
Yes
No
BCG given
Yes
No
OPV given
Yes
No
Tetracycline eye ointment
Yes
No
Vitamin K
Yes
No
Newborns Medical record number (MRN)
HIV Assessment and Services
HIV counseling offered
Yes
No
HIV testing offered
Yes
No
HIV Test accepted
Yes
No
HIV Test result
R (1)
NR (2)
I (3)
HIV positive delivery
Yes
No
Type of ARV prophylaxis provided to mother
NVP  (1)
AZT+3TC+NVP (2)
Type of ARV prophylaxis provided to newborn
NVP  (1)
AZT+NVP (2)
Counseled on infant feeding options
Yes
No
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Mother and newborn referred to chronic care
Yes
No
Total count
Number of deliveries
Number of c-sections
Number of Maternal deaths
Number of life births
Count of all weights
Count of weights under 2500g
Count of stillbirths
Count newborn deaths
Count HIV positive tests
Count HIV positive deliveries
Count deliveries with both mother and newborn
on prophylaxis
Remarks
Managed by (name and signature)
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Eligibility Breast Cancer NCT00148694
Preoperative Cisplatin in Early Stage Breast Cancer; ODM
derived from: https://clinicaltrials.gov/show/NCT00148694
All rights reserved. Please visit https://medical-data-
models.org/forms/16226
Eligibility Breast Cancer
NCT00148694
Inclusion Criteria
all tumors must be er-, pr- and her-2 negative.*
Yes
No
age > 18 years*
Yes
No
ecog performance status of less than or equal to
1*
Yes
No
absolute neutrophil count (anc) > 1,500/mm3*
Yes
No
hemoglobin > 9mm/dl*
Yes
No
platelets > 100,000/mm3*
Yes
No
creatinine < 1.5mg/dl*
Yes
No
glucose < 200mg/dl*
Yes
No
bilirubin < 1.5 x upper limit of normal (uln)*
Yes
No
sgot < 3.0 x uln*
Yes
No
Exclusion Criteria
prior chemotherapy treatment*
Yes
No
pregnant or breast-feeding women*
Yes
No
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history of serious illness, medical or psychiatric
condition requiring medical management*
Yes
No
uncontrolled infection*
Yes
No
renal dysfunction*
Yes
No
active or severe cardiovascular or pulmonary
disease*
Yes
No
peripheral neuropathy of any etiology that
exceeds grade 1*
Yes
No
prior history of malignancy*
Yes
No
uncontrolled diabetes*
Yes
No
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Eligibility Breast Cancer NCT00153894
Effects of Exercise Intervention on Insulin Levels in Breast
Cancer Survivors; ODM derived from:
https://clinicaltrials.gov/show/NCT00153894
All rights reserved. Please visit https://medical-data-
models.org/forms/16228
Eligibility Breast Cancer
NCT00153894
Inclusion Criteria
history of pathologically confirmed stage i-iiia
invasive breast cancer*
Yes
No
adjuvant chemotherapy and/or radiation must be
completed at least 3 months prior to enrollment*
Yes
No
body mass index > 25 and/or a body composition
analysis of >30*
Yes
No
Exclusion Criteria
patients taking herceptin*
Yes
No
evidence of residual or distant disease*
Yes
No
use of any medication expected to affect insulin
levels*
Yes
No
baseline exercise of more than 20 minutes two
times per week*
Yes
No
active malignancy*
Yes
No
diabetes mellitus*
Yes
No
heart disease or uncontrolled hypertension*
Yes
No
presence of any condition that might be expected
to impact a participant's ability to perform
physical activity*
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Yes
No
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AGE-Reader CARLA Follow-up
Greiser KH, Kluttig A, Schumann B, Swenne CA, Kors JA,
Kuss O, Haerting J, Schmidt H, Thiery J, Werdan K.
Cardiovascular diseases, risk factors and short-term heart
rate variability in an elderly general population: the CARLA
study 2002-2006. Eur J Epidemiol. 2009;24(3):123-42
http://www.ncbi.nlm.nih.gov/pubmed/19199053
"Cross-sectional data of a population-based cohort
including 1,779 women and men aged 45-83 years were
used to analyse associations of time and frequency domain
measures of HRV (derived from 5-min ECG segments) with
age, behavioural and biomedical risk factors and disease in
the whole sample and in a "healthy" subgroup."
publication granted by 
Dr. rer. medic. Alexander Kluttig, MPH
Leiter des Studienzentrums Halle der Nationalen Kohorte
Institut für Medizinische Epidemiologie, Biometrie und
Informatik 
Martin-Luther-Universität Halle-Wittenberg 
Magdeburger Str. 8 
D-06097 Halle/Saale
All rights reserved. Please visit https://medical-data-
models.org/forms/16230
AGE-Reader CARLA Follow-up
General information
Subject ID
Device number of AGE-Reader
Examiner ID
Date
Beginning of investigation
1. Storage number
2. Age
years
3. Sex
Male (1)
Female (2)
4. Have you applied rich cream today?
Yes
No
5. Have you ever applied self tanning cream?
Yes
No
If yes, when was the last time you used self
tanning cream?
Less than one week ago (1)
More than one week but less than one
month ago (2)
More than one month but less than three
months ago (3)
More than three months ago (4)
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7. How many days/weeks did you apply self
tanning cream?
Results
8. Body site used for AGE measurement
Left forearm (1)
Left upper arm (2)
Right forearm (3)
Right upper arm (4)
Other site (5)
8.a If another site was used, please specify
9. Type of measurement
Single measurement (1)
Triple measurement (2)
10. Mean AGE value
11. Degree of reflection
12. Was the measurement performed?
Yes
No
13. If measurement was not performed, please
indicate reason
Rich cream (1)
Scars or other changes of skin (2)
Brown or black skin color (3)
Other reasons (4)
13. If other reason applies, please specify
15. Comments
End of investigation
Data entry
1st data entry: DNo.
1st data entry: Date
2nd data entry: DNo.
2nd data entry: Date
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Ministry of Health, Ethiopia- Health Center /
Clinic / Hospital Postnatal Care Register
Form provided by Binyam Tilahun. Source:
http://www.moh.gov.et/ (Ministry of Health, Ethiopia)
All rights reserved. Please visit https://medical-data-
models.org/forms/16233
Postnatal Care Register
Personal information
Serial number
Medical Record Number of mother
Age of mother
Infants date of birth
Infants Medical record number
Sex of baby
male (1)
female (2)
Postnatal assessment
Visit number
Date of visit
Normal exam of mother
Yes
No
Complicated and managed
Yes
No
Complicated and referred
Yes
No
Vitamin A for mother
Yes
No
Mother counseled on Feeding Practice
Yes
No
Body weight of infant
grams
Breastfeeding
Yes
No
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Referred
Yes
No
Dead (age in days)
BCG given today
Yes
No
OPV given today
Yes
No
HIV test done?
Yes
No
HIV Test result
R (1)
NR (2)
I (3)
Type of ARV prophylaxis provided to mother
NVP  (1)
AZT+3TC+NVP (2)
Type of ARV prophylaxis provided to newborn
NVP  (1)
AZT+3TC+NVP (2)
Feeding decision
Yes
No
Mother and newborn referred for chronic care
and support
Yes
No
Count number of first visits
Count newborn deaths in first week of life
2 / 2
Ministry of Health, Ethiopia- Health Center / Clinic / Hospital Postnatal
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Blood pressure measurement CARLA
Follow-up
Greiser KH, Kluttig A, Schumann B, Swenne CA, Kors JA,
Kuss O, Haerting J, Schmidt H, Thiery J, Werdan K.
Cardiovascular diseases, risk factors and short-term heart
rate variability in an elderly general population: the CARLA
study 2002-2006. Eur J Epidemiol. 2009;24(3):123-42
http://www.ncbi.nlm.nih.gov/pubmed/19199053
"Cross-sectional data of a population-based cohort
including 1,779 women and men aged 45-83 years were
used to analyse associations of time and frequency domain
measures of HRV (derived from 5-min ECG segments) with
age, behavioural and biomedical risk factors and disease in
the whole sample and in a "healthy" subgroup."
publication granted by 
Dr. rer. medic. Alexander Kluttig, MPH
Leiter des Studienzentrums Halle der Nationalen Kohorte
Institut für Medizinische Epidemiologie, Biometrie und
Informatik 
Martin-Luther-Universität Halle-Wittenberg 
Magdeburger Str. 8 
D-06097 Halle/Saale
All rights reserved. Please visit https://medical-data-
models.org/forms/16234
Blood pressure measurement
CARLA Follow-up
General information
Subject ID
Date of measurement
Beginning of measurement
Examiner ID
Device number
Specific incidents
No specific incidents (0)
Specific incidents (1)
Refusal of measurement (9)
Please specify incidents if necessary
Circumference of upper arm (exact to 0.1 cm)
cm
Cuff size
small (1)
large (2)
Which arm?
Left (1)
Right (2)
After 5 min of rest
Time
1 / 3
1st blood pressure measurement
mm/Hg
Pulse
/min
Pulse quality
regular (0)
irregular (1)
not assessable (8)
not measured (9)
EE
Yes
No
After 3 min. of rest
Time
2nd blood pressure measurement
mm/Hg
Pulse
/min
Pulse quality
regular (0)
irregular (1)
not assessable (8)
not measured (9)
EE
Yes
No
After 3 min. of rest
Time
3rd blood pressure measurement
mm/Hg
Pulse
/min
Pulse quality
regular (0)
irregular (1)
not assessable (8)
not measured (9)
EE
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Blood pressure measurement CARLA Follow-up
Yes
No
End of measurement
Data entry
First data entry: DNo.
First data entry: Date
Second data entry: DNo.
Second data entry: Date
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Anthropometry Record CARLA Follow-up
Greiser KH, Kluttig A, Schumann B, Swenne CA, Kors JA,
Kuss O, Haerting J, Schmidt H, Thiery J, Werdan K.
Cardiovascular diseases, risk factors and short-term heart
rate variability in an elderly general population: the CARLA
study 2002-2006. Eur J Epidemiol. 2009;24(3):123-42
http://www.ncbi.nlm.nih.gov/pubmed/19199053
"Cross-sectional data of a population-based cohort
including 1,779 women and men aged 45-83 years were
used to analyse associations of time and frequency domain
measures of HRV (derived from 5-min ECG segments) with
age, behavioural and biomedical risk factors and disease in
the whole sample and in a "healthy" subgroup."
publication granted by 
Dr. rer. medic. Alexander Kluttig, MPH
Leiter des Studienzentrums Halle der Nationalen Kohorte
Institut für Medizinische Epidemiologie, Biometrie und
Informatik 
Martin-Luther-Universität Halle-Wittenberg 
Magdeburger Str. 8 
D-06097 Halle/Saale
All rights reserved. Please visit https://medical-data-
models.org/forms/16235
Anthropometry Record CARLA
Follow-up
General information
Subject ID
Examiner ID
Date
Anthropometry
Beginning of examination
Height (correct to 0.1 cm)
>= 0
cm
Body weight (as reported by subject)
>= 0
kg
Body weight (correct to 100 g)
>= 0
kg
BMI
Waist circumference (correct to 0.1 cm)
cm
Hip circumference (correct to 0.1 cm)
cm
End of examination
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Transition to AAI measurement and ECG
Beginning of resting time
Data entry
1st data entry: DNo.
1st data entry: Date
2nd data entry: DNo.
2nd data entry: Date
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Ankle-Arm Index CARLA
Greiser KH, Kluttig A, Schumann B, Swenne CA, Kors JA,
Kuss O, Haerting J, Schmidt H, Thiery J, Werdan K.
Cardiovascular diseases, risk factors and short-term heart
rate variability in an elderly general population: the CARLA
study 2002-2006. Eur J Epidemiol. 2009;24(3):123-42
http://www.ncbi.nlm.nih.gov/pubmed/19199053
"Cross-sectional data of a population-based cohort
including 1,779 women and men aged 45-83 years were
used to analyse associations of time and frequency domain
measures of HRV (derived from 5-min ECG segments) with
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Ankle-Arm Index CARLA
General information
Subject ID
Examiner ID
Date
Time (Beginning)
Circumference measurement
Right arm
cm
Cuff size: right arm
small (1)
large (2)
Left arm
cm
Cuff size: left arm
small (1)
large (2)
Right lower leg
cm
Cuff size: right leg
small (1)
large (2)
Left lower leg
cm
Cuff size: left leg
1 / 4
small (1)
large (2)
Blood pressure measurement I: Both arms
simultaneously
Device number: right arm
Blood pressure: right arm
mm/Hg
Pulse: right arm
/min
Device number: left arm
Blood pressure: left arm
mm/Hg
Pulse: Left arm
/min
Indicate arm with higher syst. blood pressure
left arm (left arm)
right arm (right arm)
Blood pressure measurement II: Right leg
and arm with higher syst. blood pressure
simultaneously
Device number: right leg
Device number: arm
Blood pressure measurement II: First
measurement
Beginning
Blood pressure: right leg
mm/Hg
Pulse: right leg
/min
Blood pressure: arm
mm/Hg
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Blood pressure measurement II: Second
measurement
Blood pressure: right leg
mm/Hg
Pulse: right leg
/min
Blood pressure: arm
mm/Hg
Blood pressure measurement III: Left leg
and arm with higher syst. blood pressure
simultaneously
Device number: left leg
Device number: arm
Blood pressure measurement III: First
measurement
Blood pressure: left leg
mm/Hg
Pulse: left leg
/min
Blood pressure: arm
mm/Hg
Blood pressure measurement III: Second
measurement
Blood pressure: left leg
mm/Hg
Pulse: left leg
/min
Blood pressure: arm
mm/Hg
Further information
Time (End)
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Comments
Data entry
First data entry: DNo.
First data entry: Date
Second data entry: DNo.
Second data entry: Date
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Anthropometry Record CARLA
General information
Subject ID
Examiner ID
Date
Anthropometry
Beginning of examination
Height (correct to 0.1 cm)
>= 0
cm
Body weight (as reported by subject)
>= 0
kg
Body weight (correct to 100 g)
>= 0
kg
BMI
Waist circumference (correct to 0.1 cm)
cm
Hip circumference (correct to 0.1 cm)
cm
End of examination
1 / 2
Transition to AAI measurement and ECG
Beginning of resting time
Data entry
First data entry: DNo.
First data entry: Date
Second data entry: DNo.
Second data entry: Date
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General Information about Interview:
PaReSiS UKH
General Information about Interview: PaReSiS UKH
Rehabilitation Study: "Partizipatives
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General Information about Interview:
PaReSiS UKH
Default Itemgroup
ID-Nummer
Zeitpunkt der Befragung
t1 (1)
t2 (2)
1. Beginn der Befragung
Datum
Uhrzeit
2. Anwesenheit anderer in die Befragung
eingreifender Personen
Anwesenheit anderer in die Befragung
eingreifender Personen
Ja
Nein
wenn ja, wer
3. Ausfüllen, wenn die Befragung
abgebrochen wurde
Uhrzeit der 1. Wiederaufnahme
Datum der 1. Wiederaufnahme (falls abweichend)
Uhrzeit der 2. Wiederaufnahme
Datum der 2. Wiederaufnahme (falls abweichend)
Grund für Unmöglichkeit oder Abbruch der
Befragung
1 / 10
Verwirrtheit
Ja
Nein
Artikulationsschwäche/Aphasie
Ja
Nein
schlechter Allgemeinzustand
Ja
Nein
fehlende Kooperationsbereitschaft
Ja
Nein
Terminalstadium
Ja
Nein
Teilnehmer lehnt weitere Befragung ab
Ja
Nein
Andere
Ja
Nein
Falls Andere Gründe, bitte näher ausführen
5. Familienstand
Familienstand
ledig (1)
verheiratet (2)
eheähnliche Gemeinschaft (3)
getrennt lebend/geschieden (4)
verwitwet (5)
6. Leben Sie derzeit
Leben Sie derzeit
zusammen mit einem Ehepartner (1)
zusammen mit einem Lebenspartner (2)
zusammen mit Eltern/Verwandten (3)
alleine (4)
Pflegeeinrichtung (5)
Sonstiges (6)
Falls Sonstiges, bitte näher ausführen
7. Haben Sie einen gesetzlichen Betreuer
(nach § 1896 BGB/ § 1902) und wenn ja,
wen?
Haben Sie einen gesetzlichen Betreuer (nach §
1896 BGB/ § 1902) und wenn ja, wen?
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ja (1)
nein (2)
weiß ich nicht (3)
keine Angabe (4)
Name des Betreuers 1
Art der Betreuung (Betreuer 1)
Name des Betreuers 2
Art der Betreuung (Betreuer 2)
Name des Betreuers 3
Art der Betreuung (Betreuer 3)
Mehr als 3 Betreuer
Ja
Nein
Bekommen Sie im Haushalt durch Familie
und Bekannte Hilfe und wenn ja, durch
wen?
Bekommen Sie im Haushalt durch Familie und
Bekannte Hilfe und wenn ja, durch wen?
ja (1)
nein (2)
weiß ich nicht (3)
keine Angabe (4)
Person 1
Person 2
Person 3
Mehr als 3 Personen
Ja
Nein
9. Werden Sie durch Familienmitglieder
und Bekannte gepflegt und wenn ja, durch
wen?
Werden Sie durch Familienmitglieder und
Bekannte gepflegt und wenn ja, durch wen?
ja (1)
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nein (2)
weiß ich nicht (3)
keine Angabe (4)
Person 1
Person 2
Person 3
Mehr als 3 Personen
Ja
Nein
10. Erhalten Sie sonstige Hilfe durch
Familienmitglieder und Bekannte und
wenn ja, durch wen?
Erhalten Sie sonstige Hilfe durch
Familienmitglieder und Bekannte und wenn ja,
durch wen?
ja (1)
nein (2)
weiß nicht (3)
keine Angabe (4)
Person 1
Person 2
Person 3
Art der Hilfe
Mehr als 3 Personen
Ja
Nein
Würden Sie eine von den genannten
Personen als Hauptunterstützungsperson
bezeichnen? Wenn ja, welche Person ist
das?
Würden Sie eine von den genannten Personen
als Hauptunterstützungsperson bezeichnen?
Wenn ja, welche Person ist das?
ja_______ (weiter mit Frage 13) (1)
nein, keine Hauptunterstützungsperson
(weiter mit Frage 14) (2)
Falls ja, wer?
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Wie oft können Sie die Hilfe dieser
Hauptunterstützungsperson in Anspruch
nehmen?
Wie oft können Sie die Hilfe dieser
Hauptunterstützungsperson in Anspruch
nehmen?
andauernd, rund um die Uhr (1)
täglich, stundenweise (2)
mehrmal wöchentlich (3)
einmal pro Woche (4)
keine Angabe (5)
13. Wie würden Sie Ihre Beziehung zur
Hauptunterstützungsperson am ehesten
beschreiben?
Wir haben eine innige, harmonische Beziehung
stimmt genau (1)
stimmt überwiegend (2)
stimmt ein wenig (3)
stimmt gar nicht (4)
Ich kann dieser Person voll und ganz vertrauen
stimmt genau (1)
stimmt überwiegend (2)
stimmt ein wenig (3)
stimmt gar nicht (4)
Unsere Beziehung ist oft konfliktgeladen
stimmt genau (1)
stimmt überwiegend (2)
stimmt ein wenig (3)
stimmt gar nicht (4)
14. Welche Hilfsmittel stehen Ihnen im
Moment zur Verfügung?
keine
Ja
Nein
Gehhilfen
Ja
Nein
Falls Gehhilfen, welche?
Rollstuhl
Ja
Nein
Falls Rollstuhl, bitte spezifizieren
Mobilitätshilfen
Ja
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Nein
Falls Mobilitätshilfen, welche?
Inkontinenzhilfen
Ja
Nein
Falls Inkontinenzhilfen, welche?
Hilfen gegen Dekubitus
Ja
Nein
Falls Hilfen gegen Dekubitus, welche?
Orthesen/ Schienen
Ja
Nein
Falls Orthesen, welche?
Sehhilfen
Ja
Nein
Falls Sehhilfen, welche?
Toilettenhilfen
Ja
Nein
Falls Toilettenhilfe, welche?
Andere
Ja
Nein
Falls Andere, bitte spezifizieren
15. Haben Sie seit unserer letzten
Befragung die Krankenkasse gewechselt?
Haben Sie seit unserer letzten Befragung die
Krankenversicherung gewechselt?
ja (1)
nein (2)
keine Angabe (3)
Falls ja, wie heißt Ihre neue
Krankenversicherung?
6 / 10
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16. Haben Sie eine private
Pflegezusatzversicherung?
Haben Sie eine private
Pflegezusatzversicherung?
ja (1)
nein (2)
keine Angabe (3)
17. Wurde seit unserer letzten Befragung
eine Einstufung/ Neueinstufung Ihrer
Pflegebedürftigkeit vorgenommen
Wurde seit unserer letzten Befragung eine
Einstufung/ Neueinstufung Ihrer
Pflegebedürftigkeit vorgenommen
ja (1)
nein (2)
keine Angabe (3)
18. aktuelle Pflegestufe
keine
Ja
Nein
Pflegestufe I
Ja
Nein
Pflegestufe II
Pflegestufe III
Ja
Nein
19. Ist eine Einstufung/ Neueinstufung
geplant?
Ist eine Einstufung/ Neueinstufung geplant?
ja (weiter mit Frage 20) (1)
nein (weiter mit Frage 21) (2)
keine Angabe  (3)
weiß ich nicht (4)
20. Falls ja, ist eine Einstufung /
Neueinstufung
Falls ja, ist eine Einstufung / Neueinstufung
noch nicht beantragt (1)
beantragt (2)
beantragt, aber abgelehnt (3)
Widerspruch läuft (4)
keine Angabe (5)
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21. Welche Hauptleitung der
Pflegeversicherung nehmen Sie in
Anspruch?
Welche Hauptleitung der Pflegeversicherung
nehmen Sie in Anspruch?
Sachleistung (1)
Geldleistung (2)
Kombinationsleistung (3)
Andere (4)
Falls Andere, bitte spezifizieren
22. Sind seit unserer letzten Befragung in
Ihrer Wohnung Maßnahmen zur
Wohnraumanpassung durchgeführt
worden?
Sind seit unserer letzten Befragung in Ihrer
Wohnung Maßnahmen zur Wohnraumanpassung
durchgeführt worden?
ja (weiter mit Frage 23) (1)
nein (weiter mit Frage 25) (2)
keine Angabe (3)
weiß ich nicht (4)
23. Welche wohnraumanpassenden
Maßnahmen wurden durchgeführt?
Welche wohnraumanpassenden Maßnahmen
wurden durchgeführt?
24. Wer trägt die Kosten hierfür?
Wer trägt die Kosten hierfür?
25. Sind solche Maßnahmen geplant?
Sind solche Maßnahmen geplant?
ja (weiter mit Frage 26) (1)
nein (weiter mit Frage 27) (2)
keine Angabe (3)
weiß ich nicht (4)
26. Sind die geplanten
Wohnungsanpassungen
Sind die geplanten Wohnungsanpassungen
noch nicht beantragt (1)
beantragt (2)
beantragt, aber abgelehnt (3)
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Widerspruch läuft (4)
27. Wie oft verlassen Sie Ihre Wohnung?
Wie oft verlassen Sie Ihre Wohnung?
pro Tag (1)
pro Woche (2)
pro Monat (3)
Bitte Häufigkeit spezifizieren
28. Auf welche Weise nehmen Sie
Arztbesuche war?
Auf welche Weise nehmen Sie Arztbesuche war?
Ich fahre selbstständig und alleine zum
Arzt (1)
Ich fahre in Begleitung von___zum Arzt
(2)
Mein Arzt kommt zu mir nach Hause. ->
Wie oft?____ (3)
Name der begleitenden Person
Häufigkeit der Hausbesuche
29. Falls Sie regelmäßig den Arzt
aufsuchen, welche Verkehrsmittel nutzen
Sie dazu?
eigenen PKW
Ja
Nein
PKW von Angehörigen
Ja
Nein
Bus, Straßenbahn
Ja
Nein
Taxi
Ja
Nein
Fahrdienst
Ja
Nein
Fahrrad
Ja
Nein
Sonstige
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Ja
Nein
Falls Sonstige, bitte näher benennen
30. Wie haben sich seit Ihrem
Schlaganfall Ihre Kontakte zu anderen
entwickelt?
Wie haben sich seit Ihrem Schlaganfall Ihre
Kontakte zu anderen entwickelt?
Ich habe neue  Bekannte gewonnen (1)
Keine Veränderung zu vorher (2)
Einige Kontakte habe ich aufgeben
müssen (3)
Ich habe nahezu alle wichtigen Kontakte
verloren (4)
31. Wie haben sich Ihre Interessen und
Hobbys nach dem Schlaganfall
entwickelt?
Wie haben sich Ihre Interessen und Hobbys nach
dem Schlaganfall entwickelt?
Ich habe neue Pläne und Interessen (1)
unverändert (2)
Ich habe einige Interessen aufgeben
müssen (3)
Ich habe (fast) alle Interessen/ Hobbys
verloren (4)
32. Welches sind Ihre wichtigsten
Interessen und Hobbys?
Welches sind Ihre wichtigsten Interessen und
Hobbys?
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Blood pressure measurement
CARLA
General information
Subject ID
Date of measurement
Time (Beginning)
Examiner ID
Device number
Specific incidents
No specific incidents (0)
Specific incidents (1)
Refusal of measurement (9)
Please specify incidents if necessary
Circumference of left upper arm (exact to 0.1 cm)
cm
Cuff size
small (1)
large (2)
After 5 min of rest
Time
1st blood pressure measurement
mm/Hg
1 / 3
Pulse
/min
Pulse quality
regular (0)
irregular (1)
not assessable (8)
not measured (9)
After 3 min. of rest
Time
2nd blood pressure measurement
mm/Hg
Pulse
/min
Pulse quality
regular (0)
irregular (1)
not assessable (8)
not measured (9)
After 3 min. of rest
Time
3rd blood pressure measurement
mm/Hg
Pulse
/min
Pulse quality
regular (0)
irregular (1)
not assessable (8)
not measured (9)
End of measurement
Data entry
First data entry: DNo.
First data entry: Date
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Second data entry: DNo.
Second data entry: Date
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Physical Function Cardiovascular Health
Study (CHS)
Documentation part: Record 9 Physical Function
The Cardiovascular Health Study (CHS) was initiated by
the National Heart, Lung and Blood Institute (NHLBI) in
1987 to determine the risk factors for development and
progression of cardiovascular disease (CVD) in older
adults, with an emphasis on subclinical measures. The
study recruited 5,888 adults aged 65 or older at entry in
four U.S. communities and conducted extensive annual
clinical exams between 1989-1999 along with semi-annual
phone calls, events adjudication, and subsequent data
analyses and publications. Additional data were collected
by studies ancillary to CHS. With the exception of annual
clinic visits, these activities are still ongoing.
Data obtained from: https://chs-nhlbi.org/
Permission granted by: Erika Enright.
All rights reserved. Please visit https://medical-data-
models.org/forms/16240
Physical Function Cardiovascular
Health Study (CHS)
Assessment of physical functioning
1. Do you have difficulty walking one-half a mile,
about 5-6 blocks?
no (0)
yes (1)
could do it, but don't for other reason (2)
don't know or refuse (9)
1. Do you have difficulty walking one-half a mile,
about 5-6 blocks?  
How much difficulty do you have?
some (1)
a lot (2)
unable to do (3)
don't know (9)
1. Do you have difficulty walking one-half a mile,
about 5-6 blocks? 
C. What is the main symptom that causes you to
have difficulty or prevents you form doing the
activity?
1. Do you have difficulty walking one-half a mile,
about 5-6 blocks?
D. What is the main condition that causes you to
have difficulty or prevents you from doing the
activity?
2. Do you have any difficulty walking around your
home?
no (0)
yes (1)
could do it, but don't for other reason (2)
don't know or refuse (9)
2. Do you have any difficulty walking around your
home?
B. How much difficulty do you have?
some (1)
a lot (2)
unable to do (3)
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don't know (9)
2. Do you have any difficulty walking around your
home?
C. What is the main symptom that causes you to
have difficulty or prevents you form doing the
activity?
2. Do you have any difficulty walking around your
home?
D. What is the main condition that causes you to
have difficulty or prevents you from doing the
activity?
3. Do you have any difficulty getting out of bed or
chair?
no (0)
yes (1)
could do it, but don't for other reason (2)
don't know or refuse (9)
3. Do you have any difficulty getting out of bed or
chair?
B. How much difficulty do you have?
some (1)
a lot (2)
unable to do (3)
don't know (9)
3. Do you have any difficulty getting out of bed or
chair?
C. What is the main symptom that causes you to
have difficulty or prevents you form doing the
activity?
3. Do you have any difficulty getting out of bed or
chair?
D. What is the main condition that causes you to
have difficulty or prevents you from doing the
activity?
4. Do you have any difficulty walking up 10
steps?
no (0)
yes (1)
could do it, but don't for other reason (2)
don't know or refuse (9)
4. Do you have any difficulty walking up 10
steps? 
B. How much difficulty do you have?
some (1)
a lot (2)
unable to do (3)
don't know (9)
4. Do you have any difficulty walking up 10
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steps? 
C. What is the main symptom that causes you to
have difficulty or prevents you form doing the
activity?
4. Do you have any difficulty walking up 10
steps? 
D. What is the main condition that causes you to
have difficulty or prevents you from doing the
activity?
5. Because of health or physical problems, do
you have any difficulty or are you unable to:
...do heavy housework, like scrubbing floors or
washing windows; or yard work, like raking
leaves, or moving?
no (0)
yes (1)
could do it, but don't for other reason (2)
don't know or refuse (9)
5. Because of health or physical problems, do
you have any difficulty or are you unable to:
...do heavy housework, like scrubbing floors or
washing windows; or yard work, like raking
leaves, or moving? 
B. How much difficulty do you have?
some (1)
a lot (2)
unable to do (3)
don't know (9)
5. Because of health or physical problems, do
you have any difficulty or are you unable to:
...do heavy housework, like scrubbing floors or
washing windows; or yard work, like raking
leaves, or moving? 
C. What is the main symptom that causes you to
have difficulty or prevents you form doing the
activity?
5. Because of health or physical problems, do
you have any difficulty or are you unable to:
...do heavy housework, like scrubbing floors or
washing windows; or yard work, like raking
leaves, or moving? 
D. What is the main condition that causes you to
have difficulty or prevents you from doing the
activity?
6. Because of health or physical problems, do
you have any difficulty or are you unable to:
...do light housework?
no (0)
yes (1)
could do it, but don't for other reason (2)
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don't know or refuse (9)
6. Because of health or physical problems, do
you have any difficulty or are you unable to:
...do light housework? 
B. How much difficulty do you have?
some (1)
a lot (2)
unable to do (3)
don't know (9)
6. Because of health or physical problems, do
you have any difficulty or are you unable to:
...do light housework? 
C. What is the main symptom that causes you to
have difficulty or prevents you form doing the
activity?
6. Because of health or physical problems, do
you have any difficulty or are you unable to:
...do light housework? 
D. What is the main condition that causes you to
have difficulty or prevents you from doing the
activity?
7. Because of health or physical problems, do
you have any difficulty or are you unable to:
...shop for personal items?
no (0)
yes (1)
could do it, but don't for other reason (2)
don't know or refuse (9)
7. Because of health or physical problems, do
you have any difficulty or are you unable to:
...shop for personal items? 
B. How much difficulty do you have?
some (1)
a lot (2)
unable to do (3)
don't know (9)
7. Because of health or physical problems, do
you have any difficulty or are you unable to:
...shop for personal items? 
C. What is the main symptom that causes you to
have difficulty or prevents you form doing the
activity?
7. Because of health or physical problems, do
you have any difficulty or are you unable to:
...shop for personal items?
D. What is the main condition that causes you to
have difficulty or prevents you from doing the
activity?
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8. Because of health or physical problems, do
you have any difficulty or are you unable to:
...prepare your own meals?
no (0)
yes (1)
could do it, but don't for other reason (2)
don't know or refuse (9)
8. Because of health or physical problems, do
you have any difficulty or are you unable to:
...prepare your own meals? 
B. How much difficulty do you have?
some (1)
a lot (2)
unable to do (3)
don't know (9)
8. Because of health or physical problems, do
you have any difficulty or are you unable to:
...prepare your own meals? 
C. What is the main symptom that causes you to
have difficulty or prevents you form doing the
activity?
8. Because of health or physical problems, do
you have any difficulty or are you unable to:
...prepare your own meals? 
D. What is the main condition that causes you to
have difficulty or prevents you from doing the
activity?
9. Because of health or physical problems, do
you have any difficulty or are you unable to:
...manage your money, such as paying bills?
no (0)
yes (1)
could do it, but don't for other reason (2)
don't know or refuse (9)
9. Because of health or physical problems, do
you have any difficulty or are you unable to:
...manage your money, such as paying bills? 
B. How much difficulty do you have?
some (1)
a lot (2)
unable to do (3)
don't know (9)
9. Because of health or physical problems, do
you have any difficulty or are you unable to:
...manage your money, such as paying bills? 
C. What is the main symptom that causes you to
have difficulty or prevents you form doing the
activity?
9. Because of health or physical problems, do
you have any difficulty or are you unable to:
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...manage your money, such as paying bills? 
D. What is the main condition that causes you to
have difficulty or prevents you from doing the
activity?
10. Because of health or physical problems, do
you have any difficulty or are you unable to:
...use the telephone?
no (0)
yes (1)
could do it, but don't for other reason (2)
don't know or refuse (9)
10. Because of health or physical problems, do
you have any difficulty or are you unable to:
...use the telephone? 
B. How much difficulty do you have?
some (1)
a lot (2)
unable to do (3)
don't know (9)
10. Because of health or physical problems, do
you have any difficulty or are you unable to:
...use the telephone? 
C. What is the main symptom that causes you to
have difficulty or prevents you form doing the
activity?
10. Because of health or physical problems, do
you have any difficulty or are you unable to:
...use the telephone? 
D. What is the main condition that causes you to
have difficulty or prevents you from doing the
activity?
11. Because of health or physical problems, do
you have any difficulty or are you unable to:
...eat, including feeding yourself?
no (0)
yes (1)
could do it, but don't for other reason (2)
don't know or refuse (9)
11. Because of health or physical problems, do
you have any difficulty or are you unable to:
...eat, including feeding yourself?  
B. How much difficulty do you have?
some (1)
a lot (2)
unable to do (3)
don't know (9)
11. Because of health or physical problems, do
you have any difficulty or are you unable to:
...eat, including feeding yourself?  
C. What is the main symptom that causes you to
have difficulty or prevents you form doing the
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activity?
11. Because of health or physical problems, do
you have any difficulty or are you unable to:
...eat, including feeding yourself?  
D. What is the main condition that causes you to
have difficulty or prevents you from doing the
activity?
12. Because of health or physical problems, do
you have any difficulty or are you unable to:
...dress yourself?
no (0)
yes (1)
could do it, but don't for other reason (2)
don't know or refuse (9)
12. Because of health or physical problems, do
you have any difficulty or are you unable to:
...dress yourself? 
B. How much difficulty do you have?
some (1)
a lot (2)
unable to do (3)
don't know (9)
12. Because of health or physical problems, do
you have any difficulty or are you unable to:
...dress yourself? 
C. What is the main symptom that causes you to
have difficulty or prevents you form doing the
activity?
12. Because of health or physical problems, do
you have any difficulty or are you unable to:
...dress yourself? 
D. What is the main condition that causes you to
have difficulty or prevents you from doing the
activity?
13. Because of health or physical problems, do
you have any difficulty or are you unable to:
...bathe or shower?
no (0)
yes (1)
could do it, but don't for other reason (2)
don't know or refuse (9)
13. Because of health or physical problems, do
you have any difficulty or are you unable to:
...bathe or shower? 
B. How much difficulty do you have?
some (1)
a lot (2)
unable to do (3)
don't know (9)
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13. Because of health or physical problems, do
you have any difficulty or are you unable to:
...bathe or shower?
C. What is the main symptom that causes you to
have difficulty or prevents you form doing the
activity?
13. Because of health or physical problems, do
you have any difficulty or are you unable to:
...bathe or shower? 
D. What is the main condition that causes you to
have difficulty or prevents you from doing the
activity?
14. Because of health or physical problems, do
you have any difficulty or are you unable to:
...use the toilet, including getting to the toilet?
no (0)
yes (1)
could do it, but don't for other reason (2)
don't know or refuse (9)
14. Because of health or physical problems, do
you have any difficulty or are you unable to:
...use the toilet, including getting to the toilet? 
B. How much difficulty do you have?
some (1)
a lot (2)
unable to do (3)
don't know (9)
14. Because of health or physical problems, do
you have any difficulty or are you unable to:
...use the toilet, including getting to the toilet? 
C. What is the main symptom that causes you to
have difficulty or prevents you form doing the
activity?
14. Because of health or physical problems, do
you have any difficulty or are you unable to:
...use the toilet, including getting to the toilet? 
D. What is the main condition that causes you to
have difficulty or prevents you from doing the
activity?
15. Do you have any difficulty lifting or carrying
something as heavy as 10 pounds, such as a bag
of groceries?
no (0)
yes (1)
could do it, but don't for other reason (2)
don't know or refuse (9)
15. Do you have any difficulty lifting or carrying
something as heavy as 10 pounds, such as a bag
of groceries? 
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B. How much difficulty do you have?
some (1)
a lot (2)
unable to do (3)
don't know (9)
15. Do you have any difficulty lifting or carrying
something as heavy as 10 pounds, such as a bag
of groceries? 
C. What is the main symptom that causes you to
have difficulty or prevents you form doing the
activity?
15. Do you have any difficulty lifting or carrying
something as heavy as 10 pounds, such as a bag
of groceries? 
D. What is the main condition that causes you to
have difficulty or prevents you from doing the
activity?
16. Do you have any difficulty reaching out?
no (0)
yes (1)
could do it, but don't for other reason (2)
don't know or refuse (9)
16. Do you have any difficulty reaching out? 
B. How much difficulty do you have?
some (1)
a lot (2)
unable to do (3)
don't know (9)
16. Do you have any difficulty reaching out?
C. What is the main symptom that causes you to
have difficulty or prevents you form doing the
activity?
16. Do you have any difficulty reaching out? 
D. What is the main condition that causes you to
have difficulty or prevents you from doing the
activity?
17. Do you have any difficulty gripping with your
hands?
no (0)
yes (1)
could do it, but don't for other reason (2)
don't know or refuse (9)
17. Do you have any difficulty gripping with your
hands? 
B. How much difficulty do you have?
some (1)
a lot (2)
unable to do (3)
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don't know (9)
17. Do you have any difficulty gripping with your
hands?
C. What is the main symptom that causes you to
have difficulty or prevents you form doing the
activity?
17. Do you have any difficulty gripping with your
hands? 
D. What is the main condition that causes you to
have difficulty or prevents you from doing the
activity?
For the questions above, were any OTHER
symptoms or conditions reported?
Yes
No
Other symptoms:
Other conditions/diseases:
Date of interview
Interviewer
Interview:
First edit:
Second edit:
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Blood samples CARLA
Greiser KH, Kluttig A, Schumann B, Swenne CA, Kors JA,
Kuss O, Haerting J, Schmidt H, Thiery J, Werdan K.
Cardiovascular diseases, risk factors and short-term heart
rate variability in an elderly general population: the CARLA
study 2002-2006. Eur J Epidemiol. 2009;24(3):123-42
http://www.ncbi.nlm.nih.gov/pubmed/19199053
"Cross-sectional data of a population-based cohort
including 1,779 women and men aged 45-83 years were
used to analyse associations of time and frequency domain
measures of HRV (derived from 5-min ECG segments) with
age, behavioural and biomedical risk factors and disease in
the whole sample and in a "healthy" subgroup."
publication granted by 
Dr. rer. medic. Alexander Kluttig, MPH
Leiter des Studienzentrums Halle der Nationalen Kohorte
Institut für Medizinische Epidemiologie, Biometrie und
Informatik 
Martin-Luther-Universität Halle-Wittenberg 
Magdeburger Str. 8 
D-06097 Halle/Saale
All rights reserved. Please visit https://medical-data-
models.org/forms/16241
Blood samples CARLA
General information
Subject ID
B01 Examiner ID
B02 Date
B02 Time
Preliminary questions
B03 Examiner: Does the subject agree to the
taking of blood samples?
Yes (1)
Yes, but without storage of blood for
follow-up projects (Do not take tubes 5-
9!) (2)
No (End) (3)
B03 If not, please specify reason:
B04 Do you suffer from haemophilia?
Yes (End) (1)
No (2)
B05 Have you been administered an
anticoagulant?
Yes (1)
No (2)
B06 Have you already eaten today?
Yes (1)
No (Skip question B07) (2)
B07 When was the last time you ate something
today?
1 / 3
B08 Are you allergic to latex?
Yes (Please use latex-free gloves when
taking the blood sample!) (1)
No (2)
Taking of blood samples
1. Serum-Gel-Monovette (9 ml)
ml
2. EDTA-Monovette (2.7 ml)
ml
3. EDTA-Monovette (9 ml)
ml
4. Citrate-Monovette (coagulation tube, 5 ml)
ml
5. Serum-Gel-Monovette (9 ml)
ml
6. EDTA-Monovette (2.7 ml)
ml
7. Serum-Gel-Monovette (9 ml)
ml
8. EDTA-Monovette (9 ml)
ml
9. Serum-Gel-Monovette (9 ml)
ml
10. Li-Heparin-Monovette (9 ml)
ml
11. EDTA-Monovette (4.9 ml)
ml
12. EDTA-Monovette (9 ml)
ml
13. Li-Heparin-Monovette (4.9 ml)
ml
Final information
B10 Examiner: Has the subject stated to suffer
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from hepatitis?
Yes (1)
No (2)
B11 Examiner: Has the subject stated to suffer
from an HIV-infection?
Yes (1)
No (2)
B12 Could the blood samples be taken?
Yes (1)
No (2)
B12 If not, please specify reason:
B13 End of blood taking (exact time)
B14 Comments
Data entry
First data entry: DNo.
First data entry: Date
Second data entry: DNo.
Second data entry: Date
3 / 3
Blood samples CARLA
Record Medical Exam and
Echocardiography CARLA
Greiser KH, Kluttig A, Schumann B, Swenne CA, Kors JA,
Kuss O, Haerting J, Schmidt H, Thiery J, Werdan K.
Cardiovascular diseases, risk factors and short-term heart
rate variability in an elderly general population: the CARLA
study 2002-2006. Eur J Epidemiol. 2009;24(3):123-42
http://www.ncbi.nlm.nih.gov/pubmed/19199053
"Cross-sectional data of a population-based cohort
including 1,779 women and men aged 45-83 years were
used to analyse associations of time and frequency domain
measures of HRV (derived from 5-min ECG segments) with
age, behavioural and biomedical risk factors and disease in
the whole sample and in a "healthy" subgroup."
publication granted by 
Dr. rer. medic. Alexander Kluttig, MPH
Leiter des Studienzentrums Halle der Nationalen Kohorte
Institut für Medizinische Epidemiologie, Biometrie und
Informatik 
Martin-Luther-Universität Halle-Wittenberg 
Magdeburger Str. 8 
D-06097 Halle/Saale
All rights reserved. Please visit https://medical-data-
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Record Medical Exam and
Echocardiography CARLA
Record
Subject ID
Date of general investigation/interview
Beginning of waiting time before medical exam
Entry of subject into examination room
Beginning of medical exam (arrival of physician)
End of medical exam (if known)
A medical exam has been performed
Yes
No
An echocardiography has been performed
Yes
No
Site of echocardiography
Functional diagnostics department (1)
Outpatient department (2)
ID of physician
Date
If medical exam and general
investigation/interview did not take place on the
same day, please indicate reason
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Physician not available (1)
Technical problems / Malfunction
echocardiography device (2)
Subject not available (3)
If echocardiography and general
investigation/interview did not take place on the
same day, please indicate reason
Physician not available (1)
Technical problems / Malfunction
echocardiography device (2)
Subject not available (3)
Please specify in detail
Documentation by (examiner ID)
Date of documentation
The subject has been informed about the results
of the general investigation by phone.
Yes
No
Date of telephonic information
ID of informing physician
Second Appointment
A medical exam has been performed
Yes
No
An echocardiography has been performed
Yes
No
Site of echocardiography
Functional diagnostics department (1)
Outpatient department (2)
ID of physician
Date
Beginning of waiting time before medical exam
Entry of subject into examination room
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Beginning of medical exam (arrival of physician)
End of medical exam (if known)
Documentation by (examiner ID)
Date of documentation
Data entry
1st data entry: DNo.
1st data entry: Date
2nd data entry: DNo.
2nd data entry: Date
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Eligibility Breast Cancer NCT00155259
Docetaxel, Cisplatin and Capecitabine as Neoadjuvant
Chemotherapy for Locally Advanced Breast Cancer; ODM
derived from: https://clinicaltrials.gov/show/NCT00155259
All rights reserved. Please visit https://medical-data-
models.org/forms/16243
Eligibility Breast Cancer
NCT00155259
Inclusion Criteria
women with histological proven labc, without
metastasis, and no prior therapy. labc is defined
as follows：*
Yes
No
1. tumor more than 5 cm in diameter*
Yes
No
2. tumor involvement of chest wall (ribs or
intercostals or serratus anterior muscles) or skin
(ipsilateral cutaneous edema, ulceration, or
satellite nodules)*
Yes
No
3. clinical evident inflammatory carcinoma*
Yes
No
4. ipsilateral fixed axillary adenopathy*
Yes
No
measurable disease by physical examination,
breast sonography and other image study*
Yes
No
kps≧ 70%*
Yes
No
adequate bone marrow reserve, defined as white
blood cell (wbc)≧ 3,500/ mm3, absolute
neutrophil count (anc)≧ 1,500/mm3, platelets ≧
100,000/mm3*
Yes
No
adequate liver and kidney function: total bilirubin
≦ 2.0 mg/dl, serum alanine transaminases (alt)
and aspartate transaminase (ast) ≦ 3 times upper
normal limit, serum creatinine ≦ 1.5 mg/dl*
Yes
No
patients must be ≦ 65 years old*
Yes
No
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signed informed consent*
Yes
No
Exclusion Criteria
patients who have received prior treatment
(including hormonal therapy, chemotherapy,
radiotherapy or biological therapy) for labc.
concomitant use of above therapy will no be
allowed.*
Yes
No
pregnant or lactating woman*
Yes
No
metastases disease other than regional lymph
node metastases (supraclavicular lymph node
metastases is not eligible)*
Yes
No
prior serious cardiac conditions such as angina,
myocardial infarction, cardiomyopathy, severe
cardiovascular disease or cardiac arrhythmias*
Yes
No
serious concomitant systemic disorders
incompatible with the study (at the discretion of
the investigator)*
Yes
No
secondary malignancy in past five years before
entry of the study (except in situ carcinoma of the
cervix, or adequately treated basal cell carcinoma
of the skin)*
Yes
No
active infection (at the discretion of the
investigator)*
Yes
No
significant neurological (such as seizures) or
psychiatric disorder*
Yes
No
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Eligibility Breast Cancer NCT00156130
Accelerated Radiotherapy Outcomes in Women; ODM
derived from: https://clinicaltrials.gov/show/NCT00156130
All rights reserved. Please visit https://medical-data-
models.org/forms/16246
Eligibility Breast Cancer
NCT00156130
Criteria
Inclusion Criteria
1. the female patient has a histological diagnosis
of invasive carcinoma of the breast, and no
evidence of metastatic disease.*
Yes
No
2. has had a lumpectomy (including segmental
resection and partial mastectomy), that is,
surgical excision of the tumour with a rim of
normal tissue.*
Yes
No
3. patient has not had an axillary dissection, or
for patients who have had an axillary dissection,
all nodes are negative for metastatic disease.*
Yes
No
Exclusion Criteria
1. tumour greater than 5 cm in greatest diameter
on pathological examination.*
Yes
No
2. the presence of invasive or intraductal
(noninvasive) breast cancer involving the surgical
margins.*
Yes
No
3. clinical evidence prior to surgery of infiltration
of the skin of the involved breast such as edema,
ulceration, or fixation of the tumour to underlying
muscle, or inflammatory breast cancer.*
Yes
No
4. bilateral malignancy of the breast
(synchronous or metachronous).*
Yes
No
5. more than one primary invasive tumour in the
same breast.*
Yes
No
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6. previous surgery for breast cancer.*
Yes
No
7. pathological status of axilla is unknown.*
Yes
No
8. status for adjuvant systemic therapy not
determined.*
Yes
No
9. for patients not treated with adjuvant
chemotherapy: unable to commence radiation
therapy within 16 weeks of last surgical
procedure on the breast.*
Yes
No
10. for patients treated with adjuvant
chemotherapy: unable to commence radiation
therapy within 8 weeks of the last dose of
chemotherapy.*
Yes
No
11. serious nonmalignant disease (eg.
cardiovascular, renal, etc.) which would preclude
surgical or radiation treatment.*
Yes
No
12. currently pregnant or lactating.*
Yes
No
13. breast deemed too large to permit
satisfactory radiation (ie. separation > 25 cm).*
Yes
No
14. previous concomitant malignancies of any
type except squamous, or basal cell carcinomas
of the skin, or carcinoma in situ of the cervix
which have been effectively treated.*
Yes
No
15. geographic inaccessibility for follow-up.*
Yes
No
16. psychiatric or addictive disorders which
preclude obtaining informed consent or
adherence to the protocol.*
Yes
No
2 / 2
Eligibility Breast Cancer NCT00156130
Eligibility Breast Cancer NCT00160901
Complementary Therapies for the Reduction of Side Effects
During Chemotherapy for Breast Cancer; ODM derived
from: https://clinicaltrials.gov/show/NCT00160901
All rights reserved. Please visit https://medical-data-
models.org/forms/16247
Eligibility Breast Cancer
NCT00160901
Inclusion Criteria
indication for chemotherapy for breast cancer for
at least 3 cycles*
Yes
No
Exclusion Criteria
prior chemotherapy within 12 months*
Yes
No
use of herbal or nutritional supplements or other
complementary or alternative medications ≥ 7
days prior to start of chemotherapy and during
the trial*
Yes
No
allergy to study medication*
Yes
No
selenium intoxication*
Yes
No
current use of cumarins or other medication
influencing the coagulation system*
Yes
No
edema in case of impaired cardial or renal
function*
Yes
No
other severe medical condition*
Yes
No
psychiatric or central neurological disorders*
Yes
No
regular fluid intake < 2000 ml per day*
Yes
No
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Eligibility Breast Cancer NCT00162812
Topoisomerase II Alpha Gene Amplification and Protein
Overexpression Predicting Efficacy of Epirubicin; ODM
derived from: https://clinicaltrials.gov/show/NCT00162812
All rights reserved. Please visit https://medical-data-
models.org/forms/16250
Eligibility Breast Cancer
NCT00162812
Inclusion Criteria
1. histologically-confirmed breast cancer
(operable, locally advanced or inflammatory)*
Yes
No
2. age less than 70 years*
Yes
No
3. female patient*
Yes
No
4. tumor size 2 cm at ultrasound examination.*
Yes
No
5. er-negative tumors defined according to
immunohistochemistry (i.e. < 10% of positive
cells after immunostaining).*
Yes
No
6. multifocal and multicentric breast tumors are
allowed if all foci are er-negative.*
Yes
No
7. fixed and frozen samples from the primary
tumor, obtained before treatment with epirubicin,
must be available for evaluation of biological
markers (topo ii alpha gene and protein, her-2
gene, p-53 gene, oligonucleotides microarrays).*
Yes
No
8. written informed consent before study
registration.*
Yes
No
9. performance status 0 or 1 (ecog scale)*
Yes
No
10. normal cbc, hepatic and renal functions*
Yes
No
11. normal left ventricular ejection fraction by
echocardiography or muga scan*
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Yes
No
12. negative pregnancy test for all women of
childbearing potential. patients of childbearing
potential must implement adequate non-
hormonal measures to avoid pregnancy during
treatment.*
Yes
No
Exclusion Criteria
1. metastatic breast cancer*
Yes
No
2. serious medical conditions like:*
Yes
No
1. congestive heart failure or unstable angina
pectoris, previous history of myocardial infarction
within 1 year from study entry, uncontrolled
arrhythmias.*
Yes
No
2. history of significant neurologic or psychiatric
disorders*
Yes
No
3. active uncontrolled infection*
Yes
No
4. active peptic ulcer, unstable diabetes mellitus*
Yes
No
3. concomitant contralateral invasive breast
cancer*
Yes
No
4. concurrent treatment with hormonal
replacement therapy*
Yes
No
5. concurrent treatment with any other anti-
cancer therapy*
Yes
No
6. previous treatment with anthracyclines for
breast cancer*
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Yes
No
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Eligibility Breast Cancer NCT00166543
Three Doses of TAS-108 to Treat Recurrent or Recurrent
Inoperable Breast Cancer; ODM derived from:
https://clinicaltrials.gov/show/NCT00166543
All rights reserved. Please visit https://medical-data-
models.org/forms/16252
Eligibility Breast Cancer
NCT00166543
Inclusion Criteria
postmenopausal females*
Yes
No
histologically or cytologically confirmed diagnosis
of breast carcinoma*
Yes
No
locally advanced or locally recurrent inoperable or
metastatic breast carcinoma with documented
disease progression*
Yes
No
has laboratory documentation of positive
estrogen receptor (er) and/or progesterone
receptor (pgr) status, and has responded to the
standard first or second line hormonal anti-tumor
therapy given*
Yes
No
has received and whose disease progressed
after one or two prior systemic hormonal anti-
tumor therapies*
Yes
No
performance status of greater than or equal to 2
on the zubrod scale*
Yes
No
predicted life expectancy of greater than or equal
to 12 weeks*
Yes
No
must give written informed consent*
Yes
No
measurable disease according to the response
evaluation criteria in solid tumors (recist) criteria*
Yes
No
absolute granulocyte count of greater than
1,500/meql, platelet count greater than
75,000/meql, and a hemoglobin of greater than
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10 g/dl*
Yes
No
adequate liver and renal function as defined by a
bilirubin of less than 1.5 times the upper limit of
normal and a creatinine of less than 1.5 times the
upper limit of normal*
Yes
No
transaminases must be less than 2.5 times the
upper limit of normal except for patients with liver
metastases who may have transaminases less
than 5 times the upper limit of normal.*
Yes
No
the patient has recovered from all previous anti-
cancer treatment related to toxicities to at least
grade 1.*
Yes
No
all previous investigational drugs must be
stopped at least four weeks before
commencement of treatment with tas-108.*
Yes
No
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Eligibility Breast Cancer NCT00192062
A Trial of Gemcitabine Combined With Vinorelbine as First
Line Chemotherapy for Metastatic Breast Cancer; ODM
derived from: https://clinicaltrials.gov/show/NCT00192062
All rights reserved. Please visit https://medical-data-
models.org/forms/16253
Eligibility Breast Cancer
NCT00192062
Criteria
histological or cytological diagnosis of breast
carcinoma with evidence of unresectable, locally
recurrent, or metastatic disease. lesions should
not be amenable to surgery or radiation of
curative intent.*
Yes
No
presence of metastatic or local-regional recurrent
disease, according to the american joint
committee on cancer (greenz, et al, 2002).*
Yes
No
uni-dimensionally measurable lesions with clearly
defined margin that are clearly measurable by
following methods according to computerized
tomography (ct), chest x-ray or clinical
examination, according to recist criteria
(therasse, et al, 2002).*
Yes
No
no prior chemotherapy for metastatic or
locoregionally recurrent disease. prior adjuvant or
neoadjuvant chemotherapy with anthracyclines
based regimen is mandatory. the time from the
last dose of prior adjuvant chemotherapy and
study entry must be at least 30 days and patients
must have completely recovered from all acute
chemotherapy related toxicities (with exception of
alopecia).*
Yes
No
prior radiotherapy must be completed at least 30
days before study entry.*
Yes
No
no concurrent hormonal therapy for mbc.  prior
hormonal therapy is allowed, the time from the
last dose of prior hormonal therapy for breast
cancer to study enrollment must be at least 1
week.*
Yes
No
exclusion criteria -*
Yes
No
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have received treatment within the last 30 days
with an investigational drug for any indication
before study entry.*
Yes
No
concurrent administration of other tumor therapy,
including cytotoxic chemotherapy, surgery of
cancer, radiotherapy, hormonal therapy and
immunotherapy (including herceptin).*
Yes
No
active infection that in the opinion of the
investigator would compromise the patient's
ability to tolerate therapy, unless adequately
treated.*
Yes
No
pregnancy or breast-feeding.*
Yes
No
serious concomitant disorders that would
compromise the safety of the patient or
compromise the patient's ability to complete the
study, at the discretion of the investigator.*
Yes
No
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Eligibility Breast Cancer NCT00193076
Combination Gemcitabine, Carboplatin With or Without
Trastuzumab in Patients With Metastatic Breast Cancer;
ODM derived from:
https://clinicaltrials.gov/show/NCT00193076
All rights reserved. Please visit https://medical-data-
models.org/forms/16259
Eligibility Breast Cancer
NCT00193076
Inclusion Criteria
to be included in this study, you must meet the
following criteria:*
Yes
No
locally advanced or metastatic breast cancer*
Yes
No
measurable disease as per recist criteria*
Yes
No
no prior chemotherapy in the metastatic breast
setting*
Yes
No
prior chemotherapy and/or hormonal therapy for
early stage breast cancer*
Yes
No
adjuvant herceptin is allowed*
Yes
No
prior radiation therapy in either the metastatic or
early stage setting*
Yes
No
patients may have received any number of
hormonal therapies*
Yes
No
age >18 years*
Yes
No
only women are eligible for the study*
Yes
No
able to perform activities of daily living with
minimal assistance*
Yes
No
normal organ and bone marrow function*
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Yes
No
patients who will be receiving trastuzumab must
have normal heart function*
Yes
No
sign a written informed consent document*
Yes
No
Exclusion Criteria
you cannot participate in this study if any of the
following apply to you:*
Yes
No
received prior chemotherapy for metastatic breast
cancer*
Yes
No
known leptomeningeal carcinomatosis*
Yes
No
uncontrolled brain metastasis*
Yes
No
uncontrolled intercurrent illness*
Yes
No
pregnant or lactating*
Yes
No
history of other non-breast cancer malignancy*
Yes
No
received prior chemotherapy for early stage
breast cancer within 6 months*
Yes
No
please note:  there are additional
inclusion/exclusion criteria.  the study center will
determine if you meet all of the criteria.  if you do
not qualify for the trial, study personnel will
explain the reasons.  if you do qualify, study
personnel will explain the trial in detail and
answer any questions you may have.*
Yes
No
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Eligibility Breast Cancer NCT00193115
Docetaxel Followed by Doxorubicin Plus
Cyclophosphamide for Node Positive or High-Risk Primary
Breast Cancer; ODM derived from:
https://clinicaltrials.gov/show/NCT00193115
All rights reserved. Please visit https://medical-data-
models.org/forms/16261
Eligibility Breast Cancer
NCT00193115
Inclusion Criteria
to be included in this study, you must meet the
following criteria:*
Yes
No
histologically proven breast cancer*
Yes
No
females, age greater than 18 years*
Yes
No
ability to perform activites of daily living with
minimal assistance*
Yes
No
normal cardiac function*
Yes
No
adequate bone marrow, liver and kidney*
Yes
No
signed informed consent prior to beginning
specific protocol procedures*
Yes
No
Exclusion Criteria
you cannot participate in this study if any of the
following apply to you:*
Yes
No
prior systemic anticancer therapy for breast
cancer*
Yes
No
prior anthracycline or taxane based
chemotherapy for any malignancy*
Yes
No
pregnant or breast-feeding women.*
Yes
No
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pre-existing moderate to severe motor or sensory
neurotoxicity*
Yes
No
other serious illness or medical condition*
Yes
No
please note:  there are additional
inclusion/exclusion criteria.  the study center will
determine if you meet all of the criteria.  if you do
not qualify for the trial, study personnel will
explain the reasons.  if you do qualify, study
personnel will explain the trial in detail and
answer any questions you may have.*
Yes
No
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Eligibility Breast Cancer NCT00198237
Genomic & Proteomic Analysis of Docetaxel &
Capecitabine as Primary Chemo for Stage II-III Breast
Cancer; ODM derived from:
https://clinicaltrials.gov/show/NCT00198237
All rights reserved. Please visit https://medical-data-
models.org/forms/16262
Eligibility Breast Cancer
NCT00198237
Inclusion Criteria
histologically confirmed adenocarcinoma of the
breast w/ stage ii-iii disease w/ a primary tumor
>/=2cm or clinically palpable axillary lymph
nodes.*
Yes
No
pre-treatment core or incisional bx w/ adequate
tissue for histology &*
Yes
No
genomic/proteomic analysis.*
Yes
No
primary tumor must be bi-dimensionally
measurable by physical exam or dx breast
imaging. measurements must be obtained w/in 3
wks prior to study entry.*
Yes
No
adequate organ fxn:agc>1500;
hb>/=9.0;plts>/=100k; crt</=2.0;cacl crt clr>/=50;
total bili</=uln; lfts<2.0 uln*
Yes
No
ecog performance status 0-1*
Yes
No
neg. pregnancy test*
Yes
No
Exclusion Criteria
pts may not have had definitive primary surgery.*
Yes
No
metastatic breast cancer*
Yes
No
any prior chemo or hormonal therapy for breast
cancer*
Yes
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No
prior history of malignancy w/in the previous 5
yrs.*
Yes
No
no active unresolved infection*
Yes
No
no major surgery w/in 2wks of start of study*
Yes
No
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Eligibility Atrial Fibrillation NCT00196157
Line Versus Spot Ablation in Persistent Atrial Fibrillation;
ODM derived from:
https://clinicaltrials.gov/show/NCT00196157
All rights reserved. Please visit https://medical-data-
models.org/forms/16263
Eligibility Atrial Fibrillation
NCT00196157
Inclusion Criteria
age between 18 and 80 years*
Yes
No
symptomatic persistent (> 7 days lasting) atrial
fibrillation*
Yes
No
at least one unsuccessful cardioversion or atrial
fibrillation relapse in the first 3 months after
cardioversion despite antiarrhythmic drug
therapy*
Yes
No
oral anticoagulation (> 4 weeks prior to ablation)*
Yes
No
Exclusion Criteria
moderate to severe valvular heart disease*
Yes
No
congenital heart disease*
Yes
No
lv-ef < 35%*
Yes
No
reversible cause for atrial fibrillation (e.g.,
hyperthyreosis)*
Yes
No
prior left atrial ablation or maze operation*
Yes
No
left atrial thrombus*
Yes
No
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Eligibility Breast Cancer NCT00201708
Dose-Dense Docetaxel Before or After
Doxorubicin/Cyclophosphamide in Axillary Node-Positive
Breast Cancer; ODM derived from:
https://clinicaltrials.gov/show/NCT00201708
All rights reserved. Please visit https://medical-data-
models.org/forms/16264
Eligibility Breast Cancer
NCT00201708
Inclusion Criteria
must have histologically or cytologically
confirmed breast cancer*
Yes
No
no metastatic disease*
Yes
No
prior lumpectomy or mastectomy*
Yes
No
no prior chemotherapy or hormone treatments for
breast cancer*
Yes
No
must have normal organ and marrow function.*
Yes
No
eastern cooperative oncology group (ecog)
performance status 0 or 1.*
Yes
No
Exclusion Criteria
peripheral neuropathy of grade ii or higher.*
Yes
No
history or evidence upon physical exam of cns
(central nervous system diseases)disease.*
Yes
No
history of unstable angina or myocardial infarction
within the last six months.*
Yes
No
pregnant or nursing women.*
Yes
No
known allergies to polysorbate 80.*
Yes
No
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hiv-positive patients.*
Yes
No
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Eligibility Breast Cancer NCT00201708
Eligibility Atrial Fibrillation NCT00259623
Cardiac Surgical Treatment by Radiofrequency Ablation on
Valvular Patients: Efficacy at 3 Months; ODM derived from:
https://clinicaltrials.gov/show/NCT00259623
All rights reserved. Please visit https://medical-data-
models.org/forms/16265
Eligibility Atrial Fibrillation
NCT00259623
Inclusion Criteria
adult patients with no age limit, presenting a
chronic atrial fibrillation and planned to undergo a
surgical intervention on mitral valve (valve
replacement or plasty) associated or not with
myocardial revascularization or
replacement/plasty of another valve (aortic,
tricuspid)*
Yes
No
the chronic atrial fibrillation is defined as a
continuous atrial fibrillation more than 1 month
before the surgery despite all anti-arrhythmia
treatments including cardioversion ;  the atrial
fibrillation can be associated to another rhythm
trouble except the severe ventricular rhythm
troubles.*
Yes
No
the indication for surgery is performed using the
clinical evaluation : nyha >2 and the usual
echocardiography criteria (mitral regurgitation >
grade 3,  mitral gradient >10 mm hg or valve
surface < 1,5 cm2)*
Yes
No
patients with a vital prognosis not compromised
by comorbidity in the next 2 years and with a
mental state enabling to give informed consent*
Yes
No
patients agreeing to take part in the study and
having signed the informed consent form.*
Yes
No
for the part of the study pursued in open
independent to the actual protocol, patients
having signed the modified informed consent with
approval of the new study procedure not yet
published.*
Yes
No
Exclusion Criteria
paroxystic atrial fibrillation or atrial fibrillation for
less than 1 month*
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Yes
No
atrial fibrillation never treated by cardioversion or
pharmacology before surgery.*
Yes
No
contra-indication to surgery, i.e. severe
respiratory failures, multivisceral deficiencies
(renal, cardiac or hepatic), rapidly evolutive or
metastatic cancers, malignant hemopathies not
stabilized by chemotherapy*
Yes
No
contra-indication to the following arrhythmia
treatments: class iii (amiodarone) associated to
contra-indication to class ii (beta blockers) or to
class ic (flecainide, propafenone, cibenzoline).*
Yes
No
severe decompensated heart failure.*
Yes
No
uncontrolled, repetitive, severe documented
ventricular arrhythmia (ventricular tachycardia,
ventricular fibrillation episodes)*
Yes
No
contra indication to epicardic ablation procedure
(pericardic adhesions, intra-atrial thrombus) in
these cases the ablation could be only an
endocardic ablation but it does not necessarily
exclude the patient.*
Yes
No
ventricular  "ejection fraction "  < 40%*
Yes
No
impossibility to follow the pre-inclusion phases
i.e. emergency surgery for mitral break or
evolutive endocarditis.*
Yes
No
patients with disabled mental status*
Yes
No
patient participating in another clinical study*
Yes
No
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Eligibility Atrial Fibrillation NCT00281073
Intra-Cardiac Echocardiography Guided Cardioversion(ICE-
CHIP) Study; ODM derived from:
https://clinicaltrials.gov/show/NCT00281073
All rights reserved. Please visit https://medical-data-
models.org/forms/16266
Eligibility Atrial Fibrillation
NCT00281073
Inclusion Criteria
inclusion criteria for the phase i component*
Yes
No
1. patients with spontaneous af*
Yes
No
2. patients with or without structural heart
disease.*
Yes
No
3. men or women aged 18 years or older.*
Yes
No
4. patients undergoing an invasive catheterization
procedure including right heart catheterization.*
Yes
No
5. patients who give an informed consent for
participation in the study.*
Yes
No
6. patients who have undergone a trans-thoracic
echocardiogram within the last 14 days showing
absence of intracardiac thrombi.*
Yes
No
7. patients who have undergone a trans-
esophageal echocardiogram within the last 48
hours.*
Yes
No
inclusion criteria for the phase ii component*
Yes
No
1. patients with spontaneous af*
Yes
No
2. patients with or without structural heart
disease.*
Yes
No
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3. men or women aged 18 years or older.*
Yes
No
4. patients undergoing an invasive catheterization
procedure including right heart catheterization.*
Yes
No
5. patients who give an informed consent for
participation in the study.*
Yes
No
6. patients who have undergone a trans-thoracic
echocardiogram within the last 14 days showing
absence of intracardiac thrombi.*
Yes
No
Exclusion Criteria
exclusion criteria for the phase ii component
Yes
No
1. patients anticoagulated for > 7 days.
Yes
No
2. patients who have had a cardioembolic event
within the last 1-month.
Yes
No
3. patients requiring urgent cardioversion due to
hemodynamic instability.
Yes
No
4. patients in whom placement of an ice catheter
for adequate atrial visualization is technically not
feasible.
Yes
No
5. patients with contraindications for warfarin.
Yes
No
6. women of child bearing potential, in whom
pregnancy cannot be excluded.
7. patients who need anticoagulation withdrawn
due to an elective procedure
8. patients with any medical condition or social
circumstance, which in the opinion of the
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Eligibility Atrial Fibrillation NCT00281073
investigator would make the patient's successful
completion of the study doubtful.
exclusion criteria for the phase i component*
Yes
No
1. patients in whom placement of an ice catheter
for adequate atrial visualization is technically not
feasible.*
Yes
No
2. women of child bearing potential, in whom
pregnancy cannot be excluded.*
Yes
No
3. patients with any medical condition or social
circumstance, which in the opinion of the
investigator, would make the patient's successful
completion of the study doubtful*
Yes
No
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Eligibility Atrial Fibrillation NCT00289289
Reducing Episodes by Septal Pacing Efficacy Confirmation
Trial (RESPECT); ODM derived from:
https://clinicaltrials.gov/show/NCT00289289
All rights reserved. Please visit https://medical-data-
models.org/forms/16267
Eligibility Atrial Fibrillation
NCT00289289
Inclusion Criteria
subjects with fast and/or slow heartbeats who are
in need of dual chamber pacing (pacing in both
the atria and ventricles) as determined by their
doctor.*
Yes
No
subjects who have a history of occasional fast
heartbeats originating from the upper heart
chambers.*
Yes
No
subjects who have experienced at least two
symptomatic episodes of fast heartbeats three
months prior to enrollment.*
Yes
No
subjects that are expected to stay on the same
heart medications during the length study.*
Yes
No
Exclusion Criteria
subjects who have permanent (chronic) or
persistent (not self-terminating) atrial fibrillation
(fast heartbeats originating from the upper heart
chambers).*
Yes
No
subjects who have atrial fibrillation due to a
reversible cause, i.e. electrolyte imbalance.*
Yes
No
subjects who are current or immediate
implantable cardioverter defibrillator (icd)
recipients.*
Yes
No
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Pre-Screening Log RICH study
NCT02669589
NCT02669589 EudraCT-Nr. 2014-004854-33
REGIONAL CITRATE VERSUS SYSTEMIC HEPARIN
ANTICOAGULATION FOR CONTINUOUS RENAL
REPLACEMENT THERAPY IN CRITICALLY ILL
PATIENTS WITH ACUTE KIDNEY INJURY
Study Chair: Alexander Zarbock, MD University Hospital
Muenster
All rights reserved. Please visit https://medical-data-
models.org/forms/16268
Pre-Screening Log RICH study
NCT02669589
Patient Information
ID of Center
Inclusion Criteria
Screening Date:
Age of Patient:
years
Patient's gender:
female (female)
male (male)
Oliguria?
Yes
No
Cardiovascular Score ≥3?
as soon as dose of epinephrine or norephrine is
necessary: group SOFA 3-4
Yes
No
Reason for Exclusion
Specify which incusion or exclusion criteria are
disobeyed:
(if more than 3 criteria, chose the 3 most import
ones)
Patient with high bleeding risk (01)
haemorrhagic diathesis (02)
Chronic Kidney Disease (KDOQI IV
without dialysis dependency) (03)
after Akute Kidney Injury (within the last
90 days) (04)
Chronic Kideny Disease with dialysis
dependency (05)
Systemic Anticoagulation (06)
Allergic Reaction to anticoagulation
agent or ingredients, HIT (07)
Akute Kidney Injury (by occlusion or
surgical lesion of A. renalis) (08)
Akute Kidney Injury (by  (Glomerulo-
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)neprhitis, interstitial nephritis, vaskulitis,
postrenal obstruction) (09)
patient with DNR-Order (10)
Hemolytic-uremic syndroLactic
acidosisenic purpura (11)
long lasting and severe lactic acidosis in
context with acute liver failure and/ or
shock (12)
condition after renal transplantation
within the last 12 months (13)
pregnancy or lactating (14)
abortus imminens (15)
no free dialysis machines availabe (16)
participation in other interventional trials
within the last 3 months (17)
patients who have personal relation to
one of the people who supervises the
trial (18)
people who are in an institution due to
court order or administrative order (19)
planned unlimited intensive care for at
least 3 days (98)
severe sepsis/septic shock OR high
catecholamine use OR refractory fluid
overload: imaging/worsening of lung
oedema (99)
Other reason?
Yes
No
If "other reason", specify:
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CTC PSMA-Studie Prostatakarzinom
NCT0000001
Quelle:
PSMA-Studie Prostatakarzinom
PD Dr. med. Kambiz Rahbar
UKM, Nuklearmedizin
Teil: CTC
All rights reserved. Please visit https://medical-data-
models.org/forms/16269
CTC PSMA-Studie Prostatakarzinom
NCT0000001
Baseline
Name
Datum
Neutros
N
> 2 (0)
1,5 - 2 (1)
1-1,5 (2)
1-0,5 (3)
< 0,5 (4)
Thrombos
T
>200 (0)
150-200 (1)
100-150 (2)
50 - 100 (3)
<50 (4)
Übelkeit
Yes
No
Erbrechen
Yes
No
Durchfall
Yes
No
Mundtrockenheit
keine (0)
leicht, < 1 Woche (1)
störend, 1-4 Wochen (2)
peristierned (3)
Stomatitis
Yes
No
Haarausfall
Yes
1 / 8
No
weiteres
Erster Zyklus
Neutros
N
CodelistItem 873199 (0)
CodelistItem 873200 (1)
CodelistItem 873201 (2)
CodelistItem 873202 (3)
CodelistItem 873203 (4)
Thrombos
T
CodelistItem 873204 (0)
CodelistItem 873205 (1)
CodelistItem 873206 (2)
CodelistItem 873207 (3)
CodelistItem 873208 (4)
Übelkeit
Yes
No
Erbrechen
Yes
No
Durchfall
Yes
No
Mundtrockenheit
keine (0)
leicht, < 1 Woche (1)
störend, 1-4 Wochen (2)
peristierned (3)
Stomatitis
Yes
No
Haarausfall
Yes
No
weiteres
Zyklus 2
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Neutros
N
CodelistItem 873213 (0)
CodelistItem 873214 (1)
CodelistItem 873215 (2)
CodelistItem 873216 (3)
CodelistItem 873217 (4)
Thrombos
T
CodelistItem 873218 (0)
CodelistItem 873219 (1)
CodelistItem 873220 (2)
CodelistItem 873221 (3)
CodelistItem 873222 (4)
Übelkeit
Yes
No
Erbrechen
Yes
No
Durchfall
Yes
No
Mundtrockenheit
keine (0)
leicht, < 1 Woche (1)
störend, 1-4 Wochen (2)
peristierned (3)
Stomatitis
Yes
No
Haarausfall
Yes
No
weiteres
Zyklus 3
Neutros
N
CodelistItem 873227 (0)
CodelistItem 873228 (1)
CodelistItem 873229 (2)
CodelistItem 873230 (3)
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CodelistItem 873231 (4)
Thrombos
T
CodelistItem 873232 (0)
CodelistItem 873233 (1)
CodelistItem 873234 (2)
CodelistItem 873235 (3)
CodelistItem 873236 (4)
Übelkeit
Yes
No
Erbrechen
Yes
No
Durchfall
Yes
No
Mundtrockenheit
keine (0)
leicht, < 1 Woche (1)
störend, 1-4 Wochen (2)
peristierned (3)
Stomatitis
Yes
No
Haarausfall
Yes
No
weiteres
Zyklus 4
Neutros
N
CodelistItem 873241 (0)
CodelistItem 873242 (1)
CodelistItem 873243 (2)
CodelistItem 873244 (3)
CodelistItem 873245 (4)
Thrombos
T
CodelistItem 873246 (0)
CodelistItem 873247 (1)
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CodelistItem 873248 (2)
CodelistItem 873249 (3)
CodelistItem 873250 (4)
Übelkeit
Yes
No
Erbrechen
Yes
No
Durchfall
Yes
No
Mundtrockenheit
keine (0)
leicht, < 1 Woche (1)
störend, 1-4 Wochen (2)
peristierned (3)
Stomatitis
Yes
No
Haarausfall
Yes
No
weiteres
Zyklus 5
Neutros
N
CodelistItem 873255 (0)
CodelistItem 873256 (1)
CodelistItem 873257 (2)
CodelistItem 873258 (3)
CodelistItem 873259 (4)
Thrombos
T
CodelistItem 873260 (0)
CodelistItem 873261 (1)
CodelistItem 873262 (2)
CodelistItem 873263 (3)
CodelistItem 873264 (4)
Übelkeit
Yes
No
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Erbrechen
Yes
No
Durchfall
Yes
No
Mundtrockenheit
keine (0)
leicht, < 1 Woche (1)
störend, 1-4 Wochen (2)
peristierned (3)
Stomatitis
Yes
No
Haarausfall
Yes
No
weiteres
Zyklus 6
Neutros
N
CodelistItem 873269 (0)
CodelistItem 873270 (1)
CodelistItem 873271 (2)
CodelistItem 873272 (3)
CodelistItem 873273 (4)
Thrombos
T
CodelistItem 873274 (0)
CodelistItem 873275 (1)
CodelistItem 873276 (2)
CodelistItem 873277 (3)
CodelistItem 873278 (4)
Übelkeit
Yes
No
Erbrechen
Yes
No
Durchfall
Yes
No
Mundtrockenheit
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keine (0)
leicht, < 1 Woche (1)
störend, 1-4 Wochen (2)
peristierned (3)
Stomatitis
Yes
No
Haarausfall
Yes
No
weiteres
Zyklus 7
Neutros
N
CodelistItem 873283 (0)
CodelistItem 873284 (1)
CodelistItem 873285 (2)
CodelistItem 873286 (3)
CodelistItem 873287 (4)
Thrombos
T
CodelistItem 873288 (0)
CodelistItem 873289 (1)
CodelistItem 873290 (2)
CodelistItem 873291 (3)
CodelistItem 873292 (4)
Übelkeit
Yes
No
Erbrechen
Yes
No
Durchfall
Yes
No
Mundtrockenheit
keine (0)
leicht, < 1 Woche (1)
störend, 1-4 Wochen (2)
peristierned (3)
Stomatitis
Yes
No
Haarausfall
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Yes
No
weiteres
Zyklus 8
Neutros
N
CodelistItem 873297 (0)
CodelistItem 873298 (1)
CodelistItem 873299 (2)
CodelistItem 873300 (3)
CodelistItem 873301 (4)
Thrombos
T
CodelistItem 873302 (0)
CodelistItem 873303 (1)
CodelistItem 873304 (2)
CodelistItem 873305 (3)
CodelistItem 873306 (4)
Übelkeit
Yes
No
Erbrechen
Yes
No
Durchfall
Yes
No
Mundtrockenheit
keine (0)
leicht, < 1 Woche (1)
störend, 1-4 Wochen (2)
peristierned (3)
Stomatitis
Yes
No
Haarausfall
Yes
No
weiteres
8 / 8
CTC PSMA-Studie Prostatakarzinom NCT0000001
Lu PSMA-Studie Prostatakarzinom
NCT0000001
Quelle:
PSMA-Studie Prostatakarzinom
PD Dr. med. Kambiz Rahbar
UKM, Nuklearmedizin
Teil: Lu PSMA
All rights reserved. Please visit https://medical-data-
models.org/forms/16271
Lu PSMA-Studie Prostatakarzinom
NCT0000001
Identificaton
Name
Vorname
Geburtsdatum
Anzahl Zyklen
Aktivität
Termin 1
Aktivität
Datum
Termin 2
Aktivität
Datum
Termin 3
Aktivität
Datum
Termin 4
Aktivität
Datum
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Termin 5
Aktivität
Datum
Termin 6
Aktivität
Datum
Termin 7
Aktivität
Datum
Termin 8
Aktivität
Datum
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Adverse Event: Citrate RICH study
NCT02669589
NCT02669589 EudraCT-Nr. 2014-004854-33
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REPLACEMENT THERAPY IN CRITICALLY ILL
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Study Chair: Alexander Zarbock, MD University Hospital
Muenster
All rights reserved. Please visit https://medical-data-
models.org/forms/16272
Adverse Event: Citrat RICH study
NCT02669589
Patient Information
ID of Center
ID of Patient
Adverse Event Description
Number of current Adverse Event:
Adverse Event Diagnosis
specify diagnosis if known, otherwise symptoms:
Duration
Onset: Date
End: Date
Therapy
Max. intensity:
mild (1)
moderate (2)
severe (3)
life-threatening (4)
death realted to AE (5)
Therapy of adverse event
Yes
No
Therapy of adverse event:
If "yes", please comment:
Outcome of event:
recovered (1)
recovering (2)
not recovered (3)
recovered with sequel (4)
fatal (5)
unknown (6)
Serious adverse event?
1 / 2
Yes
No
Why was this event serious?
death (1)
liferisk (2)
hospitalisation (3)
disability (4)
birth defect (5)
medically important condition (6)
Serious adverse event?
If "yes", please verify immedietly, if SAE reporting
is necessary according to protocol.
If serious, SAE report necessary according to
protocol?
Yes
No
Causal relationship with regional citrate
anticoagulation
no (0)
possible (2)
yes (3)
Action taken with regional citrate anticoagulation
due to event
no action taken (0)
therapy interrupted (1)
therapy discontinued (2)
Causal relationship with Renal Replacement
Therapy
no (0)
possible (2)
yes (3)
Comments
Comment
(please refer to AE No.):
Case report form data
Date of confirmation of CRF:
Name of authorized trial physician:
Signature of authorized trial physician:
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Adverse Event: Heparin RICH study
NCT02669589
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Adverse Event: Heparin RICH study
NCT02669589
Patient Information
ID of Center
ID of Patient
Adverse Event Description
Number of current Adverse Event:
Adverse Event Diagnosis
specify diagnosis if known, otherwise symptoms:
Duration
Onset: Date
End: Date
Therapy
Max. intensity:
mild (1)
moderate (2)
severe (3)
life-threatening (4)
death realted to AE (5)
Therapy of adverse event
Yes
No
Therapy of adverse event:
If "yes", please comment:
Outcome of event:
recovered (1)
recovering (2)
not recovered (3)
recovered with sequel (4)
fatal (5)
unknown (6)
Serious adverse event?
1 / 2
Yes
No
Why was this event serious?
death (1)
liferisk (2)
hospitalisation (3)
disability (4)
birth defect (5)
medically important condition (6)
Serious adverse event?
If "yes", please verify immedietly, if SAE reporting
is necessary according to protocol.
If serious, SAE report necessary according to
protocol?
Yes
No
Causal relationship with systemic heparin
anticoagulation
reasonable possibility (1)
no reasonable possibility (2)
Action taken with trial drug due to event
does not changed (1)
dose reduced (2)
dose increased (3)
drug withdrawal (4)
unknown (5)
not applicable (6)
Causal relationship with medical procedure
no (0)
possible (2)
yes (3)
Comments
Comment
(please refer to AE No.):
Case report form data
Date of confirmation of CRF:
Name of authorized trial physician:
Signature of authorized trial physician:
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Tumor orthopedics UKM documentation
Prof. Dr. Jendrik Hardes
Tumor orthopedics UKM documentation
All rights reserved. Please visit https://medical-data-
models.org/forms/16274
Tumor orthopedics UKM
documentation
Patienteninformation
Name
Vorname
Geburtsdatum
Geschlecht
OP-Datum
Alter
Größe
cm
Gewicht
kg
BMI
kg/ m^2
Diabetes
Ja
Nein
Nikotin
Ja
Nein
Patholog. Fraktur
Ja
Nein
Voroperationen
Ja
Nein
Diagnose
Krankheitsstadium
Rezidiv
Ja
Nein
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Therapy
Chemo
Ja
Nein
präop. Chemo
Ja
Nein
postop. Chemo
Ja
Nein
RTX
Ja
Nein
präop. RTX
Ja
Nein
postop. RTX
Ja
Nein
Silber
Anbindungsschlauch
Ja
Nein
Resektionslänge
Muskelplastik (Gastrocnemius)
Ja
Nein
Meshgraft
Ja
Nein
Zement
Ja
Nein
OP-Zeit (Min.)
minutes
präop. Leukos
<2 (1)
2 to 4 (2)
>10 (3)
Hämatom / Kompartment
Ja
Nein
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Revisionsoperationen
Ja
Nein
Komplikation I-IV
I (1)
II (2)
III (3)
IV (4)
Implantatsversagen
Grund für Versagen
Spezifikation
Henderson Versagen
Type 1 soft tissue failure (1)
Type 2 Aseptic Loosening (2)
Type 3 Structural failure (3)
Type 4 Infection (4)
Type 5 Tumor progression (5)
Reoperation
Prothesenwechsel / Ausbau
Ja
Nein
Grund Reop.
mechanisches Versagen vor Infektion (1)
Reop nach Infektion (2)
Reop nach Infektion
Ja
Nein
Art der 1. Reoperation
Zeitpunkt ab 1. OP
Art der 2. Reoperation
Zeitpunkt ab 1. OP
Art der 3. Reoperation
Zeitpunkt ab 1. OP
Monate bis Infektion
months
3 / 5
Tumor orthopedics UKM documentation
Wundheilungsstörung oberfl.
Ja
Nein
Revision oberflächlich
Ja
Nein
OP-Art
Zeitpunkt Revision (Wochen)
weeks
Wundheilung tief
Revision tief
Ja
Nein
Keimspektrum
Leukos Punktion
CRP bei Infektion
md/dl
Leukozytenszinti
Ja
Nein
Möglicher hämatogener Infektfocus postop.
Follow-up seit Infektsanierung
Ja
Nein
Anzahl Reop Prothese
Rezidiv
OP-Rezidiv
Zeitpunkt OP-Rezidiv
Zeitpunkt ab 1.OP
OP-Art
Stage of disease
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Amputation
Ja
Nein
Grund
Anderes Verfahren Limb salvage
Ja
Nein
Grund
Follow-Up
Follow-up
Ja
Nein
Abschluss Follow-up
Grund
Extension
°
Flexion
°
BPI
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SAE Form RICH study
NCT02669589
Patient Information
Report information:
Follow-up report (Follow-up report)
Inititial report (Inititial report)
ID of patient
ID of Center
Age at onset of SAE
years
Gender:
female (female)
male (male)
Weight:
kg
Height:
cm
Sponsor's Case No.
(please leave empty)
Seriousness criteria
Please check as many as apply:
Caused/prolonged inpatient
hospitalisation (Caused/prolonged
inpatient hospitalisation)
Congenital anomaly/ birth defect
(Congenital anomaly/ birth defect)
Life-threatening (Life-threatening)
Other medically important condition
(Other medically important condition)
Results in death (Results in death)
Results in persistent or significant
disability/incapacity (Results in persistent
or significant disability/incapacity)
If SAE results in death:
Date of death
1 / 5
Autopsy performed?
No (No)
Yes (if yes: Please attach copy of
autopsy report) (Yes (if yes: Please
attach copy of autopsy report))
Cause of death
(As given in certifiate of death):
Serious Adverse Event (SAE)
SAE: Diagnosis
- only one diagnosis if possible
- multiple entries only if signs, symptoms, or
diagnoses cannot be merged to one diagnosis
- multiple entries: rank by relevance. Enter most
importnant sign, symptoms or diagnosis in first
place
CTCAE grade
(Maximal grade)
Onset date
(if exact time is relevant: Please include it in the
detailed description)
Adverse Event Outcome
(Current status)
Recovered/resolved (1)
Recovering/resolving (2)
Not recovered/ resolved (3)
Recovered/resolved with sequelae (4)
Fatal (5)
Unknown (6)
End date
(if ongoing, enter "cont.")
Possible explanation(s) for SAE
(please check as many as apply, please add
details on next pages)
Investigational treatment (1)
Concomitant medication (2)
Underlying disease (3)
Pre-existing condition, concomitant/
intercurrent disease (4)
other explanation (e.g. surgery/
radiotherapy) (5)
SAE: Detailed description including symptoms
Treatment of SAE
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Treatment of SAE:
Drug treatment (Drug treatment)
None  (None )
Others (Others)
Treatment of SAE: Specification
Drugs (Investigational drug/device - this is
essential and mandatory information;
Relevant concomitant medication - please
do not enter any treatment of the SAE -
Enter only drugs the patient starte...
Brand name
Active substance
Indication
Causal relationship to SAE
Reasonable possibility (1)
No reasonable possibility (2)
Therapy dates (from - to)
(If ongoing: Enter "cont.")
Total daily dose and unit
Route of administration
(e.g. oral, iv, sc)
Total absolute cumulative dose and unit:
(if relevant; from first administration until last
administration prior to SAE; only relevant for
investigational drug/device)
Action taken in response to SAE
(if pateinte was already off therapy with this drug
prior to SAE: Enter 6)
Dose not changed (1)
Dose reduced (2)
Dose increased (3)
Drug withdrawal (4)
Unknown (5)
Not applicable (6)
If drug was withdrawn: 
Has drug been re-administered?
(Only for investigational drug/device)
Yes (1)
No (2)
Unknown (3)
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If drug was re-administered: 
Did reaction recur on re-administration?
(Only for investigational drug/device)
Yes (1)
No (2)
Unknown (3)
Relevant Medical History - Information
pertinent to understanding the case: e.g.
underlying disease, pre-existing condition,
concomitant/ intercurrent disease, surgery
Condition/ disease:
Start Date
End Date
Causal relationship to SAE
Reasonable possibility (1)
No reasonable possibility (2)
Relevant results of tests and procedures -
attach results/ findings, if appropriate
Tests and procedures:
Date
Result:
Unit of measurement
Normal range - lower limit
Normal range - upper limit
Comments
Comment
Investigator
Family name
First name
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Address of institution:
Telephone
Fax
E-Mail
Date of report
Signature
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Eligibility Hepatitis B, Chronic
NCT00034359
Safety and Antiviral Activity Study of ACH-126,443 (Beta-L-
Fd4C) in Treatment Naive Adults With Chronic Hepatitis B
Virus Infection; ODM derived from:
https://clinicaltrials.gov/show/NCT00034359
All rights reserved. Please visit https://medical-data-
models.org/forms/16276
Eligibility Hepatitis B, Chronic
NCT00034359
Inclusion Criteria
adults >= 18 years of age*
Yes
No
chronic hbv infection, known to be hbsag positive
>= 6 months*
Yes
No
plasma hbv dna level >= 100,000 copies/ml*
Yes
No
hbe-antigen positive*
Yes
No
hiv negative*
Yes
No
basic hematologic and chemistry parameters
within acceptable limits (defined in protocol*
Yes
No
no need for excluded medications*
Yes
No
subjects of reproductive capability must utilize
two approved forms of birth control, one of which
must be barrier protection.*
Yes
No
Exclusion Criteria
hiv infection*
Yes
No
hepatitis c co-infection*
Yes
No
concurrent systemic antiviral treatment*
Yes
No
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previous antiviral treatment for hbv infection
within 6 months prior to randomization or
treatment with 3tc for more than 6 months at any
time in the past*
Yes
No
previous therapy with agents with significant
systemic myelosuppressive or cytotoxic potential
within 3 months of study start or the expected
need for such therapy at study start*
Yes
No
alcohol abuse*
Yes
No
pregnancy or breast-feeding*
Yes
No
inability to tolerate oral medication*
Yes
No
ast>7.0 times the upper limit of normal*
Yes
No
alt>7.0 times the upper limit of normal*
Yes
No
any clinical condition or prior therapy that, in the
investigators opinion, would make the subject
unsuitable for the study or unable to comply with
the dosing requirements*
Yes
No
use of any investigational drug.*
Yes
No
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Protocol violation RICH study
NCT02669589
NCT02669589 EudraCT-Nr. 2014-004854-33
REGIONAL CITRATE VERSUS SYSTEMIC HEPARIN
ANTICOAGULATION FOR CONTINUOUS RENAL
REPLACEMENT THERAPY IN CRITICALLY ILL
PATIENTS WITH ACUTE KIDNEY INJURY
Study Chair: Alexander Zarbock, MD University Hospital
Muenster
All rights reserved. Please visit https://medical-data-
models.org/forms/16277
Protocol violation RICH study
NCT02669589
Patient Information
ID of Center
ID of patient
Protocol violation
Protocol violation:
Inclusion/Exclusion criteria (1)
Therapy process/ trial process (2)
test product (3)
Information given by not authorized
medical personal (4)
Other problems with informed consent
(5)
Others (6)
Date of protocol violation
Description of Protocol Violation
Reason for Protocol Violation
Planned/ performed medical procedure
Proven by:
examiner (1)
ward physician (2)
authorized medical personal (7)
Proven: Date
Signature of examiner/ authorized medical
personal
Assessment of protocol violation:
(evaluation should be performed after
consultation with biometrics and/or LKP)
Major (Major)
Minor (Minor)
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Identification and Signature
Date of report
Name of project manager
Signature of project manager
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Eligibility Hepatitis C NCT00029107
Rituximab to Treat Hepatitis C-Associated Cryoglobulinemic
Vasculitis; ODM derived from:
https://clinicaltrials.gov/show/NCT00029107
All rights reserved. Please visit https://medical-data-
models.org/forms/16278
Eligibility Hepatitis C NCT00029107
Criteria
diagnosis of hcv-cv: must have all of the
following*
Yes
No
hcv infection documented by serology and/or
plasma hcv rna.*
Yes
No
one or more organ system with objective
evidence of active vasculitis such as:*
Yes
No
palpable purpura*
Yes
No
glomerulonephritis (defined by the presence of
glomerular hematuria and/or new or worsening
proteinuria);*
Yes
No
acute peripheral neuropathy.*
Yes
No
detectable cryoglobulins and/or rf.*
Yes
No
failure of treatment with ifn-alpha and ribavirin to
control manifestations of hcv-cv or intolerance to
ifn-alpha/ribavirin regimen.*
Yes
No
patients must have a personal physician
responsible for the care of their hcv.*
Yes
No
ages of 18 and 75 years*
Yes
No
willingness to use effective contraception during
and for 12 months following rituximab treatment.
effective contraception methods include
abstinence, surgical sterilization of either partner,
barrier methods such as diaphragm, condom,
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cap or sponge, or hormonal contraception.*
Yes
No
Exclusion Criteria
recent (within 4 weeks) initiation of or increase in
immunosuppressive therapy.*
Yes
No
active systemic infection (other than hepatitis c).*
Yes
No
pregnancy or breast feeding.*
Yes
No
prior treatment with rituximab.*
Yes
No
known allergy to murine proteins.*
Yes
No
significant renal insufficiency (creatinine
clearance less than 30 ml/min).*
Yes
No
presence of life-threatening hcv-cv; defined as
rapidly progressive glomerulonephritis (defined
as a doubling of the serum creatinine over a 3
month period), cns vasculitis, cardiac disease
due to active vasculitis, or gi vasculitis (defined by
ischemic bowel, perforation, or infarction).*
Yes
No
significant hepatic insufficiency as manifested by
child-pugh classification of b or c.*
Yes
No
history of variceal bleeding, encephalopathy.*
Yes
No
history of liver transplantation.*
Yes
No
co-infection with either hbv or hiv.*
Yes
No
any underlying medical condition that in the
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judgment of the investigator would put the patient
at increased risk for serious infusion-related
adverse events.*
Yes
No
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Eligibility Breast Cancer NCT00201773
Exemestane With Celecoxib as Neoadjuvant Treatment in
Postmenopausal Women With Stage II, III, and IV Breast
Cancer; ODM derived from:
https://clinicaltrials.gov/show/NCT00201773
All rights reserved. Please visit https://medical-data-
models.org/forms/16279
Eligibility Breast Cancer
NCT00201773
Inclusion Criteria
must be female with histologically confirmed
breast cancer*
Yes
No
stage ii-iv disease*
Yes
No
er and/or pr positive*
Yes
No
ecog performance status 0-1*
Yes
No
tumor must be present following core needle
biopsy as determined by physical exam or
radiographic evaluation.*
Yes
No
postmenopausal*
Yes
No
no prior treatment for current breast cancer. no
other active malignancy is allowed.adequately
treated basal cell, squamous cell skin cancer, in
situ cervical cancer, or any other cancer from
which the patient has been disease-free for 5
years is permitted. biphosphonates and palliative
radiation for bone metastasis is permitted while
on study.*
Yes
No
hormone replacement therapy must be
discontinued. it is not permitted during the time
on study.*
Yes
No
Exclusion Criteria
known history of aspirin or nsaid induced asthma,
urticaria or allergic reactions; or allergy to
sulfonamides severe enough in nature to require
emergency room treatment or hospitalization.*
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Yes
No
history of myocardial infarction or other
thrombotic events.*
Yes
No
inflammatory breast cancer (edema or ulceration
of the skin of the breast).*
Yes
No
significant renal dysfunction (serum creatinine >
1.5 x upper limit of normal).*
Yes
No
significant hepatic dysfunction (serum bilirubin >
1.5 x upper limit of normal or ast, alt > 3 x upper
limit of normal)*
Yes
No
anc <1.5, platelets <100,000 k/ul, and
hemoglobin < 9 g/dl.*
Yes
No
use of other cox-2 inhibitors such as rofecoxib
(vioxx®, aspirin, trisalicylate (trilisate®), is not
permitted during the time on study. no washout
period is required. baby aspirin, 81 mg po daily, is
permitted.*
Yes
No
use of nsaid's such as ibuprofen (advil® or
motrin®), naproxyn (aleve® naprosyn®, or
anaprox®), etodolac (lodine®), oxaprozin
(daypro®), difusanil (dolobid®), nabumetone
(relafin®), or tolmetin (tolectin®) is not permitted
during the time on study.*
Yes
No
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Eligibility Breast Cancer NCT00201890
Trial of Decongestive Lymphatic Therapy for Lymphedema
in Women With Breast Cancer "DELTA STUDY"; ODM
derived from: https://clinicaltrials.gov/show/NCT00201890
All rights reserved. Please visit https://medical-data-
models.org/forms/16280
Eligibility Breast Cancer
NCT00201890
Inclusion Criteria
women with a histological diagnosis of breast
cancer experiencing edema in the ipsilateral arm
such that there is a minimum 15% increase in
arm volume over the opposite arm.*
Yes
No
patients must have completed all primary and
adjuvant treatments (surgery, chemotherapy,
radiotherapy) prior to randomization.  this is to
ensure that scheduling difficulties with daily
treatments do not arise.  patients may be
currently taking tamoxifen or similar hormonal
treatment.*
Yes
No
Exclusion Criteria
clinical or radiological evidence of active disease,
either local or metastatic.*
Yes
No
history of contralateral cancer, axillary surgery,
radiation or bilateral arm edema. (edema volume
will be taken as the increase in volume compared
to the unaffected arm; previous therapy in the
opposite arm will reduce the accuracy of
measuring excess volume related to
lymphedema.)*
Yes
No
previous surgery involving nodal dissection or
radiotherapy to other major node-bearing areas in
the body such as the mediastinum or pelvis.
disruption of lymphatic flow in these potentially
alternate routes may be compromised by such
interventions.  patients are eligible after a simple
hysterectomy (+/- oophorectomy).*
Yes
No
previously undergone massage therapy for arm
edema, or has used compression sleeve within
the last month.*
Yes
No
serious non-malignant disease, such as renal or
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cardiac failure, which would preclude daily
treatment and follow up.*
Yes
No
patients for whom massage is contraindicated,
such as those with untreated infections or
thromboses in the affected arm.*
Yes
No
unable to commence therapy within 7 days of
randomization.*
Yes
No
psychiatric or addictive disorders which preclude
obtaining informed consent or adherence to the
protocol.*
Yes
No
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Physician letter Internal Medicine
derived from http://www.arztbriefmanager.de/ 
(Dr. Wolfram Arends, Tutzing, Germany)
All rights reserved. Please visit https://medical-data-
models.org/forms/16281
Physician letter Internal Medicine
Anamnese
Einweisung
Die stationäre Einweisung erfolgte durch
den Hausarzt. (HA)
Die stationäre Einweisung erfolgte durch
den Notarzt. (NAW)
Die stationäre Einweisung erfolgte durch
den NFD. (NFD)
Die stationäre Einweisung erfolgte durch
den Rettungsdienst. (RTW)
Die stationäre Aufnahme erfolgte nach
Rückverlegung nach Durchführung einer
PTCA. (Rückverlegung nach PTCA)
Der Patient stellte sich selbst in unserer
Ambulanz vor. (selbst)
Beschwerden seit dem
Aufnahmegrund
Vorgeschichte bekannt
Ja
Nein
Exsikkose
Ja
Nein
Synkope
Vorbekannt war ein Sturzereignis
aufgrund einer Synkope mit kurzfristiger
Bewußtlosigkeit. (Synkope nur
internistische Behandlung, keine
Chirurgie)
Vorbekannt ist ein Sturz aufgrund einer
Synkope, als Verletzung ist dabei eine
Prellung aufgetreten. Die Erstversorgung
erfolgte zunächst in unserer
chirurgischen Ambulanz. Eine Fraktur
konnte dort ausgeschlossen werden. Die
Übernahme erfolgte anschließend auf
unsere Abteilung zur Abklärung der
Sturzursache. (Synkope Prellung
Abklärung Chirurgie, dann Übernahme)
Vorbekannt ist ein Sturz aufgrund einer
Synkope, als Verletzung ist dabei eine
Schädelprellung aufgetreten. Die
Erstversorgung erfolgte zunächst in
unserer chirurgischen Ambulanz. Eine
Fraktur konnte dort ausgeschlossen
werden. Die Übernahme erfolgte
anschließend auf unsere Abteilung zur
Abklärung der Sturzursache. (Synkope
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Schädelprellung Abklärung Chirurgie,
dann Übernahme)
thorakale Beschwerden
Ja
Nein
retrosternale Schmerzen
Ja
Nein
Rückenbeschwerden
Ja
Nein
Orthopnoe
Ja
Nein
Dyspnoe
Ja
Nein
Belastungsdyspnoe
Ja
Nein
Hyperventilation
Ja
Nein
Palpitationen
Ja
Nein
Trockener Husten
Ja
Nein
Husten mit Auswurf
Ja
Nein
Infekt obere Atemwege
Ja
Nein
Antibiotische Vorbehandlung
Ja
Nein
Übelkeit
Ja
Nein
Erbrechen
Ja
Nein
Kolik
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Ja
Nein
abdominelle Beschwerden
Ja
Nein
Hämatemesis
Ja
Nein
Diarrhoe
Ja
Nein
Obstipation
Ja
Nein
Miserere
Ja
Nein
Anurie
Ja
Nein
systematischer Schwindel
Ja
Nein
unsystematischer Schwindel
Ja
Nein
Verwirrtheit
Ja
Nein
Desorientiertheit
Ja
Nein
Angst
Ja
Nein
Panikreaktion
Ja
Nein
Unruhe
Ja
Nein
Schläfrigkeit
Ja
Nein
Nachtschweiss
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Ja
Nein
Gewichtsverlust
Ja
Nein
Nikotinabusus
Ja
Nein
Befund
Alter
Jahre
Exsikkosezeichen
Ja
Nein
Fieber
Ja
Nein
Herzinsuffizienz
Ja
Nein
Blutdruck
Herzfrequenz
/min
Pulmo o.p.B.
Ja
Nein
Atemgeräusch
O2%
%
Abdomen Normalbefund
Ja
Nein
Abdomen Befund
Neuro Normalbefund
Ja
Nein
Normalbefund in der körperlichen Untersuchung
Ja
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Nein
Klinisches Bild
stationäre Aufnahme unter klinischem Bild
TVT
Ja
Nein
Anämie
Ja
Nein
Akuter Arterienverschluss
Ja
Nein
Dyspnoe
Ja
Nein
Lungenembolie
Ja
Nein
exazerbierte COPD
Ja
Nein
Bronchitis
Ja
Nein
Bronchopneumonie
Ja
Nein
Pneumonie
Ja
Nein
Aspirationspneumonie
Ja
Nein
respiratorische Insuffizienz
Ja
Nein
Hyperglykämie
Ja
Nein
Hypoglykämie
Ja
Nein
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Insektenstich
Ja
Nein
Allergische Reaktion
Ja
Nein
Erysipel
Ja
Nein
Sepsis
Ja
Nein
Zystitis
Ja
Nein
Nierenkolik
Ja
Nein
Pyelonephritis
Ja
Nein
Urosepsis
Ja
Nein
akuter Harnverhalt
Ja
Nein
Niereninsuffizienz mit Oligourie
Ja
Nein
muskuloskeletale Thoraxschmerzen
ACS
Ja
Nein
Hypertensive Krise
Ja
Nein
Hypotonie
Ja
Nein
Synkope
Ja
Nein
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Epistaxis
Ja
Nein
Tachykardie
Ja
Nein
Bradykardie
Ja
Nein
Dekompensierte Herzinsuffizienz
Ja
Nein
Rechtsherzinsuffizienz
Ja
Nein
Linksherzinsuffizienz
Ja
Nein
Perikarditis
Ja
Nein
Gastroenteritis
Ja
Nein
obere GIT Blutung
Ja
Nein
untere GIT Blutung
Ja
Nein
abdominelle Beschwerden
Ja
Nein
Obstipation
Ja
Nein
Ileus
Ja
Nein
Cholecystitis
Ja
Nein
akute Pankreatitis
Ja
Nein
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chronische Pankreatitis
Ja
Nein
Divertikulitis
Ja
Nein
Schwindel
Ja
Nein
Synkope
Ja
Nein
cerebraler Krampfanfall
Ja
Nein
Migräne
Ja
Nein
Schlaganfall
Ja
Nein
TIA
Ja
Nein
Alkoholintoxikation
Ja
Nein
Alkoholentzug
Ja
Nein
Tablettenintoxikation
Ja
Nein
Hyperventilation
Ja
Nein
Parkinsonkrise
Ja
Nein
Allgemeine Therapie
Bilanzierte Flüssigkeit
Ja
Nein
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Glukose 5%
Ja
Nein
Diuretika
Ja
Nein
Insulinperfusor
Ja
Nein
vorlastsenkende Medikation
Ja
Nein
PPI
Ja
Nein
Schmerztherapie / Schmerzmanagement
Ja
Nein
Antivertiginosa
Ja
Nein
Heparinisierung
Ja
Nein
Antibiose ex iuvantibus
gezielte Antibiose
intravenöse Flüssigkeitsgabe
Liter
Labor
Hämoglobin
mg/dl
Ferritin
ng/ml
Leukozyten
/ul
CRP
md/dl
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Kalium
mmol/l
Kreatinin
mg/dL
Alkohol
p.p.m.
Herzinfarkt Troponin I
CK
U/l
CKMB
U/l
D-Dimer erhöht
Ja
Nein
Haemoccult
Der HC-Test war mehrfach positiv. (HC
Test mehrfach positiv)
Der Haemoccult-Test war zu jedem
Zeitpunkt negativ. (HC Test war
mehrfach negativ)
Stuhlkultur
Die bakterielle Untersuchung auf
darmpathogene Keime ergab keinen
pathologischen Befund. (Stuhlkultur
negativ)
Die Untersuchung auf darmpathogene
Keime zeigte einen positiven Befund.
(Stuhlkultur positiv)
stauungsbedingte Leberzirrhose
Ja
Nein
alkoholische Leberzirrhose
Ja
Nein
Entzündungswerte rückläufig
Ja
Nein
Kreatinin rückläufig
Ja
Nein
Diagnostik
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Duplex Sono Hals o.B.
Ja
Nein
Marcumar Diagnostik o.B.
Ja
Nein
UKG
OB-Sono
Ja
Nein
Sonographie untere Extremität
LZ-EKG Sinusrhythmus
Ja
Nein
Langzeit-EKG
Ergometrie Normalbefund
Ja
Nein
LZ-RR Normalbefund
Ja
Nein
LZ-RR
CCT
CT-Thorax
CT Abdomen
Gastroskopie Normalbefund
Ja
Nein
Gastroskopie
Coloskopie Normalbefund
Ja
Nein
Coloskopie
Coloskopie nur eingeschänkt möglich
Ja
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Nein
Keine Indikation für weitere Hohlraumdiagnostik
Ja
Nein
Histologie folgt
Ja
Nein
Lungenfunktion
Lungenfunktion starke Einschränkung,
pulmologische Anbindung empfohlen
Ja
Nein
Herz
Rechtsherzinsuffzienz
Ja
Nein
Exsikkose
Ja
Nein
Hinweis auf KHK
Ja
Nein
Indikation für Schrittmacher-Implantation
Ja
Nein
NSTEMI
Ja
Nein
STEMI
Ja
Nein
Ausschluss Herzinfarkt
Ja
Nein
Hypertonie
Ja
Nein
Hypotonie
Ja
Nein
VHF mit Konversion in Sinusrhythmus
Ja
Nein
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Nach Kardioversion Sinusrhythmus
Ja
Nein
Besserung der Schmerzen
Ja
Nein
Besserung der Thorax Schmerzen
Ja
Nein
Blutdruck normalisiert
Ja
Nein
Indikation Marcumar bei Vorhofflimmern
Ja
Nein
Marcumar für 4 Wochen
Ja
Nein
Marcumar nach Coronarangiographie
Ja
Nein
Keine Indikation für Coronarangiographie
Ja
Nein
Termin für Coronarangiographie
Blut und Gerinnung
Anämie
Ja
Nein
renale Anämie
Ja
Nein
Keine EK nötig
Ja
Nein
Anzahl EKs
Nephrologische Vorstellung zur weiteren
Diagnostik
Ja
Nein
INR
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INR bei Entlassung erreicht (1)
INR bei Entlassung nicht erreicht (2)
Thrombophilie-Screening
Marcumar Therapiedauer
Monate
Gastrointestinales System
Ausschluss obere GIT Blutung
Ja
Nein
Gabe von Verdauungsenzymen mit Besserung
Ja
Nein
Antidiabetika pausiert bei Nahrungskarenz
Ja
Nein
PEG
In Anbetracht der in der letzten Zeit
zunehmenden Dysphagie wurde mit der
bevollmächtigen Person mehrere
Gespräche über die Notwendigkeit der
Applikation einer PEG-Sonde
gesprochen. Am xxx konnte eine
komplikationslose PEG-Anlage erfolgen.
(1)
Es konnte ein komplikationsloser PEG-
Wechsel über die alte PEG-Sonde in
Seldinger Technik erfolgen. (2)
Gastroskopie im Intervall
Ja
Nein
Ausschluss untere GIT Blutung
Ja
Nein
Therapie der Obstipation
Ja
Nein
Antibiose bei Divertikulitis
Ja
Nein
Besserung der Beschwerden unter
Nahrungskarenz
Ja
Nein
Kontroll-Coloskopie
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Ja
Nein
Coloskopie im Intervall
Ja
Nein
Kapselendoskopie oder MDP empfohlen
Ja
Nein
Ascites Gewichtsverlust durch Diuretika
kg
Ascitespunktion
Liter
Diuretische Therapie bei Aszites
Ja
Nein
exokrine Pankreasinsuffizienz
Ja
Nein
Zeichen von Pankreasinsuffizienz, Therapie mit
Enzymen
Ja
Nein
Diabetes
BZ initial
mg/dl
BZ Monitoring
Ja
Nein
orales Antidiabetikum
Ja
Nein
Mischinsulin
Ja
Nein
Insulintherapie
Ja
Nein
Blutzuckerwerte
Die Blutzuckerwerte lagen unter der
entsprechenden Behandlung während
des stationären Aufenthaltes nicht im
zufriedenstellenden Bereich. Eine
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weitere Einstellung ist noch erforderlich.
(BZ Werte nicht ausreichend)
Unter der Gabe von oralen Antidiabetika
und der Therapie mit einem
Langzeitinsulin konnte im weiteren
Verlauf der Blutzucker wieder eingestellt
werden. (gut eingestellt)
Die Blutzuckerwerte lagen unter der
entsprechenden Behandlung während
des stationären Aufenthaltes weitgehend
im zufriedenstellenden Bereich. (Verlauf
gut)
Niere
HWI
Unter supportiver Behandlung zeigte
sich eine Besserung des
Harnwegsinfektes. (HWI supportiv)
Labordiagnostisch und klinisch fand sich
eine Zystitis, es erfolgte eine
entsprechende antibiotische
Behandlung, worunter die Beschwerden
deutlich zurückgingen. (Therapie mit
Antibiose)
Substitution bei Hypokaliämie
Ja
Nein
Substitution bei Hyponatriämie
Ja
Nein
Oligoanurie
Die initial bestehende Oligoanurie
besserte sich nach Stimulation mit einem
Schleifendiuretikum. (Besserung der
Oligoanurie durch Furosemid)
Trotz Stimulationsversuchen mit
Furosemid zeigte sich eine Oligoanurie.
(Oligoanurie trotz Furosemid)
ZNS
Synkope ohne kardiovaskuläre Ursache
Ja
Nein
Keine Schmerztherapie
Ja
Nein
Schmerztherapie
Ja
Nein
Stroke Therapie
Es konnte ein zunehmend verbessertes
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Sprachverständnis und
Sprachproduktion erreicht werden.
(Sprachverständnis und
Sprachproduktion gebessert)
Unter multiprofessionellem
Therapiesetting zeigte sich ein gutes
Theapiepotential mit Therapiesenisibiltät
der neurologischen Defizite.
Erfreulicherweise kam es dann im
weiteren Verlauf zu einer deutlichen
Rückbildung der bei Aufnahme
bestehenden Symptomatik. (Stroke mit
Besserung)
Bei
Thrombozytenaggregationshemmung mit
Acetylsalicylsäure wurde zusätzlich eine
low dose Heparinisierung durchgeführt
desweiteren hämodilutorische
Maßnahmen im Sinne von
Elektrolytlösungen. (Stroke Therapie)
TIA Therapie
Unter multiprofessionellem
Therapiesetting zeigte sich ein gutes
Theapiepotential mit Therapiesenisibiltät
der neurologischen Defizite. Unter
diesen Maßnahmen kam es
erfreulicherweise bereits im weiteren
Verlauf zu einer deutlichen Rückbildung
der bei Aufnahme bestehenden
Symptomatik. (TIA mit Besserung der
Beschwerden)
Bei
Thrombozytenaggregationshemmung mit
Acetylsalicylsäure wurde zusätzlich eine
low dose Heparinisierung durchgeführt
desweiteren hämodilutorische
Maßnahmen im Sinne von
Elektrolytlösungen. (TIA Therapie)
Keine weiteren Synkopen
Ja
Nein
Ambulante Vorstellung
Als weitere diagnostische Maßnahme
empfehlen wir eine ambulante HNO-
ärztliche Vorstellung (HNO-Vorstellung)
Eine neurologische Vorstellung zur
weitere Abklärung sollte noch erfolgen.
(Neurologie-Vorstellung)
Eine psychiatrische Vorstellung ist nach
Entlassung indiziert auch im Hinblick auf
eine weitere diagnostische Verifizierung
und medikamentöse Einstellung.
(Psychiatrie)
Lunge
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Ruhedyspnoe
Ja
Nein
Aspiration
Ja
Nein
Husten
Ja
Nein
Exsikkose
Ja
Nein
Fieber
°C
SPO2 Normalbefund
Ja
Nein
SpO2 unter 90%
Ja
Nein
SpO2
%
respiratorische Insuffizienz
Ja
Nein
endotracheales Sputum
Ja
Nein
kein Sputum
Ja
Nein
Atemtherapie
Ja
Nein
Kortisontherapie bei Bronchospastik
Ja
Nein
Antibiose
Pleurapunktion
Liter
Zytologie von Pleurapunktion
Ja
Nein
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Krankheitsverlauf
Unter antibiotischer Therapie und
physikalisch lungenpflegerischen
Maßnahmen (Vibraxmassage,
Inhalationen) besserte sich der AZ
zusehends. (AZ Besser	)
Das Fieber ging zurück. (Fieber geht
zurück)
Die Nahrungsaufnahme war im weiteren
Verlauf unkompliziert bei zunehmender
Verbesserung der Vigilanz bei
Fieberfreiheit und Ausgleich des Wasser-
und Elektrolytdefizites. (Kostaufbau
besser)
Labordiagnostisch besserten sich die
Werte. Die Infektion klang zusehends ab.
(Labor besser)
Anfangs bestehende, nicht
punktionswürdige Pleuraergüsse waren
zum Verlegungszeitpunkt fast komplett
unter diuretischer Therapie
zurückgebildet. (Pleuraerguss
gebessert)
Bis zur Entlassung haben wir mit der
Reduktion der Cortisondosis bereits
begonnen. Im ambulanten häuslichen
Bereich sollte versucht werden, die oral
systemisch applizierte Cortisondosis
jeden 2. Tag um 2,5 mg bis zum
kompletten Ausschleichen zu reduzieren.
(Reduktion Cortisondosis bereits
begonnen)
Es konnte im Verlauf eine Verbesserung
der respiratorischen Situation erzielt
werden. (Respiratorische Situation
deutlich Besser)
Es konnte vorübergehend eine
Verbesserung der respiratorischen
Situation erzielt werden. (Respiratorische
Situation nur wenig besser)
Bilddiagnostisch war zum
Entlassungszeitpunkt kein Infiltrat mehr
nachweisbar. (Röntgen bei Entlassung
kein Infiltrat)
Lungenembolie
Ja
Nein
Infektallergische Ursache
Ja
Nein
Pleuraerguss
Ja
Nein
exazerbierte COPD
Ja
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Nein
Bronchopneumonie
Ja
Nein
Lobärpneumonie
Ja
Nein
Aspirationspneumonie
Ja
Nein
Procedere
Im ambulanten häuslichen Bereich sollte
versucht werden, die oral systemisch
applizierte Cortisondosis jeden 2. Tag bis
zum kompletten Ausschleichen zu
reduzieren. (Cortisondosis nach
Entlassung weiter reduzieren)
Eine Sauerstoffheimtherapie besteht
bereits. (O2 Heimtherapie besteht)
Wir veranlassten für die häusliche
Versorgung einen 02-Konzentrator. (O2
Konzentrator besorgt)
Die verordnete Behandlung mit einem
inhalativen Bronchospasmolyticum sollte
entweder im Bedarfsfall oder als
Dauertherapie die systemische
Corticoidbehandlung ersetzen. (weiter
inhalatives Broncholytikum)
Psychiatrie
Verlegung in psychiatrische Klinik empfohlen
Ja
Nein
Suizidgefahr
Ja
Nein
Tranxilium
Ja
Nein
Der Patient drohte mit körperlicher Gewalt.
Ja
Nein
Keine Entzugssymptomatik
Ja
Nein
Patient psychotisch
Ja
Nein
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Patient im Verlauf psychisch unauffällig
Ja
Nein
starke Entzugssymptomatik
Ja
Nein
Patient verweigert Maßnahmen
Ja
Nein
Langzeittherapie
Ja
Nein
Verhaltenstherapie
Ja
Nein
Epikrise
Verschlechterung von Cor und Pulmo
Ja
Nein
Patient komatös
Ja
Nein
Todesdatum
Todesursache
Patientenverfügung
Es wurde in der Patientenverfügung
auch der Verzicht auf
intensivmedizinische Maßnahmen
festgelegt. (Verzicht auf
intensivmedizinische Maßnahmen)
Es wurde in der Patientenverfügung
auch der Verzicht auf weitere
Reanimationsmaßnahmen festgelegt.
(Verzicht auf Reanimation)
Wir bedauern den unglücklichen Verlauf.
Ja
Nein
Konsil
Konsil Neurologie
Konsil Chirurgie
21 / 28
Physician letter Internal Medicine
Konsil Psychiatrie
Konsil HNO
Elektive Cholecystektomie
Ja
Nein
Verlauf
AZ gebessert
Ja
Nein
Röntgenbild der Lunge gebessert
Ja
Nein
Pulsoxymetrie gute Sättigung
Ja
Nein
Restascites
Ja
Nein
Stressulcusprophylaxe
Ja
Nein
Keine Besserung unter Antibiose
Ja
Nein
Besserung unter Antibiose
Ja
Nein
Entfiebert
Ja
Nein
Entzündungsparameter besser
Ja
Nein
Tetanus
Der Tetanusimpfschutz ist nicht mehr
ausreichend. Es wurde eine
Simultanimpfung durchgeführt. (Tetanus
Auffrischung)
Der Tetanusimpfschutz besteht nicht
mehr. Es wurde eine Auffrischimpfung
durchgeführt. (Tetanus Simultanimpfung)
Der Tetanusimpfschutz besteht
anamnestisch. Es erfolgt noch eine
Vorstellung in Ihrer hausärztlichen Praxis
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zur Vorlage des Impfpasses.
(Tetanusschutz anamnestisch)
Perfusor
Bei progredienter Hypotonie erfolgte die
Behandlung mit Vasopressoren
(Dobutamin-Perfusor). (Dobutamin
Perfusor)
Im Rahmen der hypertensiven
Entgleisung zeigte sich unter einem intial
eingesetzten Ebrantil Perfusor eine
deutliche Besserung. (Ebrantil Perfusor)
Die hyperglykämische Stoffwechsellage
konnte initial mit einem Insulinperfusor
ausgeglichen werden. (Insulin Perfusor)
ZVK Anlage
Ja
Nein
initialer ZVD
letzter ZVD
Aktuelles Gewicht
kg
Gewicht bei Aufnahme
kg
Gewichtsdifferenz
kg
Thromboseprophylaxe
Hinweise für eine kritische Blutung oder
Tumorerkrankung fanden wir nicht (keine
Mikrohämaturie, kein Hinweis für
occultes Blut im Stuhl). Wir begannen
eine zu der vorausgehenden
niedermolekularen Heparinisierung
überlappende orale Antikoagulation mit
Marcumar, welche über 12 Monate
beibehalten werden sollte. (Marcumar
Behandlung begonnen)
In der Phase der Immobilisierung wurde
eine Thromboseprophylaxe mit
niedermolekularen Heparinen
durchgeführt. (Thromboseprophylaxe)
BZ Werte im Normbereich
Ja
Nein
Medikation
Die antibiotische Vorbehandlung wurde
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in unveränderter Tagesrhythmik und
Dosierung fortgesetzt. (antibiotische
Vorbehandlung fortgesetzt)
Die bestehende Vormedikation aus
kardiologischer Sicht wurde in
unveränderter Dosierung beibehalten.
(Kardiologische Vormedikation hier
beibehalten)
Die vorbestehende Vormedikation wurde
hier fortgesetzt. (Vormedikation
fortgesetzt)
auf folgende Medikation wurde verzichtet
Dauer parenterale Ernährung
Tage
Kostaufbau komplikationslos
Ja
Nein
Mobilisation und Sozialdienst
Mobilisation
Bei fehlender Mitarbeit war eine
Mobilisierung zunächst nur
eingeschränkt möglich. (keine
Mobilisation möglich bei fehlender
Mitarbeit)
Der Lagewechsel in und aus dem Bett
gelang noch mit Unterstützung einer
Hilfsperson.	 (Lagewechsel im Bett)
Eine Mobilisierung war im Bett möglich.
(Mobilisation im Bett)
Die weitere Mobilisation bei klinischer
Besserung des Patienten gelang bis in
den Lehnstuhl.	 (Mobilisation im
Lehnstuhl)
Zuletzt war die Mobilisierung in
Begleitung der Physiotherapeutin im
Zimmer möglich.	 (Mobilisation im
Zimmer)
Gegen Ende des Aufenthaltes konnte die
Mobilisierung mit fremder Unterstützung
und Supervision auf Stationsebene mit
Rollator erfolgen.	 (Stationsflur mit
Rollator)
Die Mobilisation konnte am Ende
problemlos mit krankengymnastischer
Unterstützung für ebenerdige
Spaziergänge durchgeführt werden.
(Stationsflur mit Unterstützung)
Pflegestufe
Eine Pflegestufe wurde beantragt.
(beantragt)
Eine Pflegestufe 1 liegt vor. (Stufe 1)
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Eine Pflegestufe 2 liegt vor. (Stufe 2)
Eine Pflegestufe 3 liegt vor. (Stufe 3)
Folgende Hilfsmittel wurden bestellt
Betreuung erfolgt durch Angehörige (Name Tel:).
Es wurde eine gerichtliche Betreuung durch das
Amtsgericht beantragt.
Ja
Nein
Kontakt mit Gesundheitsamt zur Klärung
häusliche Lage
Ja
Nein
Langzeitbehandlung Anmeldung erfolgt
Ja
Nein
Rehabilitation
Eine stationäre geriatrische
Rehabilitationsbehandlung ist bereits
angemeldet worden. (Ger. Reha
angemeldet)
Eine stationäre kardiologische
Rehabilitationsbehandlung ist bereits
angemeldet worden. (Kardio Reha
angemeldet)
Eine stationäre neurologische
Rehabilitationsbehandlung ist bereits
angemeldet worden. (Neuro Reha
angemeldet)
Aufklärung und Entlassung
Aufklärung Angehörige
Die Angehörigen sind über die
Erkrankung die bereits erfolgte
Behandlung und noch weitere
Therapiemöglichkeiten von uns
eingehend aufgeklärt worden. (Info an
Angehörige über Diagnostik und
Therapie)
Wir standen während des stationären
Aufenthaltes in mehrfachem Kontakt mit
den Angehörigen. (Kontakt mit
Angehörigen erfolgt)
Marcumarpass ausgehändigt, Aufklärung über
Nebenwirkungen
Ja
Nein
Procedere
Die Entlassung erfolgt vorzeitig auf
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eigene Verantwortung entgegen
ärztlichen Rat. (Entlassung gegen
ärztlichen Rat)
Die Entlassung erfolgt vorzeitig auf
eigene Verantwortung entgegen
ärztlichen Rat in die Obhut der
Erziehungsberechtigten. (Entlassung
gegen ärztlichen Rat in Obhut
Erziehungsberechtigten)
Die Entlassung erfolgt in Ihre weitere
ambulante Betreuung. (Entlassung zum
Hausarzt)
Nach ausführlichem Gespräch mit den
Angehörigen wurde derzeit bei völliger
Beschwerdefreiheit und in Anbetracht
der Aetas von einer weiteren invasiven
Diagnostik abgesehen. (keine invasive
Diagnostik bei Beschwerdefreiheit)
Bei Schwierigkeiten in der häuslichen
Versorgung erfolgte eine Verlegung zur
Kurzzeitpflege in das Pflegeheim.
(Kurzzeitpflege)
Bei Schwierigkeiten in der häuslichen
Versorgung erfolgte eine Verlegung in
das Pflegeheim. (Pflegeheim)
Wir haben während des stationären
Aufenthaltes den Angehörigen
angeboten, eine Verlegung in ein
entsprechendes Zentrum zu intensiveren
Maßnahmen zu veranlassen. Dies wurde
uns mehrfach mündlich wie schriftlich
abgelehnt. (Verlegung von Angehörigen
abgelehnt)
Die Verlegung wurde auch seitens des
Pat. abgelehnt. (Verlegung von Patient
abgelehnt)
Der Pat. wird sich im Anschluss an den
stationären Aufenthalt in Ihrer Praxis
vorstellen. (Vorstellung in Praxis nach
Entlassung)
Verlegung in andere Klinik:
Rückübernahme möglich
Ja
Nein
Verlegung in Psychiatrie mit Polizei
Ja
Nein
Rehabilitation
Zur weiteren geriatrischen Rehabilitation
erfolgte die Verlegung in Ihre Klinik.
(Geriatrische Reha)
Zur weiteren kardiologischen
Rehabilitation erfolgte die Verlegung in
Ihre Klinik. (Kardiologische Reha)
Zur weiteren neurologischen
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Rehabilitation erfolgte die Verlegung in
Ihre Klinik. (Neurologische Reha)
Procedere
Labor-Kontrolluntersuchungen
Engmaschige BB-Kontrolle (BB-
Kontrolle)
Kontrolle der Entzündungsparameter
(CRP-Kontrolle)
Kontrolle der Elektrolyte (Elektrolyt-
Kontrolle)
Kontrolle des INR-Wertes (INR)
Kontrolle von Kreatinin (Kreatinin-
Kontrolle)
Wir bitten um weitere Kontrollen der
Blutzuckerwerte und ggf. um eine
Modifikation der Behandlung
(regelmäßige BZ Kontrollen)
Diagnostik
Eine erneute Gastroskopie im Intervall
sollte noch durchgeführt werden
(erneute Gastroskopie)
Eine weitere Abklärung mittels
Kapselendoskopie oder MDP wäre bei
weiteren Beschwerden ggf. sinnvoll
(Kapselendoskopie)
Es sollte im Falle einer benignen
Histologie eine Kontrollcoloskopie
durchgeführt werden, hierzu wäre eine
stationäre Vorstellung bei uns möglich
(Kontrollcoloskopie)
ggf. weitere Kontrolle des LZ EKG
(Kontrolle LZ EKG	)
ggf. weitere Kontrolle der
Langzeitblutdruckmessung	 (Kontrolle LZ
RR)
Therapie
Ausgleich mit Actrapid n. BZ. vor
Mahlzeit n. Schema: 180-210 mg/dl 4 IE,
210-240 mg/dl 6 IE, 240-270 mg/dl 8 IE,
270-300 mg/dl 10 IE	 (Actrapid)
Die antibiotische Behandlung sollte nach
Entlassung noch in dem angegeben
Zeitfenster weiter fortgeführt werden
(Antibiose weiter)
ASS in Kombination mit Clopidogrel über
9 Monate (Clopidogrel und ASS über 9
Monate)
Die Gabe von Kortikosteroiden sollte
nach Entlassung noch weiter reduziert
werden 	 (Kortison reduzieren)
Ein orales kombiniertes Kortikoid sollte
entweder im Bedarfsfall oder als
Dauertherapie die systemische
Corticoidbehandlung ersetzen	 (Orales
Kortison)
27 / 28
Physician letter Internal Medicine
Statintherapie mit Ziel LDL unter 100
mg%	 (Statin LDL)
Tgl. Gewichtskontrolle ggf.
Therapiekorrektur der diuretischen
Medikation   	 (täglich Gewichtskontrolle)
TP 1,5-1,8 L/Tag	 (TP 1,5 l/d)
Vorstellung
Ambulante allergologische Vorstellung,
ggf. Desensibilisationstherapie
(Allergologe	)
Wir empfehlen eine erneute ambulante
D-ärztliche Vorstellung (D-Arzt)
Dermatologische Vorstellung zur
Abklärung und Behandlung der
Hauteffloreszenz 	 (Derma)
Gynäkologische Vorstellung zur weiteren
Behandlung	 (Gyn)
Wir empfehlen eine HNO ärztliche
Vorstellung	 (HNO-Vorstellung)
kardiologische Vorstellung im Intervall
zur weiteren Kontrolle  	 (Kardiologie-
Vorstellung)
Zur weiteren diagnostischen Abklärung
sollte eine neurologische Vorstellung
erfolgen	 (Neurologie-Vorstellung	)
Orthopädische Vorstellung zur weiteren
Behandlung	 (Ortho	)
Eine urologische Vorstellung sollte noch
erfolgen	 (Urologie-Vorstellung)
Vorstellung in der ambulanten
chirurgischen Sprechstunde in unserer
Klinik (WV in der Chirurgie)
Nikotinentwöhnung
Ja
Nein
Selbsthilfegruppe
Ja
Nein
Diät
Diabetes Diät (1)
Gewichtsreduktion (2)
Kaliumreiche Diät (3)
Marcumar Diät (4)
Wirkstoffgleiche Präparate können verwendet
werden
Ja
Nein
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Eligibility Breast Cancer NCT00202059
Effects of Zometa and Physical Activity on Bone Density in
Women Receiving Chemotherapy for Breast Cancer; ODM
derived from: https://clinicaltrials.gov/show/NCT00202059
All rights reserved. Please visit https://medical-data-
models.org/forms/16282
Eligibility Breast Cancer
NCT00202059
Inclusion Criteria
women with stage i - ii breast cancer*
Yes
No
ages 40 - 55*
Yes
No
pre- or peri-menopausal*
Yes
No
within 1 month of beginning adjuvant or
neoadjuvant chemotherapy*
Yes
No
baseline lumbar spine and total hip bmd > -2.0
sd*
Yes
No
able to read and write english*
Yes
No
signed consent form*
Yes
No
Exclusion Criteria
previous treatment with bisphosphonates*
Yes
No
laboratory evidence of renal disease*
Yes
No
previous tram flap reconstructive surgery*
Yes
No
positive pregnancy test*
Yes
No
mental illness that precludes the patient from
giving informed consent*
Yes
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No
laboratory evidence of hepatic disease*
Yes
No
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Eligibility Breast Cancer NCT00093002
Fulvestrant (FASLODEX™) as a Treatment in
Postmenopausal Women With Estrogen Receptor Positive
Breast Cancer; ODM derived from:
https://clinicaltrials.gov/show/NCT00093002
All rights reserved. Please visit https://medical-data-
models.org/forms/16283
Eligibility Breast Cancer
NCT00093002
Inclusion Criteria
postmenopausal women defined as women who
have stopped having menstrual periods*
Yes
No
written informed consent to participate in the trial*
Yes
No
biopsy confirmation of invasive breast cancer*
Yes
No
evidence of hormone sensitivity*
Yes
No
willingness to undergo biopsies*
Yes
No
Exclusion Criteria
any previous treatment for breast cancer*
Yes
No
unwillingness to stop taking any drug known to
affect sex hormonal status or a patient in which it
would be inappropriate to stop.*
Yes
No
any severe concurrent condition that would
preclude surgery or that would jeopardize
compliance with the study, e.g., uncontrolled
cardiac disease or uncontrolled diabetes mellitus*
Yes
No
the presence of more than one primary tumor*
Yes
No
history of hypersensitivity to castor oil*
Yes
No
history of known bleeding disorders*
Yes
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Eligibility Breast Cancer NCT00196859
Study in Elderly Patients With Early Breast Cancer (ICE);
ODM derived from:
https://clinicaltrials.gov/show/NCT00196859
All rights reserved. Please visit https://medical-data-
models.org/forms/16284
Eligibility Breast Cancer
NCT00196859
Inclusion Criteria
1. written informed consent prior to beginning
specific protocol procedures, including expected
cooperation of the patients for the treatment and
follow-up, must be obtained and documented
according to the local regulatory requirements.*
Yes
No
2. histologically confirmed unilateral or bilateral
primary carcinoma of the breast.*
Yes
No
3. age at diagnosis ≥ 65 years*
Yes
No
4. adequately surgical treatment with complete
resection (ro) of the tumor and > or = 10 axillary
nodes. sole sentinel node biopsy is allowed if the
sentinel node shows no tumor involvement.*
Yes
No
5. node positive disease irrespective of additional
risk factors or node negative disease with at least
one other risk factor (histologic tumor size > or =
2 cm, grade ii or iii, er and pr negative)*
Yes
No
6. no evidence for distant metastasis after
complete diagnostic work up*
Yes
No
7. performance status ecog < or = 2*
Yes
No
8. charlson scale of < or = 2*
Yes
No
9. estimated life expectancy of at least 5 years
(irrespective of breast cancer diagnosis)*
Yes
No
10. the patient must be accessible for treatment
and follow-up.*
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Yes
No
Exclusion Criteria
1. known hypersensitivity reaction to the
compounds or incorporated substances or known
dihydropyrimidine dehydrogenase deficiency.*
Yes
No
2. inadequate organ function including:
leucocytes < 3,5 g/l, platelets < 100 g/l , bilirubin
1.25 times above normal limits, creatinine
clearance calculated by the cockroft-gold formula
of above 50 ml/min, uncompensated cardiac
function, severe and relevant co-morbidity that
would interact with the application of cytotoxic
agents or the participation in the study*
Yes
No
3. another primary malignancy with an event-free
survival of < 5 years, except curatively treated
basalioma of the skin*
Yes
No
4. time since axillary dissection > 3 months*
Yes
No
5. locally advanced, non-operable breast cancer*
Yes
No
6. previous invasive breast carcinoma*
Yes
No
7. previous treatment with cytotoxic agents for
any reason*
Yes
No
8. concurrent treatment with hormonal
replacement therapy (treatment should be
stopped before entering the trial).*
Yes
No
9. previous treatment with bisphosphonates for
osteoporosis is allowed, however this treatment
has to be substituted by the trial medication*
Yes
No
10. concurrent specific systemic anti-tumor
treatment or treatment with experimental
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compounds within the last 6 months*
Yes
No
11. concurrent treatment with other tumor specific
experimental drugs. participation in another
clinical trial with any investigational not marketed
drug within 30 days prior to study entry.*
Yes
No
12. concurrent treatment with virostatic agents
like brivudine or analoga sorivudine, concurrent
treatment with aminoglycosides*
Yes
No
13. male patients*
Yes
No
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EBMT Inherited Disorders General
Information
ODM form derived from 16pp EBMT Multiple Myeloma
10PCD. please refer to:
http://www.ebmt.org/Contents/Data-
Management/Registrystructure/MED-
ABdatacollectionforms/Pages/MED-AB-data-collection-
forms.aspx
All rights reserved. Please visit https://medical-data-
models.org/forms/16285
EBMT Inherited Disorders
EBMT FORM GENERAL INFORMATION
EBMT Centre Identification Code (CIC)
Hospital
Unit
Name of contact person
Telephone number of contact person
Fax
E-mail
Date of this report
STUDY/TRIAL
Patient following national / international study /
trial
no (1)
yes (2)
unknown (3)
Name of study / trial
PATIENT
To be entered only if patient previously reported
Hospital Unique Patient Number or Code
First name(s)_surname(s)
Registrations will not be accepted if this item is
left blank
Date of birth
Sex
Male (1)
1 / 12
Female (2)
ABO Group
Rh factor Patient
Absent (1)
Present  (2)
Not evaluated (3)
DISEASE
Date of Diagnosis
Primary Disease Diagnosis
Acute Leukaemia (Acute Leukaemia)
Acute Lymphoblastic Leukaemia (ALL)
(Acute Lymphoblastic Leukaemia (ALL))
Acute Myelogenous Leukaemia (AML)
(Acute Myelogenous Leukaemia (AML))
Autoimmune disease (Autoimmune
disease)
Bone marrow failure including Aplastic
anaemia (Bone marrow failure including
Aplastic anaemia)
Chronic Leukaemia (Chronic Leukaemia)
Chronic Lymphocytic Leukaemia
(Chronic Lymphocytic Leukaemia)
Chronic Myeloid Leukaemia (CML)
(Chronic Myeloid Leukaemia (CML))
Haemoglobinopathies
(Haemoglobinopathiy)
Histiocytic disorders (Histiocytic
disorders)
Hodgkin´s Disease (Hodgkin´s Disease)
Inherited disorders (Inherited disorders)
Juvenile Idiopathic Arthritis (Juvenile
Idiopathic Arthritis)
Lymphoma (Lymphoma)
MD/ MPN (MD/ MPN)
MDS (MDS)
Metabolic disorders (Metabolic
disorders)
Multiple Sclerosis (Multiple Sclerosis)
Myelodysplastic syndromes
(Myelodysplastic syndromes)
Myeloma/ Plasma cell disorder
(Myeloma/ Plasma cell disorder)
Myeloproliferative neoplasm
(Myeloproliferative neoplasm)
Non Hodgkin (Non Hodgkin)
Other diagnosis (Other diagnosis)
Primary immune deficiencies (Primary
immune deficiencies)
Secondary Acute Leukaemia (do not use
if transformed from MDS/MPN)
(Secondary Acute Leukaemia (do not
use if transformed from MDS/MPN))
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Solid Tumour (Solid Tumour)
Systemic Lupus (Systemic Lupus)
Systemic Sclerosis (Systemic Sclerosis)
Other diagnosis, specify
SPECIFICATIONS OF THE DISEASE
Has the information requested in this section
been submitted with a previous HSCT
registration?
No: Proceed with this section (No:
Proceed with this section)
Yes: go to `Pre-HSCT treatment` (Yes:
go to `Pre-HSCT treatment`)
CLASSIFICATION and SPECIFICATIONS OF
THE DISEASE
primary immune deficiencies (1)
Inherited disorders of metabolism (2)
Other inherited disorders (3)
Familial lymphohistiocytosis (4)
T- B- CELLS SCID, T- B+ CELLS SCID
ADA deficiency (Adenosine deaminase
defic.) (ADA deficiency (Adenosine
deaminase defic.))
Alpha c (Alpha c)
Artemis (Artemis)
IL-7R alpha (IL-7R alpha)
JAK 3 (JAK 3)
Ligase IV (Ligase IV)
PNP (Purine nucleoside phosphorylase
defic.) (PNP (Purine nucleoside
phosphorylase defic.))
Rag-1 or Rag-2 (Rag-1 or Rag-2)
Reticular dysgenesis (Reticular
dysgenesis)
SCID other (SCID other)
T- B- cells SCID, other (T- B- cells SCID,
other)
T- B- cells SCID, unspecified (T- B- cells
SCID, unspecified)
T- B+ cells SCID, other (CD45, CD3 ) (T-
B+ cells SCID, other (CD45, CD3 ))
T- B+ cells SCID, unspecified (T- B+
cells SCID, unspecified)
ZAP 70 deficiency (ZAP 70 deficiency)
SCID (Severe Combined Immune Deficiency) if
other, please specify
CID (Combined Immune Deficiency)
Omenn syndrome (1)
CID other (2)
CID  if other, please specify
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Other primary immune deficiencies
Agranulocytosis (Kostmann) (1)
Interferon alpha (10)
IPEX syndrome (11)
Leukocyte adhesion (12)
Wiskott Aldrich syndrome (13)
X-linked lymphoproliferative syndrome
(Purtilo) (14)
Ataxia telangiectasia (2)
Bare lymphocyte syndrome (lack of HLA
ag expression) (3)
Cartilage hair hypoplasia / dyskeratosis
congenita (4)
CD40 Ligand (5)
Chediak-Higashi syndrome (6)
Chronic granulomatous disease (7)
DiGeorge syndrome (8)
Griscelli syndrome (9)
Inherited disorders of metabolism
Adrenoleukodystrophy
(Adrenoleukodystrophy)
Aspartyl glucosaminuria (Aspartyl
glucosaminuria)
B-glucuronidase deficiency (VII) (B-
glucuronidase deficiency (VII))
Fucosidosis (Fucosidosis)
Gaucher disease (Gaucher disease)
Glucose storage disease (Glucose
storage disease)
Hunter syndrome (II) (Hunter syndrome
(II))
Hurler syndrome (IH) (Hurler syndrome
(IH))
I-cell disease (I-cell disease)
Krabbe disease (globoid leukodystrophy)
(Krabbe disease (globoid
leukodystrophy))
Lesch-Nyhan (HGPRT deficiency)
(Lesch-Nyhan (HGPRT deficiency))
Mannosidosis (Mannosidosis)
Maroteaux-Lamy (VI) (Maroteaux-Lamy
(VI))
Metachromatic leukodystrophy
(Metachromatic leukodystrophy)
Morquio (IV) (Morquio (IV))
Mucolipidoses, not otherwise specified
(Mucolipidoses, not otherwise specified)
Mucopolysaccharidosis (V)
(Mucopolysaccharidosis (V))
Mucopolysaccharidosis, not otherwise
specified (Mucopolysaccharidosis, not
otherwise specified)
Neuronal ceriod – lipofuscinosis (Batten
disease) (Neuronal ceriod –
lipofuscinosis (Batten disease))
Niemann-Pick disease (Type A,B)
(Niemann-Pick disease (Type A,B))
Niemann-Pick disease (Type C,D,E)
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(Niemann-Pick disease (Type C,D,E))
Other (Other,)
Polysaccharide hydrolase abnormalities,
unspecified (Polysaccharide hydrolase
abnormalities, unspecified)
Sanfilippo (III) (Sanfilippo (III))
Scheie syndrome (IS) (Scheie syndrome
(IS))
Wolman disease (Wolman disease)
Other inherited disorders
Glanzmann (1)
Platelet defect, not otherwise specified
(2)
Osteopetrosis (3)
Osteoclast defect, not otherwise
specified (4)
Other (5)
Stored material
no  (1)
yes (2)
unknown (3)
Stored material if yes
DNA (1)
PBL (2)
B-cell line (3)
Fibroblasts (4)
Other (5)
INHERITANCE
Autosomal recessive  (Autosomal
recessive proven)
Autosomal recessive suspected
(Autosomal recessive suspected)
unknown (unknown)
X-linked proven (X-linked proven)
X-linked suspected (X-linked suspected)
Chromosome analysis
Normal (1)
Abnormal (2)
Not done or failed (3)
Unknown (4)
If abnormal
Alpha c (1)
JAK 3 (2)
Rag-1 (3)
Rag-2 (4)
ADA (5)
NUCLEOTIDES
Allele 1 (Allele 1*)
Allele 2 (Allele 2)
PROTEIN
Allele 1 (Allele 1)
Allele 2 (Allele 2)
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STATUS OF DISEASE AT HSCT
Date of HSCT
HAEMATOLOGICAL VALUES
Platelets   (1)
Reticulocytes (10)
White Blood Cells (2)
Lymphocytes (3)
T-cells (4)
CD4+ cells (5)
CD8+ cells (6)
NK cells (7)
B-cells (8)
Granulocytes (9)
Mixed leukocyte culture (MLC) reactivity
Absent (1)
Partial (2)
Normal (3)
Not evaluated (4)
Mitogen induced lymphocyte proliferation
Absent (1)
Partial (2)
Normal (3)
Not evaluated (4)
Natural killer activity
Absent (1)
Partial (2)
Normal (3)
Not evaluated (4)
IMMUNOGLOBULINS (B-CELL FUNCTION)
Serum IgM (1)
Serum IgA (2)
Serum IgG (3)
Serum IgE (4)
Antibody response
Absent (1)
Decreased (2)
Normal or elevated (3)
Not evaluated (4)
Renal impairment
no (1)
yes (2)
Not evaluated (3)
Unknown (4)
Malnutrition
No (1)
Yes (2)
Not evaluated (3)
Unknown (4)
Protracted diarrhea
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No (1)
Yes (2)
Not evaluated (3)
Unknown (4)
Respiratory impairment
No (1)
Yes (2)
Not evaluated (3)
Unknown (4)
Liver impairment
No (1)
Yes (2)
Not evaluated  (3)
unknown (4)
Infections
no (1)
yes  (2)
unknown (3)
Septicemia
Mycobacteria (1)
Pneumocystis carinii (2)
Virus (3)
Bacteria (4)
Cryptosporidia (5)
Fungi (6)
Unknown (7)
Other (8)
Septicemia if other
Pulmonary
Mycobacteria (1)
Pneumocystis carinii (2)
Virus (3)
Bacteria (4)
Cryptosporidia (5)
Fungi (6)
Unknown (7)
Other (8)
Meningeal
Mycobacteria (1)
Pneumocystis carinii (2)
Virus (3)
Bacteria (4)
Cryptosporidiosis (5)
Fungi (6)
Unknown (7)
Other (8)
Skin infection
Mycobacteria (1)
Pneumocystis carinii (2)
Virus (3)
Bacteria (4)
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Cryptosporidia (5)
Fungi (6)
Unknown (7)
Other (8)
Skin infection if other, please specify
Liver
Mycobacteria (1)
Pneumocystis carinii (2)
Virus (3)
Bacteria (4)
Cryptosporidiosis (5)
Fungi (6)
Unknown (7)
Other (8)
Liver if other, please specify
Bone or joints
Mycobacteria (1)
Pneumocystis carinii (2)
Virus (3)
Bacteria (4)
Cryptosporidia (5)
Fungi (6)
Unknown (7)
Other (8)
Bone or joints if other, please specify
Gut infection
Mycobacteria (1)
Pneumocystis carinii (2)
Virus (3)
Bacteria (4)
Cryptosporidiosis (5)
Fungi (6)
Unknown (7)
Other (8)
if other, please specify
Undetermined
Mycobacteria (1)
Pneumocystis carinii (2)
Virus (3)
Bacteria (4)
Cryptosporidia (5)
Fungi, other (6)
Unknown (7)
Other (8)
if other, please specify
Other infections
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Mycobacteria (1)
Pneumocystis carinii (2)
Virus (3)
Bacteria (4)
Cryptosporidia (5)
Fungi, other (6)
Unknown (7)
Other (8)
Other infections if other, please specify
GVHD STATUS PRIOR TO HSCT
Absent (1)
Present (2)
Not evaluated (3)
Unknown (4)
if GVHD STATUS PRIOR TO HSCT present,
Organ affected
Gut (Gut)
Liver (Liver)
Skin (Skin)
Lymphadenopathy acute GVH disease
no (no)
unknown (unknown)
yes (yes)
Cause of the GvHD
Blood transfusion (1)
Maternal engraftment (2)
unknown (3)
Number of maternal T cells
Test used
Cytogenetics (Cytogenetics)
HLA typing (HLA typing)
IL2 T cell line (IL2 T cell line)
Microsatellite (Microsatellite)
Treatment
no (no)
unknown (unknown)
yes (yes)
RBC
< 20 UNITS (< 20 UNITS)
> 50 UNITS (> 50 UNITS)
20-50 UNITS (20-50 UNITS)
NONE (NONE)
UNKNOWN (UNKNOWN)
Platelets
NONE (1)
< 20 UNITS (2)
20-50 UNITS (3)
> 50 UNITS (4)
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UNKNOWN (5)
ADDITIONAL TREATMENT POST-HSCT
ADDITIONAL DISEASE TREATMENT
Yes
No
ADDITIONAL DISEASE TREATMENT if yes
Planned (planned before HSCT took
place) (1)
Not planned (for relapse/progression or
persistent disease) (2)
BEST DISEASE RESPONSE AT 100
DAYS POST-HSCT
DISEASE STATUS AT 100 DAYS AFTER HSCT
Cured (1)
Improved (2)
No change (3)
Worse (4)
Unknown (5)
As close to the 3rd month interval as possible)
T-cell
Absent (Absent)
Absent (Absent)
Full (Full)
Mixed (Mixed)
Date achieved
B-cell
Full (1)
Partial (2)
Absent (3)
Not evaluated (4)
Granulocyte
Full (1)
Partial (2)
Absent (3)
Not evaluated (4)
Monocyte
Full (1)
Partial (2)
Absent (3)
Not evaluated (4)
Red cell
Full (1)
Partial (2)
Absent (3)
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Not evaluated (4)
Platelets
Full (1)
Partial (2)
Absent (3)
Not evaluated (4)
Overall engraftment
Full (1)
Partial (2)
Absent (3)
Haemoglobin (g/dL)
g/dL
Platelets (109/L)
109/L
T-cells (CD3+) (109/L)
B-cells (109/L)
Granulocytes (109/L)
Mixed leukocyte culture (MLC) reactivity
Absent (1)
Partial (2)
Normal (3)
Not evaluated (4)
Mitogen induced lymphocyte proliferation
Absent (Absent)
Normal (Normal)
Not evaluated (Not evaluated)
Partial (Partial)
B-cells
Serum IgM (1)
Serum IgA (2)
Serum IgE (3)
Serum IgG (4)
Antibody production after vaccination
Absent (1)
Decreased (2)
Normal or elevated (3)
Not evaluated (4)
ON-GOING TREATMENT FOR
RECONSTITUTION AT 100 DAYS
no (1)
yes (2)
unknown (3)
ON-GOING TREATMENT FOR
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RECONSTITUTION AT 100 DAYS if yes
Growth factors (cytokines) administered
to the patient? (Growth factors
(cytokines) administered to the patient?)
Patient still receiving IV Immunoglobulins
(Patient still receiving IV
Immunoglobulins)
Patient still receiving IV Immunoglobulins
no (no)
unknown (unknown)
yes (yes)
Growth factors (cytokines) administered to the
patient?
no (no)
unknown (unknown)
yes (yes)
FORMS TO BE FILLED IN
Type of Transplant
ALLOgraft or Syngeneic graft (proceed to
Allograft form) (ALLOgraft or Syngeneic
graft (proceed to Allograft form))
AUTOgraft (proceed to Autograft form)
(AUTOgraft (proceed to Autograft form))
Other (contact the EBMT Central
Registry for instructions) (Other (contact
the EBMT Central Registry for
instructions))
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EBMT Inherited Disorders Follow up
ODM form derived from EBMT Inherited Disorders Follow
up: please refer to: http://www.ebmt.org/Contents/Data-
Management/Registrystructure/MED-
ABdatacollectionforms/Pages/MED-AB-data-collection-
forms.aspx 
All rights reserved. Please visit https://medical-data-
models.org/forms/16286
EBMT Inherited Disorders Follow up
FOLLOW UP MULTIPLE SCLEROSIS
Unique Identification Code (UIC)
(if known)
Date of this report
Patient following national / international study /
trial
No (1)
Yes (2)
Not evaluated (3)
Unknown (4)
Name of study / trial
Hospital Unique Patient Number
First name(s)_surname(s)
Date of Birth
Date of last HSCT for this patient
DATE OF LAST CONTACT OR DEATH
GRAFT VERSUS HOST DISEASE
(GvHD) SINCE LAST REPORT
Acute Graft versus Host Disease (aGvHD) -
Maximum grade
grade 0 (absent) (grade 0 (absent))
grade I (grade I)
grade II (grade II)
grade III (grade III)
grade IV (grade IV)
not evaluated (not evaluated)
If present GvHD, Maximum grade
New onset (1)
Recurrent (2)
Persistent (3)
Reason Maximum grade
Tapering (1)
DLI (2)
1 / 11
Unexplained (3)
Date onset of this episode (if new or recurrent)
yyyy/mm/dd
Date onset of this episode
Not applicable (1)
aGvHD Stage Skin
0 (1)
1 (2)
2 (3)
3 (4)
4 (5)
Not evaluated (6)
unknown (7)
aGvHD Stage liver
0 (1)
1 (2)
2 (3)
3 (4)
4 (5)
Not evaluated (6)
unknown (7)
aGvHD stage gut
0 (1)
1 (2)
2 (3)
3 (4)
4 (5)
Not evaluated (6)
unknown (7)
Resolution
No  (1)
Yes (2)
aGvHD Date of resolutions
Presence of cGvHD
No (No)
Present continuously since last reported
episode (Present continuously since last
reported episode)
Resolved (Resolved)
Yes (Yes)
Date of onset
cGvHD grade
limited (1)
Extensive (2)
Organs affected
Skin (1)
2 / 11
EBMT Inherited Disorders Follow up
Gut (2)
Liver (3)
Mouth (4)
Eyes (5)
Lung (6)
Other, specify (7)
Unknown (8)
If other organs affected, please specify
cGvHD Resolved: Date of resolution
OTHER COMPLICATIONS SINCE LAST
REPORT
INFECTION RELATED COMPLICATIONS
No complications (1)
Yes (2)
Bacteremia / fungemia / viremia / parasites
Pathogen (1)
Date (2)
Septic shock
Pathogen  (1)
Date (2)
ARDS
Pathogen  (1)
Date (2)
Multiorgan failure due to infection
Pathogen  (1)
Date (2)
Pneumonia
Pathogen  (1)
Date (2)
Hepatitis
Pathogen  (1)
Date (2)
CNS infection
Pathogen  (1)
Date (2)
Gut infection
Pathogen  (1)
Date (2)
Skin infection
Pathogen  (1)
Date (2)
Cystitis
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Date (Date)
Pathogen (Pathogen)
Retinitis
Date (Date)
Pathogen (Pathogen)
Other pathogen specified
NON INFECTION RELATED COMPLICATIONS
No complications (1)
Yes (2)
Idiopathic pneumonia syndrome
No  (No )
Unknown (Unknown)
Yes (Yes)
VOD
No  (No )
Unknown (Unknown)
Yes (Yes)
Cataract
No (No)
Unknown (Unknown)
Yes (Yes)
Haemorrhagic cystitis, non infectious
No  (No )
Unknown (Unknown)
Yes  (Yes )
Specify:
ARDS, non infectious
No (No)
Unknown (Unknown)
Yes (Yes)
Multiorgan failure, non infectious
no  (no )
unknown (unknown)
yes  (yes )
HSCT-associated microangiopathy
Date (4)
No (No)
Unknown (Unknown)
Yes (Yes)
Renal failure requiring dialysis
Date (Date)
No (No)
Unknown (Unknown)
Yes (Yes)
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Haemolytic anaemia due to blood group
Date (4)
No (No)
Unknown (Unknown)
Yes (Yes)
Aseptic bone necrosis
Date (Date)
No (No)
Unknown (Unknown)
Yes (Yes)
Other type of NON INFECTION RELATED
COMPLICATIONS, please specify
Idiopathic pneumonia syndrome
ADDITIONAL THERAPIES SINCE LAST
FOLLOW UP
Additional treatment given since last report
Date (4)
No (No)
Unknown (Unknown)
Yes (Yes)
If treatment given since last report
If yes: Cellular therapy (One cell therapy regimen
is defined as any number of infusions given within
10 weeks for the same indication. If more than
one regimen of cell therapy has been given since
last report, copy this section and complete it as
many times as necessary.)
No  (1)
Yes (Mark disease status before this
cellular therapy) (2)
Unknown (3)
Disease status before this cellular therapy
CR (CR)
Not evaluated (Not evaluated)
Not in CR (Not in CR)
If yes: Type of cells
Donor lymphocyte infusion (DLI) (1)
Mesenchymal cells (2)
Other (3)
Unknown (4)
If other
Chronological number of this cell therapy for this
patient
Number of Nucleated cells infused (DLI only)
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10^8/kg
Number (1)
Not evaluated (2)
Unknown (3)
If DLI, specify the number of cells infused by
type:
CD 34+
Evaluated (Evaluated)
Not Evaluated (Not Evaluated)
Unknown (Unknown)
If DLI, specify the number of cells infused by
type: 
CD 3+
Evaluated  (Evaluated )
Not evaluated (Not evaluated)
Unknown (Unknown)
If non DLI, specify total number of cells infused:
Evaluated (Evaluated)
Not Evaluated (Not Evaluated)
Unknown (Unknown)
Cell therapy indication
Planned/protocol  (1)
Treatment for disease (2)
Prophylactic (3)
Mixed chimaerism (4)
Treatment of GvHD  (5)
Treatment viral infection (6)
Loss/decreased chimaerism  (7)
Treatment PTLD, EBV lymphoma (8)
Other, specify (9)
Number of infusions within 10 weeks (count only
infusions that are part of same regimen and given
for the same indication)
Acute Graft versus Host Disease 
(after this infusion but before any further infusion/
transplant)
Maximum grade:
grade 0 (absent) (grade 0 (absent))
grade 1 (grade 1)
grade 2 (grade 2)
grade 3 (grade 3)
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grade 4 (grade 4)
present, grade unknown (present, grade
unknown)
Disease treatment (apart from donor cell infusion
or other type of cell therapy)
No (1)
Yes: Planned (planned before HSCT took
place) (2)
Yes: Not planned (for
relapse/progression or persistent
disease) (3)
Date started
Overall main reason ADDITIONAL THERAPIES
Relapse/progression (1)
Continued from pre-HSCT (2)
unknow (3)
Planned per protocol (4)
Other (5)
Of Other, please specify
Drugs
no (no)
unknown (unknown)
yes (yes)
If yes, mark appropriate box
Alpha interferon (Alpha interferon)
Anti-lymphocyte antibodies (Anti-
lymphocyte antibodies)
Azathioprine (Azathioprine)
Interferon Beta  (Beta Interferon)
low dose (Chronic low dose)
CopI (Cop-I)
Corticosteroids (Corticosteroids)
Cyclophosphamide (Cyclophosphamide)
Mitoxantron (Mitoxantron)
high dose (Pulse high dose)
Total lymph node (TLI)
NO (NO)
UNKNOWN (UNKNOWN)
YES (YES)
Craniospinal
no (no)
unknown (unknown)
yes (yes)
Lymphocytopheresis
no (no)
unknown (unknown)
yes  (yes )
if other modality please specify:
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GRAFT ASSESSMENT AND
HAEMOPOIETIC CHIMAERISM
Graft loss
No (No)
Not evaluated (Not evaluated)
Yes (Yes)
Overall chimaerism
Aplasia (Aplasia)
95%) (Autologuos reconstitution
(recipient >)
95%) (Full (donor >)
Mixed (partial) (Mixed (partial))
Not evaluated (Not evaluated)
Date of Test
Identification of donor or Cord Blood Unit given
by the centre
Number in the infusion order
Graft loss
No (No)
Not evaluated (Not evaluated)
Yes (Yes)
Overall chimaerism
Full (donor >95%) (1)
Mixed (partial) (2)
Autologuos reconstitution (recipient >
95%) (3)
Aplasia (4)
Not evaluated (5)
Date of test
(Indicate the date(s) and results of all tests done
for all donors. Split the results by donor and by
the cell type on which the test was performed if
applicable. Copy this table as many times as
necessary.)
Identification of donor or Cord Blood Unit given
by the centre
Number in the infusion order (if applicable)
Cell type on which test was performed % Donor
cells
B-Cells
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%
BM (1)
Other, specify (10)
PB mononuclear cells (PBMC) (2)
T-cell (3)
B-cells (4)
Red blood cells (5)
Monocytes (6)
PMNs (neutrophils) (7)
Lymphocytes, NOS (8)
Myeloid cells, NOS (9)
Laboratory tests used
ABO group (ABO group)
Cytogenetic (Cytogenetic)
FISH (FISH)
Molecular (Molecular)
Other (Other)
unknown (unknown)
Test used:
If other, specify:
SECONDARY MALIGNANCY,
LYMPHOPROLIFERATIVE OR
MYELOPROLIFRATIVE DISORDER
DIAGNOSED
No at date of this follow-up (No at date of
this follow-up)
Previously reported (Previously reported)
Yes (Yes)
Date of Diagnosis
Diagnosis OTHER COMPLICATIONS SINCE
LAST REPORT
AML (AML)
Lymphoproliferative disorder
(Lymphoproliferative disorder)
MDS (MDS)
Other (Other)
Diagnosis, other:
LAST DISEASE AND PATIENT STATUS
Scripps neurological rating scale Score
Kurtzke functional systems Overall score
Kurtzke Expanded Disability Status Scale (EDSS)
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Composite Scale Score
MRI BRAIN SCAN DONE
Not done (Not done)
Yes (Yes)
Date of most recent MRI scan of brain
Results, Are new lesions present on the MRI?
no (no)
unknown (unknown)
yes (yes)
If yes Indicate new lesions present
Both (Both)
Gadolinium-enhancing (Gadolinium-
enhancing)
Unenhancing (Unenhancing)
Unknown (Unknown)
Has patient or partner become  pregnant after
this HSCT?
No (No)
Unknown (Unknown)
Yes (Yes)
Survival Status
alive (0)
dead (1)
Performance score (if alive)
Karnofsky (1)
Lansky (2)
performance status
100 (Normal, NED) (1)
10 (Moribund) (10)
Not evaluated (11)
Unknown (12)
90 (Normal activity)  (2)
80 (Normal with effort) (3)
70 (Cares for self) (4)
60 (Requires occasional assistance) (5)
50 (Requires assistance) (6)
40 (Disabled) (7)
30 (Severely disabled) (8)
20 (Very sick) (9)
Cause of death (if dead)
Relapse or progression (1)
Secondary malignancy (including
lymphoproliferative disease) (2)
HSCT related cause  (3)
Unknown (4)
Other (5)
HSCT related cause
GvHD (1)
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Veno-occlusive disease (VOD) (10)
Haemorrhage (11)
Cardiac toxicity (12)
Central nervous system toxicity (13)
Gastro intestinal toxicity (14)
Skin toxicity (15)
Renal failure (16)
Multiple organ failure (17)
Other (18)
Interstitial pneumonitis (2)
Pulmonary toxicity (3)
Infection bacterial (4)
Infection viral (5)
Infection fungal (6)
Infection parasitic (7)
Infection unknown (8)
Rejection / poor graft function (9)
ADDITIONAL NOTES IF APPLICABLE
COMMENTS
Identification
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Blutdosimetrie PSMA-Studie
Prostatakarzinom NCT0000001
Quelle:
PSMA-Studie Prostatakarzinom
PD Dr. med. Kambiz Rahbar
UKM, Nuklearmedizin
Teil: Blutdosimetrie
All rights reserved. Please visit https://medical-data-
models.org/forms/16289
Blutdosimetrie PSMA-Studie
Prostatakarzinom NCT0000001
Patient Data
Name
Vorname
Geburtsdatum
Zyklus 1
10 Min
4h
24h
48h
7 Tage
Zyklus 2
10 Min
4h
24h
48h
7 Tage
Zyklus 3
10 Min
4h
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24h
48h
7 Tage
Zyklus 4
10 Min
4h
24h
48h
7 Tage
Zyklus 5
10 Min
4h
24h
48h
7 Tage
Zyklus 6
10 Min
4h
24h
48h
7 Tage
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Zyklus 7
10 Min
4h
24h
48h
7 Tage
Zyklus 8
10 Min
4h
24h
48h
7 Tage
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Standard Activity PSMA-Studie
Prostatakarzinom NCT0000001
Quelle:
PSMA-Studie Prostatakarzinom
PD Dr. med. Kambiz Rahbar
UKM, Nuklearmedizin
Teil: Standardaktivität
All rights reserved. Please visit https://medical-data-
models.org/forms/16290
Standardaktivität PSMA-Studie
Prostatakarzinom NCT0000001
Patient Data
Name
Zyklus 1
10 Min
4h
24h
48h
7-10 Tage
Datum
Zyklus 2
10 Min
4h
24h
48h
7-10 Tage
Datum
Zyklus 3
10 Min
4h
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24h
48h
7-10 Tage
Datum
Zyklus 4
10 Min
4h
24h
48h
7-10 Tage
Datum
Zyklus 5
10 Min
4h
24h
48h
7-10 Tage
Datum
Zyklus 6
10 Min
4h
24h
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48h
7-10 Tage
Datum
Zyklus 7
10 Min
4h
24h
48h
7-10 Tage
Datum
Zyklus 8
10 Min
4h
24h
48h
7-10 Tage
Datum
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GK Dosimetrie PSMA-Studie
Prostatakarzinom NCT0000001
Quelle:
PSMA-Studie Prostatakarzinom
PD Dr. med. Kambiz Rahbar
UKM, Nuklearmedizin
Teil: GK Dosimetrie
All rights reserved. Please visit https://medical-data-
models.org/forms/16291
GK Dosimetrie PSMA-Studie
Prostatakarzinom NCT0000001
Patient Data
Name
Zyklus 1
Datum
10 Min
4h
24h
48h
7-10 Tage
Datum Messung
Zyklus 2
Datum
10 Min
4h
24h
48h
7-10 Tage
Datum Messung
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Zyklus 3
Datum
10 Min
4h
24h
48h
7-10 Tage
Datum Messung
Zyklus 4
Datum
10 Min
4h
24h
48h
7-10 Tage
Datum Messung
Zyklus 5
Datum
10 Min
4h
24h
48h
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7-10 Tage
Datum Messung
Zyklus 6
Datum
10 Min
4h
24h
48h
7-10 Tage
Datum Messung
Zyklus 7
Datum
10 Min
4h
24h
48h
7-10 Tage
Datum Messung
Zyklus 8
Datum
10 Min
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4h
24h
48h
7-10 Tage
Datum Messung
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Eligibility Breast Cancer NCT00206427
Neoadjuvant GW572016 to Treat Breast Cancer; ODM
derived from: https://clinicaltrials.gov/show/NCT00206427
All rights reserved. Please visit https://medical-data-
models.org/forms/16292
Eligibility Breast Cancer
NCT00206427
Inclusion Criteria
1. all patients must be female.*
Yes
No
2. signed informed consent.*
Yes
No
3. locally advanced breast cancers or primary
breast cancers with concomitant gross metastatic
disease are eligible. locally advanced cancers
must be of clinical and/or radiologic size >/- 5 cm,
and/or are deemed surgically inoperable, with
stage iiib, iiic, or iv disease.*
Yes
No
4. her2 overexpressing tumors defined as
herceptest score of 3+, or >/- 10% cells
moderately or strongly her2 positive by other
methods, or semi-quantitative score of >/- 5 (in
dr. allred's laboratory) or gene amplified.*
Yes
No
5. negative serum pregnancy test (bhcg) within 7
days of starting study, if of child-bearing
potential.*
Yes
No
6. kidney and liver function tests - all within 1.5
times the institution's upper limit of normal.*
Yes
No
7. performance status (who scale) less than 2
and life expectancy greater than 6 months.*
Yes
No
8. age greater than 18 years.*
Yes
No
9. no brain or leptomeningeal disease.*
Yes
No
10. no previous or current malignancies at other
sites within the last 5 years, with exception of
adequately treated core-biopsied in situ
1 / 2
carcinoma of the cervix uteri and basal or
squamous cell carcinoma of the skin.*
Yes
No
Exclusion Criteria
1. pregnancy or unwillingness to use a reliable
contraceptive method in women of child-bearing
potential.*
Yes
No
2. severe underlying chronic illness or disease.*
Yes
No
3. cardiomyopathy or baseline lvef <50%.*
Yes
No
4. other investigational drugs while on study.*
Yes
No
5. severe or uncontrolled hypertension, history of
congestive heart failure or severe coronary
arterial disease.*
Yes
No
6. malabsorption syndrome, disease significantly
affecting gastrointestinal function, or resection of
the stomach or small bowel. subjects with
ulcerative colitis are also excluded.*
Yes
No
7. taking any gw572016-prohibited medication
(see gw572016 prohibited medications list in
protocol) within 7 days of first dose of study
medications.*
Yes
No
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Stroke Impact Scale (SIS): PaReSiS UKH
Stroke Impact Scale (SIS): PaReSiS UKH Rehabilitation
Study: "Partizipatives Rehabilitationsprozessmanagement,
PaReSiS Schlaganfall in Sachsen-Anhalt" Martin-Luther-
Universität Halle-Wittenberg Medizinische Fakultät Institut
für Gesundheits- und Pflegewissenschaft Projekt:
Partizipatives Rehabilitationsprozessmanagement
„Schlaganfall in Sachsen-Anhalt“ Magdeburger Straße 8
06097 Halle (Saale), Germany E-Mail:
paresis@medizin.uni-halle.de
All rights reserved. Please visit https://medical-data-
models.org/forms/16293
Stroke Impact Scale (SIS): PaReSiS
UKH
33. In den folgenden Fragen geht es um
körperliche Probleme, die möglicherweise
in Folge Ihres Schlaganfalls aufgetreten
sind. In der vergangenen Woche, wie viel
Kraft hatten Sie Ihrer Meinung nach....
a) im Arm, der am stärksten vom Schlaganfall
betroffen war?
sehr viel Kraft (1)
ziemlich viel Kraft (2)
etwas Kraft (3)
kaum Kraft (4)
gar keine Kraft (5)
b)...beim Zugreifen mit der Hand, die am
stärksten vom Schlaganfall betroffen war?
sehr viel Kraft (1)
ziemlich viel Kraft (2)
etwas Kraft (3)
kaum Kraft (4)
gar keine Kraft (5)
c)...im Bein, das am stärksten vom Schlaganfall
betroffen war?
sehr viel Kraft (1)
ziemlich viel Kraft (2)
etwas Kraft (3)
kaum Kraft (4)
gar keine Kraft (5)
d)...im Fuß/Knöchel, der am stärksten vom
Schlaganfall betroffen war?
sehr viel Kraft (1)
ziemlich viel Kraft (2)
etwas Kraft (3)
kaum Kraft (4)
gar keine Kraft (5)
34. In den folgenden Fragen geht es um
Ihr Gedächtnis und Ihr Denkvermögen. In
der vergangenen Woche, wie schwer ist
es Ihnen gefallen....
a)...sich an etwas zu erinnern, was man Ihnen
gerade gesagt hat?
gar nicht schwer (1)
etwas schwer (2)
1 / 9
ziemlich schwer (3)
sehr schwer (4)
außerordentlich schwer (5)
b)...sich an Dinge zu erinnern, die am Vortag
passiert sind?
gar nicht schwer (1)
etwas schwer (2)
ziemlich schwer (3)
sehr schwer (4)
außerordentlich schwer (5)
c)...sich daran zu erinnern, bestimmte Dinge zu
tun? (z.B. vereinbarte Termine wahrzunehmen
oder Medikamente einzunehmen)
gar nicht schwer (1)
etwas schwer (2)
ziemlich schwer (3)
sehr schwer (4)
außerordentlich schwer (5)
d)...sich an den aktuellen Wochentag zu erinnern
gar nicht schwer (1)
etwas schwer (2)
ziemlich schwer (3)
sehr schwer (4)
außerordentlich schwer (5)
e)...sich zu konzentrieren
gar nicht schwer (1)
etwas schwer (2)
ziemlich schwer (3)
sehr schwer (4)
außerordentlich schwer (5)
f)...schnell zu überlegen?
gar nicht schwer (1)
etwas schwer (2)
ziemlich schwer (3)
sehr schwer (4)
außerordentlich schwer (5)
g)...alltägliche Probleme zu lösen (z.B. Einkauf
planen, eine Geburtstagsfeier planen)
gar nicht schwer (1)
etwas schwer (2)
ziemlich schwer (3)
sehr schwer (4)
außerordentlich schwer (5)
35. In den folgenden Fragen geht es um
Ihr Befinden seit dem Schlaganfall, um
Veränderungen in Ihrer Stimmung und die
Fähigkeit, ihre Gefühle zu beherrschen. In
der vergangenen Woche, wie oft...
a) waren Sie traurig?
nie (1)
2 / 9
Stroke Impact Scale (SIS): PaReSiS UKH
selten (2)
manchmal (3)
meistens (4)
immer (5)
b)..hatten Sie das Gefühl, dass es niemanden
gibt, der Ihnen Nahe steht?
nie (1)
selten (2)
manchmal (3)
meistens (4)
immer (5)
c)...hatten Sie das Gefühl, anderen eine Last zu
sein?
nie (1)
selten (2)
manchmal (3)
meistens (4)
immer (5)
d)...hatten Sie das Gefühl, dass es nichts gibt
worauf Sie sich freuen können?
nie (1)
selten (2)
manchmal (3)
meistens (4)
immer (5)
e)...haben Sie sich wegen Fehlern, die Sie
machten, oder wegen Missgeschicken Vorwürfe
gemacht?
nie (1)
selten (2)
manchmal (3)
meistens (4)
immer (5)
f)...haben Sie sich genauso über Dinge gefreut
wie schon immer?
nie (1)
selten (2)
manchmal (3)
meistens (4)
immer (5)
g)...fühlten Sie sich nervös?
nie (1)
selten (2)
manchmal (3)
meistens (4)
immer (5)
h)...hatten Sie das Gefühl, das Leben sei
lebenswert?
nie (1)
selten (2)
manchmal (3)
meistens (4)
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immer (5)
i)...haben Sie mindesten einmal am Tag
geschmunzelt oder gelacht?
nie (1)
selten (2)
manchmal (3)
meistens (4)
immer (5)
36. In den folgenden Fragen geht es um
Ihre Fähigkeit, sich anderen Menschen
mitzuteilen und Gelesenes oder bei einem
Gespräch gehörtes zu verstehen. In der
vergangenen Woche, wie schwer ist es
Ihne...
a)...den Namen eines Menschen zu nennen, der
vor Ihnen stand?
gar nicht schwer (1)
etwas schwer (2)
ziemlich schwer (3)
sehr schwer (4)
außerordentlich schwer (5)
b)...zu verstehen, was Ihnen während der
Unterhaltung gesagt wurde?
gar nicht schwer (1)
etwas schwer (2)
ziemlich schwer (3)
sehr schwer (4)
außerordentlich schwer (5)
c)...auf Fragen zu antworten?
gar nicht schwer (1)
etwas schwer (2)
ziemlich schwer (3)
sehr schwer (4)
außerordentlich schwer (5)
d)...Gegenstände richtig zu benennen?
gar nicht schwer (1)
etwas schwer (2)
ziemlich schwer (3)
sehr schwer (4)
außerordentlich schwer (5)
e)...sich an einem Gespräch mit mehreren Leuten
zu beteiligen?
gar nicht schwer (1)
etwas schwer (2)
ziemlich schwer (3)
sehr schwer (4)
außerordentlich schwer (5)
f)...ein Telefongespräch zu führen?
gar nicht schwer (1)
etwas schwer (2)
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ziemlich schwer (3)
sehr schwer (4)
außerordentlich schwer (5)
g)...einen anderen Menschen anzurufen,
einschließlich die richtige Telefonnummer zu
finden und diese zu wählen?
gar nicht schwer (1)
etwas schwer (2)
ziemlich schwer (3)
sehr schwer (4)
außerordentlich schwer (5)
37. In den folgenden Fragen geht es um
Tätigkeiten, die möglicherweise zu Ihrem
normalen Tagesablauf gehören. In den
vergangenen zwei Wochen, wie schwer ist
es Ihnen gefallen....
a)...das Essen mit Messer und Gabel zu
schneiden?
gar nicht schwer (1)
etwas schwer (2)
ziemlich schwer (3)
sehr schwer (4)
gar nicht möglich (5)
b)...sich oben herum anzuziehen (von der Taille
aufwärts)?
gar nicht schwer (1)
etwas schwer (2)
ziemlich schwer (3)
sehr schwer (4)
gar nicht möglich (5)
c)...sich zu waschen (Bad, Dusche...)?
gar nicht schwer (1)
etwas schwer (2)
ziemlich schwer (3)
sehr schwer (4)
gar nicht möglich (5)
d)...sich die Fußnägel zu schneiden?
gar nicht schwer (1)
etwas schwer (2)
ziemlich schwer (3)
sehr schwer (4)
gar nicht möglich (5)
e)...schnell auf die Toilette zu kommen?
gar nicht schwer (1)
etwas schwer (2)
ziemlich schwer (3)
sehr schwer (4)
gar nicht möglich (5)
f)...Ihre Blase zu kontrollieren (ohne
Missgeschicke)?
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gar nicht schwer (1)
etwas schwer (2)
ziemlich schwer (3)
sehr schwer (4)
gar nicht möglich (5)
g)...Ihren Darm zu kontrollieren (ohne
Missgeschicke)?
gar nicht schwer (1)
etwas schwer (2)
ziemlich schwer (3)
sehr schwer (4)
gar nicht möglich (5)
h)...leichte Hausarbeiten zu erledigen?
gar nicht schwer (1)
etwas schwer (2)
ziemlich schwer (3)
sehr schwer (4)
gar nicht möglich (5)
i)...einkaufen zu gehen?
gar nicht schwer (1)
etwas schwer (2)
ziemlich schwer (3)
sehr schwer (4)
gar nicht möglich (5)
j)...schwere Hausarbeiten zu erledigen?
gar nicht schwer (1)
etwas schwer (2)
ziemlich schwer (3)
sehr schwer (4)
gar nicht möglich (5)
38. In den folgenden Fragen geht es um
Ihre Bewegungsfähigkeit (Mobilität) zu
Hause und außer Haus. In den
vergangenen zwei Wochen, wie schwer ist
es Ihnen gefallen.....
a)....zu sitzen, ohne das Gleichgewicht zu
verlieren?
gar nicht schwer (1)
etwas schwer (2)
ziemlich schwer (3)
sehr schwer (4)
gar nicht möglich (5)
b)...zu stehen, ohne das Gleichgewicht zu
verlieren?
gar nicht schwer (1)
etwas schwer (2)
ziemlich schwer (3)
sehr schwer (4)
gar nicht möglich (5)
c)... zu gehen, ohne das Gleichgewicht zu
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verlieren?
gar nicht schwer (1)
etwas schwer (2)
ziemlich schwer (3)
sehr schwer (4)
gar nicht möglich (5)
d)...aus dem Bett auf einen Stuhl zu gelangen?
gar nicht schwer (1)
etwas schwer (2)
ziemlich schwer (3)
sehr schwer (4)
gar nicht möglich (5)
e)...ungefähr 100m weit zu Fuß zu gehen?
gar nicht schwer (1)
etwas schwer (2)
ziemlich schwer (3)
sehr schwer (4)
gar nicht möglich (5)
f)...schnell zu gehen?
gar nicht schwer (1)
etwas schwer (2)
ziemlich schwer (3)
sehr schwer (4)
gar nicht möglich (5)
g)...einen Treppenabsatz zu steigen?
gar nicht schwer (1)
etwas schwer (2)
ziemlich schwer (3)
sehr schwer (4)
gar nicht möglich (5)
h)...mehrere Treppenabsätze zu steigen?
gar nicht schwer (1)
etwas schwer (2)
ziemlich schwer (3)
sehr schwer (4)
gar nicht möglich (5)
i)...in ein Auto ein- und auszusteigen ?
gar nicht schwer (1)
etwas schwer (2)
ziemlich schwer (3)
sehr schwer (4)
gar nicht möglich (5)
39. In den folgenden Fragen geht es um
Ihre Fähigkeit zum Gebrauch der Hand,
die AM STÄRKSTEN von Ihrem
Schlaganfall betroffen war. In den
vergangenen zwei Wochen, wie schwer ist
es Ihnen gefallen, ...
a)...schwere Sachen zu tragen?
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gar nicht schwer (1)
etwas schwer (2)
ziemlich schwer (3)
sehr schwer (4)
gar nicht möglich (5)
b)...einen Türknauf zu drehen?
gar nicht schwer (1)
etwas schwer (2)
ziemlich schwer (3)
sehr schwer (4)
gar nicht möglich (5)
c)...eine Dose oder ein Glas zu öffnen?
gar nicht schwer (1)
etwas schwer (2)
ziemlich schwer (3)
sehr schwer (4)
gar nicht möglich (5)
d)...Schnürsenkel zu binden?
gar nicht schwer (1)
etwas schwer (2)
ziemlich schwer (3)
sehr schwer (4)
gar nicht möglich (5)
e)...eine kleine Münze aufzuheben?
gar nicht schwer (1)
etwas schwer (2)
ziemlich schwer (3)
sehr schwer (4)
gar nicht möglich (5)
40. In den folgenden Fragen geht es
darum, wie sich Ihr Schlaganfall auf Ihre
Fähigkeit ausgewirkt hat, die Dinge zu tun,
an die Sie gewöhnt waren, die Ihnen
wichtig sind und Ihrem Leben einen Sinn
...
a)...beruflicher, ehrenamtlicher oder sonstiger
Arbeit
nie (1)
selten (2)
manchmal (3)
meistens (4)
immer (5)
b)...Ihren Aktivitäten mit anderen Menschen?
nie (1)
selten (2)
manchmal (3)
meistens (4)
immer (5)
c)...ruhigen Freizeitbeschäftigungen? (z.B.
Kreuzworträtsel lösen, lesen, puzzeln...)
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nie (1)
selten (2)
manchmal (3)
meistens (4)
immer (5)
d)...aktiven Freizeitbeschäftigungen? (spazieren
gehen, Sport treiben)
nie (1)
selten (2)
manchmal (3)
meistens (4)
immer (5)
e)...Ihrer Rolle als Familienmitglied oder als
Freund/ Freundin? (z.B. in Ihren Aufgaben als
Mutter, Ehefrau/-mann, Freund etc.)
nie (1)
selten (2)
manchmal (3)
meistens (4)
immer (5)
f)....der Teilnahme an kirchlichen oder anderen
religiösen Aktivitäten?
nie (1)
selten (2)
manchmal (3)
meistens (4)
immer (5)
g)...der Fähigkeit, Ihr Leben nach Ihren eigenen
Wünschen zu bestimmen?
nie (1)
selten (2)
manchmal (3)
meistens (4)
immer (5)
h)...der Fähigkeit, anderen Menschen zu helfen?
nie (1)
selten (2)
manchmal (3)
meistens (4)
immer (5)
41. Erholung vom Schlaganfall
Inwieweit haben Sie sich - auf einer Skala von 0
bis 100 - von Ihrem Schlaganfall erholt, wobei
100 vollständige und 0 gar keine Erholung
bedeutet?
>= 0
<= 100
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Eligibility Breast Cancer NCT00212121
Radiation Dose Intensity Study in Breast Cancer in Young
Women; ODM derived from:
https://clinicaltrials.gov/show/NCT00212121
All rights reserved. Please visit https://medical-data-
models.org/forms/16294
Eligibility Breast Cancer
NCT00212121
Inclusion Criteria
age 50 years or younger.*
Yes
No
histological diagnosis of invasive mammary
cancer including all subtypes of invasive
adenocarcinoma.*
Yes
No
tumor location and extension imaged prior to
surgery using at least mammography and
ultrasound.*
Yes
No
unicentric tumors and multifocal tumors removed
using a wide local excision; microscopic radical
resection (focally involved margins allowed,
defined as:*
Yes
No
any dcis or invasive carcinoma in 3 or fewer low-
power fields (using a x 4 objective and a x 10
ocular lens, which has a diameter of 5 mm per
low-power microscopic fields).*
Yes
No
sentinel lymph node biopsy and/or axillary lymph
node dissection has been performed.*
Yes
No
breast cancer stage: pt1-2pn0-2a m0.*
Yes
No
no treatment is allowed prior to surgery (no
neoadjuvant chemotherapy, no neoadjuvant
hormonal therapy, no pre-operative
radiotherapy).*
Yes
No
in cases where no adjuvant chemotherapy is
given, wide local excision has been performed <
10 weeks before the start of radiotherapy.*
Yes
No
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in cases where adjuvant chemotherapy is given
immediately after surgery, wide local excision has
been performed < 6 months before the start of
radiotherapy, and chemotherapy should be
completed < 6 weeks before the start of
radiotherapy.*
Yes
No
in cases where hormonal treatment is planned,
this is given after completion of the radiotherapy.*
Yes
No
no previous history or synchronous malignant
tumor in the other breast, previous history of
malignant disease, except adequately treated
carcinoma in situ of the cervix or basal cell
carcinoma of the skin.*
Yes
No
ecog performance scale 2 or less.*
Yes
No
Exclusion Criteria
residual microcalcifications on mammogram.*
Yes
No
all histological types of malignancies other than
invasive adenocarcinoma.*
Yes
No
in situ carcinoma of the breast, without invasive
tumor.*
Yes
No
concurrent pregnancy.*
Yes
No
multicentric tumors, and multifocal. tumors
excised using multiple excisions **
Yes
No
invasive breast cancer in both breasts.*
Yes
No
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Eligibility Depression NCT00339066
Effect of Brain Lesion Severity on Treatment Response in
Late-Life Depression; ODM derived from:
https://clinicaltrials.gov/show/NCT00339066
All rights reserved. Please visit https://medical-data-
models.org/forms/16295
Eligibility Depression NCT00339066
Inclusion Criteria
dsm-iv of major depressive disorder (mdd)*
Yes
No
score of greater than 20 on the madrs (score of
greater than 17 for atypical depression)*
Yes
No
score of greater than 20 on the mini mental state
examination (mmse)*
Yes
No
Exclusion Criteria
any condition that may make having an mri
medically inadvisable*
Yes
No
any severe or unstable medical conditions*
Yes
No
any known primary neurological disorders,
including history of stroke*
Yes
No
any other simultaneous axis i disorder*
Yes
No
history of substance or alcohol abuse disorder
within 6 months prior to study entry*
Yes
No
currently at risk for suicide*
Yes
No
history of failed prior adequate trials of two
antidepressants for the current depressive
episode*
Yes
No
history of failed prior adequate trial of sertraline*
Yes
No
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current use of any other psychoactive
medications (medication washout will be
required)*
Yes
No
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Eligibility Breast Cancer NCT00245869
Ultrasound and Chemotherapy of Breast Cancer:
Relationship Between Early Vascular Changes of the
Tumor and Late Tumoral Response; ODM derived from:
https://clinicaltrials.gov/show/NCT00245869
All rights reserved. Please visit https://medical-data-
models.org/forms/16296
Eligibility Breast Cancer
NCT00245869
Inclusion Criteria
breast tumor (size equal to or greater than 3 cm.).
patients with diagnosis of benign breast tumor
based on biopsy will be excluded from the study
after the first ultrasound examination.*
Yes
No
neoadjuvant chemotherapy is programmed when
an epithelial carcinoma is diagnosed by
histology.*
Yes
No
performance status = 0, 1 or 2*
Yes
No
no previous surgery or local radiotherapy*
Yes
No
Exclusion Criteria
psychiatric disorders*
Yes
No
vital threat due to other disease*
Yes
No
vital prognosis < 3 months*
Yes
No
biopsy of the lesion performed within 1 month
before the ultrasonography*
Yes
No
patient known to have a coronary syndrome*
Yes
No
unstable angina and myocardial infarction*
Yes
No
acute cardiac failure, class iii/iv cardiac failure*
Yes
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No
several arrhythmias*
Yes
No
acute endocarditis*
Yes
No
prosthetic valves*
Yes
No
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Eligibility Breast Cancer NCT00266110
Vaccine Therapy, Trastuzumab, and Vinorelbine in Treating
Patients With Locally Recurrent or Metastatic Breast
Cancer; ODM derived from:
https://clinicaltrials.gov/show/NCT00266110
All rights reserved. Please visit https://medical-data-
models.org/forms/16297
Eligibility Breast Cancer
NCT00266110
Criteria
4.1 inclusion criteria 4.1.1 histologically proven
metastatic breast cancer with measurable or
evaluable disease per investigator discretion.*
Yes
No
4.1.2 patients must be 18 years of age or older.
women of child bearing potential must be
practicing barrier or oral contraception for the
duration of the study, or documented as surgically
sterile or one year post-menopausal.*
Yes
No
4.1.3 ecog performance status 0-2 (see appendix
a).*
Yes
No
4.1.5 cardiac function by muga with an ef > 45%
or an echocardiogram that shows normal lv
function.*
Yes
No
4.1.6 serum creatinine < 2.0 mg/dl. 4.1.7 hepatic
transaminases (alanine aminotransferase (alt)
and aspartate aminotransferase (ast)) ≤3.0 times
the upper limit of normal if no liver metastases or
≤5 times the upper limit of normal if liver
metastases are present.*
Yes
No
4.1.8 bilirubin no more than 2x normal.*
Yes
No
4.1.9 seronegative for hiv.*
Yes
No
4.1.10 negative for hepatitis b surface antigen.*
Yes
No
4.1.11 signed and dated informed consent.*
Yes
No
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4.1.12  hla a0201+ by dna genotyping.*
Yes
No
4.1.13  absolute neutrophil count greater than
1,500/mm3.  platelet count greater 100,000/mm3
and hemoglobin greater than or equal to 10*
Yes
No
4.1.14. 3+ expression of her-2/neu from original
pathology (diagnostic) tumor sample by ihc or 2+
expression by ihc with gene amplification by fish.*
Yes
No
4.1.15. patients will be eligible even if they have
failed treatment for metastatic breast cancer with
trastuzumab and a chemotherapy agent other
than vinorelbine or if they have progressed within
12 months of receiving adjuvant chemotherapy
using trastuzumab and a taxane.*
Yes
No
4.2 exclusion criteria*
Yes
No
4.2.1 patients with any serious medical, cardiac,
or psychiatric condition which, in the opinion of
the investigator, would make the patient
unsuitable for study participation or would impede
probable compliance with the protocol.*
Yes
No
4.2.2 patients with central nervous system
metastases must have stable disease for at least
3 months prior to study entry.*
Yes
No
4.2.3 patient is currently taking steroid
medications. systemic steroid treatment is not
allowed.*
Yes
No
4.2.4 patients that have failed prior therapy with
vinorelbine + trastuzumab will not be eligible for
therapy.*
Yes
No
4.2.5 patient has received hormonal or cytotoxic
chemotherapy within 14 days of apheresis and
within 28-30 days prior to study treatment.*
Yes
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Eligibility Atrial Fibrillation NCT00508248
Omega 3 Fatty Acids and Atrial Fibrillation; ODM derived
from: https://clinicaltrials.gov/show/NCT00508248
All rights reserved. Please visit https://medical-data-
models.org/forms/16298
Eligibility Atrial Fibrillation
NCT00508248
Inclusion Criteria
atrial fibrillation*
Yes
No
post cardioversion*
Yes
No
Exclusion Criteria
patients on anti-arrhythmic drugs*
Yes
No
left atrial size > 6 cm*
Yes
No
significant mitral valve disease*
Yes
No
myocardial infarction in the last 3 months*
Yes
No
unstable angina*
Yes
No
nyha iv heart failure*
Yes
No
cardiac surgery in the previous 3 months*
Yes
No
acute reversible conditions*
Yes
No
significant thyroid, hepatic, pulmonary disease*
Yes
No
pregnancy or child bearing potential*
Yes
No
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Eligibility Breast Cancer NCT00149214
Preoperative Treatment of Breast Cancer With Two
Different Sequential Treatment Regimens; ODM derived
from: https://clinicaltrials.gov/show/NCT00149214
All rights reserved. Please visit https://medical-data-
models.org/forms/16299
Eligibility Breast Cancer
NCT00149214
Inclusion Criteria
histologically confirmed diagnosis of primary
early breast cancer, tumor size greater than or
equal to 2 centimeters (cm), of stages t2-t4/n0-2.*
Yes
No
performance status 0-2 eastern cooperative
oncology group (ecog).*
Yes
No
adequate organ function (bone marrow, hepatic,
renal, cardiac).*
Yes
No
Exclusion Criteria
prior anthracyclines as part of prior anticancer
therapy*
Yes
No
concurrent antitumor therapy.*
Yes
No
second primary malignancy.*
Yes
No
serious concomitant systemic disorder.*
Yes
No
pre-existing sensorial or motor neuropathy*
Yes
No
grade 1.*
Yes
No
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Eligibility Breast Cancer NCT00191854
Gemcitabine Combinations in Metastatic Breast Cancer
(MBC), 1st Line; ODM derived from:
https://clinicaltrials.gov/show/NCT00191854
All rights reserved. Please visit https://medical-data-
models.org/forms/16300
Eligibility Breast Cancer
NCT00191854
Inclusion Criteria
female patients with histological or cytological
proven diagnosis of breast cancer*
Yes
No
stage iv disease*
Yes
No
performance status of 0 or 1 on the eastern
cooperative oncology group (ecog) scale*
Yes
No
patients had to have previously received
anthracycline based regimens as a adjuvant
therapy or neo-adjuvant chemotherapy and then
progressed and developed metastatic disease*
Yes
No
adequate organ function*
Yes
No
Exclusion Criteria
prior chemotherapy for metastatic disease*
Yes
No
previous radiation therapy is allowed but must not
have included whole pelvis radiation*
Yes
No
known or suspected brain metastasis. serious
concomitant disorders that would compromise the
safety of the patient or compromise the patient's
ability to complete the study, at the discretion of
the investigator*
Yes
No
concurrent administration of any other tumor
therapy, including cytotoxic chemotherapy,
hormonal therapy and immunotherapy (including
trastuzumab (herceptin))*
Yes
No
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peripheral neuropathy of common toxicity criteria
(ctc) grade greater than 1. history of significant
neurological or mental disorder, including
seizures or dementia*
Yes
No
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Eligibility Breast Cancer NCT00193180
Docetaxel Plus Imatinib Mesylate in Metastatic Breast
Cancer; ODM derived from:
https://clinicaltrials.gov/show/NCT00193180
All rights reserved. Please visit https://medical-data-
models.org/forms/16301
Eligibility Breast Cancer
NCT00193180
Inclusion Criteria
to be included in this study, you must meet the
following criteria:*
Yes
No
metastatic breast cancer confirmed by biopsy*
Yes
No
no more than one prior chemotherapy regimen
for metastatic breast cancer*
Yes
No
able to perform activities of daily living with
minimal assistance*
Yes
No
adequate bone marrow, liver and kidney function*
Yes
No
age 18 years or older*
Yes
No
give written informed consent*
Yes
No
Exclusion Criteria
you cannot participate in this study if any of the
following apply to you:*
Yes
No
moderate to severe peripheral neuropathy*
Yes
No
uncontrolled blood pressure or uncontrolled heart
beat irregularities*
Yes
No
diabetes mellitus with fasting blood sugar greater
than 200 mg %*
Yes
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No
significant heart disease within the prior 6
months*
Yes
No
severe or uncontrolled medical disease*
Yes
No
active uncontrolled infection*
Yes
No
known chronic liver disease*
Yes
No
known diagnosis of hiv infection*
Yes
No
pregnant or breast feeding females*
Yes
No
please note:  there are additional
inclusion/exclusion criteria.  the study center will
determine if you meet all of the criteria.  if you do
not qualify for the trial, study personnel will
explain the reasons.  if you do qualify, study
personnel will explain the trial in detail and
answer any questions you may have.*
Yes
No
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Eligibility Breast Cancer NCT00193206
Neo-adjuvant Gemcitabine, Epirubicin, ABI-007 (GEA) in
Locally Advanced or Inflammatory Breast Cancer; ODM
derived from: https://clinicaltrials.gov/show/NCT00193206
All rights reserved. Please visit https://medical-data-
models.org/forms/16302
Eligibility Breast Cancer
NCT00193206
Inclusion Criteria
to be included in this study, you must meet the
following criteria:*
Yes
No
locally advanced/inflammatory adenocarcinoma
of the breast*
Yes
No
18 years of age or older*
Yes
No
normal heart function*
Yes
No
able to perform activities of daily living with
minimal assistance*
Yes
No
no prior chemotherapy for breast cancer*
Yes
No
adequate bone marrow, liver and kidney function*
Yes
No
no evidence or history of significant
cardiovascular abnormalities*
Yes
No
sentinel node or axillary dissection*
Yes
No
sign an informed consent form*
Yes
No
Exclusion Criteria
you cannot participate in this study if any of the
following apply to you:*
Yes
No
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pregnant or breast feeding*
Yes
No
history of heart disease with congestive heart
failure*
Yes
No
heart attack within the previous 6 months*
Yes
No
prior chemotherapy or hormone therapy for
breast cancer*
Yes
No
history of active uncontrolled infection*
Yes
No
please note:  there are additional
inclusion/exclusion criteria.  the study center will
determine if you meet all of the criteria.  if you do
not qualify for the trial, study personnel will
explain the reasons.  if you do qualify, study
personnel will explain the trial in detail and
answer any questions you may have.*
Yes
No
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Eligibility Breast Cancer NCT00216047
PTK787 + Trastuzumab for HER2 Overexpressing
Metastatic Breast Cancer; ODM derived from:
https://clinicaltrials.gov/show/NCT00216047
All rights reserved. Please visit https://medical-data-
models.org/forms/16303
Eligibility Breast Cancer
NCT00216047
Inclusion Criteria
histologic or cytologic diagnosis of breast cancer
with evidence of measurable (1) unresectable,
locally recurrent, or (2) metastatic disease. locally
recurrent disease must not be amenable to
resection or radiation with curative intent.*
Yes
No
patient's disease may not involve more than 3
metastatic sites.  in addition, patient may not be
symptomatic from pulmonary metastasis or have
liver metastasis involving > 50% of parenchyma.*
Yes
No
her2 gene amplification by fish. her protein
overexpression by immunohistochemistry will not
be sufficient for entry.*
Yes
No
negative pregnancy test*
Yes
No
Exclusion Criteria
no prior cytotoxic chemotherapy or trastuzumab
for locally recurrent or metastatic disease.*
Yes
No
no prior treatment with any vegf inhibiting agents*
Yes
No
no history or presence of central nervous system
(cns) disease.*
Yes
No
no other forms of cancer therapy including
radiation, chemotherapy and hormonal therapy
within 21 days prior to being registered for
protocol therapy.*
Yes
No
no major surgery within 28 days prior to being
registered for protocol therapy.*
Yes
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No
no uncontrolled hypertension (sbp > 170, dbp >
90), history of labile hypertension or history of
poor compliance with antihypertensive therapy.*
Yes
No
no requirement for therapeutic anticoagulation,
regular aspirin (> 325 mg/day) or nsaid use.*
Yes
No
no current breast feeding.*
Yes
No
no impairment of gastrointestinal (gi) function that
may significantly alter the absorption of ptk787.*
Yes
No
no evidence of other serious concomitant
systemic disorders incompatible with the study (at
the discretion of the investigator).*
Yes
No
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Eligibility Breast Cancer NCT00409071
Placebo-controlled Evaluation of Cocculine® Efficacy in the
Management of Nausea After Chemotherapy in Breast
Cancer.; ODM derived from:
https://clinicaltrials.gov/show/NCT00409071
All rights reserved. Please visit https://medical-data-
models.org/forms/16304
Eligibility Breast Cancer
NCT00409071
Inclusion Criteria
women with histologically proven non metastatic
breast cancer*
Yes
No
no previous chemotherapy*
Yes
No
treatment planning including 6 adjuvant ct
courses with the first 3 being necessarily of the
fac50, fec100 or tac type*
Yes
No
age>= 18 years*
Yes
No
ecog performance status (ps) <= 2 (who scale)*
Yes
No
patient able to read and understand french*
Yes
No
written, voluntary, informed consent*
Yes
No
Exclusion Criteria
previous treatment with chemotherapy (including
neo-adjuvant chemotherapy for breast cancer)*
Yes
No
previous malignancies (except basal cell skin
cancer or cervical cancer in situ or any other
curatively treated malignancy in complete
remission for more than 5 years)*
Yes
No
contraindication to corticosteroids or 5-ht3
receptor antagonists*
Yes
No
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treatment with cocculine® or any other anti-
emetic drug in the 15 days before inclusion*
Yes
No
pregnant or lactating women*
Yes
No
follow-up impossible for social, geographical,
familial or psychological reasons*
Yes
No
patients who cannot be contacted by phone*
Yes
No
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Eligibility Breast Cancer NCT00433407
T-Cell Response in Patients Receiving Trastuzumab and/or
Chemotherapy for HER2-Positive Solid Tumors; ODM
derived from: https://clinicaltrials.gov/show/NCT00433407
All rights reserved. Please visit https://medical-data-
models.org/forms/16305
Eligibility Breast Cancer
NCT00433407
Criteria
diagnosis of solid epithelial tumor, including, but
not limited to, the following:*
Yes
No
breast cancer*
Yes
No
ovarian cancer*
Yes
No
lung cancer*
Yes
No
uterine cancer*
Yes
No
prostate cancer*
Yes
No
her2/neu-positive disease by
immunohistochemistry or fluorescent in situ
hybridization*
Yes
No
must be receiving trastuzumab (herceptin®)
and/or chemotherapy (e.g., paclitaxel, docetaxel,
fluorouracil, or estramustine)*
Yes
No
patient characteristics:*
Yes
No
absolute neutrophil count > 1,000/mm^3*
Yes
No
absolute lymphocyte count > 400/mm^3*
Yes
No
platelet count > 90,000/mm^3*
Yes
No
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hemoglobin > 8 g/dl*
Yes
No
prior concurrent therapy:*
Yes
No
no other chemotherapy within the past 4 weeks*
Yes
No
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Eligibility Breast Cancer NCT00532285
Primary Paclitaxel Plus Gemcitabine in Patients With Stage
II and III Breast Cancer; ODM derived from:
https://clinicaltrials.gov/show/NCT00532285
All rights reserved. Please visit https://medical-data-
models.org/forms/16306
Eligibility Breast Cancer
NCT00532285
Inclusion Criteria
all patients must have histologically confirmed
and newly diagnosed breast cancer: node-
positive stage iia and any stage iib, iii. pet results
will determine node positivity. if pet was not
utilized, sonographically positive node should be
confirmed cytologically by fine needle aspiration.*
Yes
No
no prior hormonal, chemotherapy or radiotherapy
is allowed.*
Yes
No
no breast operation other than biopsy to make
diagnosis is allowed.*
Yes
No
age: 18-years and older, not pregnant pre-, and
postmenopausal women with good performance
status (ecog 0-1)*
Yes
No
adequate hematopoietic function: absolute
granulocyte count ³1500/mm3, platelet
³100,000/mm3,  hemoglobin ³ 10 g/mm3*
Yes
No
adequate renal function: serum creatinine £ 1.5
mg/dl*
Yes
No
adequate hepatic function: total bilirubin: £ 1.5
mg/dl, ast/alt: £ two times normal, alkaline
phosphatase: £ two times normal*
Yes
No
adequate cardiac function: normal or nonspecific
ekg taken within 1 mo of enrollment*
Yes
No
adequate mental function to understand and sign
the consent*
Yes
No
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Exclusion Criteria
patients who received hormonal, chemotherapy
or radiotherapy for breast cancer*
Yes
No
patients who underwent surgery for breast
cancer*
Yes
No
patients with node-negative stage iia breast
cancer*
Yes
No
patients who have history of cancer other than in
situ uterine cervix cancer or nonmelanotic skin
cancer*
Yes
No
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Eligibility Breast Cancer NCT00602108
Radiation Therapy in Treating Women Undergoing
Lumpectomy for Stage I or Stage IIA Breast Cancer; ODM
derived from: https://clinicaltrials.gov/show/NCT00602108
All rights reserved. Please visit https://medical-data-
models.org/forms/16307
Eligibility Breast Cancer
NCT00602108
Criteria
histologically confirmed primary invasive breast
carcinoma*
Yes
No
stage i-iia disease (t1, n0, m0 or t2, n0, m0)*
Yes
No
pathologically determined single, discrete, and
well-defined primary tumor ≤ 5 cm in diameter*
Yes
No
pathologically negative surgical margins*
Yes
No
no multicentric disease and/or diffuse malignant
appearing microcalcifications*
Yes
No
micro-calcifications must be focal*
Yes
No
specimen radiograph is required after
lumpectomy for tumors associated with malignant
appearing calcifications to assure removal of all
malignant appearing calcifications*
Yes
No
specimen radiograph is optional if the tumor
appears as a discrete mass on mammogram*
Yes
No
no axillary lymph node involvement*
Yes
No
no evidence of metastatic breast cancer*
Yes
No
hormone receptor status not specified*
Yes
No
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patient characteristics:*
Yes
No
ecog performance status 0-2*
Yes
No
menopausal status not specified*
Yes
No
no pre-existing collagen vascular disease except
rheumatoid arthritis that does not require
immunosuppressive therapy*
Yes
No
not pregnant or nursing*
Yes
No
prior concurrent therapy:*
Yes
No
no prior irradiation to the area of planned
radiation field*
Yes
No
no prior placement of breast prosthesis in the
treated breast*
Yes
No
concurrent hormonal therapy with external-beam
irradiation allowed*
Yes
No
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Eligibility Breast Cancer NCT00208871
An Evaluation of Stereoscopic Digital Mammography for
Earlier Detection of Breast Cancer and Reduced Rate of
Recall; ODM derived from:
https://clinicaltrials.gov/show/NCT00208871
All rights reserved. Please visit https://medical-data-
models.org/forms/16308
Eligibility Breast Cancer
NCT00208871
Criteria
personal history of breast and/or ovarian cancer,
regardless of age.*
Yes
No
prior breast biopsy that included any of the
following high risk, benign lesion: lobular
carcinoma in-situ, atypical ductal hyperplasia,
atypical lobular hyperplasia, atypical columnar
hyperplasia.*
Yes
No
positive test for known mutations of brca 1 or 2
genes, regardless of age.*
Yes
No
history of chest irradiation for treatment of non-
breast disease (ex:lymphoma, lung cancer) at
least 15 years prior to enrollment.*
Yes
No
family history (over 30 years of age with any of
the following, some exceptions may appy)*
Yes
No
ashkenazi jewish ancestry, regardless of age.*
Yes
No
any history of male breast cancer on the maternal
or paternal side.*
Yes
No
breast and ovarian cancer in a close relative
(mother, sister, daughter)*
Yes
No
breast or ovarian cancer in more than one close
relative (mother,sister daughter)*
Yes
No
breast cancer in a close relative (mother, sister,
daughter) with early onset(<50 years of age)*
Yes
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No
breast and ovarian cancer in a 2nd. degree
relative (grandmother, aunt, niece) with early
onset of breast cancer. (<50 years of age)*
Yes
No
multiple history of breast cancer in 1st. and 2nd.
degree relatives.*
Yes
No
Exclusion Criteria
patient does not meet any of the inclusion
criteria,*
Yes
No
patient has had breast augmentation, except for
unilateral augmentation done for prior
mastectomy,*
Yes
No
patient has suspected or confirmed pregnancy,*
Yes
No
patient has large breasts that cannot be
adequately imaged on the 19 x 23 cm detector
surface of the ge senographe 2000d digital
mammography unit.*
Yes
No
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Eligibility Breast Cancer NCT00236275
PET and MRI in the Follow-up of Neoadjuvant
Chemotherapy of Breast Cancer; ODM derived from:
https://clinicaltrials.gov/show/NCT00236275
All rights reserved. Please visit https://medical-data-
models.org/forms/16311
Eligibility Breast Cancer
NCT00236275
Inclusion Criteria
breast cancer scheduled for neoadjuvant
chemotherapy followed by surgery*
Yes
No
Exclusion Criteria
indicated chemotherapy without that a curative
tumorectomies is foreseen(planned)*
Yes
No
patient presenting an evolutionary infectious or
inflammatory pathology, including an
inflammatory breast cancer, being able to be
source(spring) of false-positive results(profits) in
tep-fdg*
Yes
No
patient in the course of radiotherapy or of
chemotherapy or operated at the level of the
thorax in 4 weeks preceding the date
foreseen(planned) by the examination tep
(pose(installation) of implantable room(chamber)
excludes)*
Yes
No
diabetic waits*
Yes
No
patient already includes in the other protocols of
search(research) for nuclear medicine or for
imaging using ionization radiations*
Yes
No
patient not having given her lit(enlightened)
assent*
Yes
No
wait among which the surveillance tep or the mri
during the chemotherapy will be impossible (that
is by geographical or professional imperative, or if
contraindication in the mri, ex: port(bearing) of a
pacemaker, cochlear magnetic implants, metal
foreign bodies cf protocol)*
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Yes
No
of less than 18 years old or pregnant patient.*
Yes
No
breast cancer stage(stadium) iv*
Yes
No
biopsy on the already realized mammary tumor,
for the period(delay) lower than 15 j.*
Yes
No
in case of alcoholic poisoning or of antecedents
of reaction to the injection of ethanol: not
inclusion to be discussed.*
Yes
No
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Ministry of Health, Ethiopia- Patient card
Form provided by Binyam Tilahun. Source:
http://www.moh.gov.et/ (Ministry of Health, Ethiopia)
All rights reserved. Please visit https://medical-data-
models.org/forms/16312
Patient card
Patient card
Medical Record Number
Patient Name
Patient age
Sex
Male (1)
Female (2)
Date
Main diagnosis
Diagnosis, other
HMIS disease classification
Time
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Federal Ministry of Health Integrated Antenatal,
Labor, Delivery, Newborn and Postnatal Care Card
Form provided by Binyam Tilahun. Source:
http://www.moh.gov.et/ (Ministry of Health, Ethiopia)
All rights reserved. Please visit https://medical-data-
models.org/forms/16313
Integrated Antenatal, Labor, Delivery,
Newborn and Postnatal Care Card
Personal information
Date
ANC Reg.No
Medical record number
Name of client
Facility name
Address:Woreda
Address: Kebelle
Address: House number
Age
years
Last menstrual period
Estimated date of delivery
Gravida
Para
Number of living children
Marital status
Obstetric history
Previous stillbirth or neonatal loss?
Yes
No
History of 3 or more consecutive spontaneous
abortions?
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Yes
No
Birth weight of last baby < 2500g
Yes
No
Birth weight of last baby > 4000g
Yes
No
Last pregnancy: hospital admission for
hypertension or pre-eclampsia/eclampsia?
Yes
No
Previous surgery on reproductive
tract?(Myomectomy, removal of septum, fistula
repair, cone biopsy, CS, repaired rapture, cervical
circlage)
Yes
No
Current Pregnancy
Diagnosed or suspected multiple pregnancy?
Yes
No
Age less than 16 years?
Yes
No
Age more than 40 years
Yes
No
Isoimmunization Rh (-) in current or in previous
pregnancy?
Yes
No
Vaginal bleeding
Yes
No
Pelvic mass
Yes
No
Diastolic blood pressure 90mm Hg or more at
booking?
Yes
No
General medical
Diabetes mellitus
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Yes
No
Renal disease
Yes
No
Cardiac disease
Yes
No
Chronic hypertension
Yes
No
Known 'substance' abuse (including heavy
alcohol drinking, Smoking)?
Yes
No
Any other severe medical disease or condition
TB, HIV, Ca, DVT..?
Yes
No
A "Yes" to any ONE of the above questions (i.e.
ONE shaded box marked with a cross) means
that the woman is not eligible for the basic
component of the new antenatal care mode and
require more close follow up or referral to
specialty care.If she needs more frequest ANC
visits use and attach additional recoridng sheets
Initial Evaluation plus Promotive and
Preventive Care
General exam
Pallor
Yes
No
Jaundice
Yes
No
Chest abnormalities
Yes
No
Heart abnormalities
Yes
No
Vulvar ulcer
Yes
No
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Vaginal discharge
Yes
No
Pelvic Mass
Yes
No
Cervical Lesion
Yes
No
Uterine size (Wks)
Danger signs  in pregnancy & delivery advised
Yes
No
Birth Preparedness advised
Yes
No
Mother: HIV test accepted
Yes
No
HIV Test result
R (1)
NR (2)
I (3)
HIV test result  received with post test counseling
Yes
No
Counseled on  Infant feeding
Yes
No
Referred for care, treatment and support
Yes
No
Partner HIV Test result
R (1)
NR (2)
I (3)
Present Pregnancy: Follow Up
Visit number
1st visit (better before 16 weeks) (1)
2nd visit (better 24 - 28 wks) (2)
3rd visit (better 30 -32 wks) (3)
4th visit (better 36-40wks) (4)
Date of visit
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Gestational age
Blood pressure
mmHg
Body weight
kg
Pallor
Uterine height (Wks)
Fetal heart beat
Fetal Presentation
Urine test for infection
Urine test for protein
Rapid syphilis test
Hemoglobin
Blood group
Rhesus factor
TT
Iron/Folic acid
Mebendazole
Use of ITN
ARV Px type
Remarks
Danger signs identified and Investigation
Action, Advice, counseling
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Appointment for next follow-up
Name and Sign of Health care Provider
Intrapartum Care and followup
Name
Gravida
Para
Medical Record Number
Admission Date
Time of admission
Ruptured membranes
hours
Fetal heart rate
Amniotic fluid
Moulding
Cervix uteri cm per hour
cm/h
Descent of head per hour
/h
Contractions per 10 min
/10min
Oxytocin in drops per minute
Oxytocin in U/l
U/l
Drugs given
IV fluids given
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Pulse
beats/min
Blood pressure, systolic
mmHg
Blood pressure, diastolic
mmHg
Body Temperature
°C
Urine protein
Urine acetone
Urine volume
ml
Delivery Summary
Date
Time
Spontaneous Vaginal Delivery
Yes
No
Cesarean section
Yes
No
Vacuum extraction delivery
Yes
No
Forceps extraction delivery
Yes
No
Episiotomy
Yes
No
Active management of third stage labor
Ergometrine (1)
Oxytocine (2)
Misoprostol (3)
Placenta delivery
Completed (1)
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Incomplete (2)
CCT (3)
MRP (4)
Laceration repair
1rst degree (1)
2nd degree (2)
3rd degree (3)
Newborn
Single (1)
Multiple (2)
Newborn: life birth
Yes
No
Apgar score
Stillbirth
MAC (1)
Fresh (2)
Sex of newborn
Male (1)
Female (2)
Birth weight
g
Infant length
cm
Delivery preterm
Yes
No
Delivery to term
Yes
No
BCG Date
Vaccinations
BCG (1)
Polio 0 (2)
Vit K (3)
TTC (4)
Baby-Mother Bonding
Yes
No
Obstetric complications managed
Eclampsia (1)
APH (2)
Ruptured uterus (repaired) (3)
PPH (4)
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PROM/Sepsis (5)
Obst/prolg labor (6)
Obstetric complications referred
Eclampsia (1)
APH (2)
Ruptured uterus (hysterectomized) (3)
PPH (4)
PROM/Sepsis (5)
Obst/prolg labor (6)
HIV testing and counseling offered
Yes
No
HIV Test accepted
Yes
No
HIV Test result
R (1)
N (2)
I (3)
Type of ARV prophylaxis provided to mother
Type of ARV prophylaxis provided to newborn
Feeding option
EBF (1)
RF (2)
Mother and  newborn referred for care and
support
Yes
No
Remarks
Delivered by
Signature
Postpartum visit
1st visit (better at 6 hrs) (1)
2nd  (better at 6th day)   (2)
3rd visit (better at 6th wks) (3)
Date of postpartum visit
Blood Pressure
TPR
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Temperature
°C
Uterus contracted
Postpartum hemorrhage
Urine leakage or dribbling
Anemia
Vaginal Discharge after 4 weeks post delivery
Pelvic exam (only if vaginal discharge)
Breast exam
Vitamin A for mother
Counseling on danger signs, ITN and EPI
Baby Breathing
Baby breastfeeding
Baby weight
grams
Immunization
HIV test done?
Yes
No
HIV Test result
R (1)
NR (2)
Type of ARV prophylaxis provided to mother
Type of ARV prophylaxis provided to newborn
Feeding option
EBF (1)
RF (2)
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Mother referred for care and support
Newborn referred to chronic HIV infant care
FP Counseled & provided
Remarks
Action Taken
Attendant name
Signature
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and Postnatal Care Card
Ministry of Health, Ethiopia- INTEGRATED
FOLDER SUMMARY SHEET
Form provided by Binyam Tilahun. Source:
http://www.moh.gov.et/ (Ministry of Health, Ethiopia)
All rights reserved. Please visit https://medical-data-
models.org/forms/16314
INTEGRATED FOLDER SUMMARY
SHEET
Patient card
Medical Record Number
Patient Name
Date
Department providing service
Diagnosis, Complication or service detail
Serial number in service registration book
Costs
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Ministry of Health, Ethiopia- Medical record
tracer card
Form provided by Binyam Tilahun. Source:
http://www.moh.gov.et/ (Ministry of Health, Ethiopia)
All rights reserved. Please visit https://medical-data-
models.org/forms/16315
Medical record tracer card
Tracer card
Facility name
Medical Record Number
Patient Name
Serial number
Department/Person Medical Record is sent to
Receiver’s Signature
Date
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Eligibility Breast Cancer NCT00237224
Open Label Study of Postmenopausal Women With ER and
/or PgR Positive Breast Cancer Treated With Letrozole;
ODM derived from:
https://clinicaltrials.gov/show/NCT00237224
All rights reserved. Please visit https://medical-data-
models.org/forms/16316
Eligibility Breast Cancer
NCT00237224
Inclusion Criteria
1. postmenopausal woman able to comply with
the protocol requirements with primary invasive
breast cancer, histologically confirmed by core
needle biopsy, whose tumors are estrogen (er)
and / or progesterone (pgr) positive, defined by
core biopsy immunohistochemistry with > 10%
positive malignant epithelial cells.*
Yes
No
2. clinical stage *t2, t3, t4a,b,c, n0, 1 or 2, m0*
Yes
No
clinical stage t2 tumors which in the investigators
opinion would not be eligible for breast-
conserving surgery.*
Yes
No
3. post menopausal status defined by one of the
following:*
Yes
No
no spontaneous menses for at least 1 year, in
women > 55 years.*
Yes
No
spontaneous menses within the past 1 year but
amenorrhoeic in women ≤ 55 years (e.g.
spontaneous or secondary to hysterectomy), and
with postmenopausal gonadotrophin levels (lh y
fsh levels > 40 iu/l) or postmenopausal estradiol
levels (< 5 ng/dl) or according to the definition of
"postmenopausal range" for the laboratory
involved.*
Yes
No
bilateral oophorectomy. (prior to the diagnosis of
breast cancer).*
Yes
No
4. tumor measurable by clinical examination,
mammography and ultrasound.*
Yes
No
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Exclusion Criteria
1. prior treatment with letrozole or tamoxifen.*
Yes
No
2. uncontrolled endocrine disorders such as
diabetes mellitus, confirmed hypo- or
hyperthyroidism, cushing's syndrome, addison's
disease (treated or untreated).*
Yes
No
3. patients with unstable, angina, or uncontrolled
cardiac disease (e.g. class iii or iv new york heart
association's functional classification).*
Yes
No
4. patients with bilateral breast tumors*
Yes
No
5. patients who are eligible for breast conserving
surgery*
Yes
No
6. evidence of inflammatory breast cancer or
distant metastasis.*
Yes
No
other protocol-defined inclusion/exclusion criteria
may apply.*
Yes
No
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Baseline Cognitive Function Cardiovascular
Health Study (CHS)
Documentation part: Record 10 Baseline Cognitive
Function
The Cardiovascular Health Study (CHS) was initiated by
the National Heart, Lung and Blood Institute (NHLBI) in
1987 to determine the risk factors for development and
progression of cardiovascular disease (CVD) in older
adults, with an emphasis on subclinical measures. The
study recruited 5,888 adults aged 65 or older at entry in
four U.S. communities and conducted extensive annual
clinical exams between 1989-1999 along with semi-annual
phone calls, events adjudication, and subsequent data
analyses and publications. Additional data were collected
by studies ancillary to CHS. With the exception of annual
clinic visits, these activities are still ongoing.
Data obtained from: https://chs-nhlbi.org/
Permission granted by: Erika Enright.
All rights reserved. Please visit https://medical-data-
models.org/forms/16317
Baseline Cognitive Function
Cardiovascular Health Study (CHS)
Cognitive Function
1. I would like to ask you a few questions dealing
with your concentration and memory. Some are a
little bit more difficult than others.
a. What is the year?
error (0)
correct (1)
not attempted (2)
refused (9)
Record answer in error:
b. What season of the year is it?
error (0)
correct (1)
not attempted (2)
refused (9)
Season:
c. What is the date?
error (0)
correct (1)
not attempted (2)
refused (9)
Date:
d. What is the day of the week?
error (0)
correct (1)
not attempted (2)
refused (9)
Day:
e. What is the month?
error (0)
correct (1)
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not attempted (2)
refused (9)
Month:
f. What state are we in?
error (0)
correct (1)
not attempted (2)
refused (9)
State:
g. What country are you in?
error (0)
correct (1)
not attempted (2)
refused (9)
Country:
h. What (city/town) are we in?
error (0)
correct (1)
not attempted (2)
refused (9)
City:
i. What floor of the building are we on?
error (0)
correct (1)
not attempted (2)
refused (9)
Floor:
j. What is this address? (if intitutionalized: What is
the name of this place?)
error (0)
correct (1)
not attempted (2)
refused (9)
Address/home:
2. I am going to name 3 objects. After I have said
them. I want you to repeat them. Remember what
they are because I am going to ask you to name
them again in a few minutes: APPLE TABLE
PENNY
Could you repeat the 3 items for me? a. Apple
error (0)
correct (1)
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not attempted (2)
refused (9)
b. Table
error (0)
correct (1)
not attempted (2)
refused (9)
c. Penny
error (0)
correct (1)
not attempted (2)
refused (9)
3. Can you subtract 7 from 100, and then subtract
7 from the answer you get and keep subtracting 7
until I tell you to stop? Please do the subtraction
out loud. a. 93
error (0)
correct (1)
can't do (7)
not attempted/refused (9)
a.
b. 86
error (0)
correct (1)
can't do (7)
not attempted/refused (9)
b.
c. 79
error (0)
correct (1)
can't do (7)
not attempted/refused (9)
c.
d. 72
error (0)
correct (1)
can't do (7)
not attempted/refused (9)
d.
e. 65
error (0)
correct (1)
can't do (7)
not attempted/refused (9)
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e.
4. I am going to spell a word forwards and I want
you to spell it backwards. The word is world. W-
O-R-L-D. 
Spell world backwards. a. D
error (0)
correct (1)
can't do (7)
not attempted/refused (9)
b. L
error (0)
correct (1)
can't do (7)
not attempted/refused (9)
c. R
error (0)
correct (1)
can't do (7)
not attempted/refused (9)
d. O
error (0)
correct (1)
can't do (7)
not attempted/refused (9)
e. W
error (0)
correct (1)
can't do (7)
not attempted/refused (9)
5. Now what were the 3 objects I asked you to
remember?
a. apple
error (0)
correct (1)
not attempted (2)
refused (9)
b. table
error (0)
correct (1)
not attempted (2)
refused (9)
c. penny
error (0)
correct (1)
not attempted (2)
refused (9)
6. What is this called?
error (0)
correct (1)
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not attempted (2)
refused (9)
7. What is this called?
error (0)
correct (1)
not attempted (2)
refused (9)
8. I'd like you to repeat a phrase after me: No it's,
and's, or but's.
error (0)
correct (1)
refused (9)
9. Read the words on this card then do what it
says.
error (0)
correct (1)
refused (9)
10. I am going to give you a piece of paper. When
I do, take the paper in your right hand, fold the
paper in half with both hands, and put the paper
down on your lap. a. Takes paper in right
error (0)
correct (1)
refused (9)
b. Folds paper in half
error (0)
correct (1)
refused (9)
c. Puts paper down on lap
error (0)
correct (1)
refused (9)
11. Write any complete sentence on that piece of
paper for me.
error (0)
correct (1)
refused (9)
12. Here's a drawing. Please copy the drawing on
the same paper.
error (0)
correct (1)
refused (9)
13. Special problems?
Yes
No
Decribe problem and questions affected below.
14. Sum of scores in items 1 through 12:
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15. Sum of maximum scores for scored tasks:
16. Correted score (#14/#15 x 30= corrected
score)
17. Look at these boxes across the top of the
page. On the top of each box are numbers from
one through nine. On the bottom part of each box
there is a symbol. Each symbol is paired with a
number. 
--
Down here are boxes with numbers on the top,
but the bottom part is blank. I want you to put the
correct symbol in each box like this:
--
Now I want you to fill in all boxes up to this line. 
--
When I tell you to begin, start here and fill in the
boxes in these four rows. Do them in any order
and don't skip any. Please try to work as quickly
as possible. Let's begin.
--
That's good. That completes this set of tasks.
a. Test items:
not done (0)
done (1)
refused (9)
b. Number of symbols correctly coded:
c. Number of symbols incorrectly coded:
Date of interview
Interviewer
Interview:
First edit:
Second edit:
6 / 6
Baseline Cognitive Function Cardiovascular Health Study (CHS)
Spirometry Cardiovascular Health Study
(CHS)
Documentation part: Record 11 Spirometry
The Cardiovascular Health Study (CHS) was initiated by
the National Heart, Lung and Blood Institute (NHLBI) in
1987 to determine the risk factors for development and
progression of cardiovascular disease (CVD) in older
adults, with an emphasis on subclinical measures. The
study recruited 5,888 adults aged 65 or older at entry in
four U.S. communities and conducted extensive annual
clinical exams between 1989-1999 along with semi-annual
phone calls, events adjudication, and subsequent data
analyses and publications. Additional data were collected
by studies ancillary to CHS. With the exception of annual
clinic visits, these activities are still ongoing.
Data obtained from: https://chs-nhlbi.org/
Permission granted by: Erika Enright.
All rights reserved. Please visit https://medical-data-
models.org/forms/16318
Spirometry Cardiovascular Health
Study (CHS)
Spirometry
1. Did you take any pills or inhalers for breathing
problems during the last 24 hours?
don't know (don't know)
no (no)
yes (yes)
Albuterol (Y)
Yes
No
Alupent
Yes
No
Asthma-Haler
Yes
No
Asthma-Nefrin
Yes
No
Atrovent (F)
Yes
No
Bronkaid Mist
Yes
No
Bronkometer
Yes
No
Isuprel
Yes
No
Metaprel
Yes
No
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Prematine Mist
Yes
No
Proventil
Yes
No
Ventolin
Yes
No
Other
Yes
No
Aminophyline (G)
Choledyl
Yes
No
Elixophyllin
Yes
No
Lufyllin
Yes
No
Quibron
Yes
No
Slo-Phyllin
Yes
No
Tedrall
Yes
No
Theophyline
Yes
No
Theo-Dur
Yes
No
Theo-24 (W)
Yes
No
Uniphyl
Yes
No
Other/Unknown
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Yes
No
2. Did you take a beta blocker pill for high blood
pressure or heart trouble durin the last 24 hours?
don't know (don't know)
no (no)
yes (yes)
Which one?
Blocadren
Yes
No
Corgard
Yes
No
Inderal
Yes
No
Lopressor
Yes
No
Normozide
Yes
No
Sectral
Yes
No
Tenormin
Yes
No
Timolide
Yes
No
Visken
Yes
No
Other/Unknown
Yes
No
3. Did you smoke a cigarette, pipe, or cigar
during the last hour?
don't know (don't know)
no (no)
yes (yes)
4. Did you have any coffee, tea, cola or other
caffine containing drinks the past 4 hours?
don't know (don't know)
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no (no)
yes (yes)
5. Have you had a respiratory infection in the past
3 weeks? For instance, a cold, flu, bronchitis, or
pneumonia?
don't know (don't know)
no (no)
yes (yes)
Date of interview
Interviewer
Interview:
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Eligibility Depression NCT02122393
A Randomised Trial of Sertraline, Cognitive Behaviour
Therapy & Combined Therapy for Postnatal Depression;
ODM derived from:
https://clinicaltrials.gov/show/NCT02122393
All rights reserved. Please visit https://medical-data-
models.org/forms/16319
Eligibility Depression NCT02122393
Inclusion Criteria
women with an infant > 2 months and < 8 months
of age*
Yes
No
infant born after a full-term pregnancy*
Yes
No
infant born with no congenital abnormalities*
Yes
No
diagnosis of depression with postnatal onset
according to the diagnostic and statistical manual
of mental disorders 4th edition (dsm-iv).*
Yes
No
Exclusion Criteria
positive serum pregnancy test;*
Yes
No
concurrent psychiatric disorder (excepting co-
morbid anxiety);*
Yes
No
recent history of antidepressant usage (within the
last month);*
Yes
No
history of major allergy or drug allergy;*
Yes
No
history of substance abuse;*
Yes
No
prior non-response to sertraline, or prior non-
response to adequate trials of two selective
serotonin reuptake inhibitors (ssris);*
Yes
No
predisposition to headache, migraine or nausea;*
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Yes
No
tobacco habit in excess of 10 cigarettes per day;*
Yes
No
caffeine consumption in excess of 6 cups of
coffee/tea or cola-flavoured drinks per day;*
Yes
No
ongoing dental work;*
Yes
No
extreme levels of depression (psychotic);*
Yes
No
suicidal intent;*
Yes
No
participation in any medical trial within the
previous three months;*
Yes
No
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Phlebotomy Cardiovascular Health Study
(CHS)
Documentation part: Record 12 Baseline Phlebotomy
The Cardiovascular Health Study (CHS) was initiated by
the National Heart, Lung and Blood Institute (NHLBI) in
1987 to determine the risk factors for development and
progression of cardiovascular disease (CVD) in older
adults, with an emphasis on subclinical measures. The
study recruited 5,888 adults aged 65 or older at entry in
four U.S. communities and conducted extensive annual
clinical exams between 1989-1999 along with semi-annual
phone calls, events adjudication, and subsequent data
analyses and publications. Additional data were collected
by studies ancillary to CHS. With the exception of annual
clinic visits, these activities are still ongoing.
Data obtained from: https://chs-nhlbi.org/
Permission granted by: Erika Enright.
All rights reserved. Please visit https://medical-data-
models.org/forms/16320
Phlebotomy Cardiovascular Health
Study (CHS)
Adminstrative data
Phlebotomist ID:
Blood ID Number:
Has this participant been selected as a quality
control subject?
Yes
No
Quality Control ID Number:
Phlebotomy
1. Do you bleed or bruise easily?
don't know (don't know)
no (no)
yes (yes)
2. Have you ever been told you have a disorder
related to blood clotting or coagulation?
don't know (don't know)
no (no)
yes (yes)
3. Have you ever experienced fainting spells
while having blood drawn?
don't know (don't know)
no (no)
yes (yes)
4. Do you have diabetes?
don't know (don't know)
no (no)
yes (yes)
5. Do you take insulin?
Yes
No
6. Are you fasting?
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don't know (don't know)
no (no)
yes (yes)
7. Is this participant taking the Glucose Tolerance
Test?
Yes
No
8. Time glucoca administered:
Date of interview
Interviewer
Interview:
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Eligibility Depression, Involutional
NCT00033787
Serotonin Function During Depression; ODM derived from:
https://clinicaltrials.gov/show/NCT00033787
All rights reserved. Please visit https://medical-data-
models.org/forms/16322
Eligibility Depression, Involutional
NCT00033787
Criteria
36 subjects with rmdd (ages 18-60) will be
selected.  remission is defined as a period of at
least three months during which the subject has
not taken an antidepressant agent, with hamilton
depression rating scales (hdrs; 21-item) scores in
the non-depressed range (less than 8), and with
no more than one clinically significant depressive
symptom.  additional 17 subjects with current
mdd will be selected for the gaba mrs study.*
Yes
No
inclusion criteria - healthy control samples:*
Yes
No
twenty-four healthy subjects (ages 18-60) without
a known personal or family history of psychiatric
disorders in first-degree relatives will be
selected.*
Yes
No
Exclusion Criteria
subjects must not have taken antidepressant or
other medications likely to alter monoamine
neurochemistry or cerebrovascular and
cardiovascular function for at least 3 months prior
to the studies. however, effective medications will
not be discontinued for the purposes of this
study.*
Yes
No
subjects will also be excluded if they have:*
Yes
No
1. any form of past or current psychosis;*
Yes
No
2. medical or neurological illnesses likely to affect
physiology or anatomy, i.e. hypertension,
cardiovascular disorders;*
Yes
No
3. a history of drug (including benzodiazepines
[bzd]) or alcohol abuse within 1 year or a lifetime
history of alcohol or drug dependence (dsm iv
criteria) longer than 2 years;*
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Yes
No
4. current pregnancy (as documented by
pregnancy testing at screening or at days of the
challenge studies);*
Yes
No
f) current breast feeding (tryptophan depletion);*
Yes
No
g) are smokers;*
Yes
No
h) current suicidal ideation or behavior;*
Yes
No
i) general mri exclusion criteria.*
Yes
No
subjects must exhibit no or only moderate alcohol
use.*
Yes
No
subjects with current excessive use of alcohol
(greater than 8 ounces/day for men and greater
than 6 ounces/day for women) are ineligible for
participation.*
Yes
No
j) other current axis i diagnoses beside unipolar
major depressive disorder;*
Yes
No
k) lactose intolerance (tryptophan depletion).*
Yes
No
subjects beyond the age of 60 are excluded.*
Yes
No
subjects whose first major depressive episodes
arose temporally after other medical or
psychiatric conditions will also be excluded.*
Yes
No
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Eligibility Depressive Disorder, Major
NCT00186264
Does Concurrent Hydrocortisone With Venlafaxine XR
Speed Antidepressant Response?; ODM derived from:
https://clinicaltrials.gov/show/NCT00186264
All rights reserved. Please visit https://medical-data-
models.org/forms/16323
Eligibility Depressive Disorder, Major
NCT00186264
Criteria
current major depressive episode*
Yes
No
hdrs greater than or equal to 21*
Yes
No
good physical health exclusion criteria:- history of
sensitivity, intolerance, or non-response to
venlafaxine*
Yes
No
history of sensitivity to hydrocortisone*
Yes
No
history of bipolar 1 illness*
Yes
No
meets dsm-iv criteria for a current or past
psychotic disorder*
Yes
No
meets dsm-iv criteria for substance abuse or
dependence in previous 6 months*
Yes
No
significant imminent suicide risk*
Yes
No
medical condition that would compromise
participation in the study*
Yes
No
woman of child bearing potential not using
adequate birth control in the opinion of the
investigator*
Yes
No
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Ministry of Health, Ethiopia- Womans card
Form provided by Binyam Tilahun. Source:
http://www.moh.gov.et/ (Ministry of Health, Ethiopia)
All rights reserved. Please visit https://medical-data-
models.org/forms/16324
Womans card
Demographic Information
Name of health facility
Name of woman
Address:Woreda
Address: Kebele
Address: House number
Medical Record Number
Date of birth
Marital status
Educational Status
Registration date
General Medical Information
Past medical hisotory
Diabetes	 (1)
Renal	 (2)
Cardiac	 (3)
Hypertension	 (4)
Use of  known substance    	 (5)
Tuberculosis	 (6)
HIV	 (7)
Other (8)
Laboratory Test Date
Laboratory results
Date of issue of prescription
Drug prescribed
Tetanus Toxoid vaccination
TT1 (1)
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TT2 (2)
TT3 (3)
TT4 (4)
TT5 (5)
Date of vaccination
Obstetric history
Year of pregnancy
yyyy
Outcome of pregnancy
Delivery (1)
Abortion (2)
Mode of delivery of the neonate
Spontaneous  (1)
Induced  (2)
C/S (3)
Complications
Yes
No
Place of delivery
Institution (1)
Home (2)
Status of the offspring
alive (1)
dead (2)
Counseling and Testing
Date of visit
Counseling sexually transmitted infections
HIV counseling offered
Counseling feeding practice
HIV Test result
RPR test result
VDRL Test result
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Family planning
Date of visit
Blood pressure
mmHg
Weight
kg
Contraception Method provided
Emergency Contraception (EC)
Female Condom (FeC)
Injectable (Inj)
Male Condom (MaC)
Oral Contraceptive (OC)
tubal ligation (TL)
vasectomy (V)
Reason for contraceptive method change
Developed illness and disease (Ill)
Potential interaction with newly initiated
treatment ingredient (Int)
Unavailability of the method (MethUn)
Other (Oth)
Desire being pregnant (Preg)
Unwanted side effects (S/E)
Risk of STI exposure (STI)
Abortion care
Date of procedure
Gravidity
Parity
Gestational age
Weeks of pregnancy
Abortion type
Spontaneous (1)
Unsafe (2)
Safe abortion (3)
Inevitable (4)
Incomplete (5)
Complete (6)
Evacuation type
MVA (1)
E&C (2)
MA (3)
D&C (4)
3 / 4
Ministry of Health, Ethiopia- Womans card
Other (5)
Analgesia
Yes
No
Type of analgesia
Notes on analgesia
Place Procedure Performed
Inpatient (1)
Outpatient (2)
Post abortion contraception counseling
Yes
No
Contraceptive Method provided
Condition on discharge
Improved (1)
Referred (2)
Died (3)
Remarks
Signature
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Eligibility Essential Hypertension
NCT00208104
Motivational Interviewing; ODM derived from:
https://clinicaltrials.gov/show/NCT00208104
All rights reserved. Please visit https://medical-data-
models.org/forms/16325
Eligibility Essential Hypertension
NCT00208104
Inclusion Criteria
the target population consisted of hypertensive
african american patients who fulfilled the
following eligibility criteria:*
Yes
No
self-identification as african american*
Yes
No
age 18 years or older*
Yes
No
diagnosis of hypertension utilizing icd-9 codes
401-401.9 (the code for essential hypertension)*
Yes
No
taking at least one antihypertensive medication*
Yes
No
uncontrolled hypertension of a clinic blood
pressure reading >140/90 mm hg  or 130/80 mm
hg (for those with kidney disease or diabetes) on
two successive clinic visits prior to screening
(defined per jnc vi criteria)*
Yes
No
fluent in english language*
Yes
No
Exclusion Criteria
participants were excluded if they:*
Yes
No
had a diagnosis of cognitive impairment or
serious medical condition as determined by their
primary physician*
Yes
No
were unable to give informed consent*
Yes
No
refused to participate*
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No
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Eligibility Breast Cancer NCT00450762
Gemcitabine + Carboplatin in Breast Cancer; ODM derived
from: https://clinicaltrials.gov/show/NCT00450762
All rights reserved. Please visit https://medical-data-
models.org/forms/16326
Eligibility Breast Cancer
NCT00450762
Inclusion Criteria
histologically confirmed metastatic breast cancer*
Yes
No
all patients were required to give written informed
consent.*
Yes
No
prior treatment with chemotherapy, hormonal
therapy, immunotherapy or local radiotherapy was
allowed (except gemcitabine or platinum
agents).*
Yes
No
patients were required to have at least one
bidimensionally measurable lesion outside a
previous radiation port.*
Yes
No
age ≥ 18 years*
Yes
No
karnofsky performance status ≥ 70 %*
Yes
No
minimal life expectancy of 12 weeks*
Yes
No
adequate haematological, renal, cardiac and
hepatic function:*
Yes
No
1. leukocyte count   ≥ 3.0 x 109/l*
Yes
No
2. absolute neutrophil count ≥ 2.0 x 109/l*
Yes
No
3. platelet count   ≥ 100 x 109/l*
Yes
No
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4. haemoglobin    ≥ 8 g/dl*
Yes
No
5. total serum bilirubin  ≤ 1.25 x upper limit of
normal (uln) in presence of liver metastasis  ≤ 3 x
uln*
Yes
No
6. transaminase (alt,ast) level  ≤ 3 x uln in
presence of liver metastasis  ≤ 5 x uln*
Yes
No
7. alkaline phosphatase level ≤ 2.5 x uln*
Yes
No
8. creatinine clearance was required to exceed
60 ml/min.*
Yes
No
Exclusion Criteria
prior treatment with gemcitabine or platinum
agents*
Yes
No
inadequate creatinine clearance (< 60 ml/min)*
Yes
No
only bone metastases*
Yes
No
symptomatic brain metastases*
Yes
No
women who are pregnant, lactating or refuse
effective contraception*
Yes
No
secondary malignancy*
Yes
No
history of another primary malignant disease
other than in situ carcinoma of the uterine cervix
or adequately treated basal cell skin cancer*
Yes
No
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active infection*
Yes
No
any other concomitant severe clinical condition
making implementation of the protocol including
pre-hydration difficult.*
Yes
No
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Eligibility Breast Cancer NCT00540800
BREAST-10: Three-weekly Versus Weekly First-line
Chemotherapy for Metastatic or Locally Advanced Breast
Cancer; ODM derived from:
https://clinicaltrials.gov/show/NCT00540800
All rights reserved. Please visit https://medical-data-
models.org/forms/16327
Eligibility Breast Cancer
NCT00540800
Inclusion Criteria
histological diagnosis of breast cancer*
Yes
No
inoperable locally advanced or metastatic
disease not yet treated with first-line
chemotherapy*
Yes
No
age < 70 years*
Yes
No
ecog performance status < 2*
Yes
No
written informed consent*
Yes
No
Exclusion Criteria
previous or concomitant malignant neoplasm
(excluding adequately treated baso or
spinocellular skin carcinoma or carcinoma in situ
of the cervix)*
Yes
No
previous treatment with docetaxel*
Yes
No
symptomatic brain metastases*
Yes
No
neutrophil < 2000/mm3, platelets <
100,000/mm3, haemoglobin < 10 g/dl*
Yes
No
creatinine > 1.25 x  the upper normal limits*
Yes
No
got and/or gpt  > 1.25 x the upper normal limits in
absence of hepatic metastases*
Yes
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No
got and/or gpt > 2.5 x the upper normal limits in
presence of hepatic metastases*
Yes
No
bilirubin > 1.5 x the upper normal limit*
Yes
No
any concomitant pathology that would, in the
investigator's opinion, contraindicate the use of
the drugs in this study*
Yes
No
inability to provide informed consent*
Yes
No
inability to comply with follow-up*
Yes
No
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Eligibility Breast Cancer NCT00248703
Secondary Adjuvant Treatment for Patients With Isolated
Tumor Cells in Bone Marrow; ODM derived from:
https://clinicaltrials.gov/show/NCT00248703
All rights reserved. Please visit https://medical-data-
models.org/forms/16328
Eligibility Breast Cancer
NCT00248703
Inclusion Criteria
1. breast cancer with node positive disease or
high risk node negative disease (pt1c/t2gii-iiin0,
pt3n0, ct3n0). patients < 35 years with pt1a-
bn0g2-3.*
Yes
No
2. primary surgery for breast cancer completed*
Yes
No
3. completed 6 cycles of adjuvant (or
neoadjuvant) chemotherapy containing
anthracycline*
Yes
No
4. age  ≥ 18 and < 70 years*
Yes
No
5. eastern cooperative oncology group or who
performance status < 2*
Yes
No
6. written informed consent prior to beginning
protocol specific procedures*
Yes
No
7. laboratory requirements (within 5 weeks prior
to end of radiation treatment or within 5 weeks
prior to completion of baseline examinations):*
Yes
No
neutrophils  ≥ 1.1 10^9/l, platelets  ≥ 100 10^9/l,
hemoglobin  ≥ 10 g/dl, asat and alat ≤ x 2.5 unl (if
alp > 2.5 ≤ x 5 unl, then asat and alat ≤ x 1.5 unl),
alp ≤ x 5 unl (if asat and alat > 1.5 ≤ x 2.5 unl,
then alp ≤ 2.5 x unl), creatinine ≤ 175 umol/l*
Yes
No
8. completed staging analysis including chest x-
ray, bone scintigraphy or mri, liver ultrasound or
liver ct scan*
Yes
No
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Exclusion Criteria
1. other (than breast carcinoma) earlier or
concomitant carcinoma, except for skin and in
situ cervix cancer*
Yes
No
2. m1 breast cancer or locoregional recurrence of
previously diagnosed breast cancer.*
Yes
No
3. earlier treatment with paclitaxel or docetaxel.*
Yes
No
4. pre-existing motor or sensory neurotoxicity of a
severity  ≥ grade 2 by nci criteria (see appendix
ii)*
Yes
No
5. cardiac disease with symptoms classified as
nyha  ≥ 2*
Yes
No
6. definite contraindications for the use of
corticosteroids*
Yes
No
7. concurrent treatment with other experimental
drugs*
Yes
No
8. concurrent treatment with any other anti-
cancer therapy (except for endocrine therapy and
trastuzumab)*
Yes
No
9. pregnancy*
Yes
No
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Eligibility Breast Cancer NCT00623519
Assessment of Endometrial Changes in Postmenopausal
Women With Breast Cancer in Adjuvant Treatment With
Anastrozole; ODM derived from:
https://clinicaltrials.gov/show/NCT00623519
All rights reserved. Please visit https://medical-data-
models.org/forms/16329
Eligibility Breast Cancer
NCT00623519
Inclusion Criteria
provision of informed consent*
Yes
No
resectable breast cancer patients, with
histological confirmation*
Yes
No
patients eligible to receive hormonal adjuvant
treatment with anastrozole*
Yes
No
they are allowed patients treated with adjuvant
chemo or radiotherapy concurrently*
Yes
No
patients previously treated with tamoxifen that
had to withdraw treatment due to other reason
than endometrial changes are allowed*
Yes
No
postmenopausal patients(aged 50 years or over/
without menses in the last months/ fsh level
>40ui/l / women under 50 years with fsh
levels>40ui/l).*
Yes
No
women showing progesterone and/or estrogen
receptors positive.*
Yes
No
Exclusion Criteria
patients with evidence of metastatic disease*
Yes
No
patients unsuitable to receive the medication
according the anastrozole label*
Yes
No
patients not giving their informed consent*
Yes
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Eligibility Healthy NCT00543322
PET Study of the Nicotinic Receptors in Human; ODM
derived from: https://clinicaltrials.gov/show/NCT00543322
All rights reserved. Please visit https://medical-data-
models.org/forms/16330
Eligibility Healthy NCT00543322
Inclusion Criteria
general inclusion criteria:*
Yes
No
subjects under 60 years are only male.*
Yes
No
subjects from 60 to 85 may be male or female*
Yes
No
subjects that have a health insurance*
Yes
No
subjects will be asked to refrain from caffein for at
least 12 hours*
Yes
No
specific inclusion criteria for part 2:*
Yes
No
subjects with*
Yes
No
specific inclusion criteria for part 3:*
Yes
No
subjects with alzheimer diseased based on the
dsm iv and nincds-adrda criteria. with a mms
between 15 and 26 (included).*
Yes
No
subjects capable of giving an informed consent
and accompagined by a person of confidence*
Yes
No
specific inclusion criteria for part 4:*
Yes
No
subjects with adnfle with or without demonstrated
mutation on the nicotinic receptors*
Yes
No
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Exclusion Criteria
general exclusion criteria:*
Yes
No
subjects with abnormal mri findings at visual
inspection*
Yes
No
subjects with a history of significant medical
disordres, or requiering chronic treatment that
interfere with the cholinergic system*
Yes
No
subjects with abnormal plasma biological
analysis*
Yes
No
subjects with significant past and present history
of hypertension, cardiovascular disease and
diabetes mellitus*
Yes
No
subjects who have pacemakers, aneurysm clips
(metal clips) metallic prostheses (including heart
valves and cochlear implants) or shrapnel
fragments.*
Yes
No
subjects incapable of giving an informed consent*
Yes
No
specific exclusion criteria for part 2:*
Yes
No
subjects with a smoking history in the last five
years*
Yes
No
specific exclusion criteria for part 3:*
Yes
No
subjects with a smoking history in the last five
years*
Yes
No
specific exclusion criteria for part 4:*
Yes
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No
subjects with a smoking history in the last five
years*
Yes
No
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Eligibility Heart Failure NCT00146679
Psychoeducational Intervention for ICD Patients (PEACE);
ODM derived from:
https://clinicaltrials.gov/show/NCT00146679
All rights reserved. Please visit https://medical-data-
models.org/forms/16331
Eligibility Heart Failure
NCT00146679
Inclusion Criteria
all subjects must have a nonthoracotomy
insertion*
Yes
No
have a primary cardiac etiology of their
ventricular arrhythmia (coronary artery disease,
cardiomyopathy, valve dysfunction, or
combination)*
Yes
No
be fluent in english*
Yes
No
live within a 75 mile radius of the coordinating
center*
Yes
No
be accessible by telephone*
Yes
No
only those receiving their first icd, not
replacement generators, will be entered.*
Yes
No
Exclusion Criteria
being evaluated or on a waiting list for heart
transplantation*
Yes
No
congenital disease or long qt syndrome*
Yes
No
disorientation documented in the pre-implantation
hospitalization period*
Yes
No
history of psychiatric disorder or progressively
debilitating comorbidity that would confound
outcome measures*
Yes
No
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Admitted patient mental health care NMDS
2015-16 Metadata Online Registry (METeOR)
Health sector data set specifications from METeOR,
Australia's repository for national metadata standards,
developed by the Australian Institute of Health and Welfare
(http://meteor.aihw.gov.au/content/index.phtml/itemId/3451
65)
Admitted patient mental health care NMDS 2015-16
The scope of the Admitted patient mental health care
national minimum data set (NMDS) is restricted to admitted
patients receiving care in psychiatric hospitals or in
designated psychiatric units in acute hospitals. The scope
does not currently include patients who may be receiving
treatment for psychiatric conditions in acute hospitals who
are not in psychiatric units.
© Australian Institute of Health and Welfare 2015
Metadata and Classifications Unit 
Australian Institute of Health and Welfare
GPO Box 570
Canberra ACT 2601
All rights reserved. Please visit https://medical-data-
models.org/forms/16333
Admitted patient mental health care
NMDS 2015-16 Metadata Online
Registry (METeOR)
Episode of admitted patient care
Referral destination to further care (psychiatric
patients)*
Not referred (1)
Private psychiatrist (2)
Other private medical practitioner (3)
Mental health/alcohol and drug in-patient
facility (4)
Mental health/alcohol and drug non in-
patient facility (5)
Acute hospital (6)
Other (7)
Admission date*
Total leave days*
Source of referral to public psychiatric hospital*
Private psychiatric practice (01)
Other private medical practice (02)
Other public psychiatric hospital (03)
Other health care establishment (04)
Other private hospital (05)
Law enforcement agency (06)
Other agency (07)
Outpatient department (08)
Other (09)
Unknown (10)
Separation date*
Mode of separation*
Discharge/transfer to (an)other acute
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hospital (1)
Discharge/transfer to a residential aged
care service, unless this is the usual
place of residence (2)
Discharge/transfer to (an)other
psychiatric hospital  (3)
Discharge/transfer to other health care
accommodation (includes mothercraft
hospitals) (4)
Statistical discharge - type change (5)
Left against medical advice/discharge at
own risk (6)
Statistical discharge from leave (7)
Died (8)
Other (includes discharge to usual
residence, own accommodation/welfare
institution (includes prisons, hostels and
group homes providing primarily welfare
services)) (9)
Episode of care
Additional diagnosis
Mental health legal status*
Involuntary patient (1)
Voluntary patient (2)
Not reported/unknown (9)
Total psychiatric care days*
Principal diagnosis*
Establishment
Establishment identifier*
Hospital service
Care type*
Acute care (1)
Hospital boarder (10)
Mental health care (11)
Rehabilitation care (2)
Palliative care (3)
Geriatric evaluation and management (4)
Psychogeriatric care (5)
Maintenance care (6)
Newborn care (7)
Other admitted patient care (88)
Organ procurement—posthumous (9)
Patient
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Admitted patient mental health care NMDS 2015-16 Metadata Online
Registry (METeOR)
Previous specialised treatment*
Patient has no previous admission(s) or
service contact(s) for the specialised
treatment now being provided (1)
Patient has previous hospital
admission(s) but no service contact(s)
for the specialised treatment now being
provided (2)
Patient has previous service contact(s)
but no hospital admission(s) for the
specialised treatment now being
provided (3)
Patient has both previous hospital
admission(s) and service contact(s) for
the specialised treatment now being
provided (4)
Unknown/not stated (5)
Person
Type of usual accommodation*
House or flat (1)
Independent unit as part of retirement
village or similar (2)
Hostel or hostel type accommodation (3)
Psychiatric hospital (4)
Acute hospital (5)
Other accommodation (6)
No usual residence (7)
Type of accommodation*
Private residence (e.g. house, flat,
bedsitter, caravan, boat, independent
unit in retirement village), including
privately and publicly rented homes (1)
Other supported accommodation (10)
Prison/remand centre/youth training
centre (11)
Public place (homeless) (12)
Other accommodation, not elsewhere
classified (13)
Unknown/unable to determine (14)
Psychiatric hospital (2)
Residential aged care service (3)
Specialised alcohol/other drug treatment
residence (4)
Specialised mental health community-
based residential support service (5)
Domestic-scale supported living facility
(e.g. group home for people with
disability) (6)
Boarding/rooming house/hostel or hostel
type accommodation, not including aged
persons' hostel (7)
Homeless persons' shelter (8)
Shelter/refuge (not including homeless
persons' shelter) (9)
Area of usual residence (SA2)*
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Admitted patient mental health care NMDS 2015-16 Metadata Online
Registry (METeOR)
Country of birth*
Date of birth*
Indigenous status*
Aboriginal but not Torres Strait Islander
origin (1)
Torres Strait Islander but not Aboriginal
origin (2)
Both Aboriginal and Torres Strait Islander
origin (3)
Neither Aboriginal nor Torres Strait
Islander origin (4)
Not stated/inadequately described (9)
Employment status (admitted patient)*
Unemployed / pensioner (1)
Other (2)
Employment status (public psychiatric hospital
admissions)*
Child not at school (1)
Student (2)
Employed (3)
Unemployed (4)
Home duties (5)
Other (6)
Marital status
Never married (1)
Widowed (2)
Divorced (3)
Separated (4)
Married (registered and de facto) (5)
Not stated/inadequately described (6)
Person identifier*
Sex*
Male (1)
Female (2)
Intersex or indeterminate (3)
Not stated/inadequately described (9)
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Admitted patient mental health care NMDS 2015-16 Metadata Online
Registry (METeOR)
Admitted patient palliative care NMDS 2015-
16 Metadata Online Registry (METeOR)
Health sector data set specifications from METeOR,
Australia's repository for national metadata standards,
developed by the Australian Institute of Health and Welfare
(http://meteor.aihw.gov.au/content/index.phtml/itemId/3451
65)
Admitted patient palliative care NMDS 2015-16
The scope of the Admitted patient palliative care national
minimum data set (NMDS) is admitted patients receiving
palliative care in all public and private acute hospitals, and
free standing day hospital facilities. Hospitals operated by
the Australian Defence Force, correctional authorities and
Australia's external territories are not currently included.
Palliative care patients are identified by the data element
Hospital service—care type, code N[N].
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Admitted patient palliative care
NMDS 2015-16 Metadata Online
Registry (METeOR)
Episode of admitted patient care
Admission date*
Mode of admission*
Admitted patient transferred from another
hospital (1)
Statistical admission - episode type
change (2)
Other (3)
Number of days of hospital-in-the-home care*
Separation date*
Mode of separation*
Discharge/transfer to (an)other acute
hospital (1)
Discharge/transfer to a residential aged
care service, unless this is the usual
place of residence (2)
Discharge/transfer to (an)other
psychiatric hospital  (3)
Discharge/transfer to other health care
accommodation (includes mothercraft
hospitals) (4)
Statistical discharge - type change (5)
Left against medical advice/discharge at
own risk (6)
Statistical discharge from leave (7)
Died (8)
Other (includes discharge to usual
residence, own accommodation/welfare
institution (includes prisons, hostels and
group homes providing primarily welfare
1 / 3
services)) (9)
Episode of care
Additional diagnosis
Principal diagnosis*
Funding source for hospital patient*
Health service budget (not covered
elsewhere) (01)
Health service budget (due to eligibility
for Reciprocal Health Care Agreement)
(02)
Health service budget (no charge raised
due to hospital decision) (03)
Department of Veterans' Affairs (04)
Department of Defence (05)
Correctional facility (06)
Medicare Benefits Scheme (07)
Other hospital or public authority
(contracted care) (08)
Private health insurance (09)
Worker's compensation (10)
Motor vehicle third party personal claim
(11)
Other compensation (e.g. public liability,
common law, medical negligence) (12)
Self-funded (13)
Other funding source (88)
Not known (98)
Establishment
Establishment identifier*
Hospital service
Care type*
Acute care (1)
Hospital boarder (10)
Mental health care (11)
Rehabilitation care (2)
Palliative care (3)
Geriatric evaluation and management (4)
Psychogeriatric care (5)
Maintenance care (6)
Newborn care (7)
Other admitted patient care (88)
Organ procurement—posthumous (9)
Patient
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Admitted patient palliative care NMDS 2015-16 Metadata Online Registry
(METeOR)
Previous specialised treatment*
Patient has no previous admission(s) or
service contact(s) for the specialised
treatment now being provided (1)
Patient has previous hospital
admission(s) but no service contact(s)
for the specialised treatment now being
provided (2)
Patient has previous service contact(s)
but no hospital admission(s) for the
specialised treatment now being
provided (3)
Patient has both previous hospital
admission(s) and service contact(s) for
the specialised treatment now being
provided (4)
Unknown/not stated (5)
Person
Area of usual residence (SA2)*
Country of birth*
Date of birth*
Indigenous status*
Aboriginal but not Torres Strait Islander
origin (1)
Torres Strait Islander but not Aboriginal
origin (2)
Both Aboriginal and Torres Strait Islander
origin (3)
Neither Aboriginal nor Torres Strait
Islander origin (4)
Not stated/inadequately described (9)
Person identifier*
Sex*
Male (1)
Female (2)
Intersex or indeterminate (3)
Not stated/inadequately described (9)
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(METeOR)
Breast cancer (cancer registries) DSS
Metadata Online Registry (METeOR)
Health sector data set specifications from METeOR,
Australia's repository for national metadata standards,
developed by the Australian Institute of Health and Welfare
(http://meteor.aihw.gov.au/content/index.phtml/itemId/3451
65)
Breast cancer (cancer registries) DSS
This breast cancer data set is not mandated for collection
but is recommended as best practice if breast cancer data
are to be collected.
The data set would allow common, consistent and high
quality breast cancer data to be collected by State and
Territory cancer registries and collated nationally.
This data will help inform research, policy, planning and
guideline development work in the breast cancer area.
Breast cancer may be used as a forerunner for other
cancers in terms of establishing common data collections
across cancer registries.
This data set includes 20 items, with the inclusion of five
new standards and the addition of further detail to several
existing standards.
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Breast cancer (cancer registries)
DSS Metadata Online Registry
(METeOR)
Patient
Date of diagnosis of cancer*
Person with cancer
Cancer staging—M stage code*
Cancer staging—TNM stage grouping code*
Histopathological grade*
Grade 1: Low grade; well differentiated,
differentiated, NOS (1)
Grade 2: Intermediate grade, moderately
differentiated, moderately well
differentiated, intermediate differentiation
(2)
Grade 3: High grade, poorly
differentiated (3)
Grade 4: Undifferentiated, anaplastic (4)
Grade or differentiation not determined,
not stated or not applicable (9)
Human epidermal growth factor receptor-2 test
result*
Positive (1)
Negative (2)
Equivocal (3)
1 / 3
Unknown (test results not available) (7)
Not applicable (test not done) (8)
Human epidermal growth factor receptor-2 test
type*
Fluorescence in situ hybridisation (FISH)
(1)
Brightfield in situ hybridisation (2)
Immunochemistry (IHC) (3)
Other (8)
Test type not stated or unknown (9)
Laterality of primary cancer*
Bilateral (B)
Left (L)
Not applicable (N)
Right (R)
Unknown (U)
Lymphovascular invasion*
Present  (1)
Absent (2)
Suspicious (3)
Not stated or unknown (9)
Morphology of cancer*
Most valid basis of diagnosis of cancer*
Death certificate only: Information
provided is from a death certificate (0)
Clinical: Diagnosis made before death,
but without any of the following (codes 2-
7) (1)
Clinical investigation: All diagnostic
techniques, including x-ray, endoscopy,
imaging, ultrasound, exploratory surgery
(e.g. laparotomy), and autopsy, without a
tissue diagnosis (2)
Specific tumour markers: Including
biochemical and/or immunological
markers that are specific for a tumour
site (4)
Cytology: Examination of cells from a
primary or secondary site, including
fluids aspirated by endoscopy or needle;
also includes the microscopic
examination of peripheral blood and
bone marrow aspirates (5)
Histology of metastasis: Histological
examination of tissue from a metastasis,
including autopsy specimens (6)
Histology of a primary tumour:
Histological examination of tissue from
primary tumour, however obtained,
including all cutting techniques and bone
marrow biopsies; also includes autopsy
specimens of primary tumour (7)
Histology: either unknown whether of
primary or metastatic site, or not
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Breast cancer (cancer registries) DSS Metadata Online Registry
(METeOR)
otherwise specified (8)
Unknown (9)
Neo-adjuvant therapy*
Yes
No
Regional lymph nodes positive*
Number of positive sentinel lymph nodes*
Number of regional lymph nodes examined*
Number of sentinel lymph nodes examined*
Oestrogen receptor assay result*
Positive (1)
Negative (2)
Equivocal (3)
Unknown (test results not available) (7)
Not applicable (test not done) (8)
Primary site of cancer (ICD-O-3 code)*
Cancer staging—T stage code*
Cancer staging—N stage code*
Tumour size at diagnosis (solid tumours)*
mm
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Breast cancer (cancer registries) DSS Metadata Online Registry
(METeOR)
Community mental health care NMDS 2015-
16 Metadata Online Registry (METeOR)
Health sector data set specifications from METeOR,
Australia's repository for national metadata standards,
developed by the Australian Institute of Health and Welfare
(http://meteor.aihw.gov.au/content/index.phtml/itemId/3451
65)
Community mental health care NMDS 2015-16
The Community mental health care national minimum data
set (CMHC NMDS) includes data about Mental health
service contacts provided by specialised mental health
services for patients/clients, other than those admitted to
psychiatric hospitals or designated psychiatric units in
acute care hospitals, and those resident in 24 hour staffed
specialised residential mental health services.
The scope covers all ambulatory mental health care service
units that deliver clinical care and are administered or
funded by state and territory governments.
The scope of the collection includes ambulatory clinical
mental health care provided by service units covering all
target populations and includes general adult, child &
adolescent, youth, older persons and forensic community
mental health service units.  
The scope excludes ambulatory equivalent same day
separations. 
The scope excludes support services that are not
specialised mental health care services (see Specialised
mental health service) and services provided by non-
government organisations.
The following metadata items are of particular relevance to
the scope of the CMHC NMDS:
Ambulatory mental health care service
Specialised mental health service
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Community mental health care
NMDS 2015-16 Metadata Online
Registry (METeOR)
Episode of care
Mental health legal status*
Involuntary patient (1)
Voluntary patient (2)
Not reported/unknown (9)
Principal diagnosis*
Establishment
Australian State/Territory identifier
(establishment)*
New South Wales (1)
Victoria (2)
Queensland (3)
South Australia (4)
Western Australia (5)
Tasmania (6)
Northern Territory (7)
Australian Capital Territory (8)
1 / 3
Other territories (Cocos (Keeling)
Islands, Christmas Island and Jervis Bay
Territory) (9)
Region code*
Region name*
Establishment sector*
Public (1)
Private (2)
Service unit cluster identifier*
Service unit cluster name*
Mental health service contact
Patient/client participation indicator*
Yes
No
Mental health service contact date*
Mental health service contact duration
minutes
Session type*
Individual session (1)
Group session (2)
Person
Area of usual residence (SA2)*
Country of birth*
Date of birth*
Indigenous status*
Aboriginal but not Torres Strait Islander
origin (1)
Torres Strait Islander but not Aboriginal
origin (2)
Both Aboriginal and Torres Strait Islander
origin (3)
Neither Aboriginal nor Torres Strait
Islander origin (4)
Not stated/inadequately described (9)
Marital status*
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Community mental health care NMDS 2015-16 Metadata Online Registry
(METeOR)
Never Married (1)
Widowed (2)
Divorced (3)
Separated  (4)
Married (registered and de facto) (5)
Not stated/inadequately described (6)
Person identifier*
Sex*
Male (1)
Female (2)
Intersex or indeterminate (3)
Not stated/inadequately described (9)
Person identifier flag*
Yes
No
Specialised mental health service
organisation
Organisation identifier*
Organisation name*
Specialised mental health service
Ambulatory service unit identifier*
Ambulatory service unit name*
Target population*
Child and adolescent (1)
Older person (2)
Forensic (3)
General (4)
Youth (5)
Not applicable (7)
Not stated/inadequately described (9)
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Community mental health care NMDS 2015-16 Metadata Online Registry
(METeOR)
Computer Assisted Telephone Interview demographic
module DSS Metadata Online Registry (METeOR)
Health sector data set specifications from METeOR,
Australia's repository for national metadata standards,
developed by the Australian Institute of Health and Welfare
(http://meteor.aihw.gov.au/content/index.phtml/itemId/3451
65)
Computer Assisted Telephone Interview demographic
module DSS
Key demographic set for use in Computer Assisted
Telephone Interviewing (CATI) health surveys. It is intended
to be used by anyone conducting population health surveys
using the CATI mode, such as State/Territory government
health agencies. This data set is to standardise
demographic collection in all CATI surveys of health topics,
such as CATI asthma and CATI diabetes surveys.
The standardisation of the collection of health survey data
is a major focus of the National Public Health Partnership
(NPHP) work plan. The CATI demographic module DSS is
not mandated for collection but recommended as best
practice.
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Computer Assisted Telephone
Interview demographic module DSS
Metadata Online Registry (METeOR)
Household
Household annual gross income range
Less than $ 20,000 (1)
$ 20,001-$ 30,000 (2)
001 (3)
$ 50,001 - $ 100,000 (4)
More than $ 100,000 (5)
Don't know/not sure (6)
Not stated (7)
Household annual gross income range ($ 10,000
range)
Less than $ 10,000 (1)
$ 90,001 - $ 100,000 (10)
More than $ 100,000 (11)
Don't know / not sure (12)
Not stated (13)
$ 10,000 - $ 20,000 (2)
$ 20,001 - $ 30,000 (3)
$ 30,001 - $ 40,000 (4)
$ 40,001 - $ 50,000 (5)
$ 50,001 - $ 60,000 (6)
$ 60,001 - $ 70,000 (7)
$ 70,001 - $ 80,000 (8)
$ 80,001 - $ 90,000 (9)
Person (address)
Postcode—Australian
1 / 2
Suburb/town/locality name
Person
Age range
0-4 (01)
5-14 (02)
15-24 (03)
25-34 (04)
35-44 (05)
45-54 (06)
55-64 (07)
65-74 (08)
75 years or older (09)
Not stated (99)
Age
years
Country of birth
Date of birth
Indigenous status
Aboriginal but not Torres Strait Islander
origin (1)
Torres Strait Islander but not Aboriginal
origin (2)
Both Aboriginal and Torres Strait Islander
origin (3)
Neither Aboriginal nor Torres Strait
Islander origin (4)
Not stated/inadequately described (9)
Marital status
Never Married (1)
Widowed (2)
Divorced (3)
Separated  (4)
Married (registered and de facto) (5)
Not stated/inadequately described (6)
Sex
Male (1)
Female (2)
Intersex or indeterminate (3)
Not stated/inadequately described (9)
Year of arrival in Australia
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Computer Assisted Telephone Interview demographic module DSS
Metadata Online Registry (METeOR)
Elective surgery waiting times (census data) NMDS
2015- Metadata Online Registry (METeOR)
Health sector data set specifications from METeOR,
Australia's repository for national metadata standards,
developed by the Australian Institute of Health and Welfare
(http://meteor.aihw.gov.au/content/index.phtml/itemId/3451
65)
Elective surgery waiting times (census data)
The scope of this national minimum data set (NMDS) is
patients on waiting lists for elective surgery, as defined in
the Elective care waiting list episode—elective care type,
code N data element (also known as 'Waiting list category'),
which are managed by public acute hospitals. This will
include private patients treated in public hospitals, and may
include public patients treated in private hospitals.
Hospitals may also collect information for other care (as
defined in the 'Waiting list category' data element), but this
is not part of the NMDSs for Elective surgery waiting times
(census data) and Elective surgery waiting times (removals
data).
Patients on waiting lists managed by hospitals operated by
the Australian Defence Force, corrections authorities and
Australia's external territories are not currently included.
Census data:
Data are collected for patients on elective surgery waiting
lists who are yet to be admitted to hospital or removed for
another reason. The scope is patients on elective surgery
waiting lists on a census date who are 'ready for care' and
patients who are 'not ready for care', as defined in the
Elective surgery waiting list episode—patient listing status,
readiness for care code N data element.
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Elective surgery waiting times
(census data) NMDS 2015-
Metadata Online Registry (METeOR)
Elective care waiting list episode
Listing date for care*
Elective surgery waiting list episode
Clinical urgency*
Procedures that are clinically indicated
within 30 days (1)
Procedures that are clinically indicated
within 90 days (2)
Procedures that are clinically indicated
within 365 days (3)
Indicator procedure*
Cataract extraction (01)
Cholecystectomy (02)
Coronary artery bypass graft (03)
Cystoscopy (04)
Haemorrhoidectomy (05)
Hysterectomy (06)
Inguinal herniorrhaphy (07)
Myringoplasty (08)
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Myringotomy (09)
Prostatectomy (10)
Septoplasty (11)
Tonsillectomy (12)
Total hip replacement (13)
Total knee replacement (14)
Varicose veins stripping and ligation (15)
Other (88)
Overdue patient*
Overdue patient (1)
Other (2)
Patient listing status*
Ready for care (1)
Not ready for care (2)
Surgical specialty (of scheduled doctor)*
Cardio-thoracic surgery (01)
Ear, nose and throat surgery (02)
General surgery (03)
Gynaecology (04)
Neurosurgery (05)
Ophthalmology (06)
Orthopaedic surgery (07)
Plastic surgery (08)
Urology (09)
Vascular surgery (10)
Other (11)
Waiting time at a census date*
days
Establishment
Establishment identifier*
Hospital census (of elective surgery
waitlist patients)
Census date*
Person
Indigenous status*
Aboriginal but not Torres Strait Islander
origin (1)
Torres Strait Islander but not Aboriginal
origin (2)
Both Aboriginal and Torres Strait Islander
origin (3)
Neither Aboriginal nor Torres Strait
Islander origin (4)
Not stated/inadequately described (9)
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Elective surgery waiting times (census data) NMDS 2015- Metadata
Online Registry (METeOR)
Eligibility Breast Cancer NCT00251329
Docetaxel, Carboplatin, and Capecitabine as Treatment for
Patients With Locally Advanced or Inflammatory Breast
Cancer Before Surgery; ODM derived from:
https://clinicaltrials.gov/show/NCT00251329
All rights reserved. Please visit https://medical-data-
models.org/forms/16339
Eligibility Breast Cancer
NCT00251329
Inclusion Criteria
women or men > 18 years old with histologically
confirmed, by needle core biopsy (not fna),
locally advanced or inflammatory breast cancer.*
Yes
No
all patients must have either t2 lesion which is felt
to be initially resectable only through mastectomy
by the surgeon, or with a t3 n0-n2; t4 any n; or
any t with n2 or n3 clinical evidence of disease.
stage 2 patients where breast conservation
surgery is desired but impractical at diagnosis
because of anticipated poor cosmetic outcome
are eligible.  patients with inflammatory breast
carcinoma and women with ipsilateral
supraclavicular node involvement are eligible.
patients must have measurable disease defined
as a breast lesion > 2 cm or with fixed or marked
ipsilateral axillary nodes and/or ipsilateral internal
mammary nodes.*
Yes
No
pre-and post-menopausal female and male
patients are eligible.  women of childbearing
potential must have a negative pregnancy test
and, men and women must be willing to consent
to using effective dual methods of contraception
while on treatment and for three months
thereafter.*
Yes
No
life expectancy of greater than 6 months.*
Yes
No
bone scan and cat scan of chest and abdomen
negative for metastatic disease*
Yes
No
Exclusion Criteria
patients with metastatic disease.*
Yes
No
patients may not be receiving any other
investigational agents.*
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Yes
No
uncontrolled intercurrent illness including, but not
limited to, ongoing or active infection other than
mild resolving cellulitis, symptomatic congestive
heart failure (nyha > class 1), unstable angina
pectoris, uncontrolled cardiac arrhythmia, known
coronary artery disease, or psychiatric
illness/social situations that would limit
compliance with study requirements.*
Yes
No
cancer other than breast primary within the last 5
years with the exception of surgically cured non-
melanoma skin cancer or in situ carcinoma of the
cervix.*
Yes
No
women who are breast-feeding.*
Yes
No
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Eligibility Breast Cancer NCT00251329
Elective surgery waiting times (removals data)
NMDS 2015- Metadata Online Registry (METeOR)
Health sector data set specifications from METeOR,
Australia's repository for national metadata standards,
developed by the Australian Institute of Health and Welfare
(http://meteor.aihw.gov.au/content/index.phtml/itemId/3451
65)
Elective surgery waiting times (removals data)
The scope of this national minimum data set (NMDS) is
patients removed from waiting lists for elective surgery (as
defined in Elective care waiting list episode—elective care
type, code N) which are managed by public acute hospitals.
This will include private patients treated in public hospitals,
and may include public patients treated in private hospitals.
Hospitals may also collect information for other care (as
defined in the 'waiting list category' data element), but this
is not part of the NMDSs for Elective surgery waiting times
(census data) and  Elective surgery waiting times (removals
data).
Patients removed from waiting lists managed by hospitals
operated by the Australian Defence Force, corrections
authorities and Australia's external territories are not
currently included.
Removals data:
Data are collected for patients who have been removed
from an elective surgery waiting list (for admission or
another reason). Patients who were 'ready for care' and
patients who were 'not ready for care' at the time of removal
are included, as defined in the Elective surgery waiting list
episode—patient listing status, readiness for care code N
data element.
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Elective surgery waiting times
(removals data) NMDS 2015-
Metadata Online Registry (METeOR)
Elective care waiting list episode
Listing date for care*
Elective surgery waiting list episode
Clinical urgency*
Procedures that are clinically indicated
within 30 days (1)
Procedures that are clinically indicated
within 90 days (2)
Procedures that are clinically indicated
within 365 days (3)
Indicator procedure*
Cataract extraction (01)
Cholecystectomy (02)
Coronary artery bypass graft (03)
Cystoscopy (04)
Haemorrhoidectomy (05)
Hysterectomy (06)
Inguinal herniorrhaphy (07)
Myringoplasty (08)
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Myringotomy (09)
Prostatectomy (10)
Septoplasty (11)
Tonsillectomy (12)
Total hip replacement (13)
Total knee replacement (14)
Varicose veins stripping and ligation (15)
Other (88)
Overdue patient
Overdue patient (1)
Other (2)
Reason for removal from elective surgery waiting
list*
Admitted as an elective patient for
awaited procedure by or on behalf of this
hospital or the state/territory (1)
Admitted as an emergency patient for
awaited procedure by or on behalf of this
hospital or the state/territory (2)
Could not be contacted (includes
patients who have died while waiting,
whether or not the cause of death was
related to the condition requiring
treatment) (3)
Treated elsewhere for awaited
procedure, but not on behalf of this
hospital or the state/territory (4)
Surgery not required or declined (5)
Transferred to another hospital's waiting
list (6)
Not known (9)
Surgical specialty (of scheduled doctor)*
Cardio-thoracic surgery (01)
Ear, nose and throat surgery (02)
General surgery (03)
Gynaecology (04)
Neurosurgery (05)
Ophthalmology (06)
Orthopaedic surgery (07)
Plastic surgery (08)
Urology (09)
Vascular surgery (10)
Other (11)
Removal date*
Waiting time at removal from elective surgery
waiting list*
days
Establishment
Establishment identifier*
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Elective surgery waiting times (removals data) NMDS 2015- Metadata
Online Registry (METeOR)
Person
Indigenous status*
Aboriginal but not Torres Strait Islander
origin (1)
Torres Strait Islander but not Aboriginal
origin (2)
Both Aboriginal and Torres Strait Islander
origin (3)
Neither Aboriginal nor Torres Strait
Islander origin (4)
Not stated/inadequately described (9)
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Elective surgery waiting times (removals data) NMDS 2015- Metadata
Online Registry (METeOR)
Injury surveillance DSS 2013- Metadata
Online Registry (METeOR)
Health sector data set specifications from METeOR,
Australia's repository for national metadata standards,
developed by the Australian Institute of Health and Welfare
(http://meteor.aihw.gov.au/content/index.phtml/itemId/3451
65)
Injury surveillance DSS 2013-
The scope of this minimum data set is patient level data
from selected emergency departments of hospitals and
other settings.
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Injury surveillance DSS 2013-
Metadata Online Registry (METeOR)
Injury event
Activity when injured*
Activity when injured (non-admitted patient)*
Football, Australian (0)
Football, Australian (0)
Football, rugby (00)
Football, soccer (02)
Hockey (03)
Squash (04)
Basketball (05)
Netball (06)
Cricket (07)
Roller blading (08)
Other and unspecified sporting activity
(09)
Leisure activity (excluding sporting
activity) (1)
Working for income (2)
Other types of work (3)
Resting, sleeping, eating or engaging in
other vital activities (4)
Other specified activities (5)
Unspecified activities (6)
External cause*
Narrative description of injury event*
External cause—human intent*
Accident - injury not intended (01)
Intentional self-harm (02)
Sexual assault (03)
Maltreatment by parent (04)
Maltreatment by spouse or partner (05)
Other and unspecified assault (06)
Event of undetermined intent (07)
Legal intervention (including police) or
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operations of war (08)
Adverse effect or complications of
medical and surgical care (09)
Other specified intent (10)
Intent not specified (11)
Nature of main injury (non-admitted patient)*
Superficial (excludes eye injury code 13)
(01)
Open wound (excludes eye injury code
13)  (02)
Fracture (excludes dental injury code 21)
(03)
Dislocation (includes ruptured disc,
cartilage, ligament) (04)
Sprain or strain (05)
Injury to nerve (includes spinal cord;
excludes intracranial injury code 20)
(06)
Injury to blood vessel (07)
Injury to muscle or tendon (08)
Crushing injury (09)
Traumatic amputation (includes partial
amputation) (10)
Injury to internal organ (11)
Burn or corrosion (excludes eye injury
code 13) (12)
Eye injury (includes burns, excludes
foreign body in external eye code 14.1 )
(13)
Foreign body in external eye (14.1)
Foreign body in ear canal (14.2)
Foreign body in nose (14.3)
Foreign body in respiratory tract
(excludes foreign body in nose code
14.3) (14.4)
Foreign body in alimentary tract (14.5)
Foreign body in genitourinary tract (14.6)
Foreign body in soft tissue (14.7)
Foreign body, other/unspecified (14.9)
Intracranial injury (includes concussion)
(20)
Dental injury (includes fractured tooth)
(21)
Drowning, immersion (22)
Asphyxia or other threat to breathing
(excludes drowning immersion code 22)
(23)
Electrical injury (24)
Poisoning, toxic effect (excludes effect of
venom, or any insect bite code 26) (25)
Effect of venom, or any insect bite (26)
Other specified nature of injury (27)
Injury of unspecified nature (28)
Multiple injuries of more than one 'nature'
(29)
No injury detected (30)
Place of occurrence of external cause of injury
(ICD-10-AM)*
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Place of occurrence of external cause of injury
(non-admitted patient)*
Home (0)
Residential Institution  (1)
School, other institution and public
administration area (2)
School (21)
Health service area (22)
Building used by general public or public
group (23)
Sports and athletics area (3)
Street and highway (4)
Trade and service area (5)
Industrial and construction area (6)
Farm (7)
Other specified places (8)
Unspecified place (9)
Person
Bodily location of main injury*
Head (excludes face) (01)
Face (excludes eye) (02)
Neck (03)
Thorax (04)
Abdomen (05)
Lower back (includes loin) (06)
Pelvis (includes perineum, anogenital
area and buttocks) (07)
Shoulder (08)
Upper arm (09)
Elbow (10)
Forearm (11)
Wrist (12)
Hand (include fingers) (13)
Hip (14)
Thigh (15)
Knee (16)
Lower leg (17)
Ankle (18)
Foot (include toes) (19)
Unspecified bodily location (20)
Multiple injuries (involving more than one
bodily location) (21)
Bodily location not required (22)
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Online Registry (METeOR)
Health sector data set specifications from METeOR,
Australia's repository for national metadata standards,
developed by the Australian Institute of Health and Welfare
(http://meteor.aihw.gov.au/content/index.phtml/itemId/3451
65)
Maternity model of care DSS
The Maternity model of care (MoC) data set specification
(DSS) is not mandated for collection. This data set
specification enables maternity care providers to classify
models of care using the Maternity Care Classification
System (MaCCS). 
The scope of the data set is all models of maternity care
available to pregnant and birthing women. 
The MaCCS, utilising the DSS provides a standardised
nomenclature and descriptive data for maternity models of
care. National collation of these data enables meaningful
analysis and comparisons of maternal and perinatal
outcomes between differing models of care. The data
elements in the DSS describe the different characteristics
of models of maternity care based on three domains:
·	the women a model is designed for;
·	the carers working in the model; and
·	aspects of how care is provided. 
The development of the MaCCS and the MoC DSS was
undertaken as part of the National Maternity Data
Development Project under the guidance of an expert
advisory group and included wide-reaching consultation
with relevant stakeholder groups around the country.
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Maternity model of care DSS
Metadata Online Registry (METeOR)
Establishment
Establishment identifier*
Maternity model of care
Target group indicator*
Yes
No
Maternity target group
Aboriginal or Torres Strait Islander
identification (1)
Maternal diabetes and other endocrine
disorders (10)
Maternal obesity or high body mass
index (BMI) (11)
Maternal drug or alcohol use (12)
Maternal age - young (13)
Maternal mental health condition (14)
Maternal remote area of residence (15)
Migrant or refugee (2)
Low risk or normal pregnancy (3)
All excluding high risk pregnancy (4)
Complex or high risk pregnancy (5)
Breech presentation of fetus (6)
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Multi fetal pregnancy (7)
Next birth after caesarean section (8)
Other specific cultural groups not already
specified (80)
Other social groups not already specified
(81)
Other vulnerable groups not already
specified (82)
Other maternity target groups (88)
Planned homebirth (9)
Not stated/inadequately described (99)
Profession of designated maternity carer*
Specialist obstetrician - public (1)
Aboriginal maternal infant care
practitioner (10)
Nurse (11)
Shared care (12)
Multidisciplinary team (13)
Perinatal mental health worker (14)
Other allied health practitioner (15)
Medical specialist other than obstetric
(16)
Public hospital medical officer (17)
Specialist obstetrician - private (2)
General practitioner obstetrician (3)
Midwife - public (4)
Midwife - private (5)
Midwife - privately practising (6)
General practitioner (7)
Maternal - fetal medicine subspecialist
(8)
Other (88)
Aboriginal health practitioner (9)
Midwifery caseload indicator*
Yes
No
Midwifery caseload size
Extent of continuity of carer*
Antenatal period only (1)
Antenatal and intrapartum periods (2)
Antenatal and postpartum periods (3)
Intrapartum and postpartum periods (4)
Whole duration of maternity period -
antenatal, intrapartum and postpartum
(5)
No continuity of carer (6)
Not stated/inadequately described (99)
Planned collaborative maternity carer
Specialist obstetrician - public (1)
Aboriginal maternal infant care
practitioner (10)
Nurse (11)
Shared care (12)
Multidisciplinary team (13)
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Perinatal mental health worker (14)
Other allied health practitioner (15)
Medical specialist other than obstetric
(16)
Public hospital medical officer (17)
Specialist obstetrician - private (2)
General practitioner obstetrician (3)
Midwife - public (4)
Midwife - private (5)
Midwife - privately practising (6)
General practitioner (7)
Maternal - fetal medicine subspecialist
(8)
Other (88)
Aboriginal health practitioner (9)
Not stated/inadequately described (99)
Routine relocation for intrapartum care and birth
indicator*
Yes
No
Expected setting for an antenatal care visit*
Hospital clinic - onsite (1)
Hotel or hostel (10)
Hospital clinic - outreach (2)
Clinicians' private rooms (3)
Community facility (4)
Aboriginal Community Controlled Health
Service facility (5)
Home (6)
Birth centre - stand alone (7)
Birth centre - in hospital (8)
Other (88)
Hospital - excluding birth centre (9)
Not stated/inadequately described (99)
Expected setting of birth*
Aboriginal Community Controlled Health
Service facility (5)
Home (6)
Birth centre - stand alone (7)
Birth centre - in hospital (8)
Other (88)
Hospital - excluding birth centre (9)
Not stated/inadequately described (99)
Postnatal visits in a residential setting*
Yes
No
Individual or group care*
Individual sessions (1)
Group sessions (2)
Combination of individual and group
sessions (3)
Planned medical visit indicator
Yes
No
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Additional remote or rural services offered
indicator*
Yes
No
Type of additional antenatal/postnatal remote or
rural service
Fly-in-fly-out clinicians (1)
Telehealth (2)
Community-based remote-area clinicians
(3)
Other (88)
Not stated/inadequately described (99)
Expected length of time for postnatal visits in a
residential setting
1-3 days (1)
4-7 days (2)
8-14 days (3)
15-28 days (4)
29-42 days (5)
More than 42 days (6)
Not stated/inadequately described (99)
Major Model Category*
Private obstetrician (specialist) care (1)
Remote area maternity care (10)
Private obstetrician and privately
practising midwife joint care (11)
Private midwifery care (2)
General Practitioner obstetrician care (3)
Shared care (4)
Combined care (5)
Public hospital maternity care (6)
Public hospital high risk maternity care
(7)
Team midwifery care (8)
Other (88)
Midwifery group practice caseload care
(9)
Not stated/inadequately described (99)
Maternity model of care identifier*
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Non-admitted patient care hospital aggregate NMDS
2015-16 Metadata Online Registry (METeOR)
Health sector data set specifications from METeOR,
Australia's repository for national metadata standards,
developed by the Australian Institute of Health and Welfare
(http://meteor.aihw.gov.au/content/index.phtml/itemId/3451
65)
Non-admitted patient care hospital aggregate NMDS
The scope of the Non-admitted patient care hospital
aggregate national minimum data set (NMDS) is non-
admitted patient service events involving non-admitted
patients provided by public hospitals  
The NMDS is intended to capture instances of service
provision from the point of view of the patient.
The NMDS scope includes:
All arrangements made to deliver non-admitted patient
service events (not covered by the national minimum data
sets listed below) to non-admitted patients:
•	irrespective of location (includes on-campus and off-
campus), 
•	whose treatment has been funded through the
jurisdictional health authority, Local Hospital Network or
hospital, regardless of the source from which the entity
derives these funds. In particular, Department of Veterans'
Affairs, compensable and other patients funded through the
hospital (including Medicare ineligible patients) are
included; and 
•	regardless of setting or mode.
Excluded from the NMDS scope are:
All services covered by:
•	the Admitted patient care NMDS; 
•	the Admitted patient mental health care NMDS; 
•	the Non-admitted patient emergency department care
NMDS, e.g. all non-admitted services provided to admitted
patients are excluded;  
•	The Community mental health care NMDS; and 
•	service events which deliver non-clinical care, e.g.
activities such as home cleaning, meals on wheels or home
maintenance.
For the purpose of this NMDS, a non-admitted service is a
specialty unit or organisational arrangement under which a
public hospital provides non-admitted services. 
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Non-admitted patient care hospital
aggregate NMDS 2015-16 Metadata
Online Registry (METeOR)
Episode of care
Funding source for hospital patient*
Health service budget (not covered
elsewhere) (01)
Health service budget (due to eligibility
for Reciprocal Health Care Agreement)
(02)
Health service budget (no charge raised
due to hospital decision) (03)
Department of Veterans' Affairs (04)
Department of Defence (05)
Correctional facility (06)
Medicare Benefits Scheme (07)
Other hospital or public authority
(contracted care) (08)
Private health insurance (09)
Worker's compensation (10)
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Motor vehicle third party personal claim
(11)
Other compensation (e.g. public liability,
common law, medical negligence) (12)
Self-funded (13)
Other funding source (88)
Not known (98)
Establishment
Local Hospital Network identifier*
South Eastern Sydney  (101)
Sydney  (102)
South Western Sydney  (103)
Western Sydney  (104)
Nepean Blue Mountains (105)
Northern Sydney (106)
Central Coast (107)
Illawarra Shoalhaven  (108)
Hunter New England  (109)
Mid North Coast (110)
Northern NSW  (111)
Western NSW (112)
Southern NSW  (113)
Murrumbidgee  (114)
Far West (115)
Sydney Children's Hospitals Network
(117)
St Vincent's Health Network (118)
Justice Health & Forensic Mental Health
(119)
New South Wales Virtual Local Hospital
Network (199)
Beaufort and Skipton Health Service
(201)
East Grampians Health Service (202)
Ballarat Health Services  (203)
Stawell Regional Health (204)
East Wimmera Health Service (205)
Hepburn Health Service  (206)
Maryborough District Health Service
(207)
Djerriwarrh Health Service (Vic) (208)
Western Health (Vic)  (209)
Bendigo Health Care Group (210)
Heathcote Health (211)
Swan Hill District Health (212)
Cohuna District Hospital  (213)
Echuca Regional Health  (214)
Kerang District Health  (215)
Maldon Hospital (216)
Boort District Health (218)
Rochester and Elmore District Health
Service  (219)
Inglewood and District Health Service
(220)
Castlemaine Health  (221)
Kyneton District Health Service (222)
Royal Children's Hospital (Melbourne)
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(223)
Royal Women's Hospital (Melbourne)
(224)
Melbourne Health  (225)
Northern Health (Vic) (226)
Victorian Institute of Forensic Mental
Health (227)
Colac Area Health (228)
Hesse Rural Health Service
(Winchelsea) (229)
Otway Health and Community Services
(Apollo Bay)  (23)
Barwon Health (231)
Lorne Community Hospital  (232)
Alexandra District Hospital (233)
Eastern Health (Vic)  (234)
Goulburn Valley Health  (235)
Kyabram and District Health Service
(236)
Numurkah and District Health Service
(237)
Nathalia District Hospital  (238)
Cobram District Hospital  (239)
Seymour District Memorial Hospital
(240)
Kilmore and District Hospital (241)
Yea and District Memorial Hospital  (242)
Northeast Health Wangaratta (243)
Yarrawonga District Health Service
(244)
Alpine Health (Vic) (245)
Mansfield District Hospital (246)
Benalla and District Memorial Hospital
(247)
Tallangatta Health Service  (248)
Albury Wodonga Health (249)
Upper Murray Health and Community
Services (Corryong) (250)
Beechworth Health Service (251)
West Gippsland Healthcare Group (252)
Bass Coast Regional Health  (253)
Gippsland Southern Health Service
(254)
South Gippsland Hospital (Foster) (255)
Bairnsdale Regional Health Service
(256)
Yarram and District Health Service  (257)
Omeo District Health  (258)
Central Gippsland Health Service  (259)
Latrobe Regional Hospital (260)
Orbost Regional Health  (261)
St Vincent's Hospital (Melbourne)
Limited (262)
Royal Victorian Eye and Ear Hospital
(263)
Peter MacCallum Cancer Institute (Vic)
(264)
Austin Health (Vic) (266)
Mercy Public Hospital Inc. (Vic) (267)
Alfred Health (Vic) (268)
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Monash Health (269)
Peninsula Health (Vic)  (270)
Kooweerup Regional Health Service
(271)
Rural Northwest Health (Vic)  (274)
Wimmera Health Care Group (275)
Dunmunkle Health Services (276)
West Wimmera Health Service (277)
Edenhope and District Memorial Hospital
(278)
Mildura Base Hospital (279)
Mallee Track Health and Community
Service (280)
Robinvale District Health Services  (281)
Western District Health Service (Vic)
(282)
Casterton Memorial Hospital (283)
South West Healthcare (Vic) (284)
Heywood Rural Health  (285)
Timboon and District Healthcare Service
(286)
Moyne Health Services (Port Fairy)
(287)
Portland District Health  (288)
Terang and Mortlake Health Service
(Terang) (289)
Calvary Health Care Bethlehem Limited
(290)
Victoria Virtual Local Hospital Network
(299)
Cairns and Hinterland (312)
Townsville  (313)
Mackay  (314)
North West (Qld)  (315)
Central Queensland  (316)
Central West (Qld)  (317)
Wide Bay  (318)
Sunshine Coast  (319)
Metro North (Qld) (320)
Children's Health Queensland  (321)
Metro South (Qld) (322)
Gold Coast  (323)
West Moreton  (324)
Darling Downs (325)
South West (Qld)  (326)
Torres and Cape (327)
Queensland Virtual Local Hospital
Network (399)
Northern Adelaide (401)
Central Adelaide  (402)
Southern Adelaide (403)
Country Health SA (404)
Women's and Children's Health Network
(SA) (405)
South Australia Virtual Local Hospital
Network (499)
North Metropolitan Health Service (WA)
(501)
South Metropolitan Health Service (WA)
(502)
4 / 5
Non-admitted patient care hospital aggregate NMDS 2015-16 Metadata
Online Registry (METeOR)
WA Country Health Service (503)
Child Adolescent Health Service (WA)
(580)
Notional Local Hospital Network (Royal
St.) (590)
Western Australia Virtual Local Hospital
Network (599)
Tasmanian Health Organisation - South
(601)
Tasmanian Health Organisation - North
(602)
Tasmanian Health Organisation - North
West (603)
Tasmania Virtual Local Hospital Network
(699)
Top End (NT) (701)
Central Australia (NT) (702)
Northern Territory Virtual Local Hospital
Network (799)
Australian Capital Territory (801)
Australian Capital Territory Virtual Local
Hospital Network (899)
Virtual Local Hospital Network -
Unknown (900)
Not applicable (997)
Unknown (998)
Not stated/inadequately described (999)
Number of group session non-admitted patient
service events*
Number of individual session non-admitted
patient service events
Establishment identifier*
Establishment identifier
Non-admitted patient service event
Multiple health care provider indicator*
Yes (1)
No (2)
Not stated/inadequately described (9)
Non-admitted service type*
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Health sector data set specifications from METeOR,
Australia's repository for national metadata standards,
developed by the Australian Institute of Health and Welfare
(http://meteor.aihw.gov.au/content/index.phtml/itemId/3451
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Non-admitted patient care Local Hospital Network
aggregate DSS 2015-16
The scope of the Non-admitted patient care Local Hospital
Network aggregate data set specification (DSS) is non-
admitted patient service events involving non-admitted
patients provided by:
·	Local Hospital Networks 
·	other public hospital services that are managed by a state
or territory health authority and are included in the General
list of in-scope public hospital services, which have been
developed under the National Health Reform Agreement
(2011).
This also includes all in-scope services contracted by a
public hospital, Local Hospital Network or jurisdiction
regardless of the physical location of the contracting public
hospital, Local Hospital Network or jurisdiction, or the
location where the services are delivered. The DSS is
intended to capture instances of service provision from the
point of view of the patient.
The DSS scope includes:
All arrangements made to deliver non-admitted patient
service events (not covered by the national minimum data
sets listed below) to non-admitted patients:
·	irrespective of location (includes on-campus and off-
campus), 
·	whose treatment has been funded through the
jurisdictional health authority, Local Hospital Network or
hospital, regardless of the source from which the entity
derives these funds. In particular, Department of Veterans'
Affairs, compensable and other patients funded through the
hospital (including Medicare ineligible patients) are
included; and 
·	regardless of setting or mode.
Excluded from the DSS scope are:
All services covered by:
·	the Admitted patient care NMDS; 
·	the Admitted patient mental health care NMDS; 
·	the Non-admitted patient emergency department care
NMDS, e.g. all non-admitted services provided to admitted
patients are excluded;  
·	The Community mental health care NMDS; and 
·	service events which deliver non-clinical care, e.g.
activities such as home cleaning, meals on wheels or home
maintenance.
For the purpose of this DSS, a non-admitted service is a
specialty unit or organisational arrangement under which a
jurisdictional health authority, Local Hospital Network or
public hospital provides non-admitted services. 
Local Hospital Networks are defined as those entities
recognised as such by the relevant jurisdictional health
authority.
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Non-admitted patient care Local
Hospital Network aggregate DSS
2015-16 Metadata Online Registry
(METeOR)
Episode of care
Funding source for hospital patient*
Health service budget (not covered
elsewhere) (01)
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Health service budget (due to eligibility
for Reciprocal Health Care Agreement)
(02)
Health service budget (no charge raised
due to hospital decision) (03)
Department of Veterans' Affairs (04)
Department of Defence (05)
Correctional facility (06)
Medicare Benefits Scheme (07)
Other hospital or public authority
(contracted care) (08)
Private health insurance (09)
Worker's compensation (10)
Motor vehicle third party personal claim
(11)
Other compensation (e.g. public liability,
common law, medical negligence) (12)
Self-funded (13)
Other funding source (88)
Not known (98)
Establishment
Local Hospital Network identifier*
South Eastern Sydney  (101)
Sydney  (102)
South Western Sydney  (103)
Western Sydney  (104)
Nepean Blue Mountains (105)
Northern Sydney (106)
Central Coast (107)
Illawarra Shoalhaven  (108)
Hunter New England  (109)
Mid North Coast (110)
Northern NSW  (111)
Western NSW (112)
Southern NSW  (113)
Murrumbidgee  (114)
Far West (115)
Sydney Children's Hospitals Network
(117)
St Vincent's Health Network (118)
Justice Health & Forensic Mental Health
(119)
New South Wales Virtual Local Hospital
Network (199)
Beaufort and Skipton Health Service
(201)
East Grampians Health Service (202)
Ballarat Health Services  (203)
Stawell Regional Health (204)
East Wimmera Health Service (205)
Hepburn Health Service  (206)
Maryborough District Health Service
(207)
Djerriwarrh Health Service (Vic) (208)
Western Health (Vic)  (209)
Bendigo Health Care Group (210)
Heathcote Health (211)
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Swan Hill District Health (212)
Cohuna District Hospital  (213)
Echuca Regional Health  (214)
Kerang District Health  (215)
Maldon Hospital (216)
Boort District Health (218)
Rochester and Elmore District Health
Service  (219)
Inglewood and District Health Service
(220)
Castlemaine Health  (221)
Kyneton District Health Service (222)
Royal Children's Hospital (Melbourne)
(223)
Royal Women's Hospital (Melbourne)
(224)
Melbourne Health  (225)
Northern Health (Vic) (226)
Victorian Institute of Forensic Mental
Health (227)
Colac Area Health (228)
Hesse Rural Health Service
(Winchelsea) (229)
Otway Health and Community Services
(Apollo Bay)  (23)
Barwon Health (231)
Lorne Community Hospital  (232)
Alexandra District Hospital (233)
Eastern Health (Vic)  (234)
Goulburn Valley Health  (235)
Kyabram and District Health Service
(236)
Numurkah and District Health Service
(237)
Nathalia District Hospital  (238)
Cobram District Hospital  (239)
Seymour District Memorial Hospital
(240)
Kilmore and District Hospital (241)
Yea and District Memorial Hospital  (242)
Northeast Health Wangaratta (243)
Yarrawonga District Health Service
(244)
Alpine Health (Vic) (245)
Mansfield District Hospital (246)
Benalla and District Memorial Hospital
(247)
Tallangatta Health Service  (248)
Albury Wodonga Health (249)
Upper Murray Health and Community
Services (Corryong) (250)
Beechworth Health Service (251)
West Gippsland Healthcare Group (252)
Bass Coast Regional Health  (253)
Gippsland Southern Health Service
(254)
South Gippsland Hospital (Foster) (255)
Bairnsdale Regional Health Service
(256)
Yarram and District Health Service  (257)
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Omeo District Health  (258)
Central Gippsland Health Service  (259)
Latrobe Regional Hospital (260)
Orbost Regional Health  (261)
St Vincent's Hospital (Melbourne)
Limited (262)
Royal Victorian Eye and Ear Hospital
(263)
Peter MacCallum Cancer Institute (Vic)
(264)
Austin Health (Vic) (266)
Mercy Public Hospital Inc. (Vic) (267)
Alfred Health (Vic) (268)
Monash Health (269)
Peninsula Health (Vic)  (270)
Kooweerup Regional Health Service
(271)
Rural Northwest Health (Vic)  (274)
Wimmera Health Care Group (275)
Dunmunkle Health Services (276)
West Wimmera Health Service (277)
Edenhope and District Memorial Hospital
(278)
Mildura Base Hospital (279)
Mallee Track Health and Community
Service (280)
Robinvale District Health Services  (281)
Western District Health Service (Vic)
(282)
Casterton Memorial Hospital (283)
South West Healthcare (Vic) (284)
Heywood Rural Health  (285)
Timboon and District Healthcare Service
(286)
Moyne Health Services (Port Fairy)
(287)
Portland District Health  (288)
Terang and Mortlake Health Service
(Terang) (289)
Calvary Health Care Bethlehem Limited
(290)
Victoria Virtual Local Hospital Network
(299)
Cairns and Hinterland (312)
Townsville  (313)
Mackay  (314)
North West (Qld)  (315)
Central Queensland  (316)
Central West (Qld)  (317)
Wide Bay  (318)
Sunshine Coast  (319)
Metro North (Qld) (320)
Children's Health Queensland  (321)
Metro South (Qld) (322)
Gold Coast  (323)
West Moreton  (324)
Darling Downs (325)
South West (Qld)  (326)
Torres and Cape (327)
Queensland Virtual Local Hospital
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Network (399)
Northern Adelaide (401)
Central Adelaide  (402)
Southern Adelaide (403)
Country Health SA (404)
Women's and Children's Health Network
(SA) (405)
South Australia Virtual Local Hospital
Network (499)
North Metropolitan Health Service (WA)
(501)
South Metropolitan Health Service (WA)
(502)
WA Country Health Service (503)
Child Adolescent Health Service (WA)
(580)
Notional Local Hospital Network (Royal
St.) (590)
Western Australia Virtual Local Hospital
Network (599)
Tasmanian Health Organisation - South
(601)
Tasmanian Health Organisation - North
(602)
Tasmanian Health Organisation - North
West (603)
Tasmania Virtual Local Hospital Network
(699)
Top End (NT) (701)
Central Australia (NT) (702)
Northern Territory Virtual Local Hospital
Network (799)
Australian Capital Territory (801)
Australian Capital Territory Virtual Local
Hospital Network (899)
Virtual Local Hospital Network -
Unknown (900)
Not applicable (997)
Unknown (998)
Not stated/inadequately described (999)
Number of group session non-admitted patient
service events*
Number of individual session non-admitted
patient service events
Establishment identifier*
Non-admitted patient service event
Multiple health care provider indicator*
Yes (1)
No (2)
Not stated/inadequately described (9)
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Non-admitted service type*
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Non-admitted patient DSS 2015-16
Metadata Online Registry (METeOR)
Health sector data set specifications from METeOR,
Australia's repository for national metadata standards,
developed by the Australian Institute of Health and Welfare
(http://meteor.aihw.gov.au/content/index.phtml/itemId/3451
65)
Non-admitted patient DSS 2015-16
The scope of the Non-admitted patient DSS is non-
admitted patient service events involving non-admitted
patients provided by:
·	public hospitals 
·	Local Hospital Networks 
·	other public hospital services that are managed by a state
or territory health authority and are included in the General
list of in-scope public hospital services, which have been
developed under the National Health Reform Agreement
(2011).
This also includes all in scope services contracted by a
public hospital, Local Hospital Network or jurisdiction
regardless of the physical location of the contracting public
hospital, Local Hospital Network or jurisdiction, or the
location where the services are delivered. The DSS is
intended to capture instances of service provision from the
point of view of the patient. 
The scope of the DSS includes:
All arrangements made to deliver non-admitted patient
service events (not covered by the national minimum data
sets listed below) to non-admitted patients:
·	irrespective of location (includes on-campus and off-
campus), 
·	whose treatment has been funded through the
jurisdictional health authority, Local Hospital Network or
hospital, regardless of the source from which the entity
derives these funds. In particular, Department of Veterans'
Affairs, compensable and other patients funded through the
hospital (including Medicare ineligible patients) are
included; and 
·	regardless of setting or mode.
Excluded from the scope of the DSS are:
All services covered by:
·	the Admitted patient care NMDS, 
·	the Admitted patient mental health care NMDS, 
·	the Non-admitted patient emergency department care
NMDS, e.g. all non-admitted services provided to admitted
patients or emergency department patients are excluded; 
·	The Community mental health care NMDS; and 
·	service events which deliver non-clinical care, e.g.
activities such as home cleaning, meals on wheels or home
maintenance.
For the purpose of this DSS, a non-admitted service is a
specialty unit or organisational arrangement under which a
jurisdictional health authority, Local Hospital Network or
public hospital provides non-admitted services.   
Local Hospital Networks are defined as those entities
recognised as such by the relevant state or territory health
authority. 
© Australian Institute of Health and Welfare 2015
Metadata and Classifications Unit 
Australian Institute of Health and Welfare
GPO Box 570
Canberra ACT 2601
All rights reserved. Please visit https://medical-data-
models.org/forms/16345
Non-admitted patient DSS 2015-16
Metadata Online Registry (METeOR)
Episode of care
Funding source for hospital patient*
Health service budget (not covered
elsewhere) (01)
Health service budget (due to eligibility
for Reciprocal Health Care Agreement)
(02)
Health service budget (no charge raised
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due to hospital decision) (03)
Department of Veterans' Affairs (04)
Department of Defence (05)
Correctional facility (06)
Medicare Benefits Scheme (07)
Other hospital or public authority
(contracted care) (08)
Private health insurance (09)
Worker's compensation (10)
Motor vehicle third party personal claim
(11)
Other compensation (e.g. public liability,
common law, medical negligence) (12)
Self-funded (13)
Other funding source (88)
Not known (98)
Establishment
Local Hospital Network identifier*
South Eastern Sydney  (101)
Sydney  (102)
South Western Sydney  (103)
Western Sydney  (104)
Nepean Blue Mountains (105)
Northern Sydney (106)
Central Coast (107)
Illawarra Shoalhaven  (108)
Hunter New England  (109)
Mid North Coast (110)
Northern NSW  (111)
Western NSW (112)
Southern NSW  (113)
Murrumbidgee  (114)
Far West (115)
Sydney Children's Hospitals Network
(117)
St Vincent's Health Network (118)
Justice Health & Forensic Mental Health
(119)
New South Wales Virtual Local Hospital
Network (199)
Beaufort and Skipton Health Service
(201)
East Grampians Health Service (202)
Ballarat Health Services  (203)
Stawell Regional Health (204)
East Wimmera Health Service (205)
Hepburn Health Service  (206)
Maryborough District Health Service
(207)
Djerriwarrh Health Service (Vic) (208)
Western Health (Vic)  (209)
Bendigo Health Care Group (210)
Heathcote Health (211)
Swan Hill District Health (212)
Cohuna District Hospital  (213)
Echuca Regional Health  (214)
Kerang District Health  (215)
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Maldon Hospital (216)
Boort District Health (218)
Rochester and Elmore District Health
Service  (219)
Inglewood and District Health Service
(220)
Castlemaine Health  (221)
Kyneton District Health Service (222)
Royal Children's Hospital (Melbourne)
(223)
Royal Women's Hospital (Melbourne)
(224)
Melbourne Health  (225)
Northern Health (Vic) (226)
Victorian Institute of Forensic Mental
Health (227)
Colac Area Health (228)
Hesse Rural Health Service
(Winchelsea) (229)
Otway Health and Community Services
(Apollo Bay)  (23)
Barwon Health (231)
Lorne Community Hospital  (232)
Alexandra District Hospital (233)
Eastern Health (Vic)  (234)
Goulburn Valley Health  (235)
Kyabram and District Health Service
(236)
Numurkah and District Health Service
(237)
Nathalia District Hospital  (238)
Cobram District Hospital  (239)
Seymour District Memorial Hospital
(240)
Kilmore and District Hospital (241)
Yea and District Memorial Hospital  (242)
Northeast Health Wangaratta (243)
Yarrawonga District Health Service
(244)
Alpine Health (Vic) (245)
Mansfield District Hospital (246)
Benalla and District Memorial Hospital
(247)
Tallangatta Health Service  (248)
Albury Wodonga Health (249)
Upper Murray Health and Community
Services (Corryong) (250)
Beechworth Health Service (251)
West Gippsland Healthcare Group (252)
Bass Coast Regional Health  (253)
Gippsland Southern Health Service
(254)
South Gippsland Hospital (Foster) (255)
Bairnsdale Regional Health Service
(256)
Yarram and District Health Service  (257)
Omeo District Health  (258)
Central Gippsland Health Service  (259)
Latrobe Regional Hospital (260)
Orbost Regional Health  (261)
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St Vincent's Hospital (Melbourne)
Limited (262)
Royal Victorian Eye and Ear Hospital
(263)
Peter MacCallum Cancer Institute (Vic)
(264)
Austin Health (Vic) (266)
Mercy Public Hospital Inc. (Vic) (267)
Alfred Health (Vic) (268)
Monash Health (269)
Peninsula Health (Vic)  (270)
Kooweerup Regional Health Service
(271)
Rural Northwest Health (Vic)  (274)
Wimmera Health Care Group (275)
Dunmunkle Health Services (276)
West Wimmera Health Service (277)
Edenhope and District Memorial Hospital
(278)
Mildura Base Hospital (279)
Mallee Track Health and Community
Service (280)
Robinvale District Health Services  (281)
Western District Health Service (Vic)
(282)
Casterton Memorial Hospital (283)
South West Healthcare (Vic) (284)
Heywood Rural Health  (285)
Timboon and District Healthcare Service
(286)
Moyne Health Services (Port Fairy)
(287)
Portland District Health  (288)
Terang and Mortlake Health Service
(Terang) (289)
Calvary Health Care Bethlehem Limited
(290)
Victoria Virtual Local Hospital Network
(299)
Cairns and Hinterland (312)
Townsville  (313)
Mackay  (314)
North West (Qld)  (315)
Central Queensland  (316)
Central West (Qld)  (317)
Wide Bay  (318)
Sunshine Coast  (319)
Metro North (Qld) (320)
Children's Health Queensland  (321)
Metro South (Qld) (322)
Gold Coast  (323)
West Moreton  (324)
Darling Downs (325)
South West (Qld)  (326)
Torres and Cape (327)
Queensland Virtual Local Hospital
Network (399)
Northern Adelaide (401)
Central Adelaide  (402)
Southern Adelaide (403)
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Country Health SA (404)
Women's and Children's Health Network
(SA) (405)
South Australia Virtual Local Hospital
Network (499)
North Metropolitan Health Service (WA)
(501)
South Metropolitan Health Service (WA)
(502)
WA Country Health Service (503)
Child Adolescent Health Service (WA)
(580)
Notional Local Hospital Network (Royal
St.) (590)
Western Australia Virtual Local Hospital
Network (599)
Tasmanian Health Organisation - South
(601)
Tasmanian Health Organisation - North
(602)
Tasmanian Health Organisation - North
West (603)
Tasmania Virtual Local Hospital Network
(699)
Top End (NT) (701)
Central Australia (NT) (702)
Northern Territory Virtual Local Hospital
Network (799)
Australian Capital Territory (801)
Australian Capital Territory Virtual Local
Hospital Network (899)
Virtual Local Hospital Network -
Unknown (900)
Not applicable (997)
Unknown (998)
Not stated/inadequately described (999)
Establishment identifier*
Non-admitted patient service event
Care type, derived*
Rehabilitation care (1)
Palliative care (2)
Geriatric evaluation and management
(GEM) (3)
Psychogeriatric care (4)
Mental health care (5)
Other care (8)
Group session indicator*
Yes (1)
No (2)
Not stated/inadequately described (9)
Multiple health care provider indicator*
Yes (1)
No (2)
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Not stated/inadequately described (9)
Non-admitted service type*
Service event date*
Service delivery mode*
In person (1)
Telephone (2)
Videoconference (3)
Electronic mail (4)
Postal/courier service (5)
Other (8)
Service delivery setting*
On the hospital campus of the healthcare
provider (1)
Off the hospital campus of the healthcare
provider (2)
Non-admitted patient service request
Service request received date*
Service request source*
Other outpatient clinic (1.1)
Emergency department (1.2)
Elsewhere in this hospital (1.3)
Other hospital (2.0)
General practice (3.1)
Specialist practice (3.2)
Other non-hospital (3.3)
Self (4.0)
Person
Area of usual residence (SA2*
Country of birth*
Date of birth*
Indigenous status*
Aboriginal but not Torres Strait Islander
origin (1)
Torres Strait Islander but not Aboriginal
origin (2)
Both Aboriginal and Torres Strait Islander
origin (3)
Neither Aboriginal nor Torres Strait
Islander origin (4)
Not stated/inadequately described (9)
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Person identifier*
Sex*
Value	Meaning (1)
Male (1)
Female (2)
Intersex or indeterminate (3)
Not stated/inadequately described (9)
Record
Record identifier (80 character maximum)*
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Eligibility Breast Cancer NCT00676793
A Study of the Effect of Polyphenon E (Green Tea Extract)
on Breast Cancer Progression; ODM derived from:
https://clinicaltrials.gov/show/NCT00676793
All rights reserved. Please visit https://medical-data-
models.org/forms/16346
Eligibility Breast Cancer
NCT00676793
Inclusion Criteria
definitive biopsy demonstrating primary breast
cancer*
Yes
No
residual breast cancer requiring additional
surgical resection*
Yes
No
stage i, ii or iii disease*
Yes
No
patient has ability to give signed informed
consent*
Yes
No
normal hepatic and renal function
(creatinine<1.5, transaminases <1.5 times upper
limit of normal).*
Yes
No
ecog performance status of 0 or 1.*
Yes
No
age ≥ 21 years and less than 75*
Yes
No
Exclusion Criteria
prior hormonal or surgical therapy for breast
cancer*
Yes
No
abnormal liver function test*
Yes
No
liver or kidney problems that would interfere with
metabolism of study  drug*
Yes
No
any condition that would hamper informed
consent or ability to comply with study protocol*
1 / 2
Yes
No
participation in another research study in the last
three months*
Yes
No
known malignancy at any site other than breast*
Yes
No
recent consumption of green tea (5 or more cups
per day, within one week prior to biopsy)*
Yes
No
allergy or intolerance to any component of green
tea*
Yes
No
inability or refusal to comply with definitive
surgical therapy*
Yes
No
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Eligibility Breast Cancer NCT00291135
Protocol for Women at Increased Risk of Developing Breast
Cancer; ODM derived from:
https://clinicaltrials.gov/show/NCT00291135
All rights reserved. Please visit https://medical-data-
models.org/forms/16347
Eligibility Breast Cancer
NCT00291135
Inclusion Criteria
evidence of hyperplasia with/without atypia upon
random periareolar fine needle aspiration of
breast*
Yes
No
on hormone replacement therapy*
Yes
No
postmenopausal*
Yes
No
increased risk of developing breast cancer based
on personal or family history*
Yes
No
never have taken aromatase inhibitors or
selective estrogen receptor modulators in last six
months*
Yes
No
women who have a high risk of breast cancer*
Yes
No
older than 18 years*
Yes
No
Exclusion Criteria
anticoagulants*
Yes
No
marked breast tenderness*
Yes
No
pregnant or within twelve months of breast
feeding/childbirth*
Yes
No
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DSS 2015-16 Metadata Online Registry (METeOR)
Health sector data set specifications from METeOR,
Australia's repository for national metadata standards,
developed by the Australian Institute of Health and Welfare
(http://meteor.aihw.gov.au/content/index.phtml/itemId/3451
65)
Activity based funding: Emergency service care DSS 2015-
16
The scope of this DSS is emergency services provided in
activity based funded hospitals which do not meet any of
the following criteria:
•	Purposely designated and equipped area with designated
assessment; treatment and resuscitation areas. 
•	Ability to provide resuscitation, stabilisation and initial
management of all emergencies. 
•	Availability of medical staff available in the hospital 24
hours a day. 
•	Designated emergency department nursing staff 24 hours
a day, 7 days a week, and a designated emergency
department nursing unit manager. 
The care provided to patients in emergency services/urgent
care centres is, in most instances, recognised as being
provided to non-admitted patients. Patients being treated in
emergency services/urgent care centres may subsequently
become admitted. All patients remain in-scope for this
collection until they are recorded as having physically
departed the emergency service/urgent care centre,
regardless of whether they have been admitted. For this
reason there is an overlap in the scope of this DSS and the
Admitted patient care national minimum data set (APC
NMDS).
The scope also includes services where patient did not wait
or died on arrival. Patients with Department of Veterans'
Affairs or compensable funding source are also included in
the scope of the collection.
Excluded from the scope are: 
•	Care provided to patients in General Practitioner co-
located units.
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Activity based funding: Emergency
service care DSS 2015-16 Metadata
Online Registry (METeOR)
Emergency department stay
Type of visit to emergency department*
Emergency presentation (1)
Return visit, planned (2)
Pre-arranged admission (3)
Patient in transit (4)
Dead on arrival (5)
Episode of care
Department of Veterans' Affairs patient*
Yes
No
Establishment
Establishment identifier*
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Non-admitted patient emergency
department service episode
Emergency department service episode end
status*
Admitted to this hospital (either short
stay unit, hospital-in-the-home or non-
emergency department hospital ward)
(1)
Non-admitted patient emergency
department service episode completed -
departed without being admitted or
referred to another hospital (2)
Non-admitted patient emergency
department service episode completed -
referred to another hospital for admission
(3)
Did not wait to be attended by a health
care professional (4)
Left at own risk after being attended by a
health care professional but before the
non-admitted patient emergency
department service episode was
completed (5)
Died in emergency department as a non-
admitted patient (6)
Dead on arrival, emergency department
clinician certified the death of the patient
(7)
Triage category
Resuscitation: immediate (within
seconds) (1)
Emergency: within 10 minutes (2)
Urgent: within 30 minutes (3)
Semi-urgent: within 60 minutes (4)
Non-urgent: within 120 minutes (5)
Patient
Compensable status*
Compensable (1)
Non-compensable (2)
Not stated/not known (3)
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Cell Therapy Registry EBMT
The Cell Therapy Registry (CTR) aims to collect data on
fetal or adult stem cells, or progenitor cells used for
treatment other than haematopoietic stem cell
transplantation or donor lymphocyte infusion, as well as
data on the clinical characteristics and outcome of the
patients. Data will be collected on characteristics of the cell
graft, /in/ or /ex vivo/ cell manipulation and the cell origin
(autologous versus allogeneic). Data will include details on
patients treated with mesenchymal cells, for instance, to
enhance haematopoietic engraftment, for prophylaxis and
treatment of GvHD. The registry will also include data on
patients treated by other disciplines for neurologic,
rheumatologic, cardiac and inflammatory bowel diseases
and tissue regeneration. For further information, please
contact:
The registry will also include data on patients treated by
other disciplines for neurologic, rheumatologic, cardiac and
inflammatory bowel diseases and tissue regeneration. For
further information, please contact:
Dr. Katarina Le Blanc
Karolinska University Hospital
Centre for Allogeneic Stem Cell Transplantation Huddinge
SE-141 86 Stockholm Sweden
e-mail : Katarina.Leblanc@ki.se
please refer:
http://www.ebmt.org/Contents/Data-
Management/Registrystructure/MED-
ABdatacollectionforms/Pages/MED-AB-data-collection-
forms.aspx
All rights reserved. Please visit https://medical-data-
models.org/forms/16350
Cell Therapy Registry EBMT
Cell Therapy Registry – Med-A
First report – 6 months after cell therapy
CENTRE IDENTIFICATION
EBMT Code (CIC) Number
Hospital
Unit
Contact person
Phone
Fax
E-mail
REPORT INFORMATION
Date of this report
yyyy/mm/dd
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PATIENT IDENTIFICATION
Unique Patient Number or Code
Initials
Date of Birth
Gender
male  (1)
female (2)
INDICATION FOR TREATMENT If
Primary disease
Date of diagnosis
Autoimmune disease, specify
Neurologic disorder, specify
Heart disease, specify
Haematologic, specify
Other, specify
If Haematopoietic stem cell transplant related
GvHD prophylaxis (1)
GvHD treatment (2)
Prevention of rejection (3)
Graft enhancement (4)
Bone marrow failure (5)
CELL THERAPY TREATMENT
Date of first cell infusion
Performance score (if alive)
Karnofsky (1)
Lansky (2)
Score achived
10 (1)
100 (10)
20 (2)
30 (3)
40 (4)
50 (5)
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60 (6)
70 (7)
80 (8)
90 (9)
Status at therapy
Chronic (1)
Acute (2)
Acute exacerbation of chronic disease
(3)
Cell origin
Allogeneic  (1)
Autologous (2)
Tissue cell source
Bone Marrow  (1)
Peripheral Blood  (2)
Cord Blood  (3)
Adipose  (4)
Endothelial cell progenitor  (5)
Other, specify (6)
Cell characteristic
Mononuclear cells  (1)
CD34+ CD34POS (2)
Mesenchymal  (3)
Unseparated bone marrow (4)
Other, specify (5)
Cell characteristic, specify other
Chronological no. of cell therapy for this patient
GRAFT MANIPULATION
Ex-vivo manipulation
no (1)
yes (2)
unknown (3)
Growth factor (4)
Other (5)
Expansion (6)
Ex-vivo manipulation, Growth factor, specify
Ex-vivo manipulation, other
In-vivo manipulation, in the donor
No  (1)
Yes (2)
Growth factor (3)
Other (4)
unknown (5)
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In-vivo manipulation In the donor, growth factor,
specify
In-vivo manipulation  In the donor, other
In-vivo manipulation, in the patient
No  (1)
Yes (2)
Growth factor, specify (3)
Other  (4)
Unknown (5)
In-vivo manipulation in the patient, growth factor,
specify
In-vivo manipulation in the patient, other
TREATMENT
Route of infusion
Intravenous (1)
Locally intra-arterially (2)
Locally into tissue (3)
Intra bone (4)
Other route (5)
Intraperitoneal injection (6)
intrathecal (7)
Route of infusion, Locally intra-arterially, specify
artery
Route of infusion, other route
Dose
Total No of infusions (1)
No of cells infused per infusion (2)
Dose, Total No of infusions
Dose, No of cells infused per infusion
x 106/kg
Associated procedure
no (1)
yes (2)
Prior to cell therapy (3)
Simultaneous (4)
Post cell therapy (5)
unknown (6)
Associated procedure, Yes: specify
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RESPONSE
Best clinical/biological response after cell therapy
Complete sustained remission (CR) (1)
Partial sustained remission (PR) (2)
Remission (CR or PR) followed by
relapse or progression (3)
Stable (4)
Progression (5)
Unknown (6)
Laboratory response
Normalized (1)
Improvement (2)
Unchanged (3)
Worsening (4)
Specify laboratory parameter (5)
Laboratory response, Specify laboratory
parameter
DATE OF LAST CONTACT
Date of last follow up or death
Survival Status
Alive (1)
Dead (2)
Check here if patient lost to follow up (3)
Main Cause of Death
Relapse or Progression (if indication:
primary disease) (1)
HSCT related (if applicable) (2)
Cell Therapy  (3)
Other (4)
Unknown (5)
Main Cause of Death, HSCT related (if applicable
Main Cause of Death, Cell Therapy related:
Main Cause of Death, Other
CENTRE IDENTIFICATION
EBMT Code (CIC) Number
Hospital
Unit
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Contact person
Phone
Fax
Contact Person E-Mail
REPORT INFORMATION
Date of this Report
PATIENT IDENTIFICATION
Unique Patient Number or Code
Initials, first name(s), family name(s)
Date of Birth
Sex
Male (1)
Female (2)
DATE OF LAST CONTACT
DISEASE PRESENCE/DETECTION AT LAST
CONTACT
Yes
No
PATIENT STATUS, Survival Status
Alive (1)
Dead (2)
Check here if patient lost to follow up (3)
Main Cause of Death
Relapse  (1)
Progression (2)
Cell Therapy  (3)
Other (4)
Unknown (5)
Main Cause of Death, HSCT related (if
applicable)
Main Cause of Death, Cell Therapy related
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Main Cause of Death, Other
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Eligibility Breast Cancer NCT00301041
Radiation Therapy in Treating Women With Invasive Breast
Cancer; ODM derived from:
https://clinicaltrials.gov/show/NCT00301041
All rights reserved. Please visit https://medical-data-
models.org/forms/16352
Eligibility Breast Cancer
NCT00301041
Criteria
histologically confirmed invasive breast cancer*
Yes
No
underwent lumpectomy (breast-preserving
surgery) with or without adjuvant chemotherapy
within the past 12 weeks*
Yes
No
histologically negative surgical margins (i.e., no
tumor on ink)*
Yes
No
candidates for postoperative breast radiotherapy*
Yes
No
determined not to need radiotherapy to regional
nodes (e.g., third supraclavicular field)*
Yes
No
hormone receptor status not specified*
Yes
No
patient characteristics:*
Yes
No
female*
Yes
No
menopausal status not specified*
Yes
No
not pregnant or nursing*
Yes
No
negative pregnancy test*
Yes
No
fertile patients must use effective contraception*
Yes
No
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no history of scleroderma or systemic lupus
erythematosis*
Yes
No
no other prior or concurrent malignancy except
nonmelanoma skin cancer or carcinoma in situ of
the cervix*
Yes
No
prior concurrent therapy:*
Yes
No
see disease characteristics*
Yes
No
no prior breast radiotherapy*
Yes
No
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Eligibility Breast Cancer NCT00303875
Exercise and Dietary Counseling in Improving Physical
Activity, Nutrition, and Quality of Life in Older Long-Term
Cancer Survivors Who Are Overweight; ODM derived from:
https://clinicaltrials.gov/show/NCT00303875
All rights reserved. Please visit https://medical-data-
models.org/forms/16354
Eligibility Breast Cancer
NCT00303875
Criteria
diagnosed colorectal, prostate, or female breast
cancer*
Yes
No
at least 5 years beyond date of diagnosis with no
clinical evidence of progressive disease or
second primaries*
Yes
No
body mass index ≥ 25 kg/m^2 and < 40 kg/m^2*
Yes
No
currently exercising < 150 minutes/week*
Yes
No
hormone receptor status not specified*
Yes
No
patient characteristics:*
Yes
No
menopausal status not specified*
Yes
No
no serious intercurrent medical condition or
disability that could preclude study treatment,
including any of the following:*
Yes
No
severe orthopedic condition or scheduled hip or
knee replacement within the next 6 months*
Yes
No
paralysis*
Yes
No
end-stage renal disease*
Yes
No
dementia*
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Yes
No
unstable angina*
Yes
No
heart attack, congestive heart failure, or
pulmonary condition that required oxygen or
hospitalization within the past 6 months*
Yes
No
ability to read, write, and speak english*
Yes
No
prior concurrent therapy:*
Yes
No
no concurrent warfarin*
Yes
No
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Non-admitted patient emergency department care
DSS 2015-16 Metadata Online Registry (METeOR)
Health sector data set specifications from METeOR,
Australia's repository for national metadata standards,
developed by the Australian Institute of Health and Welfare
(http://meteor.aihw.gov.au/content/index.phtml/itemId/3451
65)
Non-admitted patient emergency department care DSS
2015-16
The scope of the Non-admitted patient emergency
department care data set specification (NAPEDC DSS) is
patients registered for care in emergency departments in
public hospitals where the emergency department meets
the following criteria:
•	Purposely designed and equipped area with designated
assessment, treatment and resuscitation areas. 
•	Ability to provide resuscitation, stabilisation and initial
management of all emergencies. 
•	Availability of medical staff in the hospital 24 hours a day. 
•	Designated emergency department nursing staff 24 hours
a day, 7 days a week, and a designated emergency
department nursing unit manager.
Patients who were dead on arrival are in scope if an
emergency department clinician certified the death of the
patient. Patients who leave the emergency department
after being triaged and then advised of alternative
treatment options are in scope. 
The scope includes only physical presentations to
emergency departments. Advice provided by telephone or
videoconferencing is not in scope, although it is recognised
that advice received by telehealth may form part of the care
provided to patients physically receiving care in the
emergency department. 
The care provided to patients in emergency departments is,
in most instances, recognised as being provided to non-
admitted patients. Patients being treated in emergency
departments may subsequently become admitted
(including admission to a short stay unit, admission to
elsewhere in the emergency department, admission to
another hospital ward, or admission to hospital-in-the-
home). All patients remain in-scope for this collection until
they are recorded as having physically departed the
emergency department, regardless of whether they have
been admitted. For this reason there is an overlap in the
scope of this DSS and the Admitted patient care national
minimum data set (APC NMDS).   
Excluded from the scope of the DSS are:
•	Care provided to patients in General Practitioner co-
located units; 
•	Where only a clerical service is provided to people
supporting a pre-arranged admission; and 
•	Where people are awaiting transit to another facility and
receive no clinical care.
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Non-admitted patient emergency
department care DSS 2015-16
Metadata Online Registry (METeOR)
Address
Australian postcode (address)*
Emergency department stay
ED additional diagnosis code
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ED diagnosis classification type
SNOMED-CT-AU (EDRS) (1.0)
ICD-9-CM, 2nd edition (2.0)
ICD-10-AM, 6th edition (3.6)
ICD-10-AM, 7th edition (3.7)
ICD-10-AM, 8th edition (3.8)
ICD-10-AM, 9th edition (3.9)
No diagnosis classification provided (9.0)
Emergency department physical departure date*
Emergency department physical departure time*
Date patient presents*
Time patient presents*
ED principal diagnosis code
Emergency department arrival mode - transport*
Ambulance, air ambulance or helicopter
rescue service (1)
Police/correctional services vehicle (2)
Other (8)
Not stated/unknown (9)
Type of visit to emergency department*
Emergency presentation (1)
Return visit, planned (2)
Pre-arranged admission (3)
Dead on arrival (5)
Urgency related group major diagnostic block*
Poisoning (1)
Drug reaction (1C)
Alcohol/drug abuse and alcohol/drug
induced mental disorders (1D)
Injury, multiple sites (2A)
Injury, single site, major (2B)
Injury, single site, minor (2Ba)
Circulatory system illness (3A)
Respiratory system illness (3B)
Digestive system illness (3C)
Urological system illness (3D)
Neurological system illness (3E)
Illness of the eyes (3F)
Illness of the ear, nose and throat (3G)
Musculoskeletal/connective tissue
system illness (3H)
Illness of skin, subcutaneous tissue,
breast (3I)
Blood/immune system illness (3J)
Obstetric illness (3K)
Gynaecological illness (3L)
Male reproductive system illness (3M)
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System infection/parasites (3N)
Illness of other and unknown systems
(3O)
Newborn/neonate illness (3P)
Hepatobiliary system illness (3Q)
Endocrine, nutritional and metabolic
system illness (3R)
Allergy (3S)
Psychiatric illness (4)
Social problem (5)
Other presentation (6)
Not stated/inadequately described (9)
Emergency department waiting time to clinical
care commencement
minutes
Episode of care
Department of Veterans´ Affairs patient*
Yes
No
Establishment
Establishment identifier*
Non-admitted patient emergency
department service episode
Emergency department clinical care
commencement date
Emergency department clinical care
commencement time
Emergency department episode end date*
Episode end status*
Transferred for admitted patient care in
this hospital (either short stay unit,
hospital-in-the-home or other admitted
patient care unit) (1)
Emergency department stay completed -
departed without being transferred to a
short stay unit, hospital-in-the-home or
other admitted patient care unit in this
hospital or referred to another hospital
(2)
Emergency department stay completed -
referred to another hospital for admission
(3)
Did not wait to be attended by a health
care professional (4)
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Left at own risk after being attended by a
health care professional but before the
non-admitted patient emergency
department service episode was
completed (5)
Died in emergency department (6)
Dead on arrival (7)
Emergency department episode end time*
Length of non-admitted patient emergency
department service episode*
minutes
Triage category
Resuscitation: immediate (within
seconds) (1)
Emergency: within 10 minutes (2)
Urgent: within 30 minutes (3)
Semi-urgent: within 60 minutes (4)
Non-urgent: within 120 minutes (5)
Date of triage
Time of triage
Patient
Compensable status*
Compensable (1)
Non-compensable (2)
Not stated/not known (9)
Person
Area of usual residence (SA2)*
Country of birth*
Date of birth*
Indigenous status*
Aboriginal but not Torres Strait Islander
origin (1)
Torres Strait Islander but not Aboriginal
origin (2)
Both Aboriginal and Torres Strait Islander
origin (3)
Neither Aboriginal nor Torres Strait
Islander origin (4)
Not stated/inadequately described (9)
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Person identifier*
Sex*
Male (1)
Female (2)
Intersex or indeterminate (3)
Not stated/inadequately described (9)
Record
Record identifier (80 character maximum)*
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Non-admitted patient emergency department care
NMDS 2015-16 Metadata Online Registry (METeOR)
Health sector data set specifications from METeOR,
Australia's repository for national metadata standards,
developed by the Australian Institute of Health and Welfare
(http://meteor.aihw.gov.au/content/index.phtml/itemId/3451
65)
Non-admitted patient emergency department care NMDS
2015-16
The scope of the Non-admitted patient emergency
department care national minimum data set specification
(NAPEDC NMDS) is patients registered for care in
emergency departments in public hospitals where the
emergency department meets the following criteria:
·	Purposely designed and equipped area with designated
assessment, treatment and resuscitation areas. 
·	Ability to provide resuscitation, stabilisation and initial
management of all emergencies. 
·	Availability of medical staff in the hospital 24 hours a day. 
·	Designated emergency department nursing staff 24 hours
a day, 7 days a week, and a designated emergency
department nursing unit manager.
Patients who were dead on arrival are in scope if an
emergency department clinician certified the death of the
patient. Patients who leave the emergency department
after being triaged and then advised of alternative
treatment options are in scope. 
The scope includes only physical presentations to
emergency departments. Advice provided by telephone or
videoconferencing is not in scope, although it is recognised
that advice received by telehealth may form part of the care
provided to patients physically receiving care in the
emergency department. 
The care provided to patients in emergency departments is,
in most instances, recognised as being provided to non-
admitted patients. Patients being treated in emergency
departments may subsequently become admitted
(including admission to a short stay unit, admission to
elsewhere in the emergency department, admission to
another hospital ward, or admission to hospital-in-the-
home). All patients remain in-scope for this collection until
they are recorded as having physically departed the
emergency department, regardless of whether they have
been admitted. For this reason there is an overlap in the
scope of this NMDS and the Admitted patient care national
minimum data set (APC NMDS).   
Excluded from the scope of the NMDS is:
·	Care provided to patients in General Practitioner co-
located units.
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Address
Australian postcode (address)*
Emergency department stay
ED additional diagnosis code
ED diagnosis classification type
SNOMED-CT-AU (EDRS) (1.0)
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ICD-9-CM, 2nd edition (2.0)
ICD-10-AM, 6th edition (3.6)
ICD-10-AM, 7th edition (3.7)
ICD-10-AM, 8th edition (3.8)
ICD-10-AM, 9th edition (3.9)
No diagnosis classification provided (9.0)
Emergency department physical departure date*
Emergency department physical departure time*
Date patient presents*
Time patient presents*
ED principal diagnosis code
Emergency department arrival mode - transport*
Ambulance, air ambulance or helicopter
rescue service (1)
Police/correctional services vehicle (2)
Other (8)
Not stated/unknown (9)
Type of visit to emergency department*
Emergency presentation (1)
Return visit, planned (2)
Pre-arranged admission (3)
Patient in transit (4)
Dead on arrival (5)
Urgency related group major diagnostic block*
Poisoning (1)
Drug reaction (1C)
Alcohol/drug abuse and alcohol/drug
induced mental disorders (1D)
Injury, multiple sites (2A)
Injury, single site, major (2B)
Injury, single site, minor (2Ba)
Circulatory system illness (3A)
Respiratory system illness (3B)
Digestive system illness (3C)
Urological system illness (3D)
Neurological system illness (3E)
Illness of the eyes (3F)
Illness of the ear, nose and throat (3G)
Musculoskeletal/connective tissue
system illness (3H)
Illness of skin, subcutaneous tissue,
breast (3I)
Blood/immune system illness (3J)
Obstetric illness (3K)
Gynaecological illness (3L)
Male reproductive system illness (3M)
System infection/parasites (3N)
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Illness of other and unknown systems
(3O)
Newborn/neonate illness (3P)
Hepatobiliary system illness (3Q)
Endocrine, nutritional and metabolic
system illness (3R)
Allergy (3S)
Psychiatric illness (4)
Social problem (5)
Other presentation (6)
Not stated/inadequately described (9)
Emergency department waiting time to clinical
care commencement
minutes
Episode of care
Department of Veterans´ Affairs patient*
Yes
No
Establishment
Establishment identifier*
Non-admitted patient emergency
department service episode
Emergency department clinical care
commencement date
Emergency department clinical care
commencement time
Emergency department episode end date*
Emergency department service episode end
status*
Admitted to this hospital (either short
stay unit, hospital-in-the-home or non-
emergency department hospital ward)
(1)
Non-admitted patient emergency
department service episode completed -
departed without being admitted or
referred to another hospital (2)
Non-admitted patient emergency
department service episode completed -
referred to another hospital for admission
(3)
Did not wait to be attended by a health
care professional (4)
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Left at own risk after being attended by a
health care professional but before the
non-admitted patient emergency
department service episode was
completed (5)
Died in emergency department as a non-
admitted patient (6)
Dead on arrival, emergency department
clinician certified the death of the patient
(7)
Emergency department episode end time*
Length of non-admitted patient emergency
department service episode*
minutes
Triage category
Resuscitation: immediate (within
seconds) (1)
Emergency: within 10 minutes (2)
Urgent: within 30 minutes (3)
Semi-urgent: within 60 minutes (4)
Non-urgent: within 120 minutes (5)
Date of triage
Time of triage
Patient
Compensable status*
Compensable (1)
Non-compensable (2)
Not stated/not known (9)
Person
Area of usual residence (SA2)*
Country of birth*
Date of birth*
Indigenous status*
Aboriginal but not Torres Strait Islander
origin (1)
Torres Strait Islander but not Aboriginal
origin (2)
Both Aboriginal and Torres Strait Islander
origin (3)
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Neither Aboriginal nor Torres Strait
Islander origin (4)
Not stated/inadequately described (9)
Person identifier*
Sex*
Male (1)
Female (2)
Intersex or indeterminate (3)
Not stated/inadequately described (9)
Record
Record identifier (80 character maximum)*
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Palliative care performance indicators DSS
Metadata Online Registry (METeOR)
Health sector data set specifications from METeOR,
Australia's repository for national metadata standards,
developed by the Australian Institute of Health and Welfare
(http://meteor.aihw.gov.au/content/index.phtml/itemId/3451
65)
Palliative care performance indicators DSS
This data set specification specifies information for
collection about all administrative health regions, and
whether they have developed strategic plans which
incorporate specified palliative care elements. It also
specifies information for collection about all government-
funded palliative care agencies (service provider
organisations), their approach to some aspects of service
delivery, and their efforts in specific areas of quality
improvement.
This information enables reporting of nationally-agreed
palliative care performance indicators. Currently, there are
four national performance indicators that have been agreed
for reporting by the Palliative Care Intergovernmental
Forum. These are:
1. The proportion of administrative health regions that have
a written plan for palliative care that incorporates palliative
care elements,
2. The proportion of palliative care agencies, within their
setting of care, that routinely undertake or undergo formal
assessment against the Palliative Care Australia standards,
3. The proportion of palliative care agencies, within their
setting of care, that actively collect feedback from clients
and staff (within the workforce) relating to services and
service delivery,
4. The proportion of palliative care agencies, within their
setting of care, that have formal working partnerships with
other services provider(s) or organisation(s).
© Australian Institute of Health and Welfare 2015
Metadata and Classifications Unit 
Australian Institute of Health and Welfare
GPO Box 570
Canberra ACT 2601
All rights reserved. Please visit https://medical-data-
models.org/forms/16357
Palliative care performance
indicators DSS Metadata Online
Registry (METeOR)
Administrative health region
Administrative health region palliative care
strategic plan indicator*
Yes
No
Administrative health region name*
Service provider organisation
Coordinator of volunteers indicator*
Yes
No
Feedback collection indicator*
Yes
No
Feedback collection method
Questionnaire - periodic face-to-face
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interview (1)
Questionnaire - face-to-face interview on
exit (2)
Questionnaire - periodic telephone
interview  (3)
Questionnaire - telephone interview on
exit (4)
Questionnaire - periodic written survey
(5)
Questionnaire - written survey on exit (6)
Feedback focus group (7)
Other (8)
Level of palliative care service*
Primary palliative care (1)
Specialist palliative care level 1 (2)
Specialist palliative care level 2 (3)
Specialist palliative care level 3 (4)
Most common service delivery setting*
Mostly community-based setting (1)
Mostly inpatient setting (2)
Similar proportion in both settings (3)
Partner organisation type
Palliative care services (1)
Volunteer support services (10)
Hospitals (2)
Community nursing agencies (3)
Residential aged care facilities (4)
Allied health services (5)
Aboriginal health services (6)
Medical practices (7)
Integrated health centres (8)
Universities/research centres (9)
Other (99)
Palliative care agency service delivery setting*
Private residence (1)
Residential - aged care setting (2)
Residential - other setting (3)
Non-residential setting (4)
Inpatient - designated palliative care unit
or hospice (5)
Inpatient - other than a designated
palliative care unit (6)
Outpatient - in a hospital/hospice (7)
Standards assessment indicator*
Yes
No
Standards assessment level
Formally assessed (1)
Accredited (2)
Standards assessment method
Formal self-assessment (1)
In-depth external review (2)
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Working partnership indicator*
Yes
No
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Ankle-Arm Index CARLA Follow-up
Greiser KH, Kluttig A, Schumann B, Swenne CA, Kors JA,
Kuss O, Haerting J, Schmidt H, Thiery J, Werdan K.
Cardiovascular diseases, risk factors and short-term heart
rate variability in an elderly general population: the CARLA
study 2002-2006. Eur J Epidemiol. 2009;24(3):123-42
http://www.ncbi.nlm.nih.gov/pubmed/19199053
"Cross-sectional data of a population-based cohort
including 1,779 women and men aged 45-83 years were
used to analyse associations of time and frequency domain
measures of HRV (derived from 5-min ECG segments) with
age, behavioural and biomedical risk factors and disease in
the whole sample and in a "healthy" subgroup."
publication granted by 
Dr. rer. medic. Alexander Kluttig, MPH
Leiter des Studienzentrums Halle der Nationalen Kohorte
Institut für Medizinische Epidemiologie, Biometrie und
Informatik 
Martin-Luther-Universität Halle-Wittenberg 
Magdeburger Str. 8 
D-06097 Halle/Saale
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models.org/forms/16358
Ankle-Arm Index CARLA Follow-up
General information
Subject ID
Examiner ID
Date
Time (Beginning)
Circumference measurement
Right arm
cm
Cuff size: right arm
small (1)
large (2)
Left arm
cm
Cuff size: left arm
small (1)
large (2)
Right lower leg
cm
Cuff size: right leg
small (1)
large (2)
Left lower leg
cm
Cuff size: left leg
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small (1)
large (2)
Pulse of anterior tibial artery
Is anterior tibial artery pulse in right foot
palpable?
Yes
No
Is anterior tibial artery pulse in left foot palpable?
Yes
No
Blood pressure measurement I: Both arms
simultaneously
Device number: right arm
Blood pressure: right arm
mm/Hg
Pulse: right arm
/min
Device number: left arm
Blood pressure: left arm
mm/Hg
Pulse: Left arm
/min
Indicate arm with higher syst. blood pressure
left arm (left arm)
right arm (right arm)
Blood pressure measurement II: Right leg
and arm with higher syst. blood pressure
simultaneously
Device number: right leg
Device number: arm
Blood pressure measurement II: First
measurement
Beginning of Measurement
Blood pressure: right leg
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mm/Hg
Pulse: right leg
/min
Blood pressure: arm
mm/Hg
Blood pressure measurement II: Second
measurement
Blood pressure: right leg
mm/Hg
Pulse: right leg
/min
Blood pressure: arm
mm/Hg
Blood pressure measurement III: Left leg
and arm with higher syst. blood pressure
simultaneously
Device number: left leg
Device number: arm
Blood pressure measurement III: First
measurement
Blood pressure: left leg
mm/Hg
Pulse: left leg
/min
Blood pressure: arm
mm/Hg
Blood pressure measurement III: Second
measurement
Blood pressure: left leg
mm/Hg
Pulse: left leg
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/min
Blood pressure: arm
mm/Hg
Further information
Time (End)
Comments
Data entry
First data entry: DNo.
First data entry: Date
Second data entry: DNo.
Second data entry: Date
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Public hospital establishment address details
DSS Metadata Online Registry (METeOR)
Health sector data set specifications from METeOR,
Australia's repository for national metadata standards,
developed by the Australian Institute of Health and Welfare
(http://meteor.aihw.gov.au/content/index.phtml/itemId/3451
65)
Public hospital establishment address details DSS
The Public hospital establishment address details data set
specification (DSS) is used to collect information pertaining
to the address of the hospital establishments reported in
the Public hospital establishments NMDS. 
The mandatory fields to be reported for address are:
·	Establishment—organisation identifier (Australian),
NNX[X]NNNNN 
·	Address—road number 1, road number X[6] 
·	Address—road name, text X[45] 
·	Address—road type, code AA[AA] 
·	Address—suburb/town/locality name, text X[46] 
·	Address—Australian postcode, code (Postcode datafile)
{NNNN} 
·	Address—Australian state/territory identifier, code AA[A]
All other data elements are to be reported if that data
element is a component of the address of the Public
hospital establishment.
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Public hospital establishment
address details DSS Metadata
Online Registry (METeOR)
Address
Address site name
Australian postcode (address)*
Australian state/territory identifier of address*
Australian Antarctic Territory (AAT)
Australian Capital Territory (ACT)
New South Wales (NSW)
Northern Territory (NT)
Queensland (QLD)
South Australia (SA)
Tasmania (TAS)
Victoria (VIC )
Western Australia (WA)
Complex road name
Complex road number 1
Complex road number 2
Complex road type
Access (ACCS)
Alley (ALLY)
Alleyway (ALWY)
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Amble (AMBL)
Approach (APP)
Arcade (ARC)
Arterial (ARTL)
Artery (ARTY)
Avenue (AV)
Banan (BA)
Bend (BEND)
Brace (BR)
Brae (BRAE)
Break (BRK)
Brow (BROW)
Boulevard (BVD)
Boardwalk (BWLK)
Bypass (BYPA	)
Byway (BYWY)
Circuit (CCT)
Chase (CH)
Circle (CIR)
Close (CL)
Corner (CNR)
Concourse (CON)
Cove (COVE)
Copse (CPS)
Crescent (CR)
Circus (CRCS)
Cross (CRSS)
Crest (CRST)
Cul-de-sac (CSAC)
Causeway (CSWY)
Court (CT)
Centre (CTR)
Courtyard (CTYD)
Cutting (CUTT)
Dale (DALE)
Dip (DIP)
Drive (DR)
Driveway (DVWY)
Edge (EDGE)
Elbow (ELB)
End (END)
Entrance (ENT)
Esplanade (ESP)
Expressway (EXP)
Fairway (FAWY)
Follow (FOLW)
Formation (FORM)
Frontage (FRTG)
Footway (FTWY)
Freeway (FWY)
Gap (GAP)
Gardens (GDNS)
Glade (GLDE)
Glen (GLEN)
Grove (GR)
Grange (GRA)
Green (GRN)
Gate (GTE)
Hill (HILL)
Highroad (HIRD)
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Heights (HTS)
Highway (HWY)
Interchange (INTG)
Junction (JNC)
Key (KEY)
Lane (LANE)
Line (LINE)
Link (LINK)
Lookout (LKT)
Laneway (LNWY)
Loop (LOOP)
Mall (MALL)
Mews (MEWS)
Meander (MNDR)
Motorway (MTWY)
Nook (NOOK)
Outlook (OTLK)
Pass (PASS)
Path (PATH)
Parade (PDE)
Piazza (PIAZ)
Pocket (PKT)
Plaza (PLZA)
Point (PNT)
Port (PORT)
Promenade (PROM)
Passage (PSGE)
Pathway (PWAY)
Parkway (PWY)
Quadrant (QDRT)
Quays (QYS)
Road (RD)
Ridge (RDGE)
Rest (REST)
Rise (RISE)
Ramble (RMBL)
Row (ROW)
Route (RTE)
Retreat (RTT)
Rotary (RTY)
Rue (RUE)
Subway (SBWY)
Shunt (SHUN)
Spur (SPUR)
Square (SQ)
Street (ST)
Serviceway (SVWY)
Tarn (TARN)
Terrace (TCE)
Thoroughfare (THFR)
Tollway (TLWY)
Top (TOP)
Tor (TOR)
Track (TRK)
Trail (TRL)
Turn (TURN)
Underpass (UPAS)
Vale (VALE)
Viaduct (VIAD)
View (VIEW)
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Vista (VSTA)
Walk (WALK)
Wharf (WHRF)
Walkway (WKWY)
Wynd (WYND)
Level number identifier
Road name*
Road number 1*
Road number 2
Road type*
Access (ACCS)
Alley (ALLY)
Alleyway (ALWY)
Amble (AMBL)
Approach (APP)
Arcade (ARC)
Arterial (ARTL)
Artery (ARTY)
Avenue (AV)
Banan (BA)
Bend (BEND)
Brace (BR)
Brae (BRAE)
Break (BRK)
Brow (BROW)
Boulevard (BVD)
Boardwalk (BWLK)
Bypass (BYPA	)
Byway (BYWY)
Circuit (CCT)
Chase (CH)
Circle (CIR)
Close (CL)
Corner (CNR)
Concourse (CON)
Cove (COVE)
Copse (CPS)
Crescent (CR)
Circus (CRCS)
Cross (CRSS)
Crest (CRST)
Cul-de-sac (CSAC)
Causeway (CSWY)
Court (CT)
Centre (CTR)
Courtyard (CTYD)
Cutting (CUTT)
Dale (DALE)
Dip (DIP)
Drive (DR)
Driveway (DVWY)
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Edge (EDGE)
Elbow (ELB)
End (END)
Entrance (ENT)
Esplanade (ESP)
Expressway (EXP)
Fairway (FAWY)
Follow (FOLW)
Formation (FORM)
Frontage (FRTG)
Footway (FTWY)
Freeway (FWY)
Gap (GAP)
Gardens (GDNS)
Glade (GLDE)
Glen (GLEN)
Grove (GR)
Grange (GRA)
Green (GRN)
Gate (GTE)
Hill (HILL)
Highroad (HIRD)
Heights (HTS)
Highway (HWY)
Interchange (INTG)
Junction (JNC)
Key (KEY)
Lane (LANE)
Line (LINE)
Link (LINK)
Lookout (LKT)
Laneway (LNWY)
Loop (LOOP)
Mall (MALL)
Mews (MEWS)
Meander (MNDR)
Motorway (MTWY)
Nook (NOOK)
Outlook (OTLK)
Pass (PASS)
Path (PATH)
Parade (PDE)
Piazza (PIAZ)
Pocket (PKT)
Plaza (PLZA)
Point (PNT)
Port (PORT)
Promenade (PROM)
Passage (PSGE)
Pathway (PWAY)
Parkway (PWY)
Quadrant (QDRT)
Quays (QYS)
Road (RD)
Ridge (RDGE)
Rest (REST)
Rise (RISE)
Ramble (RMBL)
Row (ROW)
Route (RTE)
5 / 6
Public hospital establishment address details DSS Metadata Online
Registry (METeOR)
Retreat (RTT)
Rotary (RTY)
Rue (RUE)
Subway (SBWY)
Shunt (SHUN)
Spur (SPUR)
Square (SQ)
Street (ST)
Serviceway (SVWY)
Tarn (TARN)
Terrace (TCE)
Thoroughfare (THFR)
Tollway (TLWY)
Top (TOP)
Tor (TOR)
Track (TRK)
Trail (TRL)
Turn (TURN)
Underpass (UPAS)
Vale (VALE)
Viaduct (VIAD)
View (VIEW)
Vista (VSTA)
Walk (WALK)
Wharf (WHRF)
Walkway (WKWY)
Wynd (WYND)
Secondary complex name
Sub-dwelling unit number
Suburb/town/locality name within address*
Establishment
Establishment identifier*
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REGIMS Multiple Sclerosis Immunotherapy
Registry Version 2016
REGIMS is a registry of the administration, adverse events
and benefit of immunotherapeutic agents in patients with
Multiple Sclerosis. REGIMS is a project from the Institute of
Epidemiology and Social Medicine of the University of
Muenster, publication granted by Prof. Dr. Berger. 
For further information (in German), please view
http://campus.uni-muenster.de/index.php?id=6075 or
http://www.kompetenznetz-multiplesklerose.de/aktuelle-
studien/regims. 
REGIMS ist ein Immuntherapieregister zur Verbesserung
der Arzneimittelsicherheit in der Multiple Sklerose Therapie
innerhalb des krankheitsbezogenen Kompetenznetzes MS.
Das primäre Ziel von REGIMS ist die Erfassung der
Häufigkeit, Charakteristika und Auswirkungen von
Nebenwirkungen aktueller und neuer Immuntherapien in
der klinischen Routinebehandlung der MS. Sekundäre Ziele
sind die Auswertung von Faktoren, die a) mit
Nebenwirkungen und b) mit guter Therapie-Adhärenz
assoziiert sind. Optional können bei Zustimmung der
Patienten Blutproben für die Biobank des KKNMS
gesammelt werden.
Patienten mit Multipler Sklerose (MS) weisen trotz des
chronischen Verlaufs eine große Heterogenität klinischer
Symptome, in Befunden der Bildgebung sowie
pathophysiologischen Prozessen auf. Faktoren, die zur
individuellen Krankheitsprognose beitragen sind kaum
bekannt, jedoch hat die Einführung neuer Substanzen die
Therapiemöglichkeiten der MS in den letzten Jahren
deutlich erweitert. Die Anwendung sogenannter
Immuntherapeutika (inklusive der neuen Substanzklasse
der Biologika) bietet in der MS-Therapie eine Reihe von
Chancen, birgt aber auch Risiken.
All rights reserved. Please visit https://medical-data-
models.org/forms/16361
Medizinischer Basisbogen Baseline
Ein-Ausschlusskriterien
Visitendatum*
Patient erfüllt die Einschlußkriterien*
Not 0
nein (0)
ja (1)
Schriftliches Einverständnis vorliegend?*
Not 0
nein (0)
ja (1)
Patientendaten
Geschlecht*
männlich (1)
weiblich (2)
Geburtsjahr*
> 1900
Größe (cm)
<= 250
> 0
cm
Körpergewicht (kg)
> 0
< 500
1 / 23
Krankheitsspezifische Angaben
Datum der ersten MS-Symptomatik: Monat/Jahr
Unbekannt
ja (1)
Datum der MS-Diagnosestellung: Monat/Jahr*
Unbekannt
ja (1)
Verlaufsform der Multiplen Sklerose*
nicht eindeutig zuordenbar (-1)
Klinisch isoliertes Syndrom (KIS) (1)
Schubförmige remittierende MS (RRMS)
(2)
Sekundär progrediente MS (SPMS) (3)
Primär progrediente MS (PPMS) (4)
Andere (5)
Wenn Andere, welche?
Anzahl der Schübe in den letzten 24 Monaten*
0 (0)
1 (1)
10 (10)
>10 (11)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
7 (7)
8 (8)
9 (9)
Besteht zurzeit ein Schub?*
nein (0)
ja (1)
EDSS-Score vor 12 Monaten
EDSS-Score*
Unbekannt
ja (1)
Heutige Scores der Funktionssysteme
Heutiger EDSS
Unbekannt / Nicht durchgeführt
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ja (1)
Pyramidal
Sensibilität
Zerebral
Kleinhirn
Blase/Mastdarm
Gehfähigkeit
Hirnstamm
Visuell
Summe
Frühere MS-Therapien
Wurde früher eine verlaufsmodifizierende MS-
Therapie durchgeführt?
ja (1)
nein, de novo Therapie (bitte weiter mit
nächstem Feld) (99)
Frühere verlaufsmodifizierende MS-
Therapien
Wirkstoff
Mitoxantron (10)
Natalizumab (Tysabri) (11)
Rituximab (14)
Fingolimod (Gilenya) (18)
Interferon ß 1A IM (Avonex) (19)
Azathioprin (2)
Interferon ß 1A SC (Rebif 22 µg, Rebif
44 µg) (20)
Interferon ß 1SC (Betaferon, Extavia)
(21)
Alemtuzumab (Lemtrada) (22)
Teriflunomide (Aubagio) (23)
Fumarat (BG-12; Tecfidera) (24)
Kortison (25)
Cyclophosphamid (4)
Glatirameracetat (Copaxone) (6)
Immunglobuline (7)
* Medikation aus einer MS-Studie (8)
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Methotrexat (9)
Andere ... (99)
anderer Wirkstoff
Beginn: Monat/Jahr
Ende: Monat
Hauptgrund für Therapieende
Nebenwirkungen (1)
Fehlende Wirksamkeit (2)
Anderer Grund (99)
wenn Anderer, bitte Grund angeben
Aktuelle MS-Therapie
Wirkstoff
Mitoxantron (10)
Natalizumab (Tysabri) (11)
Rituximab (14)
Fingolimod (Gilenya) (18)
Interferon ß 1A IM (Avonex) (19)
Azathioprin (2)
Interferon ß 1A SC (Rebif 22 µg, Rebif
44 µg) (20)
Interferon ß 1SC (Betaferon, Extavia)
(21)
Alemtuzumab (Lemtrada) (22)
Teriflunomide (Aubagio) (23)
Fumarat (BG-12; Tecfidera) (24)
Kortison (25)
Cyclophosphamid (4)
Glatirameracetat (Copaxone) (6)
Immunglobuline (7)
* Medikation aus einer MS-Studie (8)
Methotrexat (9)
Andere ... (99)
anderer Wirkstoff
Beginn: Monat/Jahr
Therapieschema
Standard (1)
Andere (99)
Bitte Dosis und Art der Verabreichung angeben
Weitere Erkrankungen
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Wurde bei diesem/r Patient/in jemals eine
Erkrankung aus den folgenden
Krankheitsgruppen ärztlich diagnostiziert?
Ja
Nein
Herz- / Kreislauferkrankungen
Herz- / Kreislauferkrankungen
NA (1)
Welche Erkrankung wurde diagnostiziert?
Bluthochdruck (02)
Herzschwäche/-insuffizienz (03)
Herzrhythmusstörung (04)
Herzinfarkt (05)
KHK / Angina Pectoris (06)
Beinvenenthrombose (07)
Lungenembolie (08)
Monat/Jahr
Datum unbekannt
ja (1)
Aktuelle medikamentöse Behandlung
nein (0)
ja (1)
Stoffwechselerkrankungen
Stoffwechselerkrankungen
NA (1)
Welche Erkrankung wurde diagnostiziert?
Diabetes mellitus (11)
Schilddrüsenunter- od. Überfunktion (12)
Monat/Jahr
Datum unbekannt
ja (1)
Aktuelle medikamentöse Behandlung
nein (0)
ja (1)
Infektionserkrankungen
Infektionserkrankungen
NA (1)
Welche Erkrankung wurde diagnostiziert?
Hepatitis B oder C (21)
HIV-Infektion (22)
Tuberkulose (23)
Opportunistische Infektionen (24)
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Herpes Infektion (25)
PML (26)
Lungenentzündung (27)
Wenn ja, welche opportunistische Infektion
Ort der Infektion
Monat/Jahr
Datum unbekannt
ja (1)
Aktuelle medikamentöse Behandlung
nein (0)
ja (1)
Gastrointestinale Erkrankungen
Gastrointestinale Erkrankungen
NA (1)
Welche Erkrankung wurde diagnostiziert?
Bauchspeicheldrüsen-Entzündung (31)
Leberzirrhose (32)
Morbus Crohn (33)
Colitis Ulcerosa (34)
Monat/Jahr
Datum unbekannt
ja (1)
Aktuelle medikamentöse Behandlung
nein (0)
ja (1)
Neurologische / Psychiatrische
Erkrankungen
Neurologische / Psychiatrische Erkrankungen
NA (1)
Welche Erkrankung wurde diagnostiziert?
Epileptische Anfälle (41)
Depression (42)
Angsstörungen, Panikattacken (43)
Migräne / Kopfschmerzen (44)
Anorexie (45)
Monat/Jahr
Datum unbekannt
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ja (1)
Aktuelle medikamentöse Behandlung
nein (0)
ja (1)
Allergien
Allergien
NA (1)
Welche Erkrankung wurde diagnostiziert?
Medikamentenallergie (51)
Hausstaub / Pollen (52)
Nahrungsmittel (53)
Nickel / Duftstoffe (54)
Insektenstiche (55)
Welches Medikament?
Monat/Jahr
Datum unbekannt
ja (1)
Aktuelle medikamentöse Behandlung
nein (0)
ja (1)
Urogenitale Erkrankungen
Urogenitale Erkrankungen
NA (1)
Welche Erkrankung wurde diagnostiziert?
Wiederkehrende Harnwegsinfekte (61)
Einschränkung der Nierenfunktion (62)
Weitere Urologische Erkrankungen (63)
Monat/Jahr
Datum unbekannt
ja (1)
Aktuelle medikamentöse Behandlung
nein (0)
ja (1)
Autoimmunerkrankungen
Autoimmunerkrankungen
NA (1)
Welche Erkrankung wurde diagnostiziert?
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Myasthenia gravis (71)
Autoimmune Schilddrüsenerkrankung
(72)
Systemischer Lupus erythematodes (73)
Psoriasis (74)
Monat/Jahr
Datum unbekannt
ja (1)
Aktuelle medikamentöse Behandlung
nein (0)
ja (1)
Blutbild / Labor
Blutbild / Labor
NA (1)
Welche Erkrankung wurde diagnostiziert?
Anämie (81)
Lymphopenia (82)
Leukopenie (83)
Neutropenia (84)
Gerinnungsstörungen (85)
Myelodysplastisches Syndrom (86)
Auffälligkeit bei Lebertest(s) (87)
Auffälligkeit bei Nierentest(s) (88)
Monat/Jahr
Datum unbekannt
ja (1)
Aktuelle medikamentöse Behandlung
nein (0)
ja (1)
Allgemeine Symptome
Allgemeine Symptome
NA (1)
Welches Symptom wurde diagnostiziert?
Haarausfall (91)
Hautausschlag (92)
lokale Symptome bei Medikamenten (93)
Retinopathie, Makulaödem (94)
Gelenkschmerzen (95)
Gewichtsverlust oder -zunahme (96)
Monat/Jahr
Datum unbekannt
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ja (1)
Aktuelle medikamentöse Behandlung
nein (0)
ja (1)
Operation
Operation
NA (1)
Welche Operationen
Monat/Jahr
Datum unbekannt
ja (1)
Aktuelle medikamentöse Behandlung
nein (0)
ja (1)
Krebserkrankungen
Krebserkrankungen
NA (1)
Welche Art von Krebs
Monat/Jahr
Welche Therapien wurden aufgrund der
Krebserkrankung durchgeführt?
Operation
nein (0)
ja (1)
Bestrahlung
nein (0)
ja (1)
Chemotherapie
nein (0)
ja (1)
Wenn Chemotherapie, bitte Substanzen angeben
nicht bekannt
ja (1)
Andere Erkrankungen
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Andere Erkrankungen
NA (1)
Welche andere Erkrankung?
Monat/Jahr
Datum unbekannt
ja (1)
Aktuelle medikamentöse Behandlung
nein (0)
ja (1)
Keine Vorerkrankungen aus diesen obigen
Krankheitsgruppen/Erkrankungen bekannt
Zutreffend
ja (1)
Schwangerschaft
Liegt aktuell eine Schwangerschaft vor?
nein (0)
ja (1)
Biologisches Material (z.B. Blut)
Probenset Nr.
Zusatz (derzeit deaktiviert)
Modul D - Meldebogen für
Schwangerschaft - Teil 1 Baseline
Meldebogen für Schwangerschaft -
Teil 2 Baseline
Medizinischer Folgebogen -
Hauptseite FU1
Allgemeines
Datum: Nachbefragung*
Heutiger EDSS-Score
>= 0
<= 10
unbekannt
ja (1)
Art der Visite bzw. dieses Kontaktes
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geplant (1)
ungeplant (2)
Grund dieser Visite bzw. dieses Kontaktes
(Mehrfachauswahl)
Therapiegabe
ja (1)
Klinischer Verlauf / Gespräch
ja (1)
Nebenwirkung / Therapieänderung
ja (1)
Symptomveränderung
ja (1)
Anderer Grund
ja (1)
Bitte angeben
Ist seit der letzten Dokumentation für
REGIMS (o. REGIMS-Visite)...
... eine Nebenwirkungen / ein neues
Krankheitsereignis aufgetreten?*
nein (0)
ja (1)
... die verlaufsmodifizierende MS-Therapie
verändert worden?*
nein (0)
ja (1)
... ein Schubereignis / Krankheitsprogression
aufgetreten?*
nein (0)
ja (1)
... eine Schwangerschaft bekannt geworden?*
nein (0)
ja (1)
Eigene Bemerkungen / Klinischer Verlauf /
Kommentar
Bemerkungen
Modul B - Änderungen der MS-
Therapie FU1
Änderungen bei der
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verlaufsmodifizierenden MS-Therapie
Welche Änderung der MS-Therapie wurde seit
dem letzten Besuch durchgeführt?
Die Medikamentendosis wurde erhöht
(1)
Die Medikamentendosis wurde reduziert
(2)
Die Therapie wurde abgesetzt und neue
begonnen (3)
Die Therapie wurde ersatzlos abgesetzt
(4)
Eine andere Änderung wurde
durchgeführt (99)
Welcher Wirkstoff wurde abgesetzt?
Mitoxantron (10)
Natalizumab (Tysabri) (11)
Rituximab (14)
Fingolimod (Gilenya) (18)
Interferon ß 1A IM (Avonex) (19)
Azathioprin (2)
Interferon ß 1A SC (Rebif 22 µg, Rebif
44 µg) (20)
Interferon ß 1SC (Betaferon, Extavia)
(21)
Alemtuzumab (Lemtrada) (22)
Teriflunomide (Aubagio) (23)
Fumarat (BG-12; Tecfidera) (24)
Kortison (25)
Cyclophosphamid (4)
Glatirameracetat (Copaxone) (6)
Immunglobuline (7)
* Medikation aus einer MS-Studie (8)
Methotrexat (9)
Andere ... (99)
Wenn Anderer, welcher?
Welche Änderung? (Bitte eintragen.)
Falls es Änderungen gab, geben Sie bitte
den Grund für den Abbruch / die
Änderung an.
Grund für den Abbruch
Nebenwirkungen (1)
Fehlende Wirksamkeit (2)
Anderer Grund (99)
Bitte anderen Grund angeben
Neue (aktuelle) MS-Therapie
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Wirkstoff
Mitoxantron (10)
Natalizumab (Tysabri) (11)
Rituximab (14)
Fingolimod (Gilenya) (18)
Interferon ß 1A IM (Avonex) (19)
Azathioprin (2)
Interferon ß 1A SC (Rebif 22 µg, Rebif
44 µg) (20)
Interferon ß 1SC (Betaferon, Extavia)
(21)
Alemtuzumab (Lemtrada) (22)
Teriflunomide (Aubagio) (23)
Fumarat (BG-12; Tecfidera) (24)
Kortison (25)
Cyclophosphamid (4)
Glatirameracetat (Copaxone) (6)
Immunglobuline (7)
* Medikation aus einer MS-Studie (8)
Methotrexat (9)
Andere ... (99)
Wenn anderer Wirkstoff, bitte beschreiben
Beginn: Monat/Jahr
Therapieschema
Standard (1)
Andere (99)
Bitte Dosis und Art der Verabreichung angeben
Modul C - Schubereignis /
Krankheitsprogression FU1
Schubereignis / Krankheitsprogression
Sind seit dem letzten Besuch / Visite ein oder
mehrere Schübe aufgetreten?
nein (0)
ja (1)
Wie viele Schübe?
0 (0)
1 (1)
10 (10)
>10 (11)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
7 (7)
8 (8)
9 (9)
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Findet zurzeit eine Behandlung mit Kortison
statt?
nein (0)
ja (1)
Weitere Änderungen
Hat sich seit dem letzten Besuch / Visite die
Verlaufsform der MS verändert (z.B. von RRMS
auf SPMS)?
nein (0)
ja (1)
Geänderte Verlaufsform der Multiplen Sklerose
nicht eindeutig zuordenbar (-1)
Klinisch isoliertes Syndrom (KIS) (1)
Schubförmige remittierende MS (RRMS)
(2)
Sekundär progrediente MS (SPMS) (3)
Primär progrediente MS (PPMS) (4)
Andere (5)
Andere Verlaufsform
Sind seit dem letzten Besuch / Visite neue MS-
Symptome aufgetreten?
nein (0)
ja (1)
Wenn ja, welche?
Modul D - Meldebogen für
Schwangerschaft - Teil 1 FU1
Daten der Patientin
Datum der Meldung*
Alter in Jahren
Größe
Gewicht
Schwangerschaft
Datum der letzten Regelblutung*
Errechneter Geburtstermin*
Anzahl früherer Schwangerschaften*
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Wenn >1, Datum der letzten Entbindung angeben
Ausgang der letzten Schwangerschaft
Lebendgeburt ohne Abnormalität (1)
Ektopische Schwangerschaft (2)
Spontanabort (3)
Schwangerschaftsabbruch (4)
Lebendgeburt mit Abnormalität (5)
Frühgeburt (6)
Totgeburt (7)
Relevante Anamnese (Grunderkrankung,
Begleiterkrankungen, Allergien,
Risikofaktoren, ...)
Relevant in der Anamnese
bestehend seit: Monat/Jahr
MS-Medikation
Medikament
Mitoxantron (10)
Natalizumab (Tysabri) (11)
Rituximab (14)
Fingolimod (Gilenya) (18)
Interferon ß 1A IM (Avonex) (19)
Azathioprin (2)
Interferon ß 1A SC (Rebif 22 µg, Rebif
44 µg) (20)
Interferon ß 1SC (Betaferon, Extavia)
(21)
Alemtuzumab (Lemtrada) (22)
Teriflunomide (Aubagio) (23)
Fumarat (BG-12; Tecfidera) (24)
Kortison (25)
Cyclophosphamid (4)
Glatirameracetat (Copaxone) (6)
Immunglobuline (7)
* Medikation aus einer MS-Studie (8)
Methotrexat (9)
Andere ... (99)
Anderes:
Dosis
Einheit
mg (2)
µg (4)
Beginn: Monat/Jahr
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fortgesetzt
nein (0)
ja (1)
Ende: Monat/Jahr
Andere Medikation vor / während der
Schwangerschaft
Begleitmedikation (Handelsname)
Dosis
Einheit
mg (2)
µg (4)
Beginn: Monat/Jahr
Ende: Monat/Jahr
Indikation
Meldebogen für Schwangerschaft -
Teil 2 FU1
2. Patientendaten
Patienten-ID
Alter
Schwangerschaftsverlauf
3. Ausgang der Schwangerschaft
Ektopische Schwangerschaft
(Ektopische Schwangerschaft)
Frühgeburt (Frühgeburt)
Lebendgeburt mit Defekten
(Lebendgeburt mit Defekten)
Lebendgeburt ohne Defekte
(Lebendgeburt ohne Defekte)
Schwangerschaftsabbruch
(Schwangerschaftsabbruch)
Spontanabort (Spontanabort)
Todgeburt (Todgeburt)
Am
In SSW
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Kurzbeschreibung (Abnormalität des Embryos,
Grund für Abbruch, Art des Defektes, usw.)
4. Komplikationen bei der Schwangerschaft
Ja, bitte erläutern (Ja, bitte erläutern)
Keine (Keine)
Ja, bitte erläutern
5. Art der Entbindung
Kaiserschnitt, Grund (Kaiserschnitt,
Grund)
Vaginal (Vaginal)
Kaiserschnitt, Grund:
6. Angaben zum Neugeborenen
Geburtsdatum
Gewicht
g
Größe
cm
Kopfumfang
cm
Geschlecht
Geschlecht unbekannt (Geschlecht
unbekannt)
männlich (männlich)
weiblich (weiblich)
Apgar - 1 Minute:
Apgar - 5 Minuten:
Apgar - 10 Minuten:
7. Abnormalitäten / Auffälligkeiten
Keine
Ja
Nein
Ja, bitte erläutern
Kausalität MS-Medikation
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8. Falls Defekte / Abnormalitäten /
Komplikationen festgestellt wurden, bitte
beurteilen Sie die
Kausalität bzgl. der verlaufsmodifizierenden MS-
Medikation
möglich (möglich)
nicht erhebbar (nicht erhebbar)
nicht kausal (nicht kausal)
unwahrscheinlich (unwahrscheinlich)
wahrscheinlich (wahrscheinlich)
Unerwünschte Ereignisse FU1
Angaben zum unerwünschtes Ereignis
Ereignis (diagnostisch oder symptomatisch)*
Andere (-1)
--- Herz-/ Kreislauferkrankungen (01)
Bluthochdruck (02)
Herzschwäche/-insuffizienz (03)
Herzrhythmusstörung (04)
Herzinfarkt (05)
KHK / Angina Pectoris (06)
Beinvenenthrombose (07)
Lungenembolie (08)
--- Stoffwechselerkrankungen (10)
Diabetes mellitus (11)
Schilddrüsenunter- od. Überfunktion (12)
--- Infektionserkrankungen (20)
Hepatitis B oder C (21)
HIV-Infektion (22)
Tuberkulose (23)
Opportunistische Infektionen (24)
Herpes Infektion (25)
PML (26)
Lungenentzündung (27)
--- Gastrointestinale Erkrankungen (30)
Bauchspeicheldrüsenentzündung (31)
Leberzirrhose (32)
Morbus Crohn (33)
Colitis Ulcerosa (34)
--- Neurologische Erkrankungen (40)
Epileptische Anfälle (41)
Depression (42)
Angsstörungen, Panikattacken (43)
Migräne / Kopfschmerzen (44)
Anorexie (45)
--- Allergien (50)
Medikamentenallergie (51)
Hausstaub / Pollen (52)
Nahrungsmittel (53)
Nickel / Duftstoffe (54)
Insektenstiche (55)
--- Nieren / Urogenitale Erkankungen
(60)
Wiederkehrende Harnwegsinfekte (61)
Nierenfunktionseinschränkung (62)
--- Autoimmunerkrankungen (70)
Myasthenia gravis (71)
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Autoimmune Schilddrüsenerkrankung
(72)
Systemischer Lupus erythematodes (73)
Psoriasis (74)
--- Blutbild / Laborveränderungen (80)
Anämie (81)
Lymphopenia (82)
Leukopenie (83)
Neutropenia (84)
Gerinnungsstörungen (85)
Myelodysplastisches Syndrom (86)
Auffälligkeit bei Lebertest(s) (87)
Auffälligkeit bei Nierentest(s) (88)
--- Allgemeine Symptome (90)
Haarausfall (91)
Hautausschlag (92)
lokale Symptome bei Medikamenten (93)
Retinopathie, Makulaödem (94)
Gelenkschmerzen (95)
Gewichtsverlust oder -zunahme (96)
Beschreibung (diagnostisch oder symptomatisch)
Weitere Angaben zum unerwünschtes
Ereignis
aufgetreten am*
Ist die Nebenwirkung / das Krankheitsereignis
dauerhaft bestehend / chronisch?*
nein (0)
ja (1)
Wenn beendet, wann?
Welche Intensität hatte das Ereignis?*
leicht (1)
mittel (2)
schwer (3)
Einstufung des Ereignisses
War das Ereignis schwerwiegend?
nein (0)
ja (1)
Warum schwerwiegend?*
Todesfolge (1)
lebensbedrohlich (2)
Krankenhausaufenthalt /
Aufenthaltsverlängerung (3)
kongen. Fehlbildungen (4)
Behinderung / Invalidität (5)
sonstiges med. wichtiges Ereignis (6)
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Ausgang
Ausgang des Ereignisses?*
unbekannt (-1)
anhaltend (1)
wiederhergestellt (2)
wiederhergestellt mit Folgen (3)
Tod (4)
Wenn bleibende Folgen, welche
Todesdatum
Ursache
Autopsie
unbekannt (-1)
nein (0)
ja (1)
Kausalität (UE & MS-Medikation)
Wie wahrscheinlich ist ein kausaler
Zusammenhang zwischen dem Ereignis und der
aktuellen MS-Therapie?*
nicht erhebbar (-1)
nicht kausal (0)
unwahrscheinlich (1)
möglich (2)
wahrscheinlich (3)
kausal (4)
MS-Medikation
MS-Medikament*
Mitoxantron (10)
Natalizumab (Tysabri) (11)
Rituximab (14)
Fingolimod (Gilenya) (18)
Interferon ß 1A IM (Avonex) (19)
Azathioprin (2)
Interferon ß 1A SC (Rebif 22 µg, Rebif
44 µg) (20)
Interferon ß 1SC (Betaferon, Extavia)
(21)
Alemtuzumab (Lemtrada) (22)
Teriflunomide (Aubagio) (23)
Fumarat (BG-12; Tecfidera) (24)
Kortison (25)
Cyclophosphamid (4)
Glatirameracetat (Copaxone) (6)
Immunglobuline (7)
* Medikation aus einer MS-Studie (8)
Methotrexat (9)
Andere ... (99)
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Anderes
Einnahme seit
bis (wenn nicht fortlaufend)
Tagesdosis
Einheit
mg (2)
µg (4)
Maßnahme
keine (0)
Dosis reduziert (1)
Dosis erhöht (2)
Unterbrechung der Medikation (3)
Medikament abgesetzt (4)
Kausalität zum Ereignis
nicht erhebbar (-1)
nicht kausal (0)
unwahrscheinlich (1)
möglich (2)
wahrscheinlich (3)
kausal (4)
Kausalität (UE & Begleitmedikation)
Wie wahrscheinlich ist ein kausaler
Zusammenhang zwischen dem Ereignis und
einem anderen zurzeit eingenommenen
Medikament?*
nicht erhebbar (-1)
nicht kausal (0)
unwahrscheinlich (1)
möglich (2)
wahrscheinlich (3)
kausal (4)
Begleitmedikation
Andere Medikation (Handelsname)
Einnahme seit
bis (wenn nicht fortlaufend)
Tagesdosis
Einheit
mg (2)
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µg (4)
Indikation
Kausalität zum Ereignis
nicht erhebbar (-1)
nicht kausal (0)
unwahrscheinlich (1)
möglich (2)
wahrscheinlich (3)
kausal (4)
Schwerwiegende unerwünschte
Ereignisse
Datum der Meldung*
SUE-Nummer*
Typ der Meldung*
Erstmeldung (1)
Folgemeldung (2)
Patientenangaben
Alter*
Jahre
Geschlecht*
männlich (1)
weiblich (2)
Gewicht
kg
Größe
cm
Schwangerschaft
nein (0)
ja (1)
falls ja, Schwangerschaftswoche
Behandlung
Behandlung des SUEs*
Keine (0)
Medikamentöse Behandlung (1)
Andere (2)
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wenn andere Behandlung, welche
Relevante Vorerkrankung / Symptome
Relevante Vorerkrankung
von
bis (wenn nicht anhaltend)
Ergebnisse der relevanten Diagnostischen
Untersuchungen
Resultate der relevanten diagnostischen Tests
(unter Angabe von Referenzwerten, falls
vorhanden)
Kontaktdaten des Berichterstatters
Name des Berichterstatters*
Telefon-Nr*
Faxnr.
Email
Unterschrift
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Eligibility Breast Cancer NCT00328432
A Study of Women With an Early Diagnosis of Breast
Cancer, Taking Celecoxib Between the Biopsy and
Lumpectomy/Mastectomy; ODM derived from:
https://clinicaltrials.gov/show/NCT00328432
All rights reserved. Please visit https://medical-data-
models.org/forms/16364
Eligibility Breast Cancer
NCT00328432
Inclusion Criteria
women with a recent diagnosis of t1 or t2 non-
invasive breast cancer by large core needle or
excisional biopsy*
Yes
No
confirmation that tissue was processed in
methods acceptable to protocol and sufficient
tissue remains post-diagnostic analyses to
perform research assessments*
Yes
No
reexcision planned within 10 days to 6 weeks
from study start*
Yes
No
if on prevention tamoxifen or raloxifene, must
have begun administration at least six weeks
prior to initial biopsy and continue through
reexcision*
Yes
No
Exclusion Criteria
no hormone replacement therapy within the 90
days prior to biopsy*
Yes
No
if on prevention tamoxifen or raloxifene, must
have begun administration at least six weeks
prior to initial biopsy and continue through
reexcision*
Yes
No
no evidence of metastatic malignancy of any
kind*
Yes
No
no history of asthma, allergy asa, nsaids,
celecoxib or other cox-2 inhibitors for a chronic
non-oncological condition with the excision of low
dose asa (160 mg daily) during 4 weeks prior to
biopsy and for the duration of the study.*
Yes
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No
no celecoxib or rofecoxib use within one month of
biopsy*
Yes
No
no history of gastrointestinal ulcer or ulcerative
colitis requiring treatment*
Yes
No
no current anticoagulants*
Yes
No
no neoadjuvant antihormone or chemotherapy as
treatment following biopsy prior to study entry or
concurrently with participation on study*
Yes
No
no aromatase inhibitor in the six months prior to
participation*
Yes
No
no concomitant lithium*
Yes
No
no known significant bleeding disorder*
Yes
No
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Eligibility Breast Cancer NCT00331097
ELDA: Elderly Breast Cancer - Docetaxel in Adjuvant
Treatment; ODM derived from:
https://clinicaltrials.gov/show/NCT00331097
All rights reserved. Please visit https://medical-data-
models.org/forms/16365
Eligibility Breast Cancer
NCT00331097
Inclusion Criteria
histologically confirmed invasive unilateral breast
cancer*
Yes
No
age > 65 and < 80 years*
Yes
No
intermediate-high risk of recurrence according to
st. gallen criteria: er negative and pgr negative,
or  axillary lymph node metastasis, or  tumor size
> 2 cm, or tumor grade 2 or 3 (intermediate or
high)*
Yes
No
Exclusion Criteria
performance status >1*
Yes
No
distant metastasis*
Yes
No
concomitant  malignancy or malignancy within
previous 5 years (except basal cell or
spinocellular skin cancer and in situ cervical
cancer if they have been adequately treated*
Yes
No
previous breast cancer treatment*
Yes
No
neutrophils < 2000/mm3 or platelets <
100000/mm3 or haemoglobin < 10 g/dl*
Yes
No
creatinine > 1.25 the upper normal limit*
Yes
No
got and-or gpt and/or bilirubin > 1.25 the upper
normal limit*
Yes
No
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concomitant conditions that contraindicate the
use of the drugs in the protocol*
Yes
No
incapacity or refusal to provide informed consent*
Yes
No
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Quality of Life: PaReSiS UKH
Quality of Life: PaReSiS UKH: PaReSiS UKH Rehabilitation
Study: "Partizipatives Rehabilitationsprozessmanagement,
PaReSiS Schlaganfall in Sachsen-Anhalt" Martin-Luther-
Universität Halle-Wittenberg Medizinische Fakultät Institut
für Gesundheits- und Pflegewissenschaft Projekt:
Partizipatives Rehabilitationsprozessmanagement
„Schlaganfall in Sachsen-Anhalt“ Magdeburger Straße 8
06097 Halle (Saale), Germany E-Mail:
paresis@medizin.uni-halle.de
All rights reserved. Please visit https://medical-data-
models.org/forms/16366
Quality of Life: PaReSiS UKH
42. Lebensqualität
Lebensqualität
sehr schlecht (1)
schlecht (2)
mittelmäßig (3)
gut (4)
sehr gut (5)
43. Gesundheit
Wie zufrieden sind Sie mit Ihrer Gesundheit?
sehr unzufrieden (1)
unzufrieden (2)
weder zufrieden noch unzufrieden (3)
zufrieden (4)
sehr zufrieden (5)
44. Stärke von Erlebnissen
a) Wie stark werden Sie durch Schmerzen daran
gehindert, notwendige Dinge zu tun?
überhaupt nicht (1)
ein Wenig (2)
mittelmäßig (3)
ziemlich (4)
äußerst (5)
b) Wie sehr sind Sie auf medizinische
Behandlung angewiesen, um das tägliche Leben
zu meistern?
überhaupt nicht (1)
ein Wenig (2)
mittelmäßig (3)
ziemlich (4)
äußerst (5)
c) Wie gut können Sie ihr Leben genießen?
überhaupt nicht (1)
ein Wenig (2)
mittelmäßig (3)
ziemlich (4)
äußerst (5)
d) Betrachten Sie Ihr Leben als sinnvoll?
überhaupt nicht (1)
ein Wenig (2)
mittelmäßig (3)
ziemlich (4)
1 / 5
äußerst (5)
e) Wie gut können Sie sich konzentrieren?
überhaupt nicht (1)
ein Wenig (2)
mittelmäßig (3)
ziemlich (4)
äußerst (5)
f) Wie sicher fühlen Sie sich in Ihrem alltäglichen
Leben? (Kriminalität, Wohnumfeld)
überhaupt nicht (1)
ein Wenig (2)
mittelmäßig (3)
ziemlich (4)
äußerst (5)
g) Wie gesund sind die die Umweltbedingungen
in Ihrem Wohngebiet? (Verkehrslärm,
Luftverschmutzung)
überhaupt nicht (1)
ein Wenig (2)
mittelmäßig (3)
ziemlich (4)
äußerst (5)
45. In den folgenden Fragen geht es
darum, in welchem Umfang Sie während
der vergangenen zwei Wochen bestimmte
Dinge erlebt haben oder in der Lage
waren, bestimmte Dinge zu tun.
a) Haben Sie genug Energie für das tägliche
Leben?
überhaupt nicht (1)
eher nicht (2)
halbwegs (3)
überwiegend (4)
völlig (5)
b) Können Sie Ihr Aussehen akzeptieren?
überhaupt nicht (1)
eher nicht (2)
halbwegs (3)
überwiegend (4)
völlig (5)
c) Haben Sie genug Geld, um Ihre Bedürfnisse
erfüllen zu können?
überhaupt nicht (1)
eher nicht (2)
halbwegs (3)
überwiegend (4)
völlig (5)
d) Haben Sie Zugang zu den Informationen, die
Sie für das tägliche Leben brauchen?
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(Informationen über Aktivitäten im näheren
Wohnumfeld z.B. Seniorentreffs,
Selbsthilfegruppen, Beratungsstellen)
überhaupt nicht (1)
eher nicht (2)
halbwegs (3)
überwiegend (4)
völlig (5)
e) Haben Sie ausreichend Möglichkeiten zu
Freizeitaktivitäten? (Hobbys, Geselligkeit,
Entspannung)
überhaupt nicht (1)
eher nicht (2)
halbwegs (3)
überwiegend (4)
völlig (5)
46. Wie gut können Sie sich fortbewegen?
Wie gut können Sie sich fortbewegen?
sehr schlecht (1)
schlecht (2)
mittelmäßig (3)
gut (4)
sehr gut (5)
47. In den folgenden Fragen geht es
darum, wie zufrieden, glücklich oder gut
Sie sich während der vergangenen zwei
Wochen hinsichtlich verschiedener
Aspekte Ihres Lebens gefühlt haben.
a) Wie zufrieden sind Sie mit Ihrem Schlaf?
sehr unzufrieden (1)
unzufrieden (2)
weder zufrieden noch unzufrieden (3)
zufrieden (4)
sehr zufrieden (5)
b) Wie zufrieden sind Sie mit Ihrer Fähigkeit,
alltägliche Dinge erledigen zu können?
sehr unzufrieden (1)
unzufrieden (2)
weder zufrieden noch unzufrieden (3)
zufrieden (4)
sehr zufrieden (5)
c) Wie zufrieden sind Sie mit Ihrer
Arbeitsfähigkeit?
sehr unzufrieden (1)
unzufrieden (2)
weder zufrieden noch unzufrieden (3)
zufrieden (4)
sehr zufrieden (5)
d) Wie zufrieden sind Sie mit sich Selbst?
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sehr unzufrieden (1)
unzufrieden (2)
weder zufrieden noch unzufrieden (3)
zufrieden (4)
sehr zufrieden (5)
Wie zufrieden sind Sie mit Ihren persönlichen
Beziehungen?
sehr unzufrieden (1)
unzufrieden (2)
weder zufrieden noch unzufrieden (3)
zufrieden (4)
sehr zufrieden (5)
f) Wie zufrieden sind Sie mit Ihrem Sexualleben?
sehr unzufrieden (1)
unzufrieden (2)
weder zufrieden noch unzufrieden (3)
zufrieden (4)
sehr zufrieden (5)
g) Wie zufrieden sind Sie mit der Unterstützung
durch Ihre Freunde?
sehr unzufrieden (1)
unzufrieden (2)
weder zufrieden noch unzufrieden (3)
zufrieden (4)
sehr zufrieden (5)
h) Wie zufrieden sind Sie mit Ihren
Wohnbedingungen?
sehr unzufrieden (1)
unzufrieden (2)
weder zufrieden noch unzufrieden (3)
zufrieden (4)
sehr zufrieden (5)
i) Wie zufrieden sind Sie mit Ihren Möglichkeiten,
Gesundheitsdienste in Anspruch nehmen zu
können?
sehr unzufrieden (1)
unzufrieden (2)
weder zufrieden noch unzufrieden (3)
zufrieden (4)
sehr zufrieden (5)
j) Wie zufrieden sind Sie mit den
Beförderungsmitteln, die Ihnen zur Verfügung
stehen? (ausreichend, um täglichen Aufgaben
und Freizeitaktivitäten nachzugehen)
sehr unzufrieden (1)
unzufrieden (2)
weder zufrieden noch unzufrieden (3)
zufrieden (4)
sehr zufrieden (5)
48. In den folgenden Fragen geht es
darum, wie oft sich während der
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vergangenen zwei Wochen bei Ihnen
negative Gefühle eingestellt haben (z.B.
Angst oder Traurigkeit).
Wie häufig haben Sie negative Gefühle wie
Traurigkeit, Verzweiflung, Angst oder
Depression?
niemals (1)
nicht oft (2)
zeitweilig (3)
oftmals (4)
immer (5)
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Geriatric Depression Scale: PaReSiS UKH
Geriatric Depression Scale: PaReSiS UKH Rehabilitation
Study: "Partizipatives Rehabilitationsprozessmanagement,
PaReSiS Schlaganfall in Sachsen-Anhalt" Martin-Luther-
Universität Halle-Wittenberg Medizinische Fakultät Institut
für Gesundheits- und Pflegewissenschaft Projekt:
Partizipatives Rehabilitationsprozessmanagement
„Schlaganfall in Sachsen-Anhalt“ Magdeburger Straße 8
06097 Halle (Saale), Germany E-Mail:
paresis@medizin.uni-halle.de
All rights reserved. Please visit https://medical-data-
models.org/forms/16367
Geriatric Depression Scale: PaReSiS
UKH
49. Mit den folgenden Fragen möchte ich
von Ihnen erfahren, wie Sie Ihr Befinden
während der letzten Woche einschätzen.
a) Sind Sie grundsätzlich mit Ihrem Leben
zufrieden?
Ja
Nein
b) Haben Sie viele von Ihren Tätigkeiten und
Interessen aufgegeben?
Ja
Nein
c) Haben Sie das Gefühl, Ihr Leben ist leer?
Ja
Nein
d) Ist Ihnen oft langweilig?
Ja
Nein
e) Sind Sie meistens guter Laune?
Ja
Nein
f) Befürchten Sie, dass Ihnen etwas Schlechtes
zustoßen wird?
Ja
Nein
g) Sind Sie meistens zufrieden?
Ja
Nein
h) Fühlen Sie sich oft hilflos?
Ja
Nein
i) Sind Sie lieber zu Hause, statt auszugehen und
etwas zu unternehmen?
Ja
Nein
j) Glauben Sie, dass Sie mit dem Gedächtnis
mehr Schwierigkeiten haben als andere Leute?
Ja
Nein
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k) Finden Sie, es sei wunderbar, jetzt zu leben?
Ja
Nein
l) Fühlen Sie sich so, wie Sie jetzt sind, eher
wertlos?
Ja
Nein
m) Fühlen Sie sich energiegeladen?
Ja
Nein
n) Finden Sie, Ihre Lage sei hoffnungslos?
Ja
Nein
o) Glauben Sie, die meisten anderen Leute
haben es besser als Sie?
Ja
Nein
Total GDS
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Symptom Checklist (SCL): PaReSiS UKH  Rehabilitation
Study: "Partizipatives Rehabilitationsprozessmanagement,
PaReSiS Schlaganfall in Sachsen-Anhalt" Martin-Luther-
Universität Halle-Wittenberg Medizinische Fakultät Institut
für Gesundheits- und Pflegewissenschaft Projekt:
Partizipatives Rehabilitationsprozessmanagement
„Schlaganfall in Sachsen-Anhalt“ Magdeburger Straße 8
06097 Halle (Saale), Germany E-Mail:
paresis@medizin.uni-halle.de
All rights reserved. Please visit https://medical-data-
models.org/forms/16368
Symptom Checklist (SCL): PaReSiS
UKH
50. Als nächstes möchte ich Sie zu
verschiedenen Problemen und
Beschwerden, die man machmal hat,
befragen. Entscheiden Sie bitte, wie stark
Sie während der vergangenen sieben
Tage bis heute durch di...
a)Kopfschmerzen
überhaupt nicht (1)
ein wenig (2)
ziemlich (3)
stark (4)
sehr stark (5)
b) Ohnmachts- oder Schwindelgefühle
überhaupt nicht (1)
ein wenig (2)
ziemlich (3)
stark (4)
sehr stark (5)
c) Herz- und Brustschmerzen
überhaupt nicht (1)
ein wenig (2)
ziemlich (3)
stark (4)
sehr stark (5)
d) Kreuzschmerzen
überhaupt nicht (1)
ein wenig (2)
ziemlich (3)
stark (4)
sehr stark (5)
e) Übelkeit oder Magenverstimmung
überhaupt nicht (1)
ein wenig (2)
ziemlich (3)
stark (4)
sehr stark (5)
f) Muskelschmerzen (Muskelkater, Gliederreißen)
überhaupt nicht (1)
ein wenig (2)
ziemlich (3)
stark (4)
sehr stark (5)
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g) Schwierigkeiten beim Atmen
überhaupt nicht (1)
ein wenig (2)
ziemlich (3)
stark (4)
sehr stark (5)
h) Hitzewallungen oder Kälteschauer
überhaupt nicht (1)
ein wenig (2)
ziemlich (3)
stark (4)
sehr stark (5)
i) Taubheit oder Kribbeln in einzelnen
Körperteilen
überhaupt nicht (1)
ein wenig (2)
ziemlich (3)
stark (4)
sehr stark (5)
j) dem Gefühl, einen Klumpen (Kloß) im Hals zu
haben
überhaupt nicht (1)
ein wenig (2)
ziemlich (3)
stark (4)
sehr stark (5)
k) Schwächegefühl in einzelnen Körperteilen
überhaupt nicht (1)
ein wenig (2)
ziemlich (3)
stark (4)
sehr stark (5)
l) Schweregefühl in den Armen oder den Beinen
überhaupt nicht (1)
ein wenig (2)
ziemlich (3)
stark (4)
sehr stark (5)
m) schlechtem Appetit
überhaupt nicht (1)
ein wenig (2)
ziemlich (3)
stark (4)
sehr stark (5)
n) Einschlafschwierigkeiten
überhaupt nicht (1)
ein wenig (2)
ziemlich (3)
stark (4)
sehr stark (5)
o) Gedanken an den Tod und ans Sterben
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überhaupt nicht (1)
ein wenig (2)
ziemlich (3)
stark (4)
sehr stark (5)
p) frühem Erwachen am Morgen
überhaupt nicht (1)
ein wenig (2)
ziemlich (3)
stark (4)
sehr stark (5)
q) unruhigem oder gestörtem Schlaf
überhaupt nicht (1)
ein wenig (2)
ziemlich (3)
stark (4)
sehr stark (5)
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Eligibility Breast Cancer NCT00337233
Yoga in Controlling Symptoms and Reducing Stress in
Women With Ovarian Cancer or Breast Cancer; ODM
derived from: https://clinicaltrials.gov/show/NCT00337233
All rights reserved. Please visit https://medical-data-
models.org/forms/16369
Eligibility Breast Cancer
NCT00337233
Criteria
diagnosis of breast or ovarian cancer*
Yes
No
must be 2-24 months post-primary treatment
(e.g., surgery) for breast cancer and/or have had
a recurrence of breast cancer within the past 24
months*
Yes
No
must be 3-24 months post-primary treatment
(e.g., surgery) for ovarian cancer and/or have had
a recurrence of ovarian cancer within the past 24
months*
Yes
No
hormone receptor status not specified*
Yes
No
patient characteristics:*
Yes
No
female*
Yes
No
menopausal status not specified*
Yes
No
zubrod performance status 0-3*
Yes
No
no medical contraindications*
Yes
No
understands written and spoken english*
Yes
No
prior concurrent therapy:*
Yes
No
see disease characteristics*
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Yes
No
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Eligibility Breast Cancer NCT00337649
A Study of Epothilone D in Combination With Herceptin
(Trastuzumab) in Patients With HER-2 Positive Advanced
or Metastatic Breast Cancer.; ODM derived from:
https://clinicaltrials.gov/show/NCT00337649
All rights reserved. Please visit https://medical-data-
models.org/forms/16370
Eligibility Breast Cancer
NCT00337649
Inclusion Criteria
women >=18 years;*
Yes
No
locally advanced or metastatic breast cancer;*
Yes
No
her-2 overexpression (fish + or ihc 3+);*
Yes
No
>=1 measurable lesion;*
Yes
No
up to one prior anthracycline-based
chemotherapy regimen in a metastatic setting.*
Yes
No
Exclusion Criteria
pre-existing neuropathy >=grade 2;*
Yes
No
known cns metastases;*
Yes
No
congestive heart failure, or myocardial infarction
within the last 6 months;*
Yes
No
previous malignancies in last 5 years, except for
cured basal cell cancer of the skin, or cancer in
situ of the cervix.*
Yes
No
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Mini Mental State Examination (MMSE): PaReSiS UKH
PaReSiS UKH Rehabilitation Study: "Partizipatives
Rehabilitationsprozessmanagement, PaReSiS Schlaganfall
in Sachsen-Anhalt" Martin-Luther-Universität Halle-
Wittenberg Medizinische Fakultät Institut für Gesundheits-
und Pflegewissenschaft Projekt: Partizipatives
Rehabilitationsprozessmanagement „Schlaganfall in
Sachsen-Anhalt“ Magdeburger Straße 8 06097 Halle
(Saale), Germany E-Mail: paresis@medizin.uni-halle.de
All rights reserved. Please visit https://medical-data-
models.org/forms/16371
Mini Mental State Examination
(MMSE): PaReSiS UKH
51. Orientierung
Was für ein Datum ist heute?
Welche Jahreszeit?
Welches Jahr haben wir?
Welcher Wochentag ist heute?
Welcher Monat?
Wo sind wir jetzt, in welchem Land?
In welchem Bundesland?
In welchem Ort/ welcher Stadt?
In welcher Klinik/Altersheim/Haus?
In welchem Stockwerk?
Summe der Punte (max. 10)
52. Merkfähigkeit
Anzahl der Versuche
1.
2.
3.
Sum
1 / 4
53. Aufmerksamkeit und Rechenfähigkeit
Ziehen Sie bitte von der Zahl 100 jeweils 7 ab.
Ja
Nein
1.
2.
3.
4.
5.
Oder: (falls der Patient die Aufgabe nicht
durchführen kann oder will: Buchstabieren Sie
das Wort "RADIO" rückwärts. Für jeden richtig
aufgezählten Buchstaben gibt es einen Punkt. O-
I-D-A-R
Ja
Nein
1.
2.
3.
4.
5.
Summe
>= 0
<= 5
54. Erinnerungsfähigkeit
Was waren die Dinge, die Sie vorher gemacht
haben? Für jedes richtig genannte Wort gibt es
einen Punkt.
Ja
Nein
1.
2.
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3.
Summe
>= 0
<= 3
55. Sprache
Ich zeige Ihnen nun zwei Gegenstände. Sagen
Sie mir bitte, was ich Ihnen zeige. (Armbanduhr,
Bleistift). Zwei Punkte möglich.
Ja
Nein
1.
2.
Sprechen Sie mir bitte nach: "Sie leiht ihm kein
Geld mehr." Nur einen Versuch zulassen, falsch:
0 Punkte, richtig: 1 Punkt
Ja
Nein
3.
Sie benötigen ein Blatt. Machen Sie bitte
folgendes: 
Nehmen Sie das Blatt in die rechte Hand. Falten
Sie es in der Mitte. Legen Sie es auf den Boden. 
3 Punkte möglich.
Ja
Nein
4.
5.
6.
Es wird ein Blatt benötigt, auf dessen Rückseite
"Augen zu!" steht. Lesen Sie, was auf dem Blatt
steht, und machen Sie dies bitte. 1 Punkt
Ja
Nein
7.
Bitte schreiben Sie einen vollständigen Satz auf
das Blatt. Nicht diktieren. 1 Punkt, wenn Subjekt
und Verb enthalten sind und der Satz
verständlich ist.
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Ja
Nein
8.
Bitte zeichnen Sie die Figur auf dem Blatt nach. 1
Punkt, wenn alle Seiten und Winkel stimmen und
die sich überschneidenden Linien ein Viereck
bilden.
Ja
Nein
9.
Gesamtpunktzahl (max. 9)
>= 0
<= 9
4 / 4
Mini Mental State Examination (MMSE): PaReSiS UKH
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Pain: PaReSiS UKH PaReSiS UKH Rehabilitation Study:
"Partizipatives Rehabilitationsprozessmanagement,
PaReSiS Schlaganfall in Sachsen-Anhalt" Martin-Luther-
Universität Halle-Wittenberg Medizinische Fakultät Institut
für Gesundheits- und Pflegewissenschaft Projekt:
Partizipatives Rehabilitationsprozessmanagement
„Schlaganfall in Sachsen-Anhalt“ Magdeburger Straße 8
06097 Halle (Saale), Germany E-Mail:
paresis@medizin.uni-halle.de
All rights reserved. Please visit https://medical-data-
models.org/forms/16373
Pain: PaReSiS UKH
56. Die meisten von uns haben von Zeit
zu Zeit Schmerzen (z.B. Kopfschmerzen,
Zahnschmerzen, bei Verstauchungen).
Litten Sie in den vergangenen 24 Stunden
an anderen als diesen
Alltagsschmerzen?)
Die meisten von uns haben von Zeit zu Zeit
Schmerzen (z.B. Kopfschmerzen,
Zahnschmerzen, bei Verstauchungen). Litten Sie
in den vergangenen 24 Stunden an anderen als
diesen Alltagsschmerzen?)
ja (weiter mit Frage 57) (1)
nein (weiter mit Frage 62) (2)
57. Genauer Ort des Schmerzes
a) Grobe schematische Zeichnung des Körpers
(von vorne und von hinten) benötigt: Wo haben
Sie Schmerzen? Bitte tragen Sie den Ort der
Schmerzen ein.
Ja
Nein
b) Schmerzen eintragen, die nicht an den Bildern
dokumentierter sind
58. Stärke der Schmerzen
Wie stark sind Ihre Schmerzen (in diesem
Moment) auf einer Skala von 0 bis 10, wenn 0
kein Schmerz bedeutet und 10 die stärksten
vorstellbaren Schmerzen?
59. Medikamente gegen die Schmerzen
Welche Behandlungen oder Medikamente
erhalten Sie gegen die Schmerzen? z.B. auch
Krankengymnastik, Elektrotherapie,
Wärmeanwendungen, Massagen, Ergotherapie...
60. Bitte denken Sie an die vergangenen
24 Stunden. Wie viel Schmerzlinderung
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haben Sie durch Behandlungen oder
Medikamente erfahren?
Bitte denken Sie an die vergangenen 24
Stunden. Wie viel Schmerzlinderung haben Sie
durch Behandlungen oder Medikamente
erfahren? Auf einer Skala von 0% bis 100%,
wenn 0% keine Linderung und 100% vollständige
Linderung bedeutet?
>= 0
<= 100
%
61.Wie stark sind Sie in den folgenden
Dingen durch Ihre Schmerzen
beeinträchtigt? Auf einer Skala von 0 bis
10, wenn 0 keine Beeinträchtigung und 10
die stärkste Beeinträchtigung darstellt?
a) Allgemeine Aktivität
>= 0
<= 10
b) Stimmung
>= 0
<= 10
c) Gehvermögen
>= 0
<= 10
d) Normale Arbeit, Belastbarkeit (sowohl
außerhalb des Hauses, als auch Hausarbeit)
>= 0
<= 10
e) Beziehungen zu anderen Menschen (durch
Gereiztheit, Unausgeglichenheit, versäumte
Verabredungen)
>= 0
<= 10
f) Schlaf
>= 0
<= 10
g) Lebensfreude
>= 0
<= 10
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Nutritional status: PaReSiS UKH PaReSiS UKH
Rehabilitation Study: "Partizipatives
Rehabilitationsprozessmanagement, PaReSiS Schlaganfall
in Sachsen-Anhalt" Martin-Luther-Universität Halle-
Wittenberg Medizinische Fakultät Institut für Gesundheits-
und Pflegewissenschaft Projekt: Partizipatives
Rehabilitationsprozessmanagement „Schlaganfall in
Sachsen-Anhalt“ Magdeburger Straße 8 06097 Halle
(Saale), Germany E-Mail: paresis@medizin.uni-halle.de
All rights reserved. Please visit https://medical-data-
models.org/forms/16374
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62. Wie groß sind Sie?
Wie groß sind Sie?
cm
63. Wie schwer sind Sie?
Wie schwer sind Sie?
kg
64. Hat sich Ihr Gewicht im letzten Monat
unbeabsichtigt verändert?
a) reduziert
Ja
Nein
b) erhöht
Ja
Nein
c) falls ja, um wie viel Kilogramm?
kg
65. Kommt es häufiger vor, dass Sie nur
eine oder gar keine Mahlzeit am Tag zu
sich nehmen?
Kommt es häufiger vor, dass Sie nur eine oder
gar keine Mahlzeit am Tag zu sich nehmen?
Ja
Nein
66. Haben Sie in den letzten 3 Tagen
erheblich weniger gegessen als
gewöhnlich?
Haben Sie in den letzten 3 Tagen erheblich
weniger gegessen als gewöhnlich?
Ja
Nein
67.Haben Sie in den letzten 3 Tagen
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erheblich weniger getrunken als
gewöhnlich?
Haben Sie in den letzten 3 Tagen erheblich
weniger getrunken als gewöhnlich?
Ja
Nein
68. Haben Sie Schwierigkeiten mit dem
Schlucken?
Haben Sie Schwierigkeiten mit dem Schlucken?
Ja
Nein
a) Benötigen Sie eine spezielle Zubereitung
fester Speisen (pürierte, zerkleinerte Kost,
spezielle Nahrungsmittel wie Brei, Joghurt)
Ja
Nein
b) Benötigen Sie eine spezielle Zubereitung
fester und flüssiger Speisen? (püriert, Flüssigkeit
eingedickt)
Ja
Nein
c) Benötigen Sie eine Sondenernährung?
Ja
Nein
Falls Sondenernährung:
teilweise (1)
vollständig (2)
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Housing conditions: PaReSiS UKH
Housing conditions: PaReSiS UKH  PaReSiS UKH
Rehabilitation Study: "Partizipatives
Rehabilitationsprozessmanagement, PaReSiS Schlaganfall
in Sachsen-Anhalt" Martin-Luther-Universität Halle-
Wittenberg Medizinische Fakultät Institut für Gesundheits-
und Pflegewissenschaft Projekt: Partizipatives
Rehabilitationsprozessmanagement „Schlaganfall in
Sachsen-Anhalt“ Magdeburger Straße 8 06097 Halle
(Saale), Germany E-Mail: paresis@medizin.uni-halle.de
All rights reserved. Please visit https://medical-data-
models.org/forms/16375
Housing conditions: PaReSiS UKH
Vom Interviewer zu beantworten
69. Erschweren Treppen oder sonstige Stufen
den Zugang zur Wohnung?
Ja
Nein
Falls ja, gibt es einen Aufzug?
Ja
Nein
70. Ist die Wohnung geräumig und frei von
Schwellen und Stolperfallen, so dass man sich
gut in ihr bewegen kann?
Ja
Nein
71. Ist die Wohnung gut und bequem beheizbar
(Gas- oder Ölheizung)?
Ja
Nein
72. Gibt es in der Wohnung warmes Wasser in
Küche und Bad?
Ja
Nein
73. Gibt es innerhalb der Wohnung ein Bad/WC,
das der Betroffene trotz körperlicher
Einschränkungen bequem nutzen kann?
Ja
Nein
74. Ist ein Telefon vorhanden?
Ja
Nein
75. Sind das Treppenhaus und die Flure gut
beleuchtet und gibt es genügend Lichtschalter?
Ja
Nein
Vom Befragten zu Beantworten
76. Sind alle Geschäfte des täglichen Bedarfs in
der Nähe Ihrer Wohnung vorhanden?
Ja
Nein
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77. Gibt es eine Haltestelle für Bus, Straßenbahn
oder Zug in der Nähe Ihrer Wohnung (<1 km)?
Ja
Nein
77. Falls ja, nutzen Sie diese?
Ja
Nein
78. Wohnen Sie schon lange Zeit in der Wohnung
(>5 Jahre)?
Ja
Nein
79. Fühlen Sie sich in Ihrer Wohnung und der
Wohngegend wohl?
Ja
Nein
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Eligibility Breast Cancer NCT00356148
The Efficacy of Prophylactic Antibiotic Administration
During Breast Cancer Surgery in Overweight Patients.;
ODM derived from:
https://clinicaltrials.gov/show/NCT00356148
All rights reserved. Please visit https://medical-data-
models.org/forms/16380
Eligibility Breast Cancer
NCT00356148
Inclusion Criteria
women at any age with early stage breast cancer
(stage i-ii) and american society of
anesthesiologists (asa) score of i-ii.*
Yes
No
Exclusion Criteria
ductal carcinoma in situ (dcis; stage 0 cancer),*
Yes
No
advanced or distant metastatic stage,*
Yes
No
receiving any neoadjuvant therapy,*
Yes
No
history of receiving any antibiotics within prior 3
months,*
Yes
No
history of immunodeficiency,*
Yes
No
having a remote infection,*
Yes
No
history of reaction to study antibiotics,*
Yes
No
denial of signing the consent form.*
Yes
No
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Eligibility Breast Cancer NCT00412022
HOBOE: A Phase 3 Study of Adjuvant Triptorelin and
Tamoxifen, Letrozole, or Letrozole and Zoledronic Acid in
Premenopausal Patients With Breast Cancer.; ODM
derived from: https://clinicaltrials.gov/show/NCT00412022
All rights reserved. Please visit https://medical-data-
models.org/forms/16381
Eligibility Breast Cancer
NCT00412022
Inclusion Criteria
histological diagnosis of breast cancer*
Yes
No
surgical resection of breast cancer (breast
conserving surgery or mastectomy)*
Yes
No
no evidence of disease*
Yes
No
indication for adjuvant hormonal therapy (er
and/or pgr positive with ihc exam in at least 1% of
primary tumor cells, according to st. gallen
criteria)*
Yes
No
patient age at least 18 years*
Yes
No
written informed consent .       premenopausal
status defined as lmp within 12 months of
randomization (fsh, lh will not be considered as
determinants of menopausal status due the
chemotherapy induced reversible ovarian
suppression)*
Yes
No
please note that patients who have received
neoadjuvant or adjuvant chemotherapy and/or
locoregional radiation therapy may be included in
the study*
Yes
No
Exclusion Criteria
performance status (ecog)>2.*
Yes
No
previous or concomitant malignancy (with the
exception of adequately treated nonmalignant
skin cancer and carcinoma in situ of the uterine
cervix*
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Yes
No
metastatic breast cancer*
Yes
No
creatinine > 1.25 times the value of upper normal
limit*
Yes
No
pregnant or lactating females*
Yes
No
clinical or radiologic evidence of bone fractures*
Yes
No
treatment with systemic cortisone therapy within
12 months prior to randomization*
Yes
No
treatment with drugs that could alter bone
metabolism (calcitonin, mithramycin, gallium
nitrate) within 2 weeks prior to randomization*
Yes
No
previous treatment with tamoxifen or aromatase
inhibitors*
Yes
No
ast and/or alt > 3 times the value of upper normal
limit with clinical and laboratory findings that
indicate a grade of hepatic insufficiency that
could potentially increase the risk of assuming
letrozole*
Yes
No
any concomitant conditions that would, in the
investigator's opinion, contraindicate the use of
any of the drugs used in this study*
Yes
No
inability to provide informed consent*
Yes
No
inability to comply with followup*
Yes
No
patient undergoing invasive dental work at time of
baseline evaluation or foreseen during the course
of adjuvant therapy*
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Yes
No
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Eligibility Breast Cancer NCT00412022
Eligibility Breast Cancer NCT00427245
Goserelin in Preventing Early Menopause in
Premenopausal Women Undergoing Chemotherapy for
Stage I, Stage II, or Stage III Breast Cancer; ODM derived
from: https://clinicaltrials.gov/show/NCT00427245
All rights reserved. Please visit https://medical-data-
models.org/forms/16382
Eligibility Breast Cancer
NCT00427245
Criteria
histologically confirmed invasive breast cancer*
Yes
No
stages i-iiib with node-positive or -negative
disease (n0-2)*
Yes
No
operable disease*
Yes
No
must meet 1 of the following criteria:*
Yes
No
has undergone mastectomy or breast-conserving
surgery with complete excision of primary tumor
within the past 8 weeks*
Yes
No
scheduled to receive neoadjuvant chemotherapy*
Yes
No
no metastatic breast cancer, including
supraclavicular fossa metastases*
Yes
No
hormone receptor status meeting 1 of the
following criteria:*
Yes
No
estrogen receptor (er) and progesterone receptor
poor or negative and not a candidate for adjuvant
endocrine therapy*
Yes
No
er positive and no requirement for ovarian
suppression as a necessary part of treatment*
Yes
No
patient characteristics:*
Yes
No
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female*
Yes
No
premenopausal with regular menses in the 12
months preceding surgery*
Yes
No
no other prior or concurrent invasive malignancy
except adequately treated basal cell or squamous
cell skin cancer or carcinoma in situ of the cervix*
Yes
No
suitable fitness status for chemotherapy*
Yes
No
adequate hepatic, renal, and bone marrow
function*
Yes
No
not pregnant or nursing*
Yes
No
fertile patients must use effective contraception*
Yes
No
prior concurrent therapy:*
Yes
No
see disease characteristics*
Yes
No
no prior chemotherapy or endocrine therapy*
Yes
No
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Eligibility Breast Cancer NCT00429247
Randomized Trial With Trastuzumab Versus Observation in
Breast Cancer Patients; ODM derived from:
https://clinicaltrials.gov/show/NCT00429247
All rights reserved. Please visit https://medical-data-
models.org/forms/16383
Eligibility Breast Cancer
NCT00429247
Inclusion Criteria
age >= 18 years.*
Yes
No
performance status (world health organization
[who]) < 3*
Yes
No
adequate bone marrow function (absolute
neutrophil count > 1000/mm^3, platelet count >
100000/mm^3, hemoglobin > 9 gr/mm^3)*
Yes
No
adequate liver (bilirubin < 1.5 times upper limit of
normal and sgot/sgpt < 2 times upper limit of
normal) and renal function ( creatinine < 2
mg/dl)*
Yes
No
adequate cardiac function (left ventricular ejection
fraction [lvef] > 50%).*
Yes
No
informed consent*
Yes
No
histologically or cytologically confirmed breast
adenocarcinoma*
Yes
No
prior surgical excision of the primary breast
tumor*
Yes
No
prior completion of standard adjuvant
chemotherapy and/or radiotherapy*
Yes
No
locally advanced disease after the completion of
neo-adjuvant chemotherapy, surgical excision
and radiotherapy provided that there was no
evidence of local or metastatic disease*
Yes
1 / 2
No
absence of any clinical or laboratory evidence of
metastatic disease*
Yes
No
detection of ctcs and/or dtcs (when it could be
feasible) before the initiation and/or after the
completion of adjuvant chemotherapy and/or
radiotherapy*
Yes
No
expression of her2/c-neu on the primary tumor is
not mandatory*
Yes
No
Exclusion Criteria
other invasive malignancy within the past 5 years
except nonmelanoma skin cancer*
Yes
No
other concurrent uncontrolled illness*
Yes
No
psychiatric illness or social situation that would
preclude study compliance*
Yes
No
pregnant or nursing*
Yes
No
positive pregnancy test*
Yes
No
history of allergic reaction attributed to
trastuzumab (herceptin)*
Yes
No
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Eligibility Breast Cancer NCT00431080
Randomized Phase III Trial Comparing Sequential
Administration of FE75C Followed by Docetaxel Versus
Paclitaxel as Adjuvant Chemotherapy in Axillary Lymph
Node (+) Breast Cancer; ODM derived from:
https://clinicaltrials.gov/show/NCT00431080
All rights reserved. Please visit https://medical-data-
models.org/forms/16385
Eligibility Breast Cancer
NCT00431080
Inclusion Criteria
women with histologically-confirmed unilateral
invasive ductal or lobular breast
adenocarcinoma*
Yes
No
within 60 days after the surgical excision of the
primary tumor with tumor-free operation margins;
at least 10 axillary lymph nodes have to be
removed.*
Yes
No
tumor involvement of at least one axillary lymph
node*
Yes
No
absence of any clinical or radiological evidence of
local or metastatic disease*
Yes
No
premenopausal or postmenopausal women aged
18-75 years old*
Yes
No
adequate bone marrow function (absolute
neutrophil count >1500/mm3, platelet count
>100.000/mm3, hemoglobin >10gr/mm3)*
Yes
No
adequate liver (bilirubin <1.0 times upper limit of
normal and sgot/sgpt <2.5 times upper limit of
normal) and renal function (creatinine
<1.5mg/dl)*
Yes
No
adequate cardiac function (lvef>50%)*
Yes
No
written informed consent*
Yes
No
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Exclusion Criteria
positive pregnancy test.*
Yes
No
psychiatric illness or social situation that would
preclude study compliance.*
Yes
No
other concurrent uncontrolled illness.*
Yes
No
prior or concurrent antineoplastic therapy e.g.
hormonal therapy, radiation therapy,
chemotherapy, biological agents.*
Yes
No
previous history of other invasive malignancy
other than non-melanomatous skin cancer.*
Yes
No
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Eligibility Breast Cancer NCT00431795
Randomized Phase II Study of Epirubicin vs Caelyx in
Pretreated Metastatic Breast Cancer; ODM derived from:
https://clinicaltrials.gov/show/NCT00431795
All rights reserved. Please visit https://medical-data-
models.org/forms/16387
Eligibility Breast Cancer
NCT00431795
Inclusion Criteria
age 18-75 years*
Yes
No
eastern cooperative oncology group (ecog)
performance status 0-2*
Yes
No
adequate bone marrow function (absolute
neutrophil count >1000/mm^3, platelet
count>100000/mm^3, hemoglobin>9gr/mm^3)*
Yes
No
histologically- or cytologically- confirmed breast
adenocarcinoma*
Yes
No
no prior anthracycline-based chemotherapy as
treatment of advanced breast cancer*
Yes
No
no prior chemotherapy with ≥ 300mg/m2
doxorubicin or  ≥ 540mg/m2 epirubicin as
adjuvant setting*
Yes
No
at least 4 weeks interval since prior anticancer
treatment*
Yes
No
measurable disease as defined by the presence
of at least one measurable lesion(except bone
metastases, ascites or pleural effusions)*
Yes
No
life expectancy > 3 months*
Yes
No
written informed consent*
Yes
No
1 / 2
Exclusion Criteria
pregnancy or nursing*
Yes
No
documented history of congestive heart failure
(chf), serious arrhythmia, or myocardial infarction
(within 6 months)*
Yes
No
other invasive malignancy except nonmelanoma
skin cancer or acute infection.*
Yes
No
radiation of measurable disease (except brain
metastases)*
Yes
No
progressive brain metastases according to
clinical or radiological criteria.*
Yes
No
brain metastases without prior radiation therapy*
Yes
No
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Ministry of Health, Ethiopia- Delivery
Register
Form provided by Binyam Tilahun. Source:
http://www.moh.gov.et/ (Ministry of Health, Ethiopia)
All rights reserved. Please visit https://medical-data-
models.org/forms/16388
Delivery Register
Identification
Serial number
Medical Record Number
Age
Delivery services
Delivery date and time
Delivery Type
SVD (1)
Caesarean section (2)
Forceps / Vacuum Extraction (3)
Other procedures (4)
Delivery Type: Episiotomy
Yes
No
Maternal status
Stable (1)
Unstable / deteriorated and referred to
the next facility (2)
Died (3)
Obstetric complications
Eclampsia (1)
APH (2)
Obstetric complications referred
Yes
No
Newborn Alive?
Yes
No
Apgar score at first minute
Apgar score at 5 min
Sex
Male (1)
Female (2)
Body weight of infant
grams
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Weight less than 2500g
Yes
No
Stillbirth
Yes
No
Live birth, died before arrival at facility
Yes
No
Live birth, died after arrival or delivery in facility
Yes
No
Preventive services
Vitamin A
Yes
No
BCG given
Yes
No
OPV given
Yes
No
Infants Medical record number
HIV Test accepted
Yes
No
HIV Test result
R (1)
NR (2)
I (3)
HIV positive delivery
Yes
No
Type of ARV prophylaxis provided to mother
Type of ARV prophylaxis provided to newborn
NVP  (1)
AZT+NVP (2)
Counseled on infant feeding options
Yes
No
Mother and infant referred to chronic care
Yes
No
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Ministry of Health, Ethiopia- Delivery Register
Managed by: (Name)
Managed by: (signature)
Total count
Count of deliveries
Count of c-sections
Count of maternal deaths
Count of life births
Count of all weights
Count of weights under 2500g
Count of stillbirths
Count of newborn deaths who died before arival
at the facility
Count of newborn deaths who died after arrival at
the facility
Count of positive tests
Count of positive deliveries
Count of deliveries with both mother and
newborn on prophylaxis
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Ministry of Health, Ethiopia- Delivery Register
Ministry of Health, Ethiopia- Health Post
Delivery Register
Form provided by Binyam Tilahun. Source:
http://www.moh.gov.et/ (Ministry of Health, Ethiopia)
All rights reserved. Please visit https://medical-data-
models.org/forms/16389
Health Post Delivery Register
Identification
Serial number
Name of woman
Age
Address:Woreda
Address: Kebele
Address:Ketena/Gott
Delivery services
Registration date
Antenatal care
Yes
No
Gravidity
Parity
Blood pressure
mmHg
Fetal heart rate
Membranes intact
Yes
No
Membranes ruptured
Yes
No
Delivery date and time
Obstetric delivery
normal (1)
complicated and referred (2)
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Postpartum examination
Stable (1)
Unstable/deteriorated and referred (2)
Died (3)
Newborn outcome
Alive (1)
Stillbirth referred (2)
Fresh stillbirth (3)
Macerated stillbirth (4)
Died after delivery (5)
Newborn weight
grams
Newborn weight under 2500g
Yes
No
Newborn sex
male (1)
female (2)
Placenta expelled
Yes
No
Placenta retained
Yes
No
Vitamin A for mother
Yes
No
Newborn preventive service
BCG given (1)
OPV0 given (2)
Tetracycline eye ointment (3)
Vitamin K (4)
Other (5)
Newborn preventive service:specify other care
Actions taken
Referral
Yes
No
Remarks
Total count
Count of deliveries
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Ministry of Health, Ethiopia- Health Post Delivery Register
Count of maternal deaths
Count of life births
Count of low weights
Count of stillbirths
Count of newborn deaths
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Ministry of Health, Ethiopia- Health Post Delivery Register
Eligibility Breast Cancer NCT00499057
Partial Breast Irradiation With Interstitial High Dose Rate
Brachytherapy; ODM derived from:
https://clinicaltrials.gov/show/NCT00499057
All rights reserved. Please visit https://medical-data-
models.org/forms/16390
Eligibility Breast Cancer
NCT00499057
Inclusion Criteria
age  > or = 40 years*
Yes
No
ecog performance status 0-2*
Yes
No
t dimensions ≤ 2.5 cm*
Yes
No
negative surgical margins*
Yes
No
negative axillary lymph nodes*
Yes
No
suitable breast anatomy for implantation*
Yes
No
Exclusion Criteria
age < 40 years*
Yes
No
ecog performance status > 2*
Yes
No
t dimensions > 2.5*
Yes
No
positive surgical margins*
Yes
No
positive axillary lymph node*
Yes
No
infiltrating lobular histology*
Yes
No
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significant areas of lobular carcinoma in situ*
Yes
No
paget's disease of the nipple*
Yes
No
extensive intraductal component (eic)*
Yes
No
lymphovascular invasion*
Yes
No
multifocality (n) skin infiltration*
Yes
No
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Eligibility Breast Cancer NCT00556777
Radiation Therapy During Surgery in Treating Older
Women With Stage I Breast Cancer; ODM derived from:
https://clinicaltrials.gov/show/NCT00556777
All rights reserved. Please visit https://medical-data-
models.org/forms/16391
Eligibility Breast Cancer
NCT00556777
Criteria
Inclusion Criteria
histologically confirmed stage i breast cancer*
Yes
No
size ≤ 20 mm (by ultrasound), n0, any quadrant*
Yes
No
hormone receptor status not specified*
Yes
No
Exclusion Criteria
distant metastases*
Yes
No
inflammatory breast cancer*
Yes
No
lobular in situ disease*
Yes
No
invasive cancer or ductal carcinoma in situ*
Yes
No
nonepithelial disease or sarcoma*
Yes
No
multicentric disease*
Yes
No
lymphatic embolism*
Yes
No
margins of safety unknown or positive (in situ or
invasive)*
Yes
No
preoperative mammography showing diffuse
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microcalcification*
Yes
No
patient characteristics:*
Yes
No
female*
Yes
No
menopausal*
Yes
No
karnofsky 70-100%*
Yes
No
no other prior cancer except basal cell skin
cancer, uterine epithelioma in situ, or other
cancer in complete remission for the past 5
years*
Yes
No
no geographic, social, or psychiatric reasons that
would impede participation in study treatment*
Yes
No
prior concurrent therapy:*
Yes
No
see disease characteristics*
Yes
No
no prior neoadjuvant therapy*
Yes
No
no concurrent participation in another study*
Yes
No
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Anthropometrics Cardiovascular Health
Study (CHS)
Documentation part: Record 13 Anthropometrics
The Cardiovascular Health Study (CHS) was initiated by
the National Heart, Lung and Blood Institute (NHLBI) in
1987 to determine the risk factors for development and
progression of cardiovascular disease (CVD) in older
adults, with an emphasis on subclinical measures. The
study recruited 5,888 adults aged 65 or older at entry in
four U.S. communities and conducted extensive annual
clinical exams between 1989-1999 along with semi-annual
phone calls, events adjudication, and subsequent data
analyses and publications. Additional data were collected
by studies ancillary to CHS. With the exception of annual
clinic visits, these activities are still ongoing.
Data obtained from: https://chs-nhlbi.org/
Permission granted by: Erika Enright.
All rights reserved. Please visit https://medical-data-
models.org/forms/16392
Anthropometrics Cardiovascular
Health Study (CHS)
Anthropometry
1. Standing height:
cm
2. Unadjusted sitting height:
cm
3. Chair height
cm
5. Weight
kg
6. Hip circumference
cm
7. Waist circumference
cm
Date of interview
Interviewer
Interview:
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Years 5&6 Phlebotomy Cardiovascular
Health Study (CHS)
Documentation part: Record 12 Years 5&6 Phlebotomy
The Cardiovascular Health Study (CHS) was initiated by
the National Heart, Lung and Blood Institute (NHLBI) in
1987 to determine the risk factors for development and
progression of cardiovascular disease (CVD) in older
adults, with an emphasis on subclinical measures. The
study recruited 5,888 adults aged 65 or older at entry in
four U.S. communities and conducted extensive annual
clinical exams between 1989-1999 along with semi-annual
phone calls, events adjudication, and subsequent data
analyses and publications. Additional data were collected
by studies ancillary to CHS. With the exception of annual
clinic visits, these activities are still ongoing.
Data obtained from: https://chs-nhlbi.org/
Permission granted by: Erika Enright.
All rights reserved. Please visit https://medical-data-
models.org/forms/16393
Phlebotomy Cardiovascular Health
Study (CHS)
Adminstrative data
Phlebotomist ID:
Blood ID Number:
Has this participant been selected as a quality
control subject?
Yes
No
Quality Control ID Number:
Phlebotomy
1. Do you bleed or bruise easily?
don't know (don't know)
no (no)
yes (yes)
2. Have you ever been told you have a disorder
related to blood clotting or coagulation?
don't know (don't know)
no (no)
yes (yes)
3. Have you ever experienced fainting spells
while having blood drawn?
don't know (don't know)
no (no)
yes (yes)
4. How many hours has it been since you last ate
or drank anything except water?
hours
5. Was any blood drawn?
yes, full sample (1)
yes, partial sample (2)
no, refused (3)
no, hard to stick (4)
no, other reason (please specify) (5)
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Other reason:
Date of interview
Interviewer
Interview:
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Years 5&6 Phlebotomy Cardiovascular Health Study (CHS)
Baseline Seated Blood Pressure
Cardiovascular Health Study (CHS)
Documentation part: Record 14 Baseline Seated Blood
Pressure
The Cardiovascular Health Study (CHS) was initiated by
the National Heart, Lung and Blood Institute (NHLBI) in
1987 to determine the risk factors for development and
progression of cardiovascular disease (CVD) in older
adults, with an emphasis on subclinical measures. The
study recruited 5,888 adults aged 65 or older at entry in
four U.S. communities and conducted extensive annual
clinical exams between 1989-1999 along with semi-annual
phone calls, events adjudication, and subsequent data
analyses and publications. Additional data were collected
by studies ancillary to CHS. With the exception of annual
clinic visits, these activities are still ongoing.
Data obtained from: https://chs-nhlbi.org/
Permission granted by: Erika Enright.
All rights reserved. Please visit https://medical-data-
models.org/forms/16394
Baseline Seated Blood Pressure
Cardiovascular Health Study (CHS)
Zero Muddler seated blood pressure and
heart rate measurement
1. Cuff size:
regular (1)
large arm (2)
thigh (3)
pediatric (4)
Pulse Obliteration Pressure
2. Palpated systolic:
3. Maximum zero level:
4. Maximal inflation level: (palpated systolic +
maximum zero level +30)
Seated Readings
5. Beats in 30 seconds:
Blood Pressure
6. First reading: systolic
6. First reading: diastolic
7. Zero: systolic
7. Zero: diastolic
8. Corrected: systolic
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8. Corrected: diastolic
9. Second reading: systolic
9. Second reading: diastolic
10. Zero: systolic
10. Zero: diastolic
11. Corrected: systolic
11. Corrected: diastolic
Date of interview
Interviewer
Interview:
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Baseline Seated Blood Pressure Cardiovascular Health Study (CHS)
Year 3 Seated Blood Pressure
Cardiovascular Health Study (CHS)
Documentation part: Record 14 Year 3 Seated Blood
Pressure
The Cardiovascular Health Study (CHS) was initiated by
the National Heart, Lung and Blood Institute (NHLBI) in
1987 to determine the risk factors for development and
progression of cardiovascular disease (CVD) in older
adults, with an emphasis on subclinical measures. The
study recruited 5,888 adults aged 65 or older at entry in
four U.S. communities and conducted extensive annual
clinical exams between 1989-1999 along with semi-annual
phone calls, events adjudication, and subsequent data
analyses and publications. Additional data were collected
by studies ancillary to CHS. With the exception of annual
clinic visits, these activities are still ongoing.
Data obtained from: https://chs-nhlbi.org/
Permission granted by: Erika Enright.
All rights reserved. Please visit https://medical-data-
models.org/forms/16395
Year 3 Seated Blood Pressure
Cardiovascular Health Study (CHS)
First surveillance seated blood pressure
and heart rate measurement
1. Time of day:
2. Hours since last meal:
3. Cuff size:
regular (1)
large arm (2)
thigh (3)
pediatric (4)
Pulse Obliteration Pressure
4. Palpated systolic:
5. Maximum zero level:
6. Maximal inflation level: (palpated systolic +
maximum zero level +30)
Seated Readings
7. Beats in 30 seconds:
Blood Pressure
8. First reading: systolic
8. First reading: diastolic
9. Zero: systolic
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9. Zero: diastolic
10. Corrected: systolic
10. Corrected: diastolic
11. Second reading: systolic
11. Second reading: diastolic
12. Zero: systolic
12. Zero: diastolic
13. Corrected: systolic
13. Corrected: diastolic
14. Standard seated blood pressure: systolic
14. Standard seated blood pressure: diastolic
15. Which blood pressure measurement was
taken first:
standard seated blood pressure (1)
random-zero blood pressure (2)
Date of interview
Interviewer
Interview:
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Year 3 Seated Blood Pressure Cardiovascular Health Study (CHS)
Eligibility Breast Cancer NCT00572416
Fatigue in Breast Cancer: A Behavioral Sleep Intervention;
ODM derived from:
https://clinicaltrials.gov/show/NCT00572416
All rights reserved. Please visit https://medical-data-
models.org/forms/16396
Eligibility Breast Cancer
NCT00572416
Inclusion Criteria
ages 19 and older*
Yes
No
diagnosed for the first time with stage i-iiia breast
cancer*
Yes
No
post-operative for breast cancer*
Yes
No
scheduled to receive anthracycline-based
adjuvant chemotherapy with our without taxane
chemotherapy*
Yes
No
english speaking*
Yes
No
karnofsky performance scale score equal to or
greater than 60*
Yes
No
Exclusion Criteria
comorbid diagnosis of chronic insomnia*
Yes
No
sleep apnea or chronic fatigue syndrome*
Yes
No
unstable congestive heart failure*
Yes
No
chronic obstructive pulmonary disease*
Yes
No
insulin-depenent diabetes*
Yes
No
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neruomuscular disease*
Yes
No
abnormal thryoid function*
Yes
No
depression, or*
Yes
No
treatment with steriods*
Yes
No
erratic sleep schedule due to working rotating
shifts*
Yes
No
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Protocol medication AIEOP-BFM ALL 2009
NCT01117441
International Collaborative Treatment Protocol For Children
And Adolescents With Acute Lymphoblastic Leukemia.
Phase 3 Study.
Documentation of administered protocol medication
Clinical Trial Number: NCT01117441.
All rights reserved. Please visit https://medical-data-
models.org/forms/16397
Protocol medication AIEOP-BFM
ALL 2009 NCT01117441
Patient Information
ID of patient
Patient Birth Date
First Element
First Element:
Other (Other)
Prot. IA (Prot. IA)
Prot. IA-CPM (Prot. IA-CPM)
Prot. IA' (Prot. IA')
Prot. IAD (Prot. IAD)
First Element:
If "other", specify:
First Element:
Therapy documentation available?
Yes
No
First Element:
Start Date
First Element:
End Date
Second Element
Second Element:
Other (Other)
Prot. IB (Prot. IB)
Prot. IB-ASP+ (Prot. IB-ASP+)
Second Element:
If "other", specify:
Second Element:
Therapy documentation available?
Yes
No
Second Element:
1 / 6
Start Date
Second Element:
End Date
Thrid Element
Third Element:
HR-1' (HR-1')
HR-2' (HR-2')
HR-3' (HR-3')
Other (Other)
Prot. M, 1st - 3rd MTX (Prot. M, 1st - 3rd
MTX)
Prot. M, 1st MTX (Prot. M, 1st MTX)
Prot. M, 1st/ 2nd MTX (Prot. M, 1st/ 2nd
MTX)
Prot. M, total (Prot. M, total)
Third Element:
If "other", specify:
Third Element:
Therapy documentation available?
Yes
No
Third Element:
Start Date
Third Element:
End Date
Fourth Element
Fourth Element:
HR-1' (HR-1')
HR-2' (HR-2')
HR-3' (HR-3')
Other (Other)
Prot. II (Prot. II)
Prot. II-ASP+ (Prot. II-ASP+)
Fourth Element:
If "other", specify:
Fourth Element:
Therapy documentation available?
Yes
No
Fourth Element:
Start Date
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Fourth Element:
End Date
Fifth Element
Fifth Element:
HR-1' (HR-1')
HR-2' (HR-2')
HR-3' (HR-3')
Other (Other)
Fifth Element:
If "other", specify:
Fifth Element:
Therapy documentation available?
Yes
No
Fifth Element:
Start Date
Fifth Element:
End Date
Sixth Element
Sixth Element:
alloSCT (alloSCT)
DNX-FLA (DNX-FLA)
HR-1' (HR-1')
HR-2' (HR-2')
HR-3' (HR-3')
Other (Other)
Prot. III (Prot. III)
Sixth Element:
If "other", specify:
Sixth Element:
Therapy documentation available?
Yes
No
Sixth Element:
Start Date
Sixth Element:
End Date
Seveneth Element
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Seventh Element:
alloSCT (alloSCT)
DNX-FLA (DNX-FLA)
HR-1' (HR-1')
HR-2' (HR-2')
HR-3' (HR-3')
Other (Other)
Prot. III (Prot. III)
Seventh Element:
If "other", specify:
Seventh Element:
Therapy documentation available?
Yes
No
Seventh Element:
Start Date
Seventh Element:
End Date
Eighth Element
Eighth Element:
alloSCT (alloSCT)
DNX-FLA (DNX-FLA)
HR-1' (HR-1')
HR-2' (HR-2')
HR-3' (HR-3')
Other (Other)
Prot. III (Prot. III)
Eighth  Element:
If "other", specify:
Eighth Element:
Therapy documentation available?
Yes
No
Eighth  Element:
Start Date
Eighth  Element:
End Date
Ninth Element
Ninth Element:
alloSCT (alloSCT)
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Protocol medication AIEOP-BFM ALL 2009 NCT01117441
DNX-FLA (DNX-FLA)
HR-1' (HR-1')
HR-2' (HR-2')
HR-3' (HR-3')
Other (Other)
Prot. III (Prot. III)
Ninth  Element:
If "other", specify:
Ninth Element:
Therapy documentation available?
Yes
No
Ninth Element:
Start Date
Ninth  Element:
End Date
Cranial radiation
Cranial radiation?
Yes
No
Cranial radiation: Start Date:
Cranial radiation: End Date
Cranial radiation: total dose
Gy
Maintenance treatment
Maintenance treatment: Start Date
Maintenance treatment:
MTX i.th. 6x
Yes
No
Comments
Comment:
Identification and Signature
Doctor's name:
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Date of report
Signature
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TER-MAG PSMA-Studie Prostatakarzinom
NCT0000001
Quelle:
PSMA-Studie Prostatakarzinom
PD Dr. med. Kambiz Rahbar
UKM, Nuklearmedizin
Teil: TER-MAG
All rights reserved. Please visit https://medical-data-
models.org/forms/16400
TER-MAG PSMA-Studie
Prostatakarzinom NCT0000001
Patientendaten
Name
70 % norm
Zyklus 1
Datum
Termag vor
Datum
TERMAG nach
Zyklus 2
Datum
TERMAG nach
Zyklus 3
Datum
TERMAG nach
Zyklus 4
Datum
TERMAG nach
Zyklus 5
Datum
1 / 2
TERMAG nach
Zyklus 6
Datum
TERMAG nach
Zyklus 7
Datum
TERMAG nach
Zyklus 8
Datum
TERMAG nach
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TER-MAG PSMA-Studie Prostatakarzinom NCT0000001
PSA Before Therapy PSMA-Studie
Prostatakarzinom NCT0000001
Quelle:
PSMA-Studie Prostatakarzinom
PD Dr. med. Kambiz Rahbar
UKM, Nuklearmedizin
Teil: PSA vor Therapie
All rights reserved. Please visit https://medical-data-
models.org/forms/16401
PSA vor Therapie PSMA-Studie
Prostatakarzinom NCT0000001
Patientendaten
Name
Measurements
PSA-5
date-5
PSA-4
date-4
PSA-3
date-3
PSA-2
date-2
PSA-1
date-1
PSA(0)=PSA EV
PSA doubling time
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Laboratory Values PSMA-Studie
Prostatakarzinom NCT0000001
Quelle:
PSMA-Studie Prostatakarzinom
PD Dr. med. Kambiz Rahbar
UKM, Nuklearmedizin
Teil: Laborwerte
All rights reserved. Please visit https://medical-data-
models.org/forms/16404
Laborwerte PSMA-Studie
Prostatakarzinom NCT0000001
Patientendaten
Name
Datum EV
Zyklus 1
Laborwert
PSA (1)
AP (10)
Krea (11)
Bili (12)
GOT (13)
GPT (14)
GGT (15)
anderer (16)
Leuko (2)
Lympho (3)
Neutro (4)
Hb (5)
Ery (6)
Thrombos (7)
GFR (8)
LDH (9)
Aufnahmetag
Entlassungstag
1 Wo p.i.
2. Woche
2.-3. Woche
4. Woche
4.-5. Woche
6. Woche
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6.-7. Woche
Zyklus 2
Laborwert
PSA (1)
AP (10)
Krea (11)
Bili (12)
GOT (13)
GPT (14)
GGT (15)
anderer (16)
Leuko (2)
Lympho (3)
Neutro (4)
Hb (5)
Ery (6)
Thrombos (7)
GFR (8)
LDH (9)
Aufnahmetag
Entlassungstag
1 Wo p.i.
2. Woche
2.-3. Woche
4. Woche
4.-5. Woche
6. Woche
6.-7. Woche
Zyklus 3
Laborwert
PSA (1)
AP (10)
Krea (11)
Bili (12)
GOT (13)
GPT (14)
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GGT (15)
anderer (16)
Leuko (2)
Lympho (3)
Neutro (4)
Hb (5)
Ery (6)
Thrombos (7)
GFR (8)
LDH (9)
Aufnahmetag
Entlassungstag
1 Wo p.i.
2. Woche
2.-3. Woche
4. Woche
4.-5. Woche
6. Woche
6.-7. Woche
Zyklus 4
Laborwert
PSA (1)
AP (10)
Krea (11)
Bili (12)
GOT (13)
GPT (14)
GGT (15)
anderer (16)
Leuko (2)
Lympho (3)
Neutro (4)
Hb (5)
Ery (6)
Thrombos (7)
GFR (8)
LDH (9)
Aufnahmetag
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Entlassungstag
1 Wo p.i.
2. Woche
2.-3. Woche
4. Woche
4.-5. Woche
6. Woche
6.-7. Woche
Zyklus 5
Laborwert
PSA (1)
AP (10)
Krea (11)
Bili (12)
GOT (13)
GPT (14)
GGT (15)
anderer (16)
Leuko (2)
Lympho (3)
Neutro (4)
Hb (5)
Ery (6)
Thrombos (7)
GFR (8)
LDH (9)
Aufnahmetag
Entlassungstag
1 Wo p.i.
2. Woche
2.-3. Woche
4. Woche
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4.-5. Woche
6. Woche
6.-7. Woche
Zyklus 6
Laborwert
PSA (1)
AP (10)
Krea (11)
Bili (12)
GOT (13)
GPT (14)
GGT (15)
anderer (16)
Leuko (2)
Lympho (3)
Neutro (4)
Hb (5)
Ery (6)
Thrombos (7)
GFR (8)
LDH (9)
Aufnahmetag
Entlassungstag
1 Wo p.i.
2. Woche
2.-3. Woche
4. Woche
4.-5. Woche
6. Woche
6.-7. Woche
Zyklus 7
Laborwert
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Laboratory Values PSMA-Studie Prostatakarzinom NCT0000001
PSA (1)
AP (10)
Krea (11)
Bili (12)
GOT (13)
GPT (14)
GGT (15)
anderer (16)
Leuko (2)
Lympho (3)
Neutro (4)
Hb (5)
Ery (6)
Thrombos (7)
GFR (8)
LDH (9)
Aufnahmetag
Entlassungstag
1 Wo p.i.
2. Woche
2.-3. Woche
4. Woche
4.-5. Woche
6. Woche
6.-7. Woche
Zyklus 8
Laborwert
PSA (1)
AP (10)
Krea (11)
Bili (12)
GOT (13)
GPT (14)
GGT (15)
anderer (16)
Leuko (2)
Lympho (3)
Neutro (4)
Hb (5)
Ery (6)
Thrombos (7)
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GFR (8)
LDH (9)
Aufnahmetag
Entlassungstag
1 Wo p.i.
2. Woche
2.-3. Woche
4. Woche
4.-5. Woche
6. Woche
6.-7. Woche
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PET, Kidney, Saliva PSMA-Studie
Prostatakarzinom NCT0000001
Quelle:
PSMA-Studie Prostatakarzinom
PD Dr. med. Kambiz Rahbar
UKM, Nuklearmedizin
Teil: PET, Niere, Speichel
All rights reserved. Please visit https://medical-data-
models.org/forms/16405
PET, Niere, Speichel  PSMA-Studie
Prostatakarzinom NCT0000001
Identification
Name
Termin 1
PET vor
PET nach
Niere vor
Niere nach
Zyklus 2
PET nach
Niere nach
Zyklus 3
PET nach
Niere nach
Zyklus 4
PET nach
Niere nach
Zyklus 5
PET nach
Niere nach
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Zyklus 6
PET nach
Niere nach
Zyklus 7
PET nach
Niere nach
Zyklus 8
PET nach
Niere nach
Saliva
Saliva 2
Saliva 2
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PET, Kidney, Saliva PSMA-Studie Prostatakarzinom NCT0000001
PET, Kidney, Saliva PSMA-Studie
Prostatakarzinom NCT0000001
Quelle:
PSMA-Studie Prostatakarzinom
PD Dr. med. Kambiz Rahbar
UKM, Nuklearmedizin
Teil: PET, Niere, Speichel
All rights reserved. Please visit https://medical-data-
models.org/forms/16407
PET, Niere, Speichel  PSMA-Studie
Prostatakarzinom NCT0000001
Identification
Name
Termin 1
PET vor
PET nach
Niere vor
Niere nach
Zyklus 2
PET nach
Niere nach
Zyklus 3
PET nach
Niere nach
Zyklus 4
PET nach
Niere nach
Zyklus 5
PET nach
Niere nach
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Zyklus 6
PET nach
Niere nach
Zyklus 7
PET nach
Niere nach
Zyklus 8
PET nach
Niere nach
Saliva
Speicheld 1
Speicheld 2
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PET, Kidney, Saliva PSMA-Studie Prostatakarzinom NCT0000001
Ministry of Health, Ethiopia- Child Growth
Monitoring Register
Form provided by Binyam Tilahun. Source:
http://www.moh.gov.et/ (Ministry of Health, Ethiopia)
All rights reserved. Please visit https://medical-data-
models.org/forms/16408
Child Growth Monitoring Register
Facility information
Region where the facility is located
Address:Woreda/Sub-City
If Health post, write the name of the kebele
where the health post is located
Name of health facility
Register Start date
Register End date
Personal information
Serial number
Childs Medical record number
Registration date
Name of Infant
Date of Birth
Sex of Child
Male (1)
Female (2)
Name of mother
Medical Record Number of mother
Address:Woreda
Address: Kebele
Address:Katena/Gott
1 / 2
Patient address: House number
Growth monitoring and services
Date of weight recording
Body weight
kg
Percent WFA
Vitamin A
Yes
No
Albendazole
Yes
No
Action/Treatment
Remarks
Appointment
Total count
Count of weight percentage >=80 percent WFA
Count of weight percentage >=60 percent WFA
Count of weight percentage <60 percent WFA
Total number of weights recorded
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Ministry of Health, Ethiopia- Child Growth Monitoring Register
Ministry of Health, Ethiopia- Health Post
Family Planning Register
Form provided by Binyam Tilahun. Source:
http://www.moh.gov.et/ (Ministry of Health, Ethiopia)
All rights reserved. Please visit https://medical-data-
models.org/forms/16409
Health Post Family Planning Register
Facility information
Region where the facility is located
Address:Woreda/Sub-City
If Health post, write the name of the kebele
where the health post is located
Name of health facility
Register Start date
Register End date
Personal information
Serial number
Name of client
Age
Sex
Male (1)
Female (2)
Address:Woreda
Address: Kebele
Address:Ketena/Gott
Family Planning and Contraceptive
Services
Registration date
New acceptor at registration
Yes
No
Repeat acceptor at registration
1 / 3
Yes
No
Family planning counseling
Yes
No
STD counseling
Yes
No
HIV counseling
Yes
No
Referral for STD testing
Yes
No
Referral for HIV testing
Yes
No
TT vaccination status checked
Yes
No
Visit number
Visit Date
Last menstrual period
Blood pressure
mmHg
Body weight
kg
Contraceptive selected
Emergency Contraception (EC)
Female Condom (FeC)
Injectable (Inj)
Male Condom (MaC)
Oral Contraceptive (OC)
Reason for method switch
Developed illness and disease (Ill)
Potential interaction with newly initiated
treatment ingredient (Int)
Unavailability of the method (MethUn)
Other (Oth)
Desire being pregnant (Preg)
Unwanted side effects (S/E)
Risk of STI exposure (STI)
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Remarks
Appointment
Total count
Count new acceptors
Count repeat acceptors
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Eligibility Breast Cancer NCT00582803
Adherence to Intensive Surveillance for Hereditary Breast
Cancer; ODM derived from:
https://clinicaltrials.gov/show/NCT00582803
All rights reserved. Please visit https://medical-data-
models.org/forms/16410
Eligibility Breast Cancer
NCT00582803
Inclusion Criteria
female*
Yes
No
age 25 years or greater*
Yes
No
genetic predisposition as defined by one of the
following:*
Yes
No
known brca1 or brca2 mutation (deleterious or
uncertain significance) or*
Yes
No
untested first-degree relative of an individual with
a known deleterious brca mutation or*
Yes
No
unaffected first-degree relative of an affected
individual within a hereditary breast-ovarian
kindred in which no testing has been performed
or testing is negative, defined as: 3 or more
women in 2 generations affected with breast or
ovarian cancer. women with bilateral breast
cancer and woman with both breast and ovarian
cancer count as single individual and 1 woman
must be first-degree relative of the other two, or
related to the other two through a male and at
least 1 woman affected with breast cancer before
age 50 or ovarian cancer at any age*
Yes
No
able to understand and complete english-
language questionnaires*
Yes
No
intend to receive clinical and radiographic follow-
up at mskcc*
Yes
No
women will not be excluded if they have
previously received clinical and radiographic
follow-up at either mskcc or another institution.*
1 / 2
Yes
No
Exclusion Criteria
prior history of breast or ovarian cancer*
Yes
No
contraindication to breast mri examination (e.g.
aneurysm clips, pacemaker, cochlear implant,
severe claustrophobia, weight over 300 pounds)
or to paramagnetic contrast (prior ige-type
allergic reaction, sickle cell anemia, renal failure)*
Yes
No
pregnant or planning to begin attempts at
conception within 1 year of enrollment. a negative
serum β-hcg will not be required for study entry,
nor for radiographic examination, as this test is
not routinely performed before clinically indicated
radiographic study.*
Yes
No
unable for physical, psychological, or financial
reasons to receive clinical and radiographic
follow-up at mskcc*
Yes
No
concurrent medical or psychological conditions
that, in the opinion of the attending physician or
principal investigator, would place the subject at
risk were she to participate*
Yes
No
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Years 4-6 Seated Blood Pressure
Cardiovascular Health Study (CHS)
Documentation part: Record 14 Years 4-6 Seated Blood
Pressure
The Cardiovascular Health Study (CHS) was initiated by
the National Heart, Lung and Blood Institute (NHLBI) in
1987 to determine the risk factors for development and
progression of cardiovascular disease (CVD) in older
adults, with an emphasis on subclinical measures. The
study recruited 5,888 adults aged 65 or older at entry in
four U.S. communities and conducted extensive annual
clinical exams between 1989-1999 along with semi-annual
phone calls, events adjudication, and subsequent data
analyses and publications. Additional data were collected
by studies ancillary to CHS. With the exception of annual
clinic visits, these activities are still ongoing.
Data obtained from: https://chs-nhlbi.org/
Permission granted by: Erika Enright.
All rights reserved. Please visit https://medical-data-
models.org/forms/16411
Years 4-6 Seated Blood Pressure
Cardiovascular Health Study (CHS)
Second follow-up seated blood pressure
and heart rate measurement
1. Time of day:
2. Hours since last meal:
3. Cuff size:
regular (1)
large arm (2)
thigh (3)
pediatric (4)
Pulse Obliteration Pressure
4. Palpated systolic:
5. Maximal inflation level: (palpated systolic +
maximum zero level +30)
Seated Readings
6. Beats in 30 seconds:
Blood Pressure
7. First reading: systolic
7. First reading: diastolic
8. Second reading: systolic
8. Second reading: diastolic
1 / 2
9. Standard seated blood pressure: systolic
9. Standard seated blood pressure: diastolic
Date of interview
Interviewer
Interview:
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Years 4-6 Seated Blood Pressure Cardiovascular Health Study (CHS)
Ministry of Health, Ethiopia- Family
Planning Register
Form provided by Binyam Tilahun. Source:
http://www.moh.gov.et/ (Ministry of Health, Ethiopia)
All rights reserved. Please visit https://medical-data-
models.org/forms/16415
Family Planning Register
Facility information
Region where the facility is located
Address:Woreda/Sub-City
If Health post, write the name of the kebele
where the health post is located
Name of health facility
Register Start date
Register End date
Personal information
Serial number
Sex
Male (1)
Female (2)
Medical Record Number
Family Planning and Contraceptive
Services
Registration date
New acceptor at registration
Yes
No
Repeat acceptor at registration
Yes
No
HIV testing offered
Yes
No
HIV Test performed
Yes
No
1 / 2
HIV Test result
R (1)
NR (2)
I (3)
HIV counseling and methods offered
Yes
No
TT vaccination status checked
Yes
No
Contraindication for hormonal method
Yes
No
Contraindication for IUD
Yes
No
Contraceptive methods permanent
Tubal ligation (1)
Vasectomy (2)
Visit number
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
Visit Date
Contraceptive selected
Diaphragm (Diaph)
Emergency Contraception (EC)
Female Condom (FeC)
Implant (Imp)
Injectable (Inj)
Intrauterine Contraceptive Device (IUCD)
Male Condom (MaC)
Oral Contraceptive (OC)
Remarks
Appointment
Total count
Count new acceptors
Count repeat acceptors
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Ministry of Health, Ethiopia- Family Planning Register
Eligibility Breast Cancer NCT00588003
Gene Expression Following Short Term Exposure to
Neoadjuvant Endocrine Therapy in Invasive Breast Cancer;
ODM derived from:
https://clinicaltrials.gov/show/NCT00588003
All rights reserved. Please visit https://medical-data-
models.org/forms/16416
Eligibility Breast Cancer
NCT00588003
Inclusion Criteria
postmenopausal patients, defined as one or more
of the following criteria:*
Yes
No
documented history of bilateral oophorectomy,
aged 60 years or more,*
Yes
No
aged 45-59 years and satisfying one or more of
the following criteria:*
Yes
No
amenorrhea for at least 12 months and intact
uterus amenorrhea for less than 12 months and
follicle stimulating hormone (fsh) concentrations
within postmenopausal range including: patients
who have had a hysterectomy and patients who
have received hormone replacement therapy in
the past.*
Yes
No
clinically palpable or non-palpable t1c or greater,
er positive invasive breast cancer diagnosed by
outside core biopsy.*
Yes
No
outside diagnosis of invasive breast cancer
confirmed at mskcc*
Yes
No
palpable or non-palpable breast mass > 1cm
highly suspicious for invasive breast cancer
based on mammographic, ultrasound and/or
physical examination findings and amenable to
diagnostic core biopsy.*
Yes
No
core biopsy diagnosis of er positive invasive
breast cancer performed at mskcc*
Yes
No
breast conserving surgery or mastectomy
scheduled at mskcc.*
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Yes
No
informed consent obtained.*
Yes
No
Exclusion Criteria
co-morbid conditions which would preclude use
of aromatase inhibitors such as: previous
hypersensitivity, severe hepatic insufficiency (sgot
or sgpt three times the upper limit of normal),
severe renal insufficiency (creatinine clearance
<10ml/min).*
Yes
No
prior radiation therapy to chest wall / breast.*
Yes
No
neoadjuvant chemotherapy*
Yes
No
hormone replacement therapy, tamoxifen or
raloxifene treatment within past 3 months*
Yes
No
er negative breast cancer*
Yes
No
history of active malignancy within the previous 5
years (except for nonmelanoma skin cancer and
breast cancer)*
Yes
No
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Ministry of Health, Ethiopia- ART-Regimen
and Enrollment Tally
Form provided by Binyam Tilahun. Source:
http://www.moh.gov.et/ (Ministry of Health, Ethiopia)
All rights reserved. Please visit https://medical-data-
models.org/forms/16417
ART-Regimen and Enrollment Tally
Facility information
Month
Year
Address:Woreda
Facility name
Monthly tally of regimen
Count of first line regimen 1a(30)=d4t(30)-3TC-
NVP
Count of first line regimen 1a(40)=d4t(40)-3TC-
NVP
Count of first line regimen 1b(30)=d4t(30)-3TC-
EFV
Count of first line regimen 1b(40)=d4t(40)-3TC-
EFV
Count of first line regimen 1c=AZT-3TC-NVP
Count of first line regimen 1d=AZT-3TC-EFV
Count of childrens first line regimen 4a=d4T-3TC-
NVP
Count of childrens first line regimen 4b=d4T-3TC-
EFV
Count of childrens first line regimen 4c=AZT-
3TC-NVP
Count of childrens first line regimen 4d=AZT-
3TC-EFV
Count of second line regimen 2a=ABC-ddl-LPV/R
Count of second line regimen 2b=ABC+ddl-NFV
1 / 3
Count of second line regimen 2c=TDF-ddl-LPV/R
Count of second line regimen 2d=TDF-ddl-NFV
Count of childrens second line regimen 5a=ABC-
ddl-LPV/R
Count of childrens second line regimen
5b=ABC+ddl-NFV
Count of childrens second line regimen 5c=TDF-
ddl-LPV/R
Count of childrens second line regimen 5d=TDF-
ddl-NFV
Month of count
1 (1)
10 (10)
11 (11)
12 (12)
13 (13)
14 (14)
15 (15)
16 (16)
17 (17)
18 (18)
19 (19)
2 (2)
20 (20)
21 (21)
22 (22)
23 (23)
24 (24)
25 (25)
26 (26)
27 (27)
28 (28)
29 (29)
3 (3)
30 (30)
31 (31)
32 (32)
33 (33)
34 (34)
35 (35)
36 (36)
4 (4)
5 (5)
6 (6)
7 (7)
8 (8)
9 (9)
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Art Enrollment Tally
Count Enrollment of Infants < 18 months
Count Enrollment of Children 19-59 months
Count Enrollment of Children 5-14 years
Count Enrollment of Non-pregnant females > 14
years
Count Enrollment of Pregnant females
Count Enrollment of Males > 14 years
Total Count of enrollments previous month
Total Count of enrollments current month
Pre-ART (HIV Care) Enrollment Tally
Count Enrollment of Infants < 18 months
Count Enrollment of Children 19-59 months
Count Enrollment of Children 5-14 years
Count Enrollment of Non-pregnant females > 14
years
Count Enrollment of Pregnant females
Count Enrollment of Males > 14 years
Total Count of enrollments previous month
Total Count of enrollments current month
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Ministry of Health, Ethiopia- ART-Register
Form provided by Binyam Tilahun. Source:
http://www.moh.gov.et/ (Ministry of Health, Ethiopia)
All rights reserved. Please visit https://medical-data-
models.org/forms/16418
ART-Register
ART-Register (1)
Month
Year
ART Start date
Unique ART Number adults
Why Eligible?
Clinical only (1)
CD4 (2)
TLC (3)
Transfer In (TI) Where ART started (4)
Medical Record Number
Name
Name of father
Name of grandfather
Sex
Male (1)
Female (2)
Age
Functional status
Ambulatory (1)
Bedridden (2)
Working (3)
Weight
Child Height/Length
cm
WHO clinical stage
CD4
Screening for TB
Yes
No
1 / 10
Active TB Diagnosis
Yes
No
Start date TB Treatment
End date TB Treatment
INH Prophylaxis
CTX Start date
CTX End date
Antenatal care registration number
Estimated date of delivery
1rst line Regimen adult
d4t(30)-3TC-NVP (1a(30))
d4t(40)-3TC-NVP (1a(40))
d4t(30)-3TC-EFY (1b(30))
d4t(40)-3TC-EFV (1b(40))
AZT-3TC-NVP (1c)
AZT-3TC-EFV (1d)
1rst line Regimen children
d4t-3TC-NVP (4a)
d4t-3TC-EFV (4b)
AZT-3TC-NVP (4c)
AZT-3TC-EFV (4d)
Regimen change in first line regimen for adults
d4t(30)-3TC-NVP (1a(30))
d4t(40)-3TC-NVP (1a(40))
d4t(30)-3TC-EFY (1b(30))
d4t(40)-3TC-EFV (1b(40))
AZT-3TC-NVP (1c)
AZT-3TC-EFV (1d)
Regimen change in first line regimen for children
d4t-3TC-NVP (4a)
d4t-3TC-EFV (4b)
AZT-3TC-NVP (4c)
AZT-3TC-EFV (4d)
Reason for regimen change
Toxicity/side effects (1)
Pregnancy (2)
Risk of pregnancy (3)
Due to new TB (4)
New drug available (5)
Drug out of stock (6)
Other reason (specify) (7)
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Specify other reason for regimen change
Date of regimen change
2nd line Regimen adult
ABC-ddl-LPV/R (2a)
ABC+ddl-NFV (2b)
TDF-ddl-LPV/R (2c)
TDF-ddl-NFV (2d)
2nd line Regimen children
ABC-ddl-LPV/R (5a)
ABC+ddl-NFV (5b)
TDF-ddl-LPV/R (5c)
TDF-ddl-NFV (5d)
Regimen change in second line regimen for
children
ABC-ddl-LPV/R (5a)
ABC+ddl-NFV (5b)
TDF-ddl-LPV/R (5c)
TDF-ddl-NFV (5d)
Regimen change in second line regimen for
adults
ABC-ddl-LPV/R (2a)
ABC+ddl-NFV (2b)
TDF-ddl-LPV/R (2c)
TDF-ddl-NFV (2d)
Reason for regimen change
Toxicity/side effects (1)
Pregnancy (2)
Risk of pregnancy (3)
Due to new TB (4)
New drug available (5)
Drug out of stock (6)
Other reason (specify) (7)
Specify other reason for regimen change
Date of regimen change
Total count of Infants < 18 months
Total count of children 19-59 months
Total count of children 5-14 years
Total count of non-pregnant females >14
Total count of pregnant females
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Total count of males > 14 years
Art Register (2)
Month
month 0 (Regimen start) (1)
month 1 (2)
month 2 (3)
month 3 (4)
month 4 (5)
month 5 (6)
month 6 (7)
Name of month the regimen was started
Year the regimen was started
Regimen collected by adult patient
d4t(30)-3TC-NVP (1a(30))
d4t(40)-3TC-NVP (1a(40))
d4t(30)-3TC-EFY (1b(30))
d4t(40)-3TC-EFV (1b(40))
AZT-3TC-NVP (1c)
AZT-3TC-EFV (1d)
ABC-ddl-LPV/R (2a)
ABC+ddl-NFV (2b)
TDF-ddl-LPV/R (2c)
TDF-ddl-NFV (2d)
Regimen collected by young patient (children and
infant)
d4t-3TC-NVP (4a)
d4t-3TC-EFV (4b)
AZT-3TC-NVP (4c)
AZT-3TC-EFV (4d)
ABC-ddl-LPV/R (5a)
ABC+ddl-NFV (5b)
TDF-ddl-LPV/R (5c)
TDF-ddl-NFV (5d)
Functional status after 6 months of treatment
Ambulatory (1)
Bedridden (2)
Working (3)
Weight after 6 months of treatment
kg
Height after 6 months of treatment
cm
CD4 count after 6 months of treatment. If patient
is a child, CD4 percentage
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Reason for leaving treatment
Facility has been notified that the patient
has died (DEAD)
Patient missed an appointment and did
not pick up medication for at least one
month (LOST)
Patient and doctor agreed to stop
treatment (STOP)
transferred out (specify transfer to:) (TO)
Month patient left treatment
0 (1)
1 (2)
2 (3)
3 (4)
4 (5)
5 (6)
6 (7)
Month
month 7  (1)
month 8 (2)
month 9 (3)
month 10 (4)
month 11 (5)
month 12 (6)
Name of month
Regimen collected by adult patient
d4t(30)-3TC-NVP (1a(30))
d4t(40)-3TC-NVP (1a(40))
d4t(30)-3TC-EFY (1b(30))
d4t(40)-3TC-EFV (1b(40))
AZT-3TC-NVP (1c)
AZT-3TC-EFV (1d)
ABC-ddl-LPV/R (2a)
ABC+ddl-NFV (2b)
TDF-ddl-LPV/R (2c)
TDF-ddl-NFV (2d)
Regimen collected by young patient (children and
infant)
d4t-3TC-NVP (4a)
d4t-3TC-EFV (4b)
AZT-3TC-NVP (4c)
AZT-3TC-EFV (4d)
ABC-ddl-LPV/R (5a)
ABC+ddl-NFV (5b)
TDF-ddl-LPV/R (5c)
TDF-ddl-NFV (5d)
Functional status after 12 months of treatment
Ambulatory (1)
Bedridden (2)
Working (3)
Weight after 12 months of treatment
kg
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Height after 12 months of treatment
cm
CD4 count after 12 months of treatment. If patient
is a child, CD4 percentage
Reason for leaving treatment
Facility has been notified that the patient
has died (DEAD)
Patient missed an appointment and did
not pick up medication for at least one
month (LOST)
Patient and doctor agreed to stop
treatment (STOP)
transferred out (specify transfer to:) (TO)
Month patient left treatment
7 (1)
8 (2)
9 (3)
10 (4)
11 (5)
12 (6)
Year
Month
month 13 (1)
month 22 (10)
month 23 (11)
month 24 (12)
month 14 (2)
month 15 (3)
month 16 (4)
month 17 (5)
month 18 (6)
month 19 (7)
month 20 (8)
month 21 (9)
Name of month
Regimen collected by adult patient
d4t(30)-3TC-NVP (1a(30))
d4t(40)-3TC-NVP (1a(40))
d4t(30)-3TC-EFY (1b(30))
d4t(40)-3TC-EFV (1b(40))
AZT-3TC-NVP (1c)
AZT-3TC-EFV (1d)
ABC-ddl-LPV/R (2a)
ABC+ddl-NFV (2b)
TDF-ddl-LPV/R (2c)
TDF-ddl-NFV (2d)
Regimen collected by young patient (children and
infant)
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d4t-3TC-NVP (4a)
d4t-3TC-EFV (4b)
AZT-3TC-NVP (4c)
AZT-3TC-EFV (4d)
ABC-ddl-LPV/R (5a)
ABC+ddl-NFV (5b)
TDF-ddl-LPV/R (5c)
TDF-ddl-NFV (5d)
Functional status after 24 months of treatment
Ambulatory (1)
Bedridden (2)
Working (3)
Weight after 24 months of treatment
kg
Height after 24 months of treatment
cm
CD4 count after 24 months of treatment. If patient
is a child, CD4 percentage
Reason for leaving treatment
Facility has been notified that the patient
has died (DEAD)
Patient missed an appointment and did
not pick up medication for at least one
month (LOST)
Patient and doctor agreed to stop
treatment (STOP)
transferred out (specify transfer to:) (TO)
Month patient left treatment
13 (1)
22 (10)
23 (11)
24 (12)
14 (2)
15 (3)
16 (4)
17 (5)
18 (6)
19 (7)
20 (8)
21 (9)
Year
Month
25 (1)
34 (10)
35 (11)
36 (12)
26 (2)
27 (3)
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28 (4)
29 (5)
30 (6)
31 (7)
32 (8)
33 (9)
Name of month
Regimen collected by adult patient
d4t(30)-3TC-NVP (1a(30))
d4t(40)-3TC-NVP (1a(40))
d4t(30)-3TC-EFY (1b(30))
d4t(40)-3TC-EFV (1b(40))
AZT-3TC-NVP (1c)
AZT-3TC-EFV (1d)
ABC-ddl-LPV/R (2a)
ABC+ddl-NFV (2b)
TDF-ddl-LPV/R (2c)
TDF-ddl-NFV (2d)
Regimen collected by young patient (children and
infant)
d4t-3TC-NVP (4a)
d4t-3TC-EFV (4b)
AZT-3TC-NVP (4c)
AZT-3TC-EFV (4d)
ABC-ddl-LPV/R (5a)
ABC+ddl-NFV (5b)
TDF-ddl-LPV/R (5c)
TDF-ddl-NFV (5d)
Functional status after 36 months of treatment
Ambulatory (1)
Bedridden (2)
Working (3)
Weight after 36 months of treatment
kg
Height after 36 months of treatment
cm
CD4 count after 36 months of treatment. If patient
is a child, CD4 percentage
Reason for leaving treatment
Facility has been notified that the patient
has died (DEAD)
Patient missed an appointment and did
not pick up medication for at least one
month (LOST)
Patient and doctor agreed to stop
treatment (STOP)
transferred out (specify transfer to:) (TO)
Month patient left treatment
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25 (1)
34 (10)
35 (11)
36 (12)
26 (2)
27 (3)
28 (4)
29 (5)
30 (6)
31 (7)
32 (8)
33 (9)
Monthly tally of regimen
Count of first line regimen 1a(30)
Count of first line regimen 1a(40)
Count of first line regimen 1b(30)
Count of first line regimen 1b(40)
Count of first line regimen 1c
Count of first line regimen 1d
Count of childrens first line regimen 4a
Count of childrens first line regimen 4b
Count of childrens first line regimen 4c
Count of childrens first line regimen 4d
Count of second line regimen 2a
Count of second line regimen 2b
Count of second line regimen 2c
Count of second line regimen 2d
Count of childrens second line regimen 5a
Count of childrens second line regimen 5b
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Count of childrens second line regimen 5c
Count of childrens second line regimen 5d
Month of count
1 (1)
10 (10)
11 (11)
12 (12)
13 (13)
14 (14)
15 (15)
16 (16)
17 (17)
18 (18)
19 (19)
2 (2)
20 (20)
21 (21)
22 (22)
23 (23)
24 (24)
25 (25)
26 (26)
27 (27)
28 (28)
29 (29)
3 (3)
30 (30)
31 (31)
32 (32)
33 (33)
34 (34)
35 (35)
36 (36)
4 (4)
5 (5)
6 (6)
7 (7)
8 (8)
9 (9)
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Ministry of Health, Ethiopia- PreART
Register
Form provided by Binyam Tilahun. Source:
http://www.moh.gov.et/ (Ministry of Health, Ethiopia)
All rights reserved. Please visit https://medical-data-
models.org/forms/16419
PreART Register
PreArt-Register
Month
Year
Date of Enrollment in Chronic HIV Care
Medical Record Number
Name
Name of father
Name of grandfather
Sex
Male (1)
Female (2)
Age
Address:Woreda
Address: Kebele
Address: House number
HIV Seropositivity confirmed
Screening for TB
Yes
No
Active TB Diagnosis
Yes
No
Start date TB Treatment
End date TB Treatment
INH Prophylaxis
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CTX Start date
CTX End date
Antenatal care registration number
Estimated date of delivery
Date removed
Reason for leaving treatment
Facility has been notified that the patient
has died (DEAD)
Patient and doctor agreed to stop
treatment (STOP)
transferred out  (TO)
Why Eligible?
Clinical only (1)
CD4 (2)
TLC (3)
Transfer In (TI) Where ART started (4)
Please enter the date when patient is medically
eligible
Please enter the date when patient is medically
eligible and ready (counseled for adherence) for
ART
ART Start date
Unique ART Number adults
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Eligibility Breast Cancer NCT00591851
Phase II Study of Dose-Dense Doxurubicin and
Cyclophosphamide (AC) Followed By Paclitaxel With
Trastuzumab in HER2/ NEU-Amplified Breast Cancer:
Feasibility; ODM derived from:
https://clinicaltrials.gov/show/NCT00591851
All rights reserved. Please visit https://medical-data-
models.org/forms/16420
Eligibility Breast Cancer
NCT00591851
Inclusion Criteria
adenocarcinoma breast cancer*
Yes
No
ecog performance status of 0 or 1*
Yes
No
peripheral neuropathy less than or equal to  1*
Yes
No
discontinued hormonal therapy as a
chemoprevention while onstudy*
Yes
No
lvef by muga > 55%?*
Yes
No
absolute neutrophil count (anc)> 1000/µl)*
Yes
No
platelet count > 100,000/µl)*
Yes
No
sgot or sgpt < 92.5 units/l*
Yes
No
Exclusion Criteria
stage iv breast cancer*
Yes
No
any chemotherapy, radiation therapy,
immunotherapy, or biotherapy for a current breast
cancer*
Yes
No
pregnant or lactating patients*
Yes
No
active second malignancy, other than adequately
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treated non-melanoma skin cancers or in situ
cervical cancer*
Yes
No
previous allergy/hypersensitivity to doxorubicin,
cyclophosphamide, paclitaxel, or other drugs
formulated in cremophor el?*
Yes
No
unstable angina, congestive heart failure, current
use of digitalis, beta-blockers, or calcium blockers
for therapy of congestive heart failure, arrhythmia
requiring medical therapy, or a history of a
myocardial infarction within 12 months*
Yes
No
psychiatric illness that prevents her from
understanding the nature of this study and
complying with protocol requirements?*
Yes
No
active, unresolved infections*
Yes
No
sensitivity to e. coli derived proteins*
Yes
No
prior chemotherapy with an anthracycline*
Yes
No
prior herceptin therapy*
Yes
No
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Eligibility Breast Cancer NCT00615602
Six vs 12 Months of Trastuzumab With Docetaxel Following
FEC as Adjuvant Treatment in N+ Breast Cancer; ODM
derived from: https://clinicaltrials.gov/show/NCT00615602
All rights reserved. Please visit https://medical-data-
models.org/forms/16421
Eligibility Breast Cancer
NCT00615602
Inclusion Criteria
women with histologically-confirmed unilateral
invasive ductal or lobular breast
adenocarcinoma*
Yes
No
her2/c-neu over expression should be
documented by either immunohistochemistry
(score 3+) or fish/cish positivity. a score of 2+ by
immunohistochemistry is acceptable only if
fish/cish positive*
Yes
No
within 60 days after the surgical excision of the
primary tumor with tumor-free operation margins;
at least 10 axillary lymph nodes have to be
removed.*
Yes
No
tumor involvement of at least one axillary lymph
node (n0 with her2/c-neu over expression are
also eligible)*
Yes
No
absence of any clinical or radiological evidence of
local or metastatic disease*
Yes
No
premenopausal or postmenopausal women aged
18-75 years old*
Yes
No
adequate bone marrow function (absolute
neutrophil count >1500/mm3, platelet count
>100.000/mm3, hemoglobin >10gr/mm3)*
Yes
No
adequate liver (bilirubin <1.0 times upper limit of
normal and sgot/sgpt <2.5 times upper limit of
normal) and renal function (creatinine
<1.5mg/dl)*
Yes
No
adequate cardiac function (lvef>50%). normal
electrocardiogram and absence of significant
1 / 2
heart disease*
Yes
No
written informed consent*
Yes
No
Exclusion Criteria
positive pregnancy test.*
Yes
No
psychiatric illness or social situation that would
preclude study compliance.*
Yes
No
other concurrent uncontrolled illness.*
Yes
No
prior or concurrent antineoplastic therapy e.g.
hormonal therapy, radiation therapy,
chemotherapy, biological agents.*
Yes
No
previous history of other invasive malignancy
other than non-melanomatous skin cancer.*
Yes
No
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Physician letter surgery
derived from http://www.arztbriefmanager.de/ 
(Dr. Wolfram Arends, Tutzing, Germany)
All rights reserved. Please visit https://medical-data-
models.org/forms/16422
Physician letter surgery
Anamnese
Einweisung
Die stationäre Einweisung erfolgte durch
den Hausarzt. (HA)
Die stationäre Einweisung erfolgte durch
den Notarzt. (NAW)
Die stationäre Einweisung erfolgte durch
den NFD. (NFD)
Die stationäre Einweisung erfolgte durch
den Rettungsdienst. (RTW)
Die stationäre Aufnahme erfolgte nach
Rückverlegung nach Durchführung einer
PTCA. (Rückverlegung nach PTCA)
Der Patient stellte sich selbst in unserer
Ambulanz vor. (selbst)
Beschwerden seit dem
Aufnahmegrund
Vorgeschichte bekannt
Ja
Nein
Vorgeschichte siehe Unterlagen
Ja
Nein
Exsikkose, Keine Nahrung und Flüssigkeit in den
letzten 24 h
Ja
Nein
Synkope Schädelprellung Abklärung Chirurgie,
dann Verlegung Innere
Ja
Nein
thorakale Beschwerden
Ja
Nein
Rückenbeschwerden
Ja
Nein
Orthopnoe
Ja
Nein
Dyspnoe
Ja
Nein
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Übelkeit
Ja
Nein
Erbrechen
Ja
Nein
Kolik
Ja
Nein
abd. Beschw.
Ja
Nein
Bluterbrechen
Ja
Nein
Diarrhoe
Ja
Nein
Diarrhoe über 10 Stühle/d
Ja
Nein
Obstipation
Ja
Nein
Koterbrechen
Ja
Nein
Anurie
Ja
Nein
Befund
Alter
Exsikkosezeichen
Ja
Nein
Fieber über 38°C
Ja
Nein
Zeichen der Herzinsuffizienz
(Unterschenkelödeme)
Ja
Nein
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RR
Herzfrequenz
/min
Pulmo o. p. Befund
Ja
Nein
Atemgeräusch
O2%
%
Abdomen Normalbefund
Ja
Nein
Abdomen Befund
Normalbefund in der körperlichen Untersuchung
Ja
Nein
Neuro Normalbefund
Ja
Nein
DMS intakt
Ja
Nein
Klinisches Bild
Die stationäre Aufnahme erfolgte unter dem
klinischen Bild eines/er
Phlegmone
Ja
Nein
Metallentfernung (ME)
Ja
Nein
Schädelprellung
Ja
Nein
HWS Distorsion und Schädelprellung
Ja
Nein
SD Resektion
3 / 15
Physician letter surgery
Ja
Nein
Pneumothorax
Ja
Nein
Thoraxprellung
Ja
Nein
Sinus Pilonidalis
Ja
Nein
Scrotalhernie
Ja
Nein
Leistenhernie
Ja
Nein
Appendektomie
Ja
Nein
CHE
Ja
Nein
Colonresektion
Ja
Nein
C2 Intoxikation
Ja
Nein
Arthroskopie Schulter
Ja
Nein
Humeruskopffraktur
Ja
Nein
Unterarmfraktur Osteosynthese
Ja
Nein
Unterarmfraktur Fix. Externe
Ja
Nein
Rhizarthrose
Ja
Nein
Distale Radiusfraktur
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Ja
Nein
Totalendoprothese (TEP) der Hüfte
Ja
Nein
TEP Implantation bei Gonarthrose
Ja
Nein
Kreuzbandruptur
Ja
Nein
Exostose Tibia
Ja
Nein
Achillessehenruptur
Ja
Nein
Weber B Fraktur
Ja
Nein
Fraktur Oberes Sprunggelenk (OSG)
Ja
Nein
Initiale Therapie
Bilanzierte Flüssigkeit
Ja
Nein
Glukose 5%
Ja
Nein
Diuretika
Ja
Nein
Insulinperfusor
Ja
Nein
vorlastsenkende Medikation
Ja
Nein
PPI
Ja
Nein
Schmerztherapie / Schmerzmanagement
Ja
Nein
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Antivertiginosa
Ja
Nein
Heparinisierung
Ja
Nein
Antibiose ex iuvantibus
gezielte Antibiose
Gentamycin
Ja
Nein
intravenöse Flüssigkeitsgabe
Liter
Labor
Hämoglobin
mg/dl
Ferritin
ng/ml
Anämie
Ja
Nein
Leukozyten
/ul
Entzündungswerte
Erfreulicherweise zeigte sich ein
Rückgang der Entzündungsparameter.
(Entzündungsparameter besser)
Initial waren die Entzündungsparameter
deutlich erhöht. (Entzündungswerte
erhöht)
CRP
md/dl
CRP erhöht unter Kortison
Ja
Nein
Kreatinin
mg/dL
Kreatinin
Die anfangs vermehrt retinierten
harnpflichtigen Substanzen bei
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Niereninsuffizienz bildeten sich zurück.
(Kreatinin bei Niereninsuffizienz
rückläufig)
Die anfangs vermehrt retinierten
harnpflichtigen Substanzen bildeten sich
zum Entlassungszeitraum zurück.
(Kreatinin rückläufig)
Die anfangs vermehrt retinierten
harnpflichtigen Substanzen bildeten sich
unter Diuretika-Gabe zurück. (Kreatinin
unter Diuretika rückläufig)
Alkohol
p.p.m.
D-Dimer erhöht
Ja
Nein
Herzinfarkt Troponin I
CK
U/l
CKMB
U/l
Ausschluss Herzinfarkt
Ja
Nein
Haemoccult
Der HC-Test war mehrfach positiv. (HC
Test mehrfach positiv)
Der Haemoccult-Test war zu jedem
Zeitpunkt negativ. (HC Test war
mehrfach negativ)
Stuhlkultur
Die bakterielle Untersuchung auf
darmpathogene Keime ergab keinen
pathologischen Befund. (Stuhlkultur
negativ)
Die Untersuchung auf darmpathogene
Keime zeigte einen positiven Befund.
(Stuhlkultur positiv)
stauungsbedingte Leberzirrhose
Ja
Nein
alkoholische Leberzirrhose
Ja
Nein
Unter Substitution stieg der Kalium Wert an auf
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mmol/l
Psychiatrie
Verlegung in psychiatrische Klinik empfohlen
Ja
Nein
Tranxilium
Ja
Nein
Der Patient drohte mit körperlicher Gewalt.
Ja
Nein
Keine Entzugssymptomatik
Ja
Nein
Patient psychotisch
Ja
Nein
Patient im Verlauf psychisch unauffällig
Ja
Nein
starke Entzugssymptomatik
Ja
Nein
Patient verweigert Maßnahmen
Ja
Nein
Langzeittherapie
Ja
Nein
Verhaltenstherapie
Ja
Nein
Epikrise
Verschlechterung von Cor und Pulmo
Ja
Nein
Patient komatös
Ja
Nein
Todesdatum
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Todesursache
Patientenverfügung
Es wurde in der Patientenverfügung
auch der Verzicht auf
intensivmedizinische Maßnahmen
festgelegt. (Verzicht auf
intensivmedizinische Maßnahmen)
Es wurde in der Patientenverfügung
auch der Verzicht auf weitere
Reanimationsmaßnahmen festgelegt.
(Verzicht auf Reanimation)
Wir bedauern den unglücklichen Verlauf.
Ja
Nein
Konsil
Konsil Innere Medizin
Konsil Psychiatrie
Konsil HNO
Einweisung in Psychiatrie bei Suizidgefahr
Ja
Nein
Einweisung in Psychiatrie
Ja
Nein
Verlauf
Postoperativer Verlauf regelrecht
Ja
Nein
eingeschränkte Beweglichkeit
Ja
Nein
AZ gebessert
Ja
Nein
Röntgenbild der Lunge gebessert
Ja
Nein
Pulsoxymetrie gute Sättigung
Ja
Nein
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Stressulcusprophylaxe
Ja
Nein
Tetanus
Der Tetanusimpfschutz ist nicht mehr
ausreichend. Es wurde eine
Simultanimpfung durchgeführt. (Tetanus
Auffrischung)
Der Tetanusimpfschutz besteht nicht
mehr. Es wurde eine Auffrischimpfung
durchgeführt. (Tetanus Simultanimpfung)
Der Tetanusimpfschutz besteht
anamnestisch. Es erfolgt noch eine
Vorstellung in Ihrer hausärztlichen Praxis
zur Vorlage des Impfpasses.
(Tetanusschutz anamnestisch)
Thromboseprophylaxe
Ja
Nein
BZ Werte im Normbereich
Ja
Nein
Keine Besserung unter Antibiose
Ja
Nein
Besserung unter Antibiose
Ja
Nein
Entfiebert
Ja
Nein
Entzündungsparameter besser
Ja
Nein
Medikation
Die antibiotische Vorbehandlung wurde
in unveränderter Tagesrhythmik und
Dosierung fortgesetzt. (antibiotische
Vorbehandlung fortgesetzt)
Die bestehende Vormedikation aus
kardiologischer Sicht wurde in
unveränderter Dosierung beibehalten.
(Kardiologische Vormedikation hier
beibehalten)
Die vorbestehende Vormedikation wurde
hier fortgesetzt. (Vormedikation
fortgesetzt)
Auf folgende Medikation wurde verzichtet
Dauer parenterale Ernährung
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Tage
Kostaufbau komplikationslos
Ja
Nein
Kostaufbau gut, Verbesserung der Vigilanz bei
Fieberfreiheit
Ja
Nein
Mobilisation und Sozialdienst
Frühmobilistation
Ja
Nein
Hilfe bei ADLs wird benötigt
Ja
Nein
Mobilisation
Zuletzt war die Mobilisierung in
Begleitung der Physiotherapeutin im
Zimmer möglich. (Mobilisierung im
Zimmer)
Es konnte der Patient an
Unterarmgehstützen auf Zimmerebene
und dem Stationsflur und Treppe
mobilisiert werden. (Mobilisierung
Treppe)
Gegen Ende des Aufenthaltes konnte die
Mobilisierung mit fremder Unterstützung
und Supervision auf Stationsebene mit
Rollator erfolgen. (Stationsflur mit
Rollator)
Am Entlassungstag bestand eine
ausreichende Mobilisierung auf
Stationsflur und Treppe mit
Unterarmgehstützen.  (Stationsflur mit
Unterstützung)
Gangschule und Physikalische Medizin nach
Entlassung notwendig
Ja
Nein
Pflegestufe
Eine Pflegestufe wurde beantragt.
(beantragt)
Eine Pflegestufe 1 liegt vor. (Stufe 1)
Eine Pflegestufe 2 liegt vor. (Stufe 2)
Eine Pflegestufe 3 liegt vor. (Stufe 3)
Folgende Hilfsmittel wurden bestellt
Betreuung erfolgt durch Angehörige (Name Tel:).
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Es wurde eine gerichtliche Betreuung durch das
Amtsgericht beantragt.
Ja
Nein
Kontakt mit Gesundheitsamt zur Klärung
häusliche Lage
Ja
Nein
Langzeitbehandlung Anmeldung erfolgt
Ja
Nein
Rehabilitation
Eine stationäre geriatrische
Rehabilitationsbehandlung ist bereits
angemeldet worden. (Ger. Reha
angemeldet)
Eine stationäre kardiologische
Rehabilitationsbehandlung ist bereits
angemeldet worden. (Kardio Reha
angemeldet)
Eine stationäre neurologische
Rehabilitationsbehandlung ist bereits
angemeldet worden. (Neuro Reha
angemeldet)
Aufklärung und Entlassung
Aufklärung Angehörige
Die Angehörigen sind über die
Erkrankung die bereits erfolgte
Behandlung und noch weitere
Therapiemöglichkeiten von uns
eingehend aufgeklärt worden. (Info an
Angehörige über Diagnostik und
Therapie)
Wir standen während des stationären
Aufenthaltes in mehrfachem Kontakt mit
den Angehörigen. (Kontakt mit
Angehörigen erfolgt)
Procedere
Die Entlassung erfolgt vorzeitig auf
eigene Verantwortung entgegen
ärztlichen Rat. (Entlassung gegen
ärztlichen Rat)
Die Entlassung erfolgt vorzeitig auf
eigene Verantwortung entgegen
ärztlichen Rat in die Obhut der
Erziehungsberechtigten. (Entlassung
gegen ärztlichen Rat in Obhut
Erziehungsberechtigten)
Die Entlassung erfolgt in Ihre weitere
ambulante Betreuung. (Entlassung zum
Hausarzt)
Nach ausführlichem Gespräch mit den
Angehörigen wurde derzeit bei völliger
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Beschwerdefreiheit und in Anbetracht
der Aetas von einer weiteren invasiven
Diagnostik abgesehen. (keine invasive
Diagnostik bei Beschwerdefreiheit)
Bei Schwierigkeiten in der häuslichen
Versorgung erfolgte eine Verlegung zur
Kurzzeitpflege in das Pflegeheim.
(Kurzzeitpflege)
Bei Schwierigkeiten in der häuslichen
Versorgung erfolgte eine Verlegung in
das Pflegeheim. (Pflegeheim)
Wir haben während des stationären
Aufenthaltes den Angehörigen
angeboten, eine Verlegung in ein
entsprechendes Zentrum zu intensiveren
Maßnahmen zu veranlassen. Dies wurde
uns mehrfach mündlich wie schriftlich
abgelehnt. (Verlegung von Angehörigen
abgelehnt)
Die Verlegung wurde auch seitens des
Pat. abgelehnt. (Verlegung von Patient
abgelehnt)
Der Pat. wird sich im Anschluss an den
stationären Aufenthalt in Ihrer Praxis
vorstellen. (Vorstellung in Praxis nach
Entlassung)
Verlegung in andere Klinik:
Rückübernahme möglich
Ja
Nein
Verlegung in Psychiatrie mit Polizei
Ja
Nein
Rehabilitation
Zur weiteren geriatrischen Rehabilitation
erfolgte die Verlegung in Ihre Klinik.
(Geriatrische Reha)
Zur weiteren neurologischen
Rehabilitation erfolgte die Verlegung in
Ihre Klinik. (Neurologische Reha)
Zur weiteren orthopädischen
Rehabilitation erfolgte die Verlegung in
Ihre Klinik. (Orthopädische Reha)
Procedere
Thromboseprophylaxe bis Erreichen
physiologischen Gangbild
Ja
Nein
Wundkontrollen nach Entlassung
Ja
Nein
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Blutbildkontrolle
Ja
Nein
Elektrolyte
Ja
Nein
CRP
Ja
Nein
Krea
Ja
Nein
INR
Ja
Nein
regelmäßige BZ Kontrollen
Ja
Nein
wenn Coloskopie-Histo benigne dann wieder
Colo
Ja
Nein
Kapselendoskopie
Ja
Nein
erneute Gastro
Ja
Nein
Kontrolle LZ RR
Ja
Nein
Kontrolle LZ EKG
Ja
Nein
Vorstellung
Ambulante allergologische Vorstellung,
ggf. Desensibilisationstherapie
(Allergologie)
Wir empfehlen eine erneute ambulante
D-ärztliche Vorstellung (D-Arzt)
Dermatologische Vorstellung zur
Abklärung und Behandlung der
Hauteffloreszenz (Derma)
Gynäkologische Vorstellung zur weiteren
Behandlung (Gyn)
Wir empfehlen eine HNO ärztliche
Vorstellung (HNO)
kardiologische Vorstellung im Intervall
zur weiteren Kontrolle (Kardio)
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Zur weiteren diagnostischen Abklärung
sollte eine neurologische Vorstellung
erfolgen (Neuro)
Orthopädische Vorstellung zur weiteren
Behandlung (Ortho)
Eine urologische Vorstellung sollte noch
erfolgen (Uro)
Vorstellung in der ambulanten
chirurgischen Sprechstunde in unserer
Klinik (WV Chirurgie)
Antibiose weiter
Ja
Nein
TP 1,5 l/d
Ja
Nein
Actrapid nach Schema
Ja
Nein
Kortison reduzieren
Ja
Nein
Orales Kortison benutzen
Ja
Nein
täglich Gewichtskontrolle, ggf. Anpassung der
Diuretika.
Ja
Nein
Schmerzmedikation beibehalten
Ja
Nein
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Eligibility Breast Cancer NCT00656604
Evaluation of Patients With Breast Cancer Using DCE-MRI,
MRS, and Proteomics; ODM derived from:
https://clinicaltrials.gov/show/NCT00656604
All rights reserved. Please visit https://medical-data-
models.org/forms/16423
Eligibility Breast Cancer
NCT00656604
Criteria
meets 1 of the following criteria:*
Yes
No
women with breast tumors planning to undergo
surgical resection*
Yes
No
healthy volunteers, including any constitutionally
healthy female with no history of breast cancer*
Yes
No
hormone receptor status not specified*
Yes
No
patient characteristics:*
Yes
No
female*
Yes
No
menopausal status not specified*
Yes
No
not pregnant or nursing*
Yes
No
negative pregnancy test*
Yes
No
fertile patients must use effective contraception*
Yes
No
not acutely ill*
Yes
No
no non-magnetic resonance-compatible
ferromagnetic materials present in the body*
Yes
No
prior concurrent therapy:*
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Yes
No
prior chemotherapy and/or radiotherapy allowed*
Yes
No
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Eligibility Breast Cancer NCT01215162
Phase II Study of Intra-Operative Electron Irradiation and
External Beam Irradiation After Lumpectomy in Patients
With T1N0M0 and T2N0M0 Breast Cancer; ODM derived
from: https://clinicaltrials.gov/show/NCT01215162
All rights reserved. Please visit https://medical-data-
models.org/forms/16424
Eligibility Breast Cancer
NCT01215162
Criteria
1. histologically proven primary invasive breast
carcinoma.*
Yes
No
2. tumor pathologically determined <= 5cm in
diameter.*
Yes
No
3. single, discrete, well-defined primary tumor.*
Yes
No
4. any micro-calcifications must be focal.  a
specimen radiograph is required after
lumpectomy to assure removal of all malignant
appearing calcifications.*
Yes
No
5. pathologically negative surgical margins.*
Yes
No
6. axillary lymph node status can be determined
by level i and ii lymph node dissection or sentinel
lymph node sampling.*
Yes
No
7. ecog performance status 0-2.*
Yes
No
contraindications:*
Yes
No
1. multicentric disease and/or diffuse malignant
appearing microcalcifications.*
Yes
No
2. evidence of metastatic breast cancer.*
Yes
No
3. axillary lymph node involvement.*
Yes
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No
4. pre-existing collagen vascular disease except
rheumatoid arthritis that does not require
immunosuppressive therapy.*
Yes
No
5. prior irradiation to the ara of planned radiation
field.*
Yes
No
6. pregnant or lactating women.*
Yes
No
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Supine Ankle-Arm Blood Pressure
Cardiovascular Health Study (CHS)
Documentation part: Record 15 Supine Anlke-Arm Blood
Pressure
The Cardiovascular Health Study (CHS) was initiated by
the National Heart, Lung and Blood Institute (NHLBI) in
1987 to determine the risk factors for development and
progression of cardiovascular disease (CVD) in older
adults, with an emphasis on subclinical measures. The
study recruited 5,888 adults aged 65 or older at entry in
four U.S. communities and conducted extensive annual
clinical exams between 1989-1999 along with semi-annual
phone calls, events adjudication, and subsequent data
analyses and publications. Additional data were collected
by studies ancillary to CHS. With the exception of annual
clinic visits, these activities are still ongoing.
Data obtained from: https://chs-nhlbi.org/
Permission granted by: Erika Enright.
All rights reserved. Please visit https://medical-data-
models.org/forms/16425
Supine Ankle-Arm Blood Pressure
Cardiovascular Health Study (CHS)
Third Follow-up Supine Ankle-arm Blood
Pressure Index
Pulse Obliteration Pressure
1. Palpated systolic:
2. Maximal inflation level: (palpated systolic +
maximum zero level +30)
Systolic Readings
3. First Readings: Right brachial systolic
3. First reading: Right posterior tibial systolic
3. First Reading: Left posterior tiabial systolic
4. Second reading: Left posterior tibial systolic
4. Second reading: Right posterior tibial systolic
4. Second reading: Right brachial systolic
5. Procedure was...
completed successfully (1)
not completed (2)
Reason procedure was not completed, right leg:
Unable to occlude
no (0)
yes (1)
unknown (9)
Ulceration
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no (0)
yes (1)
unknown (9)
Amputation
no (0)
yes (1)
unknown (9)
Unable to locate fibial artery
no (0)
yes (1)
unknown (9)
Other reason
no (0)
yes (1)
unknown (9)
If other, specify:
Reason procedure was not completed, left leg:
Unable to occlude
no (0)
yes (1)
unknown (9)
Ulceration
no (0)
yes (1)
unknown (9)
Amputation
no (0)
yes (1)
unknown (9)
Unable to locate tibial artery
no (0)
yes (1)
unknown (9)
Other reason
no (0)
yes (1)
unknown (9)
Date of interview
Interviewer
Interview:
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Orthostatic Blood Pressure Cardiovascular
Health Study (CHS)
Documentation part: Record 16 Orthostatic Blood Pressure
The Cardiovascular Health Study (CHS) was initiated by
the National Heart, Lung and Blood Institute (NHLBI) in
1987 to determine the risk factors for development and
progression of cardiovascular disease (CVD) in older
adults, with an emphasis on subclinical measures. The
study recruited 5,888 adults aged 65 or older at entry in
four U.S. communities and conducted extensive annual
clinical exams between 1989-1999 along with semi-annual
phone calls, events adjudication, and subsequent data
analyses and publications. Additional data were collected
by studies ancillary to CHS. With the exception of annual
clinic visits, these activities are still ongoing.
Data obtained from: https://chs-nhlbi.org/
Permission granted by: Erika Enright.
All rights reserved. Please visit https://medical-data-
models.org/forms/16426
Orthostatic Blood Pressure
Cardiovascular Health Study (CHS)
Orthostatic Blood Pressure and Heart
Rate Measurements
1. Cuff size:
regular (1)
large arm (2)
thigh (3)
pediatric (4)
Pulse Obliteration Pressure
2. Palpated systolic:
3. Maximal inflation level: (palpated systolic +
maximum zero level +30)
Supine Reading
4. Heart rate (30 second)
4. Heart rate Time
5. Blood pressure: systolic
5. Blood pressure: diastolic
Standing Reading (after 3 minutes of
standing)
6. Are you feeling any dizziness, lightheadedness
or faintness?
Yes
No
7. Heart rate (30 second):
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Time
8. Blood pressure: systolic
8. Blood pressure: diastolic
Date of interview
Interviewer
Interview:
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Eligibility Breast Cancer NCT02474186
Phase II Study for Solid Metastatic Tumors; ODM derived
from: https://clinicaltrials.gov/show/NCT02474186
All rights reserved. Please visit https://medical-data-
models.org/forms/16427
Eligibility Breast Cancer
NCT02474186
Inclusion Criteria
patients with histologically confirmed breast
cancer or other cancer which is persistent and
metastatic or recurrent and metastatic.*
Yes
No
patients with a history of treatment for other prior
malignancy will be eligible, provided they remain
disease-free > 2 years after initial treatment, or
were treated for non-melanoma skin cancer, or in
situ cervical cancer.*
Yes
No
patients must have at least 3 distinct measurable
metastatic sites at least 1 cm of larger in their
largest diameter.*
Yes
No
age >18 years.*
Yes
No
ecog performance status <2 (karnofsky >50%).*
Yes
No
life expectancy > 3 months.*
Yes
No
Exclusion Criteria
patients who have had immunotherapy within 4
weeks prior to entering the study.*
Yes
No
patients who have had prior allergic reaction to
gm-csf*
Yes
No
patients on steroid therapy or other
immunosuppressive therapy.*
Yes
No
patients undergoing therapy with other
investigational agents.*
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Yes
No
patients with known brain metastases can be
included in this clinical trial but brain lesions are
not eligible as target or non target lesion.*
Yes
No
uncontrolled inter-current illness including, but not
limited to ongoing or active infection,
symptomatic congestive heart failure, myocardial
infarction within the past 6 months, unstable
angina pectoris, or unstable cardiac arrhythmia
requiring assessment for clinical intervention.*
Yes
No
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Eligibility Breast Cancer NCT02491892
A Study of Pertuzumab in Participants With Metastatic
Breast Cancer; ODM derived from:
https://clinicaltrials.gov/show/NCT02491892
All rights reserved. Please visit https://medical-data-
models.org/forms/16428
Eligibility Breast Cancer
NCT02491892
Inclusion Criteria
females at least 18 years of age*
Yes
No
histologically-confirmed metastatic breast cancer
with low her2 expression and at least one
measurable lesion according to response
evaluation criteria in solid tumors (recist)*
Yes
No
karnofsky performance status at least 80%*
Yes
No
disease progression on/after up to 2 different
chemotherapy regimens, including an
anthracycline-containing therapy*
Yes
No
left ventricular ejection fraction (lvef) at least
50%*
Yes
No
adequate liver function*
Yes
No
Exclusion Criteria
pleural effusions, ascites, or bone lesions as the
only manifestation(s) of cancer*
Yes
No
pulmonary or central nervous system (cns)
metastases*
Yes
No
chemotherapy, radiotherapy, or immunotherapy
within 4 weeks; or hormone therapy within 2
weeks of day 1*
Yes
No
previous treatment with any drug that targets the
her2 receptor family*
Yes
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No
previous treatment with corticosteroids as cancer
therapy*
Yes
No
history of significant cardiac disease*
Yes
No
major surgery or trauma within 4 weeks of day 1*
Yes
No
pregnant or lactating women*
Yes
No
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Eligibility Breast Cancer NCT00896857
Studying Cells Collected Through Ductal Lavage in Women
Undergoing Surgery for Ductal Carcinoma In Situ or Other
Breast Cancer; ODM derived from:
https://clinicaltrials.gov/show/NCT00896857
All rights reserved. Please visit https://medical-data-
models.org/forms/16430
Eligibility Breast Cancer
NCT00896857
Criteria
agrees to undergo breast surgical procedure and
meets one of the following criteria:*
Yes
No
scheduled to undergo breast biopsy based on
suspicious mammographic or clinical breast
examination findings*
Yes
No
diagnosis of ductal carcinoma in situ (dcis) or
carcinoma in the breast to be studied (opposite
breast may also be studied)*
Yes
No
hormone receptor status not specified*
Yes
No
patient characteristics:*
Yes
No
female*
Yes
No
pre- or post-menopausal*
Yes
No
not currently pregnant or pregnant within the past
12 months*
Yes
No
must not have lactated within the past 12
months*
Yes
No
no active infection or inflammation in the breast to
be studied*
Yes
No
no known allergy to lidocaine, prilocaine, or
marcaine (bupivacaine)*
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Yes
No
prior concurrent therapy:*
Yes
No
see disease characteristics*
Yes
No
no prior subareolar surgery or other breast
procedure that may disrupt the ductal system
within 2 cm of the nipple in the breast to be
studied*
Yes
No
no prior breast implant that disrupts the ductal
architecture in the breast to be studied*
Yes
No
no prior silicone injections in the breast to be
studied*
Yes
No
no prior radiotherapy to the breast to be studied*
Yes
No
no chemotherapy within the past 6 months*
Yes
No
concurrent prophylactic chemotherapy allowed*
Yes
No
no concurrent participation in another research
study that may conflict with or affect the outcome
of this study*
Yes
No
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Eligibility Breast Neoplasms NCT00067314
Study in Women With Metastatic Breast Cancer Whose
Cancer Has Gotten Worse After Anthracycline and Taxane
Therapy; ODM derived from:
https://clinicaltrials.gov/show/NCT00067314
All rights reserved. Please visit https://medical-data-
models.org/forms/16431
Eligibility Breast Neoplasms
NCT00067314
Inclusion Criteria
locally advanced or metastatic breast cancer not
amenable to surgery or radiation with curative
intent*
Yes
No
must have received any chemotherapy regimen in
the past*
Yes
No
evidence of tumor resistance to last
chemotherapy defined as progression after 6
months of previous chemotherapy for advanced
disease*
Yes
No
must have measurable (by imaging techniques)
disease*
Yes
No
adequate bone marrow, liver and renal function*
Yes
No
must provide evidence of informed consent and
willingness and ability to comply with scheduled
visits, treatment plan and study procedures.*
Yes
No
Exclusion Criteria
received more than 2 prior chemotherapy
regimens for metastatic disease*
Yes
No
received in the past another drug of the same
class as the investigational drug, i.e.
topoisomerase i inhibitor*
Yes
No
enrolled in another clinical intervention study*
Yes
No
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pregnancy, breast feeding, fertile women refusing
to use reliable contraceptive methods*
Yes
No
cardiac or thrombotic event in the last 12 months*
Yes
No
brain metastases*
Yes
No
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Eligibility Breast Cancer NCT00989638
A Multi Modality Surveillance Program for Women At High
Risk for Breast Cancer; ODM derived from:
https://clinicaltrials.gov/show/NCT00989638
All rights reserved. Please visit https://medical-data-
models.org/forms/16432
Eligibility Breast Cancer
NCT00989638
Inclusion Criteria
known brca1 or brca2 carrier (regardless of age)*
Yes
No
any mutation carrier in hereditary breast cancer
susceptibility genes that is known to increase the
risk for breast cancer (regardless of age). some
examples of these would include tp53, pten,
brca1 and brca2, chek2, atm, and cdh1.*
Yes
No
for women who chose not to have genetic testing
or test negative, probability of being a brca1 or
brca2 carrier of 20% or greater based on brcapro
analysis or ≥ 25% risk of being a mutation carrier
by couch model in addition to a lifetime breast
cancer risk >=20% by gail, care, or claus model*
Yes
No
personal history of breast cancer before age 35
years*
Yes
No
any woman of african ancestry whose 1st degree
relative (mother or sister) or 2nd degree relative
(aunt, grandmother) if paternal lineage suspected
diagnosed with breast cancer under age 40,
regardless of risk calculation*
Yes
No
have a personal history of ductal carcinoma in
situ (dcis) diagnosed at or before age 35 and a
first degree relative who had been diagnosed with
breast cancer before age 50 or has a first degree
relative diagnosed with ovarian cancer at any
age*
Yes
No
any female cancer survivor who received chest
irradiation before age 30 for any disease
including hodgkin's, a sarcoma, neuroblastoma,
or other medical condition.*
Yes
No
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Exclusion Criteria
women will be excluded if they meet one of the
following:*
Yes
No
active cancer at the time of enrollment.  a prior
history of breast cancer is permitted if the subject
has completed chemotherapy and is considered
disease-free at the time of enrollment.*
Yes
No
current pregnancy*
Yes
No
presence of a pacemaker or any other metallic
foreign objects in their body that interferes with
an mri*
Yes
No
breast surgery within two weeks of study entry*
Yes
No
previous bilateral mastectomy (prophylactic or
therapeutic)*
Yes
No
history of kidney disease or abnormal kidney
tests*
Yes
No
women who test negative in a family with
identifiable brca mutations are ineligible
regardless of risk calculation*
Yes
No
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Basic Documentation Melanoma - secondary
excision and follow up care NCT00000000
Klinik und Poliklinik für Hautkrankheiten
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Basisdokumentation Melanom –
Nachexzision und regionäre
Chirurgie NCT00000000
Patientendaten
Patient Data
Secondary Excision
Nachexzisionsdatum
Sicherheitsabstand
Ergebnis
tumorfrei (1)
nicht tumorfrei (2)
kumulativer Sicherheitsabstand
Klinische Untersuchung der regionären
LK-Stationen
Palpation am:
Palpationsresultat
ohne pathologischen Befund	 (1)
Metastasen/Suspekter Befund (Kriterium
einer Makrometastase) (2)
Sonographie am
Sonographie ergebnis
ohne pathologischen Befund	 (1)
Metastasen/Suspekter Befund (Kriterium
einer Makrometastase) (2)
SLND
OP am:
Lokalisation
1 / 4
RECHTS	 (1)
LINKS (2)
Axillär	 (3)
Inguinal (4)
Ellenbeuge	 (5)
Kniebeuge (6)
Cervikal (7)
SLN Status
SLN wurde identifiziert (1)
SLN wurde nicht gefunden (2)
Gammasonde angewendet (3)
Histologie von
Hautklinik	 (1)
UKM-Patho	 (2)
andere (3)
Histologie Nummer
Kryomaterial
Ja
Nein
Kryomaterial Nummer
Histologie HE:
positiv	 (1)
negativ	 (2)
nicht durchgeführt (3)
Histologie S-100
positiv (1)
negativ (2)
nicht durchgeführt (3)
Histologie HMB-45:
positiv (1)
negativ (2)
nicht durchgeführt (3)
Andere Befunde:
Anzahl entnommen:
negative LK
Makrometastasen
Mikro (<2mm Ø und <2mm Tiefenausdehn. v.
Sinus)*
Mikro (≥2mm Ø oder ≥2mm Tiefenausdehn. v.
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NCT00000000
Sinus)*
Radikale LAD
OP am:
OP Ort
Hautklinik	 (1)
UKM	 (2)
andere, bitte im nächsten Item ausführen
(3)
andere Einrichtung
Histologie von:
Hautklinik	 (1)
UKM-Patho	 (2)
andere (3)
Histologie Nummer
Kryomaterial
Ja
Nein
Kryomaterial Nummer
Lokalisation
RECHTS (1)
LINKS (2)
Cervikal (3)
Axillär (4)
Inguinal (5)
Ellenbeuge (6)
Kniebeuge (7)
Anzahl entnommen
negative LK
positive LK
In-transit/Satelliten-Metastasen
Satellitenmetastase
Ja
Nein
In-transit-Metastase
Ja
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Nein
Diagnosedatum
OP
Ja
Nein
Histologie von
Hautklinik  (1)
UKM-Patho  (2)
andere (3)
Histologie Nummer
Kryomaterial
Ja
Nein
Kryomaterial Nummer
Lokalisation
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Basic Documentation Melanoma - Metastasation
diagnostics and diagnosis NCT00000000
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Basis Doku, Ausbreitungsdiagnostik
und Diagnose, NCT00000000
Melanom Patientendokumentation
Patientendaten
Patientenaufkleber
Ausbreitungsdiagnostik: Labor
Routine-Labor o.p.B.
Ja
Nein
Laborbefunde
S.-Bank
Ja
Nein
S-100
Ja
Nein
S-100 Messung
TSH
Ja
Nein
TSH [μU/ml]
μU/ml
LDH
Ja
Nein
LDH Messwert
Ausbreitungsdiagnostik: Stadienadaptiert
Diagnostische Maßnahme
Sono-Abdomen  (1)
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Röntgen-Thorax (2)
CT-Thorax  (3)
CT-Abdomen  (4)
MRT-Schädel (5)
Skelett-Szintigraphie (6)
PET-CT (7)
am
erfolgt
Ja
Nein
o.p.B.
Ja
Nein
oder
TNM Stadium
TNM Stadium
Karnofsky
>= 1
<= 100
Patientendaten
erhoben am:
Größe
cm
Gewicht
kg
Karnofsky-Index
>= 1
<= 100
Klinische Diagnose
Lokalisation
TD
Clark
Tumor Staging TNM
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diagnosis NCT00000000
Stadium (AJCC  2002)
Oberarzt
Datum
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Skin Score chronic GvHD of skin
NCT00000000
F_Skin Score chronische GvHD der Haut_05042016
UKM  Hautklinik	Skin Score chronische GvHD der Haut
[nach Greinix et al., 2007]
Version: 1 
Stand: 05.04.2016
Nächste Revision: 05.04.2018
Herausgeber: 
(Ihr Bereich)
[X] Ärzte 
[_] Pflege 
[_] Verwaltung
[_] Sonstige: 
Erstellt durch (Autoren):	Geprüft durch:	Freigegeben durch:
Prof. Markus Böhm	Henriette Kuithan	Dr. Carsten Weishaupt
Wichtiger Hinweis: Dieser Ausdruck ist eine unkontrollierte
Kopie. Gültig ist nur die aktuelle Version in Nexus Curator.
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Skin Score chronische GvHD der
Haut NCT00000000
Patientendaten
Name
Vorname
Geburtsdatum
Scoregegenstände
Region
Kopf, Hals (1)
Linkes/r Bein, Fuß (10)
Brust (2)
Bauch, Genitale (3)
Rücken, Gesäß (4)
Rechter Arm (5)
Rechte Hand (6)
Linker Arm (7)
Linke Hand (8)
Rechtes/r Bein, Fuß (9)
Grad
1 (1)
2 (2)
3 (3)
4 (4)
Total (5)
%
>= 1
<= 100
Fraktion von Grad 3/4 mit Erythem
0 (1)
1/4 (2)
1/2 (3)
1 / 2
3/4 (4)
1 (5)
Unterschrift
Unterschrift Arzt
date of signature
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Basis Doku, Primärtumordaten
NCT00000000 Melanom
Patientendokumentation
Primärtumordaten
Erstexzision am
Ort
Hautklinik (1)
Hautpraxis (2)
andere (3)
Histologie von
Hautklinik (1)
UKM-Patho (2)
andere (3)
Histologie Nummer
Kryomaterial
Ja
Nein
Kryomaterial Nummer
Primärer Sicherheitsabstand
<0,5 cm (1)
1,5 cm	 (2)
0,5 cm	 (3)
2,0 cm	 (4)
1,0 cm (5)
unbekannt	 (6)
andere: im nächsten Item angeben (7)
Anderer Sicherheitsabstand
Wachstumsphase
Horizontal (1)
Vertikal (2)
Keine Angaben (3)
Breslow TD
Ja
Nein
Clark_Lebvel
>= 1
<= 5
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MM-Typ
NMM	 (1)
LMM	 (2)
ALM	 (3)
Nicht klassifiziert (4)
Nicht klassifizierbar (5)
MM auf kongenitalen NZN (6)
Lokalisation I
Haut	 (1)
Schleimhaut (2)
Auge (3)
Okkult (4)
Andere: Bitte im nächsten Item
spezifizieren (5)
Andere Lokalisation
OP-Ergebnis (Erstexzision):
vollständig entfernt (1)
unvollständig entfernt (2)
unbekannt (3)
Regression:
ja (1)
nein (2)
unbekannt (3)
Ulzareation
ja (1)
nein (2)
unbekannt (3)
Lokalisation II:
Gesicht (1)
Unterarm (10)
Hand (11)
Oberschenkel/Knie (12)
Unterschenkel (13)
Fuß (14)
Sonstiger Kopf (2)
Hals (3)
Brust/Oberbauch (4)
Rücken (5)
Abdomen (6)
Gesäß (7)
Äußeres Genitale (8)
Oberarm/Ellenbog. (9)
Lokalisation 2, Position
RECHTS (1)
LINKS (2)
Median (3)
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Anamnese Melanom Teil 2 NCT00000000
Part: Vervollständigung Anamnese
All rights reserved. Please visit https://medical-data-
models.org/forms/16438
Basis Doku, Anamese 2/2
NCT00000000 Melanom
Anamnese und Risikofaktoren Fortsetzung
Systemische Immunsuppression
ja (1)
nein (2)
unbekannt (3)
berufliche sonnenexposition
ja (1)
nein (2)
unbekannt (3)
Lichtschutzmittel
nie (1)
selten (2)
gelegentlich (3)
regelmäßig (4)
Haarfarbe
blond	 (1)
braun (2)
schwarz (3)
rot (4)
Hauttyp
I (1)
II (2)
III (3)
IV (4)
V (5)
VI (6)
Anzahl Naevi (auf linken Unterarm)
Ethnie
afro/amerikanisch (1)
asiatisch (2)
kaukasisch (3)
lateinamerikanisch (4)
Südeuropa (5)
Osteuropa (6)
Vorderer Orient (inkl. Türkei und Nahost)
(7)
Solarium
>3x/Woche	 (1)
2-3x/Woche (2)
1x/Woche (3)
selten (4)
nie (5)
Outdoorsport
Laufsport (1)
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Radsport (2)
Skisport (3)
Wassersport (4)
Klettern (5)
Bergsteigen (6)
andere (7)
unbekannt (8)
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Klinik und Poliklinik für Hautkrankheiten
- Allgemeine Dermatologie und Venerologie -
Direktor: Univ.-Prof. Dr. med. Th. A. Luger
All rights reserved. Please visit https://medical-data-
models.org/forms/16439
Basis Doku, Anamnese 1/2,
Melanom NCT00000000
Patientenidentifikation
Name
Vorname
Geburtsdatum:
Geschlecht:
männlich  (1)
weiblich (2)
Zeitpunkt der Anamnese
Datum
Diagnose
Erstdiagnose (1)
Zweitmelanom (2)
Multiple Melanoma (3)
Progress
Ja
Nein
Einverständnis
Datenspeicherung Krebsregister
Ja
Nein
Hauttumorbank
Ja
Nein
abgelehnt
Ja
Nein
Anamnese und Risikofaktoren
Gewichtsverlust
ja  (1)
nein (2)
unbekannt (3)
Appetitlosigkeit
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ja (1)
nein (2)
unbekannt (3)
Nachtschweiß
ja (1)
nein (2)
unbekannt (3)
Abgeschlagenheit
ja (ja)
nein (nein)
unbekannt (unbekannt)
Thrombosen
ja (1)
nein (2)
unbekannt (3)
Schmerzempfinden:
ja (1)
nein (2)
unbekannt (3)
Raucher
ja (1)
nein (2)
unbekannt (3)
Erstmalignom: Haut
ja (1)
nein (2)
unbekannt (3)
Was?
Wann?
Andere Tumoren
ja (1)
nein (2)
unbekannt (3)
Was?
Wann?
Familiärer Hautkrebs
ja (1)
nein (2)
unbekannt (3)
Wer?
Was?
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Wann?
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Informed Consent discussion 2/2
Melanoma NCT00000000
Informed Consent discussion Melanoma NCT00000000
Part: Planned therapeutic procedures
All rights reserved. Please visit https://medical-data-
models.org/forms/16440
Aufklärungsgespräch 2/2 Melanom
NCT00000000
Therapieplanung  / Vorgehen
Nachsorge
Yes
No
Nachsorgeplan mitgegeben
Yes
No
Regelmäßige Nachsorge im Wechsel mit HFA Dr.
Yes
No
ggf. Sentinel LK Studie
Yes
No
Pat. bereits aufgeklärt und prinzipiell
einverstanden
Yes
No
Therapeutische Lymphknoten-dissektion
Yes
No
mit / ohne Radiatio
Yes
No
Pat. bereits aufgeklärt und prinzipiell
einverstanden
Yes
No
ggf. adjuvante IFN-Therapie
Yes
No
Pat. bereits aufgeklärt und prinzipiell
einverstanden
Yes
No
abwartendes Vorgehen
Yes
No
Sonstiges:
Möglichkeiten zur Teilnahme an klinischen
Studien:
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Yes
No
Studie(n):
Möglichkeit zur Einholung von Zweitmeinungen
und deren Vermittlung angesprochen (unter
Mitgabe aller Befunde)
ja (1)
Patient überlegt es sich (2)
nein (3)
Möglichkeiten supportiver Maßnahmen in
Onkologie wurden generell angesprochen
Yes
No
Im Speziellen
Beratung zu paramedizinischer Behandlung
(Physiotherapie, Pflegedienst, med. Kosmetik
etc.)
Yes
No
Beratung bzgl. Risikofaktoren (UV, familiäre
Disposition)
Yes
No
Nachbesprechung erforderlich
Yes
No
Formular Einverständnis
Krebsregister/Tumordokumentation
unterschrieben
Yes
No
Dem Patienten wurde eine Broschüre über das
Maligne Melanom ausgehändigt
Yes
No
Fragen oder Wünsche des Patienten
Yes
No
Possible Plan
weeks until debriefing
outpatient department
Yes
No
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patient return, date
Days till debriefing in skin tumor consultation hour
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informed consent discussion 1/2 Melanoma
NCT00000000
informed consent discussion Melanoma NCT00000000
To be conducted during the first inpatient stay or on the first
outpatient visit. Not in the presence oof other patients
independent from visit, if possible with reference person.
Durchzuführen erstmals während des stationären
Aufenthaltes oder beim ersten ambulanten Termin, nicht im
Beisein von Mitpatienten, unabhängig von Visite, möglichst
mit Bezugsperson
All rights reserved. Please visit https://medical-data-
models.org/forms/16441
Aufklärungsgespräch 1/2 Melanom
NCT00000000
Meta Information
Informed Consent discussion conducted with
Consulting Physician
Prof Sunderkötter (1)
Dr. Weishaupt (2)
Prof. Metze (3)
Dr. Seller (4)
Other (5)
Other Consulting physician
Date of Informed Consent Discussion
Results of investigations complete on the first
discussion
Yes
No
Missing Examination results
Discussion participant
Spouse (1)
Children (2)
Other (3)
Only Patient (4)
Other Participant
Complete education desired
Yes
No
Diagnosis and Extent discussed with patient
Yes
No
Comment
Also discussed with the patient
1 / 3
The high malignant potential of the malign
melanoma in general. The possibility of present
micro metastasis
Yes
No
already known or presumed Causes (Cancer in
general, family predisposition melanocytic
neoplasms, exogenic facors (UV-Exposition)
Yes
No
Patient's Prognosis ( Mitosis, Lymoh node status,
Comorbidity)
Yes
No
Assignment to risk group
high rist group (1)
low risk group (2)
Melanoma currently currently not manifest (
Controlled or in remission)
Yes
No
Possible limitations caused by cancer, possibly
measures for management at home
Yes
No
possible implications for the desire to have
children (family plans) were explained (depending
on risk group)
Yes
No
special remarks about porgnosis made
Patient decree made subject of discussion
patient decree received
Yes
No
Psycological counselling offered
currently desired (1)
possibly desired later (2)
currently denied (3)
psychological basic documentation
Yes
No
Counselling and discussion with social worker
(among others about the option of a rehab
measure, a disabled person's pass, care and
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support facilities, social facilities, possibly
financial support, home management)
yes, is presumed to take place (1)
has taken place (2)
no, patient refused at first (3)
First impression of patient
patient has understood the scope  (1)
displaced (2)
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Eligibility Hepatitis C NCT00328549
A Study to Evaluate the Erythropoietic Response in
Hepatitis C Virus (HCV) Patients Receiving Combination
Ribavirin (RBV)/Interferon (IFN) Therapy or RBV/PEG IFN
(NATURAL HISTORY-HCV); ODM derived from:
https://clinicaltrials.gov/show/NCT00328549
All rights reserved. Please visit https://medical-data-
models.org/forms/16442
Eligibility Hepatitis C NCT00328549
Inclusion Criteria
signed informed consent*
Yes
No
hcv- infected patients confirmed by pcr or
branched dna (b-dna)*
Yes
No
scheduled to commence combination rbv/ifn or
rbv/peg-ifn therapy on day 1*
Yes
No
normal serum creatinine*
Yes
No
life expectancy > 6 months*
Yes
No
Exclusion Criteria
hiv-infected patients*
Yes
No
history of any primary hematologic disease*
Yes
No
anemia attributable to factors such as iron or
folate deficiency,  pre-treatment*
Yes
No
hemolysis or gastrointestinal bleeding*
Yes
No
has suspected or confirmed significant hepatic
disease from an etiology other than*
Yes
No
hcv (e.g. alcohol, hbv, autoimmune disease etc)*
Yes
No
current, active substance abuser*
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Yes
No
pregnant or breast feeding*
Yes
No
women of childbearing potential not taking
adequate birth control measures*
Yes
No
exposure to epoetin alfa within three (3) months
prior to study enrollment or during study*
Yes
No
transfusion within three (3) months prior to study
entry*
Yes
No
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Eligibility Hepatitis D NCT00023322
Pegylated Interferon to Treat Chronic Hepatitis D; ODM
derived from: https://clinicaltrials.gov/show/NCT00023322
All rights reserved. Please visit https://medical-data-
models.org/forms/16443
Eligibility Hepatitis D NCT00023322
Criteria
age greater than or equal to 18 years, male or
female*
Yes
No
serum alanine or aspartate aminotransferase
activities that are above the upper limit of normal
(alt greater than 41 or ast greater than 31 u/l) on
an average of three determinations taken during
the previous 6 months.  the mean of the three
determinations will be defined as 'baseline'
levels.*
Yes
No
presence of anti-hdv in serum*
Yes
No
evidence of chronic hepatitis on liver biopsy done
within the previous 12 months with a
necroinflammatory score in histology activity
index of at least 5 (out of a maximum of 18) and
at least 1 for hepatic fibrosis (out of a maximum
of 6).*
Yes
No
presence of hdv antigen in liver tissue.*
Yes
No
written informed consent.*
Yes
No
previous standard alpha interferon or other
antiviral activity will not exclude patients.*
Yes
No
active hbv replication will not exclude patients.*
Yes
No
all ethnicities.*
Yes
No
patients will need to meet the first six entry
criteria to enroll*
Yes
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No
Exclusion Criteria
decompensated liver disease, as marked by
bilirubin greater than 4 mg%, albumin less than
3.0 gm%, prothrombin time greater than 2 sec
prolonged, or history of bleeding esophageal
varices, ascites or hepatic encephalopathy.
patients with alt levels greater than 1000 u/l
(greater than 25 times uln) will not be enrolled but
may be followed until three determinations are
below this level.*
Yes
No
pregnancy or, in women of child-bearing potential
or in spouses of such women, inability to practice
adequate contraception defined as vasectomy in
men, tubal ligation in women, or use of condoms
and spermicide, or birth control pills, or an
intrauterine device, or depo-provera, or norplant.*
Yes
No
significant systemic or major illnesses other than
liver disease, including, but not limited to,
congestive heart failure, renal failure (creatinine
clearance less than 50 ml/min), organ
transplantation, serious psychiatric disease or
depression (only if felt to be at high risk by the nih
psychiatric consultation service), and angina
pectoris.*
Yes
No
immunosuppressive therapy within the last 6
months.*
Yes
No
evidence of another form of liver disease in
addition to viral hepatitis (for example
autoimmune liver disease, wilson's disease,
alcoholic liver disease, hemochromatosis, and
alpha-1-antitrypsin deficiency).*
Yes
No
any evidence of coronary artery disease or
cerebral vascular disease, including
abnormalities on exercise stress testing in
patients with defined risk factors who will be
screened for evidence of underlying coronary
artery disease.*
Yes
No
active substance abuse, such as alcohol, inhaled
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or injection drugs within the previous year.*
Yes
No
evidence of hepatocellular carcinoma; either
alphafetoprotein (afp) levels greater than 200
ng/ml (normal less than 9 ng/ml) and/or
ultrasound (or other imaging study)
demonstrating a mass suggestive of liver cancer.*
Yes
No
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Eligibility Hepatocellular Carcinoma
NCT00154817
A Phase II Study of Radiotherapy for Locally Advanced
Hepatocellular Carcinoma (HCC); ODM derived from:
https://clinicaltrials.gov/show/NCT00154817
All rights reserved. Please visit https://medical-data-
models.org/forms/16444
Eligibility Hepatocellular Carcinoma
NCT00154817
Inclusion Criteria
1.1 patients with measurable, locally advanced
hcc that are not suitable for other local therapies,
including surgery, tae, alcohol injection, or
radiofrequency ablation.*
Yes
No
1.2 patients with histological confirmed hcc or
patients who do not have histological diagnosis
but have met all of the following criteria: 1.2.1
presence of chronic viral hepatitis and/or cirrhosis
1.2.2 presence of hepatic tumor(s) with image
findings (sonography, ct scan) compatible with
hcc.*
Yes
No
1.2.3 a persistent elevation of serum a-fetoprotein
level ³ 400 ng/ml without any evidence of ana-
fetoprotein-secreting germ cell tumor.*
Yes
No
1.3 patients without any local or systemic therapy
for hcc within 4 weeks*
Yes
No
1.4 patients with age > 20 years and < 70 years*
Yes
No
1.5 patients with a performance status of ecog
score <1*
Yes
No
1.6 patients must fulfill all of the following
criteria:.*
Yes
No
1.6.1 child-pugh’s score ≦ 7*
Yes
No
1.6.2 serum total bilirubin < 1.5 times upper
normal limit (unl).*
Yes
No
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1.6.3 serum alanine transaminase (alt) < 5 times
unl*
Yes
No
1.6.4 platelet count > 5.0 x 104 / mm3.*
Yes
No
1.6.5 white blood cell count > 3,000 / mm3*
Yes
No
1.6.6 serum creatinine < 2.0 mg/dl*
Yes
No
1.7 patient must have local tumors less than one
half of the whole liver and the tumors can be
encompassed within rt fields*
Yes
No
1.8 signed informed consent*
Yes
No
1.9 sexually active patients, in conjunction with
their partner, must practice birth control during,
and for 2 months after, thalidomide therapy.*
Yes
No
1.10 female patients in child-bearing age must
have negative pregnancy test.*
Yes
No
Exclusion criteria
2.1. patients with documented extrahepatic
metastasis
Yes
No
2.2. patients who received previous radiotherapy
to abdominal area.
Yes
No
2.3. patients who have received thalidomide
treatment prior to enrollment.
Yes
No
2.4. patients who had other investigational drug
treatment within 4 weeks prior to enrollment.
Yes
No
2 / 3
Eligibility Hepatocellular Carcinoma NCT00154817
2.5. patients with nci grade 2 or greater
peripheral neuropathy of any causes
Yes
No
2.6. patients with other systemic diseases that
required concurrent usage of glucocorticosteroid
or immunosuppressant agent(s).
Yes
No
2.7. patients who have major systemic diseases
that the attending physicians consider
inappropriate for radiotherapy or thalidomide
therapy.
Yes
No
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Eligibility Hormone-Refractory Prostate
Cancer NCT00201357
An Open Trial to Assess the Efficacy and Safety of Oral
Thalidomide in Patients With Hormone-Refractory Prostate
Cancer; ODM derived from:
https://clinicaltrials.gov/show/NCT00201357
All rights reserved. Please visit https://medical-data-
models.org/forms/16445
Eligibility Hormone-Refractory
Prostate Cancer NCT00201357
Inclusion Criteria
18 years of age or older.*
Yes
No
histologically or cytologically confirmed
adenocarcinoma of prostate that is metastatic,
hormone-refractory (confirmed by testing serum
testosterone), and clinically progressive following
at least one prior hormonal regimen.*
Yes
No
patients must have documented progression of
disease on anti-androgen withdrawal, if the
patient have documented progression on
previous anti-androgen therapy.*
Yes
No
measurable (patient with measurable bi-
dimensional disease) or evaluable disease
(defined as the presence of a nonmeasurable
abnormality on ct or on physical examination
coupled with a psa ³ 30).*
Yes
No
karnofsky performance status ³ 60%.6. adequate
bone marrow functions: granulocyte count
1,000/mm3, platelets 75,000/mm3, haemoglobin
8 g/dl.*
Yes
No
adequate renal and liver functions: creatinine <
1.5 mg/dl, bilirubin < 2 mg/dl, alt/ast less than 2.5
times the upper limit of the reference range for
the institute.*
Yes
No
patients with chemical or clinical hypothyroidism
should have their thyroid replacement prior to
starting study.*
Yes
No
patients must have recovered from the effect of
recent surgery (at least 4 weeks apart),
radiotherapy (at least 4 weeks apart).*
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Yes
No
patients have ability to complete quality of life
(qol) questionnaires.*
Yes
No
patients must sign informed consent.*
Yes
No
Exclusion Criteria
patients with advanced second primary
malignancy.*
Yes
No
patients with brain metastases.*
Yes
No
patients with hypersensitivity to thalidomide.*
Yes
No
history of myocardial infarction within past 6
months, uncontrolled congestive heart failure or
angina pectoris.*
Yes
No
patients with orthostatic hypotension before
therapy.*
Yes
No
patients with nci ctc grade  3 or greater peripheral
neuropathy of any cause that is clinically
detectable.*
Yes
No
patients with active infection, including positive
serology for hiv.*
Yes
No
patients who have received chemotherapy before
for treatment of metastases of prostate cancer, or
received other investigational agents or
corticosteroids within 4 weeks prior to enrollment
of study.*
Yes
No
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Physician letter (short)
derived from http://www.arztbriefmanager.de/ (Dr. Wolfram
Arends, Tutzing, Germany)
All rights reserved. Please visit https://medical-data-
models.org/forms/16447
Physician letter (short)
Angaben zum bisherigen Aufenthalt
Aufnahmedatum
Entlassungsdatum
Symptome
Chefarzt der jetzigen Klinik
Oberarzt der jetzigen Klinik
Stationsarzt der jetzigen Klinik
Empfänger
Anschrift
Diagnosen
Hypertonie
Ja
Nein
Pulmonale Hypertonie
Ja
Nein
Rechtsherzinsuffizienz
Ja
Nein
Linksherzinsuffizienz
Ja
Nein
Dekompensierte Herzinsuffizienz
Ja
Nein
KHK
Ja
Nein
Z.n. Stent nach Herzinfarkt
Ja
Nein
1 / 21
Linksschenkelblock
Ja
Nein
Rechtsschenkelblock
Ja
Nein
Linksherzinsuffzienz
Ja
Nein
Intermittierendes Vorhofflimmern
Ja
Nein
Permanentes Vorhofflimmern
Ja
Nein
Palpitationen
Ja
Nein
Nikotinabusus
Ja
Nein
Hypercholesterinämie
Ja
Nein
Diabetes mellitus Typ II nicht insulinpflichtig
Ja
Nein
Diabetes mellitus Typ II insulinpflichtig
Ja
Nein
Adipositas
Ja
Nein
Positive Familienanamnese
Ja
Nein
Antikoagulation mit Marcumar
Ja
Nein
Hämorrhagische Diathese durch
Antikoagulanzien
Ja
Nein
Eisenmangelanämie
Ja
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Nein
Akute Blutungsanämie
Ja
Nein
Anämie
Ja
Nein
Eisenmangelanämie durch Blutung
Ja
Nein
COPD
Ja
Nein
nicht allergisches Asthma Bronchiale
Ja
Nein
Gastrooesophageale Refluxkrankheit
Ja
Nein
Chronische Gastritis
Ja
Nein
Divertikulose
Ja
Nein
Autoimmunthyreoiditis
Ja
Nein
Hypothyreose
Ja
Nein
Hyperthyreose
Ja
Nein
Adipositas permagna
Ja
Nein
Osteoporose
Ja
Nein
kompensierte Niereninsuffizienz
Ja
Nein
Nierenzyste
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Ja
Nein
Akute Zystitis
Ja
Nein
Fibromyalgie
Ja
Nein
Restless-Legs-Syndrom
Ja
Nein
Polyarthritis
Ja
Nein
Polymyalgia rheumatica
Ja
Nein
chronische Polyarthritis
Ja
Nein
Migräne
Ja
Nein
Spannungskopfschmerz
Ja
Nein
unsystematischer Schwindel
Ja
Nein
Synkope
Ja
Nein
TIA
Ja
Nein
alter ZNS Infarkt
Ja
Nein
Z.n. ischämischem Hirninfarkt
Ja
Nein
Z.n. Apoplexie
Ja
Nein
Hirninfarkt
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Ja
Nein
Schlaffe Hemiparese
Ja
Nein
Spastische Hemiparese
Ja
Nein
Dysphagie
Ja
Nein
Dysphasie und Aphasie
Ja
Nein
Zerebrale Atherosklerose
Ja
Nein
Dementielles Syndrom
Ja
Nein
Multiinfarkt-Demenz
Ja
Nein
Vaskuläre Demenz
Ja
Nein
Essenanreichung bei Demenz
Ja
Nein
V.a. Hirnmetastasen
Ja
Nein
Morbus Parkinson
Ja
Nein
Epilepsie
Ja
Nein
Belastungsinkontinenz
Ja
Nein
Z.n. Excision
Ja
Nein
Z.n. Radiatio
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Ja
Nein
Dermatitis
Ja
Nein
Mykose
Ja
Nein
Chronisches Ulkus der Haut
Ja
Nein
Dekubitus
Ja
Nein
Gangrän
Ja
Nein
Phlegmone untere Extremität
Ja
Nein
Psoriasis
Ja
Nein
HWS Syndrom
Ja
Nein
Rezidivierendes Cervicalsyndrom bei Discopathie
Ja
Nein
Intervertebralarthrosen der HWS
Ja
Nein
HWS Syndrom bei geringgradigen degenerativen
Veränderungen
Ja
Nein
BWS Syndrom
Ja
Nein
BWS Syndrom
Ja
Nein
LWS Syndrom
Ja
Nein
Schultereckgelenkarthrose
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Ja
Nein
Impingementsyndrom Schulter
B (B)
L (L)
R (R)
Epicondylitis radialis humeri
Ja
Nein
Tendovaginitis stenosans
Ja
Nein
Carpaltunnelsyndrom
Ja
Nein
Heberden Arthrose
Ja
Nein
Bouchard-Arthrose
Ja
Nein
Coxarthrose
Ja
Nein
Gonarthrose
Ja
Nein
Katarakt
Ja
Nein
Makuladegeneration
Ja
Nein
Myopie
Ja
Nein
Presbyakusis
Ja
Nein
Z.n. MammaCa
Ja
Nein
Chronischer Alkoholabusus
Ja
Nein
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Nikotinabusus
Ja
Nein
Chronisches Schmerzsyndrom
Ja
Nein
Somatisierungsstörung
Ja
Nein
Posttraumatische Belastungsstörung
Ja
Nein
Schwere depressive Episode
Ja
Nein
mittelschwere depressive Episode
Ja
Nein
leichte depressive Episode
Ja
Nein
Panikstörung
Ja
Nein
Eßstörung
Ja
Nein
Eingeschränkte Mobilität
Ja
Nein
Immobilitätssyndrom (paraplegisch)
Ja
Nein
Sturzneigung
Ja
Nein
Zusätzliche Diagnosen
Aktuelle Medikation
Bisohexal
Ja
Nein
Concor
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Ja
Nein
Carvedilol
Ja
Nein
Selectol
Ja
Nein
Propranolol
Ja
Nein
Nebivolol
Ja
Nein
Sotalol
Ja
Nein
Beloc zok
Ja
Nein
Metoprolol
Ja
Nein
Felodipin AL
Ja
Nein
Amlodipin 1A
Ja
Nein
Verapamil 1A
Ja
Nein
Diltiazem 1A
Ja
Nein
Procorum
Ja
Nein
Carmen
Ja
Nein
Nifedipin 1A
Ja
Nein
Nitrendipin 1A
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Ja
Nein
Blopress
Ja
Nein
Micardis
Ja
Nein
MicardisPlus
Ja
Nein
Aprovel
Ja
Nein
Coaprovel
Ja
Nein
Votum
Ja
Nein
Diovan
Ja
Nein
CoDiovan
Ja
Nein
ACE Hemmer
Ja
Nein
Enalapril 1A
Ja
Nein
Lisibeta
Ja
Nein
Delix
Ja
Nein
Cibacen
Ja
Nein
Spironolacton 1A
Ja
Nein
Furo
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Ja
Nein
Xipamid
Ja
Nein
Furosemid 1A
Ja
Nein
HCT
Ja
Nein
Torem
Ja
Nein
Ramipril plus
Ja
Nein
Triarese
Ja
Nein
Ramipril/Piretanid 1A
Ja
Nein
Lisodura plus
Ja
Nein
Amilorid HCT
Ja
Nein
Molsidomin 1A
Ja
Nein
Pentalong
Ja
Nein
Isoket
Ja
Nein
Rasilez
Ja
Nein
Amiodaron 1A
Ja
Nein
Flecadura
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Ja
Nein
Digoxin 1A
Ja
Nein
Digimed
Ja
Nein
Digostada
Ja
Nein
Proscar
Ja
Nein
Marcumar
Ja
Nein
Aggrenox
Ja
Nein
Clexane
Ja
Nein
Plavix
Ja
Nein
Aspirin
Ja
Nein
Magnesium Verla
Ja
Nein
NaCl
Ja
Nein
Calcium HEXAL
Ja
Nein
Kalinor Brause
Ja
Nein
Vigantoletten
Ja
Nein
Ferro sanol
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Ja
Nein
ACC
Ja
Nein
Mucosolvan
Ja
Nein
Salbutamol-CT DA
Ja
Nein
Foster
Ja
Nein
Foradil
Ja
Nein
Berotec DA
Ja
Nein
Bronchoretard
Ja
Nein
Spiriva
Ja
Nein
Atrovent
Ja
Nein
Berodual
Ja
Nein
Singulair
Ja
Nein
Dexa CT
Ja
Nein
Decortin
Ja
Nein
Budesonid CT
Ja
Nein
Symbicort
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Physician letter (short)
Ja
Nein
Alvesco
Ja
Nein
Cetirizin-CT
Ja
Nein
Xusal
Ja
Nein
Tavegil
Ja
Nein
Fentanyl TAD
Ja
Nein
Fentanyl-CT transdermales Pflaster
Ja
Nein
Oxygesic
Ja
Nein
Tramal
Ja
Nein
Tilidin retard
Ja
Nein
Ibuprofen 1A
Ja
Nein
Diclofenac 1A
Ja
Nein
ARCOXIA
Ja
Nein
Paracetamol 1A
Ja
Nein
Novalgin
Ja
Nein
Glibenclamid 1A
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Physician letter (short)
Ja
Nein
Amaryl
Ja
Nein
NovoNorm
Ja
Nein
Glucophage
Ja
Nein
Janumed
Ja
Nein
Acarbose
Ja
Nein
Sitagliptin
Ja
Nein
Januvia
Ja
Nein
Insulin human
Ja
Nein
Huminsulin
Ja
Nein
Actraphane 30/70
Ja
Nein
Insulin human Protaphane 30/70
Ja
Nein
Levemir
Ja
Nein
Lantus
Ja
Nein
Diabetes Diät
Ja
Nein
LOCOL
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Physician letter (short)
Ja
Nein
Pravastatin 1A
Ja
Nein
Simvadura
Ja
Nein
Sortis
Ja
Nein
Bezafibrat
Ja
Nein
Inegy
Ja
Nein
Jodthyrox
Ja
Nein
Euthyrox
Ja
Nein
Carbimazol 1A
Ja
Nein
Allopurinol AL
Ja
Nein
Fosamax
Ja
Nein
Duphaston
Ja
Nein
Estreva
Ja
Nein
Gynokadin
Ja
Nein
Ovestin
Ja
Nein
Bellissima
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Physician letter (short)
Ja
Nein
Lamuna
Ja
Nein
Nexium
Ja
Nein
Omebeta
Ja
Nein
Pantozol
Ja
Nein
Movicol
Ja
Nein
Lactulose
Ja
Nein
Metoclopramid
Ja
Nein
Cefuroxim 1A
Ja
Nein
Roxi 1A
Ja
Nein
Klacid
Ja
Nein
Avalox
Ja
Nein
Ciprobay
Ja
Nein
Tavanic
Ja
Nein
Clont
Ja
Nein
Sumatriptan
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Physician letter (short)
Ja
Nein
Lyrica
Ja
Nein
Carbamazepin
Ja
Nein
Keppra
Ja
Nein
Madopar
Ja
Nein
Adartrel
Ja
Nein
Selegilin
Ja
Nein
Comtess
Ja
Nein
Akineton
Ja
Nein
Amantadin
Ja
Nein
Tolperison
Ja
Nein
Musaril
Ja
Nein
Flupirtinmaleat
Ja
Nein
Gabapentin
Ja
Nein
Reminyl
Ja
Nein
Memantin
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Physician letter (short)
Ja
Nein
Stangyl
Ja
Nein
Amitriptylin
Ja
Nein
Amitriptylinoxid
Ja
Nein
Citalopram
Ja
Nein
Cipralex
Ja
Nein
Doxepin
Ja
Nein
Sertralin
Ja
Nein
Venlafaxin
Ja
Nein
Duloxetin
Ja
Nein
Fluoxetin
Ja
Nein
Mirtazapin
Ja
Nein
Agomelatin
Ja
Nein
Dominal
Ja
Nein
Sulpirid
Ja
Nein
Promethazin
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Physician letter (short)
Ja
Nein
Melperon
Ja
Nein
Haldol
Ja
Nein
Opipramol dura
Ja
Nein
Lithiumcarbonat
Ja
Nein
Johanniskraut
Ja
Nein
Eplerenon
Ja
Nein
Zolpidemtartrat
Ja
Nein
Zopiclon
Ja
Nein
Pipamperon
Ja
Nein
Quetiapin
Ja
Nein
Oxybutynin 1A
Ja
Nein
Prostess
Ja
Nein
Tamsulosin
Ja
Nein
Trospiumchlorid
Ja
Nein
Xalatan
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Physician letter (short)
Ja
Nein
Timololmaleat
Ja
Nein
Andere Medikation
Bedarfsmedikation
21 / 21
Physician letter (short)
Eligibility Breast Cancer NCT01824498
Dietary Fat, Eicosanoids and Breast Cancer Risk; ODM
derived from: https://clinicaltrials.gov/show/NCT01824498
All rights reserved. Please visit https://medical-data-
models.org/forms/16448
Eligibility Breast Cancer
NCT01824498
Inclusion Criteria
postmenopausal women*
Yes
No
45 to 70 years old,*
Yes
No
at least one year since their last menstrual
period*
Yes
No
not  using hormone replacement therapy,*
Yes
No
bmi between 19 -29*
Yes
No
willingness to discontinue use of over-the-counter
medications with anti-prostaglandin activity such
as aspirin or non-steroidal anti-inflammatory
medications*
Yes
No
consumption of a "typical " american diet with no
unusual dietary practices such as compliance
with a strict vegetarian diet*
Yes
No
willingness to comply with the demands of the
experimental protocol.*
Yes
No
Exclusion Criteria
smoking*
Yes
No
known disease process, and 3) use of
prescription medications, including hormone
replacement therapy.*
Yes
No
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Eligibility Breast Neoplasm NCT00270894
Neoadjuvant Chemotherapy + Herceptin in HER2 Positive
Stage II-III Breast Cancer Patients; ODM derived from:
https://clinicaltrials.gov/show/NCT00270894
All rights reserved. Please visit https://medical-data-
models.org/forms/16449
Eligibility Breast Neoplasm
NCT00270894
Inclusion Criteria
non-pregnant females =/> 18 years of age*
Yes
No
non-inflammatory breast cancer stage iia - iiic or
high risk node negative*
Yes
No
core biopsy of breast demonstrating invasive
cancer and documented er/pgr receptor status*
Yes
No
normal cardiac function and adequate
hematologic function*
Yes
No
human epidermal growth factor receptor 2 protein
(her2) positive*
Yes
No
no evidence of metastatic disease*
Yes
No
ecog performance status 0 - 1*
Yes
No
women of childbearing potential must agree to
using effective contraception while on treatment
and for at least 3 months post-treatment*
Yes
No
Exclusion Criteria
treated with other investigational drugs within 30
days*
Yes
No
uncontrolled intercurrent disease or active
infection*
Yes
No
1 / 2
known sensitivity to e. coli-derived proteins or
polysorbate 80*
Yes
No
psychiatric illness or social situation that would
limit study compliance*
Yes
No
pre-existing peripheral neuropathy > grade 1*
Yes
No
cancer within 5 years of screening with the
exception of surgically cured nonmelanomatous
skin cancer; in-situ carcinoma of the cervix; or in-
situ carcinoma of the breast*
Yes
No
bilateral synchronous breast cancer*
Yes
No
inflammatory breast cancer*
Yes
No
women who are pregnant or breast feeding*
Yes
No
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Eligibility Breast Neoplasms NCT00197522
Administration of Autologous Dendritic Cells (DCs) Infected
With an Adenovirus Expressing Her-2; ODM derived from:
https://clinicaltrials.gov/show/NCT00197522
All rights reserved. Please visit https://medical-data-
models.org/forms/16450
Eligibility Breast Neoplasms
NCT00197522
Inclusion Criteria
patients with metastatic breast cancer who are
her2/neu positive (3+ by immunohistochemistry
or fish positive) and either*
Yes
No
1. currently receiving hormonal therapy or are
candidates for such or*
Yes
No
2. being considered for trastuzumab or*
Yes
No
3. their cancer has progressed on trastuzumab*
Yes
No
Exclusion Criteria
patients are excluded from the study if they meet
any one of the following criteria:*
Yes
No
age less than 16 years.*
Yes
No
pregnant or lactating female.*
Yes
No
previous malignancy other than non-melanoma
skin cancer.*
Yes
No
more than three prior courses of cytotoxic
chemotherapy for metastatic disease.*
Yes
No
concurrent use of chemotherapy, immunotherapy,
or gene therapy.  concurrent hormonal therapy
(tamoxifen, aromatase inhibitors or exemestane)
is permitted.*
Yes
No
1 / 2
treatment with trastuzumab within 16 weeks prior
to first dose of vaccine therapy.*
Yes
No
documented central nervous system
metastases.*
Yes
No
patients with any an acute illness that would
interfere with the mobilization of stem cells or the
administration of vaccination cellular therapy (ie.
unstable angina, renal or liver failure, or severe
chronic obstructive airways disease) are
ineligible.*
Yes
No
any patients requiring concurrent
immunosuppressive therapy (eg. corticosteroids)*
Yes
No
patients with a life expectancy of less than six
months.*
Yes
No
ecog performance status of >2.*
Yes
No
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Eligibility Breast Neoplasms NCT01695226
Randomized Controlled Phase II Trial of Pre-operative
Celecoxib Treatment in Breast Cancer; ODM derived from:
https://clinicaltrials.gov/show/NCT01695226
All rights reserved. Please visit https://medical-data-
models.org/forms/16451
Eligibility Breast Neoplasms
NCT01695226
Inclusion Criteria
female patients suspected of having invasive
breast cancer, >1 cm in diameter, and in whom
there is an indication for a core or incision biopsy*
Yes
No
age <75 years at time of diagnosis*
Yes
No
patient willing and able to comply with the study
prescriptions*
Yes
No
patient able to give written informed consent
before patient registration/randomisation*
Yes
No
pre- and post-menopausal patients are eligible*
Yes
No
hormone receptor positive and negative patients
are eligible*
Yes
No
a negative pregnancy test in pre-menopausal
women*
Yes
No
Exclusion Criteria
hiv, hbv or hcv positivity*
Yes
No
known hypersensitivity to nsaids*
Yes
No
a history of upper gastro-intestinal bleeding*
Yes
No
endoscopically proven upper gastro-intestinal
ulceration*
1 / 2
Yes
No
patients using nsaids, including salicyclic acid*
Yes
No
systemic use of corticosteroids*
Yes
No
a history or the presence of any other malignancy
excepting adequately treated squamous cell skin
cancer or in situ carcinoma of the cervix*
Yes
No
patients who have been treated with neo-adjuvant
chemotherapy or hormone therapy*
Yes
No
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Eligibility Breast Tumors NCT00243698
A Pilot Study Evaluation of the Efficacy of SonoVue to
Detect and Characterise Breast Lesions; ODM derived
from: https://clinicaltrials.gov/show/NCT00243698
All rights reserved. Please visit https://medical-data-
models.org/forms/16452
Eligibility Breast Tumors
NCT00243698
Inclusion Criteria
18 years of age or older*
Yes
No
woman presenting with: enlarging fibroadenoma
(less than 2 cm in diameter or woman over 40
years old with fibroadenoma less than 2 cm in
diameter) or suspect malignant nodule (less than
2 cm in diameter) or a cluster of microcalcification
or a malignant nodule (size greater than 3 cm)
diagnosed with mammography and/or mri and/or
united states (us) examination performed within 1
month before the study.*
Yes
No
woman scheduled for biopsy or surgery within 1
month from the examination.*
Yes
No
Exclusion Criteria
patients who have already performed a biopsy on
the lesion during investigation*
Yes
No
any contraindication to perform a contrast-
enhanced mri examination for the patients
presenting with a malignant nodule (size greater
than 3 cm)*
Yes
No
patients previously entered in this study or having
received an investigational drug within 30 days
prior to admission to this study*
Yes
No
patients with any medical condition or other
circumstances which would significantly decrease
the chances of obtaining reliable data or of
achieving the study objectives (drug dependence,
psychiatric disorders, dementia or other
reasons)*
Yes
No
pregnant or nursing female*
1 / 2
Yes
No
patient known to have a coronary syndrome*
Yes
No
unstable angina and myocardial infarction*
Yes
No
acute cardiac failure, class iii/iv cardiac failure*
Yes
No
severe rhythm disorders*
Yes
No
acute endocarditis*
Yes
No
prosthetic valves*
Yes
No
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Eligibility Breast Neoplasms NCT00115713
Effects of Aerobic Exercise Versus Weight Training in
Breast Cancer Survivors During Chemotherapy; ODM
derived from: https://clinicaltrials.gov/show/NCT00115713
All rights reserved. Please visit https://medical-data-
models.org/forms/16453
Eligibility Breast Neoplasms
NCT00115713
Inclusion Criteria
breast cancer early stage i –iiia*
Yes
No
completed axillary surgery*
Yes
No
scheduled to receive adjuvant chemotherapy for
9 – 24 weeks*
Yes
No
approval of the treating oncologist*
Yes
No
able to understand and provide written informed
consent in english or french (ottawa)*
Yes
No
18+ years of age*
Yes
No
no uncontrolled hypertension, cardiac illness,
psychiatric condition*
Yes
No
no contraindication to exercise as determined by
a fitness test*
Yes
No
Exclusion Criteria
pregnant.*
Yes
No
unwilling to accept randomization.*
Yes
No
any medical condition that would be a
contraindication to exercise.  the clinicians will
make this decision.*
Yes
No
1 / 2
unwilling to travel to/participate in the exercise
program as defined by the protocol.*
Yes
No
previous chemotherapy (previous cancer is not
an exclusion criteria).*
Yes
No
cancer recurrence.*
Yes
No
planned/known absence of greater than 2 weeks
during the intended study period.*
Yes
No
previous therapy for known breast cancer.*
Yes
No
those who have had tram (i.e., transabdominal
rectus abdominus muscle reconstructive surgery)
done.*
Yes
No
moderate lymphedema (>20% or >200ml
difference between the affected arm and the
unaffected arm).*
Yes
No
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Eligibility Breast Cancer NCT00283608
Pharmacogenetics of Anastrozole in Postmenopausal
Women With Estrogen Receptor-Positive and/or
Progesterone Receptor-Positive Stage I, Stage II, or Stage
III Breast Cancer; ODM derived from:
https://clinicaltrials.gov/show/NCT00283608
All rights reserved. Please visit https://medical-data-
models.org/forms/16455
Eligibility Breast Cancer
NCT00283608
Criteria
diagnosis of breast cancer*
Yes
No
stage i, ii, or iii disease*
Yes
No
resected disease*
Yes
No
planning to undergo treatment with anastrozole at
the clinically approved dose of 1 mg/day or mayo
clinic cancer center rochester patient who will be
enrolled on or has been enrolled on can-ncic-
ma27 and has not started taking the study
medication (anastrozole or exemestane)*
Yes
No
hormone receptor status:*
Yes
No
estrogen receptor-positive and/or progesterone
receptor-positive primary tumor*
Yes
No
patient characteristics:*
Yes
No
female*
Yes
No
postmenopausal*
Yes
No
able to complete questionnaires alone or with
assistance*
Yes
No
prior concurrent therapy:*
Yes
No
1 / 2
more than 6 months since prior endocrine
therapy, except tamoxifen*
Yes
No
no other prior aromatase inhibitors (e.g., letrozole
or exemestane)*
Yes
No
no prior ovarian function suppression with
surgery or radiotherapy, ovarian ablation, or
luteinizing hormone-releasing hormone
analogues (e.g., goserelin) as treatment for
cancer*
Yes
No
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Eligibility Breast Cancer NCT00283608
EBMT FOLLOW UP
MYELOPROLIFERATIVE NEOPLASM
ODM form derived from MYELOPROLIFERATIVE
NEOPLASM please refer to:
http://www.ebmt.org/Contents/Data-
Management/Registrystructure/MED-
ABdatacollectionforms/Pages/MED-AB-data-collection-
forms.aspx 
All rights reserved. Please visit https://medical-data-
models.org/forms/16456
EBMT FOLLOW UP
MYELOPROLIFERATIVE
NEOPLASM
FOLLOW UP MYELOPROLIFERATIVE
NEOPLASM
Unique Identification Code (UIC)
(if known)
Date of this report
Patient following national / international study /
trial
No (1)
Yes (2)
Not evaluated (3)
Unknown (4)
Name of study / trial
Hospital Unique Patient Number
First name(s)_surname(s)
Date of Birth
Date of last HSCT for this patient
DATE OF LAST CONTACT OR DEATH
GRAFT VERSUS HOST DISEASE
(GvHD) SINCE LAST REPORT
Acute Graft versus Host Disease (aGvHD) -
Maximum grade
grade 0 (absent) (grade 0 (absent))
grade I (grade I)
grade II (grade II)
grade III (grade III)
grade IV (grade IV)
not evaluated (not evaluated)
If present GvHD, Maximum grade
New onset (1)
1 / 11
Recurrent (2)
Persistent (3)
Reason Maximum grade
Tapering (1)
DLI (2)
Unexplained (3)
Date onset of this episode (if new or recurrent)
yyyy/mm/dd
Date onset of this episode
Not applicable (1)
aGvHD Stage Skin
0 (1)
1 (2)
2 (3)
3 (4)
4 (5)
Not evaluated (6)
unknown (7)
aGvHD Stage liver
0 (1)
1 (2)
2 (3)
3 (4)
4 (5)
Not evaluated (6)
unknown (7)
aGvHD stage gut
0 (1)
1 (2)
2 (3)
3 (4)
4 (5)
Not evaluated (6)
unknown (7)
Resolution
No  (1)
Yes (2)
aGvHD Date of resolutions
Presence of cGvHD
No (No)
Present continuously since last reported
episode (Present continuously since last
reported episode)
Resolved (Resolved)
Yes (Yes)
Date of onset
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cGvHD grade
limited (1)
Extensive (2)
Organs affected
Skin (1)
Gut (2)
Liver (3)
Mouth (4)
Eyes (5)
Lung (6)
Other, specify (7)
Unknown (8)
If other organs affected, please specify
cGvHD Resolved: Date of resolution
OTHER COMPLICATIONS SINCE LAST
REPORT
INFECTION RELATED COMPLICATIONS
No complications (1)
Yes (2)
Bacteremia / fungemia / viremia / parasites
Pathogen (1)
Date (2)
Septic shock
Pathogen  (1)
Date (2)
ARDS
Pathogen  (1)
Date (2)
Multiorgan failure due to infection
Pathogen  (1)
Date (2)
Pneumonia
Pathogen  (1)
Date (2)
Hepatitis
Pathogen  (1)
Date (2)
CNS infection
Pathogen  (1)
Date (2)
Gut infection
Pathogen  (1)
Date (2)
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Skin infection
Pathogen  (1)
Date (2)
Cystitis
Date (Date)
Pathogen (Pathogen)
Retinitis
Date (Date)
Pathogen (Pathogen)
Other pathogen specified
NON INFECTION RELATED COMPLICATIONS
No complications (1)
Yes (2)
Idiopathic pneumonia syndrome
No  (No )
Unknown (Unknown)
Yes (Yes)
VOD
No  (No )
Unknown (Unknown)
Yes (Yes)
Cataract
No (No)
Unknown (Unknown)
Yes (Yes)
Haemorrhagic cystitis, non infectious
No  (No )
Unknown (Unknown)
Yes  (Yes )
Specify:
ARDS, non infectious
No (No)
Unknown (Unknown)
Yes (Yes)
Multiorgan failure, non infectious
no  (no )
unknown (unknown)
yes  (yes )
HSCT-associated microangiopathy
Date (4)
No (No)
Unknown (Unknown)
Yes (Yes)
Renal failure requiring dialysis
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Date (Date)
No (No)
Unknown (Unknown)
Yes (Yes)
Haemolytic anaemia due to blood group
Date (4)
No (No)
Unknown (Unknown)
Yes (Yes)
Aseptic bone necrosis
Date (Date)
No (No)
Unknown (Unknown)
Yes (Yes)
Other type of NON INFECTION RELATED
COMPLICATIONS, please specify
Idiopathic pneumonia syndrome
ADDITIONAL THERAPIES SINCE LAST
FOLLOW UP
Additional treatment given since last report
Date (4)
No (No)
Unknown (Unknown)
Yes (Yes)
If treatment given since last report
If yes: Cellular therapy (One cell therapy regimen
is defined as any number of infusions given within
10 weeks for the same indication. If more than
one regimen of cell therapy has been given since
last report, copy this section and complete it as
many times as necessary.)
No  (1)
Yes (Mark disease status before this
cellular therapy) (2)
Unknown (3)
Disease status before this cellular therapy
CR (CR)
Not evaluated (Not evaluated)
Not in CR (Not in CR)
If yes: Type of cells
Donor lymphocyte infusion (DLI) (1)
Mesenchymal cells (2)
Other (3)
Unknown (4)
If other
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Chronological number of this cell therapy for this
patient
Number of Nucleated cells infused (DLI only)
10^8/kg
Number (1)
Not evaluated (2)
Unknown (3)
If DLI, specify the number of cells infused by
type:
CD 34+
Evaluated (Evaluated)
Not Evaluated (Not Evaluated)
Unknown (Unknown)
If DLI, specify the number of cells infused by
type: 
CD 3+
Evaluated  (Evaluated )
Not evaluated (Not evaluated)
Unknown (Unknown)
If non DLI, specify total number of cells infused:
Evaluated (Evaluated)
Not Evaluated (Not Evaluated)
Unknown (Unknown)
Cell therapy indication
Planned/protocol  (1)
Treatment for disease (2)
Prophylactic (3)
Mixed chimaerism (4)
Treatment of GvHD  (5)
Treatment viral infection (6)
Loss/decreased chimaerism  (7)
Treatment PTLD, EBV lymphoma (8)
Other, specify (9)
Number of infusions within 10 weeks (count only
infusions that are part of same regimen and given
for the same indication)
Acute Graft versus Host Disease 
(after this infusion but before any further infusion/
transplant)
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Maximum grade:
grade 0 (absent) (grade 0 (absent))
grade 1 (grade 1)
grade 2 (grade 2)
grade 3 (grade 3)
grade 4 (grade 4)
present, grade unknown (present, grade
unknown)
Disease treatment (apart from donor cell infusion
or other type of cell therapy)
No (1)
Yes: Planned (planned before HSCT took
place) (2)
Yes: Not planned (for
relapse/progression or persistent
disease) (3)
Date started
Overall main reason ADDITIONAL THERAPIES
Relapse/progression (1)
Continued from pre-HSCT (2)
unknow (3)
Planned per protocol (4)
Other (5)
Of Other, please specify
Drugs
no (no)
unknown (unknown)
yes (yes)
If yes, mark appropriate box
Alpha interferon (Alpha interferon)
Anti-lymphocyte antibodies (Anti-
lymphocyte antibodies)
Azathioprine (Azathioprine)
Interferon Beta  (Beta Interferon)
low dose (Chronic low dose)
CopI (Cop-I)
Corticosteroids (Corticosteroids)
Cyclophosphamide (Cyclophosphamide)
Mitoxantron (Mitoxantron)
high dose (Pulse high dose)
Total lymph node (TLI)
NO (NO)
UNKNOWN (UNKNOWN)
YES (YES)
Craniospinal
no (no)
unknown (unknown)
yes (yes)
Lymphocytopheresis
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no (no)
unknown (unknown)
yes  (yes )
if other modality please specify:
GRAFT ASSESSMENT AND
HAEMOPOIETIC CHIMAERISM
Graft loss
No (No)
Not evaluated (Not evaluated)
Yes (Yes)
Overall chimaerism
Aplasia (Aplasia)
95%) (Autologuos reconstitution
(recipient >)
95%) (Full (donor >)
Mixed (partial) (Mixed (partial))
Not evaluated (Not evaluated)
Date of Test
Identification of donor or Cord Blood Unit given
by the centre
Number in the infusion order
Graft loss
No (No)
Not evaluated (Not evaluated)
Yes (Yes)
Overall chimaerism
Full (donor >95%) (1)
Mixed (partial) (2)
Autologuos reconstitution (recipient >
95%) (3)
Aplasia (4)
Not evaluated (5)
Date of test
(Indicate the date(s) and results of all tests done
for all donors. Split the results by donor and by
the cell type on which the test was performed if
applicable. Copy this table as many times as
necessary.)
Identification of donor or Cord Blood Unit given
by the centre
Number in the infusion order (if applicable)
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Cell type on which test was performed % Donor
cells
B-Cells
%
BM (1)
Other, specify (10)
PB mononuclear cells (PBMC) (2)
T-cell (3)
B-cells (4)
Red blood cells (5)
Monocytes (6)
PMNs (neutrophils) (7)
Lymphocytes, NOS (8)
Myeloid cells, NOS (9)
Laboratory tests used
ABO group (ABO group)
Cytogenetic (Cytogenetic)
FISH (FISH)
Molecular (Molecular)
Other (Other)
unknown (unknown)
Test used:
If other, specify:
SECONDARY MALIGNANCY,
LYMPHOPROLIFERATIVE OR
MYELOPROLIFRATIVE DISORDER
DIAGNOSED
No at date of this follow-up (No at date of
this follow-up)
Previously reported (Previously reported)
Yes (Yes)
Date of Diagnosis
Diagnosis OTHER COMPLICATIONS SINCE
LAST REPORT
AML (AML)
Lymphoproliferative disorder
(Lymphoproliferative disorder)
MDS (MDS)
Other (Other)
Diagnosis, other:
LAST DISEASE AND PATIENT STATUS
Scripps neurological rating scale Score
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Kurtzke functional systems Overall score
Kurtzke Expanded Disability Status Scale (EDSS)
Composite Scale Score
MRI BRAIN SCAN DONE
Not done (Not done)
Yes (Yes)
Date of most recent MRI scan of brain
Results, Are new lesions present on the MRI?
no (no)
unknown (unknown)
yes (yes)
If yes Indicate new lesions present
Both (Both)
Gadolinium-enhancing (Gadolinium-
enhancing)
Unenhancing (Unenhancing)
Unknown (Unknown)
Has patient or partner become  pregnant after
this HSCT?
No (No)
Unknown (Unknown)
Yes (Yes)
Survival Status
alive (0)
dead (1)
Performance score (if alive)
Karnofsky (1)
Lansky (2)
performance status
100 (Normal, NED) (1)
10 (Moribund) (10)
Not evaluated (11)
Unknown (12)
90 (Normal activity)  (2)
80 (Normal with effort) (3)
70 (Cares for self) (4)
60 (Requires occasional assistance) (5)
50 (Requires assistance) (6)
40 (Disabled) (7)
30 (Severely disabled) (8)
20 (Very sick) (9)
Cause of death (if dead)
Relapse or progression (1)
Secondary malignancy (including
lymphoproliferative disease) (2)
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HSCT related cause  (3)
Unknown (4)
Other (5)
HSCT related cause
GvHD (1)
Veno-occlusive disease (VOD) (10)
Haemorrhage (11)
Cardiac toxicity (12)
Central nervous system toxicity (13)
Gastro intestinal toxicity (14)
Skin toxicity (15)
Renal failure (16)
Multiple organ failure (17)
Other (18)
Interstitial pneumonitis (2)
Pulmonary toxicity (3)
Infection bacterial (4)
Infection viral (5)
Infection fungal (6)
Infection parasitic (7)
Infection unknown (8)
Rejection / poor graft function (9)
ADDITIONAL NOTES IF APPLICABLE
COMMENTS
Identification
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Eligibility Carcinoma, Non-Small Cell Lung
NCT00263731
Metabolomic Analysis of Lung Cancer; ODM derived from:
https://clinicaltrials.gov/show/NCT00263731
All rights reserved. Please visit https://medical-data-
models.org/forms/16457
Eligibility Carcinoma, Non-Small Cell
Lung NCT00263731
Criteria
Inclusion Criteria
patients with suspected, clinically diagnosed, or
histologically diagnosed lung cancer.
occasionally, other cancers (including metastatic
cancers to the lung) may be resected for the
study as negative controls for nsclc, as warranted
by the particulars of the case.*
Yes
No
patients must have general medical conditions to
allow them to undergo surgical resection of their
primary tumor*
Yes
No
Exclusion Criteria
history of diabetes for the experimental group
(surgery + glucose); patients with a history of
diabetes are allowed in the control group
(surgery/no glucose)*
Yes
No
known hepatitis c or hiv (aids)*
Yes
No
healthy subjects (group 3)*
Yes
No
Inclusion Criteria
at least 30 years of age*
Yes
No
preferably be fasting for 12 hours (minimum 8
hours) prior to enrollment*
Yes
No
Exclusion Criteria
prior history of diagnosed lung cancer*
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Yes
No
known hepatitis c or hiv (aids)*
Yes
No
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Eligibility Carcinoma, Non-Small Cell Lung NCT00263731
Eligibility Carcinoma, Non-Small-Cell Lung
NCT00153803
Erlotinib or Placebo Following Chemoradiotherapy
(Chemo/RT) in Stage III Non-Small Cell Lung Cancer
(NSCLC); ODM derived from:
https://clinicaltrials.gov/show/NCT00153803
All rights reserved. Please visit https://medical-data-
models.org/forms/16458
Eligibility Carcinoma, Non-Small-Cell
Lung NCT00153803
Inclusion Criteria
unresectable, stage iiia or iiib nsclc (measurable
disease is not required)*
Yes
No
no evidence of metastatic disease*
Yes
No
no prior treatment*
Yes
No
adequate organ function*
Yes
No
adequate pulmonary function (fev >= 1.0l or
predicted fev >0.8l)*
Yes
No
Exclusion Criteria
Metastasis*
Yes
No
prior treatment*
Yes
No
malignant pleural or pericardial effusion*
Yes
No
peripheral neuropathy >= grade 2*
Yes
No
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MYELOPROLIFERATIVE NEOPLASM
EBMT General Information
ODM form derived from 15pp EBMT
MYELOPROLIFERATIVE NEOPLASM please refer to:
http://www.ebmt.org/Contents/Data-
Management/Registrystructure/MED-
ABdatacollectionforms/Pages/MED-AB-data-collection-
forms.aspx 
All rights reserved. Please visit https://medical-data-
models.org/forms/16459
MYELOPROLIFERATIVE
NEOPLASM EBMT General
Information
EBMT FORM GENERAL INFORMATION
TEAM
EBMT Centre Identification Code (CIC)
Hospital
Unit
Name of contact person
Telephone number of contact person
Fax
E-mail
Date of this report
Patient following national / international study /
trial
No (1)
Yes (2)
Not evaluated (3)
Unknown (4)
Name of study / trial
GENERAL INFORMATION Patient
To be entered only if patient previously reported
Hospital Unique Patient Number or Code
First name(s)_surname(s)
Date of birth
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Sex:
Female (Female)
Male (Male)
ABO Group
Rh factor
Absent (Absent)
Not evaluated (Not evaluated)
Present (Present)
DISEASE
Date of Diagnosis
Check the disease for which this transplant was
performed
Acute Leukaemia (Acute Leukaemia)
Acute Lymphoblastic Leukaemia (ALL)
(Acute Lymphoblastic Leukaemia (ALL))
Acute Myelogenous Leukaemia (AML)
(Acute Myelogenous Leukaemia (AML))
Autoimmune disease (Autoimmune
disease)
Bone marrow failure including Aplastic
anaemia (Bone marrow failure including
Aplastic anaemia)
Chronic Leukaemia (Chronic Leukaemia)
Chronic Lymphocytic Leukaemia
(Chronic Lymphocytic Leukaemia)
Chronic Myeloid Leukaemia (CML)
(Chronic Myeloid Leukaemia (CML))
Hemoglobinopathies
(Haemoglobinopathiy)
Histiocytic disorders (Histiocytic
disorders)
Hodgkin´s Disease (Hodgkin´s Disease)
Inherited disorders (Inherited disorders)
Juvenile Idiopathic Arthritis (Juvenile
Idiopathic Arthritis)
Lymphoma (Lymphoma)
MD/ MPN (MD/ MPN)
MDS (MDS)
Metabolic disorders (Metabolic
disorders)
Multiple Sclerosis (Multiple Sclerosis)
Myelodysplastic syndromes
(Myelodysplastic syndromes)
Myeloma/ Plasma cell disorder
(Myeloma/ Plasma cell disorder)
Myeloproliferative neoplasm
(Myeloproliferative neoplasm)
Non Hodgkin (Non Hodgkin)
Other diagnosis (Other diagnosis)
Primary immune deficiencies (Primary
immune deficiencies)
Secondary Acute Leukaemia (do not use
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if transformed from MDS/MPN)
(Secondary Acute Leukaemia (do not
use if transformed from MDS/MPN))
Solid Tumour (Solid Tumour)
Systemic Lupus (Systemic Lupus)
Systemic Sclerosis (Systemic Sclerosis)
If other diagnosis, specify:
SPECIFICATIONS OF THE DISEASE
MYELOPROLIFERATIVE NEOPLASM
DIAGNOSIS
SUBCLASSIFICATION Myeloproliferative
neoplasm
Chronic idiopathic myelofibrosis or
Primary myelofibrosis (1)
Mast cell sarcoma (10)
Polycythaemia vera (2)
Essential thrombocythemia (3)
Hyper eosinophilic syndrome (HES) (4)
Chronic eosinophilic leukaemia (CEL) (5)
Chronic neutrophilic leukaemia (6)
Stem cell leukemia-Lymphoma
syndrome (8p11 syndrome) (7)
Systemic mastocytosis (8)
Mast cell leukaemia (9)
Chronic eosinophilic leukaemia (CEL) With
blastic transformation
no (no)
unknown (unknown)
yes  (yes )
Include all analysis before treatment; describe
results of most recent complete analysis
Chromosome analysis
Done: abnormal (Done: abnormal)
Done: normal (Done: normal)
Not Done or failed (Not Done or failed)
Unknown (Unknown)
If abnormal: Are there 3 or more abnormalities
(complex kariotype)?
no (no)
unknown (unknown)
yes  (yes )
number of metaphases with abnormalites: If done
number of metaphases examined, if done
Abnormality chr. 1
Absent (Absent)
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Present (Present)
Abnormality chr. 5
Absent (Absent)
Present (Present)
Abnormality chr. 7
Absent (Absent)
Present (Present)
trisomy 8
Absent (Absent)
Present (Present)
trisomy 9
Absent (Absent)
Present (Present)
del 20
Absent (Absent)
Present (Present)
del 13
Absent (Absent)
Present (Present)
Other abnormalities please specify
Molecular markers
Evaluated: Absent  (1)
Evaluated: Present (2)
Not evaluated (3)
unknown (4)
JAK2 mutation
Absent (Absent)
Not evaluated (Not evaluated)
Present (Present)
unknown (unknown)
BCR/ABL
Absent (Absent)
Not evaluated (Not evaluated)
Present (Present)
unknown (unknown)
FIP1L1-PDGFR
Absent (Absent)
Not evaluated (Not evaluated)
Present (Present)
unknown (unknown)
HAEMATOLOGICAL VALUES Peripheral bloodc
CodelistItem 881663 (4)
CodelistItem 881664 (5)
blasts (blasts)
Hb (g/dL) (Hb (g/dL))
neutrophils (neutrophils)
Platelets (109/L) (Platelets (109/L))
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White Blood Cells (109/L) (White Blood
Cells (109/L))
Hb (g/dl)
g/dl
Platelets (109/L)
109/L
Peripheral Blood Analysis
If evaluated:
White Blood Cells (10^9/L)
10^9/L
Blasts
%
Monocytes
%
Neutrophils
%
Bone marrow Blasts
%
Auer rods present
no  (no )
Not evaluated (Not evaluated)
unknown (unknown)
yes (yes)
Lille score
High (High)
Intermediate (Intermediate)
Low (Low)
Unknown (Unknown)
BM INVESTIGATION (at diagnosis)
Cytology (Cytology)
Histology (Histology)
Not available (Not available)
BM INVESTIGATION RESULTS
Mild (Grade 1) (Mild (Grade 1))
Moderate (Grade 2) (Moderate (Grade
2))
No (No)
Not evaluable (Not evaluable)
Severe (Grade 3) (Severe (Grade 3))
Unknown (Unknown)
Night sweat
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No (No)
Unknown (Unknown)
Yes (Yes)
Palpable Splenomegaly
Absent  (Absent)
Not evaluated  (Not evaluated)
Present  (Present)
Unknown (Unknown)
Physical examination
Not evaluated (1)
Spleen span in ultrasound or CT scan maximum
diameter
cm
Weight loss
No (No)
Unknown (Unknown)
Yes (Yes)
FIRST LINE THERAPY
First Line Therapy given
Yes
No
SUBCLASSIFICATION AT PRIMARY
TREATMENT
MPN (as registered at diagnosis) (1)
Transformed to myelofibrosis from
Polycythaemia vera/ Essential
thrombocythemia  (2)
Transformed to AML (3)
date of transformation
Chemo/drug/agent
Yes
No
if yes including GF, hormones, etca
AML like therapy (AML like therapy)
Androgens (Androgens)
Ara-C (Ara-C)
Hydroxyurea (Hydroxyurea)
Interferon (Interferon)
Lenalidomide (Lenalidomide)
Steroids (Steroids)
Thalidomide (Thalidomide)
Tyrosine kinase inhibitor (Tyrosine kinase
inhibitor)
Radiotherapy
Yes
No
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if other Radiotherapy, please specify
If subsequent HSCT, indicate the date of the 1st
CR after this treatment
Complete remission (CR) (Complete
remission(CR))
Never in CR (Never in CR)
SUBCLASSIFICATION & STATUS OF
DISEASE AT HSCT
Date of HSCT
Splenectomy: if yes date
no  (no )
yes (yes)
Transfusional status at HSCT
No transfusions (1)
With transfusions (2)
Never transfused (3)
SUBCLASSIFICATION AT HSCT
MPN (as registered at diagnosis) (1)
Transformed to myelofibrosis from
Polycythaemia vera/ Essential
thrombocythemia  (2)
Transformed to AML (3)
If transformed into Myelofibrosis or AML, date of
transformation
STATUS OF DISEASE AT HSCT
Primary refractory phase (no change) (1)
Complete remission (CR) (2)
Improvement but no CR (3)
Relapse (after CR) (4)
Progression/worse (5)
Untreated (Supportive care or treatment
without chemotherapy) (6)
NUMBER (complete for CR or relapse)
1st (1st)
2nd (2nd)
3rd or higher (3rd or higher)
Chromosome analysis
Not done or failed (1)
Done: normal (2)
Done: abnormal (3)
Unknown (4)
If abnormal: Are there 3 or more abnormalities
(complex kariotype)?
no (1)
yes (2)
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unknown (3)
Abnormality chr. 1
Absent (1)
Present (2)
Abnormality chr. 5
Abnormality chr. 7
Absent (1)
Present (2)
trisomy 8
Absent (1)
Present (2)
trisomy 9
Absent (1)
Present (2)
del 20
Absent (1)
Present (2)
del 13
Absent (1)
Present (2)
HAEMATOLOGICAL VALUES Peripheral blood
Platelets (109/L)    (1)
Hb (g/dl) (2)
blasts  (3)
monocytes (4)
neutrophils (5)
Bone marrow
%
blasts (1)
% blasts (2)
Auer rod (3)
Lille score
Low (1)
Intermediate (2)
High (3)
Unknown (4)
Cervantes score
Low (1)
High (2)
Unknown (3)
Within 2 months of the preparative -conditoning-
regimen:
Cytology (Cytology)
Histology (Histology)
Not available (Not available)
CELLULARITY ON BM ASPIRATE / BM BIOPSY
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Acellular (1)
Hypocellular (2)
Normocellular (3)
Hypercellular (4)
Focal cellularity (5)
Unknown (6)
FIBROSIS/OSTEOSCLEROSIS ON BM BIOPSY
No (1)
Mild (Grade 1) (2)
Moderate (Grade 2) (3)
Severe (Grade 3) (4)
Not evaluable (5)
Unknown (6)
Night sweat Within 2 months of the preparative
-conditioning- regimen
Yes (1)
No (2)
Unknown (3)
Palpable Splenomegaly
Absent  (Absent)
Not evaluated  (Not evaluated)
Present  (Present)
Unknown (Unknown)
Physical examination
yes  (1)
not evaluated (2)
Physical examination below costal margin
cm
Spleen span in ultrasound or CT scan
cm
Weight loss
yes (1)
no (2)
unknown (3)
ADDITIONAL TREATMENT POST-HSCT
Additional Disease Treatment
No (No)
Unknown (Unknown)
Yes (Yes)
ADDITIONAL DISEASE TREATMENT,  if yes
Planned (planned before HSCT took
place) (1)
Not planned (for relapse/progression or
persistent disease) (2)
RESPONSE OF DISEASE
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BEST RESPONSE AT 100 DAYS AFTER HSCT
CR (maintained or achieved) (1)
improvement but no CR (2)
Unknown (3)
Relapse / Progression (4)
Not evaluable (5)
FORMS TO BE FILLED IN
TYPE OF TRANSPLANT
AUTOgraft, proceed to Autograft form (1)
ALLOgraft or Syngeneic graft, proceed to
Allograft form (2)
other (3)
if other TYPE OF TRANSPLANT, please specify
and contact the EBMT Central Registry Office for
instructions
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Eligibility Carcinoma, Non-Small-Cell Lung
NCT00157196
Safety Study of BLP25 Liposome Vaccine in Non-Small
Cell Lung Cancer Patients With Unresectable Stage III
Disease; ODM derived from:
https://clinicaltrials.gov/show/NCT00157196
All rights reserved. Please visit https://medical-data-
models.org/forms/16460
Eligibility Carcinoma, Non-Small-Cell
Lung NCT00157196
Inclusion Criteria
histologically documented unresectable stage iii
nsclc.  mediastinal (n2) involvement must be
confirmed by biopsy*
Yes
No
stable disease or clinical response after primary
therapy of chemo-radiation treatment for
unresectable stage iii disease*
Yes
No
primary therapy should be a minimum of 2 cycles
of platinum-based first-line chemotherapy, given
concurrent with thoracic radiation.  the combined
modality should consist of either:*
Yes
No
induction (2 cycles) chemotherapy followed by
concurrent chemo/rt; or*
Yes
No
concurrent chemo/rt followed by 2 cycles of
consolidation chemotherapy; or*
Yes
No
concurrent chemo/rt alone*
Yes
No
a minimum radiation dose of ≥6,000cgy should
be administered.  patients must have completed
the primary therapy at least 4 weeks and no later
than 6 months prior to study entry*
Yes
No
ecog performance status of ≤1*
Yes
No
ability to understand and willingness to sign a
written informed consent*
Yes
No
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Exclusion Criteria
undergone lung cancer specific therapy (including
surgery) prior to primary chemo/rt*
Yes
No
received immunotherapy within 4 weeks prior to
study entry*
Yes
No
received systemic immunosuppressive drugs
within 4 weeks prior to study entry*
Yes
No
received investigational systemic drugs within 4
weeks prior to study entry*
Yes
No
brain metastases*
Yes
No
pleural effusion, unless cytologically confirmed to
be non-malignant*
Yes
No
past or current history of neoplasm other than
lung carcinoma, except for curatively treated non-
melanoma skin cancer, in situ carcinoma of the
cervix or other cancer curatively treated and with
no evidence of disease for at least 5 years*
Yes
No
autoimmune disease or immunodeficiency*
Yes
No
clinically significant hepatic, renal or cardiac
dysfunction*
Yes
No
clinically significant active infection*
Yes
No
pregnant or lactating, women of childbearing
potential, unless using effective contraception as
determined by the investigator*
Yes
No
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Eligibility Carcinoma, Non-Small-Cell Lung NCT00157196
Eligibility Hypertension NCT00247910
Behavioural Treatment of Hypertension; ODM derived from:
https://clinicaltrials.gov/show/NCT00247910
All rights reserved. Please visit https://medical-data-
models.org/forms/16461
Eligibility Hypertension
NCT00247910
Inclusion Criteria
must be at least 19 years of age*
Yes
No
subjects can be male or female*
Yes
No
subjects must have an average resting blood
pressure of >140 systolic pressure an/ or >90
diastolic pressure off anti-hypertensive
medication*
Yes
No
Exclusion Criteria
must not be on more than 2 blood pressure
lowering drugs*
Yes
No
must not have known or suspected of having
secondary hypertension on initial examination*
Yes
No
must not be pregnant or anticipating pregnancy
during study period*
Yes
No
must not have history of allergy, hypersensitivity
or intolerance to diuretics*
Yes
No
must not have medical condition that may result
in an unacceptable risk of complications due to
uncontrolled hypertension during time period of
study*
Yes
No
must not have average resting bp readings that
exceed 190 systolic, or 115 diastolic, or have two
consecutive readings of 180 systolic or 110
diastolic*
Yes
No
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Eligibility Hypertension NCT00367978
Effects of Amlodipine/Benazepril in the Hypertensive
African-American Population With Type 2 Diabetes Mellitus;
ODM derived from:
https://clinicaltrials.gov/show/NCT00367978
All rights reserved. Please visit https://medical-data-
models.org/forms/16462
Eligibility Hypertension
NCT00367978
Inclusion Criteria
african-american*
Yes
No
males and females*
Yes
No
current diagnosis of type 2 diabetes documented
by medical history;*
Yes
No
mean sitting diastolic blood pressure of  ≥ 90 and
≤ 110 mm hg;*
Yes
No
hba1c ≤ 9.5%*
Yes
No
Exclusion Criteria
having unilateral or bilateral renal artery
stenosis;*
Yes
No
having clinically significant cardiac dysrhythmias;*
Yes
No
having a significant history of coronary artery
disease within the past 6 months;*
Yes
No
having a history or diagnosis of congestive heart
failure (chf);*
Yes
No
having any clinically relevant cardiac valvular
disease*
Yes
No
1 / 1
Eligibility Carcinoma, Non-Small-Cell Lung
NCT00252382
Safety and Efficacy Clinical Study of SNS-595 for Second-
Line Therapy in Patients With Advanced NSCLC; ODM
derived from: https://clinicaltrials.gov/show/NCT00252382
All rights reserved. Please visit https://medical-data-
models.org/forms/16463
Eligibility Carcinoma, Non-Small-Cell
Lung NCT00252382
Inclusion Criteria
able to understand and willing to sign a written
informed consent document*
Yes
No
patients who have recurrent or metastatic nsclc,
who have failed initial therapy with a platinum-
containing regimen and have not received any
second-line therapy (adjuvant therapy is
acceptable if it was completed greater than or
equal to 12 months before the cancer
recurrence)*
Yes
No
measurable disease*
Yes
No
eastern cooperative oncology group (ecog)
performance status score of 0 or 1*
Yes
No
laboratory values within the normal or reasonable
reference range as specified by the protocol*
Yes
No
Exclusion Criteria
prior exposure to sns-595*
Yes
No
pregnant or breastfeeding*
Yes
No
women of childbearing potential or male partners
of women of childbearing potential unwilling to
use an approved, effective means of
contraception according to the institution's
standards*
Yes
No
other active malignancies or other malignancies
within the past 12 months except non-melanoma
skin cancer, cervical intraepithelial neoplasia or
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prostatic intraepithelial neoplasia*
Yes
No
brain metastases, if present, without radiologic
evidence of progressive disease for at least 3
months after completion of therapy*
Yes
No
myocardial infarction, cerebrovascular
accident/transient ischemic attack (tia) or
thromboembolic event (deep vein thrombosis or
pulmonary embolus) within 6 months before the
first sns-595 dose*
Yes
No
requires kidney dialysis (hemodialysis or
peritoneal)*
Yes
No
prior chemotherapy, investigational agents, or
radiation therapy within 28 days before cycle 1
day 0;  however, nitrosoureas and mitomycin are
not permitted for at least 42 days before cycle 1
day 0*
Yes
No
in patients with toxicities caused by prior cancer
therapy, those toxicities must have returned to
less than or equal to grade 1, with the exception
of alopecia*
Yes
No
prior pelvic radiation therapy or radiation to
greater than or equal to 25% of bone marrow
reserve (prior palliative radiation is permitted as
long as it does not exceed 25% of bone marrow
reserve)*
Yes
No
any other medical, psychological, or social
condition that, in the opinion of the principal
investigator, would contraindicate the patient's
participation in the clinical trial due to safety
concerns or compliance with study procedures*
Yes
No
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Eligibility Carcinoma, Non-Small-Cell Lung NCT00252382
Eligibility Carcinoma, Non-Small-Cell Lung
NCT00379665
Intratumoral Cancer Chemotherapy Through a Flexible
Bronchoscope as an Adjunct to Brachytherapy; ODM
derived from: https://clinicaltrials.gov/show/NCT00379665
All rights reserved. Please visit https://medical-data-
models.org/forms/16464
Eligibility Carcinoma, Non-Small-Cell
Lung NCT00379665
Inclusion Criteria
patients with inoperable lung carcinoma and/or
recurrent disease.*
Yes
No
patients with symptomatic obstruction.*
Yes
No
occlusion or partial occlusion of bronchi.*
Yes
No
disease verified via bronchoscopy.*
Yes
No
patients with a least one endobronchial tumor,
measuring at least 0.5 cm.*
Yes
No
patients between ages of 20 and 80 years.*
Yes
No
documented informed consent must be
obtained.*
Yes
No
Exclusion Criteria
patients without diagnosis confirmed by
bronchoscopy.*
Yes
No
patients with endobronchial tumors measuring
less than 0.5 cm.*
Yes
No
patients younger than 20 or older than 80 years.*
Yes
No
patients who do not sign informed consent form.*
Yes
No
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Eligibility Hypertension NCT00541684
Health Assessment Study (0954-946); ODM derived from:
https://clinicaltrials.gov/show/NCT00541684
All rights reserved. Please visit https://medical-data-
models.org/forms/16465
Eligibility Hypertension
NCT00541684
Inclusion Criteria
newly diagnosed with mild to moderate
hypertension*
Yes
No
married male in stable heterosexual relationship*
Yes
No
no prior history of sexual dysfunction*
Yes
No
satisfied with overall sex life*
Yes
No
patient's spouse is in close proximity for the
study*
Yes
No
has had at least 2 but not more than 10 sexual
intercourse events during the 2 week period prior
to study start*
Yes
No
patient able to visit doctor in the morning of each
scheduled visit*
Yes
No
able to complete the self administered health
assessment questionnaire*
Yes
No
Exclusion Criteria
hypertension due to cancer, history of heart or
circulatory problems*
Yes
No
history of mental disorder that might impair
sexual function*
Yes
No
history or presence of drug or alcohol abuse*
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Yes
No
prior surgery for erectile dysfunction or other
urological procedure*
Yes
No
no penile implant or assist devices*
Yes
No
history of chronic liver disease, history of
diabetes*
Yes
No
history of severe life-threatening diseases such
as, cancer, aids or positive hiv test*
Yes
No
subjects with only 1 kidney*
Yes
No
mental handicap or legal incapacity*
Yes
No
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Eligibility Hypertension NCT00541684
Eligibility Carcinoma, Renal Cell
NCT00523640
A Phase II Trial of Gemcitabine, Capecitabine, and
Bevacizumab in Metastatic Renal Cell Carcinoma; ODM
derived from: https://clinicaltrials.gov/show/NCT00523640
All rights reserved. Please visit https://medical-data-
models.org/forms/16466
Eligibility Carcinoma, Renal Cell
NCT00523640
Inclusion Criteria
histologically or cytologically confirmed
metastatic clear cell renal cell cancer*
Yes
No
measurable disease*
Yes
No
age 18 or older*
Yes
No
ecog performance status of 0 - 1*
Yes
No
blood pressure less than 140/90 on 2 separate
occasions not more than 6 weeks prior to
enrollment and not less than 24 hours apart*
Yes
No
normal organ function*
Yes
No
women of child-bearing potential and men must
agree to use adequate contraception*
Yes
No
ability to understand and the willingness to sign a
written informed consent document and to follow
all required study procedures*
Yes
No
Exclusion Criteria
patients who have had chemotherapy or
radiotherapy within 4 weeks prior to entering the
study or those who have not recovered from
adverse events due to agents administered more
than 4 weeks earlier*
Yes
No
patients may not have had prior treatment with
pyrimidine analogs or vegf binding agents*
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Yes
No
patients may not be receiving any other
investigational or therapeutic agents*
Yes
No
patients may not be receiving therapeutic
anticoagulation with warfarin, its congeners,
heparin, low molecular weight heparinoids,
specific thrombin inhibitors, or other similar
agents  patients receiving low dose coumadin (1
mg daily) for central line patency are eligible*
Yes
No
major surgical procedure, open biopsy, or
significant traumatic injury within 28 days prior to
treatment start, or anticipation of need for major
surgical procedure during the course of the study
fine needle aspirations or core biopsies within 7
days prior to treatment start are acceptable*
Yes
No
serious, non healing wound, ulcer, or bone
fracture*
Yes
No
evidence of bleeding diathesis or coagulopathy*
Yes
No
patients with known brain metastases*
Yes
No
uncontrolled intercurrent illness*
Yes
No
pregnant women*
Yes
No
hiv-positive patients receiving combination anti-
retroviral therapy are excluded from the study*
Yes
No
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Eligibility Cardiovascular Diseases
NCT00603720
Role of Nitric Oxide in the Impact of Aging on Myocardial
Remodeling; ODM derived from:
https://clinicaltrials.gov/show/NCT00603720
All rights reserved. Please visit https://medical-data-
models.org/forms/16467
Eligibility Cardiovascular Diseases
NCT00603720
Inclusion Criteria
between the ages of 18-35 or 60-75*
Yes
No
normal glucose tolerance test*
Yes
No
normal plasma fasting lipid panel (fasting total
cholesterol less than 220 mg/dl)*
Yes
No
normal rest/stress echocardiogram*
Yes
No
bmi (body mass index) less than 30 kg/m2*
Yes
No
Exclusion Criteria
coronary artery disease*
Yes
No
high blood pressure*
Yes
No
current smoker*
Yes
No
diabetes mellitus*
Yes
No
cardiovascular disease (signs and symptoms of
any kind)*
Yes
No
history of stroke, peripheral vascular disease, or
arrhythmia*
Yes
No
pregnant or breastfeeding*
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Yes
No
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Eligibility Cardiovascular Diseases NCT00603720
Eligibility Chronic Heart Failure
NCT00272805
Drug Compliance and Quality of Life in Patients With Heart
Failure Dosed With Either Once-daily or Twice-daily Coreg;
ODM derived from:
https://clinicaltrials.gov/show/NCT00272805
All rights reserved. Please visit https://medical-data-
models.org/forms/16468
Eligibility Chronic Heart Failure
NCT00272805
Inclusion Criteria
ability to read english*
Yes
No
stable symptoms of mild to severe heart failure*
Yes
No
stable medical regimen for heart failure*
Yes
No
on a stable dose of coreg for at least 2 months*
Yes
No
lvef ≤40% within the previous 24 months*
Yes
No
Exclusion Criteria
uncorrected obstructive or regurgitant valve
disease*
Yes
No
complex congenital heart disease*
Yes
No
recent icd or pacemaker placement*
Yes
No
recent coronary artery bypass surgery or stroke*
Yes
No
candidate for heart transplant within 5 months of
study start*
Yes
No
present or planned use of mao inhibitors, alfpha-
blockers, combined      alpha-beta blockers, any
class i/ii anti-arrythmnic agents, (amiodarone may
be used if ≤*
Yes
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No
200mg/day). use of intravenous
vasodilator/inotropic agents.*
Yes
No
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Eligibility Chronic Heart Failure NCT00272805
Eligibility Chronic Kidney Disease
NCT00528385
Optimalization of Nephroprotection Using Agents Inhibiting
Renin-Angiotensin-Aldosterone System; ODM derived
from: https://clinicaltrials.gov/show/NCT00528385
All rights reserved. Please visit https://medical-data-
models.org/forms/16469
Eligibility Chronic Kidney Disease
NCT00528385
Inclusion Criteria
chronic kidney disease*
Yes
No
stable proteinuria above 300 mg/24 hours (no
variations above 25% in the last 6 months)*
Yes
No
normal or slightly impaired stable renal function
defined as serum creatinine level below 1.7 mg/dl
(egfr > 45 ml/min)*
Yes
No
Exclusion Criteria
nephrotic syndrome*
Yes
No
steroids or other immunosuppressive treatment
minimum during six months before the study*
Yes
No
diabetes mellitus*
Yes
No
potassium serum level > 5.1 meq/l*
Yes
No
albumin serum level < 2.0mg/dl*
Yes
No
creatinine serum level >2 mg/dl*
Yes
No
current diagnosis of heart failure new york heart
association (nyha) class ii-iv*
Yes
No
clinically significant valvular heart disease or
second or third degree heart block without a
pacemaker*
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Yes
No
history of hypertensive encephalopathy,
cerebrovascular accident or transient ischemic
cerebral attack*
Yes
No
history of myocardial infarction, unstable angina
pectoris, coronary bypass surgery, or any
percutaneous coronary intervention*
Yes
No
history of malignancy including leukemia and
lymphoma (but not basal cell skin carcinoma)
within the past five years*
Yes
No
pregnant or nursing women*
Yes
No
any surgical or medical condition which might
significantly alter the absorption, distribution,
metabolism, or excretion of study drugs.*
Yes
No
history of alcohol abuse*
Yes
No
nsaid abuse (more than 2 doses per week)*
Yes
No
known or suspected contraindications to the
study medications, including history of allergy to
ace inhibitors, at-1 receptor blockers and
aldosterone antagonists*
Yes
No
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Eligibility Hypertension NCT02242318
Study to Evaluate Efficacy of Micardis® (Telmisartan) and
Valsartan in Patients With Mild-to-moderate Hypertension
After Missing One Dose Using Ambulatory Blood Pressure
Monitoring; ODM derived from:
https://clinicaltrials.gov/show/NCT02242318
All rights reserved. Please visit https://medical-data-
models.org/forms/16470
Eligibility Hypertension
NCT02242318
Inclusion Criteria
1. mild-to-moderate hypertension defined as a
mean seated diastolic blood pressure of ≥ 95
mmhg and ≤ 109 mmhg, measured by manual
cuff sphygmomanometer, at visit 2*
Yes
No
2. 24-hour mean dbp of ≥ 85 mmhg at visit 3 as
measured by abpm*
Yes
No
3. age 18 years or older*
Yes
No
4. ability to stop any current antihypertensive
therapy without risk to the patient (investigator's
discretion)*
Yes
No
5. patient's written informed consent in
accordance with good clinical practice (gcp) and
local legislation*
Yes
No
Exclusion Criteria
1. pre-menopausal women (last menstruation ≤ 1
year prior to start of run-in period) who*
Yes
No
1. are not surgically sterile,*
Yes
No
2. are nursing,*
Yes
No
3. are of child-bearing potential and are not
practising acceptable methods of birth control, or
do not plan to continue practising an acceptable
method throughout the study. acceptable
methods of birth control include oral, implantable
or injectable contraceptives and intra uterine
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devices (iud)*
Yes
No
2. known or suspected secondary hypertension*
Yes
No
3. mean sitting sbp ≥180 mmhg or mean sitting
dbp ≥110 mmhg during any visit of the placebo
run-in period*
Yes
No
4. hepatic and/or renal dysfunction as defined by
the following laboratory parameters:*
Yes
No
1. serum glutamate-pyruvate-transaminase
(alanine aminotransferase) (sgpt (alt)) or serum
glutamate-oxaloacetate-transaminase (aspartate
aminotransferase) (sgot (ast)) > than 2 times the
upper limit of normal range,*
Yes
No
2. serum creatinine > 2.3 mg/dl (or > 203 μmol/l)*
Yes
No
5. bilateral renal artery stenosis, renal artery
stenosis in a solitary kidney, patients postrenal
transplant or with only one kidney*
Yes
No
6. clinically relevant sodium depletion,
hypokalaemia or hyperkalaemia*
Yes
No
7. uncorrected volume depletion*
Yes
No
8. primary aldosteronism*
Yes
No
9. hereditary fructose intolerance*
Yes
No
10. biliary obstructive disorders*
Yes
No
11. patients who have previously experienced
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symptoms characteristic of angioedema during
treatment with ace inhibitors or angiotensin ii
receptor antagonists*
Yes
No
12. history of drug or alcohol dependency within
six months prior to start of run-in period*
Yes
No
13. concomitant administration of any
medications known to affect blood pressure,
except medication allowed by the protocol*
Yes
No
14. any investigational therapy within one month
of signing the informed consent form*
Yes
No
15. congestive heart failure (new york heart
association (nyha) functional class congestive
heart failure (chf iii-iv))*
Yes
No
16. unstable angina within the past three months
prior to start of run-in period*
Yes
No
17. stroke within the past six months prior to start
of run-in period*
Yes
No
18. myocardial infarction or cardiac surgery within
the past three months prior to start of run-in
period*
Yes
No
19. percutaneous transluminal coronary
angioplasty (ptca) within the past three months
prior to start of run-in period*
Yes
No
20. sustained ventricular tachycardia, atrial
fibrillation, atrial flutter or other clinically relevant
cardiac arrhythmias as determined by the
investigator*
Yes
No
21. hypertrophic obstructive cardiomyopathy,
aortic stenosis, hemodynamically relevant
stenosis of the aortic or mitral valve*
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Yes
No
22. patients with insulin-dependent diabetes
mellitus whose diabetes has not been stable and
controlled for at least the past three months as
defined by an hba1c ≥ 10%*
Yes
No
23. night shift workers who routinely sleep during
the daytime and whose work hours include
midnight to 4:00 ante meridiem (am)*
Yes
No
24. known hypersensitivity to any component of
the formulations*
Yes
No
25. any clinical condition which, in the opinion of
the investigator would not allow safe completion
of the protocol and safe administration of trial
medication*
Yes
No
26. inability to comply with the protocol*
Yes
No
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Eligibility Depression NCT00214682
Beyond Ageing Project: A Study for the Prevention of
Depression; ODM derived from:
https://clinicaltrials.gov/show/NCT00214682
All rights reserved. Please visit https://medical-data-
models.org/forms/16472
Eligibility Depression NCT00214682
Inclusion Criteria
aged 65-74 years with some depressive
symptoms, assessed using the kessler 10
psychological distress scale [k10] (andrews &
slade, 2001)*
Yes
No
Exclusion Criteria
any of the following:*
Yes
No
those currently taking medication or receiving
psychological treatment for depression*
Yes
No
a report of a medical diagnosis of bipolar
disorder/mania*
Yes
No
history of epilepsy*
Yes
No
diagnosed with cancer and/or on antifolate
therapy*
Yes
No
have a diagnosis of dementia or alzheimer's
disease*
Yes
No
are currently taking vitamin supplements
containing folate, b2, b6 or b12 at a dose
exceeding 25% of the recommended daily
intake.*
Yes
No
medical contradictions to exercise (e.g.,
significant orthopaedic problems or
cardiovascular disease that would prevent regular
aerobic exercise)*
Yes
No
ongoing participation in regular aerobic exercise.*
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Yes
No
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Eligibility Depressive Disorder, Major
NCT00413023
Study Of The Effects Of A New Antidepressant Therapy In
Patients With Major Depressive Disorder (MDD); ODM
derived from: https://clinicaltrials.gov/show/NCT00413023
All rights reserved. Please visit https://medical-data-
models.org/forms/16473
Eligibility Depressive Disorder, Major
NCT00413023
Inclusion Criteria
primary diagnosis of major depressive disorder
as defined in dsm-iv.*
Yes
No
capable of giving informed consent and willing to
comply with the study requirements.*
Yes
No
women of childbearing potential must agree to
one of a number of defined acceptable methods
of birth control.*
Yes
No
Exclusion Criteria
primary diagnosis within the past 6 months of
another axis 1 disorder such as an anxiety
disorder.*
Yes
No
use of medications for a psychiatric condition
including herbals in the past 2-12 weeks
according to medication type.*
Yes
No
subjects who, in the investigator's judgement,
pose a current, serious suicidal or homicidal risk
or have made a suicide attempt within the past 6
months.*
Yes
No
subjects who currently meet or who met within 6
months prior to screening dsm-iv criteria for
substance abuse or subjects who currently meet
or who met within 6 months prior to screening
dsm-iv criteria for substance dependence (other
than nicotine).*
Yes
No
significantly abnormal blood or urine laboratory
tests or electrocardiogram (ecg).*
Yes
No
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Eligibility Colorectal Neoplasms
NCT00398333
Study to Assess the Effectiveness of a Omega-3 Enriched
Supplement on Chemotherapy Tolerance in Colon Cancer
Patients; ODM derived from:
https://clinicaltrials.gov/show/NCT00398333
All rights reserved. Please visit https://medical-data-
models.org/forms/16474
Eligibility Colorectal Neoplasms
NCT00398333
Inclusion Criteria
patients diagnosed of metastatic colon
adenocarcinoma that are going to receive first
line chemotherapy treatment in the oncology day
hospital.*
Yes
No
age over 18 years old.*
Yes
No
Exclusion Criteria
patients diagnosed of colon cancer are receiving
second line chemotherapy.*
Yes
No
antecedents of other malignant tumors with the
exception of basocellular epithelioma.*
Yes
No
chronic renal failure (creatinine > 1.7).*
Yes
No
previous diabetes mellitus.*
Yes
No
obesity (imc > 30)*
Yes
No
medical conditions that imply hepatic
encephalopathy, or ascites.*
Yes
No
severe malnutrition according to the classification
of the subjective global assessment (sga) or a
bmi < 16.5.*
Yes
No
major psychiatric disorder.*
Yes
No
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patients receiving enteral or parenteral nutrition.*
Yes
No
contraindications for the indication of the
nutritional supplement: galactosemia.*
Yes
No
seafood or seafood byproducts allergy.*
Yes
No
patients taking drugs that affect the metabolism
(anabolic steroids, orexigenic agents...).*
Yes
No
absence of the informed consent form signed by
the patient.*
Yes
No
any patient who has disability to comply with the
treatment or who has inability according to the
researcher.*
Yes
No
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Eligibility Breast Neoplasms NCT00092950
Exercise in Women at Risk for Breast Cancer; ODM
derived from: https://clinicaltrials.gov/show/NCT00092950
All rights reserved. Please visit https://medical-data-
models.org/forms/16475
Eligibility Breast Neoplasms
NCT00092950
Criteria
this study will enroll 40 breast cancer survivors
and 40 women at high risk for breast cancer.  all
participants must fulfill the following criteria:*
Yes
No
age 18 to 75.*
Yes
No
sedentary at baseline, as defined by a weekly
leisure-time activity score of 15 or less on the
godin leisure-time exercise questionnaire. this
cutoff is equivalent to engaging in moderate
activity less than 3 times a week.*
Yes
No
ability to complete all study questionnaires, or a
willing friend or family member who will assist in
questionnaire completion.*
Yes
No
ecog performance status 0-1.*
Yes
No
ability to successfully perform the level of physical
activity prescribed by the protocol, as assessed
by the physical activity readiness questionnaire
(par-q).*
Yes
No
any participant who answers yes to any of the
questions in this screening tool will undergo
medical evaluation at the clinical center, as
appropriate, prior to enrolling on the study.*
Yes
No
cardiac risk will be assessed after a complete
history and physical exam, and will be
determined by the examining physician. only
patients who are felt to be increased cardiac risk
will have an ekg performed. this will include
patients who answer yes to any of the questions
on the par-q that assess cardiac risk (#1,2,3,4,6).
patients with worrisome ekg findings or findings
in the history or physical exam that warrant
further work-up in the opinion of the health care
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provider will be referred to the cardiology consult
service, or if non-urgent, will be referred back to
their source of regular medical care for clearance
prior to enrolling on the study.*
Yes
No
if history of cancer (other than invasive breast
cancer, squamous or basal cell skin cancers),
subject must have no evidence of disease at time
of enrollment and no history of cancer directed
treatment in the 2 years preceding enrollment.*
Yes
No
breast cancer survivors:*
Yes
No
eligible breast cancer survivors will be women
with a documented history of stage i, ii or iii
invasive breast cancer who are at least two
months from the completion of their primary
therapy, including surgery, radiation and
chemotherapy. current use of hormonal therapy
such as tamoxifen or aromatase inhibitors, will be
permitted, however subjects must have
completed 2 months of hormonal therapy prior to
beginning the study in order to achieve steady
state.*
Yes
No
women at high risk for breast cancer:*
Yes
No
women will be considered at high risk for
developing breast cancer if they fulfill one of the
following criteria:*
Yes
No
a gail model risk of greater than or equal to1.7
percent over 5 years from study entry or a claus
model lifetime risk of greater than 20 percent.*
Yes
No
lobular neoplasia.*
Yes
No
atypical ductal hyperplasia.*
Yes
No
ductal carcinoma in situ (dcis) that has been
previously treated. patients must be at least 2
months from completion of primary therapy, and if
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treated with hormonal therapy, they must have
completed at least two months of hormonal
therapy.*
Yes
No
deleterious mutations in brca-1 or 2 or a priori
risk assessment of 20 percent chance or greater
of carrying a brca1/2 gene mutation. the brcapro
model (109) will be used to assess this risk.*
Yes
No
Exclusion Criteria
currently pregnant or planning to become
pregnant during the study period. pregnancy will
be assessed in women of childbearing potential
prior to enrolling in stage ii of the study.
postmenopausal women and women who have
had a previous hysterectomy, oophorectomy or
tubal ligation will not be required to undergo a
pregnancy test.*
Yes
No
uncontrolled intercurrent illness, including, but not
limited to: ongoing or active infection,
symptomatic congestive heart failure, unstable
angina pectoris, cardiac arrhythmia, recent
myocardial infarction or stroke, or psychiatric
illness/social situations that would limit
compliance with study requirements.*
Yes
No
physical conditions that preclude the amount of
daily walking prescribed by the protocol (e.g.,
severe arthritis, use of a walker or cane,
wheelchair-bound, etc.).*
Yes
No
medical or psychiatric disorder which would, in
the opinion of the principal investigator, render
the subject unable to provide informed consent.*
Yes
No
patients with metastatic or recurrent disease will
be excluded because of difficulty interpreting
results in the context of women with a disease
burden and/or on chemotherapy.*
Yes
No
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Eligibility Breast Neoplasms NCT00123799
Study of Fluorodeoxyglucose (FluGlucoScan) in Patients
With Breast Cancer: Correlation With Histologic Findings of
Sentinel Node Biopsies and Axillary Dissection; ODM
derived from: https://clinicaltrials.gov/show/NCT00123799
All rights reserved. Please visit https://medical-data-
models.org/forms/16476
Eligibility Breast Neoplasms
NCT00123799
Inclusion Criteria
male or female.  if female of child bearing
potential and outside of the window of 10 days
since the last menstrual period, a negative
pregnancy test.*
Yes
No
biopsy proven breast carcinoma (core biopsy or
fine needle aspiration, although core biopsies are
preferred.)*
Yes
No
tumour size t1-3, n0 clinically*
Yes
No
all patients will have pre-operative mammography
+/- ultrasound of the breast*
Yes
No
age equal to or greater than 18 years*
Yes
No
able and willing to follow instructions and comply
with the protocol*
Yes
No
provide written informed consent prior to
participation in this study*
Yes
No
Exclusion Criteria
nursing or pregnant females*
Yes
No
previous malignancy or diagnosis less than 10
(ten) years ago.  skin cancers (excluding
malignant melanoma) and carcinoma in situ of
the cervix are exceptions.*
Yes
No
excisional biopsy of the tumour has been
performed*
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Yes
No
age less than 18 years*
Yes
No
patient has diabetes*
Yes
No
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Eligibility Breast Neoplasms NCT00187343
A Clinical Trial to Reduce Skin Burn Induced by Breast
Radiotherapy Using Intensity Modulated Radiation Therapy
(IMRT); ODM derived from:
https://clinicaltrials.gov/show/NCT00187343
All rights reserved. Please visit https://medical-data-
models.org/forms/16478
Eligibility Breast Neoplasms
NCT00187343
Inclusion Criteria
a confirmed histological diagnosis of breast
carcinoma or dcis;*
Yes
No
treated by breast conserving surgery;*
Yes
No
adjuvant radiation to the breast only (less than 3
positive lymph nodes);*
Yes
No
having a ecog performance status of 0 or 1.*
Yes
No
having signed an informed consent.*
Yes
No
Exclusion Criteria
patients treated by mastectomy;*
Yes
No
bilateral breast cancer;*
Yes
No
having an unhealed surgical scar (skin not closed
and/or infection);*
Yes
No
having had prior radiation to the same breast;*
Yes
No
having active connective tissue disorder;*
Yes
No
patient being pregnant.*
Yes
No
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Vertigo Protocol PhenX Toolkit
The Dizziness Handicap Inventory (DHI) assesses
perceived disability due to dizziness (i.e., vertigo). This 25-
item self-administered questionnaire contains three
subscales which cover the areas of function, emotion, and
physical aspects. Points from each subscale can be
combined to assign a total score, or they can be combined
by subscale.
ODM derived from: https://cde.nlm.nih.gov
Primary source: https://www.phenxtoolkit.org/
Recent publication: Hendershot, T., Pan, H., Haines, J.,
Harlan, W.R., Marazita, M.L., McCarty, C.A., Ramos, E.M.,
and Hamilton, C.M. (2015) Using the PhenX toolkit to add
standard measures to a study. Curr. Protoc. Hum. Genet.
86:1.21.1-1.21.17. doi: 10.1002/0471142905.hg0121s86
Permission to publish granted by
Carol M. Hamilton.
All rights reserved. Please visit https://medical-data-
models.org/forms/16479
Vertigo Protocol PhenX Toolkit
PhenX - Schwindel-Protokoll
Verschlechtert das Heben des Blickes die
Symptome?
Nein (No)
Manchmal (Sometimes)
Ja (Yes)
Fühlen Sie sich wegen Ihrer Symptome
frustriert?
Nein (No)
Manchmal (Sometimes)
Ja (Yes)
Verhindern Sie Urlaubsreisen/ berufliche Reise
aufgrund der Symptome?
Nein (No)
Manchmal (Sometimes)
Ja (Yes)
Erhöht den Gang zum Supermarkt Ihr Problem?
Nein (No)
Manchmal (Sometimes)
Ja (Yes)
Haben Sie Schwierigkeiten, in das Bett oder aus
dem Bett zu kommen aufgrund der Symptome?
Nein (No)
Manchmal (Sometimes)
Ja (Yes)
Wird Ihre Teilnahme an sozialen Aktivitäten (wie
zum Beispiel das Ausgehen zum Essen, Kino,
tanzen oder auf Partys) durch die Symptome
eingeschränkt?
Nein (No)
Manchmal (Sometimes)
Ja (Yes)
Haben Sie aufgrund der Symptome
Schwierigkeiten beim Lesen?
Nein (No)
Manchmal (Sometimes)
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Ja (Yes)
Werden die Symptome durch anstrengende
Aktivitäten, wie z.B. Sport, Tanzen oder Arbeiten
im Haushalt, wie z.B. Wischen oder die
Spülmaschine ausräumen, verschlechtert?
Nein (No)
Manchmal (Sometimes)
Ja (Yes)
Haben Sie Angst, aufgrund der Symptome das
Haus ohne Begleitung zu verlassen?
Nein (No)
Manchmal (Sometimes)
Ja (Yes)
Sind Sie aufgrund der Symptome beschämt?
Nein (No)
Manchmal (Sometimes)
Ja (Yes)
Erhöhe die schnelle Bewegungen des Kopfes Ihr
Problem?
Nein (No)
Manchmal (Sometimes)
Ja (Yes)
Vermeiden Sie Höhen aufgrund der Symptome?
Nein (No)
Manchmal (Sometimes)
Ja (Yes)
Erhöht das Umdrehen im Bett Ihr Problem?
Nein (No)
Manchmal (Sometimes)
Ja (Yes)
Ist es aufgrund der Symptome schwierig für Sie
anstrengende Hausarbeit oder Gartenarbeit zu
erledigen?
Nein (No)
Manchmal (Sometimes)
Ja (Yes)
Haben Sie Angst, dass andere Leute denken, Sie
seien betrunken aufgrund der Symptome?
Nein (No)
Manchmal (Sometimes)
Ja (Yes)
Ist es schwierig für Sie, selbstständig zu laufen?
Nein (No)
Manchmal (Sometimes)
Ja (Yes)
Erhöht das Absteigen eines Bürgersteigs Ihr
Problem?
Nein (No)
Manchmal (Sometimes)
Ja (Yes)
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Haben Sie aufgrund der Symptome
Konzentrationsschwierigkeiten?
Nein (No)
Manchmal (Sometimes)
Ja (Yes)
Haben Sie Schwierigkeiten aufgrund der
Symptome im Dunkeln zu laufen?
Nein (No)
Manchmal (Sometimes)
Ja (Yes)
Haben Sie aufgrund der Symptome Angst, alleine
zu Hause zu bleiben?
Nein (No)
Manchmal (Sometimes)
Ja (Yes)
Fühlen Sie sich aufgrund der Symptome
behindert?
Nein (No)
Manchmal (Sometimes)
Ja (Yes)
Haben Ihre Symptome die Beziehungen zu
Freunden oder Familienmitgliedern gestresst?
Nein (No)
Manchmal (Sometimes)
Ja (Yes)
Sind Sie aufgrund der Symptome depressiv?
Nein (No)
Manchmal (Sometimes)
Ja (Yes)
Haben die Symptome Auswirkungen auf die
Verantwortung in Ihrem Job oder im Haushalt?
Nein (No)
Manchmal (Sometimes)
Ja (Yes)
Erhöht das Vornüberbeugen Ihr Problem?
Nein (No)
Manchmal (Sometimes)
Ja (Yes)
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Eligibility Breast Neoplasms NCT00188604
The Use of Selenium to Treat Secondary Lymphedema -
Breast Cancer; ODM derived from:
https://clinicaltrials.gov/show/NCT00188604
All rights reserved. Please visit https://medical-data-
models.org/forms/16480
Eligibility Breast Neoplasms
NCT00188604
Inclusion Criteria
patients with clinically documented lymphedema
of upper limb secondary to breast cancer
management (surgery - axillary nodal dissection,
and radiotherapy)*
Yes
No
patients who have had other modalities of
management can be included, e.g. physical
therapy, pharmacological therapy*
Yes
No
ecog performance 0-2*
Yes
No
informed consent*
Yes
No
Exclusion Criteria
active cellulitis/skin infection of the limb*
Yes
No
venous thrombosis of the upper limbs*
Yes
No
active malignancy*
Yes
No
any other medical condition or congenital or
traumatic injury involving either limb*
Yes
No
patients already on selenium medication*
Yes
No
patients participating in another clinical study
related to lymphedema*
Yes
No
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Use of services:  PaReSiS UKH PaReSiS UKH
Rehabilitation Study: "Partizipatives
Rehabilitationsprozessmanagement, PaReSiS Schlaganfall
in Sachsen-Anhalt" Martin-Luther-Universität Halle-
Wittenberg Medizinische Fakultät Institut für Gesundheits-
und Pflegewissenschaft Projekt: Partizipatives
Rehabilitationsprozessmanagement „Schlaganfall in
Sachsen-Anhalt“ Magdeburger Straße 8 06097 Halle
(Saale), Germany E-Mail: paresis@medizin.uni-halle.de
All rights reserved. Please visit https://medical-data-
models.org/forms/16481
Use of services:  PaReSiS UKH
80. Mobiler Krankenpflegedienst
Kennen Sie diesen?
Ja
Nein
Nehmen Sie davon Leistungen in Anspruch?
ja (1)
nein (2)
k.Angabe (3)
Falls ja: Grundpflege
Ja
Nein
Specification
Ja
Nein
Falls ja: Hauswirtschaftliche Versorgung
Ja
Nein
Falls ja: Beratung
Ja
Nein
Falls ja: Häusliche Pflege bei Verhinderung der
Pflegeperson
Ja
Nein
Wie oft? Regelmäßig?
Ja
Nein
__pro Tag
Ja
Nein
Falls jeden Tag, bitte Häufigkeit pro Tag
spezifizieren
__pro Woche
Ja
Nein
Falls jede Woche, bitte Häufigkeit spezifizieren
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__pro Monat
Ja
Nein
Falls jeden Monat, bitte Häufigkeit spezifizieren
Unregelmäßig, eher sporadisch
Ja
Nein
81. Stationäre/ teilstationäre
Pflegeeinrichtung
Kennen Sie diese?
Ja
Nein
Use
ja (1)
nein (2)
k.Angabe (3)
Falls ja: Tagespflege
Ja
Nein
Falls ja: Nachtpflege
Ja
Nein
Falls ja: Kurzzeitpflege
Ja
Nein
Wie oft? Regelmäßig?
Ja
Nein
__pro Tag
Ja
Nein
Falls jeden Tag, bitte spezifizieren
__pro Woche
Ja
Nein
Falls jede Woche, bitte spezifizieren
__pro Monat
Ja
Nein
Falls jeden Monat, bitte spezifizieren
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Unregelmäßig, eher sporadisch
Ja
Nein
82. Physiotherapie
Kennen Sie diese?
Ja
Nein
Nehmen Sie davon Leistungen in Anspruch?
ja (1)
nein (2)
k.Angabe (3)
Wie oft? Regelmäßig?
Ja
Nein
__pro Tag
Ja
Nein
Falls jeden Tag, bitte spezifizieren
__pro Woche
Ja
Nein
Falls jede Woche, bitte spezifizieren
___pro Monat
Ja
Nein
Falls jeden Monat, bitte spezifizieren
unregelmäßig, eher sporadisch
Ja
Nein
83. Ergotherapie
Kennen Sie diese?
Ja
Nein
Nehmen Sie davon Leistungen in Anspruch?
ja (1)
nein (2)
k.Angabe (3)
Wie oft? Regelmäßig?
Ja
Nein
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___pro Tag
Ja
Nein
Falls jeden Tag, bitte spezifizieren
__pro Woche
Ja
Nein
Falls jede Woche, bitte spezifizieren
__pro Monat
Ja
Nein
Falls jeden Monat, bitte spezifizieren
84. Logopädie
Kennen Sie dies?
Ja
Nein
Nehmen Sie davon Leistungen in Anspruch?
ja (1)
nein (2)
k.Angabe (3)
Wie oft? Regelmäßig?
Ja
Nein
__pro Tag
Ja
Nein
Falls jeden Tag, bitte spezifizieren
___pro Woche
Ja
Nein
Falls jede Woche, bitte spezifizieren
__pro Monat
Ja
Nein
Falls jeden Monat, bitte spezifizieren
Frequency
Ja
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Nein
85. Hauswirtschaftliche Dienste
Kennen Sie dies?
Ja
Nein
Nehmen Sie davon Leistungen in Anspruch?
ja (1)
nein (2)
k.Angabe (3)
Frequency
Ja
Nein
__pro Tag
Ja
Nein
Falls jeden Tag, bitte spezifizieren
___pro Woche
Ja
Nein
Falls jede Woche, bitte spezifizieren
___pro Monat
Ja
Nein
Falls jeden Monat, bitte spezifzieren
unregelmäßig, eher sporadisch
Ja
Nein
86. Essen auf Rädern
Kennen Sie dies?
Ja
Nein
Nehmen Sie davon Leistungen in Anspruch?
ja (1)
nein (2)
k.Angabe (3)
Wie oft? Regelmäßig?
Ja
Nein
Frequency
Ja
Nein
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Falls jeden Tag, bitte spezifizieren
___pro Woche
Ja
Nein
Falls jede Woche, bitte spezifizieren
__pro Monat
Ja
Nein
Falls jeden Monat, bitte spezifizieren
87. Besuchs- oder andere ehrenamtliche
Dienste
Kennen Sie dies?
Ja
Nein
Nehmen Sie Leistungen davon in Anspruch?
ja (1)
nein (2)
k.Angabe (3)
Wie oft? Regelmäßig?
Ja
Nein
__pro Tag
Ja
Nein
Falls jeden Tag, bitte spezifizieren
__pro Woche
Ja
Nein
Falls jede Woche, bitte spezifizieren
__pro Monat
Ja
Nein
Falls jeden Monat, bitte spezifizieren
unregelmäßig, eher sporadisch
Ja
Nein
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88. Nachbarschaftshilfe
Kennen Sie diese?
Ja
Nein
Nehmen Sie davon Leistungen in Anspruch?
ja (1)
nein (2)
k.Angabe (3)
Wie oft? Regelmäßig?
Ja
Nein
__pro Tag
Ja
Nein
Falls jeden Tag, bitte spezifizieren
__pro Woche
Ja
Nein
Falls jede Woche, bitte spezifizieren
__pro Monat
Ja
Nein
Falls jede Monat, bitte spezifizieren
unregelmäßig, eher sporadisch
Ja
Nein
89. Selbsthilfegruppen
Kenne Sie diese?
Ja
Nein
Nehmen Sie davon Leistungen in Anspruch?
ja (1)
nein (2)
k.Angabe (3)
Wie oft? Regelmäßig?
Ja
Nein
__pro Tag
Ja
Nein
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Falls jeden Tag, bitte spezifizieren
__pro Woche
Ja
Nein
Falls jede Woche, bitte spezifizieren
__pro Monat
Ja
Nein
Falls jeden Monat, bitte spezifizieren
unregelmäßig, eher sporadisch
Ja
Nein
90. Sportgruppen
Kennen Sie diese?
Ja
Nein
Nehmen Sie davon Leistungen in Anspruch?
ja (1)
nein (2)
k.Angabe (3)
Wie oft? Regelmäßig?
Ja
Nein
__pro Tag
Ja
Nein
Falls jeden Tag, bitte spezifizieren
__pro Woche
Ja
Nein
Falls jede Woche, bitte spezifizieren
__pro Monat
Ja
Nein
Falls jeden Monat, bitte spezifizieren
unregelmäßig, eher sporadisch
Ja
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Nein
91. Fahr- und Begleitdienst
Kennen Sie diesen?
Ja
Nein
Nehmen Sie davon Leistungen in Anspruch?
ja (1)
nein (2)
k.Angabe (3)
Wie oft? Regelmäßig?
Ja
Nein
__pro Tag
Ja
Nein
Falls jeden Tag, bitte spezifizieren
__pro Woche
Ja
Nein
Falls jede Woche, bitte spezifizieren
__pro Monat
Ja
Nein
Falls jeden Monat, bitte spezifizieren
unregelmäßig, eher sporadisch
Ja
Nein
92. Bücherdienste
Kennen Sie diesen?
Ja
Nein
Nehmen Sie davon Leistungen in Anspruch?
ja (1)
nein (2)
k. Angabe (3)
Wie oft? Regelmäßig?
Ja
Nein
__pro Tag
Ja
Nein
9 / 15
Use of services:  PaReSiS UKH
Falls jeden Tag, bitte spezifizieren
__pro Woche
Ja
Nein
Falls jede Woche, bitte spezifizieren
__pro Monat
Ja
Nein
Falls jeden Monat, bitte spezifizieren
unregelmäßig, eher sporadisch
Ja
Nein
93. Mobiler Friseur
Kenne Sie diesen?
Ja
Nein
Nehmen Sie davon Leistungen in Anspruch?
ja (1)
nein (2)
k. Angabe (3)
Wie oft? Regelmäßig?
Ja
Nein
__pro Tag
Ja
Nein
Falls jeden Tag, bitte spezifizieren
__pro Woche
Ja
Nein
Falls jede Woche, bitte spezifizieren
Frequency
Ja
Nein
Frequency
unregelmäßig, eher sporadisch
Ja
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Nein
94. Mobile Fußpflege
Kennen Sie diesen?
Ja
Nein
Nehmen Sie davon Leistungen in Anspruch?
ja (1)
nein (2)
k. Angabe (3)
Wie oft? Regelmäßig?
Ja
Nein
__pro Tag
Ja
Nein
Falls jeden Tag, bitte spezifizieren
__pro Woche
Ja
Nein
Falls jede Woche, bitte spezifizieren
__pro Monat
Ja
Nein
Falls jeden Monat, bitte spezifizieren
unregelmäßig, eher sporadisch
Ja
Nein
95. Wohlfahrtsverbände
Kennen Sie diese?
Ja
Nein
Nehmen Sie davon Leistungen in Anspruch?
ja (1)
nein (2)
k. Angabe (3)
Häusliche Pflege
Ja
Nein
Beratung und Schulung
Ja
Nein
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Hilfsmittel-/Pflegebettverleih
Ja
Nein
Begleitung zu Arztbesuchen / Rezeptversorgung
Ja
Nein
Mobiler sozialer Dienst (häusliche Hilfe durch
SFJ, Zivildienst)
Ja
Nein
Hauswirtschaftliche Versorgung
Ja
Nein
Sterbebegleitung
Ja
Nein
Vermittlung weiterer Leistungen (Essen auf
Rädern, Hausnotruf)
Ja
Nein
Falls ja, regelmäßig
Ja
Nein
Falls ja, eher unregelmäßig
Ja
Nein
96. Anbieter für Hausnotrufsysteme
Kennen Sie diese?
Ja
Nein
Nehmen Sie davon Leistungen in Anspruch?
ja (1)
nein (2)
k. Angabe (3)
97. Versorgungsamt
Kennen Sie dieses?
Ja
Nein
Nehmen Sie davon Leistungen in Anspruch?
ja (1)
nein (2)
k. Angabe (3)
98. Gemeinsame Servicestelle für
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Rehabilitation
Kennen Sie diese?
Ja
Nein
Nehmen Sie davon Leistungen in Anspruch?
ja (1)
nein (2)
k. Angabe (3)
Information / Beratung
Ja
Nein
Koordination / Unterstützung bei der
Antragstellung
Ja
Nein
Betriebl. Eingliederungsmanagement
Ja
Nein
99. Integrationsfachdienst
Kennen Sie diesen?
Ja
Nein
Nehmen Sie davon Leistungen in Anspruch?
ja (1)
nein (2)
k. Angabe (3)
Information/Beratung
Ja
Nein
Betreuung/Begleitung zum Arbeitsplatz
Ja
Nein
Falls ja, unregelmäßig
Ja
Nein
Falls ja, unregelmäßig eher sporadisch
Ja
Nein
100. Pflegestützpunkte
Kennen Sie diese?
Ja
Nein
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Nehmen Sie davon Leistungen in Anspruch?
ja (1)
nein (2)
k. Angabe (3)
Information/Beratung
Ja
Nein
Koordination/Vermittlung von Unterstützung und
Leistungen
Ja
Nein
Falls ja, regelmäßig
Ja
Nein
Falls ja, unregelmäßig, eher sporadisch
Ja
Nein
101. Sonstige Dienste
Kennen Sie diese?
Ja
Nein
Nehmen Sie davon Leistungen in Anspruch?
ja (1)
nein (2)
k. Angabe (3)
Welche?
102. Ich möchte gerne von Ihnen wissen,
ob, wie oft seit unserer letzten Befragung
und warum Sie wegen gesundheitlicher
Krisen die folgenden Dienste in Anspruch
nehmen mussten.
a) Krankenhausbesuch mit Übernachtung:
Anzahl
Krankenhausbesuch mit Übernachtung: Dauer
Krankenhausbesuch mit Übernachtung: Grund
b) Besuche der Notfallambulanz/ Erste Hilfe ohne
Übernachtung: Anzahl
Besuche der Notfallambulanz/ Erste Hilfe ohne
Übernachtung: Dauer
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Besuche der Notfallambulanz/Erste Hilfe ohne
Übernachtung: Grund
c) Andere Notfalldienste: Notfallpflege,
Bereitschaftsarzt der KV: Anzahl
Andere Notfalldienste: Notfallpflege,
Bereitschaftsarzt der KV: Dauer
Andere Notfalldienste: Notfallpflege,
Bereitschaftsarzt der KV:Grund
103. Welche Medikamente nehmen Sie
derzeit ein?
Name
Wirkstoff
Dosierung
Indikation
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Financial situation: PaReSiS UKH PaReSiS UKH
Rehabilitation Study: "Partizipatives
Rehabilitationsprozessmanagement, PaReSiS Schlaganfall
in Sachsen-Anhalt" Martin-Luther-Universität Halle-
Wittenberg Medizinische Fakultät Institut für Gesundheits-
und Pflegewissenschaft Projekt: Partizipatives
Rehabilitationsprozessmanagement „Schlaganfall in
Sachsen-Anhalt“ Magdeburger Straße 8 06097 Halle
(Saale), Germany E-Mail: paresis@medizin.uni-halle.de
All rights reserved. Please visit https://medical-data-
models.org/forms/16482
Financial situation: PaReSiS UKH
104. Kommen Sie mit Ihrem Geld gut über
die Runden?
Kommen Sie mit Ihrem Geld gut über die
Runden?
ja (1)
einigermaßen (2)
nein (3)
105. Regeln Sie Ihre
Geldangelegenheiten selbst?
Regeln Sie Ihre Geldangelegenheiten selbst?
Ja
Nein
106. Hat sich Ihre finanzielle Situation seit
dem Schlaganfall verändert?
Hat sich Ihre finanzielle Situation seit dem
Schlaganfall verändert?
Ja
Nein
Falls ja, hat sie sich verschlechtert?
Ja
Nein
107. Haben finanzielle Gründe während
des letzten Monats dazu geführt, dass Sie
a) nicht die benötigte Pflege/Hilfe erhalten
konnten?
Ja
Nein
b) nicht die benötigte ärztliche Behandlung oder
Medikation erhalten konnten?
Ja
Nein
c) nicht die benötigten Hilfsmittel erhalten
konnten?
Ja
Nein
d) sich nicht angemessen ernähren oder Ihre
Wohnung beheizen konnten?
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Ja
Nein
108. Wie viel Geld steht Ihnen monatlich
zur Verfügung?
Wie viel Geld steht Ihnen monatlich zur
Verfügung?
____ (1)
keine Angabe (2)
weiß ich nicht (3)
Falls Betrag bekannt, bitte spezifizieren
109. Ende der Erhebung
Datum
Uhrzeit
Handzeichen
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Eligibility Breast Neoplasms NCT00191672
A Trial Of Gemcitabine Plus Paclitaxel And Gemcitabine
Plus Docetaxel In Metastatic Breast Cancer; ODM derived
from: https://clinicaltrials.gov/show/NCT00191672
All rights reserved. Please visit https://medical-data-
models.org/forms/16483
Eligibility Breast Neoplasms
NCT00191672
Inclusion Criteria
advanced or metastatic breast cancer*
Yes
No
disease that can be measured by the physician or
radiologic test.*
Yes
No
may have had one chemotherapy treatment for
advanced or metastatic disease.*
Yes
No
patients may have received any prior adjuvant
chemotherapy, including taxane containing
regimens, provided this treatment was completed
at least 6 months prior to enrollment.*
Yes
No
patients may have received prior hormone
therapy or immunotherapy.*
Yes
No
Exclusion Criteria
patients with only non-measurable disease*
Yes
No
cancer that has spread to the brain*
Yes
No
a patient who received a taxane with metastatic
disease.*
Yes
No
pregnancy*
Yes
No
patients who received prior gemcitabine*
Yes
No
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Public dental waiting times NMDS 2013-
Metadata Online Registry (METeOR)
Health sector data set specifications from METeOR,
Australia's repository for national metadata standards,
developed by the Australian Institute of Health and Welfare
(http://meteor.aihw.gov.au/content/index.phtml/itemId/3451
65)
Public dental waiting times NMDS 2013- 
The purpose of the Public dental waiting times national
minimum data set (PDWT NMDS) is to describe the
information that must be collected to calculate the waiting
times for two time periods in the treatment pathway for
public dental services in Australia: 
·	The time between the date a person is placed on a waiting
list and the date they are offered dental care; and 
·	The time between the date a person is placed on a waiting
list and the date they receive dental care. 
In this data collection, person includes all persons eligible
for their state or territory public dental scheme, who were
aged 18 years or over when they were placed on a general
or prosthetic public dentistry waiting list for the purpose of
receiving treatment. 
The data collection includes:
·	all people specified above with a listing date for dental care
within the collection period 
·	all people specified above with a date of offer of dental
care within the collection period 
·	all people specified above with a date of first dental visit
within the collection period.
The data collection excludes: 
·	people who access their local public clinic but pay full price
and are not eligible for their state or territory's public dental
service 
·	people who are treated under jurisdictional priority client
schemes. 
In this data collection, treatment means any event
consisting of the provision of dental care resulting from a
person being placed on a public dental waiting list and
funded under a public dental scheme of their state or
territory. Only treatments received after a person is placed
on a public dental waiting list should be recorded.
Excluded treatments are:
·	treatment paid for in full by the person receiving the
treatment 
·	treatment provided by practitioners funded from outside of
the public dental health sector, e.g. treatment provided by
General Medical Practitioners (GPs) 
·	treatments which do not result in removal from a waiting
list, such as: 
relief of pain that does not satisfy other dental treatment
needs 
emergency treatment that does not satisfy other dental
treatment needs 
where a person is on a general care or denture care waiting
list, consultations to determine future care that do not result
in the removal from the list 
A public dental waiting list episode ends: 
·	at the date of offer of dental care, if this is the last recorded
date; or 
·	at the date of first dental visit. 
All dental services funded by the state or territory
government should be included unless otherwise noted.
© Australian Institute of Health and Welfare 2015
Metadata and Classifications Unit 
Australian Institute of Health and Welfare
GPO Box 570
Canberra ACT 2601
All rights reserved. Please visit https://medical-data-
models.org/forms/16484
Public dental waiting times NMDS
2013- Metadata Online Registry
(METeOR)
Person 1
Date of birth*
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Sex*
Male (1)
Female (2)
Intersex or indeterminate (3)
Not stated/inadequately described (9)
Address
Australian postcode (address)*
Person 2
Area of usual residence (SA2)*
Australian state/territory identifier (person)*
New South Wales (1)
Victoria (2)
Queensland (3)
South Australia (4)
Western Australia (5)
Tasmania (6)
Northern Territory (7)
Australian Capital Territory (8)
Other territories (Cocos (Keeling)
Islands, Christmas Island and Jervis Bay
Territory) (9)
Country of birth*
Indigenous status*
Aboriginal but not Torres Strait Islander
origin (1)
Torres Strait Islander but not Aboriginal
origin (2)
Both Aboriginal and Torres Strait Islander
origin (3)
Neither Aboriginal nor Torres Strait
Islander origin (4)
Not stated/inadequately described (9)
Preferred language*
Public dental waiting list episode
Public dental listing date*
Public dental waiting list type*
General dental care (1)
Denture care (2)
Assessment (3)
Not stated/inadequately described (9)
Offer of dental care date
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(METeOR)
Date of first dental visit
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(METeOR)
Eligibility Breast Neoplasms NCT00229697
Phase II Metastatic ER+/PgR+ Nolvadex +/- Iressa Study;
ODM derived from:
https://clinicaltrials.gov/show/NCT00229697
All rights reserved. Please visit https://medical-data-
models.org/forms/16486
Eligibility Breast Neoplasms
NCT00229697
Inclusion Criteria
histologically confirmed metastatic
adenocarcinoma of the breast (seetnm staging
appendix i) that is er and/or pr positive as
determined in local laboratories at each
investigator site (central verification of er status
will be performed after the patient starts
treatment*
Yes
No
a tissue block from either the metastatic or
primary tumor site is required.*
Yes
No
who performance status (ps) 0-2*
Yes
No
patients must not be pregnant or breast-feeding.
a negative pregnancy test is required within 7
days prior to randomization if pre- or peri-
menopausal. postmenopausal patients are
defined as:*
Yes
No
natural menopause with last menses > 1 year
ago,*
Yes
No
radiation induced oophorectomy with last menses
> 1 year ago,*
Yes
No
chemotherapy induced menopause with 1 year
interval since last menses, or*
Yes
No
serum fsh and lh and plasma estradiol levels in
the postmenopausal range for the institution.*
Yes
No
bilateral oophorectomy*
Yes
No
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Exclusion Criteria
patients cannot be on hormone replacement
therapy or received prior chemotherapy for
metastatic disease.*
Yes
No
patients previously treated with a tyrosine kinase
inhibitor or have evidence of an active interstitial
lung disease are not eligible.*
Yes
No
treatment with lh-rh analog.*
Yes
No
laboratory values as follow bilirubin >1.5 times
upper limit of normal uln, alanine amino
transferase (alt) or aspartate amino transferase
(ast) >2.5 times the uln if no demonstrable liver
metastases, or >5 times the uln in the presence
of liver metastases*
Yes
No
bone marrow function: wbc <1500 mm3*
Yes
No
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Eligibility Breast Neoplasms NCT00229697
Physician referral letter
derived from http://www.arztbriefmanager.de/ (Dr. Wolfram
Arends, Tutzing, Germany)
All rights reserved. Please visit https://medical-data-
models.org/forms/16487
Physician referral letter
Angaben zum bisherigen Aufenthalt
Aufnahmedatum
Verlegungsdatum
Alter der/des Patient/en
>= 0
<= 120
Jahre
Aufnahmegrund
Chefarzt der jetzigen Klinik
Oberarzt der jetzigen Klinik
Stationsarzt der jetzigen Klinik
Chefarzt Zielklinik
Abteilung der Zielklinik
Name der Zielklinik
Ort der Zielklinik
Arzt in der Zielklinik
Datum
Zeit
Verlegungsdiagnose
Herzinfarkt
Ja
Nein
Akutes Koronarsyndrom
Ja
Nein
Hypertensive Krise
Ja
1 / 25
Nein
Hypotonie
Ja
Nein
Synkope
Ja
Nein
Supraventrikuläre Tachykardie
Ja
Nein
Neuaufgetretenes Vorhofflimmern
Ja
Nein
Bradykardie, Verlegung für Schrittmacher
Ja
Nein
Dekompensierte Herzinsuffizienz
Ja
Nein
Gastrointestinaltrakt
obere Gastrointestinale Blutung (1)
untere Gastrointestinale Blutung (2)
Akutes Abdomen (3)
Ileus (4)
Cholecystitis (5)
akute Pankreatitis (6)
chronische Pankreatitis (7)
Divertikulitis (8)
Blut und Gefässe
TVT (1)
Anämie (2)
Lunge
Dyspnoe (1)
Lungenembolie (2)
exazerbierte COPD (3)
Bronchopneumonie (4)
Pneumonie (5)
Aspirationspneumonie (6)
respiratorische Insuffizienz (7)
Hyperglykämie
Ja
Nein
Hypoglykämie
Ja
Nein
Anaphylaxie
Ja
Nein
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Infektion
Erysipel (1)
Sepsis (2)
Niere
Nierenkolik (1)
Pyelonephritis (2)
Urosepsis (3)
NIS Oligourie (4)
Chirurgie
Akuter Arterieller Verschluss (art.
Verschluss)
Sturz auf die Seite, dabei Prellung vom
Becken. Klinisch Hämatom im Bereich
der Prellung und deutliche
Bewegungseinschränkung.
(Beckenprellung)
HWS Distorsion und Schädelprellung
(HWS Distorsion )
Sturz auf die Seite, dabei Prellung vom
Kniegelenk. Klinisch Hämatom und
geringer Erguss, deutliche
Bewegungseinschränkung.
(Kniegelenksprellung)
Klinisches Bild einer Leistenhernie.
(Leistenhernie)
Sturz auf die Seite mit Distorsion vom
oberen Sprungelenk. Klinisch Hämatom
im Bereich der Prellung und deutliche
Bewegungseinschränkung. (OSG
Distorsion)
Phlegmone (Phlegmone)
Pneumothorax (Pneumothorax)
Sturz auf die Seite, dabei Prellung vom
Ellbogen. Klinisch Hämatom im Bereich
der Prellung und deutliche
Bewegungseinschränkung.  (Prellung
von Ellbogen)
Sturz auf die Seite, dabei Prellung vom
Handgelenk. Klinisch Hämatom im
Bereich der Prellung und
Bewegungseinschränkung.  (Prellung
von Handgelenk)
Schädelprellung mit Kopfplatzwunde
(Schädelprellung)
Sturz auf die Schulter. Klinisch Hämatom
im Bereich der Prellung und deutliche
Bewegungseinschränkung.
(Schulterprellung)
Scrotalhernie (Scrotalhernie)
Gynäkologie
Mastitis nonpuerperalis (1)
Präeklampsie/Eklampsie (10)
HELLP-Syndrom (11)
V. a. Abort bei Gravidität im 1. Trimenon
(2)
V. a. Extrauteringravidität (3)
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Akutes Abdomen bei Gravidität im 2.
Trimenon (4)
Akutes Abdomen bei Gravidität im 3.
Trimenon (5)
Vorzeitige Wehentätigkeit (6)
Vaginale Blutung bei Gravidität (7)
V. a. Vorzeitiger Blasensprung (8)
Nabelschnurvorfall (9)
Epistaxis
Ja
Nein
Akuter Harnverhalt
Ja
Nein
cerebraler Krampfanfall
Ja
Nein
Schlaganfall
Ja
Nein
TIA
Ja
Nein
C2 Intoxikation
Ja
Nein
C2 Entzug
Ja
Nein
Parkinsonkrise
Ja
Nein
Suizidversuch
Ja
Nein
Suizidversuch
Ja
Nein
Schizophrenie
Ja
Nein
Akute Psychose
Ja
Nein
Schwere Depressive Episode
Ja
Nein
4 / 25
Physician referral letter
Andere Verlegungsdiagnose
Sonstige Diagnosen
Hypertonie
Ja
Nein
Pulmonale Hypertonie
Ja
Nein
Rechtsherzinsuffizienz
Ja
Nein
Linksherzinsuffizienz
Ja
Nein
Dekompensierte Herzinsuffizienz
Ja
Nein
KHK
Ja
Nein
Z.n. Stent nach Herzinfarkt
Ja
Nein
Linksschenkelblock
Ja
Nein
Rechtsschenkelblock
Ja
Nein
Linksherzinsuffzienz
Ja
Nein
Intermittierendes Vorhofflimmern
Ja
Nein
Permanentes Vorhofflimmern
Ja
Nein
Palpitationen
Ja
Nein
Nikotinabusus
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Ja
Nein
Hypercholesterinämie
Ja
Nein
Diabetes mellitus Typ II nicht insulinpflichtig
Ja
Nein
Diabetes mellitus Typ II insulinpflichtig
Ja
Nein
Adipositas
Ja
Nein
Positive Familienanamnese
Ja
Nein
Antikoagulation mit Marcumar
Ja
Nein
Hämorrhagische Diathese durch
Antikoagulanzien
Ja
Nein
Eisenmangelanämie
Ja
Nein
Akute Blutungsanämie
Ja
Nein
Anämie
Ja
Nein
Eisenmangelanämie durch Blutung
Ja
Nein
COPD
Ja
Nein
nicht allergisches Asthma Bronchiale
Ja
Nein
Gastrooesophageale Refluxkrankheit
Ja
Nein
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Chronische Gastritis
Ja
Nein
Divertikulose
Ja
Nein
Autoimmunthyreoiditis
Ja
Nein
Hypothyreose
Ja
Nein
Hyperthyreose
Ja
Nein
Adipositas permagna
Ja
Nein
Osteoporose
Ja
Nein
kompensierte Niereninsuffizienz
Ja
Nein
Nierenzyste
Ja
Nein
Akute Zystitis
Ja
Nein
Fibromyalgie
Ja
Nein
Restless-Legs-Syndrom
Ja
Nein
Polyarthritis
Ja
Nein
Polymyalgia rheumatica
Ja
Nein
chronische Polyarthritis
Ja
Nein
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Migräne
Ja
Nein
Spannungskopfschmerz
Ja
Nein
unsystematischer Schwindel
Ja
Nein
Synkope
Ja
Nein
TIA
Ja
Nein
alter ZNS Infarkt
Ja
Nein
Z.n. ischämischem Hirninfarkt
Ja
Nein
Z.n. Apoplexie
Ja
Nein
Hirninfarkt
Ja
Nein
Schlaffe Hemiparese
Ja
Nein
Spastische Hemiparese
Ja
Nein
Dysphagie
Ja
Nein
Dysphasie und Aphasie
Ja
Nein
Zerebrale Atherosklerose
Ja
Nein
Dementielles Syndrom
Ja
Nein
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Multiinfarkt-Demenz
Ja
Nein
Vaskuläre Demenz
Ja
Nein
Essenanreichung bei Demenz
Ja
Nein
V.a. Hirnmetastasen
Ja
Nein
Morbus Parkinson
Ja
Nein
Epilepsie
Ja
Nein
Belastungsinkontinenz
Ja
Nein
Z.n. Excision
Ja
Nein
Z.n. Radiatio
Ja
Nein
Dermatitis
Ja
Nein
Mykose
Ja
Nein
Chronisches Ulkus der Haut
Ja
Nein
Dekubitus
Ja
Nein
Gangrän
Ja
Nein
Phlegmone untere Extremität
Ja
Nein
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Psoriasis
Ja
Nein
HWS Syndrom
Ja
Nein
Rezidivierendes Cervicalsyndrom bei Discopathie
Ja
Nein
Intervertebralarthrosen der HWS
Ja
Nein
HWS Syndrom bei geringgradigen degenerativen
Veränderungen
Ja
Nein
BWS Syndrom
Ja
Nein
BWS Syndrom
Ja
Nein
LWS Syndrom
Ja
Nein
Schultereckgelenkarthrose
Ja
Nein
Impingementsyndrom Schulter
B (B)
L (L)
R (R)
Epicondylitis radialis humeri
Ja
Nein
Tendovaginitis stenosans
Ja
Nein
Carpaltunnelsyndrom
Ja
Nein
Heberden Arthrose
Ja
Nein
Bouchard-Arthrose
Ja
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Nein
Coxarthrose
Ja
Nein
Gonarthrose
Ja
Nein
Katarakt
Ja
Nein
Makuladegeneration
Ja
Nein
Myopie
Ja
Nein
Presbyakusis
Ja
Nein
Z.n. MammaCa
Ja
Nein
Chronischer Alkoholabusus
Ja
Nein
Nikotinabusus
Ja
Nein
Chronisches Schmerzsyndrom
Ja
Nein
Somatisierungsstörung
Ja
Nein
Posttraumatische Belastungsstörung
Ja
Nein
Schwere depressive Episode
Ja
Nein
mittelschwere depressive Episode
Ja
Nein
leichte depressive Episode
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Ja
Nein
Panikstörung
Ja
Nein
Eßstörung
Ja
Nein
Eingeschränkte Mobilität
Ja
Nein
Immobilitätssyndrom (paraplegisch)
Ja
Nein
Sturzneigung
Ja
Nein
Zusätzliche Diagnosen
Beta-Blocker
Bisohexal
Ja
Nein
Concor
Ja
Nein
Carvedilol
Ja
Nein
Selectol
Ja
Nein
Propranolol
Ja
Nein
Nebivolol
Ja
Nein
Sotalol
Ja
Nein
Beloc zok
Ja
Nein
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Metoprolol
Ja
Nein
Calciumantagonist
Felodipin AL
Ja
Nein
Amlodipin 1A
Ja
Nein
Verapamil 1A
Ja
Nein
Diltiazem 1A
Ja
Nein
Procorum
Ja
Nein
Carmen
Ja
Nein
Nifedipin 1A
Ja
Nein
Nitrendipin 1A
Ja
Nein
Angiotensin 2 Blocker (Sartane)
Blopress
Ja
Nein
Micardis
Ja
Nein
MicardisPlus
Ja
Nein
Aprovel
Ja
Nein
Coaprovel
Ja
Nein
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Votum
Ja
Nein
Diovan
Ja
Nein
CoDiovan
Ja
Nein
ACE Hemmer
ACE Hemmer
Ja
Nein
Enalapril 1A
Ja
Nein
Lisibeta
Ja
Nein
Delix
Ja
Nein
Cibacen
Ja
Nein
Diuretika
Spironolacton 1A
Ja
Nein
Furo
Ja
Nein
Xipamid
Ja
Nein
Furosemid 1A
Ja
Nein
HCT
Ja
Nein
Torem
Ja
Nein
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Ramipril plus
Ja
Nein
Triarese
Ja
Nein
Ramipril/Piretanid 1A
Ja
Nein
Lisodura plus
Ja
Nein
Amilorid HCT
Ja
Nein
Herzmedikamente
Molsidomin 1A
Ja
Nein
Pentalong
Ja
Nein
Isoket
Ja
Nein
Rasilez
Ja
Nein
Amiodaron 1A
Ja
Nein
Flecadura
Ja
Nein
Digoxin 1A
Ja
Nein
Digimed
Ja
Nein
Digostada
Ja
Nein
Anticoagulants
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Marcumar
Ja
Nein
Aggrenox
Ja
Nein
Clexane
Ja
Nein
Plavix
Ja
Nein
Aspirin
Ja
Nein
Antidiabetika
Glibenclamid 1A
Ja
Nein
Amaryl
Ja
Nein
NovoNorm
Ja
Nein
Glucophage
Ja
Nein
Janumed
Ja
Nein
Acarbose
Ja
Nein
Sitagliptin
Ja
Nein
Januvia
Ja
Nein
Insulin human
Ja
Nein
Huminsulin
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Ja
Nein
Actraphane 30/70
Ja
Nein
Insulin human Protaphane 30/70
Ja
Nein
Levemir
Ja
Nein
Lantus
Ja
Nein
Diabetes Diät
Ja
Nein
Antidepressiva
Stangyl
Ja
Nein
Amitriptylin
Ja
Nein
Amitriptylinoxid
Ja
Nein
Citalopram
Ja
Nein
Cipralex
Ja
Nein
Doxepin
Ja
Nein
Sertralin
Ja
Nein
Venlafaxin
Ja
Nein
Duloxetin
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Ja
Nein
Fluoxetin
Ja
Nein
Mirtazapin
Ja
Nein
Agomelatin
Ja
Nein
Lithiumcarbonat
Ja
Nein
Johanniskraut
Ja
Nein
Eplerenon
Ja
Nein
Zolpidemtartrat
Ja
Nein
Zopiclon
Ja
Nein
Pipamperon
Ja
Nein
Quetiapin
Ja
Nein
Neuroleptika
Dominal
Ja
Nein
Sulpirid
Ja
Nein
Promethazin
Ja
Nein
Melperon
Ja
Nein
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Haldol
Ja
Nein
Opipramol dura
Ja
Nein
Hormonelle Kontrazeptiva
Duphaston
Ja
Nein
Estreva
Ja
Nein
Gynokadin
Ja
Nein
Ovestin
Ja
Nein
Bellissima
Ja
Nein
Lamuna
Ja
Nein
Bronchodilatatoren
Salbutamol-CT DA
Ja
Nein
Foster
Ja
Nein
Foradil
Ja
Nein
Berotec DA
Ja
Nein
Bronchoretard
Ja
Nein
Spiriva
Ja
Nein
19 / 25
Physician referral letter
Atrovent
Ja
Nein
Berodual
Ja
Nein
Singulair
Ja
Nein
Lipidsenker
LOCOL
Ja
Nein
Pravastatin 1A
Ja
Nein
Simvadura
Ja
Nein
Sortis
Ja
Nein
Bezafibrat
Ja
Nein
Inegy
Ja
Nein
Analgetika
Fentanyl TAD
Ja
Nein
Fentanyl-CT transdermales Pflaster
Ja
Nein
Oxygesic
Ja
Nein
Tramal
Ja
Nein
Tilidin retard
Ja
Nein
20 / 25
Physician referral letter
Ibuprofen 1A
Ja
Nein
Diclofenac 1A
Ja
Nein
ARCOXIA
Ja
Nein
Paracetamol 1A
Ja
Nein
Novalgin
Ja
Nein
Antiinfektiva
Cefuroxim 1A
Ja
Nein
Roxi 1A
Ja
Nein
Klacid
Ja
Nein
Avalox
Ja
Nein
Ciprobay
Ja
Nein
Tavanic
Ja
Nein
Clont
Ja
Nein
Antiparkinsonmittel
Madopar
Ja
Nein
Adartrel
Ja
Nein
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Selegilin
Ja
Nein
Comtess
Ja
Nein
Akineton
Ja
Nein
Amantadin
Ja
Nein
Glucokortikoide
Dexa CT
Ja
Nein
Decortin
Ja
Nein
Budesonid CT
Ja
Nein
Symbicort
Ja
Nein
Alvesco
Ja
Nein
Weitere Medikation
Proscar
Ja
Nein
Magnesium Verla
Ja
Nein
NaCl
Ja
Nein
Calcium HEXAL
Ja
Nein
Kalinor Brause
Ja
Nein
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Vigantoletten
Ja
Nein
Ferro sanol
Ja
Nein
ACC
Ja
Nein
Mucosolvan
Ja
Nein
Cetirizin-CT
Ja
Nein
Xusal
Ja
Nein
Tavegil
Ja
Nein
Jodthyrox
Ja
Nein
Euthyrox
Ja
Nein
Carbimazol 1A
Ja
Nein
Allopurinol AL
Ja
Nein
Fosamax
Ja
Nein
Nexium
Ja
Nein
Omebeta
Ja
Nein
Pantozol
Ja
Nein
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Movicol
Ja
Nein
Lactulose
Ja
Nein
Metoclopramid
Ja
Nein
Sumatriptan
Ja
Nein
Lyrica
Ja
Nein
Carbamazepin
Ja
Nein
Keppra
Ja
Nein
Tolperison
Ja
Nein
Musaril
Ja
Nein
Flupirtinmaleat
Ja
Nein
Gabapentin
Ja
Nein
Reminyl
Ja
Nein
Memantin
Ja
Nein
Oxybutynin 1A
Ja
Nein
Prostess
Ja
Nein
24 / 25
Physician referral letter
Tamsulosin
Ja
Nein
Trospiumchlorid
Ja
Nein
Xalatan
Ja
Nein
Timololmaleat
Ja
Nein
Andere Medikation
Bedarfsmedikation
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Physician referral letter
Medical History Form, Study Hospital of
Medical Faculty Münster
Medical history form, Study hospital, Medical Faculty
Münster
derived from Medical history form by Dr. Schusdziarra
All rights reserved. Please visit https://medical-data-
models.org/forms/16491
Medical History Form
Demographie
Patient Name
Geburtsdatum
Tag der Untersuchung
Arzt
Aktuelle Erkankungen
Art der Beschwerden
Lokalisation der Beschwerden
Wann sind die Beschwerden zum ersten Mal
aufgetreten?
Handelt es sich um andauernde Beschwerden
oder treten sie im Intervall auf?
Permanent (1)
Intermittierend (2)
Dauer der Beschwerden und des
beschwerdefreien Intervalls
Intensität und Charakter der Beschwerden
Abhängigkeit der Beschwerden
Ausmaß der Beeinträchtigung des
Allgemeinbefindens durch die
Beschwerdesymptomatik
Welche Untersuchungen sind bereits
durchgeführt worden?
Frühere Krankheiten
Kinderkrankheiten
Krankheiten im Erwachsenenalter
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Krankenhausaufenthalte
Operationen
Verletzungen
Psychische Erkrankungen
aktive und passive Impfungen
Andere relevante Erkrankungen
Medikamentenanamnese
Art des Medikaments
Dosierung
Zeitdauer der Einnahme
Früher eingenommene Medikamente
Nicht rezeptpflichtige Medikamente
Medikamentenallergie
Berufs- und Sozialanamnese
Erlernter Beruf
Tatsächlich ausgeübter Beruf
Belastungen im Beruf
Exposition gegenüber Schadstoffen
Zufriedenheit im Beruf,allgemein
Sicherheit der Stelle
Familiäre Situation
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Familienanamnese
Familiär gehäufte Erkrankungen
Diabetes mellitus
Bluthochdruck
Blutgerinnungsstörungen
Karzinome
Fettstoffwechselstörungen
Arteriosklerose
Vegetative Anamnese
Art der Allergie-Symptomatik
Allergentestung
Kontrastmittelallergie
Medikamentenallergie
Appetit
Appetit normal (1)
Appetitverlust (2)
Nahrungsaufnahme
Normal (1)
gesteigert  (2)
vermindert (3)
Heißhunger auf bestimmte Speisen oder
Getränke
Trinkmenge
Art der Getränke
Erbrechen
Ja
Nein
Beziehung zur Nahrungsaufnahme und
3 / 6
Medical History Form, Study Hospital of Medical Faculty Münster
Zusammensetzung
Aussehen und Geschmack des Erbrochenen
Diät
Ja
Nein
Welche Diät
Grund für die Diät
Miktion Häufigkeit
Urinfarbe
Beschwerden beim Wasserlassen
Urinmenge
Nykturie Häufigkeit
Stuhlgang Frequenz
Stuhlmenge
Stuhlkonsistenz
Stuhlfarbe
Aussehen des Stuhlgangs
Auflagerungen und Beimengungen zum
Stuhlgang
Menarche: erste Periode
Menses: Regelmäßig?
Ja
Nein
Orale Kontrazeption?
Ja
Nein
Menopause?
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Ja
Nein
Geburtenanzahl
Schwangerschaftskomplikationen?
Fehlgeburten oder Abtreibungen
Letzte Vorsorgeuntersuchung
Gewicht
Größe
Gewichtszunahme Ausmaß und Zeitraum
Gewichtszunahme gewollt/ungewollt
gewollt (1)
ungewollt (2)
Diät
Gewichtsverlust Ausmaß und Zeitraum
Gewichtsverlust gewollt/ungewollt
gewollt (1)
ungewollt (2)
Reduktionsdiät?
Allgemeine Leistungsfähigkeit
Schlafstörungen
Schlafdauer
Schlaf zu welcher Tageszeit?
Husten:Dauer
Zu welcher Tageszeit hustet der Patient?
Farbe des Auswurfs
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Konsistenz des Auswurfs
Zu welcher Tagezeit hat der Patient Auswurf?
Blut im Auswurf?
Ja
Nein
Häufigkeit des Auswurfs
Wie lange dauert der produktive Husten?
Fieber:Dauer
Fieber:Verlauf
Nachtschweiß?
Ja
Nein
Belastungsabhängiges Schwitzen?
Ja
Nein
Ruhedyspnoe
Ja
Nein
Belastungsdyspnoe
Ja
Nein
Nächtliche Dyspnoe
Warum Hautjucken?
Hautjucken im Zusammenhang mit Kleidung,
Nahrung?
Anfälle
Geschlechtskrankheiten: Risikogruppen, HIV-Test
Täglicher/wöchentlicher Alkoholkonsum
Nikotingebrauch:Art, Menge und Dauer des
Nikotinkonsums
Invalidität
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Eligibility Breast Neoplasms NCT00620100
To Determine the Objective Response Rate of 4 Cycles of
Docetaxel + Anthracycline (Epirubicin or Doxorubicine)
Followed by 4 Cycles of Docetaxel Single Agent; ODM
derived from: https://clinicaltrials.gov/show/NCT00620100
All rights reserved. Please visit https://medical-data-
models.org/forms/16492
Eligibility Breast Neoplasms
NCT00620100
Inclusion Criteria
1. female patient with histologically or
cytologically documented breast
adenocarcinoma*
Yes
No
2. first local or metastatic relapse*
Yes
No
3. patients must have received a prior
neoadjuvant or adjuvant taxotere®-based
chemotherapy regimen, provided this
chemotherapy was completed > than or = to 12
months prior to enrollment date*
Yes
No
4. prior hormone or immune therapy is allowed.
antitumoral adjuvant hormone therapy may be
continued during the study period, provided it
was started > 12 months prior to study
enrollment*
Yes
No
5. her2/neu negative tumor demonstrated by
immunohistochemistry (ihc 0 or 1+) or by
fluorescence in situ hybridation (fish -). a patient
with tumor assessed as 2+ by ihc can be enrolled
if the tumor is negative by fish.*
Yes
No
6. ecog performance status of 0 to 2*
Yes
No
7. normal cardiac function confirmed by lvef or
shortening fraction (muga scan or
echocardiography, respectively, within normal
limits for the institution) assessed within 3 months
prior to study entry. an ecg must be obtained
within 4 weeks prior study entry and must
demonstrate no clinically significant abnormality.*
Yes
No
8. patients are required to have at least one
measurable lesion according to recist guidelines*
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Yes
No
9. adequate organ function defined by:*
Yes
No
1. hematology: neutrophils > than or = to 2.0
109/l, platelets > than or = to 100 109/l,
hemoglobin > than or = to 10 g/dl*
Yes
No
2. hepatic function: total bilirubin within normal
limits, ast (sgot) and alt (sgpt) < than or = to 1.5
unl, alkaline phosphatase < than or = to 2.5 unl
(unless accompanied by extensive bone
metastases)*
Yes
No
10. negative pregnancy test (urine or serum)
within 7 days prior to registration for all women of
childbearing potential*
Yes
No
11. written informed consent prior to beginning
specific protocol procedures must be obtained
and documented according to the local regulatory
requirements*
Yes
No
Exclusion Criteria
1. prior therapy for advanced or recurrent
disease*
Yes
No
2. previous cumulative exposure to epirubicin >
600 mg/m² or to doxorubicin > 300 mg/m²*
Yes
No
3. previous radiation therapy having involved
more than 25% of bone marrow; incomplete
recovery from toxicity of radiation therapy*
Yes
No
4. symptomatic brain metastases and clinically
diagnosed leptomeningeal metastases*
Yes
No
5. isolated unmeasurable bone lesions, serous
pleural effusion or pulmonary lymphangiitis (i.e.,
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unmeasurable disease according to the recist
guidelines)*
Yes
No
6. pre-existing motor or sensory neurologic
toxicity of a severity > than or = to grade 2
according to nci-ctc ae criteria version 3.0*
Yes
No
7. pregnant or lactating women or women of
childbearing potential not using adequate
contraception*
Yes
No
8. other serious illness or medical conditions,
including:*
Yes
No
1. congestive heart failure or unstable angina
pectoris, previous history of myocardial infarction
within 1 year from study entry, uncontrolled
hypertension or high-risk uncontrolled
arrhythmias*
Yes
No
2. history of significant neurologic or psychiatric
disorders including psychotic disorders, dementia
or seizures that would hamper understanding and
giving informed consent.*
Yes
No
3. active uncontrolled infection*
Yes
No
4. active peptic ulcer, uncontrolled diabetes
mellitus*
Yes
No
9. past or current history of neoplasm other than
breast carcinoma, except:*
Yes
No
1. curatively treated non-melanoma skin cancer.*
Yes
No
2. in situ carcinoma of the cervix.*
Yes
No
3. other cancer curatively treated and with no
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evidence of disease for at least 10 years*
Yes
No
10. chronic treatment with corticosteroids unless
initiated > 6 months prior to study entry and at
low dose (< than or = to 20 mg
methylprednisolone per day or equivalent)*
Yes
No
11. definite contraindications for the use of
corticosteroids*
Yes
No
12. likelihood of requiring treatment during the
study period with drugs not permitted by the
clinical study protocol (see section 6.2)*
Yes
No
13. concurrent treatment with other
investigational drugs. active treatment as part of
another clinical therapeutic trial within 30 days
prior to study entry*
Yes
No
14. concurrent treatment with any other anti-
cancer therapy, except adjuvant hormone therapy
started > than or = to 12 months prior to study
enrollment. bisphosphonates for management of
bone metastases or osteoporosis/osteopenia are
allowed*
Yes
No
15. history of hypersensitivity to docetaxel (or
drugs formulated in polysorbate 80), epirubicin or
doxorubicin*
Yes
No
16. mental condition rendering the subject unable
to understand the nature, scope, and possible
consequences of the study*
Yes
No
17. subject unlikely to comply with protocol, e.g.,
uncooperative attitude, inability to return for
follow-up visits, and unlikelihood of completing
the study*
Yes
No
the above information is not intended to contain
all considerations relevant to a patient's potential
participation in a clinical trial.*
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Yes
No
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Physical Exam Cardiovascular Health Study
(CHS)
Documentation part: Record 17 Physical Exam
The Cardiovascular Health Study (CHS) was initiated by
the National Heart, Lung and Blood Institute (NHLBI) in
1987 to determine the risk factors for development and
progression of cardiovascular disease (CVD) in older
adults, with an emphasis on subclinical measures. The
study recruited 5,888 adults aged 65 or older at entry in
four U.S. communities and conducted extensive annual
clinical exams between 1989-1999 along with semi-annual
phone calls, events adjudication, and subsequent data
analyses and publications. Additional data were collected
by studies ancillary to CHS. With the exception of annual
clinic visits, these activities are still ongoing.
Data obtained from: https://chs-nhlbi.org/
Permission granted by: Erika Enright.
All rights reserved. Please visit https://medical-data-
models.org/forms/16493
Physical Exam Cardiovascular
Health Study (CHS)
Measured Walk
1. Measured walk
A. Is the participant able to walk 15 feet?
Not able (Not able)
Not assessed (Not assessed)
Yes (Yes)
B. Time, in seconds, to walk 15 feet
seconds
Grip Strength
*2. Do you have any pain in your wrists or hands,
for example, due to arthritis or tendonitis?
Yes
No
3. Have you had any surgery on your hands or
arms during the last 13 weeks?
Yes
No
4. Code which hand is being tested.
left (left)
right  (right )
5. Position of dynamometer
6. 1st try
kg
7. 2nd try
kg
8. 3rd try
kg
9. Code which hand is being tested.
left (left)
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right  (right )
10. Position of dynamometer
11. 1st try
kg
12. 2nd try
kg
13. 3rd try
kg
General Physical Examination
Chest, lungs
*14. Bilateral rales that do not clear with coughing
Don`t know (Don`t know)
No  (No )
Yes (Yes)
15. Systolic murmur
Don`t know (Don`t know)
No  (No )
Yes (Yes)
16. Diastolic murmur
Don`t know (Don`t know)
No  (No )
Yes (Yes)
17. a. Right - Supraclavicular Fossa
Don`t know (Don`t know)
No  (No )
Yes (Yes)
b. Right - Angle of jaw
Don`t know (Don`t know)
No  (No )
Yes (Yes)
c. Intensity
angle of jaw louder (angle of jaw louder)
equal (equal)
Supraclavicular fossa louder
(Supraclavicular fossa louder)
18. a. Left - Supraclavicular Fossa
Don`t know (Don`t know)
No  (No )
Yes (Yes)
b. Left- Angle of jaw
Don`t know (Don`t know)
No  (No )
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Yes (Yes)
c. Intensity
angle of jaw louder (angle of jaw louder)
equal (equal)
Supraclavicular fossa louder
(Supraclavicular fossa louder)
19. Pitting ankle edema
Don`t know (Don`t know)
No  (No )
Yes (Yes)
Chair stands
20. Do you think it would be safe for you to try to
stand up from a chair without using your arms?
Yes
No
21. Do you think you could try to stand up from a
chair without using your arms?
Yes
No
*22. Code the reason task was not performed:
Not attempted, chair bound (Not
attempted, chair bound)
Not attempted, other (Not attempted,
other)
Not attempted, safety reasons (Not
attempted, safety reasons)
If, other specify:
*23. Number of attempts to rise
24. Rises
Attempted, but unable (Attempted, but
unable)
Rises using arms (Rises using arms)
Rises without using arms (Rises without
using arms)
25. Do you think it would be safe for you to try to
stand up from a chair, without using your arms,
five times quickly?
Yes
No
26. Reason task not attempted:
Not attempted, chair bound (Not
attempted, chair bound)
Not attempted, other (Not attempted,
other)
Not attempted, safety reasons (Not
attempted, safety reasons)
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If other, specify
*27. Heart rate (30 second) prior to chair stands:
28. Number of completed chair rises:
29. Heart rate (30 second) immediately following
chair stands:
30. Number of seconds
seconds
31. Chair height
(Centimeters from floor to lowest point)
cm
Other physical findings/comments
*32. Do you have comments to enter?
Yes
No
If yes, specify:
Date of interview
Interviewer
Interview:
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Baseline Echocardiography Cardiovascular
Health Study (CHS)
Documentation part: Record 19 Baseline Echocardiography
The Cardiovascular Health Study (CHS) was initiated by
the National Heart, Lung and Blood Institute (NHLBI) in
1987 to determine the risk factors for development and
progression of cardiovascular disease (CVD) in older
adults, with an emphasis on subclinical measures. The
study recruited 5,888 adults aged 65 or older at entry in
four U.S. communities and conducted extensive annual
clinical exams between 1989-1999 along with semi-annual
phone calls, events adjudication, and subsequent data
analyses and publications. Additional data were collected
by studies ancillary to CHS. With the exception of annual
clinic visits, these activities are still ongoing.
Data obtained from: https://chs-nhlbi.org/
Permission granted by: Erika Enright.
All rights reserved. Please visit https://medical-data-
models.org/forms/16494
Baseline Echocardiography
Cardiovascular Health Study (CHS)
Echocardiography
1. Results of examination:
Done (Done)
Incomplete (Incomplete)
Not done (Not done)
2. Reasons test incomplete or not done:
Examinee medically excluded by staff for
safety (Examinee medically excluded by
staff for safety)
Examinee refused or uncooperative
(Examinee refused or uncooperative)
Examinee unable to physically cooperate
(Examinee unable to physically
cooperate)
Hardware malfunction or lack of supplies
(Hardware malfunction or lack of
supplies)
Insufficient time available or room not
available (Insufficient time available or
room not available)
other (other)
Software malfunction (Software
malfunction)
Other, specify:
3. Were any alert conditions noted?
Don't know (Don't know)
No  (No )
Yes (Yes)
4. If yes, specify:
Date of interview
Interviewer
Interview:
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Year 7 Echocardiography Cardiovascular
Health Study (CHS)
Documentation part: Record 19 Year 7 Echocardiography
The Cardiovascular Health Study (CHS) was initiated by
the National Heart, Lung and Blood Institute (NHLBI) in
1987 to determine the risk factors for development and
progression of cardiovascular disease (CVD) in older
adults, with an emphasis on subclinical measures. The
study recruited 5,888 adults aged 65 or older at entry in
four U.S. communities and conducted extensive annual
clinical exams between 1989-1999 along with semi-annual
phone calls, events adjudication, and subsequent data
analyses and publications. Additional data were collected
by studies ancillary to CHS. With the exception of annual
clinic visits, these activities are still ongoing.
Data obtained from: https://chs-nhlbi.org/
Permission granted by: Erika Enright.
All rights reserved. Please visit https://medical-data-
models.org/forms/16495
Year 7 Echocardiography
Cardiovascular Health Study (CHS)
Echocardiography
1. Results of examination:
Done (Done)
Incomplete (Incomplete)
Not done (Not done)
2. Reasons test incomplete or not done:
Examinee medically excluded by staff for
safety (Examinee medically excluded by
staff for safety)
Examinee refused or uncooperative
(Examinee refused or uncooperative)
Examinee unable to physically cooperate
(Examinee unable to physically
cooperate)
Hardware malfunction or lack of supplies
(Hardware malfunction or lack of
supplies)
Insufficient time available or room not
available (Insufficient time available or
room not available)
other (other)
Software malfunction (Software
malfunction)
Other, specify:
3. Were any alert conditions noted?
Don't know (Don't know)
No  (No )
Yes (Yes)
4. If yes, specify:
Date of interview
Interviewer
Interview:
1 / 1
Eligibility Breast Neoplasms NCT00649337
Earlier Breast Cancer Detection Using Automated Whole
Breast Ultrasound With Mammography, Including Cost
Comparisons; ODM derived from:
https://clinicaltrials.gov/show/NCT00649337
All rights reserved. Please visit https://medical-data-
models.org/forms/16497
Eligibility Breast Neoplasms
NCT00649337
Inclusion Criteria
be at least 35 years old, unless she has a strong
pre-menstrual family history of breast cancer*
Yes
No
have had no screening mammogram in the past
10 months*
Yes
No
agree to have a screening mammogram that will
not be reviewed until after a sonociné*
Yes
No
is performed*
Yes
No
agree to have a screening mammogram in
approximately one year*
Yes
No
agree to answer follow up question in
approximately one year*
Yes
No
meet the usual criteria for breast screening (be
asymptomatic of focal breast disease)*
Yes
No
have no history of breast cancer for at least one
year*
Yes
No
agree to have both mammogram and sonociné if
a physical finding or mammographic finding
occurs within one year that requires biopsy*
Yes
No
Exclusion Criteria
greater than 7 cm compressed breast thickness
at mammography*
Yes
1 / 2
No
2 / 2
Eligibility Breast Neoplasms NCT00649337
Baseline Echocardiography Cardiovascular
Health Study (CHS)
Documentation part: Record 21 Baseline Echocardiography
The Cardiovascular Health Study (CHS) was initiated by
the National Heart, Lung and Blood Institute (NHLBI) in
1987 to determine the risk factors for development and
progression of cardiovascular disease (CVD) in older
adults, with an emphasis on subclinical measures. The
study recruited 5,888 adults aged 65 or older at entry in
four U.S. communities and conducted extensive annual
clinical exams between 1989-1999 along with semi-annual
phone calls, events adjudication, and subsequent data
analyses and publications. Additional data were collected
by studies ancillary to CHS. With the exception of annual
clinic visits, these activities are still ongoing.
Data obtained from: https://chs-nhlbi.org/
Permission granted by: Erika Enright.
All rights reserved. Please visit https://medical-data-
models.org/forms/16498
Baseline Echocardiography
Cardiovascular Health Study (CHS)
Echocardiography
1. Chest square readings: O-E measurement:
O-V6 measurements:
2. When ECG is finished, measure Heel-to-Knee
length and enter the result here:
3. Bioelectric impedence: resistence
3. Bioelectric impedence: reactance:
4. Results of ECG:
done (1)
incomplete (2)
not done (3)
5. Reason ECG incomplete or not done:
Examinee medically excluded by staff for
safety (Examinee medically excluded by
staff for safety)
Examinee refused or uncooperative
(Examinee refused or uncooperative)
Examinee unable to physically cooperate
(Examinee unable to physically
cooperate)
Hardware malfunction or lack of supplies
(Hardware malfunction or lack of
supplies)
Insufficient time available or room not
available (Insufficient time available or
room not available)
Other (Other)
Software malfunction (Software
malfunction)
Other, specify:
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6. Heart rate (60 second):
7. Were the following alert conditions noted:
Atrial fibrillation?
Yes
No
7. Were the following alert conditions noted: Atrial
flutter?
Yes
No
7. Were the following alert conditions noted: Wolf-
Parkinson White (WPW) or ventricular pre-
excitation?
Yes
No
7. Were the following alert conditions noted:
Idioventricular rhythm?
Yes
No
7. Were the following alert conditions noted:
Ventricular tachycardia?
Yes
No
7. Were the following alert conditions noted:
Complete heart block?
Yes
No
7. Were the following alert conditions noted:
Acute pericarditis?
Yes
No
7. Were the following alert conditions noted: Any
reference to injury or ischemia?
Yes
No
8. Is the participant able to do the following?
Remove shoes
Yes
No
8. Is the participant able to do the following?
Transfer off chair
Yes
No
8. Is the participant able to do the following? Get
onto table
Yes
No
8. Is the participant able to do the following? Get
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off table
Yes
No
8. Is the participant able to do the following? Put
on shoes
Yes
No
Date of interview
Interviewer
Interview:
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Years 4-11 Echocardiography
Cardiovascular Health Study (CHS)
Documentation part: Record 21 Years 4-11
Echocardiography
The Cardiovascular Health Study (CHS) was initiated by
the National Heart, Lung and Blood Institute (NHLBI) in
1987 to determine the risk factors for development and
progression of cardiovascular disease (CVD) in older
adults, with an emphasis on subclinical measures. The
study recruited 5,888 adults aged 65 or older at entry in
four U.S. communities and conducted extensive annual
clinical exams between 1989-1999 along with semi-annual
phone calls, events adjudication, and subsequent data
analyses and publications. Additional data were collected
by studies ancillary to CHS. With the exception of annual
clinic visits, these activities are still ongoing.
Data obtained from: https://chs-nhlbi.org/
Permission granted by: Erika Enright.
All rights reserved. Please visit https://medical-data-
models.org/forms/16499
Years 4-11 Echocardiography
Cardiovascular Health Study (CHS)
Echocardiography
1. Chest square readings: O-E measurement:
O-V6 measurements:
4. Results of ECG:
done (1)
incomplete (2)
not done (3)
3. Reason ECG incomplete or not done:
Examinee medically excluded by staff for
safety (Examinee medically excluded by
staff for safety)
Examinee refused or uncooperative
(Examinee refused or uncooperative)
Examinee unable to physically cooperate
(Examinee unable to physically
cooperate)
Hardware malfunction or lack of supplies
(Hardware malfunction or lack of
supplies)
Insufficient time available or room not
available (Insufficient time available or
room not available)
Other (Other)
Software malfunction (Software
malfunction)
Other, specify:
4. Heart rate (60 second):
5. Were the following alert conditions noted:
Atrial fibrillation?
Yes
No
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5. Were the following alert conditions noted: Atrial
flutter?
Yes
No
5. Were the following alert conditions noted: Wolf-
Parkinson White (WPW) or ventricular pre-
excitation?
Yes
No
5. Were the following alert conditions noted:
Idioventricular rhythm?
Yes
No
5. Were the following alert conditions noted:
Ventricular tachycardia?
Yes
No
5. Were the following alert conditions noted:
Complete heart block?
Yes
No
5. Were the following alert conditions noted:
Acute pericarditis?
Yes
No
5. Were the following alert conditions noted: Any
reference to injury or ischemia?
Yes
No
6. Test was done:
Semi-recumbant (Semi-recumbant)
Supine (Supine)
7. Is the participant able to do the following?
Remove shoes
Yes
No
7. Is the participant able to do the following?
Transfer off chair
Yes
No
7. Is the participant able to do the following? Get
onto table
Yes
No
7. Is the participant able to do the following? Get
off table
Yes
No
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7. Is the participant able to do the following? Put
on shoes
Yes
No
Date of interview
Interviewer
Interview:
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Eligibility Breast Neoplasms NCT02254031
Dose Escalation of Bivatuzumab Mertansine in Female
Patients With CD44v6 Positive Recurrent or Metastatic
Breast Cancer; ODM derived from:
https://clinicaltrials.gov/show/NCT02254031
All rights reserved. Please visit https://medical-data-
models.org/forms/16500
Eligibility Breast Neoplasms
NCT02254031
Inclusion Criteria
1. female patients aged 18 years or older*
Yes
No
2. patients with breast cancer positive for cd44v6
in at least 50 % of the tumour cells*
Yes
No
3. patients with local and / or regional recurrent
disease or distant metastases who are refractory
to anthracyclines and / or taxanes (unless
contraindications to taxanes and / or
anthracyclines) or not amenable to established
treatments*
Yes
No
4. measurable tumour deposits by one or more
radiological techniques (mri, ct)*
Yes
No
5. life expectancy of at least 6 months*
Yes
No
6. eastern cooperative oncology group (ecog)
performance score ≤ 2*
Yes
No
7. patients must have given written informed
consent (which must be consistent with
international conference of harmonisation-good
clinical practice (ich-gcp) and local legislation)*
Yes
No
Exclusion Criteria
1. hypersensitivity to humanised or murine
antibodies, immunoconjugates or the excipients
of the trial drugs*
Yes
No
2. known secondary malignancy requiring
therapy*
Yes
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No
3. active infectious disease*
Yes
No
4. brain metastases requiring therapy*
Yes
No
5. neuropathy grade 2 or above*
Yes
No
6. absolute neutrophil count less than
1,500/mm3*
Yes
No
7. platelet count less than 100,000/mm3*
Yes
No
8. bilirubin greater than 1.5 mg/dl (> 26 μmol/l,
système internationale (si) unit equivalent)*
Yes
No
9. aspartate amino transferase (ast) and/or
alanine amino transferase (alt) greater than 3
times the upper limit of normal*
Yes
No
10. serum creatinine greater than 1.5 mg/dl (>
132 μmol/l, si unit equivalent)*
Yes
No
11. concomitant non-oncological diseases which
are considered relevant for the evaluation of the
safety of the trial drug*
Yes
No
12. chemo- or immunotherapy within the past four
weeks prior to treatment with the trial drug or
during the trial (except for present trial drug)*
Yes
No
13. radiotherapy to breast and thorax region
within the past four weeks prior to treatment with
the trial drug or during the trial*
Yes
No
14. women who are sexually active and unwilling
to use a medically acceptable method of
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contraception*
Yes
No
15. pregnancy or lactation*
Yes
No
16. treatment with other investigational drugs or
participation in another clinical trial within the
past four weeks before start of therapy or
concomitantly with this trial (except for present
trial drug)*
Yes
No
17. patients unable to comply with the protocol*
Yes
No
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Eligibility C04.588.274.476.411.307
NCT00212615
XELOX III. Xeloda in Combination With Eloxatin for Patients
With Advanced or Metastatic Colorectal Cancer; ODM
derived from: https://clinicaltrials.gov/show/NCT00212615
All rights reserved. Please visit https://medical-data-
models.org/forms/16501
Eligibility C04.588.274.476.411.307
NCT00212615
Inclusion Criteria
histological proven adenocarcinoma of the colon
or rectum*
Yes
No
measurable or non-measurable disease*
Yes
No
performance status 0-2*
Yes
No
adequate renal and hepatic functions*
Yes
No
adjuvant chemotherapy must have ended 180
days before inclusion*
Yes
No
written informed consent prior to randomization*
Yes
No
Exclusion Criteria
prior treatment with eloxatin or xeloda*
Yes
No
peripheral neuropathy*
Yes
No
evidence of cns metastasis*
Yes
No
other serious illness or medical conditions
(including contraindication to 5 fu e.g.: angor,
myocardial infarction within 6 months)*
Yes
No
past history of malignant neoplasm within the
past five years, except  curatively treated non
melanoma skin cancer*
Yes
No
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administration of any other experimental drug
under investigation within 2 weeks before
randomisation*
Yes
No
pregnant or breast feeding women*
Yes
No
fertile patients must use adequate
contraceptives*
Yes
No
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Sepsis-associated organ dysfunction report
form MEDUSA project
The MEDUSA project (medical education for sepsis source
control and antibiotics) is a scientific study of the integrated
research and treatment center "Center for Sepsis Control
and Care" (CSCC) of the University Hospital Jena,
Thuringia, Germany.
Its aim is to investigate whether a multimodal and
interdisciplinary training concept for the early recognition
and standardized treatment of patients with sepsis
improves time to administration of first antibiotic and
survival of patients.
Original forms obtained from:
http://www.medusa.uniklinikum-
jena.de/Datenerfassung.html
All rights reserved. Please visit https://medical-data-
models.org/forms/16502
Sepsis-associated organ dysfunction
report form MEDUSA project
Header module
Study Subject ID
document creator
Patient demographics
Age
Sex
Male (1)
Female (2)
Hospital admission
Admission to intensive care unit
Reason for admission to intensive care
Planned surgery (1)
internal Medicine (2)
Surgery not planned - emergency (3)
other (4)
Injury (5)
Height
cm
Weight
kg
Sepsis
Sepsis ODF start time and date
Place of first onset of sepsis-associated organ
dysfunction
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Emergency room (1)
Intensive care unit (2)
Normal ward (3)
Emergency physician (4)
Intermediate Care (5)
Origin of infection
Community-Acquired Infection  (1)
Nosocomial (Normal ward)  (2)
Nosocomial (intensive care unit)  (3)
Nosocomial Nursing Homes (4)
Source of infection
Pneumonia  (1)
thoracal (10)
cardiovascular (11)
cns (12)
unknown (13)
Intraabdominal  (2)
Bacteremia  (3)
Wound Infection  (4)
Bones  (5)
Catheter infection  (6)
Respiratory System (7)
gastrointestinal (8)
genitourinary system (9)
New sepsis-associated organ dysfunction
within first 12 hours
Vigilance
Yes
No
Oxygenation impairment
Yes
No
Hypotension
Yes
No
Vasopressor
Yes
No
Inotropic agent
Yes
No
Oliguria
Yes
No
Acute Kidney Failure
Yes - with Dialysis (1)
Yes - without Dialysis (2)
No (3)
Thrombocytopenia
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Yes
No
metabolic acidosis
Yes
No
First manifestation of sepsis-associated
organ dysfunction
Vigilance
Yes
No
Oxygenation impairment
Yes
No
Hypotension
Yes
No
Vasopressor
Yes
No
Inotropic agent
Yes
No
Oliguria
Yes
No
Acute Kidney Failure
Yes
No
Thrombocytopenia
Yes
No
Metabolic acidosis
Yes
No
Exclusion criteria at time of first onset of
sepsis-associated organ dysfunction
Was the sepsis therapy initiated at another
hospital?
Yes
No
Has necessary treatment been withheld due to
therapy limitations?
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Yes
No
Has the treatment been started without transfer
of patient to intensive care?
Yes
No
Clinical data within the first 24 hours of
treatment
Simplified acute physiology score
unknown (1)
Glasgow Coma Scale
Horowitz index -  oxygenation ratio (paO2/FiO2)
mmHg
Temperature
°C
Heart rate
1/min
Respiration
normal  (1)
Tachypnea (2)
Beatmung/ CPAP (3)
Unknown (4)
Cardiovascular finding
MAP ≥ 70 mmHg (without
catecholamines)  (1)
MAP < 70 mmHg (with catecholamines)
(2)
Dopamin [≤ 5 μg/kg/min] or Dobutamin
(3)
Dopamin [> 5 μg/kg/min] or Epinephrin
[≤ 0,1 μg/kg/min] or Norepinephrin [≤ 0,1
μg/kg/min] (4)
Dopamin [> 15 μg/kg/min] or Epinephrin
[> 0,1 μg/kg/min] or Norepinephrin [> 0,1
μg/kg/min] (5)
Diuresis
ml/24h
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MEDUSA project
The MEDUSA project (medical education for sepsis source
control and antibiotics) is a scientific study of the integrated
research and treatment center "Center for Sepsis Control
and Care" (CSCC) of the University Hospital Jena,
Thuringia, Germany.
Its aim is to investigate whether a multimodal and
interdisciplinary training concept for the early recognition
and standardized treatment of patients with sepsis
improves time to administration of first antibiotic and
survival of patients.
Original forms obtained from:
http://www.medusa.uniklinikum-
jena.de/Datenerfassung.html
All rights reserved. Please visit https://medical-data-
models.org/forms/16503
Sepsis treatment associated data
report form
Header module
Study Subject ID
document creator
Lab results within the 24 hours of
treatment
Creatinine
μmol/l
Bilirubin total
μmol/l
Blood Platelets
G/l
Leukocytes
G/l
CRP
md/dl
Procalcitonin
ng/ml
Lactat
mmol/l
ph
Base excess
mmol/l
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Antibiotic therapy
Antibiotic therapy of sepsis
Start time and date (1)
previous treatment continue (2)
no antibiotic treatment (3)
In case antibiotic therapy has been started,
please indicate substance:
Previous antibiotic therapy?
Previous administration of antibiotics
no (no)
unknown (unknown)
yes (infection-related) (yes (infection-
related))
yes (prophylactic) (yes (prophylactic))
Duration (days) of antibiotic treatment prior to
diagnosis
date (1)
unknwon (2)
not applicable (3)
Blood culture
Blood culture
yes prior to antibiotic treatment (at least
one set prior to antibiotic treatment) (1)
yes after start of antibiotic treatment (all
sets after) (2)
no (3)
Amount of Blood Culture Kits
infectious source control
none  (1)
Surgery   (2)
Removal Of Foreign Body (3)
interventional (4)
point in time of infectious source control
Was the infectious source control successful?
Yes
No
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Study hospital, Medical Faculty Münster-
Clinical Examination findings
Medical history form, Study hospital, Medical Faculty
Münster
derived from Medical history form by Dr. Schusdziarra
All rights reserved. Please visit https://medical-data-
models.org/forms/16506
Clinical Examination findings
Demographics
Patient Name
Patient date of birth
Patient Occupation
Physical Examination Date
Treating physician
General Health assessment
Overall impression
Normal (1)
Feeble (2)
Critically ill (3)
Speech
Normal (1)
Slurred speech (2)
Hoarse (3)
Stutter (4)
Physical strength
Normal (1)
Reduced (2)
Trained (3)
Somatotype
ectomorph (1)
endomorph (2)
mesomorph (3)
cross type (4)
Gait
Normal (1)
Erect (2)
Piked (3)
Disability (specify) (4)
Gait:Please specify the nature of disability
Movements
Normal (1)
Impaired (2)
Restless (3)
Tremor (4)
1 / 11
Nutritional status
Normal (1)
Skinny (2)
Cachexia (3)
Adipose (4)
Body weight
Body height
Muscle mass
Average (1)
Strong (2)
Atrophic (3)
Facial expressions
Normal (1)
Face rigidity (2)
Body Temperature
Skin assessment
Skin color
Normal (1)
Pale (2)
Reddened (3)
Cyanotic (4)
Jaundice (5)
Pigmented (6)
Skin lesions
Urticaria (1)
Papules (2)
Abcesses (3)
Skin lesions (4)
Ulcers (5)
Fissures (6)
Bleeding
Petechiae (1)
Ecchymosis (2)
Suggillation (3)
Suffusions (4)
Vascular markings
Telangiectasia (1)
Spider naevus (2)
Angioma (3)
Head assessment
Skull:Shape
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Skull: percussion pain
Skull: Hair growth
Facial bones: Asymmetry, scars
Nerve exit points
Normal (1)
Pressure tenderness (2)
Assessment of Lymph nodes
Lymph nodes: Pressure tenderness
submandibular (1)
cervical (2)
preauricular (3)
retroauricular (4)
suboccipital (5)
supraclavicular (6)
axillary (7)
inguinal (8)
Lymph nodes: Size
submandibular (1)
cervical (2)
preauricular (3)
retroauricular (4)
suboccipital (5)
supraclavicular (6)
axillary (7)
inguinal (8)
Lymph nodes: Consistency
submandibular (1)
cervical (2)
preauricular (3)
retroauricular (4)
suboccipital (5)
supraclavicular (6)
axillary (7)
inguinal (8)
Lymph nodes: displaceability
submandibular (1)
cervical (2)
preauricular (3)
retroauricular (4)
suboccipital (5)
supraclavicular (6)
axillary (7)
inguinal (8)
Eyes
Eyelids
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Ptosis (1)
Edema (2)
Sclera:Color
Pupils
round (1)
miosis (2)
mydriasis (3)
asymmetric (4)
Pupil reaction
reaction to light  (1)
direct (2)
indirect (3)
Accommodation (4)
Eyeballs
Movements (1)
Strabism (2)
Nystagmus (3)
Exophthalmus (4)
Enophthalmus (5)
Visus
Normal (1)
Reduced (2)
Corrected (Glasses) (3)
Conjunctiva
Pale (1)
Reddened (2)
Ears
Auricle
External auditory canal
Hearing
Nose
Nasal airway patency
Mucous Membrane: Color, secretion
Oral cavity
Tongue: Moisture, plaque, movement
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Tonsils: Size, plaques
Tonsils: normal
Yes
No
Dentures
Restored (1)
Caries (2)
False teeth (3)
Waldeyers ring
Normal (1)
Reddened (2)
Mucus (3)
Purulence (4)
Lips:Color, Moisture, skin lesions
Neck
Thyroid gland
Normal (1)
Enlarged (2)
Thyroid nodules (3)
Whizz (4)
Neck circumference
Blood vessels
Venous Engorgement (1)
Bruit (2)
Larynx
Thorax
Form of thorax
Normal (1)
Barrel chest (2)
Breathing
Normal (1)
Symmetric (2)
Respiratory rate
Respiratory rhythm
Inspiratory chest circumference
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Exspiratory chest circumference
Vertebral column
Normal (1)
Enhanced chest kyphosis and lumbar
lordosis (2)
Scoliosis (3)
Mammae: Size,Symmetry, distance of mamillae,
knots, retractions
Lungs
Chest percussion
sonoric (1)
dull (2)
hypersonoric (3)
tympanitic (4)
Inferior margin of lower lobe of lung, right side
Inferior margin of lower lobe of lung, left side
Mobility of right lung margin
Mobility of left lung margin
Respiratory Sounds
vesicular (1)
reduced (2)
bronchial breathing (3)
Abnormal breath sounds
Wheezing (1)
Whistling sound (2)
Humming sound (3)
Fine rales (4)
Medium rales (5)
Coarse rales (6)
Sounding rales (7)
Non-sounding rales (8)
Pleural Rub (9)
Heart
Right heart margin
normal (1)
enlarged (2)
Left heart margin
normal (1)
enlarged (2)
6 / 11
Study hospital, Medical Faculty Münster- Clinical Examination findings
Apex beat
not palpable (1)
widened (2)
raising (3)
Apex beat localization
Heart sounds
Normal (1)
Light (2)
Pronounced (3)
Split (4)
Extra sounds (5)
Heart murmur (6)
Cardiac activity
Regular rhythm (1)
Arrhythmia absoluta (2)
Extrasystoles (3)
Heart rate
Blood pressure
Pulse deficit
peripheral (1)
central (2)
Abdominal Examination
Abdominal shape symmetrical?
Yes
No
Abdominal wall
Soft (1)
Sunken (2)
adipose (3)
scar(s) (4)
abdominal rigidity (5)
Hernia
Inguinal hernia (1)
Umbilical hernia (2)
Incisional hernia (3)
Closed hernia (4)
Palpation tenderness:localization
Palpation tenderness
Circumscript (1)
Diffuse (2)
Intraabdominal resistance:localization
Intraabdominal resistance: expanse
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Intraabdominal resistance:Consistency
Intraabdominal resistance:pressure pain
Intraabdominal resistance:pulsation
Intraabdominal resistance:None
Yes
No
Ascites
Yes
No
Ascites: abdominal circumference
Bowel sounds
Normal (1)
Reduced (2)
Dead silent (3)
Increased (4)
Liver
Liver size
Liver consistency
Elasic (1)
Soft (2)
Coarse (3)
Hard (4)
Liver surface
Smooth (1)
Nodular liver (2)
Liver margin
Blunt (1)
Pointed (2)
Liver pain
Indolent (1)
Painful (2)
Spleen
Spleen palpation: consistency
Spleen palpation
palpable (1)
not palpable (2)
Fibrous capsule of kidney
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Fibrous capsule of kidney
Normal (1)
Painful on percussion (2)
Pressure pain (3)
Rectal examination
Rectal inspection
Fissures (1)
Fistula (2)
Hemorrhoides (3)
Prolapse (4)
Rectal palpation
Ampulla recti normal (1)
Palpable resistencies (2)
Prostate: Size
Prostate: Consistency
Prostate: Nodules
Prostate: Pressure pain
Genitalia
Genitalia normal
Yes
No
Pubic hair
Genitalia shape
Testicle size
Extremities
Axis of limb
Active Range of Motion
Passive Range of Motion
Skeletal muscle structure
Joint swelling
9 / 11
Study hospital, Medical Faculty Münster- Clinical Examination findings
Joint pain
Flexion
normal (1)
reduced (2)
Extension
normal (1)
reduced (2)
Joint:specify location
Vascular status
Pulse taking: Palpation of A.carotis communis
palpable (1)
not palpable (2)
palpable but reduced (3)
Pulse taking: Palpation of A.brachialis
palpable (1)
not palpable (2)
palpable but reduced (3)
Pulse taking: Palpation of A.radialis
palpable (1)
not palpable (2)
palpable but reduced (3)
Pulse taking: Palpation of A.femoralis
palpable (1)
not palpable (2)
palpable but reduced (3)
Pulse taking: Palpation of A.poplitea
palpable (1)
not palpable (2)
palpable but reduced (3)
Pulse taking: Palpation of A.dorsalis pedis
palpable (1)
not palpable (2)
palpable but reduced (3)
Pulse taking: Palpation of A.tibialis posterior
palpable (1)
not palpable (2)
palpable but reduced (3)
Auscultation of Aortic murmur and heart murmur
Neurologic status
Assessment of neurologic status
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Central nervous system
Consciousness
Normal (1)
Stuporous (2)
Somnolent (3)
Semicoma (4)
Comatose (5)
Orientation as to time, place and personal
Mood
Euphorical (1)
Irritable (2)
Anxious (3)
Depressed (4)
Psychomotor
Disinhibited (1)
Impulsive (2)
Retarded (3)
Passive (4)
Peripheral nervous system
Active innervation and function of head and
extremities
Hemiplegia (1)
Hemiparesis (2)
Tetraparesis (3)
Muscle Spasticity (4)
Muscle Rigidity (5)
Tremor (6)
Physiological reflexes
Normal (1)
Symmetrical (2)
Brisk (3)
Reduced (4)
Abnormal reflexes: Babinsky reflex
Clonus exhaustible (1)
Clonus inexhaustible (2)
Coordination
Sensitivity
Combined Functions:Romberg, Unterberger
Diagnosis
Diagnosis or tentative diagnosis
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Eligibility Cancer of the Head and Neck
NCT00180921
Study of Imatinib (Glivec) in Patients With Adenoid Cystic
Carcinoma of the Head and Neck; ODM derived from:
https://clinicaltrials.gov/show/NCT00180921
All rights reserved. Please visit https://medical-data-
models.org/forms/16507
Eligibility Cancer of the Head and
Neck NCT00180921
Inclusion Criteria
histologically or cytologically proven adenoid
cystic carcinoma overexpressing kit (by
immunohistochemistry) with recurrent disease
documented by computed tomography (ct) scan
or magnetic resonance imaging (mri).*
Yes
No
presence of at least one dimensionally
measurable target lesion (contrast enhancing
lesion with the largest diameter >= 2 cm, based
on ct or mri scan done within 4 weeks before the
start of treatment).*
Yes
No
patients able to swallow an oral compound.*
Yes
No
world health organization (who) performance
status < 2.*
Yes
No
life expectancy of >= 3 months.*
Yes
No
aged >= 18 years.*
Yes
No
normal hematological (neutrophils  >= 1.5 x 10^9
cells/l, platelets >= 100 x 10^9 cells/l), hepatic
(bilirubin < 1.5 times the upper limit of the normal
range; alkaline phosphatase and transaminases
<= 2.5 x the upper limit of the normal range) and
renal (serum creatinine <= 150 mmol/l)
functions.*
Yes
No
written informed consent.*
Yes
No
Exclusion Criteria
abnormal cardiac function with history of
ischaemic heart disease in the past 6 months
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and/or abnormal 12 lead electrocardiogram
(ecg).*
Yes
No
previous or current malignancies at other sites
with the exception of cone biopsied carcinoma of
the cervix and adequately treated basal or
squamous cell skin carcinoma.*
Yes
No
concomitant treatment with warfarin or any other
anticoagulants.*
Yes
No
unstable systemic diseases or active uncontrolled
infections.*
Yes
No
patients (male and female) not using effective
contraception if of reproductive potential.*
Yes
No
females pregnant or lactating or positive beta
human chorionic gonadotropin (bhcg) at
baseline*
Yes
No
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Eligibility Carcinoma NCT00152477
A Study of Paclitaxel/Carboplatin With or Without CDP791
in Patients With Lung Cancer; ODM derived from:
https://clinicaltrials.gov/show/NCT00152477
All rights reserved. Please visit https://medical-data-
models.org/forms/16508
Eligibility Carcinoma NCT00152477
Inclusion Criteria
male and female subjects with stage iiib (with
malignant pleural effusion or if no pleural effusion
is present subjects who are not candidates for
combined modality therapy), stage iv, or recurrent
non-squamous, non-small-cell lung carcinoma.*
Yes
No
the subject must be aged 18 years or above.*
Yes
No
the subject must have ecog performance status
of 0 or 1 and a life expectancy of at least three
months.*
Yes
No
subjects will have measurable disease.*
Yes
No
the subject must be able to understand the
information provided to them and to give written
informed consent.*
Yes
No
female subjects must be either postmenopausal,
surgically sterilized, or using a method of
contraception judged reliable by the investigator.*
Yes
No
male subjects must be using a method of
contraception judged reliable by the investigator.*
Yes
No
Exclusion Criteria
subjects with squamous cell lung carcinoma.*
Yes
No
subjects with lung lesions located centrally in the
chest that involve major blood vessels.*
Yes
No
concurrent active malignancy other than
nonmelanoma skin cancer or carcinoma in situ of
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the cervix. subjects with previous malignancies
are eligible provided that they have been disease
free for five years or more.*
Yes
No
presence of additional major chronic disease
such as hepatic or renal dysfunction, cardiac
dysfunction, peripheral vascular disease,
evidence of a myocardial infarction within six
months of screening visit, tuberculosis or
epilepsy.*
Yes
No
subjects known to be infected with hepatitis b or c
virus or hiv 1 or 2.*
Yes
No
any evidence of serious active infection (ie
requiring an iv antibiotic or antiviral agent).*
Yes
No
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Eligibility Carcinoma NCT00126269
Trial Comparing Cisplatin With or Without Gemcitabine in
Patients With Carcinoma of Unknown Primary; ODM
derived from: https://clinicaltrials.gov/show/NCT00126269
All rights reserved. Please visit https://medical-data-
models.org/forms/16509
Eligibility Carcinoma NCT00126269
Inclusion Criteria
patients older than 18 years*
Yes
No
evidence of cup based on histologic examination*
Yes
No
negative search for the primary tumor site using
recommended guidelines*
Yes
No
disease classified as good prognosis according
to the french classification criteria:*
Yes
No
*performance status >2 and *normal serum ldh*
Yes
No
no prior chemotherapy*
Yes
No
no previous carcinoma, except basal-cell
carcinoma of the skin*
Yes
No
adequate renal function: measured or calculated
creatinine clearance > 60 ml/min*
Yes
No
absolute granulocyte count ≥ 1,500/mm3;
platelets ≥ 100,000 mm3; bilirubin ≤ 1.5 fold the
upper normal value*
Yes
No
signed informed consent*
Yes
No
Exclusion Criteria
patients infected by the human immunodeficiency
virus (hiv)*
Yes
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No
cup belonging to one of the following subgroups:
1) axillary lymph node of an adenocarcinoma in a
woman; 2) serous adenocarcinoma of the
peritoneum in a woman; 3) undifferentiated
carcinoma of the middle line in a young man;
4)squamous-cell carcinoma; 5) neuroendocrine
carcinoma; 6) bone metastases with elevated
serum prostate specific antigen (psa) in a man*
Yes
No
patients who do not fit inclusion criteria.*
Yes
No
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Eligibility Coronary Heart Disease
NCT00402636
Rapamycin+Estradiol- vs. Rapamycin-Eluting Stents to
Reduce Restenosis (ISAR-PEACE); ODM derived from:
https://clinicaltrials.gov/show/NCT00402636
All rights reserved. Please visit https://medical-data-
models.org/forms/16510
Eligibility Coronary Heart Disease
NCT00402636
Inclusion Criteria
patients older than age 18 with ischemic
symptoms or evidence of myocardial ischemia in
the presence of ≥50% de novo stenosis located
in native coronary vessels.*
Yes
No
written, informed consent by the patient or her/his
legally-authorized representative for participation
in the study.*
Yes
No
Exclusion Criteria
target lesion located in the left main trunk or
bypass graft.*
Yes
No
in-stent restenosis.*
Yes
No
acute st-elevation myocardial infarction.*
Yes
No
cardiogenic shock.*
Yes
No
malignancies or other comorbid conditions (for
example severe liver, renal and pancreatic
disease) with life expectancy less than 12 months
or that may result in protocol non-compliance.*
Yes
No
known allergy to the study medications: aspirin,
clopidogrel, rapamycin, estradiol, stainless steel.*
Yes
No
pregnancy (present, suspected or planned) or
positive pregnancy test.*
Yes
No
previous enrollment in this trial.*
Yes
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No
patient's inability to fully cooperate with the study
protocol.*
Yes
No
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Eligibility Coronary Heart Disease NCT00402636
Eligibility Carcinoma, Non-small Cell Lung
NCT00093132
Satraplatin for Locally Advanced Non-Small Cell Lung
Cancer With Simultaneous Radiotherapy; ODM derived
from: https://clinicaltrials.gov/show/NCT00093132
All rights reserved. Please visit https://medical-data-
models.org/forms/16511
Eligibility Carcinoma, Non-small Cell
Lung NCT00093132
Inclusion Criteria
locally advanced or medically inoperable nsclc
(stage ii or iii)*
Yes
No
ecog performance status score 0-2*
Yes
No
adequate bone marrow, liver, and pulmonary
functions*
Yes
No
life expectancy > three months.*
Yes
No
Exclusion Criteria
prior malignancy*
Yes
No
serious concurrent uncontrolled medical
disorder.*
Yes
No
uncontrolled or significant cardiovascular
disease*
Yes
No
history of mastectomy*
Yes
No
pregnant or breast-feeding patients are not
eligible*
Yes
No
prior radiotherapy to the primary tumor site or
cytotoxic chemotherapy*
Yes
No
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Public hospital establishment address details
DSS Metadata Online Registry (METeOR)
Health sector data set specifications from METeOR,
Australia's repository for national metadata standards,
developed by the Australian Institute of Health and Welfare
(http://meteor.aihw.gov.au/content/index.phtml/itemId/3451
65)
Public hospital establishment address details DSS
The Public hospital establishment address details data set
specification (DSS) is used to collect information pertaining
to the address of the hospital establishments reported in
the Public hospital establishments NMDS. 
The mandatory fields to be reported for address are:
•	Establishment—organisation identifier (Australian),
NNX[X]NNNNN 
•	Address—road number 1, road number X[6] 
•	Address—road name, text X[45] 
•	Address—road type, code AA[AA] 
•	Address—suburb/town/locality name, text X[46] 
•	Address—Australian postcode, code (Postcode datafile)
{NNNN} 
•	Address—Australian state/territory identifier, code AA[A]
All other data elements are to be reported if that data
element is a component of the address of the Public
hospital establishment.
© Australian Institute of Health and Welfare 2015
Metadata and Classifications Unit 
Australian Institute of Health and Welfare
GPO Box 570
Canberra ACT 2601
All rights reserved. Please visit https://medical-data-
models.org/forms/16513
Public hospital establishment
address details DSS Metadata
Online Registry (METeOR)
Address
Address site name
Australian postcode (address)*
Australian state/territory identifier of address*
Australian Antarctic Territory (AAT)
Australian Capital Territory (ACT)
New South Wales (NSW)
Northern Territory (NT)
Queensland (QLD)
South Australia (SA)
Tasmania (TAS)
Victoria (VIC)
Western Australia (WA)
Complex road name
Complex road number 1
Complex road number 2
Complex road type
Access (ACCS)
Alley (ALLY)
Alleyway (ALWY)
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Amble (AMBL)
Approach (APP)
Arcade (ARC)
Arterial (ARTL)
Artery (ARTY)
Avenue (AV)
Banan (BA)
Bend (BEND)
Brace (BR)
Brae (BRAE)
Break (BRK)
Brow (BROW)
Boulevard (BVD)
Boardwalk (BWLK)
Bypass (BYPA	)
Byway (BYWY)
Circuit (CCT)
Chase (CH)
Circle (CIR)
Close (CL)
Corner (CNR)
Concourse (CON)
Cove (COVE)
Copse (CPS)
Crescent (CR)
Circus (CRCS)
Cross (CRSS)
Crest (CRST)
Cul-de-sac (CSAC)
Causeway (CSWY)
Court (CT)
Centre (CTR)
Courtyard (CTYD)
Cutting (CUTT)
Dale (DALE)
Dip (DIP)
Drive (DR)
Driveway (DVWY)
Edge (EDGE)
Elbow (ELB)
End (END)
Entrance (ENT)
Esplanade (ESP)
Expressway (EXP)
Fairway (FAWY)
Follow (FOLW)
Formation (FORM)
Frontage (FRTG)
Footway (FTWY)
Freeway (FWY)
Gap (GAP)
Gardens (GDNS)
Glade (GLDE)
Glen (GLEN)
Grove (GR)
Grange (GRA)
Green (GRN)
Gate (GTE)
Hill (HILL)
Highroad (HIRD)
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Public hospital establishment address details DSS Metadata Online
Registry (METeOR)
Heights (HTS)
Highway (HWY)
Interchange (INTG)
Junction (JNC)
Key (KEY)
Lane (LANE)
Line (LINE)
Link (LINK)
Lookout (LKT)
Laneway (LNWY)
Loop (LOOP)
Mall (MALL)
Mews (MEWS)
Meander (MNDR)
Motorway (MTWY)
Nook (NOOK)
Outlook (OTLK)
Pass (PASS)
Path (PATH)
Parade (PDE)
Piazza (PIAZ)
Pocket (PKT)
Plaza (PLZA)
Point (PNT)
Port (PORT)
Promenade (PROM)
Passage (PSGE)
Pathway (PWAY)
Parkway (PWY)
Quadrant (QDRT)
Quays (QYS)
Road (RD)
Ridge (RDGE)
Rest (REST)
Rise (RISE)
Ramble (RMBL)
Row (ROW)
Route (RTE)
Retreat (RTT)
Rotary (RTY)
Rue (RUE)
Subway (SBWY)
Shunt (SHUN)
Spur (SPUR)
Square (SQ)
Street (ST)
Serviceway (SVWY)
Tarn (TARN)
Terrace (TCE)
Thoroughfare (THFR)
Tollway (TLWY)
Top (TOP)
Tor (TOR)
Track (TRK)
Trail (TRL)
Turn (TURN)
Underpass (UPAS)
Vale (VALE)
Viaduct (VIAD)
View (VIEW)
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Public hospital establishment address details DSS Metadata Online
Registry (METeOR)
Vista (VSTA)
Walk (WALK)
Wharf (WHRF)
Walkway (WKWY)
Wynd (WYND)
Level number identifier
Road name*
Road number 1*
Road number 2
Road type*
Access (ACCS)
Alley (ALLY)
Alleyway (ALWY)
Amble (AMBL)
Approach (APP)
Arcade (ARC)
Arterial (ARTL)
Artery (ARTY)
Avenue (AV)
Banan (BA)
Bend (BEND)
Brace (BR)
Brae (BRAE)
Break (BRK)
Brow (BROW)
Boulevard (BVD)
Boardwalk (BWLK)
Bypass (BYPA	)
Byway (BYWY)
Circuit (CCT)
Chase (CH)
Circle (CIR)
Close (CL)
Corner (CNR)
Concourse (CON)
Cove (COVE)
Copse (CPS)
Crescent (CR)
Circus (CRCS)
Cross (CRSS)
Crest (CRST)
Cul-de-sac (CSAC)
Causeway (CSWY)
Court (CT)
Centre (CTR)
Courtyard (CTYD)
Cutting (CUTT)
Dale (DALE)
Dip (DIP)
Drive (DR)
Driveway (DVWY)
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Public hospital establishment address details DSS Metadata Online
Registry (METeOR)
Edge (EDGE)
Elbow (ELB)
End (END)
Entrance (ENT)
Esplanade (ESP)
Expressway (EXP)
Fairway (FAWY)
Follow (FOLW)
Formation (FORM)
Frontage (FRTG)
Footway (FTWY)
Freeway (FWY)
Gap (GAP)
Gardens (GDNS)
Glade (GLDE)
Glen (GLEN)
Grove (GR)
Grange (GRA)
Green (GRN)
Gate (GTE)
Hill (HILL)
Highroad (HIRD)
Heights (HTS)
Highway (HWY)
Interchange (INTG)
Junction (JNC)
Key (KEY)
Lane (LANE)
Line (LINE)
Link (LINK)
Lookout (LKT)
Laneway (LNWY)
Loop (LOOP)
Mall (MALL)
Mews (MEWS)
Meander (MNDR)
Motorway (MTWY)
Nook (NOOK)
Outlook (OTLK)
Pass (PASS)
Path (PATH)
Parade (PDE)
Piazza (PIAZ)
Pocket (PKT)
Plaza (PLZA)
Point (PNT)
Port (PORT)
Promenade (PROM)
Passage (PSGE)
Pathway (PWAY)
Parkway (PWY)
Quadrant (QDRT)
Quays (QYS)
Road (RD)
Ridge (RDGE)
Rest (REST)
Rise (RISE)
Ramble (RMBL)
Row (ROW)
Route (RTE)
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Public hospital establishment address details DSS Metadata Online
Registry (METeOR)
Retreat (RTT)
Rotary (RTY)
Rue (RUE)
Subway (SBWY)
Shunt (SHUN)
Spur (SPUR)
Square (SQ)
Street (ST)
Serviceway (SVWY)
Tarn (TARN)
Terrace (TCE)
Thoroughfare (THFR)
Tollway (TLWY)
Top (TOP)
Tor (TOR)
Track (TRK)
Trail (TRL)
Turn (TURN)
Underpass (UPAS)
Vale (VALE)
Viaduct (VIAD)
View (VIEW)
Vista (VSTA)
Walk (WALK)
Wharf (WHRF)
Walkway (WKWY)
Wynd (WYND)
Secondary complex name
Sub-dwelling unit number
Suburb/town/locality name within address*
Establishment
Establishment identifier*
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Public hospital establishment address details DSS Metadata Online
Registry (METeOR)
Radiotherapy waiting times NMDS 2015-
Metadata Online Registry (METeOR)
Health sector data set specifications from METeOR,
Australia's repository for national metadata standards,
developed by the Australian Institute of Health and Welfare
(http://meteor.aihw.gov.au/content/index.phtml/itemId/3451
65)
Radiotherapy waiting times NMDS 2015-
The main purpose of the Radiotherapy waiting times
national minimum data set (RWT NMDS) is to describe the
information that must be collected to calculate the waiting
times for the following time period in the treatment pathway
for radiotherapy services in Australia: 
The time between the patient's ready-for-care date and the
date of the first megavoltage external beam radiotherapy
treatment.
Establishments in scope are only those healthcare
establishments that provide megavoltage external beam
radiotherapy treatment (in-scope radiotherapy treatment).
Both public and private establishments are in scope. While
it is mandatory for public establishments to report data to
the national minimum data set (NMDS), private providers
are also encouraged to participate.
The scope is not limited by diagnosis: it includes people
with cancer (notifiable and non-notifiable) and people who
do not have cancer. 
People in scope are those who started a course of
radiotherapy treatment within the reference period.
For public establishments, all in-scope activity should be
reported, including services provided by specialists
operating under right of private practice arrangements.
© Australian Institute of Health and Welfare 2015
Metadata and Classifications Unit 
Australian Institute of Health and Welfare
GPO Box 570
Canberra ACT 2601
All rights reserved. Please visit https://medical-data-
models.org/forms/16514
Radiotherapy waiting times NMDS
2015- Metadata Online Registry
(METeOR)
Address
Statistical area level 2 (SA2)*
Establishment
Establishment identifier*
Patient
Clinical emergency indicator*
Yes
No
Intention of treatment*
Prophylactic (1)
Curative (2)
Palliative (3)
Not stated/inadequately described (9)
Principal diagnosis - patient*
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Radiotherapy start date*
Ready-for-care date*
Person
Area of usual residence (SA2)*
Date of birth*
Indigenous status*
Aboriginal but not Torres Strait Islander
origin (1)
Torres Strait Islander but not Aboriginal
origin (2)
Both Aboriginal and Torres Strait Islander
origin (3)
Neither Aboriginal nor Torres Strait
Islander origin (4)
Not stated/inadequately described (9)
Person identifier*
Sex*
Male (1)
Female (2)
Intersex or indeterminate (3)
Not stated/inadequately described (9)
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Radiotherapy waiting times NMDS 2015- Metadata Online Registry
(METeOR)
Residential mental health care NMDS 2015-
16 Metadata Online Registry (METeOR)
Health sector data set specifications from METeOR,
Australia's repository for national metadata standards,
developed by the Australian Institute of Health and Welfare
(http://meteor.aihw.gov.au/content/index.phtml/itemId/3451
65)
Residential mental health care NMDS 2015-16
The scope of the Residential mental health care national
minimum data set (RMHC NMDS) is episodes of residential
care for residents in all government-funded residential
mental health care services in Australia, except those
residential care services that are in receipt of funding under
the Aged Care Act and subject to Commonwealth reporting
requirements (i.e. report to the System for the Payment of
Aged Residential Care (SPARC) collection).  
The following metadata are of particular relevance to the
scope of the RMHC NMDS:
Residential mental health care service
Specialised mental health service
© Australian Institute of Health and Welfare 2015
Metadata and Classifications Unit 
Australian Institute of Health and Welfare
GPO Box 570
Canberra ACT 2601
All rights reserved. Please visit https://medical-data-
models.org/forms/16515
Residential mental health care
NMDS 2015-16 Metadata Online
Registry (METeOR)
Episode of care
Additional diagnosis*
Mental health legal status*
Involuntary patient (1)
Voluntary patient (2)
Not reported/unknown (9)
Principal diagnosis—episode of care*
Episode of residential care
Episode of residential care end date*
Episode of residential care end mode*
Died (1)
Left against clinical advice / at own risk
(2)
Did not return from leave (3)
Formal discharge from residential care at
this establishment (4)
End of reference period (5)
Return to other residential mental health
service (6)
Unknown/not stated/inadequately
described (9)
Episode of residential care start date*
1 / 4
Episode of residential care start mode*
Start of a new residential stay (2)
Start of a new reference period (3)
Start of expected short concurrent
residential stay (on leave from other
residential mental health service) (4)
Unknown/not stated/inadequately
described (9)
Mental health care referral destination*
Specialised mental health admitted
patient care (1)
Specialised mental health residential
care (2)
Specialised mental health ambulatory
care (3)
Private psychiatrist care (4)
General practitioner care (5)
Other care (6)
Not referred (7)
Not applicable (i.e. end of reference
period or died) (8)
Unknown/not stated/inadequately
described (9)
Leave days from residential care*
days
Establishment
Australian State/Territory identifier
(establishment)*
New South Wales (1)
Victoria (2)
Queensland (3)
South Australia (4)
Western Australia (5)
Tasmania (6)
Northern Territory (7)
Australian Capital Territory (8)
Other territories (Cocos (Keeling)
Islands, Christmas Island and Jervis Bay
Territory) (9)
Region code*
Region name*
Establishment sector*
Public (1)
Private (2)
Service unit cluster identifier*
Service unit cluster name*
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Residential mental health care NMDS 2015-16 Metadata Online Registry
(METeOR)
Person
Area of usual residence (SA2)*
Country of birth*
Date of birth*
Indigenous status*
Aboriginal but not Torres Strait Islander
origin (1)
Torres Strait Islander but not Aboriginal
origin (2)
Both Aboriginal and Torres Strait Islander
origin (3)
Neither Aboriginal nor Torres Strait
Islander origin (4)
Not stated/inadequately described (9)
Marital status*
Never Married (1)
Widowed (2)
Divorced (3)
Separated  (4)
Married (registered and de facto) (5)
Not stated/inadequately described (6)
Person identifier*
Sex*
Male (1)
Female (2)
Intersex or indeterminate (3)
Not stated/inadequately described (9)
Residential stay
Residential stay start date*
Specialised mental health service
organisation
Organisation identifier*
Organisation name*
Specialised mental health service
Residential service unit identifier*
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Residential mental health care NMDS 2015-16 Metadata Online Registry
(METeOR)
Residential service unit name*
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Residential mental health care NMDS 2015-16 Metadata Online Registry
(METeOR)
Eligibility Hypertension, Pulmonary
NCT00105209
A Study of Aspirin and Clopidogrel in Patients With
Idiopathic Pulmonary Arterial Hypertension; ODM derived
from: https://clinicaltrials.gov/show/NCT00105209
All rights reserved. Please visit https://medical-data-
models.org/forms/16516
Eligibility Hypertension, Pulmonary
NCT00105209
Inclusion Criteria
diagnosis of ipah*
Yes
No
≥ 18 years of age*
Yes
No
nyha functional class i, ii, or iii*
Yes
No
clinical stability (i.e., without change in pulmonary
arterial hypertension medical regimen within one
month prior to enrollment).*
Yes
No
Exclusion Criteria
other forms of pah*
Yes
No
a contraindication to asa or clopidogrel*
Yes
No
thrombocytopenia (defined as platelet count ≤
75,000)*
Yes
No
history of intracranial hemorrhage or chronic
thromboembolic disease*
Yes
No
renal failure*
Yes
No
inability or unwillingness to avoid non-steroidal
anti-inflammatory agents, asa, or warfarin use for
the duration of the trial*
Yes
No
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Eligibility Carcinoma, Non-Small Cell Lung
NCT00190840
A Single Arm Phase 2 Study of Pemetrexed as 2nd-Line
Treatment of Advanced Non-Small Cell Lung Cancer; ODM
derived from: https://clinicaltrials.gov/show/NCT00190840
All rights reserved. Please visit https://medical-data-
models.org/forms/16519
Eligibility Carcinoma, Non-Small Cell
Lung NCT00190840
Inclusion Criteria
diagnosis of nsclc*
Yes
No
locally advanced or metastatic disease (stage iiib
or iv).*
Yes
No
patients must have previously received one
chemotherapy regimen for palliative therapy of
locally advanced or metastatic disease.*
Yes
No
disease status must be that of measurable
disease as defined by recist criteria*
Yes
No
performance status of 0 to 1 on the eastern
cooperative oncology group (ecog) scale; and
adequate organ function.*
Yes
No
Exclusion Criteria
known or suspected brain metastasis, or second
primary malignancy that is clinically detectable at
the time of consideration for study enrollment*
Yes
No
concurrent administration of any other tumor
therapy.*
Yes
No
history of significant neurological or mental
disorder, including seizures or dementia; or any
other serious concomitant disorders that would
compromise the safety of the patient or
compromise the patient's ability to complete the
study*
Yes
No
inability to interrupt aspirin or other nonsteroidal
anti-inflammatory drugs (nsaids) 2 days before,
the day of, and 2 days after the dose of
1 / 2
pemetrexed.*
Yes
No
inability or unwillingness to take folic acid, vitamin
b12 supplementation, or dexamethasone*
Yes
No
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Eligibility Carcinoma, Non-Small Cell Lung NCT00190840
Eligibility Carcinoma, Non-Small-Cell Lung
NCT00061464
Pemetrexed Plus Gemcitabine for Patients With Locally
Advanced or Metastatic NSCLC Who Have Not Had
Previous Chemotherapy.; ODM derived from:
https://clinicaltrials.gov/show/NCT00061464
All rights reserved. Please visit https://medical-data-
models.org/forms/16520
Eligibility Carcinoma, Non-Small-Cell
Lung NCT00061464
Inclusion Criteria
diagnosis of non-small cell lung cancer that can
be treated with chemotherapy*
Yes
No
have received no prior chemotherapy for non-
small cell lung cancer*
Yes
No
have at least one measurable lesion*
Yes
No
have an adequate performance status*
Yes
No
sign an informed consent*
Yes
No
Exclusion Criteria
a female who is pregnant or breastfeeding*
Yes
No
treatment with an investigational drug within the
last 30 days, previously completed or withdrawn
from this study or any other study investigating
pemetrexed*
Yes
No
treatment with radiation therapy within the last 1-
2 weeks*
Yes
No
brain metastasis that is uncontrolled*
Yes
No
active infection or other serious condition*
Yes
No
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FIDUS EMR Ophtalmology
This FIDUS-Module gives you the opportunity to store
patient data that occurs with the treatment of a patient and
to review it at any time. This way, traditional paper based
documentation will be unneccessary.
The structure of this electronic patient record orientates in
FIDUS to the specifications of BDT (Treatment data
exchange of KBV) and especially to those specified in the
codicil for ophtalmologists (BDT-A).
Other sources: "Implementation of electronic health records
at a tertiary care eye hospital"  
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DOI 10.1007/s00347-014-3124-y
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All rights reserved. Please visit https://medical-data-
models.org/forms/16521
FIDUS EMR Ophtalmology
Demographische Daten
Patientenname
Titel
Patientennummer
Geburtsdatum
Alter
years
Geschlecht
männlich (1)
weiblich (2)
Beruf
Adresse des Patienten: Straße
Adresse des Patienten: Hausnummer
Adresse des Patienten: Postleitzahl
Adresse des Patienten: Wohnort
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Telefon
Email
Krankenversicherung
Hausarzt
Zuweisender Arzt
Pachy
Dauerdiagnose(n)
Cave/Antikoagulation
Info
Anamnese
Allgemeine Anamnese
Augenanamnese
Familienanamnese
Allergien
Medikation
Augen
Diagnose(n) rechtes Auge
Diagnose(n) linkes Auge
Operationen
Befunde
Gesichtsfeld
Spalt
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FIDUS EMR Ophtalmology
Rechtes Augenlid
Linkes Augenlid
Bindehaut rechtes Auge
Linke Bindehaut
Tränenweg rechtes Auge
Tränenweg linkes Auge
Hornhaut rechtes Auge
Hornhaut linkes Auge
Rechte Vorderkammer
Linke Vorderkammer
Rechte Iris
Linke Iris
Rechte Linse
Linke Linse
Rechter Ziliarkörper
Linker Ziliarkörper
Rechter Glaskörper
Linker Glaskörper
Orthoptik Motilität
Rechter Fundus allgemein
Linker Fundus allgemein
Rechter Glaskörper
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FIDUS EMR Ophtalmology
Linker Glaskörper
Rechte Papille
Linke Papille
Rechte Makula
Linke Makula
Gefäße rechtes Auge
Gefäße linkes Auge
Netzhaut rechtes Auge
Netzhaut linkes Auge
Rechter Kammerwinkel
Linker Kammerwinkel
Testverfahren
Messungen
Autorefraktion:Sph rechtes Auge
Autorefraktion:Sph linkes Auge
Autorefraktion:Cyl rechtes Auge
Autorefraktion:Cyl linkes Auge
Autorefraktion:Achse rechtes Auge
Autorefraktion:Achse linkes Auge
Autorefraktion:Visus rechtes Auge
Autorefraktion:Visus s.c rechtes Auge
Autorefraktion:Visus linkes Auge
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FIDUS EMR Ophtalmology
Autorefraktion:Visus s.c linkes Auge
Bemerkungen
Subjektive Refraktion:Sph rechtes Auge
Subjektive Refraktion:Sph linkes Auge
Subjektive Refraktion:Cyl rechtes Auge
Subjektive Refraktion:Cyl linkes Auge
Subjektive Refraktion:Achse rechtes Auge
Subjektive Refraktion:Achse linkes Auge
Subjektive Refraktion:Visus rechtes Auge
Subjektive Refraktion:Visus s.c rechtes Auge
Subjektive Refraktion:Visus linkes Auge
Subjektive Refraktion:Visus s.c linkes Auge
Subjektive Refraktion:Visus s.c Nähe rechtes
Auge
Subjektive Refraktion:Visus s.c Nähe linkes Auge
Subjektive Refraktion:Visus s.c Nähe Binokular
Subjektive Refraktion:Visus s.c Ferne Binokular
Subjektive Refraktion: Addition1
Subjektive Refraktion: Addition2
Bemerkungen rechtes Auge
Bemerkungen linkes Auge
Alte Brille:Sph rechtes Auge
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FIDUS EMR Ophtalmology
Alte Brille :Sph linkes Auge
Alte Brille :Cyl rechtes Auge
Alte Brille:Cyl linkes Auge
Alte Brille :Achse rechtes Auge
Alte Brille :Achse linkes Auge
Alte Brille :Visus rechtes Auge
Alte Brille :Visus linkes Auge
Alte Brille : Addition1
Alte Brille :Visus s.c Nähe rechtes Auge
Alte Brille :Visus s.c Nähe linkes Auge
Tagesanamnese
Medikamente
Pupillenmotorik
Wiedervorstellung
Augendruckmessung rechtes Auge
Uhrzeit Augendruckmessung rechtes Auge
Augendruckmessung linkes Auge
Uhrzeit Augendruckmessung linkes Auge
Bemerkungen
Hornhautdicke Pupillenzentrum rechtes Auge
μm
Hornhautdicke Pupillenzentrum linkes Auge
μm
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Hornhautdicke Pupillenzentrum x[mm] rechtes
Auge
Hornhautdicke Pupillenzentrum x[mm] linkes
Auge
Hornhautdicke Pupillenzentrum y[mm] rechtes
Auge
Hornhautdicke Pupillenzentrum y[mm] linkes
Auge
Pachy Apex rechtes Auge
μm
Pachy Apex linkes Auge
μm
Pachy Apex x[mm] rechtes Auge
Pachy Apex x[mm] linkes Auge
Pachy Apex y[mm] rechtes Auge
Pachy Apex y[mm] linkes Auge
Hornhautdicke Dünnste Stelle rechtes Auge
Hornhautdicke Dünnste Stelle linkes Auge
Hornhautdicke Dünnste Stelle x[mm] rechtes
Auge
Hornhautdicke Dünnste Stelle x[mm] linkes Auge
Hornhautdicke Dünnste Stelle y[mm] rechtes
Auge
Hornhautdicke Dünnste Stelle y[mm] linkes Auge
Cornea Volumen rechtes Auge
mm³
Cornea Volumen linkes Auge
mm³
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Cornea Durchmesser rechtes Auge
mm
Cornea Durchmesser linkes Auge
mm
Kammervolumen rechtes Auge
mm³
Kammervolumen linkes Auge
mm³
Rechter Kammerwinkel
°
Linker Kammerwinkel
°
Rechte Vorderkammer Tiefe
mm
Linke Vorderkammer Tiefe
mm
Rechte Pupille
mm
Linke Pupille
mm
Augendruck (Sum) rechtes Auge
mmHg
Augendruck (Sum) linkes Auge
mmHg
Linsendicke rechtes Auge
Linsendicke linkes Auge
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Eligibility Carcinoma, Non-Small-Cell Lung
NCT00071188
ZD6474 Alone or in Combination With Paclitaxel and
Carboplatin in Subjects With Previously Untreated Locally
Advanced or Metastatic Non-small Cell Lung Cancer
(NSCLC); ODM derived from:
https://clinicaltrials.gov/show/NCT00071188
All rights reserved. Please visit https://medical-data-
models.org/forms/16522
Eligibility Carcinoma, Non-Small-Cell
Lung NCT00071188
Inclusion Criteria
signed informed consent*
Yes
No
18 years or older*
Yes
No
histologically or cytologically confirmed locally
advanced or metastatic nsclc*
Yes
No
no prior chemotherapy/biological
therapy/radiation therapy*
Yes
No
one or more measurable lesions*
Yes
No
life expectancy more than 12 weeks*
Yes
No
Exclusion Criteria
brain metastases or spinal cord compression*
Yes
No
currently active skin disease*
Yes
No
history of significant hemoptysis*
Yes
No
abnormal blood chemistry*
Yes
No
cardiac abnormalities*
Yes
No
recent significant cardiac event*
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Yes
No
coexisting malignancies*
Yes
No
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Eligibility Carcinoma, Non-Small-Cell Lung NCT00071188
Eligibility Carcinoma, Non-Small-Cell Lung
NCT00087802
Gemcitabine/Oxaliplatin (GEMOX) vs Carboplatin/Paclitaxel
(CP) in Non-Small Cell Lung Cancer (NSCLC); ODM
derived from: https://clinicaltrials.gov/show/NCT00087802
All rights reserved. Please visit https://medical-data-
models.org/forms/16523
Eligibility Carcinoma, Non-Small-Cell
Lung NCT00087802
Inclusion Criteria
newly diagnosed, stage iiib or iv nsclc, chemo or
other systemic therapy naive*
Yes
No
one (1) unidimensionally measurable lesion*
Yes
No
ecog performance status of 0 or 1, no peripheral
neuropathy >grade 1*
Yes
No
patients with clinically stable brain metastases on
a stable dose of (or no longer requiring)
dexamethasone at registration will be eligible.
patients who have received cranial radiation for
brain metastases must be at least 4 weeks from
last radiation treatment.*
Yes
No
recovery in full from any previous surgical
procedure*
Yes
No
no history of an acute cardiac or cns event within
6 months of entry or current clinical evidence of
congestive heart failure or non-stable coronary
artery disease*
Yes
No
Exclusion Criteria
hypersensitivity to any of the 4 study drugs*
Yes
No
concurrent immunotherapy or participation in any
investigational drug study within 4 weeks*
Yes
No
serious uncontrolled intercurrent medical or
psychiatric illness and organ allograft*
Yes
No
1 / 2
history of other malignancy within the last 5 years
(except for squamous or basal cell carcinoma of
the skin, carcinoma in situ of the cervix, or
superficial transitional cell carcinoma of the
bladder)*
Yes
No
patient is a pregnant or lactating female*
Yes
No
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Eligibility Carcinoma, Non-Small-Cell Lung NCT00087802
Ultrasound Cardiovascular Health Study
(CHS)
Documentation part: Record 20 Ultrasound
The Cardiovascular Health Study (CHS) was initiated by
the National Heart, Lung and Blood Institute (NHLBI) in
1987 to determine the risk factors for development and
progression of cardiovascular disease (CVD) in older
adults, with an emphasis on subclinical measures. The
study recruited 5,888 adults aged 65 or older at entry in
four U.S. communities and conducted extensive annual
clinical exams between 1989-1999 along with semi-annual
phone calls, events adjudication, and subsequent data
analyses and publications. Additional data were collected
by studies ancillary to CHS. With the exception of annual
clinic visits, these activities are still ongoing.
Data obtained from: https://chs-nhlbi.org/
Permission granted by: Erika Enright.
All rights reserved. Please visit https://medical-data-
models.org/forms/16524
Ultrasound Cardiovascular Health
Study (CHS)
Ultrasound examination report
1. Results of carotid examination:
Done (1)
Incomplete (2)
Not done (3)
2. Reason test incomplete or not done:
Computer or ultrasound equipment
malfunction (Computer or ultrasound
equipment malfunction)
Examinee physically unable (Examinee
physically unable)
Examinee refused or uncooperative
(Examinee refused or uncooperative)
other (specify in "Comments for Reading
Center") (other (specify in "Comments for
Reading Center"))
Time/staff/room constraints
(Time/staff/room constraints)
3. Was Doppler flow velocity 2.5 m/s or greater?
no (0)
yes (1)
don't know (9)
Comments for Reading Center:
4. Results of aortic examination:
Done (1)
Incomplete (2)
Not done (3)
5. Reason test incomplete or not done:
Computer or ultrasound equipment
malfunction (Computer or ultrasound
equipment malfunction)
Examinee physically unable (Examinee
physically unable)
Examinee refused or uncooperative
(Examinee refused or uncooperative)
other (specify in "Comments for Reading
Center") (other (specify in "Comments for
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Reading Center"))
Time/staff/room constraints
(Time/staff/room constraints)
6. Results/alerts:
Unable to visualize (1)
No significant aneurysm detected (2)
Aneurysm identified (3)
Comments for Reading Center:
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Ultrasound Cardiovascular Health Study (CHS)
Eligibility Insulin-Dependent Diabetes
Mellitus NCT00024518
Interferon-Alpha for Diabetes Mellitus Type 1; ODM derived
from: https://clinicaltrials.gov/show/NCT00024518
All rights reserved. Please visit https://medical-data-
models.org/forms/16525
Eligibility Insulin-Dependent
Diabetes Mellitus NCT00024518
Criteria
t1dm of less than 6 weeks duration in patients
between 3 and 25 years of age.*
Yes
No
besides t1dm, no concurrent illness.*
Yes
No
Exclusion Criteria
treatment with immunosuppressive or
immunostimulatory medications such as
azathioprine, nicotinamide, superoxide
dismutase-desferroxamine, aminoguanidine, oral
insulin or other experimental therapies at the
present time or in the past.*
Yes
No
abnormal pre-treatment white blood cell count
(wbc) or thrombocytopenia.*
Yes
No
known active diseases, e.g. cardiac, renal,
hepatic diseases or immunodeficiency.*
Yes
No
history of cancer, neuropathy seizure disorders
(except typical history of febrile seizures in
childhood), peripheral vascular disease,
coagulation abnormalities, autoimmune disease
(except type 1 diabetes) or cerebrovascular
disease.*
Yes
No
ongoing use of medications known to influence
glucose tolerance (e.g. sulfonylureas, metformin,
diphenylhydantoin, thiazide or other potassium
depleting diuretics, beta-adrenergic blockers,
niacin) except insulin.*
Yes
No
any medical condition that, in the opinion of the
investigator, will interfere with the safe completion
of the trial.*
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Yes
No
inability to give informed consent or assent.*
Yes
No
participation in a clinical trial within the previous 6
weeks.*
Yes
No
lactating or pregnant female individual
(individuals will be advised not to volunteer for
the protocol if they plan to become pregnant
during the time of the study and they are
instructed to use an effective method of
contraception).*
Yes
No
age above 25 years, since there may be several
subtypes of t1dm.*
Yes
No
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Eligibility Ischemic Heart Disease
NCT00032630
Outcomes Following Myocardial Revascularization: On and
Off Cardiopulmonary Bypass; ODM derived from:
https://clinicaltrials.gov/show/NCT00032630
All rights reserved. Please visit https://medical-data-
models.org/forms/16526
Eligibility Ischemic Heart Disease
NCT00032630
Inclusion Criteria
elective or urgent cabg*
Yes
No
cabg only procedure to be performed*
Yes
No
Exclusion Criteria
patient's surgeon is not a participant that meets
study off-pup criteria*
Yes
No
valve or valve/cabg procedure*
Yes
No
emergent, hemodynamically unstable, or in
cardiogenic shock preoperatively*
Yes
No
moderate, moderate to severe, or severe valvular
disease*
Yes
No
enrolled in another therapeutic or interventional
study*
Yes
No
majority of diffusely diseased distal vessels*
Yes
No
clinical care team has reservations*
Yes
No
history of on-compliance*
Yes
No
patient preference for treatment arm*
Yes
No
inability to provide informed consent*
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Yes
No
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Eligibility Juvenile Idiopathic Arthritis
NCT00213187
PEAK Study (Physical Exercise and Activity in Kids); ODM
derived from: https://clinicaltrials.gov/show/NCT00213187
All rights reserved. Please visit https://medical-data-
models.org/forms/16527
Eligibility Juvenile Idiopathic Arthritis
NCT00213187
Inclusion Criteria
1. age 8 - 16 years.*
Yes
No
2. diagnosis of juvenile idiopathic arthritis - based
on the revised durban criteria.*
Yes
No
3. polyarticular or pauciarticular course.*
Yes
No
4. stable disease - on a stable dose of nsaid, and
if applicable methotrexate or other second line
agents - in the preceding month, and judged by
the attending rheumatologist to be clinically
stable and unlikely to need a change in
medication over the course of the trial.*
Yes
No
5. medications. there are no restrictions on
medication use for this study; however, every
effort is made to keep medication dosage stable
over the course of study.*
Yes
No
Exclusion Criteria
1. co-morbidity with cardiac, pulmonary or
metabolic disease.*
Yes
No
2. moderate or severe hip pain while walking (as
judged by the patient and scored on a 4 point
scale) or active systemic symptoms (fever, rash).*
Yes
No
3. children who engage in more than 3 hours of
structured extracurricular physical activity weekly
may not show additional gains from fitness
training and, therefore, are not studied. children
are not otherwise excluded from the study if
currently attending a physiotherapy pool program
with emphasis on joint range of motion and
stretching.*
Yes
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No
4. children who are unable to cooperate with
testing procedures.*
Yes
No
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Eligibility Juvenile Myelomonocytic
Leukemia NCT00025038
Combination Chemotherapy Followed By Donor Bone
Marrow or Umbilical Cord Blood Transplant in Treating
Children With Newly Diagnosed Juvenile Myelomonocytic
Leukemia; ODM derived from:
https://clinicaltrials.gov/show/NCT00025038
All rights reserved. Please visit https://medical-data-
models.org/forms/16528
Eligibility Juvenile Myelomonocytic
Leukemia NCT00025038
Inclusion Criteria
newly diagnosed, previously untreated juvenile
myelomonocytic leukemia*
Yes
No
presenting with all of the following:*
Yes
No
absence of t(9;22) or bcr/abl by pcr*
Yes
No
absolute monocyte count greater than
1,000/mm^3*
Yes
No
less than 20% bone marrow blasts*
Yes
No
presenting with at least 2 of the following:*
Yes
No
elevated f hemoglobin*
Yes
No
myeloid precursors in peripheral blood*
Yes
No
wbc greater than 10,000/mm^3*
Yes
No
sargramostim (gm-csf) hypersensitivity*
Yes
No
see disease characteristics*
Yes
No
bilirubin no greater than 2.0 mg/dl*
Yes
No
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alt no greater than 3 times normal*
Yes
No
creatinine no greater than 2 times normal*
Yes
No
no concurrent sargramostim (gm-csf)*
Yes
No
no concurrent proton pump inhibitors*
Yes
No
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Eligibility Leukemia NCT00002757
TITLE:Less Intensive Therapy for Children With Non-
Hodgkin's Lymphoma; ODM derived from:
https://clinicaltrials.gov/show/NCT00002757
All rights reserved. Please visit https://medical-data-
models.org/forms/16529
Eligibility Leukemia NCT00002757
Criteria
one of the following diagnoses:*
Yes
No
newly diagnosed b-cell non-hodgkin's lymphoma
in revised european-american lymphoma (real)
categories ii 9, 10, and 11, i.e.:*
Yes
No
diffuse large cell*
Yes
No
burkitt's*
Yes
No
high-grade b-cell, burkitt's-like*
Yes
No
l3 leukemia with greater than 5% blasts in bone
marrow*
Yes
No
no anaplastic large cell ki1-positive lymphomas*
Yes
No
immunophenotype and murphy stage required
prior to randomization*
Yes
No
patient characteristics:*
Yes
No
age:*
Yes
No
over 6 months to under 21 years*
Yes
No
maximum age 18 years in france and the united
kingdom*
Yes
No
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other:*
Yes
No
no congenital immunodeficiency*
Yes
No
no prior organ transplantation*
Yes
No
no prior malignancy*
Yes
No
not hiv positive*
Yes
No
available for at least 36 months of follow-up*
Yes
No
prior concurrent therapy:*
Yes
No
biologic therapy:*
Yes
No
not specified*
Yes
No
chemotherapy:*
Yes
No
no prior chemotherapy*
Yes
No
endocrine therapy:*
Yes
No
steroids initiated no more than 72 hours prior to
entry allowed*
Yes
No
bone marrow and cerebrospinal fluid examination
required prior to steroids*
Yes
No
radiotherapy:*
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Eligibility Leukemia NCT00002757
Yes
No
emergency radiotherapy initiated no more than
72 hours prior to entry allowed*
Yes
No
surgery:*
Yes
No
not specified*
Yes
No
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Eligibility Carcinoma, Non-Small-Cell Lung
NCT00088556
Carboplatin, Paclitaxel and TLK286 (Telcyta) as First-Line
Therapy in Advanced Non-Small Cell Lung Cancer; ODM
derived from: https://clinicaltrials.gov/show/NCT00088556
All rights reserved. Please visit https://medical-data-
models.org/forms/16530
Eligibility Carcinoma, Non-Small-Cell
Lung NCT00088556
Inclusion Criteria
18 years of age or older*
Yes
No
histologically confirmed non-small cell lung
cancer (nsclc)*
Yes
No
stage iv or iiib (disease that is not eligible for
combined modality chemotherapy and radiation)*
Yes
No
measurable disease by recist*
Yes
No
ecog status of 0-1*
Yes
No
adequate liver and renal function*
Yes
No
adequate bone marrow reserves*
Yes
No
Exclusion Criteria
prior chemotherapy, immunotherapy or biologic
therapy for metastatic nsclc*
Yes
No
up to one prior adjuvant or neoadjuvant
chemotherapy is allowed*
Yes
No
history of bone marrow transplantation or stem
cell support*
Yes
No
pregnant or lactating women*
Yes
No
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Demographics: CRF Wisconsin Madison
ODM Form derived from:
https://ictr.wisc.edu/CaseReptTempt. Template Name:
Demographics.
Case Report Form (CRF)/Source Document templates
were created for University of Wisconsin-Madison
researchers.
These templates are consistent with the FDA's CDASH
(Clinical Data Acquisition Standards Harmonization)
standards. The CDASH standards identify those elements
that should be captured on a Case Report Form (CRF).
The forms serve only as templates, and must be edited to
meet the study data collection needs as described in the
protocol.
All rights reserved. Please visit https://medical-data-
models.org/forms/16531
Demographics: CRF Wisconsin
Madison
Header
PI Name
Protocol or IRB Number
Protocol Short Title
Subject Initials
Subject ID
Date
Demographics
Subject UWHC Medical Record Number
First Name
Middle Name (or initial)
Last Name
Birthdate
Gender
Male (1)
Female (2)
Unknown or not Reported (3)
Ethnicity
Hispanic (1)
Non-Hispanic (2)
Unknown or not Reported (3)
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American Indian or Alaska Native
Yes
No
Asian
Yes
No
Black or African American
Yes
No
Native Hawaiian or Other Pacific Islander
Yes
No
White or Caucasian
Yes
No
Unknown or not Reported
Yes
No
Other Medical Record Number(s)
Medical Record Number
Hospital/Care Provider (e.g VA Hospital, Meriter
Hospital, EPIC)
Contact Information
Address
Unit number
City
State
Zip
Phone number
What kind of phone number is it?
Home (1)
Cell (2)
Work (3)
Other (4)
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Demographics: CRF Wisconsin Madison
Alternate Phone Number
What kind of Phone number is it?
Home (1)
Cell (2)
Work (3)
Other (4)
Email address
Preferred method of contact
Emergency contact
Name
Address
Unit number
City
State
Zip
Phone Number
What kind of phone number is it?
Home (1)
Cell (2)
Work (3)
Other (4)
Alternate Phone Number
What kind of phone number is it?
Home (1)
Cell (2)
Work (3)
Other (4)
Email address
Form completed By
Date
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Eligibility Carcinoma, Renal Cell
NCT00106613
A Research Study for Patients With Metastatic Renal Cell
Carcinoma; ODM derived from:
https://clinicaltrials.gov/show/NCT00106613
All rights reserved. Please visit https://medical-data-
models.org/forms/16532
Eligibility Carcinoma, Renal Cell
NCT00106613
Inclusion Criteria
patients must fulfill all of the following criteria to
be eligible for study participation:*
Yes
No
age ≥ 18 years;*
Yes
No
histologically confirmed renal cell carcinoma
(rcc);*
Yes
No
metastatic disease, with measurable lesions
according to the response evaluation criteria in
solid tumors (recist);*
Yes
No
failure of prior cytokine therapy;*
Yes
No
documented progressive disease;*
Yes
No
Exclusion Criteria
patients are ineligible for entry if any of the
following criteria are met:*
Yes
No
significant cardiac disease including congestive
heart failure, history of myocardial infarction
within one year, uncontrolled dysrhythmias, or
poorly controlled angina*
Yes
No
history of serious ventricular arrhythmia*
Yes
No
corrected qt interval (qtc) ≥ 500 msec*
Yes
No
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known infection with human immunodeficiency
virus (hiv), hepatitis b, or hepatitis c;*
Yes
No
previous extensive radiotherapy involving ≥ 30%
of bone marrow*
Yes
No
coexistent second malignancy or history of prior
malignancy within previous 5 years*
Yes
No
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Eligibility Carcinoma, Renal Cell NCT00106613
Informed Consent/HIPAA Authorization
Obtained: CRF Wisconsin Madison
ODM Form derived from:
https://ictr.wisc.edu/CaseReptTempt. Template Name:
Informed Consent/HIPAA Authorization Obtained. Case
Report Form (CRF)/Source Document templates were
created for University of Wisconsin-Madison researchers.
These templates are consistent with the FDA's CDASH
(Clinical Data Acquisition Standards Harmonization)
standards. The CDASH standards identify those elements
that should be captured on a Case Report Form (CRF).
The forms serve only as templates, and must be edited to
meet the study data collection needs as described in the
protocol.
All rights reserved. Please visit https://medical-data-
models.org/forms/16533
Informed Consent/HIPAA
Authorization Obtained: CRF
Wisconsin Madison
Header
PI Name
Protocol or IRB Number
Protocol Short Title
Subject Initials
Subject ID
Informed Consent/HIPAA Authorized
Obtained
Consent Refused
Yes
No
Date Signed
Time
Document(s) signed
Document(s) signed
Version Date
Approval Date
Expiration Date
undefined itemgroup
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Consent Form, and related study documents,
was thoroughly reviewed with the subject.
Yes
No
Subject had sufficient time to review the
documents and ask questions.
Yes
No
Informed consent/HIPAA Authorization obtained
prior to any study related procedures.
Yes
No
A copy of the signed documents have been given
to the subject.
Yes
No
Name of the person that obtained consent
Comments
Informed Consent Refused
Time
Not Applicable
Yes
No
Comments
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Madison
Eligibility Criteria: CRF Wisconsin Madison
ODM Form derived from:
https://ictr.wisc.edu/CaseReptTempt. Template Name:
Eligibility Criteria. Case Report Form (CRF)/Source
Document templates were created for University of
Wisconsin-Madison researchers. These templates are
consistent with the FDA's CDASH (Clinical Data Acquisition
Standards Harmonization) standards. The CDASH
standards identify those elements that should be captured
on a Case Report Form (CRF). The forms serve only as
templates, and must be edited to meet the study data
collection needs as described in the protocol.
All rights reserved. Please visit https://medical-data-
models.org/forms/16534
Eligibility Criteria: CRF Wisconsin
Madison
Header
PI Name
Protocol or IRB Number
Protocol Short Title
Subject Initials
Subject ID
Date
Eligibility Criteria - Inclusion Criteria
Inclusion Criteria
Does this criteria apply?
Yes
No
Eligibility Criteria - Exclusion Criteria
Exclusion Criteria
Does this criteria apply?
Yes
No
undefined itemgroup
Form Completed by
Date
Site Pl Signature
1 / 2
Date
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Eligibility Criteria: CRF Wisconsin Madison
Medical History (General): CRF Wisconsin
Madison
ODM Form derived from:
https://ictr.wisc.edu/CaseReptTempt. Template Name:
Medical History (General). Case Report Form
(CRF)/Source Document templates were created for
University of Wisconsin-Madison researchers. These
templates are consistent with the FDA's CDASH (Clinical
Data Acquisition Standards Harmonization) standards. The
CDASH standards identify those elements that should be
captured on a Case Report Form (CRF). The forms serve
only as templates, and must be edited to meet the study
data collection needs as described in the protocol.
All rights reserved. Please visit https://medical-data-
models.org/forms/16535
Medical History (General): CRF
Wisconsin Madison
Header
PI Name
Protocol or IRB Number
Protocol Short Title
Subject Initials
Subject ID
Date
Medical History (General)
Insert body system being inquired about
Diagnosed condition
Yes
No
Diagnosis/Condition/Surgery
Onset Date or Year
Current Problem
Yes
No
Other (specify)
Diagnosed condition
Yes
No
Diagnosis/Condition/Surgery
Onset Date Or Year
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Current Problem
Yes
No
Additional Notes
Medical History Not Obtained
Yes
No
Medical History Obtained By
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Eligibility Carcinoma, Squamous Cell
NCT00073450
Study of Lonafarnib in Patients With Recurrent Squamous
Cell Carcinoma of the Head and Neck (Study P02530);
ODM derived from:
https://clinicaltrials.gov/show/NCT00073450
All rights reserved. Please visit https://medical-data-
models.org/forms/16536
Eligibility Carcinoma, Squamous Cell
NCT00073450
Inclusion Criteria
histologically or cytologically proven squamous
cell carcinoma of the head & neck.*
Yes
No
age greater than or equal to 18.*
Yes
No
ecog performance status of 0 to 1*
Yes
No
measurable malignant disease.*
Yes
No
patients that have failed at least one platinum-
containing regimen and have received no more
than three prior regimens and do not have other
curative treatment options.*
Yes
No
patients must be at least 2 wks post surgery or
radiation therapy*
Yes
No
patients must be at least 4 weeks post
chemotherapy*
Yes
No
meets protocol requirements for specified
laboratory values.*
Yes
No
written informed consent and cooperation of
patient.*
Yes
No
appropriate use of effective contraception if of
childbearing potential.*
Yes
No
no investigational drugs of any type within 30
days prior to administration.*
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Yes
No
Exclusion Criteria
prior exposure to farnesyl transferase inhibitors*
Yes
No
medical conditions that would interfere with taking
oral medications.*
Yes
No
patients with significant qtc prolongation at
baseline (>500 msec.)*
Yes
No
pregnant or nursing women*
Yes
No
known hiv positivity or aids-related illness.*
Yes
No
concomitant chemotherapy, hormonal therapy,
radiotherapy or immunotherapy*
Yes
No
patients with any signs of involvement of the
dura, meninges, or brain.*
Yes
No
patients with squamous cell carcinoma of the
nasopharynx*
Yes
No
patients who currently have other cancers or
have been treated in the last 5 years for any other
malignancy.*
Yes
No
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Eligibility Carcinoma, Squamous Cell
NCT02254044
Dose Escalation of Bivatuzumab Mertansine in Patients
With Advanced Squamous Cell Carcinoma of the Head and
Neck or Esophagus; ODM derived from:
https://clinicaltrials.gov/show/NCT02254044
All rights reserved. Please visit https://medical-data-
models.org/forms/16537
Eligibility Carcinoma, Squamous Cell
NCT02254044
Inclusion Criteria
1. patients from 18 to 80 years of age (both
inclusive)*
Yes
No
2. patients with histologically confirmed
squamous cell carcinoma of  the head and neck
or esophagus*
Yes
No
3. patients with local and / or regional recurrent
disease or distant metastases who are refractory
to or not amenable to established treatments*
Yes
No
4. evaluable tumour deposits*
Yes
No
5. life expectancy of at least 3 months*
Yes
No
6. eastern cooperative oncology group (ecog)
performance score ≤ 2*
Yes
No
7. patients must have given written informed
consent (which must be consistent with
international conference on harmonisation-good
clinical practice (ich-gcp) and local legislation)*
Yes
No
Exclusion Criteria
1. hypersensitivity to humanised or murine
antibodies, immunoconjugates or the excipients
of the trial drugs*
Yes
No
2. known secondary malignancy requiring
therapy*
Yes
No
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3. active infectious disease*
Yes
No
4. brain metastases requiring therapy*
Yes
No
5. neuropathy grade 2 or above*
Yes
No
6. absolute neutrophil count less than
1,500/mm3*
Yes
No
7. platelet count less than 100,000/mm3*
Yes
No
8. bilirubin greater than 1.5 mg/dl (> 26 μmol/l,
système internationale (si) unit equivalent)*
Yes
No
9. aspartate amino transferase (ast) and/or
alanine amino transferase (alt) greater than 3
times the upper limit of normal*
Yes
No
10. serum creatinine greater than 1.5 mg/dl (>
132 μmol/l, si unit equivalent)*
Yes
No
11. concomitant non-oncological diseases which
are considered relevant for the evaluation of the
safety of the trial drug*
Yes
No
12. chemo-, radio- or immunotherapy within the
past four weeks prior to treatment with the trial
drug or during the trial (except for present trial
drug)*
Yes
No
13. men and women who are sexually active and
unwilling to use a medically acceptable method of
contraception*
Yes
No
14. pregnancy or lactation*
Yes
No
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15. treatment with other investigational drugs or
participation in another clinical trial within the
past four weeks before start of therapy or
concomitantly with this trial (except for present
trial drug)*
Yes
No
16. patients unable to comply with the protocol*
Yes
No
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Concomitant Medication Log: CRF
Wisconsin Madison
ODM Form derived from:
https://ictr.wisc.edu/CaseReptTempt. Template Name:
Concomitant Medication Log. Case Report Form
(CRF)/Source Document templates were created for
University of Wisconsin-Madison researchers. These
templates are consistent with the FDA's CDASH (Clinical
Data Acquisition Standards Harmonization) standards. The
CDASH standards identify those elements that should be
captured on a Case Report Form (CRF). The forms serve
only as templates, and must be edited to meet the study
data collection needs as described in the protocol.
All rights reserved. Please visit https://medical-data-
models.org/forms/16538
Concomitant Medication Log: CRF
Wisconsin Madison
Header
PI Name
Protocol or IRB Number
Protocol Short Title
Subject Initials
Subject ID
Number of Page
Total amount of pages
Concomitant Medication Log
#
Medication/ Non-drug Therapy
Indication
Dose (per admin)
Dose Units
Schedule/Frequency
Dose Form
Route of Administration
Start Date
1 / 2
End Date
Baseline Med
Yes
No
Continuing at end of study
Yes
No
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Eligibility Cardiovascular Disease
NCT00054847
Radial Artery Versus Saphenous Vein Grafts in Coronary
Artery Bypass Surgery; ODM derived from:
https://clinicaltrials.gov/show/NCT00054847
All rights reserved. Please visit https://medical-data-
models.org/forms/16539
Eligibility Cardiovascular Disease
NCT00054847
Inclusion Criteria
patients needing coronary artery bypass grafts.*
Yes
No
Exclusion Criteria
patients who require only a single vessel bypass
and in whom the internal mammary artery will be
used for that graft*
Yes
No
patients with previous stripping and ligation of
saphenous veins and in whom no venous conduit
is available for bypass*
Yes
No
patients with raynaud's symptoms*
Yes
No
patients who have a creatinine above 2.0 mg/dl or
require hemodialysis*
Yes
No
patients with a positive allen test*
Yes
No
patients with cardiogenic shock*
Yes
No
patients who are unable to give consent*
Yes
No
patients allergic to contrast material*
Yes
No
patients undergoing repeat cabg or any form of
robotic surgery*
Yes
No
patients who do not have full use of both arms*
Yes
No
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patients who are pregnant*
Yes
No
patients with neurologic or musculoskeletal
disease affecting the arm*
Yes
No
patients who refuse to participate*
Yes
No
patient requires any concomitant valve operation
in the mitral, aortic, or pulmonary position.
isolated tricuspid annuloplasty is acceptable, but
tricuspid valve replacement excludes the patient
from consideration.*
Yes
No
patient requires concomitant dor or maze
procedure*
Yes
No
patient is in another research study*
Yes
No
no suitable radial target (there is no non-lad
vessel with a >70% stenosis)*
Yes
No
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Physical Examination: CRF Wisconsin
Madison
ODM Form derived from:
https://ictr.wisc.edu/CaseReptTempt. Template Name:
Physical Examination. Case Report Form (CRF)/Source
Document templates were created for University of
Wisconsin-Madison researchers. These templates are
consistent with the FDA's CDASH (Clinical Data Acquisition
Standards Harmonization) standards. The CDASH
standards identify those elements that should be captured
on a Case Report Form (CRF). The forms serve only as
templates, and must be edited to meet the study data
collection needs as described in the protocol.
All rights reserved. Please visit https://medical-data-
models.org/forms/16540
Physical Examination: CRF
Wisconsin Madison
Header
PI Name
Protocol or IRB Number
Protocol Short Title
Subject Initials
Subject ID
Exam Date
Physical Examination
Time
Physical Examination not performed
Yes
No
Visit Number
Visit # (1)
Visit # (2)
Visit # (3)
Visit # (4)
Visit # (5)
Visit # (6)
Body System
Body system to be examined
Finding
Normal (1)
Abnormal (2)
Not examined (3)
Comments (required if Abnormal)
1 / 2
Clinically Significant
Yes
No
Other
Other (specify in Comments)
Finding
Normal (1)
Abnormal (2)
Not examined (3)
Comments (required if Abnormal)
Clinically Significant
Yes
No
Additional notes
Physical Examination performed by
Principal Investigator Signature
Date
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Physical Examination: CRF Wisconsin Madison
Vital Sign Measurements (Standard): CRF
Wisconsin Madison
ODM Form derived from:
https://ictr.wisc.edu/CaseReptTempt. Template Name: Vital
Sign Measurements (Standard). Case Report Form
(CRF)/Source Document templates were created for
University of Wisconsin-Madison researchers. These
templates are consistent with the FDA's CDASH (Clinical
Data Acquisition Standards Harmonization) standards. The
CDASH standards identify those elements that should be
captured on a Case Report Form (CRF). The forms serve
only as templates, and must be edited to meet the study
data collection needs as described in the protocol.
All rights reserved. Please visit https://medical-data-
models.org/forms/16541
Vital Sign Measurements (Standard):
CRF Wisconsin Madison
Header
PI Name
Protocol or IRB Number
Protocol Short Title
Subject Initials
Subject ID
Exam Date
Vital Sign Measurements (Standard)
Vital Sign Measurement not performed
Yes
No
Visit Number
Visit # (1)
Visit # (2)
Visit # (3)
Visit # (4)
Visit # (5)
Visit # (6)
Height
inches
Height not measured
Yes
No
Weight
lbs
Weight not measured
Yes
No
1 / 2
Time
Temperature
Farenheit
Temperature not measured
Yes
No
Method
Oral (1)
Axillary (2)
Tympanic (3)
Respiratory Rate
breaths/min
Respiratory Rate not measured
Yes
No
Heart Rate
beats/min
Heart Rate not measured
Yes
No
Systolic Blood Pressure
mmHg
Blood Pressure not measured
Yes
No
Diastolic Blood Pressure
mmHg
Method
Manual (1)
Automated (2)
Location
Left Arm (1)
Right Arm (2)
Position
Sitting (1)
Supine (2)
Standing (3)
Additional Notes
Vital Sign Measurements obtained by
2 / 2
Vital Sign Measurements (Standard): CRF Wisconsin Madison
Screening Visit Form 4/4 Tolerability of QUTENZA™ When Applied After Pre-
treatment With Lidocaine or Tramadol in Subjects With Peripheral Neuropathic Pain
- A Randomized, Multi-center, Assessor-blinded Study NCT01416116
Study Sponsor: Astellas
Study Title
Tolerability of QUTENZA™ When Applied After Pre-
treatment With Lidocaine or Tramadol in Subjects With
Peripheral Neuropathic Pain - A Randomized, Multi-center,
Assessor-blinded Study
Medicine or Vaccine (generic name)
capsaicin
Sponsor Identification Number
QTZ-EC-0002
Trial Registry Identification Number(#'s)
NCT01416116
EudraCT Number: 2010-023258-34
Medical Condition
Neuropathic pain
Phase
Phase 4
http://clinicaltrials.gov/show/NCT01416116
Screening Visit:
Pregnancy Test
Identification of Painful Area
NPRS 'average pain' score
NPRS 'pain now' score
All rights reserved. Please visit https://medical-data-
models.org/forms/16543
Screening Visit Form 4/4 Tolerability
of QUTENZA™ When Applied After
Pre-treatment With Lidocaine or
Tramadol in Subjects With Peripheral
Neuropathic Pain - A Randomized,
Multi-center, Assessor-blinded Study
NCT01416116
Pregnancy Test
Is subject female and of childbearing potential?
No (0 )
Yes (1 )
Reason Childbearing potential - NO
Female (2 yrs post-menopausal or
surgically sterile) (1 )
Other (99 )
If 'Other', specify
Select 'Not Done' if serum/urine sample was not
taken.
Yes
No
Date of Sample Taken
Result serum/urine pregnancy test
Negative (0 )
Positive (1 )
Identification of Painful Area
Assessment Date
1 / 2
Head and Neck
Arms
Hands
Torso
Legs
Feet
Total Painful/Sensitive Area Size
cm²
NPRS 'average pain' score
Date of Assessment
NPRS 'average' pain score
0 (0 )
1 (1 )
10 (10 )
2 (2 )
3 (3 )
4 (4 )
5 (5 )
6 (6 )
7 (7 )
8 (8 )
9 (9 )
NPRS 'pain now' score
Date of Assessment
NPRS 'pain now' score
0 (0)
1 (1)
10 (10)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
7 (7)
8 (8)
9 (9)
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Screening Visit Form 4/4 Tolerability of QUTENZA™ When Applied After Pre-
treatment With Lidocaine or Tramadol in Subjects With Peripheral Neuropathic Pain
- A Randomized, Multi-center, Assessor-blinded Study NCT01416116
Screening Visit Form 1/4 Tolerability of QUTENZA™ When Applied After Pre-
treatment With Lidocaine or Tramadol in Subjects With Peripheral Neuropathic Pain
- A Randomized, Multi-center, Assessor-blinded Study NCT01416116
Study Sponsor: Astellas
Study Title
Tolerability of QUTENZA™ When Applied After Pre-
treatment With Lidocaine or Tramadol in Subjects With
Peripheral Neuropathic Pain - A Randomized, Multi-center,
Assessor-blinded Study
Medicine or Vaccine (generic name)
capsaicin
Sponsor Identification Number
QTZ-EC-0002
Trial Registry Identification Number(#'s)
NCT01416116
EudraCT Number: 2010-023258-34
Medical Condition
Neuropathic pain
Phase
Phase 4
http://clinicaltrials.gov/show/NCT01416116
Screening Visit, Form 1/4:
Date of Visit
Screening Status
Informed Consent 1
Demographics
Medical and Surgical History
All rights reserved. Please visit https://medical-data-
models.org/forms/16544
Screening Visit Form 1/4 Tolerability
of QUTENZA™ When Applied After
Pre-treatment With Lidocaine or
Tramadol in Subjects With Peripheral
Neuropathic Pain - A Randomized,
Multi-center, Assessor-blinded Study
NCT01416116
Date of Visit
Date of Visit
Screening Status
Is the subject a
screen failure
(signed an
informed
consent but
was not
randomized)?
No (0)
Yes (1)
Reason for
Not Meeting
Admission
Criteria
Not fulfill inclusion or exclusion criteria (1
)
Untoward Medical Symptoms (3 )
Withdrawal of consent (6 )
Subject lost to follow up (7 )
Other (99 )
1 / 3
If 'Other'
specify
Informed Consent 1
Date of Informed Consent
Demographics
Sex
Male (1)
Female (2)
Birth Date
Age
Years
Race
White (1 )
Black or African American (3 )
Asian (4 )
American Indian or Alaskan Native (5 )
Native Hawaiian or Other Pacific Islander
(6 )
Other (99 )
If 'Other', specify
Medical and Surgical History
Is there any
past or present
Medical
Condition?
If 'Yes',
please
provide
details below
No (0 )
Yes (1 )
MedicalCondition, specify
Onset Date
Is Medical
Condition
ongoing?
If 'No', please
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Screening Visit Form 1/4 Tolerability of QUTENZA™ When Applied After Pre-
treatment With Lidocaine or Tramadol in Subjects With Peripheral Neuropathic Pain
- A Randomized, Multi-center, Assessor-blinded Study NCT01416116
provide
'Recovered
Date'.
No (0 )
Yes (1 )
Recovered
Date
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Screening Visit Form 1/4 Tolerability of QUTENZA™ When Applied After Pre-
treatment With Lidocaine or Tramadol in Subjects With Peripheral Neuropathic Pain
- A Randomized, Multi-center, Assessor-blinded Study NCT01416116
Screening Visit Form 3/4: Laboratory tests Tolerability of QUTENZA™ When Applied
After Pre-treatment With Lidocaine or Tramadol in Subjects With Peripheral Neuropathic
Pain - A Randomized, Multi-center, Assessor-blinded Study NCT01416116
Study Sponsor: Astellas
Study Title
Tolerability of QUTENZA™ When Applied After Pre-
treatment With Lidocaine or Tramadol in Subjects With
Peripheral Neuropathic Pain - A Randomized, Multi-center,
Assessor-blinded Study
Medicine or Vaccine (generic name)
capsaicin
Sponsor Identification Number
QTZ-EC-0002
Trial Registry Identification Number(#'s)
NCT01416116
EudraCT Number: 2010-023258-34
Medical Condition
Neuropathic pain
Phase
Phase 4
http://clinicaltrials.gov/show/NCT01416116
Screening Visit Form 3/4:
Laboratory Tests: Hematology
Laboratory Tests: Biochemistry
All rights reserved. Please visit https://medical-data-
models.org/forms/16545
Screening Visit Form 3/4: Laboratory
tests Tolerability of QUTENZA™
When Applied After Pre-treatment
With Lidocaine or Tramadol in
Subjects With Peripheral
Neuropathic Pain - A Randomized,
Multi-center, Assessor-blinded Study
NCT01416116
Laboratory Tests: Hematology
Were samples taken?
No (0 )
Yes (1 )
Date of Sample Taken
LAB Interpretation
Normal (0 )
Abnormal (1 )
Laboratory Tests: Hematology,
specification
Lab Test
Basophils (BASO )
Eosinophils (EOS )
Hematocrit (HCT )
Hemoglobin (HGB )
Lymphocytes (LYMPH )
Monocytes (MONO )
Neutrophils (NEUT )
Platelets (PLT )
Red Blood Cell Count (RBC )
White Blood Cell Count (WBC )
LAB Interpretation
1 / 2
Abnormal - not clinically significant (1 )
Abnormal - clinically significant (2 )
Laboratory Tests: Biochemistry
Were samples taken?
No (0 )
Yes (1 )
Date of Sample Taken
LAB Interpretation
Normal (0 )
Abnormal (1 )
Tests: Biochemistry, specification
Lab Test
Alkaline Phosphatase (ALKP )
ALT (ALT )
AST (AST )
Blood urea nitrogen (BUN )
Chloride (CL )
Creatinine (CREAT )
Potassium (K )
Sodium (NA )
LAB Interpretation
Abnormal - not clinically significant (1 )
Abnormal - clinically significant (2 )
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Screening Visit Form 3/4: Laboratory tests Tolerability of QUTENZA™ When Applied
After Pre-treatment With Lidocaine or Tramadol in Subjects With Peripheral Neuropathic
Pain - A Randomized, Multi-center, Assessor-blinded Study NCT01416116
Screening Visit Form 2/4 Tolerability of QUTENZA™ When Applied After Pre-
treatment With Lidocaine or Tramadol in Subjects With Peripheral Neuropathic Pain
- A Randomized, Multi-center, Assessor-blinded Study NCT01416116
Study Sponsor: Astellas
Study Title
Tolerability of QUTENZA™ When Applied After Pre-
treatment With Lidocaine or Tramadol in Subjects With
Peripheral Neuropathic Pain - A Randomized, Multi-center,
Assessor-blinded Study
Medicine or Vaccine (generic name)
capsaicin
Sponsor Identification Number
QTZ-EC-0002
Trial Registry Identification Number(#'s)
NCT01416116
EudraCT Number: 2010-023258-34
Medical Condition
Neuropathic pain
Phase
Phase 4
http://clinicaltrials.gov/show/NCT01416116
Screening Visit Form 2/4:
Primary Diagnosis
Physical Examination
Vital Signs
Height and Weight
ECG: 12 Lead ECG
All rights reserved. Please visit https://medical-data-
models.org/forms/16546
Screening Visit Form 2/4 Tolerability
of QUTENZA™ When Applied After
Pre-treatment With Lidocaine or
Tramadol in Subjects With Peripheral
Neuropathic Pain - A Randomized,
Multi-center, Assessor-blinded Study
NCT01416116
Primary Diagnosis: Old diagnosis fields
Diagnosis
Postherpetic Neuralgia (1 )
Post Traumatic Peripheral Neuropathic
Pain Syndrome (2 )
Category
Post-surgical (1 )
Peripheral Nerve Injury (2 )
Other (99 )
Primary Diagnosis: New diagnosis fields
Diagnosis
Diagnosis
Date
Category
Post-traumatic (1 )
Post-surgical (2 )
Other (99)
If 'Other',
specify
1 / 4
Physical Examination
Was the Physical Examination performed?
No (0 )
Yes (1 )
Assessment Date
Vital Signs
Assessment Date
Position
Supine (1 )
Sitting (2 )
Standing (3 )
Systolic Blood Pressure
mmHg
Diastolic Blood Pressure
mmHg
Pulse Rate
bpm
Height and Weight
Assessment
Date
Height
cm
Weight
kg
ECG: 12 Lead ECG
Date ECG Performed
ECG Interpretation
Normal (0 )
Abnormal - not clinically significant (1 )
Abnormal - clinically significant (2 )
Abnormality Code
Sinus Tachycardia (101 )
Sinus Bradycardia (102 )
Atrial tachycardia - Without Block (103 )
Atrial Tachycardia - With Block (104 )
Atrial Flutter (105 )
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Screening Visit Form 2/4 Tolerability of QUTENZA™ When Applied After Pre-
treatment With Lidocaine or Tramadol in Subjects With Peripheral Neuropathic Pain
- A Randomized, Multi-center, Assessor-blinded Study NCT01416116
Atrial Fibrillation (106 )
PSVT(Paroxy smal Supraventricul ar
Tachycardia) (107 )
Variable Atrial Pacemaker (108 )
Junctional Rhythm Without Aberrancy
(109 )
Junctional Rhythm With Aberrancy (110 )
Ventricular Rhythm (111 )
Ventricular Tachycardia (112 )
Accelerated AV Conduction Pattern (113
)
Wolff - Parkinson - White Pattern (114 )
Supraventricular Ectopic Beats (115 )
Ventricular Ectopic Beats – Unifocal (116
)
Ventricular Ectopic Beats - Multifocal
(117 )
Pacemaker Rhythm (118 )
Ventricular Fibrillation (119 )
Sinus Arrest (120 )
SinusArrhythmia (121 )
Nodal Tachycardia (122 )
LGL Syndrome (123 )
Junctional escape complexes (124 )
Sino - Atrial Block (125 )
First Degree AV Block (301 )
Second Degree AV Block - Mobitz I (302
)
Second Degree AV Block - Mobitz II (303
)
Complete AV Block (304 )
Prolonged QT Interval (401 )
Prolonged QTc interval (402 )
Right Atrial Enlargement (601 )
Left Atrial Enlargement (602 )
P-Wave Abnormality (603 )
AV Dissociation (701 )
Left Anterior Hemiblock (702 )
Left Posterior Hemiblock (703 )
Right Bundle Branch Block (704 )
Incomplete Right Bundle Branch Block
(705 )
Left Bundle Branch Block (706 )
Incomplete Left Bundle Branch Block
(707 )
Nonspecific Intraventricula r Conduction
Delay (708 )
Bifascicular Block (709 )
Left Axis Deviation (710 )
Right Axis Deviation (711 )
Abnormal QRS Axis (712 )
Left Ventricular Hypertrophia (713 )
Left Ventricular Hypertrophia By Voltage
Only (714 )
Right Ventricular Hypertrophia (715 )
Old Myocardial Infarction: Antero septal
(716 )
Old Myocardial Infarction: Antero lateral
(717 )
Old Myocardial Infarction: Infero lateral
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Screening Visit Form 2/4 Tolerability of QUTENZA™ When Applied After Pre-
treatment With Lidocaine or Tramadol in Subjects With Peripheral Neuropathic Pain
- A Randomized, Multi-center, Assessor-blinded Study NCT01416116
(718 )
Old Myocardial Infarction: Infero
posterior (719 )
Old Myocardial Infarction: Postero lateral
(720 )
Old Myocardial Infarction: Lateral (721 )
Low Voltage QRS Complex (722 )
Poor R-Wave Progression (723 )
Late R-Wave Transition (724 )
Early Repolarization – Normal Variant
(725 )
Early R-Wave Transition (726 )
New Myocardial Infarction: Antero septal
(801 )
New Myocardial Infarction: Antero lateral
(802 )
New Myocardial Infarction: Infero lateral
(803 )
New Myocardial Infarction: Infero
posterior (804 )
New Myocardial Infarction: Postero
lateral (805 )
New Myocardial Infarction: Lateral (806 )
Myocardial Infarction – Nontransmural
-Acute or Evolving (807 )
ST Elevation Consistent with Ischaemia:
Anterior  (808 )
ST Elevation Consistent with Ischaemia:
Septal  (809 )
ST Elevation Consistent with Ischaemia:
Lateral (810 )
ST Elevation Consistent with Ischaemia:
Inferior (811 )
ST Elevation Consistent with Ischaemia:
Posterior (812 )
ST Elevation Consistent with
Ischaemia:High Lateral (813 )
ST Elevation Consistent With Pericarditis
(814 )
Non-Specific ST-T Change (815 )
ST-T changes - Consistent With Drug
Effects (816 )
ST Depression: Anterior (817 )
ST Depression: Septal (818 )
ST Depression: Lateral (819 )
ST Depression: Inferior (820 )
ST Depression: Posterior (821 )
ST Depression: High Lateral (822 )
ST Depression - Non-Specific (823 )
T-Wave Inversion Suggestive of Non-Q-
Wave MI (901 )
T-Wave Flattening or Inversion in Two or
More Leads (902 )
Non-Specific T-Wave changes (903 )
T-Wave Inversion Suggestive of
Ischaemia (904 )
T-Wave Peaking 998 = U-Wave
Abnormality (905 )
Other (999 )
4 / 4
Screening Visit Form 2/4 Tolerability of QUTENZA™ When Applied After Pre-
treatment With Lidocaine or Tramadol in Subjects With Peripheral Neuropathic Pain
- A Randomized, Multi-center, Assessor-blinded Study NCT01416116
Adalimumab/Ustekinumab Psoriasis MIPSO
EudraCT 2014-003022-40
MIPSO Vergleichende Untersuchung der bakteriellen
Mikrobiota in der Haut sowie dem Darm von Psoriasis-
Patienten vor und nach systemischer Behandlung mit
Adalimumab bzw. Ustekinumab oder Ciclosporin
(EudraCT 2014-003022-40)
Principal Investigator: Prof. Dr. Dr. h.c. Thomas A. Luger
All rights reserved. Please visit https://medical-data-
models.org/forms/16547
Adalimumab/Ustekinumab Psoriasis
MIPSO EudraCT 2014-003022-40
Adalimumab/Ustekinumab
Patient number
Medication of Adalimumab or Ustekinumab
Medication of Adalimumab (1)
Medication of Ustekinumab (2)
Page number
Comment Adalimumab / Ustekinumab
Medication Adalimumab/Ustekinumab
Injection number
Injection date
Injection dose
mg
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Electrocardiogram Results: CRF Wisconsin
Madison
ODM Form derived from:
https://ictr.wisc.edu/CaseReptTempt. Template Name:
Electrocardiogram Results. Case Report Form
(CRF)/Source Document templates were created for
University of Wisconsin-Madison researchers. These
templates are consistent with the FDA's CDASH (Clinical
Data Acquisition Standards Harmonization) standards. The
CDASH standards identify those elements that should be
captured on a Case Report Form (CRF). The forms serve
only as templates, and must be edited to meet the study
data collection needs as described in the protocol.
All rights reserved. Please visit https://medical-data-
models.org/forms/16548
Electrocardiogram Results: CRF
Wisconsin Madison
Header
PI Name
Protocol or IRB Number
Protocol Short Title
Subject Initials
Subject ID
Electrocardiogram Results
Date
Electrocardiogram not performed
Yes
No
Time
Visit Number
Visit # (1)
Visit # (2)
Visit # (3)
Visit # (4)
Visit # (5)
Visit # (6)
Visit # (7)
Visit # (8)
Visit # (9)
Position of Subject
Sitting (1)
Supine (2)
ECG Measurement/ Result: Heart Rate
bpm
ECG Measurement/ Result: Heart Rate
1 / 3
Normal (1)
Abnormal (2)
ECG Measurement/ Result: Heart Rate Clinically
significant
Yes
No
ECG Measurement/ Result: PR Interval
msec
ECG Measurement/ Result: PR Interval
Normal (1)
Abnormal (2)
ECG Measurement/ Result: PR Interval Clinically
significant
Yes
No
ECG Measurement/ Result: QRS Duration
msec
ECG Measurement/ Result: QRS Duration
Normal (1)
Abnormal (2)
ECG Measurement/ Result: QRS Duration
Clinically significant
Yes
No
ECG Measurement/ Result: QTc Interval
msec
ECG Measurement/ Result: QTc Interval
Normal (1)
Abnormal (2)
ECG Measurement/ Result: QTc Interval
Clinically significant
Yes
No
Cardiac Rhythm
Normal Sinus Rhythm (1)
Other: (specify) (10)
Sinus Tachycardia (11)
Supra Ventricular Tachycardia (12)
Third Degree AV Block (13)
Paced Rhythm  (14)
Other: (specify) (15)
Atrial Fibrillation (2)
First-degree Av Block (3)
Ventricular Tachycardia  (4)
Sinus Bradycardia (5)
Atrial Flutter (6)
2 / 3
Electrocardiogram Results: CRF Wisconsin Madison
Type I Second Degree Av Block (7)
Type II Second Degree AV Block (8)
Ventricular Fibrillation (9)
Cardiac Rhythm: If Other, please specify
Overall assessment
Normal (1)
Abnormal (2)
Overall assessment: Clinically significant
Yes
No
ECG done by
ECG read by
Comments
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Electrocardiogram Results: CRF Wisconsin Madison
Medical History Psoriasis MIPSO EudraCT
2014-003022-40
MIPSO Vergleichende Untersuchung der bakteriellen
Mikrobiota in der Haut sowie dem Darm von Psoriasis-
Patienten vor und nach systemischer Behandlung mit
Adalimumab bzw. Ustekinumab oder Ciclosporin
(EudraCT 2014-003022-40)
Principal Investigator: Prof. Dr. Dr. h.c. Thomas A. Luger
All rights reserved. Please visit https://medical-data-
models.org/forms/16549
Medical History Psoriasis MIPSO
EudraCT 2014-003022-40
Prior diseases
Patient number
Comment prior diseases
Prior diseases
Prior diseases: number
Prior diseases: description
Prior diseases: planned treatment
Prior diseases: current treatment
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Adverse Event Psoriasis MIPSO EudraCT
2014-003022-40
MIPSO Vergleichende Untersuchung der bakteriellen
Mikrobiota in der Haut sowie dem Darm von Psoriasis-
Patienten vor und nach systemischer Behandlung mit
Adalimumab bzw. Ustekinumab oder Ciclosporin
(EudraCT 2014-003022-40)
Principal Investigator: Prof. Dr. Dr. h.c. Thomas A. Luger
All rights reserved. Please visit https://medical-data-
models.org/forms/16550
Adverse Event Psoriasis MIPSO
EudraCT 2014-003022-40
Adverse Event
AE: Sheet number
AE: Signature date
Comment Adverse Event
Adverse Event Questionaire
AE: Number
AE: Term
AE: Start date
AE: Start time
AE: Serious event
Yes
No
AE: Severity
easy (1)
medium (2)
heavy (3)
AE: Related to study medication
no causal link (0)
not likely (1)
possible (2)
probably (3)
very likely (4)
AE: Action taken with study treatment
dose unchanged (0)
discontinued temporarily (1)
permanently discontinued (2)
dose reduced (3)
dose increases (4)
unknown (5)
not applicable (6)
AE that caused study discontinuation
Yes
1 / 2
No
AE: End date
AE: End time
AE: Ongoing
Yes
No
AE: Outcome
restored (0)
improved (1)
not yet improved (2)
recovered with permanent damage (3)
death (4)
unknown (5)
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Adverse Event Psoriasis MIPSO EudraCT 2014-003022-40
Demographics Psoriasis MIPSO EudraCT
2014-003022-40
MIPSO Vergleichende Untersuchung der bakteriellen
Mikrobiota in der Haut sowie dem Darm von Psoriasis-
Patienten vor und nach systemischer Behandlung mit
Adalimumab bzw. Ustekinumab oder Ciclosporin (EudraCT
2014-003022-40) Principal Investigator: Prof. Dr. Dr. h.c.
Thomas A. Luger
All rights reserved. Please visit https://medical-data-
models.org/forms/16551
Demographics Psoriasis MIPSO
EudraCT 2014-003022-40
Demographics
Patient number
Age
Gender
male (1)
female (2)
Diagnosis year Psoriasis
Exacerbation duration
months
Pregnancy test date
Pregnancy test not done
male (1)
other reason (2)
Pregnancy test other reason
Pregnancy test result
posotive (1)
negative (2)
Comment
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Eligibility Leukemia NCT00022126
Combination Chemotherapy With or Without Donor Bone
Marrow Transplantation in Treating Infants With Previously
Untreated Acute Lymphoblastic Leukemia; ODM derived
from: https://clinicaltrials.gov/show/NCT00022126
All rights reserved. Please visit https://medical-data-
models.org/forms/16552
Eligibility Leukemia NCT00022126
Criteria
diagnosis of previously untreated acute
lymphoblastic leukemia (all) or acute
undifferentiated leukemia*
Yes
No
cns or testicular disease allowed*
Yes
No
no l3 sig+ all or acute myelogenous leukemia*
Yes
No
at least 36 weeks gestation for congenital all*
Yes
No
patient characteristics:*
Yes
No
age:*
Yes
No
under 366 days at diagnosis*
Yes
No
performance status:*
Yes
No
not specified*
Yes
No
life expectancy:*
Yes
No
not specified*
Yes
No
hematopoietic:*
Yes
No
not specified*
1 / 3
Yes
No
hepatic:*
Yes
No
not specified*
Yes
No
renal:*
Yes
No
not specified*
Yes
No
prior concurrent therapy:*
Yes
No
biologic therapy:*
Yes
No
not specified*
Yes
No
chemotherapy:*
Yes
No
not specified*
Yes
No
endocrine therapy:*
Yes
No
steroid therapy within 48 hours of study allowed if
complete blood counts and lumbar puncture
results known*
Yes
No
no chronic steroid treatment for other disease*
Yes
No
radiotherapy:*
Yes
No
not specified*
Yes
No
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Eligibility Leukemia NCT00022126
surgery:*
Yes
No
not specified*
Yes
No
other:*
Yes
No
no other concurrent cytotoxic therapy*
Yes
No
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Eligibility Leukemia NCT00022126
Eligibility Cardiovascular Disease
NCT00066053
Periodontitis and Cardiovascular Events or "PAVE"; ODM
derived from: https://clinicaltrials.gov/show/NCT00066053
All rights reserved. Please visit https://medical-data-
models.org/forms/16554
Eligibility Cardiovascular Disease
NCT00066053
Criteria
aged 75 years or less and 50% or more blockage
of at least one artery in the heart,*
Yes
No
heart problems in the last 3 years (including
previous heart attack),*
Yes
No
previous heart bypass surgery, or previous heart
angioplasty with or without a stent, and at least 6
natural teeth present in the mouth and evidence
of mild to severe gum problems.*
Yes
No
exclusion:*
Yes
No
any of the following:*
Yes
No
a major illness requiring hospitalization,*
Yes
No
renal dialysis,*
Yes
No
serum creatinine > 3 mg/dl,*
Yes
No
organ transplant recipient requiring
immunosuppression medication,*
Yes
No
surgery needed in the next 3 years,*
Yes
No
chemotherapy in the past 3 years,*
Yes
No
head and/or neck radiation at any time in the
past,*
1 / 2
Yes
No
liver dysfunction,*
Yes
No
class iv congestive heart failure,*
Yes
No
drug or alcohol abuse,*
Yes
No
pacemaker or aicd/defibrillator.*
Yes
No
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Eligibility Cardiovascular Disease NCT00066053
Eligibility Carcinoma, Hepatocellular
NCT00243841
Dose Escalation Study for Primary Hepatocellular
Carcinoma; ODM derived from:
https://clinicaltrials.gov/show/NCT00243841
All rights reserved. Please visit https://medical-data-
models.org/forms/16555
Eligibility Carcinoma, Hepatocellular
NCT00243841
Inclusion Criteria
evaluation by the surgery and/or liver transplant
team has been performed and the patient is not
considered a candidate for either "standard"
therapy to target area (upper abdomen)*
Yes
No
adequate liver function defined as:*
Yes
No
total bilirubin < 3mg/dl, albumin > 2.5 g/dl*
Yes
No
normal pt/ptt unless on anticoagulants*
Yes
No
mild elevation of liver enzymes acceptable (must
be less than three times upper limit of normal)*
Yes
No
adequate renal function (creatinine < 1.8 mg/dl or
creatinine clearance ≥ 50 ml/min)*
Yes
No
adequate bone marrow reserve:*
Yes
No
anc count ≥ 1500 mm3*
Yes
No
platelets ≥ 50,000/mm3*
Yes
No
hemoglobin > 9 g/dl*
Yes
No
note:  lab values must be obtained within 2 weeks
prior to being registered for protocol therapy.*
Yes
No
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Exclusion Criteria
no history of systemic lupus erythematous,
rheumatoid arthritis, systemic sclerosis or
scleroderma*
Yes
No
no chemotherapy within 14 days before
radiotherapy (chemotherapy may cause transient
hepatitis with hepatomegaly)*
Yes
No
no subsequent chemotherapy planned within 2
weeks of radiotherapy*
Yes
No
no active liver infection*
Yes
No
no acute hepatitis. definition of active disease:*
Yes
No
hepatitis a: acute hepatitis determined by
presence of anti-hav-*
Yes
No
hepatitis b:*
Yes
No
1. hbsag (hb surface antigen): present in patients
with acute and chronic hepatitis*
Yes
No
2. hbv dna present in patients with active viral
replication in amounts greater than 100,000
copies*
Yes
No
3. hbeag is present in wild type hbv infection and
suggests active replication*
Yes
No
4. anti-hbs: antibody against hbsag appears after
hbv infections and confers immunity*
Yes
No
5. anti-hbc-igm: antibody against hbcag, fraction
igm, present in acute infection and often could be
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detected during periods of high viral replication in
chronic disease*
Yes
No
6. anti-hbc-igg: is present in chronic disease*
Yes
No
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Eligibility Determination Psoriasis MIPSO
EudraCT 2014-003022-40
MIPSO Vergleichende Untersuchung der bakteriellen
Mikrobiota in der Haut sowie dem Darm von Psoriasis-
Patienten vor und nach systemischer Behandlung mit
Adalimumab bzw. Ustekinumab oder Ciclosporin (EudraCT
2014-003022-40) Principal Investigator: Prof. Dr. Dr. h.c.
Thomas A. Luger
All rights reserved. Please visit https://medical-data-
models.org/forms/16556
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Patientenidentifikation
Patientennummer
Datum der Einwilligung
dd/mm/yyyy
Datum Screening
dd/mm/yyyy
Einschlusskriterien
Patienten mit mindestens mittelschwerer
Psoriasis vulgaris (PASI ≥ 10) vom Plaque-Typ.
Ja
Nein
≥18 Jahre (männlich sowie weiblich).
Ja
Nein
Indikation zur Behandlung mit Adalimumab,
Ustekinumab oder Ciclosporin entsprechend den
Leitlinien für Psoriasis vulgaris und den
jeweiligen Fachinformationen.
Ja
Nein
Patienten mit mittelschwerer bis schwerer
chronischer Plaque-Psoriasis, die auf eine
andere systemische Therapie, wie Ciclosporin,
Methotrexat oder PUVA, nicht angesprochen
haben oder bei denen eine Kontraindikation oder
Unverträglichkeit gegenüber einer solchen
Therapie vorliegt.
yes (1)
no (2)
NA (3)
Patienten mit mindestens mittelschwerer
Psoriasis vulgaris (PASI ≥ 10) vom Plaque-Typ,
die mit einer konventionellen systemischen
Therapie nicht ausreichend behandelbar sind.
yes (1)
no (2)
NA (3)
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Ausschlusskriterien
Therapie mit systemischen Immunsuppressiva
(wie Ciclosporin oder Methotrexat), Adalimumab,
Etanercept, Ustekinumab oder Infliximab in
einem Zeitraum von 5 Halbwertszeiten des
jeweiligen Medikamentes vor Entnahme der
initialen Abstrichpräparate/Biopsien.
Ja
Nein
Gleichzeitige Therapie mit systemischen
Immunsuppressiva.
Ja
Nein
Therapie mit Antibiotika in einem Zeitraum von
mindestens 4 Wochen vor Entnahme der initialen
Abstrichpräparate/Biopsien oder Therapie mit
Antibiotika während der Studie.
Ja
Nein
Psoriasis Patienten, die aktuell eine
Phototherapie erhalten oder in einem Zeitraum
von 2 Wochen vor Entnahme der initialen
Abstrichpräparate/Biopsien eine Phototherapie
erhalten haben.
Ja
Nein
Patienten, die die lokale, topische Therapie mit
Calcineurin-Inhibitoren oder Vitamin D3-Analoga
in den für die Abstrichpräparate/Biopsien
festgelegten Hautbereichen nicht unterbrechen
können. Die topische Behandlung mit
Calcineurin- Inhibitoren oder Vitamin D3-Analoga
kann in läsionalen Hautbereichen, die nicht für
die Abstrichpräparate/Biopsien vorgesehen sind,
fortgesetzt werden. In den für die
Abstrichpräparate/Biopsien festgelegten
Hautbereichen darf 7 Tage vor Entnahme der
Proben keine topische Therapie erfolgt sein.
Ja
Nein
Klinisch relevante aktive Infektionen (z.B. aktive
Tuberkulose oder andere schwere Infektionen wie
Sepsis und opportunistische Infektionen). Latente
Tuberkulose.
Anamnestisch bekannte latente oder aktive
Tuberkulose, die nicht sicher adäquat behandelt
wurde.
Ja
Nein
Chronische Träger des Hepatitis B-Virus
(HBsAG-positiv).
Ja
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Nein
HIV-positive Patienten.
Ja
Nein
Maligne Erkrankungen aktuell oder in der
Vorgeschichte.
Ja
Nein
Immundefiziente Patienten (Primärerkrankung
oder aufgrund einer Therapie).
Ja
Nein
Patienten, die aktuell eine Chemotherapie bzw.
Strahlentherapie erhalten oder innerhalb der
letzten 12 Monate vor Entnahme der initialen
Abstrichpräparate/Biopsien eine
Chemotherapie/Strahlentherapie erhalten haben.
Ja
Nein
Patienten mit unkontrollierten chronischen
Erkrankungen, die eine kontinuierliche Therapie
erfordern (wie z.B. Diabetes, Hepatitis,
Organtransplantationen) und aus Sicht des
Prüfarztes nicht stabil sind.
Ja
Nein
Patienten mit anderen chronischen
Hauterkrankungen, wie Atopische Dermatitis
oder Lupus erythematodes, die die kutane
Mikrobiota beeinflussen könnten.
Ja
Nein
Patienten mit psychiatrischer Komorbidität, die
eine mangelnde bzw. fehlende
Einwilligungsfähigkeit bedingen.
Ja
Nein
Teilnahme an einer anderen interventionellen
Prüfung vor Studieneinschluss in einem Zeitraum
von 4 Wochen bzw. 5 Halbwertszeiten des
früheren Prüfpräparates, je nachdem welcher
Zeitraum länger ist.
Ja
Nein
Schwangerschaft oder Stillzeit.
Bei gebärfähigen Frauen oder Männern mit
gebärfähigen Partnerinnen fehlende Bereitschaft,
zuverlässige Verhütungsmethoden (Pearl-Index <
1) anzuwenden. Mit Stelara® behandelte
Patienten/innen müssen diese
Verhütungsmethoden bis mind. 15 Wochen nach
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Ende der Behandlung, mit Humira® behandelte
Patienten/innen bis mind. 5 Monate nach Ende
der Behandlung fortsetzen.
Ja
Nein
Patienten, die in der Anamnese in einem
Zeitraum von 6 Monaten vor Entnahme der
ersten Abstrichpräparate/ Biopsien MRSA-positiv
waren.
Ja
Nein
Patienten mit Psoriasis vulgaris ausschließlich im
Kopfbereich.
Ja
Nein
Zusätzliche Ausschlusskriterien
Adalimumab
Überempfindlichkeit gegen den Wirkstoff oder
einen der sonstigen Bestandteile von Humira®.
yes (1)
no (2)
NA (3)
Mäßige bis schwere Herzinsuffizienz (NYHA
Klasse III/IV).
yes (1)
no (2)
NA (3)
Vorbestehende oder beginnende
demyelinisierende Erkrankungen des ZNS oder
des peripheren Nervensystems.
yes (1)
no (2)
NA (3)
Gleichzeitige Therapie mit Anakinra oder
Abatacept.
yes (1)
no (2)
NA (3)
Gleichzeitige Impfung mit Lebendimpfstoffen.
Dies gilt für einen Zeitraum bis 5 Monate nach
Ende der Therapie.
yes (1)
no (2)
NA (3)
Zusätzliche Ausschlusskriterien
Ustekinumab
Überempfindlichkeit gegen den Wirkstoff oder
einen der sonstigen Bestandteile von Stelara®,
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Allergie gegen Latex.
yes (1)
no (2)
NA (3)
Gleichzeitige Impfung mit Lebendviren oder
lebenden Bakterien. Dies gilt für einen Zeitraum
von 2 Wochen vor Beginn der Therapie mit
Stelara® bis mindestens 15 Wochen nach Ende
der Therapie.
yes (1)
no (2)
NA (3)
Zusätzliche Ausschlusskriterien
Ciclosporin
Bekannte Überempfindlichkeit gegen Ciclosporin
und/oder gegen einen der sonstigen Bestandteile
des Ciclosporin-Präparates.
yes (1)
no (2)
NA (3)
Unkontrollierte arterielle Hypertonie.
yes (1)
no (2)
NA (3)
Unkontrollierte Infektionskrankheiten.
yes (1)
no (2)
NA (3)
Nicht abgeheilte Infektionen mit Varizellen,
einschl. Herpes zoster-Infekte, Herpes simplex-
Infektionen und anderer virale Infekte (z.B.
Mollusken, Condylomata, multiple Warzen)
yes (1)
no (2)
NA (3)
Relevante Nierenfunktionsstörung
yes (1)
no (2)
NA (3)
Schwerwiegende Lebererkrankungen, GOT > 2 x
ULN, GPT > 2 x ULN , yGT > 2 x ULN , Bilirubin
> 2 x ULN
yes (1)
no (2)
NA (3)
Hyperurikämie
yes (1)
no (2)
NA (3)
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Hyperkaliämie
yes (1)
no (2)
NA (3)
Zustand nach PUVA-Vortherapie mit kumulativer
Dosis > 1000 J/cm²
yes (1)
no (2)
NA (3)
Zustand nach langjähriger Methotrexat-Therapie
yes (1)
no (2)
NA (3)
Therapie mit Etretinat innerhalb von 4 Wochen
vor Beginn der Therapie mit Ciclosporin
yes (1)
no (2)
NA (3)
Gleichzeitige Therapie mit Retinoiden
yes (1)
no (2)
NA (3)
Gleichzeitige Therapie mit Steinkohleteer
yes (1)
no (2)
NA (3)
Gleichzeitige Therapie mit Rosuvastatin
yes (1)
no (2)
NA (3)
Gleichzeitge Therapie mit Tacrolimus
yes (1)
no (2)
NA (3)
Gleichzeitige Einnahme von Johanniskraut
(Hypericum perforatum)
yes (1)
no (2)
NA (3)
Gleichzeitige Therapie mit Arzneimitteln, die
Substrate des Multidrug-Efflux-Transporter P-
Glykoproteins oder organischer
anionentransportierender Polypeptide (OATP)
sind und für die erhöhte Plasmakonzentrationen
mit schweren und/oder lebensbedrohlichen
Ereignissen verbunden sind, wie z.B. Bosentan,
Dabigatran-Etexilat und Aliskiren
yes (1)
no (2)
NA (3)
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Gleichzeitige Impfung mit Lebendimpfstoffen
yes (1)
no (2)
NA (3)
Alkoholkrankheit, Kontraindikation gegen die
Einnahme von Alkohol (z.B. bei Epilepsie)
yes (1)
no (2)
NA (3)
Erythrodermische oder pustulöse Psoriasis
yes (1)
no (2)
NA (3)
Psoriasis-Formen, die möglicherweise durch
Arzneimittel hervorgerufen oder verschlimmert
werden
yes (1)
no (2)
NA (3)
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Eligibility Cardiovascular Disease
NCT00079586
Comparing Angiomax to Heparin With Protamine in
Patients Undergoing Cardiopulmonary Bypass (CPB); ODM
derived from: https://clinicaltrials.gov/show/NCT00079586
All rights reserved. Please visit https://medical-data-
models.org/forms/16557
Eligibility Cardiovascular Disease
NCT00079586
Inclusion Criteria
provide written informed consent before initiation
of any study related procedures.*
Yes
No
be at least 18 years of age.*
Yes
No
be scheduled for cabg, cabg and single valve
surgery, or isolated single valve surgery on cpb.
patients undergoing repeat (redo) cabg are also
considered eligible for this study.*
Yes
No
Exclusion Criteria
confirmed pregnancy at time of randomization via
ivrs (if woman of child-bearing potential) (urine or
serum pregnancy test)*
Yes
No
cerebrovascular accident within 6 months, or any
cerebrovascular accident with a residual
neurological deficit.*
Yes
No
intracranial neoplasm, arteriovenous
malformation or aneurysm.*
Yes
No
dependency on renal dialysis or creatinine
clearance <30 ml/min.*
Yes
No
ongoing treatment with warfarin (or other oral
anticoagulant) at the time of randomization.*
Yes
No
patients previously treated with warfarin may be
enrolled if warfarin therapy can be safely
discontinued and baseline inr is < 1.3 times
control in the absence of heparin therapy.*
Yes
No
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known allergy to angiomax or hirudin-derived
drugs, or known sensitivity to any component of
the product.*
Yes
No
patients receiving clopidogrel (plavix®) within the
previous 5 days of randomization*
Yes
No
patients receiving a glycoprotein iib/iiia inhibitor
within the previous 48 hours if abciximab
(reopro®) or 24 hours if eptifibatide (integrilin®)
or tirofiban (aggrastat®) of randomization.*
Yes
No
patients receiving lepirudin (refludan®) or
argatroban within the previous 24 hours prior to
randomization.*
Yes
No
patients receiving lmwh or thrombolytics within
the previous 12 hours or unfractionated heparin
within 30 minutes of randomization.*
Yes
No
participation in other clinical research studies
involving the evaluation of other investigational
drugs or devices within 30 days of
randomization.*
Yes
No
refusal to undergo blood transfusion should it
become necessary.*
Yes
No
any other disease or condition, which, in the
judgment of the investigator, would place a
patient at undue risk by being enrolled in the trial,
or cause inability to comply with the trial.*
Yes
No
planned surgical procedure in which proximal
anastomoses will precede distal anastomoses of
the bypass grafts.*
Yes
No
planned (>1) double (or greater) valve repair-
replacement (e.g.: avr-mvr) surgery.*
Yes
No
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Surveillance of healthcare associated infection: Staphylococcus
aureus bacteraemia DSS Metadata Online Registry (METeOR)
Health sector data set specifications from METeOR,
Australia's repository for national metadata standards,
developed by the Australian Institute of Health and Welfare
(http://meteor.aihw.gov.au/content/index.phtml/itemId/3451
65)
Surveillance of healthcare associated infection:
Staphylococcus aureus bacteraemia DSS
The purpose of this data set specification (DSS) is to
support a comprehensive surveillance program of
healthcare associated infections (HAI). HAIs are those
infections that are not present or incubating at the time of
admission to a healthcare program or facility, develop within
a healthcare organisation or are produced by micro-
organisms acquired during admission.
This DSS is intended to support Staphylococcus aureus
bacteraemia (SAB) surveillance in Australian hospitals. It is
designed for the purposes of HAI surveillance, not
diagnosis. The value of surveillance as part of a hospital
infection control program is supported by high-grade
international and national evidence.
This DSS supports development of local forms and
systems for surveillance of HAIs and associated data
collection. This DSS applies to patient episodes of SAB in
Australian hospitals.
Case Definition – Healthcare associated Staphylococcus
aureus bacteraemia (SAB)
A patient-episode of Staphylococcus aureus bacteraemia
(SAB) is a positive blood culture for Staphylococcus aureus.
For surveillance purposes, only the first isolate per patient
is counted, unless at least 14 days has passed without a
positive culture, after which an additional episode is
recorded. 
A SAB will be considered to be a healthcare-associated
event if: 
EITHER 
•	CRITERION A. The patient’s first SAB positive blood
culture was collected more than 48 hours after hospital
admission or less than 48 hours after discharge. 
OR 
•	CRITERION B. The patient’s first positive SAB blood
culture was collected less than or equal to 48 hours after
hospital admission and one or more of the following key
clinical criteria was met for the patient-episode of SAB: 
1.	SAB is a complication of the presence of an indwelling
medical device (e.g. intravascular line, haemodialysis
vascular access, CSF shunt, urinary catheter) 
2.	SAB occurs within 30 days of a surgical procedure where
the SAB is related to the surgical site 
3.	SAB was diagnosed within 48 hours of a related invasive
instrumentation or incision 
4.	SAB is associated with neutropenia (Neutrophils: less
than 1 x 109/L) contributed to by cytotoxic therapy 
In order for jurisdictions and private hospital ownership
groups to accurately report and monitor Healthcare
Associated Infections, the data elements listed should be
collected at hospital level for each patient-episode of
Staphylococcus aureus bacteraemia. HAI patient episode
data elements for SAB, by short name 
Data elements to be collected for each patient episode	Data
elements used for calculation of SAB rates
Person identifier	Patient days
Family name	Patient episodes of healthcare associated
SAB
Given name(s)	 
Indigenous status	 
Date of birth	 
Sex	 
Address line (person)	 
Suburb/town/locality name (person)	 
Australian state/territory identifier	 
Australian postcode (address)	 
Admission date	 
Separation date	 
Ward/clinical area	 
Specimen collection date	 
Specimen collection time	 
Laboratory number	 
Specimen identifier	 
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Laboratory result identifier	 
Healthcare associated SAB clinical criteria	 
Staphylococcus aureus bacteraemia status	 
SAB methicillin susceptibility	 
Antibiotic susceptibility (MRSA isolate)	 
Antibiotic susceptibility indicator (MRSA isolate)	 
Establishment number	 
© Australian Institute of Health and Welfare 2015
Metadata and Classifications Unit 
Australian Institute of Health and Welfare
GPO Box 570
Canberra ACT 2601
All rights reserved. Please visit https://medical-data-
models.org/forms/16558
Surveillance of healthcare
associated infection: Staphylococcus
aureus bacteraemia DSS Metadata
Online Registry (METeOR)
Person 1
Person identifier
Person (name)
Family name
Given name(s)
Person 2
Indigenous status
Aboriginal but not Torres Strait Islander
origin (1)
Torres Strait Islander but not Aboriginal
origin (2)
Both Aboriginal and Torres Strait Islander
origin (3)
Neither Aboriginal nor Torres Strait
Islander origin (4)
Not stated/inadequately described (9)
Date of birth
Sex
Male (1)
Female (2)
Intersex or indeterminate (3)
Not stated/inadequately described (9)
Person (address)
Address line (person)
Address 1
2 / 5
Surveillance of healthcare associated infection: Staphylococcus aureus
bacteraemia DSS Metadata Online Registry (METeOR)
Suburb/town/locality name within address
Person 3
Australian state/territory identifier (person)
New South Wales (1)
Victoria (2)
Queensland (3)
South Australia (4)
Western Australia (5)
Tasmania (6)
Northern Territory (7)
Australian Capital Territory (8)
Other territories (Cocos (Keeling)
Islands, Christmas Island and Jervis Bay
Territory) (9)
Address 2
Australian postcode (address)
Episode of admitted patient care
Admission date
Separation date
Establishment 1
Ward/clinical area
Person 4
Specimen collection date
Specimen collection time
Laboratory
Laboratory number
Specimen identifier
Laboratory result identifier
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Patient episode of Staphylococcus aureus
bacteraemia
Healthcare associated Staphylococcus aureus
bacteraemia clinical criteria
The patient episode of SAB is a
complication of the presence of an
indwelling medical device (e.g.
intravascular line, haemodialysis
vascular access, CSF shunt, urinary
catheter) (1)
The patient episode of SAB occurs within
30 days of a surgical procedure where
the SAB is related to the surgical site (2)
The patient episode of SAB was
diagnosed within 48 hours of a related
invasive instrumentation or incision (3)
The patient episode of SAB is associated
with neutropenia (Neutrophils: less than
1 x 10^9/L) contributed to by cytotoxic
therapy (4)
Not applicable (7)
Unknown (8)
Not stated/inadequately described (9)
Staphylococcus aureus bacteraemia status
Healthcare associated (1)
Community-acquired (2)
Unknown (8)
Not stated/inadequately described (9)
Staphylococcus aureus bacteraemia methicillin
susceptibility indicator
Yes
No
Methicillin-resistant Staphylococcus
aureus isolate
Antibiotic susceptibility (Methicillin-resistant
Staphylococcus aureus isolate)
Antibiotic susceptibility indicator (Methicillin-
resistant Staphylococcus aureus isolate)
Yes
No
Establishment 2
Patient days*
days
Patient episodes of healthcare associated
Staphylococcus aureus bacteraemia*
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Cardiovascular disease (clinical) DSS
Metadata Online Registry (METeOR)
Health sector data set specifications from METeOR,
Australia's repository for national metadata standards,
developed by the Australian Institute of Health and Welfare
(http://meteor.aihw.gov.au/content/index.phtml/itemId/3451
65)
Cardiovascular disease (clinical) DSS
The collection of cardiovascular data (CV-Data) in this
metadata set is voluntary.
The definitions used in CV-Data are designed to underpin
the data collected by health professionals in their day-to-
day practice. They relate to the realities of a clinical
consultation and the ongoing nature of care and
relationships that are formed between doctors and patients
in clinical practice.
The data elements specified in this metadata set provide a
framework for:
•	promoting the delivery of high quality cardiovascular
disease preventive and management care to patients, 
•	facilitating ongoing improvement in the quality of
cardiovascular and chronic disease care predominantly in
primary care and other community settings in Australia, and
•	supporting general practice and other primary care
services as they develop information systems to
complement the above.
This is particularly important as general practice is the
setting in which chronic disease prevention and
management predominantly takes place. Having a
nationally recognised set of definitions in relation to
defining a patient's cardiovascular behavioural, social and
biological risk factors, and their prevention and
management status for use in these clinical settings, is a
prerequisite to achieving these aims.
Many of the data elements in this metadata set are also
used in the collection of diabetes clinical information.
Where appropriate, it may be useful if the data definitions in
this metadata set were used to address data definition
needs for use in non-clinical environments such as public
health surveys etc. This could allow for qualitative
comparisons between data collected in, and aggregated
from clinical settings (i.e. using application of CV-Data),
with that collected through other means (e.g. public health
surveys).
© Australian Institute of Health and Welfare 2015
Metadata and Classifications Unit 
Australian Institute of Health and Welfare
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Cardiovascular disease (clinical)
Metadata Online Registry (METeOR)
Address
Australian postcode (address)*
Division of general practice
Division of General Practice number*
Episode of care
Behaviour-related risk factor intervention -
purpose*
Smoking (1)
Nutrition (2)
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Alcohol misuse (3)
Physical inactivity (4)
Other (8)
Not stated/inadequately described (9)
Behaviour-related risk factor intervention*
No intervention (01)
Information and education (not including
written regimen) (02)
Counselling (03)
Pharmacotherapy (04)
Referral provided to a health professional
(05)
Referral to a community program,
support group or service (06)
Written regimen provided (07)
Surgery (08)
Other (98)
Not stated/inadequately defined (99)
Health service event
Fasting status*
Yes (1)
No (2)
Not stated/inadequately described (9)
Date of referral to rehabilitation
Patient
Date of diagnosis*
Person
Alcohol consumption in standard drinks per day
(self reported)*
standard drinks
Alcohol consumption frequency (self reported)*
Every day/7 days per week (01)
5 to 6 days per week (02)
3 to 4 days per week (03)
1 to 2 days per week (04)
2 to 3 days per month (05)
Once per month (06)
7 to 11 days in the past year (07)
4 to 6 days in the past year (08)
2 to 3 days in the past year (09)
Once in the past year (10)
Never drank any alcoholic beverage in
the past year (11)
Never in my life (12)
Not reported (99)
Blood pressure—diastolic (measured)*
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mmHg
Blood pressure—systolic (measured)*
mmHg
CVD drug therapy—condition*
Heart failure (01)
Ischaemic heart disease (02)
Hypertension (03)
Atrial fibrillation (AF) (04)
Other dysrhythmia or conductive disorder
(05)
Dyslipidaemia (06)
Peripheral vascular disease (PVD) (07)
Renal vascular disease (08)
Stroke (09)
Transient ischaemic attack (TIA) (10)
Other (97)
No CVD drugs prescribed (98)
Not recorded (99)
Cholesterol—total (measured)*
mmol/L
Country of birth*
Creatinine serum level (measured)*
µmol/L
Date of birth*
Diabetes status*
Type 1 diabetes (01)
Type 2 diabetes (02)
Gestational diabetes mellitus (GDM) (03)
Other (secondary diabetes) (04)
Previous gestational diabetes mellitus
(GDM) (05)
Impaired fasting glucose (IFG) (06)
Impaired glucose tolerance (IGT) (07)
Not diagnosed with diabetes (08)
Not assessed (09)
Not stated/inadequately described (99)
Diabetes therapy type*
Diet and exercise only (01)
Oral hypoglycaemic - sulphonylurea only
(02)
Oral hypoglycaemic - biguanide (eg
metformin) only (03)
Oral hypoglycaemic - alpha-glucosidase
inhibitor only (04)
Oral hypoglycaemic - thiazolidinedione
only (05)
Oral hypoglycaemic - meglitinide only
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(06)
Oral hypoglycaemic - combination (eg
biguanide & sulphonylurea) (07)
Oral hypoglycaemic - other (08)
Insulin only   (09)
Insulin plus oral hypoglycaemic (10)
Nil - not currently receiving diabetes
treatment (98)
Not stated/inadequately described (99)
Formal community support access status*
Currently accessing (1)
Currently not accessing (2)
Not known/inadequately described (9)
Height (measured)*
cm
Cholesterol—HDL (measured)*
mmol/L
Indigenous status*
Aboriginal but not Torres Strait Islander
origin (1)
Torres Strait Islander but not Aboriginal
origin (2)
Both Aboriginal and Torres Strait Islander
origin (3)
Neither Aboriginal nor Torres Strait
Islander origin (4)
Not stated/inadequately described (9)
Informal carer existence indicator*
Yes (1)
No (2)
Not stated/inadequately described (9)
Labour force status*
Employed (1)
Unemployed (2)
Not in the labour force (3)
Not stated/inadequately described (9)
Living arrangement*
Lives alone (1)
Lives with others (2)
Not stated/inadequately described (9)
Cholesterol—LDL (calculated)*
mmol/L
Tobacco smoking—consumption/quantity
(cigarettes)*
Person identifier*
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Physical activity sufficiency status*
Sufficient (1)
Insufficient (2)
Sedentary (3)
Not stated/inadequately described (9)
Preferred language*
Premature cardiovascular disease family history
(status)*
Yes (1)
No (2)
Family history status not known (3)
Not recorded (9)
Proteinuria status*
Negative for protein (1)
Microalbuminuria present (1.1)
Microalbuminuria not present (1.2)
Microalbuminuria not tested (1.3)
Proteinuria (2)
Not tested (3)
Not stated/inadequately described (9)
Renal disease therapy*
Drugs for modification of renal disease
(1)
Drugs for treatment of complications of
renal disease (2)
Peritoneal dialysis (3)
Haemodialysis (4)
Functioning renal transplant (5)
Sex*
Male (1)
Female (2)
Intersex or indeterminate (3)
Not stated/inadequately described (9)
Tobacco smoking status*
Daily smoker (1)
Weekly smoker (2)
Irregular smoker (3)
Ex-smoker (4)
Never smoked (5)
Triglyceride level (measured)*
mmol/L
Vascular history*
Myocardial infarction (01)
Unstable angina pectoris (02)
Angina (03)
Heart failure (04)
Atrial fibrillation (05)
Other dysrhythmia or conductive disorder
(06)
Rheumatic heart disease (07)
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Non-rheumatic valvular heart disease
(08)
Left ventricular hypertrophy (09)
Stroke (10)
Transient ischaemic attack (11)
Hypertension (12)
Peripheral vascular disease (includes
abdominal aortic aneurism) (13)
Deep vein thrombosis (14)
Other atherosclerotic disease (15)
Carotid stenosis (16)
Vascular renal disease (17)
Vascular retinopathy (hypertensive) (18)
Vascular retinopathy (diabetic) (19)
Other vascular (97)
No vascular history (98)
Unknown/not stated /not specified (99)
Vascular procedures (history)*
Amputation for arterial vascular
insufficiency (01)
Carotid endarterectomy (02)
Carotid angioplasty/stenting (03)
Coronary angioplasty/stenting (04)
Coronary artery bypass grafting (05)
Renal artery angioplasty/stenting (06)
Heart transplant (07)
Heart valve surgery (08)
Abdominal aortic aneurism repair/bypass
graft/stenting (09)
Cerebral circulation angioplasty/stenting
(10)
Femoral/popliteal bypass/graft/stenting
(11)
Congenital heart and blood vessel defect
surgery (12)
Permanent pacemaker implantation (13)
Implantable cardiac defibrillator (14)
Other (98)
Unknown/not recorded (99)
Waist circumference (measured)*
cm
Weight in kilograms (measured)*
Kg
Service contact date*
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AAFP: Pelvic Inflammatory Disease
Admission Order
AAFP: Pelvic Inflammatory Disease Admission Order,
Standardizes Admission Orders, Author: Robert M. Wiprud,
MD The primary purpose of these Ordersets is to decrease
unnecessary variability and to improve quality through
standardized Admission Orders. Developed by the Scott &
White Clinic at College Station, Texas. Copyright © 2006
American Academy of Family Physicians. Physicians may
photocopy or adapt for use in their own practices; all other
rights reserved. Wiprud RM. Providing consistent care with
standardized admission orders. Fam Pract Manag.
September 2006: 49-52 See
http://www.aafp.org/fpm/2006/0900/p49.html This ODM
Form includes the twenty-sixth section ("AAFP: Pelvic
Inflammatory Disease Admission Order")
All rights reserved. Please visit https://medical-data-
models.org/forms/16560
AAFP: Pelvic Inflammatory Disease
Admission Order
Default Itemgroup
Name
Age
Date of Birth
Medical record number
Status
Status
Observation (1)
Admission (2)
Medical Floor (3)
Attending
Name of attending physician
Phone number of attending physician
Admitting Diagnosis
Pelvic Inflammatory Disease Associated
Diagnoses
Condition
Condition
Stable (1)
Fair (2)
Serious (3)
Critical (4)
1 / 3
Allergies
Allergies
Diet
Routine as tolerated
Yes
No
Activity
Bed rest with bathroom privileges
Yes
No
Nursing
Vital signs: every shift
Yes
No
Notify MD for: T > 102.5; P > 120 and < 60; BP <
90/60 and > 180/110
Yes
No
Medications
Medications
Cefotetan 2gm IVPB every 23 hrs OR (1)
Cefoxitin 2 gm IVPB every 6 hrs plus
doxycycline 100 mg IV/PO every 12 hrs
OR (2)
Clindamycin 900 mg IVPB every 8 hrs
plus Gentamycin 7 mg/kg IVPB over 1 hr
per day (adjust dose according to
normagram) OR (3)
Unasyn 3 grams IVPB every 6 hrs plus
Doxycycline 100 mg IV/PO every 12 hrs
(4)
Vicodin 1-2 PO every 6-8 hrs prn pain
Yes
No
Ambien 10 mg PO @ bedtime prn insomnia
Yes
No
Phenergan 12.5-25 mg SIVP every 6-8 hrs prn
nausea/ vomiting
Yes
No
Tylenol 500 mg 1-2 every 6-8 hrs prn fever or
pain
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Yes
No
MOM 30 mL PO every 12 hrs prn constipation
Yes
No
Other
Yes
No
If Other, please specify
IV
Dextrose 5% in 1/2 normal saline @ 125 mL/hr
Yes
No
Lab
CBC, UA, urine HCG, basal metabolic profile
Yes
No
Gentamicin level 6-14 hrs after initial infusion if
using once a day
Yes
No
Gentamicin dosing
Yes
No
Cervical swab for GC/Chlaydia
Yes
No
Hemogram daily in a.m.
Yes
No
Signature
Print Name
Date and Time
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AAFP: Pyelonephritis Admission Order
AAFP: Pyelonephritis Admission Order, Standardizes
Admission Orders, Author: Robert M. Wiprud, MD The
primary purpose of these Ordersets is to decrease
unnecessary variability and to improve quality through
standardized Admission Orders. Developed by the Scott &
White Clinic at College Station, Texas. Copyright © 2006
American Academy of Family Physicians. Physicians may
photocopy or adapt for use in their own practices; all other
rights reserved. Wiprud RM. Providing consistent care with
standardized admission orders. Fam Pract Manag.
September 2006: 49-52 See
http://www.aafp.org/fpm/2006/0900/p49.html This ODM
Form includes the twenty-second section ("AAFP:
Pyelonephritis Admission Order")
All rights reserved. Please visit https://medical-data-
models.org/forms/16561
AAFP: Pyelonephritis Admission
Order
Default Itemgroup
Name
Age
Date of Birth
Medical record number
Status
Status
Observation (1)
Admission (2)
Medical floor (3)
Monitored bed (4)
Other (5)
If Other, please specify
Attending
Name of attending physician
Phone number of attending physician
Admitting Diagnosis
Pyelonephritis Associated Diagnoses
Condition
Condition
Stable (1)
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Fair (2)
Serious (3)
Critical (4)
Code Status
Full Code (1)
DNR (2)
Allergies
Allergies
Diet
NPO
Yes
No
Clear liquid
Yes
No
AHA step 2
Yes
No
ADA___calories
Yes
No
If Diet according to ADA, please specify amount
of calories
Other
Yes
No
If Other, please specify
Activity
Bed rest with bedside commode
Yes
No
bathroom privileges
Yes
No
Up ad lib
Yes
No
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Nursing
Vital signs every 4 hrs for 24 hrs then every shift
Yes
No
Notify MD for: T > 101.5, P > 120, BP < 90/60 or
> 180/110
Yes
No
Daily weight
Yes
No
I&O
Yes
No
Medications
Levaquin 500 mg IV every 24 hrs
Yes
No
Tylenol 650 mg PO every 4 hrs prn temp >
100/pain
Yes
No
Phenergan 25 mg IV/IM every 4 hrs prn nausea
Yes
No
Demerol 50 mg IM every 4 hrs prn pain
Yes
No
If toxic: consider adding Gentamycin
(7mg/kg/day) IVP; adjust for renal dose if
indicated
Yes
No
IV
Dextrose 5% in 1/2 normal saline @ 100 mL/hr
Yes
No
Other
Yes
No
If Other, please specify
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Lab
Admission: blood cultures x2 prior to antibiotics,
CBC, UA, urine culture, basal metabolic profile
Yes
No
Daily: CBC
Yes
No
Other
If history of stones or recurrent pyelo consider
IVP or renal ultrasound
Yes
No
DVT prophylaxis with Lovenox 40 mg sc daily
Yes
No
Signature
Print Name
Date and Time
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Eligibility Leukemia NCT00027560
Melphalan, Fludarabine, and Alemtuzumab Followed by
Peripheral Stem Cell Transplant in Treating Patients With
Hematologic Cancer; ODM derived from:
https://clinicaltrials.gov/show/NCT00027560
All rights reserved. Please visit https://medical-data-
models.org/forms/16562
Eligibility Leukemia NCT00027560
Inclusion Criteria
disease criteria: this trial is primarily designed for:
1) patients with relapsed or primary refractory
non-hodgkin's lymphoma*
Yes
No
disease criteria: this trial is primarily designed for:
2) chemosensitive relapsed or refractory acute
and chronic lymphocytic leukemias*
Yes
No
disease criteria: this trial is primarily designed for:
3) relapsed or primary refractory hodgkin's
disease, or advanced (durie-salmon stage ii or iii)
multiple myeloma, advanced waldenstrom
macroglobulinemia, who, by virtue of advanced
age, intensity of prior radiation and/or
chemotherapy, history of prior toxicity associated
with chemo/radiotherapy or existing organ
dysfunction, would be at undue risk of regimen
associated mortality if transplanted according to
protocols involving myeloablative conditioning
regimens.*
Yes
No
patients with aggressive nhl histologies must
have chemo/radiosensitive disease, or have non-
progressive disease, or have stable disease on
therapy, and be ineligible for an autologous hsc
transplant because of disease in the marrow.*
Yes
No
patients with chronic myeloid leukemia and high
risk forms of acute myelogenous leukemia or
myelodysplastic syndromes are also eligible in
the absence of an alternative active higher
priority allogeneic transplant protocol for which
they are eligible.*
Yes
No
age criteria: patients may be up to 70 years of
age. there is no lower age threshold. patients
above the age of 70 may also participate, after
evaluation and approval by the bmt service
attendings.*
Yes
No
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absence of active or uncontrolled bacterial, viral,
or fungal infection that would contraindicate the
use of myelosuppressive chemotherapy.*
Yes
No
patients must have a healthy hla-compatible
donor, either a matched or single hla allele
disparate related donor or a similarly compatible
unrelated donor recruited through the national
marrow donor program. related donors must be
willing to participate as research subjects and be
willing to receive g-csf to mobilize pbpc and
undergo leukapheresis to donate pbsc. unrelated
donors identified by the nmdp may elect to
donate either pbsc after treatment with g-csf, or
bone marrow. these unrelated donors will provide
informed consent and their pbsc or bone marrow
donations will be obtained at a qualified donor
center participating in the nmdp.*
Yes
No
each patient must be willing to participate as a
research subject and must sign an informed
consent form after discussion of the nature and
risks of the study prior to entering the protocol.
parents or legal guardians of patients who are
minors will sign the consent form for these
patients after discussion of the nature and risks
of the study.*
Yes
No
Exclusion Criteria
female patients who are pregnant or lactating.*
Yes
No
active or uncontrolled viral (including hiv-1),
bacterial or fungal infection.*
Yes
No
severe renal insufficiency (creatinine >2.0 or
creatinine clearance < 30ml/minute)*
Yes
No
severe hepatic dysfunction, as defined by: total
bilirubin greater than 2.5 mg/dl and ast and alt
>3xnl, unless the liver is involved with disease.*
Yes
No
severe cardiac insufficiency, defined as a resting
left ventricular ejection of less than 30% as
measured by echocardiography or radionuclide
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cardiac angiography. patients on cardiac
medications for congestive heart failure are
eligible, as long as their lvef is greater than 30%
on medication.*
Yes
No
severe pulmonary insufficiency, as defined by an
adjusted diffusing capacity of less than 40% of
predicted value.*
Yes
No
karnofsky or lansky score <40%*
Yes
No
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Eligibility Lymphoma NCT00098566
Long-Term Effects of Iodine I Tositumomab and Autologous
Bone Marrow or Stem Cell Transplantation in Patients With
Relapsed or Refractory Non-Hodgkin's Lymphoma; ODM
derived from: https://clinicaltrials.gov/show/NCT00098566
All rights reserved. Please visit https://medical-data-
models.org/forms/16563
Eligibility Lymphoma NCT00098566
Criteria
diagnosis of b-cell non-hodgkin's lymphoma*
Yes
No
relapsed or refractory disease*
Yes
No
previously treated with myeloablative doses of
iodine i^131 tositumomab and autologous bone
marrow or stem cell transplantation on 1 of the
following phase i or ii protocols:*
Yes
No
fhcrc-296*
Yes
No
fhcrc-521*
Yes
No
fhcrc-792*
Yes
No
fhcrc-915*
Yes
No
patient characteristics:*
Yes
No
18 and over*
Yes
No
performance status*
Yes
No
not specified*
Yes
No
life expectancy*
Yes
No
not specified*
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Yes
No
hematopoietic*
Yes
No
not specified*
Yes
No
hepatic*
Yes
No
not specified*
Yes
No
renal*
Yes
No
not specified*
Yes
No
prior concurrent therapy:*
Yes
No
biologic therapy*
Yes
No
see disease characteristics*
Yes
No
chemotherapy*
Yes
No
not specified*
Yes
No
endocrine therapy*
Yes
No
not specified*
Yes
No
radiotherapy*
Yes
No
see disease characteristics*
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Yes
No
surgery*
Yes
No
not specified*
Yes
No
3 / 3
Eligibility Lymphoma NCT00098566
AAFP: Seizures Admission Order
AAFP: Seizures Admission Order, Standardizes Admission
Orders, Author: Robert M. Wiprud, MD The primary
purpose of these Ordersets is to decrease unnecessary
variability and to improve quality through standardized
Admission Orders. Developed by the Scott & White Clinic at
College Station, Texas. Copyright © 2006 American
Academy of Family Physicians. Physicians may photocopy
or adapt for use in their own practices; all other rights
reserved. Wiprud RM. Providing consistent care with
standardized admission orders. Fam Pract Manag.
September 2006: 49-52 See
http://www.aafp.org/fpm/2006/0900/p49.html This ODM
Form includes the twenty-eighth section ("AAFP: Seizures
Admission Order")
All rights reserved. Please visit https://medical-data-
models.org/forms/16564
AAFP: Seizures Admission Order
Default Itemgroup
Name
Age
Date of Birth
Medical record number
Status
Status
Observation (1)
Admission (2)
Medical floor (3)
Monitored bed (4)
Telemetry (5)
ICU (6)
Attending
Name of attending physician
Phone number of attending physician
Admitting Diagnosis
Seizures Contributing Diagnoses
Condition
Condition
Stable (1)
Fair (2)
Serious (3)
Critical (4)
1 / 3
Allergies
Allergies
Diet
Diet
Activity
Bed rest with seizure precautions
Yes
No
Nursing
Vital signs: every 2 hrs with neuro checks until
stable X4, then every 4 hrs
Yes
No
Notify MD for: T > 100, BP < 90/60 or > 170/110,
seizures, glasgow coma scale < 15
Yes
No
Medications
Dilantin loading options
PO Dilantin____mg (15mg/kg) every 4
hrs X3 doses OR (1)
IV Dilantin 50 mg/min; IVP to total
of____mg (18mg/kg) then begin Dilantin
300mg PO QD OR (2)
Fosphenytoin-load (10-20 PE/kg) (3)
If PO Dilantin, please specify amount
If IV Dilantin 50 mg/min, please specify IVP to
total of
Ativan 2-4 mg slow IVP over 10 min prn active
seizures lasting more than 3 min
Yes
No
Tylenol 650 mg PO every 4-6 hrs prn fever or
pain
Yes
No
MOM 30 mL PO every 12 hrs prn constipation
Yes
No
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Other
Yes
No
If Other, please specify
Lab
Hemogram
Yes
No
Comp met profile
Yes
No
VDRL
Yes
No
Urine Toxicology screen for "drugs of abuse"
Yes
No
Other
MRI of head with and without contrast for "new
onset seizures, R/O mass, lesion"
Yes
No
EEG for " new onset seizures"; to be read by
neurologist
Yes
No
Consult
Consult
Signature
Print Name
Date and Time
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Diabetes (clinical) DSS Metadata Online
Registry (METeOR)
Health sector data set specifications from METeOR,
Australia's repository for national metadata standards,
developed by the Australian Institute of Health and Welfare
(http://meteor.aihw.gov.au/content/index.phtml/itemId/3451
65)
Diabetes (clinical) DSS
The use of this standard is voluntary. 
However, if data is to be collected the Diabetes (clinical)
Data Set Specification (DSS) aims to ensure national
consistency in relation to defining, monitoring and recording
information on patients diagnosed with diabetes.
The Diabetes (clinical) DSS relates to the clinical status of,
the provision of services for, and the quality of care
delivered to individuals with diabetes, across all health care
settings including:
·	General Practitioners; 
·	Divisions of General Practice; 
·	Diabetes Centres
·	Specialists in private practice; and 
·	Community Health Nurses and Diabetes Educators.
The Diabetes (clinical) DSS:
·	provides concise, unambiguous definitions for
items/conditions related to diabetes quality care, and 
·	aims to ensure standardised methodology of data
collection in Australia.
The expectation is that collection of this data set facilitates
good quality of care, contributes to preventive care and has
the potential to enhance self-management by patients with
diabetes.
The underlying goal is improvement of the length and
quality of life of patients with diabetes, and prevention or
delay in the development of diabetes related complications.
© Australian Institute of Health and Welfare 2015
Metadata and Classifications Unit 
Australian Institute of Health and Welfare
GPO Box 570
Canberra ACT 2601
All rights reserved. Please visit https://medical-data-
models.org/forms/16565
Diabetes (clinical) DSS Metadata
Online Registry (METeOR)
Female
Pregnancy—current status*
Yes (1)
No (2)
Not stated/inadequately described (9)
Health service event
Fasting status*
Yes (1)
No (2)
Not stated/inadequately described (9)
Laboratory standard
Microalbumin level—upper limit of normal range
(albumin/creatinine ratio)
mg/mmol
Microalbumin level—upper limit of normal range
(micrograms per minute)
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µg/min
Microalbumin level—upper limit of normal range
(milligrams per 24 hour)
mg/24h
Microalbumin level—upper limit of normal range
(milligrams per litre)
mg/L
Glycosylated haemoglobin—upper limit of normal
range (percentage)*
%
Patient
Year of diagnosis of diabetes mellitus*
Year insulin started*
Person (male)
Erectile dysfunction*
Erectile dysfunction- developed in the
last 12 months (1)
Erectile dysfunction- developed prior to
the last 12 months (2)
No erectile dysfunction (3)
Not stated/inadequately described (9)
Person
Blindness (diabetes complication)*
Blindness  (1)
Blindness  (2)
Blindness (3)
No blindness (4)
Not stated/inadequately described (9)
Blood pressure—diastolic (measured)*
mmHg
Blood pressure—systolic (measured)*
mmHg
Cardiovascular medication (current)*
Angiotensin converting enzyme (ACE)
inhibitors (1)
Angiotensin II (A2) receptor blockers (2)
Beta blockers (3)
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Calcium antagonists (4)
None of the above (8)
Not stated/inadequately described (9)
Cataract - history*
Cataract currently present or has been
previously removed from the right eye (1)
Cataract currently present or has been
previously removed from the left eye (2)
Cataract currently present or has been
previously removed from both eyes (3)
No cataract present or has not been
previously removed from either eye (4)
Not stated/inadequately described (9)
Cerebral stroke due to vascular disease (history)*
Cerebral stroke - occurred in the last 12
months (1)
Cerebral stroke - occurred prior to the
last 12 months (2)
Cerebral stroke - occurred both in and
prior to the last 12 months (3)
No history of cerebral stroke due to
vascular disease (4)
Not stated/inadequately described (9)
Cholesterol—total (measured)*
mmol/L
Coronary artery disease—history of intervention
or procedure*
CABG, angioplasty or stent - undertaken
in last 12 months (1)
CABG, angioplasty or stent - undertaken
prior to the last 12 months (2)
CABG, angioplasty or stent - both within
and prior to the last 12 months (3)
No CABG, angioplasty or stent
undertaken (4)
Not stated/inadequately described (9)
Creatinine serum level (measured)*
µmol/L
Date of birth*
Diabetes status*
Type 1 diabetes (01)
Type 2 diabetes (02)
Gestational diabetes mellitus (GDM) (03)
Other (secondary diabetes) (04)
Previous gestational diabetes mellitus
(GDM) (05)
Impaired fasting glucose (IFG) (06)
Impaired glucose tolerance (IGT) (07)
Not diagnosed with diabetes (08)
Not assessed (09)
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Not stated/inadequately described (99)
Diabetes therapy type*
Diet and exercise only (01)
Oral hypoglycaemic - sulphonylurea only
(02)
Oral hypoglycaemic - biguanide (eg
metformin) only (03)
Oral hypoglycaemic - alpha-glucosidase
inhibitor only (04)
Oral hypoglycaemic - thiazolidinedione
only (05)
Oral hypoglycaemic - meglitinide only
(06)
Oral hypoglycaemic - combination (eg
biguanide & sulphonylurea) (07)
Oral hypoglycaemic - other (08)
Insulin only   (09)
Insulin plus oral hypoglycaemic (10)
Nil - not currently receiving diabetes
treatment (98)
Not stated/inadequately described (99)
Dyslipidaemia treatment indicator*
End-stage renal disease - developed in
the last 12 months (1)
End-stage renal disease - developed
prior to the last 12 months (2)
No end-stage of renal disease (3)
Not stated/inadequately described (9)
Renal disease—end-stage (diabetes
complication)*
End-stage renal disease - developed in
the last 12 months (1)
End-stage renal disease - developed
prior to the last 12 months (2)
No end-stage of renal disease (3)
Not stated/inadequately described (9)
Foot deformity*
Yes (1)
No (2)
Not stated/inadequately described (9)
Foot lesion (active)*
Yes (1)
No (2)
Not stated/inadequately described (9)
Foot ulcer (current)*
Yes (1)
No (2)
Not stated/inadequately described (9)
Foot ulcer (history)*
Yes (1)
No (2)
Not stated/inadequately described (9)
Glycosylated haemoglobin level (measured)*
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%Health professionals attended (diabetes mellitus)*
Diabetes educator (1)
Dietician (2)
Ophthalmologist (3)
Optometrist (4)
Podiatrist (5)
None of the above (8)
Not stated/inadequately described (9)
Height (measured)*
cm
Cholesterol—HDL (measured)*
mmol/L
Hypertension - treatment*
Yes (1)
No (2)
Not stated/inadequately described (9)
Indigenous status*
Aboriginal but not Torres Strait Islander
origin (1)
Torres Strait Islander but not Aboriginal
origin (2)
Both Aboriginal and Torres Strait Islander
origin (3)
Neither Aboriginal nor Torres Strait
Islander origin (4)
Not stated/inadequately described (9)
Lower limb amputation due to vascular disease*
Lower limb amputation - occurred in the
last 12 months (1)
Lower limb amputation - occurred prior to
the last 12 months (2)
Lower limb amputation - occurred both in
and prior to the last 12 months (3)
No history of lower limb amputation due
to vascular disease (4)
Not stated/inadequately described (9)
Microalbumin level—albumin/creatinine ratio
(measured)
mg/mmol
Microalbumin level—micrograms per minute
(measured)
µg/min
Microalbumin level—milligrams per 24 hour
(measured)
mg/24h
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Microalbumin level—milligrams per litre
(measured)
mg/L
Myocardial infarction (history)*
Myocardial infarction - occurred in the
last 12 months (1)
Myocardial infarction - occurred prior to
the last 12 months (2)
Myocardial infarction - occurred both in
and prior to the last 12 months (3)
No history of myocardial infarction (4)
Not stated/inadequately described (9)
Ophthalmological assessment—outcome (left
retina)*
Normal (1)
Diabetes abnormality (2)
Non-diabetes abnormality (3)
Not visualised (4)
Not stated/inadequately described (9)
Ophthalmoscopy performed indicator*
Yes (1)
No (2)
Not stated/inadequately described (9)
Peripheral neuropathy (status)*
Yes (1)
No (2)
Not stated/inadequately described (9)
Peripheral vascular disease in feet (status)*
Yes (1)
No (2)
Not stated/inadequately described (9)
Referred to ophthalmologist (diabetes mellitus)*
Yes (1)
No (2)
Not stated/inadequately described (9)
Tobacco smoking status (diabetes mellitus)*
Yes (1)
No (2)
Not stated/inadequately described (9)
Hypoglycaemia - severe*
Yes (1)
No (2)
Not stated/inadequately described (9)
Sex*
Male (1)
Female (2)
Intersex or indeterminate (3)
Not stated/inadequately described (9)
Triglyceride level (measured)*
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mmol/L
Visual acuity (left eye)*
6/5 (01)
6/6 (02)
6/9 (03)
6/12 (04)
6/18 (05)
6/24 (06)
6/36 (07)
6/60 (08)
CF (count fingers) (09)
HM (hand movement) (10)
PL (perceive light) (11)
BL (blind) (12)
6/7.5 (13)
Not stated/inadequately described (99)
Weight in kilograms (measured)*
Kg
Service contact
Service contact date*
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Eligibility Cardiovascular Disease
NCT00079963
Gender, Obesity, C-Reactive Protein, and Oxidative Stress;
ODM derived from:
https://clinicaltrials.gov/show/NCT00079963
All rights reserved. Please visit https://medical-data-
models.org/forms/16566
Eligibility Cardiovascular Disease
NCT00079963
Inclusion Criteria
nonsmoker and not passively exposed*
Yes
No
males and females 18 year and older*
Yes
No
able to take vitamin supplements*
Yes
No
able to take acetominophen instead of aspirin or
nsaids during the study*
Yes
No
Exclusion Criteria
pregnancy or lactation*
Yes
No
history of ever smoking or passive smoke
exposure in the last year*
Yes
No
active liver disease; history of hiv/aids, diabetes,
kidney stones, hemochromatosis, or autoimmune
diseases; heart disease, stroke, or cancer in the
last 5 years*
Yes
No
user of prescribed anti-inflammatory or lipid-
lowering medications, oral contraceptives,
hormone replacement therapy, or blood-thinning
drugs*
Yes
No
user of iron supplements or vitamin e at 600 iu
per day or more*
Yes
No
consumption of more than 2 alcoholic beverages
per day*
Yes
No
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Eligibility Lymphoma NCT00113646
Non-Myeloablative HLA-Mismatched Ex-Vivo T-cell
Depleted Stem Cell Transplantation for Hematologic
Malignancies; ODM derived from:
https://clinicaltrials.gov/show/NCT00113646
All rights reserved. Please visit https://medical-data-
models.org/forms/16567
Eligibility Lymphoma NCT00113646
Inclusion Criteria
disease status: nhl, hd, mm that are
chemorefractory or relapsed; cll that is rai stage
iii or iv, or lymphocyte doubling time of 6 months,
or stage i/ii resistant to > 2 cycles of
chemotherapy regimens; cml in accelerated or
blast phase; mds with life-threatening cytopenias;
patients who have had a previous autologous or
allogeneic bone marrow or stem cell transplant;
other hematological disorders where allogeneic
transplant is appropriate and the risk of
conventional transplantation is considered to be
unacceptably high.*
Yes
No
estimated disease free survival of less than one
year*
Yes
No
ecog performance status of 0, 1, or 2*
Yes
No
hla 1 to 3 mismatched (at a, b, dr loci) related
donor*
Yes
No
Exclusion Criteria
cardiac disease: symptomatic congestive heart
failure, ejection fraction of < 45%, active angina
pectoris or uncontrolled hypertension.*
Yes
No
pulmonary disease: severe chronic obstructive
lung disease, or symptomatic restrictive lung
disease, or corrected dlco of < 50%*
Yes
No
renal disease: serum creatinine > 2.0 mg/dl or
creatinine clearance < 50 ml/min*
Yes
No
hepatic disease: serum bilirubin > 2.0 mg/dl or
alkaline phosphate, sgpt or sgot > 3 x normal*
Yes
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No
neurologic disease: symptomatic
leukoencephalopathy, active cns malignancy or
other neuropsychiatric abnormalities believed to
preclude transplantation*
Yes
No
hiv antibody or hepatitis b surface antigen
positivity*
Yes
No
uncontrolled infection*
Yes
No
presence of hama or haha in patient previously
treated with monoclonal antibody therapy or who
have received a product in which the preparation
involved a monoclonal antibody affinity step*
Yes
No
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NINDS CDE OCT Analysis – Stratus Retinal
Thickness Report  Multiple Sclerosis
NINDS Common Data Elements, Multiple Sclerosis OCT
Analysis – Stratus Retinal Thickness Report 
Used from the National Institute of Neurological Disorders
and Stroke Common Data Elements
(https://www.commondataelements.ninds.nih.gov/)
References:
Grinnon ST, Miller K, Marler JR, Lu Y, Stout A, Odenkirchen
J, Kunitz S. National Institute of Neurological Disorders and
Stroke Common Data Element Project - approach and
methods. Clin Trials. 2012;9(3):322-9.
All rights reserved. Please visit https://medical-data-
models.org/forms/16568
OCT Analysis – Stratus Retinal
Thickness Report
OCT Analysis Stratus Retinal Thickness
Report OD
Study ID
Study site name
Subject ID
Signal Strength
1 (1)
10 (10)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
7 (7)
8 (8)
9 (9)
Total macular volume
mm^3
Is the macular volume abnormally low? Choose
only one
0 Macula is of normal thickness (green
on the report)  (1)
1 Macula is abnormally thin, in the 5th
percentile (yellow on the report)  (2)
2 Macula thickness is in the 1st
percentile (red on the report)  (3)
9 Macula is abnormally thick, in the 95th
percentile (pale yellow on the report)  (4)
99 Macula is abnormally thick, in the
99th percentile (pale pink on the report)
(5)
OCT Analysis Stratus Retinal Thickness
Report OS
Signal Strength
1 (1)
10 (10)
1 / 2
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
7 (7)
8 (8)
9 (9)
Total macular volume
mm^3
Is the macular volume abnormally low? Choose
only one
0 Macula is of normal thickness (green
on the report)  (1)
1 Macula is abnormally thin, in the 5th
percentile (yellow on the report)  (2)
2 Macula thickness is in the 1st
percentile (red on the report)  (3)
9 Macula is abnormally thick, in the 95th
percentile (pale yellow on the report)  (4)
99 Macula is abnormally thick, in the
99th percentile (pale pink on the report)
(5)
2 / 2
NINDS CDE OCT Analysis – Stratus Retinal Thickness Report  Multiple
Sclerosis
NINDS CDE OCT Analysis – RNFL
Thickness Analysis  Multiple Sclerosis
NINDS Common Data Elements, Multiple Sclerosis OCT
Analysis – RNFL Thickness Analysis 
Used from the National Institute of Neurological Disorders
and Stroke Common Data Elements
(https://www.commondataelements.ninds.nih.gov/)
References:
Grinnon ST, Miller K, Marler JR, Lu Y, Stout A, Odenkirchen
J, Kunitz S. National Institute of Neurological Disorders and
Stroke Common Data Element Project - approach and
methods. Clin Trials. 2012;9(3):322-9.
All rights reserved. Please visit https://medical-data-
models.org/forms/16569
OCT Analysis – RNFL Thickness
Analysis
OCT Analysis RNFL Thickness Analysis
OD
Study ID
Study site name
Subject ID
Macular cube scan pattern (choose only one):
Cirrus RNFL Thickness Analysis: Optic
Disc Cube Scan 200 x 200  (1)
Stratus RNFL Thickness Average
Analysis Report, indicate difference in
average overall  (2)
thickness (OD-OS) (thickness (OD-OS))
Signal Strength
1    (1)
10 (10)
2    (2)
3    (3)
4    (4)
5  (5)
6    (6)
7    (7)
8    (8)
9    (9)
Average RNFL Thickness
µ
Was average RNFL thickness abnormal? Choose
only one
0 RNFL thickness is normal (green on
the report)  (1)
1 RNFL is abnormally thin, in the 5 th
percentile (yellow on the report)  (2)
2 RNFL thickness is in the 1 st
percentile (red on the report)  (3)
9  RNFL is unusually thick, in the 95 th
percentile (white on the report) (4)
RNFL thickness of the superior quadrant
µ
1 / 4
Was average RNFL thickness of the superior
quadrant abnormal? Choose only one
0 RNFL thickness is normal (green on
the report)  (1)
1 RNFL is abnormally thin, in the 5 th
percentile (yellow on the report)  (2)
2 RNFL thickness is in the 1 st
percentile (red on the report)  (3)
9  RNFL is unusually thick, in the 95 th
percentile (white on the report) (4)
RNFL thickness of the nasal quadrant
µ
Was average RNFL thickness of the nasal
quadrant abnormal? Choose only one
0 RNFL thickness is normal (green on
the report)  (1)
1 RNFL is abnormally thin, in the 5 th
percentile (yellow on the report)  (2)
2 RNFL thickness is in the 1 st
percentile (red on the report)  (3)
9  RNFL is unusually thick, in the 95 th
percentile (white on the report) (4)
RNFL thickness of the inferior quadrant
µ
Was average RNFL thickness of the inferior
quadrant abnormal? Choose only one
0 RNFL thickness is normal (green on
the report)  (1)
1 RNFL is abnormally thin, in the 5 th
percentile (yellow on the report)  (2)
2 RNFL thickness is in the 1 st
percentile (red on the report)  (3)
9  RNFL is unusually thick, in the 95 th
percentile (white on the report) (4)
RNFL thickness of the temporal quadrant
µ
Was average RNFL thickness of the temporal
quadrant abnormal? Choose only one
0 RNFL thickness is normal (green on
the report)  (1)
1 RNFL is abnormally thin, in the 5 th
percentile (yellow on the report)  (2)
2 RNFL thickness is in the 1 st
percentile (red on the report)  (3)
9  RNFL is unusually thick, in the 95 th
percentile (white on the report) (4)
OCT Analysis RNFL Thickness Analysis
OS
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NINDS CDE OCT Analysis – RNFL Thickness Analysis  Multiple
Sclerosis
Signal Strength
1    (1)
10 (10)
2    (2)
3    (3)
4    (4)
5  (5)
6    (6)
7    (7)
8    (8)
9    (9)
Average RNFL Thickness
µ
Was average RNFL thickness abnormal? Choose
only one
0 RNFL thickness is normal (green on
the report)  (1)
1 RNFL is abnormally thin, in the 5 th
percentile (yellow on the report)  (2)
2 RNFL thickness is in the 1 st
percentile (red on the report)  (3)
9  RNFL is unusually thick, in the 95 th
percentile (white on the report) (4)
RNFL thickness of the superior quadrant
µ
Was average RNFL thickness of the superior
quadrant abnormal? Choose only one
0 RNFL thickness is normal (green on
the report)  (1)
1 RNFL is abnormally thin, in the 5 th
percentile (yellow on the report)  (2)
2 RNFL thickness is in the 1 st
percentile (red on the report)  (3)
9  RNFL is unusually thick, in the 95 th
percentile (white on the report) (4)
RNFL thickness of the nasal quadrant
µ
Was average RNFL thickness of the nasal
quadrant abnormal? Choose only one
0 RNFL thickness is normal (green on
the report)  (1)
1 RNFL is abnormally thin, in the 5 th
percentile (yellow on the report)  (2)
2 RNFL thickness is in the 1 st
percentile (red on the report)  (3)
9  RNFL is unusually thick, in the 95 th
percentile (white on the report) (4)
RNFL thickness of the inferior quadrant
µ
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NINDS CDE OCT Analysis – RNFL Thickness Analysis  Multiple
Sclerosis
Was average RNFL thickness of the inferior
quadrant abnormal? Choose only one
0 RNFL thickness is normal (green on
the report)  (1)
1 RNFL is abnormally thin, in the 5 th
percentile (yellow on the report)  (2)
2 RNFL thickness is in the 1 st
percentile (red on the report)  (3)
9  RNFL is unusually thick, in the 95 th
percentile (white on the report) (4)
RNFL thickness of the temporal quadrant
µ
Was average RNFL thickness of the temporal
quadrant abnormal? Choose only one
0 RNFL thickness is normal (green on
the report)  (1)
1 RNFL is abnormally thin, in the 5 th
percentile (yellow on the report)  (2)
2 RNFL thickness is in the 1 st
percentile (red on the report)  (3)
9  RNFL is unusually thick, in the 95 th
percentile (white on the report) (4)
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NINDS CDE OCT Analysis – RNFL Thickness Analysis  Multiple
Sclerosis
NINDS CDE OCT Analysis – Low- and High-
Contrast Acuity Testing Multiple Sclerosis
NINDS Common Data Elements, Multiple Sclerosis OCT
Analysis – Low- and High- Contrast Acuity Testing
Used from the National Institute of Neurological Disorders
and Stroke Common Data Elements
(https://www.commondataelements.ninds.nih.gov/)
References:
Grinnon ST, Miller K, Marler JR, Lu Y, Stout A, Odenkirchen
J, Kunitz S. National Institute of Neurological Disorders and
Stroke Common Data Element Project - approach and
methods. Clin Trials. 2012;9(3):322-9.
All rights reserved. Please visit https://medical-data-
models.org/forms/16570
OCT Analysis – Low- and High-
Contrast Acuity Testing
OCT Analysis OD
Study ID
Study site name
Subject ID
Number of letters read correctly at 3.2 meters
(high contrast visual acuity)
Number of letters read correctly at 2 meters (low
contrast Sloan letter chart 2.5%)
Number of letters read correctly at 2 meters (low
contrast Sloan letter chart 1.25%)
Pelli-Robinson Contrast Sensitivity Test, log score
OCT Analysis OS
Number of letters read correctly at 3.2 meters
(high contrast visual acuity)
Number of letters read correctly at 2 meters (low
contrast Sloan letter chart 2.5%)
Number of letters read correctly at 2 meters (low
contrast Sloan letter chart 1.25%)
Pelli-Robinson Contrast Sensitivity Test, log score
OCT Analysis Binocular
Number of letters read correctly at 3.2 meters
(high contrast visual acuity)
1 / 2
Number of letters read correctly at 2 meters (low
contrast Sloan letter chart 2.5%)
Number of letters read correctly at 2 meters (low
contrast Sloan letter chart 1.25%)
Pelli-Robinson Contrast Sensitivity Test, log score
2 / 2
NINDS CDE OCT Analysis – Low- and High- Contrast Acuity Testing
Multiple Sclerosis
NINDS CDE OCT Analysis – Cirrus
Macular Thickness  Multiple Sclerosis
NINDS Common Data Elements, Multiple Sclerosis OCT
Analysis – Cirrus Macular Thickness 
Used from the National Institute of Neurological Disorders
and Stroke Common Data Elements
(https://www.commondataelements.ninds.nih.gov/)
References:
Grinnon ST, Miller K, Marler JR, Lu Y, Stout A, Odenkirchen
J, Kunitz S. National Institute of Neurological Disorders and
Stroke Common Data Element Project - approach and
methods. Clin Trials. 2012;9(3):322-9.
All rights reserved. Please visit https://medical-data-
models.org/forms/16571
OCT Analysis – Cirrus Macular
Thickness
OCT Analysis Cirrus Macular Thickness
OD
Study ID
Study site name
Subject ID
1)  Macular cube scan pattern (choose only one):
Macular Cube 512 x 128  (1)
Macular Cube 200 x 200 (2)
Signal Strength
1 (1)
10 (10)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
7 (7)
8 (8)
9 (9)
Total volume of the macular cube
mm^3
Is the macular volume abnormally low? Choose
only one
0 Macula is of normal thickness (green
on the report)  (1)
1 Macula is abnormally thin, in the 5th
percentile (yellow on the report)  (2)
2 Macula thickness is in the 1st
percentile (red on the report)  (3)
9 Macula is abnormally thick, in the 95th
percentile (pale yellow on the report)  (4)
99 Macula is abnormally thick, in the
99th percentile (pale pink on the report)
(5)
Average macular thickness of the cube
µ
1 / 3
Is the average macular thickness abnormally
low? Choose only one
0 Macula is of normal thickness (green
on the report)  (1)
1 Macula is abnormally thin, in the 5th
percentile (yellow on the report)  (2)
2 Macula thickness is in the 1st
percentile (red on the report)  (3)
9 Macula is abnormally thick, in the 95th
percentile (pale yellow on the report)  (4)
99 Macula is abnormally thick, in the
99th percentile (pale pink on the report)
(5)
OCT Analysis Cirrus Macular Thickness
OS
Signal Strength
1 (1)
10 (10)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
7 (7)
8 (8)
9 (9)
Total volume of the macular cube
mm^3
Is the macular volume abnormally low? Choose
only one
0 Macula is of normal thickness (green
on the report)  (1)
1 Macula is abnormally thin, in the 5th
percentile (yellow on the report)  (2)
2 Macula thickness is in the 1st
percentile (red on the report)  (3)
9 Macula is abnormally thick, in the 95th
percentile (pale yellow on the report)  (4)
99 Macula is abnormally thick, in the
99th percentile (pale pink on the report)
(5)
Average macular thickness of the cube
µ
Is the average macular thickness abnormally
low? Choose only one
0 Macula is of normal thickness (green
on the report)  (1)
1 Macula is abnormally thin, in the 5th
percentile (yellow on the report)  (2)
2 Macula thickness is in the 1st
percentile (red on the report)  (3)
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NINDS CDE OCT Analysis – Cirrus Macular Thickness  Multiple
Sclerosis
9 Macula is abnormally thick, in the 95th
percentile (pale yellow on the report)  (4)
99 Macula is abnormally thick, in the
99th percentile (pale pink on the report)
(5)
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NINDS CDE OCT Analysis – Cirrus Macular Thickness  Multiple
Sclerosis
NINDS CDE OCT Analysis – Spectralis
Report Analysis  Multiple Sclerosis
NINDS Common Data Elements, Multiple Sclerosis OCT
Analysis – Spectralis Report Analysis
Used from the National Institute of Neurological Disorders
and Stroke Common Data Elements
(https://www.commondataelements.ninds.nih.gov/)
References:
Grinnon ST, Miller K, Marler JR, Lu Y, Stout A, Odenkirchen
J, Kunitz S. National Institute of Neurological Disorders and
Stroke Common Data Element Project - approach and
methods. Clin Trials. 2012;9(3):322-9.
All rights reserved. Please visit https://medical-data-
models.org/forms/16575
OCT Analysis – Spectralis Report
Analysis
OCT Analysis Spectralis Report Analysis
OD
Study ID
Study site name
Subject ID
Is this a follow-up scan?
Yes
No
Date of follow up scan
1)  Macula volume OD
mm^3
1)  Macula volume OS
mm^3
OCT ART Mean
Quality
RNFL thickness of the superior quadrant
µ
Was average RNFL thickness of the superior
quadrant abnormal? Choose only one
0 RNFL thickness is normal (green on
the report)  (1)
1 RNFL is abnormally thin, in the 5 th
percentile (yellow on the report)  (2)
2 RNFL thickness is in the 1 st
percentile (red on the report)  (3)
9  RNFL is unusually thick, in the 95 th
percentile (white on the report) (4)
RNFL thickness of the nasal quadrant
µ
1 / 4
Was average RNFL thickness of the nasal
quadrant abnormal? Choose only one
0 RNFL thickness is normal (green on
the report)  (1)
1 RNFL is abnormally thin, in the 5 th
percentile (yellow on the report)  (2)
2 RNFL thickness is in the 1 st
percentile (red on the report)  (3)
9  RNFL is unusually thick, in the 95 th
percentile (white on the report) (4)
RNFL thickness of the inferior quadrant
µ
Was average RNFL thickness of the inferior
quadrant abnormal? Choose only one
0 RNFL thickness is normal (green on
the report)  (1)
1 RNFL is abnormally thin, in the 5 th
percentile (yellow on the report)  (2)
2 RNFL thickness is in the 1 st
percentile (red on the report)  (3)
9  RNFL is unusually thick, in the 95 th
percentile (white on the report) (4)
RNFL thickness of the temporal quadrant
µ
Was average RNFL thickness of the temporal
quadrant abnormal? Choose only one
0 RNFL thickness is normal (green on
the report)  (1)
1 RNFL is abnormally thin, in the 5 th
percentile (yellow on the report)  (2)
2 RNFL thickness is in the 1 st
percentile (red on the report)  (3)
9  RNFL is unusually thick, in the 95 th
percentile (white on the report) (4)
Average overall RNFL thickness (value in the
center of the circle on report, marked "G")
µ
Was average RNFL thickness thin compared to
the rest of the population? Choose only one
0 RNFL thickness is normal (green on
the report)  (1)
1 RNFL is abnormally thin, in the 5 th
percentile (yellow on the report)  (2)
2 RNFL thickness is in the 1 st
percentile (red on the report)  (3)
9  RNFL is unusually thick, in the 95 th
percentile (white on the report) (4)
OCT Analysis Spectralis Report Analysis
OS
2 / 4
NINDS CDE OCT Analysis – Spectralis Report Analysis  Multiple
Sclerosis
OCT ART Mean
Quality
RNFL thickness of the superior quadrant
µ
Was average RNFL thickness of the superior
quadrant abnormal? Choose only one
0 RNFL thickness is normal (green on
the report)  (1)
1 RNFL is abnormally thin, in the 5 th
percentile (yellow on the report)  (2)
2 RNFL thickness is in the 1 st
percentile (red on the report)  (3)
9  RNFL is unusually thick, in the 95 th
percentile (white on the report) (4)
RNFL thickness of the nasal quadrant
µ
Was average RNFL thickness of the nasal
quadrant abnormal? Choose only one
0 RNFL thickness is normal (green on
the report)  (1)
1 RNFL is abnormally thin, in the 5 th
percentile (yellow on the report)  (2)
2 RNFL thickness is in the 1 st
percentile (red on the report)  (3)
9  RNFL is unusually thick, in the 95 th
percentile (white on the report) (4)
RNFL thickness of the inferior quadrant
µ
Was average RNFL thickness of the inferior
quadrant abnormal? Choose only one
0 RNFL thickness is normal (green on
the report)  (1)
1 RNFL is abnormally thin, in the 5 th
percentile (yellow on the report)  (2)
2 RNFL thickness is in the 1 st
percentile (red on the report)  (3)
9  RNFL is unusually thick, in the 95 th
percentile (white on the report) (4)
RNFL thickness of the temporal quadrant
µ
Was average RNFL thickness of the temporal
quadrant abnormal? Choose only one
0 RNFL thickness is normal (green on
the report)  (1)
1 RNFL is abnormally thin, in the 5 th
percentile (yellow on the report)  (2)
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Sclerosis
2 RNFL thickness is in the 1 st
percentile (red on the report)  (3)
9  RNFL is unusually thick, in the 95 th
percentile (white on the report) (4)
Average overall RNFL thickness (value in the
center of the circle on report, marked "G")
µ
Was average RNFL thickness thin compared to
the rest of the population? Choose only one
0 RNFL thickness is normal (green on
the report)  (1)
1 RNFL is abnormally thin, in the 5 th
percentile (yellow on the report)  (2)
2 RNFL thickness is in the 1 st
percentile (red on the report)  (3)
9  RNFL is unusually thick, in the 95 th
percentile (white on the report) (4)
4 / 4
NINDS CDE OCT Analysis – Spectralis Report Analysis  Multiple
Sclerosis
AAFP: Upper GI Bleed Admission Order
AAFP: Upper GI Bleed Admission Order, Standardizes
Admission Orders, Author: Robert M. Wiprud, MD The
primary purpose of these Ordersets is to decrease
unnecessary variability and to improve quality through
standardized Admission Orders. Developed by the Scott &
White Clinic at College Station, Texas. Copyright © 2006
American Academy of Family Physicians. Physicians may
photocopy or adapt for use in their own practices; all other
rights reserved. Wiprud RM. Providing consistent care with
standardized admission orders. Fam Pract Manag.
September 2006: 49-52 See
http://www.aafp.org/fpm/2006/0900/p49.html This ODM
Form includes the twenty-ninth section ("AAFP: Upper GI
Bleed Admission Order")
All rights reserved. Please visit https://medical-data-
models.org/forms/16577
AAFP: Upper GI Bleed Admission
Order
Default Itemgroup
Name
Age
Date of Birth
Status
Status
Observation (1)
Admission (2)
Medical floor (3)
Telemetry (4)
ICU (5)
Attending
Name of attending physician
Phone number of attending physician
Admitting Diagnosis
Upper Gl Bleed Contributing Diagnoses
Condition
Condition
Stable (1)
Fair (2)
Serious (3)
Critical (4)
1 / 3
Allergies
Allergies
Diet
NPO except meds
Yes
No
NPO including meds
Yes
No
Activity
Bed rest with bedside commode
Yes
No
Bathroom privileges with assistance
Yes
No
Nursing
ICU: per routine
Yes
No
Telemetry or medical: every 1 hr until stable X4,
then every 2 hrs until stable X4, then every 4 hrs
Yes
No
Notify MD for: BP < 90/60 or > 170/110, P < 60 or
> 120, Urine output < 30 cc/hr over 4 hrs, all H/H
results
Yes
No
If NG to suction, replace NG fluid cc for cc with
NG with 20 mEq KCl every 12 hrs
Yes
No
Medications
Protonix 40 mg PO/IV every 12 hrs
Yes
No
Other
Yes
No
2 / 3
AAFP: Upper GI Bleed Admission Order
If Other, please specify
IV
Bolus normal saline___cc over__
Yes
No
If Bolus normal saline, please specify amount
If Bolus normal saline, please specify duration
Dextrose 5% normal saline with 20 mEq KCl/l
@___mL/hr total
Yes
No
If Dextrose 5% normal saline, please specify
amount
mL/hr total
Lab
Hemogram, comp met profile, PT/PTT/INR on
admission
Yes
No
HH every 4 hrs X3
Yes
No
Type and screen for __units PRBC
Yes
No
If type and screen, please specify amount of units
PRBC
Consult
Consult
Signature
Print Name
Date and Time
3 / 3
AAFP: Upper GI Bleed Admission Order
Eligibility Cardiovascular Disease
NCT00093236
Impact of Gum Infection on Heart Disease; ODM derived
from: https://clinicaltrials.gov/show/NCT00093236
All rights reserved. Please visit https://medical-data-
models.org/forms/16578
Eligibility Cardiovascular Disease
NCT00093236
Inclusion Criteria
1. the study seeks to enroll patients with
periodontal disease and no other major co-
morbidities including cardiovascular disease or
other major medical problems.*
Yes
No
2. in this intervention study, cigarette smokers will
be permitted as justified below and randomized in
stratified fashion to ensure equal numbers in the
two treatment groups.*
Yes
No
Exclusion Criteria
1. known cardiovascular disease including
coronary heart disease, cerebral vascular
disease, peripheral vascular disease, valvular
heart disease, and congestive heart failure.*
Yes
No
2. major coronary risk factors including diabetes
mellitus, hypertension, hypercholesterolemia
requiring treatment according to the atp-iii
guidelines.*
Yes
No
3. other major illness including cancer, liver
disease, renal disease, pulmonary disease,
chronic infectious disease (including hiv and
hepatitis c infection), rheumatological disease,
hematological disease, or any condition requiring
hospitalization or chronic medical therapy.*
Yes
No
4. use of antibiotics within three months.*
Yes
No
5. use of oral contraceptives or hormone
replacement therapy.*
Yes
No
6. major psychiatric illness requiring treatment or
that might interfere with the ability to understand
and cooperate with the protocol.*
1 / 2
Yes
No
7. ongoing drug or alcohol abuse.*
Yes
No
8. use of sildenafil (viagra) within 7 days because
of the risk of marked hypotension with
nitroglycerin administration.*
Yes
No
9. history of migraine headaches that might be
exacerbated by nitroglycerin.*
Yes
No
10. use of cholesterol lowering therapy,
angiotensin converting enzyme inhibitors
(subjects should not be taking these drugs
because they will have no history of
cardiovascular disease risk factors).*
Yes
No
11. antioxidant vitamins (vitamin c or vitamin e) in
doses exceeding the recommended dietary
allowances (rda), (60 mg/day and 30 iu/day,
respectively).*
Yes
No
12. pregnancy, as diagnosed by serum beta-hcg.*
Yes
No
2 / 2
Eligibility Cardiovascular Disease NCT00093236
AAFP: Neutropenic Fever Admission Order
AAFP: Neutropenic Fever Admission Order, Standardizes
Admission Orders, Author: Robert M. Wiprud, MD The
primary purpose of these Ordersets is to decrease
unnecessary variability and to improve quality through
standardized Admission Orders. Developed by the Scott &
White Clinic at College Station, Texas. Copyright © 2006
American Academy of Family Physicians. Physicians may
photocopy or adapt for use in their own practices; all other
rights reserved. Wiprud RM. Providing consistent care with
standardized admission orders. Fam Pract Manag.
September 2006: 49-52 See
http://www.aafp.org/fpm/2006/0900/p49.html This ODM
Form includes the twenty-second section ("AAFP:
Neutropenic Fever Admission Order")
All rights reserved. Please visit https://medical-data-
models.org/forms/16579
AAFP: Neutropenic Fever Admission
Order
Default Itemgroup
Name
Age
Date of Birth
Medical record number
The Neutropenic fever patient is defined
as a single oral temperature of > 38.3 C
(101 F) x1 in the absence of an obvious
environmental source or a temperature of
> 38.0 C (100.4 F) for > 1 hr in a ...
Status
Oncology ward
Yes
No
Attending
Name of attending physician
Phone number of attending physician
Admitting Diagnosis
Neutropenic Fever Contributing Diagnoses
Condition
1 / 3
Condition
Stable (1)
Fair (2)
Serious (3)
Critical (4)
Allergies
Allergies
Diet
Regular diet with no fresh fruits or vegetables
Yes
No
Activity
Bed rest with bathroom privileges with assistance
Yes
No
Nursing
Vital signs: every 2 hrs X4 then every 4 hrs X 24
hrs then every shift if stable
Yes
No
No plants in the room
Yes
No
Strict I&O
Yes
No
Medications
Start cefepime 2 mg IV every 8 hrs
Yes
No
Patient with renal insufficiency
Yes
No
If Patient with renal insufficiency
CrCl 30-60 mo/min: 2 gm IV every 12 hrs
(1)
CrCl 11-29 mL/min: 2 gm IV every 24 hrs
(2)
CrCl < 10 mL/min: 1 gm IV every 24 hrs
(3)
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AAFP: Neutropenic Fever Admission Order
If patient had anaphylaxis to a penicillin or
cephalosporin: start aztreonam 2 gm IV 18h and
clindamycin 900 mg IV every 8 hrs
Yes
No
Patient with renal insufficiency
Yes
No
If patient with renal insufficiency
CrCl 10-30 mL/min:aztreonam 2 gm x 1,
then 1 gm IV every 8 hrs (1)
CrCl < 10 mL/min: aztreonam 2 gm x 1 ,
then 1 gm IV every 12 hrs (2)
If patient has any of the following: severe
mucositis, obvious catheter related-infection,
consider starting vancomycin
Yes
No
Lab
Blood culture X 2 from different peripheral sites
Yes
No
CCMS UA and urine culture and sensitivity
Yes
No
Gram stain and culture any suspicious area plus
sputum if producing
Yes
No
Daily CBC´s
Yes
No
Signature
Print Name
Date and Time
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AAFP: Neutropenic Fever Admission Order
AAFP: Acute Pancreatitis Admission Order
AAFP: Acute Pancreatitis Admission Order , Standardizes
Admission Orders, Author: Robert M. Wiprud, MD The
primary purpose of these Ordersets is to decrease
unnecessary variability and to improve quality through
standardized Admission Orders. Developed by the Scott &
White Clinic at College Station, Texas. Copyright © 2006
American Academy of Family Physicians. Physicians may
photocopy or adapt for use in their own practices; all other
rights reserved. Wiprud RM. Providing consistent care with
standardized admission orders. Fam Pract Manag.
September 2006: 49-52 See
http://www.aafp.org/fpm/2006/0900/p49.html This ODM
Form includes the twenty-third section ("AAFP: Acute
Pancreatitis Admission Order ")
All rights reserved. Please visit https://medical-data-
models.org/forms/16580
AAFP: Acute Pancreatitis Admission
Order
Default Itemgroup
Name
Age
Date of Birth
Medical record number
Status
Status
Admission (1)
Medical floor (2)
Monitored bed (3)
ICU (4)
Attending
Name of attending physician
Phone number of attending physician
Admitting Diagnosis
Acute Pancreatitis Associated Diagnoses
Condition
Condition
Stable (1)
Fair (2)
Serious (3)
Critical (4)
1 / 4
Allergies
Allergies
Diet
NPO
Yes
No
NG tube to low suction; irrigate prn
Yes
No
Activity
Bed rest
Yes
No
Bed rest with bathroom privileges with assistance
Yes
No
Up ad lib
Yes
No
Nursing
Vital signs and temperature every 4 hrs
Yes
No
Notify MD if: systolic BP < 90 or > 180;
temperature > 101.5 PO; pulse < 55 bpm or >
120 bpm
Yes
No
I&O
Yes
No
Daily weights
Yes
No
IV
Normal saline @250 mL/hr x 2L, then D5
Yes
No
Normal saline with 20 mEq KCl/L
Yes
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No
Other
Yes
No
If Other, please specify
Yes
No
Lab
Admission: CBC, comp met profile, amylase,
lipase, UA, PT/INR
Yes
No
In a.m.: Lipid profile, amylase, CBC, basal
metabolic profile
Yes
No
Daily: CBC, basal metabolic profile, amylase
every a.m.
Yes
No
Medications
Meperidine 25-100 mg slow IVP every 2-4 hrs
prn for pain
Yes
No
Protonix 40 mg IV daily
Yes
No
Other
Yes
No
If Other, please specify
Radiology
Acute abdominal series
Yes
No
CXR-PA and Lat
Yes
No
Ultrasound RUQ-Pancreatitis
Yes
No
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CT abdomen with and without contrast
Yes
No
Consider
Gl consult
Yes
No
Lovenox ___mg subcutaneously daily for DVT
prophylaxis
Yes
No
If Lovenox, please specify amount
mg
Blood cultures X2 if febrile
Yes
No
Other Orders
Other Orders
Signature
Print Name
Date and Time
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Eligibility Cardiovascular Disease
NCT00099450
Study of the Tolerability, Pharmacokinetics, and
Pharmacodynamics of INS50589 Intravenous Infusion in
Healthy Volunteers; ODM derived from:
https://clinicaltrials.gov/show/NCT00099450
All rights reserved. Please visit https://medical-data-
models.org/forms/16582
Eligibility Cardiovascular Disease
NCT00099450
Inclusion Criteria
have body mass index (bmi) between 18.5 kg/m2
and 35 kg/m2 and body weight no greater than
120 kg.*
Yes
No
if female, must not be pregnant or lactating, and if
of childbearing potential or sexually active, must
use acceptable method of birth control.*
Yes
No
Exclusion Criteria
have clinically significant acute or chronic disease
(e.g., coronary artery disease, diabetes, chronic
renal insufficiency, asthma).*
Yes
No
have major surgery within eight weeks of dosing.*
Yes
No
have overt viral illness within four weeks of
dosing.*
Yes
No
have tendency or history in family of tendency for
bleeding.*
Yes
No
have clinically significant abnormalities on clinical
laboratory tests (chemistry, hematology,
urinalysis).*
Yes
No
have taken aspirin or any other non-steroidal anti-
inflammatory drug (nsaid) within 10 days prior to
admission to study facility.*
Yes
No
have ever taken or received any of the following
for medical conditions: (antiplatelet compounds
including clopidogrel, ticlopidine, dipyridamole,
tirofiban, eptifibatide, abciximab, adenosine, and
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prostacyclin) or (anticoagulants including vitamin
k antagonists, thrombin inhibitors, heparins,
hirudin or related compounds, argatroban and
factor xa inhibitors)*
Yes
No
have a clinically significant ecg abnormality.*
Yes
No
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Gynaecological cancer (clinical) DSS
Metadata Online Registry (METeOR)
Health sector data set specifications from METeOR,
Australia's repository for national metadata standards,
developed by the Australian Institute of Health and Welfare
(http://meteor.aihw.gov.au/content/index.phtml/itemId/3451
65)
Gynaecological cancer (clinical) DSS
The purpose of the Gynaecological cancer (clinical) data
set specification (DSS) is to define data standards for the
national collection of gynaecological cancer data so that
data collected is consistent and reliable. The data set
specification is not mandated for collection but is
recommended as best practice if gynaecological cancer
data is to be collected. It enables individual treatment
centres or health service areas to develop collection
methods and policies appropriate for their service.
The Gynaecological cancer (clinical) data set specification
is used in conjunction with the Cancer (clinical) data set
specification (CCDSS). The data elements with obligations
described as mandatory or conditional for collection are
recommended as best practice, while the data items
described as optional are for collection at the discretion of
the treating centre and may be contingent, for example, on
the availability of resources.
The scope for the Gynaecological cancer (clinical) DSS is
to collect comprehensive data encompassing the time a
person is first referred for the investigation of symptoms
and for the entire duration of their illness so that treatment
and outcomes are captured.
The definitions used in this data set specification are
designed to capture the provision of cancer care on a day-
to-day level. They relate to the realities of cancer care and
the need to optimise care by correctly diagnosing,
evaluating and managing patients with gynaecological
cancer.
The data elements specified provide a framework for:
·	providing a systematic foundation and promoting the
delivery of evidence-based care to patients with
gynaecological cancer 
·	informing treatment guidelines and professional education 
·	informing quality assurance 
·	guiding resource planning and the evaluation of cancer
control activities
Many of the data elements in this data set specification
may also be used in the collection of data for other types of
cancer.
This data set specification is primarily directed at the
clinical and clinical epidemiological use of cancer data.
Treatment centres such as hospitals, radiotherapy centres
and cancer specialist practices are the settings in which
implementation of the Gynaecological cancer (clinical) data
set specification should be considered. The data set
specification can also be used by a wider range of health
and health-related establishments that create, use or
maintain records on health-care clients.
© Australian Institute of Health and Welfare 2015
Metadata and Classifications Unit 
Australian Institute of Health and Welfare
GPO Box 570
Canberra ACT 2601
All rights reserved. Please visit https://medical-data-
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Gynaecological cancer (clinical) DSS
Metadata Online Registry (METeOR)
Person with cancer
Cytopathology result*
Positive (1)
Negative (2)
Equivocal (3)
Not applicable (7)
Not available (9)
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Lymphovascular invasion indicator*
Yes
No
Cervical lymphovascular invasion location
Lymphovascular invasion present and at
tumour interface (1)
Lymphovascular invasion present and
within cervix remote from tumour
interface (2)
Lymphovascular invasion present
(location unknown) (3)
Not applicable-pathology specimen not
obtained or no lymphovascular invasion
present (7)
Unknown whether pathology specimen
obtained (8)
Pathology specimen obtained but
lymphovascular invasion not
stated/inadequately described (9)
Corpus uteri lymphovascular invasion location
Lymphovascular invasion present and at
tumour interface (1)
Lymphovascular invasion present and
within the myometrium remote to the
tumour interface  (2)
Lymphovascular invasion present
(location unknown) (3)
Not applicable-pathology specimen not
obtained or no lymphovascular invasion
present (7)
Unknown whether pathology specimen
obtained (8)
Pathology specimen obtained but
lymphovascular invasion not
stated/inadequately described (9)
FIGO cervical cancer stage
Stage IA1 (1)
Stage IVA (10)
Stage IVB (11)
Stage IA2 (2)
Stage IB1 (3)
Stage IB2 (4)
Stage IIA1 (5)
Stage IIA2 (6)
Stage IIB (7)
Stage IIIA (8)
Stage IIIB (9)
Not available/inadequately described
(99)
FIGO endometrial cancer stage
Stage IA (1)
Stage IB (2)
Stage II (3)
Stage IIIA (4)
Stage IIIB (5)
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Stage IIIC1 (6)
Stage IIIC2 (7)
Stage IVA (8)
Stage IVB (9)
Not available/inadequately described
(99)
FIGO ovarian cancer stage
Stage IA (1)
Stage IIIA1(ii) (10)
Stage IIIA2 (11)
Stage IIIB (12)
Stage IIIC (13)
Stage IV (14)
Stage IVA (15)
Stage IVB (16)
Stage IB (2)
Stage IC1 (3)
Stage IC2 (4)
Stage IC3 (5)
Stage IIA (6)
Stage IIB (7)
Stage IIIA1 (8)
Stage IIIA1(i) (9)
Not available/inadequately described
(99)
Distant metastatic site indicator*
Yes (1)
No (2)
Not stated/inadequately described (9)
Distant metastatic site(s) at diagnosis
Lung (1)
Liver (2)
Bowel (3)
Bone (4)
Brain (5)
Other (88)
Metastatic spread indicated but site not
stated/inadequately described (99)
Depth of myometrial invasion
mm
Myometrial thickness
mm
Depth of cervical cancer invasion
mm
Tumour outside primary site indicator*
Yes (1)
No (2)
Not stated/inadequately described (9)
Tumour size outside primary site*
Macroscopic disease less than or equal
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to 2 cm outside the primary tumour site
(1)
Macroscopic disease between 2 cm and
less than 10 cm outside primary tumour
site (2)
Macroscopic disease equal to or greater
than 10 cm outside the primary tumour
site  (3)
Unknown (8)
Not stated/inadequately described (9)
Multiple primary tumours indicator*
Yes
No
Multiple primary tumours descriptor
Synchronous  (1)
Metachronous (2)
Not applicable, i.e. single primary tumour
only (7)
Number of primary tumours unknown (8)
Multiple primary tumours present, but
synchronicity not stated/inadequately
described (9)
Person
Tissue sample collected indicator*
Yes
No
Organisation
Organisation name
Medical specialist
Surgical specialty gynaecological cancer
Gynaecological oncologist (1)
Gynaecologist (2)
General surgeon (3)
Other (8)
Unknown (98)
Cancer treatment
Tumour residual post-surgery size category
Microscopic but no macroscopic residual
disease (1)
Residual tumour less than 0.5 cm (2)
Residual tumour between 0.5 cm and
less than 1 cm (3)
Residual tumour between 1 cm and 2 cm
(4)
Residual tumour greater than 2 cm (5)
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Not applicable (7)
Unknown/unable to be assessed (8)
Not stated/inadequately described (9)
Residual tumour indicator
Yes
No
Surgical treatment complication indicator*
Yes (1)
No (2)
Unknown (8)
Surgical treatment complication type
Unplanned return to theatre (1)
Death within 30 days of surgery (2)
Post-operative fistula (3)
Intra-operative haemorrhage (greater
than 6 units of transfusion) (4)
Pulmonary embolism (5)
Unplanned transfer to intensive care unit
(ICU) (6)
Post-operative stay greater than 21 days
(7)
Other complication or critical event (88)
Unknown (98)
Not stated/inadequately described (99)
Radiotherapy treatment complication indicator
Yes (1)
No (2)
Unknown (8)
Radiotherapy treatment complication type
Bowel obstruction requiring surgery (1)
Fistula requiring stoma formation (2)
Pelvic insufficiency (3)
Other (8)
Not stated/inadequately described (9)
Treatment complication description
Systemic therapy modification indicator
Yes (1)
No (2)
Unknown (8)
Systemic therapy modification type
Dose decrease (01)
Drug omission (02)
Drug delivery interval increase (03)
Dose increase (04)
Drug introduction (05)
Drug delivery interval decrease (06)
Dose increase and interval decrease
(07)
Other (88)
Not stated/inadequately described (99)
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Treatment plan modification description
Delay in primary course of chemotherapy
indicator
Yes (1)
No (2)
Unknown (8)
Primary course of chemotherapy delay reason
Delay due to toxicity (1)
Delay due to other complication (2)
Delay due to patient decision (3)
Other (8)
Not stated/inadequately described (9)
Cancer treatment type
Surgery only (1)
Radiotherapy only (2)
Systemic agent therapy only (3)
Surgery and radiotherapy (4)
Surgery and systemic agent therapy (5)
Radiotherapy and systemic agent
therapy (6)
Surgery, radiotherapy and systemic
agent therapy (7)
Not applicable—treatment was not
administered (97)
Unknown whether treatment was
administered (98)
Treatment was administered but the type
was not stated/inadequately described
(99)
Other cancer treatment description
Outcome of treatment
Complete response/no evidence of
disease (1.0)
Partial response (2.1)
Stable or static disease (2.2)
Progressive disease (2.3)
Not assessed or unable to be assessed
(7.0)
Unknown (8.0)
Not stated/inadequately described (9.0)
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Eligibility Cardiovascular Disease
NCT00200317
Interactive Technologies to Increase Exercise Behavior;
ODM derived from:
https://clinicaltrials.gov/show/NCT00200317
All rights reserved. Please visit https://medical-data-
models.org/forms/16584
Eligibility Cardiovascular Disease
NCT00200317
Inclusion Criteria
sedentary, defined as exercising less than 90
minutes per week*
Yes
No
lack of access to the internet*
Yes
No
lack of access to receiving mail*
Yes
No
Exclusion Criteria
coronary heart disease (history of myocardial
infarction or symptoms of angina)*
Yes
No
diabetes*
Yes
No
stroke*
Yes
No
osteoarthritis*
Yes
No
osteoporosis*
Yes
No
orthopedic problems which would limit treadmill
testing*
Yes
No
other medical or psychological problems that
could make adherence with the study protocol
difficult or dangerous*
Yes
No
consumption of three or more alcoholics drinks
per day*
Yes
No
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current or planned pregnancy*
Yes
No
planning to move from the area within the next
year*
Yes
No
current suicidal ideation or psychosis*
Yes
No
current clinical depression*
Yes
No
recent hospitalization due to a psychiatric
disorder*
Yes
No
taking medication that may impair physical
activity tolerance or performance (e.g., beta
blockers).*
Yes
No
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Eligibility Lymphoma, T-Cell, Cutaneous
NCT00211198
Study of ONTAK® to Treat Cutaneous T-Cell Lymphoma
(CTCL); ODM derived from:
https://clinicaltrials.gov/show/NCT00211198
All rights reserved. Please visit https://medical-data-
models.org/forms/16585
Eligibility Lymphoma, T-Cell,
Cutaneous NCT00211198
Inclusion Criteria
persistent or recurrent cutaneous t-cell lymphoma
(ctcl) stage ib-iva as defined by tnm staging.*
Yes
No
pathologic proven diagnosis (cytologically
confirmed) of ctcl documented in patient history.*
Yes
No
preserved organ function:  creatinine and/or liver
function levels <1.5 times institutional upper limits
of normal (uln).*
Yes
No
adequate liver function as indicated by bilirubin <
or equal to 1.5 times uln, alt < or equal to 2 times
uln, ast < or equal to 2 times uln.*
Yes
No
albumin >3.0 g/dl*
Yes
No
adequate renal function as indicated by scr < or
equal to 2.5 mg/dl.*
Yes
No
ecog performance status between 0-2.*
Yes
No
women of childbearing potential should be
screened for pregnancy prior to treatment and
utilize effective contraceptive methods (e.g.
barrier) during treatment period.*
Yes
No
patients over the age of 18 who are willing and
able to provide informed consent.*
Yes
No
Exclusion Criteria
pathology consistent with peripheral t-cell
lymphoma.*
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Yes
No
stage ivb (visceral involvement with ctcl, other
than lymph node involvement).*
Yes
No
history of human immunodeficiency virus (hiv),
hepatitis b or hepatitis c infection.*
Yes
No
patients who are pregnant or breast feeding.*
Yes
No
allergy to or have history of allergy to diphtheria
toxin or il-2.*
Yes
No
previous ontak® usage.*
Yes
No
unstable cardiovascular disease.*
Yes
No
patients who have received systemic or topical
antineoplastic therapy or investigational
medications within past 14 days.  exception: clear
evidence of disease progression requiring
immediate intervention and in the absence of
ongoing toxicity from prior therapy.*
Yes
No
ongoing deep vein thrombosis or a diagnosis of
deep vein thrombosis less than 3 months prior to
protocol enrollment.*
Yes
No
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Eligibility Major Depressive Disorder
NCT00562367
Biochemical Brain Changes Correlated With The
Antidepressant Effect Of Thyroid Hormones; ODM derived
from: https://clinicaltrials.gov/show/NCT00562367
All rights reserved. Please visit https://medical-data-
models.org/forms/16586
Eligibility Major Depressive Disorder
NCT00562367
Inclusion Criteria
dsm-iv diagnostic criteria for mdd (diagnosed with
the use of scid)*
Yes
No
written informed consent*
Yes
No
men or women aged 18-65*
Yes
No
a baseline hamilton-d17 score of > 16.*
Yes
No
Exclusion Criteria
subjects with suicidal ideation where outpatient
treatment is determined unsafe by the study
clinician. these patients will be immediately
referred to appropriate clinical treatment.*
Yes
No
pregnant women or women of childbearing
potential who are not using a medically accepted
means of contraception (defined as oral
contraceptive pill or implant, condom, diaphragm,
spermicide, iud, s/p tubal ligation, partner with
vasectomy)*
Yes
No
serious or unstable medical illness, including
cardiovascular, hepatic, renal, respiratory,
endocrine, neurologic or hematologic disease*
Yes
No
history of seizure disorder,*
Yes
No
history or current diagnosis of the following dsm-
iv psychiatric illness: organic mental disorder,
schizophrenia, schizoaffective disorder,
delusional disorder, psychotic disorders not
otherwise specified, bipolar disorder, patients
with mood congruent or mood incongruent
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psychotic features, patients with substance
dependence disorders, including alcohol, active
within the last 12 months.*
Yes
No
history or current diagnosis of dementia, or a
score of < 26 on the mini mental status
examination (folstein, 1975) at the screening
visit.*
Yes
No
history of multiple adverse drug reactions or
allergy to the study drugs.*
Yes
No
patients with mood congruent or mood
incongruent psychotic features.*
Yes
No
patients having shown minimal or no response to
a standard course of antidepressant treatment
with an ssri. a standard course will be defined as
the following medications taken for > 4 weeks:
fluoxetine > 20 mg/day, sertraline > 50 mg/day,
paroxetine > 20 mg/day, fluvoxamine > 50
mg/day, citalopram > 20 mg/day, venlafaxine >
150 mg/day.*
Yes
No
clinical or laboratory evidence of hypothyroidism.*
Yes
No
patients who have had electroconvulsive therapy
(ect) within the 6 months preceding baseline.*
Yes
No
history of intolerance to cytomel*
Yes
No
history of cardiac pathology or diabetes*
Yes
No
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Eligibility Metastatic Breast Cancer
NCT00214864
A Study of Weekly Taxotere and Xeloda in Metastatic
Breast Cancer; ODM derived from:
https://clinicaltrials.gov/show/NCT00214864
All rights reserved. Please visit https://medical-data-
models.org/forms/16587
Eligibility Metastatic Breast Cancer
NCT00214864
Inclusion Criteria
female patients with histopathologically proven
metastatic breast cancer.*
Yes
No
patients 18-75 years old*
Yes
No
performance status:  karnofsky > 70%*
Yes
No
patients must have measurable disease. patients
with only blastic bone lesions are ineligible.*
Yes
No
adequate bone marrow, liver, renal and cardiac
functions defined as:*
Yes
No
ability to understand the study and give informed
consent.*
Yes
No
patients may not have received more than one
prior chemotherapy for metastatic breast cancer.
5-fu or taxol given as part of an adjuvant regimen
will not render the patient ineligible.*
Yes
No
Exclusion Criteria
patients with brain metastasis, adequately treated
and stable and not requiring continued steroid
medication will be eligible if no progression for >
3 months.*
Yes
No
patients who have received any anti-cancer
investigational agent in the month prior to
inclusion.*
Yes
No
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patients previously treated with
docetaxel(taxotere)or capecitabine (xeloda).*
Yes
No
patients with lack of physical integrity of the upper
gastrointestinal tract, inability to swallow tablets
or those who have malabsorption syndrome.*
Yes
No
patients with renal impairment (creatinine
clearance below 30 ml/min calculated according
to cockcroft and gault, see appendix d), since
capecitabine is contraindicated in patients with
severe renal impairment.*
Yes
No
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Eligibility Cardiovascular Disease
NCT00470002
Effects of Growth Hormone on the Nitric Oxide Pathway;
ODM derived from:
https://clinicaltrials.gov/show/NCT00470002
All rights reserved. Please visit https://medical-data-
models.org/forms/16588
Eligibility Cardiovascular Disease
NCT00470002
Inclusion Criteria
healthy male subjects without recent severe
diseases*
Yes
No
age 50 yrs or older*
Yes
No
body mass index at or below 30 kg/m2*
Yes
No
insulin-like growth factor-1 level below 200 ng/ml*
Yes
No
evidence of a personally signed and dated
informed consent document indicating that the
subject has been informed of all pertinent
aspects of the trial*
Yes
No
subjects that are willing and able to comply with
scheduled visits, treatment plan, laboratory tests
and other study procedures*
Yes
No
Exclusion Criteria
history of any severe hepatic, renal, cardiac,
endocrine, metabolic, or malignant diseases*
Yes
No
requirement for medical drug treatment*
Yes
No
growth hormone treatment during the last 12
months*
Yes
No
drug dependence, alcohol or nicotine abuse*
Yes
No
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other severe acute or chronic medical or
psychiatric condition or laboratory abnormality
that may increase the risk associated with study
participation or may interfere with the
interpretation of study results and, in the
judgement of the investigator, would make the
subject inappropriate for entry into this study.*
Yes
No
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Indigenous primary health care DSS 2014-
15 Metadata Online Registry (METeOR)
Health sector data set specifications from METeOR,
Australia's repository for national metadata standards,
developed by the Australian Institute of Health and Welfare
(http://meteor.aihw.gov.au/content/index.phtml/itemId/3451
65)
Indigenous primary health care DSS 2014-15
The Indigenous primary health care data set specification
(IPHC DSS) is primarily designed to support the collection
of aggregate information from Indigenous-specific primary
health care services. The IPHC DSS describes the
aggregate data to be reported by those Indigenous-specific
primary health care services. Only the data, which services
aggregate using cohort definitions and specialised
software, will be supplied through the OATSIH Community
Health Reporting Environment (OCHRE), a web-based
reporting tool. No individual level client data will be supplied
to either the Australian Institute of Health and Welfare
(AIHW) or the Commonwealth Department of Health.
For the purposes of the IPHC DSS, Aboriginal and Torres
Strait Islander primary health care is defined as: 
“…socially and culturally appropriate, universally
accessible, scientifically sound, first level care. It is provided
by health services and systems with a suitably trained
workforce comprised of multidisciplinary teams supported
by integrated referral systems in a way that: gives priority to
those most in need and addresses health inequalities;
maximises community and individual self-reliance,
participation and control and; involves collaboration and
partnership with other sectors to promote public health.
Comprehensive primary health care includes health
promotion, illness prevention, treatment, and care of the
sick, community development, advocacy, and rehabilitation
services.” 
This definition has been endorsed by the Aboriginal
Medical Services Alliance of the Northern Territory
(AMSANT), the Australian General Practice Network
(AGPN), the Australian Primary Health Care Research
Institute (APHCRI), and the Australian Medical Association
(AMA).
Aboriginal and Torres Strait Islander primary health care
services include:
1. Aboriginal Community Controlled Health Service
(ACCHS): primary health care services initiated and
operated by the local Aboriginal community to deliver
holistic, comprehensive, and culturally appropriate health
care to the community which controls it (through a locally
elected Board of Management); and
2. Other Aboriginal and Torres Strait Islander primary
health care services: health services funded principally to
provide services to Aboriginal and Torres Strait Islander
individuals with funding provided by the federal and/or state
or territory governments. These non community-controlled
services mainly exist in the Northern Territory and northern
part of Queensland.
Services use a clinical audit tool program for extracting and
aggregating data from their patient information and recall
systems. The IPHC DSS has been written to inform this
program. Once aggregated, the data will be sent to the
AIHW via the OATSIH Community Health Reporting
Environment (OCHRE), a web-based reporting tool with an
‘in-confidence’ security classification. 
The IPHC DSS includes aggregate data only; it does not
include data elements describing any details relating to or
arising from individual client visits, at the client visit level,
e.g. blood pressure measurements, body mass index (BMI)
values and so on. 
Aggregate data will initially be collected from a limited
number of primary health care services, i.e. those funded
by the Office for Aboriginal and Torres Strait Islander Health
(OATSIH) via the Healthy for Life program. From mid-2012,
data collection was extended to the remainder of services
funded by OATSIH to deliver primary health care. From
mid-2013, data collection will be expanded to also include
state- and territory-funded Indigenous-specific primary
health care services not funded by OATSIH.
© Australian Institute of Health and Welfare 2015
Metadata and Classifications Unit 
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2014-15 Metadata Online Registry
(METeOR)
Birth
Birth weight*
Low birth weight (less than 2,500 grams)
(1)
Normal birth weight (2,500 grams to less
than 4,500 grams) (2)
High birth weight (4,500 grams and over)
(3)
Unknown birth weight (8)
Child
Fully immunised recorded indicator*
Yes
No
Female
Cervical screening indicator*
Yes (1)
No (2)
Not stated/inadequately described (9)
Hysterectomy indicator*
Yes
No
Person
Absolute cardiovascular disease risk assessment
recorded indicator*
Yes
No
Age
years
Alcohol consumption status recorded indicator
Yes
No
Birth weight recorded indicator
Yes
No
Blood pressure measurement result less than or
equal to 130/80 mmHg indicator
Yes
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No
Blood pressure measurement result recorded
indicator
Yes
No
Body mass index—classification
Not overweight or obese  (1)
Underweight  (1.1)
Normal range 18.50 - 24.99 Average
(1.2)
Overweight >= 25.00 Average (2)
Overweight >= 25.0 Average (2.1)
Pre Obese 25.00 - 29.99 Increased (2.2)
Obese >= 30 Increased (3)
Obese class 1 30.00 - 34.99 Moderate
(3.1)
Obese class 2 35.00 - 39.99 Severe (3.2)
Obese class 3 >= 40.00 Very severe
(3.3)
Not stated/inadequately described (9)
Body mass index recorded indicator
Yes
No
Cardiovascular disease recorded indicator*
Yes
No
Chronic obstructive pulmonary disease recorded
indicator*
Yes
No
Diabetes status*
Type 1 diabetes (01)
Type 2 diabetes (02)
Gestational diabetes mellitus (GDM) (03)
Other (secondary diabetes) (04)
Previous gestational diabetes mellitus
(GDM) (05)
Impaired fasting glucose (IFG) (06)
Impaired glucose tolerance (IGT) (07)
Not diagnosed with diabetes (08)
Not assessed (09)
Not stated/inadequately described (99)
Estimated glomerular filtration rate (eGFR)
recorded indicator*
Yes
No
Estimated glomerular filtration rate result
Kidney function stage 1 (1)
Kidney function stage 2 (2)
Kidney function stage 3a (3a)
Kidney function stage 3b (3b)
Kidney function stage 4 (4)
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Kidney function stage 5 (5)
Glycosylated haemoglobin level
Less than or equal to 7% (less than or
equal to 53 mmol/mol) (1)
Greater than 7% but less than or equal
to 8% (greater than 53 mmol/mol but
less than or equal to 64 mmol/mol) (2)
Greater than 8% but less than 10%
(greater than 64 mmol/mol but less than
86 mmol/mol) (3)
Greater than or equal to 10% (greater
than or equal to 86 mmol/mol) (4)
Glycosylated haemoglobin measurement result
recorded indicator
Yes
No
GP Management Plan indicator
Yes
No
Indigenous status*
Aboriginal but not Torres Strait Islander
origin (1)
Torres Strait Islander but not Aboriginal
origin (2)
Both Aboriginal and Torres Strait Islander
origin (3)
Neither Aboriginal nor Torres Strait
Islander origin (4)
Not stated/inadequately described (9)
Influenza immunisation indicator
Yes
No
MBS Health Assessment for Aboriginal and
Torres Strait Islander People (MBS Item 715)
indicator
Yes
No
Microalbumin urine test result*
Yes
No
Regular client indicator*
Yes
No
Sex*
Male (1)
Female (2)
Intersex or indeterminate (3)
Not stated/inadequately described (9)
Smoking status recorded indicator
Yes
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No
Team Care Arrangement (MBS Item 723)
indicator
Yes
No
Service provider organisation (address)
Address line (service provider organisation)*
Postcode—Australian (service provider
organisation)*
Building/complex sub-unit number (service
provider organisation)*
Building/property name (service provider
organisation)*
Electronic communication address (service
provider organisation)*
Electronic communication medium (service
provider organisation)*
1	Telephone (excluding mobile telephone)
(1)
2	Mobile (cellular) telephone (2)
3	Facsimile machine (3)
4	Pager (4)
5	e-mail (5)
6	URL (6)
Other (8)
Street name (service provider organisation)*
Street type code (service provider organisation)*
Suburb/town/locality name (service provider
organisation)*
Service provider organisation (name)
Name type (service provider organisation)
Organisation unit/section/division (1)
Service location name (2)
Business name (3)
Locally used name (4)
Abbreviated name (5)
Enterprise name (6)
Other (8)
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Unknown (9)
Organisation name*
Service provider organisation
Australian state/territory identifier (service
provider organisation)*
New South Wales (1)
Victoria (2)
Queensland (3)
South Australia (4)
Western Australia (5)
Tasmania (6)
Northern Territory (7)
Australian Capital Territory (8)
Other territories (Cocos (Keeling)
Islands, Christmas Island and Jervis Bay
Territory) (9)
Day of operation*
Monday (1)
Tuesday (2)
Wednesday (3)
Thursday (4)
Friday (5)
Saturday (6)
Sunday (7)
Not stated/inadequately described (9)
Full-time equivalent paid staff*
Service operation days*
days
Service operation hours*
hours
Service operation weeks*
weeks
Standards assessment indicator*
Yes
No
Standards assessment level*
Formally assessed (1)
Accredited (2)
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Eligibility Multiple Myeloma NCT00193544
Arsenic Trioxide and Thalidomide in the Treatment of
Refractory Multiple Myeloma; ODM derived from:
https://clinicaltrials.gov/show/NCT00193544
All rights reserved. Please visit https://medical-data-
models.org/forms/16590
Eligibility Multiple Myeloma
NCT00193544
Inclusion Criteria
to be included in this study, you must meet the
following criteria:*
Yes
No
confirmed diagnosis of multiple myeloma*
Yes
No
received at least one previous chemotherapy
regimen at most 3 previous*
Yes
No
thalidomide with or without dexamethasone
without chemotherapy will not factor in to total
number of regimens.*
Yes
No
age at least 18 years years*
Yes
No
able to perform activities of daily living with
minimal assistance*
Yes
No
life expectancy more than  3 months*
Yes
No
adequate bone marrow, liver and kidney function*
Yes
No
must give written informed consent in order to
participate.*
Yes
No
Exclusion Criteria
you cannot participate in this study if any of the
following apply to you:*
Yes
No
women pregnant or lactating.*
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Yes
No
pre-existing moderate neuropathy*
Yes
No
patients with significant underlying cardiac
dysfunction*
Yes
No
uncontrolled hypercalcemia*
Yes
No
active serious infections not controlled by
antibiotics*
Yes
No
history of grand mal seizures (other than infantile
febrile seizures)*
Yes
No
receiving other medications that prolong the qt
interval.*
Yes
No
please note:  there are additional
inclusion/exclusion criteria.  the study center will
determine if you meet all of the criteria.  if you do
not qualify for the trial, study personnel will
explain the reasons.  if you do qualify, study
personnel will explain the trial in detail and
answer any questions you may have.*
Yes
No
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Eligibility Multiple Sclerosis NCT00011375
Rolipram to Treat Multiple Sclerosis; ODM derived from:
https://clinicaltrials.gov/show/NCT00011375
All rights reserved. Please visit https://medical-data-
models.org/forms/16591
Eligibility Multiple Sclerosis
NCT00011375
Inclusion Criteria
inclusion criteria for pre-treatment screening:*
Yes
No
stage i:*
Yes
No
between the ages of 18 and 65 years, inclusive.*
Yes
No
subjects with clinically definite relapsing-remitting
or secondary progressive multiple sclerosis
according to pubished criteria.*
Yes
No
edss score between 4.0 and 6.5.*
Yes
No
patients have either failed standard treatment
(interferon beta, glatiramer acetate) by clinical
measures and/or were not eligible for ay of the
standard treatments available or opted not to
start or to continue with any of these treatments.*
Yes
No
stage ii:*
Yes
No
same as stage i with exceptiom that edss will be
between 1.5 and 6.5.*
Yes
No
eligibility criteria for initiating therapy:*
Yes
No
stage i:*
Yes
No
subjects must have an average of up to 2 gd-
enhancing lesions per month over the 3 month
pre-treatment baseline period (i.e. over 4 mri
scans).*
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Yes
No
stage ii:*
Yes
No
subjects must have an average of at least 0.5 gd-
enhancing lesions per month over the 4 month
pre-treatment baseline period.*
Yes
No
stage i & ii:*
Yes
No
subjects must not have a relapse during 30 days
before initiation of treatment.  if a relapse occurs
during the last 30 days of the pre-treatment
baseline period and eligibility mri criteria are
fulfilled, beginning of the treatment (day 1) is
delayed for at least so many days that treatment
starts not earlier than 30 days after the relapse
and not earlier than 60 days in case i.v.
corticosteroids had been given.  similarly, the
baseline needs to be prolonged if corticosteroid
treatments become necessary during these three
months.*
Yes
No
Exclusion Criteria
patients will be excluded from study entry if any
of the following exclusion criteria exist at the time
of enrollment.  if a washout period of previous
treatments becomes necessary, these criteria
have to be assessed again at the beginning of
the mri baseline period.  an additional
assessment of the exclusion criteria follows on
day 0 of the 6 months treatment phase.*
Yes
No
medical history: blood tests exceeding any of the
limits defined below will lead to exclusion from
the study: alt (sgpt) or ast (sgot) is greater than
three times the upper limit of normal; total white
blood cell count is less than 3,000/mm(3),
neutrophils less than 2,000; platelet count of less
than 85, 000/mm(3); creatinine greater than 1.5
mg/dl; serology indicating hiv infection or active
hepatitis a, b, or c infection; postive pregnancy
test or breast-feeding female;  nausea/vomiting
as a frequent complaint; fasting prolactin levels of
greater than 20 micrograms/l; history or signs of
immunodeficiency; history of galactorrhea and/or
history of prolactin-secreting tumors, history of
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pituitary tumors and adenomas, history of
mammary tumors; clinically relevant arrhythmia
or other ecg abnormalities.*
Yes
No
clinically significant (as determined by the
investigator) cardiac, immunological, pulmonary,
neurological, renal, and/or other major disease
including ecg, echocardiogram, and chest x-ray
examinations.*
Yes
No
patients with mental impairment that would
compromise understanding and judging the
consent will be excluded from the study and who
are thus not able to give informed consent will be
excluded fromthe study.  other neurocognitive
deficits or physical disabilities are no exclusion
criteria.*
Yes
No
treatment history: if prior treatment was recieved,
the subject must have been off treatment for the
required period prior to enrollment.*
Yes
No
miscellaneous: history of alcohol or drug abuse
within the 5 years prior to enrollment; female
subjects who are not post-menopausal or
surgically sterile who are not using an acceptable
method of contraception; male subjects not
practicing adequate contraception; breastfeeding
patients; unwillingness or inability to comply with
the requirements of this protocol including the
presence of any condition (physical, mental, or
social) that is likely to affect the subject's returing
for follow-up visits on schedule; previous
participation in this study; and inability to
understand/give the informed consent.*
Yes
No
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Eligibility Cardiovascular Disease
NCT00520819
Oslo Antioxidant Study; ODM derived from:
https://clinicaltrials.gov/show/NCT00520819
All rights reserved. Please visit https://medical-data-
models.org/forms/16593
Eligibility Cardiovascular Disease
NCT00520819
Inclusion Criteria
men aged 45-75 years*
Yes
No
daily smoker of a minimum of 5 cigarettes a day*
Yes
No
bmi <35 kg/m2 (because of difficulties that may
be experienced by morbidly obese individuals in
following the diet)*
Yes
No
stable weight range of 4 kg or less during the
previous 12 weeks*
Yes
No
Exclusion Criteria
any symptomatic cvd (myocardial infarction,
angina pectoris, cabg, pci, chf, nyha class iii-iv)*
Yes
No
diabetes type i or type ii taking drugs for
diabetes*
Yes
No
following a vegetarian diet or near-vegetarian diet
currently*
Yes
No
allergy to nuts, kiwi fruits, chocolate, strawberries
or tomatoes*
Yes
No
clinical disorders including gastrointestinal
disease impairing compliance with dietary
recommendations*
Yes
No
history of serious or unstable medical or
psychiatric disorder*
Yes
1 / 2
No
current use of or need of lipid lowering drug
treatment, aspirin or non-steroidal anti-
inflammatory drugs (nsaid), according to
assessment of the primary clinical investigator.
any "over the counter" headache/ pain or cold
remedies taken during the study must not contain
aspirin or aspirin like drugs such as ibuprofen.
these are classed as and will interfere with
platelet function, making them unresponsive for a
period of 10-14 days. paracetamol, however, can
be taken as an alternative if required*
Yes
No
history of alcohol/or drug abuse*
Yes
No
participation in a drug trial during the previous 30
days*
Yes
No
use of drugs (xenical, reductil), nutritional
supplements or herbs for weight loss within the 4
weeks prior to visit 2 or participation in an active
weight reduction program*
Yes
No
use of single vitamin or other antioxidants (must
be stopped 4 weeks prior to visit 2)*
Yes
No
individuals judged by the clinical investigator to
be unable to follow instructions and procedures of
the study.*
Yes
No
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Ciclosporin Psoriasis MIPSO EudraCT
2014-003022-40
MIPSO Vergleichende Untersuchung der bakteriellen
Mikrobiota in der Haut sowie dem Darm von Psoriasis-
Patienten vor und nach systemischer Behandlung mit
Adalimumab bzw. Ustekinumab oder Ciclosporin (EudraCT
2014-003022-40) Principal Investigator: Prof. Dr. Dr. h.c.
Thomas A. Luger
All rights reserved. Please visit https://medical-data-
models.org/forms/16594
Ciclosporin Psoriasis MIPSO
EudraCT 2014-003022-40
Cyclosporine
Patient ID
Page number
Signature date
Comments Cyclosporine
Cyclosporine medication
Start date
End date
Cyclosporine dose
mg
Cyclosporine intervall
daily (1)
every x day (2)
Cyclosporine intervall specification
day
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End of Study Psoriasis MIPSO EudraCT
2014-003022-40
MIPSO Comparative study of bacterial microbiota in the
skin and intestines of psoriasis patients before and after
systemic treatment with adalimumab or ustekinumab or
ciclosporin
(EudraCT 2014-003022-40)
Principal Investigator: Prof. Dr. Dr. H. C. Thomas A. Luger
All rights reserved. Please visit https://medical-data-
models.org/forms/16595
End of Study Psoriasis MIPSO
EudraCT 2014-003022-40
End of Study
Patient number
Date end of study
End of Study
regular end of study (1)
early study termination (2)
Early Study termination
Change of treatment required (1)
Cancelation of the entire study (10)
other reason (11)
Patient's request (2)
Inclusion/exclusion criteria were injured,
before initializing therapy (3)
Inclusion/exclusion criteria were injured,
after initializing therapy (4)
Entering pregnancy (5)
Disallowed concomitant medication
required (6)
The continued participation in the clinical
trial is medically no longer justifiable (7)
Time windows for visits could not be
complied with (8)
Lack of patient compliance (9)
End of Study Reason
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Physical Examinations MIPSO EudraCT
2014-003022-4
MIPSO Comparative study of bacterial microbiota in the
skin and intestines of psoriasis patients before and after
systemic treatment with adalimumab or ustekinumab or
ciclosporin (EudraCT 2014-003022-40) Principal
Investigator: Prof. Dr. Dr. H. C. Thomas A. Luger
All rights reserved. Please visit https://medical-data-
models.org/forms/16596
Physical Examinations MIPSO
EudraCT 2014-003022-4
Use of the form
Form has to be used several times. Please mark
the time of use.*
Screening (1)
Visite 1 (Baseline) (2)
Visite 2 (Week 4) (3)
Visite 3 (Week 8 (4)
Visite 4 (Week 12) (5)
Visite 5 (Week 16) (6)
Visite 6 (Week 20) (7)
Visite 7 (Week 24) (8)
Termination visite (9)
Physical Examination
Patient number
Visit date
Planned therapy
Adalimumab (1)
Ustekinumab (2)
Ciclosporin (3)
Body weight
kg
Identification of plaques for sampling (only
at 1st Visite)
Cutaneous plaque
Upper arm, ventral (1)
Flexor side of fingers (10)
Thigh, ventral (11)
Thigh, dorsal (12)
Patella (13)
Knee bend (14)
Lower leg, ventral (15)
Lower leg, dorsal (16)
Dorsum of foot (17)
Sole of Foot (18)
Toes (19)
Upper arm, dorsal (2)
Upper back (20)
Lower back (21)
Buttocks (22)
Rima ani (23)
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Chest (24)
Abdomen (25)
Umbilicus (26)
Elbow (3)
Crook (4)
Forearm, ventral (5)
Forearm, dorsal (6)
Back of hand (7)
Extensor side of fingers (8)
Palm (9)
non-lesional skin area
Upper arm, ventral (1)
Flexor side of fingers (10)
Thigh, ventral (11)
Thigh, dorsal (12)
Patella (13)
Knee bend (14)
Lower leg, ventral (15)
Lower leg, dorsal (16)
Dorsum of foot (17)
Sole of Foot (18)
Toes (19)
Upper arm, dorsal (2)
Upper back (20)
Lower back (21)
Buttocks (22)
Rima ani (23)
Chest (24)
Abdomen (25)
Umbilicus (26)
Elbow (3)
Crook (4)
Forearm, ventral (5)
Forearm, dorsal (6)
Back of hand (7)
Extensor side of fingers (8)
Palm (9)
Smear sample lesion
Yes
No
Biopsy lesion
Yes
No
Smear sample non-lesion
Yes
No
Biopsy non-lesion
Yes
No
Stool sample
Yes
No
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Physical Examination:
Screening/Termination visit
Body weight
kg
Height
cm
General condition
normal (1)
not normal (2)
General condition comment
Skin condition
normal (1)
not normal (2)
Skin condition comment
Head and Neck
normal (1)
not normal (2)
Head and Neck comment
Lymph nodes
normal (1)
not normal (2)
Lymph nodes comment
Thyroid gland
normal (1)
not normal (2)
Thyroid gland comment
Extremities
normal (1)
not normal (2)
Extremities comment
Cardiovascular system
normal (1)
not normal (2)
Cardiovascular system comment
Lung
normal (1)
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not normal (2)
Lung comment
Abdomen
normal (1)
not normal (2)
Abdomen comment
Nervous System
normal (1)
not normal (2)
Nervous System comment
Laboratory tests: Sampling performed
Smear sample lesion
Yes
No
Biopsy lesion
Yes
No
Stool sample
Yes
No
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Neurological History Cardiovascular Health
Study (CHS)
Documentation part: Record 22 Neurological History
The Cardiovascular Health Study (CHS) was initiated by
the National Heart, Lung and Blood Institute (NHLBI) in
1987 to determine the risk factors for development and
progression of cardiovascular disease (CVD) in older
adults, with an emphasis on subclinical measures. The
study recruited 5,888 adults aged 65 or older at entry in
four U.S. communities and conducted extensive annual
clinical exams between 1989-1999 along with semi-annual
phone calls, events adjudication, and subsequent data
analyses and publications. Additional data were collected
by studies ancillary to CHS. With the exception of annual
clinic visits, these activities are still ongoing.
Data obtained from: https://chs-nhlbi.org/
Permission granted by: Erika Enright.
All rights reserved. Please visit https://medical-data-
models.org/forms/16597
Neurological History Cardiovascular
Health Study (CHS)
Stroke
1. Has a doctor ever told you that you had a
stroke?
Don't know (Don't know)
No (No)
Yes (Yes)
2. What was the doctor's name and address?
Name:
City:
State:
3. Have you ever been hopitalized for a stroke?
Don't know (Don't know)
No (No)
Yes (Yes)
4. What was the hospital`s name and address?
Name:
City:
State:
What was the date of hospitalization?
*5. What problems or deficits did you have after
the stroke?
Weakness of: Left face
Yes
No
Is the weakness still present?
Yes
No
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*5. What problems or deficits did you have after
the stroke? Weakness of: Left arm/hand
Yes
No
Is the weakness still present?
Yes
No
*5. What problems or deficits did you have after
the stroke? Weakness of: Left leg/foot
Yes
No
Is the weakness still present?
Yes
No
*5. What problems or deficits did you have after
the stroke? Weakness of: Left side
Yes
No
*5. What problems or deficits did you have after
the stroke? Weakness of: Right side
Yes
No
Is the weakness still present?
Yes
No
*5. What problems or deficits did you have after
the stroke? Weakness of: Right face
Yes
No
Is the weakness still present?
Yes
No
*5. What problems or deficits did you have after
the stroke? Weakness of: Left arm/hand
Yes
No
Is the weakness still present?
Yes
No
*5. What problems or deficits did you have after
the stroke? Weakness of: Right leg/foot
Yes
No
Is the weakness still present?
Yes
No
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TIA
*6. Has a doctor ever told you that you had a
transient ischemic attack or TIA?
Don't know (Don't know)
No (No)
Yes (Yes)
7. What was the doctor's name and address?
Name:
City:
State:
8. Have you ever been hospitalized for a TIA?
Don't know (Don't know)
No (No)
Yes (Yes)
9. What was the hospital's name and address?
City:
State:
What was the date of hospitalization?
Sudden loss or change of speech
*10. In the past year have you had any sudden
loss or changes in speech?
Yes
No
11. How many episodes of loss or changes in
speech have you had?
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
6-20 (6-20)
more than 20 or frequent, intermittent
events, too numerous to count (more
than 20 or frequent, intermittent events,
too numerous to count)
12. When was the (most recent) episode?
1-6 months ago (1-6 months ago)
2-7 days ago (2-7 days ago)
7-12 months ago (7-12 months ago)
8-30 days ago (8-30 days ago)
in the past day (in the past day)
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more than a year ago (more than a year
ago)
13. How long did it (the longest episode) last?
at least 1 hour but less than 6 hours (at
least 1 hour but less than 6 hours)
at least 1 minute but less than 3 minutes
(at least 1 minute but less than 3
minutes)
at least 12 hours but less than 24 hours
(at least 12 hours but less than 24 hours)
at least 24 hours (at least 24 hours)
at least 3 minutes but less than 1 hour
(at least 3 minutes but less than 1 hour)
at least 30 seconds but less than 1
minute (at least 30 seconds but less than
1 minute)
at least 6 hours but less than 12 hours
(at least 6 hours but less than 12 hours)
less than 30 seconds (less than 30
seconds)
14. Did the (worst) episode come on suddenly?
Yes
No
15. How long did it take for the symptoms to get
as bad as they were going to get?
0-2 seconds (instantly) (0-2 seconds
(instantly))
at least 1 hour but less than 2 hours (at
least 1 hour but less than 2 hours)
at least 1 minute but less than 1 hour (at
least 1 minute but less than 1 hour)
at least 3 seconds but less than 1 minute
(at least 3 seconds but less than 1
minute)
16. Do any of the following describe your (worst
episode of) change in speech:
a. Slurred speech like you were drunk?
Yes
No
16. Do any of the following describe your (worst
episode of) change in speech:
b. Could talk but the wrong words came out?
Yes
No
16. Do any of the following describe your (worst
episode of) change in speech:
c. Knew what you wanted to say, but the words
would not come out?
Yes
No
16. Do any of the following describe your (worst
episode of) change in speech:
d. Could not think of right words?
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Yes
No
16. Do any of the following describe your (worst
episode of) change in speech:
e. If more than one, which of the above most
closely describes your problem?
a (a)
b (b)
c (c)
d (d)
e- Not applicable (e- Not applicable)
17. Numbness or tingling?
Yes
No
18. Did you have difficulty on:
both sides (both sides)
left side only (left side only)
right side only (right side only)
*19. Paralysis or weakness
Yes
No
20. Did you have difficulty on:
both sides (both sides)
left side only (left side only)
right side only (right side only)
*21. Lightheadedness, dizziness, or loss of
balance?
Yes
No
22. Blackouts or fainting?
Yes
No
23. Seizures or convulsions?
Yes
No
24. Headache?
Yes
No
25. Vision loss or blurring of vision?
Yes
No
26. Did you have:
Double vision
Yes
No
26. Did you have:
Vision loss in right eye only
Yes
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No
26. Did you have:
Vision loss in left eye only?
Yes
No
26. Did you have:
Total loss of vision in both eyes?
Yes
No
26. Did you have:
Trouble in both eyes seeing to the right
Yes
No
26. Did you have:
Trouble in both eyes seeing to the left?
Yes
No
26. Did you have:
Trouble in both eyes seeing to both sides or
straight ahead?
Yes
No
26. Did you have:
None of the above
Yes
No
Sudden loss of vision
*27. In the past year have you had any sudden
loss or blurring of vision, complete or partial?
Yes
No
28. How many episodes of loss or blurring of
vision have you had?
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
6-20 (6-20)
more than 20 or frequent, intermittent
events, too numerous to count (more
than 20 or frequent, intermittent events,
too numerous to count)
29. When was the (most recent) episode?
1-6 months ago (1-6 months ago)
2-7 days ago (2-7 days ago)
7-12 months ago (7-12 months ago)
8-30 days ago (8-30 days ago)
in the past day (in the past day)
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more than a year ago (more than a year
ago)
30. How long did it (the longest episode) last?
at least 1 hour but less than 6 hours (at
least 1 hour but less than 6 hours)
at least 1 minute but less than 3 minutes
(at least 1 minute but less than 3
minutes)
at least 12 hours but less than 24 hours
(at least 12 hours but less than 24 hours)
at least 24 hours (at least 24 hours)
at least 3 minutes but less than 1 hour
(at least 3 minutes but less than 1 hour)
at least 30 seconds but less than 1
minute (at least 30 seconds but less than
1 minute)
at least 6 hours but less than 12 hours
(at least 6 hours but less than 12 hours)
less than 30 seconds (less than 30
seconds)
31. Did the (worst) episode come on suddenly?
Yes
No
32. How long did it take for the symptoms to get
as bad as they were going to get?
0-2 seconds (instantly) (0-2 seconds
(instantly))
at least 1 hour but less than 2 hours (at
least 1 hour but less than 2 hours)
at least 1 minute but less than 1 hour (at
least 1 minute but less than 1 hour)
at least 3 seconds but less than 1 minute
(at least 3 seconds but less than 1
minute)
33. During the (worst) episode, which of the
following parts of your vision were affected:
both sides (both sides)
left side only (left side only)
right side only (right side only)
34. Did you have:
Trouble seeing to the right, but not to the left
Yes
No
34. Did you have:
Trouble seeing to the left, but not to the right
Yes
No
34. Did you have:
Trouble seeing to both sides or straight ahead
Yes
No
34. Did you have:
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Other
Yes
No
*35. Speech disturbance?
Yes
No
36. Numbness or tingling?
Yes
No
37. Did you have difficulty on:
both sides (both sides)
the left side only (the left side only)
the right side only (the right side only)
*38. Paralysis or weakness?
Yes
No
39. Did you have difficulty on:
both sides (both sides)
the left side only (the left side only)
the right side only (the right side only)
*40. Lightheadedness, dizziness, or loss of
balance?
Yes
No
41. Blackouts or fainting?
Yes
No
42. Seizures or convulsions?
Yes
No
43. Headache?
Yes
No
44. Flashing lights?
Yes
No
Double vision
*45. In the past year you had a sudden spell of
double vision, that is, did you see two objects
side by side, or one on top of the other?
Yes
No
46. If you closed one eye, did the double vision
go away?
Yes
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No
47. How many episodes of double vision have
you had?
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
6-20 (6-20)
more than 20 or frequent, intermittent
events, too numerous to count (more
than 20 or frequent, intermittent events,
too numerous to count)
48. When was the (most recent) episode?
1-6 months ago (1-6 months ago)
2-7 days ago (2-7 days ago)
7-12 months ago (7-12 months ago)
8-30 days ago (8-30 days ago)
in the past day (in the past day)
more than a year ago (more than a year
ago)
49. How long did it (the longest episode) last?
at least 1 hour but less than 6 hours (at
least 1 hour but less than 6 hours)
at least 1 minute but less than 3 minutes
(at least 1 minute but less than 3
minutes)
at least 12 hours but less than 24 hours
(at least 12 hours but less than 24 hours)
at least 24 hours (at least 24 hours)
at least 3 minutes but less than 1 hour
(at least 3 minutes but less than 1 hour)
at least 30 seconds but less than 1
minute (at least 30 seconds but less than
1 minute)
at least 6 hours but less than 12 hours
(at least 6 hours but less than 12 hours)
less than 30 seconds (less than 30
seconds)
50. Did the (worst) episode come on suddenly?
Yes
No
51. How long did it take for the symptoms to get
as bad as they were going to get?
0-2 seconds (instantly) (0-2 seconds
(instantly))
at least 1 hour but less than 2 hours (at
least 1 hour but less than 2 hours)
at least 1 minute but less than 1 hour (at
least 1 minute but less than 1 hour)
at least 3 seconds but less than 1 minute
(at least 3 seconds but less than 1
minute)
52. Speech disturbance?
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Yes
No
53. Numbness or tingling?
Yes
No
54. Did you have difficulty on:
both sides (both sides)
the left side only (the left side only)
the right side only (the right side only)
*55. Paralysis or weakness?
Yes
No
56. Did you have difficulty on:
both sides (both sides)
the left side only (the left side only)
the right side only (the right side only)
*57. Lightheadedness, dizziness, or loss of
balance?
Yes
No
58. Blackouts or fainting?
Yes
No
59. Seizures or convulsions?
Yes
No
60. Headache?
Yes
No
Sudden numbness or tingling
*61. In the past year have you had sudden
numbness, tingling, or loss of feeling on one side
of your body, including your face, arm or leg?
Yes
No
62. Did the feeling of numbness or tingling occur
only when you kept your arms or legs in a certain
position?
Yes
No
63. How many episodes of numbness, tingling, or
loss of sensation have you had?
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
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6-20 (6-20)
more than 20 or frequent, intermittent
events, too numerous to count (more
than 20 or frequent, intermittent events,
too numerous to count)
64. When was the (most recent) episode?
1-6 months ago (1-6 months ago)
2-7 days ago (2-7 days ago)
7-12 months ago (7-12 months ago)
8-30 days ago (8-30 days ago)
in the past day (in the past day)
more than a year ago (more than a year
ago)
65. How long did it (the longest episode) last?
at least 1 hour but less than 6 hours (at
least 1 hour but less than 6 hours)
at least 1 minute but less than 3 minutes
(at least 1 minute but less than 3
minutes)
at least 12 hours but less than 24 hours
(at least 12 hours but less than 24 hours)
at least 24 hours (at least 24 hours)
at least 3 minutes but less than 1 hour
(at least 3 minutes but less than 1 hour)
at least 30 seconds but less than 1
minute (at least 30 seconds but less than
1 minute)
at least 6 hours but less than 12 hours
(at least 6 hours but less than 12 hours)
less than 30 seconds (less than 30
seconds)
66. Did the (worst) episode come on suddenly?
Yes
No
67. How long did it take for the symptoms to get
as bad as they were going to get?
0-2 seconds (instantly) (0-2 seconds
(instantly))
at least 1 hour but less than 2 hours (at
least 1 hour but less than 2 hours)
at least 1 minute but less than 1 hour (at
least 1 minute but less than 1 hour)
at least 3 seconds but less than 1 minute
(at least 3 seconds but less than 1
minute)
68. During the (worst) episode, which part or
parts of your body were affected:
A. Left arm or hand?
Yes
No
68. During the (worst) episode, which part or
parts of your body were affected:
B. Left leg or foot?
Yes
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No
68. During the (worst) episode, which part or
parts of your body were affected:
C. Left side of face?
Yes
No
68. During the (worst) episode, which part or
parts of your body were affected:
D. Right arm or hand?
Yes
No
68. During the (worst) episode, which part or
parts of your body were affected:
E. Right foot or leg
Yes
No
68. During the (worst) episode, which part or
parts of your body were affected:
F. Right side of face?
Yes
No
68. During the (worst) episode, which part or
parts of your body were affected:
G. Other?
Yes
No
69. During this episode, did the abnormal
sensation start in one part of your body and
spread to another, or did it stay in the same
place?
In one part and spread to another (In
one part and spread to another)
Stayed in one part (Stayed in one part)
70. Speech disturbance?
Yes
No
71. Paralysis or weakness?
Yes
No
72. Did you have difficulty on:
both sides (both sides)
the left side only (the left side only)
the right side only (the right side only)
*73. Lightheadedness, dizziness, or loss of
balance
Yes
No
74. Blackouts or fainting?
Yes
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No
75. Seizures or convulsions?
Yes
No
76. Headache?
Yes
No
77. Pain in the numb or tingling arm, leg of face?
Yes
No
78. Vision loss or blurring of vision?
Yes
No
79. Did you have:
Double vision?
Yes
No
79. Did you have:
Vision loss in right eye only?
Yes
No
79. Did you have:
Total loss of vision in both eyes?
Yes
No
79. Did you have:
Trouble in both eyes seeing to the right?
Yes
No
79. Did you have:
Trouble in both eyes seeing to the left?
Yes
No
79. Did you have:
Trouble in both eyes seeing to both sides or
straight ahead?
Yes
No
79. Did you have:
None of the above?
Yes
No
Sudden paralysis or weakness
*80. In the past year have you had any sudden
episodes of paralysis or weakness on one side of
your body, including your face, arm, or leg?
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Yes
No
81. How many episodes of paralysis or weakness
have you had?
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
6-20 (6-20)
more than 20 or frequent, intermittent
events, too numerous to count (more
than 20 or frequent, intermittent events,
too numerous to count)
82. When was the (most recent) episode?
1-6 months ago (1-6 months ago)
2-7 days ago (2-7 days ago)
7-12 months ago (7-12 months ago)
8-30 days ago (8-30 days ago)
in the past day (in the past day)
more than a year ago (more than a year
ago)
83. How long did it (the longest episode) last?
at least 1 hour but less than 6 hours (at
least 1 hour but less than 6 hours)
at least 1 minute but less than 3 minutes
(at least 1 minute but less than 3
minutes)
at least 12 hours but less than 24 hours
(at least 12 hours but less than 24 hours)
at least 24 hours (at least 24 hours)
at least 3 minutes but less than 1 hour
(at least 3 minutes but less than 1 hour)
at least 30 seconds but less than 1
minute (at least 30 seconds but less than
1 minute)
at least 6 hours but less than 12 hours
(at least 6 hours but less than 12 hours)
less than 30 seconds (less than 30
seconds)
84. Did the (worst) episode come on suddenly?
Yes
No
85. How long did it take for the symptoms to get
as bad as they were going to get?
0-2 seconds (instantly) (0-2 seconds
(instantly))
at least 1 hour but less than 2 hours (at
least 1 hour but less than 2 hours)
at least 1 minute but less than 1 hour (at
least 1 minute but less than 1 hour)
at least 3 seconds but less than 1 minute
(at least 3 seconds but less than 1
minute)
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86. During the (worst) episode, which part or
parts of your body were affected:
A. Left arm or hand?
Yes
No
86. During the (worst) episode, which part or
parts of your body were affected:
B. Left leg or foot?
Yes
No
86. During the (worst) episode, which part or
parts of your body were affected:
C. Left side of face?
Yes
No
86. During the (worst) episode, which part or
parts of your body were affected:
D. Right arm or hand?
Yes
No
86. During the (worst) episode, which part or
parts of your body were affected:
E. Right foot or leg
Yes
No
86. During the (worst) episode, which part or
parts of your body were affected:
F. Right side of face?
Yes
No
86. During the (worst) episode, which part or
parts of your body were affected:
G. Other?
Yes
No
87. During this episode, did the paralysis or
weakness start in one part of your body and
spread to another, or did it stay in the same
place?
In one part and spread to another (In
one part and spread to another)
Stayed in one part (Stayed in one part)
88. Speech disturbance
Yes
No
89. Numbness or tingling?
Yes
No
90. Did you have difficulty on:
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both sides (both sides)
the left side only (the left side only)
the right side only (the right side only)
*91. Lightheadedness, dizziness, or loss of
balance?
Yes
No
92. Blackouts or fainting?
Yes
No
93. Seizures or convulsions?
Yes
No
94. Headache?
Yes
No
95. Pain in the numb or tingling arm, leg or face?
Yes
No
96. Vision loss or blurring of vision?
Yes
No
97. Did you have:
Double vision?
Yes
No
97. Did you have:
Vision loss in right eye only?
Yes
No
97. Did you have:
Total loss of vision in both eyes?
Yes
No
97. Did you have:
Trouble in both eyes seeing to the right?
Yes
No
97. Did you have:
Trouble in both eyes seeing to the left?
Yes
No
97. Did you have:
Trouble in both eyes seeing to both sides or
straight ahead?
Yes
No
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97. Did you have:
None of the above?
Yes
No
Dizziness or loss of balance
*98. In the past year have you had any sudden
spells of dizziness, loss of balance, or sensation
of spinning?
Yes
No
99. Did the dizziness, loss of balance or spinning
sensation occur only when changing the position
of your head or body?
Yes
No
100. How many episodes of dizziness, loss of
balance or spinning sensation have you had?
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
6-20 (6-20)
more than 20 or frequent, intermittent
events, too numerous to count (more
than 20 or frequent, intermittent events,
too numerous to count)
101. When was the (most recent) episode?
1-6 months ago (1-6 months ago)
2-7 days ago (2-7 days ago)
7-12 months ago (7-12 months ago)
8-30 days ago (8-30 days ago)
in the past day (in the past day)
more than a year ago (more than a year
ago)
102. How long did it (the longest episode) last?
at least 1 hour but less than 6 hours (at
least 1 hour but less than 6 hours)
at least 1 minute but less than 3 minutes
(at least 1 minute but less than 3
minutes)
at least 12 hours but less than 24 hours
(at least 12 hours but less than 24 hours)
at least 24 hours (at least 24 hours)
at least 3 minutes but less than 1 hour
(at least 3 minutes but less than 1 hour)
at least 30 seconds but less than 1
minute (at least 30 seconds but less than
1 minute)
at least 6 hours but less than 12 hours
(at least 6 hours but less than 12 hours)
less than 30 seconds (less than 30
seconds)
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103. Did the (worst) episode come on suddenly?
Yes
No
104. How long did it take for the symptoms to get
as bad as they were going to get?
0-2 seconds (instantly) (0-2 seconds
(instantly))
at least 1 hour but less than 2 hours (at
least 1 hour but less than 2 hours)
at least 1 minute but less than 1 hour (at
least 1 minute but less than 1 hour)
at least 3 seconds but less than 1 minute
(at least 3 seconds but less than 1
minute)
105. Speech disturbance?
Yes
No
106. Paralysis or weakness?
Yes
No
107. Did you have difficulty on:
both sides (both sides)
the left side only (the left side only)
the right side only (the right side only)
*108. Numbness or tingling?
Yes
No
109. Did you have difficulty on:
both sides (both sides)
the left side only (the left side only)
the right side only (the right side only)
*110. Blackouts or fainting?
Yes
No
111. Seizures or convulsions?
Yes
No
112. Headache?
Yes
No
113. Vision loss or blurring of vision?
Yes
No
114. Did you have:
Double vision
Yes
No
114. Did you have:
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Vision loss in right eye only?
Yes
No
114. Did you have:
Vision loss in left eye only?
Yes
No
114. Did you have:
Total loss of vision in both eyes
Yes
No
114. Did you have:
Trouble in both eyes seeing to the right?
Yes
No
114. Did you have:
Trouble in both eyes seeing to the left?
Yes
No
114. Did you have:
Trouble in both eyes seeing to both sides or
straight ahead?
Yes
No
114. Did you have:
None of the above?
Yes
No
*115: Spinning sensation, vertigo?
Yes
No
116. Loss of balance?
Yes
No
117. Difficulty walking?
Yes
No
118. Blackouts or fainting?
Yes
No
119. Frequent falls?
Yes
No
120. Do you usually get dizzy or light-headed
when you stand up quickly?
Yes
No
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Date of interview
Interviewer
Interview:
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PASI Psoriasis MIPSO EudraCT 2014-
003022-40
MIPSO Vergleichende Untersuchung der bakteriellen
Mikrobiota in der Haut sowie dem Darm von Psoriasis-
Patienten vor und nach systemischer Behandlung mit
Adalimumab bzw. Ustekinumab oder Ciclosporin (EudraCT
2014-003022-40) Principal Investigator: Prof. Dr. Dr. h.c.
Thomas A. Luger
All rights reserved. Please visit https://medical-data-
models.org/forms/16598
PASI Psoriasis MIPSO EudraCT
2014-003022-40
Use of the form
Form has to be used several times. Please mark
the time of use.*
Screening (1)
Visite 1 (Baseline) (2)
Visite 2 (Week 4) (3)
Visite 3 (Week 8) (4)
Visite 4 (Week 12) (5)
Visite 5 (Week 16) (6)
Visite 6 (Week 20) (7)
Visite 7 (Week 24) (8)
Termination visite (9)
Psoriasis Area and Severity Index
Erythema Head / Neck
none (0)
mild (1)
moderate (2)
severe (3)
very severe (4)
Erythema Arms
none (0)
mild (1)
moderate (2)
severe (3)
very severe (4)
Erythema Hull
none (0)
mild (1)
moderate (2)
severe (3)
very severe (4)
Erythema Legs
none (0)
mild (1)
moderate (2)
severe (3)
very severe (4)
Induration Head / Neck
none (0)
mild (1)
moderate (2)
severe (3)
very severe (4)
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Induration Arms
none (0)
mild (1)
moderate (2)
severe (3)
very severe (4)
Induration Hull
none (0)
mild (1)
moderate (2)
severe (3)
very severe (4)
Induration Legs
none (0)
mild (1)
moderate (2)
severe (3)
very severe (4)
Desquamation Head / Neck
none (0)
mild (1)
moderate (2)
severe (3)
very severe (4)
Desquamation Arms
none (0)
mild (1)
moderate (2)
severe (3)
very severe (4)
Desquamation Hull
none (0)
mild (1)
moderate (2)
severe (3)
very severe (4)
Desquamation Legs
none (0)
mild (1)
moderate (2)
severe (3)
very severe (4)
Subtotal A1
>= 0
<= 12
Subtotal A2
>= 0
<= 12
Subtotal A3
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>= 0
<= 12
Subtotal A4
>= 0
<= 12
Affected Area Head / Neck
0% (0)
<10% (1)
≥10-29% (2)
≥30-49% (3)
≥50-69% (4)
≥70-89% (5)
≥90-100% (6)
Affected Area Arms
0% (0)
<10% (1)
≥10-29% (2)
≥30-49% (3)
≥50-69% (4)
≥70-89% (5)
≥90-100% (6)
Affected Area
0% (0)
<10% (1)
≥10-29% (2)
≥30-49% (3)
≥50-69% (4)
≥70-89% (5)
≥90-100% (6)
Affected Area Legs
0% (0)
<10% (1)
≥10-29% (2)
≥30-49% (3)
≥50-69% (4)
≥70-89% (5)
≥90-100% (6)
Subtotal B1
>= 0
<= 72
Subtotal B2
>= 0
<= 72
Subtotal B3
>= 0
<= 72
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Subtotal B4
>= 0
<= 72
Subtotal
>= 0
<= 7,2
Subtotal
>= 0
<= 14,4
Subtotal
>= 0
<= 21,6
Subtotal
>= 0
<= 28,8
PASI Total
>= 0
<= 72
BSA
>= 0
<= 100
%
Signature date
PASI Comments
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Eligibility Cardiovascular Disease
NCT00520871
The Water-Blueberry Study; ODM derived from:
https://clinicaltrials.gov/show/NCT00520871
All rights reserved. Please visit https://medical-data-
models.org/forms/16599
Eligibility Cardiovascular Disease
NCT00520871
Inclusion Criteria
30-70 years for men and 45-70 years or at least
12 months postmenopausal for women*
Yes
No
at least one elevated cardiovascular risk factor,
defined as systolic blood pressure between 140
and 165 mmhg, diastolic blood pressure between
90 and 105 mmhg, low density lipoprotein (ldl)
cholesterol ≥3.4 mmol/l, total/high density
lipoprotein (hdl) cholesterol ratio >4 or smoking a
minimum of 3 cigarettes daily.*
Yes
No
Exclusion Criteria
clinically recognized chronic diseases as
impaired renal function, diabetes mellitus,
cardiovascular disease, liver or gastrointestinal
disease or cancer within the last 5 years*
Yes
No
use of lipid-lowering drugs, diuretics or hormone
replacement therapy for women*
Yes
No
subjects with a body-mass index ≥31*
Yes
No
with a alcohol consumption above 3 units/day for
men and 1 unit/day for women*
Yes
No
blood donation within the last six months*
Yes
No
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Eligibility Cardiovascular Disease
NCT00569751
TAXUS ARRIVE 2: A Multi-Center Safety Surveillance
Program; ODM derived from:
https://clinicaltrials.gov/show/NCT00569751
All rights reserved. Please visit https://medical-data-
models.org/forms/16600
Eligibility Cardiovascular Disease
NCT00569751
Criteria
patient is eligible to receive a boston scientific
taxus stent*
Yes
No
inappropriate patient criteria:*
Yes
No
known sensitivity to paclitaxel.*
Yes
No
known allergy to stainless steel.*
Yes
No
patients in whom antiplatelet and / or
anticoagulant therapy is contraindicated.*
Yes
No
patients judged to have a lesion that prevents
complete inflation of an angioplasty balloon or
proper placement of the stent or delivery device.*
Yes
No
patients with unresolved vessel thrombus at the
lesion site.*
Yes
No
patients with coronary artery reference vessel
diameters less than 2.5 mm or greater than 3.75
mm.*
Yes
No
patients with lesions located in the left main
coronary artery, ostial lesions, or lesions located
at a bifurcation.*
Yes
No
patients with diffuse disease or poor overflow
distal to the identified lesions.*
Yes
No
patients with tortuous vessels in the region of the
obstruction or proximal to the lesion.*
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Yes
No
patients with a recent acute myocardial infarction
where there is evidence of thrombus or poor
flow.*
Yes
No
2 / 2
Eligibility Cardiovascular Disease NCT00569751
EBMT Haemoglobinopathy General
Information
ODM form derived from 113pp EBMT Haemoglobinopathy
12Hgbpthy.pdf refer to: http://www.ebmt.org/Contents/Data-
Management/Registrystructure/MED-
ABdatacollectionforms/Pages/MED-AB-data-collection-
forms.aspx
All rights reserved. Please visit https://medical-data-
models.org/forms/16601
EBMT Haemoglobinopathy General
Information
GENERAL INFORMATION
GENERAL INFORMATION
Hospital
Unit
Name of a Contact Person
Telephone number of contact person
Fax
E-mail
Date of this report
Patient following national / international study /
trial
No (1)
Yes (2)
Not evaluated (3)
Unknown (4)
Name of study / trial
Patient
Unique Identification Code (UIC)
Hospital Unique Patient Number or Code
First name(s) - surname(s)
(Registration will not be accepted if this item is
left blank)
Date of birth
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Sex
Male (1)
Female (2)
ABO Group
Rh factor
Absent (1)
Present (2)
Not evaluated (3)
DISEASE
Date of diagnosis
Primary Disease Diagnosis
Acute Leukaemia (Acute Leukaemia)
Autoimmune Disease (Autoimmune
Disease)
Bone marrow failure including Aplastic
Anaemia (Bone marrow failure including
Aplastic Anaemia)
Chronic Leukaemia (Chronic Leukaemia)
Chronic Lymphocytic Leukaemia
(Chronic Lymphocytic Leukaemia (CLL))
Chronic Myeloid Leukaemia (CML)
(Chronic Myeloid Leukaemia (CML))
Haemoglobinopathy
(Haemoglobinopathy)
Histiocytic Disorders (Histocytic
Disorders)
Hodgkin´s Disease (Hodgkin´s Disease)
Inherited disorders (Inherited disorders)
Juvenile Idiopathic Arthritis (Juvenile
Idiopathic Arthritis)
Lymphoblastic (ALL) (Lymphoblastic
(ALL))
Lymphoma (Lymphoma)
MD/ MPN (MD/ MPN)
MDS (MDS)
Metabolic disorders (Metabolic
disorders)
Multiple Sclerosis (Multiple Sclerosis)
Myelodysplastic Syndromes
(Myelodysplastic Syndromes)
Myelogenous (AML) (Myelogenous
(AML))
Myeloma/ Plasma Cell Disorder
(Myeloma/ Plasma Cell Disorder)
Myeloproliferative neoplasm
(Myeloproliferative neoplasm)
Non Hodgkin (Non Hodgkin)
Other diagnosis (Other diagnosis)
Primary immune deficiencies (Primary
immune deficiencies)
Secondary Acute Leukaemia (Do not
use if transformed from MDS/ MPN)
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(Secondary Acute Leukaemia (Do not
use if transformed from MDS/ MPN))
Solid Tumor (Solid Tumor)
Systemic Lupus (Systemic Lupus)
Systemic Sclerosis (Systemic Sclerosis)
Disease Diagnosis
Thalassemia (1)
Other thalassemia (2)
Sickle cell anaemia (3)
Compound Heterozygous States (4)
Other, specify (5)
Typ of Thalassemia
ß° (1)
ß+ (2)
If use other diagnosis, specification
Sickle cell anaemia (ßS) %
Sickle (ßS) %
PRE-HSCT BIOLOGICAL FEATURES
Done (1)
Not evaluated (2)
PRE-HSCT MAIN CLINICAL FEATURES
Splenomegaly (1)
Hepatomegaly (2)
Diabetes (3)
Splenomegaly present?
Absent (1)
Present (2)
Not applicable (3)
Splenomegaly: Spleen size
cm under costal margin
Hepatomegaly
Absent (1)
Present (2)
Hepatomegaly
cm under costal margin
Diabetes
no (1)
yes (2)
Diabetes
Insulin required occasionally (1)
Insulin required regularly (2)
CLINICAL FEATURES AND
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COMPLICATIONS
Gonadal dysfunction
Absent (1)
Present (2)
Not evaluated (3)
Unknown (4)
Substitutional hormonal therapy
Absent (1)
Present (2)
Not evaluated (3)
Unknown (4)
Growth impairment
Absent (1)
Present (2)
Not evaluated (3)
Unknown (4)
Red blood cell immunization
Absent (1)
Present (2)
Not evaluated (3)
Unknown (4)
Sickle nephropathy (glomerular filtration rate 30-
50% predicted)
Absent (1)
Present (2)
Not evaluated (3)
Unknown (4)
Central nervous system haemorrhage
Absent (1)
Present (2)
Not evaluated (3)
Unknown (4)
Recurrent acute chest syndrome
Absent (1)
Present (2)
Not evaluated (3)
Unknown (4)
Impaired neuropsychologic function and
abnormal
Magnetic Resonance Imaging scan
Absent (1)
Present (2)
Not evaluated (3)
Unknown (4)
Bilateral proliferative retinopathy and visual
impairment
Absent (1)
Present (2)
Not evaluated (3)
Unknown (4)
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Osteonecrosis of multiple joints
Absent (1)
Present (2)
Not evaluated (3)
Unknown (4)
If Other CLINICAL ABNORMALITIES
INDICATING THE SEVERITY OF THE PRIMARY
DISEASE
If DISEASES NOT RELATED TO THE
TREATMENT OF HEMOGLOBINOPATHY
CHELATION TREATMENT PRE-HSCT
Yes (1)
Irregular (2)
Regular (3)
NO (4)
If CHELATION TREATMENT PRE-HSCT
STATUS OF DISEASE AT HSCT
Date of HSCT
Splenectomy
no (1)
yes (2)
Date of Splenectomy
RBC Transfusions
no (1)
yes (2)
if RBC Transfusions: Age at transfusion (months)
if RBC Transfusions: Total number of RBC units
transfused
Enzymes
LDH Value
LDH unit
LDH Times Upper Limit
LDH not evaluated
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AST (SGOT)
Unit  (1)
Times upper limit  (2)
not evaluated   (3)
Value (4)
ALT (SGPT)
Unit (1)
Times Upper Limit (2)
not evaluated  (3)
Value (4)
Gamma GT
Value (1)
Times Upper Limit  (2)
Not Evaluated (3)
Albumin
Not evaluated (1)
Bilirubin
mg/dl
Direct bilirubin  (1)
Not evaluated   (2)
Total serum bilirubin (3)
Ferritin
ng/ml
Not evaluated (1)
Total Transferrin
mg/dl
Not evaluated (1)
Unbounded Transferrin
mg/dl
LIVER FUNCTION
Evidence of hepatitis or other liver disease
no (1)
yes (2)
Types of Hepatitis
Hepatitis B (1)
Hepatitis C (2)
Hepatitis unspecified (3)
other (4)
Liver biopsy performed
no (1)
yes (2)
RESULTS OF LIVER BIOPSY
Hepatitis
Chronic persistent hepatitis (1)
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Chronic active hepatitis (2)
Absent (3)
Siderosis
Present (1)
Mild (2)
Moderate (3)
Severe (4)
Absent (5)
Fibrosis
Present (1)
Absent (2)
if Fibrosis Present
Present without bridging (1)
Present with complete porto-portal
and/or porto-central bridging (2)
Present with cirrhosis (3)
CARDIAC FUNCTION
History of cardiac insufficiency:
no (1)
yes (2)
if History of cardiac insufficiency: Type of therapy
no (1)
yes (2)
unknown (3)
Left Ventricular Ejection Fraction
%
not evaluated (1)
OTHER CLINICALLY SIGNIFICANT ORGAN
INVOLVEMENT
no (1)
yes (2)
CLASS
No hepatomegaly (or < 3 cm), No
fibrosis, Regular chelation (1)
One or two of these conditions (2)
Hepatomegaly (= 3 cm), Fibrosis, and
Irregular chelation (3)
ADDITIONAL TREATMENT POST-HSCT
ADDITIONAL DISEASE TREATMENT
no (1)
yes (2)
if ADDITIONAL DISEASE TREATMENT
Planned (planned before HSCT took
place) (1)
Not planned (for relapse/progression or
persistent disease) (2)
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FORMS TO BE FILLED IN
Type of Transplant
ALLOgraft or Syngeneic graft (proceed to
Allograft form) (ALLOgraft or Syngeneic
graft (proceed to Allograft form))
AUTOgraft (proceed to Autograft form)
(AUTOgraft (proceed to Autograft form))
Other (contact the EBMT Central
Registry for instructions) (Other (contact
the EBMT Central Registry for
instructions))
if other Type of Transplant
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Palliative and Hospice Care Drug Plan
https://www.hope-clara.de/ 
The HOPE Hospice and Palliative Care Recording standard
documentation is used for documentation of palliative care
and as an instrument for quality assurance in pallatiave
wards, hospices and oncological wards as well as in
ambulatory services and palliative teams.
All rights reserved. Please visit https://medical-data-
models.org/forms/16603
Palliative and Hospice Care Drug
Plan
Basistherapie (regelmäßig)
Medikament
8 Uhr
12 Uhr
16 Uhr
20 Uhr
24 Uhr
4 Uhr
Indikation
Ondemand Therapy
Medikament
Dosierung und Zeitabstand
Indikation
Rescue Medication
Medikation
Dosierung und Zeitabstand
Indikation
Adminstrative data
13. Datum
1 / 2
1. IDNR
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EBMT Haemoglobinopathy follow up form
ODM form derived from EBMT Haemoglobinopathy please
refer to: http://www.ebmt.org/Contents/Data-
Management/Registrystructure/MED-
ABdatacollectionforms/Pages/MED-AB-data-collection-
forms.aspx 
All rights reserved. Please visit https://medical-data-
models.org/forms/16604
EBMT Haemoglobinopathy follow up
form
FOLLOW UP Haemoglobinopathy
Unique Identification Code (UIC)
(if known)
Date of this report
Patient following national / international study /
trial
No (1)
Yes (2)
Not evaluated (3)
Unknown (4)
Name of study / trial
Hospital Unique Patient Number
First name(s)_surname(s)
Date of Birth
Date of last HSCT for this patient
DATE OF LAST CONTACT OR DEATH
GRAFT VERSUS HOST DISEASE
(GvHD) SINCE LAST REPORT
Acute Graft versus Host Disease (aGvHD) -
Maximum grade
grade 0 (absent) (grade 0 (absent))
grade I (grade I)
grade II (grade II)
grade III (grade III)
grade IV (grade IV)
not evaluated (not evaluated)
If present GvHD, Maximum grade
New onset (1)
Recurrent (2)
Persistent (3)
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Reason Maximum grade
Tapering (1)
DLI (2)
Unexplained (3)
Date onset of this episode (if new or recurrent)
yyyy/mm/dd
Date onset of this episode
Not applicable (1)
aGvHD Stage Skin
0 (1)
1 (2)
2 (3)
3 (4)
4 (5)
Not evaluated (6)
unknown (7)
aGvHD Stage liver
0 (1)
1 (2)
2 (3)
3 (4)
4 (5)
Not evaluated (6)
unknown (7)
aGvHD stage gut
0 (1)
1 (2)
2 (3)
3 (4)
4 (5)
Not evaluated (6)
unknown (7)
Resolution
No  (1)
Yes (2)
aGvHD Date of resolutions
Presence of cGvHD
No (No)
Present continuously since last reported
episode (Present continuously since last
reported episode)
Resolved (Resolved)
Yes (Yes)
Date of onset
cGvHD grade
limited (1)
Extensive (2)
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Organs affected
Skin (1)
Gut (2)
Liver (3)
Mouth (4)
Eyes (5)
Lung (6)
Other, specify (7)
Unknown (8)
If other organs affected, please specify
cGvHD Resolved: Date of resolution
OTHER COMPLICATIONS SINCE LAST
REPORT
INFECTION RELATED COMPLICATIONS
No complications (1)
Yes (2)
Bacteremia / fungemia / viremia / parasites
Pathogen (1)
Date (2)
Septic shock
Pathogen  (1)
Date (2)
ARDS
Pathogen  (1)
Date (2)
Multiorgan failure due to infection
Pathogen  (1)
Date (2)
Pneumonia
Pathogen  (1)
Date (2)
Hepatitis
Pathogen  (1)
Date (2)
CNS infection
Pathogen  (1)
Date (2)
Gut infection
Pathogen  (1)
Date (2)
Skin infection
Pathogen  (1)
Date (2)
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Cystitis
Date (Date)
Pathogen (Pathogen)
Retinitis
Date (Date)
Pathogen (Pathogen)
Other pathogen specified
NON INFECTION RELATED COMPLICATIONS
No complications (1)
Yes (2)
Idiopathic pneumonia syndrome
No  (No )
Unknown (Unknown)
Yes (Yes)
VOD
No  (No )
Unknown (Unknown)
Yes (Yes)
Cataract
No (No)
Unknown (Unknown)
Yes (Yes)
Haemorrhagic cystitis, non infectious
No  (No )
Unknown (Unknown)
Yes  (Yes )
Specify:
ARDS, non infectious
No (No)
Unknown (Unknown)
Yes (Yes)
Multiorgan failure, non infectious
no  (no )
unknown (unknown)
yes  (yes )
HSCT-associated microangiopathy
Date (4)
No (No)
Unknown (Unknown)
Yes (Yes)
Renal failure requiring dialysis
Date (Date)
No (No)
Unknown (Unknown)
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Yes (Yes)
Haemolytic anaemia due to blood group
Date (4)
No (No)
Unknown (Unknown)
Yes (Yes)
Aseptic bone necrosis
Date (Date)
No (No)
Unknown (Unknown)
Yes (Yes)
Other type of NON INFECTION RELATED
COMPLICATIONS, please specify
Idiopathic pneumonia syndrome
Graft loss
No (No)
Not evaluated (Not evaluated)
Yes (Yes)
Overall chimaerism
Full (donor >95%) (1)
Mixed (partial) (2)
Autologuos reconstitution (recipient >
95%) (3)
Aplasia (4)
Not evaluated (5)
Date of test
(Indicate the date(s) and results of all tests done
for all donors. Split the results by donor and by
the cell type on which the test was performed if
applicable. Copy this table as many times as
necessary.)
Identification of donor or Cord Blood Unit given
by the centre
Number in the infusion order (if applicable)
Cell type on which test was performed % Donor
cells
B-Cells
%
BM (1)
Other, specify (10)
PB mononuclear cells (PBMC) (2)
5 / 11
EBMT Haemoglobinopathy follow up form
T-cell (3)
B-cells (4)
Red blood cells (5)
Monocytes (6)
PMNs (neutrophils) (7)
Lymphocytes, NOS (8)
Myeloid cells, NOS (9)
Laboratory tests used
ABO group (ABO group)
Cytogenetic (Cytogenetic)
FISH (FISH)
Molecular (Molecular)
Other (Other)
unknown (unknown)
Test used:
If other, specify:
SECONDARY MALIGNANCY,
LYMPHOPROLIFERATIVE OR
MYELOPROLIFRATIVE DISORDER
DIAGNOSED
No at date of this follow-up (No at date of
this follow-up)
Previously reported (Previously reported)
Yes (Yes)
Date of Diagnosis
Diagnosis OTHER COMPLICATIONS SINCE
LAST REPORT
AML (AML)
Lymphoproliferative disorder
(Lymphoproliferative disorder)
MDS (MDS)
Other (Other)
Diagnosis, other:
ADDITIONAL THERAPIES SINCE LAST
FOLLOW UP
Additional treatment given since last report
Date (4)
No (No)
Unknown (Unknown)
Yes (Yes)
If treatment given since last report
If yes: Cellular therapy (One cell therapy regimen
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is defined as any number of infusions given within
10 weeks for the same indication. If more than
one regimen of cell therapy has been given since
last report, copy this section and complete it as
many times as necessary.)
No  (1)
Yes (Mark disease status before this
cellular therapy) (2)
Unknown (3)
Disease status before this cellular therapy
CR (CR)
Not evaluated (Not evaluated)
Not in CR (Not in CR)
If yes: Type of cells
Donor lymphocyte infusion (DLI) (1)
Mesenchymal cells (2)
Other (3)
Unknown (4)
If other
Chronological number of this cell therapy for this
patient
Number of Nucleated cells infused (DLI only)
10^8/kg
Number (1)
Not evaluated (2)
Unknown (3)
If DLI, specify the number of cells infused by
type:
CD 34+
Evaluated (Evaluated)
Not Evaluated (Not Evaluated)
Unknown (Unknown)
If DLI, specify the number of cells infused by
type: 
CD 3+
Evaluated  (Evaluated )
Not evaluated (Not evaluated)
Unknown (Unknown)
If non DLI, specify total number of cells infused:
Evaluated (Evaluated)
Not Evaluated (Not Evaluated)
Unknown (Unknown)
Cell therapy indication
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Planned/protocol  (1)
Treatment for disease (2)
Prophylactic (3)
Mixed chimaerism (4)
Treatment of GvHD  (5)
Treatment viral infection (6)
Loss/decreased chimaerism  (7)
Treatment PTLD, EBV lymphoma (8)
Other, specify (9)
Number of infusions within 10 weeks (count only
infusions that are part of same regimen and given
for the same indication)
Acute Graft versus Host Disease 
(after this infusion but before any further infusion/
transplant)
Maximum grade:
grade 0 (absent) (grade 0 (absent))
grade 1 (grade 1)
grade 2 (grade 2)
grade 3 (grade 3)
grade 4 (grade 4)
present, grade unknown (present, grade
unknown)
Disease treatment (apart from donor cell infusion
or other type of cell therapy)
No (1)
Yes: Planned (planned before HSCT took
place) (2)
Yes: Not planned (for
relapse/progression or persistent
disease) (3)
Date started
Overall main reason ADDITIONAL THERAPIES
Relapse/progression (1)
Continued from pre-HSCT (2)
unknow (3)
Planned per protocol (4)
Other (5)
Of Other, please specify
Drugs
no (no)
unknown (unknown)
yes (yes)
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If yes, mark appropriate box
Alpha interferon (Alpha interferon)
Anti-lymphocyte antibodies (Anti-
lymphocyte antibodies)
Azathioprine (Azathioprine)
Interferon Beta  (Beta Interferon)
low dose (Chronic low dose)
CopI (Cop-I)
Corticosteroids (Corticosteroids)
Cyclophosphamide (Cyclophosphamide)
Mitoxantron (Mitoxantron)
high dose (Pulse high dose)
Total lymph node (TLI)
NO (NO)
UNKNOWN (UNKNOWN)
YES (YES)
Craniospinal
no (no)
unknown (unknown)
yes (yes)
Lymphocytopheresis
no (no)
unknown (unknown)
yes  (yes )
if other modality please specify:
FIRST EVIDENCE OF DISEASE
WORSENING SINCE LAST HSCT
EVIDENCE OF DISEASE ACTIVITY
Continuous worsening since HSCT
(Continuous worsening since HSCT)
No (No)
Previously reported (Previously reported)
Yes (Yes)
Date First Noted (mm-dd-yyyy)
Number of relapses/progressions since last
HSCT
LAST DISEASE AND PATIENT STATUS
Scripps neurological rating scale Score
Kurtzke functional systems Overall score
Kurtzke Expanded Disability Status Scale (EDSS)
Composite Scale Score
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MRI BRAIN SCAN DONE
Not done (Not done)
Yes (Yes)
Date of most recent MRI scan of brain
Results, Are new lesions present on the MRI?
no (no)
unknown (unknown)
yes (yes)
If yes Indicate new lesions present
Both (Both)
Gadolinium-enhancing (Gadolinium-
enhancing)
Unenhancing (Unenhancing)
Unknown (Unknown)
Has patient or partner become  pregnant after
this HSCT?
No (No)
Unknown (Unknown)
Yes (Yes)
Survival Status
alive (0)
dead (1)
Performance score (if alive)
Karnofsky (1)
Lansky (2)
Score
100 (Normal, NED) (1)
10 (Moribund) (10)
Not evaluated (11)
Unknown (12)
90 (Normal activity)  (2)
80 (Normal with effort) (3)
70 (Cares for self) (4)
60 (Requires occasional assistance) (5)
50 (Requires assistance) (6)
40 (Disabled) (7)
30 (Severely disabled) (8)
20 (Very sick) (9)
Cause of death (if dead)
Relapse or progression (1)
Secondary malignancy (including
lymphoproliferative disease) (2)
HSCT related cause  (3)
Unknown (4)
Other (5)
HSCT related cause
GvHD (1)
Veno-occlusive disease (VOD) (10)
Haemorrhage (11)
Cardiac toxicity (12)
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Central nervous system toxicity (13)
Gastro intestinal toxicity (14)
Skin toxicity (15)
Renal failure (16)
Multiple organ failure (17)
Other (18)
Interstitial pneumonitis (2)
Pulmonary toxicity (3)
Infection bacterial (4)
Infection viral (5)
Infection fungal (6)
Infection parasitic (7)
Infection unknown (8)
Rejection / poor graft function (9)
ADDITIONAL NOTES IF APPLICABLE
COMMENTS
Identification
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AAFP: Partial Small Bowel Obstruction
Admission Order
AAFP: Partial Small Bowel Obstruction Admission Order,
Standardizes Admission Orders, Author: Robert M. Wiprud,
MD The primary purpose of these Ordersets is to decrease
unnecessary variability and to improve quality through
standardized Admission Orders. Developed by the Scott &
White Clinic at College Station, Texas. Copyright © 2006
American Academy of Family Physicians. Physicians may
photocopy or adapt for use in their own practices; all other
rights reserved. Wiprud RM. Providing consistent care with
standardized admission orders. Fam Pract Manag.
September 2006: 49-52 See
http://www.aafp.org/fpm/2006/0900/p49.html This ODM
Form includes the twenty-fourth section ("AAFP: Partial
Small Bowel Obstruction Admission Order")
All rights reserved. Please visit https://medical-data-
models.org/forms/16606
AAFP: Partial Small Bowel
Obstruction Admission Order
Default Itemgroup
Name
Age
Date of Birth
Medical record number
Status
Status
Observation (1)
Admission (2)
Medical floor (3)
Surgical (4)
Attending
Name of attending physician
Phone number of attending physician
Admitting Diagnosis
Partial Small Bowel Obstruction Contributing
Diagnoses
Condition
Condition
Stable (1)
Fair (2)
Serious (3)
Critical (4)
1 / 3
Allergies
Allergies
Diet
NPO
Yes
No
Activity
Bed rest with bathroom privileges with assistance
Yes
No
Nursing
Vital signs: every 4 hrs for 24 hrs then every shift
Yes
No
Notify MD for: T > 101.5, P > 120, BP < 90/60 or
> 180/110
Yes
No
NG tube to low continuous suction
Yes
No
I&O
Yes
No
Medications
Demerol 25-50mg slow IVP every 3-4 hrs prn
pain
Yes
No
Phenergan 12.5 mg slow IVP every 3-4 hrs
Yes
No
IV
Dextrose 5% normal saline with 20 mEq KCl
@125 mL/hr
Yes
No
Bolus_____
Yes
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No
If Bolus, please specify
Replace NG output mL per mL with___normal
saline every 12 hrs
Yes
No
Please specify amount of normal saline if NG
output is replaced by saline
Lab
Daily hemogram, basal metabolic profile in a.m.
Yes
No
Other Orders
X-ray: acute abdominal series if not done in
ER/clinic
Yes
No
Surgical consult as indicated (complete
obstruction)
Yes
No
Consider DVT prophylaxis with Lovenox 40 mg sq
daily
Yes
No
Consider gastrografin UGI with small bowel
follow-through after 24-26 hrs of NG suction
Yes
No
Signature
Print Name
Date and Time
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AAFP: Pediatric Vomiting/Diarrhea/Dehydration
Admission Order
AAFP: Pediatric Vomiting/Diarrhea/Dehydration Admission
Order, Standardizes Admission Orders, Author: Robert M.
Wiprud, MD The primary purpose of these Ordersets is to
decrease unnecessary variability and to improve quality
through standardized Admission Orders. Developed by the
Scott & White Clinic at College Station, Texas. Copyright ©
2006 American Academy of Family Physicians. Physicians
may photocopy or adapt for use in their own practices; all
other rights reserved. Wiprud RM. Providing consistent
care with standardized admission orders. Fam Pract
Manag. September 2006: 49-52 See
http://www.aafp.org/fpm/2006/0900/p49.html This ODM
Form includes the twenty-fifth section ("AAFP: Pediatric
Vomiting/Diarrhea/Dehydration Admission Order")
All rights reserved. Please visit https://medical-data-
models.org/forms/16607
AAFP: Pediatric
Vomiting/Diarrhea/Dehydration
Admission Order
Default Itemgroup
Name
Age
Date of Birth
Medical record number
Status
Status; Pediatric floor:
Observation (1)
Admission (2)
Attending
Name of attending physician
Phone number of attending physician
Admitting Diagnosis
Pediatric Vomiting/Diarrhea/Dehydration
Contributing Diagnoses
Condition
Condition
Stable (1)
Fair (2)
Serious (3)
Critical (4)
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Allergies
Allergies
Acitivity
Crib
Yes
No
Bassinet
Yes
No
Bed
Yes
No
Diet
NPO
Yes
No
Formula/Breast
Yes
No
Age appropriate diet as tolerated
Yes
No
Nursing
Vital signs: every 4 hrs
Yes
No
Medications
Tylenol (10mg/kg)____PO/PR every 4 hrs prn T >
101
Yes
No
Phenergan 12.5-25 mg PR 1 6-8 hrs prn n/v
Yes
No
IV
Replacement 1/3 over first 4 hrs with Dextrose
5% win 1/2 normal saline
Yes
No
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Replacement 1/3 over second 8 hrs with
Dextrose 5% in 1/2 or 1/4 normal saline
Yes
No
Replacement 1/3 over third 12 hrs with D5.2
normal saline
Yes
No
Replace in addition to maintenance
Yes
No
Lab
Basal metabolic profile, CBC UA on admission;
basal metabolic profile in a.m.
Yes
No
Stool for rotazyme, routine culture, O&P, yersinia
Yes
No
Call MD for
Call MD for
Signature
Print Name
Date and Time
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Blood samples Urine collection CARLA
Follow-up
Greiser KH, Kluttig A, Schumann B, Swenne CA, Kors JA,
Kuss O, Haerting J, Schmidt H, Thiery J, Werdan K.
Cardiovascular diseases, risk factors and short-term heart
rate variability in an elderly general population: the CARLA
study 2002-2006. Eur J Epidemiol. 2009;24(3):123-42
http://www.ncbi.nlm.nih.gov/pubmed/19199053
"Cross-sectional data of a population-based cohort
including 1,779 women and men aged 45-83 years were
used to analyse associations of time and frequency domain
measures of HRV (derived from 5-min ECG segments) with
age, behavioural and biomedical risk factors and disease in
the whole sample and in a "healthy" subgroup."
publication granted by 
Dr. rer. medic. Alexander Kluttig, MPH
Leiter des Studienzentrums Halle der Nationalen Kohorte
Institut für Medizinische Epidemiologie, Biometrie und
Informatik 
Martin-Luther-Universität Halle-Wittenberg 
Magdeburger Str. 8 
D-06097 Halle/Saale
All rights reserved. Please visit https://medical-data-
models.org/forms/16610
Blood samples Urine collection
CARLA Follow-up
General information
Subject ID
B01 Examiner ID Blood Taking
B02 Examiner ID Documentation
B03 Date
B03 Time
Preliminary questions
B04 Examiner: Does the subject agree to the
taking of blood samples?
Yes (1)
Yes, but without storage of blood for
follow-up projects (Do not take tubes 5-
9!) (2)
No (End) (3)
B04 If not, please specify reason:
B05 Do you suffer from haemophilia?
Yes (End) (1)
No (2)
B06 Have you been administered an
anticoagulant?
I don't know (-8)
Yes (1)
No (2)
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B07 Do you suffer from a chronic infection?
I don't know (-8)
Yes (1)
No (Proceed with B11) (2)
B08 Examiner: If yes, did the subject specify in
detail?
Yes (1)
No (2)
B09 Has the subject stated to suffer from
hepatitis (B or C)?
I don't know (-8)
Yes (1)
No (2)
B10: Has the subject stated to suffer from an
HIV-infection?
I don't know (-8)
Yes (1)
No (2)
B11 Other infections?
Yes (Please specify) (1)
No (2)
B11 Please specify any other infections
B12 Did you suffer from any acute febrile disease
or another severe illness during the last week?
Yes, febrile (1)
Yes, other (Please specify) (2)
No (3)
B12 Which (non-febrile) illness did you suffer
from?
B13 When was the last time you ate something?
Yesterday (1)
Today (2)
B13 Time of latest food intake
B14 How much did you eat?
Full meal (1)
Snack (2)
B15 When was the last time you drank something
containing caffeine (theine)?
Yesterday (1)
Today (2)
Not at all (3)
B15 Time of latest consumption of caffeine
(theine)
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B16 Type of beverage (if latest consumption of
caffeine/theine was today)
Coffee containing caffeine (1)
Tea (containing theine) (2)
Cola (3)
B17 When was the last time you drank other
(caffeine-free) beverages?
Yesterday (1)
Today (2)
B17 Time of latest consumption of a caffeine-free
beverage
B16 Type of beverage (if latest consumption of a
caffeine-free beverage was today)
Decaffeinated coffee (1)
Decaffeinated tea (2)
Juice/Lemonade (3)
Water (4)
Fruit/Herbal tea (5)
B19 Are you allergic to latex?
Yes (Please use latex-free gloves when
taking the blood sample!) (1)
No (2)
B20 Exact time at beginning of blood collection
(see clock)
Taking of blood samples
1. Serum-Gel-Monovette (9 ml)
ml
2. EDTA-Monovette (2.7 ml)
ml
3. EDTA-Monovette (9 ml)
ml
4. Citrate-Monovette (coagulation tube, 5 ml)
ml
5. Serum-Gel-Monovette (9 ml)
ml
6. Serum-Gel-Monovette (9 ml)
ml
7. EDTA-Monovette (9 ml)
ml
8. Serum-Gel-Monovette (9 ml)
ml
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9. EDTA-Monovette (9 ml)
ml
10. Li-Heparin-Monovette (4.9 ml)
ml
Final information
B22 Examiner: Could the blood samples be
taken?
Yes (1)
No (Please specify) (2)
B22 If not, please specify reason:
B23 Are the blood samples complete (all tubes
filled)?
Yes (1)
No (2)
B24 Exact time at the end of blood collection (see
clock)
B25 Any deviations/problems during blood
collection?
Yes (Specify in B26) (1)
No (Proceed with B27) (2)
B26 1. Congestion > 1 min.
Yes
No
B26 2. Hot fomentation
Yes
No
B26 3. Forced aspiration, slow blood flow
Yes
No
B26 4. Prolonged poking at the same site
Yes
No
B26 5. Secondary bleeding
Yes
No
B 26 6. Other deviations/problems
B27 Comments
End of examination
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B28 Urine collection succesful?
Yes
No
B29 Time of urine collection
Data entry
1st data entry: DNo.
1st data entry: Date
2nd data entry: DNo.
2nd data entry: Date
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Device Accountability Log: CRF Wisconsin
Madison
ODM Form derived from:
https://ictr.wisc.edu/CaseReptTempt. Template Name:
Device Accountability Log. Case Report Form
(CRF)/Source Document templates were created for
University of Wisconsin-Madison researchers. These
templates are consistent with the FDA's CDASH (Clinical
Data Acquisition Standards Harmonization) standards. The
CDASH standards identify those elements that should be
captured on a Case Report Form (CRF). The forms serve
only as templates, and must be edited to meet the study
data collection needs as described in the protocol.
All rights reserved. Please visit https://medical-data-
models.org/forms/16611
Device Accountability Log: CRF
Wisconsin Madison
Header
PI Name
Protocol or IRB Number
Protocol Short Title
Number of Page
Total amount of pages
Device Accountability Log: Device Receipt
Date Received
Batch # or Device Type
Lot #, Serial #, or Model Number(s)
Received by (staff initials)
Device Accountability Log: Device Use
Date used
Subject Study ID
Dispensed by (staff initials)
Device Accountability Log: Device
Return/Repair/Destruction
Device Position
1 / 2
Date of final Device Disposition
Reason
Confirmed by (staff initials)
Comments
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ECG CARLA Follow-up
Greiser KH, Kluttig A, Schumann B, Swenne CA, Kors JA,
Kuss O, Haerting J, Schmidt H, Thiery J, Werdan K.
Cardiovascular diseases, risk factors and short-term heart
rate variability in an elderly general population: the CARLA
study 2002-2006. Eur J Epidemiol. 2009;24(3):123-42
http://www.ncbi.nlm.nih.gov/pubmed/19199053
"Cross-sectional data of a population-based cohort
including 1,779 women and men aged 45-83 years were
used to analyse associations of time and frequency domain
measures of HRV (derived from 5-min ECG segments) with
age, behavioural and biomedical risk factors and disease in
the whole sample and in a "healthy" subgroup."
publication granted by 
Dr. rer. medic. Alexander Kluttig, MPH
Leiter des Studienzentrums Halle der Nationalen Kohorte
Institut für Medizinische Epidemiologie, Biometrie und
Informatik 
Martin-Luther-Universität Halle-Wittenberg 
Magdeburger Str. 8 
D-06097 Halle/Saale
All rights reserved. Please visit https://medical-data-
models.org/forms/16613
ECG CARLA Follow-up
General information
Subject ID
Date of birth (subject)
Examiner ID
Date of investigation
Beginning of ECG investigation
Interview / Short medical history
1. Has an ECG ever been performed on you
before?
I don't know (I don't know)
No (No)
Yes (Yes)
1 a) If yes, how long ago is your last ECG
investigation?
< 4 weeks (< 4 weeks)
> 1 year (> 1 year)
2-12 months (2-12 months)
I don't know (I don't know)
1 b) If yes, has your ECG always been normal?
I don't know (I don't know)
No (No)
Yes (Yes)
2. Have you ever been diagnosed with a cardiac
defect (currently, formerly, or during infancy)?
I don't know (I don't know)
No (No)
Yes (Yes)
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3. Are you on medication because of a
cardiovascular disease?
I don't know (I don't know)
No (No)
Yes (Yes)
4. Have you ever been diagnosed with a heart
attack?
I don't know (I don't know)
No (No)
Yes (Yes)
5. Have you been diagnosed with a cardiac
valvular defect?
I don't know (I don't know)
No (No)
Yes (Yes)
6. Did you ever have a cardiac catheterization?
I don't know (I don't know)
No (No)
Yes (Yes)
7. Have you ever been diagnosed with cardiac
arrythmia?
I don't know (I don't know)
No (No)
Yes (Yes)
8. Did you ever have heart surgery?
I don't know (I don't know)
No (No)
Yes (Yes)
9. Do you have a pacemaker?
I don't know (I don't know)
No (No)
Yes (Yes)
10. Do you/Did you ever suffer from pulmonary
disease?
I don't know (I don't know)
No (No)
Yes (Yes)
11. Do you/Did you ever suffer from a disease of
the liver?
I don't know (I don't know)
No (No)
Yes (Yes)
12. Do you/Did you ever suffer from a stroke
(apoplectic insult)?
I don't know (I don't know)
No (No)
Yes (Yes)
13. Do you/Did you ever suffer from an
angiopathy (e. g. of the leg arteries, the carotid
artery)?
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I don't know (I don't know)
No (No)
Yes (Yes)
14. Do you/Did you ever suffer from diabetes?
I don't know (I don't know)
No (No)
Yes (Yes)
Specifications
ECG: Thorax angle
Has thorax angle been used?
Missing (Missing)
No (No)
Yes (Yes)
ECG: Electrodes
Position of ECG electrodes
O.K. (O.K.)
Shifted position (Shifted position)
In case of shifted position, please specify reason
Position on nipple (1)
Other (see text) (2)
If other reason for shifted electrode position
applies, please specify
Which electrode was shifted?
Where was the electrode shifted to?
ECG: Recording
1. 10 seconds 12 channel ECG 50 mm/sec
Both missing (Both missing)
Paper (Paper)
Saved on computer (Saved on computer)
1. If ECG data (10 sec) is missing, please
indicate reason
Malfunction ECG recorder (1)
Laptop defect (2)
Vacuum pump defect (3)
Subject refuses ECG (4)
Other (Specify below) (5)
2. 5 minutes 12 channel ECG without metronome
Computer O.K. (Computer O.K.)
Missing (Missing)
With deficiencies (With deficiencies)
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2. If ECG (5 min) is deficient, please indicate
reason
Premature termination (1)
Subject coughing/talking (2)
Subject moving (3)
Subject sitting up (4)
Other (Specify below) (5)
2. If ECG data (5 min) is missing, please indicate
reason
Malfunction ECG recorder (1)
Laptop defect (2)
Vacuum pump defect (3)
Subject refuses ECG (4)
Other (Specify below) (5)
3. 20 minutes 12 channel resting ECG
Computer O.K. (Computer O.K.)
Missing (Missing)
With deficiencies (With deficiencies)
3. If resting ECG is deficient, please indicate
reason
Premature termination (1)
Subject coughing/talking (2)
Subject moving (3)
Subject sitting up (4)
Other (Specify below) (5)
3. If resting ECG data is missing, please indicate
reason
Malfunction ECG recorder (1)
Laptop defect (2)
Vacuum pump defect (3)
Subject refuses ECG (4)
Other (Specify below) (5)
If other reasons apply for any deficient ECG,
please specify
If other reasons apply for any missing data,
please specify
With metronome-controlled breathing
No (No)
Partly/Not permanently (Partly/Not
permanently)
Yes (Yes)
ECG: Description of incidents
ECG Number
Beginning of incident (time)
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End of incident (time)
Error code
If necessary, give detailed description
Final information
Comments/Special incidents
End of ECG investigation
Data entry
1st data entry: DNo.
1st data entry: Date
2nd data entry: DNo.
2nd data entry: Date
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Palliative and Hospice Care Grief
Counseling Retrospective View
https://www.hope-clara.de/ 
The HOPE Hospice and Palliative Care Recording standard
documentation is used for documentation of palliative care
and as an instrument for quality assurance in pallatiave
wards, hospices and oncological wards as well as in
ambulatory services and palliative teams. 
The questionnaire for grief counseling belongs to
documentation of the Gernan Grief Institute (Deutsches
Trauerinstitut) [Paul 2003]. The questionnaire allows to
evaluate the grief counseling retrospectively. With respect
to the major documention the questionnaire is offered as a
module. 
Paul, C. (2003). Dokumentationsbögen für ehrenamtliche
Trauerbegleitung im Rahmen von Hospizdiensten. Pallia
Med Verlag.
All rights reserved. Please visit https://medical-data-
models.org/forms/16615
Palliative and Hospice Care Grief
Counseling Retrospective View
Administrative Daten
13. Datum
1. IDNR
TR1. Begleitung
Begleitende/r
Dauer der Begleitung  
(von – bis)
Ort der Gespräche
Frequenz der Kontakte
Andere (Andere)
Monatlich (Monatlich)
Wöchentlich (Wöchentlich)
TR2. Andere Kontakte
Durch Trauernde/n - Telefonate
gar nicht (gar nicht)
häufig (häufig)
selten (selten)
Durch Trauernde/n - Briefe
gar nicht (gar nicht)
häufig (häufig)
selten (selten)
Durch Trauernde/n - E-Mails
gar nicht (gar nicht)
häufig (häufig)
selten (selten)
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Durch Begleitende/n - Telefonate
gar nicht (gar nicht)
häufig (häufig)
selten (selten)
Durch Begleitende/n - Briefe
gar nicht (gar nicht)
häufig (häufig)
selten (selten)
Durch Begleitende/n - E-Mails
gar nicht (gar nicht)
häufig (häufig)
selten (selten)
TR3. Praktische Tätigkeiten
Praktische Tätigkeiten
andere (andere)
Freizeitgestaltung (Freizeitgestaltung)
Hilfe bei Grabpflege (Hilfe bei
Grabpflege)
Sortieren von Hinterlassenschaft
(Sortieren von Hinterlassenschaft )
Spaziergang  (Spaziergang )
Vorbereitung bei Ämtergängen
(Vorbereitung bei Ämtergängen)
TR4. Gespräche über Gefühle
Gespräche über Gefühle
andere (andere)
Angst (Angst)
Dankbarkeit (Dankbarkeit)
Einsamkeit (Einsamkeit)
Erleichterung (Erleichterung)
Hoffnungslosigkeit (Hoffnungslosigkeit)
Schuldgefühle (Schuldgefühle)
Schuldzuweisungen an andere
(Schuldzuweisungen an andere)
Sehnsucht (Sehnsucht)
Wut (Wut)
Zerissenheit (Zerissenheit)
Andere:
TR5. Gespräche über die/den Tote/n
Gespräche über die/den Tote/n
anderes (anderes)
das Leid des Sterbenden (das Leid des
Sterbenden)
das Sterben (das Sterben)
die aktuelle Bedeutung des Toten im
eigenen Leben (die aktuelle Bedeutung
des Toten im eigenen Leben)
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die Beziehung (die Beziehung)
die Vorgeschichte des Sterbens (die
Vorgeschichte des Sterbens)
Dinge, die nicht gelöst werden können
(Dinge, die nicht gelöst werden können )
gute Erinnerungen (gute Erinnerungen)
schlechte Erinnerungen (schlechte
Erinnerungen)
Überlegungen, wie es dem Toten jetzt
geht (Überlegungen, wie es dem Toten
jetzt geht)
Andere:
TR6. Gespräch über praktische Probleme
Gespräch über praktische Probleme
andere (andere)
Gestaltung und Pflege des Grabs
(Gestaltung und Pflege des Grabs)
materielle Einbussen (materielle
Einbussen)
Ordnen der Hinterlassenschaft (Ordnen
der Hinterlassenschaft)
Organisation des Alltags (Organisation
des Alltags)
Andere:
TR7. Gespräch über Probleme mit
Gespräch über Probleme mit
anderen (anderen)
Arbeitgeber, KollegInnen (Arbeitgeber,
KollegInnen)
Familienmitglieder (Familienmitglieder)
Freundinnen/Freunden
(Freundinnen/Freunden)
NachbarInnen (NachbarInnen)
Anderen:
TR8. Gespräch über körperliche
Beschwerden
Gespräch über körperliche Beschwerden
andere (andere)
Angstzustände, Panikattacken
(Angstzustände, Panikattacken)
Essprobleme (Essprobleme)
Konzentrationsschwierigkeiten
(Konzentrationsschwierigkeiten)
körperliche Schwäche (körperliche
Schwäche)
Schlafschwierigkeiten
(Schlafschwierigkeiten)
Schmerzen (Schmerzen)
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Andere:
TR9. Gespräch über religiöse und
spirituelle Themen
Gespräch über religiöse und spirituelle Themen
andere (andere)
Empfindungen von Anwesenheit der/des
Toten oder von Zeichen und Botschaften
(Empfindungen von Anwesenheit
der/des Toten oder von Zeichen und
Botschaften )
Glaubensfragen (Glaubensfragen)
Sinnfragen (Sinnfragen)
Träume von der/dem Toten (Träume von
der/dem Toten)
Vorstellungen vom Leben nach dem Tod
(Vorstellungen vom Leben nach dem
Tod)
Andere:
TR10. Gespräch über andere
Lebensthemen
Gespräch über andere Lebensthemen
andere (andere)
andere Probleme oder Verletzungen
(andere Probleme oder Verletzungen)
Erfolgserlebnisse (Erfolgserlebnisse)
frühe Verluste (frühe Verluste)
Glück und Genuss (Glück und Genuss)
Andere:
TR.11 Gespräch über Veränderungen
Gespräch über Veränderungen
andere (andere)
neue FreundInnen  (neue FreundInnen )
neue Partnerschaft (neue Partnerschaft)
neue Tätigkeiten (neue Tätigkeiten)
Umzug oder Umgestaltung der
Wohnung/des Hauses (Umzug oder
Umgestaltung der Wohnung/des
Hauses)
veränderte Beziehungen innerhalb der
Familie oder des Freundeskreises
(veränderte Beziehungen innerhalb der
Familie oder des Freundeskreises )
veränderte Lebenseinstellung
(veränderte Lebenseinstellung)
Andere:
4 / 5
Palliative and Hospice Care Grief Counseling Retrospective View
TR12.  Abschied aus der Trauerbegleitung
Abschied aus der Trauerbegleitung
anders: (anders:)
ausgehend von dem Begleitenden
(ausgehend von dem Begleitenden )
ausgehend von dem Trauernden
(ausgehend von dem Trauernden )
einvernehmlich (einvernehmlich)
gegen den Widerstand des Trauernden
(gegen den Widerstand des Trauernden)
mit der Vereinbarung, weiter im Kontakt
zu bleiben (mit der Vereinbarung, weiter
im Kontakt zu bleiben)
unerwartet für den Begleitenden
(unerwartet für den Begleitenden)
Anders:
TR13. Bemerkungen
Bemerkungen
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Drug Dispension & Accountability Log: CRF
Wisconsin Madison
ODM Form derived from:
https://ictr.wisc.edu/CaseReptTempt. Template Name: Drug
Dispension & Accountability Log. Case Report Form
(CRF)/Source Document templates were created for
University of Wisconsin-Madison researchers. These
templates are consistent with the FDA's CDASH (Clinical
Data Acquisition Standards Harmonization) standards. The
CDASH standards identify those elements that should be
captured on a Case Report Form (CRF). The forms serve
only as templates, and must be edited to meet the study
data collection needs as described in the protocol.
All rights reserved. Please visit https://medical-data-
models.org/forms/16616
Drug Dispension & Accountability
Log: CRF Wisconsin Madison
Header
PI Name
Protocol or IRB Number
Protocol Short Title
Number of Pages
Total Number of Pages
Drug Dispensation & Accountability Log
Subject Initials
Subject Study ID
Lot Number(s)
Unit Dose (e.g. mg)
Drug Dispensation & Accountability Log:
Dispensed to Subject
Number of Containers Dispensed
Number of Units Dispensed
Date Dispensed
Dispensed by (staff initials)
Drug Dispensation & Accountability Log:
Returned by Subject
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Number of Containers Returned
Number of units returned
Date Returned
Verified by (staff initials)
Drug Dispensation & Accountability Log:
Compliance
Expected number of units to be used/taken
Actual number of units used/taken
% compliance
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Eligibility Cardiovascular Diseases
NCT00063531
Comparison of Two Methods to Diagnose Coronary Artery
Disease; ODM derived from:
https://clinicaltrials.gov/show/NCT00063531
All rights reserved. Please visit https://medical-data-
models.org/forms/16617
Eligibility Cardiovascular Diseases
NCT00063531
Inclusion Criteria
siblings of hospitalized index patients with
documented cad prior to 60 years of age*
Yes
No
index patients who have demonstrated
angiographic lesions greater than or equal to
50% in greater than or equal to 1 vessel,
accompanied by angina or a documented cad
event*
Yes
No
siblings with no known history of cad*
Yes
No
siblings with a positive screening test for occult
cad (abnormal ett or thallium scan, or cac score
greater than 75th  percentile) will be invited for
coronary angiography*
Yes
No
Exclusion Criteria
index patients with cad associated with some
other primary disease (e.g., collagen vascular
disease, transplantation, or chronic corticosteroid
therapy)*
Yes
No
siblings with a life-threatening comorbidity (e.g.,
aids, cancer)*
Yes
No
siblings who have had an organ transplant*
Yes
No
siblings receiving chronic glucocorticosteroids*
Yes
No
siblings with known collagen vascular disease*
Yes
No
1 / 2
siblings with a limitation that would preclude the
capacity to exercise sufficiently for the test*
Yes
No
siblings unable to give informed consent*
Yes
No
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Device Accountability Log (per subject):
CRF Wisconsin Madison
ODM Form derived from:
https://ictr.wisc.edu/CaseReptTempt. Template Name:
Device Accountability Log (per subject). Case Report Form
(CRF)/Source Document templates were created for
University of Wisconsin-Madison researchers. These
templates are consistent with the FDA's CDASH (Clinical
Data Acquisition Standards Harmonization) standards. The
CDASH standards identify those elements that should be
captured on a Case Report Form (CRF). The forms serve
only as templates, and must be edited to meet the study
data collection needs as described in the protocol.
All rights reserved. Please visit https://medical-data-
models.org/forms/16618
Device Accountability Log (per
subject): CRF Wisconsin Madison
Header
PI Name
Protocol or IRB Number
Protocol Short Title
Subject Initials
Subject ID
Number of Page
Total Number of Pages
Drug Dispensation & Accountability Log
Lot Number(s)
Randomization Number
Drug Dispensation & Accountability Log:
Dispensed to Subject
Number of Containers Dispensed
Number of Units Dispensed
Date Dispensed
Dispensed by (staff initials)
Expected Date of First Dose
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Drug Dispensation & Accountability Log:
Returned by Subject
Number of Containers Returned
Number of units returned
Date Returned
Verified by (staff initials)
Drug Dispensation & Accountability Log:
Compliance
Actual number of units used/taken
Estimated number of units to be used/taken
% compliance
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Research Sample Tracking: CRF Wisconsin
Madison
ODM Form derived from:
https://ictr.wisc.edu/CaseReptTempt. Template Name:
Research Sample Tracking. Case Report Form
(CRF)/Source Document templates were created for
University of Wisconsin-Madison researchers. These
templates are consistent with the FDA's CDASH (Clinical
Data Acquisition Standards Harmonization) standards. The
CDASH standards identify those elements that should be
captured on a Case Report Form (CRF). The forms serve
only as templates, and must be edited to meet the study
data collection needs as described in the protocol.
All rights reserved. Please visit https://medical-data-
models.org/forms/16619
Research Sample Tracking: CRF
Wisconsin Madison
Header
PI Name
Protocol or IRB Number
Protocol Short Title
Subject ID
Number of Page
Total number of Pages
Research Sample Tracking I
Storage Location (including building and room
number)
Freezer number
Shelf Number
Rack Number
Research Sample Tracking II
Box Number
Cell Number
Subject ID Number
Visit Number
Visit 1 - Initial (1)
Visit 2 - Mo. 6 (2)
Visit 3 - Mo. 12 (3)
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Visit 4 - Mo. 18 (4)
Visit 5 - Mo. 24 (5)
Date sample put in freezer
Time sample put in freezer
Time sample put in freezer: AM
Yes
No
Time sample put in freezer: PM
Yes
No
Date sample removed from freezer
Time sample removed from freezer
Time sample removed from freezer: AM
Yes
No
Time sample removed from freezer: PM
Yes
No
Sample Outcome
Shipped (1)
Analyzed (2)
Lost (3)
Other (4)
If Other, please specify
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Eligibility Cardiovascular Diseases
NCT00072995
Preventing Obesity Using Novel Dietary Strategies; ODM
derived from: https://clinicaltrials.gov/show/NCT00072995
All rights reserved. Please visit https://medical-data-
models.org/forms/16620
Eligibility Cardiovascular Diseases
NCT00072995
Inclusion Criteria
only accepting participants in the boston,
massachusetts or baton rouge, louisiana area*
Yes
No
between the ages of 30 - 70*
Yes
No
willing to modify eating pattern according to
instructions*
Yes
No
overweight or obese and in good health with a
bmi of 25-40*
Yes
No
committed to a long-term weight loss and
maintenance program*
Yes
No
willing to attend multiple weight loss group
sessions*
Yes
No
willing to increase activity level*
Yes
No
Exclusion Criteria
pregnant, planning to become pregnant, or are
breastfeeding*
Yes
No
unwilling to participate in the schedule of group
sessions and individual visits*
Yes
No
unstable or recent onset of heart disease or any
other serious illness*
Yes
No
cannot change diet due to medical or other
1 / 2
reasons*
Yes
No
planning to leave the area prior to the anticipated
end of participation*
Yes
No
current participation in another clinical trial with
an intervention that affects weight change*
Yes
No
have diabetes that is treated with insulin or
hypoglycemic oral medicines*
Yes
No
diagnosis of psychiatric or emotional problems
within 6 months of study*
Yes
No
currently have an eating disorder*
Yes
No
have hypothyroidism*
Yes
No
have an unstable weight*
Yes
No
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Eligibility Cardiovascular Diseases
NCT00073788
Wounded Spirits, Ailing Hearts: Post-Traumatic Stress
Disorder and Cardiovascular Disease in Indians; ODM
derived from: https://clinicaltrials.gov/show/NCT00073788
All rights reserved. Please visit https://medical-data-
models.org/forms/16626
Eligibility Cardiovascular Diseases
NCT00073788
Inclusion Criteria
be 18 years of age or older;*
Yes
No
not be pregnant, or breastfeeding;*
Yes
No
be free of heart disease when they participated in
the american indian services utilization,
psychiatric epidemiology, risk and protective
factors project (ai-superpfp); or change in ptsd
status from time of participation to completion of
2nd stage screening;*
Yes
No
have no medical issues that interfere with the pet
imaging such as unstable angina, myocardial
infarction in the past week, severe obstructive
lung disease, decompensated heart failure;
severe coronary disease, severe stroke, or other
medical conditions that would make it unsafe for
them to travel and complete the protocol (e.g., not
be on dialysis);*
Yes
No
not be taking any medications such as
theophylline or aminophylline or oral steroids (e.g.
prednisone);*
Yes
No
participants who use inhalers or nebulizers will be
asked to use the inhalers or nebulizers in denver
on their regular schedule. if they are able to
administer these treatments themselves on their
regular schedule, they are eligible to be brought
to denver, assuming other eligibility criteria are
met.*
Yes
No
and not have any conditions or devices, like
claustrophobia that would interfere with the heart
imaging process.*
Yes
No
not be using alcohol or any illegal substances
during denver visit and examination period.*
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Yes
No
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Eligibility Cardiovascular Diseases
NCT00074724
Dobutamine Echocardiography In Patients With Ischemic
Heart Failure Evaluated for Revascularization; ODM
derived from: https://clinicaltrials.gov/show/NCT00074724
All rights reserved. Please visit https://medical-data-
models.org/forms/16628
Eligibility Cardiovascular Diseases
NCT00074724
Criteria
Inclusion Criteria
symptomatic heart failure defined as nyha class ii
- iv (within 3 months of entry)*
Yes
No
lv less than 35% defined by cmr or gated spect
studies*
Yes
No
coronary anatomy suitable for revascularization*
Yes
No
Exclusion Criteria
primary valvular heart disease clearly defined
indicating the need for valve repair or
replacement*
Yes
No
patients with concurrent cardiogenic shock or
requiring inotropic or intra-aortic balloon support*
Yes
No
pci planned for cad treatment*
Yes
No
acute myocardial infarction within 30 days*
Yes
No
more than one prior cardiac operation*
Yes
No
non-cardiac illness with life expectancy of less
than 3 years*
Yes
No
non-cardiac illness imposing substantial operative
mortality. patients eligible to enter the study will
be further evaluated by the stich team for svr
eligibility.*
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Yes
No
2 / 2
Eligibility Cardiovascular Diseases NCT00074724
Adverse Event Tracking Log: CRF
Wisconsin Madison
ODM Form derived from:
https://ictr.wisc.edu/CaseReptTempt. Template Name:
Adverse Event Tracking Log. Case Report Form
(CRF)/Source Document templates were created for
University of Wisconsin-Madison researchers. These
templates are consistent with the FDA's CDASH (Clinical
Data Acquisition Standards Harmonization) standards. The
CDASH standards identify those elements that should be
captured on a Case Report Form (CRF). The forms serve
only as templates, and must be edited to meet the study
data collection needs as described in the protocol.
All rights reserved. Please visit https://medical-data-
models.org/forms/16629
Adverse Event Tracking Log: CRF
Wisconsin Madison
Header
PI Name
Protocol or IRB Number
Protocol Short Title
Subject Initials
Subject ID
Number of Page
Total Number of Pages
Adverse Event Tracking Log
#
Date Reported
Adverse Event Description
Adverse Event Category
Start Date
End Date
Outcome
Severity / Grade
Serious
1 / 2
Yes
No
Expected
Yes
No
AE Treatment
Action Taken
Attribution
PI Initials
Date of PI Initials
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Serious Adverse Event Part I: CRF
Wisconsin Madison
ODM Form derived from:
https://ictr.wisc.edu/CaseReptTempt. Template Name:
Serious Adverse Event Part I. Case Report Form
(CRF)/Source Document templates were created for
University of Wisconsin-Madison researchers. These
templates are consistent with the FDA's CDASH (Clinical
Data Acquisition Standards Harmonization) standards. The
CDASH standards identify those elements that should be
captured on a Case Report Form (CRF). The forms serve
only as templates, and must be edited to meet the study
data collection needs as described in the protocol.
All rights reserved. Please visit https://medical-data-
models.org/forms/16630
Serious Adverse Event Part I: CRF
Wisconsin Madison
Header
PI Name
Protocol or IRB Number
Protocol Short Title
Subject Initials
Subject ID
Serious Adverse Event
Event Start Date
Event End Date
Date Reported
Reported to Research Staff Bv
Death Date (if applicable)
Death Occurred
Within 24 hours of investigational therapy
(1)
Within 7 days of investigational therapy
(2)
Within 30 days of investigational therapy
(3)
After 30 days of investigational therapy
(4)
Did the SAE occur at your site or at a site for
which the PI is responsible?
Yes
No
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SAE Description/Narrative
Treating Physician Comments (if applicable)
PI Comments
Outcome
Fatal/ Died  (1)
Intervention for AE Continuing  (2)
Not Recovered/Not Resolved (3)
Recovered/Resolved with Sequelae  (4)
Recovered/Resolved without Sequelae
(5)
Recovering/Resolving (6)
Consent Form Change Required?
Yes
No
SAE Classification: Fatal (resulted in death)
Yes
No
SAE Classification: A life-threatening occurrence
Yes
No
SAE Classification: Requires inpatient
hospitalization or prolongation of existing
hospitalization
Yes
No
SAE Classification: Results in persistent or
significant disability/incapacity
Yes
No
SAE Classification: Results in congenital
anomaly/birth defect
Yes
No
SAE Classification: A significant medical incident
that, based upon appropriate medical judgment,
may jeopardize the subject and require medical
or surgical intervention to prevent one of the
outcomes listed above.
Yes
No
SAE Classification: Loss of confidentiality that
results in criminal or civil liability for participation
or damage to financial standing, employability,
insurability or reputation of the participant.
Yes
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Echocardiography CARLA Follow-up
Greiser KH, Kluttig A, Schumann B, Swenne CA, Kors JA,
Kuss O, Haerting J, Schmidt H, Thiery J, Werdan K.
Cardiovascular diseases, risk factors and short-term heart
rate variability in an elderly general population: the CARLA
study 2002-2006. Eur J Epidemiol. 2009;24(3):123-42
http://www.ncbi.nlm.nih.gov/pubmed/19199053
"Cross-sectional data of a population-based cohort
including 1,779 women and men aged 45-83 years were
used to analyse associations of time and frequency domain
measures of HRV (derived from 5-min ECG segments) with
age, behavioural and biomedical risk factors and disease in
the whole sample and in a "healthy" subgroup."
publication granted by 
Dr. rer. medic. Alexander Kluttig, MPH
Leiter des Studienzentrums Halle der Nationalen Kohorte
Institut für Medizinische Epidemiologie, Biometrie und
Informatik 
Martin-Luther-Universität Halle-Wittenberg 
Magdeburger Str. 8 
D-06097 Halle/Saale
All rights reserved. Please visit https://medical-data-
models.org/forms/16631
Echocardiography CARLA Follow-up
General information
Subject ID
Examiner ID
Date of investigation
Beginning of investigation
Site of echocardiography device
Room no. 119 (on the right, old device)
(A)
Room no. 111 (on the left, new device)
(N)
Medical history: 1. Heart failure /
Myocardial insufficiency
1. a) Have you been diagnosed with a heart
disease?
I don't know (-8)
Yes (1)
No (2)
1. b) Do you experience shortness of breath,
fatigue, or palpitation during physical activity ?
No (if 1.a =  (1)
During ordinary physical activity
(climbing several floors of stairs; NYHA
II) (2)
During less than ordinary activity
(climbing less than one floor of stairs;
NYHA III) (3)
At rest and during any physical activity
(NYHA IV) (4)
1. c) How often do you have these symptoms?
1 / 7
During any physical activity (1)
Max. 5 episodes/day (2)
Max. 5 episodes/week (3)
Max. 5 episodes/month (4)
Medical history: 2. Angina pectoris /
Coronary heart disease
2. a) Have you been diagnosed with coronary
heart disease (CHD)?
I don't know (-8)
Yes (1)
No (2)
2. b) Do you experience chest pain during
physical activity (angina pectoris)?
No (if 2.a = (1)
During ordinary physical activity
(climbing several floors of stairs; CCS II)
(2)
During less than ordinary activity
(climbing less than one floor of stairs;
CCS III) (3)
At rest and during any physical activity
(CCS IV) (4)
2. c) How often do you have these complaints?
During any physical activity (1)
Max. 5 episodes/day (2)
Max. 5 episodes/week (3)
Max. 5 episodes/month (4)
Medical history: 3. Cardiac arrhythmia
Do you suffer/Have you ever suffered from
tachycardia?
I don't know (-8)
Not specified (-9)
Yes (1)
No (2)
Do you suffer/Have you ever suffered from
palpitations?
I don't know (-8)
Not specified (-9)
Yes (1)
No (2)
Do you suffer/Have you ever suffered from
skipped heart beats?
I don't know (-8)
Not specified (-9)
Yes (1)
No (2)
Cardiac arrhythmia: plain text diagnosis
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Medical history: Medical history: Further
symptoms of cardiac insufficiency
4. Did you experience a syncope during the past
12 months?
I don't know (-8)
Not specified (-9)
Yes (1)
No (2)
5. Are you able to lie down?
I don't know (-8)
Not specified (-9)
Yes (1)
No (2)
6. Do you suffer from water retention in the legs
in the evening?
I don't know (-8)
Not specified (-9)
Yes (1)
No (2)
Echocardiography
Parasternal investigation possible?
Fine (1)
Limited (2)
Not sufficient for analysis (3)
Apical investigation possible?
Fine (1)
Limited (2)
Not sufficient for analysis (3)
Completeness of investigated parameters
Complete (1)
Incomplete (2)
In case of incompleteness of parameters, please
specify reason
Obesity (1)
COPD (2)
Asthenic physique (3)
Other (4)
If other reason applies, please specify
Comments
Control of findings/supervision by (physician ID):
End of echocardiography
hh:mm
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Data entry: Echocardiography
1st data entry: DNo.
1st data entry: Date
2nd data entry: DNo.
2nd data entry: Date
1. Echocardiography Online-/Offline-
Reading
Reader number
Date of reading
Beginning of reading
hh:mm
Completeness of measured parameters
Complete (1)
Incomplete (2)
In case of incompleteness of parameters, please
specify reason
Missing images/data (1)
Poor quality of images (2)
Other (3)
If other reason applies, please specify
Comments
Recommendation Text
Recommendation
Visit physician in the near future for
control/clarification (1)
Visit physician or medical emergency
service immediately (2)
Subjects needs to be informed
immediately about results (3)
In case subject needs to be informed
immediately, please specify
By telephone (1)
Preliminary dispatch (2)
Which results will the subject be informed about?
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Signature of treating physician
Name of treating physician
Data entry: Online-/Offline-Reading
1st data entry: DNo.
1st data entry: Date
2nd data entry: DNo.
2nd data entry: Date
2. Echocardiography Offline-Reading
Subject ID
Reader number
Date of reading
Beginning of reading
hh:mm
Completeness of measured parameters
Complete (1)
Incomplete (2)
In case of incompleteness of parameters, please
specify reason
Missing images/data (1)
Poor quality of images (2)
Other (3)
If other reason applies, please specify
Comments
Signature of treating physician
Name of treating physician
End of Echo-Reading
hh:mm
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Data entry: Offline-Reading
1st data entry: DNo.
1st data entry: Date
2nd data entry: DNo.
2nd data entry: Date
Final evaluation of medical investigations
Physician ID
Date
ECG evaluation: medical diagnosis
Recommendation Text
Recommendation
Visit physician in the near future for
control/clarification (1)
Visit physician or medical emergency
service immediately (2)
Subjects needs to be informed
immediately about results (3)
In case subject needs to be informed
immediately, please specify
By telephone (1)
Preliminary dispatch (2)
Which results will the subject be informed about?
Signature of treating physician
Name of treating physician
Data entry: Final evaluation
1st data entry: DNo.
1st data entry: Date
2nd data entry: DNo.
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2nd data entry: Date
7 / 7
Echocardiography CARLA Follow-up
Serious Adverse Event Part II: CRF
Wisconsin Madison
ODM Form derived from:
https://ictr.wisc.edu/CaseReptTempt. Template Name:
Serious Adverse Event Part II. Case Report Form
(CRF)/Source Document templates were created for
University of Wisconsin-Madison researchers. These
templates are consistent with the FDA's CDASH (Clinical
Data Acquisition Standards Harmonization) standards. The
CDASH standards identify those elements that should be
captured on a Case Report Form (CRF). The forms serve
only as templates, and must be edited to meet the study
data collection needs as described in the protocol.
All rights reserved. Please visit https://medical-data-
models.org/forms/16632
Serious Adverse Event Part II: CRF
Wisconsin Madison
Header
PI Name
Protocol or IRB Number
Protocol Short Title
Subject Initials
Subject ID
Serious Adverse Event
Report to the IRB
Immediately (1)
Next Continuing Review (2)
Not Applicable (3)
Course start date (Enter date that course of
treatment was initiated, if applicable)
AE Description/Details
Category
Grade/Severity
Mild (1)
Moderate (2)
Severe (3)
Life Threatening (4)
Death (Fatal) (5)
Unexpected?
Yes
No
Dose Limiting Toxicity (DLT)
Yes (1)
No (2)
Not Applicable (3)
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Action Taken
Dose Reduced (1)
Dose Interrupted, then Reduced (2)
None (3)
Regimen Interrupted (4)
Therapy discontinued (5)
Not Applicable (leave blank) (6)
Therapy
None (1)
Supportive (2)
Symptomatic (3)
Vigorous Supportive (4)
Protocol Attribution
Definite (1)
Probable (2)
Possible (3)
Unlikely (4)
Unrelated (5)
Detailed Attribution
Disease/Condition  (1)
Investigational Treatment (2)
Non-investigational Treatment (3)
Other (4)
If Disease, please specify
If Investigational Treatment, please specify
If Non-Investigational Treatment, please specify
If Other, please specify
Principal Investigator Signature
Date
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Eligibility Cardiovascular Diseases
NCT00091962
Effectiveness of Depression Treatment Following Coronary
Artery Bypass Surgery; ODM derived from:
https://clinicaltrials.gov/show/NCT00091962
All rights reserved. Please visit https://medical-data-
models.org/forms/16633
Eligibility Cardiovascular Diseases
NCT00091962
Inclusion Criteria
recently underwent cabg (combined or redo
procedure) at one of 8 pittsburgh area study
hospitals*
Yes
No
a phq score greater than 10 or if nondepressed
control, a phq score less than 5 at both 2 days
post cabg to the date of discharge following cabg
and when reassessed 2 weeks after hospital
discharge*
Yes
No
folstein mini-mental state examination (mmse)
score greater than or equal to 24*
Yes
No
able to be evaluated and treated for depression
as an outpatient post cabg*
Yes
No
has a household telephone*
Yes
No
Exclusion Criteria
presently in treatment with a mental health
specialist*
Yes
No
actively  suicidal*
Yes
No
history of psychotic illness*
Yes
No
history of bipolar illness according to subject self-
report and past medical history*
Yes
No
current alcohol dependence or other substance
abuse as evidenced by chart review and the cage
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questionnaire*
Yes
No
organic mood syndromes, including those
secondary to medical illness or drugs*
Yes
No
presence of non-cardiovascular conditions that
are likely to be fatal within 1 year*
Yes
No
unstable medical condition as indicated by
history, physical, and/or laboratory findings*
Yes
No
previous enrollment in the study cohort*
Yes
No
non-english speaking, illiterate, or possessing
any other communication barrier*
Yes
No
if nondepressed control, current or previous
diagnosis or treatment of depression*
Yes
No
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ECG CARLA
Greiser KH, Kluttig A, Schumann B, Swenne CA, Kors JA,
Kuss O, Haerting J, Schmidt H, Thiery J, Werdan K.
Cardiovascular diseases, risk factors and short-term heart
rate variability in an elderly general population: the CARLA
study 2002-2006. Eur J Epidemiol. 2009;24(3):123-42
http://www.ncbi.nlm.nih.gov/pubmed/19199053
"Cross-sectional data of a population-based cohort
including 1,779 women and men aged 45-83 years were
used to analyse associations of time and frequency domain
measures of HRV (derived from 5-min ECG segments) with
age, behavioural and biomedical risk factors and disease in
the whole sample and in a "healthy" subgroup."
publication granted by 
Dr. rer. medic. Alexander Kluttig, MPH
Leiter des Studienzentrums Halle der Nationalen Kohorte
Institut für Medizinische Epidemiologie, Biometrie und
Informatik 
Martin-Luther-Universität Halle-Wittenberg 
Magdeburger Str. 8 
D-06097 Halle/Saale
All rights reserved. Please visit https://medical-data-
models.org/forms/16634
ECG CARLA
General information
Subject ID
Date of birth (subject)
Examiner ID
Date of investigation
Beginning of ECG investigation
Interview / Short medical history
1. Has an ECG ever been performed on you
before?
I don't know (I don't know)
No (No)
Yes (Yes)
1 a) If yes, how long ago is your last ECG
investigation?
< 4 weeks (< 4 weeks)
> 1 year (> 1 year)
2-12 months (2-12 months)
I don't know (I don't know)
1 b) If yes, has your ECG always been normal?
I don't know (I don't know)
No (No)
Yes (Yes)
2. Have you ever been diagnosed with a cardiac
defect (currently, formerly, or during infancy)?
I don't know (I don't know)
No (No)
Yes (Yes)
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3. Are you on medication because of a
cardiovascular disease?
I don't know (I don't know)
No (No)
Yes (Yes)
4. Have you ever been diagnosed with a heart
attack?
I don't know (I don't know)
No (No)
Yes (Yes)
5. Have you been diagnosed with a cardiac
valvular defect?
I don't know (I don't know)
No (No)
Yes (Yes)
6. Did you ever have a cardiac catherization?
I don't know (I don't know)
No (No)
Yes (Yes)
7. Have you ever been diagnosed with cardiac
arrythmia?
I don't know (I don't know)
No (No)
Yes (Yes)
8. Did you ever have heart surgery?
I don't know (I don't know)
No (No)
Yes (Yes)
9. Do you/Did you ever suffer from pulmonary
disease?
I don't know (I don't know)
No (No)
Yes (Yes)
10. Do you/Did you ever suffer from a disease of
the liver?
I don't know (I don't know)
No (No)
Yes (Yes)
11. Do you/Did you ever suffer from a stroke
(apoplectic insult)?
I don't know (I don't know)
No (No)
Yes (Yes)
12. Do you/Did you ever suffer from an
angiopathy (e. g. of the leg arteries, the carotid
artery)?
I don't know (I don't know)
No (No)
Yes (Yes)
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ECG registration
Has thorax angle been used?
Missing (Missing)
No (No)
Yes (Yes)
ECG electrodes
O.K. (O.K.)
Shifted position (Shifted position)
10 seconds 12 channel ECG 50 mm/sec
Both missing (Both missing)
Paper (Paper)
Saved on computer (Saved on computer)
If ECG data are missing, please specify reason
Malfunction ECG recorder (1)
Laptop defect (2)
Vacuum pump defect (3)
Subject refuses ECG (4)
Other (see Comments/Special incidents)
(5)
20 minutes 12 channel resting ECG
Computer O.K. (Computer O.K.)
Missing (Missing)
With deficiencies (With deficiencies)
If resting ECG data are missing, please specify
reason
Malfunction ECG recorder (1)
Laptop defect (2)
Vacuum pump defect (3)
Subject refuses ECG (4)
Other (see Comments/Special incidents)
(5)
With metronome-controlled breathing
Yes
No
Further information
Comments/Special incidents
End of ECG investigation
Data entry
1st data entry: DNo.
1st data entry: Date
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2nd data entry: DNo.
2nd data entry: Date
Codes
CB
Code
Findings
FP-Code
Comments
ECG Analysis
ECG Quality
N-SVES
N-VES
Comments
Analyzability of ECG
not analyzable (6)
missing (9)
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Subject Deviation/Violation Form: CRF
Wisconsin Madison
ODM Form derived from:
https://ictr.wisc.edu/CaseReptTempt. Template Name:
Subject Deviation/Violation Form. Case Report Form
(CRF)/Source Document templates were created for
University of Wisconsin-Madison researchers. These
templates are consistent with the FDA's CDASH (Clinical
Data Acquisition Standards Harmonization) standards. The
CDASH standards identify those elements that should be
captured on a Case Report Form (CRF). The forms serve
only as templates, and must be edited to meet the study
data collection needs as described in the protocol.
All rights reserved. Please visit https://medical-data-
models.org/forms/16635
Subject Deviation/Violation Form:
CRF Wisconsin Madison
Header
PI Name
Protocol or IRB Number
Protocol Short Title
Subject Initials
Subject ID
Subject Deviation/Unanticipated
Event/Violation
Start Date
End Date
Reported Date
Reported By
Description of Deviation
Deviation Category
Consent Deviation (1)
Drug/Device Administration Deviation (2)
Enrollment Deviation (3)
Procedural Deviation (4)
Other (5)
Effect on Patient Care
Action Taken
Report to the IRB
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Immediately (1)
Not applicable (i.e. does not meet
Reportable Event criteria) (2)
Date Reported to the IRB
Principal Investigator Signature
Date
2 / 2
Subject Deviation/Violation Form: CRF Wisconsin Madison
Subject Deviation/Violation Log: CRF
Wisconsin Madison
ODM Form derived from:
https://ictr.wisc.edu/CaseReptTempt. Template Name:
Subject Deviation/Violation Log. Case Report Form
(CRF)/Source Document templates were created for
University of Wisconsin-Madison researchers. These
templates are consistent with the FDA's CDASH (Clinical
Data Acquisition Standards Harmonization) standards. The
CDASH standards identify those elements that should be
captured on a Case Report Form (CRF). The forms serve
only as templates, and must be edited to meet the study
data collection needs as described in the protocol.
All rights reserved. Please visit https://medical-data-
models.org/forms/16636
Subject Deviation/Violation Log: CRF
Wisconsin Madison
Header
PI Name
Protocol or IRB Number
Protocol Short Title
Subject Initials
Subject ID
Number of Pages
Total Number of Pages
Deviation Tracking Log
#
Deviation Start Date
Deviation Ende Date
Deviation Description
Deviation Category
Does the Deviation Impact Subject Safety
Yes (1)
No (2)
Not Applicable (3)
Does the Deviation Affect Data Integrity
Yes (1)
No (2)
Not Applicable (3)
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Does the Deviation Affect Subject´s Willingness
to participate?
Yes (1)
No (2)
Not Applicable (3)
Reported to IRB
Reported to IRB: Not Applicable
Yes
No
PI Initials
Date of PI Initials
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Eligibility Cardiovascular Diseases
NCT00094783
MRI-Guided Balloon Angioplasty to Treat Blood Flow
Blockage in the Legs; ODM derived from:
https://clinicaltrials.gov/show/NCT00094783
All rights reserved. Please visit https://medical-data-
models.org/forms/16637
Eligibility Cardiovascular Diseases
NCT00094783
Criteria
patients with known or suspected cardiovascular
disease will be eligible for participation in this
protocol. the patient is eligible under the following
conditions:*
Yes
No
patients age is greater than 18 years of age.*
Yes
No
undergoing a clinically-indicated therapeutic
peripheral artery catheterization procedure.*
Yes
No
target peripheral artery is aorto-illac or
femoropopliteal artery.*
Yes
No
target peripheral artery stenoses, not occlusions,
evident on magnetic resonance or x-ray
angiography.*
Yes
No
Exclusion Criteria
patients with absolute contraindications to mri
scanning will be excluded. these
contraindications include patients with the
following devices:*
Yes
No
implanted cardiac pacemaker or defibrillator.*
Yes
No
central nervous system aneurysm clips.*
Yes
No
implanted neural stimulator.*
Yes
No
cochlear implant.*
Yes
No
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ocular foreign body (e.g. metal shavings).*
Yes
No
insulin pump.*
Yes
No
metal shrapnel or bullet.*
Yes
No
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Eligibility Cardiovascular Diseases
NCT00101491
STORIES-Stories to Communicate Risk About Tobacco;
ODM derived from:
https://clinicaltrials.gov/show/NCT00101491
All rights reserved. Please visit https://medical-data-
models.org/forms/16638
Eligibility Cardiovascular Diseases
NCT00101491
Criteria
Inclusion Criteria
african americans*
Yes
No
patients not previously video/interviewed talking
about smoking and health*
Yes
No
patients willing to provide contact information for
follow up*
Yes
No
patients that are able to hear, view and
communicate their input on material*
Yes
No
Exclusion Criteria
patients other than african american*
Yes
No
admitted with issues of alcohol, drugs, and
mentally unstable*
Yes
No
patients leaving the state after hospitalization*
Yes
No
patients without contact information for follow up*
Yes
No
patients below age 19*
Yes
No
non smokers*
Yes
No
patients that use chewing tobacco*
Yes
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No
patients that are incarcerated*
Yes
No
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Telephone Contact: CRF Wisconsin
Madison
ODM Form derived from:
https://ictr.wisc.edu/CaseReptTempt. Template Name:
Telephone Contact. Case Report Form (CRF)/Source
Document templates were created for University of
Wisconsin-Madison researchers. These templates are
consistent with the FDA's CDASH (Clinical Data Acquisition
Standards Harmonization) standards. The CDASH
standards identify those elements that should be captured
on a Case Report Form (CRF). The forms serve only as
templates, and must be edited to meet the study data
collection needs as described in the protocol.
All rights reserved. Please visit https://medical-data-
models.org/forms/16639
Telephone Contact: CRF Wisconsin
Madison
Header
PI (Last Name, First Name)
IRB Number
Short Title
Subject Initials
Subject ID
Date
Telephone contact not performed, If Telephone
contact not performed, complete the Subject
Deviation Form
Yes
No
Telephone Contact: Contact Attempt #1
Date of Contact Attempt
Time: AM
Yes
No
Time: PM
Yes
No
Contact Occurred
Yes
No
Outcome
No Answer (1)
Left Voice Message (2)
Left Message w/___ (3)
Line Busy (4)
Other___ (5)
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If Left Message please specify with who
If Other, please specify
Telephone Contact: Contact Attempt #2
Date of Contact Attempt
Time: AM
Yes
No
Time: PM
Yes
No
Contact Occurred
Yes
No
Outcome
No Answer (1)
Left Voice Message (2)
Left Message w/___ (3)
Line Busy (4)
Other___ (5)
If Left Message, please specify with who
If Other, please specify
Telephone Contact: Contact Attempt #3
Date of Contact Attempt
Time: AM
Yes
No
Time: PM
Yes
No
Contact Occurred
Yes
No
Outcome
No Answer (1)
Left Voice Message (2)
Left Message w/___ (3)
Line Busy (4)
Other___ (5)
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If Left Message, please specify with who
If Other, please specify
Telephone Contact: Contact Attempt #4
Date of Contact Attempt
Time: AM
Yes
No
Time: PM
Yes
No
Contact Occurred
Yes
No
Outcome
No Answer (1)
Left Voice Message (2)
Left Message w/___ (3)
Line Busy (4)
Other___ (5)
If Left Message, please specify with who
If Other, please specify
Date telephone Contact completed
Reminders to Research Staff
Insert text as reminders to research staff
Questions to be asked
Since your last study contact, have you had any
changes in health status, medical conditions, or
adverse events?
Yes
No
Changes in health status : Form No.
Concomitant Medications Log completed (if
applicable)?
Yes
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Telephone Contact: CRF Wisconsin Madison
No
Concomitant Medications: Form No.
Adverse Event Symptoms reviewed with Subject?
Yes
No
Adverse Event Symptoms reviewed with
Subject?: Form No.
Adverse event tracking log completed (same log
from all visits)?
Yes
No
Adverse event tracking log completed?: Form No.
If any AE has "Yes" in Serious column, complete
SAE form and enter the information in Subject
Console > SAE screen of OnCore?
Yes
No
If any AE has "Yes" in Serious column, complete
SAE form and enter the information in Subject
Console > SAE screen of OnCore?: Form No.
Does the medical history form need to be
updated?
Yes
No
Does the medical history form need to be
updated?: Form No.
Were there any activities that deviated from the
defined protocol?
Yes
No
Were there any activities that deviated from the
defined protocol?: Form No.
If yes, completed the Deviation/Violation form and
enter the information in the Subject Console >
Deviations screen of OnCore?
Yes
No
If yes, completed the Deviation/Violation form and
enter the information in the Subject Console >
Deviations screen of OnCore?: Form No.
Subject payment confirmed (if applicable)
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Telephone Contact: CRF Wisconsin Madison
Yes
No
Subject payment confirmed (if applicable): Form
No.
Other Question to ask (if applicable)
Yes
No
Other Questions to ask (if applicable): Form No.
Comments
Telephone contact conduced by
Form completed by
Date
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EBMT Solid Tumors
ODM form derived from 14pp EBMT Solid Tumors
11SoTu.pdf refer to: http://www.ebmt.org/Contents/Data-
Management/Registrystructure/MED-
ABdatacollectionforms/Pages/MED-AB-data-collection-
forms.aspx
All rights reserved. Please visit https://medical-data-
models.org/forms/16640
EBMT Solid Tumors
EBMT FORM GENERAL INFORMATION
EBMT FORM GENERAL INFORMATION
Hospital
Unit
Name of contact person
Telephone
Fax
E-mail address of contact number
Date of this report
STUDY/TRIAL
Patient following national / international study /
trial
No (1)
Yes (2)
Not evaluated (3)
Unknown (4)
Name of study / trial
PATIENT
To be entered only if patient previously reported
Hospital Unique Patient Number or Code
First name(s)_surname(s)
Date of Birth
Sex
Male (1)
Female (2)
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ABO Group
Rh factor
Absent (1)
Present (2)
Not evaluated (3)
DISEASE
Date of diagnosis
Check the disease for which this transplant was
performed
Acute Leukaemia (Acute Leukaemia)
Acute Lymphoblastic Leukaemia (ALL)
(Acute Lymphoblastic Leukaemia (ALL))
Acute Myelogenous Leukaemia (AML)
(Acute Myelogenous Leukaemia (AML))
Autoimmune disease (Autoimmune
disease)
Bone marrow failure including Aplastic
anaemia (Bone marrow failure including
Aplastic anaemia)
Chronic Leukaemia (Chronic Leukaemia)
Chronic Lymphocytic Leukaemia
(Chronic Lymphocytic Leukaemia)
Chronic Myeloid Leukaemia (CML)
(Chronic Myeloid Leukaemia (CML))
Haemoglobinopathies
(Haemoglobinopathiy)
Histiocytic disorders (Histiocytic
disorders)
Hodgkin´s Disease (Hodgkin´s Disease)
Inherited disorders (Inherited disorders)
Juvenile Idiopathic Arthritis (Juvenile
Idiopathic Arthritis)
Lymphoma (Lymphoma)
MD/ MPN (MD/ MPN)
MDS (MDS)
Metabolic disorders (Metabolic
disorders)
Multiple Sclerosis (Multiple Sclerosis)
Myelodysplastic syndromes
(Myelodysplastic syndromes)
Myeloma/ Plasma cell disorder
(Myeloma/ Plasma cell disorder)
Myeloproliferative neoplasm
(Myeloproliferative neoplasm)
Non Hodgkin (Non Hodgkin)
Other diagnosis (Other diagnosis)
Primary immune deficiencies (Primary
immune deficiencies)
Secondary Acute Leukaemia (do not use
if transformed from MDS/MPN)
(Secondary Acute Leukaemia (do not
use if transformed from MDS/MPN))
Solid Tumour (Solid Tumour)
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Systemic Lupus (Systemic Lupus)
Systemic Sclerosis (Systemic Sclerosis)
SOLID TUMOURS
INITIAL DIAGNOSIS
Bone sarcoma (excluding Ewing
sarcoma/PNET) (1)
Medulloblastoma (10)
Melanoma (11)
Other, specify (12)
Breast cancer (13)
Neuroblastoma (14)
Ovarian cancer (15)
Pancreas (16)
Prostate (17)
Renal cell (18)
Retinoblastoma (19)
Central nervous system tumors (include
CNS PNET) (2)
Rhabdomyosarcoma (20)
Soft tissue sarcoma (21)
Testicular cancer (22)
Thymoma (23)
Wilms tumour (24)
Colorectal (3)
Ewing sarcoma/PNET, extra-skeletal (4)
Ewing sarcoma/PNET, skeletal (5)
Germ cell tumour, extragonadal only (6)
Hepatobiliary (7)
Lung cancer, non-small cell (8)
Lung cancer, small cell (9)
INITIAL DIAGNOSIS: if other specify
Clinical TNM classification Tumor
0 (1)
1 (2)
2 (3)
3 (4)
4 (5)
X (6)
not evaluated (7)
Clinical TNM classification Tumor Nodes
0 (1)
1 (2)
2 (3)
3 (4)
X (5)
not evaluated (6)
unknown (7)
Clinical TNM classification Metastases
0 (1)
1 (2)
X (3)
not evaluated (4)
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unknown (5)
Disease-specific staging
1 (1)
2 (2)
3 (3)
4 (4)
HISTOLOGICAL SUBCLASSIFICATION
Describe
BREAST CARCINOMA ONLY
Inflammatory (1)
Non-inflammatory (2)
RECEPTOR STATUS Estrogen (ER)
Negative (1)
Not evaluated (2)
Positive (3)
Unknown (4)
Not evaluated (5)
Unknown (6)
RECEPTOR STATUS positive: Values
RECEPTOR STATUS Progesterone (PgR)
( )
Negative (1)
Not evaluated (2)
Positive (3)
Unknown (4)
Not evaluated (5)
Progesterone Receptor Status positive: Values
RECEPTOR STATUS HER2/neu (c-erb-B2)
Negative (1)
Positive (2)
Not evaluated (3)
Unknown (4)
If RECEPTOR STATUS HER2/neu (c-erb-B2)
positiv :
IHC 3+ (1)
IHC 2+ and FISH + (2)
Unknown (3)
HISTOLOGICAL SUBCLASSIFICATION
FOR BREAST CARCINOMA
Number of positive Axillary lymph nodes
Number of examined Axillary lymph nodes
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Axillary lymph nodes Not evaluated
S.B.R. (Scarff-Bloom-Richardson)
1 (1)
2 (2)
3 (3)
not evaluated (4)
unknown (5)
Ductal carcinoma
yes (1)
no (2)
not evaluated (3)
unknown (4)
Lobular carcinoma
yes (1)
no (2)
not evaluated (3)
unknown (4)
CYTOGENETICS
CHROMOSOME ANALYSIS
Normal (1)
Abnormal (2)
Not done (3)
Unknown (4)
CHROMOSOME ANALYSIS
If aberrations, notify chromosomal
aberrations (e.g. tri/monosomy) and/or
other results, in clear (1)
Molecular markers
Evaluated: Absent  (1)
Evaluated: Present (2)
Not evaluated (3)
unknown (4)
TREATMENT GIVEN BEFORE THIS
HSCT
Treatment given
no (1)
yes (2)
FIRST LINE TREATMENT
1st line treatment started
Did the first-line treatment include HSCT
yes (1)
no (2)
if the first-line treatment include HSCT
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Upfront (1)
Adjuvant (2)
Modality
Chemotherapy (1)
Adjuvant Chemotherapy (2)
Neoadjuvant Chemotherapy (3)
Surgery (4)
Radiotherapy (5)
Other (6)
Drugs
Anthracyclines (1)
Taxanes (2)
Platinum compounds (3)
Antimetabolites (4)
Cyclophosphamide or other alkylating
agents (5)
Vinca Alkaloids (6)
Etoposide (7)
Other (8)
if other drugs
If breast cancer, type of surgery
Mastectomy (1)
Conservative (2)
if other Modality
Status of disease after first line treatment (best
response)
Complete Remission (1)
Partial Remission (2)
Not Evaluable (3)
Stable Disease (4)
Refractory Disease (5)
Criteria used for evaluation
WHO criteria (1)
RECIST criteria (2)
ADDITIONAL LINES OF TREATMENT BEFORE
THIS HSCT FOR RELAPSED/REFRACTORY
DISEASE
no (1)
yes (2)
TREATMENT HISTORY BEFORE HSCT
Date of HSCT
Total number of lines before this HSCT
1 (1)
2 (2)
3 (3)
4 (4)
>4 (5)
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unknown (6)
Modality used at least once Chemotherapy
no (1)
yes (2)
unknown (3)
Modality used at least once Surgery
no (1)
yes (2)
unknown (3)
Modality used at least once Radiotherapy
no (1)
yes (2)
unknown (3)
Modality used at least once other
no (1)
yes (2)
unknown (3)
STATUS OF DISEASE AT HSCT
STATUS OF DISEASE AT HSCT
Adjuvant (1)
Never treated (upfront) (2)
Primary refractory (3)
Complete remission (CR) (4)
1st Partial remission (PR1) (5)
Relapse (6)
Progressive disease (PD) (7)
if CR please specify
Confirmed (1)
Unconfirmed (CRU*) (2)
Unknown (3)
if Relapse please specify
Local (1)
Metastatic (2)
Complete remission (CR) Number
1st (1)
2nd (2)
3rd or higher (3)
Complete relapse Number
1st (1)
2nd (2)
3rd or higher (3)
SENSITIVITY TO CHEMOTHERAPY
Sensitive (SR:>50% response) (1)
Resistant (RR:<50% response) (2)
Untreated (3)
Organ(s) involved
Nodes Below Diaphragm (1)
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Lungs (10)
Heart (11)
Skin (12)
Urogenital tract (13)
Ovaries/Testes (14)
Bone marrow (2)
CNS (3)
Mediastinum (4)
Soft Tissue (5)
Gastrointestinal tract (6)
Liver (7)
Nodes Above Diaphragm (8)
Bone (9)
Primary site affected
yes (1)
no (2)
ADDITIONAL TREATMENT POST-HSCT
Additional Disease Treatment
Yes
No
if ADDITIONAL DISEASE TREATMENT
Planned (planned before HSCT took
place) (1)
Not planned (for relapse/progression or
persistent disease) (2)
BEST DISEASE RESPONSE AT 100
DAYS POST-HSCT
BEST RESPONSE AT 100 DAYS AFTER HSCT
Complete Remission (1)
Very Good Partial Remission (2)
Partial Remission (>50%) (3)
Not Evaluable (4)
Stable Disease (5)
Progressive Disease (6)
Minor Response (>25% and <50%) (7)
Date of Evaluation
FORMS TO BE FILLED IN
TYPE OF TRANSPLANT
AUTOgraft, proceed to Autograft form (1)
ALLOgraft or Syngeneic graft, proceed to
Allograft form (2)
Other (3)
it other type of transplant contact the EBMT
Central Registry Office for instructions
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EBMT Solid Tumors Follow up
ODM form derived from 14pp EBMT Solid Tumors
11SoTu.pdf refer to: http://www.ebmt.org/Contents/Data-
Management/Registrystructure/MED-
ABdatacollectionforms/Pages/MED-AB-data-collection-
forms.aspx
All rights reserved. Please visit https://medical-data-
models.org/forms/16641
EBMT Solid Tumors Follow up
FOLLOW UP MULTIPLE SCLEROSIS
Unique Identification Code (UIC)
(if known)
Date of this report
Patient following national / international study /
trial
No (1)
Yes (2)
Not evaluated (3)
Unknown (4)
Name of study / trial
Hospital Unique Patient Number
First name(s)_surname(s)
Date of Birth
Date of last HSCT for this patient
DATE OF LAST CONTACT OR DEATH
GRAFT VERSUS HOST DISEASE
(GvHD) SINCE LAST REPORT
Acute Graft versus Host Disease (aGvHD) -
Maximum grade
grade 0 (absent) (grade 0 (absent))
grade I (grade I)
grade II (grade II)
grade III (grade III)
grade IV (grade IV)
not evaluated (not evaluated)
If present GvHD, Maximum grade
New onset (1)
Recurrent (2)
Persistent (3)
Reason Maximum grade
Tapering (1)
DLI (2)
1 / 11
Unexplained (3)
Date onset of this episode (if new or recurrent)
yyyy/mm/dd
Date onset of this episode
Not applicable (1)
aGvHD Stage Skin
0 (1)
1 (2)
2 (3)
3 (4)
4 (5)
Not evaluated (6)
unknown (7)
aGvHD Stage liver
0 (1)
1 (2)
2 (3)
3 (4)
4 (5)
Not evaluated (6)
unknown (7)
aGvHD stage gut
0 (1)
1 (2)
2 (3)
3 (4)
4 (5)
Not evaluated (6)
unknown (7)
Resolution
No  (1)
Yes (2)
aGvHD Date of resolutions
Presence of cGvHD
No (No)
Present continuously since last reported
episode (Present continuously since last
reported episode)
Resolved (Resolved)
Yes (Yes)
Date of onset
cGvHD grade
limited (1)
Extensive (2)
Organs affected
Skin (1)
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Gut (2)
Liver (3)
Mouth (4)
Eyes (5)
Lung (6)
Other, specify (7)
Unknown (8)
If other organs affected, please specify
cGvHD Resolved: Date of resolution
OTHER COMPLICATIONS SINCE LAST
REPORT
INFECTION RELATED COMPLICATIONS
No complications (1)
Yes (2)
Bacteremia / fungemia / viremia / parasites
Pathogen (1)
Date (2)
Septic shock
Pathogen  (1)
Date (2)
ARDS
Pathogen  (1)
Date (2)
Multiorgan failure due to infection
Pathogen  (1)
Date (2)
Pneumonia
Pathogen  (1)
Date (2)
Hepatitis
Pathogen  (1)
Date (2)
CNS infection
Pathogen  (1)
Date (2)
Gut infection
Pathogen  (1)
Date (2)
Skin infection
Pathogen  (1)
Date (2)
Cystitis
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Date (Date)
Pathogen (Pathogen)
Retinitis
Date (Date)
Pathogen (Pathogen)
Other pathogen specified
NON INFECTION RELATED COMPLICATIONS
No complications (1)
Yes (2)
Idiopathic pneumonia syndrome
No  (No )
Unknown (Unknown)
Yes (Yes)
VOD
No  (No )
Unknown (Unknown)
Yes (Yes)
Cataract
No (No)
Unknown (Unknown)
Yes (Yes)
Haemorrhagic cystitis, non infectious
No  (No )
Unknown (Unknown)
Yes  (Yes )
Specify:
ARDS, non infectious
No (No)
Unknown (Unknown)
Yes (Yes)
Multiorgan failure, non infectious
no  (no )
unknown (unknown)
yes  (yes )
HSCT-associated microangiopathy
Date (4)
No (No)
Unknown (Unknown)
Yes (Yes)
Renal failure requiring dialysis
Date (Date)
No (No)
Unknown (Unknown)
Yes (Yes)
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Haemolytic anaemia due to blood group
Date (4)
No (No)
Unknown (Unknown)
Yes (Yes)
Aseptic bone necrosis
Date (Date)
No (No)
Unknown (Unknown)
Yes (Yes)
Other type of NON INFECTION RELATED
COMPLICATIONS, please specify
Idiopathic pneumonia syndrome
Graft loss
No (No)
Not evaluated (Not evaluated)
Yes (Yes)
Overall chimaerism
Full (donor >95%) (1)
Mixed (partial) (2)
Autologuos reconstitution (recipient >
95%) (3)
Aplasia (4)
Not evaluated (5)
Date of test
(Indicate the date(s) and results of all tests done
for all donors. Split the results by donor and by
the cell type on which the test was performed if
applicable. Copy this table as many times as
necessary.)
Identification of donor or Cord Blood Unit given
by the centre
Number in the infusion order (if applicable)
Cell type on which test was performed % Donor
cells
B-Cells
%
BM (1)
Other, specify (10)
PB mononuclear cells (PBMC) (2)
T-cell (3)
B-cells (4)
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Red blood cells (5)
Monocytes (6)
PMNs (neutrophils) (7)
Lymphocytes, NOS (8)
Myeloid cells, NOS (9)
Laboratory tests used
ABO group (ABO group)
Cytogenetic (Cytogenetic)
FISH (FISH)
Molecular (Molecular)
Other (Other)
unknown (unknown)
Test used:
If other, specify:
SECONDARY MALIGNANCY,
LYMPHOPROLIFERATIVE OR
MYELOPROLIFRATIVE DISORDER
DIAGNOSED
No at date of this follow-up (No at date of
this follow-up)
Previously reported (Previously reported)
Yes (Yes)
Date of Diagnosis
Diagnosis OTHER COMPLICATIONS SINCE
LAST REPORT
AML (AML)
Lymphoproliferative disorder
(Lymphoproliferative disorder)
MDS (MDS)
Other (Other)
Diagnosis, other:
ADDITIONAL THERAPIES SINCE LAST
FOLLOW UP
Additional treatment given since last report
Date (4)
No (No)
Unknown (Unknown)
Yes (Yes)
If treatment given since last report
If yes: Cellular therapy (One cell therapy regimen
is defined as any number of infusions given within
10 weeks for the same indication. If more than
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one regimen of cell therapy has been given since
last report, copy this section and complete it as
many times as necessary.)
No  (1)
Yes (Mark disease status before this
cellular therapy) (2)
Unknown (3)
Disease status before this cellular therapy
CR (CR)
Not evaluated (Not evaluated)
Not in CR (Not in CR)
If yes: Type of cells
Donor lymphocyte infusion (DLI) (1)
Mesenchymal cells (2)
Other (3)
Unknown (4)
If other
Chronological number of this cell therapy for this
patient
Number of Nucleated cells infused (DLI only)
10^8/kg
Number (1)
Not evaluated (2)
Unknown (3)
If DLI, specify the number of cells infused by
type:
CD 34+
Evaluated (Evaluated)
Not Evaluated (Not Evaluated)
Unknown (Unknown)
If DLI, specify the number of cells infused by
type: 
CD 3+
Evaluated  (Evaluated )
Not evaluated (Not evaluated)
Unknown (Unknown)
If non DLI, specify total number of cells infused:
Evaluated (Evaluated)
Not Evaluated (Not Evaluated)
Unknown (Unknown)
Cell therapy indication
Planned/protocol  (1)
Treatment for disease (2)
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Prophylactic (3)
Mixed chimaerism (4)
Treatment of GvHD  (5)
Treatment viral infection (6)
Loss/decreased chimaerism  (7)
Treatment PTLD, EBV lymphoma (8)
Other, specify (9)
Number of infusions within 10 weeks (count only
infusions that are part of same regimen and given
for the same indication)
Acute Graft versus Host Disease 
(after this infusion but before any further infusion/
transplant)
Maximum grade:
grade 0 (absent) (grade 0 (absent))
grade 1 (grade 1)
grade 2 (grade 2)
grade 3 (grade 3)
grade 4 (grade 4)
present, grade unknown (present, grade
unknown)
Disease treatment (apart from donor cell infusion
or other type of cell therapy)
No (1)
Yes: Planned (planned before HSCT took
place) (2)
Yes: Not planned (for
relapse/progression or persistent
disease) (3)
Date started
Overall main reason ADDITIONAL THERAPIES
Relapse/progression (1)
Continued from pre-HSCT (2)
unknow (3)
Planned per protocol (4)
Other (5)
Drugs
no (no)
unknown (unknown)
yes (yes)
Chemotherapy: If yes, mark appropriate box
Alpha interferon (Alpha interferon)
Anti-lymphocyte antibodies (Anti-
lymphocyte antibodies)
Azathioprine (Azathioprine)
Interferon Beta (Beta Interferon)
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low dose (Chronic low dose)
CopI (Cop-I)
Corticosteroids (Corticosteroids)
Cyclophosphamide (Cyclophosphamide)
Mitoxantron (Mitoxantron)
high dose (Pulse high dose)
Total lymph node (TLI)
NO (NO)
UNKNOWN (UNKNOWN)
YES (YES)
Craniospinal Irradiation
no (no)
unknown (unknown)
yes (yes)
Lymphocytopheresis
no (no)
unknown (unknown)
yes  (yes )
if other modality please specify:
FIRST EVIDENCE OF DISEASE
WORSENING SINCE LAST HSCT
EVIDENCE OF DISEASE ACTIVITY
Continuous worsening since HSCT
(Continuous worsening since HSCT)
No (No)
Previously reported (Previously reported)
Yes (Yes)
Date First Noted (mm-dd-yyyy)
Number of relapses/progressions since last
HSCT
LAST DISEASE AND PATIENT STATUS
Scripps neurological rating scale Score
Kurtzke functional systems Overall score
Kurtzke Expanded Disability Status Scale (EDSS)
Composite Scale Score
MRI BRAIN SCAN DONE
Not done (Not done)
Yes (Yes)
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Date of most recent MRI scan of brain
Results, Are new lesions present on the MRI?
no (no)
unknown (unknown)
yes (yes)
If yes Indicate new lesions present
Both (Both)
Gadolinium-enhancing (Gadolinium-
enhancing)
Unenhancing (Unenhancing)
Unknown (Unknown)
Has patient or partner become  pregnant after
this HSCT?
No (No)
Unknown (Unknown)
Yes (Yes)
Survival Status
alive (0)
dead (1)
Performance score (if alive)
Karnofsky (1)
Lansky (2)
Score
100 (Normal, NED) (1)
10 (Moribund) (10)
Not evaluated (11)
Unknown (12)
90 (Normal activity)  (2)
80 (Normal with effort) (3)
70 (Cares for self) (4)
60 (Requires occasional assistance) (5)
50 (Requires assistance) (6)
40 (Disabled) (7)
30 (Severely disabled) (8)
20 (Very sick) (9)
Cause of death (if dead)
Relapse or progression (1)
Secondary malignancy (including
lymphoproliferative disease) (2)
HSCT related cause  (3)
Unknown (4)
Other (5)
HSCT related cause
GvHD (1)
Veno-occlusive disease (VOD) (10)
Haemorrhage (11)
Cardiac toxicity (12)
Central nervous system toxicity (13)
Gastro intestinal toxicity (14)
Skin toxicity (15)
Renal failure (16)
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Multiple organ failure (17)
Other (18)
Interstitial pneumonitis (2)
Pulmonary toxicity (3)
Infection bacterial (4)
Infection viral (5)
Infection fungal (6)
Infection parasitic (7)
Infection unknown (8)
Rejection / poor graft function (9)
ADDITIONAL NOTES IF APPLICABLE
COMMENTS
Identification
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Eligibility Cardiovascular Diseases
NCT00113672
Make Better Choices Study; ODM derived from:
https://clinicaltrials.gov/show/NCT00113672
All rights reserved. Please visit https://medical-data-
models.org/forms/16644
Eligibility Cardiovascular Diseases
NCT00113672
Inclusion Criteria
sedentary community dwelling adults with a
suboptimal diet*
Yes
No
motivated to make changes in diet and activity
level*
Yes
No
Exclusion Criteria
few exclusion criteria will be implemented in order
to enhance generalizability*
Yes
No
for safety, participants with unstable medical
conditions (uncontrolled hypertension, diabetes,
recent myocardial infarction) will be excluded.
those with stable medical conditions will require
physician approval to participate but will not be
excluded because the prescribed changes in diet
and activity match healthy, attainable guidelines
for all americans.*
Yes
No
cannot read the study questionnaires*
Yes
No
committed to following an incompatible dietary
regimen*
Yes
No
pregnant, trying to get pregnant, or
breastfeeding*
Yes
No
people with anorexia, bulimia, or report active
suicidal ideation will not be enrolled because they
might practice overly severe dietary restrictions*
Yes
No
binge eating disorder*
Yes
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No
current substance abuse or dependence, other
than nicotine dependence will be excluded
because of concern about their ability to maintain
accurate records of intake and activity. smokers
will be accepted and during recreational
laboratory sessions will be able to smoke
cigarettes in an adjoining room that is used as a
smoking laboratory.*
Yes
No
2 / 2
Eligibility Cardiovascular Diseases NCT00113672
Eligibility Cardiovascular Diseases
NCT00123058
Comparison of Two Programs to Improve Blood Pressure
Treatment Adherence; ODM derived from:
https://clinicaltrials.gov/show/NCT00123058
All rights reserved. Please visit https://medical-data-
models.org/forms/16646
Eligibility Cardiovascular Diseases
NCT00123058
Inclusion Criteria
visited duke general internal medicine primary
care clinic at pickett road or duke outpatient clinic
between april 2003 and april 2004*
Yes
No
diagnosed with high bp*
Yes
No
currently residing in an eight county area,
including durham county, nc and surrounding
counties*
Yes
No
currently taking bp medication*
Yes
No
receives most medical care at the duke primary
care clinics*
Yes
No
able to speak and understand english over the
phone*
Yes
No
Exclusion Criteria
diagnosed with dementia*
Yes
No
diagnosed with parkinson's disease*
Yes
No
diagnosed with atrial fibrillation*
Yes
No
diagnosed with end stage kidney disease*
Yes
No
hospitalized for stroke, heart attack, or coronary
artery revascularization in the 3 months prior to
study entry*
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Yes
No
diagnosed with metastatic cancer in the 3 months
prior to study entry*
Yes
No
receiving kidney dialysis*
Yes
No
pregnant or expecting to become pregnant in the
2 years following study entry*
Yes
No
currently residing in a nursing home or receiving
home health care*
Yes
No
severely impaired speech or hearing*
Yes
No
participating in another blood pressure study*
Yes
No
has another family member participating in this
study*
Yes
No
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Eligibility Cardiovascular Diseases
NCT00128687
Improving Coronary Prevention in a County Health System;
ODM derived from:
https://clinicaltrials.gov/show/NCT00128687
All rights reserved. Please visit https://medical-data-
models.org/forms/16648
Eligibility Cardiovascular Diseases
NCT00128687
Criteria
Inclusion Criteria
the patient has cad or cad risk equivalent
(abdominal aortic aneurysm, peripheral vascular
disease, transient ischemic attack, stroke,
diabetes, or fbs ≥ 126 mg/dl ×*
Yes
No
2) and has at least one of following: sbp ≥ 130
mmhg, dbp ≥ 80 mmhg, ldl ≥ 100 mg/dl, hdl ≤ 40
mg/dl, tg ≥ 150 mg/dl, fbs ≥ 126 mg/dl, bmi ≥ 30,
or is a current smoker.*
Yes
No
the patient does not have cad or cad risk
equivalent but has at least one of the following:
sbp ≥ 160 mmhg, dbp ≥ 100 mmhg, ldl ≥ 190
mg/dl, tc ≥ 240 mg/dl, tg ≥ 500 mg/dl, hba1c ≥
8.0%, bmi ≥ 35, or is a current smoker.*
Yes
No
the patient does not have cad or cad risk
equivalent but has at least two of the following: a)
sbp ≥ 140 mmhg or dbp ≤ 90 mmhg, b) hdl ≤ 40
mm/dl or tg ≥ 200 mg/dl, c) ldl ≥ 160 mg/dl or tc ≥
240 mg/dl, d) fbs ≥ 110 mg/dl × 2, or e) male age
≥ 45 or female age ≥ 55 or with positive family
history of cad.*
Yes
No
Exclusion Criteria
resident of long-term facility*
Yes
No
lack of spoken english or spanish by patient or
household member 18 years or older who can
serve as an interpreter*
Yes
No
moving before end of intervention (30 months)*
Yes
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No
age between 35 and 85 (inclusive)*
Yes
No
significant comorbidities such as: uncontrolled
metabolic disorders (renal failure, liver failure,
etc.), active symptoms suggesting acute
myocardial infarction or decompensated
congestive heart failure, malignancy or other
condition limiting life expectancy, psychiatric
disorder with active manifestations.*
Yes
No
substance abuse.*
Yes
No
no telephone or means of contacting patient.*
Yes
No
family household member already enrolled.*
Yes
No
homeless and not living with relatives/friends.*
Yes
No
anticipated absence for more than 4 consecutive
months.*
Yes
No
difficulty coming to appointments approximately
every 1-2 months*
Yes
No
already participating in the diabetes program*
Yes
No
currently pregnant or intends to get pregnant the
next 3 years.*
Yes
No
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Eligibility Cardiovascular Diseases
NCT00275145
Effects of Resistance and Aerobic Exercise on
Cardiovascular Health; ODM derived from:
https://clinicaltrials.gov/show/NCT00275145
All rights reserved. Please visit https://medical-data-
models.org/forms/16649
Eligibility Cardiovascular Diseases
NCT00275145
Inclusion Criteria
sedentary (exercises fewer than two times per
week)*
Yes
No
overweight or mildly obese (body mass index
[bmi] of 25 to 35 kg/m2) with mild to moderate
lipid abnormalities (either ldl cholesterol 130 to
190 mg/dl or hdl cholesterol less than 40 mg/dl
for men or 5 less than 45 mg/dl for women)*
Yes
No
Exclusion Criteria
diabetes*
Yes
No
hypertension*
Yes
No
other metabolic or musculoskeletal diseases*
Yes
No
current use of or intent to diet*
Yes
No
use of confounding medication*
Yes
No
overt presence of coronary heart disease*
Yes
No
unwilling to be randomized to any group*
Yes
No
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NCT00317707
Risk and Prevention Study: Evaluation of the Efficacy of n-3
PUFA in Subjects at High Cardiovascular Risk; ODM
derived from: https://clinicaltrials.gov/show/NCT00317707
All rights reserved. Please visit https://medical-data-
models.org/forms/16651
Eligibility Cardiovascular Diseases
NCT00317707
Inclusion Criteria
multiple risk factors:*
Yes
No
diabetes,*
Yes
No
age => 65 years,*
Yes
No
male sex,*
Yes
No
hypertension,*
Yes
No
hypercholesterolemia,*
Yes
No
smoking,*
Yes
No
obesity,*
Yes
No
family history of premature cardiovascular
disease;*
Yes
No
previous manifestations of atherosclerotic
disease (ischemic stoke, transient ischemic
attack [tia], peripheral artery disease, previous
arterial revascularisation procedures, angina
pectoris)*
Yes
No
Exclusion Criteria
contraindications (known allergies to n-3 pufa) or
indications (previous myocardial infarction) for the
treatment with n-3 pufa*
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Yes
No
serious comorbidity with an unfavourable
prognosis over the short term*
Yes
No
expected non compliance over a long period of
time*
Yes
No
pregnancy*
Yes
No
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Eligibility Carpometacarpal Osteoarthritis
NCT00198029
An Open Label Trial for Treating Carpometacarpal
Osteoarthritis of the Thumb: Pilot Study; ODM derived
from: https://clinicaltrials.gov/show/NCT00198029
All rights reserved. Please visit https://medical-data-
models.org/forms/16653
Eligibility Carpometacarpal
Osteoarthritis NCT00198029
Inclusion Criteria
radiographic evidence of at least moderate
narrowing (joint space < 1mm) or the presence of
osteophytes or sclerosis at the carpometacarpal
joint*
Yes
No
patient complaint of unacceptable pain despite
modification of activity, a trial of splinting and a
therapeutic dose of nsaids*
Yes
No
if bilateral disease, only the most severely
involved hand, (as defined by vas for pain), will be
entered in the study.*
Yes
No
proficiency in english.*
Yes
No
Exclusion Criteria
previous bad injury to the thumb*
Yes
No
previous hand surgery on the study thumb*
Yes
No
known hand comorbidities (i.e. carpal tunnel
syndrome, de quervains tenosynovitis etc)*
Yes
No
rheumatoid arthritis or lupus*
Yes
No
bleeding problems*
Yes
No
being on blood thinners (except aspirin)*
Yes
No
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known allergies to any of the medications being
used*
Yes
No
allergies to chicken products*
Yes
No
current use of oral steroids*
Yes
No
cancer  that is not cured or in remission*
Yes
No
severe diabetes*
Yes
No
a serious infection somewhere else in the
subject's body*
Yes
No
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Eligibility Chronic Heart Failure
NCT00511888
Nebivolol Versus Carvedilol in Patients With Heart Failure;
ODM derived from:
https://clinicaltrials.gov/show/NCT00511888
All rights reserved. Please visit https://medical-data-
models.org/forms/16657
Eligibility Chronic Heart Failure
NCT00511888
Inclusion Criteria
left ventricular ejection fraction (lvef) < 40%;*
Yes
No
symptomatic heart failure with functional new
york heart association (nyha) class ii or iii;*
Yes
No
arterial hypertension with systolic blood pressure
>140 mmhg and diastolic blood pressure >85
mmhg;*
Yes
No
clinical stability without hospital admission for
heart failure in the previous 3 months.*
Yes
No
Exclusion Criteria
history of asthma or severe chronic obstructive
pulmonary disease;*
Yes
No
severe liver or kidney diseases;*
Yes
No
second-degree or third degree heart block
without a permanent pacemaker,*
Yes
No
sick sinus syndrome, heart rate <60 beat/min,
systolic blood pressure <90 mmhg.*
Yes
No
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NCT00095121
Safety and Efficacy of Adefovir Dipivoxil in Children and
Adolescents With Chronic Hepatitis B; ODM derived from:
https://clinicaltrials.gov/show/NCT00095121
All rights reserved. Please visit https://medical-data-
models.org/forms/16658
Eligibility Chronic Hepatitis B
NCT00095121
Criteria
positive hbsag >= 6 months prior to
randomization and positive hbeag at screening.*
Yes
No
serum hbv dna greater than or equal to 1 x
100,000 copies/ml (pcr assay) at initial or
confirmatory screening visit.*
Yes
No
serum alt levels greater than or equal to 1.5 x uln
at both initial and confirmatory screening visits.*
Yes
No
compensated liver disease with anticipated
survival greater than 12 months and with the
following laboratory and clinical parameters within
4 weeks of baseline:*
Yes
No
*prothrombin time less than or equal to 1 second
above normal range. *total bilirubin less than 1.3
mg/dl or normal direct bilirubin. *serum albumin
greater than 3 g/dl (greater than 30 g/l). *no
clinical history of ascites, variceal bleeding,
encephalopathy or splenomegaly. *adequate
renal function defined as creatinine clearance
greater than or equal to 80 ml/min (calculated
using schwartz formula).*
Yes
No
key exclusion criteria:*
Yes
No
received immunoglobulin, interferon or lamivudine
therapy within 6 months prior to initial screening
visit.*
Yes
No
participated in any investigational trial with any
investigational compound within 2 months prior to
initial screening.*
Yes
No
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organ or bone marrow transplant recipients.*
Yes
No
clinical evidence of decompensated liver
disease.*
Yes
No
a child-pugh-turcotte score greater than 6.*
Yes
No
inability to comply with study requirements.*
Yes
No
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Eligibility Chronic Hepatitis C
NCT00192647
Induction Dosing With Pegylated Interferon Alfa 2a and
Ribavirin in Patients With Chronic Hepatitis C Genotype 1;
ODM derived from:
https://clinicaltrials.gov/show/NCT00192647
All rights reserved. Please visit https://medical-data-
models.org/forms/16659
Eligibility Chronic Hepatitis C
NCT00192647
Inclusion Criteria
male and female patients >18 and ≤75 years of
age*
Yes
No
serologic evidence of chronic hepatitis c infection
(repeatedly anti-hcv positive and/or hcv-rna
positive)*
Yes
No
hcv genotype 1*
Yes
No
liver biopsy consistent with chc (a maximum
window of 3 years is permitted between biopsy
and study enrolment)*
Yes
No
compensated liver disease, child pugh score <7*
Yes
No
serum hcv-rna >600 iu/ml*
Yes
No
patients who are naïve to any hepatitis c therapy
(i.e. have not been previously treated with an
interferon or with ifn plus ribavirin)*
Yes
No
no clinical or radiological evidence of
hepatocellular carcinoma and a serum afp <100
ng/ml within 2 months of randomisation*
Yes
No
negative urine or blood pregnancy test (for
women of childbearing potential) documented
within the 24-hour period prior to the first dose of
study drug*
Yes
No
all fertile males and females receiving ribavirin
must be using two forms of effective
contraception during treatment and during the 6
1 / 2
months after treatment end*
Yes
No
australian/new zealand sites only:*
Yes
No
patients are not required to have a liver biopsy*
Yes
No
must meet section 100 (aus) or pharmac (nz)
requirements for treatment with peginterferon
alfa-2a and ribavirin*
Yes
No
Exclusion Criteria
standard exclusion criteria for pegylated
interferon and ribavirin.*
Yes
No
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Eligibility Multiple Sclerosis NCT00017628
Phase I Study of High-Dose Cyclophosphamide and Total
Body Irradiation With T Lymphocyte-Depleted Autologous
Peripheral Blood Stem Cell or Bone Marrow Rescue in
Patients With Multiple Sclerosis; ODM derived from:
https://clinicaltrials.gov/show/NCT00017628
All rights reserved. Please visit https://medical-data-
models.org/forms/16660
Eligibility Multiple Sclerosis
NCT00017628
Criteria
-disease characteristics--*
Yes
No
diagnosis of multiple sclerosis kurtzke score of
4.0-7.5 increase of 1.0 point over the past 12
months more than 3 relapses in 24 months
despite conventional disease modifying therapy
failure to stabilize active clinical progression with
a 3-day regimen of methylprednisolone iv*
Yes
No
-prior/concurrent therapy--*
Yes
No
chemotherapy: no prior cladribine*
Yes
No
radiotherapy: no prior radiotherapy to greater
than 10 cm2 of lung tissue no prior craniospinal
irradiation no prior total lymphoid irradiation*
Yes
No
-patient characteristics--*
Yes
No
hematopoietic: absolute neutrophil count at least
1,000/mm3 platelet count at least 100,000/mm3
hemoglobin at least 9.0 g/dl*
Yes
No
hepatic: hepatitis b antigen negative bilirubin no
greater than 2.0 mg/dl transaminases no greater
than 2 times upper limit of normal*
Yes
No
renal: creatinine no greater than 2.0 mg/dl*
Yes
No
cardiovascular: no history of coronary artery
disease resting lvef at least 45%*
Yes
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No
pulmonary: fev1/fvc at least 75% predicted dlco
at least 50% predicted*
Yes
No
other:*
Yes
No
not pregnant*
Yes
No
negative pregnancy test*
Yes
No
fertile patients must use effective contraception*
Yes
No
hiv negative*
Yes
No
no uncontrolled diabetes mellitus*
Yes
No
no other concurrent medical illness that would
preclude study*
Yes
No
no concurrent psychiatric illness or mental
deficiency that would preclude study*
Yes
No
no prior malignancy except localized basal cell or
squamous cell skin cancer (malignancies judged
to be cured by local surgical therapy such as
head and neck cancer or stage i breast cancer,
are considered on an individual basis)*
Yes
No
no presence of body shrapnel, metal fragments,
or unremovable devices such as a pacemaker or
aneurysm clip*
Yes
No
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Eligibility Multiple Sclerosis NCT00248378
Short-Term Effects of Medicinal Cannabis Therapy on
Spasticity in Multiple Sclerosis; ODM derived from:
https://clinicaltrials.gov/show/NCT00248378
All rights reserved. Please visit https://medical-data-
models.org/forms/16661
Eligibility Multiple Sclerosis
NCT00248378
Inclusion Criteria
clinically definite or probable, laboratory-
supported ms*
Yes
No
complaints of spasticity and at least moderate
increase in tone as evidenced by a score of >= 2
on the modified ashworth scale at either the
elbow, hip, or knee*
Yes
No
if on disease-modifying therapy ("abc"), have
been on a stable dose for at least six months*
Yes
No
fluent in english*
Yes
No
if not cannabis-naive, must refrain from smoking
cannabis for two weeks prior to screening
(confirmed by urinalysis)*
Yes
No
if on either lioresal (baclofen) or tizanadine
(zanaflex), have been on a stable dose for at
least three months*
Yes
No
>=18 years of age*
Yes
No
Exclusion Criteria
axis i psychiatric disorder especially depression
or significant neurological disease other than ms
as determined by the pi*
Yes
No
recent history of active substance abuse defined
as daily use for at least 14 days within the past
month*
Yes
No
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drug use restrictions, eg, subjects on probation or
parole, employment involving high risk to
themselves and/or the public (airline pilot, bus
driver, etc.)*
Yes
No
any unstable medical health problem*
Yes
No
any known pulmonary disorders, including
tuberculosis, asthma, or copd*
Yes
No
pregnant or nursing*
Yes
No
require benzodiazepines to control spasticity*
Yes
No
require high doses of analgesic medications on a
daily basis*
Yes
No
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Eligibility Multiple Sclerosis, Relapsing-
Remitting NCT00027300
Safety and Efficacy of Natalizumab in the Treatment of
Multiple Sclerosis; ODM derived from:
https://clinicaltrials.gov/show/NCT00027300
All rights reserved. Please visit https://medical-data-
models.org/forms/16662
Eligibility Multiple Sclerosis,
Relapsing-Remitting NCT00027300
Inclusion Criteria
diagnosis of ms, as defined by mcdonald et al.,
criteria # 1-4 (mcdonald et al., 2001)*
Yes
No
between the ages of 18 and 50, inclusive.*
Yes
No
baseline edss score between 0.0 and 5.0,
inclusive.*
Yes
No
have experienced at least one relapse within the
12 months prior to randomization.*
Yes
No
cranial mri scan demonstrating lesion(s)
consistent with ms.*
Yes
No
have given written informed consent to participate
in the study.*
Yes
No
Exclusion Criteria
primary progressive, secondary progressive, or
progressive relapsing ms.*
Yes
No
ms relapse has occurred,in the opinion of the
investigator, within 50 days prior to randomization
and/or the subject has not stabilized from a
previous relapse.*
Yes
No
a clinically significant infectious illness within 30
days prior to randomization.*
Yes
No
history of, or abnormal laboratory results
indicative of any significant cardiac,
1 / 2
endocrinologic, hematologic, hepatic,
immunologic, metabolic, urologic, pulmonary,
gastrointestinal, dermatologic, psychiatric, renal
and/or other major disease, that in the opinion of
the investigator, would preclude the
administration of a recombinant humanized
antibody immunomodulating agent for 116
weeks.*
Yes
No
history of severe allergic or anaphylactic
reactions or known drug hypersensitivity.*
Yes
No
unable to perform the timed 25-foot walk, 9hpt,
and pasat 3.*
Yes
No
abnormal blood tests performed at the screening
visit.*
Yes
No
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Eligibility Multiple Sclerosis, Relapsing-
remitting NCT00292253
Tolerability of Rebif® Injection With and Without the Use of
Rebiject™Mini in Relapsing-Remitting Multiple Sclerosis
Subjects; ODM derived from:
https://clinicaltrials.gov/show/NCT00292253
All rights reserved. Please visit https://medical-data-
models.org/forms/16663
Eligibility Multiple Sclerosis,
Relapsing-remitting NCT00292253
Inclusion Criteria
greater than or equal to 18 years of age*
Yes
No
has relapsing-remitting ms*
Yes
No
are willing and able to comply with the protocol
for the duration of the study*
Yes
No
Exclusion Criteria
has significant leukopenia/lymphopenia (white
blood cell count less than (<) 0.5 times the lower
limit of normal)*
Yes
No
has elevated liver function tests (aspartate
aminotransferase  [ast], alanine transaminase
[alt], or alkaline phosphatase greater than (>) 2
times the upper limit of normal or total bilirubin >
1.5 times the upper limit of normal)*
Yes
No
has an allergy to human serum albumin or
mannitol*
Yes
No
had treatment with an investigational product or
procedure within 3 months*
Yes
No
has the presence of systemic disease or
abnormal laboratory findings that might interfere
with subject safety, compliance or evaluation of
the condition under study*
Yes
No
has concomitant use of avonex®, betaseron®,
copaxone®, or novantrone®*
Yes
No
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Eligibility Non Small Cell Lung Cancer
(NSCLC) NCT00684385
An Expanded Access Programme With Iressa for Patients
With Non-Small-Cell Lung Cancer and Cancer of the Head
and Neck; ODM derived from:
https://clinicaltrials.gov/show/NCT00684385
All rights reserved. Please visit https://medical-data-
models.org/forms/16664
Eligibility Non Small Cell Lung
Cancer (NSCLC) NCT00684385
Inclusion Criteria
have received at least one course of standard
systemic chemotherapy or radiation therapy*
Yes
No
are ineligible for chemotherapy or radiotherapy*
Yes
No
are ineligible or not candidates for enrollment in
available zd1839 trials for nsclc or squamous cell
h&nc*
Yes
No
are, in the investigators opinion, not medically
suitable for chemotherapy.*
Yes
No
Exclusion Criteria
current eligibility (i.e., meeting the inclusion and
exclusion criteria except signed informed
consent) for any zd1839 protocol available to the
patient, or previous enrollment in a blinded
zd1839 protocol*
Yes
No
patients from a blinded protocol may be
considered for acceptance, with astrazeneca's
permission, only after trial completion and
unblinding of all patients.*
Yes
No
patients eligible for or previously enrolled in an
open-label or unblinded zd1839 clinical trial may
be considered for acceptance with astrazeneca's
permission*
Yes
No
incomplete healing from prior oncologic or other
major surgery*
Yes
No
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Eligibility Chronic Hepatitis C
NCT00199719
Study of the Pharmacokinetic Action of Amantadine and
Ribavirin in Chronic Hepatitis C. CINAM; ODM derived
from: https://clinicaltrials.gov/show/NCT00199719
All rights reserved. Please visit https://medical-data-
models.org/forms/16665
Eligibility Chronic Hepatitis C
NCT00199719
Inclusion Criteria
male and female patients >18 years of age and
<65 years of age*
Yes
No
génotype non2 non3*
Yes
No
chronic liver disease consistent with chronic
hepatitis c infection on a biopsy (obtained within
the past 24 months) as judged by a local
pathologist (metavir >a1and >f1)*
Yes
No
negative urine or blood pregnancy test (for
women of childbearing potential) documented
within the 24-hour period prior to the first dose of
study drug*
Yes
No
Exclusion Criteria
women with ongoing pregnancy or breast
feeding*
Yes
No
ifn or ribavirin therapy at any previous time*
Yes
No
positive test at screening for anti-hav igm ab,
hbsag, anti-hbc igm ab, anti-hiv ab*
Yes
No
history or other evidence of a medical condition
associated with chronic liver disease other than
hcv (e.g., hemochromatosis, autoimmune
hepatitis, metabolic liver disease, alcoholic liver
disease, toxin exposures)*
Yes
No
serum creatinine level >1.5 times the upper limit
of normal at screening*
Yes
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No
history of severe psychiatric disease, especially
depression*
Yes
No
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Eligibility Chronic Kidney Disease
NCT00155246
Efficacy of Pentoxifylline on Chronic Kidney Disease; ODM
derived from: https://clinicaltrials.gov/show/NCT00155246
All rights reserved. Please visit https://medical-data-
models.org/forms/16666
Eligibility Chronic Kidney Disease
NCT00155246
Inclusion Criteria
chronic kidney disease with serum creatinine
1.3~6.0 mg/dl*
Yes
No
Exclusion Criteria
history of allergy to pentoxifylline*
Yes
No
females are nursing or pregnant*
Yes
No
obstructive uropathy*
Yes
No
unable to stop chronic immunosuppressive
therapy, nsaid*
Yes
No
congestive heart failure (new york heart
association functional class iii or iv)*
Yes
No
unstable angina, myocardial infarction, coronary
artery bypass graft surgery, percutaneous
coronary intervention, within the past 6 months
prior to signing the informed consent form*
Yes
No
cerebral hemorrhage within the past 6 months
prior to signing the informed consent form*
Yes
No
retinal hemorrhage within the past 6 months prior
to signing the informed consent form*
Yes
No
known or suspected secondary hypertension
(e.g., primary aldosteronism, renovascular
hypertension, pheochromocytoma)*
Yes
No
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severe uncontrolled hypertension with sbp > 220
mmhg and/or dbp > 115 mmhg*
Yes
No
hepatic dysfunction as defined by the following
laboratory parameters: alt or ast > 2 times the
upper limit of the normal range*
Yes
No
biliary obstructive disorders (e.g. cholestasis)*
Yes
No
active malignancy*
Yes
No
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Subject Off Study: CRF Wisconsin Madison
ODM Form derived from:
https://ictr.wisc.edu/CaseReptTempt. Template Name:
Subject Off Study. Case Report Form (CRF)/Source
Document templates were created for University of
Wisconsin-Madison researchers. These templates are
consistent with the FDA's CDASH (Clinical Data Acquisition
Standards Harmonization) standards. The CDASH
standards identify those elements that should be captured
on a Case Report Form (CRF). The forms serve only as
templates, and must be edited to meet the study data
collection needs as described in the protocol.
All rights reserved. Please visit https://medical-data-
models.org/forms/16667
Subject Off Study: CRF Wisconsin
Madison
Header
PI Name
IRB Number
Short Title
Subject Initials
Subject ID
Date
Subject Off Study
Date subject went Off Study
Last visit completed
Screening visit (1)
Visit 1 (2)
Visit 2 (3)
Indicate the primary reason the subject is no
longer participating in the study
Study Activities Completed (1)
Subject Withdrawn (by subject) PRIOR
to enrollment (i.e. subject deemed
eligible but declined participation, etc.)
Additional explanation required.  (2)
Subject Withdrawn (by subject) AFTER
enrollment (i.e. due to personal time
constraints, etc.) Additional explanation
required.  (3)
Subject Withdrawn (by PI or study team)
PRIOR to enrollment (i.e. subject
deemed inappropriate for study
participation by the PI or study team,
explain below) (4)
Subject Withdrawn (by PI or study team)
AFTER enrollment (i.e. identification of
disease/condition after enrollment that
warrants withdrawal, participant was
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determined to be ineligible after
enrollment etc.) (5)
Adverse Events/Side
effects/Complications (complete Adverse
Tracking Log) Additional explanation
required.  (6)
Other. Additional explanation required.
(7)
Was subject treatment unblinded?
Yes (1)
No (2)
Not Applicable (3)
Additional explanation required:
Form completed by
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Eligibility Cardiovascular Diseases
NCT00664040
Heredity and Phenotype Intervention (HAPI) Heart Study;
ODM derived from:
https://clinicaltrials.gov/show/NCT00664040
All rights reserved. Please visit https://medical-data-
models.org/forms/16668
Eligibility Cardiovascular Diseases
NCT00664040
Inclusion Criteria
participant of amish family calcification study or
related to a afcs participant and at least 20 years
old.*
Yes
No
Exclusion Criteria
excluded for the entire study if the subject-*
Yes
No
1. is currently pregnant; however they will
become eligible six months after delivery.*
Yes
No
2. has severe hypertension (bp > 180/105),
making it unethical not to recommend prompt
treatment.*
Yes
No
3. takes medications that would affect the
outcome(s) to be measured and cannot willingly
and safely, in the opinion of the treating physician
and study physician, discontinue these
medications for 1 week prior to protocol initiation.
these medications include anti-hypertensive
agents (e.g., beta-blockers, calcium channel
antagonists, ace inhibitors, and diuretics), lipid
lowering agents, nitrates, systemic
glucocorticoids, adrenergic or cholinergic-acting
agents including cold formulas and
antidepressants, and diet/weight loss agents.*
Yes
No
4. is taking vitamins and are unwilling to
discontinue their use for at least 1 week prior to
study.*
Yes
No
5. has a coexisting malignancy*
Yes
No
6. has a creatinine greater than 2.0, ast or alt
greater than 2 times the upper limit of normal, hct
less than 32, or a tsh less than 0.4 or greater
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than 5.5.*
Yes
No
excluded from the cold pressor test if the subject-
*
Yes
No
1. has raynaud's disease or symptoms*
Yes
No
excluded from the high fat challenge if the
subject-*
Yes
No
1. has a malabsorption disorder or lactose
intolerance*
Yes
No
2. has symptoms of gall bladder disease or
history of pancreatitis*
Yes
No
excluded from the dietary salt intervention if the
subject-*
Yes
No
1. has stage iii or greater congestive heart failure*
Yes
No
2. has food allergies to foods included in the diet*
Yes
No
excluded from the aspirin intervention if the
subject-*
Yes
No
1. has a bleeding disorder or history of
gastrointestinal bleeding*
Yes
No
2. has a blood pressure greater than 160/95*
Yes
No
3. is currently taking aspirin and have conditions
that might place them at increased risk from
aspirin withdrawal 14 days prior to protocol
initiation, including history of unstable angina, mi,
angioplasty (including stent placement), coronary
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artery bypass surgery, atrial fibrillation, stroke or
transient ischemic attacks, type 2 diabetes, or
deep vein thrombosis or other thrombosis*
Yes
No
4. has polycythemia, or thrombocytosis (platelet
count greater than 500,000)*
Yes
No
5. has thrombocytopenia (platelet count less than
75,000)*
Yes
No
6. has had surgery within the last 6 months*
Yes
No
7. has an aspirin allergy*
Yes
No
8. is currently breast feeding*
Yes
No
9. aggregation with collagen 5 micrograms/ml is
less than 7 ohms or greater    than 31 ohms, or
no aggregation at baseline with arachadonic
acid*
Yes
No
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Eligibility Chronic Kidney Disease
NCT00324376
Study to Compare Once A Day Sevelamer Dosing With
Three Times Per Day Sevelamer Dosing; ODM derived
from: https://clinicaltrials.gov/show/NCT00324376
All rights reserved. Please visit https://medical-data-
models.org/forms/16669
Eligibility Chronic Kidney Disease
NCT00324376
Inclusion Criteria
life expectancy of at least 12 months,*
Yes
No
patients have received hemodialysis three times
per week for 3 months or longer,*
Yes
No
patients maintained on sevelamer in a daily dose
of ≤ 9,600 mg as their only phosphate binder with
serum phosphorus concentrations at the last two
measurements between 3.0 and 6.5 mg/dl (0.97
and 2.10 mmol/l).*
Yes
No
Exclusion Criteria
active bowel obstruction,*
Yes
No
dysphagia,*
Yes
No
wallowing dsisorders,*
Yes
No
severe gastrointestinal motility disorders,*
Yes
No
active ethanol or drug abuse (excluding
tobacco),*
Yes
No
need for antidysrhythmic or antiseizure
medications used to control these conditions,*
Yes
No
poorly controlled diabetes mellitus or
hypertension,*
Yes
No
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active vasculitis,*
Yes
No
active malignancy other than basal-cell
carcinoma,*
Yes
No
hiv infection,*
Yes
No
any clinically significant unstable medical
condition as judged by the investigator.*
Yes
No
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Eligibility Chronic Kidney Disease
NCT00327860
Chronic Kidney Disease in Children Prospective Cohort
Study (CKiD); ODM derived from:
https://clinicaltrials.gov/show/NCT00327860
All rights reserved. Please visit https://medical-data-
models.org/forms/16670
Eligibility Chronic Kidney Disease
NCT00327860
Inclusion Criteria
age between 1 and 16 years (before 17th
birthday)*
Yes
No
estimated (based on scr) gfr between 30 and 90
ml/min|1.73m2*
Yes
No
willingness and ability to provide informed
consent and assent*
Yes
No
Exclusion Criteria
renal, other solid organ, bone marrow or stem cell
transplantation*
Yes
No
dialysis treatment within the past three months*
Yes
No
cancer diagnosis or hiv diagnosis/treatment
within last twelve   months*
Yes
No
current pregnancy or pregnancy within past
twelve months*
Yes
No
inability to complete major data collection
procedures (e.g., allergic reaction to iodine or
iohexol)*
Yes
No
current enrollment in a randomized clinical trial in
which the specific treatment is unknown*
Yes
No
not fluent in english or spanish*
Yes
No
plans to move out of area of any participating ckid
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site (families can be transferred to another ckid
site if they move)*
Yes
No
history of structural heart disease*
Yes
No
genetic syndromes involving the central nervous
system (e.g., downs syndrome)*
Yes
No
history of severe to profound mental retardation
(i.e., iq<40, significant impairment in adaptive
function and/or inability to independently execute
self-care skills)*
Yes
No
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Eligibility Non-Small Cell Lung Cancer
NCT00293085
An Open, Randomized, Multicentre, Phase II Pilot Study;
ODM derived from:
https://clinicaltrials.gov/show/NCT00293085
All rights reserved. Please visit https://medical-data-
models.org/forms/16671
Eligibility Non-Small Cell Lung
Cancer NCT00293085
Inclusion Criteria
histologically documented nsclc stage i-ii*
Yes
No
complete resection of tumor amd resection
margins microscopically tumor free.*
Yes
No
surgical procedure: according to necessity for
oncology radicality a lobectomy, bilobectomy or
pneumectomy will be performed with either
radical mediastinal lymphadenectomy or
complete sampling of all relevant lymph node
areas.*
Yes
No
randomization within 60 days after surgical
required.*
Yes
No
initial work-up*
Yes
No
general conditions: 19-70 years, who
performance status 0-2, adequate hematological
function, adequate renal and hepatic function,
negative pregnancy test.*
Yes
No
Exclusion Criteria
nsclc stage ii-iv, sclc or alveolar carcinoma*
Yes
No
clinical evidence of cns metastases*
Yes
No
pregnant and lactating patients*
Yes
No
past or concurrent history of malignancies other
than nsclc,except for curatively treated non
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melanoma of the skin or in situ cervical
carcinoma or other curatively treated cancer with
no evidence of disease for at least five years.*
Yes
No
prior or concurrent antitumor therapy for nsclc
other than surgery.*
Yes
No
concomitant participation in clinical studies of
non-approved experimental agents or
procedures.*
Yes
No
major complications after surgery*
Yes
No
serious concomitant medical conditions*
Yes
No
psychological,familial, sociological or
geographical conditions which do not permit
compliance with the study protocol*
Yes
No
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Eligibility Non-Small-Cell Lung Carcinoma
NCT00310232
Epoetin Alfa in Advanced Non-Small Cell Lung Cancer
(EPO-CAN-20); ODM derived from:
https://clinicaltrials.gov/show/NCT00310232
All rights reserved. Please visit https://medical-data-
models.org/forms/16672
Eligibility Non-Small-Cell Lung
Carcinoma NCT00310232
Inclusion Criteria
1. histologically confirmed non-small cell lung
cancer (squamous cell, large cell,
adenocarcinoma, or some combination of these),
with clinical or pathological stage iii or iv, or
recurrent disease; and*
Yes
No
2. hemoglobin level at or below 120 g/l; and*
Yes
No
3. at least 18 years of age;*
Yes
No
Exclusion Criteria
1. systemic platinum-based chemotherapy for
lung cancer during the previous two months or
planned platinum-based chemotherapy within the
next three months;*
Yes
No
2. patients previously treated with high dose
thoracic radiation (>10 fractions), or surgery,
without objective evidence of disease
recurrence;*
Yes
No
3. planned high dose thoracic radiation therapy
(>10 fractions);*
Yes
No
4. a clinically active malignancy, other than the
underlying lung cancer which is expected to
influence qol;*
Yes
No
5. expected survival of three months or less;*
Yes
No
6. ecog performance status of 3 or 4 (see
appendix d);*
Yes
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No
7. multiple cns metastasis or a single cns lesion
that does not demonstrate radiographic stability
(screening ct of head required only if
symptomatic, no radiographic follow-up of single
resected lesions required);*
Yes
No
8. blood transfusions within the last 14 days;*
Yes
No
9. previous use of erythropoietin;*
Yes
No
10. anemia due to factors other than cancer /
radiotherapy (e.g. hemolysis or gastrointestinal
bleeding);*
Yes
No
11. evidence of untreated folate or vitamin b12
deficiency;*
Yes
No
12. history of uncontrolled hypertension or
diastolic blood pressure greater than 100 mm
hg;*
Yes
No
13. history of seizure disorder;*
Yes
No
14. known hypersensitivity to mammalian cell-
derived products, albumin or any component of
the study drug;*
Yes
No
15. pregnancy, lactation or parturition within the
previous 30 days;*
Yes
No
16. unwillingness or inability to complete the
required qol questionnaires;*
Yes
No
17. mental incompetence, including psychiatric or
addictive disorders which would preclude
meaningful completion of questionnaires;*
Yes
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No
18. geographically inaccessible for treatment or
follow-up evaluations;*
Yes
No
19. currently enrolled in an ongoing therapeutic
study;*
Yes
No
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Eligibility Chronic Kidney Insufficiency
NCT00565396
Effectiveness Study on Fosinopril and/or Losartan in
Patients With Chronic Kidney Disease Stage 3; ODM
derived from: https://clinicaltrials.gov/show/NCT00565396
All rights reserved. Please visit https://medical-data-
models.org/forms/16673
Eligibility Chronic Kidney
Insufficiency NCT00565396
Inclusion Criteria
patients aged 18-75 years old*
Yes
No
roll out secondary renal diseases*
Yes
No
do not use steroids and immunosuppresive
drugs*
Yes
No
acei/arb treated patients should have 7-14 days
wash out period，sidbp< 110mmhg*
Yes
No
willing and able to comprehend and give written
informed consent*
Yes
No
willing to follow-up regularly*
Yes
No
Exclusion Criteria
use steroids and immunosuppresive drugs*
Yes
No
secondary renal diseases*
Yes
No
acute cardio-cerebral diseases within 6 months*
Yes
No
post renal transplantation*
Yes
No
pregnant/nursing women*
Yes
No
history of hypersensitivity to acei/arb*
Yes
No
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refuse to join clinical trial*
Yes
No
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Note To File: CRF Wisconsin Madison
ODM Form derived from:
https://ictr.wisc.edu/CaseReptTempt. Template Name: Note
To File. Case Report Form (CRF)/Source Document
templates were created for University of Wisconsin-
Madison researchers. These templates are consistent with
the FDA's CDASH (Clinical Data Acquisition Standards
Harmonization) standards. The CDASH standards identify
those elements that should be captured on a Case Report
Form (CRF). The forms serve only as templates, and must
be edited to meet the study data collection needs as
described in the protocol.
All rights reserved. Please visit https://medical-data-
models.org/forms/16674
Note To File: CRF Wisconsin
Madison
Header
PI Name
Protocol or IRB Number
Protocol Short Title
Note To File
Applicability: Include subject ID(s) if NTF pertains
to a particular subject or subjects
Yes
No
RE:
Written by
Date
Explanation of Event/Issue
Description of related forms/documents (if
applicable)
Author´s Signature
Date
PI´s Signature
Date
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Screening Information QTZ-EC-0004
ELEVATE  NCT01713426
QUTENZA™ versus Pregabalin in Subjects with Peripheral
Neuropathic Pain: an Open-label, Randomized, Multicenter,
Non-inferiority Efficacy and Tolerability Study
Medicine or Vaccine (generic name)
capsaicin
Sponsor Identification Number
QTZ-EC-0004
Trial Registry Identification Number(#'s)
NCT01713426
EudraCT Number: 2011-005872-41
All rights reserved. Please visit https://medical-data-
models.org/forms/16675
Screening Information QTZ-EC-0004
ELEVATE  NCT01713426
Screen Fail Status
Is the subject a screen failure (signed an
informed consent but was not randomized/
registered)?
If Yes, please provide the eason.
Yes
No
Primary Screen Failure Reason
Adverse Event (Adverse Event)
Lost to Follow-Up (Lost to Follow-Up)
Not Fulfilling Inculsion Criteria or
Exclusion Criteria (Not Fulfilling Inculsion
Criteria or Exclusion Criteria)
Other (Other)
Pregnancy (Pregnancy)
Withdrawal by subject (Withdrawal by
subject)
If "Not fulfill inclusion or exclusion criteria" is
selected, please indicate the appropriate incusion
or exclusion criteria number:
If Primary Screen Failure Reason is "Other"
please specify:
Informed Consent
Date of Informed Consent
Demographics
Sex
Birth Date
dd/MMM/yyyy
Age
years
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Race
American Indian or Alaska Native
(American Indian or Alaska Native)
Asian (Asian)
Black or African American (Black or
African American)
Native hawaiian or other Pacific Islander
(Native hawaiian or other Pacific
Islander)
Other (Other)
White (White)
If "Other", specify:
Current Employment status
Employed, full time (Employed, full time)
Employed, part time (Employed, part
time)
Other (Other)
unemployed (unemployed)
If "Other", specify:
Inclusion Criteria
Is the subject fully eligible per the Inclusion
Criteria?
Yes
No
If No, please list each Inclusion Criterion not met
that makes the subject ineligible by adding as
many log lines necessary:
Inclusion Criterion Not Met
1. Male or female between 18 and 90
years of age, inclusive. (1. Male or
female between 18 and 90 years of age,
inclusive.)
10. Females of child bearing potential
must be willing to use highly effective
methods of birth control during the study
and for 30 days following study
termination (a highly effective method of
birth control is defined as those which
result in a low failure rate
(CHMP/ICH/286/95 modified) of less that
1% per year when used consistently and
correctly such as implants, injectables,
combined oral contraceptives, some
intrauterine devices (IUDs), sexual
abstinence or vasectomized partner).
(10. Females of child bearing potential
must be willing to use highly effective
methods of birth control during the study
and for 30 days following study
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termination (a highly effective method of
birth control is defined as those which
result in a low fail)
11. Willing and able to comply with
protocol requirements for the duration of
study participation (11. Willing and able
to comply with protocol requirements for
the duration of study participation)
12. Given written informed consent (12.
Given written informed consent)
2. In good health as determined by the
investigator. (2. In good health as
determined by the investigator.)
3. Documented diagnosis of probable or
definite PNP (Treede et al, 2008) (3.
Documented diagnosis of probable or
definite PNP (Treede et al, 2008))
4. Localized and well-defined area of
PNP, suitable for treatment with
QUTENZA (4. Localized and well-defined
area of PNP, suitable for treatment with
QUTENZA)
5a. Documented diagnosis at the
Baseline Visit of either a) PHN with pain
persisting at least 6 months since
shingles vesicle crusting (5a.
Documented diagnosis at the Baseline
Visit of either a) PHN with pain persisting
at least 6 months since shingles vesicle
crusting)
5b. PNI including post-surgical or post-
traumatic neuropathic pain, persisting for
minimum of 3 months (5b. PNI including
post-surgical or post-traumatic
neuropathic pain, persisting for minimum
of 3 months)
5c. Non-diabetic painful peripheral
polyneuropathy with pain which has
persisted for a minimum of 3 months,
including I. small-fiber neuropathy, as
confirmed by QST, laser evoked
potentials (LEP), or skin biopsy, II.
chemotherapy induced neuropathy in
subjects with stable neoplastic disease,
III. other, adequately characterized
painful peripheral polyneuropathy, based
on clinical history and examination (5c.
Non-diabetic painful peripheral
polyneuropathy with pain which has
persisted for a minimum of 3 months,
including I. small-fiber neuropathy, as
confirmed by QST, laser evoked
potentials (LEP), or skin biopsy, II.
chemotherapy induced neuropathy in
sub)
6. Average pain score ≥ 4 during
screening period, over a minimum of at
least 4 consecutive days (using the
"average pain for the past 24 hours"
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(NPRS) score (6. Average pain score ≥ 4
during screening period, over a minimum
of at least 4 consecutive days (using the
"average pain for the past 24 hours"
(NPRS) score)
7. Intact non-irritated, dry skin over the
painful area(s) to be treated (7. Intact
non-irritated, dry skin over the painful
area(s) to be treated)
8a. Naive to treatment with pregabalin
and gabapentin (8a. Naive to treatment
with pregabalin and gabapentin)
8b. in the opinion of the investigator, has
not received an adequate trial of
treatment with pregabalin or gabapentin
(8b. in the opinion of the investigator, has
not received an adequate trial of
treatment with pregabalin or gabapentin)
9. Subject is willing to receive pregabalin
or QUTENZA as part of the trial. (9.
Subject is willing to receive pregabalin or
QUTENZA as part of the trial.)
Exclusion Criteria
Is the subject fully eligible per the Exclusion
Criteria?
Yes
No
If No, please list each Exclusion Criterion that
makes the subject ineligible by adding as many
log lines necessary.
Exlusion Criterion Affecting Eligibility
1. Significant ongoing or recurrent pain
of etiology other than PHN, PNI or non-
diabetic painful peripheral
polyneuropathy, for example:
compression-related neuropathies (e.g.
spinal stenosis), radiculopathy, tumor-
related pain, fibromyalgia or athritis (1.
Significant ongoing or recurrent pain of
etiology other than PHN, PNI or non-
diabetic painful peripheral
polyneuropathy, for example:
compression-related neuropathies (e.g.
spinal stenosis), radiculopathy, tumor-
related pain, fibromyalgia or athritis)
10. Untreated ongoing generalized
anxiety disorder according to DSM-IV or
ICD-10 criteria (10. Untreated ongoing
generalized anxiety disorder according to
DSM-IV or ICD-10 criteria)
11. Severe ongoing depression
according to DSM-IV or ICD-10 criteria
(11. Severe ongoing depression
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according to DSM-IV or ICD-10 criteria)
12. Evidence of cognitive impairment
including dementia that may interfere
with subject’s ability to complete study
evaluations and recall pain levels in the
past 24 hours (12. Evidence of cognitive
impairment including dementia that may
interfere with subject’s ability to complete
study evaluations and recall pain levels
in the past 24 hours)
13. Planned elective surgery during the
trial (13. Planned elective surgery during
the trial)
14. Changes to stable neuropathic pain
background medication in the 4 weeks
prior to the Baseline Visit (14. Changes
to stable neuropathic pain background
medication in the 4 weeks prior to the
Baseline Visit)
15. Any prior receipt of QUTENZA
patches, including blinded patches
administered as part of a clinical trial (15.
Any prior receipt of QUTENZA patches,
including blinded patches administered
as part of a clinical trial)
16. Hypersensitivity to capsaicin (i.e.,
chilli peppers or Over-the-counter [OTC]
capsaicin products), any QUTENZA
excipients, local anesthetics, or
adhesives (16. Hypersensitivity to
capsaicin (i.e., chilli peppers or Over-the-
counter [OTC] capsaicin products), any
QUTENZA excipients, local anesthetics,
or adhesives)
17. Treatment with pregabalin or
gabapentin within 2 months prior to the
Baseline Visit. (17. Treatment with
pregabalin or gabapentin within 2
months prior to the Baseline Visit.)
18. Hypersensitivity to pregabalin or any
of the excipients (18. Hypersensitivity to
pregabalin or any of the excipients)
19. Use of opioids exceeding a total daily
dose of morphine of 200 mg/day, or
equivalent or any intravenous opioids or
tapentadol, regardless of dose, within 7
days preceding the Baseline Visit. (19.
Use of opioids exceeding a total daily
dose of morphine of 200 mg/day, or
equivalent or any intravenous opioids or
tapentadol, regardless of dose, within 7
days preceding the Baseline Visit.)
2. Complex Regional Pain Syndrome
(CRPS, Type I or II) (2. Complex
Regional Pain Syndrome (CRPS, Type I
or II))
20. Use of any topical pain medication,
such as non-steroidal anti-inflammatory
drugs, menthol, methyl salicylate, local
anesthetics (including patch containing
5 / 7
Screening Information QTZ-EC-0004 ELEVATE  NCT01713426
lidocaine), steroids or capsaicin products
on the painful areas to be treated within
7 days preceding the Baseline Visit (20.
Use of any topical pain medication, such
as non-steroidal anti-inflammatory drugs,
menthol, methyl salicylate, local
anesthetics (including patch containing
lidocaine), steroids or capsaicin products
on the painful areas to be treated within
7 days pr)
21. Chemotherapy within 3 months of the
Baseline Visit, except maintenance
hormone treatment (21. Chemotherapy
within 3 months of the Baseline Visit,
except maintenance hormone treatment)
22. Use of any investigational agent
within 30 days prior to Baseline Visit (22.
Use of any investigational agent within
30 days prior to Baseline Visit)
23. Active substance abuse or history of
chronic substance abuse within 1 year
prior to screening; or any prior chronic
substance abuse (including alcoholism)
likely to re-occur during the study period
as judged by the investigator (23. Active
substance abuse or history of chronic
substance abuse within 1 year prior to
screening; or any prior chronic
substance abuse (including alcoholism)
likely to re-occur during the study period
as judged by the investigator)
24. Female subjects of child-bearing
potential with a positive serum or urine
pregnancy test prior to treatment (24.
Female subjects of child-bearing
potential with a positive serum or urine
pregnancy test prior to treatment)
25. Subject, who in th eopinion of the
investigator, is not suitable for the study
for any reason. (25. Subject, who in th
eopinion of the investigator, is not
suitable for the study for any reason.)
3. Neuropathic pain related to previously
administered radiotherapy, diabetes
mellitus or HIV-AN (3. Neuropathic pain
related to previously administered
radiotherapy, diabetes mellitus or HIV-
AN)
4. Neuropathic pain areas located only
on the face, above the hairline of the
scalp, and/ or  in proximity to mucous
membranes (4. Neuropathic pain areas
located only on the face, above the
hairline of the scalp, and/ or  in proximity
to mucous membranes)
5. Severe loss of heat sensation in the
painful area, indicative of C-fiber
denervation (5. Severe loss of heat
sensation in the painful area, indicative
of C-fiber denervation)
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6. Reported daily pain score of 10 on the
NPRS for at least 4 days during the
screening period (6. Reported daily pain
score of 10 on the NPRS for at least 4
days during the screening period)
7. Past or current history of diabetes
mellitus. (7. Past or current history of
diabetes mellitus.)
8. Unstable or poorly controlled
hypertension or a recent history of a
cardiovascular event which, in the
opinion of the investigator, would put the
subject at risk of adverse cardiovascular
reactions related to the patch application
procedure (8. Unstable or poorly
controlled hypertension or a recent
history of a cardiovascular event which,
in the opinion of the investigator, would
put the subject at risk of adverse
cardiovascular reactions related to the
patch application procedure)
9. Creatinine clearance (CLcr) < 60 mL/
min according to the Cockcroft-Gault
formula (9. Creatinine clearance (CLcr) <
60 mL/ min according to the Cockcroft-
Gault formula)
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Screening Procedure QTZ-EC-0004
ELEVATE  NCT01713426
QUTENZA™ versus Pregabalin in Subjects with Peripheral
Neuropathic Pain: an Open-label, Randomized, Multicenter,
Non-inferiority Efficacy and Tolerability Study
Medicine or Vaccine (generic name)
capsaicin
Sponsor Identification Number
QTZ-EC-0004
Trial Registry Identification Number(#'s)
NCT01713426
EudraCT Number: 2011-005872-41
All rights reserved. Please visit https://medical-data-
models.org/forms/16679
Screening Procedure QTZ-EC-0004
ELEVATE  NCT01713426
Date of Visit
Was the visit performed?
If No, then all other forms with the Form Not
Done field in this visit will be marked not done.
If Yes, please provide the Date of Visit:
Yes
No
Date of Visit:
dd/MMM/yyyy
Meidcal History
Form Not Done
(Form Not Done should only be marked for
subjects that are "RANDOMIZED/ REGISTERED
BUT NEVER RECEIVED/ DISPENSED STUDY
DRUG".
Done (Done)
Not Done (Not Done)
Are there any past or present Medical
Conditions?
Yes
No
If Yes, please provide details:
Onset Date
dd/MMM/yyyy
Is Medical Condition ongoing? 
If No, please provide "Recivered Date".
Yes
No
Is Medical Condition ongoing? 
If No, please provide "Recivered Date".
dd/MMM/yyyy
Primary Diagnosis
Form Not Done
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(Form Not Done should only be marked for
subjects that are "RANDOMIZED/ REGISTERED
BUT NEVER RECEIVED/ DISPENSED STUDY
DRUG".)
Done  (Done )
Not Done (Not Done)
Date of Diagnosis
dd/MMM/yyyy
Neuropathic Pain Grading
Definite Neuropathic Pain (Definite
Neuropathic Pain)
Probable Neuropathic Pain (Probable
Neuropathic Pain)
Criteria
A history suggestive of a relevant lesion
or disease affecting the peripheral or
central somatosenosory system (A
history suggestive of a relevant lesion or
disease affecting the peripheral or
central somatosenosory system)
Demonstration of negative or positive
sensory signs, confined to the
innervations territory of the lesioned
nervous structure, ba at least one
confirmatory test (Demonstration of
negative or positive sensory signs,
confined to the innervations territory of
the lesioned nervous structure, ba at
least one confirmatory test)
Demonstration of the distinct
neuroanatomically plausible distribution
by at least one confirmatory test
(Demonstration of the distinct
neuroanatomically plausible distribution
by at least one confirmatory test)
Demonstration of the relevant lesion or
disease by at least one confirmatory test
(Demonstration of the relevant lesion or
disease by at least one confirmatory
test)
Pain with a distinct neuroanatomically
plausible distribution (Pain with a distinct
neuroanatomically plausible distribution)
Diagnosis
Non-diabetic painful peripheral
polyneuropathy (Non-diabetic painful
peripheral polyneuropathy)
Peripheral nerve injury (PNI) (Peripheral
nerve injury (PNI))
Postherpetic neuralgia (PHN)
(Postherpetic neuralgia (PHN))
If Peripheral Nerve Injury (PNI) is selected,
please provide details.
Type of Peripheral Nerve Injury (PNI):
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Other (Other)
Post-Surgical Neuropathic Pain (Post-
Surgical Neuropathic Pain)
Post-Traumatic Neuropathic Pain (Post-
Traumatic Neuropathic Pain)
If "Other", please specify:
If Non-diabetic painful peripheral polyneuropathy
is selected, please provide details.
Type of peripheral polyneuropathy
Chemotherapy induced neuropathy in
subjects with stable neoplastic disease
(Chemotherapy induced neuropathy in
subjects with stable neoplastic disease)
Other, adequately characterized painful
peripheral polyneuropathy, based on
clinical history and examination (Other,
adequately characterized painful
peripheral polyneuropathy, based on
clinical history and examination)
Small-fiber neuropathy as confirmed by
laser evoked potentials (LEP) (Small-
fiber neuropathy as confirmed by laser
evoked potentials (LEP))
Small-fiber neuropathy as confirmed by
quantitative sensory testing (QST)
(Small-fiber neuropathy as confirmed by
quantitative sensory testing (QST))
Small-fiber neuropathy as confirmed by
skin biopsy  (Small-fiber neuropathy as
confirmed by skin biopsy )
If "Other, adequately characterized painful
peripheral polyneuropathy" was selected provide
details:
Physical  Examination
Form Not Done
Done (Done)
Not Done (Not Done)
Assessment Date
dd/MMM/yyyy
Record any abnormal findings/ conditions
identified during the exam on the appropriate
form.
For Screening/ Baseline visits, report abnormal
findings/ conditions on the appropriate form
(Medical History or Adverse Events). For Post-
Baseline visits, record abnormal findings/
conditions that have worsenend from Screening/
Baseline and are clinically significant on the
Adverse Event form.
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Vital signs
Form Not Done
Done (Done)
Not Done (Not Done)
Vital Signs: Assessment Date
dd/MMM/yyyy
Position
Sitting (Sitting)
Standing (Standing)
Supine (Supine)
Systolic Blood Pressure
mmHg
Diastolic Blood Pressure
mmHg
Pulse
Beats/Min
Record any abnormal results on the appropriate
form. For Screening/Baseline visits, report
abnormal results on the appropriate form
(Medical History or Adverse Event).
For Post-Baseline visits, record abnormal results
that have worsened from Screening/ Baseline
and are clinicallly significant on the Adverse
Event form.
Height and Weight
Form Not Done
Done (Done)
Not Done (Not Done)
Assessment Date
dd/MMM/yyyy
height
cm
Weight
kg
BMI
kg/m^2
Pregnancy Test
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Form Not Done
(Mark Form Not Done only if the entire visit was
not done, otherwise provide details below)
Done  (Done )
Not Done (Not Done)
If Pregnancy Test was not done, please provide
reason:
Female (2 years post-menopausal or
surgically sterile) (Female (2 years post-
menopausal or surgically sterile))
Male (Male)
Other (Other)
If "Other", specify:
Date of Sample Taken
dd/MMM/yyyy
Result of Pregnancy Test
Negative  (Negative )
Positive (Positive)
Hematology
Form Not Done
Done  (Done )
Not Done (Not Done)
Were samples taken?
Yes
No
Date of Sample Taken
dd/MMM/yyyy
Laboratory Interpretation
(If LAB interpretetation is abnormal, please select
assessment items below and report the
interpretation for each.)
Abnormal (Abnormal)
Normal (Normal)
Laboratory Tests
Basophils (Basophils)
Eosinophils (Eosinophils)
Hematocrit (Hematocrit)
Hemoglobin (Hemoglobin)
Lymphocytes (Lymphocytes)
Monocytes (Monocytes)
Neutrophils (Neutrophils)
Platelets (Platelets)
Red Blood Cell (Red Blood Cell)
White Blood Cell Count (White Blood
Cell Count)
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Laboratory Interpretation Specification
Abnormal - clinically significant
(Abnormal - clinically significant)
Abnormal - not clinically significant
(Abnormal - not clinically significant)
Record any clinically significant abnormal
findings/conditions identified during the exam on
Medical and Surgical History and/ or Adverse
Event form.
Biochemistry
Form Not Done
Done (Done)
Not Done (Not Done)
Were samples taken?
Yes
No
Date of Samples Taken
dd/MMM/yyyy
Laboratory Interpretation
(If Laboratory Interpretation is abnormal, please
select assessment items below and report the
interpretation for each.)
Abnormal (Abnormal)
Normal  (Normal )
Laboratory Tests
Alkaline Phosphatase (Alkaline
Phosphatase)
ALT (ALT)
AST (AST)
BUN (BUN)
Creatinine (Creatinine)
Potassium (Potassium)
Sodium (Sodium)
TBL (TBL)
Laboratory Interpretation Specification
Abnormal - clinically significant
(Abnormal - clinically significant)
Abnormal - not clinically significant
(Abnormal - not clinically significant )
Record any clinically significant  abnormal
findings/conditions identified during the exam on
Medical and Surgical History and/or Adverse
Event form.
Identification of Painful Area(s)
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Form Not Done
(Form Not Done should only be marked for
subjects that are "RANDOMIZED/REGISTERED
BUT NEVER RECEIVED/DISPENSED STUDY
DRUG".)
Done (Done)
Not Done (Not Done)
Assessment Date
dd/MMM/yyyy
Treatment area: Plase tick all that apply
Arms (Arms)
Feet (Feet)
Hands (Hands)
Head and Neck (Head and Neck)
Legs (Legs)
Torso (Torso)
Total Painful/ Sensitive area Size
cm^2
Healthcare Resource Use
Form Not Done
(Form Not Done should only be marked for
subjects that are "RANDOMIZED/REGISTERED
BUT NEVER RECEIVED/DISPENSED STUDY
DRUG".)
Done (Done)
Not Done (Not Done)
Number of contacts with a healthcare
professional related to neuropathic pain, within
last month
Number of contacts with a healthcare
professional for other causes, within the last
month
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NINDS CDE Diagnosis and Disease
Characteristics  Multiple Sclerosis
NINDS Common Data Elements, Multiple Sclerosis
Diagnosis and Disease Characteristics
Used from the National Institute of Neurological Disorders
and Stroke Common Data Elements
(https://www.commondataelements.ninds.nih.gov/)
References:
Grinnon ST, Miller K, Marler JR, Lu Y, Stout A, Odenkirchen
J, Kunitz S. National Institute of Neurological Disorders and
Stroke Common Data Element Project - approach and
methods. Clin Trials. 2012;9(3):322-9.
All rights reserved. Please visit https://medical-data-
models.org/forms/16680
Diagnosis and Disease
Characteristics
Diagnosis and Disease Characteristics
Study ID
Study site name
Subject ID
1.  What is the current diagnosis? (choose only
one)
RIS (Radiologically Isolated Syndrome)
(1)
RIS (Radiologically Isolated Syndrome)
(2)
MS (Multiple Sclerosis) (Go to question 2
to specify clinical course, then skip to
question 6)  (3)
NMO (Neuromyelitis Optica) spectrum
disorder (Go to question 3 to specify
clinical course, then skip to  (4)
ADEM (Acute Disseminated
Encephalomyelitis) (Go to question 4 to
specify clinical course, then skip to  (5)
Other CNS demyelinating disorder (Go to
question 5 to specify clinical course, then
skip to question 7) (6)
question 7) (question 7))
question 7)  (question 7) )
2.   Clinical course – MS. a.  Onset Course:
Relapsing  (1)
Progressive (2)
b.  Current Disease Course:
Relapsing remitting (1)
Secondary progressive  (2)
Progressive relapsing  (3)
Primary progressive  (4)
Uncertain (5)
3.  Clinical course – NMO Spectrum Disorder: a.
Type:
Monophasic  (1)
Relapsing  (2)
Recurrent optic neuritis  (3)
Recurrent myelitis  (4)
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Unknown  (5)
Other (6)
Other, specify:
b. i.  Optic neuritis, specify laterality:
Right (1)
Left  (2)
Bilateral (3)
Unknown (4)
ii.  Acute myelitis, specify involvement of which
segments (Cervical)
Yes
No
ii.  Acute myelitis, specify involvement of which
segments (Thoracic )
Yes
No
ii.  Acute myelitis, specify involvement of which
segments (Lumbar )
Yes
No
iii.  Contiguous spinal cord lesion on MRI >3
vertebral segments
Brain MRI not meeting diagnostic criteria
for MS  (1)
NMO-IgG seropositive  (2)
NMO-IgG seronegative  (3)
NMO-IgG sero status unknown (4)
c.  Time between onset of first optic neuritis and
first myelitis: (please specify) months
4.  Clinical course – ADEM: a.  Type:
Monophasic  (1)
Recurrent  (2)
Multiphasic  (3)
Unknown  (4)
Other (5)
Other, specify:
b. Presence of encephalopathy (behavioural
change or alteration in consciousness)
Yes
No
b. Improvement by clinical exam, MRI or both
after acute event
Yes
No
b. Multifocal lesions predominantly involving white
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matter
Yes
No
b. New event of ADEM, 3 or more months with
recurrence of the initial symptoms and signs 
(recurrent ADEM)
Yes
No
b. ADEM followed by a new clinical event also
meeting criteria for ADEM, but involving anatomic
areas of the CNS
Yes
No
5.  Clinical course – Other CNS demyelinating
disorder: a.  Specify disorder:
b.  Type:
Monophasic  (1)
Recurrent  (2)
Unknown (3)
Other (4)
Other, specify:
6.  (For MS patients ONLY) Indicate which
diagnostic criteria the patient fulfills: (choose only
one) 
RRMS:
≥ 2 attacks; objective clinical evidence of
≥ 2 lesions or objective clinical evidence
of 1 lesion with reasonable historical
evidence of a prior attack =reasonable
historical evidence of a prior attack  (1)
≥ 2 attacks; objective clinical evidence of
1 lesion (2)
Dissemination in space, demonstrated by
≥ 1 T2 lesion in at least 2 of 4 MS-typical
regions of the CNS (periventricular,
juxtacortical, infratentorial,  (1)
1 attack; objective clinical evidence of ≥
2 lesions (2)
or spinal cord) (or spinal cord))
Dissemination in time, demonstrated by:
Simultaneous presence of asymptomatic
gadolinium-enhancing and
nonenhancing lesions at any time (1)
A new T2 and/or gadolinium-enhancing
lesion(s) on follow-up MRI, irrespective
of its timing with  (2)
1 attack; objective clinical evidence of 1
lesion (clinically isolated syndrome) (3)
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reference to a baseline scan (reference
to a baseline scan)
Dissemination in space and time, demonstrated
by: 
For DIS:   ≥ 1 T2 lesion in at least 2 of 4 MS-
typical regions of the CNS (periventricular,
juxtacortical, infratentorial, 
or spinal cord); and 
For DIT:
Simultaneous presence of asymptomatic
gadolinium-enhancing and
nonenhancing lesions at any time (1)
A new T2 and/or gadolinium-enhancing
lesion(s) on follow-up MRI, irrespective
of its timing with  (2)
reference to a baseline scan (reference
to a baseline scan)
PPMS: 1 year of disease progression
(retrospectively or prospectively determined) plus
2 of 3 of the following: 
Evidence for DIS in the brain based on ≥ 1 T2
lesions in the MS-characteristic (periventricular,
juxtacortical, 
or infratentorial) regions 
Evidence for DIS in the spinal cord based on ≥ 2
T2 lesions in the cord 
Positive CSF (isoelectric focusing evidence of
oligoclonal bands and/or elevated IgG index)
Yes
No
SPMS: Initial RR disease course followed by
progression with or without occasional relapses,
minor remissions, 
and plateaus
Yes
No
PRMS: Progressive disease from onset, with
clear acute relapses, with or without full recovery;
periods 
between relapses characterized by continuing
progression
Yes
No
7.  Onset History
a.  Year of first diagnosis:
b.  Did occurrence of onset clinical event occur:
Within 1 month post-infection?    (1)
Within 1 month post-vaccination?    (2)
Neither (3)
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c.  Indicate first onset was (choose only one):
Unifocal    (1)
Multifocal (2)
d.  Did the patient receive treatment for clinical
event?
Yes    (1)
No    (2)
Unknown (3)
i.  If Yes, indicate treatment (mention all that
apply:  Steroids/ Plasmapheresis/ IVig ):
e.  Was the patient fully recovered from this
relapse within a year?
Yes    (1)
No    (2)
Unknown (3)
f.  onth/Year of first symptoms:
g.  Initial symptoms: i.  Vision:
Yes    (1)
No    (2)
Unknown (3)
1.  If Yes, specify (mention all that apply:
Bilateral/   Right/   Left/   Unknown):
ii.  Motor:
Yes    (1)
No    (2)
Unknown (3)
1. If Yes, specify (mention all that apply: Bilateral/
Right/ Left/ Unknown):
iii.  Sensory:
Yes    (1)
No    (2)
Unknown (3)
1. If Yes, specify (mention all that apply: Bilateral/
Right/ Left/ Unknown):
iv.  Coordination:
Yes    (1)
No    (2)
Unknown (3)
1. If Yes, specify (mention all that apply: Bilateral/
Right/ Left/ Unknown):
v.  Bowel/Bladder:
Yes    (1)
No    (2)
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Unknown (3)
vi.  Fatigue:
Yes    (1)
No    (2)
Unknown (3)
vii.  Cognitive:
Yes    (1)
No    (2)
Unknown (3)
viii.  Encephalopathy:
Yes    (1)
No    (2)
Unknown (3)
ix.  Other, specify:
h.  Localization of clinical event: i.  Optic nerve:
Yes    (1)
No    (2)
Unknown (3)
1.  If Yes, specify observation method (mention all
that apply: Exam/   MRI/   History/   Unknown):
ii.  Cerebrum:
Yes    (1)
No    (2)
Unknown (3)
1. If Yes, specify observation method (mention all
that apply: Exam/ MRI/ History/ Unknown):
iii.  Brainstem/Cerebellar:
Yes    (1)
No    (2)
Unknown (3)
1. If Yes, specify observation method (mention all
that apply: Exam/ MRI/ History/ Unknown):
iv.  Spinal cord:
Yes    (1)
No    (2)
Unknown (3)
1. If Yes, specify observation method (mention all
that apply: Exam/ MRI/ History/ Unknown):
8.  Do you have a family history of MS?
Yes    (1)
No    (2)
Unknown (3)
6 / 6
NINDS CDE Diagnosis and Disease Characteristics  Multiple Sclerosis
NINDS CDE Multiple Sclerosis Severity
Score Multiple Sclerosis
NINDS Common Data Elements, Multiple Sclerosis Multiple
Sclerosis Severity Score
The MSSS score for an individual patient is ascertained by
finding the column corresponding to the patient's EDSS
and the row corresponding to the number of years since the
onset of multiple sclerosis. https://www-
gene.cimr.cam.ac.uk/MSgenetics/GAMES/MSSS/MSSS-
table.html
Used from the National Institute of Neurological Disorders
and Stroke Common Data Elements
(https://www.commondataelements.ninds.nih.gov/)
References:
Grinnon ST, Miller K, Marler JR, Lu Y, Stout A, Odenkirchen
J, Kunitz S. National Institute of Neurological Disorders and
Stroke Common Data Element Project - approach and
methods. Clin Trials. 2012;9(3):322-9.
All rights reserved. Please visit https://medical-data-
models.org/forms/16681
Multiple Sclerosis Severity Score
Multiple Sclerosis Severity Score
EDSS (0-9,5)
MSSS (0,01-9,91)
Years (1-30)
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NINDS CDE Godin Leisure-Time Exercise
Questionnaire Multiple Sclerosis
NINDS Common Data Elements, Multiple Sclerosis Godin
Leisure-Time Exercise Questionnaire
Used from the National Institute of Neurological Disorders
and Stroke Common Data Elements
(https://www.commondataelements.ninds.nih.gov/)
References:
Grinnon ST, Miller K, Marler JR, Lu Y, Stout A, Odenkirchen
J, Kunitz S. National Institute of Neurological Disorders and
Stroke Common Data Element Project - approach and
methods. Clin Trials. 2012;9(3):322-9.
All rights reserved. Please visit https://medical-data-
models.org/forms/16682
Godin Leisure-Time Exercise
Questionnaire
Godin Leisure Time Exercise
Questionnaire
a)	STRENUOUS EXERCISE (HEART BEATS
RAPIDLY)	 e.g., running, jogging, hockey, football,
soccer,
squash, basketball, cross country skiing, judo,
roller skating, vigorous swimming,	 vigorous long
distance bicycling)
Times Per Week
MODERATE EXERCISE (NOT EXHAUSTING)
(e.g., fast walking, baseball, tennis, easy
bicycling,volleyball, badminton, easy swimming,
alpine skiing,
popular and folk dancing)
Times Per Week
b)	MILD EXERCISE (MINIMAL EFFORT) (e.g.,
yoga, archery, fishing from river bank, bowling,
horseshoes, golf, snow-mobiling, easy walking)
Times Per Week
Weekly leisure activity score
2. During a typical 7-Day period (a week), in your
leisure time, how often do you engage in any
regular activity long enough to work up a sweat
(heart beats rapidly)?
OFTEN  (1)
SOMETIMES  (2)
NEVER/RARELY (3)
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Eligibility Chronic Lymphocytic Leukemia
NCT00100711
Study of Motexafin Gadolinium (MGd) in Patients With
Chronic Lymphocytic Leukemia or Small Lymphocytic
Lymphoma; ODM derived from:
https://clinicaltrials.gov/show/NCT00100711
All rights reserved. Please visit https://medical-data-
models.org/forms/16683
Eligibility Chronic Lymphocytic
Leukemia NCT00100711
Inclusion Criteria
≥ 18 years old*
Yes
No
cll as defined by the nci 96 criteria (exception;
patients may have bright surface immunoglobulin
staining if negative for t[11;14] translocation or
cyclin d1) or sll as defined by who classification
criteria and is refractory or relapsed as defined by
one of the following: 1) refractory disease-
progressive disease while on therapy, or 2)
relapsed disease progressive disease after at
least one treatment course of therapy with
disease response or stabilization*
Yes
No
ecog performance status score of 0, 1, or 2*
Yes
No
willing and able to provide written informed
consent*
Yes
No
Exclusion Criteria
laboratory values of:*
Yes
No
platelet count < 30,000/µl*
Yes
No
ast or alt > 2 x uln (upper limit of normal)*
Yes
No
total bilirubin > 2 x uln*
Yes
No
creatinine > 2.0 mg/dl*
Yes
No
chemotherapy, radiation therapy, immunotherapy,
systemic corticosteroids (> 10 mg oral
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prednisone or equivalent), or systemic biologic
anticancer therapy within 21 days before
beginning study treatment*
Yes
No
greater than three prior regimens (where a
regimen is defined as a treatment for cll/sll given
initially or after disease progression)*
Yes
No
uncontrolled hypertension*
Yes
No
known history of porphyria (testing not required at
screening)*
Yes
No
known history of glucose-6-phosphate
dehydrogenase (g6pd) deficiency (testing not
required at screening)*
Yes
No
known history of hiv infection (testing not required
at screening)*
Yes
No
pregnant or lactating (pregnancy test is required
for all female patients of childbearing potential)*
Yes
No
woman of childbearing potential or sexually active
man unwilling to use adequate contraceptive
protection*
Yes
No
physical or mental condition that makes patient
unable to complete specified follow-up
assessments*
Yes
No
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Eligibility Chronic Lymphocytic Leukemia
NCT00093314
HuMax-CD20 in Chronic Lymphocytic Leukemia; ODM
derived from: https://clinicaltrials.gov/show/NCT00093314
All rights reserved. Please visit https://medical-data-
models.org/forms/16684
Eligibility Chronic Lymphocytic
Leukemia NCT00093314
Inclusion Criteria
chronic lymphocytic leukemia*
Yes
No
circulating lymphocytes above a specific level*
Yes
No
circulating lymphocytes showing certain markers*
Yes
No
Exclusion Criteria
previous treatment with rituximab or
alemtuzumab within 6 months prior to enrollment
in study.*
Yes
No
previous stem cell transplantation.*
Yes
No
received any of the following treatments within 4
weeks prior to entering this trial: a) anti-cancer
therapy, b) glucocorticoids unless less than 10
mg per day, c) radiotherapy.*
Yes
No
hiv positivity.*
Yes
No
hepatitis b or hepatitis c.*
Yes
No
other cancerous diseases, except certain skin
cancers and cervix cancer.*
Yes
No
certain serious medical conditions, including
kidney or liver disease, some psychiatric
illnesses, and stomach, heart, hormonal, nerve or
blood diseases.*
Yes
No
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participation in another trial with a different new
drug 4 weeks prior to enrollment in study.*
Yes
No
current participation in any other clinical study.*
Yes
No
pregnant or breast-feeding women.*
Yes
No
women of childbearing age who are unable or
unwilling to use adequate contraception.*
Yes
No
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Eligibility Chronic Lymphocytic Leukemia
NCT00131313
Efficacy and Safety of Nipent, Cytoxan and Rituxan in the
Treatment of Chronic Lymphocytic Leukemia.; ODM derived
from: https://clinicaltrials.gov/show/NCT00131313
All rights reserved. Please visit https://medical-data-
models.org/forms/16685
Eligibility Chronic Lymphocytic
Leukemia NCT00131313
Inclusion Criteria
stage ii, iii or iv chronic lymphocytic leukemia*
Yes
No
disease requires chemotherapeutic treatment*
Yes
No
ct or mri scan confirming measurable tumor size*
Yes
No
documentation of cd markers*
Yes
No
up to one prior treatment regimen*
Yes
No
expected survival greater than 6 months*
Yes
No
ecog performance status of 0-2*
Yes
No
adequate renal, bone marrow and liver functions*
Yes
No
negative pregnancy test (females of childbearing
potential)*
Yes
No
must agree to use acceptable birth control, if
fertile*
Yes
No
must complete informed consent*
Yes
No
no heart disease and must have adequate
cardiac function*
Yes
No
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must test negative for viral hepatitis b and c*
Yes
No
Exclusion Criteria
more than one prior treatment for chronic
lymphocytic leukemia*
Yes
No
known sensitivity to nipent, rituxan or cytoxan or
any component of these drugs*
Yes
No
known hiv or aids illness*
Yes
No
thyroid disease requiring medication*
Yes
No
history of any malignancy that could affect the
diagnosis or assessment of the study treatment*
Yes
No
pregnancy or breast feeding*
Yes
No
evidence of hepatitis b or c infection*
Yes
No
inability to comply with the requirements of the
study*
Yes
No
2 / 2
Eligibility Chronic Lymphocytic Leukemia NCT00131313
Eligibility Chronic Lymphocytic Leukemia
NCT00233506
A Dose Finding Study of CpG in Patients With Chronic
Lymphocytic Leukemia Who Have Been Previously Treated;
ODM derived from:
https://clinicaltrials.gov/show/NCT00233506
All rights reserved. Please visit https://medical-data-
models.org/forms/16686
Eligibility Chronic Lymphocytic
Leukemia NCT00233506
Inclusion Criteria
diagnosis of cll*
Yes
No
cll previously treated*
Yes
No
hemoglobin >/= 10*
Yes
No
platelets >/= 50,000*
Yes
No
neutrophils >= 1,000  -*
Yes
No
Exclusion Criteria
patients with brain mets*
Yes
No
patients with autoimmune disease*
Yes
No
patients on corticosteroids or
immunosuppressants*
Yes
No
patients with uncontrolled intercurrent illness*
Yes
No
pregnant women*
Yes
No
hiv patients receiving combination anti-retroviral
therapy*
Yes
No
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Post-Treatment Assessments, Tarceva in NSCLC
patients who have EGFR-positive tumors NCT00373425
Sponsor: OSI Pharmaceuticals Information provided by
(Responsible Party): Astellas Pharma Inc ( OSI
Pharmaceuticals ) A multicenter, randomized, double-blind,
placebo-controlled, phase 3 study of single-agent Tarceva®
(erlotinib) following complete tumor resection with or
without adjuvant chemotherapy in patients with stage IB-
IIIA non-small cell lung carcinoma who have EGFR-positive
tumors. See
https://clinicaltrials.gov/ct2/show/NCT00373425
Part of Study: Post-Treatment Assessments
All rights reserved. Please visit https://medical-data-
models.org/forms/16687
Post-Treatment Assessments,
Tarceva in NSCLC patients who have
EGFR-positive tumors
NCT00373425
Vital Assessment
Date
Weight
kg
ECOG performance status
Physical Examination
Date Physical Examination performed:
Pregnancy Test
Was pregnancy test performed?
Yes
No
Date of Collection
Accession Number
Pregnancy Test: Applicable
Yes
No
Biochemistry/Proteomics
Date of Collection
Accession Number
Reason Off Treatment
Reason Off Treatment*
Completion of 2 years of study drug
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therapy (1)
Relapse of NSCLC (Complete Relapse
Report page and New Anticancer
Treatment page, if applicable) (2)
Adverse event, specify event(s) (3)
Medical or ethical reasons, or
noncompliance, following discussion
between the lnvestigator and the OSI
medical team (for reasons other than
Adverse Event), specify reason(s) (4)
Patient request (for reasons other than
Adverse Event), specify reason(s) (5)
Patient death (6)
Specify event(s) or reason(s)
Death
Did the patient die before the Post-treatment
visit?*
Yes
No
Primary Cause of Death
NSCLC Relapse (1)
Protocol-related toxicity, specify (2)
Intercurrent illness, specify (3)
Other, specify (4)
Unknown (5)
If applicable,  please specify primary cause of
death
Was an autopsy performed?
Yes (if Yes, append a copy of the autopsy
report) (1)
No (2)
Investigator Signature
Investigator's Signature
Date
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Study Drug Administration, Tarceva in NSCLC patients
who have EGFR-positive tumors NCT00373425
Sponsor: OSI Pharmaceuticals
Information provided by (Responsible Party): Astellas
Pharma Inc (OSI Pharmaceuticals)
A multicenter, randomized, double-blind, placebo-
controlled, phase 3 study of single-agent Tarceva®
(erlotinib) following complete tumor resection with or
without adjuvant chemotherapy in patients with stage IB-
IIIA non-small cell lung carcinoma who have EGFR-positive
tumors. See
https://clinicaltrials.gov/ct2/show/NCT00373425
Part of Study: Study Drug Administration
All rights reserved. Please visit https://medical-data-
models.org/forms/16688
Study Drug Administration, Tarceva
in NSCLC patients who have EGFR-
positive tumors NCT00373425
Study Drug Administration
Start Date
Administered Dose
mg
Stop Date
Dose Modification
Drug-related Toxicity (AE) (1)
Nondrug-related Toxicity (AE) (2)
Patient Request  (3)
Toxicity lmproved  (4)
No Modification (5)
Other (specify) (6)
If other, specify:
Missed Doses
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Baseline Assessments, Tarceva in NSCLC patients
who have EGFR-positive tumors NCT00373425
Sponsor:
OSI Pharmaceuticals
Information provided by (Responsible Party):
Astellas Pharma Inc ( OSI Pharmaceuticals )
A multicenter, randomized, double-blind, placebo-
controlled, phase 3 study of single-agent Tarceva®
(erlotinib) following complete tumor resection with or
without adjuvant chemotherapy in patients with stage IB-
IIIA non-small cell lung carcinoma who have EGFR-positive
tumors.
See https://clinicaltrials.gov/ct2/show/NCT00373425
Part of Study: Baseline Assessments
All rights reserved. Please visit https://medical-data-
models.org/forms/16690
Baseline Assessments, Tarceva in
NSCLC patients who have EGFR-
positive tumors NCT00373425
Significant Medical and Surgical History
Significant Medical and Surgical History?
Yes
No
Significant Medical and Surgical History
List Specific Diagnosis/Procedure
Date of Onset if Known
Active
Yes
No
NSCLC Diagnosis
Date of Initial Pathological Diagnosis
Pathological Stage
IB (1)
IIB (2)
IIA (3)
IIIA (4)
Tumor size
mm
Histology
Adenocarcinoma (1)
Squamous cell carcinoma (2)
Undifferentiated large cell carcinoma (3)
Mixed histology (specify) (4)
Other (specify) (5)
If Adenocarcinoma: Bronchoalveolar Carcinoma
Features?
Yes (1)
No  (2)
1 / 8
Unknown (3)
If mixed histology: Adenocarcinoma?
Yes
No
If mixed histology: Squamous cell carcinoma?
Yes
No
If mixed histology: Undifferentiated?
Yes
No
If mixed histology: Other? (specify)
Yes
No
If mixed histology: other, please specify
If other histologic type, please specify
NSCLC-related Surgery
Date of Surgery
Primary surgical procedure
Pneumonectomy (1)
Lobectomy (2)
Bilobectomy (3)
Sleeve Lobectomy (4)
Other (5)
If other, specify:
Were any other surgical procedures performed?
Yes
No
If Yes, specify:
How were mediastinal nodes assessed?
Node Dissection (1)
Node Sampling Only (2)
Unknown (3)
Number of nodes sampled
Tobacco/Nicotine Smoking History at
Randomization
Date of evaluation:
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Cigarette Smoking History (Please indicate one
of the following:)
Patient never smoked cigarettes. (1)
Patient has smoked ≤ 100 cigarettes in a
lifetime and stopped. (2)
Patient has smoked ≥ 100 cigarettes in a
lifetime and stopped. (3)
Patient is currently smoking cigarettes.
(4)
If patient has stopped smoking, please indicate
when stopped:
< 1 month  (1)
1 month-1 year (2)
> 1 year (3)
If patient has smoked ≥ 100 cigarettes in a
lifetime and stopped or is currently smoking
cigarettes, please indicate average number of
cigarettes smoked per day:
If patient has smoked ≥ 100 cigarettes in a
lifetime and stopped or is currently smoking
cigarettes, please indicate number of years
smoked:
Other Tobacco/Nicotine History at Randomization
Patient never used other tobacco or
nicotine products. Do not complete next
questions. (1)
Patient currently or in the past has used
other tobacco or nicotine products.
Complete next questions. (2)
Cigars and/or Pipes: Applicable?
Yes
No
Cigars and/or Pipes: Number of years used
Cigars and/or Pipes: Frequency used
at least once daily (1)
at least once weekly (2)
at least once monthly (3)
< once monthly (4)
Cigars and/or Pipes: Product stopped
no, current user (1)
< 1 month (2)
1 month-1 year (3)
> 1 year (4)
Oral Tobacco Products: Applicable?
Yes
No
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Oral Tobacco Products: Number of years used
Oral Tobacco Products: Frequency used
at least once daily (1)
at least once weekly (2)
at least once monthly (3)
< once monthly (4)
Oral Tobacco Products: Product stopped
no, current user (1)
< 1 month (2)
1 month-1 year (3)
> 1 year (4)
Nicotine replacement therapy: Applicable?
Nicotine replacement therapy: Number of years
used
Nicotine replacement therapy: Frequency used
at least once daily (1)
at least once weekly (2)
at least once monthly (3)
< once monthly (4)
Nicotine replacement therapy: Product stopped
no, current user (1)
< 1 month (2)
1 month-1 year (3)
> 1 year (4)
Other: Applicable?
Other, please specify:
Other: Number of years used
Other: Frequency used
at least once daily (1)
at least once weekly (2)
at least once monthly (3)
< once monthly (4)
Other: Product stopped
no, current user (1)
< 1 month (2)
1 month-1 year (3)
> 1 year (4)
Prior Adjuvant Chemotherapy
Prior Adjuvant Chemotherapy for NSCLC?
Yes
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No
Prior Adjuvant Chemotherapy for NSCLC
Cycle Number
Adjuvant Chemotherapy Regimen
Dose Administered: Amount
Dose Administered: Unit
Cycle Start Date
Optional Research Blood Sample
Was consent for optional research signed?
Yes
No
Date optional research consent was signed:
Was a 3-5mL whole blood sample collected?
Yes
No
If Yes, date sample was collected:
Radiology
Date chest X-ray performed:
Date chest/upper abdomen CT scan performed:
Vital Assessment
Date
Weight
kg
Height
cm
ECOG performance status:
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Physical Examination
Date
General Appearance
Normal (1)
Abnormal (2)
Not Done (3)
General appearance: If abnormal, please specify
Head/Neck
Normal (1)
Abnormal (2)
Not done (3)
Head/Neck: If abnormal, please specify
Eyes
Normal (1)
Abnormal (2)
Not done (3)
Eyes: If abnormal, please specify
Ears, Nose, Throat
Normal (1)
Abnormal (2)
Not Done (3)
Ears, Nose, Throat: If abnormal, please specify
Lungs
Normal (1)
Abnormal (2)
Not done (3)
Lungs, if abnormal, please specify
Cardiovascular
Normal (1)
Abnormal (2)
Not done (3)
Cardiovascular: If abnormal, please specify
Abdomen
Normal (1)
Abnormal (2)
Not done (3)
Abdomen: If abnormal, please specify
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Musculoskeletal
Normal (1)
Abnormal (2)
Not done (3)
Musculoskeletal: If abnormal, please specify
Neurologic (include reflexes)
Normal (1)
Abnormal (2)
Not done (3)
Neurologic: If abnormal, please specify
Genitourinary
Normal (1)
Abnormal (2)
Not done (3)
Genitourinary: If abnormal, please specify
Breast
Normal (1)
Abnormal (2)
Not done (3)
Breast: If abnormal, please specify
Rectum
Normal (1)
Abnormal (2)
Not done (3)
Rectal: If abnormal, please specify
Lymph Node
Normal (1)
Abnormal (2)
Not done (3)
Lymph Node: If abnormal, please specify
Skin
Normal (1)
Abnormal (2)
Not done (3)
Skin: If abnormal, please specify
Extremities
Normal (1)
Abnormal (2)
Not done (3)
Extremities: If abnormal, please specify
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Pregnancy Test
Pregnancy Test: Applicable
Yes
No
Was pregnancy test performed?
Yes
No
Date of Collection
Accession Number
Hematology
Date of Collection
Accession Number
Biochemistry/Proteomics
Date of Collection
Accession Number
Study Drug Dispensed for Month 1
Date dispensed
Bottle number
Investigator's Signature
Investigator's Signature
Date
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Screening Assessments, Tarceva in NSCLC patients
who have EGFR-positive tumors NCT00373425
Sponsor:
OSI Pharmaceuticals
Information provided by (Responsible Party):
Astellas Pharma Inc ( OSI Pharmaceuticals )
A multicenter, randomized, double-blind, placebo-
controlled, phase 3 study of single-agent Tarceva®
(erlotinib) following complete tumor resection with or
without adjuvant chemotherapy in patients with stage IB-
IIIA non-small cell lung carcinoma who have EGFR-positive
tumors.
See https://clinicaltrials.gov/ct2/show/NCT00373425
Part of study: Screening Assessments
All rights reserved. Please visit https://medical-data-
models.org/forms/16691
Screening Assessments, Tarceva in
NSCLC patients who have EGFR-
positive tumors NCT00373425
Header
Site Number
Patient Number
Patient Initials
Demographics
Date of birth
Gender
Male (1)
Female (2)
Ethnicity
Hispanic/Latino (1)
Not Hispanic/Latino (2)
Race
American Indian/Alaska Native (1)
Asian: Far East (2)
Asian: Southeast Asia (3)
Asian: Indian Subcontinent (4)
Black (5)
Native Hawaiian/Pacific Islander (6)
White (7)
Other (8)
If other, specify
Screening Eligibility Criteria
Did the patient meet all of the screening inclusion
criteria?
Yes
No
lf No, which was/were not met? Inclusion
1 / 2
Letter(s):
Did the patient meet any of the screening
exclusion criteria?
Yes
No
If Yes, which was/were met? Exclusion Letter(s):
lf any screening eligibility criteria were not met,
was an exemption granted by OSI?
Yes (1)
No (2)
NA (3)
Date screening consent was signed:
IVRS Screening Number
Treatment Eligibility Criteria
Did the patient meet all of the treatment inclusion
criteria?
Yes
No
lf No, which was/were not met? Inclusion
Number(s):
Did the patient meet any of the treatment
exclusion criteria?
Yes
No
If Yes, which was/were met? Exclusion
Number(s):
lf any treatment eligibility criteria were not met,
was an exemption granted by OSI?
Yes (1)
No (2)
NA (3)
Date main study consent was signed:
IVRS Randomization
Date randomized through IVRS:
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Eligibility Chronic Lymphocytic Leukemia
NCT00337519
Allogeneic Stem Cell Transplantation in Chronic
Lymphocytic Leukemia; ODM derived from:
https://clinicaltrials.gov/show/NCT00337519
All rights reserved. Please visit https://medical-data-
models.org/forms/16692
Eligibility Chronic Lymphocytic
Leukemia NCT00337519
Inclusion Criteria
written informed consent*
Yes
No
sufficient organ function*
Yes
No
availability of an hla-compatible donor (related or
unrelated)*
Yes
No
age < 65 years*
Yes
No
karnofsky index > = 70%*
Yes
No
b-cll requiring treatment after failure of at least
one prior cytostatic treatment*
Yes
No
Exclusion Criteria
positive hiv-serology*
Yes
No
pregnancy*
Yes
No
intolerance to study drugs*
Yes
No
second neoplasia*
Yes
No
serious infections*
Yes
No
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Eligibility Chronic Myelogenous Leukemia
NCT00101647
Study of Dasatinib (BMS-354825) in Patients With
Accelerated Phase Chronic Myeloid Leukemia; ODM
derived from: https://clinicaltrials.gov/show/NCT00101647
All rights reserved. Please visit https://medical-data-
models.org/forms/16694
Eligibility Chronic Myelogenous
Leukemia NCT00101647
Inclusion Criteria
subjects with philadelphia chromosome positive
(ph+) or the fused gene bcr/abl positive (bcr/abl+)
accelerated phase chronic myeloid leukemia
(cml) whose disease has primary or acquired
hematologic resistance to imatinib mesylate or
who are intolerant of imatinib mesylate.*
Yes
No
subjects must have had prior exposure to
imatinib.  however, imatinib mesylate does not
need to be their most recent cml treatment prior
to coming on this study.*
Yes
No
men and women, 18 years of age or older.*
Yes
No
adequate hepatic function.*
Yes
No
adequate renal function.*
Yes
No
women of childbearing potential (wocbp) must be
using an adequate method of contraception to
avoid pregnancy throughout the study and for a
period of least 1 month before and at least 3
months after the study in such a manner that the
risk of pregnancy is minimized.*
Yes
No
Exclusion Criteria
women who are pregnant or breastfeeding.*
Yes
No
subjects who are eligible and willing to undergo
transplantation during the screening period.*
Yes
No
a serious uncontrolled medical disorder or active
infection that would impair the ability of the
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subjects to receive protocol therapy.*
Yes
No
uncontrolled or significant cardiovascular
disease.*
Yes
No
medications that increase bleeding risk.*
Yes
No
medications that change heart rhythms.*
Yes
No
dementia or altered mental status that would
prohibit the understanding or rendering of
informed consent.*
Yes
No
history of significant bleeding disorder unrelated
to cml.*
Yes
No
concurrent incurable malignancy other than cml.*
Yes
No
evidence of organ dysfunction or digestive
dysfunction that would prevent administration of
study therapy.*
Yes
No
prior therapy with dasatinib (bms-354825).*
Yes
No
prisoners or subjects who are compulsorily
detained (involuntarily incarcerated) for treatment
of either a psychiatric or physical (e.g., infectious
disease) illness must not be enrolled into this
study.*
Yes
No
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Eligibility Cervical Cancer NCT00595725
Intra-Operative Lymphatic Mapping in Patients With
Invasive Carcinoma of the Cervix or Endometrial
Carcinoma; ODM derived from:
https://clinicaltrials.gov/show/NCT00595725
All rights reserved. Please visit https://medical-data-
models.org/forms/16695
Eligibility Cervical Cancer
NCT00595725
Inclusion Criteria
patients with endometrial cancer diagnosed on
endometrial biopsy or dilatation and curettage.*
Yes
No
patients with invasive cervical cancer diagnosed
on cervical biopsy or cone biopsy.*
Yes
No
patients with a performance status of 0, 1, 2, or 3
by the gynecologic oncology group criteria
(appendix).*
Yes
No
patients with stage i to ~iia invasive cervical
cancer disease according to the international
federation of gynecology and obstetrics (figo)
clinical staging criteria (appendix).*
Yes
No
patients with clinical stage i endometrial cancer*
Yes
No
patients who will undergo surgery to include a
hysterectomy, radical hysterectomy and/or radical
trachelectomy and bilateral lymphadenectomy via
laparotomy or laparoscopy*
Yes
No
patients who have signed an approved informed
consent.*
Yes
No
Exclusion Criteria
patients with history of prior pelvic or para-aortic
lymphadenectomy.*
Yes
No
patients with stage iib-iv invasive cervical cancer
by figo criteria.*
Yes
No
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patients with recurrent endometrial or cervical
cancer.*
Yes
No
patients with prior pelvic radiation.*
Yes
No
any patient with endometrial or cervical cancer
treated with neoadjuvant chemotherapy and
radiation therapy.*
Yes
No
patients with a performance score of 4 by the
gynecologic oncology group criteria or who are
not good surgical candidates (appendix).*
Yes
No
patients with grossly infected primary tumors.*
Yes
No
patients with known allergy to triphenyl-ethane
compounds.*
Yes
No
patients with known deficiency of glucose-g-
phosphate dehydrogenase.*
Yes
No
patients with known hemolytic anemia from
pyruvate kinase and g6pd deficiencies.*
Yes
No
severe renal disease.*
Yes
No
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Adverse Events, Tarceva in NSCLC patients who
have EGFR-positive tumors NCT00373425
Sponsor: OSI Pharmaceuticals
Information provided by (Responsible Party): Astellas
Pharma Inc (OSI Pharmaceuticals)
A multicenter, randomized, double-blind, placebo-
controlled, phase 3 study of single-agent Tarceva®
(erlotinib) following complete tumor resection with or
without adjuvant chemotherapy in patients with stage IB-
IIIA non-small cell lung carcinoma who have EGFR-positive
tumors. 
See https://clinicaltrials.gov/ct2/show/NCT00373425
Part of Study: Adverse Events
All rights reserved. Please visit https://medical-data-
models.org/forms/16696
Adverse Events, Tarceva in NSCLC
patients who have EGFR-positive
tumors NCT00373425
Adverse Events
Did any Adverse Events occur?
Yes
No
Long-Term Follow-Up Adverse Events
Sign/Symptom or Adverse Event
Severity (CTC Grade)
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
Start Date: pretreatment
Yes
No
Start Date
Stop Date: continuing
Yes
No
Stop Date
Serious
Yes
No
Related to study treatment
Yes
No
Action taken
None (1)
Dose Reduced (2)
Dose Temporarily Withheld (3)
Dose Temporarily Withheld and Reduced
(4)
1 / 2
Drug Discontinued (5)
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Baseline Visit QTZ-EC-0004 ELEVATE
NCT01713426
QUTENZA™ versus Pregabalin in Subjects with Peripheral
Neuropathic Pain: an Open-label, Randomized, Multicenter,
Non-inferiority Efficacy and Tolerability Study
Medicine or Vaccine (generic name)
capsaicin
Sponsor Identification Number
QTZ-EC-0004
Trial Registry Identification Number(#'s)
NCT01713426
EudraCT Number: 2011-005872-41
All rights reserved. Please visit https://medical-data-
models.org/forms/16700
Baseline Visit QTZ-EC-0004
ELEVATE  NCT01713426
Date of Visit
Was this visit performed?
(If No, then all other forms with the Form Not
Done field in this visit will be marked not done.)
Yes
No
If Yes, please provide the Date of Visit.
dd/MMM/yyyy
Inclusion Criteria
Is the subject fully eligible per the Inclusion
Criteria?
Yes
No
If No, please list each Inclusion Criterion not met
that makes the subject ineligible by adding as
many log lines necessary.
1.Male or female between 18 and 80
years of age, inclusive (1.Male or female
between 18 and 80 years of age,
inclusive)
10. Females of child bearing potential
must be willing to use highly effective
methods of birth control during the study
and for 30 days following study
termination (a highly effective method of
birth control is defined as those which
result in a low failure rate
(CHMP/ICH/286/95 modified) of less that
1% per year when used consistently and
correctly such as implants, injectables,
combined oral contraceptives, some
intrauterine devices (IUDs), sexual
abstinence or vasectomized partner).
(10. Females of child bearing potential
must be willing to use highly effective
methods of birth control during the study
and for 30 days following study
termination (a highly effective method of
birth control is defined as those which
result in a low fail)
11. Willing and able to comply with
protocol requirements for the duration of
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study participation (11. Willing and able
to comply with protocol requirements for
the duration of study participation)
12. Given written informed consent (12.
Given written informed consent)
2. In good health as determined by the
investigator (2. In good health as
determined by the investigator)
3. Documented diagnosis of probable or
definite PNP (Treede et al, 2008) (3.
Documented diagnosis of probable or
definite PNP (Treede et al, 2008))
4. Localized and well-defined area of
PNP, suitable for treatment with
QUTENZA (4. Localized and well-defined
area of PNP, suitable for treatment with
QUTENZA)
5a. Documented diagnosis at the
Baseline Visit of either: a. PHN with pain
persisting at least 6 months since
shingles vesicle crusting (5a.
Documented diagnosis at the Baseline
Visit of either: a. PHN with pain
persisting at least 6 months since
shingles vesicle crusting)
5b. PNI including post-surgical or post-
traumatic neuropathic pain, persisting for
a minimum of 3 months (5b. PNI
including post-surgical or post-traumatic
neuropathic pain, persisting for a
minimum of 3 months)
5c. Non-diabetic painful peripheral
polyneuropathy with pain which has
persisted for a minimum of 3 months,
including I. small-fiber neuropathy, as
confirmed by QST, laser evoked
potentials (LEP), or skin biopsy, II.
chemotherapy induced neuropathy in
subjects with stable neoplastic disease,
III. other, adequately characterized
painful peripheral (5c. Non-diabetic
painful peripheral polyneuropathy with
pain which has persisted for a minimum
of 3 months, including I. small-fiber
neuropathy, as confirmed by QST, laser
evoked potentials (LEP), or skin biopsy,
II. chemotherapy induced neuropathy in
sub)
4 during screening period, over a
minimum of at least 4 consecutive days
(using the “average pain for the past 24
hours” (NPRS) score (6. Average pain
score >)
7. Intact, non-irritated, dry skin over the
painful area(s) to be treated (7. Intact,
non-irritated, dry skin over the painful
area(s) to be treated)
8a. Naïve to treatment with pregabalin
and gabapentin (8a. Naïve to treatment
with pregabalin and gabapentin)
2 / 11
Baseline Visit QTZ-EC-0004 ELEVATE  NCT01713426
8b. In the opinion of the investigator, has
not received an adequate trial of
treatment with pregabalin or gabapentin
(8b. In the opinion of the investigator, has
not received an adequate trial of
treatment with pregabalin or gabapentin)
9. Subject is willing to receive pregabalin
or QUTENZA as part of the trial. (9.
Subject is willing to receive pregabalin or
QUTENZA as part of the trial.)
polyneuropathy, based on clinical history
and examination (polyneuropathy, based
on clinical history and examination)
Exclusion Criteria
is the subject fully eligible per the Exclusion
Criteria?
Yes
No
If No, please list each Exclusion Criterion that
makes the subject ineligible by adding as many
log lines necessary.
1. Significant ongoing or recurrent pain
of etiology other than PHN, PNI or non-
diabetic painful peripheral
polyneuropathy, for example:
compression-related neuropathies (e.g.
spinal stenosis), radiculopathy, tumor
related pain, fibromyalgia or arthritis (1.
Significant ongoing or recurrent pain of
etiology other than PHN, PNI or non-
diabetic painful peripheral
polyneuropathy, for example:
compression-related neuropathies (e.g.
spinal stenosis), radiculopathy, tumor
related pain, fibromyalgia or arthritis)
10. Untreated ongoing generalized
anxiety disorder according to DSM-IV or
ICD-10 criteria (10. Untreated ongoing
generalized anxiety disorder according to
DSM-IV or ICD-10 criteria)
11. Severe ongoing depression
according to DSM-IV or ICD-10 criteria
(11. Severe ongoing depression
according to DSM-IV or ICD-10 criteria)
12. Evidence of cognitive impairment
including dementia that may interfere
with subject’s ability to complete study
evaluations and recall pain levels in the
past 24 hours (12. Evidence of cognitive
impairment including dementia that may
interfere with subject’s ability to complete
study evaluations and recall pain levels
in the past 24 hours)
13. Planned elective surgery during the
trial (13. Planned elective surgery during
the trial)
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14. Changes to stable neuropathic pain
background medication in the 4 weeks
prior to the Baseline Visit (14. Changes
to stable neuropathic pain background
medication in the 4 weeks prior to the
Baseline Visit)
15. Any prior receipt of QUTENZA
patches, including blinded patches
administered as part of a clinical trial (15.
Any prior receipt of QUTENZA patches,
including blinded patches administered
as part of a clinical trial)
16. Hypersensitivity to capsaicin (i.e.,
chilli peppers or Over-the-counter [OTC]
capsaicin products), any QUTENZA
excipients, local anesthetics, or
adhesives (16. Hypersensitivity to
capsaicin (i.e., chilli peppers or Over-the-
counter [OTC] capsaicin products), any
QUTENZA excipients, local anesthetics,
or adhesives)
17. Treatment with pregabalin or
gabapentin within 2 months prior to the
Baseline Visit. (17. Treatment with
pregabalin or gabapentin within 2
months prior to the Baseline Visit.)
18. Hypersensitivity to pregabalin or any
of the excipients (18. Hypersensitivity to
pregabalin or any of the excipients)
19. Use of opioids exceeding a total daily
dose of morphine of 200 mg/day, or
equivalent o r any intravenous opioids or
tapentadol, regardless of dose, within 7
days preceding the Baseline Visit. (19.
Use of opioids exceeding a total daily
dose of morphine of 200 mg/day, or
equivalent o r any intravenous opioids or
tapentadol, regardless of dose, within 7
days preceding the Baseline Visit.)
2. Complex Regional Pain Syndrome
(CRPS, Type I or II) (2. Complex
Regional Pain Syndrome (CRPS, Type I
or II))
20. Use of any topical pain medication,
such as non-steroidal anti-inflammatory
drugs, menthol, methyl salicylate, local
anesthetics (including patch containing
lidocaine), steroids or capsaicin products
on the painful areas to be treated within
7 days preceding the Baseline Visit (20.
Use of any topical pain medication, such
as non-steroidal anti-inflammatory drugs,
menthol, methyl salicylate, local
anesthetics (including patch containing
lidocaine), steroids or capsaicin products
on the painful areas to be treated within
7 days pr)
21. Chemotherapy within 3 months of the
Baseline Visit, except maintenance
hormone treatment (21. Chemotherapy
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within 3 months of the Baseline Visit,
except maintenance hormone treatment)
22. Use of any investigational agent
within 30 days prior to Baseline Visit (22.
Use of any investigational agent within
30 days prior to Baseline Visit)
23. Active substance abuse or history of
chronic substance abuse within 1 year
prior to screening; or any prior chronic
substance abuse (including alcoholism)
likely to re-occur during the study period
as judged by the investigator (23. Active
substance abuse or history of chronic
substance abuse within 1 year prior to
screening; or any prior chronic
substance abuse (including alcoholism)
likely to re-occur during the study period
as judged by the investigator)
24. Female subjects of child-bearing
potential with a positive serum or urine
pregnancy test prior to treatment (24.
Female subjects of child-bearing
potential with a positive serum or urine
pregnancy test prior to treatment)
25. Subject, who in th eopinion of the
investigator, is not suitable for the study
for any reason. (25. Subject, who in th
eopinion of the investigator, is not
suitable for the study for any reason.)
3. Neuropathic pain related to previously
administered radiotherapy, diabetes
mellitus or HIV-AN (3. Neuropathic pain
related to previously administered
radiotherapy, diabetes mellitus or HIV-
AN)
4. Neuropathic pain areas located only
on the face, above the hairline of the
scalp, and/or in proximity to mucous
membranes (4. Neuropathic pain areas
located only on the face, above the
hairline of the scalp, and/or in proximity
to mucous membranes)
5. Severe loss of heat sensation in the
painful area, indicative of C-fiber
denervation (5. Severe loss of heat
sensation in the painful area, indicative
of C-fiber denervation)
6. Reported daily pain score of 10 on the
NPRS for at least 4 days during the
screening period (6. Reported daily pain
score of 10 on the NPRS for at least 4
days during the screening period)
7. Past or current history of diabetes
mellitus. (7. Past or current history of
diabetes mellitus.)
8. Unstable or poorly controlled
hypertension or a recent history of a
cardiovascular event which, in the
opinion of the investigator, would put the
subject at risk of adverse cardiovascular
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reactions related to the patch application
procedure (8. Unstable or poorly
controlled hypertension or a recent
history of a cardiovascular event which,
in the opinion of the investigator, would
put the subject at risk of adverse
cardiovascular reactions related to the
patch application procedure)
9. Creatinine clearance (CLcr) <
60mL/min according to the Cockcroft-
Gault formula (9. Creatinine clearance
(CLcr) < 60mL/min according to the
Cockcroft-Gault formula)
Physical  Examination
Form Not Done
Done (Done)
Not Done (Not Done)
Assessment Date
dd/MMM/yyyy
Record any abnormal findings/ conditions
identified during the exam on the appropriate
form.
For Screening/ Baseline visits, report abnormal
findings/ conditions on the appropriate form
(Medical History or Adverse Events). For Post-
Baseline visits, record abnormal findings/
conditions that have worsened from Screening/
Baseline and are clinically significant on the
Adverse Events form.
Vital signs
Form Not Done
Done (Done)
Not Done (Not Done)
Scheduled Time
(Within 15 minutes before topical anaesthetic
application)
Yes
No
Assessment Date
dd/MMM/yyyy
Assessment Time (00:00 - 23:59)
Position
Sitting (Sitting)
Standing (Standing)
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Supine (Supine)
Systolic Blood Pressure
mmHg
Diastolic Blood Pressure
mmHg
Pulse
Beats/Min
Record any abnormal results on the appropriate
form. For Screening/ Baseline visits, report
abnormal resutls on the appropriate form
(Medical History or Adverse Events). 
For Post-Baseline visits, record abnormal results
that have worsened from Screening/ Baseline
and are clinically significant on the Adverse
Events form.
hh:mm
Height and Weight
Form Not Done
Done (Done)
Not Done (Not Done)
Assessment Date
dd/MMM/yyyy
Height
cm
Weight
kg
BMI
kg/m^2
Pregnancy Test
Form Not Done
(Mark Form Not Done only if the entire visit was
not done, otherwise provide details below)
Done  (Done )
Not Done (Not Done)
If Pregnancy Test was not done, please provide
reason:
Female (2 years post-menopausal or
surgically sterile) (Female (2 years post-
menopausal or surgically sterile))
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Male (Male)
Other (Other)
If `Other`, specify:
Date of Sample Taken
dd/MMM/yyyy
Result of Pregnancy Test
Negative  (Negative )
Positive (Positive)
Randomization
Date of Randomization
dd/MMM/yyyy
Assigned Treatment Group
Pregabalin (Pregabalin)
Qutenza (Qutenza)
Date of First Study Drug Taken
dd/MMM/yyyy
Painful Area: Change
Form Not Done
(Form Not Done should only be marked for
subjects that are `RANDOMIZED/REGISTERED
BUT NEVER RECEIVED/DISPENSED STUDY
DRUG`.)
Done (Done)
Not Done (Not Done)
Is there any change in the painful area since
Screening visit?
Yes
No
If "Yes", please provide details on "Identifacation
of Painful Area".
Painful Area
Form Not Done
(Form Not Done should only be marked for
subjects that are `RANDOMIZED/REGISTERED
BUT NEVER RECEIVED/DISPENSED STUDY
DRUG`.)
Done (Done)
Not Done (Not Done)
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Assessment Date
dd/MMM/yyyy
Treatment area: Plase tick all that apply
Arms (Arms)
Feet (Feet)
Hands (Hands)
Head and Neck (Head and Neck)
Legs (Legs)
Torso (Torso)
Total Painful/ Sensitive area Size
cm^2
Dynamic Mechanical Allodynia
Form Not Done
Done  (Done )
Not Done (Not Done)
Intensity of dynamic mechanical allodynia
(0=No Pain; 10=Pain as bad as patient can
imagine)
0 (1)
9 (10)
10 (11)
1 (2)
2 (3)
3 (4)
4 (5)
5 (6)
6 (7)
7 (8)
8 (9)
Total surface area size of area of dynamic
mechanical allodynia
cm^2
Healthcare Resource Use
Form Not Done
(Form Not Done should only be marked for
subjects that are `RANDOMIZED/REGISTERED
BUT NEVER RECEIVED/DISPENSED STUDY
DRUG`.)
Done (Done)
Not Done (Not Done)
Number of contacts with a healthcare
professional related to neuropathic pain, since
the last visit
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Number of contacts with a healthcare
professional for other causes, since the last visit
Application of Topical Anesthetic
Form Not Done
Done (Done)
Not Done (Not Done)
Medication
Dose
Dose Unit
Route
Auricular (Otic) (Auricular (Otic))
Epidural (Epidural)
Intra-arterial (Intra-arterial)
Intra-Articular (Intra-Articular)
Intradermal (Intradermal)
Intramuscular (Intramuscular)
Intraperitoneal (Intraperitoneal)
Intrathecal (Intrathecal)
Intravenous (Intravenous)
Nasal (Nasal)
Nasogastric (Nasogastric)
Ophthalmic (Ophthalmic)
Oral (Oral)
Other (Other)
Periarticular (Periarticular)
Rectal (Rectal)
Respiratory (Inhalation) (Respiratory
(Inhalation))
Subcutaneous (Subcutaneous)
Sublingual (Sublingual)
Topical (Topical)
Transdermal (Transdermal)
Urethral (Urethral)
Vaginal (Vaginal)
Start Date
dd/MMM/yyyy
Start Time (00:00 - 23:59)
hh:mm
Stop Time (00:00 - 23:59)
hh:mm
Application of Qutenza
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Start Date
dd/MMM/yyyy
Start Time (00:00 - 23:59)
(Start time is when first patch is applied)
hh:mm
Stop Time (00:00 - 23:59)
(When all study patches have been removed,
record the time of patch removal)
Treatment Area
Arms (Arms)
Feet (Feet)
Hands (Hands)
Head and Neck (Head and Neck)
Legs (Legs)
Torso (Torso)
Treatment Area Size
cm^2
Visual Estimate of % used for each patch (0 -
100%)
>= 0
<= 100
%
Treatment Patch No.
(1 - 4)
Treatment Patch Percentage
%
Tolerability Assessment
Form Not Done
(Form Not Done should only be marked for
subjects that are "RANDOMIZED/ REGISTERED
BUT NEVER RECEIVED/ DISPENSED STUDY
DRUG").
Done (Done)
Not Done (Not Done)
Has diary been reviewed, and any existing
Adverse Events recorded in the eCRF?
Yes
No
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Long-Term Follow-Up Assessment, Tarceva in NSCLC
patients who have EGFR-positive tumors NCT00373425
Sponsor: OSI Pharmaceuticals 
Information provided by (Responsible Party): Astellas
Pharma Inc (OSI Pharmaceuticals) 
A multicenter, randomized, double-blind, placebo-
controlled, phase 3 study of single-agent Tarceva®
(erlotinib) following complete tumor resection with or
without adjuvant chemotherapy in patients with stage IB-
IIIA non-small cell lung carcinoma who have EGFR-positive
tumors. See
https://clinicaltrials.gov/ct2/show/NCT00373425 
Part of study: Long-Term Follow-Up Assessment
All rights reserved. Please visit https://medical-data-
models.org/forms/16701
Long-Term Follow-Up Assessment,
Tarceva in NSCLC patients who have
EGFR-positive tumors
NCT00373425
Long-Term Follow-Up Assessment
Follow-up Number
Date of Follow-up:
Patient Status
Alive (1)
Lost to follow-up (2)
Deceased (3)
If patient alive: Date last known to be alive
If patient alive: Has the patient had a relapse of
NSCLC since the last assessment?
Yes
No
If patient alive: Has the patient received new
anticancer treatment for NSCLC since the last
assessment?
Yes
No
If lost to follow-up: Date of last patient contact:
If lost to follow-up: What attempts were made to
follow up on the patient status?
If patient deceased: Date of death
If patient deceased: Primary Cause of Death
NSCLC Relapse (Complete Relapse
Report page, if not previously reported)
(1)
Protocol-related toxicity (specify) (2)
lntercurrent illness (specify) (3)
Other (specify) (4)
Unknown (5)
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Please specify cause of death:
If patient deceased: Was an autopsy performed?
Yes (If Yes, append a copy of the autopsy
report) (1)
No (2)
Radiology
Was a chest/upper abdomen CT scan
performed?
Yes (1)
No (2)
NA (3)
Date chest/upper abdomen CT scan performed:
If Yes, was relapse documented?
Yes
No
Was any other radiological disease assessment
performed?
Yes
No
Date of assessment
Specify type of assessment:
If Yes, was relapse documented?
Yes
No
Did the ''Other'' radiological assessment
performed include
X-Ray imaging of the chest?
Yes
No
Did the ''Other'' radiological assessment
performed include
CT imaging of the chest?
Yes
No
Did the ''Other'' radiological assessment
performed include CT imaging of the chest/upper
abdomen?
Yes
No
Long-Term Follow-Up Adverse Events
Did any Adverse Events occur?
Yes
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No
Long-Term Follow-Up Adverse Events
Sign/Symptom or Adverse Event
Severity (CTC Grade)
1 (1)
2 (2)
3 (3)
4 (4)
5 (5)
Start Date
Stop Date
Serious
Yes
No
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Relapse Report, Tarceva in NSCLC patients who
have EGFR-positive tumors NCT00373425
Sponsor: OSI Pharmaceuticals
Information provided by (Responsible Party): Astellas
Pharma Inc (OSI Pharmaceuticals)
A multicenter, randomized, double-blind, placebo-
controlled, phase 3 study of single-agent Tarceva®
(erlotinib) following complete tumor resection with or
without adjuvant chemotherapy in patients with stage IB-
IIIA non-small cell lung carcinoma who have EGFR-positive
tumors. See
https://clinicaltrials.gov/ct2/show/NCT00373425
Part of study: Relapse Report
All rights reserved. Please visit https://medical-data-
models.org/forms/16702
Relapse Report, Tarceva in NSCLC
patients who have EGFR-positive
tumors NCT00373425
Relapse Report
Date of Relapse
New Lesion Specification
Lesion number
Method of Evaluation
CT 1  (1)
Other (specify) 99 (10)
CT Spiral 2  (2)
MRI 3 (3)
Palpation 4  (4)
PET 5  (5)
Scintigraphy 6 (6)
Ultrasound 7 (7)
X-ray 8 (8)
Biopsy 9 (9)
If other, specify
Disease Site
Abdominal 1 (1)
Cervix 5 (10)
CNS/Spinal 6 (11)
Colorectal 7 (12)
Esophagus 8 (13)
Gallbladder 9 (14)
Gastric 10 (15)
Gastroesophageal Junction 36 (16)
Head & Neck 11 (17)
Kidney 12 (18)
Liver 13 (19)
Adrenal 34 (2)
Lung 14 (20)
Mediastinum 15 (21)
Omentum 17 (22)
Ovary 18 (23)
Pacreas 19 (24)
Pelvic 20 (25)
Penis 21 (26)
Pericardium 22 (27)
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Peripheral Lymph Node 16 (28)
Peritoneum 23 (29)
Ascites 33 (3)
Pleura 24 (30)
Pleural Effusion 32 (31)
Prostate 25 (32)
Retroperitoneum 35 (33)
Skin 26 (34)
Small Intestine 27 (35)
Soft Tissue 28 (36)
Spleen 29 (37)
Testis 30 (38)
Uterus 31 (39)
Bile Duct 37 (4)
Other (specify) 99 (40)
Bladder 2 (5)
Bone 3 (6)
Bone Marrow 38 (7)
Brain 39 (8)
Breast 4 (9)
If other, specify
Date of Evaluation
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New Anticancer Treatment, Tarceva in NSCLC patients
who have EGFR-positive tumors NCT00373425
Sponsor: OSI Pharmaceuticals Information provided by
(Responsible Party): Astellas Pharma Inc (OSI
Pharmaceuticals) A multicenter, randomized, double-blind,
placebo-controlled, phase 3 study of single-agent Tarceva®
(erlotinib) following complete tumor resection with or
without adjuvant chemotherapy in patients with stage IB-
IIIA non-small cell lung carcinoma who have EGFR-positive
tumors. See
https://clinicaltrials.gov/ct2/show/NCT00373425
Part of study: New Anticancer Treatment
All rights reserved. Please visit https://medical-data-
models.org/forms/16703
New Anticancer Treatment, Tarceva
in NSCLC patients who have EGFR-
positive tumors NCT00373425
New Anticancer Treatment
First Treatment Regimen:
Start Date
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Unscheduled Visit, Tarceva in NSCLC patients
who have EGFR-positive tumors NCT00373425
Sponsor: OSI Pharmaceuticals 
Information provided by (Responsible Party): Astellas
Pharma Inc (OSI Pharmaceuticals) 
A multicenter, randomized, double-blind, placebo-
controlled, phase 3 study of single-agent Tarceva®
(erlotinib) following complete tumor resection with or
without adjuvant chemotherapy in patients with stage IB-
IIIA non-small cell lung carcinoma who have EGFR-positive
tumors. See
https://clinicaltrials.gov/ct2/show/NCT00373425 
Part of study: Unscheduled Visit
All rights reserved. Please visit https://medical-data-
models.org/forms/16704
Unscheduled Visit, Tarceva in
NSCLC patients who have EGFR-
positive tumors NCT00373425
Header
Visit Number
Vital Assessment
Date
Weight
kg
ECOG performance status:
Physical Examination
Date Physical Examination performed:
Pregnancy Test
Pregnancy Test: Applicable
Yes
No
Was pregnancy test performed?
Yes
No
Date of Collection
Accession Number
Hematology
Date of Collection
Accession Number
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Biochemistry/Proteomics
Date of Collection
Accession Number
Cigarette Smoking Status
Cigarette Smoking Status: Done?
Yes
No
Date of evaluation:
Cigarette Smoking Status
Patient not currently smoking cigarettes.
(1)
Patient is currently smoking cigarettes.
(2)
If patient is currently smoking cigarettes, indicate
average number of cigarettes smoked per day:
Other Tobacco/Nicotine Use Status
Other Tobacco/Nicotine Use
Patient not currently using other tobacco
or nicotine products. Do not complete
next questions. (1)
Patient currently using other tobacco or
nicotine products. Complete next
questions. (2)
Cigars and/or Pipes: Applicable?
Yes
No
Cigars and/or Pipes: Frequency used
at least once daily (1)
at least once weekly (2)
at least once monthly (3)
< once monthly (4)
Oral Tobacco Products: Applicable?
Yes
No
Oral Tobacco Products: Frequency used
at least once daily (1)
at least once weekly (2)
at least once monthly (3)
< once monthly (4)
Nicotine replacement therapy: Applicable?
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Yes
No
Nicotine replacement therapy: Frequency used
at least once daily (1)
at least once weekly (2)
at least once monthly (3)
< once monthly (4)
Other tobacco/nicotine products: Applicable?
Yes
No
Other, please specify:
Other: Frequency used
at least once daily (1)
at least once weekly (2)
at least once monthly (3)
< once monthly (4)
Radiology
Was a chest X-ray performed?
Yes (1)
No (2)
NA (3)
Date
Was a chest/upper abdomen CT scan
performed?
Yes (1)
No (2)
NA (3)
Date chest/upper abdomen CT scan performed:
If yes, was relapse documented?
Yes
No
Was any other radiological disease assessment
performed?
Yes
No
Date of assessment
If Yes, was relapse documented?
Yes
No
Specify type of assessment:
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Did the ''Other'' radiological assessment
performed include
X-Ray imaging of the chest?
Yes
No
Did the ''Other'' radiological assessment
performed include
CT imaging of the chest?
Yes
No
Did the ''Other'' radiological assessment
performed include CT imaging of the chest/upper
abdomen?
Yes
No
Study Drug Dispensed
Study Drug Dispensed: Applicable?
Study Drug Dispensed
Date dispensed
Bottle number
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Deviation Log, Tarceva in NSCLC patients who
have EGFR-positive tumors NCT00373425
Sponsor: OSI Pharmaceuticals 
Information provided by (Responsible Party): Astellas
Pharma Inc (OSI Pharmaceuticals) 
A multicenter, randomized, double-blind, placebo-
controlled, phase 3 study of single-agent Tarceva®
(erlotinib) following complete tumor resection with or
without adjuvant chemotherapy in patients with stage IB-
IIIA non-small cell lung carcinoma who have EGFR-positive
tumors. See
https://clinicaltrials.gov/ct2/show/NCT00373425
Part of Study: Deviation Log
All rights reserved. Please visit https://medical-data-
models.org/forms/16705
Deviation Log, Tarceva in NSCLC
patients who have EGFR-positive
tumors NCT00373425
Deviation Log
Visit Name
CRF Page Number (if applicable)
Description
Site Personnel Initials
Date
Type: preapproved
Yes
No
Type
01 Not Done (1)
10 Dose Not Escalated (10)
11 lncorrectly Assigned or Stratified (11)
12 Other - Use Only As A Last Resort
(12)
02 Outside of Window (2)
03 Excluded Prior Therapy (3)
04 Excluded Concomitant Medication (4)
05 Value Out of Range (5)
06 Same Method Not Used (6)
07 lncorrect Dose (7)
08 Dose Not Held (8)
09 Dose Not Reduced (9)
Signature
Monitor Name
Monitor signature
Signature Date
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Moisturizers and Sunscreens, Tarceva in NSCLC
patients who have EGFR-positive tumors NCT00373425
Sponsor: OSI Pharmaceuticals
Information provided by (Responsible Party): Astellas
Pharma Inc (OSI Pharmaceuticals) 
A multicenter, randomized, double-blind, placebo-
controlled, phase 3 study of single-agent Tarceva®
(erlotinib) following complete tumor resection with or
without adjuvant chemotherapy in patients with stage IB-
IIIA non-small cell lung carcinoma who have EGFR-positive
tumors. See
https://clinicaltrials.gov/ct2/show/NCT00373425
Part: Moisturizers and Sunscreens
All rights reserved. Please visit https://medical-data-
models.org/forms/16706
Moisturizers and Sunscreens,
Tarceva in NSCLC patients who have
EGFR-positive tumors
NCT00373425
Moisturizers and Sunscreens
Moisturizers and/or Sunscreens used?
Yes
No
Moisturizers and Sunscreens
Intervention
Type: Moisturizer
Yes
No
Type: Sunscreen
Yes
No
Type: both
Yes
No
Date Started: prestudy
Yes
No
Date Started
Date Stopped: post treatment
Yes
No
Date stopped
1 / 1
AAFP: Intractable Headache Admission
Order
AAFP: Intractable Headache Admission Order,
Standardizes Admission Orders, Author: Robert M. Wiprud,
MD The primary purpose of these Ordersets is to decrease
unnecessary variability and to improve quality through
standardized Admission Orders. Developed by the Scott &
White Clinic at College Station, Texas. Copyright © 2006
American Academy of Family Physicians. Physicians may
photocopy or adapt for use in their own practices; all other
rights reserved. Wiprud RM. Providing consistent care with
standardized admission orders. Fam Pract Manag.
September 2006: 49-52 See
http://www.aafp.org/fpm/2006/0900/p49.html This ODM
Form includes the twentieth section ("AAFP: Intractable
Headache Admission Order")
All rights reserved. Please visit https://medical-data-
models.org/forms/16707
AAFP: Intractable Headache
Admission Order
Default Itemgroup
Name
Age
Date of Birth
Medical record number
Status
23 hr observation
Yes
No
Attending
Name of attending physician
Phone number of attending physician
Admitting Diagnosis
Intractable Headache Contributing Diagnoses
Condition
Condition
Stable (1)
Fair (2)
Serious (3)
Critical (4)
Allergies
1 / 3
Allergies
Diet
Regular, but no caffeine
Yes
No
Acitivity
Acitivity
Nursing
Notify MD for: T > 100, P < 60 or > 120, BP <
90/60 or > 170/110
Yes
No
Medications
No analgetics
Yes
No
No narcotics
Yes
No
Reglan 10 mg IV followed by DHE 0.5 mg IV
Yes
No
Then every 8 hrs give Reglan 10 mg IV followed
by DHE 1 mg IV until patient is 100% HA free X
24-48 hrs (HA scores = 0)
Yes
No
Other
Yes
No
If Other, please specify
IV
Heplock
Yes
No
Lab
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Hemogram
Yes
No
basal metabolic profile
Yes
No
Signature
Print Name
Date and Time
3 / 3
AAFP: Intractable Headache Admission Order
AAFP: Lower GI Bleed Admission Order
AAFP: Lower GI Bleed Admission Order, Author: Robert M.
Wiprud, MD The primary purpose of these Ordersets is to
decrease unnecessary variability and to improve quality
through standardized Admission Orders. Developed by the
Scott & White Clinic at College Station, Texas. Copyright ©
2006 American Academy of Family Physicians. Physicians
may photocopy or adapt for use in their own practices; all
other rights reserved. Wiprud RM. Providing consistent
care with standardized admission orders. Fam Pract
Manag. September 2006: 49-52 See
http://www.aafp.org/fpm/2006/0900/p49.html This ODM
Form includes the twenty-first section ("AAFP: Lower GI
Bleed Admission Order")
All rights reserved. Please visit https://medical-data-
models.org/forms/16709
AAFP: Lower GI Bleed Admission
Order
Default Itemgroup
Name
Age
Date of Birth
Medical record number
Status
Status
Medical floor (1)
Telemetry (2)
ICU (3)
Attending
Name of attending physician
Phone number of attending physician
Admitting Diagnosis
Lower Gl Bleed Contributing Diagnoses
Condition
Condition
Stable (1)
Fair (2)
Serious (3)
Critical (4)
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Allergies
Allergies
Diet
NPO except meds
Yes
No
Other
Yes
No
If Other, please specify
Activity
Bed rest with bedside commode
Yes
No
Bathroom privileges with assistance
Yes
No
Nursing
ICU: per routine
Yes
No
Medical: every 1 hr until stable X4, then every 2
hrs until stable X4, then every 4 hrs
Yes
No
Notify MD for: BP < 90/60 or > 180/110, P < 60 or
> 120, urine output < 30 cc/hr over 4 hrs, all H/H
results
Yes
No
Medications
Medications
IV
Bolus normal saline ____cc over ___
Yes
No
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If Bolus normal saline, please specify amount
cc
If Bolus normal saline, please specify duration
Dextrose 5% normal saline with 20 mEq KCl/L
@____mL7hr total
Yes
No
If Dextrose 5% normal saline with 20 mEq KCl,
please specify amount
mL/hr
Lab
Hemogram, comp met profile, PT/PTT/INR on
admission
Yes
No
HH every 6 hrs X24 hrs
Yes
No
Type and screen for __ units PRBC
Yes
No
If Type and screen, please specify units PRBC
Other
Have patient sign informed consent for blood
transfusion
Yes
No
Signature
Print Name
Date and Time
3 / 3
AAFP: Lower GI Bleed Admission Order
Prevention and Treatment of Skin, Hair and Nail Reactions, Tarceva
in NSCLC patients who have EGFR-positive tumors NCT00373425
Sponsor: OSI Pharmaceuticals 
Information provided by (Responsible Party): Astellas
Pharma Inc 
(OSI Pharmaceuticals) A multicenter, randomized, double-
blind, placebo-controlled, phase 3 study of single-agent
Tarceva® (erlotinib) following complete tumor resection with
or without adjuvant chemotherapy in patients with stage IB-
IIIA non-small cell lung carcinoma who have EGFR-positive
tumors. See
https://clinicaltrials.gov/ct2/show/NCT00373425 
Part of study: 
Prevention and Treatment of Skin, Hair and Nail Reactions
Due to Study Drug Administration
All rights reserved. Please visit https://medical-data-
models.org/forms/16710
Prevention and Treatment of Skin,
Hair and Nail Reactions Due to
Study Drug Administration, Tarceva
in NSCLC patients who have EGFR-
positive tumors NCT00373425
Prevention and Treatment of Skin, Hair
and Nail Reactions
Interventions used to prevent and treat skin, hair
and nail reactions
Yes
No
Prevention and Treatment of Skin, Hair
and Nail Reactions Due to Study Drug
Administration
Intervention (Use generic name when possible)
Prophylaxis
Yes
No
Route
Topical (1)
Oral (2)
IV (3)
Procedure (4)
Other (specify) (5)
If other, please specify
Indication
Skin Reaction (1)
Hair Changes (2)
Nail Changes (3)
Other (specify) (4)
If other, please specify
Date Started
Date Stopped
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Date stopped: Post treatment
Yes
No
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Baseline Local Laboratory Data, Tarceva in NSCLC
patients who have EGFR-positive tumors NCT00373425
Sponsor: OSI Pharmaceuticals 
Information provided by (Responsible Party): Astellas
Pharma Inc (OSI Pharmaceuticals) 
A multicenter, randomized, double-blind, placebo-
controlled, phase 3 study of single-agent Tarceva®
(erlotinib) following complete tumor resection with or
without adjuvant chemotherapy in patients with stage IB-
IIIA non-small cell lung carcinoma who have EGFR-positive
tumors. See
https://clinicaltrials.gov/ct2/show/NCT00373425 
Part of study: Baseline Local Laboratory Data
All rights reserved. Please visit https://medical-data-
models.org/forms/16711
Baseline Local Laboratory Data,
Tarceva in NSCLC patients who have
EGFR-positive tumors
NCT00373425
Hematology
Date
Lab Name
Hemoglobin
WBC
ANC
Platelet Count
Biochemistry
Date
Lab Name
Creatinine
Total Bilirubin
ALT (SGPT)
Sodium
Potassium
Magnesium
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Pregnancy Tests
Pregnancy Test: Applicable?
Yes
No
Was a serum pregnancy test performed?
Yes
No
If Yes, date test performed:
Pregnancy test result
Positive (1)
Negative (2)
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AAFP: Hypernatremia Admission Order
AAFP: Hypernatremia Admission Order, Standardizes
Admission Orders, Author: Robert M. Wiprud, MD The
primary purpose of these Ordersets is to decrease
unnecessary variability and to improve quality through
standardized Admission Orders. Developed by the Scott &
White Clinic at College Station, Texas. Copyright © 2006
American Academy of Family Physicians. Physicians may
photocopy or adapt for use in their own practices; all other
rights reserved. Wiprud RM. Providing consistent care with
standardized admission orders. Fam Pract Manag.
September 2006: 49-52 See
http://www.aafp.org/fpm/2006/0900/p49.html This ODM
Form includes the seventeenth section ("Hypernatremia
Admission Order").
All rights reserved. Please visit https://medical-data-
models.org/forms/16712
AAFP: Hypernatremia Admission
Order
Default Itemgroup
Name
Age
Date of Birth
Medical record number
Status
Status
Attending
Name of attending physician
Phone number of attending physician
Admitting Diagnosis
Hypernatremia Contributing Diagnoses
Condition
Condition
Stable (1)
Fair (2)
Serious (3)
Critical (4)
Allergies
Allergies
1 / 3
Activity
Bed rest and up in chair as tolerated
Yes
No
Diet
Diet
Nursing
Notify MD for T > 101, BP > 190/100 or < 90/60,
neuro changes
Yes
No
IV
___normal saline IV@ 500 mL/hr until orthostasis
resolves, then Dextrose 5% in water (if
hyperosmolar) OR Dextrose 5% in 1/2 normal
saline (if not Hyperosmolar) IV @ _____mL/hr
Yes
No
If normal saline, please specify amount of normal
saline. If Dextrose 5% in 1/2 normal saline,
please specify amount
Lasix 80 mg IV/PO daily
Yes
No
Dextrose 5% in water @___mL/hr
Yes
No
If Dextrose 5% in water, please specify amount
mL/hr
Medications
Medications
Lab
Comp met profile
Yes
No
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UA
Yes
No
Urine NA
Yes
No
TSH
Yes
No
Urine OSM
Yes
No
Signature
Print Name
Date and Time
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AAFP: Hypernatremia Admission Order
On-Treatment Assessments, Tarceva in NSCLC patients
who have EGFR-positive tumors NCT00373425
Sponsor: OSI Pharmaceuticals 
Information provided by (Responsible Party): Astellas
Pharma Inc (OSI Pharmaceuticals) 
A multicenter, randomized, double-blind, placebo-
controlled, phase 3 study of single-agent Tarceva®
(erlotinib) following complete tumor resection with or
without adjuvant chemotherapy in patients with stage IB-
IIIA non-small cell lung carcinoma who have EGFR-positive
tumors. See
https://clinicaltrials.gov/ct2/show/NCT00373425
Part of study: On-Treatment Assessments
All rights reserved. Please visit https://medical-data-
models.org/forms/16713
On-Treatment Assessments, Tarceva
in NSCLC patients who have EGFR-
positive tumors NCT00373425
Header
Month Number
Vital Assessment
Date
Weight
kg
ECOG performance status:
Physical Examination
Date Physical Examination performed:
Pregnancy Test
Pregnancy Test: Applicable
Yes
No
Was pregnancy test performed?
Yes
No
Date of Collection
Accession Number
Hematology
Date of Collection
Accession Number
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Biochemistry/Proteomics
Date of Collection
Accession Number
Cigarette Smoking Status
Date of evaluation:
Cigarette Smoking Status
Patient not currently smoking cigarettes.
(1)
Patient is currently smoking cigarettes.
(2)
If patient is currently smoking cigarettes, indicate
average number of cigarettes smoked per day:
Other Tobacco/Nicotine Use Status
Other Tobacco/Nicotine Use
Patient not currently using other tobacco
or nicotine products. Do not complete
next questions. (1)
Patient currently using other tobacco or
nicotine products. Complete next
questions. (2)
Cigars and/or Pipes: Applicable?
Yes
No
If a current user of cigars and/or pipes, indicate
frequency used:
at least once daily (1)
at least once weekly (2)
at least once monthly (3)
< once monthly (4)
Oral Tobacco Products: Applicable?
Yes
No
If a current user of oral tobacco products, indicate
frequency used:
at least once daily (1)
at least once weekly (2)
at least once monthly (3)
< once monthly (4)
Nicotine replacement therapy: Applicable?
Yes
No
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If a current user of nicotine replacement therapy,
indicate frequency used:
at least once daily (1)
at least once weekly (2)
at least once monthly (3)
< once monthly (4)
Other: Applicable?
Yes
No
Other, please specify:
If a current user of other tobacco/nicotine
products, indicate frequency used:
at least once daily (1)
at least once weekly (2)
at least once monthly (3)
< once monthly (4)
Radiology
Was a chest X-ray performed?
Yes (1)
No (2)
NA (3)
Date
Was a chest/upper abdomen CT scan
performed?
Yes (1)
No (2)
NA (3)
Date chest/upper abdomen CT scan performed:
If yes, was relapse documented?
Yes
No
Was any other radiological disease assessment
performed?
Yes
No
Date of assessment
If Yes, was relapse documented?
Yes
No
Specify type of assessment:
Did the ''Other'' radiological assessment
performed include
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X-Ray imaging of the chest?
Yes
No
Did the ''Other'' radiological assessment
performed include
CT imaging of the chest?
Yes
No
Did the ''Other'' radiological assessment
performed include CT imaging of the chest/upper
abdomen?
Yes
No
Study Drug Dispensed
Date dispensed
Bottle number
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Eligibility Chronic Myeloid Leukaemia
NCT00390897
Glivec® (Imatinib Mesylate, STI571) in Monotherapy
Versus Glivec®-Interferon Alpha in the Treatment of
Chronic-Phase Chronic Myeloid Leukaemia; ODM derived
from: https://clinicaltrials.gov/show/NCT00390897
All rights reserved. Please visit https://medical-data-
models.org/forms/16714
Eligibility Chronic Myeloid Leukaemia
NCT00390897
Inclusion Criteria
1. patients with newly-diagnosed chronic-phase
ph-positive chronic myeloid leukaemia (maximum
3 months as of the diagnosis of the disease, with
the date of the cytogenetic study regarded as
such).*
Yes
No
2. age between 18 and 72 years (both included).*
Yes
No
3. performance status < 2 on the ecog scale (see
annex 3).*
Yes
No
4. secure written or oral informed consent in the
presence of a witness and consent for biological
samples (annexes 5 and 6).*
Yes
No
Exclusion Criteria
1. criteria of acceleration or blastic crisis (see
annex 7).*
Yes
No
2. when there is a compatible family donor in
patients aged under 40 years or a non-relative
donor in patients aged under 30 years (in whom
allogenic transplant is still regarded as first-line
treatment), the possibility of performing an
allogenic transplant as first therapeutic option
should be considered. in any case, as this aspect
is still a matter of debate, it is left up to each
group to take the relevant decision depending on
the institution's policy.*
Yes
No
3. administration of other treatments before
inclusion in the protocol (a maximum of 3 months
of monotherapy with hydroxyurea is permitted).*
Yes
No
4. altered hepatic or renal function (sgot, sgpt,
1 / 2
total bilirubin and creatinine > 1.5 times the upper
limit of normality).*
Yes
No
5. uncontrolled diseases, such as thyroidal
dysfunction, diabetes mellitus, angina pectoralis,
serious heart failure (functional class iii/iv of the
new york heart association classification),
neuropsychiatric infection or disease (see annex
15).*
Yes
No
6. positive serology for hiv.*
Yes
No
7. record of cancer in the last 5 years (barring
basal cell skin carcinoma and cervical carcinoma
in situ).*
Yes
No
8. pregnancy or breastfeeding*
Yes
No
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Open-label Baseline Assessments, Tarceva in NSCLC
patients who have EGFR-positive tumors NCT00373425
Sponsor: OSI Pharmaceuticals 
Information provided by (Responsible Party): Astellas
Pharma Inc (OSI Pharmaceuticals) 
A multicenter, randomized, double-blind, placebo-
controlled, phase 3 study of single-agent Tarceva®
(erlotinib) following complete tumor resection with or
without adjuvant chemotherapy in patients with stage IB-
IIIA non-small cell lung carcinoma who have EGFR-positive
tumors. See
https://clinicaltrials.gov/ct2/show/NCT00373425
Part of study: Open-label Baseline Assessments
All rights reserved. Please visit https://medical-data-
models.org/forms/16715
Open-label Baseline Assessments,
Tarceva in NSCLC patients who have
EGFR-positive tumors
NCT00373425
Vital Assessment
Date
Weight
kg
ECOG performance status:
Physical Examination
Date Physical Examination performed:
Pregnancy Test
Pregnancy Test: Applicable
Yes
No
Was pregnancy test performed?
Yes
No
Date of Collection
Accession Number
Hematology
Date of Collection
Accession Number
Biochemistry/Proteomics
Date of Collection
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Accession Number
Cigarette Smoking Status
Date of evaluation:
Cigarette Smoking Status
Patient not currently smoking cigarettes.
(1)
Patient is currently smoking cigarettes.
(2)
If patient is currently smoking cigarettes, indicate
average number of cigarettes smoked per day:
Other Tobacco/Nicotine Use Status
Other Tobacco/Nicotine Use
Patient not currently using other tobacco
or nicotine products. Do not complete
next questions. (1)
Patient currently using other tobacco or
nicotine products. Complete next
questions. (2)
Cigars and/or Pipes: Applicable?
Yes
No
If a current user of cigars and/or pipes, indicate
frequency used:
at least once daily (1)
at least once weekly (2)
at least once monthly (3)
< once monthly (4)
Oral Tobacco Products: Applicable?
Yes
No
If a current user of oral tobacco products, indicate
frequency used:
at least once daily (1)
at least once weekly (2)
at least once monthly (3)
< once monthly (4)
Nicotine replacement therapy: Applicable?
Yes
No
If a current user of nicotine replacement therapy,
indicate frequency used:
at least once daily (1)
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at least once weekly (2)
at least once monthly (3)
< once monthly (4)
Other: Applicable?
Yes
No
Other, please specify:
If a current user of other tobacco/nicotine
products, indicate frequency used:
at least once daily (1)
at least once weekly (2)
at least once monthly (3)
< once monthly (4)
Open-Label Tarceva Dispensed for Month
1
Date dispensed
Bottle number
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AAFP: Hypokalemia Admission Order
AAFP: Hypokalemia Admission Order, Standardizes
Admission Orders, Author: Robert M. Wiprud, MD The
primary purpose of these Ordersets is to decrease
unnecessary variability and to improve quality through
standardized Admission Orders. Developed by the Scott &
White Clinic at College Station, Texas. Copyright © 2006
American Academy of Family Physicians. Physicians may
photocopy or adapt for use in their own practices; all other
rights reserved. Wiprud RM. Providing consistent care with
standardized admission orders. Fam Pract Manag.
September 2006: 49-52 See
http://www.aafp.org/fpm/2006/0900/p49.html This ODM
Form includes the eighteenth section ("Hypokalemia
Admission Order").
All rights reserved. Please visit https://medical-data-
models.org/forms/16718
AAFP: Hypokalemia Admission
Order
Default Itemgroup
Name
Age
Date of Birth
Medical record number
Status
Status
Observation (1)
Admission (2)
Monitored Bed (3)
ICU (4)
Attending
Name of attending physician
Phone number of attending physician
Admitting Diagnosis
Hypokalemia Associated Diagnoses
Condition
Condition
Full Code (1)
DNR (2)
Allergies
1 / 4
Allergies
Diet
NPO
Yes
No
Clear liquid
Yes
No
AHA step 2
Yes
No
ADA___calories
Yes
No
amount of calories
Other
Yes
No
If Other, please specify
Activity
Bed rest with bedside commode
Yes
No
Bathroom privileges
Yes
No
Up ad lib
Yes
No
Nursing
Vital signs with neuro checks every 4 hrs for 24
hrs then every shift
Yes
No
Continuous cardiac monitoring; arrhythmia orders
Yes
No
Notify MD for: T > 101.5; P > 120; BP < 90/60 or
> 180/110; presence of any muscle weakness,
hyporeflexes, paresthesias or arrhythmias
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Yes
No
Daily weight
Yes
No
I&O
Yes
No
IV/Medications
Potassium chloride 10 mEq in 100 mL normal
saline IVPB over 1 hr, times___doses
Yes
No
If Potassium chloride, please specify:
times__doses
IV fluids__with 40 mEq KCl/L @___mL/hr
Yes
No
if IV fluide, please specify IV fluids___with mEq
KCl/L
If IV fluids, please specify KCl/L @___mL/hr
Potassium chloride 20 mEq in 100 mL NSS IVPB
over on hr, times___doses
Yes
No
Please specify times__doses
IV fluids___with 40 mEq KCl/L @___mL/hr
Yes
No
If IV fluids, please specify
If IV fluids, please specify KCl/L @___mL/hr
Potassium chloride 40 mEq every __ hrs
Yes
No
If Potassium chloride, please specify frequency
hrs
Maalox 30 mL PO every 4 hrs prn indigestion
Yes
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No
MOM 30 mL PO every 12 hrs prn constipation
Yes
No
Tylenol PO every 4 hrs prn pain/fever
Yes
No
Ambien 10 mg PO at bedtime prn insomnia
Yes
No
Consider Lovenox 40 mg sc daily
Yes
No
Lab
Admission: hemagram, comp med profile, Mg,
calcium, TSH, urinalysis, urine osmo, Na,K+, Cl,
bicarb
Yes
No
Serum potassium every __ hrs
Yes
No
If serum potassium, please specify frequency
hrs
Consider: serum cortisol, renin, aldosterone,
urine myoglobin, 24 hrs urine K+, Na, creat,
protein, cortisol
Yes
No
Signature
Print Name
Date and Time
4 / 4
AAFP: Hypokalemia Admission Order
Open-label Tarceva, Tarceva in NSCLC patients
who have EGFR-positive tumors NCT00373425
Sponsor: OSI Pharmaceuticals 
Information provided by (Responsible Party): Astellas
Pharma Inc (OSI Pharmaceuticals) 
A multicenter, randomized, double-blind, placebo-
controlled, phase 3 study of single-agent Tarceva®
(erlotinib) following complete tumor resection with or
without adjuvant chemotherapy in patients with stage IB-
IIIA non-small cell lung carcinoma who have EGFR-positive
tumors. See
https://clinicaltrials.gov/ct2/show/NCT00373425 
Part of study: Open-label Tarceva Consent and Eligibility
All rights reserved. Please visit https://medical-data-
models.org/forms/16719
Open-label Tarceva Consent and
Eligibility, Tarceva in NSCLC patients
who have EGFR-positive tumors
NCT00373425
Open Label Tarceva Consent
Date addendum to main study consent was
signed:
Open-label Tarceva: please check one
Patient to receive open-label Tarceva for
up to two years and will be followed for
all On-treatment, Post-treatment and
Long-term Follow-up Assessments
according to the protocol. (Complete
Open-label Baseline Assessments.) (1)
Patient not to receive open-label Tarceva
but will remain in the study and continue
to be followed for all Post-treatment and
Long-term Follow-up Assessments.
(Complete Post-treatment Assessments
and Long-term Follow-up Assessments.)
(2)
Open-label Tarceva Eligibility
Open-label Tarceva Eligibility: Applicable?
Yes
No
Did the patient meet all of the eligibility criteria to
receive open-label Tarceva?
Yes
No
If No, which of the 4 criteria was/were not met?
Criteria 1 met?
Yes
No
If No, which of the 4 criteria was/were not met?
Criteria 2 met?
Yes
No
If No, which of the 4 criteria was/were not met?
Criteria 3 met?
Yes
1 / 2
No
If No, which of the 4 criteria was/were not met?
Criteria 4 met?
Yes
No
lf any eligibility criteria were not met, was an
exemption granted by OSI?
Yes (1)
No (2)
NA (3)
Investigator Signature
Investigator's Signature:
Date
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Withdrawal of Consent, Tarceva in NSCLC patients
who have EGFR-positive tumors NCT00373425
Sponsor: OSI Pharmaceuticals Information provided by
(Responsible Party): Astellas Pharma Inc ( OSI
Pharmaceuticals ) A multicenter, randomized, double-blind,
placebo-controlled, phase 3 study of single-agent Tarceva®
(erlotinib) following complete tumor resection with or
without adjuvant chemotherapy in patients with stage IB-
IIIA non-small cell lung carcinoma who have EGFR-positive
tumors. See
https://clinicaltrials.gov/ct2/show/NCT00373425
Part: Withdrawal of Consent
All rights reserved. Please visit https://medical-data-
models.org/forms/16720
Withdrawal of Consent, Tarceva in
NSCLC patients who have EGFR-
positive tumors NCT00373425
Withdrawal of Treatment Consent
Withdrawal of Treatment Consent: Applicable?
Yes
No
Patient withdrew treatment consent during the
study.
Date:
Withdrawal of Tissue Consent
Withdrawal of Tissue Consent: Applicable?
Yes
No
Patient withdrew tumor tissue consent during the
study.
Date:
Withdrawal of Optional Research Blood
Sample Consent
Withdrawal of Optional Research Blood Sample
Consent: Applicable?
Yes
No
Patient withdrew optional blood sample consent
during the study.
Date:
Investigator Signature
Investigator's Signature
Signature Date
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Eligibility Chronic Nephropathy
NCT00199927
Statins in Proteinuric Nephropathies; ODM derived from:
https://clinicaltrials.gov/show/NCT00199927
All rights reserved. Please visit https://medical-data-
models.org/forms/16721
Eligibility Chronic Nephropathy
NCT00199927
Inclusion Criteria
age >16 years*
Yes
No
hypertension, defined as a systolic or diastolic
blood pressure > 140 or 90 mmhg respectively
(or less in patients with concomitant
antihypertensive therapy)*
Yes
No
creatinine clearance >20 ml/min/1.73m2 (with
variation of less than 30% in the 3 months prior to
study entry)*
Yes
No
urinary protein excretion rate persistently > 1 g/24
hours (average of at least two measurements in
two urine collections two weeks apart) without
evidence of urinary tract infection or overt heart
failure (new york heart association class iii or
more)*
Yes
No
written informed consent*
Yes
No
Exclusion Criteria
specific contraindication to statin therapy
because of a previous coronary event or serum
ldl-cholesterol levels > 190 mg/dl despite a low
cholesterol (<200 mg/day) diet and a saturated
fatty acid in take less than 7% of total calories will
not be included*
Yes
No
chronic treatment with corticosteroids,
nonsteroidal anti-inflammatory drugs, or
immunosuppressive drugs*
Yes
No
acute myocardial infarction or cerebrovascular
accident in the six months preceding the study -
severe uncontrolled hypertension (diastolic blood
pressure >115 and/or systolic blood pressure
1 / 2
>220 mmhg)*
Yes
No
evidence or suspicion of renovascular disease,
obstructive uropathy, type 1 diabetes mellitus,
vasculitides, cancer*
Yes
No
elevated serum aminotransferase concentrations
- chronic cough*
Yes
No
history of poor tolerance or allergy to acei, ata or
statins*
Yes
No
drug or alcohol abuse*
Yes
No
pregnancy, breast feeding and ineffective
contraception*
Yes
No
legal incapacity and/or  other circumstances
rendering the patient unable to understand the
nature, scope and possible consequences of the
trial.*
Yes
No
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SOFA Score
The SOFA (Sequential Organ Failure Assessment) score to
describe organ dysfunction/failure.
Reference: Vincent, J.-., Moreno, R., Takala, J. et al.
Intensive Care Med (1996) 22: 707.
doi:10.1007/BF01709751
All rights reserved. Please visit https://medical-data-
models.org/forms/16722
SOFA Score
Respiration
PaO2/FiO2
mmHg
<400 (1)
<300 (2)
<200 (3)
<100 (4)
Coagulation
Platelets
1000/mm 3
<150 (1)
<100 (2)
<50 (3)
<20 (4)
Liver
Bilirubin
mg/dl (µmol/l)
1.2- 1.9 (20 - 32) (1)
2.0- 5.9 (33 - 101) (2)
6.0-11.9 (102 - 204) (3)
>12.0 (< 204) (4)
Cardiovascular
Hypotension
MAP < 70 mmHg (1)
Dopamine ≤ 5 or dobutamine (any dose)
(2)
Dopamine > 5 or epinephrine ≤ 0.1 or
norepinephrine ≤ 0.1 (3)
Dopamine > 15 or epinephrine > 0.1 or
norepinephrine > 0.1 (4)
Central nervous system
Glasgow Coma Score
13-14 (1)
10-12 (2)
6-9 (3)
<6 (4)
Renal
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Creatinine in mg/dl (µmol/l) or urine output
1.2-1.9 (110-170) (1)
2.0-3.4 (171-299) (2)
3.5-4.9 (300-440) or <500 ml/day (3)
>5.0 (>440) or <200 ml/day (4)
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Eligibility Chronic Schizophrenia
NCT00148616
Memantine for the Treatment of Negative Symptomatology;
ODM derived from:
https://clinicaltrials.gov/show/NCT00148616
All rights reserved. Please visit https://medical-data-
models.org/forms/16723
Eligibility Chronic Schizophrenia
NCT00148616
Inclusion Criteria
diagnosis of schizophrenia (dsm-iv)*
Yes
No
age 18 to 40*
Yes
No
stable negative syndrome (panss negative score
> 20)*
Yes
No
at least one previous schizophrenic episode*
Yes
No
informed consent*
Yes
No
subjects must be considered by the investigator
to be compliant with investigations and
appointments*
Yes
No
subjects must have an educational level and a
degree of understanding such that they can
meaningfully communicate with the investigator*
Yes
No
Exclusion Criteria
axis i disorder other than schizophrenia within 12
months, e.g. schizoaffective disorder*
Yes
No
severe positive symptomatology (panns positive
score > panns negative score)*
Yes
No
dependency on alcohol or addictive drugs within
6 months of the baseline evaluation*
Yes
No
contraindication of risperidone*
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Yes
No
significant neurological, cardiovascular, hepatic,
renal, metabolic, or other medical diseases or
any clinically relevant abnormalities in laboratory
tests*
Yes
No
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Eligibility Cirrhosis NCT00493480
Danish Carvedilol Study in Portal Hypertension; ODM
derived from: https://clinicaltrials.gov/show/NCT00493480
All rights reserved. Please visit https://medical-data-
models.org/forms/16724
Eligibility Cirrhosis NCT00493480
Inclusion Criteria
cirrhosis*
Yes
No
hvpg > 12 mmhg*
Yes
No
Exclusion Criteria
respiratory disease that contradict endoscopy*
Yes
No
hepatic encephalopathy*
Yes
No
hepatorenal syndrome*
Yes
No
copd or asthma*
Yes
No
treatment with vasoactive drugs within 1 week of
inclusion*
Yes
No
heart disease that contradict treatment with beta-
blocking agents*
Yes
No
iddm*
Yes
No
pregnancy*
Yes
No
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Eligibility CNS Lymphoma NCT00596154
Rituximab, Methotrexate, Procarbazine and Vincristine
Followed by High-dose Chemotherapy With Autologous
Stem-cell Rescue in Newly-diagnosed Primary CNS
Lymphoma; ODM derived from:
https://clinicaltrials.gov/show/NCT00596154
All rights reserved. Please visit https://medical-data-
models.org/forms/16725
Eligibility CNS Lymphoma
NCT00596154
Inclusion Criteria
all patients must have non-hodgkin's lymphoma
involving the brain, as demonstrated by ct or mri
and histologic confirmation by one of the
following: a positive csf cytology for lymphoma or
a monoclonal lymphocyte population as defined
by cell surface markers.*
Yes
No
a biopsy of the vitreous or uvea demonstrating
non-hodgkin's lymphoma. brain biopsy.*
Yes
No
patients must be hiv-1 negative.*
Yes
No
patient must have left ventricular ejection fraction
≥ 50%.*
Yes
No
patients must have no evidence of systemic
lymphoma. this must be demonstrated by a ct
scan of the chest, abdomen and pelvis prior to
registration.*
Yes
No
patients must have adequate bone marrow
function (defined as peripheral leucocyte count
>3000 cells/mm3 and platelet count > 100,000
cells/mm3), liver function (bilirubin < 2.0 mg%),
and adequate renal function (serum creatinine <
1.5 mg/dl or creatinine clearance >
50cc/min/1.73m2).*
Yes
No
men and women of reproductive potential must
agree to use an acceptable method of birth
control during treatment and for six months after
completion of treatment.*
Yes
No
patients must be between 18 and 72 years-old.*
Yes
No
1 / 2
patients must sign an informed consent.*
Yes
No
Exclusion Criteria
prior cranial irradiation*
Yes
No
other active primary malignancy with the
exception of basal cell carcinoma of the skin and
cervical carcinoma in situ.*
Yes
No
pre-existing immunodeficiency such as renal
transplant recipient.*
Yes
No
prior treatment with chemotherapy for cns
lymphoma.*
Yes
No
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FISH Results, Tarceva in NSCLC patients who
have EGFR-positive tumors NCT00373425
Sponsor: OSI Pharmaceuticals
Information provided by (Responsible Party): Astellas
Pharma Inc (OSI Pharmaceuticals) 
A multicenter, randomized, double-blind, placebo-
controlled, phase 3 study of single-agent Tarceva®
(erlotinib) following complete tumor resection with or
without adjuvant chemotherapy in patients with stage IB-
IIIA non-small cell lung carcinoma who have EGFR-positive
tumors. See
https://clinicaltrials.gov/ct2/show/NCT00373425
Part of Study: Results FISH
All rights reserved. Please visit https://medical-data-
models.org/forms/16727
FISH Results, Tarceva in NSCLC
patients who have EGFR-positive
tumors NCT00373425
Header
Patient's Screening Number
Specimen ID (from Pathology Report)
FISH Results
Specimen received: Blocks:
Specimen received: Slides:
Date received
Number
Technician
Number of EGFr Gene copies or Amplification:
Check the box that applies.
Disomy (≤ 2 copies of EGFr genes in >
90% of cells) (1)
Low Trisomy (≤ 2 copies of EGFr genes
in ≥ 40% of cells, 3 copies in 10% - 40%
of cells, ≥ 4 copies in < 10% of cells) (2)
High Trisomy (≤ 2 copies of EGFr genes
in ≥ 40% of cells, 3 copies in ≥ 40% of
cells, ≥ 4 copies in < 10% of cells) (3)
Low Polysomy (≥ 4 copies of EGFr
genes in 10% - 40% of cells) (4)
High Polysomy (≥ 4 copies of EGFr
genes in ≥ 40% of cells) (5)
Amplification: a ratio of EGFr gene to
chromosome 7of ≥ 2, OR (6)
Amplification: 15 copies of EGFr gene
per cell > 10% of analyzed tumor cells
(7)
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RESULT: Ratio
RESULT
Positive (Amplified or High Polysomy) (1)
Negative (Not Amplified or Not High
Polysomy) (2)
Undetermined (3)
Comments
Pathologist's Signature
Report Date
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Eligibility Cognition in Schizophrenia
NCT00628394
Treating Cognition in Schizophrenia With Atomoxetine and
Cognitive Remediation; ODM derived from:
https://clinicaltrials.gov/show/NCT00628394
All rights reserved. Please visit https://medical-data-
models.org/forms/16728
Eligibility Cognition in Schizophrenia
NCT00628394
Inclusion Criteria
dsm-iv diagnosis of schizophrenia or
schizoaffective disorder.*
Yes
No
males and females.*
Yes
No
ages 18-60 years old.*
Yes
No
all races and ethnicities.*
Yes
No
Exclusion Criteria
diagnosis of an organic brain disease.*
Yes
No
diagnosis of dsm-iv alcohol or substance abuse
within the last month or dsm-iv alcohol or
substance dependence within the last 3 months.*
Yes
No
meet criteria for primary negative symptoms,
established by clinical judgment.*
Yes
No
current or past history of clozapine treatment for
antipsychotic non-response.*
Yes
No
patients hospitalized in a psychiatric hospital
within the previous 30 days.*
Yes
No
patients with an unstable medical condition, as
determined by the investigator*
Yes
No
colorblindness*
Yes
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No
concurrent treatment with electroconvulsive
therapy or psychotherapy.*
Yes
No
pregnant women.*
Yes
No
must be able to read, speak, and understand
english.*
Yes
No
we do not have the resources necessary to
properly study non-english speaking patients in
this study.  the computer software used for
cognitive remediation and some clinical
assessments are only available in english.  the
need to provide such resources in foreign
languages would be prohibitive to the successful
completion of the study.*
Yes
No
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Concomitant Medications, Tarceva in NSCLC patients
who have EGFR-positive tumors NCT00373425
Sponsor: OSI Pharmaceuticals 
Information provided by (Responsible Party): Astellas
Pharma Inc (OSI Pharmaceuticals) 
A multicenter, randomized, double-blind, placebo-
controlled, phase 3 study of single-agent Tarceva®
(erlotinib) following complete tumor resection with or
without adjuvant chemotherapy in patients with stage IB-
IIIA non-small cell lung carcinoma who have EGFR-positive
tumors. See
https://clinicaltrials.gov/ct2/show/NCT00373425 
Part of study: Concomitant Medications
All rights reserved. Please visit https://medical-data-
models.org/forms/16730
Concomitant Medications, Tarceva in
NSCLC patients who have EGFR-
positive tumors NCT00373425
Concomitant Medications
Concomitant Medication
Yes
No
Medications
Medication (Use generic name when possible)
Prophylaxis
Yes
No
Indication
Date started: Prestudy
Yes
No
Date started
Date stopped: Post treatment
Yes
No
Date stopped
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Eligibility Cognition NCT00188331
Cognitive Function and Fatigue in Colorectal Cancer (CRC)
Patients After Chemotherapy; ODM derived from:
https://clinicaltrials.gov/show/NCT00188331
All rights reserved. Please visit https://medical-data-
models.org/forms/16731
Eligibility Cognition NCT00188331
Inclusion Criteria
histologically confirmed colorectal cancer*
Yes
No
age 18-75*
Yes
No
eastern cooperative oncology group (ecog)
performance status 0-1*
Yes
No
life expectancy of at least 12 months*
Yes
No
full recovery from any post operative sequelae*
Yes
No
adequate hepatic function as documented by a
serum bilirubin < 18 umol/l, and liver function
tests (lfts) within 1.5x normal range*
Yes
No
informed consent*
Yes
No
Exclusion Criteria
any major pre-existing psychiatric history or
dementia, alcohol abuse, or currently using a
psychotropic medication that might lead to
cognitive problems, other than short acting
benzodiazepines for nausea or sleep*
Yes
No
any evidence of metastatic disease other than
group c who may have limited metastatic disease.
if there is clinical suspicion of central nervous
system (cns) involvement patients must have
brain imaging (mri or ct scan) prior to
recruitment.*
Yes
No
ongoing sepsis or uncontrolled infection,
including hiv infection*
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Yes
No
pre-existing neurological condition likely to
interfere with ability to perform cognitive testing*
Yes
No
any other severe co-morbidity which, in the
judgement of the investigator, would make the
patient inappropriate for entry into this study*
Yes
No
active cancer within the last 5 years other than
squamous or basal cell carcinoma of the skin or
cervical cancer in situ (except for crc)*
Yes
No
previous history of chemotherapy, other than
adjuvant chemotherapy for group c metastatic
group > 1 year previously*
Yes
No
minimal english skills such that subjects would be
unable to follow simple, written english
instructions and to read questionnaires of a grade
8 standard with the help of a research assistant.*
Yes
No
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Eligibility Colon Cancer NCT00193167
Weekly Topotecan in Patients Treated for Metastatic
Colorectal Cancer; ODM derived from:
https://clinicaltrials.gov/show/NCT00193167
All rights reserved. Please visit https://medical-data-
models.org/forms/16732
Eligibility Colon Cancer
NCT00193167
Inclusion Criteria
to be included in this study, you must meet the
following criteria:*
Yes
No
metastatic colorectal cancer*
Yes
No
one previous chemotherapy for metastatic
disease*
Yes
No
measurable or evaluable disease*
Yes
No
able to perform activities of daily living with
assistance*
Yes
No
adequate bone marrow, liver, and kidney
function*
Yes
No
all patients must give written informed consent
prior to study entry.*
Yes
No
Exclusion Criteria
you cannot participate in this study if any of the
following apply to you:*
Yes
No
brain or meningeal involvement*
Yes
No
serious active infection or underlying medical
conditions*
Yes
No
other active neoplasms are ineligible*
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Yes
No
pregnant or lactating*
Yes
No
please note:  there are additional
inclusion/exclusion criteria.  the study center will
determine if you meet all of the criteria.  if you do
not qualify for the trial, study personnel will
explain the reasons.  if you do qualify, study
personnel will explain the trial in detail and
answer any questions you may have.*
Yes
No
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REGIMS Multiple Sclerosis Immunotherapy
Registry Version 2016
REGIMS is a registry of the administration, adverse events
and benefit of immunotherapeutic agents in patients with
Multiple Sclerosis. REGIMS is a project from the Institute of
Epidemiology and Social Medicine of the University of
Muenster, publication granted by Prof. Dr. Berger. 
For further information (in German), please view
http://campus.uni-muenster.de/index.php?id=6075 or
http://www.kompetenznetz-multiplesklerose.de/aktuelle-
studien/regims. 
REGIMS ist ein Immuntherapieregister zur Verbesserung
der Arzneimittelsicherheit in der Multiple Sklerose Therapie
innerhalb des krankheitsbezogenen Kompetenznetzes MS.
Das primäre Ziel von REGIMS ist die Erfassung der
Häufigkeit, Charakteristika und Auswirkungen von
Nebenwirkungen aktueller und neuer Immuntherapien in
der klinischen Routinebehandlung der MS. Sekundäre Ziele
sind die Auswertung von Faktoren, die a) mit
Nebenwirkungen und b) mit guter Therapie-Adhärenz
assoziiert sind. Optional können bei Zustimmung der
Patienten Blutproben für die Biobank des KKNMS
gesammelt werden.
Patienten mit Multipler Sklerose (MS) weisen trotz des
chronischen Verlaufs eine große Heterogenität klinischer
Symptome, in Befunden der Bildgebung sowie
pathophysiologischen Prozessen auf. Faktoren, die zur
individuellen Krankheitsprognose beitragen sind kaum
bekannt, jedoch hat die Einführung neuer Substanzen die
Therapiemöglichkeiten der MS in den letzten Jahren
deutlich erweitert. Die Anwendung sogenannter
Immuntherapeutika (inklusive der neuen Substanzklasse
der Biologika) bietet in der MS-Therapie eine Reihe von
Chancen, birgt aber auch Risiken.
All rights reserved. Please visit https://medical-data-
models.org/forms/16733
Base Sheet (Medizinischer
Basisbogen) Baseline
Ein-Ausschlusskriterien
Visitendatum*
Patient erfüllt die Einschlußkriterien*
Not 0
nein (0)
ja (1)
Schriftliches Einverständnis vorliegend?*
Not 0
nein (0)
ja (1)
Patientendaten
Geschlecht*
männlich (1)
weiblich (2)
Geburtsjahr*
> 1900
Größe (cm)
<= 250
> 0
cm
Körpergewicht (kg)
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> 0
< 500
Krankheitsspezifische Angaben
Datum der ersten MS-Symptomatik: Monat/Jahr
Unbekannt
ja (1)
Datum der MS-Diagnosestellung: Monat/Jahr*
Unbekannt
ja (1)
Verlaufsform der Multiplen Sklerose*
nicht eindeutig zuordenbar (-1)
Klinisch isoliertes Syndrom (KIS) (1)
Schubförmige remittierende MS (RRMS)
(2)
Sekundär progrediente MS (SPMS) (3)
Primär progrediente MS (PPMS) (4)
Andere (5)
Wenn Andere, welche?
Anzahl der Schübe in den letzten 24 Monaten*
0 (0)
1 (1)
10 (10)
>10 (11)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
7 (7)
8 (8)
9 (9)
Besteht zurzeit ein Schub?*
nein (0)
ja (1)
EDSS-Score vor 12 Monaten
EDSS-Score*
Unbekannt
ja (1)
Heutige Scores der Funktionssysteme
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Heutiger EDSS
Unbekannt / Nicht durchgeführt
ja (1)
Pyramidal
Sensibilität
Zerebral
Kleinhirn
Blase/Mastdarm
Gehfähigkeit
Hirnstamm
Visuell
Summe
Frühere verlaufsmodifizierende MS-
Therapien
Wurde früher eine verlaufsmodifizierende MS-
Therapie durchgeführt?
ja (1)
nein, de novo Therapie (bitte weiter mit
nächstem Feld) (99)
Wirkstoff
Mitoxantron (10)
Natalizumab (Tysabri) (11)
Rituximab (14)
Fingolimod (Gilenya) (18)
Interferon ß 1A IM (Avonex) (19)
Azathioprin (2)
Interferon ß 1A SC (Rebif 22 µg, Rebif
44 µg) (20)
Interferon ß 1SC (Betaferon, Extavia)
(21)
Alemtuzumab (Lemtrada) (22)
Teriflunomide (Aubagio) (23)
Fumarat (BG-12; Tecfidera) (24)
Kortison (25)
Cyclophosphamid (4)
Glatirameracetat (Copaxone) (6)
Immunglobuline (7)
* Medikation aus einer MS-Studie (8)
Methotrexat (9)
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Andere ... (99)
anderer Wirkstoff
Beginn: Monat/Jahr
Ende: Monat
Hauptgrund für Therapieende
Nebenwirkungen (1)
Fehlende Wirksamkeit (2)
Anderer Grund (99)
wenn Anderer, bitte Grund angeben
Aktuelle MS-Therapie
Wirkstoff
Mitoxantron (10)
Natalizumab (Tysabri) (11)
Rituximab (14)
Fingolimod (Gilenya) (18)
Interferon ß 1A IM (Avonex) (19)
Azathioprin (2)
Interferon ß 1A SC (Rebif 22 µg, Rebif
44 µg) (20)
Interferon ß 1SC (Betaferon, Extavia)
(21)
Alemtuzumab (Lemtrada) (22)
Teriflunomide (Aubagio) (23)
Fumarat (BG-12; Tecfidera) (24)
Kortison (25)
Cyclophosphamid (4)
Glatirameracetat (Copaxone) (6)
Immunglobuline (7)
* Medikation aus einer MS-Studie (8)
Methotrexat (9)
Andere ... (99)
anderer Wirkstoff
Beginn: Monat/Jahr
Therapieschema
Standard (1)
Andere (99)
Bitte Dosis und Art der Verabreichung angeben
Weitere Erkrankungen
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Wurde bei diesem/r Patient/in jemals eine
Erkrankung aus den folgenden
Krankheitsgruppen ärztlich diagnostiziert?
Ja
Nein
Herz- / Kreislauferkrankungen
Herz- / Kreislauferkrankungen
NA (1)
Welche Erkrankung wurde diagnostiziert?
Bluthochdruck (02)
Herzschwäche/-insuffizienz (03)
Herzrhythmusstörung (04)
Herzinfarkt (05)
KHK / Angina Pectoris (06)
Beinvenenthrombose (07)
Lungenembolie (08)
Monat/Jahr
Datum unbekannt
ja (1)
Aktuelle medikamentöse Behandlung
nein (0)
ja (1)
Stoffwechselerkrankungen
Stoffwechselerkrankungen
NA (1)
Welche Erkrankung wurde diagnostiziert?
Diabetes mellitus (11)
Schilddrüsenunter- od. Überfunktion (12)
Monat/Jahr
Datum unbekannt
ja (1)
Aktuelle medikamentöse Behandlung
nein (0)
ja (1)
Infektionserkrankungen
Infektionserkrankungen
NA (1)
Welche Erkrankung wurde diagnostiziert?
Hepatitis B oder C (21)
HIV-Infektion (22)
Tuberkulose (23)
Opportunistische Infektionen (24)
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Herpes Infektion (25)
PML (26)
Lungenentzündung (27)
Wenn ja, welche opportunistische Infektion
Ort der Infektion
Monat/Jahr
Datum unbekannt
ja (1)
Aktuelle medikamentöse Behandlung
nein (0)
ja (1)
Gastrointestinale Erkrankungen
Gastrointestinale Erkrankungen
NA (1)
Welche Erkrankung wurde diagnostiziert?
Bauchspeicheldrüsen-Entzündung (31)
Leberzirrhose (32)
Morbus Crohn (33)
Colitis Ulcerosa (34)
Monat/Jahr
Datum unbekannt
ja (1)
Aktuelle medikamentöse Behandlung
nein (0)
ja (1)
Neurologische / Psychiatrische
Erkrankungen
Neurologische / Psychiatrische Erkrankungen
NA (1)
Welche Erkrankung wurde diagnostiziert?
Epileptische Anfälle (41)
Depression (42)
Angsstörungen, Panikattacken (43)
Migräne / Kopfschmerzen (44)
Anorexie (45)
Monat/Jahr
Datum unbekannt
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ja (1)
Aktuelle medikamentöse Behandlung
nein (0)
ja (1)
Allergien
Allergien
NA (1)
Welche Erkrankung wurde diagnostiziert?
Medikamentenallergie (51)
Hausstaub / Pollen (52)
Nahrungsmittel (53)
Nickel / Duftstoffe (54)
Insektenstiche (55)
Welches Medikament?
Monat/Jahr
Datum unbekannt
ja (1)
Aktuelle medikamentöse Behandlung
nein (0)
ja (1)
Urogenitale Erkrankungen
Urogenitale Erkrankungen
NA (1)
Welche Erkrankung wurde diagnostiziert?
Wiederkehrende Harnwegsinfekte (61)
Einschränkung der Nierenfunktion (62)
Weitere Urologische Erkrankungen (63)
Monat/Jahr
Datum unbekannt
ja (1)
Aktuelle medikamentöse Behandlung
nein (0)
ja (1)
Autoimmunerkrankungen
Autoimmunerkrankungen
NA (1)
Welche Erkrankung wurde diagnostiziert?
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Myasthenia gravis (71)
Autoimmune Schilddrüsenerkrankung
(72)
Systemischer Lupus erythematodes (73)
Psoriasis (74)
Monat/Jahr
Datum unbekannt
ja (1)
Aktuelle medikamentöse Behandlung
nein (0)
ja (1)
Blutbild / Labor
Blutbild / Labor
NA (1)
Welche Erkrankung wurde diagnostiziert?
Anämie (81)
Lymphopenia (82)
Leukopenie (83)
Neutropenia (84)
Gerinnungsstörungen (85)
Myelodysplastisches Syndrom (86)
Auffälligkeit bei Lebertest(s) (87)
Auffälligkeit bei Nierentest(s) (88)
Monat/Jahr
Datum unbekannt
ja (1)
Aktuelle medikamentöse Behandlung
nein (0)
ja (1)
Allgemeine Symptome
Allgemeine Symptome
NA (1)
Welches Symptom wurde diagnostiziert?
Haarausfall (91)
Hautausschlag (92)
lokale Symptome bei Medikamenten (93)
Retinopathie, Makulaödem (94)
Gelenkschmerzen (95)
Gewichtsverlust oder -zunahme (96)
Monat/Jahr
Datum unbekannt
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ja (1)
Aktuelle medikamentöse Behandlung
nein (0)
ja (1)
Operation
Operation
NA (1)
Welche Operationen
Monat/Jahr
Datum unbekannt
ja (1)
Aktuelle medikamentöse Behandlung
nein (0)
ja (1)
Krebserkrankungen
Krebserkrankungen
NA (1)
Welche Art von Krebs
Monat/Jahr
Welche Therapien wurden aufgrund der
Krebserkrankung durchgeführt?
Operation
nein (0)
ja (1)
Bestrahlung
nein (0)
ja (1)
Chemotherapie
nein (0)
ja (1)
Wenn Chemotherapie, bitte Substanzen angeben
nicht bekannt
ja (1)
Andere Erkrankungen
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Andere Erkrankungen
NA (1)
Welche andere Erkrankung?
Monat/Jahr
Datum unbekannt
ja (1)
Aktuelle medikamentöse Behandlung
nein (0)
ja (1)
Keine Vorerkrankungen aus diesen obigen
Krankheitsgruppen/Erkrankungen bekannt
Zutreffend
ja (1)
Schwangerschaft
Liegt aktuell eine Schwangerschaft vor?
nein (0)
ja (1)
Biologisches Material (z.B. Blut)
Probenset Nr.
Zusatz (derzeit deaktiviert)
Pregnancy 1 (Meldebogen für
Schwangerschaft Teil 1) Baseline
Daten der Patientin
Datum der Meldung*
Alter in Jahren
Größe
Gewicht
Schwangerschaft
Datum der letzten Regelblutung*
10 / 27
REGIMS Multiple Sclerosis Immunotherapy Registry Version 2016
Errechneter Geburtstermin*
Anzahl früherer Schwangerschaften*
Wenn >1, Datum der letzten Entbindung angeben
Ausgang der letzten Schwangerschaft
Lebendgeburt ohne Abnormalität (1)
Ektopische Schwangerschaft (2)
Spontanabort (3)
Schwangerschaftsabbruch (4)
Lebendgeburt mit Abnormalität (5)
Frühgeburt (6)
Totgeburt (7)
Relevante Anamnese (Grunderkrankung,
Begleiterkrankungen, Allergien,
Risikofaktoren, ...)
Relevant in der Anamnese
bestehend seit: Monat/Jahr
MS-Medikation
Medikament
Mitoxantron (10)
Natalizumab (Tysabri) (11)
Rituximab (14)
Fingolimod (Gilenya) (18)
Interferon ß 1A IM (Avonex) (19)
Azathioprin (2)
Interferon ß 1A SC (Rebif 22 µg, Rebif
44 µg) (20)
Interferon ß 1SC (Betaferon, Extavia)
(21)
Alemtuzumab (Lemtrada) (22)
Teriflunomide (Aubagio) (23)
Fumarat (BG-12; Tecfidera) (24)
Kortison (25)
Cyclophosphamid (4)
Glatirameracetat (Copaxone) (6)
Immunglobuline (7)
* Medikation aus einer MS-Studie (8)
Methotrexat (9)
Andere ... (99)
Anderes:
Dosis
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Einheit
mg (2)
µg (4)
Beginn: Monat/Jahr
fortgesetzt
nein (0)
ja (1)
Ende: Monat/Jahr
Andere Medikation vor / während der
Schwangerschaft
Begleitmedikation (Handelsname)
Dosis
Einheit
mg (2)
µg (4)
Beginn: Monat/Jahr
Ende: Monat/Jahr
Indikation
Pregnancy 2 (Meldebogen für
Schwangerschaft Teil 2) Baseline
2. Patientendaten
Patienten-ID
Alter
Schwangerschaftsverlauf
3. Ausgang der Schwangerschaft
Ektopische Schwangerschaft
(Ektopische Schwangerschaft)
Frühgeburt (Frühgeburt)
Lebendgeburt mit Defekten
(Lebendgeburt mit Defekten)
Lebendgeburt ohne Defekte
(Lebendgeburt ohne Defekte)
Schwangerschaftsabbruch
(Schwangerschaftsabbruch)
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Spontanabort (Spontanabort)
Todgeburt (Todgeburt)
Am
In SSW
Kurzbeschreibung (Abnormalität des Embryos,
Grund für Abbruch, Art des Defektes, usw.)
4. Komplikationen bei der Schwangerschaft
Ja, bitte erläutern (Ja, bitte erläutern)
Keine (Keine)
Ja, bitte erläutern
5. Art der Entbindung
Kaiserschnitt (Kaiserschnitt, Grund)
Vaginal (Vaginal)
Kaiserschnitt, Grund:
6. Angaben zum Neugeborenen
Geburtsdatum
Gewicht
g
Größe
cm
Kopfumfang
cm
Geschlecht
Geschlecht unbekannt (Geschlecht
unbekannt)
männlich (männlich)
weiblich (weiblich)
Apgar - 1 Minute:
Apgar - 5 Minuten:
Apgar - 10 Minuten:
7. Abnormalitäten / Auffälligkeiten
Keine
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Ja
Nein
Ja, bitte erläutern
Kausalität MS-Medikation
8. Falls Defekte / Abnormalitäten /
Komplikationen festgestellt wurden, bitte
beurteilen Sie die
Kausalität bzgl. der verlaufsmodifizierenden MS-
Medikation
möglich (möglich)
nicht erhebbar (nicht erhebbar)
nicht kausal (nicht kausal)
unwahrscheinlich (unwahrscheinlich)
wahrscheinlich (wahrscheinlich)
Main Sheet (Medizinischer
Folgebogen Hauptseite) Follow Up
Allgemeines
Datum: Nachbefragung*
Heutiger EDSS-Score
>= 0
<= 10
unbekannt
ja (1)
Art der Visite bzw. dieses Kontaktes
geplant (1)
ungeplant (2)
Grund dieser Visite bzw. dieses Kontaktes
(Mehrfachauswahl)
Therapiegabe
ja (1)
Klinischer Verlauf / Gespräch
ja (1)
Nebenwirkung / Therapieänderung
ja (1)
Symptomveränderung
ja (1)
Anderer Grund
ja (1)
Bitte angeben
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Ist seit der letzten Dokumentation für
REGIMS (o. REGIMS-Visite)...
... eine Nebenwirkungen / ein neues
Krankheitsereignis aufgetreten?*
nein (0)
ja (1)
... die verlaufsmodifizierende MS-Therapie
verändert worden?*
nein (0)
ja (1)
... ein Schubereignis / Krankheitsprogression
aufgetreten?*
nein (0)
ja (1)
... eine Schwangerschaft bekannt geworden?*
nein (0)
ja (1)
Eigene Bemerkungen / Klinischer Verlauf /
Kommentar
Bemerkungen
Medication Change (Änderungen der
MS-Therapie) Follow Up
Änderungen bei der
verlaufsmodifizierenden MS-Therapie
Welche Änderung der MS-Therapie wurde seit
dem letzten Besuch durchgeführt?
Die Medikamentendosis wurde erhöht
(1)
Die Medikamentendosis wurde reduziert
(2)
Die Therapie wurde abgesetzt und neue
begonnen (3)
Die Therapie wurde ersatzlos abgesetzt
(4)
Eine andere Änderung wurde
durchgeführt (99)
Welcher Wirkstoff wurde abgesetzt?
Mitoxantron (10)
Natalizumab (Tysabri) (11)
Rituximab (14)
Fingolimod (Gilenya) (18)
Interferon ß 1A IM (Avonex) (19)
Azathioprin (2)
Interferon ß 1A SC (Rebif 22 µg, Rebif
44 µg) (20)
Interferon ß 1SC (Betaferon, Extavia)
(21)
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Alemtuzumab (Lemtrada) (22)
Teriflunomide (Aubagio) (23)
Fumarat (BG-12; Tecfidera) (24)
Kortison (25)
Cyclophosphamid (4)
Glatirameracetat (Copaxone) (6)
Immunglobuline (7)
* Medikation aus einer MS-Studie (8)
Methotrexat (9)
Andere ... (99)
Wenn Anderer, welcher?
Welche Änderung? (Bitte eintragen.)
Falls es Änderungen gab, geben Sie bitte
den Grund für den Abbruch / die
Änderung an.
Grund für den Abbruch
Nebenwirkungen (1)
Fehlende Wirksamkeit (2)
Anderer Grund (99)
Bitte anderen Grund angeben
Neue (aktuelle) MS-Therapie
Wirkstoff
Mitoxantron (10)
Natalizumab (Tysabri) (11)
Rituximab (14)
Fingolimod (Gilenya) (18)
Interferon ß 1A IM (Avonex) (19)
Azathioprin (2)
Interferon ß 1A SC (Rebif 22 µg, Rebif
44 µg) (20)
Interferon ß 1SC (Betaferon, Extavia)
(21)
Alemtuzumab (Lemtrada) (22)
Teriflunomide (Aubagio) (23)
Fumarat (BG-12; Tecfidera) (24)
Kortison (25)
Cyclophosphamid (4)
Glatirameracetat (Copaxone) (6)
Immunglobuline (7)
* Medikation aus einer MS-Studie (8)
Methotrexat (9)
Andere ... (99)
Wenn anderer Wirkstoff, bitte beschreiben
Beginn: Monat/Jahr
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Therapieschema
Standard (1)
Andere (99)
Bitte Dosis und Art der Verabreichung angeben
Multiple Sclerosis Progression
(Schubereignis /
Krankheitsprogression) Follow Up
Schubereignis / Krankheitsprogression
Sind seit dem letzten Besuch / Visite ein oder
mehrere Schübe aufgetreten?
nein (0)
ja (1)
Wie viele Schübe?
0 (0)
1 (1)
10 (10)
>10 (11)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
7 (7)
8 (8)
9 (9)
Findet zurzeit eine Behandlung mit Kortison
statt?
nein (0)
ja (1)
Weitere Änderungen
Hat sich seit dem letzten Besuch / Visite die
Verlaufsform der MS verändert (z.B. von RRMS
auf SPMS)?
nein (0)
ja (1)
Geänderte Verlaufsform der Multiplen Sklerose
nicht eindeutig zuordenbar (-1)
Klinisch isoliertes Syndrom (KIS) (1)
Schubförmige remittierende MS (RRMS)
(2)
Sekundär progrediente MS (SPMS) (3)
Primär progrediente MS (PPMS) (4)
Andere (5)
Andere Verlaufsform
Sind seit dem letzten Besuch / Visite neue MS-
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Symptome aufgetreten?
nein (0)
ja (1)
Wenn ja, welche?
Pregnancy 1 (Meldebogen für
Schwangerschaft Teil 1) Follow Up
Daten der Patientin
Datum der Meldung*
Alter in Jahren
Größe
Gewicht
Schwangerschaft
Datum der letzten Regelblutung*
Errechneter Geburtstermin*
Anzahl früherer Schwangerschaften*
Wenn >1, Datum der letzten Entbindung angeben
Ausgang der letzten Schwangerschaft
Lebendgeburt ohne Abnormalität (1)
Ektopische Schwangerschaft (2)
Spontanabort (3)
Schwangerschaftsabbruch (4)
Lebendgeburt mit Abnormalität (5)
Frühgeburt (6)
Totgeburt (7)
Relevante Anamnese (Grunderkrankung,
Begleiterkrankungen, Allergien,
Risikofaktoren, ...)
Relevant in der Anamnese
bestehend seit: Monat/Jahr
18 / 27
REGIMS Multiple Sclerosis Immunotherapy Registry Version 2016
MS-Medikation
Medikament
Mitoxantron (10)
Natalizumab (Tysabri) (11)
Rituximab (14)
Fingolimod (Gilenya) (18)
Interferon ß 1A IM (Avonex) (19)
Azathioprin (2)
Interferon ß 1A SC (Rebif 22 µg, Rebif
44 µg) (20)
Interferon ß 1SC (Betaferon, Extavia)
(21)
Alemtuzumab (Lemtrada) (22)
Teriflunomide (Aubagio) (23)
Fumarat (BG-12; Tecfidera) (24)
Kortison (25)
Cyclophosphamid (4)
Glatirameracetat (Copaxone) (6)
Immunglobuline (7)
* Medikation aus einer MS-Studie (8)
Methotrexat (9)
Andere ... (99)
Anderes:
Dosis
Einheit
mg (2)
µg (4)
Beginn: Monat/Jahr
fortgesetzt
nein (0)
ja (1)
Ende: Monat/Jahr
Andere Medikation vor / während der
Schwangerschaft
Begleitmedikation (Handelsname)
Dosis
Einheit
mg (2)
µg (4)
Beginn: Monat/Jahr
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Ende: Monat/Jahr
Indikation
Pregnancy 2 (Meldebogen für
Schwangerschaft Teil 2) Follow Up
2. Patientendaten
Patienten-ID
Alter
Schwangerschaftsverlauf
3. Ausgang der Schwangerschaft
Ektopische Schwangerschaft
(Ektopische Schwangerschaft)
Frühgeburt (Frühgeburt)
Lebendgeburt mit Defekten
(Lebendgeburt mit Defekten)
Lebendgeburt ohne Defekte
(Lebendgeburt ohne Defekte)
Schwangerschaftsabbruch
(Schwangerschaftsabbruch)
Spontanabort (Spontanabort)
Todgeburt (Todgeburt)
Am
In SSW
Kurzbeschreibung (Abnormalität des Embryos,
Grund für Abbruch, Art des Defektes, usw.)
4. Komplikationen bei der Schwangerschaft
Ja, bitte erläutern (Ja, bitte erläutern)
Keine (Keine)
Ja, bitte erläutern
5. Art der Entbindung
Kaiserschnitt (Kaiserschnitt, Grund)
Vaginal (Vaginal)
Kaiserschnitt, Grund:
6. Angaben zum Neugeborenen
Geburtsdatum
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Gewicht
g
Größe
cm
Kopfumfang
cm
Geschlecht
Geschlecht unbekannt (Geschlecht
unbekannt)
männlich (männlich)
weiblich (weiblich)
Apgar - 1 Minute:
Apgar - 5 Minuten:
Apgar - 10 Minuten:
7. Abnormalitäten / Auffälligkeiten
Keine
Ja
Nein
Ja, bitte erläutern
Kausalität MS-Medikation
8. Falls Defekte / Abnormalitäten /
Komplikationen festgestellt wurden, bitte
beurteilen Sie die
Kausalität bzgl. der verlaufsmodifizierenden MS-
Medikation
möglich (möglich)
nicht erhebbar (nicht erhebbar)
nicht kausal (nicht kausal)
unwahrscheinlich (unwahrscheinlich)
wahrscheinlich (wahrscheinlich)
Adverse Events (Unerwünschte
Ereignisse) Follow Up
Angaben zum unerwünschtes Ereignis
Ereignis (diagnostisch oder symptomatisch)*
Andere (-1)
--- Herz-/ Kreislauferkrankungen (01)
Bluthochdruck (02)
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Herzschwäche/-insuffizienz (03)
Herzrhythmusstörung (04)
Herzinfarkt (05)
KHK / Angina Pectoris (06)
Beinvenenthrombose (07)
Lungenembolie (08)
--- Stoffwechselerkrankungen (10)
Diabetes mellitus (11)
Schilddrüsenunter- od. Überfunktion (12)
--- Infektionserkrankungen (20)
Hepatitis B oder C (21)
HIV-Infektion (22)
Tuberkulose (23)
Opportunistische Infektionen (24)
Herpes Infektion (25)
PML (26)
Lungenentzündung (27)
--- Gastrointestinale Erkrankungen (30)
Bauchspeicheldrüsenentzündung (31)
Leberzirrhose (32)
Morbus Crohn (33)
Colitis Ulcerosa (34)
--- Neurologische Erkrankungen (40)
Epileptische Anfälle (41)
Depression (42)
Angsstörungen, Panikattacken (43)
Migräne / Kopfschmerzen (44)
Anorexie (45)
--- Allergien (50)
Medikamentenallergie (51)
Hausstaub / Pollen (52)
Nahrungsmittel (53)
Nickel / Duftstoffe (54)
Insektenstiche (55)
--- Nieren / Urogenitale Erkankungen
(60)
Wiederkehrende Harnwegsinfekte (61)
Nierenfunktionseinschränkung (62)
--- Autoimmunerkrankungen (70)
Myasthenia gravis (71)
Autoimmune Schilddrüsenerkrankung
(72)
Systemischer Lupus erythematodes (73)
Psoriasis (74)
--- Blutbild / Laborveränderungen (80)
Anämie (81)
Lymphopenia (82)
Leukopenie (83)
Neutropenia (84)
Gerinnungsstörungen (85)
Myelodysplastisches Syndrom (86)
Auffälligkeit bei Lebertest(s) (87)
Auffälligkeit bei Nierentest(s) (88)
--- Allgemeine Symptome (90)
Haarausfall (91)
Hautausschlag (92)
lokale Symptome bei Medikamenten (93)
Retinopathie, Makulaödem (94)
Gelenkschmerzen (95)
Gewichtsverlust oder -zunahme (96)
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Beschreibung (diagnostisch oder symptomatisch)
Weitere Angaben zum unerwünschtes
Ereignis
aufgetreten am*
Ist die Nebenwirkung / das Krankheitsereignis
dauerhaft bestehend / chronisch?*
nein (0)
ja (1)
Wenn beendet, wann?
Welche Intensität hatte das Ereignis?*
leicht (1)
mittel (2)
schwer (3)
Einstufung des Ereignisses
War das Ereignis schwerwiegend?
nein (0)
ja (1)
Warum schwerwiegend?*
Todesfolge (1)
lebensbedrohlich (2)
Krankenhausaufenthalt /
Aufenthaltsverlängerung (3)
kongen. Fehlbildungen (4)
Behinderung / Invalidität (5)
sonstiges med. wichtiges Ereignis (6)
Ausgang
Ausgang des Ereignisses?*
unbekannt (-1)
anhaltend (1)
wiederhergestellt (2)
wiederhergestellt mit Folgen (3)
Tod (4)
Wenn bleibende Folgen, welche
Todesdatum
Ursache
Autopsie
unbekannt (-1)
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nein (0)
ja (1)
Kausalität (UE & MS-Medikation)
Wie wahrscheinlich ist ein kausaler
Zusammenhang zwischen dem Ereignis und der
aktuellen MS-Therapie?*
nicht erhebbar (-1)
nicht kausal (0)
unwahrscheinlich (1)
möglich (2)
wahrscheinlich (3)
kausal (4)
MS-Medikation
MS-Medikament*
Mitoxantron (10)
Natalizumab (Tysabri) (11)
Rituximab (14)
Fingolimod (Gilenya) (18)
Interferon ß 1A IM (Avonex) (19)
Azathioprin (2)
Interferon ß 1A SC (Rebif 22 µg, Rebif
44 µg) (20)
Interferon ß 1SC (Betaferon, Extavia)
(21)
Alemtuzumab (Lemtrada) (22)
Teriflunomide (Aubagio) (23)
Fumarat (BG-12; Tecfidera) (24)
Kortison (25)
Cyclophosphamid (4)
Glatirameracetat (Copaxone) (6)
Immunglobuline (7)
* Medikation aus einer MS-Studie (8)
Methotrexat (9)
Andere ... (99)
Anderes
Einnahme seit
bis (wenn nicht fortlaufend)
Tagesdosis
Einheit
mg (2)
µg (4)
Maßnahme
keine (0)
Dosis reduziert (1)
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Dosis erhöht (2)
Unterbrechung der Medikation (3)
Medikament abgesetzt (4)
Kausalität zum Ereignis
nicht erhebbar (-1)
nicht kausal (0)
unwahrscheinlich (1)
möglich (2)
wahrscheinlich (3)
kausal (4)
Kausalität (UE & Begleitmedikation)
Wie wahrscheinlich ist ein kausaler
Zusammenhang zwischen dem Ereignis und
einem anderen zurzeit eingenommenen
Medikament?*
nicht erhebbar (-1)
nicht kausal (0)
unwahrscheinlich (1)
möglich (2)
wahrscheinlich (3)
kausal (4)
Begleitmedikation
Andere Medikation (Handelsname)
Einnahme seit
bis (wenn nicht fortlaufend)
Tagesdosis
Einheit
mg (2)
µg (4)
Indikation
Kausalität zum Ereignis
nicht erhebbar (-1)
nicht kausal (0)
unwahrscheinlich (1)
möglich (2)
wahrscheinlich (3)
kausal (4)
Schwerwiegende unerwünschte
Ereignisse
Datum der Meldung*
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SUE-Nummer*
Typ der Meldung*
Erstmeldung (1)
Folgemeldung (2)
Patientenangaben
Alter*
Jahre
Geschlecht*
männlich (1)
weiblich (2)
Gewicht
kg
Größe
cm
Schwangerschaft
nein (0)
ja (1)
falls ja, Schwangerschaftswoche
Behandlung
Behandlung des SUEs*
Keine (0)
Medikamentöse Behandlung (1)
Andere (2)
wenn andere Behandlung, welche
Relevante Vorerkrankung / Symptome
Relevante Vorerkrankung
von
bis (wenn nicht anhaltend)
Ergebnisse der relevanten Diagnostischen
Untersuchungen
Resultate der relevanten diagnostischen Tests
(unter Angabe von Referenzwerten, falls
vorhanden)
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Kontaktdaten des Berichterstatters
Name des Berichterstatters*
Telefon-Nr*
Faxnr.
Email
Unterschrift
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Admitted patient care NMDS 2015-16
Metadata Online Registry (METeOR)
Health sector data set specifications from METeOR,
Australia's repository for national metadata standards,
developed by the Australian Institute of Health and Welfare
(http://meteor.aihw.gov.au/content/index.phtml/itemId/3451
65)
Admitted patient care NMDS 2015-16
The purpose of the Admitted patient care national minimum
data set (APC NMDS) is to collect information about care
provided to admitted patients in Australian hospitals.
The scope of the APC NMDS is episodes of care for
admitted patients in all public and private acute and
psychiatric hospitals, free standing day hospital facilities
and alcohol and drug treatment centres in Australia.
Hospitals operated by the Australian Defence Force,
corrections authorities and in Australia's off-shore territories
may also be included. Hospitals specialising in dental,
ophthalmic aids and other specialised acute medical or
surgical care are included.
Hospital boarders and still births are not included as they
are not admitted to hospital. Posthumous organ
procurement episodes are also not included.
© Australian Institute of Health and Welfare 2015
Metadata and Classifications Unit 
Australian Institute of Health and Welfare
GPO Box 570
Canberra ACT 2601
All rights reserved. Please visit https://medical-data-
models.org/forms/16734
Admitted patient care NMDS 2015-
16 Metadata Online Registry
(METeOR)
Address
Australian postcode (address)*
Contracted hospital care
Contract establishment identifier*
Episode of admitted patient care
(newborn)
Number of qualified days for newborns
days
Episode of admitted patient care
Admission date*
Mode of admission*
Admitted patient transferred from another
hospital (1)
Statistical admission - episode type
change (2)
Other (3)
Urgency of admission*
Urgency status assigned - emergency
(1)
Urgency status assigned - elective (2)
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Urgency status not assigned (3)
Not known/not reported (9)
Condition onset flag*
Condition with onset during the episode
of admitted patient care (1)
Condition not noted as arising during the
episode of admitted patient care   (2)
Not reported (9)
Duration of continuous ventilatory support
hours
Intended length of hospital stay*
Intended same-day (1)
Intended overnight (2)
Length of stay in intensive care unit
hours
Number of days of hospital-in-the-home care*
days
Total leave days*
days
Admitted patient election status*
Public (1)
Private (2)
Procedure*
Source of referral to public psychiatric hospital
Private psychiatric practice (01)
Other private medical practice (02)
Other public psychiatric hospital (03)
Other health care establishment (04)
Other private hospital (05)
Law enforcement agency (06)
Other agency (07)
Outpatient department (08)
Other (09)
Unknown (10)
Separation date*
Mode of separation*
Discharge/transfer to (an)other acute
hospital (1)
Discharge/transfer to a residential aged
care service, unless this is the usual
place of residence (2)
Discharge/transfer to (an)other
psychiatric hospital  (3)
Discharge/transfer to other health care
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accommodation (includes mothercraft
hospitals) (4)
Statistical discharge - type change (5)
Left against medical advice/discharge at
own risk (6)
Statistical discharge from leave (7)
Died (8)
Other (includes discharge to usual
residence, own accommodation/welfare
institution (includes prisons, hostels and
group homes providing primarily welfare
services)) (9)
Episode of care
Additional diagnosis
Inter-hospital contracted patient*
Inter-hospital contracted patient from
public sector hospital (1)
Inter-hospital contracted patient from
private sector hospital (2)
Contracting (originating) hospital (3)
Inter-hospital contracted patient to public
sector hospital (4)
Inter-hospital contracted patient to
private sector hospital (5)
Not inter-hospital contracted (6)
Not stated (9)
Mental health legal status*
Involuntary patient (1)
Voluntary patient (2)
Not reported/unknown (9)
Total psychiatric care days*
days
Principal diagnosis—episode of care*
Funding source for hospital patient*
Health service budget (not covered
elsewhere) (01)
Health service budget (due to eligibility
for Reciprocal Health Care Agreement)
(02)
Health service budget (no charge raised
due to hospital decision) (03)
Department of Veterans´ Affairs (04)
Department of Defence (05)
Correctional facility (06)
Medicare Benefits Scheme (07)
Other hospital or public authority
(contracted care) (08)
Private health insurance (09)
Worker´s compensation (10)
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Motor vehicle third party personal claim
(11)
Other compensation (e.g. public liability,
common law, medical negligence) (12)
Self-funded (13)
Other funding source (88)
Not known (98)
Establishment
Australian State/Territory identifier
(establishment)*
New South Wales (1)
Victoria (2)
Queensland (3)
South Australia (4)
Western Australia (5)
Tasmania (6)
Northern Territory (7)
Australian Capital Territory (8)
Other territories (Cocos (Keeling)
Islands, Christmas Island and Jervis Bay
Territory) (9)
Geographic remoteness—admitted patient care*
Major cities of Australia (1)
Inner regional Australia (2)
Outer regional Australia (3)
Remote Australia (4)
Very remote Australia (5)
Migratory (6)
Not stated/inadequately described (9)
Establishment number*
Region code*
Establishment sector*
Public (1)
Private (2)
Hospital service
Care type*
Acute care (1)
Hospital boarder (10)
Mental health care (11)
Rehabilitation care (2)
Palliative care (3)
Geriatric evaluation and management (4)
Psychogeriatric care (5)
Maintenance care (6)
Newborn care (7)
Other admitted patient care (88)
Organ procurement—posthumous (9)
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Injury event
Activity when injured*
External cause*
Place of occurrence of external cause of injury
(ICD-10-AM)*
Patient
Hospital insurance status*
Hospital insurance (1)
No hospital insurance (2)
Unknown (9)
Person
Area of usual residence (SA2)*
Country of birth*
Date of birth*
Medicare eligibility status*
Eligible (1)
Not eligible (2)
Not stated/unknown (9)
Indigenous status*
Aboriginal but not Torres Strait Islander
origin (1)
Torres Strait Islander but not Aboriginal
origin (2)
Both Aboriginal and Torres Strait Islander
origin (3)
Neither Aboriginal nor Torres Strait
Islander origin (4)
Not stated/inadequately described (9)
Person identifier*
Sex*
Male (1)
Female (2)
Intersex or indeterminate (3)
Not stated/inadequately described (9)
Weight in grams (measured)
g
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Record
Record identifier (80 character maximum)*
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Admitted patient care NMDS 2015-16 Elective surgery
waiting times cluster Metadata Online Registry (METeOR)
Health sector data set specifications from METeOR,
Australia's repository for national metadata standards,
developed by the Australian Institute of Health and Welfare
(http://meteor.aihw.gov.au/content/index.phtml/itemId/3451
65)
Elective surgery waiting times cluster 
The scope of the Elective surgery waiting times data
element cluster is patients on elective surgery waiting lists
managed by public acute hospitals, in either category 1 or 2
of the 'Reason for removals from elective surgery waiting
list' data element.
This will include private patients treated in public hospitals,
and may include public patients treated in private hospitals.
Hospitals may also collect information for other care (as
defined in the 'Waiting list category' data element), but this
is not part of the national minimum data set (NMDS) for
Elective surgery waiting times.
Patients on waiting lists managed by hospitals operated by
the Australian Defence Force, corrections authorities and
Australia's external territories are not currently included.
Data set specification specific attributes: Admitted patient
care NMDS 2015-16
Conditional obligation:	This data element cluster is to be
reported for patients on waiting lists for elective surgery,
which are managed by public acute hospitals and have a
category 1 or 2 assigned for the reason for removal from
the elective surgery waiting list.
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Admitted patient care NMDS 2015-
16 Elective surgery waiting times
cluster Metadata Online Registry
(METeOR)
Elective care waiting list episode
Listing date for care*
Elective surgery waiting list episode
Clinical urgency*
Admission within 30 days desirable for a
condition that has the potential to
deteriorate quickly to the point that it may
become an emergency (1)
Admission within 90 days desirable for a
condition causing some pain, dysfunction
or disability but which is not likely to
deteriorate quickly or become an
emergency (2)
Admission at some time in the future
acceptable for a condition causing
minimal or no pain, dysfunction or
disability, which is unlikely to deteriorate
quickly and which does not have the
potential to become an emergency (3)
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Extended wait patient*
Extended wait patient (1)
Other patient (2)
Indicator procedure*
Cataract extraction (01)
Cholecystectomy (02)
Coronary artery bypass graft (03)
Cystoscopy (04)
Haemorrhoidectomy (05)
Hysterectomy (06)
Inguinal herniorrhaphy (07)
Myringoplasty (08)
Myringotomy (09)
Prostatectomy (10)
Septoplasty (11)
Tonsillectomy (12)
Total hip replacement (13)
Total knee replacement (14)
Varicose veins stripping and ligation (15)
Other (88)
Overdue patient*
Overdue patient (1)
Other (2)
Reason for removal from elective surgery waiting
list*
Admitted as an elective patient for
awaited procedure by or on behalf of this
hospital or the state/territory (1)
Admitted as an emergency patient for
awaited procedure by or on behalf of this
hospital or the state/territory (2)
Could not be contacted (includes
patients who have died while waiting,
whether or not the cause of death was
related to the condition requiring
treatment) (3)
Treated elsewhere for awaited
procedure, but not on behalf of this
hospital or the state/territory (4)
Surgery not required or declined (5)
Transferred to another hospital´s waiting
list (6)
Not known (9)
Surgical specialty (of scheduled doctor)*
Cardio-thoracic surgery (01)
Ear, nose and throat surgery (02)
General surgery (03)
Gynaecology (04)
Neurosurgery (05)
Ophthalmology (06)
Orthopaedic surgery (07)
Plastic surgery (08)
Urology (09)
Vascular surgery (10)
Other (11)
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cluster Metadata Online Registry (METeOR)
Waiting time at removal from elective surgery
waiting list*
days
Establishment
Establishment identifier
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cluster Metadata Online Registry (METeOR)
Admitted subacute and non-acute hospital care
DSS 2015-16 Metadata Online Registry (METeOR)
Health sector data set specifications from METeOR,
Australia's repository for national metadata standards,
developed by the Australian Institute of Health and Welfare
(http://meteor.aihw.gov.au/content/index.phtml/itemId/3451
65)
Admitted subacute and non-acute hospital care DSS 2015-
16
The Admitted subacute and non-acute hospital care data
set specification (DSS) aims to ensure national consistency
in relation to defining and collecting information about care
provided to subacute and non-acute admitted public and
private patients in activity based funded public hospitals.
Subacute care in this DSS is identified as admitted
episodes in rehabilitation care, palliative care, geriatric
evaluation and management care and psychogeriatric care,
whereas maintenance care is identified as non-acute care.
The scope of the DSS is:
•	Same day and overnight admitted subacute and non-acute
care episodes. 
•	Admitted public patients provided on a contracted basis by
private hospitals. 
•	Admitted patients in rehabilitation care, palliative care,
geriatric evaluation and management, psychogeriatric and
maintenance care treated in the hospital-in-the-home. 
Excluded from the scope are:
•	Hospitals operated by the Australian Defence Force,
correctional authorities and Australia's external territories.
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Admitted subacute and non-acute
hospital care DSS 2015-16 Metadata
Online Registry (METeOR)
Episode of admitted patient care
Clinical assessment only indicator
Yes (1)
No (2)
Unknown (8)
Not stated/inadequately described (9)
Palliative care phase
Stable (1)
Unstable (2)
Deteriorating (3)
Terminal (4)
Not reported (9)
Palliative care phase end date
Palliative care phase start date
Primary impairment type (AROC 2012 code)
Type of maintenance care provided
Convalescent care (1)
Respite care (2)
Nursing home type care (3)
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Other maintenance care (8)
Unknown (98)
Not stated/inadequately described (99)
Person
Level of cognitive ability (SMMSE score)
Score of 0 (0)
Score of 1 (1)
Score of 2 (2)
Score of 3 (3)
Score of 4 (4)
Score of 5 (5)
Not applicable - item has been omitted
(7)
Not known/not specified (8)
Level of functional independence (FIM™ score)
Total assistance with helper (1)
Maximal assistance with helper (2)
Moderate assistance with helper (3)
Minimal assistance with helper (4)
Supervision or setup with helper (5)
Modified independence with no helper
(6)
Complete independence with no helper
(7)
Level of functional independence (total RUG-ADL
score)
Level of psychiatric symptom severity (HoNOS
65+ score)
No problems within the period stated (0)
Minor problem requiring no action (1)
Mild problem but definitely present (2)
Moderately severe problem (3)
Severe to very severe problem (4)
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Admitted subacute and non-acute hospital care DSS 2015-16 Admitted
patient care NMDS 2015-16 Metadata Online Registry (METeOR)
Health sector data set specifications from METeOR,
Australia's repository for national metadata standards,
developed by the Australian Institute of Health and Welfare
(http://meteor.aihw.gov.au/content/index.phtml/itemId/3451
65)
Admitted patient care NMDS 2015-16
The purpose of the Admitted patient care national minimum
data set (APC NMDS) is to collect information about care
provided to admitted patients in Australian hospitals.
The scope of the APC NMDS is episodes of care for
admitted patients in all public and private acute and
psychiatric hospitals, free standing day hospital facilities
and alcohol and drug treatment centres in Australia.
Hospitals operated by the Australian Defence Force,
corrections authorities and in Australia's off-shore territories
may also be included. Hospitals specialising in dental,
ophthalmic aids and other specialised acute medical or
surgical care are included.
Hospital boarders and still births are not included as they
are not admitted to hospital. Posthumous organ
procurement episodes are also not included.
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Admitted subacute and non-acute
hospital care DSS 2015-16 Admitted
patient care NMDS 2015-16
Metadata Online Registry (METeOR)
Address
Australian postcode (address)*
Contracted hospital care
Contract establishment identifier*
Episode of admitted patient care
(newborn)
Number of qualified days for newborns
days
Episode of admitted patient care
Admission date*
Mode of admission*
Admitted patient transferred from another
hospital (1)
Statistical admission - episode type
change (2)
Other (3)
Urgency of admission*
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Urgency status assigned - emergency
(1)
Urgency status assigned - elective (2)
Urgency status not assigned (3)
Not known/not reported (9)
Condition onset flag*
Condition with onset during the episode
of admitted patient care (1)
Condition not noted as arising during the
episode of admitted patient care   (2)
Not reported (9)
Duration of continuous ventilatory support
hours
Intended length of hospital stay*
Intended same-day (1)
Intended overnight (2)
Length of stay in intensive care unit
hours
Number of days of hospital-in-the-home care*
days
Total leave days*
days
Admitted patient election status*
Public (1)
Private (2)
Procedure*
Source of referral to public psychiatric hospital
Private psychiatric practice (01)
Other private medical practice (02)
Other public psychiatric hospital (03)
Other health care establishment (04)
Other private hospital (05)
Law enforcement agency (06)
Other agency (07)
Outpatient department (08)
Other (09)
Unknown (10)
Separation date*
Mode of separation*
Discharge/transfer to (an)other acute
hospital (1)
Discharge/transfer to a residential aged
care service, unless this is the usual
place of residence (2)
Discharge/transfer to (an)other
psychiatric hospital  (3)
2 / 6
Admitted subacute and non-acute hospital care DSS 2015-16 Admitted
patient care NMDS 2015-16 Metadata Online Registry (METeOR)
Discharge/transfer to other health care
accommodation (includes mothercraft
hospitals) (4)
Statistical discharge - type change (5)
Left against medical advice/discharge at
own risk (6)
Statistical discharge from leave (7)
Died (8)
Other (includes discharge to usual
residence, own accommodation/welfare
institution (includes prisons, hostels and
group homes providing primarily welfare
services)) (9)
Episode of care
Additional diagnosis
Inter-hospital contracted patient*
Inter-hospital contracted patient from
public sector hospital (1)
Inter-hospital contracted patient from
private sector hospital (2)
Contracting (originating) hospital (3)
Inter-hospital contracted patient to public
sector hospital (4)
Inter-hospital contracted patient to
private sector hospital (5)
Not inter-hospital contracted (6)
Not stated (9)
Mental health legal status*
Involuntary patient (1)
Voluntary patient (2)
Not reported/unknown (9)
Total psychiatric care days*
days
Principal diagnosis—episode of care*
Funding source for hospital patient*
Health service budget (not covered
elsewhere) (01)
Health service budget (due to eligibility
for Reciprocal Health Care Agreement)
(02)
Health service budget (no charge raised
due to hospital decision) (03)
Department of Veterans´ Affairs (04)
Department of Defence (05)
Correctional facility (06)
Medicare Benefits Scheme (07)
Other hospital or public authority
(contracted care) (08)
Private health insurance (09)
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Worker´s compensation (10)
Motor vehicle third party personal claim
(11)
Other compensation (e.g. public liability,
common law, medical negligence) (12)
Self-funded (13)
Other funding source (88)
Not known (98)
Establishment
Australian State/Territory identifier
(establishment)*
New South Wales (1)
Victoria (2)
Queensland (3)
South Australia (4)
Western Australia (5)
Tasmania (6)
Northern Territory (7)
Australian Capital Territory (8)
Other territories (Cocos (Keeling)
Islands, Christmas Island and Jervis Bay
Territory) (9)
Geographic remoteness—admitted patient care*
Major cities of Australia (1)
Inner regional Australia (2)
Outer regional Australia (3)
Remote Australia (4)
Very remote Australia (5)
Migratory (6)
Not stated/inadequately described (9)
Establishment number*
Region code*
Establishment sector*
Public (1)
Private (2)
Hospital service
Care type*
Acute care (1)
Hospital boarder (10)
Mental health care (11)
Rehabilitation care (2)
Palliative care (3)
Geriatric evaluation and management (4)
Psychogeriatric care (5)
Maintenance care (6)
Newborn care (7)
Other admitted patient care (88)
Organ procurement—posthumous (9)
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Injury event
Activity when injured*
External cause*
Place of occurrence of external cause of injury
(ICD-10-AM)*
Patient
Hospital insurance status*
Hospital insurance (1)
No hospital insurance (2)
Unknown (9)
Person
Area of usual residence (SA2)*
Country of birth*
Date of birth*
Medicare eligibility status*
Eligible (1)
Not eligible (2)
Not stated/unknown (9)
Indigenous status*
Aboriginal but not Torres Strait Islander
origin (1)
Torres Strait Islander but not Aboriginal
origin (2)
Both Aboriginal and Torres Strait Islander
origin (3)
Neither Aboriginal nor Torres Strait
Islander origin (4)
Not stated/inadequately described (9)
Person identifier*
Sex*
Male (1)
Female (2)
Intersex or indeterminate (3)
Not stated/inadequately described (9)
Weight in grams (measured)
g
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Record
Record identifier (80 character maximum)*
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Admitted subacute and non-acute hospital care DSS 2015-16 Admitted
patient care NMDS 2015-16 Metadata Online Registry (METeOR)
Admitted subacute and non-acute hospital care DSS 2015-16 Elective
surgery waiting times cluster Metadata Online Registry (METeOR)
Health sector data set specifications from METeOR,
Australia's repository for national metadata standards,
developed by the Australian Institute of Health and Welfare
(http://meteor.aihw.gov.au/content/index.phtml/itemId/3451
65)
Elective surgery waiting times cluster 
The scope of the Elective surgery waiting times data
element cluster is patients on elective surgery waiting lists
managed by public acute hospitals, in either category 1 or 2
of the 'Reason for removals from elective surgery waiting
list' data element.
This will include private patients treated in public hospitals,
and may include public patients treated in private hospitals.
Hospitals may also collect information for other care (as
defined in the 'Waiting list category' data element), but this
is not part of the national minimum data set (NMDS) for
Elective surgery waiting times.
Patients on waiting lists managed by hospitals operated by
the Australian Defence Force, corrections authorities and
Australia's external territories are not currently included.
Data set specification specific attributes: Admitted patient
care NMDS 2015-16
Conditional obligation:	This data element cluster is to be
reported for patients on waiting lists for elective surgery,
which are managed by public acute hospitals and have a
category 1 or 2 assigned for the reason for removal from
the elective surgery waiting list.
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Admitted subacute and non-acute
hospital care DSS 2015-16 Elective
surgery waiting times cluster
Metadata Online Registry (METeOR)
Elective care waiting list episode
Listing date for care*
Elective surgery waiting list episode
Clinical urgency*
Admission within 30 days desirable for a
condition that has the potential to
deteriorate quickly to the point that it may
become an emergency (1)
Admission within 90 days desirable for a
condition causing some pain, dysfunction
or disability but which is not likely to
deteriorate quickly or become an
emergency (2)
Admission at some time in the future
acceptable for a condition causing
minimal or no pain, dysfunction or
disability, which is unlikely to deteriorate
quickly and which does not have the
potential to become an emergency (3)
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Extended wait patient*
Extended wait patient (1)
Other patient (2)
Indicator procedure*
Cataract extraction (01)
Cholecystectomy (02)
Coronary artery bypass graft (03)
Cystoscopy (04)
Haemorrhoidectomy (05)
Hysterectomy (06)
Inguinal herniorrhaphy (07)
Myringoplasty (08)
Myringotomy (09)
Prostatectomy (10)
Septoplasty (11)
Tonsillectomy (12)
Total hip replacement (13)
Total knee replacement (14)
Varicose veins stripping and ligation (15)
Other (88)
Overdue patient*
Overdue patient (1)
Other (2)
Reason for removal from elective surgery waiting
list*
Admitted as an elective patient for
awaited procedure by or on behalf of this
hospital or the state/territory (1)
Admitted as an emergency patient for
awaited procedure by or on behalf of this
hospital or the state/territory (2)
Could not be contacted (includes
patients who have died while waiting,
whether or not the cause of death was
related to the condition requiring
treatment) (3)
Treated elsewhere for awaited
procedure, but not on behalf of this
hospital or the state/territory (4)
Surgery not required or declined (5)
Transferred to another hospital´s waiting
list (6)
Not known (9)
Surgical specialty (of scheduled doctor)*
Cardio-thoracic surgery (01)
Ear, nose and throat surgery (02)
General surgery (03)
Gynaecology (04)
Neurosurgery (05)
Ophthalmology (06)
Orthopaedic surgery (07)
Plastic surgery (08)
Urology (09)
Vascular surgery (10)
Other (11)
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Waiting time at removal from elective surgery
waiting list*
days
Establishment
Establishment identifier
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Admitted subacute and non-acute hospital care DSS 2015-16 Elective
surgery waiting times cluster Metadata Online Registry (METeOR)
Cancer (clinical) DSS Metadata Online
Registry (METeOR)
Health sector data set specifications from METeOR,
Australia's repository for national metadata standards,
developed by the Australian Institute of Health and Welfare
(http://meteor.aihw.gov.au/content/index.phtml/itemId/3451
65)
Cancer (clinical) DSS
The purpose of the Cancer (clinical) data set specification
(C(C)DSS) is to define data standards for the national
collection of clinical cancer data so that data collected is
consistent and reliable. Collection of this data set
specification is not mandated but it is recommended as
best practice if clinical cancer data are to be collected. It
will facilitate more consistent data collection while enabling
individual treatment centres or health service areas to
develop data extraction and collection processes and
policies that are appropriate for their service settings.
Mandatory reporting regulations have enabled population-
based cancer registries in Australia to collect standard
information on all incident cases of cancer apart from non-
melanoma skin cancers, from which incidence, mortality
and overall survival have been determined and trends
monitored. The Cancer (clinical) data set specification
provides a framework for the collection of more detailed
and comprehensive clinical data such as stage of cancer at
diagnosis, other prognostic characteristics, cancer
treatment and patient outcomes.
The Cancer (clinical) data set specification will support
prospective data collection from the time a person with
cancer symptoms is referred or first presents to a hospital
or specialist through the entire duration of their illness.
The majority of data items in the Cancer (clinical) data set
specification are applicable to most solid tumours while
many are also relevant to the haematopoietic malignancies
such as leukaemia and lymphoma. Data set specifications
for specialist tumour streams are also under development
and these will contain supplementary data elements that
will capture the special features of specific cancer types.
The definitions used in this data set specification are
designed to capture the provision of cancer care on a day-
to-day level. They relate to the cancer care pathway and
the need to optimise care by correctly diagnosing,
evaluating and managing patients with cancer. In addition,
end-points and patterns of care can be monitored to
understand both the appropriateness and effectiveness of
cancer care.
The data elements specified provide a framework for:
•	promoting the delivery of evidence-based care to patients
with cancer 
•	facilitating the ongoing improvement in the quality and
safety of cancer management in treatment settings 
•	improving the epidemiological and public health
understanding of cancer 
•	informing treatment guidelines and professional education 
•	guiding resource planning and the evaluation of cancer
control activities 
They will facilitate the aggregation of data across different
treatment centres.
The underlying long-term goal is to provide data support to
improve outcomes for patients by increasing the quality and
length of life. For example, a comparison of the actual
management of patients with best practice guidelines may
identify shortfalls in treatment and limitations in access to
treatment modalities for some patients. 
The working group formed under the stewardship of Cancer
Australia was diverse and included representation from the
following organisations: Cancer Australia, University of
Sydney-Department of Gynaecological Oncology,
Westmead Institute for Cancer Research, Cancer Council
Victoria, Royal Brisbane & Women’s Hospital, National
Breast and Ovarian Cancer Centre, The Royal Women's
Hospital, Queensland Health, Ministry of Health, NSW
Health, TROG Cancer Research, and the Cancer Institute
NSW.
To ensure the broad acceptance of the data set
specification, the proposed list of data items was circulated
to members of Cancer Australia’s National Cancer Data
Strategy Advisory Group, a multidisciplinary group with a
broad spectrum of epidemiological knowledge and
expertise, and the inter-governmental Strategic Forum,
comprising clinicians and senior health department officials
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from the Australian Government and from each state and
territory government, and with strong community
representation. The working group also sought consultation
from cancer registry data managers, clinical leaders,
pathologists, medical oncologists and radiation oncologists
to achieve consensus when required.
The Cancer (clinical) data set specification is intended to
only describe data collected in relation to the initial course
of cancer treatment. The initial course of treatment includes
all treatments administered to the patient from diagnosis
and before disease progression or recurrence.
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Cancer (clinical) DSS Metadata
Online Registry (METeOR)
Chemotherapy for cancer cluster
Chemotherapy completion date*
Chemotherapy cycles administered*
Chemotherapy start date*
Systemic therapy agent or protocol, eviQ
Systemic therapy agent or protocol*
Hormone therapy for cancer cluster
Hormone therapy completion date*
Cancer treatment—hormone therapy start date*
Systemic therapy agent or protocol, eviQ
Systemic therapy agent or protocol
Immunotherapy for cancer cluster
Immunotherapy completion date*
Immunotherapy start date*
Systemic therapy agent or protocol, eviQ
Systemic therapy agent or protocol
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Radiotherapy for cancer cluster
Radiation dose administered*
Gy
Radiotherapy completion date*
Radiotherapy fractions administered*
Radiotherapy start date—cancer treatment*
Radiotherapy target site*
Primary site only (1)
Regional nodes only (2)
Distant metastases only (3)
Primary site and regional nodes (4)
Primary site and distant metastases (5)
Primary site, regional nodes and distant
metastases (6)
Regional nodes and distant metastases
(7)
Not applicable-radiotherapy was not
administered (97)
Unknown whether radiotherapy was
administered  (98)
Radiotherapy was administered but the
site not stated/inadequately described
(99)
Radiotherapy treatment type*
External beam radiotherapy  only (1)
Brachytherapy only (2)
Unsealed radioisotopes only (3)
External beam radiotherapy and
brachytherapy  (4)
External beam radiotherapy and
unsealed radioisotopes (5)
Brachytherapy and unsealed
radioisotopes  (6)
External beam radiotherapy,
brachytherapy and unsealed
radioisotopes (7)
Not applicable-radiotherapy was not
administered (97)
Unknown whether radiotherapy was
administered  (98)
Radiotherapy was administered but the
treatment type not stated/inadequately
described (99)
Surgery for cancer cluster
Surgery target site*
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Surgical procedure date*
Surgical procedure for cancer*
Systemic therapy procedure for cancer
cluster
Systemic therapy procedure date*
Systemic therapy procedure*
A bone marrow transplant procedure was
administered but the type was not
specified (1)
Bone marrow transplant—autologous
only (2)
Bone marrow transplant—allogeneic only
(3)
Stem cell harvest and infusion only (4)
Endocrine surgery and/or endocrine
radiation therapy only (5)
Combination of endocrine surgery and/or
radiation with a transplant procedure (6)
Other systemic therapy procedure (96)
Not applicable-no systemic therapy
procedures were administered  (97)
Unknown whether systemic therapy
procedures were administered (98)
Systemic therapy procedures were
administered but were not
stated/inadequately described (99)
Cancer staging
Cancer staging scheme source edition number*
Staging scheme source*
1	TNM Classification of Malignant
Tumours (UICC) (1)
10	Chronic Myeloid Leukaemia (CML)
staging system (10)
11	International Staging System (ISS) for
myeloma (11)
12	American Joint Committee on Cancer
(AJCC) Cancer Staging Manual (12)
96	Other reference (13)
97	Not applicable (14)
98	Unknown (15)
99	Not stated/inadequately described
(16)
2	Durie & Salmon for multiple myeloma
staging (2)
3	French-American-British (FAB) for
leukaemia classification (3)
4	Australian Clinico-Pathological Staging
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(ACPS) System for colorectal cancer (4)
5	International Federation of
Gynecologists & Obstetricians (FIGO) for
gynaecological cancers (5)
6	Dukes/Modified Dukes for colorectal
cancer (6)
7	Ann Arbor staging system for
lymphomas (7)
8	Binet Staging Classification for chronic
lymphocytic leukaemia (8)
9	Rai staging system for chronic
lymphocytic leukaemia (9)
Staging basis of cancer*
Clinical (C)
Pathological (P)
Cancer treatment
Cancer treatment type*
Surgery only (1)
Radiotherapy only (2)
Systemic agent therapy only (3)
Surgery and radiotherapy (4)
Surgery and systemic agent therapy (5)
Radiotherapy and systemic agent
therapy (6)
Surgery, radiotherapy and systemic
agent therapy (7)
Not applicable—treatment was not
administered (97)
Unknown whether treatment was
administered (98)
Treatment was administered but the type
was not stated/inadequately described
(99)
Multidisciplinary team review indicator*
Yes (1)
No (2)
Unknown (8)
Other cancer treatment description
Outcome of treatment*
Complete response/no evidence of
disease (1.0)
Partial response (2.1)
Stable or static disease (2.2)
Progressive disease (2.3)
Not assessed or unable to be assessed
(7.0)
Unknown (8.0)
Not stated/inadequately described (9.0)
Date
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Date accuracy indicator*
Day, month and year are accurate (AAA)
Day and month are accurate, year is
estimated (AAE)
Day and month are accurate, year is
unknown (AAU)
Day is accurate, month is estimated,
year is accurate (AEA)
Day is accurate, month and year are
estimated (AEE)
Day is accurate, month is estimated,
year is unknown (AEU)
Day is accurate, month is unknown, year
is accurate (AUA)
Day is accurate, month is unknown, year
is estimated (AUE)
Day is accurate, month and year are
unknown (AUU)
Day is estimated, month and year are
accurate (EAA)
Day is estimated, month is accurate,
year is estimated (EAE)
Day is estimated, month is accurate,
year is unknown (EAU)
Day and month are estimated, year is
accurate (EEA)
Day, month and year are estimated
(EEE)
Day and month are estimated, year is
unknown (EEU)
Day is estimated, month is unknown,
year is accurate (EUA)
Day is estimated, month is unknown,
year is estimated (EUE)
Day is estimated, month and year are
unknown (EUU)
Day is unknown, month and year are
accurate (UAA)
Day is unknown, month is accurate, year
is estimated (UAE)
Day is unknown, month is accurate, year
is unknown (UAU)
Day is unknown, month is estimated,
year is accurate (UEA)
Day is unknown, month and year are
estimated (UEE)
Day is unknown, month is estimated,
year is unknown (UEU)
Day and month are unknown, year is
accurate (UUA)
Day and month are unknown, year is
estimated (UUE)
Day, month and year are unknown (UUU)
Establishment
Establishment number*
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Healthcare provider
HPI-O*
Patient
Cancer status*
No evidence of cancer (1)
Evidence of cancer (2)
Unknown whether there is evidence of
cancer (8)
Not stated/inadequately described (9)
Date of last contact—cancer patient*
Date of diagnosis of cancer*
Date of diagnosis of first recurrence as distant
metastasis
Date of diagnosis of first recurrence as
locoregional cancer
Person (address)
Address line (person)*
Person (name)
Family name*
Given name(s)*
Person with cancer
Cancer staging—M stage code*
Cancer staging—stage grouping other*
Cancer staging—TNM stage grouping code*
Histopathological grade*
Grade 1: Low grade; well differentiated,
differentiated, NOS (1)
Grade 2: Intermediate grade, moderately
differentiated, moderately well
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differentiated, intermediate differentiation
(2)
Grade 3: High grade, poorly
differentiated (3)
Grade 4: Undifferentiated, anaplastic (4)
Grade or differentiation not determined,
not stated or not applicable (9)
Laterality of primary cancer*
Bilateral (B)
Left (L)
Not applicable (N)
Right (R)
Unknown (U)
Morphology of cancer*
Most valid basis of diagnosis of cancer*
Death certificate only: Information
provided is from a death certificate (0)
Clinical: Diagnosis made before death,
but without any of the following (codes 2-
7) (1)
Clinical investigation: All diagnostic
techniques, including x-ray, endoscopy,
imaging, ultrasound, exploratory surgery
(e.g. laparotomy), and autopsy, without a
tissue diagnosis (2)
Specific tumour markers: Including
biochemical and/or immunological
markers that are specific for a tumour
site (4)
Cytology: Examination of cells from a
primary or secondary site, including
fluids aspirated by endoscopy or needle;
also includes the microscopic
examination of peripheral blood and
bone marrow aspirates (5)
Histology of metastasis: Histological
examination of tissue from a metastasis,
including autopsy specimens (6)
Histology of a primary tumour:
Histological examination of tissue from
primary tumour, however obtained,
including all cutting techniques and bone
marrow biopsies; also includes autopsy
specimens of primary tumour (7)
Histology: either unknown whether of
primary or metastatic site, or not
otherwise specified (8)
Unknown (9)
Most valid basis of diagnosis of recurrence
Death certificate only: Information
provided is from a death certificate (0)
Clinical: Diagnosis made before death,
but without any of the following (codes 2-
7) (1)
Clinical investigation: All diagnostic
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techniques, including x-ray, endoscopy,
imaging, ultrasound, exploratory surgery
(e.g. laparotomy), and autopsy, without a
tissue diagnosis (2)
Specific tumour markers: Including
biochemical and/or immunological
markers that are specific for a tumour
site (4)
Cytology: Examination of cells from a
primary or secondary site, including
fluids aspirated by endoscopy or needle;
also includes the microscopic
examination of peripheral blood and
bone marrow aspirates (5)
Histology of metastasis: Histological
examination of tissue from a metastasis,
including autopsy specimens (6)
Histology of a primary tumour:
Histological examination of tissue from
primary tumour, however obtained,
including all cutting techniques and bone
marrow biopsies; also includes autopsy
specimens of primary tumour (7)
Histology: either unknown whether of
primary or metastatic site, or not
otherwise specified (8)
Unknown (9)
Regional lymph nodes positive
Number of regional lymph nodes examined
Primary site of cancer (ICD-O-3 code)*
Cancer staging—T stage code*
Region of first recurrence as distant metastasis
Region of first recurrence as locoregional cancer
Cancer staging—N stage code*
Tumour size at diagnosis (solid tumours)
mm
Person
Date of birth*
Date of death
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Medicare card number*
Indigenous status*
Aboriginal but not Torres Strait Islander
origin (1)
Torres Strait Islander but not Aboriginal
origin (2)
Both Aboriginal and Torres Strait Islander
origin (3)
Neither Aboriginal nor Torres Strait
Islander origin (4)
Not stated/inadequately described (9)
Person identifier*
Sex*
Male (1)
Female (2)
Intersex or indeterminate (3)
Not stated/inadequately described (9)
Underlying cause of death
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Local Hospital Networks DSS 2015-16
Metadata Online Registry (METeOR)
Health sector data set specifications from METeOR,
Australia's repository for national metadata standards,
developed by the Australian Institute of Health and Welfare
(http://meteor.aihw.gov.au/content/index.phtml/itemId/3451
65)
Local Hospital Networks DSS 2015-16
The scope of the Local Hospital Networks data set
specification (LHN DSS) is:
•	Local Hospital Networks
•	all public hospital services that are managed by a state or
territory health authority and are included in the General list
of In-scope Public Hospital Services, which has been
developed under the National Health Reform Agreement
(2011).
Excluded from the DSS scope are establishments which
report to the Public hospital establishments NMDS.  
Local Hospital Networks are defined as those entities
recognised as such by the relevant state or territory health
authority.
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Local Hospital Networks DSS 2015-
16 Metadata Online Registry
(METeOR)
Full-time equivalent staffing data element
cluster
Full-time equivalent staff—average*
Establishment staffing categories*
Administrative and clerical staff (1)
Trainee/pupil nurses (10)
Diagnostic and health professionals  (2)
Domestic and other staff (3)
Enrolled nurses (4)
Other personal care staff (5)
Registered nurses (6)
Specialist salaried medical officers
(SMOs) (7)
Other salaried medical officers (SMOs)
(8)
Student nurses (9)
Recurrent contracted care expenditure
data element cluster
Recurrent contracted care expenditure product
streams*
Admitted acute care (1)
Admitted subacute care (2)
Other admitted care (3)
Emergency care services (4)
Non-admitted care (in-scope for NHRA)
(5)
Direct teaching, training and research (6)
Commonwealth funded aged care (7)
Other aged care (8)
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Other (out of scope for NHRA) (88)
Non-admitted care (out of scope for
NHRA) (9)
Recurrent contracted care expenditure in
Australian dollars*
AU$
Recurrent non-salary expenditure data
element cluster
Estimated data indicator*
Yes
No
Recurrent non-salary public hospital expenditure
categories*
Administrative expenses - insurance (1)
Superannuation employer contributions
(10)
Other on-costs (11)
Supplies - drug (12)
Supplies - food (13)
Supplies - medical and surgical (14)
Visiting medical officer payments (15)
Administrative expenses - other  (2)
Depreciation - building (3)
Depreciation - other  (4)
Domestic services  (5)
Interest payments  (6)
Lease costs (7)
Patient transport costs (8)
Not elsewhere recorded (88)
Repairs and maintenance (9)
Recurrent non-salary expenditure total dollars*
AU$
Recurrent salaries and wages expenditure
data element cluster
Estimated data indicator*
Yes
No
Salaries and wages*
AU$
Establishment staffing categories*
Administrative and clerical staff (1)
Trainee/pupil nurses (10)
Diagnostic and health professionals  (2)
Domestic and other staff (3)
Enrolled nurses (4)
Other personal care staff (5)
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Registered nurses (6)
Specialist salaried medical officers
(SMOs) (7)
Other salaried medical officers (SMOs)
(8)
Student nurses (9)
Revenue data element cluster
Estimated data indicator*
Yes
No
Public hospital related revenue categories*
Department of Veterans' Affairs (1)
Other recoveries (10)
Revenue not elsewhere reported (11)
Compensable schemes (2)
Other patient revenue (3)
Commonwealth funding/subsidies (4)
State or territory health authority funding
(5)
Other state or territory funding (6)
National Health Funding Pool - state or
territory government component (7)
National Health Funding Pool -
Commonwealth government component
(8)
Infrastructure/facility fees (9)
Public hospital related revenue in Australian
dollars*
AU$
Total recurrent expenditure on National
Health Reform Agreement product
streams data element cluster
Recurrent expenditure by NHRA product
streams*
Admitted acute care (1)
Admitted subacute care (2)
Other admitted care (3)
Emergency care services (4)
Non-admitted care (in-scope for NHRA)
(5)
Direct teaching, training and research (6)
Commonwealth funded aged care (7)
Other aged care (8)
Other (out of scope for NHRA) (88)
Non-admitted care (out of scope for
NHRA) (9)
Total recurrent expenditure in Australian dollars*
AU$
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Available bed
Average available beds for admitted contracted
care*
beds
Establishment
Australian State/Territory identifier
(establishment)*
New South Wales (1)
Victoria (2)
Queensland (3)
South Australia (4)
Western Australia (5)
Tasmania (6)
Northern Territory (7)
Australian Capital Territory (8)
Other territories (Cocos (Keeling)
Islands, Christmas Island and Jervis Bay
Territory) (9)
Estimated data indicator*
Yes
No
Gross capital expenditure (accrual
accounting)—buildings and building services*
AU$
Gross capital expenditure (accrual
accounting)—constructions*
AU$
Gross capital expenditure (accrual
accounting)—equipment*
AU$
Gross capital expenditure (accrual
accounting)—information technology*
AU$
Gross capital expenditure (accrual
accounting)—intangible assets*
AU$
Gross capital expenditure (accrual
accounting)—land*
AU$
Gross capital expenditure (accrual
accounting)—major medical equipment*
AU$
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Gross capital expenditure (accrual
accounting)—other equipment*
AU$
Gross capital expenditure (accrual
accounting)—transport*
AU$
Gross capital expenditure—computer
equipment/installations*
AU$
Gross capital expenditure—intangible assets*
AU$
Gross capital expenditure—land and buildings*
AU$
Gross capital expenditure—major medical
equipment*
AU$
Gross capital expenditure—other*
AU$
Gross capital expenditure—plant and other
equipment*
AU$
Local Hospital Network identifier*
South Eastern Sydney  (101)
Sydney  (102)
South Western Sydney  (103)
Western Sydney  (104)
Nepean Blue Mountains (105)
Northern Sydney (106)
Central Coast (107)
Illawarra Shoalhaven  (108)
Hunter New England  (109)
Mid North Coast (110)
Northern NSW  (111)
Western NSW (112)
Southern NSW  (113)
Murrumbidgee  (114)
Far West (115)
Sydney Children´s Hospitals Network
(117)
St Vincent´s Health Network (118)
Justice Health & Forensic Mental Health
(119)
New South Wales Virtual Local Hospital
Network (199)
Beaufort and Skipton Health Service
(201)
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East Grampians Health Service (202)
Ballarat Health Services  (203)
Stawell Regional Health (204)
East Wimmera Health Service (205)
Hepburn Health Service  (206)
Maryborough District Health Service
(207)
Djerriwarrh Health Service (Vic) (208)
Western Health (Vic)  (209)
Bendigo Health Care Group (210)
Heathcote Health (211)
Swan Hill District Health (212)
Cohuna District Hospital  (213)
Echuca Regional Health  (214)
Kerang District Health  (215)
Maldon Hospital (216)
Boort District Health (218)
Rochester and Elmore District Health
Service  (219)
Inglewood and District Health Service
(220)
Castlemaine Health  (221)
Kyneton District Health Service (222)
Royal Children´s Hospital (Melbourne)
(223)
Royal Women´s Hospital (Melbourne)
(224)
Melbourne Health  (225)
Northern Health (Vic) (226)
Victorian Institute of Forensic Mental
Health (227)
Colac Area Health (228)
Hesse Rural Health Service
(Winchelsea) (229)
Otway Health and Community Services
(Apollo Bay)  (23)
Barwon Health (231)
Lorne Community Hospital  (232)
Alexandra District Hospital (233)
Eastern Health (Vic)  (234)
Goulburn Valley Health  (235)
Kyabram and District Health Service
(236)
Numurkah and District Health Service
(237)
Nathalia District Hospital  (238)
Cobram District Hospital  (239)
Seymour District Memorial Hospital
(240)
Kilmore and District Hospital (241)
Yea and District Memorial Hospital  (242)
Northeast Health Wangaratta (243)
Yarrawonga District Health Service
(244)
Alpine Health (Vic) (245)
Mansfield District Hospital (246)
Benalla and District Memorial Hospital
(247)
Tallangatta Health Service  (248)
Albury Wodonga Health (249)
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Upper Murray Health and Community
Services (Corryong) (250)
Beechworth Health Service (251)
West Gippsland Healthcare Group (252)
Bass Coast Regional Health  (253)
Gippsland Southern Health Service
(254)
South Gippsland Hospital (Foster) (255)
Bairnsdale Regional Health Service
(256)
Yarram and District Health Service  (257)
Omeo District Health  (258)
Central Gippsland Health Service  (259)
Latrobe Regional Hospital (260)
Orbost Regional Health  (261)
St Vincent´s Hospital (Melbourne)
Limited (262)
Royal Victorian Eye and Ear Hospital
(263)
Peter MacCallum Cancer Institute (Vic)
(264)
Austin Health (Vic) (266)
Mercy Public Hospital Inc. (Vic) (267)
Alfred Health (Vic) (268)
Monash Health (269)
Peninsula Health (Vic)  (270)
Kooweerup Regional Health Service
(271)
Rural Northwest Health (Vic)  (274)
Wimmera Health Care Group (275)
Dunmunkle Health Services (276)
West Wimmera Health Service (277)
Edenhope and District Memorial Hospital
(278)
Mildura Base Hospital (279)
Mallee Track Health and Community
Service (280)
Robinvale District Health Services  (281)
Western District Health Service (Vic)
(282)
Casterton Memorial Hospital (283)
South West Healthcare (Vic) (284)
Heywood Rural Health  (285)
Timboon and District Healthcare Service
(286)
Moyne Health Services (Port Fairy)
(287)
Portland District Health  (288)
Terang and Mortlake Health Service
(Terang) (289)
Calvary Health Care Bethlehem Limited
(290)
Victoria Virtual Local Hospital Network
(299)
Cairns and Hinterland (312)
Townsville  (313)
Mackay  (314)
North West (Qld)  (315)
Central Queensland  (316)
Central West (Qld)  (317)
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Wide Bay  (318)
Sunshine Coast  (319)
Metro North (Qld) (320)
Children´s Health Queensland  (321)
Metro South (Qld) (322)
Gold Coast  (323)
West Moreton  (324)
Darling Downs (325)
South West (Qld)  (326)
Torres and Cape (327)
Queensland Virtual Local Hospital
Network (399)
Northern Adelaide (401)
Central Adelaide  (402)
Southern Adelaide (403)
Country Health SA (404)
Women´s and Children´s Health Network
(SA) (405)
South Australia Virtual Local Hospital
Network (499)
North Metropolitan Health Service (WA)
(501)
South Metropolitan Health Service (WA)
(502)
WA Country Health Service (503)
Child Adolescent Health Service (WA)
(580)
Notional Local Hospital Network (Royal
St.) (590)
Western Australia Virtual Local Hospital
Network (599)
Tasmanian Health Organisation - South
(601)
Tasmanian Health Organisation - North
(602)
Tasmanian Health Organisation - North
West (603)
Tasmania Virtual Local Hospital Network
(699)
Top End (NT) (701)
Central Australia (NT) (702)
Northern Territory Virtual Local Hospital
Network (799)
Australian Capital Territory (801)
Australian Capital Territory Virtual Local
Hospital Network (899)
Virtual Local Hospital Network -
Unknown (900)
Not applicable (997)
Unknown (998)
Not stated/inadequately described (999)
Net capital expenditure (accrual
accounting)—buildings and building services*
AU$
Net capital expenditure (accrual
accounting)—constructions*
AU$
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Net capital expenditure (accrual
accounting)—equipment*
AU$
Net capital expenditure (accrual
accounting)—information technology*
AU$
Net capital expenditure (accrual
accounting)—intangible assets*
AU$
Net capital expenditure (accrual
accounting)—land*
AU$
Net capital expenditure (accrual
accounting)—major medical equipment*
AU$
Net capital expenditure (accrual
accounting)—other equipment*
AU$
Net capital expenditure (accrual
accounting)—transport*
AU$
Establishment number*
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Eligibility Colorectal Cancer NCT00061815
Study of Cetuximab, Oxaliplatin, 5-FU/LV Versus
Oxaliplatin, 5-FU/LV in Patients With Previously Treated
Metastatic, EGFR-Positive Colorectal Cancer; ODM derived
from: https://clinicaltrials.gov/show/NCT00061815
All rights reserved. Please visit https://medical-data-
models.org/forms/16741
Eligibility Colorectal Cancer
NCT00061815
Inclusion Criteria
documented colorectal cancer which is egfr-
positive and is metastatic.*
Yes
No
prior irinotecan, alone or in combination, as first-
line treatment of metastatic disease.*
Yes
No
Exclusion Criteria
a serious uncontrolled medical disorder that, in
the opinion of the investigator, would impair the
ability of the subject to receive protocol therapy.*
Yes
No
known dihydropyrimidine dehydrogenase (dpd)
deficiency.*
Yes
No
known metastases in the central nervous
system.*
Yes
No
symptomatic sensory or peripheral neuropathy.*
Yes
No
more than one prior chemotherapy regimen for
the treatment of metastatic colorectal cancer.*
Yes
No
prior oxaliplatin therapy.*
Yes
No
prior cetuximab or other therapy which targets the
egf pathway.*
Yes
No
prior chimerized or murine monoclonal antibody
therapy.*
Yes
No
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Health sector data set specifications from METeOR,
Australia's repository for national metadata standards,
developed by the Australian Institute of Health and Welfare
(http://meteor.aihw.gov.au/content/index.phtml/itemId/3451
65)
Public hospital establishments NMDS 2015-16
The scope of the Public hospital establishments national
minimum data set (PHE NMDS) is establishment-level data
for public acute and psychiatric hospitals, and alcohol and
drug treatment centres.
Similar data for private hospitals and free standing day
hospital facilities are collected by the Australian Bureau of
Statistics in the Private Health Establishments Collection.
Hospitals operated by the Australian Defence Force,
corrections authorities and Australia's external territories
are not currently included. Hospitals specialising in dental,
ophthalmic aids and other specialised acute medical or
surgical care are included.
© Australian Institute of Health and Welfare 2015
Metadata and Classifications Unit 
Australian Institute of Health and Welfare
GPO Box 570
Canberra ACT 2601
All rights reserved. Please visit https://medical-data-
models.org/forms/16742
Public hospital establishments
NMDS 2015-16 Metadata Online
Registry (METeOR)
Full-time equivalent staffing data element
cluster
Full-time equivalent staff—average*
Establishment staffing categories*
Administrative and clerical staff (1)
Trainee/pupil nurses (10)
Diagnostic and health professionals  (2)
Domestic and other staff (3)
Enrolled nurses (4)
Other personal care staff (5)
Registered nurses (6)
Specialist salaried medical officers
(SMOs) (7)
Other salaried medical officers (SMOs)
(8)
Student nurses (9)
Recurrent contracted care expenditure
data element cluster
Recurrent contracted care expenditure product
streams*
Admitted acute care (1)
Admitted subacute care (2)
Other admitted care (3)
Emergency care services (4)
Non-admitted care (in-scope for NHRA)
(5)
Direct teaching, training and research (6)
Commonwealth funded aged care (7)
Other aged care (8)
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Other (out of scope for NHRA) (88)
Non-admitted care (out of scope for
NHRA) (9)
Recurrent contracted care expenditure in
Australian dollars*
AU$
Recurrent non-salary expenditure data
element cluster
Estimated data indicator*
Yes
No
Recurrent non-salary public hospital expenditure
categories*
Administrative expenses - insurance (1)
Superannuation employer contributions
(10)
Other on-costs (11)
Supplies - drug (12)
Supplies - food (13)
Supplies - medical and surgical (14)
Visiting medical officer payments (15)
Administrative expenses - other  (2)
Depreciation - building (3)
Depreciation - other  (4)
Domestic services  (5)
Interest payments  (6)
Lease costs (7)
Patient transport costs (8)
Not elsewhere recorded (88)
Repairs and maintenance (9)
Recurrent non-salary expenditure total dollars*
AU$
Recurrent salaries and wages expenditure
data element cluster
Estimated data indicator*
Yes
No
Salaries and wages*
AU$
Establishment staffing categories*
Administrative and clerical staff (1)
Trainee/pupil nurses (10)
Diagnostic and health professionals  (2)
Domestic and other staff (3)
Enrolled nurses (4)
Other personal care staff (5)
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Registered nurses (6)
Specialist salaried medical officers
(SMOs) (7)
Other salaried medical officers (SMOs)
(8)
Student nurses (9)
Revenue data element cluster
Estimated data indicator*
Yes
No
Public hospital related revenue categories*
Department of Veterans' Affairs (1)
Other recoveries (10)
Revenue not elsewhere reported (11)
Compensable schemes (2)
Other patient revenue (3)
Commonwealth funding/subsidies (4)
State or territory health authority funding
(5)
Other state or territory funding (6)
National Health Funding Pool - state or
territory government component (7)
National Health Funding Pool -
Commonwealth government component
(8)
Infrastructure/facility fees (9)
Public hospital related revenue in Australian
dollars*
AU$
Total recurrent expenditure on National
Health Reform Agreement product
streams data element cluster
Recurrent expenditure by NHRA product
streams*
Admitted acute care (1)
Admitted subacute care (2)
Other admitted care (3)
Emergency care services (4)
Non-admitted care (in-scope for NHRA)
(5)
Direct teaching, training and research (6)
Commonwealth funded aged care (7)
Other aged care (8)
Other (out of scope for NHRA) (88)
Non-admitted care (out of scope for
NHRA) (9)
Total recurrent expenditure in Australian dollars*
AU$
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Address
Statistical area level 2 (SA2)*
Available bed
Average available beds for admitted contracted
care*
beds
Average available beds for overnight-stay
patients*
beds
Average available beds for same-day patients*
beds
Establishment
Australian State/Territory identifier
(establishment)*
New South Wales (1)
Victoria (2)
Queensland (3)
South Australia (4)
Western Australia (5)
Tasmania (6)
Northern Territory (7)
Australian Capital Territory (8)
Other territories (Cocos (Keeling)
Islands, Christmas Island and Jervis Bay
Territory) (9)
Estimated data indicator*
Yes
No
Establishment type*
Public day centre/hospital (N7.1)
Public freestanding day surgery centre
(N7.2)
Private day centre/hospital (N7.3)
Private freestanding day surgery centre
(N7.4)
Public community health centre (N8.1.1)
Private (non-profit) community health
centre (N8.1.2)
Public domiciliary nursing service
(N8.2.1)
Private (non-profit) domiciliary nursing
service (N8.2.2)
Private (profit) domiciliary nursing
service (N8.2.3)
Public acute care hospital (R1.1)
Private acute care hospital (R1.2)
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Veterans Affairs hospital (R1.3.1)
Defence force hospital (R1.3.2)
Other Commonwealth hospital (R1.3.3)
Public psychiatric hospital (R2.1)
Private psychiatric hospital (R2.2)
Private charitable nursing home for the
aged (R3.1)
Private profit nursing home for the aged
(R3.2)
Government nursing home for the aged
(R3.3)
Private charitable nursing home for
young disabled (R3.4)
Private profit nursing home for young
disabled (R3.5)
Government nursing home for young
disabled (R3.6)
Public alcohol and drug treatment centre
(R4.1)
Private alcohol and drug treatment
centre (R4.2)
Charitable hostels for the aged (R5.1)
State government hostel for the aged
(R5.2)
Local government hostel for the aged
(R5.3)
Other charitable hostel (R5.4)
Other State government hostel (R5.5)
Other Local government hostel (R5.6)
Public hospice (R6.1)
Private hospice (R6.2)
Geographical location of establishment*
Independent Hospital Pricing Authority funding
designation*
Activity based funded (1)
Block funded (2)
Not designated (8)
Local Hospital Network identifier*
South Eastern Sydney  (101)
Sydney  (102)
South Western Sydney  (103)
Western Sydney  (104)
Nepean Blue Mountains (105)
Northern Sydney (106)
Central Coast (107)
Illawarra Shoalhaven  (108)
Hunter New England  (109)
Mid North Coast (110)
Northern NSW  (111)
Western NSW (112)
Southern NSW  (113)
Murrumbidgee  (114)
Far West (115)
Sydney Children´s Hospitals Network
(117)
St Vincent´s Health Network (118)
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Justice Health & Forensic Mental Health
(119)
New South Wales Virtual Local Hospital
Network (199)
Beaufort and Skipton Health Service
(201)
East Grampians Health Service (202)
Ballarat Health Services  (203)
Stawell Regional Health (204)
East Wimmera Health Service (205)
Hepburn Health Service  (206)
Maryborough District Health Service
(207)
Djerriwarrh Health Service (Vic) (208)
Western Health (Vic)  (209)
Bendigo Health Care Group (210)
Heathcote Health (211)
Swan Hill District Health (212)
Cohuna District Hospital  (213)
Echuca Regional Health  (214)
Kerang District Health  (215)
Maldon Hospital (216)
Boort District Health (218)
Rochester and Elmore District Health
Service  (219)
Inglewood and District Health Service
(220)
Castlemaine Health  (221)
Kyneton District Health Service (222)
Royal Children´s Hospital (Melbourne)
(223)
Royal Women´s Hospital (Melbourne)
(224)
Melbourne Health  (225)
Northern Health (Vic) (226)
Victorian Institute of Forensic Mental
Health (227)
Colac Area Health (228)
Hesse Rural Health Service
(Winchelsea) (229)
Otway Health and Community Services
(Apollo Bay)  (23)
Barwon Health (231)
Lorne Community Hospital  (232)
Alexandra District Hospital (233)
Eastern Health (Vic)  (234)
Goulburn Valley Health  (235)
Kyabram and District Health Service
(236)
Numurkah and District Health Service
(237)
Nathalia District Hospital  (238)
Cobram District Hospital  (239)
Seymour District Memorial Hospital
(240)
Kilmore and District Hospital (241)
Yea and District Memorial Hospital  (242)
Northeast Health Wangaratta (243)
Yarrawonga District Health Service
(244)
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Alpine Health (Vic) (245)
Mansfield District Hospital (246)
Benalla and District Memorial Hospital
(247)
Tallangatta Health Service  (248)
Albury Wodonga Health (249)
Upper Murray Health and Community
Services (Corryong) (250)
Beechworth Health Service (251)
West Gippsland Healthcare Group (252)
Bass Coast Regional Health  (253)
Gippsland Southern Health Service
(254)
South Gippsland Hospital (Foster) (255)
Bairnsdale Regional Health Service
(256)
Yarram and District Health Service  (257)
Omeo District Health  (258)
Central Gippsland Health Service  (259)
Latrobe Regional Hospital (260)
Orbost Regional Health  (261)
St Vincent´s Hospital (Melbourne)
Limited (262)
Royal Victorian Eye and Ear Hospital
(263)
Peter MacCallum Cancer Institute (Vic)
(264)
Austin Health (Vic) (266)
Mercy Public Hospital Inc. (Vic) (267)
Alfred Health (Vic) (268)
Monash Health (269)
Peninsula Health (Vic)  (270)
Kooweerup Regional Health Service
(271)
Rural Northwest Health (Vic)  (274)
Wimmera Health Care Group (275)
Dunmunkle Health Services (276)
West Wimmera Health Service (277)
Edenhope and District Memorial Hospital
(278)
Mildura Base Hospital (279)
Mallee Track Health and Community
Service (280)
Robinvale District Health Services  (281)
Western District Health Service (Vic)
(282)
Casterton Memorial Hospital (283)
South West Healthcare (Vic) (284)
Heywood Rural Health  (285)
Timboon and District Healthcare Service
(286)
Moyne Health Services (Port Fairy)
(287)
Portland District Health  (288)
Terang and Mortlake Health Service
(Terang) (289)
Calvary Health Care Bethlehem Limited
(290)
Victoria Virtual Local Hospital Network
(299)
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Cairns and Hinterland (312)
Townsville  (313)
Mackay  (314)
North West (Qld)  (315)
Central Queensland  (316)
Central West (Qld)  (317)
Wide Bay  (318)
Sunshine Coast  (319)
Metro North (Qld) (320)
Children´s Health Queensland  (321)
Metro South (Qld) (322)
Gold Coast  (323)
West Moreton  (324)
Darling Downs (325)
South West (Qld)  (326)
Torres and Cape (327)
Queensland Virtual Local Hospital
Network (399)
Northern Adelaide (401)
Central Adelaide  (402)
Southern Adelaide (403)
Country Health SA (404)
Women´s and Children´s Health Network
(SA) (405)
South Australia Virtual Local Hospital
Network (499)
North Metropolitan Health Service (WA)
(501)
South Metropolitan Health Service (WA)
(502)
WA Country Health Service (503)
Child Adolescent Health Service (WA)
(580)
Notional Local Hospital Network (Royal
St.) (590)
Western Australia Virtual Local Hospital
Network (599)
Tasmanian Health Organisation - South
(601)
Tasmanian Health Organisation - North
(602)
Tasmanian Health Organisation - North
West (603)
Tasmania Virtual Local Hospital Network
(699)
Top End (NT) (701)
Central Australia (NT) (702)
Northern Territory Virtual Local Hospital
Network (799)
Australian Capital Territory (801)
Australian Capital Territory Virtual Local
Hospital Network (899)
Virtual Local Hospital Network -
Unknown (900)
Not applicable (997)
Unknown (998)
Not stated/inadequately described (999)
Establishment number*
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Establishment sector*
Public (1)
Private (2)
Specialised service indicators—acquired immune
deficiency syndrome unit*
Yes
No
Specialised service indicators—acute renal
dialysis unit*
Yes
No
Specialised service indicators—acute spinal cord
injury unit*
Yes
No
Specialised service indicators—alcohol and drug
unit*
Yes
No
Specialised service indicators—bone marrow
transplantation*
Yes
No
Specialised service indicators—burns unit (level
III)*
Yes
No
Specialised service indicators—cardiac surgery
unit*
Yes
No
Specialised service indicators—clinical genetics
unit*
Yes
No
Specialised service indicators—comprehensive
epilepsy centre*
Yes
No
Specialised service indicators—coronary care
unit*
Yes
No
Specialised service indicators—diabetes unit*
Yes
No
Specialised service indicators—domiciliary care
service*
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Yes
No
Specialised service indicators—geriatric
assessment unit*
Yes
No
Specialised service indicators—heart, lung
transplantation unit*
Yes
No
Specialised service indicators—hospice care
unit*
Yes
No
Specialised service indicators—in-vitro
fertilisation unit*
Yes
No
Specialised service indicators—infectious
diseases unit*
Yes
No
Specialised service indicators—intensive care
unit (level III)*
Yes
No
Specialised service indicators—liver
transplantation unit*
Yes
No
Specialised service indicators—maintenance
renal dialysis centre*
Yes
No
Specialised service indicators—major
plastic/reconstructive surgery unit*
Yes
No
Specialised service indicators—neonatal
intensive care unit (level III)*
Yes
No
Specialised service indicators—neurosurgical
unit*
Yes
No
Specialised service indicators—nursing home
care unit*
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Yes
No
Specialised service
indicators—obstetric/maternity*
Yes
No
Specialised service indicators—oncology unit,
cancer treatment*
Yes
No
Specialised service indicators—pancreas
transplantation unit*
Yes
No
Specialised service indicators—psychiatric
unit/ward*
Yes
No
Specialised service indicators—rehabilitation
unit*
Yes
No
Specialised service indicators—renal
transplantation unit*
Yes
No
Specialised service indicators—sleep centre*
Yes
No
Specialised service indicators—specialist
paediatric*
Yes
No
Teaching status*
Yes (1)
No (2)
Unknown (9)
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Eligibility Colorectal Cancer NCT00059930
Adjuvant Hepatic Arterial Infusion and Combination
Chemotherapy in Treating Patients With Resectable
Hepatic Metastases From Colorectal Cancer; ODM derived
from: https://clinicaltrials.gov/show/NCT00059930
All rights reserved. Please visit https://medical-data-
models.org/forms/16743
Eligibility Colorectal Cancer
NCT00059930
Criteria
history of histologically confirmed colorectal
adenocarcinoma metastatic to the liver with no
clinical or radiographic evidence of extrahepatic
disease. confirmation of diagnosis must be
performed at mskcc.*
Yes
No
potentially completely resectable hepatic
metastases without current evidence of other
metastatic disease.*
Yes
No
abdominal and pelvic ct scans and chest ct or x-
ray within 6 weeks prior to registration. (mri of
abdomen may be substituted for ct of abdomen.)*
Yes
No
lab values within 14 days prior to registration:*
Yes
No
wbc ≥ 3.0 k/ul*
Yes
No
anc >1.5 k/ul*
Yes
No
platelets ≥ 100 k/ul*
Yes
No
total bilirubin ≤ 1.5 mg/dl.*
Yes
No
prior chemotherapy is acceptable if last dose
given ≥ 3 weeks prior to registration to this study.*
Yes
No
kps ≥ 60%*
Yes
No
signed informed consent.*
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Yes
No
subject exclusion criteria:*
Yes
No
prior radiation to the liver. (prior radiation therapy
to the pelvis is acceptable if completed at least 4
weeks prior to registration.)*
Yes
No
active infection, ascites, hepatic encephalopathy*
Yes
No
prior oxaliplatin or cisplatin or hai fudr*
Yes
No
female patients who are pregnant or lactating*
Yes
No
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Alcohol and other drug treatment services NMDS
2015- Metadata Online Registry (METeOR)
Health sector data set specifications from METeOR,
Australia's repository for national metadata standards,
developed by the Australian Institute of Health and Welfare
(http://meteor.aihw.gov.au/content/index.phtml/itemId/3451
65)
Alcohol and other drug treatment services NMDS 2015-
The Alcohol and other drug treatment services national
minimum data set (NMDS) is nationally mandated for
collection and reporting.
Publicly funded government and non-government agencies
providing alcohol and/or drug treatment services. Including
community-based ambulatory services and outpatient
services.
The following services are currently not included in the
coverage:
•	services based in prisons and other correctional
institutions; 
•	agencies that provide primarily accommodation or
overnight stays such as 'sobering-up shelters' and 'half-way
houses'; 
•	agencies that provide services concerned primarily with
health promotion; 
•	needle and syringe programs; 
•	agencies whose sole function is to provide prescribing
and/or dosing of methadone; and 
•	acute care and psychiatric hospitals, or alcohol and drug
treatment units that report to the Admitted patient care
NMDS and do not provide treatment to non-admitted
patients.
Clients who are on a methadone maintenance program
may be included in the collection where they also receive
other types of treatment.
© Australian Institute of Health and Welfare 2015
Metadata and Classifications Unit 
Australian Institute of Health and Welfare
GPO Box 570
Canberra ACT 2601
All rights reserved. Please visit https://medical-data-
models.org/forms/16744
Alcohol and other drug treatment
services NMDS 2015- Metadata
Online Registry (METeOR)
Address
Australian postcode (address)*
Statistical area level 2 (SA2)*
Client
Injecting drug use status
Last injected three months ago or less
(1)
Last injected more than three months
ago but less than or equal to twelve
months ago (2)
Last injected more than twelve months
ago (3)
Never injected (4)
Not stated/inadequately described (9)
Method of use for principal drug of concern
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Ingests (1)
Smokes  (2)
Injects (3)
Sniffs (powder) (4)
Inhales (vapour) (5)
Other (6)
Not stated/inadequately described (9)
Episode of treatment for alcohol and other
drugs
Reason for cessation of treatment episode for
alcohol and other drugs*
Treatment completed (1)
Ceased to participate by mutual
agreement (10)
Drug court and /or sanctioned by court
diversion service (11)
Imprisoned, other than drug court
sanctioned (12)
Died (13)
Change in main treatment type (2)
Change in the delivery setting (3)
Change in the principal drug of concern
(4)
Transferred to another service provider
(5)
Ceased to participate against advice (6)
Ceased to participate without notice (7)
Ceased to participate involuntary (non-
compliance) (8)
Ceased to participate at expiation (9)
Other (98)
Not stated/inadequately described (99)
Client type (alcohol and other drug treatment
services)*
Own alcohol or other drug use  (1)
Other's alcohol or other drug use (2)
Other drug of concern
Principal drug of concern
Source of referral to alcohol and other drug
treatment service*
Self (01)
Family member/friend (02)
Medical practitioner (03)
Hospital (04)
Mental health care service (05)
Alcohol and other drug treatment service
(06)
Other community/health care service
(07)
Correctional service (08)
Police diversion (09)
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Court diversion (10)
Other (98)
Not stated/inadequately described (99)
Treatment delivery setting for alcohol and other
drugs*
Non-residential treatment facility (1)
Residential treatment facility (2)
Home (3)
Outreach setting (4)
Other (8)
Date of cessation of treatment episode for alcohol
and other drugs*
Date of commencement of treatment episode for
alcohol and other drugs*
Main treatment type for alcohol and other drugs*
Withdrawal management (detoxification)
(1)
Counselling (2)
Rehabilitation (3)
Pharmacotherapy (4)
Support and case management only (5)
Information and education only (6)
Assessment only (7)
Other (8)
Other treatment type for alcohol and other drugs*
Withdrawal management (detoxification)
(1)
Counselling (2)
Rehabilitation (3)
Pharmacotherapy (4)
Other (5)
Establishment
Establishment identifier*
Person
Country of birth*
Date of birth*
Indigenous status*
Aboriginal but not Torres Strait Islander
origin (1)
Torres Strait Islander but not Aboriginal
origin (2)
Both Aboriginal and Torres Strait Islander
origin (3)
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Neither Aboriginal nor Torres Strait
Islander origin (4)
Not stated/inadequately described (9)
Person identifier*
Preferred language*
Sex*
Male (1)
Female (2)
Intersex or indeterminate (3)
Not stated/inadequately described (9)
Usual accommodation type prior to service
episode*
Private residence (11)
Boarding house/private hotel (12)
Informal housing (13)
None/homeless/public place (14)
Domestic-scale supported living facility
(21)
Supported accommodation facility (22)
Short term crisis, emergency or
transitional accommodation facility (23)
Acute hospital (31.1)
Psychiatric hospital (31.2)
Rehabilitation hospital (31.3)
Other hospital (31.8)
Residential aged care facility (32.1)
Community care residential unit: Mental
health (33.1)
Community care residential unit: Alcohol
and other drugs (33.2)
Other specialised community residential
(33.8)
Prison/remand centre/youth training
centre (34)
Other (88)
Unknown (98)
Not stated/inadequately described (99)
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Alcohol and other drug treatment services NMDS 2015- Statistical
linkage key 581 cluster Metadata Online Registry (METeOR)
Health sector data set specifications from METeOR,
Australia's repository for national metadata standards,
developed by the Australian Institute of Health and Welfare
(http://meteor.aihw.gov.au/content/index.phtml/itemId/3451
65)
Statistical linkage key 581
Statistical data linkage refers to the bringing together of
data from different sources to gain a greater understanding
of a situation or individual from the combined (or linked)
dataset. This facilitates a better understanding of the
patterns of service use by groups of clients for research,
statistical or policy analysis, planning and evaluation
purposes.
Its form is: XXXXXDDMMYYYYN
The sequence in which the linkage key is completed is as
follows:
Family name (the first 3 Xs)
Given name (the 4th and 5th X)
Date of birth by day, month and four-digit year
Sex 
XXX 2nd, 3rd and 5th letters of the family name.
In the first three spaces the agency should record the 2nd,
3rd and 5th letters of the client’s family name.
For example: If the client’s family name is Smith the
reported value should be MIH. If the client’s family name is
Jones the reported value should be ONS.
Regardless of the length of a person’s name, the reported
value should always be three characters long. If the legal
family name is not long enough to supply the requested
letters (i.e. a legal family name of less than five letters) then
agencies should substitute the number ‘2’ to reflect the
missing letters. The placement of a number ‘2’ should
always correspond to the same space that the missing
letter would have within the 3-digit field. A number (rather
than a letter) is used for such a substitution in order to
clearly indicate that an appropriate corresponding letter
from the person’s name is not available.
Cases where the family name has less than 5 letters:
If a person’s family name is Farr, then value reported would
be AR2 because the 2 is substituting for a missing 5th letter
of the family name. Similarly, if the person’s family name
was Hua, then the value reported would be UA2 because
the 2 is substituting for the missing 5th letter of the family
name.
If a client’s family name is missing altogether the agency
should record the number 999 for all three spaces
associated with the family name, (not the number 2). In
some cultures it is traditional to state the family name first.
To overcome discrepancies in recording/reporting that may
arise as a result of this practice, agencies should always
ask the person to specify their legal first given name and
their legal family name separately. These should then be
recorded as first given name and family name as
appropriate, regardless of the order in which they may be
traditionally given.
If the client’s family name includes non-alphabetic
characters—for example hyphens (as in Lee-Archer),
apostrophes (as in O’Mara) or blank spaces (as in De
Vries)—these non-alphabetic characters should be ignored
when counting the position of each character.
XX 2nd and 3rd letters of given name
In the fourth and fifth spaces the agency should record the
2nd and 3rd letters of the client’s given name.
For example: If the client’s given name is Elizabeth the
reported value should be LI. If the client’s given name is
Robert the reported value should be OB.
If the client’s given name includes non-alphabetic
characters—for example hyphens (as in Jo-Anne) or
apostrophes (as in D'Arcy), these non-alphabetic
characters should be ignored when counting the position of
each character.
Regardless of the length of a person’s given name, the
reported value should always be two characters long. If the
given name of the person is not long enough to supply the
requested letters (i.e. a name of less than three letters)
then agencies should substitute the number ‘2’ to reflect the
missing letters. The placement of a number ‘2’ should
always correspond to the same space that the missing
letter would have within the 2-digit field. A number (rather
than a letter) is used for such substitutions in order to
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clearly indicate that an appropriate corresponding letter
from the person’s name is not available.
For example: If the person’s legal name was Jo then the
value reported would be O2 because the 2 is substituting
for the missing 3rd letter of the given name.
If the person’s given name is missing altogether the agency
should record 99 for the two spaces associated with the
given name. In some cultures it is traditional to state the
family name first. To overcome discrepancies in
recording/reporting that may arise as a result of this
practice, agencies should always ask the person to specify
their given name and their family name separately. These
should then be recorded as first given name and family
name as appropriate, regardless of the order in which they
may be traditionally given.
Date of Birth
DD represents the day in the month a person was born
MM represents the month in the year a person was born
YYYY represents the year a person was born
If date of birth is not known or cannot be obtained,
provision should be made to collect or estimate age.
Collected or estimated age would usually be in years for
adults and to the nearest three months (or less) for children
aged less than two years. Additionally, an estimated date
flag or a date accuracy indicator should be reported in
conjunction with all estimated dates of birth. 
For data collections concerned with children's services, it is
suggested that the estimated date of birth of children aged
under 2 years should be reported to the nearest 3 month
period, i.e. 0101, 0104, 0107, 0110 of the estimated year of
birth. For example, a child who is thought to be aged 18
months in October of one year would have his/her
estimated date of birth reported as 0104 of the previous
year. Again, an estimated date flag or date accuracy
indicator http://meteor.aihw.gov.au/content/index.phtml/
itemId/294429 should be reported in conjunction with all
estimated dates of birth.
Sex
N represents whether or not the person is a 1. Male or 2.
Female.
Operationally, sex is the distinction between male and
female, as reported by a person or as determined by an
interviewer. 
When collecting data on sex by personal interview, asking
the sex of the respondent is usually unnecessary and may
be inappropriate, or even offensive. It is usually a simple
matter to infer the sex of the respondent through
observation, or from other cues such as the relationship of
the person(s) accompanying the respondent, or first name.
The interviewer may ask whether persons not present at
the interview are male or female. 
A person's sex may change during their lifetime as a result
of procedures known alternatively as sex change, gender
reassignment, transsexual surgery, transgender
reassignment or sexual reassignment. Throughout this
process, which may be over a considerable period of time,
the person's sex could be recorded as either Male or
Female. 
In data collections that use the ICD-10-AM classification,
where sex change is the reason for admission, diagnoses
should include the appropriate ICD-10-AM code(s) that
clearly identify that the person is undergoing such a
process. This code(s) would also be applicable after the
person has completed such a process, if they have a
procedure involving an organ(s) specific to their previous
sex (e.g. where the patient has prostate or ovarian cancer).
Code 3     Intersex or indeterminate
Is normally used for babies for whom sex has not been
determined for whatever reason.
Should not generally be used on data collection forms
completed by the respondent. 
Should only be used if the person or respondent volunteers
that the person is intersex or where it otherwise becomes
clear during the collection process that the individual is
neither male nor female.
Code 9     Not stated/inadequately described
Is not to be used on primary collection forms. It is primarily
for use in administrative collections when transferring data
from data sets where the item has not been collected.
Data that has been produced by linkage for statistical and
research purposes should not be used subsequently for
client management purposes.
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Alcohol and other drug treatment services NMDS 2015- Statistical
linkage key 581 cluster Metadata Online Registry (METeOR)
This data cluster contains a set of specific data elements to
be reported on in a predetermined combination.
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Alcohol and other drug treatment
services NMDS 2015- Statistical
linkage key 581 cluster Metadata
Online Registry (METeOR)
Person
Letters of family name*
Letters of given name*
Date of birth*
Sex*
Male (1)
Female (2)
Intersex or indeterminate (3)
Not stated/inadequately described (9)
Record
Statistical linkage key 581
Date
Date accuracy indicator
Day, month and year are accurate (AAA)
Day and month are accurate, year is
estimated (AAE)
Day and month are accurate, year is
unknown (AAU)
Day is accurate, month is estimated,
year is accurate (AEA)
Day is accurate, month and year are
estimated (AEE)
Day is accurate, month is estimated,
year is unknown (AEU)
Day is accurate, month is unknown, year
is accurate (AUA)
Day is accurate, month is unknown, year
is estimated (AUE)
Day is accurate, month and year are
unknown (AUU)
Day is estimated, month and year are
accurate (EAA)
Day is estimated, month is accurate,
year is estimated (EAE)
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Day is estimated, month is accurate,
year is unknown (EAU)
Day and month are estimated, year is
accurate (EEA)
Day, month and year are estimated
(EEE)
Day and month are estimated, year is
unknown (EEU)
Day is estimated, month is unknown,
year is accurate (EUA)
Day is estimated, month is unknown,
year is estimated (EUE)
Day is estimated, month and year are
unknown (EUU)
Day is unknown, month and year are
accurate (UAA)
Day is unknown, month is accurate, year
is estimated (UAE)
Day is unknown, month is accurate, year
is unknown (UAU)
Day is unknown, month is estimated,
year is accurate (UEA)
Day is unknown, month and year are
estimated (UEE)
Day is unknown, month is estimated,
year is unknown (UEU)
Day and month are unknown, year is
accurate (UUA)
Day and month are unknown, year is
estimated (UUE)
Day, month and year are unknown (UUU)
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Eligibility Carcinoma, Non-Small-Cell Lung
NCT00622349
Randomised Study Comparing Three Chemotherapy
Regimens in Non-small Cell Lung Cancer; ODM derived
from: https://clinicaltrials.gov/show/NCT00622349
All rights reserved. Please visit https://medical-data-
models.org/forms/16746
Eligibility Carcinoma, Non-Small-Cell
Lung NCT00622349
Inclusion Criteria
histological or cytological diagnosis of non-small
cell lung cancer*
Yes
No
advanced (unresectable or functionally
inoperable) stage iii or stage iv disease*
Yes
No
availability for participating in the detailed follow-
up of the protocol*
Yes
No
presence of an evaluable or measurable lesion*
Yes
No
informed consent*
Yes
No
Exclusion Criteria
prior treatment with chemotherapy*
Yes
No
operable patient with resectable tumor*
Yes
No
performance status < 60 on the karnofsky scale*
Yes
No
a history of prior malignant tumour, except non-
melanoma skin cancer or in situ carcinoma of the
cervix and cured malignant tumour (more than 5-
year disease free interval)*
Yes
No
polynuclear cells < 2,000/mm³*
Yes
No
platelet cells < 100,000/mm³*
Yes
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No
serum bilirubin  >1.5 mg/100 ml*
Yes
No
serum creatinine > 1.5 mg/100 ml and/or
creatinine clearance < 60 ml/min*
Yes
No
perception hypoacusis*
Yes
No
peripheral neuropathy*
Yes
No
recent myocardial infarction (less than 3 months
prior to date of diagnosis)*
Yes
No
congestive cardiac failure requiring medical
therapy or uncontrolled cardiac arrhythmia*
Yes
No
uncontrolled infectious disease*
Yes
No
serious medical or psychological factors which
may prevent adherence to the treatment
schedule*
Yes
No
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Eligibility Cardiovascular Disease
NCT00277875
STRETCH Study: Effect of Distensibility on Endothelial-
Dependent Vasoreactivity in Patients With ISH; ODM
derived from: https://clinicaltrials.gov/show/NCT00277875
All rights reserved. Please visit https://medical-data-
models.org/forms/16747
Eligibility Cardiovascular Disease
NCT00277875
Inclusion Criteria
1. male or female 50 years of age or greater.*
Yes
No
2. diagnosed with systolic hypertension (systolic
blood pressure >140 mm hg and (less than or
equal to) 200 mm hg, and a diastolic blood
pressure (less than or equal to) 95 mm hg) and
elevated pulse pressure (systolic blood pressure
[sbp] minus diastolic blood pressure [dbp] greater
than 60 mm hg).*
Yes
No
3. normal left ventricular function (ejection
fraction >55%) at baseline (visit 3).*
Yes
No
4. able to perform bicycle exercise.*
Yes
No
5. able to read, understand and sign the informed
consent after the nature of the study has been
explained.*
Yes
No
6. if sexually active, the patient agrees to use
reliable contraception while participating in this
study.  if a woman, is surgically sterilized or post-
menopausal, or has a negative serum pregnancy
test.*
Yes
No
Exclusion Criteria
1. aortic stenosis, prior known coronary artery
disease (including myocardial infarction),
cerebrovascular accident, or peripheral vascular
disease.*
Yes
No
2. uncontrolled hypertension (sbp > 200/ dbp >
95 mm hg).*
Yes
No
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3. atrial fibrillation, diabetes mellitus treated with
insulin, or chronic lung disease.*
Yes
No
4. any additional condition(s) which, in the
opinion of the investigator, would prohibit the
patient from completing the study, or not be in the
best interest of the patient.*
Yes
No
5. treatment with nitrates, or a change in
antihypertensive medications within the last 1
month.*
Yes
No
6. treatment with any investigational drug within 1
month prior to study drug administration.*
Yes
No
7. previous exposure to alagebrium.*
Yes
No
8. ast (sgot) or alt (sgpt) > 2x normal limit.*
Yes
No
9. serum creatinine > 2.0 ng/ml.*
Yes
No
10. cigar/cigarette smoking.*
Yes
No
11. necessity to use smokeless tobacco or
nicotine-containing products, or to consume
caffeine, alcohol, or antioxidants starting at
midnight prior to study clinic visits. note: water is
allowed ad libitim.*
Yes
No
12. positive drug screen.*
Yes
No
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Functioning and Disability DSS Metadata
Online Registry (METeOR)
Health sector data set specifications from METeOR,
Australia's repository for national metadata standards,
developed by the Australian Institute of Health and Welfare
(http://meteor.aihw.gov.au/content/index.phtml/itemId/3451
65)
Functioning and Disability DSS
The Functioning and Disability DSS aims to ensure national
consistency in relation to defining and measuring human
functioning and disability. This DSS has been developed to
be consistent with the International Classification of
Functioning, Disability and Health (ICF).
Functioning and disability are dual concepts in a broad
framework.
Functioning is the umbrella term for any or all of: body
functions, body structures, activities and participation.
Functioning is a multidimensional concept denoting the
neutral aspects of the interaction between an individual
(with a health condition) and that individual's environmental
and personal factors. 
Disability is the umbrella term for any or all of: an
impairment of body structure or function, a limitation in
activities, or a restriction in participation. Disability is a
multi-dimensional and complex concept and is conceived
as a dynamic interaction between health conditions and
environmental and personal factors (WHO 2001:6). 
A health condition may be a disease (acute or chronic),
disorder, injury or trauma. Environmental factors make up
the physical, social and attitudinal environment in which
people live and conduct their lives. Personal factors relate
to the individual, such as age, sex and Indigenous status.
The components of functioning and disability are classified
and defined in the ICF as body structures and body
functions, activities and participation and environmental
factors. Each component is composed of various domains;
these are sets of related physiological functions, anatomical
structures, actions, tasks, areas of life, and external
influences. Qualifiers, the numeric measures coded after
the relevant domain, are usually essential to the meaningful
use of the classification because of the neutral terms of the
domains. 
Many different 'definitions' of disability are used in Australia,
both in administrative data collections and in Acts of
Parliament. The consistent identification of disability in
national data collections has been recommended in a
number of reports, for instance to enable:
•	the monitoring of access to generic services by people
with disability; 
•	the collection of more consistent data on disability support
and related services, including data on service use by
different groups; 
•	population data and service data to be related, thereby
improving the nation's analytical capacity in relation to the
need for and supply of services; and  
•	improved understanding of the relationship between
disability, health conditions and other health outcomes. 
Defining disability makes it possible to determine the
number of people in the population with disability, those
who are accessing services, both disability specific and
generic, and those with a disability in the general
population with unmet need. Better definition of disability
will aid better targeting of resources to those in need.
The concept 'Disability' can be operationalised in a wide
variety of settings and for various purposes, using a
combination of related metadata items as building blocks. 
The metadata items selected for a particular application
may vary depending on the approach to functioning and
disability. For example, in hospital rehabilitation, the focus
may be on the impairment and activity dimensions, and in
community-based care the focus may be primarily on
participation. Some applications may require a broad scope
for inclusion (e.g. discrimination legislation). Data
collections relating to services will select combinations of
the data elements, which best reflect the eligibility criteria
for the service.
The Functioning and Disability DSS comprises the following
four clusters to describe level of human functioning:
1.	Body functioning, qualified by extent of impairment 
2.	Body structure, qualified by extent, nature and location of
impairment 
3.	Activities and participation, qualified by level of difficulty
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and need for assistance with undertaking activities and
extent of and satisfaction with participation 
4.	Environmental factors, qualified by extent of influence of
the environment
Data collected using this DSS can be related to national
data collections which use ICF concepts such as the
Commonwealth State Territory Disability Agreement
(CSTDA) NMDS collection and the ABS Survey of Ageing,
Disability and Carers and, from 2006, the Census.
© Australian Institute of Health and Welfare 2015
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Functioning and Disability DSS
Metadata Online Registry (METeOR)
Activities and Participation cluster
Activity and participation life area
Extent of participation
Full participation (0)
Mild participation restriction (1)
Moderate participation restriction (2)
Severe participation restriction (3)
Complete participation restriction (4)
Not specified (8)
Not applicable (9)
Difficulty with activities
No difficulty (0)
Mild difficulty (1)
Moderate difficulty (2)
Severe difficulty (3)
Complete difficulty (4)
Not specified (8)
Not applicable (9)
Satisfaction with participation
High satisfaction with participation (0)
Moderate satisfaction with participation
(1)
Neither satisfied nor dissatisfied with
participation (2)
Moderate dissatisfaction with
participation (3)
Extreme dissatisfaction with participation
(4)
Complete restriction and dissatisfaction
(5)
Not specified (8)
Not applicable (9)
Assistance with activities
Does not need help/supervision (0)
Sometimes needs help/supervision (1)
Always needs help/supervision (2)
Unable to do this task or action, even
2 / 4
Functioning and Disability DSS Metadata Online Registry (METeOR)
with assistance (3)
Not specified (8)
Not applicable (9)
Body functions cluster
Body function*
Impairment of body function*
No impairment (0)
Mild impairment (1)
Moderate impairment (2)
Severe impairment (3)
Complete impairment (4)
Not specified (8)
Not applicable (9)
Body structures cluster
Body structure*
Impairment of body structure*
No impairment (0)
Mild impairment (1)
Moderate impairment (2)
Severe impairment (3)
Complete impairment (4)
Not specified (8)
Not applicable (9)
Location of impairment
More than one region (0)
Right (1)
Left (2)
Both sides (3)
Front (4)
Back (5)
Proximal (6)
Distal (7)
Not specified (8)
Not applicable (9)
Change to body structure
No change in structure (0)
Total absence (1)
Partial absence (2)
Additional part (3)
Aberrant dimensions (4)
Discontinuity (5)
Deviating position (6)
Qualitative changes in structure (7)
Not specified (8)
Not applicable (9)
Environmental factors cluster
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Environmental factor*
Influence of environmental factor*
No facilitator (+0)
Mild facilitator (+1)
Moderate facilitator (+2)
Substantial facilitator (+3)
Complete facilitator (+4)
Facilitator not specified (+8)
No barrier (0)
Mild barrier (1)
Moderate barrier (2)
Severe barrier (3)
Complete barrier (4)
Barrier not specified (8)
Not applicable (9)
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Eligibility Cardiovascular Disease
NCT01163773
Milk Consumption and the Metabolic Syndrome in
Menopausal Women; ODM derived from:
https://clinicaltrials.gov/show/NCT01163773
All rights reserved. Please visit https://medical-data-
models.org/forms/16749
Eligibility Cardiovascular Disease
NCT01163773
Inclusion Criteria
menopausal women (absence of menses > 12
months and fsh > 40 iu/ml), aged  between 45
and 65 years*
Yes
No
presenting 1 or more features of the mets based
on the ncep-atp iii definition*
Yes
No
average consumption of milk/dairy products fewer
than 2 portions/d (≤ 1.9)*
Yes
No
stable body weight (+/- 2 kg) for 6 months before
the beginning of the study*
Yes
No
Exclusion Criteria
previous history of cardiovascular disease, type 2
diabetes and monogenic dyslipidemia*
Yes
No
subjects taking medications for hyperlipidemia,
hypertension or hormonal replacement therapy*
Yes
No
endocrine disorders*
Yes
No
smoking*
Yes
No
food allergies, milk aversion or intolerant to
lactose*
Yes
No
women with extreme nutritional habits such as
vegetarism or alcohol consumption > 2
drinks/day*
Yes
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Eligibility Chronic Heart Failure
NCT01794598
Preliminary Study Examining Heart Failure Patients
Responses to Depression Education; ODM derived from:
https://clinicaltrials.gov/show/NCT01794598
All rights reserved. Please visit https://medical-data-
models.org/forms/16750
Eligibility Chronic Heart Failure
NCT01794598
Inclusion Criteria
Inclusion Criteria
lvef ≤ 35%.*
Yes
No
nyha class ii, iii, or iv heart failure for the previous
three months despite a minimum of 6 weeks of
treatment.*
Yes
No
must be on optimal heart failure therapy
according to aha/acc and hfsa heart failure
guidelines, including treatment with acei and
beta-blocker therapy, or have documented
rationale for variation, including intolerance,
contraindication, patient preference, or personal
physician's judgment.*
Yes
No
Exclusion Criteria
age less than 18.*
Yes
No
currently pregnant or intending to become
pregnant in the next year.*
Yes
No
cardiovascular procedure or hospitalization for
any reason planned in the next 6 months.*
Yes
No
expectation of receiving a cardiac transplant in
the next six months.*
Yes
No
unable to provide the study consent.*
Yes
No
participation another clinical trial(s) that may
interfere with follow-up or data collection for this
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study, or that may affect cardiovascular mortality.*
Yes
No
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Eligibility Chronic Hepatitis B
NCT00895596
Safety and Efficacy Study of LB80380 in the Patients With
Lamivudine-Refractory Chronic Hepatitis B; ODM derived
from: https://clinicaltrials.gov/show/NCT00895596
All rights reserved. Please visit https://medical-data-
models.org/forms/16751
Eligibility Chronic Hepatitis B
NCT00895596
Inclusion Criteria
compensated chronic hepatitis b patient*
Yes
No
presence of serum hbsag for more than 6
months.*
Yes
No
presence of hbeag for more than 1 month with
compensated liver disease*
Yes
No
confirmation of ymdd mutants (m552v, m552i and
its related double mutant at l528m) by genotyping
of the ymdd motif using line probe assay (inno-
lipa hbv dr assay)*
Yes
No
screening hbv dna value higher than or equal to
1,000,000 copies/ml (measured by the cobas
amplicor hbv monitor™ assay)*
Yes
No
screening alt value between 1.5 and 10 x uln*
Yes
No
Exclusion Criteria
co-infection with hepatitis c or d virus (hcv or hdv)
or hiv*
Yes
No
pregnancy or breast-feeding*
Yes
No
previous treatment with nucleoside analogue or
any other treatment for hbv except for lamivudine
within 6 months prior to study entry*
Yes
No
treatment with immunomodulatory agent or
corticosteroids within 6 months prior to study
entry.*
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Yes
No
de-compensated liver disease*
Yes
No
screening alpha-fetoprotein (afp) value > 20
ng/ml, and a follow-up ultrasonography performed
prior to baseline shows findings indicative of hcc.*
Yes
No
presence of anti-hbs at screening*
Yes
No
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Eligibility Chronic Hepatitis C
NCT00160251
Boceprevir (SCH 503034) Plus Peg-Intron, With and
Without Added Ribavirin, in Patients With Chronic Hepatitis
C, Genotype 1, Who Did Not Respond to Previous
Treatment With Peginterferon Alfa Plus Ribavirin (Study
P03659AM2)(COMPLETED); ODM derived from:
https://clinicaltrials.gov/show/NCT00160251
All rights reserved. Please visit https://medical-data-
models.org/forms/16752
Eligibility Chronic Hepatitis C
NCT00160251
Criteria
documented infection with chronic hepatitis c
(chc), genotype 1.*
Yes
No
documented failure to respond to an adequate
course of treatment (minimum 12 weeks) with
peginterferon-alfa plus ribavirin (failure defined as
<2 log drop in hcv-rna after 12 weeks of therapy
or those who never become hepatitis c virus
ribonucleic acid (hcv)-rna negative)*
Yes
No
no evidence of cirrhosis on liver biopsy.*
Yes
No
results of physical examination and laboratory
tests within specified ranges.*
Yes
No
abstinence from use of abused substances.*
Yes
No
key exclusion criteria:*
Yes
No
women who are pregnant or nursing a child.*
Yes
No
patients with cirrhosis, co-infection with hepatitis
b or human immunodeficiency virus (hiv), and
african-american patients (by protocol
amendment 2, african-american patients can
enroll).*
Yes
No
previous treatment with any hepatitis c virus (hcv)
polymerase or protease inhibitor.*
Yes
No
patients who relapsed following response to
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previous treatment.*
Yes
No
evidence of advanced liver disease, or liver
disease from a cause other than chc.*
Yes
No
pre-existing psychiatric condition.*
Yes
No
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Eligibility Colorectal Cancer NCT00062023
Comparison of Sulindac, Aspirin, and Ursodiol in
Preventing Colorectal Cancer; ODM derived from:
https://clinicaltrials.gov/show/NCT00062023
All rights reserved. Please visit https://medical-data-
models.org/forms/16753
Eligibility Colorectal Cancer
NCT00062023
Inclusion Criteria
1. male or female subjects, age 40-80 years*
Yes
No
2. with >5 colorectal acf and a prior history of
colorectal cancer defined as dukes a/b1
carcinoma within 5 years of entry or any stage of
colorectal cancer if at least 5 years post surgical
resection (86 subjects)*
Yes
No
3. with >5 colorectal acf and recent/current
history of colorectal adenoma(s) defined as one
of the following: one adenomatous polyp >1cm or
two or more adenomatous polyps of any size or
one adenomatous polyp of any size and a
documented history of adenomatous polyp(s) (86
subjects)*
Yes
No
4. no elevated risk of colorectal cancer or
adenomas (20 subjects)*
Yes
No
5. subjects will be permitted to use nasonex but
all other nasal steroids are prohibited. subjects
may change to nasonex but must have
discontinued previous nasal steroid use for at
least 30 days prior to study randomization.*
Yes
No
6. if participant is female and of childbearing
potential, she must agree to use adequate
contraception and must have a negative serum
pregnancy test within 14 days prior to study drug
administration*
Yes
No
7. no use of investigational agent(s) within the
last 3 months or at the discretion of the medical
monitor*
Yes
No
8. the subject will be allowed to proceed to
randomization so long as all of the following
laboratory criteria are met on baseline evaluation:
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hgb > 10.0 g/dl, platelet count > 100,000/ul; wbc
> 3,000/ul; alt < 2 x upper limit of normal; ast < 2
x upper limit of normal, and total bilirubin
<1.5mg/100ml.*
Yes
No
9. patients requiring use of hormone modulators
such as tamoxifen or arimidex will be permitted to
enroll providing they meet all of the eligibility
criteria noted above*
Yes
No
Exclusion Criteria
1. known diagnosis of fap, hereditary non-
polyposis colon cancer (hnpcc), or inflammatory
bowel disease*
Yes
No
2. history of hypersensitivity to cox-2 inhibitors,
sulfonamides, nsaids , salicylates, or
ursodeoxycholic acid*
Yes
No
3. use of nsaids, including aspirin, at any dose
during the six months prior to study entry will
require a three month washout period prior to
eligibility beginning with the time of the last dose.
participants must be off all nsaids for three
months prior to study entry. individuals on
cardioprotectant aspirin at any dose will not be
eligible.*
Yes
No
4. history of gastroduodenal ulcers documented
endoscopically would preclude a patient from
participation in the trial*
Yes
No
5. known inability to participate in the scheduled
follow-up tests.*
Yes
No
6. significant medical or psychiatric problems
which would make the patient a poor protocol
candidate, in the opinion of the principal
investigator.*
Yes
No
7. "unacceptable clinical risk" to proceed (based
upon the subclinical discoveries made via
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baseline colonoscopy and biopsies).*
Yes
No
8. patient has undergone a total colectomy*
Yes
No
9. patient has received chemotherapy within the
past 6 months of randomization into study. topical
chemotherapy will be assessed on a case-by-
case basis. any history of pelvic or rectal
radiation therapy will exclude a patient from
participating.*
Yes
No
10. history of invasive carcinoma in the past five
years (except patients with dukes a/b1 carcinoma
within 5 years of entry or any stage of colorectal
cancer if at least 5 years post surgical resection)*
Yes
No
11. patients with rectal cancer are excluded
except for transanal excision without radiation.*
Yes
No
12. patients with acute liver disease, unexplained
transaminase elevations or a history of renal
stones would be excluded.*
Yes
No
13. participants will not be permitted to be
randomized into the trial if any of the following
laboratory values are reported at baseline : hgb <
10.0 g/dl, platelet count <100,000/ul; wbc <
3,000/ul; alt > 2 x upper limit of normal; ast > 2 x
upper limit of normal, and total bilirubin
>1.5mg/100ml.*
Yes
No
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Eligibility Colorectal Cancer NCT00079872
Pemetrexed Plus a Comparator Versus a Combination of 2
Comparators in First-Line Treatment of Colorectal Cancer;
ODM derived from:
https://clinicaltrials.gov/show/NCT00079872
All rights reserved. Please visit https://medical-data-
models.org/forms/16754
Eligibility Colorectal Cancer
NCT00079872
Inclusion Criteria
the patient must have:*
Yes
No
histologic or cytologic diagnosis of
adenocarcinoma of the colon or rectum.*
Yes
No
performance status of 0 to 2 on the ecog
performance status scale.*
Yes
No
standard postoperative adjuvant radiation therapy
for rectal cancer is allowed.*
Yes
No
locally advanced or metastatic disease.*
Yes
No
must be 18 years of age.*
Yes
No
Exclusion Criteria
the patient must not have:*
Yes
No
received prior chemotherapy for advanced
disease. prior adjuvant therapy, including 5-fu, is
allowed if it has been more than 12 months since
the last treatment.*
Yes
No
received prior treatment with irinotecan in the
adjuvant setting.*
Yes
No
are unable to take vitamin b12 or folic acid.*
Yes
No
are unable to interrupt aspirin, other nonsteroidal
1 / 2
anti-inflammatory drugs, or cox-2 inhibitors for a
5-day period.*
Yes
No
have a second primary malignancy except
carcinoma in situ of the cervix or
nonmelanomatous skin cancer, unless that prior
malignancy was diagnosed and definitively
treated at least 5 years previously with no
subsequent evidence of recurrence.*
Yes
No
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derived from http://www.arztbriefmanager.de/ (Dr. Wolfram
Arends, Tutzing, Germany)
All rights reserved. Please visit https://medical-data-
models.org/forms/16755
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Anamnese
Vorgeschichte setzen wir voraus
Ja
Nein
Vorgeschichte entnehmen Sie den Unterlagen
Ja
Nein
Stat. Aufnahme Reha bei Herzneurose Burnout
Ja
Nein
Aortenstenose seit einigen Jahren, OP vor 4
Wochen
Ja
Nein
Aortenstenose, Beschwerden erst seit Monaten,
OP vor 4 Wochen
Ja
Nein
Akutes Koronarsyndrom ACS . .m i t . . S T E N T
Ja
Nein
Akutes Koronarsyndrom ACS . .kein . . S T E N T
Ja
Nein
Vegetative Anamnese
Appetit gut .
Ja
Nein
Appetit vermindert
Ja
Nein
Schlaf gut . .
Ja
Nein
Einschlafstörungen
Ja
Nein
Miktion: unauffällig, keine Nykturie. .
Ja
Nein
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Miktion: gelegentlich Nykturie.t
Ja
Nein
Miktion: Dysurie .
Ja
Nein
Keine Allergie bekannt.
Ja
Nein
Allergie
Ja
Nein
Art der Allergie
Schwitzen, Obstipation, Durchfällen,
Wasserlassen ca. alle 1 ½ Stunden.
Ja
Nein
Stuhlgang: kein Teerstuhl.
Ja
Nein
Risikofaktoren und Risikoverhalten
Arterielle Hypertonie
Ja
Nein
Bekannt und medikamentös behandelt
Ja
Nein
Arterielle Hypertonie seit ca. 6-12 Monaten
Ja
Nein
Früher fraglich arterielle Hypertonie, Medikation
seit xxx.
Ja
Nein
Wie lange werden die Antihypertensiva
eingenommen?
Kein Nikotinkonsum.
Ja
Nein
Seit über XX Jahren Nikotinkarenz
Seit wann raucht die Pat. nicht mehr?
2 / 37
Rehabilitation letter cardiology
Nikotinkonsum bis zur stat. Aufnahme
Ja
Nein
Keine erhöhten Cholesterinwerte
Ja
Nein
Intermittierend etwas erhöhte Cholesterinwerte
Ja
Nein
Erhöhte Cholesterinwerte seit ca. XX Jahren
bekannt und medikamentös behandelt.
Erhöhte Cholesterinwerte, seit Ereignis
Medikation.
Ja
Nein
Kein Diabetes mellitus.
Ja
Nein
Aktuell grenzwertig erhöhte BZ-Werte.
Ja
Nein
Diabetes Mellitus.
Ja
Nein
kein Alkoholabusus.
Ja
Nein
Gelegentlich ein Glas Wein/Bier.
Ja
Nein
Psychosoziale Belastungen.
Ja
Nein
Keine vermehrten psychosozialen Belastungen.
Ja
Nein
Wenig Sport
Ja
Nein
Regelmäßige körperliche Aktivität
Ja
Nein
Gelegentlich körperliche Bewegung
Ja
Nein
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Sehr viel körperliche Bewegung
Ja
Nein
Koronarsportgruppe
Ja
Nein
Familienanamnese
Wie alt war die Mutter bei ihrem Tod?
Todesursache der Mutter
Wie alt war der Vater bei seinem Tod?
Todesursache des Vaters
Keine Familienanamnese für kardiovaskuläre
Erkrankungen.
Ja
Nein
Jetzige Beschwerden
Normal belastbar.
Ja
Nein
Postoperativ schnelle Erschöpfung.
Ja
Nein
Zurückhaltend in Belastung
Ja
Nein
Die Pat. fühlt sich in der Belastbarkeit deutlich
eingeschränkt
Ja
Nein
Schneller erschöpft
Ja
Nein
Abends sehr müde.
Ja
Nein
Schnellere Erschöpfung und Müdigkeit
Ja
Nein
Muskuläre Schwäche
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Ja
Nein
Treppensteigen problemlos möglich.
Ja
Nein
Wieviele Treppenstufen können bewältigt
werden?
Kurz vor Aufnahme konnte die Pat. drei
Treppenetagen bewältigen
Ja
Nein
Treppensteigen von X Stufen mit wenig Dyspnoe.
Treppensteigen langsam möglich
Ja
Nein
Mobilität eingeschränkt
Ja
Nein
Wieviele Stufen konnten postoperativ bewältigt
werden?
Langsames Steigen von 1-2 Etagen
Ja
Nein
Treppensteigen mit Hilfe möglich Keine Dyspnoe
Ja
Nein
10-15 Minuten langsames spazieren gehen in der
Ebene möglich.
Ja
Nein
„Gemütliches“ spazieren gehen in der Ebene
möglich
Ja
Nein
10-15 Minuten langsames spazieren gehen in der
Ebene möglich.
Ja
Nein
Wieviele Minuten gemütliches Spazierengehen
sind möglich?
Unsicher auf den Beinen
Ja
Nein
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Wenige Meter mit dem Rollator
Ja
Nein
Postop. Taubheitsgefühl
Ja
Nein
Kein Wundschmerz.
Ja
Nein
Leichte Wundschmerzen
Ja
Nein
Wundschmerz bei Husten
Ja
Nein
Seit der Intervention keine Angina pectoris
Ja
Nein
Keine Angina pectoris.
Ja
Nein
Keine Orthopnoe.
Ja
Nein
keine Ruhedyspnoe.
Ja
Nein
Angina pectoris.
Ja
Nein
Orthopnoe
Ja
Nein
Ruhedyspnoe.
Ja
Nein
Subjektive Einschränkungen in Alltag und
Beruf
Nicht so belastbar
Ja
Nein
In der Beweglichkeit eingeschränkt
Ja
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Nein
Zusätzliche Beschwerden
Ja
Nein
Eingeschränkte Leistungsfähigkeit
Ja
Nein
Die Pat. fühlt sich in der Belastbarkeit deutlich
eingeschränkt
Ja
Nein
ausgeprägte Müdigkeit
Ja
Nein
Krankheitsverständnis und Verarbeitung
Über Erkrankungen und Risikofaktoren informiert
Ja
Nein
Das Ereignis kam für die Pat. sehr überraschend
Ja
Nein
Die Pat. ist verunsichert, inwieweit sie sich
belasten kann und darf
Ja
Nein
Unsicherheit bezüglich der weiteren Zukunft
Ja
Nein
Deutliches Informationsdefizit
Ja
Nein
Therapie bei Aufnahme
Therapie
Sozialanamnese
Beruf:
Ausbildung als:
Angestellt in
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Nebentätigkeit
Ja
Nein
Art der Nebentätigkeit
Erwerbstätig in Vollzeit
Ja
Nein
Erwerbstätig: Wo und als was?
Rentner seit wann?
Die Pat. fühlt sich sehr isoliert am Arbeitsplatz.
Ja
Nein
AU seit
keine psychosozialen Belastungsfaktoren
Ja
Nein
Verwitwet.
Ja
Nein
Verheiratet.
Ja
Nein
Erwachsene Kinder.
Ja
Nein
Anzahl erwachsene Kinder.
Enkelkinder.
Ja
Nein
Anzahl Enkelkinder.
Anzahl Kinder und Alter der Kinder
Eigenes Haus.
Ja
Nein
Eigentumswohnung
Ja
Nein
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Angehörige wohnen in wieviel km Umkreis?
Angehörigen wohnen im gleichen Haus
Ja
Nein
Angehöriger wohnt zeitweise bei Pat.
Ja
Nein
Selbstversorgung.
Ja
Nein
Altersrentner.
Ja
Nein
Komplette Selbstversorgung.
Ja
Nein
Häusliche Versorgung gewährleistet
Ja
Nein
Ambulanter Pflegedienst.
Ja
Nein
Unterstützung durch Angehörigen.
Ja
Nein
Beengte finanzielle Verhältnisse.
Ja
Nein
Beruflicher Werdegang, Arbeitsanamnese
Schulabschluss
Ja
Nein
Art des Schulabschluss:
Art der Ausbildung
Schulart, Abgangsklasse, Art der Berufstätigkeit
Beruf:
Tägliche Arbeitszeit XX Stunden und mehr
Ja
Nein
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Tägliche Arbeitszeit in Stunden
Altersteilzeit
Ja
Nein
In Vollzeit angestellt
Ja
Nein
Wo,als was und seit wann angestellt?
Normalschicht
Ja
Nein
Arbeitshaltung je zu 1/3 stehend, gehend,
sitzend.
Ja
Nein
Gemischt stehende, gehend und sitzende
Tätigkeit
Ja
Nein
Gelegentlich Außendienst
Ja
Nein
Leichte körperliche Tätigkeit
Ja
Nein
Mittelschwere körperliche Tätigkeit.
Ja
Nein
Seit Monaten viel Stress
Ja
Nein
Stressbelastung und Verantwortung.
Ja
Nein
Hohe Konzentration, Verantwortung und
Stressbelastung
Ja
Nein
Viel Stress
Ja
Nein
Rationalisierungsmaßnahmen
Ja
Nein
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Die Pat. ist mit Arbeit zufrieden
Ja
Nein
Bisher kein Reha Verfahren.
Ja
Nein
Kein GdB'
Ja
Nein
Antrag auf GdB beabsichtigt.
Ja
Nein
AU Zeiten
Arbeitsunfähig
Ja
Nein
Arbeitsunfähig seit dem Ereignis
Ja
Nein
Arbeitsunfähig seit wann?
Derzeitiger AU - Beginn am
Dauer der Arbeitsunfähigkeit
Klinische Untersuchung
Standardbefund
Ja
Nein
Sternum stabil, Narbe reizlos.
Ja
Nein
Narben reizlos.
Ja
Nein
Unterschenkelödem nach Venenentnahme.
Ja
Nein
Nahtmaterial an Drainage-Ausleitungsstellen
noch liegend.
Ja
Nein
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Nahtmaterial am Lokalbefund noch liegend.
Ja
Nein
Fähigkeits und Aktivitätseinschränkung
Eingeschränkte körperliche Belastbarkeit
Ja
Nein
Postoperativ Einschränkung der
Leistungsfähigkeit
Ja
Nein
Psychosomatische Diagnostik
Unauffälliges Ergebnis.
Ja
Nein
HADS-Score
Angst und Depressivität deutlich erhöht
Ja
Nein
Angst und Depressivität Punktzahl insgesamt
gesehen
Diagnostik Labor
Bei der routinemäßigen Laboruntersuchung
lagen die meisten Werte im Normbereich.
Ja
Nein
Die übrigen Laborparameter lagen im
Normbereich.
Ja
Nein
Standardbefund
Ja
Nein
Diagnostik EKG
Sinusrhythmus,
Ja
Nein
Vorhofflimmern,
Ja
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Nein
Lagetyp
PQ XXx s
Langsame R-Progression bis Vx
Zögerliche R-Progression bis
Q in X
Sonst Zeiten in der Norm
Ja
Nein
R/S-Umschlag in Vx.
Sokolow-Index X,X mV
U-Welle in X
Leichte ST-Senkung in xx
Angedeutet negatives T in xx
Präterminal negatives T in X
Sonst unauffälliger Stromkurvenverlauf.
Ja
Nein
Diagnostik Ergometrie bei Aufnahme
Standardbefund
Ja
Nein
Stufenweise Belastung bis X
SV-Tachykardie
Ja
Nein
Anzahl VES
bereits in Ruhe ST-Senkung
Ja
Nein
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Sprunghafter HF-Anstieg
Ja
Nein
durchgehend Sinusrhythmus,
Ja
Nein
Keine höhergradige Rhythmusstörung.
Ja
Nein
Keine AP,
Ja
Nein
Keine signifikante ST-Veränderung,
Ja
Nein
Keine höhergradige Rhythmusstörung.
Ja
Nein
keine wesentlichen Auffälligkeiten im Blutdruck-
und Pulsverhalten
Ja
Nein
Keine ST-Strecken-Veränderungen
Ja
Nein
Stufenweise Belastung
Ja
Nein
Stufenweise Belastung bis X Minute XX Sek. bei
XX Watt
Beendigung wegen subjektiver Erschöpfung.
Ja
Nein
Beendigung wegen Beinermüdung
Ja
Nein
Beendigung wegen muskulärer Erschöpfung
Ja
Nein
Abbruch wegen allgemeiner Erschöpfung und
Schweißausbruch
Ja
Nein
HF-Anstieg von XX auf XX/min,
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RR-Anstieg von XX auf XX mmHg.
RR-Anstieg von XX/XX auf XXX/XX mmHg.
Diagnostik LZ EKG
Relevante Medikation:
Durchgehend Sinusrhythmus,
Ja
Nein
Herzfrequenz maximal xxx/min und minimal
xx/min.
Durchschnittliche HF xx/min,
bpm
Herzfrequenz minimal und maximal
Herzfrequenz im Mittel XX/min.
bpm
VES.
Ja
Nein
Anzahl VES.
Couplets
Ja
Nein
Anzahl Couplets
vereinzelt SVES.
Ja
Nein
Anzahl SVES.
Isolierte supraventrikuläre Extrasystolen.
Ja
Nein
Vereinzelt isolierte SVES.
Ja
Nein
Anzahl isolierte VES.
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Keine Pausen >2,5 Sek
Ja
Nein
Keine höhergradige Rhythmusstörung,
Ja
Nein
Isolierte ventrikuläre Extrasystolen,
Ja
Nein
Keine höhergradigen ventrikulären
Herzrhythmusstörungen,
Ja
Nein
Keine höhergradigen AV-Blockierungen.
Ja
Nein
Diagnostik LZ Blutdruckmessung
Langzeit-Blutdruckmessung Überschrift
Standardbefund
Deutlich erhöhte Werte
Ja
Nein
Systolische Werte teilweise zu stark erhöht.
Ja
Nein
Nachtabsenkung findet statt, ist jedoch nicht
optimal.
Ja
Nein
Diagnostik Herz Echo UKG
Echokardiographie
Linker Vorhof XX mm.
Leichte linksventrikuläre Wandverdickung
Ja
Nein
Normal großer linker Ventrikel
Ja
Nein
Normal großer linker Ventrikel mit normaler
systolischer Funktion
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Ja
Nein
Normale systolische Funktion,
Ja
Nein
Keine regionale Wandbewegungsstörung
Ja
Nein
Systolischer Pulmonalarteriendruck
Normale systolische LV-Funktion
Ja
Nein
Septumhypokinesie.
Ja
Nein
Hypokinesie
Ja
Nein
Diskrete Septumhypokinesie.
Ja
Nein
Keine regionale Wandbewegungsstörung.
Ja
Nein
PGmax XX mmHg.
PG mean XX mmHg
(LVEDD XX mm)
Keine Compliancestörung.
Ja
Nein
Pulmonalarteriendruck XX mmHg + ZVD.
Systolischer Pulmonalarteriendruck XX mmHg +
ZVD.
Systolischer Pulmonalarteriendruck im
Normbereich.
Ja
Nein
Geringe MI,
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Ja
Nein
geringe TI
Ja
Nein
Sonst unauffällige Klappenfunktion.
Ja
Nein
Klappen o. B. Verd. a. diastolische
Funktionsstörung.
Ja
Nein
Minimaler Reflux an der Aortenklappenprothese.
Ja
Nein
Klappen ohne Befund,
Ja
Nein
Kein Perikarderguss.
Ja
Nein
Perikarderguss ca. XX cm
Kein Pleuraerguss
Ja
Nein
geringer Pleuraerguss
Rest-Pleuraerguss
Beidseits kein Pleuraerguss mehr
Ja
Nein
Reha Diagnosen
Rehabilitationsdiagnose
Reha Ziele
Die Pat. erhofft sich insbesondere mehr Stabilität
zu erreichen.
Ja
Nein
Informationsstand verbessern
Ja
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Nein
Verbesserung der Belastbarkeit
Ja
Nein
Gemeinsam mit der Pat. wurden folgende Reha-
Ziele vereinbart:
Rehabilitationsverlauf und Epikrise
Die stationäre Aufnahme erfolgte zur
kardiologischen Anschlussheilbehandlung
Ziel der Rehabilitation
Ja
Nein
Die stationäre Aufnahme erfolgte zur
kardiologischen Anschlussheilbehandlung
Ja
Nein
In den Untersuchungen kein Anhalt für eine XXX.
Nach Durchführung der Eingangsdiagnostik
weitere Untersuchungen
Ja
Nein
Duale Thrombozytenaggregationshemmung
Ja
Nein
Ap trotz Stent
Ja
Nein
Rehabilitationsverlauf positiv
Ja
Nein
Komplikationsreicher Verlauf
Ja
Nein
Echokardiographisch zeigte sich XXX.
Im Langzeit-EKG wurde ... aufgezeichnet
Durchgehend normofrequenter Sinusrhythmus im
LZ-EKG vom: "Datum"
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Keine höhergradige Rhythmusstörung
Ja
Nein
Keine relevanten Herzrhythmusstörungen
Ja
Nein
Das Belastungs-EKG war mit Ausnahme eines ...
nach Belastung unauffällig.
Das Belastungs-EKG bis XX Watt war XXx
Teilnahme an Bewegungstherapieprogramm
Version 1
Teilnahme an Bewegungstherapieprogramm
Version 2
Teilnahme an Bewegungstherapieprogramm
Version 3
Teilnahme an Bewegungstherapieprogramm
Version 4
Teilnahme an Wanderungen
Ja
Nein
Maßnahmen führten zu Verbesserung der
Leistungsfähigkeit
Ja
Nein
Hockergymnastik
Ja
Nein
Im Gehtraining konnte sie eine Strecke von XXX
m ohne Pausen zurücklegen.
Postoperative Verspannungen, durch
Rückenmassagen gelockert
Ja
Nein
Saunaprogramm
Ja
Nein
Einweisung in das Nordic Walking.
Ja
Nein
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Im Ergometertraining gut und beschwerdefrei
belastbar
Ja
Nein
Bei leichter Belastung weitgehend
beschwerdefrei
Ja
Nein
Fahrradergometer bei XX Watt,später Laufband
Ergebnis Training: Allgemein Gesund Version 1
Ergebnis Training: Allgemein Gesund Version 2
Ergebnis Training: Allgemein Gesund Version 3
Ergebnis Training: Allgemein Gesund Version 4
Ergebnis Training: Hierunter zeigten sich z. T.
einige VES
Es war während des Aufenthaltes nie zu Angina
pectoris oder Dyspnoe gekommen
Ja
Nein
Die Pat. lernte progressive Muskelrelaxation
Jacobson Version 1
Die Pat. lernte progressive Muskelrelaxation
Jacobson Version 2
Die Pat. lernte progressive Muskelrelaxation
Jacobson Version 3
Hat am Kochkurs „mediterrane Küche“
teilgenommen
Ja
Nein
Hat am Kochkurs bei bekannter
Hyperlipoproteinämie teilgenommen.
Ja
Nein
Teilnahme an Info Seminare über kardio Reha
Version 1
Ja
Nein
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Teilnahme an Info Seminare über kardio Reha
Version 2
Ja
Nein
Teilnahme an Info Seminare über kardio Reha
Version 3
Ja
Nein
Teilnahme an Info Seminare über kardio Reha
Version 4
Ja
Nein
Teilnahme an Info Seminare über kardio Reha
Version 5
Ja
Nein
Teilnahme an Info Seminare über kardio Reha
Version 6
Ja
Nein
Teilnahme an Info Seminare über kardio Reha
Version 7
Ja
Nein
Teilnahme am Seminar Gewichtsreduktion
Ja
Nein
Diätetische Beratung
Ja
Nein
Gesundheitstraining Diätetisch
Ja
Nein
Einzelgespräche
Ja
Nein
Einzelgespräche bei Burnout
Ja
Nein
Raucherentwöhnung Version 1
Ja
Nein
Raucherentwöhnung Version 2
Ja
Nein
Raucherentwöhnung Version 3
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Ja
Nein
Raucherentwöhnung Version 4
Ja
Nein
Burnout
Ja
Nein
Leistungsfähigkeit gut
Zur Unterstützung der Krankheitsverarbeitung
und Behandlung der XXX wird eine ambulante
Psychotherapie empfohlen
Entspannungstherapien,
Ja
Nein
Amiodarontherapie fortgesetzt
Ja
Nein
Engmaschige Kontrollen
Ja
Nein
Herzinsuffizienzmedikation konnte nicht erweitert
werden
Ja
Nein
Herzinsuffizienzmedikation weiter anpassen
Marcumar wurde fortgesetzt
Ja
Nein
Über mehrere Tage keine Marcumareinnahme
Ja
Nein
Bei nicht ausreichenden INR-Wert zusätzlich
Heparin
Ja
Nein
Das LDL-Cholesterin gut eingestellt.
Cholesterinwerte ausreichend gesenkt
Ja
Nein
Unter XX mg Simvastatin betrug das LDL-
Cholesterin
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Wir veränderten die Dosis des CSE Hemmers
Bei Entlassung lag das LDL im gewünschten
Bereich
LDL-Cholesterin vor Entlassung
Bei Aufnahme LDL Cholesterin nicht im
gewünschten Bereich.
Ja
Nein
Bei niedrigen Blutdruckwerten wurde das
Diuretikum reduziert
Ja
Nein
Das Diuretikum kann nach Entlassung abgesetzt
werden
Ja
Nein
Perikarderguss und Pleuraergüsse unter
diuretischer Medikation komplett rückgängig
Ja
Nein
Ein kleiner Pleuraerguss war unter diuretischer
Medikation komplett rückgängig
Ja
Nein
Kreatinin- und Harnsäureanstieg unter Diuretika
Ja
Nein
Dyspnoe besserte sich im Verlauf
Ja
Nein
Postoperativer Pleuraerguss unter diuretischer
Med. rückläufig
Ja
Nein
Wegen Persistenz des Hustenreizes ACE
abgesetzt
Ja
Nein
Wegen fehlender nächtlicher
Blutdruckabsenkung Medikation
Antihypertensive Medikation angepasst
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Zunächst noch erhöhte
Blutdruckwerte,Medikation erhöht, keine
ausreichende Blutdrucksenkung
Ja
Nein
Pat. erhielt daher noch XXX statt des XXX
Bei zunächst noch erhöhten Blutdruckwerten
wurde zunächst die XXX-Medikation erhöht,
ausreichende Blutdrucksenkung
Ja
Nein
Dosis des XXX gesteigert
Die Werte bei der Blutdruckselbstmessung lagen
eher im Normbereich.
Ja
Nein
Der Blutdruck war bei XX mmHg eingestellt
Der Blutdruck war unter Entlassungsmedikation
bei xxx/xx mmHg
Der Blutdruck lag ohne antihypertensive
Medikation bei
Die Blutdruckwerte lagen unter der gegebenen
Medikation durchschnittlich bei
Die Blutdruckwerte waren tagsüber im
grenzwertig niedrigen Bereich
Ja
Nein
Mehrere Stunden Vorhofflimmern mit tachykarder
Überleitung, Therapie erfolgreich
Vorhofflimmern mit normofrequenter Überleitung
VHF, vorübergehend die Betablocker-Dosis
erhöht
Ja
Nein
Im Hinblick auf die häufig bestehenden XXX
dosis wieder reduzieren
Kein Vorhofflimmern im LZ EKG, Medikation mit
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XX reduziert
HbA1c auf XX Prozent gesenkt unter Bewegung.
Weitere medikamentöse Maßnahmen nicht
erforderlich
Ja
Nein
HbA1C bei Aufnahme betrug XXX Prozent
Das HbA1c vor Entlassung betrug XX Prozent.
Orale Medikation bei erh. postprand. BZ
Bei zunehmender Mobilisation stabilisierten sich
die BZ-Werte im Normbereich
BZ erst erhöht dann postprandial bis XXX mg/dl.
Pat nahm am Diabetes-Seminar teil, und erhielt
Ernährungsberatungen.
Ja
Nein
BZ Gebessert durch Diät und Ausdauertraining
Regelmäßige Kontrolle sowie eine Fortführung
der Ausdaueraktivitäten
Ja
Nein
BZ Werte zuletzt im gewünschten Bereich
Nüchtern bei XXX mg/dl und postprandial
durchweg gut
Anpassung der Medikation wird empfohlen
Ja
Nein
Auf die Wichtigkeit regelmäßiger körperlicher
Aktivität und Gewichtsreduktion wurde
hingewiesen
Ja
Nein
Blutzuckerwerte sollten kontrolliert werden
Ja
Nein
Gesunde kalorienangepasste Ernährung
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Ja
Nein
Postoperativ Medikation transdermalem
Durogesic ausgeschlichen
Ja
Nein
Postoperativ Medikation transdermalem
Durogesic weiter fortgeführt
Ja
Nein
Gewicht stabil, Diuretika-Dosis geringgradig
reduzieren
Ja
Nein
Intermittierende Sauerstoffgabe sollte fortgesetzt
werden
Ja
Nein
Die Schilddrüsenwerte lagen unter Medikation
mit Carbimazol im Normbereich.
Ja
Nein
Pat.mit starken Brechdurchfällen.
Ja
Nein
Gastroenteritis.
Ja
Nein
Norovirusinfektion
Ja
Nein
Labor Nachweis eines Norovirus-Antigen
Ja
Nein
Labor nur noch CRP erhöht Laborkontrolle
Ja
Nein
Symptomatische Therapie mit Flüssigkeits- und
Elektrolytausgleich
Ja
Nein
Diuretische und antidiabetische Medikation
Ja
Nein
Angehörigen über Maßnahmen ausreichend
aufgeklärt
Ja
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Nein
Pat. aufgeklärt, Händedesinfektion
Ja
Nein
Beschwerden sistierten nach 24 Stunden
Ja
Nein
Im weiteren Verlauf beschwerdefrei.
Ja
Nein
Bei Entlassung wässrige Durchfälle
Ja
Nein
Bei Entlassung bestanden keine Beschwerden
Ja
Nein
Bei Entlassung bestanden wieder Durchfälle
Ja
Nein
Fäden an den Drainageausleitungsstellen wurden
entfernt
Ja
Nein
Leistungsfähig auf dem allgemeinen Arbeitsmarkt
Reha Ergebnis und
Abschlussuntersuchung
Belastbarkeit gesteigert
Ja
Nein
Belastbarkeit und Ausdauer gesteigert
Ja
Nein
kräftiger und ausdauernder
Ja
Nein
Optimierung der Risikofaktoren
Ja
Nein
Leichte Verbesserung des
Erschöpfungszustandes
Ja
Nein
HWS Beschwerden waren wesentlich gebessert
Ja
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Nein
Während des stationären Aufenthaltes war es nie
zu Angina pectoris oder Dyspnoe gekommen
Ja
Nein
Von Informationsveranstaltungen profitiert
Ja
Nein
Sehr zufrieden mit den hier erreichten Zielen
Ja
Nein
Psychisch auch Stabilisierung
Ja
Nein
Motiviert zu einem Lebensstil im Sinne der
Sekundärprävention
Ja
Nein
Pat fühle sich sicherer
Ja
Nein
Noch Verunsicherung bezüglich der Schwere der
Belastung
Ja
Nein
Koronarsportgruppe
Ja
Nein
Verausgabungsbereitschaft und schlechte
Abgrenzbarkeit
Ja
Nein
Eigene Gesundheit wichtig
Ja
Nein
Die Situation wurde psychologisch begleitet
Ja
Nein
Konkrete Pläne für die Zukunft
Ja
Nein
Gespräch mit dem Arbeitgeber
Ja
Nein
Tätigkeit am Arbeitsplatz setzt die Pat. unter
Druck.
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Ja
Nein
Regelmäßige Bewegung hat sich Pat.
vorgenommen
Ja
Nein
Psychologische Hilfe akzeptieren
Ja
Nein
Trotz Teilnahme am Nichtrauchertraining rauchte
Pat weiter
Ja
Nein
Treppensteigen war problemlos möglich
Ja
Nein
Langsames Treppensteigen
Ja
Nein
Zufriedenstellende Leistungssteigerung
Ja
Nein
In der Ebene ohne Hilfsmittel mobil
Ja
Nein
Bei Entlassung kardial kompensiert
Ja
Nein
Motivation und Kooperation während
Rehabilitation gut
Ja
Nein
Kardial kompensiertem Zustand
Ja
Nein
Blutdruck lag unter o. g. Medikation um XXX/XX
mmHg
Hf. normofrequent und regelmäßig
Ja
Nein
Wundverhältnisse reizlos
Ja
Nein
Sternum stabil
Ja
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Nein
Das Sternum zeigte sich stabil.
Ja
Nein
Nahtmaterial an Drainageausleitungsstellen
wurde entfernt.
Ja
Nein
Nahtmaterial n wurde entfernt
Ja
Nein
Noch leichter thorakaler Wundschmerz
Ja
Nein
Wundverhältnisse waren reizlos.
Ja
Nein
Entlassungsgewicht XX kg.
Pat hatte ca. XX kg Gewicht reduzieren können
Pat konnte ca. xx kg an Gewicht abnehmen
Während des Aufenthaltes keine
Gewichtsreduktion erzielt
Ja
Nein
Kardial kompensiert und in guter Belastbarkeit
Ja
Nein
Kardial kompensiert und in gebesserter
Belastbarkeit
Ja
Nein
Wir entließen die Pat. kardial kompensiert und in
insgesamt etwas gebesserter Belastbarkeit.
Ja
Nein
Wir entließen die Pat. kardial kompensiert und
auf niedrigem Belastungsniveau beschwerdefrei
Ja
Nein
Es wurde nochmals die Wichtigkeit
zurückhaltender Belastung besprochen
Ja
Nein
Der Ruhe-Blutdruck lag zuletzt bei XXX/XX
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mmHg
Rehaziele aus Sicht v. Pat. und Ärzte erreicht
Ja
Nein
Leistungseinschränkung aufgrund der
kardiologischen Situation
Ja
Nein
Sozialmedizinische Epikrise
Pat. wurde arbeitsfähig entlassen
Ja
Nein
Wir entließen die Pat. arbeitsfähig
Ja
Nein
Die Pat. wurde für XX Wochen arbeitsunfähig
entlassen
Wir entließen die Pat. arbeitsunfähig bis auf
Weiteres
Ja
Nein
Auf dem allgemeinen Arbeitsmarkt für XX
Stunden und mehr pro Tag leistungsfähig
Einschränkungen gelten aufgrund der
Herzerkrankung  für mittelschwere und schwere
körperliche Tätigkeiten.
Ja
Nein
Aufgrund des Erschöpfungssyndroms sollten
Stressbelastungen vermieden werden
Ja
Nein
Die Pat. wird voraussichtlich ab ca. Anfang / Mitte
XXX 20XX in ihrem Beruf und auf dem
allgemeinen Arbeitsmarkt wieder XX Stunden
und mehr täglich leistungsfähig sein.
Einschränkungen gelten aufgrund der
Herzerkrankung für schwere körperliche
Tätigkeiten.
Ja
Nein
Aufgrund Stressbelastung sollte speziell die
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Tätigkeit im Rahmen von XXX vermieden werden.
Vollschichtig für leichte - bis mittelschwere
körperliche Belastungen.
Ja
Nein
Die hohe zeitl. Belastung (auch durch die
Nebentätigkeit) und vermehrte
Stressbelastungen sollten reduziert werden
Ja
Nein
Übliche Alltagsbelastungen können
aufgenommen werden
Ja
Nein
Teilhabestörungen können gut kompensiert
werden
Ja
Nein
Für mindestens 3 Monate nach XXX im Rahmen
XXX ist das Führen eines KFZ der Gruppe 1 für
Gruppe 2 für 6 Monate - nicht zugestanden und
erst nach erneuter Untersuchung / Bestätigung
wider möglich.
Bis zur Besserung der Situation noch AU, dann
kann die berufliche Tätigkeit wieder vollschichtig
aufgenommen werden.
Ja
Nein
Pat. ist Altersruhegeldempfänger
Ja
Nein
Die Pat. traut sich eine weitgehende
Selbstversorgung weiterhin zu.
Ja
Nein
Bei Bedarf könnte sie Unterstützung vom
Ehemann bzw. der Tochter erhalten
Ja
Nein
Selbsteinschätzung des Patienten
Bei Bedarf könnte sie Unterstützung vom
Ehemann bzw. der Tochter erhalten
Ja
Nein
Die Pat. sieht sich in absehbarer Zeit ihrem Beruf
in vollem Umfang gewachsen
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Ja
Nein
Soweit absehbar fühlte sich die Pat. in der Lage,
ihren Beruf nach weiterer Rekonvaleszenz wieder
in Vollzeit auszuüben
Ja
Nein
Die Pat. ist derzeit arbeitslos. Sie könnte sich
vorstellen, nach weiterer Rekonvalszenz wieder
in ihrem Beruf zu arbeiten
Ja
Nein
Die Pat. fühlt sich in der Lage ihren Beruf
weiterhin auszuüben
Ja
Nein
Unsicher, in wieweit sie dem Beruflichen Stress
weiterhin gewachsen sein wird
Ja
Nein
Die Pat. fühlt sich derzeit noch nicht ausreichend
belastbar, ihren Beruf wieder aufzunehmen.
Ja
Nein
Rekonvaleszenz dann ggf. stufenweise
Wiedereingliederung
Ja
Nein
Tägliches körperliches Ausdauertraining
Procedere
Kontrollen des kardiovaskulären Systems
Ja
Nein
Beibehaltung einer täglichen körperlichen
Ausdaueraktivität
Ja
Nein
Zurückhaltung bei körperlicher Belastung
Ja
Nein
Generelle Empfehlungen zur Behandlung und
Stabilisierung der KHK
Ja
Nein
Ambulante Psychotherapie
34 / 37
Rehabilitation letter cardiology
Ja
Nein
Regelmäßige Blutdrucküberwachung
Ja
Nein
Schlafapnoescreening Version 1
Ja
Nein
Schlafapnoescreening Version 2
Ja
Nein
Überwachung der Gewichtssituation
Ja
Nein
Wiedervorstellung in XX zur Verlaufskontrolle
Ambulante Herzsportgruppe
Ja
Nein
Fortführung des regelmäßigen Ausdauersports
Ja
Nein
Moderate Ausdaueraktivität
Ja
Nein
Regelmäßige kardiologische Kontrollen
Ja
Nein
Kontrollen der CVRF
Ja
Nein
LZ-EKG-Kontrollen,
Ja
Nein
Im Verlauf Langzeit-Blutdruck-Messung
Ja
Nein
Stressechokardiographie oder
Myokardszintigraphie empfohlen
Ja
Nein
Herzrhythmus- und Blutdruckkontrollen,
Anpassung der Medikation
Ja
Nein
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BZ Kontrollen im Alltag
Ja
Nein
Anpassung der antidiabetischen Medikation
Ja
Nein
Kontrolle der Blutfett, CK und Leberwerte
Ja
Nein
Weitere Gewichtsreduktion
Ja
Nein
Regelmäßige moderate Ausdaueraktivität
Ja
Nein
Marcumar nach INR,
Ja
Nein
Marcumar nach INR (für 3 Monate postoperativ
Ja
Nein
Endokarditisprophylaxe
Ja
Nein
Verlaufskontrolle der Schilddrüsenwerte
Ja
Nein
Kontrolle der Schilddrüsen-Werte
Ja
Nein
Kontrolle der Nierenretentionswerte
Ja
Nein
Lipid-Kontrollen
Ja
Nein
Stuhl auf pathogene Keime
Ja
Nein
Klinische Kontrolle bei abklingender Diarrhoe
Ja
Nein
Pat. und Ehemann wurden über
Hygienemaßnahmen informiert
Ja
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Nein
Hände-Desinfektionsmittel
Ja
Nein
weitere Nikotinabstinenz
Ja
Nein
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General Info EBMT Aplastic Anemia
ODM form derived from 19pp General Info EBMT Aplastic
Anemia 06AA please refer to:
http://www.ebmt.org/Contents/Data-
Management/Registrystructure/MED-
ABdatacollectionforms/Pages/MED-AB-data-collection-
forms.aspx
All rights reserved. Please visit https://medical-data-
models.org/forms/16760
General Info EBMT Aplastic Anemia
General Information
EBMT Centre Identification Code (CIC)
Name of the hospital
Unit
Name of contact person
Telephone number
Fax
E-mail
Date of this report
Patient following national / international study /
trial
no (1)
yes (2)
unknown (3)
Name of study / trial
GENERAL INFORMATION
To be entered only if patient previously reported
Hospital Unique Patient Number or Code
First name(s)_surname(s)
Date of birth
Sex
Male (1)
Female (2)
ABO Group
1 / 14
Rh factor
Absent (1)
Present  (2)
Not evaluated (3)
GENERAL INFORMATION
Date of diagnosis
Check the disease for which this transplant was
performed
Acute Leukaemia (Acute Leukaemia)
Acute Lymphoblastic Leukaemia (ALL)
(Acute Lymphoblastic Leukaemia (ALL))
Acute Myelogenous Leukaemia (AML)
(Acute Myelogenous Leukaemia (AML))
Autoimmune disease (Autoimmune
disease)
Bone marrow failure including Aplastic
anaemia (Bone marrow failure including
Aplastic anaemia)
Chronic Leukaemia (Chronic Leukaemia)
Chronic Lymphocytic Leukaemia
(Chronic Lymphocytic Leukaemia)
Chronic Myeloid Leukaemia (CML)
(Chronic Myeloid Leukaemia (CML))
Haemoglobinopathy
(Haemoglobinopathiy)
Histiocytic disorders (Histiocytic
disorders)
Hodgkin´s Disease (Hodgkin´s Disease)
Inherited disorders (Inherited disorders)
Juvenile Idiopathic Arthritis (Juvenile
Idiopathic Arthritis)
Lymphoma (Lymphoma)
MD/ MPN (MD/ MPN)
MDS (MDS)
Metabolic disorders (Metabolic
disorders)
Multiple Sclerosis (Multiple Sclerosis)
Myelodysplastic syndromes
(Myelodysplastic syndromes)
Myeloma/ Plasma cell disorder
(Myeloma/ Plasma cell disorder)
Myeloproliferative neoplasm
(Myeloproliferative neoplasm)
Non Hodgkin (Non Hodgkin)
Other diagnosis (Other diagnosis)
Primary immune deficiencies (Primary
immune deficiencies)
Secondary Acute Leukaemia (do not use
if transformed from MDS/MPN)
(Secondary Acute Leukaemia (do not
use if transformed from MDS/MPN))
Solid Tumour (Solid Tumour)
Systemic Lupus (Systemic Lupus)
Systemic Sclerosis (Systemic Sclerosis)
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BONE MARROW FAILURE SYNDROME
(INCLUDING APLASTIC ANAEMIA)
TYPE OF TREATMENT BEING REGISTERED
WITH THIS FORM
Immunosuppressive therapy (IS)
(Immunosuppressive therapy (IS))
Includes HSCT registration (Includes
HSCT registration)
SUBCLASSIFICATION
Acquired
Yes
No
Aplastic anaemia
Moderate (Moderate)
Severe (Severe)
Very severe (Very severe)
Pure red cell aplasia (non constitutional PRCA)
Yes
No
Paroxysmal nocturnal haemoglobinuria (PNH)
Yes
No
Haemolytic
Yes
No
Aplastic
Yes
No
Thrombotic
Yes
No
Pure white cell aplasia
Yes
No
Amegakaryocytic thrombocytopenia
(non constitutional)
Yes
No
Genetic
Yes
No
Fanconi
Yes
No
FANC complementation group
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Diamond-Blackfan (congenital / constitutional
PRCA)
Yes
No
Shwachman-Diamond Syndrome
Yes
No
Dyserythropoietic Anaemia
Yes
No
Dyskeratosis congenita
Yes
No
Amegakaryocytic thrombocytopenia
Yes
No
ETIOLOGY
Idiopathic (Idiopathic)
Other (Other)
Post-hepatitis (Post-hepatitis)
Toxic (includes drug induced) (Toxic
(includes drug induced))
CYTOGENETICS
Chromosome analysis
Done: abnormal (Done: abnormal)
Done: normal (Done: normal)
Not Done or failed (Not Done or failed)
Unknown (Unknown)
CYTOGENETICS If done: Technique used
Both (Both)
Conventional  (Conventional )
FISH  (FISH )
Number of metaphases with anomalies
number of metaphases examined
trisomy 8
Absent (1)
Present (2)
trisomy 3 (for Fanconi)
Absent  (Absent )
Present (Present)
Other or associated abnormalities (specify)
Chromosomal breakage test
(for Fanconi)
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Negative  (Negative )
Not evaluated (Not evaluated)
Positive  (Positive )
HAEMATOLOGICAL VALUES
Haemoglobin
g/dL
Platelet count
Neutrophils
Reticulocytes
Ferritin
Hemoglobin
Not evaluated  (1)
Untransfused  (2)
Transfused (3)
Platelets
Not evaluated  (1)
Untransfused  (2)
Transfused (3)
COMPLICATIONS
Haemorrhages
No  (No )
Not evaluated  (Not evaluated )
Unknown (Unknown)
Yes  (Yes )
Resistance to random platelets
No  (No )
Not evaluated  (Not evaluated )
Unknown (Unknown)
Yes  (Yes )
Systemic infection
No  (No )
Not evaluated  (Not evaluated )
Unknown (Unknown)
Yes  (Yes )
PNH TESTS
Date of PNH test
PNH diagnostics by flow cytometry
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Clone absent (Clone absent)
Clone present (Clone present)
Not evaluated (Not evaluated)
Size of the PNH clone in %
%
Flow cytometry assessment done on
Both (Both)
Granulocytes (Granulocytes)
Not done (Not done)
Other (Other)
RBC (RBC)
PNH diagnostics by other test, specify
PNH diagnostics by other test
Clone absent (Clone absent)
Clone present (Clone present)
Not done (Not done)
Clinical manifestations of PNH
Yes
No
FIRST IMMUNOSUPPRESSIVE
TREATMENT EPISODE
WAS THE PATIENT TREATED BEFORE THE
HSCT PROCEDURE?
No  (1)
Date started (2)
Date treatment started
SEQUENTIAL NUMBER OF THIS TREATMENT
EPISODE
(Other treatment episodes can have been
registered
for this patient with previous data submissions)
IF 1ST TREATMENT EPISODE FOR THE
PATIENT EVER
RBC
< 20 UNITS (< 20 UNITS)
> 50 UNITS (> 50 UNITS)
20-50 UNITS (20-50 UNITS)
NONE (NONE)
UNKNOWN (UNKNOWN)
RBC irradiated
No (No)
Unknown (Unknown)
Yes (Yes)
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Platelets
NONE (1)
< 20 UNITS (2)
20-50 UNITS (3)
> 50 UNITS (4)
UNKNOWN (5)
Platelets irradiated
No (No)
Unknown (Unknown)
Yes (Yes)
IF PATIENT HAS BEEN TREATED
BEFORE
Haemoglobin
Not evaluated  (Not evaluated )
Transfused (Transfused)
Untransfused  (Untransfused )
Platelet count
1000/uL
Platelets
Not evaluated (Not evaluated)
Transfused (Transfused)
Untransfused  (Untransfused )
Neutrophils
Reticulocytes
Ferritin
REASON FOR THIS TREATMENT
Failure of first line therapy (Failure of first
line therapy)
Other (Other)
PR to previous treatment (PR to previous
treatment)
Relapse (Relapse)
Secondary clonal disorder (Secondary
clonal disorder)
Unknown (Unknown)
Medication
Alemtuzumab  (Alemtuzumab
(Campath))
Androgens (Androgens)
ATG Origin (ATG Origin)
Corticosteroid (Corticosteroid)
Cyclophosphamide (Cyclophosphamide)
Cyclosporin A (Cyclosporin A)
Erythropoietin (Erythropoietin)
G-CSF (G-CSF)
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Mycophenolate mofetil (Mycophenolate
mofetil)
Other (Other)
Rituximab  (Rituximab (Mabthera))
RESPONSE TO THIS IMMUNOSUPPRESSIVE
TREATMENT EPISODE
Complete remission  (Complete
remission )
No response  (No response )
Not evaluable (Not evaluable)
Other (Other)
Partial remission (transfusion and growth
factor independent) (Partial remission
(transfusion and growth factor
independent))
Progression  (Progression )
Unknown (Unknown)
Date response evaluated
SECONDARY CLONAL COMPLICATIONS
Yes
No
Date of diagnosis of MDS
(if applicable)
MDS WHO classification
Date of diagnosis of PNH
(if applicable)
Size of the PNH clone
%
Flow cytometry assessment done on
Both (Both)
FLWCYTAA  (FLWCYTAA )
Granulocytes  (Granulocytes )
Not done (Not done)
Other (Other)
RBC  (RBC )
Clinical manifestations of PNH
Yes
No
HAS THE PATIENT UNDERGONE AN
ADDITIONAL EPISODE OF
IMMUNOSUPPRESSIVE TREATMENT?
Yes
No
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ADDITIONAL IMMUNOSUPPRESSIVE
TREATMENT EPISODE
Date treatment started
SEQUENTIAL NUMBER OF THIS TREATMENT
EPISODE
REASON FOR THIS TREATMENT
Failure of first line therapy  (Failure of
first line therapy )
Other  (Other )
PR to previous treatment (PR to previous
treatment)
Relapse  (Relapse )
Secondary clonal disorder  (Secondary
clonal disorder )
Unknown (Unknown)
if other, please specify
Haemoglobin
Not evaluated  (Not evaluated )
Transfused (Transfused)
Untransfused  (Untransfused )
Platelet count
1000/uL
Platelets
Not evaluated (Not evaluated)
Transfused (Transfused)
Untransfused  (Untransfused )
Neutrophils
Reticulocytes
Ferritin
REASON FOR THIS TREATMENT
Failure of first line therapy (Failure of first
line therapy)
Other (Other)
PR to previous treatment (PR to previous
treatment)
Relapse (Relapse)
Secondary clonal disorder (Secondary
clonal disorder)
Unknown (Unknown)
Medication
Alemtuzumab  (Alemtuzumab
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(Campath))
Androgens (Androgens)
ATG Origin (ATG Origin)
Corticosteroid (Corticosteroid)
Cyclophosphamide (Cyclophosphamide)
Cyclosporin A (Cyclosporin A)
Erythropoietin (Erythropoietin)
G-CSF (G-CSF)
Mycophenolate mofetil (Mycophenolate
mofetil)
Other (Other)
Rituximab  (Rituximab (Mabthera))
RESPONSE TO THIS IMMUNOSUPPRESSIVE
TREATMENT EPISODE
Complete remission  (Complete
remission )
No response  (No response )
Not evaluable (Not evaluable)
Other (Other)
Partial remission (transfusion and growth
factor independent) (Partial remission
(transfusion and growth factor
independent))
Progression  (Progression )
Unknown (Unknown)
Date response evaluated
SECONDARY CLONAL COMPLICATIONS
Yes
No
Date of diagnosis of MDS
(if applicable)
MDS WHO classification
Date of diagnosis of PNH
(if applicable)
Size of the PNH clone
%
Flow cytometry assessment done on
Both (Both)
FLWCYTAA  (FLWCYTAA )
Granulocytes  (Granulocytes )
Not done (Not done)
Other (Other)
RBC  (RBC )
Clinical manifestations of PNH
Yes
No
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HAS THE PATIENT UNDERGONE AN
ADDITIONAL EPISODE OF
IMMUNOSUPPRESSIVE TREATMENT?
Yes
No
STATUS AT HSCT
Date of HSCT
Chromosome analysis
Done: abnormal (Done: abnormal)
Done: normal (Done: normal)
Not Done or failed (Not Done or failed)
Unknown (Unknown)
Chromosome analysis: If done: Technique used
Both (Both)
Conventional  (Conventional )
FISH  (FISH )
Number of metaphases with anomalies
number of metaphases examined
IF ABNORMAL, INDICATE ABNORMALITIES
FOUND (14:16)
Absent (Absent)
Not evaluated (Not evaluated)
Present (Present)
Other or associated abnormalities (specify)
Haemoglobin
g/dL
Platelet count
Neutrophils
Reticulocytes
Ferritin
Hemoglobin
Not evaluated  (1)
Untransfused  (2)
Transfused (3)
Platelets
Not evaluated  (1)
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Untransfused  (2)
Transfused (3)
Haemorrhages
No  (No )
Not evaluated  (Not evaluated )
Unknown (Unknown)
Yes  (Yes )
Resistance to random platelets
No  (No )
Not evaluated  (Not evaluated )
Unknown (Unknown)
Yes  (Yes )
Systemic infection
No  (No )
Not evaluated  (Not evaluated )
Unknown (Unknown)
Yes  (Yes )
Date of PNH test
PNH diagnostics by flow cytometry
Clone absent (Clone absent)
Clone present (Clone present)
Not evaluated (Not evaluated)
Size of the PNH clone in %
%
Flow cytometry assessment done on
Both (Both)
Granulocytes (Granulocytes)
Not done (Not done)
Other (Other)
RBC (RBC)
PNH diagnostics by other test, specify
PNH diagnostics by other test
Clone absent (Clone absent)
Clone present (Clone present)
Not done (Not done)
Clinical manifestations of PNH
Yes
No
RBC
< 20 UNITS (< 20 UNITS)
> 50 UNITS (> 50 UNITS)
20-50 UNITS (20-50 UNITS)
NONE (NONE)
UNKNOWN (UNKNOWN)
RBC irradiated
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No (No)
Unknown (Unknown)
Yes (Yes)
Platelets
NONE (1)
< 20 UNITS (2)
20-50 UNITS (3)
> 50 UNITS (4)
UNKNOWN (5)
Platelets irradiated
No (No)
Unknown (Unknown)
Yes (Yes)
ADDITIONAL TREATMENT POST-HSCT
Additional Disease Treatment
No (No)
Unknown (Unknown)
Yes (Yes)
ADDITIONAL DISEASE TREATMENT if yes
Planned (planned before HSCT took
place) (1)
Not planned (for relapse/progression or
persistent disease) (2)
BEST DISEASE RESPONSE AT 100
DAYS POST-HSCT
BEST RESPONSE AT 100 DAYS AFTER HSCT
Complete remission  (Complete
remission )
No response  (No response )
Not evaluable (Not evaluable)
Other (Other)
Partial remission (transfusion and growth
factor independent) (Partial remission
(transfusion and growth factor
independent))
Progression  (Progression )
Unknown (Unknown)
BEST RESPONSE AT 100 DAYS AFTER HSCT:
if other, please specify
Date response evaluated
FORMS TO BE FILLED IN
Type of HSCT (Check all that apply):
ALLOgraft or Synergenic graft, proceed
to Allograft form (ALLOgraft or
Synergenic graft, proceed to Allograft
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form)
AUTOgraft, proceed to Autograft form
(AUTOgraft, proceed to Autograft form)
Other, contact the EBMT Central
Registry Office for instructions (Other,
contact the EBMT Central Registry
Office for instructions)
14 / 14
General Info EBMT Aplastic Anemia
EBMT FOLLOW UP Aplastic Anemia
ODM form derived from19pp General Info EBMT Aplastic
Anemia 06AA please refer to:
http://www.ebmt.org/Contents/Data-
Management/Registrystructure/MED-
ABdatacollectionforms/Pages/MED-AB-data-collection-
forms.aspx 
All rights reserved. Please visit https://medical-data-
models.org/forms/16761
EBMT FOLLOW UP Aplastic Anemia
FOLLOW UP Aplastic Anemia
Unique Identification Code (UIC)
(if known)
Date of this report
Patient following national / international study /
trial
No (1)
Yes (2)
Not evaluated (3)
Unknown (4)
Name of study / trial
Hospital Unique Patient Number
First name(s)_surname(s)
Date of Birth
Date of last HSCT for this patient
DATE OF LAST CONTACT OR DEATH
OTHER COMPLICATIONS SINCE LAST
REPORT
INFECTION RELATED COMPLICATIONS
No complications (1)
Yes (2)
Bacteremia / fungemia / viremia / parasites
Pathogen (1)
Date (2)
Septic shock
Pathogen  (1)
Date (2)
ARDS
Pathogen  (1)
1 / 11
Date (2)
Multiorgan failure due to infection
Pathogen  (1)
Date (2)
Pneumonia
Pathogen  (1)
Date (2)
Hepatitis
Pathogen  (1)
Date (2)
CNS infection
Pathogen  (1)
Date (2)
Gut infection
Pathogen  (1)
Date (2)
Skin infection
Pathogen  (1)
Date (2)
Cystitis
Date (Date)
Pathogen (Pathogen)
Retinitis
Date (Date)
Pathogen (Pathogen)
Other pathogen specified
NON INFECTION RELATED COMPLICATIONS
No complications (1)
Yes (2)
Idiopathic pneumonia syndrome
No  (No )
Unknown (Unknown)
Yes (Yes)
VOD
No  (No )
Unknown (Unknown)
Yes (Yes)
Cataract
No (No)
Unknown (Unknown)
Yes (Yes)
Haemorrhagic cystitis, non infectious
No  (No )
Unknown (Unknown)
Yes  (Yes )
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Specify:
ARDS, non infectious
No (No)
Unknown (Unknown)
Yes (Yes)
Multiorgan failure, non infectious
no  (no )
unknown (unknown)
yes  (yes )
HSCT-associated microangiopathy
Date (4)
No (No)
Unknown (Unknown)
Yes (Yes)
Renal failure requiring dialysis
Date (Date)
No (No)
Unknown (Unknown)
Yes (Yes)
Haemolytic anaemia due to blood group
Date (4)
No (No)
Unknown (Unknown)
Yes (Yes)
Aseptic bone necrosis
Date (Date)
No (No)
Unknown (Unknown)
Yes (Yes)
Other type of NON INFECTION RELATED
COMPLICATIONS, please specify
Idiopathic pneumonia syndrome
GRAFT VERSUS HOST DISEASE
(GvHD) SINCE LAST REPORT
Acute Graft versus Host Disease (aGvHD) -
Maximum grade
grade 0 (absent) (grade 0 (absent))
grade I (grade I)
grade II (grade II)
grade III (grade III)
grade IV (grade IV)
not evaluated (not evaluated)
If present GvHD, Maximum grade
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New onset (1)
Recurrent (2)
Persistent (3)
Reason Maximum grade
Tapering (1)
DLI (2)
Unexplained (3)
Date onset of this episode (if new or recurrent)
yyyy/mm/dd
Date onset of this episode
Not applicable (1)
aGvHD Stage Skin
0 (1)
1 (2)
2 (3)
3 (4)
4 (5)
Not evaluated (6)
unknown (7)
aGvHD Stage liver
0 (1)
1 (2)
2 (3)
3 (4)
4 (5)
Not evaluated (6)
unknown (7)
aGvHD stage gut
0 (1)
1 (2)
2 (3)
3 (4)
4 (5)
Not evaluated (6)
unknown (7)
Resolution
No  (1)
Yes (2)
aGvHD Date of resolutions
Presence of cGvHD
No (No)
Present continuously since last reported
episode (Present continuously since last
reported episode)
Resolved (Resolved)
Yes (Yes)
Date of onset
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cGvHD grade
limited (1)
Extensive (2)
Organs affected
Skin (1)
Gut (2)
Liver (3)
Mouth (4)
Eyes (5)
Lung (6)
Other, specify (7)
Unknown (8)
If other organs affected, please specify
cGvHD Resolved: Date of resolution
LAST DISEASE AND PATIENT STATUS
Scripps neurological rating scale Score
Kurtzke functional systems Overall score
Kurtzke Expanded Disability Status Scale (EDSS)
Composite Scale Score
MRI BRAIN SCAN DONE
Not done (Not done)
Yes (Yes)
Date of most recent MRI scan of brain
Results, Are new lesions present on the MRI?
no (no)
unknown (unknown)
yes (yes)
If yes Indicate new lesions present
Both (Both)
Gadolinium-enhancing (Gadolinium-
enhancing)
Unenhancing (Unenhancing)
Unknown (Unknown)
Has patient or partner become  pregnant after
this HSCT?
No (No)
Unknown (Unknown)
Yes (Yes)
Survival Status
alive (0)
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dead (1)
Performance score (if alive)
Karnofsky (1)
Lansky (2)
performance status
100 (Normal, NED) (1)
10 (Moribund) (10)
Not evaluated (11)
Unknown (12)
90 (Normal activity)  (2)
80 (Normal with effort) (3)
70 (Cares for self) (4)
60 (Requires occasional assistance) (5)
50 (Requires assistance) (6)
40 (Disabled) (7)
30 (Severely disabled) (8)
20 (Very sick) (9)
Cause of death (if dead)
Relapse or progression (1)
Secondary malignancy (including
lymphoproliferative disease) (2)
HSCT related cause  (3)
Unknown (4)
Other (5)
HSCT related cause
GvHD (1)
Veno-occlusive disease (VOD) (10)
Haemorrhage (11)
Cardiac toxicity (12)
Central nervous system toxicity (13)
Gastro intestinal toxicity (14)
Skin toxicity (15)
Renal failure (16)
Multiple organ failure (17)
Other (18)
Interstitial pneumonitis (2)
Pulmonary toxicity (3)
Infection bacterial (4)
Infection viral (5)
Infection fungal (6)
Infection parasitic (7)
Infection unknown (8)
Rejection / poor graft function (9)
ADDITIONAL THERAPIES SINCE LAST
FOLLOW UP
Additional treatment given since last report
Date (4)
No (No)
Unknown (Unknown)
Yes (Yes)
If treatment given since last report
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If yes: Cellular therapy (One cell therapy regimen
is defined as any number of infusions given within
10 weeks for the same indication. If more than
one regimen of cell therapy has been given since
last report, copy this section and complete it as
many times as necessary.)
No  (1)
Yes (Mark disease status before this
cellular therapy) (2)
Unknown (3)
Disease status before this cellular therapy
CR (CR)
Not evaluated (Not evaluated)
Not in CR (Not in CR)
If yes: Type of cells
Donor lymphocyte infusion (DLI) (1)
Mesenchymal cells (2)
Other (3)
Unknown (4)
If other
Chronological number of this cell therapy for this
patient
Number of Nucleated cells infused (DLI only)
10^8/kg
Number (1)
Not evaluated (2)
Unknown (3)
If DLI, specify the number of cells infused by
type:
CD 34+
Evaluated (Evaluated)
Not Evaluated (Not Evaluated)
Unknown (Unknown)
If DLI, specify the number of cells infused by
type: 
CD 3+
Evaluated  (Evaluated )
Not evaluated (Not evaluated)
Unknown (Unknown)
If non DLI, specify total number of cells infused:
Evaluated (Evaluated)
Not Evaluated (Not Evaluated)
Unknown (Unknown)
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Cell therapy indication
Planned/protocol  (1)
Treatment for disease (2)
Prophylactic (3)
Mixed chimaerism (4)
Treatment of GvHD  (5)
Treatment viral infection (6)
Loss/decreased chimaerism  (7)
Treatment PTLD, EBV lymphoma (8)
Other, specify (9)
Number of infusions within 10 weeks (count only
infusions that are part of same regimen and given
for the same indication)
Acute Graft versus Host Disease 
(after this infusion but before any further infusion/
transplant)
Maximum grade:
grade 0 (absent) (grade 0 (absent))
grade 1 (grade 1)
grade 2 (grade 2)
grade 3 (grade 3)
grade 4 (grade 4)
present, grade unknown (present, grade
unknown)
Disease treatment (apart from donor cell infusion
or other type of cell therapy)
No (1)
Yes: Planned (planned before HSCT took
place) (2)
Yes: Not planned (for
relapse/progression or persistent
disease) (3)
Date started
Overall main reason ADDITIONAL THERAPIES
Relapse/progression (1)
Continued from pre-HSCT (2)
unknow (3)
Planned per protocol (4)
Other (5)
Of Other, please specify
Drugs
no (no)
unknown (unknown)
yes (yes)
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If yes, mark appropriate box
Alpha interferon (Alpha interferon)
Anti-lymphocyte antibodies (Anti-
lymphocyte antibodies)
Azathioprine (Azathioprine)
Interferon Beta  (Beta Interferon)
low dose (Chronic low dose)
CopI (Cop-I)
Corticosteroids (Corticosteroids)
Cyclophosphamide (Cyclophosphamide)
Mitoxantron (Mitoxantron)
high dose (Pulse high dose)
Total lymph node (TLI)
NO (NO)
UNKNOWN (UNKNOWN)
YES (YES)
Craniospinal
no (no)
unknown (unknown)
yes (yes)
Lymphocytopheresis
no (no)
unknown (unknown)
yes  (yes )
if other modality please specify:
GRAFT ASSESSMENT AND
HAEMOPOIETIC CHIMAERISM
Graft loss
No (No)
Not evaluated (Not evaluated)
Yes (Yes)
Overall chimaerism
Aplasia (Aplasia)
95%) (Autologuos reconstitution
(recipient >)
95%) (Full (donor >)
Mixed (partial) (Mixed (partial))
Not evaluated (Not evaluated)
Date of Test
Identification of donor or Cord Blood Unit given
by the centre
Number in the infusion order
Graft loss
No (No)
Not evaluated (Not evaluated)
Yes (Yes)
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Overall chimaerism
Full (donor >95%) (1)
Mixed (partial) (2)
Autologuos reconstitution (recipient >
95%) (3)
Aplasia (4)
Not evaluated (5)
Date of test
(Indicate the date(s) and results of all tests done
for all donors. Split the results by donor and by
the cell type on which the test was performed if
applicable. Copy this table as many times as
necessary.)
Identification of donor or Cord Blood Unit given
by the centre
Number in the infusion order (if applicable)
Cell type on which test was performed % Donor
cells
B-Cells
%
BM (1)
Other, specify (10)
PB mononuclear cells (PBMC) (2)
T-cell (3)
B-cells (4)
Red blood cells (5)
Monocytes (6)
PMNs (neutrophils) (7)
Lymphocytes, NOS (8)
Myeloid cells, NOS (9)
Laboratory tests used
ABO group (ABO group)
Cytogenetic (Cytogenetic)
FISH (FISH)
Molecular (Molecular)
Other (Other)
unknown (unknown)
Test used:
If other, specify:
SECONDARY MALIGNANCY,
LYMPHOPROLIFERATIVE OR
MYELOPROLIFRATIVE DISORDER
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DIAGNOSED
No at date of this follow-up (No at date of
this follow-up)
Previously reported (Previously reported)
Yes (Yes)
Date of Diagnosis
Diagnosis OTHER COMPLICATIONS SINCE
LAST REPORT
AML (AML)
Lymphoproliferative disorder
(Lymphoproliferative disorder)
MDS (MDS)
Other (Other)
Diagnosis, other:
ADDITIONAL NOTES IF APPLICABLE
COMMENTS
Identification
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Eligibility Colorectal Cancer NCT00113763
Evaluating Panitumumab (ABX-EGF) Plus Best Supportive
Care Versus Best Supportive Care in Patients With
Metastatic Colorectal Cancer; ODM derived from:
https://clinicaltrials.gov/show/NCT00113763
All rights reserved. Please visit https://medical-data-
models.org/forms/16762
Eligibility Colorectal Cancer
NCT00113763
Inclusion Criteria
pathologic diagnosis of colorectal
adenocarcinoma (diagnostic tissue obtained by
tissue biopsy)*
Yes
No
metastatic colorectal carcinoma*
Yes
No
eastern cooperative oncology group (ecog)
performance status of 0, 1 or 2*
Yes
No
documented evidence of disease progression
during, or following treatment, with
fluoropyrimidine, irinotecan and oxaliplatin
chemotherapy for metastatic colorectal cancer*
Yes
No
radiographic documentation of disease
progression during or within 6 months following
the most recent chemotherapy regimen*
Yes
No
unidimensionally measurable disease*
Yes
No
tumor expressing epidermal growth factor
receptor (egfr) by immunohistochemistry*
Yes
No
at least 2 but not more than 3 prior chemotherapy
regimens for colorectal cancer*
Yes
No
adequate hematologic, renal and hepatic
function*
Yes
No
Exclusion Criteria
symptomatic brain metastases requiring
treatment*
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Yes
No
history or evidence of interstitial pneumonitis or
pulmonary fibrosis*
Yes
No
use of systemic chemotherapy or radiotherapy
within 30 days prior to enrollment*
Yes
No
prior epidermal growth factor receptor (egfr)
targeting therapies*
Yes
No
prior anti-tumor therapies including prior
experimental agents or approved anti-tumor small
molecules and biologics of short (less than a
week) serum half life within 30 days before
enrollment, or prior experimental or approved
proteins within 3 months before enrollment.*
Yes
No
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Eligibility Colorectal Cancer NCT00083616
Evaluating Panitumumab (ABX-EGF) Monotherapy in
Patients With Metastatic Colorectal Cancer Following
Treatment With Fluoropyrimidine, Irinotecan, and
Oxaliplatin Chemotherapy; ODM derived from:
https://clinicaltrials.gov/show/NCT00083616
All rights reserved. Please visit https://medical-data-
models.org/forms/16763
Eligibility Colorectal Cancer
NCT00083616
Inclusion Criteria
pathologic diagnosis of colorectal
adenocarcinoma (diagnostic tissue obtained by
tissue biopsy)*
Yes
No
metastatic colorectal carcinoma*
Yes
No
eastern cooperative oncology group (ecog)
performance status of 0, 1 or 2*
Yes
No
documented evidence of disease progression
during, or following treatment, with
fluoropyrimidine, irinotecan and oxaliplatin
chemotherapy for metastatic colorectal cancer*
Yes
No
radiographic documentation of disease
progression during or within 6 months following
the most recent chemotherapy regimen is
required*
Yes
No
bidimensionally measurable disease*
Yes
No
tumor expressing epidermal growth factor
receptor (egfr) by immunohistochemistry*
Yes
No
at least 2 but no more than 3 prior chemotherapy
regimens for metastatic colorectal cancer*
Yes
No
adequate hematologic, renal and hepatic
function*
Yes
No
Exclusion Criteria
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symptomatic brain metastases requiring
treatment*
Yes
No
patient with a history of interstitial pneumonitis or
pulmonary fibrosis or evidence of interstitial
pneumonitis or pulmonary fibrosis*
Yes
No
use of systemic chemotherapy or radiotherapy
within 30 days before enrollment*
Yes
No
prior epidermal growth factor receptor targeting
agents*
Yes
No
prior anti-tumor therapies including prior
experimental agents or approved anti-tumor small
molecules and biologics of short (less than 1
week) serum half-life within 30 days before
enrollment, or prior experimental or approved
proteins with longer serum half-life (e.g.,
avastintm) within 6 weeks before enrollment*
Yes
No
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Eligibility Colorectal Cancer NCT00089635
ABX-EGF (Panitumumab) Monotherapy in Subjects With
Metastatic Colorectal Cancer; ODM derived from:
https://clinicaltrials.gov/show/NCT00089635
All rights reserved. Please visit https://medical-data-
models.org/forms/16764
Eligibility Colorectal Cancer
NCT00089635
Inclusion Criteria
pathologic diagnosis of colorectal
adenocarcinoma (diagnostic tissue obtained by
tissue biopsy)*
Yes
No
metastatic colorectal carcinoma*
Yes
No
eastern cooperative oncology group of 0, 1 or 2*
Yes
No
documented evidence of disease progression
during, or following treatment, with
fluoropyrimidine, irinotecan and oxaliplatin
chemotherapy for metastatic colorectal cancer*
Yes
No
radiographic documentation of disease
progression during or within 6 months following
the most recent chemotherapy regimen is
required*
Yes
No
bidimensionally measurable disease*
Yes
No
tumor expressing low to negative levels of egfr by
immunohistochemistry*
Yes
No
at least 2 but no more than 3 prior chemotherapy
regimens for metastatic colorectal cancer*
Yes
No
adequate hematologic, renal and hepatic
function*
Yes
No
Exclusion Criteria
symptomatic brain metastases requiring
treatment*
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Yes
No
patient with a history of interstitial pneumonitis or
pulmonary fibrosis or evidence of interstitial
pneumonitis or pulmonary fibrosis*
Yes
No
use of systemic chemotherapy or radiotherapy
within 30 days before enrollment*
Yes
No
prior anti-egfr antibody therapy with the exception
of the small molecule egfr tyrosine kinase
inhibitors, which are permitted*
Yes
No
prior anti-tumor therapies including prior
experimental agents or approved anti-tumor small
molecules and biologics of short (less than 1
week) serum half-life within 30 days before
enrollment, or prior experimental or approved
proteins within 6 weeks before enrollment*
Yes
No
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Eligibility Colorectal Cancer NCT00122720
The Effect of Darbepoetin Upon Rehabilitation for
Colorectal Cancer Surgery; ODM derived from:
https://clinicaltrials.gov/show/NCT00122720
All rights reserved. Please visit https://medical-data-
models.org/forms/16765
Eligibility Colorectal Cancer
NCT00122720
Inclusion Criteria
planned colonic and rectal surgery because of
presumed cancer disease in the colon and
rectum*
Yes
No
Exclusion Criteria
psychiatric disease or dementia*
Yes
No
diseases, that renders participation in the study
impossible*
Yes
No
thromboembolic disease within the last three
months*
Yes
No
dysregulated hypertension (systolic blood
pressure>175 mmhg and/or diastolic blood
pressure>105 mmhg)*
Yes
No
other diseases or causes that will contraindicate
treatment with darbepoetin alfa*
Yes
No
other diseases or causes that will contraindicate
further treatment with darbepoetin alfa*
Yes
No
patients that preoperatively and/or four days
postoperatively have a hemoglobin concentration
> 14 g/dl*
Yes
No
former cancer disease*
Yes
No
disseminated cancer disease*
Yes
No
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rectal cancer stage t4*
Yes
No
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Eligibility Colorectal Cancer NCT00133913
Circulating Tumor Cells in Patients With Metastatic
Colorectal Cancer; ODM derived from:
https://clinicaltrials.gov/show/NCT00133913
All rights reserved. Please visit https://medical-data-
models.org/forms/16766
Eligibility Colorectal Cancer
NCT00133913
Inclusion Criteria
measurable metastatic carcinoma of the colon or
rectum.*
Yes
No
1st or 2nd line chemotherapy (3rd line acceptable
with epidermal growth factor receptor [egfr]
targeted therapy)*
Yes
No
chest/abdomen/pelvis scans every 6-12 weeks*
Yes
No
ecog 0-2*
Yes
No
hemoglobin (hgb) > or = 8g/dl within 7 days prior
to enrollment*
Yes
No
age > or = to 18 years of age*
Yes
No
Exclusion Criteria
cumulative weekly blood draws exceeding
150ml/week*
Yes
No
brain metastasis*
Yes
No
prior history of other carcinoma within the last 5
years, except ductal carcinoma in situ (dcis), non-
invasive cervical cancer or non-melanoma skin
cancer*
Yes
No
surgery within 14 days of the initial blood draw,
excluding surgical placement of a central venous
device*
Yes
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Eligibility Colorectal Cancer NCT00159445
Capecitabine and Gemcitabine in Patients With Metastatic
Colorectal Cancer; ODM derived from:
https://clinicaltrials.gov/show/NCT00159445
All rights reserved. Please visit https://medical-data-
models.org/forms/16767
Eligibility Colorectal Cancer
NCT00159445
Inclusion Criteria
histologically confirmed metastatic
adenocarcinoma of the colon or rectum, with
measurable disease.  the primary histologic
diagnosis is sufficient if there is clear evidence by
imaging and/or markers of metastatic disease
sites.*
Yes
No
patients must have failed cpt-11 and oxaliplatin
based therapies.*
Yes
No
patients must have received at least two prior
chemotherapy regimens for advanced disease
(completed > 4 weeks prior to enrollment).*
Yes
No
tumor must be accessible for biopsy or paraffin
embedded tissue must be available for review.*
Yes
No
swog performance status 0-2.*
Yes
No
agc >1000, platelets >100,000.*
Yes
No
total bilirubin < 3 x upper limit of normal.
transaminase (ast and/or alt) < 2 x upper limit of
normal or < 5 x upper limit of normal in patients
with liver metastasis.*
Yes
No
patients must have a measured or calculated
creatinine clearance greater than 35 ml/min
obtained within 28 days prior to registration.*
Yes
No
age greater than or equal to 18 years*
Yes
No
patients should have hemoglobin > 9 g/dl;
patients may be transfused to achieve this level of
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hemoglobin.*
Yes
No
except for cancer-related abnormalities, patients
should not have unstable or pre-existing major
medical conditions.*
Yes
No
Exclusion Criteria
history of a malignancy other than colon or rectal
cancer, except for adequately treated basal cell
or squamous cell skin cancer, in situ cervical
cancer, or other cancer for which the patient has
been disease-free for five years.*
Yes
No
patients with brain metastasis.*
Yes
No
history of recent (within one year) myocardial
infarction or evidence of congestive heart failure.*
Yes
No
patients that have psychological, familial,
sociological, or geographical conditions that do
not permit medical follow-up and compliance with
the study protocol.*
Yes
No
patients should not have any immediate life-
threatening complications of their malignancies.*
Yes
No
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Eligibility Colorectal Cancer NCT00192075
A Randomized Trial of Avastin + Gemcitabine + 5-
Fluorouracil (5FU)/Folinic Acid Versus Avastin + Oxaliplatin
+ 5FU/Folinic Acid in Metastatic Colorectal Cancer; ODM
derived from: https://clinicaltrials.gov/show/NCT00192075
All rights reserved. Please visit https://medical-data-
models.org/forms/16768
Eligibility Colorectal Cancer
NCT00192075
Inclusion Criteria
patients must have a histological or cytological
diagnosis of the colon or rectum with stage iii
unresectable or stage iv disease.*
Yes
No
urinalysis or urine dipstick for proteinuria of less
than 1+ (i.e. either 0 or trace).  if urine dipstick is
greater than 1+, the 24 hour urine protein must
demonstrate less than 500 mg of protein in 24
hours to allow participation.*
Yes
No
no prior chemotherapy, immunotherapy, or
hormonal treatment for metastatic disease is
acceptable.  however, one prior neo-adjuvant or
adjuvant treatment is acceptable, including
capecitabine, camptothecin-11 (cpt-11), 5
fluorouracil/leucovorin  (5fu/lv) or radiation
containing regimens, (but no oxaliplatin), and only
if progression > 6 months since last adjuvant
treatment.*
Yes
No
prior radiation therapy, including radiation to the
whole pelvis, is allowed (cristy and eckerman
1987) and patients must have recovered from the
acute toxic effects of the treatment prior to study
enrollment.  prior palliative radiation therapy given
to a non-measurable diagnostic site is acceptable
if given > 4 weeks prior to treatment or if other
non-irradiated measurable disease is present.*
Yes
No
no known central nervous system (cns)
metastasis.*
Yes
No
Exclusion Criteria
histology other than adenocarcinoma*
Yes
No
tumors that demonstrate free perforation as
manifested by free air or free fluid in the
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abdomen.  patients with walled-off perforation are
eligible.*
Yes
No
gastroduodenal ulcer determined as active by
endoscopy.*
Yes
No
invasive procedures defined as follows; major
surgical procedures, open biopsy, or significant
traumatic injury within 28 days prior to
randomization, anticipation of need for major
surgical procedure during the course of study,
core biopsy or other minor procedure within 7
days prior to registration.*
Yes
No
following cardiac condition;  new york heart
association (nyha) class iii or iv, myocardial
infarction (mi) within 6 months, unstable angina
within 6 months and current symptomatic
arrhythmia.*
Yes
No
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EUROASPIRE III- Coronary heart disease
HRI Record Questionnaire
Provided by Prof. Keil
Source: Kotseva K, Wood D, De Backer G, De Bacquer D,
Pyörälä K, Keil U; EUROASPIRE Study Group.
Cardiovascular prevention guidelines in daily practice: a
comparison of EUROASPIRE I, II, and III surveys in eight
European countries. Lancet. 2009 Mar 14;373(9667):929-
40. doi: 10.1016/S0140-6736(09)60330-5. PubMed PMID:
19286092
All rights reserved. Please visit https://medical-data-
models.org/forms/16769
HRI Record Questionnaire
Inclusion criteria
Has the patient been on one or more of the
following medication? Antihypertensive drug
therapy, Lipid-lowering drug therapy, Diabetes
therapy (drug therapy or diet alone)
Yes
No
Has at least six months and at most three years
elapsed since the patient started his/her
treatment?
Yes
No
Is the patient free of CHD or other atherosclerotic
disease?
Yes
No
If the answer to all these questions is yes,please
complete this Data Form from the information
recorded in the patient's notes.
Yes
No
Personal information
Patient ID
Patient Title
Mr (1)
Miss (2)
Ms (3)
Mrs (4)
Forename(s)
Surname
Address
Telephone number
National GP number
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General practitioner name
General practitoner address
Telephone number
HRI Record Questionnaire
Date of completion of this form
Date of birth of High Risk Individual (HRI)
Sex
male (1)
female (2)
What was the drug treatment which triggered the
identification of patient?
Antihypertensive therapy  (1)
Lipid-lowering therapy
(2)
Diabetes therapy (diet and/or oral
hypoglycaemics and/or insulin) (3)
History of hypertension
Yes (1)
No (2)
Not recorded (3)
History of hypertension:if yes, Duration in months
History of hyperlipidaemia/ dyslipidaemia
Yes (1)
No (2)
Not recorded (3)
History of hyperlipidaemia/ dyslipidaemia: If yes,
duration in months
History of diabetes
Yes (1)
No (2)
Not recorded (3)
History of diabetes: If yes, duration in months
Smoking status
Non smoker 		 (1)
Is a current non smoker (but previous
smoking history unknown) 	 (2)
Has stopped smoking  (3)
2 / 10
EUROASPIRE III- Coronary heart disease HRI Record Questionnaire
Current smoker (4)
Body height
cm
Body weight
kg
Body Mass Index
kg/m2
Waist circumference
cm
Systolic blood pressure
mmHg
Diastolic blood pressure
mmHg
Heart rate
bpm
Total cholesterol
mmol/l
LDL cholesterol
mmol/l
HDL cholesterol
mmol/l
Triglycerides
mmol/l
Blood glucose level
mmol/l
HbA1C level (in diabetics)
Over the last 3 years, was the patient taking any
of the following medications listed below?
Yes (1)
No (2)
Unsure (3)
Not recorded (4)
Aspirin or other anti-platelet drugs?
Yes (1)
No (2)
Not recorded (3)
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Aspirin or other anti-platelet drugs: Generic name
Aspirin or other anti-platelet drugs: Total daily
dose
mg
Aspirin or other anti-platelet drugs?
Yes (1)
No (2)
Not recorded (3)
Aspirin or other anti-platelet drugs: Generic name
Aspirin or other anti-platelet drugs: Total daily
dose
mg
Beta blockers
Yes (1)
No (2)
Not recorded (3)
Beta blockers:Generic name
Beta Blockers Total daily dose
mg
ACE inhibitors
Yes (1)
No (2)
Not recorded (3)
ACE inhibitors: Generic name
ACE inhibitors : Total daily dose
mg
Angiotensin II receptor antagonists
Yes (1)
No (2)
Not recorded (3)
Angiotensin II receptor antagonists: Generic
name
Angiotensin II receptor antagonists: Total daily
dose
mg
Calcium antagonists
Yes (1)
No (2)
Not recorded (3)
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Calcium antagonists: Generic name
Calcium antagonists: Total daily dose
mg
If inhibitors
Yes (1)
No (2)
Not recorded (3)
If inhibitors: Generic name
If inhibitors: Total daily dose
mg
Nitrates
Yes (1)
No (2)
Not recorded (3)
Nitrates: Generic name
Nitrates: Total daily dose
mg
Diuretics
Yes (1)
No (2)
Not recorded (3)
Diuretics: Generic name
Diuretics: Total daily dose
mg
Diuretics
Yes (1)
No (2)
Not recorded (3)
Diuretics: Generic name
Diuretics: Total daily dose
mg
Other anti-hypertensive drugs
Yes (1)
No (2)
Not recorded (3)
Other Anti-hypertensive drugs: Generic name
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Other Anti-hypertensive drugs: Total daily dose
mg
Digitalis glycosides
Yes (1)
No (2)
Not recorded (3)
Digitalis glycosides: Generic name
Digitalis glycosides: Total daily dose
mg
Antiarrhythmics
Yes (1)
No (2)
Not recorded (3)
Antiarrhythmics:  Generic name
Antiarrhythmics:  Total daily dose
mg
Lipid lowering drugs: Statins
Yes (1)
No (2)
Not recorded (3)
Lipid lowering drugs (Statins): Generic name
Lipid lowering drugs (Statins): Total daily dose
mg
Lipid lowering drugs: Fibrates
Yes (1)
No (2)
Not recorded (3)
Lipid lowering drugs (Fibrates): Generic name
Lipid lowering drugs (Fibrates): Total daily dose
mg
Lipid lowering drugs: Nicotinic acid group
Yes (1)
No (2)
Not recorded (3)
Lipid lowering drugs (Nicotinic acid group):
Generic name
Lipid lowering drugs (Nicotinic acid group): Total
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daily dose
mg
Lipid lowering drugs: Cholesterol absorption
inhibitors
Yes (1)
No (2)
Not recorded (3)
Lipid lowering drugs (Cholesterol absorption
inhibitors): Generic name
Lipid lowering drugs (Cholesterol absorption
inhibitors): Total daily dose
mg
Lipid lowering drugs: Resins
Yes (1)
No (2)
Not recorded (3)
Lipid lowering drugs (Resins): Generic name
Lipid lowering drugs (Resins): Total daily dose
mg
Lipid lowering drugs: Other
Yes (1)
No (2)
Not recorded (3)
Lipid lowering drugs (Other): Generic name
Lipid lowering drugs (Other): Total daily dose
mg
Anti-diabetic drugs: Insulin
Yes (1)
No (2)
Not recorded (3)
Insulin: Generic name
Insulin: Total daily dose
mg
Anti-diabetic drugs: Insulin
Yes (1)
No (2)
Not recorded (3)
Insulin: Generic name
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Insulin: Total daily dose
mg
Anti-diabetic drugs: oral
Yes (1)
No (2)
Not recorded (3)
Oral Antidiabetics: Generic name
Oral Antidiabetics: Total daily dose
mg
Anti-diabetic drugs: oral
Yes (1)
No (2)
Not recorded (3)
Oral Antidiabetics: Generic name
Oral Antidiabetics: Total daily dose
mg
Anti-coagulants
Yes (1)
No (2)
Not recorded (3)
Anti-coagulants: Generic name
Anti-coagulants: Total daily dose
mg
Oral contraceptive pill
Yes (1)
No (2)
Not recorded (3)
Oral contraceptive pill: Generic name
Oral contraceptive pill: Total daily dose
Hormone replacement therapy
Yes (1)
No (2)
Not recorded (3)
Hormone replacement therapy: Generic name
Hormone replacement therapy: Total daily dose
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Appetite suppressants or other antiobesity
Yes (1)
No (2)
Not recorded (3)
Appetite suppressants/other antiobesity: Generic
name
Appetite suppressants or other antiobesity: Total
daily dose
mg
Nicotine replacement therapy
Yes (1)
No (2)
Not recorded (3)
Nicotine replacement therapy: Generic name
Nicotine replacement therapy: Total daily dose
mg
Nicotine replacement therapy
Chewing Gum (1)
Nasal spray (2)
Inhalator (3)
Patches (4)
Losenges (5)
Bupropion
Yes (1)
No (2)
Not recorded (3)
Bupropion: Generic name
Bupropion: Total daily dose
mg
Other medication
Yes (1)
No (2)
Not recorded (3)
Other medications: Generic name
Other medications: Total daily dose
mg
Is any of the medication prescribed a
combination of 2 drugs in one tablet?
Yes (1)
No (2)
Don´t know/Unsure (3)
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If yes, please specify
High Risk Individual Record Form completed
Yes
No
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Eligibility Chronic Hepatitis C
NCT00418054
Study of Nitazoxanide Combined With Peginterferon
Compared to Peginterferon Monotherapy in the Treatment
of Hepatitis C; ODM derived from:
https://clinicaltrials.gov/show/NCT00418054
All rights reserved. Please visit https://medical-data-
models.org/forms/16770
Eligibility Chronic Hepatitis C
NCT00418054
Inclusion Criteria
age ≥18 years.*
Yes
No
chronic hepatitis c infection (at least 6 months)
evidenced by a positive enzyme immunoassay for
anti-hcv-antibodies and a positive quantitative rt-
pcr amplification of hcv rna.*
Yes
No
chronic inflammation on liver biopsy compatible
with a diagnosis of chronic viral hepatitis.*
Yes
No
hcv genotype 4.*
Yes
No
patients that have not previously received
peginterferon.*
Yes
No
Exclusion Criteria
patients unable to take oral medications.*
Yes
No
use of ribavirin within 30 days prior to
enrollment.*
Yes
No
females who are either pregnant, breast-feeding
or not using birth control and are sexually active.*
Yes
No
any investigational drug therapy within 30 days
prior to enrollment other than through romark
study number rm01-3027.*
Yes
No
patients with other causes of liver disease.*
Yes
No
1 / 2
transplant recipients receiving immune
suppression therapy.*
Yes
No
patient co-infected with human immunodeficiency
virus, hepatitis a virus, hepatitis b virus, or
hepatitis d virus based on enzyme
immunoassay.*
Yes
No
patients with decompensated cirrhosis,
thrombocytopenia (platelet count <80,000),
neutropenia, history of variceal bleeding, ascites,
hepatic encephalopathy or ctp scores >6.*
Yes
No
patients with history of alcoholism (unless
abstinent for 2 years) or with an alcohol
consumption of >20 grams per day.*
Yes
No
patients who are clinically unstable.*
Yes
No
patients with any concomitant condition that, in
the opinion of the investigator would preclude
evaluation of response or make it unlikely that the
contemplated course of therapy and follow-up
could be completed.*
Yes
No
history of hypersensitivity or intolerance to any of
the excipients comprising the nitazoxanide tablets
or peginterferon alfa-2b solution for injection.*
Yes
No
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Eligibility Colorectal Cancer NCT00199654
Positron Emission Tomography (PET) Interest in the Follow
Up of Colorectal Cancer Stage II and III; ODM derived
from: https://clinicaltrials.gov/show/NCT00199654
All rights reserved. Please visit https://medical-data-
models.org/forms/16771
Eligibility Colorectal Cancer
NCT00199654
Inclusion Criteria
signed and dated written informed consent*
Yes
No
confirmed stage ii or iii (tnm)*
Yes
No
patient with curative surgery for colorectal
adenocarcinoma*
Yes
No
total digestive endoscopy prior or post surgery.*
Yes
No
age > 18 years old*
Yes
No
normal liver ultrasound and chest x-ray or
thoraco-abdomino pelvic computed tomography
(ct) scan.*
Yes
No
in fertile women, efficient contraception or
postmenopausal patient (amenorrhea for at least
1 year)*
Yes
No
Exclusion Criteria
serious concomitant pathology*
Yes
No
uncontrolled diabetes with a classical treatment
(glycaemia >1.4 g/l)*
Yes
No
other malignant tumour within the last 5 years
(except for curatively treated basocellular
carcinoma of the skin or in situ cervical
carcinoma).*
Yes
No
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uncontrolled infection*
Yes
No
women who are pregnant or lactating*
Yes
No
inability to understand informed consent*
Yes
No
psychological or geographic impossibility to follow
up for three years.*
Yes
No
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Clinical survey Micafungin Phase NIT
Clinical survey Micafungin Phase NIT
Principal Investigator PD Dr. Jörg Janne Vehreschild,
Universitätsklinikum Köln
Licence:CC-BY
All rights reserved. Please visit https://medical-data-
models.org/forms/16772
Clinical survey Micafungin Phase
NIT
Medical History (PGID 272)
Body Height (q_1140 - Typ 141)
cm
Body weight (q_1141 - Typ 141)
>= 0
kg
Specifiy the date of hospitalization (q_1143 - Typ
361)
Specify the date of discharge from hospital:
(q_1232 - Typ 361)
By which department was the patient treated
initially? (q_1144 - Typ 131)
Hematology/oncology (1)
Other: (10)
Surgery, visceral (2)
Surgery, traumatology (3)
Surgery, thoracic (4)
Nephrology (5)
Infectious Diseases (6)
Cardiology (7)
Ear/Nose/Throat (8)
Ophthalmology (9)
if previous answered with "other", please specify
Specify the underlying diseases/conditions
of the patient: (q_1145 - Typ 121)
AML
Yes
No
ALL
Yes
No
CML
Yes
No
CLL
Yes
No
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MDS
Yes
No
Multiple Myeloma
Yes
No
B-NHL
T-NHL
Yes
No
HD
Yes
No
Autologous Stem Cell Transplantation
Yes
No
Allogeneic Stem Cell Transplantation
Yes
No
Lung
Yes
No
Kidney
Yes
No
Liver
Yes
No
Pancreas
Yes
No
Heart
Yes
No
Other Solid Organ Transplantation
Yes
No
HIV/AIDS
Yes
No
Neurosurgical intervention
Yes
No
Diabetes mellitus
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Yes
No
Solid tumor:
Yes
No
other
Treatment
Was the patient treated on an ICU when
micafungin treatment was initiated? (q_1146 -
Typ 111)
Surgical ICU (1)
Medical ICU (2)
Anaethesiological ICU (3)
Neurological / Neurosurgical ICU (4)
Other: (5)
Patient was not treated on ICU (6)
if previous answered with "other", please specify
If yes, for how many days was the patient treated
on the ICU BEFORE initiation of micafungin
treatment? (q_1233 - Typ 141)
Indication for treatment
What was the indication for treatment with
micafungin? (q_1147 - Typ 111)
Antifungal prophylaxis (1)
Empirical antifungal treatment (2)
Current fungal infection (3)
Secondary prophylaxis (4)
Treatment failure of earlier antifungal
treatment (5)
What was the level of evidence for the fungal
infection? (q_1148 - Typ 111)
No evidence of invasive fungal infection
(1)
Possible invasive fungal infection (2)
Probable invasive fungal infection (3)
Proven invasive fungal infection (4)
I don't have access to the revised
EORTC/MSG criteria (5)
If applicable, which pathogen(s) was
micafungin treatment targeted at?
(q_1149 - Typ 121)
Candida spp
Yes
No
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Aspergillus spp
Yes
No
other pathogen
If applicable, which sites were involved in
the fungal infection? (q_1150 - Typ 121)
Blood
Yes
No
Lung
Yes
No
Spleen
Yes
No
Liver
Yes
No
Kidney
Yes
No
CNS
Yes
No
Skin
Yes
No
Other
Which risk factors for invasive fungal
disease were present in the patient?
(q_1151 - Typ 121)
Candida colonization
Yes
No
Central venous catheter
Yes
No
Dust exposure
Yes
No
Chemotherapy (any) during the last 4 week
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Yes
No
Graft versus Host Disease (GvHD)
Yes
No
Mechanical ventilation
Yes
No
Mucositis CTCAE grade III - IV (if not assessable:
unable to take in food, need of analgetics)
Yes
No
Parenteral nutrition
Yes
No
Prolonged ICU stay (> 4 days)
Yes
No
Renal failure / dialysis
Yes
No
Surgical procedure
Yes
No
T-cell depleting agents (alemtuzumab,
fludarabine) during the last 8 weeks
Yes
No
other risk factor
How many different systemically active
antibacterial drugs did the patient receive from
the time of admission until initiation of
micafungin? (q_1157 - Typ 141)
For how many days had the patient been on
antibiotic treatment before initiation of micafungin
therapy? (q_1158 - Typ 141)
APACHE Score
Was the APACHE II score calculated for the
patient within 48 hours of micafungin treatment
initiation? (q_1156 - Typ 111)
Yes
No
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APACHE II Score
Please specify the use of
immunosuppressants from the time of
hospital admission until initiation of
micafungin treatment: (q_1160 - Typ 363)
Azathioprine (Total Daily Dose (mg))
mg/d
Azathioprine (Days treated)
Days
Corticosteroids (use prednisone equivalents)
(Total Daily Dose (mg))
mg/d
Corticosteroids (use prednisone equivalents)
(Days Treated)
Days
Cyclophosphamide (Total Daily Dose (mg))
mg/d
Cyclophosphamide (Days Treated)
Days
Cyclosporine A (give lower limit of target serum
level instead of daily dose) (Total Daily Dose
(mg))
mg/d
Cyclosporine A (give lower limit of target serum
level instead of daily dose) (Days Treated)
Days
Daclizumab (Total Daily Dose (mg))
mg/d
Daclizumab (Days Treated)
Days
Infliximab (Total Daily Dose (mg))
mg/d
Infliximab (Days Treated)
Days
Methotrexate (Total Daily Dose (mg))
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mg/d
Methotrexate (Days Treated)
Days
Mycophenolatemofetil (Total Daily Dose (mg))
mg/d
Mycophenolatemofetil (Days Treated)
Days
Sirolimus (give lower limit of target serum level
instead of daily dose) (Total Daily Dose (mg))
mg/d
Sirolimus (give lower limit of target serum level
instead of daily dose) (Days Treated)
Days
Tacrolimus (give lower limit of target serum level
instead of daily dose) (Total Daily Dose (mg))
mg/d
Tacrolimus (give lower limit of target serum level
instead of daily dose) (Days Treated)
Days
Please state the types of isolation used
accomodating the patient: (q_1161 - Typ
121)
LAF (Laminar Air Flow)
Yes
No
HEPA (High Efficiency Particulate Air Filtration)
Yes
No
Reverse isolation
Yes
No
No isolation
Yes
No
Please state the total daily dose and the
days on treatment for antifungal drugs
administered BEFORE initiation of
micafungin: (q_1162 - Typ 363)
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Amphotericin B deoxycholate (Daily Dose (mg))
mg/d
Amphotericin B deoxycholate (Days on
Treatment)
Days
Amphotericin B lipid complex (Daily Dose (mg))
mg/d
Amphotericin B lipid complex (Days on
Treatment)
Days
Amphotericin B, liposomal (Daily Dose (mg))
mg/d
Amphotericin B, liposomal (Days on Treatment)
Days
Caspofungin (Daily Dose (mg))
mg/d
Caspofungin (Days on Treatment)
Days
Voriconazole (Daily Dose (mg))
mg/d
Voriconazole (Days on Treatment)
Days
Fluconazole (Daily Dose (mg))
mg/d
Fluconazole (Days on Treatment)
Days
Isavuconazole (Daily Dose (mg))
mg/d
Isavuconazole (Days on Treatment)
Days
Itraconazole (Daily Dose (mg))
mg/d
Itraconazole (Days on Treatment)
Days
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Ketoconazole (Daily Dose (mg))
mg/d
Ketoconazole (Days on Treatment)
Days
Micafungin (Daily Dose (mg))
mg/d
Micafungin (Days on Treatment)
Days
Posaconazole (Daily Dose (mg))
mg/d
Posaconazole (Days on Treatment)
Days
Please state the total daily dose and the
days on treatment for antifungal drugs
administered AFTER initiation of
micafungin: (q_1163 - Typ 363)
Amphotericin B deoxycholate (Daily Dose (mg))
mg/d
Amphotericin B deoxycholate (Days on
Treatment)
Days
Amphotericin B lipid complex (Daily Dose (mg))
mg/d
Amphotericin B lipid complex (Days on
Treatment)
Days
Amphotericin B, liposomal (Daily Dose (mg))
mg/d
Amphotericin B, liposomal (Days on Treatment)
Days
Caspofungin (Daily Dose (mg))
mg/d
Caspofungin (Days on Treatment)
Days
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Voriconazole (Daily Dose (mg))
mg/d
Voriconazole (Days on Treatment)
Days
Fluconazole (Daily Dose (mg))
mg/d
Fluconazole (Days on Treatment)
Days
Isavuconazole (Daily Dose (mg))
mg/d
Isavuconazole (Days on Treatment)
Days
Itraconazole (Daily Dose (mg))
mg/d
Itraconazole (Days on Treatment)
Days
Ketoconazole (Daily Dose (mg))
mg/d
Ketoconazole (Days on Treatment)
Days
Micafungin (Daily Dose (mg))
mg/d
Micafungin (Days on Treatment)
Days
Posaconazole (Daily Dose (mg))
mg/d
Posaconazole (Days on Treatment)
Days
Temperature
Did the patient develop temperature >= 38.0°C
possibly associated with the fungal infection
treated with micafungin? (q_1202 - Typ 112)
Yes
No
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If yes, please state the total number of days with
temperature >= 38.0°C: (q_1203 - Typ 141)
Days
Specify the first day of temperature >= 38.0°C:
(q_1204 - Typ 361)
Specify the date of defervescence: (q_1205 - Typ
361)
Please state the number of diagnostic
procedures performed in the given
categories, and how many of them
showed findings indicative for invasive
fungal infections. (q_1201 - Typ 363)
CT (Total Qty. Performed)
MRT (Total Qty. Performed)
Sonography (Total Qty. Performed)
Fundoscopy (Total Qty. Performed)
Microbiology/Serology/PCR (Total Qty.
Performed)
Tissue sample (Total Qty. Performed)
CT (Qty. Positive)
MRT (Qty. Positive)
Sonography (Qty. Positive)
Fundoscopy (Qty. Positive)
Microbiology/Serology/PCR (Qty. Positive)
Tissue sample (Qty. Positive)
CTSpecify the date of the first CT indicative for
invasive fungal infection: (q_1182 - Typ 361)
MRTSpecify the date of the first MRT indicative
for invasive fungal infection: (q_1183 - Typ 361)
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SonographySpecify the date of the first
sonography indicative for invasive fungal
infection: (q_1184 - Typ 361)
FundoscopySpecify the date of the first
fundoscopy indicative for invasive fungal infection:
(q_1185 - Typ 361)
MicrobiologySpecify the date of the first
microbiological culture indicative for invasive
fungal infection: (q_1186 - Typ 361)
Tissue specimenSpecify the date of the first
tissue sample indicative of invasive fungal
infection: (q_1187 - Typ 361)
Please indicate sites with CT
abnormalities indicative of invasive fungal
infections: (q_1188 - Typ 122)
Lung
Yes
No
Liver
Yes
No
Spleen
Yes
No
Sinus
Yes
No
CNS
Yes
No
Kidney
Yes
No
Other bone lesion
Yes
No
Other soft tissue lesion
Yes
No
Briefly describe the type of finding: (q_1195 - Typ
142)
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Please indicate sites with MRT
abnormalities indicative of invasive fungal
infections: (q_1189 - Typ 122)
Lung
Yes
No
Liver
Yes
No
Spleen
Yes
No
Sinus
Yes
No
CNS
Yes
No
Kidney
Yes
No
Other bone lesion
Yes
No
Other soft tissue lesion
Yes
No
Briefly describe the type of finding: (q_1196 - Typ
142)
Please indicate sites with sonographical
abnormalities indicative of invasive fungal
infections: (q_1190 - Typ 122)
Pleura
Yes
No
Liver
Yes
No
Spleen
Yes
No
Kidney
Yes
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No
Other soft tissue lesion
Yes
No
Briefly describe the type of finding: (q_1197 - Typ
142)
Sites of Mycosis, Fundoscopy finding
Briefly describe the type of finding: (q_1198 - Typ
142)
Please indicate sites/secretions from
where microbiological cultures indicative
of invasive fungal infection were obtained:
(q_1191 - Typ 122)
Ascites
Yes
No
BAL
Yes
No
Cerebrospinal fluid
Yes
No
Blood
Yes
No
Deep wound swabs
Yes
No
Nasopharyngeal secretion
Yes
No
Sinonasal swabs
Yes
No
Sputum
Yes
No
Superficial skin/wound swabs
Yes
No
Urine
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Yes
No
Briefly describe the type of finding: (q_1199 - Typ
142)
Please indicate sites from which tissue
samples indicative of invasive fungal
infections were obtained: (q_1192 - Typ
122)
Lung
Yes
No
Liver
Yes
No
Spleen
Sinus
Yes
No
CNS
Yes
No
Kidney
Yes
No
Other bone lesion
Yes
No
Other soft tissue lesion
Yes
No
Briefly describe the type of finding: (q_1200 - Typ
142)
By which method were tissue samples
with results indicate of invasive fungal
infection obtained? (q_1193 - Typ 122)
endoscopic biopsy
Yes
No
blind needle biopsy
Yes
No
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guided needle biopsy (CT, sonography)
Yes
No
surgical biopsy
Yes
No
Micafungin Treatment (PGID 280)
Please state the first day of micafungin treatment:
(q_1209 - Typ 361)
Please state the dosage (mg) used for the first
application micafungin (loading dose): (q_1207 -
Typ 141)
mg
Please state the dosage (mg) used after first
application of micafungin (maintenance dose):
(q_1206 - Typ 141)
mg
For how many days was the patient treated with
micafungin? (q_1208 - Typ 141)
Days
Did the patient receive hematopoietic growth
factors (e.g. G-CSF)? (q_1211 - Typ 111)
Yes
No
Did the patient receive any other concomitant
medication, that might have influenced treatment
outcome or tolerability/efficacy of micafungin?
(q_1212 - Typ 111)
Yes
No
If yes, please state the days on treatment with
that drug and the total daily dose administered:
(q_1213 - Typ 144)
Days
Please state the number of days and the
dosage of the following CYP450 inductors
used DURING treatment with micafungin:
(q_1210 - Typ 363)
Rifampicin (Daily Dose (mg))
mg/d
Rifampicin (Days on Treatment)
Days
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Phenytoin (Daily Dose (mg))
mg/d
Phenytoin (Days on Treatment)
Days
Carbamazepine (Daily Dose (mg))
mg/d
Carbamazepine (Days on Treatment)
Days
Dexamethasone (Daily Dose (mg))
mg/d
Dexamethasone (Days on Treatment)
Days
Efavirenz (Daily Dose (mg))
mg/d
Efavirenz (Days on Treatment)
Days
Nevirapine (Daily Dose (mg))
mg/d
Nevirapine (Days on Treatment)
Days
Did breakthrough fungal infections occur
during treatment with micafungin?
(q_1214 - Typ 121)
Aspergillosis
Yes
No
Candidiasis, species:
Yes
No
Fusariosis
Yes
No
Zygomycosis, species:
Yes
No
other species
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Yes
No
Which of the following adverse events
occurred during treatment that were at
least remotely related to micafungin?
(q_1215 - Typ 121)
Chills
Yes
No
Diarrhea
Yes
No
Phlebitis
Yes
No
Skin rash
Yes
No
Thrombocytopenia
Yes
No
Other, please give a list:
Did any adverse event during treatment with
micafungin or during follow up cause prolongation
of hospitalization or the need of unscheduled re-
hospitalization after discharge? (q_1216 - Typ
111)
Yes
No
Did any adverse event during treatment with
micafungin or during follow up cause permanent
impairment of any body function? (q_1217 - Typ
111)
Yes
No
Did any adverse event during treatment with
micafungin or during follow up cause a life
threatening condition? (q_1218 - Typ 111)
Yes
No
Do you know of any congenital anomalies occur
in children born during treatment or follow up?
(q_1219 - Typ 111)
Yes
No
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Did any other severe adverse event occur during
treatment with micafungin or during follow (e.g.
abnormal laboratory findings)? (q_1220 - Typ
111)
Yes
No
Please specify the laboratory parameters
before and during micafungin treatent.
(q_1164 - Typ 363)
GOT (U/l) (Before micafungin treatment)
U/I
GPT (U/l) (Before micafungin treatment)
U/I
GGT (U/l) (Before micafungin treatment)
U/I
Bilirubin (mg/dl) (Before micafungin treatment)
U/I
Alkaline phosphatase (U/l) (Before micafungin
treatment)
U/I
LDH (U/l) (Before micafungin treatment)
U/I
Creatinine (mg/dl) (Before micafungin treatment)
U/I
GOT (U/l) (During micafungin treatment)
U/I
GPT (U/l) (During micafungin treatment)
U/I
GGT (U/l) (During micafungin treatment)
U/I
Bilirubin (mg/dl) (During micafungin treatment)
U/I
Alkaline phosphatase (U/l) (During micafungin
treatment)
U/I
LDH (U/l) (During micafungin treatment)
U/I
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Creatinine (mg/dl) (During micafungin treatment)
U/I
Did the patient show a neutrophil count < 500 /µl
at any time during treatment? (q_1152 - Typ 112)
Yes
No
If patient had neutropenia, what was the first day
with a neutrophile count < 500 /µl? (q_1153 - Typ
361)
If patient had neutropenia, what was the last day
with a neutrophile count < 500 /µl? (q_1154 - Typ
361)
Outcome Micafungin (PGID 284)
Please judge the outcome of MICAFUNGIN
treatment: (q_1221 - Typ 111)
Response (1)
Stabilization (2)
Failure (3)
Did you switch to another antifungal drug at the
end of micafungin treatment? (q_1222 - Typ 111)
Yes
No
If yes, give the reason for the switch
and the dose used: (q_1223 - Typ 144)
mg
Was eradication of the causative pathogen
achieved during MICAFUNGIN treatment?
(q_1224 - Typ 112)
Yes
No
What was the total amount of days spent on the
ICU during micafungin treatment? (q_1235 - Typ
141)
Days
Was the patient transferred to the ICU during
micafungin treatment? (q_1234 - Typ 112)
Yes
No
Was the patient alive at the end of MICAFUNGIN
treatment? (q_1225 - Typ 112)
Yes
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No
If not, was death related to the fungal infection?
(q_1226 - Typ 112)
Yes
No
Other Antifungal, Outcome Final
Antifungal Treatment (PGID 286)
Please judge the outcome of #v_442# treatment:
(q_1227 - Typ 111)
Response (1)
Stabilization (2)
Failure (3)
Was eradication of the causative pathogen
achieved during #v_442# treatment? (q_1228 -
Typ 112)
Yes
No
Was the patient alive at the end of #v_442#
treatment? (q_1229 - Typ 112)
Yes
No
If not, was death related to the fungal infection?
(q_1230 - Typ 112)
Yes
No
Follow Up (PGID 287)
Did the fungal infection treated with micafungin
relapse within 28 days after treatment
discontinuation? (q_1236 - Typ 112)
No (1)
Yes (2)
Unknown (3)
Please give any comments or suggestions that
you have, be it on the documented case or on the
survey as a whole: (q_1413 - Typ 142)
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Eligibility Colorectal Cancer NCT00199797
Phase I Trial of huA33 Plus Chemotherapy in Patients With
Metastatic Colorectal Cancer; ODM derived from:
https://clinicaltrials.gov/show/NCT00199797
All rights reserved. Please visit https://medical-data-
models.org/forms/16773
Eligibility Colorectal Cancer
NCT00199797
Inclusion Criteria
patients will be eligible for enrollment if they fulfill
all of the following criteria:*
Yes
No
1. metastatic colorectal cancer*
Yes
No
2. histologically or cytologically proven colorectal
cancer*
Yes
No
3. expected survival of at least 4 months.*
Yes
No
4. not more than 2 different pretreatment
regimens*
Yes
No
5. ecog performance status 0-2.*
Yes
No
6. within the 2 weeks prior to the first dose of
hua33, the following vital laboratory parameters:*
Yes
No
lab parameter range*
Yes
No
neutrophil count > 1.5 x 109/l*
Yes
No
platelet count > 150 x 109/l*
Yes
No
serum bilirubin < 2 mg/dl*
Yes
No
creatinine clearance >50 ml/ min*
Yes
No
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7. age ≥ 18 years*
Yes
No
8. able and willing to give valid written informed
consent*
Yes
No
Exclusion Criteria
patients will be excluded from the study for any of
the following reasons:*
Yes
No
1. untreated active metastatic disease to the
central nervous system defined as new or
enlarging lesions on ct or mri.*
Yes
No
2. surgery or radiotherapy of brain metastases
within 3 months prior to the first dose of hua33.*
Yes
No
3. metastatic disease involving > 50% of liver
volume.*
Yes
No
4. other serious illnesses, eg, serious infections
requiring antibiotics, bleeding disorders.*
Yes
No
5. chemotherapy, radiation therapy, or
immunotherapy within 4 weeks prior to first
dosing (6 weeks for nitrosoureas).*
Yes
No
6. previous treatment with oxaliplatin.*
Yes
No
7. previous treatment with hua33 monoclonal
antibody or antibody fragment.*
Yes
No
8. concomitant treatment with systemic
corticosteroids.  topical or inhalational
corticosteroids are permitted.*
Yes
No
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9. known hiv, hepatitis b or c positivity.*
Yes
No
10. mental impairment that may compromise the
ability to give informed consent and comply with
the requirements of the study.*
Yes
No
11. lack of availability of the patient for clinical
and laboratory follow-up assessment.*
Yes
No
12. participation in any other clinical trial involving
another investigational agent within 4 weeks prior
to first dosing.*
Yes
No
13. pregnancy or breastfeeding.*
Yes
No
14. women of childbearing potential: refusal or
inability to use effective means of contraception.*
Yes
No
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Eligibility Colorectal Cancer NCT00208260
Intensified Chemotherapy in CRC After Resection of Liver
Metastases; ODM derived from:
https://clinicaltrials.gov/show/NCT00208260
All rights reserved. Please visit https://medical-data-
models.org/forms/16774
Eligibility Colorectal Cancer
NCT00208260
Inclusion Criteria
histologically proven adenocarcinoma of the
colon or rectum without previous resection, or
clinically asymptomatic (with or without stent)*
Yes
No
hepatic unresectable metastases r0: due to close
vascular contact, or due to liver remaining mass
less than 25 to 30 % of functional liver.*
Yes
No
not optimally resectable metastases*
Yes
No
extra-hepatic disease will be accepted in case of:
asymptomatic primary tumour  or tumor requiring
no urgent surgery (in less than 3 months); three
of less than three lung metastases (thoracic scan
diameter less than 2 cm) and potentially
respectable.*
Yes
No
synchronous and metachronous hepatic
metastases*
Yes
No
who performance status 0-1*
Yes
No
adjuvant chemotherapy allowed, except
oxaliplatin and irinotecan based combination.*
Yes
No
no prior treatment of the liver metastases,
whatever.*
Yes
No
life expectancy equal or more than 3 months*
Yes
No
Exclusion Criteria
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Eligibility Colorectal Cancer NCT00291785
Phase I/II CT 2106 and 5-FU/FA in Colorectal Cancer;
ODM derived from:
https://clinicaltrials.gov/show/NCT00291785
All rights reserved. Please visit https://medical-data-
models.org/forms/16775
Eligibility Colorectal Cancer
NCT00291785
Inclusion Criteria
histologically proven metastatic colorectal
adenocarcinoma, failing one prior treatment
containing oxaliplatin plus 5-fu/fa*
Yes
No
at least one measurable lesion according to recist
criteria for both phase i and ii*
Yes
No
ecog performance status 0 or 1*
Yes
No
adequate hematologic, renal and hepatic
function*
Yes
No
wash out period of at least 4 weeks from surgery,
4 weeks from radiotherapy*
Yes
No
Exclusion Criteria
past or concurrent history of neoplasm other than
colorectal adenocarcinoma, except curatively
treated non melanoma skin cancer or in situ
carcinoma of the cervix.*
Yes
No
pregnant or lactating patients*
Yes
No
prior treatment with camptothecins*
Yes
No
presence or history of cns metastasis or
carcinomatous leptomeningitis*
Yes
No
current active infection per investigator
assessment*
Yes
No
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unresolved bowel obstruction or partial
obstruction, uncontrolled crohn's disease or
ulcerative colitis*
Yes
No
current history of chronic diarrhea greater than or
equal to grade 1 (ctcae version 3)*
Yes
No
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Eligibility Colorectal Cancer NCT00291785
Eligibility Colorectal Cancer NCT00303771
Combination Chemotherapy as First-Line Therapy in
Treating Older Patients With Metastatic Colorectal Cancer
That Cannot Be Removed By Surgery; ODM derived from:
https://clinicaltrials.gov/show/NCT00303771
All rights reserved. Please visit https://medical-data-
models.org/forms/16776
Eligibility Colorectal Cancer
NCT00303771
Criteria
histologically confirmed adenocarcinoma of the
colon or rectum*
Yes
No
metastatic disease*
Yes
No
unresectable disease*
Yes
No
measurable disease that is outside the field of
prior irradiation*
Yes
No
no brain metastases*
Yes
No
patient characteristics:*
Yes
No
karnofsky performance status 60-100%*
Yes
No
absolute neutrophil count ≥ 1,500/mm^3*
Yes
No
platelet count ≥ 100,000/mm^3*
Yes
No
transaminases ≤ 5 times normal*
Yes
No
bilirubin ≤ 1.5 times normal*
Yes
No
alkaline phosphatase < 3 times normal (5 times
normal if due to hepatic involvement)*
Yes
No
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creatinine clearance > 45 ml/min*
Yes
No
life expectancy > 3 months*
Yes
No
no psychological, social, or geographical situation
that would preclude study treatment*
Yes
No
no chronic diarrhea or enteropathy*
Yes
No
no coronary insufficiency or symptomatic cardiac
disease*
Yes
No
no other malignancy unless curatively treated*
Yes
No
no contraindication to chemotherapy*
Yes
No
prior concurrent therapy:*
Yes
No
at least 6 months since prior adjuvant
chemotherapy for the primary tumor*
Yes
No
no prior extensive resection*
Yes
No
no other concurrent anticancer therapy*
Yes
No
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Eligibility Colorectal Cancer NCT00560365
Follow-Up Study of Patients Who Have Undergone Surgery
for Stage I, Stage II, or Stage III Colorectal Cancer; ODM
derived from: https://clinicaltrials.gov/show/NCT00560365
All rights reserved. Please visit https://medical-data-
models.org/forms/16777
Eligibility Colorectal Cancer
NCT00560365
Criteria
diagnosis of primary colorectal cancer*
Yes
No
stage i-iii disease*
Yes
No
have undergone curative resection (i.e., no
residual disease [r0])*
Yes
No
microscopically clear margins*
Yes
No
complete normal colonic imaging pre-operatively
(or post-operatively if unable to view complete
colon pre-operatively) by colonoscopy, barium
enema, ct pneumocolon, or virtual colonoscopy*
Yes
No
post-operative blood cea ≤ 10 ng/ml (if the normal
range is ≤ 5 ng/ml) or < 2 times upper limit of
normal (if normal range is > 5 ng/ml)*
Yes
No
for patients undergoing adjuvant therapy, cea
should be measured after completion of
chemotherapy*
Yes
No
has completed primary curative treatment, as
deemed by hospital clinician*
Yes
No
patients awaiting stoma closure allowed*
Yes
No
no evidence of metastatic disease on pre- or
post-operative liver ct scan (or ultrasound) and
chest ct scan (or chest x-ray)*
Yes
No
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no diagnosis of familial adenomatous polyposis
(fap) or dominantly inherited colon cancer*
Yes
No
patient characteristics:*
Yes
No
no concurrent serious illness*
Yes
No
history of other carcinoma allowed provided
primary treatment has been completed, there is
no evidence of recurrent disease, and there is no
follow-up that conflicts with study follow-up*
Yes
No
prior concurrent therapy:*
Yes
No
see disease characteristics*
Yes
No
pre-operative radiotherapy or chemoradiotherapy
for rectal cancer allowed provided curative
resection has been achieved*
Yes
No
no concurrent participation in a primary treatment
clinical trial with conflicting follow-up
requirements*
Yes
No
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IHC Results, Tarceva in NSCLC patients who
have EGFR-positive tumors NCT00373425
Sponsor: OSI Pharmaceuticals 
Information provided by (Responsible Party): Astellas
Pharma Inc (OSI Pharmaceuticals) 
A multicenter, randomized, double-blind, placebo-
controlled, phase 3 study of single-agent Tarceva®
(erlotinib) following complete tumor resection with or
without adjuvant chemotherapy in patients with stage IB-
IIIA non-small cell lung carcinoma who have EGFR-positive
tumors. See
https://clinicaltrials.gov/ct2/show/NCT00373425
Part of Study: Results - IHC
All rights reserved. Please visit https://medical-data-
models.org/forms/16778
IHC Results, Tarceva in NSCLC
patients who have EGFR-positive
tumors NCT00373425
Header
Patient's Screening Number
Specimen ID (from Pathology Report)
IHC Results
Specimen received: Blocks:
Specimen received: Slides:
Date received
Number
Technician
Result:
Positive (1)
Negative (2)
Undetermined (3)
Assess the total percentage of tumor cells with
membrane stained (any intensity) with EGFr. (%
of tumor cells)
%
Assess the highest intensity of membrane
staining in EGFr stained cells.
0, No Staining (1)
1+, Weak Staining (2)
2+, Moderate Staining (3)
3+, Strong Staining (4)
Assess the percentage of cells displaying the
highest intensity of membrane staining. (% of
cells at highest intensity)
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%Describe membrane staining as predominantly
complete or incomplete.
Complete (1)
Incomplete (2)
Assess the percentage of tumor cells showing
only cytoplasmic staining. (% of tumor cells with
cytoplasmic staining)
%
Additional Comments
Pathologist's Signature
Report Date
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IHC Results, Tarceva in NSCLC patients who have EGFR-positive tumors
NCT00373425
Protocol Waiver Approval, Tarceva in NSCLC patients
who have EGFR-positive tumors NCT00373425
Sponsor: OSI Pharmaceuticals 
Information provided by (Responsible Party): Astellas
Pharma Inc (OSI Pharmaceuticals) 
A multicenter, randomized, double-blind, placebo-
controlled, phase 3 study of single-agent Tarceva®
(erlotinib) following complete tumor resection with or
without adjuvant chemotherapy in patients with stage IB-
IIIA non-small cell lung carcinoma who have EGFR-positive
tumors. See
https://clinicaltrials.gov/ct2/show/NCT00373425
Part: Protocol Waiver Approval
All rights reserved. Please visit https://medical-data-
models.org/forms/16779
Protocol Waiver Approval, Tarceva in
NSCLC patients who have EGFR-
positive tumors NCT00373425
Header
Screening number
Site Contact
Investigator Name
Form Completed by
Date
Telephone number
Fax number
Waiver Request
Waiver request information
Screening Eligibility (1)
Treatment Eligibility (2)
If screening eligibility: Criterion Letter(s):
If treatment eligibility: Criterion Number(s):
Reason for waiver request
Covance Review
Clinical Name (please print)
Signature
1 / 2
Date
OSI Review
Clinical Name (please print)
Signature
Date
Waiver Request
Request approved (1)
Request denied (specify reason) (2)
If request denied, specify reason:
For OSI Use Only
Attention (please print)
Faxed by (please print)
Date
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Protocol Waiver Approval, Tarceva in NSCLC patients who have EGFR-
positive tumors NCT00373425
Eligibility Diabetes Mellitus Type II
NCT00151697
LANN-study: Lantus, Amaryl, Novorapid, Novomix Study;
ODM derived from:
https://clinicaltrials.gov/show/NCT00151697
All rights reserved. Please visit https://medical-data-
models.org/forms/16781
Eligibility Diabetes Mellitus Type II
NCT00151697
Inclusion Criteria
failing maximal oral treatment, defined as mean
fasting blood glucose over 8 mmol/l and hba1c
over 7.5% for three months or more*
Yes
No
bmi 25 - 35 kg/m2*
Yes
No
fasting plasma c-peptide level over 0.3 nmol/l*
Yes
No
stable metformin and sulfonylurea dose for at
least three months*
Yes
No
stable weight for at least three months (change
maximal 2 kg)*
Yes
No
Exclusion Criteria
fasting glucose over 25 mmol/l*
Yes
No
use of alpha-glucosidase inhibitors or
thiazolidinediones in the two months preceding
the study*
Yes
No
renal or liver failure defined as serum creatinine
over 150 micromol/l, liver enzymes over 1.5
upper normal limit*
Yes
No
heart failure*
Yes
No
pregnancy*
Yes
No
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alcohol more than two units per day*
Yes
No
inflammatory or infectious diseases*
Yes
No
unstable chronic disease*
Yes
No
discontinuation of smoking within three months of
randomisation date*
Yes
No
allergy for or intolerance of glimepiride or
novorapid.*
Yes
No
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Eligibility Colorectal Cancer NCT00582452
Attitudes Towards Prophylactic Colectomy in Hereditary
Non-polyposis Colorectal Cancer (HNPCC) Patients; ODM
derived from: https://clinicaltrials.gov/show/NCT00582452
All rights reserved. Please visit https://medical-data-
models.org/forms/16782
Eligibility Colorectal Cancer
NCT00582452
Inclusion Criteria
are from a family that has a known mismatch
repair mutation; or*
Yes
No
meet amsterdam i or amsterdam ii criteria that
spell out the family and personal cancer history
characteristics associated with hnpcc*
Yes
No
are considered at sufficiently high risk by their crc
specialty physician that prophylactic colectomy
may be presented as an option (excluding fap).*
Yes
No
amsterdam i criteria*
Yes
No
1. at least three relatives with a colorectal cancer
and the following criteria:*
Yes
No
one should be a first degree relative of the other
two*
Yes
No
at least two successive generations should be
affected*
Yes
No
at least one colorectal cancer should be
diagnosed before the age of 50*
Yes
No
familial adenomatous polyposis (fap) should be
excluded in the colorectal cancer case(s), if any*
Yes
No
amsterdam ii criteria (also known as revised
amsterdam criteria*
Yes
No
2. at least three relatives with an hnpcc-
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associated cancer (colorectal cancer, cancer of
the endometrium, small bowel, ureter, or renal
pelvis) *:*
Yes
No
one should be a first degree relative of the other
two*
Yes
No
at least two successive generations should be
affected*
Yes
No
at least one relative should be diagnosed before
age 50*
Yes
No
fap should be excluded in the colorectal cancer
case(s), if any *note: ovarian cancer will also be
considered an hnpccassociated cancer as per
lynch et al (nejm 2003)*
Yes
No
Exclusion Criteria
non-english speaking*
Yes
No
under the age of 18*
Yes
No
are unable to give meaningful informed consent
due to physical, psychiatric or cognitive disability*
Yes
No
are from a family affected by fap*
Yes
No
have already undergone subtotal colectomy or
total proctocolectomy*
Yes
No
are in active treatment and/or less than six
months post-surgery for cancer.*
Yes
No
have undergone genetic counseling and testing
for hnpcc at mskcc*
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Yes
No
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Eligibility Diabetes Mellitus, Type 2
NCT00288132
The Diabetes TeleCare Study; ODM derived from:
https://clinicaltrials.gov/show/NCT00288132
All rights reserved. Please visit https://medical-data-
models.org/forms/16783
Eligibility Diabetes Mellitus, Type 2
NCT00288132
Inclusion Criteria
all participants must have a confirmed physician
diagnosis of type 2 diabetes supported by
american diabetes association diagnostic criteria
for blood glucose levels or*
Yes
No
current use of oral hypoglycemic agents or insulin
as confirmed by brief medical record review.*
Yes
No
all adults (> 21 years of age) who have a a1c
value > 7.0 will be eligible.*
Yes
No
Exclusion Criteria
exclusion criteria applies to individuals with
limitations that could limit safe participation in the
study,*
Yes
No
such as metastatic cancer,*
Yes
No
multiple or recent (within six months) myocardial
infarction (mi) or stroke,*
Yes
No
dialysis for end stage renal disease,*
Yes
No
severe psychiatric disease or dementia, or*
Yes
No
inability to walk without an assistive device.*
Yes
No
we will also exclude women who are pregnant at
the time of study recruitment (based on self
report only) because of the unique needs related
to diabetes self-management during pregnancy.*
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Yes
No
we will, however, retain women in the study
should they become pregnant during the course
of the project.*
Yes
No
individuals will be excluded if they plan to move
out of the area.*
Yes
No
additional exclusions may include inability to
complete baseline tasks to the satisfaction of the
lead interventionist or other more subjective
assessment suggesting inability or unwillingness
to adhere reasonably to the intervention based on
interventionist review.*
Yes
No
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Eligibility Diabetes Mellitus, Type 2
NCT00435240
Paleolithic Diet in the Treatment of Diabetes Type 2 in
Primary Health Care; ODM derived from:
https://clinicaltrials.gov/show/NCT00435240
All rights reserved. Please visit https://medical-data-
models.org/forms/16784
Eligibility Diabetes Mellitus, Type 2
NCT00435240
Inclusion Criteria
adults with capacity to perform study*
Yes
No
diabetes mellitus type 2*
Yes
No
c-peptide > 0*
Yes
No
hba1c >5.5*
Yes
No
unchanged diabetes treatment during last 3
months*
Yes
No
weight and hba1c varied less than 5% during last
3 months*
Yes
No
no acute heart disease during last 6 months*
Yes
No
unchanged treatment with betablocker last 6
months*
Yes
No
unchanged treatment with thyroid hormone
substitution last 6 months*
Yes
No
Exclusion Criteria
treatment with insulin*
Yes
No
chronic treatment with steroids (not inhaled)*
Yes
No
treatment with waran (anticoagulant cumarin
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type)*
Yes
No
creatinin > 130 micromol/l*
Yes
No
elevated liver enzymes (alat,asat,alp or gt > 4 x
upper reference value)*
Yes
No
acute heart disease*
Yes
No
changed treatment with betablocker or thyroid
hormone substitution*
Yes
No
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Eligibility Diabetes Mellitus, Type 2 NCT00435240
Visit and Telephone Contact QTZ-EC-0004
ELEVATE  NCT01713426
QUTENZA™ versus Pregabalin in Subjects with Peripheral
Neuropathic Pain: an Open-label, Randomized, Multicenter,
Non-inferiority Efficacy and Tolerability Study
Medicine or Vaccine (generic name)
capsaicin
Visit: Week 2 - 4
Telephone Contact in Week 6
Sponsor Identification Number
QTZ-EC-0004
Trial Registry Identification Number(#'s)
NCT01713426
EudraCT Number: 2011-005872-41
All rights reserved. Please visit https://medical-data-
models.org/forms/16785
Visit and Telephone Contact QTZ-
EC-0004 ELEVATE  NCT01713426
Date of Visit
Was the visit performed?
If No, then all other forms with the Form Not
Done field in this visit will be marked not done.
If Yes, please provide the Date of Visit:
Yes
No
If Yes, please provide the Date of Visit.
dd/MMM/yyyy
Healthcare Resource Use
Form Not Done
(Form Not Done should only be marked for
subjects that are `RANDOMIZED/REGISTERED
BUT NEVER RECEIVED/DISPENSED STUDY
DRUG`.)
Done (Done)
Not Done (Not Done)
Number of contacts with a healthcare
professional related to neuropathic pain, since
the last visit.
Number of contacts with a healthcare
professional for other causes, since the last visit
Tolerability Assessment
Form Not Done
(Form Not Done should only be marked for
subjects that are `RANDOMIZED/ REGISTERED
BUT NEVER RECEIVED/ DISPENSED STUDY
DRUG`).
Done (Done)
Not Done (Not Done)
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Has diary been reviewed, and any existing
Adverse Events recorded in the eCRF?
Yes
No
Telephone Contact: Date
Was this visit performed?
(If No, then all other forms with the Form Not
Done field in this visit will be marked not done.
Yes
No
If Yes, please provide the Date of Visit
Telephone Contact: Tolerability
Assessment
Form Not Done
(Form Not Done should only be marekd for
subjects that are "RANDOMIZED/ REGISTERED
BUT NEVER RECEIVED/DISPRENSED STUDY
DRUG").
Done (Done)
Not Done (Not Done)
Has diary been reviewed, and any existing
Adverse Events recorded in the eCRF?
Yes
No
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Last Visit and End of Study QTZ-EC-0004
ELEVATE  NCT01713426
QUTENZA™ versus Pregabalin in Subjects with Peripheral
Neuropathic Pain: an Open-label, Randomized, Multicenter,
Non-inferiority Efficacy and Tolerability Study
Medicine or Vaccine (generic name)
capsaicin
Last Visit in Week 8
End of Study
Sponsor Identification Number
QTZ-EC-0004
Trial Registry Identification Number(#'s)
NCT01713426
EudraCT Number: 2011-005872-41
All rights reserved. Please visit https://medical-data-
models.org/forms/16786
Last Visit and End of Study QTZ-EC-
0004 ELEVATE  NCT01713426
Date of Visit
Was this visit performed?
(If No, then all other forms with the Form Not
Done field in this visit will be marked not done.)
Done (Done)
Not Done (Not Done)
If Yes, please provide the Date of Visit.
dd/MMM/yyyy
Biochemistry
Form Not Done
Done (Done)
Not Done (Not Done)
Were samples taken?
Yes
No
Date of Sample Taken
dd/MMM/yyyy
Laboratory Interpretation
(If LAB interpretetation is abnormal, please select
assessment items below and report the
interpretation for each.)
Abnormal (Abnormal)
Normal (Normal)
Laboratory Tests
Alkaline Phosphatase (Alkaline
Phosphatase)
ALT (ALT)
AST (AST)
BUN (BUN)
Creatinine (Creatinine)
Potassium (Potassium)
Sodium (Sodium)
TBL (TBL)
Laboratory Interpretation: Specification
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Abnormal-clinically significant
(Abnormal-clinically significant)
Abnormal-not clinically significant
(Abnormal-not clinically significant)
Record any clinically significant  abnormal
findings/conditions identified during the exam on
Medical and Surgical History and/or Adverse
Event form.
Dynamic Mechanical Allodynia
Form Not Done
(Form Not Done should only be marked for
subjects that are "RANDOMIZED/REGISTERED
BUT NEVER RECEIVED/DISPENSED STUDY
DRUG").
Done  (Done )
Not Done (Not Done)
Intensity of dynamic mechanical allodynia
(0=No Pain; 10=Pain as bad as patient can
imagine)
0 (1)
9 (10)
10 (11)
1 (2)
2 (3)
3 (4)
4 (5)
5 (6)
6 (7)
7 (8)
8 (9)
Total surface area size of area of dynamic
mechanical allodynia
cm^2
Healthcare Resource Use
Form Not Done
(Form Not Done should only be marked for
subjects that are `RANDOMIZED/REGISTERED
BUT NEVER RECEIVED/DISPENSED STUDY
DRUG`.)
Done (Done)
Not Done (Not Done)
Number of contacts with a healthcare
professional related to neuropathic pain, since
the last visit
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Number of contacts with a healthcare
professional for other causes, since the last visit
Tolerability Assessment
Form Not Done
(Form Not Done should only be marked for
subjects that are `RANDOMIZED/ REGISTERED
BUT NEVER RECEIVED/ DISPENSED STUDY
DRUG`).
Done (Done)
Not Done (Not Done)
Has diary been reviewed, and any existing
Adverse Events recorded in the eCRF?
Yes
No
End of Study
Date of Last Evaluation
dd/MMM/yyyy
Primary End of Treatment/Study Reason
(Primary End of Treatment/Study Reason: For
any randomized/registered subject that did not
receive any study drug please select
RANDOMIZED/REGISTERED BUT NEVER
RECEIVED/DISPENSED STUDY DRUG.)
(If primary "End of Treatment/Study Reason" is
"Adverse Event" or "Death", please provide
details on "Adverse Events" form.)
Adverse Event (Adverse Event)
Completed (Completed)
Death (Death)
Lack of efficacy (Lack of efficacy)
Lost to Follow-Up (Lost to Follow-Up)
Other (Other)
Progressive Disease (Progressive
Disease)
Protocol Violation (Protocol Violation)
Randomized/Registered but never
received/dispensed study drug
(Randomized/Registered but never
received/dispensed study drug)
Study terminated by sponsor (Study
terminated by sponsor)
Withdrawal by Subject (Withdrawal by
Subject)
Date of Withdrawal
dd/MMM/yyyy
If "Protocol Viiolation", specify:
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If primary reason is "Other", specify:
Ask the patient: Are you willing to continue
treatment with the study medication
Yes
No
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Eligibility Colorectal NCT00582829
Colorectal Cancer Screening Intervention for Family
Members of Colorectal Cancer Patients; ODM derived
from: https://clinicaltrials.gov/show/NCT00582829
All rights reserved. Please visit https://medical-data-
models.org/forms/16787
Eligibility Colorectal NCT00582829
Inclusion Criteria
how old is the participant? (≥ 18 years)*
Yes
No
is the participant either:*
Yes
No
currently age 40 or above (yes) or*
Yes
No
within 10 years of the age at which the
patient/proband was initially diagnosed with crc
(whichever is the younger age) (yes)*
Yes
No
is the participant a full or half biological sibling of
the patient/proband? (yes)*
Yes
No
Exclusion Criteria
is the participant currently not compliant with
standard crc screening guidelines?*
Yes
No
(no)*
Yes
No
is the participant english speaking? (yes)*
Yes
No
does the participant have a primary language
other than english? (no)*
Yes
No
does the participant have a history of
inflammatory bowel disease? (no)*
Yes
No
does the participant have a history of colorectal
cancer of colorectal polyp? (no)*
Yes
No
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does the participant have a history of hereditary
colorectal cancer syndrome?*
Yes
No
(familial adenomatous polyposis or hereditary
nonpolyposis colorectal cancer) (no)*
Yes
No
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AAFP: Hypokalemia Admission Order
AAFP: Hypokalemia Admission Order, Standardizes
Admission Orders, Author: Robert M. Wiprud, MD The
primary purpose of these Ordersets is to decrease
unnecessary variability and to improve quality through
standardized Admission Orders. Developed by the Scott &
White Clinic at College Station, Texas. Copyright © 2006
American Academy of Family Physicians. Physicians may
photocopy or adapt for use in their own practices; all other
rights reserved. Wiprud RM. Providing consistent care with
standardized admission orders. Fam Pract Manag.
September 2006: 49-52 See
http://www.aafp.org/fpm/2006/0900/p49.html This ODM
Form includes the eighteenth section ("Hypokalemia
Admission Order").
All rights reserved. Please visit https://medical-data-
models.org/forms/16788
AAFP: Hypokalemia Admission
Order
Default Itemgroup
Name
Age
Date of Birth
Medical record number
Status
Status
Observation (1)
Admission (2)
Monitored Bed (3)
ICU (4)
Attending
Name of attending physician
Phone number of attending physician
Admitting Diagnosis
Hypokalemia Associated Diagnoses
Condition
Condition
Full Code (1)
DNR (2)
Allergies
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Allergies
Diet
NPO
Yes
No
Clear liquid
Yes
No
AHA step 2
Yes
No
ADA___calories
Yes
No
Amount of calories
Other
Yes
No
If Other, please specify
Activity
Bed rest with bedside commode
Yes
No
Bathroom privileges
Yes
No
Up ad lib
Yes
No
Nursing
Vital signs with neuro checks every 4 hrs for 24
hrs then every shift
Yes
No
Continuous cardiac monitoring; arrhythmia orders
Yes
No
Notify MD for: T > 101.5; P > 120; BP < 90/60 or
> 180/110; presence of any muscle weakness,
hyporeflexes, paresthesias or arrhythmias
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Yes
No
Daily weight
Yes
No
I&O
Yes
No
IV/Medications
Potassium chloride 10 mEq in 100 mL normal
saline IVPB over 1 hr, times___doses
Yes
No
If Potassium chloride, please specify:
times__doses
IV fluids__with 40 mEq KCl/L @___mL/hr
Yes
No
if IV fluide, please specify IV fluids___with mEq
KCl/L
If IV fluids, please specify KCl/L @___mL/hr
Potassium chloride 20 mEq in 100 mL NSS IVPB
over on hr, times___doses
Yes
No
Please specify times__doses
IV fluids___with 40 mEq KCl/L @___mL/hr
Yes
No
If IV fluids, please specify
If IV fluids, please specify KCl/L @___mL/hr
Potassium chloride 40 mEq every __ hrs
Yes
No
If Potassium chloride, please specify frequency
hrs
Maalox 30 mL PO every 4 hrs prn indigestion
Yes
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No
MOM 30 mL PO every 12 hrs prn constipation
Yes
No
Tylenol PO every 4 hrs prn pain/fever
Yes
No
Ambien 10 mg PO at bedtime prn insomnia
Yes
No
Consider Lovenox 40 mg sc daily
Yes
No
Lab
Admission: hemagram, comp med profile, Mg,
calcium, TSH, urinalysis, urine osmo, Na,K+, Cl,
bicarb
Yes
No
Serum potassium every __ hrs
Yes
No
If serum potassium, please specify frequency
hrs
Consider: serum cortisol, renin, aldosterone,
urine myoglobin, 24 hrs urine K+, Na, creat,
protein, cortisol
Yes
No
Signature
Print Name
Date and Time
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AAFP: Hypokalemia Admission Order
AAFP: Hypokalemia Admission Order
AAFP: Hypokalemia Admission Order, Standardizes
Admission Orders, Author: Robert M. Wiprud, MD The
primary purpose of these Ordersets is to decrease
unnecessary variability and to improve quality through
standardized Admission Orders. Developed by the Scott &
White Clinic at College Station, Texas. Copyright © 2006
American Academy of Family Physicians. Physicians may
photocopy or adapt for use in their own practices; all other
rights reserved. Wiprud RM. Providing consistent care with
standardized admission orders. Fam Pract Manag.
September 2006: 49-52 See
http://www.aafp.org/fpm/2006/0900/p49.html This ODM
Form includes the eighteenth section ("Hypokalemia
Admission Order").
All rights reserved. Please visit https://medical-data-
models.org/forms/16789
AAFP: Hypokalemia Admission
Order
Default Itemgroup
Name
Age
Date of Birth
Medical record number
Status
Status
Observation (1)
Admission (2)
Monitored Bed (3)
ICU (4)
Attending
Name of attending physician
Phone number of attending physician
Admitting Diagnosis
Hypokalemia Associated Diagnoses
Condition
Condition
Full Code (1)
DNR (2)
Allergies
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Allergies
Diet
NPO
Yes
No
Clear liquid
Yes
No
AHA step 2
Yes
No
ADA___calories
Yes
No
amount of calories
Other
Yes
No
If Other, please specify
Activity
Bed rest with bedside commode
Yes
No
Bathroom privileges
Yes
No
Up ad lib
Yes
No
Nursing
Vital signs with neuro checks every 4 hrs for 24
hrs then every shift
Yes
No
Continuous cardiac monitoring; arrhythmia orders
Yes
No
Notify MD for: T > 101.5; P > 120; BP < 90/60 or
> 180/110; presence of any muscle weakness,
hyporeflexes, paresthesias or arrhythmias
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Yes
No
Daily weight
Yes
No
I&O
Yes
No
IV/Medications
Potassium chloride 10 mEq in 100 mL normal
saline IVPB over 1 hr, times___doses
Yes
No
If Potassium chloride, please specify:
times__doses
IV fluids__with 40 mEq KCl/L @___mL/hr
Yes
No
if IV fluide, please specify IV fluids___with mEq
KCl/L
If IV fluids, please specify KCl/L @___mL/hr
Potassium chloride 20 mEq in 100 mL NSS IVPB
over on hr, times___doses
Yes
No
Please specify times__doses
IV fluids___with 40 mEq KCl/L @___mL/hr
Yes
No
If IV fluids, please specify
If IV fluids, please specify KCl/L @___mL/hr
Potassium chloride 40 mEq every __ hrs
Yes
No
If Potassium chloride, please specify frequency
hrs
Maalox 30 mL PO every 4 hrs prn indigestion
Yes
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No
MOM 30 mL PO every 12 hrs prn constipation
Yes
No
Tylenol PO every 4 hrs prn pain/fever
Yes
No
Ambien 10 mg PO at bedtime prn insomnia
Yes
No
Consider Lovenox 40 mg sc daily
Yes
No
Lab
Admission: hemagram, comp med profile, Mg,
calcium, TSH, urinalysis, urine osmo, Na,K+, Cl,
bicarb
Yes
No
Serum potassium every __ hrs
Yes
No
If serum potassium, please specify frequency
hrs
Consider: serum cortisol, renin, aldosterone,
urine myoglobin, 24 hrs urine K+, Na, creat,
protein, cortisol
Yes
No
Signature
Print Name
Date and Time
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Cumulative QTZ-EC-0004 ELEVATE
NCT01713426
QUTENZA™ versus Pregabalin in Subjects with Peripheral
Neuropathic Pain: an Open-label, Randomized, Multicenter,
Non-inferiority Efficacy and Tolerability Study
Medicine or Vaccine (generic name)
capsaicin
Sponsor Identification Number
QTZ-EC-0004
Trial Registry Identification Number(#'s)
NCT01713426
EudraCT Number: 2011-005872-41
All rights reserved. Please visit https://medical-data-
models.org/forms/16790
Cumulative QTZ-EC-0004 ELEVATE
NCT01713426
Previous and Concomitant Medication
Form Not Done
(Form Not Done should only be akred for
subjects that are "RANDOMIZED/REGISTERED
BUT NEVER RECEIVED/DISPENSED STUDY
DRUG").
Done (Done)
Not Done (Not Done)
Are there any previous medications (concomitant
treatment taken within 30 days of the Screening
Visit) and/or concomitant medications to record?
Yes
No
Did the patient receive treatment with Pregabalin
or Gabapentin at any time prior to the screening
visit?
(If Yes, please record treatment details below and
also provide justificatin of inadequate trial)
Yes
No
For previous use of Pregabalin or Gabapentin,
specify the justification of inadequate trial:
Medication
Route
Auricular (Otic) (Auricular (Otic))
Epidural (Epidural)
Intra-arterial (Intra-arterial)
Intra-Articular (Intra-Articular)
Intradermal (Intradermal)
Intramuscular (Intramuscular)
Intraperitoneal (Intraperitoneal)
Intrathecal (Intrathecal)
Intravenous (Intravenous)
Nasal (Nasal)
Nasogastric (Nasogastric)
Ophthalmic (Ophthalmic)
Oral (Oral)
Other (Other)
Periarticular (Periarticular)
Rectal (Rectal)
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Respiratory (Inhalation) (Respiratory
(Inhalation))
Subcutaneaous (Subcutaneaous)
Sublingual (Sublingual)
Topical (Topical)
Transdermal (Transdermal)
Urethral (Urethral)
Vaginal (Vaginal)
If "Other", specify:
Start Date
dd/MMM/yyyy
Ongoing
Yes
No
Stop Date
dd/MMM/yyyy
Pain Medication
(If Pain Medication is Yes, please select one of
below options.)
Yes
No
Medication to treat neuropathic pain - chronic
treatment
Yes
No
Medication to treat neuropathic pain - acute
treatment
Yes
No
Medication to treat post-application pain
(QUTENZA arm only)
Yes
No
Medication to treat non-neuropathic pain
Yes
No
Indication
Total Daily Dose
Dose Unit
g (g)
mg (mg)
Other (Other)
ug (ug)
ug/h (ug/h)
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If "Other", specify:
Non-Medication Therapy
Form Not Done
(Form Not Done should only be marked for
subjects that are "RANDOMIZED/REGISTERED
BUT NEVER RECEIVED/DISPENSED STUDY
DRUG").
Done (Done)
Not Done (Not Done)
Is there any non-medication therapy and/or
changes in non-medication therapy to record?
Yes
No
Therapy Details:
Start Date of Therapy
dd/MMM/yyyy
Ongoing
Yes
No
Stop Date of Therapy
dd/MMM/yyyy
Pain related non-medication therapy
Yes
No
Reason for Use
Neuropathic Pain (Neuropathic Pain)
Other Pain (Other Pain)
Post Patch Application Pain (Post Patch
Application Pain)
If "Other", specify:
Adverse Event
Form Not Done
(Form Not Done should only be marked for
subjects that are "RANDOMIZED/REGISTERED
BUT NEVER RECEIVED/DISPENSED STUDY
DRUG".)
Done (Done)
Not Done (Not Done)
Were any adverse events reported or observed?
Yes
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No
Adverse Event
Onset Date
dd/MMM/yyyy
Onset Time
(00:00 - 23:59)
If the onset date is the same day as study drug
start date or if a complete onset is unknown
and/or if the date and time are unknown, please
select one.
Onset after first dose of study drug
(Onset after first dose of study drug)
Onset before first dose of study drug
(Onset before first dose of study drug)
End Date
dd/MMM/yyyy
End Time
(00:00 - 23:59)
Outcome
(If "Outcome" is FATAL, complete the "Adverse
Events" form.)
Fatal (Fatal)
Not recovered/not resolved (Not
recovered/not resolved)
Recovered/Resolved
(Recovered/Resolved)
Recovered/Resolved with sequelae
(Recovered/Resolved with sequelae)
Recovering/Resolving
(Recovering/Resolving)
Unknown (Unknown)
Course of Event
Continuous (Continuous)
Intermittent (Intermittent)
Single Episode (Single Episode)
Severity
Mild (Mild)
Moderate (Moderate)
Severe (Severe)
Serious AE?
(If "Serious AE?" is Yes, select all that apply.)
(In case of a serious adverse event (SAE),
complete a SAE report)
Yes
No
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Serious Adverse Event Number
Death
Yes
No
Requires or prolongs hospitalization
Yes
No
Congenital anomaly
Yes
No
Life-threatening
Yes
No
Persistent or significant disability/Incapacity
Yes
No
Other medical importance
Yes
No
Action Taken for Study Drug
(If "Action Taken for Study Drug" is DRUG
WITHDRAWN, complete the "End of Treatment
and Study" form/ "End of Treatment" form.
Dose increased (Dose increased)
Dose not changed (Dose not changed)
Dose reduced (Dose reduced)
Drug interrupted (Drug interrupted)
Drug withdrawn (Drug withdrawn)
Not applicable (Not applicable)
Unknown (Unknown)
Was there any treatment required?
(If Yes, please select all that apply.)
Yes
No
Medication Therapy
(If "Medication Therapy" is Yes, complete the
"Previous and Concomitant Medications" form.)
Yes
No
Non-Medication Therapy
(If "Non-Medication Therapy" is Yes, complete the
"Non-Medication Therapy" form.)
Yes
No
Relationship to Study Drug
Not related (Not related)
Possible (Possible)
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Probable (Probable)
Please confirm if the Adverse Event is an
Application site reaction.
Yes
No
Date Serious Adverse Event Reconciled
(For Astellas Use Only!)
dd/MMM/yyyy
Administration of Pregabalin
Form Not Done
(Please record every change in the dosing of
Pregabalin in a new log line, providing Start and
Stop Date)
Done (Done)
Not Done (Not Done)
Dosing Start Date
dd/MMM/yyyy
Dosing Stop Date
dd/MMM/yyyy
# of Total Capsules Taken Daily
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Cumulative QTZ-EC-0004 ELEVATE  NCT01713426
Eligibility Chronic Hepatitis C
NCT01120795
Pegylated Interferon and Ribavirin in Hepatitis C Patients
on Opioid Pharmacotherapy; ODM derived from:
https://clinicaltrials.gov/show/NCT01120795
All rights reserved. Please visit https://medical-data-
models.org/forms/16791
Eligibility Chronic Hepatitis C
NCT01120795
Inclusion Criteria
1. 18 years of age or older*
Yes
No
2. on opioid substitution therapy (methadone or
buprenorphine)*
Yes
No
3. serologic evidence of chronic hepatitis c
infection determined by a detectable anti-hcv
antibody for 6 months or greater with evidence of
detectable hcv rna*
Yes
No
4. elevated alt on at least two occasions at least
one month apart within the past 6 months, with at
least one during the screening period preceding
the initiation of study drug dosing.*
Yes
No
5. hcv treatment-naïve*
Yes
No
6. liver biopsy findings consistent with the
diagnosis of chronic hepatitis c infection (unless
contraindicated due to a bleeding disorder)*
Yes
No
7. compensated liver disease (child-pugh grade a
clinical classification).*
Yes
No
8. all fertile males and females receiving ribavirin
were required to be using two forms of effective
contraception during treatment and during the 6
months after treatment*
Yes
No
9. women of child bearing potential were required
to have a negative urine or blood pregnancy test
documented within the 24-hour period prior to the
first dose of study drug*
Yes
No
1 / 3
Exclusion Criteria
1. women who were pregnant, breastfeeding or
planning a pregnancy*
Yes
No
2. male partners of women who were pregnant*
Yes
No
3. patients who had previously received therapy
with any systemic anti-neoplastic or
immunomodulatory treatment (including
supraphysiologic doses of steroids and radiation)
6 months prior to the first dose of study drug*
Yes
No
4. recipients of any investigational drug 4 weeks
or 5 half lives, whichever was longer, prior to the
first dose of study drug*
Yes
No
5. a positive test at screening for anti-hav igm ab,
hbsag, anti-hbc igm ab, anti-hiv ab*
Yes
No
6. a history or other evidence of a medical
condition associated with chronic liver disease
other than hcv*
Yes
No
7. haemoglobin <12 g/dl in women or <13 g/dl in
men, a neutrophil count <1500 cells/mm3 or
platelet count <90,000 cells/mm3 at screening
and serum creatinine level >1.5 times the upper
limit of normal at screening.)*
Yes
No
8. a history of a severe seizure disorder or
current anticonvulsant use*
Yes
No
9. patients with a history of immunologically-
mediated disease, chronic pulmonary disease
associated with functional limitation, severe
cardiac disease, coronary artery disease,
cerebrovascular disease, major organ
transplantation or other evidence of severe
illness, malignancy, or any other conditions which
would make the patient, in the opinion of the
investigator, unsuitable for the study*
Yes
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No
10. patients with a history of thyroid disease
which is poorly controlled on prescribed
medications*
Yes
No
11. evidence of severe retinopathy*
Yes
No
12. evidence of excessive substance abuse as
judged by the investigator*
Yes
No
13. patients with an increased baseline risk for
anaemia (e.g. thalassaemia, spherocytosis,
history of gastrointestinal bleeding, etc) or for
whom anemia would be medically problematic.*
Yes
No
14. patients with a history of severe psychiatric
disease (defined as acute phase of schizophrenia
or bipolar disorder manic, mixed or depressive
phase, severe anorexia, history of severe multiple
episodes of self harm, currently screening as
high or moderate suicide risk, current major
depressive episode or current psychosis of any
cause at screening)*
Yes
No
3 / 3
Eligibility Chronic Hepatitis C NCT01120795
Eligibility Diabetes Type 2 NCT00518427
Evaluate Quality of Life in Type 2 Diabetes, Before and
After Change to Insuline Glargine; ODM derived from:
https://clinicaltrials.gov/show/NCT00518427
All rights reserved. Please visit https://medical-data-
models.org/forms/16792
Eligibility Diabetes Type 2
NCT00518427
Criteria
Inclusion Criteria
patients with type 2 diabetes inadequately
controlled on a combination of oad + nph insulin
for more than three months*
Yes
No
stable oad therapy for at least three months,
according to the following specified daily dose:
glibenclamide> 3, 5 mg, glipizid >5 mg,
glimepiride >2mg, metformin>1000 mg, acarbose
>150 mg*
Yes
No
hba1c > 7,0%*
Yes
No
ability to perform qol assessment*
Yes
No
body mass indes: women <30 and men <32*
Yes
No
Exclusion Criteria
autoimmune diabetes, as defined by who
Yes
No
ongoing treatment with thiazolidinedione drug
Yes
No
retinopathy with surgical treatment during
preceding three months of study entry or
requiring treatment within three months after
study entry
Yes
No
drug abuse
Yes
No
hypersensitivity to insulin glagine excipients
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Yes
No
the above information is not intended to contain
all considerations relevant to a patient's potential
participation in a clinical trial.
Yes
No
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Eligibility Chronic Lymphocytic Leukemia
NCT00193518
Arsenic Trioxide in Relapsed/Refractory Chronic
Lymphocytic Leukemia/Small Lymphocytic Lymphoma;
ODM derived from:
https://clinicaltrials.gov/show/NCT00193518
All rights reserved. Please visit https://medical-data-
models.org/forms/16793
Eligibility Chronic Lymphocytic
Leukemia NCT00193518
Inclusion Criteria
to be included in this study, you must meet the
following criteria:*
Yes
No
histologically proven b-cell cll/sll.*
Yes
No
must have had a minimum of 1 and a maximum
of 3 previous systemic regimens*
Yes
No
must have progressive cll/sll*
Yes
No
measurable or evaluable disease*
Yes
No
ecog performance status 0, 1, or 2*
Yes
No
age > 18 years.*
Yes
No
patients with cytopenias caused by bone marrow
involvement are eligible*
Yes
No
all patients must give written informed consent
prior to entering this study.*
Yes
No
Exclusion Criteria
you cannot participate in this study if any of the
following apply to you:*
Yes
No
unstable active infection on the basis of
neutropenia*
Yes
No
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previous severe opportunistic infections*
Yes
No
severe immune mediated anemia or
thrombocytopenia*
Yes
No
serious underlying medical conditions*
Yes
No
brain metastases or meningeal involvement*
Yes
No
history of other neoplasms*
Yes
No
significant underlying heart dysfunction*
Yes
No
women who are pregnant or*
Yes
No
please note:  there are additional
inclusion/exclusion criteria.  the study center will
determine if you meet all of the criteria.  if you do
not qualify for the trial, study personnel will
explain the reasons.  if you do qualify, study
personnel will explain the trial in detail and
answer any questions you may have.*
Yes
No
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Eligibility Heart Failure NCT00214318
Beta-2 Polymorphisms and Beta Receptor Selectivity; ODM
derived from: https://clinicaltrials.gov/show/NCT00214318
All rights reserved. Please visit https://medical-data-
models.org/forms/16794
Eligibility Heart Failure
NCT00214318
Inclusion Criteria
systolic dysfunction with ejection fraction ≤40%*
Yes
No
symptomatic heart failure class 2-3*
Yes
No
>18 years of age*
Yes
No
optimal medical therapy of hf excluding the use of
any beta-blockers within the previous 30 days of
the study*
Yes
No
Exclusion Criteria
active myocarditis*
Yes
No
hemodynamically significant valvular heart
disease*
Yes
No
hypertrophic cardiomyopathy*
Yes
No
contra-indications to beta-blockers*
Yes
No
concomitant use of beta-agonists*
Yes
No
beta-antagonist or anti-arrhythmics*
Yes
No
unstable angina*
Yes
No
myocardial infarction or bypass surgery within 3
months*
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Yes
No
significant renal insufficiency [creatinine >2.5
mg/dl], liver disease, or anemia*
Yes
No
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Eligibility Heart Failure NCT00384566
A Comparison of the Effect of Carvedilol and Metoprolol on
Airways Tone in Patients With Heart Failure; ODM derived
from: https://clinicaltrials.gov/show/NCT00384566
All rights reserved. Please visit https://medical-data-
models.org/forms/16795
Eligibility Heart Failure
NCT00384566
Inclusion Criteria
males and females over 18 years of age*
Yes
No
documented chf (nyha class ii-iv symptoms)*
Yes
No
airflow obstruction defined as patients with
symptomatic obstructive respiratory disease as
manifest by any of the following symptoms of
wheeze, primarily attributed to airflow obstruction
requirement for intermittent or regular
bronchodilator therapy fev1 less than 70%
predicted pre-salbutamol*
Yes
No
confirmed written informed consent.*
Yes
No
clinically indicated to receive β-blockade.*
Yes
No
no evidence of heart block on ecg.*
Yes
No
patients will be in one of the following
categories:*
Yes
No
currently on carvedilol, currently on toprol-xl or
metoprolol tartrate, currently on bisoprolol,
clinically indicated to receive β adrenoceptor
blockade but not currently prescribed a β
-blocker.*
Yes
No
Exclusion Criteria
women lactating, pregnant or of childbearing
potential not using a reliable contraceptive
method.*
Yes
No
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patients who had received an investigational new
drug within the last 4 weeks.*
Yes
No
patients with a history of a psychological illness
or condition such as to interfere with the patient's
ability to understand the requirements of the
study.*
Yes
No
laboratory parameters:*
Yes
No
creatinine >0.30 mmol/l liver function tests 3x uln*
Yes
No
recent (<12 months) myocarditis*
Yes
No
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Eligibility Hypercholesterolemia
NCT00145717
China Plant Sterol Trial; ODM derived from:
https://clinicaltrials.gov/show/NCT00145717
All rights reserved. Please visit https://medical-data-
models.org/forms/16796
Eligibility Hypercholesterolemia
NCT00145717
Inclusion Criteria
the key inclusion criteria will be:*
Yes
No
age between 18 and 65 years old (inclusive) at
baseline*
Yes
No
able to provide informed consent*
Yes
No
usual diet that includes significant fat
consumption at the main meals eaten each week
and/or a history of hypercholesterolemia*
Yes
No
participant is likely to comply with the study
treatment during the study period*
Yes
No
Exclusion Criteria
participants will be excluded on the basis of:*
Yes
No
known serious gastrointestinal disease or other
serious illness.  individuals with stable
cardiovascular disease will, however, be eligible*
Yes
No
known lactose intolerance or diet that excludes
dairy products*
Yes
No
known sitosterolaemia (a very rare genetic
condition causing very high blood sitosterol
levels)*
Yes
No
current hospitalisation*
Yes
No
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current use of drug with likely significant impact
on gastro-intestinal absorption of cholesterol or
plant sterol (e.g. ezetimibe, bile acid-binding
resins, or orlistat)*
Yes
No
participant is currently using or is planning to use
non-trial plant sterol/stanol-containing products
for the seven week study period*
Yes
No
participation in another study within last 3
months*
Yes
No
pregnant or planning to become pregnant in next
three months*
Yes
No
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Eligibility Hypertension NCT00151775
Assessment of Efficacy and Safety of Olmesartan
Medoxomil in Children and Adolescent Patients With High
Blood Pressure; ODM derived from:
https://clinicaltrials.gov/show/NCT00151775
All rights reserved. Please visit https://medical-data-
models.org/forms/16797
Eligibility Hypertension
NCT00151775
Inclusion Criteria
the patient's seated systolic bp (sesbp) will be
greater than or equal to 95th percentile for
gender and height-for- age, or greater than or
equal to 90th percentile if the patient is diabetic,
or has glomerular kidney disease, or has a family
history of hypertension.*
Yes
No
negative for hepatitis b and c*
Yes
No
negative for hiv*
Yes
No
Exclusion Criteria
patient should not have serious other conditions
that could interfere with the analysis of the results
or that could interfere with the well-being of the
patient in the trial.*
Yes
No
known sensitivity to olmesartan medoxomil*
Yes
No
taking prohibited medication*
Yes
No
consumed greater than 180 mg of caffeine daily*
Yes
No
malignant hypertension*
Yes
No
history of congestive heart failure,
cardiomyopathy, or obstructive valve disease*
Yes
No
renal transplant within the previous 6 months*
Yes
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No
severe nephritic syndrome not in remission*
Yes
No
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Eligibility Colorectal Neoplasms
NCT00078468
Study of the GARFT Inhibitor AG2037 in Patients With
Metastatic Colorectal Cancer Who Failed Treatment; ODM
derived from: https://clinicaltrials.gov/show/NCT00078468
All rights reserved. Please visit https://medical-data-
models.org/forms/16800
Eligibility Colorectal Neoplasms
NCT00078468
Inclusion Criteria
histologically or cytologically confirmed
metastatic adenocarcinoma of the colon or
rectum*
Yes
No
stage iv or recurrent disease*
Yes
No
measurable disease*
Yes
No
disease progression or recurrence during or after
completion of prior first-line chemotherapy with
fluorouracil and leucovorin calcium (5-fu/lv)*
Yes
No
prior irinotecan or oxaliplatin as part of the 5-fu/lv
regimen or as subsequent therapy allowed*
Yes
No
only 2 prior regimens for metastatic disease
allowed*
Yes
No
one additional regimen as adjuvant therapy
allowed provided patient remained disease-free
for > 6 months after completion of therapy**
Yes
No
newer, targeted investigational agents (e.g.,
cetuximab or bevacizumab) are not*
Yes
No
counted as a chemotherapeutic regimen unless
used in combination with a cytotoxic regimen
note: *if evidence of failure occurred within < 6
months after completion of adjuvant therapy,
patients may have received only 1 additional
regimen for metastatic disease*
Yes
No
no active brain metastases (requiring treatment
or progressing)*
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Yes
No
Exclusion Criteria
history of blood transfusion within 14 days*
Yes
No
need of concurrent administration of allopurinol*
Yes
No
history of radiotherapy or chemotherapy within 4
weeks*
Yes
No
any psychological or sociological condition,
addidtive disorder or family problems that might
preclude compliance with the protocol*
Yes
No
any unstable or severe intercurrent medical
condition that in the opinion of th einvestigator
might interfere with achievement of study
objectives*
Yes
No
receipt of an investigational agent within 28 days
prior to first day of dosing with ag-2037*
Yes
No
pregnant or breast feeding*
Yes
No
previous treatment with garft inhibitors*
Yes
No
history of a malignancy (other than colorectal
cancer) excpet those treated with curative intent
for skin cancer (other than melanoma) or in situ
breast or cervical cancer or those treated with
curative intent for any other cancer with no
evidence of disease for 5 years*
Yes
No
active brain metastases (requiring treatment or
progression)*
Yes
No
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Eligibility Hypertension NCT00151814
Olmesartan Pediatric Pharmacokinetic (PK) Study; ODM
derived from: https://clinicaltrials.gov/show/NCT00151814
All rights reserved. Please visit https://medical-data-
models.org/forms/16802
Eligibility Hypertension
NCT00151814
Inclusion Criteria
age 12 months to 16 years inclusive*
Yes
No
signed parental/guardian informed consent and
assent from the subject*
Yes
No
current treatment for hypertension, or, if not
currently treated for hypertension, systolic blood
pressure (sbp) greater than or equal to 95th
percentile for gender and height-for-age, or, if not
currently treated for hypertension, systolic blood
pressure or diastolic blood pressure greater than
or equal to 90th percentile for gender and height-
for-age and diabetic or having a family history of
hypertension*
Yes
No
glomerular filtration rate (gfr) greater than or
equal to 30 ml/min/1.73 m2, estimated using the
schwartz equation*
Yes
No
sexually active females of child-bearing potential
must be practicing an acceptable method of birth
control*
Yes
No
negative serum beta-human chorionic
gonadotropin  at screening and at admission
(female of child-bearing potential only)*
Yes
No
Exclusion Criteria
clinically significant cardiac, gastrointestinal,
hematologic, hepatic or hepatobiliary, neurologic,
or pulmonary (except asthma) disorder*
Yes
No
history of severe or symptomatic hypertension
associated with stroke, seizures, encephalopathy,
or other significant neurologic findings within 1
year prior to screening*
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Yes
No
current treatment with more than 2
antihypertensive medications*
Yes
No
secondary hypertension from uncorrected
coarctation of the aorta, bilateral renal artery
stenosis, or unilateral renal artery stenosis in a
single kidney*
Yes
No
serum albumin < 2.5 g/dl*
Yes
No
major organ or bone marrow transplantation
except for prior kidney transplantation of at least
6 months and with stable renal function meeting
the inclusion criteria*
Yes
No
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Eligibility Colorectal Neoplasms
NCT00101686
Trial Of Irinotecan In Combination With Three Methods Of
Administration Of Fluoropyrimidine.; ODM derived from:
https://clinicaltrials.gov/show/NCT00101686
All rights reserved. Please visit https://medical-data-
models.org/forms/16803
Eligibility Colorectal Neoplasms
NCT00101686
Inclusion Criteria
diagnosis of colorectal cancer (either newly
diagnosed or recurrent disease) with evidence of
metastatic disease. (stage iv distant disease)*
Yes
No
present or past histological documentation of
adenocarcinoma of the colon or rectum. the site
of the primary lesion must be or have been
confirmed endoscopically, radiologically, or
surgically to be or have been in the large bowel.
patients with a history of colorectal cancer treated
by surgical resection who develop radiological or
clinical evidence of metastatic cancer do not
require separate histological or cytological
confirmation of metastatic disease unless:*
Yes
No
an interval of greater than five years has elapsed
between the primary surgery and the
development of metastatic disease.*
Yes
No
the primary cancer was a duke's a or b1.*
Yes
No
physicians should consider biopsy of lesions to
establish the diagnosis of metastatic colorectal
cancer in each case if there is substantial clinical
ambiguity regarding the nature of source of
apparent metastases.*
Yes
No
Exclusion Criteria
patients who received any prior systemic
anticancer therapy for metastatic colorectal
cancer (e.g., chemotherapy, antibody therapy,
immunotherapy, gene therapy, vaccine therapy,
cytokine therapy, or other experimental agents).*
Yes
No
patients cannot have concurrent malignancies at
study entry.*
Yes
No
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exceptions:   patients with prior non-colorectal
malignancies will be eligible if they have been
disease-free for ³ 3 years or are deemed at low
risk for recurrence by their treating physician
(e.g., early stage prostate cancer, melanoma or
bladder cancer).  patients with squamous or
basal cell carcinoma of the skin or in situ cervical
cancer that have been effectively treated are
eligible, even if these were diagnosed within 3
years before randomization.*
Yes
No
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Eligibility Hypertension NCT00157326
Tadalafil in Subjects With Mild to Moderate Hypertension;
ODM derived from:
https://clinicaltrials.gov/show/NCT00157326
All rights reserved. Please visit https://medical-data-
models.org/forms/16804
Eligibility Hypertension
NCT00157326
Inclusion Criteria
have a documented medical history of
hypertension.*
Yes
No
have cuff seated diastolic blood pressure values
greater than or equal to 95 and less than or equal
to 104 mm at study entry*
Yes
No
have a negative serum pregnancy test at the time
of enrollment and agree to use two medically
reliable methods of contraception until study
completion, if female is of child-bearing potential,
between menarche and 1 year post menopause
and not surgically sterilized.*
Yes
No
are able to comply with study procedures and
visits*
Yes
No
Exclusion Criteria
have resistant hypertension or systolic
hypertension.*
Yes
No
are obese, defined as having body mass index
(bmi) greater than or equal to 35.*
Yes
No
are females who are pregnant or breast feeding.*
Yes
No
have a history of severe renal insufficiency or
significant thyroid, renal or hepatic disease.*
Yes
No
have a glycosylated hemoglobin a1c (hba1c)
greater than or equal to 10% during the
screening period.*
Yes
No
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have significant anemia.*
Yes
No
have a significant or unstable cardiac history
such as history of heart attack, unstable angina,
or stroke within 6 months of study entry, history of
angina that was treated with long- or short-acting
nitrates within 90 days of study entry, history of
coronary artery bypass graft surgery or cardiac
angioplasty within 90 days of study entry, history
of abnormal heart rhythms such as sick sinus
syndrome or 2nd- or 3rd-degree av block, chronic
atrial fibrillation or recurrent atrial
tachyarrhythmia, a history of recurrent ventricular
tachycardia, or symptomatic bradycardia, a
history of sudden cardiac arrest.*
Yes
No
have symptomatic heart failure requiring
treatment, or significant disease of the heart
valves.*
Yes
No
have been treated for severe asthma,
bronchospasm, or copd within 3 months of study
entry.*
Yes
No
have severe peripheral vascular disease.*
Yes
No
have a documented diagnosis of sleep apnea.*
Yes
No
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Eligibility Colorectal Neoplasms
NCT00156975
Oxaliplatin and Capecitabine Versus Follow-up After
Resection of Colorectal Liver Metastases; ODM derived
from: https://clinicaltrials.gov/show/NCT00156975
All rights reserved. Please visit https://medical-data-
models.org/forms/16812
Eligibility Colorectal Neoplasms
NCT00156975
Inclusion Criteria
patients after r0-resection of colorectal liver
metastases*
Yes
No
age: >= 18 years*
Yes
No
karnofsky-index >= 70%*
Yes
No
neutrophiles >1,5 x10e9/l, thrombocytes 100
x10e9/l*
Yes
No
adequate contraception for male and female
patients*
Yes
No
oral and written informed consent (gcp)*
Yes
No
Exclusion Criteria
other prior malignancies,  except treated in situ-
carcinoma of cervix or tumours of skin without
indication to a melanoma (or 10 years
tumourfree)*
Yes
No
other participation in clinical trials within 30 days
before randomization*
Yes
No
previous chemotherapy (except adjuvant
chemotherapy with an interval of >= 6 months)*
Yes
No
creatinine clearance <50 ml/min*
Yes
No
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hepatic insufficiency (alat, asat, bilirubin, ap >5 x
upper limit)*
Yes
No
peripheral neuropathy > ctc grade 1*
Yes
No
uncontrolled cardiac insufficiency or angina
pectoris*
Yes
No
active infections*
Yes
No
severe neurological or psychiatric illness*
Yes
No
breast-feeding or pregnant women*
Yes
No
incapacity to take part in regular visits*
Yes
No
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Eligibility Colorectal Neoplasms
NCT00188565
Celebrex With Preoperative Chemoradiation - Rectal
Cancer; ODM derived from:
https://clinicaltrials.gov/show/NCT00188565
All rights reserved. Please visit https://medical-data-
models.org/forms/16813
Eligibility Colorectal Neoplasms
NCT00188565
Inclusion Criteria
patients with resectable or potentially resectable
adenocarcinoma of the rectum*
Yes
No
clinical stage t2 n1-2 or t3-4 n0-2 (patients who
require diverting loop colostomy are eligible)*
Yes
No
age greater than 18 years, ecog performance
status < 2 (appendix, section 13.1)*
Yes
No
biopsy proven adenocarcinoma, superior margin
of the tumour within 15cm of the anal verge on
rigid sigmoidoscopy*
Yes
No
Exclusion Criteria
distant metastasis, prior pelvic irradiation,
inflammatory bowel disease, medical conditions
which preclude radical therapy*
Yes
No
history of malignancy within five years (except
nonmelanoma skin cancer, cin cervix)*
Yes
No
pregnancy*
Yes
No
hypersensitivity to celecoxib, nsaid, sulfonamides
or 5-fu*
Yes
No
significant comorbid illness*
Yes
No
history of peptic ulcer disease or nsaid-related
gastrointestinal bleeding*
Yes
1 / 2
No
use of aspirin, other nsaid or coxib in the two
weeks prior to study entry*
Yes
No
neutrophil count <1.5x109/l, platelet count
<100x109/l, serum bilirubin >1.25xuln (upper limit
of normal), ast/alt >3xuln, serum creatinine
>1.25xuln*
Yes
No
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Eligibility Colorectal Neoplasms
NCT00190515
A Trial Comparing Adjuvant Oral UFT/LV to 5-FU/l-LV in
Stage III Colorectal Cancer (JCOG-0205-MF); ODM
derived from: https://clinicaltrials.gov/show/NCT00190515
All rights reserved. Please visit https://medical-data-
models.org/forms/16814
Eligibility Colorectal Neoplasms
NCT00190515
Inclusion Criteria
1. pathologically proved colorectal cancer (either
adenocarcinoma, mucinous carcinoma, or signet-
ring cell carcinoma).*
Yes
No
2. tumor is mainly located in between cecum and
upper rectum, excluding that invades to lower
rectum.*
Yes
No
3. stage iii cancer by general rules for clinical and
pathological studies on cancer of the colon,
rectum and anus (6th ed.), excluding si(ai), n(-),
m(-).*
Yes
No
4. no synchronous colorectal cancer which
invade muscularis propria or deeper.*
Yes
No
5. tumor resection with d2 or d3 lymph node
dissection was performed.*
Yes
No
6. pathological determination of curability of
tumor resection is cur a.*
Yes
No
7. age at registration is above 20 and below 75
years old.*
Yes
No
8. ecog performance status is 0 or 1.*
Yes
No
9. no prior chemotherapy or radiation therapy.*
Yes
No
10. intake of normal diet and oral drugs is
possible.*
Yes
No
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11. major organ function is preserved.
wbc>=3,000/mcl, plt>=100,000/mcl, got<=100
iu/l, gpt<=100 iu/l, t.bil <=2.0 mg/dl, cr<=1.5
mg/dl*
Yes
No
12. adjuvant chemotherapy can be started within
9 weeks after surgery.*
Yes
No
13. written informed consent is taken.*
Yes
No
Exclusion Criteria
1. active co-existing malignancy （synchronous
or metachronous malignancy whose disease free
period is within 5 years). carcinoma in situ is
eligible.*
Yes
No
2. severe postoperative complications which do
not resolve until registration.*
Yes
No
3. there is following complication. insulin-
controlling or uncontrollable diabetes mellitus,
uncontrollable hypertension, myocardial infarction
within six month or unstable angina pectoris, liver
cirrhosis, interstitial pneumonia, pulmonary
fibrosis, severe emphysema*
Yes
No
4. pregnant or breast-feeding woman.*
Yes
No
5. difficult to participate with the trial, having
mental disorder or psychiatric symptoms.*
Yes
No
6. judged to be inappropriate to register.*
Yes
No
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Eligibility Colorectal Neoplasms
NCT00199862
Safety Study of Radio-labeled huA33 Antibody in Colorectal
Cancer; ODM derived from:
https://clinicaltrials.gov/show/NCT00199862
All rights reserved. Please visit https://medical-data-
models.org/forms/16815
Eligibility Colorectal Neoplasms
NCT00199862
Inclusion Criteria
primary or metastatic colorectal carcinoma,
histologically confirmed at memorial sloan-
kettering cancer center (mskcc).*
Yes
No
patients must be candidates for clinically
indicated surgery/biopsy for primary/metastatic
colorectal cancer*
Yes
No
expected survival of at least 3 months.*
Yes
No
karnofsky performance status ≥ 70 (ecog 0 or 1).*
Yes
No
the following laboratory results within the last 2
weeks prior to study day 1:*
Yes
No
absolute neutrophil count (anc) ≥ 1.5 x 109/l
platelet count ≥ 75 x 109/l serum bilirubin*
Yes
No
≤ 2.5 mg/dl serum creatinine ≤ 2.0 mg/dl white
blood count (wbc) ≥ 3,000/mm3 age ≥ 18 years.
children of all ages are not included as colon
cancer is extremely rare in children.*
Yes
No
women of childbearing potential with confirmed
negative pregnancy test on the day of
administration of study agent.*
Yes
No
before any trial-specific procedures or treatment
can be performed, the patient or patient's legally
authorized guardian or representative must give
witnessed written informed consent for
participation in the tria*
Yes
No
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Exclusion Criteria
clinically significant cardiac disease (new york
heart association class iii/iv).*
Yes
No
active cns tumor involvement. previous treatment
with a33 or its fragment and/or a positive test for
hua33 haha.*
Yes
No
lack of availability for immunological and clinical
follow-up assessments.*
Yes
No
participation in any other clinical trial involving
another investigational agent within 4 weeks prior
to enrollment.*
Yes
No
women who are pregnant or breast-feeding.*
Yes
No
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Unscheduled Event QTZ-EC-0004
ELEVATE  NCT01713426
QUTENZA™ versus Pregabalin in Subjects with Peripheral
Neuropathic Pain: an Open-label, Randomized, Multicenter,
Non-inferiority Efficacy and Tolerability Study
Medicine or Vaccine (generic name)
capsaicin
Sponsor Identification Number
QTZ-EC-0004
Trial Registry Identification Number(#'s)
NCT01713426
EudraCT Number: 2011-005872-41
All rights reserved. Please visit https://medical-data-
models.org/forms/16816
Unscheduled Event QTZ-EC-0004
ELEVATE  NCT01713426
Date of Visit
Was this visit performed?
(If No, then all other forms with the Form Not
Done field in this visit will be marked not done.)
Yes
No
If Yes, please provide the Date of Visit.
dd/MMM/yyyy
Unscheduled Event Checklist
Please select the procedures performed at this
visit
Biochemistry (Biochemistry)
Hematology (Hematology)
Physical Examination (Physical
Examination)
Pregnancy (Pregnancy)
Tolerability Assessment (Tolerability
Assessment)
Vital Signs 1 (Vital Signs 1)
Physical  Examination
Form Not Done
Done (Done)
Not Done (Not Done)
Assessment Date
dd/MMM/yyyy
Record any abnormal findings/ conditions
identified during the exam on the appropriate
form.
For Screening/ Baseline visits, report abnormal
findings/ conditions on the appropriate form. For
Screening/Baseline visits, report abnormal
findings/ conditions on the appropriate form
(Medical History or Adverse Events).
For Post-Baseline visits, record abnormal
findings/conditions that have worsened from
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Screening/Baseline and are clinically significant
on the Adverse Events form.
Vital signs
Form Not Done
Done (Done)
Not Done (Not Done)
Assessment Date
dd/MMM/yyyy
Position
Sitting (Sitting)
Standing (Standing)
Supine (Supine)
Systolic Blood Pressure
mmHg
Diastolic Blood Pressure
mmHg
Pulse
Beats/Min
Record any abnormal results on the appropriate
form. For Screening/Baseline visits, report
abnormal results on the appropriate form
(Medical History or Adverse Event).
For Post-Baseline visits, record abnormal results
that have worsened from Screening/ Baseline
and are clinicallly significant on the Adverse
Event form.
Pregnancy Test
Form Not Done
(Mark Form Not Done only if the entire visit was
not done, otherwise provide details below)
Done  (Done )
Not Done (Not Done)
If Pregnancy Test was not done, please provide
reason:
Female (2 years post-menopausal or
surgically sterile) (Female (2 years post-
menopausal or surgically sterile))
Male (Male)
Other (Other)
If `Other`, specify:
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Date of Sample Taken
dd/MMM/yyyy
Result of Pregnancy Test
Negative  (Negative )
Positive (Positive)
Hematology
Form Not Done
Done  (Done )
Not Done (Not Done)
Were samples taken?
Yes
No
Date of Sample Taken
dd/MMM/yyyy
LAB Interpretation
(If LAB Interpretation is abnormal, please select
assessment items below and report the
interpretation for each.)
Abnormal (Abnormal)
Normal (Normal)
LAB Test
Basophils (Basophils)
Eosinophils (Eosinophils)
Hematocrit (Hematocrit)
Hemoglobin (Hemoglobin)
Lymphocytes (Lymphocytes)
Monocytes (Monocytes)
Neutrophils (Neutrophils)
Platelets (Platelets)
Red Blood Cell (Red Blood Cell)
White Blood Cell Count (White Blood
Cell Count)
LAB Interpretation
Abnormal-clinically significant
(Abnormal-clinically significant)
Abnormal-not clinically significant
(Abnormal-not clinically significant)
Record any clinically significant abnormal
findings/conditions identified during the exam on
Medical and Surgical History and/ or Adverse
Event form.
Biochemistry
Form Not Done
Done (Done)
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Not Done (Not Done)
Were samples taken?
Yes
No
Date of Sample Taken
dd/MMM/yyyy
LAB Interpretation
(If LAB Interpretation is abnormal, please select
assessment items below and report the
interpretation for each.)
Abnormal (Abnormal)
Normal (Normal)
LAB Test
Alkaline Phosphatase (Alkaline
Phosphatase)
ALT (ALT)
AST (AST)
BUN (BUN)
Creatinine (Creatinine)
Potassium (Potassium)
Sodium (Sodium)
TBL (TBL)
LAB Interpretation
Abnormal-clinically significant
(Abnormal-clinically significant)
Abnormal-not clinically significant
(Abnormal-not clinically significant)
Record any clinically significant  abnormal
findings/conditions identified during the exam on
Medical and Surgical History and/or Adverse
Event form.
Tolerability Assessment
Form Not Done
(Form Not Done should only be marked for
subjects that are `RANDOMIZED/ REGISTERED
BUT NEVER RECEIVED/ DISPENSED STUDY
DRUG`).
Done (Done)
Not Done (Not Done)
Has diary been reviewed, and any existing
Adverse Events recorded in the eCRF?
Yes
No
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Eligibility Leukemia NCT00525603
CFAR Study in Patients With Chronic Lymphocytic
Leukemia; ODM derived from:
https://clinicaltrials.gov/show/NCT00525603
All rights reserved. Please visit https://medical-data-
models.org/forms/16817
Eligibility Leukemia NCT00525603
Inclusion Criteria
all patients must have a diagnosis of cll by
immunophenotyping and flow cytometry analysis
of blood or bone marrow and be previously
untreated.*
Yes
No
all patients must be younger than 70 years and
have a serum beta-2 microglobulin of >/=
4.0mg/l.*
Yes
No
all patients with rai stage iii-iv are eligible for
treatment on this protocol. - or- all patients with
rai stage 0-ii who meet one or more indication for
treatment as defined by the nci-sponsored
working group are eligible for treatment on this
protocol.*
Yes
No
all patients must have a zubrod performance
status of 0-3.*
Yes
No
all patients must have adequate renal and
hepatic function (serum creatinine </= 2mg/dl;
total bilirubin </= 2.5mg/dl). patients with renal or
liver dysfunction due to organ infiltration by
lymphocytes may be eligible after discussion with
the principle investigator and appropriate dose
adjustment considered.*
Yes
No
patients may not receive concurrent
chemotherapy, radiotherapy, or immunotherapy.
localized radiotherapy to an area not
compromising bone marrow function does not
apply, nor do hematopoietic growth factors such
as erythropoietin, granulocyte colony-stimulating
factor (g-csf), granulocyte-macrophage colony
stimulating factor (gm-csf), etc.*
Yes
No
patients must not have untreated or uncontrolled
life-threatening infection.*
Yes
No
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patients must sign informed consent.*
Yes
No
Exclusion Criteria
patients older than 70 years.*
Yes
No
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Eligibility Lymphoma, Non-Hodgkin
NCT00367497
Safety and Efficacy Study of Salvage Chemotherapy (R-
ESHAP) to Treat Relapsed and Refractory Aggressive Non-
Hodgkin's Lymphoma; ODM derived from:
https://clinicaltrials.gov/show/NCT00367497
All rights reserved. Please visit https://medical-data-
models.org/forms/16818
Eligibility Lymphoma, Non-Hodgkin
NCT00367497
Inclusion Criteria
clinical diagnosis of aggressive non-hodgkin's
lymphoma*
Yes
No
refractory to the first line chemotherapy or
relapsed*
Yes
No
expression of cd20 on lymphoma cells*
Yes
No
measurable lesions on imaging studies*
Yes
No
Exclusion Criteria
blood cell counts not reaching to 3,000/microliter
for white blood cells, 7 g/dl for hemoglobin, and
50,000/microliter for platelets without transfusion
at the time of registration*
Yes
No
circulating lymphoma cells equal to or more than
25,000/microliter*
Yes
No
hepatic dysfunction*
Yes
No
renal insufficiency*
Yes
No
cardiac dysfunction or arrhythmia*
Yes
No
sever infection (bacterial, viral)*
Yes
No
cns involvement*
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Yes
No
other malignancies*
Yes
No
pregnancy or breast feeding*
Yes
No
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Eligibility Coronary Artery Disease
NCT00288535
Treatment of Bifurcated Coronary Lesions With Cypher™-
Stent; ODM derived from:
https://clinicaltrials.gov/show/NCT00288535
All rights reserved. Please visit https://medical-data-
models.org/forms/16819
Eligibility Coronary Artery Disease
NCT00288535
Inclusion Criteria
1.  the target vessel must meet the following
criteria:*
Yes
No
1. bifurcated lesion type 1, 2, 3 or 4 of a native
coronary artery with a reference vessel diameter
of 2.5 mm to 4.0 mm in the main branch and of ≥
2.25 mm in the side branch.*
Yes
No
2. the target lesion (main branch and / or side
branch) must be at least 50% diameter stenosis.*
Yes
No
3. the target lesion has not been previously
treated with any interventional procedure.*
Yes
No
4. the target vessel (main branch and side
branch) must be feasible for stent implantation
(successful passage with the guide wire;
successful predilatation with an appropriately
sized balloon; no heavy calcification; no diffuse
distal disease that might impede run off).*
Yes
No
2.  patient has stable or unstable angina pectoris
(ccs classification i or greater) or a positive stress
test for ischemia.*
Yes
No
3.  patient must be ≥ 18 years of age. 4.  female
subjects of childbearing potential must have a
negative pregnancy test within 7 days before the
procedure.*
Yes
No
5. patient has no other treatment planned within
30 days of the procedure. 6. patient has been
informed of the nature of the study and agrees to
its provisions and has written informed consent
as approved by the ethics committee.*
Yes
No
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7.  patient willing to comply with required post-
procedure follow-up.*
Yes
No
Exclusion Criteria
1.   patient has had an acute myocardial
infarction (> 3x normal ck with presence of ckmb)
within 72 hours preceding the index procedure
and ck has not returned to normal limits at the
time of the procedure.*
Yes
No
2.  patient will have a known hypersensitivity or
contraindication to aspirin, heparin, clopidogrel,
stainless steel, sirolimus, or contrast sensitivity
that cannot be adequately pre-medicated.*
Yes
No
3.  patient has a platelet count of <100,000
cells/mm³ or >700,000 cells/mm³, a wbc of
<3,000 cells/mm³, or documented or suspected
liver disease.*
Yes
No
4.  patient has a history of bleeding diathesis or
coagulopathy. 5.  patient has suffered a cva or tia
within the past six months. 6.  active peptic ulcer
or upper gi bleeding within the prior 6 months. 7.
patient has a co-morbidity (i.e. cancer or
congestive heart failure) that may cause the
patient to be non-compliant with the protocol, or
is associated with limited life- expectancy (less
than 2 years).*
Yes
No
8. patient must be excluded from the study if any
of these angiographic criteria are met:*
Yes
No
1. the target vessel contains intraluminal
thrombus.*
Yes
No
2. the target lesion is located in the left main
coronary artery.*
Yes
No
3. the target lesion or vessel shows angiographic
evidence of severe calcification.*
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Yes
No
4. the patient has undergone previous pci to the
target vessel within 6 months.*
Yes
No
5. pre treatment of the lesion is done with a
technique other than balloon angioplasty (e.g.
rotablation).*
Yes
No
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Eligibility Colorectal Neoplasms
NCT00259844
Effect of TroVax in Patients Having Colorectal Cancer With
Liver Metastases Removed; ODM derived from:
https://clinicaltrials.gov/show/NCT00259844
All rights reserved. Please visit https://medical-data-
models.org/forms/16823
Eligibility Colorectal Neoplasms
NCT00259844
Inclusion Criteria
colorectal adenocarcinoma with metastases
confined only to the liver, histologically proven
and considered suitable for treatment by surgical
resection.*
Yes
No
world health organisation (who) performance
status of 0 or 1*
Yes
No
all toxic manifestations of previous treatment
must have resolved.  exceptions to this are
alopecia or certain grade 1 toxicities which in the
opinion of the investigator and cancer research
uk should not exclude the patient.*
Yes
No
Exclusion Criteria
radiotherapy, endocrine therapy, immunotherapy,
systemic steroids, or chemotherapy during the
previous four weeks (six weeks for nitrosoureas
and mitomycin-c) prior to treatment or during the
course of the trial.*
Yes
No
patients who are high medical risks because of
non-malignant systemic disease, including those
with active uncontrolled infection.*
Yes
No
concurrent serious infections within the 28 days
prior to entry to the trial*
Yes
No
current malignancies at other sites, with the
exception of adequately treated cone-biopsied in
situ  carcinoma of the cervix uteri and basal or
squamous cell carcinoma of the skin.*
Yes
No
patients known to be serologically positive for
hepatitis b, c or hiv*
Yes
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No
history of allergy to vaccinations or egg proteins.*
Yes
No
inflammatory bowel disease*
Yes
No
history of autoimmune disease*
Yes
No
clinical evidence of cerebral metastases*
Yes
No
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EUROASPIRE III- Coronary heart disease
HRI Interview Questionnaire
Provided by Prof. Keil Source: Kotseva K, Wood D, De
Backer G, De Bacquer D, Pyörälä K, Keil U; EUROASPIRE
Study Group. Cardiovascular prevention guidelines in daily
practice: a comparison of EUROASPIRE I, II, and III
surveys in eight European countries. Lancet. 2009 Mar
14;373(9667):929-40. doi: 10.1016/S0140-6736(09)60330-
5. PubMed PMID: 19286092
All rights reserved. Please visit https://medical-data-
models.org/forms/16824
HRI Interview Questionnaire
Demographic Information
Patient ID
Did the patient attend the interview?
Yes
No
If YES, date of interview
If NO, why not?
Patient died 						 (1)
Change in health status 				 (2)
No time 						 (3)
Moved away 						 (4)
Personal reasons 					 (5)
Refuse to attend for other reasons 			 (6)
Other, please specify (7)
If other reason for not attending, please specify
If patient died, please indicate cause of death
Coronary death (1)
Other cardiovascular death (2)
Unknown (3)
Other, please specify (4)
If other cause of death, please specify
If patient died, please indicate date of death
How many years have you spent in full-time
education? (99 = insufficient data)
yrs
What is the highest level of education you have
completed?
No formal schooling (1)
Less than primary school	 (2)
Primary school completed (3)
Secondary school completed (4)
High school completed (5)
Collage/ University completed (6)
Post graduate degree (7)
Insufficient data (unknown) (8)
Employment status
Full time employed (1)
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Part time employed (2)
Self employed (3)
Unemployed (4)
House person (5)
Full time education (6)
Retired (7)
Insufficient data (unknown) (8)
If retired
Age related (1)
Heart disease related (2)
Other illness (3)
Personal choice (4)
Insufficient data (unknown) (5)
Smoking
Have you ever smoked?
Yes
No
For how many years in total have you smoked?
yrs
Do you smoke now?
Yes
No
If smoking now, what type of tobacco-product?
Cigarettes (1)
Pipe (2)
Cigars (3)
How many cigarettes per day?
How much pipe tobacco in g/week?
How many cigars per day?
If not smoking now, did you quit within the last 6
months
Yes
No
If not smoking now, did you quit more than 6
months ago?
Yes
No
If not smoking now, at what age did you stop? (99
= unknown)
yrs
If smoking now In the last year, how many times
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have you quit smoking for at least 24 hours?
If smoking now: Are you seriously thinking of
quitting smoking?
Yes, within the next 30 days (1)
Yes, within the next 6 months (2)
No, not thinking of quitting (3)
Don’t know/ Unsure (4)
In the daytime or at night, do you frequently stay,
at work , in rooms where people smoke?
Yes
No
In the daytime or at night, do you frequently stay,
at home , in rooms where people smoke?
Yes
No
In the daytime or at night, do you frequently stay,
at other locations , in rooms where people
smoke?
Yes
No
Diet/Body weight
Have you ever been told by a health care
professional that your diet is unhealthy?
Yes (1)
No (2)
Don´t know/ Unsure (3)
Have you ever been told by a health care
professional that you are overweight?
Yes (1)
No (2)
Don´t know/ Unsure (3)
In the past month, have you been actively trying
to lose weight?
Yes (1)
No (2)
Don´t know/ Unsure (3)
In the past month, have you been actively trying
to keep from gaining weight?
Yes (1)
No (2)
Don´t know/ Unsure (3)
Are you seriously considering trying to lose
weight to reach your goal in the next month?
Yes (1)
No (2)
Don´t know/ Unsure (3)
Are you seriously considering trying to lose
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weight to reach your goal in the next six months?
Yes (1)
No (2)
Don´t know/ Unsure (3)
Have you maintained your desired weight for
more than 6 months?
Yes (1)
No (2)
Don´t know/ Unsure (3)
Physical activity
Do you have any long-standing illness, disability
or infirmity?
Yes (1)
No (2)
Don´t know/ Unsure (3)
Which of the following four best describes your
level of activity outside work?
No physical activity weekly (1)
Only light physical activity in most weeks
(2)
Vigorous physical activity at least 20
minutes once or twice a week (3)
Vigorous physical activity for at least 20
minutes three or more times per week
(4)
Don’t know/ Unsure (5)
Do you exercise regularly according to that (in
description) outlined definition?
Yes, I have been for MORE than 6
months (1)
Yes, I have been for LESS than 6 months
(2)
No, but I intend to in the next 30 days (3)
No, but I intend to in the next 6 months
(4)
No, and I do NOT intend to in the next 6
months  (5)
Don’t know/ Unsure (6)
Blood pressure,Cholesterol and Diabetes
Have you ever been told by a doctor (or other
health professional) that you have high blood
pressure?
Yes (1)
No (2)
Don´t know/ Unsure (3)
Are you taking (in the last two weeks) drugs
specifically prescribed to lower your blood
pressure ?
Yes (1)
No (2)
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Don´t know/ Unsure (3)
Are you on a special diet prescribed by a doctor
(or other health professional) to lower your blood
pressure level?
Yes (1)
No (2)
Don´t know/ Unsure (3)
If hypertensive, do you monitor your blood
pressure yourself?
Yes (1)
No (2)
Don´t know/ Unsure (3)
Have you ever been told by a doctor (or other
health professional) that you have a high blood
cholesterol?
Yes (1)
No (2)
Don´t know/ Unsure (3)
Are you on a special diet prescribed by a doctor
(or other health professional) to lower your blood
cholesterol level?
Yes (1)
No (2)
Don´t know/ Unsure (3)
Have you ever been told by a doctor (or other
health professional) that you have diabetes?
Yes (1)
No (2)
Don´t know/ Unsure (3)
If you have been told you have diabetes, how is it
currently being treated?
Diet only (1)
Oral anti-diabetic drugs (2)
Insulin (3)
Don’t know/Unsure (4)
If diabetic, do you monitor your blood glucose
yourself?
Yes (1)
No (2)
Don´t know/ Unsure (3)
If you monitor your blood glucose yourself,how?
Blood (1)
Urine (2)
Unkown (3)
If you monitor your blood glucose yourself,how
many times per day?
If you are on insulin, have you ever had education
regarding using it?
Yes (1)
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No (2)
Don´t know/ Unsure (3)
Risk factor awareness and targets
Was your blood pressure ever measured?
Yes (1)
No (2)
Don´t know/ Unsure (3)
Was your total cholesterol ever measured?
Yes (1)
No (2)
Don´t know/ Unsure (3)
Was your blood glucose ever measured?
Yes (1)
No (2)
Don´t know/ Unsure (3)
Was your HbA1c (in diabetics) ever measured?
Yes (1)
No (2)
Don´t know/ Unsure (3)
Are you aware of your latest weight?
Yes (1)
No (2)
Don´t know/ Unsure (3)
Current Body weight
kg
Are you aware of your target weight?
Yes (1)
No (2)
Don´t know/ Unsure (3)
What is your target weight?
kg
Are you aware of your blood pressure level?
Yes (1)
No (2)
Don´t know/ Unsure (3)
Current blood pressure
mmHg
Are you aware of your blood pressure target?
Yes (1)
No (2)
Don´t know/ Unsure (3)
What is your blood pressure target?
mmHg
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Are you aware of your total cholesterol level?
Yes (1)
No (2)
Don´t know/ Unsure (3)
Total cholesterol measurement
mmol/l
Are you aware of your total cholesterol target?
Yes (1)
No (2)
Don´t know/ Unsure (3)
What is your total cholesterol target?
mmol/l
Are you aware of your latest blood glucose level?
Yes (1)
No (2)
Don´t know/ Unsure (3)
Blood glucose measurement
mmol/l
Are you aware of your blood glucose target?
Yes (1)
No (2)
Don´t know/ Unsure (3)
What is your blood glucose target?
mmol/l
Are you aware of your latest HbA1c level?
Yes (1)
No (2)
Don´t know/ Unsure (3)
HbA1c measurement
%
Are you aware of your HbA1c target?
Yes (1)
No (2)
Don´t know/ Unsure (3)
What is your HbA1c target?
%
Lifestyle changes
Over the last 3 years, were you offered any
personal advice by a doctor or other health
professional on stopping smoking?
Yes since the index event or procedure
(1)
Yes since before the index event or
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procedure  (2)
No  (3)
Unsure/ Don’t know (4)
What type of advice did you receive for stopping
smoking?
verbal (1)
written materials (2)
referral to smoking cessation clinic/
course (3)
Nicotine replacement therapy (4)
Bupropion (5)
other (6)
Over the last 3 years, were you offered any
personal advice by a doctor or other health
professional on a healthy diet?
Yes since the index event or procedure
(1)
Yes since before the index event or
procedure  (2)
No  (3)
Unsure/ Don’t know (4)
What type of advice did you receive concerning a
healthy diet?
reduction of salt intake (1)
reduction of fat intake (2)
changing type of fat intake (3)
reduction of calorie intake (4)
eating more fruits and vegetables (5)
eating more fish (6)
eating more oily fish (7)
reducing sugar (8)
reducing excessive alcohol intake (9)
Over the last 3 years, were you offered any
personal advice by a doctor or other health
professional on weight loss?
Yes since the index event or procedure
(1)
Yes since before the index event or
procedure  (2)
No  (3)
Unsure/ Don’t know (4)
What type of advice did you receive concerning
weight loss?
following dietary recommendations (1)
participating in regular physical activity
(2)
weight reducing drugs (3)
other (please specify) (4)
What type of advice did you receive concerning
weight loss?
following dietary recommendations (1)
participating in regular physical activity
(2)
weight reducing drugs (3)
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other (please specify) (4)
Please specify other type of advice you received
concerning weight loss?
Over the last 3 years, were you offered any
personal advice by a doctor or other health
professional on increase of physical activity?
Yes since the index event or procedure
(1)
Yes since before the index event or
procedure  (2)
No  (3)
Unsure/ Don’t know (4)
What type of advice did you receive concerning
increase of physical activity?
following specific exercise advice from a
health or exercise professional (1)
attending a fitness club or leisure centre
(2)
trying to do more general everyday
physical activities (3)
joining a community walking group (4)
other (5)
Over the last 3 years, did to try to stop smoking to
reduce your risk of heart disease?
Yes (1)
No (2)
Don´t know/ Unsure (3)
Over the last 3 years, which steps did you take to
stop smoking to reduce your risk of heart
disease?
abstinence (1)
reduction (2)
smoking cessation clinic (3)
Nicotine replacement therapy (4)
Bupropion (5)
other (6)
Over the last 3 years, did you try to keep a
healthy diet to reduce your risk of heart disease?
Yes (1)
No (2)
Don´t know/ Unsure (3)
What steps did you take concerning a healthy
diet?
reduction of salt intake (1)
reduction of fat intake (2)
changing type of fat intake (3)
reduction of calorie intake (4)
eating more fruits and vegetables (5)
eating more fish (6)
eating more oily fish (7)
reducing sugar (8)
reducing excessive alcohol intake (9)
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Over the last 3 years, did you try to loose weight
to reduce your risk for heart disease?
Yes (1)
No (2)
Don´t know/ Unsure (3)
What steps did you take concerning weight loss?
following dietary recommendations (1)
participating in regular physical activity
(2)
weight reducing drugs (3)
other (4)
Over the last 3 years, did you try to increase your
physical activity to reduce your risk of heart
disease?
Yes (1)
No (2)
Don´t know/ Unsure (3)
What steps did you take to increase your physical
activity?
following specific exercise advice from a
health or exercise professional (1)
attending a fitness club or leisure centre
(2)
trying to do more general everyday
physical activities (3)
joining a community walking group (4)
other (5)
Over the last 3 years, have you received help
from any of the following professionals to achieve
your lifestyle and other risk factor targets?
Dietician (1)
Lipid specialist (10)
Diabetologist/endocrinologist (11)
Other   (please specify) (12)
Nurse (2)
Smoking cessation specialist (3)
Physiotherapist (4)
Exercise professional (5)
Hospital physician (6)
General practitioner or family doctor (7)
Cardiologist (8)
Hypertension specialist (9)
Please specify other health professional you
received help from
Risk perception
Do you believe that everyone ought to know their
own risk of heart disease in order to reduce it?
Strongly disagree	 (1)
Disagree	 (2)
Neutral	 (3)
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Agree	 (4)
Strongly agree (5)
Are you worried that you may develop heart
disease?
Strongly disagree	 (1)
Disagree	 (2)
Neutral	 (3)
Agree	 (4)
Strongly agree (5)
Are you worried about finding out your risk of
heart disease?
Strongly disagree	 (1)
Disagree	 (2)
Neutral	 (3)
Agree	 (4)
Strongly agree (5)
What do you think your risk of getting heart
disease is in the next 10 years?
Very high	 (1)
High	 (2)
Moderate	 (3)
Low	 (4)
Very Low	 (5)
Doesn’t know (6)
Do you think your risk of getting heart disease in
the next 10 years is higher, lower or about the
same as a person of the same age and sex as
you?
Much higher (1)
Higher	 (2)
About the same (3)
Lower	 (4)
Much lower (5)
Over the last 3 years, were you advised to follow
a cardiovascular disease 
prevention programme?
Yes (1)
No (2)
Don´t know/ Unsure (3)
If YES, did you attend the cardiovascular disease
prevention programme offered?
No, not at all (1)
Attended less than half of the sessions
(2)
Attended more than half of the sessions
(3)
Yes, fully (4)
If attended, please specify what you received as
part of this program
Written educational materials (1)
Teaching sessions/ health promotion
workshops (2)
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Smoking cessation (3)
Dietary modification/weight management
(4)
Supervised exercise programme (5)
Stress modification and relaxation (6)
Other   (please specify) (7)
Please specify any other part of the prevention
program you attended
Medication
Aspirin or other anti-platelet drugs?
Yes (1)
No (2)
Don´t know/ Unsure (3)
Aspirin or other anti-platelet drugs: Generic name
Aspirin or other anti-platelet drugs: Total daily
dose
mg
Aspirin or other anti-platelet drugs?
Yes (1)
No (2)
Don´t know/ Unsure (3)
Aspirin or other anti-platelet drugs: Generic name
Aspirin or other anti-platelet drugs: Total daily
dose
mg
Beta blockers
Yes (1)
No (2)
Don´t know/ Unsure (3)
Beta blockers:Generic name
Beta Blockers Total daily dose
mg
ACE inhibitors
Yes (1)
No (2)
Don´t know/ Unsure (3)
ACE inhibitors: Generic name
ACE inhibitors : Total daily dose
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mg
Angiotensin II receptor antagonists
Yes (1)
No (2)
Don´t know/ Unsure (3)
Angiotensin II receptor antagonists: Generic
name
Angiotensin II receptor antagonists: Total daily
dose
mg
Calcium antagonists
Yes (1)
No (2)
Don´t know/ Unsure (3)
Calcium antagonists: Generic name
Calcium antagonists: Total daily dose
mg
If inhibitors
Yes (1)
No (2)
Don´t know/ Unsure (3)
If inhibitors: Generic name
If inhibitors: Total daily dose
mg
Nitrates
Yes (1)
No (2)
Don´t know/ Unsure (3)
Nitrates: Generic name
Nitrates: Total daily dose
mg
Diuretics
Yes (1)
No (2)
Don´t know/ Unsure (3)
Diuretics: Generic name
Diuretics: Total daily dose
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mg
Diuretics
Yes (1)
No (2)
Don´t know/ Unsure (3)
Diuretics: Generic name
Diuretics: Total daily dose
mg
Other anti-hypertensive drugs
Yes (1)
No (2)
Don´t know/ Unsure (3)
Other Anti-hypertensive drugs: Generic name
Other Anti-hypertensive drugs: Total daily dose
mg
Digitalis glycosides
Yes (1)
No (2)
Don´t know/ Unsure (3)
Digitalis glycosides: Generic name
Digitalis glycosides: Total daily dose
mg
Antiarrhythmics
Yes (1)
No (2)
Don´t know/ Unsure (3)
Antiarrhythmics: Generic name
Antiarrhythmics:  Total daily dose
mg
Lipid lowering drugs: Statins
Yes (1)
No (2)
Don´t know/ Unsure (3)
Lipid lowering drugs (Statins): Generic name
Lipid lowering drugs (Statins): Total daily dose
mg
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Lipid lowering drugs: Fibrates
Yes (1)
No (2)
Don´t know/ Unsure (3)
Lipid lowering drugs (Fibrates): Generic name
Lipid lowering drugs (Fibrates): Total daily dose
mg
Lipid lowering drugs: Nicotinic acid group
Yes (1)
No (2)
Don´t know/ Unsure (3)
Lipid lowering drugs (Nicotinic acid group):
Generic name
Lipid lowering drugs (Nicotinic acid group): Total
daily dose
mg
Lipid lowering drugs: Cholesterol absorption
inhibitors
Yes (1)
No (2)
Don´t know/ Unsure (3)
Lipid lowering drugs (Cholesterol absorption
inhibitors): Generic name
Lipid lowering drugs (Cholesterol absorption
inhibitors): Total daily dose
mg
Lipid lowering drugs: Resins
Yes (1)
No (2)
Don´t know/ Unsure (3)
Lipid lowering drugs (Resins): Generic name
Lipid lowering drugs (Resins): Total daily dose
mg
Lipid lowering drugs: Other
Yes (1)
No (2)
Don´t know/ Unsure (3)
Lipid lowering drugs (Other): Generic name
Lipid lowering drugs (Other): Total daily dose
mg
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Anti-diabetic drugs: Insulin
Yes (1)
No (2)
Don´t know/ Unsure (3)
Insulin: Generic name
Insulin: Total daily dose
mg
Anti-diabetic drugs: Insulin
Yes (1)
No (2)
Don´t know/ Unsure (3)
Insulin: Generic name
Insulin: Total daily dose
mg
Anti-diabetic drugs: oral
Yes (1)
No (2)
Don´t know/ Unsure (3)
Oral Antidiabetics: Generic name
Oral Antidiabetics: Total daily dose
mg
Anti-diabetic drugs: oral
Yes (1)
No (2)
Don´t know/ Unsure (3)
Oral Antidiabetics: Generic name
Oral Antidiabetics: Total daily dose
mg
Anti-coagulants
Yes (1)
No (2)
Don´t know/ Unsure (3)
Anti-coagulants: Generic name
Anti-coagulants: Total daily dose
mg
Oral contraceptive pill
Yes (1)
No (2)
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Don´t know/ Unsure (3)
Oral contraceptive pill: Generic name
Oral contraceptive pill: Total daily dose
mg
Hormone replacement therapy
Yes (1)
No (2)
Don´t know/ Unsure (3)
Hormone replacement therapy: Generic name
Hormone replacement therapy: Total daily dose
mg
Appetite suppressants or other antiobesity
Yes (1)
No (2)
Don´t know/ Unsure (3)
Appetite suppressants/other antiobesity: Generic
name
Appetite suppressants or other antiobesity: Total
daily dose
mg
Nicotine replacement therapy
Yes (1)
No (2)
Don´t know/ Unsure (3)
Nicotine replacement therapy: Generic name
Nicotine replacement therapy: Total daily dose
mg
Nicotine replacement therapy
Chewing Gum (1)
Nasal spray (2)
Inhalator (3)
Patches (4)
Losenges (5)
Bupropion
Yes (1)
No (2)
Don´t know/ Unsure (3)
Bupropion: Generic name
17 / 24
EUROASPIRE III- Coronary heart disease HRI Interview Questionnaire
Bupropion: Total daily dose
mg
Other medication
Yes (1)
No (2)
Don´t know/ Unsure (3)
Other medications: Generic name
Other medications: Total daily dose
mg
Is any of the medication prescribed a
combination of 2 drugs in one tablet?
Yes (1)
No (2)
Don´t know/Unsure (3)
If yes, please specify
Over the last 3 years, have you altered the
dosage of your prescribed medication?
Never  (1)
Seldom (2)
Often (3)
Always (4)
Over the last 3 years, have you missed taking the
dosage of your prescribed medication?
Never  (1)
Seldom (2)
Often (3)
Always (4)
Family history of cardiovascular disease
History of cardiovascular disease of father
Yes (1)
No (2)
Don´t know/ Unsure (3)
Age of father at diagnosis of cardiovascular
disease
Age of father at diagnosis of cardiovascular
disease unknown
Yes
No
Father died of cardiovascular disease  (if
applicable)
Yes (1)
No (2)
Don´t know/ Unsure (3)
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Age at death from cardiovascular disease of
father (if applicable)
Age at death from cardiovascular disease of
father unknown
Yes
No
History of cardiovascular disease of mother
Yes (1)
No (2)
Don´t know/ Unsure (3)
Age of mother at diagnosis of cardiovascular
disease
Age of mother at diagnosis of cardiovascular
disease unknown
Yes
No
Mother died of cardiovascular disease  (if
applicable)
Yes (1)
No (2)
Don´t know/ Unsure (3)
Age at death from cardiovascular disease of
mother (if applicable)
Age at death from cardiovascular disease of
mother unknown
Yes
No
History of cardiovascular disease of brother
Yes (1)
No (2)
Don´t know/ Unsure (3)
Age of brother at diagnosis of cardiovascular
disease
Age of brother at diagnosis of cardiovascular
disease unknown
Yes
No
Brother died of cardiovascular disease (if
applicable)
Yes (1)
No (2)
Don´t know/ Unsure (3)
Age at death from cardiovascular disease of
brother (if applicable)
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Age at death from cardiovascular disease of
brother unknown (if applicable)
Yes
No
History of cardiovascular disease of sister
Yes (1)
No (2)
Don´t know/ Unsure (3)
Age of sister at diagnosis of cardiovascular
disease
Age of sister at diagnosis of cardiovascular
disease unknown
Yes
No
Sister died of cardiovascular disease  (if
applicable)
Yes (1)
No (2)
Don´t know/ Unsure (3)
Age at death from cardiovascular disease of
sister (if applicable)
Age at death from cardiovascular disease of
sister unknown
Yes
No
History of cardiovascular disease of son
Yes (1)
No (2)
Don´t know/ Unsure (3)
Age of son at diagnosis of cardiovascular disease
Age of son at diagnosis of cardiovascular disease
unknown
Yes
No
Son died of cardiovascular disease  (if applicable)
Yes (1)
No (2)
Don´t know/ Unsure (3)
Age at death from cardiovascular disease of son
(if applicable)
Age at death from cardiovascular disease of son
unknown
Yes
No
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History of cardiovascular disease of daughter
Yes (1)
No (2)
Don´t know/ Unsure (3)
Age of daughter at diagnosis of cardiovascular
disease
Age of daughter at diagnosis of cardiovascular
disease unknown
Yes
No
Daughter died of cardiovascular disease  (if
applicable)
Yes (1)
No (2)
Don´t know/ Unsure (3)
Age at death from cardiovascular disease of
daughter (if applicable)
Age at death from cardiovascular disease of
daughter unknown
Yes
No
Physical measurements
Body height
cm
Body weight
kg
Waist circumference
cm
1st measurement of systolic blood pressure
mmHg
1st measurement of diastolic blood pressure
mmHg
2nd measurement of systolic blood pressure
mmHg
2nd measurement of diastolic blood pressure
mmHg
Heart rate
bpm
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Carbon monoxide in breath
ppm
HAD scale: anxiety score
HAD scale: depression score
Evaluation of EQ-5D: Score 1
Evaluation of EQ-5D: Score 2
SF-12 Physical health summary measure
SF-12 Mental health summary measure
During the last 7 days, on how many days did you
do vigorous physical activities like heavy lifting,
digging, aerobics, or fast bicycling?
No vigorous activity during the last 7 days - if yes,
skip to question 3
Yes
No
How much time did you usually spend doing
vigorous physical activities on one of those days?
In hours per day?
How much time did you usually spend doing
vigorous physical activities on one of those days?
In minutes per day?
The time I spend doing vigorous physical
activities on one of those days is unknown
Yes
No
During the last 7 days, on how many days did you
do moderate physical activities like carrying light
loads, bicycling at a regular pace, or doubles
tennis?  Do not include walking
No moderate activity during the last 7 days - if
yes, skip to question 5
Yes
No
How much time did you usually spend doing
moderate physical activities on one of those
days? In hours per day?
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How much time did you usually spend doing
moderate physical activities on one of those
days? In minutes per day?
The time I spend doing moderate physical
activities on one of those days is unknown
Yes
No
During the last 7 days, on how many days did you
walk for at least 10 minutes at a time?
No walking activity during the last 7 days - if yes,
skip to question 7
Yes
No
How much time did you usually spend walking on
one of those days? In hours per day?
How much time did you usually spend walking on
one of those days? In minutes per day?
The time I spend walking on one of those days is
unknown
Yes
No
During the last 7 days, how much time did you
spend sitting on a week day?
How much time did you usually spend sitting on a
weekday? In hours per day?
How much time did you spend sitting on a
weekday? In minutes per day?
The time I spend sitting on a weekday is
unknown
Yes
No
Blood sample
Has a venous blood sample been taken from the
patient ?
Yes
No
Has a venous blood sample been taken from the
patient ? If no, please state why not
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Was the patient fasting before blood sampling ?
Yes
No
Hours of fast before blood sampling
Interview completed for this patient?
Yes
No
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Eligibility Colorectal Peritoneal
Carcinomatosis NCT01524094
Cytoreduction and Intraperitoneal Chemotherapy Versus
Systemic Chemotherapy in Colorectal Peritoneal
Carcinomatosis; ODM derived from:
https://clinicaltrials.gov/show/NCT01524094
All rights reserved. Please visit https://medical-data-
models.org/forms/16825
Eligibility Colorectal Peritoneal
Carcinomatosis NCT01524094
Inclusion Criteria
metastatic disease to the peritoneum from colon
or rectum (at least two isolated sites of disease)*
Yes
No
verified primary tumor of adenocarcinoma of the
colon or rectum*
Yes
No
potential resectability as judged by the treating
surgeon*
Yes
No
patient is available for follow-up according to the
study protocol*
Yes
No
signed informed consent*
Yes
No
Exclusion Criteria
extraabdominal metastases or liver metastases*
Yes
No
paraaortic or other inoperable lymph node
metastases*
Yes
No
clear indication for surgery only (such as
obstruction, bleeding or peritonitis)*
Yes
No
prior treatment of either arm in the study*
Yes
No
clinical or histopathological diagnosis of
peritoneal pseudomyxoma*
Yes
No
age > 80*
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Yes
No
contraindications for chemotherapy*
Yes
No
pregnancy or breastfeeding*
Yes
No
ongoing infection*
Yes
No
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EUROASPIRE III (Hospital Arm) - Coronary
heart disease Patient Record Questionnaire
Provided by Prof. Keil
Source: Kotseva K, Wood D, De Backer G, De Bacquer D,
Pyörälä K, Keil U; EUROASPIRE Study Group.
Cardiovascular prevention guidelines in daily practice: a
comparison of EUROASPIRE I, II, and III surveys in eight
European countries. Lancet. 2009 Mar 14;373(9667):929-
40. doi: 10.1016/S0140-6736(09)60330-5. PubMed PMID:
19286092
All rights reserved. Please visit https://medical-data-
models.org/forms/16827
Patient Record Questionnaire
Inclusion criteria
Has the patient been an inpatient at your hospital
for one of the following procedures or diagnoses?
Elective or emergency coronary artery by-pass
surgery; Elective or emergency percutaneous
transluminal coronary angioplasty; Acute
myocardial infarction; Acute myocardial
ischaemia
Yes
No
Has at least six months and at most 3 years
elapsed since the most recent admission for one
of these procedures or diagnoses?
Yes
No
If the answer to both questions is yes,please
complete this Data Form from the information
recorded in the patient's notes.
Yes
No
Personal information
Patient ID
Patient Title
Mr (1)
Miss (2)
Ms (3)
Mrs (4)
Forename(s)
Surname
Address
Telephone number
National hospital number:
General practitioner name
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General practitoner address
Telephone number
Patient Record Questionnaire
Date of completion of this form
Date of birth of patient
Sex
male (1)
female (2)
What was the index event or procedure which
entered the patient into this study? The event
must have occurred at least six months prior to
completion of this form.
Elective or emergency coronary artery
by-pass surgery (1)
Elective or emergency percutaneous
transluminal coronary angioplasty	 (2)
Acute myocardial infarction (3)
Acute myocardial ischaemia (4)
Date of acute event
Date of discharge
Has the Patient died?
Yes (1)
No (2)
Unsure (3)
Not recorded (4)
Date of death (if applicable)
Was CABG done during hospital admission for
Acute myocardial infarction
Yes (1)
No (2)
Unsure (3)
Not recorded (4)
Was CABG done during hospital admission for
Acute myocardial ischaemia without infarction
Yes (1)
No (2)
Unsure (3)
Not recorded (4)
Was PTCA done during hospital admission for
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Acute myocardial infarction
Yes (1)
No (2)
Unsure (3)
Not recorded (4)
Was PTCA done during hospital admission for
Acute myocardial ischaemia without infarction
Yes (1)
No (2)
Unsure (3)
Not recorded (4)
If YES to either one of the previous questions,
was the CABG or PTCA an emergency
procedure (performed during first 24 hours from
admission)?
Yes (1)
No (2)
Unsure (3)
Not recorded (4)
Did the patient have a history of coronary heart
disease, stroke or other vascular disease prior to
the index event or procedure?
Yes (1)
No (2)
Unsure (3)
Not recorded (4)
Coronary artery bypass surgery
Yes (1)
No (2)
Unsure (3)
Not recorded (4)
Coronary artery bypass surgery year of event
Percutaneous transluminal coronary angioplasty
Yes (1)
No (2)
Unsure (3)
Not recorded (4)
Percutaneous transluminal coronary angioplasty
year of event
Acute myocardial infarction
Yes (1)
No (2)
Unsure (3)
Not recorded (4)
Acute myocardial infarction year of event
Acute myocardial ischaemia
Yes (1)
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No (2)
Unsure (3)
Not recorded (4)
Acute myocardial ischaemia year of event
History of angina pectoris
Yes (1)
No (2)
Unsure (3)
Not recorded (4)
History of angina pectoris year of event
History of stroke
Yes (1)
No (2)
Unsure (3)
Not recorded (4)
History of stroke year of event
History of TIA (transient ischemic attack)
Yes (1)
No (2)
Unsure (3)
Not recorded (4)
History of TIA (transient ischemic attack) year of
event
History of PAD (peripheral artery disease)
Yes (1)
No (2)
Unsure (3)
Not recorded (4)
History of PAD (peripheral artery disease) year of
event
History of hypertension
Yes (1)
No (2)
Not recorded (3)
History of hypertension:if yes, duration in months
History of hyperlipidaemia/ dyslipidaemia
Yes (1)
No (2)
Not recorded (3)
History of hyperlipidaemia/ dyslipidaemia: If yes,
duration in months
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History of diabetes
Yes (1)
No (2)
Not recorded (3)
History of diabetes: If yes, duration in months
Smoking status
Non smoker 		 (1)
Is a current non smoker (but previous
smoking history unknown) 	 (2)
Has stopped smoking  (3)
Current smoker (4)
Body height
cm
Body weight
kg
Body Mass Index
kg/m2
Waist circumference
cm
Systolic blood pressure
mmHg
Diastolic blood pressure
mmHg
Heart rate
bpm
Total cholesterol
mmol/l
LDL cholesterol
mmol/l
HDL cholesterol
mmol/l
Triglycerides
mmol/l
Blood glucose level
mmol/l
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HbA1C level (in diabetics)
Was the patient taking any of the following
medications prior to the index event or
procedure?
Yes (1)
No (2)
Unsure (3)
Not recorded (4)
Aspirin or other anti-platelet drugs?
Yes (1)
No (2)
Not recorded (3)
Aspirin or other anti-platelet drugs: Generic name
Aspirin or other anti-platelet drugs: Total daily
dose
mg
Aspirin or other anti-platelet drugs?
Yes (1)
No (2)
Not recorded (3)
Aspirin or other anti-platelet drugs: Generic name
Aspirin or other anti-platelet drugs: Total daily
dose
mg
Beta blockers
Yes (1)
No (2)
Not recorded (3)
Beta blockers:Generic name
Beta Blockers Total daily dose
mg
ACE inhibitors
Yes (1)
No (2)
Not recorded (3)
ACE inhibitors: Generic name
ACE inhibitors : Total daily dose
mg
Angiotensin II receptor antagonists
Yes (1)
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No (2)
Not recorded (3)
Angiotensin II receptor antagonists: Generic
name
Angiotensin II receptor antagonists: Total daily
dose
mg
Calcium antagonists
Yes (1)
No (2)
Not recorded (3)
Calcium antagonists: Generic name
Calcium antagonists: Total daily dose
mg
If inhibitors
Yes (1)
No (2)
Not recorded (3)
If inhibitors: Generic name
If inhibitors: Total daily dose
mg
Nitrates
Yes (1)
No (2)
Not recorded (3)
Nitrates: Generic name
Nitrates: Total daily dose
mg
Diuretics
Yes (1)
No (2)
Not recorded (3)
Diuretics: Generic name
Diuretics: Total daily dose
mg
Diuretics
Yes (1)
No (2)
7 / 20
EUROASPIRE III (Hospital Arm) - Coronary heart disease Patient
Record Questionnaire
Not recorded (3)
Diuretics: Generic name
Diuretics: Total daily dose
mg
Other anti-hypertensive drugs
Yes (1)
No (2)
Not recorded (3)
Other Anti-hypertensive drugs: Generic name
Other Anti-hypertensive drugs: Total daily dose
mg
Digitalis glycosides
Yes (1)
No (2)
Not recorded (3)
Digitalis glycosides: Generic name
Digitalis glycosides: Total daily dose
mg
Antiarrhythmics
Yes (1)
No (2)
Not recorded (3)
Antiarrhythmics:  Generic name
Antiarrhythmics:  Total daily dose
mg
Lipid lowering drugs: Statins
Yes (1)
No (2)
Not recorded (3)
Lipid lowering drugs (Statins): Generic name
Lipid lowering drugs (Statins): Total daily dose
mg
Lipid lowering drugs: Fibrates
Yes (1)
No (2)
Not recorded (3)
Lipid lowering drugs (Fibrates): Generic name
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Lipid lowering drugs (Fibrates): Total daily dose
mg
Lipid lowering drugs: Nicotinic acid group
Yes (1)
No (2)
Not recorded (3)
Lipid lowering drugs (Nicotinic acid group):
Generic name
Lipid lowering drugs (Nicotinic acid group): Total
daily dose
mg
Lipid lowering drugs: Cholesterol absorption
inhibitors
Yes (1)
No (2)
Not recorded (3)
Lipid lowering drugs (Cholesterol absorption
inhibitors): Generic name
Lipid lowering drugs (Cholesterol absorption
inhibitors): Total daily dose
mg
Lipid lowering drugs: Resins
Yes (1)
No (2)
Not recorded (3)
Lipid lowering drugs (Resins): Generic name
Lipid lowering drugs (Resins): Total daily dose
mg
Lipid lowering drugs: Other
Yes (1)
No (2)
Not recorded (3)
Lipid lowering drugs (Other): Generic name
Lipid lowering drugs (Other): Total daily dose
mg
Anti-diabetic drugs: Insulin
Yes (1)
No (2)
Not recorded (3)
Insulin: Generic name
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Insulin: Total daily dose
mg
Anti-diabetic drugs: Insulin
Yes (1)
No (2)
Not recorded (3)
Insulin: Generic name
Insulin: Total daily dose
mg
Anti-diabetic drugs: oral
Yes (1)
No (2)
Not recorded (3)
Oral Antidiabetics: Generic name
Oral Antidiabetics: Total daily dose
mg
Anti-diabetic drugs: oral
Yes (1)
No (2)
Not recorded (3)
Oral Antidiabetics: Generic name
Oral Antidiabetics: Total daily dose
mg
Anti-coagulants
Yes (1)
No (2)
Not recorded (3)
Anti-coagulants: Generic name
Anti-coagulants: Total daily dose
mg
Oral contraceptive pill
Yes (1)
No (2)
Not recorded (3)
Oral contraceptive pill: Generic name
Oral contraceptive pill: Total daily dose
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Hormone replacement therapy
Yes (1)
No (2)
Not recorded (3)
Hormone replacement therapy: Generic name
Hormone replacement therapy: Total daily dose
Appetite suppressants or other antiobesity
Yes (1)
No (2)
Not recorded (3)
Appetite suppressants/other antiobesity: Generic
name
Appetite suppressants or other antiobesity: Total
daily dose
mg
Nicotine replacement therapy
Yes (1)
No (2)
Not recorded (3)
Nicotine replacement therapy: Generic name
Nicotine replacement therapy: Total daily dose
mg
Nicotine replacement therapy
Chewing Gum (1)
Nasal spray (2)
Inhalator (3)
Patches (4)
Losenges (5)
Bupropion
Yes (1)
No (2)
Not recorded (3)
Bupropion: Generic name
Bupropion: Total daily dose
mg
Other medication
Yes (1)
No (2)
Not recorded (3)
11 / 20
EUROASPIRE III (Hospital Arm) - Coronary heart disease Patient
Record Questionnaire
Other medications: Generic name
Other medications: Total daily dose
mg
Is any of the medication prescribed a
combination of 2 drugs in one tablet?
Yes (1)
No (2)
Don´t know/Unsure (3)
If yes, please specify
Discharge evaluation
Risk factor obesity
Yes (1)
No (2)
Unsure (3)
Not recorded (4)
History of obesity: If YES, recorded level where
applicable
Smoking status
Non smoker 		 (1)
Is a current non smoker (but previous
smoking history unknown) 	 (2)
Has stopped smoking  (3)
Current smoker (4)
History of hypertension
Yes (1)
No (2)
Not recorded (3)
History of hypertension:if yes, duration in months
History of hyperlipidaemia/ dyslipidaemia
Yes (1)
No (2)
Not recorded (3)
History of hyperlipidaemia/ dyslipidaemia: If yes,
duration in months
History of diabetes
Yes (1)
No (2)
Not recorded (3)
History of diabetes: If yes, duration in months
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Body height
cm
Body weight
kg
Body Mass Index
kg/m2
Waist circumference
cm
Systolic blood pressure
mmHg
Diastolic blood pressure
mmHg
Heart rate
bpm
Total cholesterol
mmol/l
LDL cholesterol
mmol/l
HDL cholesterol
mmol/l
Triglycerides
mmol/l
Blood glucose level
mmol/l
HbA1C level (in diabetics)
Were any of the following medications from the
list below prescribed at discharge from hospital?
(please refer to the discharge letter)
Yes (1)
No (2)
Unsure (3)
Not recorded (4)
Aspirin or other anti-platelet drugs?
Yes (1)
No (2)
Not recorded (3)
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Aspirin or other anti-platelet drugs: Generic name
Aspirin or other anti-platelet drugs: Total daily
dose
mg
Aspirin or other anti-platelet drugs?
Yes (1)
No (2)
Not recorded (3)
Aspirin or other anti-platelet drugs: Generic name
Aspirin or other anti-platelet drugs: Total daily
dose
mg
Beta blockers
Yes (1)
No (2)
Not recorded (3)
Beta blockers:Generic name
Beta Blockers Total daily dose
mg
ACE inhibitors
Yes (1)
No (2)
Not recorded (3)
ACE inhibitors: Generic name
ACE inhibitors : Total daily dose
mg
Angiotensin II receptor antagonists
Yes (1)
No (2)
Not recorded (3)
Angiotensin II receptor antagonists: Generic
name
Angiotensin II receptor antagonists: Total daily
dose
mg
Calcium antagonists
Yes (1)
No (2)
Not recorded (3)
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Calcium antagonists: Generic name
Calcium antagonists: Total daily dose
mg
If inhibitors
Yes (1)
No (2)
Not recorded (3)
If inhibitors: Generic name
If inhibitors: Total daily dose
mg
Nitrates
Yes (1)
No (2)
Not recorded (3)
Nitrates: Generic name
Nitrates: Total daily dose
mg
Diuretics
Yes (1)
No (2)
Not recorded (3)
Diuretics: Generic name
Diuretics: Total daily dose
mg
Diuretics
Yes (1)
No (2)
Not recorded (3)
Diuretics: Generic name
Diuretics: Total daily dose
mg
Other anti-hypertensive drugs
Yes (1)
No (2)
Not recorded (3)
Other Anti-hypertensive drugs: Generic name
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Other Anti-hypertensive drugs: Total daily dose
mg
Digitalis glycosides
Yes (1)
No (2)
Not recorded (3)
Digitalis glycosides: Generic name
Digitalis glycosides: Total daily dose
mg
Antiarrhythmics
Yes (1)
No (2)
Not recorded (3)
Antiarrhythmics:  Generic name
Antiarrhythmics:  Total daily dose
mg
Lipid lowering drugs: Statins
Yes (1)
No (2)
Not recorded (3)
Lipid lowering drugs (Statins): Generic name
Lipid lowering drugs (Statins): Total daily dose
mg
Lipid lowering drugs: Fibrates
Yes (1)
No (2)
Not recorded (3)
Lipid lowering drugs (Fibrates): Generic name
Lipid lowering drugs (Fibrates): Total daily dose
mg
Lipid lowering drugs: Nicotinic acid group
Yes (1)
No (2)
Not recorded (3)
Lipid lowering drugs (Nicotinic acid group):
Generic name
Lipid lowering drugs (Nicotinic acid group): Total
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daily dose
mg
Lipid lowering drugs: Cholesterol absorption
inhibitors
Yes (1)
No (2)
Not recorded (3)
Lipid lowering drugs (Cholesterol absorption
inhibitors): Generic name
Lipid lowering drugs (Cholesterol absorption
inhibitors): Total daily dose
mg
Lipid lowering drugs: Resins
Yes (1)
No (2)
Not recorded (3)
Lipid lowering drugs (Resins): Generic name
Lipid lowering drugs (Resins): Total daily dose
mg
Lipid lowering drugs: Other
Yes (1)
No (2)
Not recorded (3)
Lipid lowering drugs (Other): Generic name
Lipid lowering drugs (Other): Total daily dose
mg
Anti-diabetic drugs: Insulin
Yes (1)
No (2)
Not recorded (3)
Insulin: Generic name
Insulin: Total daily dose
mg
Anti-diabetic drugs: Insulin
Yes (1)
No (2)
Not recorded (3)
Insulin: Generic name
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Insulin: Total daily dose
mg
Anti-diabetic drugs: oral
Yes (1)
No (2)
Not recorded (3)
Oral Antidiabetics: Generic name
Oral Antidiabetics: Total daily dose
mg
Anti-diabetic drugs: oral
Yes (1)
No (2)
Not recorded (3)
Oral Antidiabetics: Generic name
Oral Antidiabetics: Total daily dose
mg
Anti-coagulants
Yes (1)
No (2)
Not recorded (3)
Anti-coagulants: Generic name
Anti-coagulants: Total daily dose
mg
Oral contraceptive pill
Yes (1)
No (2)
Not recorded (3)
Oral contraceptive pill: Generic name
Oral contraceptive pill: Total daily dose
Hormone replacement therapy
Yes (1)
No (2)
Not recorded (3)
Hormone replacement therapy: Generic name
Hormone replacement therapy: Total daily dose
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Appetite suppressants or other antiobesity
Yes (1)
No (2)
Not recorded (3)
Appetite suppressants/other antiobesity: Generic
name
Appetite suppressants or other antiobesity: Total
daily dose
mg
Nicotine replacement therapy
Yes (1)
No (2)
Not recorded (3)
Nicotine replacement therapy: Generic name
Nicotine replacement therapy: Total daily dose
mg
Nicotine replacement therapy
Chewing Gum (1)
Nasal spray (2)
Inhalator (3)
Patches (4)
Losenges (5)
Bupropion
Yes (1)
No (2)
Not recorded (3)
Bupropion: Generic name
Bupropion: Total daily dose
mg
Other medication
Yes (1)
No (2)
Not recorded (3)
Other medications: Generic name
Other medications: Total daily dose
mg
Is any of the medication prescribed a
combination of 2 drugs in one tablet?
Yes (1)
No (2)
Don´t know/Unsure (3)
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If yes, please specify
Patient record completed for this patient
Yes
No
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Eligibility Congestive Heart Failure
NCT00060840
The Effects of Nitric Oxide for Inhalation During Left
Ventricular Assists Device (LVAD) Implantation; ODM
derived from: https://clinicaltrials.gov/show/NCT00060840
All rights reserved. Please visit https://medical-data-
models.org/forms/16828
Eligibility Congestive Heart Failure
NCT00060840
Inclusion Criteria
scheduled to undergo their first lvad implantation,
(or at least 6 months after explanation of a
previous lvad).*
Yes
No
has a pulmonary vascular resistance of at least
2.5 wood units (200 dynes/sec.) in the 30 days
prior to lvad placement.*
Yes
No
greater than 18 years of age.*
Yes
No
signed irb approved informed consent.*
Yes
No
Exclusion Criteria
patients with congestive heart failure due to giant
cell myocarditis or restrictive cardiomyopathy.*
Yes
No
elective biventricular assist device (bivad)
surgery, or current support with a temporary
bivad.*
Yes
No
lvad procedure expected to be done without
cardiopulmonary bypass.*
Yes
No
pregnancy (a negative pregnancy test must be
documented prior to enrollment).*
Yes
No
received nitric oxide by inhalation therapy within
the past 24 hours.*
Yes
No
investigational drugs that are expected to change
systemic or pulmonary vascular resistance are
not allowed.*
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Yes
No
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Eligibility Congestive Heart Failure
NCT00063687
Oxypurinol Compared With Placebo for Class III-IV NYHA
Congestive Heart Failure; ODM derived from:
https://clinicaltrials.gov/show/NCT00063687
All rights reserved. Please visit https://medical-data-
models.org/forms/16829
Eligibility Congestive Heart Failure
NCT00063687
Inclusion Criteria
18-85 years old,*
Yes
No
stable nyha class iii-iv*
Yes
No
hospitalization or er visits in past 18 months for
worsening heart failure (or addition of new heart
failure medication added to regimen due to lack
of stability on current regimen.*
Yes
No
ef =< 40%*
Yes
No
Exclusion Criteria
any condition (other than chf) that could limit
exercise*
Yes
No
any concurrent disease likely to limit life
expectancy.*
Yes
No
participation in  another clinical trial*
Yes
No
primary valvular disease, active myocarditis, or
an obstructive or restrictive cardio-myopathy*
Yes
No
heart attack, stroke, unstable angina or cardiac
surgery within previous 3 months*
Yes
No
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Eligibility Congestive Heart Failure
NCT00119691
Nesiritide Infusion for the Treatment of Decompensated
Heart Failure and Renal Dysfunction; ODM derived from:
https://clinicaltrials.gov/show/NCT00119691
All rights reserved. Please visit https://medical-data-
models.org/forms/16830
Eligibility Congestive Heart Failure
NCT00119691
Inclusion Criteria
decompensated heart failure hospitalization with
at least 1 symptom and 1 sign of elevated filling
pressures*
Yes
No
admission estimated creatinine clearance =< 50
cc/min.*
Yes
No
Exclusion Criteria
systolic blood pressure < 85 mm hg*
Yes
No
cardiogenic shock*
Yes
No
volume depletion*
Yes
No
myocardial infarction, unstable angina within last
30 days*
Yes
No
significant valvular stenosis,
hypertrophic/restrictive cardiomyopathy, or
constrictive pericarditis*
Yes
No
chronic hemodialysis*
Yes
No
anticipated major procedure during
hospitalization i.e. left heart catheterization,
surgery, or transplantation*
Yes
No
enrolled in another research protocol within last
30 days.*
Yes
No
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Eligibility Congestive Heart Failure
NCT00124137
Ultrafiltration Versus Intravenous (IV) Diuretics for Patients
Hospitalized for Acute Decompensated Heart Failure:
(UNLOAD); ODM derived from:
https://clinicaltrials.gov/show/NCT00124137
All rights reserved. Please visit https://medical-data-
models.org/forms/16831
Eligibility Congestive Heart Failure
NCT00124137
Inclusion Criteria
patients hospitalized with primary diagnosis of
acute decompensated congestive heart failure
(adchf)*
Yes
No
evidence of fluid overload as indicated by:*
Yes
No
1. pitting edema (2+) of lower extremities;*
Yes
No
2. jugular venous distension;*
Yes
No
3. pulmonary edema or pleural effusion;*
Yes
No
4. ascites;*
Yes
No
5. paroxysmal nocturnal dyspnea or 2-pillow
orthopnea*
Yes
No
Exclusion Criteria
acute coronary syndrome*
Yes
No
creatinine greater than 3.0*
Yes
No
systolic blood pressure less than or equal to 90
mmhg*
Yes
No
hematocrit greater than 45%*
Yes
No
prior administration of iv vasoactive drugs in the
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emergency room (er)*
Yes
No
clinical instability requiring  pressors during
hospitalization*
Yes
No
recent use of iodinated contrast material*
Yes
No
severe concomitant disease expected to prolong
hospitalization*
Yes
No
sepsis*
Yes
No
on or requires renal dialysis*
Yes
No
had a cardiac transplant*
Yes
No
heparin allergy*
Yes
No
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Eligibility Depression NCT00375843
Brain Activity Changes and Treatment Response in
Depressed People Who Are Receiving Antidepressant
Medication; ODM derived from:
https://clinicaltrials.gov/show/NCT00375843
All rights reserved. Please visit https://medical-data-
models.org/forms/16832
Eligibility Depression NCT00375843
Inclusion Criteria
currently an outpatient with nonpsychotic,
unipolar major depressive disorder (mdd)*
Yes
No
score of 14 or greater on the 17-item hamilton
rating scale for depression (ham-d17)*
Yes
No
antidepressant treatment is deemed appropriate
by the study clinician*
Yes
No
willing to use an effective form of contraception
throughout the study*
Yes
No
Exclusion Criteria
mentally or legally incapacitated*
Yes
No
lifetime history of bipolar disorder, schizophrenia,
schizoaffective disorder, mdd with psychotic
features, or dementia*
Yes
No
patients currently suffering from anorexia
nervosa, bulimia nervosa, or obsessive
compulsive disorder*
Yes
No
history of substance abuse disorder within 6
months prior to study entry*
Yes
No
current suicidal ideation that would make
outpatient treatment unsafe*
Yes
No
past medication response that may make
escitalopram or sertraline treatment unsafe or
inappropriate (e.g., previous intolerance or lack of
response to either medication)*
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Yes
No
history of a failed treatment with escitalopram (40
mg or more) or sertraline (200 mg or more)
during the current depressive episode*
Yes
No
any medical conditions that would make
treatment with escitalopram or sertraline
medically inadvisable*
Yes
No
unstable medical illness*
Yes
No
unstable psychiatric illness likely to require
inpatient treatment within the 6 months following
study entry*
Yes
No
history of seizures, brain surgery, skull fracture,
significant head trauma, or previous abnormal
eeg*
Yes
No
pregnant or plans to become pregnant within the
12 months following study entry*
Yes
No
breastfeeding*
Yes
No
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Eligibility Diabetes Mellitus, With
Complications NCT00287651
Effects of Pulsatile IV Insulin Delivery on Diabetic
Retinopathy in Patients With Types 1 and 2 Diabetes
Mellitus; ODM derived from:
https://clinicaltrials.gov/show/NCT00287651
All rights reserved. Please visit https://medical-data-
models.org/forms/16833
Eligibility Diabetes Mellitus, With
Complications NCT00287651
Inclusion Criteria
we will include up to 500 patients both male and
female over the age of 18 diagnosed with type 1
or type 2 diabetes mellitus.*
Yes
No
all patients must be diagnosed with type 1 or type
2 diabetes.*
Yes
No
fundus photographs will be examined by an
independent retinal specialist and the patients will
be stratified into the three groups as outlined
above.*
Yes
No
endocrinologist must assess and approve patient
for participation in this study*
Yes
No
patient must have the ability to swallow without
difficulty and ability to commit to the weekly time
requirements associated with the study.*
Yes
No
Exclusion Criteria
other causes of complications not related to
diabetes*
Yes
No
lack of intravenous access*
Yes
No
pregnancy*
Yes
No
alcohol abuse, drug addiction or the use of illegal
drugs*
Yes
No
positive hiv*
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Yes
No
inability to breathe into metabolic measurement
cart for respiratory quotients*
Yes
No
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Eligibility Diabetes NCT00184613
Comparison of Insulin Glargine Against Insulin Aspart
Infused Under the Skin in Patients With Type 2 Diabetes;
ODM derived from:
https://clinicaltrials.gov/show/NCT00184613
All rights reserved. Please visit https://medical-data-
models.org/forms/16834
Eligibility Diabetes NCT00184613
Inclusion Criteria
subjects with type 2 diabetes for more than 2
years*
Yes
No
subjects currently treated with unchanged insulin
glargine dose (10 -100 units) for 2 weeks*
Yes
No
subjects currently treated with unchanged
dose(s) for at least 1 month on one or two oral
anti-diabetic drugs*
Yes
No
bmi 25 - 40 kg/m2*
Yes
No
hba1c < 9.5 %*
Yes
No
Exclusion Criteria
known or suspected allergy to trial product(s) or
related products*
Yes
No
previous randomisation in this trial*
Yes
No
pregnancy, breast-feeding, intention of becoming
pregnant or pre-menopausal women judged not
to be using adequate contraceptive measures
(only sterilisation, intra uterine devices and
contraceptive pills are considered adequate
contraceptive methods)*
Yes
No
mental incapacity, unwillingness or language
barriers precluding adequate understanding and
co-operation.*
Yes
No
any other significant illness such as endocrine,
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cardiac, neurological, malignant or other
pancreatic illness judged by investigator*
Yes
No
participation in other studies within the last three
months*
Yes
No
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Eligibility Diabetes NCT00379548
Changes in Inflammatory State in Asian Americans
Changing From Traditional Asian Diets to American Diet - a
Pilot Study; ODM derived from:
https://clinicaltrials.gov/show/NCT00379548
All rights reserved. Please visit https://medical-data-
models.org/forms/16835
Eligibility Diabetes NCT00379548
Inclusion Criteria
1. caucasian or far-east asian decent*
Yes
No
2. ages between 25 - 55 years old*
Yes
No
3. has family history of diabetes defined as
having a first degree relative diagnosed with
diabetes mellitus, and/or medical history of
gestational diabetes (gdm), impaired fasting
glucose(ifg) and impaired glucose tolerance (igt)*
Yes
No
4. bmi of 18.5 - 25.0 kg/m2*
Yes
No
5. agree to maintain constant physical activity
levels for the duration of the study*
Yes
No
6. agree to utilize contraception for the duration of
the study (for female subjects)*
Yes
No
7. have a minimum of 12 natural teeth*
Yes
No
8. scoring of 2 or more on dental screening
questionnaire (see appendix)*
Yes
No
9. ability to communicate in english*
Yes
No
Exclusion Criteria
1. acute weight loss/weight gain over the past 6
months (defined as +4 lbs or more/month)*
Yes
No
2. history of diabetes*
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Yes
No
3. current smokers (including those who quit < 1
year)*
Yes
No
4. heavy alcohol drinkers, defined as drinking
more than 7 drinks/week. those who drink alcohol
will need to be reported and documented.  they
will be asked to maintain the levels of alcohol
consumption throughout the study.*
Yes
No
5. medical history of vascular diseases (cad, mi,
stroke, cabg, angioplasty), diabetes, liver
disease, kidney disease, cancer, aids, bleeding
disorders*
Yes
No
6. history of food allergies or to any food products
in the diet menu.*
Yes
No
7. enrolled in another investigational study within
1 month prior to screening for this study*
Yes
No
8. vegetarian, those with significant food
aversions, and anyone who cannot comply with
the diet*
Yes
No
9. pregnancy or breasting feeding*
Yes
No
10. other autoimmune or inflammatory conditions
or diseases that may compromise the patient's
safety or compliance during the study on an
individual basis*
Yes
No
11. chronic use of antibiotics or anti-inflammatory
medications (>1 month) within the past year*
Yes
No
12. on medications such as statins, angiotensin
converting enzyme inhibitor, warfarin, aspirin or
other anti-inflammatory medications.  daily
multivitamins are permitted, excluding
pharmacological doses of anti- oxidants will not
2 / 3
Eligibility Diabetes NCT00379548
be allowed.*
Yes
No
13. individuals with dental needs requiring
extensive dental restorations such as cavities,
root canals, crowns, etc.*
Yes
No
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Eligibility Heart Failure NCT00158964
EASYTRAK 4 Steerable LV Lead; ODM derived from:
https://clinicaltrials.gov/show/NCT00158964
All rights reserved. Please visit https://medical-data-
models.org/forms/16836
Eligibility Heart Failure
NCT00158964
Inclusion Criteria
must receive a commercially available guidant
crt-p or crt-d device*
Yes
No
creatinine < 2.5 mg/dl obtained no more than two
weeks prior to enrollment*
Yes
No
age 18 or above, or of legal age to give informed
consent specific to state and national law*
Yes
No
willing and capable of providing informed
consent, undergoing a device implant,
participating in all testing associated with this
clinical investigation at an approved clinical
investigation center and at the intervals defined
by this protocol*
Yes
No
geographically stable residents who are available
for follow-up*
Yes
No
Exclusion Criteria
have a known hypersensitivity to a 1.0 mg (0.5
mg per electrode) nominal dose of
dexamethasone acetate*
Yes
No
have or had previous cardiac resynchronization
therapy, a coronary venous pace/sense lead or
attempted lv lead placement*
Yes
No
have pre-existing cardioversion/defibrillation
leads or right ventricular pacing leads other than
those specified in the investigational plan (unless
the investigator intends to replace them with
permitted cardioversion/defibrillation leads)*
Yes
No
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currently requiring dialysis*
Yes
No
have had a myocardial infarct, unstable angina,
percutaneous coronary intervention, or coronary
artery bypass graft during the preceding 30 days
prior to enrollment*
Yes
No
have hypertrophic obstructive cardiomyopathy or
infiltrative cardiomyopathy (e.g., amyloidosis,
sarcoidosis)*
Yes
No
documented life expectancy of less than six
months or expected to undergo heart transplant
within the next six months*
Yes
No
enrolled or participating in any concurrent study,
including drug investigations, without guidant
written approval, that may confound the results of
this study*
Yes
No
have a pre-existing unipolar pacemaker that will
not be explanted/abandoned*
Yes
No
have a mechanical tricuspid heart valve*
Yes
No
women who are pregnant or plan to become
pregnant note: women of childbearing potential
must have a negative pregnancy test  within
seven days of enrollment.*
Yes
No
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EUROASPIRE III (Hospital Arm) - Coronary
heart disease Patient Interview Questionnaire
Provided by Prof. Keil Source: Kotseva K, Wood D, De
Backer G, De Bacquer D, Pyörälä K, Keil U; EUROASPIRE
Study Group. Cardiovascular prevention guidelines in daily
practice: a comparison of EUROASPIRE I, II, and III
surveys in eight European countries. Lancet. 2009 Mar
14;373(9667):929-40. doi: 10.1016/S0140-6736(09)60330-
5. PubMed PMID: 19286092
All rights reserved. Please visit https://medical-data-
models.org/forms/16838
Patient Interview Questionnaire
Demographic Information
Patient ID
Did the patient attend the interview?
Yes
No
If YES, date of interview
If NO, why not?
Patient died 						 (1)
Change in health status 				 (2)
No time 						 (3)
Moved away 						 (4)
Personal reasons 					 (5)
Refuse to attend for other reasons 			 (6)
Other, please specify (7)
If other reason for not attending, please specify
If patient died, please indicate cause of death
Coronary death (1)
Other cardiovascular death (2)
Unknown (3)
Other, please specify (4)
If other cause of death, please specify
If patient died, please indicate date of death
Did you have any of the following prior to the
index event or procedure which included you in
the survey?
Yes (1)
No (2)
Don´t know/ Unsure (3)
Coronary artery bypass surgery
Yes (1)
No (2)
Don´t know/ Unsure (3)
Hospital admission for Coronary artery bypass
surgery?
Yes (1)
No (2)
Don´t know/ Unsure (3)
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Date of event
Percutaneous transluminal coronary angioplasty
Yes (1)
No (2)
Don´t know/ Unsure (3)
Hospital admission for Percutaneous transluminal
coronary angioplasty
Yes (1)
No (2)
Don´t know/ Unsure (3)
Date of event
Acute myocardial infarction
Yes (1)
No (2)
Don´t know/ Unsure (3)
Hospital admission for acute MI
Yes (1)
No (2)
Don´t know/ Unsure (3)
Date of event
Acute myocardial ischaemia
Yes (1)
No (2)
Don´t know/ Unsure (3)
Hospital admission for Acute myocardial
ischaemia
Yes (1)
No (2)
Don´t know/ Unsure (3)
Date of event
Angina pectoris
Yes (1)
No (2)
Don´t know/ Unsure (3)
Hospital admission for Angina pectoris
Yes (1)
No (2)
Don´t know/ Unsure (3)
Stroke
Yes (1)
No (2)
Don´t know/ Unsure (3)
Hospital admission for stroke
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Yes (1)
No (2)
Don´t know/ Unsure (3)
Date of event
TIA (Transient ischaemic attack)
Yes (1)
No (2)
Don´t know/ Unsure (3)
Hospital admission for TIA
Yes (1)
No (2)
Don´t know/ Unsure (3)
Date of event
PAD (Peripheral artery disease)
Yes (1)
No (2)
Don´t know/ Unsure (3)
Hospital admission for PAD (Peripheral artery
disease)
Yes (1)
No (2)
Don´t know/ Unsure (3)
Date of event
How old were you when your heart disease was
first diagnosed?
How many years have you spent in full-time
education? (99 = insufficient data)
yrs
What is the highest level of education you have
completed?
No formal schooling (1)
Less than primary school	 (2)
Primary school completed (3)
Secondary school completed (4)
High school completed (5)
Collage/ University completed (6)
Post graduate degree (7)
Insufficient data (unknown) (8)
Prior to the index event or procedure were you:
Full time employed (1)
Part time employed (2)
Self employed (3)
Unemployed (4)
House person (5)
Full time education (6)
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Retired (7)
Insufficient data (unknown) (8)
If retired
Age related (1)
Heart disease related (2)
Other illness (3)
Personal choice (4)
Insufficient data (unknown) (5)
Now at least 6 months after the index event or
procedure, are you:
Full time employed (1)
Part time employed (2)
Self employed (3)
Unemployed (4)
House person (5)
Full time education (6)
Retired (7)
Insufficient data (unknown) (8)
If retired
Age related (1)
Heart disease related (2)
Other illness (3)
Personal choice (4)
Insufficient data (unknown) (5)
Whose care are you currently (in the last three
months) under for your cardiac condition
(procedure or acute event)?
Cardiologist (1)
Physician (2)
General practitioner (3)
Cardiac specialist nurse (4)
Diabetologist/endocrinologist (5)
Occupational health physician (6)
Other, please specify (7)
No one (8)
Does not remember (9)
Medical history since discharge from
hospital
Did you have any of the following, since the
hospital discharge from the index event or
procedure which included you in the survey?
Yes (1)
No (2)
Don´t know/ Unsure (3)
Coronary artery bypass surgery
Yes (1)
No (2)
Don´t know/ Unsure (3)
Hospital admission for Coronary artery bypass
surgery?
4 / 27
EUROASPIRE III (Hospital Arm) - Coronary heart disease Patient
Interview Questionnaire
Yes (1)
No (2)
Don´t know/ Unsure (3)
Date of event
Percutaneous transluminal coronary angioplasty
Yes (1)
No (2)
Don´t know/ Unsure (3)
Hospital admission for Percutaneous transluminal
coronary angioplasty
Yes (1)
No (2)
Don´t know/ Unsure (3)
Date of event
Acute myocardial infarction
Yes (1)
No (2)
Don´t know/ Unsure (3)
Hospital admission for acute MI
Yes (1)
No (2)
Don´t know/ Unsure (3)
Date of event
Acute myocardial ischaemia
Yes (1)
No (2)
Don´t know/ Unsure (3)
Hospital admission for Acute myocardial
ischaemia
Yes (1)
No (2)
Don´t know/ Unsure (3)
Date of event
Angina pectoris
Yes (1)
No (2)
Don´t know/ Unsure (3)
Hospital admission for Angina pectoris
Yes (1)
No (2)
Don´t know/ Unsure (3)
Stroke
Yes (1)
No (2)
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Don´t know/ Unsure (3)
Hospital admission for stroke
Yes (1)
No (2)
Don´t know/ Unsure (3)
Date of event
TIA (Transient ischaemic attack)
Yes (1)
No (2)
Don´t know/ Unsure (3)
Hospital admission for TIA
Yes (1)
No (2)
Don´t know/ Unsure (3)
Date of event
PAD (Peripheral artery disease)
Yes (1)
No (2)
Don´t know/ Unsure (3)
Hospital admission for PAD (Peripheral artery
disease)
Yes (1)
No (2)
Don´t know/ Unsure (3)
Date of event
Smoking
Have you ever smoked?
Yes
No
For how many years in total have you smoked?
yrs
Were you smoking in the month prior to the
hospital admission for the	
index event or procedure?
Yes
No
Do you smoke now?
Yes
No
If smoking now, what type of tobacco-product?
Cigarettes (1)
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Pipe (2)
Cigars (3)
How many cigarettes per day?
How much pipe tobacco in g/week?
How many cigars per day?
If not smoking now, did you quit within the last 6
months
Yes
No
If not smoking now, did you quit more than 6
months ago?
Yes
No
If not smoking now, at what age did you stop? (99
= unknown)
yrs
If smoking now In the last year, how many times
have you quit smoking for at least 24 hours?
If smoking now: Are you seriously thinking of
quitting smoking?
Yes, within the next 30 days (1)
Yes, within the next 6 months (2)
No, not thinking of quitting (3)
Don’t know/ Unsure (4)
In the daytime or at night, do you frequently stay,
at work , in rooms where people smoke?
Yes
No
In the daytime or at night, do you frequently stay,
at home , in rooms where people smoke?
Yes
No
In the daytime or at night, do you frequently stay,
at other locations , in rooms where people
smoke?
Yes
No
Diet/Body weight
Have you been told SINCE the index event or
procedure by a health care professional that your
diet is unhealthy?
Yes (1)
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No (2)
Don´t know/ Unsure (3)
Have you ever been told by a health care
professional that you are overweight?
Yes (1)
No (2)
Don´t know/ Unsure (3)
In the past month, have you been actively trying
to lose weight?
Yes (1)
No (2)
Don´t know/ Unsure (3)
In the past month, have you been actively trying
to keep from gaining weight?
Yes (1)
No (2)
Don´t know/ Unsure (3)
Are you seriously considering trying to lose
weight to reach your goal in the next month?
Yes (1)
No (2)
Don´t know/ Unsure (3)
Are you seriously considering trying to lose
weight to reach your goal in the next six months?
Yes (1)
No (2)
Don´t know/ Unsure (3)
Have you maintained your desired weight for
more than 6 months?
Yes (1)
No (2)
Don´t know/ Unsure (3)
Physical activity
Do you have any long-standing illness, disability
or infirmity?
Yes (1)
No (2)
Don´t know/ Unsure (3)
Which of the following four best describes your
level of activity outside work?
No physical activity weekly (1)
Only light physical activity in most weeks
(2)
Vigorous physical activity at least 20
minutes once or twice a week (3)
Vigorous physical activity for at least 20
minutes three or more times per week
(4)
Don’t know/ Unsure (5)
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Do you exercise regularly according to that (in
description) outlined definition?
Yes, I have been for MORE than 6
months (1)
Yes, I have been for LESS than 6 months
(2)
No, but I intend to in the next 30 days (3)
No, but I intend to in the next 6 months
(4)
No, and I do NOT intend to in the next 6
months  (5)
Don’t know/ Unsure (6)
Blood pressure,Cholesterol and Diabetes
Have you ever been told by a doctor (or other
health professional) that you have high blood
pressure?
Yes (1)
No (2)
Don´t know/ Unsure (3)
Are you taking (in the last two weeks) drugs
specifically prescribed to lower your blood
pressure ?
Yes (1)
No (2)
Don´t know/ Unsure (3)
Are you on a special diet prescribed by a doctor
(or other health professional) to lower your blood
pressure level?
Yes (1)
No (2)
Don´t know/ Unsure (3)
If hypertensive, do you monitor your blood
pressure yourself?
Yes (1)
No (2)
Don´t know/ Unsure (3)
Have you ever been told by a doctor (or other
health professional) that you have a high blood
cholesterol?
Yes (1)
No (2)
Don´t know/ Unsure (3)
Are you on a special diet prescribed by a doctor
(or other health professional) to lower your blood
cholesterol level?
Yes (1)
No (2)
Don´t know/ Unsure (3)
Have you ever been told by a doctor (or other
health professional) that you have diabetes?
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Yes (1)
No (2)
Don´t know/ Unsure (3)
If you have been told you have diabetes, how is it
currently being treated?
Diet only (1)
Oral anti-diabetic drugs (2)
Insulin (3)
Don’t know/Unsure (4)
If diabetic, do you monitor your blood glucose
yourself?
Yes (1)
No (2)
Don´t know/ Unsure (3)
If you monitor your blood glucose yourself,how?
Blood (1)
Urine (2)
Unkown (3)
If you monitor your blood glucose yourself,how
many times per day?
If you are on insulin, have you ever had education
regarding using it?
Yes (1)
No (2)
Don´t know/ Unsure (3)
Risk factor awareness and targets
Was your blood pressure ever measured?
Yes (1)
No (2)
Don´t know/ Unsure (3)
Was your total cholesterol ever measured?
Yes (1)
No (2)
Don´t know/ Unsure (3)
Was your blood glucose ever measured?
Yes (1)
No (2)
Don´t know/ Unsure (3)
Was your HbA1c (in diabetics) ever measured?
Yes (1)
No (2)
Don´t know/ Unsure (3)
Are you aware of your latest weight?
Yes (1)
No (2)
Don´t know/ Unsure (3)
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Current Body weight
kg
Are you aware of your target weight?
Yes (1)
No (2)
Don´t know/ Unsure (3)
What is your target weight?
kg
Are you aware of your blood pressure level?
Yes (1)
No (2)
Don´t know/ Unsure (3)
Current blood pressure
mmHg
Are you aware of your blood pressure target?
Yes (1)
No (2)
Don´t know/ Unsure (3)
What is your blood pressure target?
mmHg
Are you aware of your total cholesterol level?
Yes (1)
No (2)
Don´t know/ Unsure (3)
Total cholesterol measurement
mmol/l
Are you aware of your total cholesterol target?
Yes (1)
No (2)
Don´t know/ Unsure (3)
What is your total cholesterol target?
mmol/l
Are you aware of your latest blood glucose level?
Yes (1)
No (2)
Don´t know/ Unsure (3)
Blood glucose measurement
mmol/l
Are you aware of your blood glucose target?
Yes (1)
No (2)
Don´t know/ Unsure (3)
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What is your blood glucose target?
mmol/l
Are you aware of your latest HbA1c level?
Yes (1)
No (2)
Don´t know/ Unsure (3)
HbA1c measurement
%
Are you aware of your HbA1c target?
Yes (1)
No (2)
Don´t know/ Unsure (3)
What is your HbA1c target?
%
Lifestyle changes
Over the last 3 years, were you offered any
personal advice by a doctor or other health
professional on stopping smoking?
Yes since the index event or procedure
(1)
Yes since before the index event or
procedure  (2)
No  (3)
Unsure/ Don’t know (4)
What type of advice did you receive for stopping
smoking?
verbal (1)
written materials (2)
referral to smoking cessation clinic/
course (3)
Nicotine replacement therapy (4)
Bupropion (5)
other (6)
Over the last 3 years, were you offered any
personal advice by a doctor or other health
professional on a healthy diet?
Yes since the index event or procedure
(1)
Yes since before the index event or
procedure  (2)
No  (3)
Unsure/ Don’t know (4)
What type of advice did you receive concerning a
healthy diet?
reduction of salt intake (1)
reduction of fat intake (2)
changing type of fat intake (3)
reduction of calorie intake (4)
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eating more fruits and vegetables (5)
eating more fish (6)
eating more oily fish (7)
reducing sugar (8)
reducing excessive alcohol intake (9)
Over the last 3 years, were you offered any
personal advice by a doctor or other health
professional on weight loss?
Yes since the index event or procedure
(1)
Yes since before the index event or
procedure  (2)
No  (3)
Unsure/ Don’t know (4)
What type of advice did you receive concerning
weight loss?
following dietary recommendations (1)
participating in regular physical activity
(2)
weight reducing drugs (3)
other (please specify) (4)
What type of advice did you receive concerning
weight loss?
following dietary recommendations (1)
participating in regular physical activity
(2)
weight reducing drugs (3)
other (please specify) (4)
Please specify other type of advice you received
concerning weight loss?
Over the last 3 years, were you offered any
personal advice by a doctor or other health
professional on increase of physical activity?
Yes since the index event or procedure
(1)
Yes since before the index event or
procedure  (2)
No  (3)
Unsure/ Don’t know (4)
What type of advice did you receive concerning
increase of physical activity?
following specific exercise advice from a
health or exercise professional (1)
attending a fitness club or leisure centre
(2)
trying to do more general everyday
physical activities (3)
joining a community walking group (4)
other (5)
Over the last 3 years, did to try to stop smoking to
reduce your risk of heart disease?
Yes (1)
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No (2)
Don´t know/ Unsure (3)
Over the last 3 years, which steps did you take to
stop smoking to reduce your risk of heart
disease?
abstinence (1)
reduction (2)
smoking cessation clinic (3)
Nicotine replacement therapy (4)
Bupropion (5)
other (6)
Over the last 3 years, did you try to keep a
healthy diet to reduce your risk of heart disease?
Yes (1)
No (2)
Don´t know/ Unsure (3)
What steps did you take concerning a healthy
diet?
reduction of salt intake (1)
reduction of fat intake (2)
changing type of fat intake (3)
reduction of calorie intake (4)
eating more fruits and vegetables (5)
eating more fish (6)
eating more oily fish (7)
reducing sugar (8)
reducing excessive alcohol intake (9)
Over the last 3 years, did you try to loose weight
to reduce your risk for heart disease?
Yes (1)
No (2)
Don´t know/ Unsure (3)
What steps did you take concerning weight loss?
following dietary recommendations (1)
participating in regular physical activity
(2)
weight reducing drugs (3)
other (4)
Over the last 3 years, did you try to increase your
physical activity to reduce your risk of heart
disease?
Yes (1)
No (2)
Don´t know/ Unsure (3)
What steps did you take to increase your physical
activity?
following specific exercise advice from a
health or exercise professional (1)
attending a fitness club or leisure centre
(2)
trying to do more general everyday
physical activities (3)
joining a community walking group (4)
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other (5)
Over the last 3 years, have you received help
from any of the following professionals to achieve
your lifestyle and other risk factor targets?
Dietician (1)
Lipid specialist (10)
Diabetologist/endocrinologist (11)
Other   (please specify) (12)
Nurse (2)
Smoking cessation specialist (3)
Physiotherapist (4)
Exercise professional (5)
Hospital physician (6)
General practitioner or family doctor (7)
Cardiologist (8)
Hypertension specialist (9)
Please specify other health professional you
received help from
Coronary vascular disease prevention and
rehabilitation
Were you advised to follow a cardiac
prevention/rehabilitation programme within 3
months of discharge following the index event or
procedure?
Yes (1)
No (2)
Don´t know/ Unsure (3)
If YES, did you attend the cardiovascular disease
prevention programme offered?
No, not at all (1)
Attended less than half of the sessions
(2)
Attended more than half of the sessions
(3)
Yes, fully (4)
If attended, please specify what you received as
part of this program
Written educational materials (1)
Teaching sessions/ health promotion
workshops (2)
Smoking cessation (3)
Dietary modification/weight management
(4)
Supervised exercise programme (5)
Stress modification and relaxation (6)
Other   (please specify) (7)
Please specify any other part of the prevention
program you attended
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Medication
Is the patient on any medication?
Yes (1)
No (2)
Don´t know/ Unsure (3)
Aspirin or other anti-platelet drugs?
Yes (1)
No (2)
Don´t know/ Unsure (3)
Aspirin or other anti-platelet drugs: Generic name
Aspirin or other anti-platelet drugs: Total daily
dose
mg
Aspirin or other anti-platelet drugs?
Yes (1)
No (2)
Don´t know/ Unsure (3)
Aspirin or other anti-platelet drugs: Generic name
Aspirin or other anti-platelet drugs: Total daily
dose
mg
Beta blockers
Yes (1)
No (2)
Don´t know/ Unsure (3)
Beta blockers:Generic name
Beta Blockers Total daily dose
mg
ACE inhibitors
Yes (1)
No (2)
Don´t know/ Unsure (3)
ACE inhibitors: Generic name
ACE inhibitors : Total daily dose
mg
Angiotensin II receptor antagonists
Yes (1)
No (2)
Don´t know/ Unsure (3)
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Angiotensin II receptor antagonists: Generic
name
Angiotensin II receptor antagonists: Total daily
dose
mg
Calcium antagonists
Yes (1)
No (2)
Don´t know/ Unsure (3)
Calcium antagonists: Generic name
Calcium antagonists: Total daily dose
mg
If inhibitors
Yes (1)
No (2)
Don´t know/ Unsure (3)
If inhibitors: Generic name
If inhibitors: Total daily dose
mg
Nitrates
Yes (1)
No (2)
Don´t know/ Unsure (3)
Nitrates: Generic name
Nitrates: Total daily dose
mg
Diuretics
Yes (1)
No (2)
Don´t know/ Unsure (3)
Diuretics: Generic name
Diuretics: Total daily dose
mg
Diuretics
Yes (1)
No (2)
Don´t know/ Unsure (3)
Diuretics: Generic name
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Diuretics: Total daily dose
mg
Other anti-hypertensive drugs
Yes (1)
No (2)
Don´t know/ Unsure (3)
Other Anti-hypertensive drugs: Generic name
Other Anti-hypertensive drugs: Total daily dose
mg
Digitalis glycosides
Yes (1)
No (2)
Don´t know/ Unsure (3)
Digitalis glycosides: Generic name
Digitalis glycosides: Total daily dose
mg
Antiarrhythmics
Yes (1)
No (2)
Don´t know/ Unsure (3)
Antiarrhythmics: Generic name
Antiarrhythmics:  Total daily dose
mg
Lipid lowering drugs: Statins
Yes (1)
No (2)
Don´t know/ Unsure (3)
Lipid lowering drugs (Statins): Generic name
Lipid lowering drugs (Statins): Total daily dose
mg
Lipid lowering drugs: Fibrates
Yes (1)
No (2)
Don´t know/ Unsure (3)
Lipid lowering drugs (Fibrates): Generic name
Lipid lowering drugs (Fibrates): Total daily dose
mg
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Lipid lowering drugs: Nicotinic acid group
Yes (1)
No (2)
Don´t know/ Unsure (3)
Lipid lowering drugs (Nicotinic acid group):
Generic name
Lipid lowering drugs (Nicotinic acid group): Total
daily dose
mg
Lipid lowering drugs: Cholesterol absorption
inhibitors
Yes (1)
No (2)
Don´t know/ Unsure (3)
Lipid lowering drugs (Cholesterol absorption
inhibitors): Generic name
Lipid lowering drugs (Cholesterol absorption
inhibitors): Total daily dose
mg
Lipid lowering drugs: Resins
Yes (1)
No (2)
Don´t know/ Unsure (3)
Lipid lowering drugs (Resins): Generic name
Lipid lowering drugs (Resins): Total daily dose
mg
Lipid lowering drugs: Other
Yes (1)
No (2)
Don´t know/ Unsure (3)
Lipid lowering drugs (Other): Generic name
Lipid lowering drugs (Other): Total daily dose
mg
Anti-diabetic drugs: Insulin
Yes (1)
No (2)
Don´t know/ Unsure (3)
Insulin: Generic name
Insulin: Total daily dose
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mg
Anti-diabetic drugs: Insulin
Yes (1)
No (2)
Don´t know/ Unsure (3)
Insulin: Generic name
Insulin: Total daily dose
mg
Anti-diabetic drugs: oral
Yes (1)
No (2)
Don´t know/ Unsure (3)
Oral Antidiabetics: Generic name
Oral Antidiabetics: Total daily dose
mg
Anti-diabetic drugs: oral
Yes (1)
No (2)
Don´t know/ Unsure (3)
Oral Antidiabetics: Generic name
Oral Antidiabetics: Total daily dose
mg
Anti-coagulants
Yes (1)
No (2)
Don´t know/ Unsure (3)
Anti-coagulants: Generic name
Anti-coagulants: Total daily dose
mg
Oral contraceptive pill
Yes (1)
No (2)
Don´t know/ Unsure (3)
Oral contraceptive pill: Generic name
Oral contraceptive pill: Total daily dose
mg
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Hormone replacement therapy
Yes (1)
No (2)
Don´t know/ Unsure (3)
Hormone replacement therapy: Generic name
Hormone replacement therapy: Total daily dose
mg
Appetite suppressants or other antiobesity
Yes (1)
No (2)
Don´t know/ Unsure (3)
Appetite suppressants/other antiobesity: Generic
name
Appetite suppressants or other antiobesity: Total
daily dose
mg
Nicotine replacement therapy
Yes (1)
No (2)
Don´t know/ Unsure (3)
Nicotine replacement therapy: Generic name
Nicotine replacement therapy: Total daily dose
mg
Nicotine replacement therapy
Chewing Gum (1)
Nasal spray (2)
Inhalator (3)
Patches (4)
Losenges (5)
Bupropion
Yes (1)
No (2)
Don´t know/ Unsure (3)
Bupropion: Generic name
Bupropion: Total daily dose
mg
Other medication
Yes (1)
No (2)
Don´t know/ Unsure (3)
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Other medications: Generic name
Other medications: Total daily dose
mg
Is any of the medication prescribed a
combination of 2 drugs in one tablet?
Yes (1)
No (2)
Don´t know/Unsure (3)
If yes, please specify
Since the recruiting coronary event,  have you
altered the dosage of your prescribed
medication?
Never  (1)
Seldom (2)
Often (3)
Always (4)
Since the recruiting coronary event,  have you
missed taking the dosage of your prescribed
medication?
Never  (1)
Seldom (2)
Often (3)
Always (4)
Family history of cardiovascular disease
History of cardiovascular disease of brother
Yes (1)
No (2)
Don´t know/ Unsure (3)
Age of brother at diagnosis of cardiovascular
disease
Age of brother at diagnosis of cardiovascular
disease unknown
Yes
No
Brother died of cardiovascular disease (if
applicable)
Yes (1)
No (2)
Don´t know/ Unsure (3)
Age at death from cardiovascular disease of
brother (if applicable)
Age at death from cardiovascular disease of
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brother unknown (if applicable)
Yes
No
History of cardiovascular disease of sister
Yes (1)
No (2)
Don´t know/ Unsure (3)
Age of sister at diagnosis of cardiovascular
disease
Age of sister at diagnosis of cardiovascular
disease unknown
Yes
No
Sister died of cardiovascular disease  (if
applicable)
Yes (1)
No (2)
Don´t know/ Unsure (3)
Age at death from cardiovascular disease of
sister (if applicable)
Age at death from cardiovascular disease of
sister unknown
Yes
No
History of cardiovascular disease of son
Yes (1)
No (2)
Don´t know/ Unsure (3)
Age of son at diagnosis of cardiovascular disease
Age of son at diagnosis of cardiovascular disease
unknown
Yes
No
Son died of cardiovascular disease  (if applicable)
Yes (1)
No (2)
Don´t know/ Unsure (3)
Age at death from cardiovascular disease of son
(if applicable)
Age at death from cardiovascular disease of son
unknown
Yes
No
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History of cardiovascular disease of daughter
Yes (1)
No (2)
Don´t know/ Unsure (3)
Age of daughter at diagnosis of cardiovascular
disease
Age of daughter at diagnosis of cardiovascular
disease unknown
Yes
No
Daughter died of cardiovascular disease  (if
applicable)
Yes (1)
No (2)
Don´t know/ Unsure (3)
Age at death from cardiovascular disease of
daughter (if applicable)
Age at death from cardiovascular disease of
daughter unknown
Yes
No
We would like to contact each of your first degree
relatives mentioned in your answer to question 41
if you are a patient with premature CHD, i.e. if you
are a man under 55 years or a woman under 65
years. Please provide addresses and phone
numbers of these family members. These
personal details will be kept at this centre only
and not centrally stored.
Yes
No
Identification number
Relationship
Brother (1)
Sister (2)
Son (3)
Daughter (4)
Title
Mr (1)
Miss (2)
Ms (3)
Mrs (4)
Forename(s)
Surname
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Address
Telephone number
General practitioner or relevant contact person's
name
General practitioner or relevant contact persons
address
General practitioner or relevant contact person's
telephone number
Physical measurements
Body height
cm
Body weight
kg
Waist circumference
cm
1st measurement of systolic blood pressure
mmHg
1st measurement of diastolic blood pressure
mmHg
2nd measurement of systolic blood pressure
mmHg
2nd measurement of diastolic blood pressure
mmHg
Heart rate
bpm
Carbon monoxide in breath
ppm
HAD scale: anxiety score
HAD scale: depression score
Evaluation of EQ-5D: Score 1
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Evaluation of EQ-5D: Score 2
SF-12 Physical health summary measure
SF-12 Mental health summary measure
During the last 7 days, on how many days did you
do vigorous physical activities like heavy lifting,
digging, aerobics, or fast bicycling?
No vigorous activity during the last 7 days - if yes,
skip to question 3
Yes
No
How much time did you usually spend doing
vigorous physical activities on one of those days?
In hours per day?
How much time did you usually spend doing
vigorous physical activities on one of those days?
In minutes per day?
The time I spend doing vigorous physical
activities on one of those days is unknown
Yes
No
During the last 7 days, on how many days did you
do moderate physical activities like carrying light
loads, bicycling at a regular pace, or doubles
tennis?  Do not include walking
No moderate activity during the last 7 days - if
yes, skip to question 5
Yes
No
How much time did you usually spend doing
moderate physical activities on one of those
days? In hours per day?
How much time did you usually spend doing
moderate physical activities on one of those
days? In minutes per day?
The time I spend doing moderate physical
activities on one of those days is unknown
Yes
No
During the last 7 days, on how many days did you
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walk for at least 10 minutes at a time?
No walking activity during the last 7 days - if yes,
skip to question 7
Yes
No
How much time did you usually spend walking on
one of those days? In hours per day?
How much time did you usually spend walking on
one of those days? In minutes per day?
The time I spend walking on one of those days is
unknown
Yes
No
During the last 7 days, how much time did you
spend sitting on a week day?
How much time did you usually spend sitting on a
weekday? In hours per day?
How much time did you spend sitting on a
weekday? In minutes per day?
The time I spend sitting on a weekday is
unknown
Yes
No
Blood sample
Has a venous blood sample been taken from the
patient ?
Yes
No
Has a venous blood sample been taken from the
patient ? If no, please state why not
Was the patient fasting before blood sampling ?
Yes
No
Hours of fast before blood sampling
Interview completed for this patient?
Yes
No
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Cover Page
Subject ID
Subject Initials
Protocol Version
Informed Consent
Informed Consent
Inclusion Criteria
Is the subject fully eligible per the Inclusion
criteria?
Yes
No
Institutional Review Board (IRB)/Independent
Ethics Committee (IEC)-approved written
Informed Consent and privacy language as per
national regulation (e.g. HIPAA Authorization for
U.S. sites) must be obtained from the subject or
legally authorized representative prior to any
study-related procedures (including withdrawel of
prohibited medication, if applicable).
Yes
No
Subject is male or female and 18 years and older.
Yes
No
Subject has been diagnosed with Type 2
Diabetes Mellitus for at least 6 weeks.
Yes
No
Subject has a HbA1c value between 6.8 and
9.5% at Visit 1 AND has a HbA1c value between
7.0 and 9.5%, inclusive, at Visit 3 AND does not
meet any of the fasting plasma glucose (FPG)
withdrawel criteria.
Yes
No
1 / 9
Subject is naive to anti-diabetic medication; OR is
receiving a single anti-diabetic agent or low dose
of a dual oral combination therapy (< or = 50% of
maximum doses of each component), and is
willing and able to safely discontinue anti-diabetic
therapy at Screening (for at least 8 weeks prior to
the first dose of study medication) and for the
duration of the study (24 weeks total).
Yes
No
Subject is on a stable diet and exercise program
(for at least 6 weeks prior to Screening) and is
willing to remain on this program for the duration
of the study
Yes
No
Subject has a body mass index (BMI) 20 - 45
kg/m" at Visit 1.
Yes
No
Female subject of childbearing potential has a
negative pregnancy test at Visit 1 and 4 and
agrees to use an acceptable form of
contraception throughout the duration of the
study OR is at least 2 years postmenopausal or
surgically sterile.
Yes
No
Exclusion Criteria
Is the subject fully eligible per the Exclusion
criteria?
Yes
No
Subject has any known complication of T2DM
indication a late disease state that in the
Investigator's opinion should preclude the subject
from participation.
Yes
No
Subject has type 1 diabetes mellitus.
Yes
No
Subject is in need of insulin therapy or has
received insulin within 3 months prior to Visit 1,
with the exception of acute use of <7 days.
Yes
No
Subjact has a serum creatinine higher than upper
limit of normal at Visit 1 or 3.
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Yes
No
Subject has an ALT and/or AST value higher than
3 times upper limit of normal or a total bilirubin
value more than 2 times upper limit of normal at
Visit 1 or 3.
Yes
No
Subject has a urinary microalbumin/urinary
creatinine ratio >300mg/g at Visit 1 or 3.
Yes
No
Subject has a symptomatic urinary tract infection
or genital infection at any time during the
Screening or Placebo Run-In Period, including
just prior to randomization at Visit 4.
Yes
No
Subject has persistent, uncontrolled severe
hypertension as indicated by a systolic blood
pressure >180 mmHg or a diastolic blood
pressure of >110mmHg taken in a sitting or
supine position after 5 minutes of rest on at least
2 measurements (within 30 minutes of each
other) at Visits 1, 2 or 3.
Subject has had significant cardiovascular
disease such as myocardial infarction or a
vascular intervention (e.g., angioplasty or stent)
within 3 months prior to Visit 1 or a history of
heart failure (NYHA Class III-IV).
Yes
No
Subject is known to have hepatitis or be a carrier
of hepatitis B surface antigen (HBaAg), hepatitis
C virus (HCV) antibody (ELISA plus confirmatory
test) or is known positive for HIV1 and/or HIV2.
Yes
No
Subject is currently receiving an excluded
medication (loop diuretics or systemic
corticosteroids) or is unwilling to discontinure a
restricted medication for the duration of the study.
Yes
No
Subject has a history of lactic acidosis.
Yes
No
Subject has a history of drug and alcohol
abuse/dependency within 12 months prior to Visit
1 as defined in the Diagnostic and Statistical
Manual-IV (DSM-IV).
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Yes
No
Subject has had a malignancy in the last 5 years,
except for successfully treated basal or
squamous cell carcinoma of the skin or
carcinoma insitu of the cervix
Yes
No
Female subject is lactating.
Yes
No
Subject has an unstable medical or psychiatric
illness.
Yes
No
Subject has known or suspected hypersensitivity
to, or components of, ASP1941 or metformin.
Yes
No
Subject has previously received ASP1941.
Yes
No
Subject is concurrently participating in another
drug study or has received an investigational
drug (including placebo) within 30 days prior to
Visit 1.
Yes
No
Subject has any concurrent illness which, in the
opinion of the investigator, may interfere with
treatment or evaluation of safety or completion of
this study.
Yes
No
In the Investigator's judgment, the subject is
unable to adhere to the treatment regimen,
protocol procedures or study requirements.
Yes
No
Demographics
Sex
Male (1)
Female (2)
Date of birth:
Age
years
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Race
White (1)
Black (2)
Black or African American (3)
Asian (4)
American Indian or Alaskan Native (5)
Native Hawaiian or Other Pacific Islander
(6)
Mestizo (7)
Asian-Indian (8)
Filipino (9)
Other (99)
If Other, specify:
Ethnicity
Not Hispanic or Latino (1)
Hispanic or Latino (2)
Primary Diagnosis
Medical Condition
Type II Diabetes Mellitus (1)
Date of Diagnosis
Subject Characteristics
Currently sexually active?
Yes
No
Male subject circumcised?
Yes
No
Family history of Vascular Disease
Yes
No
Date of Visit
Date of visit
Tobacco History
Tobacco History
Never used Tobacco (1)
Former Tobacco User (2)
Current Tobacco User (3)
Tobacco Type
Cigarettes (1)
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Cigars (2)
Pipes (Bowls) (3)
Chews (4)
For Former Tobacco User or Current Tobacco
User, please specify quantity (/day):
Alcohol History
Alcohol History
Never used Alcohol (1)
Former Alcohol User (2)
Current Alcohol User (3)
For Former Alcohol User or Current Alcohol User,
please specify quantity (units/week):
1 Alcohol Unit = 1 can of beer, 1 glass of wine, or
1 shot of hard liquor
Urinary Tract Infection History
Diagnosis
Urinary Tract Infection (1)
History of Urinary Tract Infection
Yes
No
History of Urinary Tract Infection
If yes, how many UTIs did the subject have in the
past year?
If one or more, please provide the details of the
most recent historical infection. 
Site of Infection:
Upper (1)
Lower (2)
Upper and Lower (3)
Unknown (4)
Organism:
Bacterial (1)
Viral (2)
Fungal (3)
Unkown (4)
Organism confirmed by Lab?
Yes (1)
No (2)
Unknown (3)
Onset Date
Is Medical Condition ongoing?
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Yes
No
Recovery Date
Was the infection symptomatic?
Symptomatic (1)
Asymptomatic (2)
Unknown (3)
Was the infection treated?
Yes (1)
No (2)
Unknown (3)
Genital Infection History
Diagnosis:
Genital Infection (1)
Does the subject have a history of Genital
Infections?
Yes
No
If yes, how many genital infections did the subject
have in the past year?
If one or more, please provide the details of the
most recent historical infection. Site of Infection:
Vaginal (1)
Labia (2)
Uterus/Fallopian Tubes/Ovaries (3)
Urethra (4)
Penis (5)
Foreskin/Glans (6)
Testicles/Epididymis (7)
Other (8)
Organism:
Bacterial (Bacterial)
Fungal (Fungal)
Unkown (Unkown)
Viral (Viral)
Confirmation by Lab?
Yes (1)
No (2)
Unknown (3)
Onset Date:
Is Medical Condition ongoing?
Yes
No
Recovery Date
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Was the infection symptomatic?
Yes (1)
No (2)
Unknown (3)
Was the infection treated?
Yes (1)
No (2)
Unknown (3)
Physical Examination
Was the physical examination performed?
Record any abnormal findings/conditions
identified during the exam on the appropriate
form.
Yes
No
Assessment Date
Orthostatic vital signs
Not done:
Yes
No
Assessment Date
Assessment Time
Position
Sitting (1)
Standing (2)
Location of blood pressure measurement
Right Arm (1)
Left Arm (2)
Systolic Blood Pressure
mmHg
Diastolic Blood Pressure
mmHg
Pulse Rate
Beats/min
12 Lead ECG 1
Date ECG was performed
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ECG Time performed
ECG Interpretation
Normal (0 )
Abnormal - not clinically significant (1 )
Abnormal - clinically significant (2 )
Height and Weight
Date of Measurements
Body height
cm
Body weight
kg
Body Mass Index
kg/m2
Previous Diabetes Medication Use
Did the subject take any Previous anti-diabetes
medication and requires a 6 week washout?
Yes
No
Pregnancy Test
Is subject female and of childbearing potential?
Yes
No
If no childbearing potential, please provide
reason why a pregnancy test not done:
Female (2yrs post menopausal or
surgically sterile) (1)
Pre-Puberty (2)
Male (3)
Other (4)
Select "Not done" if urine sample was not taken.
Not Done (1)
Date of Sample Taken
dd/MMM/yyyy
Pregnancy test result
negative (0)
positive (1)
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DM-ASP1941-1941-CL-0004
NCT01071850
A Phase 2, Double-Blind, Randomized, Placebo and
Active-Controlled Dose-Finding Study to Assess the
Efficacy, Safety and Tolerability of Multiple Oral Doses of
ASP1941 in Subjects with Type 2 Diabetes MellitusTEST
Study
Visit 2 (Washout), Visit 5, Visit 6
All rights reserved. Please visit https://medical-data-
models.org/forms/16840
Visit 2, Visit 5, Visit 6 DM-ASP1941-
1941-CL-0004 NCT01071850
Date of Visit
Date of visit
Orthostatic Vital Signs
Not done:
Yes
No
Assessment Date
Assessment Time
Vital Signs
Sitting (Sitting)
Standing (Standing)
Location of blood pressure measurement
Right Arm  (1)
Left Arm (2)
Systolic Blood Pressure
mmHg
Diastolic Blood Pressure
mmHg
Pulse Rate
Beats/min
Weight
Assessment Date
Weight
kg
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NCT01071850
A Phase 2, Double-Blind, Randomized, Placebo and
Active-Controlled Dose-Finding Study to Assess the
Efficacy, Safety and Tolerability of Multiple Oral Doses of
ASP1941 in Subjects with Type 2 Diabetes MellitusTEST
Study
Visit 3 (Washout)
All rights reserved. Please visit https://medical-data-
models.org/forms/16841
Visit 3 DM-ASP1941-1941-CL-0004
NCT01071850
Date of Visit
Date of visit
Orthostatic Vital Signs
Not done:
Yes
No
Assessment Date
Assessment Time
Vital Signs
Sitting (Sitting)
Standing (Standing)
Location of blood pressure measurement
Right Arm  (1)
Left Arm (2)
Systolic Blood Pressure
mmHg
Diastolic Blood Pressure
mmHg
Pulse Rate
Beats/min
ECG: 12 Lead ECG 1
Date ECG was performed
ECG Time performed
ECG Interpretation
Normal  (0 )
Abnormal - not clinically significant  (1 )
Abnormal - clinically significant (2 )
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Weight
Assessment Date
Weight
kg
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DM-ASP1941-1941-CL-0004
NCT01071850
A Phase 2, Double-Blind, Randomized, Placebo and
Active-Controlled Dose-Finding Study to Assess the
Efficacy, Safety and Tolerability of Multiple Oral Doses of
ASP1941 in Subjects with Type 2 Diabetes MellitusTEST
Study
Visit 10
All rights reserved. Please visit https://medical-data-
models.org/forms/16842
Visit 10 DM-ASP1941-1941-CL-0004
NCT01071850
Date of Visit
Date of visit
Orthostatic Vital Signs
Not done:
Yes
No
Assessment Date
Assessment Time
Vital Signs
Sitting (Sitting)
Standing (Standing)
Location of blood pressure measurement
Right Arm  (1)
Left Arm (2)
Systolic Blood Pressure
mmHg
Diastolic Blood Pressure
mmHg
Pulse Rate
Beats/min
Weight
Assessment Date
Weight
kg
Waist and Hip Circumference
Waist circumference
cm
1 / 2
Hip circumference
cm
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Eligibility Congestive Heart Failure
NCT00158938
Clinical Study of the EASYTRAK 3 Spiral Fixation Coronary
Venous Bipolar Pace/Sense Lead; ODM derived from:
https://clinicaltrials.gov/show/NCT00158938
All rights reserved. Please visit https://medical-data-
models.org/forms/16843
Eligibility Congestive Heart Failure
NCT00158938
Inclusion Criteria
moderate to severe heart failure (nyha class iii/iv)
including left ventricular dysfunction (ef <= 35%)
and qrs duration >= 120 ms remaining
symptomatic despite stable, optimal heart failure
drug therapy.*
Yes
No
creatinine < 2.5 mg/dl obtained no more than two
weeks prior to enrollment.*
Yes
No
age 18 or above, or of legal age to give informed
consent specific to state and national law.*
Yes
No
willing and capable of providing informed
consent, undergoing a device implant,
participating in all testing associated with this
clinical investigation at an approved clinical
investigational center and at the intervals defined
by this protocol.*
Yes
No
Exclusion Criteria
a known hypersensitivity to a 1.0 mg (0.5 mg per
electrode) dose of dexamethasone acetate.*
Yes
No
previous cardiac resynchronization therapy, a
coronary venous pace/sense lead or attempted lv
lead placement.*
Yes
No
pre-existing cardioversion/defibrillation leads
other than those specified in this investigational
plan (unless the investigator intends to replace
them with permitted cardioversion/defibrillation
leads).*
Yes
No
requiring dialysis.*
Yes
No
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a myocardial infarct, unstable angina,
percutaneous coronary intervention, or coronary
artery bypass graft during the preceding 30 days
prior to enrollment.*
Yes
No
hypertrophic obstructive cardiomyopathy or
infiltrative cardiomyopathy (e.g., amyloidosis,
sarcoidosis).*
Yes
No
a documented life expectancy of less than 6
months or expected to undergo heart transplant
within 6 months.*
Yes
No
enrolled in any concurrent study, without prior
guidant written approval, that may confound the
results of this study.*
Yes
No
have a mechanical tricuspid heart valve.*
Yes
No
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EUROASPIRE III (Hospital Arm) - Stroke
Part Patient Record Questionnaire
Provided by Prof. Keil
Source: Kotseva K, Wood D, De Backer G, De Bacquer D,
Pyörälä K, Keil U; EUROASPIRE Study Group.
Cardiovascular prevention guidelines in daily practice: a
comparison of EUROASPIRE I, II, and III surveys in eight
European countries. Lancet. 2009 Mar 14;373(9667):929-
40. doi: 10.1016/S0140-6736(09)60330-5. PubMed PMID:
19286092
All rights reserved. Please visit https://medical-data-
models.org/forms/16844
Stroke Part Patient Record
Questionnaire
Inclusion criteria
Has the patient been an inpatient at your hospital
for the diagnosis of an ischemic stroke according
to the following criteria? Duration of symptoms
>24 hours (except for patients receiving
thrombolytic therapy); First ever stroke (no history
of previous stroke with neurological deficit >24
hours; previous TIA(s) or silent stroke(s) are not
counted as a previous stroke); Ischemic stroke
verified by brain imaging (cerebral infarction
identified at cerebral imaging or no brain lesion in
a cerebral imaging of satisfactory quality although
clinical criteria of stroke are fulfilled)
Yes
No
Has at least six months and at most 3 years
elapsed since the most recent admission for one
of these procedures or diagnoses?
Yes
No
If the answer to both questions is yes,please
complete this Data Form from the information
recorded in the patient's notes.
Yes
No
Personal information
Patient ID
Patient Title
Mr (1)
Miss (2)
Ms (3)
Mrs (4)
Forename(s)
Surname
Address
1 / 25
Telephone number
National hospital number:
General practitioner name
General practitoner address
Telephone number
Patient Record Questionnaire
Date of completion of this form
Date of birth of patient
Sex
male (1)
female (2)
What was the index event or procedure which
entered the patient into this study? The event
must have occurred at least six months prior to
completion of this form.
Elective or emergency coronary artery
by-pass surgery (1)
Elective or emergency percutaneous
transluminal coronary angioplasty	 (2)
Acute myocardial infarction (3)
Acute myocardial ischaemia (4)
Date of index event
Date of hospital admission
Date of discharge
What was the discharge destination?
Home (1)
Other hospital/ other ward (2)
Community facility (nursing/ residential
home) (3)
Rehabilitation unit (4)
In-hospital death (5)
Unknown (6)
Has the Patient died?
Yes (1)
No (2)
Unsure  (3)
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Questionnaire
Not recorded (4)
Date of death (if applicable)
What kind of cerebral imaging was performed
after index event?
CT scan only (1)
MRI scan only	 (2)
CT and MRI scan (3)
Not done (4)
Unsure	 (5)
Not recorded (6)
What was the estimated size of the lesion in most
meaningful cerebral imaging?
No vascular lesion present	 (1)
Inappropriate vascular lesion present (2)
Appropriate vascular lesion present
>15mm	 (4)
Unsure	 (5)
Not recorded (6)
15mm (Appropriate vascular lesion
present <)
What was the date of the most meaningful
cerebral imaging?
<= 24 hours after onset of symptoms	 (1)
>24 hours after onset of symptoms (2)
Unsure (3)
Not recorded (4)
If appropriate vascular lesion present, what was
the location of the lesion of the index event in
cerebral imaging? (multiple choices possible)
Cerebellar infarction (1)
Brain stem infarction (2)
Subcortical infarction	 (3)
Cortical infarction (4)
Unsure (5)
Not recorded (6)
Was vascular imaging (Carotid ultrasound, DSA-
angiography, 
CT- or MRI- angiography) performed after index
event?
Yes (1)
No (2)
Unsure  (3)
Not recorded (4)
If Yes, was a relevant stenosis (>50%) of the
vessels supplying the affected vascular territory
of the index event detected?
No (1)
Yes, intracranial (2)
Yes, extracranial (3)
Unsure (4)
Not recorded (5)
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Questionnaire
Was an ECG performed?
Yes (1)
No (2)
Unsure  (3)
Not recorded (4)
If Yes, was there any arrhythmia?
No							 (1)
Atrial fibrillation				 (2)
Atrial flutter					 (3)
Other relevant arrhythmia		 (4)
Unsure						 (5)
Not recorded (6)
Was an Echocardiography performed?
No							 (1)
Yes, Trans-Thoracic-Echokardiography
(2)
Yes, Trans-Oesophageal
Echokardiography 		 (3)
Unsure							 (4)
Not recorded (5)
LA/ atrial appendage thrombus
Yes (1)
No (2)
Unsure  (3)
Not recorded (4)
LV thrombus
Yes (1)
No (2)
Unsure  (3)
Not recorded (4)
Patent foramen ovale
Yes (1)
No (2)
Unsure  (3)
Not recorded (4)
Atrial septum aneurysma
Yes (1)
No (2)
Unsure  (3)
Not recorded (4)
Dilated cardiomyopathy
Yes (1)
No (2)
Unsure  (3)
Not recorded (4)
Akinetic Left Ventricular segment
Yes (1)
No (2)
Unsure  (3)
Not recorded (4)
Hypokinetic/Dyskinetic Left Ventricular segment
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Questionnaire
Yes (1)
No (2)
Unsure  (3)
Not recorded (4)
Mechanical prosthetic valve
Yes (1)
No (2)
Unsure  (3)
Not recorded (4)
Bioprosthetic cardiac valve
Yes (1)
No (2)
Unsure  (3)
Not recorded (4)
LV ejection fraction <=40%
Yes (1)
No (2)
Unsure  (3)
Not recorded (4)
Was etiology of ischemic stroke specified in
medical records?
Yes (1)
No (2)
Unsure  (3)
Not recorded (4)
If Yes, what aetiological stroke subtype was
specified finally?
Large artery atherosclerosis					 (1)
Cardioembolism 						 (2)
Small vessel occlusion					 (3)
Other determined etiology,please specify
(4)
No etiology identified					 (5)
Concurrent etiology (multiple probable
etiologies)	 (6)
Unsure								 (7)
Not recorded (8)
If other determined etiology, please specify
Rankin Scale at discharge
No symptoms at all						 (1)
No significant disability despite
symptoms	 (2)
Slight disability						 (3)
Moderate disability, able to walk without
assistance		 (4)
Moderate disability, unable to walk
without assistance	 (5)
Severe disability						 (6)
Unsure								 (7)
Not recorded (8)
Urinary function at discharge
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Questionnaire
Incontinent, or catheterized and unable
to manage		 (1)
Occasional accident (max once per 24
hours)		 (2)
Continent							 (3)
Unsure							 (4)
Not recorded (5)
Transfer from bed to chair
Unable - no sitting balance					 (1)
Needs major help (one or two people,
physical), can sit	 (2)
Needs minor help (verbal or physical)			 (3)
Independent							 (4)
Unsure								 (5)
Not recorded (6)
Mobility
Immobile							 (1)
Propels independent in wheelchair,
including corners	 (2)
Walks with help of one person (verbal or
physical)		 (3)
Independent (but may use any aid, e.g.
stick)		 (4)
Unsure							 (5)
Not recorded (6)
Level of consciousness
Alert								 (1)
Drowsy (respond to speech)					 (2)
Semiconsciousness (not fully rousable)
(3)
Unconsciousness (response to pain only
or no response)	 (4)
Unsure								 (5)
Not recorded (6)
Aphasia
Yes (1)
No (2)
Unsure  (3)
Not recorded (4)
Dysarthria
Yes (1)
No (2)
Unsure  (3)
Not recorded (4)
Unilateral motor deficit (weakness or paresis)
affecting face
Yes (1)
No (2)
Unsure  (3)
Not recorded (4)
Unilateral motor deficit (weakness or paresis)
affecting arm/hand
Yes (1)
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Questionnaire
No (2)
Unsure  (3)
Not recorded (4)
Unilateral motor deficit (weakness or paresis)
affecting leg/foot
Yes (1)
No (2)
Unsure  (3)
Not recorded (4)
Unilateral sensory deficit affecting face
Yes (1)
No (2)
Unsure  (3)
Not recorded (4)
Unilateral sensory deficit affecting arm/hand
Yes (1)
No (2)
Unsure  (3)
Not recorded (4)
Unilateral sensory deficit affecting leg/foot
Yes (1)
No (2)
Unsure  (3)
Not recorded (4)
Visual field deficits
Yes (1)
No (2)
Unsure  (3)
Not recorded (4)
Did the patient receive thrombolysis?
Yes (1)
No (2)
Unsure  (3)
Not recorded (4)
If Yes, which types of thrombolysis?
Intravenous			 (1)
Intraarterial			 (2)
Intravenous and intraarterial 	 (3)
Unsure				 (4)
Not recorded (5)
Was the patient receiving stroke unit care?
Yes (1)
No (2)
Unsure  (3)
Not recorded (4)
If Yes, how many days did the patient stay at
Stroke Unit? (99=unknown)
Days
Did the patient have a history of coronary heart
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Questionnaire
disease, stroke or other vascular disease prior to
the index event or procedure?
Yes (1)
No (2)
Unsure  (3)
Not recorded (4)
Carotid artery surgery (carotid endartectomy)
Yes (1)
No (2)
Unsure  (3)
Not recorded (4)
Carotid artery surgery (carotid endartectomy):
Month/year of event
Percutaneous transluminal angioplasty of carotid
artery
Yes (1)
No (2)
Unsure  (3)
Not recorded (4)
Percutaneous transluminal angioplasty of carotid
artery:month/ year of event
Acute myocardial infarction
Yes (1)
No (2)
Unsure  (3)
Not recorded (4)
Acute myocardial infarction year of event
Acute myocardial ischaemia
Yes (1)
No (2)
Unsure  (3)
Not recorded (4)
Acute myocardial ischaemia year of event
History of angina pectoris
Yes (1)
No (2)
Unsure  (3)
Not recorded (4)
History of angina pectoris year of event
History of stroke
Yes (1)
No (2)
Unsure  (3)
Not recorded (4)
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Questionnaire
History of stroke year of event
History of TIA (transient ischemic attack)
Yes (1)
No (2)
Unsure  (3)
Not recorded (4)
History of TIA (transient ischemic attack) year of
event
History of PAD (peripheral artery disease)
Yes (1)
No (2)
Unsure  (3)
Not recorded (4)
History of PAD (peripheral artery disease) year of
event
History of hypertension
Yes (1)
No (2)
Not recorded (3)
History of hypertension:if yes, duration in months
History of hyperlipidaemia/ dyslipidaemia
Yes (1)
No (2)
Not recorded (3)
History of hyperlipidaemia/ dyslipidaemia: If yes,
duration in months
History of diabetes
Yes (1)
No (2)
Not recorded (3)
History of diabetes: If yes, duration in months
History of atrial fibrillation
Yes (1)
No (2)
Not recorded (3)
History of atrial fibrillation: If yes, duration in
months
History of atrial fibrillation: If yes, duration in
months
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Questionnaire
History of carotid stenosis (>50percent)
Yes (1)
No (2)
Not recorded (3)
History of carotid stenosis (>50percent) : If yes,
duration in months
History of carotid stenosis (>50percent) : If yes,
duration in months
Smoking status
Non smoker 		 (1)
Is a current non smoker (but previous
smoking history unknown) 	 (2)
Has stopped smoking  (3)
Current smoker (4)
Body height
cm
Body weight
kg
Body Mass Index
kg/m2
Waist circumference
cm
Systolic blood pressure
mmHg
Diastolic blood pressure
mmHg
Heart rate
bpm
Total cholesterol
mmol/l
LDL cholesterol
mmol/l
HDL cholesterol
mmol/l
Triglycerides
mmol/l
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Questionnaire
Blood glucose level
mmol/l
HbA1C level (in diabetics)
Was the patient taking any of the following
medications prior to the index event or
procedure?
Yes (1)
No (2)
Unsure  (3)
Not recorded (4)
Aspirin or other anti-platelet drugs?
Yes (1)
No (2)
Not recorded (3)
Aspirin or other anti-platelet drugs: Generic name
Aspirin or other anti-platelet drugs: Total daily
dose
mg
Aspirin or other anti-platelet drugs?
Yes (1)
No (2)
Not recorded (3)
Aspirin or other anti-platelet drugs: Generic name
Aspirin or other anti-platelet drugs: Total daily
dose
mg
Beta blockers
Yes (1)
No (2)
Not recorded (3)
Beta blockers:Generic name
Beta Blockers Total daily dose
mg
ACE inhibitors
Yes (1)
No (2)
Not recorded (3)
ACE inhibitors: Generic name
ACE inhibitors : Total daily dose
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Questionnaire
mg
Angiotensin II receptor antagonists
Yes (1)
No (2)
Not recorded (3)
Angiotensin II receptor antagonists: Generic
name
Angiotensin II receptor antagonists: Total daily
dose
mg
Calcium antagonists
Yes (1)
No (2)
Not recorded (3)
Calcium antagonists: Generic name
Calcium antagonists: Total daily dose
mg
If inhibitors
Yes (1)
No (2)
Not recorded (3)
If inhibitors: Generic name
If inhibitors: Total daily dose
mg
Nitrates
Yes (1)
No (2)
Not recorded (3)
Nitrates: Generic name
Nitrates: Total daily dose
mg
Diuretics
Yes (1)
No (2)
Not recorded (3)
Diuretics: Generic name
Diuretics: Total daily dose
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Questionnaire
mg
Diuretics
Yes (1)
No (2)
Not recorded (3)
Diuretics: Generic name
Diuretics: Total daily dose
mg
Other anti-hypertensive drugs
Yes (1)
No (2)
Not recorded (3)
Other Anti-hypertensive drugs: Generic name
Other Anti-hypertensive drugs: Total daily dose
mg
Digitalis glycosides
Yes (1)
No (2)
Not recorded (3)
Digitalis glycosides: Generic name
Digitalis glycosides: Total daily dose
mg
Antiarrhythmics
Yes (1)
No (2)
Not recorded (3)
Antiarrhythmics:  Generic name
Antiarrhythmics:  Total daily dose
mg
Lipid lowering drugs: Statins
Yes (1)
No (2)
Not recorded (3)
Lipid lowering drugs (Statins): Generic name
Lipid lowering drugs (Statins): Total daily dose
mg
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Questionnaire
Lipid lowering drugs: Fibrates
Yes (1)
No (2)
Not recorded (3)
Lipid lowering drugs (Fibrates): Generic name
Lipid lowering drugs (Fibrates): Total daily dose
mg
Lipid lowering drugs: Nicotinic acid group
Yes (1)
No (2)
Not recorded (3)
Lipid lowering drugs (Nicotinic acid group):
Generic name
Lipid lowering drugs (Nicotinic acid group): Total
daily dose
mg
Lipid lowering drugs: Cholesterol absorption
inhibitors
Yes (1)
No (2)
Not recorded (3)
Lipid lowering drugs (Cholesterol absorption
inhibitors): Generic name
Lipid lowering drugs (Cholesterol absorption
inhibitors): Total daily dose
mg
Lipid lowering drugs: Resins
Yes (1)
No (2)
Not recorded (3)
Lipid lowering drugs (Resins): Generic name
Lipid lowering drugs (Resins): Total daily dose
mg
Lipid lowering drugs: Other
Yes (1)
No (2)
Not recorded (3)
Lipid lowering drugs (Other): Generic name
Lipid lowering drugs (Other): Total daily dose
mg
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Anti-diabetic drugs: Insulin
Yes (1)
No (2)
Not recorded (3)
Insulin: Generic name
Insulin: Total daily dose
mg
Anti-diabetic drugs: Insulin
Yes (1)
No (2)
Not recorded (3)
Insulin: Generic name
Insulin: Total daily dose
mg
Anti-diabetic drugs: oral
Yes (1)
No (2)
Not recorded (3)
Oral Antidiabetics: Generic name
Oral Antidiabetics: Total daily dose
mg
Anti-diabetic drugs: oral
Yes (1)
No (2)
Not recorded (3)
Oral Antidiabetics: Generic name
Oral Antidiabetics: Total daily dose
mg
Anti-coagulants
Yes (1)
No (2)
Not recorded (3)
Anti-coagulants: Generic name
Anti-coagulants: Total daily dose
mg
Oral contraceptive pill
Yes (1)
No (2)
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Not recorded (3)
Oral contraceptive pill: Generic name
Oral contraceptive pill: Total daily dose
Hormone replacement therapy
Yes (1)
No (2)
Not recorded (3)
Hormone replacement therapy: Generic name
Hormone replacement therapy: Total daily dose
Appetite suppressants or other antiobesity
Yes (1)
No (2)
Not recorded (3)
Appetite suppressants/other antiobesity: Generic
name
Appetite suppressants or other antiobesity: Total
daily dose
mg
Nicotine replacement therapy
Yes (1)
No (2)
Not recorded (3)
Nicotine replacement therapy: Generic name
Nicotine replacement therapy: Total daily dose
mg
Nicotine replacement therapy
Chewing Gum (1)
Nasal spray (2)
Inhalator (3)
Patches (4)
Losenges (5)
Bupropion
Yes (1)
No (2)
Not recorded (3)
Bupropion: Generic name
Bupropion: Total daily dose
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mg
Other medication
Yes (1)
No (2)
Not recorded (3)
Other medications: Generic name
Other medications: Total daily dose
mg
Is any of the medication prescribed a
combination of 2 drugs in one tablet?
Yes (1)
No (2)
Don´t know/Unsure (3)
If yes, please specify
Discharge evaluation
Risk factor obesity
Yes (1)
No (2)
Unsure  (3)
Not recorded (4)
History of obesity: If YES, recorded level where
applicable
Smoking status
Non smoker 		 (1)
Is a current non smoker (but previous
smoking history unknown) 	 (2)
Has stopped smoking  (3)
Current smoker (4)
History of hypertension
Yes (1)
No (2)
Not recorded (3)
History of hypertension:if yes, record level when
applicable
History of hyperlipidaemia/ dyslipidaemia
Yes (1)
No (2)
Not recorded (3)
History of hyperlipidaemia/ dyslipidaemia: If yes,
record level when applicable
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History of Atrial fibrillation
Yes (1)
No (2)
Not recorded (3)
History of atrial fibrillation: If yes, record level
when applicable
History of Carotid stenosis (>50percent)
Yes (1)
No (2)
Not recorded (3)
History of Carotid stenosis (>50percent): If yes,
record level when applicable
History of diabetes
Yes (1)
No (2)
Not recorded (3)
History of diabetes: If yes, record level when
applicable
Body height
cm
Body weight
kg
Body Mass Index
kg/m2
Waist circumference
cm
Systolic blood pressure
mmHg
Diastolic blood pressure
mmHg
Heart rate
bpm
Total cholesterol
mmol/l
LDL cholesterol
mmol/l
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HDL cholesterol
mmol/l
Triglycerides
mmol/l
Blood glucose level
mmol/l
HbA1C level (in diabetics)
Is etiology of ischemic stroke recorded in
discharge letter?
Yes (1)
No (2)
Unsure  (3)
Not recorded (4)
Are any of the following drug prescriptions found
in the discharge letter?
Yes (1)
No (2)
Unsure  (3)
Not recorded (4)
Aspirin or other anti-platelet drugs?
Yes (1)
No (2)
Not recorded (3)
Aspirin or other anti-platelet drugs: Generic name
Aspirin or other anti-platelet drugs: Total daily
dose
mg
Aspirin or other anti-platelet drugs?
Yes (1)
No (2)
Not recorded (3)
Aspirin or other anti-platelet drugs: Generic name
Aspirin or other anti-platelet drugs: Total daily
dose
mg
Beta blockers
Yes (1)
No (2)
Not recorded (3)
Beta blockers:Generic name
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Beta Blockers Total daily dose
mg
ACE inhibitors
Yes (1)
No (2)
Not recorded (3)
ACE inhibitors: Generic name
ACE inhibitors : Total daily dose
mg
Angiotensin II receptor antagonists
Yes (1)
No (2)
Not recorded (3)
Angiotensin II receptor antagonists: Generic
name
Angiotensin II receptor antagonists: Total daily
dose
mg
Calcium antagonists
Yes (1)
No (2)
Not recorded (3)
Calcium antagonists: Generic name
Calcium antagonists: Total daily dose
mg
If inhibitors
Yes (1)
No (2)
Not recorded (3)
If inhibitors: Generic name
If inhibitors: Total daily dose
mg
Nitrates
Yes (1)
No (2)
Not recorded (3)
Nitrates: Generic name
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Nitrates: Total daily dose
mg
Diuretics
Yes (1)
No (2)
Not recorded (3)
Diuretics: Generic name
Diuretics: Total daily dose
mg
Diuretics
Yes (1)
No (2)
Not recorded (3)
Diuretics: Generic name
Diuretics: Total daily dose
mg
Other anti-hypertensive drugs
Yes (1)
No (2)
Not recorded (3)
Other Anti-hypertensive drugs: Generic name
Other Anti-hypertensive drugs: Total daily dose
mg
Digitalis glycosides
Yes (1)
No (2)
Not recorded (3)
Digitalis glycosides: Generic name
Digitalis glycosides: Total daily dose
mg
Antiarrhythmics
Yes (1)
No (2)
Not recorded (3)
Antiarrhythmics:  Generic name
Antiarrhythmics:  Total daily dose
mg
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Lipid lowering drugs: Statins
Yes (1)
No (2)
Not recorded (3)
Lipid lowering drugs (Statins): Generic name
Lipid lowering drugs (Statins): Total daily dose
mg
Lipid lowering drugs: Fibrates
Yes (1)
No (2)
Not recorded (3)
Lipid lowering drugs (Fibrates): Generic name
Lipid lowering drugs (Fibrates): Total daily dose
mg
Lipid lowering drugs: Nicotinic acid group
Yes (1)
No (2)
Not recorded (3)
Lipid lowering drugs (Nicotinic acid group):
Generic name
Lipid lowering drugs (Nicotinic acid group): Total
daily dose
mg
Lipid lowering drugs: Cholesterol absorption
inhibitors
Yes (1)
No (2)
Not recorded (3)
Lipid lowering drugs (Cholesterol absorption
inhibitors): Generic name
Lipid lowering drugs (Cholesterol absorption
inhibitors): Total daily dose
mg
Lipid lowering drugs: Resins
Yes (1)
No (2)
Not recorded (3)
Lipid lowering drugs (Resins): Generic name
Lipid lowering drugs (Resins): Total daily dose
mg
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Lipid lowering drugs: Other
Yes (1)
No (2)
Not recorded (3)
Lipid lowering drugs (Other): Generic name
Lipid lowering drugs (Other): Total daily dose
mg
Anti-diabetic drugs: Insulin
Yes (1)
No (2)
Not recorded (3)
Insulin: Generic name
Insulin: Total daily dose
mg
Anti-diabetic drugs: Insulin
Yes (1)
No (2)
Not recorded (3)
Insulin: Generic name
Insulin: Total daily dose
mg
Anti-diabetic drugs: oral
Yes (1)
No (2)
Not recorded (3)
Oral Antidiabetics: Generic name
Oral Antidiabetics: Total daily dose
mg
Anti-diabetic drugs: oral
Yes (1)
No (2)
Not recorded (3)
Oral Antidiabetics: Generic name
Oral Antidiabetics: Total daily dose
mg
Anti-coagulants
Yes (1)
No (2)
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Not recorded (3)
Anti-coagulants: Generic name
Anti-coagulants: Total daily dose
mg
Oral contraceptive pill
Yes (1)
No (2)
Not recorded (3)
Oral contraceptive pill: Generic name
Oral contraceptive pill: Total daily dose
Hormone replacement therapy
Yes (1)
No (2)
Not recorded (3)
Hormone replacement therapy: Generic name
Hormone replacement therapy: Total daily dose
Appetite suppressants or other antiobesity
Yes (1)
No (2)
Not recorded (3)
Appetite suppressants/other antiobesity: Generic
name
Appetite suppressants or other antiobesity: Total
daily dose
mg
Nicotine replacement therapy
Yes (1)
No (2)
Not recorded (3)
Nicotine replacement therapy: Generic name
Nicotine replacement therapy: Total daily dose
mg
Nicotine replacement therapy
Chewing Gum (1)
Nasal spray (2)
Inhalator (3)
Patches (4)
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Losenges (5)
Bupropion
Yes (1)
No (2)
Not recorded (3)
Bupropion: Generic name
Bupropion: Total daily dose
mg
Other medication
Yes (1)
No (2)
Not recorded (3)
Other medications: Generic name
Other medications: Total daily dose
mg
Is any of the medication prescribed a
combination of 2 drugs in one tablet?
Yes (1)
No (2)
Don´t know/Unsure (3)
If yes, please specify
Patient record completed for this patient
Yes
No
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Eligibility Congestive Heart Failure
NCT00158951
Device Evaluation of Contak Renewal 2and Easytrak 2 -
DECREASE-HF; ODM derived from:
https://clinicaltrials.gov/show/NCT00158951
All rights reserved. Please visit https://medical-data-
models.org/forms/16846
Eligibility Congestive Heart Failure
NCT00158951
Inclusion Criteria
meet the general indications for a crt-d device*
Yes
No
moderate or severe heart failure, defined as nyha
class iii-iv despite optimal pharmacological heart
failure therapy.*
Yes
No
a 12-lead electrocardiogram (ecg) obtained no
more than 90 days prior to enrollment
documenting a sinus rate > 50 bpm, qrs duration
³ 150 ms, and pr interval £ 320 ms measured
from any two leads, and a p-wave duration < 150
ms measured from lead v1*
Yes
No
creatinine £ 2.5 mg/dl obtained no more than 14
days prior to enrollment*
Yes
No
left ventricular ejection fraction £ 35% [measured
by echo, multiple gated acquisition (muga) scan,
cardiac catheterization, etc.] no more than 14
days prior to enrollment*
Yes
No
willing and capable of undergoing a device
implant and participating in all testing associated
with this clinical investigation*
Yes
No
have a life expectancy of more than 180 days, per
physician discretion*
Yes
No
age 18 or above, or of legal age to give informed
consent specific to state and national law*
Yes
No
Exclusion Criteria
right bundle branch block morphology (per world
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health organization guidelines) on a 12-lead ecg
obtained no more than 90 days prior to
enrollment.*
Yes
No
have had previous cardiac resynchronization
therapy, a previous coronary venous lead, or
meet the general indications for antibradycardia
pacing*
Yes
No
have a neuromuscular, orthopedic, or other non-
cardiac condition that prevents normal,
unsupported walking*
Yes
No
have an atrial tachyarrhythmia that is permanent
(i.e., does not terminate spontaneously and
cannot be terminated with medical intervention)
or persistent (i.e., can be terminated with medical
intervention, but does not terminate
spontaneously) within 180 days prior to
enrollment*
Yes
No
have a hypersensitivity to a 0.7 mg dose of
dexamethasone acetate*
Yes
No
have surgically uncorrected primary valvular
heart disease*
Yes
No
currently requiring dialysis*
Yes
No
have chronic obstructive pulmonary disease
(copd), defined as fev1/fvc < 60%*
Yes
No
have had a myocardial infarct, unstable angina,
percutaneous coronary intervention, or coronary
artery bypass graft during the 30 days prior to
enrollment*
Yes
No
have hypertrophic obstructive cardiomyopathy or
infiltrative cardiomyopathy (e.g., amyloidosis,
sarcoidosis)*
Yes
2 / 3
Eligibility Congestive Heart Failure NCT00158951
No
have a mechanical tricuspid prosthesis*
Yes
No
enrolled in any concurrent study, without guidant
written approval, that may confound the results of
this study.*
Yes
No
3 / 3
Eligibility Congestive Heart Failure NCT00158951
EUROASPIRE III- (Hospital Arm) Stroke
Part Patient Interview Questionnaire
Provided by Prof. Keil Source: Kotseva K, Wood D, De
Backer G, De Bacquer D, Pyörälä K, Keil U; EUROASPIRE
Study Group. Cardiovascular prevention guidelines in daily
practice: a comparison of EUROASPIRE I, II, and III
surveys in eight European countries. Lancet. 2009 Mar
14;373(9667):929-40. doi: 10.1016/S0140-6736(09)60330-
5. PubMed PMID: 19286092
All rights reserved. Please visit https://medical-data-
models.org/forms/16847
Stroke Part Patient Interview
Questionnaire
Demographic Information
Patient ID
Did the patient attend the interview?
Yes
No
If YES, date of interview
If NO, why not?
Patient died 						 (1)
Change in health status 				 (2)
No time 						 (3)
Moved away 						 (4)
Personal reasons 					 (5)
Refuse to attend for other reasons 			 (6)
Other, please specify (7)
If other reason for not attending, please specify
If patient died, please indicate date of death
Did you have any of the following prior to the
index event which included you in the survey?
Yes (1)
No (2)
Don´t know/ Unsure (3)
Carotid artery surgery (carotid endartectomy)
Yes (1)
No (2)
Don´t know/ Unsure (3)
Hospital admission for Carotid artery surgery
(carotid endartectomy)?
Yes (1)
No (2)
Don´t know/ Unsure (3)
Date of event
Percutaneous transluminal angioplasty of carotid
artery
Yes (1)
No (2)
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Don´t know/ Unsure (3)
Hospital admission for Percutaneous transluminal
angioplasty of carotid artery
Yes (1)
No (2)
Don´t know/ Unsure (3)
Date of event
Acute myocardial infarction
Yes (1)
No (2)
Don´t know/ Unsure (3)
Hospital admission for acute MI
Yes (1)
No (2)
Don´t know/ Unsure (3)
Date of event
Acute myocardial ischaemia
Yes (1)
No (2)
Don´t know/ Unsure (3)
Hospital admission for Acute myocardial
ischaemia
Yes (1)
No (2)
Don´t know/ Unsure (3)
Date of event
Angina pectoris
Yes (1)
No (2)
Don´t know/ Unsure (3)
Hospital admission for Angina pectoris
Yes (1)
No (2)
Don´t know/ Unsure (3)
Stroke
Yes (1)
No (2)
Don´t know/ Unsure (3)
Hospital admission for stroke
Yes (1)
No (2)
Don´t know/ Unsure (3)
Date of event
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TIA (Transient ischaemic attack)
Yes (1)
No (2)
Don´t know/ Unsure (3)
Hospital admission for TIA
Yes (1)
No (2)
Don´t know/ Unsure (3)
Date of event
PAD (Peripheral artery disease)
Yes (1)
No (2)
Don´t know/ Unsure (3)
Hospital admission for PAD (Peripheral artery
disease)
Yes (1)
No (2)
Don´t know/ Unsure (3)
Date of event
How old were you when your vascular disease
was first diagnosed?
What is your nationality?
Nationality of the father
Nationality of the mother
What is your place of birth?
Place of birth of the father
Place of birth of the mother
What is your ethnicity?
Asian							 (1)
Black							 (2)
Caucasian						 (3)
Other, please specify (4)
Please specify other ethnicity
How many years have you spent in full-time
education? (99 = insufficient data)
yrs
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What is the highest level of education you have
completed?
No formal schooling (1)
Less than primary school	 (2)
Primary school completed (3)
Secondary school completed (4)
High school completed (5)
Collage/ University completed (6)
Post graduate degree (7)
Insufficient data (unknown) (8)
Prior to the index event or procedure were you:
Full time employed (1)
Part time employed (2)
Self employed (3)
Unemployed (4)
House person (5)
Full time education (6)
Retired (7)
Insufficient data (unknown) (8)
If retired
Age related (1)
Stroke disease related (2)
Other illness (3)
Personal choice (4)
Insufficient data (unknown) (5)
Now at least 6 months after the index event or
procedure, are you:
Full time employed (1)
Part time employed (2)
Self employed (3)
Unemployed (4)
House person (5)
Full time education (6)
Retired (7)
Insufficient data (unknown) (8)
If retired
Age related (1)
Stroke disease related (2)
Other illness (3)
Personal choice (4)
Insufficient data (unknown) (5)
Whose care are you currently (in the last three
months) under for your stroke condition?
Cardiologist (1)
Physician (2)
General practitioner (3)
Neurologist (4)
Neurosurgeon (5)
Occupational health physician (6)
Other, please specify (7)
No one (8)
Does not remember (9)
Whose care are you currently (in the last three
months) under for your stroke condition? Please
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specify other
Medical history since discharge from
hospital
Did you have any of the following, since the
hospital discharge from the index event or
procedure which included you in the survey?
Yes (1)
No (2)
Don´t know/ Unsure (3)
Carotid artery surgery (carotid endartectomy)
Yes (1)
No (2)
Don´t know/ Unsure (3)
Hospital admission for Carotid artery surgery
(carotid endartectomy)?
Yes (1)
No (2)
Don´t know/ Unsure (3)
Date of event
Percutaneous transluminal angioplasty of carotid
artery
Yes (1)
No (2)
Don´t know/ Unsure (3)
Hospital admission for Percutaneous transluminal
angioplasty of carotid artery
Yes (1)
No (2)
Don´t know/ Unsure (3)
Date of event
Acute myocardial infarction
Yes (1)
No (2)
Don´t know/ Unsure (3)
Hospital admission for acute MI
Yes (1)
No (2)
Don´t know/ Unsure (3)
Date of event
Acute myocardial ischaemia
Yes (1)
No (2)
Don´t know/ Unsure (3)
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Hospital admission for Acute myocardial
ischaemia
Yes (1)
No (2)
Don´t know/ Unsure (3)
Date of event
Angina pectoris
Yes (1)
No (2)
Don´t know/ Unsure (3)
Hospital admission for Angina pectoris
Yes (1)
No (2)
Don´t know/ Unsure (3)
Stroke
Yes (1)
No (2)
Don´t know/ Unsure (3)
Hospital admission for stroke
Yes (1)
No (2)
Don´t know/ Unsure (3)
Date of event
TIA (Transient ischaemic attack)
Yes (1)
No (2)
Don´t know/ Unsure (3)
Hospital admission for TIA
Yes (1)
No (2)
Don´t know/ Unsure (3)
Date of event
PAD (Peripheral artery disease)
Yes (1)
No (2)
Don´t know/ Unsure (3)
Hospital admission for PAD (Peripheral artery
disease)
Yes (1)
No (2)
Don´t know/ Unsure (3)
Date of event
Living Situation
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What was your living situation prior to the index
event which included you in the survey?
Private household, living alone 			 (1)
Private household, living not alone			 (2)
Sheltered home					 (3)
Residential home					 (4)
Nursing home						 (5)
Unknown (6)
Did you require help from another person for
everyday activities (such as making a cup of tea)
prior to the index event which included you in the
survey?
Yes (1)
No (2)
Unknown (3)
What is your actual living situation after the index
event?
Private household, living alone 			 (1)
Private household, living not alone			 (2)
Sheltered home					 (3)
Residential home					 (4)
Nursing home						 (5)
Unknown (6)
In the last two weeks, have you required help
from another person for everyday activities (such
as making a cup of tea)?
Yes (1)
No (2)
Unknown (3)
If Yes, who did you get the most help from?
Home help or carer					 (1)
Spouse/ partner					 (2)
Daughter						 (3)
Son							 (4)
Other relative					 (5)
Friend						 (6)
Other professional care (paid/unpaid)			 (7)
Other (please specify) (8)
Don’t know (9)
Please specify other help
Disability (Barthel Index)
In the bath or shower
do you manage on your own? (1)
need help getting in and out? (2)
need other help? (3)
need to be washed in bed? (4)
never have a bath or shower? (5)
Can you climb stairs
without anyone’s help? (1)
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with someone encouraging you? (2)
with someone carrying your frame?  (3)
with physical help? (4)
not at all? (5)
Do you get dressed
without any help? (1)
just with help with buttons? (2)
with someone helping you most of the
time? (3)
Do you walk indoors
without anyone’s help or with a frame?
(1)
with one person watching over you? (2)
with one person helping you? (3)
with more than one person helping? (4)
not at all?  (5)
or do you use a wheelchair
independently (eg. round corners) ? (6)
Do you move from bed to chair
on your own? (1)
with a little help from one person? (2)
with a lot of help from one or more
people? (3)
not at all? (4)
Do you eat food
without any help? (1)
with some help (such as cutting food or
spreading butter)? (2)
with more help? (3)
Do you use the toilet or commode
without anyone’s help? (1)
with some help, but can do something ?
(2)
with quite a lot of help? (3)
Do you brush your hair and teeth, wash your face
and shave
without help? (1)
with help? (2)
Do you lose control of your bladder?
never (1)
less than once a week (2)
less than once a day (3)
more often (4)
or do you have a catheter managed for
you? (5)
Do you lose control of your bowel motions?
never  (1)
occasional accident (2)
all the time (3)
Neurological impairment at the time of
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interview
At time of interview do you have any speech
problems?
Yes (1)
No (2)
Unknown (3)
At time of interview do you have any weakness
affecting face?
Yes (1)
No (2)
Unknown (3)
At time of interview do you have any weakness
affecting arm/hand
Yes (1)
No (2)
Unknown (3)
At time of interview do you have any weakness
affecting leg/foot
Yes (1)
No (2)
Unknown (3)
At time of interview do you have any visual
problems?
Yes (1)
No (2)
Unknown (3)
Rehabilitation
Did you have any physiotherapy since the
discharge from hospital for the index event which
included you in the survey?
Yes (1)
No (2)
Unknown (3)
If Yes, did you have any physiotherapy in the last
month?
Yes (1)
No (2)
Unknown (3)
Did you have any speech therapy since the
discharge from hospital for the index event which
included you in the survey?
Yes (1)
No (2)
Unknown (3)
If Yes, did you have any speech therapy in the
last month?
Yes (1)
No (2)
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Unknown (3)
Did you have any occupational therapy since the
discharge from hospital for the index event which
included you in the survey?
Yes (1)
No (2)
Unknown (3)
If Yes, did  you have any occupational therapy in
the last month?
Yes (1)
No (2)
Unknown (3)
Smoking
Have you ever smoked?
Yes
No
For how many years in total have you smoked?
yrs
Were you smoking in the month prior to the
hospital admission for the	
index event or procedure?
Yes
No
Do you smoke now?
Yes
No
If smoking now, what type of tobacco-product?
Cigarettes (1)
Pipe (2)
Cigars (3)
How many cigarettes per day?
How much pipe tobacco in g/week?
How many cigars per day?
If not smoking now, did you quit within the last 6
months
Yes
No
If not smoking now, did you quit more than 6
months ago?
Yes
No
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If not smoking now, at what age did you stop? (99
= unknown)
yrs
If smoking now In the last year, how many times
have you quit smoking for at least 24 hours?
If smoking now: Are you seriously thinking of
quitting smoking?
Yes, within the next 30 days (1)
Yes, within the next 6 months (2)
No, not thinking of quitting (3)
Don’t know/ Unsure (4)
In the daytime or at night, do you frequently stay,
at work , in rooms where people smoke?
Yes
No
In the daytime or at night, do you frequently stay,
at home , in rooms where people smoke?
Yes
No
In the daytime or at night, do you frequently stay,
at other locations , in rooms where people
smoke?
Yes
No
Diet/Body weight
Have you been told SINCE the index event or
procedure by a health care professional that your
diet is unhealthy?
Yes (1)
No (2)
Don´t know/ Unsure (3)
Have you ever been told by a health care
professional that you are overweight?
Yes (1)
No (2)
Don´t know/ Unsure (3)
In the past month, have you been actively trying
to lose weight?
Yes (1)
No (2)
Don´t know/ Unsure (3)
In the past month, have you been actively trying
to keep from gaining weight?
Yes (1)
No (2)
Don´t know/ Unsure (3)
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Are you seriously considering trying to lose
weight to reach your goal in the next month?
Yes (1)
No (2)
Don´t know/ Unsure (3)
Are you seriously considering trying to lose
weight to reach your goal in the next six months?
Yes (1)
No (2)
Don´t know/ Unsure (3)
Have you maintained your desired weight for
more than 6 months?
Yes (1)
No (2)
Don´t know/ Unsure (3)
Physical activity
Are you limited in your physical activities in any
way?
Yes (1)
No (2)
Don´t know/ Unsure (3)
Which of the following four best describes your
level of activity outside work?
No physical activity weekly (1)
Only light physical activity in most weeks
(2)
Vigorous physical activity at least 20
minutes once or twice a week (3)
Vigorous physical activity for at least 20
minutes three or more times per week
(4)
Don’t know/ Unsure (5)
Do you exercise regularly according to that (in
description) outlined definition?
Yes, I have been for MORE than 6
months (1)
Yes, I have been for LESS than 6 months
(2)
No, but I intend to in the next 30 days (3)
No, but I intend to in the next 6 months
(4)
No, and I do NOT intend to in the next 6
months  (5)
Don’t know/ Unsure (6)
Blood pressure,Cholesterol and Diabetes
Have you ever been told by a doctor (or other
health professional) that you have high blood
pressure?
Yes (1)
No (2)
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Don´t know/ Unsure (3)
Are you taking (in the last two weeks) drugs
specifically prescribed to lower your blood
pressure ?
Yes (1)
No (2)
Don´t know/ Unsure (3)
Are you on a special diet prescribed by a doctor
(or other health professional) to lower your blood
pressure level?
Yes (1)
No (2)
Don´t know/ Unsure (3)
If hypertensive, do you monitor your blood
pressure yourself?
Yes (1)
No (2)
Don´t know/ Unsure (3)
Have you ever been told by a doctor (or other
health professional) that you have a high blood
cholesterol?
Yes (1)
No (2)
Don´t know/ Unsure (3)
Are you on a special diet prescribed by a doctor
(or other health professional) to lower your blood
cholesterol level?
Yes (1)
No (2)
Don´t know/ Unsure (3)
Have you ever been told by a doctor (or other
health professional) that you have diabetes?
Yes (1)
No (2)
Don´t know/ Unsure (3)
If you have been told you have diabetes, how is it
currently being treated?
Diet only (1)
Oral anti-diabetic drugs (2)
Insulin (3)
Don’t know/Unsure (4)
If diabetic, do you monitor your blood glucose
yourself?
Yes (1)
No (2)
Don´t know/ Unsure (3)
If you monitor your blood glucose yourself,how?
Blood (1)
Urine (2)
Unkown (3)
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If you monitor your blood glucose yourself,how
many times per day?
If you are on insulin, have you ever had education
regarding using it?
Yes (1)
No (2)
Don´t know/ Unsure (3)
Risk factor awareness and targets
Was your blood pressure ever measured?
Yes (1)
No (2)
Don´t know/ Unsure (3)
Was your total cholesterol ever measured?
Yes (1)
No (2)
Don´t know/ Unsure (3)
Was your blood glucose ever measured?
Yes (1)
No (2)
Don´t know/ Unsure (3)
Was your HbA1c (in diabetics) ever measured?
Yes (1)
No (2)
Don´t know/ Unsure (3)
Are you aware of your latest weight?
Yes (1)
No (2)
Don´t know/ Unsure (3)
Current Body weight
kg
Are you aware of your target weight?
Yes (1)
No (2)
Don´t know/ Unsure (3)
What is your target weight?
kg
Are you aware of your blood pressure level?
Yes (1)
No (2)
Don´t know/ Unsure (3)
Current blood pressure
mmHg
Are you aware of your blood pressure target?
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Yes (1)
No (2)
Don´t know/ Unsure (3)
What is your blood pressure target?
mmHg
Are you aware of your total cholesterol level?
Yes (1)
No (2)
Don´t know/ Unsure (3)
Total cholesterol measurement
mmol/l
Are you aware of your total cholesterol target?
Yes (1)
No (2)
Don´t know/ Unsure (3)
What is your total cholesterol target?
mmol/l
Are you aware of your latest blood glucose level?
Yes (1)
No (2)
Don´t know/ Unsure (3)
Blood glucose measurement
mmol/l
Are you aware of your blood glucose target?
Yes (1)
No (2)
Don´t know/ Unsure (3)
What is your blood glucose target?
mmol/l
Are you aware of your latest HbA1c level?
Yes (1)
No (2)
Don´t know/ Unsure (3)
HbA1c measurement
%
Are you aware of your HbA1c target?
Yes (1)
No (2)
Don´t know/ Unsure (3)
What is your HbA1c target?
%
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Lifestyle changes
Over the last 3 years, were you offered any
personal advice by a doctor or other health
professional on stopping smoking?
Yes since the index event or procedure
(1)
Yes since before the index event or
procedure  (2)
No  (3)
Unsure/ Don’t know (4)
What type of advice did you receive for stopping
smoking?
verbal (1)
written materials (2)
referral to smoking cessation clinic/
course (3)
Nicotine replacement therapy (4)
Bupropion (5)
other (6)
Over the last 3 years, were you offered any
personal advice by a doctor or other health
professional on a healthy diet?
Yes since the index event or procedure
(1)
Yes since before the index event or
procedure  (2)
No  (3)
Unsure/ Don’t know (4)
What type of advice did you receive concerning a
healthy diet?
reduction of salt intake (1)
reduction of fat intake (2)
changing type of fat intake (3)
reduction of calorie intake (4)
eating more fruits and vegetables (5)
eating more fish (6)
eating more oily fish (7)
reducing sugar (8)
reducing excessive alcohol intake (9)
Over the last 3 years, were you offered any
personal advice by a doctor or other health
professional on weight loss?
Yes since the index event or procedure
(1)
Yes since before the index event or
procedure  (2)
No  (3)
Unsure/ Don’t know (4)
What type of advice did you receive concerning
weight loss?
following dietary recommendations (1)
participating in regular physical activity
(2)
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weight reducing drugs (3)
other (please specify) (4)
What type of advice did you receive concerning
weight loss?
following dietary recommendations (1)
participating in regular physical activity
(2)
weight reducing drugs (3)
other (please specify) (4)
Please specify other type of advice you received
concerning weight loss?
Over the last 3 years, were you offered any
personal advice by a doctor or other health
professional on increase of physical activity?
Yes since the index event or procedure
(1)
Yes since before the index event or
procedure  (2)
No  (3)
Unsure/ Don’t know (4)
What type of advice did you receive concerning
increase of physical activity?
following specific exercise advice from a
health or exercise professional (1)
attending a fitness club or leisure centre
(2)
trying to do more general everyday
physical activities (3)
joining a community walking group (4)
other (5)
Over the last 3 years, did to try to stop smoking to
reduce your risk of heart disease?
Yes (1)
No (2)
Don´t know/ Unsure (3)
Over the last 3 years, which steps did you take to
stop smoking to reduce your risk of heart
disease?
abstinence (1)
reduction (2)
smoking cessation clinic (3)
Nicotine replacement therapy (4)
Bupropion (5)
other (6)
Over the last 3 years, did you try to keep a
healthy diet to reduce your risk of heart disease?
Yes (1)
No (2)
Don´t know/ Unsure (3)
What steps did you take concerning a healthy
diet?
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reduction of salt intake (1)
reduction of fat intake (2)
changing type of fat intake (3)
reduction of calorie intake (4)
eating more fruits and vegetables (5)
eating more fish (6)
eating more oily fish (7)
reducing sugar (8)
reducing excessive alcohol intake (9)
Over the last 3 years, did you try to loose weight
to reduce your risk for heart disease?
Yes (1)
No (2)
Don´t know/ Unsure (3)
What steps did you take concerning weight loss?
following dietary recommendations (1)
participating in regular physical activity
(2)
weight reducing drugs (3)
other (4)
Over the last 3 years, did you try to increase your
physical activity to reduce your risk of heart
disease?
Yes (1)
No (2)
Don´t know/ Unsure (3)
What steps did you take to increase your physical
activity?
following specific exercise advice from a
health or exercise professional (1)
attending a fitness club or leisure centre
(2)
trying to do more general everyday
physical activities (3)
joining a community walking group (4)
other (5)
Over the last 3 years, have you received help
from any of the following professionals to achieve
your lifestyle and other risk factor targets?
Dietician (1)
Lipid specialist (10)
Diabetologist/endocrinologist (11)
Other   (please specify) (12)
Nurse (2)
Smoking cessation specialist (3)
Physiotherapist (4)
Exercise professional (5)
Hospital physician (6)
General practitioner or family doctor (7)
Cardiologist (8)
Hypertension specialist (9)
Please specify other health professional you
received help from
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Rehabilitation program
Were you advised to follow a specific prevention
or rehabilitation programme within 3 months of
discharge following the index event?
Yes (1)
No (2)
Don´t know/ Unsure (3)
If Yes, did you attend the prevention or
rehabilitation programme offered?
No, not at all (1)
Attended less than half of the sessions
(2)
Attended more than half of the sessions
(3)
Yes, fully (4)
If Yes, where was the prevention or rehabilitation
programme offered to you?
At specialized rehabilitation unit as
outpatient (1)
At specialized rehabilitation unit as
inpatient	 (2)
By a specialized therapist as outpatient
(3)
As inpatient and outpatient				 (4)
Other (please specify): (5)
Don’t know (6)
Please specify other
Medication
Is the patient on any medication?
Yes (1)
No (2)
Don´t know/ Unsure (3)
Aspirin or other anti-platelet drugs?
Yes (1)
No (2)
Don´t know/ Unsure (3)
Aspirin or other anti-platelet drugs: Generic name
Aspirin or other anti-platelet drugs: Total daily
dose
mg
Aspirin or other anti-platelet drugs?
Yes (1)
No (2)
Don´t know/ Unsure (3)
Aspirin or other anti-platelet drugs: Generic name
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Aspirin or other anti-platelet drugs: Total daily
dose
mg
Beta blockers
Yes (1)
No (2)
Don´t know/ Unsure (3)
Beta blockers:Generic name
Beta Blockers Total daily dose
mg
ACE inhibitors
Yes (1)
No (2)
Don´t know/ Unsure (3)
ACE inhibitors: Generic name
ACE inhibitors : Total daily dose
mg
Angiotensin II receptor antagonists
Yes (1)
No (2)
Don´t know/ Unsure (3)
Angiotensin II receptor antagonists: Generic
name
Angiotensin II receptor antagonists: Total daily
dose
mg
Calcium antagonists
Yes (1)
No (2)
Don´t know/ Unsure (3)
Calcium antagonists: Generic name
Calcium antagonists: Total daily dose
mg
If inhibitors
Yes (1)
No (2)
Don´t know/ Unsure (3)
If inhibitors: Generic name
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If inhibitors: Total daily dose
mg
Nitrates
Yes (1)
No (2)
Don´t know/ Unsure (3)
Nitrates: Generic name
Nitrates: Total daily dose
mg
Diuretics
Yes (1)
No (2)
Don´t know/ Unsure (3)
Diuretics: Generic name
Diuretics: Total daily dose
mg
Diuretics
Yes (1)
No (2)
Don´t know/ Unsure (3)
Diuretics: Generic name
Diuretics: Total daily dose
mg
Other anti-hypertensive drugs
Yes (1)
No (2)
Don´t know/ Unsure (3)
Other Anti-hypertensive drugs: Generic name
Other Anti-hypertensive drugs: Total daily dose
mg
Digitalis glycosides
Yes (1)
No (2)
Don´t know/ Unsure (3)
Digitalis glycosides: Generic name
Digitalis glycosides: Total daily dose
mg
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Antiarrhythmics
Yes (1)
No (2)
Don´t know/ Unsure (3)
Antiarrhythmics: Generic name
Antiarrhythmics:  Total daily dose
mg
Lipid lowering drugs: Statins
Yes (1)
No (2)
Don´t know/ Unsure (3)
Lipid lowering drugs (Statins): Generic name
Lipid lowering drugs (Statins): Total daily dose
mg
Lipid lowering drugs: Fibrates
Yes (1)
No (2)
Don´t know/ Unsure (3)
Lipid lowering drugs (Fibrates): Generic name
Lipid lowering drugs (Fibrates): Total daily dose
mg
Lipid lowering drugs: Nicotinic acid group
Yes (1)
No (2)
Don´t know/ Unsure (3)
Lipid lowering drugs (Nicotinic acid group):
Generic name
Lipid lowering drugs (Nicotinic acid group): Total
daily dose
mg
Lipid lowering drugs: Cholesterol absorption
inhibitors
Yes (1)
No (2)
Don´t know/ Unsure (3)
Lipid lowering drugs (Cholesterol absorption
inhibitors): Generic name
Lipid lowering drugs (Cholesterol absorption
inhibitors): Total daily dose
mg
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Lipid lowering drugs: Resins
Yes (1)
No (2)
Don´t know/ Unsure (3)
Lipid lowering drugs (Resins): Generic name
Lipid lowering drugs (Resins): Total daily dose
mg
Lipid lowering drugs: Other
Yes (1)
No (2)
Don´t know/ Unsure (3)
Lipid lowering drugs (Other): Generic name
Lipid lowering drugs (Other): Total daily dose
mg
Anti-diabetic drugs: Insulin
Yes (1)
No (2)
Don´t know/ Unsure (3)
Insulin: Generic name
Insulin: Total daily dose
mg
Anti-diabetic drugs: Insulin
Yes (1)
No (2)
Don´t know/ Unsure (3)
Insulin: Generic name
Insulin: Total daily dose
mg
Anti-diabetic drugs: oral
Yes (1)
No (2)
Don´t know/ Unsure (3)
Oral Antidiabetics: Generic name
Oral Antidiabetics: Total daily dose
mg
Anti-diabetic drugs: oral
Yes (1)
No (2)
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Don´t know/ Unsure (3)
Oral Antidiabetics: Generic name
Oral Antidiabetics: Total daily dose
mg
Anti-coagulants
Yes (1)
No (2)
Don´t know/ Unsure (3)
Anti-coagulants: Generic name
Anti-coagulants: Total daily dose
mg
Oral contraceptive pill
Yes (1)
No (2)
Don´t know/ Unsure (3)
Oral contraceptive pill: Generic name
Oral contraceptive pill: Total daily dose
mg
Hormone replacement therapy
Yes (1)
No (2)
Don´t know/ Unsure (3)
Hormone replacement therapy: Generic name
Hormone replacement therapy: Total daily dose
mg
Appetite suppressants or other antiobesity
Yes (1)
No (2)
Don´t know/ Unsure (3)
Appetite suppressants/other antiobesity: Generic
name
Appetite suppressants or other antiobesity: Total
daily dose
mg
Nicotine replacement therapy
Yes (1)
No (2)
Don´t know/ Unsure (3)
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Nicotine replacement therapy: Generic name
Nicotine replacement therapy: Total daily dose
mg
Nicotine replacement therapy
Chewing Gum (1)
Nasal spray (2)
Inhalator (3)
Patches (4)
Losenges (5)
Bupropion
Yes (1)
No (2)
Don´t know/ Unsure (3)
Bupropion: Generic name
Bupropion: Total daily dose
mg
Other medication
Yes (1)
No (2)
Don´t know/ Unsure (3)
Other medications: Generic name
Other medications: Total daily dose
mg
Is any of the medication prescribed a
combination of 2 drugs in one tablet?
Yes (1)
No (2)
Don´t know/Unsure (3)
If yes, please specify
Since the recruiting coronary event,  have you
altered the dosage of your prescribed
medication?
Never  (1)
Seldom (2)
Often (3)
Always (4)
Since the recruiting coronary event,  have you
missed taking the dosage of your prescribed
medication?
Never  (1)
Seldom (2)
Often (3)
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Always (4)
Physical measurements
Body height
cm
Body weight
kg
Waist circumference
cm
1st measurement of systolic blood pressure
mmHg
1st measurement of diastolic blood pressure
mmHg
2nd measurement of systolic blood pressure
mmHg
2nd measurement of diastolic blood pressure
mmHg
Heart rate
bpm
Carbon monoxide in breath
ppm
HAD scale: anxiety score
HAD scale: depression score
Evaluation of EQ-5D: Score 1
Evaluation of EQ-5D: Score 2
SF-12 Physical health summary measure
SF-12 Mental health summary measure
During the last 7 days, on how many days did you
do vigorous physical activities like heavy lifting,
digging, aerobics, or fast bicycling?
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No vigorous activity during the last 7 days - if yes,
skip to question 3
Yes
No
How much time did you usually spend doing
vigorous physical activities on one of those days?
In hours per day?
How much time did you usually spend doing
vigorous physical activities on one of those days?
In minutes per day?
The time I spend doing vigorous physical
activities on one of those days is unknown
Yes
No
During the last 7 days, on how many days did you
do moderate physical activities like carrying light
loads, bicycling at a regular pace, or doubles
tennis?  Do not include walking
No moderate activity during the last 7 days - if
yes, skip to question 5
Yes
No
How much time did you usually spend doing
moderate physical activities on one of those
days? In hours per day?
How much time did you usually spend doing
moderate physical activities on one of those
days? In minutes per day?
The time I spend doing moderate physical
activities on one of those days is unknown
Yes
No
During the last 7 days, on how many days did you
walk for at least 10 minutes at a time?
No walking activity during the last 7 days - if yes,
skip to question 7
Yes
No
How much time did you usually spend walking on
one of those days? In hours per day?
How much time did you usually spend walking on
one of those days? In minutes per day?
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The time I spend walking on one of those days is
unknown
Yes
No
During the last 7 days, how much time did you
spend sitting on a week day?
How much time did you usually spend sitting on a
weekday? In hours per day?
How much time did you spend sitting on a
weekday? In minutes per day?
The time I spend sitting on a weekday is
unknown
Yes
No
Blood sample
Has a venous blood sample been taken from the
patient ?
Yes
No
Has a venous blood sample been taken from the
patient ? If no, please state why not
Was the patient fasting before blood sampling ?
Yes
No
Hours of fast before blood sampling
Interview completed for this patient?
Yes
No
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Eligibility Congestive Heart Failure
NCT00652652
Evaluation of Combined Action Between Natrecor and
Furosemide on Kidney and Neurohormone Responses in
Chronic Heart Failure: A Phase-IV study704.351 / DSS;
ODM derived from:
https://clinicaltrials.gov/show/NCT00652652
All rights reserved. Please visit https://medical-data-
models.org/forms/16848
Eligibility Congestive Heart Failure
NCT00652652
Inclusion Criteria
chronic symptomatic nyha class ii or iii chf for at
least 90 days before the study*
Yes
No
left ventricular systolic dysfunction as evidenced
by left ventricular ejection fraction < 40%,
measured using contrast or radionuclide
ventriculography or by echocardiography, within
180 days of the study start*
Yes
No
serum potassium > 3.5 meq/l.*
Yes
No
chronic oral daily requirement of 80-240 mg of
furosemide for at least 7 days before the study
start*
Yes
No
receiving a stable medical regimen for chf for at
least 60 days before the study start, including
angiotensin converting enzyme inhibitors (acei)
or angiotensin receptor blockers (arbs), and/or
beta-blockers.*
Yes
No
Exclusion Criteria
clinical instability such that withholding diuretic
therapy would be unsafe*
Yes
No
significant renal impairment (e.g., creatinine
clearance < 45 ml/min by the cockcroft-gault
formula), or changing renal function during the 7
days before study start, or intrinsic renal disease*
Yes
No
systolic blood pressure (sbp) consistently < 90
mm hg*
Yes
No
1 / 2
myocardial infarction within 90 days of study
start, unstable angina within 14 days of study
start, or any clinical evidence of active myocardial
ischemia*
Yes
No
percutaneous coronary intervention or cardiac
surgery within 90 days of study start*
Yes
No
restrictive or obstructive cardiomyopathy,
constrictive pericarditis, pericardial tamponade,
other conditions in which cardiac output was
dependent on venous return, or for subjects
expected to have low filling pressures*
Yes
No
prior cardiac or renal allografts*
Yes
No
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Eligibility Congestive Heart Failure
NCT00652782
Effects of MK7418 on Diuresis and Renal Function in
Congestive Heart Failure Patients; ODM derived from:
https://clinicaltrials.gov/show/NCT00652782
All rights reserved. Please visit https://medical-data-
models.org/forms/16849
Eligibility Congestive Heart Failure
NCT00652782
Inclusion Criteria
be able to provide written informed consent,*
Yes
No
be a male or female at least 18 years of age,*
Yes
No
be hospitalized for fluid overload requiring iv
diuretic therapy*
Yes
No
history of use of diuretic therapy for chf (including
this admission),*
Yes
No
be admitted to the hospital within 36 hours of the
mandatory dose of iv furosemide 40 mg at
between 2000 and 2200 hour on day -1*
Yes
No
Exclusion Criteria
have had a myocardial infarction within 30 days
prior to day -1*
Yes
No
be pregnant or breast-feeding*
Yes
No
have received intravascular contrast material
within the preceding 14 days; or have acute
contrast nephropathy*
Yes
No
have had implantation of an automated implanted
cardiac defibrillator (aicd) or synchronization
device within the preceding 7 days*
Yes
No
currently require mechanical ventilation,
ultrafiltration, or hemodialysis,*
Yes
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No
have symptomatic ventricular tachycardia*
Yes
No
be admitted for heart transplant surgery or have
had a heart transplant,*
Yes
No
have any other concomitant life-threatening
disease,*
Yes
No
have participated in a clinical trial of an
investigational drug or device within 30 days
before randomization*
Yes
No
have a positive urine pregnancy test (for women
of child-bearing capacity)*
Yes
No
have an allergy to soybean oil and/or eggs*
Yes
No
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WHO-5
WHO (Five) Well-Being Index (1998 version)
http://www.who-5.org
Also called : WHO Five, WHO 5
All rights reserved. Please visit https://medical-data-
models.org/forms/16850
WHO (Five) Well-Being Index
ባለፉት ሁለት ሳምንታት
ደስተኛነትና መንፈሰ ጠንካራነት ይሰማኛል*
ምንም (0)
አንዳንድ ጊዜ (1)
ከግማሽ ጊዚያት በታች (2)
ከግማሽ ጊዚያት በላይ (3)
በብዛት (4)
ሁልጊዜ (5)
የተረጋጋ እና ዘና ያለ ስሜት ይሰማኛል*
ምንም (0)
አንዳንድ ጊዜ (1)
ከግማሽ ጊዚያት በታች (2)
ከግማሽ ጊዚያት በላይ (3)
በብዛት (4)
ሁልጊዜ (5)
ንቁ እና የሙሉነት ስሜት ይሰማኛል*
ምንም (0)
አንዳንድ ጊዜ (1)
ከግማሽ ጊዚያት በታች (2)
ከግማሽ ጊዚያት በላይ (3)
በብዛት (4)
ሁልጊዜ (5)
ምነቃዉ በአዲስና ባረፈ መንፈስ ነዉ*
ምንም (0)
አንዳንድ ጊዜ (1)
ከግማሽ ጊዚያት በታች (2)
ከግማሽ ጊዚያት በላይ (3)
በብዛት (4)
ሁልጊዜ (5)
ቀናቶቼ በምፈለጋቸዉ ነገሮች የተሞሉ ናቸዉ*
ምንም (0)
አንዳንድ ጊዜ (1)
ከግማሽ ጊዚያት በታች (2)
ከግማሽ ጊዚያት በላይ (3)
በብዛት (4)
ሁልጊዜ (5)
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Palliative and Hospice Care Tumor-specific
Therapies in Palliative Care
https://www.hope-clara.de/ 
The HOPE Hospice and Palliative Care Recording standard
documentation is used for documentation of palliative care
and as an instrument for quality assurance in pallatiave
wards, hospices and oncological wards as well as in
ambulatory services and palliative teams.
This questionnaire is designed to record tumor-specific
therapies.
All rights reserved. Please visit https://medical-data-
models.org/forms/16851
Palliative and Hospice Care Tumor-
specific Therapies in Palliative Care
Date
Date
Date
TT1. Type of therapy
Intravenous, cyclic or ccontinuous cytotoxic
chemotherapy
CodelistItem 904275 (fortgesetzt)
CodelistItem 904276 (neu)
Oral, cyclic or ccontinuous cytotoxic
chemotherapy
CodelistItem 904277 (fortgesetzt)
CodelistItem 904278 (neu)
Tumor-specific antibody
CodelistItem 904279 (fortgesetzt)
CodelistItem 904280 (neu)
Hormone therapy
CodelistItem 904281 (fortgesetzt)
CodelistItem 904282 (neu)
Oral tyrosine-kinase inhibitor or other targeted
therapy
CodelistItem 904283 (fortgesetzt)
CodelistItem 904284 (neu)
Radiotherapy
CodelistItem 904285 (fortgesetzt)
CodelistItem 904286 (neu)
Endoscopic intervention
CodelistItem 904287 (fortgesetzt)
CodelistItem 904288 (neu)
Nuclear medicine therapy
CodelistItem 904289 (fortgesetzt)
CodelistItem 904290 (neu)
Operative intervention
CodelistItem 904291 (fortgesetzt)
CodelistItem 904292 (neu)
Other procedure (please specify:)
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CodelistItem 904293 (fortgesetzt)
CodelistItem 904294 (neu)
Other procedure (please specify:)
TT2. Number of previous treatments
Chemotherapy
Hormone therapy
TT3. Indications
Reduction of tumor size to prevent symptoms
and/or for prolongation of survival time
Yes
No
Mainly to control symptoms
Yes
No
Neurological compression + brain pressure
Yes
No
Pain
Yes
No
Shortness of breath
Yes
No
Gastrointestinal compression
Yes
No
Other:
Yes
No
Other:
TT4. Agents/Regime/Modus
Agents/Regime/Modus
TT5. Medical indication assessed by
Medical indication assessed by
CodelistItem 904297 (Eigene
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Indikationsstellung)
CodelistItem 904296 (Eigene
Indikationsstellung nach Rücksprache
mit anderen Fachdisziplinen)
CodelistItem 904295 (Vorbehandelnde
Abteilungen (bitte spezifizieren): )
Pre-treating clinic:
TT6. Palliative prognostic index PPI in pre-
treatment/ starting the new indicated
tumor treatment
Palliative performance score
0P (PPS>60) (0P (PPS>60))
2.5P (PPS 20-50) (2.5P (PPS 20-50))
4.0P (1PPS 0-20) (4.0P (1PPS 0-20))
Oral intake
0P (normal) (0P (normal))
CodelistItem 904303 (1.0P (moderat
reduziert))
CodelistItem 904302 (2.5P (stark
reduziert))
Edema
CodelistItem 904305 (0P (nein))
CodelistItem 904304 (1.0P (ja))
Dyspnoea at rest
CodelistItem 904307 (0P (nein))
CodelistItem 904306 (3.5P (ja))
Delirium
CodelistItem 904309 (0P (nein))
CodelistItem 904308 (4.0P (ja))
PPI Score
TT7. Was proceding/start of tumor therapy
based on consensus in the palliative
team?
Was proceding/start of tumor therapy based on
consensus in the palliative team?
Clear divergence of opinion, difficult
decision making (1)
Rather consensus, but also votes against
(2)
Clear consensus (3)
Reasons:
TT8. What was the subjective success of
the tumor therapy?
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What was the subjective success of the tumor
therapy?
CodelistItem 904316 (gut)
CodelistItem 904314 (schlecht)
CodelistItem 904317 (sehr gut)
CodelistItem 904313 (sehr schlecht)
CodelistItem 904315 (zufriedenstellend)
TT9. Was the tumor therapy determined
early?
Was the tumor therapy determined early?
Yes
No
TT10. If yes, what were the reasons for
the discontinuation of tumor therapy?
If yes, what were the reasons for the
discontinuation of tumor therapy?
CodelistItem 904319 (Ineffizienz der
Therapie)
CodelistItem 904318 (Toxizitäten)
CodelistItem 904320 (Verschlechterung
des Allgemeinzustandes )
CodelistItem 904321 (Wunsch des
Patienten)
Type of toxicity/ side effects
TT11. Was discontinuation of tumor
therapy based on consensus in the
palliative team?
Was discontinuation of tumor therapy based on
consensus in the palliative team?
Clear divergence of opinion, difficult
decision making (1)
Rather consensus, but also votes against
(2)
Clear consensus (3)
Reasons:
TT12. Who completes this questionnaire?
TT12. Who completes this questionnaire?
CodelistItem 904327 (Andere
Mitarbeiter)
CodelistItem 904325 (Arzt/Ärztin)
CodelistItem 904326 (Pflegende)
Medical field
CodelistItem 904330 (Anästhesie)
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CodelistItem 904329
(Hämatologie/Onkologie)
CodelistItem 904328 (Innere Medizin)
CodelistItem 904331 (Sonstige)
Other:
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Eligibility Congestive Heart Failure
NCT00690521
A Comparison of Hydrochlorothiazide and Metolazone in
Combination With Furosemide in Congestive Heart Failure
Patients; ODM derived from:
https://clinicaltrials.gov/show/NCT00690521
All rights reserved. Please visit https://medical-data-
models.org/forms/16852
Eligibility Congestive Heart Failure
NCT00690521
Inclusion Criteria
age >18 years*
Yes
No
diagnosis of chronic congestive heart failure with
an ejection fraction ≤45%*
Yes
No
currently on a stable regimen of furosemide
consisting of a daily dose of at least 80 mg for at
least two weeks.*
Yes
No
patients receiving ace-inhibitors and/or beta-
blockers must be taking these medications for at
least two weeks in stable doses.*
Yes
No
Exclusion Criteria
renal dysfunction (serum creatinine >2 mg/dl or
creatinine clearance of <30 ml/min as calculated
by the cockroft and gault equation)*
Yes
No
hepatic dysfunction (ast and alt >3 times the
upper limit of the normal)*
Yes
No
hypokalemia (<4.0 mg/dl)*
Yes
No
concomitant treatment with any diuretic other
than furosemide (with the exception of
spironolactone).*
Yes
No
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Systemic lupus erythematosus EBMT
General Information Form
ODM form derived from 119pp EBMT SLE 16SLE please
refer to: http://www.ebmt.org/Contents/Data-
Management/Registrystructure/MED-
ABdatacollectionforms/Pages/MED-AB-data-collection-
forms.aspx
All rights reserved. Please visit https://medical-data-
models.org/forms/16853
Systemic lupus erythematosus
EBMT General Information Form
GENERAL INFORMATION
EBMT Centre Identification Code (CIC)
Name of the hospital
Unit
Name of contact person
Telephone number of contact person
Fax
E-Mail
Date of this report
Patient following national / international study /
trial
no (1)
yes (2)
unknown (3)
Name of study / trial
Patient
To be entered only if patient previously reported
Hospital Unique Patient Number or Code
First name(s)_surname(s)
Date of birth
Sex
Male (1)
Female (2)
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ABO Group
Rh factor
Absent (1)
Present  (2)
Not evaluated (3)
Disease
Date of diagnosis
Primary Disease Diagnosis: Check the disease
for which this transplant was performed
Acute Leukaemia (Acute Leukaemia)
Acute Lymphoblastic Leukaemia (ALL)
(Acute Lymphoblastic Leukaemia (ALL))
Acute Myelogenous Leukaemia (AML)
(Acute Myelogenous Leukaemia (AML))
Autoimmune disease (Autoimmune
disease)
Bone marrow failure including Aplastic
anaemia (Bone marrow failure including
Aplastic anaemia)
Chronic Leukaemia (Chronic Leukaemia)
Chronic Lymphocytic Leukaemia
(Chronic Lymphocytic Leukaemia)
Chronic Myeloid Leukaemia (CML)
(Chronic Myeloid Leukaemia (CML))
Haemoglobinopathy
(Haemoglobinopathiy)
Histiocytic disorders (Histiocytic
disorders)
Hodgkin´s Disease (Hodgkin´s Disease)
Inherited disorders (Inherited disorders)
Juvenile Idiopathic Arthritis (Juvenile
Idiopathic Arthritis)
Lymphoma (Lymphoma)
MD/ MPN (MD/ MPN)
MDS (MDS)
Metabolic disorders (Metabolic
disorders)
Multiple Sclerosis (Multiple Sclerosis)
Myelodysplastic syndromes
(Myelodysplastic syndromes)
Myeloma/ Plasma cell disorder
(Myeloma/ Plasma cell disorder)
Myeloproliferative neoplasm
(Myeloproliferative neoplasm)
Non Hodgkin (Non Hodgkin)
Other diagnosis (Other diagnosis)
Primary immune deficiencies (Primary
immune deficiencies)
Secondary Acute Leukaemia (do not use
if transformed from MDS/MPN)
(Secondary Acute Leukaemia (do not
use if transformed from MDS/MPN))
Solid Tumour (Solid Tumour)
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Systemic Lupus (Systemic Lupus)
Systemic Sclerosis (Systemic Sclerosis)
SYSTEMIC LUPUS ERITHEMATOSUS
(SLE)
Name of Referring Physician
Address
Fax
Email
INITIAL DIAGNOSIS
Has the information requested in this section
been submitted with a previous transplant
registration?
No: proceed with this section (No:
proceed with this section)
Yes: proceed to “Status of Disease at
mobilisation” on page 3 (Yes: proceed to
“Status of Disease at mobilisation” on
page 3)
DIAGNOSTIC CRITERIA FOR
SYSTEMIC LUPUS ERYTHEMATOSUS
Malar rash
No  (No )
Not evaluated  (Not evaluated )
Unknown (Unknown)
Yes (Yes)
Discoid rash
No  (No )
Not evaluated (Not evaluated)
Unknown (Unknown)
Yes  (Yes )
Photosensitivity
No (No)
Not evaluated (Not evaluated)
Unknown (Unknown)
Yes (Yes)
Oral ulcers
No (No)
Not evaluated (Not evaluated)
Unknown (Unknown)
Yes (Yes)
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Arthritis
No (No)
Not evaluated (Not evaluated)
Unknown (Unknown)
Yes (Yes)
Serositis
No  (No )
Not evaluated (Not evaluated)
Unknown (Unknown)
Yes (Yes)
Renal disorder
No  (No )
Not evaluated (Not evaluated)
Unknown (Unknown)
Yes (Yes)
Neurologic disorder
No (No)
Not evaluated (Not evaluated)
Unknown (Unknown)
Yes (Yes)
Hematologic disorder
No  (No )
Not evaluated (Not evaluated)
Unknown (Unknown)
Yes (Yes)
Immunologic
disorder
No  (No )
Not evaluated (Not evaluated)
Unknown (Unknown)
Yes (Yes)
Antinuclear
antibody
No  (No )
Not evaluated (Not evaluated)
Unknown (Unknown)
Yes (Yes)
FIRST LINE THERAPIES
Date started
Androgen
No  (No )
Unknown (Unknown)
Yes (Yes)
Anti-malarials
No  (No )
Unknown (Unknown)
Yes (Yes)
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Azathioprine
no (0)
yes (1)
unknown (9)
Corticosteroids
No (No)
Unknown (Unknown)
Yes (Yes)
Cyclophosphamide
No  (No )
Unknown (Unknown)
Yes (Yes)
Cyclosporine
No  (No )
Unknown (Unknown)
Yes (Yes)
Mycophenolate mofetil
No  (No )
Unknown (Unknown)
Yes (Yes)
Intravenous immune globulin (IVIG)
No  (No )
Unknown (Unknown)
Yes (Yes)
Other drugs (additional text)
No  (No )
Unknown (Unknown)
Yes (Yes)
Lymphocytopheresis
no (1)
yes (2)
unknown (3)
Plasmapheresis
no (1)
yes (2)
unknown (3)
Other drugs, please specify
Yes
No
DATE OF HSCT
Date of Transplant
TRANSPLANT TYPE
Allogeneic (1)
Autologous (2)
Autologous
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STATUS OF DISEASE AT MOBILISATION
Was lupus nephritis present at anytime prior to
mobilisation?
Yes (1)
No  (2)
Unknown (3)
Renal biopsy done?
Yes (1)
No (2)
Unknown (3)
if renal biopsy done, date of most recent renal
biopsy
Grade Histology
Normal (I Normal)
Mesangial (II Mesangial)
Focal proliferative (III Focal proliferative)
Diffuse proliferative (IV Diffuse
proliferative)
Other (Other)
Membranous (V Membranous)
Grade Histology: if other, please specify
SLEDAI (Systemic Lupus Erythematosus
Disease Activity Index) score
Seizures
No  (No )
Not evaluated (Not evaluated)
Unknown (Unknown)
Yes  (Yes )
Psychosis
Yes (1)
No (2)
Not evaluated (3)
Unknown (4)
Organic brain syndrome
Yes (1)
No (2)
Not evaluated (3)
Unknown (4)
Visual disturbance
Yes (1)
No (2)
Not evaluated (3)
Unknown (4)
Cranial nerve disorder
No  (No )
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Not evaluated (Not evaluated)
Unknown (Unknown)
Yes (Yes)
Lupus headache
Yes (1)
No  (2)
Not evaluated (3)
Unknown (4)
CVA
Yes (1)
No (2)
Not evaluated (3)
Unknown (4)
Vasculitis
Yes (1)
No (2)
Not evaluated (3)
Unknown (4)
Arthritis
Yes (1)
No (2)
Not evaluated (3)
Unknown (4)
Myositis
Yes (1)
No (2)
Not evaluated (3)
Unknown (4)
Urinary casts
Yes (1)
No  (2)
Not evaluated (3)
Unknown (4)
Hematuria
Yes (1)
No  (2)
Not evaluated (3)
Unknown (4)
Proteinuria
Yes (1)
No (2)
Not evaluated (3)
Unknown (4)
Pyuria
Yes (1)
No (2)
Not evaluated (3)
Unknown (4)
New rash
Yes (1)
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No (2)
Not evaluated (3)
Unknown (4)
Alopecia
Yes (1)
No (2)
Not evaluated (3)
Unknown (4)
Mucosal ulcers
Yes (1)
No (2)
Not evaluated (3)
Unknown (4)
Pleurisy
Yes (1)
No (2)
Not evaluated (3)
Unknown (4)
Pericarditis
Yes (1)
No  (2)
Not evaluated (3)
Unknown (4)
Low complement
Yes (1)
No  (2)
Not evaluated (3)
Unknown (4)
Increased DNA
binding
Yes (1)
No  (2)
Not evaluated (3)
Unknown (4)
Fever >38°C. Exclude infectious cause
Yes (1)
No  (2)
Not evaluated (3)
Unknown (4)
Thrombocytopenia
Yes (1)
No  (2)
Not evaluated (3)
Unknown (4)
Leukopenia
Yes (1)
No (2)
Not evaluated (3)
Unknown (4)
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LABORATORY VALUES
Haemoglobin
g/dL
Erythrocyte Sedimentation Rate
mm/hr
Erythrocyte sedimentation rate
Not evaluated (1)
Unknown (2)
Platelets
x10^9 /l
WBC
x10^9/l
Serum creatinine
Creatinine Clearance
mL/min
Total urinary protein excretion (mg/24 h)
CH50 Complement reduced
No (1)
Yes  (2)
Not evaluated  (3)
Unknown (4)
Complement component C3 reduced
No (1)
Yes  (2)
Not evaluated  (3)
Unknown (4)
Antibodies studied
No (No)
Unknown (Unknown)
Yes (Yes)
anti-dsDNA: Antibodies studied, if yes
Normal  (1)
Elevated  (2)
Not evaluated  (3)
Unknown (4)
anti-cardiolipin IgG
Normal  (1)
Elevated  (2)
Not evaluated  (3)
Unknown (4)
anti-cardiolipin IgM
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Normal  (1)
Elevated  (2)
Not evaluated  (3)
Unknown (4)
antinuclear antibody (ANA) test
Normal  (1)
Elevated  (2)
Not evaluated  (3)
Unknown (4)
anti-Sm
Elevated  (Elevated )
Normal  (Normal )
Not evaluated  (Not evaluated )
Unknown (Unknown)
anti-SSA (anti-Ro)
Elevated  (Elevated )
Normal  (Normal )
Not evaluated  (Not evaluated )
Unknown (Unknown)
anti-SSB (anti-La)
Elevated  (Elevated )
Normal  (Normal )
Not evaluated  (Not evaluated )
Unknown (Unknown)
lupus-anticoagulant
Elevated  (Elevated )
Normal  (Normal )
Not evaluated  (Not evaluated )
Unknown (Unknown)
PATIENT’S SELF ASSESSMENT PRIOR
TO MOBILISATION
SF-36 Health Survey completed
No (1)
Yes (2)
Unknown (3)
Physical Functioning
Role Functioning-Physical
Role Functioning-Emotional
Social Functioning
Bodily Pain
Mental Health
10 / 12
Systemic lupus erythematosus EBMT General Information Form
Vitality
General Health
HEALTH ASSESSMENT
QUESTIONNAIRE (HAQ)
Did the patient complete a Health Assessment
Questionnaire (HAQ)?
No (1)
Yes (2)
Unknown (3)
Patient’s score
Worst possible score
Best possible score
STATUS OF DISEASE AT HSCT
Was lupus nephritis present at anytime prior to
HSCT?
No  (No )
Unknown (Unknown)
Yes (Yes)
if yes, date of most recent renal biopsy
Grade Histology
I Normal (I Normal)
II Mesangial (II Mesangial)
III Focal proliferative (III Focal
proliferative)
IV Diffuse proliferative (IV Diffuse
proliferative)
Other, (Other,)
V Membranous (V Membranous)
Renal biopsy done?
No (No)
Unknown (Unknown)
Yes (Yes)
ADDITIONAL TREATMENT POST-HSCT
ADDITIONAL DISEASE TREATMENT
Yes
No
11 / 12
Systemic lupus erythematosus EBMT General Information Form
FORMS TO BE FILLED IN
TYPE OF TRANSPLANT
AUTOgraft, proceed to Autograft form (1)
ALLOgraft or Syngeneic graft, proceed to
Allograft form (2)
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Eligibility Congestive Heart Failure
NCT01480921
Hospital Versus Home Based Exercise in Patients With
Chronic Stable Heart Failure; ODM derived from:
https://clinicaltrials.gov/show/NCT01480921
All rights reserved. Please visit https://medical-data-
models.org/forms/16854
Eligibility Congestive Heart Failure
NCT01480921
Inclusion Criteria
chronic stable heart failure*
Yes
No
nyha class i, ii or iii*
Yes
No
willing and able to regularly attend a supervised
exercise program*
Yes
No
provision of written, informed consent*
Yes
No
Exclusion Criteria
unstable angina in the last month*
Yes
No
recent acute mi (last 3 months) which
precipitated heart failure*
Yes
No
hospitalized for heart failure in past month*
Yes
No
severe chronic pulmonary disease (fev1 <40%)*
Yes
No
uncontrolled hypertension (b/p >140/90)*
Yes
No
orthopedic, neurological or psychiatric illness
precluding participation in exercise*
Yes
No
heart failure that is amenable to
revascularization, which is planned in the near
future*
Yes
No
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nyha class iv*
Yes
No
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Liver Abnormality QTZ-EC-0004 ELEVATE
NCT01713426
QUTENZA™ versus Pregabalin in Subjects with Peripheral
Neuropathic Pain: an Open-label, Randomized, Multicenter,
Non-inferiority Efficacy and Tolerability Study
Medicine or Vaccine (generic name)
capsaicin
Sponsor Identification Number
QTZ-EC-0004
Trial Registry Identification Number(#'s)
NCT01713426
EudraCT Number: 2011-005872-41
All rights reserved. Please visit https://medical-data-
models.org/forms/16855
Liver Abnormality QTZ-EC-0004
ELEVATE  NCT01713426
Date of Visit
Was this visit performed?
(If No, then all other forms with the Form Not
Done field in this visit will be marked not done.)
Done (Done)
Not Done (Not Done)
If Yes, please provide the Date of Visit.
dd/MMM/yyyy
Unscheduled Event: Liver Abnormality
Form Not Done
Done (Done)
Not Done (Not Done)
Substance Use - Alcohol History
Yes
No
Substance Use - Drug Abuse
Yes
No
Liver imaging
Yes
No
Serology - Liver Abnormality Assessment
Yes
No
Biochemistry - Liver Abnormality Assessment
Yes
No
Coagulation - Liver Abnormality Assessment
Yes
No
Study Drug Interruption
Yes
No
Liver Abnormality Investigator Comments
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Yes
No
Substance Use - Alcohol History
Form Not Done
Done (Done)
Not Done (Not Done)
State if Never Used Alcohol, Current Alcohol
User, or Former Alcohol User
Current (Current)
Former (Former)
Never (Never)
Substance Use - Drug Abuse
Form Not Done
Done (Done)
Not Done (Not Done)
State if Never Abused Drugs, Current Drug User,
or Former Drug User
Current (Current)
Former (Former)
Never (Never)
Liver Imaging
Form Not Done
Done (Done)
Not Done (Not Done)
Method
CT Scan (CT Scan)
Ultrasound (Ultrasound)
Date Performed
dd/MMM/yyyy
Time performed
(00:00 - 23:59)
Result
Abnormal - clinically significant
(Abnormal - clinically significant)
Abnormal - not clinically significant
(Abnormal - not clinically significant)
Normal (Normal)
If abnormal, please specify diagnosis or describe
abnormality:
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Serology - Liver Abnormality Assessment
Form Not Done
Done  (Done )
Not Done (Not Done)
LAB Test: Hepatitis B Surface Antigen
Done (Done)
Not Done (Not Done)
Date of Sample Taken
dd/MMM/yyyy
Result
dd/MMM/yyyy
Negative (Negative)
Positive (Positive)
LAB Test: Hepatitis B Surface Antibody
Done (Done)
Not Done (Not Done)
Date of Sample Taken
dd/MMM/yyyy
Result
Negative (Negative)
Positive (Positive)
LAB Test: Hepatitis B Core Antigen
Done (Done)
Not Done (Not Done)
Date of Sample Taken
dd/MMM/yyyy
Result
Negative (Negative)
Positive (Positive)
LAB Test: Hepatitis B Core Antibody
Done  (Done )
Not Done (Not Done)
Date of Sample Taken
dd/MMM/yyyy
Result
Negative (Negative)
Positive (Positive)
LAB Test: Hepatitis A Antibody IgM
Done (Done)
Not Done (Not Done)
Date of Sample Taken
dd/MMM/yyyy
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Result
Negative  (Negative )
Positive (Positive)
LAB Test: Hepatitis A Antibody IgG
Done (Done)
Not Done (Not Done)
Date of Sample Taken
dd/MMM/yyyy
Result
Negative  (Negative )
Positive (Positive)
LAB Test: HCV Antibody
Done (Done)
Not Done (Not Done)
Date Sample taken
dd/MMM/yyyy
Result
Negative (Negative)
Positive (Positive)
LAB Test: Cytomegalovirus
Done (Done)
Not Done (Not Done)
Date of Sample Taken
dd/MMM/yyyy
Result
Negative (Negative)
Positive (Positive)
LAB Test: Epstein-Barr-Virus IgM
Done (Done)
Not Done (Not Done)
Date of Sample Taken
dd/MMM/yyyy
Result
Negative (Negative)
Positive (Positive)
LAB Test: Epstein-Barr-Virus Antibody IgG
Done (Done)
Not Done (Not Done)
Date of Sample Taken
dd/MMM/yyyy
Result
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Negative (Negative)
Positive (Positive)
Biochemistry - Liver Abnormality
Form Not Done
Done (Done)
Not Done (Not Done)
Lab Name
Lab City, State/ Country
Date of Sample Taken
dd/MMM/yyyy
Alkaline Phosphatase
U/L
Alkaline Phosphatase
U/L
ALT/ SGPT
U/L
ALT/ SGPT Upper Limit
U/L
AST/SGOT
U/L
AST/SGOT Upper Limit
U/L
Total Bilirubin
Total Bilirubin: Unit
mg/dL (mg/dL)
umol/L (umol/L)
Total Bilirubin Upper Limit
Total Bilirubin: Upper Limit Unit
mg/dL (mg/dL)
umol/L (umol/L)
Coagulation - Liver Abnormality
Form Not Done
Done (Done)
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Not Done (Not Done)
Lab Name
Lab City, State/ Country
Date of Sample Taken
dd/MMM/yyyy
Prothrombin Time Intl. Normalized Ratio
Prothrombin Time Intl. Normalized Ratio Upper
Limit
Study Drug Interruption
Form Not Done
(Form Not Done should only be marked for
subjects that are "RANDOMIZED/REGISTERED
BUT NEVER RECEIVED/DISPENSED STUDY
DRUG" and if this form was added in error.)
Done (Done)
Not Done (Not Done)
Was study drug interrupted (and re-started) due
to Liver Abnormalities?
Yes
No
If Yes, please add a log line to record each date
study medication dosing was missed.
dd/MMM/yyyy
Comments
Form Not Done
(Comments must be accompanied by source
documentation)
Done (Done)
Not Done (Not Done)
Date of Comment
dd/MMM/yyyy
Liver Abnormality Investigator Comments
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Cover Page QTZ-EC-0004 ELEVATE
NCT01713426
QUTENZA™ versus Pregabalin in Subjects with Peripheral
Neuropathic Pain: an Open-label, Randomized, Multicenter,
Non-inferiority Efficacy and Tolerability Study
Medicine or Vaccine (generic name)
capsaicin
Sponsor Identification Number
QTZ-EC-0004
Trial Registry Identification Number(#'s)
NCT01713426
EudraCT Number: 2011-005872-41
All rights reserved. Please visit https://medical-data-
models.org/forms/16856
Cover Page QTZ-EC-0004 ELEVATE
NCT01713426
Patient Information
Subject ID
Subject Initials
Provide the Protocol Version/Amendment
Number the subject was enrolled under.
Enter 0 for subjects that enrolled under the
original protocol.
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EUROASPIRE III - Peripheral arterial occlusive
disease Patient Interview Questionnaire
Provided by Prof. Keil Source: Kotseva K, Wood D, De
Backer G, De Bacquer D, Pyörälä K, Keil U; EUROASPIRE
Study Group. Cardiovascular prevention guidelines in daily
practice: a comparison of EUROASPIRE I, II, and III
surveys in eight European countries. Lancet. 2009 Mar
14;373(9667):929-40. doi: 10.1016/S0140-6736(09)60330-
5. PubMed PMID: 19286092
All rights reserved. Please visit https://medical-data-
models.org/forms/16858
Peripheral arterial occlusive disease
Patient Interview Questionnaire
Demographic Information
Patient ID
Date of interview
How many years have you spent in full-time
education? (99 = insufficient data)
yrs
What is the highest level of education you have
completed?
No formal schooling (1)
Less than primary school	 (2)
Primary school completed (3)
Secondary school completed (4)
High school completed (5)
Collage/ University completed (6)
Post graduate degree (7)
Insufficient data (unknown) (8)
Prior to the diagnosis of peripheral artery
occlusive disease were you:
Full time employed (1)
Part time employed (2)
Self employed (3)
Unemployed (4)
House person (5)
Full time education (6)
Retired (7)
Insufficient data (unknown) (8)
If retired
Age related (1)
Heart disease related (2)
Other illness (3)
Personal choice (4)
Insufficient data (unknown) (5)
Now at least 6 months after the diagnosis of
peripheral artery occlusive disease, are you:
Full time employed (1)
Part time employed (2)
Self employed (3)
Unemployed (4)
House person (5)
Full time education (6)
Retired (7)
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Insufficient data (unknown) (8)
If retired
Age related (1)
Heart disease related (2)
Other illness (3)
Personal choice (4)
Insufficient data (unknown) (5)
Smoking
Have you ever smoked?
Yes
No
For how many years in total have you smoked?
yrs
Were you smoking in the month prior to the
diagnosis of your peripheral artery occlusive
disease?
Yes
No
Do you smoke now?
Yes
No
If smoking now, what type of tobacco-product?
Cigarettes (1)
Pipe (2)
Cigars (3)
How many cigarettes per day?
How much pipe tobacco in g/week?
How many cigars per day?
If not smoking now, did you quit within the last 6
months
Yes
No
If not smoking now, did you quit more than 6
months ago?
Yes
No
If not smoking now, at what age did you stop? (99
= unknown)
yrs
If smoking now In the last year, how many times
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Questionnaire
have you quit smoking for at least 24 hours?
If smoking now: Are you seriously thinking of
quitting smoking?
Yes, within the next 30 days (1)
Yes, within the next 6 months (2)
No, not thinking of quitting (3)
Don’t know/ Unsure (4)
Risk factor awareness and targets
Was your blood pressure measured since
discharge from hospital or since last contact with
our outpatient clinic?
Yes (1)
No (2)
Don´t know/ Unsure (3)
Was your total cholesterol measured since
discharge from hospital or since last contact with
our outpatient clinic?
Yes (1)
No (2)
Don´t know/ Unsure (3)
Was your blood glucose measured since
discharge from hospital or since last contact with
our outpatient clinic?
Yes (1)
No (2)
Don´t know/ Unsure (3)
Was your HbA1c (in diabetics) measured since
discharge from hospital or since last contact with
our outpatient clinic?
Yes (1)
No (2)
Don´t know/ Unsure (3)
Are you aware of your latest weight?
Yes (1)
No (2)
Don´t know/ Unsure (3)
Current Body weight
kg
Are you aware of your target weight?
Yes (1)
No (2)
Don´t know/ Unsure (3)
What is your target weight?
kg
Are you aware of your blood pressure level?
3 / 7
EUROASPIRE III - Peripheral arterial occlusive disease Patient Interview
Questionnaire
Yes (1)
No (2)
Don´t know/ Unsure (3)
Current blood pressure
mmHg
Are you aware of your blood pressure target?
Yes (1)
No (2)
Don´t know/ Unsure (3)
What is your blood pressure target?
mmHg
Are you aware of your total cholesterol level?
Yes (1)
No (2)
Don´t know/ Unsure (3)
Total cholesterol measurement
mmol/l
Are you aware of your total cholesterol target?
Yes (1)
No (2)
Don´t know/ Unsure (3)
What is your total cholesterol target?
mmol/l
Are you aware of your latest blood glucose level?
Yes (1)
No (2)
Don´t know/ Unsure (3)
Blood glucose measurement
mmol/l
Are you aware of your blood glucose target?
Yes (1)
No (2)
Don´t know/ Unsure (3)
What is your blood glucose target?
mmol/l
Are you aware of your latest HbA1c level?
Yes (1)
No (2)
Don´t know/ Unsure (3)
HbA1c measurement
%
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Are you aware of your HbA1c target?
Yes (1)
No (2)
Don´t know/ Unsure (3)
What is your HbA1c target?
%
Lifestyle changes
Since before or after your diagnosis of peripheral
artery occlusive disease, were you offered any
personal advice by a doctor or other health
professional on stopping smoking?
Yes since the index event or procedure
(1)
Yes since before the index event or
procedure  (2)
No  (3)
Unsure/ Don’t know (4)
What type of advice did you receive for stopping
smoking?
verbal (1)
written materials (2)
referral to smoking cessation clinic/
course (3)
Nicotine replacement therapy (4)
Bupropion (5)
other (6)
Since before or after your diagnosis of peripheral
artery occlusive disease, were you offered any
personal advice by a doctor or other health
professional on a healthy diet?
Yes since the index event or procedure
(1)
Yes since before the index event or
procedure  (2)
No  (3)
Unsure/ Don’t know (4)
What type of advice did you receive concerning a
healthy diet?
reduction of salt intake (1)
reduction of fat intake (2)
changing type of fat intake (3)
reduction of calorie intake (4)
eating more fruits and vegetables (5)
eating more fish (6)
eating more oily fish (7)
reducing sugar (8)
reducing excessive alcohol intake (9)
Since before or after your diagnosis of peripheral
artery occlusive disease, were you offered any
personal advice by a doctor or other health
professional on weight loss?
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Yes since the index event or procedure
(1)
Yes since before the index event or
procedure  (2)
No  (3)
Unsure/ Don’t know (4)
What type of advice did you receive concerning
weight loss?
following dietary recommendations (1)
participating in regular physical activity
(2)
weight reducing drugs (3)
other (please specify) (4)
What type of advice did you receive concerning
weight loss?
following dietary recommendations (1)
participating in regular physical activity
(2)
weight reducing drugs (3)
other (please specify) (4)
Please specify other type of advice you received
concerning weight loss?
Since before or after your diagnosis of peripheral
artery occlusive disease, were you offered any
personal advice by a doctor or other health
professional on increase of physical activity?
Yes since the index event or procedure
(1)
Yes since before the index event or
procedure  (2)
No  (3)
Unsure/ Don’t know (4)
What type of advice did you receive concerning
increase of physical activity?
following specific exercise advice from a
health or exercise professional (1)
attending a fitness club or leisure centre
(2)
trying to do more general everyday
physical activities (3)
joining a community walking group (4)
other (5)
Family history of cardiovascular disease
History of cardiovascular disease of brother
Yes (1)
No (2)
Don´t know/ Unsure (3)
Age of brother at diagnosis of cardiovascular
disease
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Age of brother at diagnosis of cardiovascular
disease unknown
Yes
No
Brother died of cardiovascular disease (if
applicable)
Yes (1)
No (2)
Don´t know/ Unsure (3)
Age at death from cardiovascular disease of
brother (if applicable)
Age at death from cardiovascular disease of
brother unknown (if applicable)
Yes
No
History of cardiovascular disease of sister
Yes (1)
No (2)
Don´t know/ Unsure (3)
Age of sister at diagnosis of cardiovascular
disease
Age of sister at diagnosis of cardiovascular
disease unknown
Yes
No
Sister died of cardiovascular disease  (if
applicable)
Yes (1)
No (2)
Don´t know/ Unsure (3)
Age at death from cardiovascular disease of
sister (if applicable)
Age at death from cardiovascular disease of
sister unknown
Yes
No
General Health assessment
SF-12 Physical health summary measure
SF-12 Mental health summary measure
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EUROASPIRE III- Coronary heart disease
Medication at discharge
Provided by Prof. Keil Source: Kotseva K, Wood D, De
Backer G, De Bacquer D, Pyörälä K, Keil U; EUROASPIRE
Study Group. Cardiovascular prevention guidelines in daily
practice: a comparison of EUROASPIRE I, II, and III
surveys in eight European countries. Lancet. 2009 Mar
14;373(9667):929-40. doi: 10.1016/S0140-6736(09)60330-
5. PubMed PMID: 19286092
All rights reserved. Please visit https://medical-data-
models.org/forms/16859
Medication at discharge
Demographic Information
Patient Name
Birth Date
Medication
Were any of the following medications from the
list below prescribed at discharge from hospital?
Yes (1)
No (2)
Don´t know/ Unsure (3)
Not recorded (4)
Aspirin or other anti-platelet drugs?
Yes (1)
No (2)
Don´t know/ Unsure (3)
Not recorded (4)
Aspirin or other anti-platelet drugs: Generic name
None (1)
Not recorded (2)
Acetylsalicylic-Acid (3)
Clopidrogel (4)
Dipyridamole (5)
Ticlopidine (6)
Other (7)
Unknown (8)
Aspirin or other anti-platelet drugs: Total daily
dose
mg
Aspirin or other anti-platelet drugs?
Yes (1)
No (2)
Don´t know/ Unsure (3)
Aspirin or other anti-platelet drugs: Generic name
None (1)
Not recorded (2)
Acetylsalicylic-Acid (3)
Clopidrogel (4)
Dipyridamole (5)
Ticlopidine (6)
Other (7)
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Unknown (8)
Aspirin or other anti-platelet drugs: Total daily
dose
mg
Beta blockers
Yes (1)
No (2)
Don´t know/ Unsure (3)
Not recorded (4)
Beta blockers:Generic name
None (1)
Metoprolol (10)
Nadolol (11)
Nebivilol (12)
Pindolol (13)
Propanolol (14)
Sotalol (15)
Timolol (16)
Other (17)
Unknown (18)
Not recorded (2)
Acebutolol (3)
Atenolol (4)
Bisoprolol (5)
Betaxolol (6)
Carvedilol (7)
Celiprolol (8)
Labetatol (9)
Beta Blockers Total daily dose
mg
ACE inhibitors
Yes (1)
No (2)
Don´t know/ Unsure (3)
Not recorded (4)
ACE inhibitors: Generic name
None (1)
Moexipril (10)
Perindopril (11)
Quinapril (12)
Ramipril (13)
Trandolapril (14)
Zofenopril (15)
Other (16)
Unknown (17)
Not recorded (2)
Benazepril (3)
Captopril (4)
Cilazapril (5)
Enalapril (6)
Fosinopril (7)
Imidapril (8)
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Lisinopril (9)
ACE inhibitors : Total daily dose
mg
Angiotensin II receptor antagonists
Yes (1)
No (2)
Don´t know/ Unsure (3)
Not recorded (4)
Angiotensin II receptor antagonists: Generic
name
None (1)
Unknown (10)
Not recorded (2)
Candesartan (3)
Eprosartan (4)
Irbesartan (5)
Losartan (6)
Telmisartan (7)
Valsartan (8)
Other (9)
Angiotensin II receptor antagonists: Total daily
dose
mg
Calcium antagonists
Yes (1)
No (2)
Don´t know/ Unsure (3)
Not recorded (4)
Calcium antagonists: Generic name
None (1)
Nicardipine (10)
Nifedipine (11)
Nimodipine (12)
Nisoldipine (13)
Nitrendipine (14)
Verapamil (15)
Other (16)
Unknown (17)
Not recorded (2)
Amlodipin (3)
Diltiazem (4)
Felodipine (5)
Galopamil (6)
Isradipine (7)
Lacidipine (8)
Lercanidipine (9)
Calcium antagonists: Total daily dose
mg
If inhibitors
3 / 11
EUROASPIRE III- Coronary heart disease Medication at discharge
Yes (1)
No (2)
Don´t know/ Unsure (3)
Not recorded (4)
If inhibitors: Generic name
None  (1)
Not recorded  (2)
Ivabradine  (3)
Other  (4)
Unknown (5)
If inhibitors: Total daily dose
mg
Metabolic agents
Yes (1)
No (2)
Don´t know/ Unsure (3)
Not recorded (4)
Metabolic agents: Generic name
None  (1)
Not recorded  (2)
Trimetazidine  (3)
Other  (4)
Unknown (5)
Metabolic agents: Total daily dose
mg
Potassium channel openers
None  (1)
Not recorded  (2)
Yes  (3)
Unknown (4)
Potassium channel openers: Total daily dose
mg
Nitrates
Yes (1)
No (2)
Don´t know/ Unsure (3)
Not recorded (4)
Nitrates: Generic name
None (1)
Not recorded (2)
Mononitrate (3)
Dinitrate (4)
GNT patch (5)
GNT spray (6)
GNT tablets (7)
Other (8)
Unknown (9)
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Nitrates: Total daily dose
mg
Diuretics
Yes (1)
No (2)
Don´t know/ Unsure (3)
Not recorded (4)
Diuretics: Generic name
None (1)
Other (10)
Unknown (11)
Not recorded (2)
Bendrofluazide (3)
Chlorthalidone (4)
Hydrochorothiazide (5)
Furosemide (6)
Indapamide (7)
Spironolactone (8)
Torasemide (9)
Diuretics: Total daily dose
mg
Diuretics
Yes (1)
No (2)
Don´t know/ Unsure (3)
Diuretics: Generic name
None (1)
Other (10)
Unknown (11)
Not recorded (2)
Bendrofluazide (3)
Chlorthalidone (4)
Hydrochorothiazide (5)
Furosemide (6)
Indapamide (7)
Spironolactone (8)
Torasemide (9)
Diuretics: Total daily dose
mg
Other anti-hypertensive drugs
Yes (1)
No (2)
Don´t know/ Unsure (3)
Not recorded (4)
Other Anti-hypertensive drugs: Generic name
None (1)
Not recorded (2)
Methyl Dopa (3)
Doxazosin (4)
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Prazosin (5)
Terazosin (6)
Other (7)
Unknown (8)
Other Anti-hypertensive drugs: Total daily dose
mg
Digitalis glycosides
Yes (1)
No (2)
Don´t know/ Unsure (3)
Not recorded (4)
Digitalis glycosides: Generic name
None (1)
Not recorded (2)
Digitoxin (3)
Digoxin (4)
Other Unknown (5)
Digitalis glycosides: Total daily dose
mg
Antiarrhythmics
Yes (1)
No (2)
Don´t know/ Unsure (3)
Not recorded (4)
Antiarrhythmics: Generic name
None (1)
Not recorded (2)
Amiodarone (3)
Disopyramide (4)
Flecainide (5)
Propafenone (6)
Other (7)
Unknown (8)
Antiarrhythmics:  Total daily dose
mg
Lipid lowering drugs: Statins
Yes (1)
No (2)
Don´t know/ Unsure (3)
Not recorded (4)
Lipid lowering drugs (Statins): Generic name
None (1)
Unknown (10)
Not recorded (2)
Atorvastatin (3)
Fluvastatin (4)
Lovastatin (5)
Pravastatin (6)
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Rosuvastatin (7)
Simvastatin (8)
Other (9)
Lipid lowering drugs (Statins): Total daily dose
mg
Lipid lowering drugs: Fibrates
Yes (1)
No (2)
Don´t know/ Unsure (3)
Not recorded (4)
Lipid lowering drugs (Fibrates): Generic name
None (1)
Not recorded (2)
Bezafibrate (3)
Ciprofibrate (4)
Fenofibrate (5)
Gemfibrozil (6)
Other (7)
Unknown (8)
Lipid lowering drugs (Fibrates): Total daily dose
mg
Lipid lowering drugs: Nicotinic acid group
Yes (1)
No (2)
Don´t know/ Unsure (3)
Not recorded (4)
Lipid lowering drugs (Nicotinic acid group):
Generic name
None  (1)
Not recorded  (2)
Nicotinic acid  (3)
Other  (4)
Unknown (5)
Lipid lowering drugs (Nicotinic acid group): Total
daily dose
mg
Lipid lowering drugs: Cholesterol absorption
inhibitors
Yes (1)
No (2)
Don´t know/ Unsure (3)
Not recorded (4)
Lipid lowering drugs (Cholesterol absorption
inhibitors): Generic name
None  (1)
Not recorded  (2)
Ezetimibe  (3)
Other  (4)
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Unknown (5)
Lipid lowering drugs (Cholesterol absorption
inhibitors): Total daily dose
mg
Lipid lowering drugs: Resins
Yes (1)
No (2)
Don´t know/ Unsure (3)
Not recorded (4)
Lipid lowering drugs (Resins): Generic name
None  (1)
Not recorded  (2)
Cholestyramine  (3)
Other  (4)
Unknown (5)
Lipid lowering drugs (Resins): Total daily dose
mg
Lipid lowering drugs: Other
None  (1)
Not recorded  (2)
Yes  (3)
Unknown (4)
Lipid lowering drugs (Other): Total daily dose
mg
Anti-diabetic drugs: Insulin
Yes (1)
No (2)
Don´t know/ Unsure (3)
Not recorded (4)
Insulin: Generic name
None (1)
Not recorded (2)
Short acting (3)
Intermediate (4)
Long acting (5)
Other (6)
Unknown (7)
Insulin: Total daily dose
mg
Anti-diabetic drugs: Insulin
Yes (1)
No (2)
Don´t know/ Unsure (3)
Insulin: Generic name
None (1)
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Not recorded (2)
Short acting (3)
Intermediate (4)
Long acting (5)
Other (6)
Unknown (7)
Insulin: Total daily dose
mg
Anti-diabetic drugs: oral
Yes (1)
No (2)
Don´t know/ Unsure (3)
Not recorded (4)
Oral Antidiabetics: Generic name
None (1)
Not recorded (2)
Chlorpropamide (3)
Glibenclamide (4)
Glimepiride (5)
Glipizide (6)
Other (7)
Unknown (8)
Oral Antidiabetics: Total daily dose
mg
Anti-diabetic drugs: oral
Yes (1)
No (2)
Don´t know/ Unsure (3)
Not recorded (4)
Oral Antidiabetics: Generic name
None (1)
Not recorded (2)
Chlorpropamide (3)
Glibenclamide (4)
Glimepiride (5)
Glipizide (6)
Other (7)
Unknown (8)
Oral Antidiabetics: Total daily dose
mg
Anti-coagulants
Yes (1)
No (2)
Don´t know/ Unsure (3)
Not recorded (4)
Anti-coagulants: Generic name
None (1)
Not recorded (2)
Warfarin sodium (3)
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Acenocumarol (4)
Other Unknown (5)
Anti-coagulants: Total daily dose
mg
Oral contraceptive pill
Yes (1)
No (2)
Don´t know/ Unsure (3)
Not recorded (4)
Oral contraceptive pill: Total daily dose
mg
Hormone replacement therapy
Yes (1)
No (2)
Don´t know/ Unsure (3)
Not recorded (4)
Hormone replacement therapy: Generic name
Hormone replacement therapy: Total daily dose
mg
Appetite suppressants or other antiobesity
Yes (1)
No (2)
Don´t know/ Unsure (3)
Not recorded (4)
Appetite suppressants or other antiobesity: Total
daily dose
mg
Nicotine replacement therapy
Yes (1)
No (2)
Don´t know/ Unsure (3)
Not recorded (4)
Nicotine replacement therapy: Generic name
Chewing Gum  (1)
Nasal spray (2)
Inhalator (3)
Losenges (4)
Patches (5)
Nicotine replacement therapy: Total daily dose
mg
Bupropion
Yes (1)
No (2)
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Don´t know/ Unsure (3)
Not recorded (4)
Bupropion: Total daily dose
mg
Other medication
Yes (1)
No (2)
Don´t know/ Unsure (3)
Not recorded (4)
Other medications: Generic name
Other medications: Total daily dose
mg
Is any of the medication prescribed a
combination of 2 drugs in one tablet?
None  (1)
Not recorded  (2)
Yes  (3)
Unknown (4)
If yes, please specify
Patient record form completed for this patient
Yes
No
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Medication Patient Interview
Provided by Prof. Keil Source: Kotseva K, Wood D, De
Backer G, De Bacquer D, Pyörälä K, Keil U; EUROASPIRE
Study Group. Cardiovascular prevention guidelines in daily
practice: a comparison of EUROASPIRE I, II, and III
surveys in eight European countries. Lancet. 2009 Mar
14;373(9667):929-40. doi: 10.1016/S0140-6736(09)60330-
5. PubMed PMID: 19286092
All rights reserved. Please visit https://medical-data-
models.org/forms/16860
Medication Patient Interview
Demographic Information
Patient Name
Birth Date
Medication
Is the patient on any medication?
Yes (1)
No (2)
Don´t know/ Unsure (3)
Aspirin or other anti-platelet drugs?
Yes (1)
No (2)
Don´t know/ Unsure (3)
Aspirin or other anti-platelet drugs: Generic name
None (1)
Acetylsalicylic-Acid (2)
Clopidrogel Dipyridamole (3)
Ticlopidine (4)
Other (5)
Unknown (6)
Aspirin or other anti-platelet drugs: Total daily
dose
mg
Aspirin or other anti-platelet drugs?
Yes (1)
No (2)
Don´t know/ Unsure (3)
Aspirin or other anti-platelet drugs: Generic name
None (1)
Acetylsalicylic-Acid (2)
Clopidrogel Dipyridamole (3)
Ticlopidine (4)
Other (5)
Unknown (6)
Aspirin or other anti-platelet drugs: Total daily
dose
mg
1 / 10
Beta blockers
Yes (1)
No (2)
Don´t know/ Unsure (3)
Beta blockers:Generic name
None (1)
Nadolol (10)
Nebivilol (11)
Pindolol (12)
Propanolol (13)
Sotalol (14)
Timolol (15)
Other (16)
Unknown (17)
Acebutolol (2)
Atenolol (3)
Bisoprolol (4)
Betaxolol (5)
Carvedilol (6)
Celiprolol (7)
Labetatol (8)
Metoprolol (9)
Beta Blockers Total daily dose
mg
ACE inhibitors
Yes (1)
No (2)
Don´t know/ Unsure (3)
ACE inhibitors: Generic name
None (1)
Perindopril (10)
Quinapril (11)
Ramipril (12)
Trandolapril (13)
Zofenopril (14)
Other (15)
Unknown (16)
Benazepril (2)
Captopril (3)
Cilazapril (4)
Enalapril (5)
Fosinopril (6)
Imidapril (7)
Lisinopril (8)
Moexipril (9)
ACE inhibitors : Total daily dose
mg
Angiotensin II receptor antagonists
Yes (1)
No (2)
Don´t know/ Unsure (3)
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Angiotensin II receptor antagonists: Generic
name
None (1)
Candesartan (2)
Eprosartan (3)
Irbesartan (4)
Losartan (5)
Telmisartan (6)
Valsartan Other (7)
Unknown (8)
Angiotensin II receptor antagonists: Total daily
dose
mg
Calcium antagonists
Yes (1)
No (2)
Don´t know/ Unsure (3)
Calcium antagonists: Generic name
None (1)
Nifedipine (10)
Nifedipine long acting (11)
Nimodipine (12)
Nisoldipine (13)
Nitrendipine (14)
Verapamil (15)
Other (16)
Unknown (17)
Amlodipin (2)
Diltiazem (3)
Felodipine (4)
Galopamil (5)
Isradipine (6)
Lacidipine (7)
Lercanidipine (8)
Nicardipine (9)
Calcium antagonists: Total daily dose
mg
If inhibitors
Yes (1)
No (2)
Don´t know/ Unsure (3)
If inhibitors: Generic name
None  (1)
Ivabradine  (2)
Other  (3)
Unknown (4)
If inhibitors: Total daily dose
mg
Metabolic agents
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Yes (1)
No (2)
Don´t know/ Unsure (3)
Metabolic agents: Generic name
None  (1)
Trimetazidine  (2)
Other  (3)
Unknown (4)
Metabolic agents: Total daily dose
mg
Potassium channel openers
None  (1)
Yes  (2)
Unknown (3)
Potassium channel openers: Total daily dose
mg
Nitrates
Yes (1)
No (2)
Don´t know/ Unsure (3)
Nitrates: Generic name
None (1)
Mononitrate (2)
Dinitrate (3)
GNT patch (4)
GNT spray (5)
GNT tablets (6)
Other (7)
Unknown (8)
Nitrates: Total daily dose
mg
Diuretics
Yes (1)
No (2)
Don´t know/ Unsure (3)
Diuretics: Generic name
None (1)
Unknown (10)
Bendrofluazide (2)
Chlorthalidone (3)
Hydrochorothiazide (4)
Furosemide (5)
Indapamide (6)
Spironolactone (7)
Torasemide (8)
Other (9)
Diuretics: Total daily dose
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mg
Diuretics
Yes (1)
No (2)
Don´t know/ Unsure (3)
Diuretics: Generic name
None (1)
Unknown (10)
Bendrofluazide (2)
Chlorthalidone (3)
Hydrochorothiazide (4)
Furosemide (5)
Indapamide (6)
Spironolactone (7)
Torasemide (8)
Other (9)
Diuretics: Total daily dose
mg
Other anti-hypertensive drugs
Yes (1)
No (2)
Don´t know/ Unsure (3)
Other Anti-hypertensive drugs: Generic name
None (1)
Methyl Dopa (2)
Doxazosin (3)
Prazosin (4)
Terazosin Other (5)
Unknown (6)
Other Anti-hypertensive drugs: Total daily dose
mg
Digitalis glycosides
Yes (1)
No (2)
Don´t know/ Unsure (3)
Digitalis glycosides: Generic name
None (1)
Digitoxin (2)
Digoxin (3)
Other Unknown (4)
Digitalis glycosides: Total daily dose
mg
Antiarrhythmics
Yes (1)
No (2)
Don´t know/ Unsure (3)
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Antiarrhythmics: Generic name
None (1)
Amiodarone (2)
Disopyramide (3)
Flecainide (4)
Propafenone Other (5)
Unknown (6)
Antiarrhythmics:  Total daily dose
mg
Lipid lowering drugs: Statins
Yes (1)
No (2)
Don´t know/ Unsure (3)
Lipid lowering drugs (Statins): Generic name
None (1)
Atorvastatin (2)
Fluvastatin (3)
Lovastatin (4)
Pravastatin (5)
Rosuvastatin (6)
Simvastatin Other (7)
Unknown (8)
Lipid lowering drugs (Statins): Total daily dose
mg
Lipid lowering drugs: Fibrates
Yes (1)
No (2)
Don´t know/ Unsure (3)
Lipid lowering drugs (Fibrates): Generic name
None (1)
Bezafibrate (2)
Ciprofibrate (3)
Fenofibrate (4)
Gemfibrozil Other (5)
Unknown (6)
Lipid lowering drugs (Fibrates): Total daily dose
mg
Lipid lowering drugs: Nicotinic acid group
Yes (1)
No (2)
Don´t know/ Unsure (3)
Lipid lowering drugs (Nicotinic acid group):
Generic name
None  (1)
Nicotinic acid  (2)
Other  (3)
Unknown (4)
Lipid lowering drugs (Nicotinic acid group): Total
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daily dose
mg
Lipid lowering drugs: Cholesterol absorption
inhibitors
Yes (1)
No (2)
Don´t know/ Unsure (3)
Lipid lowering drugs (Cholesterol absorption
inhibitors): Generic name
None  (1)
Ezetimibe  (2)
Other  (3)
Unknown (4)
Lipid lowering drugs (Cholesterol absorption
inhibitors): Total daily dose
mg
Lipid lowering drugs: Resins
Yes (1)
No (2)
Don´t know/ Unsure (3)
Lipid lowering drugs (Resins): Generic name
None  (1)
Cholestyramine  (2)
Other  (3)
Unknown (4)
Lipid lowering drugs (Resins): Total daily dose
mg
Lipid lowering drugs: Other
None  (1)
Yes  (2)
Unknown (3)
Lipid lowering drugs (Other): Total daily dose
mg
Anti-diabetic drugs: Insulin
Yes (1)
No (2)
Don´t know/ Unsure (3)
Insulin: Generic name
None (1)
Short acting (2)
Intermediate (3)
Long acting (4)
Other (5)
Unknown (6)
Insulin: Total daily dose
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mg
Anti-diabetic drugs: Insulin
Yes (1)
No (2)
Don´t know/ Unsure (3)
Insulin: Generic name
None (1)
Short acting (2)
Intermediate (3)
Long acting (4)
Other (5)
Unknown (6)
Insulin: Total daily dose
mg
Anti-diabetic drugs: oral
Yes (1)
No (2)
Don´t know/ Unsure (3)
Oral Antidiabetics: Generic name
None (1)
Chlorpropamide (2)
Glibenclamide (3)
Glimepiride (4)
Glipizide (5)
Other (6)
Unknown (7)
Oral Antidiabetics: Total daily dose
mg
Anti-diabetic drugs: oral
Yes (1)
No (2)
Don´t know/ Unsure (3)
Oral Antidiabetics: Generic name
None (1)
Chlorpropamide (2)
Glibenclamide (3)
Glimepiride (4)
Glipizide Other (5)
Unknown (6)
Oral Antidiabetics: Total daily dose
mg
Anti-coagulants
Yes (1)
No (2)
Don´t know/ Unsure (3)
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Anti-coagulants: Generic name
None (1)
Warfarin sodium (2)
Acenocumarol (3)
Other Unknown (4)
Anti-coagulants: Total daily dose
mg
Oral contraceptive pill
None  (1)
Yes  (2)
Unknown (3)
Oral contraceptive pill: Total daily dose
mg
Hormone replacement therapy
None  (1)
Yes  (2)
Unknown (3)
Hormone replacement therapy: Generic name
Hormone replacement therapy: Total daily dose
mg
Appetite suppressants or other antiobesity
None  (1)
Yes  (2)
Unknown (3)
Appetite suppressants or other antiobesity: Total
daily dose
mg
Nicotine replacement therapy
None  (1)
Yes  (2)
Unknown (3)
Nicotine replacement therapy: Generic name
Chewing Gum  (1)
Nasal spray (2)
Inhalator (3)
Losenges (4)
Patches (5)
Nicotine replacement therapy: Total daily dose
mg
Bupropion
None  (1)
Yes  (2)
Unknown (3)
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Bupropion: Total daily dose
mg
Other medication
None  (1)
Yes  (2)
Unknown (3)
Other medications: Generic name
Other medications: Total daily dose
mg
Is any of the medication prescribed a
combination of 2 drugs in one tablet?
None  (1)
Not recorded  (2)
Yes  (3)
Unknown (4)
If yes, please specify
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Eligibility Contrast Induced Nephropathy
NCT00476619
Erythropoietin in Radiocontrast Induced Nephropathy
(ERIN) Trial; ODM derived from:
https://clinicaltrials.gov/show/NCT00476619
All rights reserved. Please visit https://medical-data-
models.org/forms/16861
Eligibility Contrast Induced
Nephropathy NCT00476619
Inclusion Criteria
1. subjects age 18 and over and of either
gender.*
Yes
No
2. scheduled to receive ct scan with intravenous
contrast dye.*
Yes
No
3. non diabetics or subjects with type 1 or 2
diabetes mellitus*
Yes
No
4. written informed consent.*
Yes
No
5. subjects who are on diuretics and non-
steroidal inflammatory agents will not be
excluded.*
Yes
No
6. subjects who have received n-acetylcysteine or
sodium bicarbonate pre ct scan will not be
excluded*
Yes
No
Exclusion Criteria
1. pregnant or lactating women.*
Yes
No
2. end-stage renal disease (on hemodialysis or
peritoneal dialysis)*
Yes
No
3. a known history of  acute renal failure*
Yes
No
4. subjects receiving glucophage/metformin or
glucovance*
Yes
No
1 / 3
5. subjects who cannot give written informed
consent.*
Yes
No
6. subjects receiving peritoneal dialysis or
hemodialysis.*
Yes
No
7. subjects enrolled in another investigational
drug study ≤ 30 days of enrollment into the
present study.*
Yes
No
8. subjects with a known hypersensitivity or
anaphylaxis to contrast dye or iodine.*
Yes
No
9. subjects with known hypersensitivity or
anaphylaxis to erythropoietin, mammalian-cell
derived products, or human albumin.*
Yes
No
10. age < 18 years*
Yes
No
11. use of any erythropoietin replacement or
transfusion within the prior 3 days*
Yes
No
12. baseline hemoglobin > 12.0 g/dl*
Yes
No
13. uncontrolled hypertension, systolic bp > 180
mmhg or diastolic bp > 110 mmhg in any
recording in the past 24 hours.*
Yes
No
14. evidence of hemodynamic instability*
Yes
No
15. subject unable to follow protocol due to
mental incompetence or other reason*
Yes
No
16. inaccessibility of medical record*
Yes
No
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17. subjects with a history of mi, cva, active
angina or unstable angina within the past three
months*
Yes
No
18. subjects with a history of current malignancy,
where current malignancy is defined as subjects
undergoing treatment with chemotherapy or
radiation therapy, subjects with known metastatic
disease, and those with terminal malignant
disease.*
Yes
No
19. subject with any known history of seizure
disorders*
Yes
No
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Treatment Visit Form 5/5 Tolerability of QUTENZA™ When Applied After Pre-
treatment With Lidocaine or Tramadol in Subjects With Peripheral Neuropathic Pain
- A Randomized, Multi-center, Assessor-blinded Study NCT01416116
Study Sponsor: Astellas
Study Title
Tolerability of QUTENZA™ When Applied After Pre-
treatment With Lidocaine or Tramadol in Subjects With
Peripheral Neuropathic Pain - A Randomized, Multi-center,
Assessor-blinded Study
Medicine or Vaccine (generic name)
capsaicin
Sponsor Identification Number
QTZ-EC-0002
Trial Registry Identification Number(#'s)
NCT01416116
EudraCT Number: 2010-023258-34
Medical Condition
Neuropathic pain
Phase
Phase 4
http://clinicaltrials.gov/show/NCT01416116
Treatment:
NPRS 'pain now' score: 75 mins prior to patch
NPRS 'pain now' score: 40, 15 mins prior to patch
NPRS 'pain now' score: Post patch application and post
patch removal
Tolerability score: Post patch removal
NPRS 'average pain' score: Day 1-3
NPRS 'pain now' score: Day 1-3
All rights reserved. Please visit https://medical-data-
models.org/forms/16863
Treatment Visit Form 5/5  Tolerability
of QUTENZA™ When Applied After
Pre-treatment With Lidocaine or
Tramadol in Subjects With Peripheral
Neuropathic Pain - A Randomized,
Multi-center, Assessor-blinded Study
NCT01416116
NPRS 'pain now' score: 75 mins prior to
patch
Date of Assessment
Scheduled Time
Assessment Time
NPRS 'pain now' score
1 (1)
10 (10)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
7 (7)
8 (8)
9 (9)
NPRS 'pain now' score: 40, 15 mins prior
to patch
Date of Assessment
1 / 3
Scheduled Time
Assessment Time
NPRS 'pain now' score
1 (1)
10 (10)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
7 (7)
8 (8)
9 (9)
NPRS 'pain now' score: Post patch
application and post patch removal
Date of Assessment
Scheduled Time
Assessment Time
NPRS 'pain now' score
1 (1)
10 (10)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
7 (7)
8 (8)
9 (9)
Tolerability score: Post patch removal
Date of Assessment
Scheduled Time
Assessment Time
Tolerability score
1 (1)
10 (10)
2 (2)
3 (3)
4 (4)
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5 (5)
6 (6)
7 (7)
8 (8)
9 (9)
NPRS 'average pain' score: Day 1-3
Date of Assessment
Scheduled Time
Day 1 (Day of Patch Application) (1)
Day 2 (2)
Day 3 (3)
Assessment Time
NPRS 'average pain' score
1 (1)
10 (10)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
7 (7)
8 (8)
9 (9)
Form: NPRS 'pain now' score: Day 1-3
Date of Assessment
Scheduled Time
1: Day 1 (Day of Patch Application) (1)
2: Day 2 (2)
3: Day 3 (3)
Assessment Time
NPRS 'pain now' score
1 (1)
10 (10)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
7 (7)
8 (8)
9 (9)
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treatment With Lidocaine or Tramadol in Subjects With Peripheral Neuropathic Pain
- A Randomized, Multi-center, Assessor-blinded Study NCT01416116
Visit Checklist: UIC Quality Improvement
CRF
ODM derived from:
http://research.uic.edu/qip/toolbox/case-report-forms-crf.
Template Name: Visit Checklist.
QIP Case Report Forms, UIC Quality Improvement CRF,
Office of the Vice Chancellor for Research. 
Center for Clinical and Translational Science, UIC
University of Illinois at Chicago.
All rights reserved. Please visit https://medical-data-
models.org/forms/16864
Visit Checklist: UIC Quality
Improvement CRF
Visit Checklist
Protocol Title
Site Number
Subject ID
Visit Date
1. Did the subject attend this visit?
Yes (If yes, continue) (1)
No (If no, enter comments below) (2)
2. Study Visit: Date of Informed Consent Signed
Study Visit: Demographics
Yes
No
Study Visit: Medical History
Yes
No
Study Visit: Vital Signs
Yes
No
Study Visit: Physical Exam
Yes
No
Study Visit: Prior and Concomitant Medication
Yes
No
Study Visit: Inclusion/Exclusion Criteria
Yes
No
Study Visit: Randomization
Yes
No
Study Visit Enrollment
Yes
No
1 / 2
3. Is the subject continuing in the study?
Yes
No
Comments
Completed by (initials)
Date completed
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Treatment Visit Form 4/5 Tolerability of QUTENZA™ When Applied After Pre-
treatment With Lidocaine or Tramadol in Subjects With Peripheral Neuropathic Pain
- A Randomized, Multi-center, Assessor-blinded Study NCT01416116
Study Sponsor: Astellas
Study Title
Tolerability of QUTENZA™ When Applied After Pre-
treatment With Lidocaine or Tramadol in Subjects With
Peripheral Neuropathic Pain - A Randomized, Multi-center,
Assessor-blinded Study
Medicine or Vaccine (generic name)
capsaicin
Sponsor Identification Number
QTZ-EC-0002
Trial Registry Identification Number(#'s)
NCT01416116
EudraCT Number: 2010-023258-34
Medical Condition
Neuropathic pain
Phase
Phase 4
http://clinicaltrials.gov/show/NCT01416116
Treatment Visit Form 4/5:
Application of Lidocaine
Administration of Tramadol
NPRS 'average pain' score prior to patch application
Application of Qutenza
All rights reserved. Please visit https://medical-data-
models.org/forms/16865
Treatment Visit Form 4/5 Tolerability
of QUTENZA™ When Applied After
Pre-treatment With Lidocaine or
Tramadol in Subjects With Peripheral
Neuropathic Pain - A Randomized,
Multi-center, Assessor-blinded Study
NCT01416116
Application of Lidocaine
Start Date
Start Time
Stop Time
Number of Tubes Used
Administration of Tramadol
Dosing Date
Dosing Time
# of Tablets Taken
NPRS 'average pain' score prior to patch
application
Date of Assessment
1 / 2
NPRS 'average' pain score
0 (0 )
1 (1 )
10 (10 )
2 (2 )
3 (3 )
4 (4 )
5 (5 )
6 (6 )
7 (7 )
8 (8 )
9 (9 )
Application of Qutenza
Start Date
Start Time
Stop Time
Application of Qutenza: Treatment Area
Head and Neck
Arms
Hands
Torso
Legs
Feet
Treatment Area Size
cm²
Treatment Patch No
Patch 1 (1 )
Patch 2 (2 )
Patch 3 (3 )
Patch 4 (4 )
Treatment patch %
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treatment With Lidocaine or Tramadol in Subjects With Peripheral Neuropathic Pain
- A Randomized, Multi-center, Assessor-blinded Study NCT01416116
Treatment Visit Form 3/5 Tolerability of QUTENZA™ When Applied After Pre-
treatment With Lidocaine or Tramadol in Subjects With Peripheral Neuropathic Pain
- A Randomized, Multi-center, Assessor-blinded Study NCT01416116
Study Sponsor: Astellas
Study Title
Tolerability of QUTENZA™ When Applied After Pre-
treatment With Lidocaine or Tramadol in Subjects With
Peripheral Neuropathic Pain - A Randomized, Multi-center,
Assessor-blinded Study
Medicine or Vaccine (generic name)
capsaicin
Sponsor Identification Number
QTZ-EC-0002
Trial Registry Identification Number(#'s)
NCT01416116
EudraCT Number: 2010-023258-34
Medical Condition
Neuropathic pain
Phase
Phase 4
http://clinicaltrials.gov/show/NCT01416116
Treatment Visit Form 3/5:
Pregnancy Test
Identification of Painful Area: Change
Identification of Painful Area
Dermal Assessment
All rights reserved. Please visit https://medical-data-
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Treatment Visit Form 3/5 Tolerability
of QUTENZA™ When Applied After
Pre-treatment With Lidocaine or
Tramadol in Subjects With Peripheral
Neuropathic Pain - A Randomized,
Multi-center, Assessor-blinded Study
NCT01416116
Pregnancy Test
Is subject female and of childbearing potential?
No (0 )
Yes (1 )
Reason Childbearing potential - NO
No (0 )
Yes (1 )
If 'Other', specify
Select 'Not Done' if serum/urine sample was not
taken.
Yes
No
Date of Sample Taken
Result serum/urine pregnancy test
No (0 )
Yes (1 )
Identification of Painful Area: Change
Is there any change in most painful area?
no (0)
1 / 2
yes (1)
Identification of Painful Area
Assessment Date
Head and Neck
Arms
Hands
Torso
Legs
Feet
Total Painful/Sensitive Area Size
cm²
Dermal Assessment
Date of Assessment
Scheduled Time
1: 80 to 90  mins prior to patch
application (1)
2: 5 minutes post patch removal (2)
3: 55 minutes post patch removal (3)
Assessment Time
Dermal Assessment Scale
no evidence of irritation (0 )
minimal erythema barely perceptive (1 )
definite erythema, readily visible; minimal
edema or minimal popular response (2 )
erythema and papules (3 )
definite edema (4 )
erythema, edema, and papules (5 )
vesicular eruption (6 )
strong reaction spreading beyond test
site (7 )
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Treatment Visit Form 2/5 Tolerability of QUTENZA™ When Applied After Pre-
treatment With Lidocaine or Tramadol in Subjects With Peripheral Neuropathic Pain
- A Randomized, Multi-center, Assessor-blinded Study NCT01416116
Study Sponsor: Astellas
Study Title
Tolerability of QUTENZA™ When Applied After Pre-
treatment With Lidocaine or Tramadol in Subjects With
Peripheral Neuropathic Pain - A Randomized, Multi-center,
Assessor-blinded Study
Medicine or Vaccine (generic name)
capsaicin
Sponsor Identification Number
QTZ-EC-0002
Trial Registry Identification Number(#'s)
NCT01416116
EudraCT Number: 2010-023258-34
Medical Condition
Neuropathic pain
Phase
Phase 4
http://clinicaltrials.gov/show/NCT01416116
Treatment Visit Form 2/5:
Randomization
Vital Signs: 75 mins prior to patch application
Vital Signs: 15 mins prior to patch application
Post patch application and post patch removal
All rights reserved. Please visit https://medical-data-
models.org/forms/16867
Treatment Visit Form 2/5 Tolerability
of QUTENZA™ When Applied After
Pre-treatment With Lidocaine or
Tramadol in Subjects With Peripheral
Neuropathic Pain - A Randomized,
Multi-center, Assessor-blinded Study
NCT01416116
Randomization
Date of Randomization
Randomization Number
Dose/Group
Arm 1: Lidocaine 4% (1)
Arm 2: Tramadol (2)
Vital Signs: 75 mins prior to patch
application
Assessment Date
Scheduled Time
Assessment Time
Position
Supine (1 )
Sitting (2 )
Standing (3 )
1 / 3
Systolic Blood Pressure
mmHg
Diastolic Blood Pressure
mmHg
Pulse Rate
Vital Signs: 15 mins prior to patch
application
Assessment Date
Scheduled Time
Assessment Time
Position
Supine (1 )
Sitting (2 )
Standing (3 )
Systolic Blood Pressure
mmHg
Diastolic Blood Pressure
mmHg
Pulse Rate
Vital Signs: Post patch application and
post patch rGeemnoevraatl
Assessment Date
Scheduled Time
Assessment Time
Position
Supine (1 )
Sitting (2 )
Standing (3 )
Systolic Blood Pressure
mmHg
Diastolic Blood Pressure
mmHg
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treatment With Lidocaine or Tramadol in Subjects With Peripheral Neuropathic Pain
- A Randomized, Multi-center, Assessor-blinded Study NCT01416116
Pulse Rate
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Treatment Visit Form 1/5 Tolerability of QUTENZA™ When Applied After Pre-
treatment With Lidocaine or Tramadol in Subjects With Peripheral Neuropathic Pain
- A Randomized, Multi-center, Assessor-blinded Study NCT01416116
Study Sponsor: Astellas
Study Title
Tolerability of QUTENZA™ When Applied After Pre-
treatment With Lidocaine or Tramadol in Subjects With
Peripheral Neuropathic Pain - A Randomized, Multi-center,
Assessor-blinded Study
Medicine or Vaccine (generic name)
capsaicin
Sponsor Identification Number
QTZ-EC-0002
Trial Registry Identification Number(#'s)
NCT01416116
EudraCT Number: 2010-023258-34
Medical Condition
Neuropathic pain
Phase
Phase 4
http://clinicaltrials.gov/show/NCT01416116
Treatment Visit Form 1/5:
Date of Visit
Inclusion Criteria
Exclusion Criteria
All rights reserved. Please visit https://medical-data-
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Treatment Visit Form 1/5 Tolerability
of QUTENZA™ When Applied After
Pre-treatment With Lidocaine or
Tramadol in Subjects With Peripheral
Neuropathic Pain - A Randomized,
Multi-center, Assessor-blinded Study
NCT01416116
Date of Visit
Date of Visit
Inclusion Criteria
Inclusion Category
INCLUSION (1 )
EXCLUSION (2 )
Is the subject fully eligible per the Inclusion
Criteria?
No (0 )
Yes (1 )
Inclusion Criterion Not Met
1. Male or female between 18 and 90
years of age, inclusive. (IN01 )
2. In good health as determined by the
investigator. (IN02 )
3. Documented diagnosis at the
Treatment Visit of either: 1) PHN with
pain persisting at least 3 months since
shingles vesicle crusting, or 2)
Neuropathic pain due to peripheral nerve
injury including post-surgical neuropathic
pain syndrome, persisting for a minimum
of 3 months following the event. (IN03 )
1 / 4
4. NPRS score => 4 for average pain
both at the Screening Visit and at the
Treatment Visit. (IN04 )
5. Intact, non-irritated dry skin over the
painful area(s) to be treated. (IN05 )
6. Females of child bearing potential
must be willing to use effective methods
of birth control during the study and for
30 days following study termination.
(IN06 )
7. Willing and able to comply with
protocol requirements for the duration of
study participation. (IN07 )
8. Written informed consent has been
obtained. (IN08 )
Exclusion Criteria
Exclusion Category
INCLUSION (1)
EXCLUSION (2)
Is the subject fully eligible per the Exclusion
Criteria?
No (0)
Yes (1)
Exclusion Criteria Affecting Eligibility
1. Significant ongoing or recurrent pain
of aetiology other than PHN or peripheral
nerve injury, for example; compression-
related neuropathies (e.g. spinal
stenosis), mixed pain, fibromyalgia or
arthritis. (EX01 )
2. Pain due to Complex Regional Pain
Syndrome (CRPS, Type I). (EX02 )
3. Neuropathic pain areas located only
on the face, above the hairline of the
scalp, on the feet, and/or in proximity to
mucous membranes.  (EX03 )
4. Past or current history if Type 1 or
Type 2 diabetes mellitus.  (EX04 )
5. Active malignacy or treatment for
malignancy within a year prior to the
Treatment Visit (including radiotherapy,
chemotherapy and biologic or hormonal
therapies). A history of squamous cell
carcinoma or basal cell carcinoma not
involving the area to be treated is
allowed.  (EX05 )
6. Clinically significant cardiovascular
disease within 6 months prior to the
Treatment Visit defined as
cerebrovascular accident, unstable or
poorly controlled hypertension, transient
ischemic attack, myocardial infarction,
unstable angina, current arrhythmia, any
heart including coronary artery bypass
graft surgery, percutaneous coronary
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angioplasty/stent placement, or valvular
heart disease.=coronary artery bypass
graft surgery, percutaneous coronary
angioplasty/stent placement, or valvular
heart disease. (EX06 )
7. Clinically significant abnormal ECG at
screening. (EX07 )
8. Significant ongoing or untreated
abnormalities in cardiac, renal, hepatic,
or pulmonary function that may interfere
either with the ability to complete study
or the evaluation of AEs. (EX08 )
9. Uncontrolled epilepsy or risk of
convulsions. (EX09 )
10. Diagnosis of any major psychiatric
disorder. (EX10 )
11. Evidence of cognitive impairment
including dementia that may interfere
with subject's ability to complete study
evaluations and recall pain levels in the
past 24 hours. (EX11 )
12. Planned elective surgery during the
trial. (EX12 )
13. Any prior treatment with QUTENZA
patches, including blinded patches
administered as part of a clinical trial.
(EX13 )
14. Hypersensitivi ty to capsaicin (i.e.
chilli peppers or over-the-count er [OTC]
capsaicin products), any QUTENZA
excipients or adhesives, local
anesthetics, tramadol, or any tramadol
excipients.  (EX14 )
15. Treatment with opioids (including
tramadol) within 7 days preceding the
Treatment Visit. (EX15 )
16. Unwillingness to use opioid
analgesics during study treatment, or
high tolerance to opioids precluding the
ability to relieve treatment-asso ciated
discomfort with oral or parental opioids,
as judged by the investigator. (EX16 )
17. Treatment with carbamazepine or
MAO-inhibitors at the Treatment Visit.
(EX17 )
18. Use of any topical pain medication,
such as non-steroidal anti-inflammat ory
drugs, menthol, methyl salicylate, local
anesthetics (including patch containing
lidocaine), steroids or capsaicin products
on the painful areas within 7 days
preceding the Treatment Visit. (EX18 )
19. Participation in any other clinical
study or receipt of an investigational drug
within 30 days prior to Screening
Visit.=in any other clinical study or
receipt of an investigational drug within
30 days prior to Screening Visit. (EX19 )
20. Active substance abuse or history of
chronic substance abuse within 1 year
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prior to the Screening Visit; or any prior
chronic substance abuse (including
alcoholism) likely to re-occur during the
study period as judged by the
investigator. (EX20 )
21. Subject, who in the opinion of the
investigator is not likely to complete the
study for any reason. (EX21 )
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Eligibility Coronary Artery Bypass Surgery
NCT00653042
Clinical Study to Evaluate Nesiritide in Patients Undergoing
Coronary Artery Bypass Graft (CABG) Surgery A014 /
NAPA; ODM derived from:
https://clinicaltrials.gov/show/NCT00653042
All rights reserved. Please visit https://medical-data-
models.org/forms/16869
Eligibility Coronary Artery Bypass
Surgery NCT00653042
Inclusion Criteria
nyha class ii-iv chf*
Yes
No
presenting for cabg with or without mitral valve
repair or replacement procedure*
Yes
No
planned utilization of cpb*
Yes
No
documentation of left ventricular ejection fraction
(lvef) less than or equal to 40% measured by
nuclear scan, echocardiogram (echo), or
ventriculogram, within 90 days prior to surgery.*
Yes
No
Exclusion Criteria
planned aortic valve replacement or repair*
Yes
No
ongoing or chronic dialysis (either hemodialysis
or continuous ambulatory peritoneal dialysis)*
Yes
No
restrictive or obstructive cardiomyopathy,
constrictive pericarditis, pericardial tamponade, or
other conditions in which cardiac output is
dependent on venous return*
Yes
No
documented or suspected low cardiac filling
pressures*
Yes
No
any known congenital heart disease*
Yes
No
known allergic reaction or sensitivity to nesiritide
or excipients*
1 / 2
Yes
No
females of childbearing potential with a positive
serum pregnancy test, and nursing mothers*
Yes
No
treated with investigational drug or device within
last 30 days*
Yes
No
documented fever (>101 degrees f) within 72
hours of surgery*
Yes
No
wbc > 15,000/mm3 within 72 hours of surgery*
Yes
No
documented bacterial/fungal/viral infection
requiring administration of iv antibiotics within 7
days before surgery*
Yes
No
pulmonary disease (copd, asthma or other
condition) that required inpatient medical or
surgical treatment within 60 days before surgery.
treatment exclusion criteria (obtained after
anesthesia induction and before chest incision
prior to the start of study drug) include: mean
pulmonary artery pressure consistently < or
equal to 15mmhg*
Yes
No
central venous pressure consistently < 6 mmhg*
Yes
No
and systolic blood pressure consistently < 90
mmhg. use of open-label nesiritide within 48
hours of study drug administration.*
Yes
No
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Inclusion/Exclusion Criteria: UIC Quality
Improvement CRF
ODM derived from:
http://research.uic.edu/qip/toolbox/case-report-forms-crf.
Template Name: Inclusion/Exclusion Criteria.
QIP Case Report Forms, UIC Quality Improvement CRF,
Office of the Vice Chancellor for Research. 
Center for Clinical and Translational Science, UIC
University of Illinois at Chicago.
All rights reserved. Please visit https://medical-data-
models.org/forms/16870
Inclusion/Exclusion Criteria: UIC
Quality Improvement CRF
General Information
Protocol Title
Site Number
Subject ID
Visit Date
Study Visit
Screening (1)
Baseline (2)
Inclusion Criteria
Inclusion Description
Inclusion description fulfilled
Yes
No
Exclusion Criteria
Exclusion Description
Exclusion description fulfilled
Yes
No
Results
Did the subject meet the eligibility requirements
for this study?
Yes
No
Signature
Date
1 / 2
Printed Name
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End of Study Form 1/ Tolerability of QUTENZA™ When Applied After Pre-treatment
With Lidocaine or Tramadol in Subjects With Peripheral Neuropathic Pain - A
Randomized, Multi-center, Assessor-blinded Study NCT01416116
Study Sponsor: Astellas
Study Title
Tolerability of QUTENZA™ When Applied After Pre-
treatment With Lidocaine or Tramadol in Subjects With
Peripheral Neuropathic Pain - A Randomized, Multi-center,
Assessor-blinded Study
Medicine or Vaccine (generic name)
capsaicin
Sponsor Identification Number
QTZ-EC-0002
Trial Registry Identification Number(#'s)
NCT01416116
EudraCT Number: 2010-023258-34
Medical Condition
Neuropathic pain
Phase
Phase 4
http://clinicaltrials.gov/show/NCT01416116
End of Study Form 1/:
Vital Signs
Identification of Painful Area: Change
NPRS 'average pain' score
NPRS 'pain now' score
Adverse Event 1
Concomitant Medication 1
Any Non-medication Therapy
All rights reserved. Please visit https://medical-data-
models.org/forms/16871
End of Study Form 1/ Tolerability of
QUTENZA™ When Applied After
Pre-treatment With Lidocaine or
Tramadol in Subjects With Peripheral
Neuropathic Pain - A Randomized,
Multi-center, Assessor-blinded Study
NCT01416116
Vital Signs: 75 mins prior to patch
application
Date of Visit
Assessment Date
Position
Supine (1 )
Sitting (2 )
Standing (3 )
Systolic Blood Pressure
mmHg
Diastolic Blood Pressure
mmHg
Pulse Rate
Identification of Painful Area: Change
Is there any change in most painful area?
1 / 3
no (0)
yes (1)
NPRS 'average pain' score
Date of Assessment
NPRS 'average' pain score
0 (0 )
1 (1 )
10 (10 )
2 (2 )
3 (3 )
4 (4 )
5 (5 )
6 (6 )
7 (7 )
8 (8 )
9 (9 )
NPRS 'pain now' score: Post patch
application and post patch removal
Date of Assessment
NPRS 'pain now' score
1 (1)
10 (10)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
7 (7)
8 (8)
9 (9)
Tolerability score: Post patch removal
Date of Assessment
Tolerability score
1 (1)
10 (10)
2 (2)
3 (3)
4 (4)
5 (5)
6 (6)
7 (7)
8 (8)
9 (9)
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End of Study Form 1/ Tolerability of QUTENZA™ When Applied After Pre-treatment
With Lidocaine or Tramadol in Subjects With Peripheral Neuropathic Pain - A
Randomized, Multi-center, Assessor-blinded Study NCT01416116
Additional Information
Was any adverse event reported or observed?
no (0)
yes (1)
Is there any previous medication and /or
concomitant medication
to record?
no (0)
yes (1)
Is there any non-medication therapy and/or
changes in
non-medication therapy to record?
no (0)
yes (1)
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End of Study Form 1/ Tolerability of QUTENZA™ When Applied After Pre-treatment
With Lidocaine or Tramadol in Subjects With Peripheral Neuropathic Pain - A
Randomized, Multi-center, Assessor-blinded Study NCT01416116
End of Study Form 2/ Tolerability of QUTENZA™ When Applied After Pre-treatment
With Lidocaine or Tramadol in Subjects With Peripheral Neuropathic Pain - A
Randomized, Multi-center, Assessor-blinded Study NCT01416116
Study Sponsor: Astellas
Study Title
Tolerability of QUTENZA™ When Applied After Pre-
treatment With Lidocaine or Tramadol in Subjects With
Peripheral Neuropathic Pain - A Randomized, Multi-center,
Assessor-blinded Study
Medicine or Vaccine (generic name)
capsaicin
Sponsor Identification Number
QTZ-EC-0002
Trial Registry Identification Number(#'s)
NCT01416116
EudraCT Number: 2010-023258-34
Medical Condition
Neuropathic pain
Phase
Phase 4
http://clinicaltrials.gov/show/NCT01416116
End of Study Form 2/:
End of Study
All rights reserved. Please visit https://medical-data-
models.org/forms/16872
End of Study Form 2/  Tolerability of
QUTENZA™ When Applied After
Pre-treatment With Lidocaine or
Tramadol in Subjects With Peripheral
Neuropathic Pain - A Randomized,
Multi-center, Assessor-blinded Study
NCT01416116
End of Study
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Palliative and Hospice Care Voluntary Tasks
https://www.hope-clara.de/ 
The HOPE Hospice and Palliative Care Recording standard
documentation is used for documentation of palliative care
and as an instrument for quality assurance in pallatiave
wards, hospices and oncological wards as well as in
ambulatory services and palliative teams.
All rights reserved. Please visit https://medical-data-
models.org/forms/16873
Palliative and Hospice Care
Voluntary Tasks
Administrative Daten
13. Datum
1. IDNR
Unterstützung
Besuch  (Besuch )
Telefonat (Telefonat)
1. Unterstützung für den Sterbenden
Emotionale Unterstützung geben
Ja
Nein
Praktische Hilfe und Unterstützung leisten
Ja
Nein
Brückenfunktion bei gestörten Verbindungen
wahrnehmen
Ja
Nein
Zugang zur Außenwelt ermöglichen
Ja
Nein
Kreatives Handeln fördern
Ja
Nein
Normalität im Alltag aufrecht halten
Ja
Nein
2. Unterstützung für die Angehörigen
Emotionale Unterstützung geben
Ja
Nein
Praktische Hilfe und Unterstützung leisten
Ja
Nein
Verbindungen zur Außenwelt aufrecht erhalten
Ja
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Nein
Es ermöglichen, „draußen“ sein zu können,
Freiraum für Dinge des Alltags geben
Ja
Nein
Selbstbewusstsein stärken
Ja
Nein
Bei der Lösung von Problemen behilflich sein
Ja
Nein
3. Schützendes, sozialanwaltschaftliches
Handeln
Wunsch und Wollen des Sterbenden unterstützen
Ja
Nein
Den Sterbenden gegenüber Anderen
unterstützen
Ja
Nein
Die Angehörigen gegenüber Anderen
unterstützen
Ja
Nein
Die Angehörigen bei schwierigen
Entscheidungssituationen unterstützen
Ja
Nein
Den Sterbenden und die Angehörigen beim
Einfordern von Rechten unterstützen
Ja
Nein
4. Unterstützung des Sterbenden beim
Zugang zur Sinnklärung
Zugang zur bzw. Rückgewinnung der Spiritualität
ermöglichen
Ja
Nein
Biographisches Arbeiten fördern
Ja
Nein
Bei der Auseinandersetzung mit Schuld- und
Schamgefühlen Unterstützung leisten
Ja
Nein
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5. Hilfe bei der Organisation der „letzten
Dinge“ für den Sterbenden
Bei der Wahl der Versorgung Unterstützung
leisten
Ja
Nein
Beim Ordnen der persönlichen
Hinterlassenschaft helfen
Ja
Nein
Hinweise geben, die Zeit zur letzten Aussprache
zu nutzen
Ja
Nein
Über Patientenverfügungen und
Vorsorgevollmachten informieren
Ja
Nein
Beratungshilfen zu Regelungen bei der
Bestattung geben
Ja
Nein
6. Hilfe bei der Organisation der „l etzten
Dinge“ für die Angehörigen
Bei der Gestaltung des formalen Rahmens in der
unmittelbaren Sterbesituation helfen
Ja
Nein
Bei der Gestaltung des atmosphärischen
Rahmens in der unmittelbaren Sterbesituation
helfen und emotional unterstützen
Ja
Nein
Bei der Gestaltung des formalen Rahmens nach
dem Tod des Patienten helfen
Ja
Nein
Bei der Gestaltung des atmosphärischen
Rahmens nach dem Tod des Patienten helfen
und emotional unterstützen
Ja
Nein
Dokumentation der Unterstützung
Datum zu Beginn
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Datum Änderung des Ortes
Datum Änderung des Ortes
Datum Ende der Begleitung
1. Unterstützung für den Patienten
Emotionale Unterstützung geben
1. Änderung des Ortes (1. Änderung des
Ortes)
2. Änderung des Ortes (2. Änderung des
Ortes)
Beginn (Beginn)
Ende (Ende)
Bewertung Rückschau
kommt nicht vor (1)
selten (2)
oft (3)
immer (4)
Praktische Hilfe und Unterstützung leisten
1. Änderung des Ortes (1. Änderung des
Ortes)
2. Änderung des Ortes (2. Änderung des
Ortes)
Beginn (Beginn)
Ende (Ende)
Bewertung Rückschau
kommt nicht vor (1)
selten (2)
oft (3)
immer (4)
Unterstützung in der Kommunikation
(Familie/Umfeld)
1. Änderung des Ortes (1. Änderung des
Ortes)
2. Änderung des Ortes (2. Änderung des
Ortes)
Beginn (Beginn)
Ende (Ende)
Bewertung Rückschau
kommt nicht vor (1)
selten (2)
oft (3)
immer (4)
Normalität im Alltag aufrecht halten
1. Änderung des Ortes (1. Änderung des
Ortes)
2. Änderung des Ortes (2. Änderung des
Ortes)
Beginn (Beginn)
Ende (Ende)
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Bewertung Rückschau
kommt nicht vor (1)
selten (2)
oft (3)
immer (4)
Wunsch und Wollen des Patienten unterstützen
1. Änderung des Ortes (1. Änderung des
Ortes)
2. Änderung des Ortes (2. Änderung des
Ortes)
Beginn (Beginn)
Ende (Ende)
Bewertung Rückschau
kommt nicht vor (1)
selten (2)
oft (3)
immer (4)
Hilfe bei der Pflege
1. Änderung des Ortes (1. Änderung des
Ortes)
2. Änderung des Ortes (2. Änderung des
Ortes)
Beginn (Beginn)
Ende (Ende)
Hilfe bei der Pflege z.B.:
Bewertung Rückschau
kommt nicht vor (1)
selten (2)
oft (3)
immer (4)
Anderes:
1. Änderung des Ortes (1. Änderung des
Ortes)
2. Änderung des Ortes (2. Änderung des
Ortes)
Beginn (Beginn)
Ende (Ende)
Anderes:
Bewertung Rückschau
kommt nicht vor (1)
selten (2)
oft (3)
immer (4)
2. Unterstützung für die Angehörigen
Emotionale Unterstützung geben
1. Änderung des Ortes (1. Änderung des
Ortes)
2. Änderung des Ortes (2. Änderung des
Ortes)
Beginn (Beginn)
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Ende (Ende)
Bewertung Rückschau
kommt nicht vor (1)
selten (2)
oft (3)
immer (4)
Praktische Hilfe und Unterstützung leisten
1. Änderung des Ortes (1. Änderung des
Ortes)
2. Änderung des Ortes (2. Änderung des
Ortes)
Beginn (Beginn)
Ende (Ende)
Bewertung Rückschau
kommt nicht vor (1)
selten (2)
oft (3)
immer (4)
Freiraum für Dinge des Alltags geben
1. Änderung des Ortes (1. Änderung des
Ortes)
2. Änderung des Ortes (2. Änderung des
Ortes)
Beginn (Beginn)
Ende (Ende)
Bewertung Rückschau
kommt nicht vor (1)
selten (2)
oft (3)
immer (4)
Selbstbewusstsein stärken
1. Änderung des Ortes (1. Änderung des
Ortes)
2. Änderung des Ortes (2. Änderung des
Ortes)
Beginn (Beginn)
Ende (Ende)
Bewertung Rückschau
kommt nicht vor (1)
selten (2)
oft (3)
immer (4)
Die Angehörigen bei schwierigen
Entscheidungssituationen unterstützen
1. Änderung des Ortes (1. Änderung des
Ortes)
2. Änderung des Ortes (2. Änderung des
Ortes)
Beginn (Beginn)
Ende (Ende)
Bewertung Rückschau
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kommt nicht vor (1)
selten (2)
oft (3)
immer (4)
Trauerbegleitung
1. Änderung des Ortes (1. Änderung des
Ortes)
2. Änderung des Ortes (2. Änderung des
Ortes)
Beginn (Beginn)
Ende (Ende)
Bewertung Rückschau
kommt nicht vor (1)
selten (2)
oft (3)
immer (4)
Anderes:
1. Änderung des Ortes (1. Änderung des
Ortes)
2. Änderung des Ortes (2. Änderung des
Ortes)
Beginn (Beginn)
Ende (Ende)
Anderes:
Bewertung Rückschau
kommt nicht vor (1)
selten (2)
oft (3)
immer (4)
3. Auseinandersetzung in Glaubens- und
Lebensfragen
1. Änderung des Ortes (1. Änderung des
Ortes)
2. Änderung des Ortes (2. Änderung des
Ortes)
Beginn (Beginn)
Ende (Ende)
Konkret:
Bewertung Rückschau
kommt nicht vor (1)
selten (2)
oft (3)
immer (4)
Auseinandersetzung in Glaubens- und
Lebensfragen
1. Änderung des Ortes (1. Änderung des
Ortes)
2. Änderung des Ortes (2. Änderung des
Ortes)
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Beginn (Beginn)
Ende (Ende)
Konkret:
Bewertung Rückschau
kommt nicht vor (1)
selten (2)
oft (3)
immer (4)
4. Hilfe bei der Organisation der „letzten Dinge“ 
Bei der Gestaltung des Rahmens in der
unmittelbaren Sterbesituation helfen
1. Änderung des Ortes (1. Änderung des
Ortes)
2. Änderung des Ortes (2. Änderung des
Ortes)
Beginn (Beginn)
Ende (Ende)
Bewertung Rückschau
kommt nicht vor (1)
selten (2)
oft (3)
immer (4)
Bei der Gestaltung des Rahmens nach dem Tod
des Patienten helfen
1. Änderung des Ortes (1. Änderung des
Ortes)
2. Änderung des Ortes (2. Änderung des
Ortes)
Beginn (Beginn)
Ende (Ende)
Bewertung Rückschau
kommt nicht vor (1)
selten (2)
oft (3)
immer (4)
Anderes:
1. Änderung des Ortes (1. Änderung des
Ortes)
2. Änderung des Ortes (2. Änderung des
Ortes)
Beginn (Beginn)
Ende (Ende)
Anderes:
Bewertung Rückschau
kommt nicht vor (1)
selten (2)
oft (3)
immer (4)
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Anderes:
1. Änderung des Ortes (1. Änderung des
Ortes)
2. Änderung des Ortes (2. Änderung des
Ortes)
Beginn (Beginn)
Ende (Ende)
Anderes:
Bewertung Rückschau
kommt nicht vor (1)
selten (2)
oft (3)
immer (4)
5. Bemerkungen
6. Anzahl Besuche
6. Anzahl Telefonate
7. Zeitaufwand Gespräche
hours
7. Zeitaufwand Fahrtzeit
hours
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Eligibility Coronary Artery Disease
NCT00044213
Trial to Assess Chelation Therapy (TACT); ODM derived
from: https://clinicaltrials.gov/show/NCT00044213
All rights reserved. Please visit https://medical-data-
models.org/forms/16874
Eligibility Coronary Artery Disease
NCT00044213
Criteria
heart attack at least 6 weeks prior to study start*
Yes
No
exclusion criteria for participants:*
Yes
No
serum creatinie level greater than 2.0 mg/dl*
Yes
No
platelet count less than 100,000/µl*
Yes
No
blood pressure greater than 160/100*
Yes
No
chelation therapy within 5 years prior to study
start*
Yes
No
history of allergic reactions to edta or any of the
therapy's components*
Yes
No
coronary or carotid revascularization procedures
within 6 months prior to study start or a
scheduled revascularization*
Yes
No
cigarette smoking within 3 months prior to study
start*
Yes
No
childbearing potential*
Yes
No
history of liver disease*
Yes
No
active heart failure or heart failure hospitalization
within 6 months.*
Yes
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No
diagnoses of additional medical conditions that
could otherwise limit patient survival*
Yes
No
inability to tolerate 500-ml infusions weekly.*
Yes
No
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Eligibility Coronary Artery Disease NCT00044213
Demographics Form: UIC Quality
Improvement CRF
ODM derived from:
http://research.uic.edu/qip/toolbox/case-report-forms-crf.
Template Name: Demographics Form. QIP Case Report
Forms, UIC Quality Improvement CRF, Office of the Vice
Chancellor for Research. Center for Clinical and
Translational Science, UIC University of Illinois at Chicago.
All rights reserved. Please visit https://medical-data-
models.org/forms/16875
Demographics Form: UIC Quality
Improvement CRF
Demographics Form
Protocol Title
Site Number
Subject ID
Visit Date
1. Gender
Female (1)
Male (2)
2. Date of Birth
3. Race (select the one with which you most
closely identify)
American Indian or Alaska Native (1)
Asian (2)
Black or African-American (3)
Native Hawaiian or Other Pacific Islander
(4)
White (5)
More than one race (6)
Unknown or not reported (7)
4. Ethnicity (Select one with which you most
closely identify)
Hispanic or Latino (1)
Not Hispanic or Latino (2)
Unknown or not reported (3)
5. Informed Consent Process
Waiver of consent granted for
recruitment purposes (1)
Informed consent signed:
____(mm/dd/yy) (2)
5. Date (if informed consent signed)
Completed by (initials)
Date completed
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NCT00088179
Pexelizumab in Patients Undergoing Coronary Artery
Bypass Grafting With Cardiopulmonary Bypass (PRIMO-
CABG II); ODM derived from:
https://clinicaltrials.gov/show/NCT00088179
All rights reserved. Please visit https://medical-data-
models.org/forms/16877
Eligibility Coronary Artery Disease
NCT00088179
Inclusion Criteria
be at least 18 years of age;*
Yes
No
have 2 or more of the following risk factors:*
Yes
No
• diabetes mellitus; • repeat cabg; • the need for
urgent intervention, defined according to the
acc/aha guidelines as being patients who are
required to stay in the hospital due to medical
factors, but may be scheduled and operated on
within a normal scheduling routine, excluding
patients who have had an mi within 48 hours of
cabg; •*
Yes
No
female; • history of a neurologic event
(cerebrovascular accident, transient ischemic
attack or carotid endarterectomy); • history of
congestive heart failure (nyha chf class iii or iv); •
history of 2 mis, or an mi that occurred greater
than 48 hours but less than 4 weeks prior to
cabg;*
Yes
No
provide informed consent.*
Yes
No
Exclusion Criteria
requires salvage intervention as defined by the
acc/aha guidelines 10 as being ongoing
cardiopulmonary resuscitation on the way to the
operating room;*
Yes
No
has current cardiogenic shock, acute left
ventricular rupture, acute septal rupture or acute
papillary muscle rupture;*
Yes
No
has any active bacterial or other infection which is
clinically significant, in the opinion of the
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investigator (e.g. evaluate the evidence based on
wbc, temperature, cultures etc. as appropriate for
the patient);*
Yes
No
has a known or suspected hereditary
complement deficiency;*
Yes
No
has participated in any other investigational drug
study or was exposed to an investigational agent
or device within 30 days of randomization;*
Yes
No
is receiving, or is planning to receive, any other
investigational drug or device, or will participate in
any other research study within 30 days of
randomization;*
Yes
No
is pregnant or breast-feeding.*
Yes
No
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Medical History Form: UIC Quality
Improvement CRF
ODM derived from:
http://research.uic.edu/qip/toolbox/case-report-forms-crf.
Template Name: Medical History Form. QIP Case Report
Forms, UIC Quality Improvement CRF, Office of the Vice
Chancellor for Research. Center for Clinical and
Translational Science, UIC University of Illinois at Chicago.
All rights reserved. Please visit https://medical-data-
models.org/forms/16878
Medical History Form: UIC Quality
Improvement CRF
General Information
Protocol Title
Site Number
Subject ID
Visit Date
Study Visit
Medical History
1. HEENT
Yes
No
HEENT: UNK (unknown)
Yes
No
HEENT: If yes, Describe (include onset date)
HEENT
Current (1)
Resolved (2)
2. Respiratory
Yes
No
Respiratory: UNK
Yes
No
Respiratory: If yes, Describe (include onset date)
Respiratory
Current (1)
Resolved (2)
3. Cardiovascular
Yes
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No
Cardiovascular: UNK
Yes
No
Cardiovascular: If yes, Describe (include onset
date)
Cardiovascular
Current (1)
Resolved (2)
4. Gastrointestinal/Hepatic
Yes
No
Gastrointestinal/Hepatic: UNK
Yes
No
Gastrointestinal/Hepatic: If yes, Describe (include
onset date)
Gastrointestinal/Hepatic
Current (1)
Resolved (2)
5. Genitourinary
Yes
No
Genitourinary: UNK
Yes
No
Genitourinary: If Yes, Describe (include onset
date)
Genitourinary
Current (1)
Resolved (2)
6. Musculoskeletal
Yes
No
Musculoskeletal: UNK
Yes
No
Musculoskeletal: If Yes, Describe (include onset
date)
Musculoskeletal
Current (1)
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Resolved (2)
7. Neurological
Yes
No
Neurological: UNK
Yes
No
Neurological: If yes, Describe (include onset
date)
Neurological
Current (1)
Resolved (2)
8. Endocrine-Metabolic
Yes
No
Endocrine-Metabolic: UNK
Yes
No
Endocrine-Metabolic: If Yes, Describe (include
onset date)
Endocrine-Metabolic
Current (1)
Resolved (2)
9. Hematologic/Lymphatic
Yes
No
Hematologic/Lymphatic: UNK
Yes
No
Hematologic/Lymphatic: If Yes, Describe (include
onset date)
Hematologic/Lymphatic
Current (1)
Resolved (2)
10. Dermatologic
Yes
No
Dermatologic: UNK
Yes
No
Dermatologic: If Yes, Describe (include onset
date)
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Dermatologic
Current (1)
Resolved (2)
11. Psychiatric
Yes
No
Psychiatric: UNK
Yes
No
Psychiatric: If Yes, Describe (include onset date)
Psychiatric
Current (1)
Resolved (2)
12. Allergy
Yes
No
Allergy: UNK
Yes
No
Allergy: If Yes, Describe (include onset date)
Allergy
Current (1)
Resolved (2)
13. Surgical Procedure
Yes
No
Surgical Procedure: UNK
Yes
No
Surgical Procedure: If Yes, Describe (include
onset date)
Surgical Procedure
Current (1)
Resolved (2)
14. Other (specify)
Yes
No
Other (specify)
Yes
No
Other (specify): UNK
Yes
4 / 5
Medical History Form: UIC Quality Improvement CRF
No
Other (specify): If Yes, Describe (include onset
date)
Other (specify)
Current (1)
Resolved (2)
Completed by (initials)
Date completed
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Eligibility Coronary Artery Disease
NCT00090558
Effect of Nitric Oxide Donor on Endothelial Progenitor Cells
in Patients With Coronary Artery Disease; ODM derived
from: https://clinicaltrials.gov/show/NCT00090558
All rights reserved. Please visit https://medical-data-
models.org/forms/16879
Eligibility Coronary Artery Disease
NCT00090558
Criteria
1. adults older than 21 years.*
Yes
No
2. coronary artery disease established by
angiography.*
Yes
No
3. no myocardial infarction within 1 month.*
Yes
No
4. left ventricular ejection fraction greater than
30%.*
Yes
No
5. no congestive heart failure symptoms within 2
months.*
Yes
No
6. no associated medical, neurological or
orthopedic condition that might prohibit safe
performance of exercise.*
Yes
No
7. subject understands protocol and provides
written, informed consent in addition to
willingness to comply with specified follow-up
evaluations.*
Yes
No
patient exclusion criteria*
Yes
No
1. significant structural heart disease (e.g.
hypertrophic or dilated cardiomyopathy, valvular
heart disease) as determined by
echocardiography.*
Yes
No
2. history of recent (within 2 months) rest or
nocturnal angina*
Yes
No
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3. organic nitrate (e.g., nitroglycerin) use other
than study medication within 24 hours of exercise
testing*
Yes
No
4. hypersensitivity to organic nitrates.*
Yes
No
5. women of childbearing age unless recent
pregnancy test is negative.*
Yes
No
6. lactating women.*
Yes
No
eligibility criteria - healthy subjects*
Yes
No
healthy subjects must be older than 50 years of
age (to approximate the anticipated age of cad
patients), without known cad, and be free of the
following risk factors: blood pressure greater than
140/90 mmhg, fasting glucose greater than 110
mg/dl, smoking, total cholesterol greater than 250
mg/dl. healthy subjects taking chronic
prescription medications will be excluded.*
Yes
No
2 / 2
Eligibility Coronary Artery Disease NCT00090558
Eligibility Coronary Artery Disease
NCT00134433
Endothelial Modulation for Angiogenic Therapy; ODM
derived from: https://clinicaltrials.gov/show/NCT00134433
All rights reserved. Please visit https://medical-data-
models.org/forms/16880
Eligibility Coronary Artery Disease
NCT00134433
Inclusion Criteria
severe chronic angina*
Yes
No
multi-vessel coronary artery disease*
Yes
No
diffusely diseased left anterior descending
coronary artery (lad)*
Yes
No
at least 18 years of age at the time of written
informed consent*
Yes
No
Exclusion Criteria
pregnancy, lactation, or any child-bearing
potential*
Yes
No
patients who are candidates for percutaneous
transluminal coronary angioplasty (ptca) or
stenting*
Yes
No
severe left ventricular dysfunction (ejection
fraction < 30%)*
Yes
No
threatened proximal coronary occlusion or
unstable angina*
Yes
No
recent myocardial infarction (< 1 month)*
Yes
No
chronic renal failure (serum creatinine > 130
µmol/l)*
Yes
No
hepatic insufficiency (child-pugh class c)*
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Yes
No
clinically significant valvular heart disease*
Yes
No
personal history of neoplasia*
Yes
No
abnormal serum prostate-specific antigen (psa),
bowel neoplasia screening questionnaire, or
updated mammography report (if female) - any
test not performed within the last 6 months will be
conducted prior to confirmation of eligibility*
Yes
No
family history of cancer (i.e. ≥ 2 first-degree
relatives)*
Yes
No
history of diabetic retinopathy*
Yes
No
latent herpes infection*
Yes
No
schizophrenia*
Yes
No
claustrophobia*
Yes
No
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Eligibility Coronary Artery Disease
NCT00156845
Phase 3 Safety and Imaging Study of AI-700 in Patients
With Suspected Coronary Artery Disease Undergoing
Coronary Angiography; ODM derived from:
https://clinicaltrials.gov/show/NCT00156845
All rights reserved. Please visit https://medical-data-
models.org/forms/16881
Eligibility Coronary Artery Disease
NCT00156845
Inclusion Criteria
men and non-pregnant/non-lactating women with
a history of typical or atypical chest pain (angina)
who were 18 to 80 years of age and who had
recently undergone coronary angiography or
were scheduled for coronary angiography within
30 days after ai-700 administration were to be
enrolled.  eligible patients must have also
undergone spect for evaluation of cad within 45
calendar days prior to ai-700 administration, or be
scheduled for an “on-study” spect on the same
day as ai-700 dosing or an “off-study”*
Yes
No
spect within 15 days following ai-700 dosing.*
Yes
No
Exclusion Criteria
study candidates who have had any of the
following conditions were to be excluded from the
study: any clinically unstable condition or major
surgery within 7 days prior to ai-700 dosing; an
acute mi; cerebrovascular accident or transient
ischemic attack within 30 days prior to dosing;
congestive heart failure graded as new york heart
association grade 4 within 3 months prior to
dosing; significant left main cad; previous
coronary artery bypass graft; moderate to severe
chronic obstructive pulmonary disease; or oxygen
saturation < 90% at rest.*
Yes
No
candidates with significant cardiovascular or
pulmonary structural and/or functional
abnormality, or in whom visualization of the left
ventricle was not adequate for evaluation of
cardiac function during the exclusion echo, were
to be ineligible to participate in the study.*
Yes
No
patients who had a history of mi of non-cad
etiology or who exhibited new or changing ecg
abnormalities at any time between screening and
ai-700 dosing were to be similarly excluded.*
Yes
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No
other exclusion criteria included: participation in
an investigational drug/device study within 30
days prior to dosing (90 days in uk sites), non-
seasonal asthma within the past 3 years or recent
seasonal asthma requiring prescription
medication, organ transplant or end-stage organ
failure, and active seizure disorder.*
Yes
No
candidates were to be excluded for uncontrolled
atrial fibrillation, frequent premature ventricular or
atrial contractions,  history of prolonged qt/qtc,
use of automatic implantable
cardioverter/defibrillator or pacemaker, and any
rhythm abnormality that had not been evaluated
and treated by a specialist or for which current
treatment did not ensure patient safety.*
Yes
No
candidates who had used methylated xanthines
within 24 hours of dosing were also to be
excluded.  patients were also to be excluded if
aminophylline, theophylline, or dipyridamole were
contraindicated according to each agent’s
product labeling.*
Yes
No
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UKM-Pediatric Hematology und Oncology
Patient Admittance Form
Freigabe zur Verarbeitung durch Frau Prof. Rössig,
Quellenangabe: "Pädiatrische Hämatologie und Onkologie,
UKM" Klinik für Kinder- und Jugendmedizin,
Universitätsklinikum Münster
Released for adaption by Frau Prof. Rössig
Source:Pediatric Hematology und Oncology, University
hospital Münster
All rights reserved. Please visit https://medical-data-
models.org/forms/16882
Pädiatrischer Hämatologie und
Onkologie Aufnahmebogen
Demographie
Patienten Name
Adresse des Patienten
Versicherter
Arbeitgeber:
Kostenträger
Angehörige
Einweiser
Größe
cm
Gewicht
kg
Körperoberfläche
m²
Diagnose
Stadium
Geplante Aufnahme am
Protokoll/Arm:
Geplanter Block
Dosisreduktion
Ja
Nein
Wenn ja, welche Dosisreduktion?
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Wenn ja, warum wurde die Dosis reduziert?
Bestrahlung?
Ja
Nein
Bestrahlungsdosis
Gy
Bestrahlungsfeld
Besondere Supportivtherapie?
Ja
Nein
Welche besondere Supportivtherapie?
Warum besondere Supportivtherapie?
Sonstige Modifikation oder Besonderheiten
Ja
Nein
Welche sonstige Modifikation oder
Besonderheiten?
Klinische Untersuchung
Patient/in untersucht?
Ja
Nein
Wenn ja, Datum der Untersuchung
Wenn nicht untersucht, warum nicht?
Infektiösität
Ja
Nein
Infektiösität: bitte genauer bezeichnen
Isolierung
Ja
Nein
Klinische Kontraindikation gegen Chemo?
Ja
Nein
Wenn ja, welche Kontraindikation(en)?
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Allgemeinzustand gut
Ja
Nein
Keine Infektion
Ja
Nein
Keine Antibiose
Ja
Nein
G-CSF >48h her
Ja
Nein
Labor und apparative Untersuchungen
Blutbild
Niedrig (1)
Genügend (2)
Grenzwertprotokoll Leukozyten
/µl
Blutbild Leukozyten
/µl
Grenzwertprotokoll Granulozyten
%
Blutbild Granulozyten
%
Grenzwertprotokoll Thrombozyten
/µl
Blutbild Thrombozyten
/µl
Datum Blutbild
Elektrolyte
erforderlich, aber nicht durchgeführt (1)
pathologisch (2)
ohne Befund (3)
Elektrolyte:ggf Werte
CRP
erforderlich, aber nicht durchgeführt (1)
pathologisch (2)
ohne Befund (3)
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CRP:ggf Werte
md/dl
Kreatinin
nicht erforderlich (1)
erforderlich, aber nicht durchgeführt (2)
pathologisch (3)
ohne Befund (4)
Kreatinin
mg/dl
Kreatinin clearance nach Schwartz
nicht erforderlich (1)
erforderlich, aber nicht durchgeführt (2)
pathologisch (3)
ohne Befund (4)
Kreatinin clearance nach Schwartz
Rossl-Check vor IFO
nicht erforderlich (1)
erforderlich, aber nicht durchgeführt (2)
pathologisch (3)
ohne Befund (4)
Rossl-Check vor IFO
Leberwerte
nicht erforderlich (1)
erforderlich, aber nicht durchgeführt (2)
pathologisch (3)
ohne Befund (4)
Leberwerte (Bili,Transaminasen):Werte
Herzecho (FS)
nicht erforderlich (1)
erforderlich, aber nicht durchgeführt (2)
pathologisch (3)
ohne Befund (4)
Herzecho (FS)
FS-Wert
Hörtest
nicht erforderlich (1)
erforderlich, aber nicht durchgeführt (2)
pathologisch (3)
ohne Befund (4)
Hörtest Befund
Sonstige Untersuchungen/Narkosen etc (auch
geplant)
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Ja
Nein
Sonstige Untersuchungen/Narkosen etc (auch
geplant):Wenn ja, was und wann
Therapieplan
Therapieplan
liegt nicht bei (1)
liegt berechnet und unterschrieben bei
(2)
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Eligibility Coronary Artery Disease
NCT00225693
V-Flex Plus PTX Drug Eluting Coronary Stent; ODM
derived from: https://clinicaltrials.gov/show/NCT00225693
All rights reserved. Please visit https://medical-data-
models.org/forms/16883
Eligibility Coronary Artery Disease
NCT00225693
Inclusion Criteria
patient must be eligible to undergo planned
treatment of a single de novo lesion in a native
coronary artery.*
Yes
No
patient must be an acceptable candidate for
coronary artery bypass surgery*
Yes
No
patient or legal guardian must have given
informed consent*
Yes
No
patient agrees to return at one month for an office
visit to assess cardiovascular status and at 6
months for an office visit to assess cardiovascular
status, an ivus examination and a diagnostic
angiogram.*
Yes
No
Exclusion Criteria
patient must be less than 18 years old*
Yes
No
patient has history of bleeding diathesis or
coagulopathy or will refuse blood transfusions.*
Yes
No
patient is simultaneously participating in another
investigative interventional cardiovascular device
or drug study.*
Yes
No
patient has known hypersensitivity or
contraindication to aspirin, clopidogrel, or
stainless steel, or a sensitivity to contrast dye.*
Yes
No
women of child bearing potential.*
Yes
No
1 / 2
patient has other medical condition that any
cause non-compliance with the protocol,
confound the results or is associated with limited
life expectancy.*
Yes
No
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Eligibility Coronary Artery Disease
NCT00232791
The Study to Compare Cypher Versus Cypher Select in
Treating Cornary Artery Lesions.; ODM derived from:
https://clinicaltrials.gov/show/NCT00232791
All rights reserved. Please visit https://medical-data-
models.org/forms/16884
Eligibility Coronary Artery Disease
NCT00232791
Inclusion Criteria
1. diagnosis of angina pectoris as defined by
canadian cardiovascular society classification
(ccs i, ii, iii, iv) or unstable angina pectoris
(braunwald classification b&c, i-ii-iii) or patients
with documented silent ischemia;*
Yes
No
2. single treatment of de novo lesion in a
coronary artery which can be appropriately
covered by a study stent up to 23mm in length in
patients with single or multivessel disease;
patients with multiple lesions can be included
only if the other lesions are successfully treated
before the target lesion;*
Yes
No
3. target lesion is more than 2.5 and less than
3.5mm in diameter (visual estimate);*
Yes
No
4. target lesion is located in a native coronary
artery with a maximum lesion length that can be
adequately covered by a single 23 mm stent;*
Yes
No
5. target lesion stenosis is > 50% and < 100%
(visual estimate).*
Yes
No
Exclusion Criteria
1. a q-wave or non-q-wave myocardial infarction
within the preceding 72 hours unless the ck and
ck-mb enzymes are back to normal;*
Yes
No
2. unprotected left main coronary disease with
more than 50% stenosis;*
Yes
No
3. significant (>50%) stenoses proximal or distal
to the target lesion that might require
revascularization or impede runoff;*
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Yes
No
4. have an ostial target lesion;*
Yes
No
5. angiographic evidence of thrombus within
target lesion;*
Yes
No
6. calcified lesions which cannot be successfully
predilated;*
Yes
No
7. ejection fraction less than 30%;*
Yes
No
8. totally occluded vessel (timi 0 level);*
Yes
No
9. direct stenting;*
Yes
No
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Eligibility Coronary Artery Disease
NCT00233714
Double or Single Dose Sirolimus-Eluting Stents in Diabetic
Patients With de Novo Coronary Artery Lesions; ODM
derived from: https://clinicaltrials.gov/show/NCT00233714
All rights reserved. Please visit https://medical-data-
models.org/forms/16885
Eligibility Coronary Artery Disease
NCT00233714
Inclusion Criteria
1. the patient must be minimum 18 years of age;*
Yes
No
2. patients must be previously diagnosed with
diabetes with documented treatment with insulin,
oral medications, or diet for a minimum of 3
months;*
Yes
No
3. diagnosis of angina pectoris as defined by
canadian cardiovascular society classification
(ccs i, ii, iii, iv) or unstable angina pectoris
(braunwald classification b&c, i-ii-iii) or patients
with documented silent ischemia;*
Yes
No
4. treatment of one lesion in a native coronary
artery.  the treated lesion will be the one with the
highest % diameter stenosis by visual estimate.
additional study stents may be used for
procedural complications such as dissections.
multivessel treatment is permissible in non-target
vessels; however, additional lesions may only be
treated with commercial stents.  if other non-
target lesions are treated with commercial stents
during the index procedure, they must be
successfully treated prior to the study lesion;*
Yes
No
5. the target vessel is  2.5 mm and  3.5mm in
diameter (visual estimate);*
Yes
No
6. the target lesion is <30 mm in length (visual
estimate) located in a native coronary artery;*
Yes
No
7. target lesion stenosis is >50% and <100% (timi
i) (visual estimate);*
Yes
No
Exclusion Criteria
1. patient has experienced a q-wave or non-q-
1 / 2
wave myocardial infarction with documented total
ck>2 times normal within the preceding 24 hours
and the ck and ck-mb enzymes remains above
normal at the time of treatment;*
Yes
No
2. patients admitted for treatment of diabetic
ketoacidosis > 2 times in the past six months
(brittle diabetics);*
Yes
No
3. ejection fraction 30%;*
Yes
No
4. impaired renal function (creatinine > 2.0
mg/dl);*
Yes
No
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ODM Test Study
Test of ODM-Tools
All rights reserved. Please visit https://medical-data-
models.org/forms/16886
ODM-Test
ODM-Test Itemgroup
Bereitschaft zur Teilnahme*
Ja
Nein
Alter
>= 0
<= 120
years
Geschlecht
männlich (1)
weiblich (2)
unbekannt (3)
Geburtsdatum
Diagnose
Diagnose-Kode
ICD10-GM
Kreatinin
>= 0
<= 20
mg/dl
Uhrzeit des Laborwerts
hh:mm
Datum des Laborwerts
DD.MM.YYYY
Kommentar
Kalium
mmol/l
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Eligibility Coronary Artery Disease
NCT00233779
Evaluation of Sirolimus-Eluting, Heparin-Coated CoCr Stent
in the Treatment of de Novo Coronary Artery Lesions in
Small Vessels(EVOLUTION); ODM derived from:
https://clinicaltrials.gov/show/NCT00233779
All rights reserved. Please visit https://medical-data-
models.org/forms/16887
Eligibility Coronary Artery Disease
NCT00233779
Inclusion Criteria
1. the patient must be minimum 18 years of age;*
Yes
No
2. diagnosis of angina pectoris as defined by
canadian cardiovascular society classification
(ccs i, ii, iii, iv) or unstable angina pectoris
(braunwald classification b&c, i-ii-iii) or patients
with documented silent ischemia;*
Yes
No
3 treatment of one lesion in a native coronary
artery.  the treated lesion will be the one with the
highest % diameter stenosis by visual estimate.
additional study stents may be used for
procedural complications such as dissections.
multivessel treatment is permissible in non-target
vessels; however, additional lesions may only be
treated with commercial stents.  if other non-
target vessels are treated with commercial stents
during the index procedure, they must be
successfully treated prior to the study lesion;*
Yes
No
4. the target lesion is >/=2.0 mm and </=2.5mm
in diameter (visual estimate);*
Yes
No
5. the target lesion can be covered with a single
18mm stent;*
Yes
No
6. target lesion stenosis is >50% and <100% (timi
i) (visual estimate);*
Yes
No
Exclusion Criteria
1. patient has experienced a q-wave or non-q-
wave myocardial infarction with documented total
ck>2 times normal within the preceding 24 hours
and the ck and ck-mb enzymes remain above
normal at the time of treatment;*
Yes
No
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2. target lesion is due to in-stent restenosis;*
Yes
No
3. ejection fraction 30%;*
Yes
No
4. totally occluded vessel (timi 0 level);*
Yes
No
5. impaired renal function (creatinine > 3.0
mg/dl);*
Yes
No
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Durchgangsarztbericht
All rights reserved. Please visit https://medical-data-
models.org/forms/16888
Durchgangsarztbericht
Patienten-Informationen
Unfallversicherungsträger:
Vorame des Versicherten
Nachmane des Versicherten
Geburtsdatum des Versicherten
Beschäftigt als:
Beschäftigung seit:
Unfallbetrieb
ggf. mit Telefon-Nr. 
(Bezeichnung bzw. Name und Anschrift des
Arbeitgebers, der Kindertageseinrichtung, der
Schule oder Hochschule, des Pflegebedürftigen)
Vollständige Anschrift des Versicherten:
Informationen über Durchgangsarztbericht
Eingetroffen am
Uhrzeit
Krankenkasse
(bei Fam.-Vers. Name des Mitglieds; in diesem
Falle keine Kopie an die Krankenkasse)
Bei Pflegeunfall Pflegekasse des Pflegebürftigen
Telefon-Nr. des Versicherten
Staatsangehörigkeit
Geschlecht
Unfall
Unfalltag
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Uhrzeit
Beginn der Arbeitszeit
Uhr:
Ende der Arbeitszeit
Uhr:
Angaben des Versicherten zum Unfallort
Anagben des Versicherten zum Unfallhergang
Angaben des Versicherten zur Tätigkeit, bei der
der Unfall eingetreten ist
Verhalten des Verischerten nach dem Unfall
Behandlung und Befunde
Art der ersten (nicht durchgangsärztl.)
Versorgung
Erstmalig behandelt am:
Erstmalig behandelt durch:
Verdacht auf Alkohol-, Drogen-,
Medikamenteneinfluss?
Ja
Nein
Bei positivem Verdacht auf Alkohol-, Drogen-,
Medikamenteneinfluss, spezifizieren Sie die
Anzeichen:
Blutentnahme?
Ja
Nein
Röntgenergebnis
Erstdiagnosis (Änderungen/ Konkretisierungen
unverzüglich nachmelden)
(Auch Angabe von ICD 10, ICPM und AO-
Klassifikation)
Art der ersten Versorgung (durch den D-Arzt)
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Vom Unfall unabhängige gesundheitliche
Beeinträchtigugnen, die für die Beurteilung des
Arbeitsunfalls von Bedeutung sein können
Sprechen Hergang und Befund gegen die
Annahme eines Arbeitsunfalls?
(Wenn ja, ist keine Behandlung zu Lasten der
Unfallversicherung durchzufhren und dem
Verischerten eine Kopie des
Druchgangsarztberichtes auszuhändigen)
Ja
Nein
Sprechen Hergang und Befund gegen die
Annahme eines Arbeitsunfalls?
(Wenn ja, ist keine Behandlung zu Lasten der
Unfallversicherung durchzufhren und dem
Verischerten eine Kopie des
Druchgangsarztberichtes auszuhändigen)
Wenn ja, weil:
Besteht konkreter Anlass, dass der Versicherte
von einem Mitarbeiter des UV-Trägers beraten
wird)
Ja
Nein
Besteht konkreter Anlass, dass der Versicherte
von einem Mitarbeiter des UV-Trägers beraten
wird)
Wenn ja, weil:
Art der Heilbehandlung
Allgemeine Heilbehandlung durch
anderen Arzt (Allgemeine
Heilbehandlung durch anderen Arzt)
Allgemeine Heilbehandlung durch mich
(Allgemeine Heilbehandlung durch mich)
Besondere Heilbehandlung: ambulant
(Besondere Heilbehandlung: ambulant)
Besondere Heilbehandlung: stationär
(Besondere Heilbehandlung: stationär)
Es wird keine Heilbehandlung zu Lasten
der UV durchgeführt (Es wird keine
Heilbehandlung zu Lasten der UV
durchgeführt)
Liegt eine Verletzung nach dem
Verletzungs-/
Schwerstverletzungsartenverzeichnis
vor? Ja (Liegt eine Verletzung nach dem
Verletzungs-/
Schwerstverletzungsartenverzeichnis
vor? Ja)
Liegt eine Verletzung nach dem
Verletzungs-/
Schwerstverletzungsartenverzeichnis
vor? Nein (Liegt eine Verletzung nach
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dem Verletzungs-/
Schwerstverletzungsartenverzeichnis
vor? Nein)
Beurteilung der Arbeitsfähigkeit
arbeitsfähig (arbeitsfähig)
voraussichtlich länger als 6 Monate
arbeitsunfähig (voraussichtlich länger als
6 Monate arbeitsunfähig)
voraussichtlich wieder arbeitsunfähig
(voraussichtlich wieder arbeitsunfähig)
Wenn voraussichtlich arbeitsunfähig,
spezifizieren Sie bitte ab wann:
Wenn voraussichtlich wieder arbeitsfähig,
spezifizieren Sie bitte ab wann:
Ist die Zuziezhung von Konsiliarärzten zur
Klärung der Diagnose und/ oder Mitbehandlung
erforderlich?
Ja
Nein
Ist die Zuziezhung von Konsiliarärzten zur
Klärung der Diagnose und/ oder Mitbehandlung
erforderlich?
Wenn ja, zugezogen wird:
Nachschau ist erforderlich, sofern dann noch AU
oder Behandlungsbedürftigkeit vorliegen sollte,
am:
(bei Verschlimmerung sofort. Der Termin wurde
dem Versicherten bekannt gegeben.)
Anschrift des weiter behandelnden Arztes oder
Krankenhaus:
Identifikation und Unterschrift
Datum
Unterschrift des Durchgangsarztes
Rechnung - Nur abrechnen, wenn keine
Weiterbehandlung durch Sie vorgesehen
ist. Ansonsten Abrechnung bitte
zusammen mit Ihrer
Behandlungsrechnung.
Berichtsgebühr
(nach Nr. 132 UV GOÄ)
EUR
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Ergänzungsbericht nach Nr. (UV-GOÄ):
Ergänzungsbericht: Bezahlung
EUR
Ärztliche Leistung nach Nr. (UV-GOÄ):
Ärztliche Leistung: Bezahlung
EUR
Ärztliche Leistung: Besondere Kosten
EUR
Tetanus Hyperimmun-Globulin: Bezahlung
EUR
Tetanus Hyperimmun-Globulin: Besondere
Kosten
EUR
Aktive Immunisierung (Tetanol-Tetatoxoid):
Bezahlung
EUR
Aktive Immunisierung (Tetanol-Tetatoxoid):
Besondere Kosten
EUR
Summe Besondere Kosten
EUR
Porto: Bezahlung
EUR
zusammen:
EUR
Rechnungsnummer
Institutionskennzeichen (IK
Falls kein IK - Bankverbindung (IBAN und BIC)
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Eligibility Chronic Nephropathy
NCT00276133
Effects of Atorvastatin Versus Probucol on Small Dense
LDL; ODM derived from:
https://clinicaltrials.gov/show/NCT00276133
All rights reserved. Please visit https://medical-data-
models.org/forms/16889
Eligibility Chronic Nephropathy
NCT00276133
Inclusion Criteria
hyperlipidemic patients with non-diabetic
nephropathy*
Yes
No
Exclusion Criteria
endocrinological, hematological or hepatic
disease*
Yes
No
cerebral infarction or hemorrhage*
Yes
No
homozygous familial hypercholesterolemia*
Yes
No
uncontrolled hypertension*
Yes
No
myocardial infarction occurring within the
previous 6 months*
Yes
No
unstable angina*
Yes
No
diabetic nephropathy*
Yes
No
abnormal thyroid function*
Yes
No
receiving steroids or immunosuppressive agents*
Yes
No
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Eligibility Chronic Renal Failure
NCT02194114
Dietary Protein Requirements in Hemodialysis Patients;
ODM derived from:
https://clinicaltrials.gov/show/NCT02194114
All rights reserved. Please visit https://medical-data-
models.org/forms/16890
Eligibility Chronic Renal Failure
NCT02194114
Inclusion Criteria
ages from 30 years through 65 years*
Yes
No
both men and women and all ethnic and racial
groups*
Yes
No
treatment with mhd for 6 months or greater*
Yes
No
hemoglobin of at least 11 g/dl*
Yes
No
neurological examination indicating no severe
neuropathy*
Yes
No
a negative test for peripheral arterial occlusive
disease*
Yes
No
Exclusion Criteria
obesity: body weight greater than >115% of
standard*
Yes
No
history of active cancer other than basal cell
carcinoma*
Yes
No
symptomatic severe ischemic heart disease,
uncontrolled serious dysrhythmias, uncontrolled
congestive heart failure, poorly controlled
hypertension, severe musculoskeletal disease,
arthritis or amputations of the lower extremities*
Yes
No
insulin dependent or insulin independent diabetes
mellitus*
Yes
No
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severe lung or liver disease, uncontrolled asthma,
active vasculitis. severe chronic infection or any
other acute or chronic inflammatory or catabolic
illnesses*
Yes
No
psychosis, inability to give informed consent,
evidence that patient will not comply with study
protocol*
Yes
No
alcohol or other recreational drug abuse*
Yes
No
patients who received l-carnitine or anabolic
hormones within the previous 6 months*
Yes
No
pregnancy*
Yes
No
patients who are physically and/or
psychologically incapable of undergoing the
protocol*
Yes
No
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Eligibility Chronic Renal Failure
NCT02194114
Dietary Protein Requirements in Hemodialysis Patients;
ODM derived from:
https://clinicaltrials.gov/show/NCT02194114
All rights reserved. Please visit https://medical-data-
models.org/forms/16891
Eligibility Chronic Renal Failure
NCT02194114
Inclusion Criteria
ages from 30 years through 65 years*
Yes
No
both men and women and all ethnic and racial
groups*
Yes
No
treatment with mhd for 6 months or greater*
Yes
No
hemoglobin of at least 11 g/dl*
Yes
No
neurological examination indicating no severe
neuropathy*
Yes
No
a negative test for peripheral arterial occlusive
disease*
Yes
No
Exclusion Criteria
obesity: body weight greater than >115% of
standard*
Yes
No
history of active cancer other than basal cell
carcinoma*
Yes
No
symptomatic severe ischemic heart disease,
uncontrolled serious dysrhythmias, uncontrolled
congestive heart failure, poorly controlled
hypertension, severe musculoskeletal disease,
arthritis or amputations of the lower extremities*
Yes
No
insulin dependent or insulin independent diabetes
mellitus*
Yes
No
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severe lung or liver disease, uncontrolled asthma,
active vasculitis. severe chronic infection or any
other acute or chronic inflammatory or catabolic
illnesses*
Yes
No
psychosis, inability to give informed consent,
evidence that patient will not comply with study
protocol*
Yes
No
alcohol or other recreational drug abuse*
Yes
No
patients who received l-carnitine or anabolic
hormones within the previous 6 months*
Yes
No
pregnancy*
Yes
No
patients who are physically and/or
psychologically incapable of undergoing the
protocol*
Yes
No
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Eligibility Chronic Schizophrenia
NCT00161044
An Open-Label Investigation of the Adjuvant Therapeutic
Effects of Galantamine in Patients With Chronic
Schizophrenia and Persistent Deficit Symptoms; ODM
derived from: https://clinicaltrials.gov/show/NCT00161044
All rights reserved. Please visit https://medical-data-
models.org/forms/16892
Eligibility Chronic Schizophrenia
NCT00161044
Inclusion Criteria
fulfills dsm-iv criteria for schizophrenia.*
Yes
No
unable to achieve competitive employment status
within the past five years.*
Yes
No
unable to live independently in the community.*
Yes
No
maintained on a stable regimen of antipsychotic
medication for at least two weeks prior to
enrollment.*
Yes
No
Exclusion Criteria
history of significant hepatic, renal, pulmonary,
endocrine, active peptic ulcer disease or
cardiovascular disease.*
Yes
No
history of seizure disorder and/or head injury.*
Yes
No
co-morbid substance use/abuse disorder.*
Yes
No
received an investigational medication within the
previous month.*
Yes
No
due to the risk of adverse effects on fetal
development: women with any risk of becoming
pregnant will be excluded from this study.*
Yes
No
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Eligibility Coronary Artery Disease
NCT00235092
The REALITY Study - Head-to-Head Comparison Between
Cypher and Taxus; ODM derived from:
https://clinicaltrials.gov/show/NCT00235092
All rights reserved. Please visit https://medical-data-
models.org/forms/16893
Eligibility Coronary Artery Disease
NCT00235092
Inclusion Criteria
1. diagnosis of angina pectoris as defined by
canadian cardiovascular society classification
(ccs i, ii, iii, iv) or unstable angina pectoris
(braunwald classification b&c, i-ii-iii) or patients
with documented silent ischemia;*
Yes
No
2. treatment of up to two de novo native coronary
artery lesions in a maximum of two major
coronary arteries;*
Yes
No
3. ostial lesions;*
Yes
No
4. bifurcations;*
Yes
No
5. target vessel diameter of both lesions must be
>=2.25mm and <=3.0mm in diameter (visual
estimate);*
Yes
No
6. one target lesion must be at least 15 mm in
length and the second lesion has to be at least
10 mm in length with no upper limit on either;*
Yes
No
7. target lesion stenosis for both lesions is >50%
and <100% (visual estimate).*
Yes
No
Exclusion Criteria
1. patient has experienced a q-wave or non-q-
wave myocardial infarction with documented total
ck >2 times normal within the preceding 72 hours
and the ck and ck-mb enzymes remain above
normal at the time of treatment;*
Yes
No
2. has unstable angina classified as braunwald a
i-ii-iii;*
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Yes
No
3. any of the lesions is an unprotected left main
coronary disease with >=50% stenosis;*
Yes
No
4. angiographic evidence of thrombus within
target lesion;*
Yes
No
5. heavily calcified lesion and/or calcified lesion,
which cannot be successfully predilated (applies
to both lesions);*
Yes
No
6. documented left ventricular ejection fraction
<=25%;*
Yes
No
8. totally occluded vessel (timi 0 level) (applies to
both lesions);*
Yes
No
9. prior stent within 10mm of target lesion
(applies to both lesions).*
Yes
No
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Eligibility Rheumatoid Arthritis
NCT00412399
Job Adaptation in Patients With Rheumatoid Arthritis; ODM
derived from: https://clinicaltrials.gov/show/NCT00412399
All rights reserved. Please visit https://medical-data-
models.org/forms/16894
Eligibility Rheumatoid Arthritis
NCT00412399
Inclusion Criteria
patients are eligible if they are:*
Yes
No
over age 18;*
Yes
No
meet american rheumatism association criteria
for rheumatoid arthritis; and*
Yes
No
are employed for salary or monetary
reimbursement.*
Yes
No
controls are eligible if they are:*
Yes
No
over age 18;*
Yes
No
have no major comorbidity; and*
Yes
No
are employed for salary or monetary
reimbursement.*
Yes
No
Exclusion Criteria
patients and controls are excluded if they:*
Yes
No
have cognitive deficits and cannot provide
informed consent;*
Yes
No
do not speak english or spanish; or*
Yes
No
their physicians do not grant permission to enroll
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them.*
Yes
No
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Eligibility Rheumatoid Arthritis
NCT00579878
Triple III Comparison of Leflunomide Alone Versus Two
DMARD Combinations in the Treatment of Rheumatoid
Arthritis; ODM derived from:
https://clinicaltrials.gov/show/NCT00579878
All rights reserved. Please visit https://medical-data-
models.org/forms/16895
Eligibility Rheumatoid Arthritis
NCT00579878
Inclusion Criteria
age greater or 19 years and less than or 80 years
old*
Yes
No
duration of disease greater or equal to 6 months*
Yes
No
diagnosis of ra with criteria*
Yes
No
negative urine pregnancy test*
Yes
No
be capable of understanding and giving written,
voluntary informed consent*
Yes
No
must present with at least six swollen and six
tender joints at the screening evaluation*
Yes
No
Exclusion Criteria
patients treated previously with leflunomide*
Yes
No
patients that have been treated with methotrexate
in combination with any of the study drugs*
Yes
No
patients with a history of allergy to, or any history
of significant clinical or laboratory adverse
experience associated with any of the study
drugs*
Yes
No
doses of oral steroids that are either unstable or
greater than 10mg/day*
Yes
No
stage iv disease or other significant disease
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including chest x-rays that show evidence of
rheumatoid lung disease.  stage iv disease is
defined as x-ray evidence of cartilage/bone
destruction with fibrous or bony ankylosis;
creatinine greater than 2.0mg/dl, ast or alt greater
normal*
Yes
No
any significant liver, renal , hematologic,
pulmonary, cardiovascular disease (including
uncontrolled hypertension), any active peptic
ulcer disease, or visual problems including a
recent decrease in acuity, retinal disease, or
macular degeneration*
Yes
No
patients who are not willing to abstain from
alcohol consumption*
Yes
No
women of childbearing potential who are not
practicing a successful method of contraception,
or wish to become pregnant*
Yes
No
patients that are unable to understand the study
procedures and/or give written informed
consent.*
Yes
No
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Eligibility Schizophrenia NCT00004980
Repetitive Transcranial Magnetic Stimulation for "Voices";
ODM derived from:
https://clinicaltrials.gov/show/NCT00004980
All rights reserved. Please visit https://medical-data-
models.org/forms/16896
Eligibility Schizophrenia
NCT00004980
Criteria
Inclusion Criteria
diagnosis of schizophrenia or schizoaffective
disorder based on dsm-iv version of scid*
Yes
No
auditory hallucinations of spoken speech
occurring at least 5 times per day where subject
able to discern verbal content*
Yes
No
right-handed*
Yes
No
at least 4 weeks on stable antipsychotic
medication*
Yes
No
Exclusion Criteria
history of seizure (unless due to drug withdrawal
or medication that is no longer prescribed)*
Yes
No
history of epilepsy in first degree relatives*
Yes
No
estimated iq less than 80*
Yes
No
unable to provide informed consent*
Yes
No
significant unstable medical condition*
Yes
No
current treatment with clozapine or bupropion*
Yes
No
cochlear implants or other metal in the head
(surgical, etc.)*
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Yes
No
history of cardiac arrhythmia*
Yes
No
cardiac pacemaker*
Yes
No
active drug or alcohol abuse within prior 6 weeks*
Yes
No
pregnancy*
Yes
No
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Eligibility Schizophrenia NCT01123408
Clozapine and Olanzapine Treatment of Aggression; ODM
derived from: https://clinicaltrials.gov/show/NCT01123408
All rights reserved. Please visit https://medical-data-
models.org/forms/16897
Eligibility Schizophrenia
NCT01123408
Inclusion Criteria
age: 18 to 60 years.*
Yes
No
diagnosis of schizophrenia or schizoaffective
disorder.*
Yes
No
aggression: one episode of physical assault
directed at another person in the hospital and
persistence of violence/hostility for two weeks, as
evidenced by the presence of some other
physical, verbal or property assault or hostility,
which would result in a score of 4 or more on the
positive and negative syndrome scale (panss)
hostility item.*
Yes
No
Exclusion Criteria
patients who were hospitalized for more than a
year*
Yes
No
patients who had a history of nonresponse to
clozapine, olanzapine or haloperidol (defined as
a lack of improvement despite a contiguous
adequate trial of medication)*
Yes
No
patients who had a history of clozapine,
olanzapine, or haloperidol intolerance*
Yes
No
patients who had medical conditions that would
be adversely affected by any of these three
medications.*
Yes
No
patients who received a depot antipsychotic
within 30 days before randomization.*
Yes
No
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Eligibility Schizophrenia, First-Episode
NCT00157378
Optimization of Acute Treatment in First Episode
Schizophrenia; ODM derived from:
https://clinicaltrials.gov/show/NCT00157378
All rights reserved. Please visit https://medical-data-
models.org/forms/16898
Eligibility Schizophrenia, First-
Episode NCT00157378
Inclusion Criteria
icd-10 criteria for first episode schizophrenia*
Yes
No
age between 18 and 55*
Yes
No
informed consent*
Yes
No
Exclusion Criteria
legal reasons*
Yes
No
insufficient knowledge of the german language*
Yes
No
substance abuse or addiction*
Yes
No
pregnancy*
Yes
No
serious physical illness*
Yes
No
organic brain disease*
Yes
No
contraindication to neuroleptic treatment*
Yes
No
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Eligibility Stage I Prostate Cancer
NCT00003832
Broxuridine Plus Surgery in Treating Patients With Stage I
or Stage II Prostate Cancer; ODM derived from:
https://clinicaltrials.gov/show/NCT00003832
All rights reserved. Please visit https://medical-data-
models.org/forms/16899
Eligibility Stage I Prostate Cancer
NCT00003832
Inclusion Criteria
diagnosis of stage i or ii (t1-2) carcinoma of the
prostate*
Yes
No
psa greater than 8 ng/ml*
Yes
No
abnormal findings on digital rectal examination*
Yes
No
eligible for radical prostatectomy*
Yes
No
performance status - ecog 0 or 1*
Yes
No
no prior biologic therapy*
Yes
No
no prior chemotherapy*
Yes
No
no prior neoadjuvant hormonal therapy*
Yes
No
no prior radiotherapy*
Yes
No
see disease characteristics*
Yes
No
no prior therapy that would affect tumor growth
rates or volume*
Yes
No
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Eligibility Type 1 Diabetes Mellitus
NCT00761852
Signaling Mechanisms and Vascular Function in Diabetes
Mellitus; ODM derived from:
https://clinicaltrials.gov/show/NCT00761852
All rights reserved. Please visit https://medical-data-
models.org/forms/16900
Eligibility Type 1 Diabetes Mellitus
NCT00761852
Inclusion Criteria
subjects with diabetes mellitus will be eligible if
they are receiving dietary treatment for
hyperglycemia, sulfonylureas, metformin or
insulin*
Yes
No
Exclusion Criteria
any diabetic subject with a hgba1c level of <7%
or >11%*
Yes
No
evidence of atherosclerosis*
Yes
No
symptoms of angina*
Yes
No
symptoms of claudication*
Yes
No
symptoms of cerebrovascular ischemia*
Yes
No
findings of arterial occlusive disease, as would be
suggested by decreased pulses, asymmetric
blood pressure, bruits or reduced limb pressure
measurements*
Yes
No
hypertension defined as a systolic blood pressure
> = 150 mmhg and a diastolic blood pressure >=
95 mmhg;  (allowable blood pressure medications
for diabetic subjects include calcium channel
blockers, alpha and beta adrenergic blockers, and
diuretics)*
Yes
No
hypercholesterolemia, defined as total cholesterol
levels greater than 75th percentile for age and
sex and ldl cholesterol levels >130mg/dl.*
Yes
No
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renal insufficiency (serum creatinine >1.5 mg/dl
for men; >1.2 mg/dl for women)*
Yes
No
hepatic dysfunction defined as liver enzyme
abnormalities > two times the upper limit of
normal*
Yes
No
chronic pulmonary disease*
Yes
No
congestive heart failure*
Yes
No
pregnancy (or subjects planning to become
pregnant);*
Yes
No
history of cigarette smoking within the last five
years;*
Yes
No
history of clinically significant coronary artery or
cerebrovascular disease (defined as mi or stroke
within 6 months, or presence of unstable angina)*
Yes
No
use of any, vasoactive, cardioactive, or non-
steroidal anti-inflammatory medications within 24
hours of vascular testing visits*
Yes
No
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Eligibility Type 1 Diabetes Mellitus
NCT00762671
Signaling Mechanisms and Vascular Function in Patients
With Diabetes Mellitus; ODM derived from:
https://clinicaltrials.gov/show/NCT00762671
All rights reserved. Please visit https://medical-data-
models.org/forms/16901
Eligibility Type 1 Diabetes Mellitus
NCT00762671
Inclusion Criteria
subjects with diabetes mellitus will be eligible if
they are receiving dietary treatment for
hyperglycemia, sulfonylureas, metformin or
insulin*
Yes
No
Exclusion Criteria
any diabetic subject with a hgba1c level of <7%
or >11%*
Yes
No
evidence of atherosclerosis*
Yes
No
symptoms of angina*
Yes
No
symptoms of claudication*
Yes
No
symptoms of cerebrovascular ischemia*
Yes
No
findings of arterial occlusive disease, as would be
suggested by decreased pulses, asymmetric
blood pressure, bruits or reduced limb pressure
measurements*
Yes
No
hypertension defined as a systolic blood pressure
> = 150 mmhg and a diastolic blood pressure >=
95 mmhg;  (allowable blood pressure medications
for diabetic subjects include calcium channel
blockers, alpha and beta adrenergic blockers, and
diuretics)*
Yes
No
hypercholesterolemia, defined as total cholesterol
levels greater than 75th percentile for age and
sex and ldl cholesterol levels >130mg/dl.*
Yes
No
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renal insufficiency (serum creatinine >1.5 mg/dl
for men; >1.2 mg/dl for women)*
Yes
No
hepatic dysfunction defined as liver enzyme
abnormalities > two times the upper limit of
normal*
Yes
No
chronic pulmonary disease*
Yes
No
congestive heart failure*
Yes
No
pregnancy (or subjects planning to become
pregnant);*
Yes
No
history of cigarette smoking within the last five
years;*
Yes
No
history of clinically significant coronary artery or
cerebrovascular disease (defined as mi or stroke
within 6 months, or presence of unstable angina)*
Yes
No
use of any, vasoactive, cardioactive, or non-
steroidal anti-inflammatory medications within 24
hours of vascular testing visits*
Yes
No
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Eligibility Unipolar Depression
NCT00178074
The Effects of Sleep Deprivation on Antidepressant
Response; ODM derived from:
https://clinicaltrials.gov/show/NCT00178074
All rights reserved. Please visit https://medical-data-
models.org/forms/16902
Eligibility Unipolar Depression
NCT00178074
Inclusion Criteria
patients:*
Yes
No
dsm-iv criteria for current major depressive
disorder*
Yes
No
score of 15 or higher on the hrsd (17 item)*
Yes
No
score of 17 or higher on the folstein mini-mental
status exam*
Yes
No
control subjects:*
Yes
No
no history of psychiatric disorder or neurological
illness*
Yes
No
Exclusion Criteria
patients:*
Yes
No
lifetime diagnosis of any psychotic disorder*
Yes
No
bipolar disorder*
Yes
No
alcohol or drug abuse within the last 6 months*
Yes
No
no contraindication to ssri therapy*
Yes
No
history of seizure disorder*
Yes
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No
both patient and control subjects:*
Yes
No
current diagnosis of diabetes or significantly
altered plasma glucose levels*
Yes
No
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Eligibility Coronary Artery Disease
NCT00235170
The Arterial Revascularization Therapies Study Part II.;
ODM derived from:
https://clinicaltrials.gov/show/NCT00235170
All rights reserved. Please visit https://medical-data-
models.org/forms/16904
Eligibility Coronary Artery Disease
NCT00235170
Inclusion Criteria
1. patients with stable (canadian cardiovascular
society 1, 2, 3 or 4) or unstable (braunwald class
ib, ic, iib, iic, iiib, iiic) angina pectoris and
ischemia, or patients with atypical chest pain or
even those who are asymptomatic provided they
have documented myocardial ischaemia (e.g.
treadmill exercise test, radionuclide scintigraphy,
stress echocardiography, holter tape);*
Yes
No
2. patients who are eligible for coronary
revascularization (angioplasty or cabg);*
Yes
No
3. at least 2 lesions (located in different vessels
and in different territories) potentially amenable to
stent implantation;*
Yes
No
4. de novo native vessels;*
Yes
No
5. multivessel disease with at least one significant
stenosis in lad and with treatment of the lesion in
another major epicardial coronary artery. a two-
vessel disease or a three-vessel disease may be
viewed as a combination of a side branch and a
main epicardial vessel provided they supply
different territories; left anterior descending, left
circumflex and right coronary artery);*
Yes
No
6. total occluded vessels. one total occluded
major epicardial vessel or side branch can be
included and targeted as long as one other major
vessel has a significant stenosis amenable for sa,
provided the age of occlusion is less than one
month e.g. recent instability, infarction with ecg
changes in the area subtended by the occluded
vessel. patients with total occluded vessels of
unknown duration or existing longer than one
month and a reference over 1.50 mm should not
be included, not even as a third or fourth vessel
to be dilated;*
Yes
No
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7. significant stenosis has been defined as a
stenosis of more than 50% in luminal diameter (in
at least one view, on visual interpretation or
preferably by qca);*
Yes
No
8. left ventricular ejection fraction should be at
least 30%.*
Yes
No
Exclusion Criteria
1. congestive heart failure;*
Yes
No
2. cabg or percutaneous coronary intervention
(pci) procedure;*
Yes
No
3. planned need for major surgery (e.g. valve
surgery or resection of aortic or left ventricular
aneurysm, carotid end-arterectomy, abdominal
aortic aneurysm surgery etc.);*
Yes
No
4. congenital heart disease;*
Yes
No
5. transmural myocardial infarction within the
previous seven days and ck has not returned to
normal;*
Yes
No
6. chest pain lasting longer than 30 minutes
within 12 hours pre-procedure, if ck enzymes
positive (≥ 2x the normal upper limit).*
Yes
No
7. history of any cerebrovascular accident;*
Yes
No
8. left main stenosis of 50% or more;*
Yes
No
9. intention to treat more than 1 totally occluded
major epicardial vessel;*
Yes
No
10. single vessel (single territory) disease.*
2 / 3
Eligibility Coronary Artery Disease NCT00235170
Yes
No
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Eligibility Coronary Artery Disease
NCT00250965
MPAACS: Magnesium for the Prevention of Atrial
Arrhythmias After Cardiac Surgery; ODM derived from:
https://clinicaltrials.gov/show/NCT00250965
All rights reserved. Please visit https://medical-data-
models.org/forms/16905
Eligibility Coronary Artery Disease
NCT00250965
Inclusion Criteria
patient undergoing coronary artery bypass
surgery with or without valve procedure*
Yes
No
scheduled for on-pump or cardiopulmonary
bypass protocol*
Yes
No
Exclusion Criteria
existing atrial fibrillation/flutter in the past year or
on antiarrhythmic medications*
Yes
No
ventricular fibrillation*
Yes
No
sustained ventricular tachycardia*
Yes
No
2nd or 3rd degree heart block*
Yes
No
paroxysmal supraventricular tachycardia*
Yes
No
major aortic repair planned during open-heart
procedure*
Yes
No
permanent atrial/ventricular pacemaker
implanted*
Yes
No
dialysis dependent or creatinine clearance < 35
umoles/min or oliguric/anuric renal failure*
Yes
No
patient intolerant of beta blockers*
Yes
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No
patient has reactive airways disease dependent
on regular beta-adrenergic agents*
Yes
No
patient is scheduled to undergo off-pump surgical
protocol*
Yes
No
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Eligibility Major Depressive Disorder
NCT00215228
Effects of Duloxetine vs. Escitalopram on Heart Rate
Variability in Depression; ODM derived from:
https://clinicaltrials.gov/show/NCT00215228
All rights reserved. Please visit https://medical-data-
models.org/forms/16906
Eligibility Major Depressive Disorder
NCT00215228
Inclusion Criteria
adults 20-60 years of age*
Yes
No
a primary diagnosis of depression using dsm-iv
criteria*
Yes
No
written informed consent*
Yes
No
a negative serum pregnancy test for women of
childbearing potential*
Yes
No
Exclusion Criteria
history of cardiovascular disease*
Yes
No
history of hypertension*
Yes
No
history of bipolar disorder*
Yes
No
history of schizophrenia or other psychotic
disorder*
Yes
No
alcohol or other substance abuse within the last 3
months*
Yes
No
history of cognitive impairment*
Yes
No
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Eligibility Major Depressive Disorder
NCT00252330
Efficacy and Safety of SR58611A in Patients With Major
Depressive Disorder; ODM derived from:
https://clinicaltrials.gov/show/NCT00252330
All rights reserved. Please visit https://medical-data-
models.org/forms/16907
Eligibility Major Depressive Disorder
NCT00252330
Inclusion Criteria
main inclusion criteria:*
Yes
No
1. out-patients, 18 year and older.*
Yes
No
2. major depressive disorder (mdd) with a
recurrentmajor depressive episode (mde)
according to dsmiv-tr criteria*
Yes
No
3. duration of current episode is at least of 6
weeksunless severity of symptoms justifies
shorter duration.*
Yes
No
4. patients have been treated or hospitalized for
aprevious episode, or a previous episode
requiredantidepressant treatment(s) at the
recommended doselevel for a continuous total
duration of at least 2months.*
Yes
No
Exclusion Criteria
main exclusion criteria:*
Yes
No
1. patients at immediate risk for suicidal behavior*
Yes
No
2. patients with a mde with psychotic features,
catatonic features, seasonal pattern or
postpartum onset*
Yes
No
3. the duration of the current depressive episode
is greater than 2 years*
Yes
No
4. patients whose current depressive episode is
secondary to a general medical condition*
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Yes
No
5. patients with a lifetime history of (1) bipolar
disorder, (2) psychotic disorder, (3) antisocial
personality disorder*
Yes
No
6. patients who have received non-
pharmacologic, somatic treatments for psychiatric
disease*
Yes
No
7. patients who have initiated, stopped, or
changed the frequency or nature of
psychotherapy within 3 months prior to
screening*
Yes
No
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Eligibility Major Depressive Disorder
NCT00252356
Efficacy and Safety of SR58611A in Patients With Major
Depressive Disorder; ODM derived from:
https://clinicaltrials.gov/show/NCT00252356
All rights reserved. Please visit https://medical-data-
models.org/forms/16908
Eligibility Major Depressive Disorder
NCT00252356
Inclusion Criteria
main inclusion criteria:*
Yes
No
1. out-patients, 18 year and older.*
Yes
No
2. major depressive disorder (mdd) with a
recurrentmajor depressive episode (mde)
according to dsmiv-tr criteria*
Yes
No
3. duration of current episode is at least of 6
weeksunless severity of symptoms justifies
shorter duration.*
Yes
No
4. patients have been treated or hospitalized for
aprevious episode, or a previous episode
requiredantidepressant treatment(s) at the
recommended doselevel for a continuous total
duration of at least 2months.*
Yes
No
Exclusion Criteria
main exclusion criteria:*
Yes
No
1. patients at immediate risk for suicidal behavior*
Yes
No
2. patients with a mde with psychotic features,
catatonic features, seasonal pattern or
postpartum onset*
Yes
No
3. the duration of the current depressive episode
is greater than 2 years*
Yes
No
4. patients whose current depressive episode is
secondary to a general medical condition*
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Yes
No
5. patients with a lifetime history of (1) bipolar
disorder, (2) psychotic disorder, (3) antisocial
personality disorder*
Yes
No
6. patients who have received non-
pharmacologic, somatic treatments for psychiatric
disease*
Yes
No
7. patients who have initiated, stopped, or
changed the frequency or nature of
psychotherapy within 3 months prior to
screening*
Yes
No
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Eligibility Coronary Artery Disease
NCT00272571
The Effects of External Counter Pulsation Therapy on
Circulating Endothelial Progenitor Cells; ODM derived from:
https://clinicaltrials.gov/show/NCT00272571
All rights reserved. Please visit https://medical-data-
models.org/forms/16909
Eligibility Coronary Artery Disease
NCT00272571
Inclusion Criteria
coronary artery disease*
Yes
No
ccs angina class ii-iv*
Yes
No
Exclusion Criteria
aortic regurgitation*
Yes
No
acute myocardial infarction <3 months*
Yes
No
systemic hypertension >180/110 mm*
Yes
No
atrial fibrillation*
Yes
No
deep vein thrombosis*
Yes
No
phlebitis and hemorrhagic diathesis*
Yes
No
pregnancy*
Yes
No
abdominal aortic aneurism*
Yes
No
metastatic tumor*
Yes
No
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Eligibility Major Depressive Disorder
NCT00608543
Aripiprazole Augmentation of SSRI Therapy in Treatment
Refractory Depression; ODM derived from:
https://clinicaltrials.gov/show/NCT00608543
All rights reserved. Please visit https://medical-data-
models.org/forms/16910
Eligibility Major Depressive Disorder
NCT00608543
Inclusion Criteria
age 18-65*
Yes
No
primary diagnosis of major depressive disorder
(mdd)*
Yes
No
completion of at least 8-12 weeks (and no longer
than 6 months) of treatment with escitalopram,
citalopram, or sertraline, with at least 6 weeks at
an adequate dose (i.e., 20 mg escitalopram; 40
mg citalopram; 150 mg sertraline)*
Yes
No
hamilton rating scale for depression, 17-item
(hrsd17) score less than or equal to 14 and/or
clinical global impression - severity (cgi-s) score
less than or equal to 3*
Yes
No
self-reported difficulties with cognition and/or
concentration, and an inventory for depressive
symptomatology clinician-rated, 30-item (ids-c30)
item #16 (concentration and decision making)
score less than or equal to 2*
Yes
No
ability to read and write in english (required
because instructions for cognitive testing and
several questionnaires are available only in
english)*
Yes
No
Exclusion Criteria
presence of untreated or unstable comorbid
medical condition based on physician information
or evidence at examination, such as
hypertension, diabetes, hypothyroidism.*
Yes
No
presence of known cardiovascular disease or
seizure disorder.*
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Yes
No
presence of other primary psychiatric disorders
or conditions (including depression due to
medical conditions, currently suicidal or high
suicide risk, current or past psychotic disorders of
any type, bipolar disorder (i, ii, or not otherwise
specified [nos]), schizophrenia, schizoaffective
disorder, anorexia, bulimia, obsessive compulsive
disorder, alcohol or substance abuse or
dependence within the last 6 months)*
Yes
No
presence of organic brain injury or dementia,
based on a cutoff score of < 20 on the mini
mental status examination (mmse).*
Yes
No
concomitant pharmacological or
psychotherapeutic treatment (in addition to one
ssri as described in inclusion criteria) including
but not limited to anxiolytics, neuroleptics, mood
stabilizers*
Yes
No
Hospitalization for mental illness within the past
year.*
Yes
No
for women, currently pregnant or planning to
become pregnant in the next year.*
Yes
No
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Eligibility Coronary Artery Disease
NCT00371709
TAXUS ATLAS: TAXUS Liberté™-SR Stent for the
Treatment of de Novo Coronary Artery Lesions; ODM
derived from: https://clinicaltrials.gov/show/NCT00371709
All rights reserved. Please visit https://medical-data-
models.org/forms/16911
Eligibility Coronary Artery Disease
NCT00371709
Criteria
1. patient is ≥18 years old.*
Yes
No
2. eligible for percutaneous coronary intervention
(pci)*
Yes
No
3. documented stable angina pectoris or unstable
angina pectoris with documented ischemia or
documented silent ischemia*
Yes
No
4. left ventricular ejection fraction (lvef) of
>/=25%*
Yes
No
5. acceptable candidate for coronary artery
bypass grafting (cabg)*
Yes
No
6. patient or legal guardian understands the study
requirements and the treatment procedures and
provides written informed consent before any
study-specific tests or procedures are performed*
Yes
No
7. willing to comply with all specified follow-up
evaluations*
Yes
No
angiographic inclusion criteria:*
Yes
No
1. only one lesion (target lesion) may be treated
with the study stent. however, one additional
lesion in a non-target vessel may be treated
during the index procedure with a commercially
available bare metal stent, heparin-coated stent
or taxus express stent.*
Yes
No
2. target lesion enrolled for treatment may be
1 / 5
composed of multiple lesions (not more than
10mm between diseased segments)but must be
completely covered by one study stent.*
Yes
No
3. target lesion located within a single native
coronary artery*
Yes
No
4. cumulative target lesion length is ≥10 mm and
≤28 mm (visual estimate)*
Yes
No
5. rvd of ≥2.5 mm to ≤4.0 mm (visual estimate)*
Yes
No
6. target lesion diameter stenosis ≥50% (visual
estimate)*
Yes
No
7. target lesion is de novo (i.e., a coronary lesion
not previously treated)*
Yes
No
general exclusion criteria:*
Yes
No
1. known hypersensitivity to paclitaxel*
Yes
No
2. any previous, concurrent or planned treatment
with a non-study anti-restenotic drug-coated or
drug-eluting coronary stent.*
Yes
No
3. previous or planned use of both the study stent
and a non-study stent (i.e., commercial stent) in
the treatment of the target vessel*
Yes
No
4. previous or planned treatment with
intravascular brachytherapy in the target vessel*
Yes
No
5. planned cabg ≤9-months post-index
procedure*
Yes
No
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6. mi within 72 hours prior to the index procedure
and or creatine kinase(ck) >2x the local
laboratory's uln unless ck-mb is <2x uln.*
Yes
No
7. cerebrovascular accident (cva) within the past
6 months*
Yes
No
8. cardiogenic shock*
Yes
No
9. acute or chronic renal dysfunction*
Yes
No
10. contraindication to asa, or to both clopidogrel
and ticlopidine*
Yes
No
11. leukopenia*
Yes
No
12. thrombocytopenia or thrombocytosis*
Yes
No
13. active peptic ulcer or active gastrointestinal
(gi) bleeding*
Yes
No
14. known allergy to stainless steel*
Yes
No
15. any prior true anaphylactic reaction to
contrast agents*
Yes
No
16. patient is currently, or has been treated with
paclitaxel or other chemotherapeutic agents
within 12-months of the index procedure*
Yes
No
17. anticipated treatment with paclitaxel or oral
rapamycin during any period in the 9-months
after the index procedure*
Yes
No
18. male or female with known intention to
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procreate within 3 months after the index
procedure*
Yes
No
19. female of childbearing potential with a
positive pregnancy test within 7 days before the
index procedure, or lactating, or intends to
become pregnant during the study.*
Yes
No
20. life expectancy of less than 24-months due to
other medical condition*
Yes
No
21. co-morbid condition(s) that could limit the
patient's ability to participate in the study,
compliance with follow-up requirements or impact
the scientific integrity of the study*
Yes
No
22. currently participating in another
investigational drug or device study that has not
completed the primary endpoint or that clinically
interferes with the endpoints of this study.*
Yes
No
angiographic exclusion criteria:*
Yes
No
1. left main coronary artery disease (stenosis
>50%) whether protected or unprotected*
Yes
No
2. target lesion is ostial in location (within 3.0 mm
of vessel origin)*
Yes
No
3. target lesion and/or target vessel proximal to
the target lesion is moderately or severely
calcified by visual estimate.*
Yes
No
4. target lesion and/or target vessel proximal to
the target lesion is tortuous.*
Yes
No
5. target lesion is located within or distal to a >60
degree bend in the vessel*
Yes
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No
6. target lesion involves a bifurcation with a side
branch vessel >2.0 mm in diameter.*
Yes
No
7. target lesion is totally occluded (timi flow </=
1), either at baseline or predilation*
Yes
No
8. angiographic presence of probable or definite
thrombus*
Yes
No
9. pre-treatment of the target vessel is not
allowed with any device*
Yes
No
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Eligibility Male Breast Cancer
NCT00425672
ONTAK® in Treating Patients With Advanced Breast
Cancer That Did Not Respond to Previous Treatment; ODM
derived from: https://clinicaltrials.gov/show/NCT00425672
All rights reserved. Please visit https://medical-data-
models.org/forms/16912
Eligibility Male Breast Cancer
NCT00425672
Inclusion Criteria
patients with advanced stage refractory breast
cancer*
Yes
No
progressive or relapsed disease following
standard therapy*
Yes
No
patients must have measurable disease that can
include, but is not limited to bone; specifically,
patients must have measurable extraskeletal
disease that can be accurately measured in at
least one dimension as >= 20 mm with
conventional ct techniques or >= 10 mm with
spiral ct scan; measurable (bi-dimensional) chest
wall disease will also be allowed*
Yes
No
patients must be at least 14 days out from last
cytotoxic chemotherapy; patients on
bisphosphonates are eligible*
Yes
No
white blood cell count (wbc) > 3.0 thou/ul*
Yes
No
anc > 1.0 thou/ul*
Yes
No
platelets >= 100 thou/ul*
Yes
No
serum creatinine =< 2.0 mg/dl or creatinine
clearance (calculated) >= 60 ml/min*
Yes
No
alt/ast =< 2.0 x upper limit of normal*
Yes
No
total bilirubin =< 1.5 x upper limit of normal*
Yes
No
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albumin >= 3.0 g/dl*
Yes
No
subjects must have a performance status score
(ecog scale) =< 2*
Yes
No
subjects must have recovered from major
infections and/or surgical procedures and, in the
opinion of the investigator, not have a significant
active concurrent medical illness precluding
protocol treatment*
Yes
No
men and women of reproductive ability must
agree to contraceptive use during the study and
for 1month after ontak treatment is discontinued*
Yes
No
Exclusion Criteria
prior treatment with ontak (dab389 il-2) or dab486
il-2*
Yes
No
known history of hypersensitivity to diphtheria
toxin or il-2*
Yes
No
active autoimmune disease*
Yes
No
known history of pulmonary disease except
controlled asthma*
Yes
No
history of or pre-existing, cardiovascular disease
as defined by new york heart association (nyha)
class iii-iv categorization*
Yes
No
pregnant or breast-feeding women*
Yes
No
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Eligibility Metastatic Breast Cancer
NCT00191269
Gemcitabine Monotherapy for Metastatic Breast Cancer
After Anthracycline and Taxane Regimen; ODM derived
from: https://clinicaltrials.gov/show/NCT00191269
All rights reserved. Please visit https://medical-data-
models.org/forms/16913
Eligibility Metastatic Breast Cancer
NCT00191269
Inclusion Criteria
histologically and/or cytologically confirmed
breast cancer*
Yes
No
received prior chemotherapy for metastatic breast
cancer with anthracycline and taxane regimen*
Yes
No
to have at least one measurable region*
Yes
No
ps: 0-1*
Yes
No
to have adequate organ function (bone marrow,
liver and renal function)*
Yes
No
Exclusion Criteria
to have interstitial pneumonia or pulmonary
fibrosis*
Yes
No
to have inflammatory carcinoma*
Yes
No
within 28 days after the latest chemotherapy or
radiotherapy, 14 days after the latest
hormonal/immunotherapy or 7 days after surgery*
Yes
No
to have brain metastasis with symptom*
Yes
No
to have severe complication (cardiac infarction,
infection, drug hyper sensitivity or diabetes)*
Yes
No
1 / 1
Eligibility Multiple Myeloma and Plasma Cell
Neoplasm NCT00378768
Antithymocyte Globulin in Treating Patients Undergoing
Stem Cell Transplant for Multiple Myeloma; ODM derived
from: https://clinicaltrials.gov/show/NCT00378768
All rights reserved. Please visit https://medical-data-
models.org/forms/16914
Eligibility Multiple Myeloma and
Plasma Cell Neoplasm
NCT00378768
Criteria
histologically confirmed multiple myeloma*
Yes
No
candidate for autologous or allogeneic stem cell
transplantation within 1 to 3 months after study
treatment*
Yes
No
measurable disease, defined as serum
monoclonal protein ≥ 1 g/dl or urinary light chain
excretion = 500 mg/24 hours*
Yes
No
no malignant cns disease*
Yes
No
patient characteristics:*
Yes
No
life expectancy ≥ 6 months*
Yes
No
absolute neutrophil count ≥ 1,000/mm³*
Yes
No
platelet count > 50,000/mm³*
Yes
No
creatinine ≤ 2 mg/dl*
Yes
No
hepatic function ≤ 2 times upper limit of normal*
Yes
No
dlco ≥ 50%*
Yes
No
no active infection*
1 / 2
Yes
No
no hypersensitivity to rabbit proteins*
Yes
No
no symptomatic hyperviscosity syndrome*
Yes
No
negative pregnancy test*
Yes
No
prior concurrent therapy:*
Yes
No
more than 28 days since prior chemotherapy,
including prednisone (20 mg equivalent/day)*
Yes
No
no prior anti-thymocyte globulin*
Yes
No
no concurrent radiotherapy*
Yes
No
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Eligibility Multiple Myeloma and Plasma Cell Neoplasm NCT00378768
Eligibility Multiple Myeloma NCT00216151
Zoledronic Acid in the Management of Patients With
Asymptomatic/Early Stage Multiple Myeloma; ODM derived
from: https://clinicaltrials.gov/show/NCT00216151
All rights reserved. Please visit https://medical-data-
models.org/forms/16915
Eligibility Multiple Myeloma
NCT00216151
Inclusion Criteria
diagnosis of asymptomatic multiple myeloma as
defined by the criteria below:*
Yes
No
presence of bone marrow clonal plasma cells
(more than 10%)*
Yes
No
presence of an m-protein in serum and/or urine
(no concentration specified)*
Yes
No
serum calcium < 12 mg/dl within 14 days prior to
registration. less than 3 lytic lesions, no
pathologic fractures and no osteopenia noted on
skeletal survey*
Yes
No
no symptoms of hyperviscosity, amyloidosis or
recurrent infection*
Yes
No
bone mineral density with a t score higher than
-2.0 standard deviation (not have osteoporosis)
within 28 days prior to registration*
Yes
No
negative pregnancy test*
Yes
No
Exclusion Criteria
no previous treatment with bisphosphonates*
Yes
No
no disorders of the parathyroid or thyroid glands*
Yes
No
no current breastfeeding*
Yes
No
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no prior malignancy is allowed except for
adequately treated in situ cervical cancer,
gleason < grade 7 prostate cancers*
Yes
No
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Eligibility Multiple Myeloma NCT00216151
Eligibility Multiple Myeloma NCT00399867
Simvastatin as Inhibitor of Cell Adhesion Mediated Drug
Resistance in Patients With Refractory Multiple Myeloma.;
ODM derived from:
https://clinicaltrials.gov/show/NCT00399867
All rights reserved. Please visit https://medical-data-
models.org/forms/16916
Eligibility Multiple Myeloma
NCT00399867
Inclusion Criteria
proven multiple myeloma*
Yes
No
refractory to ongoing chemotherapy (bortezomib,*
Yes
No
bendamustin dexamethasone),*
Yes
No
measurable paraprotein,*
Yes
No
serum protein below 11 g/dl,*
Yes
No
age over 18 years,*
Yes
No
life expectancy greater 6 months,*
Yes
No
contraception in women,*
Yes
No
expected compliance,*
Yes
No
written consent*
Yes
No
Exclusion Criteria
severe heart failure,*
Yes
No
not controlled hypertension or diabetes,*
Yes
No
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risk factors for rhabdomyolysis,*
Yes
No
creatinin kinase below 30ml/min,*
Yes
No
active liver disease,*
Yes
No
myopathy,*
Yes
No
allergy to simvastatin,*
Yes
No
pregnancy,*
Yes
No
acute infectious disease*
Yes
No
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Eligibility Multiple Myeloma NCT00399867
DM-ASP1941-1941-CL-0004
NCT01071850
A Phase 2, Double-Blind, Randomized, Placebo and
Active-Controlled Dose-Finding Study to Assess the
Efficacy, Safety and Tolerability of Multiple Oral Doses of
ASP1941 in Subjects with Type 2 Diabetes MellitusTEST
Study
Visit 7, Visit 8
All rights reserved. Please visit https://medical-data-
models.org/forms/16917
Visit 7, Visit 8 DM-ASP1941-1941-
CL-0004 NCT01071850
Date of Visit
Date of visit
Orthostatic Vital Signs
Not done:
Yes
No
Assessment Date
Assessment Time
Vital Signs
Sitting (Sitting)
Standing (Standing)
Location of blood pressure measurement
Right Arm  (1)
Left Arm (2)
Systolic Blood Pressure
mmHg
Diastolic Blood Pressure
mmHg
Pulse Rate
Beats/min
ECG: 12 Lead ECG 1
Date ECG was performed
ECG Time performed
ECG Interpretation
Normal  (0 )
Abnormal - not clinically significant  (1 )
Abnormal - clinically significant (2 )
1 / 3
Weight
Assessment Date
Weight
kg
Waist and Hip Circumference
Waist Circumference
cm
Hip Circumference
cm
Pregnancy Test
Select "Not done" if urine sample was not taken.
Not Done (1)
Date of specimen collection
result pregnancy test
negative (1)
positive (2)
Meal Data
Date Food Intake
Time of first food intake
Blood Sample
Date of Dose of ASP1941 on Day of blood
sampling
Time of Last Dose of Study Drug
Date of Dose of ASP1941 on day before blood
sampling
Check if Sample Not Drawn or Not Sent to Lab
Not Done (1)
Date of Sample
2 / 3
DM-ASP1941-1941-CL-0004 NCT01071850
Sample Time
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DM-ASP1941-1941-CL-0004 NCT01071850
Eligibility Multiple Myeloma NCT00400556
ATRA Plus G-CSF for Mobilization of Hematopoietic Stem
and Progenitor Cells; ODM derived from:
https://clinicaltrials.gov/show/NCT00400556
All rights reserved. Please visit https://medical-data-
models.org/forms/16918
Eligibility Multiple Myeloma
NCT00400556
Inclusion Criteria
likely to comply with study protocol*
Yes
No
age of 18-70*
Yes
No
histologically proven multiple myeloma or
lymphoma*
Yes
No
not currently receiving cytotoxic agents however
thalidomide, prednisolone, dexamethasone are
allowable*
Yes
No
multiple myeloma patients must be receiving
regular bisphosphonates*
Yes
No
absolute neutrophil count between 1.5 and 10.0 x
10^9/l*
Yes
No
ecog performance status </= 3*
Yes
No
life expectancy of at least two months*
Yes
No
written informed consent signed by patient or
legally authorised representative*
Yes
No
Exclusion Criteria
use of other vitamin a preparations within the last
30 days*
Yes
No
active infection or fever >/= 38.2 degrees celsius*
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Yes
No
pregnancy or breast feeding. women of child
bearing potential admitted to the trial must take
adequate measures to prevent conception (at
least two different forms of contraception) and are
to undergo a pregnancy test. oral contraception
must not include low-dose progestogens*
Yes
No
known allergy to e.coli derived products*
Yes
No
current treatment with tetracycline antibiotics*
Yes
No
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Eligibility Multiple Myeloma NCT00400556
DM-ASP1941-1941-CL-0004
NCT01071850
A Phase 2, Double-Blind, Randomized, Placebo and
Active-Controlled Dose-Finding Study to Assess the
Efficacy, Safety and Tolerability of Multiple Oral Doses of
ASP1941 in Subjects with Type 2 Diabetes MellitusTEST
Study
Visit 7, Visit 8
All rights reserved. Please visit https://medical-data-
models.org/forms/16919
Visit 7, Visit 8 DM-ASP1941-1941-
CL-0004 NCT01071850
Date of Visit
Date of visit
Orthostatic Vital Signs
Not done:
Yes
No
Assessment Date
Assessment Time
Vital Signs
Sitting (Sitting)
Standing (Standing)
Location of blood pressure measurement
Right Arm  (1)
Left Arm (2)
Systolic Blood Pressure
mmHg
Diastolic Blood Pressure
mmHg
Pulse Rate
Beats/min
ECG: 12 Lead ECG 1
Date ECG was performed
ECG Time performed
ECG Interpretation
Normal  (0 )
Abnormal - not clinically significant  (1 )
Abnormal - clinically significant (2 )
1 / 3
Weight
Assessment Date
Weight
kg
Waist and Hip Circumference
Waist Circumference
cm
Hip Circumference
cm
Pregnancy Test
Select "Not done" if urine sample was not taken.
Not Done (1)
Date of specimen collection
result pregnancy test
negative (1)
positive (2)
Meal Data
Date Food Intake
Time of first food intake
Blood Sample
Date of Dose of ASP1941 on Day of blood
sampling
Time of Last Dose of Study Drug
Date of Dose of ASP1941 on day before blood
sampling
Check if Sample Not Drawn or Not Sent to Lab
Not Done (1)
Date of Sample
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DM-ASP1941-1941-CL-0004 NCT01071850
Sample Time
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DM-ASP1941-1941-CL-0004 NCT01071850
Eligibility Neoplasms, Breast NCT00263588
Lapatinib for Brain Metastases In ErbB2-Positive Breast
Cancer; ODM derived from:
https://clinicaltrials.gov/show/NCT00263588
All rights reserved. Please visit https://medical-data-
models.org/forms/16920
Eligibility Neoplasms, Breast
NCT00263588
Inclusion Criteria
signed informed consent*
Yes
No
erbb2(her2)overexpressing breast cancer.*
Yes
No
brain lesion(s) which are progressing.*
Yes
No
prior treatment of brain metastases with whole
brain radiotherapy (wbr)and/or stereotactic
radiosurgery (srs).*
Yes
No
prior treatment with trastuzumab (herceptin),
either alone or in combination with
chemotherapy.*
Yes
No
cardiac ejection fraction(lvef)within the
institutional range of normal as measured by
echocardiogram.*
Yes
No
able to swallow an oral medication.*
Yes
No
adequate kidney and liver function.*
Yes
No
adequate bone marrow function.*
Yes
No
Exclusion Criteria
pregnant or lactating females.*
Yes
No
conditions that would effect the absorption of an
oral drug.*
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Yes
No
history of immediate or delayed hypersensitivity
reaction to gadolinium contrast agents.*
Yes
No
pre-existing severe cerebral vascular disease,
such as stroke involving a major vessel.*
Yes
No
serious medical or psychiatric disorder that would
interfere with the patient's safety or informed
consent.*
Yes
No
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Eligibility Neoplasms, Breast NCT00263588
Eligibility Colorectal Cancer NCT00220155
Phase II Fixed Dose Rate Gemcitabine for Advanced or
Metastatic Colorectal Cancer; ODM derived from:
https://clinicaltrials.gov/show/NCT00220155
All rights reserved. Please visit https://medical-data-
models.org/forms/16921
Eligibility Colorectal Cancer
NCT00220155
Inclusion Criteria
age >18 years*
Yes
No
histologically proven colorectal adenocarcinoma.*
Yes
No
locally advanced (inoperable) or metastatic
colorectal carcinoma treated with at least one
prior chemotherapy regimen.*
Yes
No
progressive disease documented by ct either
during or within 3 months of completion of
previous chemotherapy*
Yes
No
no previous malignant disease other than non-
melanotic skin cancer or carcinoma-in-situ of the
uterine cervix.*
Yes
No
unidimensional measurable disease as assessed
by ct.*
Yes
No
adequate bone marrow function; hb >10g/dl,
platelets >100 x109/l, wbc >3x109/l, neut
>1.5x109/l.*
Yes
No
adequate liver function: serum bilirubin <1.5 x
upper limit of normal*
Yes
No
adequate renal function: serum creatinine < 0.11
mmol/l*
Yes
No
no concurrent uncontrolled medical conditions*
Yes
No
who performance status 0,1 or 2*
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Yes
No
adequate contraceptive precautions, if
appropriate*
Yes
No
informed written consent*
Yes
No
negative pregnancy test in women of child
bearing age*
Yes
No
life expectancy > 3 months*
Yes
No
Exclusion Criteria
medical or psychiatric condition that comprise the
patient's ability to take informed consent.*
Yes
No
patients within 4 weeks of chemotherapy or
radiotherapy (6 weeks for nitrosureas or
mitomycin c).*
Yes
No
previous treatment with gemcitabine.*
Yes
No
patients with uncontrolled cerebral metastases.*
Yes
No
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Eligibility Colorectal Cancer NCT00220155
Eligibility Colorectal Cancer NCT00251485
A Phase II Trial of Modified FOLFOX 6 and Cetuximab in
First Line Treatment of Metastatic Colorectal Cancer; ODM
derived from: https://clinicaltrials.gov/show/NCT00251485
All rights reserved. Please visit https://medical-data-
models.org/forms/16923
Eligibility Colorectal Cancer
NCT00251485
Inclusion Criteria
1. patients must have signed an irb approved
informed consent.*
Yes
No
2. patients with histologically or pathologically
documented, stage iiib or iv adenocarcinoma of
the colon or rectum.*
Yes
No
3. patients with disease that is not amenable to
potentially curative resection (i.e., inoperable
metastatic disease).*
Yes
No
4. patients with tumors that are egfr + by ihc
staining.*
Yes
No
5. patients with ecog performance status of 0 or
1.*
Yes
No
6. patients, 18 years and older, must either be not
of child bearing potential or have a negative
serum pregnancy test within 7 days prior to
registration. patients are considered not of child
bearing potential if they are surgically sterile (they
have undergone a hysterectomy, bilateral tubal
ligation or bilateral oophorectomy) or they are
postmenopausal.*
Yes
No
7. bone marrow function: absolute neutrophil
count (anc) > or = 1,500/ul, equivalent to
common terminology criteria for adverse events
(ctcae, version 3) grade 1.  platelets > or =
100,000/ul (ctcae grade 0 - 1).*
Yes
No
8. renal function: creatinine < or = 1.5 x
institutional upper limit of normal (uln), ctcae
grade 1.*
Yes
No
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9. hepatic function:  bilirubin < or = 1.5 x uln,
ctcae grade 1.  ast < or = 2.5 x uln, ctcae grade
1.*
Yes
No
Exclusion Criteria
1. patients who received prior chemotherapy for
metastatic disease.  prior adjuvant therapy with
5fu/lv and/or irinotecan is allowed provided it was
completed at least 6 months prior to enrollment in
this study.*
Yes
No
2. patents who received prior oxaliplatin.*
Yes
No
3. patients who received prior cetuximab or other
therapy which specifically and directly targets the
egf pathway.*
Yes
No
4. patients with acute hepatitis.*
Yes
No
5. patients with active or uncontrolled infection.*
Yes
No
6. patients with a significant history of cardiac
disease, i.e., uncontrolled hypertension, unstable
angina, and congestive heart failure.*
Yes
No
7. prior allergic reaction to chimerized or murine
monoclonal antibody therapy.*
Yes
No
8. any concurrent chemotherapy not indicated in
the study protocol or any other investigational
agent.*
Yes
No
9. patients with peripheral neuropathy > grade 1*
Yes
No
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Eligibility Colorectal Cancer NCT00251485
Eligibility Colorectal Cancer NCT00264979
Evaluation of 2 Resection Strategies of Synchronous
Colorectal Cancer Metastases; ODM derived from:
https://clinicaltrials.gov/show/NCT00264979
All rights reserved. Please visit https://medical-data-
models.org/forms/16924
Eligibility Colorectal Cancer
NCT00264979
Inclusion Criteria
male and female adults over 18 years old*
Yes
No
at least one adenocarcinoma of colon and/or
rectum, histologically proven.*
Yes
No
no local complication at the time of surgery (no
occlusion, no sub-occlusion, no massive
hemorrhage, no abscesses or local invasion)*
Yes
No
at least one hepatic metastasis which r0
resection is possible through a conventional
simple resection*
Yes
No
informed written consent.*
Yes
No
non inclusion criteria:*
Yes
No
heart, respiratory or renal failure*
Yes
No
physical or psychological dependence*
Yes
No
chronic liver disease*
Yes
No
extra-hepatic metastases*
Yes
No
exclusion criteria (at time of surgery)*
Yes
No
localized or diffuse peritoneal carcinomatosis*
Yes
No
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non resectable lymph node metastases*
Yes
No
colorectal or hepatic tumour extension towards
abdominal wall and/or adjacent organ making
liver r0 resection impossible immediately*
Yes
No
other hepatic lesions diagnosed with ultrasound
making liver r0 resection impossible immediately*
Yes
No
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Eligibility Colorectal Cancer NCT00264979
AAFP: Hyponatremia Admission Order
AAFP: Hyponatremia Admission Order, Standardizes
Admission Orders, Author: Robert M. Wiprud, MD The
primary purpose of these Ordersets is to decrease
unnecessary variability and to improve quality through
standardized Admission Orders. Developed by the Scott &
White Clinic at College Station, Texas. Copyright © 2006
American Academy of Family Physicians. Physicians may
photocopy or adapt for use in their own practices; all other
rights reserved. Wiprud RM. Providing consistent care with
standardized admission orders. Fam Pract Manag.
September 2006: 49-52 See
http://www.aafp.org/fpm/2006/0900/p49.html This ODM
Form includes the nineteenth section ("Hyponatremia
Admission Order").
All rights reserved. Please visit https://medical-data-
models.org/forms/16925
AAFP: Hyponatremia Admission
Order
Default Itemgroup
Name
Age
Date of Birth
Medical record number
Status
Status
Observation (1)
Admission (2)
Medical floor (3)
Telemetry (4)
ICU (5)
Attending
Name of attending physician
Phone number of attending physician
Admitting Diagnosis
Hyponatremia Associated Diagnoses
Condition
Condition
Stable (1)
Fair (2)
Serious (3)
Critical (4)
1 / 4
Code Status
Full Code (1)
DNR (2)
Allergies
Allergies
Diet
NPO
Yes
No
Clear liquid
Yes
No
AHA step 2
Yes
No
ADA_calories
Yes
No
If Diet according to ADA, please specify amount
of calories
Other Diet
Yes
No
If Other, please specify
Activity
Bed rest with bathroom privileges with assistance
Yes
No
Nursing
Orthostatic VS every 4 hrs until stable x4, then
every shift
Yes
No
Notify MD for: T > 101, BP < 90/60 or > 190/100,
neuro changes
Yes
No
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AAFP: Hyponatremia Admission Order
IV
_normal saline IV @500 mL/hr until orthostasis
resolves, then
Yes
No
following to the Item above
Dextrose 5% normal saline (if
hyperosmolar) at __mL/hr OR (1)
Dextrose 5%in 1/2 normal saline (if not
hyperosmolar) at___mL/hr (2)
If ___normal saline IV@ 500mL/hr, ,please
specify
If Dextrose 5% normal saline, please specify
amount
If Dextrose 5% in 1/2 normal saline, please
specify amount
Lasix 80 mg IV/PO daily
Yes
No
Dextrose 5% in water @___mL/hr
Yes
No
If Dextrose 5% in water, please specify amount
Lab
CMP, UA, urine Na+, TSH, urine OSM, plasma
osmolality and CXR on arrival daily BMP
Yes
No
Consider
DVT prophylaxis with Lovenox 40 mg SQ daily
Yes
No
D/C medications that could contribute to
hyponatremia (i.e., diuretics, tegratol, SSRI,
amiodarone, theophylline)
Yes
No
Signature
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AAFP: Hyponatremia Admission Order
Print Name
Date and Time
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AAFP: Hyponatremia Admission Order
AAFP: DVT Discharge
AAFP: DVT Discharge, Standardizes Admission Orders,
Author: Robert M. Wiprud, MD The primary purpose of
these Ordersets is to decrease unnecessary variability and
to improve quality through standardized Admission Orders.
Developed by the Scott & White Clinic at College Station,
Texas. Copyright © 2006 American Academy of Family
Physicians. Physicians may photocopy or adapt for use in
their own practices; all other rights reserved. Wiprud RM.
Providing consistent care with standardized admission
orders. Fam Pract Manag. September 2006: 49-52 See
http://www.aafp.org/fpm/2006/0900/p49.html This ODM
Form includes the twelfth section ("DVT Discharge").
All rights reserved. Please visit https://medical-data-
models.org/forms/16926
AAFP: DVT Discharge
Default Itemgroup
Name
Age
Date of Birth
Medical record
Status
Discharge home
Yes
No
If discharge home, please specify date
Attending
Name of attending physician
Phone number of attending physician
Discharge Diagnosis
DVT___lower extremity
Yes
No
If DVT ___ lower extremity please specify
Other DVT
Yes
No
If Other, please specify
1 / 3
Status
Status
Stable (1)
Fair (2)
Serious (3)
Critical (4)
Allergies
Allergies
Diet
Diet
Activity
As tolerated
Yes
No
Elevate affected leg as much as possible
Yes
No
No driving or prolonged standing
Yes
No
Medications
Lovenox___mg subcutaneously BID for ___days
Yes
No
If Lovenox, please specify amount
mg
If Lovenox, please specify duration in days
Coumadin__mg by mouth every day
Yes
No
If Coumadin, please specify amount
Additional medications
Yes
No
If additional medications, please specify
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AAFP: DVT Discharge
Patient Education
Lovenox self-injection
Yes
No
Dietician counseling for food-drug interactions
Yes
No
Signs and symptoms of abnormal bleeding that
need to be reported
Yes
No
Avoidance of NSAID medications (aspirin,
ibuprofen, Aleve, etc.)
Yes
No
Follow-up
Date and Time of Appointment already set
Yes
No
If Appointment set, please specify date and time
Call for an appointment in the next 3 days
Yes
No
Call for an appointment with Dr.____in the next
___days
Yes
No
Please specify name of doctor
Please specify amount of days
Other
Please fax the attached Coumadin Clinic Referral
Yes
No
Please fax the attached Discharge Summary
Yes
No
Signature
Date and Time
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AAFP: DVT Discharge
AAFP: HIV Pneumonia Admission Disorder
AAFP: HIV Pneumonia Admission Disorder, Standardizes
Admission Orders, Author: Robert M. Wiprud, MD The
primary purpose of these Ordersets is to decrease
unnecessary variability and to improve quality through
standardized Admission Orders. Developed by the Scott &
White Clinic at College Station, Texas. Copyright © 2006
American Academy of Family Physicians. Physicians may
photocopy or adapt for use in their own practices; all other
rights reserved. Wiprud RM. Providing consistent care with
standardized admission orders. Fam Pract Manag.
September 2006: 49-52 See
http://www.aafp.org/fpm/2006/0900/p49.html This ODM
Form includes the fifteenth section ("HIV Pneumonia
Admission Order").
All rights reserved. Please visit https://medical-data-
models.org/forms/16927
AAFP: HIV Pneumonia Admission
Disorder
Default Itemgroup
Name
Age
Date of Birth
Medical record
Status
Status
Medical floor (1)
ICU (2)
Attending
Name of attending physician
Phone number of attending physician
Admitting Diagnosis
HIV Pneumonia Associated Diagnoses
Condition
Condition
Stable (1)
Fair (2)
Serious (3)
Critical (4)
Allergies
1 / 3
Allergies
Diet
Regular as tolerated
Yes
No
Activity
Bed rest with bathroom privileges with assistance
Yes
No
Respiratory Isolation
Yes
No
Nursing
Every___hrs
Yes
No
Please specify frequency of nursing
hrs
Notify MD for: T > 102; P < 60 or > 120; paleo
oxygen < 90%; increased respiratory distress; BP
< 90/160 > 180/110; decreased LOC
Yes
No
Pulse ox @bedside continuously initially
Yes
No
PPD with anergy panel
Yes
No
Medications
O2 @ 2,4,6 L/min via NC or FM to keep pulse O2
> 92%
Yes
No
TMP-SMX doses
Mild-morderate PCP (P9O2 >70 mmHg)
give TMP-SMX ds 2 tabs PO every 8 hrs
(1)
Severe PCP (P9O2 < 70 mmHg) TMP-
SMX (5mg/kg IV of trimethoprim) every 8
hrs, plus Prednisone 40 mg PO bid x5
days, then 20 mg PO bid x5 days, then
2 / 3
AAFP: HIV Pneumonia Admission Disorder
20 mg PO every day (2)
Alternatives
Mild-moderate PCP: atovaquone
suspension 750 mg PO bid, clindamycin
300-450 mg q/d and primaquine 15-30
mg PO every day, dapsone 100 mg PO
every day and trimethoprim 5 mg/kg PO
tid, pentamidine 3 mg/kg/day (1)
Severe PCP alternatives:____ (2)
If Severe PCP alternatives, please specify
IV
IV
Lab
Admission
Yes
No
A.M.
Yes
No
daily
Yes
No
Consult
Consult
Other Orders
Other Orders
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AAFP: HIV Pneumonia Admission Disorder
NINDS CDE Biospecimens Summary
Statement Multiple Sclerosis
NINDS Common Data Elements, Multiple Sclerosis
Biospecimens Summary Statement Appendix B – Potential
MS Biomarkers
Used from the National Institute of Neurological Disorders
and Stroke Common Data Elements
(https://www.commondataelements.ninds.nih.gov/)
References:
Grinnon ST, Miller K, Marler JR, Lu Y, Stout A, Odenkirchen
J, Kunitz S. National Institute of Neurological Disorders and
Stroke Common Data Element Project - approach and
methods. Clin Trials. 2012;9(3):322-9.
All rights reserved. Please visit https://medical-data-
models.org/forms/16928
Biospecimens Summary Statement
Appendix B – Potential MS
Biomarkers
Potential serum biomarkers of disease
activity in MS
TNF-α
IL-10
IL-12p40
IL-17
IFN-γ
Osteopontin
IL-6
Cell surface biomarkers
K2P5.1 + T cells
IFN-γ Receptor-β
IFN-α Receptor-2
CD56bright NK cells
CD8 + CD25 + FoxP3 + Treg cells
Fas/FasL
CD80
CD86
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CD40
PD1/PDL1
PDL2
Survivin
Potential humoral and antibody
biomarkers
OCB
Aquaporin-4 (NMO) antibody
IFN-β Neutralizing antibodies
CD19 + CD138 + B cells
MOG/MBP antibodies
CD46/59 antibodies
Complement factor H
C4 fragment
EBNA IgG
Ig kappa light chains
Biomarkers related to adhesion and
migration
sVCAM
LFA1
VLA4
MMP9
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NINDS CDE Biospecimens Summary Statement Multiple Sclerosis
TIMP1
MMP-8
IL-8
IP-10
CXCL8
CCL2
CCL5
CXCR3
CXCL13
CCR5
CX3CR1
ICAM
CXCL12
NCAM
Biomarkers of tissue damage and repair
Neurofilament chains
GFAP
S100
NAA
Nitric oxide products
Pentosidine
BDNF
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NINDS CDE Biospecimens Summary Statement Multiple Sclerosis
CNTF
GDNF
NGF
NT3
NT4
Other potential biomarkers
Myxovirus resistance protein A
Myoinositol
Bri2-23
Fetuin-A
ILT3
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NINDS CDE Non-Imaging Diagnostics
Recommendations Multiple Sclerosis
NINDS Common Data Elements, Multiple Sclerosis Non-
Imaging Diagnostics Recommendations
Used from the National Institute of Neurological Disorders
and Stroke Common Data Elements
(https://www.commondataelements.ninds.nih.gov/)
References:
Grinnon ST, Miller K, Marler JR, Lu Y, Stout A, Odenkirchen
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Non-Imaging Diagnostics
Recommendations
ECG
ECG/EKG
Abnormal (1)
Not Clinically Significant  (2)
Abnormal  (3)
Clinically Significant  (4)
Other, specify (5)
Other
Pulmonary Function Tests
Pulmonary Function Tests
Scalp Electroencephalogram
Activating procedures used
Sleep  (1)
Hyperventilation  (2)
Photic stimulation (3)
Unknown  (4)
Other, specify (5)
Other
Behavioral states recorded
Awake  (1)
Asleep  (2)
Unresponsive state (3)
Indeterminate (4)
Other, specify (5)
Other
Date EEG recorded
Duration, if prolonged
Less than 24 hours (1)
Greater than or equal to 24 hours (2)
N/A  (3)
Other, specify (4)
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Other
Frequency of the posterior dominant rhythm
during relaxed wakefulness
Location
Outpatient EEG Lab (1)
Inpatient Monitoring Unit  (2)
Intensive Care Unit  (3)
Ambulatory (4)
Other, specify (5)
Other
Number of seizures with EEG only
Number of seizures with Video and EEG
Number of seizures with video only
Original purpose of EEG
Research purposes - prospective (1)
Research purposes - retrospective (2)
Clinical purposes (3)
Other, specify (4)
Other
Posterior dominant rhythm present?
Yes
No
Total number of seizures recorded
Type
routine (1)
prolonged (2)
Video?
Yes  (1)
No  (2)
Unknown (3)
Other, specify (4)
Other
Immune Cell Subsets
CD2+ (T cell % )
%
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CD2+ (T cell number  )
CD2+DR (T cell % )
%
CD2+DR (T cell number )
CD3+/CD4+  (T cell %)
%
CD3+/CD4+  (T cell number)
CD3+/CD8+  (T cell %)
%
CD3+/CD8+  (T cell number)
CD3-/CD56+ bright  (Absolute number )
CD3-/CD56+ bright  (proportional NK cells )
CD3+ (T cells %)
%
CD3+ (T cells number)
CD4/CD8 ratio
CD4+DR (T cell %)
%
CD4+DR (T cell number)
CD8+DR  (T cell % )
%
CD8+DR  (T cell number )
CD14+ (monocytes)
CD19+ (B cells %)
%
CD19+ (B cells number)
Other mononuclear subsets
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Electrophysiology
Motor EP: Arm, right and left cortex - APB
Motor EP: Leg, right and left cortex - EDB
Motor EP: Leg, right and left cortex - TA
VEP checkerboard size 16
VEP checkerboard size 32
Nerve Conduction
Fwave studies (right and 
left; M-latency, F-latency)
Median Right and Left 
(amp, latency, CV, temp)
Peroneal (amp, latency, 
CV, temp)
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Eligibility Heart Failure, Congestive
NCT00156234
Skeletal Muscle Dysfunction in Heart Failure; ODM derived
from: https://clinicaltrials.gov/show/NCT00156234
All rights reserved. Please visit https://medical-data-
models.org/forms/16930
Eligibility Heart Failure, Congestive
NCT00156234
Inclusion Criteria
coronary heart failure*
Yes
No
ejection fraction <35%*
Yes
No
nyha 2-3*
Yes
No
spirometry fev1 > 80%*
Yes
No
Exclusion Criteria
cardiomyopathy*
Yes
No
transplantation candidate*
Yes
No
active malignancy*
Yes
No
restraining skeletal-muscular disease*
Yes
No
claudication in legs*
Yes
No
hospitalized last 30 days due to acute ischemic
episode*
Yes
No
intravenous inotrope or vasodilatating drugs last
14 days prior to inclusion*
Yes
No
ami last 8 weeks prior to inclusion*
Yes
No
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organized training last 4 months*
Yes
No
smoking on daily basis last 4 months*
Yes
No
creatinin < 150microliters/liter*
Yes
No
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Imaging Analysis Technique and
Results – Baseline
T2 LESIONS ANALYSIS
Study ID
Study site name
Subject ID
Date of MRI
1)  Total volume of brain lesions on T2W image
(cc):
2)  Total T2 lesion counts:
3)  Regional T2 lesion counts:
done (1)
not done (2)
i.  Number of periventricular lesions:
ii.  Number of juxtacortical lesions:
iii.  Number of posterior fossa lesions:
iv.  Number of cortical lesions:
v.  Number of thalamus lesions:
vi.  Number of basal ganglia lesions:
vii.  Number of other lesions whose type is not
specified:
4)  Technique Used:
Manual tracing   (1)
Semi-automated (verified by experienced
reader)  (2)
Fully automated segmentation (verified
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by experienced reader)  (3)
Other, specify: (4)
If Other, please specify
5)  Image pulse sequence used (Mention all that
apply:  FLAIR; PD/T2W FSE; T2W SE; Other,
specify):
6)  Slice thickness
mm
7)  In slice resolution
mm
8)  Gap
mm
9)  Technique reference (i.e. literature citation(s),
MRI Acquisition Manual or Analysis 
Manual):
GD-ENHANCING LESIONS ANALYSIS
1)  Total number of Gd-enhancing lesions:
2)  Total volume of Gd-enhancing lesions
cc
3)  Technique Used:
T1-weighted spin echo with contrast  (1)
T1-weighted 3D gradient-echo with
contrast  (2)
Other, specify: (3)
Please mention if other:
4)  Image pulse sequence used:
5)  Slice thickness
mm
6)  In slice resolution
mm
7) Gap
mm
8) Technique reference (i.e. literature citation(s),
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MRI Acquisition Manual or Analysis Manual):
T1 HYPOINTENSE LESIONS ANALYSIS
1)  Total number of T1 hypointense lesions:
2)  Total volume of T1 hypointense lesions
ml
3)  Technique Used:
Visual determination by experienced
reader  (1)
Semi-automated (calculated through
software, verified by experienced reader)
(2)
Fully automated segmentation and
counting  (3)
Other, specify: (4)
Please mention if other:
4)  Image pulse sequence used:
T1-weighted spin echo with contrast  (1)
T1-weighted spin echo without contrast
(2)
Other, specify: (3)
If other, please specify
5)  Slice thickness
mm
6)  In slice resolution
mm
7) Gap
mm
8) Technique reference (i.e. literature citation(s),
MRI Acquisition Manual or Analysis Manual):
BRAIN VOLUME ANALYSIS  –  ANSWER
QUESTION 1 OR 2 (AND THE
CORRESPONDING SUB-QUESTIONS),
NOT BOTH
1) a.  Brain volume
ml
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b.  Technique Used:
Automated  (1)
Semi-automated  (2)
Manual (3)
c.  Image pulse sequence used:
Dual echo PD/T2W SE  (1)
FLAIR  (2)
PD SE  (3)
T2W SE  (4)
T1W SE  (5)
T1W 3D gradient-echo  (6)
Other, specify: (7)
If other, please specify
d.  Slice thickness
mm
e.  In slice resolution
mm
f.  Gap
mm
g.  Technique reference (i.e. literature citation(s),
MRI Acquisition Manual or 
Analysis Manual):
2) a.  Ventricular volume fraction:
b.  Brain volume fraction:
Automated  (1)
Semi-automated  (2)
Manual (3)
c.  Image pulse sequence used:
Dual echo PD/T2W SE  (1)
FLAIR  (2)
PD SE  (3)
T2W SE  (4)
T1W SE  (5)
T1W 3D gradient-echo  (6)
Other, specify: (7)
If other, please specify
d.  Slice thickness
mm
e.  In slice resolution
mm
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f.  Gap
mm
g.  Technique reference (i.e. literature citation(s),
MRI Acquisition Manual or 
Analysis Manual):
VENTRICULAR VOLUME ANALYSIS
ANSWER QUESTION 1 OR 2 (AND THE
CORRESPONDING SUB- QUESTIONS),
BUT NOT BOTH
1) a.  Ventricular volume
ml
b.  Technique Used:
Automated  (1)
Semi-automated  (2)
Manual (3)
c.  Image pulse sequence used:
Dual echo PD/T2W SE  (1)
FLAIR  (2)
PD SE  (3)
T2W SE  (4)
T1W SE  (5)
T1W 3D gradient-echo  (6)
Other, specify: (7)
If other, please specify
d.  Slice thickness
mm
e.  In slice resolution
mm
f.  Gap
mm
g.  Technique reference (i.e. literature citation(s),
MRI Acquisition Manual or 
Analysis Manual):
2) a.  Ventricular volume fraction:
b.  Technique Used:
Automated  (1)
Semi-automated  (2)
Manual (3)
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c.  Image pulse sequence used:
Dual echo PD/T2W SE  (1)
FLAIR  (2)
PD SE  (3)
T2W SE  (4)
T1W SE  (5)
T1W 3D gradient-echo  (6)
Other, specify: (7)
If other, please specify
d.  Slice thickness
mm
e.  In slice resolution
mm
f.  Gap
mm
g.  Technique reference (i.e. literature citation(s),
MRI Acquisition Manual or 
Analysis Manual):
GRAY MATTER VOLUME ANALYSIS  –
ANSWER QUESTION 1 OR 2, BUT NOT
BOTH, THEN PROCEED TO  QUESTION
3
1)  Gray matter volume
2)  Gray matter volume fraction:
3)  Image pulse sequence used:
Absolute gray matter volume (non-
normalized)  (1)
Absolute gray matter volume
(normalized)  (2)
Gray matter fraction  (3)
Other, specify: (4)
If other, please specify
4)  Image pulse sequence used:
Dual echo PD/T2W SE  (1)
FLAIR  (2)
PD SE  (3)
T2W SE  (4)
T1W SE  (5)
T1W 3D gradient-echo  (6)
Other, specify: (7)
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If other, please specify
5)  Slice thickness
mm
6)  In slice resolution
mm
7) Gap
mm
8) Technique reference (i.e. literature citation(s),
MRI Acquisition Manual or Analysis Manual):
GRAY MATTER LESIONS ANALYSIS
1)  Total number of gray matter lesions:
2)  Total volume of gray matter lesions
ml
3)  Technique Used:
Visual determination by experienced
reader  (1)
Semi-automated (calculated through
software, verified by experienced reader)
(2)
Fully automated segmentation,
localization, and counting  (3)
Other, specify: (4)
If other, please specify
4)  Image pulse sequence used:
FLAIR  (1)
T1W 3D gradient-echo  (2)
DIR  (3)
PSIR  (4)
Other, specify: (5)
If other, please specify
5)  Slice thickness
mm
6)  In slice resolution
mm
7) Gap
mm
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8) Technique reference (i.e. literature citation(s),
MRI Acquisition Manual or Analysis Manual):
WHITE MATTER VOLUME ANALYSIS  –
ANSWER QUESTION 1 OR 2, BUT NOT
BOTH, THEN PROCEED TO  QUESTION
3
1)  White matter volume
ml
2)  White matter volume fraction:
3)  White matter volume OR White matter volume
fraction 
a.  Technique Used:
Absolute white matter volume (non-
normalized)  (1)
Absolute white matter volume
(normalized)  (2)
White matter fraction  (3)
Other, specify (4)
If other, please specify
b.  Image pulse sequence used:
Dual echo PD/T2W SE  (1)
FLAIR  (2)
PD SE  (3)
T2W SE  (4)
T1W SE  (5)
T1W 3D gradient-echo  (6)
Other, specify: (7)
If other, please specify
c.  Slice thickness
mm
d.  In slice resolution
mm
e.  Gap
mm
f.  Technique reference (i.e. literature citation(s),
MRI Acquisition Manual or 
Analysis Manual):
REGIONAL BRAIN VOLUMETRIC
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ANALYSIS
1)  Central cerebral volume
ml
2)  Cortical thickness
mm
3)  Brain structure volumes a.  Hippocampus
ml
b.  Thalamus
ml
Other regional volumetric analyses
(COMPLETE AS MANY TIMES AS
NEEDED):
1)  Technique Used:
Central cerebral volume  (1)
Cortical thickness  (2)
Brain structure volume (3)
a.  If Brain structure volume, specify structure:
Hippocampus    (1)
Thalamus  (2)
Lobes  (3)
Other, specify: (4)
If other, please specify
2)  Image pulse sequence used:
Dual echo PD/T2W SE  (1)
FLAIR  (2)
PD SE  (3)
T2W SE  (4)
T1W SE  (5)
T1W 3D gradient-echo  (6)
Other, specify: (7)
If other, please specify
3)  Slice thickness
mm
4)  In slice resolution
mm
5)  Gap
mm
6)  Technique reference (i.e. literature citation(s),
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MRI Acquisition Manual or Analysis 
Manual):
SPINAL CORD LESIONS ANALYSIS
1)  Total number of spinal cord lesions:
2)  Spinal cord lesion region (Mention all that
apply: C1-C7;  T1-T12; L1-L5 ):
3)  Spinal cord lesions location (mention all that
apply: Anterior; Posterior; Lateral  ):
4)  Spinal cord area
mm2
4)  Spinal cord Volume
ml
5)  Technique Used:
Visual determination by experienced
reader  (1)
Semi-automated (calculated through
software, verified by experienced reader)
(2)
Fully automated segmentation,
localization and counting  (3)
Other, specify: (4)
If other, please specify
6)  Image pulse sequence used:
T2-weighted (T2)  (1)
Proton-density weighted (PD)  (2)
Short tau inversion recovery (STIR)  (3)
Other, specify: (4)
If other, please specify
7)  Slice thickness
mm
8)  In slice resolution
mm
9)  Gap
mm
10) Technique reference (i.e. literature citation(s),
MRI Acquisition Manual or Analysis 
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Manual):
SPINAL CORD VOLUME/CROSS-
SECTIONAL AREA
1)  Technique Used:
Manual tracing by experienced reader
(1)
Semi-automated (calculated through
software, verified by experienced reader)
(2)
Losseff – 3mm x 5 axial slices from C2-3
up  (3)
Fully automated segmentation  (4)
Other, specify: (5)
If other, please specify
2)  Image pulse sequence used:
T2-weighted (T2)  (1)
Proton-density weighted (PD)  (2)
Short tau inversion recovery (STIR)  (3)
T1W SE  (4)
T1W 3D gradient-echo  (5)
Other, specify: (6)
If other, please specify
3)  Slice thickness
mm
4)  In slice resolution
mm
5)  Gap
mm
6)  Technique reference ( i.e. literature citation(s),
MRI Acquisition Manual or Analysis 
Manual):
Tissue Integrity Measures
MTR
Yes
No
Sequence Type
Slice thickness
Technique Reference
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Whole Brain
Yes
No
Normal Appearing WM
Yes
No
Normal Appearing GM
Yes
No
Other Regional Measurements
Yes
No
DTI
Yes
No
Sequence Type
Slice thickness
Technique Reference
Whole Brain
Yes
No
Normal Appearing WM
Yes
No
Normal Appearing GM
Yes
No
Other Regional Measurements
Yes
No
Spectroscopy
Yes
No
Sequence Type
Slice thickness
Technique Reference
Whole Brain
Yes
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No
Normal Appearing WM
Yes
No
Normal Appearing GM
Yes
No
Other Regional Measurements
Yes
No
Other
Yes
No
Sequence Type
Slice thickness
Technique Reference
Normal Appearing WM
Yes
No
Normal Appearing GM
Yes
No
Other Regional Measurements
Yes
No
MTR – specify units and values
Mean MTR unit
Yes
No
Whole brain
Normal Appearing WM
Normal Appearing GM
MTR histogram peak position unit
Whole brain
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Normal Appearing WM
Normal Appearing GM
MTR histogram peak height unit
Whole brain
Normal Appearing WM
Normal Appearing GM
DTI – specify units and values
Mean FA unit
Whole brain
Normal Appearing WM
Normal Appearing GM
Mean ADC unit
Whole brain
Normal Appearing WM
Normal Appearing GM
Mean axial diffusivity unit
Whole brain
Normal Appearing WM
Normal Appearing GM
Mean radial diffusivity unit
Whole brain
Normal Appearing WM
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Normal Appearing GM
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Imaging Analysis Technique and
Results – Follow Up
T2 LESIONS ANALYSIS
Study ID
Study site name
Subject ID
Date of MRI
1) Total volume of brain lesions on T2W image
(cc):
cc
2) Change in T2 lesion(s) volume (mL); a. Total
number of T2 lesions:
ml
3) Number of new or enlarging non-enhancing T2
lesions:
i. Number of periventricular lesions:
ii. Number of juxtacortical lesions:
iii. Number of posterior fossa lesions:
iv. Number of cortical lesions:
v. Number of thalamus lesions:
vi. Number of basal ganglia lesions:
vii. Number of other lesions whose type is not
specified:
4) Technique reference for new lesions (i.e.
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literature citation(s), MRI Acquisition Manual or
Analysis Manual. May also include visual
observation, detection, etc.):
GD-ENHANCING LESIONS ANALYSIS
1) Total number of Gd-enhancing lesions:
2)  Number of NEW Gd-enhancing lesions:
3)  Total volume of all Gd-enhancing lesions (cc):
cc
4)  Change in volume of all Gd-enhancing lesions
(cc):
cc
5)  Technique reference (i.e. literature citation(s),
MRI Acquisition Manual or Analysis Manual):
Combined Unique Active lesions
1)  Number of CUA lesions compared to previous
time-point:
2)  Technique reference for new lesions (i.e.
literature citation(s), MRI Acquisition Manual or 
Analysis Manual. May also include visual
observation, detection, etc.):
T1 HYPOINTENSE LESIONS ANALYSIS
1) Total number of T1 hypointense lesions:
2)  Number of new T1 hypointense lesions:
3)  Total volume of T1 hypointense lesions (mL):
ml
4)  Change in volume of T1 hypointense lesions
(mL):
ml
5)  Technique reference ( i.e. literature citation(s),
MRI Acquisition Manual or Analysis Manual):
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Change in brain volume analysis
1)  a.  Change in brain volume (mL):
ml
1)  a.  Change in brain volume (%):
%
2) a.  Change in brain volume fraction (%):
%
Change in ventricular volume analysis
1) a.  Change in ventricular volume (mL):
ml
1) a.  Change in ventricular volume (%):
%
2) a. Change in ventricular volume fraction (ml):
ml
2) a. Change in ventricular volume fraction (%):
%
Gray matter volume analysis
1) a.  Change in gray matter volume
%
2) a.  Change in gray matter volume fraction (%):
%
Gray matter lesions analysis
1)  Number of new gray matter lesions:
2)  Total number of gray matter lesions:
3)  Total volume of gray matter lesions (mL):
ml
4)  Change in volume of gray matter lesions (mL):
ml
5)  Technique reference for new lesions (i.e.
literature citation(s), MRI Acquisition Manual or 
Analysis Manual. May also include visual
observation, detection, etc.):
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White matter volume analysis
1) a.  Change in white matter volume (%):
%
2) a.  Change in white matter volume fraction (%):
%
3)  Change in normal appearing white matter -
complete as many times as needed (%):
%
a.  Timepoint: [Add protocol-specific options]
Regional volumetric analysis
1) a.  Change in central cerebral volume (mL):
ml
2) a.  Change in cortical thickness (mm):
mm
3)  Brain structure volumes i) Change in
hippocampus (mL):
ml
i.  Change in thalamus (mL):
ml
Spinal cord lesions analysis
1)  Total number of spinal cord lesions:
2)  Spinal cord lesion region (mention all that
apply:  C1-C7 ; T1-T12; L1-L5 ):
3) Spinal cord lesions location (mention all that
apply: Anterior; Posterior; Lateral ):
4) Spinal cord area
mm2
4) Spinal cord Volume
ml
5)  Technique reference (i.e. literature citation(s),
MRI Acquisition Manual or Analysis Manual):
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Tissue Integrity Measures MTR – specify
units and values Table
Mean MTR unit
Whole brain
Normal Appearing WM
Normal Appearing GM
MTR histogram peak position unit
Whole brain
Normal Appearing WM
Normal Appearing GM
MTR histogram peak height unit
Whole brain
Normal Appearing WM
Normal Appearing GM
DTI – specify units and values
Mean FA unit
Whole brain
Normal Appearing WM
Normal Appearing GM
Mean ADC unit
Whole brain
Normal Appearing WM
Normal Appearing GM
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Mean axial diffusivity unit
Whole brain
Normal Appearing WM
Normal Appearing GM
Mean radial diffusivity unit
Whole brain
Normal Appearing WM
Normal Appearing GM
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Table 1 – CBC with Differential  Multiple Sclerosis
NINDS Common Data Elements, Multiple Sclerosis
Laboratory Tests Recommendations Table 1 – CBC with
Differential
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Laboratory Tests Recommendations
Table 1 – CBC with Differential
CBC with Differential
Basophils
cells/µL
Basophils
%
Eosinophils
cells/µL
Eosinophils
%
Hematocrit
cells/µL
Hematocrit
%
Lymphocytes
cells/µL
Lymphocytes
%
Mean corpuscular hemoglobin 
(MCH)
gm/dL
Mean corpuscular hemoglobin 
concentration (MCHC)
%
Mean corpuscular volume 
(MCV)
fL
Mean platelet volume (MPV)
fL
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Monocytes
cells/µL
Monocytes
%
Neutrophils
cells/µL
Neutrophils
%
Platelet count
cells/µL
Platelet count
%
RBC Morphology
cells/µL
RBC Morphology
%
Red Blood Cell (RBC) Count
cells/mcL
WBC Morphology
cells/µL
WBC Morphology
%
Blasts
cells/µL
Blasts
%
Hemoglobin electrophoresis
cells/µL
Hemoglobin electrophoresis
%
Macrophages
cells/µL
2 / 3
NINDS CDE Laboratory Tests Recommendations  Table 1 – CBC with
Differential  Multiple Sclerosis
Macrophages
%
Metamyelocytes
cells/µL
Metamyelocytes
%
Myelocytes
cells/µL
Myelocytes
%
Promyelocytes
cells/µL
Promyelocytes
%
Red blood cell distribution 
width (RDW)
%
Stab cells/Band cells/Band 
neutrophils
cells/µL
Stab cells/Band cells/Band 
neutrophils
%
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NINDS Common Data Elements, Multiple Sclerosis
Laboratory Tests Recommendations Table 2 – Chemistries
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Laboratory Tests Recommendations
Table 2 – Chemistries
Table for Chemistries
Alanine transaminase (ALT)
U/L
Albumin
g/dL
Alkaline phosphatase (ALP)
IU/L
Aspartate transaminase (AST)
IU/L
Bicarbonate
mmol/L
Bilirubin, total
mg/dL
Blood urea nitrogen (BUN)
mg/dL
Calcium
mg/dL
Chloride
mEq/L
Creatine kinase
IU/L
Glucose
mg/dL
Potassium
mEq/L
Serum creatinine
mg/dL
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Sodium
mEq/L
Total Protein
g/dL
Amylase
U/L
Anion gap
mEq/L
Bilirubin, total
mg/dL
Bilirubin, direct (conjugated)
mg/dL
Carbon dioxide
mEq/L
Ferritin
ng/mL
Gamma glutamyl transferase 
(GGT)
IU/L
Ionized Calcium
mg/dL
Iron
mcg/dL
Lactate
IU/L
Lactate dehydrogenase (LDH)
IU/L
Lipase
IU/L
Magnesium
mg/dL
Phosphate
mg/dL
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Total Iron Binding Capacity
mcg/dL
Urate
μmol/L
Urea-N
mmol/L
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Eligibility Non Small Cell Lung Cancer
NCT00160043
Safety and Efficacy Study of a New Chemotherapy Agent to
Treat Non Small Cell Lung Cancer.; ODM derived from:
https://clinicaltrials.gov/show/NCT00160043
All rights reserved. Please visit https://medical-data-
models.org/forms/16935
Eligibility Non Small Cell Lung
Cancer NCT00160043
Inclusion Criteria
non small cell lung cancer, stage iiib or stage iv*
Yes
No
one and only 1 prior platinum-based
chemotherapy*
Yes
No
no other uncontrolled concurrent illness*
Yes
No
use of highly effective birth control methods in
males or females with reproductive potential*
Yes
No
Exclusion Criteria
previous participation in another trial within the
last 4 weeks*
Yes
No
surgery within 10 days prior to the start of study
treatment*
Yes
No
brain metastases*
Yes
No
confirmed diagnosis of infection with the human
immunodeficiency virus (hiv)*
Yes
No
current treatment with warfarin sodium
(coumadin) or similar anticoagulation medication*
Yes
No
breast feeding*
Yes
No
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Laboratory Tests Recommendations
Table 3 – CSF and Table 4 – CSF
Culture
Table 3 – CSF
Albumin index
mg/dL
Albumin, CSF
mg/dL
Cell count and Diff, CSF
cells/µL
CSF lactate
mmol/L
CSF PCR for viruses
Cytopathology, CSF
Glucose, CSF
mg/dL
IgG, CSF
mg/dL
IgG Index, CSF
mg/dL
Immunofixation 
Electrophoresis, Serum
Lyme Disease Ab, CSF
MRZ Reaction
Oligoclonal Banding, 
CSF
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Protein, CSF
mg/dL
Red Blood Cell Count, 
CSF
cells/mm3
VDRL, CSF
CSF Antibodies against 
CNS antigens
CSF CXCL13
pg
CSF cytokines and 
chemokines
CSF glial fibrillary acidic 
protein (GFAP)
ng/mL
CSF IgM index
mg/dL
CSF 
immunophenotyping by 
FACS
CSF kappa
CSF myelin basic 
protein (MBP)
CSF neural cell 
adhesion molecule 
(NCAM)
ng/mL
CSF neurofilament light 
chains
CSF NMO IgG
Tears OCB
Table 4 – CSF Culture
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Bacterial, Fungal culture
Sterile fluid culture
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Table 7 – Leukapheresis
Table for Leukapheresis
Date of leukapheresis
Is another apheresis 
needed?
Yes
No
If Yes, how many ml are needed?
MSC Culture
Number of cells harvested
Procedure
Result of leukapheresis
Complete apheresis (1)
Incomplete apheresis  (2)
Apheresis not started (3)
Total volume of therapeutic 
lympapheresis taken in ml 
this time
mL
Type of leukapheresis
Full  (1)
Partial (2)
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Eligibility Coronary Artery Disease
NCT00376571
Nordic Bifurcation Study. How to Use Drug Eluting Stents
(DES) in Bifurcation Lesions?; ODM derived from:
https://clinicaltrials.gov/show/NCT00376571
All rights reserved. Please visit https://medical-data-
models.org/forms/16938
Eligibility Coronary Artery Disease
NCT00376571
Inclusion Criteria
stable or unstable ap.*
Yes
No
bifurcation lesion of "lad/diagonal", "cx/obtuse
marginal", "rca-pda/posterolateral branch or
lm/cx/lad in a right dominant system.*
Yes
No
diameter of main vessel by visual estimate > 2.5
mm.*
Yes
No
diameter of side branch by visual estimate > 2.0
mm.*
Yes
No
signed informed consent.*
Yes
No
Exclusion Criteria
st-elevation ami within 24 hours.*
Yes
No
expected survival < 1 year.*
Yes
No
s-creatinine > 200 umol/l.*
Yes
No
allergy to aspirin, clopidogrel or ticlopidine.*
Yes
No
allergy to sirolimus/paclitaxel.*
Yes
No
left main bifurcation in a non-right dominant
system.*
Yes
No
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DM-ASP1941-1941-CL-0004
NCT01071850
A Phase 2, Double-Blind, Randomized, Placebo and
Active-Controlled Dose-Finding Study to Assess the
Efficacy, Safety and Tolerability of Multiple Oral Doses of
ASP1941 in Subjects with Type 2 Diabetes MellitusTEST
Study
Dosing
All rights reserved. Please visit https://medical-data-
models.org/forms/16939
Dosing DM-ASP1941-1941-CL-0004
NCT01071850
Study Drug: oral
Type of Study Drug
Run-In Medication (1)
Randomized Study Drug (2)
Study Treatment Status Not Done
date of first dose
Date of last dose
Study Drug: Accountability - Kit 1
Dispensed Date
Kit Number assigned
Actual Kit Number
No. of capsules dispensed
Were any of the wallets within the kit returned?
Yes
No
Returned Date
No. of Capsules / Tablets returned
Comment
Study Drug: Accountability - Kit 2
Dispensed Date
Kit Number assigned
1 / 3
Actual Kit Number
No. of capsules dispensed
Were any of the wallets within the kit returned?
Yes
No
Returned Date
No. of Capsules / Tablets returned
Comment
Study Drug: Accountability - Kit 3
Dispensed Date
Kit Number assigned
Actual Kit Number
No. of capsules dispensed
Were any of the wallets within the kit returned?
Yes
No
Returned Date
No. of Capsules / Tablets returned
Comment
Study Drug: Accountability - Kit 4
Dispensed Date
Kit Number assigned
Actual Kit Number
No. of capsules dispensed
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Were any of the wallets within the kit returned?
Yes
No
Returned Date
No. of Capsules / Tablets returned
Comment
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Eligibility Coronary Artery Disease
NCT00433784
H2 Haplotype and CYP3As Polymorphisms and the
Antiplatelet Response to Clopidogrel; ODM derived from:
https://clinicaltrials.gov/show/NCT00433784
All rights reserved. Please visit https://medical-data-
models.org/forms/16940
Eligibility Coronary Artery Disease
NCT00433784
Inclusion Criteria
documented coronary artery disease (cad)
requiring an elective diagnostic  coronary
angiography with or without percutaneous
coronary intervention (pci)*
Yes
No
Exclusion Criteria
major bleeding disorders or active bleeding;*
Yes
No
acute mi within 14 days of recruitment;*
Yes
No
unstable angina with st-segment changes of > or
= 1 mm in at least two contiguous
electrocardiographic leads at rest, a troponin level
of > 0.06 ug/l or both within 14 days of
recruitment;*
Yes
No
stroke within the last 3 months;*
Yes
No
platelet count < 100 x 109/l;*
Yes
No
prothrombin time > 1.5 times control;*
Yes
No
hematocrit < 25% or hemoglobin level < 100 g/l;*
Yes
No
alcohol or drug abuse;*
Yes
No
enrolment in other investigational drug trials
within the previous month;*
Yes
No
use of thienopyridines, glycoprotein (gp) iib/iiia
1 / 2
inhibitors, warfarin or acenocoumarol within the
prior week;*
Yes
No
allergic reaction or any contraindication to
clopidogrel or aspirin.*
Yes
No
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Laboratory Test Recommendations
Table 6 – Urinalysis
Table for Urinalysis
Bacteria
present  (1)
absent (2)
Blood
present  (1)
absent (2)
Clarity
Color
Glucose
present  (1)
absent (2)
Ketones
mg/dL
Leukocytes
present  (1)
absent (2)
Leukocyte esterase
present  (1)
absent (2)
pH
Protein
mg/dL
Red cell/microscopic RBC
cells/HPF
Specific gravity
Urobilinogen
present  (1)
absent (2)
Casts
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present  (1)
absent (2)
Crystals
present  (1)
absent (2)
Epithelial cells
Hemoglobin
present  (1)
absent (2)
Pregnancy test, urine
Toxicology screen
positive  (1)
negative  (2)
not done (3)
Urine cast/LPF
present  (1)
absent (2)
White cell/microscopic WBC
cells/HPF
Yeast
present  (1)
absent (2)
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Multiple Sclerosis
DM-ASP1941-1941-CL-0004
NCT01071850
A Phase 2, Double-Blind, Randomized, Placebo and
Active-Controlled Dose-Finding Study to Assess the
Efficacy, Safety and Tolerability of Multiple Oral Doses of
ASP1941 in Subjects with Type 2 Diabetes MellitusTEST
Study
End of Study
All rights reserved. Please visit https://medical-data-
models.org/forms/16942
End of Study DM-ASP1941-1941-
CL-0004 NCT01071850
End of Treatment / Premature
Discontinuation
Date of Last Treatment Evaluation Through Visit
9
Did subject complete Study Drug Treatment?
Yes
No
End of Treatment Reason
Not fulfill inclusion or exclusion criteria
(1)
adverse event (2)
lack of efficacy (3)
withdrawal by subject (4)
subject lost to follow up (5)
protocol violation (6)
randomized/registered but never
received/dispensed study drug (7)
other (8)
If reason is "Withdrawal by Subject" please
speficy follow-up allowance
allows follow-up after withdrawal (1)
does not allow follow-up after withdrawal
(2)
Date of Withdrawal
dd/MMM/yyyy
Did AE result in death?
No (1)
Yes (2)
Unknown (3)
If protocol violation, specify
If Other, specify
End of Study
Date of Last Evaluation
End of Study Assessment
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Completed (1)
Death (2)
Lost to Follow-up (3)
Withdrawal by Subject (4)
Not Applicable (5)
Other (6)
Details of Withdrawal
If Other specify
Mortality Report
Date of Death
Cause of Death
Relationship of Study Drug to Subject's Death?
Not related (1)
Possible (2)
Probable (3)
Was autopsy performed?
No (1)
Yes (2)
Unknown (3)
Breaking the Blind
Was Blind Broken During the Study?
Yes
No
Date blind broken
Time Blind Broken
Person who requested blind to be broken
Person who broke the blind
Person contacted at Astellas
Reason for breaking the blind
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Eligibility Coronary Artery Disease
NCT00457236
Effect of Clopidogrel Loading and Risk of PCI; ODM
derived from: https://clinicaltrials.gov/show/NCT00457236
All rights reserved. Please visit https://medical-data-
models.org/forms/16943
Eligibility Coronary Artery Disease
NCT00457236
Inclusion Criteria
patients undergoing elective coronary stenting*
Yes
No
pretreatment with a bolus dose of 600mg of
clopidogrel prior to coronary stent implantation*
Yes
No
pretreatment with aspirin ≥ 100 mg per day for at
least 7 days*
Yes
No
age > 18 years*
Yes
No
written consent*
Yes
No
Exclusion Criteria
troponin t on admission > 0.03 ng/ml*
Yes
No
myocardial infarction or fibrinolytic therapy within
the previous 14 days*
Yes
No
cardiogenic shock*
Yes
No
contraindication for aspirin or clopidogrel*
Yes
No
oral anticoagulation*
Yes
No
pretreatment with heparin or a thienopyridine
within the previous 14 days*
Yes
No
use of a gp iib/iiia-receptor antagonist during pci*
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Yes
No
platelet count < 100.000/µl*
Yes
No
severe disorders of the coagulation system*
Yes
No
severe impairment of liver or kidney function*
Yes
No
cancer*
Yes
No
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Laboratory Test Recommendations
Table 5 – Blood Tests
Table for Blood Tests
Pregnancy test, blood
5, 10 Methylene Tetra 
Hydrofolate Reductase
positive (1)
negative  (2)
not done (3)
Activated Partial 
Thromboplastin Time 
(aPTT)
sec
Activated Protein C 
Resistance
positive (1)
negative  (2)
not done (3)
Ammonia
positive (1)
negative  (2)
not done (3)
Anti-CardiolipinAb, IgG, 
IgM
U/mL
positive (1)
negative  (2)
not done (3)
Anti-ds DNA Ab
U/mL
positive (1)
negative  (2)
not done (3)
Anti-ENA/ ANA Screen
U/mL
positive (1)
negative  (2)
not done (3)
Anti-HAV Hepatitis
U/mL
1 / 7
positive (1)
negative  (2)
not done (3)
Anti-HCA Hepatitis
U/mL
positive (1)
negative  (2)
not done (3)
Anti-HCB Hepatitis
U/mL
positive (1)
negative  (2)
not done (3)
Anti-HCV Hepatitis
U/mL
positive (1)
negative  (2)
not done (3)
Anti-HIV Ab
positive (1)
negative  (2)
not done (3)
Anti-HIV ½ Ab
U/mL
positive (1)
negative  (2)
not done (3)
Anti-HLTV-I Ab
U/mL
positive (1)
negative  (2)
not done (3)
Anti-Interferon Ab 
Binding
U/mL
positive (1)
negative  (2)
not done (3)
Anti-Interferon Ab 
Neutralizing
U/mL
positive (1)
negative  (2)
not done (3)
Anti-JC VAb (virus 
antibodies)
U/mL
positive (1)
negative  (2)
not done (3)
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Anti-microsomal Ab
U/mL
positive (1)
negative  (2)
not done (3)
Anti-mycoplasma Ab
U/mL
positive (1)
negative  (2)
not done (3)
AntiNeutrophil 
Cytoplasmic Antibodies
positive (1)
negative  (2)
not done (3)
Anti-nuclear Ab
positive (1)
negative  (2)
not done (3)
Anti-SSA
U/mL
positive (1)
negative  (2)
not done (3)
Anti-SSB
U/mL
positive (1)
negative  (2)
not done (3)
Antithrombin Activity 
(AT-III)
U/mL
positive (1)
negative  (2)
not done (3)
Anti-thyroglobulin Ab
U/mL
positive (1)
negative  (2)
not done (3)
Anti-thyroid Ab
Anti-VZV Ab
U/mL
positive (1)
negative  (2)
not done (3)
Arterial Blood Gases
mmHg
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β 2- glycoprotein Ab 
IgG, IgM
Ceruloplasmin
mg/dL
Cholesterol - HDL
mg/dL
Cholesterol - LDL
mg/dL
Cholesterol, total
mg/dL
Cholesterol - VLDL
mg/dL
C-reactive protein 
(CRP)
mg/L
Creatinine Clearance
mL/min
Creatine Kinase - 
Myocardial Bands
ng/mL
D-dimer
positive (1)
negative  (2)
not done (3)
Epstein-Barr virus 
(EBV) panel
positive (1)
negative  (2)
not done (3)
Erythrocyte 
Sedimentation Rate
mm/hr
Factor V Leiden 
Mutation
negative (1)
heterozygous (2)
homozygous (3)
Fibrinogen
mg/dL
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Folate, serum level
ng/mL
GAD 65 Ab
Glomerular Filtration 
Rate (eGFR)
mL/min
Glycosylated 
hemoglobin (HbA1c)
%
High sensitivity C 
Reactive Protein
mg/L
HLA-A, B, Cw
HLA-DR, DQ
Homocysteine
μmol/L
Human T-cell 
lymphotropic virus type 
1 (HTLV-1)
Human T-cell 
lymphotropic virus type 
2 (HTLV-2)
Lupus Anticoagulant
positive (1)
negative  (2)
not done (3)
Lyme disease Ab, 
Serum
positive (1)
indeterminant/borderline  (2)
negative  (3)
not done (4)
Methylmalonic acid
nmol/L
Neutralizing-IFN ab
NMO IgG
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positive (1)
negative (2)
Paraneoplastic panel/ 
Autoimmune 
encephalopathies panel
Protein C activity
Protein S activity
Prothrombin gene 
mutation
Prothrombin time/ 
international 
normalized ratio 
(PT/INR)
Protoplasmic-staining 
AntiNeutrophil 
Cytoplasmic Antibodies 
(ANCA)
Rapid plasma reagin 
(RPR/VDRL)
Rheumatoid factor
serum IgA
mg/dL
serum IgE
mg/dL
serum IgG
mg/dL
serum IgM
mg/dL
Serum protein 
electrophoresis with 
immunofixation
g/dL
Skin test 3 antigens
positive (1)
negative  (2)
not done (3)
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Stool for occult blood
positive (1)
negative  (2)
not done (3)
TB Skin testing
Thrombin time
sec
Thyroid stimulating 
hormone (TSH)
mIU/L
Triiodothyronine (T3)
mcg/dL
Thyroxine (T4), free
mcg/dL
Triglycerides
mg/dL
Troponin I
µg/L
Troponin T
µg/L
Uric acid
mg/dL
Vitamin B12, Serum 
level
ng/L
Vitamin D, 25 hydroxy
ng/mL
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Eligibility Coronary Artery Disease
NCT00482183
Comparison Between Pioglitazone and SES With type2
DM; ODM derived from:
https://clinicaltrials.gov/show/NCT00482183
All rights reserved. Please visit https://medical-data-
models.org/forms/16945
Eligibility Coronary Artery Disease
NCT00482183
Inclusion Criteria
patients with type 2 diabetes mellitus who had
received coronary stenting were eligible for the
study.*
Yes
No
Exclusion Criteria
spastic angina pectoris*
Yes
No
congestive heart failure*
Yes
No
hepatic dysfunction*
Yes
No
chronic renal disease*
Yes
No
recent stroke*
Yes
No
impaired glucose tolerance*
Yes
No
insulin dependent diabetes mellitus*
Yes
No
familial hypercholesterolemia*
Yes
No
thyroid dysfunction*
Yes
No
adrenal dysfunction*
Yes
No
an intolerance of aspirin, ticlopidine, heparin,
pioglitazone, stainless steel, or contrast material.*
Yes
1 / 2
No
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Eligibility Coronary Artery Disease
NCT00569491
TAXUS ARRIVE: TAXUS Peri-Approval Registry: A Multi-
Center Safety Surveillance Program; ODM derived from:
https://clinicaltrials.gov/show/NCT00569491
All rights reserved. Please visit https://medical-data-
models.org/forms/16946
Eligibility Coronary Artery Disease
NCT00569491
Criteria
patient is eligible to receive a boston scientific
taxus stent.*
Yes
No
inappropriate patients criteria:*
Yes
No
known sensitivity to paclitaxel.*
Yes
No
known allergy to stainless steel.*
Yes
No
patients in whom antiplatelet and / or
anticoagulant therapy is contraindicated.*
Yes
No
patients judged to have a lesion that prevents
complete inflation of an angioplasty balloon or
proper placement of the stent or delivery device.*
Yes
No
patients with unresolved vessel thrombus at the
lesion site.*
Yes
No
patients with coronary artery reference vessel
diameters < 2.5 mm or > 3.75 mm.*
Yes
No
patients with lesions located in the left main
coronary artery, ostial lesions, or lesions located
at a bifurcation.*
Yes
No
patients with diffuse disease or poor overflow
distal to the identified lesions.*
Yes
No
patients with tortuous vessels in the region of the
obstruction or proximal to the lesion.*
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Yes
No
patients with a recent acute myocardial infarction
where there is evidence of thrombus or poor
flow.*
Yes
No
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Eligibility Coronary Artery Disease
NCT00596479
Filgrastim for the Promotion of Collateral Growth in Patients
With CAD; ODM derived from:
https://clinicaltrials.gov/show/NCT00596479
All rights reserved. Please visit https://medical-data-
models.org/forms/16947
Eligibility Coronary Artery Disease
NCT00596479
Inclusion Criteria
age > 18 years old*
Yes
No
1- to 3-vessel coronary artery disease (cad)*
Yes
No
stable angina pectoris*
Yes
No
at least 1 stenotic lesion suitable for pci*
Yes
No
no q-wave myocardial infarction in the area
undergoing cfi measurement*
Yes
No
written informed consent to participate in the
study*
Yes
No
Exclusion Criteria
patients admitted as emergencies*
Yes
No
acute myocardial infarction*
Yes
No
unstable cad*
Yes
No
cad treated best by cabg*
Yes
No
patients with overt neoplastic disease*
Yes
No
patients with diabetic retinopathy*
Yes
No
1 / 2
liver or kidney disease*
Yes
No
pre-menopausal women*
Yes
No
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Eligibility Hepatitis B NCT00362674
Durability of Antiviral Activity in Chronic HBV Patients Who
Showed Complete Response in L-FMAU-301,302 or 303
Trial; ODM derived from:
https://clinicaltrials.gov/show/NCT00362674
All rights reserved. Please visit https://medical-data-
models.org/forms/16949
Eligibility Hepatitis B NCT00362674
Inclusion Criteria
1. the patients who have completed l-fmau-301, l-
fmau-302 or l-fmau-303.*
Yes
No
2. patients who have showed complete response
(alt normalization and hbv dna <4,700 copies/ml
in l-fmau-301 or l-fmau-302, in addition, hbeag
seroconverted to anti-hbe at the last two visits in
l-fmau-301) after completion of l-fmau-301 or l-
fmau-302 and treated with the clevudine.*
Yes
No
3. patients who have showed complete response
(alt normalization and hbv dna <4,700 copies/ml,
in addition hbeag seroconverted to anti-hbe at
the last two visits who showed hbeag positiv at
baseline) after completion of l-fmau-303*
Yes
No
4. patients who were able to give written informed
consent prior to study start and to comply with
the study requirements.*
Yes
No
5. patients with bilirubin levels less than 2.0
mg/dl, prothrombin time of less than 1.7 (inr), and
a serum albumin level of at least 3.5 g/dl at the
last visit in l-fmau-301, l-fmau-302 or l-fmau-303.*
Yes
No
Exclusion Criteria
1. patients who have showed complete response
but previously treated with placebo in the l-fmau-
301, l-fmau-302.*
Yes
No
2. patients who were currently receiving antiviral,
immunomodulatory or corticosteroid therapy.*
Yes
No
3. patients previously treated with interferon,
lamivudine, lobucavir, famciclovir, adefovir or any
other investigational nucleoside for hbv infection.*
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Yes
No
4. patients with a history of ascites, variceal
hemorrhage or hepatic encephalopathy.*
Yes
No
5. patients co-infected with hcv, hdv or hiv.*
Yes
No
6. patients with a liver mass (hemangioma,
nodule), biliary diseases except asymptomatic gb
stone during the l-fmau-301, l-fmau-302 or l-
fmau-303.*
Yes
No
7. patients who were pregnant or breast-feeding.*
Yes
No
8. patients with a significant gastrointestinal,
renal, hepatic (decompensated), biliary diseases
except asymptomatic gb stone,
bronchopulmonary, neurological, cardiovascular,
oncologic or allergic disease. the patients with a
benign tumor were excluded if judged by an
investigator that the continuation of study would
be interfered by benign tumor.*
Yes
No
9. patients who were not suitable to the study if
judged by an investigator.*
Yes
No
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Eligibility Hepatocellular Carcinoma
NCT00155272
Radiotherapy Plus Thalidomide in Locally Advanced
Hepatocellular Carcinoma; ODM derived from:
https://clinicaltrials.gov/show/NCT00155272
All rights reserved. Please visit https://medical-data-
models.org/forms/16950
Eligibility Hepatocellular Carcinoma
NCT00155272
Inclusion Criteria
1.1 patients with measurable, locally advanced
hcc that are not suitable for other local therapies,
including surgery, tae, alcohol injection, or
radiofrequency ablation.*
Yes
No
1.2 patients with histological confirmed hcc or
patients who do not have histological diagnosis
but have met all of the following criteria: 1.2.1
presence of chronic viral hepatitis and/or cirrhosis
1.2.2 presence of hepatic tumor(s) with image
findings (sonography, ct scan) compatible with
hcc.*
Yes
No
1.2.3 a persistent elevation of serum a-fetoprotein
level ³ 400 ng/ml without any evidence of ana-
fetoprotein-secreting germ cell tumor.*
Yes
No
1.3 patients without any local or systemic therapy
for hcc within 4 weeks.*
Yes
No
1.4 patients with age > 20 years and < 70 years.*
Yes
No
1.5 patients with a performance status of ecog
score <1*
Yes
No
1.6 patients must fulfill all of the following criteria:
1.6.1 child-pugh’s score ≦ 7.*
Yes
No
1.6.2 serum total bilirubin < 1.5 times upper
normal limit (unl)*
Yes
No
1.6.3 serum alanine transaminase (alt) < 5 times
unl*
Yes
No
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1.6.4 platelet count > 5.0 x 104 / mm3.*
Yes
No
1.6.5 white blood cell count > 3,000 / mm3.*
Yes
No
1.6.6 serum creatinine < 2.0 mg/dl*
Yes
No
1.7 patient must have local tumors less than one
half of the whole liver and the tumors can be
encompassed within rt fields*
Yes
No
1.8 signed informed consent*
Yes
No
1.9 sexually active patients, in conjunction with
their partner, must practice birth control during,
and for 2 months after, thalidomide therapy.*
Yes
No
1.10 female patients in child-bearing age must
have negative pregnancy test.*
Yes
No
Exclusion Criteria
2.1. patients with documented extrahepatic
metastasis.*
Yes
No
2.2. patients who received previous radiotherapy
to abdominal area.*
Yes
No
2.3. patients who have received thalidomide
treatment prior to enrollment.*
Yes
No
2.4. patients who had other investigational drug
treatment within 4 weeks prior to enrollment.*
Yes
No
2.5. patients with nci grade 2 or greater
peripheral neuropathy of any causes.*
Yes
No
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2.6. patients with other systemic diseases that
required concurrent usage of glucocorticosteroid
or immunosuppressant agent(s).*
Yes
No
2.7. patients who have major systemic diseases
that the attending physicians consider
inappropriate for radiotherapy or thalidomide
therapy.*
Yes
No
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Eligibility Lymphoma NCT00525876
Non-Myeloablative Allogeneic Stem Cell Transplantation;
ODM derived from:
https://clinicaltrials.gov/show/NCT00525876
All rights reserved. Please visit https://medical-data-
models.org/forms/16951
Eligibility Lymphoma NCT00525876
Inclusion Criteria
1. patients can be as old as 70 years.*
Yes
No
2. they must have a diagnosis of mcl, either (1)
recurrent, (2) newly diagnosed (after
cytoreduction with conventional chemotherapy)
but with high-risk features (blastic or blastoid
features, leukemic phase, or elevated b^2
microglobulin (> 3).*
Yes
No
3. patients that have received prior conventional
chemotherapy but have not achieved complete
response (cr).*
Yes
No
4. disease must be chemosensitive, (ie, patients
must not have had a partial response to prior
therapy).*
Yes
No
5. patients whose disease failed to respond to a
previous autologous transplantation may also be
eligible.*
Yes
No
6. patients must have a matched or 1 antigen
mismatched sibling or unrelated donor.*
Yes
No
7. point scale (ps) </= 2.*
Yes
No
8. inclusion criteria for immunomodulation post
transplantation: patients can be as old as 70
years.*
Yes
No
9. patients must have a diagnosis of mcl or cll
with one of the following characteristics: 1.
patients who develop disease progression or do
not experience a cr within 3 months post-
allogeneic transplantation 2. patients with a weak
chimerism (any mixed chimerism of donor t cells
in patients receiving campath by day 90, and less
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than 20% for patients not receiving campath) or a
drop of 20% or more with an amount of donor
cells present in the blood < 50% by pcr. patients
must have the same donor of the original
transplant willing to donate lymphocytes. 4. ps </
2.*
Yes
No
Exclusion Criteria
1. past history of anaphylaxis following exposure
to rat- or mouse-derived cdr-grafted humanized
monoclonal antibodies.*
Yes
No
2. less than 4 weeks since prior chemotherapy
counted from first day of treatment regimen.*
Yes
No
3. pregnancy or lactation.*
Yes
No
4. hiv or htlv-i positivity.*
Yes
No
5. serum creatinine concentration > 1.6 mg/dl or
serum bilirubin > 2.0 mg/dl unless due to tumor*
Yes
No
6. pulmonary function test - carbon monoxide
diffusing capacity < 40%*
Yes
No
7. cardiac ejection fraction < 40% of predicted
levels (by multiple-gated acquisition or
echocardiography).*
Yes
No
8. severe concomitant medical or psychiatric
illness.*
Yes
No
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Eligibility Multiple Myeloma NCT00375791
Efficacy of Perifosine Alone and in Combination With
Dexamethasone for Patients With Multiple Myeloma; ODM
derived from: https://clinicaltrials.gov/show/NCT00375791
All rights reserved. Please visit https://medical-data-
models.org/forms/16954
Eligibility Multiple Myeloma
NCT00375791
Inclusion Criteria
1. plasmacytomas on tissue biopsy.*
Yes
No
2. bone marrow plasmacytosis (> 30% plasma
cells).*
Yes
No
3. monoclonal immunoglobulin spike on serum
electrophoresis immunoglobulin g (igg) > 3.5 g/dl
or immunoglobulin a (iga) > 2.0 g/dl; kappa or
lambda light chain excretion > 1 g/day on 24 hour
urine protein electrophoresis.*
Yes
No
minor criteria:*
Yes
No
1. bone marrow plasmacytosis (10 to 30%
plasma cells)*
Yes
No
2. monoclonal immunoglobulin present but of
lesser magnitude than given under major criteria*
Yes
No
3. lytic bone lesions*
Yes
No
4. normal immunoglobulin m (igm) < 50 mg/dl, iga
< 100 mg/dl or igg < 600 mg/dl.*
Yes
No
any of the following sets of criteria will confirm the
diagnosis of multiple myeloma:*
Yes
No
1. any two of the major criteria.*
Yes
No
2. major criterion 1 plus minor criterion b, c or d.*
Yes
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No
3. major criterion 3 plus minor criterion a or c.*
Yes
No
4. minor criteria a, b and c or a, b and d.*
Yes
No
Exclusion Criteria
1. renal insufficiency (serum creatinine levels > 3
mg/dl).*
Yes
No
2. patients who present with either alt or ast ≥ 2.5
x upper limit of normal.*
Yes
No
3. history of allergic reactions attributed to
compounds of similar chemical or biologic
composition to perifosine (miltefosine or
edelfosine).*
Yes
No
4. concomitant therapy medications that include
corticosteroids (except as indicated for other
medical conditions, or up to 100 mgs of
hydrocortisone as premedication for
administration of certain medications or blood
products) or other chemotherapy that is or may
be active against myeloma, or therapy with
chemotherapy within 3 weeks prior to day 1.
nitrosoureas must be discontinued 6 weeks prior
to day 1.*
Yes
No
5. subjects with a hemoglobin < 8.0 g/dl.*
Yes
No
6. any condition, including laboratory
abnormalities, that in the opinion of the
investigator, places the subject at unacceptable
risk if he/she were to participate in the study.*
Yes
No
7. women of childbearing potential (wcbp) who
are pregnant, or breast-feeding or men and
women who are not using adequate
contraception are excluded.*
Yes
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No
8. plasma cell leukemia.*
Yes
No
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Eligibility Heart Failure, Congestive
NCT00400985
Sensitivity of the InSync Sentry OptiVol Feature for the
Prediction of Heart Failure; ODM derived from:
https://clinicaltrials.gov/show/NCT00400985
All rights reserved. Please visit https://medical-data-
models.org/forms/16955
Eligibility Heart Failure, Congestive
NCT00400985
Inclusion Criteria
successfully implanted insync sentry device (< 34
days post implant or pocket revision)in the
pectoral region;*
Yes
No
at least one hf-related hospitalization that
required administration of iv medication
(inotropes, nitrates, diuretics) within the last 12
months*
Yes
No
the subject has a market released, transvenous,
high voltage rv lead*
Yes
No
the subject is able to detect a patient alert signal*
Yes
No
Exclusion Criteria
<18 years of age (or under a minimum age
required by local law)*
Yes
No
moderate to severe chronic obstructive
pulmonary disease (copd)*
Yes
No
post heart transplant or awaiting heart
transplantation*
Yes
No
primary pulmonary hypertension*
Yes
No
renal insufficiency requiring dialysis*
Yes
No
Amendment to the Inclusion Criteria (Jul
06):
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inclusion of patients with concerto/virtuoso
devices.
Yes
No
at least one hf-related hospitalization that
required administration of iv (or uptitration of the
oral medication)(inotropes, nitrates,
diuretics)within the last 12 months
Yes
No
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Eligibility Coronary Artery Disease
NCT00620217
Angiogenesis Using VEGF-A165/bFGF Plasmid Delivered
Percutaneously in No-option CAD Patients; a Controlled
Trial; ODM derived from:
https://clinicaltrials.gov/show/NCT00620217
All rights reserved. Please visit https://medical-data-
models.org/forms/16956
Eligibility Coronary Artery Disease
NCT00620217
Inclusion Criteria
severe (>= ccs iii) ischemic heart disease despite
optimal medical treatment in patients not
amenable to percutaneous transluminal coronary
angioplasty or coronary artery bypass surgery*
Yes
No
left ventricular ejection fraction >35%*
Yes
No
significant stress-induced reversible ischemic
area documented on dipyridamole stress
myocardial perfusion scintigraphy*
Yes
No
able to understand and willing to sign the
informed consent*
Yes
No
older than 18 years of age*
Yes
No
Exclusion Criteria
angina <ccs iii*
Yes
No
secondary angina*
Yes
No
acute myocardial infarction within 4 weeks prior
to inclusion*
Yes
No
diabetes with proliferative retinopathy*
Yes
No
diagnosed or suspected tumor*
Yes
No
chronic inflammatory or autoimmune disease*
Yes
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No
fertile women*
Yes
No
left ventricular ejection fraction <35%*
Yes
No
patients not willing to or not able to give the
informed consent to participate in the study*
Yes
No
patients with a severe disease (other than cad)
having life-expectancy below 1 year*
Yes
No
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Eligibility Coronary Artery Disease
NCT00661232
Multicenter Myocardial Viability Trial; ODM derived from:
https://clinicaltrials.gov/show/NCT00661232
All rights reserved. Please visit https://medical-data-
models.org/forms/16957
Eligibility Coronary Artery Disease
NCT00661232
Inclusion Criteria
age: > 21 years and < 85 years*
Yes
No
sinus rhythm*
Yes
No
weight < 120 kg*
Yes
No
lvef > 30%*
Yes
No
wall motion abnormality on echo. or lv-gram*
Yes
No
scheduled for revascularization -
angioplasty/stent or cabg - within 30 days*
Yes
No
Exclusion Criteria
resting heart rate > 100 bpm*
Yes
No
frequent atrial or ventricular ectopy*
Yes
No
severe aortic stenosis or hocm*
Yes
No
unstable angina*
Yes
No
myocardial infarction within 14 days*
Yes
No
active congestive heart failure*
Yes
No
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pregnancy*
Yes
No
known allergy to gadolinium*
Yes
No
contraindication to mri*
Yes
No
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Eligibility Coronary Disease NCT00148356
Safety and Efficacy of the ZoMaxx™ Drug-Eluting Stent
System in Coronary Arteries; ODM derived from:
https://clinicaltrials.gov/show/NCT00148356
All rights reserved. Please visit https://medical-data-
models.org/forms/16958
Eligibility Coronary Disease
NCT00148356
Criteria
subject is ≥ 18 years old.*
Yes
No
female of childbearing potential must have a
negative pregnancy test within 7 days prior to
enrollment and utilize reliable birth control for
nine (9) months after enrollment.*
Yes
No
subject is eligible for percutaneous coronary
intervention (pci) and has a single lesion
requiring treatment.*
Yes
No
subject is an acceptable candidate for cabg.*
Yes
No
subject has clinical evidence of ischemic heart
disease or a positive functional study.*
Yes
No
subject has documented stable angina pectoris*
Yes
No
exclusion criteria include all of the following:*
Yes
No
evidence of an acute myocardial infarction (ami)
or ck-mb > 2x upper limit of normal within 72
hours of the intended treatment (refer to who
definition).*
Yes
No
known allergies to the following: aspirin,
clopidogrel bisulfate (plavix®) or ticlopidine
(ticlid®), heparin, stainless steel, tantalum,
contrast agent (that cannot be adequately
premedicated), paclitaxel, or drugs similar to abt-
578 (i.e. tacrolimus, sirolimus, everolimus).*
Yes
No
a platelet count < 100 x 109/l or > 700 x 109/l (<
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100,000 cells/mm3 or > 700,000 cells/mm3); a
wbc < 3,000 cells/mm3; or a hemoglobin < 10.0
g/dl.*
Yes
No
acute or chronic renal dysfunction (creatinine >
2.0 mg/dl or > 150 µmol/l).*
Yes
No
subject has had any previous or planned
brachytherapy in the target vessel.*
Yes
No
target vessel has evidence of thrombus or is
excessively tortuous (> 60 degree bend) that
makes it unsuitable for proper stent delivery and
deployment.*
Yes
No
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Eligibility Coronary Disease NCT00180466
PROSPECT: An Imaging Study in Patients With Unstable
Atherosclerotic Lesions; ODM derived from:
https://clinicaltrials.gov/show/NCT00180466
All rights reserved. Please visit https://medical-data-
models.org/forms/16959
Eligibility Coronary Disease
NCT00180466
Inclusion Criteria
1. acute cardiac pain, or angina equivalent,
consistent with unstable angina or myocardial
infarction, lasting greater than 10 minutes
duration within the past 72 hours.*
Yes
No
2. patient must have evidence of an acs requiring
catheterization documented by the presence of
any one of the following conditions:*
Yes
No
1. elevated enzymes (ck-mb or troponin i or
troponin t greater than upper limits of normal).*
Yes
No
2. st depression of >1 mm in 2 or more
contiguous leads measured at 40 ms after the j
point, in the absence of left ventricular
hypertrophy, bundle branch block, paced rhythms,
pre-excitation or other ecg artifacts or
confounding conditions.*
Yes
No
3. transient st elevation of >1 mm in 2 or more
contiguous leads lasting <30 minutes (otherwise
same criteria as above).*
Yes
No
4. st elevation myocardial infarction with onset
>24 hours previously, diagnosed with the typical
triad of nitrate unresponsive chest pain lasting
>30 minutes, st elevation of >1 mm in 2 or more
contiguous leads or new left bundle branch block,
and rise and fall of ck-mb isoenzymes.*
Yes
No
key clinical exclusion criteria:*
Yes
No
1. patient has had a documented acute st-
segment elevation myocardial infarction within the
past 24 hours.*
Yes
No
1 / 3
2. known serum creatinine > 2.5 mg/dl.*
Yes
No
3. decompensated hypotension or heart failure
requiring intubation, inotropes, intravenous
diuretics or intraaortic balloon counterpulsation.*
Yes
No
4. patient has a known hypersensitivity, allergy or
contraindication to any of the following: aspirin,
heparin, clopidogrel, and ticlopidine or to contrast
that cannot be adequately pre-medicated.*
Yes
No
5. presence of cardiac implants (i.e. implantable
defibrillators); however, prior implantation of
pacemaker or biventricular pacemaker is
permitted.*
Yes
No
6. presence of cardiogenic shock.*
Yes
No
7. patient has a known left ventricular ejection
fraction <30%.*
Yes
No
8. refractory ventricular arrhythmia requiring
either intravenous pharmacologic treatment or
defibrillator therapy (e.g. ventricular tachycardia
or fibrillation).*
Yes
No
9. acute conduction system disease requiring
temporary pacemaker insertion.*
Yes
No
10. patient has had a recent (within 6 months) pci
unless the patient is undergoing a staged
procedure for dual vessel treatment.*
Yes
No
11. patient has other medical illness (i.e., cancer
or congestive heart failure) or recent history of
substance abuse that may cause non-compliance
with the investigational plan, confound the data
interpretation or is associated with an anticipated
limited life expectancy less than one year..*
Yes
No
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12. prior participation in this study or patient is
currently enrolled in another investigational use
device or drug study that has not reached its
primary endpoint. if the patient is enrolled in
another study that is not investigational, required
visits for that trial must not interfere with the
conduct of this trial.*
Yes
No
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Eligibility Coronary Disease NCT00208832
A Randomized Controlled Trial to Improve Medication
Compliance Among Patients With Coronary Heart Disease;
ODM derived from:
https://clinicaltrials.gov/show/NCT00208832
All rights reserved. Please visit https://medical-data-
models.org/forms/16960
Eligibility Coronary Disease
NCT00208832
Inclusion Criteria
coronary heart disease, demonstrated by
documentation of > 30% stenosis of one or more
coronary vessels on cardiac catheterization,
history of coronary artery bypass graft surgery,
history of angioplasty, or documented myocardial
infarction.*
Yes
No
Exclusion Criteria
current participation in another medication
adherence study*
Yes
No
too ill*
Yes
No
does not manage their own medications*
Yes
No
no mailing address or telephone number*
Yes
No
routine prescriptions filled outside of the grady
pharmacy system*
Yes
No
psychiatric illnesses, overt delirium or dementia*
Yes
No
visual acuity worse than 20/60*
Yes
No
unable to communicate in english*
Yes
No
already using a medication pill card*
Yes
No
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Baseline Nutrition Cardiovascular Health
Study (CHS)
Documentation part: Record 25 Baseline Nutrition
The Cardiovascular Health Study (CHS) was initiated by
the National Heart, Lung and Blood Institute (NHLBI) in
1987 to determine the risk factors for development and
progression of cardiovascular disease (CVD) in older
adults, with an emphasis on subclinical measures. The
study recruited 5,888 adults aged 65 or older at entry in
four U.S. communities and conducted extensive annual
clinical exams between 1989-1999 along with semi-annual
phone calls, events adjudication, and subsequent data
analyses and publications. Additional data were collected
by studies ancillary to CHS. With the exception of annual
clinic visits, these activities are still ongoing.
Data obtained from: https://chs-nhlbi.org/
Permission granted by: Erika Enright.
All rights reserved. Please visit https://medical-data-
models.org/forms/16961
Baseline Nutrition Cardiovascular
Health Study (CHS)
Nutrition History
How often do you eat the following food from
restaurants or fast food places:
1 Fried Chicken?
almost every day (1)
2 to 4 times a week (2)
once a week (3)
1 to 3 times a month (4)
5 to 10 times a year (5)
1 to 4 times a year (6)
never, or less than once a year (7)
How often do you eat the following food from
restaurants or fast food places:
2 Burgers?
almost every day (1)
2 to 4 times a week (2)
once a week (3)
1 to 3 times a month (4)
5 to 10 times a year (5)
1 to 4 times a year (6)
never, or less than once a year (7)
How often do you eat the following food from
restaurants or fast food places:
3 Pizza?
almost every day (1)
2 to 4 times a week (2)
once a week (3)
1 to 3 times a month (4)
5 to 10 times a year (5)
1 to 4 times a year (6)
never, or less than once a year (7)
How often do you eat the following food from
restaurants or fast food places:
4 Chinese Food?
almost every day (1)
2 to 4 times a week (2)
once a week (3)
1 to 3 times a month (4)
5 to 10 times a year (5)
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1 to 4 times a year (6)
never, or less than once a year (7)
How often do you eat the following food from
restaurants or fast food places:
5 Mexican Food?
almost every day (1)
2 to 4 times a week (2)
once a week (3)
1 to 3 times a month (4)
5 to 10 times a year (5)
1 to 4 times a year (6)
never, or less than once a year (7)
How often do you eat the following food from
restaurants or fast food places:
6 Fried Fish?
almost every day (1)
2 to 4 times a week (2)
once a week (3)
1 to 3 times a month (4)
5 to 10 times a year (5)
1 to 4 times a year (6)
never, or less than once a year (7)
How often do you eat the following food from
restaurants or fast food places:
7 Other Food?
8 For about how long have you eaten the way you
do now?
years
8 For about how long have you eaten the way you
do now? If less than one year # months
months
9 Are you following a special diet?
Yes
No
Is your diet?
medically prescribed (medically
prescribed)
self-imposed (self-imposed)
10 How often do you eat the skin on chicken?
often/always (often/always)
seldom/never (seldom/never)
sometimes (sometimes)
11 How often do you eat the fat on meat?
often/always (often/always)
seldom/never (seldom/never)
sometimes (sometimes)
12 low- or reduced-sodium canned vegetables or
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soups:
often/always (often/always)
seldom/never (seldom/never)
sometimes (sometimes)
13 juice-pack or low-sugar canned fruits
often/always (often/always)
seldom/never (seldom/never)
sometimes (sometimes)
14 low-salt bread or cereal products
often/always (often/always)
seldom/never (seldom/never)
sometimes (sometimes)
15 low-calorie bread
often/always (often/always)
seldom/never (seldom/never)
sometimes (sometimes)
16 low-calorie salad dressing:
often/always (often/always)
seldom/never (seldom/never)
sometimes (sometimes)
17 reduced-sodium lunch meat or cold cuts
often/always (often/always)
seldom/never (seldom/never)
sometimes (sometimes)
18 low-fat lunch meat or cold cuts
often/always (often/always)
seldom/never (seldom/never)
sometimes (sometimes)
19 low-sodium or low-calorie frozen entrees or
dinner
often/always (often/always)
seldom/never (seldom/never)
sometimes (sometimes)
20 How often do you add salt to your food?
often/always (often/always)
seldom/never (seldom/never)
sometimes (sometimes)
21 What type of salt do you use?
Brand name/type: (sodium chloride, potassium
chloride, or other salt substitutes)
22 Is it plain or iodized salt?
don't know (don't know)
iodized (iodized)
not iodized (not iodized)
23 How often do you use fat or oil in cooking? For
example, in frying eggs, meat or vegetables?
#times
never (0)
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day (1)
week (2)
month (3)
per:
24 What kind of fat or oil do you usually cook
with?
butter (butter)
don't know or don't cook (don't know or
don't cook)
lard, fatback bacon fat (lard, fatback
bacon fat)
liquid oil  (liquid oil )
pam or no oil (pam or no oil)
soft margarine (soft margarine)
stick margarine (stick margarine)
25 What kind of fat or oil do you usually add to
vegetables, potatoes, etc.?
butter (butter)
don't add fat (don't add fat)
don't know (don't know)
half butter/ half margarine (half butter/
half margarine)
lard, fatback bacon fat (lard, fatback
bacon fat)
soft margarine (soft margarine)
stick margarine (stick margarine)
26 If you eat cold cereal, what kind do you eat
most often?
27 About how many servings of vegetables do
you eat per day or week, not counting salad or
potatoes?
#vegetables
Per:
never (0)
day (1)
week (2)
month (3)
28 How many fruits do you usually eat per day or
per week, not counting juices?
#fruits
Per:
never (0)
day (1)
week (2)
month (3)
29 How often do you eat breakfast?
never (0)
every day (1)
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some days (2)
rarely (3)
weekends only (4)
30 On Monday through Friday about what time do
you usually first eat or drink something after
waking up?
31 On Monday through Friday about what time do
you usually last eat or drink something before
going to bed?
32 On Monday through Friday how many meals
do you usually eat per day?
#meals
33 On Monday through Friday how many snacks
do you usually eat after dinner?
#meals
34 Do you ever drink beer?
Yes
No
35 About how often do you drink beer?
rarely/never (0)
daily (1)
weekly (2)
monthly (3)
yearly (4)
36 How many 12 ounce cans or bottles of beer
do you usually drink on one occasion?
#cans or bottles
37 Do you ever drink wine?
Yes
No
38 About how often do you drink wine?
rarely/never (0)
daily (1)
weekly (2)
monthly (3)
yearly (4)
39 How many medium, 6 ounce, glasses of wine
do you usually drink on one occassion?
#servings
40 Do you ever drink liquor?
Yes
No
41 About how often do you drink liquor?
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rarely/never (0)
daily (1)
weekly (2)
monthly (3)
yearly (4)
42 How many drinks, equal to 1 shot of liquor, do
you usually drink on one occassion?
#servings
43 Have you changed your pattern of beer, wine,
or liquor consumption during the past 5 years?
no (0)
yes (1)
don't know (9)
44 Was there ever a time in your life when you
drank 5 or more drinks of any kind of alcoholic
beverage almost every day?
no (0)
yes (1)
don't know (9)
45 How many periods of time during your life did
you drink 5 or more alcoholic beverages almost
every day?
#periods
46 For how long altogether did these periods of
time last?
Per:
days (1)
weeks (2)
months (3)
years (4)
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Eligibility Coronary Heart Disease
NCT00539604
Non Invasive Multicenter Italian Study for Coronary Artery
Disease; ODM derived from:
https://clinicaltrials.gov/show/NCT00539604
All rights reserved. Please visit https://medical-data-
models.org/forms/16962
Eligibility Coronary Heart Disease
NCT00539604
Inclusion Criteria
1. patients (men or women of any ethnic group)
scheduled for a coronary angiography evaluation
for a diagnostic work up.*
Yes
No
2. patients will be expected to undergo coronary
angiography within 2 weeks after the mdct study
procedure. the coronary angiography must meet
the minimum standard laid down in the protocol
(see section 8.3.3).*
Yes
No
3. patients must have hdl and total cholesterol
performed within the last year.*
Yes
No
4. patients must be willing and able to continue
study participation following the reference test to
ensure completion of all procedures and
observations required by the study.*
Yes
No
5. fully informed and signed consent must be
obtained from each patient.*
Yes
No
Exclusion Criteria
1. patients under 18 years of age.*
Yes
No
2. patients who have received any investigational
drug  within the 30 days prior to entering this
study.*
Yes
No
3. pregnant or lactating women.*
Yes
No
4. patients who have any contraindication to mdct
examination with iodinate contrast media.*
Yes
No
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5. patients with heart rate >70 bpm despite of β
-blocker treatment (see section 8.2.4.1).*
Yes
No
6. patients with no sinus rhythm.*
Yes
No
7. patients with  nyha  iii or iv class.*
Yes
No
8. patients who have previously  undergone cabg
or stenting.*
Yes
No
9. patients with a creatinine value > 2 mg/dl.*
Yes
No
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Social History Form: UIC Quality
Improvement CRF
ODM derived from:
http://research.uic.edu/qip/toolbox/case-report-forms-crf.
Template Name: Social History Form. QIP Case Report
Forms, UIC Quality Improvement CRF, Office of the Vice
Chancellor for Research. Center for Clinical and
Translational Science, UIC University of Illinois at Chicago.
All rights reserved. Please visit https://medical-data-
models.org/forms/16963
Social History Form: UIC Quality
Improvement CRF
General Information
Protocol Title
Site Number
Subject ID
Visit Date
Study Visit
Social History Form
1. Highest Level of Education
Grade school graduate (1)
Some high school (2)
High school graduate (3)
Some collage (4)
College graduate (5)
Post college graduate (6)
2. Occupation
Occupation
Full Time  (1)
Part-time (2)
Retired___ (3)
Unknown (4)
Occupation: If retired, please specify date
3a. Language(s) in which subject is fluent:
English
Yes
No
Language(s) in which subject is fluent: Spanish
Yes
No
Language(s) in which subject is fluent: Chinese
Yes
No
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Language(s) in which subject is fluent: Tagalog
Yes
No
Language(s) in which subject is fluent: Korean
Yes
No
Language(s) in which subject is fluent: Russian
Yes
No
Language(s) in which subject is fluent: Polish
Yes
No
Language(s) in which subject is fluent: Other
Yes
No
If Other, please specify
3b. Language in which subject requests study
visits to be conducted
English (1)
Spanish (2)
Chinese (3)
Tagalog (4)
Korean (5)
Russian (6)
Polish (7)
Other (8)
If Other, please specify
4. Tobacco/Nicotine History
Yes
No
Cigarettes
Yes
No
Cigarettes: Frequency
Cigarettes: Start Date
Cigarettes: Continuing
Yes
No
Cigarettes: Stop Date
Cigars
Yes
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No
Pipe
Yes
No
Chewing tobacco/snuff
Yes
No
Other
Yes
No
If Other, please specify
Cigars/Pipe/Chewing tobacco/snuff/Other:
Frequency
Cigars/Pipe/Chewing tobacco/snuff/Other: Start
Date
Cigars/Pipe/Chewing tobacco/snuff/Other:
Continuing
Yes
No
Cigars/Pipe/Chewing tobacco/snuff/Other: Stop
Date
5. Alcohol History
Yes
No
Beer
Yes
No
Beer: Frequency
Beer: Start Date
Beer: Continuing
Yes
No
Beer: Stop Date
Wine
Yes
No
Wine: Frequency
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Wine: Start Date
Wine: Continuing
Yes
No
Wine: Stop Date
Hard Liquor
Yes
No
Hard Liquor: Frequency
Hard Liquor: Start Date
Hard Liquor: Continuing
Yes
No
Hard Liquor: Stop Date
6. Illicit Substances History
Yes
No
Marijuana
Yes
No
Marijuana: Frequency
Marijuana: Start Date
Marijuana: Continuing
Yes
No
Marijuana: Stop Date
Cocaine
Yes
No
Cocaine: Frequency
Cocaine: Start Date
Cocaine: Continuing
Yes
No
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Cocaine: Stop Date
Other (specify)
Yes
No
Other: Frequency
Other: Start Date
Other: Continuing
Yes
No
Other: Stop Date
If Other, please specify
Completed by (initials)
Date completed
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Vital signs: UIC Quality Improvement CRF
ODM derived from:
http://research.uic.edu/qip/toolbox/case-report-forms-crf.
Template Name: Vital signs. QIP Case Report Forms, UIC
Quality Improvement CRF, Office of the Vice Chancellor for
Research. Center for Clinical and Translational Science,
UIC University of Illinois at Chicago.
All rights reserved. Please visit https://medical-data-
models.org/forms/16964
Vital signs: UIC Quality Improvement
CRF
General information
Protocol title
Site number
Subject ID
Visit Date
Study Visit
Screening (1)
Baseline (2)
Visit
Yes
No
Visit
Completion visit
Yes
No
Vital signs
1. Time
Time
am (1)
pm (2)
2. Height
Height
inches (1)
centimeters (2)
Height: Not Done
Yes
No
3. Weight
1 / 2
Weight
pounds (1)
kilograms (2)
Weight: Not Done
Yes
No
4. Heart Rate
bpm
Heart Rate: Not Done
Yes
No
5. Blood pressure: systolic
Blood pressure: diastolic
Blood pressure: Not Done
Yes
No
5.a BP Position
Sitting (1)
Supine (2)
Standing (3)
6. Temperature
Temperature
°F (1)
°C (2)
Temperature: Not Done
Yes
No
6.a Source
Oral (1)
Tympanic (2)
Other (specify) (3)
If Other, please specify
7. Respiratory Rate: ___/min
Respiratory Rate: Not Done
Yes
No
Completed by (initials)
Date completed
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Physical Exam: UIC Quality Improvement
CRF
ODM derived from:
http://research.uic.edu/qip/toolbox/case-report-forms-crf.
Template Name: Physical Exam. QIP Case Report Forms,
UIC Quality Improvement CRF, Office of the Vice
Chancellor for Research. Center for Clinical and
Translational Science, UIC University of Illinois at Chicago.
All rights reserved. Please visit https://medical-data-
models.org/forms/16965
Physical Exam: UIC Quality
Improvement CRF
General Information
Protocol Title
Site Number
Subject ID
Visit Date
Study Visit
Screening (1)
Baseline (2)
Visit (specification) (3)
Specification of Visit
Completion/Early Termination
Yes
No
Physical Exam
General Appearance
Normal (1)
Abnormal (2)
Not Examined (3)
General Appearance: If abnormal, please
describe
General Appearance
Yes (1)
No (2)
NA (3)
HEENT
Normal (1)
Abnormal (2)
Not Examined (3)
HEENT: If abnormal, please describe
HEENT: Change from Baseline
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Yes (1)
No (2)
NA (3)
Neck
Normal (1)
Abnormal (2)
Not Examined (3)
Neck: If abnormal, please describe
Neck: Change from Baseline
Yes (1)
No (2)
NA (3)
Chest and Lungs
Normal (1)
Abnormal (2)
Not Examined (3)
Chest and Lungs: If abnormal, please describe
Chest and Lungs: Change from Baseline
Yes (1)
No (2)
NA (3)
Cardiovascular
Normal (1)
Abnormal (2)
Not Examined (3)
Cardiovascular: If abnormal, please describe
Cardiovascular: Change from Baseline
Yes (1)
No (2)
NA (3)
Abdomen
Normal (1)
Abnormal (2)
Not Examined (3)
Abdomen: If abnormal, please describe
Abdomen: Change from Baseline
Yes (1)
No (2)
NA (3)
Genitourinary
Normal (1)
Abnormal (2)
Not Examined (3)
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Genitourinary: If abnormal, please describe
Genitourinary: Change from Baseline
Yes (1)
No (2)
NA (3)
Rectal
Normal  (1)
Abnormal (2)
Not Examined (3)
Rectal: If abnormal, please describe
Rectal: Change from Baseline
Yes (1)
No (2)
NA (3)
Musculoskeletal
Normal (1)
Abnormal (2)
Not Examined (3)
Musculoskeletal: If abnormal, please describe
Musculoskeletal: Change from Baseline
Yes (1)
No (2)
NA (3)
Lymph Nodes
Normal (1)
Abnormal (2)
Not Examined (3)
Lymph Nodes: If abnormal, please describe
Lymph Nodes: Change from Baseline
Yes (1)
No (2)
NA (3)
Extremities/Skin
Normal (1)
Abnormal (2)
Not Examined (3)
Extremities/Skin: If abnormal, please describe
Extremities/Skin: Change from Baseline
Yes (1)
No (2)
NA (3)
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Neurological
Normal (1)
Abnormal (2)
Not Examined (3)
Neurological: If abnormal, please describe
Neurological: Change from Baseline
Yes (1)
No (2)
NA (3)
Other: Please specify
Other
Normal (1)
Abnormal (2)
Not Examined (3)
Other: If abnormal, please describe
Other: Change from Baseline
Yes (1)
No (2)
NA (3)
Clinician Signature
Date Completed
Clinician Printed Name
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Physical Exam: UIC Quality Improvement CRF
Prior and Concomitant Medications: UIC
Quality Improvement CRF
ODM derived from:
http://research.uic.edu/qip/toolbox/case-report-forms-crf.
Template Name: Prior and Concomitant Medications. QIP
Case Report Forms, UIC Quality Improvement CRF, Office
of the Vice Chancellor for Research. Center for Clinical and
Translational Science, UIC University of Illinois at Chicago.
All rights reserved. Please visit https://medical-data-
models.org/forms/16966
Prior and Concomitant Medications:
UIC Quality Improvement CRF
General Information
Protocol Title
Site Number
Subject ID
Visit Date
Were any Concomitant medications taken by the
subject ___ days before or during the study? If
Yes, record below.
If yes, how many days before?
Prior and Concomitant Medications: No
Yes
No
Medications
Medication
Dose
Route (see Description)
Route: If Other, please specify
Frequency (see Description)
Frequency: If Other, please specify
Indication
Start Date
1 / 2
Stop Date OR Check If continuing at study end
Was medication used to treat AE?
Yes (1)
No (2)
If Yes, specify event
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Prior and Concomitant Medications: UIC Quality Improvement CRF
Randomization Form: UIC Quality
Improvement CRF
ODM derived from:
http://research.uic.edu/qip/toolbox/case-report-forms-crf.
Template Name: Randomization Form. QIP Case Report
Forms, UIC Quality Improvement CRF, Office of the Vice
Chancellor for Research. Center for Clinical and
Translational Science, UIC University of Illinois at Chicago.
All rights reserved. Please visit https://medical-data-
models.org/forms/16967
Randomization Form: UIC Quality
Improvement CRF
Randomization Form
Protocol Title
Site Number
Subject ID
Visit Date
1. Did the subject meet the eligibility
requirements for this study? (see description)
Yes
No
a. Date randomized (See description)
b. If eligible and not randomized, indicate reason
Failed to return (1)
Declined participation (2)
Other (specify) (3)
If Other, please specify
2. Randomized to study group or treatment
Completed by (initials)
Date completed
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CRF
ODM derived from:
http://research.uic.edu/qip/toolbox/case-report-forms-crf.
Template Name: Adverse Events. QIP Case Report Forms,
UIC Quality Improvement CRF, Office of the Vice
Chancellor for Research. Center for Clinical and
Translational Science, UIC University of Illinois at Chicago.
All rights reserved. Please visit https://medical-data-
models.org/forms/16968
Adverse Events: UIC Quality
Improvement CRF
General Information
Protocol Title
Site Number
Subject ID
Visit Date
Has the subject had any Adverse Events during
this study? (See description)
Yes
No
Adverse Events
Event Description
Start Date
Severity (see Description)
Action Taken: None
Yes
No
Action Taken
Yes
No
Action Taken: Interrupted temporarily
Yes
No
Action Taken: Reduced Dose
Yes
No
Action Taken: Increased Dose
Yes
No
Action Taken: Delayed Dose
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Yes
No
Final Outcome (see Description)
Stop Date
OR: Continuing
Yes
No
Event Analysis: Relationship to Study
Intervention (see Description)
Definitely related (1)
Possibly related (2)
Not related (3)
Event Analysis: Expected?
Yes (1)
No (2)
Event Analysis: Serious Adverse Event?
Yes (Complete an SAE report form) (1)
No (2)
PI Initials
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Study Completion Form: UIC Quality
Improvement CRF
ODM derived from:
http://research.uic.edu/qip/toolbox/case-report-forms-crf.
Template Name:  Study Completion Form. QIP Case
Report Forms, UIC Quality Improvement CRF, Office of the
Vice Chancellor for Research. Center for Clinical and
Translational Science, UIC University of Illinois at Chicago.
All rights reserved. Please visit https://medical-data-
models.org/forms/16969
Study Completion Form: UIC Quality
Improvement CRF
General Information
Protocol Title
Site Number
Subject ID
Visit Date
Study Completion
1. Date of final study visit
2. Date of last known study intervention
3. Primary reason for terminating participation in
the study
Completed study (1)
Subject was determined after enrollment
to be ineligible (Provide comments) (2)
Subject withdrew consent (Provide
comments) (3)
Adverse Event (Complete the SAE form
if applicable) (4)
Lost to follow-up (5)
Other (specify) (6)
Unknown (7)
If Other, please specify
Comments
I have reviewed all data contained on all pages of
the case report and certify that they are accurate,
complete, and a true reflection of the subject´s
record.: PI Signature
Date
PI Printed Name
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Serious Adverse Event (SAE) Report Form:
UIC Quality Improvement CRF
ODM derived from:
http://research.uic.edu/qip/toolbox/case-report-forms-crf.
Template Name: Serious Adverse Event (SAE) Report
Form. QIP Case Report Forms, UIC Quality Improvement
CRF, Office of the Vice Chancellor for Research. Center for
Clinical and Translational Science, UIC University of Illinois
at Chicago.
All rights reserved. Please visit https://medical-data-
models.org/forms/16971
Serious Adverse Event (SAE) Report
Form: UIC Quality Improvement CRF
General Information
Protocol Title
Site Number
Subject ID
Visit Date
Initial
Yes
No
Follow-Up
Yes
No
If Follow-Up: Number
Final
Yes
No
SAE
1. SAE Start Date
2. SAE Stop-Date
3. Brief description of subject with no personal
identifiers: Sex
F (1)
M (2)
Brief description of subject with no personal
identifiers: Age
4. Diagnosis for study participation
5. Brief description of the nature of the serious
adverse event
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6. Study intervention: Medication or Nutritional
Supplement
Yes
No
If Medication or Nutritional Supplement, please
specify
Study intervention: Device
Yes
No
If Device, please specify
Study intervention: Surgery
Yes
No
If Surgery, please specify
Study intervention: Behavioral/Life Style
Yes
No
If Behavioral/Life Style, please specify
7. Was study intervention interrupted due to the
adverse event?
Yes
No
8. Was study intervention discontinued due to the
adverse event?
Yes
No
9. What medications or other steps were taken to
treat the serious adverse event?
10. List any relevant tests, laboratory data,
history, including preexisting medical conditions.
11. Was this an unexpected adverse event?
Yes
No
12. Category of the serious adverse event
Death - date___ (1)
Life-threatening (2)
Hospitalization-initial or prolonged (3)
Disability / incapacity (4)
Congenital anomaly / birth defect (5)
Required intervention to prevent
permanent impairment (6)
2 / 3
Serious Adverse Event (SAE) Report Form: UIC Quality Improvement
CRF
Other:___ (7)
If Death, please specify date
If Other, please specify
13. Relationship of event to study intervention
Definitely related (clearly related to
intervention) (1)
Possibly related (may be related to
intervention) (2)
Not related (clearly not related to the
intervention) (3)
14. Outcome of serious adverse event
Resolved, No Sequelae (1)
SAE still present - no treatment (2)
SAE still present - being treated  (3)
Residual effects present - not treated  (4)
Residual effects present - treated (5)
Death (6)
Unknown (7)
15. Subject Participation
Continued in study (1)
Continued in study after temporarily
stopping study interventions (2)
Continued in follow-up only (3)
Subject withdrew from participation or
died (4)
Withdrawn from study by PI (5)
Participation completed (6)
16. Date reported to Sponsor
16. Date reported to IRB
Signature (See Description)
Date
Printed Name
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CRF
Performance-based Measurements
Cardiovascular Health Study (CHS)
Documentation part: Record 27 Performance-based
Measurements
The Cardiovascular Health Study (CHS) was initiated by
the National Heart, Lung and Blood Institute (NHLBI) in
1987 to determine the risk factors for development and
progression of cardiovascular disease (CVD) in older
adults, with an emphasis on subclinical measures. The
study recruited 5,888 adults aged 65 or older at entry in
four U.S. communities and conducted extensive annual
clinical exams between 1989-1999 along with semi-annual
phone calls, events adjudication, and subsequent data
analyses and publications. Additional data were collected
by studies ancillary to CHS. With the exception of annual
clinic visits, these activities are still ongoing.
Data obtained from: https://chs-nhlbi.org/
Permission granted by: Erika Enright.
All rights reserved. Please visit https://medical-data-
models.org/forms/16972
Performance-based Measurements
Cardiovascular Health Study (CHS)
Measured walk
1 OBSERVE: Is the participant able to do a
tandem stand (balance unaided for five
seconds)?
no (0)
yes (1)
not assessed (9)
2 OBSERVE: Does the participant use an
assistive device for walking?
no (0)
yes (1)
not assessed (9)
What type of device?
standard cane (1)
quad cane (2)
walker (3)
wheelchair (4)
white cane (5)
crutches (1 or 2) (6)
other (8)
Other, specify:
3 OBSERVE: Does the participant use a lower
extremity orthosis (plastic or metal leg brace at or
above the ankle)?
no (0)
yes (1)
not assessed (9)
4 OBSERVE: Is the participant missing any limb?
no (0)
yes (1)
not assessed (9)
Which limb(s)? Left arm
no (0)
yes (1)
not assessed (9)
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Which limb(s)? Right arm
no (0)
yes (1)
not assessed (9)
Which limb(s)? Left leg
no (0)
yes (1)
not assessed (9)
Which limb(s)? Right leg
no (0)
yes (1)
not assessed (9)
5 OBSERVE: Does the participant use prosthesis
(artificial limb)?
no (0)
yes (1)
not assessed (9)
Which limb(s)? Left arm
no (0)
yes (1)
not assessed (9)
Which limb(s)? Right arm
no (0)
yes (1)
not assessed (9)
Which limb(s)? Left leg
no (0)
yes (1)
not assessed (9)
Which limb(s)? Right leg
no (0)
yes (1)
not assessed (9)
6 OBSERVE: Is the participant able to walk 15
feet?
no (0)
yes (1)
not assessed (9)
Participant uses assissive device on walk
Yes
No
7 Time, in seconds, to walk 15 feet
seconds
8 Number of steps taken:
steps
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Grip Strength
9 OBSERVE: Can the participant lift his/her arm
to the table independently? Left arm
no (0)
yes (1)
unknown (9)
9 OBSERVE: Can the participant lift his/her arm
to the table independently? Right arm
no (0)
yes (1)
unknown (9)
10 ASK: Have you had a recent worsening of
pain or of arthritis in your wrist, or do you have
tendonitis?
no (0)
yes (1)
not assessed (9)
11 ASK: Have you had any surgery on your
hands or arms during the last 13 weeks?
no (0)
yes (1)
not assessed (9)
12 Was grip strength test done?
Yes
No
13 Code which hand is being tested. (Begin with
dominant hand
left (left)
right  (right )
unable/discontinued
(unable/discontinued)
14 1st try
kg
15 2nd try
kg
16 3rd try
kg
17 Code which hand is being tested.
left (left)
right  (right )
unable/discontinued
(unable/discontinued)
18 1st try
kg
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19 2nd try
kg
20 3rd try
kg
Chair stands
21 ASK: Do you think it would be safe for you to
try to stand up from a chair without using your
arms?
Yes
No
22 ASK: Do you think you could try to stand up
from a chair without using your arms?
Yes
No
23 Reason task was not performed:
Not attempted - chair bound (Not
attempted - chair bound)
Not attempted - other reason (Not
attempted - other reason)
Not attempted - safety reasons (Not
attempted - safety reasons)
Specify (Specify)
Specify:
24 Number of attempts to rise. [NOTE: Attempts
include rocking and weight shifting. If participant
stands on first attempt, code 1.)
attempts
25 Rises
Attempted, but unable (Attempted, but
unable)
Rises using arms (Rises using arms)
Rises without using arms (Rises without
using arms)
26 ASK: Do you think it would be safe for you to
try to stand up from a chair, without using your
arms, five times quickly?
Yes
No
27 Reason task was not performed:
Not attempted - chair bound (Not
attempted - chair bound)
Not attempted - other reason (Not
attempted - other reason)
Not attempted - safety reasons (Not
attempted - safety reasons)
Specify (Specify)
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Specify:
28 Heart rate (30 second) prior to chair stands:
beats
29 Number of completed chair rises:
rises
30 Heart rate (30 second) immediately following
chair stands:
beats
31 Number of seconds:
seconds
32 Chair height
(Centimeters from floor to lowest point)
cm
Finger-tapping test
33 Hand done first (begin with dominant hand):
Left (Left)
Not done (Not done)
Right (Right)
34 Number of taps in 15 seconds: RIGHT HAND
34 Number of taps in 15 seconds: LEFT HAND
Key in lock
35 Is the participant able to pick up key?
no  (no )
not assessed (not assessed)
yes - as instructed (yes - as instructed)
yes - picked key up, then dropped it (yes
- picked key up, then dropped it)
yes - slid key off table (yes - slid key off
table)
36 Is participant able to put key in lock?
no (0)
yes (1)
not assessed (9)
37 Is participant able to open lock?
no (0)
yes (1)
not assessed (9)
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38 Time in seconds to complete task:
seconds
Medication Container
39 Is participant able to open a standard
medication container?
no (0)
yes (1)
not assessed (9)
Standard shirt
40 Is the participant able to put on shirt?
no (0)
yes (1)
not assessed (9)
41 Is the participant able to button shirt?
no (0)
yes (1)
not assessed (9)
42 Time needed to put on and button shirt (gently
discontinue after four minutes)
<= 240
seconds
Leg lift
43 Is participant able to lift his/her leg while
standing to 90 degrees at hip and knee? LEFT
LEG
no (0)
yes (1)
unknown (9)
43 Is participant able to lift his/her leg while
standing to 90 degrees at hip and knee? RIGHT
LEG
no (0)
yes (1)
unknown (9)
Date of interview
Interviewer
Date:
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MDS Score IPSS-R
MDS Score IPSS-R
http://www.kompetenznetz-
leukaemie.de/content/aerzte/mds/scores/ipss_r/
Greenberg PL,Tuechler H, Schanz J, Sanz G, Garcia-
Manero G, Solé F, Bennett JM, Bowen D, Fenaux P,
Dreyfus F, Kantarjian H, Kuendgen A, Levis A, Malcovati L,
Cazzola M, Cermak J, Fonatsch C, Le Beau MM, Slovak
ML, Krieger O, Luebbert M, Maciejewski J, Magalhaes SM,
Miyazaki Y, Pfeilstöcker M, Sekeres M, Sperr WR, Stauder
R, Tauro S, Valent P, Vallespi T, van de Loosdrecht AA,
Germing U, Haase D. Revised international prognostic
scoring system for myelodysplastic syndromes. Blood
2012;120(12):2454-65. PMID: 22740453. doi:
10.1182/blood-2012-03-420489.
All rights reserved. Please visit https://medical-data-
models.org/forms/16974
MDS Score IPSS-R
Score Items
Cytogenetic Risk Group?
Favorable (Favorable)
Intermediate (Intermediate)
Unfavorable (Unfavorable)
Very favorable (Very favorable)
Very Unfavorable (Very Unfavorable)
Blasts in Bone marrow:
%
Hemoglobin Measurment
g/dL
Thrombocytes measurement
/μl
Absolute Neutrophil Count
/μl
Result of Score
Prognostic Risk Group?
High Risk (High Risk)
Intermediate Risk (Intermediate Risk)
Low Risk (Low Risk)
Very High Risk (Very High Risk)
Very Low Risk (Very Low Risk)
IPSS-R Score:
1 / 1
Adverse Events: CRF QMCR University of
Alberta
ODM derived from:
http://www.qmcr.ualberta.ca/en/ToolsandTemplates/CaseR
eportFormCRFTemplates.aspx. Template Name: Adverse
Events.
University of Alberta, Quality Management in Clinical
Research. Copyright: 2002-2016 University of Alberta.
All rights reserved. Please visit https://medical-data-
models.org/forms/16975
Adverse Events: CRF QMCR
University of Alberta
General Information
Study Name
Site Number
Pt_ID
Has the participant had any Adverse Events
during this Study? (see Description)
Yes
No
Adverse Events
Adverse Event
Start Date
Stop Date
Severity
Mild (1)
Moderate (2)
Severe (3)
Relationship to Study Treatment
Definitely related (1)
Possibly related (2)
Not related (3)
Action Taken (see Description)
Outcome of AE (see Description)
Expected?
Yes
No
Serious Adverse Event
Yes (complete SAE form) (1)
No (2)
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Eligibility Dementia NCT00216593
Treatment of Severe Alzheimer's Disease: Evaluation of
Efficacy and Safety of Galantamine Hydrobromide in a
Controlled Study; ODM derived from:
https://clinicaltrials.gov/show/NCT00216593
All rights reserved. Please visit https://medical-data-
models.org/forms/16976
Eligibility Dementia NCT00216593
Inclusion Criteria
diagnosis of alzheimer's type dementia, rated as
severe*
Yes
No
progressive worsening of memory and other
cognitive functions*
Yes
No
brain imaging (ctor mri scan) within last 3 years*
Yes
No
ability to be mobile (aided or unaided) with
sufficient vision and hearing to comply with
testing.*
Yes
No
Exclusion Criteria
dementia caused by cerebrovascular disease*
Yes
No
disturbances of consciousness, delirium,
psychosis*
Yes
No
severe aphasia*
Yes
No
or major sensorimotor impairment*
Yes
No
cognitive impairment due to acute cerebral
trauma, hypoxic cerebral damage, vitamin
deficiency, infections, primary of metastatic
cerebral neoplasia, endocrine or metabolic
disease or mental retardation, pregnant or
nursing women or those without adequate
contraception.*
Yes
No
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Demographics: CRF QMCR University of
Alberta
ODM derived from:
http://www.qmcr.ualberta.ca/en/ToolsandTemplates/CaseR
eportFormCRFTemplates.aspx. Template Name:
Demographics. University of Alberta, Quality Management
in Clinical Research. Copyright: 2002-2016 University of
Alberta.
All rights reserved. Please visit https://medical-data-
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Demographics: CRF QMCR
University of Alberta
General Information
Study Name
Site Number
Pt_ID
Visit Date
Visit Type
Screening (1)
Baseline (2)
Demographics
1. Gender
Female (1)
Male (2)
2. Date of Birth
3. Race (See Description)
American Indian or Alaska Native (1)
Asian (2)
Black or African-American (3)
Native Hawaiian or Pacific Islander (4)
White (5)
More than one race (6)
Unknown or not reported (7)
4. Ethnicity (See Description)
Hispanic or Latino (1)
Not Hispanic or Latino (2)
Unknown or not reported (3)
Date Informed Consent Signed
Investigator Signature
Date
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Inclusion/Exclusion Criteria: CRF QMCR
University of Alberta
ODM derived from:
http://www.qmcr.ualberta.ca/en/ToolsandTemplates/CaseR
eportFormCRFTemplates.aspx. Template Name:
Inclusion/Exclusion Criteria. University of Alberta, Quality
Management in Clinical Research. Copyright: 2002-2016
University of Alberta.
All rights reserved. Please visit https://medical-data-
models.org/forms/16978
Inclusion/Exclusion Criteria: CRF
QMCR University of Alberta
General Information
Study Name
Site Number
Pt_ID
Visit Date
Visit Type
Screening (1)
Baseline (2)
Inclusion Criteria
Inclusion Description
Applicability of inclusion criteria (See Description)
Yes
No
Exclusion Criteria
Exclusion Description
Applicability of exclusion criteria (See
Description)
Yes
No
Result
Did the participant meet the eligibility
requirements for this study?
Yes
No
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Medical History I: CRF QMCR University of
Alberta
ODM derived from:
http://www.qmcr.ualberta.ca/en/ToolsandTemplates/CaseR
eportFormCRFTemplates.aspx. Template Name: Medical
History I. University of Alberta, Quality Management in
Clinical Research. Copyright: 2002-2016 University of
Alberta.
All rights reserved. Please visit https://medical-data-
models.org/forms/16979
Medical History I: CRF QMCR
University of Alberta
General Information
Study Name
Site Number
Pt_ID
Visit Date
Visit Type
Screening (1)
Baseline (2)
Medical History (See Description)
Code
Condition/Disease
Start Day
Current/Resolved
Current (1)
Resolved (2)
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MDS Score International Prognostic
Scoring System
MDS Score International Prognostic Scoring System
http://www.kompetenznetz-
leukaemie.de/content/aerzte/mds/scores/ipss/
Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz
G, Sanz M, Vallespi T, Hamblin T, Oscier D, Ohyashiki K,
Toyama K, Aul C, Mufti G, Bennett J. International scoring
system for evaluating prognosis in myelodysplastic
syndromes. Blood. 1997;89(6):2079-88. PMID: 9058730.
Germing U, Hildebrandt B, Pfeilstocker M, Nosslinger T,
Valent P, Fonatsch C, Lubbert M, Haase D, Steidl C,
Krieger O, Stauder R, Giagounidis AA, Strupp C, Kundgen
A, Mueller T, Haas R, Gattermann N, Aul C. Refinement of
the international prognostic scoring system (IPSS) by
including LDH as an additional prognostic variable to
improve risk assessment in patients with primary
myelodysplastic syndromes (MDS). Leukemia.
2005;19(12):2223-31. PMID: 16193087. doi:
10.1038/sj.leu.2403963.
All rights reserved. Please visit https://medical-data-
models.org/forms/16980
MDS Score International Prognostic
Scoring System
Score: Items
Blasts in bone marrow
%
Number of cytopenia
(1 - 3)
Karyotype:
Favorable (Favorable)
Intermediate (Intermediate)
Unfavorable (Unfavorable)
Result of Score
IPSS  Risk Group
High Risk (High Risk)
Intermediate Risk I (Intermediate Risk I)
Intermediate Risk II (Intermediate Risk II)
Low Risk (Low Risk)
IPSS Risk Score Specification:
LDH Measurement
A (A)
B (B)
IPSS:
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Medical History II: CRF QMCR University of
Alberta
ODM derived from:
http://www.qmcr.ualberta.ca/en/ToolsandTemplates/CaseR
eportFormCRFTemplates.aspx. Template Name: Medical
History II. University of Alberta, Quality Management in
Clinical Research. Copyright: 2002-2016 University of
Alberta.
All rights reserved. Please visit https://medical-data-
models.org/forms/16981
Medical History II: CRF QMCR
University of Alberta
General Information
Study Name
Site Number
Pt_ID
Visit Date
Visit Type
Screening (1)
Baseline (2)
Medical History (See Description)
1. Head, Eye, Ear, Nose, Throat
Yes (1)
No (2)
Unknown (3)
If Yes, Explain
Current/Resolved
Current (1)
Resolved (2)
2. Respiratory
Yes (1)
No (2)
Unknown (3)
If Yes, Explain
Current/Resolved
Current (1)
Resolved (2)
3. Cardiovascular
Yes (1)
No (2)
Unknown (3)
If Yes, Explain
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Current/Resolved
Current (1)
Resolved (2)
4. Gastrointestinal
Yes (1)
No (2)
Unknown (3)
If Yes, Explain
Current/Resolved
Current (1)
Resolved (2)
5. Genitourinary
Yes (1)
No (2)
Unknown (3)
If Yes, Explain
Current/Resolved
Current (1)
Resolved (2)
6. Musculoskeletal
Yes (1)
No (2)
Unknown (3)
If Yes, Explain
Current/Resolved
Current (1)
Resolved (2)
7. Neurological
Yes (1)
No (2)
Unknown (3)
If Yes, Explain
Current/Resolved
Current (1)
Resolved (2)
8. Endocrine-Metabolic
Yes (1)
No (2)
Unknown (3)
If Yes, Explain
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Current/Resolved
Current (1)
Resolved (2)
9. Blood/Lymphatic
Yes (1)
No (2)
Unknown (3)
If Yes, Explain
Current/Resolved
Current (1)
Resolved (2)
10. Dermatologic
Yes (1)
No (2)
Unknown (3)
If Yes, Explain
Current/Resolved
Current (1)
Resolved (2)
11. Psychiatric
Yes (1)
No (2)
Unknown (3)
If Yes, Explain
Current/Resolved
Current (1)
Resolved (2)
12. Allergy
Yes (1)
No (2)
Unknown (3)
If Yes, Explain
Current/Resolved
Current (1)
Resolved (2)
13. Other (specify)
Yes (1)
No (2)
Unknown (3)
If Other, please specify
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If Yes, Explain
Current/Resolved
Current (1)
Resolved (2)
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Eligibility Dementia NCT00254033
Apathy Associated With Alzheimer's Disease; ODM derived
from: https://clinicaltrials.gov/show/NCT00254033
All rights reserved. Please visit https://medical-data-
models.org/forms/16982
Eligibility Dementia NCT00254033
Inclusion Criteria
age > 55 years*
Yes
No
meet dsm-iv criteria for primary degenerative
dementia*
Yes
No
meet nincds-arda criteria for probable alzheimer's
disease of at least one year's duration*
Yes
No
mild to moderate cognitive impairment (global
deterioration scale gds <6, mini-mental state
examination >10*
Yes
No
on a stable dose of a cholinesterase inhibitor for
at least 3 months*
Yes
No
apathetic group only: neuropsychiatric inventory
(npi) apathy subscale score >=2*
Yes
No
Exclusion Criteria
abnormal biochemical screening: blood cell
count, vitamin b12, thyroid function tests, and
syphilis screening tests*
Yes
No
significant medical illness or other
medical/neurological conditions which diminish
cognitive function*
Yes
No
evidence of seizure disorder*
Yes
No
an hachinski ischemic score >3 indicating
vascular dementia*
Yes
No
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a brain computed tomographic (ct) scan revealing
focal lesions, or inconsistent with ad*
Yes
No
electrocardiographic, laboratory or physical
evidence of significant cardiovascular disease*
Yes
No
presence of premorbid or current psychiatric
diagnosis including: major depression,
schizophrenia, psychotic symptoms of a severity
likely to provoke violent or dangerous behaviour
(i.e., command hallucinations to harm people or
persecutory delusions that provoke violent
reactions)*
Yes
No
current or past psychoactive substance abuse or
dependence (including alcohol, excluding
nicotine)*
Yes
No
contraindications to receiving dextroamphetamine
or methylphenidate*
Yes
No
have had administration of a depot neuroleptic
injection within one treatment cycle of the first
visit*
Yes
No
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Eligibility Current Major Depressive
Disorder NCT00071123
Evaluating Brain Responses to Facial Expressions in Major
Depressive Disorder; ODM derived from:
https://clinicaltrials.gov/show/NCT00071123
All rights reserved. Please visit https://medical-data-
models.org/forms/16983
Eligibility Current Major Depressive
Disorder NCT00071123
Criteria
healthy volunteers (n=65)*
Yes
No
healthy control sample (n = 30, phase 1; n = 15,
phase 3; n=20, phase 5):  right-handed subjects
(ages 18-55) will be selected who have not met
criteria for any major psychiatric disorder, have
no known first-degree relatives with mood
disorders, and have a current score on the
hamilton depression rating scale (hdrs; 17 item)
in the not depressed range (less than or equal to
7).  control subjects will be matched to depressed
subjects for age, gender, and education.*
Yes
No
mdd samples (n =80)*
Yes
No
mdd sample-currently depressed (n = 30, phase
1; n = 15, phase 3; n=20, phase 5): right-handed
subjects (ages 18-55) will be selected with
primary mdd currently depressed by dsm-iv
criteria for recurrent mdd and current hdrs score
in the moderately-to-severely depressed range
(greater than or equal to 18).*
Yes
No
mdd sample-remitted depressed (n = 15, phase
2):  right-handed subjects (ages 18-50) will be
selected with a past history of mdd by dsm-iv
criteria.*
Yes
No
healthy relatives of mdd subjects (n=45)*
Yes
No
right-handed subjects (ages 18-55) will be
selected who have a first-degree relative with
mdd but do not themselves meet criteria for a
psychiatric disorder. subjects will be matched to
depressed and control subjects for age, gender,
and education.*
Yes
No
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Exclusion Criteria
subjects will be recruited who are drug-na ve or
who have not received psychotropic drugs for at
least 3 weeks (8 weeks for fluoxetine) prior to
scanning.  effective medications will not be
discontinued for the purposes of the study.
subjects will also be excluded if they have a)
serious suicidal ideation or behavior, b) psychosis
to the extent that the ability to provide informed
consent is in doubt, c) medical conditions or
concomitant medications (see appendix iii) that
are likely to influence cerebral blood flow or
neurological function including cardiovascular,
respiratory, endocrine and neurological diseases,
d) a history of drug or alcohol abuse within 1 year
or a lifetime history of alcohol or drug
dependence (dsm-iv criteria), e) current
pregnancy (as documented by pregnancy testing
prior to scanning), f) general mri exclusion
criteria, g) history of non-response to zoloft or of
intolerable or adverse side effects during zoloft
treatment. additional exclusion criteria applied to
control subjects are:  a) subjects with a current or
past history of other axis i psychiatric conditions,
b) subjects with first-degree family members with
current or past history of mood disorder.*
Yes
No
subjects beyond age 55 are excluded to reduce
the biological heterogeneity encompassed by the
mdd criteria, and to reduce the variability of the
bold signal.  subjects whose first major
depressive episodes arose temporally after other
major medical or psychiatric conditions will also
be excluded, since their functional imaging
results generally differ from those reported in
primary mdd.*
Yes
No
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Eligibility Dementia NCT00255866
Improving Mood and Behavior in Assisted Living Residents
Through Skills Training for Their Caregivers; ODM derived
from: https://clinicaltrials.gov/show/NCT00255866
All rights reserved. Please visit https://medical-data-
models.org/forms/16984
Eligibility Dementia NCT00255866
Criteria
work in the assisted living residence for at least 6
months prior to study entry*
Yes
No
work in the assisted living residence at least 5
days a week, for at least 4 hours a day on day or
afternoon-evening shifts*
Yes
No
provide direct care for at least 1 assisted living
resident*
Yes
No
agree to attend all training sessions and complete
assessment forms*
Yes
No
able to speak, read, and understand english at a
6th grade level*
Yes
No
inclusion criteria for assisted living residents:*
Yes
No
diagnosis of dementia*
Yes
No
identified by caregiving staff as having mood or
behavioral problems*
Yes
No
have lived at the assisted living residence for at
least 3 months prior to study entry*
Yes
No
have a family member with power of attorney*
Yes
No
exclusion criteria for assisted living residents:*
Yes
No
plan to receive medication for affective or
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behavioral problems during the study*
Yes
No
history of alcohol or drug abuse*
Yes
No
have attempted suicide within 1 year prior to
study entry*
Yes
No
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Eligibility Depression NCT00057551
Research Evaluating the Value of Augmenting Medication
With Psychotherapy (REVAMP); ODM derived from:
https://clinicaltrials.gov/show/NCT00057551
All rights reserved. Please visit https://medical-data-
models.org/forms/16985
Eligibility Depression NCT00057551
Inclusion Criteria
major depressive episode*
Yes
No
depressive symptoms > 2 years without
remission*
Yes
No
ham-d score > 20*
Yes
No
fluent in english*
Yes
No
Exclusion Criteria
psychotic disorders, bipolar disorder, post
traumatic stress disorder, obsessive compulsive
disorder, or eating disorder*
Yes
No
serious, unstable, or terminal medical condition*
Yes
No
axis ii diagnosis of antisocical, schizotypal, or
severe borderline personality disorder*
Yes
No
previous treatment with cbasp*
Yes
No
previous ineffective treatment with 4 of the
medication treatments used in the study*
Yes
No
substance abuse*
Yes
No
pregnancy*
Yes
No
not willing to end other psychiatric treatment*
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Yes
No
2 / 2
Eligibility Depression NCT00057551
ICD-O-3
Example for ICD-O-3 in ODM. Source:
http://codes.iarc.fr/abouticdo.php 
The International Classification of Diseases for Oncology
(ICD-O)1 has been used for more than 35 years, principally
in tumour or cancer registries, for coding the site
(topography) and the histology (morphology) of the
neoplasm, usually obtained from a pathology report. 
Reference: International Classification of Diseases for
Oncology, first edition. Geneva, World Health Organization,
1976. 
All rights reserved. Please visit https://medical-data-
models.org/forms/16986
ICD-O-3
Topography
C00 LIP
Upper lip, NOS; skin of upper lip;
External upper lip; Vermilion border of
upper lip (C00.0)
External lower lip; Vermilion border of
lower lip; Lower lip, NOS; skin of lower lip
(C00.1)
External lip, NOS (C00.2)
Frenulum of upper lip; Mucosa of upper
lip (C00.3)
Mucosa of lower lip; Inner aspect of
lower lip; Frenulum of lower lip (C00.4)
Frenulum labii, NOS; Frenulum of lip,
NOS; Inner aspect of lip, NOS; Internal
lip, NOS; Mucosa of lip, NOS (C00.5)
Commissure of lip; Labial commissure
(C00.6)
Overlapping lesion of lip (C00.8)
Lip, NOS (C00.9)
C01 BASE OF TONGUE
Posterior third of tongue; Posterior
tongue, NOS; Dorsal surface of base of
tongue; Base of tongue, NOS; Root of
tongue (C01.9)
Morphology
Neoplasm NOS
Neoplasm, benign; Tumor, benign;
Unclassified tumor, benign (8000/0)
Neoplasm, uncertain whether benign or
malignant; Neoplasm, NOS; Tumor,
NOS; Unclassified tumor, uncertain
whether benign or malignant;
Unclassified tumor, borderline
malignancy (8000/1)
Neoplasm, malignant; Tumor, malignant,
NOS; Malignancy; Cancer; Unclassified
tumor, malignant; Blastoma,
NOS=Unclassified tumor, malignant;
Blastoma, NOS (8000/3)
Neoplasm, metastatic; Neoplasm,
secondary; Tumor, metastatic; Tumor,
secondary; Tumor embolus (8000/6)
Neoplasm, malignant, uncertain whether
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primary or metastatic; Unclassified
tumor, malignant, uncertain whether
primary or metastatic (8000/9)
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Eligibility Depression NCT00069927
Adderall XR Compared With Concerta in Treating Young
Cancer Patients With Memory, Attention, and Depression;
ODM derived from:
https://clinicaltrials.gov/show/NCT00069927
All rights reserved. Please visit https://medical-data-
models.org/forms/16987
Eligibility Depression NCT00069927
Inclusion Criteria
between the ages of 6-17 at the time of study
participation.*
Yes
No
have a diagnosis of any malignancy that required
cns treatment such as surgery and/or irradiation
and/or intrathecal chemotherapy.  (patients
treated with systemic chemotherapy alone are
not eligible to participate)*
Yes
No
off treatment and cancer free for a minimum of 6
months.*
Yes
No
have a proficiency in english.*
Yes
No
Exclusion Criteria
patients with an estimated intelligence quotient
(iq) of less than 65 (based on the wide range
achievement test (wrat-3) reading subtest) are
not eligible to continue on study.*
Yes
No
at least one standard deviation below the level of
performance predicted by their iq on at least 2 of
the 3 wisc-iii subtests.*
Yes
No
diagnosed with attention deficit disorder (add) or
attention deficit hyperactivity disorder (adhd) prior
to their cancer diagnosis.*
Yes
No
currently taking antidepressants, antipsychotics,
or other stimulants.*
Yes
No
are blind.*
Yes
No
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have glaucoma.*
Yes
No
family history of motor and phonic tics or
tourette's syndrome.*
Yes
No
have seizures not controlled by antiepileptic
drugs.  (note: patients who are not experiencing
seizure activity, having been on a stable dose of
an antiepileptic drug for at least 12 weeks may
participate)*
Yes
No
taking a monoamine oxidase (mao) inhibitor.*
Yes
No
have a history of cardiovascular disease,
uncontrolled hypertension or hyperthyroidism.*
Yes
No
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Government health expenditure NMDS
2014- Metadata Online Registry (METeOR)
Health sector data set specifications from METeOR,
Australia's repository for national metadata standards,
developed by the Australian Institute of Health and Welfare
(http://meteor.aihw.gov.au/content/index.phtml/itemId/3451
65)
Government health expenditure NMDS 2014-
The scope of the Government health expenditure national
minimum data set (GHE NMDS) is direct government and
government-funded expenditure on health and health-
related goods and services.
The purpose of the GHE NMDS is to provide an enhanced
understanding of the overall financial resources (recurrent
and capital) used by the health system, and of unit costs
and performance; to enable greater comparability of health
expenditure data between jurisdictions and over time; and
to provide a more efficient compilation of national reports
and analyses on government funded health expenditure.
Metadata and Classifications Unit 
Australian Institute of Health and Welfare
GPO Box 570
Canberra ACT 2601
All rights reserved. Please visit https://medical-data-
models.org/forms/16988
Government health expenditure
NMDS 2014- Metadata Online
Registry (METeOR)
Government health expenditure
organisation revenue data element cluster
Health industry relevant organisation type*
Hospital – public (101)
Hospital – private (excluding private free-
standing day hospital facility) (102)
Hospital – private free-standing day
hospital facility (excluding private non
free-standing day hospital facility) (103)
Residential facility – mental health care
(104)
Residential facility – other  (105)
Provider of ambulance service (106)
Medical and diagnostic laboratory (107)
Clinical practices – medical – general
(108)
Clinical practices – medical – specialist
(109)
Clinical practices – medical – other (110)
Clinical practices – dental  (111)
Clinical practices – other (112)
Community health facility – substance
abuse  (113)
Community health facility – mental
(114)
Community health facility – other  (115)
Blood and organ bank (116)
Retail sale/supplier of medical goods –
optical glasses and other vision products
(117)
Retail sale/supplier of medical goods –
hearing aids (118)
Retail sale/supplier of medical goods –
dispensing community pharmacist (119)
Retail sale/supplier of medical goods –
other  (120)
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Public health program service provider
(121)
General health administration service
provider (122)
Private health insurance (123)
Other Main Health Care Service
providers (188)
Regional health service not further
defined (198)
State/territory health authority not further
defined (199)
Pharmaceutical industry (201)
University (202)
Non-health related insurance (203)
Residential aged care facility (204)
Other Secondary/non-Health Care
Services organisation (288)
Source of public and private revenue*
Australian Health Care Agreements
(101)
Other Special Purpose Payments (102)
Medicare (103)
Pharmaceutical Benefits Scheme and
Repatriation Pharmaceutical Benefits
Scheme  (104)
National Health and Medical Research
Council (105)
Department of Veterans' Affairs  (106)
Other Australian government
departments (107)
State/Territory non-health departments
(108)
Other public sector revenue (188)
Private health insurance (201)
Workers compensation insurance (202)
Motor vehicle third party insurance (203)
Other compensation (e.g. Public liability,
common law, medical negligence) (204)
Private households (self-funded and out-
of-pocket expenditure) (205)
Non-profit institutions serving
households (206)
Corporations (other than health
insurance) (207)
Other private sector revenue (288)
Overseas (301)
Not further defined (999)
Organisation revenues
AU$
Government health expenditure
organisation expenditure data element
cluster
Health industry relevant organisation type*
Hospital – public (101)
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(METeOR)
Hospital – private (excluding private free-
standing day hospital facility) (102)
Hospital – private free-standing day
hospital facility (excluding private non
free-standing day hospital facility) (103)
Residential facility – mental health care
(104)
Residential facility – other  (105)
Provider of ambulance service (106)
Medical and diagnostic laboratory (107)
Clinical practices – medical – general
(108)
Clinical practices – medical – specialist
(109)
Clinical practices – medical – other (110)
Clinical practices – dental  (111)
Clinical practices – other (112)
Community health facility – substance
abuse  (113)
Community health facility – mental
(114)
Community health facility – other  (115)
Blood and organ bank (116)
Retail sale/supplier of medical goods –
optical glasses and other vision products
(117)
Retail sale/supplier of medical goods –
hearing aids (118)
Retail sale/supplier of medical goods –
dispensing community pharmacist (119)
Retail sale/supplier of medical goods –
other  (120)
Public health program service provider
(121)
General health administration service
provider (122)
Private health insurance (123)
Other Main Health Care Service
providers (188)
Regional health service not further
defined (198)
State/territory health authority not further
defined (199)
Pharmaceutical industry (201)
University (202)
Non-health related insurance (203)
Residential aged care facility (204)
Other Secondary/non-Health Care
Services organisation (288)
Capital consumption expenses*
AU$
Employee expenses*
AU$
Organisation expenses, total Australian currency*
AU$
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(METeOR)
Purchase of goods and services*
AU$
Type of health or health-related function*
Admitted patient care – Mental health
program  (101)
Admitted patient care – Non-mental
health program  (102)
Admitted patient care – Not further
defined (199)
Residential care – Mental health
program  (201)
Residential care – Non-mental health
program  (202)
Residential care – Not further defined
(299)
Ambulatory care – Mental health
program (301)
Ambulatory care – Emergency
department  (302)
Ambulatory care – General practitioner
(303)
Ambulatory care – Medical specialist
(304)
Ambulatory care – Imaging/pathology
(305)
Ambulatory care – Dental service (306)
Ambulatory care – Optometry service
(307)
Ambulatory care – Allied health service
(308)
Ambulatory care – Community health
service  (309)
Ambulatory care – Other  (388)
Ambulatory care – Not further defined
(399)
Public health – Communicable disease
control (401)
Public health – Selected health
promotion (402)
Public health – Organised immunisation
(403)
Public health – Environmental health
(404)
Public health – Food standards and
hygiene (405)
Public health – Breast cancer screening
(406)
Public health – Cervical screening (407)
Public health – Bowel cancer screening
(408)
Public health – Prevention of hazardous
and harmful drug use (409)
Public health – Public health research
(410)
Public health – Other public health (488)
Public health – Not further defined (499)
Health-related care – Patient transport
(501)
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(METeOR)
Health-related care – Patient transport
subsidies (502)
Health-related care – Medications (503)
Health-related care – Aids and
appliances (504)
Health-related care – Health
administration (505)
Health-related care – Health research
(506)
Health-related care – Other (588)
Health-related care – Not further defined
(599)
Other function – Home and community
care (601)
Other function – Aged care  (602)
Other function – Other welfare (603)
Other function – Other (688)
Other function – Not further defined
(699)
Government health expenditure
organisation expenditure purchase of
goods and services data element cluster
Health industry relevant organisation type
Hospital – public (101)
Hospital – private (excluding private free-
standing day hospital facility) (102)
Hospital – private free-standing day
hospital facility (excluding private non
free-standing day hospital facility) (103)
Residential facility – mental health care
(104)
Residential facility – other  (105)
Provider of ambulance service (106)
Medical and diagnostic laboratory (107)
Clinical practices – medical – general
(108)
Clinical practices – medical – specialist
(109)
Clinical practices – medical – other (110)
Clinical practices – dental  (111)
Clinical practices – other (112)
Community health facility – substance
abuse  (113)
Community health facility – mental
(114)
Community health facility – other  (115)
Blood and organ bank (116)
Retail sale/supplier of medical goods –
optical glasses and other vision products
(117)
Retail sale/supplier of medical goods –
hearing aids (118)
Retail sale/supplier of medical goods –
dispensing community pharmacist (119)
Retail sale/supplier of medical goods –
other  (120)
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(METeOR)
Public health program service provider
(121)
General health administration service
provider (122)
Private health insurance (123)
Other Main Health Care Service
providers (188)
Regional health service not further
defined (198)
State/territory health authority not further
defined (199)
Pharmaceutical industry (201)
University (202)
Non-health related insurance (203)
Residential aged care facility (204)
Other Secondary/non-Health Care
Services organisation (288)
Purchase of goods and services*
AU$
Type of health or health-related function
Admitted patient care – Mental health
program  (101)
Admitted patient care – Non-mental
health program  (102)
Admitted patient care – Not further
defined (199)
Residential care – Mental health
program  (201)
Residential care – Non-mental health
program  (202)
Residential care – Not further defined
(299)
Ambulatory care – Mental health
program (301)
Ambulatory care – Emergency
department  (302)
Ambulatory care – General practitioner
(303)
Ambulatory care – Medical specialist
(304)
Ambulatory care – Imaging/pathology
(305)
Ambulatory care – Dental service (306)
Ambulatory care – Optometry service
(307)
Ambulatory care – Allied health service
(308)
Ambulatory care – Community health
service  (309)
Ambulatory care – Other  (388)
Ambulatory care – Not further defined
(399)
Public health – Communicable disease
control (401)
Public health – Selected health
promotion (402)
Public health – Organised immunisation
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(METeOR)
(403)
Public health – Environmental health
(404)
Public health – Food standards and
hygiene (405)
Public health – Breast cancer screening
(406)
Public health – Cervical screening (407)
Public health – Bowel cancer screening
(408)
Public health – Prevention of hazardous
and harmful drug use (409)
Public health – Public health research
(410)
Public health – Other public health (488)
Public health – Not further defined (499)
Health-related care – Patient transport
(501)
Health-related care – Patient transport
subsidies (502)
Health-related care – Medications (503)
Health-related care – Aids and
appliances (504)
Health-related care – Health
administration (505)
Health-related care – Health research
(506)
Health-related care – Other (588)
Health-related care – Not further defined
(599)
Other function – Home and community
care (601)
Other function – Aged care  (602)
Other function – Other welfare (603)
Other function – Other (688)
Other function – Not further defined
(699)
Government health expenditure
organisation expenditure employee related
data element cluster
Health industry relevant organisation type
Hospital – public (101)
Hospital – private (excluding private free-
standing day hospital facility) (102)
Hospital – private free-standing day
hospital facility (excluding private non
free-standing day hospital facility) (103)
Residential facility – mental health care
(104)
Residential facility – other  (105)
Provider of ambulance service (106)
Medical and diagnostic laboratory (107)
Clinical practices – medical – general
(108)
Clinical practices – medical – specialist
(109)
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(METeOR)
Clinical practices – medical – other (110)
Clinical practices – dental  (111)
Clinical practices – other (112)
Community health facility – substance
abuse  (113)
Community health facility – mental
(114)
Community health facility – other  (115)
Blood and organ bank (116)
Retail sale/supplier of medical goods –
optical glasses and other vision products
(117)
Retail sale/supplier of medical goods –
hearing aids (118)
Retail sale/supplier of medical goods –
dispensing community pharmacist (119)
Retail sale/supplier of medical goods –
other  (120)
Public health program service provider
(121)
General health administration service
provider (122)
Private health insurance (123)
Other Main Health Care Service
providers (188)
Regional health service not further
defined (198)
State/territory health authority not further
defined (199)
Pharmaceutical industry (201)
University (202)
Non-health related insurance (203)
Residential aged care facility (204)
Other Secondary/non-Health Care
Services organisation (288)
Employee expenses*
AU$
Type of health or health-related function
Admitted patient care – Mental health
program  (101)
Admitted patient care – Non-mental
health program  (102)
Admitted patient care – Not further
defined (199)
Residential care – Mental health
program  (201)
Residential care – Non-mental health
program  (202)
Residential care – Not further defined
(299)
Ambulatory care – Mental health
program (301)
Ambulatory care – Emergency
department  (302)
Ambulatory care – General practitioner
(303)
Ambulatory care – Medical specialist
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(METeOR)
(304)
Ambulatory care – Imaging/pathology
(305)
Ambulatory care – Dental service (306)
Ambulatory care – Optometry service
(307)
Ambulatory care – Allied health service
(308)
Ambulatory care – Community health
service  (309)
Ambulatory care – Other  (388)
Ambulatory care – Not further defined
(399)
Public health – Communicable disease
control (401)
Public health – Selected health
promotion (402)
Public health – Organised immunisation
(403)
Public health – Environmental health
(404)
Public health – Food standards and
hygiene (405)
Public health – Breast cancer screening
(406)
Public health – Cervical screening (407)
Public health – Bowel cancer screening
(408)
Public health – Prevention of hazardous
and harmful drug use (409)
Public health – Public health research
(410)
Public health – Other public health (488)
Public health – Not further defined (499)
Health-related care – Patient transport
(501)
Health-related care – Patient transport
subsidies (502)
Health-related care – Medications (503)
Health-related care – Aids and
appliances (504)
Health-related care – Health
administration (505)
Health-related care – Health research
(506)
Health-related care – Other (588)
Health-related care – Not further defined
(599)
Other function – Home and community
care (601)
Other function – Aged care  (602)
Other function – Other welfare (603)
Other function – Other (688)
Other function – Not further defined
(699)
Government health expenditure
organisation expenditure capital
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(METeOR)
consumption data element cluster
Health industry relevant organisation type
Hospital – public (101)
Hospital – private (excluding private free-
standing day hospital facility) (102)
Hospital – private free-standing day
hospital facility (excluding private non
free-standing day hospital facility) (103)
Residential facility – mental health care
(104)
Residential facility – other  (105)
Provider of ambulance service (106)
Medical and diagnostic laboratory (107)
Clinical practices – medical – general
(108)
Clinical practices – medical – specialist
(109)
Clinical practices – medical – other (110)
Clinical practices – dental  (111)
Clinical practices – other (112)
Community health facility – substance
abuse  (113)
Community health facility – mental
(114)
Community health facility – other  (115)
Blood and organ bank (116)
Retail sale/supplier of medical goods –
optical glasses and other vision products
(117)
Retail sale/supplier of medical goods –
hearing aids (118)
Retail sale/supplier of medical goods –
dispensing community pharmacist (119)
Retail sale/supplier of medical goods –
other  (120)
Public health program service provider
(121)
General health administration service
provider (122)
Private health insurance (123)
Other Main Health Care Service
providers (188)
Regional health service not further
defined (198)
State/territory health authority not further
defined (199)
Pharmaceutical industry (201)
University (202)
Non-health related insurance (203)
Residential aged care facility (204)
Other Secondary/non-Health Care
Services organisation (288)
Capital consumption expenses
AU$
Type of health or health-related function
10 / 14
Government health expenditure NMDS 2014- Metadata Online Registry
(METeOR)
Admitted patient care – Mental health
program  (101)
Admitted patient care – Non-mental
health program  (102)
Admitted patient care – Not further
defined (199)
Residential care – Mental health
program  (201)
Residential care – Non-mental health
program  (202)
Residential care – Not further defined
(299)
Ambulatory care – Mental health
program (301)
Ambulatory care – Emergency
department  (302)
Ambulatory care – General practitioner
(303)
Ambulatory care – Medical specialist
(304)
Ambulatory care – Imaging/pathology
(305)
Ambulatory care – Dental service (306)
Ambulatory care – Optometry service
(307)
Ambulatory care – Allied health service
(308)
Ambulatory care – Community health
service  (309)
Ambulatory care – Other  (388)
Ambulatory care – Not further defined
(399)
Public health – Communicable disease
control (401)
Public health – Selected health
promotion (402)
Public health – Organised immunisation
(403)
Public health – Environmental health
(404)
Public health – Food standards and
hygiene (405)
Public health – Breast cancer screening
(406)
Public health – Cervical screening (407)
Public health – Bowel cancer screening
(408)
Public health – Prevention of hazardous
and harmful drug use (409)
Public health – Public health research
(410)
Public health – Other public health (488)
Public health – Not further defined (499)
Health-related care – Patient transport
(501)
Health-related care – Patient transport
subsidies (502)
Health-related care – Medications (503)
Health-related care – Aids and
appliances (504)
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Health-related care – Health
administration (505)
Health-related care – Health research
(506)
Health-related care – Other (588)
Health-related care – Not further defined
(599)
Other function – Home and community
care (601)
Other function – Aged care  (602)
Other function – Other welfare (603)
Other function – Other (688)
Other function – Not further defined
(699)
Government health expenditure function
revenue data element cluster
Source of public and private revenue*
Australian Health Care Agreements
(101)
Other Special Purpose Payments (102)
Medicare (103)
Pharmaceutical Benefits Scheme and
Repatriation Pharmaceutical Benefits
Scheme  (104)
National Health and Medical Research
Council (105)
Department of Veterans' Affairs  (106)
Other Australian government
departments (107)
State/Territory non-health departments
(108)
Other public sector revenue (188)
Private health insurance (201)
Workers compensation insurance (202)
Motor vehicle third party insurance (203)
Other compensation (e.g. Public liability,
common law, medical negligence) (204)
Private households (self-funded and out-
of-pocket expenditure) (205)
Non-profit institutions serving
households (206)
Corporations (other than health
insurance) (207)
Other private sector revenue (288)
Overseas (301)
Not further defined (999)
Organisation revenues*
AU$
Type of health or health-related function*
Admitted patient care – Mental health
program  (101)
Admitted patient care – Non-mental
health program  (102)
Admitted patient care – Not further
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defined (199)
Residential care – Mental health
program  (201)
Residential care – Non-mental health
program  (202)
Residential care – Not further defined
(299)
Ambulatory care – Mental health
program (301)
Ambulatory care – Emergency
department  (302)
Ambulatory care – General practitioner
(303)
Ambulatory care – Medical specialist
(304)
Ambulatory care – Imaging/pathology
(305)
Ambulatory care – Dental service (306)
Ambulatory care – Optometry service
(307)
Ambulatory care – Allied health service
(308)
Ambulatory care – Community health
service  (309)
Ambulatory care – Other  (388)
Ambulatory care – Not further defined
(399)
Public health – Communicable disease
control (401)
Public health – Selected health
promotion (402)
Public health – Organised immunisation
(403)
Public health – Environmental health
(404)
Public health – Food standards and
hygiene (405)
Public health – Breast cancer screening
(406)
Public health – Cervical screening (407)
Public health – Bowel cancer screening
(408)
Public health – Prevention of hazardous
and harmful drug use (409)
Public health – Public health research
(410)
Public health – Other public health (488)
Public health – Not further defined (499)
Health-related care – Patient transport
(501)
Health-related care – Patient transport
subsidies (502)
Health-related care – Medications (503)
Health-related care – Aids and
appliances (504)
Health-related care – Health
administration (505)
Health-related care – Health research
(506)
Health-related care – Other (588)
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Health-related care – Not further defined
(599)
Other function – Home and community
care (601)
Other function – Aged care  (602)
Other function – Other welfare (603)
Other function – Other (688)
Other function – Not further defined
(699)
Jurisdiction
Australian State/Territory identifier (jurisdiction)*
New South Wales (1)
Victoria (2)
Queensland (3)
South Australia (4)
Western Australia (5)
Tasmania (6)
Northern Territory (7)
Australian Capital Territory (8)
Other territories (Cocos (Keeling)
Islands, Christmas Island and Jervis Bay
Territory) (9)
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Hospital teaching and training activities DSS
2014-15 Metadata Online Registry (METeOR)
Health sector data set specifications from METeOR,
Australia's repository for national metadata standards,
developed by the Australian Institute of Health and Welfare
(http://meteor.aihw.gov.au/content/index.phtml/itemId/3451
65)
Hospital teaching and training activities DSS 2014-15
The purpose of the Hospital teaching and training activities
DSS is to collect information about teaching and training
activities, funded by the states and territories, that are
associated with Australian public hospitals.
It is intended that the DSS will capture those activities that
are unique to hospital delivery and thus activities that set
hospitals apart in terms of cost.
The scope of the DSS is establishment level data on
teaching and training activities which occur in activity based
funded hospitals.
It is anticipated that additional data elements pertaining to
research data will be added to the DSS in future years.
Research data will not be collected in the first year of the
DSS's implementation as a data standard. 
Metadata and Classifications Unit 
Australian Institute of Health and Welfare
GPO Box 570
Canberra ACT 2601
All rights reserved. Please visit https://medical-data-
models.org/forms/16989
Hospital teaching and training
activities DSS 2014-15 Metadata
Online Registry (METeOR)
Establishment
Establishment identifier*
Professional entry health professional
student cluster
Clinical placement hours (students)*
hours
Intended profession (professional entry health
professional student)*
Aboriginal and Torres Strait Islander
health worker (1.0)
Nursing (10.0)
Nursing - enrolled nurse (10.1)
Nursing - registered nurse (10.2)
Nursing - nurse practitioner (10.3)
Nursing - other nursing profession (10.8)
Occupational therapy (11.0)
Optometry (12.0)
Oral health (13.0)
Orthoptics (14.0)
Orthotics and prosthetics (15.0)
Osteopathy (16.0)
Paramedicine (17.0)
Pharmacy (18.0)
Physiotherapy (19.0)
Audiology (2.0)
Podiatry (20.0)
Psychology (21.0)
Radiation science (22.0)
Social work (23.0)
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Sonography (24.0)
Speech pathology (25.0)
Chiropractic (3.0)
Dentistry (4.0)
Dietetics (5.0)
Exercise physiology (6.0)
Medical laboratory science (7.0)
Medicine (8.0)
Medicine - prevocational postgraduate
year 1 (8.1)
Medicine - prevocational postgraduate
year 2 (8.2)
Medicine - prevocational postgraduate
year 3+ (8.3)
Midwifery (9.0)
Not stated/inadequately described (99.9)
New health professional graduate cluster
Number of new health professional graduates
(FTE)*
Qualified profession (new health professional
graduate)*
Aboriginal and Torres Strait Islander
health worker (1.0)
Nursing (10.0)
Nursing - enrolled nurse (10.1)
Nursing - registered nurse (10.2)
Nursing - nurse practitioner (10.3)
Nursing - other nursing profession (10.8)
Occupational therapy (11.0)
Optometry (12.0)
Oral health (13.0)
Orthoptics (14.0)
Orthotics and prosthetics (15.0)
Osteopathy (16.0)
Paramedicine (17.0)
Pharmacy (18.0)
Physiotherapy (19.0)
Audiology (2.0)
Podiatry (20.0)
Psychology (21.0)
Radiation science (22.0)
Social work (23.0)
Sonography (24.0)
Speech pathology (25.0)
Chiropractic (3.0)
Dentistry (4.0)
Dietetics (5.0)
Exercise physiology (6.0)
Medical laboratory science (7.0)
Medicine (8.0)
Medicine - prevocational postgraduate
year 1 (8.1)
Medicine - prevocational postgraduate
year 2 (8.2)
Medicine - prevocational postgraduate
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year 3+ (8.3)
Midwifery (9.0)
Not stated/inadequately described (99.9)
Health professional graduate trainee
cluster
Number of health professional graduate trainees
(FTE)*
Qualified profession (health professional graduate
trainee)*
Aboriginal and Torres Strait Islander
health worker (1.0)
Nursing (10.0)
Nursing - enrolled nurse (10.1)
Nursing - registered nurse (10.2)
Nursing - nurse practitioner (10.3)
Nursing - other nursing profession (10.8)
Occupational therapy (11.0)
Optometry (12.0)
Oral health (13.0)
Orthoptics (14.0)
Orthotics and prosthetics (15.0)
Osteopathy (16.0)
Paramedicine (17.0)
Pharmacy (18.0)
Physiotherapy (19.0)
Audiology (2.0)
Podiatry (20.0)
Psychology (21.0)
Radiation science (22.0)
Social work (23.0)
Sonography (24.0)
Speech pathology (25.0)
Chiropractic (3.0)
Dentistry (4.0)
Dietetics (5.0)
Exercise physiology (6.0)
Medical laboratory science (7.0)
Medicine (8.0)
Medicine - prevocational postgraduate
year 1 (8.1)
Medicine - prevocational postgraduate
year 2 (8.2)
Medicine - prevocational postgraduate
year 3+ (8.3)
Midwifery (9.0)
Not stated/inadequately described (99.9)
Medical speciality of medical graduate trainees*
Addiction medicine (1.0)
Ophthalmology (10.0)
Paediatrics and child health (11.0)
Pain medicine (12.0)
Palliative medicine (13.0)
Pathology (14.0)
Physician (15.0)
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Physician - cardiology (15.1)
Physician - endocrinology (15.2)
Physician - gastroenterology and
hepatology (15.3)
Physician - general medicine (15.4)
Physician - geriatric medicine (15.5)
Physician - medical oncology (15.6)
Physician - nephrology (15.7)
Physician - neurology (15.8)
Physician - other physician type (15.88)
Psychiatry (16.0)
Public health medicine (17.0)
Radiation oncology (18.0)
Radiology (19.0)
Anaesthesia (2.0)
Rehabilitation medicine (20.0)
Sexual health medicine (21.0)
Sport and exercise medicine (22.0)
Surgery (23.0)
Surgery - general  (23.1)
Surgery - orthopaedic (23.2)
Surgery - otolaryngology (23.3)
Surgery - plastic (23.4)
Surgery - other surgery type (23.88)
Dermatology (3.0)
Emergency medicine (4.0)
General practice (5.0)
Intensive care medicine (6.0)
Medical administration (7.0)
Obstetrics and gynaecology (8.0)
Medical profession certificate or diploma
(80.0)
Occupational and environmental
medicine (9.0)
Not stated/inadequately described (99.9)
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Eligibility Depression NCT00071110
Electroacupuncture for Major Depression; ODM derived
from: https://clinicaltrials.gov/show/NCT00071110
All rights reserved. Please visit https://medical-data-
models.org/forms/16990
Eligibility Depression NCT00071110
Inclusion Criteria
meet scid criteria for a major depressive disorder
(single or recurrent) with a current major
depressive episode of mild or moderate severity*
Yes
No
significant symptoms of depression (hrsd > 14)*
Yes
No
ability to communicate in english*
Yes
No
give informed consent in accordance with local
irb regulations*
Yes
No
Exclusion Criteria
personal physician's recommendation against
enrollment because the patient is physically
unstable or for other reasons*
Yes
No
having been treated with acupuncture for any
condition*
Yes
No
history of seizure disorder or significant risk
factors for a seizure disorder (e.g., history of
brain trauma, recent stroke, or brain tumor)*
Yes
No
need to remain on antidepressant or other
psychotropic medications*
Yes
No
absence of depressive symptoms severe enough
(i.e., hrsd < 14) at the baseline assessments*
Yes
No
significant cognitive impairment, as assessed by
a total score on the mmse < 25. a
recommendation for referral to a neurologist or a
psychiatrist will be made to the patient in these
cases.*
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Yes
No
chronic major depression (i.e, duration of 2 years
or longer) a recommendation for referral to a
psychiatrist will be made in these cases.*
Yes
No
major depressive episode severe or severe with
psychotic features (as per dsm-iv/scid) or with
acutely suicidality. a recommendation for
psychiatric referral will be made in these cases.
bipolar disorder, psychotic features, or a
psychotic disorder (specifically: schizophrenia,
delusional disorder, or schizoaffective disorder). a
recommendation for psychiatric referral will be
made in these cases.*
Yes
No
met criteria for a diagnosis of alcohol substance
abuse or dependence within the past six months.
a recommendation for referral to a mental health
professional will be made in these cases.*
Yes
No
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Eligibility Depression NCT00073411
Duloxetine Compared to Escitalopram and Placebo in the
Treatment of Patients With Depression; ODM derived from:
https://clinicaltrials.gov/show/NCT00073411
All rights reserved. Please visit https://medical-data-
models.org/forms/16991
Eligibility Depression NCT00073411
Inclusion Criteria
must be at least 18 of age*
Yes
No
must meet the criteria for major depressive
disorder*
Yes
No
you must be able to visit the doctor's office about
once a week for 2 to 3 months. after that, you will
need to visit the doctor's office once a month for
about 6 months*
Yes
No
you must be able to take the study drug as
prescribed (6 capsules per day taken once-daily)*
Yes
No
Exclusion Criteria
you are a woman and are pregnant or
breastfeeding.*
Yes
No
you have a current or previous major psychiatric
disorder other than depression, such as bipolar
disorder, schizophrenia, or other psychotic
disorder.*
Yes
No
you have a history of alcohol or drug dependence
within the past 6 months*
Yes
No
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Eligibility Colorectal Cancer NCT00271011
A Study of Mitomycin C, Irinotecan, and Cetuximab; ODM
derived from: https://clinicaltrials.gov/show/NCT00271011
All rights reserved. Please visit https://medical-data-
models.org/forms/16992
Eligibility Colorectal Cancer
NCT00271011
Inclusion Criteria
1. pathologic diagnosis of colorectal cancer.*
Yes
No
2. clinical and/or radiologic evidence of metastatic
disease.*
Yes
No
3. one previous systemic treatment for metastatic
disease.*
Yes
No
4. age > 18.*
Yes
No
5. presence of at least one measurable lesion.*
Yes
No
6. adequate hematopoetic (absolute neutrophil
count > 1500/mm3, platelet  count >
100,000/mm3), renal (serum creatinine < 1.5
mg/dl), and hepatic function (bilirubin < 1.5 and
transaminases < 5.0 x upper normal limit).*
Yes
No
7. ecog performance status 0-2.*
Yes
No
8. life expectancy > 3 months.*
Yes
No
9. patients must be informed of the investigational
nature of this study and provide written informed
consent in accordance with the institutional and
federal guidelines prior to the initiation of
therapy.*
Yes
No
Exclusion Criteria
1. no recognized brain metastasis.*
Yes
No
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2. no previous treatment with mitomycin c or
cetuximab.*
Yes
No
3. no other systemic malignancy requiring
treatment within the past one year.*
Yes
No
4. pregnant or lactating women may not
participate.  women/men of reproductive potential
must agree to use an effective contraceptive
method.*
Yes
No
5. patients must have no other serious medical or
psychiatric illness that would limit the ability of the
patient to receive protocol therapy or provide
informed consent.*
Yes
No
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Eligibility Colorectal Cancer NCT00625625
Lymphatic Mapping, Sentinel Lymph Node Analysis, and
Blood Tests in Detecting and Predicting Early
Micrometastases in Patients With Colorectal Cancer; ODM
derived from: https://clinicaltrials.gov/show/NCT00625625
All rights reserved. Please visit https://medical-data-
models.org/forms/16993
Eligibility Colorectal Cancer
NCT00625625
Criteria
diagnosis of colorectal cancer as detected by
proctosigmoidoscopy, flexible endoscopy, or
gastrografin/barium enema*
Yes
No
no evidence of distant metastases by ct scan of
the abdomen and pelvis and chest x-ray or ct
scan of the chest performed within 6 weeks prior
to enrollment*
Yes
No
preoperative ct scans and testing showing non-
specific or non-diagnostic (equivocal)
abnormalities may be eligible pending
intraoperative exploration*
Yes
No
no discovery of distant metastases intra-
operatively*
Yes
No
patient characteristics:*
Yes
No
ecog performance status (ps) or zubrod ps equal
to 2*
Yes
No
life expectancy > 5 years not including the
disease/diagnosis of colorectal cancer*
Yes
No
not pregnant or nursing*
Yes
No
negative pregnancy test*
Yes
No
fertile patients must use effective contraception*
Yes
No
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no requirement for emergent surgery (within 2
hours of presentation) to prevent a life-
threatening situation or death including:*
Yes
No
perforated colon*
Yes
No
metabolically significant complete bowel
obstruction*
Yes
No
massive gi bleeding*
Yes
No
occult bleeding or early or partial bowel
obstruction not requiring emergent surgery
allowed*
Yes
No
no history of crohn disease, chronic ulcerative
colitis, or familial polyposis*
Yes
No
no other malignancy within the past 3 years
except for completely resected cervical cancer,
skin cancer, or in situ cancer*
Yes
No
prior concurrent therapy:*
Yes
No
see disease characteristics*
Yes
No
see patient characteristics*
Yes
No
no concurrent participation in another research
protocol*
Yes
No
participation during follow up allowed*
Yes
No
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Eligibility Depression NCT00073697
Treatment of Depression in Adults; ODM derived from:
https://clinicaltrials.gov/show/NCT00073697
All rights reserved. Please visit https://medical-data-
models.org/forms/16994
Eligibility Depression NCT00073697
Inclusion Criteria
diagnosis of major depression*
Yes
No
Exclusion Criteria
history of manic or hypomanic episodes*
Yes
No
history of schizophrenia or schizoaffective
disorder*
Yes
No
diagnosis of anorexia nervosa or bulimia
nervosa*
Yes
No
current psychosis*
Yes
No
drug and/or alcohol dependence or abuse within
3 months prior to study entry. participants with
episodic abuse related to mood disorders will not
be excluded.*
Yes
No
diagnosis of antisocial personality disorder*
Yes
No
diagnosis of organic affective syndrome and
uncontrolled medical illness*
Yes
No
pregnancy*
Yes
No
require inpatient treatment for suicidal risk or
psychosis*
Yes
No
history of an inability to tolerate any of the study
treatments*
Yes
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No
currently receiving treatment with an effective
antidepressant*
Yes
No
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Eligibility Depression NCT00076258
Adding Exercise to Antidepressant Medication Treatment
for Depression; ODM derived from:
https://clinicaltrials.gov/show/NCT00076258
All rights reserved. Please visit https://medical-data-
models.org/forms/16995
Eligibility Depression NCT00076258
Inclusion Criteria
diagnosis of major depressive disorder*
Yes
No
score of 14 or higher on the hamilton depression
scale (ham-d)*
Yes
No
8 to 12 weeks of ssri treatment, with at least 6
weeks at adequate doses*
Yes
No
sedentary lifestyle*
Yes
No
physically capable of exercise*
Yes
No
body mass index (bmi) less than 40 kg/m2*
Yes
No
willing and able to comply with study
requirements*
Yes
No
Exclusion Criteria
significant cardiovascular disease or other
medical conditions*
Yes
No
uncontrolled hypertension*
Yes
No
abnormal exercise stress test*
Yes
No
hematologic disorders*
Yes
No
comorbid disorders, including depression due to
another comorbid condition, psychotic disorder,
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bipolar disorder, schizophrenia, schizoaffective
disorder, eating disorder, or obsessive
compulsive disorder (ocd)*
Yes
No
alcohol and/or substance abuse in the past 6
months*
Yes
No
hospitalization for mental illness within the past
year*
Yes
No
high suicide risk*
Yes
No
use of psychopharmacological or
psychotherapeutic treatment other than ssris*
Yes
No
failure to respond to two or more adequate
pharmacological treatments during the current
depressive episode*
Yes
No
significantly elevated blood lipids*
Yes
No
pregnancy*
Yes
No
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Protocol Deviations Log: CRF QMCR
University of Alberta
ODM derived from:
http://www.qmcr.ualberta.ca/en/ToolsandTemplates/CaseR
eportFormCRFTemplates.aspx. Template Name: Protocol
Deviations Log. University of Alberta, Quality Management
in Clinical Research. Copyright: 2002-2016 University of
Alberta.
All rights reserved. Please visit https://medical-data-
models.org/forms/16996
Protocol Deviations Log: CRF QMCR
University of Alberta
General Information
Study Name
Site Number
Pt_ID
Visit Date
Did this participant have any protocol deviations?
Yes
No
Protocol Deviations
Description of Protocol Deviation
Deviation Category (See Description)
Deviation Code
Date Deviation Occurred
Date IRB Notified (if applicable)
Principal Investigator´s Signature
Date Signed
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Randomization and Enrollment: CRF
QMCR University of Alberta
ODM derived from:
http://www.qmcr.ualberta.ca/en/ToolsandTemplates/CaseR
eportFormCRFTemplates.aspx. Template Name:
Randomization and Enrollment. University of Alberta,
Quality Management in Clinical Research. Copyright: 2002-
2016 University of Alberta.
All rights reserved. Please visit https://medical-data-
models.org/forms/16997
Randomization and Enrollment: CRF
QMCR University of Alberta
General Information
Study Name
Site Number
Pt_ID
Visit Date
Visit Type
Baseline (1)
Randomization (2)
Randomization and Enrollment Form
Is the participant eligible for the study based on
Inclusion and Exclusion Criteria?
Yes  (1)
No (leave the rest of the form blank) (2)
1. Date enrolled (meet all eligibility criteria)
2. Date randomized if different from enrolled
3. If eligible and not randomized, indicate reason
(optional)
Failed to return (1)
Declined participation (2)
Other (specify) (3)
If Other, please specify
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Serious Adverse Event (SAE) Report Form:
CRF QMCR University of Alberta
ODM derived from:
http://www.qmcr.ualberta.ca/en/ToolsandTemplates/CaseR
eportFormCRFTemplates.aspx. Template Name: Serious
Adverse Event (SAE) Report Form. University of Alberta,
Quality Management in Clinical Research. Copyright: 2002-
2016 University of Alberta.
All rights reserved. Please visit https://medical-data-
models.org/forms/16998
Serious Adverse Event (SAE) Report
Form: CRF QMCR University of
Alberta
General Information
Protocol Title
Protocol Number
Site Number
Pt_ID
SAE Report Form
1. SAE Start Date
2. SAE Stop Date
3. Location of serious adverse event
4. Was this an unexpected adverse event?
Yes
No
5. Brief description of participant(s) with no
personal identifiers: Sex
F (1)
M (2)
5. Brief description of participant(s) with no
personal identifiers: Age
6. Brief description of the nature of the serious
adverse event
7. Category of the serious adverse event
death - date:____ (1)
life-threatening (2)
hospitalization-initial or prolonged (3)
disability/incapacity (4)
congenital anomaly / birth defect (5)
required intervention to prevent
permanent impairment  (6)
Other (7)
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If Other, please specify
8. Intervention type: Medication or Nutritional
Supplement
Yes
No
Please specify
Intervention type: Device
Yes
No
Please specify
Intervention type: Surgery
Yes
No
Please specify
Intervention type: Behavioral/ Life Style
Yes
No
Please specify
9. Relationship of intervention
unrelated (clearly not related to the
intervention) (1)
possible (may be related to intervention)
(2)
definite (clearly related to intervention)
(3)
10. Was study intervention discontinued due to
event?
Yes
No
11. What medications or other steps were taken
to treat serious adverse event?
12. List any relevant tests, laboratory data,
history, including preexisting medical conditions
13. Type of report
initial (1)
follow-up (2)
final (3)
Signature of Principal Investigator
Date
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Eligibility Depression NCT00082030
Function of Catecholamines in the Brain During
Depression; ODM derived from:
https://clinicaltrials.gov/show/NCT00082030
All rights reserved. Please visit https://medical-data-
models.org/forms/17002
Eligibility Depression NCT00082030
Criteria
mdd sample: 40 subjects (ages 18-45) with
remitted mdd will be selected. mdd is defined by
the dsm-iv criteria, and one of the following
additional criteria:*
Yes
No
1. history of two or more major depressive
episodes, or*
Yes
No
2. history of one major depressive episode and a
family history for major depression. remission is
defined as a period of at least three months
during which the subject has not taken any
antidepressant agents, with the hamilton
depression rating scale (hdrs; 21-item) scores in
the non-depressed range (less than 8), and with
no more than one clinically significant depressive
symptom.*
Yes
No
unaffected mdd relative sample:*
Yes
No
40 healthy relatives of mdd probands (ages 18-
45) will be recruited. subjects will be screened to
ensure that they have no history of psychiatric
illness.*
Yes
No
unaffected bd relative sample:*
Yes
No
healthy relatives of bd probands (ages 18-45) will
be recruited. subjects will be screened to ensure
that they have no history of psychiatric illness.*
Yes
No
healthy control samples:*
Yes
No
healthy subjects (ages 18-45) without a known
personal or first-degree family history of
psychiatric disorders in first-degree relatives will
be selected.*
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Yes
No
Exclusion Criteria
any subject who appears incapable of providing
informed consent will be excluded from the
study.*
Yes
No
subjects who take effective antidepressant
medication*
Yes
No
subjects must not have taken antidepressant or
other medications likely to alter monoamine
neurochemistry or cerebrovascular and
cardiovascular function for at least 3 months prior
to the studies.*
Yes
No
subjects who have:*
Yes
No
1. psychosis to the extent that the ability to
provide informed consent is in doubt*
Yes
No
2. medical or neurological illnesses likely to affect
physiology or anatomy, i.e. hypertension,
cardiovascular disorders*
Yes
No
3. a history of drug (including benzodiazepines
[bzd]) or alcohol abuse within 1 year or a lifetime
history of alcohol or drug dependence (dsm iv
criteria) longer than 2 years*
Yes
No
4. current pregnancy (as documented by
pregnancy testing at screening or at days of the
challenge studies)*
Yes
No
5. current breast feeding*
Yes
No
6. smokers*
Yes
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No
7. serious suicidal ideation or behavior*
Yes
No
8. general mri exclusion criteria (e.g., subjects
with metallic implants that are ferromagnetic will
be excluded from the fmri scanning). subjects
must exhibit no or only moderate alcohol use.
subjects with current excessive use of alcohol
(greater than 4 ounces/day for men and greater
than 3 ounces/day for women) are ineligible for
participation, as such drug use confounds the
results*
Yes
No
9. smokers are ineligible because of the evidence
for interactions between nicotine and depression,
and the possibility of withdrawal symptoms that
may affect behavioral and neural responses to
cd*
Yes
No
10. history of suicidality and other axis i
diagnoses beside major depressive disorder*
Yes
No
11. lactose intolerance*
Yes
No
12. women not using a reliable contraception
method. finally subjects who have had an upper
respiratory tract infection in the last week will be
excluded as this may impact sense of smell.*
Yes
No
subjects beyond age 45*
Yes
No
individuals whose first major depressive episodes
arose after other medical or psychiatric
conditions*
Yes
No
subjects showing significant side effects during
ampt depletion such as dystonic reactions will
receive adequate treatment and will be excluded
from the study*
Yes
No
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Study Completion: CRF QMCR University
of Alberta
ODM derived from:
http://www.qmcr.ualberta.ca/en/ToolsandTemplates/CaseR
eportFormCRFTemplates.aspx. Template Name: Study
Completion. University of Alberta, Quality Management in
Clinical Research. Copyright: 2002-2016 University of
Alberta.
All rights reserved. Please visit https://medical-data-
models.org/forms/17003
Study Completion: CRF QMCR
University of Alberta
Study Completion
Study Name
Site Number
Pt_ID
Visit Date
1. Date of final study visit
2. Date of last known study intervention
3. Primary reason for terminating participation in
the study
Completed study (1)
Participant was determined after
enrollment to be ineligible (Provide
comments) (2)
Participant withdrew consent  (3)
In the Investigator´s opinion it was not in
the participant´s best interest to
continue. (Provide Comments) (4)
Adverse Event (If checked, complete AE
form) (5)
Death (6)
Lost to follow-up (7)
Other (specify):___ (8)
Unknown (9)
If Other, please specify
Comments
PI Signature
Date
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Visit Checklist: CRF QMCR University of
Alberta
ODM derived from:
http://www.qmcr.ualberta.ca/en/ToolsandTemplates/CaseR
eportFormCRFTemplates.aspx. Template Name: Visit
Checklist. University of Alberta, Quality Management in
Clinical Research. Copyright: 2002-2016 University of
Alberta.
All rights reserved. Please visit https://medical-data-
models.org/forms/17004
Visit Checklist: CRF QMCR
University of Alberta
General Information
Study Name
Site Number
Pt_ID
Visit Date
Visit Checklist
1. Did the participant attend this visit?
Yes (If yes, continue) (1)
No (2)
2. Please check all the assessments completed
at this visit: Demographics
Yes
No
Assessments completed at this visit: Medical
History
Yes
No
Assessments completed at this visit: Vital Signs
Yes
No
Assessments completed at this visit: Physical
Exam
Yes
No
Assessments completed at this visit: Prior and
Concomitant Medication
Yes
No
Assessments completed at this visit:
Inclusion/Exclusion Criteria
Yes
No
Assessments completed at this visit:
Randomization and Enrollment
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Yes
No
3. Is the participant continuing in the study?
Yes (schedule next visit) (1)
No (remember to complete a study
completion form) (2)
Comments
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Visit Checklist: CRF QMCR University of Alberta
Visit Checklist: CRF QMCR University of
Alberta
ODM derived from:
http://www.qmcr.ualberta.ca/en/ToolsandTemplates/CaseR
eportFormCRFTemplates.aspx. Template Name: Visit
Checklist. University of Alberta, Quality Management in
Clinical Research. Copyright: 2002-2016 University of
Alberta.
All rights reserved. Please visit https://medical-data-
models.org/forms/17005
Visit Checklist: CRF QMCR
University of Alberta
General Information
Study Name
Site Number
Pt_ID
Visit Date
Visit Checklist
1. Did the participant attend this visit?
Yes (If yes, continue) (1)
No (2)
2. Please check all the assessments completed
at this visit: Demographics
Yes
No
Assessments completed at this visit: Medical
History
Yes
No
Assessments completed at this visit: Vital Signs
Yes
No
Assessments completed at this visit: Physical
Exam
Yes
No
Assessments completed at this visit: Prior and
Concomitant Medication
Yes
No
Assessments completed at this visit:
Inclusion/Exclusion Criteria
Yes
No
Assessments completed at this visit:
Randomization and Enrollment
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Yes
No
3. Is the participant continuing in the study?
Yes (schedule next visit) (1)
No (remember to complete a study
completion form) (2)
Comments
2 / 2
Visit Checklist: CRF QMCR University of Alberta
Vital Signs: CRF QMCR University of
Alberta
ODM derived from:
http://www.qmcr.ualberta.ca/en/ToolsandTemplates/CaseR
eportFormCRFTemplates.aspx. Template Name: Vital
Signs. University of Alberta, Quality Management in Clinical
Research. Copyright: 2002-2016 University of Alberta.
All rights reserved. Please visit https://medical-data-
models.org/forms/17006
Vital Signs: CRF QMCR University of
Alberta
General Information
Study Name
Site Number
Pt_ID
Visit Date
Visit Type
Screening (1)
Baseline (2)
Visit 1 (3)
Visit 2 (4)
Visit 3 (5)
Visit 4 (6)
Visit 5 (7)
Completion Visit (8)
1. Time
Time
AM (1)
PM (2)
2. Heart Rate
bpm
Heart Rate - not done
Yes
No
3. Blood pressure (systolic)
Blood pressure (diastolic)
Blood pressure - not done
Yes
No
3.a BP position
Sitting (1)
Supine (2)
Standing (3)
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4. Temperature
Temperature
°F (1)
°C (2)
Temperature - not done
Yes
No
5. Respiratory Rate
_/min
Respiratory Rate - not done
Yes
No
6. Weight
Weight
pounds (1)
kilograms (2)
Weight - Estimated?
Yes
No
Weight - not done
Yes
No
7. Height
Height
inches (1)
centimeters (2)
Height - Estimated?
Yes
No
Height - not done
Yes
No
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Eligibility Depression NCT00131456
Free Venlafaxine Treatment for Marijuana Addiction and
Depression - 1; ODM derived from:
https://clinicaltrials.gov/show/NCT00131456
All rights reserved. Please visit https://medical-data-
models.org/forms/17007
Eligibility Depression NCT00131456
Inclusion Criteria
meets criteria for current marijuana addiction and
reports marijuana as primary drug of abuse*
Yes
No
currently meets criteria for major depression or
dysthymic disorder and receive a score of greater
than or equal to 12 on the hamilton depression
inventory*
Yes
No
clinically depressed for at least 3 months during a
period of active marijuana use*
Yes
No
women of child-bearing age will be included
provided that they are not pregnant, based on the
results of a blood pregnancy done at the time of
screening and agree to use a method of
contraception with proven efficacy and not to
become pregnant during the study. to confirm
this, blood pregnancy tests will be repeated
monthly. women will be provided a full
explanation of the potential dangers of pregnancy
while on the study. if a woman becomes
pregnant, the study medication will be
discontinued.*
Yes
No
Exclusion Criteria
meets criteria for past manic or psychotic
disorder, unless substance-related*
Yes
No
history of a seizure disorder*
Yes
No
individuals with chronic organic mental
syndrome*
Yes
No
any significant risk for suicide based on current
assessment and history of attempts*
Yes
No
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history of allergic reaction to either venlafaxine or
ven-xr*
Yes
No
unstable physical disorders that might make
participation hazardous, such as uncontrolled
hypertension and tachycardia (sbp>150, dbp >90,
or a sitting quietly hr>100), acute hepatitis
(patients with chronic mildly elevated
transaminase levels (<2x upper limit of normal
are acceptable) or unstable diabetes*
Yes
No
history of failure to respond to a previous
adequate trial of venlafaxine of at least 300 mg.
for at least a 6-week period*
Yes
No
physical dependence on any other drugs
(excluding nicotine) that would require medical
detoxification*
Yes
No
currently being prescribed psychotropic
medication by another physician (in the last 3
weeks), except for acute treatment of insomnia.*
Yes
No
pregnant or breast-feeding*
Yes
No
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Eligibility Depression NCT00136240
Automated Telephone System to Improve Treatment
Adherence in People With Depression; ODM derived from:
https://clinicaltrials.gov/show/NCT00136240
All rights reserved. Please visit https://medical-data-
models.org/forms/17008
Eligibility Depression NCT00136240
Inclusion Criteria
a clinical diagnosis of major depressive disorder,
dysthymic disorder, depressive disorder not
otherwise specified, or any combination of the
three*
Yes
No
prescribed at least one antidepressant
medication*
Yes
No
access to a telephone with touch-tone service*
Yes
No
speak and understand conversational english*
Yes
No
Exclusion Criteria
current significant alcohol or drug abuse*
Yes
No
clinical diagnosis of bipolar disorder,
schizoaffective disorder, or significant personality
disorder*
Yes
No
parkinson's disease, huntington's disease,
amyotrophic lateral sclerosis (als), or other
neurodegenerative diseases*
Yes
No
alzheimer's disease and other dementia*
Yes
No
cancer, undergoing radiation therapy or
chemotherapy*
Yes
No
suffering from renal disease or on dialysis*
Yes
No
immunologic disorder (rheumatoid arthritis,
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systemic lupus erythematosus [sle], etc.)*
Yes
No
hiv*
Yes
No
terminal illness*
Yes
No
homeless*
Yes
No
legally blind*
Yes
No
planning to leave the geographic area during the
study period*
Yes
No
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Eligibility Depression NCT00136318
Escitalopram for the Prevention of PEGASYS-associated
Depression in Hepatitis C Virus-infected Patients; ODM
derived from: https://clinicaltrials.gov/show/NCT00136318
All rights reserved. Please visit https://medical-data-
models.org/forms/17009
Eligibility Depression NCT00136318
Inclusion Criteria
chronic hepatitis c infection defined as positive
anti-hcv antibodies and serum hcv-rna >1000
iu/ml, naive to antiviral treatment*
Yes
No
age >18 years*
Yes
No
Exclusion Criteria
antidepressive treatment within the last 3 years*
Yes
No
psychiatric diseases including major depressive
disorders in past medical history*
Yes
No
active substance abuse during the last 12
months*
Yes
No
pregnancy, lactation, wish to become pregnant*
Yes
No
hepatitis b (hbv)/hiv-coinfection*
Yes
No
decompensated liver disease, hepatocellular
carcinoma, history of bleeding esophageal
varices*
Yes
No
neutropenia (<1500/ul), thrombocytopenia
(<70/nl), anemia (<12g/dl in females, <13g/dl in
males)*
Yes
No
history of autoimmune disease*
Yes
No
history of organ transplantation, concomitant liver
disease, severe cardiopulmonary disease,
1 / 2
hemolytic anemia, malignant disease*
Yes
No
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EBMT Amyloidosis
DOCUMENTED PATHOGENS (Use this table for guidance
on the pathogens of interest)
Bacteria: S. pneumoniae, Other gram positive (i.e.: other
streptococci, staphylococci, listeria …),Haemophilus
influenzae,  Other gram negative (i.e.: E. coli klebsiella,
proteus, serratia, pseudomonas …), Legionella sp,
Mycobacteria sp, Other
Fungi: Candida sp, Aspergillus sp, Pneumocystis carinii,
Other
Parasites: Toxoplasma gondii, Other
Viruses: HSV, VZV, EBV, CMV, HHV-6, RSV. Other
respiratory virus (influenza, parainfluenza, rhinovirus),
Adenovirus, HBV, HCV, HIV,Papovavirus, Parvovirus, Other
All rights reserved. Please visit https://medical-data-
models.org/forms/17010
18pp EBMT Amyloidosis
GENERAL INFORMATION TEAM
EBMT Centre Identification Code (CIC)
Name of the hospital
Unit
Name of contact person
Telephone number
Fax
E-Mail
Date of this report
Patient following national / international study /
trial
No (1)
Yes (2)
Not evaluated (3)
Unknown (4)
Name of study / trial
GENERAL INFORMATION PATIENT
Unique Identification Code (UIC)
Hospital Unique Patient Number or Code
First name(s)_surname(s)
Date of birth
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Sex
Male (1)
Female (2)
ABO Group
Rh factor
Yes
No
DISEASE
Date of diagnosis
Check the disease for which this transplant was
performed
Acute Leukaemia (Acute Leukaemia)
Acute Lymphoblastic Leukaemia (ALL)
(Acute Lymphoblastic Leukaemia (ALL))
Acute Myelogenous Leukaemia (AML)
(Acute Myelogenous Leukaemia (AML))
Autoimmune disease (Autoimmune
disease)
Bone marrow failure including Aplastic
anaemia (Bone marrow failure including
Aplastic anaemia)
Chronic Leukaemia (Chronic Leukaemia)
Chronic Lymphocytic Leukaemia
(Chronic Lymphocytic Leukaemia)
Chronic Myeloid Leukaemia (CML)
(Chronic Myeloid Leukaemia (CML))
Haemoglobinopathies
(Haemoglobinopathies)
Histiocytic disorders (Histiocytic
disorders)
Hodgkin´s Disease (Hodgkin´s Disease)
Inherited disorders (Inherited disorders)
Juvenile Idiopathic Arthritis (Juvenile
Idiopathic Arthritis)
Lymphoma (Lymphoma)
MD/ MPN (MD/ MPN)
MDS (MDS)
Metabolic disorders (Metabolic
disorders)
Multiple Sclerosis (Multiple Sclerosis)
Myelodysplastic syndromes
(Myelodysplastic syndromes)
Myeloma/ Plasma cell disorder
(Myeloma/ Plasma cell disorder)
Myeloproliferative neoplasm
(Myeloproliferative neoplasm)
Non Hodgkin (Non Hodgkin)
Other diagnosis (Other diagnosis)
Primary immune deficiencies (Primary
immune deficiencies)
Secondary Acute Leukaemia (do not use
if transformed from MDS/MPN)
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(Secondary Acute Leukaemia (do not
use if transformed from MDS/MPN))
Solid Tumour (Solid Tumour)
Systemic Lupus (Systemic Lupus)
Systemic Sclerosis (Systemic Sclerosis)
AL AMYLOIDOSIS INITIAL DIAGNOSIS
Has the information requested in this section
been submitted with a previous HSCT registration
for this patient?
Yes: go to page 3, Pre-HSCT Treatment
(1)
No: proceed with this section (2)
EVIDENCE OF UNDERLYING PLASMA CELL
DISORDER
Yes
No
In case of EVIDENCE OF UNDERLYING
PLASMA CELL DISORDER, please specify:
Monoclonal Gammopathy (Monoclonal
Gammopathy)
Multiple Myeloma (Multiple Myeloma)
Other B-cell malignancy (Other B-cell
malignancy)
If Other B-cell malignancy, specify
PLASMA CELL DISORDER
IgG (1)
IgA (2)
IgD (3)
IgE (4)
IgM (5)
Absent (6)
Not evaluated (7)
PLASMA CELL DISORDER light chain
Kappa (1)
Lambda (2)
Absent (3)
Not evaluated (4)
If Multiple myeloma: Stage at diagnosis (Salmon
and Durie) A
I (I)
II (II)
III (III)
If Multiple myeloma: Stage at diagnosis (Salmon
and Durie) B
Yes
No
DIAGNOSIS OF AMYLOIDOSIS
Excluded (1)
Not evaluated (2)
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DIAGNOSIS OF AMYLOIDOSIS via
Immunohistochemistry
Done (Done)
Not evaluated (Not evaluated)
CLINICAL AND LABORATORY DATA
Serum creatinine (1)
Serum c-Troponin T (μg/L) (10)
Hb (g/dL) (2)
Total urinary protein excretion (mg/24 h)
(3)
Total urinary albumin excretion (mg/24 h)
(4)
Serum calcium (mmol/L) (5)
Serum albumin (g/L) (6)
Serum alkaline phosphatase (IU/L) (7)
Serum bilirubin (8)
NT-proBNP  (ng/L) (9)
BM aspirate: % plasmacytosis
%
BM trephine % plasmacytosis
%
Monoclonal Ig in serum
g/L
Immunofixation of serum
Negative  (1)
Positive  (2)
Not evaluated  (3)
Unknown (4)
Free Kappa light chains in serum
mg/L
Not evaluated (1)
Lambda light chains
mg/L
Not evaluated (1)
Immunofixation of urine
Negative  (1)
Positive  (2)
Not evaluated  (3)
Unknown (4)
Monoclonal light chains in urine
g/24h
Serum Beta2 microglobulin
mg/L
Bone structure (X-ray)
Normal  (1)
Lytic lesion   (2)
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Not evaluated  (3)
Unknown (4)
Macroglossia
Absent  (1)
Present  (2)
Not evaluated  (3)
Unknown (4)
Periorbital bleeding
Absent  (1)
Present  (2)
Not evaluated  (3)
Unknown (4)
Shoulder pad sign
Absent  (1)
Present  (2)
Not evaluated  (3)
Unknown (4)
ORGAN INVOLVEMENT AT DIAGNOSIS
Soft Tissues
Additional organ involvement (Additional
organ involvement)
Biopsy (Biopsy)
Dominant organ(s) involved (Dominant
organ(s) involved)
No involvement (No involvement)
Gastrointestinal Tract
Dominant organ(s) involved (1)
Additional organ involvement (2)
Biopsy (3)
No involvement (4)
Heart
Dominant organ(s) involved (1)
Additional organ involvement (2)
Biopsy (3)
No involvement (4)
Liver
Dominant organ(s) involved (1)
Additional organ involvement (2)
Biopsy (3)
No involvement (4)
Kidney
Dominant organ(s) involved (1)
Additional organ involvement (2)
Biopsy (3)
No involvement (4)
Peripheral nerves
Dominant organ(s) involved (1)
Additional organ involvement (2)
Biopsy (3)
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No involvement (4)
Autonomic nerves
Dominant organ(s) involved (1)
Additional organ involvement (2)
Biopsy (3)
No involvement (4)
if other, please specify
Dominant organ(s) involved (1)
Additional organ involvement (2)
Biopsy (3)
No involvement (4)
Liver span in ultrasound or CT scan (cm
craniocaudal diameter)
Not evaluated (1)
NYHA class
I (1)
II (2)
III (3)
IV (4)
not done (99)
Left Ventricular Ejection Fraction
%
Interventricular septal wall thickness
mm
Weight loss
No  (1)
Yes  (2)
Not evaluated  (3)
Unknown (4)
Malabsorption
No  (1)
Yes  (2)
Not evaluated  (3)
Unknown (4)
GI bleeding
No  (1)
Yes  (2)
Not evaluated  (3)
Unknown (4)
If other evidence of gastrointestinal involvement,
please specify
Neurological exam
Abnormal  ( Abnormal )
Not evaluated or failed  ( Not evaluated
or failed )
Unknown ( Unknown)
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Normal  (Normal )
Neurological exam: If abnormal:
Specify abnormality
PNP severity
grade I  (1)
grade II  (2)
grade III  (3)
grade IV (4)
Orthostatic hypotension
Yes  (1)
No  (2)
Not evaluated  (3)
Unknown (4)
Intractable diarrhoea
Yes  (1)
No  (2)
Not evaluated  (3)
Unknown (4)
Inflexible pulse rate
Yes  (1)
No  (2)
Not evaluated  (3)
Unknown (4)
Clinical evidence for involvement of other sites
PRE-HSCT TREATMENT
WAS THE PATIENT TREATED BEFORE THE
HSCT PROCEDURE?
Yes
No
Chemotherapy
Yes
No
Modality Chemotherapy
Chemotherapy regimen (Chemotherapy
regimen)
Number of cycles (Number of cycles)
If Other Modality, please specify
HSCT
DATE OF HSCT
HSCT TYPE Allogeneic:
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Yes
No
Autologous: Date of 1st collection or pheresis
STATUS OF DISEASE AT COLLECTION
(AUTOGRAFTS ONLY)
Haematological status
>CR2  ( >CR2 VNUMSTM)
>PR2  ( >PR2 )
CR1  ( CR1 )
CR2  ( CR2 )
No change  ( No change )
PR1  ( PR1 )
Progression  ( Progression )
Unknown ( Unknown)
At diagnosis  (At diagnosis )
MR (MR)
PR2  (PR2 )
Organ status
Response  (2)
No change  (3)
Progression  (4)
Unknown (5)
STATUS OF DISEASE AT START OF
CONDITIONING FOR BMT
Haematological status
>CR2  ( >CR2 )
>PR2  ( >PR2 )
CR2  ( CR2 )
MR ( MR)
No change  ( No change )
PR1  ( PR1 )
PR2  ( PR2 )
At diagnosis  (At diagnosis )
CR1  (CR1 )
Progression  (Progression )
Unknown (Unknown)
Organ status
Response  (2)
No change  (3)
Progression  (4)
Unknown (5)
Hb
g/dl
CLINICAL AND LABORATORY DATA
Serum creatinine (1)
Serum c-Troponin T (μg/L) (10)
Hb (g/dL) (2)
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Total urinary protein excretion (mg/24 h)
(3)
Total urinary albumin excretion (mg/24 h)
(4)
Serum calcium (mmol/L) (5)
Serum albumin (g/L) (6)
Serum alkaline phosphatase (IU/L) (7)
Serum bilirubin (8)
NT-proBNP  (ng/L) (9)
BM aspirate: % plasmacytosis
%
BM trephine % plasmacytosis
%
Monoclonal Ig in serum
g/L
Immunofixation of serum
Negative  (1)
Positive  (2)
Not evaluated  (3)
Unknown (4)
Free Kappa light chains in serum
mg/L
Not evaluated (1)
Lambda light chains
mg/L
Not evaluated (1)
Immunofixation of urine
Negative  (1)
Positive  (2)
Not evaluated  (3)
Unknown (4)
Monoclonal light chains in urine
g/24h
Serum Beta2 microglobulin
mg/L
Soft Tissues
Additional organ involvement (Additional
organ involvement)
Biopsy (Biopsy)
Dominant organ(s) involved (Dominant
organ(s) involved)
No involvement (No involvement)
Gastrointestinal Tract
Dominant organ(s) involved (1)
Additional organ involvement (2)
Biopsy (3)
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No involvement (4)
Heart
Dominant organ(s) involved (1)
Additional organ involvement (2)
Biopsy (3)
No involvement (4)
Liver
Dominant organ(s) involved (1)
Additional organ involvement (2)
Biopsy (3)
No involvement (4)
Kidney
Dominant organ(s) involved (1)
Additional organ involvement (2)
Biopsy (3)
No involvement (4)
Peripheral nerves
Dominant organ(s) involved (1)
Additional organ involvement (2)
Biopsy (3)
No involvement (4)
Autonomic nerves
Dominant organ(s) involved (1)
Additional organ involvement (2)
Biopsy (3)
No involvement (4)
Liver span in ultrasound or CT scan (cm
craniocaudal diameter)
Not evaluated (1)
NYHA class
I (1)
II (2)
III (3)
IV (4)
not done (99)
Left Ventricular Ejection Fraction
%
Interventricular septal wall thickness
mm
Weight loss
No  (1)
Yes  (2)
Not evaluated  (3)
Unknown (4)
Malabsorption
No  (1)
Yes  (2)
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Not evaluated  (3)
Unknown (4)
GI bleeding
No  (1)
Yes  (2)
Not evaluated  (3)
Unknown (4)
If other evidence of gastrointestinal involvement,
please specify
Neurological exam
Abnormal  ( Abnormal )
Not evaluated or failed  ( Not evaluated
or failed )
Unknown ( Unknown)
Normal  (Normal )
Neurological exam: If abnormal:
Specify abnormality
PNP severity
grade I  (1)
grade II  (2)
grade III  (3)
grade IV (4)
Orthostatic hypotension
Yes  (1)
No  (2)
Not evaluated  (3)
Unknown (4)
Intractable diarrhoea
Yes  (1)
No  (2)
Not evaluated  (3)
Unknown (4)
Inflexible pulse rate
Yes  (1)
No  (2)
Not evaluated  (3)
Unknown (4)
Clinical evidence for involvement of other sites
STATUS OF DISEASE AT 100 DAYS
AFTER HSCT
BEST HAEMATOLOGICAL RESPONSE TO
HSCT AT 100 DAYS
>CR2 ( >CR2)
>PR2  ( >PR2 )
CR2  ( CR2 )
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MR ( MR)
Progression  ( Progression )
Unknown ( Unknown)
CR1  (CR1 )
No change  (No change )
Not evaluable  (Not evaluable )
PR1  (PR1 )
PR2  (PR2 )
DATE RESPONSE ACHIEVED OR ASSESSED
CLINICAL AND LABORATORY DATA
Serum creatinine (1)
Serum c-Troponin T (μg/L) (10)
Hb (g/dL) (2)
Total urinary protein excretion (mg/24 h)
(3)
Total urinary albumin excretion (mg/24 h)
(4)
Serum calcium (mmol/L) (5)
Serum albumin (g/L) (6)
Serum alkaline phosphatase (IU/L) (7)
Serum bilirubin (8)
NT-proBNP  (ng/L) (9)
Serum creatinine
Creatinine clearance (mL/min)
Total urinary protein excretion (mg/24 h)
Total urinary albumin excretion (mg/24 h)
Serum NT-pro-BNP (ng/L)
CLINICAL AND LABORATORY DATA
Serum c-Troponin T (μg/L)
CLINICAL AND LABORATORY DATA
BM aspirate: % plasmacytosis
%
BM trephine % plasmacytosis
%
Monoclonal Ig in serum
g/L
Immunofixation of serum
Negative  (1)
Positive  (2)
Not evaluated  (3)
Unknown (4)
12 / 28
EBMT Amyloidosis
Free Kappa light chains in serum
mg/L
Not evaluated (1)
Lambda light chains
mg/L
Not evaluated (1)
Immunofixation of urine
Negative  (1)
Positive  (2)
Not evaluated  (3)
Unknown (4)
Monoclonal light chains in urine
g/24h
Serum Beta2 microglobulin
mg/L
ORGAN-SPECIFIC RESPONSES AT 100
DAYS AFTER HSCT
Kidney
Response  (1)
No response/stable disease  (2)
Progressive disease (3)
Not evaluable  (4)
Not evaluated/not applicable  (5)
Unknown (6)
Liver
Liver span in ultrasound or CT scan (cm
craniocaudal diameter)
Hepatic response
Response  (1)
No response/stable disease  (2)
Progressive disease (3)
Not evaluable  (4)
Not evaluated/not applicable  (5)
Unknown (6)
Heart
NYHA class
I (I)
II (II)
III (III)
IV (IV)
Unknown (Unknown)
Left ventricular ejection fraction
%
Interventricular septal wall thickness
(mean # mm in echocardiogram)
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Cardiac response
No response/stable disease  ( No
response/stable disease )
Not evaluable  ( Not evaluable )
Not evaluated/not applicable  ( Not
evaluated/not applicable )
Progressive disease ( Progressive
disease)
Unknown ( Unknown)
Response  (Response )
Weight loss
No  (1)
Yes  (2)
Not evaluated  (3)
Unknown (4)
Malabsorption
No  (1)
Yes  (2)
Not evaluated  (3)
Unknown (4)
GI bleeding
No  (1)
Yes  (2)
Not evaluated  (3)
Unknown (4)
GI response
Response  (1)
No response/stable disease  (2)
Progressive disease (3)
Not evaluable  (4)
Not evaluated/not applicable  (5)
Unknown (6)
Neurological exam
Peripheral neuropathy
(Compare current situation to situation before
HSCT)
Improved  (1)
Worsened  (2)
Unchanged  (3)
Unknown (4)
PNP severity
Peripheral neuropathy
(Compare current situation to situation before
HSCT)
grade I  (1)
grade II  (2)
grade III  (3)
grade IV (4)
PN response
Peripheral neuropathy
(Compare current situation to situation before
HSCT)
No response/stable disease  (No
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response/stable disease )
Not evaluable  (Not evaluable )
Not evaluated/not applicable  (Not
evaluated/not applicable )
Progressive disease (Progressive
disease)
Response  (Response )
Unknown (Unknown)
AN response
Autonomic neuropathy
No response/stable disease  (No
response/stable disease )
Not evaluable  (Not evaluable )
Not evaluated/not applicable  (Not
evaluated/not applicable )
Progressive disease (Progressive
disease)
Response  (Response )
Unknown (Unknown)
Clinical evidence for involvement of new sites
Evidence of new organ involvement
KARNOFSKY
FORMS TO BE FILLED IN
Type of Transplant
ALLOgraft or Syngeneic graft (proceed to
Allograft form) (ALLOgraft or Syngeneic
graft (proceed to Allograft form))
AUTOgraft (proceed to Autograft form)
(AUTOgraft (proceed to Autograft form))
Other (contact the EBMT Central
Registry for instructions) (Other (contact
the EBMT Central Registry for
instructions))
FOLLOW UP AL AMYLOIDOSIS
Unique Identification Code (UIC)
(if known)
Hospital Unique Patient Number
Initials
Date of birth
Date of HSCT
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PATIENT LAST SEEN
Date of Last Contact or Death
Complete haematological remission obtained
after the HSCT in the absence of additional
disease treatment
Previously reported (1)
Yes, date (2)
No (3)
Unknown (4)
GRAFT VERSUS HOST DISEASE
(GvHD) SINCE LAST REPORT
Maximum Grade of Acute GVHD
Agvhd Grade 0 (0)
Agvhd Grade I (I)
Agvhd Grade Ii (II)
Agvhd Grade Iii (III)
Agvhd Grade Iv (IV)
Agvhd Present, Grade Unknown
(Present, grade unknown)
If present type of GvHD
New onset  (1)
Recurrent  (2)
Persistent (3)
Reason for aGvHD
DLI (DLI)
Tapering (Tapering)
Unexplained (Unexplained)
Date onset of this episode (if new or recurrent)
yyyy/mm/dd
aGvHD Stage
Stage skin (1)
Stage liver (2)
Stage gut (3)
aGvHD Resolution
No  (1)
Yes (2)
Date of resolution
yyyy/mm/dd
Presence of cGvHD
No (No)
Present continously since last reported
episode (Present continously since last
reported episode)
Resolved (Resolved)
Yes (Yes)
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Presence of cGVHD if yes
First episode (1)
Recurrence (2)
cGvHD Date of onset
yyyy/mm/dd
cGvHD grade
limited (1)
Extensive (2)
Organs affected
Skin (1)
Gut (2)
Liver (3)
Mouth (4)
Eyes (5)
Lung (6)
Other, specify (7)
Unknown (8)
If resolved, specify the date of resolution:
OTHER COMPLICATIONS SINCE LAST
REPORT
Infection related complications
Yes
No
Bacteraemia / fungemia / viremia / parasites
Pathogen (1)
Date (2)
Septic shock
Pathogen (1)
Date (2)
ARDS
Pathogen (1)
Date (2)
Multiorgan failure due to infection
Pathogen (1)
Date (2)
Pneumonia
Pathogen (1)
Date (2)
Hepatitis
Pathogen (1)
Date (2)
CNS infection
Pathogen (1)
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Gut infection
Pathogen (1)
Date (2)
Skin infection
Pathogen (1)
Date (2)
Date
Provide different dates for different episodes of
the same complication if applicable.
Cystitis
Pathogen (1)
Date (2)
Retinitis
Pathogen (1)
Date (2)
Other
Pathogen (1)
Date (2)
Non infection related complications
Yes
No
CTC grade Cardiovascular
0 (1)
1 (2)
2 (3)
3 (4)
4 (5)
Date Cardiovascular
Cardiovascular comments
CTC grade Dermatologic
0 (1)
1 (2)
2 (3)
3 (4)
4 (5)
Date Dermatologic
Comments
CTC grade Gastrointestinal
0 (1)
1 (2)
2 (3)
3 (4)
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4 (5)
Date Gastrointestinal
Gastrointestinal Comments
CTC grade Haemorrhage
0 (1)
1 (2)
2 (3)
3 (4)
4 (5)
Date Haemorrhage
Haemorrhage Comments
CTC grade Hepatic
0 (1)
1 (2)
2 (3)
3 (4)
4 (5)
Date Hepatic
Hepatic Comments
CTC grade Neurologic
0 (1)
1 (2)
2 (3)
3 (4)
4 (5)
Date Neurologic
Neurologic Comments
CTC grade Pulmonary
0 (1)
1 (2)
2 (3)
3 (4)
4 (5)
Pulmonary Date
Pulmonary Comments
CTC grade Renal
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0 (1)
1 (2)
2 (3)
3 (4)
4 (5)
Renal Date
Renal Comments
Other CTC grade
0 (1)
1 (2)
2 (3)
3 (4)
4 (5)
Date of other Type
Comments of Other type
Graft loss
No (No)
Not evaluated (Not evaluated)
Yes (Yes)
Overall chimaerism
Full (donor >95 %)  (1)
Mixed (partial) (2)
Autologous reconstitution (recipient >95
%)  (3)
Aplasia (4)
Not evaluated (5)
GRAFT ASSESSMENT AND
HAEMOPOIETIC CHIMAERISM
Date of Test
Identification of donor or Cord Blood Unit given
by the centre
Number in the infusion order (if applicable)
Cell type on which test was performed
BM
%
Bone marrow (1)
Other (10)
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PB mononuclear cells (PBMC) (2)
T-cell (3)
B-cells (4)
Red blood cells (5)
Monocytes (6)
PMNs (neutrophils) (7)
Lymphocytes (8)
Myeloid cells (9)
Laboratory tests used:
ABO group (ABO group)
Cytogenetic (Cytogenetic)
FISH (FISH)
Molecular (Molecular)
Other (Other)
unknown (unknown)
SECONDARY MALIGNANCY,
LYMPHOPROLIFERATIVE OR
MYELOPROLIFRATIVE DISORDER
DIAGNOSED
Previously reported (1)
Yes (2)
No at date of this follow-up (3)
Date of diagnosis
Diagnosis Secondary Malignant Neoplasm
AML  (1)
MDS  (2)
Lymphoproliferative disorder  (3)
Other (4)
If other diagnosis, please specify
ADDITIONAL THERAPIES SINCE LAST
FOLLOW UP
Treatment given since last report
No (No)
Unknown (Unknown)
Yes (Yes)
Date started
If yes: CELLULAR THERAPY
One cell therapy regimen is defined as any
number of infusions given within 10 weeks for the
same indication. If more than one regimen of cell
therapy has been given since last report, copy
this section and complete it as many times as
necessary.
No (1)
Yes (2)
Unknown (3)
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Disease status before this cellular therapy
CR  (1)
Not in CR  (2)
Not evaluated (3)
If yes: Type of cells
Donor lymphocyte infusion (DLI) (1)
Mesenchymal cells (2)
Other (3)
Unknown (4)
If DLI, specify the number of cells infused by
type:
Nucleated cells
Evaluated (Evaluated)
Not evaluated (Not evaluated)
unknown (unknown)
Number of cells infused by type
Nucleated cells (1)
CD 34+ (2)
CD 3+ (3)
Total number of cells
Evaluated (Evaluated)
Not Evaluated (Not Evaluated)
Unknown (Unknown)
Chronological number of this cell therapy for this
patient
Indication 
(check all that apply)
Loss/decreased chimaerism
(Loss/decreased chimaerism)
Mixed chimaerism (Mixed chimaerism)
Other (Other)
Planned/ protocol (Planned/ protocol)
Prophylactic (Prophylactic)
Treatment for disease (Treatment for
disease)
Treatment of GvHD (Treatment of GvHD)
Treatment PTLD, EBV, lymphoma
(Treatment PTLD, EBV, lymphoma)
Treatment viral infection (Treatment viral
infection)
Number of infusions within 10 weeks (count only
infusions that are part of same regimen and given
for the same indication)
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Maximum Grade of Acute GVHD
Agvhd Grade 0 (0)
Agvhd Grade I (I)
Agvhd Grade Ii (II)
Agvhd Grade Iii (III)
Agvhd Grade Iv (IV)
Agvhd Present, Grade Unknown
(Present, grade unknown)
Disease treatment (apart from donor cell infusion
or other type of cell therapy)
No (1)
Yes: Planned (planned before HSCT took
place) (2)
Yes: Not planned (for
relapse/progression or persistent
disease) (3)
FIRST EVIDENCE OF DISEASE
WORSENING SINCE LAST HSCT
EVIDENCE OF DISEASE ACTIVITY
Continuous worsening since HSCT
(Continuous worsening since HSCT)
No (No)
Previously reported (Previously reported)
Unknown (Unknown)
Yes (Yes)
If yes, date first noted
LAST DISEASE AND PATIENT STATUS
HAEMATOLOGICAL DISEASE STATUS
Complete remission (Complete
remission)
Not evaluable (Not evaluable)
Partial remission (Partial remission)
Progression (Progression)
Stable disease (Stable disease)
Unknown (Unknown)
Organ Response
Response (1)
Non Response (2)
Progression (3)
Not evaluable (4)
Unknown (5)
CLINICAL AND LABORATORY DATA
Serum creatinine (1)
Serum c-Troponin T (μg/L) (10)
Hb (g/dL) (2)
Total urinary protein excretion (mg/24 h)
(3)
Total urinary albumin excretion (mg/24 h)
(4)
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Serum calcium (mmol/L) (5)
Serum albumin (g/L) (6)
Serum alkaline phosphatase (IU/L) (7)
Serum bilirubin (8)
NT-proBNP  (ng/L) (9)
BM aspirate: % plasmacytosis
%
BM trephine % plasmacytosis
%
Monoclonal Ig in serum
g/L
Immunofixation of serum
Negative  (1)
Positive  (2)
Not evaluated  (3)
Unknown (4)
Free Kappa light chains in serum
mg/L
Not evaluated (1)
Lambda light chains
mg/L
Not evaluated (1)
Immunofixation of urine
Negative  (1)
Positive  (2)
Not evaluated  (3)
Unknown (4)
Monoclonal light chains in urine
g/24h
Serum Beta2 microglobulin
mg/L
Renal response
Response (1)
No response/stable disease (2)
Progressive disease (3)
Not evaluable (4)
Not evaluated/not applicable (5)
Unknown (6)
Liver span 
(cm craniocaudal diameter)
Hepatic response
No response/stable disease (No
response/stable disease)
Not evaluable (Not evaluable)
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Not evaluated/not applicable (Not
evaluated/not applicable)
Progressive disease (Progressive
disease)
Response (Response)
Unknown (Unknown)
NYHA class
I (1)
II (2)
III (3)
IV (4)
unknown (5)
Left Ventricular Ejection Fraction
%
Interventricular septal wall thickness
(mean # mm in echocardiogram)
Cardiac response
Response  (1)
No response/stable disease  (2)
Progressive disease (3)
Not evaluable  (4)
Not evaluated/not applicable  (5)
Unknown (6)
Weight loss
No  (1)
Yes  (2)
Not evaluated  (3)
Unknown (4)
Malabsorption
No  (1)
Yes  (2)
Not evaluated  (3)
Unknown (4)
GI bleeding
No  (1)
Yes  (2)
Not evaluated  (3)
Unknown (4)
GI response
Response  (1)
No response/stable disease  (2)
Progressive disease (3)
Not evaluable  (4)
Not evaluated/not applicable  (5)
Unknown (6)
Neurological exam
Improved  (1)
Worsened  (2)
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Unchanged  (3)
Unknown (4)
PNP severity
grade I  (1)
grade II  (2)
grade III  (3)
grade IV (4)
PN response
Response  (1)
No response/stable disease  (2)
Progressive disease (3)
Not evaluable  (4)
Not evaluated/not applicable  (5)
Unknown (6)
Autonomic neuropathy
Response  (1)
No response/stable disease  (2)
Progressive disease (3)
Not evaluable  (4)
Not evaluated/not applicable  (5)
Unknown (6)
Evidence of new organ involvement
Has patient or partner become pregnant after this
HSCT?
Yes  (1)
No  (2)
Unknown (3)
Survival Status
alive (0)
dead (1)
Type of score used
PERFORMANCE SCORE (if alive)
Karnofsky (1)
Lansky (2)
Score
100 (Normal, NED) (1)
10 (Moribund) (10)
Not evaluated (11)
Unknown (12)
90 (Normal activity)  (2)
80 (Normal with effort) (3)
70 (Cares for self) (4)
60 (Requires occasional assistance) (5)
50 (Requires assistance) (6)
40 (Disabled) (7)
30 (Severely disabled) (8)
20 (Very sick) (9)
CAUSE OF DEATH
(check only one main cause)
Due to amyloidosis (progression of
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disease) (1)
Secondary malignancy (including
lymphoproliferative disease) (2)
HSCT related cause (3)
unknown (4)
other (5)
cGvHD
Yes  (1)
No  (2)
Unknown (3)
Interstitial pneumonitis Cause of death
No  (1)
Yes (2)
Unknown (3)
Pulmonary toxicity Cause
Yes (1)
No (2)
Unknown (3)
Infection
Yes (1)
No (2)
Unknown (3)
Infection:
bacterial  (1)
viral  (2)
fungal  (3)
parasitic  (4)
unknown (5)
Rejection / poor graft function
Yes (1)
No (2)
Unknown (3)
Veno-Occlusive disease (VOD)
Yes (1)
No (2)
Unknown (3)
Haemorrhage
Yes (1)
No (2)
Unknown (3)
Cardiac toxicity
Yes (1)
No (2)
Unknown (3)
Central nervous system toxicity
Yes (1)
No (2)
Unknown (3)
Gastro intestinal toxicity
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Yes (1)
No (2)
Unknown (3)
Skin toxicity
Yes  (1)
No (2)
Unknown (3)
Renal failure
Yes (1)
No (2)
Unknown (3)
Multiple organ failure
Yes (1)
No (2)
Unknown (3)
If other HSCT related cause, please specify
ADDITIONAL NOTES IF APPLICABLE
Comments
IDENTIFICATION & SIGNATURE
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EBMT Amyloidosis
ODM form derived from Amyloidosis EBMT refer to:
http://www.ebmt.org/Contents/Data-
Management/Registrystructure/MED-
ABdatacollectionforms/Pages/MED-AB-data-collection-
forms.aspx
All rights reserved. Please visit https://medical-data-
models.org/forms/17011
EBMT Amyloidosis
GENERAL INFORMATION TEAM
EBMT Centre Identification Code (CIC)
Name of the hospital
Unit
Name of contact person
Telephone number
Fax
E-Mail
Date of this report
Patient following national / international study /
trial
No (1)
Yes (2)
Not evaluated (3)
Unknown (4)
Name of study / trial
GENERAL INFORMATION PATIENT
Unique Identification Code (UIC)
Hospital Unique Patient Number or Code
First name(s)_surname(s)
Date of birth
Sex
Male (1)
Female (2)
ABO Group
1 / 28
Rh factor
Yes
No
DISEASE
Date of diagnosis
Check the disease for which this transplant was
performed
Acute Leukaemia (Acute Leukaemia)
Acute Lymphoblastic Leukaemia (ALL)
(Acute Lymphoblastic Leukaemia (ALL))
Acute Myelogenous Leukaemia (AML)
(Acute Myelogenous Leukaemia (AML))
Autoimmune disease (Autoimmune
disease)
Bone marrow failure including Aplastic
anaemia (Bone marrow failure including
Aplastic anaemia)
Chronic Leukaemia (Chronic Leukaemia)
Chronic Lymphocytic Leukaemia
(Chronic Lymphocytic Leukaemia)
Chronic Myeloid Leukaemia (CML)
(Chronic Myeloid Leukaemia (CML))
Haemoglobinopathies
(Haemoglobinopathies)
Histiocytic disorders (Histiocytic
disorders)
Hodgkin´s Disease (Hodgkin´s Disease)
Inherited disorders (Inherited disorders)
Juvenile Idiopathic Arthritis (Juvenile
Idiopathic Arthritis)
Lymphoma (Lymphoma)
MD/ MPN (MD/ MPN)
MDS (MDS)
Metabolic disorders (Metabolic
disorders)
Multiple Sclerosis (Multiple Sclerosis)
Myelodysplastic syndromes
(Myelodysplastic syndromes)
Myeloma/ Plasma cell disorder
(Myeloma/ Plasma cell disorder)
Myeloproliferative neoplasm
(Myeloproliferative neoplasm)
Non Hodgkin (Non Hodgkin)
Other diagnosis (Other diagnosis)
Primary immune deficiencies (Primary
immune deficiencies)
Secondary Acute Leukaemia (do not use
if transformed from MDS/MPN)
(Secondary Acute Leukaemia (do not
use if transformed from MDS/MPN))
Solid Tumour (Solid Tumour)
Systemic Lupus (Systemic Lupus)
Systemic Sclerosis (Systemic Sclerosis)
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AL AMYLOIDOSIS INITIAL DIAGNOSIS
Has the information requested in this section
been submitted with a previous HSCT registration
for this patient?
Yes: go to page 3, Pre-HSCT Treatment
(1)
No: proceed with this section (2)
EVIDENCE OF UNDERLYING PLASMA CELL
DISORDER
Yes
No
In case of EVIDENCE OF UNDERLYING
PLASMA CELL DISORDER, please specify:
Monoclonal Gammopathy (Monoclonal
Gammopathy)
Multiple Myeloma (Multiple Myeloma)
Other B-cell malignancy (Other B-cell
malignancy)
If Other B-cell malignancy, specify
PLASMA CELL DISORDER
IgG (1)
IgA (2)
IgD (3)
IgE (4)
IgM (5)
Absent (6)
Not evaluated (7)
PLASMA CELL DISORDER light chain
Kappa (1)
Lambda (2)
Absent (3)
Not evaluated (4)
If Multiple myeloma: Stage at diagnosis (Salmon
and Durie) A
I (I)
II (II)
III (III)
If Multiple myeloma: Stage at diagnosis (Salmon
and Durie) B
Yes
No
DIAGNOSIS OF AMYLOIDOSIS
Excluded (1)
Not evaluated (2)
DIAGNOSIS OF AMYLOIDOSIS via
Immunohistochemistry
Done (Done)
Not evaluated (Not evaluated)
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CLINICAL AND LABORATORY DATA
Serum creatinine (1)
Serum c-Troponin T (μg/L) (10)
Hb (g/dL) (2)
Total urinary protein excretion (mg/24 h)
(3)
Total urinary albumin excretion (mg/24 h)
(4)
Serum calcium (mmol/L) (5)
Serum albumin (g/L) (6)
Serum alkaline phosphatase (IU/L) (7)
Serum bilirubin (8)
NT-proBNP  (ng/L) (9)
BM aspirate: % plasmacytosis
%
BM trephine % plasmacytosis
%
Monoclonal Ig in serum
g/L
Immunofixation of serum
Negative  (1)
Positive  (2)
Not evaluated  (3)
Unknown (4)
Free Kappa light chains in serum
mg/L
Not evaluated (1)
Lambda light chains
mg/L
Not evaluated (1)
Immunofixation of urine
Negative  (1)
Positive  (2)
Not evaluated  (3)
Unknown (4)
Monoclonal light chains in urine
g/24h
Serum Beta2 microglobulin
mg/L
Bone structure (X-ray)
Normal  (1)
Lytic lesion   (2)
Not evaluated  (3)
Unknown (4)
Macroglossia
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Absent  (1)
Present  (2)
Not evaluated  (3)
Unknown (4)
Periorbital bleeding
Absent  (1)
Present  (2)
Not evaluated  (3)
Unknown (4)
Shoulder pad sign
Absent  (1)
Present  (2)
Not evaluated  (3)
Unknown (4)
ORGAN INVOLVEMENT AT DIAGNOSIS
Soft Tissues
Additional organ involvement (Additional
organ involvement)
Biopsy (Biopsy)
Dominant organ(s) involved (Dominant
organ(s) involved)
No involvement (No involvement)
Gastrointestinal Tract
Dominant organ(s) involved (1)
Additional organ involvement (2)
Biopsy (3)
No involvement (4)
Heart
Dominant organ(s) involved (1)
Additional organ involvement (2)
Biopsy (3)
No involvement (4)
Liver
Dominant organ(s) involved (1)
Additional organ involvement (2)
Biopsy (3)
No involvement (4)
Kidney
Dominant organ(s) involved (1)
Additional organ involvement (2)
Biopsy (3)
No involvement (4)
Peripheral nerves
Dominant organ(s) involved (1)
Additional organ involvement (2)
Biopsy (3)
No involvement (4)
Autonomic nerves
Dominant organ(s) involved (1)
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Additional organ involvement (2)
Biopsy (3)
No involvement (4)
if other, please specify
Dominant organ(s) involved (1)
Additional organ involvement (2)
Biopsy (3)
No involvement (4)
Liver span in ultrasound or CT scan (cm
craniocaudal diameter)
Not evaluated (1)
NYHA class
I (1)
II (2)
III (3)
IV (4)
not done (99)
Left Ventricular Ejection Fraction
%
Interventricular septal wall thickness
mm
Weight loss
No  (1)
Yes  (2)
Not evaluated  (3)
Unknown (4)
Malabsorption
No  (1)
Yes  (2)
Not evaluated  (3)
Unknown (4)
GI bleeding
No  (1)
Yes  (2)
Not evaluated  (3)
Unknown (4)
If other evidence of gastrointestinal involvement,
please specify
Neurological exam
Abnormal  ( Abnormal )
Not evaluated or failed  ( Not evaluated
or failed )
Unknown ( Unknown)
Normal  (Normal )
Neurological exam: If abnormal:
Specify abnormality
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PNP severity
grade I  (1)
grade II  (2)
grade III  (3)
grade IV (4)
Orthostatic hypotension
Yes  (1)
No  (2)
Not evaluated  (3)
Unknown (4)
Intractable diarrhoea
Yes  (1)
No  (2)
Not evaluated  (3)
Unknown (4)
Inflexible pulse rate
Yes  (1)
No  (2)
Not evaluated  (3)
Unknown (4)
Clinical evidence for involvement of other sites
PRE-HSCT TREATMENT
WAS THE PATIENT TREATED BEFORE THE
HSCT PROCEDURE?
Yes
No
Chemotherapy
Yes
No
Modality Chemotherapy
Chemotherapy regimen (Chemotherapy
regimen)
Number of cycles (Number of cycles)
If Other Modality, please specify
HSCT
DATE OF HSCT
HSCT TYPE Allogeneic:
Yes
No
Autologous: Date of 1st collection or pheresis
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STATUS OF DISEASE AT COLLECTION
(AUTOGRAFTS ONLY)
Haematological status
>CR2  ( >CR2 VNUMSTM)
>PR2  ( >PR2 )
CR1  ( CR1 )
CR2  ( CR2 )
No change  ( No change )
PR1  ( PR1 )
Progression  ( Progression )
Unknown ( Unknown)
At diagnosis  (At diagnosis )
MR (MR)
PR2  (PR2 )
Organ status
Response  (2)
No change  (3)
Progression  (4)
Unknown (5)
STATUS OF DISEASE AT START OF
CONDITIONING FOR BMT
Haematological status
>CR2  ( >CR2 )
>PR2  ( >PR2 )
CR2  ( CR2 )
MR ( MR)
No change  ( No change )
PR1  ( PR1 )
PR2  ( PR2 )
At diagnosis  (At diagnosis )
CR1  (CR1 )
Progression  (Progression )
Unknown (Unknown)
Organ status
Response  (2)
No change  (3)
Progression  (4)
Unknown (5)
Hb
g/dl
CLINICAL AND LABORATORY DATA
Serum creatinine (1)
Serum c-Troponin T (μg/L) (10)
Hb (g/dL) (2)
Total urinary protein excretion (mg/24 h)
(3)
Total urinary albumin excretion (mg/24 h)
(4)
Serum calcium (mmol/L) (5)
Serum albumin (g/L) (6)
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Serum alkaline phosphatase (IU/L) (7)
Serum bilirubin (8)
NT-proBNP  (ng/L) (9)
BM aspirate: % plasmacytosis
%
BM trephine % plasmacytosis
%
Monoclonal Ig in serum
g/L
Immunofixation of serum
Negative  (1)
Positive  (2)
Not evaluated  (3)
Unknown (4)
Free Kappa light chains in serum
mg/L
Not evaluated (1)
Lambda light chains
mg/L
Not evaluated (1)
Immunofixation of urine
Negative  (1)
Positive  (2)
Not evaluated  (3)
Unknown (4)
Monoclonal light chains in urine
g/24h
Serum Beta2 microglobulin
mg/L
Soft Tissues
Additional organ involvement (Additional
organ involvement)
Biopsy (Biopsy)
Dominant organ(s) involved (Dominant
organ(s) involved)
No involvement (No involvement)
Gastrointestinal Tract
Dominant organ(s) involved (1)
Additional organ involvement (2)
Biopsy (3)
No involvement (4)
Heart
Dominant organ(s) involved (1)
Additional organ involvement (2)
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Biopsy (3)
No involvement (4)
Liver
Dominant organ(s) involved (1)
Additional organ involvement (2)
Biopsy (3)
No involvement (4)
Kidney
Dominant organ(s) involved (1)
Additional organ involvement (2)
Biopsy (3)
No involvement (4)
Peripheral nerves
Dominant organ(s) involved (1)
Additional organ involvement (2)
Biopsy (3)
No involvement (4)
Autonomic nerves
Dominant organ(s) involved (1)
Additional organ involvement (2)
Biopsy (3)
No involvement (4)
Liver span in ultrasound or CT scan (cm
craniocaudal diameter)
Not evaluated (1)
NYHA class
I (1)
II (2)
III (3)
IV (4)
not done (99)
Left Ventricular Ejection Fraction
%
Interventricular septal wall thickness
mm
Weight loss
No  (1)
Yes  (2)
Not evaluated  (3)
Unknown (4)
Malabsorption
No  (1)
Yes  (2)
Not evaluated  (3)
Unknown (4)
GI bleeding
No  (1)
Yes  (2)
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Not evaluated  (3)
Unknown (4)
If other evidence of gastrointestinal involvement,
please specify
Neurological exam
Abnormal  ( Abnormal )
Not evaluated or failed  ( Not evaluated
or failed )
Unknown ( Unknown)
Normal  (Normal )
Neurological exam: If abnormal:
Specify abnormality
PNP severity
grade I  (1)
grade II  (2)
grade III  (3)
grade IV (4)
Orthostatic hypotension
Yes  (1)
No  (2)
Not evaluated  (3)
Unknown (4)
Intractable diarrhoea
Yes  (1)
No  (2)
Not evaluated  (3)
Unknown (4)
Inflexible pulse rate
Yes  (1)
No  (2)
Not evaluated  (3)
Unknown (4)
Clinical evidence for involvement of other sites
STATUS OF DISEASE AT 100 DAYS
AFTER HSCT
BEST HAEMATOLOGICAL RESPONSE TO
HSCT AT 100 DAYS
>CR2 ( >CR2)
>PR2  ( >PR2 )
CR2  ( CR2 )
MR ( MR)
Progression  ( Progression )
Unknown ( Unknown)
CR1  (CR1 )
No change  (No change )
Not evaluable  (Not evaluable )
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PR1  (PR1 )
PR2  (PR2 )
DATE RESPONSE ACHIEVED OR ASSESSED
CLINICAL AND LABORATORY DATA
Serum creatinine (1)
Serum c-Troponin T (μg/L) (10)
Hb (g/dL) (2)
Total urinary protein excretion (mg/24 h)
(3)
Total urinary albumin excretion (mg/24 h)
(4)
Serum calcium (mmol/L) (5)
Serum albumin (g/L) (6)
Serum alkaline phosphatase (IU/L) (7)
Serum bilirubin (8)
NT-proBNP  (ng/L) (9)
Serum creatinine
Creatinine clearance (mL/min)
Total urinary protein excretion (mg/24 h)
Total urinary albumin excretion (mg/24 h)
Serum NT-pro-BNP (ng/L)
CLINICAL AND LABORATORY DATA
Serum c-Troponin T (μg/L)
CLINICAL AND LABORATORY DATA
BM aspirate: % plasmacytosis
%
BM trephine % plasmacytosis
%
Monoclonal Ig in serum
g/L
Immunofixation of serum
Negative  (1)
Positive  (2)
Not evaluated  (3)
Unknown (4)
Free Kappa light chains in serum
mg/L
Not evaluated (1)
Lambda light chains
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mg/L
Not evaluated (1)
Immunofixation of urine
Negative  (1)
Positive  (2)
Not evaluated  (3)
Unknown (4)
Monoclonal light chains in urine
g/24h
Serum Beta2 microglobulin
mg/L
ORGAN-SPECIFIC RESPONSES AT 100
DAYS AFTER HSCT
Kidney
Response  (1)
No response/stable disease  (2)
Progressive disease (3)
Not evaluable  (4)
Not evaluated/not applicable  (5)
Unknown (6)
Liver
Liver span in ultrasound or CT scan (cm
craniocaudal diameter)
Hepatic response
Response  (1)
No response/stable disease  (2)
Progressive disease (3)
Not evaluable  (4)
Not evaluated/not applicable  (5)
Unknown (6)
Heart
NYHA class
I (I)
II (II)
III (III)
IV (IV)
Unknown (Unknown)
Left ventricular ejection fraction
%
Interventricular septal wall thickness
(mean # mm in echocardiogram)
Cardiac response
No response/stable disease  ( No
response/stable disease )
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Not evaluable  ( Not evaluable )
Not evaluated/not applicable  ( Not
evaluated/not applicable )
Progressive disease ( Progressive
disease)
Unknown ( Unknown)
Response  (Response )
Weight loss
No  (1)
Yes  (2)
Not evaluated  (3)
Unknown (4)
Malabsorption
No  (1)
Yes  (2)
Not evaluated  (3)
Unknown (4)
GI bleeding
No  (1)
Yes  (2)
Not evaluated  (3)
Unknown (4)
GI response
Response  (1)
No response/stable disease  (2)
Progressive disease (3)
Not evaluable  (4)
Not evaluated/not applicable  (5)
Unknown (6)
Neurological exam
Peripheral neuropathy
(Compare current situation to situation before
HSCT)
Improved  (1)
Worsened  (2)
Unchanged  (3)
Unknown (4)
PNP severity
Peripheral neuropathy
(Compare current situation to situation before
HSCT)
grade I  (1)
grade II  (2)
grade III  (3)
grade IV (4)
PN response
Peripheral neuropathy
(Compare current situation to situation before
HSCT)
No response/stable disease  (No
response/stable disease )
Not evaluable  (Not evaluable )
Not evaluated/not applicable  (Not
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evaluated/not applicable )
Progressive disease (Progressive
disease)
Response  (Response )
Unknown (Unknown)
AN response
Autonomic neuropathy
No response/stable disease  (No
response/stable disease )
Not evaluable  (Not evaluable )
Not evaluated/not applicable  (Not
evaluated/not applicable )
Progressive disease (Progressive
disease)
Response  (Response )
Unknown (Unknown)
Clinical evidence for involvement of new sites
Evidence of new organ involvement
KARNOFSKY
FORMS TO BE FILLED IN
Type of Transplant
ALLOgraft or Syngeneic graft (proceed to
Allograft form) (ALLOgraft or Syngeneic
graft (proceed to Allograft form))
AUTOgraft (proceed to Autograft form)
(AUTOgraft (proceed to Autograft form))
Other (contact the EBMT Central
Registry for instructions) (Other (contact
the EBMT Central Registry for
instructions))
FOLLOW UP AL AMYLOIDOSIS
Unique Identification Code (UIC)
(if known)
Hospital Unique Patient Number
Initials
Date of birth
Date of HSCT
PATIENT LAST SEEN
15 / 28
EBMT Amyloidosis
Date of Last Contact or Death
Complete haematological remission obtained
after the HSCT in the absence of additional
disease treatment
Previously reported (1)
Yes, date (2)
No (3)
Unknown (4)
GRAFT VERSUS HOST DISEASE
(GvHD) SINCE LAST REPORT
Maximum Grade of Acute GVHD
Agvhd Grade 0 (0)
Agvhd Grade I (I)
Agvhd Grade Ii (II)
Agvhd Grade Iii (III)
Agvhd Grade Iv (IV)
Agvhd Present, Grade Unknown
(Present, grade unknown)
If present type of GvHD
New onset  (1)
Recurrent  (2)
Persistent (3)
Reason for aGvHD
DLI (DLI)
Tapering (Tapering)
Unexplained (Unexplained)
Date onset of this episode (if new or recurrent)
yyyy/mm/dd
aGvHD Stage
Stage skin (1)
Stage liver (2)
Stage gut (3)
aGvHD Resolution
No  (1)
Yes (2)
Date of resolution
yyyy/mm/dd
Presence of cGvHD
No (No)
Present continously since last reported
episode (Present continously since last
reported episode)
Resolved (Resolved)
Yes (Yes)
Presence of cGVHD if yes
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First episode (1)
Recurrence (2)
cGvHD Date of onset
yyyy/mm/dd
cGvHD grade
limited (1)
Extensive (2)
Organs affected
Skin (1)
Gut (2)
Liver (3)
Mouth (4)
Eyes (5)
Lung (6)
Other, specify (7)
Unknown (8)
If resolved, specify the date of resolution:
OTHER COMPLICATIONS SINCE LAST
REPORT
Infection related complications
Yes
No
Bacteraemia / fungemia / viremia / parasites
Pathogen (1)
Date (2)
Septic shock
Pathogen (1)
Date (2)
ARDS
Pathogen (1)
Date (2)
Multiorgan failure due to infection
Pathogen (1)
Date (2)
Pneumonia
Pathogen (1)
Date (2)
Hepatitis
Pathogen (1)
Date (2)
CNS infection
Pathogen (1)
Gut infection
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Pathogen (1)
Date (2)
Skin infection
Pathogen (1)
Date (2)
Date
Provide different dates for different episodes of
the same complication if applicable.
Cystitis
Pathogen (1)
Date (2)
Retinitis
Pathogen (1)
Date (2)
Other
Pathogen (1)
Date (2)
Non infection related complications
Yes
No
CTC grade Cardiovascular
0 (1)
1 (2)
2 (3)
3 (4)
4 (5)
Date Cardiovascular
Cardiovascular comments
CTC grade Dermatologic
0 (1)
1 (2)
2 (3)
3 (4)
4 (5)
Date Dermatologic
Comments
CTC grade Gastrointestinal
0 (1)
1 (2)
2 (3)
3 (4)
4 (5)
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Date Gastrointestinal
Gastrointestinal Comments
CTC grade Haemorrhage
0 (1)
1 (2)
2 (3)
3 (4)
4 (5)
Date Haemorrhage
Haemorrhage Comments
CTC grade Hepatic
0 (1)
1 (2)
2 (3)
3 (4)
4 (5)
Date Hepatic
Hepatic Comments
CTC grade Neurologic
0 (1)
1 (2)
2 (3)
3 (4)
4 (5)
Date Neurologic
Neurologic Comments
CTC grade Pulmonary
0 (1)
1 (2)
2 (3)
3 (4)
4 (5)
Pulmonary Date
Pulmonary Comments
CTC grade Renal
0 (1)
1 (2)
2 (3)
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3 (4)
4 (5)
Renal Date
Renal Comments
Other CTC grade
0 (1)
1 (2)
2 (3)
3 (4)
4 (5)
Date of other Type
Comments of Other type
Graft loss
No (No)
Not evaluated (Not evaluated)
Yes (Yes)
Overall chimaerism
Full (donor >95 %)  (1)
Mixed (partial) (2)
Autologous reconstitution (recipient >95
%)  (3)
Aplasia (4)
Not evaluated (5)
GRAFT ASSESSMENT AND
HAEMOPOIETIC CHIMAERISM
Date of Test
Identification of donor or Cord Blood Unit given
by the centre
Number in the infusion order (if applicable)
Cell type on which test was performed
BM
%
Bone marrow (1)
Other (10)
PB mononuclear cells (PBMC) (2)
T-cell (3)
B-cells (4)
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Red blood cells (5)
Monocytes (6)
PMNs (neutrophils) (7)
Lymphocytes (8)
Myeloid cells (9)
Laboratory tests used:
ABO group (ABO group)
Cytogenetic (Cytogenetic)
FISH (FISH)
Molecular (Molecular)
Other (Other)
unknown (unknown)
SECONDARY MALIGNANCY,
LYMPHOPROLIFERATIVE OR
MYELOPROLIFRATIVE DISORDER
DIAGNOSED
Previously reported (1)
Yes (2)
No at date of this follow-up (3)
Date of diagnosis
Diagnosis Secondary Malignant Neoplasm
AML  (1)
MDS  (2)
Lymphoproliferative disorder  (3)
Other (4)
If other diagnosis, please specify
ADDITIONAL THERAPIES SINCE LAST
FOLLOW UP
Treatment given since last report
No (No)
Unknown (Unknown)
Yes (Yes)
Date started
If yes: CELLULAR THERAPY
One cell therapy regimen is defined as any
number of infusions given within 10 weeks for the
same indication. If more than one regimen of cell
therapy has been given since last report, copy
this section and complete it as many times as
necessary.
No (1)
Yes (2)
Unknown (3)
Disease status before this cellular therapy
CR  (1)
Not in CR  (2)
Not evaluated (3)
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If yes: Type of cells
Donor lymphocyte infusion (DLI) (1)
Mesenchymal cells (2)
Other (3)
Unknown (4)
If DLI, specify the number of cells infused by
type:
Nucleated cells
Evaluated (Evaluated)
Not evaluated (Not evaluated)
unknown (unknown)
Number of cells infused by type
Nucleated cells (1)
CD 34+ (2)
CD 3+ (3)
Total number of cells
Evaluated (Evaluated)
Not Evaluated (Not Evaluated)
Unknown (Unknown)
Chronological number of this cell therapy for this
patient
Indication 
(check all that apply)
Loss/decreased chimaerism
(Loss/decreased chimaerism)
Mixed chimaerism (Mixed chimaerism)
Other (Other)
Planned/ protocol (Planned/ protocol)
Prophylactic (Prophylactic)
Treatment for disease (Treatment for
disease)
Treatment of GvHD (Treatment of GvHD)
Treatment PTLD, EBV, lymphoma
(Treatment PTLD, EBV, lymphoma)
Treatment viral infection (Treatment viral
infection)
Number of infusions within 10 weeks (count only
infusions that are part of same regimen and given
for the same indication)
Maximum Grade of Acute GVHD
Agvhd Grade 0 (0)
Agvhd Grade I (I)
Agvhd Grade Ii (II)
Agvhd Grade Iii (III)
Agvhd Grade Iv (IV)
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Agvhd Present, Grade Unknown
(Present, grade unknown)
Disease treatment (apart from donor cell infusion
or other type of cell therapy)
No (1)
Yes: Planned (planned before HSCT took
place) (2)
Yes: Not planned (for
relapse/progression or persistent
disease) (3)
FIRST EVIDENCE OF DISEASE
WORSENING SINCE LAST HSCT
EVIDENCE OF DISEASE ACTIVITY
Continuous worsening since HSCT
(Continuous worsening since HSCT)
No (No)
Previously reported (Previously reported)
Unknown (Unknown)
Yes (Yes)
If yes, date first noted
LAST DISEASE AND PATIENT STATUS
HAEMATOLOGICAL DISEASE STATUS
Complete remission (Complete
remission)
Not evaluable (Not evaluable)
Partial remission (Partial remission)
Progression (Progression)
Stable disease (Stable disease)
Unknown (Unknown)
Organ Response
Response (1)
Non Response (2)
Progression (3)
Not evaluable (4)
Unknown (5)
CLINICAL AND LABORATORY DATA
Serum creatinine (1)
Serum c-Troponin T (μg/L) (10)
Hb (g/dL) (2)
Total urinary protein excretion (mg/24 h)
(3)
Total urinary albumin excretion (mg/24 h)
(4)
Serum calcium (mmol/L) (5)
Serum albumin (g/L) (6)
Serum alkaline phosphatase (IU/L) (7)
Serum bilirubin (8)
NT-proBNP  (ng/L) (9)
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BM aspirate: % plasmacytosis
%
BM trephine % plasmacytosis
%
Monoclonal Ig in serum
g/L
Immunofixation of serum
Negative  (1)
Positive  (2)
Not evaluated  (3)
Unknown (4)
Free Kappa light chains in serum
mg/L
Not evaluated (1)
Lambda light chains
mg/L
Not evaluated (1)
Immunofixation of urine
Negative  (1)
Positive  (2)
Not evaluated  (3)
Unknown (4)
Monoclonal light chains in urine
g/24h
Serum Beta2 microglobulin
mg/L
Renal response
Response (1)
No response/stable disease (2)
Progressive disease (3)
Not evaluable (4)
Not evaluated/not applicable (5)
Unknown (6)
Liver span 
(cm craniocaudal diameter)
Hepatic response
No response/stable disease (No
response/stable disease)
Not evaluable (Not evaluable)
Not evaluated/not applicable (Not
evaluated/not applicable)
Progressive disease (Progressive
disease)
Response (Response)
Unknown (Unknown)
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NYHA class
I (1)
II (2)
III (3)
IV (4)
unknown (5)
Left Ventricular Ejection Fraction
%
Interventricular septal wall thickness
(mean # mm in echocardiogram)
Cardiac response
Response  (1)
No response/stable disease  (2)
Progressive disease (3)
Not evaluable  (4)
Not evaluated/not applicable  (5)
Unknown (6)
Weight loss
No  (1)
Yes  (2)
Not evaluated  (3)
Unknown (4)
Malabsorption
No  (1)
Yes  (2)
Not evaluated  (3)
Unknown (4)
GI bleeding
No  (1)
Yes  (2)
Not evaluated  (3)
Unknown (4)
GI response
Response  (1)
No response/stable disease  (2)
Progressive disease (3)
Not evaluable  (4)
Not evaluated/not applicable  (5)
Unknown (6)
Neurological exam
Improved  (1)
Worsened  (2)
Unchanged  (3)
Unknown (4)
PNP severity
grade I  (1)
grade II  (2)
grade III  (3)
grade IV (4)
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PN response
Response  (1)
No response/stable disease  (2)
Progressive disease (3)
Not evaluable  (4)
Not evaluated/not applicable  (5)
Unknown (6)
Autonomic neuropathy
Response  (1)
No response/stable disease  (2)
Progressive disease (3)
Not evaluable  (4)
Not evaluated/not applicable  (5)
Unknown (6)
Evidence of new organ involvement
Has patient or partner become pregnant after this
HSCT?
Yes  (1)
No  (2)
Unknown (3)
Survival Status
alive (0)
dead (1)
Type of score used
PERFORMANCE SCORE (if alive)
Karnofsky (1)
Lansky (2)
Score
100 (Normal, NED) (1)
10 (Moribund) (10)
Not evaluated (11)
Unknown (12)
90 (Normal activity)  (2)
80 (Normal with effort) (3)
70 (Cares for self) (4)
60 (Requires occasional assistance) (5)
50 (Requires assistance) (6)
40 (Disabled) (7)
30 (Severely disabled) (8)
20 (Very sick) (9)
CAUSE OF DEATH
(check only one main cause)
Due to amyloidosis (progression of
disease) (1)
Secondary malignancy (including
lymphoproliferative disease) (2)
HSCT related cause (3)
unknown (4)
other (5)
cGvHD
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Yes  (1)
No  (2)
Unknown (3)
Interstitial pneumonitis Cause of death
No  (1)
Yes (2)
Unknown (3)
Pulmonary toxicity Cause
Yes (1)
No (2)
Unknown (3)
Infection
Yes (1)
No (2)
Unknown (3)
Infection:
bacterial  (1)
viral  (2)
fungal  (3)
parasitic  (4)
unknown (5)
Rejection / poor graft function
Yes (1)
No (2)
Unknown (3)
Veno-Occlusive disease (VOD)
Yes (1)
No (2)
Unknown (3)
Haemorrhage
Yes (1)
No (2)
Unknown (3)
Cardiac toxicity
Yes (1)
No (2)
Unknown (3)
Central nervous system toxicity
Yes (1)
No (2)
Unknown (3)
Gastro intestinal toxicity
Yes (1)
No (2)
Unknown (3)
Skin toxicity
Yes  (1)
No (2)
Unknown (3)
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Renal failure
Yes (1)
No (2)
Unknown (3)
Multiple organ failure
Yes (1)
No (2)
Unknown (3)
If other HSCT related cause, please specify
ADDITIONAL NOTES IF APPLICABLE
Comments
IDENTIFICATION & SIGNATURE
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Eligibility Depression NCT00158301
Cognitive Behavioral Therapy for Depression Relapse
Prevention in Children and Adolescents; ODM derived
from: https://clinicaltrials.gov/show/NCT00158301
All rights reserved. Please visit https://medical-data-
models.org/forms/17012
Eligibility Depression NCT00158301
Inclusion Criteria
diagnosis of nonpsychotic major depressive
disorder at least 4 weeks prior to study entry*
Yes
No
clinical global impression severity score of 4 or
greater*
Yes
No
children's depression rating scale score of 40 or
greater*
Yes
No
currently attending school*
Yes
No
willing and able to use acceptable methods of
contraception, if applicable*
Yes
No
in good general health*
Yes
No
parent or guardian willing to provide informed
consent, if applicable*
Yes
No
Exclusion Criteria
history of psychotic disorders*
Yes
No
alcohol or substance abuse or dependence within
6 months prior to study entry*
Yes
No
history of anorexia nervosa or bulimia*
Yes
No
chronic medical illness requiring regular
medication*
Yes
No
1 / 2
current use of medication with psychotropic
effects*
Yes
No
first-degree relatives (e.g., mother, father, sister,
brother) with bipolar i disorder*
Yes
No
at risk for suicide*
Yes
No
failure of a previous adequate treatment with
fluoxetine (defined as at least 40 mg/day for 4
weeks)*
Yes
No
iq less than 80*
Yes
No
pregnancy or breastfeeding*
Yes
No
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End of Study Form 5 Tolerability of QUTENZA™ When Applied After Pre-treatment
With Lidocaine or Tramadol in Subjects With Peripheral Neuropathic Pain - A
Randomized, Multi-center, Assessor-blinded Study NCT01416116
Study Sponsor: Astellas
Study Title
Tolerability of QUTENZA™ When Applied After Pre-
treatment With Lidocaine or Tramadol in Subjects With
Peripheral Neuropathic Pain - A Randomized, Multi-center,
Assessor-blinded Study
Medicine or Vaccine (generic name)
capsaicin
Sponsor Identification Number
QTZ-EC-0002
Trial Registry Identification Number(#'s)
NCT01416116
EudraCT Number: 2010-023258-34
Medical Condition
Neuropathic pain
Phase
Phase 4
http://clinicaltrials.gov/show/NCT01416116
End of Study
End of Study
All rights reserved. Please visit https://medical-data-
models.org/forms/17013
End of Study Form 5  Tolerability of
QUTENZA™ When Applied After
Pre-treatment With Lidocaine or
Tramadol in Subjects With Peripheral
Neuropathic Pain - A Randomized,
Multi-center, Assessor-blinded Study
NCT01416116
End of Study
Did subject complete the study?
no (0)
yes (1)
Withdrawal Date
Primary Reason for Withdrawal
undefined item
Adverse event (1 )
Withdrawal of consent (2 )
Subject lost to follow up (3 )
Protocol violation (4 )
Pregnancy (5 )
Other (6 )
If 'Protocol Violation', specify
If 'Other', specify
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ODM form derived from EBMT Allograft. please refer to:
http://www.ebmt.org/Contents/Data-
Management/Registrystructure/MED-
ABdatacollectionforms/Pages/MED-AB-data-collection-
forms.aspx
All rights reserved. Please visit https://medical-data-
models.org/forms/17016
EBMT Allograft
ANTIBODIES IN THE PATIENT
HIV
Negative  (Negative )
Not evaluated  (Not evaluated )
Positive  (Positive )
Unknown (Unknown)
HIV ANTIGENS
(if testing applicable)
Negative  (Negative )
Not evaluated  (Not evaluated )
Positive  (Positive )
Unknown (Unknown)
CMV
Negative  (Negative )
Not evaluated  (Not evaluated )
Positive  (Positive )
Unknown (Unknown)
EBV
Negative  (Negative )
Not evaluated  (Not evaluated )
Positive  (Positive )
Unknown (Unknown)
HBVs
Negative  (Negative )
Not evaluated  (Not evaluated )
Positive  (Positive )
Unknown (Unknown)
HBVs ANTIGENS (if testing applicable)
Negative  (Negative )
Not evaluated  (Not evaluated )
Positive  (Positive )
Unknown (Unknown)
HBVc
Negative  (Negative )
Not evaluated  (Not evaluated )
Positive  (Positive )
Unknown (Unknown)
HBVe
Negative  (Negative )
Not evaluated  (Not evaluated )
Positive  (Positive )
Unknown (Unknown)
HCV
Negative (Negative)
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Not evaluated  (Not evaluated )
Positive (Positive)
Unknown (Unknown)
HCV ANTIGENS  (if testing applicable)
Negative (Negative)
Not evaluated  (Not evaluated )
Positive (Positive)
Unknown (Unknown)
HTLV
Negative  (Negative )
Not evaluated  (Not evaluated )
Positive  (Positive )
Unknown (Unknown)
Toxoplasmosis
Negative  (Negative )
Not evaluated  (Not evaluated )
Positive  (Positive )
Unknown (Unknown)
if other Antibodies in the patient
Negative  (Negative )
Positive  (Positive )
Specify (Specify)
PRE-TRANSPLANT HISTORY OF
DOCUMENTED INVASIVE FUNGAL
INFECTION SINCE INITIAL DIAGNOSIS
PRE-TRANSPLANT HISTORY OF
DOCUMENTED INVASIVE FUNGAL INFECTION
SINCE INITIAL DIAGNOSIS
No (No)
Unknown (Unknown)
Yes (Yes)
Candida
No (No)
Unknown (Unknown)
Yes  (Yes )
Aspergillus
No (No)
Unknown (Unknown)
Yes (Yes)
Pneumocystis carinii
No  (No )
Unknown (Unknown)
Yes  (Yes )
Other
Yes
No
Other if yes, please specify
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PERFORMANCE SCORE
Type of score used
Karnofsky (Karnofsky)
Lansky (Lansky)
Not evaluated (Not evaluated)
Unknown (Unknown)
Score
100 (Normal, NED) (1)
10 (Moribund) (10)
Not evaluated (11)
Unknown (12)
90 (Normal activity)  (2)
80 (Normal with effort) (3)
70 (Cares for self) (4)
60 (Requires occasional assistance) (5)
50 (Requires assistance) (6)
40 (Disabled) (7)
30 (Severely disabled) (8)
20 (Very sick) (9)
Weight
kg
Height
>= 0
cm
DONOR AND STEM CELL SOURCE
Multiple donors
Yes
No
different stem cell products of same donor or cord
blood units
SOURCE OF STEM CELLS FOR THIS
DONOR/PRODUCT
Bone marrow (Bone marrow)
Cord blood (Cord blood)
Peripheral blood (Peripheral blood)
Identification of Donor or Cord Blood Unit
Number in the infusion order
HLA MATCH TYPE
> 2 HLA antigen mismatch (> 2 HLA
antigen mismatch)
1 HLA antigen mismatch ALLMISRL (1
HLA antigen mismatch ALLMISRL)
HLA-identical sibling (may include non-
monozygotic twin) (HLA-identical sibling
(may include non-monozygotic twin))
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HLA-matched other relative (HLA-
matched other relative)
HLA-mismatched relative:Degree of
allele mismatch (HLA-mismatched
relative:Degree of allele mismatch)
Syngeneic (monozygotic twin)
(Syngeneic (monozygotic twin))
Unrelated donor (Unrelated donor)
Name of the Donor registry
BMDW / WMDA code for the donor registry (up to
4 characters)
Name of the Cord blood bank
Eurocord code for the cord blood bank
HLA MISMATCHES BETWEEN DONOR
AND PATIENT
Serology A
match (0)
one mismatch (1)
2 mismatches (2)
not evaluated (N/E)
Serology B
match (0)
one mismatch (1)
2 mismatches (2)
not evaluated (N/E)
Serology C
match (0)
one mismatch (1)
2 mismatches (2)
not evaluated (N/E)
Serology DRB1
match  (0)
one mismatch (1)
2 mismatches  (2)
not evaluated (N/E)
Serology DQB1
match  (0)
one mismatch (1)
2 mismatches  (2)
not evaluated (N/E)
Serology DPB1
match  (0)
one mismatch (1)
2 mismatches  (2)
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not evaluated (N/E)
DNA A
match  (0)
one mismatch (1)
2 mismatches  (2)
not evaluated (N/E)
DNA B
match  (0)
one mismatch (1)
2 mismatches  (2)
not evaluated (N/E)
DNA C
match  (0)
one mismatch (1)
2 mismatches  (2)
not evaluated (N/E)
DNA DRB1
match  (0)
one mismatch (1)
2 mismatches  (2)
not evaluated (N/E)
DNA DQB1
match  (0)
one mismatch (1)
2 mismatches  (2)
not evaluated (N/E)
DNA DPB1
match  (0)
one mismatch (1)
2 mismatches  (2)
not evaluated (N/E)
BLOOD GROUP, DATE OF BIRTH AND
SEX OF DONOR
ABO group
A (A)
AB (AB)
B (B)
O (O)
Date of birth
Sex
Male (1)
Female (2)
STATUS OF THE DONOR OR CORD
BLOOD UNIT BEFORE HSCT
HIV
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Negative  (Negative )
Not evaluated  (Not evaluated )
Positive  (Positive )
Unknown (Unknown)
HIV ANTIGENS
(if testing applicable)
Negative  (Negative )
Not evaluated  (Not evaluated )
Positive  (Positive )
Unknown (Unknown)
CMV
Negative  (Negative )
Not evaluated  (Not evaluated )
Positive  (Positive )
Unknown (Unknown)
EBV
Negative  (Negative )
Not evaluated  (Not evaluated )
Positive  (Positive )
Unknown (Unknown)
HBVs
Negative  (Negative )
Not evaluated  (Not evaluated )
Positive  (Positive )
Unknown (Unknown)
HBVs ANTIGENS (if testing applicable)
Negative  (Negative )
Not evaluated  (Not evaluated )
Positive  (Positive )
Unknown (Unknown)
HBVc
Negative  (Negative )
Not evaluated  (Not evaluated )
Positive  (Positive )
Unknown (Unknown)
HBVe
Negative  (Negative )
Not evaluated  (Not evaluated )
Positive  (Positive )
Unknown (Unknown)
HCV
Negative (Negative)
Not evaluated  (Not evaluated )
Positive (Positive)
Unknown (Unknown)
HCV ANTIGENS  (if testing applicable)
Negative (Negative)
Not evaluated  (Not evaluated )
Positive (Positive)
Unknown (Unknown)
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HTLV
Negative  (Negative )
Not evaluated  (Not evaluated )
Positive  (Positive )
Unknown (Unknown)
Toxoplasmosis
Negative  (Negative )
Not evaluated  (Not evaluated )
Positive  (Positive )
Unknown (Unknown)
if other Antibodies in the patient
Negative  (Negative )
Positive  (Positive )
Specify (Specify)
Date of harvest or cord blood collection
GROWTH FACTORS ADMINISTERED TO THE
DONOR
No (No)
Unknown (Unknown)
Yes (Yes)
HISTOCOMPATIBILITY RESULTS
Laboratory / Hospital
Unit
Contact number
Technique Used
Serology (antigenic) HLA typing done
Yes
No
DNA (Allelic/molecular) HLA typing done
DNA (Allelic/molecular) HLA typing done
Yes
No
DNA (Allelic/molecular) HLA typing done: Locus
A (A)
B (B)
C (C)
DPB1 (DPB1)
DQB1 (DQB1)
DRB1 (DRB1)
HLA string
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NMDP code
Serology (antigenic) HLA typing done
Serology (antigenic) HLA typing done
Yes
No
HLA Serology
A (A)
B (B)
C (C)
DPB1 (DPB1)
DQB1 (DQB1)
DRB1 (DRB1)
GRAFT MANIPULATION
Identification of donor or Cord Blood Unit given
by the centre
Number in the infusion order (if applicable)
GRAFT MANIPULATION EX-VIVO (INCLUDING
T-CELL DEPLETION)
Yes
No
NEGATIVE SELECTION
No  (No )
Unknown (Unknown)
Yes (Yes)
if negative selection, specify
B-cell depletion by MoAB  (B-cell
depletion by MoAB )
Elutriation  (Elutriation )
NK cell depletion by MoAB  (NK cell
depletion by MoAB )
Other (Other)
T-cell depletion by MoAB (do not enter
(T-cell depletion by MoAB (do not enter )
if positive selection, splease specify:
No (No)
unknown (unknown)
Yes: Monoclonal antibodies (Yes:
Monoclonal antibodies)
Monoclonal antibodies
No (No)
Unknown (Unknown)
Yes (Yes)
Monoclonal antibodies: if yes
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CD 34+  (CD 34+ )
Other (Other)
EXPANSION
No (No)
Unknown (Unknown)
Yes (Yes)
GENE MANIPULATION (gene
transfer/transduction)
No (No)
Unknown (Unknown)
Yes (Yes)
CELL INFUSION
IF MULTIPLE DONORS: Identification of donor or
Cord Blood Unit given by the centre (please, use
same ID as in the preceding sheets)
Number in the infusion order (if applicable)
CELL INFUSION METHOD
Fill in for Cord Blood HSCT only
intrabone / intramedullary (intrabone /
intramedullary)
Intravenous (IV) (Intravenous (IV))
Other, specify (Other, specify)
unknown (unknown)
Route of infusion: If other, please specify:
Infusion method
DMSO (DMSO)
Other, specify (Other, specify)
Wash (Rubinstein/New York) (Wash
(Rubinstein/New York))
Infusion method: if other, please specify
CELL VIABILITY RESULTS AT HSCT
CENTRE
Tests performed after thawing of an aliquot on
Contiguous segment  (Contiguous
segment )
Reference bag  (Reference bag )
unknown (unknown)
Method used
7-AAD (7-AAD)
Acridine orange-ethidium bromide
(Acridine orange-ethidium bromide)
Acridine orange-ethidium iodide
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(Acridine orange-ethidium iodide)
Other, specify (Other, specify)
Trypan blue (Tryptan blue)
unknown (unknown)
Viability of all cells
Viability of CD34+ cells
CELLS INFUSED FROM THIS DONOR
AND STEM CELL SOURCE
COMBINATION
Bone Marrow: Total number of cells actually
infused
CD 34+ (cells/kg*)    (1)
Nucleated cells (/kg*) (2)
T-cells (CD 3+) (cells/kg*) (3)
Bone Marrow: Total number of cells actually
infused, specify:
Not evaluated  (Not evaluated )
unknown (unknown)
Peripheral Blood: Total number of cells actually
infused
T-cells (CD 3+) (cells/kg*)  (1)
Nucleated cells (/kg*) (2)
CD 34+ (cells/kg*) (3)
Peripheral Blood: Total number of cells actually
infused
unknown (1)
not evluated (2)
Cord Blood: Total number of cellsactually infused
CD 34+ (cells/kg*)    (1)
Nucleated cells (/kg*) (2)
T-cells (CD 3+) (cells/kg*) (3)
Cord Blood: Total number of cellsa ctually infused
Not evaluated  (Not evaluated )
unknown (unknown)
HSC TRANSPLANTATION
Chronological number of HSCT for this patient
Donor the same as for previous HSCT?
No  (No )
Previous HSCT(s) autologous (Previous
HSCT(s) autologous)
Yes  (Yes )
Date of previous HSCT
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Type of previous HSCT
Allo (Allo)
Auto (Auto)
Reason for this transplant
Graft failure after allo BMT (Graft failure
after allo BMT)
Other (Other)
Relapse/progression after previous
HSCT (Relapse/progression after
previous HSCT)
HSCT part of a multiple sequential graft protocol
No (No)
Unknown (Unknown)
Yes (Yes)
Type of multiple graft protocol
Graft number in the protocol
total number of HSCTs in the program
PREPARATIVE TREATMENT
(conditioning)
PREPARATIVE (CONDITIONING) REGIMEN
GIVEN
Yes
No
Was regimen intended to be myeloablative
No (No)
Unknown (Unknown)
Yes (Yes)
Reason not myeloablative
Age of recipient (Age of recipient)
Comorbid conditions (Comorbid
conditions)
Other, specify (Other, specify)
Prior HSCT (Prior HSCT)
Protocol driven (Protocol driven)
Drugs
No (No)
Unknown (Unknown)
Yes (Yes)
Drugs
NAME OF DRUG
PRESCRIBED CUMULATIVE DOSE AS PER
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PROTOCOL (DAILY DOSE BY NUMBER OF
DAYS)
IF MONOCLONAL ANTIBODY, RADIO
LABELLED?
No (1)
Yes (2)
Unknown (3)
UNITS IF RADIO LABELLED
mCi (1)
mBq (2)
Route of administration
Both (Both)
IV  (IV )
Oral  (Oral )
Animal origin
Horse  (Horse )
Other, specify (Other, specify)
Rabbit  (Rabbit )
TBI
No  (No )
Unknown (Unknown)
Yes  (Yes )
Total dose (Gy)
Number of fractions
radiation days
TLI / TNI / TAI
No (No)
Unknown (Unknown)
Yes (Yes)
Local radiotherapy
No  (No )
Unknown (Unknown)
Yes  (Yes )
TREATMENT DURING THE IMMEDIATE
POST-TRANSPLANT PERIOD
GROWTH FACTORS (CYTOKINES)
nknown (nknown)
No (No)
Yes (Yes)
GROWTH FACTORS: If yes, please specify
Date started
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CELLULAR THERAPY
No (No)
Unknown (Unknown)
Yes (Yes)
Date of first infusion
CELLULAR THERAPY: if yes, specify:
Donor lymphocyte infusion (DLI) (only
lymphocytes from same donor(s) as
HSCT) (Donor lymphocyte infusion (DLI)
(only lymphocytes from same donor(s)
as HSCT))
Mesenchymal cells (Mesenchymal cells)
Other (Other)
Unknown (Unknown)
Number of cells infused by type
Nucleated cells
/kg*
Nucleated cells
(/kg*
Not evaluated (Not evaluated)
unknown (unknown)
CD 34+ (cells/kg*)
cells/kg*
CD 34+ (cells/kg*)
cells/kg*
Not evaluated (1)
unknown (2)
CD 3+ (cells/kg*)
cells/kg*
CD 3+ (cells/kg*)
cells/kg*
Not evaluated (1)
unknown (2)
Total number of cells infused
All cells (cells/kg*)
(non DLI only)
cells/kg*
Chronological number of this cell therapy for this
patient
Indication
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Loss/decreased chimaerism
(Loss/decreased chimaerism )
Mixed chimaerism (Mixed chimaerism)
Other (Other)
Planned/protocol  (Planned/protocol )
Treatment for disease (Treatment for
disease)
Treatment of GvHD  (Treatment of GvHD
)
Treatment PTLD, EBV lymphoma
(Treatment PTLD, EBV lymphoma)
Treatment viral infection (Treatment viral
infection)
Number of infusions within 10 weeks
count only infusions that are part of same
regimen and given for the same indication
GVHD PREVENTION IN THE RECIPIENT
(THERAPEUTIC IMMUNOSUPPRESSION)
No (1)
Yes (2)
Unknown (3)
chemotherapy
ATG/ALG (if started after day 0)
(ATG/ALG (if started after day 0))
Corticosteroids (if started after day 0)
(Corticosteroids (if started after day 0))
Cyclosporine (Cyclosporine)
Extra-corporeal photopheresis (ECP)
(Extra-corporeal photopheresis (ECP))
Methotrexate (Methotrexate)
Monoclonal antibodies, specify
(Monoclonal antibodies, specify)
Mycophenolate (Mycophenolate)
Other (Other)
Tacrolimus (Tacrolimus)
Monoclonal antibodies, specify
Drugs: If Other, please specify
GRAFT PERFORMANCE
GRAFT PERFORMANCE
Lost graft (Lost graft)
No reconstitution (No reconstitution)
Yes (Yes)
Neutrophils > 0.5 x 109/l reached?
Never below this level (Never below this
level)
No (No)
Yes (Yes)
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Platelets > 20 x 109/l reached?
Yes (1)
No (2)
Never below this level (3)
Date last assessment
Date of graft failure
Overall chimaerism
Aplasia (Aplasia)
Autologous reconstitution (recipient >95
%)  (Autologous reconstitution (recipient
>95 %) )
Full (donor >95 %)  (Full (donor >95 %) )
Mixed (partial) (Mixed (partial))
Not evaluated (Not evaluated)
DATE(S) AND RESULTS OF ALL TESTS
DONE FOR ALL DONORS
undefined item
Date of test
Identification of donor or Cord Blood Unit given
by the centre
Number in the infusion order (if applicable)
Cell type on which test was performed (% Donor
Cells):
BM
%
Cell type on which test was performed (% Donor
cells):
PB mononuclear cells (PBMC)
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%Cell type on which test was performed
Cell type on which test was performed (% Donor
cells):
B-Cells
%
Cell type on which test was performed (% Donor
cells):
Red blood cells
%
Cell type on which test was performed (% Donor
cells):
Monocytes
%
Cell type on which test was performed (% Donor
cells):
PMNs (neutrophils)
%
Cell type on which test was performed (% Donor
cells):
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Lymphocytes, NOS
%
Cell type on which test was performed (% Donor
cells):
Myeloid cells, NOS
%
Cell type on which test was performed (% Donor
cells):
Other
%
Test used
ABO group (ABO group)
Cytogenetic (Cytogenetic)
FISH (FISH)
Molecular (Molecular)
Other (Other)
unknown (unknown)
TREATMENT FOR FAILURE
(If engraftment failure)
No (1)
Growth factors GRFAIGRF (2)
Subsequent transplant (please complete
a new transplant form) (3)
AUTOgraft (must have prior conditioning)
(4)
ALLOgraft (5)
Autologous PBSC re-infusion (no
preparative treatment or conditioning) (6)
Autologous BM re-infusion (no
preparative treatment or conditioning) (7)
Other (8)
ACUTE GRAFT VERSUS HOST
DISEASE (GvHD)
Maximum grade
ACUTE GRAFT VERSUS HOST DISEASE
(AGVHD)
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grade 0 (Absent)  (1)
grade I  (2)
grade II  (3)
grade III  (4)
grade IV  (5)
Not evaluated (6)
Date of onset
Stage skin
0 (1)
1 (2)
2 (3)
3 (4)
4 (5)
Not evaluated (6)
unknown (7)
Stage liver
0 (1)
1 (2)
2 (3)
3 (4)
4 (5)
Not evaluated (6)
unknown (7)
Stage gut
0 (1)
1 (2)
2 (3)
3 (4)
4 (5)
Not evaluated (6)
unknown (7)
Resolution
No  (1)
Yes (2)
Date of resolution
yyyy/mm/dd
Treatment
Yes
No
Treatment, if yes
ATG/ALG (ATG/ALG)
Corticosteroids (Corticosteroids)
MoAB (MoAB)
Other (Other)
COMPLICATIONS WITHIN THE FIRST
100 DAYS.
INFECTION RELATED COMPLICATIONS
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Yes
No
Pathogen
Bacteraemia/ fungemia / viremia /
parasites (1)
Cystitis (10)
Other (11)
Septic shock (2)
ARDS (3)
Multiorgan failure due to infection (4)
Pneumonia (5)
Hepatitis (6)
CNS infection (7)
Gut infection (8)
Retinitis (9)
NON INFECTION RELATED COMPLICATIONS
No complications (1)
Yes (2)
Specify: Idiopathic pneumonia syndrome
No  (No )
Unknown (Unknown)
Yes (Yes)
Specify: 
VOD
No  (No )
Unknown (Unknown)
Yes (Yes)
Specify:
Haemorrhagic cystitis, non infectious
No  (No )
Unknown (Unknown)
Yes  (Yes )
Specify:
ARDS, non infectious
No (No)
Unknown (Unknown)
Yes (Yes)
Multiorgan failure, non infectious
Yes (1)
No (2)
Unknown (3)
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Specify:
HSCT-associated microangiopathy
No (No)
Unknown (Unknown)
Yes (Yes)
Specify:
Renal failure requiring dialysis
No (No)
Unknown (Unknown)
Yes (Yes)
Specify:
Haemolytic anaemia due to blood group
No (No)
Unknown (Unknown)
Yes (Yes)
Other type of infection
Yes
No
Idiopathic pneumonia syndrome date
Date VOD
Date Haemorrhagic cystitis, non infectious
Date ARDS, non infectious
Date Multiorgan failure, non infectious
Date HSCT-associated microangiopathy
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Date Renal failure requiring dialysis
DAte Haemolytic anaemia due to blood group
Date of other Type
STATUS AT 100 DAYS
Date of Last Contact
Presence of cGVHD
No (1)
Yes, First Episode (2)
Yes, Recurrence (3)
Onset
cGvHD grade
limited (1)
Extensive (2)
not evaluated (3)
Organs affected
Skin (1)
Gut (2)
Liver (3)
Mouth (4)
Eyes (5)
Lung (6)
Other, specify (7)
Unknown (8)
Relapse or progression
Previously reported (1)
No (2)
yes (3)
Continuous progression since transplant
(4)
Unknown (5)
RELAPSE OR PROGRESSION: If yes, date
diagnosed
Method of detection
Cinical/haematological relapse or progression
No (1)
Yes (2)
Not evaluated (3)
Date assessed
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Date first seen
Cytogenetic relapse or progression
No (1)
Yes (2)
Not evaluated (3)
Cytogenetic relapse or progression: Date
assessed
Cytogenetic relapse or progression: Date first
seen
Molecular relapse or progression
No (1)
Yes (2)
Not evaluated (3)
Molecular relapse or progression: date assessed
Molecular relapse or progression: Date first seen
LAST DISEASE STATUS
Clinical/haematological
No (1)
Yes (2)
Not evaluated (3)
Last date evaluated/Last date assessed
yyyy/mm/dd
Cytogenetic/FISH
No (1)
Yes: Considered disease
relapse/progression No (2)
Yes: Considered disease
relapse/progression Yes (3)
Yes: Considered disease
relapse/progression Not evaluated (4)
Last date assessed
Molecular
No (No)
No Considered disease
relapse/progression (No Considered
disease relapse/progression)
Not evaluated (Not evaluated)
yes (yes)
Yes Considered disease
relapse/progression (Yes Considered
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disease relapse/progression)
Survival Status
alive (0)
dead (1)
If alive: Type of score used:
Karnofsky (Karnofsky)
Lansky (Lansky)
Not evaluated (Not evaluated)
Unknown (Unknown)
Score
100 (Normal, NED) (1)
10 (Moribund) (10)
Not evaluated (11)
Unknown (12)
90 (Normal activity)  (2)
80 (Normal with effort) (3)
70 (Cares for self) (4)
60 (Requires occasional assistance) (5)
50 (Requires assistance) (6)
40 (Disabled) (7)
30 (Severely disabled) (8)
20 (Very sick) (9)
Cause of death (if dead)
Relapse or progression (1)
Secondary malignancy (including
lymphoproliferative disease) (2)
Transplantation related cause  (3)
Unknown (4)
Other (5)
If dead and HSCT related cause of death, specify
(check as many as apppropriate):
GvHD
No  (No )
Unknown (Unknown)
Yes (Yes)
If dead and HSCT related cause of death, specify
(check as many as apppropriate):
Interstitial Pneumonitis
No  (No )
Unknown (Unknown)
Yes (Yes)
If dead and HSCT related cause of death, specify
(check as many as apppropriate): 
Pulmonary toxicity
No  (No )
Unknown (Unknown)
Yes (Yes)
Infection:
bacterial  (1)
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viral  (2)
fungal  (3)
parasitic  (4)
unknown (5)
Rejection / poor graft function
Yes (1)
No (2)
Unknown (3)
Veno-Occlusive disease (VOD)
Yes (1)
No (2)
Unknown (3)
If dead and HSCT related cause of death, specify
(check as many as apppropriate): 
Haemorrhage
No  (No )
Unknown (Unknown)
Yes (Yes)
If dead and HSCT related cause of death, specify
(check as many as apppropriate): 
Cardiac toxicity
No  (No )
Unknown (Unknown)
Yes (Yes)
If dead and HSCT related cause of death, specify
(check as many as apppropriate): 
Central nervous system toxicity
No  (No )
Unknown (Unknown)
Yes (Yes)
If dead and HSCT related cause of death, specify
(check as many as apppropriate): 
Gastro intestinal toxicity
No  (No )
Unknown (Unknown)
Yes (Yes)
If dead and HSCT related cause of death, specify
(check as many as apppropriate): 
Skin toxicity
No  (No )
Unknown (Unknown)
Yes (Yes)
If dead and HSCT related cause of death, specify
(check as many as apppropriate): 
Renal failure
No  (No )
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Unknown (Unknown)
Yes (Yes)
If dead and HSCT related cause of death, specify
(check as many as apppropriate): 
Multiple organ failure
No  (No )
Unknown (Unknown)
Yes (Yes)
COMMENTS
IDENTIFICATION & SIGNATURE
ADDITIONAL NOTES IF APPLICABLE
ALLOGRAFT APPENDIX
Ethnicity
Hispanic or Latino (1)
Not Hispanic or Latino (2)
Race
White (1)
Black (2)
Asian (3)
American Indian or Alaska Native (4)
Native Hawaiian or Pacific Native (5)
Other (6)
COMORBID CONDITIONS
Yes
No
Solid tumor
No (No)
Not evaluated (Not evaluated)
Yes (Yes)
Inflammatory bowel disease
No  (No )
Not evaluated (Not evaluated)
Yes (Yes)
Infection
No (No)
Not evaluated (Not evaluated)
Yes (Yes)
Diabetes
No  (No )
Not evaluated (Not evaluated)
Yes (Yes)
Serum creatinine
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mg/dL
No (No)
Not evaluated (Not evaluated)
Yes (Yes)
Chronic hepatitis
No (No)
Not evaluated (Not evaluated)
Yes (Yes)
Liver cirrhosis
No (No)
Not evaluated (Not evaluated)
Yes  (Yes )
Arrhythmia
No (No)
Not evaluated (Not evaluated)
Yes (Yes)
Coronary artery disease
No (No)
Not evaluated (Not evaluated)
yes (yes)
Cerebrovascular disease
No (No)
Not evaluated (Not evaluated)
Yes (Yes)
Heart valve disease
No (No)
Not evaluated (Not evaluated)
Yes (Yes)
FEV1 66-80%
No (No)
Not evaluated (Not evaluated)
Yes (Yes)
FEV1 ≤ 65%
No (No)
Not evaluated (Not evaluated)
Yes (Yes)
Obesity
No (No)
Not evaluated (Not evaluated)
Yes (Yes)
Peptic ulcer
No (No)
Not evaluated (Not evaluated)
Yes (Yes)
Psychiatric disturbance
No (No)
Not evaluated (Not evaluated)
Yes (Yes)
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other comorbidity, please specify
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Cumulative Form 3/3 Tolerability of QUTENZA™ When Applied After Pre-treatment
With Lidocaine or Tramadol in Subjects With Peripheral Neuropathic Pain - A
Randomized, Multi-center, Assessor-blinded Study NCT01416116
Study Sponsor: Astellas
Study Title
Tolerability of QUTENZA™ When Applied After Pre-
treatment With Lidocaine or Tramadol in Subjects With
Peripheral Neuropathic Pain - A Randomized, Multi-center,
Assessor-blinded Study
Medicine or Vaccine (generic name)
capsaicin
Sponsor Identification Number
QTZ-EC-0002
Trial Registry Identification Number(#'s)
NCT01416116
EudraCT Number: 2010-023258-34
Medical Condition
Neuropathic pain
Phase
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Cumulative Form 2/2
Non-medication Therapy
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QUTENZA™ When Applied After
Pre-treatment With Lidocaine or
Tramadol in Subjects With Peripheral
Neuropathic Pain - A Randomized,
Multi-center, Assessor-blinded Study
NCT01416116
Non-medication Therapy
Therapy Details
Pain Non Medication Therapy
No (0)
Yes (1)
Pain Therapy acute
No (0)
Yes (1)
Indication
Start Date of Therapy
Ongoing
No (0)
Yes (1)
End Date of Therapy
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Study Sponsor: Astellas
Study Title
Tolerability of QUTENZA™ When Applied After Pre-
treatment With Lidocaine or Tramadol in Subjects With
Peripheral Neuropathic Pain - A Randomized, Multi-center,
Assessor-blinded Study
Medicine or Vaccine (generic name)
capsaicin
Sponsor Identification Number
QTZ-EC-0002
Trial Registry Identification Number(#'s)
NCT01416116
EudraCT Number: 2010-023258-34
Medical Condition
Neuropathic pain
Phase
Phase 4
http://clinicaltrials.gov/show/NCT01416116
Cumulative
Adverse Event 2
All rights reserved. Please visit https://medical-data-
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Cumulative Form 1/3  Tolerability of
QUTENZA™ When Applied After
Pre-treatment With Lidocaine or
Tramadol in Subjects With Peripheral
Neuropathic Pain - A Randomized,
Multi-center, Assessor-blinded Study
NCT01416116
Adverse Event 2
Adverse Event
Onset Date
Onset Time
If the onset date is unknown or the same day as
pre-treatment,
please select one.
Onset before Pre-treatment (1)
Onset after start of (2)
Pre-treatment (3)
If the onset date is unknown or is the same day
as application of
Qutenza, please select one.
Onset before Application ofQutenza (1)
Onset after start of Applicationof
Qutenza (2)
End Date
End Time
Outcome
Recovered (1)
Recovering (2)
Not Recovered (3)
1 / 3
Recovered with Sequelae (4)
Fatal (5)
Unknown (6)
If 'Recovered with Sequelae is selected, please
specify.
Course of Event
Continuous (Continuous)
Intermittent (Intermittent)
Single Episode (Single Episode)
Severity
Mild (1)
Moderate (2)
Severe (3)
Serious AE
no (0)
yes (1)
Number
Death
Yes
No
Requires or prolongs hospitalization
Yes
No
Congenital anomaly
Yes
No
Life-threatening
Yes
No
Persistent or significant disability/incapacity
Yes
No
Other Medical importance
Yes
No
Action Taken for QUTENZA
Dose Not Changed (1)
Dose Reduced (2)
Permanent Discontinuation (3)
Not Applicable (4)
Action Taken for Pretreatment
Dose Not Changed (1)
Permanent Discontinuation (2)
Not Applicable (3)
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With Lidocaine or Tramadol in Subjects With Peripheral Neuropathic Pain - A
Randomized, Multi-center, Assessor-blinded Study NCT01416116
Treatment Required: None
Yes
No
Treatment Required: Drug Treatment
Treatment Required: Non-Medication Therapy
Yes
No
Relationship to QUTENZA
Not Related (1)
Possible (2)
Probable (3)
Please confirm if the Adverse Event is an
Application Site
Reaction
no (0)
yes (1)
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Study Sponsor: Astellas
Study Title
Tolerability of QUTENZA™ When Applied After Pre-
treatment With Lidocaine or Tramadol in Subjects With
Peripheral Neuropathic Pain - A Randomized, Multi-center,
Assessor-blinded Study
Medicine or Vaccine (generic name)
capsaicin
Sponsor Identification Number
QTZ-EC-0002
Trial Registry Identification Number(#'s)
NCT01416116
EudraCT Number: 2010-023258-34
Medical Condition
Neuropathic pain
Phase
Phase 4
http://clinicaltrials.gov/show/NCT01416116
Cumulative:
Previous and/or Concomitant Medication
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Previous and/or Concomitant Medication
Medication
Dose
Dose Units
Frequency
Route
Oral (1)
Inhaled (10)
Continuous inhalation (11)
Swish & Spit/Swallow (12)
Intranasal (13)
Transdermal (14)
Vaginal (15)
Rectal (16)
Epidural (17)
Intrathecal (18)
Intra-articular (19)
Intravenous (2)
Peri-articular (20)
Intraperitoneal (21)
Intradermal (22)
Intra-arterial (23)
Intra-urethral (24)
Unknown (25)
Other (26)
Topical (3)
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Nasogastric (4)
Subcutaneous (5)
Intramuscular (6)
Ear/Auricular (7)
Ophthalmic (8)
Sublingual (9)
If 'Other', please specify
Pain Medication
no (0)
yes (1)
Start Date
Ongoing
No (0)
Yes (1)
Stop Date
Chronic medication for neuropathic pain
No (0)
Yes (1)
Rescue Pain Medication
Other Pain Medication
No (0)
Yes (1)
Indication
2 / 2
Cumulative Form 2/3 Tolerability of QUTENZA™ When Applied After Pre-treatment
With Lidocaine or Tramadol in Subjects With Peripheral Neuropathic Pain - A
Randomized, Multi-center, Assessor-blinded Study NCT01416116
Unscheduled Visit >> Unscheduled Event Form 2/2 Tolerability of QUTENZA™ When
Applied After Pre-treatment With Lidocaine or Tramadol in Subjects With Peripheral
Neuropathic Pain - A Randomized, Multi-center, Assessor-blinded Study NCT01416116
Study Sponsor: Astellas
Study Title
Tolerability of QUTENZA™ When Applied After Pre-
treatment With Lidocaine or Tramadol in Subjects With
Peripheral Neuropathic Pain - A Randomized, Multi-center,
Assessor-blinded Study
Medicine or Vaccine (generic name)
capsaicin
Sponsor Identification Number
QTZ-EC-0002
Trial Registry Identification Number(#'s)
NCT01416116
EudraCT Number: 2010-023258-34
Medical Condition
Neuropathic pain
Phase
Phase 4
http://clinicaltrials.gov/show/NCT01416116
Unscheduled Visit >> Unscheduled Event Form 
Pregnancy Test
Unscheduled Event
All rights reserved. Please visit https://medical-data-
models.org/forms/17023
Unscheduled Visit >> Unscheduled
Event Form 2/2 Tolerability of
QUTENZA™ When Applied After
Pre-treatment With Lidocaine or
Tramadol in Subjects With Peripheral
Neuropathic Pain - A Randomized,
Multi-center, Assessor-blinded Study
NCT01416116
Pregnancy Test
Is subject female and of childbearing potential?
No (0)
Yes (1)
Reason Childbearing potential - NO
Female (2 yrs post-menopausal or
surgically sterile) (1)
Other (2)
If 'Other', specify
Select 'Not Done' if serum/urine sample was not
taken.
Yes
No
Date of Sample Taken
Result serum/urine pregnancy test
Negative (0)
Positive (1)
Unscheduled Event
Date of Visit
1 / 2
Physical Examination
Vital signs
ECG: 12 Lead ECG
Hematology
Biochemistry
Pregnancy Test
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Unscheduled Visit >> Unscheduled Event Form 1/2 Tolerability of QUTENZA™ When
Applied After Pre-treatment With Lidocaine or Tramadol in Subjects With Peripheral
Neuropathic Pain - A Randomized, Multi-center, Assessor-blinded Study NCT01416116
Study Sponsor: Astellas
Study Title
Tolerability of QUTENZA™ When Applied After Pre-
treatment With Lidocaine or Tramadol in Subjects With
Peripheral Neuropathic Pain - A Randomized, Multi-center,
Assessor-blinded Study
Medicine or Vaccine (generic name)
capsaicin
Sponsor Identification Number
QTZ-EC-0002
Trial Registry Identification Number(#'s)
NCT01416116
EudraCT Number: 2010-023258-34
Medical Condition
Neuropathic pain
Phase
Phase 4
http://clinicaltrials.gov/show/NCT01416116
Unscheduled Visit >> Unscheduled Event
Physical Examination
Vital Signs
12 Lead ECG
Laboratory Tests: Hematology
All rights reserved. Please visit https://medical-data-
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NCT01416116
Physical Examination
Was the Physical Examination performed
No (0)
Yes (1)
Assessment Date
Vital Signs
Assessment Date
Position
Supine (1)
Sitting (2)
Standing (3)
Systolic Blood Pressure
Diastolic Blood Pressure
mmHg
Pulse Rate
bpm
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ECG: 12 Lead ECG
Date ECG Performed
No (0)
Yes (1)
ECG Interpretation
Normal (1)
Abnormal - not clinically (2)
significant (3)
Abnormal - clinically (4)
significant (5)
Abnormality Code
Sinus Tachycardia  (1)
Junctional Rhythm Without (10)
T-Wave Peaking (100)
U-Wave Abnormality (101)
Other (102)
Aberrancy (11)
Junctional Rhythm With (12)
Aberrancy (13)
Ventricular Rhythm (14)
Ventricular Tachycardia (15)
Accelerated AV Conduction (16)
Pattern (17)
Wolff - Parkinson - White (18)
Pattern (19)
Sinus Bradycardia (2)
Supraventricular Ectopic Beats (20)
Ventricular Ectopic Beats –Unifocal (21)
Ventricular Ectopic Beats -Multifocal (22)
Pacemaker Rhythm (23)
Ventricular Fibrillation (24)
Sinus Arrest (25)
Sinus Arrhythmia (26)
Nodal Tachycardia (27)
LGL Syndrome (28)
Junctional escape complexes (29)
Atrial Tachycardia - Without Block (3)
Sino - Atrial Block (30)
First Degree AV Block (31)
Second Degree AV Block -Mobitz I (32)
Second Degree AV Block -Mobitz II (33)
Complete AV Block (34)
Prolonged QT Interval (35)
Prolonged QTc interval (36)
Right Atrial Enlargement (37)
Left Atrial Enlargement (38)
P-Wave Abnormality (39)
Atrial Tachycardia - With Block (4)
AV Dissociation (40)
Left Anterior Hemiblock (41)
Left Posterior Hemiblock (42)
Right Bundle Branch Block (43)
Incomplete Right Bundle (44)
Branch Block (45)
Left Bundle Branch Block (46)
Incomplete Left Bundle BranchBlock (47)
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Nonspecific Intraventricular (48)
Conduction Delay (49)
Atrial Flutter (5)
Bifascicular Block (50)
Left Axis Deviation (51)
Right Axis Deviation (52)
Abnormal QRS Axis (53)
Left Ventricular Hypertrophia (54)
Left Ventricular Hypertrophia (55)
By Voltage Only (56)
Right Ventricular Hypertrophia (57)
Old Myocardial Infarction:Antero septal
(58)
Old Myocardial Infarction:Antero lateral
(59)
Atrial Fibrillation (6)
Old Myocardial Infarction:Infero lateral
(60)
Old Myocardial Infarction:Infero posterior
(61)
Old Myocardial Infarction:Postero lateral
(62)
Old Myocardial Infarction:Lateral (63)
Low Voltage QRS Complex (64)
Poor R-Wave Progression (65)
Late R-Wave Transition (66)
Early Repolarization - Normal (67)
Variant (68)
Early R-Wave Transition (69)
PSVT(Paroxysmal (7)
New Myocardial Infarction:Antero septal
(70)
New Myocardial Infarction:Antero lateral
(71)
New Myocardial Infarction:Infero lateral
(72)
New Myocardial Infarction:Infero
posterior (73)
New Myocardial Infarction:Postero lateral
(74)
New Myocardial Infarction:Lateral (75)
Myocardial Infarction -Nontransmural
-Acute orEvolving (76)
ST Elevation Consistent with (77)
Ischaemia: Anterior (78)
ST Elevation Consistent withIschaemia:
Septal (79)
Supraventricular Tachycardia) (8)
ST Elevation Consistent withIschaemia:
Lateral (80)
ST Elevation Consistent withIschaemia:
Inferior (81)
ST Elevation Consistent withIschaemia:
Posterior (82)
ST Elevation Consistent
withIschaemia:High Lateral (83)
ST Elevation Consistent With (84)
Pericarditis (85)
Non-Specific ST-T Change (86)
ST-T changes - Consistent WithDrug
3 / 5
Unscheduled Visit >> Unscheduled Event Form 1/2 Tolerability of QUTENZA™ When
Applied After Pre-treatment With Lidocaine or Tramadol in Subjects With Peripheral
Neuropathic Pain - A Randomized, Multi-center, Assessor-blinded Study NCT01416116
Effects (87)
ST Depression: Anterior (88)
ST Depression: Septal (89)
Variable Atrial Pacemaker (9)
ST Depression: Lateral (90)
ST Depression: Inferior (91)
ST Depression: Posterior (92)
ST Depression: High Lateral (93)
ST Depression - Non-Specific (94)
CodelistItem 918442 (95)
T-Wave Inversion Suggestiveof Non-Q-
Wave MI (96)
T-Wave Flattening or Inversionin Two or
More Leads (97)
Non-Specific T-Wave changes (98)
T-Wave Inversion Suggestiveof
Ischaemia (99)
Clinically Significant?
Yes (0)
No (1)
Comment on Abnormal Result (For abnormal
code 'Other', Please
also specify the abnormality).
Laboratory Tests: Hematology
Were samples taken?
No (0)
Yes (1)
Date of Sample Taken
LAB Interpretation
Normal  (1)
Abnormal (2)
Abnormal Lab tests: Hematology
Lab Tests
Red Blood Cell Count 5 (1)
Platelets (10)
White Blood Cell Count (2)
Lymphocytes (3)
Neutrophils (4)
Eosinophils (5)
Basophils (6)
Monocytes (7)
Hemoglobin (8)
Hematocrit (9)
Lab interpretation
Abnormal - not clinically significant (1)
Abnormal - clinically significant (2)
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Laboratory Tests: Biochemistry
Were samples taken?
No (0)
Yes (1)
Date of Sample Taken
LAB Interpretation
Normal (1)
Abnormal (2)
Abnormal Lab tests: Biochemistry
Lab Test
AST (1)
ALT (2)
Alkaline Phosphatase (3)
Chloride (4)
Sodium (5)
Potassium (6)
Blood urea nitrogen (7)
Creatinine (8)
LAB Interpretation
Abnormal - not clinically significant (1)
Abnormal - clinically significant (2)
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Nicotinsäure und Naftidrofuryl bei
pAVK-Patienten nach Angioplastie
Prüfbogen
Zentrums-Nr.:
Patienten-Nr
Baseline-Untersuchung (T0) – Eine
Woche nach der Operation
am
Einverständniserklärung, Der Patient gab sein
Einverständnis am
Vermerke zum ärztlichen Aufklärungsgespräch:
Unterschrift
Datum
Unterschrift des Prüfarztes
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DM-ASP1941-1941-CL-0004
NCT01071850
A Phase 2, Double-Blind, Randomized, Placebo and
Active-Controlled Dose-Finding Study to Assess the
Efficacy, Safety and Tolerability of Multiple Oral Doses of
ASP1941 in Subjects with Type 2 Diabetes MellitusTEST
Study
Cumulative
All rights reserved. Please visit https://medical-data-
models.org/forms/17029
Cumulative DM-ASP1941-1941-CL-
0004 NCT01071850
Targeted Medical History
Mecial Condition
History
Yes
No
Onset Date
Is Medical Condition ongoing?
Yes
No
Currently treated with medication?
Yes
No
Medical History
Is there any past or present Medical Condition?
Yes
No
Medical Condition, specify:
Onset date Medical Condition
Is Medical Condition ongoing?
If no, please provide Recovered Date.
Yes
No
Recovered Date
Currently treated with medication?
Yes
No
Concomitant Medication
Is there any previous medication and/or
concomitant medication to record?
Yes
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No
Medication
Route of administration
oral (1)
inhaled (10)
continuous inhalation (11)
swish & spit/swallow (12)
intranasal (13)
transdermal (14)
vaginal (15)
rectal (16)
epidural (17)
intrathecal (18)
peri-articular (19)
intravenous (2)
intraperitoneal (20)
intradermal (21)
intra-arterial (22)
intra-urethral (23)
unknown (24)
other (25)
topical (3)
nasogastric (4)
subcutaneous (5)
intramuscular (6)
ear/auricular (7)
ophthalmic (8)
sublingual (9)
Start date
Stop Date
Ongoing
Yes
No
Dose
Dose Units
Frequency
Indication
Reason for Use
Primary Diagnosis (1)
For Medical History (2)
For AE (3)
Prophylaxis (4)
Other (5)
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Adverse Events
Was any adverse event reported or observed?
Yes
No
Adverse Events
Onset Date
If the AE onset date is the same day as the First
Date of Randomized Study Drug, please select
one:
Onset before first dose of study drug (1)
Onset after first dose of study drug (2)
Adverse Event End Date
Adverse Event Outcome
Recovered / Resolved (1)
Recovering / Resolving (2)
Not Recovered / Not Resolved (3)
Recovered / Resolved with Sequelae (4)
Fatal (5)
Unknown (6)
Adverse Event Course
Single Episode (1)
Intermittent (2)
Continuous (3)
Adverse Event Severity
Mild (1)
Moderate (2)
Severe (3)
Serious AE?
If seriousness is "yes", tick all that apply
Yes
No
Serious AE Number
Death?
Yes (1)
Requires or prolongs hospitalization?
Yes (1)
Congenital Anomaly
Yes (1)
Life Threatening?
Yes (1)
Persistent or significant disability / incapacity
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Yes (1)
Other medical importance?
Yes (1)
Action taken with study treatment
Dose not changed (1)
drup interrupted (2)
drug withdrawn (3)
Not Applicable (4)
Unknown (5)
Treatment required?
Yes
No
Drug Treatment required?
Yes (1)
Non Medication Therapy
Yes (1)
Relationship to Study Drug
Not related (1)
possible (2)
probable (3)
Was the infection symptomatic? (Only
UTI/Genital Infection)
No (1)
Yes (2)
Unknown (3)
Was the infection confirmed by a laboratory?
(Only UTI/Genital Infection)
No (1)
Yes (2)
Unknown (3)
Hypoglycemic Event Classification
Severe Hypoglycemia (1)
Documented symptomatic Hypoglycemia
(2)
Asymptomatic Hypoglycemia (3)
Probable symptomatic Hypoglycemia (4)
Relative Hypoglycemia (5)
Was a glucometer reading taken prior to treating
the Hypoglycemic Event?
Yes
No
glucometer reading
mmol/L
Number of hours since the last meal/ snack?
hours
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Number of hours since the last dose of ASP1941
study medication.
hours
Number of hours since the last dose of Metformin
study medication.
hours
Serious Adverse Event reconciled?
Yes (1)
Reviewed (2)
Adjudication Reference ID
Hospitalization Records
Was the subject hospitalized from the time of
First Dose of Randomized Study Drug through
Visit 11?
Yes
No
Date of admission:
Ongoing?
Yes
No
Date of discharge:
Type of Hospitalization
Non ICU (1)
ICU (2)
Reason for Hospitalization
Adverse Event (1)
Other (2)
If Other, specify
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Eligibility Depression NCT00177671
Antidepressant Medication Plus Donepezil for Treating
Late-life Depression; ODM derived from:
https://clinicaltrials.gov/show/NCT00177671
All rights reserved. Please visit https://medical-data-
models.org/forms/17031
Eligibility Depression NCT00177671
Inclusion Criteria
current episode of major depression*
Yes
No
hrs-d 17-item score of 15 or higher*
Yes
No
must be able to speak english*
Yes
No
willing to discontinue other psychotropics*
Yes
No
availability of family member/caregiver*
Yes
No
hearing capacity adequate to respond to raised
conversational voice*
Yes
No
must have no formal diagnosis of dementia*
Yes
No
Exclusion Criteria
meets dsm-iv criteria for bipolar disorder,
schizophrenia, schizoaffective disorder, or a
psychotic disorders*
Yes
No
alcohol/drug abuse within 12 months of study
entry*
Yes
No
history of treatment non-adherence in other clinic
protocols*
Yes
No
history of non-response to citalopram in other
clinic protocols*
Yes
No
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history of non-tolerance to ssri therapy*
Yes
No
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Eligibility Depression NCT00177294
Augmenting Antidepressant Treatment With Interpersonal
Psychotherapy for Treating Late-life Depression; ODM
derived from: https://clinicaltrials.gov/show/NCT00177294
All rights reserved. Please visit https://medical-data-
models.org/forms/17032
Eligibility Depression NCT00177294
Inclusion Criteria
diagnosis of unipolar major depression*
Yes
No
hamilton rating scale for depression (hrsd) (17
item) score of 15 or higher*
Yes
No
speaks english*
Yes
No
willing to discontinue other psychotropic
medications*
Yes
No
availability of family member or other caregiver*
Yes
No
hearing capacity adequate to respond to a raised
conversational voice*
Yes
No
Exclusion Criteria
lifetime diagnosis of bipolar disorder,
schizophrenia, schizoaffective disorder, or any
psychotic disorder*
Yes
No
folstein mini-mental status exam (mmse) of 17 or
lower*
Yes
No
suicidal*
Yes
No
history of treatment non-adherence in other
center protocols*
Yes
No
history of documented non-response to
citalopram in other center protocols*
Yes
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No
history of non-tolerance to escitalopram therapy*
Yes
No
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UKM-Pediatric Hematology and Oncology
Admission Exam-Form
Freigabe zur Verarbeitung durch Frau Prof. Rössig,
Quellenangabe: "Pädiatrische Hämatologie und Onkologie,
UKM" Klinik für Kinder- und Jugendmedizin,
Universitätsklinikum Münster
Released for adaption by Frau Prof. Rössig
Source: Pediatric Hematology und Oncology, University
hospital Münster
All rights reserved. Please visit https://medical-data-
models.org/forms/17033
Pädiatrische Hämatologie und
Onkologie Aufnahmeuntersuchung
Demographie
Patienten Name
Adresse des Patienten
Versicherter
Arbeitgeber:
Kostenträger
Angehörige
Einweiser
Größe
cm
Gewicht
kg
Klinische Untersuchung
Diagnose
Diagnosedatum
EDV
Schutzimpfungen
BCG
Ja
Nein
Datum der BCG-Impfung
Pertussis
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Ja
Nein
Datum der Pertussis Impfung
HIB
Ja
Nein
Datum der HIB Impfung
Masern
Ja
Nein
Datum der Masern Impfung
Mumps
Ja
Nein
Datum der Mumps Impfung
Röteln
Ja
Nein
Datum der Röteln Impfung
Hepatitis B
Ja
Nein
Datum der Hepatitis B Impfung
Diphtherie
Ja
Nein
Datum der Diphtherie Impfung
Tetanus
Ja
Nein
Datum der Tetanus Impfung
Polio (IPV/OPV)
Ja
Nein
Datum der Polio (IPV/OPV) Impfung
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Andere Impfungen
Datum andere Impfungen
Tuberkulintest(e)
Allergien
Medizinische Vorgeschichte
Vorgeschichte nach Angabe von:
Aufnehmender Arzt
Datum
Behandelnde Ärzte
Geburtsdatum des Vaters
Krankheiten des Vaters
Geburtsdatum der Mutter
Krankheiten der Mutter
Geburtsdatum Geschwister
Geburtsdatum Geschwister
Geburtsdatum Geschwister
Geburtsdatum Geschwister
Geburtsdatum Geschwister
Krankheiten Geschwister
Krankheiten Geschwister
Krankheiten Geschwister
Krankheiten Geschwister
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Krankheiten Geschwister
Erbkrankheiten bei Blutsverwandten?
Welche Blutsverwandte haben eine
Erbkrankheit?
Fehlgeburten
Krankheiten während der Schwangerschaft
Medikamente während der Schwangerschaft
Alkoholgenuss während der Schwangerschaft
Nikotinkonsum während der Schwangerschaft
Geburt in der wievielten
Schwangerschaftswoche?
Geburtsgewicht
grams
Kopfumfang
cm
APGAR
Länge
cm
Besonderheiten bei der Geburt?
Vitamin D Prophylaxe des Neugeborenen
Ernährung des Neugeborenen
Entwicklung: Fixieren
Entwicklung:Lachen
Entwicklung:Greifen
Entwicklung: Sitzen
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Entwicklung: 1.Zahn
Entwicklung: Laufen
Entwicklung: Sprechen
Entwicklung: Sauberkeit
Entwicklung: Kindergarten
Entwicklung: Schulklasse
Entwicklung: Schulleistungen
Kinderkrankheiten: Windpocken
Kinderkrankheiten: Masern
Kinderkrankheiten: Röteln
Kinderkrankheiten: Mumps
Kinderkrankheiten:Scharlach
Kinderkrankheiten:Keuchhusten
Sonstige Erkrankungen
Ansteckende Krankheiten in der Umgebung
Medikamente
Jetzige Erkrankungen
Aufnahmebefund
Aufnahmebefund
Korperlänge/-höhe
cm
Gewicht
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Kopfumfang
cm
Hautzustand (auch Impfnarben)
Fettpolster
Mundhöhle,Rachen, Zähne
Ohren
Lymphknoten
Hals
Atmungsorgane
Herz, periphere Pulse
Blutdruck
mmHg
Wo wurde der Blutdruck gemessen?
Arm re (1)
Arm li (2)
Bein re (3)
Bein li (4)
Abdomen
Geschlechtsorgane
Tannerstadium Schambehaarung
Tannerstadium der weiblichen Brust
Tannerstadium der männlichen Genitalien
Hoden re/li
ml
Nervensystem
Sinnesorgane
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Muskulatur
Vorlaufige Diagnose
Therapieplan
Datum
Name des Arztes
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Eligibility Depression NCT00186056
Mifepristone in Refractory Depression; ODM derived from:
https://clinicaltrials.gov/show/NCT00186056
All rights reserved. Please visit https://medical-data-
models.org/forms/17034
Eligibility Depression NCT00186056
Inclusion Criteria
21-item ham-d score of 20 or above.*
Yes
No
if currently taking antipsychotic, antidepressant,
anticonvulsant, and/or mood-stabilizing
medications, must be stable on the medication for
at least three weeks prior to entering the study.*
Yes
No
at least 2 failed antidepressant medication trials
of adequate dose and duration.*
Yes
No
between 18 and 75 years of age.*
Yes
No
not currently pregnant or trying to become
pregnant.*
Yes
No
Exclusion Criteria
history of schizophrenia or other psychotic
disorders.*
Yes
No
transcranial magnetic stimulation treatment or ect
in the 3 months prior to starting the study.*
Yes
No
history of vagus nerve stimulation treatment.*
Yes
No
no unstable or untreated cardiovascular disease,
hypertension, or endocrine disorder.*
Yes
No
current use of oral contraceptives or any other
drug that may result in adverse drug-mifepristone
interactions effects (including amiodarone,
clarithromycin, erythromycin, fluconazole,
fluvoxamine, indinavir, intraconazole,
ketoconazole, metronidazole, miconazole,
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nefazodone, nelfinavir, norfloxacin, omeprazole,
quinine, ritonavir, saquinavir, troleandomycin,
zafirlukast, carbamazepine, dexamethasone,
ethosuximide, phenobarbital, phenytoin,
primidone, rifabutin, rifampin, troglitazone).  a 30-
day wash-out period for oral contraceptives is
required before mifepristone begins.*
Yes
No
previous allergic reaction to mifepristone or drugs
of similar chemical structure.*
Yes
No
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Eligibility Depression NCT00218764
Cognitive Therapy Versus Medication Treatment for
Preventing Depression Relapse; ODM derived from:
https://clinicaltrials.gov/show/NCT00218764
All rights reserved. Please visit https://medical-data-
models.org/forms/17035
Eligibility Depression NCT00218764
Inclusion Criteria
diagnosis of recurrent unipolar major depressive
disorder*
Yes
No
at least 2 episodes of major depression within
lifetime, including present episode*
Yes
No
speaks and reads english*
Yes
No
seeking cognitive therapy treatment*
Yes
No
at least one period of complete inter-episode
recovery or a history of dysthymia prior to the
onset of the presenting or past episodes*
Yes
No
Exclusion Criteria
active alcohol or other substance dependence
within the 6 months prior to study entry*
Yes
No
active suicidal ideation with possible intent or
probable risk*
Yes
No
mood disorder due to a medical condition or
substance use, bipolar disorder, schizophrenia, or
schizoaffective  disorder*
Yes
No
unable to stop mood altering medications*
Yes
No
concurrent medication or exclusionary medical
disorders (diabetes, head injury, stroke, cancer,
multiple sclerosis) that may cause depression*
Yes
No
unable to attend clinic during business hours
(monday-thursday, 8am-5pm) twice weekly*
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Yes
No
unable to complete questionnaires*
Yes
No
unsuccessful treatment after 8 weeks of cognitive
therapy with a certified therapist*
Yes
No
unsuccessful treatment after 6 weeks of 40 mg of
fluoxetine (prozac)*
Yes
No
pregnant or plans to become pregnant in the next
11-12 months*
Yes
No
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UKM-Pediatric Hematology and Oncology
outpatient department and polyclinic - patient chart
Freigabe zur Verarbeitung durch Frau Prof. Rössig,
Quellenangabe: "Pädiatrische Hämatologie und Onkologie,
UKM" Klinik für Kinder- und Jugendmedizin,
Universitätsklinikum Münster Released for adaption by Frau
Prof. Rössig Source: Pediatric Hematology und Oncology,
University hospital Münster
All rights reserved. Please visit https://medical-data-
models.org/forms/17036
Padiatrische Hämatologie und
Onkologie Ambulanz und Tagesklinik
- Kurvenblatt
Demographie
Datum
Patienten-ID:
Cave
Körpergewicht
kg
Größe
cm
KOF m²
m²
Behandlungstag
Laborergebnisse
Leukozyten
/µl
Hämoglobin
g/dL
Thrombozyten
/µl
ANC
/µl
Retikulozyten
u/00
CRP
mg/dl
BSG
mm/Std
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Blutzucker (BZ):
mg/dl
Puls
beats/min
Blutdruck
mmHg
O2 Sättigung
%
Temperatur
°C
Medikamente oral
TMP/SMX Dosis
Andere orale Medikamente
Andere orale Medikamente Dosis
Verantwortlicher Arzt
Verantwortliche Pflegekraft
Infusionen/Injektionen
NaCl 0,9% Volumen/Dosis
Päd I Volumen/Dosis
Päd II Volumen/Dosis
Glucose 5% Volumen/Dosis
Andere intravenöse Medikamente
Andere intravenöse Medikamente Volumen/Dosis
Verantwortlicher Arzt
Verantwortliche Pflegekraft
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polyclinic - patient chart
Medikation bei Allergie
Medikation bei Allergie
Medikation bei Allergie Dosis
Verantwortlicher Arzt
Verantwortliche Pflegekraft
Transfusionen
Transfusion Nummer
Anordnungen /Diagnostik
Anordnungen
Diagnostik
Arzt
Pflegeassessment
Datum
Nummer
Pflegebedarf
Pflegeressource
Pflegemassnahme
Pflegeziel
Verantwortliche Pflegekraft
Pflegedokumentation
Datum
Schmerzskala
KUSS (1)
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0-12 (2)
1-6 (3)
ZVK-B iock mit 250 IE Heparin=5 ml
Ja
Nein
Port
Brovi-Rot
Brovi-Weiß
Brovi-Blau
ZVK VW
Stuhlverhalten
geformt (1)
flüssig (2)
breiig (3)
Datum letzter Stuhl
Urin Erythrozyten
neg (1)
pos (2)
Urin pH
Erbrechen
Ja
Nein
Häufigkeit des Erbrechens
Verantwortliche Pflegekraft
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Eligibility Depression NCT00231959
Effectiveness of Pramipexole for Treatment-Resistant
Depression; ODM derived from:
https://clinicaltrials.gov/show/NCT00231959
All rights reserved. Please visit https://medical-data-
models.org/forms/17037
Eligibility Depression NCT00231959
Inclusion Criteria
meets diagnostic criteria for major depressive
disorder*
Yes
No
meets criteria for current major depressive
episode*
Yes
No
score of at least 18 on the montgomery-asberg
depression rating scale (madrs) at the baseline
visit*
Yes
No
currently being treated with antidepressant
monotherapy at an adequate dose for 6 weeks or
willing to enter open lead-in treatment*
Yes
No
agrees to use an effective form of contraception
throughout the study*
Yes
No
Exclusion Criteria
pregnant*
Yes
No
at risk for suicide or homicide*
Yes
No
unstable medical illness (e.g., cardiovascular,
liver, kidney, respiratory, endocrine, or neurologic
disease, including uncontrolled seizure disorder)*
Yes
No
history of a substance use disorder within 6
months of study enrollment*
Yes
No
history of or current psychotic features*
Yes
No
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currently being treated with typical or atypical
antipsychotic medications*
Yes
No
currently being treated with a medication known
to significantly decrease pramipexole clearance
(e.g., cimetidine, ranitidine, diltazem, verapamil,
quinine or triamterene)*
Yes
No
clinical or laboratory evidence of untreated
hypothyroidism*
Yes
No
history of a 2-week or longer course of
pramipexole*
Yes
No
intolerance of pramipexole at any dose*
Yes
No
any investigational psychotropic drug use within
the last three months*
Yes
No
level 3 or greater antidepressant resistance as
assessed by the athf*
Yes
No
three or more episodes of self-harm in the year
prior to study enrollment*
Yes
No
documented history of poor treatment adherence
or frequently missed appointments*
Yes
No
parkinson's disease*
Yes
No
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Mental health non-government organisation establishments DSS 2015- Mental
health organisation details cluster Metadata Online Registry (METeOR)
Health sector data set specifications from METeOR,
Australia's repository for national metadata standards,
developed by the Australian Institute of Health and Welfare
(http://meteor.aihw.gov.au/content/index.phtml/itemId/3451
65)
Mental health organisation details cluster
The scope of the Mental health non-government
organisation establishments data set specification (MH
NGOE DSS) is mental health-related non-government
organisations which provide one or more of the service
types included in the service taxonomy: Counselling—face-
to-face, Counselling, support, information and
referral—telephone, Counselling, support, information and
referral—online, Self-help—online, Group support activities,
Mutual support and self-help, Staffed residential services,
Personalised support—linked to housing, Personalised
support—other, Family and carer support, Individual
advocacy, Care coordination, Service integration
infrastructure, Education, employment and training, Sector
development and representation, Mental health promotion,
and Mental illness prevention.
Mental health non-government organisations are private
organisations (both not-for-profit and for-profit) that receive
Australian and/or state or territory government funding
specifically for the provision of services where the principal
intent is targeted at improving mental health and well-being
and delivered to people affected by mental illness, their
families and carers, or the broader community. These
services focus on providing well-being, support and
assistance to people who live with a mental illness rather
than the assessment, diagnostic and treatment tasks
undertaken by clinically focused services.
This data element cluster describes data items relating to a
mental health non-government organisation service at the
organisation level.
Obligation: Mandatory
Metadata and Classifications Unit 
Australian Institute of Health and Welfare
GPO Box 570
Canberra ACT 2601
All rights reserved. Please visit https://medical-data-
models.org/forms/17039
Mental health non-government
organisation establishments DSS
2015- Mental health organisation
details cluster Metadata Online
Registry (METeOR)
Service provider organisation 1
Mental health government funding source*
NSW Health (101)
Victorian Department of Health (201)
Queensland Department of Health (301)
SA Health (401)
Western Australian Mental Health
Commission (501)
Tasmanian Department of Health and
Human Services (601)
NT Department of Health (701)
ACT Government Health Directorate
(801)
Commonwealth Department of Health
(901)
Commonwealth Department of Social
Services (921)
1 / 2
Entity
Australian business number (ABN)*
Organisation
Organisation name*
Address
Statistical area level 2 (SA2)*
Service provider organisation 2
Quality accreditation/certification standard type*
National Standards for Mental Health
Services (1)
International Organization for
Standardization (ISO 9000) (2)
Quality Improvement Council (QIC)
Health and Community Service
Standards (3)
National Safety and Quality Health
Service (NSQHS) Standards (4)
Quality accreditation/certification standard
indicator*
Yes, the service provider organisation is
accredited or compliant with relevant
industry quality standards. (1)
No, the service provider organisation is
not accredited or compliant with relevant
industry quality standards. (2)
Undergoing assessment. The service
provider organisation is undergoing the
applicable accreditation/certification
process but has not yet been granted
accreditation/certification. (3)
Not applicable. The standard is not
applicable to the service provider
organisation. (7)
Not-for-profit indicator*
Yes
No
Consumer-managed organisation indicator*
Yes
No
Full-time equivalent paid overhead staff
(average)*
2 / 2
Mental health non-government organisation establishments DSS 2015- Mental
health organisation details cluster Metadata Online Registry (METeOR)
Mental health non-government organisation establishments DSS 2015-
Counselling—face-to-face mental health service type cluster Metadata Online
Registry (METeOR)
Health sector data set specifications from METeOR,
Australia's repository for national metadata standards,
developed by the Australian Institute of Health and Welfare
(http://meteor.aihw.gov.au/content/index.phtml/itemId/3451
65)
Counselling—face-to-face mental health service type
cluster
Obligation: Conditional
The scope of the Mental health non-government
organisation establishments data set specification (MH
NGOE DSS) is mental health-related non-government
organisations which provide one or more of the service
types included in the service taxonomy: Counselling—face-
to-face, Counselling, support, information and
referral—telephone, Counselling, support, information and
referral—online, Self-help—online, Group support activities,
Mutual support and self-help, Staffed residential services,
Personalised support—linked to housing, Personalised
support—other, Family and carer support, Individual
advocacy, Care coordination, Service integration
infrastructure, Education, employment and training, Sector
development and representation, Mental health promotion,
and Mental illness prevention.
Mental health non-government organisations are private
organisations (both not-for-profit and for-profit) that receive
Australian and/or state or territory government funding
specifically for the provision of services where the principal
intent is targeted at improving mental health and well-being
and delivered to people affected by mental illness, their
families and carers, or the broader community. These
services focus on providing well-being, support and
assistance to people who live with a mental illness rather
than the assessment, diagnostic and treatment tasks
undertaken by clinically focused services.
This data element cluster describes Counselling—face to
face activities in a mental health non-government
organisation service.
Metadata and Classifications Unit 
Australian Institute of Health and Welfare
GPO Box 570
Canberra ACT 2601
All rights reserved. Please visit https://medical-data-
models.org/forms/17040
Mental health non-government
organisation establishments DSS
2015- Counselling—face-to-face
mental health service type cluster
Metadata Online Registry (METeOR)
Service provider organisation 1
Mental health government funding source*
NSW Health (101)
Victorian Department of Health (201)
Queensland Department of Health (301)
SA Health (401)
Western Australian Mental Health
Commission (501)
Tasmanian Department of Health and
Human Services (601)
NT Department of Health (701)
ACT Government Health Directorate
(801)
Commonwealth Department of Health
(901)
Commonwealth Department of Social
Services (921)
1 / 2
Entity
Australian business number (ABN)*
Service provider organisation 2
Program name*
Number of clients*
Unique client count accuracy descriptor*
Actual count (1)
Estimated count (2)
Unknown count type (8)
Number of individual sessions*
Number of group sessions*
Number of individual session hours*
hours
Number of group session hours*
hours
Mental health funding provided to NGOs from
government authorities*
AU$
Full-time equivalent paid staff*
Hours worked—volunteer/unpaid staff*
hours
Full-time equivalent paid peer workers (average)*
Outcome measurement tool indicator*
Yes (1)
No (2)
Not applicable (9)
Address
Statistical area level 2 (SA2)*
2 / 2
Mental health non-government organisation establishments DSS 2015-
Counselling—face-to-face mental health service type cluster Metadata Online
Registry (METeOR)
Mental health non-government organisation establishments DSS 2015-
Counselling, support, information and referral—telephone mental health service
type cluster Metadata Online Registry (METeOR)
Health sector data set specifications from METeOR,
Australia's repository for national metadata standards,
developed by the Australian Institute of Health and Welfare
(http://meteor.aihw.gov.au/content/index.phtml/itemId/3451
65)
Counselling, support, information and referral—telephone
mental health service type cluster
The scope of the Mental health non-government
organisation establishments data set specification (MH
NGOE DSS) is mental health-related non-government
organisations which provide one or more of the service
types included in the service taxonomy: Counselling—face-
to-face, Counselling, support, information and
referral—telephone, Counselling, support, information and
referral—online, Self-help—online, Group support activities,
Mutual support and self-help, Staffed residential services,
Personalised support—linked to housing, Personalised
support—other, Family and carer support, Individual
advocacy, Care coordination, Service integration
infrastructure, Education, employment and training, Sector
development and representation, Mental health promotion,
and Mental illness prevention.
Mental health non-government organisations are private
organisations (both not-for-profit and for-profit) that receive
Australian and/or state or territory government funding
specifically for the provision of services where the principal
intent is targeted at improving mental health and well-being
and delivered to people affected by mental illness, their
families and carers, or the broader community. These
services focus on providing well-being, support and
assistance to people who live with a mental illness rather
than the assessment, diagnostic and treatment tasks
undertaken by clinically focused services.
This data element cluster describes Counselling, support,
information and referral—telephone activities in a mental
health non-government organisation service.
Obligation: Conditional
Metadata and Classifications Unit 
Australian Institute of Health and Welfare
GPO Box 570
Canberra ACT 2601
All rights reserved. Please visit https://medical-data-
models.org/forms/17041
Mental health non-government
organisation establishments DSS
2015- Counselling, support,
information and referral—telephone
mental health service type cluster
Metadata Online Registry (METeOR)
Service provider organisation 1
Mental health government funding source*
NSW Health (101)
Victorian Department of Health (201)
Queensland Department of Health (301)
SA Health (401)
Western Australian Mental Health
Commission (501)
Tasmanian Department of Health and
Human Services (601)
NT Department of Health (701)
ACT Government Health Directorate
(801)
Commonwealth Department of Health
(901)
Commonwealth Department of Social
Services (921)
1 / 2
Entity
Australian business number (ABN)*
Service provider organisation 2
Program name*
Number of clients*
Unique client count accuracy descriptor*
Actual count (1)
Estimated count (2)
Unknown count type (8)
Number of service provision telephone calls*
Mental health funding provided to NGOs from
government authorities*
AU$
Full-time equivalent paid staff*
Hours worked—volunteer/unpaid staff*
hours
Full-time equivalent paid peer workers (average)*
2 / 2
Mental health non-government organisation establishments DSS 2015-
Counselling, support, information and referral—telephone mental health service
type cluster Metadata Online Registry (METeOR)
Mental health non-government organisation establishments DSS 2015-
Counselling, support, information and referral—online mental health service type
cluster Metadata Online Registry (METeOR)
Health sector data set specifications from METeOR,
Australia's repository for national metadata standards,
developed by the Australian Institute of Health and Welfare
(http://meteor.aihw.gov.au/content/index.phtml/itemId/3451
65)
Counselling, support, information and referral—online
mental health service type cluster
The scope of the Mental health non-government
organisation establishments data set specification (MH
NGOE DSS) is mental health-related non-government
organisations which provide one or more of the service
types included in the service taxonomy: Counselling—face-
to-face, Counselling, support, information and
referral—telephone, Counselling, support, information and
referral—online, Self-help—online, Group support activities,
Mutual support and self-help, Staffed residential services,
Personalised support—linked to housing, Personalised
support—other, Family and carer support, Individual
advocacy, Care coordination, Service integration
infrastructure, Education, employment and training, Sector
development and representation, Mental health promotion,
and Mental illness prevention.
Mental health non-government organisations are private
organisations (both not-for-profit and for-profit) that receive
Australian and/or state or territory government funding
specifically for the provision of services where the principal
intent is targeted at improving mental health and well-being
and delivered to people affected by mental illness, their
families and carers, or the broader community. These
services focus on providing well-being, support and
assistance to people who live with a mental illness rather
than the assessment, diagnostic and treatment tasks
undertaken by clinically focused services.
This data element cluster describes Counselling, support,
information and referral—online activities in a mental health
non-government organisation service.
Obligation: Conditional
Metadata and Classifications Unit 
Australian Institute of Health and Welfare
GPO Box 570
Canberra ACT 2601
All rights reserved. Please visit https://medical-data-
models.org/forms/17042
Mental health non-government
organisation establishments DSS
2015- Counselling, support,
information and referral—online
mental health service type cluster
Metadata Online Registry (METeOR)
Service provider organisation 1
Mental health government funding source*
NSW Health (101)
Victorian Department of Health (201)
Queensland Department of Health (301)
SA Health (401)
Western Australian Mental Health
Commission (501)
Tasmanian Department of Health and
Human Services (601)
NT Department of Health (701)
ACT Government Health Directorate
(801)
Commonwealth Department of Health
(901)
Commonwealth Department of Social
Services (921)
1 / 2
Entity
Australian business number (ABN)*
Service provider organisation 2
Program name*
Number of visits to a website*
Number of online chat sessions conducted with
clients*
Mental health funding provided to NGOs from
government authorities*
AU$
Full-time equivalent paid staff*
Hours worked—volunteer/unpaid staff*
hours
Full-time equivalent paid peer workers (average)*
2 / 2
Mental health non-government organisation establishments DSS 2015-
Counselling, support, information and referral—online mental health service type
cluster Metadata Online Registry (METeOR)
Mental health non-government organisation establishments DSS 2015- Self-
help—online mental health service type cluster Metadata Online Registry
(METeOR)
Health sector data set specifications from METeOR,
Australia's repository for national metadata standards,
developed by the Australian Institute of Health and Welfare
(http://meteor.aihw.gov.au/content/index.phtml/itemId/3451
65)
Self-help—online mental health service type cluster
The scope of the Mental health non-government
organisation establishments data set specification (MH
NGOE DSS) is mental health-related non-government
organisations which provide one or more of the service
types included in the service taxonomy: Counselling—face-
to-face, Counselling, support, information and
referral—telephone, Counselling, support, information and
referral—online, Self-help—online, Group support activities,
Mutual support and self-help, Staffed residential services,
Personalised support—linked to housing, Personalised
support—other, Family and carer support, Individual
advocacy, Care coordination, Service integration
infrastructure, Education, employment and training, Sector
development and representation, Mental health promotion,
and Mental illness prevention.
Mental health non-government organisations are private
organisations (both not-for-profit and for-profit) that receive
Australian and/or state or territory government funding
specifically for the provision of services where the principal
intent is targeted at improving mental health and well-being
and delivered to people affected by mental illness, their
families and carers, or the broader community. These
services focus on providing well-being, support and
assistance to people who live with a mental illness rather
than the assessment, diagnostic and treatment tasks
undertaken by clinically focused services.
This data element cluster describes Self-help—online
activities in a mental health non-government organisation
service.
Obligation: Conditional
Metadata and Classifications Unit 
Australian Institute of Health and Welfare
GPO Box 570
Canberra ACT 2601
All rights reserved. Please visit https://medical-data-
models.org/forms/17043
Mental health non-government
organisation establishments DSS
2015- Self-help—online mental
health service type cluster Metadata
Online Registry (METeOR)
Service provider organisation 1
Mental health government funding source*
NSW Health (101)
Victorian Department of Health (201)
Queensland Department of Health (301)
SA Health (401)
Western Australian Mental Health
Commission (501)
Tasmanian Department of Health and
Human Services (601)
NT Department of Health (701)
ACT Government Health Directorate
(801)
Commonwealth Department of Health
(901)
Commonwealth Department of Social
Services (921)
1 / 2
Entity
Australian business number (ABN)*
Service provider organisation 2
Program name*
Number of registered users*
Mental health funding provided to NGOs from
government authorities*
AU$
Full-time equivalent paid staff*
Full-time equivalent paid peer workers (average)*
2 / 2
Mental health non-government organisation establishments DSS 2015- Self-
help—online mental health service type cluster Metadata Online Registry
(METeOR)
Mental health non-government organisation establishments DSS 2015- Group
support activities mental health service type cluster Metadata Online Registry
(METeOR)
Health sector data set specifications from METeOR,
Australia's repository for national metadata standards,
developed by the Australian Institute of Health and Welfare
(http://meteor.aihw.gov.au/content/index.phtml/itemId/3451
65)
Group support activities mental health service type cluster
The scope of the Mental health non-government
organisation establishments data set specification (MH
NGOE DSS) is mental health-related non-government
organisations which provide one or more of the service
types included in the service taxonomy: Counselling—face-
to-face, Counselling, support, information and
referral—telephone, Counselling, support, information and
referral—online, Self-help—online, Group support activities,
Mutual support and self-help, Staffed residential services,
Personalised support—linked to housing, Personalised
support—other, Family and carer support, Individual
advocacy, Care coordination, Service integration
infrastructure, Education, employment and training, Sector
development and representation, Mental health promotion,
and Mental illness prevention.
Mental health non-government organisations are private
organisations (both not-for-profit and for-profit) that receive
Australian and/or state or territory government funding
specifically for the provision of services where the principal
intent is targeted at improving mental health and well-being
and delivered to people affected by mental illness, their
families and carers, or the broader community. These
services focus on providing well-being, support and
assistance to people who live with a mental illness rather
than the assessment, diagnostic and treatment tasks
undertaken by clinically focused services.
This data element cluster describes Group support
activities in a mental health non-government organisation
service.
Obligation: Conditional
Metadata and Classifications Unit 
Australian Institute of Health and Welfare
GPO Box 570
Canberra ACT 2601
All rights reserved. Please visit https://medical-data-
models.org/forms/17044
Mental health non-government
organisation establishments DSS
2015- Group support activities
mental health service type cluster
Metadata Online Registry (METeOR)
Service provider organisation 1
Mental health government funding source*
NSW Health (101)
Victorian Department of Health (201)
Queensland Department of Health (301)
SA Health (401)
Western Australian Mental Health
Commission (501)
Tasmanian Department of Health and
Human Services (601)
NT Department of Health (701)
ACT Government Health Directorate
(801)
Commonwealth Department of Health
(901)
Commonwealth Department of Social
Services (921)
1 / 2
Entity
Australian business number (ABN)*
Service provider organisation 2
Program name*
Number of clients*
Unique client count accuracy descriptor*
Actual count (1)
Estimated count (2)
Unknown count type (8)
Number of attendances at events*
Mental health funding provided to NGOs from
government authorities*
AU$
Full-time equivalent paid staff*
Hours worked—volunteer/unpaid staff*
hours
Full-time equivalent paid peer workers (average)*
Address
Statistical area level 2 (SA2)*
2 / 2
Mental health non-government organisation establishments DSS 2015- Group
support activities mental health service type cluster Metadata Online Registry
(METeOR)
Mental health non-government organisation establishments DSS 2015- Mutual
support and self-help mental health service type cluster Metadata Online Registry
(METeOR)
Health sector data set specifications from METeOR,
Australia's repository for national metadata standards,
developed by the Australian Institute of Health and Welfare
(http://meteor.aihw.gov.au/content/index.phtml/itemId/3451
65)
Mutual support and self-help mental health service type
cluster
The scope of the Mental health non-government
organisation establishments data set specification (MH
NGOE DSS) is mental health-related non-government
organisations which provide one or more of the service
types included in the service taxonomy: Counselling—face-
to-face, Counselling, support, information and
referral—telephone, Counselling, support, information and
referral—online, Self-help—online, Group support activities,
Mutual support and self-help, Staffed residential services,
Personalised support—linked to housing, Personalised
support—other, Family and carer support, Individual
advocacy, Care coordination, Service integration
infrastructure, Education, employment and training, Sector
development and representation, Mental health promotion,
and Mental illness prevention.
Mental health non-government organisations are private
organisations (both not-for-profit and for-profit) that receive
Australian and/or state or territory government funding
specifically for the provision of services where the principal
intent is targeted at improving mental health and well-being
and delivered to people affected by mental illness, their
families and carers, or the broader community. These
services focus on providing well-being, support and
assistance to people who live with a mental illness rather
than the assessment, diagnostic and treatment tasks
undertaken by clinically focused services.
This data element cluster describes Mutual support and
self-help activities in a mental health non-government
organisation service.
Obligation: Conditional
Metadata and Classifications Unit 
Australian Institute of Health and Welfare
GPO Box 570
Canberra ACT 2601
All rights reserved. Please visit https://medical-data-
models.org/forms/17045
Mental health non-government
organisation establishments DSS
2015- Mutual support and self-help
mental health service type cluster
Metadata Online Registry (METeOR)
Service provider organisation 1
Mental health government funding source*
NSW Health (101)
Victorian Department of Health (201)
Queensland Department of Health (301)
SA Health (401)
Western Australian Mental Health
Commission (501)
Tasmanian Department of Health and
Human Services (601)
NT Department of Health (701)
ACT Government Health Directorate
(801)
Commonwealth Department of Health
(901)
Commonwealth Department of Social
Services (921)
1 / 2
Entity
Australian business number (ABN)*
Service provider organisation 2
Program name*
Number of clients*
Unique client count accuracy descriptor*
Actual count (1)
Estimated count (2)
Unknown count type (8)
Number of service provision telephone calls*
Number of attendances at events*
Mental health funding provided to NGOs from
government authorities*
AU$
Full-time equivalent paid staff*
Hours worked—volunteer/unpaid staff*
hours
Full-time equivalent paid peer workers (average)*
2 / 2
Mental health non-government organisation establishments DSS 2015- Mutual
support and self-help mental health service type cluster Metadata Online Registry
(METeOR)
Mental health non-government organisation establishments DSS 2015- Mutual
support and self-help mental health service type cluster Metadata Online Registry
(METeOR)
Health sector data set specifications from METeOR,
Australia's repository for national metadata standards,
developed by the Australian Institute of Health and Welfare
(http://meteor.aihw.gov.au/content/index.phtml/itemId/3451
65)
Mutual support and self-help mental health service type
cluster
The scope of the Mental health non-government
organisation establishments data set specification (MH
NGOE DSS) is mental health-related non-government
organisations which provide one or more of the service
types included in the service taxonomy: Counselling—face-
to-face, Counselling, support, information and
referral—telephone, Counselling, support, information and
referral—online, Self-help—online, Group support activities,
Mutual support and self-help, Staffed residential services,
Personalised support—linked to housing, Personalised
support—other, Family and carer support, Individual
advocacy, Care coordination, Service integration
infrastructure, Education, employment and training, Sector
development and representation, Mental health promotion,
and Mental illness prevention.
Mental health non-government organisations are private
organisations (both not-for-profit and for-profit) that receive
Australian and/or state or territory government funding
specifically for the provision of services where the principal
intent is targeted at improving mental health and well-being
and delivered to people affected by mental illness, their
families and carers, or the broader community. These
services focus on providing well-being, support and
assistance to people who live with a mental illness rather
than the assessment, diagnostic and treatment tasks
undertaken by clinically focused services.
This data element cluster describes Mutual support and
self-help activities in a mental health non-government
organisation service.
Obligation: Conditional
Metadata and Classifications Unit 
Australian Institute of Health and Welfare
GPO Box 570
Canberra ACT 2601
All rights reserved. Please visit https://medical-data-
models.org/forms/17046
Mental health non-government
organisation establishments DSS
2015- Mutual support and self-help
mental health service type cluster
Metadata Online Registry (METeOR)
Service provider organisation 1
Mental health government funding source*
NSW Health (101)
Victorian Department of Health (201)
Queensland Department of Health (301)
SA Health (401)
Western Australian Mental Health
Commission (501)
Tasmanian Department of Health and
Human Services (601)
NT Department of Health (701)
ACT Government Health Directorate
(801)
Commonwealth Department of Health
(901)
Commonwealth Department of Social
Services (921)
1 / 2
Entity
Australian business number (ABN)*
Service provider organisation 2
Program name*
Number of clients*
Unique client count accuracy descriptor*
Actual count (1)
Estimated count (2)
Unknown count type (8)
Number of service provision telephone calls*
Number of attendances at events*
Mental health funding provided to NGOs from
government authorities*
AU$
Full-time equivalent paid staff*
Hours worked—volunteer/unpaid staff*
hours
Full-time equivalent paid peer workers (average)*
2 / 2
Mental health non-government organisation establishments DSS 2015- Mutual
support and self-help mental health service type cluster Metadata Online Registry
(METeOR)
Mental health non-government organisation establishments DSS 2015- Staffed
residential services mental health service type cluster Metadata Online Registry
(METeOR)
Health sector data set specifications from METeOR,
Australia's repository for national metadata standards,
developed by the Australian Institute of Health and Welfare
(http://meteor.aihw.gov.au/content/index.phtml/itemId/3451
65)
Staffed residential services mental health service type
cluster
Obligation: Conditional
The scope of the Mental health non-government
organisation establishments data set specification (MH
NGOE DSS) is mental health-related non-government
organisations which provide one or more of the service
types included in the service taxonomy: Counselling—face-
to-face, Counselling, support, information and
referral—telephone, Counselling, support, information and
referral—online, Self-help—online, Group support activities,
Mutual support and self-help, Staffed residential services,
Personalised support—linked to housing, Personalised
support—other, Family and carer support, Individual
advocacy, Care coordination, Service integration
infrastructure, Education, employment and training, Sector
development and representation, Mental health promotion,
and Mental illness prevention.
Mental health non-government organisations are private
organisations (both not-for-profit and for-profit) that receive
Australian and/or state or territory government funding
specifically for the provision of services where the principal
intent is targeted at improving mental health and well-being
and delivered to people affected by mental illness, their
families and carers, or the broader community. These
services focus on providing well-being, support and
assistance to people who live with a mental illness rather
than the assessment, diagnostic and treatment tasks
undertaken by clinically focused services.
This data element cluster describes Staffed residential
services in a mental health non-government organisation
service.
Metadata and Classifications Unit 
Australian Institute of Health and Welfare
GPO Box 570
Canberra ACT 2601
All rights reserved. Please visit https://medical-data-
models.org/forms/17047
Mental health non-government
organisation establishments DSS
2015- Staffed residential services
mental health service type cluster
Metadata Online Registry (METeOR)
Service provider organisation 1
Mental health government funding source*
NSW Health (101)
Victorian Department of Health (201)
Queensland Department of Health (301)
SA Health (401)
Western Australian Mental Health
Commission (501)
Tasmanian Department of Health and
Human Services (601)
NT Department of Health (701)
ACT Government Health Directorate
(801)
Commonwealth Department of Health
(901)
Commonwealth Department of Social
Services (921)
1 / 2
Entity
Australian business number (ABN)*
Service provider organisation 2
Program name*
Number of clients*
Unique client count accuracy descriptor*
Actual count (1)
Estimated count (2)
Unknown count type (8)
Episode of residential care
Number of episodes of residential care*
Establishment
Accrued mental health care days*
days
Service provider organisation 3
Mental health funding provided to NGOs from
government authorities*
AU$
Full-time equivalent paid staff*
Hours worked—volunteer/unpaid staff*
hours
Full-time equivalent paid peer workers (average)*
Outcome measurement tool indicator*
Yes (1)
No (2)
Not applicable (9)
Address
Statistical area level 2 (SA2)*
2 / 2
Mental health non-government organisation establishments DSS 2015- Staffed
residential services mental health service type cluster Metadata Online Registry
(METeOR)
Mental health non-government organisation establishments DSS 2015-
Personalised support—linked to housing mental health service type cluster
Metadata Online Registry (METeOR)
Health sector data set specifications from METeOR,
Australia's repository for national metadata standards,
developed by the Australian Institute of Health and Welfare
(http://meteor.aihw.gov.au/content/index.phtml/itemId/3451
65)
Personalised support—linked to housing mental health
service type cluster
Obligation: Conditional
The scope of the Mental health non-government
organisation establishments data set specification (MH
NGOE DSS) is mental health-related non-government
organisations which provide one or more of the service
types included in the service taxonomy: Counselling—face-
to-face, Counselling, support, information and
referral—telephone, Counselling, support, information and
referral—online, Self-help—online, Group support activities,
Mutual support and self-help, Staffed residential services,
Personalised support—linked to housing, Personalised
support—other, Family and carer support, Individual
advocacy, Care coordination, Service integration
infrastructure, Education, employment and training, Sector
development and representation, Mental health promotion,
and Mental illness prevention.
Mental health non-government organisations are private
organisations (both not-for-profit and for-profit) that receive
Australian and/or state or territory government funding
specifically for the provision of services where the principal
intent is targeted at improving mental health and well-being
and delivered to people affected by mental illness, their
families and carers, or the broader community. These
services focus on providing well-being, support and
assistance to people who live with a mental illness rather
than the assessment, diagnostic and treatment tasks
undertaken by clinically focused services.
This data element cluster describes Personalised
support—linked to housing activities in a mental health
non-government organisation service.
Metadata and Classifications Unit 
Australian Institute of Health and Welfare
GPO Box 570
Canberra ACT 2601
All rights reserved. Please visit https://medical-data-
models.org/forms/17048
Mental health non-government
organisation establishments DSS
2015- Personalised support—linked
to housing mental health service
type cluster Metadata Online
Registry (METeOR)
Service provider organisation 1
Mental health government funding source*
NSW Health (101)
Victorian Department of Health (201)
Queensland Department of Health (301)
SA Health (401)
Western Australian Mental Health
Commission (501)
Tasmanian Department of Health and
Human Services (601)
NT Department of Health (701)
ACT Government Health Directorate
(801)
Commonwealth Department of Health
(901)
Commonwealth Department of Social
Services (921)
1 / 2
Entity
Australian business number (ABN)*
Service provider organisation 2
Program name*
Number of clients*
Unique client count accuracy descriptor*
Actual count (1)
Estimated count (2)
Unknown count type (8)
Number of service contacts*
Number of contact hours*
hours
Mental health funding provided to NGOs from
government authorities*
AU$
Full-time equivalent paid staff*
Hours worked—volunteer/unpaid staff*
hours
Full-time equivalent paid peer workers (average)*
Outcome measurement tool indicator*
Yes (1)
No (2)
Not applicable (9)
Address
Statistical area level 2 (SA2)*
2 / 2
Mental health non-government organisation establishments DSS 2015-
Personalised support—linked to housing mental health service type cluster
Metadata Online Registry (METeOR)
Mental health non-government organisation establishments DSS 2015-
Personalised support—other mental health service type cluster Metadata Online
Registry (METeOR)
Health sector data set specifications from METeOR,
Australia's repository for national metadata standards,
developed by the Australian Institute of Health and Welfare
(http://meteor.aihw.gov.au/content/index.phtml/itemId/3451
65)
Personalised support—other mental health service type
cluster
The scope of the Mental health non-government
organisation establishments data set specification (MH
NGOE DSS) is mental health-related non-government
organisations which provide one or more of the service
types included in the service taxonomy: Counselling—face-
to-face, Counselling, support, information and
referral—telephone, Counselling, support, information and
referral—online, Self-help—online, Group support activities,
Mutual support and self-help, Staffed residential services,
Personalised support—linked to housing, Personalised
support—other, Family and carer support, Individual
advocacy, Care coordination, Service integration
infrastructure, Education, employment and training, Sector
development and representation, Mental health promotion,
and Mental illness prevention.
Mental health non-government organisations are private
organisations (both not-for-profit and for-profit) that receive
Australian and/or state or territory government funding
specifically for the provision of services where the principal
intent is targeted at improving mental health and well-being
and delivered to people affected by mental illness, their
families and carers, or the broader community. These
services focus on providing well-being, support and
assistance to people who live with a mental illness rather
than the assessment, diagnostic and treatment tasks
undertaken by clinically focused services.
This data element cluster describes Personalised
support—other activities in a mental health non-
government organisation service.
Obligation: Conditional
Metadata and Classifications Unit 
Australian Institute of Health and Welfare
GPO Box 570
Canberra ACT 2601
All rights reserved. Please visit https://medical-data-
models.org/forms/17049
Mental health non-government
organisation establishments DSS
2015- Personalised support—other
mental health service type cluster
Metadata Online Registry (METeOR)
Service provider organisation 1
Mental health government funding source*
NSW Health (101)
Victorian Department of Health (201)
Queensland Department of Health (301)
SA Health (401)
Western Australian Mental Health
Commission (501)
Tasmanian Department of Health and
Human Services (601)
NT Department of Health (701)
ACT Government Health Directorate
(801)
Commonwealth Department of Health
(901)
Commonwealth Department of Social
Services (921)
1 / 2
Entity
Australian business number (ABN)*
Service provider organisation 2
Program name*
Number of clients*
Unique client count accuracy descriptor*
Actual count (1)
Estimated count (2)
Unknown count type (8)
Number of service contacts*
Number of contact hours*
hours
Mental health funding provided to NGOs from
government authorities*
AU$
Full-time equivalent paid staff*
Hours worked—volunteer/unpaid staff*
hours
Full-time equivalent paid peer workers (average)*
Outcome measurement tool indicator*
Yes (1)
No (2)
Not applicable (9)
Address
Statistical area level 2 (SA2)*
2 / 2
Mental health non-government organisation establishments DSS 2015-
Personalised support—other mental health service type cluster Metadata Online
Registry (METeOR)
Mental health non-government organisation establishments DSS 2015- Family and
carer support mental health service type cluster Metadata Online Registry
(METeOR)
Health sector data set specifications from METeOR,
Australia's repository for national metadata standards,
developed by the Australian Institute of Health and Welfare
(http://meteor.aihw.gov.au/content/index.phtml/itemId/3451
65)
Family and carer support mental health service type cluster
Obligation: Conditional
The scope of the Mental health non-government
organisation establishments data set specification (MH
NGOE DSS) is mental health-related non-government
organisations which provide one or more of the service
types included in the service taxonomy: Counselling—face-
to-face, Counselling, support, information and
referral—telephone, Counselling, support, information and
referral—online, Self-help—online, Group support activities,
Mutual support and self-help, Staffed residential services,
Personalised support—linked to housing, Personalised
support—other, Family and carer support, Individual
advocacy, Care coordination, Service integration
infrastructure, Education, employment and training, Sector
development and representation, Mental health promotion,
and Mental illness prevention.
Mental health non-government organisations are private
organisations (both not-for-profit and for-profit) that receive
Australian and/or state or territory government funding
specifically for the provision of services where the principal
intent is targeted at improving mental health and well-being
and delivered to people affected by mental illness, their
families and carers, or the broader community. These
services focus on providing well-being, support and
assistance to people who live with a mental illness rather
than the assessment, diagnostic and treatment tasks
undertaken by clinically focused services.
This data element cluster describes Family and carer
support activities in a mental health non-government
organisation service.
Metadata and Classifications Unit 
Australian Institute of Health and Welfare
GPO Box 570
Canberra ACT 2601
All rights reserved. Please visit https://medical-data-
models.org/forms/17050
Mental health non-government
organisation establishments DSS
2015- Family and carer support
mental health service type cluster
Metadata Online Registry (METeOR)
Service provider organisation 1
Mental health government funding source*
NSW Health (101)
Victorian Department of Health (201)
Queensland Department of Health (301)
SA Health (401)
Western Australian Mental Health
Commission (501)
Tasmanian Department of Health and
Human Services (601)
NT Department of Health (701)
ACT Government Health Directorate
(801)
Commonwealth Department of Health
(901)
Commonwealth Department of Social
Services (921)
1 / 2
Entity
Australian business number (ABN)*
Service provider organisation 2
Program name*
Number of clients*
Unique client count accuracy descriptor*
Actual count (1)
Estimated count (2)
Unknown count type (8)
Mental health funding provided to NGOs from
government authorities*
AU$
Full-time equivalent paid staff*
Hours worked—volunteer/unpaid staff*
hours
Full-time equivalent paid peer workers (average)*
Address
Statistical area level 2 (SA2)*
2 / 2
Mental health non-government organisation establishments DSS 2015- Family and
carer support mental health service type cluster Metadata Online Registry
(METeOR)
Mental health non-government organisation establishments DSS 2015- Individual
advocacy mental health service type cluster Metadata Online Registry (METeOR)
Health sector data set specifications from METeOR,
Australia's repository for national metadata standards,
developed by the Australian Institute of Health and Welfare
(http://meteor.aihw.gov.au/content/index.phtml/itemId/3451
65)
Individual advocacy mental health service type cluster
The scope of the Mental health non-government
organisation establishments data set specification (MH
NGOE DSS) is mental health-related non-government
organisations which provide one or more of the service
types included in the service taxonomy: Counselling—face-
to-face, Counselling, support, information and
referral—telephone, Counselling, support, information and
referral—online, Self-help—online, Group support activities,
Mutual support and self-help, Staffed residential services,
Personalised support—linked to housing, Personalised
support—other, Family and carer support, Individual
advocacy, Care coordination, Service integration
infrastructure, Education, employment and training, Sector
development and representation, Mental health promotion,
and Mental illness prevention.
Mental health non-government organisations are private
organisations (both not-for-profit and for-profit) that receive
Australian and/or state or territory government funding
specifically for the provision of services where the principal
intent is targeted at improving mental health and well-being
and delivered to people affected by mental illness, their
families and carers, or the broader community. These
services focus on providing well-being, support and
assistance to people who live with a mental illness rather
than the assessment, diagnostic and treatment tasks
undertaken by clinically focused services.
This data element cluster describes Individual advocacy
activities in a mental health non-government organisation
service.
Obligation: Conditional
Metadata and Classifications Unit 
Australian Institute of Health and Welfare
GPO Box 570
Canberra ACT 2601
All rights reserved. Please visit https://medical-data-
models.org/forms/17051
Mental health non-government
organisation establishments DSS
2015- Individual advocacy mental
health service type cluster Metadata
Online Registry (METeOR)
Service provider organisation 1
Mental health government funding source*
NSW Health (101)
Victorian Department of Health (201)
Queensland Department of Health (301)
SA Health (401)
Western Australian Mental Health
Commission (501)
Tasmanian Department of Health and
Human Services (601)
NT Department of Health (701)
ACT Government Health Directorate
(801)
Commonwealth Department of Health
(901)
Commonwealth Department of Social
Services (921)
1 / 2
Entity
Australian business number (ABN)*
Service provider organisation 2
Program name*
Number of clients*
Unique client count accuracy descriptor*
Actual count (1)
Estimated count (2)
Unknown count type (8)
Number of service contacts*
Number of contact hours*
hours
Mental health funding provided to NGOs from
government authorities*
AU$
Full-time equivalent paid staff*
Hours worked—volunteer/unpaid staff*
hours
Full-time equivalent paid peer workers (average)*
Address
Statistical area level 2 (SA2)*
2 / 2
Mental health non-government organisation establishments DSS 2015- Individual
advocacy mental health service type cluster Metadata Online Registry (METeOR)
Mental health non-government organisation establishments DSS 2015- Care
coordination mental health service type cluster Metadata Online Registry
(METeOR)
Health sector data set specifications from METeOR,
Australia's repository for national metadata standards,
developed by the Australian Institute of Health and Welfare
(http://meteor.aihw.gov.au/content/index.phtml/itemId/3451
65)
Care coordination mental health service type cluster
The scope of the Mental health non-government
organisation establishments data set specification (MH
NGOE DSS) is mental health-related non-government
organisations which provide one or more of the service
types included in the service taxonomy: Counselling—face-
to-face, Counselling, support, information and
referral—telephone, Counselling, support, information and
referral—online, Self-help—online, Group support activities,
Mutual support and self-help, Staffed residential services,
Personalised support—linked to housing, Personalised
support—other, Family and carer support, Individual
advocacy, Care coordination, Service integration
infrastructure, Education, employment and training, Sector
development and representation, Mental health promotion,
and Mental illness prevention.
Mental health non-government organisations are private
organisations (both not-for-profit and for-profit) that receive
Australian and/or state or territory government funding
specifically for the provision of services where the principal
intent is targeted at improving mental health and well-being
and delivered to people affected by mental illness, their
families and carers, or the broader community. These
services focus on providing well-being, support and
assistance to people who live with a mental illness rather
than the assessment, diagnostic and treatment tasks
undertaken by clinically focused services.
This data element cluster describes Care coordination
activities in a mental health non-government organisation
service.
Obligation: Conditional
Metadata and Classifications Unit 
Australian Institute of Health and Welfare
GPO Box 570
Canberra ACT 2601
All rights reserved. Please visit https://medical-data-
models.org/forms/17052
Mental health non-government
organisation establishments DSS
2015- Care coordination mental
health service type cluster Metadata
Online Registry (METeOR)
Service provider organisation 1
Mental health government funding source*
NSW Health (101)
Victorian Department of Health (201)
Queensland Department of Health (301)
SA Health (401)
Western Australian Mental Health
Commission (501)
Tasmanian Department of Health and
Human Services (601)
NT Department of Health (701)
ACT Government Health Directorate
(801)
Commonwealth Department of Health
(901)
Commonwealth Department of Social
Services (921)
1 / 2
Entity
Australian business number (ABN)*
Service provider organisation 2
Program name*
Number of clients*
Unique client count accuracy descriptor*
Actual count (1)
Estimated count (2)
Unknown count type (8)
Number of service contacts*
Number of contact hours*
hours
Mental health funding provided to NGOs from
government authorities*
AU$
Full-time equivalent paid staff*
Hours worked—volunteer/unpaid staff*
hours
Full-time equivalent paid peer workers (average)*
Address
Statistical area level 2 (SA2)*
2 / 2
Mental health non-government organisation establishments DSS 2015- Care
coordination mental health service type cluster Metadata Online Registry
(METeOR)
Mental health non-government organisation establishments DSS 2015- Service
integration infrastructure mental health service type cluster Metadata Online
Registry (METeOR)
Health sector data set specifications from METeOR,
Australia's repository for national metadata standards,
developed by the Australian Institute of Health and Welfare
(http://meteor.aihw.gov.au/content/index.phtml/itemId/3451
65)
Service integration infrastructure mental health service type
cluster
The scope of the Mental health non-government
organisation establishments data set specification (MH
NGOE DSS) is mental health-related non-government
organisations which provide one or more of the service
types included in the service taxonomy: Counselling—face-
to-face, Counselling, support, information and
referral—telephone, Counselling, support, information and
referral—online, Self-help—online, Group support activities,
Mutual support and self-help, Staffed residential services,
Personalised support—linked to housing, Personalised
support—other, Family and carer support, Individual
advocacy, Care coordination, Service integration
infrastructure, Education, employment and training, Sector
development and representation, Mental health promotion,
and Mental illness prevention.
Mental health non-government organisations are private
organisations (both not-for-profit and for-profit) that receive
Australian and/or state or territory government funding
specifically for the provision of services where the principal
intent is targeted at improving mental health and well-being
and delivered to people affected by mental illness, their
families and carers, or the broader community. These
services focus on providing well-being, support and
assistance to people who live with a mental illness rather
than the assessment, diagnostic and treatment tasks
undertaken by clinically focused services.
This data element cluster describes Service integration
infrastructure activities in a mental health non-government
organisation service.
Obligation: Conditional
Metadata and Classifications Unit 
Australian Institute of Health and Welfare
GPO Box 570
Canberra ACT 2601
All rights reserved. Please visit https://medical-data-
models.org/forms/17053
Mental health non-government
organisation establishments DSS
2015- Service integration
infrastructure mental health service
type cluster Metadata Online
Registry (METeOR)
Service provider organisation 1
Mental health government funding source*
NSW Health (101)
Victorian Department of Health (201)
Queensland Department of Health (301)
SA Health (401)
Western Australian Mental Health
Commission (501)
Tasmanian Department of Health and
Human Services (601)
NT Department of Health (701)
ACT Government Health Directorate
(801)
Commonwealth Department of Health
(901)
Commonwealth Department of Social
Services (921)
1 / 2
Entity
Australian business number (ABN)*
Service provider organisation 2
Program name*
Number of clients*
Unique client count accuracy descriptor*
Actual count (1)
Estimated count (2)
Unknown count type (8)
Mental health funding provided to NGOs from
government authorities*
AU$
Full-time equivalent paid staff*
Address
Statistical area level 2 (SA2)*
2 / 2
Mental health non-government organisation establishments DSS 2015- Service
integration infrastructure mental health service type cluster Metadata Online
Registry (METeOR)
Mental health non-government organisation establishments DSS 2015- Education,
employment and training mental health service type cluster Metadata Online
Registry (METeOR)
Health sector data set specifications from METeOR,
Australia's repository for national metadata standards,
developed by the Australian Institute of Health and Welfare
(http://meteor.aihw.gov.au/content/index.phtml/itemId/3451
65)
Education, employment and training mental health service
type cluster
The scope of the Mental health non-government
organisation establishments data set specification (MH
NGOE DSS) is mental health-related non-government
organisations which provide one or more of the service
types included in the service taxonomy: Counselling—face-
to-face, Counselling, support, information and
referral—telephone, Counselling, support, information and
referral—online, Self-help—online, Group support activities,
Mutual support and self-help, Staffed residential services,
Personalised support—linked to housing, Personalised
support—other, Family and carer support, Individual
advocacy, Care coordination, Service integration
infrastructure, Education, employment and training, Sector
development and representation, Mental health promotion,
and Mental illness prevention.
Mental health non-government organisations are private
organisations (both not-for-profit and for-profit) that receive
Australian and/or state or territory government funding
specifically for the provision of services where the principal
intent is targeted at improving mental health and well-being
and delivered to people affected by mental illness, their
families and carers, or the broader community. These
services focus on providing well-being, support and
assistance to people who live with a mental illness rather
than the assessment, diagnostic and treatment tasks
undertaken by clinically focused services.
This data element cluster describes Education,
employment and training activities in a mental health non-
government organisation service.
Obligation: Conditional
Metadata and Classifications Unit 
Australian Institute of Health and Welfare
GPO Box 570
Canberra ACT 2601
All rights reserved. Please visit https://medical-data-
models.org/forms/17055
Mental health non-government
organisation establishments DSS
2015- Education, employment and
training mental health service type
cluster Metadata Online Registry
(METeOR)
Service provider organisation 1
Mental health government funding source*
NSW Health (101)
Victorian Department of Health (201)
Queensland Department of Health (301)
SA Health (401)
Western Australian Mental Health
Commission (501)
Tasmanian Department of Health and
Human Services (601)
NT Department of Health (701)
ACT Government Health Directorate
(801)
Commonwealth Department of Health
(901)
Commonwealth Department of Social
Services (921)
1 / 2
Entity
Australian business number (ABN)*
Service provider organisation 2
Program name*
Number of clients*
Unique client count accuracy descriptor*
Actual count (1)
Estimated count (2)
Unknown count type (8)
Number of service contacts*
Number of contact hours*
hours
Mental health funding provided to NGOs from
government authorities*
AU$
Full-time equivalent paid staff*
Hours worked—volunteer/unpaid staff*
hours
Full-time equivalent paid peer workers (average)*
Address
Statistical area level 2 (SA2)*
2 / 2
Mental health non-government organisation establishments DSS 2015- Education,
employment and training mental health service type cluster Metadata Online
Registry (METeOR)
Mental health non-government organisation establishments DSS 2015- Sector
development and representation mental health service type cluster Metadata Online
Registry (METeOR)
Health sector data set specifications from METeOR,
Australia's repository for national metadata standards,
developed by the Australian Institute of Health and Welfare
(http://meteor.aihw.gov.au/content/index.phtml/itemId/3451
65)
Sector development and representation mental health
service type cluster
This data element cluster describes Sector development
and representation activities in a mental health non-
government organisation service.
Obligation: Conditional
The scope of the Mental health non-government
organisation establishments data set specification (MH
NGOE DSS) is mental health-related non-government
organisations which provide one or more of the service
types included in the service taxonomy: Counselling—face-
to-face, Counselling, support, information and
referral—telephone, Counselling, support, information and
referral—online, Self-help—online, Group support activities,
Mutual support and self-help, Staffed residential services,
Personalised support—linked to housing, Personalised
support—other, Family and carer support, Individual
advocacy, Care coordination, Service integration
infrastructure, Education, employment and training, Sector
development and representation, Mental health promotion,
and Mental illness prevention.
Mental health non-government organisations are private
organisations (both not-for-profit and for-profit) that receive
Australian and/or state or territory government funding
specifically for the provision of services where the principal
intent is targeted at improving mental health and well-being
and delivered to people affected by mental illness, their
families and carers, or the broader community. These
services focus on providing well-being, support and
assistance to people who live with a mental illness rather
than the assessment, diagnostic and treatment tasks
undertaken by clinically focused services.
Metadata and Classifications Unit 
Australian Institute of Health and Welfare
GPO Box 570
Canberra ACT 2601
All rights reserved. Please visit https://medical-data-
models.org/forms/17057
Mental health non-government
organisation establishments DSS
2015- Sector development and
representation mental health service
type cluster Metadata Online
Registry (METeOR)
Service provider organisation 1
Mental health government funding source*
NSW Health (101)
Victorian Department of Health (201)
Queensland Department of Health (301)
SA Health (401)
Western Australian Mental Health
Commission (501)
Tasmanian Department of Health and
Human Services (601)
NT Department of Health (701)
ACT Government Health Directorate
(801)
Commonwealth Department of Health
(901)
Commonwealth Department of Social
Services (921)
1 / 2
Entity
Australian business number (ABN)*
Service provider organisation 2
Program name*
Mental health funding provided to NGOs from
government authorities*
AU$
Full-time equivalent paid staff*
Hours worked—volunteer/unpaid staff*
hours
Full-time equivalent paid peer workers (average)*
Address
Statistical area level 2 (SA2)*
2 / 2
Mental health non-government organisation establishments DSS 2015- Sector
development and representation mental health service type cluster Metadata Online
Registry (METeOR)
Mental health non-government organisation establishments DSS 2015- Mental
health promotion mental health service type cluster Metadata Online Registry
(METeOR)
Health sector data set specifications from METeOR,
Australia's repository for national metadata standards,
developed by the Australian Institute of Health and Welfare
(http://meteor.aihw.gov.au/content/index.phtml/itemId/3451
65)
Mental health promotion mental health service type cluster
The scope of the Mental health non-government
organisation establishments data set specification (MH
NGOE DSS) is mental health-related non-government
organisations which provide one or more of the service
types included in the service taxonomy: Counselling—face-
to-face, Counselling, support, information and
referral—telephone, Counselling, support, information and
referral—online, Self-help—online, Group support activities,
Mutual support and self-help, Staffed residential services,
Personalised support—linked to housing, Personalised
support—other, Family and carer support, Individual
advocacy, Care coordination, Service integration
infrastructure, Education, employment and training, Sector
development and representation, Mental health promotion,
and Mental illness prevention.
Mental health non-government organisations are private
organisations (both not-for-profit and for-profit) that receive
Australian and/or state or territory government funding
specifically for the provision of services where the principal
intent is targeted at improving mental health and well-being
and delivered to people affected by mental illness, their
families and carers, or the broader community. These
services focus on providing well-being, support and
assistance to people who live with a mental illness rather
than the assessment, diagnostic and treatment tasks
undertaken by clinically focused services.
This data element cluster describes Mental health
promotion activities in a mental health non-government
organisation service.
Obligation: Conditional
Metadata and Classifications Unit 
Australian Institute of Health and Welfare
GPO Box 570
Canberra ACT 2601
All rights reserved. Please visit https://medical-data-
models.org/forms/17058
Mental health non-government
organisation establishments DSS
2015- Mental health promotion
mental health service type cluster
Metadata Online Registry (METeOR)
Service provider organisation 1
Mental health government funding source*
NSW Health (101)
Victorian Department of Health (201)
Queensland Department of Health (301)
SA Health (401)
Western Australian Mental Health
Commission (501)
Tasmanian Department of Health and
Human Services (601)
NT Department of Health (701)
ACT Government Health Directorate
(801)
Commonwealth Department of Health
(901)
Commonwealth Department of Social
Services (921)
1 / 2
Entity
Australian business number (ABN)*
Service provider organisation 2
Program name*
Number of schools participating*
Mental health funding provided to NGOs from
government authorities*
AU$
Full-time equivalent paid staff*
Hours worked—volunteer/unpaid staff*
hours
Full-time equivalent paid peer workers (average)*
Address
Statistical area level 2 (SA2)*
2 / 2
Mental health non-government organisation establishments DSS 2015- Mental
health promotion mental health service type cluster Metadata Online Registry
(METeOR)
Mental health non-government organisation establishments DSS 2015- Mental
illness prevention mental health service type cluster Metadata Online Registry
(METeOR)
Health sector data set specifications from METeOR,
Australia's repository for national metadata standards,
developed by the Australian Institute of Health and Welfare
(http://meteor.aihw.gov.au/content/index.phtml/itemId/3451
65)
Mental illness prevention mental health service type cluster
The scope of the Mental health non-government
organisation establishments data set specification (MH
NGOE DSS) is mental health-related non-government
organisations which provide one or more of the service
types included in the service taxonomy: Counselling—face-
to-face, Counselling, support, information and
referral—telephone, Counselling, support, information and
referral—online, Self-help—online, Group support activities,
Mutual support and self-help, Staffed residential services,
Personalised support—linked to housing, Personalised
support—other, Family and carer support, Individual
advocacy, Care coordination, Service integration
infrastructure, Education, employment and training, Sector
development and representation, Mental health promotion,
and Mental illness prevention.
Mental health non-government organisations are private
organisations (both not-for-profit and for-profit) that receive
Australian and/or state or territory government funding
specifically for the provision of services where the principal
intent is targeted at improving mental health and well-being
and delivered to people affected by mental illness, their
families and carers, or the broader community. These
services focus on providing well-being, support and
assistance to people who live with a mental illness rather
than the assessment, diagnostic and treatment tasks
undertaken by clinically focused services.
This data element cluster describes Mental illness
prevention activities in a mental health non-government
organisation service.
Obligation: Conditional
Metadata and Classifications Unit 
Australian Institute of Health and Welfare
GPO Box 570
Canberra ACT 2601
All rights reserved. Please visit https://medical-data-
models.org/forms/17059
Mental health non-government
organisation establishments DSS
2015- Mental illness prevention
mental health service type cluster
Metadata Online Registry (METeOR)
Service provider organisation 1
Mental health government funding source*
NSW Health (101)
Victorian Department of Health (201)
Queensland Department of Health (301)
SA Health (401)
Western Australian Mental Health
Commission (501)
Tasmanian Department of Health and
Human Services (601)
NT Department of Health (701)
ACT Government Health Directorate
(801)
Commonwealth Department of Health
(901)
Commonwealth Department of Social
Services (921)
1 / 2
Entity
Australian business number (ABN)*
Service provider organisation 2
Program name*
Mental health funding provided to NGOs from
government authorities*
AU$
Full-time equivalent paid staff*
Hours worked—volunteer/unpaid staff*
hours
Full-time equivalent paid peer workers (average)*
Address
Statistical area level 2 (SA2)*
2 / 2
Mental health non-government organisation establishments DSS 2015- Mental
illness prevention mental health service type cluster Metadata Online Registry
(METeOR)
Mental health seclusion and restraint DSS
2015- Metadata Online Registry (METeOR)
Health sector data set specifications from METeOR,
Australia's repository for national metadata standards,
developed by the Australian Institute of Health and Welfare
(http://meteor.aihw.gov.au/content/index.phtml/itemId/3451
65)
Mental health seclusion and restraint DSS 2015-
The scope of the Mental health seclusion and restraint data
set specification (SECREST DSS) is all specialised mental
health public hospital acute service units. Short stay mental
health units are in scope, e.g. Psychiatric Emergency Care
Centres.
Wards or units other than specialised mental health
services, such as emergency departments, are out of
scope.
Specialised mental health acute forensic hospital services
are in scope, regardless of which department manages the
service, for example health versus correctional services
department.
Physical and mechanical restraint are in scope for this
collection. While chemical/pharmacological restraint is
defined in some jurisdictional Mental Health Acts, issues
around definitions and collection preclude nationally
comparable data supply activities for this category of
restraint. Therefore, chemical/pharmacological restraint is
out of scope for the purposes of data collection for the
SECREST DSS.
Metadata and Classifications Unit 
Australian Institute of Health and Welfare
GPO Box 570
Canberra ACT 2601
All rights reserved. Please visit https://medical-data-
models.org/forms/17060
Mental health seclusion and restraint
DSS 2015- Metadata Online Registry
(METeOR)
Mental health restraint events cluster
Number of restraint events*
Type of restraint event*
Mechanical restraint (1)
Physical restraint (2)
Unspecified mechanical or physical
restraint (3)
Address
Statistical area level 2 (SA2)*
Establishment
Accrued mental health care days*
days
Australian State/Territory identifier
(establishment)*
New South Wales (1)
Victoria (2)
Queensland (3)
South Australia (4)
1 / 2
Western Australia (5)
Tasmania (6)
Northern Territory (7)
Australian Capital Territory (8)
Other territories (Cocos (Keeling)
Islands, Christmas Island and Jervis Bay
Territory) (9)
Region code*
Hospital
Hospital identifier*
Hospital name*
Specialised mental health service
organisation
Organisation identifier*
Specialised mental health service
Co-location status of mental health service*
Co-located (1)
Not co-located (2)
Number of episodes of admitted mental health
care*
Number of episodes with seclusion*
Number of seclusion events*
Seclusion duration*
hours
Specialised mental health service target
population*
Child and adolescent (1)
Older person (2)
Forensic (3)
General (4)
Youth (5)
Not applicable (7)
Not stated/inadequately described (9)
2 / 2
Mental health seclusion and restraint DSS 2015- Metadata Online
Registry (METeOR)
Screening: Inclusion criteria Nicotinsäure und
Naftidrofuryl bei pAVK-Patienten nach Angioplastie
Leiter der Klinischen Prüfung:
PD. Dr. med. Knut Kröger
Klinik für Angiologie
Universitätsklinikum Essen
Hufelandstr. 55
45122 Essen
Telefon: 0201/723-2530
Fax: 0201/723-5967
Sponsor:
Universitätsklinikum Essen
Hufelandstraße 55
45122 Essen
Datenmanagement und Biometrie
C. Ose und Chr. Lösch
Zentrum für Klinische Studien Essen
Leiter: Prof. Dr. K.-H. Jöckel
Hufelandstr. 55, 45122 Essen
Universitätsklinikum Essen
Telefon.: 0201/723-4519
Fax: 0201/723-5933
E-Mail: claudia.ose@uk-essen.de
Screening: Inclusion criteria
All rights reserved. Please visit https://medical-data-
models.org/forms/17061
Screening: Inclusion criteria
Nicotinsäure und Naftidrofuryl bei
pAVK-Patienten nach Angioplastie
Identifikation
Zentrums-Nr.:
Pat-Nr.
Einschlusskriterien für den Patienten
Patienten im Alter von 45-85 Jahren
Ja
Nein
Symptomatische Oberschenkelstenose (A. fem.
superficialis ggf. A. poplitea), angiografischer
Nachweis vor Angioplastie
Ja
Nein
pAVK im Stadium II-IV nach Fontaine
Ja
Nein
Schriftliches Einverständnis des Patienten zur
Teilnahme an der Studie
Ja
Nein
Patient bereit und in der Lage, regelmäßig zu den
Untersuchungs- bzw. Nachsorgeterminen zu
erscheinen
Ja
Nein
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Eligibility Depression NCT00232284
Treatment of Comorbid Depression and Substance Abuse
in Young People; ODM derived from:
https://clinicaltrials.gov/show/NCT00232284
All rights reserved. Please visit https://medical-data-
models.org/forms/17062
Eligibility Depression NCT00232284
Inclusion Criteria
16 and 26 years of age*
Yes
No
acute major depressive episode (more than one
month)*
Yes
No
concurrent dsm-iv substance abuse/dependence
or the use of any illicit drug on a weekly basis in
the month prior to referral, or alcohol
consumption exceeding nhmrc guidelines*
Yes
No
english as their preferred language*
Yes
No
estimated iq >80*
Yes
No
Exclusion Criteria
current or past history of psychosis*
Yes
No
significant head injury*
Yes
No
seizures*
Yes
No
history or current evidence of any other
significant clinical condition*
Yes
No
treatment with an antidepressant within past 30
days*
Yes
No
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Perinatal NMDS 2014- Metadata Online
Registry (METeOR)
Health sector data set specifications from METeOR,
Australia's repository for national metadata standards,
developed by the Australian Institute of Health and Welfare
(http://meteor.aihw.gov.au/content/index.phtml/itemId/3451
65)
Perinatal NMDS 2014-
The scope of the Perinatal national minimum data set
(NMDS) is all births in Australia in hospitals, birth centres
and the community. The data set includes information on all
births, both live births and stillbirths, of at least 20 weeks
gestation or 400 grams birth weight.
These data have two dimensions, which are the baby and
the mother. All data relevant to the birth are conveyed in
relation to one of these.
Metadata and Classifications Unit 
Australian Institute of Health and Welfare
GPO Box 570
Canberra ACT 2601
All rights reserved. Please visit https://medical-data-
models.org/forms/17063
Perinatal NMDS 2014- Metadata
Online Registry (METeOR)
Birth event
Anaesthesia administered indicator*
Yes
No
Analgesia administered indicator*
Yes
No
Method of birth*
Vaginal - non-instrumental (1)
Vaginal - forceps (2)
Caesarean section (4)
Vaginal - vacuum extraction (5)
Not stated/inadequately described (9)
Birth plurality*
Singleton (1)
Twins (2)
Triplets (3)
Quadruplets (4)
Quintuplets (5)
Sextuplets (6)
Other (8)
Not stated (9)
Presentation at birth*
Vertex (1)
Breech (2)
Face (3)
Brow (4)
Other (8)
Not stated/inadequately described (9)
Labour onset type*
Spontaneous (1)
Induced (2)
No labour (3)
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Not stated (9)
Actual place of birth*
Hospital, excluding birth centre (1)
Birth centre, attached to hospital (2)
Birth centre, free standing (3)
Home (4)
Other (8)
Not stated (9)
State/Territory of birth*
New South Wales (1)
Victoria (2)
Queensland (3)
South Australia (4)
Western Australia (5)
Tasmania (6)
Northern Territory (7)
Australian Capital Territory (8)
Other territories (Cocos (Keeling)
Islands, Christmas Island and Jervis Bay
Territory) (9)
Type of anaesthesia administered during a birth
event
Local anaesthetic to perineum (2)
Pudendal block (3)
Epidural or caudal block (4)
Spinal block (5)
General anaesthesia (6)
Combined spinal-epidural block (7)
Other anaesthesia (88)
Not stated/inadequately described (99)
Type of analgesia administered during a birth
event
Nitrous oxide (2)
Epidural or caudal block (4)
Spinal block (5)
Systemic opioids (6)
Combined spinal-epidural block (7)
Other analgesia (88)
Not stated/inadequately described (99)
Birth
Apgar score at 5 minutes*
Birth order*
Singleton or first of a multiple birth (1)
Second of a multiple birth (2)
Third of a multiple birth (3)
Fourth of a multiple birth (4)
Fifth of a multiple birth (5)
Sixth of a multiple birth (6)
Other (8)
Not stated (9)
2 / 4
Perinatal NMDS 2014- Metadata Online Registry (METeOR)
Status of the baby*
Live birth (1)
Stillbirth (fetal death) (2)
Not stated (9)
Infant weight, neonate, stillborn*
g
Episode of admitted patient care
Separation date*
Establishment
Establishment identifier*
Female (mother)
Postpartum perineal status*
Intact (1)
1st degree laceration/vaginal graze (2)
2nd degree laceration (3)
3rd degree laceration (4)
Episiotomy (5)
4th degree laceration (7)
Other perineal laceration, rupture or tear
(88)
Not stated/inadequately described (99)
Female (pregnant)
Number of tobacco cigarettes smoked per day
after 20 weeks of pregnancy
Tobacco smoking indicator, after 20 weeks of
pregnancy*
Yes (1)
No (2)
Not stated/inadequately described (9)
Tobacco smoking indicator, first 20 weeks of
pregnancy*
Yes (1)
No (2)
Not stated/inadequately described (9)
Female
Caesarean section at most recent previous birth
indicator*
Yes (1)
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No (2)
Not applicable (7)
Not stated/inadequately described (9)
Antenatal care visits*
Parity*
Person
Area of usual residence (SA2)*
Country of birth*
Date of birth*
Indigenous status*
Aboriginal but not Torres Strait Islander
origin (1)
Torres Strait Islander but not Aboriginal
origin (2)
Both Aboriginal and Torres Strait Islander
origin (3)
Neither Aboriginal nor Torres Strait
Islander origin (4)
Not stated/inadequately described (9)
Person identifier*
Sex*
Male (1)
Female (2)
Intersex or indeterminate (3)
Not stated/inadequately described (9)
Pregnancy
Pregnancy duration at the first antenatal care
visit*
completed weeks
Product of conception
Gestational age*
completed weeks
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Eligibility Depression NCT00276900
Sertraline for the Prevention of Recurrent Postpartum
Depression; ODM derived from:
https://clinicaltrials.gov/show/NCT00276900
All rights reserved. Please visit https://medical-data-
models.org/forms/17064
Eligibility Depression NCT00276900
Inclusion Criteria
pregnant*
Yes
No
presents by week 36 gestation for first two study
visit interviews (interviews may be combined)*
Yes
No
history of dsm-iv major depression after the age
of 15*
Yes
No
score no higher than 19 on the 29-item sigh-ads
at week 36*
Yes
No
medically healthy, as determined by a physician*
Yes
No
Exclusion Criteria
current major depression*
Yes
No
urine screen positive for drugs*
Yes
No
currently using other therapies for depression*
Yes
No
dsm-iv diagnoses of bipolar 1 or 2 disorder or any
psychotic episode*
Yes
No
history of substance abuse within 6 months prior
to study entry*
Yes
No
has not received any obstetrical care*
Yes
No
use of medications for medical disorders (except
for treatment of stable disorders)*
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Yes
No
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UKM-Pediatric Hematology and Oncology,
Clinic for childrens and adolescent medicine
Freigabe zur Verarbeitung durch Frau Prof. Rössig,
Quellenangabe: "Pädiatrische Hämatologie und Onkologie,
UKM" Klinik für Kinder- und Jugendmedizin,
Universitätsklinikum Münster Released for adaption by Frau
Prof. Rössig Source: Pediatric Hematology und Oncology,
University hospital Münster
All rights reserved. Please visit https://medical-data-
models.org/forms/17066
UKM-Pediatric Hematology and
Oncology, Clinic for childrens and
adolescent medicine- Physicians
documentation
Demographie
Patienten ID
Patientenname
Blatt-Nr
Datum
Zustand
Allgemeinzustand
0 (0)
1 (1)
2 (2)
3 (3)
4 (4)
? (5)
Übelkeit
0 (0)
1 (1)
2 (2)
3 (3)
4 (4)
? (5)
Erbrechen
0 (0)
1 (1)
2 (2)
3 (3)
4 (4)
? (5)
Diarrhoe
0 (0)
1 (1)
2 (2)
3 (3)
4 (4)
? (5)
Fieber
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0 (0)
1 (1)
2 (2)
3 (3)
4 (4)
? (5)
Infektion
0 (0)
1 (1)
2 (2)
3 (3)
4 (4)
? (5)
Stomatitis
0 (0)
1 (1)
2 (2)
3 (3)
4 (4)
? (5)
Haut
0 (0)
1 (1)
2 (2)
3 (3)
4 (4)
? (5)
Herz
0 (0)
1 (1)
2 (2)
3 (3)
4 (4)
? (5)
Gehör
0 (0)
1 (1)
2 (2)
3 (3)
4 (4)
? (5)
Neuro zentral
0 (0)
1 (1)
2 (2)
3 (3)
4 (4)
? (5)
Neuro peripher
0 (0)
1 (1)
2 (2)
3 (3)
2 / 4
UKM-Pediatric Hematology and Oncology, Clinic for childrens and
adolescent medicine
4 (4)
? (5)
Schmerz
0 (0)
1 (1)
2 (2)
3 (3)
4 (4)
? (5)
Andere
Andere
0 (0)
1 (1)
2 (2)
3 (3)
4 (4)
? (5)
Lmyphknoten
ohne Befund (1)
pathologisch (2)
Lunge
ohne Befund (1)
pathologisch (2)
Abdomen
ohne Befund (1)
pathologisch (2)
Leber (cm>RB)
Milz (cm>RB)
Genitale
ohne Befund (1)
pathologisch (2)
Lansky/Karnofsky
%
Zwischenanamnese und Klinischer
Befund
Zwischenanamnese und Klinischer Befund
Zwischendiagnosen
Durchgeführte Diagnostik
3 / 4
UKM-Pediatric Hematology and Oncology, Clinic for childrens and
adolescent medicine
Weitere Planung
Termine
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UKM-Pediatric Hematology and Oncology-
ORBIS®NICE Laboratory results
Freigabe zur Verarbeitung durch Frau Prof. Rössig,
Quellenangabe: "Pädiatrische Hämatologie und Onkologie,
UKM" Klinik für Kinder- und Jugendmedizin,
Universitätsklinikum Münster Released for adaption by Frau
Prof. Rössig Source: Pediatric Hematology und Oncology,
University hospital Münster
All rights reserved. Please visit https://medical-data-
models.org/forms/17067
UKM-Pediatric Hematology and
Oncology- ORBIS®NICE Laboratory
Results
Serumchemie
Datum
Natrium
mmol/L
Kalium
mmol/l
Kalzium
mmol/l
Chlorid
mmol/l
Phosphat
mg/dl
Eiweiß
g/dL
Glukose
mg/dl
Harnsäure
md/dl
Harnstoff-N
mg/dL
Kreatinin
mg/dl
Bilirubin gesamt
mg/dl
GOT (AST)
U/l
GPT (ALT)
U/l
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Gamma-GT
U/l
Alkalische Phosphatase
U/l
LDH
U/L
alpha-Amylase
U/l
Lipase
U/L
CRP
md/dl
Albumin
g/dL
Kleines Blutbild
Leukozyten
/µl
Erythrozyten
/µl
Hämoglobin
g/dL
Hämatokrit
%
MCV
fl
MCH
pg
MCHC
g/dl
Thrombozyten
/µl
Urin-Status
2 / 4
UKM-Pediatric Hematology and Oncology- ORBIS®NICE Laboratory
results
Dichte
g/ml
pH (Stix)
Leukozyten (Stix)
positiv (1)
negativ (2)
Leukozyten (Stix)
/µl
Nitrit
positiv (1)
negativ (2)
Nitrit
Protein (Stix)
positiv (1)
negativ (2)
Protein (Stix)
mg/dl
Glucose (Stix)
norm (1)
path (2)
Glucose (Stix)
mg/dl
Keton (Stix)
positiv (1)
negativ (2)
Keton (Stix)
mg/dl
Urobilinogen
norm (1)
path (2)
Urobilinogen
mg/dl
Bilirubin (U)
positiv (1)
negativ (2)
Bilirubin (U)
mg/dl
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results
Erythrozyten (Stix)
positiv (1)
negativ (2)
Erythrozyten (Stix)
/µl
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results
Eligibility Depression NCT00385437
Sedating Antidepressant Improves Driving Safety in
Patients With Major Depressive Disorder; ODM derived
from: https://clinicaltrials.gov/show/NCT00385437
All rights reserved. Please visit https://medical-data-
models.org/forms/17068
Eligibility Depression NCT00385437
Inclusion Criteria
fulfilling dsm-iv criteria for major depressive
disorder*
Yes
No
score of hamilton rating scale for depression
(hdrs-17) > 17*
Yes
No
patient to be prescribed mirtazapine (remeron) as
determined by          physician*
Yes
No
subject has no known clinically significant
abnormal vital signs or other clinical findings at
screening.*
Yes
No
patients should have a driving license for more
than 3 years and drive over 15,000 km year.*
Yes
No
females of childbearing potential must willingly
use effective birth control.*
Yes
No
Exclusion Criteria
night shift workers.*
Yes
No
a history or present condition of: bipolar disorder
or depressive disorder not otherwise
specified,schizophrenia or other psychotic
disorders (according to dsm-iv), schizotypal or
borderline personality disorder, organic mental
disorders*
Yes
No
a present condition of:  anxiety disorders
(according to dsm-iv), eating disorders,
postpartum depression*
Yes
No
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epilepsy or a history of seizure disorder or ever
received treatment with anticonvulsant
medication for epilepsy or seizures*
Yes
No
psg recording of an extremely abnormal sleep
eeg (other than that which would be expected
with depression)*
Yes
No
alcohol or substance abuse (according to dsm-iv)
during the last 6months prior to baseline.*
Yes
No
any physical disease, which may explain the
symptoms of depression.*
Yes
No
any chronic physical disease, which is not
stabilized.*
Yes
No
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UKM-ORBIS® General Laboratory report
Freigabe zur Verarbeitung durch Frau Prof. Rössig,
Quellenangabe: "Pädiatrische Hämatologie und Onkologie,
UKM" Klinik für Kinder- und Jugendmedizin,
Universitätsklinikum Münster Released for adaption by Frau
Prof. Rössig Source: Pediatric Hematology und Oncology,
University hospital Münster
All rights reserved. Please visit https://medical-data-
models.org/forms/17069
UKM-ORBIS® General Laboratory
report
Demographie
Patienten ID
Auftragsannahme
Auftragsnummer
Diagnostik Labor
Untersuchung
Wert
Einheit
Referenzbereich
Status
Klinische Relevanz
klinisch nicht relevant (not clinical
significant, n.c.s.) (1)
klinisch relevant (2)
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Eligibility Depression NCT00402389
Use of Omega-3 Fatty Acids for Perinatal Depression; ODM
derived from: https://clinicaltrials.gov/show/NCT00402389
All rights reserved. Please visit https://medical-data-
models.org/forms/17070
Eligibility Depression NCT00402389
Inclusion Criteria
women who are pregnant (12 to 32 weeks
gestation) or postpartum*
Yes
No
meets criteria for a major depressive episode*
Yes
No
scores a minimum of 9 on the edinburgh
postnatal depression scale*
Yes
No
must be able to be treated on an outpatient
basis*
Yes
No
Exclusion Criteria
known intolerance or allergy to omega-3 fatty
acid or fish oil*
Yes
No
presently taking antidepressant medication*
Yes
No
currently using heparin or warfarin (compounds
used to prevent blood from clotting)*
Yes
No
presence of psychotic symptoms*
Yes
No
history of mania (abnormally elevated mood
state) or hypomania (same as mania but occurs
at a much lesser degree)*
Yes
No
active suicidal ideation (desire to commit
suicide)*
Yes
No
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UKM-ORBIS® Laboratory report Clinic for childrens and
adolescent medicine- Pediatric Hematology and oncology
Freigabe zur Verarbeitung durch Frau Prof. Rössig,
Quellenangabe: "Pädiatrische Hämatologie und Onkologie,
UKM" Klinik für Kinder- und Jugendmedizin,
Universitätsklinikum Münster Released for adaption by Frau
Prof. Rössig Source: Pediatric Hematology and Oncology,
University hospital Münster
All rights reserved. Please visit https://medical-data-
models.org/forms/17072
UKM-ORBIS® Laboratory report
Clinic for childrens and adolescent
medicine- Pediatric Hematology and
oncology
Demographie
Patienten ID
Auftragsannahme
Auftragsnummer
Material
Diagnostik Labor
Untersuchung: Blutbild
Leukozyten (1)
Erythrozyten (2)
Hämoglobin (3)
Hämatokrit (4)
MCV (5)
MCH (6)
MCHC (7)
Thrombozyten (8)
Neutrophile (9)
Untersuchung: Differenzialblutbild
Segmentkernige Granulozyten (1)
Eosinophile Granulozyten (2)
Monozyten (3)
Lymphozyten (4)
Wert Blutbild
Wert Differenzialblutbild
Einheit
Referenzbereich
Datum und Uhrzeit Fertigstellung
Status
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Eligibility Depression NCT00430404
Screening and Treatment of Depression in the Community;
ODM derived from:
https://clinicaltrials.gov/show/NCT00430404
All rights reserved. Please visit https://medical-data-
models.org/forms/17074
Eligibility Depression NCT00430404
Inclusion Criteria
> 60 years without dementia,*
Yes
No
major depressive disorder,*
Yes
No
bipolar disorder,*
Yes
No
dysthymia disorder,*
Yes
No
anxiety disorder,*
Yes
No
mania/hypomania*
Yes
No
Exclusion Criteria
severe post-stroke dementia or aphasia,*
Yes
No
history of mania, psychiatric consultation or
admission to hospital in past 3 months,*
Yes
No
mmse score <18,*
Yes
No
fully dependent at 3 or more basic activities of
daily living,*
Yes
No
very high bdi score (>=30),*
Yes
No
serious suicidal risk,*
Yes
No
current psychotic symptoms,*
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Yes
No
current alcohol abuse,*
Yes
No
very high gds score (>=12) confirmed by scid*
Yes
No
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UKM-ORBIS® Clinic for childrens and adolscent
medicine-Department of childrens and neonatal surgery
Freigabe zur Verarbeitung durch Frau Prof. Rössig,
Quellenangabe: "Pädiatrische Hämatologie und Onkologie,
UKM" Klinik für Kinder- und Jugendmedizin,
Universitätsklinikum Münster Released for adaption by Frau
Prof. Rössig Source: Pediatric Hematology and Oncology,
University hospital Münster
All rights reserved. Please visit https://medical-data-
models.org/forms/17079
UKM-ORBIS® Clinic for childrens
and adolscent medicine-Department
of childrens and neonatal surgery
Bericht über ambulante Operation
Operationsdatum
OP-Nummer
Patientenname
Patient Geburtsdatum
Fall Nummer
Aufnahmedatum und Zeit
Adresse des Patienten
Ambulanz
Postoperative Diagnose
Art der Operation
Anästhesie Team
Op-Team
Operationsbericht
Unterschrift erster Operateur
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Eligibility Depression NCT00497874
An Expert System to Reduce Depression in Primary Care;
ODM derived from:
https://clinicaltrials.gov/show/NCT00497874
All rights reserved. Please visit https://medical-data-
models.org/forms/17080
Eligibility Depression NCT00497874
Inclusion Criteria
at risk for or experiencing depression (i.e., beck
depression inventory-ii (bdi) score of 10 or
higher; current major depression, minor
depression, or dysthymia; or past major
depression, minor depression, or dysthymia)*
Yes
No
Exclusion Criteria
younger than age 18*
Yes
No
involved in counseling or planning counseling in
the next 30 days*
Yes
No
taking antidepressant medication or planning to
take antidepressants in the next 30 days
(exclusion criterion for untreated sample only)*
Yes
No
suicidal ideation*
Yes
No
severe depression (bdi > 28) and deemed
inappropriate for study by site clinician*
Yes
No
bdi <10 and in the maintenance stage for using
effective methods to prevent or reduce
depression*
Yes
No
history of bipolar disorder*
Yes
No
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Eligibility Depression NCT00429169
Paroxetine/Bupropion in Suicide Attempters/Ideators With
Major Depression; ODM derived from:
https://clinicaltrials.gov/show/NCT00429169
All rights reserved. Please visit https://medical-data-
models.org/forms/17081
Eligibility Depression NCT00429169
Inclusion Criteria
currently suffering from a major depressive
episode (unipolar only)*
Yes
No
history of a past suicide attempt or score greater
than 2 on the hamilton depression rating scale
(hdrs) item #3 (suicide) at in-person screening
interview. patients with suicidal plan or intent will
only be enrolled as inpatients if independent
inpatient treatment team agrees.*
Yes
No
patients 60 years of age and older must score at
least 25 on mmse at screening.*
Yes
No
patients 60 years of age and older must have a
normal ecg within the past year.*
Yes
No
Exclusion Criteria
any of the following conditions: bipolar disorder;
current psychotic symptoms; bulimia or anorexia
that is current or within the past year, or current
purging at least twice a week for three months;
already taking selective serotonin reuptake
inhibitors (ssris) or bupropion for other indications
(such as anxiety disorders)*
Yes
No
primary disorder is an anxiety disorder (e.g.,
panic disorder, general anxiety disorder,
obsessive compulsive disorder, social anxiety
disorder), with secondary depression*
Yes
No
drug or alcohol dependence within 6 months prior
to study entry (current drug or alcohol abuse may
be permitted if study officials determine that the
abuse is of lesser importance than the major
depressive episode)*
Yes
No
systolic blood pressure greater than or equal to
140 mm hg or diastolic blood pressure greater
than or equal to 90 mm hg*
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Yes
No
significant active physical illness, particularly
those that may affect the brain or serotonergic
system (e.g., blood dyscrasias lymphomas,
hypersplenism, endocrinopathies, kidney failure,
severe chronic obstructive lung disease,
autonomic neuropathies, active malignancy)*
Yes
No
active medical problems*
Yes
No
requires antipsychotic medication*
Yes
No
history of hypomania or mania while taking
antidepressants*
Yes
No
any condition that may make the use of an ssri or
bupropion medically inadvisable*
Yes
No
currently using zyban*
Yes
No
failure to respond to adequate trials of three ssris,
paroxetine, or bupropion within 2 years prior to
study entry (failure to respond to therapeutic trial
defined as at least 2/3 maximal daily dose [pdr]
for at least 6 weeks)*
Yes
No
pregnant, breastfeeding, or plans to become
pregnant during the course of study participation*
Yes
No
currently on effective treatment, requires
adjunctive antipsychotic or mood stabilizing
medication, or is unlikely to respond to single
agent treatment for depression*
Yes
No
patients with ferrous metal implants in their
bodies, or a history of claustrophobia that
precludes mri, will be excluded.*
Yes
No
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patients assessed as being unlikely to tolerate
the maximum 2-week delay to start of treatment.*
Yes
No
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Eligibility Depression, Involutional
NCT00084162
Neurocardiac Control in Major Depression; ODM derived
from: https://clinicaltrials.gov/show/NCT00084162
All rights reserved. Please visit https://medical-data-
models.org/forms/17082
Eligibility Depression, Involutional
NCT00084162
Criteria
two groups of right-handed subjects, male or
premenopausal female, who are drug-naive or
who have not received psychotropic drugs for at
least 3 weeks (8 weeks for fluoxetine), will be
recruited for studies under this protocol:  unipolar
depressives and healthy controls individually
matched to depressives by age, gender and
smoking status.  because effective treatment will
not be discontinued for the purposes of this
protocol, subjects in the patient groups will be
identified who have never been treated for or who
have discontinued medication due to lack of
efficacy, noncompliance, physician order or other
reason prior to study entry.*
Yes
No
the presence of inclusion and exclusion criteria
will be established using both an unstructured
clinical interview with a psychiatrist and the
structure clinical interview for dsm-iv (scid).
family history of mental illness will be obtained
using the family interview of genetic studies.*
Yes
No
Exclusion Criteria
subjects will be excluded if they have:*
Yes
No
serious suicidal ideation or behavior;*
Yes
No
inability to provide informed consent;*
Yes
No
medical or neurological illnesses likely to affect
physiology or anatomy;*
Yes
No
a history of drug or alcohol abuse within 1 year or
a lifetime history of alcohol or drug dependence
(dsm-iv criteria);*
Yes
No
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current or past history of other axis i disorders
that preceded the onset of mdd;*
Yes
No
current pregnancy (documented by pregnancy
testing prior to scanning);*
Yes
No
current breast feeding;*
Yes
No
general mri exclusion criteria;*
Yes
No
vision and/or hearing problems severe enough to
interfere with testing.*
Yes
No
exposure within two weeks to medications likely
to affect cerebral blood glow or heart rate.*
Yes
No
any condition that may prevent the subject from
performing the run/walk test, or*
Yes
No
irregular menstrual cycles so that menstrual
phase cannot be reliably determined, or*
Yes
No
any ecg finding that would contraindicate pet
scanning or run/walk testing (e.g. non-sinus
rhythm, significant tachycardia, st segment
elevation or depression, q waves) or arrhythmia
that would obviate accurate calculation of hrv
indices.  cardiology consultation will be obtained
for abnormal ecg findings unless it is
unequivocally clear in the judgment of the study
physician that such consultation is medically
unnecessary.*
Yes
No
subjects who are beyond age 50 who are either
postmenopausal or perimenopausal are excluded
to reduce the biological heterogeneity in
autonomic function which may be associated with
difference in menstrual status.*
Yes
No
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Year 5 Medical & Personal History
Cardiovascular Health Study (CHS)
Documentation part: Record 29 Year 5 Medical & Personal
History
The Cardiovascular Health Study (CHS) was initiated by
the National Heart, Lung and Blood Institute (NHLBI) in
1987 to determine the risk factors for development and
progression of cardiovascular disease (CVD) in older
adults, with an emphasis on subclinical measures. The
study recruited 5,888 adults aged 65 or older at entry in
four U.S. communities and conducted extensive annual
clinical exams between 1989-1999 along with semi-annual
phone calls, events adjudication, and subsequent data
analyses and publications. Additional data were collected
by studies ancillary to CHS. With the exception of annual
clinic visits, these activities are still ongoing.
Data obtained from: https://chs-nhlbi.org/
Permission granted by: Erika Enright.
All rights reserved. Please visit https://medical-data-
models.org/forms/17083
Year 5 Medical & Personal History
Cardiovascular Health Study (CHS)
Medical History
1 Would you say, in general, your health is:
a doctor recommended that I eat less (a
doctor recommended that I eat less)
a medical or dental problem interferes
with eating (a medical or dental problem
interferes with eating)
I am less able to shop or prepare food
than before (I am less able to shop or
prepare food than before)
I am taking medicine that decreases my
appetite (I am taking medicine that
decreases my appetite)
my appetite has decreased for other
reasons (my appetite has decreased for
other reasons)
my physical activity has decrease (my
physical activity has decrease)
2 Would you say your health compares to other
persons your age?
no (0)
yes (1)
don't know (9)
3 During the past two weeks, how many days
have you stayed in bed all or most of the day
because of illness or injury?
days
11 Have you stayed overnight as a patient in a
nursing home or rehabilitation center since we
spoke to you on the phone about six months
ago?
no (0)
yes (1)
don't know (9)
A. If you answered YES, record the reason you
were admitted, the name of the hospital, and the
month and year you were a patient for EACH time
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you stayed overnight in a nursing home or
rehabilitation center. (Use another sheet of paper
to list additional admissions.) Reason for
admission:
Hospital name:
City:
Date of hospitalization:
length of stay
days
B. Are you currently staying in a nursing home?
no (0)
yes (1)
don't know (9)
12 Have you had pneumonia since we saw you
last year?
no (0)
yes (1)
don't know (9)
13 Have you had an attack of bronchitis since we
saw you last year?
no (0)
yes (1)
don't know (9)
A. Was it confirmed by a doctor?
no (0)
yes (1)
don't know (9)
14 Has a doctor ever told you that you had any of
the following conditions or diseases; and if so,
when were you FIRST told that you had the
condition?
A. High blood pressure
a doctor recommended that I eat more (a
doctor recommended that I eat more)
a medical or dental problem has been
resolved (a medical or dental problem
has been resolved)
I am more able to shop or prepare food
than before (I am more able to shop or
prepare food than before)
I am taking medicine that increases my
appetite (I am taking medicine that
increases my appetite)
my appetite has increased for other
reasons (my appetite has increased for
other reasons)
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my physical activity has increased (my
physical activity has increased)
14 Has a doctor ever told you that you had any of
the following conditions or diseases; and if so,
when were you FIRST told that you had the
condition?
B. Diabetes
no (0)
yes (1)
don't know (9)
14 Has a doctor ever told you that you had any of
the following conditions or diseases; and if so,
when were you FIRST told that you had the
condition?
C. Atrial Fibrillation
no (0)
yes (1)
don't know (9)
14 Has a doctor ever told you that you had any of
the following conditions or diseases; and if so,
when were you FIRST told that you had the
condition?
D. Deep vein thrombosis (or blood clots in your
legs)
no (0)
yes (1)
don't know (9)
14 Has a doctor ever told you that you had any of
the following conditions or diseases; and if so,
when were you FIRST told that you had the
condition?
E. Rheumatic fever or heart valve problems
no (0)
yes (1)
don't know (9)
15 Has a doctor ever told you that you had other
heart or circulatory problems since we saw you
last year?
no (0)
yes (1)
don't know (9)
Specify:
16 Are you currently taking medication prescribed
by a doctor for any of the following conditions?
A. High blood pressure
no (0)
yes (1)
don't know (9)
16 Are you currently taking medication prescribed
by a doctor for any of the following conditions?
B. Diabetes
no (0)
3 / 23
Year 5 Medical & Personal History Cardiovascular Health Study (CHS)
yes (1)
don't know (9)
16 Are you currently taking medication prescribed
by a doctor for any of the following conditions?
C. Atrial Fibrillation
no (0)
yes (1)
don't know (9)
16 Are you currently taking medication prescribed
by a doctor for any of the following conditions?
D. Deep vein thrombosis (or blood clots in your
legs)
no (0)
yes (1)
don't know (9)
17 Have you had coronary angiography or heart
catheterization as an out patient procedure since
we saw you last year?
no (0)
yes (1)
don't know (9)
18 Have you ever had any pain or discomfort in
your chest?
Yes
No
A. Do you feel pain when you walk uphill or
hurry?
no (0)
yes (1)
don't know (9)
B. Do you feel the pain when you walk at an
ordinary pace or level?
Yes
No
C. What do you do if you feel it while you are
walking?
no (0)
yes (1)
don't know (9)
D. If you stand still, what happens to the pain?
no (0)
yes (1)
don't know (9)
E. Where do you get this pain or discomfort?
no (0)
yes (1)
don't know (9)
Other, specify:
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F. Have you had this pain in the past two weeks?
Yes
No
If yes, how many times in the past two weeks
have you had this pain?
times
G. Has there been an increase in the frequency
or severity in the past two weeks?
Yes
No
H. Have you seen a doctor about this pain?
Yes
No
I. Have you ever had a severe pain accross the
front of your chest lasting for half an hour or
more?
Yes
No
J. Did you see a doctor because of this pain?
K. If you saw a doctor, what did your doctor say it
was?
no (0)
yes (1)
don't know (9)
K. If you saw a doctor, what did your doctor say it
was?
no (0)
yes (1)
don't know (9)
19 Have you had to sleep on 2 or more pillows to
help you breathe since we saw you last year?
no (0)
yes (1)
don't know (9)
20 Have you been awakened at night by trouble
breathing since we saw you last year?
no (0)
yes (1)
don't know (9)
21 Do you get short of breath...
A. While resting in a chair?
no (0)
yes (1)
never do this activity (2)
don't know (9)
21 Do you get short of breath...
B. When walking on level ground?
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no (0)
yes (1)
never do this activity (2)
don't know (9)
21 Do you get short of breath...
C. When walking quickly or uphill?
no (0)
yes (1)
never do this activity (2)
don't know (9)
21 Do you get short of breath...
D. With light physical activity, such as walking
down a flight of stairs, dressing or showering
without stopping, cleaning windows, stripping and
making the bed, mopping floors, hanging washed
clothes, pushing a power lawn mower, bowling, or
playing golf (walk and carry clubs)
no (0)
yes (1)
never do this activity (2)
don't know (9)
21 Do you get short of breath...
E. With moderate physical activity, such as
carrying anything up a flight of stairs without
stopping, dancing a foxtrot, gardening, raking,
weeding, having sexual intercourse, or walking 4
miles an hour over level ground?
no (0)
yes (1)
never do this activity (2)
don't know (9)
21 Do you get short of breath...
F. With strenuous physical activity, such as doing
outdoor work (shoveling snow, spading soil),
playing squash or handball, jogging or walking 5
miles an hour, or carrying objects that weigh at
least 80 pounds?
no (0)
yes (1)
never do this activity (2)
don't know (9)
22 Have you had swelling of your feet or ankles
since we saw you last year?
no (0)
yes (1)
don't know (9)
A. Did it tend to come on during the day and do
down overnight?
no (0)
yes (1)
don't know (9)
23 Do you get pain in either leg when walking?
no (0)
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yes (1)
don't know (9)
A. Does this pain ever begin when you are
standing still or standing?
no (0)
yes (1)
don't know (9)
B. Do you feel this pain in your calf or calves?
no (0)
yes (1)
don't know (9)
C. Do you feel it when you walk uphill or hurry?
no (0)
yes (1)
don't know (9)
D. Do you feel it when you walk at an ordinary
pace on the level?
no (0)
yes (1)
don't know (9)
E. Does this pain ever disappear while you are
walking?
no (0)
yes (1)
don't know (9)
F. What do you do if you feel it while you are
walking?
continue at same pace (continue at
same pace)
stop or slow down (stop or slow down)
G. What happens to the pain if you stand still?
don't know (don't know)
not relieved (not relieved)
relieved in 10 minutes or less (relieved in
10 minutes or less)
takes longer than 10 minutes to be
relieved (takes longer than 10 minutes to
be relieved)
24 Have you been told by a doctor that you
currently have any of the following?
A. Arthritis of hands
no (0)
yes (1)
don't know (9)
24 Have you been told by a doctor that you
currently have any of the following?
B. Arthritis of shoulder
no (0)
yes (1)
don't know (9)
24 Have you been told by a doctor that you
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currently have any of the following?
C. Arthritis of hips or knees
no (0)
yes (1)
don't know (9)
24 Have you been told by a doctor that you
currently have any of the following?
D. Osteoporosis
no (0)
yes (1)
don't know (9)
24 Have you been told by a doctor that you
currently have any of the following?
E. Liver disease, cirrhosis or hepatitis
no (0)
yes (1)
don't know (9)
24 Have you been told by a doctor that you
currently have any of the following?
F. Kidney (renal) disease or failure
no (0)
yes (1)
don't know (9)
25 During the last year, have you had pain in any
bones or joints for at least half the days of a
month?
no (0)
yes (1)
don't know (9)
Please indicate where you had this pain:
A. Hands
no (0)
yes (1)
don't know (9)
Please indicate where you had this pain:
B. Feet
no (0)
yes (1)
don't know (9)
Please indicate where you had this pain:
C. Knees
no (0)
yes (1)
don't know (9)
Please indicate where you had this pain:
D. Hips
no (0)
yes (1)
don't know (9)
Please indicate where you had this pain:
E. Neck
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no (0)
yes (1)
don't know (9)
Please indicate where you had this pain:
F. Back
no (0)
yes (1)
don't know (9)
Please indicate where you had this pain:
G. Shoulders
no (0)
yes (1)
don't know (9)
Please indicate where you had this pain:
H. Other
no (0)
yes (1)
don't know (9)
Please indicate where you had this pain:
H. Other, specify:
26 Have you been told by a doctor that you
currently have cancer?
If you answered YES, please specify the kind of
cancer(s):
A. Breast cancer
no (0)
yes (1)
don't know (9)
If you answered YES, please specify the kind of
cancer(s):
B. Blood cancer, leukemia or lymphoma
If you answered YES, please specify the kind of
cancer(s):
C. Colon (bowel) or rectum cancer
no (0)
yes (1)
don't know (9)
If you answered YES, please specify the kind of
cancer(s):
D. Lung cancer
no (0)
yes (1)
don't know (9)
If you answered YES, please specify the kind of
cancer(s):
E. Malignant melanoma
no (0)
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yes (1)
don't know (9)
If you answered YES, please specify the kind of
cancer(s):
F. Other skin cancer
no (0)
yes (1)
don't know (9)
If you answered YES, please specify the kind of
cancer(s):
G. Prostate cancer
no (0)
yes (1)
don't know (9)
If you answered YES, please specify the kind of
cancer(s):
H. Pancreatic cancer
no (0)
yes (1)
don't know (9)
If you answered YES, please specify the kind of
cancer(s):
I. Esophageal cancer
no (0)
yes (1)
don't know (9)
If you answered YES, please specify the kind of
cancer(s):
J. Other cancer
no (0)
yes (1)
don't know (9)
If you answered YES, please specify the kind of
cancer(s):
J. Other cancer, specify:
27 Have you been treated by a doctor for any of
the following since we saw you last year?
A. Broken hip (fracture)
no (0)
yes (1)
don't know (9)
B. Broken lower leg (fracture)
no (0)
yes (1)
don't know (9)
C. Broken arm, wrist or shoulder (fracture)
no (0)
yes (1)
don't know (9)
D. Spine (vertebral) compression fracture
10 / 23
Year 5 Medical & Personal History Cardiovascular Health Study (CHS)
no (0)
yes (1)
don't know (9)
E. Other injury
no (0)
yes (1)
don't know (9)
Specify
F. Did you have arthritis that was treated with
medication?
no (0)
yes (1)
don't know (9)
28 During the last year, have you had any sudden
spells of dizziness, loss of balance, or sensation
of spinning?
no (0)
yes (1)
don't know (9)
29 Have you ever accidentally lost control of your
urine (wet yourself) more than one time in a
month?
no (0)
yes (1)
don't know (9)
30 Do you wake up to urinate more than three
nights per week?
no (0)
yes (1)
don't know (9)
31 During the last year, have you had a fall? )Do
not include falls during skiing, skating or other
activities that may affect balance.)
no (0)
yes (1)
don't know (9)
A. How many times have you fallen during the
last year?
times
32 During the last year, have you gained or lost
more than 10 pounds?
lost more than 10 pounds (1)
gained more than 10 pounds (2)
both lost and gained more than 10
pounds (3)
no change (4)
don't know (9)
A. Was diet for the purpose of losing or gaining
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weight a major factor in your weight change?
no (0)
yes (1)
don't know (9)
B. Was surgery, illness or medication a major
factor in your weight change?
no (0)
yes (1)
don't know (9)
C. Was exercise a major factor in your weight
change?
no (0)
yes (1)
don't know (9)
33 How would you compare your TOTAL average
daily intake of food this year to your intake when
we saw you last year?
eat a lot more (1)
eat a little more (2)
eat about the same (3)
eat a little less (4)
eat a lot less (5)
A. If you answered EAT A LOT MORE or EAT A
LITTLE MORE, the main reason is:
a doctor recommended that I eat more (a
doctor recommended that I eat more)
a medical or dental problem has been
resolved (a medical or dental problem
has been resolved)
I am more able to shop or prepare food
than before (I am more able to shop or
prepare food than before)
I am taking medicine that increases my
appetite (I am taking medicine that
increases my appetite)
my appetite has increased for other
reasons (my appetite has increased for
other reasons)
my physical activity has increased (my
physical activity has increased)
Other:
B. If you answered EAT A LOT LESS or EAT A
LITTLE LESS, the main reason is:
a doctor recommended that I eat less (a
doctor recommended that I eat less)
a medical or dental problem interferes
with eating (a medical or dental problem
interferes with eating)
I am less able to shop or prepare food
than before (I am less able to shop or
prepare food than before)
I am taking medicine that decreases my
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appetite (I am taking medicine that
decreases my appetite)
my appetite has decreased for other
reasons (my appetite has decreased for
other reasons)
my physical activity has decrease (my
physical activity has decrease)
Other:
34 Are you following a special diet?
no (0)
yes (1)
don't know (9)
A. What is the purpose of the diet?
To lose weight
no (0)
yes (1)
don't know (9)
A. What is the purpose of the diet? To gain
weight
no (0)
yes (1)
don't know (9)
A. What is the purpose of the diet? For diabetes
no (0)
yes (1)
don't know (9)
A. What is the purpose of the diet? For kidney
failure
no (0)
yes (1)
don't know (9)
A. What is the purpose of the diet? For ulcers
no (0)
yes (1)
don't know (9)
A. What is the purpose of the diet? For
diverticulitits
no (0)
yes (1)
don't know (9)
A. What is the purpose of the diet? For allergies
no (0)
yes (1)
don't know (9)
A. What is the purpose of the diet? For heart
trouble
no (0)
yes (1)
don't know (9)
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A. What is the purpose of the diet? For high blood
pressure
no (0)
yes (1)
don't know (9)
A. What is the purpose of the diet? For other
reason
no (0)
yes (1)
don't know (9)
Other:
B. What kind of diet is it? Low calorie
no (0)
yes (1)
don't know (9)
B. What kind of diet is it? High calorie
no (0)
yes (1)
don't know (9)
B. What kind of diet is it? High protein
no (0)
yes (1)
don't know (9)
B. What kind of diet is it? Low fat
no (0)
yes (1)
don't know (9)
B. What kind of diet is it? High fat
no (0)
yes (1)
don't know (9)
B. What kind of diet is it? Low carbohydrate
no (0)
yes (1)
don't know (9)
B. What kind of diet is it? High carbohydrate
no (0)
yes (1)
don't know (9)
B. What kind of diet is it? Low sugar
no (0)
yes (1)
don't know (9)
B. What kind of diet is it? Low salt
no (0)
yes (1)
don't know (9)
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B. What kind of diet is it? Low cholesterol
no (0)
yes (1)
don't know (9)
B. What kind of diet is it? Low fiber
no (0)
yes (1)
don't know (9)
B. What kind of diet is it? High fiber
no (0)
yes (1)
don't know (9)
B. What kind of diet is it? Bland diet
no (0)
yes (1)
don't know (9)
B. What kind of diet is it? Other diet
no (0)
yes (1)
don't know (9)
Other:
C. About how long have you been following this
diet? YEARS
Years
C. About how long have you been following this
diet? MONTHS
Months
D. Was this diet recommended by your
physician?
no (0)
yes (1)
don't know (9)
35 Have you gone off a special diet since we saw
you last year?
no (0)
yes (1)
don't know (9)
Medical History: Myocardical Infarction
4 Has a doctor ever told you that you had a
myocardial infarction or heart attack?
no (0)
yes (1)
don't know (9)
A. What was the doctor's name and city? Name
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A. What was the doctor's name and city?
Address
A. What was the doctor's name and city? City
A. What was the doctor's name and city? State
B. Date of event or diagnosis:
C. How many times altogether did you see a
doctor for this condition since we last spoke to
you?
times
D. Were you in the hospital at least one night for
this condition since we last spoke to you?
no (0)
yes (1)
don't know (9)
E. How many different times were you in the
hospital for this condition?
times
F. Please record the admission date of each
hospitalization and the name and location of the
hospital. Date of Hospitalization:
F. Please record the admission date of each
hospitalization and the name and location of the
hospital. 
Hospital name
F. Please record the admission date of each
hospitalization and the name and location of the
hospital. City
F. Please record the admission date of each
hospitalization and the name and location of the
hospital. State
G. How many days altogether were you
hospitalized for this condition?
days
Medical History: Angina
5 Has a doctor ever told you that you had a new
incident of angina pectoris or chest pain due to
heart disease since we spoke with you on the
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phone about six month ago?
no (0)
yes (1)
don't know (9)
A. What was the doctor's name and city? Name
A. What was the doctor's name and city?
Address
A. What was the doctor's name and city? City
A. What was the doctor's name and city? State
B. Date of event or diagnosis:
C. How many times altogether did you see a
doctor for this condition since we last spoke to
you?
times
D. Were you in the hospital at least one night for
this condition since we last spoke to you?
no (0)
yes (1)
don't know (9)
E. How many different times were you in the
hospital for this condition?
times
F. Please record the admission date of each
hospitalization and the name and location of the
hospital. Date of Hospitalization:
F. Please record the admission date of each
hospitalization and the name and location of the
hospital. 
Hospital name
F. Please record the admission date of each
hospitalization and the name and location of the
hospital. City
F. Please record the admission date of each
hospitalization and the name and location of the
hospital. State
G. How many days altogether were you
hospitalized for this condition?
days
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Date of interview
Interviewer
Interview:
Medical History: Congestive heart failure
6 Has a doctor ever told you that you had a new
incident of heart failure or congestive heart failure
since we spoke with you on the phone about six
month ago?
A. What was the doctor's name and city? Name
A. What was the doctor's name and city?
Address
A. What was the doctor's name and city? City
A. What was the doctor's name and city? State
B. Date of event or diagnosis:
C. How many times altogether did you see a
doctor for this condition since we last spoke to
you?
times
D. Were you in the hospital at least one night for
this condition since we last spoke to you?
E. How many different times were you in the
hospital for this condition?
times
F. Please record the admission date of each
hospitalization and the name and location of the
hospital. Date of Hospitalization:
F. Please record the admission date of each
hospitalization and the name and location of the
hospital. 
Hospital name
F. Please record the admission date of each
hospitalization and the name and location of the
hospital. City
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F. Please record the admission date of each
hospitalization and the name and location of the
hospital. State
G. How many days altogether were you
hospitalized for this condition?
days
Medical History: Intermittent claudication
7 Has a doctor ever told you that you had a new
incident of intermittent claudication or pain in your
legs from a blockage of the arteries since we
spoke with you on the phone about six month
ago?
no (0)
yes (1)
don't know (9)
A. What was the doctor's name and city? Name
A. What was the doctor's name and city?
Address
A. What was the doctor's name and city? City
A. What was the doctor's name and city? State
B. Date of event or diagnosis:
C. How many times altogether did you see a
doctor for this condition since we last spoke to
you?
times
D. Were you in the hospital at least one night for
this condition since we last spoke to you?
no (0)
yes (1)
don't know (9)
E. How many different times were you in the
hospital for this condition?
times
F. Please record the admission date of each
hospitalization and the name and location of the
hospital. Date of Hospitalization:
F. Please record the admission date of each
hospitalization and the name and location of the
hospital. 
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Hospital name
F. Please record the admission date of each
hospitalization and the name and location of the
hospital. City
F. Please record the admission date of each
hospitalization and the name and location of the
hospital. State
G. How many days altogether were you
hospitalized for this condition?
days
Medical History: Cerebrovascular accident
8 Has a doctor ever told you that you had a new
stroke or cerebrovascular accident since we
spoke with you on the phone about six month
ago?
A. What was the doctor's name and city? Name
A. What was the doctor's name and city?
Address
A. What was the doctor's name and city? City
A. What was the doctor's name and city? State
B. Date of event or diagnosis:
C. How many times altogether did you see a
doctor for this condition since we last spoke to
you?
times
D. Were you in the hospital at least one night for
this condition since we last spoke to you?
lost more than 10 pounds (1)
gained more than 10 pounds (2)
both lost and gained more than 10
pounds (3)
no change (4)
don't know (9)
E. How many different times were you in the
hospital for this condition?
times
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F. Please record the admission date of each
hospitalization and the name and location of the
hospital. Date of Hospitalization:
F. Please record the admission date of each
hospitalization and the name and location of the
hospital. 
Hospital name
F. Please record the admission date of each
hospitalization and the name and location of the
hospital. City
F. Please record the admission date of each
hospitalization and the name and location of the
hospital. State
G. How many days altogether were you
hospitalized for this condition?
days
Medical History: Transient ischemic attack
9 Has a doctor ever told you that you had a new
transient ischemic attack or TIA or silent stroke
since we spoke with you on the phone about six
month ago?
eat a lot more (1)
eat a little more (2)
eat about the same (3)
eat a little less (4)
eat a lot less (5)
A. What was the doctor's name and city? Name
A. What was the doctor's name and city?
Address
A. What was the doctor's name and city? City
A. What was the doctor's name and city? State
B. Date of event or diagnosis:
C. How many times altogether did you see a
doctor for this condition since we last spoke to
you?
times
D. Were you in the hospital at least one night for
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this condition since we last spoke to you?
a doctor recommended that I eat more (a
doctor recommended that I eat more)
a medical or dental problem has been
resolved (a medical or dental problem
has been resolved)
I am more able to shop or prepare food
than before (I am more able to shop or
prepare food than before)
I am taking medicine that increases my
appetite (I am taking medicine that
increases my appetite)
my appetite has increased for other
reasons (my appetite has increased for
other reasons)
my physical activity has increased (my
physical activity has increased)
E. How many different times were you in the
hospital for this condition?
times
F. Please record the admission date of each
hospitalization and the name and location of the
hospital. Date of Hospitalization:
F. Please record the admission date of each
hospitalization and the name and location of the
hospital. 
Hospital name
F. Please record the admission date of each
hospitalization and the name and location of the
hospital. City
F. Please record the admission date of each
hospitalization and the name and location of the
hospital. State
G. How many days altogether were you
hospitalized for this condition?
days
Medical History: Other conditions
10 Have you stayed overnight as a patient in a
hospital for any other reason not reported in
Questions 3 through 9 since we spoke to you on
the phone about six months ago?
no (0)
yes (1)
don't know (9)
Hospital name:
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City:
Date of hospitalization:
length of stay
days
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Item List QS System UKM Part 1 from 61
Item list consisting of 100 items from QS System (GE)
(August 2016), which is in use at the University Hospital
Muenster, Germany.
Permission granted by Dr. Volkert. This is item list part 1
from 61.
Original QS Item Ids are represented by ItemDef OIDs
All rights reserved. Please visit https://medical-data-
models.org/forms/17084
QS Items UKM
Alle Items
ABPSYS*
<= 300.0
ABPDIA*
<= 300.0
ABPMEA*
<= 300.0
avDO2*
AoSYS*
<= 300.0
AoDIA*
<= 300.0
AoMEA*
<= 300.0
ARRHYTHMIA*
Asystolie (1)
Sinus Tachykardie (10)
Sinus Bradykardie (11)
früher ventrikulärer Schlag (12)
mehrfach ventr. vorzeit. Schlag (13)
ventrikulärer vorzeitiger Schlag (14)
Pacer nicht gefunden (15)
Pacer hält nicht den Schritt (16)
Pacer nicht angepaßt (17)
fehlender Schlag (18)
Aterieller vorzeitiger Schlag (19)
ventrikuläres Flimmern (2)
Abnormaler Schlag (20)
Paceschlag (21)
Irregulär (22)
Regulär (23)
Arrhythmie aus (24)
Arrhythmie vorübergehend aus (25)
lernt (26)
Artefakt (27)
neu lernend (28)
ventrikuläreTachykardie (3)
beschleunigter idioventrikulärer Rythmus
(4)
idioventriklärer Rythmus (5)
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supraventrikuläreTachykardie (6)
PAAR (7)
BIG (8)
Trigeminus (9)
ARTSYS*
<= 300.0
ARTDIA*
<= 300.0
ARTMEA*
<= 300.0
AUX*
AWAVE*
AWRR*
AXI*
<= 110.0
BLA*
<= 110.0
BLOODT*
>= 30.0
<= 45.0
BSA*
<= 4.0
CI*
<= 6.0
CO*
<= 50.0
CPCO2*
CPO2*
CPP*
<= 200.0
ZVD*
<= 50.0
ECG*
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ESO*
<= 110.0
ETCO2*
<= 100.0
FIO2*
>= 10.0
<= 100.0
FMNOTE*
FMSTAT*
FWAVE*
GENPURP*
HF*
<= 400.0
HT*
ICP*
<= 120.0
IERATIO*
<= 5.0
IMCO2*
<= 200.0
IUP*
LAPSYS*
<= 300.0
LAPDIA*
<= 300.0
LAPMEA*
<= 50.0
LVSW*
<= 100.0
LVSWI*
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<= 200.0
N2O*
<= 100.0
NAS*
<= 110.0
NBPSYS*
<= 300.0
NBPDIA*
<= 300.0
NBPMEA*
<= 200.0
PAPSYS*
<= 80.0
PAPDIA*
<= 80.0
PAPMEA*
<= 80.0
PCWP*
<= 80.0
PAEDP*
PBV-ALARM*
APNEA Alarm (1)
Disconnected Patient Alarm (10)
Fail to Cycle Alarm (11)
Loss of PEEP Alarm (12)
Low Minute Volume Alarm (13)
High Minute Volume Alarm (14)
High Frequency Alarm (15)
Oxygen Concentration Alarm (16)
User Alarm (17)
Gas Supply Alarm (18)
APNEA Ventilation Alarm (2)
Disconnected Ventilator Alarm (3)
Exhalation Valve Leak Alarm (4)
Low Battery Alarm (5)
Low Pressure Air Inlet Alarm (6)
Low Pressure O2 Inlet Alarm (7)
General Alarm (8)
High Pressure Alarm (9)
PEAKAIRPR*
<= 80.0
4 / 9
Item List QS System UKM Part 1 from 61
PEEPCPAP*
<= 40.0
PLETH*
<= 300.0
Tavegil
<= 6.0
PRESSUP*
<= 300.0
Puls*
>= 10.0
<= 400.0
PVR*
<= 400.0
PVRI*
<= 400.0
RAPSYS*
<= 300.0
RAPDIA*
<= 300.0
RAPMEA*
<= 50.0
REC*
>= 32.0
<= 42.0
RESP*
<= 120.0
RESP-S*
<= 70.0
RVSW*
<= 30.0
RVSWI*
<= 30.0
SpO2*
<= 150.0
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SKN*
<= 110.0
SO2*
ST*
SvO2*
<= 100.0
SV*
<= 200.0
SVI*
<= 60.0
SVR*
<= 2000.0
SVRI*
<= 4000.0
T1*
>= 10.0
<= 42.0
T2*
>= 32.0
<= 42.0
T3*
>= 32.0
<= 42.0
T4*
>= 32.0
<= 42.0
T1T2*
<= 10.0
TIDEVOL-S*
<= 2000.0
UNITS*
Englisch (1)
Metrisch (2)
VENTMODE*
CMV (1)
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EEMV (10)
Einleitung (11)
Standby/Ambient (12)
Spontan (13)
CPAP Demand (14)
CPAP kontinuierlich (15)
IMV Demand (16)
IMV kontinuierlich (17)
DK/CMV (18)
SIMV DK (19)
kontrolliert/assistiert (2)
Manuell (20)
HF Ventilation (21)
s600apm CPAP (oscilloscope) (22)
s600apm Automatic (23)
Französiche CMV (24)
Französiche SIMV (25)
Französiche CPAP (26)
IPPV (27)
Manuell/Spontan (28)
Erwachsen (29)
IMV (3)
Kinder (30)
Neugeboren (31)
SIMVCPAP (32)
SIMV CF (33)
BadMode (34)
ACTCPL (35)
IMVTCPL (36)
ACV (37)
Square (38)
Taper (39)
SIMV (4)
Sine (40)
Ac Taper (41)
De Taper (42)
BIPAP-SIMV (43)
IPPV ASB (44)
MMV ASB Autoflow (45)
ASB (46)
CPAP ASB (47)
ASB/CPAP (48)
CPPB ASB (49)
MMV (5)
CPPV (50)
BIPAP (51)
BiSIMV A (52)
Bi APRV (53)
DS (54)
Master (55)
Slave (56)
Apnoemodus (57)
ASB/CPAP (58)
SIMV ASB Autoflow (59)
druckunterstützt (6)
IPPV Autoflow (60)
IPPV ASB Autoflow (61)
CPPV (62)
BIPAPASB (63)
CPAP Druckunterstützt (64)
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BIPAP mit ASB (65)
PVC AC (66)
PVC CPAP (67)
CPAP (7)
druckkontrolliert (8)
SIMV druckunterstützt (9)
VPB*
WT*
PT-Adresse*
PT-ADMITDATE*
PT-ADMITDOC*
PT-ADMITDX*
PT-ADTLOG*
PT-Alter*
<= 100.0
PT-AGETYPE*
PT-ALIAS*
PT-ALTID*
PT-ATTENDDOC*
Allgemeinchirurgie (1)
Hals-Nasen-Ohrenklinik (10)
Internistische Intensivmedizin (11)
Kardiologie (12)
Kinderchirurgie (13)
Mund-Kiefer-Gesichtschirurgie (14)
Nephrologie (15)
Neurochirurgie (16)
Neurologie (17)
Nuklearmedizin (18)
Orthopädie (19)
Anästhesie (2)
Pädiatrie (20)
Psychiatrie (21)
Psychosomatik (22)
Radiologie (23)
Strahlentherapie (24)
Thorax-, Herz-, Gefäßchirurgie (25)
Transfusionsmedizin (26)
Unfallchirurgie (27)
8 / 9
Item List QS System UKM Part 1 from 61
Urologie (28)
Zahnklinik (29)
Augenklinik (3)
Rhythmologie (30)
Transplantationshepatologie (31)
Thorax-Chirurgie (32)
sonstige Klinik (33)
EMAH (4)
Gastroenterologie (5)
Gefäßchirurgie (6)
Gynäkologie (7)
Hämatologie (8)
Hämostasiologie (9)
PT-ATTENDID*
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Perinatal DSS 2015-16 Perinatal NMDS
2014- Metadata Online Registry (METeOR)
Health sector data set specifications from METeOR,
Australia's repository for national metadata standards,
developed by the Australian Institute of Health and Welfare
(http://meteor.aihw.gov.au/content/index.phtml/itemId/3451
65)
Perinatal DSS 2015-16 (Perinatal NMDS 2014-)
The scope of the Perinatal data set specification (DSS) is
all births in Australia in hospitals, birth centres and the
community. The data set includes information on all births,
both live births and stillbirths, of at least 20 weeks gestation
or 400 grams birth weight.
These data have two dimensions, which are the baby and
the mother. All data relevant to the birth are conveyed in
relation to one of these.
Metadata and Classifications Unit 
Australian Institute of Health and Welfare
GPO Box 570
Canberra ACT 2601
All rights reserved. Please visit https://medical-data-
models.org/forms/17085
Perinatal DSS 2015-16 Perinatal
NMDS 2014- Metadata Online
Registry (METeOR)
Birth event
Anaesthesia administered indicator*
Yes
No
Analgesia administered indicator*
Yes
No
Method of birth*
Vaginal - non-instrumental (1)
Vaginal - forceps (2)
Caesarean section (4)
Vaginal - vacuum extraction (5)
Not stated/inadequately described (9)
Birth plurality*
Singleton (1)
Twins (2)
Triplets (3)
Quadruplets (4)
Quintuplets (5)
Sextuplets (6)
Other (8)
Not stated (9)
Presentation at birth*
Vertex (1)
Breech (2)
Face (3)
Brow (4)
Other (8)
Not stated/inadequately described (9)
Labour onset type*
Spontaneous (1)
Induced (2)
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No labour (3)
Not stated (9)
Actual place of birth*
Hospital, excluding birth centre (1)
Birth centre, attached to hospital (2)
Birth centre, free standing (3)
Home (4)
Other (8)
Not stated (9)
State/Territory of birth*
New South Wales (1)
Victoria (2)
Queensland (3)
South Australia (4)
Western Australia (5)
Tasmania (6)
Northern Territory (7)
Australian Capital Territory (8)
Other territories (Cocos (Keeling)
Islands, Christmas Island and Jervis Bay
Territory) (9)
Type of anaesthesia administered during a birth
event
Local anaesthetic to perineum (2)
Pudendal block (3)
Epidural or caudal block (4)
Spinal block (5)
General anaesthesia (6)
Combined spinal-epidural block (7)
Other anaesthesia (88)
Not stated/inadequately described (99)
Type of analgesia administered during a birth
event
Nitrous oxide (2)
Epidural or caudal block (4)
Spinal block (5)
Systemic opioids (6)
Combined spinal-epidural block (7)
Other analgesia (88)
Not stated/inadequately described (99)
Birth
Apgar score at 5 minutes*
Birth order*
Singleton or first of a multiple birth (1)
Second of a multiple birth (2)
Third of a multiple birth (3)
Fourth of a multiple birth (4)
Fifth of a multiple birth (5)
Sixth of a multiple birth (6)
Other (8)
Not stated (9)
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Status of the baby*
Live birth (1)
Stillbirth (fetal death) (2)
Not stated (9)
Infant weight, neonate, stillborn*
g
Episode of admitted patient care
Separation date*
Establishment
Establishment identifier*
Female (mother)
Postpartum perineal status*
Intact (1)
1st degree laceration/vaginal graze (2)
2nd degree laceration (3)
3rd degree laceration (4)
Episiotomy (5)
4th degree laceration (7)
Other perineal laceration, rupture or tear
(88)
Not stated/inadequately described (99)
Female (pregnant)
Number of tobacco cigarettes smoked per day
after 20 weeks of pregnancy
Tobacco smoking indicator, after 20 weeks of
pregnancy*
Yes (1)
No (2)
Not stated/inadequately described (9)
Tobacco smoking indicator, first 20 weeks of
pregnancy*
Yes (1)
No (2)
Not stated/inadequately described (9)
Female
Caesarean section at most recent previous birth
indicator*
Yes (1)
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No (2)
Not applicable (7)
Not stated/inadequately described (9)
Antenatal care visits*
Parity*
Person
Area of usual residence (SA2)*
Country of birth*
Date of birth*
Indigenous status*
Aboriginal but not Torres Strait Islander
origin (1)
Torres Strait Islander but not Aboriginal
origin (2)
Both Aboriginal and Torres Strait Islander
origin (3)
Neither Aboriginal nor Torres Strait
Islander origin (4)
Not stated/inadequately described (9)
Person identifier*
Sex*
Male (1)
Female (2)
Intersex or indeterminate (3)
Not stated/inadequately described (9)
Pregnancy
Pregnancy duration at the first antenatal care
visit*
completed weeks
Product of conception
Gestational age*
completed weeks
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Eligibility Depressive Disorder
NCT00135512
Study Of 323U66 SR In Major Depressive Disorder; ODM
derived from: https://clinicaltrials.gov/show/NCT00135512
All rights reserved. Please visit https://medical-data-
models.org/forms/17087
Eligibility Depressive Disorder
NCT00135512
Inclusion Criteria
met dsm-iv-tr criteria for major depressive
disorder for their current episode for at least 8
weeks prior to screening visit.*
Yes
No
must give a written informed consent. but if the
patient is under 20, both the patient
himself/herself and his/her proxy consenter must
give written informed consent.*
Yes
No
must have rating scores as outlined.*
Yes
No
Exclusion Criteria
current or past history of seizure disorder or brain
injury.*
Yes
No
current or past history of anorexia or bulimia
nervosa.*
Yes
No
history of manic episode.*
Yes
No
past or current dsm- iv-tr diagnosis of
schizophrenia or other psychotic disorder.*
Yes
No
diagnosis of substance abuse (alcohol or drug)
by the dsm-iv-tr criteria.*
Yes
No
pregnant, possibly pregnant or lactating.*
Yes
No
must not be suicidal.*
Yes
No
1 / 2
blood pressure of sbp>160mmhg,
dbp>100mmhg.*
Yes
No
history or complication of cancer or malignant
tumour.*
Yes
No
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Perinatal DSS 2015-16 Metadata Online
Registry (METeOR)
Health sector data set specifications from METeOR,
Australia's repository for national metadata standards,
developed by the Australian Institute of Health and Welfare
(http://meteor.aihw.gov.au/content/index.phtml/itemId/3451
65)
Perinatal DSS 2015-16
The scope of the Perinatal data set specification (DSS) is
all births in Australia in hospitals, birth centres and the
community. The data set includes information on all births,
both live births and stillbirths, of at least 20 weeks gestation
or 400 grams birth weight.
These data have two dimensions, which are the baby and
the mother. All data relevant to the birth are conveyed in
relation to one of these.
Metadata and Classifications Unit 
Australian Institute of Health and Welfare
GPO Box 570
Canberra ACT 2601
All rights reserved. Please visit https://medical-data-
models.org/forms/17088
Perinatal DSS 2015-16 Metadata
Online Registry (METeOR)
Birth event
Additional indication for caesarean section
Fetal compromise (1)
Lack of progress; less than or equal to 3
cm cervical dilatation (10)
Lack of progress in the first stage;
greater than 3 cm to less than 10 cm
cervical dilatation (11)
Lack of progress in the second stage
(12)
Placenta praevia (13)
Placental abruption (14)
Vasa praevia (15)
Antepartum/intrapartum haemorrhage
(16)
Multiple pregnancy     (17)
Unsuccessful attempt at assisted
delivery     (18)
Cord prolapse (19)
Suspected fetal macrosomia (2)
Previous adverse perinatal outcome (20)
Previous caesarean section (21)
Previous severe perineal trauma (22)
Previous shoulder dystocia (23)
Other obstetric, medical, surgical,
psychological indications (29)
Malpresentation (3)
Maternal choice in the absence of any
obstetric, medical, surgical,
psychological indications (30)
Not stated/inadequately described (99)
Additional indication for induction of labour
Prolonged pregnancy (1)
Body Mass Index (BMI) (10)
Maternal mental health indication (11)
Previous adverse perinatal outcome (12)
Other maternal obstetric or medical
indication (19)
Prelabour rupture of membranes (2)
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Fetal compromise (includes suspected)
(20)
Fetal growth restriction (includes
suspected) (21)
Fetal macrosomia (includes suspected)
(22)
Fetal death (23)
Fetal congenital anomaly (24)
Diabetes (3)
Hypertensive disorders (4)
Multiple pregnancy (5)
Chorioamnionitis (includes suspected)
(6)
Cholestasis of pregnancy (7)
Antepartum haemorrhage (8)
Administrative or geographical indication
(80)
Maternal choice in the absence of any
obstetric, medical, fetal, administrative or
geographical indication (81)
Other indication not elsewhere classified
(89)
Maternal age (9)
Not stated/inadequately described (99)
Main indication for caesarean section
Fetal compromise (1)
Lack of progress; less than or equal to 3
cm cervical dilatation (10)
Lack of progress in the first stage;
greater than 3 cm to less than 10 cm
cervical dilatation (11)
Lack of progress in the second stage
(12)
Placenta praevia (13)
Placental abruption (14)
Vasa praevia (15)
Antepartum/intrapartum haemorrhage
(16)
Multiple pregnancy     (17)
Unsuccessful attempt at assisted
delivery     (18)
Cord prolapse (19)
Suspected fetal macrosomia (2)
Previous adverse perinatal outcome (20)
Previous caesarean section (21)
Previous severe perineal trauma (22)
Previous shoulder dystocia (23)
Other obstetric, medical, surgical,
psychological indications (29)
Malpresentation (3)
Maternal choice in the absence of any
obstetric, medical, surgical,
psychological indications (30)
Not stated/inadequately described (99)
Main indication for induction of labour
Prolonged pregnancy (1)
Body Mass Index (BMI) (10)
Maternal mental health indication (11)
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Previous adverse perinatal outcome (12)
Other maternal obstetric or medical
indication (19)
Prelabour rupture of membranes (2)
Fetal compromise (includes suspected)
(20)
Fetal growth restriction (includes
suspected) (21)
Fetal macrosomia (includes suspected)
(22)
Fetal death (23)
Fetal congenital anomaly (24)
Diabetes (3)
Hypertensive disorders (4)
Multiple pregnancy (5)
Chorioamnionitis (includes suspected)
(6)
Cholestasis of pregnancy (7)
Antepartum haemorrhage (8)
Administrative or geographical indication
(80)
Maternal choice in the absence of any
obstetric, medical, fetal, administrative or
geographical indication (81)
Other indication not elsewhere classified
(89)
Maternal age (9)
Not stated/inadequately described (99)
Female
Blood transfusion for primary PPH
Yes (1)
No (2)
Not stated/inadequately described (9)
Diabetes during pregnancy*
Yes (1)
No (2)
Not stated/inadequately described (9)
PPH blood loss
500–999 mls (1)
1000–1499 mls (2)
1500 mls or more (3)
Not stated/inadequately described (9)
Hypertension during pregnancy*
Yes (1)
No (2)
Not stated/inadequately described (9)
Primary postpartum haemorrhage indicator*
Yes (1)
No (2)
Not stated/inadequately described (9)
Diabetes mellitus type during pregnancy
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Pre-existing Type 1 diabetes (1)
Pre-existing Type 2 diabetes (2)
Gestational diabetes mellitus (GDM) (3)
Other type of diabetes mellitus (8)
Not stated/inadequately described (9)
Diabetes therapy type during pregnancy
Insulin (1)
Oral hypoglycaemic (2)
Diet and exercise (3)
Not stated/inadequately described (9)
Hypertension type during pregnancy
Eclampsia (1)
Preeclampsia (2)
Gestational hypertension (3)
Chronic hypertension (4)
Not stated/inadequately described (9)
Person
Height (measured)
cm
Height (self-reported)
cm
Weight in kilograms (measured)*
Kg
Weight (self-reported)
Kg
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Eligibility Depressive Disorder, Major
NCT00057213
An 8 Week Study Of Depression In Adults Diagnosed With
Major Depressive Disorder; ODM derived from:
https://clinicaltrials.gov/show/NCT00057213
All rights reserved. Please visit https://medical-data-
models.org/forms/17090
Eligibility Depressive Disorder, Major
NCT00057213
Inclusion Criteria
diagnosis of major depressive disorder (mdd)*
Yes
No
duration of current depressive episode 12 weeks
- 24 months*
Yes
No
patients can read and write at a level sufficient to
provide a signed consent*
Yes
No
if female, patients must be practicing an
acceptable method of birth control*
Yes
No
Exclusion Criteria
patients have other psychiatric disorders that
would affect patient's response to treatment*
Yes
No
patients have not responded to two or more
adequate courses of antidepressant therapy*
Yes
No
patients cannot be currently abusing illicit drugs
or alcohol*
Yes
No
patients are not currently receiving
psychotherapy*
Yes
No
patients have received electroconvulsive therapy
within 6 months prior to screening*
Yes
No
patients are pregnant or lactating*
Yes
No
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DSS Metadata Online Registry (METeOR)
Health sector data set specifications from METeOR,
Australia's repository for national metadata standards,
developed by the Australian Institute of Health and Welfare
(http://meteor.aihw.gov.au/content/index.phtml/itemId/3451
65)
Prisoner health DSS: Prison clinic contact DSS
The Prisoner health data set specification (DSS) describes
data collected from all public and private prisons throughout
Australia on prison entrants, prisoners who visit a prison
clinic, prisoners who are taking repeat medication while in
custody, prison clinic services and staffing levels. The data
are used to report against the National Prisoner Health
Indicators, assist in monitoring the health of prisoners and
inform prisoner health service planning and delivery.
In this collection, public and private prisons include those
administered by Corrective Services departments, including
correctional facilities and remand centres. Excluded from
the collection are periodic detention centres, court and
police cells, juvenile detention centres, immigration
detention centres, secure psychiatric facilities, military
prisons, and home detention programs.
The Prisoner health DSS contains four component data set
specifications:
Prison entrants DSS, Prison clinic contact DSS, Prisoners
in custody repeat medications DSS, and Prison
establishments DSS.
The Prison clinic contact DSS describes data from all visits
by prisoners to the prison clinic during the National
Prisoner Health Census period regarding the number of
clinic contacts each prisoner made and the reason for clinic
attendance (Obligation: Mandatory, Maximum occurences:
Unlimited).
Metadata and Classifications Unit 
Australian Institute of Health and Welfare
GPO Box 570
Canberra ACT 2601
All rights reserved. Please visit https://medical-data-
models.org/forms/17091
Prisoner health DSS Prison clinic
contact DSS Metadata Online
Registry (METeOR)
Person 1
Person identifier*
Date of birth*
Sex*
Male (1)
Female (2)
Intersex or indeterminate (3)
Not stated/inadequately described (9)
Transgender*
Yes (1)
No (2)
Not stated/inadequately described (9)
Indigenous status*
Aboriginal but not Torres Strait Islander
origin (1)
Torres Strait Islander but not Aboriginal
origin (2)
Both Aboriginal and Torres Strait Islander
origin (3)
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Neither Aboriginal nor Torres Strait
Islander origin (4)
Not stated/inadequately described (9)
Health service event 1
Initiator of prison clinic visit*
Prisoner (1)
Staff (2)
Not stated/inadequately described (9)
Person 2
Reason for health clinic attendance*
Health check (01)
Diabetes (02)
Mental health condition (03)
Pathology (04)
Skin condition (excluding cancer and
communicable diseases) (05)
Drug and alcohol issue (06)
Medication (07)
Vaccination  (08)
Musculoskeletal injury  (09)
Musculoskeletal condition (excluding
arthritis, injury or cancer)   (10)
Cardiovascular disease  (11)
Respiratory condition (excluding asthma,
cancer or communicable diseases)  (12)
Communicable disease   (13)
Dental    (14)
Digestive condition (excluding cancer)
(15)
Wound care   (16)
Asthma   (17)
Sensory conditions (ear and eye
conditions) (18)
Neurological condition  (19)
Malignancy (cancer, excluding non-
melanoma skin cancer)   (20)
Arthritis   (21)
Women's health   (22)
Other (25)
Not stated/inadequately described (99)
Health service event 2
Type of service provider consulted*
2 / 2
Prisoner health DSS Prison clinic contact DSS Metadata Online Registry
(METeOR)
Eligibility Depressive Disorder, Major
NCT00057226
An 8 Week Study Of Adults Diagnosed With Major
Depressive Disorder; ODM derived from:
https://clinicaltrials.gov/show/NCT00057226
All rights reserved. Please visit https://medical-data-
models.org/forms/17092
Eligibility Depressive Disorder, Major
NCT00057226
Inclusion Criteria
diagnosis of major depressive disorder (mdd)*
Yes
No
duration of current depressive episode 12 weeks
- 24 months*
Yes
No
patients can read and write at a level sufficient to
provide a signed consent*
Yes
No
if female, patients must be practicing an
acceptable method of birth control*
Yes
No
Exclusion Criteria
patients have other psychiatric disorders that
would affect patient's response to treatment*
Yes
No
patients have not responded to two or more
adequate courses of antidepressant therapy*
Yes
No
patients cannot be currently abusing illicit drugs
or alcohol*
Yes
No
patients are not currently receiving
psychotherapy*
Yes
No
patients have received electroconvulsive therapy
within 6 months prior to screening*
Yes
No
patients are pregnant or lactating*
Yes
No
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Appendix 1: Documentation and progress report of
hepatocellular carcinoma for liver transplantation
Richtlinie gemäß § 16 Abs. 1 S. 1 Nrn. 2 u. 5 TPG
für die Wartelistenführung und Organvermittlung zur
Lebertransplantation
Source:
http://www.bundesaerztekammer.de/richtlinien/richtlinien/tr
ansplantationsmedizin/richtlinien-fuer-die-
wartelistenfuehrung-und-die-organvermittlung/
All rights reserved. Please visit https://medical-data-
models.org/forms/17094
Appendix 1: Documentation and
process of hepatocellular carcinoma
for liver transplantation
Patient information
patient name
ET number
Date
Diagnosis
initial hepatocellular carcinoma
Yes
No
progress report (recertification)
Yes
No
amount of hcc nodes
milan-criteria met
Yes
No
diagnosis of hepatocellular carcinoma was
secured
Yes
No
diagnosis of liver cirrhosis was secured
diagnostic procedure used
MRI (1)
CT (2)
Ultrasonography (3)
Lesion 1
size of lesion
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liver segment
contrast phase in which was measured
late arterial phase (1)
portal phase (2)
delayed phase (120-180 sec after
application) (3)
strong enhancement in late arterial phase
Yes
No
early wash out in portal venous phase
Yes
No
Pseudocapsule in portal venous phase
Yes
No
Wash out in delayed phase (120-180 sec after
application)
Yes
No
pseudocapsule in delayed phase (120-180 sec
after application)
Yes
No
macrovascular invasion in delayed phase (120-
180 sec after application)
Yes
No
Lesion 2
size of lesion
liver segment
contrast phase in which was measured
late arterial phase (1)
portal phase (2)
delayed phase (120-180 sec after
application) (3)
strong enhancement in late arterial phase
Yes
No
early wash out in portal venous phase
Yes
No
Pseudocapsule in portal venous phase
Yes
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No
Wash out in delayed phase (120-180 sec after
application)
Yes
No
pseudocapsule in delayed phase (120-180 sec
after application)
Yes
No
macrovascular invasion in delayed phase (120-
180 sec after application)
Yes
No
Lesion 3
size of lesion
liver segment
contrast phase in which was measured
late arterial phase (1)
portal phase (2)
delayed phase (120-180 sec after
application) (3)
strong enhancement in late arterial phase
Yes
No
early wash out in portal venous phase
Yes
No
Pseudocapsule in portal venous phase
Yes
No
Wash out in delayed phase (120-180 sec after
application)
Yes
No
pseudocapsule in delayed phase (120-180 sec
after application)
Yes
No
macrovascular invasion in delayed phase (120-
180 sec after application)
Yes
No
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Lesion 4
size of lesion
liver segment
contrast phase in which was measured
late arterial phase (1)
portal phase (2)
delayed phase (120-180 sec after
application) (3)
strong enhancement in late arterial phase
Yes
No
early wash out in portal venous phase
Yes
No
Pseudocapsule in portal venous phase
Yes
No
Wash out in delayed phase (120-180 sec after
application)
Yes
No
pseudocapsule in delayed phase (120-180 sec
after application)
Yes
No
macrovascular invasion in delayed phase (120-
180 sec after application)
Yes
No
Lesion 5
size of lesion
liver segment
contrast phase in which was measured
late arterial phase (1)
portal phase (2)
delayed phase (120-180 sec after
application) (3)
strong enhancement in late arterial phase
Yes
No
early wash out in portal venous phase
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Yes
No
Pseudocapsule in portal venous phase
Yes
No
Wash out in delayed phase (120-180 sec after
application)
Yes
No
pseudocapsule in delayed phase (120-180 sec
after application)
Yes
No
macrovascular invasion in delayed phase (120-
180 sec after application)
Yes
No
Date
signature of radiologist
date
signature of representative of transplantation
conference
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Eligibility Colorectal Cancer NCT00633607
Hereditary Colorectal Tumor Registry; ODM derived from:
https://clinicaltrials.gov/show/NCT00633607
All rights reserved. Please visit https://medical-data-
models.org/forms/17095
Eligibility Colorectal Cancer
NCT00633607
Inclusion Criteria
hnpcc- rc less than the age of 50*
Yes
No
colorectal polyps less than the age of 40*
Yes
No
hnpcc-rc at any age but a fdr with hnpcc-rc less
than 50*
Yes
No
anyone with msi positive high or
immunohistochemistry - for hmlh1, hsh2, hsh6*
Yes
No
anyone at any age with 2 hnpcc-rc (including
synchronous or metachronous crc)*
Yes
No
crc diagnosed in at least 2 fdr or sdr relatives with
hnpcc-rc regardless of age*
Yes
No
anyone who is a fdr(first degree relative) to those
who meet the inclusion criteria above*
Yes
No
because some of the familial cancers involve
children and standard of care involves screening
of children during puberty, they will also be
included but with parental consent.*
Yes
No
individuals must be able to complete all
questionnaires.*
Yes
No
ability to give informed consent*
Yes
No
Exclusion Criteria
individuals who do not meet the above criteria*
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Yes
No
individuals who do not desire to consent to any
part of the registry*
Yes
No
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Eligibility Congestive Heart Failure
Exacerbation NCT00186329
BNP for Cardio-Renal Decompensation Syndrome (BNP-
CARDS); ODM derived from:
https://clinicaltrials.gov/show/NCT00186329
All rights reserved. Please visit https://medical-data-
models.org/forms/17096
Eligibility Congestive Heart Failure
Exacerbation NCT00186329
Inclusion Criteria
acute admission to hospital with chf
exacerbation*
Yes
No
calculated creatinine clearance between 15-
60ml/min using the cockroft gault equation.*
Yes
No
Exclusion Criteria
hypotension (sbp < 90mmhg)*
Yes
No
hypertension (sbp > 170 mmhg) necessitating
vasodilator therapy*
Yes
No
known allergy to natrecor*
Yes
No
history of heart transplantation*
Yes
No
contraindications to vasodilator therapy (i.e.
severe aortic stenosis)*
Yes
No
up-front use of inotropes*
Yes
No
mental incompetence meaning inability to provide
informed consent*
Yes
No
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Screening: exclusion criteria Nicotinsäure und
Naftidrofuryl bei pAVK-Patienten nach Angioplastie
Leiter der Klinischen Prüfung:
PD. Dr. med. Knut Kröger
Klinik für Angiologie
Universitätsklinikum Essen
Hufelandstr. 55
45122 Essen
Telefon: 0201/723-2530
Fax: 0201/723-5967
Sponsor:
Universitätsklinikum Essen
Hufelandstraße 55
45122 Essen
Datenmanagement und Biometrie
C. Ose und Chr. Lösch
Zentrum für Klinische Studien Essen
Leiter: Prof. Dr. K.-H. Jöckel
Hufelandstr. 55, 45122 Essen
Universitätsklinikum Essen
Telefon.: 0201/723-4519
Fax: 0201/723-5933
E-Mail: claudia.ose@uk-essen.de
Sreening: Exclusion criteria
All rights reserved. Please visit https://medical-data-
models.org/forms/17097
Screening: Ausschlusskrieterien;
Nicotinsäure und Naftidrofuryl bei
pAVK-Patienten nach Angioplastie
Identifikation
Zentrums-Nr.:
Pat-Nr.
Ausschlusskriterien
Teilnahme an einer klinischen Studie innerhalb
der letzten 30 Tage oder dieser Studie zu einem
früheren Zeitpunkt
nein (0)
ja (1)
gleichzeitige Teilnahme an einer anderen
klinischen Prüfung
nein (0)
ja (1)
Frauen im gebärfähigen Alter ohne
ausreichenden Konzeptionsschutz (Als effektiver
Konzeptionsschutz gelten: Hormonale
Kontrazeptiva, Intraunterinpessar plus Kondom
oder Spermizid plus Kondom)
no (0)
yes (1)
Schwangerschaft oder Stillzeit (ggf.
Schwangerschaftstest)
no (0)
yes (1)
Alkoholiker, Medikamenten- oder
Drogenabhängige
no (0)
1 / 2
yes (1)
terminale Erkrankungen (z.B. Krebs)
no (0)
yes (1)
Beinamputation beim Patienten im nächsten Jahr
zu erwarten
no (0)
yes (1)
Kontraindikationen gegen Nicotinsäure und zwar
•	bekannte Gallenerkrankung
•	instabile Angina pectoris 
•	akuter Myokardinfarkt
•	Gicht
•	bekannter Ikterus
•	Magengeschwüre
•	Symptome die auf eine Rhabdomyolyse
hindeuten wie z.B (Muskelschmerzen, Erhöhung
von Creatinkinease oder Kalium)
no (0)
yes (1)
Kontraindikationen gegen Naftidrofuryl
•	dekompensierte Herzinsuffizienz
•	schwere Überleitungsstörung im Herzen
•	schwere Angina pectoris
•	arterielle Blutungen
•	Hypotonie (< 90 mmHg)
•	orthostatische Dysregulation
•	frischer hämorrhagischer Insult
•	klinisch bekannte Leberfunktionsstörungen
•	bekannte Hyperoxalurie od. calciumhaltige
Nierensteine
•	cerebrales Anfallsleiden
•	Überempfindlichkeit gegenüber Naftidrofuryl
oder anderen Bestandteilen
no (0)
yes (1)
Nicht zulässige Begleitmedikation
•	Antikoagulantien (Marcumar, Heparin)
•	Antiarrhythmika
•	Ganglienblocker
•	Anionenaustauscherharze
no (0)
yes (1)
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UKM-ORBIS® Clinic for childrens and adolscent medicine-Outpatient
department of childrens and neonatal surgery; surgery protocol
Freigabe zur Verarbeitung durch Frau Prof. Rössig,
Quellenangabe: "Pädiatrische Hämatologie und Onkologie,
UKM" Klinik für Kinder- und Jugendmedizin,
Universitätsklinikum Münster Released for adaption by Frau
Prof. Rössig Source: Pediatric Hematology and Oncology,
University hospital Münster
All rights reserved. Please visit https://medical-data-
models.org/forms/17098
UKM-ORBIS® Clinic for childrens
and adolscent medicine-Outpatient
department of childrens and
neonatal surgery; surgery protocol
Organisatorische Informationen
Patientenname
Patient Geburtsdatum
Patienten Geschlecht
männlich (1)
weiblich (2)
Operationsdatum und Uhrzeit
OP-Nummer
Op-Saal
Op-Buch
Op-Buch Nummer
Dienstart
Kostenübernehmer
OP-Orgaeinheit
Fall Nummer
Fallstatus
Hausarzt
Dringlichkeit
Anmerkung
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Sterilität
Sauberkeitsgrad
OP-Team
1. Operateur: Titel, Vorname,Name
Anwesenheitsdauer: Von ... Uhr bis ... Uhr
1. Assistent: Titel, Vorname, Name
Anwesenheitsdauer: Von ... Uhr bis ... Uhr
Instrumenteur: Titel, Vorname,Name
Anwesenheitsdauer: Von ... Uhr bis ... Uhr
Springer: Titel, Vorname, Name
Anwesenheitsdauer: Von ... Uhr bis ... Uhr
Springer: Titel, Vorname, Name
Anwesenheitsdauer: Von ... Uhr bis ... Uhr
Springer: Titel, Vorname, Name
Anwesenheitsdauer: Von ... Uhr bis ... Uhr
Springer: Titel, Vorname, Name
Anwesenheitsdauer: Von ... Uhr bis ... Uhr
Schleusen / Lagern: Titel, Vorname,Name
Anwesenheitsdauer: Von ... Uhr bis ... Uhr
Op-Zeiten
OP-Phase
Beginn der OP-Phase
2 / 7
UKM-ORBIS® Clinic for childrens and adolscent medicine-Outpatient
department of childrens and neonatal surgery; surgery protocol
Ende der OP-Phase
Dauer in min
Diagnosen
Code
Diagnose
Uhrzeit
Seite
Haupt- oder Nebendiagose?
Diagnosekennzeichen
Zustand nach (1)
Verdacht  auf (2)
Gesichert (3)
Ausschluss von (4)
OP-Ursache
Ja
Nein
Komplikationen
Ja
Nein
Orgaeinheit
Mitarbeiter
Prozeduren
ICPM
Prozedur Text
Seite
Haupt-/oder Nebenprozedur?
Orgaeinheit
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Mitarbeiter
Uhrzeit
Lagerung
Lagerung
Mitarbeiter
Lagerungsbeginn
Lagerungsende
HF-Chirurgie
HF-Chirurgie
Platzierung der Elektrode
Mitarbeiter
Uhrzeit
Hautdesinfektion
Desinfektionsmittel
Hautreaktion
Menge
ml
Mitarbeiter
Uhrzeit
Siebe
Siebbezeichnung
Siebnummer
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Vollständig
Ja
Nein
Chargennummer
Material
Artikelnummer
Artikelbezeichnung
Anzahl
Einheit
Uhrzeit
Nahtmaterial
Artikelnummer
Artikelbezeichnung
Anzahl
Einheit
Uhrzeit
Zählkontrolle
Zählartikel Bezeichnung
Anzahl vor OP
Anzahl während OP
Gesamtanzahl
Anzahl gebraucht
Anzahl ungebraucht
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Gesamtanzahl
Differenz
Uhrzeit
Mitarbeiter 1
Mitarbeiter 2
Artikelbezeichnung
Zusatzleistungen
Leistung
Kategorie
Anästhesieart
Anzahl
Mitarbeiter
Anwesenheitsdauer: Von ... Uhr bis ... Uhr
Historie der Protokollerstellung
Datum/ Uhrzeit
Ersteller
Abschluss durch
Abschluss am
Nachtragsgrund
Dokumentationsverantwortlicher
Beginn
Ende
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Arbeitsplatz
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Eligibility Depressive Disorder, Major
NCT00067444
Depression Study In Elderly Patients; ODM derived from:
https://clinicaltrials.gov/show/NCT00067444
All rights reserved. Please visit https://medical-data-
models.org/forms/17100
Eligibility Depressive Disorder, Major
NCT00067444
Inclusion Criteria
diagnosis of major depressive disorder (mdd).*
Yes
No
current major depressive episode at screen at
least 2 months duration.*
Yes
No
must be at least 60 years of age.*
Yes
No
Exclusion Criteria
patients with a primary diagnosis other than
mdd.*
Yes
No
patients with a history of schizophrenia,
schizoaffective disorder, bipolar disorder or
dementia.*
Yes
No
patients with a history of brief depressive
episodes lasting less than 8 weeks.*
Yes
No
patients receiving formal psychotherapy within 12
weeks of study.*
Yes
No
patients who are suicidal.*
Yes
No
patients who have received electroconvulsive
therapy or transcranial magnetic stimulation
within 6 months prior to screening.*
Yes
No
patients with a history or seizure disorders.*
Yes
No
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Deutscher Diabetes Risiko Test DIfE
Extract of the German Diabetes Risk Test. Auszug aus
DRT. Mit Hilfe des vom Deutschen Institut für
Ernährungsforschung Potsdam-Rehbrücke (DIfE)
entwickelten Risiko-Tests können Sie Ihr persönliches
Risiko ermitteln, innerhalb der nächsten 5 Jahre an einem
Typ-2-Diabetes zu erkranken. Der Test ist nicht anwendbar,
wenn bei Ihnen bereits ein Diabetes bekannt ist. Source:
www.dife.de
All rights reserved. Please visit https://medical-data-
models.org/forms/17103
Deutscher Diabetes Risiko Test
Deutscher Diabetes Risiko Test
Wie alt sind Sie in Jahren?
<35 (0 Punkte)
35-39 (1 Punkt)
50-54 (10 Punkte)
55-59 (13 Punkte)
60-64 (16 Punkte)
65-69 (19 Punkte)
70-74 (22 Punkte)
≥ 75 (25 Punkte)
40-44 (4 Punkte)
45-49 (7 Punkte)
Sind Sie pro Woche mindestens 5 Stunden aktiv?
(z. B. Sport, Gartenarbeit, Radfahren)
Ja (0 Punkte)
Nein (1 Punkt)
Wurde bei Ihnen schon einmal ein Bluthochdruck
festgestellt?
Nein (0 Punkte)
Ja (5 Punkte)
Wie viele Scheiben Vollkornbrot, -brötchen und
Portionen Müsli (1 Portion = 3 Esslöffel) essen
Sie am Tag?
>4 (0 Punkte)
4 (1 Punkt)
3 (2 Punkte)
2 (3 Punkte)
1 (4 Punkte)
0 (5 Punkte)
Wie oft essen Sie Rind-, Schweine oder
Lammfleisch (keine Wurstwaren)?
Nie oder sehr selten (0 Punkte)
1-2 mal pro Woche  (1 Punkt)
3-4 mal pro Woche  (3 Punkte)
5-6 mal pro Woche  (5 Punkte)
Täglich (6 Punkte)
Mehrmals täglich (8 Punkte)
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Prisoner health DSS Prisoners in custody repeat
medications DSS Metadata Online Registry (METeOR)
Health sector data set specifications from METeOR,
Australia's repository for national metadata standards,
developed by the Australian Institute of Health and Welfare
(http://meteor.aihw.gov.au/content/index.phtml/itemId/3451
65)
Prisoner health DSS: Prisoners in custody repeat
medications DSS
The Prisoner health data set specification (DSS) describes
data collected from all public and private prisons throughout
Australia on prison entrants, prisoners who visit a prison
clinic, prisoners who are taking repeat medication while in
custody, prison clinic services and staffing levels. The data
are used to report against the National Prisoner Health
Indicators, assist in monitoring the health of prisoners and
inform prisoner health service planning and delivery.
In this collection, public and private prisons include those
administered by Corrective Services departments, including
correctional facilities and remand centres. Excluded from
the collection are periodic detention centres, court and
police cells, juvenile detention centres, immigration
detention centres, secure psychiatric facilities, military
prisons, and home detention programs.
The Prisoner health DSS contains four component data set
specifications:
Prison entrants DSS, Prison clinic contact DSS, Prisoners
in custody repeat medications DSS, and Prison
establishments DSS.
The Prisoners in custody repeat medications DSS
describes data regarding all instances of prisoners in
custody taking repeat medication (Obligation: Mandatory).
Metadata and Classifications Unit 
Australian Institute of Health and Welfare
GPO Box 570
Canberra ACT 2601
All rights reserved. Please visit https://medical-data-
models.org/forms/17105
Prisoner health DSS Prisoners in
custody repeat medications DSS
Metadata Online Registry (METeOR)
Person
Person identifier*
Date of birth*
Sex*
Male (1)
Female (2)
Intersex or indeterminate (3)
Not stated/inadequately described (9)
Transgender*
Yes (1)
No (2)
Not stated/inadequately described (9)
Indigenous status*
Aboriginal but not Torres Strait Islander
origin (1)
Torres Strait Islander but not Aboriginal
origin (2)
Both Aboriginal and Torres Strait Islander
origin (3)
Neither Aboriginal nor Torres Strait
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Islander origin (4)
Not stated/inadequately described (9)
Medication type*
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Prisoner health DSS Prison entrants DSS
Metadata Online Registry (METeOR)
Health sector data set specifications from METeOR,
Australia's repository for national metadata standards,
developed by the Australian Institute of Health and Welfare
(http://meteor.aihw.gov.au/content/index.phtml/itemId/3451
65)
Prisoner health DSS: Prison entrants DSS
The Prisoner health data set specification (DSS) describes
data collected from all public and private prisons throughout
Australia on prison entrants, prisoners who visit a prison
clinic, prisoners who are taking repeat medication while in
custody, prison clinic services and staffing levels. The data
are used to report against the National Prisoner Health
Indicators, assist in monitoring the health of prisoners and
inform prisoner health service planning and delivery.
In this collection, public and private prisons include those
administered by Corrective Services departments, including
correctional facilities and remand centres. Excluded from
the collection are periodic detention centres, court and
police cells, juvenile detention centres, immigration
detention centres, secure psychiatric facilities, military
prisons, and home detention programs.
The Prisoner health DSS contains four component data set
specifications:
Prison entrants DSS, Prison clinic contact DSS, Prisoners
in custody repeat medications DSS, and Prison
establishments DSS.
The Prison entrants DSS describes data about all persons
aged 18 years and over entering prison system during the
National Prisoner Health Census reporting period
(Obligation: Mandatory).
Metadata and Classifications Unit 
Australian Institute of Health and Welfare
GPO Box 570
Canberra ACT 2601
All rights reserved. Please visit https://medical-data-
models.org/forms/17106
Prisoner health DSS Prison entrants
DSS Metadata Online Registry
(METeOR)
Establishment (prison)
Prison establishment identifier*
Establishment
Australian State/Territory identifier
(establishment)*
New South Wales (1)
Victoria (2)
Queensland (3)
South Australia (4)
Western Australia (5)
Tasmania (6)
Northern Territory (7)
Australian Capital Territory (8)
Other territories (Cocos (Keeling)
Islands, Christmas Island and Jervis Bay
Territory) (9)
Person 1
Person identifier*
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Date of birth*
Age
years
Country of birth*
Main language other than English spoken at
home*
Sex*
Male (1)
Female (2)
Intersex or indeterminate (3)
Not stated/inadequately described (9)
Transgender*
Yes (1)
No (2)
Not stated/inadequately described (9)
Indigenous status*
Aboriginal but not Torres Strait Islander
origin (1)
Torres Strait Islander but not Aboriginal
origin (2)
Both Aboriginal and Torres Strait Islander
origin (3)
Neither Aboriginal nor Torres Strait
Islander origin (4)
Not stated/inadequately described (9)
Highest year of school completed*
Year 12 (1)
Year 11 (2)
Year 10 (3)
Year 9 (4)
Year 8 or below (5)
No schooling (6)
Not stated/inadequately described (9)
Non-school qualification cluster
Non-school qualification indicator*
Yes (1)
No (2)
Not stated/inadequately described (9)
Level of highest non-school qualification
Trade Certificate (Certificate I-IV) (1)
Advanced Diploma and Diploma (2)
Bachelor degree (3)
Graduate Diploma and Graduate
Certificate (4)
Postgraduate degree (5)
2 / 7
Prisoner health DSS Prison entrants DSS Metadata Online Registry
(METeOR)
Not stated/inadequately described (9)
Prison entrant 1
Education attendance status 30 days prior to
imprisonment*
Full-time study (1)
Part-time study (2)
Not studying (3)
Not stated/inadequately described (9)
Labour force status 30 days prior to
imprisonment*
Full-time work (1)
Part-time work or casual work (2)
Unemployed and looking for work (3)
Unemployed and not looking for work (4)
Unable to work due to disability, age or
health condition (5)
Not stated/inadequately described (9)
First time in prison or juvenile detention indicator*
Yes
No
Incarceration history cluster
Prison entrant number of times in prison or
juvenile detention*
Type of corrective services facility*
Adult prison (1)
Juvenile detention centre (2)
Prison entrant 2
Prison entrant age at first detention
years
Legal status of prison entrant*
Remand (1)
Sentenced (2)
Imprisonment in the last 12 months indicator*
Yes
No
Person 2
Mental health disorder indicator*
Yes
No
Medication for mental health disorder indicator
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Yes
No
Prison entrant 3
Distress related to current imprisonment
indicator*
Yes (1)
No (2)
Not applicable (9)
Chronic condition cluster
Specific chronic condition indicator*
Yes
No
Type of chronic condition
Asthma (1)
Cancer  (2)
Cardiovascular disease (3)
Arthritis  (4)
Diabetes (5)
Chronic condition indicator
Yes
No
Health service utilisation cluster
Service provider consulted indicator*
Yes
No
Type of service provider consulted (prison
entrant)
Prisoner location when service provider utilised
In the community (1)
In prison (2)
Health service non-utilisation cluster
Service provider needed but not utilised
indicator*
Yes
No
Type of service provider needed but not utilised
Prisoner location when service provider was
needed, but not utilised
In the community (1)
In prison (2)
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Prison entrant 4
Reason for non-utilisation of health service
Cost (01)
Discrimination (02)
Cultural inappropriateness (03)
Indifference or unwillingness (04)
Difficulty in attending health service (05)
Waiting time too long or service not
available at time required (06)
Required service not available in a
specific location (07)
Too busy (08)
Legal reasons (09)
Intoxication (10)
Other reasons (20)
Not stated/inadequately described (9)
Person 3
Blow to the head indicator*
Yes (1)
No (2)
Not stated/inadequately described (9)
Self-harm indicator*
Yes
No
Self-harm ideation in the last 12 months*
Yes (1)
No (2)
Not stated/inadequately described (9)
AUDIT score of risky alcohol consumption
cluster
Alcohol consumption frequency*
Never (0)
Monthly or less (1)
2-4 times a month (2)
2-3 times a week (3)
4 or more times a week (4)
Alcohol consumption in standard drinks per day
(self reported)
standard drinks
Frequency consumed 6 or more standard drinks
on one occasion
Never (0)
Less than monthly (1)
Monthly (2)
Weekly (3)
Daily or almost daily (4)
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Smoking status cluster
Ever smoked a full cigarette indicator*
Yes (1)
No (2)
Not stated/inadequately described (9)
Tobacco smoking start age
years
Current smoking status
Yes (1)
No (2)
Not stated/inadequately described (9)
Tobacco smoking frequency
Occasionally, but less than once a week
(1)
Occasionally, not every day, but at least
once a week (2)
Regularly, every day or most days (3)
Substances used illicitly cluster
Substance used illicitly indicator*
Yes (1)
No (2)
Not stated/inadequately described (9)
Type of substance used illicitly
Opioid pharmacotherapy treatment cluster
Previous opioid pharmacotherapy treatment
program indicator*
Yes
No
Current opioid pharmacotherapy treatment
program indicator*
Yes
No
Type of opioid pharmacotherapy treatment
Methadone (1)
Other opioid pharmacotherapy (2)
Female
Cervical screening indicator
Yes (1)
No (2)
Not stated/inadequately described (9)
Pregnancy status cluster
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Ever been pregnant indicator*
Yes (1)
No (2)
Not stated/inadequately described (9)
Age at first pregnancy
years
Prison entrant 5
Mental health service referral*
Yes (1)
No (2)
Not stated/inadequately described (9)
At risk of suicide or self-harm indicator*
Yes
No
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Eligibility Depressive Disorder, Major
NCT00097175
Effects of Tryptophan Depletion on Brain Processing of
Emotions in Patients With Mood Disorders; ODM derived
from: https://clinicaltrials.gov/show/NCT00097175
All rights reserved. Please visit https://medical-data-
models.org/forms/17108
Eligibility Depressive Disorder, Major
NCT00097175
Criteria
healthy volunteers*
Yes
No
right-handed subjects (ages 18-50) will be
selected who have not met criteria for any major
psychiatric disorder, have no known first-degree
relatives with mood disorders, and have a current
score on the hamilton depression rating scale
(hdrs; 17 item) in the not depressed range (    7).
control subjects will be matched to depressed
subjects and their relatives for age, gender, and
education.*
Yes
No
mdd samples*
Yes
No
right-handed subjects (ages 18-50) will be
selected with a past history of mdd by dsm-iv
criteria.*
Yes
No
healthy relatives*
Yes
No
healthy, right-handed, first-degree relatives of
patients with mdd will be recruited.*
Yes
No
Exclusion Criteria
subjects must not have taken antidepressant
drugs for at least 3 months (4 months for
fluoxetine) prior to the fmri studies or other
medications likely to alter monoamine
neurochemistry or cerebrovascular and
cardiovascular function for at least 3 weeks prior
to imaging. however, effective medications will not
be discontinued for the purposes of this study.
subjects will also be excluded if they have:*
Yes
No
1. psychosis*
Yes
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No
2. medical or neurological illnesses likely to affect
physiology or anatomy, i.e. hypertension,
cardiovascular disorders*
Yes
No
3. a history of drug (including benzodiazepines
(bzd)) abuse within 1 year or a lifetime history of
drug dependence (dsm iv criteria)*
Yes
No
4. a history of alcohol abuse within 1 year or a
lifetime history of alcohol dependence (dsm iv
criteria)*
Yes
No
5. current pregnancy (as documented by
pregnancy testing at screening or at days of the
challenge studies)*
Yes
No
6. current breast feeding*
Yes
No
7. are smokers*
Yes
No
8. serious suicidal ideation or behavior. in this
study, there is a small risk of transient depressive
symptoms occurring after ingesting the amino
acid mixture. therefore, if volunteers manifest
evidence of serious suicidal ideation or behavior,
they will be excluded from participating. criteria
for meeting suicidal ideation include but are not
limited to: 1) thoughts of suicide within the past 3
months which are accompanied by intent to harm
oneself, serious consideration of means or plan
to attempt suicide, evidence of arranging for a
suicide attempt (e.g. giving away prized
possessions or updating a will), or clear desire to
commit suicide, 2) severity of past suicide events,
if applicable or 3) a current plan for harming
themselves. all assessments will be conducted by
an experienced, nimh credentialed health
professional, such as a psychiatrist or psychiatric
nurse who will use their expert knowledge and
experiences in determining the authenticity of a
participant   s information and handle the
situation accordingly.*
Yes
No
9. general mri exclusion criteria*
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Yes
No
subjects must exhibit no or only moderate alcohol
use. subjects with current or previous regular use
(greater than 4 weeks) of bzds and excessive use
of alcohol (greater than 8 ounces/day for men
and greater than 6 ounces/day for women) in the
past or present are ineligible for participation, as
such drug use may confound the results. smokers
(regular use within the last 3 months) are
ineligible because of the evidence for interactions
between nicotine and depression, and the
possibility of withdrawal symptoms that may
affect behavioral and neural responses to td.*
Yes
No
subjects beyond age 50 are excluded to address
the biological heterogeneity encompassed by the
mdd criteria, since depressives whose age-at-
onset is later than 50 have a far greater likelihood
of having mri correlates of cerebrovascular
disease than age-matched healthy controls or
age-matched early-onset depressives. subjects
whose first major depressive episodes arose
temporally after other medical or psychiatric
conditions will also be excluded, since their
functional imaging results generally differ from
those reported in primary mdd.*
Yes
No
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Year 5 Medical & Personal History
Cardiovascular Health Study (CHS)
Documentation part: Record 29 Year 5 Medical & Personal
History
The Cardiovascular Health Study (CHS) was initiated by
the National Heart, Lung and Blood Institute (NHLBI) in
1987 to determine the risk factors for development and
progression of cardiovascular disease (CVD) in older
adults, with an emphasis on subclinical measures. The
study recruited 5,888 adults aged 65 or older at entry in
four U.S. communities and conducted extensive annual
clinical exams between 1989-1999 along with semi-annual
phone calls, events adjudication, and subsequent data
analyses and publications. Additional data were collected
by studies ancillary to CHS. With the exception of annual
clinic visits, these activities are still ongoing.
Data obtained from: https://chs-nhlbi.org/
Permission granted by: Erika Enright.
All rights reserved. Please visit https://medical-data-
models.org/forms/17114
Year 5 Medical & Personal History
Cardiovascular Health Study (CHS)
Medical History
1 Would you say, in general, your health is:
a doctor recommended that I eat less (a
doctor recommended that I eat less)
a medical or dental problem interferes
with eating (a medical or dental problem
interferes with eating)
I am less able to shop or prepare food
than before (I am less able to shop or
prepare food than before)
I am taking medicine that decreases my
appetite (I am taking medicine that
decreases my appetite)
my appetite has decreased for other
reasons (my appetite has decreased for
other reasons)
my physical activity has decrease (my
physical activity has decrease)
2 Would you say your health compares to other
persons your age?
no (0)
yes (1)
don't know (9)
3 During the past two weeks, how many days
have you stayed in bed all or most of the day
because of illness or injury?
days
11 Have you stayed overnight as a patient in a
nursing home or rehabilitation center since we
spoke to you on the phone about six months
ago?
no (0)
yes (1)
don't know (9)
A. If you answered YES, record the reason you
were admitted, the name of the hospital, and the
month and year you were a patient for EACH time
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you stayed overnight in a nursing home or
rehabilitation center. (Use another sheet of paper
to list additional admissions.) Reason for
admission:
Hospital name:
City:
Date of hospitalization:
length of stay
days
B. Are you currently staying in a nursing home?
no (0)
yes (1)
don't know (9)
12 Have you had pneumonia since we saw you
last year?
no (0)
yes (1)
don't know (9)
13 Have you had an attack of bronchitis since we
saw you last year?
no (0)
yes (1)
don't know (9)
A. Was it confirmed by a doctor?
no (0)
yes (1)
don't know (9)
14 Has a doctor ever told you that you had any of
the following conditions or diseases; and if so,
when were you FIRST told that you had the
condition?
A. High blood pressure
a doctor recommended that I eat more (a
doctor recommended that I eat more)
a medical or dental problem has been
resolved (a medical or dental problem
has been resolved)
I am more able to shop or prepare food
than before (I am more able to shop or
prepare food than before)
I am taking medicine that increases my
appetite (I am taking medicine that
increases my appetite)
my appetite has increased for other
reasons (my appetite has increased for
other reasons)
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my physical activity has increased (my
physical activity has increased)
14 Has a doctor ever told you that you had any of
the following conditions or diseases; and if so,
when were you FIRST told that you had the
condition?
B. Diabetes
no (0)
yes (1)
don't know (9)
14 Has a doctor ever told you that you had any of
the following conditions or diseases; and if so,
when were you FIRST told that you had the
condition?
C. Atrial Fibrillation
no (0)
yes (1)
don't know (9)
14 Has a doctor ever told you that you had any of
the following conditions or diseases; and if so,
when were you FIRST told that you had the
condition?
D. Deep vein thrombosis (or blood clots in your
legs)
no (0)
yes (1)
don't know (9)
14 Has a doctor ever told you that you had any of
the following conditions or diseases; and if so,
when were you FIRST told that you had the
condition?
E. Rheumatic fever or heart valve problems
no (0)
yes (1)
don't know (9)
15 Has a doctor ever told you that you had other
heart or circulatory problems since we saw you
last year?
no (0)
yes (1)
don't know (9)
Specify:
16 Are you currently taking medication prescribed
by a doctor for any of the following conditions?
A. High blood pressure
no (0)
yes (1)
don't know (9)
16 Are you currently taking medication prescribed
by a doctor for any of the following conditions?
B. Diabetes
no (0)
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yes (1)
don't know (9)
16 Are you currently taking medication prescribed
by a doctor for any of the following conditions?
C. Atrial Fibrillation
no (0)
yes (1)
don't know (9)
16 Are you currently taking medication prescribed
by a doctor for any of the following conditions?
D. Deep vein thrombosis (or blood clots in your
legs)
no (0)
yes (1)
don't know (9)
17 Have you had coronary angiography or heart
catheterization as an out patient procedure since
we saw you last year?
no (0)
yes (1)
don't know (9)
18 Have you ever had any pain or discomfort in
your chest?
Yes
No
A. Do you feel pain when you walk uphill or
hurry?
no (0)
yes (1)
don't know (9)
B. Do you feel the pain when you walk at an
ordinary pace or level?
Yes
No
C. What do you do if you feel it while you are
walking?
no (0)
yes (1)
don't know (9)
D. If you stand still, what happens to the pain?
no (0)
yes (1)
don't know (9)
E. Where do you get this pain or discomfort?
no (0)
yes (1)
don't know (9)
Other, specify:
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F. Have you had this pain in the past two weeks?
Yes
No
If yes, how many times in the past two weeks
have you had this pain?
times
G. Has there been an increase in the frequency
or severity in the past two weeks?
Yes
No
H. Have you seen a doctor about this pain?
Yes
No
I. Have you ever had a severe pain accross the
front of your chest lasting for half an hour or
more?
Yes
No
J. Did you see a doctor because of this pain?
K. If you saw a doctor, what did your doctor say it
was?
no (0)
yes (1)
don't know (9)
K. If you saw a doctor, what did your doctor say it
was?
no (0)
yes (1)
don't know (9)
19 Have you had to sleep on 2 or more pillows to
help you breathe since we saw you last year?
no (0)
yes (1)
don't know (9)
20 Have you been awakened at night by trouble
breathing since we saw you last year?
no (0)
yes (1)
don't know (9)
21 Do you get short of breath...
A. While resting in a chair?
no (0)
yes (1)
never do this activity (2)
don't know (9)
21 Do you get short of breath...
B. When walking on level ground?
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no (0)
yes (1)
never do this activity (2)
don't know (9)
21 Do you get short of breath...
C. When walking quickly or uphill?
no (0)
yes (1)
never do this activity (2)
don't know (9)
21 Do you get short of breath...
D. With light physical activity, such as walking
down a flight of stairs, dressing or showering
without stopping, cleaning windows, stripping and
making the bed, mopping floors, hanging washed
clothes, pushing a power lawn mower, bowling, or
playing golf (walk and carry clubs)
no (0)
yes (1)
never do this activity (2)
don't know (9)
21 Do you get short of breath...
E. With moderate physical activity, such as
carrying anything up a flight of stairs without
stopping, dancing a foxtrot, gardening, raking,
weeding, having sexual intercourse, or walking 4
miles an hour over level ground?
no (0)
yes (1)
never do this activity (2)
don't know (9)
21 Do you get short of breath...
F. With strenuous physical activity, such as doing
outdoor work (shoveling snow, spading soil),
playing squash or handball, jogging or walking 5
miles an hour, or carrying objects that weigh at
least 80 pounds?
no (0)
yes (1)
never do this activity (2)
don't know (9)
22 Have you had swelling of your feet or ankles
since we saw you last year?
no (0)
yes (1)
don't know (9)
A. Did it tend to come on during the day and do
down overnight?
no (0)
yes (1)
don't know (9)
23 Do you get pain in either leg when walking?
no (0)
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yes (1)
don't know (9)
A. Does this pain ever begin when you are
standing still or standing?
no (0)
yes (1)
don't know (9)
B. Do you feel this pain in your calf or calves?
no (0)
yes (1)
don't know (9)
C. Do you feel it when you walk uphill or hurry?
no (0)
yes (1)
don't know (9)
D. Do you feel it when you walk at an ordinary
pace on the level?
no (0)
yes (1)
don't know (9)
E. Does this pain ever disappear while you are
walking?
no (0)
yes (1)
don't know (9)
F. What do you do if you feel it while you are
walking?
continue at same pace (continue at
same pace)
stop or slow down (stop or slow down)
G. What happens to the pain if you stand still?
don't know (don't know)
not relieved (not relieved)
relieved in 10 minutes or less (relieved in
10 minutes or less)
takes longer than 10 minutes to be
relieved (takes longer than 10 minutes to
be relieved)
24 Have you been told by a doctor that you
currently have any of the following?
A. Arthritis of hands
no (0)
yes (1)
don't know (9)
24 Have you been told by a doctor that you
currently have any of the following?
B. Arthritis of shoulder
no (0)
yes (1)
don't know (9)
24 Have you been told by a doctor that you
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currently have any of the following?
C. Arthritis of hips or knees
no (0)
yes (1)
don't know (9)
24 Have you been told by a doctor that you
currently have any of the following?
D. Osteoporosis
no (0)
yes (1)
don't know (9)
24 Have you been told by a doctor that you
currently have any of the following?
E. Liver disease, cirrhosis or hepatitis
no (0)
yes (1)
don't know (9)
24 Have you been told by a doctor that you
currently have any of the following?
F. Kidney (renal) disease or failure
no (0)
yes (1)
don't know (9)
25 During the last year, have you had pain in any
bones or joints for at least half the days of a
month?
no (0)
yes (1)
don't know (9)
Please indicate where you had this pain:
A. Hands
no (0)
yes (1)
don't know (9)
Please indicate where you had this pain:
B. Feet
no (0)
yes (1)
don't know (9)
Please indicate where you had this pain:
C. Knees
no (0)
yes (1)
don't know (9)
Please indicate where you had this pain:
D. Hips
no (0)
yes (1)
don't know (9)
Please indicate where you had this pain:
E. Neck
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no (0)
yes (1)
don't know (9)
Please indicate where you had this pain:
F. Back
no (0)
yes (1)
don't know (9)
Please indicate where you had this pain:
G. Shoulders
no (0)
yes (1)
don't know (9)
Please indicate where you had this pain:
H. Other
no (0)
yes (1)
don't know (9)
Please indicate where you had this pain:
H. Other, specify:
26 Have you been told by a doctor that you
currently have cancer?
If you answered YES, please specify the kind of
cancer(s):
A. Breast cancer
no (0)
yes (1)
don't know (9)
If you answered YES, please specify the kind of
cancer(s):
B. Blood cancer, leukemia or lymphoma
If you answered YES, please specify the kind of
cancer(s):
C. Colon (bowel) or rectum cancer
no (0)
yes (1)
don't know (9)
If you answered YES, please specify the kind of
cancer(s):
D. Lung cancer
no (0)
yes (1)
don't know (9)
If you answered YES, please specify the kind of
cancer(s):
E. Malignant melanoma
no (0)
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yes (1)
don't know (9)
If you answered YES, please specify the kind of
cancer(s):
F. Other skin cancer
no (0)
yes (1)
don't know (9)
If you answered YES, please specify the kind of
cancer(s):
G. Prostate cancer
no (0)
yes (1)
don't know (9)
If you answered YES, please specify the kind of
cancer(s):
H. Pancreatic cancer
no (0)
yes (1)
don't know (9)
If you answered YES, please specify the kind of
cancer(s):
I. Esophageal cancer
no (0)
yes (1)
don't know (9)
If you answered YES, please specify the kind of
cancer(s):
J. Other cancer
no (0)
yes (1)
don't know (9)
If you answered YES, please specify the kind of
cancer(s):
J. Other cancer, specify:
27 Have you been treated by a doctor for any of
the following since we saw you last year?
A. Broken hip (fracture)
no (0)
yes (1)
don't know (9)
B. Broken lower leg (fracture)
no (0)
yes (1)
don't know (9)
C. Broken arm, wrist or shoulder (fracture)
no (0)
yes (1)
don't know (9)
D. Spine (vertebral) compression fracture
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no (0)
yes (1)
don't know (9)
E. Other injury
no (0)
yes (1)
don't know (9)
Specify
F. Did you have arthritis that was treated with
medication?
no (0)
yes (1)
don't know (9)
28 During the last year, have you had any sudden
spells of dizziness, loss of balance, or sensation
of spinning?
no (0)
yes (1)
don't know (9)
29 Have you ever accidentally lost control of your
urine (wet yourself) more than one time in a
month?
no (0)
yes (1)
don't know (9)
30 Do you wake up to urinate more than three
nights per week?
no (0)
yes (1)
don't know (9)
31 During the last year, have you had a fall? )Do
not include falls during skiing, skating or other
activities that may affect balance.)
no (0)
yes (1)
don't know (9)
A. How many times have you fallen during the
last year?
times
32 During the last year, have you gained or lost
more than 10 pounds?
lost more than 10 pounds (1)
gained more than 10 pounds (2)
both lost and gained more than 10
pounds (3)
no change (4)
don't know (9)
A. Was diet for the purpose of losing or gaining
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weight a major factor in your weight change?
no (0)
yes (1)
don't know (9)
B. Was surgery, illness or medication a major
factor in your weight change?
no (0)
yes (1)
don't know (9)
C. Was exercise a major factor in your weight
change?
no (0)
yes (1)
don't know (9)
33 How would you compare your TOTAL average
daily intake of food this year to your intake when
we saw you last year?
eat a lot more (1)
eat a little more (2)
eat about the same (3)
eat a little less (4)
eat a lot less (5)
A. If you answered EAT A LOT MORE or EAT A
LITTLE MORE, the main reason is:
a doctor recommended that I eat more (a
doctor recommended that I eat more)
a medical or dental problem has been
resolved (a medical or dental problem
has been resolved)
I am more able to shop or prepare food
than before (I am more able to shop or
prepare food than before)
I am taking medicine that increases my
appetite (I am taking medicine that
increases my appetite)
my appetite has increased for other
reasons (my appetite has increased for
other reasons)
my physical activity has increased (my
physical activity has increased)
Other:
B. If you answered EAT A LOT LESS or EAT A
LITTLE LESS, the main reason is:
a doctor recommended that I eat less (a
doctor recommended that I eat less)
a medical or dental problem interferes
with eating (a medical or dental problem
interferes with eating)
I am less able to shop or prepare food
than before (I am less able to shop or
prepare food than before)
I am taking medicine that decreases my
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appetite (I am taking medicine that
decreases my appetite)
my appetite has decreased for other
reasons (my appetite has decreased for
other reasons)
my physical activity has decrease (my
physical activity has decrease)
Other:
34 Are you following a special diet?
no (0)
yes (1)
don't know (9)
A. What is the purpose of the diet?
To lose weight
no (0)
yes (1)
don't know (9)
A. What is the purpose of the diet? To gain
weight
no (0)
yes (1)
don't know (9)
A. What is the purpose of the diet? For diabetes
no (0)
yes (1)
don't know (9)
A. What is the purpose of the diet? For kidney
failure
no (0)
yes (1)
don't know (9)
A. What is the purpose of the diet? For ulcers
no (0)
yes (1)
don't know (9)
A. What is the purpose of the diet? For
diverticulitits
no (0)
yes (1)
don't know (9)
A. What is the purpose of the diet? For allergies
no (0)
yes (1)
don't know (9)
A. What is the purpose of the diet? For heart
trouble
no (0)
yes (1)
don't know (9)
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A. What is the purpose of the diet? For high blood
pressure
no (0)
yes (1)
don't know (9)
A. What is the purpose of the diet? For other
reason
no (0)
yes (1)
don't know (9)
Other:
B. What kind of diet is it? Low calorie
no (0)
yes (1)
don't know (9)
B. What kind of diet is it? High calorie
no (0)
yes (1)
don't know (9)
B. What kind of diet is it? High protein
no (0)
yes (1)
don't know (9)
B. What kind of diet is it? Low fat
no (0)
yes (1)
don't know (9)
B. What kind of diet is it? High fat
no (0)
yes (1)
don't know (9)
B. What kind of diet is it? Low carbohydrate
no (0)
yes (1)
don't know (9)
B. What kind of diet is it? High carbohydrate
no (0)
yes (1)
don't know (9)
B. What kind of diet is it? Low sugar
no (0)
yes (1)
don't know (9)
B. What kind of diet is it? Low salt
no (0)
yes (1)
don't know (9)
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B. What kind of diet is it? Low cholesterol
no (0)
yes (1)
don't know (9)
B. What kind of diet is it? Low fiber
no (0)
yes (1)
don't know (9)
B. What kind of diet is it? High fiber
no (0)
yes (1)
don't know (9)
B. What kind of diet is it? Bland diet
no (0)
yes (1)
don't know (9)
B. What kind of diet is it? Other diet
no (0)
yes (1)
don't know (9)
Other:
C. About how long have you been following this
diet? YEARS
Years
C. About how long have you been following this
diet? MONTHS
Months
D. Was this diet recommended by your
physician?
no (0)
yes (1)
don't know (9)
35 Have you gone off a special diet since we saw
you last year?
no (0)
yes (1)
don't know (9)
A. What is the purpose of the diet?
To lose weight
no (0)
yes (1)
don't know (9)
A. What is the purpose of the diet? To gain
weight
no (0)
yes (1)
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don't know (9)
A. What is the purpose of the diet? For diabetes
no (0)
yes (1)
don't know (9)
A. What is the purpose of the diet? For kidney
failure
no (0)
yes (1)
don´t know (9)
A. What is the purpose of the diet? For ulcers
no (0)
yes (1)
don´t know (9)
A. What is the purpose of the diet? For
diverticulitits
no (0)
yes (1)
don´t know (9)
A. What is the purpose of the diet? For allergies
no (0)
yes (1)
don´t know (9)
A. What is the purpose of the diet? For heart
trouble
no (0)
yes (1)
don´t know (9)
A. What is the purpose of the diet? For high blood
pressure
no (0)
yes (1)
don´t know (9)
A. What is the purpose of the diet? For other
reason
no (0)
yes (1)
don´t know (9)
Other:
B. What kind of diet is it? Low calorie
no (0)
yes (1)
don't know (9)
B. What kind of diet is it? High calorie
no (0)
yes (1)
don't know (9)
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B. What kind of diet is it? High protein
no (0)
yes (1)
don't know (9)
B. What kind of diet is it? Low fat
no (0)
yes (1)
don't know (9)
B. What kind of diet is it? High fat
no (0)
yes (1)
don't know (9)
B. What kind of diet is it? Low carbohydrate
no (0)
yes (1)
don't know (9)
B. What kind of diet is it? High carbohydrate
no (0)
yes (1)
don't know (9)
B. What kind of diet is it? Low sugar
no (0)
yes (1)
don't know (9)
B. What kind of diet is it? Low salt
no (0)
yes (1)
don't know (9)
B. What kind of diet is it? Low cholesterol
no (0)
yes (1)
don't know (9)
B. What kind of diet is it? Low fiber
no (0)
yes (1)
don't know (9)
B. What kind of diet is it? High fiber
no (0)
yes (1)
don't know (9)
B. What kind of diet is it? Bland diet
no (0)
yes (1)
don't know (9)
B. What kind of diet is it? Other diet
no (0)
yes (1)
don't know (9)
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Other:
C. About how long have you been following this
diet? YEARS
Years
C. About how long have you been following this
diet? MONTHS
Months
D. Was this diet recommended by your
physician?
no (0)
yes (1)
don't know (9)
36 During the past two weeks, have you taken a
multiple vitamin or any other vitamin
supplements?
no (0)
yes (1)
don't know (9)
A. Multiple vitamin
no (0)
yes (1)
don't know (9)
If you answered YES, how many days during the
past two weeks did you take a multiple vitamin?
days
B. Vitamin A or beta-carotene
no (0)
yes (1)
don't know (9)
If you answered YES, how many days during the
past two weeks did you take a vitamin A or beta-
carotene?
days
C. Vitamin C
no (0)
yes (1)
don't know (9)
If you answered YES, how many days during the
past two weeks did you take a vitamin C?
days
D. Vitamin E?
no (0)
yes (1)
don't know (9)
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If you answered YES, how many days during the
past two weeks did you take a vitamin E?
days
37 Are you usually sleepy in the daytime? (Do not
include taking a regular daily nap as "feeling
sleepy".)
no (0)
yes (1)
don't know (9)
38 Do you feel groggy and unrefreshed for more
than a half hour after waking up in the morning?
no (0)
yes (1)
don't know (9)
39 Has your spouse or roommate complained
about your loud snoring?
no (0)
yes (1)
don't know (9)
40 Has anyone observed you while sleeping to
have episodes where you stop breathing for a
while and then snore or snort loudly?
no (0)
yes (1)
don't know (9)
41 Do you usually have trouble falling asleep?
no (0)
yes (1)
don´t know (9)
42 Do you usually wake up sevaral times at
night?
no (0)
yes (1)
don't know (9)
43 Do you usually wake up far too early?
no (0)
yes (1)
don't know (9)
44 Can you see well enough to drive, with or
without glasses?
don't drive (don't drive)
don't know (don't know)
no (no)
yes (yes)
45 Can you see well enough to watch TV, with or
without glasses?
no (0)
yes (1)
don't know (9)
46 Can you see well enough to recognize
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someone across the room, with or without
glasses?
no (0)
yes (1)
don't know (9)
47 Can you see well enough to read the
newspaper, with or without glasses?
no (0)
yes (1)
don't know (9)
48 Can you hear well enough to use the
telephone, with or without a hearing aid?
no (0)
yes (1)
don't know (9)
49 Can you hear well enough to listen to a radio,
with or without hearing aid?
no (0)
yes (1)
don't know (9)
50 Can you hear well enough to carry on a
conversation in a crowded room, with or without a
hearing aid?
no (0)
yes (1)
don't know (9)
51 Have you smoked cigarettes during the last 30
days?
no (0)
yes (1)
don't know (9)
A. On average, how many cigarettes do you
usually smoke per day?
cigarettes
52 Which of the following best describes your
current smoking status?
current smoker (current smoker)
don't know (don't know)
former smoker, quit less than 1 year ago
(former smoker, quit less than 1 year
ago)
former smoker, quit more than 1 year
ago (former smoker, quit more than 1
year ago)
never smoked (never smoked)
53 Does anyone living with you smoke cigarettes
regularly? (This includes any other member of
your household.)
no (0)
yes (1)
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don't know (9)
54 Do you ever use snuff or smokeless tobacco?
no (0)
yes (1)
don't know (9)
55 Do you ever drink beer?
no (0)
yes (1)
don't know (9)
A. About how often do you drink beer?
daily (daily)
monthly (monthly)
rarely/never (rarely/never)
weekly (weekly)
yearly (yearly)
B. How many 12-ounce cans or bottles of beer do
you usually drink on one occassion?
56 Do you ever drink wine?
no (0)
yes (1)
don't know (9)
A. About how often do you drink wine?
daily (daily)
monthly (monthly)
rarely/never (rarely/never)
weekly (weekly)
yearly (yearly)
B. How many medium, six-ounce glasses of wine
do you usually drink on one occassion?
servings
56 Do you ever drink liquor?
no (0)
yes (1)
don't know (9)
A. About how often do you drink liquor?
daily (daily)
monthly (monthly)
rarely/never (rarely/never)
weekly (weekly)
yearly (yearly)
B. How many drinks, equal to one shot of liquor,
do you usually drink on one occassion?
servings
58 Are you currently involved in any medical
studies other than CDS?
no (0)
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yes (1)
don't know (9)
58 Are you currently involved in any medical
studies other than CDS?
Medical History: Women only
59 Are you currently taking estrogens such as
Premarin, Estrace, Ogen or any other estrogen?
no (0)
yes (1)
don't know (9)
A. How many days per month do you take
estrogen?
days
B. For how long have you been taking estrogen?
years
B. For how long have you been taking estrogen?
Months
C. Why are you taking estrogen? TO PREVENT
HOT FLASHES
no (0)
yes (1)
don't know (9)
C. Why are you taking estrogen? TO PREVENT
OTHER POST-MENOPAUSAL SYMPTOMS
no (0)
yes (1)
don't know (9)
C. Why are you taking estrogen? TO PREVENT
OSTEOPOROSIS OR BONE LOSS
no (0)
yes (1)
don't know (9)
C. Why are you taking estrogen? TO PREVENT
HEART DISEASE
no (0)
yes (1)
don't know (9)
C. Why are you taking estrogen? FOR OTHER
REASONS
no (0)
yes (1)
don't know (9)
Other:
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60 If you are NOT currently taking estrogens
such as Premain, Estrace, Ogen or any other
estrogen, have you taken estrogen in the past?
no (0)
yes (1)
don't know (9)
A. How many days per month did you take
estrogen?
days
B. When did you stop?
year
B. When did you stop?
C. For how long have you been taking estrogen?
years
C. For how long have you been taking estrogen?
Months
D. Why did you take estrogen? TO PREVENT
HOT FLASHES
no (0)
yes (1)
don't know (9)
D. Why did you take estrogen? TO PREVENT
OTHER POST-MENOPAUSAL SYMPTOMS
no (0)
yes (1)
don't know (9)
D. Why did you take estrogen? TO PREVENT
OSTEOPOROSIS OR BONE LOSS
no (0)
yes (1)
don't know (9)
D. Why did you take estrogen? TO PREVENT
HEART DISEASE
no (0)
yes (1)
don't know (9)
D. Why did you take estrogen? FOR OTHER
REASONS
no (0)
yes (1)
don't know (9)
Other:
61 Are you currently taking progestins such as
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Provera or Norlutate?
no (0)
yes (1)
don't know (9)
A. How many days per month do you take
progestin?
days
B. For how long have you been taking progestin?
years
B. For how long have you been taking progestin?
Months
62 If you are NOT currently taking progestin such
as Provera or Norlutate, have you taken progestin
in the past?
no (0)
yes (1)
don't know (9)
A. How many days per month did you take
progestin?
days
B. When did you stop?
year
B. When did you stop?
C. For how long have you been taking progestin?
years
C. For how long have you been taking progestin?
Months
Medical History: Myocardical Infarction
4 Has a doctor ever told you that you had a
myocardial infarction or heart attack?
no (0)
yes (1)
don't know (9)
A. What was the doctor's name and city? Name
A. What was the doctor's name and city?
Address
A. What was the doctor's name and city? City
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A. What was the doctor's name and city? State
B. Date of event or diagnosis:
C. How many times altogether did you see a
doctor for this condition since we last spoke to
you?
times
D. Were you in the hospital at least one night for
this condition since we last spoke to you?
no (0)
yes (1)
don't know (9)
E. How many different times were you in the
hospital for this condition?
times
F. Please record the admission date of each
hospitalization and the name and location of the
hospital. Date of Hospitalization:
F. Please record the admission date of each
hospitalization and the name and location of the
hospital. 
Hospital name
F. Please record the admission date of each
hospitalization and the name and location of the
hospital. City
F. Please record the admission date of each
hospitalization and the name and location of the
hospital. State
G. How many days altogether were you
hospitalized for this condition?
days
Medical History: Angina
5 Has a doctor ever told you that you had a new
incident of angina pectoris or chest pain due to
heart disease since we spoke with you on the
phone about six month ago?
no (0)
yes (1)
don't know (9)
A. What was the doctor's name and city? Name
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A. What was the doctor's name and city?
Address
A. What was the doctor's name and city? City
A. What was the doctor's name and city? State
B. Date of event or diagnosis:
C. How many times altogether did you see a
doctor for this condition since we last spoke to
you?
times
D. Were you in the hospital at least one night for
this condition since we last spoke to you?
no (0)
yes (1)
don't know (9)
E. How many different times were you in the
hospital for this condition?
times
F. Please record the admission date of each
hospitalization and the name and location of the
hospital. Date of Hospitalization:
F. Please record the admission date of each
hospitalization and the name and location of the
hospital. 
Hospital name
F. Please record the admission date of each
hospitalization and the name and location of the
hospital. City
F. Please record the admission date of each
hospitalization and the name and location of the
hospital. State
G. How many days altogether were you
hospitalized for this condition?
days
Medical History: Congestive heart failure
6 Has a doctor ever told you that you had a new
incident of heart failure or congestive heart failure
since we spoke with you on the phone about six
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month ago?
A. What was the doctor's name and city? Name
A. What was the doctor's name and city?
Address
A. What was the doctor's name and city? City
A. What was the doctor's name and city? State
B. Date of event or diagnosis:
C. How many times altogether did you see a
doctor for this condition since we last spoke to
you?
times
D. Were you in the hospital at least one night for
this condition since we last spoke to you?
E. How many different times were you in the
hospital for this condition?
times
F. Please record the admission date of each
hospitalization and the name and location of the
hospital. Date of Hospitalization:
F. Please record the admission date of each
hospitalization and the name and location of the
hospital. 
Hospital name
F. Please record the admission date of each
hospitalization and the name and location of the
hospital. City
F. Please record the admission date of each
hospitalization and the name and location of the
hospital. State
G. How many days altogether were you
hospitalized for this condition?
days
Medical History: Intermittent claudication
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7 Has a doctor ever told you that you had a new
incident of intermittent claudication or pain in your
legs from a blockage of the arteries since we
spoke with you on the phone about six month
ago?
no (0)
yes (1)
don't know (9)
A. What was the doctor's name and city? Name
A. What was the doctor's name and city?
Address
A. What was the doctor's name and city? City
A. What was the doctor's name and city? State
B. Date of event or diagnosis:
C. How many times altogether did you see a
doctor for this condition since we last spoke to
you?
times
D. Were you in the hospital at least one night for
this condition since we last spoke to you?
no (0)
yes (1)
don't know (9)
E. How many different times were you in the
hospital for this condition?
times
F. Please record the admission date of each
hospitalization and the name and location of the
hospital. Date of Hospitalization:
F. Please record the admission date of each
hospitalization and the name and location of the
hospital. 
Hospital name
F. Please record the admission date of each
hospitalization and the name and location of the
hospital. City
F. Please record the admission date of each
hospitalization and the name and location of the
hospital. State
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G. How many days altogether were you
hospitalized for this condition?
days
Medical History: Cerebrovascular accident
8 Has a doctor ever told you that you had a new
stroke or cerebrovascular accident since we
spoke with you on the phone about six month
ago?
A. What was the doctor's name and city? Name
A. What was the doctor's name and city?
Address
A. What was the doctor's name and city? City
A. What was the doctor's name and city? State
B. Date of event or diagnosis:
C. How many times altogether did you see a
doctor for this condition since we last spoke to
you?
times
D. Were you in the hospital at least one night for
this condition since we last spoke to you?
lost more than 10 pounds (1)
gained more than 10 pounds (2)
both lost and gained more than 10
pounds (3)
no change (4)
don't know (9)
E. How many different times were you in the
hospital for this condition?
times
F. Please record the admission date of each
hospitalization and the name and location of the
hospital. Date of Hospitalization:
F. Please record the admission date of each
hospitalization and the name and location of the
hospital. 
Hospital name
F. Please record the admission date of each
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hospitalization and the name and location of the
hospital. City
F. Please record the admission date of each
hospitalization and the name and location of the
hospital. State
G. How many days altogether were you
hospitalized for this condition?
days
Medical History: Transient ischemic attack
9 Has a doctor ever told you that you had a new
transient ischemic attack or TIA or silent stroke
since we spoke with you on the phone about six
month ago?
eat a lot more (1)
eat a little more (2)
eat about the same (3)
eat a little less (4)
eat a lot less (5)
A. What was the doctor's name and city? Name
A. What was the doctor's name and city?
Address
A. What was the doctor's name and city? City
A. What was the doctor's name and city? State
B. Date of event or diagnosis:
C. How many times altogether did you see a
doctor for this condition since we last spoke to
you?
times
D. Were you in the hospital at least one night for
this condition since we last spoke to you?
a doctor recommended that I eat more (a
doctor recommended that I eat more)
a medical or dental problem has been
resolved (a medical or dental problem
has been resolved)
I am more able to shop or prepare food
than before (I am more able to shop or
prepare food than before)
I am taking medicine that increases my
appetite (I am taking medicine that
increases my appetite)
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my appetite has increased for other
reasons (my appetite has increased for
other reasons)
my physical activity has increased (my
physical activity has increased)
E. How many different times were you in the
hospital for this condition?
times
F. Please record the admission date of each
hospitalization and the name and location of the
hospital. Date of Hospitalization:
F. Please record the admission date of each
hospitalization and the name and location of the
hospital. 
Hospital name
F. Please record the admission date of each
hospitalization and the name and location of the
hospital. City
F. Please record the admission date of each
hospitalization and the name and location of the
hospital. State
G. How many days altogether were you
hospitalized for this condition?
days
Medical History: Other conditions
10 Have you stayed overnight as a patient in a
hospital for any other reason not reported in
Questions 3 through 9 since we spoke to you on
the phone about six months ago?
no (0)
yes (1)
don't know (9)
Hospital name:
City:
Date of hospitalization:
length of stay
days
Date of interview
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Interviewer or Reviewer
Interview:
For CHS field center use only:
interviewer-administered (interviewer-
administered)
self-administered (self-administered)
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Year 5 Medical & Personal History
Cardiovascular Health Study (CHS)
Documentation part: Record 29 Year 5 Medical & Personal
History
The Cardiovascular Health Study (CHS) was initiated by
the National Heart, Lung and Blood Institute (NHLBI) in
1987 to determine the risk factors for development and
progression of cardiovascular disease (CVD) in older
adults, with an emphasis on subclinical measures. The
study recruited 5,888 adults aged 65 or older at entry in
four U.S. communities and conducted extensive annual
clinical exams between 1989-1999 along with semi-annual
phone calls, events adjudication, and subsequent data
analyses and publications. Additional data were collected
by studies ancillary to CHS. With the exception of annual
clinic visits, these activities are still ongoing.
Data obtained from: https://chs-nhlbi.org/
Permission granted by: Erika Enright.
All rights reserved. Please visit https://medical-data-
models.org/forms/17115
Year 5 Medical & Personal History
Cardiovascular Health Study (CHS)
Medical History
1 Would you say, in general, your health is:
a doctor recommended that I eat less (a
doctor recommended that I eat less)
a medical or dental problem interferes
with eating (a medical or dental problem
interferes with eating)
I am less able to shop or prepare food
than before (I am less able to shop or
prepare food than before)
I am taking medicine that decreases my
appetite (I am taking medicine that
decreases my appetite)
my appetite has decreased for other
reasons (my appetite has decreased for
other reasons)
my physical activity has decrease (my
physical activity has decrease)
2 Would you say your health compares to other
persons your age?
no (0)
yes (1)
don't know (9)
3 During the past two weeks, how many days
have you stayed in bed all or most of the day
because of illness or injury?
days
11 Have you stayed overnight as a patient in a
nursing home or rehabilitation center since we
spoke to you on the phone about six months
ago?
no (0)
yes (1)
don't know (9)
A. If you answered YES, record the reason you
were admitted, the name of the hospital, and the
month and year you were a patient for EACH time
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you stayed overnight in a nursing home or
rehabilitation center. (Use another sheet of paper
to list additional admissions.) Reason for
admission:
Hospital name:
City:
Date of hospitalization:
length of stay
days
B. Are you currently staying in a nursing home?
no (0)
yes (1)
don't know (9)
12 Have you had pneumonia since we saw you
last year?
no (0)
yes (1)
don't know (9)
13 Have you had an attack of bronchitis since we
saw you last year?
no (0)
yes (1)
don't know (9)
A. Was it confirmed by a doctor?
no (0)
yes (1)
don't know (9)
14 Has a doctor ever told you that you had any of
the following conditions or diseases; and if so,
when were you FIRST told that you had the
condition?
A. High blood pressure
a doctor recommended that I eat more (a
doctor recommended that I eat more)
a medical or dental problem has been
resolved (a medical or dental problem
has been resolved)
I am more able to shop or prepare food
than before (I am more able to shop or
prepare food than before)
I am taking medicine that increases my
appetite (I am taking medicine that
increases my appetite)
my appetite has increased for other
reasons (my appetite has increased for
other reasons)
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my physical activity has increased (my
physical activity has increased)
14 Has a doctor ever told you that you had any of
the following conditions or diseases; and if so,
when were you FIRST told that you had the
condition?
B. Diabetes
no (0)
yes (1)
don't know (9)
14 Has a doctor ever told you that you had any of
the following conditions or diseases; and if so,
when were you FIRST told that you had the
condition?
C. Atrial Fibrillation
no (0)
yes (1)
don't know (9)
14 Has a doctor ever told you that you had any of
the following conditions or diseases; and if so,
when were you FIRST told that you had the
condition?
D. Deep vein thrombosis (or blood clots in your
legs)
no (0)
yes (1)
don't know (9)
14 Has a doctor ever told you that you had any of
the following conditions or diseases; and if so,
when were you FIRST told that you had the
condition?
E. Rheumatic fever or heart valve problems
no (0)
yes (1)
don't know (9)
15 Has a doctor ever told you that you had other
heart or circulatory problems since we saw you
last year?
no (0)
yes (1)
don't know (9)
Specify:
16 Are you currently taking medication prescribed
by a doctor for any of the following conditions?
A. High blood pressure
no (0)
yes (1)
don't know (9)
16 Are you currently taking medication prescribed
by a doctor for any of the following conditions?
B. Diabetes
no (0)
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yes (1)
don't know (9)
16 Are you currently taking medication prescribed
by a doctor for any of the following conditions?
C. Atrial Fibrillation
no (0)
yes (1)
don't know (9)
16 Are you currently taking medication prescribed
by a doctor for any of the following conditions?
D. Deep vein thrombosis (or blood clots in your
legs)
no (0)
yes (1)
don't know (9)
17 Have you had coronary angiography or heart
catheterization as an out patient procedure since
we saw you last year?
no (0)
yes (1)
don't know (9)
18 Have you ever had any pain or discomfort in
your chest?
Yes
No
A. Do you feel pain when you walk uphill or
hurry?
no (0)
yes (1)
don't know (9)
B. Do you feel the pain when you walk at an
ordinary pace or level?
Yes
No
C. What do you do if you feel it while you are
walking?
no (0)
yes (1)
don't know (9)
D. If you stand still, what happens to the pain?
no (0)
yes (1)
don't know (9)
E. Where do you get this pain or discomfort?
no (0)
yes (1)
don't know (9)
Other, specify:
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F. Have you had this pain in the past two weeks?
Yes
No
If yes, how many times in the past two weeks
have you had this pain?
times
G. Has there been an increase in the frequency
or severity in the past two weeks?
Yes
No
H. Have you seen a doctor about this pain?
Yes
No
I. Have you ever had a severe pain accross the
front of your chest lasting for half an hour or
more?
Yes
No
J. Did you see a doctor because of this pain?
K. If you saw a doctor, what did your doctor say it
was?
no (0)
yes (1)
don't know (9)
K. If you saw a doctor, what did your doctor say it
was?
no (0)
yes (1)
don't know (9)
19 Have you had to sleep on 2 or more pillows to
help you breathe since we saw you last year?
no (0)
yes (1)
don't know (9)
20 Have you been awakened at night by trouble
breathing since we saw you last year?
no (0)
yes (1)
don't know (9)
21 Do you get short of breath...
A. While resting in a chair?
no (0)
yes (1)
never do this activity (2)
don't know (9)
21 Do you get short of breath...
B. When walking on level ground?
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no (0)
yes (1)
never do this activity (2)
don't know (9)
21 Do you get short of breath...
C. When walking quickly or uphill?
no (0)
yes (1)
never do this activity (2)
don't know (9)
21 Do you get short of breath...
D. With light physical activity, such as walking
down a flight of stairs, dressing or showering
without stopping, cleaning windows, stripping and
making the bed, mopping floors, hanging washed
clothes, pushing a power lawn mower, bowling, or
playing golf (walk and carry clubs)
no (0)
yes (1)
never do this activity (2)
don't know (9)
21 Do you get short of breath...
E. With moderate physical activity, such as
carrying anything up a flight of stairs without
stopping, dancing a foxtrot, gardening, raking,
weeding, having sexual intercourse, or walking 4
miles an hour over level ground?
no (0)
yes (1)
never do this activity (2)
don't know (9)
21 Do you get short of breath...
F. With strenuous physical activity, such as doing
outdoor work (shoveling snow, spading soil),
playing squash or handball, jogging or walking 5
miles an hour, or carrying objects that weigh at
least 80 pounds?
no (0)
yes (1)
never do this activity (2)
don't know (9)
22 Have you had swelling of your feet or ankles
since we saw you last year?
no (0)
yes (1)
don't know (9)
A. Did it tend to come on during the day and do
down overnight?
no (0)
yes (1)
don't know (9)
23 Do you get pain in either leg when walking?
no (0)
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yes (1)
don't know (9)
A. Does this pain ever begin when you are
standing still or standing?
no (0)
yes (1)
don't know (9)
B. Do you feel this pain in your calf or calves?
no (0)
yes (1)
don't know (9)
C. Do you feel it when you walk uphill or hurry?
no (0)
yes (1)
don't know (9)
D. Do you feel it when you walk at an ordinary
pace on the level?
no (0)
yes (1)
don't know (9)
E. Does this pain ever disappear while you are
walking?
no (0)
yes (1)
don't know (9)
F. What do you do if you feel it while you are
walking?
continue at same pace (continue at
same pace)
stop or slow down (stop or slow down)
G. What happens to the pain if you stand still?
don't know (don't know)
not relieved (not relieved)
relieved in 10 minutes or less (relieved in
10 minutes or less)
takes longer than 10 minutes to be
relieved (takes longer than 10 minutes to
be relieved)
24 Have you been told by a doctor that you
currently have any of the following?
A. Arthritis of hands
no (0)
yes (1)
don't know (9)
24 Have you been told by a doctor that you
currently have any of the following?
B. Arthritis of shoulder
no (0)
yes (1)
don't know (9)
24 Have you been told by a doctor that you
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currently have any of the following?
C. Arthritis of hips or knees
no (0)
yes (1)
don't know (9)
24 Have you been told by a doctor that you
currently have any of the following?
D. Osteoporosis
no (0)
yes (1)
don't know (9)
24 Have you been told by a doctor that you
currently have any of the following?
E. Liver disease, cirrhosis or hepatitis
no (0)
yes (1)
don't know (9)
24 Have you been told by a doctor that you
currently have any of the following?
F. Kidney (renal) disease or failure
no (0)
yes (1)
don't know (9)
25 During the last year, have you had pain in any
bones or joints for at least half the days of a
month?
no (0)
yes (1)
don't know (9)
Please indicate where you had this pain:
A. Hands
no (0)
yes (1)
don't know (9)
Please indicate where you had this pain:
B. Feet
no (0)
yes (1)
don't know (9)
Please indicate where you had this pain:
C. Knees
no (0)
yes (1)
don't know (9)
Please indicate where you had this pain:
D. Hips
no (0)
yes (1)
don't know (9)
Please indicate where you had this pain:
E. Neck
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no (0)
yes (1)
don't know (9)
Please indicate where you had this pain:
F. Back
no (0)
yes (1)
don't know (9)
Please indicate where you had this pain:
G. Shoulders
no (0)
yes (1)
don't know (9)
Please indicate where you had this pain:
H. Other
no (0)
yes (1)
don't know (9)
Please indicate where you had this pain:
H. Other, specify:
26 Have you been told by a doctor that you
currently have cancer?
If you answered YES, please specify the kind of
cancer(s):
A. Breast cancer
no (0)
yes (1)
don't know (9)
If you answered YES, please specify the kind of
cancer(s):
B. Blood cancer, leukemia or lymphoma
If you answered YES, please specify the kind of
cancer(s):
C. Colon (bowel) or rectum cancer
no (0)
yes (1)
don't know (9)
If you answered YES, please specify the kind of
cancer(s):
D. Lung cancer
no (0)
yes (1)
don't know (9)
If you answered YES, please specify the kind of
cancer(s):
E. Malignant melanoma
no (0)
9 / 32
Year 5 Medical & Personal History Cardiovascular Health Study (CHS)
yes (1)
don't know (9)
If you answered YES, please specify the kind of
cancer(s):
F. Other skin cancer
no (0)
yes (1)
don't know (9)
If you answered YES, please specify the kind of
cancer(s):
G. Prostate cancer
no (0)
yes (1)
don't know (9)
If you answered YES, please specify the kind of
cancer(s):
H. Pancreatic cancer
no (0)
yes (1)
don't know (9)
If you answered YES, please specify the kind of
cancer(s):
I. Esophageal cancer
no (0)
yes (1)
don't know (9)
If you answered YES, please specify the kind of
cancer(s):
J. Other cancer
no (0)
yes (1)
don't know (9)
If you answered YES, please specify the kind of
cancer(s):
J. Other cancer, specify:
27 Have you been treated by a doctor for any of
the following since we saw you last year?
A. Broken hip (fracture)
no (0)
yes (1)
don't know (9)
B. Broken lower leg (fracture)
no (0)
yes (1)
don't know (9)
C. Broken arm, wrist or shoulder (fracture)
no (0)
yes (1)
don't know (9)
D. Spine (vertebral) compression fracture
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no (0)
yes (1)
don't know (9)
E. Other injury
no (0)
yes (1)
don't know (9)
Specify
F. Did you have arthritis that was treated with
medication?
no (0)
yes (1)
don't know (9)
28 During the last year, have you had any sudden
spells of dizziness, loss of balance, or sensation
of spinning?
no (0)
yes (1)
don't know (9)
29 Have you ever accidentally lost control of your
urine (wet yourself) more than one time in a
month?
no (0)
yes (1)
don't know (9)
30 Do you wake up to urinate more than three
nights per week?
no (0)
yes (1)
don't know (9)
31 During the last year, have you had a fall? )Do
not include falls during skiing, skating or other
activities that may affect balance.)
no (0)
yes (1)
don't know (9)
A. How many times have you fallen during the
last year?
times
32 During the last year, have you gained or lost
more than 10 pounds?
lost more than 10 pounds (1)
gained more than 10 pounds (2)
both lost and gained more than 10
pounds (3)
no change (4)
don't know (9)
A. Was diet for the purpose of losing or gaining
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weight a major factor in your weight change?
no (0)
yes (1)
don't know (9)
B. Was surgery, illness or medication a major
factor in your weight change?
no (0)
yes (1)
don't know (9)
C. Was exercise a major factor in your weight
change?
no (0)
yes (1)
don't know (9)
33 How would you compare your TOTAL average
daily intake of food this year to your intake when
we saw you last year?
eat a lot more (1)
eat a little more (2)
eat about the same (3)
eat a little less (4)
eat a lot less (5)
A. If you answered EAT A LOT MORE or EAT A
LITTLE MORE, the main reason is:
a doctor recommended that I eat more (a
doctor recommended that I eat more)
a medical or dental problem has been
resolved (a medical or dental problem
has been resolved)
I am more able to shop or prepare food
than before (I am more able to shop or
prepare food than before)
I am taking medicine that increases my
appetite (I am taking medicine that
increases my appetite)
my appetite has increased for other
reasons (my appetite has increased for
other reasons)
my physical activity has increased (my
physical activity has increased)
Other:
B. If you answered EAT A LOT LESS or EAT A
LITTLE LESS, the main reason is:
a doctor recommended that I eat less (a
doctor recommended that I eat less)
a medical or dental problem interferes
with eating (a medical or dental problem
interferes with eating)
I am less able to shop or prepare food
than before (I am less able to shop or
prepare food than before)
I am taking medicine that decreases my
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appetite (I am taking medicine that
decreases my appetite)
my appetite has decreased for other
reasons (my appetite has decreased for
other reasons)
my physical activity has decrease (my
physical activity has decrease)
Other:
34 Are you following a special diet?
no (0)
yes (1)
don't know (9)
A. What is the purpose of the diet?
To lose weight
no (0)
yes (1)
don't know (9)
A. What is the purpose of the diet? To gain
weight
no (0)
yes (1)
don't know (9)
A. What is the purpose of the diet? For diabetes
no (0)
yes (1)
don't know (9)
A. What is the purpose of the diet? For kidney
failure
no (0)
yes (1)
don't know (9)
A. What is the purpose of the diet? For ulcers
no (0)
yes (1)
don't know (9)
A. What is the purpose of the diet? For
diverticulitits
no (0)
yes (1)
don't know (9)
A. What is the purpose of the diet? For allergies
no (0)
yes (1)
don't know (9)
A. What is the purpose of the diet? For heart
trouble
no (0)
yes (1)
don't know (9)
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A. What is the purpose of the diet? For high blood
pressure
no (0)
yes (1)
don't know (9)
A. What is the purpose of the diet? For other
reason
no (0)
yes (1)
don't know (9)
Other:
B. What kind of diet is it? Low calorie
no (0)
yes (1)
don't know (9)
B. What kind of diet is it? High calorie
no (0)
yes (1)
don't know (9)
B. What kind of diet is it? High protein
no (0)
yes (1)
don't know (9)
B. What kind of diet is it? Low fat
no (0)
yes (1)
don't know (9)
B. What kind of diet is it? High fat
no (0)
yes (1)
don't know (9)
B. What kind of diet is it? Low carbohydrate
no (0)
yes (1)
don't know (9)
B. What kind of diet is it? High carbohydrate
no (0)
yes (1)
don't know (9)
B. What kind of diet is it? Low sugar
no (0)
yes (1)
don't know (9)
B. What kind of diet is it? Low salt
no (0)
yes (1)
don't know (9)
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B. What kind of diet is it? Low cholesterol
no (0)
yes (1)
don't know (9)
B. What kind of diet is it? Low fiber
no (0)
yes (1)
don't know (9)
B. What kind of diet is it? High fiber
no (0)
yes (1)
don't know (9)
B. What kind of diet is it? Bland diet
no (0)
yes (1)
don't know (9)
B. What kind of diet is it? Other diet
no (0)
yes (1)
don't know (9)
Other:
C. About how long have you been following this
diet? YEARS
Years
C. About how long have you been following this
diet? MONTHS
Months
D. Was this diet recommended by your
physician?
no (0)
yes (1)
don't know (9)
35 Have you gone off a special diet since we saw
you last year?
no (0)
yes (1)
don't know (9)
A. What is the purpose of the diet?
To lose weight
no (0)
yes (1)
don't know (9)
A. What is the purpose of the diet? To gain
weight
no (0)
yes (1)
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don't know (9)
A. What is the purpose of the diet? For diabetes
no (0)
yes (1)
don't know (9)
A. What is the purpose of the diet? For kidney
failure
no (0)
yes (1)
don´t know (9)
A. What is the purpose of the diet? For ulcers
no (0)
yes (1)
don´t know (9)
A. What is the purpose of the diet? For
diverticulitits
no (0)
yes (1)
don´t know (9)
A. What is the purpose of the diet? For allergies
no (0)
yes (1)
don´t know (9)
A. What is the purpose of the diet? For heart
trouble
no (0)
yes (1)
don´t know (9)
A. What is the purpose of the diet? For high blood
pressure
no (0)
yes (1)
don´t know (9)
A. What is the purpose of the diet? For other
reason
no (0)
yes (1)
don´t know (9)
Other:
B. What kind of diet is it? Low calorie
no (0)
yes (1)
don't know (9)
B. What kind of diet is it? High calorie
no (0)
yes (1)
don't know (9)
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B. What kind of diet is it? High protein
no (0)
yes (1)
don't know (9)
B. What kind of diet is it? Low fat
no (0)
yes (1)
don't know (9)
B. What kind of diet is it? High fat
no (0)
yes (1)
don't know (9)
B. What kind of diet is it? Low carbohydrate
no (0)
yes (1)
don't know (9)
B. What kind of diet is it? High carbohydrate
no (0)
yes (1)
don't know (9)
B. What kind of diet is it? Low sugar
no (0)
yes (1)
don't know (9)
B. What kind of diet is it? Low salt
no (0)
yes (1)
don't know (9)
B. What kind of diet is it? Low cholesterol
no (0)
yes (1)
don't know (9)
B. What kind of diet is it? Low fiber
no (0)
yes (1)
don't know (9)
B. What kind of diet is it? High fiber
no (0)
yes (1)
don't know (9)
B. What kind of diet is it? Bland diet
no (0)
yes (1)
don't know (9)
B. What kind of diet is it? Other diet
no (0)
yes (1)
don't know (9)
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Other:
C. About how long have you been following this
diet? YEARS
Years
C. About how long have you been following this
diet? MONTHS
Months
D. Was this diet recommended by your
physician?
no (0)
yes (1)
don't know (9)
36 During the past two weeks, have you taken a
multiple vitamin or any other vitamin
supplements?
no (0)
yes (1)
don't know (9)
A. Multiple vitamin
no (0)
yes (1)
don't know (9)
If you answered YES, how many days during the
past two weeks did you take a multiple vitamin?
days
B. Vitamin A or beta-carotene
no (0)
yes (1)
don't know (9)
If you answered YES, how many days during the
past two weeks did you take a vitamin A or beta-
carotene?
days
C. Vitamin C
no (0)
yes (1)
don't know (9)
If you answered YES, how many days during the
past two weeks did you take a vitamin C?
days
D. Vitamin E?
no (0)
yes (1)
don't know (9)
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If you answered YES, how many days during the
past two weeks did you take a vitamin E?
days
37 Are you usually sleepy in the daytime? (Do not
include taking a regular daily nap as "feeling
sleepy".)
no (0)
yes (1)
don't know (9)
38 Do you feel groggy and unrefreshed for more
than a half hour after waking up in the morning?
no (0)
yes (1)
don't know (9)
39 Has your spouse or roommate complained
about your loud snoring?
no (0)
yes (1)
don't know (9)
40 Has anyone observed you while sleeping to
have episodes where you stop breathing for a
while and then snore or snort loudly?
no (0)
yes (1)
don't know (9)
41 Do you usually have trouble falling asleep?
no (0)
yes (1)
don´t know (9)
42 Do you usually wake up sevaral times at
night?
no (0)
yes (1)
don't know (9)
43 Do you usually wake up far too early?
no (0)
yes (1)
don't know (9)
44 Can you see well enough to drive, with or
without glasses?
don't drive (don't drive)
don't know (don't know)
no (no)
yes (yes)
45 Can you see well enough to watch TV, with or
without glasses?
no (0)
yes (1)
don't know (9)
46 Can you see well enough to recognize
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someone across the room, with or without
glasses?
no (0)
yes (1)
don't know (9)
47 Can you see well enough to read the
newspaper, with or without glasses?
no (0)
yes (1)
don't know (9)
48 Can you hear well enough to use the
telephone, with or without a hearing aid?
no (0)
yes (1)
don't know (9)
49 Can you hear well enough to listen to a radio,
with or without hearing aid?
no (0)
yes (1)
don't know (9)
50 Can you hear well enough to carry on a
conversation in a crowded room, with or without a
hearing aid?
no (0)
yes (1)
don't know (9)
51 Have you smoked cigarettes during the last 30
days?
no (0)
yes (1)
don't know (9)
A. On average, how many cigarettes do you
usually smoke per day?
cigarettes
52 Which of the following best describes your
current smoking status?
current smoker (current smoker)
don't know (don't know)
former smoker, quit less than 1 year ago
(former smoker, quit less than 1 year
ago)
former smoker, quit more than 1 year
ago (former smoker, quit more than 1
year ago)
never smoked (never smoked)
53 Does anyone living with you smoke cigarettes
regularly? (This includes any other member of
your household.)
no (0)
yes (1)
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don't know (9)
54 Do you ever use snuff or smokeless tobacco?
no (0)
yes (1)
don't know (9)
55 Do you ever drink beer?
no (0)
yes (1)
don't know (9)
A. About how often do you drink beer?
daily (daily)
monthly (monthly)
rarely/never (rarely/never)
weekly (weekly)
yearly (yearly)
B. How many 12-ounce cans or bottles of beer do
you usually drink on one occassion?
56 Do you ever drink wine?
no (0)
yes (1)
don't know (9)
A. About how often do you drink wine?
daily (daily)
monthly (monthly)
rarely/never (rarely/never)
weekly (weekly)
yearly (yearly)
B. How many medium, six-ounce glasses of wine
do you usually drink on one occassion?
servings
56 Do you ever drink liquor?
no (0)
yes (1)
don't know (9)
A. About how often do you drink liquor?
daily (daily)
monthly (monthly)
rarely/never (rarely/never)
weekly (weekly)
yearly (yearly)
B. How many drinks, equal to one shot of liquor,
do you usually drink on one occassion?
servings
58 Are you currently involved in any medical
studies other than CDS?
no (0)
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yes (1)
don't know (9)
58 Are you currently involved in any medical
studies other than CDS?
Medical History: Women only
59 Are you currently taking estrogens such as
Premarin, Estrace, Ogen or any other estrogen?
no (0)
yes (1)
don't know (9)
A. How many days per month do you take
estrogen?
days
B. For how long have you been taking estrogen?
years
B. For how long have you been taking estrogen?
Months
C. Why are you taking estrogen? TO PREVENT
HOT FLASHES
no (0)
yes (1)
don't know (9)
C. Why are you taking estrogen? TO PREVENT
OTHER POST-MENOPAUSAL SYMPTOMS
no (0)
yes (1)
don't know (9)
C. Why are you taking estrogen? TO PREVENT
OSTEOPOROSIS OR BONE LOSS
no (0)
yes (1)
don't know (9)
C. Why are you taking estrogen? TO PREVENT
HEART DISEASE
no (0)
yes (1)
don't know (9)
C. Why are you taking estrogen? FOR OTHER
REASONS
no (0)
yes (1)
don't know (9)
Other:
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60 If you are NOT currently taking estrogens
such as Premain, Estrace, Ogen or any other
estrogen, have you taken estrogen in the past?
no (0)
yes (1)
don't know (9)
A. How many days per month did you take
estrogen?
days
B. When did you stop?
year
B. When did you stop?
C. For how long have you been taking estrogen?
years
C. For how long have you been taking estrogen?
Months
D. Why did you take estrogen? TO PREVENT
HOT FLASHES
no (0)
yes (1)
don't know (9)
D. Why did you take estrogen? TO PREVENT
OTHER POST-MENOPAUSAL SYMPTOMS
no (0)
yes (1)
don't know (9)
D. Why did you take estrogen? TO PREVENT
OSTEOPOROSIS OR BONE LOSS
no (0)
yes (1)
don't know (9)
D. Why did you take estrogen? TO PREVENT
HEART DISEASE
no (0)
yes (1)
don't know (9)
D. Why did you take estrogen? FOR OTHER
REASONS
no (0)
yes (1)
don't know (9)
Other:
61 Are you currently taking progestins such as
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Provera or Norlutate?
no (0)
yes (1)
don't know (9)
A. How many days per month do you take
progestin?
days
B. For how long have you been taking progestin?
years
B. For how long have you been taking progestin?
Months
62 If you are NOT currently taking progestin such
as Provera or Norlutate, have you taken progestin
in the past?
no (0)
yes (1)
don't know (9)
A. How many days per month did you take
progestin?
days
B. When did you stop?
year
B. When did you stop?
C. For how long have you been taking progestin?
years
C. For how long have you been taking progestin?
Months
Medical History: Myocardical Infarction
4 Has a doctor ever told you that you had a
myocardial infarction or heart attack?
no (0)
yes (1)
don't know (9)
A. What was the doctor's name and city? Name
A. What was the doctor's name and city?
Address
A. What was the doctor's name and city? City
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A. What was the doctor's name and city? State
B. Date of event or diagnosis:
C. How many times altogether did you see a
doctor for this condition since we last spoke to
you?
times
D. Were you in the hospital at least one night for
this condition since we last spoke to you?
no (0)
yes (1)
don't know (9)
E. How many different times were you in the
hospital for this condition?
times
F. Please record the admission date of each
hospitalization and the name and location of the
hospital. Date of Hospitalization:
F. Please record the admission date of each
hospitalization and the name and location of the
hospital. 
Hospital name
F. Please record the admission date of each
hospitalization and the name and location of the
hospital. City
F. Please record the admission date of each
hospitalization and the name and location of the
hospital. State
G. How many days altogether were you
hospitalized for this condition?
days
Medical History: Angina
5 Has a doctor ever told you that you had a new
incident of angina pectoris or chest pain due to
heart disease since we spoke with you on the
phone about six month ago?
no (0)
yes (1)
don't know (9)
A. What was the doctor's name and city? Name
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A. What was the doctor's name and city?
Address
A. What was the doctor's name and city? City
A. What was the doctor's name and city? State
B. Date of event or diagnosis:
C. How many times altogether did you see a
doctor for this condition since we last spoke to
you?
times
D. Were you in the hospital at least one night for
this condition since we last spoke to you?
no (0)
yes (1)
don't know (9)
E. How many different times were you in the
hospital for this condition?
times
F. Please record the admission date of each
hospitalization and the name and location of the
hospital. Date of Hospitalization:
F. Please record the admission date of each
hospitalization and the name and location of the
hospital. 
Hospital name
F. Please record the admission date of each
hospitalization and the name and location of the
hospital. City
F. Please record the admission date of each
hospitalization and the name and location of the
hospital. State
G. How many days altogether were you
hospitalized for this condition?
days
Medical History: Congestive heart failure
6 Has a doctor ever told you that you had a new
incident of heart failure or congestive heart failure
since we spoke with you on the phone about six
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month ago?
A. What was the doctor's name and city? Name
A. What was the doctor's name and city?
Address
A. What was the doctor's name and city? City
A. What was the doctor's name and city? State
B. Date of event or diagnosis:
C. How many times altogether did you see a
doctor for this condition since we last spoke to
you?
times
D. Were you in the hospital at least one night for
this condition since we last spoke to you?
E. How many different times were you in the
hospital for this condition?
times
F. Please record the admission date of each
hospitalization and the name and location of the
hospital. Date of Hospitalization:
F. Please record the admission date of each
hospitalization and the name and location of the
hospital. 
Hospital name
F. Please record the admission date of each
hospitalization and the name and location of the
hospital. City
F. Please record the admission date of each
hospitalization and the name and location of the
hospital. State
G. How many days altogether were you
hospitalized for this condition?
days
Medical History: Intermittent claudication
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7 Has a doctor ever told you that you had a new
incident of intermittent claudication or pain in your
legs from a blockage of the arteries since we
spoke with you on the phone about six month
ago?
no (0)
yes (1)
don't know (9)
A. What was the doctor's name and city? Name
A. What was the doctor's name and city?
Address
A. What was the doctor's name and city? City
A. What was the doctor's name and city? State
B. Date of event or diagnosis:
C. How many times altogether did you see a
doctor for this condition since we last spoke to
you?
times
D. Were you in the hospital at least one night for
this condition since we last spoke to you?
no (0)
yes (1)
don't know (9)
E. How many different times were you in the
hospital for this condition?
times
F. Please record the admission date of each
hospitalization and the name and location of the
hospital. Date of Hospitalization:
F. Please record the admission date of each
hospitalization and the name and location of the
hospital. 
Hospital name
F. Please record the admission date of each
hospitalization and the name and location of the
hospital. City
F. Please record the admission date of each
hospitalization and the name and location of the
hospital. State
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G. How many days altogether were you
hospitalized for this condition?
days
Medical History: Cerebrovascular accident
8 Has a doctor ever told you that you had a new
stroke or cerebrovascular accident since we
spoke with you on the phone about six month
ago?
A. What was the doctor's name and city? Name
A. What was the doctor's name and city?
Address
A. What was the doctor's name and city? City
A. What was the doctor's name and city? State
B. Date of event or diagnosis:
C. How many times altogether did you see a
doctor for this condition since we last spoke to
you?
times
D. Were you in the hospital at least one night for
this condition since we last spoke to you?
lost more than 10 pounds (1)
gained more than 10 pounds (2)
both lost and gained more than 10
pounds (3)
no change (4)
don't know (9)
E. How many different times were you in the
hospital for this condition?
times
F. Please record the admission date of each
hospitalization and the name and location of the
hospital. Date of Hospitalization:
F. Please record the admission date of each
hospitalization and the name and location of the
hospital. 
Hospital name
F. Please record the admission date of each
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hospitalization and the name and location of the
hospital. City
F. Please record the admission date of each
hospitalization and the name and location of the
hospital. State
G. How many days altogether were you
hospitalized for this condition?
days
Medical History: Transient ischemic attack
9 Has a doctor ever told you that you had a new
transient ischemic attack or TIA or silent stroke
since we spoke with you on the phone about six
month ago?
eat a lot more (1)
eat a little more (2)
eat about the same (3)
eat a little less (4)
eat a lot less (5)
A. What was the doctor's name and city? Name
A. What was the doctor's name and city?
Address
A. What was the doctor's name and city? City
A. What was the doctor's name and city? State
B. Date of event or diagnosis:
C. How many times altogether did you see a
doctor for this condition since we last spoke to
you?
times
D. Were you in the hospital at least one night for
this condition since we last spoke to you?
a doctor recommended that I eat more (a
doctor recommended that I eat more)
a medical or dental problem has been
resolved (a medical or dental problem
has been resolved)
I am more able to shop or prepare food
than before (I am more able to shop or
prepare food than before)
I am taking medicine that increases my
appetite (I am taking medicine that
increases my appetite)
30 / 32
Year 5 Medical & Personal History Cardiovascular Health Study (CHS)
my appetite has increased for other
reasons (my appetite has increased for
other reasons)
my physical activity has increased (my
physical activity has increased)
E. How many different times were you in the
hospital for this condition?
times
F. Please record the admission date of each
hospitalization and the name and location of the
hospital. Date of Hospitalization:
F. Please record the admission date of each
hospitalization and the name and location of the
hospital. 
Hospital name
F. Please record the admission date of each
hospitalization and the name and location of the
hospital. City
F. Please record the admission date of each
hospitalization and the name and location of the
hospital. State
G. How many days altogether were you
hospitalized for this condition?
days
Medical History: Other conditions
10 Have you stayed overnight as a patient in a
hospital for any other reason not reported in
Questions 3 through 9 since we spoke to you on
the phone about six months ago?
no (0)
yes (1)
don't know (9)
Hospital name:
City:
Date of hospitalization:
length of stay
days
Date of interview
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Interviewer or Reviewer
Interview:
For CHS field center use only:
interviewer-administered (interviewer-
administered)
self-administered (self-administered)
32 / 32
Year 5 Medical & Personal History Cardiovascular Health Study (CHS)
Eligibility Depressive Disorder, Major
NCT00102492
Study Of GW679769 In Major Depressive Disorder; ODM
derived from: https://clinicaltrials.gov/show/NCT00102492
All rights reserved. Please visit https://medical-data-
models.org/forms/17117
Eligibility Depressive Disorder, Major
NCT00102492
Inclusion Criteria
subjects must have the ability to comprehend the
key components of the consent form.*
Yes
No
subject must have met dsm-iv-tr (diagnostic and
statistical manual of mental disorders, fourth
edition, text revision) criteria for current mde
(major depressive episode) for at least 8 weeks
prior to the screening visit.*
Yes
No
if female, subjects must be practicing an
acceptable method of birth control.*
Yes
No
subjects must have rating scores as outlined.*
Yes
No
Exclusion Criteria
subjects whose symptoms of the mde are better
accounted for by another diagnosis.*
Yes
No
subjects with a history of schizophrenia,
schizoaffective disorders or bipolar disorder.*
Yes
No
subjects have a positive urine test for illicit drug
use and/or a history of substance abuse or
alcohol dependence within the past 12 months.*
Yes
No
subjects with an unstable medical disorder.*
Yes
No
if female, pregnant or lactating.*
Yes
No
subjects who have received ect
(electroconvulsive therapy) or tms (transcranial
magnetic stimulation) within the 6 months
preceding screening or who have ever been
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homicidal.*
Yes
No
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Eligibility Depressive Disorder, Major NCT00102492
Common Data Elements Myeloid Leukemia
Lab: Blood Panel
Common Data Element for Myeloid Leukemia (MDS, AML,
CML) for use
in clinical routine and clinical trial documentation.
All rights reserved. Please visit https://medical-data-
models.org/forms/17119
Lab: Blood Panel
Lab: Blood Panel
White Blood Count/Leukocytes
10*9/L
Hemoglobin
g/dL
Hematokrit
%
Dyserythropoiesis
Yes
No
Erythropoeitin
U/L
Platelets
10*9/L
Promyelocytes (%)
%
Myelocytes (%)
%
Absolute Neutrophil count
Neutrophils % (Segmented+ Band)
%
Band neutrophil (%)
%
Segmented neutrophils (%)
%
Dysgranulopoiesis
Yes
No
Eosinophils (%)
%
Basophils (%)
%
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Monocytes (%)
%
Lymphocytes
%
Dysmegakaryopoiesis
Yes
No
Peripheral blasts
%
Normoblasts (%)
%
Erythroblasts peripheral (%)
%
Other Cells
% of Leukocytes
Uric acid
mg/dL
Urea
mg/dL
Blood Urea Nitrogen
mg/dL
Serum Creatinine
mg/dL
Serum Creatinine Clearance
ml/min
Magnesium
mmol/L
Total Bilirubin
mg/dL
Bilirubin direct
umol/L
Bilirubin indirect
umol/L
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Common Data Elements Myeloid Leukemia Lab: Blood Panel
SGPT
U/L
SGOT
U/L
Alkaline phosphatase
U/L
Triacylglycerol lipase
U/L
Amylase
U/L
Lactate dehydrogenase (LDH)
U/L
Creatinine phosphokinase
U/L
Total Serum Protein
g/dL
Albumin
g/dL
Serum/Plasma Glucose
mg/dL
Hemoglobin A1c
%
Total triglycerides
mg/dL
Total cholesterol
mg/dL
INR
activated Partial Thromboplastin Time aPTT
s
Fibrinogen
mg/dL
C-reactive Protein
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Common Data Elements Myeloid Leukemia Lab: Blood Panel
mg/dl
Bloodgroup patient (recipient)
0 (0)
A (A)
AB (AB)
B (B)
Bloodgroup donor
0 (0)
A (A)
AB (AB)
B (B)
Rhesus factor of Patient
Rhesus factor of Donor
Thyrotropin
mU/L
Ferritin
µg/L
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Eligibility Depressive Disorder, Major
NCT00149643
Effectiveness of Fluoxetine in Young People for the
Treatment of Major Depression and Marijuana
Dependence; ODM derived from:
https://clinicaltrials.gov/show/NCT00149643
All rights reserved. Please visit https://medical-data-
models.org/forms/17122
Eligibility Depressive Disorder, Major
NCT00149643
Inclusion Criteria
dsm-iv diagnosis of current marijuana abuse or
dependence, confirmed by scid-sud*
Yes
No
dsm-iv diagnosis of current major depressive
disorder, confirmed by the k-sads*
Yes
No
marijuana use of at least two days within the
week prior to enrollment*
Yes
No
demonstrated adequate levels of depressive
symptoms within the week prior to enrollment*
Yes
No
Exclusion Criteria
dsm-iv diagnosis of bipolar disorder,
schizoaffective disorder, or schizophrenia*
Yes
No
hypo or hyperthyroidism*
Yes
No
significant cardiac, neurological, or kidney
impairment*
Yes
No
liver disease (sgot, sgpt, or gamma-gtp greater
than 3 times the normal level)*
Yes
No
use of antipsychotic or antidepressant medication
in the month prior to enrollment*
Yes
No
dsm-iv dependence on any substance except
marijuana or nicotine; alcohol dependence, or
history of drug use*
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Yes
No
history of significant medication side effects from
any ssri antidepressant*
Yes
No
pregnant*
Yes
No
unable to use adequate contraceptive methods
for the duration of the study*
Yes
No
inability to read or understand english*
Yes
No
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Eligibility Depressive Disorder, Major NCT00149643
Eligibility Depressive Disorder, Major
NCT00186498
Memantine as an Adjunctive Agent to Reduce
Neurocognitive Deficits Following Unilateral ECT for the
Treatment of a Severe Major Depressive Episode; ODM
derived from: https://clinicaltrials.gov/show/NCT00186498
All rights reserved. Please visit https://medical-data-
models.org/forms/17124
Eligibility Depressive Disorder, Major
NCT00186498
Criteria
meets dsm-iv criteria for major depressive
disorder*
Yes
No
18 to 75 years of age and able to provide legal
consent*
Yes
No
referred to stanford ect service by treating
physician for unilateral electroconvulsive therapy
with inpatient hospitalization*
Yes
No
competed process for consenting to the clinical
use of ect according to california state law*
Yes
No
females of childbearing potential will be required
to use a double-barrier method of contraception,
which includes foam and either condom and
diaphragm, iud, and/or implant during study.
exclusion criteria:- treatment with ect in the 6
months prior to screening*
Yes
No
meets criteria for drug or alcohol abuse or
dependence in the 6 months prior to screening*
Yes
No
use of alcohol or illegal drugs within seven days
of randomization or during study. patients may be
excluded for use during a period greater than 7
days, per study physician's discretion*
Yes
No
presence of unstable or untreated cardiovascular
disease, hypertension, or endocrine disorder as
determined by the investigator*
Yes
No
use of antipsychotic, antidepressant, or other
prescription medications unless dose is stable for
at least 7 days prior to randomization.*
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Yes
No
use of any investigational treatment within 30
days of randomization*
Yes
No
previous allergic reaction to memantine or drugs
of similar chemical structure.*
Yes
No
women who are pregnant or breastfeeding are
not advised to participate in the research study*
Yes
No
any neurological disorder or organic brain
condition that would confound neurocognitive
testing*
Yes
No
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Eligibility Depressive Disorder, Major
NCT00191685
Duloxetine in the Treatment of Melancholic Depression;
ODM derived from:
https://clinicaltrials.gov/show/NCT00191685
All rights reserved. Please visit https://medical-data-
models.org/forms/17125
Eligibility Depressive Disorder, Major
NCT00191685
Inclusion Criteria
have a diagnosis of major depression with
melancholic features, as defined by diagnostic
and statistical manual of mental disorders fourth
edition [dsm-iv] criteria.*
Yes
No
experienced their first episode of major
depression prior to age 50.*
Yes
No
have a hamd17 total score of less than or equal
to 20 at visits 1 and 2.*
Yes
No
test negative for a urine pregnancy test at visit 1
(females).*
Yes
No
agree to use medically acceptable and reliable
means of birth control during the study, as
determined by the investigator (females of child-
bearing potential, not surgically sterilized and
between menarche, and one year post-
menopausal).*
Yes
No
Exclusion Criteria
have any current and primary axis i mood
disorder other than mdd, including, but not limited
to, dysthymia, seasonal affective disorder or
psychotic depression.*
Yes
No
have a current episode of major depression that
has failed to respond to two or more courses of
antidepressant therapy or, in the judgment of the
investigator, meets criteria for treatment-resistant
depression*
Yes
No
are at serious suicidal risk as determined by the
investigator.*
Yes
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No
have a serious medical illness or clinically
significant laboratory abnormalities that, in the
judgment of the investigator, are likely to require
medication/*
Yes
No
intervention/ hospitalization during the course of
the study.*
Yes
No
had treatment with a monoamine oxidase
inhibitor (maoi) within 14 days prior to visit 2 or
potential need to use a maoi during the study or
within 14 days of discontinuation of study drug.*
Yes
No
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Eligibility Congestive Heart Failure
NCT00122135
A Culturally Sensitive Values-Guided Aid for End of Life
Decision-Making; ODM derived from:
https://clinicaltrials.gov/show/NCT00122135
All rights reserved. Please visit https://medical-data-
models.org/forms/17126
Eligibility Congestive Heart Failure
NCT00122135
Inclusion Criteria
eligible patients will be at risk for 6-12 month
mortality and have one of the following
diagnoses:*
Yes
No
congestive heart failure, with ejection fraction of
<25%;*
Yes
No
severe chronic obstructive pulmonary
disease/emphysema with dependence on
oxygen;*
Yes
No
chronic liver disease with cirrhosis and ascites;*
Yes
No
colon carcinoma with liver metastases; or*
Yes
No
non-small cell cancer of the lung, stage iii or iv.*
Yes
No
all participants will be age 55 years or older and
will be recruited through the clinics at the houston
vamc.*
Yes
No
Exclusion Criteria
patients with dementia*
Yes
No
patients less than 55 years old*
Yes
No
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Eligibility Congestive Heart Failure
NCT00160134
Study to Evaluate Cardiac Hemodynamics and Safety of
SLV320 in Subjects With Congestive Heart Failure; ODM
derived from: https://clinicaltrials.gov/show/NCT00160134
All rights reserved. Please visit https://medical-data-
models.org/forms/17127
Eligibility Congestive Heart Failure
NCT00160134
Inclusion Criteria
history of chronic, symptomatic, mild to severe
(nyha class ii-iv) chf for at least three months
requiring treatment with diuretics and with
documented systolic dysfunction*
Yes
No
on stable doses of their individually optimized
medication regimen for at least one week prior to
enrollment*
Yes
No
Exclusion Criteria
required hospitalization (for cardiovascular
disease) or adjustment of background
medications for chf*
Yes
No
orthostatic hypotension or symptomatic
orthostasis*
Yes
No
sitting systolic or diastolic blood pressure < 90
mmhg*
Yes
No
2nd or 3rd degree atrio-ventricular block or sick
sinus syndrome*
Yes
No
heart rate of < 50 or > 110 bpm on the ecg*
Yes
No
transplanted heart*
Yes
No
heart failure due to primary valvular disease
(unless surgically corrected), obstructive
cardiomyopathy, pericardial disease, cor
pulmonale or congenital heart disease*
Yes
No
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hemodynamically significant left ventricular
outflow tract obstruction*
Yes
No
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Eligibility Coronary Artery Disease Amenable
to Bypass Graft Surgery NCT00259493
Graft Patency in Beating Heart Vs. Conventional CABG
Using Cardiac CT; ODM derived from:
https://clinicaltrials.gov/show/NCT00259493
All rights reserved. Please visit https://medical-data-
models.org/forms/17128
Eligibility Coronary Artery Disease
Amenable to Bypass Graft Surgery
NCT00259493
Inclusion Criteria
surgery indicated*
Yes
No
patient is hemodynamically stable*
Yes
No
isolated coronary artery surgery (no valve)*
Yes
No
no contraindications to cardiopulmonary bypass*
Yes
No
no previous surgery (not redo cabg)*
Yes
No
Exclusion Criteria
critically ill patient with hemodynamic instability.*
Yes
No
concomitant cardiac procedures.*
Yes
No
inability to provide written informed consent.*
Yes
No
prior severe reaction to contrast dye :*
Yes
No
life-threatening anaphylactoid reactions*
Yes
No
cardiac dysrhythmias and arrest*
Yes
No
cardiovascular and pulmonary collapse*
Yes
No
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elevated serum creatinine (>150 mmol/l).*
Yes
No
contraindications to cardiopulmonary bypass.*
Yes
No
age < 18 years .*
Yes
No
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NCT00259493
Eligibility Depressive Disorder, Major
NCT00223288
Impact of Caregiver Depression on Asthma in the Child;
ODM derived from:
https://clinicaltrials.gov/show/NCT00223288
All rights reserved. Please visit https://medical-data-
models.org/forms/17133
Eligibility Depressive Disorder, Major
NCT00223288
Inclusion Criteria
primary caregiver of a child currently hospitalized
at children's medical center of dallas for an
asthma exacerbation and between the ages of 5
and 16 years old*
Yes
No
male and female*
Yes
No
english or spanish speaking*
Yes
No
between the ages of 18 and 70 years old*
Yes
No
caregivers with major depressive disorder will be
offered treatment*
Yes
No
Exclusion Criteria
at risk for suicide defined by multiple suicide
attempts (greater than or equal to 3 in the past),
and/or current suicidal ideation with a well-formed
plan or intent*
Yes
No
unlikely to attend follow-up appointments*
Yes
No
mentally retarded or suffer from other severe
cognitive impairment*
Yes
No
pregnant or nursing, or women of childbearing
age who will not use methods of birth control or
abstinence during the study*
Yes
No
suffering from a severe or life-threatening medical
illness which would make completion of the study
1 / 2
unlikely*
Yes
No
suffering from treatment refractory depression
defined by failing three adequate trials of
antidepressants*
Yes
No
depression as part of bipolar disorder or
schizophrenia or schizoaffective disorder, or
current depression secondary to a medication or
general medical condition, or with psychotic
features*
Yes
No
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Eligibility Depressive Disorder, Major
NCT00316160
Sexual Functioning Study With Antidepressants; ODM
derived from: https://clinicaltrials.gov/show/NCT00316160
All rights reserved. Please visit https://medical-data-
models.org/forms/17134
Eligibility Depressive Disorder, Major
NCT00316160
Inclusion Criteria
primary diagnosis of major depressive disorder
(mdd)*
Yes
No
must have met dsm-iv criteria for current major
depressive episode for at least 8 weeks but no
long than 2 years.*
Yes
No
ham-d17 total score of >17 at screening and
baseline.*
Yes
No
severity of illness score of >4 at screening and
baseline.*
Yes
No
willing to discuss sexual functioning with
investigator or designee.*
Yes
No
sexual activity that leads to orgasm at least every
2 weeks.*
Yes
No
Exclusion Criteria
past or current dsm-iv diagnosis of bipolar
disorder i or ii, schizophrenia or another psychotic
disorder(s).*
Yes
No
primary dsm-iv diagnosis or received treatment
for panic disorder, obsessive compulsive disorder
or post stress disorder within previous 12
months.*
Yes
No
poses a homicidal or serious suicidal risk, have
made an attempt within months prior to screening
or who has ever been homicidal.*
Yes
No
1 / 2
myocardial infarction with 1 year of screening.*
Yes
No
taken ibupropion hydrochloride or venlafaxine in
the last 6 months.*
Yes
No
positive urine test for illicit drug use or alcohol or
substance abuse within the past 12 months.*
Yes
No
psychotherapy within 3 months.*
Yes
No
pregnant.*
Yes
No
electroconvulsive therapy or transcranial
magnetic stimulation within 6 months prior of
screening.*
Yes
No
ecg or clinical evidence of atrial or ventricular
hypertrophy.*
Yes
No
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Application for psychotherapy- beneficiary
Formulare für die vertragsärztliche Versorgung Freigabe
durch Dezernat 4 - Ärztliche Leistungen und
Versorgungsstruktur Geschäftsbereich Sicherstellung und
Versorgungsstruktur Abteilung Sicherstellung Herbert-
Lewin-Platz 2
10623 Berlin
Tel: + 49 (0) 30 - 4005 -1418
Fax: + 49 (0) 30 - 4005 - 271418
Email: SJohn@KBV.de
Web: www.kbv.de
Quelle: http://www.kbv.de/html/formulare.php
Forms for contract medical care Released by Department 4
- Medical treatment and structure of supply, division
ensurance and structure of supply, department ensurance
Herbert-Lewin-Platz 2
10623 Berlin
Tel: + 49 (0) 30 - 4005 -1418
Fax: + 49 (0) 30 - 4005 - 271418
Email: SJohn@KBV.de
Web: www.kbv.de
Source: http://www.kbv.de/html/formulare.php
All rights reserved. Please visit https://medical-data-
models.org/forms/17135
Application for psychotherapy-
beneficiary
Patientendaten
Krankenkasse bzw. Kostenträger
Nachname
Patientenname
Adresse des Patienten
Patient Geburtsdatum
Kostenträgerkennung
Versichertennummer
Status
Betriebsstättennummer
Arzt- Nr.
Datum
Chiffre des Patienten
Mitgliedsnummer
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Antrag
Ich beantrage die Feststellung der
Leistungspflicht für
Tiefenpsychologisch fundierte
Psychotherapie (1)
Analytische Psychotherapie (2)
Verhaltenstherapie (3)
Grund für den Antrag
Erstantrag (1)
Umwandlung/Fortführung der
Behandlung (2)
Wurde vor der jetzigen Behandlung bereits
Psychotherapie durchgeführt?
Ja
Nein
Wenn vor der jetzigen Behandlung bereits
Psychotherapie durchgeführt wurde, wie?
Ambulant (1)
Stationär (2)
Start der Behandlung
Ende der Behandlung
Behandler/Klinik/Institution
Kostenträger
Behandler/Klinik/Institution
Kostenträger
Behandler/Klinik/Institution
Kostenträger
Ist ein Rentenantrag gestellt?
Ja
Nein
Falls ein Rentenantrag gestellt wurde, wann?
Bei wem wurde der Rentenantrag gestellt?
Ich erkläre mich damit einverstanden, dass der
Therapeut die zur Prüfung des Antrags
notwendigen Angaben. insbesondere zur
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Application for psychotherapy- beneficiary
Feststellung der Erkrankung, vorangegangenen
Behandlungen und Begutachtungen und zur
Wahl des Behandlungsverfahrens, der
Krankenkasse mitteilt
Ja
Nein
Datum
Unterschrift des Patienten, der Patientin oder des
gesetzlichen Vertreters
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Application for psychotherapy- beneficiary
Eligibility Diabetes Mellitus NCT00064714
Effect of AC2993 With or Without Immunosuppression on
Beta Cell Function in Patients With Type I Diabetes; ODM
derived from: https://clinicaltrials.gov/show/NCT00064714
All rights reserved. Please visit https://medical-data-
models.org/forms/17136
Eligibility Diabetes Mellitus
NCT00064714
Criteria
t1dm for at least 5 years as defined by the
following:*
Yes
No
1. insulin dependence (with an insulin
requirement less than 0.8 units/kg/day).*
Yes
No
2. current or past anti-islet antibodies (anti-insulin
before initiation of insulin therapy, anti-islet cell
(ica), anti-tyrosine phosphatase ia-2, and/or anti-
glutamic acid decarboxylase (gad65)
antibodies).*
Yes
No
3. bmi greater than or equal to 20 kg/m(2) and
less than or equal to 30 kg/m(2).*
Yes
No
c-peptide greater than or equal to 0.3 and less
than or equal to 1.2 ng/ml at baseline or during
an arginine-stimulated c-peptide test.*
Yes
No
age 18 to 60 years, inclusive.*
Yes
No
Exclusion Criteria
symptomatic gastroparesis.*
Yes
No
diabetic nephropathy with a creatinine clearance
less than 60 cc/min or 24-hour urine albumin
greater than 300 mg.*
Yes
No
insulin requirements greater than 0.8
units/kg/day.*
Yes
No
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hypoglycemia unawareness:  unless easily
corrected via simple modifications in the patient's
diabetes regimen, the potential enrollee will be
excluded if he/she has suffered greater than or
equal to 2 episodes of severe hypoglycemia
during the most recent 12 months, defined as
requiring assistance from a third party, receiving
assistance from medics, visiting an er or being
hospitalized due to the hypoglycemia.*
Yes
No
evidence of chronic infection.*
Yes
No
history of any malignancy.*
Yes
No
any chronic medical condition that unduly
increase risk for the potential enrollee as judged
by study investigators.*
Yes
No
hematologic abnormalities:*
Yes
No
1. anemia (hematocrit less than 31.8% in women
and less than 36.7% in men).*
Yes
No
2. leukopenia (wbc count less than 3.4 k/mm(3)).*
Yes
No
3. thrombocytopenia (platelet count less than 162
k/mm(3)).*
Yes
No
hypertension, whether untreated or resistant to
medical treatment, with blood pressure greater
than 140/85 mm hg.*
Yes
No
pregnancy, breastfeeding or planned pregnancy
within two years.*
Yes
No
unable to identify primary care provider willing to
partner with study investigators.*
Yes
No
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Eligibility Diabetes Mellitus NCT00228865
Clinical Effects of Pulsatile Insulin Delivery on Cognitive
Function- Phase 1; ODM derived from:
https://clinicaltrials.gov/show/NCT00228865
All rights reserved. Please visit https://medical-data-
models.org/forms/17137
Eligibility Diabetes Mellitus
NCT00228865
Inclusion Criteria
inclusion criteria:*
Yes
No
diagnosed with type 1 or type 2 diabetes
mellitus.*
Yes
No
self reporting or diagnosed with memory
changes*
Yes
No
taking oral agents and/or insulin for diabetic
control*
Yes
No
under endocrinologist's supervision for diabetes
management*
Yes
No
endocrinologist must assess and approve patient
for participation in this study*
Yes
No
ability to swallow without difficulty*
Yes
No
ability to commit to the weekly time requirements
associated with the study*
Yes
No
Exclusion Criteria
other causes of cognitive impairment not related
to diabetes*
Yes
No
inability to take cognitive testing*
Yes
No
lack of intravenous access*
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Yes
No
pregnancy*
Yes
No
alcohol abuse, drug addiction or the use of illegal
drugs*
Yes
No
positive hiv*
Yes
No
inability to breathe into machine for respiratory
quotients*
Yes
No
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Eligibility Diabetes Mellitus NCT00228865
Prisoner health DSS Prison establishments
DSS Metadata Online Registry (METeOR)
Health sector data set specifications from METeOR,
Australia's repository for national metadata standards,
developed by the Australian Institute of Health and Welfare
(http://meteor.aihw.gov.au/content/index.phtml/itemId/3451
65)
Prisoner health DSS: Prison establishments DSS
The Prisoner health data set specification (DSS) describes
data collected from all public and private prisons throughout
Australia on prison entrants, prisoners who visit a prison
clinic, prisoners who are taking repeat medication while in
custody, prison clinic services and staffing levels. The data
are used to report against the National Prisoner Health
Indicators, assist in monitoring the health of prisoners and
inform prisoner health service planning and delivery.
In this collection, public and private prisons include those
administered by Corrective Services departments, including
correctional facilities and remand centres. Excluded from
the collection are periodic detention centres, court and
police cells, juvenile detention centres, immigration
detention centres, secure psychiatric facilities, military
prisons, and home detention programs.
The Prisoner health DSS contains four component data set
specifications:
Prison entrants DSS, Prison clinic contact DSS, Prisoners
in custody repeat medications DSS, and Prison
establishments DSS.
The Prison establishments DSS describes data on services
provided in prison health clinics (Obligation: Mandatory). 
Metadata and Classifications Unit 
Australian Institute of Health and Welfare
GPO Box 570
Canberra ACT 2601
All rights reserved. Please visit https://medical-data-
models.org/forms/17140
Prisoner health DSS Prison
establishments DSS Metadata
Online Registry (METeOR)
Establishment (prison) 1
Prison establishment identifier*
Service provider organisation (name)
Organisation name*
Establishment
Australian State/Territory identifier
(establishment)*
New South Wales (1)
Victoria (2)
Queensland (3)
South Australia (4)
Western Australia (5)
Tasmania (6)
Northern Territory (7)
Australian Capital Territory (8)
Other territories (Cocos (Keeling)
Islands, Christmas Island and Jervis Bay
Territory) (9)
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Establishment (prison)
ACCHO/AMS visitation frequency*
Every day (1)
At least once a week (2)
At least once every two weeks (3)
At least once a month (4)
Less often than once a month (5)
Never (6)
ACCHO/AMS service provider type
Prisoner health discharge summary
cluster
Number of prisoners released*
Legal status of prisoner*
Remand (1)
Sentenced (2)
Prisoner health discharge summary indicator*
Yes
No
Vaccines administered cluster
Number of doses of vaccines administered in a
prison*
Type of vaccine administered*
Hepatitis B vaccine (1)
Human papillomavirus (HPV) vaccine (2)
Meningococcal vaccine (3)
Full-time equivalent prison staff cluster
Number of full-time equivalent prison staff*
Prison health worker type*
Establishment (prison) 2
Number of pregnant prisoners
Hospital transfer cluster
Number of hospital transfers*
Planned hospital transfer indicator*
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Prisoner health DSS Prison establishments DSS Metadata Online
Registry (METeOR)
Yes
No
Sex of prison entrants cluster
Number of prison entrants*
Sex*
Male (1)
Female (2)
Intersex or indeterminate (3)
Not stated/inadequately described (9)
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Prisoner health DSS Prison establishments DSS Metadata Online
Registry (METeOR)
Registered health labour force DSS Registered chiropractic
labour force DSS Metadata Online Registry (METeOR)
Health sector data set specifications from METeOR,
Australia's repository for national metadata standards,
developed by the Australian Institute of Health and Welfare
(http://meteor.aihw.gov.au/content/index.phtml/itemId/3451
65)
Registered health labour force DSS: 
All health professionals listed with the Australian Health
Practitioner Regulation Agency (AHPRA) during the
reference period. This encompasses health professions
that require registration under the National Registration and
Accreditation Scheme and includes, but is not limited to:
·	chiropractic   
·	dentistry   
·	dental hygiene   
·	dental prosthetics   
·	dental therapy   
·	medicine   
·	midwifery   
·	nursing (enrolled, registered, practitioner)   
·	optometry   
·	osteopathy   
·	pharmacy   
·	physiotherapy   
·	podiatry   
·	psychology 
This DSS includes health professionals who are currently
registered with AHPRA and health professionals who are
no longer registered but remain listed with AHPRA.
Registered chiropractic labour force DSS:
All chiropractors listed with the Australian Health
Practitioner Regulation Agency during the reference period.
Chiropractors included in this DSS may be currently
registered or they may be listed but not currently registered.
Metadata and Classifications Unit 
Australian Institute of Health and Welfare
GPO Box 570
Canberra ACT 2601
All rights reserved. Please visit https://medical-data-
models.org/forms/17142
Registered health labour force DSS
Registered chiropractic labour force
DSS Metadata Online Registry
(METeOR)
Labour force status cluster
Country of employment in registered profession
Australia (1)
Other country (2)
Not stated/inadequately described (9)
Extended leave status in registered profession
On extended leave (3 months or more)
(1)
Not on extended leave (2)
Unknown/inadequately described (9)
Jobseeker status in registered profession
Looking for work in Australia (1)
Not looking for work in Australia (2)
Unknown/inadequately described (9)
Employment status—health professional
Employed in the registered profession (1)
Employed outside the registered
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profession (2)
Not employed (3)
Unknown/inadequately described (9)
Retirement status in registered profession
Retired (1)
Not retired (2)
Unknown/inadequately described (9)
Main job of registered chiropractor cluster
Hours worked in health profession - total
hours
Principal role - health profession
Clinician (1)
Administrator (2)
Teacher/educator (3)
Researcher (4)
Other (5)
Not stated/inadequately described (9)
Work sector - health professional
Public (1)
Private (2)
Work setting - chiropractor
Solo private practice (A01)
Group private practice (A02)
Locum private practice (A03)
Aboriginal health service (B00)
Community health care service (C00)
Hospital (D00)
Residential health care facility (E00)
Commercial/business service (F00)
Educational facility (G00)
Correctional services (H00)
Defence forces (I00)
Other government department or agency
(J00)
Other (Y00)
Unknown/inadequately described/not
stated (Z99)
Postcode—Australian (workplace)*
Suburb/town/locality name (workplace)*
Second job of registered chiropractor
cluster
Hours worked in health profession - total
hours
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Registered health labour force DSS Registered chiropractic labour force
DSS Metadata Online Registry (METeOR)
Principal role - health profession
Clinician (1)
Administrator (2)
Teacher/educator (3)
Researcher (4)
Other (5)
Not stated/inadequately described (9)
Work sector - health professional
Public (1)
Private (2)
Work setting - chiropractor
Solo private practice (A01)
Group private practice (A02)
Locum private practice (A03)
Aboriginal health service (B00)
Community health care service (C00)
Hospital (D00)
Residential health care facility (E00)
Commercial/business service (F00)
Educational facility (G00)
Correctional services (H00)
Defence forces (I00)
Other government department or agency
(J00)
Other (Y00)
Unknown/inadequately described/not
stated (Z99)
Postcode—Australian (workplace)*
Suburb/town/locality name (workplace)*
Work setting hours cluster
Hours worked in health profession - total
hours
Work sector - health professional
Public (1)
Private (2)
Work setting - registered health professional
Private practice (A00)
Aboriginal health service (B00)
Community health care service (C00)
Hospital (D00)
Residential health care facility (E00)
Commercial/business services (F00)
Educational facility (G00)
Correctional services (H00)
Defence forces (I00)
Other government department or agency
(J00)
Other  (Y00)
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Registered health labour force DSS Registered chiropractic labour force
DSS Metadata Online Registry (METeOR)
Unknown/inadequately described/not
stated (Z99)
Person (address)
Postcode—Australian (person)*
Suburb/town/locality name (person)*
Person
Australian state of birth
New South Wales (1)
Victoria (2)
Queensland (3)
South Australia (4)
Western Australia (5)
Tasmania (6)
Northern Territory (7)
Australian Capital Territory (8)
Other territories (Cocos (Keeling)
Islands, Christmas Island and Jervis Bay
Territory) (9)
Country of birth
Date of birth*
Indigenous status
Aboriginal but not Torres Strait Islander
origin (1)
Torres Strait Islander but not Aboriginal
origin (2)
Both Aboriginal and Torres Strait Islander
origin (3)
Neither Aboriginal nor Torres Strait
Islander origin (4)
Not stated/inadequately described (9)
Sex*
Male (1)
Female (2)
Intersex or indeterminate (3)
Not stated/inadequately described (9)
Registered health professional
Hours worked in health profession - clinical
hours
Hours worked in health profession - total
hours
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Registered health labour force DSS Registered chiropractic labour force
DSS Metadata Online Registry (METeOR)
Hours worked in health profession - non-clinical
hours
Hours worked in health profession - private sector
hours
Hours worked in health profession - public sector
hours
Intended years in health profession
years
Length of employment in health profession
years
Visa type - health professional
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Registered health labour force DSS Registered chiropractic labour force
DSS Metadata Online Registry (METeOR)
Registered health labour force DSS Registered dental and allied dental
health professional labour force DSS Metadata Online Registry (METeOR)
Health sector data set specifications from METeOR,
Australia's repository for national metadata standards,
developed by the Australian Institute of Health and Welfare
(http://meteor.aihw.gov.au/content/index.phtml/itemId/3451
65)
Registered health labour force DSS: 
All health professionals listed with the Australian Health
Practitioner Regulation Agency (AHPRA) during the
reference period. This encompasses health professions
that require registration under the National Registration and
Accreditation Scheme and includes, but is not limited to:
·	chiropractic   
·	dentistry   
·	dental hygiene   
·	dental prosthetics   
·	dental therapy   
·	medicine   
·	midwifery   
·	nursing (enrolled, registered, practitioner)   
·	optometry   
·	osteopathy   
·	pharmacy   
·	physiotherapy   
·	podiatry   
·	psychology 
This DSS includes health professionals who are currently
registered with AHPRA and health professionals who are
no longer registered but remain listed with AHPRA.
Registered dental and allied dental health professional
labour force DSS:
All dental and allied dental health professionals listed with
the Australian Health Practitioner Regulation Agency during
the reference period. Dental and allied dental health
professionals included in this DSS may be currently
registered or they may be listed but not currently registered.
Metadata and Classifications Unit 
Australian Institute of Health and Welfare
GPO Box 570
Canberra ACT 2601
All rights reserved. Please visit https://medical-data-
models.org/forms/17143
Registered health labour force DSS
Registered dental and allied dental
health professional labour force DSS
Metadata Online Registry (METeOR)
Labour force status cluster
Country of employment in registered profession
Australia (1)
Other country (2)
Not stated/inadequately described (9)
Extended leave status in registered profession
On extended leave (3 months or more)
(1)
Not on extended leave (2)
Unknown/inadequately described (9)
Jobseeker status in registered profession
Looking for work in Australia (1)
Not looking for work in Australia (2)
Unknown/inadequately described (9)
Employment status—health professional
Employed in the registered profession (1)
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Employed outside the registered
profession (2)
Not employed (3)
Unknown/inadequately described (9)
Retirement status in registered profession
Retired (1)
Not retired (2)
Unknown/inadequately described (9)
Main job of registered dental and allied
dental health professional cluster
Hours worked in health profession - total
hours
Area of practice - dental
General dental practice (01)
Dento-maxillofacial radiology (02)
Endodontics (03)
Oral and maxillofacial surgery (04)
Oral surgery (05)
Oral medicine (06)
Oral pathology (07)
Orthodontics (08)
Paedodontics (09)
Periodontics (10)
Prosthodontics (11)
Public health dentistry (12)
Special needs dentistry (13)
Not stated/inadequately described (99)
Principal role - health profession
Clinician (1)
Administrator (2)
Teacher/educator (3)
Researcher (4)
Other (5)
Not stated/inadequately described (9)
Work sector - health professional
Public (1)
Private (2)
Work setting - dental
Solo private practice (A01)
Group private practice (A02)
Locum private practice (A03)
Aboriginal health service (B00)
Health promotion service (C05)
Other community health care service
(C07)
Hospital (D00)
Residential health care facility (E00)
Commercial/business service (F00)
Tertiary educational facility (G01)
School (G02)
Other educational facility (G03)
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Registered health labour force DSS Registered dental and allied dental
health professional labour force DSS Metadata Online Registry (METeOR)
Correctional services (H00)
Defence forces (I00)
Other government department or agency
(J00)
Other (Y00)
Unknown/inadequately described/not
stated (Z99)
Postcode—Australian (workplace)*
Suburb/town/locality name (workplace)*
Second job of registered dental and allied
dental health professional cluster
Hours worked in health profession - total
hours
Area of practice - dental
General dental practice (01)
Dento-maxillofacial radiology (02)
Endodontics (03)
Oral and maxillofacial surgery (04)
Oral surgery (05)
Oral medicine (06)
Oral pathology (07)
Orthodontics (08)
Paedodontics (09)
Periodontics (10)
Prosthodontics (11)
Public health dentistry (12)
Special needs dentistry (13)
Not stated/inadequately described (99)
Principal role - health profession
Clinician (1)
Administrator (2)
Teacher/educator (3)
Researcher (4)
Other (5)
Not stated/inadequately described (9)
Work sector - health professional
Public (1)
Private (2)
Work setting - dental
Solo private practice (A01)
Group private practice (A02)
Locum private practice (A03)
Aboriginal health service (B00)
Health promotion service (C05)
Other community health care service
(C07)
Hospital (D00)
Residential health care facility (E00)
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Registered health labour force DSS Registered dental and allied dental
health professional labour force DSS Metadata Online Registry (METeOR)
Commercial/business service (F00)
Tertiary educational facility (G01)
School (G02)
Other educational facility (G03)
Correctional services (H00)
Defence forces (I00)
Other government department or agency
(J00)
Other (Y00)
Unknown/inadequately described/not
stated (Z99)
Postcode—Australian (workplace)*
Suburb/town/locality name (workplace)*
Work setting hours cluster
Hours worked in health profession - total
hours
Work sector - health professional
Public (1)
Private (2)
Work setting - registered health professional
Private practice (A00)
Aboriginal health service (B00)
Community health care service (C00)
Hospital (D00)
Residential health care facility (E00)
Commercial/business services (F00)
Educational facility (G00)
Correctional services (H00)
Defence forces (I00)
Other government department or agency
(J00)
Other  (Y00)
Unknown/inadequately described/not
stated (Z99)
Person (address)
Postcode—Australian (person)*
Suburb/town/locality name (person)*
Person
Australian state of birth
New South Wales (1)
Victoria (2)
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Registered health labour force DSS Registered dental and allied dental
health professional labour force DSS Metadata Online Registry (METeOR)
Queensland (3)
South Australia (4)
Western Australia (5)
Tasmania (6)
Northern Territory (7)
Australian Capital Territory (8)
Other territories (Cocos (Keeling)
Islands, Christmas Island and Jervis Bay
Territory) (9)
Country of birth
Date of birth*
Indigenous status
Aboriginal but not Torres Strait Islander
origin (1)
Torres Strait Islander but not Aboriginal
origin (2)
Both Aboriginal and Torres Strait Islander
origin (3)
Neither Aboriginal nor Torres Strait
Islander origin (4)
Not stated/inadequately described (9)
Sex*
Male (1)
Female (2)
Intersex or indeterminate (3)
Not stated/inadequately described (9)
Registered health professional
Hours worked in health profession - clinical
hours
Hours worked in health profession - total
hours
Hours worked in health profession - non-clinical
hours
Hours worked in health profession - private sector
hours
Hours worked in health profession - public sector
hours
Intended years in health profession
years
Length of employment in health profession
years
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Registered health labour force DSS Registered dental and allied dental
health professional labour force DSS Metadata Online Registry (METeOR)
Visa type - health professional
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Registered health labour force DSS Registered dental and allied dental
health professional labour force DSS Metadata Online Registry (METeOR)
Registered health labour force DSS Registered medical
professional labour force DSS Metadata Online Registry (METeOR)
Health sector data set specifications from METeOR,
Australia's repository for national metadata standards,
developed by the Australian Institute of Health and Welfare
(http://meteor.aihw.gov.au/content/index.phtml/itemId/3451
65)
Registered health labour force DSS: 
All health professionals listed with the Australian Health
Practitioner Regulation Agency (AHPRA) during the
reference period. This encompasses health professions
that require registration under the National Registration and
Accreditation Scheme and includes, but is not limited to:
·	chiropractic   
·	dentistry   
·	dental hygiene   
·	dental prosthetics   
·	dental therapy   
·	medicine   
·	midwifery   
·	nursing (enrolled, registered, practitioner)   
·	optometry   
·	osteopathy   
·	pharmacy   
·	physiotherapy   
·	podiatry   
·	psychology 
This DSS includes health professionals who are currently
registered with AHPRA and health professionals who are
no longer registered but remain listed with AHPRA.
Registered medical professional labour force DSS:
All medical professionals listed with the Australian Health
Practitioner Regulation Agency during the reference period,
including:
·	medical practitioners;   
·	medical specialists; and   
·	medical specialists-in-training.
Medical professionals included in this DSS may be
currently registered or they may be listed but not currently
registered.
Metadata and Classifications Unit 
Australian Institute of Health and Welfare
GPO Box 570
Canberra ACT 2601
All rights reserved. Please visit https://medical-data-
models.org/forms/17144
Registered health labour force DSS
Registered medical professional
labour force DSS Metadata Online
Registry (METeOR)
Labour force status cluster
Country of employment in registered profession
Australia (1)
Other country (2)
Not stated/inadequately described (9)
Extended leave status in registered profession
On extended leave (3 months or more)
(1)
Not on extended leave (2)
Unknown/inadequately described (9)
Jobseeker status in registered profession
Looking for work in Australia (1)
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Not looking for work in Australia (2)
Unknown/inadequately described (9)
Employment status—health professional
Employed in the registered profession (1)
Employed outside the registered
profession (2)
Not employed (3)
Unknown/inadequately described (9)
Retirement status in registered profession
Retired (1)
Not retired (2)
Unknown/inadequately described (9)
Main job of registered medical
professional cluster
Hours worked in health profession - total
hours
Principal role - health profession
Clinician (1)
Administrator (2)
Teacher/educator (3)
Researcher (4)
Other (5)
Not stated/inadequately described (9)
Work sector - health professional
Public (1)
Private (2)
Work setting - medical practitioner
Solo private practice (A01)
Group private practice (A02)
Locum private practice (A03)
Aboriginal health service (B00)
Community mental health service (C02)
Community drug and alcohol service
(C03)
Other community health care services
(C07)
Outpatient services (D01)
Other hospital services (D02)
Residential mental health care services
(E02)
Other residential health care facility
(E05)
Commercial/business services (F00)
Tertiary educational facility (G01)
School (G02)
Other educational facility (G03)
Correctional services  (H00)
Defence forces (I00)
Other government department or agency
(J00)
Other (Y00)
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Registered health labour force DSS Registered medical professional
labour force DSS Metadata Online Registry (METeOR)
Unknown/inadequately described/not
stated (Z99)
Postcode—Australian (workplace)*
Suburb/town/locality name (workplace)*
Second job of registered medical
professional cluster
Hours worked in health profession - total
hours
Principal role - health profession
Clinician (1)
Administrator (2)
Teacher/educator (3)
Researcher (4)
Other (5)
Not stated/inadequately described (9)
Work sector - health professional
Public (1)
Private (2)
Work setting - medical practitioner
Solo private practice (A01)
Group private practice (A02)
Locum private practice (A03)
Aboriginal health service (B00)
Community mental health service (C02)
Community drug and alcohol service
(C03)
Other community health care services
(C07)
Outpatient services (D01)
Other hospital services (D02)
Residential mental health care services
(E02)
Other residential health care facility
(E05)
Commercial/business services (F00)
Tertiary educational facility (G01)
School (G02)
Other educational facility (G03)
Correctional services  (H00)
Defence forces (I00)
Other government department or agency
(J00)
Other (Y00)
Unknown/inadequately described/not
stated (Z99)
Postcode—Australian (workplace)*
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Registered health labour force DSS Registered medical professional
labour force DSS Metadata Online Registry (METeOR)
Suburb/town/locality name (workplace)*
Work setting hours cluster
Hours worked in health profession - total
hours
Work sector - health professional
Public (1)
Private (2)
Work setting - registered health professional
Private practice (A00)
Aboriginal health service (B00)
Community health care service (C00)
Hospital (D00)
Residential health care facility (E00)
Commercial/business services (F00)
Educational facility (G00)
Correctional services (H00)
Defence forces (I00)
Other government department or agency
(J00)
Other  (Y00)
Unknown/inadequately described/not
stated (Z99)
Person (address)
Postcode—Australian (person)*
Suburb/town/locality name (person)*
Person
Australian state of birth
New South Wales (1)
Victoria (2)
Queensland (3)
South Australia (4)
Western Australia (5)
Tasmania (6)
Northern Territory (7)
Australian Capital Territory (8)
Other territories (Cocos (Keeling)
Islands, Christmas Island and Jervis Bay
Territory) (9)
Country of birth
Date of birth*
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Registered health labour force DSS Registered medical professional
labour force DSS Metadata Online Registry (METeOR)
Indigenous status
Aboriginal but not Torres Strait Islander
origin (1)
Torres Strait Islander but not Aboriginal
origin (2)
Both Aboriginal and Torres Strait Islander
origin (3)
Neither Aboriginal nor Torres Strait
Islander origin (4)
Not stated/inadequately described (9)
Sex*
Male (1)
Female (2)
Intersex or indeterminate (3)
Not stated/inadequately described (9)
Registered health professional
Hours worked in health profession - clinical
hours
Hours worked in health profession - total
hours
Hours worked in health profession - non-clinical
hours
Hours worked in health profession - private sector
hours
Hours worked in health profession - public sector
hours
Intended years in health profession
years
Length of employment in health profession
years
Field of medicine - medical practitioner
General practitioner (GP) (1)
Hospital non-specialist (salaried) (2)
Specialist (3)
Specialist-in-training (4)
Other clinician (5)
Non-clinician (6)
Not stated/inadequately described (9)
Visa type - health professional
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Registered health labour force DSS Registered medical professional
labour force DSS Metadata Online Registry (METeOR)
Eligibility Diabetes Mellitus NCT00228878
Effect Pulsatile IV Insulin Therapy on the Quality of Life in
Patients With Types 1 and 2 Diabetes; ODM derived from:
https://clinicaltrials.gov/show/NCT00228878
All rights reserved. Please visit https://medical-data-
models.org/forms/17145
Eligibility Diabetes Mellitus
NCT00228878
Inclusion Criteria
the researchers will include up to 200 patients
both male and female between the ages of 21
and 85 diagnosed with type 1 or type 2 diabetes
mellitus.*
Yes
No
self reporting or diagnosed with significant
complications resulting from diabetes*
Yes
No
taking oral agents and/or insulin for diabetic
control*
Yes
No
under an endocrinologists supervision for their
diabetes management. endocrinologist must
assess and approve patient for participation in
this study*
Yes
No
ability to swallow without difficulty*
Yes
No
ability to commit to the weekly time requirements
associated with the study*
Yes
No
Exclusion Criteria
other causes of complications not related to
diabetes*
Yes
No
inability to respond to 44 item questionnaire*
Yes
No
lack of intravenous access*
Yes
No
pregnancy*
Yes
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No
alcohol abuse, drug addiction or the use of illegal
drugs*
Yes
No
positive hiv*
Yes
No
inability to breathe into machine for respiratory
quotients*
Yes
No
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Eligibility Diabetes Mellitus NCT00228878
Eligibility Diabetes Mellitus Type 2
NCT00272012
OPAL - Insulin Glulisine, Diabetes Mellitus; ODM derived
from: https://clinicaltrials.gov/show/NCT00272012
All rights reserved. Please visit https://medical-data-
models.org/forms/17146
Eligibility Diabetes Mellitus Type 2
NCT00272012
Inclusion Criteria
type 2 diabetes mellitus, previously treated with
combination therapy of insulin glargine + oad
(maximal tolerated dose / approved in
combination with insulin according to local spcs
(summary of product characteristics), not
including use of a-glucosidase inhibitors) for at
least 3 months*
Yes
No
pre-screening hba1c value greater/equal 7% -
smaller/equal 9%*
Yes
No
fbg (fasting blood glucose) smaller/equal 120
mg/dl (6.6 mmol/l)*
Yes
No
women are either not of childbearing potential
(surgically sterile, or postmenopausal for more
than 2 years) or are not pregnant and agree to
use a reliable contraceptive measure for the
duration of the study.  reliable contraceptive
measures include the following:  systemic
contraceptive (oral, implant, injections),
diaphragm with intravaginal spermicide, cervical
cap, intrauterine device, or condom with
spermicide.*
Yes
No
ability and willingness to perform blood glucose
monitoring using the sponsor-provided blood
glucose meter and subject diary at home*
Yes
No
Exclusion Criteria
more than two fbg greater 120 mg/dl (6.6 mmol/l)
as measured on 5 consecutive days before visit
ii*
Yes
No
active proliferative diabetic retinopathy, as defined
by the application of focal or panretinal
photocoagulation or vitrectomy, in the 6 months
prior to visit 1, or any other unstable (rapidly
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progressing) retinopathy that may require surgical
treatment (including laser photocoagulation)*
Yes
No
clinically relevant cardiovascular, hepatic,
neurologic, endocrine, or other major systemic
disease making implementation of the protocol or
interpretation of the study results difficult*
Yes
No
known impaired hepatic and renal function*
Yes
No
history of drug or alcohol abuse*
Yes
No
history of hypersensitivity to insulin or insulin
analogues or any of the excipients in the insulin
glulisine formulation*
Yes
No
treatment with any investigational drug in the last
month before visit i*
Yes
No
pregnant or breast-feeding women, or women
planning to become pregnant during the study*
Yes
No
treatment or likelihood of requiring treatment
during the study period with drugs not permitted
by the clinical study protocol*
Yes
No
night shift workers if they are unable to comply
with the treatment regimen*
Yes
No
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Eligibility Diabetes Mellitus Type 2 NCT00272012
MDS Score WHO classification-based
prognostic scoring system
MDS Score WHO classification-based prognostic scoring
system
Malcovati L, Germing U, Kuendgen A, Della Porta MG,
Pascutto C, Invernizzi R, Giagounidis A, Hildebrandt B,
Bernasconi P, Knipp S, Strupp C, Lazzarino M, Aul C,
Cazzola M. Time-dependent prognostic scoring system for
predicting survival and leukemic evolution in
myelodysplastic syndromes. J Clin Oncol.
2007;25(23):3503-10. PMID: 17687155. doi:
10.1200/JCO.2006.08.5696.
All rights reserved. Please visit https://medical-data-
models.org/forms/17147
MDS Score WHO classification-
based prognostic scoring system
Score Items
WHO MDS Subcategory
RA / RARS / 5q-  (RA / RARS / 5q- )
RAEB I  (RAEB I )
RAEB II (RAEB II)
RCMD / RSCMD  (RCMD / RSCMD )
Karyotype:
Favorable (Favorable)
Intermediate (Intermediate)
Unfavorable (Unfavorable)
Need for blood transfusion 
(The need for blood transfusion: at least one
transfusion within 8 weeks for a time period of 3
months)
No (No)
Regulary (Regulary)
Result of Score
WPSS - Risk group
WPSS
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MDS Score CMML-Specific Prognostic
Scoring System
MDS Score CMML-Specific Prognostic Scoring System
Such E, Germing U, Malcovati L, Cervera J, Kuendgen A,
Della Porta MG, Nomdedeu B, Arenillas L, Luno E, Xicoy B,
Amigo ML, Valcarcel D, Nachtkamp K, Ambaglio I,
Hildebrandt B, Lorenzo I, Cazzola M, Sanz G. Development
and validation of a prognostic scoring system for patients
with chronic myelomonocytic leukemia. Blood.
2013;121(15):3005-15. PMID: 23372164. doi:
10.1182/blood-2012-08-452938.
All rights reserved. Please visit https://medical-data-
models.org/forms/17148
MDS Score CMML-Specific
Prognostic Scoring System
Score: Items
WHO Types:
CMML I (CMML I)
CMML II (CMML II)
Leukocytes
/μl
Risk Group: Karyotype
High (High)
Intermediate (Intermediate)
Low  (Low )
Patient is dependent on blood transfusion?
(at least one red blood transfusion in 8 weeks
over a time period of 4 months)
Yes
No
Result of Score
Prognostic Risk Group?
High Risk (High Risk)
Intermediate Risk (Intermediate Risk)
Low Risk (Low Risk)
Very High Risk (Very High Risk)
Very Low Risk (Very Low Risk)
CPSS Score
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MDS Score Nordic Score
MDS Score Nordic Score
Hellstrom-Lindberg E, Negrin R, Stein R, Krantz S,
Lindberg G, Vardiman J, Ost A, Greenberg P. Erythroid
response to treatment with G-CSF plus erythropoietin for
the anaemia of patients with myelodysplastic syndromes:
proposal for a predictive model. British journal of
haematology. 1997;99(2):344-51. PMID: 9375752.
All rights reserved. Please visit https://medical-data-
models.org/forms/17149
MDS Score Nordic Score
Score Items
Need of blood transfusion:
< 2 Red Blood Transfusions/ months (< 2
Red Blood Transfusions/ months)
≥ 2 Red Blood Transfusions/ months (≥ 2
Red Blood Transfusions/ months)
Serum EPO Level:
< 500 U/l (< 500 U/l)
≥ 500 U/l (≥ 500 U/l)
Result of Score
Result
Score 0 (Score 0)
Score 1 (Score 1)
Score 2 (Score 2)
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Eligibility New Onset Type 1 Diabetes
Mellitus NCT00214214
A Pilot Study to Determine the Safety of Campath-1H (Anti-
CD52 Antibody) Therapy in Newly Diagnosed Subjects
With Type 1 Diabetes Mellitus; ODM derived from:
https://clinicaltrials.gov/show/NCT00214214
All rights reserved. Please visit https://medical-data-
models.org/forms/17150
Eligibility New Onset Type 1
Diabetes Mellitus NCT00214214
Inclusion Criteria
adult subjects ages 18-35, with new onset type 1
diabetes mellitus (within 2-12 weeks of
diagnosis), one or more islet autoantibody to gad,
ia2, iaa or islet cell cytoplasmic antibody (ica)
within 2 weeks of diabetes diagnosis.*
Yes
No
Exclusion Criteria
subjects under 18 years of age or over 35 years
of age.*
Yes
No
subjects who have previously received an organ
transplant.*
Yes
No
subjects who are currently receiving systemic
corticosteroids for other medical diseases in
which the physician feels discontinuation of
corticosteroids is contraindicated.*
Yes
No
subjects with a history of other medical
condition(s) known to affect blood glucose values
(i.e., cushing's disease, acromegaly).*
Yes
No
subjects with a history of other chronic systemic
inflammatory or autoimmune disease or other
severe medical condition. (a history of treated
hypothyroidism with documentation of normal
serum thyroid hormone levels will not be
exclusionary.)*
Yes
No
patients with a history of hepatitis b, hepatitis c,
or hiv.*
Yes
No
ppd positive at the time of evaluation.*
Yes
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No
thrombocytopenia or neutropenia. individuals will
be considered to have thrombocytopenia if they
have a platelet count <100,000 platelets/mm2 or
<3,000 wbc/ml.*
Yes
No
subjects with a history of renal, pulmonary, or
cardiac failure*
Yes
No
subjects with severe systemic infections. only
those subjects who have completed treatment
and have shown a complete clinical resolution will
be considered eligible for the study.*
Yes
No
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Eligibility Diabetes Mellitus Type 2
NCT00354939
Insulin Analogue With Continuous Glucose Monitoring
System (CGMS) Measurement; ODM derived from:
https://clinicaltrials.gov/show/NCT00354939
All rights reserved. Please visit https://medical-data-
models.org/forms/17151
Eligibility Diabetes Mellitus Type 2
NCT00354939
Inclusion Criteria
subjects with type 2 diabetes mellitus (no history
of ketoacidosis)and stable treatment with nph
insulin(once or twice daily)and mealtime insulin
for at least 3 months.*
Yes
No
hba1c values smaller/equal 8.0%(measured at
screening visit, visit 1).*
Yes
No
ability and willingness to perform continuous and
self monitoring blood glucose profiles, using a
self monitoring blood glucose meter as well as
carrying the continuous blood glucose meter at
least two times for 72 hours throughout the study
at home.*
Yes
No
Exclusion Criteria
all forms of diabetes other than type 2 diabetes
mellitus.*
Yes
No
oral antidiabetic drugs(oads)and/or insulins other
than nph and mealtime insulins, except
metformin(stable dose for a minimum of 3
months, no dose adjustments during the study).*
Yes
No
pregnant(as determined by urine pregnancy test
at visit 1)or breast-feeding.*
Yes
No
women of childbearing potential who did not take
adequate contraceptive protection such as
systemic hormones or who planned to become
pregnant during the study.*
Yes
No
likelihood of requiring treatment during the study
period with drugs not permitted by the study
protocol (e.g. systemic corticosteroids).*
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Yes
No
history of hypersensitivity to the study medication
or to drugs with similar chemical structures.*
Yes
No
treatment with any investigational drugs in the
last month before study entry.*
Yes
No
history of drug or alcohol abuse.*
Yes
No
diabetic retinopathy with surgical treatment (laser
photocoagulation or vitrectomy) in the 3 months
prior to study entry or which required surgical
treatment within the study.*
Yes
No
clinically relevant cardiovascular, gastrointestinal,
hepatic, neurological, endocrine, hematological or
other major systemic diseases making
implementation of the protocol or interpretation of
the study results difficult.*
Yes
No
known impaired hepatic or renal function.*
Yes
No
the above information is not intended to contain
all considerations relevant to a patient's potential
participation in a clinical trial.*
Yes
No
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Eligibility Diabetes Mellitus Type 2
NCT00600236
HLA and it Relation With the Development of Proliferative
Diabetic Retinopathy in Mexican Population; ODM derived
from: https://clinicaltrials.gov/show/NCT00600236
All rights reserved. Please visit https://medical-data-
models.org/forms/17152
Eligibility Diabetes Mellitus Type 2
NCT00600236
Inclusion Criteria
diabetes mellitus type 2 with 10 years of
diagnosis and no diabetic retinopathy*
Yes
No
diabetes mellitus type 2 with 10 years of
diagnosis and proliferative retinopathy*
Yes
No
Exclusion Criteria
systemic hipertension*
Yes
No
cardic disease*
Yes
No
lupus*
Yes
No
any kind of artritis*
Yes
No
allergies*
Yes
No
optic neuritis*
Yes
No
vkh*
Yes
No
cancer*
Yes
No
inmunological diseases*
Yes
No
1 / 1
Eligibility Diabetes Mellitus Type 2
NCT00612625
Near Normalisation of BG Improves the Potentiating Effect
of GLP-1; ODM derived from:
https://clinicaltrials.gov/show/NCT00612625
All rights reserved. Please visit https://medical-data-
models.org/forms/17153
Eligibility Diabetes Mellitus Type 2
NCT00612625
Inclusion Criteria
age 18-70 years*
Yes
No
type 2 diabetes diagnosed after 30 years of age*
Yes
No
bmi > 25*
Yes
No
Exclusion Criteria
severe complications to diabetes*
Yes
No
abnormal liver og kidney function*
Yes
No
haemoglobin below the lower limit*
Yes
No
macroalbuminuria*
Yes
No
systemic disease*
Yes
No
pregnancy*
Yes
No
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Application for psychotherapy-
Psychotherapists statements
Formulare für die vertragsärztliche Versorgung Freigabe
durch Dezernat 4 - Ärztliche Leistungen und
Versorgungsstruktur Geschäftsbereich Sicherstellung und
Versorgungsstruktur Abteilung Sicherstellung Herbert-
Lewin-Platz 2 10623 Berlin Tel: + 49 (0) 30 - 4005 -1418
Fax: + 49 (0) 30 - 4005 - 271418 Email: SJohn@KBV.de
Web: www.kbv.de Quelle:
http://www.kbv.de/html/formulare.php Forms for contract
medical care Released by Department 4 - Medical
treatment and structure of supply, division ensurance and
structure of supply, department ensurance Herbert-Lewin-
Platz 2 10623 Berlin Tel: + 49 (0) 30 - 4005 -1418 Fax: + 49
(0) 30 - 4005 - 271418 Email: SJohn@KBV.de Web:
www.kbv.de Source: http://www.kbv.de/html/formulare.php
All rights reserved. Please visit https://medical-data-
models.org/forms/17155
Application for psychotherapy-
Psychotherapists statements
Versicherungsdaten
Name und Anschrift der Krankenkasse
Chiffre des Patienten
Kurzzeittherapie
Kurzzeittherapie
Erstantrag (1)
erneuter Antrag (2)
Kurzzeittherapie mit max 25 Std
tiefenpsychologisch fundierte
Psychotherapie (1)
Verhaltenstherapie (2)
Leistungen
EBM Nummer
Leistungen
EBM Nummer
Anzahl Teilnehmer je Gruppe
Leistungen
EBM Nummer
Diagnose(n)
Die KZT wird durchgeführt
als Behandlungsverfahren mit
voraussichtlich ausreichendem
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Behandlungserfolg (1)
zur Überprüfung einer
Indikationsstellung für Langzeittherapie
(2)
als Sofortmaßnahme zur
Krisenintervention (3)
Begründung des Behandlungsplans
Langzeittherapie
Langzeittherapie
Erstantrag (1)
Umwandlungsantrag (2)
Fortführungsantrag (3)
Langzeittherapie, Nummer des
Fortführungsantrags
Langzeittherapie, voraussichtliche Stundenanzahl
Langzeittherapie
tiefenpsychologisch fundierte
Psychotherapie (1)
analytische Psychotherapie (2)
Verhaltenstherapie (3)
Leistungen
EBM Nummer
Anzahl der Sitzungen in der Woche
Leistungen
EBM Nummer
Anzahl der Sitzungen in der Woche
Leistungen für Einbeziehung der Bezugsperson
EBM Nummer
Anzahl der Sitzungen in der Woche
Leistungen für Einbeziehung der Bezugsperson
EBM Nummer
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Anzahl der Sitzungen in der Woche
Behandlungsbeginn am
Behandlungsbeginn seit Diagnose(n)
Vorgutachter und Datum seiner letzten
Stellungnahme
Bisheriger Behandlungsumfang im laufenden
Verfahren
Kurzzeittherapie (1)
Langzeittherapie (2)
Bisheriger Behandlungsumfang im laufenden
Verfahren
Einzelbehandlung (1)
Gruppenbehandlung (2)
EBM Nummer
Bisheriger Behandlungsumfang im laufenden
Verfahren: Anzahl Sitzungen
Bisheriger Behandlungsumfang im laufenden
Verfahren
Kurzzeittherapie (1)
Langzeittherapie (2)
Bisheriger Behandlungsumfang im laufenden
Verfahren
Einzelbehandlung (1)
Gruppenbehandlung (2)
Bisheriger Behandlungsumfang im laufenden
Verfahren: Anzahl Sitzungen
EBM Nummer
Erklärung des Therapeuten: Innerhalb der letzten
2 Jahre wurde bereits eine Psychotherapie
durchgeführt
Ja
Nein
Erklärung des Therapeuten: Ich führe die
beantragte Psychotherapie nach den jeweils
geltenden Bestimmungen der vertragsärztlichen
Versorgung durch
Ja
Nein
Erklärung des Therapeuten: Ich erkläre, den
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Bericht an den Gutachter vollständig selbst
verfasst zu haben.
Ja
Nein
Erklärung des Therapeuten: Ich habe von der
zuständigen kassenärztlichen Vereinigung die
Abrechnungsgenehmigung für
tiefenpsychologisch fundierte Psychotherapie
Ja
Nein
Erklärung des Therapeuten: Ich habe von der
zuständigen kassenärztlichen Vereinigung die
Abrechnungsgenehmigung für analytische
Psychotherapie
Ja
Nein
Erklärung des Therapeuten: Ich habe von der
zuständigen kassenärztlichen Vereinigung die
Abrechnungsgenehmigung für Verhaltenstherapie
Ja
Nein
Erklärung des Therapeuten: Ich habe von der
zuständigen kassenärztlichen Vereinigung die
Abrechnungsgenehmigung für EMDR
Ja
Nein
Erklärung des Therapeuten: Ich habe von der
zuständigen kassenärztlichen Vereinigung die
Abrechnungsgenehmigung für die Behandlung
von Kindern und Jugendlichen
Ja
Nein
Erklärung des Therapeuten: Ich habe von der
zuständigen kassenärztlichen Vereinigung die
Abrechnungsgenehmigung für die Behandlung
von Erwachsenen
Ja
Nein
Erklärung des Therapeuten: Ich habe von der
zuständigen kassenärztlichen Vereinigung die
Abrechnungsgenehmigung für die Behandlung in
Gruppen
Ja
Nein
Von der Genehmigungspflicht im
Gutachterverfahren für KZT befreit durch KV
Ja
Nein
Von der Genehmigungspflicht im
Gutachterverfahren für KZT befreit durch: Name
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der KV
Ausstellungsdatum
KV-Abrechnungsnummer
Unterschrift des Therapeuten
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Registered health labour force DSS Registered nursing professional
labour force DSS Metadata Online Registry (METeOR)
Health sector data set specifications from METeOR,
Australia's repository for national metadata standards,
developed by the Australian Institute of Health and Welfare
(http://meteor.aihw.gov.au/content/index.phtml/itemId/3451
65)
Registered health labour force DSS: 
All health professionals listed with the Australian Health
Practitioner Regulation Agency (AHPRA) during the
reference period. This encompasses health professions
that require registration under the National Registration and
Accreditation Scheme and includes, but is not limited to:
·	chiropractic   
·	dentistry   
·	dental hygiene   
·	dental prosthetics   
·	dental therapy   
·	medicine   
·	midwifery   
·	nursing (enrolled, registered, practitioner)   
·	optometry   
·	osteopathy   
·	pharmacy   
·	physiotherapy   
·	podiatry   
·	psychology 
This DSS includes health professionals who are currently
registered with AHPRA and health professionals who are
no longer registered but remain listed with AHPRA.
Registered nursing professional labour force DSS:
All nursing professionals listed with the Australian Health
Practitioner Regulation Agency during the reference period,
including:
·	enrolled nurses; 
·	registered nurses; and 
·	nurse practitioners.
Nursing professionals included in this DSS may be
currently registered or they may be listed but not currently
registered.
Metadata and Classifications Unit 
Australian Institute of Health and Welfare
GPO Box 570
Canberra ACT 2601
All rights reserved. Please visit https://medical-data-
models.org/forms/17157
Registered health labour force DSS
Registered midwifery labour force
DSS Metadata Online Registry
(METeOR)
Labour force status cluster
Country of employment in registered profession
Australia (1)
Other country (2)
Not stated/inadequately described (9)
Extended leave status in registered profession
On extended leave (3 months or more)
(1)
Not on extended leave (2)
Unknown/inadequately described (9)
Jobseeker status in registered profession
Looking for work in Australia (1)
Not looking for work in Australia (2)
Unknown/inadequately described (9)
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Employment status—health professional
Employed in the registered profession (1)
Employed outside the registered
profession (2)
Not employed (3)
Unknown/inadequately described (9)
Retirement status in registered profession
Retired (1)
Not retired (2)
Unknown/inadequately described (9)
Main job of registered nursing professional
cluster
Hours worked in health profession - total
hours
Area of practice - nursing
Aged care (01)
Child and family health (02)
Community health (03)
Critical care and emergency  (04)
Education (05)
Management (06)
Medical (07)
General practice/Medical practice (08)
Mental health (09)
Midwifery (10)
Paediatrics (11)
Peri-operative (12)
Rehabilitation and disability (13)
Research (14)
Surgical (15)
Other (16)
Not stated/inadequately described (99)
Principal role - health profession
Clinician (1)
Administrator (2)
Teacher/educator (3)
Researcher (4)
Other (5)
Not stated/inadequately described (9)
Work sector - health professional
Public (1)
Private (2)
Work setting - nurse
Locum private practice (A03)
General Practitioner (GP) practice (A05)
Other private practice (A06)
Aboriginal health service (B00)
Community mental health service (C02)
Community drug and alcohol service
(C03)
Other community health care service
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(C07)
Outpatient service (D01)
Other hospital service (D02)
Residential aged care facility (E01)
Residential mental health care service
(E02)
Hospice (E04)
Other residential health care facility
(E05)
Commercial/business service (F00)
Tertiary educational facility (G01)
School (G02)
Other educational facility (G03)
Correctional services (H00)
Defence forces (I00)
Other government agency or department
(J00)
Other (Y00)
Unknown/inadequately described/not
stated (Z99)
Postcode—Australian (workplace)*
Suburb/town/locality name (workplace)*
Second job of registered nursing
professional clusterr
Hours worked in health profession - total
hours
Area of practice - nursing
Aged care (01)
Child and family health (02)
Community health (03)
Critical care and emergency  (04)
Education (05)
Management (06)
Medical (07)
General practice/Medical practice (08)
Mental health (09)
Midwifery (10)
Paediatrics (11)
Peri-operative (12)
Rehabilitation and disability (13)
Research (14)
Surgical (15)
Other (16)
Not stated/inadequately described (99)
Principal role - health profession
Clinician (1)
Administrator (2)
Teacher/educator (3)
Researcher (4)
Other (5)
Not stated/inadequately described (9)
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Work sector - health professional
Public (1)
Private (2)
Work setting - nurse
Locum private practice (A03)
General Practitioner (GP) practice (A05)
Other private practice (A06)
Aboriginal health service (B00)
Community mental health service (C02)
Community drug and alcohol service
(C03)
Other community health care service
(C07)
Outpatient service (D01)
Other hospital service (D02)
Residential aged care facility (E01)
Residential mental health care service
(E02)
Hospice (E04)
Other residential health care facility
(E05)
Commercial/business service (F00)
Tertiary educational facility (G01)
School (G02)
Other educational facility (G03)
Correctional services (H00)
Defence forces (I00)
Other government agency or department
(J00)
Other (Y00)
Unknown/inadequately described/not
stated (Z99)
Postcode—Australian (workplace)*
Suburb/town/locality name (workplace)*
Work setting hours cluster
Hours worked in health profession - total
hours
Work sector - health professional
Public (1)
Private (2)
Work setting - registered health professional
Private practice (A00)
Aboriginal health service (B00)
Community health care service (C00)
Hospital (D00)
Residential health care facility (E00)
Commercial/business services (F00)
Educational facility (G00)
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Correctional services (H00)
Defence forces (I00)
Other government department or agency
(J00)
Other  (Y00)
Unknown/inadequately described/not
stated (Z99)
Person (address)
Postcode—Australian (person)*
Suburb/town/locality name (person)*
Person
Australian state of birth
New South Wales (1)
Victoria (2)
Queensland (3)
South Australia (4)
Western Australia (5)
Tasmania (6)
Northern Territory (7)
Australian Capital Territory (8)
Other territories (Cocos (Keeling)
Islands, Christmas Island and Jervis Bay
Territory) (9)
Country of birth
Date of birth*
Indigenous status
Aboriginal but not Torres Strait Islander
origin (1)
Torres Strait Islander but not Aboriginal
origin (2)
Both Aboriginal and Torres Strait Islander
origin (3)
Neither Aboriginal nor Torres Strait
Islander origin (4)
Not stated/inadequately described (9)
Sex*
Male (1)
Female (2)
Intersex or indeterminate (3)
Not stated/inadequately described (9)
Registered health professional
Hours worked in health profession - clinical
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hours
Hours worked in health profession - total
hours
Hours worked in health profession - non-clinical
hours
Hours worked in health profession - private sector
hours
Hours worked in health profession - public sector
hours
Intended years in health profession
years
Length of employment in health profession
years
Visa type - health professional
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Registered health labour force DSS Registered midwifery
labour force DSS Metadata Online Registry (METeOR)
Health sector data set specifications from METeOR,
Australia's repository for national metadata standards,
developed by the Australian Institute of Health and Welfare
(http://meteor.aihw.gov.au/content/index.phtml/itemId/3451
65)
Registered health labour force DSS: 
All health professionals listed with the Australian Health
Practitioner Regulation Agency (AHPRA) during the
reference period. This encompasses health professions
that require registration under the National Registration and
Accreditation Scheme and includes, but is not limited to:
·	chiropractic   
·	dentistry   
·	dental hygiene   
·	dental prosthetics   
·	dental therapy   
·	medicine   
·	midwifery   
·	nursing (enrolled, registered, practitioner)   
·	optometry   
·	osteopathy   
·	pharmacy   
·	physiotherapy   
·	podiatry   
·	psychology 
This DSS includes health professionals who are currently
registered with AHPRA and health professionals who are
no longer registered but remain listed with AHPRA.
Registered midwifery labour force DSS:
All midwives listed with the Australian Health Practitioner
Regulation Agency during the reference period. Midwives
included in this DSS may be currently registered or they
may be listed but not currently registered.
Metadata and Classifications Unit 
Australian Institute of Health and Welfare
GPO Box 570
Canberra ACT 2601
All rights reserved. Please visit https://medical-data-
models.org/forms/17158
Registered health labour force DSS
Registered midwifery labour force
DSS Metadata Online Registry
(METeOR)
Labour force status cluster
Country of employment in registered profession
Australia (1)
Other country (2)
Not stated/inadequately described (9)
Extended leave status in registered profession
On extended leave (3 months or more)
(1)
Not on extended leave (2)
Unknown/inadequately described (9)
Jobseeker status in registered profession
Looking for work in Australia (1)
Not looking for work in Australia (2)
Unknown/inadequately described (9)
Employment status—health professional
Employed in the registered profession (1)
Employed outside the registered
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profession (2)
Not employed (3)
Unknown/inadequately described (9)
Retirement status in registered profession
Retired (1)
Not retired (2)
Unknown/inadequately described (9)
Main job of registered midwife cluster
Hours worked in health profession - total
hours
Principal role - health profession
Clinician (1)
Administrator (2)
Teacher/educator (3)
Researcher (4)
Other (5)
Not stated/inadequately described (9)
Work sector - health professional
Public (1)
Private (2)
Work setting - midwife
Locum private practice (A03)
Other private practice (A06)
Aboriginal health service (B00)
C000Community health care service
(C000Community health care service)
Outpatient service (D01)
Other hospital service (D02)
Tertiary educational facility (G01)
Other (Y00)
Unknown/inadequately described/not
stated (Z99)
Postcode—Australian (workplace)*
Suburb/town/locality name (workplace)*
Second job of registered midwife cluster
Hours worked in health profession - total
hours
Principal role - health profession
Clinician (1)
Administrator (2)
Teacher/educator (3)
Researcher (4)
Other (5)
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Not stated/inadequately described (9)
Work sector - health professional
Public (1)
Private (2)
Work setting - midwife
Locum private practice (A03)
Other private practice (A06)
Aboriginal health service (B00)
C000Community health care service
(C000Community health care service)
Outpatient service (D01)
Other hospital service (D02)
Tertiary educational facility (G01)
Other (Y00)
Unknown/inadequately described/not
stated (Z99)
Postcode—Australian (workplace)*
Suburb/town/locality name (workplace)*
Work setting hours cluster
Hours worked in health profession - total
hours
Work sector - health professional
Public (1)
Private (2)
Work setting - registered health professional
Private practice (A00)
Aboriginal health service (B00)
Community health care service (C00)
Hospital (D00)
Residential health care facility (E00)
Commercial/business services (F00)
Educational facility (G00)
Correctional services (H00)
Defence forces (I00)
Other government department or agency
(J00)
Other  (Y00)
Unknown/inadequately described/not
stated (Z99)
Person (address)
Postcode—Australian (person)*
Suburb/town/locality name (person)*
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Person
Australian state of birth
New South Wales (1)
Victoria (2)
Queensland (3)
South Australia (4)
Western Australia (5)
Tasmania (6)
Northern Territory (7)
Australian Capital Territory (8)
Other territories (Cocos (Keeling)
Islands, Christmas Island and Jervis Bay
Territory) (9)
Country of birth
Date of birth*
Indigenous status
Aboriginal but not Torres Strait Islander
origin (1)
Torres Strait Islander but not Aboriginal
origin (2)
Both Aboriginal and Torres Strait Islander
origin (3)
Neither Aboriginal nor Torres Strait
Islander origin (4)
Not stated/inadequately described (9)
Sex*
Male (1)
Female (2)
Intersex or indeterminate (3)
Not stated/inadequately described (9)
Registered health professional
Hours worked in health profession - clinical
hours
Hours worked in health profession - total
hours
Hours worked in health profession - non-clinical
hours
Hours worked in health profession - private sector
hours
Hours worked in health profession - public sector
hours
Intended years in health profession
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years
Length of employment in health profession
years
Visa type - health professional
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Eligibility Diabetes Mellitus, Insulin-
Dependent NCT00069615
Pilot Study of the GlucoWatch G2 Biographer for the
Management of Type 1 Diabetes in Children; ODM derived
from: https://clinicaltrials.gov/show/NCT00069615
All rights reserved. Please visit https://medical-data-
models.org/forms/17159
Eligibility Diabetes Mellitus, Insulin-
Dependent NCT00069615
Inclusion Criteria
diagnosis of type 1 diabetes*
Yes
No
duration of diabetes > 1 year*
Yes
No
daily insulin therapy (pump or at least 2
injections/day)*
Yes
No
stable insulin regimen; not expected to change
administration modality within the next 3 months
(e.g., injection user switching to pump)*
Yes
No
Exclusion Criteria
the presence of skin abnormalities or a significant
medical disorder that in the judgment of the
investigator will affect the wearing of the sensors
or the completion of any aspect of the protocol.*
Yes
No
prior use of a gwb prescribed for home use (prior
use of a gwb as part of a research study is
allowable)*
Yes
No
the presence of any of the following diseases:*
Yes
No
asthma if treated with systemic or inhaled
corticosteroids in the last 6 months*
Yes
No
cystic fibrosis*
Yes
No
other major illness that in the judgment of the
investigator might interfere with the completion of
the protocol*
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Yes
No
adequately treated thyroid disease and celiac
disease do not exclude*
Yes
No
inpatient psychiatric treatment in the past 6
months for either the subject or the subject’s
primary care giver (i.e., parent or guardian).*
Yes
No
current use of oral/inhaled glucocorticoids or
other medications, which in the judgment of the
investigator would be a contraindication to
participation in the study.*
Yes
No
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Registered health labour force DSS Registered optometry
labour force DSS Metadata Online Registry (METeOR)
Health sector data set specifications from METeOR,
Australia's repository for national metadata standards,
developed by the Australian Institute of Health and Welfare
(http://meteor.aihw.gov.au/content/index.phtml/itemId/3451
65)
Registered health labour force DSS: 
All health professionals listed with the Australian Health
Practitioner Regulation Agency (AHPRA) during the
reference period. This encompasses health professions
that require registration under the National Registration and
Accreditation Scheme and includes, but is not limited to:
·	chiropractic   
·	dentistry   
·	dental hygiene   
·	dental prosthetics   
·	dental therapy   
·	medicine   
·	midwifery   
·	nursing (enrolled, registered, practitioner)   
·	optometry   
·	osteopathy   
·	pharmacy   
·	physiotherapy   
·	podiatry   
·	psychology 
This DSS includes health professionals who are currently
registered with AHPRA and health professionals who are
no longer registered but remain listed with AHPRA.
Registered optometry labour force DSS:
All optometrists listed with the Australian Health Practitioner
Regulation Agency during the reference period.
Optometrists included in this DSS may be currently
registered or they may be listed but not currently registered.
Metadata and Classifications Unit 
Australian Institute of Health and Welfare
GPO Box 570
Canberra ACT 2601
All rights reserved. Please visit https://medical-data-
models.org/forms/17160
Registered health labour force DSS
Registered optometry labour force
DSS Metadata Online Registry
(METeOR)
Labour force status cluster
Country of employment in registered profession
Australia (1)
Other country (2)
Not stated/inadequately described (9)
Extended leave status in registered profession
On extended leave (3 months or more)
(1)
Not on extended leave (2)
Unknown/inadequately described (9)
Jobseeker status in registered profession
Looking for work in Australia (1)
Not looking for work in Australia (2)
Unknown/inadequately described (9)
Employment status—health professional
Employed in the registered profession (1)
Employed outside the registered
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profession (2)
Not employed (3)
Unknown/inadequately described (9)
Retirement status in registered profession
Retired (1)
Not retired (2)
Unknown/inadequately described (9)
Main job of registered optometrist cluster
Hours worked in health profession - total
hours
Principal role - health profession
Clinician (1)
Administrator (2)
Teacher/educator (3)
Researcher (4)
Other (5)
Not stated/inadequately described (9)
Work sector - health professional
Public (1)
Private (2)
Work setting - optometrist
Solo private practice (A01)
Group private practice (A02)
Locum private practice (A03)
Aboriginal health service (B00)
Community health care service (C00)
Hospital (D00)
Residential health care facility (E00)
Commercial/business services (F00)
Educational facility (G00)
Correctional services  (H00)
Defence forces (I00)
Other government department or agency
(J00)
Other (Y00)
Unknown/inadequately described/not
stated (Z99)
Postcode—Australian (workplace)*
Suburb/town/locality name (workplace)*
Second job of registered optometrist
cluster
Hours worked in health profession - total
hours
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Principal role - health profession
Clinician (1)
Administrator (2)
Teacher/educator (3)
Researcher (4)
Other (5)
Not stated/inadequately described (9)
Work sector - health professional
Public (1)
Private (2)
Work setting - optometrist
Solo private practice (A01)
Group private practice (A02)
Locum private practice (A03)
Aboriginal health service (B00)
Community health care service (C00)
Hospital (D00)
Residential health care facility (E00)
Commercial/business services (F00)
Educational facility (G00)
Correctional services  (H00)
Defence forces (I00)
Other government department or agency
(J00)
Other (Y00)
Unknown/inadequately described/not
stated (Z99)
Postcode—Australian (workplace)*
Suburb/town/locality name (workplace)*
Work setting hours cluster
Hours worked in health profession - total
hours
Work sector - health professional
Public (1)
Private (2)
Work setting - registered health professional
Private practice (A00)
Aboriginal health service (B00)
Community health care service (C00)
Hospital (D00)
Residential health care facility (E00)
Commercial/business services (F00)
Educational facility (G00)
Correctional services (H00)
Defence forces (I00)
Other government department or agency
(J00)
Other  (Y00)
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Unknown/inadequately described/not
stated (Z99)
Person (address)
Postcode—Australian (person)*
Suburb/town/locality name (person)*
Person
Australian state of birth
New South Wales (1)
Victoria (2)
Queensland (3)
South Australia (4)
Western Australia (5)
Tasmania (6)
Northern Territory (7)
Australian Capital Territory (8)
Other territories (Cocos (Keeling)
Islands, Christmas Island and Jervis Bay
Territory) (9)
Country of birth
Date of birth*
Indigenous status
Aboriginal but not Torres Strait Islander
origin (1)
Torres Strait Islander but not Aboriginal
origin (2)
Both Aboriginal and Torres Strait Islander
origin (3)
Neither Aboriginal nor Torres Strait
Islander origin (4)
Not stated/inadequately described (9)
Sex*
Male (1)
Female (2)
Intersex or indeterminate (3)
Not stated/inadequately described (9)
Registered health professional
Hours worked in health profession - clinical
hours
Hours worked in health profession - total
hours
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Hours worked in health profession - non-clinical
hours
Hours worked in health profession - private sector
hours
Hours worked in health profession - public sector
hours
Intended years in health profession
years
Length of employment in health profession
years
Visa type - health professional
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Registered health labour force DSS Registered osteopathy
labour force DSS Metadata Online Registry (METeOR)
Health sector data set specifications from METeOR,
Australia's repository for national metadata standards,
developed by the Australian Institute of Health and Welfare
(http://meteor.aihw.gov.au/content/index.phtml/itemId/3451
65)
Registered health labour force DSS: 
All health professionals listed with the Australian Health
Practitioner Regulation Agency (AHPRA) during the
reference period. This encompasses health professions
that require registration under the National Registration and
Accreditation Scheme and includes, but is not limited to:
·	chiropractic   
·	dentistry   
·	dental hygiene   
·	dental prosthetics   
·	dental therapy   
·	medicine   
·	midwifery   
·	nursing (enrolled, registered, practitioner)   
·	optometry   
·	osteopathy   
·	pharmacy   
·	physiotherapy   
·	podiatry   
·	psychology 
This DSS includes health professionals who are currently
registered with AHPRA and health professionals who are
no longer registered but remain listed with AHPRA.
Registered osteopathy labour force DSS:
All osteopaths listed with the Australian Health Practitioner
Regulation Agency during the reference period. Osteopaths
included in this DSS may be currently registered or they
may be listed but not currently registered.
Metadata and Classifications Unit 
Australian Institute of Health and Welfare
GPO Box 570
Canberra ACT 2601
All rights reserved. Please visit https://medical-data-
models.org/forms/17161
Registered health labour force DSS
Registered osteopathy labour force
DSS Metadata Online Registry
(METeOR)
Labour force status cluster
Country of employment in registered profession
Australia (1)
Other country (2)
Not stated/inadequately described (9)
Extended leave status in registered profession
On extended leave (3 months or more)
(1)
Not on extended leave (2)
Unknown/inadequately described (9)
Jobseeker status in registered profession
Looking for work in Australia (1)
Not looking for work in Australia (2)
Unknown/inadequately described (9)
Employment status—health professional
Employed in the registered profession (1)
Employed outside the registered
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profession (2)
Not employed (3)
Unknown/inadequately described (9)
Retirement status in registered profession
Retired (1)
Not retired (2)
Unknown/inadequately described (9)
Main job of registered osteopath cluster
Hours worked in health profession - total
hours
Principal role - health profession
Clinician (1)
Administrator (2)
Teacher/educator (3)
Researcher (4)
Other (5)
Not stated/inadequately described (9)
Work sector - health professional
Public (1)
Private (2)
Work setting - osteopath
Solo private practice (A01)
Group private practice (A02)
Locum private practice (A03)
Aboriginal health service (B00)
Community health care service (C00)
Hospital (D00)
Residential health care facility (E00)
Commercial/business service (F00)
Educational facility (G00)
Correctional services (H00)
Defence forces (I00)
Other government department or agency
(J00)
Other (Y00)
Unknown/inadequately described/not
stated (Z99)
Postcode—Australian (workplace)*
Suburb/town/locality name (workplace)*
Second job of registered osteopath cluster
Hours worked in health profession - total
hours
Principal role - health profession
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Clinician (1)
Administrator (2)
Teacher/educator (3)
Researcher (4)
Other (5)
Not stated/inadequately described (9)
Work sector - health professional
Public (1)
Private (2)
Work setting - osteopath
Solo private practice (A01)
Group private practice (A02)
Locum private practice (A03)
Aboriginal health service (B00)
Community health care service (C00)
Hospital (D00)
Residential health care facility (E00)
Commercial/business service (F00)
Educational facility (G00)
Correctional services (H00)
Defence forces (I00)
Other government department or agency
(J00)
Other (Y00)
Unknown/inadequately described/not
stated (Z99)
Postcode—Australian (workplace)*
Suburb/town/locality name (workplace)*
Work setting hours cluster
Hours worked in health profession - total
hours
Work sector - health professional
Public (1)
Private (2)
Work setting - registered health professional
Private practice (A00)
Aboriginal health service (B00)
Community health care service (C00)
Hospital (D00)
Residential health care facility (E00)
Commercial/business services (F00)
Educational facility (G00)
Correctional services (H00)
Defence forces (I00)
Other government department or agency
(J00)
Other  (Y00)
Unknown/inadequately described/not
stated (Z99)
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Registered health labour force DSS Registered osteopathy labour force
DSS Metadata Online Registry (METeOR)
Person (address)
Postcode—Australian (person)*
Suburb/town/locality name (person)*
Person
Australian state of birth
New South Wales (1)
Victoria (2)
Queensland (3)
South Australia (4)
Western Australia (5)
Tasmania (6)
Northern Territory (7)
Australian Capital Territory (8)
Other territories (Cocos (Keeling)
Islands, Christmas Island and Jervis Bay
Territory) (9)
Country of birth
Date of birth*
Indigenous status
Aboriginal but not Torres Strait Islander
origin (1)
Torres Strait Islander but not Aboriginal
origin (2)
Both Aboriginal and Torres Strait Islander
origin (3)
Neither Aboriginal nor Torres Strait
Islander origin (4)
Not stated/inadequately described (9)
Sex*
Male (1)
Female (2)
Intersex or indeterminate (3)
Not stated/inadequately described (9)
Registered health professional
Hours worked in health profession - clinical
hours
Hours worked in health profession - total
hours
Hours worked in health profession - non-clinical
hours
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Registered health labour force DSS Registered osteopathy labour force
DSS Metadata Online Registry (METeOR)
Hours worked in health profession - private sector
hours
Hours worked in health profession - public sector
hours
Intended years in health profession
years
Length of employment in health profession
years
Visa type - health professional
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Registered health labour force DSS Registered osteopathy labour force
DSS Metadata Online Registry (METeOR)
Eligibility Diabetes Mellitus, Insulin-
Dependent NCT00069628
Randomized Clinical Trial to Assess the Effectiveness of
the GlucoWatch Biographer; ODM derived from:
https://clinicaltrials.gov/show/NCT00069628
All rights reserved. Please visit https://medical-data-
models.org/forms/17162
Eligibility Diabetes Mellitus, Insulin-
Dependent NCT00069628
Inclusion Criteria
clinical diagnosis of type 1 diabetes*
Yes
No
insulin therapy (either a pump or at least 2
injections per day) for at least one year prior to
study entry*
Yes
No
hba1c between 7.0 and 11.0%*
Yes
No
stable insulin regimen for the 2 months prior to
study entry and no plans to switch the modality of
insulin administration during the next 6 months
(e.g., injection user switching to a pump, pump
user switching to injections, or the addition of
lantus [glargine] insulin)*
Yes
No
agree to comply with study requirements,
including the performance of at least 4 fingerstick
glucose checks a day using a home glucose
monitor*
Yes
No
comprehend written english*
Yes
No
female participants must not intend to become
pregnant during the next 6 months*
Yes
No
plan to remain in the area of the clinical center
during the next 6 months*
Yes
No
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Registered health labour force DSS Registered pharmacy
labour force DSS Metadata Online Registry (METeOR)
Health sector data set specifications from METeOR,
Australia's repository for national metadata standards,
developed by the Australian Institute of Health and Welfare
(http://meteor.aihw.gov.au/content/index.phtml/itemId/3451
65)
Registered health labour force DSS: 
All health professionals listed with the Australian Health
Practitioner Regulation Agency (AHPRA) during the
reference period. This encompasses health professions
that require registration under the National Registration and
Accreditation Scheme and includes, but is not limited to:
·	chiropractic   
·	dentistry   
·	dental hygiene   
·	dental prosthetics   
·	dental therapy   
·	medicine   
·	midwifery   
·	nursing (enrolled, registered, practitioner)   
·	optometry   
·	osteopathy   
·	pharmacy   
·	physiotherapy   
·	podiatry   
·	psychology 
This DSS includes health professionals who are currently
registered with AHPRA and health professionals who are
no longer registered but remain listed with AHPRA.
Registered pharmacy labour force DSS:
All pharmacists listed with the Australian Health Practitioner
Regulation Agency during the reference period.
Pharmacists included in this DSS may be currently
registered or they may be listed but not currently registered.
Metadata and Classifications Unit 
Australian Institute of Health and Welfare
GPO Box 570
Canberra ACT 2601
All rights reserved. Please visit https://medical-data-
models.org/forms/17163
Registered health labour force DSS
Registered pharmacy labour force
DSS Metadata Online Registry
(METeOR)
Labour force status cluster
Country of employment in registered profession
Australia (1)
Other country (2)
Not stated/inadequately described (9)
Extended leave status in registered profession
On extended leave (3 months or more)
(1)
Not on extended leave (2)
Unknown/inadequately described (9)
Jobseeker status in registered profession
Looking for work in Australia (1)
Not looking for work in Australia (2)
Unknown/inadequately described (9)
Employment status—health professional
Employed in the registered profession (1)
Employed outside the registered
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profession (2)
Not employed (3)
Unknown/inadequately described (9)
Retirement status in registered profession
Retired (1)
Not retired (2)
Unknown/inadequately described (9)
Main job of registered pharmacist cluster
Hours worked in health profession - total
hours
Principal role - health profession
Clinician (1)
Administrator (2)
Teacher/educator (3)
Researcher (4)
Other (5)
Not stated/inadequately described (9)
Work sector - health professional
Public (1)
Private (2)
Work setting - pharmacist
Medical centre (A04)
Other private practice (A06)
Aboriginal health service (B00)
Community health care service (C00)
Hospital (D00)
Residential health care facility (E00)
Retail pharmacy (F01)
Wholesale pharmacy (F02)
Pharmaceutics manufacturing (F03)
Other commercial/business (F05)
Educational facility (G00)
Correctional services  (H00)
Defence forces (I00)
Other government department or agency
(J00)
Other (Y00)
Unknown/inadequately described/not
stated (Z99)
Postcode—Australian (workplace)*
Suburb/town/locality name (workplace)*
Second job of registered pharmacist
cluster
Hours worked in health profession - total
hours
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Registered health labour force DSS Registered pharmacy labour force
DSS Metadata Online Registry (METeOR)
Principal role - health profession
Clinician (1)
Administrator (2)
Teacher/educator (3)
Researcher (4)
Other (5)
Not stated/inadequately described (9)
Work sector - health professional
Public (1)
Private (2)
Work setting - pharmacist
Medical centre (A04)
Other private practice (A06)
Aboriginal health service (B00)
Community health care service (C00)
Hospital (D00)
Residential health care facility (E00)
Retail pharmacy (F01)
Wholesale pharmacy (F02)
Pharmaceutics manufacturing (F03)
Other commercial/business (F05)
Educational facility (G00)
Correctional services  (H00)
Defence forces (I00)
Other government department or agency
(J00)
Other (Y00)
Unknown/inadequately described/not
stated (Z99)
Postcode—Australian (workplace)*
Suburb/town/locality name (workplace)*
Work setting hours cluster
Hours worked in health profession - total
hours
Work sector - health professional
Public (1)
Private (2)
Work setting - registered health professional
Private practice (A00)
Aboriginal health service (B00)
Community health care service (C00)
Hospital (D00)
Residential health care facility (E00)
Commercial/business services (F00)
Educational facility (G00)
Correctional services (H00)
Defence forces (I00)
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Registered health labour force DSS Registered pharmacy labour force
DSS Metadata Online Registry (METeOR)
Other government department or agency
(J00)
Other  (Y00)
Unknown/inadequately described/not
stated (Z99)
Person (address)
Postcode—Australian (person)*
Suburb/town/locality name (person)*
Person
Australian state of birth
New South Wales (1)
Victoria (2)
Queensland (3)
South Australia (4)
Western Australia (5)
Tasmania (6)
Northern Territory (7)
Australian Capital Territory (8)
Other territories (Cocos (Keeling)
Islands, Christmas Island and Jervis Bay
Territory) (9)
Country of birth
Date of birth*
Indigenous status
Aboriginal but not Torres Strait Islander
origin (1)
Torres Strait Islander but not Aboriginal
origin (2)
Both Aboriginal and Torres Strait Islander
origin (3)
Neither Aboriginal nor Torres Strait
Islander origin (4)
Not stated/inadequately described (9)
Sex*
Male (1)
Female (2)
Intersex or indeterminate (3)
Not stated/inadequately described (9)
Registered health professional
Hours worked in health profession - clinical
hours
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Registered health labour force DSS Registered pharmacy labour force
DSS Metadata Online Registry (METeOR)
Hours worked in health profession - total
hours
Hours worked in health profession - non-clinical
hours
Hours worked in health profession - private sector
hours
Hours worked in health profession - public sector
hours
Intended years in health profession
years
Length of employment in health profession
years
Visa type - health professional
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Registered health labour force DSS Registered pharmacy labour force
DSS Metadata Online Registry (METeOR)
Registered health labour force DSS Registered physiotherapy
labour force DSS Metadata Online Registry (METeOR)
Health sector data set specifications from METeOR,
Australia's repository for national metadata standards,
developed by the Australian Institute of Health and Welfare
(http://meteor.aihw.gov.au/content/index.phtml/itemId/3451
65)
Registered health labour force DSS: 
All health professionals listed with the Australian Health
Practitioner Regulation Agency (AHPRA) during the
reference period. This encompasses health professions
that require registration under the National Registration and
Accreditation Scheme and includes, but is not limited to:
·	chiropractic   
·	dentistry   
·	dental hygiene   
·	dental prosthetics   
·	dental therapy   
·	medicine   
·	midwifery   
·	nursing (enrolled, registered, practitioner)   
·	optometry   
·	osteopathy   
·	pharmacy   
·	physiotherapy   
·	podiatry   
·	psychology 
This DSS includes health professionals who are currently
registered with AHPRA and health professionals who are
no longer registered but remain listed with AHPRA.
Registered physiotherapy labour force DSS:
All physiotherapists listed with the Australian Health
Practitioner Regulation Agency during the reference period.
Physiotherapists included in this DSS may be currently
registered or they may be listed but not currently registered.
Metadata and Classifications Unit 
Australian Institute of Health and Welfare
GPO Box 570
Canberra ACT 2601
All rights reserved. Please visit https://medical-data-
models.org/forms/17164
Registered health labour force DSS
Registered physiotherapy labour
force DSS Metadata Online Registry
(METeOR)
Labour force status cluster
Country of employment in registered profession
Australia (1)
Other country (2)
Not stated/inadequately described (9)
Extended leave status in registered profession
On extended leave (3 months or more)
(1)
Not on extended leave (2)
Unknown/inadequately described (9)
Jobseeker status in registered profession
Looking for work in Australia (1)
Not looking for work in Australia (2)
Unknown/inadequately described (9)
Employment status—health professional
Employed in the registered profession (1)
Employed outside the registered
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profession (2)
Not employed (3)
Unknown/inadequately described (9)
Retirement status in registered profession
Retired (1)
Not retired (2)
Unknown/inadequately described (9)
Main job of registered physiotherapist
cluster
Hours worked in health profession - total
hours
Principal role - health profession
Clinician (1)
Administrator (2)
Teacher/educator (3)
Researcher (4)
Other (5)
Not stated/inadequately described (9)
Work sector - health professional
Public (1)
Private (2)
Work setting - physiotherapist
Solo private practice (A01)
Group private practice (A02)
Locum private practice (A03)
Aboriginal health service (B00)
Domiciliary service (C01 )
Rehabilitation/physical developmental
service (C06)
Other community health care service
(C07)
Outpatient service (D01)
Other hospital service (D02)
Residential aged care facility (E01)
Other residential health care facility
(E05)
Sports centre/clinic (F04)
Other commercial/business service (F05)
Educational facility (G00)
Correctional services  (H00)
Defence forces (I00)
Other government department or agency
(J00)
Other (Y00)
Unknown/inadequately described/not
stated (Z99)
Postcode—Australian (workplace)*
Suburb/town/locality name (workplace)*
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Registered health labour force DSS Registered physiotherapy labour
force DSS Metadata Online Registry (METeOR)
Second job of registered physiotherapist
cluster
Hours worked in health profession - total
hours
Principal role - health profession
Clinician (1)
Administrator (2)
Teacher/educator (3)
Researcher (4)
Other (5)
Not stated/inadequately described (9)
Work sector - health professional
Public (1)
Private (2)
Work setting - physiotherapist
Solo private practice (A01)
Group private practice (A02)
Locum private practice (A03)
Aboriginal health service (B00)
Domiciliary service (C01 )
Rehabilitation/physical developmental
service (C06)
Other community health care service
(C07)
Outpatient service (D01)
Other hospital service (D02)
Residential aged care facility (E01)
Other residential health care facility
(E05)
Sports centre/clinic (F04)
Other commercial/business service (F05)
Educational facility (G00)
Correctional services  (H00)
Defence forces (I00)
Other government department or agency
(J00)
Other (Y00)
Unknown/inadequately described/not
stated (Z99)
Postcode—Australian (workplace)*
Suburb/town/locality name (workplace)*
Work setting hours cluster
Hours worked in health profession - total
hours
Work sector - health professional
Public (1)
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Registered health labour force DSS Registered physiotherapy labour
force DSS Metadata Online Registry (METeOR)
Private (2)
Work setting - registered health professional
Private practice (A00)
Aboriginal health service (B00)
Community health care service (C00)
Hospital (D00)
Residential health care facility (E00)
Commercial/business services (F00)
Educational facility (G00)
Correctional services (H00)
Defence forces (I00)
Other government department or agency
(J00)
Other  (Y00)
Unknown/inadequately described/not
stated (Z99)
Person (address)
Postcode—Australian (person)*
Suburb/town/locality name (person)*
Person
Australian state of birth
New South Wales (1)
Victoria (2)
Queensland (3)
South Australia (4)
Western Australia (5)
Tasmania (6)
Northern Territory (7)
Australian Capital Territory (8)
Other territories (Cocos (Keeling)
Islands, Christmas Island and Jervis Bay
Territory) (9)
Country of birth
Date of birth*
Indigenous status
Aboriginal but not Torres Strait Islander
origin (1)
Torres Strait Islander but not Aboriginal
origin (2)
Both Aboriginal and Torres Strait Islander
origin (3)
Neither Aboriginal nor Torres Strait
Islander origin (4)
Not stated/inadequately described (9)
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Registered health labour force DSS Registered physiotherapy labour
force DSS Metadata Online Registry (METeOR)
Sex*
Male (1)
Female (2)
Intersex or indeterminate (3)
Not stated/inadequately described (9)
Registered health professional
Hours worked in health profession - clinical
hours
Hours worked in health profession - total
hours
Hours worked in health profession - non-clinical
hours
Hours worked in health profession - private sector
hours
Hours worked in health profession - public sector
hours
Intended years in health profession
years
Length of employment in health profession
years
Visa type - health professional
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Registered health labour force DSS Registered physiotherapy labour
force DSS Metadata Online Registry (METeOR)
Registered health labour force DSS Registered podiatry
labour force DSS Metadata Online Registry (METeOR)
Health sector data set specifications from METeOR,
Australia's repository for national metadata standards,
developed by the Australian Institute of Health and Welfare
(http://meteor.aihw.gov.au/content/index.phtml/itemId/3451
65)
Registered health labour force DSS: 
All health professionals listed with the Australian Health
Practitioner Regulation Agency (AHPRA) during the
reference period. This encompasses health professions
that require registration under the National Registration and
Accreditation Scheme and includes, but is not limited to:
·	chiropractic   
·	dentistry   
·	dental hygiene   
·	dental prosthetics   
·	dental therapy   
·	medicine   
·	midwifery   
·	nursing (enrolled, registered, practitioner)   
·	optometry   
·	osteopathy   
·	pharmacy   
·	physiotherapy   
·	podiatry   
·	psychology 
This DSS includes health professionals who are currently
registered with AHPRA and health professionals who are
no longer registered but remain listed with AHPRA.
Registered podiatry labour force DSS:
All podiatrists listed with the Australian Health Practitioner
Regulation Agency during the reference period. Podiatrists
included in this DSS may be currently registered or they
may be listed but not currently registered.
Metadata and Classifications Unit 
Australian Institute of Health and Welfare
GPO Box 570
Canberra ACT 2601
All rights reserved. Please visit https://medical-data-
models.org/forms/17165
Registered health labour force DSS
Registered podiatry labour force
DSS Metadata Online Registry
(METeOR)
Labour force status cluster
Country of employment in registered profession
Australia (1)
Other country (2)
Not stated/inadequately described (9)
Extended leave status in registered profession
On extended leave (3 months or more)
(1)
Not on extended leave (2)
Unknown/inadequately described (9)
Jobseeker status in registered profession
Looking for work in Australia (1)
Not looking for work in Australia (2)
Unknown/inadequately described (9)
Employment status—health professional
Employed in the registered profession (1)
Employed outside the registered
profession (2)
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Not employed (3)
Unknown/inadequately described (9)
Retirement status in registered profession
Retired (1)
Not retired (2)
Unknown/inadequately described (9)
Main job of registered podiatrist cluster
Hours worked in health profession - total
hours
Principal role - health profession
Clinician (1)
Administrator (2)
Teacher/educator (3)
Researcher (4)
Other (5)
Not stated/inadequately described (9)
Work sector - health professional
Public (1)
Private (2)
Work setting - podiatrist
Solo private practice (A01)
Group private practice (A02)
Locum private practice (A03)
Aboriginal health service (B00)
Rehabilitation/physical developmental
service (C06)
Other community health care service
(C07)
Outpatient service (D01)
Other hospital service (D02)
Residential aged care facility (E01)
Disability institution (E03)
Hospice (E04)
Other residential health care service
(E05)
Sports centre/clinic (F04)
Other commercial/business service (F05)
Educational facility (G00)
Correctional services  (H00)
Defence forces (I00)
Other government department or agency
(J00)
Other (Y00)
Unknown/inadequately described/not
stated (Z99)
Postcode—Australian (workplace)*
Suburb/town/locality name (workplace)*
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Registered health labour force DSS Registered podiatry labour force
DSS Metadata Online Registry (METeOR)
Second job of registered podiatrist cluster
Hours worked in health profession - total
hours
Principal role - health profession
Clinician (1)
Administrator (2)
Teacher/educator (3)
Researcher (4)
Other (5)
Not stated/inadequately described (9)
Work sector - health professional
Public (1)
Private (2)
Work setting - podiatrist
Solo private practice (A01)
Group private practice (A02)
Locum private practice (A03)
Aboriginal health service (B00)
Rehabilitation/physical developmental
service (C06)
Other community health care service
(C07)
Outpatient service (D01)
Other hospital service (D02)
Residential aged care facility (E01)
Disability institution (E03)
Hospice (E04)
Other residential health care service
(E05)
Sports centre/clinic (F04)
Other commercial/business service (F05)
Educational facility (G00)
Correctional services  (H00)
Defence forces (I00)
Other government department or agency
(J00)
Other (Y00)
Unknown/inadequately described/not
stated (Z99)
Postcode—Australian (workplace)*
Suburb/town/locality name (workplace)*
Work setting hours cluster
Hours worked in health profession - total
hours
Work sector - health professional
Public (1)
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Registered health labour force DSS Registered podiatry labour force
DSS Metadata Online Registry (METeOR)
Private (2)
Work setting - registered health professional
Private practice (A00)
Aboriginal health service (B00)
Community health care service (C00)
Hospital (D00)
Residential health care facility (E00)
Commercial/business services (F00)
Educational facility (G00)
Correctional services (H00)
Defence forces (I00)
Other government department or agency
(J00)
Other  (Y00)
Unknown/inadequately described/not
stated (Z99)
Person (address)
Postcode—Australian (person)*
Suburb/town/locality name (person)*
Person
Australian state of birth
New South Wales (1)
Victoria (2)
Queensland (3)
South Australia (4)
Western Australia (5)
Tasmania (6)
Northern Territory (7)
Australian Capital Territory (8)
Other territories (Cocos (Keeling)
Islands, Christmas Island and Jervis Bay
Territory) (9)
Country of birth
Date of birth*
Indigenous status
Aboriginal but not Torres Strait Islander
origin (1)
Torres Strait Islander but not Aboriginal
origin (2)
Both Aboriginal and Torres Strait Islander
origin (3)
Neither Aboriginal nor Torres Strait
Islander origin (4)
Not stated/inadequately described (9)
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Registered health labour force DSS Registered podiatry labour force
DSS Metadata Online Registry (METeOR)
Sex*
Male (1)
Female (2)
Intersex or indeterminate (3)
Not stated/inadequately described (9)
Registered health professional
Hours worked in health profession - clinical
hours
Hours worked in health profession - total
hours
Hours worked in health profession - non-clinical
hours
Hours worked in health profession - private sector
hours
Hours worked in health profession - public sector
hours
Intended years in health profession
years
Length of employment in health profession
years
Visa type - health professional
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Registered health labour force DSS Registered podiatry labour force
DSS Metadata Online Registry (METeOR)
Registered health labour force DSS Registered psychology
labour force DSS Metadata Online Registry (METeOR)
Health sector data set specifications from METeOR,
Australia's repository for national metadata standards,
developed by the Australian Institute of Health and Welfare
(http://meteor.aihw.gov.au/content/index.phtml/itemId/3451
65)
Registered health labour force DSS: 
All health professionals listed with the Australian Health
Practitioner Regulation Agency (AHPRA) during the
reference period. This encompasses health professions
that require registration under the National Registration and
Accreditation Scheme and includes, but is not limited to:
·	chiropractic   
·	dentistry   
·	dental hygiene   
·	dental prosthetics   
·	dental therapy   
·	medicine   
·	midwifery   
·	nursing (enrolled, registered, practitioner)   
·	optometry   
·	osteopathy   
·	pharmacy   
·	physiotherapy   
·	podiatry   
·	psychology 
This DSS includes health professionals who are currently
registered with AHPRA and health professionals who are
no longer registered but remain listed with AHPRA.
Registered psychology labour force DSS:
All psychologists listed with the Australian Health
Practitioner Regulation Agency during the reference period.
Psychologists included in this DSS may be currently
registered or they may be listed but not currently registered.
Metadata and Classifications Unit 
Australian Institute of Health and Welfare
GPO Box 570
Canberra ACT 2601
All rights reserved. Please visit https://medical-data-
models.org/forms/17166
Registered health labour force DSS
Registered psychology labour force
DSS Metadata Online Registry
(METeOR)
Labour force status cluster
Country of employment in registered profession
Australia (1)
Other country (2)
Not stated/inadequately described (9)
Extended leave status in registered profession
On extended leave (3 months or more)
(1)
Not on extended leave (2)
Unknown/inadequately described (9)
Jobseeker status in registered profession
Looking for work in Australia (1)
Not looking for work in Australia (2)
Unknown/inadequately described (9)
Employment status—health professional
Employed in the registered profession (1)
Employed outside the registered
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profession (2)
Not employed (3)
Unknown/inadequately described (9)
Retirement status in registered profession
Retired (1)
Not retired (2)
Unknown/inadequately described (9)
Main job of registered psychologist cluster
Hours worked in health profession - total
hours
Area of practice - psychology
Assessment (01)
Psychological intervention (02)
Community psychology (03)
Management/Administration (04)
Organisational psychology (05)
Research (06)
Teaching/supervision (07)
Not stated/inadequately described (99)
Principal role - health profession
Clinician (1)
Administrator (2)
Teacher/educator (3)
Researcher (4)
Other (5)
Not stated/inadequately described (9)
Work sector - health professional
Public (1)
Private (2)
Work setting - psychologist
Solo private practice (A01)
Group private practice (A02)
General practitioner (GP) practice (A05)
Other private practice (A06)
Aboriginal health service (B00)
Community mental health service (C02)
Drug and alcohol service (C04)
Rehabilitation/physical developmental
service (C06)
Other community health care service
(C07)
Hospital (D00)
Disability institution (E03)
Other residential health care facility
(E05)
Commercial/business service (F05)
Tertiary educational facility (G01)
School (G02)
Other educational facility (G03)
Correctional services (H00)
Defence forces (I00)
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Registered health labour force DSS Registered psychology labour force
DSS Metadata Online Registry (METeOR)
Other government department or agency
(J00)
Other (Y00)
Unknown/inadequately described/not
stated (Z99)
Postcode—Australian (workplace)*
Suburb/town/locality name (workplace)*
Second job of registered psychologist
cluster
Hours worked in health profession - total
hours
Area of practice - psychology
Assessment (01)
Psychological intervention (02)
Community psychology (03)
Management/Administration (04)
Organisational psychology (05)
Research (06)
Teaching/supervision (07)
Not stated/inadequately described (99)
Principal role - health profession
Clinician (1)
Administrator (2)
Teacher/educator (3)
Researcher (4)
Other (5)
Not stated/inadequately described (9)
Work sector - health professional
Public (1)
Private (2)
Work setting - psychologist
Solo private practice (A01)
Group private practice (A02)
General practitioner (GP) practice (A05)
Other private practice (A06)
Aboriginal health service (B00)
Community mental health service (C02)
Drug and alcohol service (C04)
Rehabilitation/physical developmental
service (C06)
Other community health care service
(C07)
Hospital (D00)
Disability institution (E03)
Other residential health care facility
(E05)
Commercial/business service (F05)
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Registered health labour force DSS Registered psychology labour force
DSS Metadata Online Registry (METeOR)
Tertiary educational facility (G01)
School (G02)
Other educational facility (G03)
Correctional services (H00)
Defence forces (I00)
Other government department or agency
(J00)
Other (Y00)
Unknown/inadequately described/not
stated (Z99)
Postcode—Australian (workplace)*
Suburb/town/locality name (workplace)*
Work setting hours cluster
Hours worked in health profession - total
hours
Work sector - health professional
Public (1)
Private (2)
Work setting - registered health professional
Private practice (A00)
Aboriginal health service (B00)
Community health care service (C00)
Hospital (D00)
Residential health care facility (E00)
Commercial/business services (F00)
Educational facility (G00)
Correctional services (H00)
Defence forces (I00)
Other government department or agency
(J00)
Other  (Y00)
Unknown/inadequately described/not
stated (Z99)
Person (address)
Postcode—Australian (person)*
Suburb/town/locality name (person)*
Person
Australian state of birth
New South Wales (1)
Victoria (2)
Queensland (3)
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Registered health labour force DSS Registered psychology labour force
DSS Metadata Online Registry (METeOR)
South Australia (4)
Western Australia (5)
Tasmania (6)
Northern Territory (7)
Australian Capital Territory (8)
Other territories (Cocos (Keeling)
Islands, Christmas Island and Jervis Bay
Territory) (9)
Country of birth
Date of birth*
Indigenous status
Aboriginal but not Torres Strait Islander
origin (1)
Torres Strait Islander but not Aboriginal
origin (2)
Both Aboriginal and Torres Strait Islander
origin (3)
Neither Aboriginal nor Torres Strait
Islander origin (4)
Not stated/inadequately described (9)
Sex*
Male (1)
Female (2)
Intersex or indeterminate (3)
Not stated/inadequately described (9)
Registered health professional
Hours worked in health profession - clinical
hours
Hours worked in health profession - total
hours
Hours worked in health profession - non-clinical
hours
Hours worked in health profession - private sector
hours
Hours worked in health profession - public sector
hours
Intended years in health profession
years
Length of employment in health profession
years
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DSS Metadata Online Registry (METeOR)
Visa type - health professional
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DSS Metadata Online Registry (METeOR)
Eligibility Diabetes Mellitus, Type 1
NCT00063128
Safety and Efficacy of Human Insulin Inhalation Powder in
Patients With Type 1 Diabetes Mellitus.; ODM derived from:
https://clinicaltrials.gov/show/NCT00063128
All rights reserved. Please visit https://medical-data-
models.org/forms/17167
Eligibility Diabetes Mellitus, Type 1
NCT00063128
Inclusion Criteria
you are at least 18 years old.*
Yes
No
you have had type 1 diabetes for at least 2
years.*
Yes
No
you are injecting insulin lispro (humalog), an
insulin lispro mixture (humalog mixture), regular
human insulin mixture (humulin mixture) before
meals using a syringe or injection pen, not an
insulin pump.*
Yes
No
if you are female and could become pregnant,
you test negative for pregnancy based on blood
test at the beginning of the study, do not intend to
become pregnant, and agree to use a form of
birth control approved by the investigator during
the study.*
Yes
No
you have not smoked for at least 1 year, and you
agree not to smoke or use smokeless tobacco
during the study.*
Yes
No
Exclusion Criteria
you have used an experimental drug during the
last 30 days or have ever taken part in a study of
any type of inhaled insulin.*
Yes
No
you have a history of asthma or allergies.*
Yes
No
you have a chronic cough.*
Yes
No
you have had a kidney transplant, are on dialysis,
or have poor kidney function.*
Yes
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No
you have a history of chest pain, heart attack, or
you have a heart condition that limits your
physical activity due to discomfort.*
Yes
No
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Eligibility Osteoarthritis NCT00612248
Functional Splint for Osteoarthritis of the
Trapeziometacarpal Joint; ODM derived from:
https://clinicaltrials.gov/show/NCT00612248
All rights reserved. Please visit https://medical-data-
models.org/forms/17168
Eligibility Osteoarthritis
NCT00612248
Inclusion Criteria
clinical and radiological diagnosis of idiopathic
grade ii and iii oa of the tmc joint on the dominant
hand;*
Yes
No
either gender;*
Yes
No
over 40 years of age;*
Yes
No
pain in the base of the thumb of the dominant
hand greater than three and less than or equal to
seven on the 0 to 10-cm visual analogue scale
(vas) for pain.*
Yes
No
Exclusion Criteria
severe deformities of the dominant hand that did
not allow gripping between the first, second and
third fingers;*
Yes
No
deformities of distal interphalangeal joint;*
Yes
No
use of a splint on the thumb in the previous six
months;*
Yes
No
surgery on the hand under study in the previous
six months or scheduled in the upcoming six
months;*
Yes
No
allergy to the splint material;*
Yes
No
incapacity to respond to the questionnaire and
perform the tests;*
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Yes
No
geographic inaccessibility;*
Yes
No
injections in the hand under study in the previous
six months;*
Yes
No
other associated diseases such as carpal tunnel
syndrome, fractures in the carpus, tendonitis,
chronic inflammatory arthropathy;*
Yes
No
alterations in the use of anti-inflammatory
medication and analgesics in the previous three
months.*
Yes
No
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Eligibility Osteoarthritis, Knee
NCT00279903
Is Botox Effective in Relieving Pain From Knee
Osteoarthritis?; ODM derived from:
https://clinicaltrials.gov/show/NCT00279903
All rights reserved. Please visit https://medical-data-
models.org/forms/17169
Eligibility Osteoarthritis, Knee
NCT00279903
Inclusion Criteria
1. a history of knee joint pain for greater than 6
months.*
Yes
No
2. medial or lateral tibiofemoral joint line
tenderness.*
Yes
No
3. unilateral knee pain 6/10 or greater, on
average, on the visual analog scale (vas), that
interferes with function most days per week.*
Yes
No
4. prior failed treatment with acetaminophen
and/or non steroidal anti-inflammatory
medications, and physical therapy (quadriceps
strengthening).*
Yes
No
5. kellgren grade ii or iii radiographic changes of
osteoarthritis.*
Yes
No
Exclusion Criteria
1. age less than 40 years.*
Yes
No
2. anticoagulation with warfarin or heparin.*
Yes
No
3. known allergy or sensitivity to any of the
components of the study medications.*
Yes
No
4. body mass index greater than 35.*
Yes
No
5. previous major reconstructive surgery on the
affected knee.*
Yes
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No
6. previous arthroscopic surgery on the affected
knee in the past 12 months.*
Yes
No
7. history of crystal induced arthropathy.*
Yes
No
8. use of aminoglycoside antibiotics, curare-like
agents, or history of neuromuscular disease such
as myasthenia gravis, amyotrophic lateral
sclerosis, or myopathy.*
Yes
No
9. history of or evidence of active rheumatologic
disease, diabetes, severe peripheral neuropathy,
clinically evident cardiac or respiratory disease
that interferes with functional status, or other
serious diseases, including psychiatric
disorders.*
Yes
No
10. evidence of recent alcohol or drug abuse, or
history of medication misuse or addiction.*
Yes
No
11. females who are pregnant, breastfeeding, or
planning a pregnancy during the study, or who
think that they may be pregnant at the start of the
study, or females of childbearing potential who
are unable or unwilling to use a reliable form of
contraception during the study.*
Yes
No
12. intra-articular (knee) or systemic steroids in
the past 6 months, or intra-articular knee
hyaluronic acid injection in the past 6 months.*
Yes
No
13. patients who rate their average daily pain as
less than 6 on a 10 point vas scale at the
screening visit.*
Yes
No
14. concurrent participation in another
investigational drug or device study or
participation in the 30 days immediately prior to
study enrollment.*
Yes
No
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Eligibility Parkinson's Disease
NCT00260793
Open Label High Dose Ropinirole (Requip) Study for
Patients With Parkinson's Disease; ODM derived from:
https://clinicaltrials.gov/show/NCT00260793
All rights reserved. Please visit https://medical-data-
models.org/forms/17170
Eligibility Parkinson's Disease
NCT00260793
Inclusion Criteria
patients must give written informed consent prior
to any specific study procedures.*
Yes
No
males or females; females of childbearing age
who are not currently pregnant must agree to use
a medically accepted method of contraception
throughout the study.*
Yes
No
age greater than or equal to 25 years.*
Yes
No
patients must be on a maximum dose of
dopamine agonist drug (pergolide 4mg/day,
pramipexole 4.5 mg/day or ropinirole 24mg/day).*
Yes
No
stable dose of all medications for 4 weeks.*
Yes
No
Exclusion Criteria
current hallucinations.*
Yes
No
history of disabling hallucinations or
hallucinations in past requiring treatment.*
Yes
No
troublesome edema (swelling).*
Yes
No
unstable depression.*
Yes
No
female who is pregnant or lactating.*
Yes
No
use of an investigational drug with in the last 30
days.*
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Yes
No
other inclusion or exclusion criteria to be
evaluated by the physician.*
Yes
No
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Eligibility Parkinson's Disease
NCT00375778
Parkinson's Disease Evaluated by PET and the Effect of
Memantine; ODM derived from:
https://clinicaltrials.gov/show/NCT00375778
All rights reserved. Please visit https://medical-data-
models.org/forms/17171
Eligibility Parkinson's Disease
NCT00375778
Inclusion Criteria
parkinson's disease (british brain bank criteria)*
Yes
No
age 50-70y*
Yes
No
Exclusion Criteria
tobacco use*
Yes
No
any serious medical conditions (heart disease,
kidney disease, liver disease, endocrinological
disorders etc)*
Yes
No
metal implants contraindicating mr scan*
Yes
No
drug use affecting the central nervous system*
Yes
No
psychiatric disorders*
Yes
No
head trauma or any disorders of the head, skull
or brain*
Yes
No
drug addiction or use of any kind of illegal
substance affecting the central nervous system*
Yes
No
pregnancy*
Yes
No
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Formulare für die vertragsärztliche Versorgung Freigabe
durch Dezernat 4 - Ärztliche Leistungen und
Versorgungsstruktur Geschäftsbereich Sicherstellung und
Versorgungsstruktur Abteilung Sicherstellung Herbert-
Lewin-Platz 2 10623 Berlin Tel: + 49 (0) 30 - 4005 -1418
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medical care Released by Department 4 - Medical
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(0) 30 - 4005 - 271418 Email: SJohn@KBV.de Web:
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All rights reserved. Please visit https://medical-data-
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Application for psychodynamic or
analytic psychotherapy with children
and adolescents-Report to the
expert
Versicherungsdaten
Name und Adresse des Therapeuten (lt Stempel)
KV-Abrechnungsnummer des Therapeuten
Krankenversicherung: Name und Anschrift
Chiffre des Patienten
Art des Berichts
KZT-Antrag (PT 3/KZT[K]) (1)
zum Erst- bzw Umwandlungsantrag/LZT
(PT 3a [K]) (2)
zum Fortführungsantrag (PT 3b [K]) (3)
Ergänzungsbericht (PT 3c [K]) (4)
Patientendaten
Alter in Jahren und Monaten
Geschlecht
männlich (M)
weiblich (W)
Geschwisteranzahl
Position
Erlernter Beruf
Zuletzt ausgeübte Tätigkeit
Schulform
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Klasse
Schulabschluß
Patient lebt bei/in
Eltern (1)
Großeltern (2)
Internat (3)
andere (4)
Patient lebt bei/in: bitte "andere" genauer
angeben
Alter der Eltern
Beruf der Eltern
Antrag: Art der Therapie
Anzahl beantragter Sitzungen
Behandlungsfrequenz pro Woche
Therapieform
Tiefenpsychologisch fundierte
Psychotherapie (1)
Analytische Psychotherapie (2)
Therapieform:Tiefenpsychologisch fundierte
Psychotherapie
Kurztherapie (1)
Fokaltherapie (2)
Dynamische Psychotherapie (3)
Niederfrequente Therapie (4)
Therapieform:Tiefenpsychologisch fundierte
Psychotherapie
als Einzeltherapie (1)
als Gruppentherapie (2)
als Kombination von Einzel und
Gruppentherapie (nur bei
niederfrequenter Therapie) (3)
Tiefenpsychologisch fundierte Gruppentherapie:
Anzahl Teilnehmer
Therapieform:Analytische Psychotherapie
als Einzeltherapie (1)
als Gruppentherapie (2)
Analytische Psychotherapie- Gruppentherapie:
Anzahl Teilnehmer
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Eligibility Diabetes Mellitus, Type 1
NCT00105352
Improving Metabolic Assessments in Type 1 Diabetes
Mellitus Clinical Trials; ODM derived from:
https://clinicaltrials.gov/show/NCT00105352
All rights reserved. Please visit https://medical-data-
models.org/forms/17173
Eligibility Diabetes Mellitus, Type 1
NCT00105352
Criteria
age 8 - 35 years at the time of inclusion*
Yes
No
body weight > 30 kg*
Yes
No
type 1 diabetes defined by: ada (american
diabetes association) criteria or judgment of
physician*
Yes
No
duration of diabetes: 1 month to 3* years (*the
trialnet coordinating center will monitor fasting c-
peptide levels as they are reported to ensure that
a wide range of values is included.  this review
may result in widening the duration of diabetes
window to allow for subjects with low c-peptide).*
Yes
No
must maintain good glycemic control*
Yes
No
be willing to travel to a trialnet clinical center for a
minimum of four separate visits that are spaced
3-10 days apart, and be willing to complete the
study within a six week period.*
Yes
No
Exclusion Criteria
actual treatment with drugs influencing beta cell
function (e.g. oral hypoglycaemic agents, beta-2-
receptor agonists)*
Yes
No
actual treatment with drugs influencing insulin
sensitivity (e.g. steroids)*
Yes
No
significant concomitant disease likely to interfere
with glucose metabolism (e.g. febrile illness
within the prior 3 days)*
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Yes
No
expected poor compliance*
Yes
No
if a female of child-bearing age, currently
pregnant or not using a form of birth control*
Yes
No
any other condition that by the judgement of the
investigator may be potentially harmful to the
patients*
Yes
No
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Eligibility Diabetes Mellitus, Type 1
NCT00290979
Efficacy and Safety of Insulin Glulisine in Type 1 Diabetes
Mellitus; ODM derived from:
https://clinicaltrials.gov/show/NCT00290979
All rights reserved. Please visit https://medical-data-
models.org/forms/17174
Eligibility Diabetes Mellitus, Type 1
NCT00290979
Inclusion Criteria
men or women with type 1 diabetes mellitus, an
hba1c range of >=6.0 - =<11.0%, and on a basal-
bolus insulin regimen. they must have had at
least 1 year of continuous insulin treatment at the
date of informed consent.*
Yes
No
Exclusion Criteria
subjects who received an oral hypoglycemic
agent other than insulin within 4 weeks prior to
informed consent*
Yes
No
subjects who received oral or intravenous
corticosteroid within 4 weeks prior to informed
consent*
Yes
No
subjects who were treated with another
investigational product within 12 weeks prior to
informed consent*
Yes
No
subjects with likelihood of requiring concomitant
treatment during the study period with drugs not
permitted by this study protocol*
Yes
No
subjects with clinically relevant cardiovascular,
hepatic, neurologic, endocrine, active cancer,
other serious complication or systemic disease
making implementation of the protocol or
interpretation of the study results difficult*
Yes
No
subjects who have undergone pancreatectomy or
pancreas/islet cell transplant*
Yes
No
night shift workers*
Yes
No
subjects unlikely to comply with the study
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protocol, e.g., inability to periodic return for
follow-up visits, and unlikelihood of completing
the study*
Yes
No
subjects who have previously been treated with
hmr1964*
Yes
No
subjects who are pregnant, breast feeding or
wish to become pregnant during the study
period*
Yes
No
female subjects who are possibly pregnant
[female subjects of reproductive potential who
have serum human chorionic gonadotropin (hcg)
level > 0.7 miu/ml as determined by central
laboratory, srl medisearch inc., during screening
phase]*
Yes
No
subjects with diabetic retinopathy who received
surgical treatments (laser photocoagulation or
vitrectomy) within 24 weeks prior to informed
consent, or who are expected to have these
surgical treatments during the study period*
Yes
No
subjects with history of alcohol abuse*
Yes
No
subjects with hypersensitivity to insulin
preparations*
Yes
No
subjects with impaired hepatic function (sgot or
sgpt ³=<80 iu/l determined by central laboratory,
srl medisearch inc., during screening phase) or
impaired renal function (serum creatinine =<2.0
mg/dl determined by central laboratory, srl
medisearch inc., during screening phase)*
Yes
No
subjects who are judged by the investigator or
subinvestigator as inappropriate as the subjects
of this study for any other reason*
Yes
No
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Eligibility Diabetes Mellitus, Type 2
NCT00086502
Pioglitazone Add-on Study in Patients With Type 2 Diabetes
Mellitus; ODM derived from:
https://clinicaltrials.gov/show/NCT00086502
All rights reserved. Please visit https://medical-data-
models.org/forms/17176
Eligibility Diabetes Mellitus, Type 2
NCT00086502
Inclusion Criteria
patient has type 2 diabetes mellitus (t2dm)*
Yes
No
patient is 18 years of age (or older)*
Yes
No
patient is not pregnant or breast-feeding and
does not plan to become pregnant for the
duration of the study and poststudy follow-up
period*
Yes
No
Exclusion Criteria
patient has a history of type 1 diabetes mellitus or
a history of ketoacidosis*
Yes
No
patient required insulin within the prior 8 weeks*
Yes
No
patient is on a weight loss program and is not in
the maintenance phase*
Yes
No
patient started on a weight loss medication (e.g.,
orlistat or sibutramine) within the prior 8 weeks*
Yes
No
patient is on or likely to require treatment with
treatment with immunosuppressive agents (e.g.,
cyclosporin, methotrexate)*
Yes
No
patient has cirrhosis, active liver disease (other
than fatty liver) or symptomatic gallbladder
disease*
Yes
No
patient has chronic myopathy, or a progressive
neurological or neuromuscular disorder (e.g.,
multiple sclerosis or polymyositis)*
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Yes
No
patient has any of the following disorders within
the past 6 months:*
Yes
No
acute coronary syndrome (e.g., mi or unstable
angina), coronary artery intervention, stroke or
transient ischemic neurological disorder.*
Yes
No
patient has new or worsening signs or symptoms
of coronary heart disease within the past 3
months*
Yes
No
patient has severe peripheral vascular disease*
Yes
No
patient has congestive heart failure*
Yes
No
patient is hiv positive*
Yes
No
patient has a clinically important hematological
disorder (e.g., aplastic anemia, myeloproliferative
or myelodysplastic syndromes,
thrombocytopenia)*
Yes
No
patient has a history of neoplastic disease*
Yes
No
patient has a history of alcohol or drug abuse
within the past 3 years*
Yes
No
patient has viral hepatitis (hepatitis b or c)*
Yes
No
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Eligibility Prostate Cancer NCT00499421
Evaluation of Intraprostatic Fiducial Markers For External
Beam Radiation Therapy; ODM derived from:
https://clinicaltrials.gov/show/NCT00499421
All rights reserved. Please visit https://medical-data-
models.org/forms/17177
Eligibility Prostate Cancer
NCT00499421
Inclusion Criteria
1. patients with pathologic diagnosis of prostate
cancer.*
Yes
No
2. patients must plan to have external beam
radiation as the definitive treatment for their
prostate cancer with daily localization.*
Yes
No
3. patients must be able to tolerate transrectal or
transperineal implantation of three fiducial
markers into the prostate.*
Yes
No
4. patients must be able to tolerate frequent (e.g.
three ct scans per week) ct scanning.*
Yes
No
5. patients must be able to lie flat and still for the
duration of the fiducial-based localization and ct
scanning sessions.*
Yes
No
6. patients must have anatomy that will allow an
adequate pelvic image on portal imaging and ct
scanning.*
Yes
No
7. if patients received hormone therapy, then it
must have started more than 8 weeks prior to
implantation of fiducials.*
Yes
No
8. patients on hormonal therapy at the time of
simulation must remain on hormone therapy until
their radiation course is complete.*
Yes
No
9. patients must understand and sign informed
consent.*
Yes
No
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Exclusion Criteria
1. patients who are not candidates for trans-rectal
prostate biopsy or cannot tolerate placement of
three fiducial prostate markers.*
Yes
No
2. patients with an estimated prostate volume of
less than 20 cc.*
Yes
No
3. patients who have had prior prostate surgery
or are planned to have prostate surgery for
prostate cancer.*
Yes
No
4. patients who have had previous radiation
therapy to the pelvis.*
Yes
No
5. patients who have had prior prostate
brachytherapy implant or who have a planned
course of therapy using prostate brachytherapy
(permanent seeds or high dose rate).*
Yes
No
6. patients with a body habitus that the ct bore of
the ct/linac treatment machine cannot
accommodate (i.e. height greater than 6' 3" or
body weight greater than 300 pounds).*
Yes
No
7. patients on anticoagulant medication (e.g.,
coumadin, clopidogrel, low-molecular weight
heparin) other than aspirin will not be eligible.
patients on aspirin should discontinue aspirin 7
days prior to fiducial placement and for 5 days
afterward.*
Yes
No
8. patients with hip prostheses will not be
eligible.*
Yes
No
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Baseline Phone Follow up Cardiovascular
Health Study (CHS)
Documentation part: Record 31 Baseline Phone Follow up
The Cardiovascular Health Study (CHS) was initiated by
the National Heart, Lung and Blood Institute (NHLBI) in
1987 to determine the risk factors for development and
progression of cardiovascular disease (CVD) in older
adults, with an emphasis on subclinical measures. The
study recruited 5,888 adults aged 65 or older at entry in
four U.S. communities and conducted extensive annual
clinical exams between 1989-1999 along with semi-annual
phone calls, events adjudication, and subsequent data
analyses and publications. Additional data were collected
by studies ancillary to CHS. With the exception of annual
clinic visits, these activities are still ongoing. 
Data obtained from: https://chs-nhlbi.org/ Permission
granted by: Erika Enright.
All rights reserved. Please visit https://medical-data-
models.org/forms/17178
Baseline Phone Follow up
Cardiovascular Health Study (CHS)
Surveillance telephone interview
1 Hello, this is [your name] from the
Cardiovascular Health Study. May I speak with
[participant]
participant answers (participant answers)
participant deceased (participant
deceased)
participant not in (participant not in)
Can you tell me when I should call for the
interview?
2 Did you receive our letter?
Yes
No
Interview:
interview started (interview started)
participant refuses interview (participant
refuses interview)
participant wants to reschedule interview
(participant wants to reschedule
interview)
Interview started time:
Reason:
Participant wants to reschedule interview:
4 Has the participant moved during the last six
month?
excellent? (excellent?)
fair? (fair?)
good? (good?)
poor? (poor?)
refused/don't know (refused/don't know)
very good? (very good?)
Did you move during the last month?
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no (0)
yes (1)
unknown (9)
5 I would like to ask you some questions that we
also asked you 6 months ago. The reason for
asking them again is that we are interested in
possible changes that might have occurred.
Would you say, in general, your health is:
excellent? (excellent?)
fair? (fair?)
good? (good?)
poor? (poor?)
refused/don't know (refused/don't know)
very good? (very good?)
6 How would you say your health compares to
other persons of your age? Would you say your
health is:
Better than others of your age? (1)
About the same as others your age? (2)
Worse than others your age? (3)
Don´t know (9)
7 How does your to when we saw you in [month]?
Would you say your health is?
about the same (about the same)
better (better)
don't know (don't know)
worse (worse)
8 During the past two weeks, how many days
have you stayed in bed all or most of the day
because of illness or injury? Do not include past
days in a hospital or nursing home?
>= 0
<= 14
days
9 What illness caused you to stay in bed?
arthritis (arthritis)
cancer (cancer)
cold or flu (cold or flu)
diabetes (diabetes)
don't know (don't know)
general fatique or weakness (incl. old
age) (general fatique or weakness (incl.
old age))
heart attack/heart failure (heart
attack/heart failure)
injury (injury)
lung disease or emphysema, bronchitis
(lung disease or emphysema, bronchitis)
mental illness (mental illness)
other (other)
stroke (stroke)
10 Now I would like to find out if you had any
major changes in your health since we saw you in
[month]. Have you been told by a physician that
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you had: HEART FAILURE OR CONGESTIVE
HEART FAILURE
Yes
No
Physician:
Physician address
Phone
Stroke or cerebrovascular accident
Yes
No
Physician:
Physician address
Phone
Transient ischemic attack or TIA or silent stroke
Yes
No
Physician:
Physician address
Phone
Myocardial infarction or heart attack
Yes
No
Physician:
Physician address
Phone
Angina pectoris or chest pain due to heart
disease
Yes
No
Physician:
Physician address
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Phone
Intermittent claudication or pain in your legs from
a blockage of the arteries
Yes
No
Physician:
Physician address
Phone
11 Have you stayed overnight as a patient in a
hospital since we saw you in [month].
Yes
No
13 Have you stayed overnight as a patient in a
nursing home or rehabilitation center since
[month]?
Yes
No
15 I am now going to ask you about a number of
events that commonly happen in peoples's lives
and tha can affect your health. In some cases, I
will ask whether the event has happened to you
or a member of your familiy during the past 6
months. In other cases, I will ask only whether it
happened to you. When I ask a question about
your spouse, I am referring to both married
spouses and unmarried partners who live
together. Please respond YES if the event
happened and NO if it didn't.
Have you retired or changed or lost your job since
we saw you in [month]?
no (0)
yes (1)
unknown (9)
When did this happen?
don't know (don't know)
during last month (during last month)
not during the last month (not during the
last month)
Was this job change, loss or retirement positive
or negative?
don't know (don't know)
neg (neg)
pos (pos)
16 Have you had a grandchild born since we saw
you in [month]?
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no (0)
yes (1)
unknown (9)
17 Has caring for a sick or disabled relative
become a significant problem for you since we
saw you in [month]?
no (0)
yes (1)
unknown (9)
Has providing care become significantly harder
than last month?
no (0)
yes (1)
unknown (9)
18 Has there been a significant change in your
personal finances since we saw you in [month]?
no (0)
yes (1)
unknown (9)
When did this happen?
don't know (don't know)
during last month (during last month)
not during the last month (not during the
last month)
Was this change positive or negative?
don't know (don't know)
neg (neg)
pos (pos)
19 Did you or a very close friend or close family
member have a serious accident or illness since
we saw you in [month]?
no (0)
yes (1)
unknown (9)
When did this accident or illness occur?
don't know (don't know)
during last month (during last month)
not during the last month (not during the
last month)
20 Have you, your spouse or partner, or a
member of your immediate family been assaulted
or robbed since we saw you in [month]?
no (0)
yes (1)
unknown (9)
When did this assault or robbery happen?
don't know (don't know)
during last month (during last month)
not during the last month (not during the
last month)
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21 Have you had any important relationship, for
example with your spouse or a good friend,
become significantly worse since we saw you in
[month]?
no (0)
yes (1)
unknown (9)
When did this relationship worsen?
don't know (don't know)
during last month (during last month)
not during the last month (not during the
last month)
22 Did someone you were close to die since we
saw you in [month]?
no (0)
yes (1)
unknown (9)
When did this person die?
no (0)
yes (1)
unknown (9)
23 Have any other important things happened to
you or your spouse or partner since [month] that
made this period significantly different from the
previous six months?
no (0)
yes (1)
unknown (9)
What happened?
Was it positive or negative?
don't know (don't know)
neg (neg)
pos (pos)
25 You previously provided us with information
about someone who could provide information
and answer questions for you in the event that
you were unable to answer yourself. Please tell
me if the information I have is still correct.
Yes
No
26 You previously provided us with information
about friends or relatives who you are likely to
keep in touch with, but who do not live with you,
and who are not planning to move anytime soon.
Please tell me if the information I have is still
correct.
Yes
No
27 Do you plan to be out of the area 6 months
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from now?
Yes
No
Are you moving out of the area permanently or
will you only be gone temporarily?
permanently (permanently)
temporarily out of the area (vacation,
business, etc.) (temporarily out of the
area (vacation, business, etc.))
Do you know what your new address and
telephone number will be?
Yes
No
Street:
City
State
Telephone number
Do you know which general area you will be
moving to?
When will you return?
mo/yr
29 Time interview ended:
30 May I please speak with [name]?
Not in (Not in)
Can you tell me when I should call [participant] to
make the interview?
Hospitalizatiuon
Name, city and state of the hospital
12 Please tell me the reason you were admitted,
the name and location of the hospital, and the
month and year you were a patient for each time
you stayed overnight in a hospital.
Mo/Yr
mo/yr
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Nursing home admission
14 Please tell me the reason you were admitted,
the name and location of the nursing home, and
the month and year you were a patient for each
time you stayed overnight in a nursing home or
rehabilitation center. 
Reason for nursing home admission
Name, city and state of nursing home
Mo/Yr
mo/yr
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Eligibility Diabetes Mellitus, Type 2
NCT00087516
Monotherapy Study in Patients With Type 2 Diabetes
Mellitus (0431-021); ODM derived from:
https://clinicaltrials.gov/show/NCT00087516
All rights reserved. Please visit https://medical-data-
models.org/forms/17179
Eligibility Diabetes Mellitus, Type 2
NCT00087516
Inclusion Criteria
patients with type 2 diabetes mellitus*
Yes
No
patient is not pregnant or breastfeeding*
Yes
No
male or female patient unlikely to conceive*
Yes
No
patient not on an antihyperglycemic drug*
Yes
No
Exclusion Criteria
patient has history of type 1 diabetes mellitus*
Yes
No
patient has history of ketoacidosis*
Yes
No
patient requires insulin within 8 weeks prior to
start of study*
Yes
No
patient on weight loss program and is not in
maintenance phase*
Yes
No
patient taking weight loss medication within 8
weeks prior to start of study*
Yes
No
patient on or likely to require = 14 days or
repeated courses of corticosteroids*
Yes
No
patient taking
immunosuppressive/immunomodulating
medication*
Yes
No
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patient taking digoxin or other cardiac
medication*
Yes
No
patient has undergone surgical general
anesthesia within 30 days prior to start of study*
Yes
No
patient taking investigational drug within 8 weeks
prior to start of study*
Yes
No
patient is diagnosed with liver disease*
Yes
No
patient has chronic myopathy, progressive
neurological/neuromuscular disorder*
Yes
No
patient has with severe cardiac conditions within
the last 6 months*
Yes
No
patient is human immunodeficiency virus (hiv)
positive*
Yes
No
patient has hematological disorder*
Yes
No
patient has history of malignancy*
Yes
No
patient has history of alcohol or drug abuse within
the past 3 years*
Yes
No
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Eligibility Prostate Cancer NCT00607932
Brassica Vegetables or Indole-3-Carbinol in Treating
Patients With PSA Recurrence After Surgery for Prostate
Cancer; ODM derived from:
https://clinicaltrials.gov/show/NCT00607932
All rights reserved. Please visit https://medical-data-
models.org/forms/17180
Eligibility Prostate Cancer
NCT00607932
Inclusion Criteria
diagnosis of prostate cancer with psa recurrence
after prostatectomy*
Yes
No
psa recurrence is defined as two consecutively
rising psa tests ≥ 8 weeks since the post-surgical
nadir, with a minimal interval of 2 weeks between
tests and at least 1 psa test > 0.4 ng/ml*
Yes
No
Exclusion Criteria
life expectancy ≥ 9 months*
Yes
No
no predictors of poor adherence (e.g., erratic life-
style, mental incompetence)*
Yes
No
prior concurrent therapy: see disease
characteristics*
Yes
No
no other concurrent brassica vegetable
consumption > 1 serving/day*
Yes
No
no other concurrent indole-3-carbinol
supplements*
Yes
No
no endocrine or radiation treatment within past 4
weeks*
Yes
No
no other scheduled treatment during study
intervention*
Yes
No
concurrent prescription medications during the
trial allowed*
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Yes
No
at least 2 weeks since prior and no concurrent
vitamin or herbal supplement use*
Yes
No
patients refusing to stop non-study supplements
will be asked to maintain constant use*
Yes
No
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Eligibility Diabetes Mellitus, Type 2
NCT00094991
Mechanism of Action and Efficacy of Muraglitazar in Type 2
Diabetes; ODM derived from:
https://clinicaltrials.gov/show/NCT00094991
All rights reserved. Please visit https://medical-data-
models.org/forms/17181
Eligibility Diabetes Mellitus, Type 2
NCT00094991
Inclusion Criteria
type 2 diabetes;*
Yes
No
serum triglyceride concentration < or = 600
mg/dl;*
Yes
No
body mass index < or = 37 kg/m2*
Yes
No
Exclusion Criteria
type 1 diabetes;*
Yes
No
history of myocardial infarction (mi), coronary
angioplasty, bypass graft(s), valvular disease,
unstable angina pectoris, transient ischemic
attack (tia), or cerebrovascular accident (cva)
within 6 months;*
Yes
No
congestive heart failure (nyha class iii and iv);*
Yes
No
uncontrolled hypertension;*
Yes
No
women of child bearing potential*
Yes
No
history of renal disease, peripheral vascular
disease (pvd), pulmonary disease,
gastrointestinal disease, active liver disease, or
endocrine disease*
Yes
No
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Eligibility Prostatic Neoplasms
NCT00383487
A Phase II Trial of Calcitriol and Naproxen in Patients With
Recurrent Prostate Cancer; ODM derived from:
https://clinicaltrials.gov/show/NCT00383487
All rights reserved. Please visit https://medical-data-
models.org/forms/17182
Eligibility Prostatic Neoplasms
NCT00383487
Inclusion Criteria
must give written informed consent*
Yes
No
histologically confirmed adenocarcinoma of the
prostate*
Yes
No
biochemical relapse after primary radiation
therapy or surgery*
Yes
No
normal testosterone levels*
Yes
No
3 rising psa after nadir, with interval between psa
determinations > 2 weeks*
Yes
No
Exclusion Criteria
local recurrence by ct scan*
Yes
No
distant metastases by bone scan*
Yes
No
hypercalcemia*
Yes
No
nephrolithiasis*
Yes
No
renal insufficiency (serum creatinine > 1.8 mg/dl)*
Yes
No
pancreatitis*
Yes
No
history of ulcer or gastrointestinal bleeding*
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Yes
No
more than 6 months of hormone ablation therapy*
Yes
No
concurrent therapy for prostate cancer*
Yes
No
uncontrolled htn*
Yes
No
h/o mi, cva, tia*
Yes
No
known coronary disease/cerebrovascular
disease*
Yes
No
platelet counts <50*
Yes
No
patients on anticoagulants*
Yes
No
patients on lithium*
Yes
No
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Eligibility Diabetes Mellitus, Type 2
NCT00099853
Efficacy and Safety of Vildagliptin in Combination With
Pioglitazone in Patients With Type 2 Diabetes; ODM
derived from: https://clinicaltrials.gov/show/NCT00099853
All rights reserved. Please visit https://medical-data-
models.org/forms/17183
Eligibility Diabetes Mellitus, Type 2
NCT00099853
Inclusion Criteria
blood glucose criteria must be met*
Yes
No
previously responded, as defined by the protocol,
to treatment with pioglitazone or rosiglitazone*
Yes
No
body mass index (bmi) in the range 22-45*
Yes
No
Exclusion Criteria
type 1 diabetes*
Yes
No
pregnancy or lactation*
Yes
No
evidence of serious cardiovascular
complications*
Yes
No
evidence of serious diabetic complications*
Yes
No
laboratory value abnormalities as defined by the
protocol*
Yes
No
known sensitivity to pioglitazone*
Yes
No
other protocol-defined exclusion criteria may
apply*
Yes
No
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Eligibility Prostatic Neoplasms
NCT00401765
A Study of CNTO 328 in Patients With Metastatic Hormone-
Refractory Prostate Cancer; ODM derived from:
https://clinicaltrials.gov/show/NCT00401765
All rights reserved. Please visit https://medical-data-
models.org/forms/17184
Eligibility Prostatic Neoplasms
NCT00401765
Inclusion Criteria
histologically or cytologically confirmed
adenocarcinoma of the prostate*
Yes
No
radiologically documented metastatic disease*
Yes
No
no prior systemic chemotherapy for metastatic
hormone refractory prostate cancer*
Yes
No
progressive hormone-refractory disease after
orchiectomy or gonadotropin-releasing hormone
analog and/or anti-androgen treatment within 12
months of screening based on 1 of the following:
transaxial imaging tumor progression, rise in 2
consecutive prostate-specifec antigen (psa)
values obtained at least 7 days apart or
radionucleotide bone scan progression*
Yes
No
karnofsky performance status of greater than or
equal to 60*
Yes
No
Exclusion Criteria
prostate cancer that does not express serum psa
or is less than 5.0 ng/ml at screening*
Yes
No
received any investigational drug/agent within 30
days or 5 half-lives, whichever is longer*
Yes
No
prior malignancy (other than prostate cancer)
except adequately treated basal cell or squamous
cell carcinoma of the skin or other cancer for
which the subject has been disease-free for
greater than or equal to 3 years*
Yes
No
known central nervous system metastases*
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Yes
No
received any over-the-counter or herbal treatment
for prostate cancer (eg, pc spes [an herbal
refined powder]) within 4 weeks prior to
screening.*
Yes
No
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Eligibility Diabetes Mellitus, Type 2
NCT00099918
Efficacy and Safety of Vildagliptin Compared to
Rosiglitazone in Drug Naive Patients With Type 2 Diabetes;
ODM derived from:
https://clinicaltrials.gov/show/NCT00099918
All rights reserved. Please visit https://medical-data-
models.org/forms/17185
Eligibility Diabetes Mellitus, Type 2
NCT00099918
Inclusion Criteria
blood glucose criteria must be met*
Yes
No
not currently on drug therapy for type 2 diabetes*
Yes
No
body mass index (bmi) in the range 22-45*
Yes
No
Exclusion Criteria
pregnancy or lactation*
Yes
No
type 1 diabetes*
Yes
No
evidence of serious diabetic complications*
Yes
No
evidence of serious cardiovascular conditions*
Yes
No
laboratory value abnormalities as defined by the
protocol*
Yes
No
other protocol-defined exclusion criteria may
apply*
Yes
No
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Eligibility Rheumatoid Arthritis
NCT00152386
A Placebo Controlled Study to Assess Efficacy and Safety
of Certolizumab Pegol in the Treatment of Rheumatoid
Arthritis; ODM derived from:
https://clinicaltrials.gov/show/NCT00152386
All rights reserved. Please visit https://medical-data-
models.org/forms/17186
Eligibility Rheumatoid Arthritis
NCT00152386
Inclusion Criteria
male and female, aged at least 18 years old at
the screening visit.*
Yes
No
a clear chest x-ray within 3 months prior to
baseline visit.*
Yes
No
a diagnosis of adult-onset ra (of at least six
months duration but not longer than 15 years
prior to screening) as defined by the 1987
american college of rheumatology classification
criteria.*
Yes
No
active ra disease at screening and baseline as
defined by:*
Yes
No
≥9 tender joints.*
Yes
No
≥9 swollen joints. and fulfilling 1 of the following 2
criteria:*
Yes
No
≥30 mm/hour esr (westergren), or*
Yes
No
crp >15 mg/l.*
Yes
No
must have received a stable dose of mtx with or
without folic acid for at least 3 months prior to
baseline visit.  the minimum dose is 10 mg mtx
weekly.*
Yes
No
patient must be willing to attend for a week 52 x-
ray of the hands and feet even if they are no
longer receiving study treatment but have not
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withdrawn their informed consent.*
Yes
No
Exclusion Criteria
a diagnosis of any other inflammatory arthritis
e.g., psoriatic arthritis or ankylosing spondylitis.*
Yes
No
a secondary, non-inflammatory type of arthritis
(e.g. oa or fibromyalgia) that in the investigator's
opinion is symptomatic enough to interfere with
evaluation of the effect of cdp870 on the patient's
primary diagnosis of ra.*
Yes
No
a history of an infected joint prosthesis at any
time with prosthesis still in situ.*
Yes
No
does not meet exclusionary concomitant
medication criteria.*
Yes
No
a history of a lymphoproliferative disorder
including lymphoma or signs and symptoms
suggestive of lymphoproliferative disease at any
time.*
Yes
No
patients at a high risk of infection in the
investigator's opinion (e.g. leg ulcers, indwelling
urinary catheter and persistent or recurrent chest
infections).*
Yes
No
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Eligibility Diabetes Mellitus, Type 2
NCT00099931
Efficacy and Safety of Vildagliptin in Combination With
Insulin in Patients With Type 2 Diabetes; ODM derived
from: https://clinicaltrials.gov/show/NCT00099931
All rights reserved. Please visit https://medical-data-
models.org/forms/17187
Eligibility Diabetes Mellitus, Type 2
NCT00099931
Inclusion Criteria
blood glucose criteria must be met*
Yes
No
on a stable dose of insulin as defined by the
protocol*
Yes
No
body mass inde (bmi) in the range 22-45*
Yes
No
Exclusion Criteria
type 1 diabetes*
Yes
No
pregnancy or lactation*
Yes
No
evidence of serious diabetic complications*
Yes
No
evidence of serious cardiovascular
complications*
Yes
No
laboratory value abnormalities as defined by the
protocol*
Yes
No
other protocol defined exclusion criteria may
apply*
Yes
No
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Eligibility Rheumatoid Arthritis
NCT00264537
A Study of the Safety and Efficacy of Golimumab in
Subjects With Rheumatoid Arthritis That Are Methotrexate-
naive; ODM derived from:
https://clinicaltrials.gov/show/NCT00264537
All rights reserved. Please visit https://medical-data-
models.org/forms/17188
Eligibility Rheumatoid Arthritis
NCT00264537
Inclusion Criteria
have a diagnosis of rheumatoid arthritis (ra)
(according to the revised 1987 criteria of the acr)
for at least 3 months prior to first administration of
study agent*
Yes
No
are methotrexate (mtx)-naïve (ie, have not
received more than 3 weekly doses of mtx for ra
at any time)*
Yes
No
have active ra as defined by persistent disease
activity with at least 4 swollen and 4 tender joints,
at the time of screening and baseline, and at
least 2 of the following 4 criteria: a) c-reactive
protein (crp) >=1.5 mg/dl at screening or
erythrocyte sedimentation rate (esr) by
westergren method of >= 28 mm in the first hour
at screening or baseline, b)morning stiffness of
>= 30 minutes at screening and baseline, c)bone
erosion by x-ray and/or mri prior to first
administration of study agent, d)anti-cyclic
citrullinated peptide (anti-ccp) antibody-positive or
rheumatoid factor (rf) positive at screening*
Yes
No
if using oral corticosteroids, must be on a stable
dose equivalent to <= 10 mg of prednisone/day
for at least 2 weeks prior to first administration of
study agent.*
Yes
No
Exclusion Criteria
can not have inflammatory diseases other than ra
that might confound the evaluation of the benefit
of golimumab therapy*
Yes
No
no treatment with disease-modifying anti-
rheumatic drugs (dmards)/systemic
immunosuppressives during the 4 weeks prior to
the first administration of study agent*
Yes
No
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no prior treatment with biologic anti-tnf drugs
(infliximab, etanercept, adalimumab)*
Yes
No
no history of, or ongoing, chronic or recurrent
infectious disease*
Yes
No
no serious infection within 2 months prior to first
administration of study agent.*
Yes
No
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Eligibility Rheumatoid Arthritis
NCT00264550
An Efficacy and Safety Study of Golimumab in Patients
With Active Rheumatoid Arthritis Despite Methotrexate
Therapy; ODM derived from:
https://clinicaltrials.gov/show/NCT00264550
All rights reserved. Please visit https://medical-data-
models.org/forms/17189
Eligibility Rheumatoid Arthritis
NCT00264550
Inclusion Criteria
have a diagnosis of rheumatoid arthritis (ra)
(according to the revised 1987 criteria of the acr)
for at least 3 months prior to screening*
Yes
No
must have been treated with and tolerated
methotrexate (mtx) at a dose of at least 15
mg/week for at least 3 months prior to screening,
and have a mtx dose of >=15 mg/week and <=25
mg/week and stable for at least 4 weeks prior to
screening*
Yes
No
have active ra as defined by persistent disease
activity with at least 4 swollen and 4 tender joints,
at the time of screening and baseline, and at
least 2 of the following 4 criteria: a)c-reactive
protein (crp) >=1.5 mg/dl at screening or
erythrocyte sedimentation rate (esr) by
westergren method of >= 28 mm in the first hour
at screening or baseline, b)morning stiffness of
>= 30 minutes at screening and baseline, c)bone
erosion by x-ray and/or magnetic resonance
imaging (mri) prior to first administration of study
agent, d)anti-cyclic citrullinated peptide (anti-ccp)
antibody-positive or rheumatoid factor (rf) positive
at screening*
Yes
No
if using oral corticosteroids, must be on a stable
dose equivalent to <= 10 mg of prednisone/day
for at least 2 weeks prior to first administration of
study agent*
Yes
No
are considered eligible according to specified
tuberculosis (tb) screening criteria*
Yes
No
Exclusion Criteria
have inflammatory diseases other than ra that
might confound the evaluation of the benefit of
golimumab therapy*
Yes
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No
have had treatment with disease-modifying anti-
rheumatic drugs (dmards)/systemic
immunosuppressives other than mtx, during the 4
weeks prior to the first administration of study
agent*
Yes
No
have had prior treatment with biologic anti-tumor
necrosis factor (tnf) drugs (infliximab, etanercept,
adalimumab)*
Yes
No
have had history of, or ongoing, chronic or
recurrent infectious disease.*
Yes
No
have serious infection within 2 months prior to
first administration of study agent*
Yes
No
have a history of latent or active granulomatous
infection, including tb, histoplasmosis, or
coccidioidomycosis, prior to screening*
Yes
No
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Eligibility Rheumatoid Arthritis
NCT00432484
Lingzhi and Sen Miao San for the Treatment of Rheumatoid
Arthritis; ODM derived from:
https://clinicaltrials.gov/show/NCT00432484
All rights reserved. Please visit https://medical-data-
models.org/forms/17190
Eligibility Rheumatoid Arthritis
NCT00432484
Inclusion Criteria
fulfilled the 1987 american college of
rheumatology (acr) criteria for ra.*
Yes
No
the presence of 2 or more swollen or tender
joints, based on 28-joint count.*
Yes
No
morning stiffness lasting for 30 minutes.*
Yes
No
erythrocyte sedimentation rate (esr) of 28
mm/hour, despite treatment with disease
modifying agent including mtx, sulphasalazine,
hydroxychloroquine, auranofin or azathioprine
were recruited into the study.*
Yes
No
patients taking glucocorticoids (prednisone < 7.5
mg/day) and/or nonsteroidal antiinflammatory
drugs must have been taking a stable dosage for
at least 4 weeks before entering the trial and
were required to take the same dosage
throughout the trial.*
Yes
No
patients had radiographic erosive diseases.*
Yes
No
Exclusion Criteria
patients who are pregnant or nursing mothers.*
Yes
No
severe liver disease (e.g cirrhosis, chronic active
hepatitis)*
Yes
No
renal impairment (serum creatinine level >
150mmol/l)*
Yes
No
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known hypersensitivity to herbal medicine*
Yes
No
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Eligibility Schizophrenia NCT00150176
To Determine Long Term Efficacy and Safety of Asenapine
in Schizophrenic Patient Population
(A7501012)(COMPLETED)(P05770); ODM derived from:
https://clinicaltrials.gov/show/NCT00150176
All rights reserved. Please visit https://medical-data-
models.org/forms/17191
Eligibility Schizophrenia
NCT00150176
Criteria
have a primary diagnosis of schizophrenia*
Yes
No
history of at least 1 prior episode of acute
schizophrenia in the 3 years preceding
screening*
Yes
No
history of schizophrenia requiring continuous
antipsychotic treatment for at least 1 years
preceding screening*
Yes
No
clinically stable at the time of entry defined by at
least a 4 week period of stable symptoms*
Yes
No
key exclusion criteria:*
Yes
No
have an uncontrolled, unstable clinically
significant medical condition*
Yes
No
history of suicide attempt or significant violence
to others in the past 2 years*
Yes
No
a substance-induced psychotic disorder or
behavioral disturbance thought to be due to
substance abuse*
Yes
No
current substance abuse/dependence*
Yes
No
concurrent psychiatric disorder other than
schizophrenia.*
Yes
No
1 / 1
Eligibility Schizophrenia NCT00209027
The Effects of Aripiprazole on the Processing of Rewards in
Schizophrenia; ODM derived from:
https://clinicaltrials.gov/show/NCT00209027
All rights reserved. Please visit https://medical-data-
models.org/forms/17192
Eligibility Schizophrenia
NCT00209027
Criteria
Inclusion Criteria
diagnosed with schizophrenia*
Yes
No
male*
Yes
No
age 20-50*
Yes
No
right handed*
Yes
No
Exclusion Criteria
no current or past drug or alcohol problems
(dependance or abuse)*
Yes
No
not color blind*
Yes
No
Inclusion Criteria control subjects
male*
Yes
No
age 20-50*
Yes
No
right handed*
Yes
No
Exclusion Criteria control subjects
no current psychiatric problems*
Yes
No
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no current or past drug or alcohol problems*
Yes
No
not color blind*
Yes
No
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Eligibility Schizophrenia NCT00210548
A Study to Evaluate the Effectiveness and Safety of 3
Doses of Paliperidone Palmitate in Treating Subjects With
Schizophrenia; ODM derived from:
https://clinicaltrials.gov/show/NCT00210548
All rights reserved. Please visit https://medical-data-
models.org/forms/17193
Eligibility Schizophrenia
NCT00210548
Inclusion Criteria
a dsm-iv diagnosis of  schizophrenia
(disorganized, catatonic, paranoid, residual, or
undifferentiated type) for at least 1 year before
the screening evaluation*
Yes
No
a total panss score of 70 to 120 at screening and
baseline (pre-treatment) evaluations*
Yes
No
a body mass index (bmi [weight
(kilograms)]/[height (meters)]²) of more than 17.0
kg/m²*
Yes
No
Exclusion Criteria
a primary active dsm-iv axis i diagnosis other
than schizophrenia*
Yes
No
a decrease of 25% or more in the total panss
score between screening and baseline
evaluations*
Yes
No
a dsm-iv diagnosis of active substance
dependence within 3 months of screening
evaluation*
Yes
No
a history of treatment resistance as defined by
failure to respond to 2 adequate trials of different
antipsychotic medications*
Yes
No
a woman who is pregnant, breast-feeding, or
planning to become pregnant during the study
period.*
Yes
No
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Baseline (T0): Demografie und
Risikofaktoren Nicotinsäure und
Naftidrofuryl bei pAVK-Patienten
nach Angioplastie
Teilnehmer Identifikation
Zentrums-Nr.:
Patienten-Nr
Demografie
Geburtsjahr
Geschlecht
männlich (1)
weiblich (2)
Körpergewicht
kg
Größe:
cm
Nationalität
deutsch (1)
andere (2)
und zwar
Schulabschluss
Hauptschulabschluss/Volksschulabschlu
ss (1)
Realschulabschluss (Mittlere
Reife)/POS, 10. Klasse) (2)
Fachhochschulreife (Abschluss einer
Fachoberschule) (3)
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Abitur (Gymnasium bzw. EOS) (4)
Sonderschulabschluss (5)
Schule beendet ohne Schulabschluss (6)
Anderer Schulabschluss (7)
Berufstätigkeit zur Zeit: Ausgeübter Beruf
beschäftigungszustand
nicht berufstätig (z. B. Hausmann) (1)
Rentner (2)
voll berufstätig (3)
Teilzeit oder stundenweise berufstätig (4)
Auszubildender (z. B. Lehrling) (5)
vorübergehende Freistellung (z. B.
Erziehungsurlaub) (6)
arbeitslos (7)
Risikofaktoren
Rauchen
nie (0)
gelegentlich (1)
täglich (2)
seit mehr als einem Jahr nicht mehr (3)
in den letzten 12 Monaten aufgehört (4)
Pfeife/Zigarren (8)
Nur bei Antwort 2 und 4: Anzahl der Zigaretten
pro Tag:
Diabetes mellitus
nein (0)
ja (1)
Hypertonie
nein (0)
ja (1)
Hyperlipidämie
nein (0)
ja (1)
Therapie mit Statinen
nein (0)
ja (1)
Hat der Patient weitere Begleiterkrankungen bzw.
nimmt er Medikamente ein
nein (0)
ja (1)
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Naftidrofuryl bei pAVK-Patienten nach Angioplastie
Yrs 4-11 Phone Follow up Cardiovascular
Health Study (CHS)
Documentation part: Record 32 Years 4-11 Phone Follow
up
The Cardiovascular Health Study (CHS) was initiated by
the National Heart, Lung and Blood Institute (NHLBI) in
1987 to determine the risk factors for development and
progression of cardiovascular disease (CVD) in older
adults, with an emphasis on subclinical measures. The
study recruited 5,888 adults aged 65 or older at entry in
four U.S. communities and conducted extensive annual
clinical exams between 1989-1999 along with semi-annual
phone calls, events adjudication, and subsequent data
analyses and publications. Additional data were collected
by studies ancillary to CHS. With the exception of annual
clinic visits, these activities are still ongoing. 
Data obtained from: https://chs-nhlbi.org/ Permission
granted by: Erika Enright.
All rights reserved. Please visit https://medical-data-
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Yrs 4-11 Phone Follow up
Cardiovascular Health Study (CHS)
Introduction
Did you receive our letter?
Yes
No
Interview completed by:
participant (participant)
proxy (proxy)
If by proxy, reason:
cognitive (cognitive)
hearing (hearing)
hospitalized (hospitalized)
other (other)
other illness (other illness)
Other, specify:
10 Now I would like to find out if you had any
major changes in your health since we saw you in
[month]. Have you been told by a physician that
you had: HEART FAILURE OR CONGESTIVE
HEART FAILURE
Yes
No
Physician:
Physician address
Phone
Stroke or cerebrovascular accident
Yes
No
Physician:
Physician address
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Phone
Transient ischemic attack or TIA or silent stroke
Yes
No
Physician:
Physician address
Phone
Myocardial infarction or heart attack
Yes
No
Phone
Angina pectoris or chest pain due to heart
disease
Yes
No
Physician:
Physician address
Phone
Intermittent claudication or pain in your legs from
a blockage of the arteries
Yes
No
Physician:
Physician address
Phone
11 Have you stayed overnight as a patient in a
hospital since we saw you in [month].
Yes
No
13 Have you stayed overnight as a patient in a
nursing home or rehabilitation center since
[month]?
Yes
No
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15 I am now going to ask you about a number of
events that commonly happen in peoples's lives
and tha can affect your health. In some cases, I
will ask whether the event has happened to you
or a member of your familiy during the past 6
months. In other cases, I will ask only whether it
happened to you. When I ask a question about
your spouse, I am referring to both married
spouses and unmarried partners who live
together. Please respond YES if the event
happened and NO if it didn't.
Have you retired or changed or lost your job since
we saw you in [month]?
no (0)
yes (1)
unknown (9)
When did this happen?
don't know (don't know)
during last month (during last month)
not during the last month (not during the
last month)
Was this job change, loss or retirement positive
or negative?
don't know (don't know)
neg (neg)
pos (pos)
16 Have you had a grandchild born since we saw
you in [month]?
no (0)
yes (1)
unknown (9)
17 Has caring for a sick or disabled relative
become a significant problem for you since we
saw you in [month]?
no (0)
yes (1)
unknown (9)
Has providing care become significantly harder
than last month?
no (0)
yes (1)
unknown (9)
18 Has there been a significant change in your
personal finances since we saw you in [month]?
no (0)
yes (1)
unknown (9)
When did this happen?
don't know (don't know)
during last month (during last month)
not during the last month (not during the
last month)
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Was this change positive or negative?
don't know (don't know)
neg (neg)
pos (pos)
19 Did you or a very close friend or close family
member have a serious accident or illness since
we saw you in [month]?
no (0)
yes (1)
unknown (9)
When did this accident or illness occur?
don't know (don't know)
during last month (during last month)
not during the last month (not during the
last month)
20 Have you, your spouse or partner, or a
member of your immediate family been assaulted
or robbed since we saw you in [month]?
no (0)
yes (1)
unknown (9)
When did this assault or robbery happen?
don't know (don't know)
during last month (during last month)
not during the last month (not during the
last month)
21 Have you had any important relationship, for
example with your spouse or a good friend,
become significantly worse since we saw you in
[month]?
no (0)
yes (1)
unknown (9)
When did this relationship worsen?
don't know (don't know)
during last month (during last month)
not during the last month (not during the
last month)
22 Did someone you were close to die since we
saw you in [month]?
no (0)
yes (1)
unknown (9)
When did this person die?
no (0)
yes (1)
unknown (9)
23 Have any other important things happened to
you or your spouse or partner since [month] that
made this period significantly different from the
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previous six months?
no (0)
yes (1)
unknown (9)
What happened?
Was it positive or negative?
don't know (don't know)
neg (neg)
pos (pos)
25 You previously provided us with information
about someone who could provide information
and answer questions for you in the event that
you were unable to answer yourself. Please tell
me if the information I have is still correct.
Yes
No
26 You previously provided us with information
about friends or relatives who you are likely to
keep in touch with, but who do not live with you,
and who are not planning to move anytime soon.
Please tell me if the information I have is still
correct.
Yes
No
27 Do you plan to be out of the area 6 months
from now?
Yes
No
Are you moving out of the area permanently or
will you only be gone temporarily?
permanently (permanently)
temporarily out of the area (vacation,
business, etc.) (temporarily out of the
area (vacation, business, etc.))
Do you know what your new address and
telephone number will be?
Yes
No
Street:
City
State
Telephone number
Do you know which general area you will be
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moving to?
When will you return?
mo/yr
29 Time interview ended:
30 May I please speak with [name]?
Not in (Not in)
Can you tell me when I should call [participant] to
make the interview?
Hospitalizatiuon
Name, city and state of the hospital
12 Please tell me the reason you were admitted,
the name and location of the hospital, and the
month and year you were a patient for each time
you stayed overnight in a hospital.
Mo/Yr
mo/yr
Nursing home admission
14 Please tell me the reason you were admitted,
the name and location of the nursing home, and
the month and year you were a patient for each
time you stayed overnight in a nursing home or
rehabilitation center. 
Reason for nursing home admission
Name, city and state of nursing home
Mo/Yr
mo/yr
30 months follow-up telephone interview
1 Has the participant moved during the last six
month?
no (0)
yes (1)
unknown (9)
Did you move during the last month?
no (0)
yes (1)
unknown (9)
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2 What is your current marital status? Are you:
divorced (divorced)
married (married)
never marriedd (never marriedd)
other (specify) (other (specify))
separated (separated)
widowed (widowed)
Other, specify:
3 I would like to ask you some questions that we
also asked you 6 months ago. The reason for
asking them again is that we are interested in
possible changes that might have occurred.
Would you say, in general, your health is:
excellent? (excellent?)
fair? (fair?)
good? (good?)
poor? (poor?)
refused/don't know (refused/don't know)
very good? (very good?)
4 How would you say your health compares to
other persons of your age? Would you say your
health is:
Better than others of your age? (1)
About the same as others your age? (2)
Worse than others your age? (3)
Don´t know (9)
5 How does your to when we saw you in [month]?
Would you say your health is?
about the same (about the same)
better (better)
don't know (don't know)
worse (worse)
6 During the past two weeks, how many days
have you stayed in bed all or most of the day
because of illness or injury? Do not include past
days in a hospital or nursing home?
>= 0
<= 14
days
7 What illness caused you to stay in bed?
arthritis (arthritis)
cancer (cancer)
cold or flu (cold or flu)
diabetes (diabetes)
don't know (don't know)
general fatique or weakness (incl. old
age) (general fatique or weakness (incl.
old age))
heart attack/heart failure (heart
attack/heart failure)
injury (injury)
lung disease or emphysema, bronchitis
(lung disease or emphysema, bronchitis)
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mental illness (mental illness)
other (other)
stroke (stroke)
8 Have you had coronary bypass surgery (CABG)
since we saw you about six month ago?
no (0)
yes (1)
unknown (9)
9 Have you had a cardiac catheterization or
coronary angiography since we saw you about six
month ago?
no (0)
yes (1)
unknown (9)
10a. Has a doctor told you that you had a new
myocardial infarction or heart attack since we saw
you about six month ago?
Yes
No
b. Date of event or diagnosis
c. How many times altogether did you see a
doctor for this condition over the last six months,
that is, since [month]?
times
Physician:
Physician address
e. Were you in the hospital at least one night for
this condition over the last six months?
f. How many different times were you in the
hospital for this condition?
times
h. How many days altogether were you
hospitalized for this condition?
days
Hospitalization Myocardial Infarction
Date
Hospital name and city
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Eligibility Type 2 Diabetes Mellitus
NCT00265746
Prevention of Diabetes Mellitus Development in Women
Who Had Already Experienced A Gestational Diabetes;
ODM derived from:
https://clinicaltrials.gov/show/NCT00265746
All rights reserved. Please visit https://medical-data-
models.org/forms/17196
Eligibility Type 2 Diabetes Mellitus
NCT00265746
Inclusion Criteria
gdm - experienced during pregnancy (diagnosis
of gdm according to who-criteria)*
Yes
No
breast-feeding of the newborn finished (lactation
finished)*
Yes
No
actual bmi >= 25 kg/ m2*
Yes
No
written consent for participation in the study*
Yes
No
a hitherto prevailing good cooperation with the
patient*
Yes
No
Exclusion Criteria
cholestasis during the past pregnancy*
Yes
No
any hepatic diseases in the past (viral hepatitis,
toxic   hepatic damage,jaundice of unknown
etiology)*
Yes
No
serum aspat and/or alat level exceeding more
than twice normal laboratory values*
Yes
No
pregnancy planned during the coming two years*
Yes
No
presence of contradictions for metformin
administration according to demands of the drug
admission committee in poland*
Yes
No
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Eligibility Type 2 Diabetes NCT00159211
Abdominal Adipose Tissue Distribution in Type 2 Diabetic
Patients Treated During 6 Months With Pioglitazone or
Insulin; ODM derived from:
https://clinicaltrials.gov/show/NCT00159211
All rights reserved. Please visit https://medical-data-
models.org/forms/17197
Eligibility Type 2 Diabetes
NCT00159211
Inclusion Criteria
type 2 diabetes*
Yes
No
bmi= 26kg/m2*
Yes
No
maximal treatment with metformin and
sulfonylurea*
Yes
No
hba1c between 7.5 and 9.5%*
Yes
No
Exclusion Criteria
anterior treatment with glitazones*
Yes
No
anterior treatment with insulin*
Yes
No
known heart failure*
Yes
No
hepatopathy*
Yes
No
renal filtration less than 60ml/min, hb<10g/dl*
Yes
No
corticoids treatment*
Yes
No
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Baseline-Untersuchung (T0):
Anamnese – pAVK Nicotinsäure und
Naftidrofuryl bei pAVK-Patienten
nach Angioplastie
Teilnehmer Identifikation
Zentrums-Nr.:
Patienten-Nr
Anamnese pAVK
Seit wann besteht pAVK
Datum der Angioplastie am
Lokalisation der Stenose
rechtes Bein       (1)
linkes Bein (2)
Abstand zur Bifurcation
cm
Bestehen weitere Stenosen
nein (0)
ja (1)
PAVK Stadium (Fontaine)
Stadium I (1)
Stadium II  (2)
Stadium III (3)
Stadium IV (4)
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maximale Gehstrecke
max. Gehstrecke ≤200m  (0)
max. Gehstrecke >200m (1)
Farbduplexsonografie Angioplastiertes
Gefäßsegment
cm/s
Farbduplexsonografie Vorgeschaltetes
Referenzsegment
cm/s
Andere Befunde:
o.B. (0)
m.B. (1)
und zwar
Pulsstatus/Knöcheldrücke
Arterie
A. brachialis (1)
A. brachialis 	 (2)
A. tib. Posterior  (3)
A. tib. Anterior (4)
Systole/Diastole
Systole (1)
Diastole (2)
Körperseite
rechts (1)
links (2)
Blutdruck
mmHg
Hautveränderungen und trophische Läsionen an
den Beinen und Körperliche Untersuchung:
normal 		 (1)
blass  		 (2)
rot (3)
Gelbfärbung  (4)
Blaufärbung 	 (5)
marmorisierte (6)
Hautdefekte
nein (0)
ja (1)
Nagelmykosen
nein (0)
ja (1)
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Health insurance request for evaluation of
application for psychotherapy
Formulare für die vertragsärztliche Versorgung Freigabe
durch Dezernat 4 - Ärztliche Leistungen und
Versorgungsstruktur Geschäftsbereich Sicherstellung und
Versorgungsstruktur Abteilung Sicherstellung Herbert-
Lewin-Platz 2 10623 Berlin Tel: + 49 (0) 30 - 4005 -1418
Fax: + 49 (0) 30 - 4005 - 271418 Email: SJohn@KBV.de
Web: www.kbv.de Quelle:
http://www.kbv.de/html/formulare.php Forms for contract
medical care Released by Department 4 - Medical
treatment and structure of supply, division ensurance and
structure of supply, department ensurance Herbert-Lewin-
Platz 2 10623 Berlin Tel: + 49 (0) 30 - 4005 -1418 Fax: + 49
(0) 30 - 4005 - 271418 Email: SJohn@KBV.de Web:
www.kbv.de Source: http://www.kbv.de/html/formulare.php
All rights reserved. Please visit https://medical-data-
models.org/forms/17199
Health insurance request for
evaluation of application for
psychotherapy
Briefkopf
Krankenversicherung: Name und Anschrift
Name und Adresse des Gutachters
Chiffre des Patienten
Kassenmitarbeiter
Telefonnummer Kassenmitarbeiter
Art der Therapie
Art der beantragten Therapie
KZT- Antrag (1)
Erstantrag/LZT (2)
Antrag auf Umwandlung von
Kuzzeittherapie in Langzeittherapie (PTV
2 zur Kurzzeittherapie ist beigefügt) (3)
Fortführungsantrag (4)
Ergänzungsbericht (5)
Datum PTV 2 zur Kurzzeittherapie
Name des Gutachters des Erstantrags
Datum des Vorgutachtens
Ergänzende Angaben über den Patienten
Arbeitsunfähigkeit in den letzten 2 Jahren
Startdatum
Arbeitsunfähigkeit in den letzten 2 Jahren
Enddatum
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Arbeitsunfähigkeit in den letzten 2 Jahren
Diagnose
Stationäre/Teilstationäre
Krankenhausbehandlung in den letzten 5 Jahren
Startdatum
Stationäre/Teilstationäre
Krankenhausbehandlung in den letzten 5 Jahren
Enddatum
Stationäre/Teilstationäre
Krankenhausbehandlung in den letzten 5 Jahren
Krankenhaus
Kuren oder Heilverfahren in den letzten 5 Jahren
Startdatum
Kuren oder Heilverfahren in den letzten 5 Jahren
Enddatum
Rehabilitationsdiagnose
Kurort
Kostenträger
Datum der Unterschrift
Unterschrift
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